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Word of Welcome
On behalf of the EHA Board and the Scientific Program Committee we are pleased to introduce to you
this year’s Abstract Program. The richness of the program is a testament to EHA’s spirit: unity through
diversity.
The Scientific Program Committee has compiled an exciting program of Simultaneous Oral and
Poster Sessions from close to 2500 submitted abstracts representing all fields of hematology. For the
second year, a number of presenters will have the opportunity to pitch their abstract. These Poster
pitches are an exciting opportunity to promote basic science and research, and to invite delegates to the
poster walks. 
The six Best Abstracts will be presented during the Presidential Symposium on Friday afternoon. This
will be a session not to miss. During this plenary session EHA is also awarding, for the first time, the
best abstracts by trainees in four categories in basic and clinical hematology research. These awardees
and the travel grant winners can be found on the next page. YoungEHA are the future of hematology!
The late breaking abstract submission is an integral part of the scientific program. The late breaking
submission is intended for abstracts with “hot” data that were not available by the time of the regular
submission deadline. Only few abstracts, with the most exciting results are selected for a presentation
in the Late Breaking Oral Session on Sunday morning. 
A selection of abstracts will be presented during the regular Poster Walks. The Poster Session con-
sists of two parts: the Poster Walk and dedicated Poster Browsing Time. This setup guarantees suffi-
cient time for discussion of the important research presented, so look out for the Poster Walk
Moderators in their red baseball caps! There will also be E-posters available on the E-poster screens,
for which a specific time is allocated during the Poster Browsing Time at the end of each Walk. The
Simultaneous Oral Sessions are spread over three days (Friday to Sunday) providing you with ample
opportunity to attend a number of these important sessions.
All posters can be viewed on the E-poster screens from Friday morning to Saturday evening. All the
abstracts are also available on the EHA Learning Center, for which you have complimentary access after
the congress: learningcenter.ehaweb.org.
On behalf of the EHA Board, the committees and all the people involved in this year’s EHA Congress,
we thank you for coming to Madrid and wish you a great meeting.
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Travel Grant Winners
For this Congress 140 travel grants have been awarded to junior members of EHA, based on the mean score
of their abstracts.
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K C Pawlyn, United Kingdom
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K O Schwartzman, Israel
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K JG Barcia Duran, USA
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K F Vinchi, Italy
Travel Grant supported by Giuseppe Bigi Association
Salvatore D, Italy
YoungEHA Best Abstract Awards
One of the primary missions of the European Hematology Association is to support young hematology clinicians and
researchers. This year we are proud to announce the launching of the YoungEHA Best Abstract Awards. These will be
awarded to the highest ranking abstracts in the following four categories: Clinicians or medical students training for
a PhD degree, PhD research students, postdoctoral fellows and clinical hematology trainees. We are honored that
these outstanding YoungEHA trainees will be presenting during the EHA congress – they are the future of Hematology!
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SIMULTANEOUS SESSIONS I
New advances in plasma cell disorders
and implications for therapy
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NEXT GENERATION SEQUENCING METHODOLOGY FOR DETERMINING
CYTOGENETIC RISK STATUS IN THE DARATUMUMAB PHASE 3 CASTOR
AND POLLUX STUDIES IN RELAPSED OR REFRACTORY MULTIPLE
MYELOMA
C. Chiu1,*, D. Soong1, I. Spicka2, M. Beksac3, M. Schaffer1, J. Schecter4,
N. J. Bahlis5, M. A. Dimopoulos6
1Janssen Research & Development, LLC, Spring House, PA, United States,
2First Faculty of Medicine, Charles University, Prague, Czech Republic, 3Ankara
University, Ankara, Turkey, 4Janssen Research & Development, LLC, Raritan,
NJ, United States, 5Tom Baker Cancer Center, University of Calgary, Calgary,
Alberta, Canada, 6National and Kapodistrian University of Athens, Athens,
Greece
Background: Cytogenetic risk status in multiple myeloma (MM) studies is tra-
ditionally determined by using fluorescence in situ hybridization (FISH) or kary-
otyping to assess chromosomal abnormalities. However, these technologies
have limited resolution and a narrow target range, and reproducible interpreta-
tion may be confounded by inter-laboratory variation.
Aims: To describe the NGS methodology used to determine cytogenetic risk
status in the daratumumab phase 3 CASTOR and POLLUX studies in RRMM.
Methods: Bone marrow aspirates were collected at screening and assessed
centrally via NGS. Whole exome sequencing (exome-seq) and RNA sequencing
(RNA-seq) was performed using the Illumina HiSeq platform to identify the
presence or absence of defined risk markers: t(4;14), t(14;16), or del17p. The
use of RNA-seq allowed for investigation of chromosomal translocations in
expressed genomic locations at a higher resolution than FISH, and exome-seq
data was used to derive the copy number status in coding regions across the
genome. RNA-seq was performed using total RNA and rRNA removal to capture
translocations involving coding and intronic regions. Translocation calls were
made using two fusion callers, and gene expression was quantified to allow for
evaluation of genes associated with translocation events. For t(4;14) translo-
cations, the detected events involved RNA-seq reads fused between IgH and
WHSC1 or FGFR3. For t(14;16), the detected translocations involved IgH and
WWOX. Manual inspection of patients with t(4;14) showed higher WHSC1 or
FGFR3 expression, whereas t(14;16) patients showed higher MAF and CCND2
expression. For del17p detection, exome data of each tumor was compared
against 100 peripheral blood mononuclear cell (PBMC) control samples from
CASTOR and POLLUX studies. Copy number variation data from two callers
were combined to utilize information on relative read depth, systematic biases
(observed in pooled normal controls), as well as SNP allele frequency (indicative
of loss of heterozygosity events). A del17p event was detected when >50% of
the 17p region was deleted.
Results: Based on the RNA-Seq and exome results, cytogenetic risk status in
the CASTOR and POLLUX studies was defined as high risk with having either
t(4;14), t(14;16), or del17p, and standard risk with the confirmed absence of
these molecular abnormalities. Comparisons of NGS with FISH showed high
concordance for t(4;14), t(14;16), and del17p in both studies (Table 1).
Table 1.
PFS analyses investigating differences between treatment groups and between
risk groups using FISH-derived risk and NGS-derived risk showed consistent
results between FISH and NGS, with improvements in PFS being associated
with the addition of daratumumab to standard-of-care regimens in both high-
and standard-risk subgroups (Figure 1).
Summary/Conclusions: These studies represent the first, comprehensive use
of NGS in global phase 3 clinical trials in RRMM. The NGS methodology accu-
rately identified the presence of defined risk populations t(4;14), t(14;16), and
del17p and showed good concordance with FISH. As FISH was performed
locally with different probes and pathologists, the high degree of concordance
between FISH and NGS is notable and supports the use of NGS for determining
cytogenetic risk in patients with RRMM. The utility of NGS in these clinical stud-
ies extends far beyond the detection of cytogenetic abnormalities and additional




EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN
COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR
BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY
MULTIPLE MYELOMA
J. San-Miguel1,*, K. Weisel2, G. Cook3, M. Leiba4, K. Suzuki5, S. Kumar6,
M. Cavo7, H. Avet-Loiseau8, H. Quach9, V. Hungria10, S. Lentzsch11,
R. Hajek12, P. Sonneveld13, K. Wu14, X. Qin14, C. Chiu14, D. Soong14, M. Qi14,
J. Schecter15, M.A. Dimopoulos16
1Clínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain, 2Universi-
taetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere
Medizin II, Tuebingen, Germany, 3St James’s Institute of Oncology, Leeds
Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom,
4Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, 5Japanese Red
Cross Medical Center, Department of Hematology, Tokyo, Japan, 6Division of
Hematology, Mayo Clinic, Rochester, MN, United States, 7Department of Exper-
imental, Diagnostic and Specialty Medicine, University of Bologna, Bologna,
Italy, 8Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France,
9University of Melbourne, St. Vincent’s Hospital, Victoria, Australia, 10Irmandade
Da Santa Casa De Misericordia De São Paulo, São Paulo, Brazil, 11Division of
Hematology/Oncology, Columbia University, New York, NY, United States,
12Department of Haematooncology, University Hospital Ostrava and Faculty
of Medicine and Faculty of Science, University of Ostrava, Ostrava, Czech
Republic, 13Department of Hematology, Erasmus MC, Rotterdam, Netherlands,
14Janssen Research & Development, LLC, Spring House, PA, 15Janssen
Research & Development, Raritan, NJ, United States, 16National and Kapodis-
trian University of Athens, Athens, Greece
Background: Daratumumab (D) is a human CD38-targeting monoclonal anti-
body that exerts its antimyeloma activity through both direct (on-tumor) and
indirect (immunomodulatory) mechanisms of action. Two randomized phase 3
trials in patients with relapsed or refractory multiple myeloma (RRMM) demon-
strated that combining D with the standard-of-care regimens lenalidomide +dex-
amethasone (Rd, POLLUX) or bortezomib +dexamethasone (Vd, CASTOR)
significantly improved progression-free survival (PFS) and achieved higher
overall response rates (ORRs) compared with the respective standard-of-care
regimen alone (Dimopoulos MA et al., N Engl J Med 2016;375(14):1319-1331;
Palumbo A et al., N Engl J Med 2016;375(8):754-766.). Due to its novel mech-
anisms of action, addition of D to standard-of-care regimens may benefit RRMM
patients who have poor prognoses resulting from high-risk cytogenetic abnor-
malities. 
Aims: To examine the efficacy of DRd and DVd in RRMM patients with stan-
dard or high cytogenetic risk status. 
Methods: Bone marrow aspirates were collected at screening visits from
311/569 patients from POLLUX and from 353/498 patients from CASTOR, and
cytogenetic abnormalities were detected via next-generation sequencing
(NGS). Patients were considered to be of high cytogenetic risk status if they
had ≥1 of the following abnormalities: t(4;14), t(14;16), or del17p; patients were
considered to be of standard cytogenetic risk if they lacked these abnormalities.
Minimal residual disease (MRD) was assessed at suspected complete
response (CR) at 3 sensitivity thresholds (10–4, 10–5, and 10–6) using the
ClonoSEQ™ NGS-based assay (Adaptive Biotechnologies, Seattle, WA). Effi-
cacy analyses included PFS, ORR, and MRD-negative rates.
Results: For POLLUX, the median follow-up was 17.3 months. Treating high-
risk patients with DRd significantly prolonged median PFS vs Rd (top panel
Figure 1) and numerically increased ORR (85% vs 67%; P=0.14). Responses
to DRd vs Rd included CR or better in 33% vs 6% of these patients, and very
good partial responses (VGPR) or better in 63% vs 31%. In standard-risk
patients, DRd vs Rd also resulted in significant improvements in median PFS
(Figure 1) as well as ORR (95% vs 82%; P=0.0020). Responses to DRd vs Rd
included CR or better in 52% vs 24% of these patients, and VGPR or better in
84% vs 51%. At 10–5 sensitivity threshold, MRD-negative rates for DRd vs Rd
were 18% vs 0% (P=0.0027) among high-risk patients and 30% vs 10%
(P<0.0001) for standard-risk patients. For CASTOR, the median follow-up was
13.0 months. Treating both high- and standard-risk patients with DVd vs Vd
significantly prolonged median PFS (bottom panel Figure 1) and increased
ORR (high risk: 82% vs 62%; P=0.039; standard risk: 85% vs 64%; P=0.0003).
Responses to DVd vs Vd among high-risk patients included CR or better in
30% vs 9% of patients and VGPR or better in 64% vs 34%; among standard-
risk patients, responses included CR or better in 25% vs 8% of patients and
VGPR or better in 64% vs 27%. At 10–5 sensitivity threshold, MRD-negative
rates for DVd vs Vd were 14% vs 0% (P=0.0018) among high-risk patients and
12% vs 2% (P=0.0011) for standard-risk patients.
Figure 1.
Summary/Conclusions: Adding D to Rd or Vd improved treatment outcomes
irrespective of cytogenetic risk status in patients with RRMM. Both DRd and
DVd appear to benefit RRMM patients who have poor prognoses due to high-
risk cytogenetic abnormalities. Updated data, including analyses based on indi-
vidual cytogenetic abnormalities, will be presented at the meeting based on
longer follow-up.
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MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER FLOW CYTOMETRY
IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED
MULTIPLE MYELOMA: RESULTS FROM THE EMN02/HO95 PHASE 3 TRIAL 
S. Oliva1,*, D. Hofste op Bruinink2, L. Říhová3, S. Spada1, B. van der Holt4,
R. Troia1, M. Gambella1, L. Pantani5, S. Grammatico5, M. Gilestro1,
M. Offidani5, R. Ribolla5, M. Galli5, R. Hajek6, A. Palumbo7, M. Cavo5,
P. Omedè1, V. van der Velden8, M. Boccadoro1, P. Sonneveld2
1Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy, 2Depart-
ment of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands,
3Department of Hematology, University Hospital Brno, Brno, Czech Republic,
4Department of Hematology, Erasmus MC Cancer Institute, HOVON Data Center,
Rotterdam, Netherlands, 5Italian Multiple Myeloma Network, GIMEMA, Italy,
6Department of Haematooncology, Faculty of Medicine, University of Ostrava
and University Hospital of Ostrava, Ostrava, Czech Republic, 7Myeloma Unit,
Division of Hematology, University of Torino - Currently Takeda Pharmaceuticals
Co., Torino, Zurich, Italy, Switzerland, 8Department of Immunology, Erasmus MC,
University Medical Center Rotterdam, Rotterdam, Netherlands
Background: Multiple myeloma (MM) is still an incurable disease and patients
may relapse despite achievement of complete remission (CR). Available data
show that MRD detection is a sensitive strategy to appropriately measure
response in MM patients.
Aims: We evaluated MRD by MFC in patients with newly diagnosed MM
enrolled in the EMN02/HO95 phase 3 trial.
Methods: Patients were ≤65 years of age and treatment consisted of Borte-
zomib-Cyclophosphamide-Dexamethasone (VCD) induction, mobilization and
stem cell collection, intensification with Bortezomib-Melphalan-Prednisone
(VMP) vs High-Dose-Melphalan (HDM) followed by stem cell transplant, con-
solidation with Bortezomib-Lenalidomide-Dexamethasone (VRD) vs no con-
solidation, and Lenalidomide maintenance. MRD was assessed in patients
achieving at least a very good partial response (VGPR) before starting main-
tenance (after HDM, VMP or VRD) and during maintenance every 6-12 months;
samples were centralized to 3 European labs. MFC was performed on bone
marrow according to Euroflow-based methods (8 colors, 2 tubes) with a sen-
sitivity of 10-5. Quality checks were done to compare sensitivity and to show
correlation between protocols (Hofste op Bruinink D, ASH 2016 abstract 2072).
Results: A total of 316 patients could be evaluated before maintenance: median
age was 57 years (IQR: 52-62), 18% (57/316) had ISS III and 22% (70/316)
had high risk cytogenetic abnormalities defined as presence of either one
among del17, t(4;14) or t(14;16); 63% (199/316) had received HDM and 37%
(117/316) VMP; thereafter 51% (160/316) had received VRD. After a median
follow-up of 30 months from MRD enrolment, 76% (239/316) patients were
MRD-negative: 64% (153/239) in the HDM vs 36% (86/239) in the VMP groups.
The 3-year PFS was 50% in MRD-positive vs 77% in MRD-negative patients
(HR 2.87, 95% CI: 1.75 - 4.72; p<0.001). Subgroup analyses were carried out
to assess the risk factors for MRD-positivity according to baseline characteris-
tics and therapies: high risk cytogenetic abnormalities were the most important
risk factors (HR 9.87, 95% CI: 4.3 – 22.63; interaction-p=0.001). Finally, 48%
of MRD positive patients at pre-maintenance who had a second MRD evalua-
tion after at least 1 year of lenalidomide became MRD-negative.
Summary/Conclusions: MRD by MFC is a strong prognostic factor in MM
patients receiving intensification with novel agents or transplant; lenalidomide
maintenance further improved depth of response; high risk cytogenetic abnor-
malities are the most important prognostic factors in MRD-positive patients.
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PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN
RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/ REFRACTORY
MULTIPLE MYELOMA
W. Zhang1,*, W. Zhao1, J. Liu1, A. He1, Y. Chen1, X. Cao1, N. Yang1, B. Wang1,
P. Zhang1, Y. Zhang1, F. Wang1, B. Lei1, L. Gu1, Y. Yang1, J. Bai1, R. Zhang1,
X. Wang1, X. Ma1, J. Wang1, J. Wang1, L. Wei1, J. Zhang1, X. Zang1,
Q. Zhuang2, F.X. Fan2
1Hematology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an,
2Nanjing Legend Biotech, Nanjing, China
Background: Immunotherapy has emerged as a potentially curative treatment
in hematological malignancies. Uniformly expressed in plasma cells, B-cell
maturation antigen (BCMA) is an appropriate target antigens for CAR T-cell
therapies in multiple myeloma.
Aims: This phase I, open-label trial was conducted to assess the efficacy and
2 | haematologica | 2017; 102(s2)
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safety profile of LCAR-B38M anti-BCMA CAR T cells in patients with
relapsed/refractory multiple myeloma.
Methods: All patients underwent leukapheresis to obtain peripheral blood
mononuclear cells and their T cells were engineered to express anti-BCMA
CAR. Three doses of 300 mg/m2 cyclophosphamide were administered on day
-5, -4, and -3 (before the recruitment, patients took the same chemotherapy to
identify they were refractory to cyclophosphamide monotherapy) and engi-
neered-T cells were reinfused on day 0, 2, and 6. This trial was divided into the
dose escalation stage and expansion cohort. Toxicity and responses were
assessed according to the Common Terminology Criteria for Adverse Events
(version 4.0) and International Myeloma Working Group (IMWG) Uniform
Response Criteria for Multiple Myeloma, respectively.
Results: As of the February 20th, 2017 data cut-off, 22 patients had been
enrolled, two of whom were diagnosed as plasma cell leukemia. The male: female
ratio was 11:11 and median age was 53.5 years. Chromosomal abnormalities
were detectable by FISH in eight patients, two of whom involved in the deficiency
of p53. Eleven patients were triple refractory (chemotherapy, proteasome
inhibitors, and immunomodulatory drugs), 11 resisted to double prior treatments
(chemotherapy and proteasome inhibitors/ immunomodulatory drugs), and four
relapsed after autologous hematopoietic stem cell transplant. The median number
of infused CAR T cells was 4.0×10E6 (range, 1.5×10E6-7.0×10E6) per kg. The
median follow-up was 131.5 (range, 29-327) days. 100% of patients achieved an
objective response. The first six patients achieved complete responses with flow
MRD-negative; 14 patients achieved very good partial responses; one patient,
with renal failure, achieved partial response; all these 22 patients had kept their
best response at the end of follow-up. The pictures we enclosed were the sub-
cutaneous nodules in one patient with extramedullary plasmacytoma. We found
that the nodules were obviously decreased after the infusion and disappeared
finally. Another one achieved transient partial response, which last for 12 days.
He then took the secondary infusion but failed since the post-operation large-
dose administration of corticosteroid for spinal meningioma. He terminally died
of the progression of myeloma. The most common toxicity attributable to CAR T
cells was cytokine release syndrome (CRS). Toxicities were minimal except for
two grade 3 CRS and one grade 4 CRS. All CRSs were controllable with nons-
teroidal anti-inflammatory drugs (NSAIDs) or tocilizumab and no dose-limiting
toxicities or treatment-related deaths were observed (Figure 1).
Figure 1.
Summary/Conclusions: Our findings demonstrated the safety and antimyelo-
ma activity of LCAR-B38M anti-BCMA CAR T cells.
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PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS TREATED WITH NEOD001
ACHIEVE RAPID ORGAN RESPONSES THAT ARE INDEPENDENT OF
PREVIOUS PLASMA CELL–DIRECTED THERAPIES
M.A. Gertz1,*, R.L. Comenzo2, H. Landau3, V. Sanchorawala4, B.M. Weiss5,
J.A. Zonder6, J. Walling7, G.G. Kinney8, M. Koller8, D.B. Schenk8,
S.D. Guthrie8, E. Liu8, M. Liedtke9
1Mayo Clinic, Rochester, 2Tufts Medical Center, Boston, 3Memorial Sloan Ket-
tering Cancer Center, New York, 4Boston University School of Medicine and
Boston Medical Center, Boston, 5University of Pennsylvania, Philadelphia, 6Kar-
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Background: Light chain (AL) amyloidosis is a rare and often fatal disease
caused by the accumulation of misfolded light chain (LC) aggregates that can
lead to progressive failure of critical organs, causing significant morbidity and
mortality. Patients’ survival depends upon rapid suppression of the misfolded
LC and stabilization or recovery of organ function. Current therapies limit LC
production; however, ~75% of patients have persistent organ dysfunction.
NEOD001 is a novel investigational monoclonal antibody that targets misfolded
LC and may neutralize circulating LC aggregates and clear insoluble deposits. 
Aims: To assess the association between responses and time, depth, number
or type of previous plasma cell–directed (PCD) treatments and organ response.
Methods: Inclusion criteria for this trial were: completed ≥1 PCD treatment
before enrollment, attained partial hematologic response (HR) or better to any
previous therapy, and have persistent organ dysfunction. NEOD001 was admin-
istered intravenously every 28 days. During the dose-escalation phase, 27
patients received NEOD001 at 0.5, 1, 2, 4, 8, 16, or 24 mg/kg in a 3+3 study
design. In the expansion phase, 42 additional patients with renal, cardiac, or
nerve involvement were enrolled and treated (24 mg/kg). We assessed cardiac
and renal best responses based on consensus criteria. Peripheral nervous sys-
tem (PN) responses were assessed at month 10 (after 9 infusions) using the
Neuropathy Impairment Score–Lower Limbs (NIS-LL). We explored the poten-
tial impact on organ response of the number and type of organs affected and
the number of, type of, and time since previous therapies at baseline.
Results: In the overall population (N=69), the median age was 61 years (61%
male). Median (range) time since diagnosis was 2.9 (0.4-16.0) years, and 45%
of patients underwent ≥3 previous PCD regimens. Median time to first best
response was 1.8 (cardiac), 3.7 (renal), and 1.0 (PN) months. Best response
rate indicating organ response was observed in 53% of cardiac-evaluable patients
(n=19/36) and 64% of renal-evaluable patients (n=23/36). PN responses were
observed in 82% (n=9/11) of PN-evaluable patients. Time from patients’ best HR
to previous PCD treatment was not related to the attainment of NEOD001 organ
response (responder/stable: 35.6/36/6 months [cardiac] and 30.6/32.5 months
[renal]; P>0.05). Depth of patients’ best HR also was not related to the attainment
of NEOD001 organ response (percentage of patients with organ response in
CR/VGPR/PR after PCD: 47.1/66.7/42.9% [cardiac] and 68.8/63.6/62.5% [renal];
P>0.05). Similarly, time or depth of patients’ last HR did not impact the NEOD001
organ response rate (P>0.05). Patients with NEOD001 organ responses were
no more likely to have had their last PCD therapy <6 than ≥6 months from their
first NEOD001 dose. Patients’ previous PCD treatment type was not related to
the attainment of NEOD001 organ response (percentage of patients undergoing:
stem cell transplantation, 55.6/61.1% [cardiac/renal]; bortezomib-based therapy,
52.0/68.8%; or other chemotherapy, 50.0/57.1%; P>0.05). Exploratory analyses
showed no association between the time to response or percentage of responders
and the number of previous PCD treatments.
Summary/Conclusions: NEOD001 specifically targets disease-causing, mis-
folded LC aggregates in AL amyloidosis. Organ responses in patients treated
with monthly NEOD001 infusions were achieved rapidly and independently of
time since previous chemotherapy, depth of hematologic response, or predom-
inant type of PCD treatment.
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RITUXIMAB MAINTENANCE AFTER AUTOLOGOUS TEM CELL TRANS-
PLANTATION PROLONGS SURVIVAL IN YOUNGER PATIENTS WITH
MANTLE CELL LYMPHOMA: FINAL RESULTS OF THE LYMA TRIAL OF
THE LYSA/GOELAMS GROUP
S. Le Gouill1,*, C. Thieblemont2, L. Oberic3, A. Moreau4, K. Nouabdallah5,
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Background: Mantle cell lymphoma (MCL) is currently an incurable disease.
In spite of high complete response rates (CR) after initial immunochemotherapy
induction followed by autologous stem cell transplantation (ASCT), MCL
patients experience iterative relapses. 
Aims: We investigated whether or not rituximab maintenance (RM; 375mg/m2
every 2 months for 3 years) after ASCT prolongs response duration.
Methods: This phase III trial included 299 patients (<66y) at diagnosis, of
whom 240 were randomly assigned to RM or observation after ASCT. The pri-
mary end point was event-free survival (EFS) (progression, relapse, death,
severe infection during RM) after ASCT. 
Results: After 4 courses of immunochemotherapy induction (R-DHAP; Ritux-
imab, dexamethasone, cytarabine, platinium derivative), overall response and
CR rates were 89.3% and 77.3%, respectively. ASCT was performed in 257
patients. Median follow-up from randomization after ASCT was 50.2 (46.4-
54.2) months. Starting from randomization, 4-year EFS was 78.9% (95%CI;
69.5 to 85.6) for RM (n=120) versus 61.4% (95%CI; 51.3 to 69.9) for observa-
tion (n=120) (p=0.0012), 4-year progression-free survival (PFS) was 82.2%
(95%CI; 73.2 to 88.4) for RM versus 64.6% (95%CI; 54.6 to 73) for observation
(p=0.0005) and OS was 88.7% (95%CI; 80.7 to 93.5) for RM versus 81.4%
(95%CI; 72.3 to 87.7) for observation (p=0.0413). The death rate was lower
for patients in the RM arm were less likely to die (hazard ratio (HR)=0.5; 95%CI,
0.255 to 0.986) than for patients in the observation arm. 
Summary/Conclusions: The LyMa trial demonstrates for the first time that
RM after ASCT prolongs EFS, PFS and OS. Thus, 4 courses of R-DHAP plus
ASCT (without TBI) followed by RM maintenance (one infusion every 2 month
for 3 years) is a new standard of care for young MCL patients.
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POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB,
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS
WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
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Background: Polatuzumab vedotin (pola) is an antibody drug conjugate con-
taining the anti-mitotic MMAE targeting CD79b, an antigen expressed ubiqui-
tously in DLBCL. Pola as monotherapy and in combination with anti-CD20 anti-
bodies demonstrated encouraging efficacy in r/r DLBCL.1,2 The initial dose-
escalation portion of this multicenter, open-label Ph Ib/II study of pola in com-
bination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-
R-CHP) showed an acceptable safety profile and established a recommended
Ph II dose of pola at 1.8 mg/kg.3 We report updated safety and efficacy results
for the Ph II dose in 45 previously untreated DLBCL patients (pts) (ClinicalTri-
als.gov NCT01992653).
Aims: To evaluate the safety and efficacy of pola-R-CHP as first-line treatment
in patients with DLBCL.
Methods: Five pts of the dose escalation phase and the 40 pts of the expansion
phase were included in this analysis. All pts provided informed consent to par-
ticipate in the study. All had newly diagnosed DLBCL and were treated with
pola at 1.8 mg/kg and R-CHP at standard doses every 21 days for 6 or 8 cycles.
Investigator assessments for anti-tumor activity were performed according to
IWG 2007 following 4 cycles and at the end of study treatment (EOT). 
Results: All 45 pts received at least one dose of study drug. The median age
was 69 years; 93% were >60 years, 33% ECOG >1, 82% Stage III/IV, and 78%
IPI 3-5. Of the 29 pts with cell of origin (COO) status by digital gene expression,
11 (38%) were ABC, 14 (48%) were GCB, while 4 (14%) were unclassified. Forty
patients completed 6 or 8 cycles (23 and 17 pts respectively). All pts experienced
at least one AE. Grade (Gr) 3/4 AEs occurred in 58%, and one pt experienced a
Gr 5 atrial fibrillation. Gr 3/4 neutropenia and febrile neutropenia (FN) occurred
in 27% and 11%. Serious adverse events (SAEs) were reported in 17 pts (38%)
including 3 FN, and 2 each of neutropenia, pneumonia, pulmonary embolism
and influenza A. Peripheral neuropathy (PN) occurred in 18 (40%) patients.
Among these pts with PN, 12 were Gr 1, 4 were Gr 2, and 2 were Gr 3. All Gr 2/3
PN attributed to pola occurred at C5 or later. Four pts discontinued pola early for
the following reasons: Gr 5 atrial fibrillation (after C2, not attributed to pola by
investigator), E. coli UTI (C5), worsening essential tremor (C3), PN (C7). During
treatment, 6 pts had dose reductions in pola and 1 pt had cyclophosphamide
and doxorubicin dose reductions. ORR by PET at EOT was 91%; 78% had a CR
and 13% PR. 3 pts progressed and 1 was unevaluable. In the COO determined
population, CR was 91% in ABC and 86% in GCB pts. At the data cutoff of
November 4, 2016 with a median study duration of 9.5 months, (range 1.3-28
months), only 1 pt had a disease progression in follow up. 
Summary/Conclusions: Pola at 1.8 mg/kg in combination with R-CHP in 1L
DLBCL has an acceptable safety profile and produced promising response
rates at the end of treatment. The majority of the patients in this trial represented
a poor prognosis group by age and IPI. In this context, treatment response to
this regimen may warrant further exploration.
References
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RITUXIMAB SC AND IV PLUS CHOP SHOW SIMILAR EFFICACY AND
SAFETY IN THE RANDOMIZED MABEASE STUDY IN FIRST-LINE DLBCL 
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Background: Intravenous (IV) rituximab plus chemotherapy is standard treat-
ment for diffuse large B-cell lymphoma (DLBCL). A subcutaneous (SC) formu-
lation of rituximab may simplify treatment and reduce burden.
Aims: MabEase (NCT01649856) studied efficacy, safety and patient (pt) sat-
isfaction with rituximab SC or IV plus CHOP as first-line DLBCL treatment.
Methods: Pts were randomized 2:1 to rituximab SC (IV 375mg/m2 cycle 1; SC
1400mg cycles 2–8) or IV (375mg/m2 cycles 1–8) plus CHOP every 14 or 21
days. The primary endpoint was investigator-assessed complete response
(CR)/unconfirmed CR (CRu) at the end of induction (EOI). Secondary endpoints
included safety, survival, treatment satisfaction (Cancer Treatment Satisfaction
Questionnaire [CTSQ], Rituximab Administration Satisfaction Questionnaire
[RASQ]) and time savings. Follow-up continued until at least 24 months after
EOI in the last patient recruited.
Results: Of 576 pts (381 SC; 195 IV), 572 (378 SC; 194 IV) received treatment.
EOI CR/CRu rates were 50.6% (95% CI 45.3–55.9) and 42.4 (95% CI 35.1–
49.7) in the SC and IV groups, respectively (Table 1). After 35 months’ median
follow-up, median progression-free survival (PFS), event-free survival (EFS) and
overall survival (OS) were not reached in either arm and no statistically significant
differences were observed between treatment arms. PFS, EFS and OS rates
were also similar at 24 months’ follow-up (non-significant differences; Table 1).
Grade ³3 adverse events (58.3% SC; 54.3% IV) and administration-related reac-
tions (21% in both groups) were similar between arms. Of SC recipients, 5.7%
had injection site reactions vs none in the IV group (p<0.001). Febrile neutropenia
occurred more often in the SC arm (12.5% vs 6.9% in IV, p=0.06). RASQ scores
for ‘impact on activities of daily living’, ‘convenience’ and ‘satisfaction’ were
improved with SC vs IV; CTSQ scores were similar between arms (Figure 1).
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When pts in the SC group were asked, if given the option, which treatment they
would prefer, 90.8% stated a preference for SC over IV. Median administration
time (6 minutes SC vs 2.6–3.0 hours IV) and chair/bed and overall hospital times
were shorter with SC than with IV treatment.
Table 1. Efficacy endpoints in the intent-to-treat population.
Figure 1. Patient satisfaction at cycle 3 and cycle 7 of treatment.
Summary/Conclusions: Rituximab SC had similar efficacy and safety to the
IV form, with improvements in patient satisfaction ratings, and
administration/hospital time savings. Our findings support the use of rituximab
SC in this setting. 
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ANALYSIS AND CHARACTERIZATION OF HEMATOLOGIC CANCERS
USING A COMPREHENSIVE NGS PANEL COMPRISED OF DNA AND RNA
BAITS TARGETING 704 GENES 
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Background: As next-generation sequencing (NGS) methodologies improve,
so does the ability to characterize hematopoietic and lymphoid neoplasm
genomes. This promises to revolutionize oncology, allowing more accurate and
precise classification of patients and potentially leading to novel targeted and
combination therapies with improved outcomes.
Aims: We constructed a custom targeted sequencing panel, MyHEME™, to
comprehensively identify and characterize DNA and RNA changes in a broad
range of hematologic malignancies, including Non-Hodgkin lymphoma
(NHL).
Methods: The MyHEME targeted sequencing panel is comprised of two inde-
pendent bait sets that target a combined 704 genes known or predicted to con-
tribute to hematologic cancers (DNA baits for 571 genes and RNA baits for 361
genes; 228 genes are found in common between the two bait sets). Libraries
were constructed using 1μg of DNA or 0.1μg of RNA and sequenced on an Illu-
mina platform. Sequenced reads are analyzed using proprietary MyInformat-
ics™ software to identify single nucleotide variants (SNVs), indels and structural
variants (SVs). Both the MyHEME panel and MyInformatics software were cre-
ated under ISO13485 design control. To characterize the performance metrics
of the MyHEME panel, we used the NIST human reference sample NA12878
along with combinations of hematologic cancer derived cell lines with known
pathogenic variants at various allelic frequencies.
Results: Analytical validation of the MyHEME panel established an average
read depth of 1,175x (with a median read depth of 1,088x) for the DNA targets
and an average transcripts per million (TPM) of 2,256 (with a median TPM of
743) for the RNA targets. For the DNA targets, we establish sensitivity >95%
(99.8% for SNVs at a 2.5% limit of detection (LOD); 100% for coding indels at
a 5.0% LOD) and specificity >95% (95.5% for SNVs at a 2.5% LOD; 97.7% for
coding indels at a 5.0% LOD). We also show the ability to cross-confirm results
between the 228 genes common to both the DNA and RNA targets. Importantly,
novel gene fusions, which are generally difficult to detect and validate, were
cross-confirmed when observed in both the DNA and RNA targets. For example,
we identified a novel t(9;22) translocation causing a NUP214-XKR3 gene fusion
using both the DNA and RNA targets. Additionally, while RNA data provides
the fused exons of the transcripts, DNA data gives the precise genomic break-
point coordinat
Summary/Conclusions: MyHEME is an extensive panel for sensitively and
specifically identifying SNV, indel and SV mutations in 704 target genes. This
panel can comprehensively characterize mutations in multiple diverse hema-
tologic cancer samples, including Non-Hodgkin Lymphoma, AML, ALL, and
Multiple Myeloma. By utilizing a high depth of coverage, MyHEME can accu-
rately detect clones present down to 5% of a patient’s sample. In addition, by
targeting both DNA and RNA, MyHEME contains a built in validation method
to cross-confirm novel variants of interest.
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TP53 MUTATIONS, BUT NOT DELETION OF TP53 AND CDKN2A, HAVE
INDEPENDENT PROGNOSTIC VALUE IN MANTLE CELL LYMPHOMA
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Background: During the past decades, the outcome of MCL treatment has
improved substantially in younger patients. However, the course of disease
remains heterogeneous, and there is a need for better stratification of patients
with poor responses from those with durable responses. The Nordic trials,
MCL2 and MCL3, represent standard-of-care regimens for younger MCL
patients.
Aims: Preliminary analyses of diagnostic samples from MCL2 and MCL3, show
that TP53 mutations are associated with significantly poorer outcome. Recently,
deletions of TP53 and CDKN2A was shown to confer negative impact in a
cohort similar to the Nordic.(Delfau-Larue et al., 2015) Thus, in this study we
aim to describe the prevalence and impact of deletions of TP53 and CDKN2A
in the light of TP53 mutations.
Methods: Fresh frozen DNA from diagnostic bone marrow samples from MCL2
and MCL3 were analyzed. In both trials, patients received intensified first-line
induction therapy with alternating courses of R-CHOP and R-hd-Cytarabine
and consolidation with high-dose therapy and ASCT. (Geisler et al., 2008; Kol-
stad et al., 2014). Targeted NGS of ATM, CCND1, TP53, KMT2D, NOTCH1,
NOTCH2, WHSC1 and BIRC3 was performed by Ion Torrent Technology. Cut-
off for calling a mutation was set to a variant allele frequency >3%. Median
coverage was >2700X. Copy Number Variations (CNVs) of TP53 and CDKN2A
were measured by droplet digital PCR by commercially available assays, and
RPP30 used as a standard control.
Results: We investigated the presence of CDKN2A and TP53 deletions in diag-
nostic samples from 175 and 157 patients, respectively. Patients were untreated
and <66 years (median 58, range 37-65). Fifty-three percent were either MIPI
intermediate- or high-risk, 17% had blastoid morphology and 42% had
Ki67≥30%, and 83% had bone marrow involvement at diagnosis. After a median
follow-up of 9.2 years, median overall (OS), progression-free survival (PFS)
and cumulated incidence of relapse (CIR) of all patients were 12.4 and 8.2 and
10.2 years, respectively. In our mutational analyses (n=147), only TP53 had
prognostic impact in multivariate analyses (MVAs). Outcome of the 15 patients
(10%) with TP53-mutations was poor with a median OS, PFS and CIR of 1.8,
1.0 and 1.2 years (p<0.0001 for all three outcomes), respectively. Preliminary
data shows deletions of TP53 in 28 patients (18%) and deletion of CDKN2A in
38 (22%). Eight patients carried both deletions. Del-CDKN2A was significantly
associated with mutations of TP53, MIPI high risk, blastoid morphology and
Ki67>30%. Del-TP53 was associated with Ki67>30%, but no other high risk
markers. Altogether, 31 (25%) of 122 patients harbored a deletion and/or muta-
tion in TP53 and 4 (3%) carried both aberrations. In univariate analyses, del-
TP53 was significantly associated with poor OS (p=0.01), but not PFS and CIR,
whereas del-CDKN2A was significant for CIR (p=0.02), but not OS and PFS.
Patients with both deletions did significantly worse for all three endpoints. In
MVA, (including all factors with significance in univariate analyses: MIPI, blastoid
morphology, Ki67-index>30%, NOTCH1 mutations, TP53 mutations, del-TP53
and del-CDKN2A) only mutations of TP53 remained a significant predictor of
outcome.
Summary/Conclusions: Here we evaluate the impact of TP53- and CDKN2A-
deletions in the context of TP53 mutations of younger, optimally treated MCL
patients. In line with previous reports, both deletions were associated with poor-
er outcome; however, in multivariate analyses only TP53 mutations was an
independent prognostic factor, substantiating its role as a biomarker for
response to the standard-of-care immune-chemotherapy.
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DEEP MOLECULAR RESPONSE TO GILTERITINIB IMPROVES SURVIVAL
IN FLT3 MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE
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Background: Mutations in Fms-like tyrosine kinase 3 (FLT3) are common in
patients with acute myeloid leukemia (AML) and are associated with an aggressive
disease course and a poor prognosis. Notably, FLT3 internal tandem duplications
(ITD) predict early relapse and short overall survival (OS) after chemotherapy.
Gilteritinib, a highly selective FLT3/AXL inhibitor, has displayed antileukemic activity
in FLT3 mutation-positive (FLT3mut+) relapsed/refractory (R/R) AML in the
CHRYSALIS Phase 1/2 study (NCT02014558), specifically at doses ≥80 mg/d.
Aims: To assess molecular response to gilteritinib in a CHRYSALIS subpop-
ulation. 
Methods: This exploratory analysis evaluated molecular response in patients
aged ≥18 years with FLT3mut+R/R AML who had been treated with 120 or 200
mg/d gilteritinib. These doses were identified due to their ability to induce high
clinical response rates, and consistent, potent FLT3 inhibition in correlative
assays. Molecular response was assessed in patients who had bone marrow
aspirates obtained at baseline and at ≥1 additional time point. FLT3-ITD and
total FLT3 were quantified by next-generation sequencing to assess molecular
response. A Cox regression model of OS by Kaplan-Meier estimation estab-
lished a FLT3-ITD:total FLT3 ratio (ITD signal ratio) of 10−2 as the threshold for
improved survival. 
Results: Of the 147 FLT3-ITDmut+patients who had received gilteritinib 120 or
200 mg/d, 80 patients had bone marrow aspirates at baseline and at ≥1 addi-
tional time point, and were included in this analysis. The composite response
rate (defined as CR plus CRi plus CRp) for these 80 patients was 55%. During
response, 20 patients (25%) had an ITD signal ratio of ≤10−2. Of these 20
patients, 18 had an ITD signal ratio of ≤10−3 (major molecular response [MMR])
and 13 had an ITD signal ratio of ≤10−4 (minimal residual disease [MRD] neg-
ative). The median time to achieve minimum ITD signal ratio was 54 days.
Elimination of morphologic leukemia was observed in 80% of patients with ITD
signal ratios <10−2. Patients who had an ITD signal ratio ≤10−2, MMR, or were
MRD negative had significantly longer median OS than those who did not
(Table 1 and Figure 1).
Table 1. Overall survival in subjects who achieved a molecular response
compared with those who did not by depth of response.
Figure 1.
Summary/Conclusions: Molecular responses to gilteritinib in FLT3-
ITDmut+R/R AML correlated with clinical response and improved OS. This is
the first demonstration of a robust molecular response to a FLT3 inhibitor in
AML. These data suggest that the ITD signal ratio may predict a durable clinical
benefit of gilteritinib therapy and validate FLT3 as a critical therapeutic target
in AML. 
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RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH
NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE
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Background: A comprehensive AML risk assessment, based on the integration
of cytogenetic/genetic data and minimal residual disease (MRD) status, can
help optimize patients’ (pts) therapeutic post-remission allocation. 
Aims: To evaluate the feasibility and results of a phase II trial of intensive
chemotherapy in which risk-assignment and post-remission therapy of young
patients with AML was based on pre-treatment cytogenetic/genetic data and
post-consolidation levels of MRD.
Methods: Between January 2012 and May 2015, 515 pts with de novo AML,
18 to 60 years old, seen at 55 GIMEMA institutions were enrolled in the trial.
Induction consisted of i.v. daunorubicin 50 mg/m2 daily on days 1,3 and 5; i.v.
etoposide 50 mg/m2 daily on days 1 to 5; i.v. cytarabine 100 mg/m2 as a daily
continuous infusion, days 1 to 10. All pts in CR/CRi after 1-2 induction cycles,
received 1 consolidation course consisting of i.v. daunorubicin 50 mg/m2 daily
on days 4,5 and 6 and i.v. cytarabine 500 mg/m2 every 12 hours on days 1 to
6. In pts belonging to ELN low or intermediate-risk category, peripheral blood
stem cell collection was attempted by initiating, on day 20 from the start of
consolidation therapy, G-CSF until completion of stem cell collection. Post-
consolidation therapy was based on risk-allocation. Low-risk pts (NPM1 positive
FLT3-ITD negative or CBF positive without c-Kit mutations) were to receive
AuSCT; high-risk pts (adverse karyotype or FLT3-ITD positive) were to receive
ASCT; intermediate-risk pts (intermediate karyotype or FLT3-TKD positive or
c-kit mutated CBF positive) were to receive AuSCT or ASCT depending on the
levels of MRD, measured by flow cytometry after consolidation therapy. Allo-
cation to ASCT required the procedure to be performed whatever the source
of stem cells (identical sibling, unrelated, cord blood, haploidentical).
Results: 500/515 pts started treatment and were available for the analysis.
Median age was 49 (18-61) years and 52% were males. Of 429 evaluable pts,
ELN cytogenetic distribution was: low-risk 11%, intermediate-risk 73% and
poor-risk 16%. RUNX1/RUNX1T1 was detected in 5% of 499 evaluable cases,
CBFbeta/MYH11 in 7% of 496, FLT3-ITD in 25% of 497 and NPM1 in 37% of
499. In 494 evaluable pts, complete remission rate (CR) was 73% (361), 18%
had refractory AML and 9% died early during induction. Three hundred-41 pts
completed the consolidation phase and were risk allocated: 114 (33%) to the
low-risk category (=AuSCT), 122 (36%) to the high-risk (=ASCT) and 78 (23%)
to the intermediate category (=AuSCT or ASCT). In 27 pts (8%) belonging to
the intermediate-risk category, a leukemia associated phenotype was not found
and they were to receive AuSCT. Overall, 109 (33%) and 123 (36%) of 341 pts
received AuSCT and ASCT, respectively. Median follow-up was 27.9 months.
At 24 months, overall (OS) and disease free survival (DFS) of the whole series
was 55.9% and 54.9%, respectively; cumulative incidence of relapse was
32.9%. At the same time point of 24 months, OS and DFS in the low-risk cat-
egory was 74.8% and 63.8%, respectively; in the high-risk category 42.5% and
44.8%, respectively; in the intermediate-risk category MRD negative 78.6%
and 61.4%, respectively; in the intermediate-risk category MRD positive 69.8%
and 66.6%, respectively (Figure 1).
Summary/Conclusions: A program of risk-adapted, MRD-driven therapy is
feasible in a multicenter, cooperative setting. In the intermediate-risk category,
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ASCT can be avoided if MRD is not detectable; if MRD is positive, ASCT can
prolong OS and DFS to equalize those of the low-risk category. ASCT was
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Background: The detection of minimal residual disease (MRD) in patients with
acute myeloid leukemia (AML) may improve future risk-adapted strategies of
AML treatment. The presence of MRD after induction treatment has firmly been
shown to predict for relapse and overall outcome, irrespective of type of post-
remission treatment (PRT). Currently it is unknown whether and how the pres-
ence or absence of MRD should guide the application of allogeneic hematopoi-
etic stem cell transplantation (alloHSCT) as PRT.
Aims: We addressed whether and to what extent alloHSCT quantitatively
reduces relapse as compared to conventional post-remission treatment (PRT)
in upfront treated patients with MRD positive or MRD negative AML in first
hematological complete remission (CR1).
Methods: A total of 1,511 patients were treated in subsequent HOVON-SAKK
AML trials of whom 547 patients obtained a CR1, received PRT and had avail-
able flow cytometric MRD prior to PRT. MRD positivity was defined by more
than 0.1% cells with a leukemia associated phenotype within the white blood
cell compartment. MRD status was not known by clinicians during AML treat-
ment. PRT consisted of alloHSCT (n=282), or conventional PRT by a third cycle
of chemotherapy (n=160) or autologous HSCT (n=105). Endpoints of the study
included overall survival (OS), relapse-free survival (RFS), and cumulative inci-
dences of relapse and non-relapse mortality (NRM) at 4 years. A time-depen-
dent analysis was performed by applying multivariable Cox regression with
time-dependent covariate alloHSCT with the cumulative incidence of relapse
as primary endpoint.
Results: MRD was positive in 129 (24%) patients after induction chemotherapy
before proceeding to PRT. The latest European LeukemiaNET risk classification
was similarly distributed among MRD negative and MRD positive patients. No
differences were present in transplant characteristics in MRD positive and MRD
negative patients. OS and RFS was significantly better in patients without MRD
prior to PRT as compared to MRD positive patients (65±2% compared to 50±5%
at 4 years, p=0.002, and 58±3% compared to 38±4%, p<0.001, respectively).
Improved outcome was mainly caused by a lower cumulative incidence of
relapse in MRD negative patients as compared to MRD positive patients
(32±2% compared to 54±4% at 4 years, p<0.001, respectively), while NRM
was not significantly different and estimated 10±1%. NRM split by EBMT risk
score showed less NRM in patients with a low EBMT-risk score as compared
to patients with a high EBMT risk score (≤2 compared to >2, 10±2% compared
to 22±4%, p=0.005, respectively). Multivariable analysis with adjustment for
covariates showed that the incidence of relapse was significantly reduced fol-
lowing alloHSCT as compared to chemotherapy or autologous HSCT (HR 0.36,
p<0.001), which was similarly exerted in MRD negative and positive patients
(HR 0.38, p<0.001 and HR 0.35, p<0.001). RFS was also improved following
alloHSCT as compared to chemotherapy or autoHSCT (HR 0.53, p<0.001),
while no significant differences were found for OS (Figure 1).
Figure 1.
Summary/Conclusions: The graft-versus-leukemia effect of alloHSCT is
equally present in MRD positive and MRD negative patients, which advocates
a personalized application of alloHSCT taking the risk of relapse determined
by AML risk group and MRD status as well as the counterbalancing risk of NRM
into account.
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Background: Despite up-to-date risk algorithms, outcome in acute myeloid
leukemia patients is still difficult to predict. Even in good risk patients relapses
occur. Further refinement of currently used risk classifications is therefore war-
ranted. Measurable residual disease (MRD) is a well-known risk factor and the
independent prognostic impact of MRD was shown for patients independent
on risk groups. Nowadays prospective studies are designed on which therapy
is adapted based on MRD-positivity or negativity. Although this is a major
improvement for risk stratification, relapses occur in a substantial proportion of
MRD-negative patients. Previous retrospective studies have shown that the
leukemic stem cell (LSC) frequency harbors important prognostic information
as well (Bradbury et al., Leukemia 2015), even within MRD-negative patients
(Terwijn et al. Plos one, 2013).
Aims: In this study we used data of the HOVON/SAKK H102 trial to prospec-
tively define, using flow cytometry, the leukemic CD34+CD38- stem cell fre-
quencies and MRD frequencies to investigate impact on patient outcome. 
Methods: In 242 patients who achieved morphologic complete remission, both
LSC and MRD data after two cycles of chemotherapy treatment were available.
MRD-positivity was defined as a percentage of MRD-positive cells above 0.1%
(as compared to total amount of WBCs) and LSC-positivity was defined as a
CD34+CD38-LSC percentage above 0.0000% (LSC cut-off 0.0000%; thus no
CD34+CD38-LSC events measured).
Results: Cumulative incidence of relapse (CIR) and overall survival (OS) data
were investigated for four different MRD/LSC groups: 1. MRDneg +LSCnegpa-
tients (n=136) 2. MRDpos +LSCneg patients (n=28) 3. MRDneg +LSCpospatients
(n=58) and 4. MRDpos +LSCpos patients (n=20). Results showed that MRDpos
+LSCpospatients have the worst prognosis. 3-year CIR for the four above-
defined groups was 35% (SE 4), 43% (SE 9), 53% (SE 7), and 100% (SE 0),
respectively. Similar results were found for OS: 3-year OS was 66% (SE 4),
68% (SE 9), 53% (SE 8), and 100%, respectively, with 17 patients dead and 3
censored in the latter group. When investigating the impact of MRD/LSC status
in the good, intermediate, poor and very poor risk group (according to HOVON),
patient numbers were sometimes small; however, results show that MRDpos
+LSCposAML patients in all different risk categories have a very poor prognosis.
Moreover, multivariate analyses, containing all well known risk factors including
risk group and post remission treatment, showed that MRDpos +LSCpospatients
have a significantly worse cumulative incidence of relapse (hazard ratio [HR]
5.89; 95% CI 3.32-10.47) and overall survival (HR 3.62; 95% CI 1.86-7.04) as
compared to the MRDneg +LSCneg patient group.
Summary/Conclusions: Overall, we conclude that our prospective results
show that CD34+CD38-LSC frequency has important additional value in MRD
assessment and that it especially enables to identify very poor risk patients in
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all different currently used risk categories. These data urge to include both
MRD and LSC in future AML risk classification to better inform post-remission
treatment.
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Background: In AML response by morphology after a first cycle of induction
therapy is used to guide further therapy including second cycles of induction
and choice of consolidation. It is still uncertain how the quality of response
post cycle 1 with inclusion of MRD assessment impacts on outcomes within
AML risk subgroups including NPM1 wild type standard risk and whether this
adds information to MRD status in CR post cycle 2. 
Aims: To quantify the effect of MRD positivity for response after each cycle of
induction therapy in younger patients with AML.
Methods: As part of the UK NCRI AML17 trial (ISRCTN: 55675535) for patients
with AML or high risk MDS up to the age of 60, prospective flow cytometric
MRD (MFC-MRD) monitoring was performed after each course of induction.
Any level of MRD detected was considered MRD+(sensitivity thresholds:
~0.02% by tracking diagnostic leukemic aberrant phenotypes /LAIP, ~0.05-
0.1% by “different-from normal” blast LAIP). Clinicians were not informed of
MFC-MRD results. Following their first cycle of induction with daunorubicin/ara-
C based therapy, patients were allocated a risk group by a validated score
(comprising cytogenetics, WBC, age, secondary disease, blast response to
cycle 1 and mutation status). Poor risk patients received intensified therapy in
cycle 2 with a view of proceeding to SCT.
Results: MFC-MRD results after either induction course are available for 1555
patients randomised from 4/09-12/14 (median age 51, range 0-73). Cycle 1
(C1) response data with MFC-MRD was available for 1,400 patients. 70%
achieved morphological CR at this time-point; 14% had resistant disease (RD)
and 16% were in partial remission (PR) according to clinician. Of patients in
CR (n=984) 56% had detectable MFC-MRD (MRD+). Excluding poor-risk
patients 14% of patients did not achieve CR (7% RD, 7% PR), 51% of patients
in CR were MRD+. 5 year OS for MRD- vs MRD+vs PR vs RD were 63% vs
44% vs 37% vs 25% for all patients; 69% vs 51% vs 50% vs 30% excluding
poor risk patients and 66% vs 49% vs 49% vs 30% for standard risk alone
(Figure 1). The similar OS in this group between CR MRD+and PR at C1 was
maintained in NPM1wt standard risk patients and if censored at stem cell trans-
plant. 771 patients were in CR post cycle 2 (C2) and provided MFC-MRD data.
As expected, there were significant differences in 5 year OS between CR MFC
MRD+vs CR MFC MRD- for all patients (35% vs 63%) and excluding poor-risk
(38% vs 70%, n=512). Importantly post cycle 2 MFC-MRD status also differ-
entiated OS for NPM1wt standard risk patients with 5 year OS of 32% vs 64%
(P=0.002) for MRD+vs MRD- (Figure 1). In stratified analyses, there was some
evidence that the effect of MRD positivity on OS was lower in poor-risk patients
(test for trend p=0.02 for both C1 and C2). The effect of MFC-MRD status on
relapse and OS appeared greater at C2 (relapse, OR 2.00(1.56- 2.55), p<0.001;
survival, OR 1.80(1.42-2.28) p<0.001) than C1 (relapse, OR 1.69(1.37- 2.07),
p<0.001; survival, OR 1.46(1.19-1.79) p<0.001). In patients with data for both
time points, C2 MRD remained significant on OS when adjusting for C1
response. 24 patients converted from C1 MRD- to C2 MRD+, with a poor prog-
nosis (15 relapses, 13 deaths). C1 MRD-/C2 MRD- had the best prognosis. 
Figure 1.
Summary/Conclusions: MFC-MRD in CR post cycle 1 has similar outcomes
to partial remission in younger patients with AML, particularly in patients with
good and standard risk disease. Assessment of MFC-MRD post cycle 2
appears to provide additional discrimination to cycle 1: MFC-MRD in courses
1-2 may be useful in further stratifying standard risk patients.
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Background: Recent studies have revealed the presence and prognostic
impact of small mutated subclones in chronic lymphocytic leukemia (CLL)
(Rossi et al 2014, Nadeu et al 2016, Rasi et al 2016). Although these studies
focused only on a small subset of 5 genes, their results opened a new per-
spective where the proportion of cells carrying each specific driver mutation
may be relevant to the evolution of this disease. Moreover, the subclonal and
mutational complexity estimated by the presence of subclonal driver alterations
(Landau et al 2013, Landau et al 2015) or the accumulation of driver alterations
(Puente et al 2015) have been proposed as promising indicators of clinical
behavior. 
Aims: The goal of this study was to determine the relevance of the quantitative
subclonal architecture and mutational complexity in the evolution of CLL inte-
grating the deep sequencing analysis of a large panel of driver genes and DNA
copy number alterations (CNA).
Methods: The mutational status of 28 driver genes was investigated in 406 pre-
viously untreated CLL patients by targeted-deep next-generation sequencing
(NGS). Mutations present in less than 1% of tumor cells were identified. All low
frequency mutations were verified by allele-specific PCR or a second round of
NGS. CNA were analyzed by SNP-arrays. Alterations were classified as clonal if
their CCF was ≥85%, and subclonal otherwise. All patients gave informed con-
sent.
Results: Using a highly sensitive NGS strategy we observed that small subclonal
mutations were the sole alteration in 22% of the mutated cases, and were fre-
quently detected in nearly all investigated genes. We identified three gene-specific
patterns that linked the magnitude of the mutated clones (or mutated cancer cell
fraction, CCF) with the prognosis of the patients: i) CCF-independent pattern:
mutations at any CCF had prognostic value, ii) CCF-gradual pattern: the poor
prognostic impact was a continuous variable directly related to the size of the
clone, and iii) CCF-clonal pattern: only mutations with a CCF above a certain
threshold impacted the outcome of the patients. Combining mutations and driver
CNA, 86% of the patients carried at least one driver alteration, which was clonal
in 66%. On the other hand, subclonal driver alterations were present in 60% of
the patients. The mutational complexity (accumulation of 1 to ≥4 driver alterations),
but not the presence of subclonal driver populations, gradually shortened the
time to first treatment independently of the IGHV mutational status and Binet
stage. Conversely, the subclonal complexity, defined as the accumulation of driver
alterations with the presence of at least one driver subclone, predicted for a worse
overall survival independently of the IGHV and Binet stage. Patients with a pure
clonal population (presence of one or more driver alterations in all tumor cells)
had a similar overall survival than patients without any alteration.
Summary/Conclusions: Our study shows that the prognostic impact of differ-
ent driver mutations is related to the size of the mutated population. Therefore,
the clinical evaluation of gene mutations should consider the quantitative rep-
resentation of the mutations and not only their presence or absence. In addition,
the mutational complexity predicts for shorter time to first treatment independ-
ently of the IGHV and Binet stage, whereas the subclonal complexity confers
an independent adverse impact for overall survival. Altogether, the integration
of the subclonal architecture and mutational complexity in prognostic indexes
may improve the stratification of CLL patients.
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Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease
with recurrent mutations that are of pathogenic and prognostic relevance. Muta-
tions in FBXW7 are among the most common mutations in CLL, yet their func-
tional consequences are unknown. FBXW7 is an E3 ubiquitin ligase that ubiq-
uitylates oncoproteins like NOTCH1, HIF1-α and c-MYC and thereby targets
them for proteasomal degradation.
Aims: 2.5-4% of CLL patients harbor FBXW7 mutations. Approximately 60%
of FBXW7 mutations alter arginine residues that are involved in substrate tar-
geting. In T-cell acute lymphoblastic leukemia these arginine mutations are
associated with chemotherapy resistance. In CLL however, the role of dysfunc-
tional FBXW7 is unclear. We therefore aimed to delineate the prevalence of
FBXW7 mutations in CLL patient cohorts and characterize its functional role.
Methods: FBXW7 mutations were analyzed via amplicon-based targeted next
generation sequencing in primary CD19-sorted samples of previously untreated
CLL patients (n=905) as well as in CLL (n=8), MCL (n=5), T-ALL (n=2), Burkitt
lymphoma (n=1) and LCL cell lines (n=3). In silico modeling with PolyPhen-2
predicted a potential impact of the mutations on the structure and function of
FBXW7. For functional analysis, FBXW7 mutations were induced using
CRISPR/Cas9 in the CLL cell line HG3, which does not harbor a NOTCH1
mutation. Both in this CRISPR/Cas9 mutated cell line and in primary CLL cells
with FBXW7 mutations, the protein levels of FBXW7 substrates were examined.
In addition, we quantified NOTCH1 and HIF1-α activity with Luciferase reporter
assay in FBXW7 mutated HG3 cell lines.
Results: Heterozygous mutations in FBXW7 were found in 41/905 (4.5%) of
CLL patients. The most common mutations of FBXW7 were missense mutations
(32/41) that target the substrate binding domain of the FBXW7 protein as well
as non-sense mutations (4/41). Interestingly, 5 patients harbored two concurrent
FBXW7 mutations. By the use of the PolyPhen-2 software, all except one mis-
sense mutation in FBXW7 were predicted to be most likely damaging. No muta-
tions in FBXW7 were found in the CLL, MCL and LCL cell lines analyzed. To
determine the functional consequence of FBXW7 mutations in CLL, we induced
either a heterozygous or a homozygous truncation of FBXW7 in the CLL cell
line HG3, resulting in the loss of the substrate binding site of the WD40 domain.
The homozygous truncation of FBXW7 resulted in an increase of NOTCH1,
HIF1-α and c-MYC protein levels, whereas no difference of Cyclin E protein
amount was detectable. In addition, an elevation of NOTCH1 activity was found
in both the heterozygously and homozygously truncated mutant cell lines in
comparison to the wildtype HG3 cell line. To confirm this finding, protein levels
of 5 CLL patients with FBXW7 mutations were analyzed with a similar outcome.
Summary/Conclusions: Mutations in FBXW7 are frequently found in CLL,
especially missense and nonsense mutations affecting the WD40 domain. We
hypothesize that this has functional consequences on FBXW7 substrate binding
and hence leads to accumulation of oncogenes. In line, the induced truncation
of the WD40 domain of FBXW7 in the HG3 cell line resulted in the accumulation
of protein substrates and corresponding increase of their activity implicated in
the pathogenesis of CLL. Taken together our data show that FBXW7 can target
proteins for degradation that are commonly dysregulated in CLL and that drive
disease progression.
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Background: Different omics studies have focused on the analysis of individual
layers of information in chronic lymphocytic leukemia (CLL), such as the genome,
transcriptome and DNA methylome. However, besides the DNA methylome, other
layers of the epigenome, like histone modifications, remain relatively unexplored
and an integrative molecular portrait of CLL is not available yet. 
Aims: The aim of this study was to extensively map and analyse the epigenome
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of CLL in relation to the mutational, transcriptional and three-dimensional (3D)
chromatin landscape.
Methods: Seven CLL patients with distinct clinico-pathological features and
five mature B-cell subpopulations were extensively analysed using (i) ChIP-
seq of six different histone marks with non-overlapping features (H3K27ac,
H3K4me1, H3K4me3, H3K9me3, H3K27me3 and H3K36me3); (ii) single
stranded RNA-seq; iii) transposase-accessible chromatin assays (ATAC-seq)
and iv) whole-genome bisulfite sequencing (WGBS), creating a unique refer-
ence epigenome for CLL. These data were complemented with the 3D chro-
matin landscape in one CLL case measured by high-throughput chromatin con-
formation capture (HiC-seq) and promoter capture Hi-C (PCHi-C). Furthermore,
we mapped the active chromatin landscape of 100 CLL patients by H3K27ac
ChIP-seq and ATAC-seq. Whole-genome sequencing data was available for
44 of these patients. We applied a broad range of bioinformatic tools to analyze
the data in an integrative way.
Results: CLL is distinct from normal B cells for all layers of the reference
epigenome (7 CLLs) and the active chromatin landscape (100 CLLs). CLL
though is closer to naive and memory B cells than to germinal center B cells
and plasma cells. Interestingly, in CLL we not only saw activation of regions
that are active in naive and memory B cells, but also an unexpected activation
of genomic regions that are specifically active in germinal center B cells and
plasma cells. Changes in activation in these and other regions could further-
more distinguish the two major clinical subgroups of CLL with unmutated and
mutated immunoglobulin heavy chains (IGVH). CLLs did not only differ from
normal B cells regarding the separate layers of information, but also using
combined patterns of histone marks, which for example can define regulatory
elements as active promoters (H3K4me3 and H3K27ac) or active enhancers
(H3K27ac and H3K4me1). More specifically, we detected 534 genomic regions
with de novo gain (n=498) or loss (n=36) of active regulatory regions in CLL.
Large regions (>10kb) showing de novo gain of regulatory elements in CLL
(n=51), were located into, close to, or interacted in 3D space with genes impor-
tant for CLL pathogenesis, e.g., LEF1, BCL2 and FMOD. Interestingly, non-
coding somatic mutations in IGVH mutated CLLs accumulate in these and
other active regulatory regions, likely being off-target effects of the somatic
hypermutation machinery. Besides changes in regulatory elements, we
observed that CLLs lose poised promoters, which are replaced by
repressed/inactive regions. This change, mainly occurring in developmental
genes, does not affect gene expression levels, as these genes are already
silent in normal B cells. It may however represent loss of plasticity during CLL
pathogenesis in which these genes become permanently inactive.
Summary/Conclusions: With this integrative study, we generated new con-
ceptual avenues to understand the complex link among the epigenetic, muta-
tional, transcriptional and 3D chromatin landscape in CLL. In addition we pro-
vide the community with an extensive resource of epigenetic information of
this lymphoid neoplasm.
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THERAPEUTIC DISRUPTION OF THE BAFF- B-CELL RECEPTOR CROSS-
TALK IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
C. Paiva1, T. Rowland1, B. Sreekantham1, O. Danilova1, A. Danilov1,*
1Oregon Health and Science University, Portland, United States
Background: Although small molecule inhibitors of BCR-associated kinases
(BCRi) revolutionized therapy in CLL, they provide incomplete responses.
Tumor necrosis factor receptor superfamily ligands BAFF and APRIL induce
NFκB, which in turn upregulates pro-survival Bcl-2 family proteins and thereby
drives anti-apoptotic responses, potentially accounting for resistance to BCRi.
The exact roles of the individual NFκB pathways, as well as the implications of
targeting BCR in context of BAFF signaling in CLL remain understudied.
Aims: We explored the mechanistic underpinnings of CLL cell survival in
response to BAFF signaling.
Methods: We established a novel BAFF-expressing stromal co-culture model
and employed inhibitors of Bruton tyrosine kinase (BTK, ibrutinib), phospho-
inositide-3 kinase (PI3K, idelalisib) and spleen tyrosine kinase (SYK, entosple-
tinib). We quantified CLL cell apoptosis, migration, NFκB activity, protein and
mRNA expression by flow cytometry, immunoblotting, ELISA, RT-PCR and
immunocytochemistry.
Results: CLL cells co-cultured with BAFF-expressing stroma were resistant
to spontaneous apoptosis (12.3±3.2% after 24 h, vs 34.8±6.2% off stroma)
and chemotherapy agents (bendamustine, fludarabine). Gene expression
profiling exposed the NFκB pathway gene targets as the most significantly
upregulated upon BAFF stimulation (p<0.0001). We and others have shown
that CD40L-expressing stroma induces canonical and non-canonical NFκB
in CLL. By contrast, while BAFF led to strong activation of the non-canonical
NFκB with processing of p100 (to p52) by 4 h and a 5-fold increase in p52
DNA-binding activity by 24 h, canonical NFκB (RelA) activation was less pro-
nounced. BAFF predominantly induced Mcl-1, compared to CD40L which
strongly upregulated Bcl-X. BCR is a major driver of canonical NFκB signaling
in CLL. Thus, we studied whether BAFF co-opted BCR signaling in CLL.
BAFF induced rapid (15 min) phosphorylation of the proximal BCR kinases
SYKand LYN, sustained for up to 4 h, as well as ERK, in CLL cells. AKT acti-
vation occurred late (>2 h), suggesting that BAFF induced AKT independent
of BCR. BAFF-mediated BCR activation did not correlate with IGHV muta-
tional status. Like IgM, BAFF induced CLL cell chemotaxis. SYK inhibition
effectively antagonized survival and chemotaxis of BAFF-stimulated CLL
cells. By contrast, targeting BTK or PI3K was less effective. All BCRi’s fully
blocked canonical NFκB activation in BAFF-stimulated CLL cells (suggesting
its dependence on BCR signaling), but none inhibited the non-canonical path-
way. By contrast, pevonedistat, an inhibitor of Nedd8-activating enzyme which
we have previously shown to abrogate TNFR-mediated NFκB activation,
blocked both canonical and non-canonical NFκB activity in BAFF-simulated
CLL cells. SYK inhibitor entospletinib, but not other BCRi’s, decreased Mcl-
1 expression in CLL cells co-cultured with BAFF-expressing stroma and abro-
gated BAFF-mediated upregulation of pSTAT3, a transcription factor which
regulates Mcl-1. This was accompanied by a decrease in Mcl-1 transcript.
BAFF receptor signals via the TRAF complex to induce non-canonical NFκB
activation in neoplastic B-cells. We supposed that TRAF complex could be
directly responsible for SYK activation by BAFF. Indeed, IP experiments
demonstrated that SYK directly complexed with TRAF2/3 in BAFF-stimulated
neoplastic B-cells.
Summary/Conclusions: Thus, BAFF-mediated induction of BCR-associated
kinases and Mcl-1 contributes to CLL cell survival. SYK inhibition is a promising
therapeutic strategy uniquely poised to antagonize crosstalk between BAFF and
BCR, thereby disrupting the pro-survival microenvironment signaling in CLL.
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LOW MYBL2 EXPRESSION OBSERVED IN MYELODYSPLASTIC SYN-
DROME PATIENTS WITH WORSE PROGNOSIS IS ASSOCIATED WITH
ALTERED DNA REPAIR MECHANISMS IN HAEMATOPOETIC STEM CELLS 
R. Bayley1, L. Cancian1, C. Ward1, G. Volpe1, S. Dumon1, J. Gujar1, G. Stewart1,
E. Petermann1, P. Garcia1,*
1Institute of Cancer and Genomic Science, University of Birmingham, Birming-
ham, United Kingdom
Background: MYBL2 is a transcription factor with roles in the cell cycle and
genome integrity. MYBL2 is located on chromosome 20, within a region com-
monly deleted in human blood disorders (del20q). Our published data shows
that reduced levels of MYBL2 predispose to development of myelodysplastic
syndrome (MDS)-like disease in mouse models during ageing, indicating that
MYBL2 could be acting as a tumour suppressor gene within del20q abnormality.
Moreover, our previous work demonstrated that regardless of del20q deletion,
MYBL2 expression is reduced in CD34+bone marrow cells from MDS patients
with worse prognosis. Because it has been shown that the cell of origin of MDS
is the haematopoietic stem cell (HSC) and given the role of MYBL2 in DNA
replication fork progression and maintenance of genome integrity, we hypoth-
esised that low MYBL2 levels in HSC could contribute to elevated somatic
mutations through changes in DNA repair pathways and drive disease devel-
opment.
Aims: The aim of this study was to determine if low MYBL2 levels affect the
double strand break (DSB) DNA repair damage response in HSC. 
Methods: In this study we used our mouse model in which animals express
~50% normal levels of MYBL2 (Mybl2+/∆). We characterised the ability of HSCs
from young (7 weeks) and old (70 weeks) animals to respond to in vivo ionising
radiation (2Gy) in terms of proliferation, apoptosis and colony forming ability.
We measured the activation of the two main DNA repair pathways operating in
the cells to deal with DSB: the error prone non-homologous-end-joining (NHEJ)
and the error-free homologous recombination (HR) by assessing 53BP1 and
Rad51 recruitment by immunofluorescence, respectively. Finally, we analysed
the frequency of chromosome abnormalities present in the progeny of Mybl2+/∆
HSC that have previously been irradiated to determine the long term effects of
changes in DNA repair. 
Results: We observed that Mybl2+/∆ HSCs had limited proliferative potential
and displayed an increased sensitivity to ionizing radiation which increased
during ageing. Mybl2+/∆ HSCs also displayed altered kinetics of 53BP1 and
Rad51 recruitment and clearance, including retention of 53BP1 foci at later
time points following irradiation and decreased levels of Rad51 foci when com-
pared to Mybl2+/+HSCs. Using plasmid functional assays, we showed that
Mybl2+/∆ HSCs repair quite efficiently by NHEJ, but this efficiency is disrupted
when cells are challenged with ionising radiation. Furthermore, Mybl2+/∆ HSCs
have increased sensitivity to inhibition of DNA-PKC (required for NHEJ) but
not ATM (required by HR). We also observed that after ionizing irradiation
Mybl2+/∆ HSCs progeny displayed an increased percentage of chromatids with
fragile telomeres. Moreover, by making use of publically available RNA-seq
datasets from MDS patients, we have identified a clear association between
low MYBL2 levels and low expression of DNA-repair genes in patients with
worse prognosis. 
Summary/Conclusions: In summary, we have shown that decreased expres-
sion of MYBL2 leads to an imbalance in the DSB DNA-repair pathway choice,
ultimately resulting in increased genomic instability of the blood cell progeny.
These findings are supported by a signature of deregulated DNA-repair genes
which strongly associates with low MYBL2 levels in MDS patient samples, pro-
viding a mechanistic understanding for the progression of blood disorders occur-
ring during ageing. This study demonstrates a novel role for MYBL2 in DSB
repair in HSCs and suggests that low levels of MYBL2 in human MDS could
contribute to the emergence of further genetic abnormalities by deregulation of
DNA-repair pathways.
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A NOVEL GENETIC AND MORPHOLOGIC PHENOTYPE OF ARID2-
MEDIATED MYELODYSPLASTIC SYNDROMES
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Background: Clinical heterogeneity of myelodysplastic syndromes (MDS) and
related myeloid neoplasms reflects molecular diversity. Most common genetic
associations with distinct clinical or pathomorphologic phenotypes have been
already reported, but many other common somatic lesions exist and their clinical
context still remains elusive. AT rich interactive domain 2 (ARID2), which is
located on chromosome 12q, encodes a component of the SWI/SNF complex
that is involved in chromatin remodeling. In recent years multiple groups detect-
ed ARID2 mutations in a variety of solid tumors. 
Aims: Here, we present whole exome sequencing-guided identification of novel
ARID2 mutations in myeloid neoplasms. Specifically, in addition to copy number
analysis and deep targeted and exome sequencing, here we include RNA
sequencing and splicing analyses of the roles of spliceosomal mutations in
ARID2 missplicing and gene expression.
Methods: Bone marrow aspirates or blood samples were collected from 1,473
patients with MDS (n=455), myelodysplastic/myeloproliferative neoplasms
(MDS/MPN) (n=201), myeloproliferative neoplasms (MPN) (n=56), sAML
(n=221), and primary acute myeloid leukemia (pAML) (n=540) at the Cleveland
Clinic and The University of Tokyo; the registered data at The Cancer Genome
Atlas were also included. Diagnoses were classified using World Health Organ-
ization criteria. Informed consent for sample collection was obtained according
to a protocol approved by each Institutional Review Board in accordance with
the Declaration of Helsinki.
Results: By comprehensive genetic investigation of these cases, we characterized
here cases (10%) in which decreased expression of ARID2 mediated their clinical
effects in MDS and other myeloid neoplasms via multiple kinds of genetic lesions.
We showed that insufficient ARID2 expression mainly in MDS arose from ARID2
mutations, deletions, and missplicing due to U2AF1 mutations that yielded defec-
tive ARID2 transcripts. Clonal architecture analyses showed that ARID2 mutations
and deletions occurred as initial events of MDS or myelodysplastic/myeloprolifer-
ative neoplasms, and not during progression to acute myeloid leukemia. Morpho-
logically, progressive maturation in myeloid and erythroid lineages and hypolobated
megakaryocytes (indicated by arrow heads in Figure 1) were common in cases
with ARID2 mutations and deletions, and were also found in cases with U2AF1
mutations. Functionally, we utilized in vitro knockdown models of ARID2 expression
in hematopoietic cell lines and bone marrow mononuclear cells. Since no homozy-
gous deletion or mutation of ARID2 was identified, we transduced shRNA in neo-
plastic and healthy hematopoietic cells to obtain disease models with partial reduc-
tion of ARID2 expression. Two myeloid cell lines (HL60 and K562) in which ARID2
expression was knocked down showed significantly lower cell counts compared
to those with normal ARID2 expression, compatible with more apoptotic cells in
knockdown experiments. Flow cytometric analysis of the cell lines with reduced
ARID2 expression revealed increased cell-surface maturation markers, CD11b
and glycophorin A (GPA), suggesting that reduced expression of ARID2 resulted
in more differentiation in myeloid and erythroid lineages. Knockdown of ARID2
failed to reduce colony formation in bone marrow mononuclear cells. These results
indicate that reduced ARID2 expression might induce more differentiation in
myeloid/erythroid lineages and more apoptosis to reduce cell populations without
reduction of proliferation capacity in hematopoietic progenitor cells. Finally, we
examined morphological findings associated with knockdown ARID2 expression.
Compared to control cells, K562 cells with reduced ARID2 expression formed
more hypolobated megakaryocytes, which confirmed morphological findings seen
in ARID2 and U2AF1 defects.
Figure 1.
Summary/Conclusions: ARID2 is a MDS-suppressor gene whose expression
is attenuated by multiple mechanisms as it shapes the distinct morphological
phenotype of a subset of myelodysplasia.
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THE VALUE OF NGS PANEL SEQUENCING TO MOLECULARLY DEFINE
MYELOID MALIGNANCIES AND CLARIFY BORDERLINE CASES: A
STUDY ON 39 GENES IN 1143 PATIENTS 
C. Baer1,*, K. Perglerová2, W. Kern1, C. Haferlach1, T. Haferlach1
1MLL Munich Leukemia Laboratory, Munich, Germany, 2MLL2 s.r.o., Prague,
Czech Republic
Background: The 2016 revision of the WHO classification for myeloid malig-
nancies includes numerous molecular markers for classification and prognos-
tication. Next generation sequencing allows analyzing relevant genes in one
panel.
Aims: Exploit clinical usefulness of panel sequencing in routine diagnostics in
order to describe genetic changes and use respective patterns in cases with
undefinitive morphology. 
Methods: According to WHO 2016, 1143 patients were morphologically cate-
gorized as AML (n=261), MDS (n=176), MPN (n=19), CMML (n=51) or
AML/MDS (n=21) and MDS/MPN overlap (n=28). Patients, who did not fulfill
all characteristic criteria or had insufficient sample quality, were classified as
“possible” AML (n=28), MDS (n=211), MPN (n=5), CMML (n=14) and as reactive
(n=193) or unclear (n=136). DNA was isolated from BM (n=958) or PB (n=185)
for NextSeq or MiSeq sequencing after TruSeq library preparation (all Illumina,
San Diego, CA). Data was analyzed with SeqNext 4.3 (JSI Medical Systems,
Kippenheim, Germany). FLT3-ITD and KMT2A-PTD data was obtained accord-
ing to standard protocols.
Results: Analyzing 39 genes, we found ≥1 molecular change in 90% of patients
(500/556) with a definite morphologic diagnosis (median: 2 genes; max: 7).
In de novo AML, 212/229 (93%) patients showed ≥1 molecular hit, of which
211 (92%) had aberrations that define WHO categories or have prognostic
(according to ELN/MRC) or predictive value. More than one mutation was found
in 166/229 patients (72%), including information of adverse impact (e.g. of 68
NPM1 positive patients, 17 had DNMT3A mutations and 20 FLT3-ITD). Fol-
lowing NPM1, RUNX1 was the second most frequently mutated gene (46/225;
20%) and mutations were significantly more common in patients with ≥3 aber-
rations (38/104; 37% vs 8/96; 8%; p<0.001). A similar RUNX1 pattern was
found in s-AML and t-AML. In the cohort of “possible AML” (including MDS
overlap), 45/48 (94%) patients had ≥1 hit. Most frequently mutated were ASXL1
(16/48; 33%), TET2 (32%; 14/44) and SRSF2 (29%; 14/48); 16% had all three
mutated. This combination is also the most frequent three-way interaction in
CMML (10/44; 23%). In MDS, 124/157 (79%) cases showed mutations, of
which 108 had ≥1 prognostic change (according to Bejar, 2015). The prognos-
tically favorable SF3B1 mutation was present in 31/157 (20%) and significantly
enriched among cases with ring sideroblasts (p<0.001). Overall, TET2 showed
the highest mutation rate (25%) and was also the most commonly mutated
gene in cases with “possible” MDS (36/190; 19%), reactive morphologic
changes (17/201; 8%) or even unclear morphology (19/116; 17%). Of these
three subsets, five patients had only the TET2 mutation with <10% burden,
which is observed in clonal hematopoiesis of indeterminate potential (CHIP),
too. However, using panel sequencing in cases with possible MDS, unclear or
reactive morphology revealed at least one molecular marker for clonal disease
in 47% (91/199), 36% (43/118) or 17% (36/211) of cases, respectively (exclud-
ing sole ASXL1, DNMT3A, TET2 mutations with <10% burden).
Summary/Conclusions: WHO 2016 requires information on numerous genes
for diagnosis, prognosis and therapeutic decisions. This challenges conven-
tional laboratory approaches and suggests panel sequencing. We demonstrate
the feasibility in routine settings for a broad spectrum of myeloid malignancies
and identify 1) relevant patterns and mutation interactions; 2) genetic aberra-
tions supporting diagnosis for samples with borderline morphology or poor
quality and 3) patient-specific clonality useful for follow-up.
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Background: The myelodysplastic syndromes (MDS) are disorders of the
hematopoietic stem cell (HSC) and patients suffer from anemia and other
cytopenias and show increasing bone marrow blasts over time. Mutations in
spliceosomal genes (including SF3B1, SRSF2 and U2AF1) occur in >50% of
MDS patients.
Aims: We aimed to identify the deregulated pathways and gene ontology (GO)
categories associated with aberrantly spliced genes in CD34+cells and in dif-
ferentiated cells of MDS-affected lineages isolated from the bone marrow of
MDS patients harboring spliceosome mutations.
Methods: Transcriptome data were generated using RNA sequencing (RNA-
seq) and splicing factor mutant cases were compared to wildtype cases and to
healthy controls. Aberrant (including cryptic) splicing events were identified
using rMATS. Deregulated pathways and GO themes were identified using
Ingenuity Pathway Analysis and GOseq.
Results: RNA-Seq was performed on CD34+cells obtained from the bone mar-
row of 91 MDS patients (including 28, 8 and 6 cases with SF3B1, SRSF2 or
U2AF1 mutations, respectively) and 8 healthy controls. The aberrant splicing
events associated with each mutated splicing factor tended to affect different
sets of genes, although some overlap was observed. GO analysis of the aber-
rantly spliced genes associated with SF3B1, SRSF2 or U2AF1 mutations
showed a marked convergence of significantly enriched ontology themes: 26
of the top 30 most significant GO categories, including ‘RNA splicing’ and ‘trans-
lation’, in the comparison of mutant cases for each splicing factor gene to
healthy controls (18 of 30 in the comparison to wildtype cases) were common
to all three mutated splicing factor genes. Pathway analysis revealed deregu-
lated pathways (e.g. ‘oxidative phosphorylation’ and ‘mitochondrial dysfunction’)
that were common to more than one mutated gene (i.e. SF3B1 and SRSF2),
and pathways specific for one mutated splicing factor gene (e.g. ‘protein ubiq-
uitination’ in SF3B1 mutant cases). An analysis of upstream transcriptional reg-
ulators showed a significant overlap between the aberrantly spliced genes
associated with each mutant splicing factor gene (in the comparison to both
wildtype cases and to healthy controls) and genes regulated by several tran-
scription factors, including E2F1. RNA-Seq was also performed on CD34+cells
and on differentiated erythroid, granulocytic and monocytic cell populations
isolated from the bone marrow of each of 7 SF3B1 mutant MDS cases, 7 wild-
type cases and 5 healthy controls, in order to explore similarities/differences
between aberrantly spliced genes and deregulated pathways and GO themes
in cells of different lineages. There were many aberrantly spliced genes in one
cell population that did not overlap with aberrantly spliced genes in other pop-
ulations. A small proportion (i.e. <5%) of aberrantly spliced genes were common
to all four cell populations. GO analysis of the aberrantly spliced genes identified
showed that 6 of the top 30 most significant categories (including ‘RNA binding’
and ‘translation’) in the comparison of SF3B1 mutant cases to healthy controls
(4 of 30 in the comparison to wildtype cases) were common to all four cell pop-
ulations studied. Pathway analysis revealed that several pathways were dereg-
ulated in specific cell populations (e.g. ‘mTOR signaling’ in erythroid cells), and
some pathways (e.g. ‘EIF2 signaling’, involved in protein synthesis initiation)
were deregulated in all four cell populations studied.
Summary/Conclusions: Our study has identified aberrantly spliced genes
and deregulated pathways associated with spliceosome mutations in the HSCs
and the major cell lineages affected in MDS, providing new insights into how
these mutations impact cellular processes in this disorder.
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TRANSCRIPTOME SEQUENCING REVEALS DISTINCT SUBTYPES OF
MYELODYSPLASIA WITH PROGNOSTIC SIGNIFICANCE
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Background: Myelodysplastic syndromes (MDS) and related myeloid disor-
ders (“myelodysplasia”) are a heterogeneous group of clonal hematopoietic
disorders with a highly variable clinical outcome.
Aims: The purpose of this study was to establish a novel gene expression-
based classification of myelodysplasia for better prognostication.
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Methods: We performed transcriptome sequencing of bone marrow mononu-
clear cells (BMMNCs) and/or CD34+cells obtained from patients with myelodys-
plasia. Consensus clustering was used to identify stable patient clusters. A
classifier of the gene expression-based subgroups was constructed using the
100 CD34+cell samples as a training set, followed by validation in an inde-
pendent cohort of 183 MDS patients. Another classifier was constructed using
BMMNC samples from 51 patients, who had been assigned to the subgroups
by the gene expression data of their CD34+cells. Prognostic significance of
the model was tested in 114 patients of myelodysplasia.
Results: Unsupervised clustering of gene expression data of bone marrow
CD34+cells from 100 patients identified two subgroups (Class-I and Class-II).
The patients in the Class-II subgroup had higher percentages of bone marrow
blasts compared to those in the Class-I subgroup (median 2% vs 11%, P
<0.001). Pathway analysis revealed up-regulation of many signaling pathways
in the Class-II subgroup. The Class-I subtype showed highly significant up-reg-
ulation of the genes related to erythroid lineages. The erythroid signature was
rather suppressed in the Class-II subtype, which was characterized by
increased expression of genes related to progenitor cells. Compared to the
Class-I subtype, the Class-II subtype was associated with a significantly shorter
survival in both univariate (hazard ratio [HR] 5.0 [95% CI, 1.8–14], P <0.001)
and multivariate analysis (HR 6.8 [95% CI, 1.5–32], P=0.015). High frequency
of leukemic transformation in the Class-II subgroup (38%) contrasted to no
leukemic transformation in the Class-I subgroup. The prognostic significance
of our classification was validated in an independent cohort of 183 patients.
We also constructed a model to predict the subgroups using gene expression
profiles of BMMNCs. The model was applied to 114 patients with BMMNC sam-
ples, of whom 47 (41%) were predicted to be the Class-II subgroup. Compared
to the predicted Class-I subgroup, the Class-II subgroup was associated with
a significantly shorter survival in univariate analysis (HR 7.2 [95% CI, 3.0–17],
P <0.001). Again, association was more pronounced for leukemic transforma-
tion (HR 18 [95% CI, 4.2–80], P <0.001) than for overall survival. Multivariate
analysis also demonstrated that the predicted Class-II subgroup was independ-
ently associated with leukemic transformation (HR 7.3 [95% CI, 1.3–41],
P=0.024). Finally, we compared the prognostic value of our model with that of
the LSC17 score, which has recently been proposed to predict a subset of poor
risk acute myeloid leukemia based on the expression of 17 genes related to a
leukemic stem cell signature. Our model outperformed the LSC17 score in pre-
dicting clinical outcomes of myelodysplasia, especially leukemia progression.
The Class-II signature was shown to be more dramatically up-regulated during
clonal evolution of myelodysplasia than the LSC17 score, which might be the
basis of a better prediction of leukemia progression in our model.
Summary/Conclusions: Comprehensive transcriptomic analysis identified two
subgroups of myelodysplasia with biological and clinical relevance, which could
improve risk prediction and treatment stratification of myelodysplasia.
Lymphoma biology
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GENETIC ALTERATIONS INVOLVING PROGRAMMED DEATH LIGANDS
IN EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOMAS
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Background: Checkpoint blockade using anti-PD-1/PD-L1 antibodies is a high-
ly promising therapy for cancer, frequently showing dramatic anti-tumor
responses in a wide variety of tumor types. Particularly, an exceptional response
to anti-PD-1 antibodies has been demonstrated for classical Hodgkin lymphoma
(HL), which is characterized by frequent copy number gains/amplifications
involving PD-L1 and/or PD-L2, suggesting a close link between PD-L1/PD-L2
genetic alterations and the therapeutic response to these agents. Recently, we
have reported frequent structural variations (SVs) in adult T-cell leukemia/lym-
phoma (ATL) caused by human T-cell leukemia virus type-1 (HTLV-1). These
SVs invariably affect 3′-untranslated region (UTR) of PD-L1, leading to promi-
nent PD-L1 overexpression. Providing that viral antigens induce potent cellular
immunity to virally infected cells, we hypothesized that a deregulated PD-1/PD-
L1 axis might play a critical role in evasion from anti-viral immunity before these
cells are clonally selected for neoplastic proliferation.
Aims: Epstein-Barr virus is a DNA tumor virus closely associated with various
human cancers, including B- and natural killer (NK)/T-cell lymphomas, in which
genetic alterations involving PD-L1/PD-L2 may also be relevant to cancer evo-
lution. In this study, to assess this hypothesis, we interrogated a variety of lym-
phomas for genetic abnormalities affecting PD-L1 and PD-L2, especially focus-
ing on EBV-associated lymphomas.
Methods: SVs and other genetic lesions affecting PD-L1 and PD-L2 were ana-
lyzed using targeted-capture sequencing with cRNA baits designed for captur-
ing the entire sequences of PD-L1 and PD-L2 genes, including exons, introns,
and 5′- and 3′-UTRs. More than 400 samples were analyzed obtained from dif-
ferent subtypes of non-Hodgkin lymphomas, including EBV-associated lym-
phomas, such as EBV-positive diffuse large B-cell lymphoma (DLBCL) and
NK/T-cell malignancies.
Results: SVs and/or focal copy number gains involving PD ligands were suc-
cessfully detected in various B-cell and T/NK-cell lymphomas, albeit at generally
low frequencies (<10%). These lesions were the most frequently observed in
PMBCL, accounting for more than 60% of the cases. Of note, high frequency
(17−57%) of PD-L1/PD-L2-involving abnormalities were observed in mature
NK/T-cell neoplasms, including extranodal NK/T-cell lymphoma, aggressive NK
cell leukemia, and EBV-positive T-cell lymphoproliferative disorder, all of which
were positive for EBV. Moreover, a substantial proportion (22%) of EBV-positive
DLBCL cases possessed these lesions, whereas EBV-negative cases rarely
exhibited these alterations (2%, P<0.01). For both PD-L1 and PD-L2 SVs,
despite a large diversity of SV type (deletions, inversions, tandem duplications,
and translocations), most of SVs resulted in 3’-UTR truncation, while the
replacement of PD-L1 or PD-L2 promoter with an ectopic regulatory element
was rarely observed. Interestingly, PD-L1 SVs were detected in both B- and T-
cell lymphomas, whereas PD-L2 SVs were found exclusively in B-cell lym-
phomas.
Summary/Conclusions: We delineate the entire picture of genetic alterations
involving PD ligands, and confirm the close association between these lesions
and EBV-associated lymphomas. Our finding help to understand their patho-
genesis and develop a new diagnostic strategy to identify patients who poten-
tially benefit from PD-1/PD-L1 blockade therapy in non-Hodgkin lymphomas.
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FOXO1 CONTROL CD20 EXPRESSION AND INFLUENCE B-CELL
LYMPHOMA RESPONSE TO RITUXIMAB-BASED IMMUNOTHERAPY
M. Dwojak1,*, B. Pyrzynska1, A. Zerrouqi1, G. Morlino2, P. Zapala1, N. Miazek1,
K. Bojarczuk1, M. Bobrowicz1, M. Machnicki1, J. Golab1, D. Calado2,
M. Winiarska1
1Department of Immunology, Medical University of Warsaw, Warsaw, Poland,
2The Francis Crick Institute, London, United Kingdom
Background: Recurrent somatic mutations of N-terminal region of FOXO1,
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shown previously to increase FOXO1 nuclear localization and activity, have
been linked to diminished survival in DLBCL patients uniformly treated with rit-
uximab-based immunotherapy. Although the contribution of FOXO1 mutations
to the therapeutic resistance of B-NHLs becomes apparent, the molecular
mechanism underlying this phenomenon has not been explained so far. The
diminished levels of CD20 on the cell surface of tumor cells are among several
potential mechanisms underlying the resistance to treatment with anti-CD20
monoclonal antibodies.
Aims: We have recently reported that the tonic BCR signaling activates
FOXO1, and that inhibitors of the downstream BCR signaling pathways down-
regulate CD20 expression. Therefore, here we sought to determine whether
FOXO1 might regulate the abundance of CD20 on the surface of tumor cells
thus influencing the response to rituximab-based therapies.
Methods: We used CRISPR/Cas9 genome editing technology and lentiviral
transduction to study the role of FOXO1 protein in CD20 regulation. qRT-PCR
and Dual Luciferase Assays was done to determine the influence of FoXO1 on
CD20 transcription. To get insight into molecular interaction between FOXO1
and CD20 promoter we performed EMSA and ChIP experiments. For animal
studies we used SCID Fox Chase mice model. All in vivo experiments were
carried out at the animal facility of The Francis Crick Institute in accordance
with the guidelines and were approved by the Ethics Committee.
Results: To determine the potential role of FOXO1 protein in CD20 regulation,
we disrupted FOXO1 locus using the CRISPR/Cas9 genome editing technology
in Raji cells. In in vitro complement-dependent cytotoxicity assay we show that
ablation of FOXO1 results in upregulation of CD20 levels and improvement of
rituximab efficacy. To see whether FOXO1-dependent up-regulation of CD20
translates into improved antitumor efficacy of rituximab in vivo we have used
SCID Fox Chase mice model. We found that mice treated with systemic ritux-
imab survived longer when inoculated with sgFOXO1-transduced Raji cells as
compared with mice inoculated with control Raji cells. Consistently, using clin-
ically tested PI3K-AKT inhibitors - MK-2206 and GDC-0068 – in a set of CLL
primary samples we show that also pharmaceutical inhibition of FOXO1 activity
upregulated surface CD20 levels. Moreover, we demonstrated that FOXO1
regulate the CD20 promoter activity. In different B-cell lymphoma cell lines MK-
2206 and GDC-0068 significantly downregulated the levels of MS4A1 transcript
(encoding CD20). Finally, using both EMSA and ChIP assays we detected spe-
cific binding of FOXO1 to the MS4A1 promoter to the extent comparable to
other known FOXO1 target genes.
Summary/Conclusions: Collectively, our results indicate that FOXO1 is strong
negative regulator of CD20 expression and add new insights into the mecha-
nisms underlying the contribution of FOXO1 mutations to the resistance of B-
NHLs to R-CHOP therapy. In light of current knowledge and our observations
presented in this study, FOXO1 inhibition represents a novel strategy to
increase the efficacy of anti-CD20 monoclonal antibodies. 
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ALPHA-KETOGLUTURATE EXPOSES METABOLIC VULNERABILITIES IN
B-CELL LYMPHOMAS
D. Jiang1, A.-P. Lin1, L. Wang1, R. Aguiar1,*
1Hematology/Oncology - Medicine, University of Texas Health Science Center,
San Antonio, United States
Background: Metabolic rewiring is a cancer hallmark. These metabolic
changes can be secondary to a broader oncogenic-driven deregulation (e.g.,
MYC), or they may be more specific and result from mutations in enzymes
(e.g., IDH1 and IDH2) that directly control energy flux in the cell. Mutant IDH
acquires a neomorphic activity and aberrantly generates high levels of D2-
hydroxyglutarate (D2-HG), a natural metabolite with marked structural similarity
to alpha-ketoglutarate (α-KG). D2-HG functions as an oncometabolite by com-
petitively inhibiting the activity of multiple α-KG-dependent dioxygenases,
including TET DNA hydroxylases and JmJC HDMs. The role of a D2-HG/α-KG
metabolic imbalance in cancer was expanded by our recent discovery of somat-
ic loss-of-function mutations in D2HGDH in diffuse large B cell lymphomas
(DLBCL) (Nat Commun. 2015 Jul 16; 6:7768). D2HGDH catalyzes the conver-
sion of D2-HG into α-KG, and D2HGDH -mutant DLBCLs display deficiency of
α-KG with attending impaired dioxygenase function. Together, these data sug-
gest that while D2-HG is an oncometabolite, α-KG may function as tumor sup-
pressive metabolite.
Aims: To explore the concept that α-KG has tumor suppressor activities, and
to characterize the signaling nodes that mediate the anti-lymphoma activity of
this intermediated metabolite.
Methods: We utilized a panel of 14 well-characterized DLBCL cell lines to test
the growth suppressive activity of cell-permeable synthetic α-KG derivative,
dimethyl-α-KG (DM-KG), using cell proliferation and apoptosis assays. The
cell line data was expanded to primary mature B cell tumors as well as normal
B cells. These in vitro assays were complemented by xenografts models of
human DLBCL. Functional studies were performed in cell lines and primary
tumors, and included the enzymatic quantification of ATP synthase activity, the
effects of α-KG on cellular ATP levels, the measurement of AMPK activity and
of the mTORC1 kinase.
Results: The cell-permeable DM-KG induced a marked dose-dependent
growth suppression in a panel of DLBCL cell lines that encompasses the molec-
ular heterogeneity of this disease (ABC, n= 5, GCB, n=5 and OxPhos, n=4). In
most instances, the growth inhibition exceeded 80% of vehicle control exposed
cells and it could be detected as early as 24h and reached its peak at 72-96h
post-exposure (Figure 1A). In all cell lines examined, induction of apoptosis
accounted for most of the anti-lymphoma effects of DM-KG. There was no
clear segregation between the DLBLC molecular subtype and DM-KG-induced
growth inhibition (e.g., the ABC cell lines Ly10 and Ly3 were the most sensitive
and most resistant, respectively, Figure 1A). Remarkably, we found that normal
mature B cells (murine and human) were resistant to growth inhibition and
apoptosis induced by DM-KG (Figure 1C). Contrary to that, exposing viable
primary CLL, FL and DLBCL cells to DM-KG significantly induced apoptosis
(p<0.01) in all tumors examined (n=17). In xenograft models of GCB- or ABC-
DLBCLs (Ly7 and Ly10, respectively), DM-KG dosed intra-peritoneally signifi-
cantly inhibited tumor growth in comparison to vehicle treated mice (p<0.01,
n=16) (Figure 1B). To determine how DM-KG may induce growth
suppression/apoptosis in mature B cell tumors, we first showed that in DLBCL
cell lines α-KG inhibited the activity of ATP synthase, a key enzyme in the mito-
chondrial electron transport chain that generates most of the cellular ATP.
Accordingly, short exposure (8h) to DM-KG suppressed ATP levels in all 14
DLBCL cell lines examined (mean=21%, range 3% to 50%). Next, we examined
how the fuel stress generated by the α-KG-mediated ATP synthase inhibition
influenced energy-saving cellular signals. We found that in cell lines and primary
tumors, DM-KG consistently activated the kinase AMPK, with consequent
marked inhibition of mTORC1. Importantly, these signals were also engaged
in normal B cells, but they did not result in growth inhibition or apoptosis, thus
highlighting the unique sensitivity of cancer cells to the modulation of energy
metabolism.
Figure 1.
Summary/Conclusions: We showed that α-KG induces growth suppression
and apoptosis in mature B cell tumors, in vitro and in vivo. We demonstrated
that proximally α-KG exerts its tumor suppressive effects by inhibiting ATP syn-
thase activity and ATP generation. This energy stress activates AMPK and sup-
presses mTORC1 resulting in growth inhibition and apoptosis in malignant
cells, but not in their normal counterparts. These data highlight a metabolic
cancer dependency and vulnerability that can be exploited therapeutically.
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DELETION OF THE F-BOX PROTEIN NIPA (NUCLEAR INTERACTION
PARTNER OF ALK) IMPAIRS NPM-ALK DRIVEN TRANSFORMATION
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Background: ALCL is a high grade lymphoma characterized by anaplastic
morphology, expression of CD30 (Ki-1) and T- or null cell phenotype. In 60%
of systemic ALCL, the translocation t(2;5)(p23;q35) leads to expression of the
oncogenic tyrosine kinase NPM-ALK. NIPA (Nuclear Interaction Partner of ALK)
is an F-Box-Protein contributing to the timing of mitotic entry by defining an
oscillating ubiquitin E3 ligase. NIPA deficient mice are viable but sterile due to
impaired DNA double strand break repair. Co-expressed with NPM-ALK, NIPA
is constitutively phosphorylated. However, the role of NIPA in NPM-ALK induced
lymphomagenesis and the functional impact of this interaction remain unknown.
Aims: In this study, we aim to investigate the effect of Nipa deficiency on NPM-
ALK driven cell proliferation and transformation in order to characterize the
function of the protein in ALCL-induced lymphomagenesis.
Methods: Primary Nipa-/- MEFs infected with NPM-ALK were plated in softagar
assays to evaluate their transformation ability. Moreover, NIPA was downregu-
lated through targeted genetic approaches in Karpas299 and NPM-ALK infected
Ba/F3 cells, which were analyzed regarding proliferation, signaling, and apop-
tosis. To assess the impact of Nipa deletion in vivo, we used a retroviral bone
marrow transplantation model resembling human ALCL. Based on a Cre/loxP
system under the LCK-Promotor, NPM-ALK expression and Nipa-deletion are
restricted to early T cells. In wildtype background, mice die of systemic
Thy1.2+lymphoma with a latency of 4-6 months, developing neoplastic T-cell
infiltration of bone marrow and lymphatic organs. Lymphomas were analyzed
regarding immunphenotype and clinical presentation.
Results: Primary Nipa-/-MEFs plated in softagar showed significantly reduced
colony formation potential upon NPM-ALK expression (38 vs 79 CFUs;
p<0.001). These results were substantiated in human and murine cell lines,
where significantly reduced proliferation ability was observed in NIPA down-
regulating NPM-ALK expressing Ba/F3 cells (74% of ctrl; p<0.001) as well as
in Karpas299 cells infected with NIPA miR (66% of wt growth; p<0.01). More-
over, treatment with the ALK inhibitor TAE-684 gave evidence of possible syn-
ergistic effects of ALK inhibition and NIPA knockdown. Mice transplanted with
Lck-CreTG/wtNipaflox/floxMSNAIE infected bone marrow cells showed significantly
prolonged disease development and progression (mean survival 143d vs 121d
in wt). Morphologically, mice presented with enlarged thymi, splenomegaly,
lymphadenopathy, and bone marrow infiltration. Immunphenotyping showed a
pure T-cell phenotype in Nipa-/- lymphomas, thus resembling wildtype. In a
long-latency model of NPM-ALK expression in enriched HSCs, a significantly
prolonged survival (110 vs 80 days; p<0.01) and reduction of spleen colonies
(10 vs 28 colonies/spleen; p<0.001) in mice transplanted with MigNPM-ALKNipa-
/- bone marrow compared to control animals were observed, thereby suggesting
a crucial role of NIPA in NPM-ALK driven lymphomagenesis. To investigate the
precise mechanism undelaying these results, we performed cell cycle analyses
as well as cell viability assays. Indeed, we were able to detect significant dif-
ferences in the cell viability in Nipa deficient NPM-ALK expressing cells, where-
as cell cycle distribution seems not to be altered in knockout cells. 
Summary/Conclusions: Taken together, we were able to show that NIPA is
crucial for cell proliferation and transformation upon NPM-ALK expression.
Investigations of the NIPA knockout mouse in a clinical relevant ALCL model
highlight the importance of the NIPA/NPM-ALK axis in lymphoma development.
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Background: Gene therapy for transfusion dependent beta-thalassemia, as
an alternative cure to allogeneic HSCT, is based on the autologous transplan-
tation of hematopoietic stem cells (HSCs) engineered by lentiviral vectors
expressing a transcriptionally regulated human beta-globin gene.
Aims: Our contribution to this field was devoted to the clinical development of
a gene therapy protocol based on high-titer vector GLOBE, use of lenograstim
and plerixafor as source of HSCs and a conditioning regimen based on mye-
loablative treosulfan and thiotepa favoring efficient engraftment of corrected
cells with reduced toxicity (TIGET-BTHAL; EudraCT number 2014-004860-39).
Methods: On the basis of extensive efficacy and safety preclinical studies the
clinical trial TIGET-BTHAL was approved and started in 2015 at Scientific Insti-
tute San Raffaele, Milan, Italy. The clinical study foresees treatment of 10
patients: 3 adults followed by 7 minors, with a staggered enrolment strategy
based on evaluation of safety and preliminary efficacy in adult patients by an
independent data safety monitoring board before inclusion of pediatric subjects.
The chosen route of administration of gene modified HSCs is intraosseous in
the posterior-superior iliac crests, bilaterally, with the aim of enhancing engraft-
ment and minimizing first-pass intravenous filter.
Results: As of February 2017, seven patients (3 adults and 4 pediatric patients)
with different genotypes (β0/β0, β+/β+and β0/β+) have been treated with GLOBE-
transduced CD34+cells at a dose of 16x106-19.5x106 cells/kg and a vector
copy number (VCN)/cell ranging from 0.7 to 1.5. The procedure was well toler-
ated by all patients, with no product-related adverse events. Multilineage
engraftment of gene-marked cells was observed in all tested peripheral blood
and bone marrow samples. Polyclonal vector integrations profiles have been
detected in the first 3 patients tested.
Summary/Conclusions: So far, the clinical outcome indicates reduction in
transfusion requirement in adult patients and greater clinical benefit in younger
patients. Follow up analysis are ongoing and updated clinical outcome will be
presented.
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LUSPATERCEPT INCREASES HEMOGLOBIN AND DECREASES
TRANSFUSION BURDEN IN ADULTS WITH Β-THALASSEMIA
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Background: Luspatercept (ACE-536), a fusion protein containing a modified
activin receptor type IIB, is being developed for the treatment of β-thalassemia.
Luspatercept binds to select TGF-β superfamily ligands (such as GDF11) reduc-
ing aberrant Smad2/3 signaling and promoting late-stage erythroid differentia-
tion and increased hemoglobin (Hgb). Luspatercept corrected the effects of
ineffective erythropoiesis in a mouse model of thalassemia (Suragani R, Blood,
2014) and increased Hgb and was well tolerated in a phase 1 study in healthy
volunteers (Attie K, Am J Hematol, 2014).
Aims: This ongoing, phase 2, multicenter, open-label study followed by a long-
term extension (ext) study evaluates the effects of luspatercept in patients (pts)
with either transfusion-dependent (TD) or non-transfusion dependent (NTD) β-
thalassemia with key endpoints of erythroid response (including Hgb increase)
and pt-reported quality-of-life (QoL) in NTD patients, and reductions in RBC
transfusion burden in TD patients.
Methods: Inclusion criteria: age ≥18 yr and either TD (≥4 RBC U/8 weeks prior
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to first dose, confirmed over 6 months) or NTD (<4 RBC U/8 weeks prior to
first dose with baseline Hgb <10 g/dL). Pts were treated every 3 weeks subcu-
taneously for up to 5 doses; 6 cohorts were treated at dose levels from 0.2-
1.25 mg/kg. Pts in the expansion cohort and those who rolled over to the ext
study were treated at ≥0.8 mg/kg with titration up to 1.25 mg/kg (base complet-
ed NCT01749540; ext ongoing NCT02268409).
Results: As of 02Sept2016, a total of 64 pts enrolled in the base study (31 TD,
33 NTD) and, of those, 51 enrolled in the ext study (24 TD, 27 NTD). Median
(range) age (yr) was 38.5 (20-62); 67% had prior splenectomy. For TD pts, at
baseline, median (range) transfusion burden was 8 U/12 weeks (4-18 U); mean
(SD) liver iron concentration (LIC, mg/g dw) was 5.0 (5.3). For NTD pts, at
baseline, median (range) Hgb (g/dL) 8.5 (6.5-9.8); mean (SD) LIC (mg/g dw)
was 5.4 (3.8). In base and ext, respectively, 22/31 (71%) and 20/24 (83%) TD
pts achieved ≥33% and 17/31 (55%) and 17/24 (71%) achieved ≥50% reduction
in transfusion burden over any 12-week period compared to baseline. Median
duration of ≥33% reduction was 6.3 months (treatment ongoing). In base and
ext, respectively, in NTD pts treated with ≥0.6 mg/kg, 13/21 (62%) and 21/27
(78%) achieved ≥1.0 g/dL and 7/21 (33%) and 14/27 (52%) achieved ≥1.5 g/dL
increases in mean Hgb over any 12-week period compared to baseline. Median
duration of Hgb increase ≥1.0 g/dL over 12 weeks in responders was 13.5
months (treatment ongoing). Increases in mean Hgb over a 12-week period
correlated with improvement in a pt-reported QoL questionnaire, FACIT-F. Lus-
patercept was generally well tolerated, with no related serious adverse events
and few grade 3 related AEs: bone pain (n=3), asthenia (n=2), and headache
(n=1). The most frequent related AEs (≥10%) were bone pain, myalgia,
headache, musculoskeletal pain, arthralgia, and injection site pain. 
Summary/Conclusions: Long-term luspatercept treatment in pts with β-tha-
lassemia was generally safe and well tolerated. Efficacy was clinically relevant
in both TD pts (decreased transfusion burden) and NTD pts (increased Hgb
levels, improved QoL). A Phase 3, double-blind, placebo-controlled study of
luspatercept in regularly transfused adults with β-thalassemia is ongoing
(NCT02604433).
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Background: Osteoporosis is a common complication of thalassemia major
(TM) with a complex pathophysiology. We have previously shown that RANKL,
the most potent osteoclast activator, is elevated in the serum of TM patients
and correlates with reduced bone mineral density (BMD). Denosumab (DMB)
is a human monoclonal antibody that targets and binds to RANKL and has
been licensed for patients with different types of osteoporosis. However, there
are no prospective data for the effects of DMB on TM-induced osteoporosis.
Aims: The primary objective of this study was to evaluate the results of DMB
on lumbar spine (L1-L4) BMD in patients with TM and osteoporosis as com-
pared to placebo at 12 months. Secondary endpoints included the evaluation
of the effects of DMB on femoral neck (FN) and wrist (WR) BMD at 12 months,
the safety profile of DMB as well as its effects on bone turnover.
Methods: This was a single-site, randomized, placebo-controlled, double blind
phase 2b clinical trial. Main inclusion criteria included adult patients (>30 years
of age) with TM and BMD T-score between -2.5 and - 4.0 in at least one of the
examined sites (L1-L4, FN, WR). Main exclusion criteria included: impaired
renal function (eGFR of ≤30 mL/min); elevated ALT and/or AST >2 fold the
upper limit of normal (UNL), or elevated direct bilirubin >1.5xUNL; heart failure
(NYHA above 2); administration of bisphosphonates within one year of study
enrolment; presence of any other disorder that affects bone metabolism.
Patients were assigned into two treatment groups: in group A, 60 mg DMB
was administered sc, every 6 months for 12 months for a total of 2 doses (day
0 and day 180); in group B, placebo was administered sc, at the same time. All
patients received calcium and vitamin D supplementation. Measurement of
BMD with dual energy X-ray absorptiometry at three body sites (L1-L4, FN,
WR) was performed during the screening period and at the end of the study.
Results: Sixty-three patients with TM and osteoporosis participated in the
study (group A, n=31; group B, n=32). Patients of groups A and B showed no
differences in BMD of all evaluated sites at baseline. Patients of group A (DMB
arm) achieved an increase in both L1-L4 BMD (mean±SD: 0.811±0.105 g/cm2
vs 0.772±0.098, p<0.001) and FN BMD (0.653±0.121 g/cm2 vs 0.631±0.103,
p=0.022), while there were no changes in WR BMD. Patients of group B (place-
bo arm) achieved a slight increase in their L1-L4 BMD (0.801±0.097 g/cm2 vs
0.775±0.080, p=0.004) and a significant decrease in their WR BMD
(0.520±0.099 g/cm2 vs 0.549±0.098, p=0.008). The percentage increase of
L1-L4 BMD was higher in DMB arm than in placebo arm (6.02±5.30% vs
3.11±5.46%, respectively; p=0.03), while the advantage of DMB regarding WR
BMD was much higher compared to placebo (-0.22±5.40% vs -4.15±8.58%,
respectively; p=0.02) as well as in FN BMD (p<0.001). No grade 3 or 4 toxicity
was observed in this study.
Summary/Conclusions: This first analysis of our phase 2B study regarding
the effects of DMB on BMD of different sites (the results of bone markers will
be presented in the conference), suggests that DMB, given twice per year,
increases the BMD of the L1-L4 more efficiently than placebo (in combination
with vitamin D and calcium), after 12 months, in patients with TM and osteo-
porosis, with excellent safety profile. Furthermore, DMB increased the FN BMD,
which was not increased in the placebo arm, while DMB has also a positive
effect on WR BMD compared to placebo. These data support the use of DMB
for the management of TM-induced osteoporosis.
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LONG-TERM HEALTH STATUS AFTER HSC TRANSPLANTATION FOR
THALASSEMIA: THE FRENCH EXPERIENCE
I. Rahal1, C. Galambrun1, Y. Bertrand2, C. Paillard3, P. Frange4, C. Pondarré5,
R. Peffault De Latour6, M. Michallet7, D. Steschenko 8, C. Piguet9, C. Berger10,
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gie pédiatrique, CHRU Jean Minjoz, Besançon, 18Reference Center for Tha-
lassemia, Pediatric onco-hematology, Hopital de la Timone, Assistance
publique-hôpitaux de Marseille, Marseille, France
Background: In clinical practice, allogeneic hematopoietic stem cell trans-
plantation (HSCT) is the only treatment offering a definitive cure for patients
with beta-thalassemia. Its outcome has improved over the last 3 decades with
currently a disease free survival rate of 90% when transplant is performed in
childhood from an HLA-identical sibling. Few data are available on long-term
toxicity and frequency of chronic complications after transplant.
Aims: The purpose of this study was to evaluate the long-term health status
after a successful allogeneic HSCT for beta-thalassemia major in a national
cohort of patients.
Methods: This French retrospective study included patients who successfully
received allogeneic HSCT between 1985 -2012 and were alive at least 2 years
after HSCT. Study was based on data collected in the national registry of
patients with beta-thalassemia and conducted in collaboration with the French
society of HSCT (SFGM-Tc). Late effect data were recorded by physicians
through reference or transplant center visits. Collected data included medical
examination results, long-term treatments administered and laboratory tests
(serum ferritin, Hb, liver enzymes, creatinine level and thyroid evaluation). Lin-
ear-mixed model was used to analyze data evolution over time (for height and
weight SDS, SF, Hb values).
Results: A total of 134 patients had received allogeneic HSCT for beta-tha-
lassemia in France from 1985 to 2012. 107/134 patients experienced successful
HSCT (6 after a second transplant) and were alive 2 years after transplantation.
Six were not analyzed (back to their country or lost of follow-up) and two died of
chronic graft-versus-host disease. 99 patients were analyzed for long-term
effects. Median age at HSCT was 5.9 years (8 month-26 years). The source was
bone marrow in 85% of cases and a matched sibling donor was used in 90% of
cases. Conditioning mostly consisted (85%) of busulfan and cyclophosphamide
(oral busulfan in 52%). Median age at the last visit was 19 years. Chronic com-
plications, similar to those observed in patients treated with transfusion and chela-
tion therapy occurred after transplant in 12% of patients: 7 hypothyroidism, 2
heart failure, 5 diabetes. 2 patients had chronic respiratory failure related to trans-
plant. The height SDS improved after HSCT if performed at a young age. Weight
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SDS values increased with time, especially in females. Although gonadal dys-
function was observed in 60% of women aged at least 13 years at the last eval-
uation, 12/27 aged more than 20 years experimented at least one successful
pregnancy. 93 patients had stopped their immunosuppressive treatment two
years after HSCT. 37 were treated with iron chelation therapy and/or phle-
botomies. At least half of patients are receiving a long-term hormonal treatment
or antibiotic prophylaxis at the last visit. Decrease in serum ferritin values after
transplant was significantly influenced by age at transplant and pre-transplant
serum ferritin value. The median hemoglobin value was 12.5 g/dL (86-165) at a
mean age of 18 years and Hb values were significantly influenced by age, the
sex of the donor and the presence of donor thalassemia trait.
Summary/Conclusions: A comprehensive and regular long-term follow-up
should be established for all patients receiving allogeneic HSCT for beta-tha-
lassemia major. In this national cohort, endocrinological complications were
frequent after transplant. Fertility can be partly preserved, but this result has to
be reevaluated with the more recent use of intravenous busulfan. 
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CD34+AND HUMAN INDUCED PLURIPOTENT STEM CELL
DIFFERENTIATION TO TRANSFUSION READY RED BLOOD CELLS 
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Background: Donor-derived red blood cells (RBC) are the most common form
of cellular therapy. However the source of cells is dependent on donor avail-
ability with a potential risk of allo-immunization and blood borne diseases.
Aims: We aim to produce unlimited numbers of cultured RBC with a defined
`universal donor´ phenotype for transfusion purposes. 
Methods: To this end we prepare for a clinical test using autologous cultured
RBC to test their in vivo stability. In parallel we develop methods for unlimited
production of cultured RBC. An immortal source to produce in vitro cultured
RBCs (cRBC), such as iPSCs would allow selection of `universal donor` RBC,
or provide an autologous end product with the absence of immune reactions.
Results: The in vitro production of RBC has proven to be successful, however
there are barriers to overcome prior to clinical application. e.g: xeno-free cul-
turing methods, scale up cultures to obtain transfusion units (1-2*1012 erythro-
cytes), and for iPSC we need virus- and transgene-free reprogramming proto-
cols. To solve the above mentioned issues a customized humanized GMP-
grade medium (Cellquin) was generated in order to control erythroid culture
parameters and to reduce culture costs. This medium allowed 1*108 times ery-
throid expansion from PBMCs to pure adult EBL cultures within 25 days, com-
parable to non-GMP commercial media. To generate iPSC, a non-integrative
polycistronic episomal vector containing (OCT4-SOX2-KLF4-cMYC-LIN28) was
used to reprogram PBMC-expanded EBLs to iPSC, displaying pluripotency
potential and normal karyotype. iPSCs were adapted to single cell passage
allowing directed colony differentiation using a feeder-free monolayer approach.
From day 6 of differentiation Cellquin was applied with lineage-specific growth
factors, resulted iPSC differentiation to EBLs which was initiated by the appear-
ance of hemogenic endothelium following hematopoietic specification. Our dif-
ferentiation method resulted in ~150*106 CD41- CD34-
CD71+CD235+CD36+expanded EBLs from 1200iPSCs within 21 days (12
days of iPSC diff. +9 days of expansion). Further maturation of iPSC-EBLs
yielded CD71+CD235+CD36- pure orthochromatic normoblasts expressing
mainly gamma globin chains (fetal) and small amount of beta globins (adult) in
agreement with literature. Currently we are testing enucleation potential of
matured iPSC-EBLs.
Summary/Conclusions: Here we showed that our monolayer approach is sim-
ple, highly controlled and compatible with upscaling. Avoiding virus-, integrative
reprogramming, feeders and with our GMP-grade media we maintained a cost
effective system moving toward clinical application.
AML Biology I: Towards molecular therapies
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FUNCTIONAL PROTEOMICS IDENTIFIES SETD2 AS A CRITICAL
EFFECTOR OF MLL FUSION PROTEINS TO SAFEGUARD GENOMIC
INTEGRITY
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Background: Acute Myeloid Leukemia (AML) frequently harbors chromosomal
rearrangements involving the Mixed Lineage Leukemia (MLL) gene. More than
65 different MLL fusion genes exist and many of them have been described to
act as strong cancer drivers. While critical effectors of several distinct MLL
fusion proteins (MLL-FPs) were identified, it is not clear if transforming mech-
anisms are conserved across the entire family of MLL fusions. 
Aims: We hypothesized that common oncogenic mechanisms are encoded in
stable physical and genetic MLL-fusion-specific interaction networks. Thus, we
aimed to identify common critical effectors of different MLL fusion proteins that
are presumed to employ different mechanisms of oncogenic transformation. 
Methods: Protein complexes of 7 molecularly distinct, affinity-tagged MLL-FPs
(MLL-AF4, MLL-AF9, MLL-ENL, MLL-CBP, MLL-EEN, MLL-GAS7 and MLL-
AF1p) were purified from stable cell lines allowing for inducible, single-copy
transgene expression and characterized by mass spectrometry. Data analysis
identified a comprehensive protein-protein interaction network, which was func-
tionally interrogated by a subtractive shRNA screening approach. Validation
experiments included detailed RNAi- and CRISPR/Cas9-mediated loss of func-
tion experiments in cell lines and primary cells in vitro and in vivo, using read-
outs for changes in proliferation, differentiation, apoptosis and DNA damage.
Results: Characterization of the protein complexes nucleated by 7 MLL fusion
proteins by affinity purification coupled to mass spectrometry (AP-MS) revealed
a densely interconnected protein-protein interaction network of 963 proteins,
comprising previously known MLL-interacting protein complexes (such as PRC2
or SWI/SNF), as well as a high number of new interaction partners of MLL. 128
proteins were found to interact with ≥5 of all 7 MLL-fusions. This subset of con-
served MLL-interaction partners was highly enriched for proteins with function
in chromatin metabolism and transcriptional control. Systematic functional
investigation of the conserved MLL-fusion interactome using subtractive shRNA
screens identified the methyltransferase SETD2 as a critical effector of MLL
fusion proteins. Both RNAi-based suppression and CRISPR/Cas9-mediated
mutagenesis of SETD2 induced myeloid differentiation and apoptosis in human
and mouse MLL-rearranged cell lines, while having only modest effects on the
proliferation of MLL-wild-type leukemia cells. Depletion of Setd2 in MLL-fusion-
transformed mouse fetal liver cells resulted in loss of serial re-plating capacity
in vitro and prolonged disease onset in vivo. Furthermore, knockdown of SETD2
caused a proliferative disadvantage in primary cells from AML patients with dif-
ferent MLL-rearrangements without affecting MLL-wild-type AML cells. We
found that SETD2 was essential for efficient repair of DNA breaks, as SETD2-
deficient leukemia cells showed increased levels of DNA damage and activation
of p53, leading to the accumulation of mutations.
Summary/Conclusions: In summary, our data highlight the functional rele-
vance of combined proteomic-genomic cellular screening to identify critical
effectors of MLL-FPs. In addition, our study identifies a novel role for SETD2
in the maintenance of genomic integrity during initiation and progression of
MLL-rearranged AML and establishes SETD2 as a therapeutic target in
leukemia with low genomic complexity.
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CEBPA-MUTANT ACUTE MYELOID LEUKEMIA IS SENSITIVE TO
SMALL-MOLECULE-MEDIATED INHIBITION OF THE MENIN-MLL
INTERACTION
L. Schmidt1,*, E. Heyes1, T. Eder1, J. Grembecka2, F. Grebien1
1Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria, 2Department
of Pathology, University of Michigan, Ann Arbor, United States
Background: The CEBPA gene - encoding for the transcription factor C/EBPα
- is mutated in 9% of patients with acute myeloid leukemia (AML). CEBPA N-
terminal mutations lead to selective loss of full length C/EBPα p42 expression
without affecting translation of the shorter p30 isoform. As a balanced ratio of
C/EBPα isoforms is crucial for hematopoietic homeostasis, depletion of p42
leads to increased cell growth and blocks myeloid differentiation, resulting in
the development of AML. We have recently shown that the p30 variant of
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C/EBPα can act as a gain-of-function allele with distinct molecular properties.
However, the mechanistic basis of C/EBPα p30-induced leukemogenesis is
incompletely understood.
Aims: We hypothesized that the interaction between the oncogenic C/EBPα
p30 isoform and the MLL/SET histone methyltransferase complex is required
for p30-dependent epigenetic and transcriptomic changes that contribute to
leukemogenesis. Therefore, we aimed to investigate the sensitivity of CEBPA-
mutant AML to perturbation of MLL/SET function.
Methods: We used CRISPR/Cas9-mediated mutagenesis to interfere with the
MLL/SET complex in myeloid progenitor cells from a Cebpap30/p30 AML mouse
model. Cellular competition assays were used to assess changes in prolifera-
tive capacity of mutant cells. Further, MLL activity was inhibited by the use of
small molecules that block the Menin-MLL interaction. In both cases, prolifer-
ation, myeloid differentiation and apoptosis were used as readouts. Global
changes in gene expression were measured by RNA-seq.
Results: We initially confirmed, via ChIP, that C/EBPα and MLL co-localize on
the promoters of p30 target genes, indicating functional cooperativity in gene
regulation. To investigate the importance of different, annotated functional
domains within the MLL protein in the context of C/EBPα p30 expression, we
introduced targeted mutations across the Mll gene in Cebpap30/p30 cells using
the CRISPR/Cas9 system. This analysis revealed a strong dependence of
Cebpap30/p30 cells on the expression of an intact MLL protein. Surprisingly,
loss of the enzymatic activity of Mll by mutational targeting of the SET domain
did not significantly affect cell survival. In contrast, cells were particularly sen-
sitive to mutagenesis of the Menin-binding motif in MLL. Mll targeting strongly
induced myeloid differentiation in Cebpap30/p30 cells as measured by increased
levels of myeloid surface markers. To investigate functional consequences
upon pharmacological perturbation of the MLL/SET complex, we used MI-463,
a potent small-molecule inhibitor of the Menin-MLL interaction. Inhibitor treat-
ment led to a time- and dose-dependent impairment of proliferation, induction
of cell cycle arrest and increased apoptosis in Cebpap30/p30 cells. RNA-seq
analysis showed that inhibitor treatment induced the expression of genes asso-
ciated with myeloid differentiation, which could be confirmed by flow cytometry.
Importantly, expression of C/EBPα p30 was associated with hypersensitivity
to Menin-MLL inhibition, as Cebpap30/p30 cells were 2-6 fold more sensitive
than other leukemia cell lines of mouse and human origin.
Summary/Conclusions: We show that CEBPA-mutated AML is highly sensi-
tive to perturbation of the MLL/SET complex, either via genetic ablation of MLL
or through pharmacological inhibition of the Menin-MLL interaction. Our data
indicate that leukemic mutations of C/EBPα selectively cooperate with the
SET/MLL complex to regulate gene expression. These findings expand our
understanding of and may inform new therapeutic strategies for N-terminal
CEBPA mutated AML.
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THERAPEUTIC STRATEGY IN ACUTE MYELOID LEUKEMIA
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Background: Functionally critical decreases in PU.1 levels or activity are pres-
ent across various different genetic and epigenetic subtypes of AML, and overall
represent more than 50% of AML cases (Sive et al. Leukemia. 2016). However,
approaches for the specific therapeutic targeting of these patients are thus far
lacking. 
Aims: Retroviral restoration of PU.1 expression has previously been explored
but is difficult to achieve pharmacologically. Here, we tested the inverse strat-
egy. As complete loss of PU.1 leads to stem cell failure, we hypothesized that
AML cells harboring already low levels of PU.1 may be more vulnerable to fur-
ther PU.1 inhibition. 
Methods: We used two alternative approaches: RNA interference and newly
developed small molecule PU.1 inhibitors. 
Results: We found that inhibition of PU.1 with different shRNAs led to a sig-
nificant decrease in proliferation and clonogenicity, and increased apoptosis of
mouse and human leukemic cell lines with low PU.1 levels, as well as the
majority of primary human AML cells tested. The pharmacologic targeting of
transcription factor-DNA major groove interactions is challenging. However,
specific PU.1 binding to chromatin critically depends on additional minor groove
contacts upstream of the core ETS binding motif, which determine selectivity
for PU.1. We used an integrated screening strategy utilizing biosensor surface
plasmon resonance, DNA footprinting, and cell-based dual-color PU.1 reporter
assays to develop novel small molecules of the heterocyclic diamidine family
as first-in-class PU.1 inhibitors. Targeted occupancy by our compounds in the
minor groove induces perturbations in DNA conformation that are transmitted
to the PU.1 site in the major groove and thus inhibit PU.1 binding via an
allosteric mechanism. Functionally, treatment with 3 different compounds
decreased cell growth and colony forming capacity, increased apoptosis, and
disrupted serial replating capacity of PU.1low AML cell lines, and a majority of
primary AML cell samples. ChIP and expression analysis showed that the com-
pounds disrupt PU.1-promoter interaction and lead to downregulation of canon-
ical PU.1 transcriptional targets in AML cells, confirming on-target activity.
Genome-wide analysis showed highly significant enrichment of known tran-
scriptional targets of PU.1, and selectivity over other ETS family members.
Comparison with published transcriptomic and PU.1 ChIP-seq data sets, as
well as ARACNe analysis of the PU.1 regulon in primary AML cells, demon-
strated that the inhibitors antagonized PU.1-regulated pathways at a genome-
wide level. Treatment of normal HSPC in colony forming assays led to
decreased production of mature granulo-monocytic cells, consistent with PU.1’s
known role in this lineage. However, this effect was reversible upon drug
removal, and serial replating capacity was not affected suggesting no significant
effects on normal HSPC. Lastly, in vivo treatment with PU.1 inhibitors in mouse
and human AML (xeno)transplantation models significantly decreased tumor
burden and increased survival.
Summary/Conclusions: Our study describes for the first time a strategy
inhibiting PU.1 in AML, establishing proof-of-concept for this approach. Fur-
thermore, we report the development of first-in-class PU.1 inhibitors which
interfere with PU.1-DNA interaction through an allosteric, minor groove-medi-
ated mechanism. Our work shows that it is feasible to pharmacologically target
PU.1, and raises intriguing possibilities for the potential targeting of other tran-
scription factors through minor groove-directed approaches. 
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METABOLIC ADAPTATIONS TO TARGETED THERAPY IN FLT3 MUTATED
ACUTE MYELOID LEUKAEMIA
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Background: FLT3 tyrosine kinase (TK) activating mutations (FLT-3mut) are
amongst the most frequent in AML and are associated with a poor outcome.
FLT-3mutpromote constitutive activation of survival/proliferation pathways and
have also been shown to lead to changes in cellular metabolism, such as
increased glycolysis. The FLT3 TK represents a valid therapeutic target and
several FLT3 TK inhibitors (TKI) have been developed. However despite show-
ing activity in the preclinical setting, FLT3 TKI have displayed limited efficacy
in clinical trials. Resistance mechanisms to FLT3 TKI include receptor mutations
and cell intrinsic adaptive mechanisms. Amongst the latter, metabolic adapta-
tions might play a significant role although the exact mechanisms are still ill-
defined.
Aims: We hypothesised that metabolic adaptations facilitate FLT3 TKI resist-
ance and aimed to identify early metabolic changes in FLT-3mut AML, following
TKI treatment, in an attempt to unveil novel therapeutic vulnerabilities. 
Methods: Liquid chromatography coupled to mass spectrometry (LC/MS),
using stable isotope-based carbon flux tracing, and oxygen consumption
rate/extracellular acidification rate as measured by an extracellular flux analyser
(Seahorse, Agilent Technologies) were used to assess metabolic changes in
FLT3mut cells after FLT3 TKI treatment. Gene expression changes were meas-
ured in the same conditions by RNA sequencing. Changes in viability and reac-
tive oxygen species (ROS) in various culture conditions were measured by
FACS. Gene silencing was performed using CRISPR-Cas9 gene editing and
inducible short hairpin RNA interference.
Results: Analysis of published gene expression datasets demonstrated that
glycolytic, citric acid cycle (CAC), and oxidative phosphorylation genes are
upregulated in FLT-3mut compared to FLT3 wild-type (FLT3wt) patient samples
at diagnosis. We then confirmed that both human and murine FLT-3mut cells
display increased glycolytic and respiratory capacity compared to FLT-3wt cells.
Upon treatment with the highly selective FLT-3 TKI AC220 (quizartinib), cur-
rently used in a number of clinical trials, these metabolic phenotypes were par-
tially reversed. However, whilst glucose uptake was reduced upon FLT3 TK
inhibition, glutamine uptake was not affected. Metabolic flux analysis using [U-
13C]glutamine demonstrated that glutamine, while providing carbons for the
CAC, was primarily used to support production of the major intracellular antiox-
idant glutathione upon AC220 treatment. This antioxidant function is necessary
because, as expected, FLT-3mut cells displayed a large increase in ROS levels
following TKI treatment when grown in the absence of glutamine and these
changes correlated with a significant reduction in viability in the same condi-
tions. Glutamine dependency of FLT3mut cells upon FLT3 TKI treatment was
independently validated via a CRISPR-Cas9 drop-out genome-wide screen as
glutaminase (GLS), the first enzyme in glutamine catabolism, and several CAC
enzymes were shown to be synthetically lethal with AC220. We went on to
show that the combination of AC220 with a specific clinical grade GLS inhibitor
(CB-839) or GLS gene silencing resulted in a significant reduction in viability
and increase in ROS levels which could be rescued by supplementation of the
media with the antioxidant N-acetylcysteine or a cell-permeable form of the
CAC intermediate α-ketoglutarate.
18 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Summary/Conclusions: Our data suggest that upon AC220 treatment, gluta-
mine metabolism becomes a critical metabolic dependency in FLT3mut AML.
Glutamine metabolism is mostly channelled towards glutathione production,
while also supporting the CAC and both these fates contribute to its protective
effects following FLT3 TK inhibition by respectively counteracting oxidative
damage and sustaining macromolecule biosynthesis and cellular energetics.
These data predict that a combined inhibition of glutamine metabolism and
FLT3 TK activity may improve the eradication of FLT3mut AML cells.
Hematopoiesis, stem cells and microenvironment
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STEP-WISE REPROGRAMMING OF ENDOTHELIAL CELLS INTO
IMMUNE-COMPETENT HEMATOPOIETIC STEM CELLS
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Background: The molecular pathways and microenvironmental cues that
choreograph the conversion of endothelial cells (ECs) into long-term repopu-
lating hematopoietic stem cells (HSCs) remain poorly defined. This is due to
lack of models that recreate the ephemeral transition of an endothelial cell to a
hemogenic state to the emergence of HSCs.
Aims: To reprogram adult mouse ECs into long-term repopulating HSCs that
give rise to all hematopoietic lineages, including functional T cells in vivo.
To provide a platform to deconvolute the process by which endothelial-to-
hematopoietic transition is possible.
Methods: Here, we have developed a modular in vitro model in which—by
precise, conditional expression of transcription factors: FosB, Gfi1, Runx1, and
Spi1 (FGRS), and reintroduction of a proper inductive niche—adult mouse ECs
were reprogrammed into HSCs (rEC-HSCs) with multi-lineage engraftment
potential (rEC-MPPs). Adult, non-lymphatic ECs isolated from various organs
of Runx1-IRES-GFP reporter mice were transduced with FGRS and co-cultured
in direct contact with vascular niche.
Results: Within 14 days, ECs initiated a hematopoietic program, turning on
the endogenous expression of Runx1 and transitioning into hematopoietic cells.
Expansion of these cells for another 14 days resulted in generation of rEC-
HSCs and rEC-MPPs. Transplantation of rEC-HSCs and rEC-MPPs (CD45.2+)
into lethally irradiated mice (CD45.1+) reconstituted both short-term (rEC-MPPs)
and long-term hematopoiesis, with secondary engraftment potential (rEC-
HSCs). rEC-HSCs gave rise to both functional myeloid and lymphoid cells with
full complement of polarized T cell subsets. rEC-HSC-derived T cells undergo
T-cell receptor (TCR) rearrangement and restore adaptive immune function in
Rag1-/- mice.
Summary/Conclusions: This multi-phasic, step-wise approach provided an
interrogable model to decipher pathways involved in EC transition into
hematopoietic cells. This will provide cues to devise strategies to convert autol-
ogous ECs into large numbers of HSCs for genetic modification and subsequent
treatment of both genetic and acquired hematological disorders.
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MARROW MESENCHYMAL STEM CELLS RESCUE BONE MARROW
ENDOTHELIAL CELLS SUFFERING CHEMOTHERAPY STRESS BY
TRANSFERRING MITOCHONDRIA THROUGH NANOTUBES
Y. Feng1,*, R. Zhu 2, W. Lu3, J. Shen4, J. WU5, J. Zhang3, Y. Y. Zhang6, K. Liu3
1Peking University People’s hospital, Institute of Hematology, Beijing, 2Centre
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3Peking University People’s hospital, Institute of Hematology, 4 The Third Hos-
pital of Peking University , Cardiovascular Institute, Beijing, 5 The Third Hospital
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Background: The tunneling nanotube (TNT) is a newly discovered,long and
thin tubular structure between cells and can facilitate the intercellular exchange
of diverse cellular signals and components ranging from electrical signalling to
organelles .
Recent reports show that mesenchymal stem cells (MSC) rescue injured target
cell and promote target cell recovery from a variety of stress including oxidative
tress. ultraviolet radiation, ischemia/reperfusion (SI/R)etal .However, it is still
unclear if bone marrow mesenchymal stem cells (BMMSC) can also form TNT
to communicate and rescue injured bone marrow -derived endothelial cells
(BMdEC)and promote it recovery from chemotherapy stress . In our study, we
set out to test the hypothesis that BMMSC can rescure suffering endothelial
cells by transferring mitochondria to endothelial cells through nanotubes. 
Aims: To investigate the novel intercellular communication TNT between BMMSC
and BMdECs or HUVEC, illuminating its constituent and investigating the signif-
icance of transport of mitochondrial through TNT between BMMSC and BMdECs
or HUVEC suffering from chemotherapy stress of cytosine arabinoside.
Methods: We established two direct co-culture system for human primary bone
marrow mesenchymal stem cells (BMMSCs) and bone marrow-derived
endothelial cells (BMdECs) or Human umbilical cord vein endothelial cells
(HUVECs) respectively. 
Results: Firstly, We observed the TNTs formed between BMMSCs and
endothelial cells including HUVECs and BMdECs. We identified the TNT struc-
ture between BMMSCs and HUVECs or BMdECs are composed with F-actin,
microtubule in addition to membrane. Live cell imaging showed the two xeno-
geneic cells form TNTs by retaining a thin thread of membrane upon dislodge-
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ment .Besides,we observed that TNT was more likely to occur between healthy
bone marrow mesenchymal stem cell and endothelial cells after cytarabine
(Ara-C) treatment. Single-cell analysis showed that stressed endothelial cells
and cell lines in the early stages of apoptosis caused by cytarabine (Ara-C)
treatment form TNT to interact with untreated BMMSCs and then mesenchymal
stem cells transport mitochondria to injured endothelial cell or cell
line.Notably,the rescue effect was inhibited when the formation of TNTs were
impaired by incubating with an F-actin-depolymerizing drug and tubline -depoly-
merizing drug, indicated that these TNTs transferring mitochondria have a dis-
tinct cytoskeletal composition which composed with F-actin and microtubule.
Our results also suggest that the delivery of functional mitochondria from
untreated BMMNCs to HUVECs via TNTs can mediate the recovery of injured
HUVECs from the apoptosis, contribute to proliferation and remodel the for-
mation of capillary-like structures in Matrigel®-coated plates of HUVECs suffer
from chemotherapy stress of Ara-C.
Summary/Conclusions: BMMSCs can transfer mitochondria via TNTs formed
between endothelial cells and rescued endothelial cellssuffering chemotherapy
stress,which can alleviate apoptosis of stressed endothelial cells, relieve its
proliferation inhibition and alter its formation of capillary-like structures.Our
study offers the clues to help know about cell-cell communication of niche com-
ponents in the HSC niche in bone marrow.
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SHORT-TERM FEEDING OF A HIGH-FAT DIET DISTURBS LIPID RAFT/
TGF-ΒETA SIGNALING-MEDIATED QUIESCENCE OF HEMATOPOIETIC
STEM CELLS IN C57BL/6J MOUSE BONE MARROW
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Background: Some studies show that a high-fat diet (HFD) induces major
perturbations in murine hematopoietic stem cells (HSC) and hematopoietic
system homeostasis. However, it is currently difficult to say whether these alter-
ations are related to direct effects such as changes in lipid metabolism in HSC
or indirect “side effects” on HSC, such as pathophysiology related to obesity
or inflammation observed after an extended diet over several months or a diet
very rich in fat (>60 kJ% of fat). For example, HFD-induced obesity significantly
alters hematopoiesis in bone marrow (BM), with a decreased proliferation of
HSC, a general suppression of progenitors, an enhancement of lymphopoiesis,
and an activation of myeloid cell production from BM progenitors. Inflammation
also affects HSC homeostasis, as Interferon alpha is well-known to activate
dormant HSC in vivo.
Aims: Our strategy is to characterize the impact of a short-term HFD on HSC
and hematopoiesis in non-obese C57BL/6J mice.
Methods: In a prospective study, C57BL/6J mice were fed a control diet (4
kJ% of fat) or HFD (42 kJ% of fat), over a short period of 4 weeks, to investigate
the direct-impact of such a diet on hematopoiesis.
Results: While fat intake leaded to an increase in plasma cholesterol levels,
mice did not develop obesity, and no inflammatory monocytes and no modu-
lation of pro-/anti-inflammatory cytokine levels were detected in blood and BM,
respectively. No significant impact was observed on the total number of cells
in blood and BM. However, we noted an increase in the number of progenitors
and a loss of more than 50% of the most primitive HSC (SLAM). We validated
this loss via transplantation of BM isolated from HFD-fed mice (Ly.1) in com-
petition with control BM (Ly.2), in lethally irradiated recipient mice which only
reconstitute 20% of the recipient hematopoiesis from HFD HSC. To further
investigate lipid metabolism in HSC, we quantified the major lipid constituents
in control and HFD HSC. Among altered lipids, cholesterol was the most affect-
ed in HFD HSC. These changes might alter the structure of the HSC plasma
membrane such as lipid rafts (LR), which are important for signal transduction
in hematopoiesis, driving the retention/dormancy of HSC in BM. To determine
if fat intake may affect LR quantity in hematopoietic cell membrane, we stained
Lineage-negative (Lin-) cells with the cholera toxin subunit B (CTB) and ana-
lyzed the distribution of different populations of hematopoietic cells, expressing
either high (CTBhi) or low (CTBlo) levels of LR. Fat intake disrupts CTBhi cells
in the Lin- Sca-1+ c-Kit+(LSK) and LSK-CD34- compartments, while no variation
was detectable among progenitors (Lin- c-Kit+and Lin-). Importantly, we dis-
covered that CTBhi cells were enriched with SLAM HSC (46%, versus 2% for
the CTBlo). While we found ~50% of CTBhi cells among LSK-CD34- HSC in
control diet-fed mice, a HFD has led to a loss of the CTBhi population. Using
the proliferation marker Ki67, we observed a decrease in the proportion of
LSK-CD34- primitive HSC in G0, meaning that HSC quiescence state was
affected by a HFD. Transforming growth factor (TGF)-β signaling has long been
known to be involved in modulating HSC quiescence, partly by preventing HSC
re-entry into the cell cycle. As a HFD induced a loss of LR on HSC, we looked
at the localization of TGF-β receptor 1 (TR1) on the LSK-CD34-cell surface.
While TR1 strongly colocalized with LR in macrodomains on HSC, we observed
that LR were more organized in microdomains and the delocalization of TR1
among LR was furthermore detected when mice were fed a HFD. Moreover,
reduced phospho-Smad2/3 indicated lower activation of the TGF-β pathway in
HSC purified from HFD-fed mice. Finally, injection of recombinant TGF-β1 led
to the rescue of the 4 week HFD-dependent SLAM HSC depletion, which clearly
highlights that a HFD affects TGF-β signaling on HSC.
Summary/Conclusions: In conclusion, HFD markedly and rapidly affects prim-
itive hematopoiesis and impairs the maintenance of primitive HSC in non-obese
mice. Not only our results uncover the impact of HFD independently of obesity
but they also identify the disturbance of LR/TGF-β signaling-mediated quies-
cence as its main molecular mechanism of action.
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A NOVEL MODEL OF HUMAN LYMPHO-MYELOID PROGENITOR
HIERARCHY BASED ON SINGLE CELL FUNCTIONAL AND
TRANSCRIPTIONAL ANALYSIS
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Background: Human hemopoiesis produces 10 billion new, terminally mature,
blood cells daily; a production that is also rapidly responsive to external change.
Dysregulation of this complex process can lead to hemopoietic and immune
deficiencies and blood cancers. In humans the hemopoietic progenitor hierar-
chy producing lymphoid and granulocytic-monocytic (myeloid) lineages is
unclear. Multiple progenitor populations give rise to lymphoid and myeloid cells
but they remain incompletely characterized at the immunophenotypic, tran-
scriptional and functional level. 
Aims: Here, we aim to understand the clonal functional output and transcrip-
tional programs of current primary human lympho-myeloid containing progenitor
populations - the lymphoid-primed multi-potential progenitor (LMPP)1, multi-
lymphoid progenitor (MLP)2 and granulocyte-macrophage progenitor (GMP). 
Methods: We devised a FACS-staining and sorting strategy to prospectively
purify eight human hematopoietic stem and progenitor cell (HSPC) populations.
We compared function of LMPP, MLP and GMP in vitro by quantitative CFU
assays, single cell liquid cultures or limit dilution analysis and in vivo by trans-
plantation into humanized ossciles. We performed population RNA sequencing
and single cell RT-PCR analysis to understand the relationship between func-
tional and transcriptional heterogeneity.
Results: Our study comprehensively characterized the LMPP, MLP and GMP
lympho-myeloid populations. Both LMPP and MLP are very rare within the
mononuclear fraction (1 in 104 to 1 in 105). We cultured 3806 single LMPP,
GMP and MLP cells (isolated from 21 cord blood units and equivalent to ~1011
mononuclear cells) under three different culture conditions. We observed
marked functional heterogeneity in the three lympho-myeloid progenitor pop-
ulations. Focusing on the wells that gave single cell initiated cultures the major-
ity of cells from LMPP, MLP and GMP gave unilineage output (50-80%). Bi-lin-
eage output was the next most common output, while multilineage output was
rare and only seen from LMPP and GMP cells (9-15%). In vivo transplantation
using a novel humanized ossicle assay increased the engraftment of lympho-
myeloid progenitors 10-fold compared to previous reports. In vivo, the LMPP
and GMP gave robust engraftment but the MLP substantially less engraftment.
The LMPP gave rise to both GM and B cell engraftment, the GMP myeloid
engraftment and the MLP mainly B cell output. RNA-Seq revealed distinct tran-
scriptional signatures of these populations: MLP signature enriched for lym-
phoid-affiliated genes and transcription factors (TF), GMP gene signature
enriched for myeloid-affiliated genes and TF and LMPP a hybrid lympho-
myeloid signature. Analysis of the expression of 72 genes in 919 single LMPP,
MLP and GMP shows that the 3 populations form a transcriptional continuum.
Moreover, this analysis allowed us to further purify the myeloid potential of
GMP population with the use of an alternative sorting strategy.
Summary/Conclusions: These data change our understanding of human
hematopoiesis and propose a radically new model of lympho-myeloid progen-
itor specification. This model has important implications for human immune
deficiencies and hemopoietic malignancies.
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WILMS’ TUMOR 1 RNA-ELECTROPORATED DENDRITIC CELL
VACCINATION AS POST-REMISSION TREATMENT TO PREVENT OR
DELAY RELAPSE IN ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A
PHASE II STUDY IN 30 PATIENTS
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Background: Relapse is a major problem in acute myeloid leukemia (AML)
and adversely impacts survival. 
Aims: The aim of this phase II study was to determine the clinical efficacy of
dendritic cell (DC) vaccine therapy in AML, and, more specifically, whether this
form of immunotherapy can be applied in the post-remission adjuvant setting to
decrease the risk of relapse following chemotherapy and to improve survival.
Methods: We vaccinated 30 AML patients in remission following poly-
chemotherapy, but at very high risk of relapse with autologous DCs loaded with
the Wilms’ tumor 1 (WT1) antigen by means of mRNA electroporation, a tech-
nique that allows for human leukocyte antigen haplotype-independent, multi-
epitope antigen presentation to T-cells. The vaccines were administered intra-
dermally. WT1 mRNA levels in blood and marrow were followed as a measure
of minimal residual disease. Circulating WT1-specific CD8+T-cells obtained
before vaccination and after the 4th dose of DCs were stained with WT1 pep-
tide-HLA-A*0201 tetramers.To assess cell-mediated immunity in vivo, delayed
type hypersensitivity (DTH) skin testing was performed 2 weeks after the 4th
DC vaccination by intradermal injection; DTH-infiltrating lymphocytes collected
from skin biopsies were expanded for 2-3 weeks in medium with interleukin-2,
harvested and tested for WT1 specificity and reactivity.
Results: There was a demonstrable anti-leukemic response in 13/30 patients
(overall response rate 43%). Nine patients achieved molecular remission as
demonstrated by normalization of WT1 transcript levels, 5 of which are sus-
tained after a median follow-up of 109.4 months, including 1 patient who went
from partial remission to complete remission by DC vaccination only. In the
remaining 4 responding patients, the clinical response was characterized by
stable disease as demonstrated by elevated but stable WT1 transcript levels
in blood for 3-12 months and stable blood values without blasts. Five-year
overall survival was 40%, as compared to 24.7% in the SEER data of the
National Cancer Institute; it was significantly higher in responders than in
non-responders (53.8% vs 25.0%; P=0.01). In patients receiving DCs in first
complete remission (CR1), there was a vaccine-induced relapse reduction
rate of 25% and the 5-year relapse-free survival was significantly higher in
responders than in non-responders (50% vs 7.7%; P<0.0001). In patients
≤65 and >65 years who received DCs in CR1, 5-year overall survival was
69.2% and 30.8% respectively. Of the 30 patients, 11 are alive in CR, including
5 who relapsed after DC vaccination; 2 proceeded to allogeneic stem cell
transplantation, while the 3 other patients were brought back into CR by
chemotherapy alone, 2 of them surviving more than 7 and 4 years respectively
after reachieving CR. Long-term clinical response was correlated with
increased circulating frequencies of poly-epitope WT1-specific
tetramer+CD8+T-cells. Long-term overall survival was correlated with inter-
feron-γ+and tumor necrosis factor-α+ WT1-specific responses in DTH-infil-
trating CD8+T-lymphocytes. 
Summary/Conclusions: Vaccination of AML patients with WT1 mRNA-elec-
troporated DCs can be an effective and non-toxic strategy to prevent or delay
leukemia relapse after standard chemotherapy, translating into improved overall
survival rates, which are correlated with the induction of WT1-specific CD8+T-
cell responses.
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Background: To test the safety and efficacy of the CAR T cell modality in
relapsed/refractory multiple myeloma (MM), we have designed a second-gener-
ation CAR construct targeting B cell maturation antigen (BCMA) to redirect T cells
to MM. bb2121 consists of autologous T cells transduced with a lentiviral vector
encoding a novel CAR incorporating an anti-BCMA scFv, a 4-1BB costimulatory
motif and a CD3-zeta T cell activation domain. We will report updated safety and
efficacy results following promising initial results (Berdeja et al., ENA 2016).
Aims: The primary objective is to determine the maximally tolerated dose of
bb2121 in subjects with MM whose tumors express BCMA, to determine and
test a recommended phase 2 dose for future studies. The secondary objective
is to provide preliminary efficacy data on the anti-tumor effects of treatment
with bb2121 in subjects with MM whose tumors express BCMA.
Methods: CRB-401 (NCT02658929) is a multi-center phase 1 dose escalation
trial of bb2121 in patients with relapsed and/or refractory MM who have received
≥3 prior regimens, including a proteasome inhibitor and an immunomodulatory
agent, or are double-refractory, and have ≥50% BCMA expression on plasma
cells. Peripheral blood mononuclear cells are collected via leukapheresis. Patients
undergo lymphodepletion with Flu (30 mg/m2) Cy (300 mg/m2) daily for 3 days
then receive 1 infusion of bb2121. The study follows a standard 3+3 design with
planned dose levels of 5.0, 15.0, 45.0, 80.0 and 120 x 107CAR+T cells.
Results: Asof November 18, 2016, 11 patients had been infused with bb2121
in the first 4 dose cohorts, and 9 patients had reached at least 1 month of fol-
low-up. As of data cut-off, no dose limiting toxicities, and no >Grade 2 neuro-
toxicities or cytokine release syndrome (CRS) had been observed. Grade 1-2
CRS has been reported in 8/11 (73%) treated patients. All patients treated with
doses of 15.0 x 107 or higher remained on study and the overall response rate
(ORR) in the 9 evaluable patients is 100%, including 2 sCRs and 2 MRD-neg-
ative responses (sCR and VGPR). CAR+T cell expansion has been demon-
strated consistently. An additional 6 months of follow up on reported results
and initial data from an additional ~10 patients will be presented.
Summary/Conclusions: bb2121 shows promising efficacy at dose levels above
5.0 x 107CAR+T cells, including 2 sCRs and ongoing clinical responses at 6
months with mild and manageable CRS to date. These initial data support the
potential of CAR T therapy with bb2121 as a new treatment paradigm in MM.
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BASELINE AND EARLY POST-TREATMENT CLINICAL AND LABORATORY
FACTORS ASSOCIATED WITH SEVERE NEUROTOXICITY FOLLOWING
19-28Z CAR T CELLS IN ADULT PATIENTS WITH RELAPSED B-ALL 
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Background: CD19-specific chimeric antigen receptor (CAR) modified T cells
produce high anti-tumor activity in relapsed or refractory (R/R) ALL, but can be
associated with cytokine release syndrome (CRS) and neurotoxicity (NTX). 
Aims: We examined baseline and post-treatment clinical and laboratory para-
meteres to identify factors associated with severe NTX (≥Grade 3) in our phase
I clinical trial of CD19-specific 19-28z CAR T cells for adult patients (pts) with
R/R B-ALL (NCT01044069). 
Methods: 51 adult pts with R/R B-ALL were treated with 19-28z CAR T cells fol-
lowing conditioning chemotherapy at MSKCC. In order to identify clinical and
serum biomarkers associated with severe NTX (sNTX), we examined demo-
graphic, treatment, and clinical blood parameters as well as in vivo CAR T expan-
sion and serum cytokines, and performed univariate and multivariate analysis. 
Results: In this cohort of ALL pts, 20, 8, 2, 18 and 3 pts experienced Gr 0, 1,
2, 3, and 4 NTX, respectively. No pt developed grade 5 NTX and no cerebral
edema was seen. Disease burden (≥50% blasts) at the time of T cell infusion
(p=0.0045) and post-treatment ≥Gr3 CRS (p=0.0010) were significantly asso-
ciated with sNTX, but we found no association with age, weight, T cell dose,
choice of conditioning chemotherapy (Flu/Cy s. Cy), and prior lines of treatment.
Among the clinical and blood parameters, fever, low PLT, high ferritin and MCHC
as well as elevated GM-CSF, IFNγ, IL-15, IL-5, IL-10, IL-2 at day 3 of T cell
infusion at day 3 of T cell infusion were significantly associated with sNTX (all
p<0.01). While some of these cytokines were also elevated in severe CRS cas-
es, IL-5 and IL-2 at day 3 were unique to sNTX. Furthermore, in vivo peak CAR
T expansion at day 7 (p=0.0001) significantly correlated with sNTX (p<0.01).
Lastly, multivariate analysis revealed baseline PLT <60 or MCHC >33.2% and
morphologic disease (>5% blasts) has 95% sensitivity and 70% specificity of
identifying sNTX pts. 
Summary/Conclusions: These data provide a characterization of early clinical
and serum biomarkers of sNTX in adult pts receiving 19-28z CAR T cells and
should help identify appropriate pts for early intervention strategy to mitigate NTX. 
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Background: Fanconi anemia (FA), is a monogenic inherited syndrome asso-
ciated with bone marrow failure (BMF), that has been considered a candidate
disorder for hematopoietic stem cell (HSC) gene therapy. Up to date, three
clinical trials have been performed, all of which failed to demonstrate engraft-
ment of corrected HSCs.
Aims: To demonstrate engraftment of gene-corrected HSCs in non-conditioned
Fanconi anemia patients.
Methods: To improve previous results, we proposed a new approach based
on two clinical trials. First, to increase the HSC collection, we designed a trial
employing a plerixafor plus G-CSF mobilization regimen. Second, to improve
the quality of corrected HSCs, cells were pre-stimulated for only 8-10 hours
and transduced with a new lentiviral vector (PGK-FANCA.Wpre*) for 12-14h,
a substantially shorter duration than in previous trials. To avoid chemotherapy-
induced damage, a conditioning regimen was not included in the trial, based
on the expected proliferative advantage of autologous corrected HSCs.
Results: Eight patients have been included so far in the HSC collection trial.
No severe adverse events (SAE) related to the procedure have been reported.
The most relevant AE has been the transfusion of packed red blood cells and
platelets. Six FA patients aged 3-6 years underwent collections after mobiliza-
tion of significant numbers of CD34+cells (10 to 70 CD34+cells/µL) to peripheral
blood. Two patients (15 and 16 years) failed to mobilize. On average, 5 million
CD34+cells/Kg were collected, with 45% recovery after immunoselection. In
the first patient included in the gene therapy trial, fresh immunoselected
CD34+cells were transduced with the therapeutic vector. Subsequently, two
patients, were infused with transduced CD34+cells that remained cryopre-
served for almost 2 years. Infused cell products contained 0.5 to 1.4 million
CD34+cells/kg, and vector copy numbers per cell (VCN/cell) that ranged
between 0.17 to 0.45. To-date, there has been no SAE related to the procedure.
Engraftment of gene corrected cells has been observed in the three patients.
Notably, increased gene marking levels and significant phenotypic correction
in the hematopoietic progenitor cells, deduced from the acquired resistance of
the colony forming cells to mitomycin C (15% of BM CFCs survived to 10 nM
MMC), have been demonstrated after 9 months of follow up in one of the
patients.
Summary/Conclusions: Our preliminary results show that 1) HSCs collection
is both safe and efficient in very young FA patients after mobilization with G-
CSF and plerixafor, and 2) Engraftment and proliferation advantage of gene-
corrected HSPCs has been demonstrated in FA patients even in the absence
of conditioning regimens.
The long-term follow up of patients included in these clinical trials will demon-
strate the feasibility of restoring the hematopoietic function of FA patients by
means of a gene therapy approach in the absence of conditioning.
S145
TARGETING FLT3 WITH CHIMERIC ANTIGEN RECEPTOR T CELLS
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Background: Adoptive immunotherapy with chimeric antigen receptor (CAR)-
modified T cells has therapeutic potential in hematologic malignancies. We are
pursuing FMS like tyrosine kinase 3 (FLT3) as a novel CAR target in acute
myeloid leukemia (AML). FLT3 is a homodimeric transmembrane protein with
uniform expression on AML, irrespective of cytogenetic and histomorphologic
subtype. FLT3 provides survival signals to AML blasts and is a key driver of
leukemia-genesis in AML cases with internal tandem duplication (FLT3-ITD).
These attributes suggest FLT3 may be an ‘Achilles heel’, making AML blasts
susceptible to CAR T-cell mediated recognition and elimination. 
Aims: We therefore explored the anti-leukemia efficacy of FLT3-CAR modified
T cells against FLT3-ITD+and FLT3 wild type AML in pre-clinical models in vitro
and in vivo.
Methods: A FLT3-CAR comprising a single-chain variable fragment (4G8),
fused to an IgG-Fc spacer, and signaling module with CD3 zeta and CD28
was encoded in a lentiviral vector (epHIV7) for gene-transfer into CD8+and
CD4+T cells of healthy donors (n>4) and AML patients. CAR T-cell mediated
cytolytic activity was evaluated in FACS-/luminescence-based assays, cytokine
production analyzed by ELISA and proliferation assessed by CFSE dye dilution.
Immunodeficient NSG mice were engrafted with AML cell line (Molm-13) or
primary AML blasts and treated with 5x106CAR-modified or control T cells
(CD8:CD4 ratio=1:1). 
Results: We confirmed specific recognition and high-level cytolytic activity of
CD8+FLT3-CAR T cells against a panel of AML cell lines including THP-1 (FLT3
wild type), and Molm-13 (FLT3-ITD heterozygous). Both CD8+and CD4+FLT3-
CAR T cells produced IFN-γ and IL-2, and underwent proliferation after antigen
stimulation. FLT3-CAR T cells that we prepared from AML patients exerted
specific anti-leukemia reactivity against autologous primary AML blasts, with
near-complete cytolysis within 24 hours of co-culture. Further, FLT3-CAR T
cells conferred a potent anti-leukemia effect in in vivo models of systemic
leukemia, both with AML cell lines (Molm-13) and primary AML blasts. A single
dose of FLT3-CAR T cells conferred complete eradication of leukemia from
peripheral blood, bone marrow and spleen, as confirmed by bioluminescence
imaging and flow cytometry. FLT3 is not expressed in any normal solid tissues
and mature hematopoietic cells, but shows limited expression in hematopoietic
progenitors and hematopoietic stem cells (HSCs). Preliminary data show that
FLT3-CAR T cells recognize FLT3+/high normal HSCs and interfere with normal
hematopoiesis, but preserve a proportion of HSCs capable of reconstituting
hematopoietic lineages. Studies to assess recognition of normal HSCs in vivo
are ongoing. 
Summary/Conclusions: Collectively, our data demonstrate that T cells
expressing a FLT3-specific CAR mediate potent reactivity against FLT3 wild
type and FLT3-ITD+AML in vitro and in vivo, and establish FLT3 as a novel
CAR target in AML. FLT3-ITD positivity identifies a high-risk AML subgroup
that may particularly benefit from adoptive therapy with FLT3-CAR T cells, e.g.
in order to achieve ‘minimal residual disease’ (MRD) negativity prior to allo-
geneic HSC transplantation. Our data further suggest that in contrast to CD33
and CD123, which are pursued as alternative CAR targets in AML, targeting of
FLT3 may preserve a fraction of normal HSC and enable the implementation
of CAR therapy outside the transplant setting.
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BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9
SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL
TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL
MALIGNANCIES AND NON-MALIGNANT CONDITIONS
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Background: Allogeneic haploidentical hematopoietic stem cell transplant
(HSCT) offers curative therapy for children who lack an available HLA-identical
donor with hematopoietic disorders such as Primary Immune Disorders (PIDs),
hemoglobinopathies, erythroid disorders and acute leukemias. αβ T-cell deple-
tion mitigates the risk of GVHD after haplo-HSCT, but is associated with extend-
ed immunodeficiency, leading to complications due to infections . We have per-
formed αβ TCR-depleted haplo-HSCT with post-transplant infusion of BPX-
501 gene modified T cells to allow for more rapid immune reconstitution. Upon
occurrence of GVHD, administration of rimiducid (AP1903) dimerizes the Cas-
pase 9 suicide switch and rapidly induces apoptosis of the transduced BPX-
501 cells and mitigates the GVHD.
Aims: This study was performed to determine the impact of BPX-501 T cell
infusion on outcomes (treatment related mortality (TRM), disease recurrence,
GvHD incidence and immune reconstitution) after HSCT.
Methods: We report on a large multicenter, prospective Phase I-II study
enrolling children receiving αβ T-cell depleted Haplo-HSCT. Patients were
infused with BPX-501 T cells 2 weeks post-transplant. 104 patients have >100
day follow-up, 81 patients have follow up ≥180 days and 51 with >1 year fol-
low-up. All patients received myeloablative therapy and low dose ATG prior to
transplant. No pharmacologic GvHD prophylaxis was given (Table 1).
Table 1. Diagnoses of Patients with >100 day follow-up.
Results: Cumulative incidence of TRM remains very low at 100 days (0%),
180 days (1.6%) and 1 year (2.8%). Of the 81 patients with >180 day follow-
up, 20 patients had acute GvHD 1-3 (24.7%) (Figure 1A); 10 with Grade 1, 8
with Grade 2, 2 with Grade 3 and one Grade 4 skin. Mild cGvHD was seen in
2 patients, moderate cGvHD in 2 patients and one case of severe cGvHD in a
malignant patient, attributed to the allograft, not BPX-501. Rimiducid was used
in 4 patients with Grade 2 GvHD with rapid resolution of symptoms, as it did in
the severe cGvHD patient. In both malignant and non-malignant patients. CD3,
CD4, CD8 (Figure 2B) and B cells (Figure 3C) immune reconstitution was brisk.
CD3+/CD19+ T-cells were detectable at one year via flow cytometry analysis
of peripheral blood. In Wiskott-Aldrich patients, platelet recovery remains in the
normal range at 180 days with mean platelet counts of 246.3x103/uL. At 180
days and 1 year, the patients with hemoglobinopathies remain transfusion-free
with a normal mean HgB value of 11.4 g/dL.
Summary/Conclusions: These data suggest that infusion of BPX-501 modified
T cells may facilitate T cell depleted Haplo-HSCT in children who would benefit
from HSCT for either malignant or non-malignant conditions. The availability of
a suicide gene mechanism in donor T cells infused after T depleted Haplo-
HSCT, results in low rates of infection and rapidly reversible GvHD when the
dimerizer is infused to activate the suicide switch. Rapid cellular and humoral
immune reconstitution makes BPX-501 after T depletion a safe and viable
option for children who do not have a matched donor transplant and in whom
transplantation has been deemed curative.
Figure 1.
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RE-CREATING HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN
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THALASSEMIA
M. Lin1, E. Paik1, B. Mishra1, S. Chou1, D. Burkhardt1, A. Kernytsky1,
M. Pettiglio1, S. Corcoran1, Y.-S. Chen1, K. Tomkinson1, A. Sanginario1,
A. Woo1, Y. Zhang1, M.J. Lee1, M. Allen1, T. Cradick1, S. Tan1, J. West1,
M. Weinstein1, M. Cortes1, T. Borland1, L. Klein1, W. Fodor2, A. Yen3,
S. Mahajan3, M. Wood3, E. Chan3, B. Eustace3, M. Porteus4, C. Lee5, G. Bao5,
A. Miccio6,7,8, A. Lattanzi6, F. Mavilio6, T. Chakraborty1, C. Cowan1, R. Novak1,
A. Lundberg1,*
1CRISPR Therapeutics, Cambridge, 2Cell Therapy Group, Madison, CT, 3Ver-
tex Pharmaceuticals Incorporated, Boston, 4Stanford University, Stanford, 5Rice
University, Houston, United States, 6Genethon, Evry, 7INSERM, 8Imagine
Institue, Paris, France
Background: Extensive human genetic and epidemiological data demonstrate
that the genetic condition Hereditary Persistence of Fetal Hemoglobin (HPFH)
substantially ameliorates the pathology of Sickle Cell Disease (SCD) and β-
thalassemia (β-Thal). This condition is associated with several genetic variants
at the β-globin locus that lead to transcriptional reactivation of γ-globin genes,
resulting in upregulation of fetal hemoglobin (HbF).
Aims: CRISPR/Cas9 is a revolutionary technology that allows for precise,
directed changes to genomic DNA. Our strategy is to use CRISPR/Cas9 in
human primary CD34+ hematopoietic stem and progenitor cells (HSPCs) to re-
create specific HPFH genetic variants as well as other variants associated with
elevated HbF and demonstrate their causal relationship to elevated HbF as a
potential therapeutic strategy to treat SCD and β-Thal.
Methods: Using CRISPR/Cas9 gene editing, we have successfully re-created
genetic variants linked to high HbF levels in HSPCs from healthy donors and
SCD and β-Thal patient samples, and determined the relationship of different
genetic variants to upregulation of γ-globin in bulk and clonal populations of
differentiated erythrocytes. Off-target editing was assessed, and on-target edit-
ing in long-term repopulating subsets of HSPCs was measured in vitro and by
engraftment in immunocompromised mice. Finally, editing rates at clinical scale
in a GMP-capable manufacturing facility were demonstrated.
Results: We first optimized cell culture and electroporation conditions that led
to high rates of genomic editing across multiple loci, achieving 84.9±6.2%
(Mean±SD) editing efficiency at key regions of interest in CD34+ HSPCs from
mobilized peripheral blood of healthy donors (n=16). Similar rates of editing
were attained using CD34+ HSPCs derived from healthy-donor bone marrow
(n=6). Cas9 delivery as recombinant protein improved cell viability when com-
pared to mRNA-based delivery (88.8±3.7% compared to 75.5±9.3%, Mean±SD,
n=56 for each) with no observed reduction in editing efficiencies. To investigate
gene editing impact on HbF, edited cells were erythroid differentiated from
healthy donors as well as from SCD and β-Thal patients. Specific gene edits
significantly increased γ-globin mRNA expression to therapeutically-relevant
levels (increased expression to 29-37% as a ratio of γ/α in one β-Thal patient
sample and to 25-45% as a ratio of γ/(γ+β) in six SCD patient samples). We
demonstrated similarly high rates of editing in the CD34+CD38-CD90+CD45RA-
long-term repopulating HSPCs and bulk CD34+ HSPCs (87.9±6.4% compared
to 89.7±3.6%, Mean±SD, n=4). We confirmed that engraftment levels of edited
cells in immunocompromised mice were similar to control cells (% human CD45
in peripheral blood = 28.6±6.9% in controls versus 27.1±6.6% and 26.3±7.9%
for two guide targets, Mean±SD, n=48 for each). In-depth off-target analysis
haematologica | 2017; 102(s2) | 23
for a selected guide RNA confirmed no detectable genomic cleavage at over
5000 predicted off-target sites with a detection sensitivity of 0.2%, supporting
its safety for clinical use. Finally, we have demonstrated editing rates of >85%
at clinical scale in a GMP-capable manufacturing facility to enable clinical devel-
opment for SCD and β-Thal. Required safety toxicology studies are ongoing.
Summary/Conclusions: Using CRISPR/Cas9 we successfully created gene
edits that upregulate HbF in both healthy donor and patient samples. We have
also dissected the genotype-phenotype relationship for specific genetic modi-
fications, identifying the editing strategies which are most promising for re-
expressing HbF. We have optimized the conditions for modifying HSPCs,
including at clinical scale in a GMP-compliant setting, and demonstrated poten-
tial safety with no detectable off-target editing. These experiments support the
further development of specific CRISPR/Cas9 editing strategies of HSPCs to
treat SCD and β-Thal patients.
S148
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Background: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) of
childhood remains a major cause of death in high-income countries. It has a
yet unexplained peak incidence between 2-6 years of age and a potential
trigger was theorized a century ago with several possibilities of exposure to
infection in infancy. Recently in vitro and in vivo evidence strengthened the
causal role of exposure to infection in BCP-ALL (1, 2). However, it remains
unknown which molecular BCP-ALL subtype can be triggered by exposure to
infection and how the pre-leukemic clone evolves to BCP-ALL.
Aims: Aiming to understand the role of infection exposure in the etiology of
childhood BCP-ALL.
Methods: We have developed and characterized two independent GEMMs,
in addition to the Pax5+/- infection model (1), which were exposed to a common
infection environment. These represent childhood BCR-ABL1p190 BCP-ALL
and the most common subtype ETV6-RUNX1 BCP-ALL. Both model systems
ensure Sca1-directed expression of BCR-ABL1p190 or ETV6-RUNX1 in
HSC/PC in C57BL/6 x CBA mice and were characterized extensively with
respect to clinical, immunephenotypic and molecular genetic characteristics.
Whole exome (WES) and whole genome sequencing (WGS) was performed
of murine BCP-ALL on a HiSeq 2500 (Illumina) platform.
Results: Pax5+/- and Sca1-ETV6-RUNX1 mice develop BCP-ALL only after
exposure to common pathogens whereas BCR-ABL1p190micedevelop BCP-
ALL independent of exposure to common infection. The molecular mechanism
leading to BCP-ALL identified in the infection dependent GEMMs is determined
by the genetic predisposition (Pax5+/- or ETV6-RUNX1). Pax5+/- mice acquire
constitutive activating Jak3 mutations (6/9) in a susceptible B-cell precursor
population ((pro+pre)-B and immature B cells) (1). On the other hand Sca1-
ETV6-RUNX1 mice develop BCP-ALL at a low penetrance (10.75%; 10 out of
93) with a CD19+B220+IgM- cell surface phenotype and manifested with blast
cells in the peripheral blood (PB) and clonal immature BCR rearrangement.
High expression of Recombination Activating Gene 1 (Rag1) and loss of func-
tion mutations in Ebf1 were identified in murine BCP-ALL and are well known
in the context of human ETV6-RUNX1 leukemia. Additionally we identified a
high proportion of mutations in genes implicated in histone modification, i.e.
Kdm5c (no. J408) causing a premature stop. CRISPR-Cas9 knock down stud-
ies of KDM5C in a precursor B-cell line revealed facilitated Rag1/2 binding to
the histone complex (H3K4me3) as a potential molecular mechanism inducing
Rag1 off target activity in pre-leukemic ETV6-RUNX1 HSC/PC after exposure
to infection. In contrast to Pax5+/- and Sca1-ETV6-RUNX1 mice, Sca1-BCR-
ABL1p190 mice develop BCP-ALL independent of exposure to common
pathogens by reprogramming of a HSC/PC and subsequent loss of Pax5.
Summary/Conclusions: In summary, exposure to common pathogens can
trigger childhood BCP-ALL based on Pax5 loss of function or the common
ETV6-RUNX1 rearrangement. However the underlying molecular mechanism
(Jak-Stat signaling in Pax5+/- mice and histone modification in ETV6-RUNX1
mice) triggered by exposure to common infection is determined by the genetic
predisposition. On the other hand BCP-ALL, which emerge on the basis of a
potent oncogene (such as BCR-ABL1p190) can develop independent of expo-
sure to infection. These findings are important for encouraging the prospect of
novel interventions that might help to prevent or treat a significant proportion
of childhood BCP-ALLs.
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REVERSIBLE PHARMACOLOGICAL TARGETING OF RHOA ALLOWS
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Background: The use of platelets in transfusion has increased dramatically in
the last three decades. Cold temperature induces changes in glycosylation
and clustering of platelet glycoprotein (GP) Ib and cytoskeletal rearrangements,
which are recognized by host receptors resulting in lectin-mediated platelet
phagocytosis and clearance from circulation. As a result, current practice of
platelet storage for transfusion uses room temperature and associates with a
relatively high risk of bacterial growth and infection in susceptible patients.
Aims: Due to the cytoskeletal nature of the platelet changes upon refrigeration,
we hypothesized that the RHO family GTPase activity is pivotal in the cold
platelet lesion. Targeted intervention may benefit refrigerated storage.
Methods: Analysis of RhoA, Rac1 and Cdc42 activity was performed using
GST-Rhotekin and GST-PAK effector domain pulldown assays. Platelets were
obtained from anticoagulated (CPD or EDTA) human, Rhesus monkey and
murine whole blood. G04, NSC23766 and Casin, specific inhibitors for RhoA,
Rac and Cdc42, respectively, were titered and used at concentrations of 75
mcM, 50 mcM and 10 mcM, respectively. RhoA deficient murine platelets were
obtained from polyI:C-treated Mx1-Cre;RhoA f/f mice. Aspirin was administered
at a dose of 5 mg/Kg b.w. to mice and monkeys. Bleeding time was performed
using standard animal protocols. Transfused human/monkey platelets were
stored in plasma or PAS-III (67%)/plasma(33%) at RT or 1-9C for 7 days or 1-
4 hours for murine platelets.
Results: We found that either short- or long-term refrigeration activates RHOA
and RAC1, but not CDC42. Genetic deletion of RhoA or RHOA inhibition with the
small molecule inhibitor G04 suffices to completely prevent cold-induced platelet
clearance after long-term cold storage of murine or human platelets. The effect
of G04 is on-target since it mimics but does not modify the response of RhoA-
deficient platelets. The effect of G04 is reversible since removal of G04 after 7-
day storage restores RHOA activity to normal levels and allows normal extent of
shape change and spreading on fibrinogen. To analyze the kinetics and hemo-
static activity of cold stored inhibitor treated human platelets after xenotransfusion,
we analyzed the survival of xenotransfused human platelets after long term (7-
day) refrigeration in the presence and absence of inhibitors cocktail or individual
inhibitors in macrophage depleted, sub-lethally irradiated NSG mice (N=20/group)
as well as autologously transfused platelets in a crossover trial in Rhesus mon-
keys (n=5). Our results show that reversible inhibition of RHOA in refrigerated
platelets suffices to survival levels similar to the unrefrigerated control in 100%
of mice and 80% of monkeys (p<0.001). Our data further show that washing of
platelets stored for 7 days in G04/plasma maintains collagen–induced shape
change as well as normal aggregation of human platelets and restores bleeding
time correction after congenic or autologous transfusion in all aspirinated mice
and 80% of aspirinated Rhesus monkeys, respectively. RHOA inhibition
blocks the process of intracellular traffic of GP through lipid rafts and endocytotic
intermediates as assessed by confocal microscopy of GpIb and the vacuolar
sorting protein VPS33b, as well as biochemical fractionation of detergent-insol-
uble membrane lipid rafts, resulting in reduced blebbing and formation of
microparticles upon storage in G04/plasma.
Summary/Conclusions: We demonstrate that activation of RHOA is a pivotal
mechanism of refrigerated platelet storage lesion and phagocytosis. Reversible
inhibition of RHOA allows the extended cold storage of platelets which are
effective in vitro and in vivo, suitable for use in clinical safety and efficacy trials.
Our study also provides the mechanism and a stringent proof-of-principle for
the translational application of a novel approach to refrigerated platelet storage. 
S150
TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE
HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS
OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE
GERMAN HODGKIN STUDY GROUP
P. Borchmann1,*, H. Goergen1, C. Kobe2, M. Fuchs1, R. Greil34, J. M. Zijlstra5,
A. Hüttmann6, J. Markova7, J. Meissner8, M. Feuring-Buske9, M. Bentz10,
J. Dierlamm11, D. Kühnhardt12, A. Lohri13,14, U. Novak14,15, D. Eichenauer1,
H. Eich16, C. Baues17, H. Stein18, V. Diehl1, G. Kuhnert2, M. Dietlein2,
A. Engert1
1Department I of Internal Medicine, 2Department of Nuclear Medicine, Univer-
sity Hospital of Cologne, Cologne, Germany, 3IIIrd Medical Department,
Paracelcus Medical University and Salzburg Cancer Research Institute, 4AGMT
(Arbeitsgemeinschaft medikamentöse Tumortherapie), Salzburg, Austria, 5VU
University Medical Center, Amsterdam, Netherlands, 6Department of Hema-
tology, University Hospital of Essen, Essen, Germany, 7Third Faculty of Med-
icine, University Hospital Kralovske Vinohrady, Prag, Czech Republic, 8Uni-
24 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
versity of Heidelberg, Heidelbarg, 9Department of Internal Medicine III, Univer-
sity Hospital of Ulm , Ulm, 10Medizinische Klinik, Städtisches Klinikum , Medi-
zinische Klinik, Städtisches Klinikum , Karlsruhe, 11University Hospital Ham-
burg-Eppendorf, Hamburg, 12Zentrum für Innere Medizin, Hämatologie/ Onkolo-
gie, Charité Campus Mitte, Berlin, Germany, 13Cantonal Hospital Baselland,
Liestal, 14Swiss Group for Clinical Cancer Research (SAKK), 15ChurInselspital,
Bern University Hospital, Bern, Switzerland, 16Department of Radiotherapy,
University Hospital of Münster, Münster, 17Department of Radiotherapy, Uni-
versity Hospital of Cologne, Cologne, 18Berlin Reference Center for Lymphoma
and Haematopathology, Berlin, Germany
Background: The German Hodgkin Study Group (GHSG) applies the intensive
eBEACOPP regimen (dose-escalated bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and prednisone) to all newly diag-
nosed advanced-stage HL patients regardless of their individual risk-profile.
However, some patients might not be in need of such an intensive treatment to
achieve cure. Unfortunately, baseline risk factors as defined in the international
prognostic score cannot identify these patients reliably. Recent clinical research
suggests that early metabolic response assessment after 2 cycles of therapy
using FDG-PET (PET-2) can better predict the individual outcome. In particular,
a rapid response as determined by PET-2 negativity might allow reducing the
overall treatment intensity.
Aims: To assess the feasibility of decreasing the number of eBEACOPP cycles
in patients with negative PET-2 without loss of efficacy as determined by pro-
gression-free survival (PFS).
Methods: Between 05/2008 and 07/2014, we recruited patients with newly
diagnosed, advanced-stage HL aged 18–60 years. All patients gave written
consent before study entry. PET-2 was centrally assessed with FDG uptake
not higher than the mediastinal blood pool defined as negative. Patients with
negative PET-2 were randomly assigned to receive 6 or 2 additional cycles
(i.e. 8 or 4 cycles of eBEACOPP in total, respectively). PET-positive residues
after chemotherapy were irradiated. Based on the results of our previous HD15
trial, the protocol was amended in June 2011 and the standard therapy was
reduced from 8 to 6 cycles of eBEACOPP in total. The trial was designed to
exclude inferiority of 6% or more of the experimental treatment (4 cycles of
eBEACOPP) compared with the pooled standard treatment (8 or 6x cycles of
eBEACOPP) at 5 years.
Results: We enrolled 2,101 patients. 1,005 patients with negative PET-2 were
randomly assigned to either 8/6 cycles of eBEACOPP (n=504) or 4 cycles of
eBEACOPP (n=501). With a median follow-up of 55 months, estimated 5-year
PFS in the per-protocol set was 90.8% (87.9–93.7) with 8/6 cycles of eBEA-
COPP and 92.2% (89.4–95.0) with 4 cycles eBEACOPP (difference +1.4%,
95% CI -2.7–5.4, excluding the non-inferiority margin of -6%). In the standard
arm, 95% of patients had at least one acute hematological toxicity of CTCAE
grade 3-4 compared with 90% in the experimental arm, including severe infec-
tions in 75 (15%) and 40 (8%) patients, respectively. Acute severe organ toxi-
cities were documented for 91 (18%) and 38 (8%), respectively. 25 patients
(5%) in the standard group (8/6 cycles of eBEACOPP and 9 (2%) in the exper-
imental group (4 cycles of eBEACOPP) died; most frequent cause of death
was second malignancy (11 and 1 patient, respectively). No patient in the exper-
imental group died from treatment-related toxicities. Estimated 5-year overall
survival (OS) in the per-protocol set was 95.4% (93.4–97.4) with standard
eBEACOPP, and 97.7% (96.2–99.3) with 4 cycles of eBEACOPP (log-rank
p=0.004).
Summary/Conclusions: Metabolic response assessment using FDG-PET
after 2 cycles of eBEACOPP allows the reduction from therapy with 8/6 to only
4 cycles without loss of efficacy as determined by PFS in advanced-stage HL
patients. Furthermore, the abbreviated treatment with 4 cycles of eBEACOPP
is associated with improved tolerability and consequently leads to a significant
OS benefit over standard therapy. PET-guided reduced therapy with eBEA-
COPP combines outstanding efficacy with high safety. We therefore recom-
mend this treatment strategy for advanced-stage HL patients.
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TARGETED SINGLE CELL SEQUENCING TO IDENTIFY MUTATIONAL
HIERARCHY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
J. De Bie1,*, S. Demeyer1, E. Geerdens1, A. Uyttebroeck2, N. Boeckx3,
J. Cools1
1CME, KU Leuven, 2Pediatric Oncology, 3Laboratory Medicine, UZ Leuven,
Leuven, Belgium
Background: Acute lymphoblastic leukemia (ALL) is a common childhood
malignancy caused by clonal proliferation of immature B or T lymphoid cells.
ALL patients are primarily young children who respond well to chemotherapy,
with survival rates above 85%. However, if relapse develops, survival rates
drop to 15-50%. Recent studies have shown that at diagnosis, different ALL
subclones are present that are likely the result of clonal branched evolution.
Understanding this clonal evolution and the order at which mutations are
acquired can provide improved insights into the origins of leukemia relapse. 
Aims: To use single-cell sequencing to investigate (i) the heterogeneity of
leukemic T-ALL cells present at diagnosis and (ii) unravel the order in which
mutations were acquired during leukemia evolution.
Methods: Bone marrow samples taken at diagnosis and remission from 4 T-
ALL patients underwent whole genome and RNA sequencing. Somatic muta-
tions, indels and chromosomal translocations were confirmed using Sanger
sequencing. Primers were designed to specifically target these genetic alter-
ations, and included 40 primers against heterozygous SNPs for quality control
assessment.  A total of 1517 single cells (average of 379 cells per patient),
were sorted using flow cytometry or a microfluidic device and analyzed with
targeted sequencing. Cells were discarded from further analysis if locus and
allelic drop-out exceeded 33,3%. Jaccard hierarchical clustering was applied
to identify subclones and a new graph-based algorithm was developed to deter-
mine the order of mutation acquisition. Single CD34+CD38- hematopoietic
stem/progenitor cells (HSPCs) from the same samples were also isolated to
test for the presence of mutations in early progenitors.
Results: We detected between 2 and 4 separate clones in each T-ALL patient
sample. Every patient harboured one dominant clone comprising 46 to 98% of
all single cells that was highly mutated, accompanied by a number of smaller
subclones carrying fewer mutations. No mutually exclusive mutations, fusion
genes or deletions were observed between the clones arguing against inde-
pendent leukemic clonal initiation events. Instead, a more stepwise clonal hier-
archy became likely, with each clone harbouring more mutations than the last.
Using our newly developed graph-based algorithm, we found that early muta-
tions mostly occurred in genes of unknown significance and may represent a
pre-leukemic state. Three out of four patients also had an early mutation event
in a known oncogene (MED12, STAT5B or NOTCH1). Intermediate events
included loss of 9p and appearance of fusion genes, while alterations in
NOTCH1 were usually late events. Analysis of 185 single CD34+CD38- HSPCs
from the diagnostic and remission samples found that most early mutations
were detected in HSPCs at diagnosis and remained detectable at remission,
further confirming the pre-leukemic nature of these variants. Interestingly, 2 of
4 T-ALL cases had HSPCs at diagnosis in which all mutations could be detect-
ed, indicating that the accumulation of mutations can occur in progenitor cells
or in committed T-cells. During remission, we could no longer detect HSPCs
with all leukemic mutations.
Summary/Conclusions: We demonstrate that T-ALL patients have limited
heterogeneity at diagnosis and that targeted single cell sequencing can be
used to determine the cell of origin and the order of mutation acquisition. These
data also illustrate that HSPCs at remission carry a few early, pre-leukemic
events, while highly mutated HSPCs are eradicated during treatment, which is
in line with long term remission in T-ALL.
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Background: The ribosomal protein L10 (RPL10) R98S mutation occurs in
8% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases. RPL10
R98S leads to a proliferation defect in lymphoid cells but its oncogenic contri-
bution in pediatric T-ALL remains unclear. Treatment intensification and risk
stratification has reduced the relapse rate of T-ALL to ~15% but further improve-
ments will require strategies that focus on specific subtypes as RPL10 R98S;
if the long-term sequalae of toxic therapy are to be avoided.
Aims: 1) Explore the oncogenic contribution of the RPL10 R98S mutation in pedi-
atric T-ALL. 2) Define new therapeutic opportunities for RPL10 R98S defective T-
ALL. 3) Identify a biomarker indicative of the RPL10 R98S mutation in T-ALL.
Methods: Quantitative label-free proteomics was used to screen for protein dif-
ferences between RPL10 WT and R98S expressing Ba/F3 cells. Hits were con-
firmed by western blot in lineage negative (lin-) bone marrow (BM) cells extracted
from RPL10 WT and R98S knock-in mice and in RPL10 WT and R98S pediatric
T-ALL samples. Serial re-plating was established by plating 2000 cells/ml in
Methocult. Oxidative stress and mitochondrial activity was determined by Dihy-
droethidium and mitotracker. Viable cell counts were determined by Annexin V
exclusion. Chromatin immunoprecipitation was performed using the Imprint Ch-
IP kit followed by qRT-PCR. Human pediatric T-ALL samples were transplanted
into NOD-SCID/IL2γ-/-(NSG) mice for in vitro and in vivo inhibitor studies.
Results: The RPL10 R98S mutation provided a cell survival advantage in Ba/F3
cells and in serial re-plating assays of lin- BM cells derived from RPL10 R98S
knock-in mice. Proteomic profiling revealed metabolic reprogramming in RPL10
R98S cells through enhanced expression of peroxisomal enzymes Acox1, Acox3
and Paox. This expression facilitated peroxisomal β-oxidation of long chain fatty
acids which are substrates for PPARγ and which were consequently upregulated
together with CPT1A. Peroxisomal hyperactivation causes high intracellular H2O2
levels, explaining the observed elevated levels of reactive oxygen species (ROS)
in RPL10 R98S cells that could not be scavenged by the increased catalase
expression. High ROS levels and enhanced PPARγ binding drives the constitutive
overexpression of anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), responsible
for the leukemia cell survival benefit of RPL10 R98S cells. Bcl-2 targeted therapy
using venetoclax (ABT-199) reduced the expansion of RPL10 R98S knock-in
BM cells by 50%, while RPL10 WT BM cells were not inhibited by ABT-199. In
vivo, DMSO or ABT-199 50mg/kg therapy was started after the engraftment of
>2% human cells in the blood of mice xenografted with T-ALL samples and was
maintained 1/wk till disease end stage. RPL10 R98S xenografted mice that
received ABT-199 therapy presented a complete inhibition of human CD45+
leukemia progression in the blood, which was characterized by a 70-85% reduc-
tion in spleen weights, and 20-50% reduction of bone marrow engraftment.
Spleen weights of ABT-199 treated RPL10 R98S xenografted mice were only
slightly increased as compared to spleen weights of healthy NSG mice. In con-
trast, mice xenografted with RPL10 WT T-ALL samples showed poor in vivo
responses to ABT-199 treatment and all animals showed progressive disease.
Bcl-2 overexpression induced by peroxisomal hyperactivation was defined as
new target in RPL10 R98S defective T-ALL. Additionally, due to peroxisomal
hyperactivation, a peroxisomal oxidase involved in purine degradation may have
contributed to the observation that the waste product of purine degradation, uric
acid, was elevated above reference levels in the blood of RPL10 R98S mutant
pediatric T-ALL patients at diagnosis (Figure 1).
Figure 1.
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Summary/Conclusions: Uric acid provides an indicative biomarker of RPL10
R98S mutations in pediatric T-ALL patients, which may be used for screening,
providing early diagnosis and appropriate selection of patients in whom a Bcl-
2 targeted therapeutic approach could be considered.
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Background: We previously described a recurrent arginine-to-serine mutation
on residue 98 (R98S) in ribosomal protein L10 (RPL10), with a frequency of
8.6% in pediatric T-ALL cases. The R98 mutated residue contacts the catalytic
core (peptidyltransferase center, PTC) of the ribosome and causes ribosome
biogenesis and translational fidelity defects in yeast and lymphoid cells. These
observations suggest that the RPL10-R98S mutation may contribute to T-ALL
pathogenesis by inducing translational changes.
Aims: The spectrum of translated proteins (translatome) of RPL10 R98S
mutants was investigated in order to identify translational changes caused by
the mutation and potentially driving oncogenesis.
Methods: We performed ribosome footprinting (RNA sequencing of ribosome
bound RNA), polysomal RNA sequencing, total RNA sequencing and mass
spectrometry based quantitative proteomics on engineered RPL10-R98S or
RPL10-WT mouse lymphoid Ba/F3 cells.
Results: RPL10 R98S cells showed significant upregulation for 3% (n=178) of
the measured proteins and a downregulation of 1% (n=68). Moreover, polyso-
mal RNA sequencing and ribosome footprinting showed respectively 57 and
22 genes with significantly higher translational efficiency in RPL10 R98S, and
22 and 29 genes, with reduced translational efficiency. Among them, we also
found genes involved in T cell differentiation and proliferation. In particular,
Mapk6 presented reduced translational efficiency in the ribosome footprinting,
potentially due to differences in ribosome occupancy of an upstream ORF,
whereas the transcription factor Ikzf2, a master regulator of the upregulated
transcripts, was overexpressed at the transcriptional and protein level. Inter-
estingly, the results from the mass spectrometry and the polysomal RNA
sequencing datasets showed a significant enrichment and upregulation of mem-
bers of the JAK-STAT signaling pathway with Csf2rb/2, Jak1 and several Stats
being 1-3-fold elevated at the protein level and higher translation efficiency for
Lif, Socs1, Pim1, Osm, Il10ra, Cish and Il21r. Another interesting candidate
showing 5-fold upregulated protein levels was phosphoserine phosphatase
(Psph), a key enzyme in serine biosynthesis. Ribosome footprinting revealed
that this upregulation originates from a combination of higher transcription and
translational efficiency of the encoding gene. Elevated Psph protein levels were
confirmed by immunoblots in the RPL10 R98S Ba/F3 cells and in hematopoietic
cell cultures derived from Rpl10 R98S knock-in mice. Interestingly, exhausted
medium from RPL10 R98S Ba/F3 cells contained higher residual serine levels
as compared to RPL10 wild type expressing cells and this medium could sup-
port the survival of wild type Ba/F3 cells. Our data suggest that RPL10 R98S
expressing cells enhance their endogenous serine production, leaving more
serine that can support survival of neighboring cells.
Summary/Conclusions: Analysis of the translational changes associated with
the RPL10 R98S mutation reveals alterations for genes involved T cell differen-
tiation and proliferation: the atypical MAP kinase Mapk6, whose reduced trans-
lational efficiency still needs to be validated at the protein level, and the tran-
scription factor Ikzf2. Alterations were also found in the JAK-STAT signaling, an
established oncogenic cascade in T-ALL. Moreover, this is the first description of
a mutation in T-ALL that is linked to alterations in cellular serine biosynthesis.
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Background: Remarkable improvements made in the treatment of childhood
acute lymphoblastic leukaemia (ALL) in past decades have resulted in 5-year
survival rates approaching 90%. However, prognosis remains dismal for certain
subgroups of high-risk patients, including poor responders to induction therapy,
infants with ALL that harbor rearrangement of the Mixed Lineage Leukaemia
(MLL/KMT2A) gene, and children with Philadelphia chromosome positive ALL.
In particular, infant ALL patients with MLL disease have survival rates below
50% despite the use of intensified treatments, necessitating the development
of more effective, less toxic therapeutics for them.
Aims: The aim of this study is to identify candidates that target MLL-rearranged
leukaemia cells using drug-repurposing, whereby an approved drug is applied
to treat a disease other than the one for which it was originally intended. This
drug discovery strategy is gaining popularity as it potentially avoids the lengthy
process of drug development and FDA approval.
Methods: 3707 approved drugs and pharmacologically active compounds were
initially screened against an infant ALL cell line with MLL-rearrangement, PER-
485 and a paediatric leukaemia cell line wild-type for MLL, CEM, using a
resazurin-based cell viability assay. Hit compounds were further tested in a
panel of 16 leukaemia cell lines, seven solid tumour lines and two normal cell
lines. Compounds were subsequently evaluated in vitro for cytotoxic activity
against a panel of 20 paediatric high-risk ALL patient-derived xenograft (PDX)
cells. Apoptosis was measured by Annexin V positivity and PARP cleavage.
Reactive oxygen species (ROS) levels were assessed by DCF-DA staining and
detection by flow cytometry. Nrf2 protein expression levels were measured by
Western blotting.
Results: The screen resulted in the identification of two FDA-approved drugs
that were preferentially cytotoxic against MLL-rearranged ALL and other
leukaemia cell lines, compared to solid tumours and normal cells. Auranofin
was originally developed for rheumatoid arthritis and was later fast-tracked into
Phase II clinical trial for adult chronic lymphocytic leukaemia, while Disulfiram,
which was developed for treatment of chronic alcoholism, is currently in several
clinical trials for cancers including metastatic melanoma and glioblastoma.
These drugs also showed potent activity in high-risk paediatric leukaemia PDX
cells cultured in vitro, including MLL-rearranged ALL and Philadelphia-positive
ALL with IC50 values between 100-400 nM for Auranofin and 30-60 nM for
Disulfiram. Induction of apoptosis was evident at 6 hours post Auranofin treat-
ment, or after 12 hours Disulfiram treatment. Each drug significantly increased
intracellular ROS as early as one hour post-treatment (p<0.01), which was
accompanied by induction of Nrf2, a master regulator of the antioxidant
response. Incubation with ROS scavenger N-acetyl cysteine prior to treatment
with either drug prevented the increase in cellular ROS levels (p<0.05) and
rescued cells from apoptosis (p<0.0001), indicating involvement of reduction-
oxidation and increased ROS generation as mechanisms of leukaemia cell
death induced by these drugs.
Summary/Conclusions: In summary, we have identified two FDA-approved
drugs that demonstrated potent anti-leukaemia activity through induction of
ROS, potentially opening up new avenues for clinical treatment of high-risk
paediatric leukaemia. We will now be testing these potential therapies in vivo
using relevant PDX models of high-risk paediatric ALL.
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Background: Polychemotherapy resistance is a major challenge in the treat-
ment of children with relapsed acute lymphoblastic leukemia (ALL). Mutation
of TP53 is tightly associated with poor response to treatment in ALL relapse
patients.
Aims: We studied mutations of TP53 in ALL relapses and in six ALL cell lines to
shed light on mechanisms and pathways mediating TP53 dependent drug resist-
ance in relapsed ALL. First, we analyzed the spectrum of TP53 mutations in ALL
relapses and correlated it to treatment response of patients. Second, we studied
drug sensitivity in TP53 wild type (wt) versus TP53 mutant ALL cell lines.
Methods: TP53 was sequenced by the method of Sanger. Drug sensitivity was
determined by IC50 in ALL cell lines. Drugs included in the study were DNA
damage inducing agents as topoisomerase II inhibitors, alkylating agents,
nucleotide analoga, and other agents, most of which are used in ALL relapse
treatment protocols.
Results: We identified 20 different TP53 mutations in 34 patients. We clas-
sified TP53 mutations into ‘hot spot’ (R175, G245, R248, R273 and R282),
non-hot spot and frameshift, respectively. We found that hot spot TP53 muta-
tions were enriched in ALL relapse patients with non-response to treatment
compared to good responding patients (64 versus 27%). In ALL cell lines, we
confirmed TP53 mutations in Jurkat (R196*) and Loucy (V272M) and identi-
fied R248P in MHH. Three ALL cell lines were TP53 wt (SUP-B15, UOC-B6,
NALM-6) and used as controls. Topoisomerase II inhibitors upregulated
expression of wt p53. In contrast, nucleotide analoga showed no p53 induc-
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tion. IC50 measurements showed that TP53 mutations lead to resistance
against topoisomerase II inhibitors and alkylating agents, but not against oth-
er drugs. The upstream pathway of p53 (CHK1, CHK2) and DNA damage
recognition (γH2AX) were not impaired in the six ALL cell lines. To study the
effect of TP53 mutation on resistance to treatment in more detail, we focused
on the R248P mutation, located in hot spot codon 248, that we found in a
relapse patient with non-response to treatment and in the MHH cell line.
Using a CRISPR/Cas9 knockout (KO) of endogenous p53 and lentiviral based
re-expression in NALM-6, we generated p53 KO, and KO+wt p53, KO+R248P
and KO+GFP cell lines. The KO cells showed a similar resistance to DNA
damage inducing drugs as KO+R248P cells. Overexpression of wt p53 in
KO cells restored the sensitivity to DNA damage inducing drugs. In contrast
to wt p53, R248 did not inhibit cell proliferation under drug treatment. We
found that this mutant was unable to induce downstream targets of p53 (p21,
BAX). Moreover, ChIP-seq showed that R248P cannot bind the promotor
and induce expression of typical p53 targets MDM2, p21, BAX, BCC3/PUMA,
FAS or RRM2B/p53R2. This result indicates that R248P is deficient in binding
the consensus element of p53. However, the binding motif analysis showed
that the R248P mutant still binds DNA at a different and purine-rich sequence.
In summary, R248P leads to loss of wt p53 function and mediates resistance
to topoisomerase II inhibitors and alkylating agents.
Summary/Conclusions: Overall, our results show that mutations
affecting TP53 hot spots, in particular codon 248, are associated with resistance
of ALL cells to chemotherapy and reveal first insights into underlying mecha-
nisms and pathways.
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Background: T-cell acute lymphoblastic leukemia (T-ALL) and T-cell acute
lymphoblastic lymphoma (T-LBL) are aggressive immature T-cell malignancies
that are considered one disease entity according to the World Health Organi-
zation (WHO). Both T-ALL and T-LBL are often characterized by improper T-
cell receptor (TCR) recombinations leading to aberrant activation of proto-onco-
genes.
Aims: Despite some genetic and phenotypic similarities between T-ALL and
T-LBL, T-ALL risk group stratification cannot be extrapolated to T-LBL patients.
Therefore, it is our goal to find new T-LBL markers and develop new targeted
therapies based on those T-LBL specific markers.
Methods: Here, we used Targeted Locus Amplification (TLA, de Vree et al., Nat
Biotechnol, 2014) to identify a novel translocation (leading to PIM1 kinase over-
expression) in a human T-LBL patient. Unraveling the importance of PIM1 acti-
vation in T-LBL disease biology prompted us to do both RNA sequencing and
phosphoproteomic studies to identify its downstream targets. T-LBL patient
engraftment in NSG mice enabled us to study the therapeutic potential of PIM1
inhibition.  
Results: Applying the TLA technique lead to the identification of a novel
TCRβ driven t(6;7)(p21;q34) translocation in a human T-LBL patient resulting
in aberrant activation of the PIM1 proto-oncogene. PIM1 is a constitutively
active serine/threonine kinase involved in cell cycle progression, apoptosis,
transcription and drug resistance and is overexpressed in a variety of human
cancers. Further characterization of this PIM1 rearranged patient sample
revealed cooperative genetic alterations that target known T-ALL/T-LBL onco-
and tumor suppressor genes, including NOTCH1, IKZF1, EP300 and
CDKN2A. Comparing PIM1 expression between normal T-cell subsets, T-
ALL and T-LBL patient samples showed that T-LBL patients express signifi-
cantly higher PIM1 levels, confirming PIM1 activation is implicated in T-LBL
disease biology. Next, we looked at allelic expression ratios of PIM1 and
interestingly, we found skewed allelic expression in T-LBL, but not in T-ALL
patients. To study the oncogenic properties of PIM1 in the context of malig-
nant T-cell transformation, we did RNA sequencing and phosphoproteomics
on the T-ALL/T-LBL tumor line HSB-2 (high PIM1) after PIM inhibition with
TP-3654 (Foulks et al., Neoplasia, 2014). These data revealed that PIM1
inhibition has broad effects on transcription and phosphorylation substrates
involved in cell cycle, translation and apoptosis. Finally, we evaluated the
therapeutic potential of PIM1 inhibition. Daily TP-3654 treatment (4 weeks)
of T-LBL engrafted NSG mice resulted in strong anti-leukemic effects. Cur-
rently, we are evaluating if combination of PIM1 inhibition with chemothera-
peutics triggers a more profound anti-leukemic response (Figure 1). 
Summary/Conclusions: All together, our study identifies PIM1 as a putative
oncogene in T-LBL and suggests that inhibition of this serine/threonine kinase
could serve as a novel therapeutic strategy in this aggressive T-cell neoplasm.
Figure 1.
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Background: T-cell acute lymphoblastic leukemia (T-ALL) constitutes an aggres-
sive subset of ALL, the most frequent childhood malignancy. T-ALL cases are
high risk and a significant fraction of the patients still relapse despite intensive
chemotherapy, prompting the need for a deeper understanding of T-ALL biology
in order to develop novel therapies. Autophagy is a homeostatic intracellular
process characterized by the sequestration of cytoplasmic compartments within
double-membrane vesicles (autophagosomes) to promote their degradation.
Importantly, autophagy is upregulated during starvation, cellular stress or in rap-
idly dividing cells, such as cancer cells, as a compensatory mechanism to provide
nutrients and stress relief. By mitigating stress and allowing cell survival,
autophagy may serve as a pro-tumoral mechanism. On the other hand, persistent
autophagy can lead to cell death and thereby prevent tumor growth. Interleukin-
7 (IL-7) is essential for normal T-cell development but there is considerable evi-
dence that IL-7-mediated signaling can also contribute to leukemogenesis. A
majority of T-ALL patients expresses the IL-7 receptor and IL-7 accelerates T-
ALL disease progression in vivo and promotes T-ALL cell proliferation, survival
and metabolic activation in vitro via PI3K/Akt/mTOR pathway (a master negative
regulator of autophagy). IL-7 can also activate MEK/Erk pathway (which has
been implicated in promotion of autophagy).
Aims: Since IL-7 has the ability to activate signaling pathways with potentially
opposing roles in autophagy regulation, our goal was to explore the actual
impact of IL-7 on the autophagic process in T-ALL cells and elucidate its molec-
ular mechanisms and functional consequences.
Methods: We used an IL-7-dependent leukemia T-cell line (TAIL7) and “primary”
cells from patient-derived xenografts (PDX). We used inhibitors of PI3K
(LY294002), mTOR (rapamycin), MEK1/2 (UO126) and ULK1/2 (MRT68921).
Analysis of viability and cell size was performed by flow cytometry. Signaling
pathway activation and LC3-I/-II conversion was performed by western blot analy-
sis. LC3 puncta formation was assessed by confocal microscopy. Autophago-
some/autolysosome formation was analyzed by electron microscopy.
Results: We show that in optimal culture conditions (medium with serum) IL-7
inhibits autophagy in T-ALL, albeit in a complex manner that involves triggering
both pro- (via MEK/Erk) and anti- (via PI3K/Akt/mTOR) autophagic signaling. In
this scenario, IL-7-mediated viability relies on the latter pathway, as we previously
described. In contrast, under stress conditions (serum starvation) IL-7 promotes
autophagy in leukemia cells. In this situation, IL-7-mediated survival partially
relies on autophagy activation and strictly requires MEK/Erk activation. Mecha-
nistically, we provide evidence that depending on culture conditions, IL-7 can
balance the relative activation of PI3K/Akt/mTOR and MEK/Erk pathways towards
or against autophagy in order to consistently promote T-ALL cell viability.
Summary/Conclusions: Our results suggest that IL-7 makes use of a ‘flexible
strategy’ to promote T-ALL cell viability by recruiting both pro- and anti-
autophagic pathways, which are differentially recruited to prevent tumor cell
death depending on the microenvironmental conditions. Our data strengthen
the notion that combination therapies against PI3K/Akt/mTOR and MEK/Erk
pathways may be of particular relevance in the context of T-ALL.
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Background: B-cell acute lymphoblastic leukemia (B-ALL) is the most common
malignancy of childhood and is highly curable with modern risk-adapted
chemotherapy. However, 15-20% of children and >60% of adults with B-ALL
develop chemoresistance and relapse, indicating need for new therapies. Addi-
tion of kinase inhibitors to chemotherapy for patients with BCR-ABL1-
rearranged (Ph+) B-ALL has dramatically improved event-free and overall sur-
vival, and similar approaches are now under active clinical investigation in
patients with BCR-ABL1-like (Philadelphia chromosome-like or Ph-like) B-ALL.
Recent studies have demonstrated activated spleen tyrosine kinase (SYK) sig-
naling in various genetic subtypes of B-ALL and preclinical activity of the
SYK/FLT3/JAK inhibitor fostamatinib. However, SYK activation in B-ALL and
potential correlation with specific leukemia-associated mutations remains
incompletely characterized. We hypothesized that constitutive activation of SYK
signaling occurs across a genetic spectrum of infant and high-risk childhood B-
ALL and can be therapeutically targeted in vivo with the selective SYK inhibitor
entospletinib (ento).
Aims: (1) Assess basal SYK signaling activation in childhood B-ALL speci-
mens. (2) Quantify treatment efficacy, pharmacokinetics (PK), and pharmaco-
dynamic (PD) effects of ento in childhood B-ALL patient-derived xenograft
(PDX) models.
Methods: Total and phosphorylated (p) SYK levels were assessed by Simple
Western analysis of splenic lysates from NSG mice well-engrafted with primary
pediatric B-ALL specimens (n=19 Ph-like, n=4 infant KMT2A-rearranged (R),
and n=4 infant non-KMT2A-R PDX models) to identify leukemias with consti-
tutive SYK signaling activation. To assess in vivo activity of SYK inhibition,
selected B-ALL PDX models with high basal pSYK (n=2) were treated with con-
tinuously provided control, ento 0.03%, or ento 0.07% chow. Cohorts of mice
were sacrificed after 21-28 days, and peripheral blood and spleens were har-
vested for downstream studies. Flow cytometric analyses of murine tissues
were performed to assess initial human ALL engraftment and to measure ento
treatment responses. PK and PD assessments were performed in terminal
peripheral blood and spleens, respectively.
Results: Constitutive pSYK signaling was observed in 10/19 Ph-like, 4/4
KMT2A-R, and 1/4 non-KMT2A-R B-ALL specimens. Ento treatment of KMT2A-
MLLT3 (ALL3103) and Ph-like NUP214-ABL1 (NH011) PDX models signifi-
cantly inhibited ALL proliferation in vivo versus control animals at both 0.03%
and 0.07% chow formulations (representative data in Figure 1; p<0.05). Steady
state concentrations were maintained throughout the study duration with ter-
minal PK values of 3.3 (± 0.5) and 7.9 (± 1.0) μM (0.03% and 0.07% ento arms,
respectively). PD studies demonstrated dose-dependent in vivo inhibition of
pERK measured in human leukemia cells within spleens of ento-treated mice
without alterations in total SYK protein levels. In general, PD inhibition of SYK
target phosphoproteins was more pronounced in 0.07% ento-treated animals.
Figure 1.
Summary/Conclusions: Constitutive activation of SYK signaling occurs fre-
quently in childhood Ph-like and infant KMT2A-R childhood B-ALL. Ento treat-
ment of B-ALL PDX models potently inhibited SYK pathway signaling proteins
and significantly inhibited leukemia proliferation in vivo. 
P159
PHARMACOLOGICAL ACTIVITY OF CB-103 – AN ORAL PAN-NOTCH
INHIBITOR WITH A NOVEL MODE OF ACTION
R. Lehal1,*, D. Weber1, V. Frismantas2, J.-P. Bourquin2, M. Bauer1, M. Murone1,
F. Radtke3
1Cellestia Biotech AG, Basel, 2University Children`s Hospital, Zürich, 3Swiss
Institute for Experimental Cancer Research, EPFL, Lausanne, Switzerland
Background: NOTCH signalling is a developmental pathway known to play
critical roles during embryonic development as well as for the regulation of self-
renewing tissues. Aberrant activation of NOTCH signalling leads to deregulation
of the self-renewal process resulting in sustained proliferation, evasion of cell
death, loss of differentiation capacity, invasion and metastasis, all of which are
hallmarks of cancer. When the NOTCH pathway is inappropriately activated by
genetic lesions (over expression of NOTCH ligands/receptors, GOF mutations
in NOTCH receptors as well as chromosomal translocations), it becomes a
major driver for NOTCH-dependent cancers and resistance to standard of care
treatment. Over 250´000 patients are annually diagnosed with NOTCH depend-
ent cancers, with no specific therapy available to date.
Aims: Given the importance of NOTCH signalling in human cancers, several
therapeutic approaches have been utilized to block NOTCH signalling. Two of
these strategies are; a) the use of monoclonal blocking antibodies (mAbs)
against NOTCH ligands and receptors and b) the use of small molecule gam-
ma-secretase inhibitors (GSIs). However, these approaches can only be effec-
tive if tumor cells express full-length ligand or receptor molecules. As validation
of NOTCH as a therapeutic target, clinical activity of these in clinical studies
were was observed in various trials for some of these inhibitors (mAbs, GSIs),
but treatment and exposure were usually limited due to toxicities, mainly related
to gastro-intestinal adverse events. On the contrary, in human cancers har-
bouring NOTCH gene fusion due to chromosomal translocations or specific
NOTCH mutations, the use of mAbs and GSIs will have very limited clinical
benefits. Cellestia has decided to follow a disruptive approach, by blocking
NOTCH signalling in the most downstream part of the NOTCH cascade, at the
level of the NOTCH transcriptional activation complex, using small molecule
inhibitors.
Methods: Here we report the pharmacological characterization of CB-103, a
first-in-class orally-active small molecule inhibitor of the NOTCH transcriptional
activation complex.
Results: We demonstrate that in vitro CB-103 potently inhibits NOTCH sig-
nalling in various leukemic and lymphoma cell lines, and T-ALL blasts derived
from relapse/refractory patients. In addition, CB-103 exhibited anti-tumor effi-
cacy in multiple in vivo models of NOTCH-driven T-ALL using T-ALL cell lines
and patients derived xenograft models.
Summary/Conclusions: Toxicology studies have been completed and clinical
development of CB-103 with a first-in-human Phase I/IIA clinical study in
advanced solid tumors and haematological malignancies is under preparation.
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IKZF1Δ4-7 CAN BE EASILY SCREENED BY PCR BUT DOES NOT PRE-
DICT OUTCOME IN ADULTS WITH ACUTE LYMPHOBLASTIC
LEUKAEMIA; DATA FROM 490 PATIENTS ENROLLED ON THE UKALL14
TRIAL
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Background: The IKZF1 gene encodes the IKAROS zinc finger transcription
factor and master regulator of lymphocyte differentiation. IKZF1 lesions are
common in acute lymphoblastic leukaemia (ALL) and have been reported as
independent prognostic factors for poor outcome. IKZF1Δ4-7, resulting in the
dominant negative IK6 isoform is the most common single IKZF1 deletion.
Aims: We aimed to generate and validate a simple, PCR-based screening
assay for IKZF1Δ4-7 and to determine its utility as a prognostic marker in B
precursor ALL using data from UKALL14 (ISRCTN 66541317)- a multicentre
phase 3 randomised trial for adults aged 25-65 years.
Methods: Diagnostic DNA from 490 bone marrow samples was screened for
IKZF1Δ4-7 using an endpoint PCR assay using primers located in introns 3
and 7. The lower limit of detection was determined by serial dilution of DNA
from the IK6-expressing cell line SUP-B15 and calculated to be 0.001%. A total
of 95 samples were also tested using the MLPA P335 kit to detect the full spec-
trum of IKZF1 deletion. Sanger sequencing confirmed the breakpoints in 27
cases.
Results: The median age of the patients tested was 46 years (range 25-65).
Overall IKZF1Δ4-7 was detected in 97/490 (20%) patients but the frequency
varied by genetic subtype. Patients with BCR-ABL1 fusion had the highest
IKZF1Δ4-7 frequency (46/150, 31%) followed by patients with B-other ALL
(29/154, 19%). Patients with other classic cytogenetic abnormalities harboured
significantly fewer IKZF1Δ4-7 – low hypodiploidy (3/26), MLL gene fusions
(3/31), t(1;19), (1/11), high hyperdiploidy (2/9) and iAMP21 (0/3). MLPA did not
detect any IKZF1Δ4-7 deletions that were not detected by PCR but did identify
several samples with alternative IKZF1 deletions affecting different exons (see
Table 1). By contrast, the PCR assay did detect six IKZF1Δ4-7 deletions unde-
tected by MLPA, consistent with the higher sensitivity of this approach. Inter-
estingly, three of these samples harboured alternative IKZF1 deletions in addi-
tion to IKZF1Δ4-7. In 70 (14%) cases, we observed a “faint” PCR band. Since
the biological relevance of this was not clear, the ‘faint’ bands were not included
in the main analysis. Interestingly the frequency of these “faint” bands was
similar across all genetic subtypes: BCR-ABL1 (14%), B-other (15%), MLL
(21%), low hypodiploidy (19%). We examined the impact of IKZF1Δ4-7 on
achievement of CR, persistence of minimal residual disease (MRD) at >1 x 10-
4 (Ig/TCR quantitation by EuroMRD criteria) after courses 1 and 2 of therapy,
EFS, OS and time to relapse, at a median follow-up of 23.1 months. Two thirds
of patients (44/66) with IKZF1Δ4-7 were MRD positive at the end of phase 1
compared with 147/273 (54%) patients without the deletion (p=0.059). Howev-
er, this relationship between IKZF1Δ4-7 and MRD did not persist after phase
2. We did not identify any association between IKZF1Δ4-7 and any of the other
outcome parameters tested.
Table 1.
Summary/Conclusions: IKZF1Δ4-7 can be detected by a simple and cheap
PCR assay, which is more sensitive than MLPA. The frequency of IKZF1Δ4-7
was broadly comparable with previous studies. However, we did not find an
association between IKZF1Δ4-7 and clinical outcome in this large clinical trial
sample set. We are in the process of evaluating the impact of other IKZF1
lesions.
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PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE
DETECTED BY MLL FUSION GENE TRANSCRIPTS IN INFANT ACUTE
LYMPHOBLASTIC LEUKEMIA. UPDATED RESULTS OF 76 PATIENTS
ENROLLED INTO MLL-BABY STUDY
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Background: Fusion gene transcripts (FGTs) are rarely used for minimal resid-
ual disease (MRD) monitoring in acute lymphoblastic leukemia (ALL) cases,
except of Ph-positive ALL. However in infant ALL, where MLL gene rearrange-
ments are found the majority of cases, MLL FGTs are attractive targets for
MRD detection.
Aims: To estimate prognostic significance of MRD by qualitative detection of
different MLL FGTs in infant ALL treated by MLL-Baby protocol.
Methods: Seventy six infants (27 boys and 49 girls) with median age of 5.8
months (range 0.03-11.83) were included in the current study. Among them
there were 39 (51.3%) MLL-AF4-positive cases, 14 (18.4%) MLL-MLLT1-pos-
itive, 12 (15.8%) MLL-MLLT3-positive, 6 (7.9%) MLL-MLLT10-positive, 4 (5.3%)
MLL-EPS15-positive ones. MRD detection was performed in BM samples by
real-time quantitative PCR and nested RT-PCR with sensitivity non-less than
1E-04. MRD-negativity was defined as absence of FGTs in the both assays.
Median of follow-up period in the observed group was 6.4 years. Informed con-
sent was obtained in all cases.
Results: We confirmed our earlier finding that the most informative TP for the
MRD detection was TP4 (G. Tsaur at al, EHA 2012 abs O1096). MRD-positivity
at TP4 led to unfavorable outcome in both MLL-AF4-positive patients stratified
to high-risk arm of MLL-Baby protocol (EFS 0.05±0.04 vs 0.78±0.07 p<0.0001;
cumulative incidence of relapse 0.78±0.10 vs 0.11±0.07 p<0.0001, respectively)
and for all others MLL-rearranged patients treated by intermediate risk (ImR)
arm (EFS 0.00 vs 0.71±0.11 p<0.0001; cumulative incidence of relapse 1.0 vs
0.29±0.10 p<0.0001, respectively). There were no significant differences in initial
patients’ characteristics and treatment response criteria (on days 8, 15, 36)
among 38 MRD-positive and 38 MRD-negative patients. Multivariate analysis
revealed that initial CNS disease (hazard ratio (HR) 2.703, 95% CI 1.255-5.284,
p=0.011), non-M1 status of BM on day 15 (HR 3.090, 95% CI 1.465-6.515,
p=0.003) and MRD-positivity at TP4 (HR 6.950 95% CI 2.617-18.456) were sig-
nificant covariates with negative impact on hazard of unfavorable event. Based
on dismal outcome of MRD-positive ImR patients we tried to augment their ther-
apy and relocated 5 of them from ImR group to HR arm after TP4. Although all
of them subsequently relapsed. We also wanted to find out which characteristics
might predict relapse in ImR patients who were MRD-negative at TP4 (n=5). Of
note, all these 5 relapsed patients (100%) had initial CNS disease while CNS
disease was detected only in 2 out of 19 ImR patients (10.5%) who stayed in
complete hematological and molecular remission (p=0.003). Also all 5 relapsed
ImR patients who were MRD-negative at TP4 had breakpoint positions within
intron 11 of MLL gene and they were MRD-positive by flow cytometry (MRD
≥0.01%) on day 15. None of MRD-negative patients by flow cytometry (MRD
<0.01%) on day 15 relapsed later on (p<0.001).
Summary/Conclusions: MRD monitoring by detection of MLL FGTs was fea-
sible and had significant prognostic impact. MRD-positivity at TP4 was an inde-
pendent factor of unfavorable outcome in infants with MLL-rearranged ALL
enrolled into MLL-Baby protocol irrespective of treatment arm. Treatment inten-
sification for MRD-positive at TP4 ImR patients did not improve their outcome.
MRD-positivity at TP4 in ImR group was associated with MRD-positivity by
flow cytometry on day 15, MLL breakpoint positions within intron 11 gene and
initial CNS disease.
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PRO-T CELL ALL/LBL: AN ULTRA-HIGH RISK CD2-NEGATIVE DISEASE
SUBTYPE IN ADULTS DEFINED BY FLOW CYTOMETRY
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Background: Risk fators for T-LBL have not been systematically evaluated, in
contrast to T-ALL
Aims: Our aim was to define immunophenotype of T-LBL/ALL in 71 consecutive
patients by use of the flow cytometry (FCM) of tissue aspirates if peripheral
blood (PB) and bone marrow (BM) were uninvolved. We also evaluated prog-
nostic value of immunophenotype according to WHO 2008 subtype and ETP
(Early T-cell Phenotype) definition in adult patients with T-ALL/LBL treated on
uniform ALL protocol
Methods: Between 1997 and 2015, 71 adult patients with T-LBL/ALL were
treated according to the GMALL 05/93 and T-LBL/2004 protocols.
Immunophenotype was determined by immunohistochemical staining and by
FCM of cellular suspension obtained from lymph nodes (n=31), mediastinal
mass (n=12) or nasopharyngeal/perimandibular infiltration (n=2) by fine nee-
dle aspiration biopsy (FNAB), as well as of BM (n=10), PB (n=7) and pleural
fluid (n=9). Disease subtype was defined according to WHO 2008 classifica-
tion: pro-T (CD2-), pre-T (CD2+), cortical (CD1a+), medullary/mature
(sCD3+). Recognition of pan-T cell CD antigens (pTAg) expression included:
CD1a, CD2, sCD3, CD4, CD5, CD7, CD8. ETP-ALL/LBL immunophenotype
was defined as follows: absent (up to 5%positive cells) CD1a and CD8
expression, absent or dim (75% positive cells) CD5 expression, expres-
sion(25% positive cells) of 1 or more myeloid (CD13,CD33, CD15) or stem
cell (CD34, HLA-DR) markers.
Results: Patient characteristics: ALL (BM+ >20%): n=26(37%), LBL:
n=45(63%), BM+<20% involvement (LBL): 27%, age<35ys: 72%, males: 67%,
mediastinal mass (MM): 92%, primary CNS+: 8%.Immunophenotype: pro-T:
21%, pre-T: 17%, cortical: 55%, medullary: 7%. Number of pTAg present: 0-3:
n=25(36%) or 4-7: n=45(64%) of pts. Most frequently expressed pTAg were:
CD7: 97%, CD5: 87%, CD2: 74%, CD1a: 58%. Myeloid markers: CD13/33/15
were expressed in 13%/26%/10% and stem cell markers: CD34% in 42% of
pts. Overall, 19% (13/67) of the study population had ETP-ALL/LBL: CD1a-
/CD8-, but CD5 negative: 46% and CD5 weaker (20-71%): 54%, CD34/HLA-
DR/13/33/15 expressed in 100%/50%/50%/75%/14% of ETP pts. 4 pts(31%)
with ETP were categorized as pre-T and 9 pts(69%) as pro-T. With a median
(95%CI) follow up of 137 (0.99, 1.733)months, 5-yr OS and DFS (95%C.I.) was
53% (0.42, 0.65) and 48% (0.36, 0.59),respectively. 5-yr OS (95%C.I.) for pts
with CD2, CD1a and more than 3 pTAg present was 64% (0.511, 0.776), 66%
(0.512, 0.803) and 64% (0.5, 0.782) compared to 11% (0.034, 0.256), 32%
(0.152, 0.494) and 27% (0.097, 0.452) for pts without CD2, CD1a and 3 or less
pTAg, (P<0.001, 0.009 and 0.002),respectively. OS and DFS was dependent
on WHO subtype (p<0.001/p=0.002). 5-yr OS (95%C.I.):cortical: 69% (0.547,
0.837), pre-T 48% (0.196, 0.776),mature 40% (0.029, 0.829) and pro-T 10%
(0.072, 0.272). There was no significant difference in OS and DFS in pts with
ETP vs non-ETP (P=0.186, 0.159), 5-yr OS (95%C.I.): 31% (0.57, 0.559) and
55% (0.418, 0.685) for ETP and non-ETP pts, respectively. Among ETP pts,
4/13(31%) are alive, 3/4(75%) pts with pre-T and only 1/9((11%) with pro-T
phenotype.3/7 pts were rescued with allo-HCT (Figure 1).
Figure 1.
Summary/Conclusions: Survival of T-LBL/ALL pts depends on CD1a and
CD2 expression as well as on WHO subtype. ETP is a non-uniform category
by pro-T/pre-T-cell origin. ETP phenotype was non-significant factor for OS/DFS
(p=0.186/p=0.159) unless consistent with pro-T subtype (CD2-), only 1/9 pts
alive. Pro-T (CD2-) is an ultra-high risk subtype of T-ALL/LBL and novel treat-
ments are needed to improve pts outcomes.
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Background: In pediatric ALL end of induction minimal residual disease (EOI
MRD) evaluated at day 29-33 after the first chemotherapy course is a primary
determinant of outcome. The significance of EOI MRD in adult ALL is less clear.
Aims: To assess EOI MRD and its impact on survival and relapse risk in adult
patients with Philadelphia-negative (Ph-) ALL in complete remission (CR) with
a single chemotherapy course.
Methods: Induction chemotherapy for patients in the Northern Italy Leukemia
Group 10/07 trial (ClinicalTrials.gov NCT-00795756; Blood 2016;128:176
[abstract]) consisted of CY/PDN pre-phase on days -5 to -1, VCR on days
1,8,15,22; Idarubicin on days 2,3; Dexa on days 1-5 and 15-18; L-Asp on days
9,11,13,16,18,20; intrathecal MTX, Ara-C, Dexa on days 1 and 15; and G-CSF
from day 4. CR was assessed on day 28 by means of bone marrow morphology
and MRD evaluation (RQ-PCR with case-specific probes, sensitivity ≥10-4).
EOI MRD was correlated with risk subset, week 10 MRD, systemic relapse
incidence (RI) and relapse-free survival (RFS), defining as favorable (i.e. neg-
ative) a response <10-4. In this risk-oriented protocol MRD-based risk stratifi-
cation was deferred until after early consolidation (week 10), at which point
standard- and high-risk (SR, HR) patients with MRD ≥10-4 and very HR patients
irrespective of MRD study results were eligible to allogeneic stem cell trans-
plantation.
Results: Of 163 study patients, 139 were in CR after cycle 1 (85.2%), 95 had
a sensitive molecular marker (68.3%) and 90 were successfully studied for EOI
MRD. Median patient age was 39 years (range 17-67 years), 58.9% were male,
64.4% and 35.6% had B- and T-ALL, respectively, 44.4% were SR, 10% HR
and 45.6% very HR (leukocytes >100, highly adverse cytogenetics [18.8%],
early/mature-T phenotype). EOI MRD was undetectable in 34 (37.7%) and <10-
4 in 14 (15.1%), for an overall molecular response of 53.3%, while it was ≥10-
4 in 42 (≥10-3 in 28, 31.1%). EOI MRD did not correlate with patient age and
leukocyte count but showed a more favorable course in patients with SR (n=40:
<10-4 62.5%, ≥10-322.5%) rather than HR/very HR features such as pro-B phe-
notype (n=11: 27.2%, 54.5%), early-T phenotype (n=12: 41.6%, 50%) and high-
ly adverse cytogenetics (n=17: 47%, 41.1%). Notably most EOI MRD respon-
ders (42/44, 95.4%) and many of those in the 10-4-10-3 range (10/14, 71.4%)
were confirmed negative at week 10, contrary to only 7/28 (25%) with EOI MRD
≥10-3(P<0.0001). Five-year RI and RFS rates of EOI MRD negative vs positive
groups (n=48 vs 42) were 15% vs 44% (P=0.01) and 68% vs 41% (P=0.03),
respectively. The correlation between EOI and week 10 MRD identified three
distinct prognostic groups: both timepoints negative (n=42), RI 14%, RFS 74%;
any one positive (n=19), 43%, 49%; both positive (n=23); 44%, 31% (P=0.04
for RI; P=0.005 for RFS). In a multivariable prognostic model an EOI MRD ≥10-
3increased greatly the risk of relapse (hazard ratio 2.67, P=0.01), followed by
leukocytosis (>30 in B-ALL and >100 in T-LL; hazard ratio 2.35, P=0.04), while
patient age and adverse phenotype or cytogenetics were not significant.
Summary/Conclusions: EOI MRD allows to differentiate early on the patients
with the more favorable or most unfavorable treatment outcome, with cutoffs at
<10-4 (confirmed at week 10) or ≥10-3, respectively. This information can be
incorporated into treatment algorithms for adult ALL and prompts the use of
new agents/immunotherapeutics in induction regimens to optimize the rate of
MRD negative CR.
P164
RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2
STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC
LEUKAEMIA
N. Morley1,*, A. Kirkwood2, A. Moorman3, L. Clifton-Hadley2, C. Rowntree4,
B. Wrench5, E. Marwood2, P. Patrick2, J. Snowden6, A. Rijneveld7, D. Marks8,
A. Fielding2
1Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,
2CR UK and UCL Cancer Trials Centre, London, 3Newcastle University, New-
castle, 4University Hospital Wales, Cardiff, 5Barts Health NHS Trust, London,
6Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United King-
dom, 7Erasmus Medical Centre, Rotterdam, Netherlands, 8University Hospitals
Bristol NHS Trust, Bristol, United Kingdom
haematologica | 2017; 102(s2) | 31
Madrid, Spain, June 22 – 25, 2017
Background: The outcome for older adults with acute lymphoblastic leukaemia
(ALL) is unsatisfactory. The UKALL12/ECOG2993 study showed that high risk
cytogenetic abnormalities, were common, as well as lower rates of complete
remission (CR) and 5 year overall survival (OS) in those aged 55- 65 years of
age as compared to younger persons. There are few studies which focus on
older patients with ALL, despite an increasing incidence with age.
Aims: A trial to establish age-appropriate baseline chemotherapy from which
to design widely-applicable studies of novel agents in older people with ALL.
Methods: UKALL60+ offers five ‘Arms’ to be decided by investigator and
patient choice; Arm A= Philadelphia chromosome positive (Ph+), Arm B= Non-
intensive (designed to be delivered primarily out of hospital), Arm C= Intensive,
Arm D= Intensive+, and Arm E= Registration only (in which treatment is at
investigators discretion, including no active therapy). Any elderly patient with
newly diagnosed ALL is eligible. There are no exclusions for co-morbidities,
including prior malignancies. Baseline characteristics of each group including
Charlson index, ECOG, Karnofsky and CRASH scores are being collected.
The primary endpoint is the rate of complete remission (CR) after 2 phases of
induction. Secondary objectives include determination of MRD status at 3 time
points, EFS and OS at 1 year, treatment related mortality and quality of life.
Results: Since December 2012 85 patients have been recruited (4 excluded
due to misdiagnosis) with a median age of 67 years (Range 55 – 83). Median
follow up is 18.1 months. ECOG performance status was 0 in 33 (41%), 1 in
37 (46%), 2 in 8 (10%) and ≥3 in 3 (4%). Treatment allocation has been Ph+
n=18, Intensive n=34, non-Intensive n=11, Intensive+ n=7, and Registration
only n=11 patients. It is too early to perform a full analysis of the reasons given
for choosing each regimen but age appears to be a major factor for Ph-ve
patients, with a median age of 74 years (Range 64-82) in the non-Intensive
arm compared with 66 years (Range 56 -76) in the Intensive and Intensive+
arms. A total of  36/61 (57%) patients had high risk cytogenetics including BCR-
ABL1 (n=21), low hypodiploidy (n=10), complex karyotype (n=1) and KMT2A-
AFF1 (aka MLL-AF4) (n=4). Charlson index and CRASH score data is awaited.
At the end of 2 phases of treatment on Arm A (Ph+ve) 17/18 (94%) patients
achieved CR. On Arms B-D 27/52 (52%) patients achieved CR. Grade 3/4 AEs
were seen in the majority of patients. The most common toxicities were haema-
tological and infections. So far 30 relapses have been reported. 25 are isolated
medullary relapses, 4 isolated CNS and combined in 1 patient. To date, 41
deaths have been reported; 32 patients died of ALL, 7 of infection, 1 cardiac
and 1 multi-organ failure. Fifty one patients have had a PFS event. The median
PFS is 13.2 months in Arm A (Philadelphia +ve) and 11.3 months Arm B-D.
The median OS is 19.5 months in Arm A (Philadelphia +ve) and 15.5 months
in Arms B-D (Figure 1).
Figure 1.
Summary/Conclusions: ALL in older patients is challenging to treat, with a dif-
ficult balance between efficacy and toxicity. We observed a high rate of high risk
cytogenetics, especially notable being the rate of low hypodiploidy. Initial high
CR rates are seen in those with Ph+ve disease, this does not appear to translate
into improved PFS and OS when compared with Philadelphia negative disease.
The commonest cause of death in this group is ALL. We will use our baseline
data to develop appropriate regimens for future studies of novel agents.
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Background: Elderly acute lymphoblastic leukemia/lymphoma (ALL) is a rare
disease with a poor prognosis and is underrepresented in clinical trials. This
thought to be due to comorbidities, early death during induction, lower rates of
complete remission, and higher risk of relapse with poor biological features
(Gokbuget, Blood, 2013).
Aims: Describe clinical outcomes and prognostic factors of elderly ALL.
Methods: After IRB approval, we performed a retrospective study of patients
(pts) age ≥60 diagnosed with ALL from 2000 to 2016 at Mayo Clinic Rochester.
Statistical analysis was performed using JMP 10.0 software.
Results: Out of 210 adult ALL pts, we identified 63 (30%) consecutive pts with
elderly ALL. The average age at time of diagnosis was 67 (60-82), & 38 (60%)
were males. Median follow up was 16.1 months (0.23-126), during which time
40 (63%) deaths occurred; 25 (63%) related to the disease, & 15 (37%) sec-
ondary to infection or other causes. Baseline characteristics at time of diagno-
sis: 54 (86%) pts had B-cell phenotype, 19 (35%) were Ph+. Only 9 (14%) pts
had T-cell phenotype. 20 (31%) pts had a Charlson Comorbidity Index ≥2 & 17
(27%) presented with ECOG PS ≥2. Median Hgb was 10.6 g/dl (4.9-18.5),
WBC 6.2 x 109/l(0.5-160.8), PLT 51 x 109/l(4-750), peripheral blast 30% (0-
95), marrow blast 87.5% (0-100), & LDH 381.5 U/L (141-8440). Lymphoblastic
lymphoma was only evident in 3 (5%) pts. Among pts with available data, 34/58
(59%) had B symptoms, 16/57 (28%) lymphadenopathy, 7/57 (12%)
splenomegaly, 6/60 (10%) pleural effusions & 10/45 (22%) of pts had CNS
leukemia. Cytogenetics at time of diagnosis: Of 48 pts with available data, 20
(41%) had complex cytogenetics (≥5 abnormalities), 18 (38%) had a monoso-
mal karyotype, 8 (17%) were hypodiploid, 4 (8%) were hyperdiploid, & 2 (4%)
were a mix of hypo- & hyper-diploid. FISH studies were available for 50 pts: 10
(20%) had CDKN2A del, 3 (6%) t(4;11) MLL-AF4, 2 (4%) t(1;19) E2A-PBX1, 1
(2%) IKZF1 deletion. Treatment and Outcomes: 10 (16%) pts received palliative
therapy only, which included TKIs, chemotherapy, or hospice.  The other 53
(84%) received induction chemotherapy. Only 12 (23%) had an up-front dose
reduction due to comorbidities. 32 (60%) received Hyper-CVAD, concomitantly
with rituximab in 11 (34%) pts, & TKIs in 9 (28%) pts. 21 (40%) pts received
other regimens, of which 14 (67%) had asparaginase-based chemotherapy.
Only 2 (4%) pts who received induction chemotherapy died within the first 60
days; both received Hyper-CVAD. Median number of cycles to achieve CR
was 1 (1-8) with CR/CRi rate of 93%, & median time to CR1 was 34 days (19-
459). 3 pts who underwent palliative chemotherapy achieved CR (all had Ph+
disease & received TKIs). 7 pts (13%) had primary induction failure. 50% of
pts relapsed within a median time of 12.6 (3.6-72.8) months. Only 10 pts under-
went allogeneic hematopoietic stem cell transplantation (HSCT), of which 2
(20%) relapsed in less than 180 days. Median survival after HSCT was not
reached. Predictors of survival: Elderly ALL has worse mOS compared to our
adult ALL cohort, 17.2 (IQR; 11.7-32.9) vs 52.1 (IQR; 27.6-169.9) mon
(p=0.0016). In a univariate analysis model which included multiple variables,
only ECOG PS ≥2, WBC>30,000, CDKN2A del, & CNS leukemia were statis-
tically significant, however only CNS leukemia (p=.0009) & WBC (p=0.0168)
retained statistical significance in multivariate mode, with a trend in CDKN2A
del (p=0.06) (Figure 1).
Figure 1.
Summary/Conclusions: Elderly pts with ALL have worse survival compared to
younger adults. However, this was not reflected by a low CR rate, or a high rate
of mortality during induction, but by grim disease overall. We report for the first
time the incidence of 20% for CDKN2A del in this disease group. Further studies
are needed to confirm this finding, as it could be a target for novel therapies.
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MANAGEMENT AND OUTCOME OF ADULT PH+ ACUTE LYMPHOBLASTIC
LEUKEMIA PATIENTS TREATED AT THE “SAPIENZA” UNIVERSITY
BETWEEN 1996 AND 2016
S. Chiaretti1,*, V. Gianfelici1, R. Agrippino1, L. Elia1, F. Paoloni2, S. Capria1,
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C. Minotti1, A.P. Iori1, F. Mancini1, M.S. De Propris1, A. Guarini1, A. Vitale1,
R. Foa1
1Division of Hematology, Department of Cellular Biotechnologies and Hema-
tology, Sapienza University of Rome, 2GIMEMA Data Center, Rome, Italy
Background: The outcome of adults and elderly (>60 years) patients with Ph+
ALL has improved since the introduction of tyrosine kinase inhibitors (TKI),
used alone or in combination with chemotherapy during induction. Before 2005,
all these patients were treated with chemotherapy; from 2005, a TKI-based
“chemo-free” induction strategy was applied.
Aims: To evaluate the outcome of patients followed from 1996 at a single Cen-
ter, and to correlate the short- and long-term responses with: a) induction treat-
ment (chemotherapy or TKI); b) age; c) TKI used (imatinib or dasatinib); d)
fusion protein; e) allogeneic stem cell transplant (SCT).
Methods: Sixty-eight patients (29M/39F) were treated; median age was 50
years (20-88) and 16 were elderly patients; 43 cases had the p190 protein, 19
the p210 and 6 had both; the latter 2 groups were merged together for further
analyses. Fifty-two patients were enrolled in clinical trials. Median follow-up is
105 months (13-224).
Results: As induction, 28 patients received chemotherapy, 2 chemotherapy+TKI
(considered as “chemotherapy±TKI group”) and 38 TKI alone (24 imatinib and
14 dasatinib). All cases received TKI during consolidation/maintenance when it
became available. All elderly patients but 1 received a TKI alone (plus steroids).
Upon induction, 44 patients received consolidation chemotherapy, including 5
elderly. A SCT - carried out virtually only in adults - was performed in first complete
remission (CR) in 13 cases (5 in the chemotherapy±TKI and 8 in the TKI groups).
Overall, 91% patients achieved a CR; OS and DFS at 100 months are 42% and
45.5%, respectively. Among the 30 patients in the chemotherapy±TKI group, 25
(83%) achieved a CR, 4 were refractory and 1 died in induction; in the TKI group
(n=38), 37 (97%) achieved a CR and 1 was refractory. Differences are statistically
significant (p=0.03). Refractoriness was more frequent in p210+ than in p190+
cases (12% vs 5%): this finding did not translate into significantly different OS
and DFS (30% vs 48% and 32% vs 51%, respectively). When patients were strat-
ified by age, adults had a significantly better OS and DFS at 100 months than
elderly (53% vs 19%, p= 0.04, and 57% vs 20%, p= 0.03, respectively), even
more when considering only cases treated with TKI alone (75% vs 20%, p=0.01
and 73% vs 21.4%, p=0.017, respectively). The TKI used (imatinib or dasatinib)
did not impact in adults, while a significant advantage in OS and DFS was
observed for elderly patients receiving dasatinib (Figure 1): this might be due to
the greater activity of dasatinib and also highlights the importance of consolidation
chemotherapy, performed almost exclusively in adults. Considering adults only,
within the chemotherapy±TKI group, 5 patients were transplanted and 19 were
not: all transplanted cases are in CR, while in the non-transplanted cases 6 are
in CR, 11 have relapsed and 2 have died in CR (p=0.01); within the TKI group, 8
patients underwent a SCT and 15 did not: of the transplanted cases, 6 are in CR
and 2 have died due to complications, while 11 of the non-transplanted patients
are in first CR, 3 have relapsed and 1 has died in first CR (p=n.s.). Of the 5
patients transplanted in second CR, only 1 is alive.
Figure 1.
Summary/Conclusions: This study further underlines the benefit of an induc-
tion based on a TKI alone. Since age holds strong prognostic significance, our
results suggest that while imatinib followed by consolidation chemotherapy is
the optimal choice for adults, in elderly cases dasatinib is more appropriate,
since patients are often unfit to receive further chemotherapy. Finally, the advan-
tage of SCT needs to be carefully redefined in the TKI era.
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THE TETRASPANIN CD9 IS A PROGNOSTIC MARKER FOR PREDICTING
SURVIVAL OUTCOMES OF PEDIATRIC B-PRECURSOR ACUTE
LYMPHOBLASTIC LEUKEMIA
K.T. Leung1,*, K.Y.Y. Chan1, C. Zhang1, A.W.K. Leung1, F.W.T. Cheng1,
J.W.S. Yu1, T.F. Leung1, K. Li1, C.K. Li1
1Paediatrics, The Chinese University of Hong Kong, Shatin, Hong Kong
Background: B-precursor acute lymphoblastic leukemia (B-ALL) is the most
common childhood malignancy, accounting for approximately 30% of pediatric
cancers. With advances in risk-adapted chemotherapy, the overall cure rate of
newly diagnosed B-ALL is approaching 85% in most developed countries. How-
ever, relapse still occurs in ~20% of patients and a significant portion of them
are not initially classified in the high-risk disease entity, underscoring the need
for development of additional informative prognostic biomarkers. 
Aims: CD9, a tetraspanin family protein, regulates multiple physiologic process-
es including cell migration and adhesion, and has been associated with metas-
tasis and progression of various types of cancers. In this study, we aim to eval-
uate its expression pattern and prognostic significance in pediatric B-ALL.
Methods: Cell surface CD9 expression on leukemic blasts at disease presen-
tation was characterized by multicolor flow cytometry in a cohort of pediatric B-
ALL patients. The CD9 expression status was correlated with clinical parame-
ters, including age, sex, white cell count, cytogenetics and prednisone
response. Kaplan-Meier survival analysis was performed to investigate the pos-
sible association of CD9 expression with clinical outcomes. The potential role
of CD9 expression as a predictor of 5-year survival outcomes was evaluated
using Cox regression models.
Results: Among 118 cases tested, blasts of 92 patients (78.0%) were CD9+
(≥20% of CD9-expressing blasts). There were no significant differences in age,
sex and white cell count between CD9+ and CD9- patients. Major cytogenetics
subgroups were similarly distributed except for hyperdiploidy (all patients were
CD9+; P=0.022) and ETV6-RUNX1 translocation (higher prevalence in CD9-
patients; P=0.001). Significantly more CD9+ patients were stratified into the
intermediate-risk group (P=0.044) and a higher proportion of CD9- patients
was stratified into the high-risk group (P=0.025). Besides, CD9- patients had
poorer prednisone response (P=0.014). The 5-year overall survival (OS) and
relapse-free survival (RFS) rates of CD9+ patients were significantly lower than
those in CD9- patients (P ≤0.029). Subgroup analysis revealed remarkably
poorer outcomes in CD9+ patients of the high-risk group (P ≤0.045). A similar
trend was also observed in patients of the intermediate-risk group but not in
the standard-risk group. In univariate analysis, CD9 positivity, age <1 year,
white cell count ≥100 × 109/L and poor prednisone response were associated
with lower RFS rate (P ≤0.050). In multivariate analysis, CD9 positivity (HR=6.0;
P=0.019) and poor prednisone response (HR=3.9; P=0.015) remained as inde-
pendent prognostic factors for lower RFS rates.
Summary/Conclusions: Our data indicate that expression of CD9 was signif-
icantly associated with inferior survival outcomes in pediatric B-ALL. The
observed difference was most prominent for patients in the high-risk group,
suggesting that CD9 expression could potentially be used in conjunction with
other known prognostic factors for refinement of risk group stratification. Our
study also lays the foundation for future development of CD9-targeted therapy
for high-risk and relapsed/refractory pediatric B-ALL.
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PEDIATRIC MLL ACUTE LEUKEMIA PATIENTS SHOW DIFFERENTIAL
HDAC EXPRESSION 
N. Vega-Garcia1,*, R. Malatesta1, C. Estella1, M. Torrebadell12, S. Gassiot1,
A. Català2,3, R. Berrueco2,3, A. Ruiz-Llobet3, A. Alonso-Saladrigues3,
M. Mesegue3, M. Trabazo3, S. Rives2,3, M. Camos1,2
1Hematology Laboratory, Institut de Recerca Pediàtrica Hospital Sant Joan de
Deu, Barcelona, 2Centro de Investigación Biomédica en Red de Enfermedades
Raras (CIBERER), Instituto de Salud Carlos III, Madrid, 3Clinical Department
of Pediatric Hematology and Oncology, Institut de Recerca Pediàtrica Hospital
Sant Joan de Deu, Barcelona, Spain
Background: Overexpression of histone deacetylases (HDACs) is a common
feature in acute leukemias. Consequently, HDAC inhibitors (HDACi) have
emerged as promising targeted therapy. However, non-specific HDACi may
lead to accumulation of double stranded DNA lesions, so more selective isoform
specific HDACi are needed. Expression patterns of HDACs in childhood
leukemia have been scarcely studied.
Aims: To analyze the expression of HDAC isoforms in different subtypes of
pediatric leukemia and correlate them with prognosis and clinico-biological fea-
tures.
Methods: We evaluated the mRNA gene expression profile of class I, II and IV
HDAC genes (HDAC 1-11) by quantitative PCR in 126 leukemic pediatric sam-
ples and a pool of non-neoplastic samples as calibrator. Patients were treated
according to the Spanish Hemato-Oncology Cooperative Group protocols in a
single center. The HDAC expression levels in different groups were compared
by the Mann-Whitney test. The level of significance was set up at p<0.05. The
analyses were performed with SPSS 24.0.
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Results: Our series included 69 boys and 57 girls diagnosed with acute
leukemia, with a median age of 5.1 years (range 0-17.4 years). We included
12 infant patients (<1 year old). Eighty-two (65%) patients had B-cell precursor
acute lymphoblastic leukemia (BCP-ALL), 24 patients T-cell ALL and 20 patients
had acute myeloblastic leukemia (AML). Globally, we found higher expression
levels of class I HDAC isozymes (HDAC 1, 2, 3 & 8) in leukemic samples as
compared to non-neoplastic samples, as previously reported. Interestingly,
some HDAC isoforms associated with specific genetic aberrations. Those
patients with rearrangement of MLL (KMT2A) gene (n=18, including 9 BCP-
ALL and 9 AML; 7 infants and 11 pediatric) showed a significantly higher expres-
sion of HDAC9 (p<0.0001) and a statistically significant underexpression of
HDAC1 and HDAC3 (p=0.003 & p=0.02, respectively, see Figure 1). Infants
(n=12) had also a significantly lower expression of HDAC7 (p=0.043). In the
same line, all pediatric patients with pro-B phenotype (CD10 negative) had low
levels of HDAC7, but differences did not reach a statistical significance. After
a median follow-up of 5.9 years, 15 patients died, with an overall survival (OS)
of 96±2% for BCP-ALL, 82±8% for T-ALL and 55±13% for AML patients
(p<0.0001). In the BCP-ALL subgroup, the expression of HDACs did not predict
outcome, and only CNS infiltration and leukocytosis were unfavorable risk fac-
tors for OS. Again, CNS+, high WBC count and presence of minimal residual
disease (MRD) post-induction were predictive for worse event free survival
(EFS). Although the number of cases is low and these results must be taken
with caution, T-ALL patients with the highest expression of HDAC3 (upper quar-
tile) significantly correlated with worse OS (94% vs 25%, p=0.001) and a trend
towards worse EFS (89% vs 53%, p=0.06). The only significant risk factor for
EFS in this subgroup was the presence of MRD after induction (p=0.003).
Figure 1.
Summary/Conclusions: We have observed a specific pattern of HDACs
expression in pediatric patients with MLL rearrangement. Our study, if further
confirmed, suggests that specific HDACi would potentially be a useful targeted
treatment for pediatric patients with MLL rearranged leukemia.
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MINIMAL DISSEMINATED DISEASE DETECTION BY FLOWCYTOMETRIC
IMMUNOPHENOTYPING IN T-CELL ACUTE LYMPHOBLASTIC LYM-
PHOMA
G.K. Viswanathan1,*, P. Tembhare1, N. Patkar1, S. Gujral1, P.G. Subraman-
ian1
1Hematopathology Laboratory, Advanced Centre for Treatment, Research and
Education in Cancer (ACTREC) - Tata Memorial Centre (TMC), Mumbai, India
Background: T-cell acute lymphoblastic lymphoma (T-LBL) with minimal dis-
seminated disease (MDD) is defined as the presence of T-LBL with <25%
blasts in the peripheral blood (PB) and/or bone marrow (BM) by morphology
and the presence of immunophenotypically abnormal T-lymphoblasts in bone
marrow by flowcytometry. Published literature regarding the prevalence and
clinical significance of this rare subgroup is sparse. In this study we analysed
the presence of minimal disseminated disease is cases of T-LBL with <25%
blasts using 8-10 colour flowcytometric immunophenotyping.
Aims: To evaluate the prevalence of minimal disseminated disease in bone
marrow in cases of T-cell acute lymphoblastic lymphoma with <25% blasts in
PB and BM using 8-10 colour flowcytometric immunophenotyping and evaluate
the clinical and immunophenotypic features.
Methods: This study was a retrospective analysis of 42 patients of T-LBL with
predominantly lymphomatous presentation with <25% blasts in peripheral and
bone marrow. The following parameters were taken into account including com-
plete hemogram, peripheral blood examination, bone marrow morphology and
immunophenotyping, CSF analysis, pleural fluid morphology and immunophe-
notyping, tissue biopsy (lymph node or mediastinal mass), PET-CT findings
and LDH levels. Flowcytometric immunophenotyping on bone marrow was per-
formed on a 3 laser 10 color Beckman-Coulter Navios® platform and analysed
using Kaluza® software. A minimum of 1,00,000 events were acquired and the
presence of minimal disseminated disease was noted. 
Results:A retrospective analysis of 42 cases of T-LBL with <25% blasts in periph-
eral and bone marrow was done. The mean age was 12.2 years (Range:2-48
years). M:F ratio was 1:1.7. Nearly all patients had normal haemoglobin, total
leukocyte count and platelet counts. LDH was raised in majority of the patients
(Mean 674U/L; N<190U/L). CSF examination was negative in all cases indicating
that it is unlikely to have CNS involvement in patients with <25% blasts in PB
and BM.  Minimal disseminated disease was seen in 12 cases (12/42=28.6%) of
cases. Of the 12 cases with minimal disseminated disease two cases were near
early T-cell precursor acute lymphoblastic leukemia (near ETP-ALL) type and
none were of ETP-ALL type. None of the cases showed circulating blasts in PB.
The mean (range) bone marrow blast count in the group without MDD was 2.4%
(0-4%) and in the group with MDD was 5.1% (0-15%). In the group with MDD
(12 cases), only 5 cases showed >5%blasts/hematogones identifiable by mor-
phology. This indicates flowcytometry is necessary in cases with <5% blasts to
pick up cases of MDD. PET-CT was not sensitive to pick-up MDD as increased
FDG uptake was seen in only a single case of MDD; it was negative in all cases
without MDD. MDD by flowcytometry ranged from 0.007% to 18.5% (mean: 3.6%;
median: 4%) (Figure 1).
Figure 1.
Summary/Conclusions: Our study shows that minimal disseminated disease
is seen in more than one-fourth of cases (28.6%) of T-LBL with <25% blasts in
PB and BM. This underlines the importance of flowcytometric evaluation of
bone marrow in cases with <25% blasts identified by morphology.  The identi-
fication of minimal disseminated disease in T-LBL is important as studies have
shown inferior event free survival in T-LBL with minimal disseminated disease
as compared to patients without minimal disseminated disease.
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INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY
CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR
OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED
RESULTS FROM A PHASE I/II TRIAL
N. Short1,*, H. Kantarjian1, S. O’Brien2, F. Ravandi1, D. Thomas1,
G. Garcia-Manero1, N. Daver1, G. Borthakur1, N. Jain1, M. Konopleva1,
K. Sasaki1, N. Pemmaraju1, Y. Alvarado1, J. Jacob1, R. Garris1, P. Thompson1,
J. Cortes1, E. Jabbour1
1The University of Texas MD Anderson Cancer Center, Houston, 2The Univer-
sity of California - Irvine, Orange, United States
Background: Older patients (pts) with acute lymphoblastic leukemia (ALL)
have poor tolerance of intensive chemotherapy, and novel strategies are need-
ed in this population. In pts with relapsed/refractory ALL, inotuzumab ozogam-
icin (InO), an anti-CD22 antibody-drug conjugate, has been shown to improve
survival compared to salvage chemotherapy.
Aims: We designed a phase I/II trial to evaluate the safety and efficacy of low-
intensity chemotherapy (mini-hyper-CVD) plus InO as frontline treatment for
older pts with newly diagnosed ALL.
Methods: Pts ≥60 years of age with newly diagnosed Philadelphia chromo-
some-negative pre-B received mini-hyper-CVD (compared to hyper-CVAD: no
anthracycline, 50% dose reductions of cyclophosphamide and dexamethasone,
75% dose reduction of methotrexate, 83% dose reduction of cytarabine). InO
was given on day 3 of the first 4 cycles. The first 6 pts received InO at a dose
of 1.3 mg/m2 for cycle 1 followed by 0.8 mg/m2 for cycles 2-4; pts 7-34 received
1.8 mg/m2 for cycle 1 followed by 1.3 mg/m2 for cycles 2-4. Due to concern
for veno-occlusive disease (VOD), the protocol was amended so that pts 35+
received InO at a dose of 1.3 mg/m2 for cycle 1 followed by 1.0 mg/m2 for
cycles 2-4. Rituximab was given during the first 4 cycles in pts with CD20
expression ≥20%; all pts received IT chemotherapy prophylaxis with the first 4
cycles. Pts in CR after 8 cycles then received POMP maintenance for up to 3
years.
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Results: Between 4/2012 and 12/2016, 47 pts have been treated, 4 of whom
had received 1 cycle of prior therapy and were in CR at the time of enrollment.
The median age was 68 years (range, 60-81), and median CD22 expression
was 97% (range, 72-100%). Of 43 pts evaluable for response, 42 responded
(ORR=98%). Best response was CR in 36 pts (84%), CRp in 5 (12%) and CRi
in 1 (2%). MRD negativity by 6-color multiparameter flow cytometry was
achieved in 31 of 41 evaluable pts (76%) on day 21 and in 44 of 46 evaluable
pts (96%) within 12 weeks of treatment.
The median follow-up was 24 months (range, 1-55 months). 3 pts (6%) under-
went allogeneic stem cell transplantation (ASCT) in first remission. Of the 46
responders, 6 pts (13%) have relapsed. 16 pts have died, 1 due to resistant
disease, 4 after relapse, 1 after ASCT and 10 in CR/CRp. 21 pts remain on
treatment (consolidation, n=3; POMP maintenance, n=19), and 5 pts have com-
pleted all therapy. The 3-year continuous CR and OS rates were 72% and 54%,
respectively. Compared to a historical cohort of 79 older pts treated at our insti-
tution with hyper-CVAD ± rituximab, mini-hyper-CVD+InO resulted in signifi-
cantly improved OS (3-year OS rate: 54% vs 31%; median OS not reached
versus 16 months; P=0.007).
Treatment was overall well-tolerated. The median times to platelet and ANC
recovery in cycle 1 were 22 days (range, 11-91 days) and 16 days (range, 0-
49 days), respectively. In cycles 2-8, the median times to platelet and ANC
recovery were 22 days and 17 days, respectively. Prolonged thrombocytopenia
(i.e. lasting >6 weeks) occurred in 37 pts (79%) at some point during therapy;
8 pts (17%) experienced prolonged thrombocytopenia during induction and 36
(77%) during 1 or more subsequent courses. Grade ≥3 transaminase elevation
occurred in 9 pts (19%), hyperbilirubinemia in 8 (17%) and hemorrhage in 7
(15%). 4 pts (9%) developed VOD (1 after ASCT, 3 unrelated to ASCT). 
Summary/Conclusions: The combination of InO with mini-hyper-CVD is safe
and effective in older pts with newly diagnosed ALL, resulting in a promising 3-
year OS rate of 54%. These results appear superior to the outcomes of older
pts treated with hyper-CVAD.
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RECURRENT MYB REARRANGEMENT IN BLASTIC PLASMACYTOID
DENDRITIC CELL NEOPLASM
K. Suzuki1,*, Y. Okuno2, Y. Suzuki3, A. Hama1, H. Muramatsu1, M. Nakatochi2,
M. Gunji4, D. Ichikawa1, M. Hamada1, R. Taniguchi1, S. Kataoka1, N. Murakami1,
D. Kojima1, Y. Sekiya1, E. Nishikawa1, N. Kawashima1, A. Narita1, N. Nishio2,
Y. Nakazawa5, H. Iwafuchi6, K. Watanabe7, M. Ito4, S. Kojima1, S. Kato3,
Y. Takahashi1
1Department of Pediatrics, Nagoya University Graduate School of Medicine,
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of Pediatrics, Shinshu University School of Medicine, Matsumoto, 6Department
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Hospital, Shizuoka, Japan
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare
hematological malignancy that is derived from plasmacytoid dendritic cell pre-
cursors. BPDCN tends to occur in elderly people with frequent skin involvement
and is associated with an aggressive clinical course and a poor prognosis.
Although optimized diagnostics and therapies should improve patient outcomes,
the pathobiological and genetic aspects of BPDCN remain unclear.
Aims: We planned this study to identify a critical genetic event in BPDCN,
which could provide better understanding of BPDCN pathogenesis.
Methods: We enrolled fourteen patients (five children and nine adults) with
BPDCN who were treated in our institutions. We primarily performed RNA
sequencing-based comprehensive transcriptome analysis with their samples
at the onset to detect gene fusions. These results were then used as the basis
for genetic validation studies and functional analyses with an exogenous
expression model.
Results: We identified a recurring gene rearrangement that involved the MYB
proto-oncogene in all five pediatric patients (100%) and four of nine adult patients
(44%) with BPDCN. The resulting fusion genes included MYB-ZFAT (four
patients), MYB-PLEKHO1 (three patients), MYB-DCPS (one patient), and MYB-
MIR3134 (one patient), none of which have been previously reported to our
knowledge. The translocations corresponding to these fusions were not detected
by the metaphase analysis except in one patient with t(1;6), who harbored MYB-
PLEKHO1. These fusion genes were detectable at diagnosis and relapse but
not at remission. Fluorescence in situ hybridization (FISH) analysis efficiently
detected the breaking apart of MYB in formalin-fixed, paraffin-embedded sec-
tions. Consequent to the rearrangement, the negative regulatory domain of MYB
was truncated, leading to constitutive MYB transcriptional activation, as
described in other malignancies. Exogenous MYB-PLEKHO1 expression in HEK
293T cells led to the upregulation of several known downstream MYB targets.
Gene set enrichment analysis also confirmed the activation of MYB target gene
sets. The identified significantly upregulated genes included cell surface mole-
cule-encoding genes such as NCAM1 (also termed CD56), CD68, S1PR1, and
CXCR4, possibly providing targets for antibody-mediated anticancer therapies.
We performed whole-exome sequencing of paired tumor–germline samples at
diagnosis for four pediatric patients, which revealed a total of 91 (6–45 per
patient) somatic mutations, a relatively large number compared with other pedi-
atric cancers. However, no driver mutations were identified from the existing lit-
erature and database entries; only one missense mutation, KMT2D
p.Cys1403Gly, was present on a driver gene, although this exact mutation had
not been previously reported. Furthermore, we performed targeted sequencing
covering genes associated with hematological malignancies in the remaining
10 patients. Consequently, children were not found to carry any identifiable driver
mutations, whereas all adult patients harbored at least one point mutation in
genes such as TET2, ASXL1, IKZF1, ZRSR2, NRAS, and EZH2, most of which
were reported to be mutated in BPDCN and myeloid malignancies.
Summary/Conclusions: We identified a high frequency of MYB rearrange-
ments that promoted the MYB transcriptional activity in BPDCN. MYB split
FISH analysis can constitute a valuable diagnostic tool for detecting MYB
rearrangements. We expect that our findings provide critical insights regarding
BPDCN pathogenesis and contribute to molecular biology-oriented diagnostic
techniques and molecular-targeted therapies for this intractable malignancy.
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BRANCHED CHAIN AMINO ACID METABOLISM REGULATES
ALPHA-KETOGLUTARATE HOMEOSTASIS RESEMBLING MUTANT-IDH
DRIVEN DNA HYPERMETHYLATION IN AML
S. Raffel1,2,3,*, M. Falcone1, N. Kneisel4, J. Hansson5, W. Wang4, C. Lutz3,
L. Bullinger6, S. Cocciardi6, P. Wuchter3, C. Thiede7, A. Flörcken8,
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Background: The branched chain amino acids (BCAAs) valine, leucine, and
isoleucine are essential AAs for the human body. The activity of BCAA metab-
olism and high levels of the enzyme BCAA Transaminase 1 (BCAT1) have
recently been associated with aggressiveness in several cancer entities. How-
ever, the mechanistic role of BCAT1 in this process remains uncertain.
Aims: To elucidate the mechanistic link between BCAT1 function and epige-
netic deregulation in leukaemia stem cells (LSCs) and consequences on clin-
ical outcome.
Methods: High-resolution proteomics of LSCs, Knockdown and overexpression
of BCAT1 in AML patient samples and AML cell lines, Gene set enrichment
analysis, BCAA tracing experiments, Xenotransplantations, Metabolomics,
DNA methylation arrays, correlative and mechanistic link to clinical data sets.
Results: We performed high-resolution proteomic analysis of human acute
myeloid leukaemia (AML) stem cell (LSC) and non-LSC populations, which have
been functionally validated by xenotransplantation into NSG mice, and we found
the BCAA pathway enriched and BCAT1 overexpressed in LSCs. We show that
BCAT1, which transfers α-amino groups from BCAAs to α-ketoglutarate (αKG), is
a critical regulator of intracellular αKG homeostasis. Next to its role in the tricar-
boxylic acid (TCA) cycle αKG is an essential co-factor for αKG-dependent dioxy-
genases such as EGLN1 and the TET family of DNA demethylases. Knockdown
(KD) of BCAT1 in leukaemia cells caused accumulation of αKG resulting in HIF1
protein degradation mediated by EGLN1. This resulted in a growth and survival
defect and abrogated leukaemia-initiating potential. In contrast, overexpression
(OE) of BCAT1 in leukaemia cells decreased intracellular αKG levels and caused
DNA hypermethylation. BCAT1high AML samples displayed a DNA hypermethy-
lation phenotype similar to IDHmut cases, in which TET2 is inhibited by the
oncometabolite 2-hydroxyglutarate. High levels of BCAT1 were strongly correlated
with shorter overall survival in IDHwtTET2wt, but not IDHmutor TET2mutAMLs.
Gene sets characteristic for IDHmut AMLs were enriched both in IDHwtTETwtB-
CAT1high patient samples and in BCAT1-OE leukaemia cells. BCAT1high samples
showed robust enrichment for LSC signatures and paired sample analysis
revealed a significant increase of BCAT1 levels upon relapse of the disease.
Summary/Conclusions: In summary, BCAT1 reduces dioxygenase activity by
limiting intracellular αKG, thus linking BCAA catabolism to HIF1a stability and
DNA hypermethylation. Our results suggest the BCAA-BCAT1-αKG pathway as
a therapeutic target to compromise LSC function in IDHwtTET2wt AML patients.
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NUCLEAR RE-LOCALIZATION OF NPM1C+ INDUCES DIFFERENTIATION
AND CELL GROWTH ARREST
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Background: NPM1 mutated (NPM1c+) acute myeloid leukemia (AML) is a
distinct entity of the 2016 WHO classification of hematopoietic tumors. NPM1
is a multifunctional nucleolar chaperone. All the mutations in NPM1 described
so far result in cytoplasmic protein localization (NPM1c) through the acquisition
of a nuclear export signal (NES) at the C-terminus, indicating that the cyto-
plasmic localization is critical for the leukemic phenotype. The most frequent
NPM1 mutation is a heterozygous 4bp insertion in exon 12 (mutA).
Aims: Use gene editing and targeted drug treatment to determine whether NPM1
mutated AML cells are dependent on the cytoplasmic localization of NPM1c.
Methods: We sought to introduce indels adjacent to the mutation to disrupt
the C-terminal NES in the NPM1 mutated AML cell line OCI-AML3 and create
novel edited alleles encoding for a mutant NPM1 with nuclear localization.
Exploiting our optimized CRISPR-Cas9 protocol (Gundry et al., Cell Reports
2016), we electroporated OCI-AML3 cells with an sgRNA spanning the 4bp
insertion of mutA (NPM1c sgRNA). As a control, we targeted coding regions of
PTPRC and CD19. Editing efficiency was assessed by high throughput ampli-
con sequencing. The dynamics of the nuclear re-localization of NPM1c upon
drug treatment was studied using a CRISPR-Cas9 engineered NPM1c-GFP
OCI-AML3 line generated in house.
Results: While the NPM1mutA allele showed 70-90% indel frequencies, the
NPM1wt allele was intact. The novel edited alleles could direct nuclear localiza-
tion of a reporter GFP-NPM1 fusion construct, and re-localization cytoplasmic
NPM1 in edited cells was confirmed by immunofluorescence. Return of NPM1
protein to the nucleus was followed by significant impairment of cell growth (~4
fold decrease in cell counts), colony forming ability (16-20 fold reduction) and
engraftment in xenograft models. Flow cytometry analysis showed terminal dif-
ferentiation and cell cycle arrest in G1 phase (controls 453%, NPM1c sgRNA
68 1.5%) 9 days after NPM1c sgRNA transfection. Furthermore, transcriptome
analysis on NPM1mutA-targeted and control OCI-AML3 cells revealed a fast
and deep downregulation of the HOXA and HOXB cluster genes as well as
MEIS1 in treated cells (4 to 5 fold average reduction). In order to verify that
nuclear re-localization of NPM1c accounted for the dramatic changes, we treated
OCI-AML3 cells with the nuclear export inhibitor selinexor (KPT-330). The impact
of KPT-330 treatment mirrored the genome editing experiments, resulting in
clear growth arrest, differentiation, and NPM1c localization with similar dynamics.
Importantly, selinexor produced an almost complete loss of HOXA, HOXB and
MEIS1 expression after 6 days of treatment.
Summary/Conclusions: Allele-specific editing is a powerful tool to probe
mechanistic aspects of oncogene dependencies. By achieving nuclear re-local-
ization of mutant NPM1, we demonstrated that cytoplasmic localization of
NPM1c is necessary for OCI-AML3 cells to maintain their leukemic phenotype.
Drugs promoting mutant NPM1 nuclear localization are attractive candidates
for clinical success in NPM1 mutated AML.
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Background: Background: The prognostic significance of long non-coding
RNA expression (lncRNAs) in older (≥60 years) patients (pts) with cytogeneti-
cally normal acute myeloid leukemia (CN-AML) was recently reported (Garzon
et al., 2014). The lncRNA HOXB-AS3, which is embedded in the HOXB-locus,
was identified among the lncRNAs that associated with mutated NPM1
(NPM1mut) in CN-AML.
Aims: Aims: Our aims were to evaluate the biologic significance of HOXB-
AS3 expression in NPM1mut AML.
Methods: Methods: HOXB-AS3 expression profiling was performed by real-
time PCR. Knock-down (KD) of HOXB-AS3 was performed in vitro and in vivo
[in a pt-derived xenograft (PDX) model] with locked nucleic acid-modified gap-
mers. Comparative proteomic analysis was conducted with a modified version
of the RNA antisense purification (RAP) protocol (McHugh et al., 2015). Direct
visualization of the HOXB-AS3 was performed using custom-designed Basec-
ope probes (Advanced Cell Diagnostics, Newark, CA) according to the manu-
facturer’s instructions.
Results: Results: Of 6 AML cell lines that were tested, only OCI-AML3 cells,
which harbor NPM1mut, showed detectable levels of HOXB-AS3 expression.
Five- and 3-prime Rapid Amplification of cDNA Ends (RACE) assays in OCI-
AML3 cells identified 3 previously annotated (NR_033201/NR_
033203/ENST000491264) and 1 novel variant of HOXB-AS3. NPM1mut pt
samples exhibited higher expression of HOXB-AS3 compared to those with
wild-type (WT) NPM1 (P=.001) and healthy donors (P=.001). In vitro KD of
HOXB-AS3 led to decreased proliferation of OCI-AML3 cells, as measured by
BrdU-based cell cycle analysis (S-phase average% in control vs KD: 24% vs
16%, P=.02). HOXB-AS3 KD also led to a reduction in the number of formed
colonies by OCI-AML3 cells in colony-forming assays (P=.002). HOXB-AS3
KD in NPM1mut pt blasts (n=3) led to a decrease in the number of formed
colonies (P<.001). To evaluate the effect of HOXB-AS3 KD in vivo we generated
a murine PDX model by engrafting NSG mice with blasts of a NPM1mut AML
pt. Treatment of the engrafted mice with nanoparticle-formulated anti-HOXB-
AS3 gapmers led to significant prolongation of survival compared to treatment
with non-targeting control gapmers in 2 independent experiments (P=.01 and
P=.005). Mass spectrometry and comparative proteomic analysis of HOXB-
AS3- and U1-specific RNA-protein complexes identified EBP1 and NPM1 as
candidate HOXB-AS3-binding proteins. RNA-immunoprecipitation experiments
validated the interaction of HOXB-AS3 with EBP1 (20-fold increase of HOXB-
AS3 abundancy in EBP1-precipitate compared to normal IgG control, P=.001).
Direct visualization of HOXB-AS3 showed co-localization of the lncRNA and
WT NPM1 in the nucleolus. EBP1 has been previously shown to interact with
NPM1 and to regulate ribosomal biogenesis and growth of AML cells (Nguyen
et al., 2016). We hypothesized that HOXB-AS3 could affect the EBP1-NPM1
interaction and impact on the ribosomal biogenesis process. In consistency
with this hypothesis, HOXB-AS3 KD led to a decrease in the transcription of
rRNA species in OCI-AML3 cells (P=.001) and in vivo-treated blasts of 2
NPM1mut pts (P<.001). HOXB-AS3 KD also led to a reduction of protein syn-
thesis in the AML cells, as measured by incorporation of fluorochrome-tagged
tracers in newly translated polypeptides.
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Summary/Conclusions: Conclusions: HOXB-AS3 is strongly associated with
NPM1 mutations in AML. HOXB-AS3 interacts with EBP1 and NPM1 and reg-
ulates ribosomal biogenesis in the leukemic blasts. From a therapeutic stand-
point, HOXB-AS3 constitutes a promising target, as in vivo anti-HOXB-AS3
treatment prolonged survival in a murine PDX model.
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A DUAL BH3-MIMETIC APPROACH TARGETING BOTH BCL-2 AND MCL1
IS HIGHLY EFFICACIOUS AND WELL-TOLERATED IN ACUTE MYELOID
LEUKEMIA
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Background: Identification of a chemotherapy-free option for acute myeloid
leukemia (AML) represents a highly desired and important research objective.
Perturbation of cell survival is an essential hallmark of cancer now amenable
to precision targeting by small molecule BH3-mimetics able to inhibit pro-sur-
vival BCL-2 (e.g. Souers et al Nat Med 2013 and Roberts et al., NEJM 2016),
BCL-XL (Lessene et al., Nat Chem Biol, 2013) and MCL1 (Kotschy et al., Nature
2016). We hypothesize that simultaneous pharmacological targeting of BCL-2
and MCL1 will enhance apoptotic death of AML blasts, without increased toxicity
to non-malignant cells.
Aims: To assess the feasibility and efficacy of targeting multiple BCL-2 pro-
survival proteins using small molecule BH3-mimetics in pre-clinical models of
AML
Methods: AML cell lines were obtained from ATCC or DSMZ. S55746 (BCL-
2 inhibitor) and S63845 (MCL1 inhibitor with 6-fold higher affinity to human
than mouse Mcl1) were obtained from Servier and A1155463 (BCL-XL
inhibitor) from Guillaume Lessene (WEHI). Primary AML cells were obtained
from patients providing informed consent. For in vivo experiments, NSG;
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) or NOD/Rag-/-/Il2rgtm1Wjl (NRGS)
mice were used.
Results: S55746 and S63845 showed strong synergy (Loewe score >5) in 13
AML cell lines tested, suggesting this dual BH3-mimetic targeting approach
was highly efficacious (Figure 1A). S55746 and S63845 lowered the LC50 in
primary AML samples by 10-1000-fold in the majority of cases tested, confirming
remarkable anti-leukemic activity across a spectrum of AML cases with diverse
cytogenetic and molecular pathologies (Figure 1B).
Figure 1. (A) Loewe Score (0 → Additive, >1 → Weak Synergy, >2 → Syn-
ergy, >5 → Strong Synergy) in AML cell lines (Lehar, Nat. Biotech 2009). (B)
LC50 of primary AML after 48hr treatment (C) NSG mice engrafted with
MV4;11 AML and treated with i) vehicle, ii) S55746 100 mg/kg/d (x 4 wks),
iii) S63845 25mg/kg IV (2x/wk x 4 wks) or iv) combined S55746 and S63845.
(D) hCD45+ staining of NRGS sternums showing 2 representative exam-
ples of PDX AML one week after treatment with i) vehicle x5d, ii) S55746
100 mg/kg/d x 5d, iii) S63845 25mg/kg IV x 2d and iv) S55746+S63845.
A smaller fraction of AML samples were also sensitised to combined A1155463
and S63845 therapy. Bioluminescent imaging showed rapid and sustained
clearance of xenografted MV4;11 AML (FLT3-ITD mutant and MLL re-arranged)
cells, translating into significant prolongation of survival (Figure 1C) from com-
bined S55746+S63845, but not from treatment with either BH3-mimetic alone.
Similar in vivo efficacy was observed with xenografted OCI-AML3 cells harbor-
ing mutant NPM1 and DNMT3A. Patient-derived xenograft models revealed
rapid reduction of established AML in the bone marrow one week of treatment
with S55746 and S63845 (Figure 1D). Safety and tolerability of this approach
was confirmed using normal CD34+ stem and progenitor cells in short-term
cell culture (48h) and long-term (2-3 weeks) clonogenic assays and from his-
tological and biochemical examination of mice receiving treated for up to 8
weeks at doses shown to be highly efficacious against AML.
Summary/Conclusions: Dual BH3-mimetic targeting of BCL-2 and MCL1
induces rapid and synergistic cytoreduction of human AML cell line and primary
AML samples in vitro and in vivo and across a diverse range of AML genotypes.
We therefore report for the first time, that dual pharmacological inhibition of both
BCL-2 and MCL1 represents a novel approach to treating AML without need for
additional chemotherapy and with an acceptable therapeutic safety margin. Our
results support the translational investigation of dual BH3-mimetic targeting of
BCL-2 and MCL1 in the clinic for the treatment of patients with AML.
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FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS
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Background: Acute promyelocytic leukemia (APL) is driven by the oncogene
PML-RARA which is generated by fusion of the promyelocytic leukemia (PML)
and retinoic acid receptor alpha (RARA) genes, and which strongly interferes
with downstream signalling and the architecture of multiprotein structures known
as PML nuclear bodies (NBs). NB disruption is a diagnostic hallmark of APL;
however, the importance of this phenomenon has only been studied in vitro.
Aims: The aim of this study was to decipher the impact of Pml NB disruption
in APL pathogenesis.
Methods: We engineered a knock-in mouse model with NB disruption achieved
through mutation of key zinc-binding cysteine residues (C62A/C65A) in the Pml
RING domain.
Results: While no leukemias or tumors developed in PmlC62A/C65A mice, the
forced dimerization of RARα - mediated artificially by linking RARα to the dimeri-
sation domain of the NFκB p50 subunit - in cooperation with NB disruption was
associated with doubling in the rate of leukemia (p<0.0001), with a reduced laten-
cy period (p=0.008). Moreover, response to targeted therapy with ATRA signifi-
cantly improved the survival of mice transplanted with PmlWT-p50-RARα or PML-
RARα leukemic blasts, but not with PmlC62A/C65A-p50-RARα, revealing the
essential role of NBs for an effective response to differentiating drug. While for-
mation of the PML-RARA fusion is considered an initiating event in APL patho-
genesis, it is insufficient for the full leukemic phenotype. Moreover, whole exome
sequencing analyses have consistently identified presence of cooperating muta-
tions. Since Pml and Pml NBs have established roles in DNA repair and in the
maintenance of genomic stability, we speculated that loss of NB integrity could
affect these functions. Here, whole exome sequencing revealed a trend of higher
genomic instability in PmlC62A/C65A-p50-RARα leukemia as compared to PmlWT-
p50-RARα, with detection of mutations found in human APL, including Kras,
Ptpn11 and Usp9y. Using DNA repair reporter assays, we demonstrated that
DNA repair via both non-homologous end joining (NHEJ; p=0.01) and homolo-
gous recombination (HR; p=0.006) pathways was less efficient in PmlC62A/C65A
primary cells than in PmlWT cells. Importantly, using a PML-RARα-inducible cell
line, comparable defects in the NHEJ and HR pathways, which were PML-RARα
dependent, were identified. These data were also supported by an increase in
sister-chromatid exchange (p<0.0001) and chromosome abnormality (p=0.0002)
rates in the context of PmlC62A/C65A versus PmlWT. Interestingly, the kinetics of
repair of ionising radiation (IR)-induced DNA double-strand breaks, assessed by
analysis of γH2AX foci formation and clearance, was not affected. None of the
DNA repair players analysed (e.g. Blm, Rad51 and 53BP1) failed to form foci in
response to IR. However, their basal levels of foci were significantly greater in
the presence of PmlC62A/C65A (p<0.04; quantified using Amnis ImageStreamX
Mk II imaging flow cytometer). Additionally, we found that Rad51 foci showed a
defect in localisation post-IR when PmlC62A/C65A was expressed, with impairment
of Rad51 co-localisation and interaction with γH2AX.
Summary/Conclusions: Our study highlights the importance of re-formation
of NBs for an efficient response to targeted therapy, the significant contribution
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of Pml NB to the effectiveness of DNA damage repair processes, and the man-
ner in which their disruption mediated by the PML-RARα oncoprotein can assist
APL pathogenesis.
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DECIPHERING THE ONCOGENIC NETWORK OF PRC2 LOSS GUIDED
LEUKEMOGENISIS
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Background: Loss of function mutations in EZH2 (including the chromosomal
abnormalities -7/-7q) and other PRC2 subunits have been identified in adults
with MDS, MPN and AML. Moreover children with JMML and up to 30% of chil-
dren with Down syndrome related AML present with mutations in PRC2 sub-
units. Since myeloid neoplasms are elicited by accumulation of cooperating
mutations and the study of isolated mutations is unlikely to unveil the molecular
processes guiding transformation, we set out to decipher the oncogenic network
guided by loss of PRC2-activity.
Aims: Through identification of collaborating mutations driving AML with loss
of PRC2 function followed by molecular profiling we aimed to identify novel
therapeutic targets in AML.
Methods: To model the complex interplay of mutational networks we performed
CRISPR-Cas9 screenings with oncogene/tumor suppressor pools in vitro and
in vivo. Cellular resources generated were subjected to mutational and molec-
ular profiling.
Results: To this end, a 96-well based CRISPR-Cas9 immortalization assay
allowing fast and quantifiable genetic cooperation screenings was established.
Four out of six CRISPR-Cas9 pools tested –comprised of five genes each and
representing 148 mutation combinations- reproducibly transformed LSK cells
with distinct clonal output. Transplantation of in vitro immortalized clones yielded
robust engraftment with multi-lineage contribution in mice but no overt leukemia
was detected, indicating that induced mutations select for a preleukemic state
in vitro. We thus tested every oncogene/tumor suppressor pool from the in
vitro setting in a murine bone marrow transplantation model with freshly trans-
duced LSK cells which resulted in robust induction of leukemia. Analysing the
mutational spectrum of derived clones we were able to raise a list of potential
partners cooperating with Ezh2 loss, which highlighted Nf1(Ras-signaling), loss
of Dnmt3a, and loss of Runx1 as cooperating partners, whereas loss of cohesin
complex subunits (Smc3, Stag2) seems to be dispensable during the induction
of Ezh2-loss guided leukemogenesis. To define oncogenic dependencies in
myeloid malignancies with PRC2-loss we analysed gene expression spectra
of the generated samples. While in vitro transformed clones presented with
distinct expression signatures clearly separating from controls a partially over-
lapping expression signature could be established. Through identification of
these collaborating mutations and the resulting gene expression signature,
which will be validated in a CRISPR-Cas9 knock-out screening we aim to iden-
tify novel therapeutic targets in AML.
Summary/Conclusions: Our study highlights the power of the CRISPR-Cas9
system to probe oncogenic interaction. Mutational CRISPR screenings in vivo,
and a newly established in vitro CRSIPR-Cas9 immortalization assay for high
throughput screening of sgRNA pools, delivered potential cooperating partners
of Ezh2 loss in AML, and provides rich cellular resources to identify molecular




ACUTE MYELOID LEUKEMIA EVOLUTION CAN BE RECONSTRUCTED
BY ANALYSIS OF NON-LEUKEMIC CELLULAR SUBCOMPARTMENTS
AND MULTI-LINEAGE ENGRAFTED MICE
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(EMBL), Heidelberg, Germany
Background: Hematopoietic Stem Cells (HSC) isolated from patients with
Acute Myeloid Leukemia (AML) have been shown to carry leukemia-specific
mutations leading to the concept of pre-leukemic HSC. In order to understand
the evolution from multi-potent pre-leukemic HSC to fully transformed AML, an
accurate molecular comparison of patient matched HSC and leukemic cells is
essential. Recently we have shown that functionally normal HSC can be sep-
arated from a subgroup of AML patients using the surface marker combination
CD34+CD38- and high ALDH enzyme activity (CD34+CD38-ALDH+).
Aims: In this study we aim to understand the leukemic evolution from pre-
leukemic HSC to fully transformed AML.
Methods: Whole exome sequencing (WES) of 12 diagnostic AML samples
with the matched germ-line controls (T cells or buccal swab) was performed.
Leukemia-specific mutations were identified according to specific criteria (Allele
Frequency (AF) >0.20, Sorting Intolerant From Tolerant (SIFT)-Score <0.05,
coverage >10 reads, support >2 reads, and GMAF <0.05) and validated. Iden-
tified AML-specific mutations were tracked in different cellular compartments
(T- and B-cells) as well as in single HSC colonies derived from diagnostic AML
samples. To test the functional properties of pre-leukemic HSC in vivo, we
transplanted bulk AML in NOD/SCID-IL2Rγnull (NSG) mice and analyzed human
subpopulations (myeloid and lymphoid) of multi-lineage engrafted animals for
the presence of leukemia-specific mutations.
Results: WES identified 64 AML-specific mutations. Most cases (8 out of 12)
showed 4-6 AML specific mutations per sample (1-18 mutations/ AML) including
mutations in genes that are recurrently mutated in AML (DMNT3A, IDH1, IDH2,
NRAS and KIT). Tracking of AML-specific mutations in non-leukemic T- and B-
cells showed that some AML mutations like DNMT3A, IDH1, IDH2, EZH2 and
ZNF536 were already detectable in T- and B-cells indicating their pre-leukemic
status. Furthermore, analysis of multi-lineage engrafted xenografts detected
leukemia-specific mutations in human myeloid and lymphoid sub-compartments
suggesting that these animals were engrafted from functionally normal pre-
leukemic HSC. To reconstruct the sequence of pre-leukemic mutations single-
cell HSC were seeded and the resulting colonies analyzed for the presence of
the respective leukemia specific mutations. Based on the different mutational
data, combined with the cellular context in which these were detectable the
leukemic evolution of most patients could be reconstructed. In one patient we
detected a DNMT3A mutation in myeloid and lymphoid cells, whereas NPM1
and FLT3-ITD mutations were only detectable in leukemic cells proving the
pre-leukemic status of DNMT3A in this case. In another patient we found
DNMT3A and IDH2 in T- and B-cells whereas Trisomy 8 and a STAG2 deletion
were only detectable in leukemic cells. By analyzing colonies from single cell
HSC we were able to detect complex pre-leukemic hierarchies with one exam-
ple in which a ZNF536 mutation could be identified as initiating event that hasn’t
been described in leukemia yet.
Summary/Conclusions: WES can identify leukemia specific mutations including
mutations in genes that haven’t been described in AML yet. Tracking of these
mutations in various non-leukemic cellular compartments including HSC and
multi-lineage engrafted mice allows reconstruction of the individual leukemic evo-
lution. A better understanding of these processes may pave the way for new
treatment strategies with the aim to target the relevant leukemic mutations.
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THE ESSENTIAL ROLE OF THE ENHANCERS OF POLYCOMB EPC1 AND
EPC2 IN MLL-AF9 ACUTE MYELOID LEUKAEMIA IS A ‘COMPLEX’ STORY
N. Mannion1,*, X. Huang2
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Background: The Enhancers of Polycomb (EPC) proteins EPC1 and EPC2 are
required for the survival of MLL-rearranged acute myeloid leukemia (AML). Most
importantly, loss of EPC1 or EPC2 in MLL leukemia stem cells, but not normal
hematpoietic stem cells and progenitor cells, leads to the induction of cellular
apoptosis. To date little is known about the functional contribution of EPC1 and
EPC2 in AML. EPC1 is an essential component of the highly conserved NuA4
histone acetyltransferase complex. Additionally, EPC1 has been found in com-
plexes with the Enhancer of zeste homolog 2 (EZH2), a catalytic core subunit of
the histone methyltransferase Polycomb repressive complex 2 (PRC2). NuA4
and PRC2 are two major chromatin modifying complexes encompassing oppos-
ing epigenetic activities and both are known to be deregulated in AML.
Aims: A systems biology approach to understand the essential contribution of
the homologous chromatin regulatory proteins EPC1 and EPC2 in AML in
search for novel therapeutic targets.
Methods: Mass spectrometry (MS) analysis was performed on immunopre-
cipitated protein using EPC1 antibody from human THP1 MLL-AF9 AML cell
extracts. Chromatin immunoprecipitation (ChIP) was performed using HighCell
ChIP Kit and iPure kit V2 (Diagenode) followed by NextSeq500 Illumina
sequencing in THP1 cells. ChIP enriched regions were identified using SICER
peak calling and ChIPpeakAnno. Lentiviral supernatants were prepared and
THP1 cells were infected with viral particles containing pLKO.1 puro lentiviral
vectors expressing shRNAs. RNA was extracted 72 hr following lentiviral trans-
ductions and whole transcriptome sequencing was performed. DESeq2 was
used for differential expression analysis.
Results: MS analysis identified the core NuA4 complex components (TIP60,
ING3, RUVBL1, RUVBL2, EP400 and DMAP1) and also revealed additional
chromatin modifying proteins (HAT1 and HDAC2) copurify with EPC1. ChIP
sequencing analysis on THP1 cells for EPC1 and EPC2 revealed both proteins
bind in close proximity to genes enriched for the PRC2-associated repressive
histone H3K27 trimethylation signature. Next we examined the genome-wide
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histone methylation and acetylation profiles following lentiviral shRNA knock-
down (KD) of EPC1 or EPC2 in THP1 cells. Interestingly, we find significant
changes in histone H3K27 trimethylation levels as well as changes in the levels
of histone H3 and H4 acetylation following KD of either EPC1 or EPC2 expres-
sion. Notably, the identified regions demonstrating changes in histone
H3K27me3 levels are enriched for PRC2 target genes. RNA sequencing fol-
lowed by gene-set enrichment analysis indicated significant transcriptional
changes in PRC2 regulated genes following lentiviral shRNA knockdown of
EPC1 or EPC2. Meta-analysis of this PRC signature identified a sub-group of
genes that are directly regulated by the EPC complex which include the mono-
cytic differentiation inducer MAFB, the H2A ubiquitin ligase TRIM37 and the
pro-apoptotic tumor suppressor CMTM3.
Summary/Conclusions: Our data suggests that EPC1 and EPC2 are required
for the recruitment of certain chromatin proteins to form EPC-associated com-
plexes which are essential for the maintenance of an AML epigenetic signature
and an aberrant transcriptional profile that supports leukemia stem cell survival.
We have identified and characterized the EPC complex components in human
AML. Additionally, we have refined a subgroup of PRC target genes that are
regulated by the EPC complex which represent potential novel therapeutic tar-
gets in human AML. Overall we present a comprehensive analysis of the aber-
rant epigenomic landscape of THP1 MLL-AF9 AML cells in relation to EPC1
and EPC2 and provide new insight into their deregulated role in AML.
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STROMA-DERIVED FACTORS STIMULATE JAK/STAT SIGNALING IN AML
CELLS RESULTING IN RESISTANCE TO BCL2 INHIBITOR VENETOCLAX
R. Karjalainen1,*, M. Popa2, M. Liu1, K.K. Javarappa1, M. Kontro3,4, A. Parsons1,
K. Porkka3,4, K. Wennerberg1, E. McCormack2,5, B.T. Gjertsen2, C.A. Heckman1
1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland, 2Centre for
Cancer Biomarkers CCBIO, Department of Clinical Science, University of
Bergen, Bergen, Norway, 3Hematology Research Unit Helsinki, University of
Helsinki, 4Department of Hematology, Helsinki University Hospital Comprehen-
sive Cancer Center, Helsinki, Finland, 5Department of Internal Medicine, Hauke-
land University Hospital, Bergen, Norway
Background: The bone marrow (BM) microenvironment is known to protect
AML cells from drug therapy. We showed earlier that conditioned medium (CM)
from the BM stromal cell line HS-5 increased cell viability and led to resistance
to specific drug classes.
Aims: Here, we investigate the mechanisms mediating the BM stromal cell
induced resistance to venetoclax and its reversal by ruxolitinib.
Methods: Phospho-flow analysis was done by stimulating AML patient cells
with GM-CSF, G-CSF, IL-6, IL-8 or MIP-3α (10 ng/mL) for 20 min, after which
the cells were stained with Alexa 647-anti-phospho-Stat5 (pY694), PE188
CF594-anti-phospho-Stat3 (pY705), BV421-anti-phospho-Akt (pS473) and PE-
anti-phospho-Erk1/2 (pT202/pY204). For co-culture and transwell assays AML
cells were added directly to MSCs from AML patients or separated by a 0.4 μm
pore membrane. Vehicle (DMSO), ruxolitinib (300 nM), venetoclax (100 nM) or
their combination were incubated for 48h and AML cells labeled with PE-Annex-
in V, 7AAD, PE-Cy7-CD34, BV605-CD45. In vivo drug efficacy was tested on
NSG mice inoculated i.v. with MOLM-13lucAML cells. Mice were divided into
control, venetoclax (25 mg/kg, i.p.), ruxolitinib (50 mg/kg BID, p.o) and combi-
nation groups (all n=6) and treated for 3 weeks, 5 days a week with 2 days off.
Results: To identify the factors contributing to BM mediated drug resistance of
AML cells, we analyzed the effect of IL-6, IL-8, MIP-3α, GM-CSF and G-CSF,
cytokines enriched in the HS-5 CM, on proliferation of MNCs collected from
AML patients. GM-CSF and to some extent G-CSF alone conferred resistance
to venetoclax similar to CM that we showed earlier to reduce sensitivity to BCL2
inhibitors. To identify the impact of stroma-derived factors on cellular signaling
we stimulated AML patient cells with CM and analyzed the phosphorylation of
STAT3, STAT5, ERK and AKT. Compared to control conditions, CM rapidly
induced phosphorylation of STAT5 in primary AML cells. When the effect of
individual cytokines was tested, we noted that GM-CSF and G-CSF alone could
mimic the effect of CM on cellular signaling. Gene expression data showed the
receptor for GM-CSF (CSFR2A) is more highly expressed in AML patient cells
compared to healthy controls. Taken together, these results show that cytokines
such as GM-CSF from BM stromal cells increase JAK/STAT signaling, which
may lead to enhanced survival of AML cells. To determine whether the protective
effect of stroma on BCL2 inhibition was dependent on cell-to-cell interactions
we cultured AML patient cells either in direct contact with MSCs or separated
from stroma with a 0.4 μm pore membrane. 48h treatment with 100 nM vene-
toclax did not result in significant reduction of CD34+ AML cells regardless of
whether AML cells were directly cultured with stroma or separated by a mem-
brane, further indicating that stroma-derived soluble factors are sufficient to
reduce sensitivity to venetoclax. Since the most abundant cytokines secreted
by HS-5 cells, GM-CSF and G-CSF led to increased phosphorylation of STAT5,
a downstream effector of JAKs, we tested a combination of venetoclax and
JAK1/2 inhibitor ruxolitinib. We found that ruxolitinib potentiated sensitivity to
venetoclax when tested with AML patient cells in HS-5 CM and in co-culture
and transwell assays. Significantly, the combination was more effective at reduc-
ing tumor burden in a xenograft mouse model of AML than either drug alone.
Summary/Conclusions: In conclusion, our data demonstrate that BM secreted
soluble factors drive cytoprotection against BCL2 antagonist venetoclax that
can be overcome by combined blockade of JAK/STAT and BCL2 pathways
with ruxolitinib and ventoclax in ex vivo co-culture models and in vivo in an
AML mouse model.
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IDENTIFICATION OF NOVEL GENE FUSIONS IN ACUTE MYELOID
LEUKEMIA WITH COMPLEX KARYOTYPE BY TRANSCRIPTOME ANALYSIS
USING RNA SEQUENCING
F. G. Rücker1,*, X. Gong2, A. Dolnik1, M. Hoyos1, S. Grasedieck1, J. Biscocho2,
T. Blätte1, J. Swoboda1, A.S. Pollack2, A. Turchiano1, H. Döhner1, K. Döhner1,
J.R. Pollack2, L. Bullinger1
1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany,
2Department of Pathology, Stanford University, Stanford, United States
Background: Acute myeloid leukemia with complex karyotype (CK-AML),
defined as having ≥3 acquired cytogenetic aberrations in the absence of WHO-
designated recurring translocations or inversions, represents about 15% of
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adult AML cases. Despite having poor outcomes, CK-AML is the least under-
stood at the molecular level, except for the finding that about two-thirds of
cases carry TP53 alterations. In particular, because cytogenetic alterations
appear to be distinct among different patients, it is unclear whether they are
cause of leukemogenesis, or merely reflect a state of genomic instability.
Aims: We have hypothesized that cytogenetic aberrations in CK-AML create
gene fusions that, although not recurrent across patients, nonetheless dereg-
ulate cancer genes that contribute to leukemogenesis in individual patients.
Methods: We performed a transcriptome analysis using Illumina paired-end
(101bpx2) RNA sequencing of 65 CK-AML cases to identify gene fusions using
multiple independent algorithms (as paired reads that flank, or single-reads
that span fusion junctions). Identified gene fusions were in part independently
validated by array-based genomic profiling and/or long range PCR followed by
use of long-read Oxford Nanopore sequencing technology.
Results: We identified 54 gene fusion events in 30 of the 65 cases (46%) with
up to four fusions per case. All fusions are supported by 10-50+ junction-span-
ning reads, and most are independently supported and/or validated by evidence
of genomic DNA breakpoints from array-based genomic profiling and/or long
range PCR, respectively. About 35% of the fusions were in-frame, encoding
chimeric proteins. The remainder encoded either C-terminally truncated 5’
fusion partners, or else N-terminally truncated (or rarely full-length) 3’ fusion
partners in instances where the 5’ partner contributed only the 5’UTR. In many
instances, the fusions are predicted to lead to the overexpression or chimeric
activation of known or putative novel cancer genes. Of the 54 fusions, only
three (RUNX1-MECOM, MN1-ETV6, and ETV6-MN1) were previously reported
in AML. The most frequently affected genes were RUNX1 (n=5), KMT2A, and
MECOM (n=3 each). Based on the affected genes the fusions can be catego-
rized into six functional fusion clusters. Many of the fusions contained at least
one known AML gene (n=16; e.g. RUNX1, MECOM, DEK, ETV6, KMT2A)
together with a novel fusion partner, clearly suggesting pathogenic relevance.
Other fusions were predicted to disrupt known tumor suppressors (n=4; e.g.
TP53, NF1), or to activate known oncogenes (n=3; e.g. MYB). Others encoded
chimeric proteins of unclear pathogenic relevance, but that could nonetheless
encode novel epitopes created by the fusion junction (n=26).
Summary/Conclusions: Detailed molecular characterization of CK-AML
revealed a high incidence of novel gene fusions in about 50% of cases. The
affected genes suggest a more general role in leukemogenesis than reflecting
a state of genomic instability. Furthermore, identifying gene fusions in each
individual patient might lead to more effective, personalized treatments that
target the gene fusion itself, enable immunologic therapies against the fusion
junction epitopes, and provide private patient-specific biomarkers to track
leukemic burden for the monitoring of disease remission and relapse.
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H3K27ME3 LEVEL ON THE HIST1 CLUSTER: A POWERFUL EPIGENETIC
BIOMARKER THAT STRATIFIES TWO GROUPS OF NPM1-MUTATED AML
DIFFERING IN THEIR OUTCOME AND EXPRESSION PROFILE
S. Garciaz1,2,3,*, C. Chevalier2, P. Finetti1,2, J. Vernerey2, F. Bertucci2,3,4,
B. Calmels2,3,5, C. Recher6, C. Chabannon2,3,5, N. Vey1,2,3, E. Duprez2,3
1Hematology, Paoli-Calmettes Institute, 2INSERM 1068, Cancer research cen-
ter, 3Aix-Marseille University, 4Oncology, 5Cell therapy facility, Paoli-Calmettes
Institute, Marseille, 6Hematology, Toulouse Cancer University Institute,
Toulouse, France
Background: NPM1 mutation (NPM1mut) is the most frequent genetic alter-
ation found in cytogenetically normal acute myeloid leukemia (CN-AML).
Patients harboring NPM1mut without FLT3 internal tandem duplication (FLT3-
ITD) are considered to have favorable outcome. Yet, some of them relapse
and become resistant to chemotherapy. Little is known about biological
processes underlying treatment failure. Our group previously described a new
epigenetic biomarker corresponding to an abnormal gain of the repressive
H3K27me3 histone mark within the HIST1 locus on the 6.p22 referred as
H3K27me3 HIST1high. This epigenetic biomarker had an impact on clinical out-
come as CN-AML patients with H3K27me3 HIST1high had a higher overall sur-
vival (OS) and leukemia-free survival (LFS) than H3K27me3 HIST1low patients
(Tiberi et al., 2015). 
Aims: We studied the impact of H3K27me3 HIST1 in an NPM1mut CN-AML
cohort. Firstly, we asked whether H3K27me3 HIST1 could help to stratify
NPM1mut CN-AML patients independently of known genetic alterations. Sec-
ondly, we studied gene expression profile (GEP) related to H3K27me3 HIST1
to explore biological pathways associated with treatment failure.
Methods: Blood or bone marrow samples with at least 70% blast involvement
collected from 2005 to 2014 were recovered from the Paoli-Calmettes Cancer
Institute Biobank and analyzed as training set. A validation set of samples col-
lected during the conduct of two GOELAMS clinical trials (LAM2006IR and
LAM2007SA) was used for validation. We performed H3K27me3 HIST profiling
by chromatin immunoprecipitation followed by quantitative polymerase chain
reaction (ChIP-QPCR) on five histone genes of the HIST1 cluster. We also
sequenced frequently mutated genes in AML (FLT3, CEBPα, DNMT3A, IDH1,
IDH2, MLL, EZH2, TET2, P53, WT1 and ASXL1). GEP was done on Affymetrix
whole-transcript DNA microarray and we used gene set enrichment analysis
(GSEA, Subramanian et al., 2005) along with the Gene Ontology database as
statistical methodology.
Results: We pooled the 103 samples of patients with NPM1mut CN-AML of
the training and validation sets together. Median age was 60 [37-76] and medi-
an leucocyte count was 76 G/L [10-352]. ChIP-QPCR Profiling identified 74
H3K27me3 HISThigh and 29 H3K27me3 HIST1low patients. FLT3-ITD was
found in 33 (43%) of H3K27me3 HIST1high and 18 (38%) of H3K27me3
HIST1low patients. We confirmed that H3K27me3 HIST1high was associated
with higher 5-year OS and LFS rates: 37% and 44% versus 17% and 19%
(p=.005 and .01) for the H3K27me3 HIST1high and the H3K27me3 HIST1low
patients, independently of other genetic alterations. Combining our biomarker
with FLT3 mutational status, we identified two subgroups of patients with very
different outcome: 49% and 56% versus 18% and 18% (p=.004 and .01) for
the H3K27me3 FLT3wt HIST1high and the FLT3wt H3K27me3 HIST1low
patients, respectively (Figure 1). We performed GEP for 27 NPM1mut patients
(12 H3K27me3 HIST1low and 15 H3K27me3 HIST1high). GSEA analysis
revealed a strong enrichment in immune functions and leucocyte activation in
the H3K27me3 HIST1high group, evoking differentiated AML. While H3K27me3
HIST1low samples had GSEA associated with chromatin remodeling factors
and DNA replication. Considering only FLT3wt patients, the H3K27me3
HIST1low subgroup had a gene expression signature characterized by a high
expression level of genes from the HIST1 cluster which expression is known
to be upregulated during S-phase of cell cycle.
Figure 1.
Summary/Conclusions: the biomarker H3K27me3 HIST1high is correlated
with a better LFS and OS in NPM1mut CN-AML patient, independently of other
known genetic alterations in particular FLT3 ITD. The worse outcome of FLT3-
wt H3K27me3 HISTlowpatients is concomitant with high expression of replica-
tion-dependent HIST1 genes that could explain treatment failure.
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FUNCTIONAL ASSESSMENT OF NOVEL DIAGNOSTIC FLT3 MUTATIONS
AND INHIBITION BY KINASE INHIBITORS
K. Tarlock1,2,*, T.A. Hylkema2, J.A. Pollard3, M.E. Hansen4, R. Ries2, R. Sweat5,
S. Meshinchi2
1Hematology/Oncology, Seattle Children’s Hospital, 2Clinical Research Divi-
sion, Fred Hutchinson Cancer Research Center, Seattle, 3Pediatric Hematol-
ogy/Oncology, Maine Medical Center, Portland, 4University of Rochester,
Rochester, 5Arog Pharmaceuticals, Dallas, United States
Background: Somatic mutations in FLT3 are among the most common events
in AML, with FLT3/ITD mutations in the juxtamembrane domain (JMD) as well
as D835 missense mutations in the kinase domain (KD) the predominant
events. Sequencing of FLT3 in a cohort of 788 children with de novo AML treat-
ed on contemporary Children’s Oncology Group protocols demonstrated that
in addition to the previously described FLT3 mutations (ITD and D835), numer-
ous other variants, including several novel variants, were present in 8% of
patients at diagnosis, leading to a cumulative FLT3 mutation prevalence of
27% in children and young adults. These variants mostly occurred in the JMD
and KD and were predicted to activate FLT3, therefore increasing the number
of patients who might be amenable to FLT3 inhibitor therapy.
Aims: We evaluated the oncogenic capability of each of these mutations by
assessing their ability to result in aberrant FLT3 and STAT5 phosphorylation, as
well as response to the tyrosine kinase inhibitors crenolanib and quizartinib.
Methods: Point mutations were introduced into HEK293 cells using retroviral
transduction. Following transduction, phosphorylation status of FLT3 (pFLT3)
and downstream STAT5 (pSTAT5) were evaluated by immunoblotting. Phos-
phorylation status was quantified by chemiluminescence analysis and the quan-
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tity of protein expression was normalized to actin. That ratio of phosphorylated
protein to total protein for FLT3 and STAT5 was determined and normalized to
that observed in the D835Y mutation as a positive control. A value of >10%
pFLT3 was considered positive. All mutations that resulted in FLT3 phosphory-
lation were subsequently evaluated for inhibition by crenolanib and quizartinib
following 60-minute exposure to the compounds.
Results: A total of 24 non-ITD and non-ALM FLT3 mutations were evaluated
for autonomous FLT3 and STAT5 phosphorylation. Eleven mutations resulted
in pFLT3 and pSTAT5, including 4 mutations with >50% pFLT3. All mutations
that demonstrated aberrant pFLT3 also had aberrant pSTAT5, however a direct
correlation of pFLT3 and pSTAT5 was not always observed. Overall, 87% (n=86
patients) of all non-ITD mutations evaluated resulted in autonomous FLT3 acti-
vation. Excluding D835 mutations, 64% (n=39) of patients harbored an activat-
ing mutation. Many of the mutations that were not found to be activating had
the lowest prevalence, often present in only one patient. Evaluation of inhibition
of phosphorylation demonstrated that in every case of aberrant activation,
crenolanib resulted in potent inhibition of phosphorylation of FLT3 and STAT5
with an IC50 range of 1.3-13.9 nM and 0.6-6.5 nM respectively. Many of the
mutations tested were exquisitely sensitive to crenolanib, with 9 of 10 mutations
tested demonstrating an IC50 of pFLT3 inhibition ≤5.6 nM. Inhibition of down-
stream kinases are necessary for optimal efficacy of any FLT3 inhibitor and
phosphorylation of STAT5 was potently inhibited by crenolanib in all cases.
Quizartinib inhibited pFT3 and pSTAT5 with an IC50 range of 1.8-151.7 nM
and 1-33.9 nM respectively, demonstrating less effective inhibition specifically
at mutations including D835Y, D839E, N676K, M664I.  
Summary/Conclusions: We have previously presented that FLT3 mutations,
including novel mutations in addition to the FLT3/ITD and D835, are prevalent
in children and young adults with AML. Here we demonstrate that many of the
non-ITD/835 mutations also result in aberrant FLT3 phosphorylation and are
amenable to inhibition by FLT3 inhibitors. Crenolanib resulted in potent inhibition
of FLT3 and downstream STAT5 in all mutations tested. This data supports
expanding the cohort of pediatric patients with activating FLT3 mutations who




THE BCL-2 INHIBITOR VENETOCLAX INHIBITS NRF2 ANTIOXIDANT
PATHWAY ACTIVATION INDUCED BY HYPOMETHYLATING AGENTS IN
ACUTE MYELOID LEUKEMIA
L.X.T. Nguyen1,*, A. Kalvala1, E. Troadec1, B. Kumar1, S. Forman1, G. Marcucci1,
V. Pullarkat2
1City of Hope Medical Center, Duarte, United States, 2Hematology, City of Hope
Medical Center, Duarte, United States
Background: The selective Bcl-2 inhibitor Venetoclax (ABT-199) has shown
potent antileukemic activity against Acute Myeloid Leukemia (AML) in preclinical
and early clinical studies and impressive results have been achieved using the
combination of hypomethylating agents (HMA) with venetoclax suggesting syn-
ergy between these agents.
Induction of Reactive Oxygen Species (ROS) is important for the cytotoxicity
of various AML therapies including HMA. Induction of ROS by various cytotoxic
therapies concurrently activates the Nrf2 antioxidant response pathway which
in turn results in induction of antioxidant enzymes that neutralize ROS. Upon
ROS induction, the transcription factor Nrf2 is released from its adaptor protein
Keap 1 in the cytoplasm whereby Nrf 2 enters the nucleus and binds to antiox-
idant response element sequences  in the promoters of various genes. Nrf 2
pathway activation has been shown to mediate chemoresistance in various
cancers including AML. Low ROS levels have been shown to be a hallmark of
leukemia stem cells  and are critical to their self renewal capacity. In this study,
we examined whether Nrf2 inhibition is an additional mechanism responsible
for the marked antileukemic activity in AML seen with the combination of HMAs
and venetoclax.
Aims: To determine the effect of veneoclax on ROS levels after HMA exposure
in AML cells and to examine the effect of Bcl-2 inhibition on Nrf-2 antioxidant
pathway activation in response to HMA
Methods: The effect of combination of venetoclax and HMA on ROS levels
and apoptosis was measured by flow cytometry. Effcet of venetoclax and HMA
on Nrf2 nuclear translocation was analyzed by immunostaining after cellular
fractionation. Effcet of venetoclax treatment on the association of Bcl2 with
Nrf2 Keap 1 complex was assessed by western blot analysis, immunoprecipi-
tation and in vitro assay for ubiquitination.
Results: Our results demonstrated that combination of HMA with venetoclax aug-
mented cellular and mitochondrial ROS induction and apoptosis compared to
treatment HMA alone. Treatment of AML cell lines as well as primary AML cells
with the hypomethylating agent decitabine resulted in increased nuclear translo-
cation of Nrf2 (Figure 1) and induction of downstream antioxidant enzymes includ-
ing HO-1 and NQO1. Immunofluoresence studies confirmed the inhibition of
nuclear translocation of Nrf2 by venetoclax. Immunoprecipitation studies indicated
that Bcl-2, Keap 1 and Nrf2 associate in a protein complex in the cytoplasm and
that treatment with venetoclax leads to dissociation of Bcl-2 from the Nrf2/Keap 1
complex and targets Nrf2 to ubiqitination and proteosomal degradation.
Figure 1.
Summary/Conclusions: In conclusion, inhibition of Nrf2 pathway may explain
the marked potentiation of HMA activity by venetoclax that is observed in clinical
trials. We show that ROS induction at least partially mediates the cytotoxicity
of HMA and ROS induction after HMA treatment is augmented by venetoclax.
We demonstrate for the first time that venetoclax is a potent inhibitor of Nrf2
activation via disruption of the association between Nrf2, Keap-1 and Bcl-2.
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UNRAVELING EPIGENOMIC REGULATION IN THE EVOLUTION OF
RELAPSING PEDIATRIC AML
C. Wiggers1,2,*, M. Baak1, M. Creyghton1, M. Bartels2
1Hubrecht Institute, 2Pediatrics, University Medical Center Utrecht, Utrecht,
Netherlands
Background: In comparison with pediatric acute lymphoblastic leukemia, pedi-
atric acute myeloid leukemia (AML) is characterized by a high relapse rate
(~30%), and lower overall survival rates of 60-70%. It is therefore crucial to
increase our insights in pathophysiological mechanisms underlying AML relapse,
including chemotherapy resistance, clonal evolution, and clonal selection. There
is increasing evidence that epigenetic deregulation is involved in the initiation
and progression of cancers, including adult AML. Epigenetic regulation involves
the activity of non-coding regulatory DNA elements such as enhancers, which
interact with promoters to fine-tune gene expression. Importantly, epigenetic sig-
natures at enhancers are highly cell state specific. Since little is known concerning
the epigenetic landscape of pediatric AML, it is crucial to gain more insights into
the epigenome of relapsed and non-relapsed AML in children.
Aims: To identify differential epigenomic regulatory pathways involved in AML
relapse by exploring the epigenome of relapsed (RP) and non-relapsed pedi-
atric AML patients (NRPs).
Methods: The epigenome of 20 AML patients, harboring known molecular aber-
rations (including MLL-rearrangement, CBF-related and Flt3-ITD), was analyzed
to identify active regulatory pathways. Acetylation of lysine 27 on the tail of histone
H3 (H3K27ac) marks active regulatory DNA elements and was therefore used to
identify active promoters and enhancers using Chromatin-Immunoprecipitation-
sequencing (ChIP-seq) experiments. Additionally, single-cell RNA-seq data were
generated for selected AML patients to analyze clonal heterogeneity.
Results: All genomic regions that were significantly enriched by H3K27ac were
analyzed, resulting in ~30.000 active promoters and enhancers per sample.
Genome-wide Pearson correlation of all enriched regions showed subclustering
of patients based on molecular aberration. Interestingly, epigenomic analysis
showed that the initial diagnosis (Dx) and the patient’s relapse (Rel) sample
were highly correlated. Also, single-cell RNA-seq analysis identified two highly
identical homogeneous populations at Dx and Rel. Following the fact that no
major differences were observed between AML cells at diagnosis and relapse,
NRPs were analyzed. Here striking differences in H3K27ac enrichment were
observed in MLL-rearranged patients between NRPs and RPs. Enhancers and
promoters were differentially enriched at diagnosis, of which Sphk1, a kinase
involved in proliferation and survival, was significantly more enriched in RPs,
while the promoter of transcription factor ELF1 and nearby located enhancers
were active in NRPs only.
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Summary/Conclusions: Analysis of promoters and especially enhancers is a
highly useful approach to identify cell state specific regulation. Here, we ana-
lyzed pediatric AML patients at diagnosis and at relapse to gain more insight
into specific cell states which are involved in relapse. Our data revealed high
similarity between diagnosis and relapse samples, while, strikingly, in the WHO
intermediate-risk group containing MLL-rearranged patients, differential epige-
nomic regulation was observed between NRPs and RPs. Taken together, our
preliminary data suggests that already at diagnosis, AML cells display an epige-
nomic fingerprint associated with the development of AML relapse during the
course of disease. We are currently validating these data.
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MECHANISTICALLY INFORMED COMBINATIONS OF SY-1425, A POTENT
AND SELECTIVE RARΑ AGONIST, WITH HYPOMETHYLATING OR
ANTI-CD38 TARGETED AGENTS IN AML AND MDS
M. Mckeown1,*, K. Austgen2, C. Fiore2, E. Lee1, D. Smith2, C. Fritz2, T. Lodie2,
E. di Tomaso1, E. Olson2
1Translational Medicine, 2Biology, Syros Pharmaceuticals, Cambridge, United
States
Background: The complex pathogenesis of cancer often necessitates combi-
nation therapies to optimize patient benefit. Thus, we investigated preclinical
combinations of SY-1425 (tamibarotene) and other agents to build on the
monotherapy strategy with SY-1425 in biomarker selected AML and MDS
patients (Phase 2 study, NCT02807558). Based on the RARα mediated myeloid
gene activation of SY-1425, epigenetic priming with hypomethylating agents
(HMAs) and CD38 induction were explored.
Aims: We sought to investigate mechanistically informed combinations of SY-
1425 with standard of care agents and with potential novel agents in AML. We
hypothesized that the HMA azacitidine could prime AML cells for SY-1425 medi-
ated reprogramming by relieving aberrant methylation of RARα target genes
and that strong upregulation of the maturation marker CD38 in AML cells by
SY-1425 could induce sensitivity to the anti-CD38 therapeutic antibody dara-
tumumab (DARA).
Methods: HMA synergy was tested in vitro in AML cell lines over a range of
concentrations for SY-1425 and azacitidine. In vivo studies used a disseminated
patient derived xenograft (PDX) model of AML expressing high levels of RARA.
SY-1425 induction of CD38 was assessed by H3K27ac ChIP-seq, RARα ChIP-
seq, RNA-seq and flow cytometry. Antibody dependent cell-mediated cytotox-
icity (ADCC) was tested in an ex vivo co-culture model of human NK cells and
AML cell lines.
Results: RARα acts as a repressive transcription factor until bound by SY-
1425 leading to potent, targeted activation of myeloid genes. HMAs can further
prime this activation by depleting repressive methylation of these target genes.
The combination of SY-1425 and azacitidine showed synergy in RARA-high
AML cell lines, but not in RARA-low AML cell lines, with combination indices
less than 0.5. Co-administration in a RARA-high AML PDX demonstrated supe-
rior reduction of tumor burden (<1% detectable tumor cells) vs either treatment
alone (7% with SY-1425 and 8% with azacitidine). Various combination regi-
mens evaluated in the PDX model over two cycles (56 days) found that 1 week
of azacitidine followed by 3 weeks of SY-1425 maximized for anti-tumor activity
(<5% AML cells in periphery, bone marrow and spleen) and tolerability (<8%
weight loss). RARα binds directly to the CD38 locus and induces H3K27 acety-
lation in response to SY-1425 causing CD38 to be one of the most upregulated
mRNA transcripts in RARA-high models. SY-1425 treatment of four RARA-
high AML cell lines and three RARA-high primary AML patient samples induced
cell surface CD38 to high levels comparable to those of DARA sensitive multiple
myeloma cells. In contrast, no CD38 induction was observed in RARA-low cell
lines. RARA-high AML cell lines treated with SY-1425 and DARA were six fold
more sensitive to NK cell mediated ADCC compared to single agent controls
and exhibited a 5-10 fold increase in NK cell-dependent activation measured
by IFNγ secretion.
Summary/Conclusions: The RARA biomarker dependent synergy with azac-
itidine and SY-1425 is hypothesized to work through hypomethylation based
priming of myeloid differentiation by SY-1425 agonism of formerly repressed
RARα target genes. Since CD38 is one of the most strongly induced RARα
target genes in response to SY-1425, AML blasts can be sensitized to DARA
in a biomarker dependent manner. The preclinical synergistic effects and antic-
ipated non-overlapping clinical toxicity profiles of the respective agents provide
a strong rationale for clinical evaluation of each SY-1425 combination in bio-
marker selected AML and MDS patients.
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FLT3 INHIBITION OVERCOMES RESISTANCE TO THE BCL-2 SELECTIVE
ANTAGONIST, VENETOCLAX, IN FLT3-ITD MUTANT AML MODELS
D. Sampath1,*, R. Mali1, E. Lasater1, K. Doyle2, R. Malla1, E. Boghaert2,
A. Souers2, J. Leverson2
1Translational Oncology, Genentech, South San Francisco, 2Oncology, Abbvie,
North Chicago, United States
Background: FLT3 internal tandem duplication (ITD) mutations account for
~20-25% of adult AML cases and are associated with worse prognosis.
Although FLT3 inhibitors show clinical activity, relapse occurs quickly. Veneto-
clax is a potent, selective inhibitor of the anti-apoptotic protein BCL-2 that
demonstrated monotherapy activity in relapsed/refractory AML (ORR 19%);
however, no activity was seen in FLT3 mutant cases (Konopleva, Can Disc
2016). FLT3-ITD regulates expression of the anti-apoptotic proteins BCL-XL
and MCL-1, but not BCL-2, and FLT3 inhibition synergizes with the dual BCL-
2/BCL-XL inhibitor ABT-737 in vitro in FLT3-ITD+ cells (Kohl, Leukemia 2007). 
Aims: Expression of BCL-XL and MCL-1 are known resistance factors to vene-
toclax, therefore targeting pathways that regulate BCL-XL or MCL-1 in combi-
nation with venetoclax may enhance cell death and improve efficacy. Based
on this hypothesis, we interrogated if selective inhibition of BCL-2 by venetoclax
in combination with quizartinib, a potent FLT3 inhibitor, resulted in synergistic
anti-tumor effects in FLT3-ITD+ AML models.
Methods: FLT3-ITD+ (Molm13 and MV4;11) and wild type (wt; HL60 and OCI-
AML3) cell lines were evaluated in vitro. Proliferation was measured by cell
titer glo and apoptosis by Annexin V staining. In vivo efficacy was determined
in a MV4;11 xenograft model.
Results: Sensitivity to venetoclax was initially assessed in vitro. Dose depend-
ent growth inhibition and induction of apoptosis was observed in the MV4;11,
Molm13 and HL60 cell lines following 48hr venetoclax treatment, with the
MV4;11 cell line most sensitive. Modulation of BCL-2, BCL-XL and MCL-1
expression by FLT3 inhibition was determined following 8-24hr treatment with
quizartinib. Quizartinib reduced BCL-XL and MCL-1 protein, but not BCL-2, in
the FLT3-ITD+ cells. Quizartinib had no affect on expression of these three
proteins in FLT3 wt cells. To interrogate the combination of quizartinib and
venetoclax in vitro, cell lines were treated for 48hrs with venetoclax, quizartinib
or the combination. Combination treatment led to significant reduction in pro-
liferation and increased apoptosis in the FLT3-ITD+ cells compared to either
single agent. FLT3 wt cells were not sensitive to quizartinib as a single agent
or in combination with venetoclax. The combination translated in vivo as syn-
ergy between quizartinib and venetoclax was observed in the MV4;11 xenograft
model. Together, this data underscores the dependency of these cells on the
FLT3-ITD mutation for growth and its use as a predictive biomarker of veneto-
clax resistance. To determine the dependence of FLT3-ITD+ cells on other
anti-apoptotic proteins, cell lines were treated with selective antagonists to
BCL-XL (A1331852) or MCL-1 (A1210477) in combination with venetoclax.
Treatment with either antagonist in combination with venetoclax reduced the
growth of the cell lines compared to venetoclax alone. However, co-inhibition
of BCL-XL or MCL-1 and FLT3-ITD did not reduce cellular growth compared to
quizartinib alone, indicating that maximum anti-tumor responses may be
achieved when all three anti-apoptotic proteins are targeted.   
Summary/Conclusions: Quizartinib treatment in FLT3-ITD+ AML models
decreased expression of the anti-apoptotic proteins BCL-XL and MCL-1 and
synergized with venetoclax in vitro and in vivo at clinically relevant doses for
each compound. These data suggest that co-targeting FLT3-ITD with selective
inhibitors and BCL-2 with venetoclax induces apoptosis to a greater extent
than FLT3 inhibition alone. Importantly, our preclinical data supports further
clinical investigation of this combination to treat FLT3-ITD+ AML.
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SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA STEM CELLS BY
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 
H.J. Verhagen1, N. van Gils 1, A. van Rhenen1, A. Rutten1, M. Smit1,
M.-L. Tsui1, L.L. de Vos Klootwijk 1, R.X. Menezes2, M.G. Roemer1, F. Brocco1,
F. Denkers1, E. Vermue1, S. Heukelom3, S. Zweegman1, J.J. Janssen1,
G.J. Ossenkoppele1, G.J. Schuurhuis1, L. Smit1,*
1Hematology, 2Epidemiology and Biostatistics, 3Radiology, VU University Med-
ical Center, Amsterdam, Netherlands
Background: Only 30-40% of acute myeloid leukemia (AML) patients survive
five years after diagnosis. This extreme poor prognosis is mainly caused by
treatment failure due to chemotherapy resistance.  Leukemic stem cells (LSCs)
are thought to be major determinants of AML recurrence due to their potential
for self-renewal and chemotherapy resistance. LSCs co-reside with normal
CD34+CD38- hematopoietic stem cells (HSCs) in the AML bone marrow.
Increasing the dose of chemotherapy might eliminate these chemotherapy
resistant cells, however will inevitable result in the non-specific elimination of
HSCs, delaying or even preventing the recovery of normal hematopoiesis after
therapy. To significantly improve the outcome of AML patients, the discovery of
alternative therapies that specifically eliminate LSCs while sparing HSC are
urgently needed. To develop these specific anti-LSC therapies, identification
of genes differentially expressed between LSCs and HSCs and between LSCs
and the AML bulk is crucial.
Aims: To identify specific therapeutic strategies that have the potential to elim-
inate AML relapse-initiating cells.
Methods: We generated gene expression profiles of HSCs, LSCs and leukemic
progenitors all derived from the same AML bone marrow and identified Insulin
growth factor binding protein 7 (IGFBP7) as one of the top differentially expressed
genes. As low IGFBP7 expression is a feature of LSCs, we hypothesized that
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decreased expression of IGFBP7 might be associated with decreased chemother-
apy sensitivity. To this end, we generated cell lines with IGFBP7 knockdown and
subjected the cells to chemotherapy. Furthermore, to test whether increasing the
IGFBP7 levels might be a strategy to deplete leukemic (stem) cells, we overex-
pressed IGFBP7 in or added recombinant human IGFBP7 (rhIGFBP7) to primary
AML cells and measured clonogenic capacity, differentiation and cell survival in
vitro. To study the effect of IGFBP7 on AML cell survival and engraftment potential
in vivo, primary AML cells were transplanted into immune deficient mice and the
mice were subsequently treated with rhIGFBP7. To study the effect of rhIGFBP7
on LSC survival, human AML cells derived from the first transplanted mice were
re-transplanted into secondary recipients and engraftment and survival of the
mice were monitored.
Results: Knockdown of IGFBP7 results in reduced sensitivity to chemotherapy
and comparing matched diagnosis and relapsed AML samples showed that
IGFBP7 expression is frequently downregulated at relapse, suggesting a sur-
vival advantage of IGFBP7lowAML cells during chemotherapy treatment. Impor-
tantly, enhancing cytoplasmic or extracellular IGFBP7, by overexpression or
addition of rhIGFBP7, resulted in induction of differentiation and apoptosis,
increased sensitivity to chemotherapy and inhibited AML blast and leukemic
stem/progenitor cell survival in vitro and in vivo. IGFBP7 had no influence on
the survival of normal hematopoietic (stem) cells. Moreover, treatment with
rhIGFBP7 can add to chemotherapy treatment by elimination of chemotherapy
resistant refractory AML (stem) cells.
Summary/Conclusions: Altogether, these data suggest that addition of IGF-
BP7 to the currently used chemotherapy regimens might be a promising strat-
egy to specifically eradicate LSCs and decrease AML relapse rates.
Acute myeloid leukemia - Clinical 1
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ONGOING PHASE 2 CLINICAL TRIAL OF SL-401 IN PATIENTS WITH
BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM: STAGE 1 AND
STAGE 2 RESULTS 
N. Pemmaraju1,*, K. Sweet2, A. Lane3, A. Stein4, S. Vasu5, W. Blum5,
D. Rizzieri6, E. Wang7, M. Duvic1, J. Chen8, S. Shemesh8, P. McDonald8,
C. Brooks8, J. Lancet2, H. Kantarjian1, M. Konopleva1
1MD Anderson Cancer Center, Houston, TX, 2H. Lee Moffitt Cancer Center,
Tampa, FL, 3Dana-Farber Cancer Institute, Boston, MA, 4City of Hope National
Medical Center, Duarte, CA, 5The Ohio State University, Colombus, OH, 6Duke
Univiersity Medical Center, Durham, NC, 7Roswell Park Cancer Institute, Buf-
falo, NY, 8Stemline Therapeutics, New York, NY, United States
Background: SL-401 is a targeted therapy directed to interleukin-3 receptor α
(CD123), a target overexpressed on a variety of cancers including blastic plas-
macytoid dendritic cell neoplasm (BPDCN), a highly aggressive malignancy
with poor outcomes and unmet medical need. 
Aims: This Phase 2 trial is a single-arm, open-label, study designed to generate
efficacy and safety data to support potential registration in BPDCN
Methods: In this ongoing Phase 2 single-arm trial, patients with BPDCN (n=32)
or relapsed/refractory (R/R) AML (n=48) received SL-401 as a daily IV infusion
at 7, 9, 12, or 16 ug/kg/day for days 1-5 of a 21-day cycle in stage 1. In stages
2 and 3, patients received SL-401 at the dose determined in stage 1. 
Results: 32 adult BPDCN patients received SL-401 in stage 1 (n=9) and stage
2 (n=23), including 19 first-line and 13 R/R patients. Stage 3 patients will be
reported separately. Median age was 72 years (range: 30-85 years). In stage
1, 12 ug/kg was the highest tested dose for BPDCN; MTD was not reached in
BPDCN. Median follow-up was 4.3 months (range: 0.5-22.9 months). ORR of
84% (27/32) was observed in all patients: 95% (18/19) in first-line and 69%
(9/13) in R/R. 88% (14/16) of first-line patients treated at 12 ug/kg had a com-
plete remission: CR (n=10), CR with incomplete hematologic recovery (CRi)
(n=1) or clinical CR (CRc; residual skin disease) (n=3) based on investigator
assessment. 56% (9/16) of these patients were progression free for 4 to 22.9
months (ongoing), including 3 patients on SL-401 in remission (4 to 18 months,
ongoing) and 7 patients who were bridged to stem cell transplant (SCT; 3 auto-
SCT and 4 allo-SCT). A R/R patient was also bridged to allo-SCT. Overall, most
common ≥Grade 3 treatment-related AEs were transaminase elevation (22%)
and thrombocytopenia (16%). Safety precautions, including daily monitoring of
albumin and body weight during study drug infusions, have been implemented
to minimize risk of severe capillary leak syndrome (CLS). Three patients had
Grade 5 CLS: BPDCN (7 ug/kg); R/R AML (16 ug/kg); BPDCN (12 ug/kg) out
of 118 patients who received SL-401 across all trials and regimens; 3/89 (3.4%)
patients of which were enrolled in this clinical trial.
Summary/Conclusions: SL-401 continues to demonstrate single agent activ-
ity, including multiple CRs, in patients with BPDCN, with 25% (8/32) of patients
bridged to SCT after a major response from SL-401. SL-401 side effect profile
consists largely of transaminitis and thrombocytopenia. CLS can be fatal. Side
effects have generally tended to decrease in frequency and severity with
increasing cycles. Updated data, including detailed safety analysis across all
ongoing SL-401 studies will be presented at the meeting.
P192
PROGNOSTIC IMPACT OF SOMATIC MUTATION CLEARANCE IN
PATIENTS WITH ACUTE MYELOID LEUKEMIA
K. Takahashi1,*, F. Wang1, K. Patel1, C. Bueso-Ramos1, G. Issa1, X. Song1,
J. Zhang1, C. Gumbs1, F. Ravandi1, T. Kadia1, N. Daver1, C. DiNardo1,
M. Konopleva1, M. Andreeff1, J. Cortes1, G. Garcia-Manero1, E. Jabbour1,
A. Futreal1, H. Kantarjian1
1Leukemia, UT MD Anderson Cancer Center, Houston, United States
Background: Persistence of somatic mutations at the time of complete remis-
sion (CR) was associated with poor outcome in patients (pts) with AML. 
Aims: To analyze differential pattern of mutation clearance based on the genes
and affected pathway and to assess prognostic impact of mutation clearance
in AML patients.
Methods: We studied 95 pts with AML who were treated with frontline induction
and subsequently achieved CR. We sequenced pre-treatment and CR bone mar-
row samples by targeted capture sequencing of 295 genes (median 280x cover-
age). We defined 3 levels of mutation clearance (MC) based on variant allele fre-
quency (VAF): 1) MC2.5, persistent mutation with VAF<2.5%, 2) MC1.0, persistent
mutation with VAF<1%, and 3) complete mutation clearance (CMC). 
Results: In the pre-treatment samples, we detected 597 mutations in 78 genes
in 87 (92%) patients. In the matching CR samples, 62 (10%) and 82 (14%)
mutations persisted at VAF≥2.5% and ≥1%, respectively, which corresponded
to 43 (49%), 34 (39%), and 30 (34%) patients achieving MC2.5, MC1.0 and
CMC, respectively. Table 1 shows the differential patterns of MC based on the
mutations and pathways. Mutations associated with clonal hematopoiesis of
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indeterminate potential (CHIP), DNA methylation, and splicing pathways had
low rate of MC, whereas mutations in transcription factors or receptor tyrosine
kinase (RTK) had high rate of MC. Pts who achieved MC1.0 (median 31.2 vs
12.5 months, P=0.04) or CMC (median 31.2 vs 12.5 months, P=0.049) had
significantly better relapse-free survival (RFS).
Table 1.
Summary/Conclusions: Somatic mutations associated with CHIP, DNA
methylation, and splicing pathways persisted frequently in CR samples sug-
gesting preleukemic origin. Pts with deeper MC had significantly better RFS.
Somatic mutation clearance may help risk prediction of AML.
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DO EDUCATION AND INCOME AFFECT TREATMENT AND OUTCOME IN
ACUTE MYELOID LEUKEMIA IN A TAX-SUPPORTED HEALTH CARE
SYSTEM? A DANISH NATIONAL POPULATION-BASED COHORT STUDY
L.S. Østgård1,2,*, M. Nørgaard2, B.C. Medeiros3, L.S. Friis4, C. Schöllkopf5,
M. Severinsen6, C.W. Marcher7, J.M. Nørgaard1
1Department of Hematology, 2Department of Clinical Epidemiology, Aarhus
University Hospital, Aarhus, Denmark, 3School of Medicine, Stanford University,
Stanford, United States, 4Department of Hematology, Copenhagen University
Hospital, Copenhagen, 5Department of Hematology, Herlev University Hospital,
Herlev, 6Department of Hematology, Aalborg University Hospital, Aalborg,
7Department of Hematology, Odense University Hospital, Odense, Denmark
Background: No larger study has investigated the association between indi-
vidual-level education or income level and clinical prognostic markers, treat-
ment, and outcome in acute myeloid leukemia (AML). Understanding how
socioeconomic status (SE) affects survival in AML patients may improve prog-
nosis through targeted support among patients with different SE risk profiles.
Aims: We investigate effects of education as a knowledge-related SE factor
and income as a measure of material resources in a tax-supported health care
system linking individual-level SE information from Statistics Denmark to clinical
data from the Danish National Leukemia Registry.
Methods: We conducted a nationwide population-based cohort study and
included AML patients ≥25 years diagnosed in Denmark 2000-2014 (end of
follow-up, Feb 2016). KM curves and Cox regression (Hazard ratios; HRs) was
used to compare survival by education (low, medium, and high) and income
level (tertiles). We repeated the survival analysis within educational groups by
year of diagnosis (2000-2004, 2005-2009, 2010-2014), stratified by time period,
and calculated crude survival (%) at 1, 3, and 5 years. We used logistic regres-
sion (odds ratios; ORs) to compare treatment intensity, chance of clinical trial
inclusion, and complete remission (CR) between groups. Results were given
crude and with different levels of adjustments for age and sex, SES factors,
and clinical prognostic markers, overall and stratified by age (<60/≥60 years).
Results: Of 2992 patients, 1588 (53.1%) received remission induction
chemotherapy. Forty-five percent (n=1336) completed a low-level education,
38% (n=1138) a medium education, and 17.3% (n=518) a higher education.
Patients with higher education tended to be younger and to be male. In inten-
sive therapy patients <60 years, survival was superior in high-education
patients evident a year from diagnosis (1-year survival: high 65.2%, HR
1.0, medium 59.2%, adjusted HR 1.55 (CI=1-21-1.98), low 57.7%, 1.47
(CI=1.11-1.93)). Allogeneic transplantation rates in CR1 were significantly high-
er in high-education compared with low-education patients (16.3% versus
8.7%). Only survival in high-education patients improved over time; HR 0.78
(CI=0.61-0.99), medium 0.99 (CI=0.84-1.16), and low 1.03 (CI=0.84-1.27)
increasing the survival gap between educational groups (Low: year 2000-2004
HR 1.28 (CI=0.88-1.85), 2004-2009 HR 1.55 (CI=1.01-2.44) 2010-2014 HR
2.09 (CI=1.27-3.44), high 1.0); Figure 1). In older patients, low education was
associated with lower chance of intensive chemotherapy (30% versus 48%;
adjusted OR 0.65 (CI=0.44-0.98)) compared to high-education, however neither
CR rates in intensive therapy patients nor survival overall or in intensive therapy
patients was affected. Low-income patients where less likely to be enrolled in
clinical trials (low-income 22.8%, adjusted OR 0.55 (CI=0.39-0.79) medium
28.2%, adjusted OR 0.71 (CI=0.53-0.94)) compared to high-income (37.2%,
HR 1.0), however, income was not associated with therapy intensity, chance
of CR, or survival (intensive therapy-only; high income adjusted HR 1.0, medi-
um 0.96 (CI=0.82-1.12), low 1.06 (CI=0.88-1.27)).
Figure 1.
Summary/Conclusions: In Denmark where health-care is free and uniform,
high SE status does not affect treatment intensity in younger patients or
response to therapy. However, educational level, but not income, influences
alloHSCT rates and has a major impact on survival in younger AML patients.
Since 2000, survival improvements have exclusively benefitted well-educated
patients and additional attention during treatment and follow-up towards low-
educated patients may increase transplantation rates and improve survival.
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IDENTIFICATION OF PATTERNS IN CO-OCCURRING MUTATIONS IN AML
PATIENTS WITH GERMLINE AND SOMATIC RUNX1 MUTATIONS 
U. Borate1,*, B. Wilmot1, B. Norris1, P. Lo1, D. Bottomly1, S. McWeeney1,
J. Tyner1, A. Agarwal1
1Oregon Health & Science University, Portland, United States
Background: RUNX1 plays a vital role in leukemogenesis through its interac-
tion with core binding factor-β complex and other genes involved in
hematopoiesis (1,2). Familial platelet disorder with predisposition to acute
myeloid leukemia (FPD/AML) is linked to germline RUNX1 mutations (3). This
autosomal dominant disorder is characterized by thrombocytopenia and poten-
tial for transformation to AML. AML patients with somatic RUNX1 mutations
have a poor prognosis (6,7) independent of other risk factors. The role of co-
occurring mutations in leukemogenesis in FPD/AML patients with germline
RUNX1 mutations and AML patients with de novo somatic RUNXI mutations is
not fully understood.
Aims: In order to further characterize co-occurring mutations in patients with
both germline and somatic RUNX1 mutations, we analyzed a large cohort of
AML tumor samples along with several paired normal tissue samples.
Methods: We sequenced a cohort of 482 diagnostic bone marrow or peripheral
blood samples from AML patients by deep whole-exome sequencing. Samples
were collected through the “Beat AML” project, an ongoing program at Oregon
Health & Science University in collaboration with the Leukemia & Lymphoma
Society. RUNX1 mutations were classified using VarScan which defined somat-
ic and germline mutations as follows: somatic if p <0.1 and germline if not
called as somatic and normal variant allele frequency >0.1.
Results: Twenty AML samples had 21 germline RUNX1 mutations with a total
of 6 different germline variants; 31 other patient samples had 38 somatic
RUNX1 mutations with 31 unique somatic variants. One sample had 2 RUNX1
germline mutations; 6 samples had >1 somatic RUNX1 mutations. The most
common germline variant, missense mutation p.L56S, was found in 16 (76%)
of the 21 HCG RUNX1 mutations identified. Significantly, the germline variants
occurred mutually exclusive of the somatic variants. Out of 20 patients with
germline RUNX1 mutations, 16 had co-occurring known pathogenic mutations
in AML-related genes. Most significantly, 62% (10/16) and 51% (14/27) of
patients with germline or somatic RUNX1 mutations, respectively, had 7 co-
occurring AML-related pathogenic mutations that were exclusive to their cohort
(Table 1). Both germline and somatic RUNX1 mutational cohorts had 12 over-
lapping co-occurring mutations. The most common mutations, for both groups,
were in FLT3 (14/43), ASXL1 (8/43), and IDH2 (7/43) (Table 1). Patient demo-
graphics and treatment-related outcomes were similar for both cohorts.
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Table 1.
Summary/Conclusions: The incidence of RUNX1 mutations seen in our 482-
patient Beat AML cohort (4.3% germline, 6.4% somatic) is consistent with
results from other studies (8). Our study suggests that germline and somatic
RUNX1 mutations in AML patients are mutually exclusive, as are several co-
occurring pathogenic mutations that contribute to leukemogenesis. Our study
adds to the already described mutually exclusive mutations in germline RUNX1
by identifying WT1, CHEK2, CCND3, and others. Similarly, in samples with
somatic RUNX1 mutations, we found mutually exclusive mutations in CBL,
JAK2, MLL, EZH2 and others, in addition to the previously described IDH1
(8).Further characterization of these results and analyses of additional samples
using our whole-exome sequencing and our bioinformatics platform will help
us better elucidate the molecular events underlying AML progression and help
us establish novel prognostic/therapeutic markers aimed at early intervention




MULTIPLE LEUKEMIC STEM CELL MARKER EXPRESSION IS ASSOCIATED
WITH POOR PROGNOSIS IN DE NOVO ACUTE MYELOID LEUKEMIA
T. Yabushita1,*, Y. Shimomura1, D. Katoh1, Y. Ono1, N. Hiramoto2, S. Yoshioka1,
N. Yonetani1, A. Matsushita1, H. Hashimoto2, T. Ishikawa1
1Hematology, Kobe City Medical Center General Hospital, 2Hematology, Insti-
tute of Biomedical Research and Innovation Hospital, Kobe City, Japan
Background: Acute myeloid leukemia (AML) is believed to originate from a
small population of leukemic stem cells (LSCs). Current chemotherapy regi-
mens target the majority of more mature leukemic blasts, but cannot efficiently
eliminate LSCs, resulting in early treatment failure and relapse. Thus, the
expression of LSC-specific markers could be used as a predictive factor of clin-
ical outcomes in AML patients. Recently, the clinical impact of individual LSC
markers has been documented in several reports, but the combined effect of
different LSC markers remains unexamined.
Aims: This study aimed to estimate the prognostic impact of the expression of
multiple LSC markers on the outcome of AML patients.
Methods: Ninety consecutive patients diagnosed with de novo AML at our insti-
tution and eligible for intensive chemotherapy were enrolled from September 2010
to March 2016. We excluded 10 patients with acute promyelocytic leukemia. This
study was approved by the institutional review board of the Ethics Committee and
complied with the Declaration of Helsinki. We analyzed the expression of three
LSC markers, CD25, CD96, and CD123, in de novoAML patients. The expression
of these markers on gated leukemic blasts was evaluated using 6-color flow cytom-
etry. When over 20% of leukemic blasts were positive for any marker, the sample
was defined as positive for that marker. We stratified de novo AML patients into
two groups: LSCHighwas defined as positivity for two or three LSC markers, and
LSCLowwas defined as negativity for all markers or positivity for a single LSC
marker. The primary endpoint was overall survival (OS). The secondary endpoint
was progression-free survival (PFS). OS and PFS were estimated using the
Kaplan-Meier method, and assessed using the log-rank test. Multivariate analysis
using Cox proportional hazard ratio was performed for OS and PFS.
Results: The median follow-up for patients still alive at the end of the study
was 38.9 months (range: 1.5-64.8 months). The median patient age was 60
years (range: 17-78 years). There was no statistical significance between
LSCHigh patients (n=30) and LSCLow patients (n=50) in sex, age, laboratory
data, NPM1 mutation, or European Leukemia Net karyotype risk group. FLT3
mutation was associated with the LSCHigh group (p=0.003). Three-year OS
and PFS were significantly better in the LSCLowgroup than in the LSCHigh-
group (Figure 1) (OS: 65.0% vs 18.2%, p <0.001; PFS: 49.3% vs 19.4%, p
<0.001). In multivariate analysis controlled for age and karyotype (Table1),
being in the LSCHighgroup was an independent prognostic factor for OS (haz-
ard ratio: 3.17; 95% CI: 1.64-6.15; p <0.001) and PFS (hazard ratio: 2.25;
95% CI: 1.24-4.08; p=0.007). Being in the LSCHighgroup had incremental val-
ue for OS compared with the karyotype risk (Harrell’s C index: 0.80 vs 0.70;
p = 0.028). Moreover, this classification based on LSC marker expression
allowed subgroups with unfavorable prognosis to be identified among patients
in the intermediate karyotype risk group (3y-OS 54.6% vs 14.5%, p=0.013),
as well as those in the favorable karyotype risk group (3y-OS 94.1% vs 50.0%,
p=0.021).
Figure 1.
Table 1. Univariate and multivariate analysis for OS.
Summary/Conclusions: We demonstrated that multiple LSC marker expres-
sion predicts poor clinical outcomes in newly diagnosed de novo AML patients,
and may facilitate better stratification even among patients with intermediate-
risk and favorable-risk karyotypes.
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NEXT GENERATION SEQUENCING TARGETED PANEL FOR MINIMAL
RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA
V. Mcclain1,*, A.R. Carson1, B.A. Patay1, L. Chamberlain1, C. Chander1,
S. Zheng1, W. Huang1, O. Kiya1, D. Hubbard2, D. Caguioa2, Z. Xie1,
J. Thornes2, T. Stenzel1, J. E. Miller1,2
1Invivoscribe, 2LabPMM LLC, San Diego, United States
Background: Many personalized therapies for acute myeloid leukemia (AML)
have been developed targeting specific biomarkers. Unfortunately, the efficacies
of these therapies are inconsistent while the need to determine successful ther-
apies prior to patient relapse is critical. Minimal residual disease (MRD) moni-
toring can help determine effective treatments and predict potential relapse.
While there are now several MRD tests available on the market, most target
single or small numbers of biomarkers, which can limit detection of residual
AML heterogeneity. Thus, full characterization of a sample may require testing
with multiple MRD assays, which can be impractical in a clinical setting. We
have developed a target capture-based assay (MyMRDTM), which allows char-
acterization of the entire therapeutic AML biomarker repertoire and can inform
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the molecular remission status of a patient’s malignancy. This targeted panel
can identify the mutations in driver clones that cause relapse in ~90% of all
AML patients, as well as common drivers in myeloid prolific neoplasms (MPN)
and myelodysplasic syndromes (MDS).
Aims: To establish a sensitive and reliable targeted NGS assay to compre-
hensively detect and monitor the majority of known driver mutations in AML
and other myeloid malignancies.
Methods: Whole genome libraries, made from DNA extracted from cell lines
and clinical samples, were hybridized with MyMRD probes targeting mutation
hotspots in 23 genes associated with AML. In addition to single nucleotide vari-
ants (SNVs) and indels in 21 of these genes, 5 structural variant (SV) break-
points within 3 genes were also targeted. Enriched libraries were sequenced
with the MiSeq® platform and analyzed using proprietary Invivoscribe (IVS)
MyInformaticsTM software. To validate mutations detected by the MyMRD
assay, samples were additionally tested with IVS developed capillary elec-
trophoresis (CE) assays and NGS-based assays targeting common mutations
in FLT3 and NPM1.
Results: The linearity and limit of detection (LOD) of the MyMRD assay were
assessed using data generated from contrived cell line DNA containing known
AML driver mutations with a range of variant allele frequencies (VAFs). The
assay shows strong linearity (R2=0.96 – 0.99) in the entire range of tested
VAFs (0.1– 20%). Overall, we established a LOD of 0.5% for >95% of the tar-
geted sites in the assay with lower LODs for specific mutations of interest (e.g.
0.1% for a 30bp FLT3 ITD and 0.2% for FLT3 p.D835Y). In addition, using clin-
ical samples the MyMRD assay shows excellent concordance with the standard
FLT3 CE assays for variants with VAFs above the CE detection threshold (5%).
Samples below the CE detection threshold were additionally evaluated with
IVS FLT3 ITD MRD and NPM1 MRD amplicon assays which showed 100%
concordance with the MyMRD panel assay for variants with VAFs above the
MyMRD LOD.
Summary/Conclusions: The IVS developed MyMRD targeted panel is a
sensitive and reliable assay to monitor residual AML driver mutations. The
assay is shown to have excellent linearity and a LOD of 0.5% (tenfold lower
than the standard CE assay LOD) at >95% of the targeted sites. Additionally,
specific mutations of interest, such as those used for residual disease mon-
itoring (e.g. FLT3 ITD), demonstrate LODs as low as 0.1%. The MyMRD
assay provides an accurate method for detecting mutations in multiple targets
in patients and can be used to effectively stratify patients for therapy and
clinical trials.
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BIALLELIC CEBPA GENE MUTATIONS USING NGS PANELS?
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1Biomedical Engineering, School of Engineering, University of Navarra, 2Mol-
ecular Oncology, Biodonostia HRI, Donostia University Hospital, San Sebast-
ian, 3Haemato-Oncology, CIMA LAB Diagnostics, University of Navarra,
4Haematology and Haemotherapy, Clinic of the University of Navarra, Pam-
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Background: CEBPA gene encodes a leucine zipper transcription factor that
is important for normal myeloid cell differentiation. Biallelic CEBPA (biCEBPA)
mutations are associated with favourable prognosis in patients with acute
myeloid leukaemia (AML); therefore, accurate molecular testing of this gene is
crucial in the clinical setting. Molecular pathology labs routinely analyse CEBPA
through fluorescence-based multiplex-PCR fragment analysis or, more fre-
quently, Sanger sequencing. Lately, it is increasingly common to use next-gen-
eration sequencing (NGS) technology in the pathology labs, and CEBPA gene
is indeed included in the majority of NGS panels commercially available for
testing of patients with neoplasias of the myeloid lineage.
Aims: We set ourselves to compare the performance of two different NGS tar-
geted panels and of direct Sanger sequencing for detection of CEBPA molec-
ular aberrations, with a particular focus on biCEBPA mutations.
Methods: DNA specimens from 173 myeloid cases were subjected to Sanger
(n=92) or to NGS (n=81) sequencing, including the TruSight Myeloid Sequenc-
ing Panel (Illumina) (n=59), and the Ion AmpliSeq AML Community Panel (Ther-
mo Fisher Scientific) (n=22). Cases showing two variants were further analysed
through cloning of the whole length of CEBPA and subsequent Sanger
sequencing of at least 10 colonies from each case.
Results: We called 10 CEBPA variants affecting 7 samples through NGS.
Both NGS panels are designed to cover CEBPA through overlapping ampli-
cons (6 or 9). However, we found that an average of 3.5 amplicons were cov-
ered <500x, and more worryingly, we realised that at least one of those ampli-
cons was shallowly (<100x) covered in 97% of the cases. Indeed both panels
showed significantly lower average coverage levels of this gene compared
to the panel as a whole (Figure 1). This might not be surprising, since CEBPA
is encoded within a CpG-rich region, and therefore its amplification needs
tailored PCR conditions, hard to address in the multiplexed PCR step includ-
ed in their library prep protocols. Therefore, both NGS approaches are prone
to miss variants. In contrast, Sanger sequencing protocol (which includes
optimized PCR conditions for correct amplification of the CEBPA gene) man-
aged to cover the whole length of the gene. We were able to detect 26 vari-
ants affecting 20 AML cases through Sanger sequencing. Cases showing
two variants were manually curated (through Chromas or IGV tools) to con-
firm if they affected different alleles. However, in 6 cases both mutations laid
on different amplicons, which made not possible to univocally conclude if
they were biallelic. These inconclusive cases were subjected to DMSO-Pfu-
PCR in order to amplify the whole length of CEBPA coding region, followed
by cloning. Colony sequencing showed independent clones harbouring dif-
ferent variants (i.e. bona fide biCEBPA mutations) in the majority of the cases,
but crucially, not in all of them. This result highlights the need of implementing
techniques able to accurately assess CEBPA biallelism, others than plain
calling of more than one variant.
Figure 1.
Summary/Conclusions: Since AML patients with biCEBPA mutations have
relatively favourable overall survival, it is important in the clinical setting to
accurately assess CEBPA molecular status. In our study, we have tested the
ability of three different assays to detect CEBPA mutations in 173 samples.
Sanger sequencing was the only method actually covering the entire coding
region of CEBPA. Both NGS amplicon-based panels failed to fully cover the
coding region of the gene, and therefore have likely missed mutations. Cru-
cially, even when any of the three methods detected more than one variant,
cloning studies confirmed biCEBPA mutations only in a fraction of the cases.
In summary, none of the amplicon-based tested methods can reliably deter-
mine if multiple mutations affect two different alleles; therefore biCEBPA
mutations would still need additional confirmation. We are currently exploring
the ability of capture-based NGS approaches coupled to appropriately tailored
bioinformatic analysis of sequencing data to detect biCEBPA mutations.
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EXPERIENCE WITH MINIMAL RESIDUAL DISEASE MONITORING IN AML
WITH RUNX1-RUNX1T1: A STUDY ON 186 PATIENTS
A. Hoellein1,*, M. Meggendorfer1, A. Fasan1, W. Kern1, C. Haferlach1,
T. Haferlach1
1Munich Leukemia Laboratory, Munich, Germany
Background: The cure rate in AML is dependent on patient’s age and per-
formance status, cytogenetics, early blast clearance and sustainable first com-
plete remission. Investigation of minimal residual disease (MRD) is possible
by multiparameter-flow cytometry (MFC) or molecular techniques. Recent find-
ings have further depicted a broad spectrum of molecular markers in AML in
99% of pts (TCGA, NEJM, 2013). This broadens the set of targets for MRD
and will hopefully help to better individualize treatment strategies. In this analy-
sis we focused on MRD monitoring in RUNX1-RUNX1T1 positive AML in an
unselected cohort.
Aims: To understand the clinical use of PCR based MRD monitoring in AML
with RUNX1-RUNX1T1 fusion.
Methods: Between 2005 und 2017 we investigated a total of 186 intensively
treated AML patients with RUNX1-RUNX1T1 fusion, 130 of them diagnosed
at our laboratory and 56 with follow up samples available. 1448 individual
samples were analyzed during the course of disease. We applied quantitative
real-time PCR to detect RUNX1-RUNX1T1/ABL ratios. Complete molecular
remission (CMR) was defined as one valid qPCR ratio of 0, while low MRD
was assigned to patients with a >0 but <0.01 ratio and high MRD was
assigned to all patients with a ratio above 0.01. As a comparator log fold
change to baseline was independently assessed. Median age was 51 years
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(18-83 years). All patients were treated with standard induction and consoli-
dation protocols.
Results: Median time between two investigations was 2.8 months (range for
all 0.1-115 months). A complete molecular remission was reached in 90/130
pts (69%) after a median of 5 months. 19/130 (14.6%) pts reached low level
MRD and 20/130 (15.4%) high level MRD. Median event free survival (EFS) of
patients with CMR was not reached (EFS at 2 years 82%). 16 (18%) of those
patients relapsed in the course of follow up with a median time to relapse of
12.7 months (range 4.1 to 38.3 months). Median EFS for MRD low and MRD
high patients was 18.4 months and 10.8 months respectively (all 3 groups,
p<0.0001). For patients with CMR, rising MRD levels accurately predicted
relapse with a median latency of 5.5 months from loss of CMR to relapse. We
next used the widely accepted log fold change from baseline to define high
and low risk patients in our cohort. 123/130 (95%) patients reached a >3 log
fold reduction in RUNX1-RUNX1T1/ABL ratio within the first 200 days following
first diagnosis. Median EFS for those patients was not reached (EFS at 2 years
66%). The 7/130 (5%) patients with a <3 log fold reduction had a median EFS
of 14.7 months (2 groups, p=0.017). A total of 59/185 patients received allo-
geneic SCT. Among the 130 patients diagnosed at our laboratory 34 (26%)
received allogeneic SCT, 12 (9%) were transplanted in first CR and 17 (13%)
were transplanted for relapse. Following allogeneic SCT 11/17 patients (65%)
reached a second CR with CMR.
Summary/Conclusions: Our data shows that MRD testing is routinely per-
formed in RUNX1-RUNX1T1 AML outside of clinical studies. Defining MRD
levels by RUNX1-RUNX1T1/ABL ratios resulted in a better classifier for high
and low risk patients than log fold change. However, despite CMR 16/90 (18%)
patients relapsed with a maximum time from first achievement of CMR of 38.3
months. We conclude that 1) MRD monitoring could serve to guide BMT deci-
sions in RUNX1-RUNX1T1 positive AML, 2) allogeneic BMT can rescue the
majority of relapsed patients and 3) molecular monitoring can reliably identify
patients with high risk for relapse.
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NUMBER OF TP53 ABNORMALITIES AND THEIR CLINICAL RELEVANCE
IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC
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K. Takahashi1, C. DiNardo1, E. Jabbour1, G. Borthakur1, N. Pemmaraju1,
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Background: Mutations in TP53 can be detected in up to 16-19% patients
with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
TP53 mutations confer adverse prognosis irrespective of currently available
therapies. The clinical impact of the type and number of TP53 abnormalities is
unclear.
Aims: To evaluate the prognostic impact of the number of TP53 abnormalities
in AML and MDS.
Methods: We evaluated 1401 patients with previously untreated AML or MDS
treated at The University of Texas MD Anderson Cancer Center from 2012 to
2016. Sequencing data was obtained by use of a 28 or 53-gene targeted PCR-
based next generation sequencing platform. Response was defined following
2003 IWG criteria for patients with AML and 2006 revised IWG criteria for
patients with MDS. Generalized linear models were used to study the associ-
ation of overall response (OR), complete response (CR) and risk factors.
Kaplan-Meier produce limit method was used to estimate the median overall
survival (OS).
Results: A total of 593 (42%) patients had MDS and 808 (56%) had AML. In a
total of 984 (70%) patients, data on therapy with sufficient follow up and response
evaluation was available, with 494 (35%) patients receiving therapy with
hypomethylating agents (HMAs) and 373 (27%) with chemotherapy regimens. A
total of 384 mutations in TP53, involving 208 unique mutations, were detected
among 300 (21%) patients with R273H, R248W, Y220C and R175H being the
most prevalent. Overall frequency of TP53 mutations was higher among patients
with MDS (25%, n=146) compared to AML (19%, n=154) (p=0.012) with 251
(84%) of detected mutations happening in patients with complex karyotype
(p<0.001). Among patients with TP53-mutant disease, 221 (74%) had 1
detectable mutation, 76 (25%) had 2 and 3 (1%) had 3. Additionally, 188 (13%)
patients had TP53 deletions evidenced by presence of monosomy 17 or del(17p).
In 167 (89%) of these patients, chr17 abnormalities were detected in the context
of a complex karyotype and in 127 (42%) a co-occurring TP53 mutation was
detected. Correlation between TP53 mutations and deletions (r=0.443, p<0.001)
was observed with 172 (12%) patients having 1 TP53 abnormality, 169 (12%)
having 2 and 20 (1%) having 3 abnormalities. Patients with multiple detectable
TP53 mutations were less likely to have co-occurring chr17 abnormalities (79%
vs 22%, OR 0.28, CI 0.15-0.50, p=0.03). Median follow up was 8.6 months (range
0-167 months). Presence of a TP53 mutation adversely impacted OS (MDS:
12.4 vs 111.7 months, HR=5.98, CI 4.28-8.35, p<0.001; AML: 5.3 vs 16.9 months,
HR=2.81, CI 2.26-3.50, p<0.001). Increasing number of TP53 abnormalities neg-
atively impacted OS of patients with AML (Figure 1A) but not that of patients with
MDS (Figure 1B). No difference in survival was observed between patients with
two TP53 mutations and those with TP53 mutation+deletion (p=0.730). Presence
and number of TP53 mutations did not predict for response (OR: 60 vs 63%,
p=0.498; CR: 34 vs 36%, p=0.695) to HMAs, but was associated with significantly
lower likelihood of response to intensive chemotherapy (OR: 41 vs 86%, p<0.001;
CR: 33 vs 75%, p<0.001).
Figure 1.
Summary/Conclusions: Presence of multiple TP53 abnormalities can be
observed in up to 13% patients with AML and MDS. Second TP53 abnormalities
more commonly involve TP53 deletions with additional TP53 mutations being
less common and generally mutually exclusive with TP53 deletions. The num-
ber of TP53 abnormalities impacts the survival of patients with AML but not
that of patients with MDS. Presence and number of TP53 mutations do not
seem to impact response to HMAs but are associated with lower responses to
chemotherapy.
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FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIAF.
Ravandi1,*, A. Stein2, H. Erba3, J. Lancet4, E. Stein5, S. Faderl6, R. Walter7,
A. Advani8, D. DeAngelo9, T. Kovacsovics10, A. Jillella11, D. Bixby12, M. Levy13,
M. O’Meara14, P. Ho14, A. Fathi15
1Department of Leukemia, MD Anderson, Houston, 2Gehr Family Center for
Leukemia Research, City of Hope, Duarte, 3Hematologic Malignancy Program,
University of Alabama at Birmingham, Birmingham, 4Malignant Hematology,
Moffitt Cancer Center, Tampa, 5Hematology, Memorial Sloan Kettering, New
York City, 6Leukemia, John Theurer Cancer Center, Hackensack, 7Hematology,
Fred Hutchinson Cancer Center, Seattle, 8Hematology and Oncology, Cleve-
land Clinic, Cleveland, 9Hematology and Oncology, Dana-Farber Cancer Insti-
tute, Boston, 10Hematology and Oncology, Huntsman Cancer Institute, Salt
Lake City, 11Hematology and Oncology, Winship Cancer Institute, Atlanta,
12Hematology and Oncology, University of Michigan Comprehensive Cancer
Center, Ann Arbor, 13Hematology and Oncology, Baylor Charles A. Sammons
Cancer Center, Dallas, 14Clinical Development, Seattle Genetics, Inc., Bothell,
15Hematology and Oncology, Massachusetts General Hospital Cancer Center,
Boston, United States
Background: Treatment of AML among the elderly is challenging. HMAs are
commonly used, but yield suboptimal response rates and modest
survival.  Deep remissions are difficult to achieve; in a study of MRD response
by flow cytometry in patients treated with single-agent HMA therapy at MD
Anderson Cancer Center, only 13/58 (22%) responding patients achieved min-
imal residual disease (MRD) negativity (F Ravandi, MD, unpublished data,
Jan2017). Vadastuximab talirine (SGN-CD33A; 33A) is a CD33-directed anti-
body conjugated to 2 molecules of a pyrrolobenzodiazepine (PBD) dimer. Upon
binding, 33A is internalized and transported to the lysosomes where PBD dimer
is released via proteolytic cleavage of the linker, crosslinking DNA, and leading
to cell death.
Aims: A cohort in a phase 1 study (NCT01902329) was designed to evaluate
the safety, tolerability, PK, and antileukemic activity of 33A in combination with
an HMA.
Methods: Eligible patients (ECOG status 0-1) had previously untreated CD33-
positive AML. One dose of 33A (10 mcg/kg) was administered outpatient IV
every 4 weeks on the last day of HMA (azacitidine or decitabine [5-day regi-
men], standard dosing). CRi required either platelet count of ≥100,000/µL or
neutrophils of ≥1,000/µL (Cheson 2003). MRD was measured by multipara-
meter flow cytometry.
Results: Fifty-three patients (median age 75 years [range, 60-87]) were treated
with 33A+HMA. Patients had adverse (38%) or intermediate (62%) cytogenetics
(per MRC); patients were either unfit for (40; 75%) or declined (13; 25%) inten-
sive therapy. The median treatment duration is currently 19.3 weeks (range, 2-
86) with 8 patients still on treatment; no DLTs were reported. Adverse events
(AEs) ≥Grade 3 reported in ≥15% of patients were thrombocytopenia (55%),
febrile neutropenia (49%), anemia (46%), neutropenia (42%), pneumonia
(19%), and leukopenia (17%); no ≥Grade 4 bleeding events were observed.
Treatment-emergent (TE) liver lab elevations (≥Grade 3) were rare: ALT (8%),
AST (2%), and total bilirubin (2%). Other non-heme TEAEs reported in ˃25%
of patients regardless of relationship to study treatment were fatigue (60%),
nausea (49%), constipation (43%), peripheral edema (42%), decreased
appetite (40%), dyspnea (34%), pyrexia (32%), diarrhea, vomiting (28% each),
and dizziness (26%). Thirty- and 60-day mortality rates were 2% and 8%,
respectively, with no treatment-related deaths reported. A total of 39% (103/263)
of doses were delayed due to AEs mostly from myelosuppression (neutropenia
18%, thrombocytopenia 7%, and febrile neutropenia 3%). High remission rates
(37/49 [76%] CR+CRi) were maintained across adverse disease subsets
including adverse cytogenetics (16/18, 89%), TP53-mutated (6/7, 86%), sec-
ondary AML (18/22, 82%), and age ≥75 years (18/26, 69%). Of all responding
patients, 19/37 (51%) achieved MRD negativity. Two patients went on to sub-
sequent allo-HSCT, and no SOS/VOD was observed. The median relapse-free
survival was 9.1 months (range, 0.1-19.4+) and OS continues to evolve with
15 patients (28%) alive (11.3 month median follow-up) (Figure 1).
Summary/Conclusions: 33A+HMA is well tolerated with a safety profile con-
sistent with on-target myelosuppression. The CR+CRi rate of 76% and low
early mortality in older AML patients with poor risk factors is particularly encour-
aging, and activity appears markedly improved compared to the historical expe-
rience of HMA monotherapy. The MRD clearance rate among responding
patients who received 33A+HMA is higher than the rate observed with single
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agent HMAs. Survival data are evolving and compare favorably to historical
controls. CASCADE, a phase 3 trial investigating 33A+HMA v. HMA alone in
older AML patients, is enrolling (NCT02785900).
Figure 1.
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Background: Acute myeloid leukemia (AML) with intermediate-risk (IR) cyto-
genetics includes a substantial proportion of patients with favorable molecular
profile (FMP); in which AML cells harbor the NPM1 mutation or CEBPA biallelic
mutation without internal tandem duplication of the FLT3 gene (FLT3-ITD). The
role of allogeneic hematopoietic transplantation (allo-HCT) in first complete
remission (CR) in these patients remains controversial.
Aims: To analyze the results and prognostic factors of IR-FMP AML patients in
a large series of patients treated by the Spanish CETLAM group.
Methods: Patients with primary AML diagnosed at 19 institutions from the
Spanish CETLAM group and treated between 2003 and 2017. Induction
chemotherapy included idarubicin and cytarabine (standard or intermediate-
dose) in all cases, consolidation with intermediate or high-dose cytarabine
(HDAC) and, depending on the protocol, additional HDAC, autologous or allo-
geneic hematopoietic transplantation.
Results: Two-hundred twenty-one patients were analyzed. Median age of
the series was 54 years (range 18 to 72). 152 patients had an age up to 60
years and 69 (31%) were older. Median WBC count was 19x10e9/l (range
0.55-282). One-hundred eighty-two patients had a normal karyotype and it
was abnormal in 34 (5 patients no metaphases). One hundred ninety-one
patients had NPM1 mutated and FLT3-ITD wild type (NPM1+/FLT3-ITD-) and
30 CEBPα biallelic mut /FLT3-ITD wild type (CEBPα+/FLT3-ITD-). There were
no significant differences in the main clinical or biological parameters in these
two groups. The CR rate in the overall group was very high (92%) without
significant differences between the two molecular groups. Chemo-resistance
was observed in only 2 patients of the NPM1+/FLT3-ITD- group (1%). Death
during induction was observed in 16 patients (7%), all of them with
NPM1+/FLT3-ITD-. Induction results according to age were similar in both
groups. Event-free survival and overall survival are reported at 8 years and
were 52±8% and 70±4%, respectively. In univariate comparisons, better EFS
and OS was observed in CEBPα+/FLT3-ITD- patients compared to those with
NPM1+/FLT3-ITD- (p=0.03 and p= 0.02, respectively) . When analyzing post-
remission treatment, patients treated with HDAC only had an excellent prog-
nosis, even better than those receiving an autologous or allogeneic trans-
plantation. One patient died in CR in the HDAC group, another in the autol-
ogous transplant group and 7 in the allo-HCT group (p<0001). In multivariate
analysis of pretransplant characteristics, age up to 60 years and
CEBPα+/FLT3-ITD- associated to improved EFS (RR=0.42) and OS
(RR=0.29). Interestingly, in a subgroup of 123 patients with data on MRD
after consolidation chemotherapy (flow citometry, cut-off: 0.12%), positivity
was associated with worse EFS (0.02). Despite age was a prognostic factor,
patients older than 60 years with IR-FMP AML had remarkable EFS of 36±3%
and OS 54±10% at 8 years (Figure 1).
Figure 1.
Summary/Conclusions: Patients with primary AML, IR cytogenetics and
FMP have a good outcome. Best results are achieved in patients with
CEBPα+/FLT3-ITD-, particularly if age is up to 60 years. In this subset, OS
at 8 years is 96±7%, comparable to current results achieved in acute promye-
locytic leukemia. Patients above 60 years treated intensively may achieve a
long term survival of more than 50%. Chemotherapy without subsequent
transplantation is a valid option. MRD monitoring after treatment has to be
taken into account since in the subset of patients analyzed this vas an inde-
pendent prognostic factor for EFS.
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Background: The outcomes for elderly patients (pts) with acute myeloid
leukemia (AML) remain poor due to limited tolerance of intensive cytotoxic
chemotherapy and low response rate, therefore newer and less toxic therapies
are urgently needed. The binding of E-selectin (E-sel), an adhesion molecule
expressed in the vasculature of the bone marrow, to the leukemic cell surface
activates survival pathways and promotes chemotherapy resistance. GMI-1271,
a novel E-sel antagonist, disrupts these survival pathways and enhances
chemotherapy response (Becker ASH 2013; Winkler ASH 2014). Protection
from common toxicities (neutropenia and mucositis) has also been observed
in preclinical models, affording survival benefit (Winkler ASH 2013). Additionally,
preclinical toxicology studies have indicated a benign safety profile. We report
interim Phase 2 data for GMI-1271 plus anthracycline-based induction
chemotherapy in elderly untreated pts with AML.
Aims: A Phase 2 open label trial of patients ≥60 yrs with untreated AML
assessed safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),
and antileukemic activity of GMI-1271.
Methods: Eligible pts had ECOG 0-2, WBC <40K/uL, no active CNS disease,
and adequate renal and hepatic function. Prior treatment of MDS was allowed.
GMI-1271 (10 mg/kg) was given 24 hrs prior, then every 12 hrs during and for
48 hrs post induction with infusional cytarabine and idarubicin (7+3). Two cycles
of induction were allowed and responders could receive consolidation with
GMI-1271 plus intermediate dose cytarabine.  Dose-limiting toxicity (DLT),
defined as myelosuppression in the absence of disease or related Grade 3
(Gr) non-hematologic toxicity beyond day 42, was assessed in the first 3
pts.  Baseline E-selectin ligand expression on leukemic blasts in the bone mar-
row (CD45/SSC by flow) is reported.
haematologica | 2017; 102(s2) | 49
Madrid, Spain, June 22 – 25, 2017
Results: 24 pts have been enrolled to date and 17 are evaluable for
response. The median age was 68 years (range, 60-79) with 58% male pts,
and 25% with high-risk cytogenetics (by SWOG). 50% (12/24) were pts with
secondary AML (sAML), half of whom had prior hypomethylating therapy
(50%; 6/12), . This study had a rolling safety run-in and the first 3 pts had no
DLT, allowing enrollment to proceed. Common Gr 3/4 AEs included febrile
neutropenia (47%), pneumonia (20%), pulmonary edema (13%) and non-
fatal respiratory failure (13%).  2 pts died of sepsis within 60 days.  The remis-
sion rate (CR/CRi) was 12/17 (71%). CR/CRi rate was 75% for pts with de
novo disease and 67% for pts with sAML.  The PK profile in this elderly pop-
ulation was consistent with that of younger adults (median age <60 years)
with relapsed or refractory AML in Phase 1 (DeAngelo, EHA 2016); no accu-
mulation or evidence of drug-drug interactions were apparent. The median
E-sel ligand expression at baseline was 29% (range, 2-67%) of blasts in the
bone marrow.
Summary/Conclusions: The addition of a novel E-selectin antagonist, GMI-
1271, to anthracycline-based induction chemotherapy in untreated elderly pts
with AML, including patients with secondary AML, demonstrates a high remis-
sion rate with acceptable side effect profile resulting in low induction
mortality.  This study compares favorably to previous studies (Lancet, ASCO
2016). E-selectin ligand was expressed on leukemic blasts in the majority of
pts, therefore supporting its relevance as a target. A randomized trial is being
planned.
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Background: Glasdegib, a selective, once-daily (QD), oral Smoothened (SMO)
inhibitor, demonstrated significant improvement in overall survival (OS) when
used in combination with low-dose cytarabine (LDAC) vs LDAC alone in a ran-
domized (2:1) open-label trial in 132 patients (pts) not suitable for induction
chemotherapy (ICT). Preclinical studies showed that glasdegib limits leukemia
stem cell proliferation and provided evidence of glasdegib synergy with
chemotherapy.
Aims: Primary objective of this open-label, single-arm Ph 2 study
(NCT01546038) was to determine complete remission (CR) rate with glasdegib
in combination with cytarabine and daunorubicin in untreated AML or high-risk
MDS pts suitable for ICT. OS was the key secondary endpoint.
Methods: Pts suitable for ICT (ECOG PS 0-1, creatinine ≤1.3 mg/dL, no severe
cardiac disease) gave informed consent and received glasdegib 100 mg QD
from day -3 in combination with cytarabine 100 mg/m2 CI for 7 days and
daunorubicin 60 mg/m2 IV for 3 days, followed by 2-4 consolidation cycles
(cytarabine 1 g/m2 Q12 hrs on days 1, 3, 5). Maintenance (up to 6 months)
included glasdegib 100 mg QD. Pts were assessed for efficacy, safety and tol-
erability.
Results: All Pts: As of 1 Dec 2016, 71 pts (66 AML, 5 MDS) were enrolled
and 69 pts received glasdegib and ICT (2 pts not treated due to ineligibility).
Among AML pts (47 de-novo; 19 secondary), 20% had favorable, 32% inter-
mediate (int)-I, 21% int-II and 26% adverse cytogenetic abnormalities (1 pt
not assessed). Among MDS pts (5 de-novo), 20% had good, 40% int and
40% poor risk cytogenetic abnormalities. Median age was 64 (27-75) years.
Median treatment duration was 48 (10-502) days. The most common NCI-
CTC v4.0 grade 3-4, non-hematologic all-cause adverse events (AEs) includ-
ed: hypokalemia (13%), hyponatremia (11.6%) and hypertension (10.1%).
Grade 5 AEs within 28 days from last dose (5 pts, 7.2%) included pneumonia,
sepsis, septic shock (1 pt each) and disease progression (2 pts). The
observed steady-state plasma exposures for glasdegib were as expected at
the 100 mg dose level. Based on investigator’s assessment, CR was 41%
(80% CI 33.2-47.9) and CR/CRi was 49%. CR for good/int. risk pts (n=49)
was 49% and for poor risk pts (n=19) 21%. Forty-one (59%) pts died (33
[48%] due to disease progression) with median follow up of 30.1 months; 24
(35%) remain in follow up. The median OS (mOS) was 14.9 months (80% CI
13.4-19.3); 16.3 months for AML pts and 13.0 months for MDS pts. Twenty-
three (33%) pts received a transplant and mOS censored for transplant was
17.7 months. AML Pts >60 yrs: The mOS for 44 AML pts age >60 yrs is pre-
sented in the Table 1, in the context of historical control.
Table 1. mOS in Pts >60 Yrs Stratified by European Leukemia Net (ELN)
Risk Criteria
*1 pt was not classifiable by ELN risk.
Summary/Conclusions: Although the CR rates do not appear to be higher
than those reported historically for AML pts receiving ICT, the mOS for AML
pts >60 yrs stratified by subgroup compares favorably by adding glasdegib.
It is possible that this is a result of the effect of glasdegib on the leukemia
stem cells. The combination of glasdegib with ICT was well tolerated, with a
safety profile consistent with that in AML pts receiving standard ICT. Further
studies are warranted.
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CM942 IS A NEW SMALL MOLECULE THAT TARGETS SET-PP2A
INTERACTION AND INHIBITS GROWTH OF ACUTE MYELOID LEUKEMIA
CELLS
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Background: Acute myeloid leukemia (AML) is a heterogeneous malignant
disorder of hematopoietic progenitor cells in which several genetic and epi-
genetic aberrations have been described. Nevertheless, outcome for most
patients is poor, and it is necessary to develop more effective treatment
strategies. Our group showed that the inactivation of the tumor suppressor
PP2A is a recurrent event in AML, and that overexpression of SET, an
endogenous inhibitor of PP2A, is a poor prognostic factor in this disease.
Furthermore, the anticancer activity of FTY720, a PP2A-activating drug
(PAD), depends on its interaction with SET. FTY720 is a relatively nontoxic
drug currently used in patients with relapsing multiple sclerosis; however,
this drug cannot be used in cancer patients due to its toxicity at the needed
anti-neoplastic dose. Therefore, investigation of alternative agents for reac-
tivation of PP2A is warranted.
Aims: To test the efficacy of CM942, a FTY720 analogue, on AML cell lines
and primary patient samples, and investigate its mechanism of action.
Methods: AML cell lines and 29 de novo AML samples were analyzed by
treatment with FTY720 and CM942, MTS (viability), apoptosis, cell cycle and
PP2A activity assays, and western blot.
Results: CM942 exhibited notable cytotoxicity on all human AML cell lines
with SET overexpression (n=10). By using phosphatase assays we confirmed
that CM942 treatment activated PP2A on cell lines, similarly to FTY720.
Immunoprecipitation of PP2Ac in untreated cells confirmed that SET interacts
with PP2Ac, and that treatment with CM942 effectively disrupted this asso-
ciation. Furthermore, CM942 had a caspase-dependent pro-apoptotic effect,
and decreased phosphorylation of the PP2A target ERK1/2. Microarray data
from vehicle-treated and CM942-treated HL-60 cells showed a high correla-
tion between the gene expression profiles of the samples. This analysis iden-
tified up-regulated and down-regulated genetic pathways by treatment with
CM942, providing mechanistic insights into the anti-tumor mechanism of this
small molecule. Our analyses in primary AML samples showed that 7 out of
29 (24%) samples treated with CM942 had a significant reduction in prolifer-
ation. By western blot analyses we found that those patients responding to
CM942 treatment had SET overexpression. Of note, treatment of peripheral
blood mononuclear cells from healthy donors with CM942 had no effects on
cell viability. Therefore, although FTY720 and CM942 have similar effects
inhibiting cellular proliferation, CM942 was less toxic when assayed on nor-
mal peripheral blood cells.
Summary/Conclusions: CM942 inhibits growth of AML cells in both cell
lines and primary patient samples, exerting its antileukemic effects through
reactivation of PP2A activity. Although treatment with FTY720 was somewhat
more effective than CM942 in primary samples of AML, fewer cytotoxic effects
were observed after CM942 treatment in peripheral blood from healthy
donors. Further experiments would be necessary to confirm the in vivo anti-
tumor activity of CM942 in AML models. New compounds have been devel-
oped for the treatment of AML, although few have been translated into clinical
practice; nevertheless, it is unlikely that any of these compounds, when used
as single agents, will cure the disease, which suggests the need for combi-
natorial therapy. Our results indicate that PADs may be a valid therapeutic
option for AML, especially for treating leukemias characterized by SET-depen-
dent inactivation of PP2A.
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Background: Clonal heterogeneity occurs in many cancers, including Acute
Myeloid Leukemia (AML). In cases of relapse, chemotherapy has triggered
clonal selection with minor or evolved sub-clones driving relapse. A better under-
standing of the underlying clonal architecture, the extent of genetic heterogene-
ity and its response to therapy is necessary to better understand mechanisms
of therapy escape and relapse.
Aims: In this study we aim to define the clonal architecture of AML during the
course of therapy and in leukemia propagating cells.
Methods: We sequenced 12 AML samples at the time of diagnosis and in one
case also at the time of relapse with at least 80% blasts per sample. 6/12
patients displayed a normal karyotype while the other 6 patients showed various
cytogenetic abnormalities (inversion 16 (2), trisomy 8 (1), add(19)(p13.3) (1),
complex aberrant karyotype (2)). Whole-exome sequencing (WES) was per-
formed with the appropriate germ line controls. WES data were clustered using
empirical Bayesian clustering.
Results: WES identified more than 3000 variants in total. By setting distinct fil-
tration criteria (20% allele frequency (AF), ≥10 reads coverage, ≥2 reads sup-
port of the detected variant, SIFT-score <0,05 and GMAF <5%) 64 leukemia
specific mutations were detected (1-18 mutations/AML). As expected, these
included recurrently mutated genes like DNMT3A (in 4 patients), IDH1 and 2
(each in one patient), KIT and NRAS (both in 2 patients). Categorization of
identified mutations showed that these mutations affected genes involved in
various cellular processes including transcriptional regulation (15), cell differ-
entiation (6), cell cycling (5), apoptosis/survival signals (5), proliferation (3), cell
growth (3) and splicing (3). Empirical Bayesian clustering of all detected variants
according to their respective AF resulted in 2-5 different clusters per AML.
Based on this cluster analysis we were able to predict the founding
cluster/clone. Assuming that most of the mutations are heterozygous and con-
sidering the blast percentage at diagnosis, mutations of the biggest clusters
are present in every cancer cell and the mutations of the smaller clusters in
proportionately smaller fractions. Based on the clustering information we were
able to model the potential clonal hierarchies. Using a combinatorial approach,
clonal modelling can identify which theoretically existing clones (2n-1; n= num-
ber of clusters) were present at the time of diagnosis and in which order they
evolved (Figure 1). Through comparison of clusters from diagnosis and relapse
clonal selection can also be detected and via modelling the most likely clonal
architectures can be identified. By assigning our 64 identified leukemia-specific
mutations to the defined clusters we can now track the different clusters/clones
in phenotypically distinct subpopulations and during xenotransplantations by
targeted sequencing. An update of this analysis will be presented at EHA.
Figure 1.
Summary/Conclusions: WES can identify leukemia specific mutations that
are involved in various cellular functions including mutations that have been
shown to be recurrently mutated in AML like DNMT3A. Sequencing data can
also be used in combination with mathematical modelling approaches to recon-
struct the clonal architecture of AML at the time of diagnosis and relapse allow-
ing estimations of the clonal complexity at these time points.
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TREATMENT OF PRACINOSTAT AND AZACITIDINE IN ELDERLY
PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): CORRELATION
BETWEEN MUTATION CLEARANCE AND CLINICAL RESPONSE
K. Takahashi1,*, Y. Abaza1, F. Wang1, C. Gumbs1, S. Xingzhi1, A. Futreal1,
E. Atallah2, B. Medeiros3, S. Khaled4, M. Arellano5, M. Patnaik6, E. Palmesino7,
G. Garcia-Manero1
1University of Texas MD Anderson Cancer Center, Houston, 2Medical College
of Wisconsin, Milwaukee, 3Stanford University, Stanford, 4City of Hope, Duarte,
5Emory University School of Medicine, Atlanta, 6Mayo Clinic, Rochester, United
States, 7Helsinn, Pazzallo, Switzerland
Background: In a phase 2 study of 50 elderly patients (≥65 years) with AML
who were not eligible for intensive chemotherapy, treatment with the investiga-
tional HDAC inhibitor pracinostat+azacitidine (AZA) was well tolerated and led
to 42% complete remission (CR) rate and a median overall survival (OS) of
19.1 months (Blood 2016; 128:100). Responses were durable (median CR+CRi
17.2 months), blast clearance was rapid (median 8 weeks), and maximum clin-
ical benefit required prolonged therapy (>6 months) in some patients.
Aims: Our aim was to understand the impact of somatic mutations and their
clearance on disease response and survival outcomes in AML patients treated
with pracinostat+AZA.
Methods: 88 samples from 41 study patients were sequenced. Pre-treatment
samples were available for analysis from all 41 patients, and a median of 3 lon-
gitudinal samples were analyzed from 19 patients between Cycle 2 and 9.
Leukemia mutations were detected by SureSelect targeted capture exon
sequencing (Agilent) of 295 genes that are recurrently mutated in hematologic
malignancies (median coverage 507x [range: 111-777x]). Longitudinal mutation
clearance was analyzed by tracking variant allele frequency (VAF). Informed
consent was obtained from all patients.
Results: At baseline, 96 mutations in 28 genes were detected in 38 (93%)
patients, with the most frequent being in SRSF2 (27%), DNMT3A (20%),
IDH2 (17%), RUNX1 (17%), and TET2 (17%). The median number of muta-
tions detected per patient was 2 (range: 0-6). Among the 33 patients with
evaluable treatment response, CR was observed in 13 (39%) patients. The
rate of CR was significantly higher in patients with mutations in NPM1 or in
one of the DNA methylation pathway genes, while patients with TP53 muta-
tion had a trend for poor CR (Table 1). The median follow up duration of the
41 patients was 23.8 months (95% CI: 20.4-27.1 months) with median OS
of 18.1 months (95% CI: 10.1-26.1 months), patients with CEBPA mutation
had a trend toward better OS, whereas patients with NF1 mutation had sig-
nificantly worse OS (Table). Considering mutations associated with AML
ontogeny (Lindsley RC, Blood 2015;125:1367-76), median OS was 17.7
months in 20 patients with mutations typically associated with secondary
AML and 18.1 months in 18 patients with mutations typically associated with
de novo AML. Among the 19 patients whose longitudinal specimens were
analyzed, 10 achieved CR. Of those 10 patients, 9 (90%) had persistently
detectable mutations in their bone marrow at the time of CR, however, in 7
of them, continued exposure to pracinostat+AZA lowered the VAF or cleared
residual mutations. Mutations in genes associated with DNA methylation,
RNA splicing, clonal hematopoiesis of indeterminate potential (CHIP), and
receptor tyrosine kinase (RTK) pathways had poor clearance of mutation,
while transcription factors or cohesin had better clearance with
pracinostat+AZA treatment. In 2 patients, relapsed samples were sequenced
and showed re-expansion of the founder clone.
Table 1.
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Summary/Conclusions: Mutations in NPM1, and DNA methylation pathway
were associated with a better response to pracinostat+AZA, while TP53 muta-
tion was associated with a trend toward poor response. Persistent mutation at
the time of CR suggests residual preleukemic clonal hematopoiesis in this eld-
erly population. Benefit of prolonged exposure to pracinostat+AZA was also
confirmed at molecular level where continued decline of mutation VAF was
seen after achieving CR.
Acute myeloid leukemia - Clinical 3
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STABLE DISEASE WITH HEMATOLOGIC IMPROVEMENT IS CLINICALLY
MEANINGFUL FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA
TREATED WITH AZACITIDINE
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Background: Effects on overall survival (OS) are of primary importance when
evaluating AML treatments (Tx). Though complete remission (CR) rates are
lower with azacitidine (AZA) than with intensive chemotherapy (IC), OS is sim-
ilar with AZA and IC (Dombret et al., Blood, 2015). The 2017 European
LeukemiaNet (ELN) recommendations acknowledge that hypomethylating
agents, including AZA, may alter the natural course of AML in some patients
(pts) who do not achieve CR (Döhner et al., Blood, 2017). According to IWG
criteria for AML (Cheson et al., J Clin Oncol, 2003), stable disease (SD) is con-
sidered non-response to Tx. Yet AML is a progressive disease; potentially, sta-
ble health status may reflect delayed disease progression and result in
improved OS.
Aims: This post hoc analysis evaluated OS outcomes among older pts with
AML treated with AZA or conventional care regimens (CCR) who maintained
SD, with or without hematologic improvement (HI), in the phase 3 AZA-AML-
001 study.
Methods: Pts aged ≥65 years with AML (>30% marrow blasts), ECOG PS
score ≤2, NCCN-defined intermediate- or poor-risk cytogenetics, and WBC
count ≤15x109/L received AZA (75mg/m2 x7 days [d]/28d cycle) or a CCR (IC
[standard 7+3 regimen], low-dose cytarabine [20mg BID x 10d/28d cycle], or
best supportive care). OS was assessed using Kaplan-Meier methods for pts
with SD at 2-, 4-, and 6-month landmarks. SD was protocol-defined as the
absence of an IWG-defined AML response and no progressive disease (PD),
whether or not HI was attained. Pts with SD could have had an IWG-defined
response or PD at any time other than at the specified landmarks. OS was
also evaluated in pts with HI as their best response; attainment of HI must
have begun on or before, and been sustained past, each landmark, and lasted
for ≥56 consecutive days.
Table 1.
Results: Median OS for all SD pts was 2.1-2.5 months longer with AZA vs
CCR, and estimated 1-year survival was ~15% higher at each landmark in the
AZA arm (Table 1). Hazard ratios for OS among all SD pts treated with AZA vs
CCR ranged from 0.81–0.88. Median OS among pts with SD and no HI ranged
from 12.6–13.3 months in the AZA arm and from 11.1-12.2 months in the CCR
arm. Within Tx arms, AZA-treated pts with HI had meaningfully improved OS
at all landmarks, ranging from 3.7 to 7.9 months longer than OS for pts without
HI (Table 1). In contrast, HI attained with CCR did not largely influence OS; dif-
ferences between pts who attained HI vs no HI ranged from -0.2 to 2.9 months.
Median durations of HI in the AZA vs CCR arms, respectively, were 183 vs 166
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days at 2 months, 176 vs 148 days at 4 months, and 176 vs 138 days at 6
months. Estimated 1-year survival within the AZA arm was 4.9%–27.4% greater
for pts with HI than for pts with no HI, but for CCR-treated pts with HI, 1-year
survival was 0%–10.3% greater. Between Tx arms, 1-year survival with AZA in
pts with HI was 9.6%–33.3% greater than for CCR-treated pts with HI.
Summary/Conclusions: Maintaining SD during AZA or CCR Tx is associated
with relatively favorable OS outcomes, as median OS in pts with SD exceeded
that for all pts in the AZA-AML-001 trial (10.4 months with AZA vs 6.5 months
with CCR; Dombret et al., Blood, 2015). Pts with SD who also attained HI during
early AZA Tx had meaningfully improved OS, whereas similar CCR-treated pts
did not, suggesting that HI with AZA is qualitatively different from HI with CCR.
The prognostic relevance of HI in AML requires further study.
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Background: Fludarabine and clofarabine are purine nucleoside analogues
with clinical activity in acute myeloid leukemia (AML).
Aims: We designed a randomized phase II trial to evaluate the efficacy and
safety of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine
(FIA) in adults with newly diagnosed AML. The primary objective was to com-
pare the EFS rates of the two regimens.  
Methods: Adults with newly diagnosed AML deemed suitable for intensive
chemotherapy were randomized using a Bayesian adaptive design to receive
CIA or FIA. All patients (pts) received idarubicin 10 mg/m2 IV on D1-3 and
cytarabine 1 g/m2 IV daily on D1-5. Clofarabine and fludarabine were given at
doses of 15 mg/m2 and 30 mg/m2, respectively, IV daily on D1-5. Pts with FLT3-
ITD mutations could receive concomitant sorafenib. Responding pts could
receive up to 6 cycles of consolidation at attenuated doses. Outcomes were
compared to a historical cohort of pts <60 years of age who received idarubicin
and cytarabine (IA) without a nucleoside analogue.
Results: Between 8/2011 and 6/2016, 182 pts were enrolled (CIA, n=106; FIA,
n=76; Table 1).
Table 1.
The imbalance of the arms was due to the better performance of CIA during
the initial period of the trial. Treatment arms were well-balanced after random-
ization. 12 pts (55%) in the CIA arm and 8 (53%) in the FIA arm received
sorafenib. The composite CR/CRp rate was similar between the two arms (80%
for CIA vs 82% for FIA; P=0.84). CR was achieved in 72% and 74% in the CIA
and FIA arms, respectively. MRD negativity rates at remission by multiparameter
flow cytometry were higher in the CIA arm (80% vs 65%; P=0.07). 37 pts (35%)
in the CIA arm and 28 (38%) in the FIA arm underwent allogeneic stem cell
transplant in first remission. The median duration of follow-up was 27 months
(range, 1-58). Median EFS for pts who received CIA and FIA were 13 months
and 12 months, respectively; the 2-year EFS rate was 44% in both arms
(P=0.91). Median OS were 24 months and not reached, and the 2-year OS
rates were 51% and 57%, respectively (P=0.23). No differences in EFS or OS
were observed according to baseline factors, including cytogenetics, mutations
or ELN risk group. CIA was generally associated with more adverse events
compared to FIA, including a higher rate of transaminase elevation (29% vs
4%), hyperbilirubinemia (26% vs 9%), and rash (29% vs 12%). Early mortality
was similar in the 2 arms (60-day mortality: 4% for CIA vs 1% for FIA; P=0.32).
We compared outcomes of pts treated with either CIA/FIA to a historical cohort
treated with IA (n=92). Pts in the CIA/FIA group with FLT3 mutations who
received sorafenib (n=20) were excluded from this analysis. The two cohorts
were similar with respect to pretreatment characteristics analyzed, including
age, cytogenetics, and ELN risk. No differences were observed in CR/CRp
rates, EFS or OS between the two groups. However, among pts <50 years of
age, the median EFS for pts who received FIA (n=36), CIA (n=28) and IA (n=34)
was not reached, 10 months and 9 months, and the 2-year EFS rates were
58%, 33% and 30%, respectively (P=0.05 for FIA vs IA; P=0.79 for CIA vs IA).
For these pts <50 years of age, the median OS was not reached, 22 months
and 15 months, and the 2-year OS rates were 72%, 46% and 36%, respectively
(P=0.009 for FIA vs IA; P=0.23 for CIA vs IA).
Summary/Conclusions: CIA and FIA have similar efficacy in younger pts with
newly diagnosed AML, although FIA is associated with a better toxicity profile.
FIA may improve outcomes compared to IA in pts <50 years of age.
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Background: Approximately 20% to 30% of patients with acute myeloid
leukemia (AML) have FLT3 mutations; these patients often experience rapid
post-induction relapse, highlighting the need for therapies that provide an
improved bridge to stem cell transplantation. CPX-351 is a liposomal formulation
that delivers a synergistic 5:1 molar ratio of cytarabine and daunorubicin. CPX-
351 demonstrated significantly prolonged overall survival (OS) versus cytara-
bine/daunorubicin (7+3) in a randomized, open-label, controlled phase 3 trial
in patients aged 60 to 75 years with newly diagnosed, high-risk AML (Lancet,
et al. ASCO 2016). A study of the ex vivo cytotoxicity of CPX-351 found that
AML blasts with the FLT3-ITD phenotype were 5-fold more sensitive to CPX-
351 than those with wild type FLT3 (Gordon, et al. Leuk Res. 2017;53:39-49).
Aims: The current analysis of the phase 3 trial therefore investigated outcomes
in the subset of patients with FLT3 mutations.
Methods: Enrolled patients were randomized 1:1 to receive induction with 1 to
2 cycles of CPX-351 (100 units/m2 [cytarabine 100 mg/m2+daunorubicin 44
mg/m2] on Days 1, 3, and 5 [2nd induction: Days 1 and 3 only]) or 7+3 (cytara-
bine 100 mg/m2/day x 7 days [2nd induction: x 5 days]+daunorubicin 60 mg/m2
on Days 1, 2, and 3 [2nd induction: Days 1 and 2 only]). Patients who achieved
complete remission (CR) or CR with incomplete platelet or neutrophil recovery
(CRi) could receive up to 2 consolidation cycles.
Results: Of the 274 patients who were assessed for FLT3 mutations and
received study treatment, 22/138 (16%) patients in the CPX-351 arm and
20/136 (15%) patients in the 7+3 arm had baseline FLT3 mutations. AML sub-
types in FLT3+ patients were: therapy-related AML (19%); AML after myelodys-
plastic syndrome (MDS) with (38%) or without (10%) prior hypomethylating
agents; AML after chronic myelomonocytic leukemia (12%); and de novo AML
with MDS karyotype (21%). In FLT3+ patients, median OS was longer with
CPX-351 (10.25 months) versus 7+3 (4.55 months; hazard ratio=0.57 [95%
CI: 0.24, 1.33]; P=0.093; see Figure 1), and the rate of CR+CRi was higher
(68% vs 25%). A greater number of FLT3+ patients treated with CPX-351 were
able to undergo stem cell transplantation (n=10/22 [45%]; 4 patients were alive
as of this analysis, after a median post-transplant follow up of 692 days [range:
96-769]) compared with 7+3 (n=2/20 [10%]; neither patient was still alive). The
adverse event profile (reported during treatment or within 30 days of discontin-
uation) of CPX-351 in FLT3+ patients was comparable to that of 7+3 and con-
sistent with the overall study population. Serious treatment-emergent adverse
events (TEAEs) were experienced by 7 (32%) FLT3+ patients in the CPX-351
arm and 10 (50%) patients in the 7+3 arm; individual serious TEAEs in ≥2
patients included febrile neutropenia (n=2 in each arm), respiratory failure (n=1
in each arm), cardiac failure (n=2 with CPX-351), and cerebral hemorrhage
(n=2 with 7+3).
Summary/Conclusions: CPX-351 demonstrated numerical improvement in
median OS in older patients with newly diagnosed, FLT3+ high-risk AML and
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allowed more patients to undergo stem cell transplantation. The safety of CPX-
351 in this subpopulation was in line with that of previous studies and the




NIVOLUMAB MAINTENANCE THERAPY FOR PATIENTS WITH HIGH-RISK
ACUTE MYELOID LEUKEMIA IN REMISSION
T. Kadia1,*, H. Kantarjian1, E. Jabbour2, F. Ravandi1, N. Daver1, P. Cardenas1,
M. Brandt1, M. Konopleva1, J. Cortes1
1Leukemia, 2MD Anderson Cancer Center, Houston, United States
Background: Dose intensification and newer drug combinations during induc-
tion have led to high rates of complete remission (CR) in pts with newly diag-
nosed AML. However, disease relapse remains a major source of failure. With
the exception of allogeneic (allo) stem cell transplant (SCT), there are few
options for post-consolidation maintenance of remission in high-risk pts. Prior
attempts to develop maintenance therapy using cytotoxic drugs in AML have
been unsuccessful. Immune mediated disease control by engaging tumor-spe-
cific cytotoxic T-cells may be important in suppressing leukemia relapse, as is
seen with graft vs leukemia effect following allo SCT. Immune checkpoint
inhibitors may be effective in restoring host immune surveillance in the setting
of post-remission maintenance.
Aims: We designed a pilot phase II clinical trial studying the efficacy and safety
of nivolumab (nivo) as maintenance therapy in AML pts with high-risk disease
in remission, who were not being considered for SCT.
Methods: AML pts ≥18 years with a high-risk feature in 1st CR (CR1) or any
patient in 2nd CR (CR2) who had received induction and at least 1 consolidation
cycle were eligible for enrollment. Pts should be within 12 months of achieving
CR, have PS ≤2, and adequate organ function. Pts were treated with nivo
3mg/kg IV every 2 weeks for 6 months. 1 cycle was 4 weeks. After 6 months,
nivo could be given every 4 weeks until 12 months on study, and then every 3
months until relapse. All pts had baseline cytogenetic and molecular testing,
and minimal residual disease (MRD) assessment by flow cytometry. Peripheral
blood and bone marrow samples were collected at baseline and during treat-
ment for immune correlative studies to explore immune cell repertoire and bio-
markers for response.
Results: Eight pts have been treated, with a median age of 60 years (range,
49-71). 7 pts were in CR and 1 in CRi at the time of enrollment; 5 pts (63%)
were in CR1, 2 pts (25%) were in CR2, and 1 pt (13%) in CR4 was inadvertently
enrolled and treated on the trial. Baseline characteristics are outlined in Table
1. AML-related mutations detected at start of therapy include: IDH2 (n=2),
NPM1 (2), TET2 (2), and 1 each of TP53, JAK2, ASXL1, and DNMT3a. High
risk features at the time of enrollment were as follows: 2 (25%) persistent MRD,
2 (25%) adverse karyotype, 1 (13%) adverse mutational profile, and 3 pts
(38%) in CR2 or beyond. Pts have received a median of 4 (1 – 13) cycles of
therapy. With a median followup of 6+ months (1 – 14), the 6- and 12-month
estimated RFS were 88% and 73%, respectively. The 6- and 12-month esti-
mated OS were 100% (Figure 1). The one patient who died was discovered
after enrollment to actually be in CR4. This patient relapsed approximately 8
months after achieving CR4. The regimen was well tolerated overall, with 4 pts
having possible immune-related events. 1 patient had grade 3 thyroiditis leading
to hypothyroidism, treated successfully with steroids and thyroid hormone sup-
plementation, who continues on treatment. 1 patient had grade 4 transaminase
elevation which responded to dose interruption and who continues on treat-
ment. 2 pts had grade 3 possible pneumonitis treated successfully with steroids
and dose interruption – both of whom continue on treatment (Table 1).
Summary/Conclusions: Nivo appears to be a feasible maintenance strategy
in high-risk AML pts who are not candidates for SCT. The study continues to
surpass the pre-specified expected rate of 6-month relapse-free survival of
high-risk pts based on a historical cohort. Correlative studies profiling the





HIGHER EXPRESSION OF LONG NON-CODING RNA KIAA0125 IS
ASSOCIATED WITH CHARACTERISTIC CLINICAL AND BIOLOGICAL
FEATURES AND IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN
ACUTE MYELOID LEUKEMIA
S.-Y. Hung1,*, C.-C. Lin1,2,3, H.-A. Hou1, W.-C. Chou1,2, H.-F. Tien1
1Division of Hematology, Department of Internal Medicine, 2Department of Lab-
oratory medicine, National Taiwan University Hospital, 3Graduate Institute of
Clinical Medicine, College of Medicine, National Taiwan University, Taipei City,
Taiwan, Republic of China
Background: Long non-coding RNAs (lncRNAs) are non-protein coding RNAs
longer than 200 nucleotides. Recently, a number of lncRNAs have been shown
to play important roles in cancer biology. lncRNA KIAA0125 is one of the 11
genes in an expression signature significantly associated with prognosis in
cytogenetically normal acute myeloid leukemia (AML) patients as shown in our
previous report. It is also among another set of 17 leukemia stem cell (LSC)
genes, identified through xenotransplantation model in NSG mice, which predict
inferior treatment response in AML.
Aims: KIAA0125 gene is localized on chromosome 14q32.33; its functions
remain unexplored. One study reported that it might be involved in neurogen-
esis including induction of astrocytosis, preventing formation of dopaminergic
neurons. Another study showed that it could potentiate cell invasion and migra-
tion in gallbladder cancer. Its clinical significance in hematologic malignancies
has not been explored yet. Since independent studies have reported KIAA0125
as an important gene for unfavorable prognosis, in this study we aimed to
investigate its clinical relevance in AML. 
Methods: We performed global mRNA arrays for bone marrow samples from
347 newly diagnosed de novo AML patients in the National Taiwan University
Hospital, who had adequate cryopreserved cells and detailed demographic,
clinical, and genetic data for analysis. The KIAA0125 expression level extracted
from the array data was analyzed for its clinical relevance. We also validated
our findings by analyzing the public databases of AML.
Results: The 347 patients were divided into two groups based on the median
level of KIAA0125 expression on the arrays. Higher KIAA0125 expression was
inversely associated with favorable karyotypes including t(8;21) and t(15;17).
Patients with M1 by the French-American-British classification more frequently
had higher KIAA0125 expression (p <0.001), while those with M3 (acute
promyelocytic leukemia) had significantly lower levels of KIAA0125 expression
(p <0.001). To investigate the association of gene mutations with KIAA0125
expression in AML, we analyzed mutations of 17 AML-associated genes. We
found that patients with higher KIAA0125 expression had significantly higher
incidence of FLT3-ITD (28.7% vs 19.7%, p=0.048), and mutations of RUNX1
(18.4% vs 10.4%, p=0.034), and DNMT3A (24.1% vs 13.9%, p=0.015), com-
pared to those with lower KIAA0125 expression. Among the 227 patients who
received standard chemotherapy, those with higher KIAA0125 expression had
a lower complete remission rate (61.2% vs 84.7%, p <0.001), and shorter over-
all survival (median OS, 23.7 months vs 116.8 months, p = 0.001) than those
with lower KIAA0125 expression after a median follow-up of 57.0 months. The
prognostic significance could be validated in another two independent cohorts,
TCGA and GSE12417. In multivariate analyses, higher expression of KIAA0125
remained to be an unfavorable prognostic factor for OS independent of age,
white blood cell counts, karyotype, FLT3-ITD, CEBPA double mutations,
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RUNX1 mutation, MLL-PTD, WT1 mutation, and TP53 mutation (p=0.011).
Summary/Conclusions: Higher expression of KIAA0125 in AML patients was
correlated with mutations of RUNX1, DNMT3A, and FLT3-ITD but negatively
associated with favorable karyotypes such as t(8;21) and t(15;17). Higher
expression of KIAA0125 appeared to be an independent unfavorable prognostic
factor in our cohort, and its negative prognostic impact could be validated in
another two large independent cohorts of AML. The close association of
KIAA0125 expression with LSC signatures might in part explain its unfavorable
impact on the survival of AML patients.
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LEUKEMIC STEM CELLS CAN BE DETECTED IN A CONSIDERABLE
PERCENTAGE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AT
DIAGNOSIS AND IS A SIGNIFICANT PROGNOSTIC FACTOR
O. Pérez-López1,*, T. Caballero-Velázquez1, I. Álvarez-Laderas1,
P. Hernández-Díaz1, A. M. Márquez-Matito1, J. González-Campos1,
R. Morales-Camacho1, C. Prats-Martín1, M.T. Vargas-de los Monteros1,
R. Bernal-Ruíz1, J.A. Pérez-Simón1
1Virgen del Rocío University Hospital, Sevilla, Spain
Background: There is a growing interest on the identification of leukemic stem
cells (SC) as a potential prognostic factor in patients with acute myeloid
leukemia (AML). Several studies identify these cells as CD34+CD38-Lin-,
although there is a controversy about its phenotypic identification and prognostic
value.
Aims: To identify SC in a cohort of patients with AML and evaluate their prog-
nostic value in a series of newly diagnosed AML patients.
Methods: The presence of SC (CD34+CD38-Lin-) in bone marrow samples
was prospectively evaluated in a consecutive series of 67 newly diagnosed
AML patients by flow cytometry, between may’13-oct’16. All patients receive
intensive chemotherapy according to PETHEMA protocol. We evaluated
response, relapse rate and overall (OS) and event free survival (EFS).
Results: Out of the 67 patients [34 men/33 women, median age 54 (0-78)], 58
(86.6%) have SC at diagnosis. 37.9% of them (n=22) achieved complete remis-
sion (CR) with a negative minimal residual disease (MRD) vs 77.8% (7/9)
among patients without SC (p=0.03). Among patients who obtained CR with a
negative MRD (n=29), no one suffer a leukemic relapse in the non SC vs 5/22
(22.7%) in the SC group (p=0.2). Considering the intermediate risk group
according to cytogenetic / molecular features, 100% of patients without SC at
diagnosis achieve a negative MRD (5/5) vs 14/41 (34.1%) among those in the
SC group (p=0.008). OS at 9 months was 89 vs 56% (p=0.043), and the EFS
78 vs 48% (p=0.054) in the non SC and SC group, respectively (Figure 1).
Figure 1.
Summary/Conclusions: SC can be detected in a considerable group of
patients with AML at diagnosis. The presence of SC is a prognostic factor in
terms of response, OS and EFS. Accordingly, SC detection could help to identify
prognosis subgroups of patients with different prognostic among those in the
intermediate risk group by genetics/molecular assays.
P214
POST-REMISSIONAL AND PRE-TRANSPLANT ROLE OF MINIMAL
RESIDUAL DISEASE DETECTED BY WT1 IN ACUTE MYELOID LEUKEMIA:
A RETROSPECTIVE COHORT STUDY
C. Frairia1,*, S. Aydin1, E. Audisio1, L. Riera2, S. Aliberti2, B. Allione1, A. Busca3,
S. D’Ardia1, C.M. Dellacasa3, A. Demurtas2, A. Evangelista4, G. Ciccone4,
P. Francia di Celle2, B. Nicolino1, A. Stacchini2, F. Marmont1, U. Vitolo1
1Department of Hematology, 2Department of Pathology, 3Bone Marrow Trans-
plant Center, University-Hospital Città della Salute e della Scienza, Torino, Italy,
4Unit of Clinical Epidemiology, University-Hospital Città della Salute e della
Scienza and CPO Piemonte, Torino, Italy
Background: In acute myeloid leukemia (AML) the detection of residual
leukemic cells at a submicroscopic level (minimal residual disease - MRD) is
still under investigation. In about 30-40% of AML lacking a specific molecular
target, quantitative real-time polymerase chain reaction (QRT-PCR) has been
used to detect transcripts commonly overexpressed in AML. Among a large
number of candidates, Wilms tumor gene 1 (WT1) has been proposed as a
promising MRD marker.
After the standardization of QRT-PCR on behalf of the European LeukemiaNet
(ELN), subsequent studies investigated the role of WT1 expression in AML with
controversial results. 
Aims: To assess the role of WT1 expression as a MRD marker after intensive
induction chemotherapy and before allogeneic hematopoietic cell transplantation
HCT (allo-HCT) in a large cohort of AML patients treated in a single institution.
Methods: The present retrospective cohort study included adult patients with
untreated AML consecutively diagnosed between 2004 and 2014 in the Hema-
tology Unit of the University-Hospital Città della Salute e della Scienza of Torino,
Italy. The study was approved by the Ethical Committee and was registered at
www.clinicaltrials.gov as NCT02714790. Among 255 enrolled patients, MRD
was investigated in those in first complete remission (CR) with an available at
diagnosis and at two further time-points: after induction (n=117) and prior allo-
HCT (n=65). Patients with baseline WT1 <250 copies were excluded. All
patients underwent intensive induction chemotherapy with curative intent and
subsequent consolidation chemotherapy according to the AML risk assessment
(autologous peripheral stem cell transplantation for low risk and allo-HCT for
intermediate and high risk patients). Effect of post induction WT1 expression
on disease-free survival (DFS) and overall survival (OS) and of pre allo-HCT
WT1 on the cumulative incidence of relapse (CIR) were investigated. 
Results: Baseline BM WT1 expression were not found significantly associated
with demographic, clinical and disease biological features at diagnosis. Baseline
BM WT1 expression lacked even to show an association with response to
induction chemotherapy (OR 1.16; 95% CI 0.90-1.50, p=0.244).
Median OS and DFS were significantly shorter in patients in first CR with >350
WT1 copies after induction compared to those with ≤350 (OS 17 vs 95 months
with HR 2.13; 95% CI 1.14-3.97, p=0.018 and 3-year DFS rates 15% vs 55%
with a HR of 2.81; 95% CI 1.14-6.93, p=0.025).
Adding the BM WT1 in the model along with other factors determines an
increase of the C-statistic from 0.6996 to 0.7193 for OS (NRI=0.384) and from
0.7413 to 0.7920 (NRI=0.4037) for DFS. Before allo-HCT, patients with WT1
>150 copies (n=18) had a significantly higher CIR compared to those with WT1
≤150 (n=47), HR 4.61; 95% CI 1.72-12.31, p=0.002. 
Summary/Conclusions: The results of the present study showed that BM
WT1 is associated with survival in patients in CR in two decisive time-point for
treatment planning: after induction treatment and before allo-HCT. The prog-
nostic role of WT1 resulted independent from other well-established risk factors.
Therefore, WT1 may represent an additional MRD tool for risk stratification in
patients nowadays classified in CR, especially in the high risk MRD positive
subgroup in which a risk-adapted approach may have a role. Published evi-
dences available so far supported these suggestions, but mainly due to method-
ological issues, the role of WT1 is still a matter of debate. Prospective random-
ized studies are required to confirm these results.
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DIFFERENTIATION SYNDROME ASSOCIATED WITH ENASIDENIB
(AG-221), A SELECTIVE INHIBITOR OF MUTANT ISOCITRATE DEHYDRO-
GENASE 2 (MIDH2)
A.T. Fathi1,2,*, C.D. DiNardo3, I. Kline4, L. Kenvin4, I. Gupta4, E.C. Attar5,
E.M. Stein67, S. de Botton8
1Massachusetts General Hospital Cancer Center, 2Harvard Medical School,
Boston, 3The University of Texas MD Anderson Cancer Center, Houston, 4Cel-
gene Corporation, Summit, 5Agios Pharmaceuticals, Inc, Cambridge, 6Memorial
Sloan Kettering Cancer Center, 7Weill Cornell Medical College, New York, Unit-
ed States, 8Institut Gustave Roussy, Villejuif, France
Background: Enasidenib (AG-221) is an oral, selective, small-molecule
inhibitor of mIDH2 enzymes. Preclinical studies showed that exposing
myeloblasts from patients (pts) with acute myeloid leukemia (AML) to enasi-
denib ex vivo resulted in differentiation of leukemic marrow blasts into mature,
fully functional neutrophils (Yen et al., Cancer Discov, 2017).  Enasidenib can
result in IDH-inhibitor-associated differentiation syndrome (IDH-DS) in treated
pts, with manifestations akin to retinoic acid syndrome seen during therapy of
acute promyelocytic leukemia. 
Aims: To characterize the prevalence, characteristics, and course of IDH-DS
in pts with relapsed or refractory (R/R) AML receiving enasidenib 100 mg daily
in a phase 1 dose-escalation and expansion study (NCT01915498). This dose
is currently under study in a multicenter, randomized, phase 3 trial comparing
enasidenib with conventional care regimens in R/R AML pts (NCT02577406).
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Methods: An independent Differentiation Syndrome Review Committee (DSRC)
was formed to review potential cases of IDH-DS. The DSRC identified and
agreed upon a series of signs and symptoms possibly characteristic of IDH-DS,
including fever, lung infiltrates, pleural or pericardial effusions, rapid weight gain,
edema, and azotemia. In all, 27 cases (8 of investigator-reported IDH-DS and
19 with characteristics suggestive of IDH-DS) were identified and retrospectively
reviewed by the DSRC to determine their consistency with IDH-DS.
Results: The DSRC determined 13 cases (11.9% of 109 R/R AML pts in the
enasidenib 100 mg/day dosing cohort) to be consistent with IDH-DS. Median
time to onset was 30 days (range 7-116). Manifestations of IDH-DS in >2 pts
were dyspnea (n=10), pyrexia (9), lung infiltrates (8), pleural effusion (5), and
kidney injury (3). IDH-DS was effectively managed with systemic corticosteroids
in 12/13 cases. Leukocytosis accompanied 4/13 cases, for which hydroxyurea
was employed for cytoreduction. Enasidenib was interrupted for 9 pts (for a
median of 7 days), but dose reductions or enasidenib discontinuation were not
required for pts with IDH-DS. Six of the 13 pts had clinical responses (2 com-
plete remissions [CR], 2 CRs with incomplete hematologic recovery, 1 partial
remission, and 1 morphologic leukemia-free state), 6 pts had stable disease,
and 1 pt had progressive disease.
Summary/Conclusions: Systemic corticosteroids, close hemodynamic man-
agement, and hydroxyurea (in the presence of leukocytosis) are effective
IDH-DS management strategies; they should be administered promptly when
IDH-DS is suspected, and continued until improvement. Enasidenib interrup-
tion can be considered if initial intervention is unsuccessful. IDH-DS repre-
sents a novel clinical finding in pts with mIDH2 AML treated with enasidenib,
and is likely due to its suggested mechanism of action, myeloblast differen-
tiation.




OUTCOME OF PATIENTS WITH INTRAVASCULAR B-CELL LYMPHOMA,
A RETROSPECTIVE STUDY CONDUCTED ON BEHALF OF THE
LYMPHOMA STUDY ASSOCIATION GROUP
A. Bonnet1,*, L. Gabelier2, J. Rohmer3, C. Bossard4, C. Sarkozy5, V. Roland6,
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Background: Intravascular large B-cell lymphoma (lVLBCL) is a rare type of
extranodal large B-cell lymphoma characterized by the selective growth of lym-
phoma cells within the lumina of vessels, classically reported with poor respons-
es to chemotherapy. Due to its low incidence and rarety of tumor cells, diag-
nosis of IVLBCL remains difficult and many issues remain unresolved, regard-
ing both clinical features and therapeutic strategies.
Aims: Our work aims to describe clinical presentation and outcome of lVLBCL
patients treated in French LYSA centers between 2000 and 2016. 
Methods: All LYSA centers were asked to report and update clinical data about
IVLBCL patients treated. No central pathology review was performed for the
present study, but all cases were classified by LYSA pathologists. Local inves-
tigators reported disease characteristics and updated patients’ outcome (clinical
examination, standard biological parameters, bone marrow biopsy, CT scan at
baseline, CT response evaluation and outcome).
Results: We identify 65 IVLBCL patients treated in 23 LYSA centers during
the studied period. Median age was 67.8 years (range 22-91). In note, two
third of patients presented with IPI score >3 (67%) and all patients had a stage
IV disease. As expected in Western patients, cutaneous and CNS involvement
were highly frequent, respectively 33% and 39%. But interestingly, hemophago-
cytic syndrome were observed in nearly half of the patients (41%), while it was
mainly described in Asian series. Despite classically delayed diagnosis in IVL-
BCL, only 2 cases were confirmed post-mortem and almost all alive patients
at diagnosis (n=58) were treated with rituximab-containing chemotherapy reg-
imen (92%). Regarding first line treatment, 83% of patients were treated with
anthracycline-based regimens, with CNS prophylaxis for half of them (47%),
and seven patients underwent autologous stem cell transplantation upfront.
The median progression free survival was 29.4 months and median overall
survival was 63.8 months (Figure 1). Pathological features (including cell of
origin characterization, C-MYC expression, adhesion protein expression level)
investigation is ongoing and will be presented at the time of the meeting.
Figure 1.
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Summary/Conclusions: The present study is the largest European IVLBCL
series. It shows that despite the use of modern immune-chemotherapy, IVLBCL
remains an aggressive lymphoma entity. In particular, these patients are highly
exposed to early relapse and therefore should be considered for innovative
frontline therapies.
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OUTCOME OF ELDERLY DLBCL PATIENTS (≥80 YEARS) TREATED WITH
ANTHRACYCLINE BASED CHEMOTHERAPY; R-CHOP DOSE REDUCTION
IS NOT NECESSARY FOR EVERYBODY
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Background: Management of elderly patients (above ≥80y) is difficult and only
limited number of patients could be treated by curative approach with anthracy-
cline based chemotherapy. Dose reduction of particular drugs is used very often
and it varies based on pt’s characteristics and center preferences. There is how-
ever lack of randomized or at least non-randomized historical comparisons. 
Aims: The objective of this study is to analyze elderly DLBCL patients prospec-
tively registered in NiHiL Lymphoma Project and treated anthracycline based
regimen in real world outside of clinical trials. 
Methods: Patients (pts.) with informed consent are prospectively followed in
multicenter Lymphoma Project since 1999. Diagnostic, therapeutic and follow
up data are prospectively collected. There were 399 DLBCL pts older than
80year diagnosed in period 1999-2014 identified. Among 372 pts. with pathol-
ogy review and essential data there were 112 pts. (30.1%) treated with R-
CHOPlike chemotherapy. Analysis of clinical prognostic factors, therapy and
toxicity was performed. Pearson, Kaplan-Maier and log rank tests were used. 
Results: Median age was 81 years (80-88), 51.8% of men.  Proportion of pts
³85 was 14.3%, with PS ≥2 (ECOG) 34.0%, with higher LDH 64.3%, with high
or intermediate high IPI 49.1%,  with bulky disease (≥10 cm) 17.0%, with
lower albumin 27.7%, with Charlson Comorbidity Score (CCS) ≥4 25%.
According to treatment choice of physician (intent to treat), pts. could be divid-
ed into 3 groups R-CHOP (CH) (cyclophosphamide –CF 750 mg/m2, adri-
amycin – A - 50 mg/m2) or R-MiniCHOP (miniCH) (CF 400 mg/ m2, A 25 mg/
m2, Peyrade 2011) or modified R-CHOP (modiCH) (CF 750 mg/m2and A 25
mg/m2or any other dose between CHOP and miniCHOP). There were 21 pts
(18.8%) treated with CH, 38 (33.9%) with miniCH and 53 (47.3%) with
modiCH. There were no signficant differences between the subgroups, except
higher proportion of bulk in modiCH vs miniCH and CH (35% vs 12.9% vs
7.7% resp.; p 0.04) and cardiac comorbidity (60.5% vs 33.3% vs 30.2% resp.;
p 0.02). Six and more cycles were administered in 71.4%, 63.1% and 58.5%
pts. in CH, miniCH and modiCH resp. Following proportion of pts. received
>80% (>50%) of original CHOP dose. For cyclophosphamide it was 66.7%
(81%), 0% (50%) and 62.2% (79.2%) resp. and for A it was 57.1% (76.1%),
2.6% (15.8%) and 13.2% (49%) resp. for CH, miniCH and modiCH
resp.  There were observed 11 treatment related deaths (6 cardiac toxicity
and 4 infection), 5 in miniCH and 6 in modiCH groups. The overall response
rate was 76.8% with 59.8% CR/CRu. Median PFS and OS were 2.8y and
3.5y resp. (Figure 1A) with median follow up of 3.3y. There were found high
beta2microglobulin (HR 2.2, p 0.05), low albumin (HR 1.9, p 0.05)  and PS
(p 0.05) as the only factors correlated with OS as well as PFS (data not
shown). Pts who achieved CR or PR have significantly better OS median (as
well as PFS) compared to stable or progressive disease with 4.6 vs 3.5 vs
0.8 vs 0.5 y. There was numerically (not significantly) better OS median for
R-CHOP (4.6y) vs R-miniCHOP (3.2y) and R-modiCHOP (2.9y) (Figure 1B).
Figure 1.
Summary/Conclusions: Only one third of elderly DLBCL pts (≥80y) is treated
with anthracycline based regimen. Performance status, albumin and
beta2microblobulin levels were significantly associated with prognosis. In minor-
ity of these pts full dose of R-CHOP could be safely used and there is trend to
better overall survival.
Supported by AZV 16-31092A.
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LYMPHOMA UP TO AGE 70 ONLY: A POPULATION-BASED STUDY ON
INCIDENCE, PRIMARY TREATMENT AND SURVIVAL IN THE
NETHERLANDS, 1989-2015
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Background: PCNSL is a rare, aggressive form of an extranodal non-Hodgkin
lymphoma that exclusively affects the CNS. Recent findings from the few avail-
able prospective studies demonstrated improved outcome in PCNSL. However,
the results from such studies are inherent to patient selection. Population-based
studies that assess long-term patterns of incidence, treatment and survival in
PCNSL are virtually lacking.
Aims: The aim of this comprehensive nationwide population-based study was
to assess trends in incidence, primary treatment and survival among adult
PCNSL patients (pts) diagnosed during a 27-year period in the Netherlands.
Methods: We selected all adult (≥18 years) pts diagnosed with PCNSL of the
diffuse large B-cell type in the Netherlands between 1989-2015 from the nation-
wide Netherlands Cancer Registry with survival follow-up through February,
2016. Pts diagnosed without pathological or cytological confirmation (n=50)
and pts diagnosed at autopsy were excluded (n=32). Age-standardized inci-
dence rates (ASR) were calculated per 1,000,000 person-years and standard-
ized according to the European standard population. Data on primary treatment
(i.e. no therapy, chemotherapy (CT) alone, radiotherapy (RT) alone, and
CT+RT) were available for individual pts. Pts were categorized into 4 periods
(1989-1994, 1995-2000, 2001-2007 and 2008-2014) and 3 age groups (18-60,
61-70 and >70 years). We calculated relative survival (RS) and the relative
excess risk of mortality as measures of disease-specific survival.
Results: We included a total of 1,673 newly diagnosed PCNSL pts in the study
(median age, 65 years; age range, 19-89 years; 53% males). The ASR of PCNSL
increased from 3.0 in the first period (1989-1995) to 4.4 in the last period (2009-
2015), which was consistently higher among males than in females throughout
the entire study (4.8 v 4.0 in the last period). The age-specific incidence rates
were 2.3, 9.0 and 10.0 in the first period for the three age groups (18-60, 61-70
and >70 years), as compared with 2.7, 18.7 and 19.5 in the last period. The appli-
cation of CT+RT increased exclusively among pts age 18-60. More specifically,
the proportions for the three age groups were 26, 18 and 4% in the first period,
as compared with 60, 10 and 4% in the last period. The use of RT alone among
pts age >60 decreased with each period, following the wider use of CT alone
over time, especially for pts age 61-70 years. The proportions of CT alone for the
three  age groups were 11, 8 and 2% in the first period, as compared with 31, 64
and 32% in the last period. Of note, 38 and 26% of pts age >70 received no ther-
apy and RT alone in the last period, respectively. Five-year RS only improved for
pts age 18-70 (Figure 1). Five-year RS (95% confidence intervals) was 22%
(16%>30%), 13% (7%>22%), and 3% (1%>10%) in the first period for the three
age groups, as compared with 56% (47%>64%), 35% (28%>43%) and 6%
(2%>13%) in the last period. A multivariable survival model confirmed the adverse
effect of older age on excess mortality and an improvement of survival over time.
However, when information on treatment was added to that model, the effect of
period lost statistical significance. This suggest that treatment contributed to the
improved survival over time. Older age remained a predictor of poor prognosis.
Figure 1.
Summary/Conclusions: The incidence of PCNSL steadily increases among
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pts >60 years, which might in part be related to improved diagnostic practices
among the elderly over time. RS increased over the past decades for pts age
70 or below. This is largely explained by the increased use of intensive therapy
over time. Although the use of CT alone gradually increased among pts >70
years, their survival is still poor. Therefore, there is an urgent need to design
specific trials for elderly PCNSL pts to improve their survival.
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CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF
TREATMENT OF DIFFUSE LARGE HEPATITIS C - ASSOCIATED
NON-HODGKIN LYMPHOMA (DLBCL+C)
S. Lepkov1,*, I. Subortseva2, G. Tumyan3, P. Zejnalova3, O. Kolomejtsev3,
Y. Ryabukhina 3, A. Semenova3, N. Kokosadze3, N. Kupryshina3, I. Komarov3,
O. Malikhova3, S. Borisovskaya1, O. Ettinger1, I. Lazarev4, V. Ivanova4,
R. Ivashhenko5, A. Kovrigina2, I. Nikitin1, Y. Kemizh6
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Background: In the WHO classification (2008), hepatitis C virus distinguish
as one of the etiological factors of multistage etiopathogenesis DLBCL.
Aims: The purpose of this study  was evaluation of clinical features and results
of treatment of diffuse krepnokletochnoy lymphoma associated with hepatitis
C in comparison with a control group of patients with diffuse large lymphoma
without viral hepatitis markers.
Methods: It was included 521 patients with DLBCL: 98 patients with DLBCL
and markers of hepatitis C (DLBCL+C) and a control group of 422 patients
with DLBCL without markers of hepatitis C (DLBCL-C).
Results: Patient’s age ranged from 21 to 76 years (median was 47 years) in DLB-
CL+C; ranged from 23 to 81 years (median 61) in DLBCL -C (p=0.02). The male:
female ratio was 1: 1.3 in patients with DLBCL +C; 1: 1.7 in the group DLBCL – C.
Stage I and II were in 11%  patients with DLBCL+C, and 48% patients with DLBCL
- C; III and stage IV were detected in 89% patients with DLBCL+C and 52% of
DLBCL-C (p=0.00002). Extranodal lesions detected in 72% in DLBCL+ C and in
26% in C DLBCL-C (p=0.006). In comparable groups localization of extranodal
lesions was: spleen (52% to 23%), bone marrow involvement (43% and 27%),
liver (18% and 1%). GCB / non-GCB histological variants ratio was 55% / 45% in
DLBCL+C; 36% / 64% in DLBCL -C ratio GCB / (p=0.001). Hepatitis C virus RNA
in blood was detected by PCR. Viral RNA  was found in 78% (74 patients). High
viral load was in 21% of patients. In 22% of cases markers of hepatitis C virus in
blood were identified by ELISA. All patients received chemotherapy according to
the scheme CHOP / R-CHOP. The frequency of complete remission was 60% in
the group of patients with DLBCL+C and 63% of DLBCL-C. Median overall survival
(OS) was 46 months in group DLBCL +C  and 71 months in DLBCL -C (p=0.0003).
Median progression-free survival (PFS) was 28 months in DLBCL+C 47 months
in the control group (p=0.0002). According to the immunohistochemical variant of
DLBCL: GCB DLBCL: median OS of 45 months in GCB DLBCL+C and 62 months
in GCB DLBCL - C (p=0.002). Median PFS was 36 and 47 months in comparable
group. Median OS was  18 months in non-GCB DLBCL+C and 70 months in non-
GCB DLBCL-C (p=0.00001). Median PFS groups was 13 and 42 months, respec-
tively. 58 patients received antiviral therapy after chemotherapy. Median OS was
63 months in GCB DLBCL+C with antiviral therapy and 28 months in GCB DLB-
CL+C without antiviral therapy (p=0.00002). Median PFS was 46 and 20 months,
respectively. Median OS was 22 months in non-GCB DLBCL+C with antiviral ther-
apy and 17 months in non-GCB DLBCL+C without antiviral therapy. Median PFS
in the group was 11 and 15 months, respectively.
Summary/Conclusions: DLBCL+C characterized by aggressive course of the
disease (younger age at onset of the disease, advanced stages, extranodal
involvement), which is one more evidence possibility of separating DLBCL+C
in a separate group. Although there is no difference in the effectiveness of the
therapy. But  disease-free survival in DLBCL patients+C was significantly worse.
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MAGNETIC RESONANCE IMAGING FOR EARLY DETECTION OF
ANTHRACYCLINE CARDIOTOXICITY IN MALIGNANT LYMPHOMA
A.H. Laursen1,*, J.J. Thune2, M.B. Elming3, P. Hasbak4, R.S. Ripa4,
M. Hutchings1
1Department of Haematology, Rigshospitalet, 2Department of Cardiology ,
Bipebjerg and Frederiksberg Hospital, 3Department of Cardiology, 4Department
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Background: Doxorubicin is a cornerstone of curative lymphoma treatment.
However, doxorubicin therapy is limited by cardiac side effects including high-
mortality heart failure (HF). Signs of cardiotoxicity often appear too late to avoid
irreversible myocardial damage. 
Aims: The aim of our study is to investigate the value of rubidium 82 positron
emission tomography (82Rb PET), iodine 123 metaiodobenzylguanidine (123I
MIBG) and cardiac magnetic resonance (MR) imaging in early detection of dox-
orubicin-induced cardiomyopathy and prediction of HF in patients with malignant
lymphoma. We aim to identify early signs of cardiotoxic injury that predict the for-
mation of interstitial fibrosis and subsequent HF. Here we present our preliminary
MR data. 82Rb PET and 123I MIBG data will be analysed later.
Methods: The study is a prospective, clinical, single-centre study. The study
aims to include 70 consecutive chemotherapy-naive lymphoma patients sched-
uled for intended curative chemotherapy without planned mediastinal radiation
therapy. All patients undergo routine clinical examinations, but with supple-
mentary imaging, including 1) baseline 82Rb PET and MR (prior to treatment);
2) acute 82Rb PET and MR (within 1 week of the first treatment); 3) subacute
123I-MIBG (after 2-3 months of therapy) and 4) late MR (1 year after the start
of treatment). 82Rb PET imaging is performed at rest and during pharmaco-
logical stress testing with adenosine. It is primarily used to evaluate the acute
effects of doxorubicin on myocardial perfusion. 123I MIBG is used for detection
of doxorubicin-induced subacute changes in the myocardial adrenergic neu-
rons. Cardiac MR is performed with late gadolinium enhancement and provides
information on acute and late changes in left and right ventricular function,
atrial and ventricular volumes, myocardial mass and interstitial fibrosis. Statis-
tical analyses were done in R (version 3.2.0) as paired difference tests using
Wilcoxon signed rank test. P-values <0.05 were considered significant. 
Results: As of March 1st 2017, 61 patients have been included. In 33 cases,
the time of intended follow-up has been reached. Four patients died prior to
follow-up, including one patient who died before the acute imaging procedures.
Four patients were excluded due to compliance problems. One patient was
excluded due to disease downstaging resulting in omittance of doxorubicin
from the treatment plan. Of the 24 patients with complete data from both the
baseline and late MR scans, 16 had lower LVEF values at follow-up: 0-5%
(n=3), 6-10% (n=8), 10-15% (n=4) and >20% (n=1). Mean LVEF at follow-up
was significantly lower (57.1%) compared to baseline LVEF (62.0%; p=0.01)
and acute LVEF (64.3%; p=0.002). The LVEF decline from baseline to follow-
up was paralleled by an increase in mean left ventricular end diastolic volume
(LVEDV) of 10.0mL (p=0.03). Interestingly, an increase in LVEDV was already
registered at the acute MR scan (7.3mL; p=0.03). The increase in LVEDV from
the acute MR to follow-up was not significant. We also registered an acute
increase of 7.4mL in mean stroke volume (SV) (p=0.02). However, from the
acute MR to follow-up MR we found a significant decline in SV (p=0.02). There
was no difference in SV from baseline to follow-up (p=0.7). The acute changes
in LVEDV did not predict LVEF declines from baseline to follow-up (Figure 1).
Figure 1.
Summary/Conclusions: Our preliminary show that cardiac MR can be used
for detection of declining LV function 1 year after after doxorubicin exposure.
It appears that cardiac MR may also provide information on acute functional
changes in LVEDV and SV. We hope that our 82 Rb PET and 123I MIBG data
will provide additional early signs of doxorubicin cardiotoxicity that can be used
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Background: The use of surveillance computed tomography (CT) is usual
practice for cases of complete remission (CR) in aggressive non-Hodgkin lym-
phoma (aNHL). However, there is a lack of evidence to support this strategy. 
Aims: To determine whether surveillance CT could contribute to the improve-
ment of survival in relapsed aNHL patients, we retrospectively analyzed our
institutional lymphoma registry, which enrolled consecutive patients with lym-
phoma from June 1995 to October 2016. Of 1,385 aNHL patients in the registry,
664 patients achieved CR and received follow-up through clinical visits, with or
without surveillance CT. 
Methods: Patients who met the following inclusion criteria were selected: i) his-
tologic diagnosis of aNHL (diffuse large B-cell lymphoma, Burkitt lymphoma, and
B-cell lymphoblastic lymphoma, peripheral T-cell lymphoma not otherwise spec-
ified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, NK/T-
cell lymphoma, and T-cell lymphoblastic lymphoma); ii) patients who achieved
CR after frontline or salvage chemotherapy with curative intent; and iii) time from
the date of diagnosis to the date of last follow-up longer than 12 months. All
patients in CR after frontline therapy were followed-up with clinical visits (symptom
assessment, physical examination, and blood tests) every 1 to 6 months. Sur-
veillance CT covering the neck, chest, or abdomen were performed every 3 or 6
months or when clinically indicated in the first 2 years, and then every 6 or 12
months or when clinically indicated thereafter. The decisions regarding the sur-
veillance strategy (clinical visit with appropriate blood chemistry with or without
regular surveillance CT) were at the discretion of the treating physicians.
Results: Relapse was detected in 171 patients, of whom 152 had undergone
surveillance CT during follow-up. Of these 152 patients, asymptomatic relapse
was detected in 67 (44%) by surveillance CT and symptomatic relapse outside
the surveillance interval was detected in the other 85 (56%). Detection of
asymptomatic relapse by surveillance CT did not improve either the overall or
post-relapse survival in the relapsed aNHL patients. In addition, the interval of
surveillance CT (3 or 6 months) did not affect survival. No subgroups were
identified that favored the use of surveillance CT to detect relapse. Additionally,
we analyzed the impact of surveillance CT in patients with refractory or relapsed
aNHL who achieved CR after salvage chemotherapy (CR2). Of 315 aNHL
patients relapsed/refractory to frontline chemotherapy (144 refractory and 171
relapsed patients), 99 patients achieved CR after salvage chemotherapy (18
refractory and 81 relapsed patients) and these patients were followed with clin-
ical visits, with or without surveillance CT. Relapse was detected in 42 patients
(42/99; 42.4%). A total of 27 (64.3%) and 15 patients (35.7%) were identified
as relapsed by methods other than CT scan and using surveillance CT, respec-
tively. There was no significant difference in the median PRS between the two
groups (12.5 months, 95% CI: 2.8 to 22.1 months vs 10.7 months, 95% CI: 0
to 41.5 months; p=0.182] (Table 1).
Summary/Conclusions: In conclusion, this study suggests that routine sur-
veillance CT in aNHL patients for the detection of asymptomatic relapse might
have a limited role in improving survival. Therefore, surveillance CT to identify
relapse would only be recommended when relapse is clinically suspected.
Table 1.
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A MULTI-CENTER STUDY OF GLIDE CHEMOTHERAPY CONSOLIDATED
WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY
DIAGNOSED STAGE IV AND RELAPSED EXTRANODAL NATURAL
KILLER/T-CELL LYMPHOMA PATIENTS
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Background: The prognosis of advanced-stage and relapsed extranodal NK/T
cell lymphoma(ENKTL) is poor, with long term survival rate of 30%. Our previ-
ous study of GLIDE (gemcitabine, L-asparaginase, ifosfamide, dexamethasone
and etoposide) chemotherapy reported complete response(CR) rate and 3-
year overall survival(OS) of these patients were 57.1% and 56% respectively.
We assumed autologous stem cell transplantation may further improve the
prognosis of these patients.
Aims: We conducted this clinical trial to address the efficacy and safety of our
treatment strategy, GLIDE induction followed by ASCT, in newly diagnosed
stage IV and relapsed ENKTL.
Methods: We treated 60 patients with newly diagnosed stage IV(n=49) and
relapsed(n=11) ENKTL from 2010 to 2016. The median age at recruitment was
38 years and the median follow-up period was 13.4 months. Patients were
treated with GLIDE (gemcitabine 800 mg/m2D1,5; L-asparaginase 6000
u/m2D4,6,8,10,12 or peg-asparaginase 2500 u/m2D4,11; ifosfamide 1000
mg/m2D1-3; dexamethasone 20mg D1-4; etoposide 100 mg/m2D1-3) every 4
weeks, and responses were evaluated with PET/CT every 2 cycles. Patients
achieving CR underwent ASCT or continued with GLIDE up to 6 cycles. Others
finished 6 cycles of GLIDE. Overall response rate(ORR), CR, OS and progres-
sion free survival(PFS) were calculated using standard methods. Statistical
analysis was done using Fishers exact test or Chi-square test / Kruskal-Wallis
test. Kaplan-Meier method was used for time-to-event analysis including overall
survival and progression free survival. The Log-rank test was used to evaluate
the difference in time-to-event endpoints between patient groups.
Results: Fifty-seven patients had finished planed treatment with 1 withdraw of
informed consent after cycle 1, and 2 death of sepsis during cycle 1 and cycle
2 respectively. Twenty-one patients underwent ASCT. The ORR was 81.4%
and the CR was 69.5% with early CR (CR after 2 cycles) of 57.6%. Estimated
5-year OS and PFS rates of the whole cohort and patients underwent ASCT
were 68.7%, 54.0%, 79.6% and 85.2% respectively. Univariate analysis
revealed that ECOG ≤1, IPI≤2, early CR and ASCT were associated with less
relapse and death. Multivariate analysis showed ECOG ≥2 was an independent
risk factor for disease progression (HR=4.321, 95% CI 1.127~16.572, P=0.033)
and death (HR=46.254, 2.150~993.190, P=0.014) and ASCT was associated
with better PFS (HR=0.058, 95% CI 0.007~0.495, P=0.009) and OS
(HR=0.019,95% CI 0.001~0.596, P=0.024).  Figure 1 highlights the OS and
PFS of whole cohort (A) and ASCT patients (B). Myelosuppression was the
most common adverse reaction(AE). The incidences of level 4 neutropenia,
thrombocytopenia and anemia were 46.6%, 28.6% and 5.3% respectively. The
most common non-hematologic AE was fever with neutropenia (36.5% of total
cycles), while others were mild and manageable.
Figure 1.
Summary/Conclusions: GLIDE is an effective regiment for newly diagnosed
stage IV and relapsed ENKTL. Up-front ASCT after achieving CR can reduce
relapse and prolong survival. Treatment related adverse reactions and support
care need concerns.
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Background: Despite improvement in the outcome for some subtypes of lym-
phoma, the prognosis of patients with peripheral T-cell lymphoma (PTCL)
remains unsatisfactory. The recent data on dose-dense intensified cyclophos-
phamide, doxorubicine, vincristine and prednisone (CHOP) with addition of
etoposide followed by autologous stem cell transplantation (ASCT) are encour-
aging. After achieving very promising results with in enteropathy associated T-
cell lymphomas (EATL), we prospectively evaluated the alternative approach
with more intensive treatment with ifosfamide, etoposide, epirubicin / methotrex-
ate and ASCT (IVE/MTX–ASCT) in patients with other subtypes of PTCL.
Aims: To asses the long-term follow-up results of first line high-dose therapy
IVE/MTX–ASCT in patients with PTCL.
Methods: The regimen was piloted for patients with a de-novo diagnosis of
PTCL eligible for intensive treatment. The therapy delivers one cycle of CHOP,
followed by 3 courses of IVE alternating with intermediate dose MTX. Stem
cells are harvested after IVE and complete and partial remissions were con-
solidated with ASCT. The patients were evaluated with an intention-to-treat
analysis for feasibility, response, progression free survival (PFS) and overall
survival (OS) and late events.
Results: 30 patients were included: 17 peripheral T-cell lymphoma NOS, 6
anaplastic large cell lymphoma (ALCL) ALK positive, 4 extranodal NK/T-cell
lymphoma nasal type, 2 ALCL ALK negative and 1 hepatosplenic T-cell lym-
phoma. The median age at diagnosis was 42 years (range 22 – 64), 37%
patients were female, 28% presented with ECOG >1 and 57% with advanced
stage disease. The age adjusted IPI was calculated for 22 patients with primary
nodal disease and 41% of patients were in high intermediate and high risk.
Three patients discontinued treatment prematurely due to disease progression
and one due to poor general condition. Of the remaining 26 patients 19 went
on to receive ASCT. ASCT was omitted due to: insufficient stem cell mobilisation
in 4 patients, refractory disease in 2 and poor general condition in one. Toxicity
was acceptable for such an intensive regimen. At final evaluation, complete
remission (CR) was confirmed in 23/30 (77%) patients and partial remission
(PR) in 2/30 (7%) patients. When the patients with ALCL ALK positive were
excluded, the remission rates remained the same: CR 18/24 (75%) and PR
2/24 (8%); p>.999. During the study time 13/30 (43%) patients died, 11 due to
lymphoma. For all patients 5-years PFS was 57% and OS 63%. These results
were unchanged after the exclusion of ALCL ALK positive: 50% and 58%;
p=.587 and p=.70; respectively. The 5-year PFS and OS of histological sub-
groups were as follows: ALCL, ALK positive: both 83%, PTCL NOS: 47% and
53%, ALCL, ALK negative: 0% and 50%, extranodal NK/T-cell lymphoma, nasal
type: both 100% and for hepatosplenic T-cell lymphoma: both 0%. During the
median follow-up time of 6.35 years, 13 patients had a relapse of underlying
disease, six of them had received no treatment and died shortly after the diag-
nosed of relapse, further six received systemic chemotherapy and in one patient
no information on relapse treatment was available. Among the six patients
treated with systemic chemotherapy four received curative treatment including
high-dose chemotherapy with allogenic stem transplant (alloSCT) in three
patients and two received palliative treatment. Only two patients who received
dexamethasone, high-dose cytarabine and cisplatin (DHAP) followed with
alloSCT achieved a long lasting remission. Seven years post IVE/MTX-ASCT
one patient developed secondary malignancy ALM/MDS and died shortly after
the diagnosis.
Summary/Conclusions: IVE/MTX-ASCT significantly improves outcome in
patients with PTCL, and has acceptable toxicities. Where feasible patients with
PTCL could be considered for aggressive treatments, like IVE/MTX–ASCT as
primary therapy, further studies are required.
Bone marrow failure syndromes incl. PNH - Biology
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IDENTIFICATION OF A NOVEL GERMLINE MECOM / EVI1 VARIANT THAT
RUNS IN A PEDIGREE WITH RADIOULNAR SYNOSTOSIS AND
AMEGAKARYOCYTIC THROMBOCYTOPENIA AND PREDISPOSES TO
ADULT ONSET MYELOID MALIGNANCY
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Background: Radioulnar synostosis and amegakaryocytic thrombocytopenia
(RUSAT), one of the rare bone marrow failure syndromes, is caused by a
point mutation in HOXA11. In three simplex patients, de novo missense vari-
ants in MECOM have recently been reported as an alternative cause in indi-
viduals with RUSAT. MECOM, identified as a common ecotropic viral inte-
gration site 1 (EVI1) in murine myeloid leukemia, is known as a key tran-
scriptional regulator in hematopoiesis and is frequently involved in sporadic
myeloid leukemia.
Aims: To screen for the causative genetic alteration in a family with four affected
individuals out of three generations with radioulnar synostosis, incompletely
penetrant congenital thrombocytopenia, hearing impairment due to dysplastic
middle ear bones, patellar hypoplasia, and hand and foot dysmorphisms.
Notably, two of four affected individuals in our family developed adult onset
myeloid malignancies (i.e. myelodysplastic syndrome (MDS) with excess blasts
and MDS/myeloproliferative neoplasm-unclassifiable). No HOXA11 mutation
was identified in this family.
Methods: Whole exome sequencing was performed in three affected individuals
using a Nextera Rapid Capture kit and a NextSeq 500 instrument (Illumina,
Munich, Germany). Identified sequence variants were filtered for those that are
(i) called in all three subjects, (ii) predicted to be damaging (SIFT, Polyphen, and
MetaLR), (iii) reported to have an allele frequency of ≤0.1% (1000G, ESP6500,
ExAc), and (iv) not listed in our in-house database of recurrent variants.
Results: Following this approach, a novel MECOM missense variant (i.e.
Cys766Gly, UniProtKB Q03112-1) was identified. The missense mutation
affects a heavily conserved cysteine residue in C2H2-zinc finger motif 9 in the
C-terminal zinc finger domain of MECOM. This residue is crucial for the tetra-
hedral coordination of a zinc ion stabilizing the zinc finger conformation and
thus, is essential for DNA binding of the C-terminal zinc finger domain.
Summary/Conclusions: Our findings confirm the causality of MECOM mis-
sense mutations targeting the C-terminal zinc finger domain in subjects with
RUSAT and indicate that MECOM needs to be considered in RUSAT pedigrees
with no HOXA11 mutation. We report here for the first time that MECOM
germline mutations are associated with an increased risk for adult onset
myeloid malignancies. This extends the RUSAT-associated phenotype and
proposes that MECOM germline mutations can cause a genetic predisposition
to adult onset myeloid malignancy.
[BZ and DS contributed equally to this work].
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LOSS OF THE HOMOLOGOUS RECOMBINATION GENE RAD51 LEADS
TO FANCONI ANEMIA-LIKE SYMPTOMS IN ZEBRAFISH
J. Botthof1,2,3,*, E. Bielczyk-Maczyńska1,2,4, L. Ferreira1,2,3, A. Cvejic1,2,3
1Department of Haematology, University of Cambridge, 2Wellcome Trust
Sanger Institute, 3Wellcome Trust-Medical Research Council Cambridge Stem
Cell Institute, University of Cambridge, 4NHS Blood and Transplant, Cambridge,
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Background: Fanconi anemia (FA) is a hereditary DNA repair disorder charac-
terized by various congenital abnormalities, progressive bone marrow failure and
cancer predisposition. RAD51 has recently been designated as a Fanconi anemia
(FA) gene, following the discovery of two patients carrying dominant negative
mutations. RAD51 is an indispensable homologous recombination protein, nec-
essary for strand invasion and crossing over. It has been extensively studied in
prokaryotes and lower eukaryotes. However, there is a significant lack of knowl-
edge of the role of this protein and its regulation in an in-vivo context in vertebrates
due to the early embryonic lethality of murine Rad51 mutants.
Aims: Here we aim to utilize the powerful genetics and translucency of
zebrafish to dissect the role of rad51 in hematopoiesis and to explore the molec-
ular basis of Fanconi anemia pathogenesis.
Methods: Zebrafish carrying homozygous loss of function mutations in rad51
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generated by ENU mutagenesis were characterized in terms of their hematopoi-
etic and non-hematopoietic phenotypes during embryonic development and
adulthood. 
Results: The rad51 mutant fish developed key features of FA, including hypocel-
lular kidney marrow (equivalent to mammalian bone marrow), sensitivity to
crosslinking agents and decreased size. Interestingly, although mutants can sur-
vive to adulthood, they develop exclusively as sterile males. We show that some
of the hematological symptoms stem from both decreased proliferation and
increased apoptosis of embryonic hematopoietic stem and progenitor cells. Co-
mutation of p53 was able to rescue the embryonic and adult hematopoietic defects
seen in the single mutants, but led to early tumor development in the adult double
mutants. We further establish that prolonged inflammatory stress can exacerbate
the hematological impairment, leading to an additional decrease in kidney marrow
cell numbers linked to excess p53 expression (Figure 1).
Figure 1. Example image of a p53, rad51 double mutant fish with a tumor
 behind the eye (A). Histological analysis showed the tumour to be a malig-
nant peripheral nerve sheath tumor (B). The scale bar is 500 and 10µm
respectively.
Summary/Conclusions: We demonstrate that zebrafish lacking functional
rad51 are viable and develop symptoms resembling FA. These findings
strengthen the assignment of RAD51 as a Fanconi gene and provide more evi-
dence for the notion that aberrant p53 signaling during embryogenesis leads
to the hematological defects seen during later stages of life in FA patients. Fur-
ther research on this novel zebrafish FA model will lead to a deeper under-
standing of the molecular basis of bone marrow failure in FA and the cellular
role of the RAD51 protein.
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MACROCYTOSIS AND MILD VARIABLE CYTOPENIAS
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Background: Telomerase RNA component (TERC), encoded by the TERC gene,
is an essential component of telomerase, a polymerase that adds the telomeric
repeat to the 3’ lagging strand of DNA during cell replication. TERC variants have
been causally associated with several haematological disorders, including auto-
somal dominant dyskeratosis congenita (DKC), aplastic anaemia, myelodysplas-
tic syndrome and acute leukaemia, sometimes accompanied by non-haemato-
logical phenotypes. Here we report a likely pathogenic TERC variant associated
with a haematological phenotype that predominantly affects the red cell lineage.
Aims: To describe the genotypic and phenotypic relationship of a new TERC
variant.
Methods: Genomic DNA samples were analysed for sequence variants using
the Oxford Red Cell Panel, a panel of 33 genes previously associated with
human red cell disorders. Sanger sequencing was used to confirm the genetic
variant. Telomere lengths were performed at the Laboratory for Molecular
Haemato-Oncology (LMH), Rayne Institute, Kings College Hospital.
Results: The index case AM (I.1) was a female who presented at age 56 with
fatigue, and was noted to have a longstanding non progressive mild macrocytic
anaemia with very minimal thrombocytopenia. Further investigations (Table 1)
revealed normal reticulocyte count, LDH, haematinics, thyroid function, liver and
renal function. Bone marrow aspirate demonstrated abnormal erythropoiesis
with nucleo-cytoplasmic asynchrony, nuclear atypia, ragged cytoplasm,
basophilic stippling and bi-nucleate forms. Granulopoiesis and megakaryopoiesis
were normal. The two daughters of I.1 also had abnormal blood counts and her
paternal grandfather died of “pernicious anaemia”. None of the family have
somatic features associated with DKC. The elder daughter (age 30) TW (II.1),
had isolated lifelong macrocytosis and previous mild neutropenia (Table 1). The
younger daughter (age 27) BM (II.2) had macrocytic anaemia, thrombocytopenia
(Table 1) and a recent pregnancy complicated by worsening thrombocytopenia,
pre-eclampsia, placental dysfunction, liver dysfunction and foetal loss. Following
delivery her liver function slowly returned to normal and a fibroscan was within
normal limits. All three pedigree members with macrocytosis had a
Chr3:169482668 (GRChr37) single nucleotide variant corresponding to a
n.181A>C substitution in TERC (relative to transcript ENST00000602385.1),
within the pseudoknot domain. Residue n.181 is highly conserved across mam-
malian species. This variant is absent from the gnomAD database of more than
230,000 TERC alleles, and the HGMD databases. The variant is within a TERC
region in which previously reported variants have been associated with haema-
tological phenotypes. In order to determine the pathogenicity of this variant,
telomere lengths were assessed and found to be short in both Case I.1 and II.2
(Table 1). There were no other likely pathogenic variants in the Oxford Red Cell
Panel genes. Together, these observations suggest that the n.181A>C substi-
tution is causally associated with the macrocytosis phenotype.
Table 1.
Summary/Conclusions: This report demonstrates a likely causal association
between a newly identified TERC variant, short telomere length and a relatively
mild haematological phenotype that is largely restricted to red cells. This empha-
sises the phenotypic heterogeneity associated with TERC variants, justifies the
rationale of screening multiple genes simultaneously and suggests that TERC
variant could potentially underlie a broader range of unexplained heritable blood
cell abnormalities.
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GENERATION OF X-LINKED DYSKERATOSIS CONGENITA-LIKE HUMAN
HEMATOPOIETIC STEM CELLS
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Background: X-linked Dyskeratosis congenita (X-DC) is an inherited syndrome
caused by mutations in the DKC1 gene that encodes for the dyskerin nucleolar
protein. These mutations reduce the telomerase activity leading to premature
telomere length attrition. Several organs can be affected in these patients, although
the bone marrow failure (BMF) is the main cause of death in X-DC patients (more
than 70% of cases). So far, the only curative treatment for BMF in DC patients is
hematopoietic stem cell (HSC) transplantation. However, risks derived from con-
ditioning regimes and the difficulties to find a compatible donor suggest that gene
therapy may constitute a promising alternative in treating DC patients.
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Aims: Because of the difficulties associated to the use of primary HSCs from DC
patients for experimental studies, this study was focused on the generation of X-
DC-like human HSCs by means of the down-regulated expression of dyskerin in
cord blood HSCs using different anti-DKC1 short hairpin RNAs (shRNA).
Methods: CD34+ cells were obtained by immunomagnetic purification from
healthy human umbilical cord blood samples. These cells were then pre-stim-
ulated and exposed to two cycles of transduction with lentiviral vectors carrying
both an anti-DKC1 shRNA and the puromycin-resistance gene. Transduced
samples were then selected for 2 days with puromycin, and cultured in vitro or
transplanted into immunodeficient NSG mice to evaluate the effects of shRNAs.
Results: Based on the inhibition of DKC1 gene expression, 3 shRNAs were
selected among 7 designed shRNAs. Interfered HSCs showed an inhibited
telomerase activity, as well as a reduced clonogenic and hematopoietic recon-
stitution potential in NSG mice. Additionally, an increase in DNA damage and
senescence was observed in DKC1-interferred CD34+ cells.
Summary/Conclusions: In vitro and in vivo data obtained from DKC1-inter-
ferred CD34+ cells show that these cells mimic the phenotype of primary X-
DC-HSCs. The generation of X-DC-like HSCs will facilitate the understanding
of the molecular basis of the HSC defects characteristic of X-DC and contribute
to the development of new experimental therapies for the treatment of the BMF
of X-DC patients.
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Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a disease char-
acterized by complement-mediated hemolysis (Brodsky et al. Hematology, 2008).
Complement can induce the production of extracellular vesicles (EV) (Burnouf
et al. Transfus Apher Sci, 2015). These EV are cell-derived vesicles whose the
size-range is around 50 and 1000nm. They can expose phosphatidylserine (PS-
anionic phospholipid) and tissue factor (TF), which explains their involvement in
the coagulation cascade (Owens et al. Circ Res, 2011). The EV could have a
role in the thrombus formation, the leading cause of death in PNH patients (Brod-
sky et al. Hematology, 2008; Simak et al. Br J Haematol, 2004; Hugel et al. Blood,
1999). Eculizumab, a human anti-C5 monoclonal antibody, used in the treatment
of PNH seems to decrease the thrombosis frequency (relative reduction of 85%
of thromboembolism event rate with the introduction of the treatment in the
patients) (Hillmen et al. Blood, 2007; Kelly et al. Ther Clin Risk Manag, 2009;
Weitz et al. Thromb Res, 2012; Al-Jafar et al. Hemato Rep, 2015).
Aims: The general purpose of this project is a better understanding about the
role of EVs in thrombosis in the context of PNH patients under eculizumab.
We assessed the impact of eculizumab on the EV quantification and on their
procoagulant activity, in order to check, if the antithrombotic activity of the
eculizumab could be in part explained by its interaction with the EVs. 
Methods: We conducted a pilot prospective open label longitudinal clinical study
with six PNH patients treated with eculizumab. The study was led according to
the declaration of Helsinki and approved by the local Ethic Committee. Informed
consent was obtained for each patient. The aim was to measure, by flow cytom-
etry, the production of EVs in patient’s platelet-free plasma (PFP) before the start
of eculizumab, after 4 weeks and after 11 weeks of treatment.  We also assessed
the procoagulant activity in PFP by STA®-Procoag-PPL assay and by thrombin
generation assay (TGA). A more sensitive version of TGA was also performed to
study the procoagulant profile induced by the EVs (use of EVs pelleted from
PFP). We used mixed-effects linear regression (R 3.1.2 with nlme package) with
logarithmic transformation for flow cytometry results. We compared the results
after 4 weeks or 11 weeks of treatment against the inclusion value.
Results: We observed a decrease in platelet EVs with the eculizumab treatment
(p<0.05). STA®-Procoag-PPL assay showed a decrease of the procoagulant
profile induced by procoagulant phospholipids (PL) with the treatment. These
results were not confirmed by TGA on PFP, due to a lack of sensitivity. By this
way, we performed a more sensitive version of TGA that allows to observe vari-
ation in the procoagulant profile induced by the EV with the eculizumab (p<0.05).
Summary/Conclusions: Eculizumab has an impact on the amount and the pro-
coagulant profile induced by the procoagulant PL and the EVs. The anti-thrombotic
performance of the eculizumab can be in part explained by its action on EVs.
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Background: Classical Dyskeratosis Congenita (DKC) is a multisystem disorder
caused by defective telomere maintenance, mostly due to mutations in genes
related to functional activity of telomerase or accessibility of the telomeres them-
selves. Clinical characteristics are mucocutaneous abnormalities, bone marrow
failure, an increased predisposition to cancer and other variable features. While
classical DKC is typically diagnosed in childhood or adolescence, the incidence of
cryptic DKC variants typically presenting with a clinically more heterogeneous pic-
ture also involving the liver, gut and respiratory system in adults up to 50 years of
age is unknown. Accelerated shortening of Telomere length (TL) in peripheral
blood leucocytes represents the functional read-out of altered telomere mainte-
nance and thus allows for a screening of patients with suspected DKC. On the
basis of TL measured below the 1% percentile of age adjusted healthy controls,
next-generation-sequencing (NGS) analysis for underlying mutations was trig-
gered.
Aims: In this study, we report the first results of such a clinical routine screening
for telomeropathies carried out within the Aachen Telomeropathy Registry (ATR).
Methods: 184 patients from 52 participating centers (80% academic centers)
within Germany, Austria and Switzerland were screened for premature telomere
shortening and included with informed consent into the ATR since November
2014. Inclusion criteria and reason for screening was either the clinical suspi-
cion of the treating physician for a telomere maintenance disorder and/or the
recommendations of the German Society of Hematology and Oncology
(DGHO) published via Onkopedia. TL analysis of peripheral blood granulocytes
and lymphocytes was carried out using combined fluorescence in situ hybridiza-
tion and flow cytometry (flow-FISH). Mutations in genes suspected to cause
telomeropathies (i.e. TERT, TERC, DKC1, NOP10, NHP2, USB1, CTC1,
RTEL1, TIN2, TCAB1) were analyzed by NGS using customized primer panels
and amplicon-based sequencing on a Miseq sequencer (Illumina) in all patients
with TL in lymphocytes below the 1% percentile of healthy controls.
Results: Underlying initial diagnosis by the treating physician leading to TL
screening were aplastic anemia (AA, n=72, 39% of cases), unexplained cytope-
nias (UC, n=21, 11%), myelodysplastic syndrome (MDS, n=18, 10%), family
members (FM) of known DKC patients (FM-DKC, n=17, 9%), atypical squa-
mous cell cancer of the head-and-neck (SCCHN, n=10, 6%), paroxysmal noc-
turnal hemoglobinuria (PNH, n=9, 5%), acute myeloid leukemia (AML, n=5,
3%) as well as other disorders (e.g. lung fibrosis, Diamond-Blackfan-Anemia,
Dubowitz-syndrome, etc., n=32, 17%). Median age was 41.5 y (range from 0.5
to 88 y). TL screening revealed 20% (38/184) patients with lymphocyte TL and
16% (30/184) of patients with granulocyte TL below the 1% percentile. NGS
screening identified typical mutations associated with altered telomere main-
tenance in 15 out of 38 patients (40%) representing 8,2% of the total patient
population. Median age of patients with mutations was 45.0 y (range 21 to 68
y). Mutations were detected in RTEL1 (n=3), TERC (n=6), TERT (n=3) and
DKC1 (n=3). Mutations were observed in 5% of all AA, 12% of all UC, 50% of
all FM-DKC, 13% of all SCCHN, 20% of all screened AML patients.
Summary/Conclusions: We provide the first analysis of a routine TL screening
program (within the ATR) for clinically suspected telomeropathy in patients up
to the age of 88 y. TL screening is feasible in a routine clinical setting identifying
approximately 20% of all samples to reside below the 1% percentile. Genetic
testing confirmed the diagnosis of cryptic DKC in a variety of initial diagnoses.
This study highlights both the diagnostic value of TL screening for cryptic DKC
as well as its underrated incidence in adults. Proper diagnosis of DKC however
is of utmost importance given its significant individual clinical implications
towards prognosis, treatment and family counseling.
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Background: Mortality following HSCT in SAA pts over the age of 40 is reported
to be in the order of 50%, without taking in to account long term sequelae such
as chronic GvHD, known to be more frequent in older patients. This has prompt-
ed international guidelines to recommend first line immunosuppressive therapy
above 40 years of age. The question is whether this is still true in 2017.
Aims: Assess whether TRM in SAA patients grafted 2010-2015 is reduced, as
compared to the era 2001-2009.
Methods: We used the WPSAA EBMT registry, and identified 748 pts  aged 40
years or more, with acquired SAA, grafted between 2001 and 2015. We divided
pts in 2 transplant eras:2001-2009 (n=327) and 2010-2015 (n=407). In the
more recent period (2010-2015) pts were older (53 vs 49 year, p<0.01), were
more often grafted from alternative donors (ALT) (64% vs 43%, p<0.01), with
a greater use of BM (54% vs 41%, p<0.01), and with a longer interval dx-tx
(317 vs 258 days , p0.01), and more often received a fludarabine containing
regimen (55% vs 42%, p<0.01).
Results: The overall survival 5 year survival of pts grafted in 2001-2009 was
57% , compared with 55% for pts grafted 2010-2015 (p-=0.7). In multivariate
analysis, including the interval diagnosis transplant, patient’s age, donor type,
stem cell source and conditioning regimen, the lack of improved survival in
2010-2015 was confirmed (p=0.3).A very strong age effect was shown both in
univariate and multivariate analysis: survival of pts aged 40-50 years, 51-60
years and >61 years , was respectively 64%, 54%, 41% (p<0.0001) and this
was confirmed in multivariate analysis. The conditioning regimen , also proved
to be a significant predictor, with improved survival for ALT transplants receiving
FLU containing regimens (56% vs 46%, p<0.001). In general pts receiving
either CY200 or a FLU containing regimen , did significantly better than pts
receiving other preparative regimens (58% vs 50%, p=0.02). The use of a
sibling donor (SIB) did not prove to predict survival in multivariate analysis. Pts
receiving Campath in the conditioning , did significantly better than pts not
receiving Campath (65% vs 54% p<0.01); similarly survival of patients with
ATG was superior 59% vs 41% compared to patients not receiving ATG
(p<0.01). When pts receiving either Campath or ATG (n=564) were compared
to patients not receiving either (n=161), the difference in survival was 61% vs
41% (p<0.0001), and this was significant also in multivariate analysis. Com-
bined primary and secondary graft failure was reduced from 16% to 12% in the
two time periods (p=0.02), acute GvHD grade II-IV was reduced from 15% to
11% (p=0.1) and chronic GvHD was also reduced from 32% to 26%
(p=0.04)  Infections remain the leading cause of death in both transplant eras
(18% and 22% respectively), followed by GvHD (5% and 4%) and graft failure
(5% and 2%), whereas PTLD have been reduced from 3% to 0,5% (Figure 1).
Figure 1.
Summary/Conclusions: HSCT in pts with acquired SAA aged 40 and over,
continues to carry a significant risk of TRM also in 2010-2015, ranging from
36% in younger pts (40-50) to 59% in older pts (>60 years). Survival is predicted
in multivariate analysis, by two crucial predictors:patients age and the use of
either Campath or ATG,the latter giving a 20% survival advantage over no Cam-
path /ATG. ALT and SIB donors produce similar survival. This study gives further
support to current guidelines, suggesting first line therapy with ATG+CsA, in
pts over the age of 40.
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CLINICAL AND GENETIC DIVERSITY IN DIAMOND-BLACKFAN ANAEMIA:
AN UPDATE FROM THE UNITED KINGDOM
D. Iskander1,*, C. Miller2, M. Alikian3, Y. Harrington 2, Q. Al-Oqaily1, I. Roberts4,
A. Karadimitris1, J. de la Fuente5
1Centre for Haematology, Imperial College London, 2Department of Paediatrics,
St. Mary’s Hospital, Imperial College Healthcare Trust, 3Imperial Molecular
Pathology Laboratory, Imperial College Healthcare Trust and Academic Health
Sciences Centre, London, 4Department of Paediatrics, Children’s Hospital and
Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford
University and John Radcliffe Hospital, Oxford, 5Department of Paediatrics, St.
Mary’s Hospital, Imperial College Healthcare Trust, London, UK, London, United
Kingdom
Background: Diamond-Blackfan anaemia (DBA) is an inherited bone marrow
failure syndrome (IBMFS) caused by mono-allelic, loss-of-function mutations
in ribosomal protein (RP) genes. DBA is rare and has a wide spectrum of clinical
manifestations, hence the utility of patient registries.
Aims: We evaluated the clinical and genetic spectrum of DBA in a large cohort
of patients in the UK, aiming to identify novel features of the disease.
Methods: We performed a retrospective analysis of data from 103 confirmed
cases of DBA, including 4 multiplex families. All living patients had undergone
at least one assessment at our specialized centre in the last 5 years. Data were
collected from family interviews, patient records and referring clinicians.
Results: The 103 patients with DBA were born in a 48-year period (1967-2015),
i.e., an incidence of 3 per million live births. Demographic and clinical charac-
teristics are shown in Table 1. NGS analysis of 80 RP genes plus GATA-1 iden-
tified pathogenic mutations in 71% of cases and 7 putative novel mutations,
currently undergoing validation. To date, mutation screening of both parents
has been performed in 32 families with DBA. Twenty-five mutations are sporadic
while 7 are autosomal dominant; in 3 of the latter, the parent is a silent ‘carrier’
without anaemia. In one case of an affected child, the causative mutation was
undetected in the peripheral blood of both parents but was present in 7/22
embryos generated for in vitro fertilisation, suggesting germline mosaicism.
80.5% of cases in our cohort presented within the first year of life. For the first
time we report a high rate of perinatal problems in DBA. Prematurity +/-
intrauterine growth restriction (IUGR) occurred in 31/87 (35.6%) of evaluable
patients. Specific abnormalities included: hydrops fetalis (3/87), prematurity
(22/87) and IUGR (16/87). In addition to congenital anomalies classically asso-
ciated with DBA, we identified abnormalities of the spine and axial skeleton in
9.2% of patients. These did not correlate with a particular genotype. Our cohort
exhibited multiple comorbidities, including some not previously reported to be
associated with DBA: herniae (10.7%), neuropsychiatric (17.4%) and gastroin-
testinal (GI) disorders (25.7%). These complications were not associated with
particular treatment regimens. In terms of the natural history of DBA, a lower
proportion of our patients (22%) than previously reported in the literature (40%)
were able to maintain a normal Hb on long-term steroids. Three patients failed
a metoclopramide trial. In total there were 4 incidents of malignancy (MDS, B-
ALL, BCC and cervical intraepithelial neoplasia) in 4 different patients. The
lower incidence in our cohort compared with that reported by the North Amer-
ican DBA registry may be explained by differences in the median ages of the 2
cohorts (12y versus 18y, respectively) and the shorter follow-up of our patients.
Table 1.
Summary/Conclusions: This retrospective analysis of the UK’s DBA cohort
confirmed several findings from other registries but also revealed novel features,
including a high prevalence of i) premature birth and neonatal complications ii)
abnormalities of the axial skeleton and iii) neuropsychiatric disorders. Prospec-
tive longitudinal studies are warranted to better characterise these co-morbidi-
ties and to confirm whether they are intrinsic to DBA or arise as complications
of treatment. Above all, the observed clinical heterogeneity in our cohort high-
lights the need for novel therapies that target the multisystem manifestations
of DBA, not just the anaemia.
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Background: Differential diagnosis between acquired and congenital forms
of Marrow Failure (MF), has always represented a crucial point in the diagnostic
work-up, since genetic forms do require a different therapeutic approach. It is
also known that patients with congenital MF may also show immunodeficiency
that, in some cases, can represent the first/ or revalent sign of the disease and
therefore can be misinterpreted as a Primary Immunodeficiency (PID). On the
other hand, patients with PIDs may also show MF as a result of an immune-
mediated attack of marrow precursors thus generating a phenotypic overlap
that can impair the correct diagnosis.
Aims: In this report we analyzed all patients with MF evaluated in our Unit with
the aim to identify the type and incidence of underlying molecular defects, in
particular those related to PIDs.
Methods: We retrospectively evaluated all diagnosis performed in patients
with single/multi-lineage MF followed in our Unit. DEB test was used to screen
Fanconi Anemia (FA). Other congenital MFs have been searched by Sanger
and/or NGS molecular analysis depending on the available tools over the years.
Results: Between 2009-2016, 88 patients have been studied for single-lineage
(25) or multilieage (63) MF. 48 (54%) were classified as having an acquired
MF, 27 (30%) were diagnosed with a congenital MF (FA 11, Diskeratosis Con-
genita 5, Severe Congenital Neutropenia 6, Blackfan-Diamond Anemia 3, Con-
genital Amegakaryiocitic Thrombocytopenia 2), and the remaining 13 patients
(14%) were found to have an underlying PID. Table 1 shows clinical character-
istics and mutations of patients with PIDs.
Table 1.
Summary/Conclusions: This report shows that patients presenting with sin-
gle/multi-lineage MF may have an underlying PID in a considerable number of
cases. We also show that MF represented the most relevant clinical sign in
patients with PI3KCD, TACI, or CD40L mutations, thus widening their clinical
phenotype. We conclude that an accurate immunological work-up should be
performed in all patients with MF and that PIDs-related genes should be includ-
ed in the molecular screening of MF in order to identify specific disorders that
may potentially receive targeted treatment and/or the appropriate conditioning
regimen for SCT.
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Background: Paroxysmal nocturnal haemoglobinuria (PNH) leads to episodic
haemolysis secondary to an acquired deficiency of PIGA anchor molecules on
the surface of erythrocytes which play a critical role in protecting the cells from
complement mediated lysis. Until the advent of eculizumab, a monoclonal anti-
body which prevents the cleavage of C5 to C5a and C5b, PNH was associated
with considerable morbidity and a poor long-term prognosis. However,
eculizumab needs to be administered by health care professionals by intra-
venous infusion which may interfere with the life-styles, occupations and per-
sonal privacy of patients and the interval dosing has led to concerning break-
through haemolysis. Coversin is a protein suitable for small-volume subcuta-
neous (SC) injection which can be self-administered by patients. 
Aims: The aim of this study is to investigate the safety and efficacy of the com-
plement C5 inhibitor Coversin in the treatment of PNH.
Methods: A Phase 2 single arm open label trial of Coversin is currently ongoing
under which patients, either newly diagnosed with PNH or who have not pre-
viously had access to complement inhibitors, are treated for 90 days. Coversin
is supplied as a lyophilised powder, reconstituted with water for injection to
give a buffered aqueous solution of Coversin 30mg/mL. The trial population
consists of up to 10 adult patients with a diagnosis of PNH confirmed by flow
cytometry. Treatment commences with an ablating regime (AR) consisting of
a fixed dose of 60mg followed by 3 doses of 30mg q12 hours delivered by SC
injection. After being suitably instructed patients are encouraged to self-inject
the drug. Following the AR, a dose of 15mg q12 hours is given for a further 26
days when, if the patient’s disease is well controlled, they switch to 30mg q24
hours for the remainder of the trial. The dose can be increased by two incre-
mental steps according to a pre-specified algorithm for patients not satisfactorily
controlled on the basis of serum lactate dehydrogenase (LDH) or clinical
grounds at any time during the 90-day period. The primary endpoints are safety
and reduction of serum LDH to ≤1.8 X the upper limit of normal (ULN) for the
local laboratory. Secondary endpoints include LDH at 28, 60 and 90 days, ter-
minal complement activity assessed by CH50 ELISA (Quidel®), sheep ery-
throcyte haemolysis assay, PK (free and bound Coversin levels), anti-drug anti-
bodies (ADA) and quality of life.
Results: The trial is still ongoing and has currently enrolled 5 patients, four of
whom remain on Coversin. Three patients have required single dose increases
during the initial 28-day period, one of whom was later withdrawn when a co-
morbidity was suspected. Two patients have moved to a single daily dose.
Updated results of these and any patients enrolled subsequently will be pre-
sented. To date 2 patients have achieved the primary efficacy endpoint, two
have not yet reached the 28-day point. There have been no serious or signifi-
cant adverse events and the drug has been well-tolerated. A few mild injection
site reactions have been recorded but these appear to diminish with time. There
has been no evidence of the formation of neutralising antibodies.
Summary/Conclusions: It currently appears that treatment with Coversin is
safe and effective in controlling hemolysis in PNH and that patients are capable
of self-administering the drug. Coversin may be an effective alternative for
patients with PNH who prefer the independence of self-administration. The rel-
atively short dose interval may also help to reduce breakthrough events due to
trough levels of drugs administered at two weekly intervals or longer.
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GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC
LYMPHOCYTIC LEUKEMIA
G. Tiao1, M. R. Improgo1,2,3, S. Kasar1,2,3, W. Poh1,2,3, A. Kamburov1,
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Background: CLL is a highly heritable cancer.  Although GWAS have identified
~30 independent SNPs associated with CLL, these are estimated to account
for only 19% of the inherited component of CLL.
Aims: We hypothesized that this missing heritability might arise from rare cod-
ing variants (MAF <0.01), and sought to identify these through an exome-wide
association study comparing rare germline variants between CLL patients and
controls.
Methods: We investigated 516 CLL patients of European descent who were
compared to 8,920 ethnically matched, non-cancer population controls. CLL
cohorts included 235 CLL patients from DFCI (128 previously reported, 107
unpublished exomes), and 281 CLL patients enrolled on the CLL8 trial of the
German CLL Study Group (WES data reported previously). An additional 130
CLL patients in an extension cohort included 24 from our published whole-
genome sequencing study and 106 from an early publication of the ICGC. Non-
cancer controls came from 3 sources:  2,520 from the 1000 Genomes Project;
6,852 from the Exome Sequencing Project; and 7,611 from a study of genetic
risk for myocardial infarction. We combined these heterogeneous datasets by: (i)
processing sequencing data from all cohorts together and consistently; (ii) jointly
calling the variants across all cases and controls; and (iii) analyzing only ethnically
matched, unrelated samples over DNA sites with sequencing coverage sufficient
to achieve high-confidence genotype calls. This quality control resulted in 8,920
controls available for the association analysis. We further controlled for residual
population stratification by correcting for three principal components.
Results: Using an unbiased, gene-based rare variant association analysis com-
paring cases to controls, we identified two genes significantly enriched for rare
coding variants in CLL cases: CDK1 and ATM (OR 5.8, C.I.2.6-13.1, p=5.8x10-7
and OR 1.6, C.I. 1.3-2.0, p=1.4x10-6, respectively).  CDK1 variants were observed
in 8 of 516 CLLs and 24 of 8,920 controls (1.6% vs 0.3%, OR=5.8, 95% CI 2.6-
13.1). One recurrent missense variant, CDK1 p.R59C, observed in 5 cases and
10 controls, is predicted to be possibly damaging by the PolyPhen2 prediction
tool, and is driving the association. The second significant gene was ATM, in
which we found a total of 112 cases carrying 52 distinct rare germline variants
and 1296 controls carrying 292 rare variants (21.7% vs 14.5%; OR=1.6, 95% CI
1.3-2.0). The majority of recurrent rare variants in ATM were non-synonymous
missense variants, with L2307F one of the most enriched (2.3% cases, OR=10.1,
4.9-20.7). Subsequent validation in 149 independent CLL cases revealed a similar
frequency of 2.01% (3 out of 149) of the L2307F variant.  We then added 130
CLL cases and performed an expanded joint analysis, which has been shown to
improve the statistical power of detecting genetic associations compared to a
two-stage replicate analysis. We identified 42 additional patients with rare ATM
variants, and the significance of ATM was greatly increased (q=0.00016, OR
1.79, CI 1.49-2.15). We integrated somatic and germline sequencing data and
found that patients with rare germline variants in ATM were more likely to harbor
an additional ATM somatic lesion (p=9.1x10-4). Furthermore, 80% of patients
with both a rare germline variant in ATM and a somatic 11q deletion lost the wild-
type ATM allele during deletion (p=0.012), suggesting that the germline variants
behave as tumor suppressor alleles.
Summary/Conclusions: To our knowledge this analysis represents the first
germline association analysis based on exome sequencing data in CLL, and
our results implicate rare germline variation in ATM in CLL predisposition.
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DIFFERENTIAL ENHANCER TRANSCRIPTION ASSOCIATED WITH RISK
ALLELE GENOTYPE IN CLL
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Background: Genome-wide association studies (GWAS) have identified mul-
tiple loci that are statistically associated with CLL susceptibility. These single
nucleotide polymorphisms (SNPs) are primarily located in non-protein coding
genomic regions. Data suggest that these variants are enriched in regulatory
elements.
Aims: We tested the hypothesis that CLL risk variants are in or near regulatory
elements that influence nearby target genes.
Methods: To investigate SNP allele-specific impacts on gene expression, we
selected 15 SNPs from 13 loci that achieved genome wide significance in initial
CLL GWAS studies. We investigated either the published GWAS SNP (if pres-
ent on the Affymetrix 6.0 SNP array) or proxy SNP(s) chosen using the SNP
Annotation and Proxy Search (SNAP) software, based on their high linkage
disequilibrium (LD) (r2>0.68) with the selected GWAS SNP. Genotypes were
determined in tumor (n=143) and saliva (n=79) DNA from CLL patients (who
had provided written informed consent); tumor and saliva DNAs were concor-
dant in at least 96% of cases (except rs477184 at 92%). Given the high con-
cordance with saliva, which is likely related to the stable genome of CLL, SNP
genotypes from tumor samples were used for the analysis in order to signifi-
cantly increase our sample size.  Allele-specific gene expression was then eval-
uated in tumor samples (n=143) using Affymetrix U133 Plus 2.0 array gene
expression data, focusing on genes within 1 Mb in either direction from a given
SNP. In order to elucidate whether these associations were due to functional
effects on transcription, we used a novel assay called precision run-on sequenc-
ing (PRO-seq). PRO-seq efficiently maps active transcription regulatory ele-
ments (TREs) and provides a sensitive, quantitative and directional map of
transcriptionally-engaged RNA polymerases. The algorithm, discriminative reg-
ulatory-element detection from GRO/PRO-seq (dREG), is then used to predict
the presence of TREs from raw PRO-seq data, allowing for identification of
functional elements in the vicinity of SNPs and quantification of their allele-spe-
cific effect on enhancer activity and gene transcription.
Results: Our gene expression analysis demonstrated 6 significant SNP-gene
associations: rs674313 (6p21.3) with HLA-DQA1 (p <0.0001), rs872071
(6p25.3) with IRF4 (p=0.01), rs4777184 (15q23; proxy for rs7176508) with
TLE3 (p=0.009), rs783540 (15q25.2) with CPEB1 (p=0.01), rs305088 (16q24.1;
proxy for rs305061) with COX4NB/EMC8 (p=0.03) and rs4802322 (19q13.32;
proxy for rs11083846) with FKRP (p <0.0001). Two associations were success-
fully validated in a completely independent gene expression replication analysis
(n=54): rs674313 with HLA-DQA1 (p<0.0001) and rs4777184 with TLE3
(p=0.0118). To annotate candidate regulatory elements, we evaluated tran-
scription level at or near all six significant SNPs in the initial gene expression
analysis in a cohort of 12 CLL samples. Transcription level at or near 3 SNPs
(rs674313, rs4777184, rs305088) correlated with genotype in a dose dependent
manner. When we expanded the analysis to the entire region of LD around
each SNP, we were able to demonstrate a dose-dependent effect in all SNPs
except rs872071.
Summary/Conclusions: We conclude that PRO-seq and dREG analysis iden-
tifies evidence of active differential transcription based on genotype in the region
of 5 out of 6 GWAS-identified SNPs that we have investigated so far.
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HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF
17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY
K. Plevova1,2,*, J. Malcikova1,2, S. Pavlova1,2, J. Kotaskova1,2, L. Poppova1,2,
J. Smardova3, E. Diviskova2, K. Durechova2, A. Oltova2, Y. Brychtova2,
A. Panovska2, M. Doubek1,2, S. Pospisilova1,2
1Central European Institute of Technology, Masaryk University, 2Department
of Internal Medicine - Hematology and Oncology, 3Department of Pathology,
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Background: TP53 gene defects represent an adverse prognostic marker in
chronic lymphocytic leukemia (CLL). In the majority of affected cases, TP53 is
inactivated on both alleles due to the concurrent mutation and 17p deletion
[del(17p)]. However, in about one third of cases, only TP53 mutation (TP53mut)
without deletion is detected. It was reported that in some of these patients,
copy-neutral loss of heterozygosity (cn-LOH), also leading to biallelic TP53
defect, might be present; however the frequency of such event has not been
thoroughly investigated.
Aims: We aimed to perform a detailed analysis of the second TP53 allele status
in cases with a TP53 mutation in the absence of del(17p), and to assess genom-
ic makeup and clinical outcome in these patients.
Methods: We searched for patients with TP53mut in absence of del(17p) within
the cohort of 200 CLL patients positive for TP53mut as determined using FASAY
(Functional Analysis of Separated Alleles in Yeast) coupled to direct sequencing;
haematologica | 2017; 102(s2) | 65
Madrid, Spain, June 22 – 25, 2017
17p13 deletions were assessed by FISH (MetaSystems). More than a half of
the cohort (57%) was also tested using ultra-deep NGS for TP53 exons 2-11.
Genome-wide analysis was performed on CytoScanHD arrays (Affymetrix) and
correlated to conventional cytogenetics (CpG/IL-2 stimulation).
Results: Out of the cohort positive for TP53mut, 72/200 patients (36%) harbored
single dominant TP53mut without del(17p). We selected 43 of these cases with
variant allele frequency (VAF) >10% for CytoScan analysis to explore the potential
presence of 17p cn-LOH. In 42% (18/43) of the cases, cn-LOH in 17p locus was
detected in a proportion of CLL clone correspondingly to the TP53 VAF (median
TP53 VAF 59.4%, range 12.9–99.9%). In 3/43 cases, heterozygous deletion pre-
viously undetected by FISH was newly revealed. Thus, the truly monoallelic
mutations were confirmed in 51% (22/43) of the cases, where no cytogenetic
abnormality in 17p locus was observed (median TP53 VAF 43.5%, range 10.5–
51.3%). Applying a VAF cut-off of 55% indicating fully expanded heterozygous
mutation (taking into account the potential unequal representation of forward and
reverse strands in NGS data), 7/29 (24%) cases below the cut-off still harbored
17p cn-LOH. These results show that it is not possible to use an arbitrary VAF
cut-off (>50%) to identify biallelic mutations due to cn-LOH. When we compared
genomic complexity of leukemic clones with monoallelic vs biallelic TP53mut as
determined by the CytoScan array, the latter group exhibited significantly more
genomic abnormalities (p=0.0388) and also preference for different recurrent
chromosomal abnormalities (p<0.0001; 17p locus excluded from this analysis).
However, there was no significant difference in overall survival between the
groups (p=0.5856).
Summary/Conclusions: cn-LOH in 17p locus is present in approximately half
of the patients with single dominant TP53mut and results in biallelic TP53 gene
inactivation despite the absence of del(17p); truly monoallelic TP53 gene muta-
tions with an intact second allele occur in CLL with comparable frequency.
Although 17p cn-LOH is associated with increased genomic instability, it does
not have worse impact on clinical outcome than truly monoallelic TP53mut.
Supported by the projects AZV-MZCR 15-31834A, 15-30015A, 15-29793A,
the EU Horizon2020 project No. 692298, and MEYS CEITEC2020 LQ1601.
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INTERGRATED OLIGO/SNP ARRAY- AND NEXT GENERATION
SEQUENCING BASED ANALYSIS IS REQUIRED TO DETERMINE TP53/17P
STATUS IN CLL PATIENTS 
M. Stevens-Kroef1,*, A. Eijkelenboom1, L. Kroeze1, D. Olde Weghuis1,
P. Groenen1
1Radboud university medical center, Nijmegen, Netherlands
Background: B-cell chronic lymphocytic leukemia (CLL) exhibits a highly het-
erogeneous clinical course, with overall survival rates varying from several
months to decades. Mutation status of the IGHV genes and specific genomic
abnormalities, such as deletion of 11q22 en loss of the 13q14 region provide
prognostic information. However, more importantly deletion of 17p and/or the
presence of a TP53 mutation, which are both associated with a poor prognosis
identify CLL patients with the highest risk profile. Recently clinical trials with
tyrosine kinase inhibitors such as ibrutinib and idelalisib have demonstrated
good responses in CLL patients with 17p deletion and/or TP53 mutations. In
many studies interphase fluorescence in situ hybridization (FISH) for the detec-
tion of 17p deletions and Sanger sequencing of exons 4-10 of the TP53 gene
are applied, resulting in incorrect classification of patients belonging to the
highest risk group, due to absence of information regarding the heterozygosity
status and low sensitivity of the sequencing technology.
Aims: We have applied an integrated approach to determine the TP53/17p
status in CLL patients using oligo/SNP-based array which allows a genome-
wide detection of copy number alterations (CNAs), down to 100 kb in size, and
regions of copy neutral loss of heterozygosity (CNLOH). In addition the pres-
ence of TP53 mutations was evaluated with high sensitivity using next gener-
ation sequencing approaches.
Methods: We have studied bone marrow or peripheral blood samples of 179
CLL patients that were referred to our diagnostic genetic center for analysis of
17p deletion, 17p CNLOH and the TP53 mutation. To determine the TP53
mutation status (exons 2-11) sequence analysis was performed by next gen-
eration sequencing with a sensitivity up to 1% mutant allele frequency. For the
determination of the 17p status we have used a high resolution CytoScan HD
Array (Affymetrix) platform which allows the detection of copy number alter-
ations (e.g. deletions) as well as CNLOH.
Results: Twenty-one of the 179 CLL patients exhibited a loss or CNLOH of
the short arm of chromosome 17 as demonstrated by oligo/SNP-based array.
Eight of these cases had a CNLOH of 17p and would not have been observed
in case interphase FISH had been performed. In addition, by applying TP53
mutation analysis 26 patients were identified in whom the TP53 gene was inac-
tivated. In six of these cases the mutant allele frequency was below 20% and
would have escaped detection by Sanger sequencing. Therefore ten of the 26
(38%) patients with TP53/17p aberration would not have been indentified in
case diagnostics was based on FISH and Sanger sequencing. To evaluate
whether both alleles of the TP53 gene were inactivated the data of the 17p
deletion, 17p heterozygosity status and TP53 mutation status were integrated.
It appeared that in all 13 patients with a 17p deletion the other TP53 allele was
inactivated due to a mutation. In all patients demonstrating CNLOH of the chro-
mosome 17p region the TP53 gene was also inactivated due to a mutation. In
the other 5 patients with a TP53 mutation no loss or CNLOH of 17p was demon-
strated. However, two of these patients harbored two different TP53 mutations,
suggestive for inactivation of both TP53 alleles.
Summary/Conclusions: By applying an integrated approach for determination
of the TP53/17p status a substantial higher amount of patients were categorized
to the highest risk group of CLL patients with TP53/17p abnormalities.
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CYTOGENETIC CLONAL EVOLUTION OCCURS AT THE TIME OF DIS-
EASE PROGRESSION DURING IBRUTINIB THERAPY IN PATIENTS WITH
RELAPSED/REFRACTORY CLL
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N. Jain1, E. Zeev1, W. Wierda1
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Background: Patients (pts) with del(17p) and complex karyotype (CKT) have
increased likelihood of disease progression during ibrutinib therapy for CLL.
Cytogenetic clonal evolution (CCE) is frequent at the time of disease progres-
sion following chemotherapy, particularly emergence of del(17p). Additionally,
pts with del(17p) or TP53 mutations frequently develop additional copy number
alterations (CNAs) following chemotherapy. 
Aims: To determine whether CCE occurs during ibrutinib therapy and at dis-
ease progression.
Methods: We analyzed 336 pts treated on investigational studies with ibrutinib
or ibrutinib plus rituximab for CLL. In pts who progressed, we analyzed FISH
and cytogenetic results pre-treatment and at progression, to identify CCE. Addi-
tionally, we identified a sub-group of 97 relapsed/refractory pts who had serial
FISH analysis performed in bone marrow ≥1 year apart, to determine whether
there were significant changes in sub-clonal composition of CNAs detected by
FISH during treatment in the absence of disease progression.
Results: In total, 37 of 336 pts (11%) progressed during ibrutinib-based ther-
apy. Of these pts, 15 had FISH analysis both pre-treatment and at progres-
sion: pre-treatment, 10 had del(17p), 1 had del(11q) and 4 had isolated
del(13q). All 4 of the pts with isolated del(13q) pre-treatment had new sub-
clonal FISH abnormalities detected at progression: two pts had del(17p), 1
had del(11q); a 4th pt developed two additional copies of all targeted regions
at progression, suggestive of tetraploidy. The pt with del(11q) pre-treatment
who progressed developed Richter Transformation (RT) in the bone marrow
at progression, without either del(11q) or del(17p) identified by FISH, sug-
gesting that the RT arose from a common ancestral clone without del(11q)
or was clonally unrelated. Median FISH%del(17p) pre-treatment in those with
del(17p) was 72%; only 1 pt had <50% del(17p) pre-treatment. All these pts
had persistence of del(17p), at progression, without significant changes in
allelic frequency. Two pts with del(17p) pre-treatment had additional abnor-
malities detected by FISH at progression: sub-clonal biallelic del(13q) was
seen in two pts, one of whom also developed tetrasomy 12. In the absence
of disease progression, the only CCE detected was emergence of small sub-
clones with biallelic del(13q) in two patients who initially had monoallelic
del(13q). Notably, in responding pts, there was no expansion of high-risk
sub-clones. Conventional karyotyping was performed in 10/37 patients who
progressed both pre-treatment and at progression. In 4 pts, CCE was iden-
tified at progression, including 17 new abnormalities in one pt. All 4 pts had
complex karyotype and del(17p) by FISH pre-treatment and 3 of 4 had evi-
dence of multiple, related, complex sub-clones pre-treatment. Figure 1 shows
inferred clonal evolution pattern for one pt.
Figure 1.
66 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Summary/Conclusions: Emergence of high-risk clones containing del(17p)
and or del(11q) may be seen at disease progression in ibrutinib-treated patients.
Analogous to allelic expansion of TP53 mutations after chemotherapy, we
hypothesize that small del(17p) or del(11q) subclones were present prior to
therapy in these pts, below the sensitivity of existing FISH techniques and
expanded under the selective pressure of ibrutinib treatment. Development of
a more sensitive technique to identify small sub-clones with del(11q) or del(17p)
may therefore be important. Additionally, complex CCE occurred at progression
in several cases, indicating genomic instability and potentially contributing to
therapeutic failure.
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LANDSCAPE OF SOMATIC MUTATIONS AND THEIR IMPACT ON
RESPONSE AND OUTCOMES FROM LENALIDOMIDE-BASED
THERAPIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
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Background: Lenalidomide, either as a single agent or in combination with
anti-CD20 monoclonal antibody, is clinically active in CLL and offers durable
response in some pts. Predictive and prognostic impact of somatic mutations
are not well known in pts with CLL who have received lenalidomide-based
therapies.
Aims: Investigate the overall landscape of CLL gene mutations in both previ-
ously untreated and relapsed/refractory (R/R) pts. Determine associations
between CLL gene mutations and clinical characteristics. Establish predictive
and prognostic impact of CLL mutations in the context of lenalidomide-based
therapies.
Methods: In the 288 pts with CLL who were treated in one of the lenalidomide-
based clinical trials at our institution, we performed targeted gene capture
exome sequencing of 295 genes that have been recurrently mutated in hema-
tologic malignancies on pre-treatment samples. This sequencing platform also
included more than 1000 cyto SNP position that allowed copy number variation
(CNV) estimation. We used Mutect and Pindel algorithms to call high-confidence
somatic mutations and used in-house algorithm to detect copy number varia-
tions (CNVs) in CLL samples.
Figure 1.
Results: Among the 288 CLL pts treated with lenalidomide, 102 (35%) were
previously untreated and 186 had R/R CLL. Ninety two patients (32%)
received lenalidomide as a single agent and 196 patients (68%) received in
combination with rituximab or ofatumumab. In total, we detected 470 high-
confidence somatic mutations in 61 genes in 281 pts (76%). In addition to
the well-known arm-level chromosomal abnormalities like del(13q), del(11q),
tri(12), and del(17p), we also detected amp(2p), del(6q), del(8p), amp(8q)
and tri(19). The most frequently mutated gene was SF3B1 (15%), followed
by NOTCH1 (14%) and TP53 (14%) with 13 gene mutations occurring ≥3%.
The number of mutations was similar between untreated and R/R pts (median
number of mutations 1 [IQR: 0-2] vs 1 [IQR: 1-2], P=0.44) with increased
enrichment of complex cytogenetics, TP53 mutation and del(17p) in the R/R
cohort (p=0.006, p=0.014 and p=0.031, respectively). The pts with unmutated
IGHV status had higher number of mutations compared to mutated IGHV
(median 1 [IQR: 1-2] vs 1[IQR: 0-2], P=0.002) with MYD88 mutation and
del(13q) being significantly enriched in IGHV mutated pts (p=0.005 and
p=0.028, respectively) while NOTCH1 and XPO1 mutations were significantly
enriched in IGHV unmutated patients (p=0.035 and p=0.047, respectively).
Pairwise association showed statistically significant co-occurrence between
tri(12) and mutations in KRAS/BCOR (both q<0.05), NOTCH1 mutation and
ZMYM3 (q<0.01)/SPEN (q<0.05) mutations, and TP53 mutation and del(17p)
(q <0.01)/complex karyotypes (q <0.05). When correlating with clinical
response to lenalidomide, worse overall response (OR) in the untreated group
was associated with del(17p) (p=0.019) and KRAS mutation (p=0.05), where-
as mutation in SF3B1 (p=0.025), MGA (p=0.035), DDX3X (p=0.002), TP53
(p<0.001), complex karyotype (p=0.035) and del(17p) (p=0.031) were asso-
ciated with worse OR in R/R group. In the untreated group, del(17p) and
TP53 were associated with worse progression-free (PFS)(p=0.002 and 0.003,
respectively). In R/R cohort, complex karyotype, del(17p) and mutations in
SF3B1 and TP53 were associated with worse OS and PFS while DDX3X was
associated with worse PFS but not OS (refer to provided Figure 1). In one of
the multivariate models, SF3B1 (P=0.005) mutation and having TP53 or
del(17p) (p=0.02) were prognostic for survival in R/R cohort.
Summary/Conclusions: Tumor mutational heterogeneity in CLL is due to
intrinsic tumor biology and selective drivers from previous treatments, which
can then affect response and survival in lenalidomide-based therapies.
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LEUKEMIA PATIENTS ASSIGNED TO STEREOTYPED SUBSET #4: NOVEL
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Background: Chronic lymphocytic leukemia (CLL) clones assigned to stereo-
typed subset #4 are characterized clinically by a young age at diagnosis and
an indolent disease course, and molecularly by B-cell receptor immunoglobulins
(BcR IGs) that exhibit distinctive immunogenetic features. More specifically,
they are IgG-switched, composed of heavy and light chains encoded by the
IGHV4-34 and IGKV2-30 genes, respectively, and their heavy chain comple-
mentarity determining region 3 (VH CDR3s) is long and enriched in positively
charged residues, reminiscent of pathogenic anti-DNA antibodies. In addition,
both the VH and VK domains of subset #4 demonstrate a high impact of somatic
hypermutation (SHM), highly indicative of an (auto)antigen selection.
Aims: To obtain comprehensive insights into the ontogeny and evolution of
CLL subset #4 using next-generation sequencing (NGS) for in-depth immuno-
profiling of the clonotypic BcR IG genes, particularly focusing on analyzing
intraclonal diversification (ID) within the IG gene sequences.
Methods: Peripheral blood samples were collected at multiple time-points
over a 10-year period from 6 CLL subset #4 patients. The clonotypic IGHV-
IGHD-IGHJ and IGKV-IGKJ rearrangements were amplified by PCR using
cDNA and sequenced on the MiSeq (Illumina). Our experimental design
involved paired-end sequencing, thus allowing sequencing of the CDR3
twice/read, so as to increase the accuracy of results. To maintain stringency,
raw NGS reads were subjected to purpose-built, bioinformatics algorithms,
which performed: (i) length and quality filtering of raw reads; (ii) merging of
filtered-in paired reads via local alignment; and, (iii) length and quality filtering
of stitched sequences. No base calls of Q-score<30 were allowed in the 75
nucleotide stretch preceding the GXG motif, further increasing CDR3
sequencing reliability. Data was then analyzed using the IMGT/HighV-QUEST
database and clonotype computation was performed using an in-house bioin-
formatics pipeline.
Results: Overall, 48 samples were analyzed, producing 12,386,554 and
4,506,464 total reads for heavy and light chain, respectively. In addition to fil-
tering out poor quality, incomplete, out-of-frame and unproductive rearrange-
ments, specific parameters were applied regarding V-region identity (>85%),
usage of subset #4-specific V- and J-genes, CDR3 length and landmark
residues. Applying these strict criteria resulted in 84.1% (median 401,133
reads/sample) and 90.3% (median 141,549.5 reads/sample) of the total
sequences obtained for the heavy and light chain, respectively, passing filters.
Clonotype computation was solely based on the filtered-in sequences and
revealed a median of 1332.5 clonotypes/sample (range: 879-3432) for the
heavy chains while a median of 202.5 clonotypes/sample (range: 125-395)
was evidenced for the light chains. Overall, our longitudinal analysis revealed:
(i) a hierarchical pattern of subclonal evolution showing which SHMs were
negatively or positively selected; (ii) distinct clusters of subcloned sequences
which at later time-points had often disappeared and hence been selected
against; and, (iii) that despite the high intensity of ID, certain residues
remained essentially unaltered alluding to strong functional constraints.
Summary/Conclusions: Detailed molecular immunoprofiling by NGS afford-
ed the possibility to gain novel insights into the pathogenesis of CLL subset
#4, thus providing conclusive evidence that these patients continue to acquire
SHMs within their IG genes; an observation best explained by a clear role for
antigen selection in clonal evolution.
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FAILED HYDROXYMETHYLATION CONTRIBUTES TO A CHRONIC
LYMPHOCYTIC LEUKEMIA SPECIFIC EPIGENOTYPE
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S. Hild1, J. Duyster1, H. Busch2, M. Börries2, R. Claus1
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Freiburg Medical Center, 2Institute of Molecular Medicine and Cell Research,
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Background: During normal hematopoiesis, a coordinated epigenetic and
transcriptional programming is necessary to achieve lineage development. B
cell differentiation is predominantly related to loss of DNA methylation at the
enhancers and promoters of B cell-specific genes; e.g. transcription factors
(TFs). In chronic lymphocytic leukemia (CLL), failure of proper epigenetic pro-
gramming contributes to deregulation of B cell transcriptional programs and
results in CLL phenotypes with highly variable outcomes. The mechanisms
leading to failed epigenetic programming and to establishment of a CLL
epigenome are not well understood. Genomic sites of failed epigenetic pro-
gramming coincide with binding sites of key B cell TFs. Active DNA demethy-
lation through TET-dioxygenase mediated conversion of 5-methylcytosine
(5mC) to 5-hydroxymethylcytosine (5hmC) and subsequent products is one of
the mechanisms involved in physiological epigenetic B cell programming, and
deregulation of this process could contribute to establishment of the CLL
epigenome.
Aims: Here, we investigated the role of TET2-mediated DNA demethylation
through differential 5hmC acquisition in healthy and in CLL B cells. We further
studied mechanisms and TFs involved in regulation of 5hmC conversion during
CLL pathogenesis.
Methods: Clonal B cell specimens from 122 CLL patients were subjected to
DNA methylation profiling using Illumina 450k arrays. 17 CLL and 4 healthy B
cell samples (CD19+) were used for DNA methylation profiling using Illumina
Epic arrays and for hydroxymethylated DNA immunoprecipitation (hMeDIP)
using a monoclonal 5hmC mouse antibody and the NEBNext Ultra DNA Library
Prep Kit for analysis on a Illumina HiSeq2000 sequencer. Global 5hmC levels
were quantified by dot blots. TET2, and EBF1 mRNA and protein expression
was evaluated by qPCR and Western Blot, respectively.
Results: By dot blot, we found decreased 5hmC levels in CLL as compared to
CD19+ B lymphocytes. 5hmC was further reduced in IGHV unmutated com-
pared to IGHV mutated CLL patients. To identify distinct regions with gain or
loss of 5hmC, we performed genome-wide 5hmC profiling by hMeDIP. We con-
firmed a significantly lower number of hydroxymethylated peaks in CLL
(137114) compared to HBC (249421) which remained stable when separating
to good (133234, p<0.0102) or bad prognosis CLL (140441; p<0.0161) patients
(defined by the IGHV mutation status, Rai/Binet stages, CD38 positivity,
del(11q) and del(17p)). Differential binding analysis (DBA) revealed 5988 sig-
nificantly differentially hydroxymethylated reads between CLL and HBC sam-
ples (FDR<0.05). Pathway analysis showed that regions which lost hydrox-
ymethylation in CLL were involved in B cell receptor (BCR), Class I PI3K,
CXCR-4, c-Mec and IL3 signaling. To further identify mechanisms that are
involved in failed hypomethylation and 5hmC loss in CLL, we aimed at profiling
sequence characteristics at the respective genomic sites. In our genome-wide
DNA methylation data set, we confirmed highly significant enrichment of the
EBF1 motif at the respective sites in 122 CLL patients. EBF1 mRNA and protein
expression was significantly reduced in the majority of 17 CLL samples com-
pared to HBC. TET2, a potential interaction partner of EBF1, was upregulated
in CLL samples on RNA level and expressed to different degree on protein lev-
el.
Summary/Conclusions: Here, we demonstrate that 5hmC loss in CLL con-
tributes to a disease specific epigenotype as described earlier. First evidences
indicate that alterations of an interaction between the EBF1 and TET2 are
mechanistically involved in insufficient hydroxymethylation and consequently
failed DNA hypomethylation.
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DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA
PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A
DIFFERENT CELLULAR ORIGIN FOR SUBSET #2?
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Background: Subsets of CLL patients carrying stereotyped B cell receptors
(BcRs) display distinct biological and clinical features; however, the DNA methy-
lation landscape for these patients remains largely unexplored. 
Aims: To investigate the DNA methylation profiles in three major stereotyped
subsets.
Methods: By applying high-resolution 450K methylation arrays, we studied the
clinically aggressive subsets #1 (Clan I genes/IGKV(D)1-39, IGHV unmutated,
n=37) and #2 (IGHV3-21/IGLV3-21, mixed IGHV mutation status, n=35) and the
indolent subset #4 (IGHV4-34/IGKV2-30, IGHV mutated, n=28). In addition, a
series of sorted normal subpopulations spanning different stages of B-cell differ-
entiation (e.g. naïve, centrocytes, centroblasts, memory) were analyzed. 
Results: Unsupervised principal component analysis demonstrated that the
investigated subsets formed distinct subgroups and these findings were cor-
roborated by hierarchical clustering analysis. We next explored if and how
these subsets match to the recently proposed epigenetic classification of CLL,
which subgroups patients into three categories, defined as i) poor-prognostic,
naïve like CLL (n-CLL), ii) good-prognostic, memory like CLL (m-CLL), broadly
corresponding to IGHV unmutated and mutated CLL, respectively; and iii) a
third intermediate CLL subgroup (i-CLL), which have borderline mutated IGHV
genes and an intermediate outcome. For this purpose, we utilized the same
methylation arrays to study a cohort of CLL cases that did not express stereo-
typed BcRs (‘non-subset’, n=325). Comparison of subset vs non-subset CLL,
grouped based on their epigenetic classification, revealed that subset #1 clus-
tered with n-CLL, subset #4 with m-CLL, while subset #2 clustered separately
with i-CLL. We have recently shown that the number of epigenetic changes
that a tumor acquired, compared to its cellular origin (i.e. ‘epigenetic burden’),
may be a powerful predictor of clinical aggressiveness (Queiros et al., Cancer
Cell 2017). Following this approach in CLL, when comparing specific subsets
vs their non-subset cases matched by epigenetic subgroup, we noted a signif-
icant difference in the epigenetic burden amongst the various groupings; more
specifically, in subset #1 vs n-CLL (72K vs 67K, p<0.05) and in subset #2 vs i-
CLL (76K vs 68K, p=0.001), while no difference was observed between subset
#4 vs m-CLL (83K vs 82K, p=not significant). This implies that subsets #1 and
#2 have a higher epigenetic burden than n-CLL, which is in line with the more
aggressive disease seen in these two subsets compared to the broader cate-
gory of n-CLL patients. Focusing on subset #2, we observed that almost all
cases clustered separately from i-CLL in supervised clustering analysis, pro-
viding further support that subset #2 forms a distinct subgroup of i-CLL. Subset
#2 cases frequently carry del(11q) and harbor SF3B1 mutations, however, nei-
ther the IGHV mutation status nor the presence of del(11q) or SF3B1 mutations
had any impact on the epigenetic burden within subset #2. 
Summary/Conclusions: Stereotyped CLL subsets differed significantly in their
methylation profiles. That said, subset #1 and #4 clustered at large with n-CLL
and m-CLL categories, respectively, implying common cellular origin. In con-
trast, subset #2 emerged as the first defined member of the i-CLL group, which
in turn alludes to a distinct cellular origin for subset #2 and i-CLL patients. Both
subsets #1 and #2 displayed a higher epigenetic burden compared to n-CLL
and i-CLL, respectively, which is likely reflected in the very poor outcome asso-
ciated with these two subsets.
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ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL
CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6
MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE
BLOODWISE TAP ICICLLE EXTENSION STUDY 
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S. Dalal3, R. de Tute2, O. Sheehy4, A. Pettitt5, C.P. Fox6, C. Fegan7,
S. Devereux8, D. MacDonald9, A. Bloor10, P. Hillmen2
1HMDS, St. James’s Institute of Oncology, 2St. James’s Institute of Oncology,
Leeds, 3Cancer Research UK Clinical Trials Unit, University of Birmingham,
Birmingham, 4Belfast City Hospital HSC Trust, Belfast, 5Royal Liverpool and
Broadgreen University Hospitals NHS Trust, Liverpool, 6Nottingham University
Hospitals NHS Trust, Nottingham, 7University Hospital of Wales, Cardiff, 8Kings
College Hospital NHS Foundation Trust, 9Hammersmith Hospital, Imperial Col-
lege Healthcare NHS Foundation Trust, London, 10The Christie NHS Founda-
tion Trust, Manchester, United Kingdom
Background:A major aim of CLL treatment is to eradicate detectable minimal resid-
ual disease (MRD). Ibrutinib is an effective treatment for CLL that results in immediate
lymphocytosis persisting in most patients for several months. Obinutuzumab is a
second generation anti-CD20 monoclonal antibody which can effect rapid resolution
of lymphocytosis and eradication of MRD in some CLL patients. The IcICLLe Exten-
sion Study expands on the IcICLLe trial (ISRCTN12695354) to examine the efficacy
and safety of the combination treatment of obinutuzumab and ibrutinib.
Aims: The IcICLLe trial was a single-arm, multicentre feasibility study that recruited
40 participants with CLL requiring treatment, 20 treatment-naïve (TN) and 20
relapsed/refractory (RR), to receive continuous ibrutinib therapy until confirmed
MRD negative remission (<0.01% residual disease) or disease progression. The
IcICLLe Extension Study adds 40 RR participants with CLL requiring treatment to
receive continuous ibrutinib therapy from day 0 and 6 cycles of obinutuzumab
from day 1. 30 participants have no prior ibrutinib treatment (ibrutinib-naïve), and
10 are pre-treated with ≥12 months of ibrutinib on IcICLLe. The primary outcome
for the IcICLLe Extension Study is the proportion of patients achieving MRD-neg-
ative remission by IWCLL criteria (depletion of CLL below 0.01% in the peripheral
blood and bone marrow) at or before 9 month assessment.
Methods: Adverse Events are collected from registration until 30 days after end
of treatment and reported using the Common Terminology Criteria for Adverse
Events v4.0. MRD was assessed by multiparameter flow cytometry according to
ERIC 2016 guidelines with a detection limit ≤0.004%.
Results: 31 participants (22 ibrutinib-naïve and 9 pre-treated) are evaluable
for response assessment after 1 month of combination treatment. There have
been no reports of tumour lysis syndrome within the first month of combination
treatment. There were 2 separate reports of grade 2 infusion related reactions,
both on day 1 of obinutuzumab. In the 22 ibrutinib-naïve cases peripheral blood
(PB) CLL counts remained at or below baseline levels in 17/22 cases from
week 1 onwards. After 1 month of combination therapy the PB CLL count was
a median 31% of baseline levels (range <1%>174%) compared to median
215% (range 29%>3570%) for RR patients on ibrutinib monotherapy. Percent-
age CLL cells in the bone marrow (BM) aspirate after 1 month of combination
therapy reduced from a median 83% (range 23-94%) to a median 47% (range
5-85%, P=0.003, Wilcoxon matched-pairs signed ranks). For RR patients on
ibrutinib monotherapy there was no change in BM at 1 month: baseline median
85% (range 11-96%) compared to median 86% (range 50-98%, P=0.96).
Changes in BM aspirate CLL percentage were confirmed by morphological
assessment of a trephine biopsy with all evaluable patients receiving obinu-
tuzumab showing improvements in the cellularity and/or extent of infiltration.
BM assessment at 1 month was not mandated for the 9 pre-treated patients
but all showed decreased PB CLL counts with 4/9 achieving <0.01% residual
disease within 3 months of starting obinutuzumab. 13 patients have completed
6 months of obinutuzumab treatment with marrow assessment at 9 months
showing a further ≥1 log depletion in CLL percentage in 9/13 patients with 4/6
pre-treated patients achieving <0.01% residual disease.
Summary/Conclusions: The data indicate that for RR patients, the addition of
obinutuzumab to ibrutinib results in a substantial improvement over ibrutinib
monotherapy in the depletion of CLL cells from peripheral blood and bone marrow
after 1 month of combination therapy, and continued improvement after 6 months
combination therapy, with MRD-negative BM responses for patients who have had
>1yr prior ibrutinib monotherapy. Residual disease levels in the BM after the 6
months of combination treatment will be available for 25 participants by June-2017.
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CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPRESSING THE LIGHT
CHAIN IGLV3-21 HAVE A POOR PROGNOSIS INDEPENDENTLY OF HEAVY
CHAIN IGHV3-21 OR THE IGHV MUTATIONAL STATUS
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Background: The immunoglobulin heavy-chain gene (IgHV) mutational status
is currently considered the gold standard of prognostication in Chronic Lym-
phocytic Leukemia (CLL): unmutated (UM) immunoglobulin heavy chain region
(IgHV) is associated with poor prognosis while patients with mutated IgHV (M)
have more indolent disease. An exception are patients with IgHV3-21/IgLV3-
21 who have poor prognosis irrespectively of the IgHV mutational status. Inter-
estingly, IgHV3-21 is co-expressed with IgLV3-21 in the majority of cases.
Aims: Here we aimed to study the impact of the light chain IgLV3-21 on CLL
prognosis. This light chain has never been characterized independently of the
heavy chain IgHV3-21.
Methods: Based on 405 CLL patients from 3 independent cohorts (A. an initial
cohort of 32 patients with  aggressive CLL, and 2 cohorts of CLL patients where
samples were obtained at diagnosis (B: n=270 and C: n=103), we analyzed
the impact of the presence of IgLV3-21 on treatment-free (TFS) and overall
(OS) survival. IgLV3-21 positivity was determined by real-time PCR and con-
firmed by Sanger sequencing.
Results: Among the 32 patients with aggressive CLL, we found that 9 (28%)
patients who had an IgLV3-21 rearrangement, but only 1 patient carried the
heavy chain IgHV3-21: IgLV3-21 patients had a median TFS of 17 months
compared to 44 months in patients with another light chain (P=0.0270). Sim-
ilarly, IgLV3-21 patients had a shorter median OS (88 months vs >192 months,
P=0.0287). We verified these results in 2 independent cohort obtained at
diagnosis. In cohort B (n=270), 30 (11%) expressed an IgLV3-21 light chain
and 10 (4%) an IgHV3-21 (of which 8/10 also carried the light chain IgLV3-
21 rearrangement). Patients with IgLV3-21 had a median TFS/OS of 29/183
months compared to patients without IgLV3-21 who had a median TFS/OS
of 88/292 months (P=0.0003/P=0.0142). In cohort C (n=103), 9 (9%)
expressed an IgLV3-21 light chain but only 1 (1%) had a heavy chain IgHV3-
21. In this cohort, IgLV3-21 patients had a median TFS of 21 months not sta-
tistically different from IgHV UM patients (28 months) while IgHV M patients
had a median TFS of 93 months (P<0.0001). We then pooled the 3 popula-
tions (n=405) in order to increase the under-represented subgroups and ana-
lyzed the association of the IgLV3-21 with the IgHV mutational status: patients
with either IgHV3-21 or IgLV3-21 (with a M or UM IgHV) displayed a prognosis
similar to UM patients: median TFS was 129, 48, 36, 24, 23 months for M,
IgLV3-21/M (P=0.0005), UM (P<0.0001), IgLV3-21/UM (P<0.0001) and
IgHV3-21 (P<0.0001) patients, respectively (Figure 1A). Similar results were
observed for OS with a median OS of 292, 88, 174, 90 and 183 months M,
IgLV3-21/M (P<0.0001), UM (P<0.0001), IgLV3-21/UM (P<0.0001) and
IgHV3-21 (P=0.0021) patients, respectively (Figure 1B). If all IgLV3-21 (n=48)
were considered independently of their heavy chain, IgLV3-21 median TFS
(24 months) was similar to UM patients (36 months, P=0.5824) and statisti-
cally different from M patients (129 months – P<0.0001, Figure 1C). Similar
results were observed for OS (Figure 1D).
Figure 1.
Summary/Conclusions: Our results highlight for the first time the independ-
ent prognostic significance of the light chain IgLV3-21 in CLL: the presence
of an IgLV3-21 light chain confers a poor prognosis similar to UM patient irre-
spectively of concurrent expression of IgHV3-21 heavy chain or IgHV muta-
tional status.
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DURABILITY OF RESPONSES ON CONTINUOUS THERAPY AND
FOLLOWING DRUG CESSATION IN DEEP RESPONDERS WITH
VENETOCLAX AND RITUXIMAB
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Background: Venetoclax is a potent BCL-2 inhibitor that is approved as
monotherapy for certain patients with relapsed or refractory chronic lymphocytic
leukemia (CLL) in the United States, the European Union, and other countries.
Aims: Venetoclax combined with rituximab is being assessed in an ongoing
Phase 1b study.
Methods: Minimal residual disease (MRD) was assessed in bone marrow
using ≥4-color flow cytometry (minimum sensitivity: 0.01%). Patients who
achieved complete remission (CR) or MRD-negativity could stop venetoclax
and remain on study. Patients who manifested progressive disease while off
therapy could re-initiate venetoclax and rituximab.
Results: Forty-nine patients, with a median of 2 (range: 1–5) prior regimens,
were enrolled. As of July 2016, the overall response rate was 86%, the CR
rate was 51%, and the bone marrow MRD-negativity rate was 57% (28/49)
[Seymour et al Lancet Oncol 2017]. The 24-month estimate for progression
free survival was 78.8% and that for duration of response was 87.8% (100%
for patients with MRD-negative CR). Of the 28 patients attaining MRD-nega-
tivity, 22 achieved the status at 7 months, which was the first mandatory time
point for assessment. The remaining six patients achieved MRD-negativity at
the second assessment, which ranged from 12 to 22 months, since the timing
of this test was not mandated. Twenty (41%) patients discontinued the study.
Eleven had progressive disease while on therapy: five with Richter’s transfor-
mation between 1–9 months and six with CLL progression after a median of
26.4 months (range: 12–37). The other nine patients: withdrew consent (n=3),
failed to report for follow-up evaluations (n=1), discontinued due to adverse
events related to venetoclax (n=2; tumor lysis syndrome and worsening of
peripheral neuropathy), or discontinued due to adverse events considered not
related to therapy (n=3). Seventeen patients continue on therapy: 8 MRD-neg-
ative CR, 2 MRD-positive CR, 5 MRD-negative PR, and 2 MRD-positive PR.
Median duration of response on therapy is 27.9 months (range: 20.3–40.2).
Sixteen patients discontinued venetoclax and remained on study as allowed
per protocol following the achievement of a deep response (12 MRD-negative
CR, 2 MRD-negative PR, 2 MRD-positive CR) (Figure 1). Their median time
on venetoclax is 16.3 months (range: 5–38). Twelve of these patients remain
in active follow-up and four discontinued without evidence of progression after
achieving MRD-negative CR. Two patients with MRD-positive CR had increas-
ing absolute lymphocyte count (ALC) and asymptomatic progression 24 months
after stopping venetoclax. Both re-started venetoclax, 2 and 6 months after
ALC >5x109/L, and achieved partial remissions. The 10 patients with MRD-
negativity in the bone marrow who remain in follow-up have a median duration
of ongoing response off venetoclax of 13 months (range: 3–34).
Figure 1.
Summary/Conclusions: Venetoclax with rituximab induces deep and durable
responses, with 51% patients achieving CR and 57% achieving marrow MRD-
negativity. Patients on continued therapy have durable responses. Additionally,
responses are sustained at a median of 13 months among patients who achieve
bone marrow MRD-negativity and elected per protocol to stop therapy, demon-
strating that it is possible to discontinue venetoclax and maintain prolonged
treatment free remission. The 2 patients who progressed at 2 years off therapy
responded to the reintroduction of venetoclax.
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Background: Recurrent mutations in genes such as TP53, SF3B1 and
NOTCH1 are frequent in CLL and have in previous studies been associated
with outcome. SF3B1mut, TP53mut, BIRC3mut and XPO1mut were adverse prog-
nostic factors in patient cohorts with different therapies, and NOTCH1mut asso-
ciated with poor outcome when rituximab was added to standard chemotherapy.
This indicated NOTCH1mut as a predictive factor in the context of chemoim-
munotherapy.
Aims: We assessed the incidence and clinical associations of mutations
in TP53, SF3B1, NOTCH1, ATM, BIRC3, FBXW7, MYD88, EGR2 and XPO1 in
the COMPLEMENT-2 trial (relapsed/refractory CLL, FC vs FC+ofatumumab
(FCO), Robak et al., Leuk Lymphoma, 2017).
Methods: Baseline samples were available from 325 of 365 patients (89%)
representative of the full analysis set of the clinical trial. Mutation analyses
were performed via custom targeted Next Generation Sequencing (tNGS) for
TP53, ATM, BIRC3, FBXW7, MYD88, EGR2 (all coding exons), SF3B1 (exon
14-16, 18), NOTCH1 (exon 34) and XPO1 (exon 15, 16). All mutations with a
variant allelic fraction >5% were considered significant.
Figure 1.
Results: In total we identified 365 mutations across the 9 genes in 202 of 325
patients (62.2%), with incidences of SF3B1mut 19.7%, TP53mut 18.8%,
NOTCH1mut 16.3%, ATMmut 13.8%, XPO1mut 11.4%, BIRC3mut 4%, EGR2mut
3.1%, FBXW7mut 2.7% and MYD88mut 0.9%. We identified a variety of asso-
ciations of mutational subgroups with genetic, clinical and laboratory parame-
ters, such as TP53mut with del17p (p<0.01), NOTCH1mut, FBWX7mutand
BIRC3mut with +12q (p<0.01, p=0.01 and p=0.05) and ATMmutwith del11q
(p<0.01). XPO1mut and ATMmut associated with unmutated IGHV. CD79B
expression on cell surface measured via flow cytometry was lower in ATMmut
patients, whereas CD20 expression did not differ among the different mutational
subgroups. TP53mut, EGR2mutandSF3B1mut patients had worse overall
response to therapy (68% p<0.01, 50% p=0.02 and 72% p=0.05 respectively,
vs 81% overall). Similar to the full analysis set, FCO as compared to FC resulted
in significant improved PFS (median 28.1 vs 18.8 months, HR=0.67, p<0.01).
TP53mut and XPO1mutwere adverse prognostic factors for PFS (HR 1.93
p<0.01 and HR 1.85, p<0.01 respectively), but only TP53mut for decreased OS
(HR 2.11 p<0.01). All other mutations, in particular SF3B1mut and NOTCH1mut,
did not significantly impact PFS or OS. To identify factors of independent clinical
70 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
impact, we performed multivariable Cox regressions for PFS and OS including
treatment, IGHV status and all cytogenetic and mutational subgroups.  For
PFS, the following independent prognostic factors were identified: FCO therapy
(HR 0.64 p<0.01), del17p (HR 5.08 p<0.01), unmutated IGHV (HR 2.0 p<0.01),
TP53mut (HR 1.75 p<0.01) and XPO1mut(1.86 p<0.01). Del17p (HR 4.79
p<0.01), unmutated IGHV (HR 1.69 p=0.04) and TP53mut (HR 1.76 p=0.03)
were identified as independent prognostic factors for OS. With focus on the
predictive value of gene mutations, we found a beneficial effect of the addition
of ofatumumab to chemotherapy irrespective of TP53 mutation (HR 0.52 p=0.02
for TP53mut and HR 0.68, p=0.02 for TP53wt). Regarding NOTCH1, ofatumum-
ab was only beneficial in NOTCH1wt but not in NOTCH1mut patients (HR 0.64,
p<0.01 and HR 0.86, p=0.67) (Figure 1).
Summary/Conclusions: In the COMPLEMENT-2 trial evaluating FCO against
FC in relapsed/refractory CLL patients, we found TP53mut and XPO1mut but
not SF3B1mut or NOTCH1mut as independent prognostic factors for PFS.
Notably, a benefit of ofatumumab addition to FC treatment was observed
among NOTCH1wt but not among NOTCH1mut patients
indicating NOTCH1 mutation status as a predictive marker in the context of
type-1 CD20 antibody addition to chemotherapy.
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RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB
PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED
CHRONIC LYMPHOCYTIC LEUKEMIA
A. Danilov1,*, H. Yimer2, M. Boxer3, N. Di Bella4, S. Babu5, J. Li6, Y. Mun6,
S. Skettino6, J. Sharman7
1Oregon Health and Science University, Portland, 2Texas Oncology, Tyler, 3Ari-
zona Oncology, Tucson, 4Rocky Mountain Cancer Centers, Aurora, 5Fort
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7Willamette Valley Cancer Institute and Research Center, Eugene, United
States
Background: Bendamustine (B) plus rituximab (R; BR) is a commonly used
first-line (1L) treatment for chronic lymphocytic leukemia (CLL). The CLL10
study reported an overall response rate (ORR) of 96% and complete response
(CR) rate of 31% with BR. Obinutuzumab (GA101; G) is a glycoengineered,
type II anti CD20 monoclonal antibody. A randomized Phase III trial in 1L CLL
pts showed that G significantly improved progression-free survival (PFS) and
CR rate compared with R, when used in combination with chlorambucil (Goede
2014). B plus G (BG) was evaluated in a subgroup of CLL pts in the GREEN
study (Stilgenbauer 2015).
Aims: The aim of this Phase II study (NCT02320487) is to evaluate the efficacy
and safety of BG as 1L treatment for CLL pts.
Methods: 102 pts with previously untreated CLL received BG, consisting of 6
cycles of G (cycle [C] 1: 100mg day (D) 1, 900mg D2, 1000mg D8 and D15; C2–
6: 1000mg D1) and B (90mg/m2: C1, D2 and D3; C2–6, D1 and D2). Each cycle
was 28 days. The primary endpoint was CR assessed using iwCLL criteria. Sec-
ondary endpoints included ORR, PFS, overall survival, and minimal residual dis-
ease (MRD). Median follow-up at the time of analysis was 11.0 months.
Results: Median pt age was 61 yrs (range 35–90); 68.6% were male; 44.1%
had Rai stage 3–4. For evaluated pts, IgVH status was 32.9% mutated and 67.1%
unmutated. The incidences of trisomy 12, normal cytogenetics, and deletions of
13q, 11q, and 17p were 23.4%, 37.5%, 17.2%, 15.6%, and 6.3%, respectively.
Investigator-assessed CR rate was 49.0% (95% CI 39.0–59.1) and ORR was
89.2% (95% CI 81.5–94.5) after 6 cycles. MRD negativity in blood, as measured
by 4-color flow cytometry, was achieved in 42.7% of pts at the end of induction
response assessment and in 75.5% of pts at any time following treatment. MRD
negativity in bone marrow (BM) was 60.8% in pts with BM samples. The most
common adverse events (all grades [Gr]) were infusion reactions (72.5%), nausea
(52.0%), pyrexia (36.3%), neutropenia (34.3%), fatigue (34.3%), constipation
(26.5%), and rash (26.5%). The most common Gr 3–4 adverse event was neu-
tropenia (26.5%). Incidence of Gr 3–4 infections was 11.8%. Incidence of tumor
lysis syndrome was 4.9% (all Gr 3). Three pts died; none were deemed related
to study treatment or CLL by investigators.
Summary/Conclusions: BG is an effective regimen for 1L treatment of CLL
pts, inducing a high CR rate after 6 cycles of therapy. No unexpected safety
signals were observed.
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RELATIVE SURVIVAL REACHES A PLATEAU IN HAIRY CELL LEUKEMIA:
A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT
AND SURVIVAL AMONG 1,427 PATIENTS DIAGNOSED IN THE
NETHERLANDS, 1989-2014
A. Dinmohamed1,2,3,*, O. Visser4, W. Posthuma5, R. Raymakers6, J. Doorduijn3
1Research, Netherlands Comprehensive Cancer Organisation (IKNL), 2Public
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Background: The introduction of cladribine and pentostatin has revolutionized
the management of HCL as from the late 80s. As a result of that revolution,
HCL patients (pts) are rarely included in clinical trials. Population-based studies
can inform on issues related to outcomes of HCL pts managed in daily practice.
At present, however, population-based studies that assess patterns of inci-
dence, treatment and survival in HCL are very scarce.
Aims: The aim of this comprehensive nationwide population-based study was
to assess trends in incidence, primary treatment and survival among HCL pts
diagnosed in the Netherlands.
Methods: We selected all adult (≥18 years) pts diagnosed with classic HCL in
the Netherlands between 1989-2014 from the nationwide Netherlands Cancer
Registry with survival follow-up through February, 2016. Age-standardized inci-
dence rates (ASR) were calculated per 1,000,000 person-years and standard-
ized according to the European standard population. Data on primary treatment
(i.e. no therapy, chemotherapy [CT] and immumotherapy [IT]) were available
for individual pts. Pts were categorized into 2 periods (1989-2000 and 2001-
2014) and 3 age groups (18-59, 60-69 and ≥70 years). We calculated relative
survival (RS) and the relative excess risk of mortality as measures of disease-
specific survival.
Results: We included a total of 1,427 newly diagnosed HCL pts in the study
(median age, 59 years; age range, 22-95 years; 77% males). The annual
ASR of HCL remained quite stable over time and was 3.1 and 3.3 in the first
and last period, respectively. Men had a higher overall incidence than women
(5.3 v 1.3 in 2001-2014). The age-specific incidence rates for males were
5.5, 15.0 and 15.3 in 2001-2014 for the three age groups. The corresponding
rates for females were 1.2, 3.1 and 5.5. The application of CT increased over
time for all age groups. The proportions of CT for the three age groups were
56, 51 and 34% in 1989-2000, as compared with 81, 73 and 53% in 2001-
2014. The corresponding proportions for IT were 21, 13 and 17% in 1989-
2000, as compared with 2, 1 and 4% in 2001-2014. Lastly, the corresponding
proportions for pts who did not receive therapy were 23, 36 and 49% in 1989-
2000, as compared with 17, 26 and 42% in 2001-2014. Overall, when cor-
rected for age and sex, pts diagnosed in 2001-2014 had 49% lower excess
mortality during the first 10 years after HCL diagnosis, as compared with pts
diagnosed in 1989-2000 (P=.005). Ten-year RS (95% confidence intervals)
was impressive for pts age 18-59, namely 92% (88% - 96%) and 98% (94%
- 100%; P=.176) in the first and last period, respectively (Figure 1a). Most of
the significant improvement was observed in pts age ≥60. More specifically,
10-year RS for pts age 60-69 increased from 82% (71% - 92%) to 99% (89%
- 106%; P=.009; Figure 1b), and for pts age ≥70 from 67% (49% - 86%) to
85% (68% - 102%; P=.366; Figure 1c) between the first and last periods. In
addition, older age (P<.001), but not sex (P=.058), was associated with higher
excess mortality.
Figure 1.
Summary/Conclusions: The incidence of HCL remained stable during a 26-
year period in the Netherlands. RS for pts diagnosed in the period 2001-2014
eventually reached a plateau, indicating that by then their survival is comparable
to that of the general population. Survival was already excellent for younger
patients throughout the entire study period. Survival improvement was most
pronounced for pts age ≥60, although it was not statistically significant for pts
age ≥70. This could be explained by the increased use CT over time. Popula-
tion-based cancer registries are useful instruments to assess outcomes of pts
rarely included in clinical trials.
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CUMULATIVE ILLNESS RATING SCALE PROVIDES PROGNOSTIC
INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR
CHRONIC LYMPHOCYTIC LEUKEMIA: AN ACROSS-TRIAL ANALYSIS BY
THE GCLLSG
V. Goede1,2,*, J. Bahlo1, S. Robrecht1, O. Al-Sawaf1, A.-M. Fink1, C.-M. Wendtner3,
S. Stilgenbauer4, K. Fischer1, B. Eichhorst1, M. Hallek1,5
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Background: CLL-IPI is a prognostication tool to stratify patients with chronic
lymphocytic leukemia (CLL) for low, intermediate, high, or very high risk. CLL-
IPI uses age, Binet stage, beta-2-microglobulin, 17p deletion / TP53 mutation,
IGHV mutational status, but not comorbidity as weighted factors to model prog-
nosis. CIRS is a tool which allows assessing and quantifying burden of comor-
bidity in individual patients.
Aims: To validate CIRS in CLL and to assess whether CIRS is of further value
when estimating prognosis by CLL-IPI in CLL.
Methods: This is a comprehensive evaluation of CIRS in 2158 patients pooled
from the CLL8, CLL10, and CLL11 trials of the German CLL Study Group
(GCLLSG). Median observation time was 55 months. All patients had CIRS
data prospectively assessed prior to study treatment (689 FCR, 409 FC, 279
BR, 333 GCLB, 330 RCLB, 118 CLB).
Figure 1.
Results: Median age was 64 years; 69% of patients were males, and 50% had
ECOG performance score of 1 or higher. Complete information on age, Binet
stage, b2-microglobulin, 17p deletion and/or TP53 mutation, and IGHV mutational
status was available in 1761 of the 2158 patients. Distribution of CLL-IPI risk
groups was as follows: 275 (16%) low risk, 653 (37%) intermediate risk, 712
(40%) high risk, 121 (7%) very high risk. The median total CIRS score was 3
(range 0-22); 81% of the patients had a total CIRS score of at least 1 and 28%
of greater than 6. Comorbidities were most frequently captured under the follow-
ing CIRS organ categories: cardiac, blood pressure, respiratory, musculoskeletal,
or endocrine/metabolic. A severity score of >=2 and >=3 in at least one CIRS
organ category was present in 46% and 11% of the patients, respectively. There
was a positive correlation between total CIRS score and age (rs=0.5, p<0.001)
as well as ECOG performance score (rs=0.4, p<0.001) and an inverse association
between total CIRS score and creatinine clearance (rs=-0.3, p<0.001). In uni-
variate analysis, increased total CIRS score was associated with shorter overall
survival (OS); with poorer OS determined by severity rather than numbers of
comorbidities (log-rank: p<0.001, Figure 1A and 1B). In multivariate analysis,
total CIRS score was an independent risk factor for OS when used as continuous
or categorical variable together with age, gender, Binet stage, ECOG perform-
ance score, thymidine kinase, beta-2-microglobulin, IGHV, and 17p deletion
(adjusted for treatment intensity). Total CIRS score also remained an independent
risk factor for OS when added to the CLL-IPI. Weight of CIRS was highest in the
CLL8 and lower in the CLL10 and CLL11 trials as expressed by the hazard ratios
(Figure 1C). There was no significant association between total CIRS score and
progression-free survival or time-to-next treatment. However, increased total
CIRS score was associated with higher risk of grade 3/4 adverse events as well
as premature treatment discontinuation during or after treatment with FCR / FC
/ BR but not GCLB / RCLB / CLB.
Summary/Conclusions: Findings suggest that CIRS provides prognostic infor-
mation beyond the CLL-IPI. Systematic comorbidity assessment (e.g. by CIRS)
in addition to the CLL-IPI therefore appears reasonable when estimating overall
prognosis and deciding treatment in CLL.
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A PHASE II RANDOMISED STUDY INVESTIGATING THE EFFICACY OF
STANDARD OR HIGH-DOSE OFATUMUMAB IN COMBINATION WITH
CHEMOTHERAPY IN RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA
D. Allsup1,2,*, D. Howard3, T. Munir4, A. Hockaday3, A. Rawstron5, L. Collett3,
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Background: The outcome of CLL patients relapsing after chemoim-
munotherapy (CIT) has been transformed by targeted therapies, however a
proportion of such patients may be successfully retreated with CIT. CD20-
monoclonal-antibody-based CIT has been successfully deployed for the
retreatment of relapsed patients but the optimum dosage of antibody is
unknown.
Aims: COSMIC (Chemotherapy plus Ofatumumab at Standard or Mega dose
In CLL) was a phase II randomised study assessing the efficacy of standard
(sOf) and high (megaOf) dose ofatumumab in combination with either fludara-
bine cyclophosphamide (FC) or bendamustine (B). The primary endpoint was
complete response (CR/CRi) rate independently assessed 3 months post-ther-
apy. Secondary endpoints were the proportion of participants with undetectable
minimal residual disease (MRD); overall response rate; progression-free sur-
vival; overall survival; time to MRD relapse; dynamics of MRD relapse; safety
and toxicity. Using the A’Hern exact one-stage design with 80% power and 1-
sided type 1 error of 5%, 10 CRs were required from 37 recruits in either arm
to justify further investigation in a phase III study. Total sample size was intend-
ed to be 82 allowing for drop-outs.
Methods: CLL patients relapsing after a minimum of 6 months from the most
recent course of chemotherapy, and fit for FC or B, were eligible. Treatment
comprised sOf (total 6.3g of ofatumumab: 0.3g day 1 cycle 1, 1.0g day 8 cycle
1, 1.0g day 1 monthly cycles 2-6), or megaOf (total 22.3g of ofatumumab: 0.3g
day 1 cycle 1, 2.0g weekly for remainder of monthly cycles 1-2, 2.0g day 1
cycles 3-6) given in combination with FC or B at conventional doses. The choice
of FC or B was decided pre-randomisation by the local investigator.
Results: Recruitment was slow with 61 patients randomised and treated, sOf
(32: 21 FC and 11 B), and megaOf (29: 17 FC and 12 B). 77% were previously
treated with purine analogues and 79% had experienced a remission of greater
than 24 months after their most recent therapy. 26% had an 11q deletion and
67% had unmutated VH genes or expressed VH3-21.
With 61 participants, there was 71% power to observe 8 CRs from 28 partici-
pants in either arm. In the intention-to-treat (ITT) population 6(19%) sOf and
7(24%) megaOf patients achieved a CR/CRi; 22(69%) sOf and 21(72%)
megaOf did not; and 4(12%) sOf and 1(4%) megaOf were unassessable. Rates
were similar between FC(26%) and B(19%).  Overall responses (CR/CRi+PR)
were achieved in 20(63%) sOf and 20(69%) megaOf patients. In the ITT pop-
ulation, 4(13%) sOf and 6(21%) megaOf patients were MRD negative in marrow
3 months post-therapy. Overall, therapy was deliverable with 66% of partici-
pants receiving the proscribed 6 cycles of CIT (19(59%) sOf, 21(72%) megaOf).
42 serious adverse reactions were reported (21 sOf, 21 megaOf), 28(67%)
being grade 3 or above (13(62%) sOf, 15(71%) megaOf), with the commonest
events related to infections (45%) and cytopenias (21%). There was one treat-
ment-related death (sOf-FC).
Summary/Conclusions: The CR rates observed in both treatment arms failed
to meet pre-specified levels for the primary endpoint. Response rates observed
in both arms are comparable to those obtained in previous studies of CIT in
this group and suggest that dose escalation of ofatumumab in relapsed CLL
does not lead to a worthwhile improvement in outcomes. However, CIT is deliv-
erable with acceptable toxicity and should still be considered an option, partic-
ularly for patients with long-remissions to first line therapy and who do not pos-
sess high-risk cytogenetic markers.
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FINAL RESULTS OF THE PHASE IB GALTON TRIAL IN CHRONIC
LYMPHOCYTIC LEUKEMIA: DURABLE REMISSIONS WITH FRONTLINE
OBINUTUZUMAB (G) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE
(G-FC) OR BENDAMUSTINE (G-B)
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J. Hirata8, T.J. Kipps9
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Background: GALTON was an open-label, parallel-arm, non-randomized, mul-
ticenter, Phase Ib study (NCT01300247) investigating safety and preliminary
efficacy of G-FC or G-B in previously untreated CLL. 
Aims: We report final results for the planned 36-months’ (mo) follow-up (35/41
pts; median observation 40.4 [17.6–43.6] mo); initial results were reported pre-
viously (Brown et al. 2015).
Methods: Eligible pts met iwCLL 2008 criteria for therapy, were considered fit
for chemoimmunotherapy by the investigator, and provided informed consent.
Each center selected treatment (G-FC or G-B) for their pts. G was administered
intravenously (IV; 100mg day [D] 1, 900mg D2, 1000mg D8 and 15 cycle [C] 1;
1000mg D1 C2–6) with FC (fludarabine 25mg/m2 IV and cyclophosphamide
250mg/m2 IV D2–4 C1, D1–3 C2–6) or B (90mg/m2 IV D2–3 C1, D1–2 C2–6).
Each cycle was 28 days. The primary endpoint was safety and tolerability of G-
chemotherapy. 
Results: 21 pts were enrolled in the G-FC arm and 20 in the G-B arm. Median
age was 60 (25–80) years, 78% of pts were male, and around one-third had
Rai stage III/IV disease. Median time from diagnosis to therapy was 24 mo (G-
FC) and 32 mo (G-B). At data cut-off, 37 pts were alive in follow-up: G-FC
(n=18: 2 lost to follow-up) and G-B (n=19). 1 event of progressive disease
occurred in each arm, and 1 pt per arm died due to an adverse event (AE; G-
B: respiratory failure; G-FC: unknown in the setting of unresolved Grade (Gr)
4 pancytopenia); neither was considered treatment related. Due to the small
number of events, median PFS and OS could not be estimated; however, 3-
year OS was 95% for each arm (95% CI G-FC, 68–99; G-B, 70–99). Post-treat-
ment, 10/41 pts (24.4%) experienced ≥1 Gr3–5 AE: 2/21 pts (9.5%) in the G-
FC arm and 8/20 pts (40.0%) in the G-B arm. 7 serious AEs were reported in
4 pts, all in the G-B arm; these included pneumonitis and respiratory failure (as
noted above; both Gr5), Gr4 leukopenia/neutropenia, small cell lung cancer
and Gr4 pneumothorax, and melanoma. During follow-up, 6 pts had ≥1 Gr3–4
AE of neutropenia, including 4/20 pts (20.0%) in the G-B arm and 2/21 pts
(9.5%) in the G-FC arm. At end of treatment, all pts were B-cell depleted (B-
cell count <0.07x109/L). Within 6–12 mo of follow-up, very few pts had recov-
ered from B-cell depletion (G-FC: 2/19 pts [10.5%]; G-B: 0/20 pts). At 36 mo
follow-up, 9/19 pts (47.3%) in the G-FC arm had recovered, 3/19 (15.8%) were
still depleted, and 7/19 did not have data available. In the G-B arm, 6/20 pts
(30%) had recovered, 1 was still depleted, and 13/20 had no available data. In
a single center exploratory analysis, 9 pts (G-FC) underwent 4-color flow cytom-
etry testing of peripheral blood for minimal residual disease (MRD) 6–14 mo
after therapy; all were negative. 8 of these pts (G-FC) who were MRD-negative
by 4-color flow cytometry were also tested with the ClonoSEQ immunoglobulin
sequencing assay: 4 were MRD-positive and 4 MRD-negative. 4 pts who were
MRD-negative with both assays remain in remission, while 2/4 pts who were
positive by ClonoSEQ died after follow-up, one of Richter’s transformation com-
plicated by pneumonia and the other related to MDS. Another pt who was MRD
positive by ClonoSEQ underwent allogeneic stem cell transplantation and
remains in remission.
Summary/Conclusions: We conclude that G plus either FC or B results in
excellent long-term disease control in previously untreated pts with CLL, and
has comparable side-effects to other chemo-immunotherapy regimens.
We thank N Crompton, N Tyson, M Rahman (Roche Products Ltd) and R Morar-
iu-Zamfir (F. Hoffmann-La Roche Ltd) for their support.
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THE PROGNOSTIC SIGNIFICANCE OF CLL-IPI AFTER REDUCED
INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANT IN
CHRONIC LYMPHOCYTIC LEUKEMIA: THE MAYO CLINIC EXPERIENCE
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Background: Allogeneic stem cell transplant (SCT) remains the only potentially
curative option for chronic lymphocytic leukemia (CLL) patients. However, up
to 40% of patients treated with Reduced Intensity Conditioning (RIC) - SCT
relapse after transplantation. Recently the CLL International Prognostic Index
(CLL-IPI) was validated as a predictor of 5 year overall survival in CLL patients.
Aims: In this analysis, we aimed to elucidate the factors that may predict the
outcomesfollowing RIC SCT, including the CLL-IPI.
Methods: This is a retrospective analysis of all CLL patients who underwent
RIC-SCT at Mayo Clinic between 2006-2013. The study was approved by the
Institutional Review Board. The prognostic value of several CLL, patient and
transplant related variables were analyzed. Continuous variables were reported
as mean and compared using the T-test. Dichotomous outcomes were com-
pared using the chi-square test. Survival was estimated and compared using
the Kaplan Meier and Log Rank tests.
Results: Between 2006 and 2013, 50 patients with a median age of 56 years
old underwent RIC-SCT for the treatment of CLL. The median time from diag-
nosis to RIC-SCT was 4.7 (0.6-22.9) years. Fourteen (28%) patients had 17p
deletion at time of transplantation. CLL-IPI prognostic score calculated prior to
transplant was intermediate in 30%, high in 42% and very high in 28% of
patients. Disease status at the time of transplant was partial or complete remis-
sion in the majority of patients (39 patients, 78%). The overall transplant related
mortality (TRM) was 6% and the 5-year non-relapse mortality was 14%.
Relapse rates at 5 years were 54%. Acute graft versus host disease (GVHD)
developed in 30 (60%) of patients and chronic GVHD was noted in 32 patients
(64%).We evaluated the impact of CLL characteristics, disease status, and
patient and transplant characteristics on clinical outcomes. Development of
chronic GVHD post-transplant was the dominant predictor of both disease-free
survival (DFS) (HR 0.29, 95% CI=0.10-0.69, P=0.006) and OS (HR 0.04, 95%
CI=0.01-0.19, P&lt;0.0001, Figure 1A). Very high CLL-IPI risk category (28%
of patients) was associated with high relapse rates (82%) post RIC-SCT. DFS
was also different between different CLL-PI categories (18.2% in very high
52.9% in high vs 66.7% in intermediate, p=0.04, Figure 1B). However, there
was no significant difference in overall survival suggesting potential benefits
from novel therapies in relapsed patients.Given that development of chronic
GVHD was the most significant predictor for OS, we evaluated what pre-treat-
ment patient, disease (including CLL-IPI), and transplant characteristics pre-
dicted for subsequent development of chronic GVHD. ZAP70 over expression
(OR 0.09 [95% CI 0.01-0.79], p=0.03), disease status at transplant (progression
versus remission OR 0.22 [95% CI 0.05-0.92], p=0.038), and alemtuzumab
exposure within 3 months of transplantation were associated with lower rates
of chronic GVHD (OR 0.08 [95% CI 0.01-0.79], p=0.03). CLL-IPI was not a sig-
nificant predictor for the development of chronic GVHD in our analysis.
Figure 1.
Summary/Conclusions: This study found that the development of chronic
GVHD post-transplant is themost significant predictor for both OS and DFS in
surviving patients after RIC-SCT in CLL. Interestingly, 82% of patients with very
high risk CLL-IPI relapsed after RIC-SCT. This is the first report to evaluate the
prognostic significance of CLL-IPI for stratifying post-transplant outcomes and
to identify high relapse rates in the very high risk CLL-IPI category.
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IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE
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Background: Several studies showed that tyrosine kinase inhibitors (TKIs)
can safely be discontinued in patients with sustained deep molecular response.
So far, deep molecular response (DMR) and treatment duration were predictive
for successful treatment-free remission (TFR) whereas age, risk scores, gender
and molecular response level before stopping were without influence (Mahon
FX. et al. and Pfirrmann M. et al., ASH 2016). In addition, biomarkers like NK-
cells and CD86+ cells (Ilander M. et al. and Schütz C. et al., Leukemia 2017)
seem to be of impact. ABCG2, OCT1 and ABCB1 are known to play a crucial
role in acquired pharmacokinetic drug resistance and DMR in the context of
nilotinib, imatinib and dasatinib. The influence of these mechanisms have not
yet been analyzed for their correlation with TFR.
Aims: In a substudy of the EUROSKI trial, expression levels of the influx trans-
porter OCT1 and the efflux transporters ABCG2 and ABCB1 (MDR1) have
been quantified in order to investigate their impact on TFR. As all patients are
in DMR, we investigate whether these transporters confer a constitutional dis-
position for TFR.
Methods: The expression levels of OCT1, ABCG2 and ABCB1 have been
determined by an absolute transcript quantification method in the peripheral
blood of patients, enrolled in the EUROSKI trial and screened in our center.
Minimal inclusion criteria were three years TKI treatment and one year MR4
duration (BCR-ABLIS <0.01%). Plasmid standards have been designed includ-
ing the genes OCT1, ABCG2, ABCB1 together with GUS as reference gene.
Expression measurements were performed by qRT-PCR on baseline (day of
stopping TKI treatment) samples. Cutoff levels were determined by the minimal
p-value approach and adjusted for multiple testing by the Bonferroni method.
The predictive significance of the efflux and influx channel transcript levels was
quantified by a multivariate Cox’s regression model. Relapse has been defined
as loss of major molecular response at one time point.
Results: In our cohort, 132 chronic phase CML patients discontinued TKI treat-
ment (87% imatinib 1st line treatment), showing a relapse rate of 46%. Median
MR4 and TKI treatment duration was 4.3 and 7.6 years respectively. The major-
ity of patients were positive for the e14a2 transcript (e14a2+: 63%, e13a2+:
28%, e13a2+/e14a2+: 9%). The mean expression of OCT1 and ABCB1
between ‘relapse’ and ‘no-relapse’ patients showed no significant difference
(p=0.99 and p=0.66), whereas ABCG2 showed a weak differential expression
(1.1% vs 0.8%, p=0.065). Cutoff analyses showed a significant risk stratification
only for the ABCG2 efflux transporter at a distinct cutoff value of 4.5‰ (p=0.04).
Patients with an ABCG2/GUS transcript level above 4.5‰ (n=93) had a 30-
months TFR of 47%, whereas patients with low ABCG2 expression (<4.5‰,
n=39) showed a 12-months TFR of 67%. The hazard ratio and predictive sig-
nificance of the ABCG2 transcript levels were investigated by a multivariate
Cox’s regression model. Only ABCG2 expression was retained as independent
covariate in this model (p=0.033). Thus, patients with an ABCG2/GUS transcript
level above 4.5‰ showed an up to two-time higher risk of relapse after treat-
ment discontinuation (HR=2.1, 95% CI: 1.06-4.05).
Summary/Conclusions: Here we investigated for the first time the impact of
pharmacokinetics in the context of a CML discontinuation trial. ABCG2 but not
OCT1 and ABCB1 (MDR1) predicted treatment-free remission after TKI dis-
continuation. High expression of the ABCG2 efflux transporter correlated with
a two-time higher risk of relapse in multivariate analysis. Further prospective
validation is warranted.
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Background: The human leukocyte antigen-G (HLA-G) gene encodes a tolero-
genic protein known to promote tumor immune-escape mechanisms. 
Aims: We investigated the potential role of HLA-G polymorphisms and soluble
HLA-G molecules in susceptibility to chronic myeloid leukemia (CML), as well
as in achievement and maintenance of deep molecular remission (MR4.5) in
68 patients treated with tyrosine kinase inhibitors (TKIs). 
Methods: The entire HLA-G gene was amplified by long-range PCR and
sequenced using next-generation sequencing (NGS) with Illumina’s Nextera®
technology and a 300 bp paired-end read protocol. The BioVendor sHLA-G
ELISA (RD194070100R sHLA-G ELISA - EXBIO Praha a.s. BioVendor)
immunoassay was used for the quantitative measurement of HLA-G1 and HLA-
G5 soluble forms in EDTA-plasma samples
Results: The frequency of the G*01:03 allele was significantly associated to
CML (10,29% vs 4,46; p=0.001). Patients carrying the G*01:01:01 or
G*01:01:02 allele had a significantly higher mean value of soluble HLA-G com-
pared to patients carrying G*01:01:03 (109.2±39.5 vs 39.9±8.8 units/ml;
p=0.03), and showed significantly lower EFS compared to patients with other
allelic combinations (62.3% vs 90.0%; p=0.05). Moreover patients carrying the
G*01:01:03 allele had significantly higher rates of MR4.5 (100% vs 65%), with
earlier achievement of deep MR4.5 (median of 8 vs 58 months, p=0.001). TKIs
were discontinued in 24 patients after 2 years of confirmed MR4.5. Treatment
free remission (TFR) was 57.7%. None of the patients homozygous for the
G*01:01:01 or G*01:01:02 allele remained in TFR (0% vs 68.4%, p=0.023)
(Figure 1). All patients carrying the G*01:01:03 allele remained in TFR.
Figure 1.
Summary/Conclusions: HLA-G alleles with higher secretion of soluble HLA-
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G would seem to be associated with lower EFS and TFR, possibly because of
a stronger inhibitory effect on the immune system in favor of tumor escape
mechanisms. Conversely, the allele associated to lower levels of sHLA-G pro-
moted achievement of MR4.5 and TFR, suggesting increased cooperation of
the host immune system in CML cell clearance.
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Background: ENESTop (NCT01698905) is evaluating the ability to stop treat-
ment and remain in TFR in pts with CML-CP who achieved a sustained deep
molecular response (MR) after switching from imatinib (IM) to NIL. In the primary
analysis, 57.9% of pts (73/126) who stopped treatment remained in TFR (no
loss of major MR [MMR; BCR-ABL1 ≤0.1% on the International Scale (IS)], no
confirmed loss of MR4 [BCR-ABL1IS ≤0.01%], and no treatment reinitiation) at
48 wk.
Aims: To evaluate the proportion of pts remaining in TFR at 96 wk after stopping
second-line NIL in ENESTop.
Methods: Eligible pts had ≥3 y of prior tyrosine kinase inhibitor treatment (>4
wk IM, then ≥2 y NIL) and achieved MR4.5 (BCR-ABL1IS ≤0.0032%) after
switching to NIL. All pts provided informed consent. Enrolled pts continued NIL
for 1 y in the consolidation phase (MR assessed every 12 wk). Pts without con-
firmed loss of MR4.5 during consolidation were eligible to enter the TFR phase
(MR assessed every 4 wk for the first 48 wk, every 6 wk for the second 48 wk,
then every 12 wk). Pts with loss of MMR or confirmed loss of MR4 reinitiated
NIL. This analysis was conducted when all pts who entered the TFR phase
had completed 96 wk of TFR, reinitiated treatment, or discontinued from the
study (data cutoff, 7 Nov 2016).
Results: At 96 wk of the TFR phase, 67 of the 126 pts (53.2% [95% CI, 44.1%
- 62.1%]) who entered the TFR phase remained in TFR. Four pts who were in
TFR at 48 wk reinitiated NIL due to confirmed loss of MR4 at 60, 72, 90, and
96 wk, respectively. Two other pts discontinued from the study between 48 and
96 wk due to pregnancy (last BCR-ABL1IS of 0.0035% at 60 wk) and pt decision
(maintained MR4.5 through 90 wk), respectively. Based on Kaplan-Meier analy-
sis, the median duration of treatment-free survival has not been reached and
the curve appeared to plateau (Figure 1). Of 56 pts who reinitiated NIL by the
data cutoff, 52 (92.9%) regained MR4 and MR4.5, and the time by which 50%
regained MR4 and MR4.5 was 12.0 and 13.1 wk, respectively. The time by which
50% of pts regained MR4.5 was shorter for pts who reinitiated NIL due to con-
firmed loss of MR4 (n=22; 11.0 wk) vs loss of MMR (n=34; 16.0 wk). Two of the
4 re-treated pts who did not regain MR4 were ongoing in the treatment reiniti-
ation phase (duration, 87.9 and 6.9 wk, respectively); the other 2 discontinued
from the study before 48 wk, 1 due to not regaining MMR (retreatment duration,
20 wk) and 1 due to an adverse event (AE) after regaining MMR. Two deaths
occurred after the first 48 wk of TFR, both in post-treatment follow-up: 1 due to
cardiopulmonary failure 111 days after pt discontinued retreatment due to an
AE, and 1 due to adenocarcinoma 77 days after pt discontinued retreatment
due to initiation of chemotherapy for secondary malignancy. Among pts who
remained in TFR for >48 wk (n=73), rates of all-grade AEs were 82.2% and
63.0% during the first and second 48 wk of TFR, respectively, vs 79.5% during
the consolidation phase. Rates of musculoskeletal pain-related AEs were 47.9%
and 15.1% during the first and second 48 wk of TFR, respectively, vs 13.7%
during the consolidation phase.
Summary/Conclusions: Updated 96-wk analyses from ENESTop showed sta-
bility of the TFR rate, with few pts reinitiating treatment between 48 and 96 wk
after stopping second-line NIL. Rates of overall and musculoskeletal pain-relat-
ed AEs decreased in the second 48 wk of TFR vs the first 48 wk. Overall, these
results demonstrate the durability of TFR after stopping NIL in pts who achieved
a sustained deep MR after switching from IM to NIL.
Figure 1.
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Background: Impaired glucose and lipid metabolism is an adverse effect asso-
ciated with nilotinib (NILO), a tyrosine kinase inhibitor (TKI) used in the treatment
of chronic myeloid leukaemia (CML). Indeed the 5-year safety analysis of the
ENESTnd trial observed elevations in blood glucose and lipid levels in the NILO
arms; importantly NILO-treated patients also showed an increased incidence of
arterial occlusive events. Adipose tissue is a key regulator of lipid and glucose
homeostasis; dysregulation of adipogenesis, altered adipocyte lipid accumulation
and reduced insulin sensitivity are implicated in the pathogenesis of metabolic
disease. We investigated the effect of NILO on adipose tissue to explain the
mechanisms behind NILO-associated metabolic adverse effects. 
Aims: i) To study the effect of NILO and imatinib (IMA) on adipocyte function
and adipokine secretion using an in vitro adipocyte model; ii) To utilise the in
vitro model to explore potential therapeutic strategies to reverse NILO-mediated
effects, and iii) To validate the in vitro results in a pilot patient cohort.
Methods: Differentiating 3T3-F442A murine adipocytes were incubated with
clinically relevant concentrations of NILO (1-20µM) and IMA (5µM), in the pres-
ence or absence of telmisartan (1-10µM), an angiotensin receptor blocker with
potential beneficial effects on insulin sensitivity and lipid homeostasis. Cyto-
toxicity and adipogenesis were assessed by MTT assay and Oil Red O staining,
respectively. Expression of adipogenic genes, peroxisome proliferator-activated
receptor gamma (PPARγ), lipin1 (LPIN1), sterol regulatory element-binding
protein 1 (SREBP1) and glucose transporter 4 (GLUT4) were investigated by
quantitative PCR and secreted adiponectin was measured by ELISA. Plasma
samples were collected from 30 CML patients on either NILO (first line, n=6;
second line, n=9) or IMA (first line, n=15) at baseline and at 3 and 12 months
of therapy, and adiponectin was measured by ELISA. Data are presented as
mean ± SD for 20µM incubations but full concentration response relationships
were measured.
Results: Neither NILO nor IMA were cytotoxic to the adipocytes at clinically
relevant concentrations. A dose dependent reduction in lipid accumulation was
observed for NILO (for 20µM, 0.76 ± 0.005 absorbance units; p<0.01) but not
IMA (0.98± 0.007), compared to vehicle control. NILO, but not IMA, dose
dependently downregulated the mRNA expression of PPARγ (52% downregu-
lation), LPIN1 (28% downregulation) and SREBP1 (54% downregulation). Both
NILO and IMA resulted in significant downregulation of GLUT4 mRNA (NILO,
93%; IMA, 79%; p<0.01) and of secreted adiponectin (NILO, 5.99ng/ml; IMA,
31ng/ml; both p<0.01 in comparison to vehicle control, 79.2ng/ml). Co-incuba-
tion with telmisartan resulted in significant reversal of NILO-mediated effects
on lipid accumulation, adipogenic gene expression and adiponectin secretion.
In the patient cohort, IMA resulted in a significant increase in adiponectin levels
at 3 (38.4±7.1mg/l; p<0.01) and 12 (36.7±7.2mg/l; p<0.01) month time points
compared to baseline (27.3±5.7mg/l). In contrast, second line NILO showed a
trend for reduction in adiponectin at both 3 (15.2±1.8mg/l; p=NS) and 12
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(14.6±1.7mg/l; p=NS) months compared to baseline (21.3±3.4); however this
was not evident in the first line NILO-treated group.  
Summary/Conclusions: NILO-induced detrimental effects on adipocyte lipid
accumulation and adiponectin secretion could be the mechanistic basis for
NILO-mediated metabolic dysfunction. This was reversed by telmisartan, a
PPARg partial agonist. A larger sample size is required to fully characterise the
effect of TKIs on metabolic parameters in the patient population.
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Background: A BCR-ABL1 transcript level at 3 months after the initiation of
imatinib therapy has shown to predict the long-term clinical outcomes in patients
with chronic myeloid leukemia in chronic phase (CP-CML). The levels obtained
earlier than 3 months may also have a similar prognostic significance.
Aims: To assess the prognostic value of the BCR-ABL1 transcript levels at
baseline, and 1 and 3 months after the initiation of a tyrosine kinase inhibitor
(TKI) in predicting the major molecular response (MMR) achievement by 12
months, and to compare the patterns of molecular response (MR) to a TKI
therapy between good and poor responders using a nonlinear model.
Methods: The clinical data were collected from the 178 patients with newly
diagnosed CP-CML who were treated with a TKI at Seoul St. Mary’s Hospital.
BCR-ABL1 transcript levels were obtained at baseline, and 1, 3, 6 and 12
months after the initiation of a TKI. The levels were reported as the percent
ratio relative to the control gene ABL1 in accordance with the International
Scale (BCR-ABL1/ABL1IS[%]). A confirmed MMR was defined as a BCR-
ABL1/ABL1IS≤0.1% on two consecutive occasions. The predictability of the
levels at baseline, and 1 and 3 months post TKI therapy for the achievement
of a confirmed MMR by 12 months was evaluated using a logistic regression
method with a receiver operating characteristic (ROC) analysis. The areas
under the ROC curve (AUCs) were calculated to quantify the predictability. In
addition, the patterns of molecular responses over time were described by a
nonlinear model to compare the model-derived parameters between the
patients who achieved a confirmed MMR by 12 months (“good responders”)
and who did not achieve the MMR (“poor responders”).
Results: Of 178 patients, 67 achieved a confirmed MMR by 12 months but
111 did not. At baseline, the transcript level was not useful to predict the
achievement of a confirmed MMR by 12 months. At 1 month post therapy, the
levels measured at 1 month significantly (p <0.0001) predicted the MMR with
an AUC of 0.77. The patients with the level of 38% or less at 1 month had a
better chance to achieve the MMR. By 3 months post therapy, the transcript
level measured at 3 months (p <0.0001) accurately predicted the MMR with
the AUC of 0.87. The patients with the level of 0.48% or less at 3 months had
a better chance to achieve the MMR. A nonlinear sigmoid model was used to
fit the transcript data from 149 patients as follows: MR=MR0 [1 – tγ / (t50γ+tγ)];
where MR0 is the predicted molecular response at baseline; t, time post TKI
initiation; γ, slope factor; t50, time required to achieve 50% reduction in MR.
Statistically significant differences were observed between the good and poor
responders in the median values for the model-derived parameters of MR0
(73.3% vs 82.2%; p=0.003), γ (4.98 vs 3.32; p <0.0001) and t50 (0.95 month
vs 1.12 month; p=0.002).
Summary/Conclusions: A BCR-ABL1 transcript level measured at 1 month
after the initiation of a TKI may be used as an early indicator to reliably predict
the MMR achievement by 12 months in patients with CP-CML. The level
obtained at 3 months appears to accurately predict the MMR. Further studies
are needed to evaluate the association between the transcript level at 1 month
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Background: Digital PCR (dPCR) generates an absolute read out that is large-
ly robust to variations in PCR efficiency and should reduce the requirement for
standardisation by laboratory-specific conversion factors. DPCR is an appeal-
ing technology for quantitative detection of specific mutations with simultaneous
measurement of the reference gene and is particularly suitable for minimal
residual disease (MRD) diagnostics in chronic myeloid leukaemia (CML). How-
ever, a limitation of the dPCR assays compared to standard quantitative PCR
(qPCR) is the background (termed lower limit of blank, LoB) of 1 or 2 positive
droplets for BCR-ABL (Franke et al., ASH 2015, Cross et al., Leukemia 2016).
The resulting false positive rate (FPR) limits the sensitivity and the ability to
detect deep molecular remissions. This has hindered the definition of the lower
limit of detection (LoD). We report here on the LoB and and the LoD of a newly
developed assay.
Aims: Determination of LoB, LoD, linearity and precision of an optimized BCR-
ABL digital PCR assay.
Methods: The assay was developed by Bio-Rad laboratories and consisted of
a reverse transcriptase reaction followed by a duplex PCR detecting ABL and
both the b2/a2 and b3/a2 transcripts of BCR-ABL. Digital droplet PCR was
performed using the Bio-Rad QX200 system.
LoB and cross-hybridisation were assessed in non-template controls (NTC),
BCR-ABL negative cell lines and healthy wild-type donor samples. LoD, preci-
sion and linearity were measured in serial dilutions of patient’s cDNA in healthy
donor’s cDNA to simulate MMR, MR4, MR4.5, MR5 and MR5.5. Finally, the
assay was tested on a certified CAP MR4.7 sample.
Results: The specificity was >95% for both BCR-ABL and ABL in NTC and wild
type samples. Extensive NTC analysis yielded no false positives for BCR-ABL
PCR (n=0/176; LoB=0) and 1% false positives in ABL PCR (n=2/176; 1-2 positive
droplets, LoB=0). The BCR-ABL assays of healthy donors were positive in 2%
(n=5/234) with 1 positive droplet/positive sample. For 2 wells analysis, the detec-
tion rate for BCR-ABL for MR4.5 and MR5 was 100 and 88%, resulting in a LoD
between 6 and 3 BCR-ABL copies/2 wells. Although the ABL copy number was
only 200000 for 2 wells, the MR5.5detection rate was 42%. However, in a merged
4 wells analysis, the detection rate was 100% for MR5 and 67% for MR5.5 with
an average of 6 and 2 BCR-ABL copies/4 wells (see Table 1). The MR4.7sample
was analyzed repeatedly, with 59 of 60 replicates evaluable. A total of 89 BCR-
ABL copies (1.51/replicate) and 4,329,846 ABL copies (73387/replicate) were
detected, resulting in a ratio of 0.0021 (MR4.69). The false negative rate was
below 3% when combining any pair of replicates, indicating an LoD of MR4.7 for
assays carried out in duplicate.
Table 1.
Summary/Conclusions: We report here on an optimized digital PCR assay
with a LoB of zero and a LoD of 3 copies/2 wells. This highly sensitive and spe-
cific assay allows accurate detection of MRD in BCR-ABL positive diseases
with a detection rate of 100% for MR5 and 67% for MR5.5 in a 4 wells analysis.
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Background: Risk scores in chronic myeloid leukemia (CML) use baseline
characteristics of CML patients in chronic phase to predict outcome and can
be used to make decisions regarding first line TKI choice and monitoring fre-
quencies. Until recently, risk stratification of CML patients was used based on
scores developed in the pre-imatinib era (Sokal and Hasford risk score) with
overall survival as the end point of interest. After the introduction of imatinib,
the EUTOS score was established to predict the chance of achieving CCyR at
18 months, as a proxy for survival. However, since the major causes of death
of CML patients are no longer CML-related, the need for baseline risk prediction
has shifted from overall survival towards disease specific mortality. Therefore,
recently the EUTOS long-term survival (ELTS) score was introduced to predict
the risk of dying of CML in patients treated with first line imatinib.
Aims: The primary objective of this study was to perform a validation of the
ELTS score in an independent cohort of “real-world” population-based CML
patients.
Methods: Data from chronic phase CML patients were derived from the
PHAROS-CML population based registry and Hemobase. Patients were strat-
ified into a low, intermediate and high risk group according to the ELTS score.
Data on “death due to CML” were provided by the Netherlands comprehensive
cancer organization (IKNL) in combination with details from the patient records
and a competing risk analysis was performed, to take death due to other causes
into account.
Results: In total 349 patients were eligible for analysis; 273 patients (78%)
were treated with first line imatinib and 76 patients (22%) were treated with a
first line second generation TKI (2GTKI). Sokal, Hasford and EUTOS risk scores
all did not predict differences in risk of “death due to CML”. The ELTS score
identified 163 patients as low risk (47%), 127 patients as intermediate risk
(36%) and 59 patients as high risk (17%) at diagnosis. The 5 year cumulative
incidence of “death due to CML” was indeed significantly higher in the high risk
group (11%) compared to both the intermediate risk group (2%, p=0.02) and
the low risk group (1%, p=<0.001). Between the intermediate and low risk group
no statistically significant difference in risk of dying from CML was observed. A
subgroup analysis of only imatinib treated patients showed similar results.
Summary/Conclusions: In the current study based on a “real-world” popula-
tion-based CML patient cohort, we were able to validate the predictive value of
ELTS high risk stratification  for “death due to CML” in the current TKI era.
Therefore, the ELTS score should be preferred over Sokal, Hasford and EUTOS
scores in clinical practice.
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FINAL STUDY RESULTS OF DISCONTINUATION OF DASATINIB IN
PATIENTS WITH CML WHO MAINTAINED DEEP MOLECULAR RESPONSE
FOR LONGER THAN ONE YEAR (DADI TRIAL) AFTER THREE YEARS OF
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Background: A second-generation tyrosine kinase inhibitor (TKI), dasatinib, is
more potent in inhibiting BCR-ABLkinase activity than imatinib. We had previ-
ously reported an interim analysis of 63 patients with CML-CP who had dis-
continued dasatinib treatment after maintaining a deep molecular response
(DMR) for more than a year (Lancet Haematology, 2015; 2 (12):e528-35) and
demonstrated that dasatinib could be safely discontinued in patients with a
DMR of at least 12 months. However, longer follow-up results would clinically
be more critical in the treatment of CML.
Aims: In this trial, the total follow-up duration was set as 36 months after the
discontinuation. The aim of the current follow-up study was to investigate
whether those patients were able to discontinue dasatinib treatment for a longer
follow-up period without relapse.
Methods: The eligibility criteria for pre-registration included CML-CP patients,
15 years or older, receiving dasatinib treatment as the second-line or subse-
quent therapy after imatinib. All participants gave written informed consent.
In this trial, DMR was defined as “no detectable BCR-ABL1 transcript deter-
mined using the international scale-based RQ-PCR at a single central labora-
tory (BML Inc., Tokyo, Japan; the cutoff corresponded to BCR-ABL1 0.0069%
IS or molecular response (MR) 4.0).” Patients who showed a sustained DMR
for 1 year (1-year consolidation phase) were subsequently included in the dasa-
tinib-discontinuation stage. RQ-PCR was performed monthly for the first 12
months, and then every 3 months for the second year, and every 6 months for
the third year, after discontinuing dasatinib. Relapse was defined as any posi-
tivity of BCR-ABL1 transcript by RQ-PCR even at one analysis point. In the
present study, we assessed the estimated overall treatment-free remission
(TFR) after discontinuing dasatinib, with 3 years of follow-up.
In addition, we also evaluated the impact of immunological profiles, including
the cell counts of T and NK cell subsets in the peripheral blood throughout the
1-year consolidation phase, on TFR.
Results: Sixty-three patients were included in the dasatinib-discontinuation
stage. The median follow-up was 44.0 months (IQR 40.5–48.0). After the 1-
year-data cutoff, two additional molecular relapses were detected at 18 and 21
months after dasatinib discontinuation. After molecular relapse, 1 patient
showed fluctuating BCR-ABL1 transcript values below MR 4.0 without restarting
dasatinib therapy. A total of 35 out of 63 patients showed molecular relapse.
No patient showed disease progression. The estimated overall TFR rate was
44.4% (95% confidence interval [CI], 32.0-56.2) at 36 months. A high count of
two NK-cell phenotypes (CD3-CD56+ cells ≥539 cells/μl and CD16+CD56+
cells ≥506 cells/μl) and a low count of gd+ T-cells (<120 cells/μl) were detected
to be significant factors affecting molecular relapse in the interim analysis; these
showed sustained significance as predictors of a favorable TFR (P=0.0475,
0.0202, and 0.0093, respectively).
Summary/Conclusions: As the overall provability of TFR was relatively stable
even for a longer follow-up period, our findings provided more compelling evi-
dence supporting dasatinib discontinuation after a DMR for more than 1 year;
this is feasible especially in patients with imatinib intolerance. We also recon-
firmed that the counts of NK cells and functionally specific T-cells in the periph-
eral blood during dasatinib treatment might affect the TFR following dasatinib
discontinuation.
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ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE
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Background: The biological and clinical behavior of hematological malignancies
is not only determined by the properties of the leukemic cells themselves, but it
is also highly affected by the interaction with the microenvironment, pointing to
the existence of an active crosstalk between the two compartments. Previous
studies showed that acute myeloid leukemia (AML) actively modify endothelial
cells ex vivo via several pathways, mainly mediated by VEGF. However, anti-
VEGF therapies haven’t produced successful results in clinical trials.
Aims: Our aim is to perform an extensive study of the vascular niche in the
bone marrow (BM) of AML xenografts to provide a global picture of the vascu-
lature in AML disease and design new therapeutic strategies.
Methods: We combined the use of mouse models of AML, human AML derived
xenografts (PDX) and direct analysis of patients derived samples to study the
vascular niche in AML disease. We used two-photon confocal microscopy as
a powerful tool to functionally image the BM vasculature in vivo.  We used
RNA-sequencing to study the AML-associated transcriptomic profile in vascular
endothelial cells.
Results: We found several abnormalities in the vascular architecture and func-
tion in PDX, such as increased number of endothelial cells, increased microvas-
cular density (MVD), loss of normal sinusoidal architecture and increased
hypoxia. Moreover, vascular permeability was increased as measured via two-
photon imaging. Interestingly, induction chemotherapy failed to normalize the
vascular permeability in the BM, although it significantly reduced the AML
engraftment. Via high-throughput transcriptomic analysis, we showed that AML-
induced hypoxic environment altered the molecular signature of vascular
endothelial cells, activating pro-angiogenic pathways and positively regulating
the response to hypoxia. We identified increased nitric oxide (NO) as a major
mediator of the AML-induced vascular leakiness in the BM. Notably, increased
NO levels were found also in BM aspirates of patients at diagnosis compared
to healthy donors, and failure in reducing NO levels after chemotherapy
appeared to be associated with a higher incidence of unsuccessful treatment.
Strikingly, inhibition of NO production in mouse models of AML and in AML-
derived PDX reduced vascular permeability, preserved normal HSC function
and significantly improved treatment response (Figure 1).
Figure 1.
Summary/Conclusions: We have shown an altered highly permeable vascular
niche in the BM of AML PDX, mainly caused by increased NO production by the
endothelial niche, contributing to disease progression and treatment failure. Our
data call for clinical trials incorporating NOS inhibitors during the remission phase,
to target the abnormal vascular niche and improve AML treatment response.
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Background: Previously, we have reported that our human bone marrow-like
scaffold (huBM-sc) xenograft model allows the engraftment and outgrowth of
normal and malignant hematopoiesis (e.g. multiple myeloma (MM) and acute
lymphoblastic leukemia (ALL) (Groen et al. Blood 2012; Gutierrez et al. JCI
2014) and more recently acute myeloid leukemia (AML; Antonelli et al. Blood
2016). These studies show that i) engraftment is not correlated with prognostic
risk-groups, ii) there is preferential outgrowth in humanized scaffolds compared
to the murine BM, iii) the huBM-sc environment results in better maintenance
of self-renewal potential and less clonal drift of the leukemic cells. Although
the presence of human osteoblasts and bone mimics a human BM niche more
closely than the murine BM in standard xenotransplant models (e.g. NOD-
SCID/NSG mice), still some essential components of the human BM niche, i.e.
human blood vessels, are missing.
Aims: To implement human vasculature in the huBM-sc xenograft model in
order to create a multi-tissue compartment that “maximally humanizes” the
BM-like niche of our scaffolds.
Methods: Towards successful implementation of a human vascular system
we compared: i) scaffold material composition (biphasic calcium phosphate
(BCP) vs tricalcium phosphate (TCP)); ii) scaffold shape (particles vs tubes);
iii) different types of matrigel for cord blood-derived endothelial progenitor cells
(CB-EPCs) embedding.
Results: Histological analysis of these fully humanized scaffolds showed a large
number of functional human CD31-positive blood vessels, and additional CD44,
CD146, LEPR and nestin-positive stromal niche cells. Comparison of the com-
position and the shapes of the scaffolds indicated superiority of TCP and tube-
shaped scaffolds in supporting the formation of vessels. Engraftment of BM-
derived CD34+ cells in the CB-EPC embedded huBM-sc resulted in increased
multilineage hematopoietic engraftment, as compared to huBM-sc without CB-
EPCs. Moreover, we observed that incorporation of CB-EPCs provides faster
kinetics of engraftment of both patient-derived MM and AML cells, and proved to
be essential for the engraftment of blast cells from myelofibrosis patients.
Summary/Conclusions: Thus, with the addition of human CB-EPCs and BM
stromal cells, our scaffold systems now simulate both endosteal and vascular
niches of the BM, thereby more closely recapitulating the human hematopoietic
microenvironment.
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Background: Adult bone marrow (BM) cavities host continuous, demand
adapted and high throughput blood cell production, which is maintained by a
rare population of self-renewing, multipotent hematopoietic stem cells (HSCs).
Aside from its diverse hematopoietic content, the BM is populated by a hetero-
geneous fraction of mesenchymal, endothelial and neural stromal cells, which
provide the necessary tissue infrastructure for hematopoiesis to unfold while
playing fundamental regulatory roles in hematopoietic development. Recent
evidence suggests that tissue regions around BM venous microvessels (termed
sinusoids), which are enriched for mesenchymal CXCL12-abundant reticular
cells (CARc), serve as the principal regulatory niches for HSCs as well as other
hematopoietic progenitor populations. Despite this proposed role as putative
specific niche-restricted components, comprehensive data on the frequency,
global spatial distribution and topology of sinusoidal endothelial and CAR cell
networks is largely lacking to date.
Aims: The principal aim of our work is to employ state of the art imaging tech-
niques to perform a detailed 3D quantitative and structural analysis of the BM
stromal infrastructure, with a special focus on sinusoidal microvasculature and
the CAR cell mesenchymal component, both of which are essential regulators
of HSC maintenance.
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Methods: We have developed i) advanced microscopy techniques allowing
multiscale 3D visualization of entire bone marrow cavities with cellular and sub-
cellular detail ii) customized computational tools enabling the detection and
quantification of discrete cell subsets/structures in 3D images of the BM in an
unbiased fashion, as well as a rigorous spatial statistical analysis of cellular
interactions.
Results: Using 3D-quantitative microscopy (3D-QM) we uncover that BM stro-
mal cells are in fact 15-20 fold more abundant than previously reported. The
massive underestimation of these relevant cell subsets results from the highly
inefficient isolation of these cellular types with currently employed flow cytometry
protocols. Our image-based analyses further reveals that sinusoidal and CAR
cell stromal networks occupy a disproportionately large fraction of the BM
space, consequently constraining the tissue volume available for hematopoietic
cell distribution. In fact, the vast majority of BM resident hematopoietic cells
are unavoidably in direct contact with the CAR cellular projections and in close
proximity (<25µm) to the extraluminal surface of sinusoidal endothelium. 
Summary/Conclusions: Collectively, our quantitative description of stromal
microarchitecture, challenges current models of cell type-specific niche inter-
actions in the BM, which are based in largely inaccurate estimations of cell fre-
quency and spatial confinement of stromal cells in this organ.
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Background: Recently, large LAIR1 insertions at the V-D junction were
described as a novel mechanism to generate antibodies against P. falciparum
RIFIN antigens on infected erythrocytes (Tan et al., Nature 2016). These tem-
plated insertions potentially add a novel biological mechanism used by the
immune system to generate B-cell receptor repertoire diversity.
Aims: We investigated whether templated insertions occur in the B-cell reper-
toire of healthy donors and whether such insertions could be functionally
expressed to explore their biological function.
Methods: We obtained >52,000 unique full-length VDJ sequences of IgM, IgG,
IgA, and IgE isotypes by unbiased ARTISAN PCR (Koning et al., BJH 2016)
from 6 healthy donors. Abnormally long sequences and junctions were searched
for templated insertions by BLAST. Identified VDJ carrying templated insertions
were co-expressed with a panel of 172 light chains on multiple myeloma cell
lines and assessed for surface expression of transgenic immunoglobulin. The
VDJ described by Tan et al. were included as controls. 
Results: Six unique VDJ sequences, all from the same donor, carried a tem-
plated insertion in-frame (E=10-37 – 0). These sequences represented all VDJ
sequences with a CDR3 region >150 bp. Exonic sequences from RPLP0,
ZNF316, and an inverted IGHV-IGHD sequence were identified as insertions
in unmutated IgM VDJ transcripts. The LAIR1 exon described by Tan et al. and
an intergenic region adjacent to IGHD3-22 were identified as insertions in IgG
VDJ transcripts. One IgA VDJ contained two intergenic sequences positioned
closely together on chromosome 22. Somatic hypermutation burden correlated
strongly between the the IGHV segment and the templated insertions (r=0.9944;
p<0.001). All templated insertions harboured cryptic RSS sites at their termini.
All three IgM VDJ carrying templated insertions and the IgG rearrangement
with the IGHD locus templated insertion gave rise to detectable surface
immunoglobulin after coexpression with at least one light chain in the panel.
The IgG VDJ carrying the LAIR1 templated insertion produced no detectable
surface immunoglobulin. In contrast, the VDJ sequences carrying LAIR1 tem-
plated insertions as described by Tan et al. could be expressed with the majority
of the light chains. The IgA rearrangement remains to be tested in this system.
Summary/Conclusions: Templated insertions represent a novel antibody
diversification mechanism. Their presence in naïve B-cells, their exclusive posi-
tioning in VDJ junctions, and the universal presence of cryptic RSS sites point
to primary VDJ recombination or secondary V gene editing as the generating
mechanism. Certain loci (e.g. LAIR1) and certain individuals appear to have
increased susceptibility. The available data suggest RAG to be involved in these
insertions. We propose that templated insertions represent inserted signal
sequences from aberrantly rearranged chromosomal sequences with cryptic
RSS sites.
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Background: Caspases, which are key effectors of apoptosis, have demon-
strated non-apoptotic functions. One of these functions is the differentiation
into macrophages of peripheral blood monocytes exposed to Colony-Stimulat-
ing Factor-1 (CSF1). Conversely, GM-CSF induces the differentiation of mono-
cytes into macrophages in a caspase-independent manner. Macrophages gen-
erated by CSF1 and GM-CSF have distinct polarity. 
Aims: Macrophage polarization plays an important role in the pathogenesis of
diverse human diseases as cancer, leading us to explore if caspase inhibition
would affect macrophage polarization.
Methods: To explore the role of caspases in CSF1 differentiation, we used
human monocytes sorted from buffy coats or from blood of NOX2-deficient
patients treated by cytokines, and we generated monocyte-restricted caspase-
8 knockout and caspase-3/caspases-7 double knockout mice, which were treat-
ed with bleomycin to induce pulmonary fibrosis. 
Results: Caspase activation is involved in the generation of M2 polarized
macrophages. Caspase inhibition delays the ex vivo differentiation of peripheral
blood monocytes exposed to CSF1 and modifies the phenotype of generated
macrophages, e.g. cell shape, surface markers and cytokine secretion. In mice,
caspase knock-out also modified the phenotype of monocytes induced to dif-
ferentiate into macrophages. Caspase activation appeared to be prominent at
the mitochondria level and responsible for the NOX2-dependent generation of
cytosolic radical oxygen species (ROS). Activation of the NOX2 complex is
associated with p47phox cleavage by caspases. Mice treated with bleomycin
typically develop a pulmonary fibrosis. Bleomycin-induced lung fibrosis was
delayed in monocyte-restricted caspase-8 knockout mice and prevented by
treatment with a caspase inhibitory molecule, including zVAD-fmk and the clin-
ically developed IDN6556. This effect was associated with a change in the
polarization of lung-infiltrating macrophages.
Summary/Conclusions: Caspase inhibition in monocytes prevent the devel-
opment of bleomycin-induced lung fibrosis by modifying macrophage polariza-
tion, suggesting that caspase inhibitory molecules may be an exciting thera-
peutic strategy to modulate macrophage polarization with diverse applications
including cancer treatment.
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MULTIPLE MYELOMA-POLARIZED M2C MACROPHAGES PROMOTE A
TUMOR-SUPPORTIVE OSTEOLYTIC MICROENVIRONMENT VIA CXCL13 
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Background: Previous studies including our work revealed a role of MM-edu-
cated M2-like macrophages (MΦ) in MM survival and drug resistance. However,
the mechanism by which neoplastic plasma cells shape BM microenvironment
and affect MΦ polarization is still poorly defined.
Aims: To investigate tumor-promoting changes in the myeloid compartment of
the BM niche that are initiated by MM cells.
Methods: We utilized our in vivo xenograft model of BM-disseminated
human myeloma. The CRISPR/Cas9 technology was used to knockdown
CXCL13 expression in MM cell lines.
Results: BM analysis of mice inoculated with human CXCR4-expressing
RPMI8226 cells revealed a significant increase in M2 MΦ in comparison to
non-injected controls (p<0.01). Characterization of MM-associated changes in
the BM milieu revealed murine chemoattractant CXCL13 being one of the most
profoundly increased factors upon MM development. Elevated CXCL13 was
also detected in blood of MM-bearing animals comparing to healthy controls.
IHC staining identified myeloid cells as the main source of increased murine
CXCL13 detected in MM-occupied BM. Murine BM CXCL13 mRNA expression
strongly correlated with human β2-microgllobulin mRNA levels (p<0.0001
R2=0.64), indicating the interrelation between tumor burden and CXCL13 induc-
tion. Reduction of MM load upon the treatment with anti-myeloma agents borte-
zomib and panobinostat resulted in corresponding correlated decrease in
murine CXCL13, both in BM and blood, suggesting the possible utilization of
CXCL13 levels as surrogate marker of anti-MM treatments response.
CXCL13 expression by MΦ is known to represent specific anti-inflammatory
M2c phenotype acquisition. Indeed, we observed a significant up-regulation of
additional M2c markers, such as MERTK and MRC1 in the BM occupied with
MM in strong correlation with CXCL13 expression (p<0.001 R2=0.65). In vitro
studies confirmed the ability of MM cell lines (n=6) to induce CXCL13 and con-
current expression of M2c markers (MERTK, CD206, CD163) in co-cultured
human monocytes and MΦ. Interaction with MΦ reciprocally induced CXCL13
expression in MM cell lines and primary human CD138+ cells. Mechanistically,
TGFβ signaling was involved in CXCL13 induction in both MM cells and MΦ,
as TGFβ receptor inhibitor SB431542 interfered with CXCL13 induction. Osteo-
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clastogenic assays were used to elucidate the down-stream effects of the ele-
vated CXCL13. Recombinant CXCL13 as well as medium produced by co-cul-
tured MM-MΦ increased RANKL expression and induced TRAP+ osteoclast
(OC) formation in vitro, while CXCL13 neutralization blocked these activities.
We next abrogated CXCL13 expression in MM cell lines using the
CRISPR/Cas9 technology. The loss of CXCL13 had no effect on MM in vitro
growth or drug sensitivity. However, mice inoculated with CXCL13-silenced
MM cells developed significantly weaker BM disease compared to mice receiv-
ing the non-manipulated cells. Reduced tumor load correlated with decreased
numbers of M2c MΦ in BM, decreased bone disease, and lower expression of
OC-associated genes. Finally, the presence of CXCL13 in primary MM samples
was evaluated. Elevated levels of CXCL13 transcript and protein were detected
in BM aspirates from MM patients (n=24) in comparison to normal BM (n=5)
and were in correlation with gene expression signature associated with OC
activation and M2c MΦ phenotype (Figure 1).
Figure 1.
Summary/Conclusions: Our findings suggest that bidirectional interactions
of MΦ with MM tumor cells result in M2c MΦ polarization, CXCL13 induction
and subsequent OC activation, enhancing their ability to support bone resorp-
tion and MM progression. CXCL13 may thus serve as potential novel target
for the diagnosis and treatment of MM.
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RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN
FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN
FETAL B PROGENITOR
S. O’Byrne1,*, N. Elliott1, G. Buck1, B. Liu1, B. Povinelli 2, N. Fordham2,
E. Louka2, K. Bartolovic2, A. Karadimitris3, A. Mead2, I. Roberts12, A. Roy1
1Paediatrics, University of Oxford, 2MHU, Weatherall Institute of Molecular
Medicine, Oxford, 3Centre for Haematology, Imperial College London, London,
United Kingdom
Background: The cellular hierarchy of normal human fetal B-lymphopoiesis
remains poorly defined. We have previously identified a novel population of
PreProB progenitors (CD34+CD19+CD10-) in fetal liver (FL)[1] that is further
expanded in fetal bone marrow (FBM)[2], and co-exists with adult-type
CD34+CD19+CD10+ ProB progenitors. Increasing evidence indicates that
infant ALL and many cases of childhood ALL arise in fetal life, suggesting that
ontogeny-related changes in B-cell development may be important for in utero
leukaemia initiation. Therefore, understanding the human fetal B cell hierarchy,
especially the differences between PreProB and ProB progenitors may be key
to understanding the origins of infant and childhood leukaemia.
Aims: To determine B cell developmental pathways in human second trimester
FBM, with a view to establishing the fetal B cell hierarchy.
Methods: The characteristics of the haematopoietic stem cell (HSC), lym-
phomyeloid multipotent progenitor (LMPP), early lymphoid progenitor (ELP)
and committed B-progenitor compartments of FBM samples were analysed by
multiparameter flow cytometry, differentiation and clonogenic assays, transcrip-
tome analysis and single cell RQ-PCR.
Results: All stages of B cell development were demonstrable in human FBM
up to transitional B cells with a rapid expansion of B progenitor numbers from
the LMPP stage. FBM HSC, progenitors (MPP, LMPP, ELP, PreProB and ProB-
progenitors) and B-cells were FACS-sorted for functional/ molecular assays.
Functional assays: B cell differentiation assays demonstrated expected multi-
lineage output from HSC, MPP and LMPP, but a pure B cell output from
PreProB and ProB progenitors. While PreProB progenitors gave rise to ProB
progenitor cells in vitro, the converse was not true; thereby placing PreProB
upstream of ProB in the B cell hierarchy. Myeloid colony assays gave expected
multilineage output from HSC/MPP; and GM colonies from LMPP; while ELP,
PreProB and ProB progenitors generated no colonies, confirming their lymphoid
commitment. Transcriptome analysis and single cell RQ-PCR: Fetal HSPC
populations were flow sorted and analysed by RNASeq of bulk populations as
well as single cell RQ-PCR using a customised 96-gene panel. Stem cell pop-
ulations (HSC, MPP and LMPP) showed good spatial segregation from lym-
phoid progenitors (ELP, PreProB and ProB) by principal component analysis
both at bulk and single cell level. Single cell analysis demonstrated a differen-
tiation trajectory from HSC to mature B cells with PreProB progenitors clustering
between LMPP and ProB. There was sequential upregulation of B lymphoid
specific genes from HSC to ProB progenitors and the level of expression was
always lower in PreProB compared to ProB, suggesting they are upstream of
ProB. PreProB progenitors demonstrated a distinct gene expression profile
compared to ProB progenitors. 739 genes were significantly differentially
expressed (FDR<0.1) between these two populations with 538 of these being
upregulated in PreProB, including some myeloid and leukaemia-associated
genes. Genes overexpressed in ProB included B cell specific genes. 
Summary/Conclusions: Detailed immunophenotypic, functional and molec-
ular studies allow us to propose a human fetal B cell developmental hierarchy
for the first time in which the unique PreProB progenitors are distinct from and
lie upstream of the ProB progenitors. These results may have important impli-
cations in understanding the pathogenesis of infant and childhood leukaemias.
References: [1] Roy, A. et al., PNAS, 2012. [2] Roy, A. et al. Blood 2014.
124:4331.
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HUNDREDS OF EMBRYONIC HEMATOPOIETIC PRECURSORS
CONTRIBUTE TO LIFE-LONG HEMATOPOIESIS
M. Ganuza Fernandez1,*, T. Hall1, D. Finkelstein2, A. Chabot1, G. Kang3,
S. McKinney-Freeman1
1Experimental Hematology, 2Department of Computational Biology, 3Depart-
ment of Biostatistics, St. Jude Children’s Research Hospital, Memphis, United
States
Background: Prior studies of the frequency of emerging hematopoietic stem
cells (HSCs) and their precursors during mammalian ontogeny have all required
embryo disruption, transplantation assays and concluded that very few HSC
emerge from endothelial precursors during embryogenesis to establish life-
long hematopoiesis. An alternative approach independent of embryo disruption
or transplantation would more accurately reflect the true dynamics of HSC
emergence during mammalian development.
Aims: To determine the frequency of emerging HSCs and their precursors
throughout mammalian ontogeny.
Methods: Here, we employed the Confetti allele, in which a cassette targeted
to the ROSA26 locus randomly and permanently marks cellular progeny with
GFP, YFP, RFP or CFP when exposed to Cre recombinase. We determined
empirically that sample-to-sample variance in the distribution of Confetti colors
in the blood of the following adult mice inversely correlated with the number of
hematopoietic precursors specified during the indicated window of Cre recom-
binase activity: ROSA26(Confetti/+) Flk1(+/Cre) (mesodermal precursors, E7),
ROSA26(Confetti/+) VE-cadherin(+/Cre) (mid-gestation endothelial precursors,
E8.5-E10.5), and ROSA26(Confetti/+) Vav1(+/Cre) (hematopoietic progenitors
E11.5-E14.5). This correlation was used to estimate the number of hematopoi-
etic precursors emerging during each stage of development.
Results: An inverse correlation of sample-to-sample variance in the distribution
of Confetti colors and numbers of labeled initiating events was established in
vitro by plating limiting dilution replicates of immortalized Confetti+ fibroblasts
and assessing the resulting sample-to-sample Confetti variance of each cell
dose plated. We thus derived a linear formula to estimate numbers of initiating
events using the sample-to-sample Confetti color variance in a particular tissue
(e.g. peripheral blood (PB)). We tested this formula in vivo via limiting dilution
transplantation with Confetti+ bone marrow. Classic limiting dilution analysis
of transplanted mice revealed about 1/12,000 repopulating units in the trans-
planted BM. The sample-to-sample variance in the distribution of Confetti colors
in the PB of recipients yielded a similar estimate of the frequency of repopulat-
ing events, validating our empirically-derived formula. We further validated our
approach in vivo by calculating 222 repopulating units in transplant recipients
of dissociated cultured E11.5 aorta-gonad-mesonephros (AGMs) explants. This
finding correlates very well with previous reports that E11.5 cultured AGM
explants contain about 150 transplantable HSCs. Analyses of the sample-to-
sample variance of the Confetti colors in the blood of cohorts of ROSA26(Con-
fetti/+) Flk1(+/Cre), ROSA26(Confetti/+) VE-cadherin(+/Cre) and ROSA26
(Confetti/+) Vav1(+/Cre) mice revealed that about 719 mesodermal precursors,
633 endothelial precursors and 545 fetal liver hematopoietic precursors con-
tribute to the emerging hematopoietic system. Our findings are in sharp contrast
to previous reports that very few precursors and emerging hematopoietic pro-
genitors establish the hematopoietic system. Our data further suggest that a
“developmental bottleneck” exists after the fetal liver stage of hematopoietic
ontogeny that restricts the numbers of precursors that ultimately contribute to
life-long hematopoiesis.
Summary/Conclusions: We report here a novel approach to examine the
complexity of the emerging hematopoietic system without perturbing the devel-
oping embryo. This represents a new platform to identify biologically relevant
processes that govern the dynamics of different populations during embryonic
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development. We thereby report for the first time that the clonal origin of blood
is much more complex than previously thought, with hundreds of precursors
contributing to the establishment of the mammalian blood system at multiple
stages of ontogeny.
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A20 RESTRAINS THYMIC REGULATORY T CELL DEVELOPMENT
T. Haas1,*, J.C. Fischer1, V. Otten1, S. Spoerl1, H. Poeck1
1Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, TU
München, München, Germany
Background: Maintaining immune tolerance requires the production of Foxp3
expressing T regulatory (Treg) cells in the thymus. Activation of NF-κB tran-
scription factors is critically required for Treg cell development, partly via initi-
ating Foxp3 expression. NF-κB activation is controlled by a negative feedback
regulation through the ubiquitin editing enzyme A20, which reduces pro-inflam-
matory signaling in myeloid cells and B cells. In naive CD4+ T cells, A20 pre-
vents necroptosis and promotes inflammation. 
Aims: This study is aimed at analyzing the role of the NF-κB regulator A20 in
Treg cell development and function.
Methods: We used A20F/F CD4Cre mice, which specifically lack A20 in T cells,
to analyze the Treg cell compartment in vivo. We characterized expansion and
differentiation of A20-deficient Treg cells in vitro. We performed competitive
bone marrow engraftment between WT and A20-deficient bonemarrow in vivo
to analyze whether one bone marrow compartment would outperform another
or would favor development of certain T cell or other immune cell subsets. We
performed alloegeneic hematopoietic stem cell transplantation with WT BM+T
cells  ± WT vs A20-deficient Treg cells to analyze whether A20-deficient T reg
cells would reduce GVHD to the same extent as WT Treg cells.  
Results: Using mice deficient for A20 in T lineage cells, we show that thymic
and peripheral Treg cell compartments are quantitatively enlarged due to a
cell-intrinsic developmental advantage of A20-deficient Treg cells. A20-/- Treg
cells efficiently suppressed effector T cell mediated graft-versus-host disease
after allogeneic hematopoietic stem cell transplantation, demonstrating normal
suppressive functionality. Holding thymic production of natural Treg cells in
check, A20 thus integrates reduced regulatory T cell activity and increased
effector T cell survival into an efficient CD4+ T cell response.
Summary/Conclusions: In light of the largely anti-inflammatory effects that
have been attributed to A20 in many cell types, this proinflammatory aspect of
A20 physiology in effector and regulatory CD4+ T cells is particularly important
since it may contribute to a change of perception of the functions of A20 as a
negative regulator of NF-κB in the context of inflammation. Whether targeted
modulation of A20 activity allows the induction of Treg cell mediated immune
tolerance or, alternatively, boosting of favorable T cell immunity is a question
of translational relevance that needs to be addressed in the future.  .
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THE TRANSCRIPTION FACTOR C/EBPG REGULATES MAST CELL
DEVELOPMENT AND FUNCTION
M. Kardosova1,*, L. Potuckova2, I. Halova2, P. Zjablovskaja1, L. Draberova2,
P. Draber2, M. Alberich-Jorda1
1Hematooncology, 2Laboratory of Signal Transduction, Institute of Molecular
Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Repub-
lic
Background: Mast cells are key effector cells involved in protection against
infection and allergic responses. Defects in mast cells are related to immuno-
logical disorders, and therefore it is critical to fully understand the transcriptional
network that controls their generation and activity. Differentiation of progenitors
to mature mast cells is promoted by several transcription factors, such as
GATA1, GATA2, STAT5, and MITF, and requires downregulation of C/EBPα.
Recently, we identified another member of the C/EBP family of transcription
factors, C/EBPγ, as a direct C/EBPα target gene. However, the role of C/EBPγ
in mast cells remains so far elusive.
Aims: In this study we aim to determine the role of the transcription factor
C/EBPγ in mast cell development and function. Next, we investigate the mech-
anisms by which C/EBPγ is controlling these processes. 
Methods: In order to determine the role of C/EBPγ in murine mast cells, we
generated Cebpg conditional knockout mice, which allow excision of Cebpg in
the hematopoietic system from the early embryogenesis. We employed
Cebpgflox/flox Vav-1Cre- and Cebpgflox/flox Vav-1Cre+ mice, referred here as
WT and Cebpg KO, respectively. Excision of Cebpg was assessed by RT-PCR
and western blot analysis in bone marrow and spleen cells. Using flow cytom-
etry, we enumerated mast cell counts in the peritoneal cavity of healthy WT
and Cebpg KO mice. To elucidate whether C/EBPγ plays role in mast cell
response to bacterial infection, we challenged these mice intraperitoneally with
lipopolysaccharide (LPS). Finally, we used intraperitoneal injection of distilled
water to eradicate peritoneal mast cells and then monitored repopulation of
peritoneum over time. To further explore the role of C/EBPg in mast cells in
vitro, we established bone marrow derived mast cells (BMMCs) and determined
their growth (cell numbers), morphology (toluidine blue staining), and transcrip-
tion factors expression (RT-PCR) at different time points. Degranulation poten-
tial of BMMCs was specified by measuring the percentage of b-glucuronidase
released to the supernatant upon anti-TNP IgE sensitization and TNP-BSA acti-
vation. To investigate the effects of absence of Cebpg during mast cell migra-
tion, we employed transwell migration assays. 
Results: We verified efficient ablation of Cebpg on mRNA and protein level in
bone marrow and spleen of Cebpg KO mice. Analysis of peritoneal cavity of
WT and Cebpg KO mice showed similar frequency and numbers of mast cells
in steady state conditions. However, Cebpg deficient mice exhibit increased
number of peritoneal mast cells after LPS stimulation in comparison to WT con-
trol littermates. Surprisingly, mice lacking Cebpg presented defective peritoneal
mast cell repopulation. Since mast cells are scarce and difficult to isolate from
in vivo models, we employed BMMCs to investigate the effects of Cebpg abla-
tion in mast cell development and function. We observed that bone marrow
from Cebpg KO mice generated reduced number of BMMCs in comparison to
WT controls. Functionally, we demonstrated that deletion of Cebpg reduced
mast cell migration towards antigen, SCF or PGE, and impaired degranulation
upon FcεRI-mediated activation. Further, BMMCs exhibit increased expression
of C/EBPα in the absence of C/EBPγ.
Summary/Conclusions: In summary, we revealed C/EBPγ as important tran-
scription factor which suppresses C/EBPα expression, thereby favoring mast
cell development and function. Our data identifies a new component of the
mast cell transcriptional network and provides a better understanding of mast
cells in normal physiological conditions and disease.
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TRANSCRIPTIONAL DIVERSITY AND DEVELOPMENTAL POTENTIAL OF
EARLY HEMATOPOIETIC PROGENITORS REVEALED BY CELLULAR
BARCODING AND TRANSCRIPTOME-WIDE PROFILING
D. Tronik-Le Roux1,*, A. Legrand2, V. Michaels2, J. Renard1, S. Chalabi3,
R. Olaso3, J.-F. Deleuze3, C. Battail3, S. Ezine2
1CEA, 2INSERM, Paris, 3CEA, Evry, France
Background: One of the main complications of anti-cancer therapies or bone
marrow transplantation protocols is their deleterious effect on the blood system,
leading to prolonged neutropenia and increased risk for infections. Manipulating
hematopoietic stem cells differentiation pathways to favor production of specific
lineage-committed progenitors might optimize blood recovery. 
Aims: In this study we aimed 1) to determine and quantify the contribution of
medullary progenitor populations (MPP) to the repopulation of the T cell pathway
using the barcode cellular labelling strategy that we have previously developed
and 2) to decipher the heterogeneity of these MPP at the transcriptional level. 
Methods: Three different MPP subsets, of the following phenotype:
VCAM1+Flt3 (MPP1); VCAM1-Flt3+ (MPP2) and VCAM-1Flt3+ILR7 (CLP),
were tagged with different barcodes carried by a collection of lentivirus and
transplanted in mice. Barcoded cells in recipient mice were analyzed by flow
cytometry. For whole transcriptome strand-specific sequencing, three biological
replicates, per cell population, were sequenced at high depth of coverage (2 x
120 million reads).
Results: The results allowed the in vivo dynamic tracking of the progeny of the
barcoded progenitors in transplanted recipients. Moreover, transcriptome-wide
profiling allowed to identify, by cluster analysis of RNAseq profiles together with
gene ontology annotation, unique co-expressed markers for the prospective
isolation of these populations. Unsupervised classification correctly classified
reference surface markers, currently used to purify progenitors, which validate
our bioinformatic methodology. Transcriptional regulation of these cell surface
markers was further assess by searching for co-expressed transcription factors
and enriched binding sites in their promoters. Their grouping enabled to estab-
lish undescribed regulatory networks, specific to each progenitor cell. 
Summary/Conclusions: Collectively, the cellular barcoding tool and the molec-
ular changes observed at RNA and functional levels as they occur in vivo in the
context of physiologic commitment processes, highlighted data that contribute
to a deeper understanding of the dynamic of T-lineage differentiation and the
lineage restriction process.
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LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-
PREDOMINANT HODGKIN LYMPHOMA TREATED WITHIN THE RANDOM-
IZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN
STUDY GROUP
D.A. Eichenauer1,*, A. Plütschow1, M. Fuchs1, B. von Tresckow1, V. Diehl2,
P. Borchmann1, A. Engert1
1First Department of Internal Medicine, 2German Hodgkin Study Group, Uni-
versity Hospital Cologne, Cologne, Germany
Background: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
is a rare entity accounting for approximately 5% of all Hodgkin lymphoma (HL)
cases. Pathological and clinical features differ from classical HL (cHL). Patho-
logically, the malignant lymphocyte predominant (LP) cells stain consistently
positive for CD20 and are negative for CD30. Clinically, NLPHL often has a
rather indolent course. Despite of these differences, the first-line treatment of
NLPHL is mostly very similar to cHL. However, analyses on the long-term
course of patients with NLPHL who were treated identically to cHL are scarce.
Aims: To shed more light on characteristics and outcome of NLPHL patients
treated identically to cHL, we performed an analysis using the database of the
German Hodgkin Study Group (GHSG).
Methods: A total of 471 patients with NLPHL who had received first-line treat-
ment within the randomized GHSG HD7-HD15 trials for newly diagnosed HL
were identified. The studies were conducted between 1993 and 2009. Patients
at all stages (early favorable: HD7, HD10, HD13; early unfavorable: HD8, HD11,
HD14; advanced: HD9, HD12, HD15) were included.
Results: Among the 471 NLPHL patients, the median age was 39 years;
76% of patients were male; 53% of patients had early favorable, 16% had
early unfavorable and 31% had advanced-stage disease. Study treatment
consisted of ABVD- or BEACOPP-based chemotherapy alone, radiotherapy
(RT) alone or combined-modality treatment (CMT). After a median observa-
tion of 9.2 years, the 8-year progression-free survival (PFS) rate for the whole
patient group was 81.3% (83.2% for early favorable, 85.2% for early unfa-
vorable, 76.2 for advanced stages). 80 of 471 patients (17%) had refractory
disease or relapsed during the course of follow-up (primary disease progres-
sion: 8 patients; early relapse: 6 patients; late relapse: 66 patients). Second
malignancies including histological transformation into aggressive B-cell non-
Hodgkin lymphoma (NHL) occurred in 48/471 patients (10%) (solid tumor:
25 patients; leukemia: 7 patients; NHL: 13 patients; unspecified malignancy:
4 patients). For all 471 patients included in the present analysis, the 8-year
overall survival (OS) rate was 93.3% (95.1% for early favorable, 98.6% for
early unfavorable, 87.4% for advanced stages). A total of 43 deaths were
observed during follow-up resulting in a death rate of 9%. However, only a
minority of these deaths was NLPHL-related (n=10). In contrast, most patients
died from second malignancies (n=20) or due to other causes (n=13) such
as heart failure and lung disease.
Summary/Conclusions: Taken together, the results from this large analysis
on NLPHL patients prospectively treated and followed within randomized clin-
ical studies for newly diagnosed HL indicate an excellent lymphoma-specific
outcome. Nonetheless, further treatment optimization is necessary as the
majority of the observed deaths were not NLPHL-related but due to second
malignancies or other treatment-related late effects. Thus, future clinical trials
including NLPHL patients should evaluate whether it is possible to reduce the
treatment intensity without compromising efficacy. This goal may be achieved
by the partial replacement of conventional chemotherapy by targeted drugs
such as anti-CD20 antibodies as well as the reduction of RT fields and doses.
P276
ADVANCED HODGKIN LYMPHOMA IN THE EAST OF ENGLAND CANCER
NETWORK: A 10-YEAR COMPARATIVE ANALYSIS OF OUTCOMES FOR
ABVD AND ESCALATED-BEACOPP TREATED PATIENTS AGED 16–59
J. Russell1,*, A. Collins2, A. Fowler3, M. Karanth4, C. Saha2, V. Shyamsundar1,
S. Docherty1, K. Maw5, J. Padayatty6, A. Hodson7, J. Wimperis2, S. Sadullah5,
N. Grigoropoulos1, B. Uttenthal1, G. Follows1
1Cambridge University Hospitals NHS Foundation Trust, Cambridge, 2Norfolk
and Norwich University Hospital, Norwich, 3Peterborough City Hospital, Peter-
borough, 4West Suffolk Hospital, Bury Saint Edmunds, 5James Paget Univer-
sity Hospital, Great Yarmouth, 6Queen Elizabeth Hospital, King’s Lynn, 7Ipswich
Hospital, Ipswich, United Kingdom
Background: The majority of young patients with advanced-stage Hodgkin
lymphoma (HL) in the UK are managed with ABVD. However, following publi-
cation of the HD9 trial results in 2009, escalated-BEACOPP (escB) was intro-
duced by some UK centres to improve disease control in poor-risk patients.
Aims: We present a 10-year retrospective multicentre analysis for advanced-
stage HL patients, aged 16–59, diagnosed between 2004–2014 in the East of
England Cancer Network and treated predominantly outside of clinical trials.
Our study period includes the 5 years before, and after, the introduction of
escB. We estimated the 5-year progression-free survival (PFS) and overall
survival (OS) rates for the whole cohort, and treatment subgroups, to assess
the impact of escB on survival outcomes.
Methods: We collected data retrospectively from 8 hospitals in the East of
England using electronic medical records and cancer registry data. Only
patients with a minimum follow-up of 18 months from diagnosis were included.
The 5-year PFS and OS were estimated using the Kaplan-Meier method, and
subgroups were compared using the standard log-rank test.
Results: We identified 250 patients (stage IIA bulk–IVB) treated in the East
of England Cancer Network over a 10-year period from a referral population
of 2.64 million (incidence: 0.95 cases per 100,000). Six of the 8 centres intro-
duced escB for poor-risk patients, as determined by physician and patient
choice; 44 patients were treated with escB, 202 with ABVD, 3 with alternative
regimens, and 1 died pre-treatment. The median age at diagnosis was 35
years (16–59) and the median follow-up was 72 months (19–139). The 5-
year PFS for all patients was 82% and 5-year OS was 92%. There was evi-
dence of a physician–patient preference to treat poor-risk patients with escB,
as a greater proportion of escB patients had a high international prognostic
score (IPS 3+) than in ABVD patients (escB 75% vs ABVD 38%, p<0.0001).
For the whole cohort, PFS was better for patients treated with escB compared
with ABVD (5-year PFS 95% vs 80%; HR 4.3 (95% CI:1.97–9.7), p=0.0261),
but there was no difference in OS (5-year OS 97% vs 92%; HR 2.6 (95%
CI:0.69–10.4), p=0.312). However, patients with IPS 3+ had both a PFS and
OS advantage when treated with escB compared with ABVD (5-year PFS
96% vs 74%; HR 9.24 (95% CI:3.43–24.89), p=0.012: 5-year OS 100% vs
84%; p=0.0325). Twenty-nine ABVD patients and 3 escB patients had at least
1 subsequent stem cell transplant (including 6 allografts post-ABVD and 3
allografts post-escB), and there was equal use of consolidation radiotherapy
between regimens (11% of both ABVD and escB patients). Treatment-related
infertility is an important consideration for escB patients. In our patient pop-
ulation, of the 20 pre-menopausal women treated with escB, 11 of the 14
(78.6%) aged <30 years at diagnosis regained menstrual periods during fol-
low-up, 5 (45.5%) of whom subsequently conceived (including 6 live births,
1 miscarriage, and 1 termination). Only 1 of the 6 (16.7%) pre-menopausal
women aged >30 years at diagnosis regained menstrual periods, which were
not sustained beyond 3 years’ follow-up.
Summary/Conclusions: Our data reflect clinical trials results which indicate
a first-remission PFS but not OS advantage for unselected young advanced-
stage HL patients treated with escB compared with ABVD. However, our data
strongly suggest that patients with a poor IPS score derive a PFS and OS ben-
efit from treatment with escB compared with ABVD.
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IMPACT ON SURVIVAL OF EARLY DETECTION OF RECURRENCE IN THE
FOLLOW-UP OF HIGH RISK HODGKIN LYMPHOMA IN FIRST COMPLETE
REMISSION
N. Pugliese1,*, L. Simeone1, R. Della Pepa1, C. Giordano1, I. Cappuccio1,
I. Zacheo1, G. Campagna1, C. Cerchione1, P. Zeppa2, C. Salvatore3, F. Pane1,
M. Picardi1
1Hematology, University of Naples Federico II, Naples, 2Department of Medi-
cine and Surgery, University Medical School, Salerno, Salerno, 3Department
of Economics, University of Molise, Campobasso, Italy
Background: Despite the high complete response (CR) rate to anthracycline-
including first-line therapy, approximately one-third of patients with advanced-
stage Hodgkin lymphoma (HL) relapses. Many relapses (30–50%) are clinically
asymptomatic, without any physical and/or laboratory signs. For patients at
high-risk of relapse, a close monitoring, based on imaging procedures is justi-
fied if an early detection of recurrence would allow a timely administration of
salvage therapy and a survival improvement. 
Aims: The purpose of this study was to evaluate the response rate to salvage
therapy of relapsed HL by comparing patients who received surveillance with
conventional clinical assessments versus patients who received surveillance
with imaging procedures. The primary end-point was to assess the rate of CR
to salvage therapy at first relapse (confirmed by FDG PET/TC performed before
ASCT). Secondary endpoints were: the overall rate of recurrence after first
CR, the stage and extranodal involvement at relapse, and the disease-free
survival (DFS), from the end of salvage treatment.
Methods: Between June 2001 and December 2009, we analyzed 306 patients
with high-risk HL in CR after anthracycline-including induction treatment. In
this case-control study, the first cases (n=156) consisted of patients who
received a conventional follow-up program including symptom assessment,
blood tests and physical examination; in these patients imaging procedures
were performed only in case of suspected relapse (Historical group). Subse-
quent patients (n=150) received routine imaging procedures comprising ultra-
sonography (US) for the evaluation of superficial, anterosuperior mediastinal,
abdominal, and pelvic lymph nodes (SMAP US), and chest radiography (CXR),
as integrated part of the follow-up strategy (Imaging group). Follow-up proce-
dures were performed at 4, 8, 12, 16, 20, 24, 30, 36, 48, 60, 84, and 108
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months after treatment discontinuation in both groups. Relapses were docu-
mented by histologic examination in both groups. When relapse was docu-
mented all patients received salvage therapy with high dose chemotherapy
(DHAP), for at least two courses, followed, in case of CR, by ASCT. 
Results: After a median 62-months observation (range, 4–108), 83 patients,
evenly distributed in the two groups, had a relapse of disease. Of these, 29 of
43 patients (67.4%) of the historical cohort vs 17 of 40 patients (42.5%) of the
imaging cohort, showed a larger spread of disease at restaging, i.e. stage supe-
rior to IIB, and a more frequent extranodal involvement, 10/43 (23.3%) patients
in the historical group vs 3/40 (7.5%) patients in the imaging group (p=0.01).
Furthermore, if we considered only asymptomatic patients, one recurrence was
detected in 26 of 43 patients in the imaging group and 17 of 40 patients in the
historical group, p=0.02. CR rate with second line therapy were higher in the
imaging group (27, 67.5%) compared with the historical group (19, 44.2%;
p=0.032). The 3-years DFS was 75% in the imaging group and 36% in the his-
torical group, p=0.02.
Summary/Conclusions: This is the first prospective case-control study using
SMAP-US plus CXR to monitor patients with advanced stage HL. We show
that SMAP-US plus CXR is a valuable tool to improve follow-up in patients with
a high risk of recurrence. Our data indicate that the early detection of HL recur-
rence allows to begin rescue therapy in patients with a more limited disease
and, consequently, increase its effectiveness in terms of probability to response
and DFS.
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LATER LINE DRUG TREATMENT PATTERNS OF CLASSICAL HODGKIN’S
LYMPHOMA PATIENTS IN CANADA, FRANCE, GERMANY AND THE UNITED
KINGDOM
K. Byrne1,*, A. Juarez Garcia2, P. Hallworth1, S. Blackburn1, M. Lees3
1Adelphi Real World, Bollington, United Kingdom, 2WW HEOR, Bristol-Myers
Squibb, Mexico City, Mexico, 3WW HEOR, Bristol-Myers Squibb, Paris, France
Background: Whilst cHL is seeing increasing ‘cure’ rates, a cohort of patients
remain who, due to multiple relapses, require 3rd (3L) or 4th (4L) lines of drug
treatment. Real world treatment patterns for RRHL patients are currently less
understood.
Aims: To understand the drug treatment patterns of cHL patients in 3rd or later
lines. 
Methods: Real-world data were collected through a cross-sectional survey
administered to physicians in Canada (Ca), France (Fr), Germany (Ge), and
the UK between May and Sep 2016. Physicians provided data on the last 8
cHL patients receiving 3rd or 4th line drug treatment. Data captured included
demographics, disease history and treatment patterns. Auto/allo stem cell
transplants (auto/alloSCT) were not classified as a treatment line and limited
data was available to determine when a SCT was received. Summary statis-
tics were reported and differences between sub-groups assessed using chi-
square tests.
Results: In total 116 physicians (Ca, 16; Fr, 31; Ge, 44; and UK, 25) provided
information on 959 cHL patients (Ca, 128; Fr, 243; Ge, 351; and UK, 237) on
3rd or later lines of drug treatment. Data for 954 cHL patients on 3rd line drug
treatment was captured. Patients had a mean age of 54.0 years (SD: 16.79) at
the point of data capture. 57% were male, 43% female. 30% had bulky disease.
84% of patients had been tested for the Epstein Barr virus (EBV), 36% con-
firmed as positive. The most commonly prescribed 3rd line drug treatment was
a brentuximab-vedotin (BV) based regimen (35%). BV use was significantly
different across the markets; Canada (34%), France (35%), Germany (30%)
and the UK (44%) (p=0.010). The next most commonly prescribed 3rd line treat-
ments were DHAP (8%), BEAM (7%) and bendamustine (7%). 4% of 3rd line
patients received a PD-1 inhibitor. Of 3rd line BV patients the majority received
ABVD (69%) or BEACOPP (19%) at 1st line. Their most common 2nd line drug
treatments were DHAP (21%), ICE (10%), ESHAP (9%) and BEACOPP (9%).
59% of all 3rd line BV patients had undergone an auto/alloSCT at some point
during their treatment history. Of 3rd line patients receiving non BV-based reg-
imens 6% had been treated with BV previously (1st / 2nd line). Of 3rd line patients
treated with a PD-1 inhibitor 7% had been previously treated with BV. Data for
453 cHL patients on 4th line drug treatment was captured. 4th line patients had
a mean age of 55.5 years (SD: 16.79) at the point of data capture. 56% were
male, 44% female. 83% had been tested for EBV, 38% confirmed positive. 30%
of 4th line patients received a BV based regimen – BV use across markets was
significantly different; Canada (20%), France (38%), Germany (23%) and the
UK (36%) (p=0.007). At 3rd line this cohort had most commonly received DHAP
(16%), BEAM (15%) or ICE (11%). 5% of 4th line BV patients also received a
BV based regimen at 3rd line. 129 4th line patients had received a BV regimen
at 3rd line. At 4th line 38% of this cohort received a PD-1 inhibitor, 19% ben-
damustine and 9% gemcitabine.
Summary/Conclusions: Real-world data indicates an unmet medical need for
cHL patients with multiple relapses, reinforced by the use of PD-1 inhibitors in
those relapsing post BV based regimen at 3rd line. There also appears to be
no clear standard of care at 3rd line, again highlighted by use of a range of reg-
imens and PD-1’s. 
This study was sponsored by Bristol-Myers Squibb.
P279
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Background: Early stage classical Hodgkin Lymphoma (cHL) has been
shown to have an excellent outcome. Recent studies have therefore focused
on decreasing the toxicity that results from the addition of radiation therapy
to chemotherapy. However, it remains unclear whether omitting radiation as
part of the initial therapy of cHL is associated with a similar survival
Aims: The primary aim of this study is thus to investigate the outcomes
observed in a statewide cancer registry for cHL patients treated with
chemotherapy alone vs patients treated with both chemotherapy and
radiation. 
Methods: All adult patients (older than 18) diagnosed with cHL in Kentucky
Cancer Registry (KCR) from 2005-2014 were retrospectively reviewed. Base-
line characteristics including age at diagnosis, gender, histology, stage, B
symptoms, extranodal involvement, and the site involved were collected. First
line treatment modalities as well as overall survival outcomes were reviewed.
Stage I and II patients without B symptoms were considered favorable, while
those with B symptoms were considered unfavorable. Patients with stage III
and IV disease were given an advanced stage designation. To adjust for
selection bias, patient deaths during the first 6 months of diagnosis were cen-
sored for overall survival analysis. 
Results: A total of 961 patients were identified.  Median age was 41 (range
18-91) and 60.9% (n=585) were younger than 50.  The group included a mild
predominance of males (55.5%).  Only 1.7% (n=16) had extranodal involve-
ment at presentation.  Of those with known histology (78.6%), the most com-
mon was nodular sclerosis (71.2%), followed by mixed cellularity (22.8%),
lymphocyte rich (3.8%) and lymphocyte depleted (1.9%). Median follow up
time was 45 months (range 0-136). The 10-year overall survival for the favor-
able group (n=329) was 77% (95% CI: 71.1-88.8) versus 68% for the unfa-
vorable group (n=144) and 42% for the advanced group (372) (p<0.001).
There was no statistical difference in survival between stage I (n=170), and
stage II (n=385) disease (p=0.99). Treatment modalities were then compared
for the favorable risk group alone. Those who received chemotherapy alone
(n=145) were compared to those who received combined chemotherapy and
radiation (n=148) as their primary therapy. The 10-year overall survival for
the cohort receiving chemotherapy and radiation was 87% compared to 75%
for those receiving only chemotherapy (p<0.001) (Figure 1). When adjusted
by multivariate analysis for risk factors affecting 10 year survival of the favor-
able cohort, only age <50 and the treatment modality were independently
associated with a statistically significant difference in overall survival (HR of
0.11 (p<0.001) and 3.94 (p=0.001), respectively).
Figure 1.
Summary/Conclusions: Our large data cohort shows the presence of B symp-
toms was more prognostic than the number of nodal regions involved for early
stage disease. Although the use of radiation as part of initial therapy for early
stage disease might have increase long term toxicity, it continued to provide
superior survival at 10 years.
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THE IMPACT OF TREATMENT WITH BRENTUXIMAB VEDOTIN ON
OVERALL SURVIVAL OF PATIENTS WITH HODGKIN LYMPHOMA
RELAPSED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION.
A NATIONWIDE POPULATION BASED ANALYSIS 
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Background: Patients with Hodgkin Lymphoma (HL) who relapse after autol-
ogous Stem Cell Transplantation (auto-SCT) have a dismal prognosis.
Advanced disease stage, presence of B-symptoms, extranodal involvement at
the time of relapse and duration of remission of less than 12 months are param-
eters associated with decreased overall survival (OS). Brentuximab Vedotin
(BV), an anti-CD30 monoclonal antibody conjugated to a microtubule-disrupting
agent, has shown clinical efficacy in HL. Although in the setting of post-auto-
SCT relapse, BV produces an overall response rate of approximately 75% with
a median progression free survival (PFS) of 9 months, the impact of BV on OS
has not been addressed in previously published studies 
Aims: To examine the impact of treatment with BV on OS of patients with HL
relapsed after auto-SCT.  
Methods: Data for patients with HL who underwent auto-SCT in Greece during
the last 20 years were collected. Study group consisted of 214 patients who
experienced post auto-SCT relapse. In order to examine the impact of BV on
OS, patients were divided in 2 cohorts depending of the date of BV availability
in Greece (January/2013). Cohort 1 consisted of 178 patients who relapsed
before January/2013, while Cohort 2 consisted of 36 patients relapsed after
BV became available. Patient’s characteristics are shown in Table 1.
Table 1. Patients characteristics.
The following variables were included in a multivariate Cox proportional hazard
regression analysis model: 1) age of patient, 2) Sex, 3) B-symptoms (yes vs
no), 4) Stage of disease (I-II vs III-IV), 5) extranodal disease, 6) time from auto-
SCT to relapse (≤12 vs >12 months), 7) Relapse before or after BV availability
(Cohort 1 vs Cohort 2). In order to exclude any confounding effect of subse-
quent treatments, analysis was performed by censoring patients at the time of
allogeneic SCT or treatment with immune checkpoint inhibitors (IC-inhibitors).
Results: In multivariate analysis the following variables were statistically asso-
ciated with OS: 1) The presence of B-symptoms [HR=2.07, (95% CI, 1.39-
3.07), p<0.001] and 2) Relapse in less than 12 months after auto-SCT
[HR=2.02, (95% CI, 1.22- 3.35), p= 0.005] were associated with decreased
OS, while 3) Response after 1st salvage [HR=0.46, (955 CI, 0.31- 0.68),
p<0.001], and 4) BV availability [HR=0.36, (95% CI, 0.16-0.79), p= 0.011] were
associated with increased OS (Figure 1). Similar results were obtained when
analysis was performed without censoring patients at the time of allo-SCT or
treatment with IC-inhibitors (data not shown). 
Summary/Conclusions: Patients in Cohort 2 survived longer even when cen-
sored for allo-SCT or treatment with IC-inhibitors. All patients in Cohort 2 treated
with BV while only 18% of patients in Cohort 1 received treatment with BV. The
results of our study strongly suggest that BV improves OS in patients with HL
relapsed after auto-SCT. To our knowledge this is the first study showing an
OS advantage of treatment with BV.
Figure 1.
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Background: The programmed death-1 (PD-1) inhibitors have been approved
by FDA for patients who relapse following autologous stem cell transplantation
and brentuximab vedotin (BV) therapy.
Aims: This retrospective multicenter study aimed to provide information about
the efficacy and safety of nivolumab in the “real-life” setting in Turkey.
Methods: 23 centers from Turkey participated in this study. Eligible patients
were required those treated with at least 1 course of nivolumab and with avail-
able radiological response evaluation. The decision about inclusion of patients
with organ dysfunction was made by the attending physician. Patients received
nivolumab via a named-patient program, and there was no restriction for BV-
and/or transplantation-naïve cases. Nivolumab was adminstered at a dose of
3 mg/kg iv infusion over 60 min q2wk in outpatient setting until death of any
cause, unacceptable toxicity, withdrawal of consent, or primary physician’s
decision. The study was approved by the local ethical commitee. The primary
endpoint was the overall response rate (ORR); secondary endpoints were over-
all survival (OS), PFS, and safety. The response was assessed by positron-
emission tomography/computed tomography or CT. Early radiological evalua-
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tion was defined as imaging at or before week 12 of treatment, whereas late
radiological evaluation was performed at or after week 16. Response evaluation
was performed according to the Lugano Classification and its update regarding
immunomodulatory therapy.
Results: Between 06/2015-11/2016, 87 patients were enrolled in a name-based
program in Turkey. Two, 19, and 3 patients who had not yet received nivolumab,
had not reach the time for early radiological evaluation, and who died before
any radiological evaluation were excluded from the analysis. Thus, 63 patients
from 23 centers were retrospectively analyzed. Median follow-up was 6 months,
median age was 29 (18-75) and patients had a median 5 (2-11) previous lines
of therapy. 44 patients (70%) had been treated by stem cell transplantation
(SCT) and 48 (76%) patients had been treated by BV. The ORR was 68% with
15 CR (95%CI 0.020-0.28; CR 26%, PR 42%, SD 12%, PD 20%) among 59
patients evaluated in 12 weeks of nivolumab treatment. The ORR was 67%
with 9 (24%) patients with CR after 16 weeks of treatment (95%CI 0.004-0.26;
CR 24%,PR 43%, SD 6%,PD 27%). Estimated OS was 95% (95%CI 0.80-
0.98) and estimated PFS was 71% (95%CI 0.55-0.82) at 12-months. Median
OS was not reached, while, according to the late response rates, the median
PFS was 14 months. However, it was only 3 months in patients with PD at the
late radiological evaluation. Regarding responses to last treatment prior to
nivolumab, we detected that 28 (67%) of 42 PD cases had objective early
responses and 70% of PD cases had ORR in the late response evaluation (CR
in 4, PR in 12 pts). 8 patients underwent transplantation following nivolumab.
Among 5 patients who had been treated by allo-SCT, 4 had CR at the time of
transplantation and they are alive with ongoing response. Safety profile was
acceptable and only two patients required cessation of nivolumab due to serious
adverse events: one due to autoimmune encephalitis and one due to aggrava-
tion of graft versus host disease. At the time of analysis, 40 cases were still on
nivolumab treatment (64%). Among the 40 cases with early objective responses
to nivolumab, 35 (88%) showed ongoing objective responses. All 24 cases with
objective responses in the late evaluation had ongoing responses at the time
of analysis (Figure 1).
Figure 1.
Summary/Conclusions: In conclusion PD-1 blockers are new options to meet
the unmet need in patients with cHL refractory to BV treatment, and possibly a
bridge for these patients before transplantation.
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Background: In classical Hodgkin lymphoma (cHL) the low representation (1-
5%) of Reed-Sternberg cells (RS) challenged tumor genotyping on the diag-
nostic tissue biopsy. Consistently, the mutational profile of newly diagnosed
cHL is poorly characterized, and the genetics of refractory disease is completely
unknown. Cell free DNA (cfDNA) is shed into the blood by tumor cells under-
going apoptosis and can be used as source of tumor DNA for the identification
of somatic mutations. In addition cfDNA is representative of the entire tumor
heterogeneity, thus allowing the identification of mutations from tumor cells
residing in non-biopsied sites.
Aims: This study aims: i) at providing the evidence that the mutational profile of
cHL can be tracked by using plasma cfDNA; and ii) at characterizing the genetics
of newly diagnosed cHL and, for comparative purposes, of refractory cHL.
Methods: The study incudes 28 newly diagnosed cHL and 9 chemorefractory
cHL. All cases were provided with cfDNA from plasma collected at baseline,
before treatment start, and paired DNA from granulocytes as source of
germline DNA to filter out polymorphisms and sequencing noise. Paired
genomic DNA from formalin fixed paraffin embedded (FFPE) tumor tissue
biopsies was available for 17 patients, including 3 cases for which RS
enriched areas were macrodissected. A targeted resequencing panel opti-
mized to include the coding exons and splice sites of 77 genes (192Kb) that
are recurrently mutated in B-cell lymphomas was used for genotyping.
Libraries were prepared from plasma cfDNA, germline gDNA and tumor gDNA
according to the CAPP-seq targeted enrichment strategy (Nimblegen) and
subjected to ultra-deep-next generation sequencing (NGS) on the MiSeq plat-
form (Illumina). The sequencing was tailored to obtain a depth of coverage
>2000x in >80% of the target region in all samples, which allowed a sensitivity
of 3x10-3. The somatic function of VarScan2 was used to call non-synony-
mous somatic mutations, and a stringent bioinformatic pipeline was applied
to suppress tha background noise and to filter out sequencing errors.
Results: In newly diagnosed cHL patients, genotyping of plasma cfDNA iden-
tified non-synonymous somatic mutations in STAT6 (43%), TNFAIP3 (43%),
ITPKB (32%) B2M (21%), GNA13 (14%), CIITA (7%), XPO1 (7%) and CD58
(4%) among the most recurrently affected genes (Figure 1A-B). In refractory
cHL patients, genotyping of plasma cfDNA identified non-synonymous somat-
ic mutations in ITPKB (44%), TNFAIP3 (33%), KMT2D (33%), B2M (33%),
GNA13 (33%), XPO1 (22%), TET2 (22%), IKBKB (22%), BIRC3 (22%) and
STAT6 (22%) among the most recurrently affected genes. Mutations of
KMT2D (33%) and TET2 (22%) were enriched in refractory cHL patients com-
pared to newly diagnosed cases, suggesting that they contributed to the
chemorefractory phenotype (Figure 1C-D). By using highly sensitivity tech-
niques, most of the mutations discovered in cfDNA were also identified in
pair tumor DNA from the tissue biopsy and/or macrodissected RS cells, thus
confirming their tumor origin (Figure 1F). By pathway analysis, the mutational
profile pointed to the involvement of PI3K/AKT signaling, cytokines signaling,
NF-kB signaling and the immune escape in cHL. ITPKB (a negative regulator
of the PI3K/AKT signaling pathway) was specifically mutated in cHL across
aggressive B cell lymphomas.
Figure 1.
Summary/Conclusions: This study provides the evidence that cHL can be
genotyped using plasma cfDNA as source of tumor DNA, pointed to a non
overlapping genotype between newly diagnosed and refractory cases, and
identified ITPKB as a new gene specifically involved in ~30-50% of cHL
patients.
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FDG PET-CT MAYBE A USEFUL TOOL TO IDENTIFY DOXORUBICIN
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Background: Doxorubicin (DXR) induced cardiotoxicity is related to several
mechanisms, including interference of mitochondrial respiratory chain and
acceleration of glycolysis.We previously reported that this treatment may
enhance myocardial FDG uptake. 
Aims: The present study aimed to verify whether this metabolic response on
serial PET/CT imaging can predict myocardial function, non-invasively evalu-
ated by follow-up echocardiography (ECHO).
Methods: 18F-FDG PET/CT of 25 patients affected by Hodgkin Disease (HD),
treated following ABVD scheme were analyzed. Inclusion criteria were: 1) avail-
ability of 4 consecutive PET/CT scan for staging (PET1), interim (PET2), post-
therapy (PET3) and six months follow-up evaluation (PET4); 2) full remission
after two ABVD cycles; 3) normal baseline EKG and ECHO findings and 4) no
concurrent treatment with external thoracic radiotherapy. A volume of interest
was manually drawn on the left ventricular myocardium. Average standardized
uptake value within this region was normalized for the corresponding blood
pool index measured in the inferior vena cava to obtain LV-SUV. All patients
underwent a 12 months cardiological follow-up assessment encompassing
clinical evaluation, EKG and ECHO. A cardiologist unaware of PET findings
performed this procedure
Results: LV-SUV progressively increased from PET1 to PET4 in 6 patients
(24%, 2 females, mean age 39±17, termed “increasers”) being 1.34±0.9,
3.34±2.6, 4.32±2.8 and 4.43±1.5 respectively. In the remaining 19 patients
(76%, 7 females, 36±14), FDG uptake showed a largely variable response
without any progressive increase. Accordingly, the ratio between PET4 and
PET1 LV-SUV in the two subgroups was 3.85±0.8 and 1.06±0.4, respectively
(p<0.001). Up to six months after therapy discontinuation, none of the 25
patients showed signs or symptoms potentially related to DXR cardiotoxicity.
However, late follow-up ECHO detected the appearance of first-degree diastolic
impairment with respect to baseline in 9 of the 25 examined patients (36%, 4
females, mean age 36 ±18). This finding occurred in 5/6 “increasers” (83%)
and in only 4/19 non-increasers (21%) (p<0.001).
Summary/Conclusions: The present data indicate that DXR related myocar-
dial damage can be preceded by an enhanced glucose uptake.  18F-FDG
PET/CT imaging might represent a useful tool to identify high-risk patients and
to implement personalized program to monitor and prevent DXR-induced car-
diotoxicity.
Iron metabolism, deficiency and overload
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Background: Increasing evidence from animal studies suggests that free heme
exerts vasculotoxic, pro-inflammatory and pro-atherogenic effects due to its
ability to trigger endothelial and immune cells activation. Moreover, we recently
demonstrated a role for iron in the pathogenesis of atherosclerosis, analyzing
a mouse model of type IV hereditary hemochromatosis, hallmarked by severe
iron overload. We also showed that iron-deficient diet and chelation therapy
prevent atherosclerosis progression in those mice.
Aims: Here we aimed at evaluating the clinical relevance of these findings and
whether parameters of vascular status correlate with iron levels and suggest
a predisposition to vascular dysfunction and atherogenesis in iron-overloaded
individuals.
Methods: To this purpose we examined serum samples from a cohort of patients
with β-thalassemia major and intermedia, who received recurrent blood transfu-
sions but inconsistent chelation therapy, and a cohort of patients with hereditary
hemochromatosis (HFE C282Y homozygous mutation), treated with phlebotomy.
Results: β-thalassemia patients show high systemic heme and iron levels,
which correlate with a severe drop in the plasma scavengers for hemoglobin
and heme, Haptoglobin and Hemopexin, respectively. Hemochromatotic patients
show high systemic iron levels and reduced hepcidin levels. Consistently, in the
two cohorts, transferrin saturation, non-transferrin bound iron (NTBI) and serum
ferritin are elevated. Interestingly, both thalassemic and hemochromatotic
patients present with high systemic levels of soluble adhesion molecules
(sVCAM-1, sICAM-1, sE-Selectin, sP-Selectin) and reduced nitrotyrosine levels,
hallmarks of endothelial activation and vascular dysfunction. In addition, they
show increased serum lipid peroxidation, elevated circulating oxidized LDLs
and high pro-inflammatory cytokines, which are known to promote atheroscle-
rosis. All parameters significantly correlate with increased systemic heme and
iron indices, including NTBI, as well as decreased scavenger levels.
Summary/Conclusions: These results emphasize the involvement of serum
hemoglobin, heme and iron in the pathogenesis of vascular dysfunction in β-tha-
lassemia and hemochromatosis and suggest a pro-atherosclerotic role for these
molecules. These findings are relevant, on one side, for cardiovascular diseases
and vasculopathy, when iron parameters are altered, and on the other, for iron
overload disorders, where premature atherosclerosis might develop. Finally, our
data highlight the key protective role of heme/iron scavengers and support the
potential therapeutic benefit of chelation therapy to counteract heme-/iron-driven
vascular toxicity and atherosclerosis in hemolytic and iron-overload conditions.
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REAL-WORLD ADHERENCE TO IRON CHELATION THERAPY: COMPARING
A FILM-COATED TABLET VERSUS DISPERSIBLE TABLET OF
DEFERASIROX 
W. Cheng1, Y. Xiao2, P. Bobbili1, A. Coe3, Y. Hao3, C. Paley3, Q. Said3,*,
V. Huang3, M.S. Duh1, M. Blinder4
1Analysis Group, Inc., Boston, United States, 2Groupe d’analyse, Ltée, Mon-
treal, Canada, 3Novartis Pharmaceuticals, East Hanover, 4Washington Uni-
versity School of Medicine, St. Louis, United States
Background: Iron chelation therapy (ICT) is effective in removing excess iron
and preventing iron overload-related complications in patients (pts) with trans-
fusion-related iron overload. However, adherence to ICT has historically been
suboptimal. While deferasirox (DFX) dispersible tablet (DT) has shown better
adherence than other oral and non-oral ICT agents, adherence could be further
improved. The recently approved DFX film-coated tablet (FCT) provides a sim-
pler method of oral ICT administration, and was found to have improved patient
adherence as compared to DFX DT in the recent ECLIPSE clinical trial
(NCT02125877). Real-world evidence outside of a trial is lacking.
Aims: To assess and compare real-world adherence and persistence to ICT
in pts switching from DFX DT to DFX FCT.
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Methods: A retrospective pre-post cohort study was conducted in pts switching
from DFX DT to FCT using pharmacy and medical claims (06/2014 - 05/2016)
from the Symphony Health Solutions’ Integrated Dataverse (IDV®) database.
Eligible pts were ≥2 years old, had a diagnosis of an inherited or acquired
hematological disorder requiring transfusions (e.g., sickle cell disease,
myelodysplastic syndrome), ≥2 DFX FCT claims (1st claim=index date), ≥2
DFX DT claims pre-index, and ≥6 months of continuous clinical activity (baseline
period) pre-index. Medication possession ratio (MPR) (percentage of time with
access to medication) was computed for DFX DT during the “DFX DT period”
(from earliest DFX DT claim to index date) and for DFX FCT during the “DFX
FCT period” (from index date to end of data availability/ICT switch). Proportion
of days covered (PDC) and persistence (without a gap ≥30 or 60 days between
claims) were assessed in the DFX DT and DFX FCT periods over fixed intervals
of 3 and 6 months, which started from the index date in the DFX FCT period,
or dispensing date of the most recent DFX DT claim prior to the beginning of a
3- or 6- month interval in the DFX DT period. Comparisons between the two
periods were made using the Wilcoxon sign-rank test for continuous data and
McNemar’s test for dichotomized data.
Results: Of the 606 eligible pts, 56% were female, 64% were <35 years old,
and 42% had transfusions during the baseline period. The median durations
of the DFX DT and DFX FCT periods were 356.5 days and 290.0 days,
respectively. Compared with adherence to DFX DT, adherence to DFX FCT
was significantly improved across all measures. Mean MPR of DFX FCT vs
DFX DT was 0.80 vs 0.76 (p<0.001); 60.9% pts had a mean MPR ≥0.8 during
the DFX FCT period compared to 54.3% during the DFX DT period (p<0.01).
Mean 3-month PDC of DFX FCT vs DT was 0.83 vs 0.71 (p<0.001); 50.0%
pts had mean 3-month PDC ≥0.8 during the DFX FCT period compared to
34.5% during the DFX DT period (p<0.001). The proportion of pts with 3-
month persistence to DFX FCT vs DFX DT (without a gap ≥30 days) was
87.2% vs 63.4% (p<0.01). Similarly consistent and significant results for PDC
and persistence were observed using a 6-month time interval and/or a 60-
day gap between claims.
Summary/Conclusions: Adherence and persistence to ICT was significantly
improved in pts who switched from DFX DT to DFX FCT. Reasons for switch-
ing, which may contribute to improved adherence, were not examined in this
study. Nevertheless, since the majority of pts were already adherent to DFX
DT, the improvement with DFX-FCT suggests that ICT can be further aug-
mented with this formulation. This real-world study complements the
ECLIPSE trial results and supports previous evidence of improved adherence
to DFX FCT.
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MEDIATION BY PATIENT-REPORTED OUTCOMES ON THE ASSOCIATION
BETWEEN FILM-COATED VERSUS DISPERSIBLE FORMULATIONS OF
DEFERASIROX AND SERUM FERRITIN REDUCTION: A POST HOC
ANALYSIS OF THE ECLIPSE TRIAL
A.T. Taher1,*, R. Origa2, S. Perrotta3, A. Kouraklis4, K. Belhoul5, V. Huang6,
J. Han6, A. Bruederle7, P. Bobbili8, M.S. Duh8, J.B. Porter9
1American University of Beirut Medical Center, Beirut, Lebanon, 2Ospedale
Pediatrico Microcitemico ‘A.Cao’, University of Cagliari, Cagliari, 3Second Uni-
versity of Naples, Naples, Italy, 4Hematology Division, Department of Internal
Medicine, University of Patras Medical School, Patras, Greece, 5Dubai Health
Authority Thalassemia Center, Dubai, United Arab Emirates, 6Novartis Phar-
maceuticals Corporation, East Hanover, United States, 7Novartis Pharma AG,
Basel, Switzerland, 8Analysis Group, Boston, United States, 9University College
London, London, United Kingdom
Background: The ECLIPSE clinical trial (NCT02125877) demonstrated that a
new film-coated tablet (FCT) formulation of deferasirox (DFX) had a similar
safety profile, with fewer patients (pts) experiencing severe gastrointestinal
(GI)-related adverse events (AEs), and more favorable patient-reported out-
comes (PROs) compared to the dispersible tablet (DT). PROs of FCT pts
showed better adherence, satisfaction, palatability and fewer concerns about
iron chelation therapy (ICT). FCT pts had a higher median absolute reduction
in serum ferritin (SF) from baseline to the end of treatment (tx) (-350.0 vs -85.5
ng/mL), despite tx groups receiving similar mean actual ICT doses, suggesting
better efficacy of FCT (Taher AT, et al. Am J Hematol. 2017). Since DFX FCT
has the same active ingredient as DT and was developed to enhance pt adher-
ence, it is hypothesized that the observed difference in efficacy may be due to
differences in adherence. PROs may be a useful surrogate marker of actual pt
adherence to ICT.
Aims: To estimate the proportion of the association between tx with DFX FCT
versus DT and SF reduction from baseline that is mediated through PROs, in
a post hoc analysis.
Methods: The ECLIPSE trial was a phase II, randomized open-label study in
which 173 pts with transfusion-dependent thalassemia or myelodysplastic syn-
drome were randomized to receive DFX FCT (N=87) or DT (N=86) at average
planned doses of 21.5 mg/kg/day (DT equivalent dose=30.7 mg/kg/day due to
differing bioavailability) and 28.7 mg/kg/day, respectively. PROs were assessed
at weeks 2, 3, 13, and 24 (end of tx) using the Palatability and modified Satis-
faction with Iron Chelation Therapy (mSICT) questionnaires, the latter assessing
3 domain scores: adherence, satisfaction, and concerns. Frequency of GI-relat-
ed AEs was assessed during the tx period. Mediation analysis, i.e., comparing
a model adjusted for hypothesized mediators to an unadjusted model (Lin DY,
et al. Stat Med. 1997), was used to compute proportion mediated (PM). PM
quantifies how much of the association between tx with DFX FCT versus DT
and SF reduction from baseline is operationalized through pt-reported adher-
ence score, other PRO scores, and frequency of GI-related AEs during tx. The
analysis was adjusted for confounders including age, sex, race, underlying
hematological disease, prior use of DFX DT, baseline level of iron overload
severity, average planned dose, and number of blood transfusions on tx. Sen-
sitivity analyses were conducted in subgroups of pts who had prior use of DFX
DT (DT non-naïve), had thalassemia, and were DT non-naïve pts with tha-
lassemia.
Results: The association between tx with DFX FCT versus DT and SF reduc-
tion was substantially mediated by pt-reported adherence (PM=66.6%, p=0.01).
Pt-reported adherence, along with pt-reported satisfaction, concerns, and
palatability scores, and frequency of GI-related AEs together mediated 76.7%
of the association (p=0.02). The proportion mediated was increased in the DT
non-naïve subgroup (PM=92.7%, p=0.03). Similarly, an increased PM was seen
in the subgroup of DT non-naïve pts with thalassemia compared to all tha-
lassemia pts (PM=70.1%, p=0.08 vs PM=56.5%, p=0.12, respectively).  
Summary/Conclusions: Better PROs, especially increased pt-reported
adherence, due to improved attributes associated with DFX FCT are signifi-
cant intermediates of the association between tx with DFX FCT versus DT
and SF reduction from baseline. The proportion mediated was increased in
pts with prior DT exposure, suggesting their enhanced appreciation for DFX
FCT over DT.
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ASSESSMENT OF THE PERFORMANCE OF A WIDELY AVAILABLE T2*/R2*
LIVER IRON CONCENTRATION METHOD USED IN CLINICAL PRACTICE
IN A POPULATION OF THALASSEMIA PATIENTS
N. Ngoc Trang1, N.T. Thu Ha2, D. Thai Ton1, N. Khoi Viet2, P. Minh Thong1,
N. Anh Tri2, B. Quoc Khanh2, M. House3,4, W. Pang4, S. Boulos4, T. St Pierre3,*
1Radiology Department, Bach Mai Hospital, 2National Institute of Hematology
and Blood Transfusion, Hanoi, Viet Nam, 3School of Physics, The University of
Western Australia, Crawley, 4Resonance Health, Claremont, Australia
Background: Measurements of liver iron concentration (LIC) by magnetic reso-
nance imaging (MRI) have become established and validated in several research
intensive centers. While the validity of spin density projection assisted (SDPA)
R2-MRI together with a core laboratory service has been validated in routine clin-
ical practice settings, methods relying on in-house establishment of data acqui-
sition protocols and data analysis have not yet been validated in this way.
Aims: To determine the limits of agreement between measurements of LIC by
a widely available T2*/R2* MRI method and a reference standard SDPA R2-
MRI method in a routine clinical practice setting.
Methods: Thalassemia patients (N=100) referred by the National Institute of
Haematology and Blood Transfusion, Hanoi, Vietnam for routine LIC measure-
ment by MRI were prospectively recruited with informed consent. Patients were
randomised to be scanned in either a Philips Ingenia or a Siemens Avanto 1.5T
scanner. The LIC of each patient was measured twice, once by a T2*/R2* tech-
nique using freely available software and protocols (Iron Health Calculator:
http://www.ironcalculator.com) and once by SDPA R2-MRI using a quality con-
trolled core laboratory data analysis service (FerriScan®). Analysts using the
T2*/R2* data analysis method were blinded from the SDPA R2-MRI results and
vice versa. Reported data were analysed using the statistical methods of Bland
and Altman.
Results: A plot of the T2*/R2* LIC against the SDPA R2-MRI LIC (Figure 1)
shows the vast majority of the data falling below the line of equivalence indi-
cating that the T2*/R2* method is underestimating the LIC relative to the SDPA
R2-MRI validated reference standard. The geometric mean ratio of T2*/R2*
LIC to SDPA R2-MRI LIC was 0.44 (95% CI 0.36 –0.55) indicating severe under-
estimation of LIC by the T2*/R2* method. The geometric mean ratios of the two
LIC measurements were significantly different for the two scanners (0.28 for
Philips and 0.68 for Siemens, p <0.0001) indicating that the bias of the T2*/R2*
method against the reference standard is not universal but is dependent on
both/either scanner type and/or data acquisition method. Bland Altman analysis
indicates that 95% of pairs of measurements are predicted to have ratios
between 3.73 and 0.05 indicating a very large random variability between the
T2*/R2* method and the reference standard. The performance of the T2*/R2*
method in predicting SDPA R2-MRI LIC values above the clinically relevant
thresholds of 7 and 15 mg Fe/g dw is characterized in the Table 1 showing
positive predictive values (PPVs) and negative predictive values (NPVs) togeth-
er with their 95% CIs.
Table 1.
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Figure 1.
Summary/Conclusions: The data indicate that the T2*/R2* method of meas-
urement of LIC is not safe for routine clinical measurement of LIC because of
the extremely poor NPVs which could result in inappropriate clinical decision
making. The severe discrepancies of the T2*/R2* method from the reference
standard are likely caused by several factors including non-optimal curve fitting
algorithms, lack of a method to identify non-analysable data, and the use of a
calibration curve from the literature generated from data acquisition and analy-
sis methods different from those used locally. These or similar pitfalls are likely
to be encountered in many MR centres using non-regulated MR methods of
LIC measurement.
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SIMILAR TRENDS IN RENAL FUNCTION AS MEASURED BY SERUM
CREATININE DURING LONG-TERM IRON CHELATION TREATMENT WITH
OR WITHOUT DEFERASIROX IN PATIENTS WITH TRANSFUSIONAL
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1Ospedale Pediatrico Microcitemico ‘A Cao’, University of Cagliari, Cagliari,
2University of Turin, Orbassano, Turin, 3Università della Campania “Luigi Van-
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Italy, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis Pharmaceuticals
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Background: Regular transfusion and iron chelation therapy (ICT) are often
indicated for patients with β thalassemia, sickle cell disease (SCD) and other
anemias, and can be lifelong requirements. As most patients now survive into
adulthood and many experience prolonged exposure to ICT, there is increased
risk of age-, disease- or drug-related complications, including changes in renal
function. Evidence suggests that some patients receiving ICT experience
changes in markers of renal function, mostly within normal limits, non-progres-
sive and reversible with dose reduction and/or interruption. Recently, we report-
ed a retrospective analysis of patients with transfusion-dependent anemias
during a decade of deferasirox treatment indicating stable and a lack of any
progressive worsening of renal function (Origa R et al. Blood 2016).
Aims: To assess serum creatinine (SCr) during long-term deferasirox treatment
in subgroups of Italian patients with transfusional hemosiderosis who participated
in the deferasirox registration studies and were then followed retrospectively.
Methods: Italian patients with β thalassemia, SCD, myelodysplastic syndromes
or other anemias who received ≥1 deferasirox dose in the registration studies
(studies 105, 106, 107, 108 or 109), had ≥1 post-baseline (BL) SCr measure-
ment, and had medical records available were included. SCr values were col-
lected retrospectively in 3-month periods from registration trial end until the
latest patient assessment. Primary endpoint was SCr over time. SCr values
during the retrospective period were evaluated by subgroups: here we report
those who received only deferasirox and those who received no deferasirox
but other ICT during the retrospective period.
Results: 282 patients were included in the retrospective study who received
≥1 deferasirox dose in registration studies; of these, during the retrospective
period, 98 (35%) received only deferasirox (group A) and 62 (22%) received
no deferasirox but other ICT (group B). In group A, mean (SD) age at first quar-
ter was 25.9 (12.1) years and 36 (37%) were male; in group B, mean (SD) age
at first quarter was 27.0 (10.9) years and 25 (40%) were male. The proportion
of pediatric patients was 28% (n=27) in group A and 19% (n=12) in group B.
Mean (SD) duration of deferasirox exposure in group A was 7.5 (1.7) years;
mean daily deferasirox dose was 1440.0 (423.6) mg.
In both subgroups analyzed, mean SCr was within normal limits and remained
stable over time during the retrospective period (Figure 1). Analysis in adults
showed mean SCr values were stable over time. As expected in growing chil-
dren who are gaining height and weight, pediatric mean SCr absolute values
increased from baseline in proportion with an almost linear increase in muscle
mass over time.
Figure 1.
Summary/Conclusions: This retrospective study of long-term renal safety in
patients receiving iron chelation for transfusional iron overload suggests that
long-term deferasirox treatment, or administration of ≥1 deferasirox dose fol-
lowed by other chelators, did not have an overall detrimental long-term effect
on renal function as monitored by SCr. This analysis provides no evidence of
progressive renal function worsening over time, which is consistent with previ-
ous results demonstrating deferasirox has a mild, generally reversible renal
hemodynamic effect.
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WHEN IRON LEADS TO RED CELLS (AND VICE VERSA): A
COMPREHENSIVE PHENOTYPE -TOWARDS NGS/WES PATHWAY FOR
THE DIAGNOSIS OF RED CELL AND IRON DISORDERS
M. Giansily Blaizot1, S. Cunat1, O. Guillot1, G. Moulis1, P. Aguilar Martinez1,*
1Hematology, Hopital Saint Eloi, Montpellier Cedex 5, France
Background: Despite thorough clinical and biological phenotypic investiga-
tions, a number of red cell disorders remain uncharacterized. In addition, some
of them are accompanied by overt iron overload and can be initially misdiag-
nosed as disorders of genes involved in iron metabolism. Next Generation
Sequencing (NGS) has become an attractive technique to decipher constitu-
tional disorders as it allows analyzing a large number of disease-causing genes.
However an initial complete clinical, biological and morphological assessment
is mandatory to correctly orientate towards the correct gene panel and to inter-
pret the various molecular variations identified. We have set up in our center,
a specialized outpatient consultation for both iron and red cell disorders. Spe-
cialized phenotypic investigations including biological and morphological tests
followed by standard or second level genotyping can be prescribed.
Aims: The aims of this study was to characterize the molecular background of
patients with iron or red cell disorders, or with a possible combination of both,
and to propose key steps towards this genetic diagnosis.
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Methods: A cohort of 25 well characterized patients was analyzed. Eighteen
were initially referred to our center for unexplained hyperferritinemia (HF), two
for proven iron overload (IO) by MRI, 2 for chronic hemolysis and 3 for aregen-
erative anemia. A set of phenotypic tests was systematically assessed, including
CBC, reticulocyte count, serum haptoglobin and measure of the Liver Iron Con-
tent (LIC) by MRI. For all patients with HF, causes linked to hepatic disease,
inflammation and cancers were ruled out and standard HFE genotyping was
performed. Phenotypic investigations failed to clearly identify the cause of the
disorder. Therefore, each patient was tested for a panel of 32 genes involved
either in iron homeostasis or hereditary anemias, using NGS. Libraries were
obtained using the Custom SureSelectQXT Target Enrichment system (Agilent,
Santa Clara Ca USA) and sequenced on a MiSeq platform (Illumina, San Diego,
Ca, USA). Each deleterious variation was independently checked using con-
ventional Sanger sequencing. Written informed consent was obtained from all
the patients for NGS genetic analyses.
Results: Initial phenotypic reassessment allowed classifying the patients into
5 different groups: 1/ isolated hyperferritinemia (n=1) 2/ HF and IO (MRI ≥90
µmole/g dry weight) (n=17); 3/ hemolytic anemia (HA) without IO (n=2) ; 4/ HA
and IO (n=2); 5/ aregenerative anemia with IO (n=3). Among patients with an
initial diagnosis of iron disorder, the reticulocyte count identified 2 undiagnosed
chronic fully compensated hemolysis. Systematic screening using the gene
panel identified a total of 14 sequence variations of clinical significance in 9 dif-
ferent genes and 9 patients. An isolated mutation was found in 7 and 2 patients
with an initial diagnosis of iron or of red cell disorder respectively. A combined
anomaly of red cell and iron genes was identified in 3 patients who displayed
IO and compensated hemolysis or anemia. Digenism involving an HFE
C282Y/wt or C282Y/H63D genotype and another “iron gene” was also shown
in 3 patients with IO (without anemia or hemolysis). No sequence variation of
clinical significance was found in the sequenced genes of eleven of the studied
patients.
Summary/Conclusions: On the phenotypic point of view, the present study
highlights the importance to check for hematological data (CBC and reticulo-
cytes) in patients with HF, because this can allow discovering fully compensated
hemolysis and bringing towards a red cell disorder. On the other hand, it also
underlines the importance to systematically check for IO all patients with a red
cell disorder, who may display high LIC. Our present genotypic data (and pre-
vious ones) suggest a relative frequency of combined inherited disorders of
iron and red cells, making the combined search for both disorders quite relevant
in clinical practice. This is now possible with the use of NGS analysis, which
allows sequencing large numbers of genes. For those patients with no identified
mutation, approaches using whole exome or genome can be proposed as the
next step.
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CHANGES IN LIVER IRON CONCENTRATION R2 MRI MEASUREMENT
ACROSS DIFFERENT CHELATION REGIMENS IN PATIENTS WITH
HEMATOLOGICAL DISORDERS: REAL-LIFE EXPERIENCE FROM LICNET
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Background: The liver plays a central role in iron regulation and remains the
primary site of iron storage, with liver iron concentration (LIC) being a strong
surrogate of total body iron. Both R2 and T2* can accurately measure LIC. R2
MRI is a robust and validated technique (FerriScan® Resonance Health Lim-
ited, Claremont, WA, Australia) approved by the FDA. The LICNET (Liver Iron
Cutino NETwork) was established by Foundation Franco e Piera Cutino of
Palermo and is addressed to diagnostics of liver iron overload by R2 MRI in
subjects with hemochromatosis in haematological disorders. The LICNET pro-
tocol was approved on December 4, 2012 by our Ethics Committee. Baseline
data from LICNET were, recently, published (Vitrano et al., 2016, EJH). 
Aims: The aim of this study was to evaluate longitudinal changes in LIC meas-
urements across different iron chelation regimens in a real-life cohort of patients
with transfusional iron overload included in LICNET.
Methods: This was retrospective cohort study of patients with haematological
disorders attending 9 Italian centres participating in the LICNET who had two
R2 MRI scans recorded in the database and receiving the same iron chelation
in between. Bivariate comparisons were made using the chi-squared and Fish-
er’s exact tests for categorical variables and the Wilcoxon or Mann–Whitney
test for continuous variables.
Results: A total of 130 patients were evaluated in this analysis, with a median
(range) age years of 35 (range: 6–78) and including 60 (46.2%) men. The
underlying diagnoses were regularly transfused thalassemia major (n=86,
66.2%), thalassemia Intermedia (n=33, 25.4%), sickle cell disease (n=6, 4.6%),
myelodysplastic syndrome (n=3, 2.3%), and Diamond-Blackfan anemia (n=2,
1,5%). The median duration (range) between the first and second MRI was
483 days (184-1076) and was comparable between iron chelation regimens.
Median pre-transfusion hemoglobin level and blood requirement were similar
at both MRIs.The median change in LIC (range) in mg Fe/g dw was not signif-
icant in patients receiving DFP (n=29, median change -1.9, p=0.55), DFX (n=52,
median change -0.5, p= 0.515), DFO+DFP (n=10, median change -2.2,
p=0.074), or other combinations (n=7, median change -1.3, p=1.000), while it
decreased significantly on DFO monotherapy (n=32, median change -
1.4,p=0.002). Among oral chelators, DFX showed to be more effective, during
the period of the study, in stabilizing iron body burden in 65.4% patients, even
if they had baseline LIC values <7mg Fe/g dw (median 4.0 mg Fe/g dw)  and
with similar response as combined treatment DFO+DFP (Figure 1).
Figure 1.
Summary/Conclusions: This cohort study suggests that stabilization of LIC
is achievable, during a median of 483 days, with different iron chelation regi-
mens in real life experience, with considerable proportions of patients shifting
to more favourable LIC categories. Therefore, the periodic determination of
LIC by MRI has to be strongly recommended for management and prevention
of iron overload and subsequent complications in haematological disorders.
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IN UTERO IRON STATUS AND AUDITORY NEURAL MATURATION IN FULL
TERM INFANTS BORN TO MOTHERS WITH IRON DEFICIENCY ANEMIA
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Background: Iron deficiency is the most important cause of nutritional anemia
and is the most common micronutrient deficiency worldwide, especially in devel-
oping countries. Iron is crucial for fetal brain development; hence, there is a
paramount need for diagnostic neurofunctional screening that could identify
low CNS iron stores. However, there are insufficient data regarding the effects
of maternal iron deficiency anemia (IDA) on auditory neural maturation. 
Aims: We aimed to evaluate the effect of maternal IDA on auditory neural
myelination in full term neonates using the auditory brainstem evoked response
(ABR) as noninvasive neurophysiological assessment tool. 
Methods: This prospective case-control study was conducted at Ain Shams
University Hospitals and included 100 neonates. Out of 223 pregnant women,
50 were diagnosed as having IDA anemia and 50 healthy mothers were enrolled
as a control group. Neonates were studied focusing on anthropometric meas-
ures, hematologic profiles and iron status. Auditory brainstem response (ABR)
test was done for the studied neonates within 48 hours after birth and at 3
months. 
Results: Hemoglobin and iron profile were lower in neonates born to anemic
mothers compared with controls. Of 100 neonates screened for ABR, 25 failed
the test (all of them were born to anemic mothers). Neonatal birth weight, crown-
heel length, BMI, occipitofrontal circumference (OFC) and mid arm circumfer-
ence were significantly lower in neonates who failed the ABR test than those
who passed it (p<0.05). Moreover, maternal and neonatal hemoglobin, red
blood cells indices, serum iron, ferritin and transferrin saturation were signifi-
cantly lower in neonates who failed the ABR test than those who passed it
(p<0.05). Most neonates (88%) who failed the screening ABR test had latent
iron deficiency (cord blood ferritin 11-75 µg/L). After 3 months, 85 underwent
diagnostic ABR test which revealed significantly prolonged interpeak latencies
I-III, III-V, and I-V among neonates of anemic mothers compared with the non-
anemic group. All interpeak latencies were more prolonged in neonates with
latent iron deficiency and those born to mothers with serum ferritin <15 µg/L.
Logistic regression analysis showed that maternal hemoglobin and mean cor-
puscular volume were the significant independent variables that could predict
neonatal ABR results. 
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Summary/Conclusions: IDA during late pregnancy adversely affects cord blood
iron and hearing status. ABR results are closely related to the severity of maternal
and neonatal iron status. Antenatal screening of pregnant mothers is needed to
improve fetal iron status and prevent abnormal auditory maturation.
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CONCENTRATION IN PEDIATRIC CANCER SURVIVORS
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Background: There is increasing recognition that pediatric cancer survivors
are at risk of transfusion-related iron overload related to intensive treatment
regimes and improved survival rates. Current screening approaches rely on
serum ferritin (SF). However, little is known about the SF to liver iron concen-
tration (LIC) relationship in pediatric cancer survivors and whether SF thresh-
olds derived from other iron overload disorders or age groups are appropriate.
Aims: The aim of this study was to investigate the relationship between SF
and LIC in pediatric cancer survivors and to determine SF thresholds for pre-
dicting clinically significant LICs in this patient group.
Methods: In this retrospective study, patient data were extracted on survivors
with elevated ferritin or iron overload from the University of Minnesota Child-
hood Cancer Survivor Program research database. All patients were enrolled
into the database via an informed consent process according to the guidelines
of the University of Minnesota Institutional Review Board. Survivors were re-
consented once they reached 18 years of age. Seventeen individual survivors
were identified where both SF and LIC data were available and the time
between the SF and LIC measurement was less than 30 days. Eleven of the
17 survivors had multiple SF measurements producing a final dataset with 34
pairs of SF and LIC measurements. Blood for serum ferritin was collected dur-
ing clinic visits and analyzed by the University of Minnesota Medical Center,
Fairview CLIA-certified clinical laboratory. Liver iron concentration measure-
ments were made using spin density projection-assisted R2-MRI (FerriScan®).
Linear regression was used to determine the relationship between SF and LIC.
Receiver operating characteristic (ROC) curve analysis was used to assess
the sensitivity and specificity of SF concentrations for predicting LIC.
Results: The average age of the cohort (6 females and 11 males) at their first
SF/LIC measurement was 18.3 years (range 9 to 30.3 years). Acute lymphoblas-
tic leukemia (N=5) and acute myeloid leukemia (N=4) were the most common
diseases and 15 of the 17 survivors had received a haematopoietic stem cell
transplant (HSCT). The average length of time between the final treatment and
the first SF/LIC measurement was 5.4 years (range 0 to 12.5 years). A linear fit
to all 34 LIC-SF measurement pairs (Figure 1) produced a gradient of 63 ± 15
(mg ferritin). (g dry liver tissue)/(mg Fe)/(L serum) and an intercept of 509 ± 157
mg ferritin/L (r2=0.36). The ROC curve analysis (Table 1) indicated that, in this
cohort, a SF cut-off of 1270 mg /L potentially has good sensitivity and specificity
for predicting a LIC above 15 mg Fe/g and a SF cut-off of 1076 mg /L has poor
diagnostic performance for predicting a LIC above 7 mg Fe/g.
Table 1. ROC Curve Analysis.
AUC, area under the receiver operating characteristic curve.
Figure 1.
Summary/Conclusions: In this study of pediatric cancer survivors, the gradi-
ent between SF and LIC and the SF cutoffs identified for predicting clinically
important LIC values are considerably lower than observed for thalassemia or
adult HSCT patients. This difference in the relationship between SF and LIC
for different patient and age groups highlights the difficulty in relying on SF to
screen for and define iron overload.
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Background: Sustained iron deficiency is a major determinant of erythropoietin
(Epo) resistance and consequent persistence of anemia in severely affected
Hereditary Hemorrhagic Telangiectasia (HHT) patients with uncontrolled chron-
ic bleeding. The mechanisms underlying erythroid suppression in these cases
are still not fully understood. 
Aims: We sought to investigate the potential impact of pro-inflammatory
cytokines on the erythroid suppression associated with extreme iron deficient
in HHT patients, focusing on MCP-1, recently described as a negative regulator
of cellular iron uptake.
Methods: the study includes 18 HHT patients, 9 males and 9 females, aged
32-79 years , followed at the Hematology Service of CHP-HAS from 2013 to
2017. They all had history of persistent epistaxis (with variable frequency and
severity) with or without gastrointestinal bleeding. The most severe cases (n=6)
were resistant to iron treatment being transfusion dependent. Blood samples
were collected in all cases for determination of erythroid parameters (including
reticulocyte counts, Epo and soluble transferrin receptors (sTfR) levels) iron
parameters (transferrin saturation, serum ferritin and hepcidin) and a cytokine
profile (GM-CSF, IFN-γ, IL-10, Il-15, IL-1β, IL6, TNF-α, IP-10 and MCP1). The
same parameters were determined in a group of 16 patients (5 males and 11
females aged 31-81 years) with iron deficiency (ID) due to chronic gastroin-
testinal bleeding under intravenous  iron treatment and in a control group of 21
apparently healthy blood donors (9 males and 12 females aged 39-62 years).
Magnetic Resonance Imaging (MRI) was used to assess tissue iron stores in
liver, spleen and bone marrow.
Results: Severe anemia with absolute iron deficient (confirmed by appropriate
hepcidin downregulation and absence of bone marrow iron stores by MRI) was
evident in transfusion dependent HHT patients (TDHHT).  Epo resistance in
these cases was evidenced by an exponential increase of Epo levels correlated
with parameters of severe anemia and ID with highly increased sTfR but inap-
propriate reticulocyte counts. Significantly decreased MCP-1 levels were
observed in TDHHT patients but also in the other iron deficient groups. No sig-
nificant alterations were observed in other cytokines except for IP-10 which
was also decreased in TDHHT patients. In general, there is a linear decrease
of MCP-1 with decreasing Hgb and increasing Epo levels. This effect, however,
seems to be “blunted” in severely anemic TDHHT patients with Epo levels
above 200 UI/L. 
Summary/Conclusions: What is the sensing pathway downregulating MCP-
1, and whether an insufficient MCP-1 downregulation contributes to Epo resist-
ance and persistence of severe anemia in TDHHT patients, these are pending
questions deserving further investigation.
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FERRIC CARBOXYMALTOSE VERSUS IRON SUCROSE COMPLEX IN
WOMEN WITH IRON DEFICIENCY ANEMIA – A RANDOMISED
CONTROLLED TRIAL
G. Chaudhry1,*
1Obstetrics & Gynaecology, SBAMI, New Delhi, India
Background: Anemia is a condition in which the number of red blood cells or
their oxygen-carrying capacity is insufficient to meet physiologic needs, which
vary by age, sex, altitude, smoking, and pregnancy status. The WHO Global
Database on Anaemia for 1993–2005, covering almost half the world’s popu-
lation, estimated the prevalence of anaemia worldwide at 25 percent. India
falls in ‘severe’ category of public health significance. Ferric carboxymaltose
(FCM) comprises of a macromolecular iron hydroxide complex of polynuclear
Fe3+ hydroxide tightly bound in a carbohydrate shell. The molecular structure
of ferric carboxymaltose ensures controlled delivery of iron within cells of retic-
uloendothelial system and subsequent delivery to the iron binding proteins fer-
90 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
ritin and transferrin, with minimal risk of release of large amounts of ionic iron
in the serum. 
Aims: To compare safety and efficacy of Ferric Carboxymaltose (FCM) with
Iron Sucrose complex (ISC) regarding improvement in haematological param-
eters and side effects in women with iron deficiency anemia (IDA).
Methods: Prospective randomized controlled study conducted in department
of Obstetrics & Gynecology, in a tertiary care hospital in Delhi, India. 60 women
having Iron deficiency Anaemia with Hb 6-8 g% were randomized 1:1 into two
groups and were given 1000mg parenteral iron. One group received intra-
venous 500mg Ferric Carboxymaltose on day 0 and 8. 200mg Iron Sucrose
complex was given in second group on alternate days for 5 doses. Haemato-
logical parameters - Hb. Reticulocyte count, RBC indices, S. ferritin; clinical
parameters - fatigue, dyspnoea on exertion and adverse effects were studied
on day 0, 7, 14 & 28. 
Results: Two FCM infusions vs five ISC infusions were required. On day 28
Hb increment ≥3g%seen in 63,33% and MCV>80FL seen in 100% of  FCM
group vs 0%and 43.33% in ISC group. FCM group had 3.17 g/dl increment in
Hb vs 1.9 g/dl in ISC group. S. Ferritin increased to 147ng/ml in FCM group vs
98 ng/ml in ISC group. Significant improvement in RBC indices & rectic count
was seen in FCM group. Earlier and  significant improvement in fatigability &
dyspnoea on exertion was observed in FCM group. Both groups had similar
safety profile except for thrombophlebitis was observed in 6.67% FCM group
vs 50.00% ISC group.
Summary/Conclusions: Intravenous Ferric Carboxymaltose is more effective
and safer than Iron Sucrose complex in treatment of Iron deficiency anaemia.
Lymphoma biology
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Background: Several susceptibility loci for Hodgkin lymphoma (HL) have been
reported, however much of the heritable risk and biological relevance remains
unknown.
Aims: To identify novel risk loci for HL and histological subtypes and to further
our understanding of how genetic risk loci influence disease susceptibility.
Methods: To our knoweldge, we have performed the largest genome-wide
association study of HL totalling 5,156 cases and 16,763 controls across 10
million single nucleotide polymorphisms.  We have integrated gene expression,
chromatin state, transcription factor (TF) binding and capture Hi-C in model B-
cells to functionally annotate new and existing risk loci.
Results: We identified risk loci for all HL at 6q22 (rs9482849, PTPRK, P=1.52 ×
10-8) and for nodular sclerosis HL (NSHL) at 3q28 (rs4459895, LPP, P=9.43 ×
10-17), 6q23 (rs6928977, AHI1, P=4.62 × 10-11), 10p14 (rs3781093,
GATA3, P=9.49 × 10-13), 13q34 (rs112998813, UPF3A, P=4.58 × 10-8) and 16p13
(rs34972832, CLEC16A, P=1.29 × 10-8). Additionally, independent loci within the
HLA region were observed for NSHL (rs9269081, HLA-DPB1*03:01, Val86 in
HLA-DRB1) and mixed cellularity HL (rs1633096, rs13196329, Val86 in HLA-
DRB1). Expression quantitative trait loci were observed in lymphoblastoid cells
from 825 individuals at 6q23 (AHI, PSMR=8.63x10-6) and10p14(GATA3,
PSMR=4.70x10-8). Across new and established risk loci we confirmed a significant
enrichment of DNase hypersensitivity in GM12878 cells (P=1.20 × 10-5), as well
as regulatory elements in primary B-cells (P=6.0 × 10-6) and GM12878 cells
(P=6.85 × 10-3). Analysis of ChIP-seq data on 82 transcription factors (TFs) in
GM12878 cells, showed an over-representation of the binding of TFs that play a
central role in B-cell signalling-networks such as RELA (nuclear factor NF-kap-
pa-B p65), EBF1 (early B-cell factor 1), RUNX3 (runt-related transcription factor
3) and BATF (basic leucine zipper transcription factor, ATF-like).
Summary/Conclusions: These observations support the assertion that risk
loci for HL mediate their effects through B-cell developmental networks, and
are involved in transcriptional initiation and enhancement. Furthermore, our
findings emphasise the differences between the major subtypes, which are
likely reflective of differences in disease aetiology.
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SOX11 PROMOTES TUMOR PROTECTIVE MICROENVIRONMENT
INTERACTIONS IN MANTLE CELL LYMPHOMA
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Background: Mantle Cell lymphoma (MCL) is one of the most aggressive lym-
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phoid neoplasms characterized by highly infiltrated tumor cells in lymphoid tis-
sues and extra nodal sites. The patients have short responses to current ther-
apies and frequent relapses. However, recent studies have identified a subset
of MCL with indolent clinical behavior that tends to present with leukemic dis-
ease instead of extensive nodal infiltration, and that is characterized by the
absence of the transcription factor SOX11 [SRY (Sex determining region-Y)-
box11]. However, SOX11 oncogenic pathways driven MCL tumor progression
are poorly known.
Aims: The goal of our study was to identify the spectrum of genes regulated by
SOX11 in malignant lymphoid cells and provide insights on how the constitutive
overexpression of SOX11 may contribute to the oncogenic development of MCL. 
Methods: We first generated a stable transduced SOX11-silenced MCL cell line
with reduced SOX11 protein levels by infecting MCL cell lines with lentiviral par-
ticles carrying shRNA plasmids specifically targeting SOX11. SOX11-positive
MCL cell line was infected with the empty vector and used as a control. These
two MCL cell lines were injected in two different mice models to analyze in vivo
the tumorigenic potential of SOX11,  subcutaneous (sc) and intravenous (iv)
xenograft tumor models. To analyze the crosstalk between MCL and microenvi-
ronment, we did in vitro cocultures experiments using accessory cells at the
tumor microenvironment, as endothelial and bone marrow mesenchymal cells.
Results: In the sc mice model, we observed that SOX11 silencing reduced
tumor growth compared to SOX11-positive control tumors. We analyzed the
gene expression profiling of these xenograft tumors and of SOX11-positive
and negative primary cases and we observed than different microenvironment-
related signatures were enriched in SOX11-positive compared with SOX11-
negative cells, as angiogenesis, migration and stromal stimulation. By ChIP-
chip data, we observed than SOX11 is regulating transcription of different genes
involved in these signatures, between them PDGFA. This data indicated a role
for SOX11 in the crosstalk of MCL with tumor microenvironment. We found
that SOX11 promotes angiogenesis in MCL cells through PDGFA regulation,
promoting tumor growth and vasculature. Inhibition of PDGFA on endothelial
cells impaired SOX11-enforced angiogenesis in MCL, and the treatment of
SCID mice with a PDGFA inhibitor reduced tumor growth and angiogenesis of
SOX11-positive MCL xenograft tumors. We also observed that SOX11 pro-
motes migration, pseudoemperipolesis (migration of tumor cells beneath stro-
mal cells) and cell adhesion mediated-drug resistance (CAM-DR) in MCL cells,
increasing their survival and proliferation, and that these mechanisms were
reduced in SOX11-negative cells. In the iv mice model, we observed that
SOX11-positive cells were able to migrated and infiltrated bone marrow and
lymph nodes, whereas SOX11-negative cells were retained in peripheral blood. 
Summary/Conclusions: In conclusion, our results show that SOX11 is regu-
lating essential processes involved in aggressiveness of MCL tumor cells, as
angiogenesis, invasion and drug resistance. Inhibition of SOX11-target genes
may represent an efficient strategy for the treatment of aggressive MCL.
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Background: Diffuse large B-cell lymphomas (DLBCLs) are aggressive tumors
derived from germinal center (GC) or post-GC B cells.   Previous work from
our group established that inferior outcome in DLBCL is associated with higher
degrees of intra-tumor and inter-tumor cytosine methylation heterogeneity,
although the molecules driving this epigenetic perturbation remain unknown.
Aims: We investigated the contribution of activation-induced cytidine deaminase
(AICDA) to cytosine methylation heterogeneity in DLBCLs. AICDA is highly
expressed in GC B cells where it drives somatic hypermutation (SHM) and also
mediates DNA hypomethylation and epigenetic heterogeneity. AICDA is also
expressed in a subset of DLBCLs and high level of AICDA in CHOP-treated
DLBCL patients is associated with unfavorable prognosis. Thus, we hypothe-
sized that AICDA could contribute to a more aggressive behavior of DLBCLs by
facilitating epigenetic plasticity through the redistribution of cytosine methylation.
We propose: AIM1. To characterize the effects of AICDA on the methylome and
transcriptome of neoplastic B cells. AIM2. To determine the contribution of AIC-
DA-mediated epigenetic modifications to DLBCL pathogenesis.
Methods: We overexpressed AICDA in bone marrow cells from VavP-Bcl2
transgenic mice, which develop B cell lymphomas of GC origin. We transplant-
ed AICDA-overexpressing (VavP-Bcl2+Aicda) or control (VavP-Bcl2) cells into
lethally irradiated recipients. We studied survival, characterized disease biology
and analyzed epigenome, genome and transcriptome of lymphomas. In addi-
tion, we studied GC B-cells from WT and Aicda-/- mice and analyzed the
epigenome of primary DLBCLs samples, classified as AICDAhigh and AICDAlow
cases according to their AICDA expression.
Results: We observed more aggressive lymphoma phenotype in VavP-
Bcl2+Aicda mice (n=7) compared to VavP-Bcl2 mice (n=6), based on greater
disruption of the splenic architecture and higher degree of B cell infiltration in
organs such as lung, liver and kidney. Notably, the overexpression of AICDA
reduced significantly the lifespan of the mice (Log-rank test p=0.0289). Neo-
plastic B cells from VavP-Bcl2+Aicda (n=4) and VavP-Bcl2 (n=4) mice displayed
similar mutation and indel burdens, suggesting that the more aggressive phe-
notype of AICDA-overexpressing mice was not likely due to increased muta-
genesis. We profiled then the DNA methylation landscape of neoplastic B cells
from VavP-Bcl2+Aicda and VavP-Bcl2 mice. A principal component analysis of
all CpGs, represented by its mean DNA methylation and heterogeneity
(interquartile range) differences across replicates, revealed methylation loss
and increased intertumor heterogeneity within VavP-Bcl2+Aicda methylomes
compared to VavP-Bcl2 (49,750 AICDA-perturbed CpGs). These altered CpGs
were depleted in promoters and enriched in introns and intergenic regions. We
observed a remarkably similar pattern of focal heterogeneity and demethylation
in primary DLBCLs with high AICDA compared to low AICDA expression
(37,557 AICDA-perturbed CpGs); and a reciprocal pattern of gain of methylation
and reduced methylation heterogeneity in Aicda-/- compared to Aicda+/+ GC B
cells (64,323 AICDA-perturbed CpGs), suggesting a conserved epigenetic func-
tion of AICDA in GC B cells and human and mouse GC-derived lymphomas.
Finally, we found significant overlap between genes affected by AICDA-per-
turbed CpGs in human AICDA high DLBCLs and murine VavP-Bcl2+AICDA
lymphomas (P=2.21e-23) and with the genes affected by AICDA in GC B-cells
(P=8.48e-33).
Summary/Conclusions: Our results demonstrate that AICDA acts as a methy-
lome modifier in GC-derived lymphomas, introducing epigenetic heterogeneity,
which may provide tumor cells with higher capacity to adapt to an evolving
environment. These findings are relevant not only for B-cell lymphomas, but
also for other types of cancer expressing cytosine deaminases.
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Background: Primary central nervous system lymphoma (PCNSL) is an non-
Hodgkin lymphoma localized in the CNS. Approximately 95% of PCNSL are
classified as diffuse large B-cell lymphoma (DLBCL), being most of them related
to activated B-cell type (ABC-DLBCL). PCNSL is associated with poor progno-
sis, particularly because of the difficulty for drugs to cross the blood brain bar-
rier. High dose methotrexate is the most effective treatment, but relapse is very
common and salvage treatment options are scarce. Also, in patients with sys-
temic lymphoma, the secondary infiltration of the CNS is a fatal event, with a
global overall survival of less than six months. Therefore, the development of
new drugs with ability to penetrate the CNS is highly needed. Selinexor (KPT-
330) is a Selective Inhibitor of Nuclear Export (SINE) that inactivates XPO-1
protein and induces anti-tumor effects mainly due to forcing nuclear retention
and activation of tumor suppressors. Selinexor has shown excellent brain pen-
etrance and promising results in pre-clinical models of glioblastoma and can
inhibit both BCR and NF-kB signaling in malignant B-cells. 
Aims: In order to provide a pre-clinical rationale for the design of new therapies
for patients with CNS lymphoma our main aim is to assess the role of XPO-1
inhibition in intracerebral xenograft murine models.  
Methods: We in vitro tested the sensitivity of DLBCL cell lines to selinexor and
ibrutinib by MTS and AnnexinV/PI assay. We established an orthotopic
xenograft model of PCNSL by stereotactic injection of OCI-Ly10 (ABC, MYD8
and CD79b mut) cells expressing luciferase into the cerebral parenchyma of
nude athymic mice. We longitudinally quantified intracerebral tumoral growth
by bioluminescence detection. 
Results: To compare the sensitivity of DLBCL cell lines to selinexor we deter-
mined the IC50 in terms of survival and proliferation in 4 ABC and 5 GCB
DLBCL cell lines. DLBCL cell lines had equivalent sensitivity to selinexor,
regardless cell of origin (COO). In detail, survival by AnnexinV-PI exclusion
showed that mean ID50 for ABC cell lines was 4.98 µM +/- 3.6 and 6.3 µM
+/- 3.8 for GCB (p=0.9). Proliferation by MTS was also blocked by selinexor
(mean ID50 for ABC-DLBCL was 1.35 µM +/- 0.7 vs 16.16 µM +/- 11.17 for
GCB-DLBCL (p=0.41)). Since SINE compounds have been shown to inhibit
the BCR, we next tested the potential synergy between ibrutinib and selinex-
or. In 3 out of 4 ABC-DLBCL cell lines there was a strong synergy. In contrast,
none of the 3 GCB-DLBCL cell lines analyzed were sensitive to up to 100
µM ibrutinib; interestingly, however, treatment with selinexor sensitized
SUDHL4 cells to ibrutinib and showed strong synergism between the two
drugs. Finally, we established an orthotopic xenograft model of PCNSL by
stereotactic injection of OCI-Ly10 cells expressing luciferase into the cerebral
parenchyma of nude athymic mice. Eleven days after the injection of cells all
animals had developed detectable tumors confined to the CNS. Tumor size
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was measured and animals were randomly distributed into drug or vehicle
group. At this time point mice were treated with 5mg/kg of selinexor or vehicle
via oral gavage three times a week; subsequently, bioluminiscence was
assessed twice a week. Treatment with selinexor significantly increased mice
survival, with a median survival of 48 days in the treatment group compared
to 34 days in the vehicle group (p<0.0001; Figure 1A). Mice in the treatment
group showed a significantly slower increase in tumor size (two-way ANOVA:
p<0.0001; Figure 1B). Specific time-point analysis showed that differences
were significant as soon as 8 days after treatment. At final point, histopatho-
logical analysis showed diffuse infiltration in meninges and cerebral paren-
quima of highly proliferative CD20-positive B-cells. Currently, we are evalu-
ating the synergy between ibrutinib and selinexor in vivo. For that we have
used the same experimental setting and assigned 12 mice to each of the fol-
lowing groups: selinexor only (5mg/kg three times a week via oral gavage),
ibrutinib only (25mg/kg daily in drinking water), combination or vehicle.
Results will be available at the time of the meeting.
Figure 1.
Summary/Conclusions: Selinexor inhibits proliferation and survival of DLBCL
cell lines regardless of COO and it can synergize with ibrutinib. Treatment of
mice with CNS confined ABC-DLBCL with selinexor significantly reduces tumor
growth and increases survival. Our results provide pre-clinical evidence for the
development of selinexor as new therapeutic option for PCNSL or DLBCL with
CNS involvement.
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Background: Peripheral T-cell lymphomas (PTCLs) are a highly heteroge-
neous group of mature T-cell neoplasms. In particular, accounting for the major-
ity of PTCL, PTCL-not other specified (PTCL-NOS) is a diagnosis of exclusion
and as such, is expected to include many heterogeneous tumors. In fact, recent
genetic studies have suggested that a subset of PTLC-NOS is closely related
to angioimmunoblastic T-cell lymphoma (AITL); both lymphoma types show
follicular helper T-cell (TFH) phenotypes and share mutational targets in com-
mon, such as RHOA, TET2, DNMT3A, and IDH2. However, with the lack of
comprehensive genetic analyses, the molecular pathogenesis is poorly under-
stood in the majority of PTCL-NOS cases.
Aims: The aim of this study is to clarify a landscape of somatic mutations in
PTCL-NOS.
Methods: We performed whole-genome/exome and transcriptome sequencing
of PTCL-NOS and other related PTCLs, followed by targeted-capture sequenc-
ing of candidate drivers in T-cell lymphomas in 100 PTCL-NOS samples.
Results: Consistent with previous reports, TET2 (38%) was the most fre-
quently mutated gene in PTCL-NOS, followed by RHOA (28%), TP53 (18%),
KMT2C (13%), IDH2 (11%), and PLCG1 (11%). Frequently altered genes
included signal transduction molecules (such as RHOA, PLCG1, STAT3 and
SOCS1), chemokine receptors (CCR4 and CCR7), epigenetic modifiers
(TET2, KMT2C, IDH2, DNMT3A, CREBBP, and KDM6A), and molecules
associated with immune evasion (HLA-A, HLA-B, B2M, and CD58). Novel
targets of recurrent mutation were also identified, including PDCD1,
YTHDF2, and LRP1B, which were frequently targeted by nonsense and
frameshift mutations distributed throughout the entire genes. Among these,
PDCD1 encodes PD-1, which transmits an inhibitory signal from PD-L1 and
PD-L2 ligands, and therefore loss of function of this gene is predicted to
enable malignant T-cells to escape from the negative signaling. By contrast,
recurrent mutations in YTHDF2 and LRP1B mutations in T-cell lymphoma-
genesis is unexpected. These genes encode a reader protein of N6-methy-
ladenosine (YTHDF2), and a member of the low density lipoprotein receptor
family (LRP1B). Although the function of these genes in T-cells are unknown,
our findings suggest their unresolved roles, whose dysfunction may lead to
malignant T-cell proliferation.Finally, we investigated the co-occurrence
between frequently mutated genes in PTCL-NOS. In accordance with previ-
ous observation, mutations characteristic of TFH lymphomas (TET2, RHOA,
IDH2, and DNMT3A) tended to co-occur in a subset of PTCL-NOS cases,
but were almost mutually exclusive with mutations in TP53 and chemokine
receptor genes. These observations further support the molecular distinction
between TFH and non-TFH lymphomas in PTCL-NOS: the former is more-
related to AITL and discriminated from the latter in terms of their mutational
profiles.
Summary/Conclusions: In summary, our findings illustrate the landscape of
somatic alterations in PTCL-NOS and provide a novel insight into their genetic
and molecular heterogeneity, which should help to devise a novel molecular
classification of PTCLs and to exploit a new therapeutic strategy to combat
these intractable T-cell malignancies.
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Background: In the last years, a large body of evidence has been accumulated
demonstrating that DNA methylation is not only widely altered in B-cell lymphoid
tumors (and cancer in general) but it is also defining cell lineage and maturation
stage. However, an integrative study of the whole DNA methylome of neoplastic
B cells from different maturation stages has not been performed yet.
Aims: The aim of this study was to extensively dissect the dynamics of DNA
methylation in B-cell neoplasias in the light of normal B cell maturation program.
The ultimate goal of this study was to generate new clinically relevant knowl-
edge with diagnostic and prognostic value.
Methods: Our dataset included whole-genome bisulfite sequencing data
(n=57) and high-density methylation arrays (n=1161) from acute lymphoblastic
leukemia (ALL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), follic-
ular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), chronic lym-
phocytic leukemia (CLL) and multiple myeloma (MM) patients as well as from
ten different normal B cell subpopulations. As DNA methylation estimates in
neoplastic samples are influenced both by tumor cell content and composition
of the micro environment, we developed a new method to deconvolute and
in silico purify the methylation signal of tumors arising in different niches
(bone marrow, peripheral blood an lymph node). The data were analyzed by
a series of bioinformatic and biostatistical approaches and correlated with
clinical variables. 
Results: The initial bioinformatic approach to purify of DNA methylation signals
in B cell tumors revealed that samples with less than 55% tumor cell content
could not be accurately purified. This strategy reduced the initial 1,044 tumor
samples to 866. An unsupervised principal component analysis of in silico puri-
fied data revealed that each type of B-cell neoplasm clusters separately. ALLs
clustered closer to precursor B cells, CLL and MCL closer to mature B cells
and both DLBCL and MM showed the largest deviation from normal B cells.
We then performed a differential methylation analysis comparing each sample
vs normal B cell maturation stages, and thoroughly annotated the results to
biological and clinical features. From the clinical perspective, we identified that
for tumor samples with similar cellular origin, the higher the epigenetic deviation
from healthy B cells (number of DNA methylation changes) the worse the clinical
behavior of the patients. Furthermore, for each tumor entity, we could identify
from 5 to 19 epigenetic biomarkers that could classify each entity with high
sensitivity and specificity.
Summary/Conclusions: In this study, we show that in silico purification of
DNA methylation data is a powerful strategy to accurately measure DNA methy-
lation alterations in tumor cells. Using a large dataset, we have developed a
set of epigenetic biomarkers with high differential diagnostic power and identi-
fied that the epigenetic drift is a universal prognostic factor that can be applied
to different B cell tumors.
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Background: Angioimmunoblastic T-cell lymphoma (AITL) is a distinct subset
of peripheral T-cell lymphoma with follicular helper T-cell (TFH) features. We
and others previously found mutations of RHOA, encoding p.Gly17Val (G17V
RHOA mutation) together with those in an epigenetic regulator, tet methylcy-
tosine dioxygenase 2 in up to 70% of AITL and other TFH lymphoma (a sub-
group of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS))
samples. RHOA, a small GTPase, is converted from the GDP-bound inactive
form to the active GTP-bound form by guanine nucleotide exchange factors
(GEFs). The G17V RHOA mutant has been shown to be defective in RHOA
signaling, because it does not bind GTP. Therefore, it has remained unknown
how G17V RHOA is involved in lymphomagnesis. VAV1 serves as an impor-
tant mediator of T-cell receptor (TCR) signaling pathway through its GEF-
dependent and –independent function. VAV1 activation is tightly regulated
by autoinhibitory mechanisms in the unstimulated state. Phosphorylation of
VAV1 occurs within seconds in response to antigen stimulation of the TCRs
by Syk and Src-family tyrosine kinases and initiates downstream TCR sig-
naling.
Aims: We aim at clarifying the downstream signaling of the G17V RHOA
mutant in AITL/TFH lymphoma. 
Methods: Proteomic screening was performed to identify G17V RHOA-spe-
cific binding partners. Binding was validated by co-immunoprecipitation of
G17V RHOA and the candidate partners. Simultaneously, RNA sequencing
was performed for 9 PTCL samples, including 6 AITL and 3 PTCL-NOS. Tar-
geted deep sequencing of VAV1 was performed for 126 PTCL samples,
including 69 AITL and 57 PTCL-NOS, 37 of which had RHOA mutations. The
specific binding partner proteins of the G17V RHOA mutant were examined
by high throughput screening in Jurkat cells. Nuclear factor of activated T
cell (NFAT) activity in response to TCR stimulation was examined in Jurkat
cells expressing wild-type (WT) and G17V RHOA mutant, and WT and various
VAV1 mutants. Whole transcriptome was compared in Jurkat cells inducibly
expressing each cDNA, in conditions with or without TCR stimulation. Expres-
sion of phospho-Vav1 was examined by immunostaining for AITL/TFH lym-
phoma samples. 
Results: Proteomic screening identified the VAV1 protein as a G17V RHOA-
binding partner. RNA sequencing identified a fusion gene involving VAV1 and
STAP2 in an AITL sample without RHOA mutations. Moreover, targeted
sequencing of VAV1 identified 2 in-flame deletion mutations in an acidic region
(c.C518_529del:p.173_177del and c.C494_520del:p.165_174del) in AITL sam-
ples and 2 missense mutations in a zinc finger and SH3-SH2-SH3 module
(c.G1668C:p.Glu556Asp and c.C1844T:p.Pro615Leu) in PTCL-NOS and AITL
samples, respectively. Phosphorylation of VAV1 at Tyr 174 was enhanced in
Jurkat cells expressing the G17V RHOA or VAV1-STAP2 cDNA than those
expressing each WT cDNA or mock. Phosphorylation was blocked by the dasa-
tinib at 1-10 nM concentrations. The G17V RHOA, VAV1-STAP2 and various
VAV1 mutants enhanced NFAT reporter activities and interleukin-2 (IL-2) mRNA
levels compared to their WT or mock in Jurkat cells. Dasatinib completely
blocked both of these TCR indicators at the concentration range similar to
block VAV1 phosphorylation. Moreover, the aberrant reporter activity was also
blocked by the dasatinib treatment. The levels of IL-2 mRNA were higher in
Jurkat cells expressing either G17V RHOA or VAV1-STAP2 than those with
their WT or mock. Gene set enrichment analysis showed that cytokine and
chemokine-related pathways were enriched in Jurkat cells expressing the G17V
RHOA compared to those with WT or mock. Finally, phospho-VAV1 was co-
stained with PD-1, a TFH marker, in 7 out of 10 PTCL samples with RHOA or
VAV1 mutations.
Summary/Conclusions: The G17V RHOA and VAV1 mutants both intensify
the TCR pathway through hyper-phosphorylation of Vav1. Our data suggest
that the RHOA-VAV1 axis in AITL/TFH lymphoma may contribute to their clinical
features and stand as a possible new therapeutic target.
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Background: Chronic active Epstein-Barr virus infection (CAEBV) is a rare dis-
order characterized by clonal proliferation of EBV-infected T or NK cells and
associated with severe systemic inflammation. Chemotherapy-resistant lym-
phoma or hemophagocytic lymphohistiocytosis can develop during the course
of CAEBV, and the only curative treatment strategy is hematopoietic stem cell
transplantation. In addition, why EBV persistently infects T or NK cells and how
the disorder develops in patients have not been elucidated yet. The outcome of
CAEBV remains poor, and the establishment of an effective chemotherapy based
on the molecular mechanisms of CAEBV development is an urgent issue.
Aims: We designed this study to investigate STAT3 activation and its contri-
bution to CAEBV development, because it was recently indicated that STAT3
was constitutively activated in some T- or NK-cell malignancies. We also exam-
ined the effects of JAK inhibitors on CAEBV. 
Methods: The EBV-positive T- and NK-cell lines SNT8, SNT15, SNT16 and
the NK-cell lines SNK1, SNK6, SNK10 were examined. EBV-positive T or NK
cells were obtained from peripheral blood mononuclear cells (PBMCs) of CAE-
BV patients who were diagnosed according to the previously described diag-
nostic criteria (Blood 2012; 119:673-86). To detect and isolate EBV-infected
cells, T and NK cells were separated from PBMCs using magnetic beads. Gene
expression was examined using one-color microarray-based analysis (Agilent
Technologies, Santa Clara, CA, USA). The direct sequencing analysis of exons
19 to 24 of STAT3, which encode the SH2 domain, was performed using
primers from the previous report (N Engl J Med 2012; 366: 1905-13). EBV-
negative T- and NK-cell lines and PBMCs from healthy donors were used as
negative controls. Cell survival and apoptosis were examined by an XTT assay
and Annexin V assay, respectively. The mRNA expression of cytokines was
examined by TaqMan® Gene Expression Assays.
Results: STAT3 was constitutively phosphorylated on Y705 and S727 and was
localized in the nucleus in EBV-positive T- or NK-cell lines and PBMCs from
the CAEBV patients, as indicated by western blotting. The microarray analysis
of EBV-positive T or NK cells derived from CAEBV patients demonstrated that
the expression of STAT3-responsive genes, including interferon-γ, were upreg-
ulated in these cells compared with EBV-negative cells. No mutation was
detected in the SH2 domain of STAT3 in patient-derived cells by direct sequenc-
ing. The JAK inhibitors ruxolitinib and tofacitinib suppressed STAT3 activation
and cell survival by inducing apoptosis of the cell lines and PBMCs from CAEBV
patients. Ruxolitinib also inhibited the mRNA expression of TNF-α and inter-
feron-γ in CAEBV patient-derived cells.
Summary/Conclusions: STAT3 is constitutively activated in EBV-positive T
or NK cells from CAEBV patients. The inhibition of STAT3 by ruxolitinib could
be an attractive and effective treatment for CAEBV by suppressing not only
EBV-infected cell survival but also the accompanying inflammation.
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Background: Follicular lymphoma (FL) is the most common low grade B cell
malignancy accounting for ~20% of all non-Hodgkin lymphomas. Approximately
30% of the FL cases suffer a histological transformation to a much more aggres-
sive subtype of lymphoma drastically reducing the overall survival from 10
years to just 14 months. Despite being a critical event during disease progres-
sion it is molecularly poorly understood and no biomarkers exist to predict this
phenomenon. Previous studies have suggested the possibility that deregulation
of microRNA expression (miRNAs, small endogenously produced non-coding
RNAs) could be implicated in the development of FL disease as well as in the
transformation event. We hypothesise that mutations in miRNA binding sites
may also have a role in this process.
Aims: We set ourselves to find predictive biomarkers of transformation for FL,
with a special focus on sequence variants affecting miRNA binding sites.
Methods: We interrogated whole genome sequencing (WGS HiSeq, Illumina)
data from sequentially obtained samples of 6 FL patients that underwent trans-
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formation using a bespoke bioinformatic pipeline based on TargetScan predic-
tion algorithm in order to identify mutations in putative miRNA binding sites.
Once identified, in order to validate them and test their recurrence in an extend-
ed cohort (60 samples from 31 FL patients who underwent transformation plus
21 samples of non-transformed FL patients) we designed an Ampliseq (Ion Tor-
rent, Life Technologies) NGS custom panel. Finally, we selected a number of
variants for assessing the variant effect on the miRNA:mRNA interaction, by
means of a combination of an in silico predictive algorithm and in vitro luciferase
assays.
Results: 36% of somatic variants from WGS data arose in 3´UTR, and 68% of
these were putative miRNA-binding sites (525 mutations in 497 genes). Inter-
estingly, the ontogeny analysis showed that these mutations were not randomly
distributed but rather there was enrichment in genes associated with haema-
tological malignances (P=2.18x10-4).We then validated 85% of these mutations
using targeted resequencing and found a total of 103 recurrent variants located
in putative miRNA binding sites. QC criteria filtering led us to prioritise 38 vari-
ants in 25 genes to be functionally tested. Crucially, ontogeny analysis showed
that these genes were highly enriched for GC-like B-cell lymphoma genes
(P=4.39x10-5), strongly suggesting that these variants may have a biological
significance in the disease. We then performed an in silico approach based on
TargetScan miRNA target prediction algorithm to evaluate the effect of the
mutations on the binding of the miRNAs to their target sites. Based on these
results we prioritized some of these genes to perform luciferase assays. We
experimentally demonstrated not only that the majority of these loci are bona
fide miRNA targets sites, but also that the presence of a number of these vari-
ants cause a dysregulation of the normal miRNA regulatory activity (Figure 1).
Figure 1.
Summary/Conclusions: Our data show that the identified mutations do not
occur randomly, but preferentially in putative microRNA binding sites of genes
related to lymphomagenesis, supporting their role in FL pathogenesis. Further-
more, the presence of some of the identified variants in miRNA binding sites
indeed promotes a dysregulation of the normal miRNA regulatory activity, sug-
gesting that they might have a biological significance in FL.
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Background: Within the landscape of mutated genes in mantle cell lymphoma
(MCL), only TP53 disruption has been so far associated with outcome. 
Aims: Here we present the clinical update of the deep sequencing MCL gene
panel analysis in the prospective FIL-MCL0208 phase III trial (NCT02354313,
high-dose immunochemotherapy followed by autologous transplantation for
untreated, advanced stage <65 years MCL) based on the data from the second
interim analysis. 
Methods: A targeted resequencing gene panel, including coding exons and
splice sites of the ATM, BIRC3, CCND1, KMT2D, TP53, TRAF2, WHSC1, and
NOTCH1 genes was analyzed in tumor DNA from baseline bone marrow
CD19+ purified MCL cells and, to filter out polymorphisms, in the paired normal
genomic DNA (55% of cases) using a TruSeq Custom Amplicon target enrich-
ment system followed by deep next generation sequencing (Illumina, median
depth of coverage 2356x). Variants represented in >10% of the alleles were
called with VarScan2 with the somatic function when the paired germline DNA
was available. For patients lacking germline DNA, a bioinformatics pipeline
including a number of stringent filters was applied to protect against the mis-
classification of polymorphisms as somatic variants. Clinical data were updated
at the time of the second interim analysis (January, 2017).
Results: Out of the 300 enrolled patients, 174 were evaluable for mutations.
Median follow-up of the cohort was 36 months, and 3-years PFS and OS were
67% and 86%, respectively. Patients not included in the study, due to unavailable
tumor DNA (n=126) showed superimposable clinical features and outcome. Muta-
tions of TP53 (8% of cases) and KMT2D (11% of cases) associated with an
increase in the hazard of progression both in univariate analysis as well as after
adjusting for MIPI, Ki67 and blastoid variant: HR 3.87 (95% CI 1.64 to 9.13),
p<0.002 and HR 3.66 (95% CI 1.77 to 7.56), p<0.001, respectively. These results
translated into an increase of the hazard of death in both TP53 and KMT2D
mutated patients both in univariate analysis as well as adjusting for MIPI, Ki67
and blastoid variant HR 4.26 (95% CI 1.34 to 13.57), p=0.014 and HR 3.09 (95%
CI 1.07 to 8.86), p=0.036, respectively. On these bases, a survival model was
proposed based on the TP53 and KMT2D mutation status: 3-years PFS and OS
were 26% and 64% for patients carrying either TP53 or KMT2D mutations or
both vs 75% and 92% for patients without any of these mutations (Figure 1).
Figure 1.
Summary/Conclusions: The updated clinical results of the FIL-MCL0208 trial
show that: i) both TP53 and KMT2D mutations independently associate with
shorter PFS and OS in younger MCL patients receiving high-dose therapy; ii)
KMT2D mutations seem to be as detrimental as TP53 mutations, at least in
terms of PFS; iii) given the negative prognostic impact of these mutations, they
might be used to select high-risk patients for novel therapeutic approaches.
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Background: Von Willebrand Disorder (VWD) has a prevalence of approximately
1% in the general population and is due to quantitative deficiencies or qualitative
defects of the Von Willebrand Factor (VWF) protein. VWF is a large meltimeric
protein with multiple functions. It carries and protects factor VIII and helps in the
binding of FVIII, platelets and the vascular endothelium at sites of injury. VWF
binding to platelets is through several receptors most notably the glycoprotein
1b (GP1b) and collagen exposed at site of injury is important for VWF adhesion
to the subendothelial matrix forming an adhesive anchor. Classification of VWD
is based on the quantitative deficiencies (Type 1 and 3) and VWD type 2 are
qualitative defects of the VWF protein with or without quantitative deficiency as
well. Type 2 VWD is further subdivided into type 2A,2B,2M and 2N. These sub-
types depend on a number of laboratory assays that measure the FVIII activity,
VWF protein level (VWFAg assay) and the function of the protein i.e its ability to
bind to 1) FVIII(FVIII - VWF binding assays),2) platelets (VWF ricof assay)  and
3) collagen (VWFCB assay). Other tests include ristocetin induced platelet aggre-
gation (RIPA), multimer analysis, assay ratios and VWF genetic analysis. No
single commercially available laboratory method can achieve to test all the param-
eters required to clinch the accurate diagnosis of the subtypes of VWD. Use of
those multiple assays with VWF ricof/VWFAg ratio, VWF CB (VWF-CB)/ (VWF
Ag)  ratio have helped in the better identification of VWD and the subtypes.
Aims: To assess recent various VWF investigation panels and assay ratios, VWF
genetic analysis, multimeric patterns of the VWF protein in accurate diagnosis of
the VWD subtypes. VWD 2A and 2M shows similarities in certain aspects and it
is important to differentiate these 2 subtypes as new therapies become available
and personalised treatment approaches of VWD become a reality.
Methods: Clinicians who have made a diagnosis of VWD for individuals referred
for a bleeding state work up would classify the subtypes of the VWD according
to the results of the investigations available at the time of seeing the patients.  All
patients with an inherited bleeding disorder would then be registered in the centre
and details would be put into a database. We have looked back into the database
from the period of 2000 to end of 2016 and focussed on the VWD types 2A and
2M. Current VWD diagnostic panel in our centre  includes the following tests:
FVIII one stage assay, VWFAg Elisa,VWF ricof; Platelet agglutination method,
VWF CB Elisa methods, VWF multimeric analysis by gel chromatography and
VWF exon 27/28 genetic mutations are routinely done. New information and new
set of results for the registered patients have been taken into account the clas-
sification of VWD type 2A and 2M and the database are updated.
Results: In the VWD database 38 patients classified as 2M and 19 patients as
type2A have been recorded from 2000 to end of 2016. With the updated results
and genetic analysis and the response to DDAVP, around 30% of the patients
have had their subtypes changed. This exercise confirms that no singular test
can be used to accurately diagnose the VWD and its subtypes and illustrates
the importance of DDAVP testing and the difficulty of interpreting assay ratios
for subtyping when VWFricof levels are <15u/dl.
Summary/Conclusions: VWD may be misdiagnosed, underdiagnosed or
overdiagnosed. Appropriate and complete investigative panel is necessary for
complete classification of VWD and its subtypes.
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Background: Dysfibrinogenemia (DF) and hypodysfibrinogenemia (HDF)
patients (pts) experience hemorrhages or thromboses, and the clinical man-
agement can be difficult.
Aims: Aim of this study is to obtain information on DF/HDF clinical phenotype
and management.
Methods: This is a spontaneous, retrospective, multicenter national study.
Data are collected from clinical records.
Results: Forty-one pts have been enrolled in 3 centers: 35 DF (85%), 6 HDF
(15%); 18M, 23F. Median follow-up: 7.4 months (1-203). Median age at diag-
nosis: 36 years (range 3-81). Median fibrinogen activity/antigen level: 53 mg/dL
(0-156) and 250 mg/dL (66-380), respectively. Fourteen pts experienced hem-
orrhages: epistaxis, hematuria (presence of kidney stones), hematomas, ecchi-
moses, menometrorrhagia, and gastro-intestinal (presence of esophageal
varices). No specific therapy was administered. A portal venous thrombosis
occurred in 1 DF splenectomized patient in absence of replacement therapy;
he was treated with warfarin without anti-hemorrhagic prophylaxis. Forty-one
minor/major surgeries were performed in 23 pts. In 10/41 (24%) cases, pro-
phylaxis was administered [fresh frozen plasma in 3, fibrinogen concentrate
(FC) in 1, tranexamic acid in 6]; in 5/41 (12%) cases, low molecular weight
heparin (LMWH) was administered; no hemorrhage occurred. Thirteen preg-
nancies were initiated in 9 women. In 1 case, LMWH prophylaxis was admin-
istered during pregnancy, and in 1 other during puerperium. In 2 cases, FC
was administered at the time of spontaneous delivery (SD). Nine SD and 4
cesarian sections were performed without complications.
Summary/Conclusions: Pts from this case series experienced few hemor-
rhagic/thrombotic events. The majority was asymptomatic and the most severe
events were related to concomitant pathologies. Nonetheless, this study has
the potential to collect data from a numerous population of pts who live in the
same country, and therefore to provide useful information to better characterize
and manage these rare diseases.  .
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OSTEOPOROSIS IN PATIENTS WITH HEMOPHILIA
V. Zorenko1,*, T. Polyanskaya1, E. Karpov1, A. Kovrigina1, T. Tupoleva1,
A. Golobokov1, N. Sadykova1, G. Mishin1, M. Sampiev1, D. Vasiliev1,
D. Petrovskii1, A. Koroleva1
1National Research Center for Hematology, Moscow, Russian Federation
Background: Osteoporosis is often a co-morbidity of hemophilia, which exac-
erbates the hemophilic arthropathy and affects the long-term stability of the
components after the arthroplasty. We present our results for the presence of
osteoporosis in 148 patients with haemophilia and hemophilic arthropathy.
Aims: To prevent progression of hemophilic arthropathy and increase the long-
term stability of the components after the arthroplasty.
Methods: . In the period from 2015 to 2016. the presence of osteoporosis sur-
veyed 148 patients with haemophilia who are hospitalized in the department of
reconstructive orthopedics for patients with hemophilia (Moscow, Russia): 121
(81.8%) - hemophilia A, 21 (14.2%) - and hemophilia B 6 (4%) – haemophilia
with inhibitor. The average age of the patients was 39.3 years (range 10 to 69
years). 121 patients with hemophilic arthropathy performed primary total arthro-
plasty (98 knee, 20 hip, 3 shoulder joints); 18 patients underwent revision arthro-
plasty (5 - purulent infection, 7 - instability of the implants, 4 - fractures, 2 - loss
of motion in the operated joint). 40 patients underwent ultrasound densitometry.
Results: As a result of ultrasound densitometry in 17.5% (7 patients) of cases
revealed osteopenia and 20% (8) T-highest index. 105 patients underwent his-
tological study in which 93 (88.6%) bone resorption, 58 (55.2%) intraosseous
hemorrhage which 53 (50,5%) cases were accompanied by bone resorption.
In total (histologically and of ultrasound densitometry) 99(66.9%)  patients with
haemophilia had osteopenia.
Summary/Conclusions: The data indicate that osteoporosis at patients with
haemophilia considerably more common than in the general population.
Intraosseous hemorrhage identified in more than half of the cases, exacerbate
the decline in bone mineral density.
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PREVALENCE OF GENETIC MARKERS OF OXIDATIVE STRESS IN
PATIENTS WITH SEVERE HEMOPHILIA FROM NORTH-WESTERN RUSSIA
S. Kapustin1,*, L. Aleksanyan1, L. Rybakova1, V. Kargin2, V. Burakov2,
S. Svitina1, A. Titov2, V. Soldatenkov2, A. Chechetkin3
1Laboratory of Biochemistry, 2Surgery Department, 3Russian Research Institute
Of Haematology And Transfusiology, Saint-Petersburg, Russian Federation
Background: Severe haemophilia (SH) is often complicated by chronic
arthropathy due to recurrent haemorrhagic events and activation of such bio-
logical mechanisms as oxidative stress (OS) and inflammation. We have pre-
viously shown that the biochemical markers of OS and/or deficiency of antiox-
idant system (AOS) are frequently seen in SH patients affected with joint(s)
destruction. Until now, there is a little data on the frequency of genetic variants
predisposing to OS or decreased AOS activity in patients with SH.
Aims: To assess the prevalence of several genetic variants predisposing to
OS or decreased AOS activity in patients with SH from North-Western Russia
(NWR).
Methods: We studied 71 men with severe haemophilia A or B (62 and 9
patients, respectively). Osteoarthritis of large joint(s) was detected in each
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patient, with the rate of recurrent haemorrhagic events in joint(s) from 6 to 13
per year. The control group consisted of 255 age-matched healthy men. Gene
polymorphism of apolipoprotein E (ApoE e2/e3/e4), paraoxonase (PON1
Gln192Arg), methylenetetrahydrofolate reductase (MTHFR C677T), catalase
(CAT C-262T) and plasmatic glutathione peroxidase (GPX3 T-65C) was studied
by PCR-RFLP technique. Statistical differences between the patient and control
groups were assessed by Fisher’s exact test. Odds ratios (OR) with their 95%
confidence intervals (CI) and p-value were calculated by using GraphPad Prism
5.0 software.
Results: We found abnormal distribution of ApoE genotypes in the patient
group. Absence of ApoE e3 allele was observed in 7 (9.9%) men with SH and
8 (3.1%) controls (OR=3.4, 95% CI: 1.2-9.7, p=0.025). In particular, the fre-
quency of ApoE e2/e2 genotype was 10-fold increased in patients when com-
pared to healthy men (4.2% vs 0.4%, OR=11.2, 95% CI: 1.1-109.5, p=0.034).
ApoE e2/e4 and e4/e4 genotypes were also more prevalent in SH than in the
control group (2.8% vs 0.8% and 2.8% vs 2.0%, respectively). In the patient
group, we observed the positive association between the PON1 192Gln/Gln
variant and heterozygous GPX3 -65TC genotype (OR=5.8, 95% CI: 1.3-25.7,
p=0.021). Simultaneous presence of these genetic variants was more than 5-
fold frequently found in SH than in controls (8.5% vs 1.6%, OR=5.5, 95% CI:
1.3-22.8, p=0.016).
Summary/Conclusions: Our results indicate that OS-provoking variants of
ApoE, PON1 and GPX3 genes are frequently seen in SH patients with chronic
arthropathy and joint(s) destruction.
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THE ROLE OF DNA METHYLATION AND EXPRESSION OF MMP-2 AND
MMP-9 IN PATHOGENESIS OF INTRACEREBRAL HEMORRHAGE IN
CONGENITAL FACTOR XIII DEFICIENCY
A. Noroozi-Aghideh1,*, N. Lashgari2, A. Dorgalaleh3, Z. Kashanikhatib4,
S. Alizadeh5
1Hematology and Blood Transfusion, Faculty of Paramedicine, AJA UNIVER-
SITY OF MEDICAL SCIENCES, 2MICROBIOLOGY, Faculty of Medicine, AJA
UNIVERSITY OF MEDICAL SCIENCES, 3Hematology and Blood Transfusion,
Allied Medical School, Iran University of Medical Sciences, 4Hematology and
Blood Transfusion, High Institute for Education & Research in Transfusion Med-
icine, 5Hematology , Allied Medical School, Tehran University of Medical Sci-
ences, Tehran, Iran, Islamic Republic Of
Background: Congenital factor XIII deficiency (CFXIIID) is a rare bleeding dis-
order. Intracerebral hemorrhage (ICH) is a leading cause of mortality and mor-
bidity in this disorder. Matrix metalloproteinase-2 (MMP-2) and MMP-9 are
reported to be associated with ICH.
Aims: The purpose of this study was to investigate the association of MMP-2
and MMP-9 methylation and their expression with ICH.
Methods: Patients with abnormal clot solubility test as well as a positive family
history of FXIII deficiency were participated in the study. Methylation status
was analyzed by Bisulﬁte Sequencing PCR. Gene expression in mRNA and
protein levels was assayed by Quantitative real-time RT-PCR and ELISA,
respectively.
Results: We found an unmethylated profile for both MMP-2 and MMP-9 in
patients with ICH. Both of these genes were partially methylated in controls.
Percent of methylated CGs are also higher for MMP-9 than MMP-2. Higher
expression of MMP-9 in both of mRNA and protein levels was found in ICH
compared to non-ICH group. However, there were no significant differences in
MMP-2 expression levels (neither mRNA nor protein) between two groups.
Summary/Conclusions: Our findings showed that gene methylation con-
tributes effectively in regulation of MMP-9 expression. Furthermore, our data
suggest that MMP-2 expression in CFXIIID may not be controlled by gene
methylation alone because methylation status of this gene did not correlate
with expression levels (neither mRNA nor protein). Further investigations are
needed for better understanding the exact role of these MMPs in the patho-
genesis of ICH in CFXIIID and also identifying the regulatory mechanisms.
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GENETIC CONFIRMATION AND FINDING NOVEL MUTATIONS IN
GLANZMANN THROMBASTHENIA AND VON WILLEBRAND DISEASE
FAMILIES BY DIAGNOSTIC EXOME SEQUENCING
Y.J. Shim1,*, E.M. Choi1, H.S. Kim1, J.M. Lee2
1Pediatrics, Keimyung University School of Medicine and Dongsan Medical
Center, 2Pediatrics, Yeungnam University, College of Medicine, Daegu, Korea,
Republic Of
Background: Congenital platelet function disorders and von Willebrad disease
(vWD) are very heterogeneous group resulting in primary hemostatic defects.
Physicians generally have difficulty to confirm them due to complicated diag-
nostic technique.
Aims: We intended to apply diagnostic exome sequencing (DES) for genetic
confirmation and finding causative variants in children with primary hemostatic
problems.
Methods: Library preparation was performed with TruSight One sequencing
panel (Illumina, USA), which enriches about 4,800 genes with clinical relevance.
Massively parallel sequencing was conducted with NextSeq (Illumina). Variants
were annotated with population databases (1000 Genomes Project, Exome
Variant Server, Exome Aggregation Consortium) and disease databases
(OMIM). For missense variant, in-silico analysis was done with SIFT, PolyPhen-
2, and MutationTaster. Candidate variants were confirmed by Sanger sequenc-
ing and family study. For VWF gene, multiplex ligation dependent probe ampli-
fication assay was also done using SALSA MLPA probemix P011-B3/P012-B3.
Among variants from genes of primary interest, common variant with minor
allele frequency ≥1% using population databases were filtered out. In addition,
variants detected in more than 2% in in-house database were further filtered
out to remove population specific polymorphism or platform specific errors. For
VWF exons of either incomplete coverage or low mapping quality due to highly
homologous region (exon 26, 24), additional Sanger sequencing was per-
formed. Genes of primary interest were those associated with platelet dysfunc-
tion; vWD (VWF), Bernard–Soulier syndrome (GP1BA, GP1BB, GP9), Glanz-
mann thrombasthenia (GT) (ITGA2B, ITGB3), Thromboxane A2 receptor defect
(TBXA2R), ADP receptor defect (P2RY12), Gray platelet syndrome (NBEAL2),
Quebec platelet disorder (PLAU), ARC syndrome (VPS33B), Hermansky-Pud-
lak syndrome (HPS1, AP3B1, HPS3, HPS4, HPS5, HPS6, DTNBP1,
BLOC1S3), Chediak-Higashi syndrome (LYST), Griscelli syndrome (MYO5A,
RAB27A, MLPH), Scott syndrome (ABCA1).
Results: Twelve children with easy bruising, frequent epistaxis, or menorrhagia
and their family members were enrolled. Two unrelated children were confirmed
as GT. One proband had compound heterozygous variants of c.1913+5G>T and
c.1451G>T (p. Gly484Val) in ITGB3. The former was pathogenic which results in
aberrant splicing and the latter is novel. The other proband had homozygous
variant of c.1913+5G>T in ITGB3. Three unrelated children were confirmed as
vWD. One proband had compound heterozygous variants of c.2574C>G
(p.Cys858Trp) and c.3390C>T (p.Pro1127_Gly1180delinsArg) in VWF, especially
the latter synonymous variant previously confirmed to be resulted in exon 26
skipping. Another proband had a novel variant, c.2008C>T (p.Arg670Cys). The
last proband had a known VWF pathogenic variant of c.1728G>T (p.Met576Ile).
Summary/Conclusions: DES is a valuable method to confirm GT or vWD.
Further study is needed to find out unidentifiable mutations by this strategy.
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HPA-3A/3A GENOTYPE IS A POSSIBLE RISK FACTOR OF SEVERE
HEMORRHAGIC SYNDROME IN PATIENTS WITH CHRONIC IMMUNE
THROMBOCYTOPENIA
Z. Irina1,*, K. Sergey1, G. Sergey1, M. Natalya1, G. Svetlana1, B. Stanislav1,
C. Aleksandr1
1hematology, Russian Research Institute of hematology, Saint-Petersburg,
Russian Federation
Background: The main clinical manifestation of primary immune thrombocy-
topenia (ITP) is hemorrhagic syndrome (HS) of different severity-from a lack or
minimal cutaneous hemorrhages to severe life-threatening bleeding. It is well
known, that there is no stable correlation between the platelets count or other
parameter(s) and the hemorrhage grade in ITP patients. Possibly, the geneti-
cally-based individual mechanisms of immune response impairment could affect
the clinical course of ITP, in particular, the severity of HS.
Aims: To reveal genetic risk factor(s) for severe HS in patients with chronic ITP.
Methods: A total of 67 patients (58 women and 9 men) with chronic ITP were
involved in the study. The median age of the group was 57 years (range: 24-
77). The mean duration of ITP was 7 years (2-48). Hemorrhage was graded
according to WHO scale. Taking into account the severity of HS, all the patients
were divided into two groups. The first group included 40 patients with HS of
0-1 grade and the second consisted of 27 patients with HS of 2-3 grade. All
patients of the second group needed the use of different methods of emergency
haemostatic therapy and we consider it as a “severe ITP”. We analyzed DNA
polymorphism of 8 genes responsible for the formation of specific human
platelet alloantigen systems (HPA-1, -2, -3 and -5) or associated with impaired
immune response (IL-1B, IL-6, IL-10 and TNF-A). The differences in genotype
frequencies between the groups 1 and 2 were assessed by Fisher’s exact
method. Odds ratios (OR), their 95% confidence intervals (CI) and p-values
were calculated with GraphPad Prism 5.0 software.
Results: The frequency of HPA-3a/3a (GpIIb 2622TT, 843 Ile/Ile) genotype
was more than 2-fold increased in ITP patients with severe HS (55.6% vs 25.0%
in the group with HS of 0-1 grade; OR=3.8, 95% CI: 1.3-10.7, p=0.02). HPA-
1a/1a and HPA-2a/2a genotypes were also more frequently seen in patients
with HS of grade 2-3 when compared to the group HS 0-1 (77.8% vs 72.5%
and 92.6% vs 80.0%, respectively), but these differences were not statistically
different (p=0.78 and p=0.19, respectively). Moreover, in the group with “severe
ITP” we found almost 2-fold increase of the IL-6 -174CC genotype frequency
(26.9% vs.15.0% in HS 0-1; OR=2.1, 95% CI: 0.6-7.1, p=0.34). Patients positive
for IL-10 -592A allele were also more frequently seen in the group with HS of
2-3 grade (48.1% vs.26.3% in HS 0-1; OR=2.6, 95% CI: 0.9-7.4, p=0.11).
Summary/Conclusions: Our data indicate that HPA-3a/3a variant could be a
possible risk factor for severe HS in ITP patients.
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AN ALGORITHM TO IDENTITY CASES OF SEVERE HEMORRHAGE IN
ROUTINELY COLLECTED HEALTHCARE DATA
A. Kreuger1,2,*, R. middelburg1, J.L. Kerkhoffs3, J. van der Bom1
1Center for Clinical Transfusion Research, Sanquin Research, 2clinical epidemi-
ology, LUMC, Leiden, 3Hematology, Hagaziekenhuis, den haag, Netherlands
Background: Many patients with a hematological malignancy have an
increased risk of hemorrhages. Research addressing the causes of these hem-
orrhages, especially those on major hemorrhages, are hampered by the diffi-
culty to find sufficient and representative cases of major hemorrhage. Unfortu-
nately, electronic health records generally do not codify hemorrhages. 
Aims: The aim of this study was to develop an algorithm that can be used to
find patients who suffered from major hemorrhages (WHO grade 3 or 4) within
electronic health records.
Methods: An algorithm was developed using electronic health record data of
a cohort of patients with acute leukemia, who received platelet transfusions
between June 2011 and December 2015 at the Leiden University Medical Cen-
ter in the Netherlands. Chart review was performed for a stratified, random
sample of observation days. Discriminative performance of three indicators
was assessed: CT-brain, drop in hemoglobin level and transfusion need within
24 hours. The cut off values for hemoglobin drop and transfusion need with
the best discriminating capacity and CT-brain were entered in the final algo-
rithm. The C-statistic was calculated and calibration plots were made. The
algorithm will be externally validated in two other academic hospitals.
Results: The derivation cohort consisted of 255 patients comprising 10,638
observation days and chart review was performed for 353 days. The incidence
of major hemorrhage was 0.22 per 100 observation days. The final algorithm
consisted of information on CT-brain (yes/no), a hemoglobin drop of ≥2.8 g/dl
and the need of six or more transfusions (yes/no). The C-statistic of the algo-
rithm was 0.93 (95% confidence interval (CI) 0.86 to 0.99). The incidence of
bleedings with all grades of severity was 8.4 per 100 days. The algorithm for
bleedings of all grades had a c-statistic of 0.54 (CI 0.53 to 0.55). The results
of the external validation are not available yet. 
Summary/Conclusions: An algorithm using information on CT-brain, hemo-
globin drop and transfusion can accurately identify cases of major hemorrhage
within electronic health care data. External validation will be performed.
Myelodysplastic syndromes – Clinical 1
P313
MOLECULAR MECHANISMS AND CLINICAL SIGNIFICANCE OF
REDUCED PTPN1 EXPRESSION IN MYELODYSPLASTIC SYNDROMES
M. Shiseki1,*, M. Isii1, M. Ohwashi1, N. Mori1, K. Yoshinaga 1, J. Tanaka1
1Department of Hematology, Tokyo Women’s Medical University, Tokyo, Japan
Background: Previously we determined common deleted region (CDR) of
del(20q) observed in MDS by CGH-array. Our data showed that the PTPN1
gene is located within CDR of del(20q).  The PTPN1 gene encodes PTP-1B,
a non-receptor type protein tyrosine phosphatase, which is involved in multiple
physiological and pathological cellular processes via dephosphorylation of sev-
eral tyrosine kinases, and other molecules. Although roles of PTP-1B in normal
and pathological hematopoiesis has not been elucidated, it may function neg-
ative regulator for cellular processes mediated by tyrosine kinases, including
JAK2, and SRC. We hypothesized that the PTPN1 gene is a target gene disrupt
by del(20q), resulting in haplo-insufficiency, and involved in MDS molecular
pathogenesis.
Aims: We attempted to examine PTPN1 expression level in bone marrow cells
of MDS patients with or without del(20q), and to investigate its clinical and bio-
logical significance.
Methods: Total RNA was extracted for cDNA synthesis from bone marrow
samples taken at the time of diagnosis with written informed consent from
patients and control subjects were used for the present study. Real-time RT-
PCR was carried out to quantify PTPN1 expression by the TaqMan probe
method using an ABI 7500 real-time PCR system (Applied Biosystems).  Data
including patients’ demographic, disease status, medical history, clinical and
laboratory findings, and outcome, were collected from medical records and
laboratory data base. A non-parametric Mann-Whiteny-Wilcoxon test was used
to examine whether expression levels among groups are statistically different.
The Kaplan-Meier model was used to analyze the impact of PTPN1 expression
on overall survival, and log-rank test was used for statistical analysis.  We also
examined the effect of 5-azacytidine treatment on PTPN1 expression in primary
bone marrow cells from MDS patients. Bone marrow cells were cultured with
or without 5mM of 5-azacytidine for 48 hours. Expression level of PTPN1 was
examined by quantitative RT-PCR described as above.
Results: A total of 118 MDS patients, 71 males and 47 females with median
age of 68 years (range: 20-91 years) and 19 control subjects were included in
the present study. The patients were classified as RCUD (n=18), RCMD (n=58),
RARS (n=8), RAEB-1 (n=20), and RAEB-2 (n=14) according to WHO classifi-
cation. Relative PTPN1 expression level was significantly decreased in MDS
patients with del(20q) (P<0.001) compared with control subjects. Moreover,
relative PTPN1 expression level in MDS patients without del(20q) also signifi-
cantly decreased (P<0.001).  Expression patterns of PTPN1 among five WHO-
subtypes, were statistical different (P=0.0201). Median values of relative
PTPN1 expression level in RCUD, RCMD, RARS, RAEB-1, and RAEB-2 were
1.52, 1.95, 1.94, 1.46, and 1,26 respectively. Relative PTPN1 expression level
in WHO-subtypes with high blast counts (RAEB-1 and RAEB-2) was signifi-
cantly lower than that in WHO-subtypes with less blast counts (RCUD, RCMD,
RARS) (median value: 1.41 vs 1.89, P=0.0074). To investigate prognostic impli-
cation of PTPN1 expression in MDS, we analyzed impact of PTPN1 expression
on overall survival (OS). Based on PTPN1 expression level, 118 patients were
divided into four groups, high (Q1), intermediate (Q2, Q3), and low (Q4) quar-
tiles. Kaplan-Meier analysis demonstrated that the lowest quartile (Q4) showed
significantly worse survival compared with remaining quartiles (Q1, Q2, Q3)
(P=0.048). The estimated 5-year OS rates in Q1-3 group and Q4 group were
69% and 49.8%, respectively. We examined whether PTPN1 expression is
induced by 5-azacytidine in primary bone marrow cells of 17 MDS patients.
Real-time PCR analyses indicated that 5-azacytidine treatment significantly
induced PTPN1 expression. 
Summary/Conclusions: The present study demonstrated that PTPN1 expres-
sion is reduced in MDS patients by haplo-insufficiency due to del(20q) and
methylation of promotor region of the PTPN1 gene. Low PTPN1 expression is
associated with advanced disease and poorer clinical outcome, indicating that
PTPN1 expression level could be a useful prognostic marker in MDS.  .
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MOLECULAR MARKERS PREDICTING RESPONSE TO AZACITIDINE
TREATMENT FOR MYELODYSPLASTIC SYNDROMES
Y. Nannya1,*, J. Takeda1, Y. Shiozawa2, Y. Shiraishi3, Y. Okuno4, K. Kataoka1,
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Background: DNA hypomethylating agents (HMAs) comprise standard therapy
for non-transplant-candidate high-risk myelodysplastic syndromes (MDS). How-
ever, little is known about the exact mechanism of their effects to MDS or no
reliable makers predicting the response to HMAs have been developed,
although a recent study reported a very high response rate of TP53-mutated
AML and MDS to decitabine. 
Aims: The purpose of this study is to elucidate the clonal dynamics and molec-
ular signatures that correlate with response to azacitidine therapy for MDS,
focusing on the role of TP53-mutations.
Methods: We conducted a prospective multicenter trial of azacitidine treatment
for high-risk MDS patients, in which the efficacy was compared between the 5-
day and 7-day regimens.  A total of 107 patients were enrolled between 2013
and 2016. For all cases, a bone marrow specimens collected before treatment
was analyzed for mutations using targeted-capture sequencing. Mutations were
also interrogated after 4 cycles of azacitidine therapy in 48 (45%) cases. An
additional 24 cases was also analyzed for mutations who received azacitidine
therapy for MDS and whose bone marrow specimens were available both
before and after therapy. RNA baits were designed for detection of both onco-
genic variants in 67 known driver genes in myeloid neoplasms and copy number
alterations on the same platform. Response was evaluated according to the
IWG 2006 criteria. We also evaluated the difference in the size of clones show-
ing the maximum allelic burden between pre- and post-treatment specimens
(ΔTCF: tumor cell fraction). 
Results: On average, 2.7 mutations (range 0-9) were detected per sample
before azacitidine treatment. TP53 represented the most common mutational
target affecting 29 (27%) and 10 (42%) cases in the on- and off-protocol cohort,
respectively, followed by ASXL1, RUNX1, TET2, and SRSF2. TP53-mutated
cases had significantly lower number of driver mutations (1.7 vs 3.1/sample,
p<0.001) and higher number of copy number changes (9.6 vs 2.1, p<0.001),
compared with unmutated cases. Clinical response was observed in 25 cases
in the on-protocol cohort, including 6 complete remission (CR) (5.6%) and 19
marrow CR (mCR) (17.8%) and 7 (29%) cases (all CR) in the off-protocol
cohort. Notably, CR was obtained almost exclusively in TP53-mutated cases
(5/6 and 5/7 CR cases in the on- and off-protocol cohort. No other mutations
were significantly associated with clinical response. Median time to CR was
119 days (range: 81–721), which lasted for a median duration of 217 days
(range 10 –783). ΔTCF was evaluable for 62 cases who had one or more fol-
low-up specimens and carried at least one mutation in either pre- or post-treat-
ment with an average of –0.075 (range: –0.75–0.72). ΔTCF was significantly
lower in responders than non-responders (–0.18 vs –0.0002, p=0.0068) and in
TP53-mutated than unmutated cases (–0.25 vs 0.0058, p=0.001).
Summary/Conclusions: Our study revealed a significant positive association
of TP53 mutations with favorable responses to azacitidine for MDS, although
the response was transient and the expected response rate seems to be much
lower compared to that reported for decitabine. Given that decitabine is not
approved for MDS in many areas (e.g. EU and Japan), our results suggests a
potential role of azacitidine as a key agent to improve the notoriously dismal
clinical outcomes of TP53-mutated tumors. Further study should be warranted
to confirm its efficacy and to develop an optimal post-remission therapy to over-
come the short remission period.
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UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR
PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC
SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
G. Montalban-Bravo1,*, P. Bose1, Y. Alvarado1, N. Daver1, F. Ravandi1,
G. Borthakur1, K. Takahashi1, M. Andreeff1, J. Cortes1, C. DiNardo1, E.J. Jabbour1,
T. Kadia1, S. Kornblau1, M. Ohanian1, A. Alfonso2, X. Huang3, G. Nogueras
Gonzalez3, K. Bodden1, S. Pierce1, C. Bueso-Ramos4, H. Kantarjian1,
G. Garcia-Manero1
1Leukemia, 2MD Anderson Cancer Center, Houston, United States, 3Biostatis-
tics, 4Hematopathology, MD Anderson Cancer Center, Houston, United States
Background: Improving the current response and survival outcomes of patients
with higher risk MDS and CMML is fundamental. Guadecitabine is a next gen-
eration hypomethylating agent with increased length of exposure compared to
decitabine and clinical activity in patients with MDS. 
Aims: To evaluate the activity of guadecitabine in previously untreated patients
with higher-risk MDS or CMML.
Methods: We conducted a single arm phase II clinical trial of guadecitabine at
a dose of 60mg/m2 sc daily for 5 days (days 1-5) every 28 days for patients
with newly diagnosed MDS or CMML classified as Intermediate-2 or High risk
by IPSS. Primary endpoint was complete response (CR). Responses were
evaluated following the revised 2006 International Working Group criteria.
Sequencing data was obtained at the time of pre-treatment evaluation by the
use of a 28-gene next generation sequencing platform. Study included stopping
rules for response and toxicity. Overall survival (OS) was censored at the time
of transplant.
Results: A total of 53 patients have been enrolled: 50 (94%) are evaluable for
toxicity and 44 (83%) for response. Median age is 67 years (49-87). A total of
43 (86%) patients have MDS and 7 (14%) have CMML. A total of 21 (42%)
have complex karyotype. Sequencing data was available in 48 (96%) patients
with TP53 mutations being the most frequently detected in 36% patients. After
a median of 6 treatment cycles (1-20), the ORR is 71% including 32% CR.
Median best response occurred by 3 cycles (1-6). Seven (21%) out of 33 evalu-
able patients achieved a complete cytogenetic response. Ten (20%) subjects
proceed to allogeneic stem cell transplantation. Median follow up was 6.3
months (0-23). Median OS is 14.1 months (CI 13.3-14.9 months) and median
EFS is 8.4 months (CI 5.6-11.2 months). Forty-five (90%) patients experienced
at least one AE during therapy. Most common grade 1-2 AEs included fatigue
(66%), nausea (38%) and dyspnea (26%). Dose reductions due to cytopenias
were required in 17 (34%) patients. Early 8-week mortality occurred in 3 (6%)
patients.
Summary/Conclusions: Guadecitabine is well-tolerated and active in patients
with higher-risk MDS and CMML even in the presence of adverse biological
features such as high frequency of complex karyotype, therapy related disease
and TP53 mutations.
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AZACITIDINE IMPROVES OUTCOME IN HIGH RISK MDS PATIENTS WITH
CHROMOSOME 7 ABNORMALITIES: RETROSPECTIVE COMPARISON OF
GESMD AND GFM REGISTRIES
M. Díez Campelo1,*, J.I. Lorenzo1, R. Itzykson2, S.M. Rojas1, C. Berthon2,
E. Luño1, O. Beyne-Rauzy2, J. Pérez-Oteiza3, N. Vey2, J. Bargay1, S. Park2,
T. Cedena1, D. Bordessoule4, J.A. Muñoz1, E. Gyan2, E. Such1, S. Visanica2,
F. López Cadenas1, S. de Botton2, J.M. Hernández Rivas1, S. Ame2,
A. Stamatoullas5, J. Delaunay2, C. Salanoubat2, F. Isnard2, R. Guieze2,
G. Sanz1, C. Cañizo1, P. Fenaux2
1Hematology, GESMD, Valencia, Spain, 2Hematology, GFM, Paris, France,
3Hematolgy, GESMD, Valencia, 4Hematology, GFM, Paris, Spain, 5GFM, Paris,
France
Background: A benefit of treatment with azacitidine (AZA) in higher-risk (inter-
mediate-2 and high risk by IPSS) Myelodysplastic syndromes (HR-MDS)
patients with abnormalities of chromosome 7 (Abn 7) has been suggested in
relatively small studies. 
Aims: Our purpose was to confirm this benefit in a larger patient series. 
Methods: Retrospective study of 235 HR-MDS patients with Abn 7 treated with
AZA (n=115) vs best supportive care (BSC; n=120), assessing AZA treatment
as time-varying variable in multivariable analysis.
Results: Seventy-four (64%) of AZA patients had de novo MDS and 41 (36%)
had therapy related (secondary MDS), compared to 70 (90%) and 8 patients
(10%) in the BSC group (P=0.0001). According to WHO 2008 classification,
65% in the AZA group and 48% in the BSC groups had refractory anemia with
excess of blasts type 2 (RAEB-2) or secondary acute myeloid leukemia (AML
with <30% of blasts) (p=0.015). The AZA and BSC groups were well balanced
in terms of age, gender, cytogenetic risk category, and IPSS risk. In the AZA
group, 55% patients were IPSS high-risk and 45% intermediate-2-risk and 61%
had Complex-K, 23% non-complex -7, 14% non-complex del(7q), and only 2
patients (1.8%) had non-complex 7p-. Nevertheless, regarding MDS classifi-
cation and MDS subtype (de novo vs secondary) was unbalanced with more
patients with RAEB-2+AML (65% vs 48%, p<0.015) and secondary MDS (36%
vs 10% <0.001), in the AZA group as compared to BSC patients. Median fol-
low-up time from diagnosis was 47.5 months (95% CI: 24.2 – 122.9) in the AZA
group and 59.8 months (95% CI: 15.5 - not reached) in the BSC group (P=ns).
Median time from diagnosis to AZA treatment was 2 months (range 0 – 66.2).
Ninety-two patients (80%) received AZA according to the conventional 7 days
every 28 days schedule whereas 20% received 5-day cycles. The median num-
ber of AZA cycles received was 5 (range, 1-32). Response to AZA: Twelve
patients were not evaluable for response according to IWG 2006 criteria
because no complete data was recovered. In the 103 patients evaluable for
response in the AZA group, the overall RR (ORR) was 37.9% (39/103), including
14.6% CR and 23.3% SD with HI. Among AZA non-responders (62.1%), 27.1%
had SD without HI, 23.3% PD, and 11.7% (n=12) had early death (8, infection;
1, bleeding, 3, unknown cause).  According to cytogenetic, the ORR was 38.1%
in patients with CK, 32% in patients with non complex -7 and 46.2% in patients
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with non complex del(7q) (P=ns for complex vs non complex, chi-square test).
The ORR was 37.5% in “de novo” and 38.4% in secondary MDS, respectively
(P=ns). Impact of AZA treatment compared to BSC on overall survival: Results
of this multivariable analysis of OS at different time points are presented in
Table 2. Chromosome 7 cytogenetic categories and IPSS retained a poor prog-
nosis over time with a constant value of poor prognosis. AZA treatment had a
favorable impact on OS during the first 3 years of treatment, compared to BSC,
confirming results obtained in univariable analysis. Nevertheless, the benefit
of AZA treatment as compared to BSC approach decreased as time spends
and the HR value increased over time: HR of 0.3 at 6 months, 0.5 at 1 year
and 0.7 at 2 and 3 years after treatment. (Figure 1). This benefit was present
in all chromosome 7 categories with a a trend towards better impact among
patients with complex karyotype but no significant differences between the 3
categories (-7, del(7q) and CK).
Figure 1.
Summary/Conclusions: This study confirms the benefit of AZA treatment on
outcome in patients with HR-MDS and cytogenetic abnormalities involving
chromosome 7.
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UN UPDATE OF A PHASE II EXPLORATORY STUDY OF OPN-305, A
TOLL-LIKE RECEPTOR 2 ANTIBODY, IN PATIENTS WITH LOWER RISK
MYELODYSPLASTIC SYNDROMES WITH PRIOR HYPOMETHYLATING
AGENT THERAPY
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C. DiNardo1, N. Daver1, M. Konopleva1, K. Hearn1, R. Miller2, S. Arbe-Barnes2,
P. McGuirk2, T. Kearney2, B. Keogh2, H. Kantarjian1, M. Reilly2
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Background: Alterations of innate immune signaling, including overexpression
of TLR2, are common in MDS. Significant TLR2 overexpression in MDS bone
marrow CD34+ cells, especially after HMA therapy, has been reported. OPN-
305 is a fully humanized antagonistic IgG4 kappa monoclonal antibody to TLR2
which significantly increases the formation of erythroid colonies (CFU-E) in BM
CD34+ cells isolated from pts with lower-risk MDS in vitro.  
Aims: To evaluate the potential therapeutic value of OPN-305 in patients (pts)
with MDS
Methods: We designed a phase I/II trial of OPN-305 for pts with Low or Int-1
risk MDS by IPSS after failure to prior therapy with a HMA (≥4 cycles). Pts
where required to be transfusion dependent (≥2 units in 8 weeks). Pts with iso-
lated del(5q) should have received therapy with lenalidomide. Because, OPN-
305 had not been previously used in pts with hematological malignancies, the
study had an initial phase of N=10 pts using OPN-305 at a dose of 5 mg/kg
every 4 weeks for a maximum of 9 cycles. Therapy could be repeated as long
as there was no excess toxicity or progression. If after 16 weeks of therapy,
there was no response, azacitidine on a 3 day schedule, could be added to
OPN-305. Responses were evaluated following the revised 2006 IWG criteria.
This initial cohort allowed evaluation of toxicity, pharmacokinetic analysis,
receptor occupancy, and sequential analysis of cytokine profile. An extension
dose escalation phase to 10mg/kg was planned for N=30 pts.
Results: At the time of this report, 31 pts have been enrolled, 11 at the initial
5 mg dose and 21 at 10 mg/kg. A total of 21 pts are evaluable for toxicity and
response. Median age was 72 years (range 42-87). Nine (43%) pts were clas-
sified as Low risk and 12 (57%) as Intermediate-1 risk by IPSS. Thirteen pts
had normal karyotype, 2 del(5q), 2 trisomy 8, 1 del(20q), 1 monosomy Y and
2 other single or double abnormalities. Median number of prior therapies was
2 (range 1-4) with a median duration of prior therapies of 23 months (range 6-
56). A total of 5 (29%) pts developed AEs related to OPN-305. All AEs were
grade 1 with gastrointestinal disorders being the most frequent (23%). At this
point, no significant drug related toxicity has been documented with no excess
infectious complications. Overall response rate in the form of hematological
improvement was 53% (8/21) with 3 (20%) pts achieving transfusion independ-
ence and 5 (33%) minor hematological improvement. Half-lives of OPN-305 in
serum were >200 h at 5 mg/kg and >300 h at 10 mg/kg. There was a greater-
than-dose proportional increase in mean OPN-305 exposure (AUC) between
5 and 10 mg/kg. PK profiles after repeated dosing at 5 mg/kg in N=2 subjects
and pre-dose (trough) levels in other subjects indicated some variability in the
potential for accumulation. TLR-2 receptor occupancy in blood PBMCs and
bone marrow aspirates was complete in virtually all samples taken after OPN-
305 administration. There is no evidence of treatment related anti-drug anti-
bodies. Compared with baseline, no significant changes of IL-23, IL-18, IFN-r,
IL-10, IL-1β, IL-6, IL-12 (p40), IL-12 (p70) and IL-8 levels where observed
among responders or non-responders or based on OPN-305 dosing. A trend
to increased response was observed in patients with higher TLR2 expression,
with no differences in response based on cytogenetic or mutational profile.
Summary/Conclusions: Treatment with OPN-305 in pts with previously treat-
ed lower-risk MDS was well tolerated with no significant toxicities and 53%
ORR including 20% transfusion independence, and potential association
between TLR2 levels and response.
P318
IN PATIENTS UNDEGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR MDS DEVELOPMENT OF CHRONIC GVHD
COULD AMELIORATE THE ADVERSE IMPACT OF SPECIFIC SOMATIC
MUTATIONS
J.C. Caballero Berrocal1,*, M. Sánchez Barba2, J.M. Hernández Sánchez3,
M. Del Rey3, K. Janusz3, C. Chillón4, E. Such5, C. José5, G. Sanz5,
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Background: Approximately 90% of patients with Myelodysplastic Syndromes
(MDS) have somatic mutations in driver genes detected by Next Generation
Sequencing (NGS). In the last years, several studies have related these muta-
tions with prognosis, disease characteristics and response to therapy, including
allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Development of
Chronic Graft Versus Host Disease (cGVHD) has been reported as one of the
most powerful antineoplastic mechanisms after HSCT. 
Aims: To evaluate the impact of specific somatic mutations in patients with
MDS undergoing HSCT and if the development of cGVHD can modify their
prognosis.
Methods: The results of HSCT in 115 MDS patients from five centres in Spain
were retrospectively analyzed. Bone marrow samples were collected a median
of 27 days prior to transplant and DNA was screened for somatic mutations by
NGS, using a NextSeq platform (Illumina). Two myeloid genes panels that
included the most frequently mutated genes in myeloid malignancies were
used. 
Results: Median age was 53 years (range from 19 to 70). Fifty-eight percent
were male and 79.13% were classified as de novo MDS. According to WHO
2008 classification 4 (3.5%) were RCUD, 2 (1.8%) RARS, 22 (19.50%) RCMD,
28 (24.8%) RAEB-1, 32 (28.3%) RAEB-2, 12 (10.6%) Unclassifiable MDS, 9
(8%) CMML and 4 (3.5%) were AML (FAB RAEB-T). Among patients with cal-
culated Revised IPSS (R-IPSS) (85 of 115 patients) 2 (2.4%) had very low risk,
15 (17.6%) low risk, 21 (24.7%) intermediate risk, 22 (25.9%) high risk and 16
(18.8%) had very high risk; 9 patients with CMML (10.6%) were categorized
separately. Among patients with known karyotype (101 of 115), 7 of them (6.9%)
had a complex kariotype (CK). Regarding mutational study, 44 patients (38.3%)
didn’t shown any mutation before transplant; 27 patients (23.5%) had 1 mutated
gene, 15 (13%) had 2, 19 (16.5%) had 3, 6 (5.2%) had 4, 3 (32.6%) had 5 and
only 1 patient (0.9%) had 6 different mutated genes. The most frequently mutat-
ed genes were: TP53 in 15 patients (13%), SRSF2 in 14 (12.2%), TET2 in 13
(11.3%), DNMT3A in 9 (7.8%), RUNX1 in 9 (7.8%), SF3B1 in 9 (7.8%) and
ASXL1 in 8 (7%) patients. After a median of follow up for survivors of 2.02
years, Overall Survival (OS) was 48.1% (63.4% at 1 year; median 5.96).
Patients were divided into 2 groups: group 1, with 2 or less mutated genes
(74.5%) and group 2, with more than 2 mutated genes (25.2%). Group 2 had
a lower OS (46.9% vs 69.6% at 1 year; p=0.035) and a higher Cumulative Inci-
dence of Relapse (CIR) (25.3% vs 10.1% at 1 year; p=0.007). Development of
cGVHD significantly improved outcome in both groups (Figure 1). Univariate
analysis determined that developing of cGVHD, CK, number of mutated genes
(more than 2 mutated genes) and mutations in TET2 significantly impacted on
outcome. Nevertheless, only the development of cGVHD as a time-dependent
variable (HR 0.046, 95%CI 0.016-0.138, p<0.001) and TET2 mutations (HR
2.562, 95%CI 1.018-6.447, p=0.046) significantly influenced on OS in multi-
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variate analysis. We also observed the unfavourable impact of TP53 mutations
on relapse risk: CIR was 41.7% (95% CI 22.5-77.1) at 1 year for TP53 mutated
vs 9.8% (95% CI 5.3-18.1) at 1 year for non TP53 mutated patients (p=0.006).
Figure 1.
Summary/Conclusions: We conclude that the number of mutated genes prior
to transplant could be a prognostic factor of OS and CIR. Mutations in some
genes, like TET2 and TP53, could also have an adverse impact on outcome.
However, cGVHD could ameliorate the poor prognosis of somatic mutations in
transplanted patients with MDS. 
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VOSAROXIN PLUS AZACITIDINE TREATMENT FOR PATIENTS WITH
MYELODYSPLASTIC SYNDROME: A PHASE 1/COHORT EXPANSION
STUDY
M.A. Jacoby1,*, M.J. Walter1, J.F. DiPersio1, C.N. Abboud1, P. Westervelt1,
A.F. Cashen1, K. Stockerl-Goldstein1, T. Fletcher1, G.L. Uy1
1Medicine, Washington University Medical School, St. Louis, United States
Background: Although hypomethylating agents are the mainstay of treatment
for myelodysplastic syndromes (MDS), these agents result in remissions in a
minority of patients and are not curative. Vosaroxin is a first-in-class quinolone
derivative that intercalates DNA and inhibits topoisomerase II. Vosaroxin is
active with a tolerable safety profile in acute myeloid leukemia (AML) and the
novel combination of vosaroxin and azacitidine was found to be synergistic in
primary myeloblasts. 
Aims: This phase 1/cohort expansion study was designed to determine the
maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of vosaroxin
when given in combination with azacitidine, and to evaluate the efficacy and
safety of the combination treatment.
Methods: Patients with MDS ≥18 years old with cytopenias requiring transfu-
sions, an IPSS score of intermediate (INT)-1 or greater, or chronic myelomono-
cytic leukemia were eligible. Vosaroxin (initial dose: 50 mg/m2/d) was admin-
istered on Days 1 and 4, and azacitidine (75 mg/m2/d) on Days 1-7 of a 28-day
cycle, in an outpatient setting, for up to 6 cycles in a 3+3 design (additional
cycles were permitted if a clear benefit for the patient was demonstrated). Once
the MTD was determined, an expansion cohort of 20 evaluable patients (≥1
cycle) was enrolled.
Results: A total of 35 patients enrolled in the dose escalation (n=13) and expan-
sion (n=22) phases. The median age of the entire cohort was 66 years (range
38-77) with IPSS scores of low (n=1); INT-1 (n=13); INT-2 (n=15); and high risk
(n=6). The median ECOG score for the entire cohort was 1 (range 0-2). In the
dose escalation phase, at the initial dose of vosaroxin 50 mg/m2/d (n=6), the
median number of total cycles was 2 (range: 1-4); 2 of 6 patients experienced
a DLT at this dose (grade 4 hyperbilirubinemia and grade 4 neutropenia >42
days). At the de-escalated dose of 34 mg/m2/d (n=7), the median number of
cycles was 2 (range: 1-18); 1 patient experienced a DLT at this dose (grade 4
mucositis). The MTD of vosaroxin was determined to be 34 mg/m2/d and this
dose was used in the expansion phase. Incidences of ≥grade 3 non-hemato-
logic adverse events considered possibly, probably, or definitely drug-related
for the total cohort (n=35) included infections (n=38), non-neutropenic fever
(n=1); neutropenic fever (n=23); bleeding (n=9); and GI (mucositis/colitis/dys-
phagia; n=4). Two deaths were considered possibly treatment-related (sepsis
and diffuse alveolar hemorrhage). No cardiac toxicity attributable to study treat-
ment was observed, even with prolonged therapy. Of the 35 enrolled patients,
32 have completed ≥1 cycle and are evaluable for response. Among these
patients, median number of cycles completed is 3 (range, 1-18), with 5 still
continuing with therapy. Best response rates are shown in the Table 1. The
median number of cycles to best response was 1 (range: 1-6). Sixteen patients
have received transplant to date.
Table 1.
Summary/Conclusions: The MTD of vosaroxin in MDS patients was 34
mg/m2/d when given on Days 1 and 4 with a fixed dose of 75 mg/m2 of azaci-
tidine on Days 1-7. The major non-hematologic toxicities were infections, febrile
neutropenia, and bleeding. The combination of vosaroxin and azacitidine
showed promising activity with responses rates comparable or better than those
generally observed with azacitidine alone. Additionally, the transplant rate
observed was encouraging in this patient population.
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ADVANCED STAGE MYELOMA IS CHARACTERIZED BY A SIGNIFICANT
INCREASE OF MUTATIONS IN GENES ASSOCIATED WITH DRUG
RESPONSE 
S. Barrio1,*, M. Da-Via1,2, T. Stühmer1, A. Garitano-Trojaola1, L. Bruins3,
I. Cuenca4, M. Schreder1, R. Tibes1, P. Sonneveld5, M.S. Raab67, J. Martinez-
Lopez4, A. Rosenwald8, R.C. Bargou9, E. Braggio3, A.K. Stewart3,10, H. Einsele1,
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tal., 9Comprehensive Cancer Center Mainfranken , Würzburg University Hos-
pital, Würzburg, Germany, 10Center of Individualized Medicine, Mayo Clinic,
Rochester, United States
Background: The amount of genomic data available in Multiple Myeloma (MM)
is exponentially increasing, however, hardly any of that information is translated
into the clinic. A number of genes has been associated with resistance to com-
monly used anti MM compounds. This, most importantly, includes immunomod-
ulators (IMiDs) and proteasome inhibitors (PIs). However, no mutation screen-
ing has yet been amended to our MM routine diagnostic workflows. We inves-
tigated 458 MM patients by targeted sequencing, including the largest cohort
of previously treated MM patients so far. We identified an increased mutation
incidence in treated patients, yet unreported mutations and functionally vali-
dated a subset. 
Aims: To describe the mutational spectrum in genes of pathways targeted by
standard of care (SOC) therapies in a cohort of pretreated and previously
untreated patients. 
Methods: Tumor-germline paired samples of five contributing sites were pooled
(Würzburg, Heidelberg, Madrid, Rotterdam and Mayo Clinic). Analysis included
310 untreated and 148 IMiD and/or PI treated patients. Targeted sequencing
was performed using the M3P (v2.0 or v3.0) gene selection, that includes most
commonly mutated MM genes, actionable drug targets and genes being asso-
ciated with drug resistance. Average sequencing depth increased 700X. Func-
tional analyses of PSMB5 mutations were conducted using Sleeping beauty
vectors transposed into AMO1 cell line.
Figure 1. A: Mutation incidence in IMID related and PI related genes. B:
Functional analysis of PSMB5mut expressing AMO-1 cells with different
PI inhibitors and the P97 inhibitor CB-5083.
Results: Our analysis included five genes each with known association to drug
response to IMiDs (CRBN, CUL4B, IKZF1, IKZF3 and IRF4) and PIs (PSMB5,
PSMB8, PSMB9, PSMD1 and XBP1). Based on the increased sequencing
depth, the mutation incidence in untreated patients is higher than in the CoMM-
Pass dataset (IMiDs: 5.8% vs 3.9%; PIs: 1.9% vs 1.4%). Furthermore, pre-
treated patients showed a significant mutational increase compared with
untreated pts (IMiDs: 19.7%, Z-score: -4.2, p<0.001; PIs: 7.3%, Z-score: -2.6,
p=0.009). We observed a Gly159Arg mutation within the Lenalidomide (Len)
degron sequence of IKZF3 in a patient progressing on Len and Pomalidomide
(Pom), as well as two XBP1 truncating mutations in PI refractory patients. Of
note, among three treated cases with mutations in the β5 (PSMB5) or β5i
(PSMB8) PI binding subunit of the proteasome, one patient harbored not less
than 4 subclonal mutations. This is the first description of PSMB5 mutations in
human MM, identified in a patient with long term history of PI treatment. All
mutations were located in or close to the Bor binding site of PSMB5. The func-
tional analysis demonstrated induction of resistance not only to Bor
(IC50PSMB5wt= 2 nM vs IC50PSMB5mut= 4.5-8 nM), but also to the second gen-
eration PI Ixazomib (IC50PSMB5wt= 5.2 nM vs IC50PSMB5mut= N/A) and Carfil-
zomib (IC50PSMB5wt= 8 nM vs IC50PSMB5mut= 13-22 nM). Of interest, the P97
blockade of the protein homeostasis by the investigational compound CB5083
remains still possible in the mutated cell lines and the resistance can be over-
come. Finally, Pom treatment eradicated two of the PSMB5 containing sub-
clones (Figure 1).
Summary/Conclusions: Under the selective pressure of anti-MM therapy the
incidence of mutations in genes associated with drug resistance increases
over time. Resistance mechanisms evolve in parallel in competing (sub)clones
of the disease, mimicking phenotype and behavior. Remarkably, despite our
restrictive gene selection, a quarter of our treated cohort is affected by at least
one mutation. Aim of future therapy may be the eradication of selected clones
or subclones, which, according to our data, appears possible.
P321
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE
RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED
MULTIPLE MYELOMA
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Background: The 1q21 amplification, which occurs in approximately 40% of
de novo and 70% of relapsed Multiple Myeloma (MM), is among the most fre-
quent chromosomal aberrations in MM patients and is considered a very high-
risk genetic feature that is especially correlated with disease progression and
drug resistance. The 1q21 amplicon contains many genes, and while it is unlike-
ly that all contribute to the pathobiology of high-risk MM, the critical genes that
do drive this high-risk phenotype have not yet been fully clarified. Identifying
such genes and their contributions to this phenotype would enable the devel-
opment of new and effective targeted therapy strategies for high-risk MM and
thus improve their survival outcomes.
Aims: In our study we wanted to investigate the biological and molecular mech-
anisms behind the 1q21 amplification’s contribution to high-risk MM with the
ultimate goal of obtaining a list of validated therapeutic targets to inform the
design of novel translational clinical trials for this subgroup of patients.
Methods: We conducted a high-resolution analysis of recurrent copy number
alterations and expression profiles in a collection of 254 MM samples included
in MMRC database. To define the discrete minimal common 1q21 region that
is recurrently amplified in MM, we used Genomic Identification of Significant
Targets in Cancer, a systematic method that identifies regions of genome that
are recurrently amplified or deleted across a set of samples. These genes were
enlisted into an in vitro screening strategy that employed a single-shRNA-per-
96-well approach and GFP-competitive cell growth assay to identify 1q21 genes
whose loss of function resulted in the selective death and/or growth inhibition
of MM cells carrying the 1q21 amplification but not MM cells without the 1q21
amplification.
Results: We identified MCL1, UBAP2L, INTS3, LASS2, KRTCAP2 and ILF2
as potential 1q21-specific vulnerability targets whose expression is driven by
copy number. We functionally validated, both in vitro and in vivo, Interleukin-2-
enhancer binding factor 2 (ILF2) as a key 1q21 amplification-specific gene.
Our results show that ILF2 impacts homologous recombination (HR) and
induces resistance to DNA damaging agents routinely used in the treatment of
MM, which is consistent with the observation that ILF2 expression correlates
with poor survival in MM patient treated with high-dose melphalan followed by
tandem autologous transplantation. On the mechanistic level, ILF2 interacts
with numerous RNA binding proteins directly involved in the regulation of DNA
Damage Response (DDR) by modulating alternative splicing of specific pre-
mRNAs.  RNA sequencing experiment confirmed that ILF2 knockdown results
in aberrant splicing of genes involved in the DDR pathways and, strikingly,
ILF2 RIP-seq analysis showed that ILF2 directly binds to transcripts involved
in the regulation of the HR pathway, including components of BRCA1 protein
complex. Furthermore, we found that ILF2 mediates drug resistance in dose-
dependent manner by modulating YB-1 nuclear localization and interaction
with the splicing factor U2AF65 to promote mRNA processing and stabilization
of DDR genes in response to DNA damage (Figure 1).
Summary/Conclusions: In conclusion, our study reveals an intimate relation-
ship among 1q21 amplification, mRNA splicing and DNA repair in the control
of DDR in MM. On the basis of our findings, we propose that 1q21-driven ILF2
overexpression deregulates HR by stabilizing the mRNA splicing of critical HR
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effectors, which enables genomic instability, promotes adaptive mechanisms
to genotoxic stress, and enhances cell survival, thereby promoting drug resist-
ance and disease progression. Given that 1q21 amplification is one of the most
frequent copy number alterations in cancer, synthetic lethality approaches
based on targeting gain-of-function associated to ILF2 may have a broad spec-




PROGNOSTIC IMPLICATION OF SOMATIC MUTATIONS BY NEXT
GENERATION SEQUENCING: AN ANALYSIS FROM THE MMRF
COMMPASS STUDY IN NEWLY DIAGNOSED MULTIPLE MYELOMA
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Background: High throughput techniques, such as next generation sequenc-
ing, are becoming an appealing approach to characterize multiple myeloma
(MM) genomic profiles and better define risk assessment. However, the clinical
relevance of such approaches is still largely unknown. The Multiple Myeloma
Research Foundation (MMRF) CoMMpass trial (NCT01454297) has collected
data from 1154 newly-diagnosed MM patients enrolled worldwide. Comprehen-
sive analysis of somatic mutations in MM cells at diagnosis could unravel prog-
nostically relevant disease characteristics not detectable with traditional
approaches.
Aims: We analyzed data from the interim analysis 8 cohort (August 2015) to
create a prognostic model.
Methods: CD138+ purified MM specimens from bone marrow aspirates and
peripheral blood cells were collected at diagnosis. Whole exome libraries from
both tumor and constitutional DNA samples were created. Somatic single
nucleotide variants (SNV) were identified, only nonsynonymous SNV were
included in the analysis. We evaluated the impact on progression free survival
(PFS) of recurrently mutated genes (with at least a nonsynonymous SNV with
an allele frequency of more than 5% in more than 10 patients) in a multivariable
Cox model adjusted for international staging system (ISS) and cytogenetic pro-
file (high risk, standard risk and missing). A backward selection based on the
Akaike Information Criterion (AIC) was used to identify the final Cox model
used to create a scoring system.
Results: 517 patients with baseline somatic mutation data were included in the
analysis. Median age at diagnosis was 64 years (range 27-93), all patients
received novel agents as first line treatment, 236 (45.6%) received autologous
stem cell transplantation (ASCT). The most recurrent mutated genes were KRAS
(25%) and NRAS (19.5%). Consistently with other works, DNA allele frequency
data revealed that, in the great majority of cases, only a subclonal portion of MM
cell DNA harbors a selected somatic SNV (data not shown). Based on the impact
on PFS of recurrently mutated genes, a scoring system was developed. Four
groups were identified according to the mutational status of 9 genes selected in
a nonbiased manner (Table 1): group I (score 0-2, 17%); group II (score 3, 51%),
group III (score 4-5, 26%) and group IV (score >5; 6%). After a median follow-up
of 371 days, the 18-month PFS was 93% for group I, 85% for group II, 73% for
group III and 40% for group IV (Figure 1). The hazard ratio was 2.31 (p=0.118)
for group II versus group I, 4.45 (p=0.006) for group III versus I and 17.38
(p<0.001) for group IV vs I. The prognostic trend of the score was confirmed in
different patient subgroups including ASCT/no ASCT, standard/high risk cytoge-
netic profile, ISS I, II, or III. Of note, 23% of patients in group I had ISS III and
34% of patients in group IV had ISS I.
Table 1.
Figure 2.
Summary/Conclusions: The use of a prognostic model based on the muta-
tional status of 9 recurrently mutated genes could improve risk assessment of
newly-diagnosed MM patients. Longer follow-up and validation in independent
cohorts of patients are needed to confirm our findings. Updated results with a
longer follow-up will be presented at the meeting.
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TARGETING GENE DEPENDENCY OF 1Q AMPLIFICATION IN MULTIPLE
MYELOMA
S. Manier1,2,*, D. Huynh2, J. Park2, K. Salem2, X. Leleu3, I. Ghobrial4
1Hematology, Lille Hospital, Lille, France, 2Medical Oncology, Dana-Farber
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Background: Gain of 1q is one of the most frequent copy number variations
across cancer types and in Multiple Myeloma (MM). Gain of 1q is associated
with a poor outcome, indicating it is a potential driver in MM progression and
resistance to treatment. While the whole 1q arm can be amplified in some cas-
es, a specific minimal amplified region has been identified by CGH array, includ-
ing approximately 500 genes in the 1q21.1-23.3 region. However, the driver
genes in the 1q region are unknown.
Aims: We hypothesize that specific genes present in the 1q minimal amplified
region are critical regulators of clonal evolution and tumor progression in MM. 
Methods: To explore gene dependency in 1q21.1-23.3 in MM, lung, breast and
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ovarian cancers, we performed an shRNA targeted screen, using the C911
technology as a control. We used 14 cell lines including MM, lung, and breast
cancer cell lines. We designed a pooled library targeted shRNA/C911 screen
containing 6 shRNAs along with their matched control for each of the 500
genes in the 1q21.1-23.3 region, including lncRNA and miRNA in addition to
protein coding genes. The pooled library contained 6500 shRNAs, including
C911 controls. The differential expression from each shRNA and its own C911
control was calculated and we used the RIGER software to call hits, using the
Kolmogorov-Smirnov algorithm. To complement the 1q-targeted shRNA screen-
ing, we studied both the Achilles dataset and patients’ gene expression profiling
from the Multiple Myeloma Genomic portal (MMGP) and the Cancer Genome
Atlas (TCGA). Using a list of candidate genes, we then interrogated a large
expression-profiling resource developed by the Library of Integrated Network-
based Cellular Signatures (LINCS) program to identify potentially active drug
targeting our candidate genes. Finally, a targeted drug screening was per-
formed using 179 compounds identified through the LINCS program and using
the FDA-approved drug library. Compounds with higher toxicity were further
validated in 1q+ (OPM2, H929 and KMS11) and non 1q cell lines (KMS18).
Results: We were able to identify 10 candidate genes, for which knockdown
significantly impaired proliferation of gain of 1q cell lines. Several candidate genes
were identified as being the top genes preferentially affecting the proliferation of
gain of 1q cell lines. To further confirm that our candidate genes are overex-
pressed in gain of 1q patients, we studied publicly available gene expression
profiling from the MMGP and TCGA. Five of the 10 genes were significantly over-
expressed in patients with gain of 1q. We then generated a gain of 1q signature
by analyzing publicly available gene expression profiling from patients with MM,
lung and breast cancers. Each dataset was divided equally into training and val-
idation sets. We identified differentially expressed genes in tumors with gain of
1q vs no gain of 1q in these three different cancer types in the training sets. We
then combined the three signatures to generate a ‘pan-cancer’ gain of 1q core
signature, which was significantly enriched by using Gene Set Enrichment Analy-
sis (GSEA) in patients with gain of 1q in the validation sets (shown here for MM).
We next queried the core signature against the MSigDB ‘c2’ canonical pathways
and ‘c3’ transcription factor pathways in GSEA and consistently identified a sig-
nificant enrichment of cell cycle and E2F pathways. A targeted drug screen was
then performed using FDA approved drugs and based on specific targets iden-
tified in the LINCS database. Compounds that showed high toxicity were further
validated in 1q vs non 1q+ MM cell lines, and indeed showed significant differ-
ential activity of these compounds on 1q vs non 1q+ MM cell lines. 
Summary/Conclusions: Gain of 1q is one of the defining features of high-risk
MM and is associated with adverse outcomes. We developed a systematic
approach to determine gene dependencies in gain of 1q MM combining a loss-
of-function pooled screen, a computational approach and a drug screen to
identify novel therapeutic targets in MM .
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DUAL INHIBITION OF DNMT1 AND EZH2 CAN EFFECTIVELY OVERCOME
BOTH INTRINSIC AND ACQUIRED RESISTANCE OF MYELOMA CELLS
TO IMIDS
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1Hematology, 2Pathology, Rigshospitalet, 3BRIC, Copenhagen, Denmark,
4Urology, USC, Los Angeles, United States
Background: The introduction of novel agents for the treatment of multiple
myeloma (MM), mainly proteasome inhibitors and immunomodulatory agents
(IMiDs), has significantly improved the survival rates of the patients, and both
classes of drugs stand as the main treatment options for MM. Several studies
have identified Cereblon (CRBN) as the direct target of not only thalidomide,
but also lenalidomide and pomalidomide, and suggested that its expression is
essential for the anti-myeloma effect of these drugs. However, even though
the expression levels of CRBN have been associated with response to IMiDs,
not all studies have confirmed this finding, as for example patients or cell lines
with high levels of CRBN might not exhibit sensitivity to IMiDs. Thus, the expres-
sion of CRBN does not consistently explain the lack of IMiD sensitivity and the
precise mechanisms behind IMiD resistance still remain elusive.
Aims: The aims of this study were to examine the importance of epigenetic
modifications for the expression of CRBN and subsequently the development
of IMiD resistance, as well as investigate whether restoration of sensitivity to
IMiDs is feasible through epigenetic reprogramming by epigenetic modulators.
Methods: For the development of IMiD-resistant cell lines (OPM2-LR and-PR,
H929-LR and -PR), we treated OPM2 and NCI-H929 continuously with increas-
ing doses of either lenalidomide or pomalidomide for 4-6 months, until cell via-
bility and proliferation were not affected. Nucleosome positioning (chromatin
accessibility) was assessed using AcceSssIble, with all the analyses performed
in the statistical software R, using the package minfi. RNA-seq is currently being
performed for OPM2, NCI-H929 their IMiD-resistant as well as resensitized
counterparts (N=10) in collaboration with BGI, using BGISEQ500 platform.
Results: Using AcceSssIble, we we found that acquired resistance for both
lenalidomide and pomalidomide was primarily associated with a global
decrease in chromatin accessibility and to a much lesser extent with DNA
methylation changes. Interestingly, neither CRBN nor any of the other mole-
cules involved in the CRBN pathway (IKZF1, IKZF3, IRF4) exhibited changes
in either promoter DNA methylation or chromatin accessibility. We then treated
the IMiD-resistant cells with the combination of 5-Azacytidine (a DNMT1
inhibitor) and EPZ-6438 (an EZH2 inhibitor) for 48 hours, before exposing the
cells again to IMiDs, and found that resistant cells treated with this combination
showed increased sensitivity to both lenalidomide and pomalidomide, with sig-
nificantly increased apoptotic response, similar to the sensitive cell lines. Even
more interestingly, we found that the treatment with 5-Aza and EPZ-6438
almost completely restored the global chromatin accessibility changes associ-
ated with acquired IMiD resistance back to the initial state, even though the
same was not observed for DNA methylation changes. Finally, the combination
of 5-Aza and EPZ-6438 was also effective in sensitizing the majority of cell
lines with intrinsic resistance to IMiDs. We also observed that treatment with
the combination of 5-Aza and EPZ-6438 failed to induce a significant upregu-
lation of CRBN in the IMiD-resistant cell lines, thus suggesting that the process
of resensitization to IMiDs is CRBN-independent. Moreover, we show that the
degradation of IKZF1 is abrogated on the resistant cell lines, and remains as
such despite their resensitization, meaning that the CRBN-IKZF1/IKZF3 path-
way might be bypassed and other important regulatory networks might be as
important for sensitivity to IMiDs. Therefore, we are currently performing RNA-
seq, which might, in combination with accessibility data, give information about
the regulatory mechanisms behind acquired IMiD resistance.
Summary/Conclusions: In conclusion, our study is the first one to ever show
that acquired IMiD-resistance is mainly an epigenetic event that is potentially
reversible through a combination of two epigenetic compounds, 5-Azacitidine
and EPZ-6438. These drugs have been shown to have low levels of toxicity,
thus making them very good candidates for a prospective phase I study to
examine their potential as “IMiD-resensitizers”, which may improve the outcome
treatment of MM patients with drug-resistant myeloma clones and a potentially
high-risk disease.
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Background: Most of the published omics studies in multiple myeloma (MM)
have focused on the analysis of the genome, transcriptome and DNA methy-
lome. Over the last years, the chromatin structure and histone modifications
are emerging as essential epigenetic layers to understand gene deregulation
in cancer, although this field remains widely unexplored in MM.
Aims: We herein aim to elaborate a comprehensive description of the MM
epigenome including multiple layers of information.
Methods: We performed ChIP-seq of six histone modifications with non-over-
lapping functions (H3K4me3, H3K4me1, H3K27ac, H3K36me3, H3K27me3, and
H3K9me3), ATAC-seq for chromatin accessibility, Whole Genome Bisulfite
Sequencing (WGBS) for DNA methylation, and RNA-seq for gene transcription
in purified bone marrow plasma cells from four MM patients and, as healthy con-
trols, naive B cells, germinal center B cells, memory B cells and plasma cells.
Data were extensively mined using a battery of different bioinformatic tools.
Results: An initial unsupervised approximation showed that each epigenetic
layer cluster MM patient cells separately from normal B cells, which in turn also
show differences according to their maturation stage. Moreover, an integrative
analysis of ChIP-seq data from six histone marks allowed us to segment the
genome into functional chromatin states, such as promoters, enhancers, tran-
scribed regions and repressed/heterochromatic regions. In order to detect
regions with significant differences in chromatin activity between MM and normal
plasma cells, we elaborated a new algorithm that allowed us to transform the
qualitative chromatin state data into a quantitative chromatin activation score
(ChromAS). When we compared the ChromAS between MM and normal plasma
cells, we detected over 13000 regions with differential activity in MM, from which
near 90% were gaining activity in MM, suggesting a widespread activation of
their chromatin landscape. To further characterize this phenomenon, we calcu-
lated the mean ChromAS per gene and performed a K-means clustering of MM
and control cells. Interestingly, we identified the presence of a cluster comprising
over 2000 genes whose chromatin was increasing activation in MM as compared
to all normal cells. These findings were further validated by ChIP-seq in an addi-
tional series of 10 MM patients. We next focused on the genes that gained de
novo activity in MM and were completely inactive (i.e. heterochromatic) in normal
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cells. Out of this list, we observed that two adjacent genes, PRDM5 and NDNF,
were co-activated in MM. The analysis of their expression in additional patient
cohorts indicated that their co-upregulation is a consistent event in MM patho-
genesis and that their levels were negligible in bone marrow and tonsillar plasma
cells. When analyzing chromatin topology by 4C-Seq, we identified 3D interac-
tions between both gene loci only in MM cells, suggesting that DNA looping
between the two genes may be related to their co-activation in MM. Finally,
knockdown of each of these genes using inducible shRNAs, decreased cell pro-
liferation and induced apoptosis in MM cells. 
Summary/Conclusions: Collectively, our initial exploration of histone modifi-
cation profiles in MM has revealed an extensive activation of the MM chromatin
landscape, which targets new candidate oncogenes. Reversing this global acti-
vation by epigenetic drugs, such as BET inhibitors, may represent an attractive
therapeutic option for MM.
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Background: Introduction of novel treatments; Lenalidomide, high-dose alky-
lating agents (Melphalan) conditioning prior to autologous stem cell transplant
(ASCT) over the last few decades has improved overall survival in patients
with Multiple Myeloma (MM). In spite of enhanced survival rates, some thera-
pies (especially Lenalidomide maintenance post ASCT) have come under
scrutiny for causing therapy related myeloid neoplasms and second primary
malignancies (SPM) like Myelodysplastic syndrome (MDS) and Acute myeloid
Leukaemia (AML). Clonal haematopoiesis resulting in sequential accumulation
of a combination of driver-passenger genetic mutations (in upto 80% of MDS
& >95% AML patients) steer MDS/AML disease pathogenesis and clinical out-
come. Therefore, we hypothesised that detection of Clonal Hematopoiesis of
Indeterminate Potential (CHIP) in haematopoetic stem cells (HSCs) prior to
ASCT in patients with MM treated with a range of therapies could be utilised
for predicting patients at risk of developing SPMs i.e. MDS/AML.
Aims: To ascertain baseline mutational spectrum [especially low-level clones
with variant allele frequency (VAF) ≥5%] of MDS/AML associated gene muta-
tions in HSCs prior to ASCT in order to predict patients at risk of clonal evolution,
transformation to MDS/AML.
Methods: DNA was isolated from mononuclear cells (MNCs) collected by leuco-
pheresis prior to ASCT from 128 MM patients. A customised amplicon-based Illu-
mina MiSeq panel was used for the sensitive interrogation of 24 most common
genes harbouring mutations in MDS/AML (splicing factor genes;
SF3B1, SRSF2, U2AF1 and ZRSR2, genes implicated in epigenetic
regulation; TET2, IDH1/2, ASXL1, EZH2 & DNMT3A, known oncogenes/genes
involved in cell signalling/transcription regulation and cohesion
complex; TP53, FLT3, NRAS, KRAS, ETV6, RUNX1, CCBL, C-
KIT, JAK2, MPL, CEBPA, STAG2, GATA2, KDM6A and NPM1). Variant analysis
was performed using Illumina Variant Studio (≥5% VAF & read depth ≥150X
threshold). To accommodate for the lack of germ line material to confirm the
somatic nature of the variants, SNPs occurring at a frequency of ≥0.001% in the
healthy population [e.g. dbSNP132, UCSC genome browser, Exome sequencing
project (esp6500), Exome Aggregation Consortium (ExAc)] were excluded. 
Results: Seven patients (6.25%) contained heterozygous somatic mutations
(VAF range 7-50%) in DNMT3A, IDH1, IDH2, TET2, ETV6 and CBL genes
(Table 1). Four missense mutations identified in DNMT3A were aggregated in
the Mtase domain responsible for its methyltransferase activity indicating a
strong intent to abrogate this function. Previous studies confirm R882 variant
(accounts for ~ 60% DNMT3A mutations) as a founder lesion in MDS/AML
strongly associated with clonal haematopoiesis and HSC differentiation. Mis-
sense mutation in CBL (I429F) has been previously reported in CMML cases
( while translocations and deletions of ETV6 are more common in AML M0
(5%) compared to mutations suggesting its role as a tumor-supressor . Genes
identified in our cohort are frequently associated with MDS & AML; IDH1/IDH2
(5 & 20%), TET2 (12 & 20%), DNMT3A (8 & 20%) and associated with poor
prognosis (DNMT3A, IDH1/IDH2). SNP array karyotyping on 4/7 cases (patients
1-4) displayed no chromosomal abnormalities. Median age at diagnosis in these
four cases was 65 (range 60-70), long-term follow up (3-5 yrs) revealed relapse
of MM in patient 1 and 3, acute kidney injury with myeloma in patient 2 and
transformation to AML in patient 4.
Summary/Conclusions: Our data identifies for the first time a subgroup of
MM patients (6.25%) with no morphological evidence of MDS/AML prior to
ASCT but harbouring CHIP in CD34+ harvest stem cells and later developing
MDS/AML. These findings are pivotal for identification of such patients at risk
of clonal evolution and transformation prior to ASCT since it can be a significant
parameter in determining appropriate treatment modality i.e. whether or not to
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M. Ishibashi1,*, H. Tamura1, T. Asayama1, Y. Kuribayashi-hamada1,
A. Onodera1, K. Moriya1, M. Sasaki2, H. Handa3, Y. Imai4, J. Tanaka5,
S. Tanosaki6, S. Ito7, K. Inokuchi1
1Division of Hematology, Department of Medicine, Nippon Medical School,
2Division of Hematology, Department of Internal Medicine, Juntendo University
School of Medicine, Tokyo, 3Department of Medicine and Clinical Science, Gun-
ma University Graduate School of Medicine, Maebashi, 4Department of Hema-
tology/Oncology, the Institute of Medical Science, the University of Tokyo,
5Department of Hematology, Tokyo Women’s Medical University, 6Department
of Hematology, Fraternity Memorial Hospital, Tokyo, 7Department of Medical
Oncology, Iwate Medical University School of Medicine, Morioka, Japan
Background: The signaling lymphocytic activation molecule family 3 (SLAMF3)
is a member of the immunoglobulin superfamily expressed on T, B, and natural
killer cells and modulates the activation and cytotoxicity of these cells via self-
ligand binding. SLAMF3 is also expressed on plasma cells from patients with
multiple myeloma (MM), although its role in MM pathogenesis remains unclear.
Aims: To clarify this, we investigated the expression and functions of SLAMF3
in MM.
Methods: 1) Two hundred thirty patients comprising 153 newly diagnosed (19
asymptomatic and 134 symptomatic) MM patients, 30 refractory/relapsed MM
patients, and 47 patients with monoclonal gammopathy of undetermined sig-
nificance were enrolled. SLAMF3 and CD138 expression levels on clonal plas-
ma cells were analyzed using flow cytometry (FCM). Soluble SLAMF3
(sSLAMF3) serum levels were measured using ELISA. 2) Drug sensitivity to
antimyeloma agents (melphalan and bortezomib) and the proliferation potential
in MM cell lines KMS18 and U266 were analyzed using FCM and the MTT
assay. SLAMF3 knockdown MM cell lines were obtained using the lentiviral
shRNA system and siRNA. Stable transfected KMS34 cell lines overexpressing
full-length SLAMF3 and cytoplasmic domain-truncated SLAMF3 (ΔSLAMF3)
were established through corresponding vectors. Single-nucleotide polymor-
phism (SNP) genotyping was analyzed by real-time PCR. The adaptor protein
of SLAMF3 was identified by Western blotting and immunoprecipitation.
Results: 1) SLAMF3 was highly expressed on plasma cells in almost all MM
patients, even in relapsed/refractory disease, although CD138 expression levels
were decreased in some with advanced disease. 2) The proliferative potential
and percentage of antimyeloma agent-induced apoptosis in SLAMF3high cells
were significantly higher and lower than in SLAMF3low cells, respectively. The
cell proliferation and drug resistance in SLAMF3-expressing KMS34 cells were
promoted in comparison with ΔSLAMF3 and control cells. That malignant potential
in MM cells was cancelled by SLAMF3 knockdown. Furthermore, the proliferation
of MM cells and resistance to antimyeloma agents were inhibited by anti-SLAMF3
antibody. Adaptor proteins, SHP2 and GRB2, were expressed in MM cell lines,
but neither SAP nor EAT-2 were. SLAMF3 interacted directly with SHP2 and
GRB2, and SHP2 also interacted with GRB2. SHP2 inhibitor-treated or
SHP2/GRB-knockdown cells had characteristics similar to SLAMF3-knockdown
cells. 3) The frequency of GG genotypes of SLAMF3 SNP rs509749 in MM
patients was 63.6% (n=28), of AG 29.5% (n=13), and of AA 6.8% (n=3). Patients
with GG genotypes tended to have shorter overall survival times than patients
with AG genotypes. 4) sSLAMF3 levels were significantly higher in symptomatic
MM than in asymptomatic MM and markedly increased in advanced MM. MM
patients with high levels (≥3.3 ng/ml, n=62) of sSLAMF3 progressed to the
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advanced stage significantly more often and had shorter progression-free survival
times than those with low levels (<3.3 ng/ml, n=32) (P=0.032).
Summary/Conclusions: This study revealed that SLAMF3 molecules consis-
tently expressed on MM cells may transmit positive signals mediated via the
complex of SHP2 and GRB2 by self-ligand interaction between MM cells and
induce a high malignant potential in MM. Furthermore, high levels of serum
sSLAMF3 may reflect MM disease progression and be a useful prognostic fac-
tor in MM. Thus, SLAMF3 molecules may be a new potential target for future
immunotherapy and chemotherapy.
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TARGETING CD74 IN MULTIPLE MYELOMA WITH A NOVEL ANTIBODY
DRUG CONJUGATE, STRO-001
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Background: CD74 is a transmembrane glycoprotein involved in MHC protein
formation and transport. CD74 expression has been observed in up to 90% of
B-cell malignancies, including multiple myeloma (MM), with minimal expression
in normal tissues. CD74 is rapidly internalized, making it an attractive target for
ADCs. STRO-001 is a novel ADC comprised of an aglycosylated anti-CD74 IgG1
human antibody (SP7219) conjugated covalently to the non-natural amino acid
para-azido-methyl-L-phenylalanine (pAMF) with a non-cleavable dibenzocyclooc-
tyne (DBCO)-maytansinoid linker-warhead. Highly efficient site-specific conju-
gation enabled by novel cell-free antibody production and click chemistry results
in a well-defined homogeneous ADC drug product with a drug-antibody ratio
(DAR) of 2.
Aims: The in vitro cytotoxicity and in vivo efficacy of STRO-001 was investi-
gated in MM cell lines and xenografts. An exploratory toxicology study was
conducted in a non-human primate model. 
Methods: DBCO-Alexa647-conjugated SP7219 staining and flow cytometry
were used for detection and quantitation of CD74 expression on MM cell lines.
STRO-001 was used to determine the EC50 and percent span of killing in MM
cell lines. The anti-tumor activity of STRO-001 was evaluated in the dissemi-
nated ARP-1 and MM.1S MM models. In vivo bioluminescence imaging (BLI)
for animals bearing MM.1s-luc cells was performed using an IVIS Spectrum.
BLI images were collected 7, 14, 21, and 28 days post-tumor cell inoculation.
STRO-001 was administered to cynomolgus monkeys in an exploratory dose-
escalating study of repeat IV doses of 1, 3, 10 and 30 mg/kg on days 1 and 15.
Results: In vitro cytotoxicity assays show nanomolar potency of STRO-001 in
five MM cell lines: MC/CAR (EC50 0.8 nM), ARD (EC50 6.5 nM), MM.1S (EC50
10-11 nM), U266B1 (EC50 8.5-9.3 nM), and ARP-1 (EC50 4.3-22 nM). CD74 cell
surface expression is required for STRO-001 cytotoxic activity but expression
level, as measured by antibody-binding capacity, does not correlate strongly with
in vitro potency (R2=0.5837 for MM cell lines). STRO-001 inhibits the growth of
CD138+ plasma cells in bone marrow (BM) and formation of visceral tumors
(p=0.002 for kidney; p<0.0001 for ovary) after 4 weekly doses of 3 mg/kg in the
ARP-1 disseminated MM xenograft model. STRO-001 dosed at 3 mg/kg and 10
mg/kg weekly x 3 also eradicates malignant BM plasma cells by day 32 post-
inoculation (p<0.0001) and prolongs survival in the MM.1S disseminated model.
At termination of the study, 129 days post-inoculation, 100% of the STRO-001
treated animals survived and showed no evidence of disease with no CD138+
cells in their bone marrow, while mean survival of vehicle-treated control animals
was 35 days with almost 50% of their bone marrow containing myeloma cells.
BLI of luciferase-expressing MM.1S (MM.1S-luc) tumor cell lines enabled non-
invasive quantitation of tumor burden. Single doses of 1, 3, and 10 mg/kg STRO-
001 (administered on day 7 post-inoculation) resulted in eradication of myeloma
by day 28 based on bioluminescence signal and quantification of CD138+ cells
in bone marrow. In addition, STRO-001 produced a dose-dependent reduction
in normal B-cells in cynomolgus monkeys, providing pharmacodynamic evidence
of B-cell targeting (Figure 1).
Figure 1.
Summary/Conclusions: STRO-001 demonstrates potent in vitro cytotoxicity
in MM cell lines and reduces tumor burden in MM xenograft models, including
significant prolongation of survival in the MM.1S model. Based on these encour-
aging observations, STRO-001 is advancing to the clinic for the treatment of
CD74-expressing B-cell malignancies.
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GENOTYPE CHARACTERIZATION OF LIGHT CHAIN AMYLOIDOSIS BY
WHOLE EXOME SEQUENCING
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Background: Immunoglobulin light-chain amyloidosis (AL) is a heterogeneous
and multifactorial disease with high genetic complexity. Until now, no common
factor o unique mutation associated with this disease has been described.
Whole exome sequencing in Multiple Myeloma (MM) patient’s tests allowed to
known important genes and pathways that are involved in the disease. How-
ever, few evidences through next generation sequencing (NGS) analysis were
described in AL. Consequently, the application of NGS technologies permits
unraveling the genomic landscape of AL to better disentangle the biology of
the disease, allowing the identification of new therapeutic targets as in MM.
Aims: Genotype characterization of novel molecular alterations in AL plasma
cell by whole-exome sequencing technology.
Methods: We studied 40 paired samples (sorted pathological plasma cells
and peripheral blood) from 20 patients with AL. Whole exome and regulatory
regions were captured using Agilent’s SureSelect Human All Exon V6+UTR kit
and sequenced on the Illumina NextSeq 500 platform with pair-end sequencing
technique with a global mean depth coverage of 70x, on target coverage of
96.5% and a Phred quality score of 91.3% up to Q30. Data were analyzed with
Strelka software to discard germinal mutations, wANNOVAR for functional
annotation, and a data reduction strategy to identify candidate variants.
Results: After analysis of patient samples we got an average of 76 (range 18-
177) mutations per patient. 28.4% of the mutations was located on regulatory
regions (5’ UTR, 3’ UTR). So far, we did not identify recurrent mutations
between the patients, although some patients presented different mutations
on the same gene.
The mutation pattern was very heterogeneous between patients. We identified
alterations in genes involved in extracellular matrix (MMP2), cell proliferation,
differentiation and development (TFGA), transcription factors (ZFHX3, HNRP-
NPL), adherent junction function (RASSF8), GTPases (RAPGEF2, RAB40A),
and genes of the collagenase family (COL9A1, COL1A2) among others.
Summary/Conclusions: Taken together, these results suggest that the muta-
tion pattern in AL is heterogeneous with no common mutated gene among all
patients. However, we described novel mutations in the context of AL in regu-
latory genes or over-representing cancer-related pathways that can help to
elucidate the molecular biology of the disease.
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IMPROVED SURVIVAL IN 21,465 MULTIPLE MYELOMA PATIENTS: 
RESULTS FROM A POPULATION-BASED STUDY
S. Thorsteinsdottir1,*, P.W. Dickman2, I. Turesson3, O. Landgren4,
M. Hultcrantz5,6, M. Björkholm5, S.Y. Kristinsson1,5
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of Iceland, Reykjavik, Iceland, 2Department of Medical Epidemiology and Bio-
statistics, Karolinska Institutet, Stockholm, 3Department of Hematology and
Coagulation Disorders, Skane University Hospital, Malmö, Sweden, 4Myeloma
Service, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer
Center, New York, United States, 5Department of Medicine, Division of Hema-
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Background: Multiple myeloma (MM) is generally considered an incurable dis-
ease, however advances in the treatment options for MM have been great in
recent years. Recent studies on these new agents indicate an improvement in
survival, nevertheless population-based studies have had contradicting findings,
especially in the elderly patients. 
Aims: The aim of the study was to evaluate the survival of all patients diag-
nosed with MM in Sweden in the years 1973 to 2013 and to relate the survival
pattern to trends in treatment strategies. 
Methods: Patients diagnosed with MM in the period from January 1, 1973 to
December 31, 2013 were identified from the Swedish Cancer Registry. Infor-
mation on sex, date of birth, date of diagnosis, and date of death was collected.
Relative survival ratios (RSRs) were used to provide a measure of excess mor-
tality of MM patients compared to a comparable group from the general popu-
lation. RSRs with 95% confidence intervals (Cis) were found for 1-, 5-, and 10-
years for 4 calendar periods; 1973-1982, 1983-1992, 1993-2002, and 2003-
2013 and furthermore for 6 age categories at diagnosis (0-40, 41-50, 51-60,
61-70, 71-80 and >80). Short-term survival, as defined by RSR of less than 3
months, was also defined for all calendar periods.
Results: A total of 21,465 patients (54% males, median age at diagnosis 72
years) with MM were recorded in the time period. Overall, the 1- and 5- and 10-
year RSRs improved in the whole period, with the greatest improvement in the
two most recent calendar periods. The 1-year RSR increased significantly
between all calendar periods (0.69, 0.74, 0.77 and 0.82, respectively). The 5-
year RSR increased significantly between the two last calendar periods (0.28,
0.31, 0.33 and 0.41, respectively; Figure 1) as well as the 10-year RSR (0.10,
0.12, 0.14 and 0.20, respectively). Short-term survival increased significantly
between the first two and last two calendar periods (the RSR were 0.83, 0.88,
0.89 and 0.93 respectively). Females had a lower excess mortality compared
to males (excess mortality ratio 0.91).
Figure 1.
Summary/Conclusions: In this population-based study, based on more than
21,000 MM patients diagnosed during more than a 40-year period, we showed
that with an increased use of novel agents in MM patients, survival has
improved significantly. This is especially prominent during the last 10 years.  Our
findings are important, since new agents are approved based on clinical trials,
where certain groups, such as older patients and patients with significant comor-
bidities are often excluded.
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PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK
ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE
MYELOMA
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Background: Cytogenetic evaluation using fluorescence in situ hybridization
(FISH) at the time of diagnosis is essential for initial risk stratification in multiple
myeloma. The presence of specific cytogenetic high-risk abnormalities (HRA)
is known to confer a poor prognosis, less is known about the cumulative effect
of multiple such abnormalities.
Aims: To evaluate the prognostic implications of the presence of multiple HRA
at the time of diagnosis.
Methods: We studied 1181 patients who were diagnosed with multiple myeloma
between July 2005 and July 2015 at Mayo Clinic Rochester, underwent FISH
evaluation within 6 months of diagnosis, and received first-line therapy with at
least 1 novel agent (immunomodulator or proteasome inhibitor). HRA were
defined as t(4;14), t(14;16), t(14;20), del(17p), and gain(1q). Bone marrow aspi-
rates were evaluated for deletions, monosomies, trisomies, and tetrasomies using
chromosome- or centromere-specific FISH probes. IGH rearrangements were
evaluated using an IGH break-apart probe and evaluating up to 5 potential part-
ners (FGFR3, CCND1, CCND3, MAF, and MAFB). Kaplan-Meier overall survival
estimates were calculated and the log-rank test was used to compare overall
survival in patients with and without HRA (stratified by the number of HRA). A
multivariable-adjusted Cox regression model was used to assess the effect of
HRA on overall survival adjusting for age, sex, International Staging System (ISS)
stage, and first-line therapy (immunomodulator, proteasome inhibitor, upfront
autologous hematopoietic stem cell transplantation). Patients diagnosed after
2014 (approximately 15% of the cohort) routinely underwent evaluation for
gain(1q), therefore the hazard ratios represent conservative effect estimates. P-
values below 0.05 were considered statistically significant.
Results: The median age at diagnosis was 65 years (28 - 95), 708 (60%) of the
patients were male. There were 375 HRA in 327 patients (28% of the cohort): 170
(45%) del(17p), 110 (29%) t(4;14), 45 (12%) t(14;16), 8 (2%) t(14;20), and 42
(12%) gain(1q). Of the 280 patients with 1 HRA 130 (46%) had del(17p), 120
(43%) had a high-risk translocation, and 30 (11%) had gain(1q). Of the 46 patients
with 2 HRA 34 (76%) had del(17p) and a high-risk translocation, 6 (13%) had a
high-risk translocation and gain(1q), 5 (11%) had del(17p) and gain(1q), and 1
had 2 high-risk translocations. There was 1 patient with 3 HRA: del(17p) and
t(4;14) and gain(1q). The median overall survival was 6.6 years (6.0 - 8.0) for the
entire cohort (n=1181), 8.3 years (6.7 - 8.9) for those without HRA (n=854, 72%),
4.9 years (3.9 - 5.6) for those with one HRA (n=280, 24%), and 2.7 years (2.1 -
3.8) for those with 2 or more (2+) HRA (n=47, 4%). Figure 1 shows the Kaplan-
Meier overall survival estimates stratified by the number of HRA (n=1181). The
presence of 1 HRA (versus 0, HR 1.57, 95% CI 1.26 - 1.96, p <0.001, n=1181)
and the presence of 2+ HRA (versus 1, HR 3.37, 95% CI 2.21 - 5.14, p <0.001,
n=1181) were of prognostic significance after adjusting for age, sex, ISS stage,
and first-line therapy. When adjusting for the revised ISS instead of the ISS the
hazard was attenuated for 1 HRA (versus 0, HR 1.42, 95% CI 1.12 - 1.80, p=0.004,
n=1087) and 2+ HRA (versus 1, HR 2.82, 95% CI 1.81 - 4.40, p <0.001, n=1087).
Figure 1.
Summary/Conclusions: Approximately 1 in 4 patients with newly diagnosed
multiple myeloma presented with 1 HRA at the time of diagnosis, approximately
1 in 25 with 2 or more HRA. These patients experienced inferior overall survival
suggesting a cumulative effect of multiple HRA.
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LENALIDOMIDE MAINTENANCE VS PLACEBO AFTER STEM CELL
TRANSPLANT FOR PATIENTS WITH MULTIPLE MYELOMA: OVERALL
SURVIVAL AND PROGRESSION-FREE SURVIVAL AFTER ADJUSTING
FOR TREATMENT CROSSOVER IN CALGB
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Background: At a prespecified interim analysis (December 2009), the phase
3 CALGB/ECOG 100104 (Alliance) study results surpassed the prespecified
superiority boundary (significantly improved progression-free survival [PFS] for
lenalidomide [LEN] maintenance vs placebo [PBO] after SCT) and the majority
of PBO arm patients without progressive disease (PD) crossed over to LEN
maintenance. An updated analysis (cutoff March 2015), showed significantly
longer overall survival [OS] with LEN maintenance (HR, 0.56; 95% CI, 0.42-
0.76). However, the crossover from PBO to LEN makes it difficult to assess
the true treatment effect of LEN.
Aims: To examine the effect of LEN vs PBO on OS and PFS from randomiza-
tion, adjusting for effects of crossover.
Methods: The rank-preserving structural failure time model (RPSFTM; Robins,
Commun Stat Theory Methods, 1991) was used for crossover adjustment; the
iterative parameter estimation (IPE; Branson, Stat Med, 2002) algorithm was
used as validation. Survival was partitioned assuming a residual LEN effect
after discontinuation. A landmark analysis was also performed at the Dec 2009
interim for patients who remained on treatment. Patients in the trial provided
informed consent.
Results: Patients were randomized to LEN maintenance (n=231) and PBO
(n=229) (intent-to-treat [ITT] population); 76 patients without PD crossed over
from PBO to LEN. The median time from randomization to crossover was 11.5
months. The relative treatment effect for OS and PFS increased for LEN vs
PBO when adjusting for crossover using RPSFTM and IPE (Table 1). The land-
mark analysis at the Dec 2009 interim (PBO crossover, n=76; No crossover,
n=34) showed the treatment effect is not dissimilar to the ITT analysis (HR
0.53; 95% CI, 0.25-1.13). Sensitivity analyses showed consistent results.
Updated data will be presented at the meeting.
Table 1.
Summary/Conclusions: Adjusting for the potential diluting effects of crossover
reduced median OS and PFS with PBO, and improved the treatment effect in
the ITT analyses for OS and PFS for LEN vs PBO maintenance after SCT. The
statistical significance of the ITT analyses was maintained throughout.
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UPDATED RESULTS FROM ASPIRE AND ENDEAVOR, RANDOMISED,
OPEN-LABEL, MULTICENTRE PHASE 3 STUDIES OF CARFILZOMIB IN
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Background: In RRMM, carfilzomib, lenalidomide, and dexamethasone (KRd)
was superior to Rd in ASPIRE (Stewart, N Engl J Med. 2015), and carfilzomib
and dexamethasone (Kd) was superior to bortezomib and dexamethasone
(Vd) in ENDEAVOR (Dimopoulos, Lancet Oncol. 2016) for the primary endpoint
of progression-free survival (PFS) by independent review. 
Aims: To report safety and efficacy data after 6-7 months of additional follow-up.
Methods: Adults with RRMM who received 1–3 prior regimens were randomised
1:1. In ASPIRE, patients received lenalidomide (25 mg) on days 1–21 and dex-
amethasone (40 mg) on days 1, 8, 15, and 22 (28-day cycle). KRd patients
received carfilzomib on days 1, 2, 8, 9, 15, and 16 during cycles 1–12 (20 mg/m2
[days 1 and 2 of cycle 1]; 27 mg/m2 thereafter); carfilzomib was omitted on days
8 and 9 in cycles 13–18. In ENDEAVOR, Kd patients received carfilzomib (20
mg/m² on days 1 and 2 of cycle 1; 56 mg/m² thereafter) on days 1, 2, 8, 9, 15,
and 16 and dexamethasone (20 mg) on days 1, 2, 8, 9, 15, 16, 22, and 23 (28-
day cycle). In the Vd group, bortezomib was given (1.3 mg/m²; intravenously or
subcutaneously) on days 1, 4, 8, and 11, and dexamethasone (20 mg) on days
1, 2, 4, 5, 8, 9, 11, and 12 (21-day cycle). Comparisons were per stratified log-
rank test; data presented here are per investigator assessment.
Results: In ASPIRE, 792 patients were randomised. Baseline characteristics
were balanced between arms. At a median follow-up of 37.8 months (KRd)
and 37.0 months (Rd), median PFS was 26.1 months (KRd) and 16.6 months
(Rd) (hazard ratio [HR]: 0.67; 95% confidence interval [CI]: 0.56–0.80; P
<0.0001); 18-month PFS rates were 64.5% (KRd) and 46.6% (Rd). Median
time to progression (TTP) was 30.5 months (KRd) and 18.9 months (Rd) (HR:
0.62; 95% CI: 0.51–0.76; P <0.0001). Median time to next treatment (TTNT)
was not estimable (KRd) and 24.3 months (Rd) (HR: 0.62; 95% CI: 0.50–0.77;
P <0.0001). 16.8% (KRd) and 19.0% (Rd) of patients discontinued because of
adverse events (AEs). Grade ≥3 AE rates were 5.9% and 2.2% for hyperten-
sion, 3.9% and 1.8% for cardiac failure, and 4.6% and 5.4% for peripheral neu-
ropathy for KRd and Rd, respectively. In ENDEAVOR, 929 patients were ran-
domised. Baseline characteristics were balanced between arms. At a median
follow-up of 19.4 months (Kd) and 17.7 months (Vd), median PFS was 17.6
months (Kd) and 9.4 months (Vd) (HR: 0.53; 95% CI: 0.44–0.63; P <0.0001);
18-month PFS rates were 48.7% (Kd) and 23.9% (Vd). Median TTP was 19.4
months (Kd) and 10.2 months (Vd) (HR: 0.50; 95% CI: 0.42–0.60; P <0.0001).
Median TTNT was 26.1 months (Kd) and 14.5 months (Vd) (HR: 0.49; 95% CI:
0.40–0.60; P <0.0001). 15.8% (Kd) and 14.9% (Vd) of patients discontinued
because of AEs. Grade ≥3 AE rates were 13.8% and 3.3% for hypertension,
5.2% and 2.0% for cardiac failure, and 2.4% and 8.6% for peripheral neuropa-
thy for Kd and Vd, respectively.
Summary/Conclusions: Consistent with the primary analyses, these results
show that incorporation of carfilzomib into treatment regimens in patients with
RRMM results in clinically meaningful improvements in PFS and a favourable
benefit-risk profile.
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M.A. Dimopoulos1,*, P. Moreau2, H. Nahi3, T. Plesner4, H. Goldschmidt5,
K. Suzuki6, R.Z. Orlowski7, N. Rabin8, M. Leiba9, A. Oriol10, A. Chari11,
J. San-Miguel12, P.G. Richardson13, S.Z. Usmani14, L. O’Rourke15, K. Wu15,
T. Casneuf16, C. Chiu15, X. Qin15, N.J. Bahlis17
1National and Kapodistrian University of Athen, Athens, Greece, 2Hematology,
University Hospital Hôtel-Dieu, Nantes, France, 3Karolinska Institute and the
Department of Medicine, Division of Hematology, Karolinska University Hospital
at Huddinge, Stockholm, Sweden, 4Vejle Hospital and University of Southern
Denmark, Vejle, Denmark, 5University Hospital Heidelberg and German Cancer
Research Center, Heidelberg, Germany, 6Japanese Red Cross Medical Center,
Department of Hematology, Tokyo, Japan, 7Department of Lymphoma/Myelo-
ma, The University of Texas MD Anderson Cancer Center, Houston, United
States, 8Department of Haematology, University College London Hospitals
NHS Trust, London, United Kingdom, 9Sheba Medical Center, Tel Hashomer,
Ramat Gan, Israel, 10Institut Català d’Oncologia, HGTiP, Barcelona, Spain,
11Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY ,
United States, 12Clínica Universidad de Navarra-CIMA, IDISNA, Pamplona,
Spain, 13Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA,
14Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC,
15Janssen Research & Development, LLC, Spring House, PA, United States,
16Janssen Research & Development, Beerse, Belgium, 17Tom Baker Cancer
Center, University of Calgary, Calgary, Alberta, Canada
Background: Daratumumab, a human monoclonal antibody targeting CD38,
significantly prolongs progression-free survival (PFS) and achieves deep and
durable responses when combined with other established standard-of-care
regimens in patients with RRMM.
Aims: To provide updated efficacy and safety data from POLLUX, a multicenter,
phase 3, randomized study of DRd versus Rd in RRMM.
Methods: Eligible patients with ≥1 prior line of therapy were randomly assigned
to Rd (25 mg PO lenalidomide on Days 1-21 of each every-4-week [Q4W]
cycle; 40 mg dexamethasone weekly) with or without daratumumab (16 mg/kg
IV once weekly for Cycles 1 and 2, every 2 weeks for Cycles 3-6, then Q4W
until disease progression). Patients who were refractory to lenalidomide were
excluded. Progression-free survival (PFS) was the primary endpoint. Bone
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marrow samples were collected, and minimal residual disease (MRD) was
assessed at the time of suspected complete response (CR) and at 3 and 6
months after suspected CR at 3 different sensitivity thresholds (10–4, 10–5, and
10–6) using the ClonoSEQ™ next-generation sequencing-based assay (Adap-
tive Biotechnologies, Seattle, WA). Additional reflex testing using an anti-idio-
type antibody was used to confirm CRs in cases in which daratumumab inter-
ference with serum M-protein quantitation was suspected in patients with pos-
sible CR. 
Results: Patients received a median (range) of 1 (1-11) prior lines of therapy;
55% of patients had received immunomodulatory agents (IMIDs), and 18% had
been exposed to lenalidomide. After median follow-up of 17.3 months, DRd sig-
nificantly prolonged PFS compared with Rd alone (median: not reached vs 17.5
months; hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.28-0.50;
P<0.0001), with 18-month PFS rates of 76% and 49%, respectively. Responses
continued to deepen in the DRd group with longer follow-up, with significantly
higher overall response rate (ORR; 93% vs 76%) and rates of very good partial
response (VGPR) or better (78% vs 45%) and CR or better (46% vs 20%) with
DRd versus Rd alone (P<0.0001 for all). MRD-negative rates were >3 times high-
er with DRd compared with Rd alone at all 3 sensitivity thresholds (31.8% vs
8.8% at 10–4; 24.8% vs 5.7% at 10–5; and 11.9% vs 2.5%, at 10–6; P<0.0001 for
all), and MRD negativity was associated with prolonged PFS at 10–5 (Figure 1).
Overall survival (OS) data are immature, with 40 (14%) deaths in the DRd group
and 56 (20%) deaths in the Rd group (HR, 0.63; 95% CI, 0.42-0.95). Neutropenia
was the most common grade 3 or 4 treatment-emergent adverse event (53%
with DRd vs 38% with Rd), and no new safety signals were reported with longer
follow up. We will present updated efficacy and safety data based on approxi-
mately 25 months follow up at the meeting.
Figure 1.
Summary/Conclusions: DRd significantly improved outcomes compared with
Rd alone, including PFS, ORR, depth of response, and MRD-negative rates,
with a favorable safety profile that was maintained after longer follow up. These
updated data continue to support the use of DRd in patients with RRMM who
received ≥1 prior therapy.
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Background: Daratumumab (D) used in combination with bortezomib and dex-
amethasone (Vd; CASTOR) or lenalidomide and dexamethasone (Rd; POL-
LUX) significantly prolongs progression-free survival (PFS) with a manageable
safety profile compared with either Vd or Rd alone in patients (pts) with RRMM.
Aims: Here in this subgroup analysis we investigated the safety and efficacy
of DVd and DRd in elderly pts aged ≥75 years from the CASTOR and POLLUX
phase 3 studies.
Methods: Overall, pts enrolled in the CASTOR and POLLUX studies had ≥1
prior line of therapy. Pts in CASTOR received up to 8 cycles of Vd with or
without D; pts in the DVd group then continued to receive D monotherapy q4w
until disease progression or unacceptable toxicity. Pts in POLLUX were treated
until progression. Dosing schedules for D (16 mg/kg) were different between
CASTOR (qw in Cycles 1-3, q3w for Cycles 4-8, and q4w thereafter) and POL-
LUX (qw for Cycles 1-2, q2w for Cycles 3-6, and q4w thereafter). All elderly pts
received a reduced dose of dexamethasone (20 mg once weekly vs 40 mg
once weekly) in both studies.
Results: In CASTOR, 23/251 pts in the DVd group and 35/247 pts in the Vd
group were ≥75 years; the median (range) age for this group of pts was 78
(75-88) and 78 (75-85) years, respectively, with 100% and 94% with an ECOG
status ≤1. At a median follow-up of 13.0 months, discontinuation rates due to
treatment-emergent adverse events (TEAEs) were similar with DVd and Vd
(15% vs 20%). Common (≥10%) grade 3/4 TEAEs for DVd were thrombocy-
topenia (45% vs 37% with Vd), fatigue (15% vs 11%), pneumonia (15% vs
17%), and anemia (10% vs 11%). Infusion-related reactions (IRR) occurred
in 13 (65%) pts, with 10% having grade 3/4 IRR, but no pts discontinued due
to IRR. Median PFS was significantly prolonged with DVd versus Vd (not
reached [NR] vs 8.1 months; hazard ratio [HR], 0.27; 95% confidence intervals
[CI], 0.12-0.61; P=0.0007), consistent with the overall PFS observed in CAS-
TOR (Figure). Higher overall response rate (ORR; 95% vs 79%) and rates of
complete response (CR) or better (25% vs 3%) and very good partial
response (VGPR) or better (70% vs 18%) were achieved with DVd versus
Vd, respectively, consistent with the overall population. In the POLLUX study,
29/286 pts in the DRd group and 35/283 pts in the Rd group were aged ≥75
years; the median (range) age for this group of pts was 77 (75-89) and 78
(75-87) years, respectively, with 86% and 91% with an ECOG status ≤1. At a
median follow-up of 17.3 months, 10% of pts in the DRd group and 11% in
the Rd group discontinued due to TEAEs. Common (≥10%) grade 3/4 TEAEs
for DRd were neutropenia (45% vs 31% with Rd), hypokalemia (14% vs 3%),
and pneumonia (10% vs 11%). D-associated IRR occurred in 12 (41%) pts in
the DRd group, with 4 (14%) pts having grade 3/4 IRR. No patient discontin-
ued DRd because of IRR. Median PFS was significantly prolonged with DRd
compared with Rd in the elderly subgroup (NR vs 11.4 months; HR, 0.19;
95% CI, 0.06-0.55; P=0.0007), consistent with the overall PFS observed in
POLLUX (Figure 1). ORR was higher with DRd versus Rd (93% vs 77%),
and rates of CR or better (52% vs 9%) and VGPR or better (72% vs 41%)
were also higher with DRd versus Rd.
Figure 1.
Summary/Conclusions: The results in elderly pts were consistent with those
observed in the overall study populations in terms of efficacy. Rates of most
common grade 3/4 hematologic TEAEs in elderly pts were similar to that of
the overall populations, and IRR were manageable. This subgroup analysis
supports the addition of D to standard-of-care regimens in elderly pts with
RRMM.
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Background: Ixazomib is a novel, effective oral proteasome inhibitor with a
favorable toxicity profile. Recent studies showed significant activity as single
agent with dexamethasone and in combination with other agents. The Tour-
maline trial showed superior PFS with ixazomib plus lenalidomide and dexam-
ethasone in pts with relapsed or refractory myeloma (RRMM).
Aims: Here, we evaluate the activity and tolerability of ixazomib plus thalido-
mide and dexamethasone (IxaThalDex) in pts with RRMM.
Methods: Pts with RRMM and one or more prior lines of therapy (TX) with the
following criteria were eligible: Measurable disease, ECOG PS ≤2, ANC
≥1000/µL, platelet count ≥50000µL, GFR ≥15mL/min. Treatment regimen: Ixa-
zomib (4mg, d 1, 8 and 15), thalidomide (100mg/d), and dexamethasone (40mg
d 1, 8, 15). Pts aged ≥75 years received lower doses of thalidomide (50mg/d)
and of dexamethasone (20mg). Pts were scheduled for 8 cycles followed by ixa-
zomib maintenance therapy (4mg, days 1, 8, 15 of a 28 cycle and 3mg in pts
aged ≥75 years) for one year. Primary objective was PFS, and secondary objec-
tives were ORR, OS, impact of cytogenetic risk and of renal impairment, safety
and health related QoL
Results: Sixty-seven of 77 planned pts have been enrolled so far. The following
patient characteristics were recorded in the intent-to treat group (ITT): median
age: 67, range 41 to 84 years, ISS stage I: 28, II 22, III: 16, not known: 1, median
number of prior TX lines: 1 (range: 1-8). 9 pts discontinued TX before completion
of 2 cycles. Presently, 5 pts are too early for evaluation per protocol (PP). Full
documentation of ≥2 cycles is available for 52 pts, with a median number of 4
cycles and a median F/U of 7.4 mos. A PR or better was achieved in 33 pts
(63%), nCR: 2 pts (4%), VGPR: 10 (19%), PR: 21 (40%), MR: 2 (4%), yielding a
clinical benefit rate (CBR) of 67%. FISH data are available in 43 of the 52 PP pts.
≥PR was seen in 11/18 (61%) pts with t (4; 14) and/or t (14; 16) and/or del17p
and in 15/25 (60%) with standard risk cytogenetics. Median PFS at the time of
reporting is 11.6 mos. in the ITT and 10.4 mos. in the PP group. Median OS has
not been reached in neither group. Patients with high-risk cytogenetics did not
show statistically significant differences in PFS (10.4 mos. vs 10.3 mos., p=0.882)
and OS (11.6 mos vs median n.r., p=0.061).  Global health status/QoL as
assessed by EORTC QLQ C-30 instrument revealed clinical meaningful (>5
points) improvement in QoL, which was slightly more pronounced in pts with
≥PR (Figure1). Neutropenia was noted in 19 pts (28%), (15 grade 2 and 4 grade
3). Leucopenia was seen in 19 pts (28%), (14 grade 2 and 5 grade 3). 32 pts
(47%) had anemia (23 grade 1/2 and 9 grade 3). Thrombocytopenia was record-
ed in 11 pts (14%, 4 grade 2 and 6 grade 3). The most frequent non-hematological
toxicities were fatigue observed in 21 pts (32%) and infections noted in 27 pts
(including 6 pts with pneumonia and 1 pt with sepsis). Polyneuropathy was seen
in 19 pts (28%, 18 grade 1 or 2, one grade 3). During the study, the incidence of
new PNP was relatively low (17 new and two worsening PNP).
Figure 1.
Summary/Conclusions: The all oral IxaThalDex regimen showed an ORR of
63% with no difference in pts with/without high-risk cytogenetics, a CBR of 67%,
and a PFS of 10.4 mos in pts with RRMM. The regimen was well tolerated and
was associated with a low incidence of mainly grade ≤2 PNP, which required
dose reduction in one patient only. Response rates improved with continuation
of therapy and treatment was associated with an increase in health related QoL.
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Background: Growth differentiation factor-15 (GDF-15), is a member of the
TGF-beta family, and is involved in several pathological conditions, including
inflammation, cancer, cardiovascular, pulmonary and renal diseases. Serum
GDF-15 levels add prognostic information to conventional prognostic factors,
such as NT-proBNP and troponins, in cardiovascular disorders and has also
shown to be associated with renal damage and risk of end stage renal disease
in patients with diabetes. Increased serum GDF-15 levels have also shown to be
correlated with early death and shorter survival independently of other cardio-
biomarkers and Mayo stage. Because GDF-15 was also associated with renal
outcomes we evaluated the prognostic value of GDF-15 levels in two independent
cohorts of patients with AL amyloidosis and renal involvement who were treated
in two different centers (Pavia Amyloidosis Center and Department of Clinical
Therapeutics, Athens).
Aims: To evaluate the prognostic value of GDF-15 levels in independent
cohorts of patients with AL amyloidosis and renal involvement .
Methods: Circulating levels of GDF-15 were measured by a novel pre-com-
mercial immunoassay (Roche Diagnostics) in stored serum. The Pavia cohort
included 135 and the Athens cohort included 76 patients with AL amyloidosis
and renal involvement. Standard criteria were used for the diagnosis, evaluation
of organ involvement and cardiobiomarker-based risk stratification. Renal stag-
ing was based on the system proposed by Palladini et al., based on baseline
proteinuria >5 gr/day and eGFR <50 ml/min.
Results: Median age and involved FLC levels were similar between the two
cohorts. However, heart involvement was more common in Pavia cohort (72% vs
53% f, p=0.005). Mayo stage disposition was also different (17%, 46% & 37% for
stage 1,2 & 3 in Pavia vs 30%, 43% & 27% in Athens cohort, p=0.08, but stage
3B was similar, 13% vs 12%). Also there were differences in peripheral nerve
involvement (9% in Pavia vs 21% in Athens cohort, p=0.025). Median eGFR and
renal stage distribution (26%, 54%, 20% vs 20%, 54%, 26% for renal stage-1, 2
& 3 respectively) were similar between the two cohorts (p=0.544). Median follow
up for the Pavia cohort was 18 months and for the Athens cohort was 45 months
(p<0.001). Survival at 2 years was 59% for Pavia and 56% for Athens cohort.
Median GDF-15 levels was 3454 pg/ml in Pavia (range 624 to >100000) and 4152
pg/ml (range 626 – 71475) in Athens cohort (p=0.09), while 93% and 94% of
patients in the two cohorts had GDF-15 levels >1200 pg/ml (the upper limit of nor-
mal for individuals without cardiovascular disease). We then evaluated the prog-
nostic significance regarding renal outcomes (dialysis): GDF-15 >4000 pg/ml was
associated with a HR of 6 (95% CI 2015.6, p=0.001) in Athens cohort (progression
to dialysis within 2 years in 7% vs 47%); while, by applying the same cutoff in
patients in Pavia cohort, 2-year dialysis rate was 10% vs 37% (HR: 3, 95% CI 1.6-
15, p=0.004). Although renal stage discriminated 3 groups in univariate analysis
in each cohort, in multivariate analysis, GDF-15 >4000 pg/ml outperformed renal
stage by eGFR and proteinuria and was the only independent prognostic factor
for progression to dialysis in each cohort (Figure 1).
Figure 1.
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Summary/Conclusions: Our study validated and confirmed in two independent
cohorts, with differences in their characteristics, the prognostic value of GDF-15,
which emerges as a novel biomarker with prognostic implications for different
outcomes in patients with AL amyloidosis. Importantly, GDF-15 emerges as a
strong biomarker for renal outcomes in patients with AL amyloidosis.
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Background: Proteasome inhibitor (PI)-based combinations are standards of
care in all lines of MM therapy. As the treatment paradigm moves to focus more
on extended therapy, new combinations are needed that will be efficacious and
tolerable, while giving pts the flexibility of taking their treatment at home. Com-
binations of ixazomib, the first oral PI, with immunomodulatory drugs (IMiDs)
are feasible and effective; however, there may be pts for whom the use of IMiDs
is not desirable. Therefore, triplet combinations of ixazomib with alkylators have
been studied.
Aims: This phase 2 study (NCT02046070) evaluated the safety and efficacy
of the all-oral ICd regimen in transplant-ineligible pts with NDMM. Primary end-
point was rate of CR+VGPR during induction. Secondary endpoints included
tolerability and toxicity, overall response rate (CR+VGPR+PR) throughout treat-
ment, time to response, PFS, and quality of life (QoL).
Methods: Adult pts with NDMM who were transplant-ineligible were randomized
(1:1) to receive oral ixazomib 4.0 mg plus oral cyclophosphamide 300 mg/m2
(Arm A) or 400 mg/m2 (Arm B) on days 1, 8, and 15, and dexamethasone 40
mg on days 1, 8, 15, and 22, for up to 13 x 28-day cycles as induction. Pts with
≥SD and an acceptable toxicity profile then received single-agent ixazomib
maintenance therapy until PD, death, or unacceptable toxicity. 
Results: 70 NDMM pts were enrolled (n=36 Arm A; n=34 Arm B): median age
73 years (range 61–87); 47% male; 31%/33%/29% ISS stage I/II/III MM; 50%
had a cardiovascular/pulmonary comorbidity; 9% had high-risk cytogenetics
(t(4;14), t(14;16), del 17p). At data cut-off (29 June 2016), pts had received a
median of 19 cycles; 66% had completed 13 ICd induction cycles and proceed-
ed to ixazomib maintenance therapy; 10% were ongoing on therapy, and 53%
had discontinued due to AEs (24%), PD (16%), patient withdrawal (3%), or
other reasons (10%). Confirmed responses by investigator assessment are
shown in the Table 1. Median time to first/best response across arms was 2/4
months. After a median follow-up of 17.9/18.5 months in Arm A/B, median PFS
was not reached. Combined PFS at 12/18/24 months was 81%/66%/59% (24-
month PFS 64%/56% for Arm A/B). In Arm A/B, 94%/100% reported AEs;
72%/74% reported grade ≥3 AEs; and 47%/56% reported SAEs. The most
common all-grade AEs were neutropenia (22 [31%]), anemia (19 [27%]), diar-
rhea, nausea, peripheral edema (each 18 [26%]), vomiting (15 [21%]), fatigue,
and constipation (each 14 [20%]). The most common grade ≥3 AEs were neu-
tropenia (22 [31%]), anemia (10 [14%]), lower respiratory tract and lung infec-
tions (9 [13%]), and supraventricular arrhythmias (5 [7%]). There were 5 on-
study deaths, none considered related to treatment. QoL (by EORTC QLQ-
C30; Global Health Status) was maintained from baseline during the study.
Table 1.
Summary/Conclusions: Based on this phase 2 study, ICd is an active treatment
regimen for pts with NDMM who are ineligible for transplant. This trial captured
a population of pts that was elderly and with multiple comorbidities. In this con-
text, the results with ICd, an all-oral triplet including a PI and alkylator, provide
evidence of clinical efficacy with a manageable safety profile. With a median fol-
low-up of ~18 months, median PFS was not reached and outcomes appear
comparable to other regimens in elderly transplant-ineligible pts with NDMM.
The preferred cyclophosphamide dose for ICd phase 3 studies is 300 mg/m2,
based on the similar PFS, higher response rate, and numerically lower rate of
AEs vs 400mg/m2. Updated PFS results will be presented at the meeting.
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Background: Bortezomib-MP is a standard-of-care regimen for elderly NDMM
pts. Whereas bortezomib is administered IV or SC, ixazomib is an oral protea-
some inhibitor with a safety profile amenable to extended dosing that is
approved in the US and EU, in combination with lenalidomide-dexamethasone,
for the treatment of MM pts who have received at least 1 prior therapy. Based
on the demonstrated feasibility and efficacy of a proteasome inhibitor-MP com-
bination, the all-oral ixazomib-MP (IMP) regimen was evaluated in elderly, trans-
plant-ineligible NDMM pts.
Aims: Primary phase 1 objectives were to determine the safety, MTD, and rec-
ommended phase 2 dose (RP2D) of ixazomib in combination with MP. The pri-
mary phase 2 objective was to determine the rate of CR+VGPR; secondary
objectives included PFS and OS.
Methods: In phase 1, pts were enrolled to 4 arms – Arm A: ixazomib 3.0–3.7
mg (days 1, 4, 8, 11, 22, 25, 29, 32) plus M 9 mg/m2 and P 60 mg/m2 (days 1–
4) in 42-day cycles (max 9 cycles); Arm B: ixazomib 3.0–4.0 mg (days 1, 8, 15)
plus M 6 mg/m2 and P 60 mg/m2 (days 1–4) in 28-day cycles (max 13 cycles);
Arm C/D: ixazomib 3.0–4.0 mg (days 1, 8, 15, 22, 29)/ixazomib 4.0 mg (days
1, 8, 22, 29) plus M 9 mg/m2 and P 60 mg/m2 (days 1–4) in 42-day cycles (max
9 cycles). In phase 2, an expansion cohort was enrolled at the RP2D. On all
arms, after IMP induction, pts could receive maintenance with single-agent ixa-
zomib (days 1, 8, 15; 28-day cycles).
Table 1.
Results: 61 pts were enrolled, 11, 34, 11, and 5 to Arms A, B, C, and D (median
age 74 yrs; 31% ISS stage III, 56% creatinine clearance ≤60 mL/min). Among
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38 DLT-evaluable pts in phase 1, 10 had DLTs of Gr 3 rash (n=2, Arm A), Gr 3-
4 thrombocytopenia (n=4, 1 pt in each arm), Gr 3-4 neutropenia (n=1, Arm A;
n=4, Arm C, n=1, Arm D), Gr 4 hemorrhagic oesophageal ulcer (n=1, Arm B),
Gr 3 ileus/neurogenic bladder (n=1, Arm B), Gr 3 vomiting/diarrhea (n=1, Arm
B), and Gr 3 respiratory infection (n=1, Arm C). The RP2D was ixazomib 4.0
mg in Arm B, based on observed rates of toxicity; this cohort was expanded to
26 pts. Among all 61 pts, the median number of treatment cycles was 16; 36
pts (13 at RP2D) completed IMP induction and entered maintenance. Median
number of maintenance cycles was 12. The maximum treatment duration was
1841 days (>5 yrs) at RP2D. Five pts remain on treatment (2 at RP2D); primary
reasons for discontinuation were disease progression (48%) and adverse
events (AEs, 21%). CR+VGPR rate was 43% (43% at RP2D), including 28%
(22%) ≥CR and 19% (17%) sCR; median time to first response was 1.7 mos,
and responses continued to mature over a long period (Table 1). Depth of
response improved during ixazomib maintenance in 9/36 (25%) pts (VGPR to
sCR in 5 pts; VGPR to CR in 2 pts; CR to sCR in 2 pts). Median TTP/PFS are
shown in Table 1; median OS was not reached after median follow-up of
42.6/46.9 mos overall/at RP2D.
Summary/Conclusions: The RP2D was weekly ixazomib 4.0 mg plus M 6
mg/m2 and P 60 mg/m2 (days 1–4) in 28-day cycles, consistent with the ixa-
zomib dose and schedule in TOURMALINE-MM1. AEs were mainly hemato-
logic, infections, PN, and diarrhea. The all-oral IMP regimen is active in NDMM,
with a 28% CR rate (19% sCR), a 43% ≥VGPR rate, and a median PFS of
23.5 mos; responses continued to improve over a prolonged period.
Myeloma and other monoclonal gammopathies -
Clinical 2
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Background: There is a high rate of toxicity-related discontinuation in elderly
patients with NDMM, negatively affecting outcome. In order to predict feasibility
of treatment the IMWG developed the frailty score based on age, (instrumental)
Activities of Daily Living and the Charlson comorditity index.
Methods: Patients were treated with 9 cycles of MPV: Mel 6 mg/m2, day 1-4;
Pred 30 mg/m2, day 1-4; and Bort 1.3 mg/m2 day 1,8,15 and 22 of a 35-day
cycle. This first planned analysis was restricted to the first 140 consecutive
patients out of 240 planned patients.
Results: Of the 139/140 eligible patients none were fit (because of age ≥75
years), 30/139 (22%) were unfit, 100/139 (72%) were frail, and 9/139 (6%)
unknown. The median follow up was 17.0 months. The discontinuation rate of
MPV in the total population was 42%; 27% in unfit and 46% in frail patients
(p=0.09). When also patients were included who discontinued bortezomib only
these numbers were 27% in unfit and 52% in frail (p=0.02). Importantly, 6 cycles
of MPV were found to be feasible in 70% of patients, both in unfit (80%) and
frail (69%) patients. Age >80 years was associated with a significantly higher
discontinuation rate of MPV or bortezomib only (70% versus 35% in patients
aged 75-80 years, p=0.01). WHO performance was not associated with dis-
continuation rate. Response on protocol was ≥PR 73%, ≥VGPR 38% and ≥CR
11%, not significantly different in unfit versus frail patients. Response after 6
cycles was ≥PR 69%, ≥VGPR 35% and ≥CR 2%. Median progression free sur-
vival (PFS) was 17 months: 20 for unfit and 16 months for frail patients (p=0.13).
Overall survival at 18 months was 76%: 89% for unfit and 72% for frail patients
(p=0.22). Frail patients were found to have significantly less grip strength and
lower walking speed as compared to unfit patients (Table 1).
Table 1.
However, 58% and 59% of frail patients had an intermediate or high walking
speed and grip strength respectively. Vice versa, 8% of patients with low
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walking speed and 12% of patients with low grip strength, were not frail but
unfit according to the IMWG frailty index. Discontinuation rate in patients with
highest and lowest walking speed was 16/41 (39%) and 18/41 (44%). These
numbers were 14/42 (33%) versus 17/43 (40%) for patients with the highest
versus the lowest grip strength. PFS was not significantly different between
patients with highest versus lowest walking speed (p=0.38). However, in con-
trast to comparable PFS in unfit and frail patients, there was a trend for better
PFS in patients with highest versus lowest grip strength (20 versus 17 months,
p=0.05).
Summary/Conclusions: Nine cycles of dose-adjusted MPV results in a high
discontinuation rate of 42% in NDMM patients ≥75 years: 27% in unfit versus
46% in frail patients. Importantly, 6 cycles of MPV were found to be feasible
with comparable response rate, also in frail. Preliminary analyses showed that
functional geriatric assessments differed within IMWG frailty groups and that
grip strength was associated with PFS, whereas frailty was not. Therefore,
functional assesments will hopefully be complementory to the IMWG frailty
score in guiding future therapy in unfit and frail patients.
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THE EUROPEAN MYELOMA NETWORK EMN09 STUDY: CARFILZOMIB,
BENDAMUSTINE, AND DEXAMETHASONE IS EFFICIENT AND SAFE IN
PATIENTS WITH ADVANCED MULTIPLE MYELOMA
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Background: Even after a prolonged treatment patients with multiple myeloma
may have received little chemotherapy, however many may suffer from borte-
zomib induced peripheral neuropathy (PN). Bendamustine (Benda) leads to
increased levels of defective ribosomale products (DRiPs). Carfilzomib (Carf),
a proteasome inhibitor not inducing PN, inhibits degradation of DRiPs leading
to plasma cell apoptosis. 
Aims: With this scientific rationale a CBd combination of Carf and Benda and
low dose dexamethasone (dex) was evaluated in a phase 1/2 trial in patients
with relapsed/refractory multiple myeloma (RRMM). 
Methods: Sixty-three patients with RRMM with ≥2 lines of prior therapy were
enrolled with the last patient included in February 2017. Treatment consisted
of 28-day cycles of Benda 70 mg/m2 on day 1 and 8, Carf was given on day 1,
2, 8, 9, 15, 16 at 27 mg/m2 after an initial dose of 20 mg/m2. In 6 patients in the
phase 1 part of the trial Carf was escalated to 36 mg/m2. This was found to be
the MTD. 20 mg dex was added on every treatment day and day 22 and 23.
After 8 cycles, responding patients received maintenance only every 14 days
with Carf for two days plus dex until progression. 
Results: The phase 1 part of the trial suggested Carf at the 27 mg/m2 level for the
phase 2 part. Forty-one patients were evaluated for response and efficacy. At last
data cut-off, the median follow-up was 5.95 months. Number of prior treatment
lines ranged from 2 to 9, and ≥85% of patients had received previously transplan-
tation, bortezomib and immunomodulatory drugs. The median time elapsed from
diagnosis to treatment start was 5.8 years. Forty-three percent of patients achieved
at least a PR including 28% ≥VGPR and an overall benefit of 92%. Median pro-
gression-free survival was 11.4 months and the 1-year overall survival was 75%.
Hematological toxicity was well manageable. Non-hematological adverse events
≥grade 3 were infections, followed by dyspnea, cardiac events and thromboem-
bolism. These data will be up-dated before the meeting.
Summary/Conclusions: In this elderly RRMM patients treated late in their dis-
ease, the combination of CBd provides effective outpatient therapy. Neither nau-
sea, hair loss nor PN were an issue. Although cardiopulmonary as well as vascular
signs need attention, CBd appears a very tolerable treatment option. In this heavily
immunosuppressed patient population infection prophylaxis is mandatory.
Clinical trial information: NCT02056756.
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CHEMOTHERAPY BEFORE AND AFTER HEART TRANSPLANTATION FOR
PATIENTS WITH ADVANCED CARDIAC AL AMYLOIDOSIS, SINGLE
CENTER RESULTS WITH LONG-TERM FOLLOW-UP
U. Hegenbart1,*, K. Haack1, A. Kristen2, P. Blum2, C. Kimmich1, H. Katus2,
A. D. Ho3, A. Ruhparwar4, P. Raake2, S. Schönland1
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Background: Survival rates for patients with light-chain (AL) amyloidosis are
gravely reduced by advanced cardiac involvement at Mayo cardiac stage IV
with a median survival of 6,5 months. High-dose Melphalan (HDM) and autol-
ogous stem cell transplantation (ASCT) or other intense chemotherapy regimen
cannot be applied to those patients due to the high risk of therapy-related mor-
tality. One approach to improve the catastrophic prognosis of those patients is
to perform a heart transplantation followed by intense chemotherapy.
Aims: Our aim was to examine the cases of cardiac AL patients treated with
heart transplantation (HTx) at our center and to evaluate the clinical outcome
of this treatment approach.
Methods: Data from 41 patients (21m, 20f) suffering from cardiac AL who were
treated in our hospital between 2002 and 2017 were retrospectively analyzed.
All patients were high-urgency listed for orthotopic HTx due to poor perspective
of survival. Until 2009, 13 patients were listed, 8 of them with multiple organ
involvement. Thereafter, we excluded patients with multiple organ involvement.
All data are derived as medians with range or absolute numbers. Survival
curves were calculated using the Kaplan-Meier method.
Results: Median age was 51 years (35-63) at diagnosis. Amyloidogenic lambda
light-chains (LC) were detected in 35 and kappa LC in 6 patients. Median dFLC
was 331 (69 – 2752) and median plasma cells in bone marrow were 13% (5-35).
Median NT-proBNP was 6.332 ng/l (1.500 -53.194), median cTNT 0,11 µg/l (0,01-
0,52) and median hsTNT was 60 ng/l (28-448) at diagnosis. Median NYHA stage
was 3 (2-3) and median MAYO 2004 stage was 3 (2-3). Serum creatinine was at
a median of 0,94 mg/dl (0,66-2,45), proteinuria at 0,1 g/day (range 0-10,7).
Patients stayed on the high-urgency waiting list for a median of 26 (range 3-54)
before 2009, and a median of 64 days (8-259) after 2009. 35 patients were treated
with chemotherapy prior to HTx (mostly dexa w/o Bortezomib) to reduce dFLC
during the waiting time. Eight patients died before receiving HTx with a median
survival (start point: HU listing) of 26 days (6-177). With a median of 5 months
after HTx (4-29), 18 patients received ASCT. HDM was used with either 200
mg/m2 (N=10) or reduced dosage (N=8) in patients with reduced kidney function
(mostly due to renal complications after HTx). Complete remission (CR) was
achieved in 7 patients (24% of all transplanted pts, n=29; 2 patients have not fin-
ished treatment yet), very good partial remission (VGPR) in 6 patients (21%) and
partial remission (PR) in 7 patients (24%). Overall, 25 patients died. Cause of
death was either progression of AL (N=16), sepsis (n=4), heart transplant rejection
(n=3) or other (n=2). Patients that underwent HTx had a median survival of 46
months (2-177, 1-year survival: 77%).
Summary/Conclusions: HTx followed by chemotherapy is a feasible treatment
approach in patients with advanced cardiac amyloidosis. Patients who reach
HTx have a nearly 50% chance for a very good hematologic remission (VGPR
or better) and consecutively a favorable survival probability with a median OS
of nearly 6 years in our series.
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Background: RI is a common comorbidity in pts with multiple myeloma (MM)
that increases in incidence as the disease progresses and is associated with
poor prognosis. Approximately 20% to 30% of pts with MM have RI at time of
diagnosis; ≈ 2% to 13% of whom will require dialysis. The immunomodulatory
agent, POM, in combination with LoDEX demonstrated comparable efficacy
and tolerability in pivotal RRMM trials in pts with moderate RI. However, this
regimen had not previously been fully studied in pts with severe RI or pts requir-
ing hemodialysis. 
Aims: To present updated safety and efficacy analyses from the multicenter,
phase 2 MM-013 trial, in which pts with RRMM and moderate or severe RI,
including those on hemodialysis, were treated with POM+LoDEX.
Methods: Three cohorts of pts with RRMM and RI were enrolled: (A) ‒ mod-
erate RI (estimated glomerular filtration rate [eGFR] ≥30 to <45 mL/min/1.73m2),
(B) ‒ severe RI (eGFR <30 mL/min/1.73m2) without hemodialysis, and (C) ‒
severe RI requiring hemodialysis. All pts must have received ≥1 prior treatment
including LEN and progressed during or after their last anti-myeloma treatment
before entering the study. Pts received POM+LoDEX until disease progression
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or unacceptable toxicity. Supportive care was allowed; thromboprophylaxis
was required for all pts not on hemodialysis. The primary endpoint was overall
response rate (ORR). Key secondary endpoints included safety, renal
response, time to myeloma response, time to renal response, duration of
response, progression-free survival (PFS), time to progression, and overall
survival (OS). All pts provided informed consent.
Results: Enrollment has been completed with 81 pts (33 in cohort A; 34 in cohort
B; 14 in cohort C), of which 13 (16.0%) were still on treatment as of January 28,
2017. Median follow-up for OS was 7.8 months. A total of 68 pts (84.0%) discon-
tinued treatment; 39 (48.1%) due to PD. Median age was 72 yrs (range, 52-86
yrs), 60.5% of pts were male, and median time from diagnosis was 3.8 yrs (range,
0.03-19.44 yrs). Pts received a median of 4 (range, 1-10) prior anti-myeloma
therapies. All pts had prior treatment with LEN (100%) and nearly all with BORT
(97.5%). Median relative dose intensity of POM was 0.94 in both cohorts A and
B, and 0.99 in cohort C. ORR was 39.4%, 29.4%, and 14.3% in cohorts A, B,
and C respectively. PFS and OS results are presented in the Table 1. Grade 3/4
anemia and thrombocytopenia occurred more frequently in cohort C, likely due
to severe RI requiring dialysis (Table 1). AEs leading to dose reductions were
18.2%, 14.7%, and 14.3% in cohorts A, B, and C, respectively. 
Table 1.
Summary/Conclusions: POM+LoDEX is efficacious in pts with RRMM with
moderate or severe RI, including those on hemodialysis, who had more
advanced disease due to worse renal function. The safety profile was accept-
able among the three groups and no new safety signals were observed. This
study demonstrates that POM+LoDEX can be administered in pts with moder-
ate or severe RI, including those on hemodialysis.
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Background: Treatment options are needed for patients with RRMM. PD-L1
is expressed in patients with multiple myeloma, and blocking the programmed
death 1 (PD-1) pathway may provide antitumor activity. Pembrolizumab is a
humanized, high-affinity monoclonal antibody directed against PD-1 with robust
antitumor activity and favorable safety in several solid and hematologic malig-
nancies. KEYNOTE-013 (NCT01953692) is a multicohort phase 1b study of
pembrolizumab monotherapy in patients with hematologic malignancies; results
are reported for patients with RRMM.
Aims: To determine the safety, tolerability, and antitumor activity of pem-
brolizumab monotherapy in patients with RRMM.
Methods: Patients with RRMM who have failed ≥2 prior lines of therapy includ-
ing a proteasome inhibitor and immunomodulatory drug (IMiD) received pem-
brolizumab 10 mg/kg every 2 weeks or 200 mg fixed dose every 3 weeks. Pri-
mary end points were safety, tolerability, and objective response rate (ORR)
as determined by investigators, per International Myeloma Working Group 2006
criteria.
Results: At data cutoff of January 2, 2017, 30 patients were treated. The medi-
an (range) duration of follow-up was 15 (1-32) months. 28 (93%) patients dis-
continued the study; the most common reason was disease progression in 14
(47%) patients and clinical progression in 9 (30%) patients. 2 (7%) patients
are still on treatment. Median (range) age was 70 (56-81) years. 21 (70%)
patients had an ECOG performance status of 1. Patients received a median
(range) of 4 (2-10) prior lines of therapy. 20 (67%) patients were lenalidomide
refractory, 10 (33%) were double-refractory, 9 (30%) were triple refractory, and
1 (3%) patient was quadruple refractory. Among patients who received pem-
brolizumab at 10 mg/kg, the median (range) of pembrolizumab exposure was
6 (2-15) cycles; among those who received 200-mg fixed dose of pembrolizum-
ab, the exposure was 3 (2-6) cycles. No patient experienced a response. Sev-
enteen (57%; 95% CI, 37-75%) patients had stable disease. 13 (43%; 95% CI,
26-63%) patients had progressive disease as their best response. Treatment-
related adverse events (TRAEs) occurred in 12 (40%) patients. The most com-
mon TRAE was asthenia (n=5, 17%); arthralgia, aspartate aminotransferase
increased, fatigue, hyperglycemia, hypothyroidism, myalgia, pruritus, and
blurred vision occurred in 1 patient each. A grade 3 TRAE (myalgia) occurred
in 1 (3%) patient. There were no grade 4 TRAEs and no deaths due to TRAEs.
1 (3%) patient had an immune-related adverse event (grade 1 pruritus).
Summary/Conclusions: The safety profile of pembrolizumab in RRMM was
consistent with that observed with other cancers. Best response observed while
on pembrolizumab monotherapy was stable disease. Recent results of ongoing
studies, such as KEYNOTE-023 (NCT02036502), demonstrate promising effi-
cacy of pembrolizumab in combination with IMiDs (lenalidomide) and dexam-
ethasone in patients with RRMM.
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Background: Treatment with autologous transplantation (ASCT) remains the
standard of care upfront for Multiple Myeloma patients considered eligible for
transplant. Peripheral blood stem cell (PBSC) collection, also called mobilisa-
tion, is needed prior to ASCT. The optimal methodology for mobilizing PBSC
has yet to be defined, with either G-CSF alone, also called steady state proce-
dure, or use of Plerixafor, a CXCR4 antagonist (Mozobil®)+G-CSF or high
dose cyclophosphamide (usually administered at a dose of 1.5 to 6g/m2 IV for
one to two days)+G-CSF. The former is rarely used with the most recent induc-
tion regimens, and the 2 latter have demonstrated similar PBSC collection
rates. Because of the intense competition for hospital resources and the staff
required to manage patients preparing for mobilization and transplantation, it
is important to quantify the total impact of mobilization on staff resource and
cost to the hospital.
Aims: We aimed at better evaluate the respective cost of the 2 techniques of
mobilization for the French health care system, high dose cyclophosphamide
(n=57) versus plerixafor (n=55).
Methods: This is an observational cohort database analysis of 112 consecutive
patients with MM treated upfront with ASCT between 2009 and 2013 and that
had been mobilized with either high dose cyclophosphamide or plerixafor from
15 IFM centers. Patients must have successfully underwent ASCT. This study
was not aimed at evaluating the suitability or advisability of one therapy versus
another. A cost-consequences analysis of the different regimens of mobilization
will be performed. Cost will be quantified using “microcosting” approach. Only
direct medical costs are included in this economic analysis. Hospital resources
will be calculated using two different approaches: per diem hospitalization costs
(excluding direct medical costs) versus French public diagnosis-related group
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(DRG). The point of view of the French Public Health System is adopted for this
study. Monetary values for 2012 euros prices will be used for all components.
Results: Median (range) age was 59.5 (24-72), sex ratio was 1.5, ISS 3 was
26% in either group, all patients were collected to allow the number of graft
requested by the hematologist of reference. The median CD34 collected was
8.9 (4-30) for HD cyclophosphamide and 5.8 (2-15) for plerixafor. The analysis
demonstrated that days in the hospital were the primary cause for cost differ-
ence across the 2 mobilization techniques. In that regards, plerixafor appeared
very cost effective compared to HD cyclophosphamide. All data will be updated
at EHA 2017 including cost comparison.
Summary/Conclusions: For a long time HD cyclophosphamide was recom-
mended for mobilization upfront in Myeloma therapy, as it was needed to
improve response rate and depth of response, despite only 10% of the patients
improving. With the progress made recently with the induction regimens, the
choice for the mobilization regimen is now based more on safety and cost sav-
ing. In that regards, one must acknowledge that plerixafor has become one, if
not the, most attractive option for Myeloma.
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Background: Based on the current guideline, bortezomib-based two or three
drug regimens are mainly listed as a category 1 primary treatment option for
transplant-eligible patients with myeloma. However, to date there are few direct
head-to-head randomized controlled trials (RCTs) comparing effects of these
recommended regimens, which makes it difficult to assess which treatment is
most favorable to obtaining high response rates.
Aims: to determine the ranking of the currently recommended induction regi-
mens and to compare efficacy of all available treatments.
Methods: We conducted a systematic literature review to identify all eligible RCTs
that include at least one currently recommended regimen by searching PubMed,
Web of Science, ASH, ASCO, EHA, and ESMO databases. A Bayesian network
meta-analysis (NMA) with a fixed-effect model was performed to rank the regi-
mens of their very good partial response rates or better (≥VGPR) and provide a
comparison of treatment options. One of the most commonly utilized regimens,
lenalidomide-dexamethasone, was used as reference treatment.
Results: Ten RCTs were identified including nine treatment regimens : vincristine-
doxorubicin-dexamethasone (VAD), thalidomide-dexamethasone (TD), borte-
zomib-dexamethasone (VD), bortezomib-doxorubicin-dexamethasone (PAD),
bortezomib-cyclophosphamide-dexamethasone (VCD), bortezomib-thalidomide-
dexamethasone (VTD), bortezomib-thalidomide-dexamethasone-cyclophos-
phamide (VTDC), lenalidomide- dexamethasone (RD) and bortezomib-lenalido-
mide-dexamethasone (VRD). Figure 1 shows the probability of being the best
induction treatment. The Figure 1 also presents the postinduction odds ratios for
achieving a ≥VGPR and 95% credible intervals (CrI) versus RD. This analysis
showed a significantly higher ≥VGPR with VRD compared with most of the other
investigated interventions, including VD, PAD, VCD and RD (OR [95% Crl]): VD
4.4 [1.2–19.6]; PAD 3.8 [1.1–16.2]; VCD 3.4 [1.1–14.2]; RD 1.7 [1.1–2.5]. The
similar result was also seen in comparing with VTD and VTDC, but the difference
did not reached statistically significant level : VTD 2.4 [0.7–10.4]; VTDC 2.4 [0.5-
13.7]. VRD was identified as the best induction treatment since it was the most
favorable in terms of i) only treatment that was significantly better than RD, and
ii) probability of being best regimen (84% of the simulations).
Figure 1.
Summary/Conclusions: Our systematic review and NMA included most of
the recommended induction treatments for transplant-eligible myeloma patients
and identified VRD as being most effective in achievement of ≥VGPR. NMAs
can provide an overview of the best treatment and each regimen’s relative effi-
cacy in case of lacking head-to-head RCTs, thereby supporting clinical deci-
sion-making.
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Background: Recent  International Myeloma Working Group( IMWG)  guidelines
recommend that conventional skeletal surveys should be supplanted by low dose
whole body computed tomography (CT),whole body magnetic resonance imaging
(MRI) and or 18fluoro-deoxyglucose (18F-FDG/PET)1 .However, resource, funding
and radiology capacity issues, have posed significant challenges to implementing
these recommendations. The risk of progression of Monoclonal Gammopathy of
Undetermined Significance (MGUS) to a neoplastic plasma cell disorder is
approximately 1% per year2 and even lower in low risk MGUS.  It is thus not nec-
essary to perform imaging in unselected MGUS patients.
Aims: To look at all skeletal surveys requested across 3 large hospitals in UK
over a year and analyze their justification, effectiveness and utility.
To decide if a rational clinico–biochemical algorithm could be used to reduce
the number of imaging requests, thereby avoiding unnecessary radiation expo-
sure, and make a possible switch to modern imaging methods cost effective
Methods: A total of 397 skeletal surveys were performed across three hospitals
over one year. The data set was analyzed for clinical indications, paraprotein
level, rationale for requesting the skeletal survey, the diagnostic yield and also
the number of follow up CT/ PET or MRI required.
A pragmatic algorithm was developed and applied to see if the requests were
justified and could have been safely reduced. (Figure1).
Results: Of the 397 analyzable skeletal surveys performed, 266 were on myelo-
ma, 81 for MUGS, 48 were for non-paraprotein related indications. Of the 266
myelomas, 30% of skeletal surveys were reported as positive according to
IMWG criteria1.  A detailed analysis of 130 myeloma patients revealed a signif-
icant proportion of false negatives (6%) and false positives (7%), highlighting
the insensitivity and poor specificity of this imaging modality. More importantly
more than a third (38%) of myeloma patients required follow up imaging with
MRI, PET or WBLDCT irrespective of the initial skeletal survey result, indicating
a significant duplication rate and waste of resources. In the MGUS group, major-
ity of skeletal surveys were negative (91%) but 9% were reported as positive.
Follow up imaging with CT and MRI was performed in 23% of the MGUS group.
However none these were positive. When the clinico-biochemical algorithm
was applied, the number of requests was reduced by at least a quarter (24%),
avoiding unnecessary radiation exposure and precious resources.
Figure 1.
Summary/Conclusions: - Skeletal survey has very limited role in investigation
of paraproteinaemia and should be abandoned. - Our pragmatic clinic-biochem-
ical imaging algorithm reduced imaging requests significantly( 24%) allowing
the preferred imaging modalities to be performed productively in a cost effective
way in face of ever increasing health care cost and demands.
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Background: In multiple myeloma (MM), abnormal serum free light chain ratios
(FLCr) after therapy associate with poor prognosis, independent of depth of
response. However the value of FLCr in the context of minimal residual disease
(MRD) remains unclear. A proportion of MRD-negative patients experience
early relapses and conversely, some MRD-positive patients can endure long-
term survival; which may result from improved immunosurveillance following
normal plasma-cell recovery. 
Aims: We hypothesised that serum FLC levels and ratios add clinical value at
the time of MRD assessment. 
Methods: The study included 275 intact immunoglobulin MM patients from the
IFM2009 clinical trial who achieved at least a very good partial response
(VGPR) after consolidation therapy. Median PFS from the end of consolidation
was 38.3 months; median OS was not reached. Serum FLCs were measured
using Freelite immunoassays (The Binding Site). Normal range for k/l FLCr
was 0.26-1.25. We defined immunosuppression as levels of both the uninvolved
(polyclonal) FLC+uninvolved heavy+light chain (HLC; measured with Hevylite)
below their normal range. MRD assessment in bone marrow samples was
based on 4-colour multiparametric flow cytometry (MFC).
Results: At the end of consolidation, 79/275 (29%) patients were MRD-positive,
79/275 (29%) had abnormal FLCr, 16/275 (6%) had elevated iFLC, with
immunosuppression identified in 52/275 (19%). Using Cox regression all the
variables associated with shorter PFS (p<0.001 for all) and OS (p<0.050 for
all; except elevated iFLC which showed a trend towards shorter OS (p=0.070)).
Among 196 MRD-negative patients, 37/196 (19%) had abnormal FLCr, 2/196
(1%) had elevated iFLC with immunosuppression identified in 23/196 (12%).
Median PFS for MRD-negative patients was not reached; however both an
abnormal FLCr (median PFS: 31.4 months; p<0.001) and immunosuppression
(median PFS: 31.4 months; p=0.005) identified a group of patients with poorer
outcomes. On the other hand, median PFS for MRD-positive patients was 21.3
months; 42(53%) of these patients had abnormal FLCr and dismal outcomes
(median PFS 12.6 vs 30.7 months for abnormal vs normal FLCr, respectively;
p=0.004). Absolute FLC measurements did not reach statistical significance
for PFS in these patients.
Summary/Conclusions: Serum FLC measurements in combination with low-
sensitivity MFC bone marrow assessment at the end of consolidation therapy
render the most powerful prognostic information in MM patients achieving deep
responses. In those where disease is no longer detected using MFC, abnormal
FLCr confer poor prognosis, which may partly be due to inefficient immune
recovery. Absolute FLC measurements were not informative, supporting the
rationale of evaluating biomarkers of the tumour and immune system recovery.
Our results warrant further studies to validate the clinical utility of FLC meas-
urements in combination with next-generation (8-colours) flow cytometry.
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Background: The cytogenetic abnormality t(11;14) is common, occurring in
approximately 20% of patients with newly diagnosed multiple myeloma
(NDMM) (Avet-Loiseau, Leukemia, 2013). Historically, t(11;14) has been asso-
ciated with standard-risk multiple myeloma (MM) and generally favorable out-
comes (Avet-Loiseau, Leukemia, 2013). However, some retrospective analyses
have reported the presence of t(11;14) to be a poor prognostic factor (Kaufman,
Leukemia, 2016).  Connect MM is a largely community-based, US prospective
observational cohort study that collects data on management and natural his-
tory of patients with NDMM in clinical practice. 
Aims: This analysis assessed the impact of t(11;14) on survival outcomes in
African American and non-African American patients in a mostly community-
based setting.
Methods: Adult patients with NDMM within 60 days of diagnosis were eligible
for enrollment in the registry. Patients who completed induction and were tested
for t(11;14) by fluorescence in situ hybridization or cytogenetics were grouped
by race (African American and non-African American). Endpoints were pro-
gression-free survival (PFS) and overall survival (OS). Kaplan-Meier analyses
were adjusted for cohort, age, International Staging System stage, transplant
intent, presence of t(4;14), diabetes history, and baseline levels of hemoglobin,
platelets, calcium, and creatinine. Data cutoff was Jul 7, 2016.
Results: 3011 patients were enrolled in 2 cohorts. Cohort 1 enrolled 1493
patients from Sep 2009–Dec 2011; median follow-up was 39.3 months. Cohort
2 enrolled 1518 patients from Dec 2012–Apr 2016; median follow-up was 16.4
months. A total of 1539 (52%) patients were tested for t(11;14). Of these, 363
(24%) were positive for t(11;14). By race, 53 (26%) of 205 African American
and 310 (23%) of 1334 non-African American patients were positive for t(11;14).
First-line bortezomib exposure was similar across all groups. In African Amer-
ican patients, the presence of t(11;14) resulted in a trend toward shorter PFS
compared to those without t(11;14) (Table 1. Additionally, African American
patients with t(11;14) had significantly higher risk of death compared to African
American patients without t(11;14). A higher rate of early mortality was observed
vs non-African American patients. In non-African American patients, no differ-
ences in PFS or OS were noted based on the presence or absence of t(11;14).
For OS, the interaction between race and t(11;14) status was statistically sig-
nificant (P=0.004).
Table 1.
Summary/Conclusions: In Connect MM, the effect of t(11;14) on OS was sig-
nificantly different between African American and non-African American
patients. Specifically, t(11;14) was associated with poorer survival outcomes
in African American patients, and not in non-African American patients. Thus,
the presence of t(11;14) may be a risk factor for poor prognosis in African Amer-
ican patients. Additional analyses will be conducted to elucidate the role of
induction treatment, transplant and maintenance in African American and non-
African American patients with t(11;14).
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Background: Juvenile myelomonocytic leukemia (JMML) is an aggressive
myeloproliferative disorder of early childhood. While some cases show spon-
taneous remission, allogeneic hematopoietic stem cell transplantation (HSCT)
remains the only curative treatment option for the majority of patients, however,
the 5-year event-free survival reaches only about 50%. Hyperactive RAS sig-
naling is assumed to be the main driving event in JMML. It is caused by genetic
alterations in CBL, KRAS, NF1, NRAS, or PTPN11 in about 90% of patients.
So far, there is no clear understanding of how RAS pathway mutations relate
to the heterogeneous disease biology and variable clinical outcome seen in
JMML patients. As a consequence, established clinical and genetic markers
fail to fully represent the observed disease heterogeneity.
Aims: We hypothesized that DNA methylation profiling, either alone or in com-
bination with genetic alterations, might provide a molecular basis for disease
classification.
Methods: Genome wide DNA methylation analysis using the HumanMethyla-
tion450 Bead Chip array was performed in a discovery cohort of 20 JMML
patients. We developed a strategy to eliminate methylation events that attribute
to epigenetic changes in normal hematopoiesis. The clinical relevance of our
findings was assessed in an unselected sample set consisting of 148 consec-
utive patients with JMML (n=130) or Noonan syndrome associated myelopro-
liferative disorder (n=18) registered in the EWOG-MDS 1998 & 2006 trials.
Data integration was performed in a subset of patients with available exome
sequencing (n=50) and expression profiling (n=15) data.
Results: Systematic DNA methylome analysis of JMML samples identified
three subgroups with low, intermediate and high methylation levels (LM, IM,
and HM). Detailed analysis of the validation cohort not excluding the Noonan
patients identified an association of methylation groups with clinical features.
The HM subgroup (n=41) was enriched for high-risk characteristics: All HM
cases had elevated levels of HbF, 88% were older than 2 years at diagnosis,
74% had low platelets (<70/nl), and 66% carried somatic PTPN11 mutations.
In contrast, the LM subgroup (n=62) was enriched for patients with low-risk
disease: All 18 patients with Noonan syndrome, 13/14 patients with CBL syn-
drome, and 15/19 patients with NRAS mutations were assigned to the LM
group. The IM group (n=45) was enriched for cases with monosomy 7 and
somatic KRAS mutations. The unfavorable risk profile in the HM group trans-
lated into poor 5-year survival (HM 57%, LM 87%; log rank p<0.01) and a high
incidence of relapse after HSCT (HM 48%, LM 9%; Gray’s test p=0.01). In a
multivariate Cox regression model, only methylation group (HM vs LM: RR 10.9
[1.8-66.2]) and PTPN11 mutation status (PTPN11-mutant vs other: RR 3.3 [1.2-
8.9]) remained as independent prognostic factors for CIR (p=0.01).
JMML-specific differentially methylated probes were significantly enriched for
regions decorated with H3K27me3 or PRC2 components and for genes asso-
ciated with oncogenic RAS-signaling. Integrative analysis of genetic and epi-
genetic events in these cases identified additional gene alterations leading to
frequent co-occurrence of ≥2 mutations activating the RAS-RAF-MEK-ERK
pathway in the HM and IM subgroups. This finding was paralleled by a signifi-
cant up-regulation of DNMT1 and DNMT3B expression suggesting aberrant
activation of the DNA methylation machinery in this context.
Summary/Conclusions: Our integrated approach identified three JMML sub-
groups characterized by distinct clinical and biological features. We provide evi-
dence for a molecular mechanism by which additional genetic events, presumably
further activating the RAS-RAF-MEK-ERK pathway, mediate DNA hypermethy-
lation via up-regulation of DNMTs in more aggressive JMML cases.
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Background: The molecular and phenotypic correlates of cytogenetic abnor-
malities in primary myelofibrosis (PMF) have been widely investigated. This
information in post-polycythemia vera (post-PV) and post-essential thrombo-
cythemia (post-ET) myelofibrosis (referred to as secondary myelofibrosis, SMF)
is scant. The MYSEC project (Myelofibrosis Secondary to PV and ET Collabo-
ration) collected 781 SMF patients in Europe and United States and recently
disclosed phenotype-genotype associations in SMF (Leukemia, 2017). 
Aims: The primary objective of this study is to report cytogenetic abnormalities
in SMF on a large scale and to assess molecular and phenotypic correlations
of cytogenetic abnormalities. In addition, prognostic relevance of different cyto-
genetic patterns is investigated.
Methods: Diagnosis of SMF was performed according to the IWG-MRT criteria
(2008). The MYSEC study was approved by the Review Board of each Institution
and conducted in accordance with the Declaration of Helsinki. Bone marrow cyto-
genetic analysis was made at time of SMF diagnosis and considered evaluable
if at least 20 metaphases were available. Results were described according to
the International System for Human Cytogenetic Nomenclature. Karyotype was
defined abnormal if a structural or numeric chromosomic alteration was present
in at least two metaphases. The presence of three or more aberrations defined
a complex karyotype; two or more distinct autosomal monosomies or single auto-
somal monosomy associated with at least one structural abnormality defined
monosomal karyotype (MK). Continuous values were compared via non-para-
metric Mann-Whitney U tests, with Holm corrections for multiple testing; categor-
ical feature counts were compared with Fisher’s exact tests. Time-to-event analy-
sis used Kaplan-Meier estimators and Cox models for regression. 
Results: Within the whole cohort of 781 SMF patients, 376 had cytogenetic
data. Cytogenetic abnormalities were reported in 128 (34.1%) cases: 72 (60%)
were sole, 22 (18.3%) double, 26 (21.7%) complex, 11 (9.2%) MK (all included
in complex karyotype) and eight unknown. The most prevalent individual abnor-
malities were 20q- (25%), 13q- (20.8%), +8 (8.3%) and +9 (5.6%). Patients
with post-PV MF had significantly higher frequency of abnormal karyotype than
those with post-ET MF (P=.012). Chromosomal abnormalities did not cluster
differently among the different genotypes (JAK2, CALR, MPL and triple nega-
tivity). Abnormal karyotype was significantly associated with lower platelet count
(P=.004), larger spleen size (P=.016), higher circulating blasts (P <.001) and
presence of constitutional symptoms (P=.014) at the time of SMF diagnosis.
Within abnormal karyotypes, we found that patients with MK tended to have
lower platelet count (P=.04) with respect to those with sole aberrations. Overall
survival (OS) was significantly inferior in patients with abnormal karyotype
(P=.012), even adjusting for SMF diagnosis type (P=.02). When investigating
OS according to different abnormalities, we found that patients with MK have
inferior OS respect to those with sole abnormality (P <.0001) (Figure 1).
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Figure 1.
Summary/Conclusions: Abnormal karyotype was found in 34.1% of SMF
patients at diagnosis and was over-represented in post-PV MF. No different
distribution was detected among genotypes. Abnormal karyotype was associ-
ated with lower platelet count, larger splenomegaly, higher circulating blast
cells and presence of constitutional symptoms. Concerning outcome, the pres-
ence of abnormal karyotype implied inferior survival and, among subtypes, MK
remained the most powerful predictor.
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Background: MDS/MPN-U is a rare, poorly characterized myeloid neoplasm
within the MDS/MPN category in the World Health Organization (WHO) clas-
sification. A median survival of 12.4 months from time of referral was previously
reported for a cohort of 85 patients with MDS/MPN-U seen at the MD Anderson
Cancer Center (MDACC, DiNardo et al. Leukemia 2014). The International
Prognostic Scoring System (IPSS) for MDS (Greenberg et al. Blood 1997) dis-
criminated amongst prognostically distinct categories in that cohort, while nei-
ther the IPSS for primary myelofibrosis (PMF, Cervantes et al. Blood 2009) nor
the revised IPSS (IPPS-R) for MDS (Greenberg et al. Blood 2012) did. Median
survival of 21.4 months from the time of diagnosis was reported in a multi-insti-
tutional cohort (n=69, Wang et al. Blood 2014). Information on the genomic
landscape of MDS/MPN-U is limited to one report on the frequency of SETBP1
mutations (8.3%, Meggendorfer et al. Leukemia 2013).
Aims: To describe the mutational landscape of MDS/MPN-U using targeted
multi-gene sequencing.
Methods: Targeted sequencing was performed on DNA from 97 patients with
MDS/MPN-U (diagnosed per WHO 2008 criteria but excluding refractory anemia
with ringed sideroblasts and thrombocytosis) seen across 4 US institutions
(MDACC, 43; Cleveland Clinic, 29; Moffitt Cancer Center, 16; Vanderbilt Univer-
sity, 9). Gene panels used varied between institutions, with 20 genes (ASXL1,
CBL, DNMT3A, ETV6, EZH2, IDH1, IDH2, JAK2, KIT, NPM1, NRAS, PHF6,
RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1, ZRSR2) in common. 
Results: Mutational frequencies for the 20 genes tested in all 97 patients were
as follows: TET2, 28%; ASXL1, 27%; JAK2, 25%; SRSF2, 22%; EZH2, 15%;
SF3B1, 12%; RUNX1, 12%; ZRSR2, 11%; SETBP1, 11%; U2AF1, 11%; NRAS,
10%; DNMT3A, 9%; TP53, 8%; CBL, 4%; ETV6, 4%; NPM1, 4%; IDH2, 2%;
KIT, 2%; PHF6, 1% and IDH1, 0%. In addition, the frequency of mutations in
ten other genes of interest in hematologic malignancies was assessed: BRAF,
0% (n=52); CSF3R, 4% (n=52); CALR, 4% (n=53); MPL, 3% (n=68); MLL, 1%
(n=72); STAG2, 6% (n=72); CEBPA, 4% (n=73); KRAS, 4% (n=81); PTPN11,
4% (n=82) and FLT3, 2% (n=82). Median survival for the whole cohort (n=97)
was 12.4 months (range, 1-173). The 43 MDACC patients in this analysis were
included in the cohort of 85 previously reported by DiNardo et al. Median age
was 70 years (21-89). Median (range) values for leukocytes, neutrophils, hemo-
globin, platelets and bone marrow blasts at the time of sample collection for
sequencing were 13.4 (1-179) x 109/L, 7.9 (0.4-152.4) x 109/L, 9.1 (3.1-15)
g/dL, 123 (6-1168) x 109/L and 2% (0-17), respectively. On univariate analysis
(n=97), only the presence of EZH2 and ZRSR2 mutations were associated
with trends towards statistical significance for survival. Mutated EZH2 adversely
impacted survival (p=0.056), while mutated ZRSR2 had a favorable impact on
survival (p=0.074). The IPSS-R for MDS was useful to differentiate between
risk groups with different survival times (p=0.065) while the dynamic IPSS for
PMF (Passamonti et al. Blood 2010) was not (p=0.39). On multivariate analysis,
only EZH2 mutations and IPSS-R very low risk (versus all other categories
combined) were statistically significantly associated with inferior and superior
survival, respectively.
Summary/Conclusions: In this cohort of 97 patients with WHO-defined
MDS/MPN-U, mutations in genes encoding epigenetic regulators (e.g., TET2,
ASXL1, EZH2), spliceosome components (e.g., SRSF2, SF3B1, ZRSR2,
U2AF1), signaling molecules (JAK2, NRAS), the transcription factor RUNX1
and SETBP1 were found at frequencies ≥10%. Although the analysis is limited
by small numbers, EZH2 mutations were independently associated with poor
survival. This represents the largest cohort of patients with MDS/MPN-U inter-
rogated for mutations in multiple genes to date.
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Background: Juvenile myelomonocytic leukemia (JMML) is a myeloprolifera-
tive disorder of childhood that is initiated by mutations in the Ras pathway.
Outcomes in this disease vary dramatically from resolution with minimal or no
therapy to relapse despite hematopoietic stem cell transplantation. Identifying
biomarkers to distinguish patients with aggressive disease courses from those
who can receive minimal therapy remains a priority for clinicians.
Aims: We utilized an unbiased screening approach to investigate genome-
wide DNA methylation in newly diagnosed JMML patients. We then sought to
determine whether a specific DNA methylation signature was capable of pre-
dicting outcomes in this heterogeneous disease, with a particular emphasis on
identifying a biomarker predictive of spontaneous resolution.
Methods: Genome wide DNA methylation analysis was carried out using the
Illumina 450k BeadChip platform in a discovery cohort of 39 well-character-
ized patients with JMML enriched for those who experienced spontaneous
resolution without chemotherapy. A separate cohort of 40 patients with JMML
was then used for validation. Of note, patients with Noonan syndrome were
excluded from both cohorts. All 79 patients were then compared to 22 healthy
controls between 1 and 5 years of age using peripheral blood derived DNA.
Results: JMML patients with aggressive disease have a distinctly hyperme-
thylated DNA profile at the most variable CpG sites compared to patients
with less aggressive disease as well as healthy controls. Methylation patterns
did not differ based on the tissue of origin (peripheral blood, splenic tissue,
or bone marrow) and were similar between monocyte enriched cell popula-
tions and unsorted mononuclear cells. Unsupervised clustering of the dis-
covery cohort based on the most highly variable CpG sites (top 0.5% ranked
by standard deviation, 1527 CpG sites) identified three clusters. For patients
in the cluster with the lowest levels of methylation, only one patient out of 15
(7%) had an event at 4 years (95% confidence interval [CI], 2-32%). This
compared to 45% (5/11) (CI, 17-77%) for patients in the cluster of intermedi-
ate levels of methylation and 61% (8/13) (CI, 32-86%) in those patients with
the highest level of methylation. The proportion of patients with events differed
significantly by cluster (p=0.0039) and remained independently prognostic
in multivariable analysis (p=0.033) in the context of age and the number of
somatic mutations at diagnosis. We next sought to validate our findings in an
independent cohort of 40 patients. We classified each patient in the validation
cohort into one of the three clusters defined by the discovery cohort. The
proportion of patients having an event at four years was 8% (1/12) (CI, 0-
38%) in those with the lowest level of methylation. This compared to 36%
(4/11) (CI, 11-69%) for patients with intermediate levels of methylation and
76% (13/17) (CI, 50-93%) for those with the highest levels of methylation.
We then compared our combined cohort of 79 JMML patients with 22 healthy,
age-appropriate controls. Remarkably, using the same set of CpG sites
defined in the discovery cohort, 27/79 JMML patients clustered more closely
with the controls than with other patients. Of these 27 patients, 14 (52%)
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experienced spontaneous resolution and only two (7%) experienced an event
at 4 years. 
Summary/Conclusions: Using a genome-wide methylation analysis, patients
with the lowest degree of DNA methylation within the most variable CpG sites
had improved event free survival compared to patients with higher degrees of
methylation. Interestingly, patients who experienced spontaneous resolution of
their disease clustered more closely with healthy controls than to patients with
aggressive JMML. DNA methylation is a robust biomarker independently capa-
ble of predicting outcome and should be tested prospectively in the context of
clinical trials.
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Background: Leukemic transformation occurs in 8% to 23% of myelofibrosis
patients in the first 10 years after diagnosis and in 4% to 8% of polycythemia
vera and essential thrombocytosis patients within 18 years of diagnosis and is
almost always fatal.
Aims: We retrospectively analyzed the survival outcome of patients with myelo-
proliferative neoplasms (MPNs) who progressed to acute myeloid leukemia
(AML) based on the treatments received, response, different prognosis groups
according to the (ELN) and based on a next-generation DNA sequencing profile
(NGS).
Methods: A total of 72 patients diagnosed in our institute with AML secondary to
MPNs between 2000 and 2016 were retrospectively analyzed. NGS was per-
formed in 44 cases. Mutations found by NGS were classified according three dif-
ferent cellular functions of interest (Tumors suppressor (TP53), ADN/Histones’
epigenetic (DNMT3A, EZH2,IDH1/2,ASXL1) and alternative splicing
(SRSF2,U2AF1,ZRSR2,PRPF8,SF3B1)) and three groups were determined:
Group A: patients without altered cellular function; Group B: patient with one
altered function; Group C: patients with more one altered functions. AML treatment
response was evaluated according Mascarenhas’ proposed criteria for response
assessment of AML secondary to MPNs. Overall survival (OS) was calculated
according the different treatments, treatment response and NGS profiles.
Results: 72 patients who developed AML secondary to MPNs were included
in the study.43.6% (N=31) had prior ET, 25% (N= 18) PV, 20.8% (N=15) PMF
and 11.1% (N=8) secondary myelofibrosis. The median age at AML transfor-
mation was 70 (range: 38-89). The median time to AML transformation from
MPNs diagnosis was 108 months (range: 2.4-408). Among these 72 AML, 5.6%
(N=4) belonged to the favorable risk category according to ELN 2017, 13.9%
(N= 10) belonged to the intermediate risk category and 55.6% (N=40) to the
adverse risk category. 45.8% (N=33) patients were treated with intensive
chemotherapy (IC), 15.3% (N=11) with azacitidine (AZA) and 38.9 (N=28) with
supportive care (BSC). Median OS was 4.5 months (range, 0.1-65), with no
significant difference between the three ELN 2017 risk categories (respectively
2.5 months (range: 1-9), 5.5 months (range: 1-60) and 5 months (range: 1-36)
in the favorable, intermediate and adverse risk categories). Patients who
received IC (p<0.01) or AZA (p<0.05) have a significant better OS (median OS
of 7 months (range: 0.5-65) and 8.5 months (range: 3-24) respectively) than
patients who received BSC (median OS of 2 months, range: 0.1-36). However,
there is no significant difference between the IC and HMA groups (p=0.44). 7
Patients in Complete Cytogenetic Response (CCR) or Acute Leukemia
Response-Complete (ALR-C) received an alloSCT had a better median OS
than the 9 patients who did not (23 vs 6.5 months, p=0.063). Patients with
group A and B NGS profiles have a significant better median OS (respectively
14 and 8 months) than Group C (3 months) (p <0.05).
Summary/Conclusions: Our results confirm the poor outcome of patients with
secondary AML treated with IC and suggest that AZA provides comparable OS.
ELN2017 risk stratification predicted poorly patients outcome although a NGS-
based classification performed better.
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Background: Mastocytosis is a clonal disease characterized by heterogeneous
manifestations and a normal life expectancy in the majority of cases. In such a
condition, it is important to ascertain if other diseases, and particularly solid
malignancies, can worsen the prognosis.
Aims: To assess incidence and outcome of secondary primary malignancies
(SPM) in adult mastocytosis patients.
Methods: We performed a retrospective analysis of 826 adult (>18 years at
diagnosis) mastocytosis patients diagnosed and regularly followed in 6 Italian
Institutions. SPM were defined as de novo cancers diagnosed after mastocy-
tosis. We excluded from the analysis non-melanoma skin cancers due to the
possible under-reporting of such neoplasms by patients themselves. Also, we
did not consider newly hematological neoplasms, as they mainly represent a
progression from Systemic Mastocytosis (SM) to SM with an Associated Hema-
tological Neoplasm (AHN). Standardized Incidence Ratio (SIR) was calculated
as the ratio between the observed cases in our cohort and the expected cases
in the sex- and age-matched general Italian population in the same time period
(these data were retrieved from http://www.registri-tumori.it). Times to event
(patient-years) were calculated from the diagnosis of mastocytosis to the date
of SPM diagnosis, death, or last contact, whichever comes first. Survival curves
were estimated according to the Kaplan-Meier method.
Results: Males were 450 (54%). Median age at diagnosis was 49.3 years
(range 19-84). Median follow-up was 2.3 years (range 0-41). Subtype diag-
noses were: Cutaneous Mastocytosis (n=46), Indolent SM (n=633), Smol-
dering SM (n=10), SM-AHN (n=34), Aggressive SM (n=47) and Mast cell
leukemia (n=2). Fifty-four patients were classified as having mastocytosis in
the skin. Overall, 42 patients had a history of malignancies prior to the diag-
nosis of mastocytosis: in these patients we did not detect any relapse of their
prior malignancy after the diagnosis of mastocytosis. A total of 35 SPM were
diagnosed in 34 patients (4.1%). Median age at SPM was 56.4 years (range
37-76). Median time from mastocytosis to SPM was 22 months. The overall
rate of SPM was 12.8 per 1,000 person-years (95%CI: 9.1-17.6) while the
rate in the general adult population was 7.6 per 1,000 person-years (95%CI:
7.5-7.7) resulting in an increased hazard ratio of 1.7 (95%CI: 1.2-2.3). The
risk for SPM was higher than expected in females (SIR 1.93, 95%CI: 1.2-3.1)
while it was not significantly increased in males (SIR 1.46, 95%CI: 0.9-2.4).
We found a clearly increased risk for melanoma (n=8, SIR 15.9, 95%CI: 7.9-
31.9) and thyroid cancer (n=3, SIR 9, 95%CI: 2.9-27.9) while a non-significant
increased risk was found for prostate cancer in males (n=5, SIR 2.06, 95%CI:
0.8-4.9) and breast cancer in females (n=3, SIR 1.7, 95%CI: 0.5-5.3). All the
other malignancies were sporadic (one or two cases for each cancer type)
and comparison to the general population was not significant. The death rate
in patients with SPM was 14.7% with a median overall survival (OS) from
SPM diagnosis of 38 months. OS was significantly inferior in patients with
SPM as compared to patients without secondary neoplasia (5-year OS 77.6%
vs 93.7% respectively, p=.019) (Figure 1).
Figure 1.
Summary/Conclusions: Patients with mastocytosis may have a significantly
higher risk of developing a secondary non hematological cancer as compared
to the matched general population. Careful follow-up of these patients is war-
ranted as the rate of malignancies may increase over time and reduce life
expectancy.
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Background: Colony stimulating factor 3 receptor gene (CSF3R)-mutated
chronic neutrophilic leukemia (CNL) is a rare chronic myeloproliferative neo-
plasm.  There is the limited information on the clinical course of CNL.
Aims: To explore the clinical course of patients with CSF3R-mutated CNL and
identify risk factor(s) associated with survival.
Methods: A retrospective study was conducted to assess natural history and
identify risk factor(s) for survival in patients with CSF3R-mutated CNL. Sur-
vival analysis was performed by the Kaplan-Meier method taking the interval
from the date of diagnosis to death or last contact. The log-rank test was
used to compare survival data. Cox regression model was used for multi-
variable analysis.
Results: Data of 47 patients with CSF3R-mutated CNL were collected and
analyzed.  35 (76%) patients were male.  Median age was 62 years (range,
16-92 years).  At diagnosis, 17 (36%) patients had fatigue, 2 (4%) had a fever,
8 (17%) experienced diarrhea or abdominal discomfort, 20 (43%) were asymp-
tomatic and leukocytosis had been mostly an incidental laboratory finding. 20
(43%) patients had palpable splenomegaly, and 4 (9%), palpable
hepatomegaly.  PB parameters, median and (range), were WBC 42.4×10^9/L
(14.4-217.0), hemoglobin 100g/L (42-157), platelets 165×10^9/L (17-570), blast
percentage 0% (0-10), neutrophil percentage 82% (70-99).  The median of
blast cells in bone marrow were 1% (range, 0-12%).  46 (98%) patients were
in the chronic phase and 1 (2%) in the accelerated phase at diagnosis.  Most
of the CSF3R mutations was T618I (n=45, 96%), others were T568M (n=1,
2%) and O706T (n=1, 2%).  34 (72.3%) patients and 41 (87.2%) patients were
screened for ASXL1 and SETBP1 mutations, respectively.  21 (61.8%) patients
harbored ASXL1 mutation and 22 (53.7%) harbored SETBP1 mutation.  All
patients were BCR-ABL1, PDGFR and FGR mutation negative, 2 were CALR
mutation and JAK2V617F mutation positive, respectively.  Hydroxyurea was
the most frequently used therapy (n=46). Other therapies included interferon-
a (n=7), hypomethylating agents (n=4), thalidomide (n=2), ruxolitinib (n=1),
imatinib (n=3), dasatinib (n=1), chemotherapy (n=6), and transplant (n=2).  With
a median follow up of 17 months (range, 2-103 months), 7 patients progressed
to blastic phase or acute myeloid leukemia (n=6) or myelodysplastic syndrome
(n=1), 17 patients died.  Survival rate at 30 months was 55%.  Median survival
was 39 months (95% CI 8.5-69.5).  Multivariate analysis showed that WBC
>40×10^9/L (HR=3.26, 95% CI 1.14-9.30, p= 0.027) was the sole risk factor
for survival. However, SETBP1 or ASXL1 mutation was not associated with
survival.
Summary/Conclusions: High WBC count was independently predictive of
shortened survival in patients with CSR3R-mutated CNL.
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Background: The World Health Organization (WHO) classification system for
myeloid neoplasms was recently revised in 2016. The revised WHO criteria
underscore the importance of differentiating prefibrotic PMF (prePMF) from
“true” essential thrombocythemia (ET) as these two entities have different clin-
ical outcomes. For these reasons, standardization of morphologic findings in
the bone marrow biopsy and an explicit definition of minor clinical criteria for
the diagnosis of prePMF have been added (anemia, leukocytosis >11 x109/L,
palpable splenomegaly, increased LDH). 
Aims: To compare the clinical phenotype at diagnosis and the outcome of ET
and prePMF diagnosed according to the new 2016 WHO criteria.
Methods: We identified in our database all patients affected with ET, prePMF
and PMF diagnosed according to 2008 WHO criteria who satisfied these two
requirements: a bone marrow fibrosis grade 0-1 at diagnosis and at least one
DNA sample to define the mutational status. Firstly, the bone marrow morphol-
ogy of all 404 identified patients was reviewed by an expert pathologist. Then,
we reclassified patients according to the new 2016 WHO criteria as follows:
patient with ET morphology were classified as ET, patients with PMF morphol-
ogy and at least one clinical criteria (leukocytes, anemia, increased LDH,
splenomegaly) were classified as prePMF, patients with PMF morphology but
without clinical criteria were classified as myeloproliferative neoplasms unclas-
sifiable (MPNu). 
Results: According to the new criteria our cohort included 269 patients with
ET, 109 patients with prePMF and 26 with MPNu. By comparing clinical phe-
notype at diagnosis in prePMF, MPNu, and ET respectively, we observed that
prePMF showed higher leukocyte count, lower hemoglobin levels, higher
platelet count, higher LDH values, higher number of circulating CD34-positive
cells, and showed more frequently splenomegaly (Table 1). The higher fre-
quency of CALR mutations in prePMF compared to ET might contribute to the
high level of platelet count observed in prePMF. ET and MPNu did not differ in
terms of leukocyte count, hemoglobin, platelet count, LDH, circulating CD34-
positive cells and splenomegaly (Table 1). The 26 patients with MPNu were
not further considered in the analysis of disease complications and overall sur-
vival due to the low number. PrePMF patients had lower overall survival (overall
survival at 10 years 86.4% vs 96.6%, P <.001) and a trend to a higher incidence
of leukemic evolution (cumulative incidence of acute myeloid leukemia at 10
years 2.3% vs 1.9%, P .067) compared to ET patients, while they did not differ
in terms of thrombotic complications (cumulative incidence of thrombosis at 10
years 18.5% vs 18%, P>.90). Finally, we analyzed the subgroup of “old” ET
diagnosed according to 2008 WHO criteria. Of 358 “old” ET, 268 were reclas-
sified as ET, 25 as MPNu and 65 as prePMF. The “old” ET reclassified as
prePMF had a higher risk of overt myelofibrotic evolution compared to the “old”
ET reclassified as ET (cumulative incidence of overt myelofibrosis at 10 years
9.7% vs 0%, P=.033).
Table 1.
Summary/Conclusions: ET and prePMF diagnosed according to 2016 WHO
criteria are two entities with a different clinical phenotype at diagnosis and a
different outcome. The clinical phenotype at disease onset of MPNu and ET is
similar.
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Background: The minimal effective treatment in Essential Thrombocythemia
(ET) patients is tailored mainly on the basis of thrombotic risk scores (primum
non nocere).The Revised International Prognostic Score for Thrombosis in ET
(R-IPSET-Th) is based on different combinations of Age >60 yrs (Age >60),
JAK2 V617F mutation (JAK2+) and Prior Thrombosis (PrTh+).
Aims: To validate the R-IPSET-Th in a cohort of ET patients reclassified accord-
ing to the WHO 2016 criteria.
Methods: The web-based Registro Italiano Trombocitemie (RIT) recruited since
2005 patients with thrombocythemic bcr/abl negative chronic myeloproliferative
neoplasms (MPN). ET patients (reclassified according to WHO 2016 criteria)
with complete information (characteristics at diagnosis, antiplatelet and/or
cytoreductive treatment, date and description of thrombotic events during the
follow-up) were considered for this analysis. According to the R-IPSET-Th score,
the patients were divided in 4 thrombotic risk groups: Very Low Risk (VLR: Age
<60, absence of JAK2 mutations, no PrTh+), Low risk (LR: only JAK2+), Inter-
mediate Risk (IR: only Age >60), High Risk (HR: PrTh+, or Age >60 with JAK2+).
The rates (n and%, n/100 pt-yrs) of first thrombotic events during the follow-up
(Th-FUP) were reported for each risk group. The thrombosis free survival (TFS,
time from diagnosis to the first thrombosis) was determined for each risk group
(Kaplan Meier analysis), and the curves were compared with the log-rank test.
The concordance between the R-IPSET-Th score and the IPSET-Th score was
evaluated (Harrell C concordance index).
Results: Overall, 734 ET patients were analyzed (females 62%). Data at diag-
nosis were: Age >60 in 286 (39%), JAK2+ in 417 (57%), and PrTh in 126 (17%)
patients. Moreover: CVRFs in 66%, PLT >1000 x 109/L in 17%, and WBC >10
x 109/L in 21% of patients. The patients in the 4 R-IPSET-Th score risk groups
were: VLR 193 (26%), LR 197 (27%), IR 79 (11%), HR 265 (36%). The median
follow-up was 12, 12, 9, and 11 years, respectively (whole cohort, 11 years).
The rates of treatment were: 88%, 94%, 92%, 91%, respectively (whole cohort,
91%), with anti-platelet drugs (mainly low dose aspirin); 71%, 62%, 95%, 95%,
respectively (whole cohort, 80%), with cytoreductive drugs (mainly hydroxy-
carbamide). The Th-FUP were 103 (14.0%), with a rate increasing with the risk
score (p <0.001): in VLR (n 15, 8%), in LR (n 20, 10%), in IR (n 12, 15%), in
HR (n 56, 21%). The Th-FUP/100 pt-yrs increased (p <0.01) as follows: 0.60%,
0.79%, 1.61%, and 1.91%, respectively. TFS progressively decreased (p
<0.001) from VLR group to HR group (Figure 1). In detail, the probability of
TFS was 0.98, 0.97, 0.94, 0.88 at 5 years, and 0.85, 0.87, 0.78, 0.54 at 20years.
The patient stratification according to the R-IPSET-Th and the IPSET-Th scores
showed a concordance of 0.82 (Harrell C index).
Figure 1.
Summary/Conclusions: In this study of the Registro Italiano Trombocitemie
(RIT), we confirmed that the Revised International Prognostic Score for Throm-
bosis in ET (R-IPSET-Th) separated ET patients in 4 groups with increasing
risk of thrombosis during the follow-up (p <0.001). According to the R-IPSET-
Th score, an over-treatment seems to have occurred in this cohort of ET
patients (anti-platelets in almost all cases, and cytoreduction in around 2/3 of
VLR and LR cases), probably because other adjunctive risk factors have been
considered.
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Background: Myelofibrosis (MF) is characterized by significant inflammation
driven by clonal dysregulation and subsequent disruption of cellular signaling
cascades. Studies have confirmed a close relationship between circulating
inflammatory BMKs and baseline symptom burdens, along with the potential to
mitigate symptoms upon improvement of these proteins (Dueck Blood, 2013).
To date, no study has evaluated the correlations between elevated biomarkers
(BMKs) and specific MF symptoms. 
Aims: In this analysis of the phase-III placebo controlled COMFORT-I study
we investigated the relationships between blood BMKs and individual MF symp-
toms at baseline and post-treatment with ruxolitinib. 
Methods: Biomarker levels at baseline, week 4 and 24 were measured along
with MF symptoms (MFSAF 2.0-Mesa JCO 2013; collected during blinded
phase of COMFORT-I). Patients were randomized to ruxolitinib vs placebo.
BMKs were assessed using Rules-Based Medicine, Inc. (Austin, TX) Human
MAP panel. Associations between the individual symptoms measured within
the MFSAF and log2-transformed biomarker data were investigated at base-
line using Spearman correlations. Mixed models were used to assess symp-
tom and BMKs changes over time. Models included terms for visit, arm, vis-
it-by-arm interaction, age, sex, and body mass index (BMI).
Results: Study Population. A total of 309 subjects were randomized in COM-
FORT-I with median age of 68 (range 40-91). Approximately 46% of patients
were female and 50% had primary myelofibrosis (61% high risk). All 309 subjects
had BMKs measured at one or more of the three visits included in this analysis,
with 308 having biomarker values paired with MFSAF symptom scores at the
same visit. Correlations of Baseline Biomarkers and Symptoms. Total symptom
score (TSS) statistically significantly (p<0.05) correlated with 20 BMKs at baseline
(Table 1). For individual symptoms, spleen-related symptoms appeared to statis-
tically significantly correlate more frequently with BMKs at baseline: abdominal
discomfort (23 BMKs), feeling full (20 BMKs), and pain under left ribs (19 BMKs).
Night sweats, itchiness, and bone or muscle pain significantly correlated with 15,
14, and 10 BMKs each. The BMKs with the strongest correlations (absolute
Spearman correlation of at least 0.20 with p<0.001) with at least one symptom
included APOA1, EPO, FERRITIN, MIP1A, and PSAF. Associations with Symp-
tom and Biomarker Change Over the Trial Course. Twenty BMKs were signifi-
cantly associated with TSS over time. Like at baseline, BMKs appeared to be
more often statistically significantly (p<0.05) associated with spleen-related symp-
toms over time including 25 and 24 BMKs for abdominal discomfort and feeling
full, respectively. Night sweats, pain under left ribs, bone or muscle pain, and
itchiness were associated with 20, 12, 12, and 9 BMKs each. Strongest associ-
ations (p<0.001) between symptoms and BMKs over time included VCAM1 (4/6
symptoms+TSS), B2MICG (3/6 symptoms+TSS), LEPTIN (3/6 symptoms+TSS),
TIMP1 (2/6 symptoms+TSS), TNFRII (2/6 symptoms+TSS), INTLK18 (2/6 symp-
toms+TSS), and VWD (1/6 symptoms).
Table 1.
Summary/Conclusions: Spleen-related symptoms demonstrate close asso-
ciation with BMKs at baseline as well as BMKs over time, after taking into
account age, sex, BMI, and treatment. At baseline and over time, abdominal
symptoms remained the most frequently correlated or associated symptoms
with biomarker levels. More research is needed to determine the role of some
of these key BMKs in altered cellular signaling and potentially targetable path-
ways for symptom reduction.
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1Department of Hematology, Hokkaido University Graduate School of Medicine,
2Department of Hematology, 3Clinical Laboratory, Hokkaido University Hospital,
Sapporo, 4Department of Advanced Diagnosis, Clinical Research Center,
National Hospital Organization Nagoya Medical Center, Nagoya, Japan
Background: Congenital macrothrombocytopenia is a rare platelet disorder
and its cause is genetically heterogeneous. Recently, integrin αIIb and β3 muta-
tions have been identified in congenital macrothrombocytopenia patients with
platelet aggregation dysfunction. Here, we found a novel, heterozygous ITGB3
mutation in a pedigree and examined how this mutation contributed congenital
macrothrombocytopenia.
Aims: To detect gene mutations responsible for the congenital macrothrom-
bocytopenia in this pedigree and reveal the molecular pathophysiology.
Methods: Whole exome sequencing (WES) was performed to detect gene
mutations. Expression and activation state of αIIbβ3 in platelets was evaluated
by flow cytometry (FCM) and western blotting (WB). The effects of mutations
on αIIbβ3 activation state, phosphorylation of FAK, and morphological changes
were analyzed in transfected cells by WB and immunofluorescence staining.
Results: The patients were 56-year-old Japanese woman and 2 of her 3 sons.
They had no bleeding tendencies and near-normal bleeding time (Duke’s
method). Hematological examination revealed their decreased platelet counts
(58-86 x 109/l) with increase of mean platelet volume (12.8-14.5 fl). In all affect-
ed family members, giant platelets were observed on the peripheral blood
smears. Platelet aggregation induced by ADP (1-10 µmol/l) and collagen (2
µg/ml) was obviously reduced although that induced by ristocetin (1.5 mg/ml)
was within normal limit. The family pedigree indicates that the inheritance pat-
tern is autosomal dominant. Common congenital macrothrombocytopenias,
such as MYH9 disorders, Bernard-Soulier syndrome and type 2B von Wille-
brand disease were excluded by the absent leukocyte inclusion bodies, normal
ristocetin-induced platelet aggregation and normal platelet GPIb/IX expression,
normal von Willebrand factor assays, respectively. WES revealed that all affect-
ed family members had a heterozygous ITGB3 p.T746del mutation. FCM
showed decreased surface expression level of αIIbβ3 in the affected member’s
platelets. However WB of platelet lysates showed that there was no difference
in the total amount of αIIbβ3 among the affected and unaffected members and
normal controls. FCM showed a constitutive activation of αIIbβ3 on the patient’s
platelets as reflected by the spontaneous binding of PAC-1 antibody. Immuno-
fluorescence staining using CHO cells showed membrane localization of αIIbβ3
in wild-type αIIb/β3-expressing cells and cytoplasmic localization in αIIb/β3
(p.T746del)-expressing cells. ITGB3 p.T746del led to spontaneous tyrosine
phosphorylation of FAK and morphological changes, such as rhomboidal
changes, elongated changes, abnormal cytoplasmic protrusions, and mem-
brane ruffling, in transfected cells. FAK inhibitor (1,2,4,5-Benzenetetraamine
tetrahydrochloride) hindered the localization change of αIIbβ3 and the mor-
phological changes in transfected cells by dose dependent manner.
Summary/Conclusions: The autosomal dominant heterozygous ITGB3
p.T746del mutation was found to be responsible for constitutive activation of
αIIbβ3 in the patients’ platelets as well as transfected cells. It is considered
that ITGB3 p.T746del mutation unclasps the highly conserved membrane prox-
imal complex of αIIb and β3 cytoplasmic tails and renders the activated form.
Activation of αIIbβ3 leads to phosphorylation of FAK causing morphological
changes in transfected cells, which is considered to reflect abnormal throm-
bopoiesis leading to the production of giant platelets. We conclude that platelet
aggregation dysfunction is due to decrease of αIIbβ3 expression on the platelet
membrane surface due to cytoplasmic localization. These results suggest that
the gain-of-function mutation around membrane region of αIIbβ3 leads to
macrothrombocytopenia with impaired surface αIIbβ3 expression.
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CHANGES IN THE GENE EXPRESSION PROFILE OF IMMUNE
THROMBOCYTOPENIA PATIENTS TREATED WITH ELTROMBOPAG 
J. Bastida1,*, J. Hernandez-Sanchez2, A. Rodriguez2, D. Alonso-Lopez2,
E. Lumbreras2, M. Lopez-Parra1, R. Bueno2, A. Veiga1, J. Hernandez-Rivas2,
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1Department of Hematology, Hospital Universitario de Salamanca-IBSAL,
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Background: Eltrombopag (ETP) is an orally bioavailable, small non-peptide
molecule thrombopoietin receptor agonist that stimulates platelet production
by a mechanism similar, but not identical to, endogenous thrombopoietin. ETP
interacts with the transmembrane domain of thrombopoietin receptor, initiating
a JAK/STAT signaling pathway inducing the proliferation and differentiation of
the megakaryocytes to increase platelets production. 
Aims: To assess the gene expression profile (GEP) and the underlying signal-
ing pathways modified before and during the ETP treatment in chronic immune
thrombocytopenia (ITPc) patients.
Methods: ITPc patients (n=14) treated with ETP were evaluated. Complete
response (CR) was defined as a platelet count of ≥100x103/mm3 and treatment
failure was defined as a platelet count of≤20 x103/mm3for 4 consecutive weeks
at the highest recommended dose of ETP, a major bleeding event, or the need
to change therapy. RNA was isolated from mononucleated cells pre/post ETP
treatment. The “paired” GEP of the ITPc patients included the semi-supervised
analysis cluster samples before and after (28 day) the treatment with ETP to
detect changes attributed to ETP. This paired GEP was showed in Figure 1.
The GEP workflow consisted of the following steps: 28-paired samples were
hybridized to GeneChip® Human Gene 2.0 ST Array (Affymetrix’s). The robust
microarray analysis (RMA) algorithm was used for background correction and
normalization, while signal expression was calculated by significance analysis
of each microarray to provide a robust statistical inference by a permutation
method. P-values were provided and adjusted by multiples testing using a false
discovery rate (FDR). The pathways and upstream regulators related with the
most differentially expressed genes were analyzed by in silico analysis tools:
Advaita Bio’s iPathwayGuide (http://www.advaitabio.com/ipathwayguide)” and
DAVID Bioinformatics Resources. 
Results: The median age of the 14 ITPc patients enrolled in the study was 77
years (range, 35-87y). 64% patients (n=9) were treated with ETP after ≥2 lines
of treatments. Only 3 patients were splenectomized. Median platelet (P) and
white blood cell counts (WBC) increased after treated by ETP at day 28. (P
and WBC pre: 14,15x103/mm3 and 6,85x103/mm3 vs P and WBC post:
132x103/mm3 and 9,1x103/mm3). All but two patients achieved CR (85,7%)
and other 2 were considered failure of treatment. Regarding the gene expres-
sion profile, in silico analysis showed that the expression of 147 genes was
modified after ETP treatment; all of them were overexpressed after treat-
ment.  Semi-supervised cluster analysis showed 2 groups: pre and post ETP
treatment (Figure 1). Pathway analysis revealed that 38 genes were involved
in the maintenance of hemostasis, most of them related to platelet activation
(PTGS1, GP1BA or GP6). Interestingly, the paired GEP pointed out E2F1 and
GFI1B as possible leaders of the increase of the megakaryopoiesis. Other sig-
naling pathways overexpressed by ETP treatment are downstream routes of
PI3K/Akt (GFI1B, JAM3, ITGB3 and ITGA2B) and platelet activation (GP6,
GP9, GP1BA or PTGS1).
Figure 1.
Summary/Conclusions: In ITPc patients, ETP can induce overexpression of
genes involved in platelet activation and megakaryopoiesis and also alter
key/relevant/important-signaling pathways such as JAK/STAT and PI3K/Akt.
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DEFECTIVE PTEN REGULATION CONTRIBUTES TO B CELL HYPERRE-
SPONSIVENESS IN CHRONIC IMMUNE THROMBOCYTOPENIA
S. Wang1,*, Y. Guan1, H. Li1, R. Yang1, Y. Wang2
1State Key Laboratory of Experimental Hematology, Institute of Hematology
and Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking
Union Medical College, Tianjin, China, Tianjin, 2Second Affiliated Hospital of
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Background: Immune thrombocytopenia (ITP) is a complex autoimmune dis-
ease characterized by low platelet counts. The autoantibodies produced by
autoreactive B cells against self-antigens, specifically immunoglobulin G (IgG)
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antibodies against glycoprotein IIb (GPIIb)/IIIa and/or GPIb/IX, are considered to
play a crucial role. B cell homeostasis and function are controlled by cell surface
receptor-ligand interactions. The activation of PI3K is initiated by engagement of
the pre-B cell receptor (BCR) and the BCR. The phosphatase and tensin homolog
(PTEN) suppress the activity of the PI3K pathway. As a consequence, loss of
PTEN function leads to excessive PI (3, 4, 5) P 3 at the plasma membrane and
to recruitment and activation of Akt family members that potently drive cell survival
and proliferation .PTEN regulates normal signaling through the B cell receptor
(BCR). In immune thrombocytopenia (ITP), enhanced BCR signaling contributes
to increased B cell activity, but the role of PTEN in human ITP has remained
unclear. Both IL-21/IL-21R signaling and PI3K-PTEN molecules are involved in
maintaining normal humoral immunity and deletion of autoreactive B cells. In this
study, we want to determine whether abnormalities in PTEN might contribute to
increase B cell responsiveness in this disease and IL-21 mediated PTEN induc-
tion was defective. Meanwhile, we want to evaluate the relation between the
expression of PTEN in B cells and the prognosis of ITP, which will provide a the-
oretical basis of new treatment strategy for the ITP patient.
Aims: PTEN is involved in maintaining normal B cell function. Since B cell
overactivity is characteristic ofImmune thrombocytopenia(ITP) we sought to
determine whether abnormalities in PTEN might contribute to increase B cell
responsiveness in this disease.
Methods: 1. This study recruited 28 newly-diagnosed CITP patients and 26
sex and age matched health volunteers as health controls(HC)Peripheral blood
mononuclear cells were isolated from collected anti-coagulated blood. 2. Flow
cytometry and real time quantitative PCR were used for detecting the level of
PTEN from PBMC cells of HC and CITP patients. 3. The relationship between
PTEN levels and the disease severity of CITP was analyzed. 4. PBMC cells
were incubated with human rIL-2 rIL-21r CD40L or anti-IgM alone or in combi-
nation for 72h and after that the PTEN level was detected by flow cytometry
.The proportion and surface activated marker of B cells were determined by
flow cytometry
Results: 1. Compared to HC the expression of PTEN was diminished in each
CITP B cell population except IgD-CD38low/-memory B cells. In addition PTEN
mRNA was also decreased in ITP B cells. 2. The level of PTEN in B cells was
slightly correlated with blood platelet count (p=0.008) and also directly corre-
lated with the positive serum platelet-specific antibody (P=0.03). 3. The capacity
of IL-21 to induce PTEN expression in B cells of HC was found by flow cytom-
etry. Importantly.We found that CD40L and anti-IgM were the most potent induc-
ers of PTEN expression in normal B cells, followed by IL-21 and IL-2. Neither
IL-21 alone nor CD40L plus anti-IgM nor the three in combination stimulated
PTEN protein up-regulation in B cells in CITP patients. 4. These immature B
cells in CITP patients had a greater expression of CD95 but less PTEN com-
pared to HC suggesting that down-regulation of PTEN was associated with an
increasing proportion of immature B cells with a more activated phenotype in
CITP patients (Figure 1).
Figure 1.
Summary/Conclusions: Immune thrombocytopenia B cell showed decreased
levels of PTEN and the decrease was associated with low platelet count and
positive serum platelet-specific antibody.The capacity of IL-21 to induce PTEN
was defect in CITP.Together,these data suggesting that the defective PTEN
expression,regulation and function contribute to B cell hyper-responsiveness
in CITP.
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A DECREASED INTRACELLULAR S1P LEVEL AND S1P RECEPTORS
EXPRESSED ON MEGAKARYOCYTES POSSIBLY CONTRIBUTE TO
DEFECTIVE PROPLATELETS FORMATION IN IMMUNE THROMBOCY-
TOPENIA
J. Xue1, J. Zhang1, Q. Wang1, L. Xu1, X. Zhu1, Y. He1, Y. Kong1, Y. Chang1,
X. Zhao1, X. Zhao1, M. Lv1, L. Xu1, K. Liu1, X. Huang1, X. Zhang1,*
1Peking University Institute of Hematology, Peking University People’s Hospital,
Beijing, China
Background: Immune thrombocytopenia (ITP) is a common autoimmune dis-
order characterized by increased bleeding tendency and isolated thrombocy-
topenia. The precise pathogenesis of the decreased thrombopoiesis in ITP
remains unknown. It has been demonstrated that megakaryocytes (MKs) in
ITP show impaired proplatelets formation (PPF) (Br J Haematol.2014;165:854-
64). However, the pathogenesis of the impaired PPF in ITP is not entirely under-
stood. Additionally, the lipid mediator sphingosine 1-phosphate (S1P) plays a
critical role in megakaryocytic PPF in the bone marrow (BM) niche ( J Exp Med.
2012;209:2137-40). It has been demonstrated that cell-surface S1P receptors
(S1PR) on MKs trigger the activation of Gi/Rac GTPase signaling. Sphingosine
kinase 2 (Sphk2) is the major isoenzyme regulating intracellular synthesis of
S1P in MKs. Additionally, intracellular S1P influences the expression of Src
family kinase (SFK) in MKs, including 6 members (Fyn, Lyn, Src, Yes, Fgr, and
Hck), which mutually regulate each other with Rac GTPase.
Aims: To determine whether the S1P levels in both the BM niche and within
MKs, as well as S1PR expression of MKs contribute to the defective throm-
bopoiesis in ITP through impaired PPF.
Methods: The PPF of ITP-MKs was measured by an in vitro PPF assay using
HSCs from the BM. (FASEB J. 2010;24:4701-10). Additionally, all-trans-retinoic
acid (ATRA), the S1pr1-specific agonist SEW2871, and extracellular S1P were
used as interference factors. The concentration of S1P in the plasma and BM
was analysed by ELISA. The concentration of intracellular S1P was measured
using liquid chromatography mass spectrometry (LC/MS) analysis. Intracellular
Sphk2 , SFKs and cell-surface S1PR were measured using PCR and western
blotting. The location of Sphk2 was analysed by immunofluorescence using an
anti-human Sphk2 antibody. The activities of Rac-GTP were quantified by pull-
down assay.
Results: Significantly fewer numbers of proplatelet-forming MKs were observed
in ITP cultures. The concentration of S1P in the plasma and in BM of patients
with ITP was measured, of which the results showed no significant difference
in the plasma/BM S1P ratio. Decreased expression of S1PR1 and S1PR4 was
observed in ITP MKs. We found that downstream Gi/Rac GTPase signalling
activated by S1PR1 was down-regulated. ITP-MKs exhibited decreased intra-
cellular Sphk2, indicating less biosynthesis of intracellular S1P. Immunostaining
of Sphk2 in ITP MKs was performed, showing that less Sphk2 was primarily
localized to the nucleus of ITP MKs. Intracellular S1P of ITP MKs was further
explored showing a decrease of megakaryocytic S1P production ascribed to
significantly reduced Sphk2. Furthermore, the gene expression and protein lev-
els of family of SFKs were examined in ITP MKs, and the overall mRNA expres-
sion was significantly limited in ITP MKs. The total Src protein levels and p-
SFKs (phospho-tyrosine-418) were significantly reduced in ITP MKs, indicating
significant reduction of SFK activity. ATRA, SEW2871 and extracellular S1P
enhanced Rac GTPase activity and SFK expression, which rescued the defect
of PPF in ITP.
Summary/Conclusions: Decreased intracellular S1P ascribed to significantly
reduced Sphk2, results in down-regulated SFK expression and activity, and
decreased S1PR1 and S1PR4 down-regulate Gi/Rac GTPase signalling in ITP-
MKs. Therefore, abnormal S1P/S1PR possibly plays a role in the pathogenesis
of impaired PPF in ITP, which may be therapeutically regulated by ATRA.
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ANTIBODY MEDIATED GLYCAN MODIFICATION: A POTENTIAL ROLE IN
PLATELET DESTRUCTION IN AUTOIMMUNE THROMBOCYTOPENIA 
I. Marini1,*, R. Jouni1, J. Alex2, A. Greinacher2, T. Bakchoul1
1Center for Clinical Transfusion Medicine, University Hospital of Tübingen ,
Tübingen, 2Transfusion Medicine , Universitätsmedizin Greifswald, Greifswald,
Germany
Background: Immune thrombocytopenia (ITP) is a bleeding disease caused
by autoantibodies (AAbs) directed against platelet (PLT) glycoproteins (GP). A
novel mechanism of antibody-mediated PLT destruction based on Fc-indepen-
dent PLT clearance via Ashwell-Morell receptors (AMRs), which recognize gly-
can modifications on the surface of PLTs, has been suggested in mice.
Aims: In this study we investigated the effects of human AAbs from ITP patients
on the glycan pattern of human PLTs and the consequent impact on their sur-
vival in vivo.
Methods: Monoclonal platelet antigen capture assay (MAIPA) and lectin binding
assay (LBA) were used to analyzed sera from ITP patients and healthy donors.
In LBA, after incubation with sera and PLTs from healthy donors, the modifica-
tion in glycan pattern was investigated by flow cytometry using lectins; Ricinus
communis agglutinin (RCA), Erythrina cristagalli lectin (ECL) and Peanut agglu-
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tinin (PNA) that bind to galactose, N-acetyllactosamine and N-acetylgalac-
tosamine residues, respectively. The NOD/SCID mouse model was used to
study the impact of different glycan patterns on the survival of human PLTs.
Results: In this work 37 sera from ITP patients and 25 sera from healthy donors
were analyzed. In the LBA, after incubation with AAbs, different patterns of gly-
can modification were observed. 17/37 sera caused a significant increase in
PNA binding compared to heathy donors: (median fold increase (FI): 1.21,
range: 1.08 – 1.40). 9/37 sera induced higher ECL binding (median FI: 1.02,
range: 1.08 – 1.15). In contrast, 8/37 sera showed strong decrease in RCA
binding (median FI: 0.52, range: 0.50 – 0.59). Sera from healthy donors did
not induced significant change. Interestingly, not only GP-Ib/IX AAbs but also
GPIIb/IIIa AAbs were able to modify glycan pattern. In NOD/SCID mice the
administration of AAbs induced an accelerated clearance of human PLTs from
the circulation. The destruction of human PLTs by ITP-AAbs was decreased
but not completely prevented by a specific neuraminidase inhibitor that blocks
glycan changes on PLT surface (survival of human PLTs after 5h: 48%, range
41-53% vs 29%, range 22-40%).
Summary/Conclusions: Our results demonstrate that AAbs from ITP patients
are able to induce cleavage of glycan moieties on the PLT surface in distinct
manners. Antibody-mediated modification of glycan patterns seems to con-
tribute to AAb-mediated PLT destruction.
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NOVEL RUNX1 MUTATIONS IN FAMILIES WITH INHERITED
THROMBOCYTOPENIA
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Background: Familial platelet disorder with propensity to acute myeloid leukemia
(FPD/AML) is a rare autosomal dominant inherited thrombocytopenia (IT) caused
by mutations in the hematopoietic transcription factor RUNX1; an important hall-
mark of this IT is the increased risk of developing myeloid neoplasms, such as
AML and myelodysplastic syndromes (MDS). FPD/AML is caused by different
mutations of RUNX1 encoding the DNA binding subunit (known as core binding
factor-alpha, CBF-alpha) of the CBF transcription complex. The N-terminus
domain of RUNX1 (runt-homologous domain) mediates DNA binding and het-
erodimerization to CBF-beta, the other subunit of the CBF complex. The C-ter-
minus of RUNX1 includes domains that are involved in transcription activation
and repression. This IT is characterized by impaired megakaryopoiesis and mod-
erate thrombocytopenia, with normal-sized and dysfunctional platelets. 
Aims: To unravel the molecular basis of ITs and to improve our knowledge on
the molecular basis and clinical-laboratory picture of FPD/AML.
Methods: Whole exome sequencing (WES) was performed in 86 propositi with
an unknown IT after the diagnostic workup based on the most updated diag-
nostic algorithm for ITs (Clin Genet 2016;89:141). RUNX1 variants detected
by WES were confirmed by Sanger sequencing in the propositi and all available
family members, which also undergo clinical-laboratory characterization. The
study was approved by the Institutional Review Board of the IRCCS Policlinico
S. Matteo Foundation; all patients gave written informed consent.
Results: We identified three pedigrees (families 1-3) with different RUNX1 het-
erozygous mutations, all segregating with thrombocytopenia in the respective
families: the novel variants c.578T>A and c.967+2_5del, and the known
c.351+1G>A. The thirteen individuals carrying the RUNX1 mutations had mild
thrombocytopenia (platelet count ranging from 70 to 130 x 109/L) with mild
bleeding tendency. Platelet sizes were within the normal range in all the six
patients analyzed, and the serum level of thrombopoietin was normal or mod-
erately increased. No specific morphological alteration of platelets was detect-
ed, except for moderate reduction in the alpha-granule content in family 1, con-
firmed by immunofluorescence analysis. The surface expression of the major
platelet glycoprotein (GP) complexes GPIIb-IIIa and GPIb-IX-V was normal. In
family 1 a moderate reduction of GPIa-IIa was detected, regardless of geno-
types at the ITGA2 locus. A defective aggregation was detected after platelet
stimulation with collagen 4 mcg/ml and ADP 2 mcM in the five patients inves-
tigated; normal responses were obtained using collagen 20 mcg/mL, ADP 20
mcM and ristocetin 1.5 mg/mL, suggesting mild functional platelets defects. Of
note, three patients from two families developed AML, with a prevalence lower
than reported in literature, probably because of a different criteria of enrolment
(RUNX1 germline mutations are usually searched in ITs associated with AML).
No solid/hematological cancer was reported in family 1.
Summary/Conclusions: FPD/AML is an IT lacking pathognomonic laboratory
criteria: it is characterized by a mild functional defect and, much more impor-
tantly, by a normal platelet size, similarly to the other ITs predisposing to hema-
tological malignancies (ANKRD26 and ETV6-related thrombocytopenias). Giv-
en the importance of recognizing these diseases for patients counseling, fol-
low-up, and therapeutic approach, we recommend a systematic screening for
RUNX1, ANKRD26, and ETV6 mutations in all patients with an autosomal




A SINGLE-ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY
STUDY OF SUBCUTANEOUS ROMIPLOSTIM IN CHILDREN WITH IMMUNE
THROMBOCYTOPENIA
J. Grainger1,*, J. Bussel2, N. Cooper3, M. Tarantino4, V. Blanchette5,
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Background: The use of romiplostim in children with ITP has been evaluated
in phase 1/2 and 3 studies. Here we describe children with ITP who will receive
open-label SC romiplostim for up to 3 years (y).
Aims: To assess platelet responses in children with ITP receiving romiplostim.
Methods: Eligible children, recruited in 16 countries worldwide, had ITP for ≥6
months, ≥1 prior ITP therapy, and platelet (plt) counts ≤30×109/L. Weekly SC
dosing started at 1 μg/kg and was titrated in 1 μg/kg increments up to 10 μg/kg
to target plt counts of 50-200×109/L. The primary endpoint was the% of time
in the first 6 months with a plt response (plt count ≥50×109/L without rescue
medication use in the past 4 weeks).
Figure 1.
Results: As of 15 Mar 2016, 145 patients received ≥1 dose. At baseline, medi-
an (min-max) age was 10 (2-17) y; 51% were female; 4% had prior splenecto-
my. Median (min-max) ITP duration was 1.9 (0.5-12.3) y and plt count was
13 (2-168)×109/L. The median (Q1, Q3)% of time with a plt response in the
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first 6 months was 50% (0%, 83.3%); that of months 7-12 was 92% (33%,
100%). Overall, 80% (114/143) of patients had a plt response. The median
(Q1, Q3)% of time with an increase in plt counts ≥20×109/L above baseline
was 60% (25%, 84%). The median dose increased to 10 μg/kg by week 32.
Median (min-max) treatment duration to date was 25 (1-67) weeks for a total
exposure to date of 79 patient-years. Median (min-max) average weekly romi-
plostim dose over the course of the study was 6.1 (0.4-9.0) µg/kg. 32 patients
(22%) discontinued treatment for lack of efficacy (n=17), required other therapy
(n=5), patient request (n=4), noncompliance (n=2), adverse event (AE) (n=2)
(interstitial lung disease in a 15 y old boy and abdominal pain, vomiting, and
headache related to treatment per investigator in a 9 y old girl), administrative
decision (n=1), and investigator decision (n=1). 34 (23%) patients received res-
cue medications.  15 (10.3%) patients had serious AEs (SAEs) including epis-
taxis (n=4), petechiae (n=2), decreased plt count (n=2), and thrombocytopenia
(n=2). A case of abdominal pain was the only SAE deemed treatment-related
by the investigator. CTCAE grade 3 bleeding was seen in 8 patients (6%) and
included epistaxis (n=5), ecchymosis (n=2), petechiae (n=2), and 1 case each
of hematemesis, hematoma, SC hemorrhage, injection site hemorrhage, and
mouth hemorrhage. No grade 4 or 5 bleeding was observed. No neutralizing
antibodies against romiplostim or TPO were identified. Of 30 patients with base-
line bone marrow biopsies (bone marrow biopsies were obtained at European
sites), all had modified Bauermeister scores of grade 0 (no reticulin) or 1 (fine
fibers) and bone marrows typical for ITP. Of these 30 patients, 21 had evaluable
on-study biopsies obtained after ~1 year of treatment, with no increases in 2 or
more grades, findings of collagen, or bone marrow abnormalities (Figure 1).
Summary/Conclusions:
In this year 1 datacut of an ongoing open-label study of romiplostim in children
with ITP, the% of time in the first 6 months with a platelet response was 50%,
with 80% of children having a platelet response at some point on study. The
median romiplostim dose reached 10 μg/kg and there were no new safety sig-
nals. No effects of romiplostim were observed on the bone marrow in the subset
of patients with bone marrow biopsies. Future datacuts for years 2 and 3 in this
study, the largest of romiplostim in children with ITP with 79 patient-years of
exposure to date, will provide more information on platelet response, dose
requirements, and safety.
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NOVEL THIENOPYRIDINES AS POTENT PLATELET INHIBITORS: FUTURE
TREATMENTS FOR PLATELET HYPERACTIVITY DISORDERS?
N. Binsaleh1,*, C. Wigley1, K. Whitehead1, D. Moreno-Martinez1, S. Daniels1,
S. Jones1, M. van Rensburg2, L. Pilkington2, D. Barker2, N. Dempsey-Hibbert1
1School of Healthcare Science, Manchester Metropolitan University, Manches-
ter, United Kingdom, 2School of Chemical Sciences, University of Auckland,
Auckland, New Zealand
Background: Platelet hyperactivity is associated with a number of disorders
including Acute Coronary Syndromes (ACS) and manifests as increased platelet
activation and often inappropriate thrombus formation. The thienopyridine class
of anti-platelet drugs, of which clopidogrel and prasurgrel are the most well
known, target the P2Y12 receptor on platelets, blocking the effects of the platelet
agonist ADP. However, the effect of these drugs is variable amongst patients,
with some patients responding well and some remaining at risk of thrombosis.
This variability highlights a need for a refinement of this class of P2Y12 inhibitor.
Aims: The aim of this study was to assess the efficacy of six novel thienopyri-
dine derivatives synthesized by our group by examining their potential as in-
vitro inhibitors of platelet function.
Methods: Healthy human platelets were isolated and incubated with novel
thienopyridine compounds (DJ0081, DJ0199, DJ0021, DJ0206, DJ0171,
DJ0097) (10µM, 30min) prior to stimulation with ADP (10µM) and analysis of
alpha granule secretion (CD62P expression), GPIIbIIIa activation (PAC1
expression) and platelet leukocyte aggregate (PLA) formation using flow cytom-
etry. Furthermore, light transmission aggregometry (LTA) was used to assess
ADP-stimulated aggregation after these treatments. As clopidogrel is usually
prescribed in combination with the COX-1 inhibitor acetylsalicylic acid (ASA),
synergy of the novel compounds with ASA (30µM) was also analysed by LTA.
All results were compared to ADP-stimulated samples and samples treated
with clopidogrel (10µM, 30min) prior to ADP stimulation.
Results: All six novel compounds demonstrated a significant reduction in ADP-
mediated platelet aggregation (P<0.001), CD62P expression (p<0.001), PAC1
expression (p<0.01) and PLA formation (p<0.05). These compounds were also
shown to enhance the inhibitory effects of ASA. DJ0171 and DJ0199 were par-
ticularly potent, displaying greater inhibitory effect than clopidogrel.
Summary/Conclusions: The study demonstrates the potential for new thienopy-
ridine compounds as modulators of platelet function and points to the possibility
of future use in patients at risk of platelet hyperactivity and thrombosis.
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PATIENT-REPORTED OUTCOMES AND HEALTHCARE RESOURCE
UTILIZATION BEFORE AND DURING TREATMENT WITH ECULIZUMAB:
RESULTS FROM THE INTERNATIONAL PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA REGISTRY
P. Muus1,*, S. Langemeijer1, B. Höchsmann2, A. Hill3, L. Arnold3, G. Tjønnfjord4,
B. Donato5, P. Gustovic6, A. Wilson5, J. Szer7
1Radboud University Medical Center, Nijmegen, Netherlands, 2Institute for Clin-
ical Transfusion Medicine and Immunogenetics, University Hospital Ulm, Ulm,
Germany, 3St. James’s University Hospital, Leeds, United Kingdom, 4Oslo Uni-
versity Hospital, Oslo, Norway, 5Alexion Pharmaceuticals, Inc., Lexington, MA,
United States, 6Alexion Pharma GmbH, Zurich, Switzerland, 7Royal Melbourne
Hospital and University of Melbourne, Melbourne, Australia
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease
caused by somatic phosphatidylinositol glycan class A (PIGA) gene mutation
in bone marrow stem cells. Clinical manifestations may include fatigue, abdom-
inal pain, dyspnea, dysphagia, erectile dysfunction, anemia, sudden hemoglobin
level reductions due to complement-induced hemolysis, and PNH-related com-
plications such as thrombosis, chronic kidney disease, and pulmonary hyper-
tension, all of which impair quality of life (QoL) and could impact survival.
Eculizumab, a humanized monoclonal antibody approved for treatment of PNH,
reduces intravascular hemolysis, thrombosis rates, and other PNH-associated
comorbidities. The International PNH Registry (NCT01374360) is an ongoing
prospective, multinational, observational study established to record the natural
history of patients with PNH and collect data on long-term efficacy and safety
of eculizumab treatment.
Aims: Analyze patient-reported outcomes (PRO) and healthcare resource uti-
lization (HRU) before and during eculizumab treatment.
Methods: Patient assessment questionnaire (PAQ) data for patients with PNH
who commenced eculizumab after Registry enrollment and had data available
as of August 1, 2016, were analyzed. Patients had to have non-missing data
on demographics, ≥1 recorded PAQ within 12 months prior to eculizumab ini-
tiation, and ≥1 PAQ recorded ≥6 months after initiation. Outcomes of interest
included changes in QoL assessments (Functional Assessment of Chronic Ill-
ness Therapy [FACIT]-Fatigue score; EORTC QLQ-C30 score, disease symp-
toms, Karnofsky Performance scale, HRU, and missed work days. 
Results: Of 4082 enrolled patients, 649 had non-missing data on demographics
and initiated treatment with eculizumab as of August 1, 2016; 229 patients
(55% female; 86% white; 74% from Europe) of the 649 met inclusion criteria
for the current analysis. Median (min, max) interval between PNH disease start
and initiation of treatment was 4.4 (0.1, 44.9) years. Clinically meaningful
improvement in FACIT-Fatigue score (≥4-point increase) was reported by 53%
of patients after initiating eculizumab (mean change, 5.2 points, Figure 1). Clin-
ically meaningful improvement (≥10-point increase) was also observed in
EORTC QLQ-C30 mean scores for global health/QoL (mean change, 15.1),
role functioning (16.3), emotional functioning (12.1), and social functioning
(13.9) subscales. PNH-related symptoms disappeared in 19–44% of patients
who reported the symptom prior to eculizumab across all assessed symptoms
except erectile dysfunction, which did not disappear in any of the 21 patients
who answered this question both before initiation and during eculizumab treat-
ment. Mean Karnofsky scale scores improved by 8.4 points after eculizumab
initiation. HRU decreased for emergency room visits and number of missed
work days while patients received eculizumab (incidence rate ratio [IRR] [95%
confidence interval (CI)], 0.33 [0.20, 0.54] and 0.48 [0.25, 0.93], respectively)
and increased for healthcare provider visits and hospital admissions (IRR [95%
CI], 1.47 [1.22, 1.77] and 1.17 [0.60, 2.27], respectively).
Figure 1.
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Summary/Conclusions: In this cohort of patients from the International PNH
Registry, treatment with eculizumab was associated with clinically meaningful
improvements in PROs, including assessments of fatigue, global health status,
patient functioning, and disease-related symptoms, as well as a decrease in
emergency room visits and number of missed work days.
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ECONOMIC IMPACT OF INTRODUCING AGE-ADJUSTED D-DIMER
CUT-OFF LEVELS IN THE DIAGNOSIS STRATEGY OF VENOUS
THROMBOEMBOLISM
P. Toulon1,*, N. De Pooter2, M. Brionne-François3, M. Smahi4, L. Abecassis5
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Background: The diagnosis of venous thromboembolism (VTE) can be safely
excluded in the case of D-dimer levels below a well defined cut-off level in
patients with a low or intermediate pre-test probability (PTP), as the test neg-
ative predictive value (NPV) is close to 100%. As ageing is associated with
increased D-dimer levels, the question arose whether D-dimer measurement
was useful to rule out VTE in elderly patients.
Aims: The aim of the present study was to evaluate the clinical performance
of a diagnosis strategy based on age-adjusted cut-off values calculated by
multiplying the patient’s age by 10 in patients aged over 50, and to evaluate its
economic impact.
Methods: We included 1255 consecutive outpatients with non-high PTP of VTE
referred to the emergency departments at 5 French centres (2 university hospi-
tals, and 3 general hospitals, in whom D-dimer testing was prescribed. The same
standardized procedure was used in the 5 centres i.e. D-dimer measurement in
patients with a non-high PTP, and imaging techniques (usually computed pul-
monary angiography in case of suspected PE and Doppler ultrasonography in
case of suspected DVT) in the case of D-dimer above the cut-off level. D-dimer
levels were evaluated using the same fully automated latex-based assay (Hemo-
sIL D-dimer HS500, Instrumentation Laboratory), the usual cut-off level for VTE
exclusion being 500 ng/mL (fibrinogen equivalent units, FEU).
Results: VTE diagnosis was established by objective testing in 115 patients
(9.2%): 88 of the 1082 patients referred for suspected PE (8.1%) and 27 of the
173 patents referred for suspected DVT (15.6%). D-dimer levels were above
500 ng/mL in all patients with VTE and in 521 of the 1140 patients without VTE
(45.7%), leading to test NPV and sensitivity of 100%. The overall test specificity
was 54.3%, even though it significantly decreased in an age-dependent manner
over 60 years old. This is due to increased D-dimer levels in older patients par-
ticularly in those above 80 years. Using age-adjusted cut-off levels, calculated
by multiplying the patient’s age by 10, significantly improved the overall test
specificity (60.2%). The NPV remained high (99.9%), even though a 78 y-old
female with a low PTP of PE would have been misdiagnosed as her D-dimer
level (540 ng/mL) was above 500 ng/mL but below the age-adjusted cut-off
value. Such an improvement in test performance was found both in patients
with suspected PE and DVT (Table). As such an increase in test specificity
would have led to exclude VTE in a higher percentage of patients in the studied
population, we evaluated the cost-effectiveness of both strategies, taking into
account the local reimbursement rates of D-dimer testing, angiography and
Doppler ultrasonography (16.20, 58.72, and 75.60 Euros respectively). The
economic impact of the proposed diagnosis strategy was a decreased of 6.9%
of total costs (45,023.4 vs 48,356.4 Euros) for PE diagnosis and 5.1% (9,909
vs 10,438.2 Euros) for DVT. If such an analysis was used in the US, where
angiography and Doppler US were more expensive (648 and 226 US$ respec-
tively), and D-dimer less costly (14 US$), the cost savings would have been
even higher (-11.0% for PE, and -6.3% for DVT). 
Summary/Conclusions: The use of age-adjusted cut-off levels for D-dimer,
in patients aged over 50 years old, led to a significant increase in the test speci-
ficity, but correlatively to slightly decreased NPV and sensitivity. Even though
some patients with D-dimer levels above 500 ng/mL but below the age-adjusted
cut-off value could be misdiagnosed, such a strategy was found to be safe in
our studied population with a high NPV (99.9%) and sensitivity (99.1%), and
cost-effective.
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IMPACT OF CELLULAR THERAPY ON THE ECONOMIC BURDEN AND
SURVIVAL FOLLOWING RELAPSE AFTER HLA IDENTICAL HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA AND
MYELODYSPLASTIC SYNDROME
S. Lachance1,*, J. Bibeau2, N. Ladjemil3, J. Lachaine4
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Background: Relapse following allogeneic hematopoietic stem cell transplant
(aHSCT) is associated to a very poor outcome and remains an unmet medical
needs. The impact of treatment approach on costs and survival remains
unknown. The development of innovative cellular therapy for the treatment of
relapse following aHSCT may change its dismal outcome but the cost of such
intervention has prohibited its large-scale development. 
Aims: The objective of this study was to measure the economic burden asso-
ciated with the management of relapse following aHSCT and to evaluate the
impact of treatment choice on survival and health care costs.  
Methods: A retrospective medical chart review was conducted at Maison-
neuve-Rosemont Hospital (HMR) after research and ethic committee approval.
Patients were selected using the Hematopoietic Stem Cell Transplant (HSCT)
program database. Eligible patients were diagnosed with acute leukemia (AL)
or MDS and relapsed following a HLA identical aHSCT between January 1st
2011 and December 31st 2014. Patients’ and disease characteristics and
relapse-related health care resource utilization were collected from the date of
post transplant relapse until death or last follow-up. Canadian unit costs for
each intervention/treatment were obtained from literature and governmental
publications.
Results: During the study period, 645 HSCT were performed at HMR, 303
were allogeneic. A total of 36 patients met the inclusion criteria and were includ-
ed in the analysis. 32 recipients were diagnosed with AL and 4 with MDS.
Treatment approaches following aHSCT relapse were divided in three groups
according to patient and physician choices: group 1 received supportive care
(n=9), group 2 received chemotherapy or tyrosine kinase inhibitors (n=21) and
group 3 received a cellular based therapy, either donor lymphocyte infusion
(DLI) or a second aHSCT (n=6). The mean cost of care per patient per month
was C$20,239 (SD=17,079). The median survival following relapse for the
entire cohort was 12.4 months (SD=2.8).  For group 1, 2 and 3, the mean cost
of care per patient per month was C$17,436 (SD=16,447), C$22,914
(SD=18,474) and C$15,082 (SD=12,954), respectively. The median survival
was 4.0 months (SD=2.0), 7.2 months (SD=1.6), and 44.6 months (SD=8.4),
for treatment group 1,2 and 3 respectively (Figure1).
Figure 1. Survival according to treatment group.
Summary/Conclusions: Relapse following AHSCT is associated to a poor prog-
nosis and survival and to significant use of health care resources. Despite the
selection bias, only patients who received cellular based therapy, either DLI or
another HSCT, enjoyed a prolonged survival. Healthcare resources devoted to
the care of patients in relapse post AHSCT provide a comparative basis for cost
efficiency analysis in the development of innovative cellular therapy.
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ACUTE MYELOID LEUKEMIA TREATMENT PRACTICE PATTERNS,
HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS IN A US
COMMERCIALLY-INSURED POPULATION
M. Hagiwara1,*, A. Sharma1, K. Chung2, T. E. Delea1
1Policy Analysis Inc., Brookline, MA, 2Jazz Pharmaceuticals, Palo Alto, CA,
United States
Background: AML is a rapidly progressive hematologic malignancy that
accounts for 25% of adult leukemias in the Western world, with an estimated
5-year survival of 26%, and is associated with high HRU and costs.
Aims: To estimate HRU and costs among newly-diagnosed AML patients (pts)
in a US commercially insured population by receipt of chemotherapy (CT) or
stem cell transplant (SCT).
Methods: This was a retrospective observational study using the PharMetrics
Plus® database. Pts were adults with AML (ICD-9-CM code 205.0x and corre-
sponding ICD-10-CM codes) diagnosed between Jan 2007 and Jun 2016
(study period). Pts were excluded if: first AML claim was for remission/relapse;
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not continuously enrolled for 12-months (mos) before the first AML claim (index
date); evidence of acute promyelocytic leukemia anytime during the study peri-
od; missing enrollment information; or ≥1 hospitalizations during follow-up (FU)
with missing cost. Pts were classified as treated or untreated, with treatment
defined based on receipt of CT (inpatient or outpatient) or SCT. For treated pts,
FU was partitioned into 2 periods: index date to 6 mos and >6 mos post index
date. Mean HRU and costs over the FU period were calculated by receipt of
treatment and, for treated pts, by time since index date.
Results: 10,197 pts met study criteria including 6,862 treated pts (67%) and
3,335 untreated pts (33%). Mean age was 55 and 60 years in treated and
untreated pts, respectively. Mean follow-up was 19.3 mos in treated pts and
18.1 mos in untreated pts. Mean total costs were higher for treated pts
($386,711) vs untreated pts ($83,274). In treated pts, mean total costs were
$166,156 during the first 6 mos (mean duration 3.9 mos), and $220, 555 during
the remaining follow-up period (mean duration 19 mos). 26% of treated pts had
SCT. Costs of inpatient and outpatient CT during the first 6 mos were $86,188,
representing 22% of the total cost for treated pts (Table 1).
Table 1.
Summary/Conclusions: HRU and costs of managing AML pts are consider-
able, with greatest HRU and cost in pts receiving CT or SCT.
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HEALTH-RELATED QUALITY OF LIFE IN AL AMYLOIDOSIS PATIENTS
WITH NERVOUS SYSTEM INVOLVEMENT 
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M. Bayliss1
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Background: In light chain (AL) amyloidosis, misfolded light chains accumulate
and cause progressive peripheral neuropathy (PN) and failure of critical organs
such as the heart and kidneys. Consequently, a progressive, ascending sen-
sorimotor neuropathy is often a related clinical finding.
Aims: This study describes disease characteristics and health-related quality
of life (HRQoL) in AL amyloidosis patients with peripheral nerve involvement
(AL-PN).
Methods: An online survey was administered to AL-PN (n=126) and non-
nerve–affected (n=215) patients to assess patient characteristics and HRQoL
(based on the SF-36v2® Health Survey [SF-36v2]). The survey measures
eight domains including physical functioning (PF), role physical (RP) due to
health-related physical limitations, bodily pain (BP), general health (GH), vital-
ity (VT), social functioning (SF), role emotional (RE), mental health (MH), in
addition to physical (PCS) and mental component summary (MCS) measures.
Patient characteristics were compared using chi-square tests. Differences in
symptomatic and HRQoL burden were tested with multivariable logistic and
linear models, respectively. Differences in mean HRQoL between AL-PN and
non-AL-PN patients were compared to established minimally important dif-
ferences (MIDs).
Results: Compared to non-nerve–affected patients, greater proportions of AL-
PN patients visited ≥6 doctors (42.1 vs 19.5%, p <0.001) and ≥6 specialists
(24.6 vs 9.9%, p <0.001). AL-PN patients also had symptoms for ≥1 year prior
to receiving a diagnosis (50.8 vs 39.1%, p=0.035), relative to non-nerve–affect-
ed patients. Nearly all AL-PN patients (97.6%) reported multi-system involve-
ment. Gastrointestinal involvement was more prevalent in AL-PN patients ver-
sus non-AL-PN patients (68.3 vs 28.8%, p <0.001). There were greater odds
of experiencing numbness (OR=4.23, 95% CI: 2.45–7.30, p <0.001) and fatigue
(OR=3.09, 95% CI: 1.36–7.02, p <0.01) among AL-PN patients as compared
to non-AL-PN patients, even after controlling for other types of organ involve-
ment. Similar findings were observed for gastrointestinal symptoms, such as
alternating bouts of constipation or diarrhea (OR=1.92, 95% CI: 1.12–3.34,
p=0.019) and early satiety/feeling fullness in the stomach (OR=1.80, 95% CI:
1.03–3.16, p=0.04). With the exception of RE, MH, and MCS, there were sig-
nificant differences in SF-36v2 scores among AL-PN patients as compared to
non-AL-PN patients (p <0.05 for all). These significant differences also exceed-
ed the thresholds for clinically meaningful differences between the two groups.
Summary/Conclusions: This study suggests that the burden of illness from
AL amyloidosis may be greater for those with PN involvement versus those
without. AL-PN patients also experienced more complicated journeys to diag-
nosis and significantly worse symptoms related to nervous systems and phys-
ical HRQoL. The SF36v2, a reliable and valid assessment of HRQoL in AL
amyloidosis studies, was sensitive to differences in HRQoL between AL-PN
and non-AL-PN patients. Future research should examine whether improve-
ments in neuropathy symptoms following treatment subsequently lead to
improvements in HRQoL among patients with AL-PN. These findings are helpful
for patient-focused drug development and supportive treatments.
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ACCESS TO COMMUNITY CHEMOTHERAPY IMPROVES PATIENT
QUALITY OF LIFE
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Background: Deciding how services for people with haematological cancers
are to be delivered is going to be an important challenge in the coming years.
Clinics have limited clinic capacity in terms of staff and bed space to cope with
increased demand. In Wales many day units are already at capacity, over-
crowded and have long waits for treatment. Ambulatory care, including diagno-
sis, observation, consultation, intervention, and rehabilitation, has the potential
to improve the patient experience, if traditionally-based hospital services are
moved into the community. We used a Mobile Unit – a 34-tonne articulated
lorry which opens out to become a bespoke clinical space - to deliver treatments
in a community setting to a range of haematology patients for a period of 12
months in South Wales.
Aims: We aimed to explore whether the administration of cytotoxic therapy on
a Mobile Unit in a community setting for patients with haematological cancers
could prove to be a safe and efficient alternative to hospital therapy, and in par-
ticular whether this model of service delivery would be acceptable to patients.
Our target group was patients with myeloma, aiming for up to 20 a day once or
twice a week.
Methods: The first drugs administered on the Mobile Unit were zoledronate
infusions, followed by bortezomib. When twice weekly doses were required,
patients collected an additional injection pack which they could self-administer
in their own homes, thereby saving another trip into hospital. Immunoglobulin
infusions, taking between 1-2 hours, were also administered. There was a con-
sultant review clinic on board for patients receiving bortezomib which further
reduced the numbers of hospital visits for patients and also a nurse-led Quality
of Life clinic.
Results: In one year 548 treatments were administered on 91 days to a total
of 54 individual patients. All 54 patients had a diagnosis of myeloma. 56% are
female and 44% are male with an age range of 46 to 90 years of age, with 48%
over 70 years of age. 37 patients are married and all but 4 classed themselves
as White British. The greatest number of patients treated in a single day was
16. Patient experience was measured using self-administered questionnaires
which 50 patients completed. 100% of patients thought it was convenient or
extremely convenient having their treatment on a Mobile Unit. 98% felt safe
having their treatment outside hospital and 92% said their experience was
better than hospital. Patients could drive right up to the door of the Mobile Unit
and the average time waiting from arrival to treatment chair was 2 minutes,
with many people not having to wait at all. Uptake of the psychosocial support
services was lower than expected with only 10 people opting for additional sup-
port. Any criticisms received focused on the locations we chose to site the
Mobile Unit in relation to accessibility via public transport.
Summary/Conclusions: Treatment in the community alleviates the stress of
treatment and with minimal waiting times it gives some patients the ability to
maintain family life and where possible to continue to work. It is both feasible
and acceptable to begin to ambulate many different sorts of treatments. The
possibilities opening up for haematology include rituximab maintenance; com-
munity blood transfusions; delivering pentamidine for patients at risk of pneu-
mocystis infection; late effects clinics for teenage and young adult cancer
patients; and myeloproliferative neoplasm clinics, possibly near community
pharmacies to facilitate dispensing medicines such as hydroxycarbamide.
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THE BUDGET IMPACT OF TREATMENT-FREE REMISSION FOR FIRST-
LINE NILOTINIB OR GENERIC IMATINIB IN TREATING CHRONIC PHASE
PHILADELPHIA-POSITIVE CHRONIC MYELOID LEUKEMIA
D. Tran1, S. Brown1, N. Goyert1, P. Brandt2,*, D. Grima1
1Cornerstone Research Institute, Burlington, Canada, 2Global Value & Access,
Novartis Pharmaceuticals Corporation, East Hanover, United States
Background: The 2013 European LeukemiaNet (ELN) guidelines recommend
switching from first-line therapy as early as 6 months with poor molecular
response (MR). They also recognize the possibility of treatment-free remission
(TFR), requiring deep MR (MR4 or MR4.5). These emerging shifts in practice
will dramatically change chronic myeloid leukemia (CML) treatment patterns.
Occurring in parallel to this is the introduction of generic imatinib in Europe,
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which will have a substantial price difference compared with nilotinib. However,
given the possible changes in switching patterns and use of TFR, this price dif-
ference may not translate into a similar magnitude of difference in drug budget
for first-line nilotinib vs imatinib due to better MR with nilotinib.   
Aims: To estimate the budget impact for first-line nilotinib vs imatinib when
considering generic imatinib pricing, early treatment-switching, and TFR.
Methods: A state transition model was developed to project the impact of ELN
switching and TFR use on clinical outcomes and treatment costs. Analyses
were run for 1000 patients with newly diagnosed CML, starting either nilotinib
or imatinib, over a 5-year time horizon and using French drug pricing. It was
assumed that all patients in the model would switch therapy (imatinib to nilotinib,
and nilotinib to dasatinib) based on the failure criteria of the ELN guidelines.
As such, ENESTnd trial data were re-analyzed to estimate switching based on
MR. The model assumed that patients could enter first-line or second-line TFR
after 36 months of continuous therapy where the last 12 months were at MR4.5.
Duration of first-line or second-line TFR was based on an extrapolation of
ENESTfreedom and ENESTop treatment-free survival curves, respectively.
Monthly drug costs were €2,952 for first-line nilotinib and €1,063 for generic
imatinib, assuming a 50% discount to brand pricing.
Results: A greater number of patients in the first-line nilotinib arm remained
on first-line therapy (690 vs 479 at 15 mos., and 542 vs 368 at 60 mos.);
achieved MR4.5 on first-line therapy (442 vs 248 by 60 mos.); entered TFR on
first-line therapy (347 vs 183 by 60 mos.); entered TFR on either first- or sec-
ond-line (494 vs 400 by 60 mos.); and was in any TFR at 60 months (293 vs
200). The incremental budget impact per patient for first-line nilotinib vs imatinib
decreased each year from €16,482 in Year 1 to €377 in Year 5. Overall, the
64% lower drug acquisition costs per month of imatinib (€1,063) vs nilotinib
(€2,952) provided only a 17% lower total budget impact over five years
(€141,204 vs €170,002) per patient.
Summary/Conclusions: Results from the model considered more switching
as per 2013 ELN guidelines, which resulted in greater and quicker switching
than observed in ENESTnd. Overall, it was projected that compared with ima-
tinib, patients who receive first-line nilotinib would have earlier and more sus-
tained molecular response-requirements for TFR eligibility—and be subject to
less treatment-switching. The model projected that less than 50% of patients
would remain on first-line imatinib at 15 months. This would significantly reduce
the budget benefits of a lower imatinib acquisition price. The budget impact
between first-line imatinib and nilotinib would be further reduced by TFR, which
occurred in the model more frequently in the nilotinib group. The superior effi-
cacy of nilotinib and the associated differences in switching and TFR eligibility
are predicted to substantially offset the lower unit cost for generic imatinib.
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GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER
PATIENTS (>65 YEARS) DIAGNOSED WITH HEMATOLOGICAL
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Background: The Geriatric Assessment in Hematology (GAH) scale is a newly
developed tool that is intended to be an ancillary questionnaire to better cate-
gorize older patients diagnosed with common hematological neoplasms for
intensive treatment in routine clinical practice. It is a brief (<12 min) and easy
instrument, which takes into account 8 dimensions of geriatric assessment that
were initially dichotomized into 0 or 1. The GAH scale has recently been shown
to be psychometrically valid, responsive to clinical change, and able to predict
survival.
Aims: To determine the weights for each dimension of the GAH scale and the
cut-off points for the scale to be used as a tool to predict treatment tolerability
in older patients diagnosed with myelodysplastic syndrome / acute myeloblastic
leukemia, multiple myeloma, or chronic lymphocytic leukemia.
Methods: This was a multicenter, retrospective, observational study conducted
at 14 Spanish sites. Prior participants of the GAH study were given treatment
within 3 months after having completed the GAH scale were eligible for inclu-
sion after giving informed consent.
A logistic regression model and a full multiple linear regression model were
calculated to determine the weights for each dimension to find out its contribu-
tion to the final score; the ROC curve analysis was used to calculate the cut-
off points that defined three groups: “go-on” (low probability to develop toxicity
regardless of intensive or attenuated therapy), “slow-go” (high probability to
develop toxicity with intensive therapy but low probability with attenuated ther-
apy), and “no-go” (high probability to develop toxicity regardless of therapy).
Results: A total of 108 patients (women, 53.7%; median age [IQR], 78 [73-83]
years) out of 360 included in the main study were evaluated. During treatment
administration, 61 (56.5%) patients developed treatment-related toxicities,
requiring discontinuation/modification of the initial therapy. The coefficients for
the dimensions are: 7 for number of drugs, -10 for gait speed, 2 for mood, 23
for activities of daily living, 6 for subjective health status, 27 for nutrition, -5 for
mental status, and 1 for comorbidities. The sum of the GAH scale score, ranging
from 0 to 66, plus a factor derived from the treatment intensity (34 points for
intensive therapy or 0 for attenuated) leads to a maximum score of 100 points,
with a cut-off point set at 47. Figure 1 shows the GAH scale score for treatment
toxicity prediction and the classification of patients according to their score.
Among the 97 (89.8%) patients that received intensive therapy, 26 patients
were classified as go-on, 48 as slow-go, and 23 as no-go. The proportion of
patients that developed toxicities for each group was 34.6%, 56.3%, and 78.3%,
respectively with a statistically significant difference (P=0.002).
Figure 1.
Summary/Conclusions: The GAH scale appears to have the potential to give
guidance for election of individual treatment regimens. By identifying elderly
patients at high risk to develop toxicities, it may help to choose low-toxicity
combinations, to avoid harmful therapies and to identify those patients that
could benefit from more intensive treatment. Nonetheless prospective studies
with larger populations should be performed to confirm these findings and to
try to determine particular cut-off points for different diseases.
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NUTRITIONAL NEEDS AND PREFERENCES OF MYELOPROLIFERATIVE
NEOPLASM PATIENTS: PHASE IA OF THE NUTRIENT STUDY
R. Scherber1,2,*, H. Geyer3, A. Dueck4, C. Johnston5, B. Langlais4, L. Padrnos1,
J. Palmer1, A. Fleischman6, R. Mesa1
1Hematology and Oncology, Mayo Clinic, Scottsdale, 2Hematology and Oncol-
ogy, Oregon Health and Science University, Portland, 3Internal Medicine, 4Bio-
statistics, Mayo Clinic, Scottsdale, 5Arizona State University, Phoenix, 6Hema-
tology and Oncology, University of California, Irvine, Irvine, United States
Background: Cachexia, weight loss, and malnutrition in cancer patients are
important contributors of adverse outcomes of cancer patients. MPN patients
have abnormal cytokine expression (e.g., IL-1, IL-6, IL-8, and TNF-a) that con-
tributes to symptom burden (e.g., fatigue, pruritus, night sweats, bone pain)
and nutritional deficiencies (e,g., hypocholesterolemia, hypoalbuminemia,
weight loss). Diets rich in fruits, vegetables, legumes, whole grains, fish, nuts,
and low-fat dairy products are associated with a decrease in inflammatory (e.g.,
TNF-a, IL-6, and CRP) and thrombotic markers (e.g., homocysteine, fibrinogen;
Chrysohoou 2004, Smidowicz 2015). To date, no studies have evaluated the
nutritional needs or preferences of MPN patients in regards to dietary change.
Aims: The aim of this project was to determine the nutritional needs and prefer-
ences that will help inform the creation of a tailored MPN dietary intervention.
Methods: An internet-based survey was hosted by the Mayo Clinic Survey
Research Center and promoted on multiple MPN-based forums, Facebook
pages and websites during February of 2017. The survey included data on
demographics, MPN characteristics, nutritional habits, supplement use, and
symptom burden using the MPN-SAF TSS/MPN-10 (Emanuel 2012).
Results: Demographics and symptom burden: 919 international MPN patients
responded to the online survey of which 22.5% were diagnosed with MF, 37.1%
with PV, and 37.4% with ET. Respondents represented MPN patients from 37
countries, although the highest proportion of respondents were from the United
States (48.8%), United Kingdom (32.7%), Australia (6%), and Canada (3.6%).
Average MPN-SAF TSS score was 33.6 (SD=17). Dietary Habits: 22.5% of
patients endorsed having food allergies or intolerances (Table 1). 31.4% of
individuals followed a specific diet or had dietary restrictions. On average, MPN
patients ate 2.1 meals outside the home per week. Among those taking sup-
plements, 16.6% took supplements with the intent of reducing inflammation.
Half (47.5%) of these individuals felt that the supplements they used made
them feel better. Approximately 15% of respondents had tried alternative med-
icine to help treat their MPN. Among these, 44.8% were under the care of a
naturopath and 60.2% endorsed that their treatment plan included dietary
change. Nutritional Education Preferences: Overall, 34.4% of patients endorsed
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using diet to help control their symptoms or MPN disease. Patients most often
utilized books (28.2%), websites (27.1%), health care providers such as physi-
cians, NPs or naturopaths (28.2%), online forums (23.2%), friends (12.2%),
nutritionists(9.5%), phone or tablet applications (9.1%), or videos (4.2%) for
nutritional education. The vast majority (95.9%) of MPN patients endorsed
being willing to eat only certain foods if it helped to control symptom burden
and or could help their MPN to stabilize or reduce the risk of their MPN getting
worse (98.0%).
Table 1.
Summary/Conclusions: There remains an unmet need for symptom burden
improvement in low-risk MPN patients or among those who have reoccurrence
of symptoms while on JAK inhibitor therapy. Nutritional interventions for MPN
patients have not previously been investigated and have the potential to be
paired with traditional interventions to allow MPN patients to self-manage symp-
tom burden. This study represents the first evaluation of MPN-related nutritional
habits and preferences. These results will be used to inform the creation of an
MPN nutritional intervention with the goal of improving symptom burden and
reducing inflammation.
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DO PHYSICIANS NEED HELP TO ADEQUATELY INFORM AND SUPPORT
PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS FROM
A QUALITATIVE STUDY IN GREECE 
C. Karamanidou1,*, A. Xochelli1, V. Koutkias1, P. Ghia2, K. Stamatopoulos1
1Institute of Applied Biosciences, CERTH, Thessaloniki, Greece, 2Division of
Experimental Oncology and Department of Onco-Hematology, Università Vita-
Salute San Raffaele and IRCCS San Raffaele Scientific Institute, Milan, Italy
Background: Despite recent progress in prognostication and management,
chronic lymphocytic leukemia (CLL) remains unpredictable at diagnosis, while
virtually incurable, posing challenges to physicians on how to properly commu-
nicate the actual nature of the disease. Moreover, the great majority (~85%) of
patients do not need treatment at diagnosis, creating a major cognitive disso-
nance between the perception of leukemia diagnosis and the “wait & watch”
strategy usually applied, that may become a major reason of anxiety and quality
of life (QoL) impairment for patients and frustration for physicians. Evidently,
both patients and physicians need parameters that would allow co-decision
making tailored to each particular case.
Aims: To identify physicians’ needs in order to improve their communication
skills and thus facilitate CLL patient empowerment through a patient-centered-
ness model.
Methods: An in-depth qualitative study with semi-structured interviews was
conducted within hematologists (n=30) all over Greece. Data collection was
considered as completed when saturation was reached i.e. no new themes
emerged as assessed by the investigators. Content analysis was performed
separately by a hematologist and a health psychologist with 98% inter-rater
reliability score.
Results: None of the participants had ever received formal communication train-
ing but rather adopted the techniques of senior physicians or developed their
own through experience alone, thus frequently doubting their approaches
(n=12/30, 40%). The most popular communication technique mentioned was
adaptation of the quality and quantity of information provided according to each
patient’s characteristics (n=29/30, 96.7%); followed by the use of caregivers as
mediators for the communication of difficult issues (n=24/30, 80%); balance of
realism and hope (n=21/30, 70%); careful choice of wording (e.g. lymphocytosis
instead of leukemia) (n=18/30, 60%); gradual disclosure (n=17/30, 56.7%); and,
descriptions through pictorial representations or metaphors (n=16/30, 53.3%).
Even though physicians did not systematically assess patients’ anxiety and
depression levels, they often found themselves dealing with patients’ emotions
(n=29/30, 96.7%) through lengthy discussions. With regards to decision making,
some mentioned that physicians should make all the decisions (n=9/30, 30%)
and that patients are not always willing to take part in the decision-making process
(n=8/30, 26.7%), while others were keener on stirring patients towards a decision
(n=15/30, 50%), taking into account patients’ preferences (n=10/30, 33.3%). Most
physicians felt uncomfortable delivering bad news such as initial diagnosis,
relapse and poor prognosis (n=25/30, 83.3%). Self-reported needs included (i)
communication skills training (n=20/30, 66.7%); (ii) psychological support (n=7/30,
23.3%); and, (iii) working in a multidisciplinary team (n=8/30, 26.7%).
Summary/Conclusions: In the absence of structured communication guidance
there is great uncertainty among physicians concerning their skills on communi-
cating CLL nature and handling difficult situations, leading to distress endangering
their engagement in a healthy relationship with the patient. Additional studies are
warranted at European level for identifying physician needs in different countries
aiming at improving their communication skills to support and empower CLL
patients for participating in their own care and enhance their QoL.
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OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR PATIENTS WITH ACUTE LEUKEMIA ABOVE 70 YEARS OF
AGE: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE
EBMT
O. Ringdén1, A. Boumendil2, M. Labopin2, B. Sadeghi1, B. Savani3,
M. Mohty4, A. Nagler5,*
1LABMED, Translational Cell therapy Research, Karolinska Institutet, Stock-
holm, Sweden, 2Hôpital Saint Antoine, Paris, France, 3Division of Hematol-
ogy/Oncology, Medical Center Drive, Nashville, United States, 4Hôpital Saint
Antoine, Paris, France, 5Chaim Sheba Medical Center, , Tel-Hashomer, Israel
Background: The average age of patients (pts) with AML is about 67 years.
Historically, many of these pts were not considered as viable candidates for allo-
geneic transplantation (HCT) because of concerns about increased transplanta-
tion-related toxicity and excessive non-relapse mortality (NRM), a challenging
problem especially in older individuals. However the development of reduced-
intensity conditioning (RIC) regimens and the improvement in HCT supporting
care allowed the successful application of HCT in older pts with AML.
Aims: Compare outcome of allo SCT in acute myeloid leukemia AML patients
aged above 70 years with that of younger patients.
Methods: AML patients aged between 50 and 90 years old receiving a first or
second allo SCT between 2004 and 2014 with MSD or UD donor were included
in the study. Comparison of outcomes of patients aged above 70 with that of
patients between 50-70 years were performed for the whole group and sepa-
rately according to disease status at SCT (CR1, CR2, above).
Results: Altogether N=16874 pts were included in the study, N=713 were aged
above 70 years old (median 72, IQR 71-73) and N=16161 between 50 and 70
(median 59, IQR 55-63) . Older pts were more often male (62 vs 55%, p<0.001),
had more often secondary AML (42% vs 28%, p<0.001), more advanced dis-
ease (42% vs 27%, p<0.001), more often peripheral blood stem cell grafts (96
vs 91%, p<0.001), more often unrelated donors (79% vs 59%, p<0.001) and
poorer Karnofsky score (36% below 90 vs 29%, p<0.001), received more often
reduced intensity conditioning (80 vs 63%, p<0.001). Incidence of acute GVHD
II/IV, III/IV, chronic GVHD and relapse were the same in the two groups in mul-
tivariate analysis. Non-relapse mortality (NRM) at two years was 34% (95%CI
31%>38%) in pts above and 24% (25%>32%) in those below 70 years of age
(p<0.001). Overall survival and leukemia-free survival (LFS) at 2 years was
38% (95%CI 34-42) vs 50% (95%CI 49-50) p<0.001 and 33% (95%CI 29-37)
vs 44% (95%CI 43-45) in the two groups, respectively (p<0.001). Among pts
in CR1, 2 years survival was 43%(95%CI 37-51) vs 57%(95%CI 56-58)
(p<0.001), in CR2 it was 36% (95%CI 27-27) vs 52% (95%CI 50-54) (p=0.002)
and in advanced disease 35% (95%CI 29-41) vs 33% (95%CI 31-34) (p=0.36)
in pts above and below 70 years of age, respectively. Among pts older than 70
years of age a Karnofsky score <80% was associated with improved survival
and LFS in multivariate analysis (HR 0.7 95%CI 0.5-0.9 , p=0.005 and HR 0.7
95%CI 0.5-0.9 , p=0.003 respectively).
Summary/Conclusions: In AML with CR1, CR2 status at allo SCT, pts above
70 years of age have worse NRM, survival and LFS compared to pts 50-70
years of age. In pts above 70 years of age Karnofsky score is of significant
importance for outcome.
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BLOOD BAALC AND MN1 COPY NUMBER ASSESSMENT BY DIGITAL
DROPLET PCR PRIOR TO ALLOGENEIC TRANSPLANTATION PREDICTS
RELAPSE IN ACUTE MYELOID LEUKEMIA PATIENTS
M. Jentzsch1,*, M. Bill1, J. Schulz1, J. Grimm1, J. Häntschel1, S. Beinicke1,
K. Schubert1, W. Pönisch1, G. Behre1, G.-N. Franke1, T. Lange1, V. Vucinic1,
D. Niederwieser1, S. Schwind1
1Hämatologie und int. Onkologie, UNIVERSITÄTSKLINIKUM LEIPZIG, Leipzig,
Germany
Background: Acute myeloid leukemia (AML) patients (pts) that relapse after
allogeneic stem cell transplantation (HSCT) have a dismal prognosis. Identifi-
cation of pts at high risk of relapse may allow preemptive therapy & improve
outcomes. At diagnosis high expression of the AML associated genes BAALC
(brain and acute leukemia, cytoplasmic) & MN1 (meningioma 1) adversely
impact on AML pts outcomes, but little is known about their usability for residual
disease detection. Recently, we demonstrated a higher cumulative incidence
of relapse (CIR) for pts with high pre-HSCT BAALC copy numbers in 82 AML
pts (ASH 2016, #517). Until today no study assessed the prognostic impact of
MN1 copy numbers prior to HSCT.
Aims: To assess the prognostic impact of peripheral blood (PB) pre-HSCT
BAALC & MN1 copy numbers in an expanded set of AML pts in hematologic
CR using digital droplet (dd) PCR.
Methods: We identified 118 AML pts (median age at HSCT 64 [range 31-76]
years [y]) in first (55%) or second complete remission (CR; 23%) or CR with
incomplete recovery (22%) with PB prior to HSCT (median 7, range 0-29 days)
available. All pts received non-myeloablative (NMA) conditioning (fludarabine
3x30 mg & 200 cGy total body irradiation). At diagnosis karyotypes & NPM1,
CEBPA gene mutations (mut) & presence of FLT3-TKD & FLT3-ITD were
assessed. Quantification of BAALC & MN1 normalized to ABL1 copy numbers
in pre-HSCT PB of the AML pts & in PB of healthy controls (n=7, median age
63 [range 40-82]y) was performed by ddPCR. Median follow up after HSCT for
pts alive was 1.8y.
Results: European LeukemiaNet (ELN) 2010 classification was 20% favorable,
25% intermediate-I, 24% intermediate-II, 31% adverse. AML pts & healthy con-
trols did not differ in age (P=1), sex (P=1) or mean BAALC (P=.37, Figure 1A)
or MN1 (P=.96, Figure 1B) copy numbers. BAALC & MN1 copy numbers cor-
related well in pts (R=.80) & healthy controls (R=.75). The previously deter-
mined cut-off of 0.14 BAALC copy numbers (in 82 pts; ASH 2016, #517) defined
pts with high (27%) & low (73%) pre-HSCT BAALC copy numbers. A cut-off of
0.74 MN1 copy numbers was determined using the R package ‘OptimalCut-
points’ & defined pts with high (12%) & low (88%) pre-HSCT MN1 copy num-
bers. Applying these cut-offs, 71% of the pts had low BAALC & MN1 copy num-
bers & 10% had high BAALC & MN1 copy numbers, 2% had high MN1 but low
BAALC & 17% had high BAALC but low MN1 copy numbers. Pts with high &
low pre-HSCT MN1 copy numbers did not differ significantly in pre-treatment
characteristics or remission status at HSCT (CR vs CRi) while pts with high
pre-HSCT BAALC copy numbers were less often in CRi at HSCT (P=.02). Both
high pre-HSCT BAALC & MN1 copy numbers significantly associated with
higher CIR (P=.02, Figure 1C & P<.001, Figure 1D, respectively). In multivariate
analyses, high pre-HSCT BAALC (Hazard Ratio [HR] 2.5, Confidence Interval
[CI] 1.1-5.7, P<.001) & high pre-HSCT MN1 copy numbers (HR 5.6, CI 2.6-
12.2, P<.001) retained their prognostic impact on CIR after adjustment for ELN
2010 genetic risk groups.
Figure 1.
Summary/Conclusions: High pre-HSCT copy numbers of BAALC & MN1
associated with higher CIR in univariate & multivariate models and might indi-
cate residual disease burden in these AML pts. High copy number pts should
be closely monitored for relapse in the post-transplant period. Prospective clin-
ical trials are needed to validate the determined cut-offs, to evaluate if BAALC
or MN1 copy numbers or a combination of the genes represents the most suit-
able prognosticator pre-HSCT and whether AML pts with high pre-HSCT
BAALC or MN1 copy numbers benefit from additional pre- or post-HSCT treat-
ment.
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THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE
CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL
STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLO-
BINOPATHIES AND ERYTHROID DISORDERS
A. Bertaina1,*, P. Merli1, K. Mahadeo2, A. Woolfrey3, F. Galaverna1, M. Algeri1,
P. Merli1, D. Pagliara1, G. Li Pira1, A. Moseley4, J. Weinberg4, F. Locatelli1
1Ospedale Pediatrico Bambino Gesu, Rome, Italy, 2Childrens Hospital at Mon-
tefiore, Bronx, 3Fred Hutchinson cancer Research Center, Seattle, 4Bellicum
Pharmaceuticals Inc., Houston, United States
Background: Allogeneic HSCT from either an HLA-identical sibling or an unre-
lated donor is a potentially curative treatment for patients with hemoglo-
binopathies and erythroid disorders (ED), such as Thalassemia Major (TM),
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Sickle Cell Disease (SCD) and Diamond-Blackfan Anemia (DBA). Bertaina et
al (Blood, 2014) have previously shown that abTCR depleted haplo-transplan-
tation in children with multiple types of non-malignant disorders was feasible.
An ongoing Phase I/II trial evaluates the safety and efficacy of post-transplant
infusion of donor T-cells transduced with the iC9 suicide gene (BPX-501 cells).
(ClinicalTrials.gov identifier: NCT02065869). The iC9 vector contains
the sequence for the CD19 marker, so that the BPX-501 cells (CD3+/CD19+)
can be tracked in peripheral blood. We report on 15 children with hemoglo-
binopathies and ED.
Aims: This study was performed to determine the clinical impact of infusing
BPX-501 T cells post αβ T-cell depleted haplo-identical HSCT in pediatric
patients with hemoglobinopathies.
Methods: Fourteen patients were transplanted from a parent and one patient
was transplanted from a sibling. Conditioning regimen included busulfan,
thiotepa and fludarabine. Low dose ATG was administered to prevent graft-
versus-host disease (GvHD) and graft failure. No post-transplantation GvHD
prophylaxis was given. Median follow-up is 387 days (range 126-631 days).
Six patients were males and nine females, and median age at diagnosis and
at HSCT was 0.8 and 8.9 years (range 2.5-19.2), respectively. Two patients
had DBA and four with SCD. All 9 TM patients were βo/βo, and among the
those with TM, 4 patients belonged to class I and 3 to class II of the Pesaro
classification. All 15 patients were transfusion-dependent and receiving iron-
chelation therapy before haplo-HSCT. 13/15 patients maintained full donor
chimerism. The patients with secondary graft failure were re-transplanted from
the same donor and maintained full donor chimerism.
Results: All patients are alive and well with no Treatment Related Mortality
(TRM). Initial discharge was at a median of 23.5 days(range 14-55) and there
were two patients re-hospitalized at 30, 163 days respectively. Grade I/II skin
acute GvHD occurred in four patients and one patient had acute skin GvHD
Grade IV. No chronic GVHD was observed. Median time to neutrophil recovery
was 14 days (range 10-32 days), while median time to platelet recovery was
11 days (range 8-12 days). Median time to last RBC transfusion was 8 days (5
– 34 days). See Figure 1 for individual Hemoglobin levels. Median time of infu-
sion of 1x106 BPX-501 T cells/kg was 14 days after HSCT (range 10-26). BPX-
501 cells expanded after infusion and still persist in all patients. Immune recon-
stitution with normal cellular and humoral immunity present at 180 days post
HSCT. All patients remain transfusion-free with a median hemoglobin of 11 or
greater after 6 months.
Figure 1.
Summary/Conclusions: These data suggest that Haplo-HSCT combined with
infusion of BPX-501 T cells with a suicide gene may be a safe and curative
option for children with hemoglobinopathies and ED who lack a matched donor.
Infusion of gene modified T cells with an inducible suicide mechanism, com-
bined with selective αβ T-cell depletion, offers the potential to rapidly reverse
GvHD and eliminate the need for the use of GvHD prophylaxis. Additionally,
this approach results in rapid hematological and immune reconstitution for Hap-
lo-HSCT recipients.
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EXCELLENT RESPONSE, LOW TRM AND GOOD SURVIVAL IN PATIENTS
WITH THERAPY-REFRACTORY AGVHD AFTER TREATMENT WITH
EQUIPOTENT MSCS OF A SERUM-FREE MSC-BANK GENERATED FROM
POOLED BM-MNCS OF MULTIPLE DONORS
P. Bader1, Z. Kuci1, S. Bakhtiar1, O. Basu2, G. Bug3, M. Dennis4, J. Greil5,
K. Kállay6, P. Lang7, G. Lucchini8, R. Pol9, A. Schulz10, K.-W. Sykora11,
I. von Luettichau12, P. Remény13, L. Gopcsa13, A. Jarisch1, J. Soerensen1,
E. Salzmann1, E. Seifried14, T. Klingebiel1, H. Boenig14, S. Kuci1,*
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Manchester, United Kingdom, 5University Children’s Hospital Heidelberg, Hei-
delberg, Germany, 6Pediatric Hematology and Stem Cell Transplantation Unit,
United St István and St László Hospita, Budapest, Hungary, 7University Children’s
Hospital Tuebingen, Tuebingen, Germany, 8Department of Hematology/Oncology,
Great Ormond Street Hospital, London, 9Department of Hematology, University
of Sheffield, Sheffield, United Kingdom, 10University Children’s Hospital Ulm,
Ulm, 11University Children’s Hospital Hannover, Hannover, 12Division of Pediatric
Hematology/Oncology, Children’s Hospital Munich Schwaben, Technical Univer-
sity Munich, Munich, Germany, 13Adult HSCT Unit, Department of Hematology
and Stem Cell Transplantation, St. István and St. László Hospital, Budapest,
Hungary, 14German Red Cross Blood Center Frankfurt and Institute of Transfu-
sion Medicine and Immunohematology, Frankfurt, Germany
Background: All clinical data published thus far on the use of MSCs were gen-
erated using cells expanded from individual bone marrow donors hence suffer
from huge inter-donor differences in MSC generation, expansion and
immunomodulatory potential. To control these variables and to be able to admin-
ister to all patients highly similar MSC products, we established a proprietary
pooling procedure and generated a large bank of MSC end-of-passage-1 vials
from which end-of-passage-2 MSC products are expanded for clinical use. The
manufacturing process is fully GMP-compliant and generates an animal serum-
free MSC product with near-identical phenotype and in-vitro immunomodulatory
potency. Importantly, they showed a significantly higher allosuppressive poten-
tial than the mean allosuppressive potential of MSCs generated from individual
donors. All tested individual MSC doses were equipotent in suppression of the
alloantigen-driven reaction in mixed lymphocyte reactions (Kuçi et al. Haema-
tologica 2016: 101 (8); 985-994).
Aims: A “hospital exemption” issued by the national regulatory authority Pau-
Ehrlich-Institute (Number: PEI: A.11748.01.1) licenses the clinical use of these
products for patients with steroid refractory GVHD. On the basis of this licence
patients were with severe GVHD were treated who were either non responsive
to any other treatment or who were resistant steroids after 7 days.
Methods: Using these standardized MSC products altogether 52 patients were
treated between December 2014 and December 2016. Patients were male
(n=31, 60%) or female (n=21, 40%) and were transplanted for leukemia (n=38,
73%) or non-malignant (n=14, 27%) diseases. Median age was 8y (range: 0.5-
52 years). Stem cell source MSD (n=9, 17%), MUD (n=33, 63%) or MMFD
(n=10, 19%) and derived from BM (n=27, 52%), peripheral blood (n=24, 46%)
or cord blood (n=1, 2%). Patients were suffering from aGVHD grade II (n=3,
5.5%), III (n=14, 27%), or IV (n=31, 60%) or extensive cGVHD (n=4, 7.5%).
Acute GVHD occurred at a median time of 52 days (5-280 days) after transplant.
Patients received in weekly intervals up to four MSC infusions after having
failed to respond to the treatment with either two lines (n=10, 19%), three lines
(n=20, 38%), four lines (n=10, 19%), 5 lines (n=7, 13%), six lines (n=4, 8%), or
7 lines (n=1, 2%) of immune suppressive drugs.
Results: Response was defined as either complete response (CR) in patients
who showed complete resolution of all signs of GVHD, partial response (PR)
in patients who showed one overall GVHD grade less according to the Glucks-
berg criteria, or non response (NR) at day 28 after first MSC transfusion.
At day +28, 12 patients (23%) achieved CR, 29 patients (57%) PR (overall
response= 80%), 9 patients (17%) NR, and in 2 patients (4%) no data were
available at day +28. At the last follow up of GVHD, 29 patients (56%) were in
CR, 13 patents (25%) in PR, 9 patients (17%) in NR, and for 1 patient (2%) no
data were available. At 2 years these response rates resulted in a non-relapse
mortality rate (NRM) of 27±6%, cumulative relapse incidence (CIR) of 14±4%,
and an overall survival rate (OS) of 59±9%. Patients with aGVHD III and IV
had an OS survival probability at 2 years of 77±12% and 59±35%, respectively
thus dramatically in excess of expected survival rates for patients with such
severe aGvHD. There was no difference between younger (n=40) and older
patients (n=12) than 16 years.
Summary/Conclusions: Treatment with standardized equipotent MSCs from
the “FRANKFURT MSC-BANK” offers an excellent chance to overcome treat-
ment-resistant and steroid-refractory acute GVHD.
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HIGHER PEAK TACROLIMUS CONCENTRATIONS AFTER ALLOGENEIC
TRANSPLANTATION INCREASE THE RISK OF ENDOTHELIAL CELL
DAMAGE COMPLICATIONS
T. Morishita1,*, M. Ohbiki1, M. Osaki1, M. Yoshino1, S. Ikeno1, M. Nakashima1,
T. Sato1, Y. Kagaya1, Y. Ozawa1, K. Miyamura1
1Hematology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan
Background: Noninfectious transplantation-related complications (TRC) such
as GVHD and endothelial cell damage (TRC-EC) including sinusoidal obstructive
syndrome (SOS), transplant-associated microangiopathy (TAM), idiopathic pneu-
monia syndrome (IIP) are dismal complications after allogeneic hematopoietic
stem cell transplantation (allo-HSCT).Calcineurin inhibitors such as tacrolimus
(TAC) have been broadly utilized to manage post-transplant complications. Higher
blood levels of TAC were expected to reduce the risk of GVHD, but may increase
the risk of endothelial damage. Since TRC-EC often developed in patients with
GVHD, it is difficult to judge appropriateness of immunosuppression clinically. 
Aims: Here we evaluated the impact of TAC blood levels upon TRC-EC occur-
rence and prognosis after allo-HSCT.
Methods: Two hundred sixty-one consecutive patients (pts) who received TAC
as a GVHD prophylaxis after allo-HSCT at our institute from 2009 to 2015 were
candidates for this retrospective study. Pts who received haploidentical allo-HSCT
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and pts with unavailable TAC concentration data were excluded. A total of 253
pts was eligible. All pts received standard GVHD prophylaxis by continuous intra-
venous (iv) TAC with starting dose of 0.02 mg/kg/day from 1 day before allo-
HSCT (day -1) and iv methotrexate on day 1, 3, 6 at dose of 10 mg/m2, 7mg/m2,
7 mg/m2, respectively. TAC dosage was adjusted to target the serum concentra-
tion of 8-12 ng/ml until at least day 30 and then tapered. TAC was rapidly tapered
in case of the pathological diagnosis of TAM.TAC serum concentration was
sequentially examined triad weekly until day 35 at least. The primary endpoint of
this study was to evaluate the cumulative incidence of TRC-EC in relation to
weekly mean/peak TAC concentration. Secondary endpoint was OS.
Results: Median patient age was 45 years (16-68). The risks of disease were
standard in 168 and high in 85 pts. Forty pts were diagnosed of TRC-EC; SOS:
7 pts (median onset: day 24 (17-40)), TAM: 27 pts (median onset: day 40 (25-
128)), IIP: 6 pts (median onset: day 161.5 (46-223)).The cumulative incidence of
TRC-EC at day 250 was 0.16 (95%CI, 0.12-0.21). Univariate analysis showed
that higher peak TAC concentrations (PTC) during day 22-28 (P=0.013), male
pts (P=0.018) and grade 3-4 acute GVHD (P<0.01) were significantly associated
with the development of TRC-EC. Higher mean TAC concentrations (MTC) during
day 0-7 was correlated with higher incidence of TRC-EC, but not significant
(P=0.069).  In multivariate Fine-Gray analysis, high PTC during day 22-28 (HR:
1.92, 95%CI, 1.07-3.45, P=0.028) and grade 3-4 acute GVHD (HR: 8.33, 95%CI,
4.18-16.59, P<0.01) remained associated with TRC-EC occurrence. The proba-
bility of OS at 15-months was 0.56 (95%CI, 0.47-0.64). Univariate analysis
showed that pts diagnosed TRC-EC (P<0.01), pts older than 50 (P<0.01), pts
with high disease risk (P<0.01) and pts who received reduced intensity condi-
tioning regimens (P=0.010) were significantly associated with poor OS. PTC and
MTC at any time-period were not significant factors for OS. By Cox proportion-
al-hazards regression models, TRC-EC diagnosis (HR: 1.90, 95%CI, 1.16-3.11,
P=0.011) and high disease risk at transplant (HR: 1.76, 95%CI, 1.14-2.73,
P=0.011) were significantly associated with poor OS (Figure 1).
Figure 1.
Summary/Conclusions: Higher peak TAC concentrations during 22-28 days
after allo-HSCT increased the risk of TRC-EC. And the development of TRC-
EC was associated with poor OS.
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Background: T-cell replete haplo-identical stem cell transplantation (hap-
loSCT) is a valid therapeutic option for adult patients (pts) with high risk acute
myeloid leukemia (AML) lacking a sibling or unrelated donor. However the
impact of reduced intensity (RIC) vs myeloablative (MAC) conditioning regi-
mens is not conclusive as no randomized study addressing this question is yet
available.
Aims: In the present study we compared the outcome of RIC and MAC in pts
with AML older than 45 years (yrs) undergoing  haploSCT. The aim of the study
was to confirm the efficacy and feasibility of RIC among a population for which
the choice of conditioning intensity is more related to center strategy than pts
comorbidities or disease status.
Methods: We retrospectively compared the outcomes of 614 pts with de novo
or secondary AML transplanted between 2007 and 2015 from an haplo-identical
donor using either RIC (n=365) or MAC (n=249) regimens. Age was categorized
in three subgroups (45-55 yrs, 55-60 yrs, >60 yrs). Patients receiving a previous
allogeneic transplantation were excluded. RIC was defined according to EBMT
definitions.
Results: The median follow up for MAC and RIC was 24 and 20 months,
respectively and the median year of transplant was 2013 for both. Pts receiving
a RIC were older (55 yrs in MAC vs 61 yrs in RIC, p=<10-4). Secondary AML
was more frequent in RIC vs MAC (31% vs 22%) while 77% of MAC and 68%
of RIC were transplant for de novo AML, p=0.01. No differences were found on
disease status and Karnofsky performance status (KPS) at transplant: pts were
in CR1 (MAC: 44%, RIC: 40.5%), CR2/3 (MAC: 17%; RIC: 17%) or had active
disease (MAC: 40%; RIC: 43%), p=0.68; 12% of pts in both groups had
KPS<80, p=0.95. The most frequently used MAC regimen was TBF (56%),
while in RIC it was miniTBF (27%) and low dose TBI+Fludarabine (24%). RIC
regimens were more frequently associated with the use of peripheral blood as
stem cell source (MAC 42% vs RIC 55%, p=0.002). Post-transplant cyclophos-
phamide was used in 69% of both RIC and MAC, p=0.39. Main outcomes were
not different according to conditioning regimen: at 2 years RI was 26% vs 32%
(p=0.29), NRM 31% vs 34% (p=0.62), aGVHD II-IV 24% vs 31% (p=0.05), and
cGVHD 27% vs 26% (p=0.94), LFS 42% vs 39% (p=0.17), OS 46% vs 39%
(p=0.15), GRFS 36% vs 28% (p=0.10) for MAC vs RIC, respectively. The results
according to RIC and MAC were not different in any of the three age subgroups.
338 patients died; main causes of death were infections and GVHD to be fol-
lowed by disease recurrence. In multivariate analysis, the type of conditioning
regimen was not associated with risk of relapse or treatment failure: RI (HR:
1.22, p=0.28), NRM (HR: 0.92, p=0.63), acute GVHD grade II-IV (HR: 1.14,
p=0.48), chronic GVHD (HR: 1.26, p=0.30), LFS (HR: 1.03, p=0.77), GRFS
(HR: 1.07, p=0.55), OS (HR: 1.05, p=0.68). Disease status was associated
with outcomes (active disease vs CR): RI (HR: 2.44, p=<10-4), LFS (HR: 1.75,
p=<10-4), GRFS (HR: 1.72, p=<10-4), OS (HR: 1.71, p=<10-4) as well as
KPS>90: NRM (HR: 0.53, p=0.0002), LFS (HR: 0.67, p=0.001), GRFS (HR:
0.74, p=0.014), OS (HR: 0.62, p=0.0002).
Summary/Conclusions: In our study no differences were found between RIC
and MAC regimens for haplo-SCT in adults with AML including the age stratified
populations. Disease status and performance status were the major predictors
of transplantation outcome, while conditioning intensity had no effect. These
results may serve as the background for a well design randomized study com-
paring RIC vs MAC for haplo-SCT in adult pts with AML.
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Background: Patients with aggressive adult T cell leukemia-lymphoma (ATL)
have a dismal outcome even with an intensive chemotherapy. There is still
controversy regarding the indication of up-front allogeneic hematopoietic stem
cell transplantation (allo-HSCT) as no prospective randomized controlled trial
(RCT) has been conducted due to a rarity of patients with ATL even in Japan.
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Decision analysis is a computerized modeling analysis which can simulate the
clinical outcomes of different therapeutic strategies and identify an appropriate
therapeutic strategy. 
Aims: The aim of this study is to compare the life expectancy (LE) of
chemotherapy followed by up-front allo-HSCT to that of chemotherapy alone
using decision analysis in patients with aggressive ATL using database con-
structed by a nationwide survey.
Methods: We constructed a Markov decision analysis model to compare the
outcomes in 2 therapeutic strategies: chemotherapy followed by upfront allo-
HSCT vs chemotherapy alone. The transition probabilities between each health
states were calculated from the database of 1,792 patients and patients were
stratified into low-, intermediate- and high-risk groups according to the risk strat-
ification system which we developed previously (Fuji S et al. 18th International
Conference on Human Retrovirology). The model simulated the LE, quality-
adjusted LE (QALE) and survival curve after diagnosis of aggressive ATL. Since
QoL data for patients with aggressive ATL are lacking, estimates from a similar
decision analysis study of patients with acute myeloid leukemia were used. In
terms of the timing of up-front allo-HSCT, it was set as all patients receive up-
front allo-HSCT from 2 to 6 months if ATL did not progress before allo-HSCT.
We used the TreeAge Pro 2016 software package for decision analysis
(TreeAge Software Inc., Williamstown, MA).
Results: In all patients, up-front allo-HSCT was associated with higher LE in com-
parison to chemotherapy alone (2.26 years vs 1.75 years). Stratified into 3 groups
according to the prognostic scoring system, LE of up-front allo-HSCT was higher
compared to that of chemotherapy alone in the intermediate- (2.27 years vs 1.66
years) and high-risk groups (1.50 years vs 0.91 years). The estimated survival
curve depicted by TreeAge showed the superiority of up-front allo-HSCT as shown
in Figure 1A-D. The Monte Carlo simulation showed that the probability of supe-
riority of up-front allo-HSCT was 100% in all patients, 97.1% in the low-risk group,
100% in the intermediate-risk group, and 100% in the high-risk group in terms of
LE, and was 99.8% in all patients, 75.2% in the low-risk group, 100% in the inter-
mediate-risk group, and 100% in the high-risk group in terms of QALE.
Figure 1.
Summary/Conclusions: Based on decision analysis, up-front allo-HSCT was
associated with higher LE and QALE in the intermediate- and high-risk groups
in comparison to chemotherapy alone in patients with aggressive ATL. In the
absence of prospective randomized controlled trials, our results suggest that
up-front allo-HSCT for aggressive ATL is the favored treatment strategy in the
intermediate- and high-risk groups.
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Background: Cord blood transplantation (CBT) is an established alternative
source for hematopoietic stem-cells in patients without matched donor. How-
ever, the most commonly used high-dose total-body-irradiation (TBI) myeloab-
lative conditioning (MAC) results in high treatment related mortality (TRM).
Non-myeloablative and reduced-intensity conditioning (RIC) have been studied
to decrease TRM and provide curative chance to the elderly and those with co-
morbidities. However, these strategies are associated with higher relapse-rate
and graft rejection. A novel-RIC using addition of thiotepa and higher dose of
TBI to standard RIC has shown to result in sustained donor engraftment. Our
study compares transplant-related-outcomes in patients who underwent first
double-unit CBT with standard-RIC regimen of fludarabine (Flu, 200mg/m2),
cyclophosphamide (Cy, 50mg/kg), and TBI (200cGy or 300cGy) versus this
standard-RIC regimen with addition of thiotepa (10mg/kg) and increased dose
of TBI (400cGy).
Aims: 1. To compare transplant related outcomes in CBT recipients who
received standard-RIC (FluCyTBI) to those who received novel-RIC (FluCy
with addition of thiotepa and increased dose of TBI).  2. To identify optimal con-
ditioning regimen in patients undergoing UCT.
Methods: After IRB approval, consecutive patients undergoing CBT from
08/2009 to 08/2016 were evaluated and data retrospectively abstracted. Patient
selection, graft-versus-host disease prophylaxis and transfusions were per insti-
tutional standards and conditioning regimens were compared as described.
Results: Of the 99 patients who underwent allogeneic double-CBT, 52 received
standard-RIC and 47 received novel-RIC. Median age at transplant was 67 years
(range, 24-74) and 54 years (range, 25-67) in standard-RIC and novel-RIC cohort
respectively. Acute myeloid leukemia was the major indication for transplant in
both cohorts. Median hematopoietic stem-cell transplant comorbidity-index (HSCT-
CI) was 3 (range, 0-6) and 1 (range, 0-6) in standard-RIC and novel-RIC groups
respectively. Four patients suffered engraftment failure (2 in each cohort). Median
neutrophil engraftment was 13 days (range, 6-42) and 21 days (range, 12-43)
while median platelet engraftment was 37 days (range, 26- 70) and 38 days (range,
24-74) in standard-RIC and novel-RIC groups respectively. Fifty-three suffered
acute-GVHD which occurred in 21 (40%) patients (grade 2-4: n=15, 29%; grade
3-4: n=2, 4%) in standard-RIC group and in 32 (68%) patients (grade 2-4: n=29,
62%; grade 3-4: n=5, 11%) in novel-RIC group. Chronic-GVHD (cGVHD) occurred
in 18 patients (n=7, 14% in standard-RIC; n=11, 23% in novel-RIC group). The
one-year cumulative incidence of relapse was 36% (n=15) in standard-RIC while
it was 15% (n=5) in novel-RIC cohort. Median relapse free survival (RFS) was
significantly improved in novel-RIC cohort compared to standard-RIC (HR, 0.32,
CI:0.11- 0.76, p=0.01). Median RFS was 29 months in standard-RIC cohort while
median RFS was not reached in novel-RIC cohort. The one-year cumulative inci-
dence of transplant related mortality (TRM) was 22% (n=10) in those who received
standard-RIC while it was 16% (n=7) in those who received novel-RIC. TRM was
not significantly different between the standard-RIC and novel-RIC cohorts. Median
follow-up in standard-RCI cohort was 9.3 months (range, 0.16- 79) and 13 months
(range, 1.4- 36) in novel-RCI cohort. The overall survival (OS) was significantly
better in novel-RCI cohort compared to standard-RCI (HR 0.49, CI: 0.25- 0.94, p=
0.03). Median OS was 17 months in standard-RIC cohort while median OS was
not reached in novel-RIC group (Figure 1).
Figure 1.
Summary/Conclusions: In our study, RIC consisting of FluCy with addition of
thiotepa and increased dose of TBI in patients undergoing double-cord UCT
was associated with improved OS and improved RFS without increase in TRM
as compared to standard RIC. While older and more comorbid patients might
experience increased TRM with the thiotepa based regimen, these data suggest
that consideration of this regimen may be appropriate in fit, older patients.
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Background: Post-transplant relapse is a major cause of transplant failure.
Because impending relapse can be indicated by minimal residual disease (MRD)
after allogeneic hematopoietic stem cell transplantation (allo-HSCT), MRD-direct-
ed intervention may be a reasonable option for relapse prophylaxis.
Aims: We investigated the efficacy of MRD-directed interferon-α (IFN-α) treat-
ment in acute leukemia patients who were positive for MRD after allo-HSCT.
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Methods: A total of 107 patients who were MRD-positive after allo-HSCT were
enrolled. MRD-positive status was defined as positivity for leukemia-associated
aberrant immune phenotypes or positivity for Wilms’ tumor gene 1 in a single
bone marrow sample. Recombinant human IFN-α-2b injections were adminis-
tered subcutaneously 2–3 times per week for 6 months.
Results: The 2-year cumulative incidence of severe acute and chronic graft-
versus-host disease after IFN-α treatment was 5.7% and 6.6%, respectively.
Eighty-one (75.7%) patients turned MRD-negative after IFN-α treatment, includ-
ing 42 (39.3%), 6 (5.6%), 7 (6.5%), and 26 (24.3%) who turned MRD-negative
1, 2, 3, and >3 months after MRD-directed IFN-α treatment, respectively. Twelve
patients showed relapse after IFN-α treatment, and 4 patients died of non-
relapse mortality (NRM). The 2-year cumulative incidence of relapse and NRM
after IFN-α treatment was 11.5% and 4.3%, respectively. The 2-year probabil-
ities of event-free survival and disease-free survival after IFN-α treatment were
66.5% and 82.4%, respectively. Persistent MRD after IFN-α treatment was sig-
nificantly associated with higher relapse risk and poorer survival. 
Summary/Conclusions: These data confirmed that MRD-directed IFN-α treat-
ment is effective for patients who were MRD-positive after allo-HSCT.
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Background: Allogeneic stem-cell transplantation (SCT) is curative therapy in
AML. Most deaths after SCT occur within the first 2 years. Prior large cohort
studies showed that patients (pts) surviving leukemia free 2 years after SCT
have high probability of survival at 10 years. Most of these studies were done in
younger pts following myeloablative conditioning (MAC). Marked improvement
has been achieved in SCT from unrelated donors (UD) in recent years due to
improvement in tissue typing, donor selection and supportive care. However,
there is relatively limited data on the comparative long-term outcomes (beyond
10 years) of SCT in AML pts (age ≥50 years) from sibling and UD in this setting. 
Aims: To compare the long-term outcomes after SCT from sibling and UD
using different conditioning intensities in AML pts age ≥50 years.
Methods:
We analyzed long-term outcomes in a relatively large cohort of pts with de-
novo AML (n=1134), age ≥50 years, who were alive and leukemia-free 2 years
after SCT from matched siblings (n=848) or UD (n=286), in the years 2000-
2007, median follow up 8.6 years (2-16.4).
Results: The median patient age was 56 years (50-75) and 58 years (50-74)
after SCT from siblings and UD, respectively (P=0.005). 77%, 12% and 11% in
the sibling group were in CR1, CR2 and active leukemia at SCT compared to
50%, 25% and 25% in the UD group, respectively (P<0.001). 37% and 38% had
reduced-intensity conditioning according to EBMT definitions (P=0.78), while
27% and 70% had in-vivo T-cell depletion (TCD), respectively (P<0.001). Chronic
GVHD prior to the 2 year time-point occurred in 61% and 53%, respectively
(P=0.02). The 10-year leukemia-free survival (LFS) of pts surviving leukemia-
free 2 year after SCT was 72% (68-75) and 62% (55-70) after SCT from sibling
and UD, respectively (P=0.30). Multivariate analysis (MVA) identified active
leukemia at SCT (HR 1.8, P<0.001) or CR2 (HR 1.5, P=0.02) compared to CR1
and female recipient (HR 0.7, P=0.005) as independent factors predicting LFS.
The donor type, conditioning regimen, age, cytogenetics and prior acute or chron-
ic GVHD were not significant. The 10-yearr overall survival was 74% (70-77)
and 66% (59-74), respectively (P=0.42). Relapse occurred in 15% (13-18%) and
17% (12-22%, P=0.97), respectively. MVA identified SCT in active disease (HR
2.2, P<0.001) or CR2 (HR 1.9, P=0.006), poor cytogenetics (HR 5.8, P=0.02),
in-vivo TCD (HR 5.5, P=0.03) and female gender (HR 0.6, P=0.03) as risk factors
for late relapse. Non-relapse mortality (NRM) occurred in 13% (11-16%) and
21% (15-28%, P=0.15), respectively. Advanced age was the only risk factor for
late NRM (HR, 1.6, P=0.03). Donor and conditioning type were not predictive of
late relapse or NRM. A center effect was documented for NRM (P<0.001) and
LFS (P=0.05). There were 209 late deaths after sibling and 72 after UD SCT.
Relapse was the cause of death in 53% and 37% of late deaths, respectively
(P=0.06). GVHD was the cause of death in 16% and 22% and infection in 9%
and 19%, respectively (P=0.05). Second malignancy was the cause of death in
13% and 12% of late deaths, respectively.
Summary/Conclusions: Long term outcome is similar after SCT form sibling
or UD in pts with AML, age ≥50 years. Pts who are leukemia free 2 years after
SCT can expect good and similar subsequent outcome with both donor types.
Disease status was the major predictor of subsequent LFS while conditioning
intensity had no effect. While relapse is the major cause of late death after
both donor types, NRM and in particular GVHD and infections are more com-
mon causes of late death after SCT from UD.
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Background: Myelodysplastic syndrome (MDS) is a heterogeneous myeloid
stem cell disorder with ineffective hematopoiesis, dysplastic cell morphology,
and a propensity for progression to acute myeloid leukemia. Allogeneic
hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy
for MDS. In recent years, azacitidine (AZA) has been increasingly used as pre-
transplant induction therapy in high-risk MDS patients. However, the benefits
of pretransplant therapy in these patients are unclear, and the optimal therapy
regimen remains unknown. 
Aims: We conducted a retrospective analysis to elucidate the clinical impact
of prior treatment with AZA on outcomes after allo-HSCT in high-risk MDS
patients.
Methods: Clinical data were collected from the registry database of the Japan
Society for Hematopoietic Cell Transplantation. We selected patients with high-
risk MDS at diagnosis (IPSS intermediate 2 or high), aged 16 years or older,
who underwent their first transplantation between January 2009 and December
2014 and received AZA or best supportive care (BSC) before allo-HSCT.
Patients who received conventional chemotherapy or immunosuppressive ther-
apy prior to allo-HSCT were excluded. We compared overall survival (OS),
relapse, non-relapse mortality (NRM), and hematopoietic recovery after allo-
HSCT patients were pretreated with AZA or BSC.
OS was estimated by the Kaplan–Meier method, and a log-rank test was used
for comparisons. Relapse and NRM were considered competing risk events
and were compared using Gray’s test. The cumulative neutrophil and platelet
recoveries were also compared by Gray’s test, considering death without these
events as a competing risk. In a multivariate analysis, the Cox proportional
hazard model and Fine-Gray methods were used for OS and cumulative inci-
dence of relapse and NRM and hematopoietic recovery, respectively, using
the following variables: age, gender, performance status at transplantation,
marrow blast at diagnosis, cytogenetic risk, donor source, donor-recipient gen-
der mismatch, ABO mismatch, and conditioning regimen.
Results: Of the 485 patients, 161 patients (33.2%) received AZA and 324
patients (66.8%) received BSC before allo-HSCT. The median age was 60
(18–70) and 56 (18–74) years, respectively (P=0.002). A higher proportion of
BSC patients received cord blood transplantation (P=0.005). Bone marrow
blast at diagnosis was significantly higher in AZA patients (P <0.001) and cyto-
genetic risk was better in AZA patients (P=0.02) than those in BSC patients.
No differences were observed in other factors. The 2-year OS rate (46.7% and
50.8%, P=0.66), relapse (31.5% and 28.6%, P=0.59), NRM (26.5% and 26.1%,
P=0.99), 30-day neutrophil engraftment (88.2% and 83.6%, P=0.18), and 60-
day platelet engraftment (72.0% and 69.4%, P=0.36) were not significantly dif-
ferent between the AZA and BSC groups. In multivariate analysis, AZA and
BSC showed comparable OS (HR, 1.16; P=0.31), relapse (HR, 1.13; P=0.50),
NRM (HR, 0.92; P=0.64), neutrophil engraftment (HR, 1.01; P=0.89), and
platelet engraftment (HR, 1.07; P=0.59).
Summary/Conclusions: Our study showed that pretransplant AZA and BSC
provide similar outcomes of allo-HSCT in high-risk MDS patients. Further analy-
sis is needed to clarify the role of pretransplant therapy in high-risk MDS and
to identify the subset of patients who may benefit from pretransplant AZA.
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LOW-DOSE DECITABINE IMPROVES PLATELET RECOVERY IN PATIENTS
WITH ISOLATED THROMBOCYTOPENIA AFTER HSCT
Y. Han1,2,*, Y. Tang1, Y. Zhao1, M. Huang1, J. Chen1, J. Qi3, Y. Wang1, X. Wu1,
X. Ma1, F. Chen1, X. He1, C. Ruan1, D. Wu12
1The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, 2Institute of Blood and Marrow Transplantation,Collaborative Innovation
Center of Hematology, 3Soochow University, Suzhou, China
Background: Isolated thrombocytopenia is a common complication of
hematopoietic stem-cell transplantation (HSCT), which was defined as consis-
tent low platelet counts with recovery of the other two cell lines after transplan-
tation. This status leads to an increased risk of life-threatening hemorrhage,
frequent requirements of platelet transfusion and extended hospital stays, rep-
resenting a challenging clinical problem. Previous studies have demonstrated
that decitabine, a hypomethylating agent, may increase platelet counts by pro-
moting megakaryocyte maturation and platelet release in mouse model.
Aims: In order to investigate the role of decitabine in patients after HSCT suf-
fering from isolated thrombocytopenia, we conduct a clinical trial to validate
this effect in post-HSCT setting.
Methods: We performed a prospective open-label study to evaluate the treat-
ment of low-dose decitabine in patients with hematological malignancies who
received allogeneic HSCT and suffered from isolated thrombocytopenia. The
inclusion criteria were: (1) Platelet count ≤30 × 109/L persistently at day 60
post-HSCT or later; (2) Recovered neutrophil and hemoglobin; (3) Full donor
chimerism; and (4) No response to conventional treatments for a duration of at
least 4 weeks. Patients with malignancy relapse, active infections, uncontrolled
graft-versus-host disease, severe organ damage or transplant-related throm-
bosis were excluded. From July 2013 to July 2016, 38 patients were randomly
assigned into either the control group to receive conventional treatment only,
or the test group to receive additional decitabine (15mg/m2, intravenously daily
for 3 consecutive days).
Results: Major response was observed in 16 out of 19 patients (84.2%) in
decitabine group, with a median time of 22 days to achieve platelet transfu-
sion-independence. Two patients (10.5%) showed a minor response and 1
patient (5.3%) failed. In contrast, 3 out of 19 patients in the control group
(15.8%) showed a major response, 2 patients (10.5%) showed a minor
response, 14 patients (73.7%) did not show any improvement, of which 1 patient
died of severe hemorrhage in week 5. For bone marrw morpholocial analysis,
all 38 patients showed low levels of megakaryocytes at week 0. However, the
megakaryocyte counts in decitabine group were significantly increased at week
4, while no significant difference was recorded in control group. After decitabine
treatment, we did not observe a change in anti-platelet antibodies levels and T
cell subsets ratios. However, reactive oxygen species (ROS) and megakary-
ocyte counts increased in the test group. No considerable myelosuppression,
febrile neutropenia, and nonhematologic toxicities associated with the treatment
were observed.
Summary/Conclusions: Our data showed an encouraging efficacy of decitabine
in patients after HSCT suffering from isolated thrombocytopenia owing to remark-
ably increased megakaryocyte counts. Decitabine may improve isolated throm-
bocytopenia via regulating ROS and megakaryocyte reconstitution.
Thalassemia
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QUANTITATIVE PROTEOMICS OF PLASMA EXTRACELLULAR VESICLES
TO IDENTIFY NOVEL BIOMARKERS OF CLINICAL SEVERITY FOR
HBE/Β-THALASSEMIC PATIENTS
J. Kittivorapart1,2,3,*, V. Karamatic Crew1, N. Siritanaratkul4, A. Mark Toye1,2
1Bristol Institute for Transfusion Sciences (BITS), NHS Blood and Transplant,
2School of Biochemistry, University of Bristol, Bristol, United Kingdom, 3Depart-
ment of Transfusion Medicine, 4Department of Medicine, Faculty of Medicine
Siriraj Hospital, Bangkok, Thailand
Background: Hemoglobin (Hb) E/β-thalassemia has a wide spectrum of clinical
manifestations that cannot be explained purely by its genetic background. Extra-
cellular vesicles (EV) are one factor that may indicate and/or contribute to dis-
ease severity because there is an observed increase in EV release due to the
enhanced oxidative stress in thalassemic erythrocytes.
Aims: This study aims to explore the differences in protein composition and
abundance between circulating EV from HbE/β-thalassemic patients and nor-
mal individuals.
Methods: 15 HbE/β-thalassemia patients and 15 matched-controls from Thailand
were fully consented and recruited for this study. Pooled EVs isolated from five
thalassemic samples were compared to pooled EVs from five matched controls
using a Duplex-Tandem Mass Tag (TMT) mass spectrometry (TMT-MS) analysis.
This experiment was repeated three times in total, using different patient and
control samples to identify consistent alterations of protein expression in EVs.
Finally, protein differences were also confirmed using Western blotting.
Results: The total proteins identified across the three experimental TMT-MS
datasets ranged from 1,764 to 2,534 proteins. When restricted to proteins that
contained more than one unique peptide, the range of proteins was reduced to
685 to 1,127 proteins. Many proteins were previously reported EV constituents.
19 proteins were consistently increased in patient samples compared to controls
across all data sets. The majority of these proteins were chaperone proteins and
antioxidant enzymes. Alpha Hemoglobin Stabilizing Protein (AHSP) had the high-
est increase of between 31 to 47-fold. Other proteins that exhibited increased
abundance in thalassemic circulating EV included catalase, superoxide dismu-
tase, T-complex proteins, heat shock protein 70 and ferritin light chain. Importantly,
the heme scavenger and plasma proteins – haptoglobin and hemopexin were
observed to be consistently decreased in patients’ EV across all data sets.
Immunoblotting results corroborated the TMT-MS findings.
Summary/Conclusions: We have successfully identified consistent alterations
in protein expression levels between EV generated by HbE/β-thalassemic
patients and normal individuals. These findings may potentially lead to the
development of a prognostic marker, and therefore may improve the therapeutic
outcome for the patients suffering from thalassemia.
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A SELECTIVE ORAL GLYT1 INHIBITOR IMPROVES ANEMIA IN A MOUSE
MODEL OF BETA-THALASSEMIA
A. Matte’1, M. Winter2, E. Beneduce1, E. Federti1, A. Siciliano1, A. Macias-garcia3,
A. Iolascon4, T. Singer2, O. Khwaja2, A. Korner2, J.-J. Chen3, A. Harmeier2,
C. Brugnara5, L. De Franceschi1,*
1Medicine, University of Verona, Verona, Italy, 2Pharmaceutical Research and
Early Development, Hoffmann-La Roche , Basel, Switzerland, 3MIT, MIT, Camb-
dridge, United States, 4Biotecnologie Avanzate-CEINGE, Federico II University,
Naples, Italy, 5Lab of Medicine, Children’s hospital Harvard Medical School,
Boston, United States
Background: The anemia of β-thalassemia is due to a combination of reduced
red cell survival in the peripheral circulation and ineffective erythropoiesis, the
latter due to unbalanced hemoglobin chain synthesis, and hemichrome-induced
oxidative damage. Here we used a specific and selective inhibitor of the plasma
membrane expressed glycine transporter GlyT1 (RO4917838) in a mouse mod-
el for β-thalassemia (Hbb3th/+). A previous study in Wistar rats has shown that
RO4917838 induces a dose-dependent decrease in MCH, Hb, soluble trans-
ferrin receptor, and increase in absolute reticulocytes and RBC counts (Winter
et al. Exp Hematol, DOI: 10.1016/j.exphem.2016.07.003). This has been linked
to the ability of RO4917838 to reduce glycine bioavailability in erythroblasts
and decreased heme biosynthesis.
Aims: To evaluate the impact of the glycine transporter GlyT1 selective inhibitor
RO4917838 on anemia of a mouse model for β-thalassemia. 
Methods: Wild-type control (WT) C57B6/2J, and Hbbth3/+ mice (β-Thal) aged
between 3 to 4 months were treated daily with either vehicle or RO4917838 at
dosages of 3, 10, 30 mg/kg/d for 4-6 weeks by gavage. Hematological parameters,
analysis of erythropoiesis, molecular studies of sorted erythroid precursors, indices
of hemolysis, hepcidin liver expression and Pearls staining were carried out. 
Results: RO4917838 administration was associated with an improvement of  β-
Thal hematologic phenotype, as supported by (i) the amelioration of red cell
morphology; (ii) the increase in Hb levels; (iii) the reduction in reticulocyte count
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and in the percentage of circulating erythroblasts; (iv) the increase in β Thal red
cell survival.  RO4917838 induced a significant reduction in extramedullary ery-
thropoiesis as well as in the amount of insoluble alpha chain aggregates in cir-
culating red cells. It is of note that in β-Thal sorted erythroblasts we found a
reduction in HRI and in phospho-eIF2a, indicting a reduction in free heme, which
shall resulted in the activation of HRI, in RO4917838 treated β -Thal mice (10
mg/Kg/d, 6 weeks). Finally, in β-Thal mice treated with RO4917838 (4 weeks at
30 mg/kg/d) a reduction in liver and spleen iron-overload was identified, which
was associated with increased hepcidin liver expression. 
Summary/Conclusions: Our data suggest that RO4917838 ameliorates ane-
mia and ineffective erythropoiesis by reduction of heme biosynthesis in a mouse
model for β-thalassemia. RO4917838 is a potential, novel therapeutic approach
for the treatment of anemia in patients affected by beta-thalassemia.
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MAY MUTATIONS IN THE KLF1 GENE HAVE WORSENING EFFECTS ON
THE BETA THALASSEMIA PHENOTYPE?
M.R. Storino1, M. Giuliano1, G. Fioretti2, S. Puzone1, R. Sessa1, L. Vicari2,
M.P. Ottaiano1, M. Caldora3, S. Costantini4, C. Matarese3, A. Sarappa3,
G. Amendola5, A. Filosa4, P. Izzo1, M. Grosso1,*
1Dep. Molecular Medicine and Medical Biotechnology, University of Naples
Federico II, 2UOSC Genetica Medica, AORN A. Cardarelli, 3UOC Patologia
Clinica, P.O. Pellegrini, ASL NA1, 4UOSD Malattie rare del globulo rosso, AORN
A. Cardarelli, Naples, 5UOC Pediatria-TIN, P.O. Umberto I, Nocera Inf. , Italy
Background: Kruppel-like factor 1 (KLF1) is a pleiotropic erythroid transcrip-
tional factor that plays a key role in erythropoiesis (Siatecka M, Blood 2011;
118: 2044-521). Accordingly, KLF1 mutations have been found to be respon-
sible for a variety of hematological disorders. KLF1 also contributes directly or
indirectly to regulate the expression of genes in the beta-globin gene cluster
and the fetal-to-adult globin gene switching (Waye JS et al Int. J. Lab. Hem.
2015; 37: 78-84). It has been reported that mutations leading to KLF1 haploin-
sufficiency are linked to increased fetal hemoglobin (HbF) levels with amelio-
rative effects on the severity of beta-thalassemia (Liu D. et al. Blood 2014;
124: 803-811; Perkins A. et al. Blood 2016; 127: 1856-1862).
Aims: This study was aimed at providing a functional characterization of known
and novel mutations in the KLF1 gene associated with atypical beta-tha-
lassemia phenotypes.
Methods: Hematological parameters were measured using an automated
hematology analyzer (Beckman Coulter) and high performance liquid chro-
matography (Variant II, Bio-Rad Laboratories). Screening of KLF1 mutations
was performed by Sanger sequencing on an Applied Biosystems 3730 DNA
analyzer. Functional studies were performed by gene reporter assays and
expression vectors for KLF1 mutants in the human K562 erythroleukemia cell
line. This study was performed on 19 adult subjects, including 11 beta-tha-
lassemia heterozygotes with an unexpected phenotype of intermediate tha-
lassemia (moderate or severe anemia, elevated HbA2 and/or HbF levels) and
8 subjects with normal erythrocyte indices and borderline HbA2 and/or HbF
levels without mutations in alpha- and beta-globin gene clusters.
Figure 1.
Results: Of the 19 patients who were tested, 15 were found to be positive for
mutations in the KLF1 gene. More in detail, we found 7 mutations, comprising
a nucleotide variation (c.-251 C>G) already reported as a single nucleotide poly-
morphism and a known mutation (c.-148 G>A) in the proximal promoter region,
3 known mutations associated with increased HbA2 and/or HbF levels (S102P,
F182L and M39L) (Radmilovic M. et al. Ann. Hematol 2013; 92: 53-58) and two
novel mutations (C94X and P173Pfs*236), all of them in the proline-rich domain
in exon 2. Functional studies were performed in K562 cells in order to clarify the
pathogenic significance of these mutations and to better define the role of KLF1
in atypical thalassemia phenotypes. Interestingly, the c.-251 C>G polymorphism
was found to be associated with an increased transcriptional activity of the KLF1
promoter (Figure 1A), thus allowing us to exclude for this nucleotide variation
the condition of a neutral polymorphism. Furthermore, unexpectedly, the novel
P173Pfs*236 mutation was found to be associated with a dramatic reduction of
the beta-globin gene expression levels (Figure 1B).
Summary/Conclusions: Our study confirmed the ameliorative effect of some
KLF1 mutations on the thalassemia phenotype that were found to be associated
with increased fetal- and/or beta-globin gene expression. In other cases we
demonstrated that KLF1 mutations may contribute to worsen the beta tha-
lassemia phenotype or result in a silent beta thalassemia trait. This study pro-
vides further insights into the multiple roles of KLF1 in erythropoiesis and high-
lights an intriguing effect of a subset of KLF1 mutations that may contribute to
the severity of the thalassemia phenotype, thus reinforcing the relevant impli-
cations of KLF1 screening for genetic counseling and for effectiveness of pre-
vention screening programs for hemoglobinopathies.
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SECONDARY SOLID TUMORS FOLLOWING HEMATOPOIETIC CELL
TRANSPLANTATION FOR THALASSEMIA MAJOR
A. Meloni1,*, A. Natale2, S. Santarone2, M. Di Ianni3, S. Angelini4, L. Pistoia1,
L. Cuccia5, A. Spasiano6, A. Pepe1, P. Di Bartolomeo2
1Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2Bone Marrow
Transplant Center, Pescara, 3University of L’Aquila, L’Aquila, 4Tor Vergata Uni-
versity, Roma, 5ARNAS Civico “Benfratelli-Di Cristina”, Palermo, 6AORN A.
Cardarelli, Napoli, Italy
Background: Secondary solid tumors (SST) have been described after HCT,
in particular for patients affected by hematologic malignancies. There is limited
information about the incidence of SST following HCT for thalassemia major
(TM).
Aims: The aim of this study was to determine the incidence of SST in 134
patients with TM who received HCT in our Center between 1983 and 2013
Methods: 117 patients survived more than 3 years after HCT and were enrolled
in the study. Of them, 57 were males and 60 females. Their median age at
time of HCT was 10 years (1-29). As conditioning regimen, they received Busul-
fan (14 mg/Kg) and Cyclophosphamide (200 mg/Kg). The GvHD prophylaxis
included Cyclosporine and Methotrexate. All patients received bone marrow
cells from an HLA identical donor.
Results: At time of this report, 112 patients were cured, whereas 5 patients
rejected their graft and are now under regular transfusion treatment.
Overall, the median follow-up after HCT was 24 years (3-34). Seven patients
developed a malignancy 3.2 to 28 years (median 16,4 years) after HCT including
2 carcinomas of the tongue, 1 oral squamous cell carcinoma, 1 colorectal cancer,
1 thyroid carcinoma, 1 carcinoma of the uterine cervix, and 1 parotid carcinoma.
The 30-yr cumulative incidence (CI) of developing SST was 10±0.17%. All patients
underwent surgical resection of the tumor and in addition 4 of them received
chemotherapy and/or radiotherapy. Of relevance, the 3 patients with cancer of
the oral cavity were affected by severe chronic GvHD with buccal cavity involve-
ment. Two patients (1 with parotid and 1 with tongue carcinoma) died of tumor
progression and 5 are living. We compared these results with 2 case control pop-
ulations. First of all, we investigated the occurrence of solid tumors in the 117 indi-
viduals (64 males, median age 10 years at time of marrow donation), who served
as stem cell donors for HCT. One donor developed breast cancer 29 years after
marrow donation at age of 38. The 30-yr CI of developing solid tumor for donors
was 4.5±0.21% with a statistically significant difference (p=0.03) as compared to
that of transplanted patients. The second case control population consisted of
117 patients affected by TM treated with transfusions and iron chelation. The
matching technique applied was based on the variables age and sex. One control
per case (transplanted patient) was randomly selected from the MIOT (Myocardial
Iron Overload in Thalassemia) registry and matched by sex and age with the
transplanted patient population. Two patients developed an hepatocellular carci-
noma (HCC) at age of 39 and 44 years, respectively. One patient died and one is
living. Using the event rate measure, we observed an event rate of 0.102 at 30
years for the transplant group and 0.041 for the nontransplant group (p=0.106).
Summary/Conclusions: This study shows that the magnitude of increased
risk of SST is twofold to threefold for patients treated with HCT as compared
with an age- and sex matched nontransplant TM patients or with stem cell
donors. Notably, among the transplanted patients we didn’t observe any case
of HCC, which is one of the most frequent solid tumor in nontransplant TM
patients, whereas we observed 4 cases of head/neck cancers. In our series,
cGvHD seems to be a strong risk factor in the development of new solid tumors.
Patients with cGvHD, especially those with involvement of the oral cavity, must
receive a very long careful monitoring and surveillance in order to prevent the
development of secondary cancers.
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VALIDATING A NOVEL CAPILLARY ELECTROPHORESIS: THE MOST
SUITABLE PLATFORM FOR THE NATIONAL NEWBORN SCREENING
PROGRAM IN A REGION WITH HIGH PREVALENCE OF THALASSEMIA
AND HEMOGLOBINOPATHIES
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J. Pooliam2, V. Viprakasit1,3
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Background: Newborn screening program for thalassemia (thal) and hemo-
globinopathies (NBS-Hbs) is crucial for early detecting patients with serious
hemoglobinopathies (Hb variants) e.g. Sickle cell anemia (Hb SS). NBS-Hbs
has been incorporated into a routine neonatal service in several developed
countries. However its role on early detection other forms of globin disorders
remains unclear. Moreover, NBS-Hbs can detect several types of thalassemia
and Hb variants carriers. This application could be useful for the national pre-
vention and control program for severe thalassemia syndromes in many devel-
oping countries including Thailand where these conditions are highly prevalent
especially β-thal major, Hb E/β-thal and Hb Bart’s hydrops fetalis (caused by
αº-thalassemia). Recently a new capillary electrophoresis (CE) has been devel-
oped specifically for NBS-Hbs. However there is a limited data on validation of
this technology on detecting several types of thalassemia and Hb variants found
in Southeast Asia.
Aims: To evaluate and validate a new CE system to screen globin disorders in
newborn to initiate the national NBS-Hbs for Thailand
Methods: After informed consent, 1,213 blood samples of 2-day old newborns
were collected by heel prick puncture into 5-dried blood spots. After elution,
dried blood samples were analyzed by Capillarys 2 NEONAT FAST® (SEBIA,
Évry, France). All samples were also extracted for DNA and genotyped by our
extensive PCR based panel to detect >98% of abnormal globin alleles found
in Thailand using α-thal GAP-PCR, α-thal ARMS-PCR, β-thal ARMS-PCR, and
PCR-RFLP for Hb E. We compared CE data with each globin genotypes and
use a ROC curve to set up new diagnostic criteria using% Hbs from CE for
future cases.
Results: Identification of Hb Bart’s provided 100% of sensitivity, specificity and
accuracy in most individuals with α-thal. Using ROC analysis, we proposed dif-
ferent cut-off values of Hb Bart’s to differentiate Hb H disease, αo-thal and non-
deletional α+-thal traits; ≥7.40%, ≥0.85%, ≥0.45%, respectively with excellent
accuracy (Table 1). Interaction of Hb E with these α-thal genotypes has no
effect on these cut-off values (Table 1). However, there was a limitation to iden-
tify deletional α+-thal trait using CE by the level of Hb Bart’s ≥0.10% (detectable
level). A cut-off level to distinguish Hb EE from Hb E trait was suggested at
≥4.95% vs ≥0.7%. Two patients with Hb E/β-thalassemia were identified through
this study with different CE pattern from Hb EE. 11 β-thalassemia traits was
identified and they had a lower level of Hb A as compared to their gestational
age (GA)-sex matched controls with normal β globin genotypes (n=148). We
recommend Hb A level ≤10.35%; a cut-off to primarily consider for β-tha-
lassemia carrier followed by molecular analysis.
Table 1.
Summary/Conclusions: This newborn CE platform showed a high efficiency
for detecting several types of thalassemia and Hb variants in particular α-thal,
β-thal and Hb E using cut-off levels of each Hb species described herein.
Besides early detecting of Hb S, we can now apply this NBS into a routine
service in order to early detect Hb H disease, Hb E/β thalassemia and the
majority of common thalassemia carriers. This NBS-Hbs approach can reinforce
and leverage our current program on prevention and control for severe tha-
lassemia syndromes in our region. Moreover, due to population migration from
The East to the West, our new diagnostic guideline by CE could be useful and
applicable for existing NBS programs currently available in several European
countries.
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TRANSIENT ELASTOGRAPHY IN NON TRANSFUSION DEPENDENT
THALASSEMIA: A SUCCESSFUL TOOL TO ASSESS AND MONITORING
LIVER FIBROSIS
A. Marcon1,*, G. Graziadei1, M. Pennisi1, M. Migone De Amicis1, M. Fraquelli2,
M.D. Cappellini3
1Rare Diseases Center, Department of Medicine and Medical Specialities,
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of Pathophysiology and Organ Transplantation, 3Department of Clinical Sci-
ences and Community Health, University of Milan, Milan, Italy
Background: Non Transfusion Dependent Thalassemia (NTDT) patients are
at risk for several complications due to chronic anemia, hypoxia and iron over-
load. Over the recent years hepatic complications are more frequently observed
in these patients probably due to the aging and poor care: monitoring liver fibro-
sis is becoming part of the follow up. Liver stiffness measurement (LSM) by
transient elastography (TE), a widely-used non-invasive tool, in our centre has
been included in the regular follow-up of patients with NTDT
Aims: To evaluate by TE liver fibrosis in NTDT patients, its correlation with bio-
chemical, hematological and clinical parameters at baseline and after 5 years
Methods: Hepatic fibrosis and siderosis were evaluated in 101 NTDT patients
using respectively TE, and liver iron concentration (LIC) derived from T2* Mag-
netic Resonance Imaging (MRI) at baseline and, in a subset of patients, after
5 years. The following TE thresholds were taken into account: <5.0 kPa no
fibrosis (F0), 5.1-7.9 kPa mild fibrosis (F1), >7.9 kPa moderate fibrosis (F2),
>10.3 advanced fibrosis (F3), >11.9 kPa cirrhosis (F4). Biochemical and hema-
tological blood test were collected too. Patients were also tested for HCV anti-
bodies and HCV RNA. Data were analyzed retrospectively
Results: Patient’s mean age was 46±11 years, 37/101 (36.6%) were splenec-
tomized, 51/101 (50.5%) had never been transfused, 46/101 (45.5%) were
occasionally transfused and 4/101 (3.9%) had been regularly transfused for
10+5yrs. At baseline (T0), the overall mean LSM was 5.9 ±2.6 kPa, mean LIC
6.68±5.37 mg/g dw, ferritin 700±596 ng/ml, Hb 9.3±1.3 g/dl, AST, ALT GGT
and ALP were normal. LSM correlate with GGT (p <0.001) and AST values
(p=0.02). Seven/101 (6.9%) patients were HCV RNA positive, one of them
had never been transfused. At baseline 37/101 (36.6%) patients were on iron
chelation (ICT) (29 deferoxamine, 7 deferasirox, 1 deferiprone). At T0 patients
with fibrosis (any grade) didn’t show differences compared with patients without
fibrosis (F0) regarding age, splenectomy, transfusions, ICT and all biochemical
tests except for GGT (mean GGT 16.1 ± 10.9 U/L in F0 group, GGT 27.1 ±
24.8 U/L in patients with any grade of fibrosis, p <0.05). For 60 patients data
at 5±1 years (T1) were available. LSM remained stable in 35/60 (58.3%): 24
patients did not show fibrosis in both T0 and T1 evaluations, 10 patients
showed a F1 fibrosis in both evaluations and one remained in the F4 class.
Among these patients 13/35 (37.1%) were on ICT. A reduction in LSM was
found in 21/60 (35%) patients (T0=7.09±1.63 kPa, T1=5.07±1.61 kPa,
p<0.001), with a reduction trend in LIC (T0 =6.79±4.09 mg/g dw, T1=5.18±3.04
mg/g dw; p=0.09 ns) and a statistical significant reduction in ferritin levels
(T0=709±458 ng/ml, T1 436±280 ng/ml, p=0.005); 14/21 (66.6%) were on ICT.
Comparing patients who remained stable with patients who ameliorate the
grade of fibrosis, a significant difference was found regarding the number of
patients on ICT (37.1% vs 66.6% respectively, p <0.05). A worsening in LSM
was observed in 4/60 (6.6%) patients: among them LSM changed from F0 to
F1 in 2 patients, and from F2 to F4 in the other 2 patients. None of these
patients presented HCV RNA positivity
Summary/Conclusions: NTDT patients could benefit from regular non-inva-
sive assessment of liver fibrosis. In our study subject who received ICT had
best chance to reduce the grade of fibrosis through the reduction in iron over-
load. In these patients, that usually are HCV RNA negatives, monitoring and
treating iron overload is a crucial point in the prevention of hepatic fibrosis being
the hepatic siderosis the primary cause of hepatic tissue damage, cirrhosis and
hepatocellular carcinoma.
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INCREASING INCIDENCE OF MALIGNACIES IN AGING THALASSEMIC
PATIENTS: A SINGLE INSTITUTION’S LONGITUDINAL EXPERIENCE
E. Repousi1,*, M. Moraki1, D. Kyriakopoulou1, P. Delaporta1, A. Kafourou1,
A. Kattamis1
1Thalassemia Unit,First Department of Pediatrics, National and Kapodistrian
University of Athens, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece
Background: The introduction of close monitoring, regular blood transfusions
and systematic iron chelation in the management of thalassemia have signifi-
cantly changed the clinical phenotype of the patients and improved their sur-
vival. The patients, who have benefited of the current therapeutic regimen, are
now reaching middle age, and they have started facing problems more com-
monly seen in older people. Recent observations suggest of an increased inci-
dence of malignancies in the aging group of thalassemic patients.
Aims: The purpose of this study is to determine the longitudinal changes in the
incidence of malignancies, along with possible correlations to different aspects
of the disease.
Methods: A retrospective study in the largest Thalassemia Unit in Greece has
been conducted spanning an observation period from 2001-2016. The occur-
rence and type of cancer, as well as history on transfusion dependence, liver
failure, HCV infection and chelation therapy were recorded and analyzed. Sta-
tistical analysis was performed with SPSS software package, v. 20. A p-val-
ue<0.05 was considered statistically significant.
Results: Records from 591 patients (338 with thalassemia major and 253 with
thalassemia intermedia) were evaluated. 27 patients (11 males and 16 females)
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with malignancies were identified (incidence: 4.6%). The mean age of the diag-
nosis of the malignancy was 41.6 years (36.6 years for thyroid gland cancer,
45.8 years for liver, 38 years for hematologic malignancies and 46 for renal
cancer). 24 patients were transfusion dependent (TD) (7% of the patients) and
3 non transfusion dependent (1.18%). Liver cancer had the highest incidence
29.6%, following by thyroid gland cancer 25.9%, hematologic malignancies
11.1% and renal cancer 14.8%. HCV infection was found in 56.7% of the
patients and a statistical significant relationship between HCV infection and
cancer (p=0.001) was detected. No correlation between liver failure and cancer
was detected. In the TD group, the age specific ratio of cancer increased with
age with the patients >50 years having the highest ratio of 42.3, compared to
36.9 and 17.1 observed in the 46-50 years and 41-45 years age groups, respec-
tively. In regards to chelation therapy, at the time of diagnosis 40.9% of the
patients were receiving deferasirox (DFX), 22.7% deferiprone (DFP), 22.7%
deferoxamine (DFO), 9.1% no chelation therapy and 4.5% DFO/DFP. No sta-
tistical significant difference was observed between the different chelation ther-
apies (p=0.119). As the utilization of different types of chelation changed
throughout the years, according to the availability of the chelating agents, we
analyzed separately, the patients that developed malignancies in the period
after 2010 when longitudinal exposure to all three chelators can be assumed.
Even though the results showed a difference (p=0.027) between the different
groups with 47.1% of those patients receiving DFX at the time of the diagnosis
compared to 27.1% receiving DFP and to 11.8% receiving DFO, this distribution
reflects the overall distribution of chelator usage during that period. Apart from
the incidence, there was no statistical significant difference between TD and
NTD patients with cancer regarding the gender, age and year of diagnosis.
The mean cancer mortality rate was 48%, but varied significantly with the type
of cancer with liver cancer and hematological malignancies having a mortality
of 66% .Overall only 2% of the deaths occurring in our group of patients were
attributed to cancer.
Summary/Conclusions: This retrospective study has confirmed the increased
incidence of malignancies in thalassemia patients in Greece, which is, at least,
partially related to the aging of this population. Based on these observations,
adaptation of monitoring guidelines is essential for optimal management of
thalassemic patients. Periodic screening for malignancies, especially hepatic,
thyroid and hematologic, will allow early detection and timely, and thus, more
efficacious treatment of the neoplasia.
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SAFETY AND EFFICACY OF EARLY START WITH SUBOPTIMAL DOSE
OF DEFERIPRONE IN MINIMALLY TRANSFUSED INFANTS WITH
TRANSFUSION DEPENDENT THALASSEMIA: A RANDOMIZED TRIAL
M. Elalfy1,*, B. Helal2, V. Berdoukas3, F. Tricta4, M. Tarif1, H. Awad5, A. Adly1
1AinShams university, 2Ain Shams University, Cairo, Egypt, 33 Oasis Interna-
tional Hospital, Beijing, China, Beijing, China, 44 ApoPharma Inc., Toronto,
Canada, 5National Research Center, Cairo, Egypt
Background: Early exposure to Iron toxicity is the main risk factor for morbidity
and mortality in patients with transfusion-dependent thalassemia. Current prac-
tice is to start chelation therapy only after 10-20 transfusions, or when the
serum ferritin (SF) level rises above 1,000 μg/L. 
Aims: To evaluate the safety and efficacy of the early use of low-dose
deferiprone in minimally transfused pediatric thalassemia patients and to eval-
uate if it can postpone iron overload in these group of patients. 
Methods: In the current trial (ClinicalTrials.gov Identifier: NCT02173951),
sixty-four children recently diagnosed with thalassemia major who had
begun receiving blood transfusions in first year of life to keep pre-transfusion
Hb above 10 gm/dl, had not yet started iron chelation therapy and had SF
≥400 μg/L or transferrin saturation (TSAT) ≥70% or labile plasma iron (LPI)
≥0.2 µM were randomized to start deferiprone (DFP) at a sub-therapeutic
dose (50 mg/kg/day) or no chelation (NC). Median age at 1st transfusion
was 8 months for both DFP-treated and for NC children. The percentage of
patients with LPI ≥0.6 µM, SF ≥1000 μg/L or TSAT ≥70% in each study arm
was assessed at 6, 9 and 12 months (patients confirmed SF ≥1000 ng/mL
were withdrawn from the study and placed on a standard chelation regi-
men).  Complete blood count was done weekly in DFP treated and every 3-
4 weeks in NC.
Results: Table 1. Summary of the efficacy results of SF, TSAT, and LPI.
Table 1.
All NC patients were removed from the trial prior to completing 7 months of fol-
low-up (9-11 transfusions ) due to confirmed SF ≥1000 μg/L. Mean ± SD time
of follow up was 10.4± 4.9 and 5.9 ± 2.5 months for DFP and NC respectively.
Most common adverse events in patients on DFP versus NC were diarrhoea
(19% vs 13%, p= 0.73), vomiting (13% vs 13%, p=1.00), abdominal colic (13%
vs 13%), elevated liver enzymes (6% vs 3%, p=1.00) and neutropenia (6% vs
6%). All adverse events were mild in severity and did not require interruption
of DFP use. There were no cases of agranulocytosis or moderate neutropenia,
no arthralgia and no serious infections in DFP-treated patients. DFP therapy
was associated with a significant reduction in the rate of iron accumulation as
measured by SF (P<0.0001), LPI (P<0.001)and TSAT (P<0.001) (Figure 1a,
b, c). LPI ≥0.6 µM appeared as early as after 5 transfusions in NC children and
was delayed to at least 10 transfusions with DFP therapy. TSAT ≥70% appeared
after 10 transfusions in NC children and was delayed to at least 17 transfusions
with DFP therapy.The results of this study show that LPI and TSAT may reach
values ≥0.6 µM and ≥70%, respectively, after 5 -10 transfusions in children
with TM and all NC children had SF ≥1000 μg/L after 8-9 transfusions.
Figure 1.
Summary/Conclusions: A sub-therapeutic dose of deferiprone for a mean of
12 months in children with TM and low iron overload was not associated with
safety concerns and able to significantly reduce the rate of iron accumulation
as measured by SF , LPI and TSAT.
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LONGITUDINAL PROSPECTIVE MRI STUDY IN PEDIATRIC PATIENTS
WITH THALASSEMIA MAJOR
M. Casale1,*, A. Meloni2, A. Filosa1, L. Pistoia2, F. Sorrentino3, A. Quarta4,
A. Carollo5, M. C. Cirotto6, V. Positano2, E. Grassedonio7, M. Missere8,
A. Pepe2
1AORN A. Cardarelli, Napoli, 2Fondazione G. Monasterio CNR-Regione
Toscana, Pisa, 3Ospedale “Sant’Eugenio”, Roma, 4Ospedale “A. Perrino”, Brin-
disi, 5Azienda Ospedaliera “Sant’Antonio Abate”, Trapani, 6ASL N°1 Sassari,
Sassari, 7Policlinico “Paolo Giaccone”, Palermo, 8Fondazione di Ricerca e
Cura “Giovanni Paolo II”, Campobasso, Italy
Background: No studies are available in literature evaluating, on repeated
magnetic resonance (MRI) imaging assessments, changes in myocardial and
hepatic iron overload, biventricular function, and development of macroscopic
myocardial fibrosis in pediatric patients with thalassemia major (TM)    
Aims: This is the first longitudinal prospective MRI study in pediatric TM
patients.
Methods: We considered 68 TM patients enrolled in the MIOT (Myocardial
Iron Overload in Thalassemia) project with less than 18 years at the first MRI
scan and who performed a follow-up (FU) study at 18±3 months.
Myocardial and hepatic iron burdens were quantified by the T2* technique.
Atrial dimensions and biventricular function were quantified by cine images.
Late gadolinium enhancement (LGE) images were acquired to detect myocar-
dial fibrosis.
Results: At the baseline MRI, 16 (23.5%) patients showed myocardial iron
overload (MIO; global heart T2*<20 ms) and 54 patients liver iron overload
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(79%). Figure 1 shows the changes in iron levels. Twenty-five patients changed
the chelation regimen after the baseline MRI. Globally, a worsening in cardiac
iron was found in the 3% of the patients while a worsening in hepatic iron in the
21% of the patients (P=0.003). The LV end-diastolic volume index and all RV
volumes as well as the LV mass index were significantly lower at the FU MRI.
No significant improvement in left or right global systolic function was found.
For 40 patients the presence of myocardial fibrosis was investigated at both
baseline and FU scans. Six patients (15.0%) had myocardial fibrosis at the
baseline MRI and myocardial fibrosis was detected for all of them also at the
FU. The extent of myocardial fibrosis was comparable between the two scans
(0.77±0.42% vs 0.79±0.51%; P=0.686). At the FU 4 new occurrences of
myocardial fibrosis were detected. In patients with baseline MIO no significant
correlation was found between the percentage change in cardiac iron and the
changes in hepatic iron or the baseline hepatic iron.
Figure 1.
Summary/Conclusions: Magnetic resonance monitoring in children with TM
demonstrated a good control of cardiac iron overload in terms of prevention
and treatment but the need for further improvement of liver iron overload.
Myocardial fibrosis appears mainly multifocal, non progressive and not
reversible over a 18- month period. A prompt and aggressive approach to iron
overload and a chelation regimen consistent with the high iron intake and the
high rate of severe liver iron overload is recommended in children.
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LONG TERM FOLLOW-UP OF A COHORT OF WELL TREATED
Β-THALASSEMIA MAJOR PATIENTS BY MULTI-ORGAN R2* MAGNETIC
RESONANCE IMAGING
V.M. Pinto1, L. Bacigalupo2, B. Gianesin1, M. Balocco1, M. Lamagna1,
S. Quintino1, G.L. Forni1,*
1Haematology-Centro Microcitemia Anemie Congenite, 2Radiology Unit,
Ospedale Galliera Genova, Genova, Italy
Background: The introduction of non-invasive multi-organ evaluation of iron
overload by R2* Magnetic Resonance Imaging (MRI) in β-thalassemia major
(TM) patients has improved the patient care allowing a more careful tailoring
of iron chelation therapy.
Aims: We report a cross-sectional and longitudinal experience with the use of
MRI-R2* heart, liver and pancreas in a cohort of well treated TM patients.
Methods: TM patients underwent contemporaneous assessment of pancreatic,
cardiac and hepatic MRI-R2* (1.5 T GE HDx scanner) in the period Jan08-
Dec16.
Results: 69 TM patients: 43% male, age 38±9yrs, median number of observa-
tions/patient 6 (IQR:5-7), median number of yrs of the follow-up (f.u.) 8 (IQR:7-
8). Iron chelation regimens included deferiprone (basal 30%>f.u.32%),
deferasirox (basal 45%>f.u.52%), daily alternating deferasirox+deferiprone
(basal 3% -f.u.6%), deferoxamine (basal 9%>f.u.6%) deferoxamine+
deferiprone (basal 13%>f.u.4%). The observation at the baseline showed a
positive strong correlation between R2* values of pancreas and both of liver
(Rp=0.68, p<0.001) and heart (Rp=0.75, p<0.001), in accordance with literature.
Moreover, the ROC analysis confirms the value of 100 Hz for the pancreatic-
R2* as the predictor of cardiac R2*>50Hz (Noetzli et al. Blood 2009). We
observed a significative correlation of ferritin values with R2* of liver
(Rp=0.53,p<0.001), heart (Rp=0.24, p=0.04) and pancreas (Rp=0.35,p=0.003).
At f.u. the number of cases of moderate/severe iron overload decreases in the
liver (from 11 to 0), in the heart (from 14 to 2) and in the pancreas (from 27 to
23) and the correlation of R2* of pancreas with R2* of heart (Rp=0.25, p=0.034)
and liver (Rp=0.42, p<0.001) is weaker in respect to the baseline. We observed
a significative decrease of R2* values both in the liver (p=0.0012), heart
(p=0.017) and pancreas (p=0.018). Once again we found a correlation between
the values of ferritin and R2* of liver (Rp=0.37,p=0.0015), heart (Rp=0.26,
p=0.028) and pancreas (Rp=0.23,p=0.05). Moreover the variations of ferritin
correlate with the variations of R2* of the liver (Rp=0.6,p<0.001), heart (Rp=0.25,
p=0.04) and pancreas (Rp=0.41,p= p<0.001). Finally, assuming the cutoff value
of 100 Hz for the pancreatic-R2* as the predictor of a cardiac R2*>50Hz, we
calculated the numbers of false/true positive/negative according to the rule
above. At the baseline we can observe that the number of false positive is the
14/27 (52%). The percentage increases to 91% (21/23) after f.u.: the pancreas-
R2*>100Hz in 23 patients but only 2 has iron overload in the heart; the total
number of patients with pancreatic-R2*>100Hz is quite the same before and
after f.u. (27 compared to 23). We found no correlation between the false pos-
itive predicted and particular conditions such as impaired glucose tolerance,
diabetes or adipose involution (Table 1).
Table 1.
Summary/Conclusions: In this experience we observed that the regular mul-
ti-organ assessment of iron overload by R2* is concomitant with a reduction of
the iron burden in this cohort of well treated patients confirming that is a careful
method to tailoring the iron chelation therapy. However pancreatic-R2* remains
above the cut-off for the prediction of cardiac iron overload, so this parameter
should be considered with caution in the tuning of the chelation therapy, in
order to avoid over-chelation risk. Ferritin values trend agree with R2* values
confirming the reliability of this parameter. These results were obtained with a
prevalent use of oral chelation regiment (90% of patients).
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DEVELOPMENT OF HTLV-1 HYPERIMMUNE GLOBULINS AGAINST
HTLV-1 INFECTION
T. Mizukami1,*, K. Nojima1, R. Sobata2, W. Kuribayashi3, C. Matsumoto2,
Y. Sato1, E. Sasaki1, K. Furuhata1, Y. Hiradate1, K. Ohkuma1, S. Matsuoka1,
M. Satake1, I. Hamaguchi1
1Department of Safety Research on Blood and Biologicals, National Institute
of Infectious Diseases, 2Central Blood Institute, Japanese Red Cross, 3Depart-
ment of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba
University, Tokyo, Japan
Background: Adult T-cell leukemia (ATL) is a malignant disease caused by
infection with human T-lymphotropic virus (HTLV-1). The prevention of HTLV-
1 infection is the most effective strategy to eradicate ATL. However, there is no
effective vaccine or anti-viral agent for HTLV-1.
Aims: The aim of this study was to develop an effective HTLV-1 hyperimmune
globulin (HTLV-IG) isolated from HTLV-1 positive carriers screened at the
Japanese Red Cross.
Methods: We developed two in vitro and in vivo screening methods to evaluate
and characterize the anti-viral effect of HTLV-1 positive plasma and HTLV-IG.
Results: HTLV-1 positive plasma isolated from an HTLV-1 carrier with a proviral
load (PVL) >4 inhibited both HTLV-1 infection and syncytia formation. We purified
HTLV-IG from the HTLV-1 positive plasma (PVL >4) and evaluated its effect in a
humanized mouse model. NOG (NOD.Cg-Prkdcscid Il2rgtm1Sug/Jic) mice were
treated with HTLV-IG for 5 days before HTLV-1 infection. During the monitoring
period up to 40 days after post-infection, HTLV-1 infection was observed in
untreated infected mice, but not in HTLV-IG-treated mice. The inhibitory effect of
HTLV-IG was observed at the early stage of HTLV-1 Infection. Treatment with
HTLV-IG at 20 days after HTLV-1 infection had a partial inhibitory effect. HTLV-1
gp46 expression in HTLV-1 infected cells was slightly reduced and the localization
of these cells was changed in each tissue after the first line of treatment. These
data suggest HTLV-IG is effective at the early phase of HTLV-1 infection. We
also assessed the viral safety of HTLV-1 during the HTLV-IG manufacturing
process. High log reduction values of HTLV-1 were observed during the Cohn
fractionation process. Virus safety was assessed by PCR based assay and in
vitro and in vivo infection assays. We next assess the viral safety of HTLV-1
during the HTLV-IG manufacturing process. High log reduction values of HTLV-
1 can be seen during the Cohn fractionation process. Virus safety was assessed
with PCR based assay and in vitro and vivo infection assay.
Summary/Conclusions: These data suggest HTLV-IG is effective and safe
for the prevention of HTLV-1 infection.
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THE CONTAMINATION OF TUMOR CELLS IN THE APHERESIS MATERIAL
DOES NOT PREDICT THE RESPONSE OF MULTIPLE MYELOMA
PATIENTS TO AUTOLOGOUS TRANSPLANTATION
M.L. Lozano1,*, F. De Arriba1, M. Sola1, A. Sanchez-Fuentes1, N. Revilla1,
F. Ortuno1, A. Jerez1, I. Heras1, P. Iniesta1, O. Lopez-Godino1, M.D. Garcia-Malo1,
V. Vicente1
1Hematology and Clinical Oncology. Hospital Universitario Morales Meseguer,
Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca,
CB15/00055-CIBERER, Murcia, Spain
Background: The use of high dose of chemotherapy followed by autologous
stem cell transplantation (ASCT) has improved the prognosis of patients with mul-
tiple myeloma (MM) and plasma cell dyscrasia. However, there is controversy
over the effect of infusion of atypical plasma cells (PC) on the apheresis product.
Aims: To analyze whether in MM malignant plasma cell reinfusion could neg-
atively affect responses to ASCT.
Methods: Patients (n=114) undergoing ASCT (n=120) for MM between June
2003 and February 2016 were enrolled in a retrospective study to analyze the
prognostic value of aberrant (CD38++CD138+CD19-CD45weak) to
normal  phenotype (CD38++CD138+CD19+CD45+) plasma cells (A:T PC ratio)
in the autograft by flow cytometry. The Durie-Salmon stage at diagnosis,
response of disease to induction treatment, biological parameters, pre-ASCT
percentage of PC in bone marrow and at day +100, and the mobilization
scheme were determined. Response was assessed at day +100 after ASCT
using the 2006 International Myeloma Working Group uniform response criteria.
Data were analyzed with SPSS v20.
Results: Patient characteristics are shown in Table 1. Patients with a better pre-
ASCT response to induction therapy (complete response [CR] or very good
partial response [VGPR]) had a non-significant different median A:T PC ratio
content in the apheresis material, than those with a poorer response (partial
response [PR], stable [SD] or progressive disease [PD]), (0.4 vs 1, p=0.28). Sim-
ilarly, a non-significant difference (p=0.251) was observed in the number of atyp-
ical PC contained in the autograft of patients with a better vs poorer pre-ASCT
response (0.06 vs 0.08 ×10^6/kg). There was no difference between the type of
mobilization (G-CSF vs chemotherapy+G-CSF) and the degree of apheresis
contamination (median A:T PC ratio 0.5 vs 0.8; P=0.86). There was a statistical
trend between the degree of infiltration of PC in the bone marrow before ASCT
and the detection of atypical PC in the graft (p=0.06). At day +100, 94% of patients
with CR or VGPR to induction therapy maintained the response, and 49% of
patients in PR, SD or PD achieved post-ASCT CR or VGPR (p=1.24^-7). There
was no association between the content of atypical PC in the graft and the
response to day +100. However, the percentage of pre-ASCT PC in the bone
marrow was significantly related to the response at day +100 (CR or VGPR vs
PR, SD or PD), p=0.003, as well as the pre-ASCT monoclonal component
(p=4.03^-7).
Table 1.
Summary/Conclusions: Infusion of PC with atypical phenotype does not
appear to affect the response at day+100 following ASCT, in patients with MM
or plasma cell dyscrasia. Conversely, the quality of response to induction ther-
apy was significantly associated to 100-day outcome after transplantation.
These data support that in vivo persistent residual cells, but not those being
infused with the graft, are the main source of relapse in MM.
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EVALUATION OF THERAPEUTIC PLASMA EXCHANGE AT A TERTIARY
LONDON HOSPITAL
R. Moll1,*, D. Warcel1, S. Clark1, M. Sekhar1
1Haematology, Royal Free Hospital , London, United Kingdom
Background: Therapeutic plasma exchange (TPE) is used to treat a number
of haematological, renal and neurological conditions. Pathogenic antibodies
or other plasma molecules are removed, and plasma volume is replaced with
fluid. Human albumin solution (HAS) is usually preferred, except in cases of
Thrombotic Thrombocytopenic Purpura (TTP) and related conditions. TPE may
result in dilutional coagulopathy, and reactions such as hypersensitivity can
occur. The British Society for Haematology (BSH) published a 2015 guideline
to assist the use of TPE in UK clinical practice, providing evidence-based indi-
cations and recommended schedules.
Aims: To evaluate the use of elective TPE at a large tertiary London hospital,
compare clinical practice against BSH guideline recommendations, and explore
the effect of TPE on coagulation test results.
Methods: Data was collected prospectively over a 2 month period, using patient
notes and electronic transfusion records. A data collection form recorded the
indication, treatment schedule, replacement fluid, complications, the presence
of a written treatment plan, and frequency and results of coagulation testing.
Results: 24 plasma exchanges took place over the period of data collection;
there were no cases of TTP. Adherence to BSH guidelines was variable; although
most cases (88%) had an evidence-based clinical indication for TPE, just 4%
had a full written treatment plan, and only 17% of courses followed recommended
scheduling. 75% of patients had received at least one prior course, some outside
guideline indications for repeat courses. Most patients (83%) initially received
appropriate replacement fluid (HAS), however 87% received FFP at some point
during TPE, with 42% receiving Solvent Detergent FFP. In 17% of patients this
fluid change was due to a reaction, but for the remainder it was due to dilutional
coagulopathy. The guidelines recommend fibrinogen monitoring, and although
most patients had baseline measurement (75%), subsequent testing showed
wide variation. Despite this, 71% had a fibrinogen of ≤1 g/l measured during
TPE. Fibrinogen levels showed some correction by the next day but usually still
abnormal. A prolonged APTT and PT was also seen in most patients immediately
following TPE, which almost always corrected by the next day.
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Summary/Conclusions: TPE use was generally compliant with BSH guidelines
regarding clinical indication and initial replacement fluid. However many patients
were changed from HAS to FFP due to measured or predicted coagulopathy.
This is a recognised complication of TPE, and the guidelines suggest that if pos-
sible, TPE can take place on alternate days to ameliorate this. Fluid change to
FFP is recommended only for those at increased haemorrhagic risk. Almost all
the TPE courses in our study took place over 3 to 5 subsequent days, reflected
in the high frequency of hypofibrinogenemia. The optimum frequency of fibrinogen
monitoring, and the level that should prompt change to the TPE schedule, require
further exploration. The following are planned to enhance adherence to BSH
guidelines and improve patient care: 1. Documented treatment plans with clinical
indication, proposed treatment schedule, replacement fluid. 2. Local trust guide-
lines to include recommended TPE schedules, agreed parameters to monitor
response, frequency of fibrinogen monitoring, common complications and their
management. Where possible, TPE should take place on alternate days to reduce
dilutional coagulopathy. 3. Education of staff involved with service provision, and
strengthening of the role of apheresis nurse as lead.
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A COMPREHENSIVE PROTEOMICS STUDY ON PLATELET
CONCENTRATES: PLATELET PROTEOME, STORAGE TIME AND
MIRASOL PATHOGEN REDUCTION TECHNOLOGY
V. Salunkhe1, F. van Alphen2, I.M. De Cuyper1, B. Nota1, C. van der Zwaan2,
P.F. van der Meer3, B.B. Daal3, D. De Korte3, A.B. Meijer2, T.K. van den Berg1,
L. Gutierrez4,*
1Blood Cell Research, 2Plasma Proteins, Sanquin Research, 3Product and
Process Development, Sanquin Blood Bank, Amsterdam, Netherlands, 4Hema-
tology, IdISSC, Madrid, Spain
Background: Platelet concentrates (PCs) represent a blood transfusion product
with a major concern for safety as their storage temperature (20-24ºC) allows bac-
terial growth, and their maximum storage time period (less than a week) precludes
complete microbiological testing. Pathogen reduction technologies (PRTs) provide
an additional layer of safety to the blood transfusion products from known and
unknown pathogens (such as bacteria, viruses and parasites). In this context,
PRTs (such as Mirasol technology) have been developed and are implemented in
many countries. However, several studies have shown in vitro that Mirasol PRT
induces a certain level of platelet shape change, hyperactivation, basal degranu-
lation and increased oxidative damage during storage. It has been suggested that
Mirasol PRT might accelerate what has been described as the platelet storage
lesion (PSL), but supportive molecular signatures have not been obtained.
Aims: We aimed at dissecting the influence of both variables, i.e. Mirasol PRT
and storage time, at the proteome level.
Methods: We present comprehensive proteomics data analysis of control PCs
and PCs treated with Mirasol PRT at storage day 2, 6 and 8. Our workflow was
set to perform proteomics analysis using a gel-free and label-free quantification
(LFQ) approach. Semi-quantification was based on LFQ signal intensities of
identified proteins using MaxQuant/Perseus software platform. 
Results: We identified marginal differences between Mirasol PRT and untreat-
ed PCs during storage. However, those significant changes at the proteome
level were specifically related to the functional aspects previously described to
affect platelets upon Mirasol PRT, and in addition, the effect of Mirasol PRT on
the platelet proteome appeared not to be exclusively related to proteomic
changes due to PSL.
Summary/Conclusions: In summary, semi-quantitative proteomics allows to
discern between proteome changes due to Mirasol PRT or PSL, and proves to
be a methodology suitable to phenotype platelets in an unbiased manner, in
various physiological contexts.
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USE OF A SURVEY TO ASSESS AND IMPROVE ADHERENCE TO UK
BLOOD TRANSFUSION GUIDELINES IN A HOSPITAL SETTING
D. Warcel1,*, R. Moll1, A. Li1
1Haematology, Royal Free Hospital , London, United Kingdom
Background: UK guidelines to provide evidence-based support for decisions to
transfuse packed red cells were published in 2015 by NICE (National Institute for
Health and Care excellence). The guidelines specified Hemoglobin (Hb) targets
for transfusion, use of single unit transfusion to avoid over-transfusion, information
provision to patients for informed consent, and avoidance of pre-operative trans-
fusion by timely identification of iron deficiency for referral through an anemia
pathway.  A local baseline audit of NICE compliance at our London tertiary referral
hospital showed low overall compliance with these recommendations.
Aims: To determine knowledge amongst the prescriber group of transfusion
recommendations for stable patients, to gain insight into current patterns of
decision-making for transfusion and to impart knowledge of the key NICE guid-
ance to prescribers.
Methods: An online survey, designed to both evaluate and inform participants,
was targeted at doctors of different training grades and specialties during a two
week period. The outcomes of this are being used to guide further training.
Results: Of 141 participants who took part in the survey, 31% (43) had been
qualified for less than two years and 47% (65) were consultants. Specialties
included Surgery, Anesthetics, Internal Medicine, Hemato-Oncology and Inten-
sive Care. 60% (84) had prescribed blood within the last month. Despite only
51% (72) awareness of the NICE guidelines, a significant majority (73%, 103)
selected the correct Hb threshold of ≤70g/L for transfusion in patients without
acute coronary syndrome (ACS). For patients with ACS, the correct Hb thresh-
old of ≤80g/L was selected by 42% (58), but there was a wide spread of
answers. 65% (90) of participants were aware that, in a stable patient Hb is
checked after each unit of red cell transfusion, but surprisingly a few (4%, 5)
did not check post transfusion Hb at all. Ferritin measurement was inconsistent
with only 47% (66) routinely measuring this prior to transfusion, and only 31%
(44) aware that a ferritin result over 30 days old should be rechecked. This
highlighted potentially inadequate identification of iron deficiency anemia. In
addition only 40% (57) were aware of the existence of a hospital anaemia clinic
for referral. When reflecting on consent methods, 96% (135) of participants
explained the indication to patients, and 90% (127) gave an opportunity to ask
questions and ensured the patient was content to proceed. Provision of written
information was poor (26%, 37) and only 55% (78) recorded the discussion in
patients’ notes. Exploring barriers to consent, 24% (32) expressed difficulty in
obtaining a patient information leaflet, and issues relating to lack of time and
confidence were 16% (22) and 9% (12) respectively.
Summary/Conclusions: Although the majority of participants expressed aware-
ness of the NICE guidance, knowledge was not reflected in subsequent questions.
The survey allowed simultaneous assessment of knowledge and provision of key
information as a factsheet. Almost all participants felt that completion of the survey
had been helpful, and as a tool to reach a highly mobile group, the survey is a
constructive and supportive method to facilitate implementation of national guid-
ance by medical staff. We were also able to identify areas that need further devel-
opment including the clinical referral pathway for the anemia clinic and improving
the availability of patient information leaflets on hospital wards. At present we are
updating the hospital transfusion policy, which will be disseminated to all hospital
staff, and carrying out structured case based discussion sessions with junior doc-
tors to enhance knowledge and confidence.
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SCREENING OF TRANSFUSION PRODUCTS FOR PRION DISEASES
USING APTAMERS AND TUNABLE RESISTIVE PULSE SENSING
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Background: Prion diseases are a group of fatal transmissible neurological
conditions whose disease etiology is characterised by the change in confor-
mation of the normal intrinsic cellular prion protein (PrPc) in to the highly ordered
insoluble amyloid state conformer (PrPsc). The significant event fundamental
to the progression of these diseases is the self-catalytic, and perpetuating,
nature of the conversion of PrPc in the presence of PrPsc aggregates. The
emergence of Variant Creutzfeldt-Jakob disease (vCJD), the most predominant
prion disease in humans in the United Kingdom during the 1990s, is considered
to be an effect of dietary exposure to the bovine spongiform encephalopathy
(BSE) agent through contaminated meat products. To date, the widely accepted
estimate for the prevalence of vCJD in the UK puts the number of potential car-
riers at 1 in 2000. Since the disease is known to be infectious and transmissible,
the iatrogenic ability of this disease is a significant risk to public health through
transfusion products and surgical procedures.
Aims: We aim to develop a reliable and robust assay that can be used as a
screening tool to detect the infectious PrPsc protein at low levels in human
blood with high selectivity and high sensitivity. 
Methods: Here we use a technique based on the Coulter Counter principle
that uses tunable elastomeric nanopores termed Tunable Resistive Pulse Sens-
ing (TRPS) to detect the prion protein without an amplification step. The first
stage optimises the grafting of an ssDNA aptamer onto nanoparticles. In proof
of concept work, the functionalized nanoparticles were then used to detect the
cellular prion protein in phosphate buffered saline by monitoring the relative
change in velocity through the nanopore, which is then converted to zeta poten-
tial. The method was then applied to protein rich samples and serum. 
Results: By varying the concentration of aptamer relative to the binding capacity
of the nanoparticles, a significant change (p=0.05) in zeta distributions was
observed. Here mean zeta values were -1.94 mV for 0%; -4.43 mV for 33%; and
-7.30 mV for 100%. The assay was further developed by monitoring the function-
alized particle’s translocation velocity as a function of prion protein concentration.
Increasing the concentration of the protein caused shielding of the polyanionic
DNA by the positive protein at pH 7.4, therefore the velocity of the protein/particle
conjugate decreased. The lowest concentration to have a significant change
(p=0.05) in velocity distribution was 1 nM, with a 2.5% decrease relative to 0 nM.
The higher concentration of 50 nM had a bigger effect of 24% decrease. 
Summary/Conclusions: TRPS technology presented here offers the ability to
observe the interaction of an aptamer and the prion protein using a particle by
particle assay design. Any relative change to the functionalized particle’s signal
could be observed, demonstrating its capability and suitability to detect biolog-
ical targets.
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SIMULTANEOUS SESSIONS II
Front-line combinations in multiple myeloma and
amyloidosis
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QUADRUPLET VS SEQUENTIAL TRIPLET INDUCTION THERAPY FOR
MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY
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Background: Combining anti-myeloma induction therapies limits the impact
of clonal heterogeneity on resistance to therapy, maximising response and
associated clinical outcomes. Triplet combinations induce deeper, longer remis-
sions than doublets and those containing an immunomodulatory agent, a pro-
teasome inhibitor (PI) or both are the current standard of care in Europe/US.
Potential approaches to further improve outcomes include response-adapted
induction, treating suboptimal responders with sequential treatment using an
agent with a different mechanism of action, or intensifying induction for all
patients by the use of quadruplet combinations upfront.
Aims: The UK NCRI Myeloma XI trial is a large, phase III study comparing, in
transplant eligible (TE) patients, the induction quadruplet carfilzomib,
cyclophosphamide, lenalidomide and dexamethasone (KCRD) to the sequen-
tial strategy of triplet immunomodulatory combinations (with thalidomide or
lenalidomide) followed by additional pre-transplant consolidation with PI triplet
therapy for those with a suboptimal response.
Methods: In 2013, the TE pathway of the Myeloma XI study was amended to
include KCRD given in 28 day cycles (carfilzomib 36mg/m2 IV d1-2,8-9,15-16
(20mg/m2 #1d1-2), cyclophosphamide (cyclo) 500mg PO d1,8, lenalidomide
(len) 25mg PO d1-21, dexamethasone (dex) 40mg PO d1-4,8-9,15-16).
Patients were randomised to this up-front quadruplet or the sequential strategy
of CRD (cyclo 500mg PO d1,8, len 25mg PO d1-21 PO daily, dex 40mg PO
d1-4, 12-15) or CTD (cyclo 500mg PO d1,8,15 thalidomide 100-200mg PO
daily, dex 40mg PO d1-4,12-15) given to max. response. Patients with
VGPR/CR proceeded straight to ASCT, those with PR/MR were randomised to
sequential CVD (cyclo 500mg d1,8,15, bortezomib 1.3mg/m2 IV/SC d1,4,8,11,
dex 20mg PO d1,2,4,5,8,9,11,12) or nothing and those with SD/PD all received
sequential CVD. At day 100 post ASCT there was a maintenance randomisation
between lenalidomide and observation. The trial has now closed to recruitment
and all patients have completed induction therapy. This analysis compares
responses and toxicity of the different regimens.
Table 1.
Results: 2568 TE patients underwent induction randomisation (CTD 1021,
CRD 1021, KCRD 526). Patients were comparable with respect to age (median
59 years), sex and other key laboratory parameters. Patients were mandated
to receive a minimum of 4 cycles of initial induction with therapy continued to
maximum response. The median number of cycles delivered was CTD: 5, CRD:
5, KCRD: 4. Grade ≥3 haematological toxicities differed between the groups.
(Neutropenia CTD: 12%, CRD: 22%, KCRD: 16%; Thrombocytopenia CTD:
3.4%, CRD: 4.5%, KCRD: 8.1%; Anaemia CTD: 6.7%, CRD: 9.6%, KCRD
10%). Grade ≥2 neurological toxicity was greater with the thalidomide-contain-
ing regimen (Sensory neuropathy CTD: 9.5%, CRD: 3.4%, KCRD: 2.3%). There
was no statistically significant difference in rates of investigator reported, all-
grade, thromboembolic events between regimens (CTD: 11.8%, CRD 11.1%,
KCRD 14.7%). Response to initial induction and following ASCT is shown in
Table 1 indicating deeper responses with the quadruplet compared to triplets
both at the end of first induction regimen (p<0.0001) and, importantly, post-
ASCT (p<0.0001). These differences were observed despite the use of ran-
domised pre-transplant consolidation for suboptimal responders to triplet
immunomodulatory therapy.
Summary/Conclusions: Induction therapy with KCRD, an outpatient delivered
quadruplet regimen, was associated with deeper responses than immunomod-
ulatory triplet therapy (CRD/CTD) and was well tolerated. Deeper responses
persisted after ASCT, with an impressive response rate ≥VGPR of 92% with
KCRD.
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Background: Triplet combinations that include a proteasome inhibitor (PI)
have been proven superior to doublets in newly diagnosed multiple myeloma
(NDMM) (San Miguel et al, N Engl J Med 2008, Durie et al, Lancet 2017). The
all-oral combination of the novel PI ixazomib plus lenalidomide-dexamethasone
(IRd) was evaluated as an induction regimen in NDMM patients, followed by
single-agent ixazomib maintenance.
Aims: Here we report updated efficacy and long-term safety data for patients
who did not withdraw from the study in order to receive stem cell transplantation
(SCT).
Table 1.
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Methods: In this phase 1/2 study (NCT01217957), patients with NDMM
received weekly oral ixazomib (1.68-3.95mg/m2; days 1, 8, and 15) plus
lenalidomide (25mg, days 1-21) and dexamethasone (40mg, days 1, 8, 15, and
22) for up to twelve 28-day induction cycles, followed by maintenance therapy
with weekly single-agent ixazomib, at the last tolerated dose given during induc-
tion, until disease progression or toxicity.
Results: Of the 65 enrolled patients, 42 continued on study treatment without
early withdrawal for SCT; the long-term follow-up of these 42 patients is report-
ed here. Baseline patient characteristics included: median age, 68 years (range
34-86); ISS stage I/II/III in 40%/43%/17%. As of October 18, 2016, with median
follow-up of 56 months, the confirmed overall response rate (ORR; ≥ partial
response [PR]) was 80%, complete plus very good partial response
(CR+VGPR) rate was 63%, and CR rate was 32%. Median time to first
response was rapid (0.95 months), while median time to CR was 5.6 months.
Median progression-free survival (PFS) in these patients not receiving SCT
was 25.3 months. Median overall survival (OS) has not been reached at a
median follow-up of 56 months; 3-year OS estimate was 87%. Safety findings
are summarized in the Table; 74% of patients had grade ≥3 treatment-related
adverse events (AEs), and 26% of the patients had treatment-related serious
AEs. Among treatment-related AEs of interest, grade ≥3 rash and peripheral
neuropathy were infrequent. There was one treatment-related death due to
respiratory syncytial viral pneumonia. After completing 12 cycles of induction
therapy with IRd, 25 patients went on to receive maintenance single-agent
ixazomib. In these 25 patients, at the end of the induction period ORR was
100%, including 44% VGPR and 32% CR. Responses deepened during main-
tenance; at data cut-off, the response rates in this maintenance therapy pop-
ulation were ORR 100%, VGPR 32%, and CR 44%. Median PFS for patients
who received maintenance therapy was 24 months. The occurrence of the
most common treatment-related grade ≥3 AEs (neutropenia, thrombocytope-
nia, and fatigue) was confined almost exclusively to the induction period. Dur-
ing the maintenance period no patients reported onset of grade ≥3 peripheral
neuropathy or rash.
Summary/Conclusions: In patients with NDMM, weekly ixazomib plus Rd,
followed by single-agent ixazomib maintenance, was highly active, resulting in
deep and durable responses, long PFS, and a high 3-year OS estimate. IRd
followed by single-agent ixazomib maintenance also showed an acceptable
safety profile, with less toxicity reported during the maintenance (single-agent
ixazomib) vs induction (IRd) periods, with no evidence of cumulative toxicities.
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Background: Bortezomib plus melphalan and prednisone (VMP) and lenalido-
mide plus low-dose dexamethasone (Rd) are two standards of care for elderly
untreated MM patients. In order to improve its outcome, we decided to use
both VMP and Rd for 18 cycles in a sequential or alternating scheme. After a
median f/u of 27 months, both regimens (sequential and alternating) showed
similar efficacy with an acceptable toxicity profile. 
Aims: To consolidate data, we have updated the outcome with long f/u (51
months), evaluating the role of Complete Response and Minimal Residual Dis-
ease (MRD) by multiparametric flow cytometry. 
Methods: 242 pts were randomized to receive 9 cycles of VMP followed by 9
cycles of Rd or the same regimens in an alternating approach (one cycle of
VMP alternating with one Rd, up to 18 cycles. VMP included the iv administra-
tion of weekly bortezomib (except in the first cycle that was given twice weekly)
at 1.3mg/m2 in combination with oral melphalan 9mg/m2 and prednisone
60mg/m2 once daily on days 1-4. Rd treatment consisted on len 25mg daily on
days 1-21 plus dex 40mg weekly. MRD was evaluated by second generation
flow (sensitivity level of 10-5). 
Results: 233 pts were evaluable for efficacy. Baseline characteristics of the
pts were well balanced in both arms. The median progression-free survival
(PFS) was of 30m in the sequential and 32m in the alternating arm (p>0,5).
The median overall survival (OS) has been reached in the sequential arm (64m)
whilst has not been reached yet in the alternating arm (63% at 5y) (p>0,5). 95
patients (41%) achieved >CR (49 and 46 patients in the sequential and alter-
nating arms, respectively). Pts who achieved >CR had a significantly longer
PFS (median of 45m) as compared with pts who didn’t (median of 22,3 m) (HR:
0,32; p<0.0001). This translated into a benefit in OS: 73% of pts that achieved
>CR remain alive at 5 years whilst the median OS was of 49m for patients that
didn’t achieve CR (HR: 0,34; p<0,0001). No differences were observed between
the sequential and alternating arms. Minimal residual disease MRD was eval-
uated in 83 out of the 95 pts who achieved >CR. In 46 of them (55%) cells
were undetectable with a sensitivity threshold of 10-5, and were considered as
MRD-ve patients. These pts displayed a significantly longer PFS (median not
reached) as compared to MRD+ve pts (median PFS of 40m) (HR: 0.32;
p=0,006) as well as significantly longer OS (HR: 0.26; p=0.012). FISH was
available in 174 patients: 32 (18%) were considered high-risk (t(4;14), t(14;16)
or del 17p). Outcomes were inferior but not significantly different between the
high- and standard-risk groups in terms of PFS (26m vs. 33 months (p=0.11)).
The achievement of >CR completely overcome the adverse prognosis of the
presence of high-risk cytogenetic abnormalities with a median PFS of 47m and
50m in the high and standard-risk subgroup, respectively (p>0.5). This effect
was also evident when MRD negativity was achieved. In terms of OS, the out-
come for both high and standard risk subgroup of pts was superimposable dur-
ing the first 20 months but the curves separated since this point, resulting in a
median OS of 40m and 63m (p=0,001), respectively. This effect was maintained
for pts that achieved >CR including MRD negativity. 
Summary/Conclusions: The present therapeutic approach, based on VMP
and Rd for newly diagnosed elderly MM pts represents an optimal therapeutic
option for fit elderly patients. Pts who achieved >CR and MRD-flow had signif-
icantly longer PFS and OS. The achievement of >CR and MRD negativity is
able to overcome the poor prognosis of the presence of high risk cytogenetic
abnormalities in terms of PFS but continuous therapy is probably required for
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Background: Previous phase I-II studies showed that Carfilzomib-Lenalido-
mide-Dexamethasone (KRd) and Carfilzomib-Cyclophosphamide-Dexametha-
sone (KCd) combinations are safe and effective in patients with newly diag-
nosed multiple myeloma (NDMM) (Jakubowiak Blood 2012, Bringhen Blood
2014).
Aims: The FORTE trial compared KCd vs KRd in transplant-eligible patients.
Here we report results of the first planned safety interim analysis on induction
and mobilization, and preliminary efficacy data.
Methods: NDMM patients younger than 65 years of age were included. Patients
were randomized (1:1:1; stratification ISS and age) to: 4 28-day KCd cycles
(carfilzomib:20/36mg/m2 IV d 1, 2, 8, 9, 15, 16; cyclophosphamide 300mg/m2
d 1, 8, 15; dexamethasone: 20mg d 1, 2, 8, 9, 15, 16) followed by high-dose
melphalan and autologous stem cell transplantation (MEL200-ASCT) and con-
solidation with 4 KCd cycles; or 4 28-day KRd cycles (carfilzomib and dexam-
ethasone as above; lenalidomide:25mg d 1-21) followed by MEL200-ASCT
and 4 KRd cycles; or 12 KRd cycles. After the 4th induction cycle, all patients
received Cyclophosphamide 2 g/m2, followed by peripheral blood stem cell col-
lection. For the present interim analysis, we pooled together data of the two
KRd groups, because patients in the two groups in fact received the same
treatment until mobilization. Data cut-off was October 30, 2016. 
Results: A total of 281 patients were evaluated (94 assigned to KCd treatment
and 187 to KRd treatment). The most frequent grade 3-4 adverse events (AEs)
and serious AEs (SAEs) in both arms were hematological (mainly neutropenia)
and infections (mainly pneumonia/fever); increased AST/ALT/GGT (mainly
reversible) and dermatological (rash) AEs were more frequent among KRd
patients; cardiac AEs were 2% with KRd (including atrial fibrillation [1%] and
ischemic heart disease [1%]) vs 1% with KCd (atrial fibrillation). Death occurred
in 1 patient in the KCd group (infection not treatment-related) vs 3 patients in
the KRd group (2 cardiac arrest [1 not treatment-related], 1 infection not treat-
ment-related). In the KCd vs KRd arms, 99% vs 95% (P=0.44) of pts mobilized
stem cells (median number of PBSC collected: 9 vs 6x10^6CD34/Kg with KCd
vs KRd). Plerixafor was required in 10% vs 24% (P=0.01), respectively. At least
a very good partial response (VGPR) was reported in 61% of patients receiving
KCd vs 74% receiving KRd (P=0.05). 
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Table 1.
Summary/Conclusions: Safety profile was acceptable; more patients required
plerixafor in the KRd arm. Rate of VGPR was higher with KRd. Updated data
on a higher number of patients will be presented at the meeting. The trial is
registered at Clinicaltrials.gov: NCT02203643
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Background: Bortezomib (B) has been reported to be very effective in AL
amyloidosis with overall response rates (ORR) varying between 50-80%. How-
ever, there are no prospective data from multicenter studies on B treatment in
de novo patients. We investigated the efficacy and safety of B-Dexamethasone
(BD) induction treatment followed by HDM+SCT in de novo AL amyloidosis
patients.
Aims: The primary aim was to improve the hematological CR rate at 6 months
after SCT on intention to treat analysis from 30 to 50%. Secondary aims were
OS, PFS, hematologial response rate after BD treatment, organ responses,
safety and prognostic factors for survival.
Methods: Patients with biopsy proven AL amyloidosis, aged between 18-70
years, with detectable M-protein and/or level of involved FLC >50mg/L, WHO
performance status 0-2, NYHA stage 1-2 and ejection fraction >45% were
included. Major exclusion criteria were symptomatic orthostatic hypotension,
NT proBNP level >5000 pg/ml, Troponin T> 0.06 ug/l, Bilirubin >2x ULN,
eGFR<30 ml/min, CTCAE grade peripheral sensory neuropathy > grade 2 or
> grade 1 with pain. Inclusion and exclusion criteria were installed both at entry
and before stem cell mobilization (SCM). B was given subcutaneously
1.3mg/m2 twice a week for 2 weeks in a 21-day cycle, D 20mg orally on each
B day and the following day. HDM dosage was 200mg/m2. Hematological
responses were defined according to consensus criteria with the addition of
very good partial response (VGPR), defined as the difference between involved
and uninvolved FLC<40mg/L. Cardiac, renal and liver response and progres-
sion criteria were defined according to consensus criteria with addition of NT
proBNP. 
Results: Median age was 59 years (range 26-70) and 60% were male. NYHA
stage was 1 in 56% and 2 in 42% of patients. Mayo cardiac risk score was I
(30%), II (36%), III (34%). Organ involvement was 82% renal, 66% heart, 28%
liver, 14% neurological, 8% gastrointestinal and 38% of patients had 3 or more
organs involved. Bone marrow plasmacells were >10% in 28% of patients. The
median FU for patients alive is 24 (10-55) months. Twelve of 50 (24%) patients
could not proceed to SCM. Four patients due to B related toxicity, 3 patients
did not fulfill criteria to proceed, 2 patients died (both amyloidosis related) and
3 miscellaneous. Of these 38 patients, 3 went subsequently off protocol
because of ineligibility for HDM. Thirty-five out of 50 patients (70%) received
HDM + SCT, one patient died of a cardiac arrest after the SCT procedure.
The ORR after induction was 80%, ≥VGPR in 54% and CR in 6% of patients.
The ORR in the 35 patients at 6 months after SCT was 80%, ≥VGPR in 51%
and CR in 43% of patients. On intention to treat analysis the CR rate at 6
months after SCT was 30%. Organ responses at 6 months after SCT were
16/29 renal, 2/8 liver and 13/23 heart. No baseline characterics were identified
to be predictive for OS or PFS. BD doses were reduced and delayed after 2
cycles in almost half of patients, mostly because of neurotoxicity, Sensory neu-
ropathy grade 2 or higher was seen in 36% of patients and autonomic neu-
ropathy, mostly dizziness and collapse, in 22%. 
Summary/Conclusions: This final analysis demonstrates that the primary aim
of improving CR rate at 6 months after SCT from 30 to 50% was not met. This
was mainly caused by the high dropout rate before SCT. This may be due to
patient selection, but we also demonstrate that BD, given twice weekly sc,
despite good efficacy, cannot prevent early amyloidosis related toxicity and
can induce grade 2 or higher neurotoxicity.
Trial registration www.trialregister.nl (NTR 3220), EudraCT 2010-021445-42,
supported by the Dutch Cancer Society (UU 2010-4884 ) and by an unrestricted
grant from Janssen-Cilag.
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Background: Nivolumab, a fully human IgG4 monoclonal antibody targeting
programmed death-1, is an immune checkpoint inhibitor that augments T-cell
activation and antitumor responses. Nivolumab is indicated for pts with
relapsed/refractory (RR) classical Hodgkin lymphoma (cHL) following autolo-
gous stem cell transplantation (ASCT) and brentuximab vedotin (BV) treatment.
The multicohort phase 2 CheckMate 205 trial (NCT02181738) enrolled pts with
RR cHL after ASCT. Initial analyses revealed high objective response rates
(ORR), encouraging duration of response (DOR) and an acceptable safety pro-
file (Younes A et al, Lancet Oncol 2016). Durable responses to therapy are
valuable in pts with progressive disease after failure of ASCT due to their limited
treatment options.
Aims: To report extended follow-up data for all pts with RR cHL after failure of
ASCT in CheckMate 205.
Methods: This single-arm multicenter trial enrolled pts (age ≥18 y) with RR
cHL after ASCT into 1 of 3 independent cohorts (Cohort A: BV-naïve; Cohort B:
BV only after ASCT; Cohort C: BV before and/or after ASCT). All pts received
nivolumab 3mg/kg every 2 wk until disease progression or unacceptable toxicity.
Pts in Cohort C with a persistent complete response (CR) for 1 y were to dis-
continue nivolumab and could resume at relapse. Primary endpoint was ORR
per Independent Radiology Review Committee. Secondary endpoints included
DOR; progression-free survival (PFS), overall survival (OS), and safety were
exploratory endpoints. All pts provided written informed consent.
Figure 1.
Results: In total, 243 pts were treated: 63 in Cohort A (BV-naïve), 80 in Cohort
B (BV after ASCT), and 100 in Cohort C (BV before [n=33], after [n=58], or
before and after [n=9] ASCT). Median (range) age was 34 (18-72) y and 77%
of pts had advanced (stage III+) disease at study entry. BV-naïve pts had fewer
prior lines of therapy (median of 2 vs 4 with prior BV). At Dec 2016 database
lock, median (min, max) follow-up was 19 (1, 25), 23 (2, 27) and 16 (1, 20) mo
in Cohorts A, B, and C, respectively. Overall, 40% of pts were still on treatment;
the most common reason for discontinuation was disease progression (26%).
ORR was 65% in Cohort A, 68% in Cohort B, and 73% in Cohort C, with 29%,
13%, and 12% CR, respectively. Median (95% CI) DOR was 20 (13, 20), 16 (8,
20), and 15 (9, 17) mo in Cohorts A, B, and C, respectively. DOR for patients
with CR was 20 months for BV-naïve patients (Cohort A) and ≥15 mo for BV-
treated patients (Cohorts B and C); DOR for patients with partial response (PR)
was 17 and ≥11 months, respectively. PFS by cohort is shown (Figure 1). Pro-
longed median PFS was seen for patients with CR (≥17 mo in each cohort),
PR (≥15 mo in each cohort), and stable disease (≥9 mo in each cohort). Median
OS was not reached in any cohort. The most common drug-related AEs were
fatigue (23%), diarrhea (15%), infusion reactions (IRs; 14%), and rash (12%);
grade 3-4 drug-related AEs in ≥3% of pts were lipase increases (5%), alanine
aminotransferase increases (3%), and neutropenia (3%). The most common
drug-related serious AEs were IRs (2%) and pneumonitis (1%). To facilitate
translation to practice, efficacy results by sequencing of prior BV treatment will
be presented.
Summary/Conclusion: With extended follow-up, high and durable rates of CR
and PR to nivolumab therapy were observed in pts with RR cHL after ASCT,
irrespective of BV treatment history.
Study funding: BMS; medical writing support: M Thomas (Caudex), funded by
BMS.
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Background: Interim 2-[18F]fluoro-2-deoxy-D-glucose Positron Emission
Tomography (FDG-PET) performed after 2 chemotherapy cycles (PET2) is the
most powerful predictor of treatment outcome in ABVD-treated, advanced-stage
classical Hodgkin Lymphoma (cHL). Preliminary reports showed that adapting
treatment to PET2 result could increase the efficacy of standard ABVD.
Aims: To confirm in a prospective setting the favorable prognosis of advanced
stage PET2 negative patients treated with ABVD, as well as the safety and effi-
cacy of escalated BEACOPP given to PET2 positive patients.
Methods: We conducted a prospective clinical trial (HD0607 ClinicalTRial.gov
identifier 00795613), in which advanced-stage (IIB-IVB) cHL patients were treat-
ed with 2 ABVD courses, and PET2 performed afterwards. The latter was blindly
and independently reviewed by a panel of nuclear medicine experts, using the
Deauville 5-point scale (5-PS). PET2+ patients (5-PS 4-5) were randomized to
either BEACOPP escalated (Be) plus BEACOPP baseline (Bb) (4+4 courses)
or Be+Bb (4+4) and Rituximab (R). PET2- (5-PS 1 to 3) patients continued
ABVD treatment with 4 more cycles and, upon CR achievement, randomized
to either consolidation radiotherapy (Rxt) on the sites of initial large nodal mass
(LNM: diameter >5cm) or no further treatment (NFT).
Results: Starting from June 2008 till June 2014, 782 cHL patients were con-
secutively enrolled in 24 Italian and 1 Israeli centers. The median age was 31
years (14-60); 35% had stage IIB, 32% stage III and 32% stage IV. The Inter-
national Prognostic Score (IPS) was 0-1 in 36.6%, 2-3 in 51%, >3 in 12.5%.
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Overall, 150 (19.2%) proved PET2+ (97 score 4, 53 score 5) and 630 (80.5%)
PET2-. PET2+ patients were more frequently male (56.7% vs 47.1%, p=.03),
had higher IPS score (P=.0002) and bulky disease (28.0% vs 17.9%; p=.0002).
Out of 149 PET2+ patients randomized to Be+Bb (76) or Be+Bb+R (73), 136
were evaluable for response: 93 obtained CR and 43 had a treatment failure.
Of the remaining 13 patients, 3 died, 7 withdrew their consent and 3 stopped
treatment for toxicity. As per study protocol, 627 out of 630 PET2- patients con-
tinued with 4 ABVD cycles and 3 withdrew their consent. Out of 296 with LNM,
148 were randomized to RxT and 148 to NFT. Among 627 patients, 574 (91.5%)
achieved CR, 50 (8.0%) had a treatment failure and 3 (0.4%) withdrew their
consent. Overall, 30 patients (3.8%) died, due to early death (n=2), resistant
disease (n=18; 12 with a positive and 6 with a negative PET2), transplant relat-
ed toxicity (n=5), infections (n=4) and pulmonary fibrosis (n=1). After a median
follow-up of 1303 days (2-2857), the 4-Y PFS and OS for all 782 patients was
83% (95% CI 80%>86%) and 96% (95% CI 94%>97%), respectively. For
PET2+ and PET2- patients, the 4-Y PFS was 69% (95% CI 60%>76%) and
87% (95% CI 84%>89%), while the 4-Y OS was 89% (95% CI 82%>93%) and
97% (95% CI 95%>98%) (Figure 1, Panel A and B). No outcome difference
was observed for Be+Bb vs Be+Bb+R patients, with a 4-Y PFS of 69% (95%
CI 57%>79%) and 68% (95% CI 55%>78%), respectively (p=.9731). Consoli-
dation RxT in PET2- patients in CR after 6 ABVD and LNM did not translate in
to a significant benefit, with a 4-Y PFS of 96% (95% CI 91%>98%) for RxT and
93% (95% CI 87%>96%) for NFT (p=.2882).
Figure 1.
Summary/Conclusions: These data suggest that 1) an early switch from
ABVD to escalated BEACOPP can be safely done in PET2+ advanced-stage
cHL; 2) the long-term outcome for the entire patient cohort is superior to stan-
dard ABVD; 3) no clinical benefit is associated with post ABVD RxT in PET2-
patients presenting with large nodal mass; 4) the addition of Rituximab does
not increase the effectiveness of Be+Bb in PET2+ patients.
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Background: Data on disease presentation, therapeutic options and survival
after 3rd or higher relapse of classical Hodgkin lymphoma (cHL) are sparse.
Therefore the additional benefit of new agents, which are usually initially inves-
tigated after several relapses of cHL, is difficult to estimate.
Aims: The aim of this study was to define and describe a historical control
group in European patients from the German Hodgkin Study Group (GHSG)
data for comparison of safety and efficacy of novel therapeutic agents.
Methods: Cases with at least three consecutive tumor-related events, either
progressive refractory or relapsed disease, were identified in the GHSG data-
base. Detailed information was added from case report forms and physician’s
letters. Overall survival (OS) was the main and progression free survival (PFS),
response to therapy, adverse events, disease and treatment characteristics as
secondary endpoints. 
Results: Among 12,584 HL patients in the GHSG first-line trials HD7 to HD15
and 449 HL patients in the trials HDR1 and HDR2 a total of 69 cHL patients
with ≥3 tumor events were identified. The dates of occurrence of 3rd relapse
ranged between 15th of January 1993 and 21st of June 2013. The sample con-
sisted of 51 male (74%) and 18 female (26%) patients. At time of 3rd relapse
the age of the patients ranged from 20 to 79 years (mean 39.2 years, standard
deviation (SD) 14.0 years) and the majority of patients presented with stage III
or IV disease (67%). Time from end of 3rd-line treatment to 3rd relapse was ≤3
months (i.e. GHSG definition of refractory disease) in 15 cases (22%), ≤12
months (early relapse) in 19 cases (28%) and >12 months (late relapse) in 35
cases (51%). All 69 patients were pretreated with chemotherapy, 35 (50.7%)
with BEACOPP, 30 (43.5%) with ABVD and no BEACOPP, and 32 (46.6%)
with another type of chemotherapy. The number of prior chemotherapies
ranged from one to three (median 3). Pretreatment with radiotherapy was
observed in 57 (82.6%) patients, with salvage chemotherapy aimed to induce
a remission prior to a stem-cell transplantation (SCT) in 58 (84.1%), and with
high dose chemotherapy followed by autologous SCT in 50 (72.5%) patients.
Four patients (5.8%) had received allogeneic SCT as 3rd-line treatment. None
of the patients had received brentuximab vedotin or anti-PD1 antibodies before
3rd relapse. With a median observation time of 63.3 months for OS after 3rd
relapse, 45 patients (65.2%) had died and 60 (87.0%) had another PFS event.
Twelve months after the 3rd relapse OS was 73.2% (95%>CI 62.6% to 83.8%)
and PFS 50.8% (95%>CI 38.9% to 62.8%, Table 1).
Table 1.
Summary/Conclusions: Patients with a 3rd relapse or progression of cHL
have a dismal, mostly palliative prognosis due to frequent tumor progression.
Within one year half of the patients have a PFS event and one fourth die.
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Background: Waldenström’s macroglobulinemia (WM) is a rare low-grade B-
cell lymphoma characterized by the lymphoplasmacytic bone marrow infiltration
and the presence of monoclonal IgM immunoglobulin in the serum. WM is an
indolent lymphoma that has heterogeneous clinical manifestations and patients
with this disease may have a prolonged disease course; however, there are
groups of patients with poor outcomes after a relatively short disease course.
In order to develop a robust staging system a collaborative effort resulted in
the formulation of the International Prognostic Scoring System for WM (IPSS-
WM) which was developed in 2009 based on data of patients that were treated
primarily without rituximab and mainly with alkylators and nucleoside ana-
logues. IPSSWM is based on five covariates (age, hemoglobin, platelet counts,
IgM levels and b2 microglobulin) and stratifies WM patients into 3 broad risk
groups. IPSSWM does not take into account non-WM related mortality, which
is common and quite different among patients over the age of 75 year and
does not include LDH, which is a well identified prognostic factor both in lym-
phomas and multiple myeloma.
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Aims: The aim of the current study was to revise the current IPSSWM by using
a large dataset of symptomatic WM patients treated with different types of pri-
mary therapy that included rituximab and other new agents.
Methods: The analysis included 492 patients from the prospectively maintained
database of the Greek Myeloma Study Group with a median follow up of 10
years. All patients fulfilled criteria for diagnosis and for treatment initiation
according to Consensus Recommendations.
Figure 1.
Results: In univariate analysis factors such as age, beta-2 microglobulin, serum
albumin and LDH were all associated with poor outcome. The IPSSWM includes
age and b2 microglobulin but not serum albumin, or LDH, while the presence
of very high IgM (>7gr/dl) was quite rare and of limited prognostic value. The
presence of anemia <11.5gr/dl was common across all subgroups while low
platelet counts <100x109/L was found in relatively few patients and had no
prognostic significance. Based on ROC analysis for early death (within 3 years),
serum albumin <3.5gr/dL and b2microglobulin >4mg/L were the two most impor-
tant prognostic factors of early WM-related death. Age >65 years was associ-
ated with increased risk of death, however, age >75 years conferred additional
risk (double hazard of death compared to those 65-75 years and fourfold com-
pared to patients <65 years). Thus, we formulated a score in which high b2
microglobulin, elevated LDH and low serum albumin are scored with 1 point
each, age 66-75 years is scored with 1 point but age >75 years is scored with
2. As a result, patients with scores 0, 1, 2, 3 or 4-5 had 3-year WM-related
death rate of 3%, 7%, 14%, 19% and 48% (chi-square: 80.7, p<0.001). Regard-
ing overall survival, 10-year survival rate was 85%, 59%, 39%, 28% and 12%
(p<0.001) (Figure 1). Because age is a major determinant of disposition we
also evaluated this staging system in patients >65 years and retained it prog-
nostic significance. Compared to IPSSWM, this new staging system outper-
formed ISSWM: c-statistics, a measure of performance of a prognostic tool,
was 0.652 for IPSSWM (95%CI 0.627-0.677) vs 0.711 (95% CI 0.659-0.763)
for the new staging system.
Summary/Conclusions: A revised staging system, based on b2 microglobulin,
elevated LDH, low serum albumin and age identifies groups with very different
outcomes among patients with symptomatic WM treated with contemporary
regimens and may outperform IPSSWM.
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Background: Rituximab monotherapy has been used successfully in the treat-
ment of SMZL and it can replace splenectomy, at least in 1st line.
Aims: To present our data on the outcome of R monotherapy treated pts after
a long term follow-up.
Methods: The diagnosis of SMZL was based on the WHO criteria. Criteria for
treatment initiation included: bulky/symptomatic splenomegaly, cytopenias or
presence of B-symptoms. All pts received 6 weekly cycles of R as 1st line ther-
apy at a dose of 375mg/m2 (induction phase). None of the pts had been
splenectomised before R treatment. Maintenance with R at a dose of 375mg/m2
every 2 months for 1-2 years was given according to physician’s discretion.
Response assessment was based on the SLSG consensus criteria. Survival
curves were estimated using the Kaplan Meier method and compared by log-
rank test.
Results: 104 pts with SMZL were included. 45% were males with a median
age of 66 y (41-91). At diagnosis all pts had bone marrow infiltration with a
median % of infiltration of 40 (10-85). Anemia and thrombocytopenia were pres-
ent in 30% and 19%, respectively. 40% had absolute lymphocytosis. LDH was
elevated in 43%. According to the SLSG prognostic system, 39% were classified
in group A, 56% in group B and 5% in group C. The median time from diagnosis
to treatment initiation was 2 months (0-203). 71 pts received R maintenance.
The overall response rate 2 months after the end of induction treatment was
93% (CR, CRu and PR in 42%, 21% and 30%, respectively). Maintenance ther-
apy improved the quality of response in 19 of them, 52 pts maintained their
initial response and one relapsed during maintenance phase. The 5- and 10-
year PFS, OS and CSS were 70% and 64%, 93% and 88%, 99% and 93%,
respectively. Maintenance therapy was associated with better PFS (p=0.008).
22 pts relapsed (6 of them with histologic transformation to DLBCL). 11/22 were
retreated with R and 9/11 responded. 8 deaths were recorded: 3 of them dis-
ease related. R therapy was well tolerated. Only one pt could not complete
treatment due to intolerance.
Table 1.
Summary/Conclusions: The present study, includes a large number of pts
with a long follow-up, confirms that R monotherapy is very effective in SMZL
with minimal toxicity and is recommended as the treatment of choice for this
disease.
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Biology of MPN: JAK2 and beyond
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Background: The JAK-STAT pathway is a critical controller of cellular prolif-
eration, differentiation, survival and apoptosis in response to external stimuli.
Promiscuous activation of this pathway is an important driver in the pathogen-
esis of BCR/ABL-negative chronic myeloproliferative neoplasms. The JAK2-
V617F allele is the most common and characterized mutation linked to this
class of leukemia. The increased activation of JAK-STAT signaling in JAK2-
V617F cells can be partially explained by increased JAK2 autophosphorylation.
It is unclear however if these effects are sufficient to fully account for the strong
activation of the JAK-STAT pathway induced by JAK2-V617F. We recently
described programmed -1 ribosomal frameshifting (-1 PRF) as a novel mech-
anism regulating the expression of ~10% of human genes, including cytokine
receptors (Belew AT et al, Nature, 2014). In this process, cis-acting mRNA ele-
ments (-1 PRF signals, which consist of a slippery site followed by a pseudo-
knot) direct translating ribosomes to slip by one base in the 5’ direction, estab-
lishing a new reading frame. This directs ribosomes towards premature termi-
nation codons, resulting in destabilization of the -1 PRF signal-containing
mRNA via nonsense-mediated mRNA decay (Figure 1). There is thus an
inverse relationship between -1 PRF efficiency and mRNA stability.
Aims: To investigate whether the JAK2-V617F mutation, shown here to be
located in the pseudoknot of a -1 PRF signal in the JAK2 mRNA, impacts dis-
ease progression through ablation of -1 PRF.
Methods: Computationally predicted -1 PRF signals were validated using dual
luciferase reporters and proteomic analysis of a -1 PRF fusion protein. -1 PRF
as well as mRNA abundance and decay were assayed in HEK293T and HeLa
cells. Transformation assays were performed in hEpoR expressing Ba/F3 cells.
in vivo experiments were performed in BALB/c mice.
Figure 1.
Results: We demonstrate in human cell lines that the JAK2-V617F mutation
structurally disrupts the -1 PRF signal in the JAK2 mRNA, leading to ~2-fold
lower rates of -1 PRF and increased abundance of the JAK2 mRNA and protein.
The transforming potential of a series of mutants designed to manipulate -1
PRF independent of V617F was assayed in a Ba/F3 cell model. Silent protein
coding changes in the pseudoknot of the -1 PRF signal at position V617
(V617m) or the slippery site (SSm), both of which reduced frameshifting,
increased JAK2 expression and led to transforming activity, albeit less than
V617F. Importantly, the V617F+SSm combination conferred an additive effect
on cellular transformation. Ba/F3 cells expressing these JAK2 variants were
also introduced into mice. Whereas mice injected with wild type JAK2 remained
healthy, both V617m and SSm induced similar leukemia phenotypes as V617F
and V617F+SSm, with a ~2-fold longer disease latency of 8-10 weeks.
Increased JAK2 mRNA abundance in JAK2-V617F homozygous patients as
well as the presence of three additional -1 PRF signals in the JAK2 mRNA fur-
ther suggest a prominent role for -1 PRF in controlling JAK2 production.
Summary/Conclusions: We demonstrate that the JAK2-V617F mutation
diminishes -1 PRF on the JAK2 transcript, stabilizing the mRNA and increasing
JAK2 expression, contributing to its transforming activity in vitro and disease
onset in vivo. We suggest that -1 PRF normally provides a layer of control by
limiting JAK2 translation. Defective -1 PRF synergizes with the transforming
activity of the JAK2-V617F protein by causing its overexpression, explaining
why this particular mutation causes such aggressive malignancies. In support
of this, the combination of ruxolitinib and an HSP-90 inhibitor, which reduce
kinase activity and JAK2 expression respectively, leads to increased therapeutic
efficacy in myeloproliferative neoplasms (Bhagwat N et al, Blood, 2014).
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Background: Treatment of MPN with JAK1/2 inhibitors ameliorates symptoms
and splenomegaly but does not meaningfully reduce the JAK2V617F allele bur-
den. Though curative, stem cell transplantation is associated with extensive
morbidity and mortality highlighting the need for novel effective therapies. The
histone “lysine-specific demethylase 1A” (LSD1/KDM1A) is being explored as
a drug target in AML with several inhibitors already in the clinic. The enzyme
is critical for sustaining self-renewal in leukemic initiating cells; inhibiting LSD1
induces monocytic differentiation and reduces engraftment of AML cell in vivo.
LSD1 is over-expressed in a number of myeloid diseases including MPN. Pre-
liminary data in a mutant Mpl mouse model of MPN showed that a 28-day
course of LSD1 inhibition had a beneficial impact on spleen size, cytokines
and mutant cell burden. In a mutant JAK2 mouse model of MPN, we have
characterized the disease-modifying activity of the LSD1 inhibitor (IMG-7289),
a compound in clinical development for myeloid diseases (NCT02842827). 
Aims: We assessed the pharmacodynamic effects of continuous daily treat-
ment with IMG-7289 in a JAK2V617F knock-in murine MPN with established
disease. Animals were treated for up to 56 days. Outcome measures included
complete blood counts (CBC), hematological phenotype, overall survival,
spleen size, bone marrow morphology and the JAK2V617F allele burden. More-
over, pro-inflammatory cytokine were monitored during the course of treatment
as well as chromatin changes by western blotting and ChIPseq.
Methods: Jak2V617F-L2 mice were crossed to MxCRE mice and displayed a
fulminant MPN phenotype without dIdC induction. CBC and BM FACS analysis
were conducted as previously described. We designed a qPCR assay to quan-
titate murine JAK2V617F allele burden. 
Results: IMG-7289 treatment was exceptionally well tolerated and mice
showed drastic decreases in platelet count (208 vs 2063*103/μl), reticulocytes
(800 vs 1674*103/μl), monocytes and neutrophils 14 days after the start of
treatment. HCT and WBC started to decrease after 28 days. While the JAK2
mutant allele burden increased over time in untreated mice, it decreased in
IMG-7289 treated mice and was statistically significantly lower in peripheral
blood as well as in spleen. We observed a drastic increase in the pro-inflam-
matory cytokine CXCL5 in untreated mice during the course of investigation
while CXCL5 levels of treated mice decreased to levels of wild-type littermates.
Moreover, treated mice showed a highly significantly increased survival over
untreated mice, even in a late stage of disease. Lastly, we were able to show
that global H3K9me2, which is generally associated with gene expression
silencing, was increased in the bone marrow of IMG-7289 treated mice com-
pared to control mice. The remaining pathophysiological data and functional
data on epigenetic regulation will be presented. 
Summary/Conclusions: The LSD1 inhibitor IMG-7289 normalizes or stabilizes
elevated CBCs in a JAK2V617F MPN mouse model. It decreases JAK2 mutant
allele burden, pro-inflammatory cytokine levels and confers a clear survival
advantage. Our preliminary data show that LSD1 is a potent target with dis-
ease-modifying potential in MPN. Clinical studies with IMG-7289 testing this
hypothesis have just begun. Owing to its mode of action, altering epigenetics,
and the potential reversibility of drug-induced epigenetic remodeling, a long
treatment period in MPN patients may be necessary to eliminate disease. Com-
bining IMG-7289 with JAK1/2 inhibitors might accelerate treatment effects. 
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Background: Chronic myelomonocytic leukemia (CMML) is characterized by
increased proliferation and myelomonocytic lineage commitment of hematopoi-
etic stem cells (HSCs). Mutations in the RAS-pathway occur frequently in CMML
patients and lead to a CMML-like myeloproliferative disorder (CMML-MPD) in
mice via causing hypersensitivity to GM-CSF. Loss of RAF kinase inhibitor pro-
tein (RKIP), a negative regulator of RAS signaling, is frequent in myelomono-
cytic and monocytic subtypes of acute myeloid leukemia (AML) and is often
associated with RAS mutations. Moreover, RKIP loss has recently been shown
to increase the proliferation of AML cell lines.
Aims: In this work, we aimed at investigating the role of RKIP in the develop-
ment of CMML.
Methods: RKIP expression was measured by immunoblot and quantitative
real-time PCR in 23 primary CMML patient samples as well as in CD34+ HSCs,
B-lymphocytes, granulocytes and monocytes of four healthy donors. Sequence
analysis of CMML samples was done with an Ion Torrent Next Generation
Sequencing platform using an amplicon panel covering 39 genes recurrently
mutated in myeloid neoplasms. Effects of RKIP on GM-CSF-induced
myelomonocytic differentiation were studied in human CD34+ HSCs lentivirally
transduced with RKIP shRNA, as well as in a genetic mouse model for RKIP
deletion (RKIP-/-). Effects of RKIP on CMML development were initially studied
in the same RKIP-/- model. Additionally, these mice were crossed with animals
exhibiting a somatically inducible mutation in NRAS (RKIP-/-Mx1-Cre-
NRASG12D) and the severity of CMML-MPD onset was studied at an age of six
months.
Results: Loss of RKIP protein expression was observed in 6/23 (26%) CMML
patient specimens and was associated with decreased mRNA levels as well
(P<0.001). Patients with RKIP loss exhibited an increased percentage of
myelomonocytic cells in the peripheral blood (86% vs 75%; P=0.0226). One or
more mutations affecting the RAS signaling pathway were detected in all spec-
imens with RKIP loss. In addition to the previously demonstrated induction of
proliferation, we then aimed to delineate a role of RKIP loss in myeloid lineage
commitment. When studying healthy donors, we observed that RKIP expression
was high in HSCs and lymphoid cells, but significantly decreased in cells
belonging to the myeloid lineage (monocytes, P=0.001 and granulocytes,
P<0.001). In functional experiments, knockdown of RKIP increased the GM-
CSF-induced myelomonocytic lineage commitment of both, human and murine
HSCs (P<0.05 and P=0.0295, respectively). These results could be corrobo-
rated in-vivo, as intraperitoneal injection of GM-CSF caused a significant
increase of myelomonocytic cells in the intraperitoneal cavity (P=0.006), bone
marrow (P=0.007) and peripheral blood (P=0.027) in RKIP-/- mice when com-
pared to their wildtype littermates. In a final step, we evaluated the potential of
RKIP loss to cause CMML-MPD in mice. While it proved to be insufficient to
cause the disease as a single event in RKIP-/- mice, it aggravated the CMML-
MPD phenotype in animals carrying an additional mutation in NRAS. In this
case, RKIP deletion caused worsening of leucocytosis (P=0.036) and
splenomegaly (P=0.035), which was associated with increased levels of
myelomonocytic cells in the bone marrow (P=0.028), peripheral blood (P=0.002)
and spleen (P=0.025).
Summary/Conclusions: RKIP loss is a frequent event in CMML and is asso-
ciated with mutations affecting the RAS signaling cascade. Loss of RKIP is
functionally involved in myelomonocytic lineage commitment of HSCs and
aggravates CMML-MPD development in mice carrying an additional mutation
in NRAS.
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Background: JAK2 V617F is the most common somatic mutation in the clas-
sical myeloproliferative neoplasms (MPNs) and is also frequent amongst
healthy individuals with age-related clonal haemopoiesis (ARCH).
Aims: To investigate the pre-clinical clonal evolution of MPNs. 
Methods: We identified 12 individuals with JAK2 V617F mutant MPN from
whom blood DNA was available from the time of MPN diagnosis and also from
an earlier time point of between 4.5-15.2 years previously (median 10.2 years)
when blood was donated for registration to the Cyprus Bone Marrow Donor
Registry. We used deep DNA sequencing to interrogate all 24 samples at 15
myeloid mutation hotspots including JAK2 V617, using an established multiplex
PCR/MiSeq sequencing protocol that reliably detects nucleotide substitutions
present at a variant allele fraction (VAF) ≥0.008. Additionally, for 12 samples
with sufficient DNA available, we performed targeted DNA capture for all exons
of 41 genes recurrently mutated in myeloid neoplasms using a custom RNA-
bait library followed by sequencing on Illumina HiSeq 2500. Finally, we geno-
typed archival Registry samples for the rs12343867 single nucleotide polymor-
phism (SNP) (C/T) linked to the JAK2 46/1 haplotype.
Figure 1.
Results: Amplicon sequencing returned a median coverage of 6641 reads per
nucleotide (nt) at the studied hotspots. This confirmed the presence of JAK2
V617F in all 12 diagnostic and 9 of 12 archival samples. The remaining 3 sam-
ples were JAK2 V617F negative at the sensitivity of our assay (VAF≥0.008).
The only other hotspot mutation identified was SRSF2 P95R in one patient,
P3, whom had a diagnosis of myelofibrosis. Pulldown sequencing of all exons
of 41 genes from 12 samples with sufficient DNA returned an average coverage
of 1978 reads per nt and showed a close correlation in JAK2 V617F and SRSF2
P95R VAF quantitations with amplicon sequencing. The JAK2 V617F VAF at
MPN diagnosis differed between patients as expected, however the average
rate of clonal growth also varied widely between individuals, ranging from 0.36
to 6.2% per annum (Figure 1). Targeted exon capture from 12 of 24 samples,
only identified one co-mutation with a VAF >0.02, the SRSF2 P95R in patient
P3. As this locus was also amplified by amplicon sequencing, we were able to
quantify the SRSF2 P95R VAF in both the diagnostic and the archival DNA
sample taken 12.6 years earlier. In the P3 diagnostic sample the VAFs for JAK2
V617F and SRSF2 P95R were similar (0.37 and 0.41 respectively) indicating
that they co-occurred in most cells of the neoplastic clone. In the archival sample
from P3, the SRSF2 P95R was detectable at a VAF of 0.06, however the JAK2
V617F was absent/undetectable at the sensitivity of our method (VAF≥0.008)
indicating the SRSF2 P95R was the clone-founding mutation in this neoplasm.
The genotyping results for the rs12343867 SNP revealed a tentative association
in our small cohort between homozygosity for the risk allele (C) linked to the
JAK2 46/1 haplotype and the average annual increase in JAK2 V617F VAF.
This will need to be verified in larger studies.
Summary/Conclusions: Our findings reveal that JAK2 V617F neoplasms
develop from clonal haematopoiesis over many years. The rate of clonal expan-
sion of JAK2 V617F clones in the pre-clinical phase was highly variable and
although it was tentatively associated with the 46/1 haplotype, the high vari-
ability observed suggests that other factors likely influence clonal progression.
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Background: The hematopoietic stem cell (HSC) compartment in mice encom-
passes a broad range of heterogeneous cell types including highly lineage-
biased HSCs, such as platelet-biased HSCs (PMID:23934107). Myeloprolifer-
ative neoplasms (MPNs) are a heterogeneous spectrum of clonal hematopoi-
etic disorders, that includes essential thrombocythemia (ET), a MPN-subtype
usually presenting with isolated thrombocytosis. Most ET patients carry a gain-
of-function point mutation in JAK2 (JAK2V617F), with several other collabo-
rating hits reported to co-occur with JAK2V617F at lower frequencies, including
loss-of-function mutations of the epigenetic regulator EZH2, which are more
frequent in advanced MPN.
Aims: Although it is broadly accepted that MPNs are propagated by counter-
parts of HSCs, the impact of collaborating MPN-associated mutations arising
in different HSC subsets remains unclear. We aimed to explore the possibility
that platelet-biased HSCs might selectively promote development of an ET
phenotype.
Methods: We generated a novel mouse model of MPN that carries a condi-
tional knock-in of heterozygous human JAK2V617F (hJAK2V617F) and the
conditional knock-out (KO) of EZH2 together with an inducible Mx1-Cre trans-
gene. To analyse platelet-biased HSC subsets upon onset of the mutation(s),
we also crossed in the vwf-eGFP transgene, which is selectively expressed in
platelet-biased HSCs.
Results: Compared to wild-type and single mutant mice, EZH2-KO
hJAK2V617F mice showed increased platelet counts, including a subset of
mice which became acutely unwell with an extreme thrombocytosis. Strikingly,
in serial bone marrow (BM) transplantation assays, EZH2-KO fully rescued
the previously described hJAK2V617F-associated transplantation defect
(PMID:20489053). EZH2-KO hJAK2V617F BM recipients showed long-term
serial engraftment that was fully restricted to the platelet and myeloid lineages
with a persistent thrombocytosis and absence of lymphoid reconstitution. RNA-
sequencing revealed upregulation of several signaling pathways, including
Hedgehog, and increased inflammation associated gene expression in EZH2-
KO hJAK2V617F HSCs. Unexpectedly in this mouse model of thrombocytosis,
phenotypic analysis of the HSC compartment in the BM showed that vwf-
eGFP+ve HSCs were selectively lost (fold change[FC]=0.12 p=0.009), while
vwf-eGFP–ve HSC numbers remained unaffected (FC=1.06 p=0.88) in Ezh2-
KO hJAK2V617F mice. To assess a differential contribution of vwf-eGFP+ve
HSCs vs vwf-eGFP-ve HSCs in the ability to propagate MPN, we sorted HSCs
according to vwf-eGFP expression and transplanted them into recipient mice.
Unlike their normal counterparts, which showed lymphoid-biased reconstitu-
tion, vwf-eGFP–ve HSCs from Ezh2-KO hJAK2V617F mice primarily gave
rise to platelets and myeloid cells. In contrast, vwf-eGFP+ve HSCs from Ezh2-
KO hJAK2V617F mice engrafted poorly without recapitulating the disease in
recipients.
Summary/Conclusions: In this novel Ezh2-KO hJAK2V617F mouse model,
Ezh2 loss collaborates to worsen thrombocytosis and rescue the HSC function
defect in hJAK2V617F mice. We also observed a striking disruption of pheno-
typic and functional HSC heterogeneity in Ezh2-KO hJAK2V617F mice with
an unexpected and selective loss of vwf-eGFP+ve HSCs together with sub-
version of vwf-eGFP–ve HSCs towards platelet-myeloid lineage committment.
This previously undescribed disruption of HSC heterogeneity in myeloid malig-
nancy together with the clonal advantage conferred to HSCs by EZH2-KO
helps to explain how this collaborating mutation might promote the development
of more advanced MPN.
Clinical trials including treatment discontinuation
in CML
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Background: As safe and effective frontline treatment options for children and
adolescents with CML are limited, and no approved therapies exist for patients
(pts) resistant/intolerant to imatinib (IM), additional treatment options and alter-
native formulations are greatly needed for this younger population. Dasatinib
(DAS) has proven efficacy in adults with newly diagnosed CML-CP, as well as
those resistant/intolerant to IM (Cortes JCO 2016, Shah AJH 2016). Results of
a phase 1 study confirmed its dosing and safety in pediatric pts (Zwaan JCO
2013); however, a larger prospective study is necessary to further support the
use of DAS in pediatric pts with newly diagnosed or IM-resistant/intolerant
CML-CP.
Aims: To determine whether DAS is safe and effective in pediatric pts with
CML-CP newly diagnosed or resistant/intolerant to IM enrolled in a phase 2,
open-label, nonrandomized prospective clinical trial (CA180-226/NCT0077
7036).
Table 1.
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Methods: Pts aged <18 years were recruited into 3 separate cohorts: (1) IM-
resistant/intolerant CML-CP treated with DAS tablets 60mg/m2 QD, (2) IM-
resistant/intolerant CML-AP/BP or Ph+ ALL (enrollment closed early due to
poor response), and (3) newly diagnosed CML-CP treated with DAS tablets
60mg/m2 or DAS 72mg/m2 powder for oral suspension (PFOS) QD for ≥1 year.
PFOS dose was increased by 20% to match the exposure of the tablet in order
to maintain a desired efficacy based on the findings from a bioequivalence
study in adults. Primary objectives were major cytogenetic response (MCyR)
for CML-CP resistant/intolerant to IM and complete cytogenetic response
(CCyR) for newly diagnosed CML-CP (MCyR >30% and CCyR >55% consid-
ered of clinical interest). Study cohorts were not designed to be comparative.
Results: From 145 pts enrolled, 130 were treated; 54% were aged ≥12-<18
years. Within the IM resistant/intolerant group, 25 were resistant, 2 were intol-
erant, and 2 were undetermined. For pts with CML-CP (n=113), 48% of pts
with IM-resistant/intolerant CML-CP and 73% with newly diagnosed CML-CP
remained on treatment at the time of this analysis (table 1). Cumulative rate of
MCyR >30% was reached as early as 3 months for IM-resistant/intolerant CML-
CP, and a cumulative rate of CCyR >55% was reached as early as 6 months
for newly diagnosed CML-CP (table). Estimated progression-free survival (PFS)
by 48 months was 78% for IM-resistant/intolerant CML-CP and 93% for newly
diagnosed CML-CP (table). Reasons for progression were loss of MCyR (n=3
IM-resistant/intolerant; n=4 newly diagnosed), loss of complete hematologic
response (n=2 each), and development of CML-BP (n=2 IM-resistant/intolerant;
n=1 newly diagnosed). One death was reported in the IM-resistant/intolerant
CML-CP cohort 1 year after stopping DAS (gastrointestinal bleeding). Adverse
events (AEs) were consistent with reports in DAS-treated adults, except no
DAS-related pleural/pericardial effusion, pulmonary edema/hypertension, or
pulmonary arterial hypertension were reported here. Hypersensitivity in a newly
diagnosed pt was the only DAS-related AE that led to discontinuation.
Summary/Conclusions: Results from the largest prospective and registrational
trial of pediatric pts with CML-CP demonstrate that DAS is a safe and effective
treatment for pediatric CML-CP. Target responses to first- or second-line that
DAS were met as early as 3 and 6 months, respectively, and deep responses
were observed. Efficacy and safety of DAS in pediatric pts were similar to those
observed in adults; however, unlike in adults, no cases of pleural/pericardial
effusion were reported.
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Background: In CML, there is considerable current interest in whether some
patients can safely discontinue tyrosine kinase inhibitor (TKI) therapy. However,
all studies so far have examined patients in stable MR4 at entry, i.e. BCR-
ABL1/ABL1 ratio ≤0.01%. Patients in stable major molecular response (MMR)
but not MR4 (<0.1 but >0.01%) have not been formally studied; neither have
the effects of stepwise TKI withdrawal.
Aims: The present British De-Escalation and Stopping Therapy with Imatinib,
Nilotinib or sprYcel (DESTINY) study examines treatment de-escalation as a
prelude to complete cessation, in patients in not only stable MR4 but also those
with MMR but not MR4.
Methods: Trial entry required first chronic phase of CML, TKI treatment for ≥3
years, and either the same TKI (imatinib, dasatinib or nilotinib) since diagnosis
or only one switch for intolerance. All PCR tests (minimum of 3) in the 12 months
before trial entry must have been ≤0.1% (i.e. MMR), each with ≥10,000 ABL1
control transcripts; those with all results ≤0.01% were allocated to the ‘stable
MR4’ group; the remainder to the ‘MMR but not MR4’ group. Entry criteria were
thus virtually identical to the EUROSKI study except that patients with MMR
but not MR4 were also separately eligible. TKI treatment was reduced to half
the standard dose (imatinib 200mg daily, dasatinib 50mg daily or nilotinib 200mg
twice daily) for the first 12 months, then stopped completely. Central PCR mon-
itoring was carried out monthly, expressed according to International Scale.
Molecular recurrence was timed as the first of 2 consecutive samples with loss
of MMR (>0.1%) and mandated resumption of full TKI dose.
Results: 174 patients (male 98; female 76) were recruited after giving informed
consent from 20 UK centres. At entry, 148 patients were receiving imatinib, 16
nilotinib and 10 dasatinib, for a median duration of 6.8 years. We reported at
ASH 2016 that after 12 months of half-dose therapy, molecular recurrence was
lower in patients with stable MR4 at entry (3 of 125 patients; 2.4%) than in
those in MMR but not MR4 (9 of 49 patients; 18.4%) (p<0.001). We now show
in the Figure below that during the subsequent 12 months of complete treatment
cessation in 117 stable MR4 patients, only 26 further recurrences and 4 with-
drawals occurred, giving a recurrence free survival (RFS) of 77% (90% CI: 71-
83%) for the overall 24 months for this patient group. The recurrence rate on
cessation is higher in the MMR but not MR4 group (20 recurrences and 4 with-
drawals among 36 patients during cessation; 39% RFS overall (90% CI: 29-
52%); p=<0.001). In both the stable MR4 group and the MMR but not MR4
groups, no difference in RFS was seen between patients in MR4.5 at entry and
those not. In multivariable Cox proportional hazards modelling, addition of the
baseline entry PCR result did not add to the predictive effect on RFS of the
prior 12 month PCR pattern, whereas the duration of TKI treatment was an
additional predictive factor (p=0.058; HR 0.93), in line with recent data from
EUROSKI. The probability of RFS remains unrelated to age, gender, perform-
ance status or prior TKI (imatinib vs second generation). No progression to
advanced phase was seen; one case lost haematological response.
Figure 1.
Summary/Conclusions: The present 24 month RFS of 77% for the overall 24
months in patients in stable MR4 appears better than in any comparable study
to date, and implies that the initial 12 months of dose reduction may be respon-
sible, perhaps via improved compliance in the few months prior to stopping or
through an as yet undefined mechanism.
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Background: The optimum initial treatment of chronic myeloid leukemia (CML)
is unknown.
Aims: CML-study IV was designed to confirm the International Randomized
Study on Interferon (IFN) and STI571 (IRIS) and to explore whether treatment
with imatinib (IM) at 400mg/day could be optimized.
Methods: From July 2002 to March 2012, 1551 newly diagnosed patients in
chronic phase (CP) were randomized into a 5-arm study. 1536 patients were
evaluable, 400 for IM400mg, 430 for IM + IFN, 420 for IM800mg, 158 for IM +
cytarabine and 128 for IM-after-IFN-failure. Recruitment to the latter two arms
was stopped after a pilot-phase.
Results: After a median observation time of 9.5 years, 10-year overall survival
(OS) of all patients was 82%, 10-year progression free survival 80% and, 10-
year relative survival 92%. 10-year OS was 80% with IM400mg, 84% with IM +
IFN, 79% with IM800mg, 84% with IM + cytarabine and 79% with IM after IFN
(Figure 1). The differences were not significant in spite of faster response with
IM800mg. In a multivariate analysis, risk group, comorbidities, major route chro-
mosomal aberrations, smoking and type of treatment center (academic vs other)
influenced survival, but not gender, transcript type or any form of treatment opti-
mization. Patients reaching the molecular response milestones at 3, 6 and 12
months had a significantly better survival, the faster response of a treatment
group (IM800mg) did not translate into a detectable survival advantage.
Figure 1.
Summary/Conclusions: Monotherapy with IM400mg provides a close to nor-
mal life expectancy. Faster response does not necessarily translate into better
survival. Outcome of CML is currently more determined by disease biology
and demographics than by treatment optimization.
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Background: Bosutinib (BOS) is a potent, dual SRC/ABL tyrosine kinase
inhibitor approved for treatment of adults with Philadelphia chromosome-pos-
itive (Ph+) chronic myeloid leukemia (CML) resistant or intolerant to prior ther-
apy.
Aims: To assess the efficacy and safety of BOS versus imatinib (IM) for first-
line treatment of chronic phase (CP) CML in the BFORE trial (NCT02130557).
Methods: In this ongoing, multinational, phase 3, open-label study, 536 patients
with newly diagnosed CP CML were randomized 1:1 to BOS 400mg once daily
(n=268) or IM 400mg once daily (n=268 [3 not treated]). Informed consent was
obtained from all patients. Per protocol, efficacy was assessed in a modified
intent-to-treat (mITT) population of 487 Ph+ patients (BOS, n=246; IM, n=241)
with e13a2/e14a2 transcripts; Ph– patients and those with unknown Ph status
and/or BCR-ABL transcript type were excluded from this population.
Results: After ≥12 months of follow-up, 78.0% of BOS and 73.2% of IM patients
remain on treatment with median treatment durations of 14.1 months and 13.8
months, respectively. Major molecular response (MMR) rate at 12 months (pri-
mary endpoint) was significantly higher with BOS versus IM in the mITT pop-
ulation (47.2% vs 36.9%; P=0.02) as well as in the ITT population of all ran-
domized patients (46.6% vs 36.2%; P<0.02). In the mITT population, time to
MMR was shorter for BOS (hazard ratio=1.34 based on cumulative incidence;
P<0.02). Rate of complete cytogenetic response (CCyR) by 12 months was
also significantly higher with BOS versus IM (77.2% vs 66.4%; P<0.008), with
time to CCyR shorter for BOS (hazard ratio=1.38; P≤0.001). Rate of BCR-ABL
transcripts ≤10% (Intl. Scale) at 3 months was higher with BOS versus IM
(75.2% vs 57.3%; P<0.001); rates of deep molecular response over time were
also generally higher with BOS (Table). Results for molecular endpoints were
similar in the ITT population. The only baseline characteristic identified as a
significant predictor of MMR at 12 months besides treatment arm was Sokal
risk group (high vs low; P<0.0001 and intermediate vs low; P<0.05 [mITT]).
On-treatment progression to accelerated or blast phase occurred in 4 patients
(1.6%) receiving BOS and 6 patients (2.5%) receiving IM in the mITT popula-
tion. One BOS-treated and 4 IM-treated patients discontinued treatment due
to progression to accelerated or blast phase. Among all treated patients, there
were no deaths within 28 days of last dose of BOS and 4 with IM. Safety data
for treated patients were consistent with the known safety profiles of BOS and
IM. Discontinuation due to drug-related toxicity occurred with 12.7% of BOS
patients and 8.7% of IM patients. Grade ≥3 diarrhea (7.8% vs 0.8%) and
increased alanine (19.0% vs 1.5%) and aspartate (9.7% vs 1.9%) aminotrans-
ferase levels were more common with BOS. Cardiovascular, peripheral vascu-
lar, and cerebrovascular events were infrequent in both groups (all grades:
3.0%, 1.5%, and 0% BOS vs 0.4%, 1.1%, and 0.4% IM; grade ≥3: 1.5%, 0%,
and 0% BOS vs 0%, 0%, and 0.4% IM).
Table 1.
Summary/Conclusions: Patients on BOS had significantly higher rates of 12-
month MMR and CCyR and achieved responses faster than those on IM. Con-
sistent with the known safety profile, higher incidences of gastrointestinal events
and transaminase elevations were observed with BOS. Primary results from
this study suggest BOS may be an important treatment option for patients with
newly diagnosed CP CML.
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Background: With imatinib (IM), most patients with chronic myeloid leukemia
(CML) achieve deep molecular responses. Six months after stopping tyrosine
kinase inhibitor in deep response in the EURO-SKI trial, 61% of the patients
were in molecular relapse-free survival (RFS) i.e. alive and in major molecular
remission (3-log reduction in BCR-ABL1 levels) (Mahon ASH 2016). Between
patients with and without BCR-ABL1, the difference in RFS at 6 months was
not significant when assessing BCR-ABL1 detectability at the MR4.5 level (at
least a 4.5-log reduction in BCR-ABL1) (Pfirrmann ASH 2016).
Aims: For 91 of 448 patients of the EURO-SKI learning sample, the sensitivity
to claim undetectable disease at the MR4.5 level was not given. Aim was to
investigate whether RFS probabilities would be different when comparing
detectable and undetectable disease at the MR4 level.
Methods: Detectability of BCR-ABL1 depends on the number of control gene
transcripts. To reduce bias when comparing “MR4 detectable disease” (MR4
but still detectable BCR-ABL1 transcripts; i.e. 0.01- 0.0033% IS) and “MR4
undetectable disease” (MR4 without detectable BCR-ABL1; based on 10,000-
31,999 ABL1 or 24,000-76,999 GUSB copies), two samples with similar sensi-
tivity of identifying BCR-ABL1 were to be identified using propensity score (PS)
matching (Rosenbaum, Rubin 1983). Apart from type (ABL1 or GUSB) and
number of control gene transcripts, matching variables were interferon alpha
pre-treatment, duration of MR4, and the IM treatment time before observation
of MR4. Logistic regression was used to compare RFS at 6 months. Signifi-
cance level was 0.05.
Results: A total of 448 patients had eligible, complete, and sufficient molecular
data prior to and within the first 6 months after stopping IM treatment. All molecular
results had sensitivity at the MR4 level with yet detectable disease in 196 patients
(44%). With small differences in GUSB copy numbers (used in 96 of 448 cases,
U test (detectable vs undetectable): P>0.5), prior to PS matching, median num-
bers of ABL1 transcripts were higher with MR4 detectable disease (78,975 vs
68,925 with undetectable disease; P=0.0511, not significant (n.s.)). In 196 patients
with detectable disease, RFS at 6 months was 52% (95% confidence interval
(CI): 45-59%) and in 252 patients with undetectable disease 63% (CI: 58-69%).
Relapse was significantly higher in patients with detectable disease (odds ratio:
1.603 (CI: 1.096-2.343). PS matching resulted in 173 patients per group. Median
numbers of ABL1 transcripts changed to 82.142 (detectable) and 75.750 (unde-
tectable disease; n. s.). At 6 months, patients with detectable disease again had
52% (95% confidence interval (CI): 45-59%) RFS probability, and patients with
undetectable disease 59% (CI: 52-66%). In the logistic model stratified for the
matched pairs, for relapse at 6 months, the odds ratio for MR4 with detectable to
undetectable disease was 1.308 (CI: 0.862-1.984, n. s.).
Summary/Conclusions: Using the MR4 threshold, after matching on number
of control transcripts and other factors, results suggest little or no impact of
detectability of BCR-ABL1 on RFS. Time in deep response seems to be more
important. In daily routine, many labs produce reliable outcome at the MR4 but
not always at the MR4.5 level. Discontinuation at the MR4 level, irrespective of
detectability of BCR-ABL1 residual disease, appears safe, with a good chance
of success when performed as in EURO-SKI. With PS matching, bias and dif-
ferences but also power was reduced. To judge whether molecular response
on the MR4 level is sufficient, further data is welcome.
AML Biology II:  Epigenetic targets
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Background: Deregulated expression programs due to genetic alterations,
such as gene fusions affecting transcription and/or epigenetic factors is the
hallmark of acute myeloid leukemia (AML) and the basis for the associated dif-
ferentiation block of hematopoietic progenitors. Acute megakaryoblastic
leukemia (AMKL) is a subtype of poor prognosis AML affecting primarily young
children. Recently, the ETO2-GLIS2 fusion has been identified in 20-30% of de
novo AMKL and associated with the worst prognosis in this subtype of AML.
Aims: Our goal was to characterize the mechanisms of cellular transformation
induced by ETO2-GLIS2.
Methods: We first defined the consequences of ETO2-GLIS2 expression on
hematopoietic progenitors and the contribution of ETO2 and GLIS2 on differ-
entiation and self-renewal by methylcellulose replating assays and phenotype
characterization. We then assessed global expression profiling and ETO2-
GLIS2 direct binding on DNA by ChIPseq experiments. With immunoprecipita-
tion experiments, we identified some ETO2-GLIS2 complex members. Finally,
we tested the effects of a small peptide that could inhibit ETO2-GLIS2 complex
stabilization both in vitro and in vivo.
Results: We showed that the GLIS2 moiety drives the megakaryocytic pheno-
type whereas both the ETO2 and GLIS2 moieties are required for maintaining
self-renewal. Global expression profiling and comparison to patients’ signature
consistently identified ETO2-GLIS2-mediated deregulation of major transcrip-
tional regulators of hematopoiesis and leukemogenesis. Especially, ETO2-
GLIS2 brings on an unbalance in ETS/GATA factors illustrated by an extinction
of GATA1 and an overexpression of the ERG oncogene. We identified that
ETO2-GLIS2 directly binds DNA via ETO2 complexes and through its GLIS2
moiety. Moreover, the ETO2-GLIS2 fusion localizes at half of H3K27ac-dense
enhancers, so called super-enhancers, to control transcription of associated
genes, in close association with ERG. Dimerization of ETO2-GLIS2 and inter-
action with endogenous ETO2 via its NHR2 domains were demonstrated with
immunoprecipitation experiments. A NHR2 peptide-interference strategy inhib-
ited the oligomerization, reversed the transcriptional activation at enhancers,
promoted megakaryocytic differentiation and abrogated human AMKL cells
maintenance in vivo. So, the interaction of ETO2-GLIS2 with ETO2 complexes
is an essential node for the transcriptional control by the fusion at enhancer
elements. Finally, ERG is localized at super-enhancers and is associated with
up-regulation of associated genes. ERG knockdown or genetic inactivation
downregulates expression of ETO2-GLIS2 targets required for leukemic cells
survival. Together, the strong up-regulation of ERG by the fusion and the pres-
ence of ERG at super-enhancers suggest a feed forward mechanism to impose
gene deregulation.
Summary/Conclusions: In conclusion, we propose that the megakaryocytic
differentiation arrest and self-renewal controlled by ETO2-GLIS2 results from
imbalanced expression of master transcription factors imposed by aberrant
chromatin structures at enhancers that may be disrupted by targeting the NHR2
interface.
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Background: Acute myeloid leukemia (AML) is characterized by rapid growth
and block in differentiation of myeloid progenitors. The AML blast is defined by
having “open” chromatin. We hypothesized that alterations of chromatin com-
paction may promote AML. Reversing those changes could represent a novel
therapeutic approach.
Aims: Gain of chr21q22 is the most common focal amplification in complex
karyotype AML. HMGN1 is a chromatin-regulatory protein on 21q22 known to
affect lymphoid development, and our preliminary data suggested that HMGN1
could directly mediate a myeloid differentiation block. Since HMGN1 is known
to decompact chromatin and alter histone marks, our goal was to define and
therapeutically target the mechanisms by which HMGN1 overexpression dis-
rupts myeloid differentiation and promotes clonal dominance.
Methods: We immortalized bone marrow progenitors from wild-type (WT) or
OE-HMGN1 mice (transgenic overexpressing HMGN1) with an estrogen
receptor-HoxB8 fusion protein. Using exogenous estrogen to control nuclear
translocation of HoxB8, we analyzed synchronized myeloid differentiation by
flow cytometry, RNAseq, and TMT proteomic analysis. We performed MINT-
ChIP-seq (MNase Indexed T7-chromatin IP) to measure the histone marks
H3K27ac, H3K27me3, H3K4me3 and total Histone H3. We also measured
histone marks in hematopoietic stem and progenitor subpopulations in vivo.
We performed competitive bone marrow transplantation with CD45.1 WT and
CD45.2 OE-HMGN1 donors and measured the relative contribution to
hematopoiesis over time.
Results: Synchronized differentiation in WT cells progressed over 6 days from
myeloid progenitors to mature neutrophils and monocytes, analyzed by cell
surface markers, morphology, and gene and protein expression. OE-HMGN1
cells proliferated faster and remained as undifferentiated myeloblasts (84%
Cd11b+Gr1+ in WT vs 4% in OE-HMGN1, p=0.002; Fig A). Gene set enrich-
ment analysis revealed more similarity to undifferentiated hematopoiesis and
leukemia signatures in OE-HMGN1 cells. MINT-ChIP indicated higher global
and locus-specific levels of H3K27ac in OE-HMGN1 cells (Fig B, upper panel),
consistent with an increase in gene transcription, confirmed by RNA-seq. We
found a specific increase in HoxA cluster expression in OE-HMGN1 cells, high-
est at HoxA7 and HoxA9, genes known to be important in AML pathogenesis.
In agreement with gene expression, among the most differentially measured
histone peaks genome-wide were higher H3K27ac at HoxA gene promoters at
all differentiation time points analyzed (Fig B, lower panel). Competitive trans-
plantation demonstrated an advantage to OE-HMGN1 stem and progenitor
cells. The clonal dominance of OE-HMGN1 over WT cells extended to all pop-
ulations analyzed (long- and short-term HSCs, multipotent progenitors, CMP,
GMP and MEP; Fig C) and to mature lineages (myeloid, B and T cells). MINT-
ChIP in LK and LKS stem and progenitor cells revealed an increase in H3K27ac
peaks at cell cycle and leukemia-related genes in the context of OE-HMGN1.
H3K27 acetylation is catalyzed by the CBP/p300 histone acetyltransferase
(HAT), suggesting that HAT inhibition could target leukemias with HMGN1 over-
expression. Indeed, treatment of myeloid progenitors with the CBP/p300
inhibitor C646 rescued the differentiation block in OE-HMGN1 cells (93%
CD11b+Gr1+ in WT vs 80% in OE-HMGN1, p=NS).
Figure 1.
Summary/Conclusions: Our study suggests that HMGN1 overexpression
blocks myeloid differentiation and promotes proliferation in hematopoietic pro-
genitors via increased H3K27 acetylation. Targeting epigenetic changes down-
stream of HMGN1 or interfering with HMGN1 itself may represent a novel ther-
apeutic strategy in AML.
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Background: Piwi proteins are critically important for maintaining the self-
renewing stem cell population in lower organisms through epigenetic silencing
of transposable elements via DNA methylation and H3K9me3 marks, in close
interaction with a novel class of non-coding RNA called piwi interacting RNA
(piRNA).
Aims: There are neither precise data on the function of Piwi proteins in human
acute myeloid leukemia (AML), nor are there reports on expression of piRNAs
in this disease. We employed functional techniques and NGS to understand
the role of human PIWI-like protein, PIWIL4 and its associated piRNA in AML.
Methods: We assessed the expression of human PIWIL genes in AML and
healthy bone marrow cells using qRT-PCR. Murine stem progenitors were
transduced with AML specific oncogenes to evaluate the effect on Piwil4
expression. shRNA mediated knockdown (KD) of PIWIL4 was performed on
AML cell lines, AML patient bone marrow (BM) cells and healthy cord blood
CD34+ stem progenitors and the impact on growth was determined using in
vitro and in vivo assays. Western blot, ChIP-seq for H3K9me3 and RNA-seq
were performed to assess the impact of PIWIL4 KD on the epigenetic land-
scape and transcriptome of the AML cell line THP-1. IP for PIWIL4 followed by
LC-MS was performed to determine the binding partners of PIWIL4. PAR-CLIP
and microarray were performed to identify piRNAs that physically bind to
PIWIL4 and to test the impact of PIWIL4 KD on piRNA expression.
Results: Among the family of human PIWIL genes, PIWIL4 showed the highest
expression level and was ubiquitously expressed in healthy hematopoietic
stem/progenitors, mature lymphoid and myeloid cells. Importantly, PIWIL4 was
aberrantly higher expressed in more than 89% of the AML patients (n=68;
p<0.0001) compared to normal CD34+ BM and total BM cells (n=3). Overex-
pression of AML specific oncogenes in murine stem progenitors, within 96h
post-transduction, induced a 6 to 8 fold increase in Piwil4 expression compared
to GFP control (n=3, p<0.0001). Knockdown (KD) of PIWIL4 in AML cell lines
significantly impaired proliferation and clonogenic growth in vitro (n=3; p<0.001)
and delayed onset of leukemia in NSG mice (n=8; p<0.0001). PIWIL4 KD in
primary AML patient BM cells lead to 5-fold decrease in clonogenicity (n=3,
p<0.001), but had no impact on clonogenicity of healthy stem progenitors in
vitro (n=4). Western blot and ChIP-seq (n=2, MACS1.4, p<0.01, FDR<0.01) in
THP-1 cell line revealed a marked global reduction in repressive H3K9me3
marks upon PIWIL4 KD. Over 500 promoter and 600 gene body associated
loci exhibited loss of H3K9me3 marks. RNA-seq analyses revealed over 4000
differentially expressed genes upon PIWIL4 depletion. 30% of the loci that lost
H3K9me3 marks at promoters and gene body were differentially expressed in
RNA-seq (fold>0.05, adj. p<0.01). These genes belonged to pathways asso-
ciated with RNA metabolism, transcription and cell death. Moreover, these
genes were enriched for binding sites of SETDB1, an H3K9me3 establishing
histone methyltransferase (ENRICHR, p<0.01, FDR<0.01). Notably, using
IP/LC-MS, PIWIL4 was found to associate with SETDB1 in 293T cells. 560
unique piRNAs were found to physically bind to PIWIL4 and 981 unique piRNAs
were differentially expressed upon PIWIL4 depletion in THP-1 cells.
Summary/Conclusions: Thus, collectively, we could show for the first time
that PIWIL4 expression is deregulated in human AML and acts as a piRNA
binding, epigenetically active growth regulatory protein in human AML.
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Background: Acute myeloid leukaemia (AML) patient survival remains below
30% and there have been no major new anti-AML therapies for decades.
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Aims: To identify novel therapeutic vulnerabilities of AML.
Methods: A CRISPR-Cas9 drop-out screen was used to identify genetic vul-
nerabilities of AML. Downstream, we study the function of the RNA methyl-
transferase METTL3, a novel therapeutic vulnerability of AML. These included
in-vitro and in-vivo validation of METTL3 as a therapeutic target using
CRISPR/gRNA or shRNA, and investigation of its function using ChIP-seq,
RNA-IP-seq, ribosome footprinting (RFP) and bioinformatic analyses.
Results: We performed a genome-wide CRISPR screen on AML cells from
Flt3ITD/+;RosaCas9/+ mice transformed with MLL-AF9 lentivirus and identified
>1500 cell-essential genes of which ~250 were AML-specific and included
many MLL-AF9 interactors and several putative RNA methyltransferase genes:
METTL1, METTL3, METTL14 and METTL16 (Fig 1A). Focusing on METTL3,
we show that its disruption with Cas9/gRNA promoted differentiation of murine
and human MLL-AF9 AML cells and inhibited their growth in vitro and in vivo
(Fig 1B), but did not affect primary murine haematopoietic stem/progenitor cells.
To investigate METTL3 function we performed chromatin immunoprecipitation
(ChIP) for METTL3 and H3K4me3 and identified 126 METTL3 peaks, localized
mainly at promoters with bimodal H3K4me3. METTL3 binding was highest at
transcription start sites (TSS) (Fig 1C) and the most enriched transcription
factor motif at METTL3 sites was that for the NFY complex. Using available
ChIP-seq datasets we found that NFYA, NFYB, H3R2me2s, WDR5 and KLF9
showed strong co-binding with METTL3. Also shRNA knock-down (KD) of
WDR5, led to reduced METTL3 binding to target genes SP1 and SP2. 
To investigate if/how METTL3 controls expression of target genes we first noted
that their mRNA levels were unaffected by METTL3 KD. As METTL3 is an N6-
methyladenosine (m6A) methyltranferase, we then performed RNAseq after IP
with an m6A-specific antibody (m6A-IP). This identified >4000 METTL3-depen-
dent m6A peaks on poly-A+ RNA. m6A peaks were seen on 72.4% of MET-
TL3-bound gene transcripts and were located in the coding region (CDS) in
contrast to STOP codon enrichment in the general transcriptome (Fig 1D). Also,
METTL3-bound transcripts were enriched for the [GAG]n motif, which was
almost always in the +2 reading frame (Fig1E). As this raised the possibility
that m6A may regulate translation of these transcripts, we performed RFP on
wild type (WT) and METTL3 KD MOLM13 cells, to evaluate translational effi-
ciency (TE). Strikingly, upon METTL3 KD, m6A-marked genes had increased
TE, whilst transcripts with METTL3 at their TSS had reduced TE (Fig1F). We
then mapped ribosomal pausing sites on mRNAs from METTL3-bound TSSs
and found that GAN codons were more occupied (paused) in METTL3 KD vs
WT cells (Fig1G). To understand consequences at the protein level, we studied
METTL3 targets SP1 and SP2. Remarkably, in contrast to their mRNA levels,
SP1 and SP2 proteins were markedly reduced upon METTL3 KD (Fig1H). SP1
and SP2 targets including c-MYC, were also downregulated upon METTL3 KD
and simultaneous SP1/SP2 gRNA KD markedly reduced proliferation of MLL-
AF9/Flt3ITD/+ cells.
Figure 1.
Summary/Conclusions: Our results show that METTL3 controls translation
of specific mRNAs by binding their TSS and introducing m6A at [GAG]n motifs
within their CDS, in turn increasing their TE. These mRNAs code for proteins
essential for AML cell survival, making METTL3 a novel therapeutic vulnerability
of AML.
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THE COMBINATION OF ORAL ALL-TRANS RETINOIC ACID AND DANAZOL
VS DANAZOL AS SECOND-LINE TREATMENT IN ADULT IMMUNE
THROMBOCYTOPENIA: A MULTICENTRE, RANDOMIZED, OPEN-LABEL
TRIAL
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Background: Immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by increased platelet destruction and impaired platelet production.
Despite decades of basic and clinical research, the treatment of severe, corti-
costeroid-resistant or relapsed disease remains a great challenge. Our prelim-
inary study indicated the effectiveness of all-trans retinoid acid (ATRA) for ITP
(Wang M, et al. ASH 2012, Abstract #3338). This has been coupled with pre-
vious discoveries of an immune-modulation effect of ATRA in ITP, including its
role to induce changes in Treg cells (Ruan CG 2016), and to correct the imbal-
ance of aberrant macrophage polarization (unpublished data), indicating ATRA
as a potential therapeutic regimen. Danazol has been used in the treatment of
ITP for more than 30 years. Apart from its haemopoietic stimulatory and
immune-modulatory effect, it has recently been shown to reverse abnormal
telomere/telomerase function in patients with thrombocytopenia (Townsley DM
2016). The combination of ATRA and danazol may work synergistically based
on the mechanism of action targeting both increased platelet destruction and
insufficient platelet production.
Aims: To investigate the efficacy and safety of ATRA plus danazol in patients
with corticosteroid-resistant and/or relapsed ITP.
Methods: A multicentre prospective study was performed in non-splenec-
tomized corticosteroid resistant/relapsed ITP patients. Participants were at least
18 years of age, had a platelet count of less than 30×109/L at enrolment, and
did not achieve a sustained response to treatment with full-dose corticosteroids
for a minimum duration of 4 weeks or relapsed during steroid-tapering or after
its discontinuation. Written informed consents were obtained from all of the
participants. The primary endpoint was a sustained response. The secondary
endpoints included overall response, time of response, duration of response,
incidence of bleeding symptoms and safety.
Results: From 2012 to 2016, 130 consecutive patients were enrolled from 5
different tertiary medical centres in China. Thirty-seven patients were ineligible
and excluded, leaving 93 patients randomized to the ATRA+danazol group
(n=45) and the danazol group (n=48). At 12 months’ follow-up, sustained partial
or complete response was achieved in 71.6% of patients in the danazol+ATRA
group, significantly higher than 47.2% for danazol monotherapy (p<0.001).
Additionally, 92.5% and 42.5% of patients receiving ATRA+danazol achieved
at least one response (R), while only 58.3% and 11.1% of patients with danazol
monotherapy achieved R and CR, respectively. In patients achieving CR or R,
the median time to treatment response was 30.5 days with a peak platelet
count of 155×109/L in the danazol+ATRA group compared with 49 days with a
peak PLT of 69×109/L in the danazol group. Multivariate analysis revealed that
the initial response at day 28 and the median ITP duration were the potential
variables associated with a sustained response. There was no treatment-related
death due to adverse events. One patient receiving danazol monotherapy died
from intracranial haemorrhage 4 weeks after study enrollment.
Summary/Conclusions: Our findings demonstrate that the combination of
ATRA and danazol is safe and effective in achieving a rapid and long-lasting
response, making it a potential promising therapeutic option for patients with
non-splenectomized corticosteroid-resistant/relapsed ITP. This study is regis-
tered at www.clinicaltrials.gov as # NCT01667263.
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NOVEL PERSPECTIVES IN GENOTYPE-PHENOTYPE CORRELATIONS IN
MYH9-RELATED DISEASE: NO LONGER JUST A MATTER OF HEAD OR
TAIL
C. Zaninetti1,*, D. De Rocco2, A. Pastore2, V. Bozzi1, S. Barozzi1, F. Melazzini1,
A. Savoia2, P. Noris1, C.L. Balduini1, A. Pecci1
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Background: MYH9-related disease (MYH9-RD) is an autosomal-dominant
disorder caused by mutations in MYH9, the gene for non-muscle myosin heavy
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chain IIA (NMMHC-IIA), and represents the most frequent inherited thrombo-
cytopenia worldwide. NMMHC-IIA comprises two distinct domains, the N-ter-
minal globular head domain (HD) and the C-terminal tail domain (TD), and
causative mutations hit either the HD or the TD. All patients present at birth
with macrothrombocytopenia and only some of them develop during life addi-
tional manifestations, including nephropathy often leading to end-stage renal
disease (ESRD), sensorineural deafness, and/or cataract. Thus, the search
for genotype-phenotype correlations in MYH9-RD has been an important
research topic since the identification of the disorder. In 2008, the analysis of
108 patients allowed to conclude that the mutations affecting the HD were
associated with evolution to early-onset ESRD and deafness, whereas the risk
of non-hematological manifestations was much lower for patients carrying
mutations of the TD. In 2014, raising to 255 the number of patients, we sug-
gested that evolution to juvenile ESRD associated only with the most frequent
among HD mutations, i.e. substitution of the arginine 702 (R702). Conversely,
the other HD mutations, which were almost all localized in a distinct hydropho-
bic region at the interface between the SH3 subdomain and the motor domain
(SH3/MD interface), may be associated with a much less severe evolution.
Aims: To improve prognostic assessment of patients with MYH9-RD.
Methods: All the consecutive patients enrolled in the Italian registry for MYH9-
RD until June 2016 were included. The association of MYH9 genotype with
phenotype was assessed by a generalized linear regression model (event-free
survival analysis).
Results: We enrolled 350 patients belonging to 199 MYH9-RD pedigrees.
Mutational screening allowed us to identify 6 novel causative mutations in the
HD in 6 different pedigrees. Interestingly, all of these variants were localized in
the hydrophobic region at the SH3/MD interface. By raising the number of
patients with mutations in this region from 14 to 26, and increasing the obser-
vation time, we could demonstrate that the mutations in the SH3/MD interface
are associated with development of deafness at young-middle age, but low
risk of kidney disease and cataract. The other previously identified genotype-
phenotype correlations were confirmed. In particular, mutations hitting the R702
in the HD resulted in constant evolution toward juvenile ESRD and severe
deafness. Among mutations different from R702 substitutions, the p.D1424H
in the TD associated with the highest risk to develop non-congenital manifes-
tations of the disease.
Summary/Conclusions: Mutations in the HD of the NMMHC-IIA are almost
all localized in a specific region at the SH3/MD interface, which therefore rep-
resents a critical region for MYH9-RD pathogenesis. Most importantly, patients
with HD mutations are distinguished into two different prognostic groups: sub-
jects with R702 substitutions are expected to early develop a severe syndromic
disorder, whereas mutations in the SH3/MD interface are associated with evo-
lution to a milder phenotype, characterized by development of hearing impair-
ment only (“auditory” phenotype). Our study confirmed a genotype-phenotype
model for MYH9-RD that overcomes the previously reported dualism between
HD vs TD mutation.
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A MONOALLELIC LOSS-OF-FUNCTION MUTATION IN THE THROMBOPOIETIN
(THPO) GENE IS RESPONSIBLE FOR A NEW FORM OF INHERITED
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Background: The THPO-MPL axis plays a central role in platelet biogenesis:
it activates the signaling cascade inducing megakaryocytes (MKs) differentia-
tion from progenitor cells and regulates MKs maturation, proplatelet extension,
and nascent platelets release into the bloodstream. Different diseases are
known to derive from inherited abnormalities of MPL and THPO. Gain-of-func-
tion mutations in both genes cause congenital thrombocytosis, while loss-of-
function mutations in MPL result in congenital amegakaryocytic thrombocy-
topenia: patients affected by this form of inherited thrombocytopenia (IT) pres-
ent at birth with isolated thrombocytopenia, which always evolves into severe
bone marrow aplasia. Similarly, a homozygous loss-of-function variant in the
THPO gene was found to be responsible for recessive aplastic anemia in a
Micronesian family. 
Aims: To unravel the molecular basis of ITs and to improve the clinical and
laboratory characterization of the new ITs identified.
Methods: Whole exome sequencing (WES) was performed in 86 propositi with
an unknown IT. They were part of our case series of 274 consecutive families,
151 of which remained without a definite diagnosis at the end of the diagnostic
workup carried out according to the diagnostic algorithm proposed in 2003 by
the Italian platelet study group and subsequently updated to include the most
recent discovered disorders (Clin Genet 2016;89:141). The investigation was
approved by the Institutional Review Board of the IRCCS Policlinico San Matteo
Foundation and all patients gave written informed consent.
Results: WES in 86 propositi with unknown IT identified 2 unrelated individuals
(family A and B) carrying the heterozygous variant c.91C>T (p. Arg31*), which
is expected to result in a mutant protein degradation and THPO haploinsuffi-
ciency. In each family the segregation with the disorder was confirmed ana-
lyzing one affected relative. Bleeding tendency was absent in all cases. All
patients had mild thrombocytopenia; blood film examination did not identify
any morphological abnormality of platelets, except for some elements with
slightly increased size in patients of family A. In vitro platelet aggregation and
surface expression of GPIIb/IIIa and GPIb/IX were investigated in the two
patients of Family B and gave normal results. The mild severity of thrombo-
cytopenia and the absence of qualitative platelet defects, at least in the two
patients of family B, are consistent with the absence of bleeding tendency in
affected subjects. THPO serum level was at the lower limit of the normal range
in the two subjects of family B, the only available for this assay. This result
was in agreement with our hypothesis that THPO mutations were expected to
result in haploinsufficiency.
Summary/Conclusions: The p.Arg31* mutation in THPO causes a new auto-
somal dominant form of mild, non-syndromic thrombocytopenia. This innocuous
disorder is relatively rare (1.3% of families of our case series) but it has to be
distinguished from the more severe autosomal dominant ITs with normal platelet
size deriving from mutations in ETV6, ANKRD26 and RUNX1, since they pre-
dispose to the development of hematological malignancies. Because of the
similarity of the clinical features and the lack of reliable laboratory markers, we
suggest to perform genetic analysis in all subjects with autosomal dominant
thrombocytopenia and normal platelet size in order to identify their disorders,
define prognosis and organize an appropriate follow-up regimen.
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POSITION OF THE GFI1B ZINC FINGER MUTATION DECOUPLES CD34
EXPRESSION FROM ALPHA-GRANULE DEFICIENCY IN GFI1B-RELATED
PLATELET DISORDERS
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Background: GFI1B is a transcription factor that plays an important role in
haematopoiesis. Families with a mutation of the fifth DNA-binding zinc-finger
domain of GFI1B experience bleeding and have a platelet phenotype charac-
terised by macrothrombocytopenia, increased CD34 expression and alpha-
granule deficiency.
Aims: To explore the function of other zinc finger domains of GFI1B we have
characterised two unrelated families with a GFI1B variant, C168F, predicted to
disrupt the first Zn-finger domain and compared the phenotype with a previously
described pedigree with the H294fs mutation that disrupts the fifth Zn-finger
domain.
Methods: Clinical platelet phenotypes were determined by light and transmis-
sion electron microscopy and functional studies performed by light transmission
and whole blood impedance aggregometry. Platelet protein expression was
measured by flow cytometry and western blotting. DNA-binding of variants was
determined by gel mobility shift assays (EMSA) and changes in gene tran-
scription by luciferase assays. Cellular phenotypes were then studied in patient
specific iPSC derived megakaryocytes.
Results: Individuals with GFI1B C168F are thrombocytopenic (mean platelet
count =107 x109/L, n=8) but lack the collagen induced aggregation defects
and bleeding symptoms observed in individuals with H294fs (ISTH BAT,
P=0.015). Alpha granule content observed by microscopy and quantitated by
western blotting of granule related proteins, P-selectin and fibrinogen, were
similar between C168F and control platelets and this was significantly greater
than that observed for the H294fs mutation (P<0.01). EMSA studies indicate
that the C168F variant retains the ability to bind DNA whereas the H294fs
mutation altering Zn finger 5 abrogates DNA binding. Despite retaining the abil-
ity to bind DNA, the C168F variant de-represses gene transcription at TUBB1,
MEIS1 and CD34 target genes (P<0.01). This de-repression is less marked
than that observed with the non-DNA-binding H294fs mutation (P<0.01). The
transcriptional de-repression observed at the CD34 promoter with both Zn fin-
ger domain 1 and 5 variants was validated by an increase in platelet surface
CD34 measured by flow cytometry and total CD34 protein measured by west-
ern blotting (P<0.01). This increased CD34 expression appears specific for
GFI1B mutation as increased CD34 expression was not observed in platelets
derived from individuals with FLI1, RUNX1 or MYH9 mutation. To validate these
clinical observations, iPSCs were generated from the different pedigrees and
megakaryocyte differentiation performed in vitro. Megakaryocyte CD34 expres-
sion was increased in cells derived from individuals with both C168F and
H294fs variants but alpha granule deficiency was only observed in cells con-
taining the non-DNA-binding H294fs mutation.
Summary/Conclusions: Mutations altering GFI1B Zn finger 1 cause throm-
bocytopenia with increased CD34 expression but these platelets retain rela-
tively normal alpha-granule content and these individuals lack clinical bleeding
symptomatology. This mutation is mechanistically distinct from the Zn finger 5
mutation that abrogates DNA binding with a subsequent phenotype charac-
terised by alpha-granule deficiency and clinical bleeding.
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TREATMENT OF PRIMARY ADULT CHRONIC IMMUNE THROMBOCYTOPENIA
(CITP) WITH FOSTAMATINIB, AN ORAL SYK INHIBITOR: RESULTS OF
TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
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Background: ITP is characterized by autoantibody-directed platelet destruction
mediated by activated monocyte Fc receptors which signal via spleen tyrosine
kinase (syk). A Phase 2 trial of the oral syk inhibitor Fostamatinib (FOSTA) in
16 patients (pts) with refractory ITP provided preliminary efficacy and safety
data (Podolanczuk et al., 2009).
Aims: To evaluate the efficacy and safety of FOSTA in adult cITP in 2 parallel,
identical, multi-center, randomized, double-blind phase 3 studies (S047 and
S048) of 24 weeks duration, followed by an open label study (S049).
Methods: 150 pts with 3 platelet (plt) counts (ct) <30K/µL were enrolled (76 in
S047, 74 in S048) with a 2:1 randomization to FOSTA 100mg or placebo bid,
and stratification by prior splenectomy and baseline plt ct<or ≥15K/μL. Sixty-
one % of pts were female; median age was 54 y (20-88); 93% were Caucasian;
93% had cITP; median disease duration: 8.5 y; median baseline plt ct: 16K/μL.
Prior therapies received by pts included 94% steroids, 47% TPO-RAs, 35%
splenectomy, and 32% rituximab. Stable response (SR) was defined as a plt ct
≥50K/μL at 4 of 6 biweekly visits over Weeks 14-24; intermediate response
(IR) as at least 2 consecutive bi-weekly plt cts ≥50K/μL, both without rescue
treatment.
Results: Across both studies, a SR occurred in 18/101 (18%) FOSTA vs 1/49
(2%) placebo pts (p=0.007); 11 additional FOSTA and no placebo patients
achieved an IR, making the overall response rate 29% (29/101) for FOSTA vs
2% (1/49) for placebo (p<0.0001). The median plt cts were 95K, 49K, 20.5K
and 17.5K/μL in SR, IR, non-responders (NR) and placebo pts, respectively. In
SR and IR, median time to first plt ct ≥50K/μL was 2 weeks. Age (< or ≥65 y),
gender, baseline plt ct <15K/µL, prior TPO-RA or splenectomy did not substan-
tially affect response. In S049, 9/41 (22%) pts newly treated with FOSTA have
a SR, consistent with S047 and S048. Fifty-four of 101 (54%) FOSTA pts and
14/49 (29%) placebo pts had a plt increase ≥20K/μL (p=0.005). Three of 18
(17%) SR and 1/11 (9%) IR to FOSTA compared to 26/72 (36%) NR and 22/49
(45%) of the placebo group received ≥1 rescue medication, respectively. In
S047-S048, serious bleeding occurred in 5.6% of the NR and 10.2% of placebo
pts, but not in the 29 responders. The number of pts with ≥1 adverse event
(AE) was similar in FOSTA vs placebo (83% vs 75%). The majority AEs on
FOSTA were mild or moderate; all resolved over time. Most common AEs were:
diarrhea (29% vs 15%), nausea (19 vs 8%), hypertension (20% vs 8%),
ALT/AST increase (10% vs 0%). Serious AEs were reported in 13% FOSTA vs
21% placebo pts.
Summary/Conclusions: Fostamatinib substantially improves plt cts in certain
pts with heavily pre-treated, severe cITP of long disease duration. AEs are
mostly mild or moderate in severity. Given its unique mechanism of action
based on inhibition of syk, FOSTA could, if approved, be an important alternative
as single agent and be a useful component of combination therapy for pts with
difficult cITP.
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THE YING AND YANG OF JAK SIGNALING : LOSS OF USP9X BUFFERS
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Background: Children with Down syndrome (DS) are prone to development
of high risk B cell precursor (BCP) acute lymphoblastic leukemias (DS-ALL)
that differ genetically from most sporadic pediatric ALLs. Chromosomal
rearrangements causing increased expression of CRLF2, the receptor for
thymic stromal lymphopoietin (TSLP), characterize about half of DS-ALLs. 
Aims: Understanding the pathogenesis of relapse of DS-ALL relating to their
CRLF2 status.
Methods: Integrative genomic analysis of matched diagnosis remission and
relapse DS-ALLs, pharmacological inhibition and genetic CRISPR mediated
silencing.
Results: Genomic analysis of 25 matched diagnosis remission and relapse
DS-ALLs reveled lesions affecting known driver genes in the samples. In 80%
of the patients we detected activating mutations in genes whose protein prod-
ucts are involved in signaling, including receptors (CRLF2, IL7R, FLT3), or
downstream effector enzymes (JAK1/2, KRAS and NRAS). In contrast to a
previous report, we observed that lesions in CRLF2 are early events during
DS-ALL evolution, as is evident by its high allelic frequency, and are main-
tained at relapse. The genetic make-up differed significantly between these
two major subtypes of DS-ALLs. CRLF2neg DSALLs were characterized by
enhanced RAS signaling coupled by mutations in chromatin remodeling
genes, in particular CREBBP. In contrast CRLF2pos DS-ALLs were charac-
terized by high dynamics of proliferative signaling. At diagnosis CRLF2
rearrangements were almost always combined with secondary activating sig-
naling events in JAK-STAT pathway suggesting that signaling is driving the
development of these leukemias. However JAK2 mutations were often lost
at relapse and replaced by clones with mutated RAS. Thus the presence of
JAK2 activating mutations at the time of diagnosis are associated with sen-
sitivity to upfront chemotherapy. Surprisingly we discovered loss-of-function
mutations or deletions of USP9X, a deubiquitinase previously described as
an oncogene that positively regulates JAK2 signaling, in 25% of CRLF2pos
ALLs, in both our study and published data,. We therefore tested the coun-
terintuitive hypothesis that loss of a positive regulator of JAK2 enhances the
fitness of JAK-STAT driven JAK2 mutated leukemic cells. Both pharmacolog-
ical inhibition and genetic CRISPR mediated silencing of USP9X reduced
STAT5 phosphorylation and enhanced the survival of CRLF2-JAK2R683Gs
transduced ALL cells. To test directly the effect of JAK inhibition, we treated
CRLF2/JAK2R683G transduced cells with increasing doses of ruxolitinib, a
JAK inhibitor currently in clinical trials for CRLF2-JAK-STAT ALLs. Strikingly
while high doses (>2μM) were cytotoxic, low doses (0.25μM) enhanced the
survival of CRLF2-JAK2R683Gs expressing ALL cells.
Summary/Conclusions: These observations suggest that genetic or pharma-
cological restraining of JAK-STAT signaling may be beneficial to leukemic B
cell precursors by enhancing the fitness of JAK-STAT “driven” ALL. This and
the reduction of JAK-mutated clones at relapse suggest that the therapeutic
effect of JAK2 specific inhibitors may be limited. Rather, combined signaling
inhibitors or direct targeting of the TSLP receptor may be a useful therapeutic
strategy for DS-ALL.
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Background: Persistence of residual leukemia cells, due to deficiencies in
apoptotic programs, is a major driver of relapse. Activation of alternative non-
apoptotic cell death pathways such as necroptosis represents an attractive strat-
egy to eliminate residual leukemia cells and prevent relapse. We have previously
shown that SMAC-mimetics (SM) potently induce cell death by simultaneous
RIP1-dependent apoptosis and necroptosis in a subset of refractory acute lym-
phoblastic leukemia (B-ALL) patient-derived samples. The molecular signals
that drive sensitivity to RIP1-dependent cell death remained elusive so far.
Aims: The aim of this project was to understand the mechanisms that deter-
mine the specific vulnerability to necroptosis in ALL.
Methods: To identify molecular determinants of sensitivity to SM, we correlated
the gene expression profiles of 17 primary samples with high and low sensitivity
to SM with the IC50 in response to two SM compounds, birinapant and LCL161.
We confirmed the top scoring genes including TNF receptor 1 (TNFR1) and
TNFR2 by quantitative RT-PCR in patient-derived xenografts. We further vali-
dated our results by quantifying the expression of the candidate genes in an
independent cohort of relapsed primary B-ALL and by screening samples with
different expression levels of TNFR1 and 2 for their response to SM in vitro.
To assess the mechanistic role of TNFR1 and 2 in the response to SM, we
generated patient-derived TNFR1 and TNFR2 knockout cells using the
CRISPR/Cas9 gene editing technology, and evaluated their response to SM in
vitro and in vivo using a CRISPR selection model. Additionally, we overex-
pressed TNFR2 and evaluated the cell death phenotype. To determine the
mechanism of TNFR2-mediated sensitization to SM, we investigated the for-
mation of the pro-death RIP1-TNFR1 complex in wild type versus TNFR2ko
and in SM sensitive and resistant ALL by immunoprecipitation in primary ALL
samples.
Results: Comparative gene expression profiling indicated a correlation of the
expression of TNFR2 with sensitivity to SM in primary ALL. Using an independ-
ent cohort of relapsed ALL samples, we found that high TNFR2 expression
predicted sensitivity to SM in an ex vivo model of the bone marrow. Deletion of
either TNFR1 or TNFR2 using CRISPR/Cas9 in patient-derived ALL conferred
resistance to treatment with SM in vivo in the xenograft model, indicating that
TNFR1 and 2 are both functionally required for cell death. In agreement with
an important role for TNFR2 in the response to SM, the overexpression of
TNFR2 leads to increased sensitivity to the TNFR1/RIP1 death axis. On the
mechanistic level, recruitment of RIP1 to TNFR1 is a key event in the activation
of cell death, which is abolished in TNFR2-deficient leukemia and does not
occur in SM resistant cases.
Figure 1.
Summary/Conclusions: Taken together, our data reveal a novel function of
TNFR2 in cell death signaling, as TNFR2 predicts sensitivity to SMAC mimetics
and plays a key role in activating the TNFR1/RIP1 cell death pathway, which
underlies the switch from RIP1-controlled cell survival to cell death and char-
acterizes a distinct vulnerability in ALL.
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THERAPEUTIC TARGETING OF ONCOGENIC MYB ACTIVITY IN T-ALL
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Background: T-lineage acute lymphoblastic leukemia (T-ALL) is an aggressive
hematologic malignancy that accounts for 10%–15% of pediatric and 25% of
adult ALL cases. The prognosis of T-ALL has gradually improved, however,
the outcome of T-ALL patients with primary resistant or relapsed leukemia
remains poor. Thus, further advances in the treatment of T-ALL require the
development of effective and highly specific molecularly targeted antileukemic
drugs. The proto-oncogene MYB (encodes c-MYB) is aberrantly activated in a
subset of T-ALL patients through T-cell receptor driven translocations or genom-
ic duplications of the MYB locus itself. Recently, a new genetic mechanism for
the generation of oncogenic super-enhancers in malignant T cells was identi-
fied, and suggests a general role for MYB in the regulation of T-cell specific
super-enhancer activity.
Aims: We want to identify the role of enhanced MYB activity in super-enhancer
driven oncogenic transcription in the context of malignant T-cell development
and investigate the in vivo role of cMyb in the initiation and maintenance of T-
ALL.
Methods: To evaluate if cMyb could act as a bona fide oncogene in the patho-
genesis of T-ALL, we developed a conditional R26-driven cMyb overexpression
mouse model. For this, we used a targeting vector that contained a floxed stop
cassette followed by the cMyb gene and a EGFP/luciferase reporter, which
was subsequently targeted in mESCs using recombinase-mediated cassette
exchange (RMCE).
Results: Here, we report a novel conditional Myb knockin mouse model (R26-
Myb). To study the in vivo oncogenic capacity of Myb, we initially crossed this
conditional Myb knockin model with VaviCre mice, in order to obtain
hematopoeitic specific expression of Myb and the EGFP/luciferase from the
ROSA26-promoter. Notably, Vav-iCretg/+ R26-Mybtg/tg mice developed T-cell
lymphomas with a median latency of 77 weeks, suggesting that Myb can act
as a bona fide oncogene in malignant T-cell transformation (Figure 1A). Next,
we crossed our Myb transgenic model with Pten conditional knockout mice, to
allow comparative analysis of tumors with and without T-cell specific Myb
expression. Genetic inactivation of Pten is frequently observed in human T-
ALL, and T-cell specific deletion of Pten (using Lck-Cre) results in T-cell
leukemia/lymphoma development with an average of 17 weeks. Using this
strategy, we obtained mice that overexpress R26-driven cMyb and lack Pten
in developing T-cells and found that cMyb expression synergizes with Pten
deletion, resulting in fully penetrant and accelerated T-ALL formation (median
survival of 84 days instead of 118; p =0.0003; Figure 1B). Finally, we used this
novel murine T-ALL model to identify new therapeutic strategies for MYB
dependent T-ALL. Importantly, the tumor cells from the cMyb knockin mice are
luciferase-positive and are therefore suitable for in vivo drug testing using bio-
luminescence. Using this model, we evaluated the in vivo anti-leukemic efficacy
of a variety of small molecules and identified new drugs that impede Myb protein
stability or Myb-mediated transactivation in Myb driven tumorigenesis.
Figure 1.
Summary/Conclusions: We developed a novel Myb-driven T-ALL mouse
model and could demonstrate a pathogenic role for cMYB in T-cell leukemia.
In addition, the Myb-driven preclinical mouse model will open new avenues for
therapeutic intervention in T-ALL. 
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Background: Several somatic ribosome defects have recently been discovered
in cancer, yet their underlying oncogenic mechanisms remain poorly understood.
Alterations in ribosomal protein genes RPL5, RPL10, and RPL22 have been
described in ~20% of T-cell acute lymphoblastic leukemia (T-ALL) cases. Where-
as RPL5 and RPL22 show heterozygous inactivating mutations and deletions,
RPL10 contains a clear mutational hotspot at residue arginine 98 (R98), with
8% of pediatric T-ALL patients harboring this RPL10 R98S missense mutation.
Aims: Investigating the pathogenic role of the recurrent R98S mutation in ribo-
somal protein L10 (RPL10) in T-ALL.
Methods: A label-free quantitative proteomics experiment was performed to
screen for differentially expressed proteins in engineered mouse lymphoid
Ba/F3 cells expressing RPL10 WT or RPL10 R98S. Differences in protein
expression were further validated in hematopoietic cells derived from a trans-
genic RPL10 R98S knock-in mouse model and in material derived from
xenografted T-ALL patient samples.
Figure 1.
Results: The differential proteome screen revealed overexpression of several
Jak-Stat signaling components (Csf2rb/2, Jak1, Stat1, Stat3, Stat5a/b and
Stat6) in engineered RPL10 R98S mouse lymphoid cells, which we confirmed
in hematopoietic cells derived from a transgenic RPL10 R98S mouse model.
The relevance of this overexpression was illustrated by enhanced Jak-Stat
pathway activation upon cytokine stimulation in RPL10 R98S lymphoid cells,
as well as increased sensitivity of these cells to clinically used JAK-STAT
inhibitors ruxolitinib and pimozide. RPL10 R98S positive leukemia patients like-
wise showed overexpression of IL7RA, JAK1 and STAT5, increased sensitivity
to pimozide, as well as a mutually exclusive mutation pattern between RPL10
R98S and JAK-STAT lesions, suggesting that RPL10-R98S also modulates the
cascade in human T-ALL. Programmed -1 ribosomal frameshifting (-1 PRF)
recently emerged as a post-transcriptional mechanism regulating expression
of cytokine receptors. We identified -1 PRF signals in mouse and human Jak-
Stat genes and observed RPL10 R98S associated frameshifting reduction in
several of these, which may contribute to their overexpression. Altered levels
of -1 PRF can however only partially explain observed JAK-STAT protein
expression changes, and transcriptional changes and altered protein stability
are also involved. Indeed, our data point to altered proteasome activity and
composition in RPL10 R98S cells, with upregulation of immunoproteasome
specific catalytic subunits, which may explain the increased stability of particular
proteins such as Jak1. Of further medical interest, RPL10 R98S cells showed
reduced proteasome activity and enhanced sensitivity to the clinically used pro-
teasome inhibitors bortezomib and carfilzomib.
Summary/Conclusions: We explored the molecular mechanism by which the
RPL10 R98S mutation contributes to the pathogenesis of T-ALL. We propose
a model in which R98S associated decreases in -1 PRF levels, combined with
changes in the degradation of particular proteins and potential other mecha-
nisms such as transcriptional regulation, leads to selective upregulation of the
oncogenic JAK-STAT cascade (Figure 1). Besides expanding the relevance of
the JAK-STAT cascade in T-ALL and leukemia in general, our results have ther-
apeutic potential since cells harboring the RPL10 R98S mutation are sensitized
towards clinically used JAK-STAT and proteasome inhibitors.
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Background: Transcriptional read-through of a single mRNA between con-
tiguous loci, or cis-splicing of adjacent genes (cis-SAGe), results in transcription
of intergenically-spliced chimeric RNAs (ISCs) in the absence of structural
genomic changes. Recent advances in high-throughput RNA-sequencing analy-
sis have permitted identification of aberrant ISC expression as a potential can-
cer driver, but knowledge of leukaemia-related ISCs is lacking.
Aims: To examine whether cis-SAGe generates biologically important ISCs in
T-acute lymphoblastic leukemia (T-ALL).
Methods: We performed RNA-sequencing of 12 cases of T-ALL and normal
thymic RNA, and used targeted analysis pipelines to detect T-ALL-specific
fusion chimeras.
Results: We identified 140 T-ALL-specific fusions, of which 55 involved genes
located within 30kb of each other, in the same transcriptional orientation. This
distance is consistent with that previously observed for cis-SAGE, suggesting
that ISC expression is common in T-ALL. In total, putative ISCs were detected
in 10/12 samples, with a median of 4 (range 0-15) per patient. We performed
further analysis on the candidate ISC NFATC3-PLA2G15, which includes the
Nuclear Factor of Activated T-cells (NFAT) family member NFATC3, a critical
regulator of normal thymopoiesis and known modulator of T-ALL biology. We
found that primary T-ALLs exhibited a wide range of NFATC3-PLA2G15 expres-
sion, while levels in normal tissue were either very low or undetectable. 5’ RACE
PCR analysis of leukemic cDNA revealed that fusion transcription was initiated
in exon 1 of NFATC3. We also performed array competitive genomic hybridiza-
tion of 115 diagnostic T-ALL samples, and found no evidence of microdeletions
that would result in NFATC3-PLA2G15 expression, providing strong evidence
that NFATC3-PLA2G15 is a true ISC that is generated by cis-SAGe. We found
that the NFATC3-PLA2G15 fusion had lower activity than wild-type NFATC3 in
both luciferase reporter experiments and proliferation and survival complemen-
tation assays in NFAT-null ALL cell lines in vitro. Gene set enrichment analysis
revealed that primary T-ALL blasts with elevated NFATC3-PLA2G15 levels had
reduced transcription of canonical NFAT target genes in vivo, suggesting that
these cases may have lower activity of normal physiological NFAT pathways.
Strikingly, we found that higher NFATC3-PLA2G15 levels strongly correlated
with both shorter time to leukemia development (p=0.01) and survival (p=0.003)
in patient-derived T-ALL xenografts in immunodeficient mice. These findings
were corroborated by survival analyses of human T-ALL patients treated as part
of the Francophone multinational GRAALL-2003 and -2005 studies, as cases
with the highest quartile of NFATC3-PLA2G15 expression had significantly
reduced 5 year overall survival (52.6%, 95% CI 33.3% - 68.7%) compared with
NFATC3-PLA2G15 low cases (69.8%, 95% CI 58.8% - 78.3%, p=0.047).
Summary/Conclusions: Our results suggest that ISC expression is common
in T-ALL, and that high expression of the NFATC3-PLA2G15 ISC correlates
with reduced canonical NFAT pathway activity and poor patient outcome.
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ASSESSING THE RISK-BENEFIT OF ANTICOAGULANTS IN ELDERLY
PATIENTS WITH CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM:
A POPULATION BASED STUDY
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Background: Cancer patients have a higher risk of venous thromboembolism
(VTE) which conveys a higher subsequent mortality risk; conversely, they also
have a higher risk for bleeding due to many factors including abnormal tumor
anatomy and the use of chemotherapy agents with the associated risk for
thrombocytopenia. However, the consequences of a recurrent VTE or a major
bleeding (MB) event might be different in terms of mortality. As a result, the
risk of VTE recurrence or a MB event might bear different weights. A previous
systematic review has suggested that the case fatality rates of VTE recurrence
and MB are similar. However, heterogeneity in study design, outcomes and in
particular the types of populations included, limited the interpretation and appli-
cability of the results. Clinical decision making uses estimations of risk and
benefit for any given intervention. In the case of VTE, anticoagulants are the
cornerstone of treatment having a proven benefit in reducing the risk of recur-
rent VTE events with an associated increase in the risk of bleeding. Therefore,
determining the risk-benefit of anticoagulants might allow for better informed
treatment decisions, in particular in a population at high risk for both ends of
the spectrum. Therefore, herein we sought to estimate the risk and benefit of
anticoagulant therapy in cancer patients developing a VTE using data from
administrative databases.
Aims: To estimate case fatality rates of VTE recurrence and MB, as well as
the case fatality rate-ratio for MB and VTE recurrence in cancer patients devel-
oping a VTE treated with anticoagulants.
Methods: We conducted a retrospective population-based cohort study in
Ontario, Canada using de-identified linked administrative healthcare databases
housed at the Institute for Clinical Evalutive Sciences (ICES). We included
patients over 65 years of age with a diagnosis of cancer defined using provin-
cial, ICD-9 and ICD-10 codes for major malignancies and who developed a
VTE event within 6 months of the initial cancer diagnosis. VTE was identified
through a previously validated algorithm using a combination of diagnostic
codes for deep vein thrombosis (DVT) and pulmonary embolism (PE) and
codes identifying diagnostic procedures for VTE (i.e. ultrasound, CT pulmonary
angiography, lung scintigraphy) within 7 days of each other. Recurrent VTE
and MB events were assessed within 180 days from the index date. MB was
identified using a previously validated algorithm and included upper and lower
gastrointestinal and intracranial bleeding events. Treatment was classified
based on the first available prescription within 7 days of the index VTE. We
estimated mortality within 7 days of the VTE recurrence or MB events using an
unadjusted Cox proportional hazards model and competing risk analysis. Ratios
of the mortality for MB compared to VTE recurrence were calculated and 95%
confidence intervals were estimated using non-parametric models.
Results: Between 2004 and 2014 there were 6967 VTE events identified in
cancer patients over 65 years of age and treated with an anticoagulant. Mean
age was 75 years, and 47.6% patients were women. Of all patients, 59.9%
received prescriptions for LMWH alone, 15.3% for LMWH followed by warfarin,
22.1% for warfarin and 2.7% for rivaroxaban. At 180 days after the index VTE
event there were 235 (3%) MB events and 1184 (17%) VTE recurrences. Within
7 days of the outcome event there were 26 (11%) deaths after MB and 6 (0.5%)
after VTE. The mortality ratio for MB versus VTE was 21.8 (95% CI 9-53). In
exploratory analyses we did not find differences according to type of anticoag-
ulant prescription.
Summary/Conclusions: In cancer patients 65 years or older treated with anti-
coagulants for a VTE, the 7 days mortality after a MB event is at least 9 times
higher than after a VTE recurrence, although the estimate is imprecise. This
data should be taken into consideration when designing studies and interven-
tions involving anticoagulant therapy in this population.
This study was supported by the Institute for Clinical Evaluative Sciences
(ICES), which is funded by an annual grant from the Ontario Ministry of Health
and Long-Term Care (MOHLTC). The opinions, results and conclusions report-
ed in this paper are those of the authors and are independent from the funding
sources. No endorsement by ICES or the Ontario MOHLTC is intended or
should be inferred. AL-L was supported in part for this study by a grant from
the Canadian Institutes of Health Research (CanVECTOR Network CDT-
142654).
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Background: Lymphoma is a malignancy that originates in lymph nodes and
lymphoid tissue. The main category of lymphomas is non-Hodgkin’s lymphoma
(NHL). NHL comprise about 3% of all cancers in Sweden. Some are aggressive
and fast growing, while others are more indolent and do not necessarily require
treatment. It is well known that cancer increases the risk of thrombosis, espe-
cially venous thromboembolism, but data are scarce on the risk of thrombosis
in NHL patients.
Aims: The aim of this study is to evaluate the risk of thrombosis in NHL patients
compared to controls and to study time trends in the risk of thromboembolism
with recent advances in the treatment of these diseases. 
Methods: The study population consisted of individuals diagnosed with NHL
in Sweden 1980-2013 (n=40,354), and up to four matched controls
(n=115,677). The risk of the first thrombosis was evaluated after the diagnosis
of NHL (and corresponding date for controls) and the ones that occurred less
than 30 days prior to diagnosis of NHL. Kaplan-Meier survival analysis was
used to estimate the risk of thrombosis and a log-rank test performed to assess
statistical significance. Cox regression analysis was used to calculate hazard
ratios (HRs) and 95% confidence intervals (CI) (adjusting for age, sex, year of
diagnosis, and previous history of thrombosis). Risk of deep vein thrombosis,
pulmonary embolism and arterial thrombosis was evaluated. Arterial thrombosis
was defined as cerebral infarct, transient ischemic attack, angina pectoris,
myocardial infarction, and arterial embolism and thrombosis.
Results: NHL patients had a statistically significant increase in risk of any
type of thrombosis compared to controls (HR: 1.58, 95% CI: 1.53-1.62). The
risk was significantly increased for all three types of thrombosis; deep vein
thrombosis (HR: 3.11; 95% CI: 2.93-3.31), pulmonary embolism (HR: 3.16;
95% CI: 2.95-3.39) and arterial thrombosis (HR:1.20; 95% CI: 1.16-1.23). The
risk of thrombosis did not change during the study period for the NHL patients.
There was an increased risk of thrombosis for NHL patients when compared
to controls, independent of previous history of thrombosis (HR: 1.64; 95% CI:
1.59-1.69 if no previous history, HR: 1.43; 95% CI: 1.37-1.50 if previous history
of thrombosis). The incidence of thrombosis for NHL patients started to
increase about five months before the diagnosis of NHL, and reached its peak
a month before diagnosis. The incidence stayed increased for the first year
after diagnosis.
Summary/Conclusions: In this large, population-based, study based on more
than 40,000 patients with NHL and almost 116,000 controls, we demonstrated
that there is an increased risk of thrombosis in patients with NHL when com-
pared to controls. This is true for all types of thrombosis. We therefore conclude
that hypercoagulability seems to increase with diagnosis of NHL. Several fac-
tors may contribute to this prothrombotic state, including chemotherapy and
other treatment related factors as well as the disease itself. Considering that
the increase in the incidence of thrombosis was highest before and around the
time of diagnosis for NHL patients, that indicates that the tumor itself may have
a great impact on the hypercoagulability of these patients.
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Background: Actual guidelines recommend Padua and Khorana score for
thromboembolic (TE) risk estimation for cancer patients in general. These exist-
ing models are quite limited for designation of lymphoma patients for TE events,
as their development is not based on features specific for hematological
patients. 
Aims: The aim of this study was to compare diagnostic performance of these
suggested predictive models, as well as Thrombosis lymphoma (Throly) score,
developed by our group, which is more specific for lymphoma patients. 
Methods: The study population included all consecutive patients with a con-
firmed diagnosis of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL),
and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL),
who were treated in the Lymphoma Departments of Clinical Center Serbia and
Clinical Center Kragujevac in period from 2006 to 2014. Data for newly diag-
nosed and relapsed patients who had completed a minimum of one chemother-
apy cycle were prospectively collected for all venous and arterial TE events
from time of diagnosis to 3 months after the last cycle of therapy. Data for spe-
cific demographic, clinical, and laboratory variables known to be associated
with TE from Padua and Khoranapredictive scores were also extracted. More-
over, potential disease-related risk factors were gathered. The study population
was divided based on a split-sample random method into the model developing
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and validation cohorts. The ThroLy model was developed using data solely
from a derivation cohort, which included 1236 patients. Variables were evalu-
ated by univariate logistic regression analysis, while the model was developed
using a stepwise multivariate logistic regression analysis. Once a final model
was defined, patients were divided into low risk and at risk groups. The final
model was assessed in the validation cohort (584 patients). The studied pop-
ulation was also divided, based on Khorana and Padua score, into low risk and
at risk groups. 
Results: The study population included 1820 eligible lymphoma patients. The
mean patient’s age was 53.1 years (range, 15–87 years). Most patients (83%)
were newly diagnosed and had advanced stage disease: Ann Arbor stage III,
14.7% and stage IV, 44%. A total of 778 patients (42.7%) had high-grade lym-
phoma; 351 (19.3%) had low-grade lymphoma; 266 (14.6%) had HL; 156
(8.6%) had other forms; and 269 (14.8%) had CLL/SLL. Of all the patients
included in the study, 99 (5.4%) developed at least one TE during the follow-
up period. There were 73 patients with venous TE (73.7%), and 25 with arterial
TE (25.3%), while 1 patient had both. Patients with aggressive NHL had signif-
icantly higher odds of developing TE compared to patients with any other lym-
phoma type (RR=1.5; 95% CI for RR 1.1–2.4; p=0.027). The incidence of throm-
boembolism was 81 (5.3%) in the newly diagnosed patients and 18 (6.2%) in
relapsed patients. Overall, 35.4% (35/99) of the patients with thromboembolism
experienced the event before the start of chemotherapy. The majority of patients
(64.6%) had TE events during chemotherapy or within 3 months after
chemotherapy. For patients classified at risk according to ThroLy score in der-
ivation cohort, the model produced negative predictive value (NPV) of 98.5%,
positive predictive value (PPV) of 25.1%, sensitivity of 75.4%, and specificity
of 87.5%. In validation cohort PPV for Throly score was 28.9%. Padua and
Khorana score had PPV of 15.5% and 14.8% in derivation, and 11.5% and
14.8% in validation cohort, respectively. 
Summary/Conclusions: Lymphoma patients are at increased risk of throm-
boembolic events but thromboprophylaxis in these patients is largely under-
used. ThroLy score is more specific for lymphoma patients than suggested
Padua and Khorana score, but external validation in large prospective cohort
studies is required.
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THROMBOEMBOLISM PREVENTION IN HOSPITALISED CANCER
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Background: Onco-hematologic hospitalised patients constitute a group at
high risk of venous thromboembolism (VTE). Current clinical practice guidelines
recommend prophylaxis with low molecular weight heparin (LMWH) during hos-
pitalisation, unless contraindicated. However, its underuse is a worldwide prob-
lem. Electronic alert systems (e-alerts) can improve the use of appropriate
thromboprophylaxis and reduce the incidence of VTE. 
Aims: To evaluate the impact of a new version (v2.0) of our e-alert system for
VTE prevention compared with the initial software version. Secondary endpoints
try to identify predictive factors for prophylaxis use and thrombotic events.
Methods: Prospective study including consecutive adult cancer patients admit-
ted at our centre. From April 2014 to June 2015 (first period) the initial e-alert
system version remained operative and from July 2015 to December 2016
(second period) the new version was active. The v2.0 displayed a second win-
dow that asked physicians about the reason why LMHW was not prescribed.
The main outcomes were: VTE (confirmed by objective methods), clinically rel-
evant bleeding, and mortality. All patients were followed-up during hospitalisa-
tion and 30 days after discharge. Descriptive statistical analysis and correlation
between clinical variables and main outcomes were performed by using the
software package SSPS v20.
Results: 1251 patients were included, 782 patients in the first period and 469
in the second one (main clinical features are shown in Table 1). E-alerts v2.0
was associated with an increase of appropriate LMWH prophylaxis during hos-
pitalisation (65.2% vs 72.2%; p=0.015). However, this improvement did not
result in a reduction of VTE during admission or follow-up (2.3% vs 2.3%;
p=0.89). Interestingly, almost 80% of VTE events occurred despite LMWH use.
No differences in the rate of major bleeding (2.8% vs 3.2%; p=0.83), and mor-
tality (10.6% vs 14.3%; p=0.07) were observed, either. The main reason for not
prescribing LMWH prophylaxis was bleeding risk, but in 17% of cases physi-
cians did not consider that the patient really had a high VTE risk. No significant
correlation was found between any of the clinical variables analyzed and the
risk of VTE. Prophylaxis use was more frequent among patients with solid can-
cer (vs hematologic), advanced stage, active chemotherapy treatment and
longer hospital stay.
Table 1.
Summary/Conclusions: The new e-alert system further increases the use of
VTE prophylaxis in hospitalised cancer patients, although this was not associ-
ated with a reduction in the VTE incidence. A relevant number of VTE events
occur despite prophylaxis with standard LMWH. Identificaton of risk factors for
thromboprophylaxis failure is needed.
This work has been funded by a biomedical research grant with the Laboratory
of Pharmaceutical ROVI and an aid to the research projects of the Instituto de
Salud Carlos III and the FEDER (PI13 / 01029).
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IDENTIFICATION OF A NEW AND RELATIVELY FREQUENT SERPINC1
GENE DEFECT CAUSING ANTITHROMBIN DEFICIENCY HARDLY
DETECTED BY CURRENT MOLECULAR METHODS: DUPLICATION OF
EXON 6
M.E. De La Morena-Barrio1,2,*, B. de la Morena-Barrio1, J. Padilla1, R. Teruel1,2,
S. Asenjo3, E. Wypasek4, A. Miñano1, V. Vicente1,2, J. Corral1,2
1Servicio de Hematología y Oncología Médica, Hospital Universitario Morales
Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-
Arrixaca, 2Centro de Investigación Biomédica en Red de Enfermedades Raras
(CIBERER), Instituto de Salud Carlos III (ISCIII), Murcia, 3Servicio de Hema-
tología, Hospital Clínico San Carlos, Madrid, Spain, 4The John Paul II Hospital,
Kraków, Poland; Institute of Cardiology, Jagiellonian University Medical College,
Krakow, Poland
Background: Antithrombin (AT) deficiency was the first thrombophilia described
50 years ago and so far the strongest one. Up to 78% of cases are explained
by point mutations or small deletion/insertions in exons or flanking regions of
SERPINC1 that are easily detected by sequencing analysis. A low proportion
of cases (2%) is explained by gross gene defects, mainly deletions, which are
detected by multiplex ligation-dependent probe amplification (MLPA) analysis.
However, the molecular base of AT deficiency is unknown using current meth-
ods in 20% of cases.
Aims: To identify new SERPINC1 defects causing AT deficiency.
Methods: We studied 271 unrelated cases with AT deficiency. Functional and
biochemical assays characterized plasma AT. Genetic analyses involved
Sanger and Next Generation Sequencing (NGS) (PGM, Ion Torrent), MLPA
and specific PCR designs.
Results: Sanger sequencing of PCR amplicons with primers flanking the 7
exons and further analysis with SeqscapeTM detected pathogenic mutations
in 173 cases. Whole gene sequencing identified 5 mutations in regulatory
regions. MLPA analysis revealed 5 cases with whole or partial deletion of the
gene. Moreover, 13 cases had disorders of glycosylation. Interestingly, the
analysis of the PCR product and the electropherogram of exon 6 of a 42 year-
old male patient (P1) with deep venous thrombosis and 75% of anti-FXa activity
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with no apparent gene defect by either Sanger sequencing of 7 exons or by
NGS analysis of the whole gene using the Ion Torrent platform, revealed a 193
bp insertion, which corresponded to a tandem duplication involving exon 6.
Family studies revealed the same duplication in 5 relatives, all with AT defi-
ciency (60-75%). The first MLPA analysis of this case failed to detect the dupli-
cation and only after a fine readjustment, it was detected. MLPA analysis under
the new conditions of the remaining 59 cases with unknown molecular base
for their AT deficiency identified one additional case, P2, with potential dupli-
cation of exon 6. P2 was a 17 year-old female with 41% of anti-FXa activity,
who developed deep venous thrombosis. Sanger and NGS sequencing also
failed to detect any genetic defect in P2. A set of primers specific to detect tan-
dem duplications of exon 6 was designed with forward primer from 3’ end of
exon 6, and reverse primer from 5’ of exon 6. This set of primers only rendered
amplification in the two cases with exon 6 duplication. The second patient (P2)
had a new 863 bp duplication in tandem of exon 6. Sanger sequencing of the
specific amplicons in the two cases with tandem duplication of exon 6 revealed
Alu sequences surrounding these duplications. Finally, one out of 5 cases with
gene deletions involved breakpoints affecting intron 5 (deletion of exons 2-5).
Summary/Conclusions: Our study identified a new and relatively frequent
SERPINC1 gene defect causing AT deficiency that is hardly identified by cur-
rent molecular methods: duplication of exon 6. This genetic defect was detect-
ed in 1% of our cohort, and represents nearly half of the total gross gene
defects causing AT deficiency. The small size of this exon makes difficult the
identification of this defect by MLPA. The presence of 6 Alu elements up and
downstream exon 6 makes this region a hotspot for unequal recombination
that may cause deletions, tandem duplications and potentially transpositions,
which may produce AT deficiency (both severe and mild) by an aberrant splic-
ing. We also developed a simple and specific method to detect duplications
in tandem of exon 6.
Stem cell transplantation - Experimental
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CYTOSOLIC NUCLEIC ACID SENSORS PROMOTE INTESTINAL EPITHELIAL
INTEGRITY DURING ACUTE TISSUE DAMAGE AND PROTECT FROM
GRAFT-VERSUS-HOST DISEASE
J.C. Fischer1, G. Eisenkolb1, M. Bscheider1, A. Wintges1, C. Peschel1,
C.A. Lindemans2, A.M. Hanash3, R. Jenq3, J. Dudakov4, T. Haas1,
M.R. van den Brink3, H. Poeck1,*
13. Medizinische Klinik; Klinikum Rechts der Isar, Technische Universität
München, München, Germany, 2Pediatric Blood and Bone marrow Transplant
Program, University Medical 20 Center Utrecht,, Utrecht, Netherlands, 3Depart-
ment of Medicine, Memorial Sloan Kettering Cancer Center, New York, 4Clinical
Research Division, Fred Hutchinson 44 Cancer Center, Seattle, United States
Background: The epithelial lining of the gastrointestinal (GI) tract represents
the first line of defense mediating protection from microbial challenge. Next to
producing antimicrobial molecules, Paneth cells contribute to this defense by
providing a supportive niche for intestinal stem cells (ISCs) maintaining the
epithelium. Loss of intestinal barrier function by total body irradiation (TBI) or
chemotherapy (CTx) is an essential step in enhancing the development of
inflammatory disease associated with epithelial surface such as graft versus-
host disease (GVHD) after allogeneic hematopoietic stem cell transplantation
(allo-HSCT). Our current limited ability to protect epithelium and promote regen-
eration in GVHD is at least in part due a limited understanding of ISC function
and epithelial regeneration in the allo-HSCT setting. Recent work suggests a
protective function of Type I Interferons (IFN-I) at epithelial surfaces and in the
preventon of GVHD. Yet, the molecular pathways that trigger those functions
during acute tissue damage are poorly understood. Given that the RIG-I-MAVS
and STING pathways are important regulators of IFN-I production and IFN-Is
can initiate epithelial repair, we hypothesized that activation of these pathways
during conditioning therapy may protect epithelial integrity and could be exploit-
ed interventionally to promote intestinal barrier function and prevent GVHD. 
Aims: We aimed at characterizing the role of of RIG-I/MAVS and STING during
allo-HSCT, and at understanding mechanisms by which activation of these
pathways can promote barrier function to enhance healing after genotoxic tis-
sue damage.
Methods: We used an integrated approach with pathophysiologic mechanistic
studies on IECs in experimental mouse models (MHC-mismatched and minor
histocompatibility antigen (miHA)-mismatched transplants to model highly
aggressive GVHD; genotoxic stress induced by TBI and CTx) and evaluation
of immune-mediated regenerative strategies to promote epithelial barrier func-
tion (organoid cultures, barrier function test)
Results: Mice lacking MAVS were more sensitive to total body irradiation (TBI)-
and chemotherapy induced intestinal barrier damage, and, like RIG-I-deficient
mice, developed worse graft transplantation (allo-HSCT). This phenotype was
not associated with changes in the intestinal microbiota, but with reduced
epithelial integrity and regeneration. Conversely, targeted activation of the RIG-
I pathway during damage promoted these processes and ameliorated GVHD.
Mechanistically, IFN-I (RIG-I-induced or recombinant) could promote growth
of intestinal organoid cultures and production of RegIIIγ. Importantly,our findings
were not confined to RIG-I/MAVS signaling, as interventional engagement of
the STING pathway also protected from loss of barrier function and GVHD and
led to IFN-I-dependent intestinal organoid growth. Consistent with this, STING-
deficient animals suffered from worse GVHD.
Summary/Conclusions: Our studies may have the potential to develop novel
targeted therapies (i) to promote intestinal barrier integrity, (ii) to prevent the
development of GVHD, and (iii) for the regenerative response of other tissues.
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CD4 T CELLS RECOGNIZING MISMATCHED HLA-DP AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION SHOW TISSUE SPECIFIC REACTIVITIES
P. van Balen1,*, W. de Klerk1, M. van de Meent1, C. J. Halkes1, I. Jedema1,
J. Falkenburg1
1Hematology, Leiden University Medical Center, Leiden, Netherlands
Background: Expression of HLA class II molecules is under non-inflammatory
conditions predominantly restricted to hematopoietic cells. However, donor CD4
T cells directed against mismatched HLA-DP can cause Graft-versus-Host Dis-
ease (GVHD) after allogeneic stem cell transplantation (alloSCT) or donor lym-
phocyte infusions from HLA 10/10 matched but HLA-DP mismatched donors due
to upregulation of HLA class II expression under inflammatory conditions. It is
often assumed that allo-HLA-DP directed CD4 T cells recognize peptides encoded
by household genes presented in foreign HLA-DP and that every cell that express-
es the mismatched HLA-DP allele is a target for these T cells. However, in vitro
experiments illustrated that allo-HLA-DP directed CD4 T cells were not always
recognizing patient derived fibroblasts induced to express HLA-DP. We hypothe-
sized that HLA-DP directed CD4 T cells can have tissue specificity if the presented
peptides in HLA-DP are encoded by genes with tissue specific expression.
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Aims: The aim of the study is to investigate whether donor CD4 T cells recog-
nizing mismatched HLA-DP show tissue specific reactivities.
Methods: In a randomized clinical trial we treat patients 3 months after T cell
depleted alloSCT from HLA 10/10 matched, HLA-DP mismatched, donors with
0.25-0.50 x 106/kg donor CD4 T cells to promote immune reconstitution. In 4
patients, Graft-versus-Leukemia reactivity and/or organ specific GVHD
occurred after the infusion. To characterize the immune responses in these
patients, in vivo activated T cells were clonally isolated and tested for reactivity
against a panel of target cells, including patient and donor derived hematopoi-
etic cells, third party hematopoietic cells as well as different GVHD target cells
(patient skin fibroblasts, third party colon carcinoma cells, biliary epithelial
cells and lung fibroblasts) expressing the mismatched, patient variant, HLA-
DP molecule.
Results: Allo-HLA-DP directed CD4 T cells showing differential recognition of
target cells were found in all 4 patients. A total of 33 HLA-DPB1*04:01 reactive
CD4 T cell clones were isolated from patient 1 who suffered GVHD of skin and
colon, but not liver. Within these 33 clones, 3 clones recognized only hematopoi-
etic target cells, 9 clones recognized hematopoietic, skin and colon derived
target cells and 5 clones recognized hematopoietic and colon derived cells
only. None of the T cell clones recognized biliary epithelial cells. From patient
2 total of 230 HLA-DPB1*03:01 reactive CD4 T cell clones were isolated, of
which 27 recognized only hematopoietic target cells and 96 clones also recog-
nized GVHD target cells with differences in tissue specificity. 32 HLA-
DPB1*03:01 reactive T cell clones were found from patient 3, of which 6 rec-
ognized only hematopoietic target cells, whereas other clones again showed
various tissue specificities. From patient 4, 26 HLA-DPB1*01:01 reactive T cells
could be isolated which all recognized biliary epithelial cells with or without co-
recognition of other target cells. In addition, also 11 HLA-DPB1*03:01 reactive
T cells were isolated, again with different tissue specificities. 
Summary/Conclusions: These results illustrate that donor CD4 T cells direct-
ed against mismatched HLA-DP show differential recognition of target cells
including restricted specificity for cells of hematopoietic origin. Donor CD4 T
cells recognizing hematopoietic target antigens in the context of patient specific
HLA-DP alleles can be used to mediate tumor specific immune responses after
HLA 10/10 matched unrelated stem cell transplantation.
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MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION
AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS
V. Van Hoeven1,2,*, J. M. Munneke1,2, A. Cornelissen3, S. Omar2, M. Spruit2,
M. Kleijer3, J. Bernink2, B. Blom2, C. Voermans3, M. Hazenberg1,2
1Department of Hematology, 2Department of Experimental Immunology, Aca-
demic Medical Center Amsterdam, 3Department of Hematopoiesis, Sanquin
Research and Landsteiner Laboratory, Amsterdam, Netherlands
Background: Infusion of mesenchymal stromal cells (MSCs) is a promising
and increasingly applied therapy for patients who suffer from graft-versus-host
disease (GvHD), a common and life-threatening complication of allogeneic
stem-cell transplantations (ASCT). The therapeutic effect of MSCs is mainly
ascribed to their suppression of (alloreactive) lymphocyte proliferation and
enhancement of tissue-repair activity. However, only about half of the GvHD
patients benefit from MSC therapy, and which factors determine MSC respon-
siveness is unclear. We recently observed that relatively high frequencies of
activated type 3 innate lymphoid cells (ILC3s) before and/or after ASCT were
associated with a lower risk to develop GvHD, which may be related to the pro-
duction of tissue-protective IL-22 by ILC3s.
Figure 1.
Aims: To investigate if ILC3s can contribute to the therapeutic effect of MSCs,
we studied the interaction between MSCs and ILC3s in vitro.
Methods: ILC3s isolated from human tonsils were CellTrace-labeled and co-
cultured with bone-marrow derived MSCs for 5 days in the presence of IL-2.
Results: Co-culture with MSCs significantly enhanced the proliferation of ILC3s
and their IL-22 production. Reciprocally, ILC3s promoted ICAM-1 and VCAM-
1 expression on MSCs. Transwell experiments revealed that for both directions,
the interaction is mainly dependent on cell-cell contact or close proximity of
MSCs and ILC3s. Addition of blocking antibodies against ICAM-1, VCAM-1, or
their integrin ligands, did not affect ILC3 proliferation, suggesting that ILC3
stimulation is ICAM/VCAM independent. Soluble factors also contributed to the
interaction, as ILC3s proliferated slightly better in the presence of MSC culture
supernatant compared to IL-2 only. Based on experiments with blocking anti-
bodies, we found IL-7 to be the likely candidate for this effect.
Summary/Conclusions: We show that via cell-cell contact and IL-7, MSCs
promote the proliferation and IL-22 production by ILC3s in vitro, suggesting
ILC3s may play a role in the control of GvHD upon MSC therapy.
S449
ABERRANT T CELL RESPONSES IN THE BONE MARROW MICROENVI-
RONMENT OF PATIENTS WITH POOR GRAFT FUNCTION AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Y. Kong1,*, Y.-T. Wang1, X.-N. Cao1, Y. Song1,2, Y.-H. Chen1, Y.-Q. Sun1,
Y. Wang1, X.-H. Zhang1, L.-P. Xu1, X.-J. Huang1,2
1Peking University People’s Hospital, Peking University Institute of Hematology,
2Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisci-
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Background: Poor graft function (PGF) remains a life-threatening complication
following allogeneic hematopoietic stem cell transplantation (allo-HSCT), and
the underlying mechanisms have not yet been elucidated. Considerable evi-
dence from murine studies has demonstrated that effective hematopoiesis
depends on the specific bone marrow (BM) microenvironment, where
hematopoietic stem cells reside. In this regard, we previously reported that
PGF patients had impaired BM endosteal and vascular microenvironment
(BBMT 2013; BMT 2016; Oncotarget 2016; Blood 2016). Moreover, our pilot
study found that both CD4+ and CD8+ T cells were polarized towards a type 1
immune response in the BM microenvironment of PGF patients (N=10) com-
pared to those in matched good graft function (GGF) patients(N=20) (BBMT
2016). Nevertheless, whether abnormalities of T cell subsets in the BM immune
microenvironment, including Th17, Tc17, Th1, Tc1, Th2, Tc2 cells and regulatory
T cells (Tregs), are involved in the pathogenesis of PGF remains to be explored.
Aims: To compare the T cell subsets in the BM immune microenvironment,
including Th1, Tc1, Th2, Tc2, Th17, Tc17 cells and Tregs, between patients
with PT and GGF after allo-HSCT.
Methods: This prospective nested case-control study enrolled 20 patients with
PGF, 40 matched patients with good graft function (GGF) after allo-HSCT, and
20 healthy donors (HD). Th17, Tc17, Th1, Tc1, Th2, Tc2 cells, Tregs and their
subsets were analyzed by flow cytometry. The study was approved by the
Ethics Committee of Peking University People’s Hospital, and written informed
consent was obtained from all the patients before study-entry in accordance
with the Declaration of Helsinki.
Results: The demographic and clinical characteristics were similar between
allo-HSCT patients with PGF and those with GGF. The percentages of Th1 (37%
vs. 26.4%, P=0.0005) and Tc1 (52.4% vs. 19%, P<0.0001) cells were signifi-
cantly higher in PGF patients than in GGF patients, whereas the percentages
of Th2 (0.8% vs. 2.4%, P<0.0001) and Tc2 (0.5% vs. 1.1%, P<0.0001) cells
were markedly lower in the PGF group than in the GGF group. PGF patients
showed significantly greater Th1 cell/Th2 cell (31.6 vs. 10.8, P<0.0001) and Tc1
cell/Tc2 cell ratios (108.8 vs. 18.4, P<0.0001) than those for GGF patients. More-
over, a significantly higher proportion of stimulated CD4+ T cells that produced
IL-17 (Th17) was found in the BM of PGF patients than in the BM of GGF patients
and HD (3.7% vs. 1.6% vs. 1.1%, P<0.05), whereas the percentages of Tregs
in PGF patients were comparable to those in GGF patients and HD, resulting in
a dramatically elevated ratio of Th17 cells/Tregs in the BM of PGF patients rel-
ative to those in GGF patients (1.01 vs. 0.57, P=0.04).
Summary/Conclusions: The present study revealed that aberrant T cell
responses in the BM immune microenvironment may be involved in the patho-
genesis of PGF after allo-HSCT. These findings will facilitate the optimization
of immune regulation strategies and improve the outcome of PGF patients post-
allotransplant.
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HIGHER FREQUENCY OF SWITCHED MEMORY B CELLS PREDICTS THE
INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
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Background: Aberrant B-cell homeostasis has been described in patients (pts)
with chronic graft-versus-host disease (cGVHD) following allogeneic stem cell
transplantation (allo-SCT). However, there is no information on the predictive
value of specific B-cell subsets of the incidence of cGVHD.
Aims: We sought to determine if B-cell subsets measured around day 100
after allo-SCT predict the subsequent occurrence of cGVHD in a prospective
clinical study.
Methods: Peripheral blood (PB) samples were obtained from consented
patients (pts) between day 80 and 110 (D100) after allo-SCT at The University
of Texas MD Anderson Cancer Center from 2012 to 2015. Only pts who had
not been diagnosed with cGVHD or progression of underlying malignancy by
D100 were eligible for this study. We analyzed CD19+CD20+ B cell subsets
by FACS. Subsets were defined as naïve (CD27-IgD+), unswitched
(CD27+IgD+) and switched (CD27+IgD-) memory cells. Receiver Operating
Characteristic (ROC) curve was used to identify threshold levels of B cell %
and numbers that predict the incidence of cGVHD. cGVHD diagnosis was
based on the 2014 National Institutes of Health guidelines.
Results: A total of 80 pts were enrolled in the study. The median age at SCT
was 49 years (range 21-75). The majority (80%) of pts received myeloablative
conditioning, and 75% received tacrolimus with methotrexate or mycopheno-
late mofetil for GVHD prophylaxis. Diagnosis was myeloid (61%) or lymphoid
(34%) malignancy in the majority of pts. Grafts source was primarily PB or
bone marrow from matched- unrelated (61%) or related (24%) donors. Grade
2-4 acute GVHD had occurred in 45% of pts before D100. Thirty-six percent
of pts were receiving steroids at D100. Forty-seven (59%) pts had detectable
(≥0.1%) CD19+CD20+ signal on D100. In this subset, median B cell % was 3
(range 0.25-34) and median absolute number was 23 (1.8-419) x103 cells
/µL. Median % naïve, unswitched, and switched B cells was 89% (54-99),
1.85% (0.3-8.5), and 2.1% (0-30), respectively. A total of 15 pts were diag-
nosed with cGVHD within 1 year after D100 including 11 with detectable B
cells. ROC analysis did not identify predictive thresholds for overall B cell %
or numbers. However, it identified predictive thresholds for each of the B cell
subsets analyzed. The area under the curve (AUC) analysis indicated that %
naïve (cutoff 87.3%) and % switched (cutoff 4%) B cells were the most signif-
icant (AUC 86%) predictors of the incidence of cGVHD. Rounding up the cutoff
values, we grouped pts into 3 mutually exclusive groups: 1) naïve B cells
≥90% (n=23, none had >5% switched B cells), 2) naïve B cells <90% and
switched B cells ≤5% (n=11), and 3) naïve B cells <90% and switched B cells
>5% (n=13). Patients (n=33) with undetectable B cells were considered togeth-
er as one group. The rate of cGVHD after D100 was significantly higher in pts
with <90% naïve and >5% switched B cells (HR=7, p<0.001) with a 1-year
cumulative incidence of 61% (Figure). None of the characteristics listed above
were significantly associated with the rate of cGVHD. Percent naive and
switched B cells did not correlate with receipt of steroids on D100. Patients
with undetectable B cells were significantly more likely to have an underlying
lymphoid vs myeloid malignancy (58% vs 33%, p< 0.001); and those with
≥90% naïve B cells were significantly more likely to be ≤55 years of age at the
time of allo-SCT (83% vs 42%, p=0.004).
Figure 1.
Summary/Conclusions: In conclusion, D100 frequency of naïve and switched
B cells predicts the subsequent development of cGVHD. Lymphoid malignan-
cies and older age may be associated with aberrant B-cell reconstitution. Con-
sideration of D100 B-cell subsets may improve risk stratification models for the
development of cGVHD.
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EFFECTS OF AG-348, A PYRUVATE KINASE ACTIVATOR, IN PATIENTS
WITH PYRUVATE KINASE DEFICIENCY: UPDATED RESULTS FROM THE
DRIVE PK STUDY
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Background: Pyruvate kinase (PK) deficiency is a congenital hemolytic anemia
caused by deficiency of the glycolytic enzyme, red cell PK (PK-R). AG-348 is
an orally available, small molecule, allosteric activator of PK-R that activates
the wild-type and a range of mutated PK-R enzymes in vitro, and increases
PK-R activity and restores adenosine triphosphate levels in red blood cells
from patients with PK deficiency ex vivo.
Aims: To report on preliminary efficacy and safety data from the use of AG-
348 in the ongoing DRIVE PK study (NCT02476916), an open-label dose-
ranging trial of AG-348 in transfusion-independent adults with PK deficiency.
Methods: After providing informed consent, patients were randomized to AG-
348 50mg or 300mg orally twice daily (BID) for 6 months (Core Period). At the
end of the Core Period, patients can continue on treatment for another 2 years
in the Extension Period. Transfusion independence is defined as ≤3 units of
red blood cells transfused in the 12 months preceding the first dose of AG-348
and no transfusions in the 4 months preceding the first dose. Patients are fol-
lowed weekly for Weeks 1-3, every 3 weeks for Weeks 4-12, monthly for Weeks
13-24 and then every 3 months until the end of the study. Hormone and iron
status are evaluated at Baseline, Week 12 and End of Core Period, and then
every 6 months in the Extension Period.
Results: As of 18 Jan 2017, goal enrolment has been met and all 52 patients
are evaluable for safety and efficacy; 24 have completed the Core Period and
23 are ongoing in the Core Period. Five patients discontinued from the Core
Period, owing to adverse events (AEs) (n=2) or consent withdrawal (n=3). Of
the 24 subjects who completed the Core Period, 21 entered the Extension
Period and 20 are still on treatment; 1 was discontinued by the investigator.
Patients are currently receiving doses ranging between <25mg BID and 300mg
BID. As of the previous data cutoff date of 23 Sep 2016 (where N=34), AG-348
had an acceptable AE profile, with headache (44%), nausea (41%) and insom-
nia (38%) being the most frequently reported events. Serum levels of sex
steroids measured at Baseline, Week 12 and Week 24 in the Core Period
demonstrated increases in free and total testosterone, and decreases in estra-
diol and estrone, consistent with the known effect of aromatase inhibition by
AG-348. Of the 32 patients evaluable for efficacy at 23 Sep 2016, 15 (47%)
had a maximal increase in hemoglobin (Hb) >1 g/dL. Hb responses were seen
across a range of four doses, and were rapid and sustained. For a subset of
patients (n=8), the rate of glycolytic metabolism in peripheral blood samples
was assessed before and after treatment, and a positive correlation was
observed between increases in glycolytic flux through the PK-R pathway and
increases in Hb. Updates on safety, clinical efficacy measures (including Hb
levels) and genotype–response correlations will be provided.
Summary/Conclusions: AG-348 is a novel, first-in-class PK-R activator under-
going clinical testing in patients with PK deficiency. The ongoing DRIVE PK
study has now met goal enrolment of 52 patients, and data from these patients
will be available at the time of presentation. Chronic daily dosing with AG-348
is well tolerated and has demonstrated clinically relevant, durable increases in
Hb across a range of doses from <25mg BID to 300mg BID. These data high-
light the potential of AG-348 to be the first disease-altering treatment for patients
with PK deficiency.
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Background: Pyruvate kinase deficiency (PKD) is the most common glycolytic
enzyme defect causing hereditary non-spherocytic hemolytic anemia. PKD
does not have a specific curative treatment. Therefo re treatment is mainly sup-
portive, consisting of regular red blood cell transfusions, splenectomy and chela-
tion therapy for iron overload. This does impact life expectancy and quality of
life for affected patients. Hematopoietic allogeneic stem cell transplantation
(HSCT) has the potential to cure the disease. However, there is little experience
in applying HSCT in PKD and guidelines are not available. To date, only four
cases of HSCT have been published. Thus, additional data are required to help
the establishment of HSCT guidelines and support future strategies, such as
gene therapy.
Aims: The aim of this study was to make a worldwide inventory of all cases of
PKD that have been treated by HSCT, and to evaluate indication, procedures
employed, and outcome.
Methods: This is an international case series. Queries were send to national
and international databanks and to physicians involved in HSCT on PKD
patients. The latter were asked to complete a questionnaire on disease char-
acteristics, pre-transplant condition, transplant regimen and post-transplant
outcome. Two additional cases were included from a recently published report
(Kim. 2016. Bone Marrow Transplantation).
Table 1.
Results: From 1996 to 2016 a total of 16 PKD-patients were reported to have
been treated by stem cell transplantation. Eight patients were treated in the EU
and eight in Asian centres, respectively. No patient resulted to be transplanted
in the US. Median age at transplantation was 6,5 years. (10 patients (62,5%)
were <10 years; 6 (37,5%) >10 years), seven patients (43,8%) were splenec-
tomized at the time of HSCT. Fifteen patients (94%) reached engraftment. The
sixteenth patient showed mixed chimerism followed by spontaneous transition
to full donor chimerism after splenectomy six months post transplantation. Two
patients suffered from secondary graft loss. One of these had recovery to 91%
donor chimerism after donor lymphocyte infusion. Outcome in the other patient
is unknown. GvHD grade 4 was reported in 6/16 cases (38%). There was no
obvious relation between GvHD prophylaxis or any other clinical factors and
the occurrence of GvHD grade 2-4 in our patients. Two-year cumulative survival
was 74%. Two patients did not reach the two-year milestone yet. All five patients
who did not survive died of transplant-related causes. Patients who did not sur-
vive were significantly older (p=0.036) and were all treated in a European center
(p=0.026) (see Table). Also, they had suffered more often from GvHD grade 2-
4 (p=0.031). Nine out of ten patients (90%) younger than ten years old survived
transplantation, whereas two out of six (33.3%) patients older than ten survived.
Patients younger than ten years old were less often splenectomized (p=0.001).
All Asian patients (8/8) survived transplantation, whereas three out of eight
European patients survived. Patients treated in Asian hospitals differed from
European patients in that they were younger (p=0.001), less often splenec-
tomized (p=0.041) and had a lower ferritin level prior to transplantation
(p=0.048). They were more often transplanted with peripheral blood stem cells
(p=0.014) and more often conditioned on a cyclophosphamide (p=0.007) reg-
imen.
Summary/Conclusions: This is the first study on outcome of HSCT in PKD
patients. Due to the still relatively small number of cases no definite conclusions
on the safety of HSCT in PKD can be drawn. However, we observed a better
survival for patients transplanted before the age of ten. This difference could
also explain difference in survival between patients transplanted in Europe ver-
sus Asia. The high rate of severe GvHD in this cohort is a reason for concern.
The strong decline in survival of patients older than ten years of age indicates
the need for very careful selection of HSCT-candidates.
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Background: Dehydrated hereditary stomatocytosis, also called hereditary
xerocytosis (HX), is a dominant non-spherocytic chronic hemolytic anemia char-
acterized by an increased leak of monovalent cations through the red cell mem-
brane leading to dehydration and a shortened red cell survival. HX is difficult to
diagnose because of its rarity and the heterogeneity in its clinical presentation.
Aims: Our study aims to characterize the clinical and biological features at HX
diagnosis in a retrospective multicentric series of 103 patients from 49 families.
Methods: HX diagnosis was based on the typical left-shifted curve of osmolar
gradient ektacytometry performed at CHU Bicêtre from 1993 to 2016. All patients
were from European origin. They were referred to our center for: chronic non-
spherocytic hemolysis (30), thrombotic events after splenectomy (8), hyperfer-
ritinemia with hemolytic features (5), unexplained perinatal oedema (6) or family
study (54) after diagnosis in a first-degree probands. PIEZO1 and KCNN4 were
analyzed by Sanger sequencing of the exons and intron-exon junctions.
Results: Clinical features: Most of HX diagnosis was made in adults (median
age 31.5 years, range 0-88), children less than 10 years representing only 21%
of all cases. 71 patients (69%) were already followed for unexplained hemolysis.
Hyperferritinemia and/or a chelation therapy were noticed for 26 patients among
the 55 for whom this data was available (47%). 19 patients were treated for
iron overload: phlebotomy (14) and/or Deferasirox (6) and/or Deferoxamine (6)
and/or Deferiprone (1). A perinatal edema history was noted in 17 (16,5%)
patients. A history of thrombotic complication was reported in 12 (11,6%)
patients, corresponding to a total number of 17 thrombotic events including
post-embolic pulmonary hypertension (2), arterial events (3), pulmonary
embolism (4), portal thrombosis (4), splenic infarcts (2) and deep venous throm-
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bosis (2). 10 among these 12 patients (83%) were splenectomized, confirming
the very high risk of thrombosis after splenectomy in HX. Two patients under-
went a thrombotic event without splenectomy: one cerebral stroke and one
splenic infarct.
Biological features:The median hemoglobin level was in the normal range:
135±19 g/L (range 71-195) with a slight macrocytosis (median MCV: 99±8fL)
and a marked reticulocytosis (median reticulocyte count: 252±141G/L). Of note,
57 patients (55%) presented a totally compensated hemolysis with a hemo-
globin level above 115g/L. MCHC was in the normal range (median 35±1,3g/dL)
but was above 36 g/dL for 28 (27,1%) patients. Stomatocytes were noticed on
the blood smear in 42 patients over 70 available, numbered as rare (19%), few
(60%) or numerous (21%). Genetics could be performed in 45 subjects from
22 distinct families. At least one PIEZO1 mutation was identified in very affected
subjects. No KCNN4 mutations were found in these typical ektacytometric
forms of HX.
Summary/Conclusions: This work represents the largest HX series and high-
lights the important heterogeneity in the clinical features at diagnosis. One
important finding is that most patients were not anemic and presented a com-
pensated hemolysis. In a significant percentage of cases, diagnosis was made
in the exploration of extra hematological features including perinatal edema or
hemochromatosis occurring despite the absence of any red blood cells trans-
fusion. Moreover, we confirmed the very high risk of thrombotic events after
splenectomy, underlining the absolute necessity of formally eliminating HX in
any unexplained chronic hemolysis each time splenectomy is considered.
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Background: Sickle cell-related pain crises (SCPCs) are a substantial cause
of morbidity in patients with sickle cell disease (SCD). At a dose of 5.0mg/kg,
the P selectin inhibitor crizanlizumab, delivered intravenously every 4 weeks
after loading, was shown to significantly reduce the frequency of SCPC events
and was well tolerated in the 52-week SUSTAIN study (Ataga KI et al. N Engl
J Med 2017;376:429-439).
Aims: This post-hoc analysis evaluated patients who did not experience a
SCPC for the duration of the trial.
Methods: SUSTAIN was a randomized, double-blind, placebo-controlled,
Phase II study (NCT01895361). Patients aged 16–65 years with SCD (including
HbSS, HbSC, HbSβ0–thalassaemia, and HbSβ+–thalassaemia genotypes) and
2-10 SCPC events in the previous 12 months were included. Concomitant use
of hydroxyurea (HU) was permitted if the patient had been using it for ≥6 months
and at a stable dose for ≥3 months. Patients were randomized 1:1:1 to receive
intravenous crizanlizumab 5.0mg/kg, 2.5mg/kg or placebo. Loading doses were
administered on days 1 and 15, followed by routine treatment every 4 weeks
to week 50, with the final assessment visit at week 52. Descriptive statistics
were used to summarize the frequency of patients who were SCPC event-free
for the duration of the study, based on the intent-to-treat (ITT) population overall
and by prior SCPC events, SCD genotype and HU use at baseline.
Table 1.
Results: Among the 198 patients included in the study (ITT population), 62.6%
and 37.4% had experienced 2-4 and 5-10 SCPC events in the previous year,
respectively, and 62.1% were taking HU at baseline. HbSS was the most com-
mon genotype (71.2%; HbSC: 16.2%, HbSβ0–thalassemia: 6.1%, HbSβ+–tha-
lassemia: 5.1%, other: 1.5%). Overall, more patients in the crizanlizumab
5.0mg/kg group (n=24/67; 35.8%) were SCPC event-free than in the 2.5mg/kg
(n=12/66; 18.2%) and placebo (n=11/65; 16.9%) groups. In each of the prior
SCPC events, SCD genotype and HU use subgroups, a greater proportion of
patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared
with those in the crizanlizumab 2.5mg/kg or placebo arms (Table 1). In sub-
populations considered to be at increased risk of experiencing a SCPC (patients
with 5-10 SCPC events in the previous year and/or with the homozygous HbSS
genotype), a higher proportion of patients treated with crizanlizumab 5.0mg/kg
were SCPC event-free compared with those in the placebo arm (28.0% vs
4.2% and 31.9% vs 17.0%, respectively). Additionally, 33.3% of patients who
were taking HU and treated with crizanlizumab 5.0mg/kg were SCPC event-
free during the study, compared with 17.5% in the placebo arm, possibly sug-
gesting an additive effect.
Summary/Conclusions: Treatment with crizanlizumab 5.0mg/kg appears to
increase the likelihood of adult patients with SCD being SCPC event-free while
on treatment, even in high-risk subpopulations. Crizanlizumab 5.0mg/kg was
also effective in those who had experienced at least two SCPCs in the previous
year despite taking HU, suggesting that this dose is effective as a disease-
modifying agent that meets an unmet medical need.
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Background: Chronic hemolysis is a hallmark of sickle cell disease (SCD).
Hemolysis in SCD has been associated with elevated levels of heme in the cir-
culation of both human patients and SCD mice. It was shown that TNF-α treat-
ment induces experimental vaso-occlusive crisis (VOC) in SCD mice, associ-
ated with the formation of neutrophil extracellular traps (NETs) as shown by
staining of lung sections (Chen et al. Blood 2014). In addition, the administration
of DNase I to degrade NETs led to improved survival. Furthermore, it was
shown that plasma from SCD patients obtained during SCD crisis induced NET
formation by TNF-α primed neutrophils. Free heme was suggested to mediate
the formation of NETs in SCD, as treatment of SCD mice with the heme-binding
protein hemopexin (Hpx) to scavenge free heme led to reduced NET formation
(Chen et al. Blood 2014).
Figure 1.
Aims: To verify the potential therapeutic use of Hpx administration to block
NET formation and the occurrence of VOC in human SCD, we aimed to deter-
166 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
mine whether ex vivo Hpx addition to human SCD sera would prevent NET for-
mation.
Methods: Patient serum and plasma samples were obtained from 32 incidents
of VOC in 24 adult SCD patients, with informed consent. Moreover, steady
state samples were obtained at least 4 weeks after discharge from the hospital.
Patients having had a blood transfusion in the 3 months prior to admission
were excluded. NET formation by human neutrophils from healthy donors was
studied using confocal fluorescence microscopy and staining for extracellular
DNA with the cell nonpermeable dye Sytox Green. The presence of extracellular
DNA that stains positive for citrullinated histone H3 confirmed the formation of
NETs (Figure 1A).
Results: Indeed, we found that hemin (ferriprotoporphyrin IX) activated neu-
trophils to generate reactive oxygen species and release NETs, which was pre-
vented by addition of plasma-derived Hpx. Moreover, exposure of neutrophils
to sera from patients with SCD promoted NET formation, which was significantly
enhanced during VOC. However, we observed that circulating free heme levels
were elevated in SCD patient serum irrespective of disease state, and serum
concentrations of Hpx were reduced in both VOC and steady state compared
to healthy donor serum. Strikingly, addition of Hpx in supraphysiological con-
centrations failed to prevent the formation of NETs in all SCD sera tested. We
and others (Chen et al. Blood 2014) have found that, in contrast to hemin, pro-
toporphyrin IX does not trigger NET formation, revealing that the iron atom is
required for the release of NETs. This observation led us to investigate whether
free iron may directly induce NET formation. When neutrophils were exposed
to Fe-NTA or serum from a thalassemia patient with iron overload, NETs were
formed. Scavenging of free iron by addition of the iron-chelator deferoxamine
or the specific iron-binding protein apotransferrin prevented NET release (Figure
1B). Moreover, we found that sequestration of free iron prevented NET forma-
tion induced by a subset (6 out of 11 tested), but not all, sera of patients with
VOC (Figure 1C and D). In addition, sickled red blood cells (RBCs) are known
to bind to neutrophils in vitro. Here, we found that neutrophils released NETs
in response to sickled RBCs, even in the presence of Hpx. By contrast, blocking
of complement C5 activation completely prevented the formation of NETs when
neutrophils were exposed to sickled RBCs (Figure 1E).
Summary/Conclusions: In summary, we observed that sequestration of free
iron with the iron-chelator deferoxamine or the iron-binding protein apotrans-
ferrin was effective in more than half of the SCD patient sera, while the binding
of heme to Hpx did not prevent NET release in human SCD patient sera. There-
fore, we propose that targeting free iron with these iron binding compounds
may be explored therapeutically to prevent or treat VOC development in SCD.
Finally, complement activation in the presence of sickled RBCs activates neu-
trophils to release NETs, which may also contribute to VOC and SCD patho-
genesis. Therefore, anti-C5 IgG may represent an alternative therapeutic strat-
egy to prevent VOC in SCD.
New drugs for rescue in relapsed/refractory
multiple myeloma
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Background: Elotuzumab is an immunostimulatory monoclonal antibody that
targets SLAMF7, a glycoprotein highly expressed on multiple myeloma (MM)
cells and natural killer cells. Elotuzumab exerts a dual effect, directly activating
natural killer cells and mediating MM cell death via antibody-dependent cell-medi-
ated cytotoxicity. In a 3-year follow-up of ELOQUENT-2 (NCT01239797), elo-
tuzumab plus lenalidomide/dexamethasone (ELd) demonstrated a sustained 27%
reduction in the risk of disease progression/death and an overall survival (OS)
trend towards benefit compared with lenalidomide/dexamethasone (Ld) alone in
patients with relapsed/refractory (RR) MM (Dimopoulos et al, ASH 2015).
Aims: To evaluate the long-term efficacy and safety of ELd following extended
4-year follow-up (median 46 months).
Methods: RRMM patients with 1-3 prior lines of therapy randomized 1:1
received ELd or Ld in 28-day cycles until disease progression/unacceptable
toxicity or consent withdrawal. Co-primary endpoints were progression-free
survival (PFS) and overall response rate (ORR); OS was a secondary endpoint
(analysis not prespecified for this data cut) and safety an exploratory endpoint.
Written informed consent was obtained for all patients.
Figure 1. OS Kaplan-Meyer Curve (all randomized patients).
Results: In total, 646 RRMM patients were randomized: 321 to ELd and 325
to Ld. At 4-year follow-up (data cut-off: Oct 18, 2016), nearly twice as many
patients remained on ELd therapy vs Ld (17% vs 9%). With the extended fol-
low-up, ELd demonstrated a sustained relative improvement of 50% in PFS
rates vs Ld (21% vs 14%) and maintained reduction in the risk of
progression/death of 29% for ELd vs Ld (all randomized patients: HR 0.71;
95% CI 0.59, 0.86). Patients with ≥very good partial response (VGPR) (ELd
112 [35%] vs Ld 95 [29%]) had the greatest reduction (35%) in risk of progres-
sion/death (HR 0.65; 95% CI 0.46, 0.94). ORR was greater with ELd vs Ld
(79% vs 66%) and the duration of response benefit was maintained over time
(HR 0.77; 95% CI 0.62, 0.95). Early separation of the Kaplan–Meier survival
curves, which remained consistently separated over time, supports a sustained
OS benefit in favor of ELd vs Ld (Figure). Grade 3-4 adverse events (AEs) in
≥5% of patients were generally comparable between ELd and Ld arms-vascular
diseases (10% vs 8%; mostly venous-related), second primary malignancies
(SPMs; 9% vs 6%) and cardiac disorders (5% vs 8%); the exception was a
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slightly higher incidence of infection with ELd (33% vs 26%). Overall rate (any
grade) of infection (84% vs 75%) and SPMs (17% vs 11%) was also higher for
ELd vs Ld. However, exposure to ELd was longer than to Ld (median [Q1, Q3]
treatment cycles: 19 [9, 42] vs 14 [6, 25]). Disease progression and infection
were major causes of mortality in both arms; however, fewer deaths were
reported with ELd vs Ld (165 vs 186).
Summary/Conclusions: At 4 years, ELd has the longest median follow-up of
an immuno-oncology agent in MM. The data continue to show that adding elo-
tuzumab to Ld results in durable long-term responses, clinically relevant
improvement in PFS, sustained reduction in risk of progression/death, and a
survival trend in favor of ELd. Overall, these data continue to support the
durable efficacy of ELd. Updated safety and tolerability, including rate of SPMs,
was consistent with previous findings despite longer exposure, with minimal
incremental AEs compared with Ld therapy.
Study funding: BMS. Writing support: C Tomas, Caudex, funded by BMS.
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Background: Isatuximab (ISA) is an anti-CD38 monoclonal antibody, which
kills tumor cells via multiple mechanisms. Here, we report preliminary data
from the dose-escalation cohorts, and the first 3 patients (pts) of the expansion
cohort, of a Phase 1b study of ISA plus Pom/Dex in pts with RRMM
(NCT02283775).
Aims: To evaluate combination therapy with ISA plus Pom/Dex in pts with
RRMM.
Methods: Pts with RRMM (≥2 prior MM therapies, including lenalidomide and
a proteasome inhibitor) were sequentially enrolled to ISA 5, 10, or 20mg/kg (4
weekly doses, then every 2 wks until disease progression or intolerable toxicity)
with Pom 4mg (Days 1–21) and Dex 40mg (Days 1, 8, 15, and 22; 20mg if ≥75
yrs old), in 28-day cycles. An expansion cohort was initiated at ISA 10mg/kg
(plus Pom/Dex) based on preliminary safety, efficacy, and PK data. Primary
objective: determine maximum tolerated dose (MTD). All patients were required
to provide informed consent.
Results: 26 pts were analyzed (5mg/kg [n=8]; 10mg/kg [n=12]; 20mg/kg [n=6]),
median age 65 (42-80) yrs. Median 4.0 (2-11) prior treatment regimens, with
20 (77%) pts refractory to prior immunomodulatory drug therapy. At data cut-
off (Nov 8, 2016), median duration of ISA treatment was 19.0 wks and 16 pts
remained on treatment. 2 pts at 10mg/kg discontinued therapy due to adverse
events (AEs) (grade [Gr] 5 perforated bowel; Gr 3 infusion-associated reaction
[IAR]). Dose-limiting toxicities reported in 1 pt at each dose level (Gr 4 neu-
tropenia; Gr 4 neutropenic infection; Gr 3 confusional state), and MTD has not
been reached. Most common TEAEs, besides IARs, were fatigue (62%), diar-
rhea (35%), and dyspnea (31%). Most frequent Gr 3/4 hematologic abnormality
(laboratory assessment) was neutropenia (Gr 3, 40%; Gr 4, 52%). Gr 3/4 throm-
bocytopenia was reported in 8 (32%) pts (Gr 3, 16%; Gr 4, 16%). IARs occurred
in 12 (46%) pts (Gr ≥3 in 1 pt); only with 1st infusion in 9/12 pts. 16 (62%) pts
achieved at least PR (5, 8, and 3 pts at 5, 10, and 20mg/kg), including 1 CR,
8 VGPR, and 7 PR. Clinical benefit rate (≥MR) was 73%. Median time to 1st
response, 4.2 wks; median duration of response, 25.6wks. The PK parameters
of ISA were not affected by co-administration with Pom/Dex.
Summary/Conclusions: The combination of ISA and Pom/Dex was manage-
able and clinically active in heavily pretreated RRMM. A Phase III trial of this
combination is ongoing.
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Background: In a phase 3 head-to-head comparison of two proteasome
inhibitors (PIs) in patients with relapsed or refractory multiple myeloma
(RRMM), ENDEAVOR, progression-free survival (PFS) was shown to be sig-
nificantly longer with carfilzomib and dexamethasone (Kd) than with bortezomib
and dexamethasone (Vd) (median 18.7 months vs 9.4 months, hazard ratio
[HR], 0.53; 95% confidence interval [CI], 0.44-0.65; P<0.0001; Dimopoulos MA
et al. Lancet Oncol. 2016;17:27-38).
Aims: Results from a planned second interim overall survival (OS) analysis of
ENDEAVOR are presented here.
Methods: Patients who had RRMM and had received 1–3 prior lines of therapy
were randomized in a 1:1 ratio to receive Kd or Vd. In the Kd arm, carfilzomib
was given on days 1, 2, 8, 9, 15, and 16 (20mg/m2 on days 1, 2 of cycle 1;
56mg/m2 thereafter) and dexamethasone 20mg was given on days 1, 2, 8, 9,
15, 16, 22, and 23 of 28-day cycles. In the Vd arm, bortezomib (1.3mg/m2)
was given intravenously or subcutaneously on days 1, 4, 8, and 11 and dex-
amethasone 20mg was given on days 1, 2, 4, 5, 8, 9, 11, and 12 of 21-day
cycles. Patients were treated until progression or withdrawal of consent. OS
was compared between treatment arms using a stratified log-rank test.
Results: The median treatment duration was 48 weeks for carfilzomib (N=464)
and 27 weeks for bortezomib (N=465), with a median follow up of 38 months
for Kd and 37 months for Vd. The median OS (95% CI) was 47.6 (42.5-NE)
months in the Kd arm and 40.0 (32.6-42.3) months in the Vd arm, and all-
cause mortality was significantly reduced with Kd vs Vd (HR, 0.791; 95% CI,
0.648-0.964; 1-sided p=0.0100). The overall survival benefit was consistent
regardless of prior bortezomib therapy (HR 0.75 for Kd vs Vd, no prior borte-
zomib; HR 0.84 for Kd vs Vd, prior bortezomib) and across all age groups (HR,
0.85 <65 yo; 0.71, 65-74 yo; 0.84, ≥75 yo), baseline ECOG performance status
groups (HR, 0.81, ECOG 0; 0.80, ECOG 1; 0.50, ECOG 2), cytogenetic risk
groups (HR, 0.83, high risk; 0.85, standard risk), and number of prior lines of
therapy (HR, 0.83, 1 prior line; 0.76, 2-3 prior lines). The most frequent any-
grade adverse events in the Kd arm were (Kd vs Vd) anemia (42.5% vs 28.3%),
diarrhea (36.3% vs 40.6%), pyrexia (32.4% vs 15.4%), dyspnea (32.2% vs
13.6%), fatigue (32.2% vs 30.7%), and hypertension (32.2% vs 9.9%). Grade
3 or higher adverse events were experienced by 81.4% of patients in the Kd
arm and 71.1% of patients in the Vd arm.
Summary/Conclusions: ENDEAVOR was the first randomized phase 3 trial
to directly compare two different PIs in RRMM. Patients who received Kd had
significantly longer OS compared with patients who received Vd. Safety results
were comparable with those previously reported in the PFS interim analysis
for ENDEAVOR.
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EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB AND
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(VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM):
UPDATED ANALYSIS OF CASTOR
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Background: Daratumumab is a human monoclonal antibody targeting CD38
that induces deep and durable responses with significant clinical benefit and
is well tolerated as monotherapy and in combination with established stan-
dard-of-care regimens in patients with RRMM.
Aims: To provide updated efficacy and safety data from CASTOR, a multicen-
ter, phase 3, randomized, active-controlled study of DVd vs Vd in RRMM.
Methods: Eligible patients with ≥1 prior line of therapy were randomly assigned
to 8 cycles (every 3 weeks) of Vd (1.3mg/m2 SC bortezomib on Days 1, 4, 8,
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and 11; 20mg PO/IV dexamethasone on Days 1-2, 4-5, 8-9, and 11-12) with or
without daratumumab (16mg/kg IV once weekly in Cycles 1-3, every 3 weeks
for Cycles 4-8, then every 4 weeks until progression). Patients who were refrac-
tory to bortezomib were excluded. Progression-free survival (PFS) was the pri-
mary endpoint. Minimal residual disease (MRD) was assessed at suspected
complete response (CR) and at 6 and 12 months after first dose at 3 sensitivity
thresholds (10-4, 10-5, and 10-6) using the ClonoSEQ™ next-generation
sequencing (NGS)-based assay (Adaptive Biotechnologies, Seattle, WA).
Results: A total of 498 patients were randomized with median (range) age of
64 (30-88) years. Patients received a median (range) of 2 (1-10) prior lines of
therapy; 66% of patients previously received bortezomib, and 21% were refrac-
tory to lenalidomide in their last prior line of therapy. After median follow-up of
13.0 months, DVd significantly prolonged PFS compared with Vd alone (median:
not reached vs 7.1 months; hazard ratio [HR], 0.33; 95% confidence interval
[CI], 0.26-0.43; P<0.0001). Twelve-month PFS rates were 60% versus 22%,
respectively. Significant PFS benefit was observed with DVd over Vd regardless
of the number of prior lines of therapy, although the greatest benefit was seen
in patients with 1 prior line of therapy (median: not reached vs 7.9 months; HR,
0.22; 95% CI, 0.14-0.34; P<0.0001). Overall response rate (ORR; 84% vs 63%)
and rates of very good partial response (VGPR) or better (62% vs 29%) and CR
or better (26% vs 10%) continued to be significantly higher with DVd compared
with Vd (P<0.0001 for all). MRD-negative rates were more than 4 times higher
at all 3 sensitivity thresholds with DVd versus Vd: 18.3% versus 3.6% at 10–
4(P<0.0001), 10.4% versus 2.4% at 10–5 (P<0.01), and 4.4% versus 0.8% at
10–6 (P<0.01). MRD-negative patients had prolonged PFS compared with MRD-
positive patients at 10–5sensitivity threshold (Figure). At the clinical cut-off date,
37 (15%) deaths in the DVd group and 58 (24%) in the Vd group have been
observed (HR, 0.63; 95% CI, 0.42-0.96), and follow up is ongoing. Thrombocy-
topenia was the most common grade 3 or 4 treatment-emergent adverse event
(45% with DVd vs 33% with Vd). No new safety signals were reported after
median treatment duration of 11 months with daratumumab. Updated efficacy
and safety data with longer follow up will be presented at the meeting.
Figure 1.
Summary/Conclusions: DVd is superior to Vd in terms of PFS, ORR, depth of
response, and MRD-negative rates, with no new safety signals reported. These
updated data further support the use of DVd as a standard of care in RRMM,
with the greatest benefit observed in patients with 1 prior line of therapy.
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A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB
AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY
MULTIPLE MYELOMA
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Background: Venetoclax (VEN) is a potent, selective, orally bioavailable small-
molecular inhibitor of BCL-2. When combined, VEN can enhance the activity
of bortezomib in multiple myeloma (MM) cell lines and xenograft models.
Aims: The objectives of the study are to evaluate safety and preliminary efficacy
of VEN with bortezomib and dexamethasone in relapsed/refractory (RR) MM.
Methods: Phase 1b study of patients (pts) with R/R MM who received daily
VEN (50-1200mg for dose escalation cohorts; 800mg in safety expansion) with
standard bortezomib (1.3mg/m2 SC) and dexamethasone (20mg PO).
Results: As of 19Aug2016, 66 pts were enrolled. Median age was 64 years; 9
(14%) pts had t(11;14), 5 (8%) had t(4;14), 15 (23%) had del(17p), and 30
(45%) had del(13q) abnormalities. Median number of prior therapies was 3
(range: 1-13), with 39% of pts refractory to prior bortezomib, 14% to carfilzomib,
53% to lenalidomide, and 21% to pomalidomide. Median time on study was
5.9 months (range: 0.3–29.8). Forty-six (70%) pts discontinued, with 36 due to
disease progression (PD). Common AEs in ≥30% of pts were diarrhea (46%),
constipation (41%), thrombocytopenia (39%), nausea (38%), peripheral neu-
ropathy (33%), and insomnia (32%). Common grade 3/4 AEs in ≥10% of pts
were thrombocytopenia (29%), anemia (15%) and neutropenia (14%). Serious
AEs in ≥2 pts were febrile neutropenia, thrombocytopenia, cardiac failure, pyrex-
ia, influenza, lower respiratory tract infection, pneumonia, sepsis, acute kidney
injury, respiratory failure, embolism, and hypotension. Dose-limiting toxicities
were grade 3 cardiac failure in the 300mg cohort (possibly related to dexam-
ethasone) and grade 3 thrombocytopenia during the first cycle in the safety
expansion. No events of laboratory or clinical TLS were reported. Four deaths
were due to PD and 1 due to respiratory syncytial virus infection. Overall
response rate (ORR) for all pts was 67% (44/66); 28 (42%) pts achieved very
good partial response (VGPR) or better (3 stringent complete response [sCR],
10 CR, 15 VGPR). Pts non-refractory to prior proteasome inhibitors (PI) or
immunomodulatory drugs (IMiDs) had higher ORR than refractory pts (PI, 92%
vs 32%; IMiDs, 82% vs 57%). Among pts refractory to any 2 or more (n=15), 3
or more (n=7), or all 4 (n=4) prior therapies (bortezomib, carfilzomib, lenalido-
mide, pomalidomide), ORR was 40%, 43%, and 25%, respectively. Median
time to progression (~10 vs 3 months) and duration of response (~10 vs 7
months) were longer for pts not refractory to any of these therapies versus
refractory pts. ORR for pts with or without cytogenetic abnormalities, respec-
tively, was as follows: 78% vs 65% for t(11;14), 60% vs 67% for t(4;14), 47%
vs 73% for del(17p), and 63% vs 69% for del(13q).
Summary/Conclusions: VEN combined with bortezomib and dexamethasone
has an acceptable safety profile with promising anti-myeloma activity, and the
highest response rates were observed in R/R MM pts who were not refractory
to PI or IMiDs. These data support the ongoing phase 3 trial with this regimen
in R/R MM.
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CYTOGENETIC COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA:
DEFINITIONS, ASSOCIATIONS WITH OTHER BIOMARKERS AND CLINICAL
IMPACT; A RETROSPECTIVE STUDY ON BEHALF OF ERIC
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Background: Recent evidence suggests that complex karyotype (CK) identi-
fied by chromosome banding analysis (CBA) may be a relevant biomarker for
treatment decisions in CLL, especially regarding the response to signaling
inhibitors. However, many challenges towards routine clinical application of
CBA still need to be overcome. 
Aims: Reappraisal of definitions for CK in CLL and systematic investigation of
clinicobiological associations and prognostic impact. 
Methods: 3580 CLL and monoclonal B-cell lymphocytosis (MBL) patients
(CLL=3322, 93% and MBL=258, 7%, respectively) were analysed with CpG-
oligodeoxynucleotides/interleukin 2 (CPG/IL2, n=379, 11%), phorbol-12-myris-
tate-13-acetate (TPA, n=1846, 52%) or both (n=1355, 37%). CBA was mostly
performed within the first year from diagnosis and before treatment adminis-
tration (79% and 88%, respectively). Main features of the studied cohort: medi-
an age: 65.6 years/ males: 2252 (63%)/ Binet A/B/C: 2356/357/258
(79%/12%/9%: MBL and Binet A were grouped together)/ IG-unmutated CLL
(U-CLL): 829/2051 (40%)/del(13q), 1769/3271 (54%)/ trisomy 12, 507/3260,
16%/ del(11q): 377/3256 (12%)/ TP53 abnormality (TP53abn i.e. del(17p)
and/or TP53 mutations): 299/3308 (12%).
Results: Following the current definition for CK i.e. ≥3 structural and/or numer-
ical aberrations, 381/3580 cases (11%) displayed CK, with no difference in the
detection rate between different cell stimulation protocols. CK was significantly
associated (p<0.05) with male gender, advanced clinical stage (Binet B/C), U-
CLL, del(13q), +12, del(11q) and TP53abn. On univariate analysis, CK was
associated with inferior OS (median: 11.5 years); CK remained significant also
on multivariate analysis along with older age, Binet B/C stage, U-CLL and
TP53abn. Considering earlier evidence in smaller series that CLL cases with
≥3 structural and/or numerical cytogenetic aberrations are not equivalent, we
assessed the relevance of other numerical cut-offs for CK, while also investi-
gating the impact of the type of aberrations (i.e. structural versus numerical).
CK cases were stratified into those with 3 (‘low-CK’, n=200, 52%), 4 (‘interme-
diate-CK’, n=82, 22%) and ≥5 (‘high-CK’, n=99, 26%) aberrations. High-CK
cases differed significantly (p<0.05) from the other two subgroups, being
enriched for U-CLL and TP53abn (79% and 57%, respectively). The median
OS was 5.1 years for the high-CK vs not reached for the low- and intermedi-
ate-CK groups (p<0.0001). We also identified 46 cases (12% of those with ≥3
aberrations) who carried +12,+19 plus other numerical and/or structural abnor-
malities and displayed extremely indolent clinical course (median OS not yet
reached and only 4 deaths at a median follow-up of 5.2 years). When high-CK
was assessed as an independent parameter, it was correlated with inferior OS
in the univariate analysis, retaining significance also in the multivariate analysis
(p=0.012) independently of the remaining parameters, including clinical stage,
U-CLL and TP53 status. In contrast, low/intermediate-CK had no impact on
OS, not even in univariate analysis (p=0.57).
Summary/Conclusions: CK defined by the presence of ≥3 numerical and/or
structural abnormalities should not be axiomatically considered unfavorable in
CLL, representing a heterogeneous group with variable clinical behavior. High-
CK with ≥5 chromosomal aberrations emerges as prognostically adverse, inde-
pendently of clinical stage, IG somatic hypermutation and TP53 status.
Prospective clinical validation is warranted before finally incorporating high-
CK in risk stratification in CLL.
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Background: Chemoimmunotherapy (CIT) is the standard treatment for young
and fit treatment-naïve patients with CLL. The median progression-free-survival
(PFS) in patients treated with CIT is about 5-6 years and the overall survival
(OS) is increased by 5-10% compared to those treated with chemotherapy
only. Patients with mutated IGHV genes (M-CLL) and no unfavorable cytoge-
netic alterations (i.e. del(17p)/TP53 mutation, and del(11q)) have a better out-
come than those with unmutated IGHV genes (U-CLL) and/or poor FISH cyto-
genetics and show a plateau in survival curves, suggesting that a fraction of
these patients may have a survival similar to general population. Nevertheless,
the possibility that some M-CLL patients without unfavorable cytogenetics are
overtreated is of concern because of the treatment toxicity related to CIT, par-
ticularly FCR.
Aims: The aim of this study was to analyse the outcome of M-CLL patients
with no unfavorable cytogenetics CLL according to the type of therapy. 
Methods: We analysed 816 CLL patients from Sant Pau Hospital, Barcelona,
Spain; Uppsala Universitary Hospital, Sweden and IRCCS San Raffaele Sci-
entific University, Milan, Italy for whom IGHV mutational status was available.
Endpoints were OS and TFS.
Table 1.
Results: 488 patients had mutated IGHV genes (400 without unfavorable FISH
cytogenetics; 26 had either del(11q) and/or del(17p), and in 62 cases FISH
was not available) and 328 patients carried unmutated IGHV genes. The main
clinical and biological characteristics at diagnosis are shown in Table 1. OS at
5 and 10 years was 93% (CI, 95-91) and 81% (CI, 85-77) for M-CLL cases and
78% (CI, 83-73) and 46% (CI, 52-39) for U-CLL cases (p<0.05). TFS at 5 and
10 years was 73% (CI, 77-69) and 61% (CI, 66-56) and 28% (CI, 33-23) and
10% (CI, 14-6) for M-CLL and U-CLL, respectively (p<0.05). After a median
follow-up of 8 years (range, 1-26), 424 patients [161 M-CLL (136 without poor-
prognostic FISH cytogenetics, 13 with either del(11q) and/or del(17p) and 12
cases in whom FISH information was not available) and 263 U-CLL] required
therapy. Front-line treatment consisted of purine analogues (PA)-based therapy
(n=83), alkylating agents (n=212), anti-CD20 moAbs with PA or bendamustine
(n=75), anti-CD20 moAbs with alkylating agents (n=21), BCR-signal inhibitors
or BCL2 antiapoptotic agents (n=9), others (n=23), and unknown (n=1). The
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median duration of response to first therapy was 42 months (range, 33-52) in
M-CLL cases vs 24 months (range, 18-30) in U-CLL patients (p<0.001). 282
patients received a second line of therapy: PA-based therapy (n=95), alkylating
agents (n=82), anti-CD20 moAbs with PA or bendamustine (n=33), anti-CD20
moAbs with alkylating agents (n=16), BCR-signal inhibitors or BCL2 antiapop-
totic agents (n=12), others (n=39), and unknown (n=5). In 481 of 816 patients
in whom detailed information on treatment regimens beyond second-line was
available, 99 patients received a third-line treatment including PA-based therapy
(n=15), alkylating regimens (n=20), anti-CD20 MoAbs with PA or bendamustine
(n=15), anti-CD20 moAbs with alkylating agents (n=8), BCR or BCL2 inhibitors
(n=11), others (n=28) and unknown (n=2); 49 patients received four or more
lines of therapy. In M-CLL patients without poor FISH cytogenetics (n=136) the
type of therapy did not impact patients´ outcome. Thus, the median survival
was not reached in patients treated with CIT as first-line (i.e FCR, BR) as com-
pared to 202 months in those not having received CIT (p=0.317). In contrast,
in U-CLL patients the OS was highly dependent on the type of therapy. In detail,
U-CLL patients who received anti-CD20 MoAbs with PA or bendamustine either
as first line or subsequent lines (60 of 120 patients) showed significantly longer
survival than those who did not receive these therapeutic regimens (median
survival: 173 vs 103 months, p=0.001). On the contrary, in M-CLL cases no dif-
ferences in survival were observed in those receiving anti-CD20 MoAbs with
PA or bendamustine vs who did not (p=0.558).
Summary/Conclusions: This retrospective study suggests that OS of CLL
patients with mutated IGHV genes and no unfavorable FISH cytogenetics do
not depend on the type of therapy. This has important clinical implications and
provides background for randomized studies aimed at identifying the optimal
treatment strategy for this group of patients.
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Background: Patients with mutated IGHV (IGHV-M) have favorable long-term
outcomes (10-year PFS of >60%) after receiving first-line FCR. 
Aims: To develop an FC-based chemoimmunotherapy regimen of finite duration
that included ibrutinib and obinutuzumab. The intent was to limit FC to 3 cours-
es, potentially reducing short- and long-term toxicity, while maintaining efficacy
through the addition of ibrutinib and a more potent antibody (obinutuzumab).
Methods: We designed an investigator-initiated phase II trial with ibrutinib, flu-
darabine, cyclophosphamide, and obinutuzumab (iFCG) for previously untreat-
ed pts with IGHV-M CLL (NCT02629809). The intent was to limit FC to 3 cours-
es, potentially reducing short- and long-term toxicity, while maintaining efficacy
through addition of ibrutinib and obinutuzumab. Key eligibility included age ≥18,
IGHV-M, no del17p. Pts received 3 courses of iFCG. G-CSF was not mandated.
Primary endpoint: CR/CRi with bone marrow (BM) MRD-neg (4-color flow-
cytometry) after 3 courses of iFCG. Pts meeting primary endpoint received
ibrutinib with obinutuzumab (iG) for C3-6, then ibrutinib C7-12. Pts not achieving
primary endpoint received iG (C4-12). All pts who are MRD neg at 1 year will
stop all therapy, including ibrutinib. Pts MRD+ at 1 year may continue ibrutinib.
Historic C3 BM MRD-neg with FCR in IGHV-M 26% (Strati, Blood 2014). Target
BM MRD-neg after iFCG x3 is 45%. Sample size 45.
Results: Since activation (April 2016), 26 patients were consented; 23 initiated
treatment. We report data on these 23 patients. This is the first report of this
trial. Median age is 59 years (range, 25-71); there were 18 men. Prognostic
markers included [FISH: del13q (n=17), negative (n=3); trisomy 12 (n=3);
CD38+ (n=7); ZAP70+ (n=6/21 evaluated)]. By trial design, all patients had
IGHV-M. Median B2M was 2.6 (range, 1.4-8.1). Median pretreatment WBC
count was 81.1 K/µL (range, 3.1-224), platelet count 120 K/µL (range, 62-292),
hemoglobin 12.4 g/dL (range, 9.1-15.6). Eighteen patients have completed 3
courses of iFCG and had initial response assessment (the remaining 5 patients
have not yet completed 3 courses of treatment). All 18 patients achieved a clin-
ical response; 14/18 (78%) achieved MRD-negative remission in the marrow
at 3 month (Table 1) and 16/18 (89%) achieved MRD-negative remission as
their overall best response. Overall, 7/18 achieved CR/CRi with MRD-negative
status in bone marrow at 3 months. All patients with PR had bulky adenopathy
at baseline, and had residual lymphadenopathy ranging from 1.8 to 3.5 cm
after 3 courses of iFCG. No patient has progressed, and all but one continue
to receive treatment on protocol. Of the 23 pts, 11 pts had G3-4 neutropenia
and 5 pts had G3-4 thrombocytopenia. 4 pt had neutropenic fever. 1 pt who
achieved MRD-neg CR developed pulmonary MAC infection, and declined fur-
ther therapy. 1 pt had atrial fibrillation. G3 ALT developed in 3 pts. FC was dose
reduced in 10 pts; ibrutinib dose-reduced in 2 pts.
Table 1.
Summary/Conclusions: iFCG achieves high rate of MRD-neg remission after
3 courses. Pt enrollment continues, and updated results will be presented at
the EHA meeting.
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BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND
VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL
STUDY GROUP (GCLLSG)
P. Cramer1,*, J. von Tresckow1, J. Bahlo1, S. Robrecht1, O. Al Sawaf1,
P. Langerbeins1, A. Engelke1, A.-M. Fink1, K. Fischer1, T. Seiler2, L. Fischer
von Weikersthal3, H. Hebart4, K.-A. Kreuzer5, M. Ritgen6, M. Kneba6,
C.-M. Wendtner7, S. Stilgenbauer8, B. Eichhorst1, M. Hallek1
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3Gesundheitszentrum St. Marien, Amberg, 4Stauferklinikum, Schwäbisch-
Gmünd, 5Department I of Internal Medicine, University Hospital Cologne,
Cologne, 6Department II of Internal Medicine, Campus Kiel, University of
Schleswig-Holstein, Kiel, 7Department of Hematology, Oncology, Immunology,
Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum
Schwabing, Munich, 8Department III of Internal Medicine, University Hospital
Ulm, Ulm, Germany
Background: Based on the theoretical “sequential triple-T” concept [Hallek
M., Blood 2013; 122(23): 3723-34] of a tailored and targeted treatment aiming
for total eradication of minimal residual disease (MRD), the GCLLSG designed
the CLL2-BAG trial.
Aims: This prospective, open-label, multicenter phase-II trial investigates a
sequential treatment with a B debulking, followed by G and A as induction and
maintenance therapy in an all-comer population of physically fit and unfit, treat-
ment-naïve (TN) and relapsed/refractory (R/R) CLL pts.
Methods: Pts with an absolute lymphocyte count (ALC) ≥25.000/µl and/or
lymph nodes (LN) ≥5cm were to receive 2 cycles of B as debulking (70mg/m2
d1&2 q28 days), unless contraindicated. In the induction G (1000mg) was
administered 3 times in cycle 1 (days 1/2, 8 & 15) and every 4 weeks in cycles
2-6. A was added in cycle 2 with a dose ramp-up (to 400mg daily) over 5 weeks
and several safety precautions. In the maintenance therapy, daily intake of A
was continued and G administered every 3 months until achievement of a MRD-
negative complete response or for up to 24 months. The primary endpoint is
the overall response rate (ORR) at the end of induction therapy; secondary
endpoints include MRD evaluations, safety and survival parameters. This pri-
mary endpoint analysis is based on uncleaned data, the final analysis will be
presented at the meeting.
Table 1.
Results: Between May 2015 and January 2016, 66 pts were enrolled. Two
R/R pts died of a sepsis and 1 TN pt discontinued due to toxicity during the first
induction cycle; these 3 pts with <2 induction cycles were excluded from the
analysis as predefined by protocol. 34 pts were treatment-naïve and 29 had
R/R CLL (median number of prior therapies: 2, range: 1-8). Median age was 59
(28-77) years, the median CIRS score was 2 (0-14) and 16 pts (25%) had a
creatinine clearance of 30-70ml/min. 11 of 59 pts (19%) had a del(17p) and 45
of 61 (74%) had an unmutated IGHV status. Risk categories for TLS at baseline
were: low (ALC <25.000/µl & LN <5cm): 9 pts (15%), intermediate (ALC
≥25.000/µl or LN 5-10cm): 35 (58%) and high (ALC ≥25.000/µl & LN 5-10cm
or LN >10cm): 16 (27%), 3 missing. 45 pts (71%) received B debulking, 18
(29%) pts immediately started with the induction. 60 pts completed 6 induction
cycles with G and A. All TN (100%) and all but two of the R/R pts (93%) respond-
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ed (table 1); with an ORR of 97% at the end of induction, the primary endpoint
was met. MRD negativity (<10-4 by flow cytometry) in peripheral blood (pB)
was achieved in 56 pts (89%); MRD assessment from bone marrow was avail-
able in 8 pts (4 TN and 4 R/R, among them 4 with a CR and 4 with a PR) and
were all negative. As of January 9th2017, 83 serious adverse events (SAEs)
were reported in 37 pts, including 69 SAEs (83%) related to study treatment.
66 SAEs (80%) were CTC°3-4 and 1 had a fatal outcome (sepsis in 4th induc-
tion cycle). Most SAEs occurred in the R/R cohort (61 SAEs, 74%) and during
the induction phase (63 SAEs, 76%). Most common SAEs were infections (27
in 16 pts; including 13 CTC°3-5) and hematological disorders (18 in 10 pts; 10
CTC°3-4), followed by infusion-related reactions (6 in 6 pts), laboratory TLS (5
in 5 pts; 1 during B debulking, 1 in induction cycle 1 with G, 2 in cycle 3 and 1
in cycle 4 with G and A) and ischemic coronary artery disorders (5 in 4 pts). No
clinical TLS occured.
Summary/Conclusions: With an ORR of 97% and a MRD negativity rate of
89% in pB at the end of induction phase this sequential treatment of B debulk-
ing, followed by G and A was very efficacious in a heterogeneous study popu-
lation and well tolerated except for 3 fatal septicaemias in R/R pts.
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SAFETY RESULTS OF TERMINATED PHASE 2 STUDY OF IDELALISIB
PLUS RITUXIMAB IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL) WITH DEL(17P)
P. Hillmen1,*, X. Badoux2, J. Delgado3, V. Leblond4, A. Mato5, M. Simkovic6,
R.L. Dubowy7, Y. Kim7, A. Pluta8, M. Montillo9
1The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United
Kingdom, 2St. George Hospital, Kogarah, Australia, 3Hospital Clinic de
Barcelona, Barcelona, Spain, 4Hôpital de la Pitié-Salpétrière, Paris, France,
5Hospital of the University of Pennsylvania, Philadelphia, United States, 6Uni-
versity Hospital and Charles University, Faculty of Medicine, Hradec Králové,
Czech Republic, 7Gilead Sciences, Inc., Foster City, United States, 8Specialistic
Hospital, Brzozow, Poland, 9Niguarda Hospital, Hematology Department,
Niguarda Cancer Center, Milano, Italy
Background: Idelalisib (IDELA) is an oral PI3Kδ inhibitor approved in the EU
for use with rituximab (R) or ofatumumab in patients (pts) with previously treated
CLL or as first-line treatment of CLL with either del(17p) or TP53 mutation in
pts unsuitable for other therapies. Prior single arm studies have suggested
that front line use of IDELA may be associated with an increased frequency of
transaminase elevations compared to relapsed pts.
Aims: To describe: 1) the safety of IDELA plus rituximab in previously untreated CLL
pts with del(17p) in this terminated study, and 2) the relation of key AEs and age.
Methods: Treatment-naïve pts with CLL and confirmed del(17p) were treated
in a single arm study with R 375mg/m² IV weekly x8 and IDELA 150mg PO
BID continuously until disease progression or intolerability. Informed consent
was obtained. The study was fully enrolled when terminated early due to infec-
tion related safety concerns observed in a pooled analysis of ongoing Ph3
IDELA trials in front/early line therapy; the planned independent efficacy analy-
sis was not performed, but investigator assessment is available.
Results: 102 pts (median age, 66; range, 37-86) were enrolled between Aug
2014 and Jan 2016 and received IDELA for a median (med) duration of 6.4
months (range, 0.7-17.0). The study was terminated in Mar 2016, >8 wks after
dosing of the last enrolled pt. 77 pts (75.5%) remained on study at the time of
study termination. The reasons for discontinuation from study were death
(4.9%), progressive disease (3.9%, 1 fatal), investigator discretion (9.8%), with-
drawal of consent (2.9%), other anticancer therapy (2.0%), and lost to follow
up (1.0%). The investigator assessed response rate was 79%. 101 pts (99%)
had adverse events (AEs); Gr ≥3 occurred in 80.4%, the most frequent Gr ≥3
were ALT increased (27.5%), neutropenia (20.6%), infections (18.6%), and
diarrhea (14.7%). Laboratory Gr ≥3 ALT and/or AST elevations were seen in
41.2%, with med time of onset of 8.1 wks (range 4.1-24.1). The med age of pts
both with and without Gr ≥3 ALT/AST was 66 years, and the incidence of Gr
≥3 ALT/AST was similar in younger (43.9%, <65yr) and older (39.3%, ≥65yr)
pts. Gr ≥3 diarrhea/colitis occurred in 17.1% of pts <65yr and in 14.8% of pts
≥65yr. Dose interruptions due to AEs occurred in 71 pts (70%), most frequently
due to transaminase elevations (37.3%), and diarrhea/colitis (15.7%). Discon-
tinuation due to AEs occurred in 27% of pts, most frequently due to ALT/AST
elevation (9.8%). Serious adverse events were reported in 46 (45.1%), includ-
ing pyrexia (10.8%), diarrhea/colitis (11.8%). AEs of special interest included
Gr ≥3 infections in 20 pts (19.6%) of whom 5 had CMV and 3 had PJP (none
on prophylaxis), Gr ≥3 febrile neutropenia in 5 (4.9%) and any grade pneu-
monitis in 5 (4.9%). Of the 5 pts with CMV, all were CMV IgG+ at screening
and 2 also were IgM+. There were 6 on-study deaths, 3 associated with infec-
tion, 2 due to CLL progression and 1 due to heart failure.
Summary/Conclusions: In IDELA plus rituximab treated front-line CLL, the
pattern of AEs was similar to that seen in relapsed CLL studies at similar dura-
tion of therapy, however the frequency of Gr ≥3 ALT/AST was increased com-
pared to the relapsed setting. There was no significant effect of age on the risk
of either ALT/AST elevations or diarrhea/colitis. The occurrence of CMV and
PJP infections is consistent with current IDELA labeling and speaks to the
potential benefit of risk mitigation through PJP prophylaxis and CMV monitoring
during treatment. NCT02044822.
Aggressive Non-Hodgkin lymphoma -
Relapsed/refractory
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CLINICAL AND BIOLOGIC COVARIATES OF OUTCOMES IN ZUMA-1: A
PIVOTAL TRIAL OF AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19)
IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN
LYMPHOMA (NHL)
F.L. Locke1, S.S. Neelapu2, N.L. Bartlett3, L.J. Lekakis4, D. Miklos5,
C.A. Jacobson6, I. Braunschweig7, O. Oluwole8, T. Siddiqi9, Y. Lin10,*,
J. Timmerman11, P.M. Reagan12, A. Bot13, J. Rossi13, L. Navale13, Y. Jiang13,
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University Medical Center, Nashville, 9City of Hope, Duarte, 10Mayo Clinic,
Rochester, 11University of California at Los Angeles, Los Angeles, 12University
of Rochester School of Medicine, Rochester, 13Kite Pharma, Santa Monica,
United States
Background: Outcomes for pts with refractory aggressive NHL are poor with
current therapies (Crump, ASCO 2016). Results from the interim analysis of (n=62)
of ZUMA-1, the 1st multicenter trial of an anti-CD19 chimeric antigen receptor
(CAR) T cell, axi-cel, in refractory aggressive NHL, showed an objective response
rate (ORR) of 79% (complete response [CR] 52%; Blood 2016;128:LBA-6). Here
we present results from the primary analysis of ZUMA-1.
Aims: Here we present results from the primary analysis of the ZUMA-1 trial.
Methods: Pts received a target dose of 2 × 106 anti-CD19 CAR T cells/kg after
low- dose conditioning with cyclophosphamide and fludarabine. Eligible pts
(≥18 y) had diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell
lymphoma (PMBCL) or transformed follicular lymphoma (TFL); an ECOG per-
formance status (PS) 0-1; and refractory disease (progressive or stable disease
as best response to last prior therapy, or relapsed ≤12m of autologous stem
cell transplant [ASCT]). The primary endpoint for this analysis was ORR in the
combined DLBCL, PMBCL, and TFL population. Key secondary endpoints
were duration of response (DOR), overall survival (OS), and frequency of
adverse events (AEs). The primary analysis was triggered when 92 pts had at
least 6m of follow-up
Results: As of January 27, 2017, 111 pts from 22 institutions were enrolled;
101 pts (91%) received axi-cel. Median age was 58 y (range, 23-76), 67%
male, 85% stage III-IV, 47% IPI 3-4, 77% refractory to ≥2nd line of therapy,
and 21% relapsed ≤12m of ASCT. Axi-cel was successfully manufactured in
110/111 (99%) pts with an average turnaround time from apheresis to the clin-
ical site of 17 d. With an ORR of 82% (n=92; P<.0001) the study met the primary
endpoint. The ORR in the mITT analysis set of 101 pts was 82% (CR 54%, PR
28%), and was consistent across key covariates including disease subtype,
refractory status, stage, and IPI score. At a median follow up of 8.7 m, 44% of
pts were in response and 39% were in CR. The median DOR was 8.2m overall
and not reached for pts who achieved a CR. Median OS was not reached;
80% of pts remained alive at 6 m. The most common Gr ≥3 treatment-emergent
AEs were neutropenia (66%), leukopenia (44%), anemia (43%), febrile neu-
tropenia (31%), and encephalopathy (21%). Gr ≥3 cytokine release syndrome
(CRS) and neurologic events (NE) occurred in 13% and 28% of pts, respec-
tively. All CRS and all NE resolved except 1 Gr 1 memory impairment. As pre-
viously reported, there were 3 Gr 5 AEs (3%). Peak CAR T levels and AUC
post–axi-cel were associated with durable responses. Additionally, this pres-
entation will include an expanded analysis of efficacy outcomes by novel bio-
logic and clinical covariates including key molecular phenotypes and tocilizum-
ab/corticosteroid interventions used for management of adverse events.
Summary/Conclusions: Axi-cel significantly improved ORR in patients with
refractory aggressive NHL. The CR rate was 7-fold higher compared to histor-
ical controls (Crump, ASCO 2016) and nearly half the patients had an ongoing
response. Axi-cel demonstrated significant clinical benefit with a manageable
safety profile in pts lacking curative treatment options.
Drs Locke and Neelapu contributed equally to this study
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CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): PHASE IB
STUDY IN RELAPSED OR REFRACTORY PATIENTS WITH DIFFUSE
LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, OR MARGINAL
ZONE LYMPHOMA
J.-M. Michot1, R. Bouabdallah2,*, J.K. Doorduijn3,4, U. Vitolo5, M.J. Kersten4,6,
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Background: CC-122 is a cereblon modulating agent that degrades Aiolos and
Ikaros, resulting in potent anti-lymphoma and immunomodulatory effects on T-
and NK-cell function. Phase I clinical data revealed promising activity of CC-
122 against follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
Preclinical combination of CC-122 with obinutuzumab has shown synergism in
FL and additive effects in DLBCL vs either single agent (Chiu. ASH 2015), sup-
porting further study of this combination’s therapeutic potential.
Aims: The current phase Ib study (EUDRACT 2014-003333-26; NCT02417285)
evaluates the safety and efficacy of CC-122 plus obinutuzumab in patients with
relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).
Methods: Patients at study entry must have R/R CD20+ B-cell NHL after ≥1
prior regimens for FL/marginal zone lymphoma (MZL) and ≥2 regimens and/or
ASCT for DLBCL. CC-122 was given orally (5 of 7 d) for 28-d cycles in esca-
lating doses plus a fixed dose of intravenous obinutuzumab 1000mg on d2, 8,
15 of cycle 1 (c1) and d1 of c2-8, upon informed consent. CC-122 was con-
tinued until progressive disease (PD) or unacceptable toxicity. CC-122 active
ingredient in capsule formulation (AIC) 1, 2, 3, and 4mg and CC-122 formu-
lated capsules (F6) 3 and 4mg were evaluated in separate cohorts. Primary
endpoints included safety and tolerability, non-tolerated dose (NTD), and max-
imum tolerated dose (MTD). Response was assessed using the international
Cheson 2007 criteria every 2 cycles to c6, every 3 cycles to c12, and every 6
cycles thereafter.
Results: As of January 12, 2017, 34 R/R B-cell NHL patients with DLBCL
(n=18), FL (n=15), or MZL (n=1) were enrolled. At study entry, median age was
60 y (26-81), most patients were male (68%), and Ann Arbor was extended
stage III/IV in 76% of patients. Of the 18 DLBCL patients, 8 had transformed
FL. Of the 16 FL/MZL patients, 44% relapsed in <12 months after first-line treat-
ment. The median number of prior regimens was 4 (range, 1-11), and 13 (38%)
patients had received prior SCT. One patient experienced a dose-limiting toxicity
(DLT) of grade 4 neutropenia (CC-122 dose level of AIC 3mg); no dose was
yet an NTD. Median CC-122 duration was 22 wks (range, 3-71) equivalent to
6 cycles (range, 1-18). CC-122 dose reduction or temporary interruption
occurred in 10 (29%) or 26 (76%) of patients, respectively, primarily due to
adverse events (AEs). Most patients (56%) had <1 wk of interruption due to
AEs. The most common (≥10%) grade 3/4 treatment-emergent AEs (TEAEs)
were neutropenia (50%) and thrombocytopenia (21%). Fifteen patients (44%)
had ≥1 serious TEAE, including 2 each of febrile neutropenia (related to CC-
122), cytokine release syndrome (related to obinutuzumab), and pneumonia.
Three deaths occurred during the study (2 PD; 1 AE-related). Overall response
rate (ORR) was 59%, including 26% CR and 32% PR (Table 1). Median time
to best response was 57 d, and median duration of response was not yet
reached. In evaluable patients, 6-mo progression-free survival (PFS) was 63%.
Table 1.
Summary/Conclusions: The combination of CC-122 and obinutuzumab was
well tolerated and demonstrates promising response rates and durable remis-
sions in R/R patients with B-cell NHL. CC-122 doses of ≥3mg and obinutuzum-
ab have shown best response rates to date. The study is ongoing to establish
the phase II recommended dose.
S468
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR
OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A
PHASE 1B/2 STUDY
M. Matasar1,*, A.F. Herrera2, M. Kamdar3, A. Mehta4, S. Assouline5, I. Fleury6,
T.M. Kim7, W.S. Kim8, F. Bosch9, J. Radford10, C.R. Flowers11, L. Bu12,
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Background: Transplant ineligible patients (pts) with relapsed/refractory (R/R)
FL or DLBCL have poor outcomes. Polatuzumab vedotin (pola) is an antibody
drug conjugate that targets delivery of the microtubule inhibitor MMAE to cells
expressing CD79b. Pola + rituximab (R) previously showed promising respons-
es in R/R FL and DLBCL. Adding bendamustine (B) to pola-R and substituting
obinutuzumab (G) for R could improve outcomes. We report updated results
from the Phase 1b/2 (P1b/2) study evaluating pola + BR or BG in R/R FL and
DLBCL and the expansion cohorts evaluating pola + BG in R/R FL and DLBCL
(ClinicalTrials.gov NCT02257567).
Aims: The primary aim is to assess safety and tolerability of pola + BR/BG in
R/R FL and DLBCL. Secondary aims include assessing safety and efficacy of
pola + BG in an expansion cohort.
Methods: All pts provided informed consent to participate in the study and
were treated with pola (1.8mg/kg) + B (90mg/m2) and R (375mg/m2) or G
(1000mg) every 28 days (FL) or 21 days (DLBCL) for 6 cycles. Responses
were assessed by modified Lugano 2014 criteria after 3 cycles, end of treatment
(tx), and every 6 months for 2 years during follow-up (fu).
Results: As of 14 Nov 2016, 65 pts were enrolled: 24 pts (12 FL, 12 DLBCL) in
P1b and 41 pts (20 FL and 21 DLBCL) in P2. In safety evaluable pts, FL pts
(N=32) were median age of 63 yr (37-86), 82% ECOG 0-1 and 6% ECOG 2,
44% FLIPI1 3-5, 78% Stage III/IV, 2 (1-7) median lines of prior tx, 38% refractory
to last tx, 13% prior transplant (BMT). DLBCL pts (N=32) were median age 66
(30-86), 88% ECOG 0-1 and 13% ECOG 2, 59% IPI 3-5, 75% Stage III/IV, 2 (1-
7) median lines of prior tx, 82% refractory to last tx, 3% prior BMT. Among 64
pts who received ≥1 dose, the adverse events (AEs) that occurred in >20% of
pts were: fatigue (67%), nausea (54%), diarrhea (54%), vomiting (42%), pyrexia
(39%) and constipation (39%). As expected, grade (Gr) 3/4 cytopenias were
common: neutropenia (34% FL, 28% DLBCL), thrombcytopenia (16% FL, 13%
DLBCL), anemia (6% FL, 9% DLBCL). Tx emergent neuropathy occurred in
19/64 (30%) of pts, with 1 Gr 3 event, and led to pola discontinuation in 1 pt,
dose reduction in 2 pts, and interruption in 1 pt. In FL, 75% (24/32) had Gr 3/4
AEs and 41% (13/32) had serious AEs (SAEs). The only SAE occurring in ≥10%
was infection (22%). The most common Gr 3/4 non-heme AEs were infection
(16%) and hypokalemia (9%). AEs led to study tx discontinuation in 6 pts. B was
stopped in 2 pts due to Gr 3 thromboctyopenia. Of 4 deaths: 2 were PD and 2
were Gr 5 AEs, 1 tx related (PML), 1 tx unrelated. In DLBCL, 88% (28/32) had
Gr 3/4 AEs and 63% (20/32) had SAEs. Most common Gr 3/4 non-heme AEs
were febrile neutropenia (13%), fatigue (13%), and diarrhea (13%). SAEs occur-
ring in ≥10% of pts were infection (33%) and pyrexia (22%). AEs led to study tx
interruption in 19 pts and discontinuation in 8 pts. There were 13 deaths: 9 PD,
4 AE (all unrelated to tx). Responses by modified Lugano 2014 criteria are shown
in Table1. Median duration of response (DoR) for FL P1b pts was 16 months
(mo)(median fu 14.5 mo). Median DoR for FL P2 (median fu 6.5 mo) and DLBCL
P1b/2 (median fu 13.7 mo P1b, 6.4 mo P2) have not been reached.
Table 1.
Summary/Conclusions: Updated evaluation of pola + BR shows promising
durable responses and an acceptable safety profile in heavily pre-treated R/R
FL and DLBCL pts. Safety and efficacy data will be updated at the time of pres-
entation.
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SINGLE AGENT ORAL SELINEXOR EXHIBITS DURABLE RESPONSES IN
RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
(DLBCL) OF BOTH GCB AND NON-GCB SUBTYPES: THE PHASE 2B
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Background: Patients (pts) with persistent DLBCL after two or more lines of
therapy have limited effective treatment options. The nuclear export protein
exportin 1 (XPO1) is upregulated in hematologic malignancies, including DLB-
CL, and has pleiotropic effects on tumorigenesis including functional downreg-
ulation of tumor suppressor proteins (TSPs) and increased export and trans-
lation of mRNAs for oncoproteins c-Myc and key survival proteins such as Bcl-
2. Selinexor (SEL), an oral XPO1 inhibitor, causes sequestration of TSPs
including p53, p21, and IkBa, the latter of which serves to suppress NF-kB
driven transcription, along with reductions in c-Myc and Bcl-2 family proteins.
In a Phase I clinical study, pts with relapsed/refractory (R/R) DLBCL treated
with SEL presented an overall response rate (ORR) of 32% including 4 CRs.
Interestingly, 2 of these pts remain in CR for >1 yr.
Aims: In this clinical study we assess the efficacy of single agent SEL in pts
with R/R DLBCL after ≥2 prior regimens.
Methods: Pts with R/R DLBCL were randomized to 60 or 100mg of SEL twice
weekly (8 doses) per 28-day cycle. Pts were also stratified by DLBCL subtype
(GCB or non-GCB). The primary objectives are to determine the ORR and
evaluate the safety of 60 vs 100mg doses. Disease response was assessed
by an Independent Central Radiological Review (ICRR), using the Lugano
Classification (Cheson, 2014).
Results: 72 pts were enrolled: 37 pts on 60mg (24 M/ 13 F, median age 71
yrs) and 35 pts on 100mg (23 M/ 12 F, median age 68 yrs). Both groups had a
median of 3 prior treatment regimens. The most common related adverse
effects (AEs) across both dosing groups (Grade 1/2) were: fatigue (47%), nau-
sea (46%), anorexia (42%), and vomiting (33%). Common Grade 3/4 AEs were:
thrombocytopenia (39%), fatigue (18%), neutropenia (18%), and anemia (13%).
These were managed with dose interruption/reduction, platelet stimulators,
and/or standard supportive care. Grade 3/4 fatigue (26% v 11%) and thrombo-
cytopenia (46% v 32%) were higher in 100mg arm as compared to the 60mg
arm. Among the 63 evaluable pts (9 pts pending response), the ICRR deter-
mined ORR was 28.5% (Table 1). Nine responders, including 6 pts in CR,
remain on treatment. Responders on the 60mg arm have a median time on
treatment of 8.9 months as compared with 3.8 months on the 100mg arm.
Table 1. Independent Central Radiological Review-Best Response.
Summary/Conclusions: SEL monotherapy shows activity in pts with R/R DLB-
CL including in pts with GCB subtype. 60mg SEL twice weekly was more tol-
erable than 100mg twice weekly, with fewer interruptions due to toxicity. Objec-
tive responses to SEL were durable at 60mg BIW, suggesting these responses
were associated with clinical benefit.
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Background: The Fc-enhanced CD19 antibody MOR208 and the
immunomodulatory drug LEN have demonstrated single agent activity in
patients with R-R DLBCL. MOR208 and LEN have shown synergy in vitro and
in vivo in preclinical lymphoma models.
Aims: This ongoing phase II study was designed to assess the safety and effi-
cacy of MOR208 plus LEN in patients with R-R DLBCL.
Methods: Patients >18 years of age with R-R DLBCL, ECOG performance sta-
tus 0-2, adequate organ function, having previously received at least 1 but not
more than 3 prior therapies, including at least 1 CD20-targeting regimen and
who are not candidates for autologous stem cell transplant (ASCT), are eligible.
Treatment comprises up to 12, 28-day cycles of MOR208 12mg/kg IV, admin-
istered weekly during cycles 1-3 (loading dose day 4 of cycle 1) and every sec-
ond week during cycles 4-12 plus LEN 25mg administered po days 1-21 of each
cycle. Patients progression-free after 12 cycles receive up to 12 additional cycles
of MOR208 12mg/kg IV, administered every second week. The primary endpoint
is the overall response rate (ORR) by central radiology assessment. Secondary
endpoints include disease control, duration of response, progression-free and
overall survival, safety, and response by cell of origin and other biomarkers. A
preplanned safety evaluation was undertaken.
Results: 31 of 80 planned patients were enrolled prior to data cutoff (3 January
2017). Median age was 74 years (range 47–82); 45% of patients received ≥2
prior lines of therapy; 23% had rituximab refractory disease; 74% had Ann
Arbor stage ≥III disease; 65% had elevated lactate dehydrogenase level, and
52% had a poor revised International Prognostic Index (3–5). The most com-
mon treatment-emergent adverse events (any grade/grade ≥3 [% patients])
were neutropenia (39/26), anemia (23/0) thrombocytopenia (16/6), infections
(26/10) diarrhea (13/0), pyrexia (13/0), and rashes (13/6). Of 26 response
evaluable patients (median follow-up 3.3 months), ORR (investigator assessed)
was 58% (15 patients), with 7 (27%) complete responses. Median time to
response was 1.8 months.
Summary/Conclusions: The combination of MOR208 plus LEN is well tolerated
and shows promising activity in patients with R-R DLBCL. Accrual and follow-up
of patients is ongoing, as are cell of origin and other biomarker analyses.
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Background: Recurrent mutations in isocitrate dehydrogenase 2 (mIDH2)
occur in ~12% of AML patients (pts). mIDH2 proteins synthesize an
oncometabolite, 2-hydroxyglutarate (2HG), causing DNA and histone hyper-
methylation and blocked myeloid differentiation. Enasidenib (AG-221) is an
oral, selective, small-molecule inhibitor of mIDH2 proteins. Differentiation of
myeloblasts, not cytotoxicity, appears to drive the clinical efficacy of enasidenib.
In preclinical studies, bone marrow blasts from pts with mIDH2 AML exposed
to enasidenib ex vivo were shown to produce mature, fully functioning neu-
trophils with conserved mIDH2 allele frequency, indicating differentiation of
mature cells from the mIDH2 blasts (Yen et al, Cancer Discov, 2017). Addition-
ally, no apoptosis was observed in mIDH2-R140 erythroleukemia (TF-1) cells
treated with enasidenib for 7 days in vitro.
Table 1.
Aims: Evaluate the maximum tolerated dose (MTD), pharmacokinetic (PK) and
pharmacodynamic (PD) profiles, safety, and clinical activity of enasidenib in
pts with mIDH2 advanced myeloid malignancies.
Methods: This phase 1/2 study included pts aged ≥18 years (yrs) with mIDH2
WHO-defined AML, or with mIDH2 MDS with refractory anemia with excess
blasts, and ECOG PS scores ≤2. Pts were relapsed or refractory (R/R) to prior
anti-cancer therapy, or had untreated AML if aged ≥60 years and not eligible
for standard-of-care treatment (Tx). Safety for all pts and clinical efficacy in the
largest pt subgroup, those with R/R AML, from the phase 1 dose-escalation
and expansion phases are reported.
Results: In all, 239 pts received enasidenib. Median age was 70 yrs. In the
dose-escalation phase (n=113), pts received daily enasidenib doses of 50-
650mg. The MTD was not reached. Median 2HG reductions from baseline at
cycle 2 day 1 were 92%, 90%, and 93% for pts receiving <100mg, 100mg, and
>100mg/day, respectively. Enasidenib 100mg QD was chosen for the expansion
phase (n=126) based on PK/PD profiles and demonstrated efficacy. Median
number of enasidenib cycles was 5 (range 1-25). Grade 3-4 investigator-report-
ed Tx-related adverse events included indirect hyperbilirubinemia (12%) and
IDH-inhibitor-associated differentiation syndrome (IDH-DS; ie, retinoic acid syn-
drome) (7%). Of 176 R/R AML pts, 94 (53%) had received ≥2 prior AML-directed
Tx. Overall response rate (ORR; complete remission [CR] + CR with incomplete
hematologic recovery + morphologic leukemia-free state + partial remission) in
R/R AML pts was 40.3%, including 34 pts (19.3%) who attained CR (Table).
Median time to 1st response was 1.9 months (mos); 87.3% of responding pts
attained a 1st response by cycle 5. Median response duration was 5.8 mos. Of
pts who achieved CR, 7 pts (21%) did so by cycle 3, 23 (68%) by cycle 5, and
28 (82%) by cycle 7. Median duration of CR was 8.8 mos. ORR with enasidenib
100mg/day was 38.5% (Table). Seventeen pts (11%) proceeded to stem cell
transplant. Response was associated with cellular differentiation, typically with
no evidence of aplasia. Median overall survival (OS) of R/R AML pts was 9.3
mos. For pts who attained CR, OS was 19.7 mos. Pts who had received ≥2
prior AML Tx had a median OS of 8.0 mos.
Summary/Conclusions: Enasidenib was well tolerated, induced CRs in R/R
AML pts, and was associated with OS of >9 mos in pts who had failed prior
AML Tx. A randomized phase 3 study of enasidenib vs conventional care in
older pts with late-stage R/R AML is ongoing (NCT02577406).
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Background: Newly diagnosed patients (pts) with AML aged ≥65 years and
ineligible for standard induction therapy have limited treatment options, and
low overall survival. VEN is an orally bioavailable, selective BCL-2 inhibitor that
has displayed single-agent activity in pts with relapsed/refractory AML. VEN at
escalating doses combined with hypomethylating agents (HMAs) has demon-
strated antileukemic activity, with an overall response rate (ORR) including
complete remission [CR], and CR with incomplete marrow recovery of 60%.
Combining VEN with HMAs, such as decitabine (DEC) or azacitidine (AZA),
may provide a novel low-intensity approach for treating AML. Preliminary results
from the expansion stage of a phase 1b trial comparing 2 doses of VEN plus
either DEC or AZA (NCT02203773) are reported.
Aims: To evaluate the safety and efficacy of VEN at 400-mg vs 800-mg doses
plus DEC or AZA. 
Methods: This open-label, nonrandomized, two-stage phase 1b study evalu-
ated the safety and efficacy of VEN plus DEC or AZA in treatment-naive pts
≥65 years with AML. Eligibility included: ECOG PS ≤2; ineligible for standard
induction therapy; intermediate- or poor-risk karyotype. Pts received DEC (Arm
D, 20mg/m2/day [d];intravenous [IV]) on d 1–5, or AZA (Arm E, 75mg/m2/d;
subcutaneous or IV) on d 1–7 of each 28-d cycle (C) in combination with once-
daily oral VEN. The dose-expansion stage consisted of 2 VEN dose cohorts
(continuous 400-mg and interrupted 800-mg dosing) in each arm (D1, D2, E1,
and E2, respectively) to determine optimal dose. Tumor lysis syndrome (TLS)
prophylaxis was administered in C1 to all pts during VEN dose ramp-up until
final dose was reached. All pts provided informed consent.
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Results: As of 13/09/16, 100 pts were enrolled in the expansion stage: 25 pts
in each arm. Overall, 61% pts were male; 59% had ECOG PS 1 and 15%
ECOG PS 2; mean age was 73.9 (range 65–86); 53% had adverse karyotype;
and 22% had secondary AML. Median time on study was 6 (4-9), 6 (0.2-9), 5
(0.5-9), and 4 (1-8) mo for arms D1, D2, E1, and E2, respectively. The incidence
of adverse events (AEs) was generally comparable between the 4 arms. Over-
all, the most common treatment-emergent AEs (TEAEs; in ≥30% of pts) were
nausea (59%), diarrhea (42%), febrile neutropenia (FN; 41%), constipation
(39%), fatigue, and decreased white blood cell count (31% each). The most
frequent grade 3/4 TEAE and serious AE was FN (41% and 29%, respectively).
No TLS was observed. Overall, 29 pts discontinued the study for ≥1 reason,
including progressive disease (PD) per protocol (n=10), “other” (n=10; 9/10
proceeded to stem cell transplantation) and AEs not related to progression
(n=10). A total of 16 deaths occurred; 12 pts died within 30 d of initiating VEN
and HMA due to AEs (n=12) and PD (n=1). The ORR was 68%, with rates of
76% (19/25), 71% (17/24), 68% (17/25), and 60% (15/25) observed in arms
D1, D2, E1, and E2, respectively. The Kaplan-Meier survival curve for all pts
with a median follow-up time of 5.4 mo is shown. 
Figure 1.
Summary/Conclusions: Overall, the safety profile was favorable when com-
bining VEN at either dose with DEC or AZA in treatment-naive elderly AML pts.
Promising activity with high ORRs was observed at the lower 400-mg VEN
dose in both HMA arms. A Phase 3 study of VEN plus AZA is planned.
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Background: Incidence of acute myeloid leukemia (AML) increases with age,
and patients (pts) ≥65 years have a poor prognosis, with 5-year survival rates
of <10%. Treatment with low-dose cytarabine (LDAC) in this population results
in modest complete remission (CR)/CR with incomplete blood count recovery
(CRi) rates of 11-19% and median survival of 5-6 months. Venetoclax (VEN),
an orally bioavailable, potent, selective BCL-2 inhibitor, has shown single-agent
activity in heavily pretreated pts with relapsed/refractory AML (Konopleva et al
2016). In combination with LDAC, the recommended phase 2 dose (RP2D) of
VEN is 600mg QD (Lin et al, ASCO 2016); preliminary data show the combi-
nation is tolerable and exhibits significant and durable activity in older AML pts
ineligible to receive intensive induction chemotherapy (Wei et al, ASH 2016).
Updated safety and efficacy data from the RP2D 600-mg dose cohorts of this
study (NCT02287233) are presented.
Aims: Evaluate the safety and efficacy of VEN+LDAC in older pts with untreat-
ed AML.
Methods: In this open-label phase 1/2 study, pts ≥65 years with untreated
AML, ineligible for standard induction chemotherapy, with an ECOG perform-
ance status of 0-2 received oral VEN QD on days (d) 1-28 and subcutaneous
LDAC 20mg/m2 QD on d 1–10 of each 28-d cycle. VEN target dose evaluation
followed a 3+3 design, ranging from 600–800mg; 18 pts were enrolled and the
RP2D was established as 600mg. Safety and efficacy of VEN at RP2D were
evaluated in the expansion phase. All pts were hospitalized and received pro-
phylaxis before a dose ramp-up of VEN during cycle 1 to mitigate the risk of
tumor lysis syndrome (TLS). Adverse events (AEs) were graded by NCI CTCAE
V4.0. Pts enrolled as of May 2016 are included in this analysis; data cutoff was
August 2016. All pts provided informed consent.
Results: In total, 61 pts, including 8 from phase 1, were treated at the RP2D
of 600mg (median age 74 years; ECOG 1–2 70%; adverse karyotypes 31%;
secondary AML 44%; prior hypomethylating agent [HMA] 28%). AEs (all grade;
≥30% pts; excluding cytopenias) were nausea (72%), hypokalemia (46%), diar-
rhea (44%), fatigue (43%), and decreased appetite (41%). Grade 3/4 AEs
(≥10% pts) were febrile neutropenia (34%), hypokalemia (15%), hypophos-
phatemia (13%), and hypertension (10%). No pts had clinical TLS; 1 pt had
laboratory TLS, which was managed. The 30-d and 60-d mortality rates were
3% and 15%, respectively. The CR/CRi rate was 54% (33/61; 21% CR and
33% CRi). The overall response rate (ORR; CR+CRi+partial remission) was
61% (37/61). VEN+LDAC was shown to be active across a wide range of cyto-
genetic mutations and pt profiles (ORR: 70% in pts ≥75 years; 52% in second-
ary AML; 47% in pts with adverse karyotypes; 53% in pts with prior HMA).
Among response-evaluable pts, those achieving an objective response have
longer survival than pts who do not achieve an objective response (Figure 1).
Figure 1.
Summary/Conclusions: VEN (RP2D 600mg) and LDAC exhibited an accept-
able safety profile and durable efficacy in pts aged ≥65 years with untreated
AML who are ineligible for or unable to receive intensive induction chemother-
apy. ORR highly correlated with overall survival, with better survival observed
in responders compared with nonresponders. A planned phase 3 randomized
trial has commenced.
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Background: Blocking PD-1/PD-L1 pathways enhances anti-leukemia
responses in murine AML (Zhang et al, Blood 2009). PD-1 positive CD8 T-cells
are increased in bone marrow (BM) of pts with AML (Daver et al, AACR 2016).
AZA up-regulates PD-1 and interferon-gamma signaling in AML and the up-
regulation of PD-1 has been associated with emergence of resistance to AZA
(Yang et al., Leukemia 2013).
Aims: To assess the best response to Aza+Nivo at the end of 3 courses of
combination therapy.
Methods: Pts were eligible if they had AML and failed prior therapy, had ade-
quate performance status (ECOG ≤2), and organ function. The first six pts
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received AZA 75mg/m2 Days 1-7 with nivolumab 3mg/kg on Day 1 and 14.
Courses were repeated every 4-5 weeks indefinitely. Only one of six pts had a
dose limiting toxicity (grade 3 pneumonitis) and this dose was RP2D. 60 addi-
tional pts have been treated at the RP2D.
Results: 66 pts with a median age of 71 years (range, 44-90), secondary AML
(39%), poor risk cytogenetics (35%), median number of prior regimens 2 (range,
1-7) have been enrolled. All 66 pts had baseline next generation sequencing:
TP53 (n=14), DNMT3A (n=12), ASXL1 (n=10), TET2 (N=9), and RAS (n=9),
IDH2 (n=9), IDH1 (n=6), CEBPA (n=7). 63 pts are evaluable for response: 14
(22%) achieved complete remission (CR)/complete remission with insufficient
recovery of counts (CRi) (3 CR, 11 CRi), 7 (11%) had hematologic improvement
(HI), 13 (21%) had ≥50% BM blast reduction, 5 pts (8%) had stable disease >6
months, and 24 (38%) had progression. 3 pts are too early for response assess-
ment (<3 courses). The median number of courses to CR/CRi/HI was 2 (range,
1-4+). The med OS among the CR/CRi patients was 15.3 months (range, 2.29-
17.25+), HI pts was 9.7 months (range, 4.67-17.45+), and NR was 5.0 months
(range, 0.29-16.16). The 4- and 8-week mortality were 5% and 11%, respec-
tively. The median OS for the 63 evaluable pts on Aza+Nivo compares favorably
to historical median OS with AZA-based salvage protocols in similar pts treated
at MDACC (P=0.10) (Fig 1A and Fig 1B). Grade 3/4 and Grade 2 immune tox-
icities were observed in 8 (12%) and 7 (11%) pts, respectively. The most com-
mon Grade 3/4 AEs on treatment included pneumonitis, colitis, nephritis, skin
rash, and hypophysitis. One pt died from grade 4 pneumonitis/epiglottitis. In
the remaining 14 cases the toxicities responded rapidly to steroids and 13 of
these pts were successfully rechallenged with nivolumab. Time to onset of tox-
icities ranged from 4 days to 3.5 months. Multicolor flow-cytometry studies and
Mass-cytometry (CyTOF) studies are conducted by the Immunotherapy Plat-
form on baseline and on-treatment BM aspirate (end of cycle 1, 2, 4, 8). Base-
line and end of cycle (EOC) 1 and 2 BM was evaluated in 6 responders and 19
non-responders. Pts who achieved a response had a baseline higher live total
CD3 (P=0.10), CD8+ T-cells (P=0.02), and lower live CD4+Foxp3+PD1+ T-reg-
ulatory (T-reg) cells (P=0.01) infiltrate in BM. Patients who had a response had
progressive increase in BM CD3+ cells and BM CD8+ cells, with increased
ICOS (activation) marker on BM CD4-effector cells at EOC 1 and EOC 2 as
compared to those who had no response. The CTLA4 on CD8 T-cells went up
in both responders and non-responders after PD1 based therapy.
Figure 1.
Summary/Conclusions: Full dose AZA and nivolumab are tolerable and pro-
duce an encouraging response rate with durable responses in relapsed AML
with poor risk features. Immune mediated toxicities occur and may be ade-
quately managed with early recognition and systemic steroids. Up-regulation
of CTLA4 may be a mechanism of resistance to PD1 based therapies in AML
and suggest role for combination therapy. 
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Background: The presence of a FMS-like tyrosine kinase 3 (FLT3) Internal
Tandem Duplication (ITD) mutation in pts with AML is associated with an
increased early relapse rate and a dismal prognosis. Quizartinib is a potent,
selective oral FLT3 receptor tyrosine kinase inhibitor that conferred median OS
(mOS) of 23 weeks and remission rate of 46% in a single-arm phase 2 study
(AC220-002) in pts with AML with a FLT3-ITD mutation who were relapsed or
refractory (R/R) to second line therapy. (Levis, et al., ASH 2012) As context, a
study of AML pts, regardless of FLT3 mutation status, receiving second-salvage
therapy reported mOS of only 1.5 months. (Giles F, et al. Cancer 104 (3), 2005).
Such poor-risk pts may benefit from a stem cell transplant (SCT), if available.
Aims: The primary aim was to compare SCT rates and outcomes of pts on
quizartinib from an exploratory selected cohort in the AC220-002 study with
those from a historical cohort of 1388 AML pts with confirmed FLT3-ITD muta-
tions in the UK NCRI database. 
Methods: Within AC220-002, 58 pts with a FLT3-ITD mutation were identified
who had received intensive chemotherapy, and were relapsed (n=53), or refrac-
tory (n=5) to salvage therapy prior to entry. Applying the same entry criteria to
the NCRI database, we identified 118 pts who received only recognized
chemotherapy regimens prior to eligibility (relapsed n=99; refractory n=19). To
avoid biases where those dying early would predominantly contribute to the
NCRI group (reflecting that pts in AC220-002 had to be fit enough to be
enrolled), pts in this cohort entered analysis 14 days following being identified
as R/R. Multivariable Cox/logistic regression was used to compare remission
rates and survival stratified for known prognostic factors. A landmark analysis
excluding deaths before day 90 (allowing for those too unfit for SCT) was per-
formed on the pooled sample (n=176) of the AC220-002 and NCRI cohorts to
compare survival between transplanted and non-transplanted pts.
Results: Overall, quizartinib-treated pts had significantly greater remission
rates, consisting mainly of complete remission without normal blood counts
(CRi), vs NCRI pts (40% vs 3%, adjusted OR 0.05 (0.01-0.21), p<0.0001) and
improved mOS (140d vs 54d, adjusted HR 0.38 (0.25-0.58) p<.0001). A greater
proportion of pts in AC220-002 proceeded to SCT: 23/58 (40%) vs 9/118 (8%).
Comparing survival in SCT vs no-SCT in a landmark analysis, 18-month survival
was significantly greater in the SCT group (29% vs 7%, adjusted HR 0.36 (0.20-
0.65) p=0.0005). Significance persisted in sensitivity analyses with the landmark
set at 120 or 150 days indicating an association between long-term survival
and SCT. A similar analysis in an unmatched cohort consisting of SCT-naïve
pts in first relapse also found better survival for SCT vs no-SCT, confirming a
potential benefit of SCT in this poor risk population. 
Summary/Conclusions: When compared to a large historical cohort, quizar-
tinib was associated with greater remission rates and opportunity to receive
SCT in pts who relapsed after salvage therapy. While varying practice patterns
and patient factors obviously influence treatment choices and outcomes, pts
with AML with FLT3-ITD mutation appeared to benefit with longer survival
observed with SCT. This data suggests quizartinib may show promise in poten-
tially improving long-term survival by bridging patients to SCT.
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GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019
IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY
(R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE
INTERIM ANALYSIS
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Background: The CD19-targeted chimeric antigen receptor (CAR) T-cell ther-
apy CTL019, an investigational therapy that reprograms cytotoxic T cells to
eliminate target cells, resulted in high response rates and a manageable safety
profile in pediatric/young adult patients (pts) with R/R B-cell ALL in a single-
center trial.
Aims: We report an updated interim analysis from the first multicenter global
pivotal registration trial of a CAR T-cell therapy (ELIANA; NCT02435849) includ-
ing data for 68 pts infused with CTL019, 50 of whom were followed for ≥6 mo.
Methods: This is a single-arm, open-label, multicenter, global, phase 2 study
of CTL019 in pediatric/young adult pts with CD19+ R/R B-cell ALL with ≥5%
bone marrow lymphoblasts by morphology. CTL019 was manufactured from
leukapheresed autologous peripheral blood T cells at a centralized manufac-
turing facility. The primary endpoint was overall remission rate (complete remis-
sion [CR] + CR with incomplete blood count recovery [CRi]) within 3 mo. Sec-
ondary endpoints included duration of remission (DOR), overall survival, safety,
and cellular kinetics.
Results: As of November 2016, 88 pts were enrolled. There were 7 (8%) man-
ufacturing failures, 9 (10%) pts were not infused due to death or adverse events
(AEs), and 4 pts (5%) were pending infusion at the time of data cutoff. Following
lymphodepleting chemotherapy in most pts (fludarabine/cyclophosphamide
[n=64]) or other [n=1]), 68 pts were infused with a single dose of CTL019 (median
dose, 3.0×106 [range, 0.2-5.4×106] transduced CTL019 cells/kg), with a median
study follow-up of 6.4 mo. Median age was 12 y (range, 3-23 y); 59% of pts had
prior allogeneic stem cell transplant (alloSCT). Five infused patients had not
reached 3 mo of follow-up; among 63 evaluable pts, 52 (83% [95% CI, 71%-
91%]) achieved CR/CRi within 3 mo of CTL019 infusion, all of whom had minimal
residual disease–negative marrow. The relapse-free probability at 6 mo after
remission onset was 75% (95% CI, 57%-87%; median DOR not reached). The
probability of survival was 89% (95% CI, 77%-94%) at 6 mo and 79% (95% CI,
63%-89%) at 12 mo. Seven pts (13% of responders) proceeded to alloSCT
within 6 months while in remission. Cytokine release syndrome (CRS) was grad-
ed using the UPenn scale and managed using a protocol-specific algorithm;
CRS occurred in 78% of pts (21% grade 3; 27% grade 4); no CRS-associated
deaths occurred. 38% of pts received tocilizumab for treatment of CRS with or
without other anti-cytokine therapy. Most common grade 3/4 nonhematologic
AEs (>15%) other than CRS were hypotension (22%), hypoxia (18%), and
increased aspartate aminotransferase (16%). The incidence of serious AEs
within 8 weeks of infusion was 69%. 15% of pts experienced grade 3 neuropsy-
chiatric AEs, with no grade 4 events and no cerebral edema reported. Grade
3/4 neutropenia with high (>38.3˚C) fever occurred in 60% of pts. 2 pts died
within 30 days of infusion (ALL progression, n=1; cerebral hemorrhage, n=1),
and 9 pts died >30 days after infusion (ALL relapse/progression, n=6; HHV-6
encephalitis, pneumonia, systemic mycosis, n=1 each). CTL019 expansion in
vivo correlated with CRS severity, and persistence of CTL019 along with B-cell
aplasia in peripheral blood was observed for ≥1 year in some responders.
Summary/Conclusions: The ELIANA study confirmed the efficacy of a single
infusion of CTL019, without additional therapy, observed in a previous interim
analysis and a prior single-center CTL019 trial. AEs were effectively and repro-
ducibly managed globally by appropriately trained personnel at study sites.
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Background: CTL019 is an investigational therapy whereby autologous T cells
are genetically engineered with a chimeric antigen receptor (CAR) to identify
and eliminate CD19-expressing malignant B cells. Data from 2 phase 2 studies
(ELIANA; NCT02435849 and ENSIGN; NCT02228096) in pediatric and young
adult R/R B-cell ALL were pooled to evaluate cellular kinetics of CTL019.
Aims: We report cellular kinetics, humoral immunogenicity, AUC0-28d (expo-
sure)-response analysis and impact of intrinsic/extrinsic and manufacturing
factors on CTL019 expansion.
Methods: Cellular kinetic parameters of CTL019 post infusion were derived
using traditional pharmacokinetic principles and reported by response category
(complete response [CR]/CR with incomplete blood count recovery [CRi] vs
no response [NR]) using 2 assays of peripheral blood cells: qPCR and flow
cytometry. AUC0-28d-response relationships were evaluated by logistic regres-
sion. Relationships between manufacturing specifications, therapies for
cytokine release syndrome (CRS) management, and anti-CAR19 antibodies
on cellular kinetics were explored using summary statistics and graphical- and
model-based analyses.
Figure 1.
Results: Data from 79 pts (ELIANA, n=50; ENSIGN, n=29) were pooled for
analysis. Using qPCR, pts with CR/CRi (n=62) had ≈ 2-fold higher CTL019
expansion than pts with NR (n=7) (Cmax, 73.5% higher geometric [geo] mean;
AUC0-28d, 104% higher geo mean; Table 1). Pts with NR had delayed Tmax
compared with pts with CR/CRi (20 vs 10 days). Intrinsic pt factors including
baseline cytogenetics, disease characteristics, and disease status did not
appear to affect Cmax or AUC0-28d with the exception that pts with a higher
tumor burden at enrollment generally had higher expansion, based on box
plots and summary statistics. Extrinsic factors (prior lines of therapy, stem cell
transplant) and parameters related to the manufactured product (% T cells,
transduction efficiency, cell viability, total cell count), did not appear to impact
cellular kinetics, based on graphical analysis. AUC0-28d increased with pres-
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ence and severity of CRS. Pts who received anti-cytokine agents for grade 3/4
CRS also had higher expansion. CR/CRi pts treated with tocilizumab and
steroids (n=17) had 89% higher AUC0-28d than CR pts who did not receive
tocilizumab and steroids (n=45). Experience is limited in NR pts with (n=4) and
without (n=4) tocilizumab. Moderate correlation was observed between trans-
gene levels and CAR surface expression in peripheral blood (r2=0.592) by
qPCR and flow cytometry, respectively, when matched by time points from the
cellular kinetic profile. Slower B-cell recovery was observed in pts with AUC0-
28d above the median. Post-dose anti-CAR19 antibody responses were deter-
mined from the fold change of anti-CAR19 antibodies above the baseline pre-
dose value. Pts with treatment-induced or boosted anti-CAR19 antibody
responses generally had lower expansion, based on box plots, compared with
pts with treatment-unaffected anti-CAR19 antibody responses, although AUC0-
28d was variable. The boosted levels of anti-CAR19 did not impact clinical
response or relapse.
Table 1.
Summary/Conclusions: There was increased expansion of CTL019 in pts
with higher tumor burden at enrollment, which correlated with higher CRS
grade. There was no relationship between dose and expansion, supporting the
wide dose range used. Expansion was not attenuated by tocilizumab or
steroids, indicating therapies for CRS do not abrogate CTL019 proliferation.
Cellular kinetics are important to understand the determinants of tumor
response with CAR T-cell therapy.
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Background: Adults with B-cell precursor (BCP) acute lymphoblastic leukemia
(ALL) often relapse following standard induction/consolidation chemotherapy
(CTX). Prognosis following second and successive CTX salvage regimens
(S2+) is poor compared with first salvage (S1) or frontline therapy, with less
favorable outcomes among patients with shorter CR duration. Blinatumomab
links cytotoxic CD3-positive T cells and CD19-positive B cells to induce tumor
cell lysis. In a randomized phase 3 trial of blinatumomab vs investigator’s choice
of 4 standard of care CTX (SOC) regimens, median OS was 7.7 months in the
blinatumomab group vs 4.0 months with SOC (Kantarjian H, et al., NEJM 2017).
Here, we evaluate outcomes by salvage status for patients in this study
(NCT02013167).
Aims: To evaluate responses to blinatumomab vs SOC in patients with
relapsed/refractory ALL by prior salvage therapy status.
Methods: Patients with relapsed/refractory (R/R) BCP-ALL in this international
multicenter trial were randomized 2:1 to blinatumomab (n=271) or SOC (n=134).
For this analysis, salvage status was adjudicated separately from prior ran-
domization strata. Blinatumomab was given by continuous IV infusion (9 µg/d
in week 1 of cycle 1, then 28 µg/d) in cycles of 4 weeks on, 2 weeks off. The
primary endpoint was overall survival (OS), determined from time of random-
ization until death due to any cause. Adverse events (AE) of interest were coded
according to MedDRA version 16.0.
Results: At baseline, patient characteristics were balanced between groups
within salvage designations. The rate of complete remission, with or without
full hematologic recovery (CR/CRh/CRi) in both the S1 and S2+ groups was
higher in the blinatumomab arm compared with the SOC arm (Table 1). Patients
randomized to blinatumomab had a median (95% CI) of 11.1 (8.2, NR) months
vs 5.1 (3.2, 7.1) months overall survival for S1 vs S2+ subgroup, compared
with 5.5 (3.7, 9.0) months vs 3.0 (2.1, 4.0) months in the SOC arm (Figure 1).
For both S1 and S2+ subgroups, blinatumomab patients had longer median
survival time. Grade 3 or worse AEs were experienced by 61% and 83% of S1
patients in the blinatumomab and SOC group, respectively. These percentages
were 68% and 75%, respectively, in S2+ patients. Grade 4 or worse AEs
occurred in 34% and 51% S1 patients, and in 36% and 54% S2+ patients. Neu-
rologic events of grade ≥3 occurred in 9% and 9% of S1 patients, and in 10%
and 9% S2+ patients, respectively. Grade ≥3 cytokine release syndrome (CRS)





Summary/Conclusions: Patients in this trial receiving blinatumomab for R/R
ALL achieved improved OS and remission rates compared with SOC regardless
of prior salvage therapy. Improved OS compared with SOC in S1 patients sup-
ports earlier use of blinatumomab.
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DURABLE LONG-TERM SURVIVAL OF ADULT PATIENTS WITH B-ALL
AFTER CD19 CAR (19-28Z) T CELL THERAPY
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Background: CD19-specific chimeric antigen receptor (CAR) T cells have
demonstrated high initial responses in patients with relapsed B-ALL. However,
clinical characteristics associated with the durability of response remain unde-
fined.
Aims: We performed a retrospecive analysis of our phase I clinical trial of 19-
28z CAR T cells in adult patients with relapsed B-ALL (NCT01044069) with a
focus to identify those patients who optimally benefit from 19-28z CAR T cell
therapy with durable long-term survival and reduced toxicities. 
Methods: Adults with relapsed B-ALL were infused with autologous T cells
expressing the 19-28z CAR following conditioning chemotherapy. Disease bur-
den was assessed by bone marrow biopsy immediately prior to T cell infusion;
patients with <5% blasts were classified as minimal residual disease (MRD)
cohort vs patients ≥5% blasts as morphologic disease cohort. Response
assessment occurred at 4 weeks. Median follow-up duration was 18 months
(range, 0.2-57.3).
Results: 51 adults received 19-28z CAR T cells; 20 in the MRD and 31 in the
morphologic cohort. Complete remission (CR) rates were comparable (95%
and 77%, respectively). However, median event-free and overall survivals wide-
ly diverged among the 42 patients who achieved MRD-negative CR: not
reached (NR) (95% confidence interval [CI]: 4.2-NR) vs 6.3 months (95% CI,
4.8-9.0) (p=0.0005), and NR (95% CI, 15.3-NR) vs 17 months (95% CI, 8.5-
36.2) (p=0.0189), in the MRD and morphologic cohorts, respectively. Subse-
quent allogeneic HSCT in either cohort did not improve survival (p=0.8). MRD
cohort patients developed substantially less severe cytokine release syndrome
(CRS) and neurotoxicity, and both toxicities significnatly correlated with peak
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CAR T cell expansion (p=0.0326 and p=0.0001, respectively). No case of cere-
bral edema was observed.
Summary/Conclusions: Despite comparable initial CR rates regardless of
pre-treatment disease burden, durability of 19-28z CAR T cell mediated remis-
sions and survival in adult patients with relapsed B-ALL positively correlated to
a low disease burden and do not appear to be enhanced by allogeneic trans-
plant. Our findings strongly support the early incorporation of CD19 CAR ther-
apy before morphologic relapse in B-ALL. 
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Background: ETV6-RUNX1 fusion is a common genetic aberration in child-
hood acute lymphoblastic leukemia (ALL) and is associated with good progno-
sis in the context of contemporary treatment regimens. The required treatment
intensity for this well-described biologic subgroup with low risk of relapse is not
known so far. In trial AIEOP-BFM ALL 2000, feasibility of reduction of delayed
intensification treatment to reduce the burden of chemotherapy was tested in
a randomized approach in the standard-risk group. Treatment reduction was
not successful in the total cohort (8-year probability of disease-free survival
(8y-pDFS, ± standard error) 89.2±1.3% for reduced delayed intensification
treatment, 92.3±1.2% for the standard treatment (log-rank P=0.04) due to evi-
dence of more relapses observed in patients treated less intensively.
Aims: The retrospective subgroup analysis presented here focuses on the
ETV6-RUNX1-positive patients included in the group of randomized standard-
risk patients.
Methods: From 07/2000 to 06/2006, 4741 eligible patients with ALL (age range
1-17 years) were enrolled in the trial AIEOP-BFM ALL 2000 (NCT 00430118
(BFM) and NCT 00613457 (AIEOP)). Of those, 1164 patients were considered
at standard risk of relapse, defined by lack of genetic high-risk criteria and
absence of minimal residual disease at day 33 and week 12 of treatment (tested
by immunoglobulin/T-cell receptor gene rearrangement polymerase chain reac-
tion). They were randomly assigned to either receive the reduced-intensity pro-
tocol III (P-III), or standard protocol II (P-II) for delayed intensification. P-III is
shorter than P-II (duration 29 vs 49 days), the dose of dexamethasone in P-III
is 30% lower, and the dose of vincristine, doxorubicin, and cyclophosphamide
are reduced by 50% as compared to P-II. The intention was to prove non-infe-
riority of the reduced-intensity treatment compared to standard treatment.
Results: ETV6-RUNX1-positive patients (n=367) accounted for 34% of ran-
domized standard-risk patients (Age: <6 years n=260, 6 to <10 years n=79,
≥10 years n=28; early cytologic response evaluation in bone marrow on day
15 of induction treatment: M1 n=218, M2 n=74). Of those, 188 were treated
with the experimental P III, 179 received the standard P-II. With a median fol-
low-up of 8.6 years, the as-treated analysis showed an 8y-pDFS of 94.5±1.7%
for P-III, and 94.4±1.8% for patients with P-II (log-rank P=0.74). Cumulative
incidence of relapse at 8 years was 3.3±1.3% and 4.3±1.6% (Gray P=0.09),
and 8-year overall survival was 96.9±1.4% and 98.8±0.9% (P=0.27) for P III
and P II, respectively. Analysis of ETV6-RUNX1-positive patients by age groups
or treatment response on day 15 allowed no further refinement of prognostic
subgroups.
Summary/Conclusions: There was no evidence of prognostic disadvantage
in ETV6-RUNX1-positive standard-risk patients when treated with the reduced-
intensity experimental arm. No clear age- or response-dependent differences
could be revealed for this group, which is in line with the biologic understanding
of this genetic subgroup. Hence, it might be postulated that treatment reduction
might be feasible in this clearly defined biologic subgroup. However, the present
data is not result of a sufficiently powered non-inferiority study question focused
on the subgroup of ETV6-RUNX1-positive patients, but reflects a subgroup
analysis with descriptive character. Therefore, any decision for treatment reduc-
tion should be considered carefully.
Biology and disease monitoring in CML
S481
A SECOND GENERATION LYSOSOMOTROPIC AGENT DRIVES
LEUKAEMIC STEM CELL DIFFERENTIATION AND SENSITIZES THEM TO
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Background: Autophagy is a conserved catabolic process that delivers cyto-
plasmic constituents to the lysosomes. We have previously shown that the
lysosomotropic agent hydroxychloroquine (HCQ) inhibits autophagy and sen-
sitizes Chronic Myeloid Leukaemia (CML) stem cells (LSCs) to tyrosine kinase
inhibitors (TKIs) treatment. However, the biological effects of autophagy inhi-
bition in LSCs in vivo are currently unknown and remain to be investigated.
Furthermore, recent clinical studies showed that maximum tolerated dose of
HCQ does not achieve consistent autophagy inhibition in cancer patients.
Therefore further pre-clinical studies using more potent 2nd generation lysoso-
motropic agents, alone and in combination with TKIs, are vital. 
Aims: Here we aim to investigate the functional effects of autophagy inhibition
in LSCs both in vitro and in vivo using the highly potent lysosomotropic agent
Lys05. Additionally, we aim to address whether Lys05 achieves autophagy inhi-
bition in the most primitive LSC populations in vivo and whether it targets LSCs
more effectively than HCQ when combined with TKIs.
Methods: In this study, we used primary stem-cell enriched samples (CD34+
cells) derived from CML patients at diagnosis. For in vivo studies, we used a
human patient-derived xenograft (PDX) model and an inducible transgenic
CML model in which the expression of BCR-ABL is induced at a stem/progenitor
level (Scl-tTa-BCR-ABL). To accurately measure autophagy flow in long term
LSCs in vivo, we generated the transgenic mouse Scl-tTa-BCR-ABL/GFP-LC3
by crossing the Scl-tTa-BCR-ABL model with a mouse bearing the autophagy
marker LC3 fused to GFP.
Results: Firstly, we show that Lys05 targets LSCs more potently than HCQ in
vitro by achieving a 60% and a 35% reduction in number of CD34+CD38- and
CFSEmax/CD34+CD133+cells respectively. Interestingly, Lys05 promoted a
40% loss of quiescent cells and induced myeloid differentiation of CD34+ cells.
Functional long-term culture initiating cell (LTC-IC) assay demonstrated that,
while HCQ had moderate effects, Lys05 decreased the number of LSC-derived
colonies by 80%. Additionally, we show that Lys05 inhibits autophagy flow more
efficiently than HCQ both in the Scl-tTa-BCR-ABL/GFP-LC3 model and in
patient-derived progenitor cells. Analysis of bone marrow (BM) cells from Lys05-
treated leukaemic mice (but not from HCQ-treated mice), showed a statistically
significant 35% decrease (p=0.0469) in the most primitive population Lin-Sca+c-
kit+CD48-CD150+ followed by a 50% increase (p=0.0231) of progenitors Lin-
Sca+c-kit+. This result indicates differentiation of LSCs towards a more pro-
genitor phenotype following potent autophagy inhibition. Finally, to test the in
vivo effect of Lys05 on the most primitive human LSCs we transplanted CD34+
CML cells into irradiated NSG mice. Remarkably, using this PDX model we
show that while 3 weeks in vivo treatment with HCQ had no effects when com-
bined with TKIs, Lys05 and TKI treatment nearly eliminated engrafted primitive
Philadelphia positive CD34+CD38- and CD34+CD133+cells.
Summary/Conclusions: Overall, we demonstrate that lysosomal inhibition
induces loss of quiescence and drives differentiation of LSCs in vitro and in
vivo. Furthermore, our results show that Lys05 achieves autophagy inhibition in
LSCs and effectively sensitizes LSCs to TKIs in vitro and in vivo. Therefore, 2nd
generation lysosomotropic agents should be considered as a potential alterna-
tive to HCQ in order to eliminate LSCs and achieve cure for CML patients.
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Background: Chronic myeloid leukemia (CML) is provoked by the chromoso-
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mal translocation t(9;22) that gives rise to the oncogenic tyrosine kinase Bcr-
Abl. Implementation of tyrosine kinase inhibitor (TKI) therapy resulted in signif-
icant clinical success but with TKIs failing to eradicate the disease initiating
leukemic stem cell population (LSC), this treatment is not curative in the vast
majority of patients. By using a transgenic CML mouse model, we previously
showed that LSC persist despite complete Bcr-Abl kinase inhibition due to a
lack of oncogene-addiction. Subsequently, we identified the ITIM carrying Fc
gamma receptor IIb (FcγRIIb; CD32) to be 2.8-fold upregulated in Bcr-Abl+ ver-
sus control LSK (lin-;Sca-1+;c-kit+) cells using microarray and qRT-PCR.
Aims: In this study, we first aimed to validate Bcr-Abl mediated FcγRIIb upreg-
ulation on mRNA and protein level in leukemic cells. Next, we tested the effect
of shRNA mediated FcγRIIb knock-down and depletion on CFU (colony forming
unit) capacity, proliferation and leukemic signaling in vitro. Finally, we studied
the disease-initiating potential of primitive CML stem and progenitor cells upon
FcγRIIb knock down.
Methods: qRT-PCR and western blot analyses were applied using cell lines,
primary murine cells and HoxB8 immortalized murine bone marrow (BM) cells
for studying FcγRIIb expression and signaling. In order to test the biology of
CML cells in vitro, we performed CFU and proliferation assays. Moreover, we
performed viral infection of 5-FU treated SCLtTA/Bcr-Abl BM using
FcγRIIb:shRNA or scrambled control and subsequent transplantation, followed
by analyses of the disease, including immune-phenotyping, RNA and protein
expression as well as histological analysis.
Results: Bcr-Abl increased FcγRIIb mRNA (13.2-fold, p≤0.001) and protein
expression in primary murine lineage negative (lin-) BM cells. Reduction of
FcγRIIb in immortalized SCLtTA/Bcr-Abl progenitor cells significantly reduced
CFU potential by nearly 10-fold (p≤0.01) and it impaired the proliferation rate in
these cells (2.27-fold, p≤0.001). Moreover, transplantation of SCLtTA/Bcr-Abl-
shRNA:FcγRIIb BM cells (CD45.1+) into FVB/N wildtype (WT) CD45.2+ recipi-
ents reduced spleen weight (352 ± 59.13mg), as compared to scrambled shRNA
(568.1 ± 101.72mg). FACS analysis revealed a decrease in GFP+;CD45.1+ BM
cells (1.43-fold, p≤0.001) upon FcγRIIb knock down. Likewise, donor-derived
Gr-1+ cells (Gr-1+;CD45.1+;GFP+) were reduced in the BM (1.28-fold, p≤0.01)
of these mice. Flow-cytometric analysis of the stem cell compartment revealed
decreased leukemic BM LSK cells (lin-, c-kit+, Sca-1+, CD45.1+, GFP+, 1.38-
fold, p≤0.05) in mice transplanted with shRNA:FcγRIIb vs scrambled control.
We previously observed similar effects upon FcγRIIb depletion (FcγRIIb-/-) vs
wildtype (FcγRIIb+/+), combined with virally induced Bcr-Abl expression. Inter-
estingly, Bcr-Abl signaling induces FcγRIIb phosphorylation in leukemic cells.
Analysis of downstream signal pathways showed decreased levels of p-ERK,
p-BTK, p-PLCγ1 in FcγRIIb-/-, compared to FcγRIIb+/+ Bcr-Abl transduced
immortalized primary murine BM cells.
Summary/Conclusions: FcγRIIb is upregulated in LSC derived from transgenic
CML mice upon Bcr-Abl expression. Complete depletion or knock down of the
receptor reduces CFU capacity and cell growth in CML cells and significantly
impairs CML development and LSC burden in vivo, presumably due to impaired
leukemic downstream signaling. Our data demonstrate that FcγRIIb is critical and
disease specific making it a potential novel therapeutic target in CML stem cells.
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Background: The expression of miRNAs is regulated at transcriptional and
posttranscriptional levels. Dysregulation of miRNAs could directly induce or be
a consequence of oncogenic pathways. Chronic myeloid leukemia (CML) is
characterized by reduced miR-150 levels leading to an insufficient repression
of its target, oncogene MYB. CML treatment with imatinib normalizes miR-150
levels. Thus miR-150 is crucial for CML biology, however, little is known about
its upstream transcriptional regulation. MiR-150 is an inhibitor of oncogene
MYB, which is required for BCR-ABL1-dependent leukemogenesis in CML blast
crisis. Our recent work brought an evidence of mutual BCR-ABL1/MYC/miR-
150/MYB regulatory links in CML, sustained in CML resistant cells. We found
low levels of miR-150 to be a hallmark of CML and impaired signaling pathway
MYB/BCR-ABL1/MYC/miR-150/miR-155/PU.1 leading to a progressive cell dif-
ferentiation block. 
Aims: To delineate potential mechanisms of the miR-150 transcription regula-
tion via the oncogenic transcription factor MYC in CML.
Methods: Primary bone marrow cells from CML (N=28), CML cell lines K562
and KCL-22 and imatinib resistant (K562R, KCL-22R). Expression analysis:
RT-PCR. Protein levels: WB. ChIP: chromatin from the cell lines. SiRNA inhi-
bition: AMAXA electroporation. DNA methylation analysis: Methylated DNA
immunoprecipitation. 
Results: We observed that unlike MLL-AML diagnosis (Jiang et al. 2012), CML
is not characterized by a block of miR-150 maturation and that miR-150 levels
negatively correlated with MYC mRNA levels in CML HSPCs (p˂0.001). Role
of MYC in CML was further strengthen by imatinib induced MYC downregulation
and restored miR-150 levels in K562 and KCL22. Imatinib resistance in K562R
and KCL-22R was characterized by further miR-150 downregulation. To assess
the MYC role on regulating miR-150 levels we tested the MYC binding sites
upstream the miR-150 gene. We detected MYC binding to the upstream CpG
of the MIR150 gene in K562 and KCL-22. We also found a depletion of MYC
from the miR-150 locus after the imatinib treatment. We suggested potentially
synergistic route for imatinib-induced BCR-ABL1 inhibition. This could be
processed not only directly but also through an inhibition of a mutual positive
regulatory loop between MYC and BCR-ABL1 (Xie et al. 2002). We also noticed
MIR150-neighboring gene FCGRT (which is adjacent to the studied miR-150
CpG) to become activated by imatinib. We observed MYC levels dependent
regulation of both genes, but FCGRT is activated by MYC. This different MYC
regulatory role may be facilitated by the detected transcription factor CTCF
binding to an insulator site between miR-150 promoter and the CpG. An acti-
vation of the insulator via CTCF binding changes an interaction between
enhancers and promoters (Bell et al. 2000). CTCF was previously described to
be an inhibitor of MYC transcription and we show CTCF transcription to be
induced by imatinib. CTCF binding to DNA is prevented by DNA methylation.
We did not detect DNA methylation within MIR150 upstream region. 
Summary/Conclusions: A miR-150 transcription regulation involves transcrip-
tion factors-dependent epigenetic changes within the promoter and distal
enhancers. We outlined a new insight into MYC/MIR150/BCR-ABL1/imatinib
regulation loop in CML. Our work revealed a MYC role in miR-150 repression
underlying the CML leukemogenesis, where miR-150 functions as a pivotal
gatekeeper and its repression is probably required for CML establishment and
is enforced in imatinib resistant CML.
Support: LH15104 of MSMT and 00023736 of MZCR
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Background: Real-time reverse transcriptase quantitative PCR (RQ-PCR) for
BCR-ABL1 mRNA is widely used for the monitoring of chronic myeloid
leukaemia (CML). Pre-analytical factors, such as the rate of degradation of the
target mRNA, and methodological factors, such as the choice of control gene,
may influence the final result. In contrast the genomic DNA is stable, and the
number of copies of BCR-ABL1 DNA is directly proportional to the number of
CML cells. Measuring both DNA and RNA may enable us to understand the
contribution of expression and cell number to the RQ-PCR response.
Aims: To compare BCR-ABL1 DNA Q-PCR and routine RQ-PCR monitoring
of CML.
Methods: Fifty-nine newly diagnosed chronic phase CML patients from the
ALLG CML9 (TIDEL II) trial were included in this sub-study. Samples were test-
ed prior to commencing TKI treatment (baseline), at 1, 2, and 3 months, and
every 3 months to 24 months (total 568 samples). Since we wanted to compare
the sensitivity of the Q-PCR methods we selected 19 patients who had achieved
undetectable minimal residual disease (UMRD) by RQ-PCR within 24 months,
and an additional 40 patients unselected for response. RQ-PCR results were
expressed on the International Scale (IS), whereas DNA results were expressed
relative to the individual patient’s baseline. Quantification of BCR-ABL1 DNA
was performed using GUSB as the control gene by real-time Q-PCR (n=40) or
by digital PCR (dPCR, n=19) using the Fluidigm BioMark HD System. The
mean detection limit of RQ-PCR was 4.5-log, and 5.4-log for DNA methods.
Results: We first demonstrated that DNA dPCR and real-time Q-PCR gave
comparable results: 45 samples from 6 patients were quantified by both meth-
ods and logarithmically transformed. The mean bias was -0.15 (1.4-fold) with
95% limits of agreement ranging from -1.19 to 0.88. Subsequently, DNA and
mRNA values were compared in paired samples. The median BCR-ABL1IS at
baseline was 58% (range, 2.4% - 487%) versus 93% by DNA methods (range,
2.4% - 235%). Interestingly, BCR-ABL1 DNA was significantly higher than
mRNA at 1, 2, and 3 months (Figure). There was good agreement between
positive results from 6 months of TKI therapy onwards (mean bias -0.02; 95%
limits of agreement from -1.15 to 1.11). Comparing the limit of detection, BCR-
ABL1 DNA was detectable in 60/148 (41%) samples with undetectable mRNA
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(median 0.002%, range 0.0003-0.07%). Finally, 88% (15/17) of patients with
e14a2 transcripts achieved MMR by 12 months, in comparison with 63%
(20/32) of patients with e13a2 transcripts. BCR-ABL1 mRNA expression levels
were significantly lower in e13a2 patients than in e14a2 patients in all follow-
up samples analysed (ratio of BCR-ABL1 mRNA:DNA for e13a2 0.44 vs e14a2
0.57; p=0.016).
Figure 1.
Summary/Conclusions: In the first 1-3 months BCR-ABL1 mRNA fell more
rapidly than DNA, likely reflecting the time taken for normal haematopoietic
cells to recover. At later time-points there was good agreement between meth-
ods, indicating that later reduction in BCR-ABL1IS is closely related to depletion
of leukaemic cells. Normalised to BCR-ABL1 DNA the expression of e13a2
BCR-ABL1 mRNA was lower than that of e14a2, an observation that requires
confirmation. DNA methods were more sensitive: following the achievement of
UMRD by RQ-PCR patients could, on average, be monitored by DNA Q-PCR
for an additional 5 months.
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Background: Benchtop next generation sequencers are gradually replacing
Sanger sequencers in diagnostics labs because of greater throughput, better
sensitivity and increasing cost-effectiveness. In chronic myeloid leukemia
(CML) patients (pts) on tyrosine kinase inhibitor (TKI) therapy, BCR-ABL1
kinase domain (KD) mutation screening is a precious tool for timely and rational
therapeutic reassessment and is recommended in case of Failure and Warning.
A multicenter, multilaboratory prospective study (‘NEXT-IN-CML’) has been
conducted to assess the feasibility, cost, turnaround times and clinical utility of
a next generation amplicon deep sequencing (Deep Seq) strategy for routine
BCR-ABL1 KD mutation screening.
Aims: The first phase of the study was aimed to i) create a network of 4 labs
sharing a common protocol, a joint database for clinical and mutational data
storage and a common pipeline of data analysis, interpretation and reporting,
and ii) verify accuracy and inter-laboratory reproducibility of results. The second
phase of the study, involving 39 Italian Hematology Units, was meant to
prospectively assess the frequency of low burden mutations in CML pts with
Failure or Warning to any TKI.
Methods: In the first phase, centrally prepared identical batches of 32 blinded
samples (24 clinical samples with known mutation status/load as assessed by
Sanger Seq plus 8 T315I+ BaF3 cell line dilutions simulating mutation loads
between 20% and 1%) were distributed and analyzed in parallel by each of the
4 participating labs. In the second phase, 159 consecutive CML pts were
prospectively studied in parallel by Sanger Seq and by Deep Seq: 101 Failures
(57 pts on 1st-line TKI [IM, n=38; DAS, n=12; NIL, n=7] therapy; 35 pts on 2nd-
line TKI [DAS, n=14; NIL, n=17; IM, n=2; BOS, n=1; PON, n=1] therapy; 5 pts
on 3rd-line TKI [DAS, n=4; NIL, n=1] therapy and 4 pts on 4th-line TKI [BOS,
n=1; PON, n=3] therapy) and 58 Warnings (38 on 1st-line TKI [IM, n=28; DAS,
n=4; NIL, n=5; BOS, n=1] therapy and 20 on 2nd-line TKI [NIL, n=10; DAS,
n=9; PON, n=1] therapy).
Results: In the first phase, 504/512 amplicons were successfully generated
and sequenced, with a median number of forward and reverse reads of 1,757
(range 544-5,838). In the 128 samples analyzed, 51/52 expected mutations
were consistently detected by all 4 labs and quantitation of mutation load was
highly reproducible across a wide range of frequencies (2%>100%). Three out
of 4 labs failed to detect the 1% T315I+ dilution. In clinical samples, additional
low burden mutations <3% were occasionally called by one or two labs only,
suggesting that this value should be taken as a threshold below which mutation
detection is not reproducible and sequencing artifacts and errors cannot be
ruled out. In the second phase of the study, pts positive for mutations were
25/159 (16%; 23 Failures and 2 Warnings) by Sanger Seq and 52/159 (33%;
44 Failures and 8 Warnings) by Deep Seq. Among the pts with low burden
mutations detectable by Deep Seq, 4 had a T315I; 34 had other known TKI-
resistant mutations; 14 had only mutations with unknown clinical significance.
Pts positive for mutations by Deep Seq were more frequent in the High and
Intermediate Sokal risk group. The number of positive pts and the number of
mutations per pt were not significantly higher in those receiving 2nd- or subse-
quent-line TKI therapy than in those receiving 1st-line TKI therapy. Compound
mutations were found only in 2 out of 52 mutated pts (both in blastic phase).
Summary/Conclusions: 1) Results of the ‘NEXT-IN-CML’, the first prospective
study evaluating the routine diagnostic use of Deep Seq of BCR-ABL1, show
that this technology can successfully be implemented in national lab networks
and is feasible, robust and reproducible; 2) in a relatively large, nonselected
cohort of CML pts analyzed for mutations because of a Failure or Warning
response, Deep Seq confirmed that enhancing sensitivity enables to detect
BCR-ABL1 KD mutations in twice as many pts as compared to Sanger Seq
(33% vs 16%); 3) all the pts who need to be switched to another TKI would
benefit from sensitive BCR-ABL1 KD mutation screening by Deep Seq.
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Background: Cytopenia is a hallmark in myelodysplastic syndrome (MDS),
however, many patients with persistent cytopenia do not fulfill the criteria for
MDS. These patients are now classified as idiopathic cytopenia of undetermined
significance (ICUS) or if a mutation is detected as clonal cytopenia of undeter-
mined significance (CCUS). Little is known about these new entities in regards
to survival and prognostication. 
Aims: In this study we want to compare ICUS patients with MDS patients
having low- or very low-risk disease according to the IPSS-R. We also wanted
to investigate if sequencing of the cohort could bring additional information in
regards to overall survival. 
Methods: All patients underwent a bone marrow biopsy, cytogenetics and a
broad range of blood tests. Furthermore, all ICUS patients underwent a blinded
morphology review by two experienced pathologists; these review data will be
ready for presentation at EHA. ICUS was defined as persistent cytopenia for
more than six months, no chromosomal aberrations and common causes of
cytopenia were ruled out. The patients were sequenced with a targeted
sequencing panel, either using a customized Haloplex panel or a customized
sequencing panel for the Ion Torrent platform. We analyzed 20 genes which
are the most commonly mutated genes in MDS.
Results: So far we included 157 patients, 122 were classified as ICUS and 35
as MDS and the median age is 65 and 68 years, respectively (p=0.27). We
have sequenced 78% of the ICUS patients and 74% of the MDS patients. In
total 53% and 73% of the ICUS and MDS patients had at least one mutation
detected, respectively. If the patients carried a mutation, the median number of
mutations was two in both the CCUS and the MDS group. The most commonly
mutated genes were TET2, SRSF2, DNMT3A and ASXL1 in 38 patients (31%),
n=16 (13%), n=10 (8%), n=10 (8%), respectively. There were no significant dif-
ferences in the distribution between the two groups. Mutations in NRAS, KRAS,
TP53 were only identified in one patient each. The overall survival between the
ICUS and the low-risk MDS patients did not differ (p=0.18) (figure 1). We also
subdivided the ICUS patients into non-clonal ICUS and CCUS, but observed
no difference between these two groups (p=0.355).
Eight of the patients categorized as ICUS progressed to a myeloid neoplasm
during the follow up, and of these seven had a detectable mutation at time of
enrollment, only one ICUS patient without a detectable mutation progressed
(p=0.06).
Figure 1.
Summary/Conclusions: We here demonstrate that low-risk MDS and ICUS
patients share similar survival patterns, however, larger studies with longer fol-
low up are needed. Mutations are most commonly found in the epigenetic reg-
ulators in this cohort of ICUS and low-risk MDS, while mutations in classical
tumor suppressors and oncogenes such as TP53 and NRAS are rare. Muta-
tional screening seems promising in detecting patients at risk of progression,
however, other biomarkers for prognostication are warranted. 
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Background: Outcomes of pts with MDS after hypomethylating agent (HMA)
failure remain poor. Upregulation of PD-1, PD-L1 and CTLA-4 in MDS CD34+
cells after exposure and loss of response to HMA have been reported. Nivo
and Ipi are monoclonal antibodies targeting PD-1 and CTLA-4, respectively,
with clinical activity in solid tumors.
Aims: To evaluate the potential activity of immune checkpoint antibodies in
patients with previously treated or untreated MDS.
Methods: We designed a phase II study of Nivo or Ipi in monotherapy or com-
bination for pts with MDS. Pts with prior therapy with HMA were to be treated in
one of 3 consecutive cohorts: cohort #1: Nivo 3mg/kg iv days 1 and 15 of a 28
day cycle; cohort #2: Ipi 3mg/kg iv on day 1 of a 21 day cycle; cohort #3: Nivo
3mg/kg iv on days 1 and 15 + Ipi 3mg/kg iv on day 1 of a 28 day cycle. The
study design allowed for AZA add-back after 6 cycles of therapy if there was no
response or progression. Pts with previously untreated MDS were to be treated
in one of 3 consecutive cohorts combining AZA 75mg/m2 iv daily days 1-5 of a
28 day cycle with: cohort #4: Nivo 3mg/kg iv Days 6 and 20; cohort #5: Ipi 3mg/kg
iv on day 6; and cohort #6: Nivo 3mg/kg iv on days 6 and 20 + Ipi 3mg/kg iv on
day 6. The maximum size per cohort is 20 pts. The primary endpoint is to deter-
mine the safety of Nivo or Ipi as single agents or in combination with AZA. Sec-
ondary objectives included overall response rate (ORR) and assessment of bio-
logical activity. Responses were evaluated following the revised 2006 IWG cri-
teria. The study included stopping rules for response and toxicity.
Results: A total of 63 pts have been enrolled, 54 (86%) are evaluable for
response and toxicity including 21 treated with frontline AZA+Nivo, and 15 and
18 with Nivo or Ipi after HMA failure, respectively Median age is 69 years (range
39-85). The median number of treatment cycles was 3 (range 1-11). A total of
3 (27%) pts in the AZA+Nivo cohort, 6 (40%) in the Nivo cohort, and 3 (33%)
in the Ipi cohort having related grade ≥3 non-hematologic AEs. Therefore, the
stopping rule for toxicity was not met in any of the cohorts. Delays of therapy
due to AEs were required in 9 pts due to: rash (N=1), adrenal insufficiency
(N=1), colitis (N=1), thyroiditis (N=2), pneumonitis (N=3), and nephritis (N=1).
Early 8-week mortality occurred in 1 patient due to a non-related intracranial
hemorrhage. The ORR was 80% (13/21) in the AZA+Nivo cohort including 6
CR. The ORR was 0% and 30% (5/18) in the Nivo and Ipi arms, respectively.
Therefore, the stopping rule for response was met on the Nivo arm, and enroll-
ment after patient 15 was stopped. Immunophenotypic analysis of stem cell
and progenitor compartments was performed in 27 pts, including PD-1 and
PD-L1 expression analysis in 16 pts. Increased PD-1 and PD-L1 expression
on progenitor and stem cell compartments was observed in 3 and 4 pts, respec-
tively. Treatment with PD-1 inhibitors could not overcome the aberrant differen-
tiation patterns. No differences in response were observed based on PD-1
bone marrow expression.
Summary/Conclusions: Preliminary results indicate that PD-1 blockade with
Nivo in combination with AZA in untreated higher-risk MDS pts is associated
with a tolerable safety profile and clinical activity. Single-agent Ipi is capable of
inducing responses in previously treated MDS pts. Single-agent Nivo did not
show clinical activity. 
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ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH
ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC
SYNDROMES (MDS): EFFECTS IN TREATMENT NAÏVE AND
RELAPSED/REFRACTORY PATIENTS
S. Navada1,*, G. Garcia-Manero2, K. Hearn2, R. Odchimar-Reissig1, E. Demakos1,
P. Fenaux3, M. Petrone4, P. Zbyszewski4, S. Fruchtman4, L. Silverman1
1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York,
2MD Anderson Cancer Center, Houston, United States, 3Hôpital Saint-Louis
University, Paris, France, 4Onconova Therapeutics, Newtown, United States
Background: Azacitidine (AZA) is first line therapy for patients (pts) with higher
risk MDS and demonstrated efficacy in older pts with AML (Dombret et al, Blood
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2015; Fenaux et al, J Clin Oncol 2010). Rigosertib (RIG) interferes with the
RAS-binding domains of RAF kinases and inhibits the RAS-RAF-MEK and the
PI3Ks pathways. In vitro, the combination of RIG with AZA synergistically
inhibits growth and induces apoptosis of leukemic cells in a sequence-depen-
dent manner (Skidan et al, AACR 2006). RIG’s effective inhibition of human
hematopoietic tumor cell lines in vitro, favorable clinical adverse event (AE)
profile, and its synergy with AZA suggests the potential value of combination
treatment.
Aims: Phase I/II results are presented for pts with MDS, either hypomethylating
(HMA) treatment naïve or progressing on or failing to respond to prior HMA, and
those with AML (per WHO 2002 criteria) with relapsed or refractory disease.
Methods: Oral RIG was administered twice daily on Day 1-21 of a 28-day
cycle in escalating cohorts and then at the recommended Phase II dose (560mg
qAM and 280mg qPM). AZA 75mg/m2/d SC or IV was administered for 7 days
starting on Day 8. A CBC was performed weekly, and a bone marrow
aspirate/biopsy were performed at baseline, D29, and then every 8 weeks
thereafter. Response was determined by IWG criteria for MDS (2006) and AML
(2003). Stable disease in AML was defined as not meeting criteria for any other
treatment response (CR, CRi, PR, disease progression, or treatment failure).
Results: The combination of oral RIG and AZA was administered to 54 pts, of
whom 40 had MDS; HMA-treatment-naïve (N=23) and previously HMA-failed
pts (N=17). 17 MDS pts received prior HMA therapy: 12 AZA, 4 decitabine,
and 1 both. Ten pts had AML, and 6 had CMML. 2 MDS patients with 20-<30%
marrow blasts were also included in the AML analysis. Median age was 68
years; 67% of pts were male; and ECOG performance status was 0-1 in 95%
of pts. Pts have received 1-37+ cycles of treatment (median, 3.5 cycles), with
a median duration of treatment of 17 weeks (range 4 to 158+ weeks). Of the
10 pts with AML, 6 had relapsed AML, 2 secondary AML and 2 with AML trans-
formed from MDS. Eight pts were evaluable for response. There were 3
responses seen, for an ORR of 37.5%, with responses in both secondary and
refractory AML. Two additional pts had stable disease (25%). Responses were
durable, with the longest response approaching one year (Table 1). Among 33
evaluable MDS pts, overall response by IWG criteria was 76%: complete remis-
sion (CR) in 8 (24%), concurrent marrow CR (mCR) and hematologic improve-
ment (HI) in 10 (30%), mCR alone in 6 (18%), and HI alone in 1 (3%). Overall
response was 85% in HMA naïve pts and 62% in HMA resistant pts. Correlative
studies suggest that RIG has chromatin modifying effects in combination with
AZA which may overcome clinical AZA resistance (Chaurasia EHA 2017). Medi-
an duration of CR was 8 months for the combination. Median time to initial
response was 2 cycles, and median time to best response was 3 cycles. The
most frequently reported AEs were diarrhea (70%), nausea (50%), back pain
(40%), constipation (40%), fatigue (40%), and peripheral edema (40%).
Table 1.
Summary/Conclusions: The combination of oral RIG and standard-dose AZA
was well tolerated in repetitive cycles in pts with AML and MDS. Response
was observed both in HMA-treatment-naïve pts (85%) and in pts failing HMA
therapy (62%), suggesting the addition of RIG can overcome HMA clinical
resistance by acting as a chromatin modifying agent. In AML, responses were
seen in 37.5% of evaluable pts. Based on these results, continued study in
AML is warranted. A Phase III study of the combination of oral RIG and AZA in
pts with treatment naïve MDS is planned.
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IMPACT OF THE MUTATIONAL PROFILE AT THE TIME OF DIAGNOSIS IN
RESPONSE OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYN-
DROMESAND CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH
HYPOMETHYLATING AGENTS
G. Montalban-Bravo1,*, A. Alfonso1, K. Patel2, E. Jabbour1, C. Benton1,
T. Kadia1, F. Ravandi1, J. Cortes1, C. DiNardo1, N. Daver1, G. Borthakur1,
N. Pemmaraju1, M. Konopleva1, I. Ganan-Gomez1, G. Nogueras-Gonzalez3,
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Background: Hypomethylating agents (HMA) such as azacitidine and
decitabine remain the standard of care for the treatment of myelodysplastic
syndromes (MDS) however, loss of response to therapy is associated with
poor outcomes. Multiple studies have tried do identify biomarkers of response
but the impact of the mutational architecture present at the time of diagnosis
in response outcomes is unclear.
Aims: To evaluate the impact of the mutational architecture present at the time
of diagnosis in response outcomes is unclear.
Methods: We evaluated 222 previously untreated patients with MDS or CMML
that received HMA therapy at The University of Texas MD Anderson Cancer
Center. Next generation sequencing analyzing a panel of 28 genes was per-
formed prior to therapy with HMA. VAF estimates were used to evaluate clonal
and subclonal relationships within each individual sample with clonal hetero-
geneity being defined in cases with Pearson goodness-of-fit p-values <0.05.
Generalized linear models were used to study association of response rates
(ORR=overall and CR=complete) and risk factors. Response was defined fol-
lowing 2006 IWG criteria.
Results: A total of 143 patients (79%) had MDS and 43 (19%) had CMML,
including 108 (49%) with lower-risk based on IPSS and 114 (51%) with high-
er-risk disease. Therapy consisted in azacitidine monotherapy in 60 (27%)
patients, decitabine monotherapy in 57 (26%), guadecitabine in 46 (21) and
combinations in 59 (27%). The ORR was 61% (135/222) with 80 (36%)
patients achieving CR. A total of 161 (73%) patients had at least one detectable
mutation. Median number of mutations was 1 (range 0-5). Frequencies of
detected mutations are shown in Figure 1A. Among 70 (32%) patients evalu-
able for clonal heterogeneity testing, 38 (55%) where clonally heterogeneous
and carried at least 1 subclone. Pairwise associations of mutations revealed
distinct and significant co-mutation patterns (Figure 1B). Within these co-
mutation associations, there were no clear hierarchical patterns of clonality in
patients evaluable for clonal heterogeneity, as indicated in Figure 1B. By uni-
variate analysis, presence of mutations in ASXL1 (OR 0.45, CI 0.22-0.93,
p=0.03) and RUNX1 (0.44, CI 0.20-0.96, p=0.038) as well as that of TP53
mutations with VAF ≥0.31 (OR 0.21, CI 0.05-0.8, p=0.024) predicted for a
lower likelihood of response. Analysis of functional pathways revealed that
patients with mutations in chromatin (OR 0.43, CI 0.21-0.86, p=0.017) and
signaling genes (OR 0.48, CI 0.23-1.00, p=0.049) had lower likelihood of
achieving response. Additionally, patients with ASXL1 mutations (OR 0.24,
CI 0.09-0.64, p=0.005), particularly in the absence of co-occurring TET2, as
well as those with increased number of mutations, particularly if more than 3
(OR 0.21, CI 0.06-0.73, p=0.014), or signaling gene mutations (OR 0.32, CI
0.13-0.80, p=0.015), had a lower likelihood of achieving a CR. A longer time
to response was observed in patients with DNMT3A mutations with VAF ≥0.35
(3.4 vs 1 months, OR 0.22, CI 0.06-0.76, p=0.017). Among patients who
achieved CR, presence of 3 or more mutations (2.6 vs 1.3 months, OR 1.35,
CI 1.00-1.83, p=0.049) and TP53 mutations with VAF ≥0.31 (0 vs 3.7 months,
OR 2.03, CI 1.03-3.98, p=0.040) predicted for shorter CR duration. Presence
of clonal heterogeneity, as well as the identified pairwise co-mutation patterns
did not predict for any of the response outcomes.
Figure 1.
Summary/Conclusions: The type, number and burden of mutations at the
time of diagnosis may predict response to therapy with HMA in patients with
MDS and CMML.
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STUDY OF THE EFFECT OF MIRNAS TARGETING RPS14 ON CELLULAR
BIOLOGICAL BEHAVIOR OF MYELODYSPLASTIC SYNDROMES
Y. Nie1,*, B. Xiong1, X. Zuo1, S. Wang2
1Zhongnan Hospital of Wuhan University, Wuhan, 2Institute of Hematology &
Blood Disease Hospital, CAMS & PUMC, Tianjin, China
Background: As key factors in gene post-transcriptional regulation, microR-
NAs(miRNAs) have been identified to play important roles in carcinogenesis in
various tumors. Myelodysplastic syndrome(MDS) is a group of clonal myeloid
disorders characterized by refractory quantitative and qualitative abnormalities
of hemocytes and its pathogenesis is poorly understood. Some studies have
showed that abnormal expressions of some miRNAs have close relationship
with the pathogenesis of MDS. Recently, low RPS14 expression is found com-
mon in all kinds of myelodysplastic syndromes including patients without 5q
deletion, but its mechanism remains unclear. 
Aims: To determine the cause of RPS14 reduction in MDS except 5q- syn-
drome, influence of miRNAs on RPS14 expression was analyzed, and the role
of specific miRNA on proliferation, differentiation and apoptosis of hematopoietic
stem cells were evaluated. This research will help reveal the pathogenesis of
MDS from a new angle and provide new ideas for the diagnosis, treatment and
prognosis evaluation of MDS.
Methods: Firstly, we predicted that miR-223 may target 3’UTR of RPS14 by
bioinformatics software, then verified if the special miRNA could target RPS14
by assay of luciferase activity. Secondly, the mRNA expression level of miR223
were detected in the bone marrow BM selected from 28 MDS patients including
ten RCUD patients, ten RCMD patients, four RAEB-1 patients and four RAEB-
2 patients, meanwhile, the miR223 expression status were tested in four kinds
cell lines including SKM-1, HL-60,K562 and THP-1 cell lines through qRT-PCR
and RPS14 expression was detected by means of immunofluorescence(IF).
Thirdly, constructing lentivirus which carried miR223 overexpression vector and
inhibitor were infected to the SKM-1 cell line and k562 cell line which had the
highest level of RPS14, then apoptotic analysis was detected by flow cytometry
method and proliferation was tested by CCK-8 assay. Fourthly, hemin (50μM,)
was used to induce erythroid differentiation of K562 cells which carried miR223
overexpression We used flow cytometry method CD71 and CD235a makers
and qRT-PCR(CD235 and r-globin) to detect the erythroid proliferation.
Results: 1.We verified miR223 could target RPS14 by assay of luciferase activ-
ity. 2.MDS patients had higher miR-223 expression compared with health con-
trols especially the types of RAEB-1 and RAEB-2 (P0.05). In MDS patients,
RAEB patients expressed higher level of miR223 than other types of
MDS.Meanwhile, in cell lines, K562 cell line showed the highest level of RPS14
and lowest level of miR223. 3. Infecting miR223 overexpression lentivirus could
promote cell proliferation and inhibit cell apoptosis while infecting miR223
inhibitor lentivirus had the opposite effect in SKM-1 and K562 cell lines. 4. We
found that forced expression of miR-223 suppresses commitment of r-globin,
CD235a and CD71 labeling, in contrast, underexpression of miR-223 promoted
terminal erythropoiesis in K562 cell line.
Figure 1.
Summary/Conclusions: MDS patients had higher miR-223 expression com-
pared with health controls. We demonstrated that miR223 could promote cell
proliferation, inhibit cell apoptosis and suppress terminal erythropoiesis through
target RPS14.
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SERIAL SEQUENCING REVEALS CLONAL ORIGINS AND STRATEGIES
FOR EARLY DETECTION OF POST-ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HCT) RELAPSE IN ACUTE MYELOID
LEUKEMIA (AML)
T. Kim1,2,*, J.-S. Ahn3,4, M. Tyndel2,5, H.-J. Kim3,6, Y.-K. Kim3,6, S.-S. Lee3,6,
S.-Y. Ahn3,6, S.-H. Jung3,6, D.-H. Yang3, J.-J. Lee3,6, S. H. Choi6, J.-Y. Lee6,
M.-G. Shin7, H. Kook8, S.-K. Park9, S. H. Kim10,11, Z. Zhang12,12, D.D.H. Kim13
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University of Toronto, Toronto, Canada, 6Genomic Research Center for
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of Pediatrics, Chonnam National University Hwasun Hospital, Hwasun, 9Depart-
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Background: Clinical applications of next generation sequencing (NGS) in allo-
geneic hematopoietic stem cell transplantation are a topic of interest. Mutation
dynamics post-HCT using longitudinal NGS have not been thoroughly examined.
We hypothesized that serial sequencing of pre-HCT and post-HCT in AML
patients could provide a much deeper and broader understanding of clonal ori-
gin/hierarchy of relapse after allogeneic HCT. The present study aimed to evaluate
mutation dynamics in AML using serial samples from pre- and post-HCT with
respect to transplant outcomes, particularly overall survival (OS) and relapse.
Aims: To track origins of post-HCT relapse in AML using serial sequencing 
Methods: 88 AML patients were enrolled and sequenced using an Illumina
HiSeq 2000 sequencer (84 myeloid custom gene panel) on 419 bone marrow
samples at diagnosis (n=88), pre-HCT (n=88), 21 days after HCT (n=88), and
at relapse (n=20). Two patients relapsed by day 21. T-cell (n=80) and donor
samples (n=57) were also sequenced. All computational and statistical analyses
were performed using Python and R.
Figure 1.
Results: The mean on-target coverage in 419 samples was 1773.7x. In total,
we detected 217 mutations throughout the course of treatment in 79/88 patients
(89.8%). NPM1 (26.1%), DNMT3A (26.1%), CEBPA (13.6%), IDH2 (13.6%),
FLT3 (12.5%), and PTPN11 (11.4%) were commonly mutated at diagnosis.
Unsurprisingly, most mutations appeared at initial diagnosis (200/217, 92.1%).
Only 1, 2, and 14 mutations were acquired/selected at pre-HCT (0.5%), day 21
(0.9%), and relapse (6.5%), respectively. Most mutations were cleared at pre-
HCT (mean mutation allele frequency (VAF) from 27.4% to 2.9%) and were
further reduced after HCT (mean VAF from 2.9% to 0.7%) (Fig A). Leveraging
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serial samples, we inferred the clonal relationships between original and
relapse samples in 20 patients (Fig B). Mutations from initial diagnosis re-
appeared in 17 patients. The relapse clone of 13 patients was identical to or
clonally evolved from the initial AML clone (7 and 6 patients, respectively).
Relapse clones of 4 patients evolved from an inferred ancestral clone, distinct
from the initial AML clone. The remaining 3 patients’ relapse clones appear to
be genetically distinct from the initial AML clone (Fig B). Among 61 mutations
from relapsed patients, 37 were stable, whereas 9 were cleared and 15
acquired (or selected) at relapse. Overall, serial samples and donor samples
de-convoluted origins of relapse clone from all 20 patients. Among the 13
patients whose donor samples were sequenced, no mutation that was trans-
ferred from donor to recipient expanded at relapse. We then assessed whether
the mutation status at pre- and post-HCT has any impact on OS and relapse
after HCT. With a follow-up duration of 6.9 years, patients with VAF ≥0.2% at
day 21 in any gene showed worse OS (HR 2.9, p=0.006) as well as increased
risk of relapse (HR 5.3, p=0.0003) (Fig C-D). Multivariate analyses verified
that VAF ≥0.2% at day 21 was a prognostic factor independent of age and
cytogenetics risk group for OS (HR 3.2, p=0.003). Non-relapse mortality did
not show significant difference (p=0.3). Thirteen patients carried 20 mutations
at day 21 (≥0.2%), 16 of which originated from the initial AML clone. Noticeably,
9 of these mutations (from 9 patients) were in DNMT3A, where one of them
was a transferred mutation from the donor through HCT (donor VAF: 8.18%,
VAF at day 21: 3.42%, non-relapse case). Mutation status at any other time
points in any gene, defined with a hard cut-off (VAF >2%), was neither signifi-
cantly associated with overall survival nor relapse incidence after HCT.
Summary/Conclusions: This study revealed origins of mutations detected at
post-HCT relapse. It also revealed that the presence of mutations immediately
after HCT, within 21 days, with low VAF (0.2%) can be used to predict relapse
after HCT, illustrating the value of longitudinal NGS-based monitoring strategies
for AML patients after allogeneic HCT. 
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IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER
FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A
MULTICENTER OPEN-LABEL PHASE 2 STUDY
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Background: There are no approved therapies for chronic GVHD (cGVHD)
after failure of steroids. Both B and T cells play a role in the pathophysiology
of cGVHD. In preclinical models, ibrutinib (ibr) reduced the severity of cGVHD
through inhibition of Bruton’s tyrosine kinase (BTK) and interleukin-2–inducible
T-cell kinase (ITK). 
Aims: This phase 2 study evaluated the efficacy and safety of ibr in patients
(pts) with steroid dependent/refractory cGVHD in need of additional therapy. 
Methods: Eligible pts had ≤3 prior regimens for cGVHD and either >25% body
surface area erythematous rash or a NIH mouth score >4. Informed consent
was obtained from all pts. Pts were treated with ibr 420mg/d until cGVHD pro-
gression or unacceptable toxicity. The primary end point was cGVHD response
based on 2005 NIH consensus response criteria. Secondary end points includ-
ed rate of sustained response, change in Lee cGVHD symptom scale, change
in steroid dose over time, and safety. The pharmacodynamics (PD) of ibr and
its effects on biomarkers associated with GHVD, inflammation, and fibrosis
were evaluated. 
Results: A recommended phase 2 dose of 420mg was identified in phase 1b
(n=6). For 42 pts in phase 2, the median number of prior cGVHD regimens
was 2 (range, 1–3). At a median follow-up of 13.9 mo, overall response rate
(ORR) was 67% (CR, 21%), with 71% of responders showing a sustained
response of ≥20 weeks; 79% responded by the first response assessment.
Median steroid dose decreased in responders from 0.29mg/kg/d at baseline to
0.12mg/kg/d at week 49. Overall, 62% of pts achieved steroid doses
<0.15mg/kg/d while on ibr; 5 responders discontinued steroids. Organs with
cGVHD involvement including skin, mouth, and gastrointestinal system showed
similar responses (~90%). Of 25 responders with ≥2 involved organs, 20 (80%)
showed a response in ≥2 organs. Improvement in Lee cGVHD symptom score
was reported for 43% of responders by month 6 and 61% overall, compared
with 11% of nonresponders by month 6 and overall. Ibr blocked BTK-driven
basophil activation in an ex vivo IgE stimulation assay and ITK-mediated acti-
vation of PLCγ1-Y783 in CD4 T-cells. Analysis of soluble plasma factors asso-
ciated with inflammation, fibrosis, and cGVHD from all treated pts showed a
significant decrease over time with ibr. Adverse events (AEs) were largely grade
1 or 2 events; AEs occurring in ≥20% of pts were fatigue, diarrhea, muscle
spasms, nausea, and bruising. Grade ≥3 AEs occurring in ≥10% of pts were
pneumonia, fatigue, and diarrhea. Serious AEs (SAEs) occurred in 52% of pts;
grade ≥3 SAEs were reported in 40% of pts and included pneumonia, septic
shock, and pyrexia. Two fatal events (multilobular pneumonia and bronchopul-
monary aspergillosis) were reported. Fourteen pts discontinued ibr for AEs, 5
pts for progressive cGVHD, and 2 pts after resolution of cGVHD symptoms;
29% continued ibr.
Summary/Conclusions: With an ORR of 67% and a sustained response rate
of ≥20 weeks of 71%, treatment with ibr resulted in clinically meaningful and
durable responses in pts who failed at least 1 prior treatment for cGVHD. Most
responders were able to reduce steroid dose. PD and biomarker changes sup-
port a beneficial effect of ibr on immune cell subsets in pts with cGVHD. The
safety profile was consistent with those previously reported for pts with B cell
malignancies and those seen in cGVHD pts on concomitant steroids. Respons-
es in this pretreated, high-risk population support study of ibr for frontline treat-
ment of cGVHD.
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Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is
the standard of care for patients (pts) with intermediate (int-AML) or high-risk
AML. In pts lacking matched sibling (MSD), HSCT from haploidentical donors
(HAPLO) is an emerging option
Aims: The aim of the study was to compare outcomes of non T cell-depleted
HAPLO HSCT to those from MSD
Methods: Included were adults with AML in first CR undergoing transplantation
from HAPLO vs MSD from 2007-2015. Due to significant interaction between
karyotype and donor type, int- and high-risk AML were studied separately. In
addition because of some characteristic differences between the 2 groups the
propensity score technique was used: 2 MSD were matched with each haplo.
The following factors were included in the propensity score model: patient,
year of HSCT, time from diagnosis to HSCT, conditioning (RIC), source of stem
cells (BM/PB), cytogenetic group, patient and donor CMV serology status
Results: We identified 2654 pts (HAPLO=185; MSD=2469) for int-AML (HAP-
LO=122; MSD=1888) or high risk-AML (HAPLO=63; MSD=581). Median follow
up was 30 (1-116) months. Median age at HSCT was 50 (18-74)years. Among
HAPLO recipients, 74% received PTCY and 26% ATG. Conditioning regimen
was myeloablative in 50% vs 52% (p=0.52) of HAPLO and MSD pts, respec-
tively. HAPLO pts had a longer interval from diagnosis to HSCT (6 vs 4 months;
p<0.01), had more often high risk-AML (34% vs 23%; p<0.01), bone marrow
as stem cell source (49% vs 19%; p<0.01) and CMV positive donors (72% vs
61%; p<0.01). Graft failure occurred more frequently after HAPLO (3% vs 1%;
p=0.002).For pts with int-AML CI of aGVHD and cGVHD was 29% vs 20%
(p<0.03) and 30% vs 36% (p<0.02) in HAPLO and MSD pts, respectively. At
two years, NRM and RI were 26% vs 10% (p<0.01) and 17% vs 20% (p=0.52)
while LFS and OS were 56% vs 70% (p<0.01) and 68% vs 79% (p<0.01) in
HAPLO and MSD pts, and GRFS was 45% vs 53% (p<0.05), respectively. In
multivariate analysis HAPLO was associated with reduced LFS (HR 1.74; 95%
CI 1.30-2.33; p<0.01), OS (HR 1.80; 95% CI 1.32-2.45; p<0.01) and GRFS
(HR 1.32; 95% CI 1.01-1.72; p<0.05) and higher NRM (HR 3.03; 95% CI 1.98-
4.62; p<0.01). Incremental age was independently associated to lower LFS,
OS, GRFS and higher NRM and cGVHD. MAC was associated with lower RI
and higher GVHD. A female donor into male recipient was associated to higher
GHVD and lower GRFS. A longer interval from diagnosis to HSCT was asso-
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ciated to lower LFS. Donor CMV seropositivity was associated with lower GRFS
and higher NRM and aGVHD. In high risk-AML aGVHD and cGVHD were 36%
vs 24% (p=0.03) and 39% vs 33% (p=0.80) for HAPLO and MSD pts, respec-
tively. At two years, NRM and RI were 18% vs 10% (p=0.16) and 21% vs 36%
(p<0.02) while LFS and OS were 61% vs 55% (p=0.14) and 67% vs 66%
(p=0.26) in HAPLO and MSD pts; GRFS was 49% vs 40% (p=0.17). In multi-
variate analysis risk of grade II-IV aGVHD (HR: 2.20; 95% CI: 1.29-3.74;
p<0.01) was increased after Haplo as compared to MSD and no difference was
observed in LFS, OS and GRFS, respectively. Conditioning regimen was asso-
ciated with lower NRM and higher GRFS, while younger age and donor CMV
status were associated with lower RI, higher LFS and OS. Results were con-
firmed in the analysis done with the the propensity score technique as for RI,
NRM, LFS, OS and GRFS
Summary/Conclusions: As per our registry based study in intermediate risk
AML results of HSCT from matched sibling donor are superior to those of HAP-
LO-HSCT, while in high risk-AML relapse is lower in the HAPLO transplants
and NRM, LFS and OS is similar
S494
INDIVIDUAL OUTCOME PREDICTION FOR MDS AND SECONDARY AML
AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
BASED ON GENETIC, PATIENT- AND TRANSPLANTATION-ASSOCIATED
RISK FACTORS
M. Heuser1,*, R. Gabdoulline1, P. Loeffeld1, V. Dobbernack1, H. Kreimeyer1,
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B. Schlegelberger1, G. Göhring1, H.-H. Kreipe1, U. Germing3, A. Ganser1,
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Background: Prediction of individual outcomes after allogeneic hematopoietic
cell transplantation (alloHCT) is difficult, as it is influenced by a multitude of
risk factors.
Aims: To develop a tool that predicts individual outcomes of patients with
myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia from
MDS (sAML) after alloHCT.
Methods: We integrated molecular data with available prognostic factors in
patients undergoing alloHCT for MDS and sAML to evaluate their impact on
prognosis. 304 patients with MDS or sAML who underwent alloHCT were
sequenced for mutations in 54 genes. We used a Cox multivariate model and
competing risk analysis with internal and cross validation to identify factors
prognostic of overall survival (OS), cumulative incidence of relapse (CIR) and
non-relapse mortality (NRM).
Figure 1.
Results: In multivariate analysis, mutated NRAS, U2AF1, IDH2, TP53 and/or a
complex karyotype were significant prognostic markers for OS besides age
above 60 years, remission status treated but not in CR, IPSS-R cytogenetic
risk, HCT-CI >2 and female donor sex. Mutated NRAS, IDH1, EZH2 and TP53
and/or a complex karyotype were genetic aberrations with prognostic impact on
CIR. No molecular markers were associated with the risk of NRM. The addition
of molecular information significantly improved the risk prediction for OS and
CIR as assessed by the Akaike information criterion. Internal and cross validation
confirmed the robustness of our comprehensive risk model. We developed an
interactive risk prediction tool to provide personalized predictions for OS, CIR
and NRM outcome after alloHCT. An individualized prediction for a 53-year-old
male with sAML with trisomy 11, mutated NRAS, IDH2 and DNMT3A and com-
plete remission after double induction is shown in Figure 1. The probability of
CIR at 2 years was 45% and the patient relapsed after 0.61 years. The probability
of OS at 2 years was 41% and the patient died after 0.88 years.
Summary/Conclusions: We combine molecular, cytogenetic, patient- and trans-
plantation associated risk factors into a comprehensive risk score to provide per-
sonalized predictions for outcome after alloHCT. Upon validation in larger patient
cohorts, this will improve patient information before alloHCT and provide a plat-
form to improve treatment strategies for patients with high risk of CIR or NRM.
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IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS
GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE
(BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ΑLPHA-BETA
T-CELL DEPLETED HAPLO-HSCT
P. Merli1,*, A. Bertaina1, F. Galaverna1, M. Algeri1, D. Pagliara1, G. Li Pira1,
J. Weinberg2, A. Moseley2, F. Locatelli1
1Ospedale Pediatrico Bambino Gesu, Rome, Italy, 2Bellicum Pharmaceuticals
Inc., Houston, United States
Background: HLA-haploidentical allogeneic hematopoietic stem cell transplant
(haplo-HSCT) offers an option for children with acute leukemia in need of a
transplant and lacking an available HLA-identical donor. However, performing
haploidentical-HSCT without any graft manipulation has historically been asso-
ciated with a high risk of acute and chronic graft-versus-host disease (GVHD).
T cell depletion reduces the risk of GVHD, but leads to delayed immune recon-
stitution, predisposing to serious infection and leukemia relapse due to the lack
of a T-cell mediated graft-versus-leukemia (GvL). To address these challenges,
we have infused mature BPX-501 T cells (donor peripheral lymphocytes which
have been modified with the iCasp9 suicide gene) after αβ T-cell depleted haplo
HSCT to facilitate immune reconstitution and GvL effect. BPX-501 T-cells are
genetically modified with the iCasp9 suicide safety switch and a truncated CD19
marker. In the event of GvHD, the switch is activated by an infusion of the drug
rimiducid (AP1903) resulting in rapid T cell apoptosis and GvHD reversal.
CD3+/CD19+ T-cells can be tracked by flow cytometry.
Aims: This study was performed to evaluate both safety and efficacy of BPX-
501 T cell infusion post αβ T-cell depleted haplo HSCT in pediatric patients
with high risk ALL and AML in CR1 and CR2. 
Methods: : A prospective Phase I-II study enrolling children with hematopoietic
disorder who lack a matched donor. 38 patients have been enrolled and treated
with αβ TCR depleted haplo HSCT after a myeloablative preparative regimen
followed by BPX-T cell infusion to date; of them, 24 had ALL and 14 AML (21%
CR1, 79% CR2). Median follow-up is 11 months (range 3-24).
Results: All patients engrafted and no secondary graft failure was recorded.
Median time to neutrophil and platelet recovery was 16 days (range 8-33) and
11 days (range 7-19), respectively. With a median follow-up of 11 months (range
3-24 months), the cumulative incidence of NRM and relapse was 3.7% and
12.0%, respectively, while the disease-free survival probability was 84.2% (Fig
1). All aGVHD resolved (5 Grade I skin, 5 Grade II skin, 2 Grade III GI). One
child received rimiducid to treat steroid-resistant grade II skin with complete
resolution in 24 hours (Fig 2). There were 3 cases of chronic GvHD, 2 were
mild; 1 severe and fatal in a patient whose donor had VZV reactivation during
mobilization. CD3+ T cells reached 500 cells/μl by day 90, with normalized
CD4/CD8 T cell ratio by day 180.
Figures.
Summary/Conclusions: Engraftment was brisk and T cell recovery normalized
by 6 months. Overall incidence of severe aGVHD was low and the safety switch
was successfully activated with rimiducid infusion. Cumulative incidence of
NRM compares favorably to historic controls at the lead center, where a value
of of 2.4% for matched related donors (MR), 11.8% for matched unrelated
donors (MUD) and 5% for αβ T cell depletion haplo HSCT (Haplo αβ) without
BPX-501 infusion was recorded (Bertaina, 2015 ASH). The cumulative inci-
dence of relapse was 12.0% for BPX-501, 32.3% for MR, 22.2% for MUDs and
21.9% Haplo-αβ. Disease-free survival in the BPX-501 treated patients was
84.2% compared to 65.4% for MR, 66.1% for MUDs and 73.1% for Haplo-αβ.
However, length of follow-up on the control cohorts differed from that of BPX-
501 treated patients. These data suggest that BPX-501 T cells modified with
the iCasp9 safety switch, infused after selective αβ T-cell depletion, are safe
and result in a rapid immune reconstitution and a potentially stronger GvL effect
in children with high-risk leukemia who lack a matched donor.
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HEREDITARY HEMATOLOGIC MALIGNANCIES: GENETIC COUNSELING
IMPLEMENTATION IN A LARGE LEUKEMIA CENTER
C. Dinardo1,*, S. Bannon2, K. Takahashi1, C. Benton1, M. Routbort3,
N. Pemmaraju1, N. Daver1, T. Kadia1, G. Garcia-Manero1, K. Patel3, H. Kantarjian1,
A. Futreal4
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Background: Hematologic malignancies have rarely been targets for genetic
evaluation, even in familial cases. Over the past decade, more than 12 genes
have been identified to cause inherited predispositions to hematologic malig-
nancies. Genetic counseling, testing, and surveillance protocols for these fam-
ilies are not well-established. Additionally, many families with high incidence of
blood cancers do not have described syndromes suggesting additional genes
remain to be identified.
Aims: To identify individuals with inherited susceptibilities to hematologic malig-
nancies, the Hereditary Hematologic Malignancy Clinic (HHMC) was established
in April 2014 at The University of Texas M. D. Anderson Cancer Center. The
clinic provides genetic counseling, clinical and research testing for patients with
hematologic malignancies suspected to have inherited predisposition syndromes.
Methods: Individuals were referred to the HHMC for several indications: (1)
bone marrow failure/aplastic anemia/hypocellular MDS, (2) personal history of
hematologic malignancy with ≥1 first-degree relative or ≥2 second-degree rel-
atives with hematologic malignancy, (3) personal history of multiple primary
cancers, (4) germline evaluation of presumed somatic mutations identified on
next-generation leukemia prognostication panels, (5) management and/or sur-
veillance of a previously-identified genetic syndrome, or (6) solid tumor hered-
itary syndrome evaluation in patients with active hematologic malignancy. Over
the past 3 years, 152 probands were evaluated (n=152). Skin biopsies were
performed to obtain germline DNA, and next-generation sequencing approach-
es on both a clinical and research basis were utilized.
Results: Clinical genetic testing was performed in 97/152 individuals (64%).
Research testing was performed in 46/152 (30%), particularly in patients neg-
ative for known susceptibility genes or without features suggestive of a clinical
syndrome. Nine (6%) individuals did not undergo genetic testing. Clinical testing
identified 23/97 (24%) individuals with a germline susceptibility to hematologic
malignancy. Seven probands (7%) were identified to have RUNX1 mutations
associated with familial platelet disorder with myeloid malignancy (FPD-AML).
Six (6%) were identified to have the telomere disorder dyskeratosis congenita;
only one of them met clinical diagnostic criteria with the “classic triad” of symp-
toms. Three (3%) patients were identified to have Li-Fraumeni syndrome due
to constitutional TP53 mutations. Two adults (2%) were diagnosed with Dia-
mond-Blackfan anemia; both of these individuals developed adult-onset
myelodysplastic syndrome after a long latency period and prior spontaneous
remission of their childhood anemia. Two young adults (2%) with Fanconi ane-
mia were diagnosed, and one patient each with DDX41 mutation and CBL (Noo-
nan-like syndrome with JMML) were identified. Counseling, testing, and sur-
veillance of identified mutation carriers in many affected families is ongoing.
Summary/Conclusions: Individuals with hereditary susceptibilities to hema-
tologic malignancies are not as rare as previously thought. Clinical evaluation
of these patients through genetic counseling and testing is high yield for iden-
tified at-risk families. Research-based sequencing for novel mutations is indi-
cated and ongoing.
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SECONDARY LEUKEMIAS IN GENETIC SUBTYPES OF CONGENITAL
NEUTROPENIA (ELANE, HAX1, WASP, G6PC3, ETC.): A LONG-TERM
ANALYSIS OF THE SCNIR EUROPE
C. Zeidler1,*, M. Klimiankou2, A. Nickel1, S. Mellor-Heineke1, J. Skokowa2,
K. Welte3
1SCNIR, Medical School Hannover, Hannover, 2Department of Hematology,
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atric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany
Background: Leukemia predisposition is well known in congenital neutropenia
(CN) subtypes. By taking all patients with known and unclassified CN together
the incidence of secondary leukemia accounts for more than 10 percent.
Advanced molecular diagnostics and the identification of inherited and acquired
gene mutations have improved our understanding of leukemic transformation
in CN patients.
Aims: In the European SCNIR 449 patients with congenital neutropenia and
91 patients with cyclic neutropenia (CyN) have been enrolled since 1994. These
449 patients can be differentiated by causative gene mutation in more than 10
genetic subtypes: ELANE, HAX1, G6PT, G6PC3, WAS, SBDS, TAZ1 and p14
or no identified mutation, respectively. Our aim is to assess the risk of leukemic
transformation within these genetic subgroups.
Methods: Here we report the leukemia incidence of genetic subtypes analyzing
all available long-term data from the European Branch of the Severe Chronic
Neutropenia Registry (SCNIR). In addition, we analyzed 91 patients with CyN
with or without ELANE mutations.
Results: Results from genetic testing were available for 314 of 449 CN patients,
of whom 118 patients revealed ELANE, 48 HAX1, 71 SBDS, 28 G6PT, 9
G6PC3, 7 WAS, 5 TAZ1 mutations and 27 other rare gene mutations (e.g. p14,
CXCR4). 135 patients remain unclassified. In addition, 48 of 91 patients with
CyN revealed ELANE mutations. Secondary myelodysplastic syndrome (MDS)
or leukemia occurred in 49 of the 449 CN patients and in 1 of the 48 ELANE-
CyN patients. Acquired CSF3R nonsense truncating mutations have been
detected in the bone marrow cells of about 80% of CN patients who progress
to MDS or acute myeloid leukemia (AML) and around 30-35% of non-leukemic
CN patients, supporting the association between the acquisition of CSF3R
mutations and leukemic transformation. These mutations have been shown to
be acquired in hematopoietic cells only and therefore are not the primary cause
of CN. The time between first detection of CSF3R mutations and signs of malig-
nant transformation is highly variable. Some patients progressed to MDS/AML
within a few months. In others, CSF3R mutant clones persisted for many years
without progression to leukemia. The distribution by genetic subtypes and the
frequency of CSF3R mutations is shown in the table below:
Table 1.
*Gene mutations without leukemia :(G6PC3 n=9, TAZ1 n=5, p14 n=4, digenic mutations n=4,
COH1 n=4, CXCR4 n=3, germline extracellular CSF3R n=2, C16ORF57 n=2, Pearson syndrome
n=2, LYST n=1)
All subgroups benefit from G-CSF treatment. However, patients requiring main-
tenance doses of G-CSF above 8µg/kg/day are at greater risk of leukemic
transformation.
Summary/Conclusions: Conclusion: The incidence of secondary AML reflects
the genetic heterogeneity of CN.
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EFFECT OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLO-
BINURIA (PNH) PATIENTS WITH OR WITHOUT HIGH DISEASE ACTIVITY:
RESULTS FROM THE INTERNATIONAL PNH REGISTRY
B. Höchsmann1,*, F. Sicre de Fontbrune2, J.W. Lee3, A. Kulagin4, P. Hillmen5,
A. Wilson6, J. Marantz6, H. Schrezenmeier1
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4Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russ-
ian Federation, 5St. James’s University Hospital, Leeds, United Kingdom, 6Alex-
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Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progres-
sive, life-threatening disease caused by somatic phosphatidylinositol glycan
class A (PIGA) gene mutation in bone marrow stem cells. The International
PNH Registry (NCT01374360) is a prospective, multinational, observational
study to record the natural history of PNH and collect data on long-term efficacy
and safety of treatment with eculizumab (ecu), a humanized monoclonal anti-
body approved for treatment of PNH.
Aims: Evaluate the effect of ecu in patients with PNH with or without high dis-
ease activity (HDA).
Methods: Patients enrolled in the Registry as of December 5, 2016, were strat-
ified by HDA and ecu treatment status into 4 groups: HDA/ecu-treated;
HDA/never ecu-treated; no-HDA/ecu-treated; no-HDA/never ecu-treated. HDA
is defined as lactate dehydrogenase (LDH) ratio ≥1.5x upper limit of normal
within 6 months of baseline and history of any of the following: fatigue, hemo-
globinuria, abdominal pain, dyspnea, anemia (hemoglobin <100 g/L), major
adverse vascular event (MAVE; including thromboembolism [TE]), dysphagia,
or erectile dysfunction. Patients were assessed at baseline (date of enrollment
in never ecu-treated patients; date of initiation of ecu in ecu-treated patients)
and at last follow-up. Outcomes include changes from baseline to last follow-
up in LDH ratio, GPI-deficient granulocytes, red blood cell transfusions
received, MAVE, and Functional Assessment of Chronic Illness Therapy (FAC-
IT)-Fatigue score in patients with at least 6 months of follow-up.
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Results: 4717 patients were enrolled; of these, 2670 had non-missing data on
ecu and HDA status, and were included in the current analysis (HDA/ecu-treated,
n=785; HDA/never ecu-treated, n=636; no-HDA/ecu-treated, n=111; no-HDA/never
ecu-treated, n=1138). Median (min, max) duration of follow-up after baseline was
longer for the ecu-treated patients compared with the never ecu-treated patients
for both the HDA and no-HDA groups (see Table). Results for changes from base-
line to last follow-up in outcomes of interest are summarized in the Table. Data
show that patients in the ecu-treated cohort had high burden of disease at baseline.
Specifically, in the HDA population, a higher proportion of ecu-treated patients had
a history of MAVE (33.3%) vs never ecu-treated patients (13.7%). A similar disparity
at baseline was also observed in the no-HDA population (33.0% vs 11.0%, respec-
tively). Following ecu treatment, the divergence in the proportion of patients with
MAVE has substantially narrowed for the HDA patients (3.9% for ecu-treated vs
3.3% for never ecu-treated) despite longer follow-up for the treated patients. Similar
findings were seen in no-HDA patients (5.3% vs 2.1% respectively). In patients
with HDA status, treatment with ecu was associated with meaningful improvement
in mean (standard deviation [SD]) reduction from baseline in LDH ratio (-5.0 [3.7]
vs -0.4 [2.3]) and proportion of red blood cell transfusion-free patients (37.6% vs
15.8%). The FACIT-Fatigue data, while limited, showed the HDA/ecu-treated group
experienced greater mean (SD) score improvement than the HDA/never ecu-
treated group (4.1 [10.3] vs 0.5 [6.8] points).
Table 1.
Summary/Conclusions: Our analysis of real-world data from the International
PNH Registry has demonstrated that treatment with eculizumab was associated
with improved outcomes in patients with HDA. Our findings are consistent with
the notion that patients with HDA, including those with a history of MAVE, should
be treated with eculizumab.
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CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA: FUNCTIONAL
RESCUE OF A NOVEL MPL MUTANT IN PRIMARY HEMATOPOIETIC
CELLS USING CRISPR-CAS9
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Background: Thrombopoietin (Tpo) and its receptor, Mpl, are the principal reg-
ulators of early/late thrombopoiesis and hematopoietic stem cells maintenance.
Mutations in MPL can drastically impair its function and be a contributing factor
in multiple hematologic malignancies, including congenital amegakaryocytic
thrombocytopenia (CAMT). CAMT is a rare inherited syndrome characterized
by thrombocytopenia at birth, progressing to bone marrow failure and pancy-
topenia. The functional impact of CAMT mutations on Mpl is yet to be deter-
mined. Here we report unique familial cases of CAMT presenting with a previ-
ously unreported MPL mutation: T814C (W272R) in the background of the acti-
vating MPL G117T (K39N or Baltimore) mutation.
Aims: This study focuses on the functional characterization of this novel Mpl
mutant and the use of genome editing as a novel therapeutic option for CAMT.
Methods: Human megakaryoblastic UT-7 and murine Ba/F3 cells stably
expressing human wild-type (WT) Mpl or mutant Mpl fused to mNeonGreen
were used as models. Confocal microscopy, proliferation and surface biotiny-
lation assays, as well as co-immunoprecipitation and western blotting analysis,
were used to elucidate the function and trafficking of Mpl mutants. Multiplex,
flow-based, CRISPR-Cas9 gene editing was used to repair mutant MPL and
rescue its function. Cord blood from the younger male sibling was used as a
source of primary homozygous Mpl K39N/W272R CD34+ cells. CD34+ cells
were edited using ribonucleoproteins electroporation followed by sequencing
and functional assays such as flow cytometry and single colony assays.
Results: Consanguineous parents and their eldest daughter, all heterozygous
for Mpl K39N/W272R, do not present any signs of disease. Their monozygotic
twin daughters presented at birth with severe thrombocytopenia leading to a
diagnosis of CAMT type I. Whole blood sequencing revealed the presence of a
homozygous double Mpl K39N/W272R mutation, as their younger male sibling.
One of the twins died after bone marrow transplant. Confocal microscopy shows
that a significant fraction of chimeric WT Mpl protein reaches the cell surface.
Significant surface expression is also noted for Mpl K39N. In contrast, the
chimeric Mpl protein bearing the W272R mutation, alone or together with the
K39N mutation, showed no detectable surface expression of the Tpo receptor
while being strongly co-localized with ER marker calreticulin. Both WT and K39N-
mutated Mpl were found signaling competent, while single or double mutants
bearing W272R were unresponsive to Tpo. Tpo-induced signaling was partially
restored via GRASP55 over-expression (forcing ER-trapped Mpl to traffic to the
cell surface). Genome editing performed on cells carrying the W272R mutation
restored the WT sequence and the response to Tpo, with similar cell proliferation
as WT Mpl cells. Finally, when applied to primary Mpl K39N/W272R CD34+
cells, CRISPR-based gene editing rescued surface expression of Mpl and
response to Tpo, as assessed by flow cytometry. Furthermore, edited CD34+
cells were able to generate a similar number of megakaryocytic colonies as con-
trol CD34+ cells in a single colony assay. Non-edited cells failed to do so.
Summary/Conclusions: We report a new double in cis mutation of Mpl
(K39N/W272R) in the context of CAMT. Function of the deficient Mpl receptor
could be rescued using two separate approaches: GRASP55 over-expression
and CRISPR-Cas9 genome engineering. Successful editing of primary
hematopoietic stem cells indicates direct therapeutic applications for gene edit-
ing in this disease.
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Background: Paroxysmal nocturnal hemoglobinuria (PNH) and atypical
hemolytic uremic syndrome (aHUS) are well-characterized diseases of com-
plement dysregulation. The only approved therapeutic for these diseases is
Soliris® (Eculizumab, Alexion), a monoclonal antibody that binds and inhibits
the cleavage of complement C5. Soliris® requires lifelong intravenous admin-
istration by a medical professional every two weeks. An orally bioavailable small
molecule inhibitor of complement C5 to treat these and other complement medi-
ated diseases represents a potential paradigm shift in the treatment of diseases
of complement dysregulation.
Aims: To demonstrate the utility of an orally available, small molecule Comple-
ment C5 inhibitor for the treatment of complement mediated disorders.
Methods: Surface Plasmon Resonance (SPR) and Fluorescent Polarization
assays (FP) were used to evaluate the affinity and specificity of the binding
interaction between complement C5 and small molecule inhibitors. Determina-
tion of binding site, mechanism of action and potency were achieved by X-ray
crystallography studies, Wieslab ELISA, and a sheep erythrocyte hemolysis
based assay. The ability of the small molecules to prevent the hemolysis of
PNH erythrocytes was evaluated using a modified Ham test. Pharmacokinetic
studies were performed in rodents. 
Results: Here we describe a series of first in class, orally bioavailable small
molecules that bind to C5 with high affinity and inhibit its cleavage into C5a and
C5b. These molecules demonstrate desirable drug-like properties with molecular
weights under 500 amu and tPSA<100 Å2. A high-resolution co-crystal structure
with C5 shows a unique binding site on the 188 kDa C5 protein, and specific
binding of these molecules to C5 has been demonstrated by surface plasmon
resonance (SPR) and fluorescence polarization (FP) assays. The position of
the binding site suggests that these molecules will inhibit C5 cleavage in patients
with the R885H/C polymorphism, which confers resistance to eculizumab. The
molecules inhibit the terminal complement complex activity with single digit
nanomolar IC50 as measured by inhibition of hemolysis in a highly sensitive
antibody-sensitized sheep erythrocytes assay. In addition, they inhibit MAC dep-
osition on complement-activating surfaces and prevent the cleavage of C5 to
C5a and C5b as confirmed by ELISAs that directly detect generation of C5a
and MAC. This series of inhibitors prevents the complement-mediated hemolysis
of PNH erythrocytes (Type III) in a dose-dependent manner. More broadly, this
series of molecules has been profiled by in vitro and in vivo ADME disposition
studies and exhibits oral bioavailability (%F~30-50) in pre-clinical species.
Summary/Conclusions: The results presented here highlight, for the first time,
the feasibility of an oral, potent small molecule inhibitor of C5. The development
of an orally available complement C5 inhibitor has the potential to provide a
new therapeutic modality to treat both rare and common conditions where ter-
minal complement cascade inhibition is desired.
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QUALITY OF LIFE WITH MELPHALAN/PREDNISONE PLUS EITHER
THALIDOMIDE (MPT-T) OR LENALIDOMIDE (MPR-R) IN NON-TRANS-
PLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS
OF THE HOVON87/NMSG18 STUDY
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Background: We recently reported the results of the phase III randomized
HOVON87/NMSG18 study showing comparable efficacy of treatment with mel-
phalan, prednisolone and thalidomide following by thalidomide maintenance
(MPT-T) versus melphalan, prednisolone and lenalidomide followed by lenalido-
mide maintenance (MPR-R) (Zweegman S et al. Blood 2016;127(9):1109-
1116). As not only efficacy but also potential toxicity affecting quality of life
(QoL) guides the choice of treatment, health-related (HR) QoL is important.
Aims: To evaluate the HRQoL results of the HOVON87/NMSG18 study.
Methods: Two validated HRQoL instruments (EORTC QLQ-C30 and MY20)
were obtained at baseline, after 3 and 9 induction cycles (3ID and 9ID) and
after 6 and 12 months of maintenance therapy (6MT and 12MT). The subscales
global QoL, physical functioning, pain, fatigue, constipation, diarrhea,
nausea/vomiting, insomnia, disease symptoms, side effects of treatment and
neuropathy were analysed. Change in HRQoL score over time between treat-
ment arms was assessed by linear mixed models. Independent sample t-tests
were used to determine changes from baseline. Minimal important difference
(MID) within arms was defined as a difference in score of ≥1 standard error of
measurement (SEM) or, if a subscale consisted of one parameter only, MID-
levels described in previous literature were used. To determine clinically rele-
vant superiority of one arm, a difference in score of ≥5 was used and in addition
significance level was calculated.
Results: From 553 (90.2%) of the 613 patients who participated in the HRQoL
part of the study a baseline questionnaire was available. Forty (15%) of patients
randomized to MPT-T versus 68 (24%) of patients randomized to MPR-R com-
pleted therapy until 12 months of maintenance therapy. Change in HRQoL
between arms over time: in MPT-T improvement of HRQoL over time as com-
pared to MPR-R was found for the subscales diarrhea and insomnia. In con-
trast, MPR-R showed improvement over time for the subscales pain, constipa-
tion, side effects of treatment and neuropathy, as compared to MPT-T. Change
in HRQoL per arm: In MPT-T MID was reached for the following subscales;
global QoL increased after 9ID until 12MT (MID range 7-13), pain decreased
at every time point (MID range -21 to -23), disease symptoms deceased after
9ID (MID -12), fatigue decreased during MT (MID 12) and insomnia decreased
at each time point (MID range -11 to -21). In MPR-R the MID was reached for
the following subscales; global QoL increased after 9ID until 12MT (MID range
8-14), physical functioning increased at 12MT (MID 13), pain decreased at
every time point (MID range -14 to -26) and insomnia decreased at 6MT (MID
-10). Difference between MPT-T and MPR-R: In the MPT-T arm significantly
(p<0.05) and/or clinically (mean score difference (MSD) ≥5 points) less pain
and disease symptoms at 3ID, less fatigue at 3ID and 9ID, less diarrhea and
less insomnia at all time points were observed. In contrast, patients on MPR-
R reported better global QoL, better physical functioning and less pain at 12MT,
in general less side effects of treatment, and less constipation and neuropathy
separately, at all time points than patients treated with MPT-T.
Table 1.
Summary/Conclusions: Both treatment with MPT-T and MPR-R controlled
pain and resulted in an improvement in global QoL as compared to baseline
after 9ID and during maintenance. Treatment with thalidomide initially resulted
in less pain and disease symptoms. At all treatment stages thalidomide caused
less diarrhea, fatigue and insomnia as compared to treatment with lenalidomide.
In contrast, therapy with lenalidomide resulted in less side effects of treatment,
less constipation and less neuropathy as compared to thalidomide at all stages
of treatment. In addition, long term maintenance therapy with lenalidomide result-
ed in better global QoL, better physical functioning and less pain.
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HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE PHASE III
GALLIUM STUDY OF OBINUTUZUMAB-BASED AND RITUXIMAB-BASED
THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED
INDOLENT NON-HODGKIN LYMPHOMA
A. Davies1,*, P. Trask2, J. Demeter3, A. Florschütz4, M. Hänel5, X. Hong6,
T. Kinoshita7, R. Pettengell8, H. Quach910, S. Robinson11, S. Sadullah12,
J.-M. Sancho13, M. Udvardy14, M. Witzens-Harig15, K. Rufibach16, H. Zeuner16,
M. Unterhalt17
1Cancer Research UK Centre, University of Southampton, Southampton, Unit-
ed Kingdom, 2Genentech Inc., South San Francisco, United States, 3Semmel-
weis University, Budapest, Hungary, 4Städtisches Klinikum Dessau, Dessau-
Roßlau, 5Klinikum Chemnitz gGmbH, Chemnitz, Germany, 6Fudan University
Shanghai Cancer Center, Shangai, China, 7Aichi Cancer Center Hospital, Aichi,
Japan, 8St George’s University, London, United Kingdom, 9St. Vincent’s Hos-
pital, 10University of Melbourne, Melbourne, Australia, 11Bristol Haematology
and Oncology Centre, Bristol, 12James Paget Hospital, Great Yarmouth, United
Kingdom, 13Hospital Universitari Germans Trias i Pujol, Barcelona, Spain,
14University of Debrecen Medical and Health Science Center, Debrecen, Hun-
gary, 15Uniklinik Heidelberg, Heidelberg, Germany, 16F. Hoffmann-La Roche
Ltd, Basel, Switzerland, 17Ludwig-Maximilians-University Munich, Munich, Ger-
many
Background: Maintenance of pretreatment health-related quality of life
(HRQoL) and/or meaningful improvements in HRQoL are important for previ-
ously untreated indolent non-Hodgkin lymphoma (iNHL) patients (pts). GALLI-
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UM (NCT01332968) is an open-label, randomized Phase III study of obinu-
tuzumab (GA101; G) plus chemotherapy (chemo) followed by G maintenance
(G-chemo) compared with rituximab (R) plus chemo followed by R maintenance
(R-chemo) in pts with previously untreated iNHL. In GALLIUM, G-chemo pro-
duced a clinically meaningful improvement in investigator-assessed progres-
sion-free survival (PFS) among follicular lymphoma (FL) pts (34% reduction in
risk of a PFS event relative to R-chemo). Grade 3–5 and serious adverse events
were more common with G-chemo.
Aims: To compare changes in HRQoL in FL pts receiving G-chemo and R-
chemo during GALLIUM.
Figure 1.
Methods: Enrolled pts were aged ≥18 years with documented, previously
untreated FL (grades 1-3a), advanced disease (stage III/IV or stage II with
tumor diameter ≥7cm), ECOG performance status 0-2, and requiring treatment
according to GELF criteria. Pts were randomized 1:1 to R 375mg/m2 on day
(D) 1 of each cycle (C) or G 1000mg on D1, 8, and 15 of C1 and D1 of C2-8,
for 6 or 8 cycles depending on chemo (CHOP, CVP or bendamustine). Respon-
ders continued to receive R or G every 2 months (mo) for 2 years or until pro-
gression. The Functional Assessment of Cancer Treatment-Lymphoma (FACT-
Lym) questionnaire (Webster et al. 2005) was used to assess overall HRQoL,
physical and functional well-being, and disease- and treatment-related symp-
toms. FACT-Lym was administered on D1 of C1 and C3 during induction, at
the end of induction, and at mo 2 and 12 during maintenance/follow-up. For
each FACT-Lym scale, mean and 95% confidence interval (CI) were derived
for recorded scores at each visit and changes from baseline. Minimally impor-
tant differences (MIDs) were used to calculate the proportion of pts reporting
improvement on the FACT-Lym lymphoma subscale (LYMS; ≥3 points), Trial
Outcome Index (TOI; ≥6 points), and lymphoma total score (Lym-Total; ≥7
points). All pts gave informed consent.
Results: Of 1202 FL pts randomized (median age, 59 yrs; 53.2% female; medi-
an observation time, 34.5 mo [range 0-54.5]), 556/601 (92.5%; G-chemo) and
550/601 (91.5%; R-chemo) completed all FACT-Lym scales at baseline. Base-
line demographics and disease characteristics were balanced between arms.
At baseline, mean HRQoL scores were similar in the two treatment arms, with
all pts having some impairment of physical function, functional wellbeing, emo-
tional and social function. Over the course of treatment, mean HRQoL was
similar in the two treatment arms. From end of induction onwards, pts in both
arms experienced clinically meaningful improvements from baseline in LYMS
scores (Figure), and the summary scales that included this subscale (TOI, Lym-
Total). On each summary scale, ~50% of patients in each arm reported clinically
meaningful improvements. There were no clear differences between arms in
HRQoL scores over the course of therapy.
Summary/Conclusions: In previously untreated FL pts in GALLIUM, G-chemo
and R-chemo produced similar improvements in HRQoL. These results suggest
that lymphoma-related symptoms were reduced by both treatments and that
the resulting improvements in well-being were not abrogated by treatment-
related side effects. When viewed in the context of longer PFS, these results
further support the relative benefit of G-chemo over R-chemo in GALLIUM. 
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EFFECTIVE KEY WORKERS REDUCE THE NEED FOR CANCER
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FROM GREATER MANCHESTER CANCER PATHWAY BOARD (GMCPB)
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Background: Cancer patient support groups appear to provide an important
source of support to many patients and carers. In recent years there has been
an increasing focus in the UK for services to provide cancer support groups,
however it is unclear what proportion of patients believe access to these support
groups would improve their experience of living with and beyond cancer.
Aims: A patient experience survey was undertaken by the Haematology-Oncol-
ogy GMCPB across 10 NHS hospital trusts, where there are a number of cancer
support groups.
Methods: The sample for the survey included all adult (aged >16) patients with
a confirmed diagnosis of a haematological cancer who attended a haemato-
logical oncology outpatient appointment during a 4 month period (June-Sep-
tember 2016). The survey was available for competition on paper or online and
was completed anonymously. A translation/interpretation facility was not pro-
vided for patients whose first language was not English (due to funding
restraints).
Results: 277 responses were returned with 1 response excluded (non-haema-
tological malignancy). Haematological diagnoses included acute leukaemia
(n=40), chronic leukaemia (n=35), lymphoma (n=62), myeloma (n=102), MDS
(n=15), MPD (n=12), other (n=2) and not specified (n=7). 257 (93.1%) patients
had received anticancer therapy, 218 (79%) were receiving treatment at the
time of survey and 54% had ongoing symptoms related to their treatment or
cancer. 197 (71.4%) patients did not want access to a support group, 23 (19%)
wanted access, 51 (8.3%) were not aware of the possibility and 6 (1.8%) did
not respond. 51.8% of patients were aware of the existing support groups,
38.8% were not sure, 2.9% were not aware and 1.8% did not respond. The
cohort of patients who did or did not want access to a support group was
analysed further. 88% of patients had been given a key worker (eg clinical
nurse specialist, research nurse, advanced nurse practitioner or nurse clinician);
of the those 88% were satisfied and 1% were partly satisfied with the support
they had received with 11% not responding. 93% (n=231) of patients were sat-
isfied with the information they had received at diagnosis and 90% (n=224) felt
their diagnosis had been given sensitively. Only 20% of patients currently on
treatment wanted access to a support group and 24% not on treatment wanted
access to a support group. Date of diagnosis was divided into three groups.
Grp A: before 2005 (n=15), Grp B: after 2006 (n=229) and not stated (n=14).
There was no difference in the three groups when asked if they wanted access
to support group (13%, 22%, 7% respectively; p=0.3) or awareness that support
group was available (40%, 57%, 50% respectively; p=0.6). There were addi-
tional comments from patients that support from family and online forums in
addition to key workers was extremely valuable to them. On univariate analysis
patients who were satisfied with their key worker support did not want access
to a support group (p=0.04). There was no effect on wanting access to a support
group and diagnosis (p=0.67), treating hospital (p=0.5), information given
(p=0.6), need for in-patient treatment (p=0.3), quality of care (p=0.8) or satis-
faction with overall care (p=0.8).
Summary/Conclusions: Our results suggest that a large majority of patients
with a haematological malignancy do not want access to a cancer support
group but providing satisfactory support through key workers and other health
care professionals is likely to achieve better patient experiences.
Acknowledgements: We would like to acknowledge the members of the
GMCPB and patients for their contribution to the survey.
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FRONT-LINE VASCULAR ACCESS DEVICES IN ACUTE LEUKEMIAS-
PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) VERSUS
TRADITIONAL CENTRAL VENOUS CATHETER (CVC): A PHASE IV
RANDOMIZED TRIAL (NCT02405728)
C. Cerchione1,*, M. Di Perna1, R. Della Pepa1, N. Pugliese1, F. Pane1, M. Picardi1
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Background: The use of PICC as an alternative to other CVC devices, partic-
ularly for prolonged infusions of cytotoxic agents, blood products and/or other
supportive therapy, is becoming very frequent in cancer patients. PICCs are
easier to insert, and associated to a lower rate of severe complications than
traditional CVCs. However, there is limited information on the feasibility and
safety of PICC as primary vascular access device in the setting of high-risk
hematological patients. 
Aims: Our Hematology Department is conducting a Phase IV randomized trial
on this topic. We compare PICCs versus traditional CVCs as front-line venous
access device in patients with acute leukemias undergoing intensive
chemotherapy for remission induction (NCT02405728; ongoing). Primary end-
point is the occurrence of catheter-related bloodstream infections and/or throm-
bosis. Secondary endpoints are the occurrence of other complications, such
as pneumothorax or catheter occlusion, and patients’quality of life. Question-
naire covering functional status, sleep and hygiene disturbance had been given
to assess patients’ quality of life.
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Methods: From April 2015 to February 2017, 152 consecutive patients with
acute leukemia planned for remission induction chemotherapy were randomly
assigned (1:1) to PICC (Arm A) or traditional CVC (Arm B) (Table 1). Inclusion
criteria were age >18 years, expected survival >4 weeks, and need of central
venous access (long-term >4 weeks). Exclusion criteria were ongoing uncon-
trolled systemic infection, presence of significant thrombosis/stenosis in arm
or central veins, and inability to communicate and/or to sign informed consent.
All insertions were followed by ultrasonography assessments and chest X-ray.
Results: 152 patients (130 AML and 22 ALL) with a median age of 47 years
(range, 13-82), were randomized in the two arms. In the Arm A, 76 PICCs
(power injectable PICCs, in new generation polyurethane, open-ended) were
inserted in 76 patients. Double lumen PICCs (5 Fr) were inserted in 70 patients,
single lumen PICCs (4 Fr) were inserted in 5 patients, and triple lumen PICC
(6 Fr) was inserted in 1 patient. 68 PICCs were inserted in the right basilica
vein, 5 PICCs were inserted in the left basilica vein and 3 PICCs were inserted
in the left brachial vein. In Arm B, 76 traditional CVCs (untunneled heparin-
coated Vialon CVC, Becton-Dickinson) were inserted by the Seldinger tech-
nique in other 76 patients. 45 CVCs were inserted in subclavian vein and 31
CVCs were inserted in internal jugular vein. Overall, the median duration of in
situ catheter placement was 5 months: 6 months (range, 3-12) in the arm A vs.
3 months (range, 1-10) in the arm B. In the arm A, catheter-related thrombosis
occurred in 8 patients (6 basilica veins, 2 brachial veins) and catheter-related
bloodstream infections in 4 patients (4 coagulase-negative staphylococci; of
them, 2 meticillin-resistants). In the arm B, 20 cases of catheter-related throm-
bosis (7 subclavian veins, 13 internal jugular veins) and 15 cases of catheter-
related bloodstream infections (10 enterobacteriaceae; 5 coagulase-negative
staphylococci, and, of them, 3 meticillin-resistants) were observed. Thus, PICCs
were significantly associated with fewer major complications than traditional
CVCs (catheter-related thrombosis: 10.5% in the arm A vs. 26% in the arm B,
p=0.01 by χ2 test; catheter-related bloodstream infections: 5% in the arm A vs.
19% in the arm B, p= 0.007 by χ2 test) (Figure 1). Questionnaire covering
activities of daily living confirmed improvement of quality of life.
Figure 1.
Summary/Conclusions: The preliminary observations of this ongoing Phase
IV randomized study, focusing on front-line use of central venous access device
in a high risk hematological population, suggest that the use of PICC represents
an advance in terms of decrease of complication rate and improvement of qual-
ity of life for patients with acute leukemia.
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Background: Pharmacologic therapy stabilizes hematologic counts and
splenomegaly in myeloproliferative neoplasms (MPN), however only partial
symptom improvement typically occurs. Evidenced-based integrative care may
address this need, however data is limited in patients with MPNs. 
Aims: To investigate integrative therapy utilization association with symptom
burden, quality of life, depression, and fatigue in MPN patients.
Methods: Patients were recruited via social media. Informed consent and
online self-report surveys (Qualtrics) were completed capturing patient demo-
graphics, disease specific data, supportive care utilization, MPN symptom bur-
den via MPN-SAF TSS, depression via Patient Health Questionnaire (PHQ)-
9, fatigue via Brief Fatigue Inventory (BFI) Usual, and an overall quality of life
(QOL) single question assessment. ANOVA, chi square tests, and Wilcoxon
rank sum tests methods were applied.
Results: Patients: A total of 1087 patient surveys were consented. Of these,
858 had 10 or more responses. There were 338 essential thrombocytosis (ET),
188 myelofibrosis (MF), 315 polycythemia vera (PV), and 17 other. In MF:
DIPSS risk categories included low (8%), Int-1 (19%), Int-2 (29%), high (12%),
and unknown (32%). Symptom association: Overall, patients had lower MPN
related symptoms when participating in aerobic activity (p<0.001), massage
(p=<0.001), yoga (p=0.02), strength training (p<0.001), breathing exercises
(p=<0.001), and support groups (0.001). Overall quality of life was higher with
aerobic activity (p=<0.001), massage (p=0.02), yoga (p=0.02), strength training
(p=<0.001), breathing exercises (p=0.01), and support groups (p=0.001).
Depression (PHQ-9 total >3 category) was lower in aerobic activity group
(p=0.001), yoga (p=0.001), strength training (p=0.001), and meditation (p=0.2).
Fatigue was lower in aerobic activity (p=<0.001), massage (p=0.04), strength
training (p=<0.001), breathing exercises (p=<0.001), and support groups
(p=0.001). In subgroup analysis, ET and PV patients had lower symptom bur-
den (MPN-SAF TSS) with aerobic activity (p=<0.001, <0.001), massage (p=
0.01, 0.02), and strength training (p=0.03,0.02). Support groups were found to
be associated with lower symptoms in ET patients (p=0.03). In MF, breathing
exercises (p=<0.001) and support groups (p=0.03) were associated with lower
symptom burden. See Table #1.
Table 1.
Summary/Conclusions: Integrative therapies are associated with improved
symptom burden, quality of life, depression, and fatigue in MPN patients. Inter-
estingly, unique patterns were associated within MPN subtypes. Further studies
are needed to understand the benefits of integrative therapies in MPN patients.
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Background: B cell acute lymphoblastic leukemia (B-ALL) relapse contributes
to the predominant mortality after allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT). However, the mechanism of B-ALL relapse after allo-HSCT
remains unknown. Eradication of leukemia in allo-HSCT settings largely relies
on graft-versus-leukemia (GVL) effects mediated by donor T cells. T cell
exhaustion characterized by increased expression of inhibitory receptors includ-
ing PD-1 and Tim-3 and impaired function may blunt the GVL effects and was
reported in acute myeloid leukemia relapse after allo-HSCT. whether T cell
exhaustion is involved in B-ALL relapse after allo-HSCT remains unknown.
Aims: To evaluate whether T cell exhaustion is involved in B-ALL relapse after
allo-HSCT,and investigate the correlation of inhibitory ligands on leukemic cells,
leukemic load and T cell exhaustion, as well as the impact of treatment outcome
on T cell exhaustion.
Methods: Our study enrolled 18 B-ALL patients who underwent first hemato-
logical relapse after allo-HSCT and18 matched B-ALL patients in remission
(without minimal residual disease MRD) and 14 healthy donors from April 2016
to November 2016 at the Peking University People’s Hospital, Institute of Hema-
tology. Transplant protocol and post-transplant time were matched in relapsed
and non-relapsed patients. Post-transplant time were matched as follows:
±14days within 12 months ±1months from 12 to18months, ±3months from 18
to 36 months, ±12months over 3 years. Extra-medullary relapse were excluded
in our study. All patients had achieved full donor chimerism before relapse or
bone marrow collection. Peripheral blood (PB) were collected at the same day
of bone marrow collection in relapsed patients. For patients who received re-
induction therapy, we prospectively collected BM at least once after therapy.
Sample collection was performed after patients was informed consent and
approval by the institutional Human Ethics Review Committee of Peking Uni-
versity People’s Hospital in accordance with the Declaration of Helsinki.phe-
notypic and functional studies of T cells in those patients were performed using
multi-color flow cytometry.
Results: In the current study, we observed that increased co-expression of
PD-1 and Tim-3 was observed in both CD4+ and CD8+ T cells in relapse set-
tings. Moreover, both CD4+ and CD8+ T cells exhibited compromised prolifer-
ative capacity, cytokine production and cytotoxic potentials such as degranua-
tion and granzyme B production (preferentially on CD4+T cells) in relapsed
patients. In addition, T cells at the tumor site are more easily exhausted than
those in peripheral blood. Reversal of T cell exhaustion was associated with
effective anti-leukemic response in relapsed patients who underwent re-induc-
tion therapy.
Summary/Conclusions: In conclusion,our study suggested that T cells expe-
rienced exhaustion with comprehensively functional impairments in B-ALL
relapse setttings after allo-HSCT and reversal of T cell exhaustion was asso-
ciated with effective anti-leukemic responses. These results also provide a
foundation for the development of novel effective leukemia therapeutics, such
as anti-PD-1 or PD-L1 therapy, by targeting T cell exhaustion
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Background: Relapse remains the major cause of treatment failure in patients
with Philadelphia chromosome-positive acute lymphoblastic leukemia
(Ph+ALL), even in the modern era of tyrosine kinase inhibitors (TKIs). Relapse
of Ph+ALL may result from the persistence of leukemia-propagating cells
(LPCs), which are defined by their ability to initiate human leukemia and self-
renew in immunocompromised mice. Using an anti-CD122-conditioned
NOD/SCID xenograft mouse assay, LPCs were reported to be enriched in the
CD34+CD38-CD58- fraction in human Ph+ALL (YK,…,XJH*. Leukemia. 2014).
Furthermore, a cohort study demonstrated that Ph+ALL patients with LPCs
phenotype at diagnosis exhibited a significantly higher cumulative incidence of
relapse than did the group with other phenotypes, even when receiving uniform
front-line imatinib-based therapy pre- and post-allotransplant (YK,…,XJH*.
BMT. 2015). Therefore, it is imperative to identify novel therapeutic strategies
based on LPCs to improve the prognosis of Ph+ALL patients.
Aims: To identify the potential molecular basis of LPC-mediated relapse, RNA
sequencing(RNA-seq) and real-time reverse transcription-PCR (qRT-PCR)
were performed to analyze the gene expression profiles of sorted LPCs and
cells of other phenotypes from Ph+ALL patients. To investigate whether selec-
tive BCR-ABL/JAK2 dual inhibition therapy could more effectively eliminate
LPCs in vitro and in humanized Ph+ALL mice.
Methods: RNA-seq and qRT-PCR were performed to analyze the gene expres-
sion profiles of sorted LPCs and cells of other phenotypes from patients with
de novo Ph+ALL. In order to assess the effects of the selective BCR-ABL and/or
JAK2 inhibition therapy by the treatment with single agents or a combination of
ruxolitinib and imatinib or nilotinib on Ph+ALL LPCs, drug-induced apoptosis of
LPCs was investigated in vitro, as well as in vivo using sublethally irradiated
and anti-CD122-conditioned NOD/SCID xenograft mouse assay. Moreover,
western blot analyses were performed on the BM cells harvested from the dif-
ferent groups of recipient mice.
Results: Using RNA-seq and qRT-PCR, we found that JAK2 was more highly
expressed in the sorted LPCs than in the cells of other phenotypes in patients
with de novo Ph+ALL. in vitro study, cotreatment with nilotinib and ruxolitinib
induced significantly higher levels of apoptosis in LPCs. In humanized Ph+ALL
mice model, treatment with the nilotinib and ruxolitinib combination, compared
with either ruxolitinib or TKIs alone, led to the most significant reduction in
human Ph+ALL engraftment in the recipients. Further evidence that the most
effective anti-LPCs effect occurred with the combination treatment was derived
by the engraftment analysis of BCR/ABL expressing cells using a qRT-PCR
assay and HE and IHC with anti-hCD19 staining. Moreover, the combination of
nilotinib and ruxolitinib more effectively reduced the LPCs capacity through a
deeper suppression of phospho-CrKL, JAK2 and STAT5 activities at the molec-
ular level.
Summary/Conclusions: JAK2 was more highly expressed in the sorted LPCs
than in other cell phenotypes in patients with de novo Ph+ALL. Furthermore,
selective BCR-ABL/JAK2 dual inhibition with nilotinib/ruxolitinib more effectively
eliminated LPCs than either ruxolitinib or TKIs alone. Therefore, this pre-clinical
study appears to provide scientific rationale for simultaneously targeting BCR-
ABL and JAK2 activities, which represents a promising anti-LPCs therapeutic
approach for patients with de novo Ph+ALL.
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PREDICTING ANTI-LEUKEMIA ACTIVITY OF THE BCL-2-SELECTIVE
INHIBITOR ABT-199 IN BCP-ALL BY FUNCTIONAL ASSESSMENT OF
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Background: Although survival rates of pediatric BCP-ALL patients have con-
tinuously improved during the past decades, therapy-related toxicity and relapse
occurring in 10-20 % of patients are associated with poor outcome, clearly
emphasizing the need of novel, targeted treatment strategies. Deregulated sur-
vival pathways and cell death resistance contribute to treatment failure and
reoccurrence of the disease. ABT-199 (venetoclax) is a small molecule inhibitor
of BCL-2 demonstrating anti-cancer activity among different malignancies. How-
ever, predictive biomarkers are required for up-front identification of patients
who would benefit from BCL-2 directed therapies.
Aims: The aims of this study were to assess the efficacy of ABT-199 in BCP-
ALL, to functionally evaluate factors mediating ABT-199 susceptibility or resist-
ance and to identify markers indicative of successful anti-leukemia activity.
Methods: The activity of ABT-199 was assessed by cell viability assays in
BCP-ALL cell lines (N=6) and patient-derived xenograft (pdx) samples (N=27),
analyzing half maximal effective concentrations (EC50). Expression of apopto-
sis regulators was detected by western blot analysis. MCL-1 deficient cell lines
were generated by CRISPR/Cas9 gene editing. BH3 profiling was used to
measure the mitochondrial dependence of leukemia cells on anti-apoptotic
BCL-2 family proteins. In vivo treatment of ABT-199 was performed in a set of
three distinct ALL pdxs.
Results: Different sensitivities of ABT-199 were observed in a series of BCP-
ALL pdxs and cell lines with heterogeneous anti-leukemia activities upon drug
exposure. The majority of BCP-ALL samples showed sensitivity to ABT-199-
induced cell death in the nanomolar range (EC50 <1µM) with four out of six
cell lines and 20 of 27 pdxs, while ABT-199 insensitivities with EC50s of more
than 1µM were identified in 26% of pdx leukemias. ABT-199 induces apoptosis
by selectively inhibiting BCL-2 with a sub-nM binding-affinity thereby releasing
pro-apoptotic molecules; however, the sequestration of drug-released BIM by
anti-apoptotic MCL-1 might lead to resistance. Therefore, we investigated pro-
tein expression of both regulators and found the ratio (BCL-2/MCL-1) to be cor-
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related with ABT-199 sensitivity (rs=-0.71, p=0.008), highlighting the importance
of simultaneous assessment of the direct target molecule and additional resist-
ance mediating molecules. In line, MCL-1 knockout in two ABT-199-resistant
cell lines led to sensitization towards ABT-199, however, resulted in different
effects of sensitization, emphasizing that ABT-199 resistance is determined by
the interplay of several apoptosis regulators. Therefore, we characterized the
functional dependence of pdx leukemias on anti-apoptotic BCL-2 family mem-
bers by BH3 profiling. Mitochondrial dependence on BCL-2 (mitochondrial prim-
ing by the BAD-peptide measuring BCL-2, BCL-XL and BCL-W, and subtracting
the response to the HRK-peptide measuring BCL-XL) was found to be tightly
correlated with ABT-199 sensitivity. In contrast, ABT-199-resistant samples
were characterized by low BCL-2-dependence and addiction to other BCL-2
family members, including BCL-XL or MCL-1. Finally, we evaluated prediction
of in vivo ABT-199 sensitivity in a pre-clinical ALL pdx mouse model by func-
tional BH3 profiling. Strikingly, high mitochondrial BCL-2-dependency was
clearly associated with prolonged leukemia-free survival upon ABT-199-therapy
(two pdxs, log ranks p=0.0035 and <0.0001), in contrast to another leukemia
with low BCL-2-dependence and in vivo ABT-199 resistance (log rank p=0.144).
Summary/Conclusions: BCP-ALL displays heterogenous ABT-199 sensitivi-
ties characterized by the level of the target molecule but also other interacting
regulators. Functionally, mitochondrial BCL-2-dependence assessed by the
BH3 profiling assay is clearly associated with ABT-199 sensitivity. Importantly,
in vivo anti-leukemia activity of ABT-199 therapy in individual pdx leukemias is
predicted by mitochondrial BCL-2 dependence, emphasizing the utility of iden-
tification of patients and guidance of future clinical application by functional
assessment of apoptosis signaling.
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CD45RA- MEMORY T CELLS EXPRESSING AN NKG2D-CAR TARGET
PEDIATRIC ACUTE LEUKEMIA
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Background: Lymphoid and myeloid acute leukemia are the most frequent
type of cancer and the most frequent cause of cancer related death in children.
Relapse and refractory disease are the main clinical problems that current ther-
apies are still unable to solve. One of the main NK cell activating receptors is
NK cell group 2D (NKG2D). NKG2D receptor recognizes human MICA, MICB
and ULBP1-6 ligands. These NKG2D ligands (NKG2DL) are expressed in
leukemia cells and constitute suitable targets for immunotherapy.
Aims: The aim of thi study was to analyze the NKG2DL expression on pediatric
acute leukemia cells and determine their susceptibility to an NKG2D CAR cell
based immunotherapy.
Methods: The expression of NKG2DL was analyzed in Peripheral Blood
Mononuclear Cells (PBMCs) from patients suffering from acute leukemia, as
well as in leukemia cell lines, by flow cytometry (FCM) using specific mono-
clonal antibodies directed against MICA, MICAB, ULBP-1, ULBP-2, ULBP-3
and ULBP-4, and by quantitative PCR using TaqMan probes. PBMC from
healthy donors were labeled with CD45RA microbeads and depleted using
AutoMACS device. The HL20i4r-MNDantiCD19bbz lentiviral vector was derived
from the clinical vector CL20i4r-EF1a-hgcOPT27 but contained the extracellular
domain of NKG2D, the hinge region of CD8a and the signaling domains of 4-
1BB and CD3-z. The cassette was driven by MND promoter. Viral supernatant
was produced by transient transfection of HEK293T cells with the vector
genome plasmid and lentiviral packaging helper plasmids pCAGG-HIVgpco,
pCAGG-VSVG and pCAG4-RTR2. Cytogenetic studies and array Comparative
Genomic Hybridization were performed to analyze the genetic stability of lentivi-
ral-transduced memory T cells. The in vitro cytotoxicity of CD45RA-
NKG2DCAR+ memory T cells against leukemia cells, healthy PBMC and Mes-
enchymal Stem cells (MSC) was evaluated by performing conventional 4-hour
europium-TDA release assays or by FCM using CFSE and 7AAD labeling of
target cells.
Results: NKG2DL were heterogeneously expressed in leukemia primary cells
and cell lines. For B cell ALL primary samples, we found expression of MICA/B,
MICA and ULBP1 decreased in refractory disease compared to remission.
Lentiviral transduction of NKG2D-4-1BB-CD3z increased NKG2D surface
expression in CD45RA- memory T cells, which became consistently more cyto-
toxic than untransduced cells against leukemia cells. Additionally, no chromo-
somal aberrations nor cytotoxic activity against healthy PBMC or Mesenchymal
Stem cells was observed in NKG2D CAR expressing T cells.
Summary/Conclusions: Our results show NKG2D-CAR redirected CD45RA-
memory T cells target NKG2DL expressing leukemia cells in vitro and could be
a promising and safe immunotherapeutic approach for pediatric acute leukemia
patients.
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A BILINEAL ACUTE LYMPHOBLASTIC LEUKEMIA ORIGINATING AT A
COMMON LYMPHOID PROGENITOR
A. Gonzalez-Murillo1,*, C. Sánchez-Valdepeñas1, C. Robledo2, A. Castillo1,
L. Abad1, C. Hernandez-Marques1, D. Ruano1, L. Madero1, J. Alonso2,
M. Ramirez1
1Pediatric Hematology & Oncology, Hospital Universitario Niño Jesus, Madrid,
2Instituto de Investigacion en Enfermedades Raras, Instituto de Salud Carlos
III, Majadahonda, Spain
Background: Genetic mutations are crucial events during leukemogenesis
and provide specific markers for backtracking the cellular origin of acute
leukemias up to immature uni- or multi-potent progenitor cells in the hierarchy
of the hematopoietic system.
Aims: To characterize the clonal architecture and cell of origin in a case of
bilineal T- and B-ALL.
Methods: Bone marrow cells obtained at diagnosis were used for all studies.
Immunophenotyping was done by flow cytometry. T- and B-leukemic cell purifi-
cation was performed by immunomagnetics methods and DNA extracted after-
ward. TCR-gamma gene rearrangement was studied in T- and B-leukemic
cells independently by PCR spectratyping. Somatic mutations in purified T-
and B-leukemic cells were identified by deep-sequencing using a panel of
160 genes frequently mutated in cancer (Human comprehensive cancer panel,
Qiagen). Mutations were validated by Sanger sequencing. Myeloid and ery-
throid clonogenic progenitors were isolated from methylcellulose cultures,
DNA extracted, and assessed for the presence of the H3F3A p.K28N mutation
by Sanger sequencing.
Results: The patient was a 10 years old boy. At diagnosis, the bone marrow
was infiltrated by 60% leukemic cells, with 2 immunophenotypically different
populations: a common B-ALL (54%) and a pro-T-ALL (6%). The patient
showed a mediastinal mass in the chest X-ray image. A common TCR-gamma
rearrangement was detected in purified (>95% pure) T-ALL and B-ALL cells,
suggesting a common origin for both leukemic subpopulations. The B-ALL cells
presented a c.35G>A p.G12D mutation in the KRAS gene, absent in the T-
ALL. The T-ALL cells presented a c.35G>A (p.G12D) mutation in the NRAS
gene, absent in the B-ALL. A c.1126_1127insTAGA (p.P376Lfs*10) mutation
in the WT1 gene was also detected only in the T-ALL. A c.84G>T (p.K28N)
mutation in the H3F3A gene was detected in both the B-ALL and T-ALL sub-
populations, confirming the involvement of a Common Lymphoid Progenitor in
the process of leukemogenesis. The presence of the H3F3A p.K28N mutation
in the myeloid compartment would point to a multipotent myeloid-lymphoid
rather than a lymphoid-restricted progenitor as the cell origin of the leukemia.
Therefore, we cultured myeloerythroid-committed progenitor cells in clonogenic
cultures and sequenced the H3F3A gene. None of the 122 myeloid or erythroid
clonogenic progenitors (41 CFU-GM, 73 BFU-E and 8 CFU-GEMM) presented
the p.K28N mutation in the H3F3A gene.
Summary/Conclusions: Our results indicate the involvement of a Common
Lymphoid Progenitor as the cell of origin in this case of bilineal ALL, as well as
the crucial role of H3F3A and RAS family genes in the leukemogenesis process
coupled with B and T differentiation.
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CYSTEINE AND GLYCINE-RICH PROTEIN 2 (CSPR2) TRANSCRIPT LEVELS
CORRELATE WITH LEUKEMIA RELAPSE AND LEUKEMIA-FREE
SURVIVAL IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH
NORMAL CYTOGENETICS
S.-J. Wang1,*, P.-Z. Wang2, R. Gale3, Y.-Z. Qin1, Y.-R. Liu1, Y.-Y. Lai1, H. Jiang1,
Q. Jiang1, X.-H. Zhang1, B. Jiang1, L.-P. Xu1, X.-J. Huang4, K.-Y. Liu1, G.-R. Ruan1
1Peking University Peoples Hospital and Institute of Hematology, Beijing Key
Laboratory of Hematopoietic Stem Cell Transplantation, 2Department of
Immunology, School of Basic Medical Sciences, Peking University Health Sci-
ence Center., Beijing, China, 3Haematology Research Center, Division of
Experimental Medicine, Department of Medicine, Imperial College London,
London, United Kingdom, 4Peking University Peoples Hospital and Institute of
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Background: Outcome of adults with B-cell acute lymphoblastic leukemia
(ALL) remains poor and relapse is the major cause of treatment-failure.
Identifying new biomarkers in B-cell ALL especially in those with normal
cytogenetics and studying their clinical significance and biological function
will be helpful for risk-stratification, treatment decision and targeted thera-
py.CSRP2 (cysteine and glycine rich protein 2) maps to chromosome sub-
band 12q21.1, which is frequently abnormal in diverse cancers. Increased
CSRP2 transcript levels are associated with de-differentiation in hepatocel-
lular carcinoma and CSRP2 is proved to be a new invadopodia actin
bundling factor that critically promotes breast cancer cell invasion and
metastasis. However, the clinical significance and biological function of
CSRP2 in B-cell ALL remains unknown.
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Aims: To identify novel biomarkers in B-cell ALL based on bioinformatics analy-
ses; to examine the expression and clinical significance of CSRP2 in adults
with B-ALL; to explore effects of CSRP2 on biological function of B-cell ALL.
Methods: We did bio-informatics analyses to identify mRNA transcripts aber-
rantly-expressed in B-cell ALL. RT-qPCR (real-time quantitative polymerase
chain reaction) was used to examine CSRP2 transcript levels in bone marrow
samples from 236 adults with B-cell ALL compared with samples from normal.
A prognostic value was assessed in 168 subjects. CSRP2-knockdown and
CSRP2-over-expression cell models were constructed to study the biological
function of CSRP2 in B-cell ALL.
Results: We selected 9 candidate genes for validation 7 of which proved sig-
nificantly-associated with B-cell ALL. CSRP2 was the most differentially
expressed gene in our validation studies. CSRP2 was over-expressed in 228
out of 236 adults (97%) with newly-diagnosed B-cell ALL. In subjects with nor-
mal cytogeneticsthose with high CSRP2 transcript levels had a higher 5-year
cumulative incidence of relapse (CIR) and worse relapse-free survival (RFS)
compared with subjects with low transcript levels (56% [95% confidence interval
53-59%] vs 19% [18- 20%]; P=0.011 and 41% [17-65%] vs 80% [66-95%];
P=0.007). In multivariate analyses a high CSRP2 transcript level was inde-
pendently-associated with CIR (HR=5.32 [1.64-17.28]; P=0.005) and RFS
(HR=5.56 [1.87-16.53]; P=0.002). Functional analyses indicated CSRP2 pro-
moted cell proliferation, cell-cycle progression, in vitro colony formation and
migration. Abnormal CSRP2 expression was associated with resistance to
chemotherapy; sensitivity was restored by down-regulating CSRP2 expression.
CSRP2 activated ERK1/2 signaling pathway, regulated cell-cycle related protein
and activated CREB signaling pathway, whose activation was associated with
poor prognosis in adults with B-cell ALL.
Summary/Conclusions: CSRP2 was widely over-expressed in adults with B-
cell ALL. Determination of CSPR2 transcript levels in subjects with normal cyto-
genetics might inform therapy-decisions. Consideration could be given to down-
regulating CSPR2 expression as a way to reverse drug resistance.
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THERAPEUTIC TARGETING OF PRE-B CELL RECEPTOR SIGNALLING IN
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Background: Acute lymphoblastic leukaemia (ALL) is the most common malig-
nancy in children and adolescents and relapsed ALL remains one of the leading
causes of cancer-related deaths in children. Components of the precursor-B
cell receptor (Pre-BCR) signalling pathway are hijacked in ALL cells and this
dependence may be therapeutically targeted. A number of tyrosine kinase
inhibitors (TKIs) targeting effectors of this signalling pathway are showing great
promise in the clinic and warrant preclinical evaluation in paediatric ALL. They
include Dasatinib (BCR-ABL/SRC inhibitor), Fostamatinib R406 (SYK inhibitor),
Ibrutinib (BTK inhibitor) and CAL-101 (PI3K-δ inhibitor).
Aims: To preclinically evaluate these candidate TKIs, as novel, targeted drugs
for high risk and relapsed ALL. 
Methods: ALL cell lines (Reh, Nalm-6, PreB 697 and its glucocorticoid resistant
descendant, R3F9) and 36 primary-derived xenograft (PDX) cells from 16 ALL
were used in the study. Cell viability was assessed by Resazurin. Pre-BCR
expression (µHc, Vpreb and λ5) and functionality using a Calcium flux assay
were detected by Flow cytometry. Intracellular phospho-flow cytometry was
used to detect constitutive phosphorylation and activation in response to anti-
Igµ antibody, as well as drug pharmacodynamic measures (p-BTK, p-SYK, p-
AKT, p-ERK, p-PLC-ϒ2, p-BLNK). Apoptosis and cell cycle were analysed by
flow cytometry using Annexin V and Propidium Iodide. RQ-PCR was used to
measure GILZ expression. Bim induction, GR expression and phosphorylation
were detected by western blotting.
Results: ALL cell lines were modestly sensitive to Dasatinib (mean GI50 5.33
µM, range 2.45 µM-12.5 µM) and R406 (mean GI50 4.32 µM, range 2.88 µM-
5.83 µM). However, cells were resistant to Ibrutinib (mean GI50 15.9 µM, range
11.47 µM-18.3 µM) and CAL-101 (mean GI50 52.08 µM, range 25 µM-77.83
µM). Cell cycle arrest and significant apoptosis was seen with R406 and Ibru-
tinib treatment, while Dasatinib and CAL-101 were cytostatic, causing G1 arrest
with no substantial cell death. Pharmacodynamic assays confirmed inhibition
of the relevant drug targets. PDX cells showed greater sensitivity than the cell
lines to Dasatinib (4 out of 16 patient samples <0.5µM), R406 (7 out of 16
patient samples <5µM), Ibrutinib (3 out of 15 patient samples <5µM) and CAL-
101 (3 out of 15 patient samples <2µM). Pre-BCR positive ALL cell lines and
PDX cells were sensitive to R406 and Dasatinib, with a Ph+ PDX confirming
sensitivity to the latter. Combining TKIs with the glucocorticoid (GC), Dexam-
ethasone showed synergism in ALL cell lines and was particularly notable for
Dasatinib and R406 in PreB cell receptor positive lines. Synergism was asso-
ciated with significantly enhanced apoptosis, an increase in expression of the
GR target gene, GILZ and for Dasatinib, enhanced expression of the pro-apop-
totic, Bim. Control REH cells (GC receptor negative) showed no synergism.
Summary/Conclusions: Significant sensitivity of TKIs targeting Pre-BCR sig-
nalling have been identified at clinically achievable concentrations. Dasatinib
and R406 sensitivity was associated with Pre-BCR positive ALL and combina-
tion with Dexamethasone showed significant synergism in GC resistant cell
lines and PDX samples. TKIs were also effective in some Pre-BCR negative
ALL cells, however, predictive biomarkers need to be established. Confirmation
of these data in preclinical models in vivo may define new therapies for high
risk ALLs.
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BMP-4 LEVELS IN CHILDHOOD B-ALL OF LOW-/INTERMEDIATE-RISK
GROUPS IDENTIFY CHILDREN WITH POOR OUTCOME
L.M. Fernández-Sevilla1,*, C. Sánchez-Valdepeñas2, A. Gonzalez-Murillo2,
A. Entrena1, C. Martinez-Laperche2, G. Melen2, A. Varas1, A. Vicente1, M. Ramirez2
1School of Medicine, Universidad Complutense, 2Pediatric Hematology &
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Background: Leukemic relapses among children with acute lymphoblastic
leukaemia (ALL) from low/intermediate-risk groups is a challenge for the cure
of this disease. New biomarkers are needed for identifying children at high risk
of relapses. Bone Morphogenetic Proteins (BMPs) are multifunctional secreted
growth factors that belong to the TGF-β superfamily and are well-known for
their indispensable roles in vertebrate development. In the cellular context,
BMPs regulate fundamental processes such as cell proliferation, differentiation,
migration and survival. In last years, important new information has been gen-
erated on the contribution of BMP family members, such as BMP4, in cancer
pathogenesis.
Aims: Here we have evaluated the relevance of BMP4 signaling in ALL.
Methods: The expression levels of BMP-4 related genes (bmp-4, and bmp-
receptors, signaling mediators, inhibitors and targets) in ALL blasts obtained at
the time of diagnosis (n=56), and the BMP-4 levels in central system fluid sam-
ples (CSF), were quantitated by RT-qPCR or ELISA. The engrafting potential
of primary ALL cells, exhibiting high or low BMP4 levels, were assessed in
xenotransplantation experiments using unirradiated NSG mice.
Results: BMP4 was expressed at significantly higher levels in ALL blasts of
children who later relapsed (178,78 versus 26,68, arbitrary units, AU, p<0,05).
Relapses among children with high BMP-4 expression occured significantly
later than those with low BMP-4 expression (845 days versus 282 days,
p<0,05). The difference in the cumulative incidence of relapses (CIR) was qua-
si-significant between both groups (p=0,0831). The ratio Smad7:Smad1, sug-
gesting inhibition of the Smad-dependent signaling pathway, was significantly
higher in ALL blasts of children who later relapsed (14,33 versus 5,13, AU,
p<0,05). CIR was significantly higher (p<0,05) in the group of children with the
Smad-dependent pathway inhibited. All these differences were detected con-
sidering the whole population, as well as only the low/intermediate-risk groups.
BMP4 levels were significantly higher in CSF samples of children with leukemic
infiltration of the central nervous system (16pg/ml versus 3,4pg/ml, p<0,001),
as well as in the group of children who relapsed (10,6 pg/ml versus 1,8 pg/ml,
p<0,001). Hematopoietic engraftment (marrow, spleen and peripheral blood)
and CNS leukaemia occured only in ALL samples with high BMP4 levels. Even
more, no signs of disease were detected in mice transplanted with primary
cells which expressed low levels of BMP4. In independent experiments, phar-
macological blockade of the canonical BMP signaling pathway significantly
decreased infiltration of CNS and consistently resulted in amelioration of clinical
parameters including neurologic score.
Summary/Conclusions: These results indicate that high BMP4 levels are
required for both bone marrow engraftment and CNS infiltration by B-ALL cells.
BMP4 levels in leukemia cells could be a useful biomarker to identify children
with poor outcome in the childhood B-ALL of low-/intermediate-risk groups.
Furthermore, BMP4 could be a new therapeutic target to blockade leukemic
CNS disease.
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TARGETING LOCALIZATION OF THE IL-7 RECEPTOR WITHIN LIPID
RAFTS AS A THERAPEUTIC STRATEGY FOR T-CELL ACUTE LYMPHOBLASTIC
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R. Quéré1
1Signaling And Physiology In Hematological Research, UMR1231 Inserm, Uni-
versité Bourgogne Franche-Comté, AgroSup, Dijon, 2Institut Curie, PSL
Research University, UMR9187 U1196, CNRS-Institut Curie, Inserm, Centre
Universitaire, Orsay, 3Commissariat à l’Energie Atomique et aux Energies Alter-
natives (CEA), DSV-IRCM-SCSR-LSHL, Inserm UMR 967, Fontenay-aux-Ros-
es, 4Clinical Hematology Department, François Mitterand University Hospital,
Dijon, France
Background: T-cell acute lymphoblastic leukemia (T-ALL) is a hematological
malignancy characterized by immature T-cell excessive proliferation. To achieve
remission, patients typically undergo 2 years of chemotherapy, associated with
acute and chronic side effects. To enable reduced chemotherapy intensity and
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treat relapsed patients, there is still a need to develop new and effective targeted
therapies. Previous evidence has shown IL-7 as a fundamental cytokine for nor-
mal T-cell development and homeostasis, as well as an important determinant
for the T-ALL cell viability and proliferation in vitro and in vivo. Several strategies
have been explored for the treatment of T-ALL, and targeting Interleukin 7 recep-
tor alpha-chain (IL-7Rα) and downstream IL-7 signaling offers a potentially effec-
tive therapeutic strategy for T-ALL. The IL-7Rα is recruited and concentrated
into lipid rafts thereby amplifying its downstream signaling pathway. The IL-
7/STAT5 signaling pathway mediates downregulation of pro-apoptotic signals
on human T-cells such as BAD and BIM. Moreover, we have previously reported
that a new compound named Pyrido[4,3-b]Quinoxaline (PyQ) has an anti-
tumoral effect on Acute Myeloblastic Leukemia (AML). It strongly interacts with
the plasma membrane of AML cells and affects the positioning of the protein
tyrosine phosphatase CD45, which is usually organized in microdomains into
lipid rafts floating on the cell surface, and is delocalized by PyQ.
Aims: The aim of this study was to assess the anti-tumoral effect of PyQ on T-
ALL cells and to identify which signaling pathway is affected by the compound.
Methods: We have 2 models of human T-ALL which can be studied in vitro
when cocultured with murine stromal MS5 cells and in vivo when transplanted
into immunodeficient NOD/SCID/γc−/− (NSG) mice. We also work on primary
T-ALL blasts isolated from 10 patients suffering of T-ALL and maintained frozen
in a biobank.
Results: In this study, we have shown that PyQ delocalizes the IL-7Rα away
from lipid rafts on the cell surface of human T-ALL cells. We have also proved
that localization of the IL-7Rα among lipid rafts plays a crucial role in human
T-ALL maintenance in vitro. Its delocalization leads to IL-7 signaling pathway
inactivation, upregulation of BAD and BIM genes involved in apoptosis and T-
ALL cells apoptosis. We furthermore assessed effect of PyQ on 10 samples of
primary T-ALL blasts. All of them were sensitive to IL-7-dependent cell survival
and revealed a marked response to PyQ treatment (Mean IC50=5.7 ng/mL).
For this work, T-ALL cells were co-cultured on murine stromal MS5 cells and
PyQ has affected mainly T-ALL cell growth. No effect was observed on the
stromal feeder cells, suggesting that injection of PyQ in vivo would not impact
the stromal microenvironment in bone marrow. Finally, we provided evidence
that PyQ delayed T-ALL progression in vivo, after treatment of immunodeficient
mice xenografted with T-ALL cells.
Summary/Conclusions: The findings of this study highlight the importance of
the IL-7Rα localization in maintenance of T-ALL cells and may lead to the
design of a new generation of anti-cancer drugs able to modulate the protein
positioning into lipid rafts.
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Background: Cure rates for acute lymphoblastic leukemia (ALL) have
increased to ~90% in the last decades, but come at a high cost as a substantial
proportion of these children sustain toxic side-effects. Osteonecrosis (ON) is
one of the most common and debilitating side effects, which severely impacts
quality of life.
Aims: To analyze whether systematic magnetic resonance imaging (MRI)
screening of adolescents can identify those with asymptomatic ON (stage I
and II), who subsequently develop symptomatic ON.
Methods: Children diagnosed with ALL aged ≥10 years, who were enrolled in
the ongoing prospective multicenter OPAL (osteonecrosis in pediatric patients
with ALL or lymphoblastic lymphoma LBL) trial, were analyzed. Standardized
MRI screening of the hips and knees was scheduled at diagnosis and 6, 9, 12,
15, 18 and 24 months into treatment. All patients were assessed according to
a standardized case report form recording symptoms and activities of daily liv-
ing and functional impairments of the hips and knees based on modified Harris
Hip and Knee Society scores every 3 months from diagnosis to the end of
antileukemic treatment.
Results: Between 03/2013-12/2016, 64 patients (pts) were enrolled, median
age at ALL diagnosis was 15 years (range 10-17), median time under evaluation
was 11 months (range 0-45). 31 (48.4%) pts were male, 33 (51.6%) female. 61
(95.3%) were diagnosed with ALL, 3 (4.7%) with LBL. 36 (56.2%) pts were
treated according to the AIEOP-BFM 2009 trial, 25 (39.1%) pts to the CoALL-
08-09 trial and 3 (4.7%) pts were enrolled in the NHL-BFM registry and treated
accordingly. Until December 31st, 2016, 2 (3.1%) pts died treatment related, 4
(6.3%) underwent allogeneic stem cell transplantation, and 5 (7.8%) pts each
relapsed while under treatment and dropped out for other reasons. Thus, so
far, 166 MRIs comprising 664 joints could be evaluated. At initial diagnosis of
the leukemia, MRI showed asymptomatic osteonecrotic lesions stage II or high-
er in 3 of 60 pts (5%), at 6 months in 7 of 34 pts (20.6%) osteonecrotic lesions,
at 9 months in 14 of 23 pts (60.9%), at 12 months in 14 of 23 pts (60.9%), at
15 months in 3 of 11 pts (27.3%), at 18 months in 2 of 9 pts (22.2%), and at
the end of treatment in 2 of 6 pts (33.3%). 11 (17.2%) pts developed sympto-
matic ON between 6 and 15 months from diagnosis (median 10 months). Of
23 pts, in whom screening MRI revealed ON stage II or higher, 11 pts (47.8%)
subsequently developed symptomatic ON whereas in all adolescents devel-
oping symptomatic ON MRI had previously shown signs of ON. Median vol-
umes of epiphyseal necrosis in pts with ON stage II remaining asymptomatic
were 0.6 ml (range 0.1-7.2) and in pts developing symptomatic ON 12.5 ml
(range 12.0-13.9) in the hips and 2 ml (range 0.4-20.5) and 30.5 ml (range
18.3-57) in the knees respectively. Epiphyseal involvement exceeded 30% in
all symptomatic pts, but only in 2 pts remaining asymptomatic. With regard to
the distribution pattern of ON, about twice as many knees as hips were affected
by ON stage II or higher. MRI revealed ON stage III or higher in at least one
joint in 12 pts (20%), predominantly in the knees. Radiological leukemic infil-
tration of bone detected by single screening MRI at diagnosis did not identify
children at high risk of developing asymptomatic ON at six months into therapy
or symptomatic ON anytime in the course of antileukemic treatment. These
findings should be confirmed in larger patient numbers.
Summary/Conclusions: The first analysis of the OPAL trial shows that early
MRI screening identifies extensive asymptomatic lesions in adolescents sub-
sequently developing symptomatic ON.
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FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC
AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR
PH+/BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND
IMPLICATIONS OF MRD ANALYSIS
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Background: Front-line imatinib (IM) plus chemotherapy followed by allogeneic
hematopoietic stem cell transplantation (HSCT) is standard therapy for patients
(pts.) with Ph+ ALL. Relapse after HSCT remains a major cause of treatment
failure, and pts. in whom BCR-ABL transcripts are detectable after HSCT are
at particular risk. Posttransplant maintenance using tyrosine kinase inhibitors
(TKIs) to reduce the relapse rate remains a subject of uncertainty, as data from
prospective studies are limited.
Aims: To determine the impact of IM administration after HSCT on patient out-
come and assess the predictive value of minimal residual disease (MRD) analy-
sis by qRT-PCR of BCR-ABL1 transcripts.
Methods: In this prospective, multicentre trial by the GMALL study group, adult
pts. (≥ 18 y) with Ph+ ALL in CR at HSCT were randomly assigned (1:1) to
receive IM prophylactically after SCT or pre-emptively upon detection of MRD.
Inclusion criteria included engraftment, sufficient hematopoietic and organ func-
tion, no uncontrolled GVHD or infections. Target dose of IM was 600mg/d,
400mg recommended as starting dose. Primary endpoint was molecular or
hematologic relapse, secondary endpoints included survival, DFS, severe tox-
icity and transplant-related mortality. All pts. were followed by frequent serial
MRD analysis after HSCT. An interim analysis was reported previously. We
here provide results of the final analysis of this trial, with long-term follow-up of
up to 11 years after HSCT.
Results: 74 pts. were evaluable, 36 received prophylactic and 38 pts. pre-emp-
tive IM. Median age was 41 y (18-69) and 44 y (19-68), respectively. Disease
status at HSCT was CR1 (n= 67), CR2 (n=5), CR3 (n=1), unknown (n=1). Most
pts. received a PBSC graft (n=71) and myeloablative TBI-based conditioning
(n=65), 8 pts. underwent RIC with 2Gy or 4Gy TBI (n=6) or non-TBI RIC (n=2).
Median time from HSCT to starting IM was 48d and 77d, respectively. IM dose
was 600mg/d in 22% of pts., remaining pts. received 400mg. Treatment was
prematurely discontinued in 56% and 59% of pts., median time to discontinuation
was 251d and 192d. Median follow-up of surviving pts. is 5.6 y (2.4-10.8) and
6.9 y (1.8-11). Relapse rate (14% vs. 18%), NRM (12% vs. 11%) and ongoing
CR (69% vs. 71%) were not significantly different between arms. Probability of
DFS and overall survival at 10 years was 64% vs 69% and 68% vs 71% with
prophylactic and pre-emptive IM, respectively (p=ns). MRD levels were signifi-
cantly predictive of relapse: BCR-ABL1/ABL1 (B/A) ratio ≥10-3 within 6 weeks
prior to HSCT was associated with a higher cumulative incidence of relapse
(CIR) at (47.5% vs 10.6%, p=0.006) and inferior DFS (45% vs 79%, p=0.027)
at 10y. B/A ratio ≥10-4 within 100d after HSCT was likewise associated with a
higher CIR (45% vs 13%, p=0.0046) and inferior DFS (55% vs 71%, p=0.054)
at 8 y. An algorithm combining pre- and early (<100 days) post-transplant MRD
levels (pre: ≥10-3; post: any positivity including below quantitative range) iden-
tified patients with a 60% vs 8.5% CIR at 10 y.
Summary/Conclusions: Post-HSCT intervention with prophylactic or pre-emp-
tive IM is associated with a low relapse risk and excellent long-term survival
and might be considered standard of care in Ph+ ALL pts. undergoing HSCT.
BCR-ABL1 transcript levels prior to and early after SCT are predictive of out-
come and identify a small subset of patients unlikely to benefit, emphasizing
the need for rigorous MRD monitoring. The identified MRD thresholds should
be validated in an independent dataset. Their applicability in the setting of RIC
transplant or 2nd/3rd G TKI remain to be determined.
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ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019
IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/
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Background: The CD19-targeted chimeric antigen receptor (CAR) T-cell ther-
apy CTL019, an investigational therapy that uses reprogrammed cytotoxic T
cells to recognize and eliminate target cells, has shown high response rates in
clinical trials for pediatric/young adult R/R B-ALL. The safety profile in this pop-
ulation has been limited to a single-center trial.
Aims: To identify any new safety issues with CTL019 emerging from use in
multicenter trials.
Methods: Pooled data from 2 single-arm, multicenter phase 2 trials of CTL019
therapy in pediatric/young adult patients (pts) with R/R B-ALL (NCT02435849
and NCT02228096) were used to further characterize the safety of CTL019.
Table 1.
Results: 123 pts were enrolled, 26 were not infused and not included in this
analysis (10 deaths, 9 manufacturing failures, 3 adverse events [AEs], 4 pts
pending infusion). 97 pts received a single infusion of transduced CTL019 cells
(median dose, 3.2×106 [range, 0.2-5.4×106] cells/kg). Median age was 12y
(range, 3-25). During the first 8 wk after infusion, 98% of pts experienced an
AE of any grade (G), 82% experienced G3/4 AEs, and 72% experienced a seri-
ous AE (SAE). Common nonhematologic G3/4 AEs (≥10%) during the first 8
wk were cytokine release syndrome (CRS; 44%), hypotension (24%),
decreased appetite (21%), increased AST (19%) and ALT (12%), hypoxia
(16%), hypokalemia (13%), hypophosphatemia (11%), and pulmonary edema
(10%). Rates of G3/4 AEs and SAEs decreased substantially >8 wk post infu-
sion (41% and 24%, respectively). 21 pts died post infusion: 16 (76%) from B-
ALL (n=2, ≤30 days after infusion; n=14, >30 days); cerebral hemorrhage (n=1)
and embolic infectious stroke (n=1) (both ≤30 days); and infection (n=3, >30
days). Safety events were similar across pt subgroups based on age, sex, prior
allogeneic stem cell transplant (alloSCT) (n=57), and Down syndrome (n=7).
CRS, graded on the UPenn scale, occurred in 81% of pts (Table 1.). All CRS
events occurred <8 wk post infusion. CRS was managed with supportive care,
and 34% of pts were treated with anti-IL-6 agents. No deaths were attributed
to CRS. Pts with ≥50% bone marrow (BM) blasts at enrollment (n=68) were
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twice as likely to develop G3/4 CRS than pts with <50% BM blasts (n=29) (53%
vs 24%). Earlier-onset fever correlated with severity of CRS. CRS grade cor-
related with serum IL-6 levels. CRS-associated coagulopathy with fibrinogen
levels <1.0 g/L was observed in 10% of pts. Neuropsychiatric AEs occurred
during or shortly after CRS resolution, were self-limiting, and were more likely
in pts with severe CRS or history of CNS leukemia or other CNS diseases. No
G4 neuropsychiatric events were observed. Other AEs of special interest within
the first 8 wk included G3/4 neutropenia with high (>38.3˚C) fever (61%) and
infections (G3/4, 22%). Prolonged G3/4 neutropenia (not resolved >28 days)
occurred in 59 pts (61%). 36% of pts with prolonged G3/4 neutropenia had
G3/4 infections after day 28. One pt with prior alloSCT was diagnosed with
unconfirmed gut GVHD. Responding pts developed prolonged B-cell aplasia
that was managed with immunoglobulin replacement. Tumor lysis syndrome
was uncommon (3%).
Summary/Conclusions: This pooled analysis of global experience with
CTL019 across 25 sites and 11 countries found no new safety issues. CRS
and neuropsychiatric events, which are class effects of CAR T-cell therapy,
were effectively managed. CTL019 appears similarly safe in pts with Down
syndrome or prior alloSCT and across age groups. Prolonged follow-up will be
required to determine the long-term safety of B-cell aplasia.
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UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS
PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA
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Background: Ponatinib is a third-generation pan-BCR-ABL inhibitor that is
effective in Philadelphia chromosome-positive (Ph+) acute lymphoblastic
leukemia (ALL) and overcomes the T315I gatekeeper mutation.
Aims: We designed a phase II trial to evaluate the efficacy and safety of hyper-
CVAD plus ponatinib in adults with newly diagnosed Ph+ ALL.
Methods: Adults with newly diagnosed Ph+ ALL received 8 cycles of hyper-
CVAD alternating with high dose MTX/Ara-C every 21-28 days, as permitted by
peripheral count recovery. Patients (pts) who had received 1-2 courses of prior
chemotherapy with or without other TKIs were still eligible. Ponatinib was given
at 45mg daily on days 1-14 of cycle 1. Initially, pts then received ponatinib 45mg
daily continuously beginning with cycle 2. Due to concern for potential cardio-
vascular toxicity with ponatinib, after 39 pts had been treated, the protocol was
amended so that, beginning in cycle 2, pts in CR received ponatinib at a dose
of 30mg daily and pts in complete molecular response (CMR) received 15mg
daily. Rituximab was given during the first 4 cycles in pts with CD20 expression
≥20%; all pts received IT chemotherapy prophylaxis with the first 4 cycles. Pts
in CR after 8 cycles of hyper-CVAD received maintenance with ponatinib, vin-
cristine and prednisone for 2 years followed by indefinite daily ponatinib.
Results: To date, 64 pts have been treated; 10 pts had received prior treatment
at the time of enrollment, 8 of whom were in CR and 2 of whom were not in CR.
Median age was 48 years (range, 21-80 years). 23 pts (36%) were positive for
CD20 expression. BCR-ABL1 transcript was p190 in 45 pts (70%), p210 in 18
(28%) and unknown in 1 (2%). Of 56 pts not in CR at the time of study enroll-
ment, 100% achieved CR; all but 1 pt achieved CR after the first cycle. The
complete cytogenetic response rate was 98%, major molecular response (MMR)
rate was 97% and CMR rate was 77%. The median time to MMR was 3 weeks
(range, 2-14 weeks), and the median time to CMR was 10 weeks (range, 2-96
weeks). The median follow-up was 33 months (range, 2-62 months), and median
number of cycles received was 6 (range, 2-8 cycles). 10 pts (16%) underwent
allogeneic stem cell transplantation (ASCT) in first remission. Overall, 8 pts
have relapsed (3 while still on ponatinib, 3 while on another TKI, 1 while not
receiving a TKI, and 1 after ASCT). 14 pts have died, 8 of whom were in CR.
Two deaths were attributed to ponatinib (both from MI while in CR). 38 pts are
still receiving treatment (consolidation, n=7; maintenance, n=14; post-mainte-
nance TKI, n=17). The 3-year continuous CR and OS rates were 79% and 76%,
respectively. In a 4-month landmark analysis to assess the impact of ASCT,
continued CR and OS did not differ according to whether ASCT was performed
in first remission. Treatment was overall well-tolerated. Myelosuppression was
as anticipated with hyper-CVAD-based therapy, with median times to platelet
and ANC recovery in cycle 1 of 22 days (range, 17-35 days) and 18 days (range,
13-29 days), respectively. In cycles 2-8, the median times to platelet and ANC
recovery were 22 days and 16 days, respectively. Grade ≥3 adverse events
included pancreatitis in 12 pts (19%), hypertension in 8 (13%), thrombotic events
in 4 (6%) and MI in 3 (5%). No grade ≥3 cardiovascular events have occurred
after the protocol amendment with ponatinib dose reductions.
Summary/Conclusions: Hyper-CVAD plus ponatinib is effective in patients
with newly diagnosed Ph+ ALL, resulting in a CMR rate of 77% and encourag-
ing long-term survival.
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PROGNOSTIC IMPLICATIONS OF PRETREATMENT CYTOGENETICS IN
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Background: In the phase 3 INO-VATE study of relapsed/refractory acute lym-
phoblastic leukemia (R/R ALL) patients, inotuzumab ozogamicin (InO) showed
improved complete remission or complete remission with incomplete hemato-
logic recovery (CR/CRi) rates versus standard care (SC; 80.7% vs 29.4%;
P<0.001) (NCT01564784; Kantarjian NEJM 2016 [data cutoff date: Oct 2, 2014]).
Aims: To assess the impact of baseline karyotype on response and toxicities
in R/R ALL patients receiving InO from the INO-VATE study
Methods: Full study details have been previously published. At screening,
karyotyping was performed locally; ≥20 metaphase count was recommended
for cytogenetic analysis. Karyotypes were interpreted using the International
System for Cytogenetic Nomenclature. CR/CRi and minimal residual disease
(MRD) negativity rates (defined as <0.01% bone marrow blasts as assessed
at a central laboratory) were compared using a chi-square test or Fisher exact
test. Survival estimates were compared using a log-rank test. Data as of March
8, 2016, are presented. Informed consent was obtained from all patients. All
analyses presented were not adjusted for multiple testing.
Results: Of 326 patients randomized, 284 had cytogenetic data at screening
(InO: 144; SC: 140). Of 164 InO-treated patients, 21.3% had normal diploid
karyotype (≥20 metaphases), 17.1% complex (≥5 abnormalities), 13.4%
Philadelphia-chromosome positive (Ph+) disease, 6.7% diploid (<20 or
unknown metaphases), 4.9% hyperdiploidy >50, 4.9% aberrations involving
mixed lineage leukemia (MLL), 1.8% low hypodiploidy/near-triploidy, 1.2% Del
(9p), 16.5% other chromosomal abnormalities, and 12.2% missing. Of 164
InO-treated patients, CR/CRi rate was 73% (95% confidence interval [CI]
66‒80; Table) and MRD negativity rate was 59% (95% CI, 51‒67). With InO,
CR/CRi and MRD negativity rates were similar between the various cytogenetic
subgroups. CR/CRi rates were significantly higher with InO versus SC in diploid
(≥20 metaphases), complex, other, and missing cytogenetic subgroups
(P≤0.015) and numerically higher in the other cytogenetic subgroups. With
InO, more patients with diploid (≥20 metaphases) karyotype proceeded to stem
cell transplant versus other cytogenetic subgroups. With InO, the duration of
remission (DoR) was significantly different between cytogenetic subgroups
(P<0.0001), with diploid (≥20 metaphases) and other subgroups having the
longest median DoR numerically and MLL subgroup having the shortest median
DoR numerically; no significant differences in DoR were seen between cyto-
genetic subgroups with SC (P=0.3783). Significant differences in PFS were
seen between cytogenetic subgroups with InO (P=0.0063); no significant dif-
ferences were seen between cytogenetic subgroups with SC (P=0.5427). With-
in the InO and SC arms, overall survival (OS) differences between cytogenetic
subgroups were not significant (P=0.1629 and 0.3040, respectively); however,
although not statistically significant based on 97.5% CI for hazard ratio (HR),
OS was numerically longer (HR <1) with InO versus SC in diploid (≥20
metaphases), MLL, complex, other, and missing cytogenetic subgroups. Gen-
erally, adverse event profiles did not vary by cytogenetic subgroup.
Table 1.
Summary/Conclusions: In patients with diploid (≥20 metaphases), complex,
other, and missing cytogenetic karyotypes, CR/CRi rates were significantly
higher with InO versus SC. In the diploid (≥20 metaphases), MLL, complex,
other, and missing cytogenetic subgroups, OS favored InO versus SC, though
not statistically significant. Safety profiles generally were similar to the overall
study population.
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Background: Clofarabine (CLO) was demonstrated active in R/R ALL in com-
bination with cyclophosphamide (CY) and/or other agents. An encouraging
complete remission rate (CR 4/6, 67%) was obtained with a reference CLO-
CY combination (Karp J et al, Blood 2007), however severe toxicity partly relat-
ed to very high CY dosage forced stepwise reduction of CLO from 40 to 20-
10mg/m2/d.
Aims: A modified schedule combining full-dose CLO with attenuated CY (given
after 2 hrs to inhibit CLO-damaged DNA repair) was piloted by GIMEMA. Here
we report the activity and toxicity of the new CLO-CY regimen.
Methods: Study GIMEMA LAL1610 (EudraCT 2010-019742-12) had a two-
stage Simon design, with an exploratory cohort of 10 patients and, provided a
complete remissions (CR) was achieved in 3, an extension cohort of 17 patients.
Primary study endpoint was CR rate, with 11 CRs (40%) required to declare
CLO-CY worthy of further investigation. CRi was CR with incomplete recovery
of neutrophils (<1.0) and/or platelets (<100). Eligible patients were adults with
Philadelphia-negative (Ph-) R/R ALL, either primary refractory or in first isolated
marrow relapse <24 months from first CR, including relapse after allogeneic
stem cell transplant (SCT). CLO was administered IV at 40mg/m2/d for 5 con-
secutive days, followed after 2 hrs by IV CY 400mg/m2/d. Clinical and hema-
tological response was assessed on day 28 or later, according to clinical course
and patient condition. One/two courses were planned, followed by allogeneic
SCT when possible.
Results: From October 2012 to December 2015, 35 patients were screened
and 27 enrolled. Median patient age was 38.7 years (range 20.5-59.6), 15 were
male, 4 with T- and 23 B-precursor ALL, 2 refractory and 25 relapsed (after a
median of 5.9 months, range 1.9-23.4), 5/11 evaluable with high-risk cytoge-
netics [2 complex; 2 t(4;11), 1 MLL-rearranged]. Median white blood cells and
marrow blast percentage were 5.67 (range 1-55) and 73 (range 8-100), respec-
tively. All but one patient (treatment interruption due to traumatic fall) received
CY-CLO as planned. Nine patients achieved CR and 7 CRi after course 1 (over-
all response 59.2%; 6/10 in study stage one), 2 had a partial response, 5 were
refractory, 3 died early and one survived with pancytopenic marrow. In relapsed
patients, only the length of prior remission affected the probability of CR, from
44.4% (n=8/18) to 100% (n=6/6) if ≤ or >12 months, respectively (P=0.02). In
10 evaluable patients, median post-induction MRD was 0.01% (<0.001% in 3).
Six CR patients received a second course, which was curtailed in 2 due to tox-
icity, and 10 responders had an allogeneic SCT (62.2%). Concerning toxicity,
10 patients experienced grade ≥2 toxicity, but apart from expected myelosup-
pression/infections only 6 therapy-related grade >2 adverse events occurred:
hepatic (n=4), renal (n=1) and neurological (n=1). After a median follow-up of
17.7 months (range 1.2-29.5), 5 patients are in continuous CR, 5 relapsed, and
6 died in CR (3 post-allograft; SCT-related mortality 30%). Median and 1-year
overall and disease-free survival (OS, DFS) are 6.5 months and 28.6% (95%
CI, 15.3-53.3%), and 4.5 months and 34.7% (95% CI, 17.3-69.7%), and apart
from patient age (OS: HR 1.053, P=0.01) no other risk factor or length of prior
CR affected DFS/OS probabilities.
Summary/Conclusions: Although the management of R/R Ph- ALL remains
largely unsatisfactory, this regimen with full-dose CLO plus attenuated CY
proved feasible and yielded an appreciable CR rate in adult patients suffering
from isolated marrow relapse within 24 months from date of first CR. 
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BLINATUMOMAB USE IN PEDIATRIC AND ADOLESCENT PATIENTS WITH
RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC
LEUKEMIA FROM AN OPEN-LABEL, MULTICENTER, EXPANDED ACCESS
STUDY
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M. O’Brien8, L. Belton9, R. Handgretinger10
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Background: Blinatumomab, a bispecific T-cell engager antibody construct,
has shown antileukemia activity and tolerability in patients with relapsed/refrac-
tory B-precursor acute lymphoblastic leukemia (ALL). 
Aims: We further evaluated safety and efficacy of blinatumomab in pediatric
and adolescent patients with relapsed/refractory B-precursor ALL enrolled in
an expanded access study (NCT02187354).
Methods: Eligible patients (aged >28 days to <18 years) had ≥5% blasts and
relapsed/refractory B-precursor ALL (refractory to prior treatments, second or
later relapse, or relapse after allogeneic hematopoietic stem cell transplantation
[alloHSCT]). Blinatumomab was dosed by continuous intravenous infusion (4
weeks on/2 weeks off) for up to five cycles (≥5 to <25% blasts: 15µg/m2/day;
≥25% blasts: 5µg/m2/day on days 1-7 in cycle 1, then 15 µg/m2/day). The pri-
mary endpoint was incidence of treatment-emergent (TE) and treatment-related
(TR) adverse events (AEs). Key efficacy endpoints were complete response
and minimal residual disease (MRD, measured by polymerase chain reaction
or flow cytometry) response within the first two cycles, relapse-free survival,
overall survival, and incidence of alloHSCT.
Results: Among the first 40 treated patients (median age, 9 [range, 1–17]
years), 24 (60%) had experienced ≥2 relapses, 20 (50%) had relapsed after
alloHSCT, and 5 (13%) were primary refractory; 18 (45%) had ≥50% blasts
and 21 (53%) had prior alloHSCT. Safety and key efficacy outcomes are shown
in the table. Twenty-five patients (63%) achieved a complete response within
the first two cycles, 19 of whom had an MRD response. Eight patients relapsed
and 20 died after treatment. Regardless of causality, the most frequent TEAEs
were pyrexia (78%), cytokine release syndrome (CRS; 23%), vomiting (23%),
and anemia (20%). All nine CRS events were grade 1 or 2, and one tumor lysis
syndrome was grade 3. Ten (25%) patients interrupted treatment and two (5%)
discontinued due to TRAEs; 13 (33%) patients had grade ≥3 TRAEs, including
two of three neurologic events (depressed level of consciousness and
headache; both grade 3). Two patients experienced fatal AEs, both of which
were considered unrelated to blinatumomab. 
Table 1.
aWithin the first two cycles
Summary/Conclusions: Blinatumomab showed antileukemia activity in pedi-
atric and adolescent patients with high-risk relapsed/refractory B-precursor ALL
including t(17;19) and AEs were consistent with those previously reported for
relapsed/refractory ALL. 
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PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION
OF ANTI-CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE
CILOLEUCEL (AXI-CEL)
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Background: The incidence of acute lymphoblastic leukemia (ALL) is increas-
ing, with nearly 6600 new diagnoses expected in 2016, of which >40% will
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affect adults aged >20 years (https://seer.cancer.gov). Adult patients (pts) with
B cell ALL show high-risk disease biology, high rates of relapse, and poor sur-
vival (J Clin Oncol 2011;29:532; Blood 2012;119:34). Promising results have
been observed with KTE-C19, an anti-CD19 chimeric antigen receptor (CAR)
T cell therapy, in refractory, aggressive non-Hodgkin lymphoma (Blood
2016;128:LBA-6), and suggest an opportunity to improve outcomes in ALL.
Here, we present updated results from the phase 1 portion of ZUMA-3, a mul-
ti-center study of KTE-C19 in pts with high tumor burden ALL.
Aims: The goal of this study is to assess safety and efficacy of KTE-C19 in
adult pts with relapsed/refractory ALL who have high disease burden.
Methods: Eligible pts were ≥18 years of age with relapsed/refractory ALL (Ph+
pts eligible), ≥25% bone marrow lymphoblasts, adequate organ function, and
Eastern Cooperative Oncology Group status 0-1. Pts received 1 or 2 × 106
CAR T cells/kg after conditioning with cyclophosphamide and fludarabine. The
primary endpoint of phase 1 was incidence of dose-limiting toxicity (DLT). Sec-
ondary endpoints were efficacy outcomes of KTE-C19, including complete
response (CR) rates and biomarker associations.
Results: As of Nov 1, 2016, 11 pts were enrolled, and 10 were treated with
KTE-C19. One pt had a serious adverse event prior to dosing and was not
treated. KTE-C19 was successfully manufactured in a centralized facility for
all pts across a broad range of baseline absolute lymphocyte counts in 6 days,
with a turnaround time of ~2 weeks. Pts were 60% men, with 1-4 prior lines of
therapy and high disease burden (median, 81% bone marrow lymphoblasts).
No pt (0/3) experienced a DLT at the 2 × 106dose, and phase 1 was then
expanded to 6 pts at the 2 × 106dose. One pt experienced a grade 5 adverse
event of multi-organ failure due to cytokine release syndrome (CRS), and sub-
sequent pts (n=4) received 1 × 106 CAR T cells/kg. Across all pts, the most
common grade ≥3 adverse events were cytopenias (80%), febrile neutropenia
(50%), pyrexia (40%), and transaminitis (40%). Grade ≥3 CRS and neurologic
events were reported in 20% and 40% of pts, respectively. Cerebral edema
was not observed. All CRS events resolved (except the grade 5 event); neu-
rologic events resolved in 5 of 6 pts (1 grade 3 neurologic event ongoing at
cut-off). Anti-CD19 CAR T cells achieved peak expansion within two weeks of
infusion. Of the 8 efficacy evaluable pts, 6 (75%) achieved remission (including
CR and CR with either partial or incomplete hematopoietic recovery) by day
28 disease assessment or earlier. All remissions (100%) were minimal residual
disease-negative. Of the 6 pts achieving minimal residual disease-negative
CR, two eventually relapsed, one with CD19- disease and one with CD19+
disease. Safety and efficacy data were similar across KTE-C19 doses. Updated
pt number, follow-up, and biomarker data will be presented.
Summary/Conclusions: No DLTs were observed with KTE-C19 in adult pts
with high BM disease burden; one pt with high disease burden had grade 5
CRS after completion of the DLT cohort. Manufacturing was successful in all
pts; most pts achieved a minimal residual disease-negative CR. These results
demonstrate promising efficacy with a manageable safety profile. Based on
these results, ZUMA-3 continues to enroll pts, adding measures to further
enhance safety and with planned expansion to phase 2.
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Background: The incidence of acute lymphoblastic leukemia (ALL) is increas-
ing, with nearly 6600 new diagnoses expected in 2016, of which >40% will
affect adults aged >20 years (https://seer.cancer.gov). Adult patients (pts) with
B cell ALL show high-risk disease biology, high rates of relapse, and poor sur-
vival (J Clin Oncol 2011;29:532; Blood 2012;119:34). Promising results have
been observed with KTE-C19, an anti-CD19 chimeric antigen receptor (CAR)
T cell therapy, in refractory, aggressive non-Hodgkin lymphoma (Blood
2016;128:LBA-6), and suggest an opportunity to improve outcomes in ALL.
Here, we present updated results from the phase 1 portion of ZUMA-3, a mul-
ti-center study of KTE-C19 in pts with high tumor burden ALL.
Aims: The goal of this study is to assess safety and efficacy of KTE-C19 in
adult pts with relapsed/refractory ALL who have high disease burden.
Methods: Eligible pts were ≥18 years of age with relapsed/refractory ALL (Ph+
pts eligible), ≥25% bone marrow lymphoblasts, adequate organ function, and
Eastern Cooperative Oncology Group status 0-1. Pts received 1 or 2 × 106
CAR T cells/kg after conditioning with cyclophosphamide and fludarabine. The
primary endpoint of phase 1 was incidence of dose-limiting toxicity (DLT). Sec-
ondary endpoints were efficacy outcomes of KTE-C19, including complete
response (CR) rates and biomarker associations.
Results: As of Nov 1, 2016, 11 pts were enrolled, and 10 were treated with
KTE-C19. One pt had a serious adverse event prior to dosing and was not
treated. KTE-C19 was successfully manufactured in a centralized facility for
all pts across a broad range of baseline absolute lymphocyte counts in 6 days,
with a turnaround time of ~2 weeks. Pts were 60% men, with 1-4 prior lines of
therapy and high disease burden (median, 81% bone marrow lymphoblasts).
No pt (0/3) experienced a DLT at the 2 × 106dose, and phase 1 was then
expanded to 6 pts at the 2 × 106dose. One pt experienced a grade 5 adverse
event of multi-organ failure due to cytokine release syndrome (CRS), and sub-
sequent pts (n=4) received 1 × 106 CAR T cells/kg. Across all pts, the most
common grade ≥3 adverse events were cytopenias (80%), febrile neutropenia
(50%), pyrexia (40%), and transaminitis (40%). Grade ≥3 CRS and neurologic
events were reported in 20% and 40% of pts, respectively. Cerebral edema
was not observed. All CRS events resolved (except the grade 5 event); neu-
rologic events resolved in 5 of 6 pts (1 grade 3 neurologic event ongoing at
cut-off). Anti-CD19 CAR T cells achieved peak expansion within two weeks of
infusion. Of the 8 efficacy evaluable pts, 6 (75%) achieved remission (including
CR and CR with either partial or incomplete hematopoietic recovery) by day
28 disease assessment or earlier. All remissions (100%) were minimal residual
disease-negative. Of the 6 pts achieving minimal residual disease-negative
CR, two eventually relapsed, one with CD19- disease and one with CD19+
disease. Safety and efficacy data were similar across KTE-C19 doses. Updated
pt number, follow-up, and biomarker data will be presented.
Summary/Conclusions: No DLTs were observed with KTE-C19 in adult pts
with high BM disease burden; one pt with high disease burden had grade 5
CRS after completion of the DLT cohort. Manufacturing was successful in all
pts; most pts achieved a minimal residual disease-negative CR. These results
demonstrate promising efficacy with a safety profile. Based on these results,
ZUMA-3 continues to enroll pts, adding measures to further enhance safety
and with planned expansion to phase 2.
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Background: Blinatumomab, a bispecific T-cell engager antibody construct,
has shown improved overall survival vs standard of care (SOC) chemotherapy
in patients with Philadelphia chromosome−negative relapsed/refractory B-pre-
cursor acute lymphoblastic leukemia (ALL) in a randomized phase 3 study (N
Engl J Med 2017;376:836-847).
Aims: We compared the incidence of adverse events (AEs) observed with bli-
natumomab vs SOC after adjusting for varying treatment exposure times for a
more comprehensive evaluation of safety and tolerability.
Methods: Adults (aged ≥18 years) with relapsed/refractory B-precursor ALL
(refractory to primary induction therapy or salvage therapy, first relapse <1
year, second or later relapse, or relapse after allogeneic hematopoietic stem
cell transplantation) were randomized to receive either blinatumomab or SOC
(1 of 4 predefined regimens). Blinatumomab was dosed by continuous intra-
venous infusion (4 weeks on/2 weeks off) for up to five induction cycles (9
µg/day on days 1-7 of cycle 1 and 28 µg/day thereafter). Up to four maintenance
cycles (4 weeks on/8 weeks off) were allowed for up to 12 months. Exposure-
adjusted event rates were calculated as the number of events x 100/total expo-
sure time (shown in the table).
Results: Median (range) number of cycles were 1 (1-4) for SOC and 2 (1-9)
for blinatumomab. The highest exposure-adjusted event rates (per 100 patient-
years) were for pyrexia (507 SOC vs 376 blinatumomab), anemia (987 vs 229),
thrombocytopenia (750 vs 126), and neutropenia (351 vs 121), all of which
were lower for blinatumomab than for SOC. Febrile neutropenia (365 vs 93)
and infections (1216 vs 436) were also lower for blinatumomab than for SOC
(p<0.0001). Exposure-adjusted event rates for neurologic events were 743 for
SOC vs 472 for blinatumomab, with median time (range) to onset of 7 (1−43)
days and 7 (1−190) days, respectively, and grade ≥3 cytokine release syn-
drome (CRS) rates were 0 for SOC vs 10 for blinatumomab. The most fre-
quently reported AEs in both cycles 1 and 2 were pyrexia, nausea, and anemia
in both arms; CRS events in the blinatumomab arm decreased between cycle
1 and cycle 2 (14% vs 2%). The majority of fatal AEs were related to infection
in both arms.
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Table 1.
aPer 100 patient-years
Summary/Conclusions: In this study, blinatumomab showed an AE profile
consistent with that previously reported for relapsed/refractory ALL, including
similar rates of manageable CRS and neurologic events. Exposure-adjusted
event rates were generally higher in SOC vs blinatumomab, including for
cytopenias and infections.
P525
FACTORS ASSOCIATED WITH STEM CELL TRANSPLANTATION OUTCOMES
IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC
LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN VERSUS
CONVENTIONAL CHEMOTHERAPY
M. Stelljes1,*, D. J. DeAngelo2, P. Kebriaei3, N. Gökbuget4, H. M. Kantarjian3,
A. Advani5, A. Merchant6, T. Wang7, F. Loberiza8, B. Sleight7, E. Vandendries9,
D. I. Marks10
1University of Münster, Münster, Germany, 2Dana-Farber Cancer Institute,
Boston, 3MD Anderson Cancer Center, Houston, United States, 4Goethe Uni-
versity, Frankfurt, Germany, 5Cleveland Clinic, Cleveland, 6University of South-
ern California, Los Angeles, 7Pfizer Inc, Groton, 8Pfizer Inc, New York, 9Pfizer
Inc, Cambridge, United States, 10University Hospitals Bristol NHS Foundation
Trust, Bristol, United Kingdom
Background: Inotuzumab ozogamicin (InO) therapy in relapsed/refractory
acute lymphoblastic leukemia (R/R ALL) resulted in superior complete remission
(CR)/CR with incomplete hematologic recovery (CRi) rates versus (v) conven-
tional chemotherapy (C) in the Phase 3 INO-VATE trial (NCT01564784; Kan-
tarjian NEJM 2016 [data as of October 2, 2014). More InO v C patients (pts)
proceeded to hematopoietic stem cell transplantation (HSCT; 41% [45/109] v
11% [12/109]; P<0.001).
Aims: To assess factors associated with outcomes after allogeneic HSCT in
patients with R/R ALL who were previously treated with InO.
Methods: Full details have been published. Informed consent was obtained
from all patients. Multivariate analyses (MVA) using Cox regression modeling
were conducted to determine predictors of non-relapse mortality (NRM) and
overall survival (OS).
Results: As of March 8, 2016, 108/326 pts underwent allogeneic HSCT (InO
n=77; C n=31). Baseline characteristics were generally similar, except baseline
platelet values were lower in InO v C pts. More InO v C pts achieved minimal
residual disease negativity during study therapy (MRDneg [best status]; 71% v
26%; P<0.0001). Less InO v C pts received additional therapy before HSCT
(14% v 55%, P<0.0001). NRM rates were higher in InO v C pts at 1 year (yr;
36% [95% CI 26–47] v 20% [8–36]) and 2 yrs (39% [27–51] v 31% [13–51]),
but relapse rates were lower (1 yr, 23% [15–33] v 29% [13–48]; 2 yrs, 33%
[22–44] v 46% [24–65]). No significant difference in post-HSCT survival was
detected in InO v C pts; however, visual inspection of the curve suggested the
survival probability varied before and after 15 months post-HSCT (1 yr, 44%
[95% CI 33–55] v 65% [44–79]; 2 yr, 39% [28–50] v 34% [15–54]). Fatal veno-
occlusive disease (VOD) was observed in 5 InO pts (all during the first 100
days from the date of HSCT) and no C pts. MVA showed that conditioning reg-
imens without dual alkylators and thiotepa were associated (2-sided; P<0.05)
with lower risk of NRM and post-HSCT survival, respectively.
Summary/Conclusions: Compared with C, InO permitted more pts with R/R
ALL to proceed to HSCT in CR/CRi with MRDneg (best status). Despite
increased NRM and fatal VOD, long-term survival was attainable in InO pts. In
pts previously treated with InO, interventions to reduce NRM and improve OS
after HSCT include avoiding dual alkylator conditioning regimens, especially
those containing thiotepa.
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DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779,
SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL
TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS
AND MULTI-DOSE REGIMENS
S. Adams1,*, A. Wilhelm1, L. Harvey1, L. Flaherty1, K. Watkins1, S. Sikka1,
P. Shah1, W. Li1, Y. Kovtun1, C. Sloss1, K. Lai1, M. Miller1, G. Payne1
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Background: Antibody-drug conjugates (ADCs) targeting CD33 are promising
therapeutics in AML, where challenges are achieving efficacy while maintaining
tolerability. Here, we report the payload/ linker design and selection resulting
in a high-Therapeutic Index (TI) ADC with favorable preclinical toxicity profile
across multiple species and antitumor activity in disseminated AML models and
in multi-dose regimens. IMGN779, the final ADC design, is comprised of an
indolino-benzodiazepine mono-imine DNA-alkylating payload, DGN462, cou-
pled by a cleavable N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (s-
SPDB) linker to a CD33-targeting antibody.
Aims: Select the best ADC out of multiple preclinical anti-CD33 ADC candi-
dates, and assess its activity in vitro and in vivo in AML models.
Methods: Unconjugated payloads were evaluated in vitro for cytotoxicity on
human AML cell lines. Payloads were compared, as CD33-targeting conjugates,
in vitro for cytotoxicity on human AML cell lines and in vivo for tolerability in
mice and TI against human AML xenografts. ADCs with cleavable and non-
cleavable linkers were evaluated for cytotoxicity on MDR-positive and -negative
AML cell lines, for tolerability in mice and TI in AML xenografts. IMGN779, the
final ADC design, was evaluated in vivo for toxicity in rats and cynomologus
monkeys. IMGN779’s antitumor activity was evaluated in disseminated models
and in fractionated- and multi-dose regimens in AML xenografts.
Results: First, we selected a high affinity antibody to CD33 with retained ADCC
activity. Next, given concerns for long-term toxicity of DNA crosslinkers, we
prepared DNA alkylating (single strand DNA damage) and DNA crosslinking
(double strand DNA damage) versions of our novel IGN payload class. Both
versions had comparable IC50s on human AML cell lines as free drugs (12-
260 vs. 5-77 pM) and as CD33-targeting ADCs (0.7 vs. 0.5 pM). However, in
vivo, the CD33-targeting DNA alkylating ADC had a 5-fold higher MTD (maxi-
mum tolerated dose) in mice and 5-fold larger TI in AML xenograft models (MTD
950 vs. 190 µg/kg, by payload; TI of 95 vs. 19). In addition, the DNA crosslinking
version led to delayed systemic toxicity at MTD, not seen in the DNA alkylating
version even at its 5-fold higher MTD. Thus we selected the DNA alkylating
version for further development. To determine the optimal linker design, we
created ADCs with three different linkers, one non-cleavable and two cleavable,
and based on improved in vitro efficacy (IC50) and in vivo safety/efficacy (MTD,
TI), the s-SPDB cleavable linker with the DNA alkylating payload was chosen
as the lead clinical compound, and named IMGN779. In multiple species,
IMGN779 had a consistent toxicity profile (mice, rats and monkeys), producing
reversible cytopenias with no or minor changes in transaminases and without
histologic evidence of hepatotoxicity. Importantly, IMGN779 was highly active
at a single dose 10 µg/kg (payload) in an MV4-11 (FLT3-ITD+) disseminated
AML xenograft model, producing a 90% increased life span, and was well-tol-
erated and highly active in repeat dosing regimens (10 or 30 µg/kg, qw x 3 and
q3d x 3) in a HL60 AML xenograft model. Similarly, in a MV4-11 xenograft mod-
el, fractionated dosing (5 µg/kg, qw x 2 or q3d x 2) generated 33% more long-
term tumor-free survivors compared to single-dose (10 µg/kg), demonstrating
tolerability and enhanced efficacy in multi-dose and fractionated regimens.
Summary/Conclusions: IMGN779, designed as the next generation CD33-
targeting ADC, utilizes a novel DNA alkylating DGN462 payload and a cleavable
disulfide linker, selected to maximize anti-AML activity and preclinical safety.
IMGN779 is highly active in multiple AML xenograft models, including models
with poor prognostic factors, and is well-tolerated in preclinical repeat dosing
regimens, where an additional benefit was achieved with a fractionating the
dosing regimen over a single high dose. These results provide the foundation
for the clinical evaluation of IMGN779 in AML.
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THE MIXED LINEAGE LEUKEMIA FUSION PARTNER ENL RECRUITS PAF1
TO CLEAR POLYCOMB-INDUCED TRANSCRIPTIONAL REPRESSION
K. Hetzner1, M. Garcia-Cuellar1, C. Büttner2, R. Slany1,*
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Background: In mixed lineage leukemia ENL is frequently found juxtaposed
to MLL creating MLL-ENL fusion proteins that initiate leukemogenic transfor-
mation. Interestingly, mutations of ENL have also been found in Wilms’ Tumor,
a pediatric nephroblastoma. In its wild-type configuration ENL serves as scaf-
folding factor in protein complexes that stimulate transcriptional elongation but,
paradoxically, it also co-purifies with polycomb repressive complex 1 (PRC1).
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Aims: This work examines how ENL influences PRC1 repressive activity.
Methods: The effect of ENL on transcriptional activity of model promoters and
endogenous transcriptional control elements was studied by biochemical and
molecular biology methods.
Results: Here we demonstrate that ENL overcomes polycomb induced silenc-
ing through recruitment of polymerase associated factor 1 (PAF1) a chromatin
reader linked to a histone ubiquitination complex. The ability to bind PAF1 con-
trolled the ability of ENL to neutralize polycomb-mediated repression in an
elongation reporter system and also during transformation of primary cells by
MLL-ENL in vivo. Inactivation of polycomb by ENL was accompanied by ubiq-
uitination of histone H2B, the hallmark activity of PAF1 allied enzymes. On a
global level ChIP-Seq and nascent RNA-Seq demonstrated that MLL-ENL tar-
get genes stood out with a supraphysiological accumulation of H2BUb accom-
panied by hyper-accelerated transcription rates. Interestingly, examination of
Wilms tumor specific ENL mutants allowed to elucidate the underlying mech-
anism of the MLL-fusion induced ENL hyperactivity. Introduction of Wilms-spe-
cific ENL mutants into primary hematopoietic cells induced aberrant transcrip-
tion and H2BUb modification of Hoxa9 and Meis1, two sentinel loci for poly-
comb action. This was dependent on the conserved YEATS domain of ENL
that operated as “switch” binding either histone H3 or PAF1 thus effectively
regulating ENL function as anti-repressor or elongation factor, respectively.
Wilms-mutations aberrantly favored interaction with PAF1 and thus perturbed
proper silencing. This effect was intensified in a MLL-ENL fusion where MLL
itself provided a constitutive tether to PAF1 effectively creating a “super-tran-
scription factor” that constitutively combined anti-repression with elongation
capabilities.
Summary/Conclusions: In summary, targeting histone ubiquitination may be
an additional Achilles heel for mixed lineage leukemia that merits further inves-
tigation of therapeutical utility.
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Background: Although numerous genetic mutations contribute to the etiology
and pathophysiology of acute myeloid leukemia (AML), the molecular machin-
ery that is not mutated but supports AML biology remains largely unknown.
Several studies have shown that AML cells, irrespective of genetic sub-type,
display an oxidized intracellular redox environment compared to their healthy
counterparts. The redox environment of AML cells is largely due to the elevated
reactive oxygen species (ROS) levels, which are a class of free radical mole-
cules. Though ROS are by-products of several cellular processes, in excess,
they can damage DNA and destroy organelles, resulting in the acquisition of
genetic mutations or cell death. As a result, ROS homeostasis is tightly regu-
lated by an array of molecular pathways. Although ROS is elevated in AML
cells, the role of ROS and the identity of its regulators remain largely unknown.
Here we report that the serine/threonine kinase, PKCε regulates the ROS-neu-
tralizing enzyme SOD2 to support mitochondrial redox homeostasis and AML
progression.
Aims: The goal of this study was to identify and subsequently assess how tar-
geting key ROS-regulatory pathways impacts AML biology.
Methods: Loss-of-function studies for PKCε and SOD2 were performed with
recombinant lentiviruses expressing gene-targeting shRNAs. Recombinant
retroviruses expressing either PKCε and SOD2/Catalase were used for gain-
of-function assays. Cytoplasmic and mitochondrial superoxides and peroxides
were measured using redox-sensitive GFP (roGFP) probes followed by flow
cytometric analysis. Mitochondrial superoxides were also assessed by flow
cytometric analysis of MitoSox stained cells. Proteomic analysis was achieved
using nano LC-MS/MS. Annexin-V staining was analyzed by flow cytometry to
measure cell death. In vivo and in vitro mouse studies were performed by
FACS-based purification of shRNA-expressing cells followed either by: 1)
growth in cytokine-enriched media or 2) transplantation into syngenic mice for
survival analysis. 
Results: We have discovered that inhibition of PKCε: 1) promoted the death
of human and murine AML cell lines in vitro, 2) reduced AML progression driven
by MLL-AF9 in vivo (p=0.0014) and 3) obstructed the growth of 5 out of 7 PD-
AML samples in vitro. At the molecular level, we observed that PKCε inhibition
led to a significant and dose-dependent increase in mitochondrial-produced
superoxides–a specific type of ROS. Moreover, we found that enforced expres-
sion of PKCε can protect AML cells from lethal effects of superoxide-inducing
agents 2-thenoyltrifluoroacteone and Antimycin A. To identify potential ROS-
regulatory enzymes downstream of PKCε, we performed whole cell proteomics
and found that the mitochondrial superoxide-neutralizing enzyme SOD2 is
decreased in AML cells depleted of PKCε. Similar to PKCε inhibition, we also
observed that genetic inhibition of SOD2 reduced the expansion of AML cell
lines and PD-AMLs in vitro as well as significantly extended the onset of MLL-
AF9-driven AML in vivo (p=0.0042). Finally, we also found that enforced expres-
sion of SOD2 in tandem with another anti-oxidant enzyme Catalase, reverses
the anti-leukemia effects of PKCε inhibition confirming that PKCε supports AML
pathophysiology by maintaining mitochondrial redox homeostasis.
Summary/Conclusions: Our results indicate that PKCε and SOD2 regulate
mitochondrial redox homeostasis to support AML cell survival and disease pro-
gression and thus may represent a foundation for designing and developing




ROLE OF SHP2 IN A MOUSE MODEL OF AML CARRYING FLT3-ITD
ALONG WITH LOSS OF TET2
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Background: SHP2, a protein tyrosine phosphatase coded by Ptpn11, is an
essential protein that integrates signals from several different tyrosine kinase
receptors with all the major intracellular signaling pathways such as ERK, PI3K
and STAT pathways and regulates cell survival, proliferation and differentiaition.
One of the SHP2 dependent cytokine receptor kinase, FLT3 when mutated to
be constitutively activated co-operates with other genetic lesions like loss of
Tet2 and Dnmt3a leading to transformation of myeloproliferative neoplasm
(MPN) to acute myeloid leukemia (AML) in mouse models. Tet2 and Dnmt3a
are involved in regulation hematopoietic stem cell (HSC) self-renewal and dif-
ferentiation programs through regulation of DNA methylation. One their own
each of them leads to MPN but when present in combination, leads to AML.
These mouse models of AML have a more pronounced stem cell phenotype
and are resistant to traditional chemotherapy or FLT3 targeted kinase inhibitor.
Aims: Inhibition of SHP2 catalytic activity by a small molecule allosteric inhibitor
has been recently demonstrated to retard the growth of receptor tyrosine kinase
driven malignancies. Therefore, we wanted to investigate the role of SHP2 in
leukemogenesis driven by loss of an epigenetic regualtor (Tet2) and aberrant
cytokine receptor tyrosine kinase (Flt3-ITD) signaling.
Methods: Mice were intercrossed to generate Ptpn11F/FTet2-/-
Flt3ITD/+Mx1Cre+ or Ptpn11F/FTet2-/-Flt3ITD/+Mx1Cre- mice. Deletion of Ptpn11
was induced at 8-10 week of age by injecting poly IC and changes in the
hematopoietic compartment were analyzed by flow cytometry. Cell autonomous
and non-autonomous effects of Ptpn11 on leukemogenesis were also evaluated
in transplantation models.
Results: After ploy IC induced deletion of Ptpn11 there was a significant dif-
ference in the median survival between leukemic mice with with deletion of
Ptpn11 versus non-deleted (n=8). Though the Ptpn11 deleted leukemic mice
showed almost complete loss of long term HSC with concomitant increase in
short term proliferating HSC in the bone marrow, they were still able to home
and engraft in lethally irradiated recipient mice. These results indicate that loss
of Ptpn11 does not impair the engraftment of leukemic stem cells though in
normal mice deletion of Ptpn11 impairs the ability to stem cells to home to
bone marrow niche and engraft. Deletion of Ptpn11 in both primary mice and
secondary recipients was also associated with deregulation of myeloid and
lymphoid cell distribution both in the periphery and bone marrow. Mice with
deletion of Ptpn11 in the context of Flt3ITD/+did not generate immature or mature
B cells. The effects of Ptpn11 deletion were more severe in primary mice as
compared to mice that received Ptpn11 deleted cells or when Ptpn11 was delet-
ed after transplantation suggesting a role for SHP2 function in the bone marrow
microenvironment in this model of leukemogenesis.
Summary/Conclusions: SHP2 has been recognized as a proto-oncogene on
the basis of its ability to induce hematological malignancies when it is constitu-
tively active and loss of SHP2 catalytic activity is associated with inhibition of
tyrosine kinase driven malignancies. Our results demonstrate that the role of
SHP2 in AML is dependent upon the presence of other genetic mutations. SHP2
regulates AML with loss of Tet2 with concomitant expression of Flt3-ITD through
influence on both leukemic cells and the bone marrow microenvironment.
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TRIGGERS A PROFOUND TUMOR REGRESSION OF DIVERSE ORIGINS
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Background: Although Runt-related transcription factor 1 (RUNX1) has been
generally considered to be a tumor suppressor, a growing body of evidence
suggests its pro-oncogenic property in acute myeloid leukemia (AML).
Aims: Demonstrate the anti-tumor potential of cluster regulation of RUNX with
a “gene-switch” in AML as well as in dismal-prognostic solid tumors arising
from diverse origins in vivo.
Methods: To assess the effect of RUNX-inhibition in AML cells, we performed
series of shRNA-mediated RUNX knockdown experiments. To achieve cluster
regulations of RUNX, we have computationally designed an agent which could
irreversibly block the RUNX cluster genes expression profiling through disman-
tling protein-DNA interactions sequence-specifically (CRoX-1).
Results: Firstly, shRNA-mediated silencing of RUNX1 stimulated cell cycle
arrest at G0/G1 phase and induced apoptosis in AML cells bearing wild-type
p53. Besides, RUNX1 depletion induced remarkable induction of p53 as well
as its target gene products and additive knockdown of p53 in these cell lines
reverted the phenotype of RUNX1-depletion, indicating that RUNX1 is func-
tionally dependent on proficient p53 pathway. In addition, cycloheximide chase
assay revealed that RUNX1 negatively regulates the protein stability of p53 in
AML cells. In silico data analysis and ChIP-seq experiments together with series
of knockdown and restore experiments identified BCL11A and TRIM24 as crit-
ical mediators of p53 pathway activation in RUNX1-inhibited AML cells.
Though RUNX1-depleted AML cells exhibited drastically slowed proliferation
rate, a small sub-population of leukemia cells retained the proliferation potential
even after the silencing of RUNX1. Analysis of these residual AML cells revealed
the reciprocal up-regulation of RUNX2 and RUNX3 expressions, suggesting
that RUNX2 and RUNX3 might compensate for the loss of RUNX1 functions.
As expected, additional knockdown of RUNX2 and RUNX3 in RUNX1-depleted
AML cells effectively suppressed their proliferations. Thus the simultaneous
targeting of all RUNX family members as a cluster provides more stringent con-
trol of leukemia cells. Finally, we examined the antitumor potency of CRoX-1-
mediated cluster regulations of RUNX. CRoX-1 treatment was indeed highly
effective against leukemia as well as dismal-prognostic solid tumors arising
from diverse origins in vitro. Moreover, this reagent was exceptionally well-tol-
erated in mice and exerted excellent efficacy against xenograft mice models of
AML, acute lymphoblastic leukemia, lung and gastric cancers, extending their
overall survival periods in vivo. Since RUNX families take part in diverse phys-
iologic functions not only in AML cells but also in normal hematopoietic cells
and in various other vital organ tissues, we might expect criticisms in targeting
whole RUNX family that it could trigger undesirable side-effects in vivo. Intrigu-
ingly, however, our drug was well-tolerated in vivo and through these experi-
ments, we have coincidentally found that the amount of total RUNX expressions
was consistently higher in malignant tissues compared to their normal counter-
part ones, and we believe that this gap offers pharmacological window to be
targeted in anti-tumor strategies. Furthermore, we found that higher expressions
of estimated total RUNX amount demarcate significantly poorer-prognostic
patient cohorts in a wide variety of cancers, underpinning the rationality of
RUNX-inhibition strategies in cancer treatment.
Summary/Conclusions: This work identified the crucial role of RUNX cluster
in the maintenance and the progression of cancer cells, and the indicated gene
switch technology-dependent its modulation would be a novel strategy to control
malignancies.
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PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH
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Background: Kinase signalling is frequently deregulated in cancer cells. In the
case of AML, the high recurrence of activating mutations in kinases and other
kinase signalling regulators including FLT3 and RAS has stimulated the inves-
tigation of treatments based on kinase inhibitors. The success of kinase
inhibitors depends of an accurate stratification of patients into response groups.
The impact of genetic mutations on the sensitivity of primary AML to kinase
inhibitors remains poorly defined and these have not been translated into effec-
tive therapies. The activity of a kinase can be affected by factors other than
gene mutations and the sensitivity of leukemic cells to kinase inhibition depends
not only on the activity of the targeted kinase. Thus, the integrative analysis of
different biochemical features could improve the implementation of precision
medicine therapies based on kinase inhibitors.
Aims: By the integration of multiple omics approaches, we aimed to generate
molecular signatures, which can rationalize why some primary AML cells are
resistant to treatment with different kinase inhibitors while others are sensitive
to the same treatments.
Figure 1.
Methods: In this investigation, we used a multiomics approach to stratify 36 AML
biopsies as a function of their cellular sensitivity to “ex vivo” treatment with TAK-
715, silmitasertib, PF03758309, midostaurin and trametinib, which target P38,
CK2, PAK, FLT3/PKC and MEK, respectively. The same samples were analysed
using different omics platforms: (i) mass spectrometry for phosphoproteomics,
proteomics and kinomic profiling, (ii) mass cytometry for immunophenotyping
and (iii) next generation sequencing for mutational profiling.
Results: Our integrative analysis identified two independent signatures that
stratified our cohort of patients in sets of differentiated and undifferentiated cas-
es. The phosphoproteomics signature divided our set of AML cases in the M1-
like and M4-like groups (Figure 1A). The mass cytometry signature, which rep-
resented myelomonocytic markers that were co-expressed at the cell surface,
split our cohort of patient in the CDs+ and CDs- groups. Remarkably, the M4-
Like and CDs+ groups representing the differentiated cases, as well as the M1-
Like and CDs- groups representing the non-differentiated cases, showed a high
degree of overlap. Differentiated groups over-phosphorylated 3 times as many
proteins as the non-differentiated groups, including kinases at sites linked to
their activity. Mutations in genes involved in kinase signalling were also more
frequent in differentiated cases. Kinase activity analysis using KSEA estimated
that differentiated groups presented an enriched activity for PAK, MEK, ERK or
PKC. Ontology analysis showed that non-differentiated cells over-phosphory-
lated nuclear proteins with DNA binding properties, while the differentiated cells
increased the phosphorylation of membrane and cytoplasmic proteins linked
to the small GTPase signalling. More interestingly, cases in differentiated groups
were more sensitive to PF03758309, trametinib and midostaurin than those in
the non-differentiated sets (Figure 1B for groups defined by the phosphopro-
teomics signature). Finally, differentiated cases as defined by the mass cytom-
etry signature in our cohort of patients, or by a CD marker mRNA expression
signature in the ATCG database, presented with significantly reduced survival
when compared to the groups of non-differentiated cases.
Summary/Conclusions: Our data indicate that differentiated cells activate pro-
survival kinases like PAK, PKCD or MEK which make them more sensitive to
the inhibitors PF03758309, midostaurin or the FDA-approved drug tramentinib.
Since patients with differentiated cells present a reduced overall survival, treat-
ment with these compounds may benefit patients in this higher risk group.
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Background: Based on the prognostic significance, as well as the association
with certain biological and clinical features, acute myeloid leukemia (AML) with
biallelic mutations in the CCAAT/enhancer-binding protein-alpha (CEBPAbi)
gene has been included as a distinct entity into the 2016 revision to the World
Health Organization classification of myeloid neoplasms and acute leukemia.
CEBPA mutations (CEBPAmut) are mainly found in AML with normal cytoge-
netics, and approximately 60% of the mutated patients (pts) carry biallelic muta-
tions. Several studies showed that CEBPAbi occur almost mutually exclusive
with regard to other AML associated gene mutations such as NPM1 or FLT3-
ITD mutations. Recently, mutations in the tet oncogene family member 2
(TET2mut) gene were described as a frequent concurrent mutation of CEBPAbi.
Both genes are involved in the control of proliferation (CEBPA, TET2) and dif-
ferentiation (CEBPA) of myeloid progenitors. Preliminary data suggest that pts
harboring the CEBPAbi/TET2mut genotype have a significantly worse overall
survival (OS).
Aims: To evaluate the frequency and the clinical impact of TET2mut within a
large cohort of CEBPAmut AML pts.
Methods: In total 200 AML pts (age 18 to 78 years) with CEBPAbi (n=113) or
CEBPA single mutations (CEBPAsm) (n=87) were analysed for the presence
of TET2mut. All pts were enrolled in one of 6 AMLSG treatment trials applying
intensive therapy [AMLHD93 n=14; AMLHD98A (NCT00146120) n=53; AML-
HD98B n=12; AMLSG 07-04 (NCT00151242) n=74; AMLSG 06-04
(NCT00151255) n=25 and AMLSG 12-09 (NCT01180322) n=22]. TET2 muta-
tion screening was performed using a DNA-based PCR-assay covering exons
3 to 9 followed by Sanger sequencing.
Results: In total we detected 52 TET2mutin 39 of the 200 pts (19.5%); in 16
pts TET2mut co-occurred with CEBPAbi (16/113, 14.2%), 23 pts had concurrent
CEBPAsm (23/87, 26.4%). All TET2mut were heterozygous, with 13 pts having
two mutations. The median follow-up of the 200 pts was 76.3 months (95%>CI:
68.5–84.2). TET2mut were restricted to the cytogenetic intermediate-risk group
(100%), and pts with TET2mut were significantly older than pts with TET2 wild-
type (TET2wt) (64y vs 49y, P <.0001). In addition, TET2mut were more frequent
in secondary/therapy-related AML (P =.04), and there was a significant asso-
ciation with SRSF2 gene mutations (P =.01). With regard to outcome, pts with
TET2mut had a significantly shorter event-free (EFS), relapse-free (RFS), and
OS compared to TET2wtpts (P <.0001, P <.0001 and P =.0001, respectively).
Evaluating the impact of TET2mut within the subgroup of CEBPAbi pts (n=113),
we found a significant association of TET2mut with older age (49y vs 46y, P
=.05), and an inferior EFS (P =.001), RFS (P =.0003), and OS (P =.007). Finally,
we analysed the impact of TET2mut within the subgroup of CEBPAsm pts (n=87).
Also, in this subgroup TET2mut were found to be significantly associated with
older age (66y vs 51y, P <.0001), and with SRSF2 mutations (P =.02). Clinically,
pts with TET2mut had a shorter RFS (P =.02) and OS (P =.05), and in trend a
shorter EFS (P =.09).
Summary/Conclusions: In our study on a large cohort of CEBPAmutAML pts
we could confirm the high incidence of concomitant TET2 mutations (19.5%).
Pts with concurrent TET2mut were significantly older and had an inferior out-
come.
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Background: Myelodysplastic syndromes (MDS) and acute myeloid leukemia
(AML) are hematopoetic disorders, which affect the myeloid lineages of
hematopoiesis. Both are characterized by an accumulation of blast cells in the
bone marrow (BM) that have the lost the ability to differentiate to mature cells.
The proper differentiation of hematopoietic stem cells (HSCs) is regulated by
transcription factors. Growth factor independence 1b (Gfi1b) is a repressing
transcription factor regulating quiescence of HSCs and the proper emergence
and maturation of erythrocytes and platelets.
Aims: Aim of the study was to identify I) do different level of Gfi1b influence
onset and development of MDS and AML in human patients II) how does Gfi1b
act in MDS/AML development on a molecular level.
Methods: We correlated Gfi1b expression level in blast cells of patients with
MDS and AML with the overall disease course. To get a better insight how does
different Gfi1b level influence MDS/AML development, we used three different
murine models of human AML with expression of different oncogenes
(NUP98/HOXD13, MLL-AF9 and expression of a mutated K-Ras). In these mod-
els we either downregulated or conditionally knocked out Gfi1b expression.
Finally, we performed ChIP Seq analysis as well as whole genome gene expres-
sion arrays to study the molecular functions of Gfi1b in AML development.
Results: Low expression or absence of Gfi1b expression was associated with
an inferior outcome with regard to overall-survival as well as event-free survival
of MDS/AML patients. Using the above murine models of MDS/AML, loss or
low expression of Gfi1b accelerated AML development. Additionally we could
show that loss of Gfi1b significantly enhanced number of functional leukemic
stem cells. It is well known that Gfi1b has a function to recruit histone modifying
enzymes to induce among other deacetylation of H3K9. ChIP seq data of Gfi1b
deficient leukemic cells revealed that loss of Gfi1b led to a higher H3K9 acety-
lation of a number of target genes, among them a number of oncogenes.
Among these target genes, we found MAPK as well as Reactive oxygen
species (ROS) signalling, as one of the top hit in our data. Previously it was
reported that loss of Gfi1b enhanced the ROS level in HSCs. In our case we
also see an increased expression of ROS in Gfi1b deficient leukemic cells, a
higher activity of the FOXO pathway as well as reduced p38 activity. The com-
bination of these foundings contributes to the higher number of leukemic stem
cells in Gfi1b deficient leukemic cells. To reduce the high level of ROS in
leukemic stem cells we use with N-Acetylcystein (NAC). Use of NAC impeded
growth of Gfi1b deficient cells in-vitro.
Summary/Conclusions: Gfi1b act as a tumorsuppressor by restricting number
of leukemic stem cells and treatment with NAC opens a potential targeted ther-
apy for AML patients with low/absent expression of Gfi1b.
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Background: Background: Recent next-generation sequencing (NGS) studies
have improved our understanding of the genomic landscape of CBF-AML
(Faber et al. Nat Genet 2016; Duployez et al. Blood 2016). While these studies
have mainly focused on the genetic differences between inv(16)- and t(8;21)-
AML at the time of diagnosis, the clonal architecture of relapsed disease is not
well defined. Mutations affecting signaling genes, such as KIT and NRAS are
known to be among the most common oncogenic drivers in CBF-AML, however
their impact at relapse remains unclear.
Aims: To characterize clonal evolution in paired samples obtained at diagnosis,
during remission and at relapse under treatment with dasatinib vs conventional
chemotherapy, and ii) to conduct gene set enrichment analyses. 
Methods: Whole-exome-sequencing (WES) was performed in paired diagno-
sis, remission and relapse samples of 36 patients with CBF-AML [inv(16), n=24;
t(8;21), n=12] using paired-end sequencing (read length 100 bp) on an Illumina
HiSeq platform. Library preparation was done with the Nextera® Rapid Capture
Exome kit following manufacturer’s instructions. All patients were treated within
one of five trials of the German-Austrian Study Group (AMLSG). In two of the
trials (AMLSG 11-08, NCT00850382; AMLSG 21-13, NCT02013648) patients
received intensive chemotherapy in combination with the multi-kinase inhibitor
dasatinib. 
Results: The mean WES coverage was 133x. Mutations and indels were called
with a threshold >10% variant allele frequency (VAF) after filtering for SNPs
and sequencing artefacts. In sum, we identified 587 variants in 430 genes. At
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diagnosis, 8.9 variants per patient were found as compared to 5.7 at relapse.
52% variants were present at diagnosis, 26% at relapse only, and 22% were
present at both, diagnosis and relapse. With regard to the most commonly
altered signaling genes KIT and NRAS we found the following pattern: The
median VAF at diagnosis was 23% and 26% for KIT and NRAS, respectively.
Of note, the initial KIT and NRAS clone was lost (VAF <5%) in 71% (exon 17,
n= 9; exon 8, n=2; exon 11, n=1) and 100% of cases (exon 2, n=5; exon 3,
n=3). Comparing the VAF kinetics between patients treated with and without
dasatinib, baseline KIT mutations became subclonal (VAF <5%) in all patients
receiving dasatinib (n=8), whereas they were still detectable in 4/6 (67%)
patients who were intensively treated without the addition of dasatinib. NRAS
became subclonal (n=8) irrespective of the treatment regimen. In one KIT mutat-
ed patient treated with dasatinib the baseline KITD816V mutation (exon 17) was
lost at the time of relapse, but a KITD419Y mutation (exon 8) was acquired
instead. Gene set enrichment analyses revealed different mutation signatures
at diagnosis and relapse: At diagnosis, there was a significant enrichment for
genes associated with MYC overexpression. Variants that were recurrently
present at diagnosis and relapse showed enrichment for genes affected in
KRAS overexpression models. Relapse samples were additionally enriched
for gene mutations involved in the mitotic spindle assembly.
Summary/Conclusions: Differences in the allelic composition were found
between diagnosis and relapse regardless of the CBF-AML subtype. Our data
suggest that the KIT clone might be successfully eradicated under dasatinib
treatment whereas persistence of KIT mutant clones was more commonly seen
under conventional chemotherapy. The frequent loss of KIT and NRAS muta-
tions during therapy suggests that relapse is triggered by alternative genetic
lesions. Relapsed disease may represent a distinct biology which is character-
ized by mutations that cluster in different pathways. Further analyses are ongo-
ing including study cohort expansion, as well as inclusion of RNA sequencing
results. 
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EFFECT ON PP2A ACTIVITY IN ACUTE MYELOID LEUKEMIA
E. Arriazu1,*, C. Vicente1, R. Pippa1, N. Marcotegui1, A. Igea2, E. Leon1,
S. Chocarro1, M. Soto1, Á.R. Nebreda2, M.D. Odero1,3,4
1Oncohematology, Center for applyed medical research University of Navarre,
Pamplona, 2Institute for Research in Biomedicine, Barcelona, 3Instituto de
Investigación Sanitaria de Navarra (IdiSNA),, Navarra, 4Department of Bio-
chemistry and Genetics, University of Navarra, Pamplona, Spain
Background: Despite improvements in our understanding of the molecular
evolution of acute myeloid leukemia (AML), the overall cure rates remain low,
and most patients die from the disease despite achieving initial remission upon
treatment. It is therefore necessary to open new therapeutic perspectives aimed
at molecular targets. PP2A phosphatase inactivation is a recurrent event in
hematological tumors. Our group has reported that SET, an endogenous
inhibitor of PP2A, is overexpressed in 28% of patients with AML. Furthermore,
the anticancer activity of PP2A activating drugs (PADs) depends on the inter-
action/sequestration of SET, pointing out the significance of this oncogene in
AML. Drug inhibition of several MAPKs in AML cell lines showed that only p38
inhibitors activate PP2A and decrease SET protein.
Aims: Therefore, we hypothesized that p38 could regulate SET at posttrans-
lational level, leading to PP2A inactivation.
Methods: AML cell lines and primary human samples were analyzed by west-
ern blot, immunoprecipitation, immunofluorescence, treatment with pharmaco-
logical inhibitors and siRNAs. Phosphorylation assays by in vitro kinase assay
with recombinant proteins were performed.
Results: Knockdown of the two major isoforms of p38-MAPK, p38α and p38β,
demonstrated that only p38β was able to reduce SET protein levels and
increase PP2A activity. To decipher this mechanism of action, we performed
protein immunoprecipitation and immunofluorescence in the AML cell lines HL-
60 and MOLM-13. p38β co-localized and bound to SET mostly in the cytoplasm
stabilizing it, since treatment with ciclohexymide in the absence of p38β induced
SET degradation. The stabilization role was in coordination with SETBP1, which
co-localized with both SET and p38β. Interestingly, 12 out of 14 AML cell lines
tested showed high expression of p38β protein levels but not of p38α, as well
as 5 out of 7 AML primary patient samples. Furthermore, expression analysis
in a large series of adult de novo AML cases previously reported (Cancer
Genome Atlas Research Network, 2013) showed a positive correlation between
p38β (MAPK11) and SET (R2=0.416, p<0.001), but not between p38α and SET.
We and others have shown that PADs retain SET in the nucleus. Our results
showed that p38 phosphorylates SET not directly, but through the activation of
casein kinase 2 (CK2), leading to the retention of SET in the nucleus and,
therefore, contributing to the inactivation of PP2A in AML cells. Of note, CK2 is
overexpressed in both AML cell lines and patient samples.
Summary/Conclusions: p38 is able to activate CK2 which phosphorylates
SET and, as consequence, facilities its trafficking to the cytoplasm, contributing
to PP2A inactivation in AML cells. Moreover, p38β binds to SET in the cytoplasm,
contributing to its stability and leading to PP2A inactivation. In this regard, we
have preliminary evidences that combination therapy with PADs and the CK2
inhibitor CX4945 reduces significantly the viability of AML cells, supporting that
novel treatment modalities that can target multiple components of the same
pathway may help to achieve a more sustained therapeutic benefit.
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GENETIC LANDSCAPE OF ACUTE ERYTHROID LEUKEMIA
J. Takeda1,*, L.-Y. Shih2, K. Chiba3, Y. Shiraishi3, Y. Shiozawa4, H. Makishima1,
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Background: Acute erythroid leukemia (AEL) is a unique subtype of acute
myeloid leukemia (AML) characterized by the predominance of erythroid com-
ponents with increased ring sideroblasts as well as frequent myelodysplasia.
However, due to its rarity, the molecular pathogenesis of AEL has not fully been
elucidated, except for frequent TP53 mutations.
Aims: This study was designed to clarify the mutation profile of AEL distinct
from other types of AML and myelodysplastic syndromes (MDS).
Methods: We performed a comprehensive genetic study, in which paired
tumor/normal DNA from 22 AEL cases were analyzed using whole exome
sequencing (WES). Whole-exome sequencing data from 3 AELs generated by
The Cancer Genome Atlas (TCGA) was also included in the analysis. Subse-
quently, a total of 84 AEL cases were screened for mutations in 67 driver genes
associated with myeloid malignancies using targeted-capture sequencing, in
which RNA baits were also designed for a total of 1158 single nucleotide poly-
morphism sites to allow for genome wide copy number abnormalities and other
allelic imbalances.
Results: Median age at diagnosis was 58.5 (21-87) years old. Among the 77
patients with clinical information available, 62 patients were diagnosed with de
novo AML, 13 with secondary AML, and 2 with treatment-related AML. On aver-
age, 18.4 and 3.4 mutations were detected per sample in whole-exome and
targeted-capture sequencing in AEL, as compared to 12.2 and 2.9 mutations
(P<0.001 and 0.05) in other AML, respectively. Both platforms being combined,
most frequently observed was TP53 mutations (n=26, 31%) with complex kary-
otype being accompanied in most cases (25 cases), which were associated
with a significantly shorter overall survival (P<0.001). Other frequently mutated
genes were those encoding major components of the cohesin complex, includ-
ing STAG2 (24%), SMC1A (4.8%) and RAD21 (2.4%), which were mutated in
as high as 30% of the cases. The splicing machinery (18%) and epigenetic
regulators (45%) were also common targets of mutations, including SRSF2
(12%), U2AF1 (4.8%), WT1 (15%), TET2 (19%) and IDH1/2 (12%). TP53 muta-
tions were mutually exclusive with cohesin mutations (p<0.01) and those in
epigenetic regulators (p=0.014). Compared to other types of AML cases report-
ed from TCGA, AEL showed a significantly higher frequency of mutations in
TP53, STAG2, SRSF2, ASXL1, BCOR, WT1, and TET2. These mutations have
previously been shown to be enriched in secondary AML and MDS relative to
de novo AML, which were also confirmed in our analysis involving 2,250 MDS
cases. By contrast, FLT3 (12%) and DNMT3A (12%) mutations and SF3B1
mutations (0%) were significantly less frequent in AEL, compared to de novo
AML and MDS. The frequency of these mutations was not statistically different
between de novo AEL and secondary AEL. 
Summary/Conclusions: WES and follow-up targeted-capture sequencing
revealed a landscape of mutations in AEL. Frequent mutations in TP53, splicing
factors, the cohesin complex, and epigenetic regulators were characteristic of
AEL and thought to be involved in its pathophysiology. Mutations in TP53
defined a subgroup with distinct genetic and prognostic features. Our result
indicated a similarity between AEL and high-risk MDS/secondary AML, sup-
porting the recent revision of the WHO classifications, in which AEL was re-
classified into MDS and AML not otherwise unspecified.
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THE MOLECULAR LANDSCAPE OF MLL-PTD AML: SPECIFIC CONCURRENT
MUTATIONS, CLINICAL OUTCOME AND GENE EXPRESSION
SIGNATURES
A. Al Hinai1,2,*, F. Kavelaars1, T. Grob1, M. Sanders1, P. Valk1
1Hematology, Erasmus University Medical Center, Rotterdam, Netherlands,
2National Genetic Centre, Muscat, Oman
Background: Partial tandem duplications (PTDs) in the Mixed Lineage
Leukemia (MLL) gene, currently known as Lysine Methyltransferase 2A
(KMT2A) are acquired in-frame internal duplications present in 5–11% of acute
myeloid leukemia (AML). MLL-PTDs are predominantly present in cytogenetic
normal AML and occasionally in AML with trisomy of chromosome 11. MLL-
PTDs are generally considered as a poor prognostic marker in AML.
Aims: Evaluate the mutational landscape, prognostic value and gene expres-
sion signatures of MLL-PTD AMLs in comparison to a well-characterized AML
cohort without MLL-PTD.
Methods: cDNA of 2310 AML patients enrolled in the adult HOVON-SAKK clin-
ical trials (from 1995 to 2013) were analyzed for the presence of an MLL-PTD.
Mutational screening based on next generation sequencing (NGS) was per-
formed using the Illumina Trusight Myeloid panel on the Illumina HiSeq2500. An
independent cohort of 632 de novo AML patients without MLL-PTD served as
control. The gene expression profiling was assessed of all AML cases using
Affymetrix HGU133 Plus2.0 GeneChips as previously described (Verhaak et al.,
2009).
Results: MLL-PTD was detected in 118 (5.1%) out of 2310 AML patients. MLL-
PTDs were significantly associated with trisomy 11: 7% vs 1% (p=0.0037), nor-
mal karyotype: 65% vs 53% (p=0.0102) and complex karyotype: 1% vs 14%
(p=0.0004). None of the MLL-PTD AML patients had any of the core binding
leukemia fusion genes. The targeted NGS was performed on 87 out of 118
patients due to availability of gDNA. The number of mutation detected in MLL-
PTD AMLs ranged from 0–6 mutations with an average of 3 mutations per
patient. The most frequently mutated genes in MLL-PTD AMLs were DNMT3A,
FLT3-ITD, IDH2, RUNX1, IDH1, and TET2. In the context of the 632 AMLs
without MLL-PTD mutations in several genes appeared to be significantly asso-
ciated with the MLL-PTD, i.e., FLT3-ITD: 34% vs 13% (p<0.0001), IDH1: 16%
vs 9% (p=0.0133), U2AF1: 9% vs 3% (p=0.0158) and IDH2: 23% vs 12%
(p=0.0181) or inversely associated, i.e., NPM1: 3% vs 32% (p<0.0001), NRAS:
5% vs 22% (p=0.0002) and TP53: 3% vs 10% (p=0.0487). Overall, the numbers
of mutations in the spliceosome (p=0.03), tumor suppressor (p=0.0388), and
transcription factor genes (p=0.0408) were significantly higher in MLL-PTD
AMLs compared to MLL wild-type AMLs. As expected, the MLL-PTD appeared
to be significantly associated with inferior outcome (MLL-PTD (n=74) and with-
out MLL-PTD (n=1764); OS: p=0.05). Association of the presence of an MLL-
PTD with EFS was only borderline significant (p=0.07). Within MLL-PTD AML,
DNMT3A mutations are associated with inferior overall survival (HR: 2.06;
95%CI: 1.19-3.58; p=0.010). Although low numbers, MLL-PTD AML patients
that harbor NRAS mutations do even worse (HR: 6.54; 95%CI: 2.45-17.49;
p<0.001. In multivariate analysis both markers remain significant when com-
bined with WBC counts and cytogenetics. Multiple homeobox-related gene
family members were overexpressed in MLL-PTD AML. The top-35 differentially
expressed genes included HOXB5, HOXB6, HOXB7, HOXB8, HOXB9 and
NKX2.3. In an association model, which takes all other known subsets of AML
into account, other HOX-related genes, such as HOXA7, HOXA9 and NKX2.5,
also appeared significantly differentially expressed. In both analyses MLL itself
seemed to be most consistently overexpressed in MLL-PTD AML. In contrast,
these specific gene expression changes were absent in AML with translocations
involving MLL on 11q23. Additional analyses in AML subsets based on the con-
current mutations will be carried out to investigate whether these are limited to
certain MLL-PTD AML molecular subsets.
Summary/Conclusions: MLL-PTD AML carries specific gene expression sig-
natures and specific subsets of concurrent mutations with clinical value.
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EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS
ON CHROMATIN ARCHITETCURE IN MDS/AML
J. Smith1,*, K. Savage1, K. Mills1
1Centre for Cancer Research and Cell Biology, Queens University Belfast,
Belfast, United Kingdom
Background: The Cohesin complex is an evolutionarily conserved multimeric
protein complex consisting of SMC1, SMC3, RAD21, STAG1 & STAG2. The
complex plays pivotal roles within mitosis and sister chromatid cohesion how-
ever, substantial data exists elucidating roles for the complex within the DNA
damage response, homologous recombination and long-range interaction
between cis regulatory elements of the genome. Within hematological malig-
nancies upwards of 20% of patients diagnosed with either Acute Myeloid
Leukemia (AML), Myelodysplastic syndrome (MDS) or Myeloproliferative neo-
plasm (MPN) have been shown to harbour mutations within the Cohesin com-
plex, with many more showing significantly reduced expression of core complex
members.
Aims: To explore the impact of a loss of function STAG2 mutation on the chro-
matin architecture within a isogenic cell based model.
Methods: Using an CRISPR generated isogenic model we have investigated
the impact loss of STAG2 has on the chromatin architecture of a hematopoietic
environment. Genome wide binding profiles for STAG1, STAG2 and CTCF
were generated using ChIP-Seq to elucidate areas of differential between
STAG members. In addition, binding profiles for H3K27ac, H3K27me3 and
H3K4me1 were generated using ChIP-Seq to provide genome wide identifica-
tion of active and repressed enhancer regions, with the regions ranked to iden-
tify both normal and super-enhancer regions. These samples were matched to
ATAC-Seq profiling of open and closed chromatin regions as well as RNA-seq
samples to provide information on gene activity in relation to chromatin state
in the absence of STAG2.
Results: Our results indicate that STAG1 bindng profiles alter following loss of
function of STAG2, with an increase in binding peaks from ~17,000 to 25,000,
however several sites identified by ChIP-Seq are not compensated for. Histone
mark profiling identified wide spread expansion of the H3K27ac mark and a
decrease in regions of H3K27me3 consistent with loss of boundaries within topo-
logically associated domains. This spread of an activator mark correlates with
altered gene expression and the changes observed in ATAC-seq profiling of
altered chromatin accessibility. The open chromatin regions identified through
the use of ATAC-seq peak motif analysis yielded information regarding transcrip-
tion factor occupancy. An enrichment for transcription factors relevant for myeloid
transcriptional programmes was observed. This increase in enrichment aids in
the suggestion that the impact of mutated/altered cohesin complex function
relates directly to the specific cell type and maturation state at which it occurs.
Summary/Conclusions: This research into the aberrant and non-canonical
nature of the cohesin complex provides evidence of the impact of mutant
STAG2 on the spatio-temporal genomic architecture in hematological malig-
nancies and begins to yield insight into the clinical implications of mutations
within the cohesin complex.
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NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR
MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9
LEUKEMIA
I.-J. Lau1,*, A. Thomas1, J. Kerry1, L. Godfrey1, C. Nerlov1, P. Vyas1, T. Milne1
1MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine,
University of Oxford, Oxford, United Kingdom
Background: Mutations involving the MLL gene at 11q23 are found in 10% of
adult and 18% of childhood acute myeloid leukaemia (AML) cases. The most
frequently occurring MLL mutations are chromosome translocations that fuse
the MLL gene in-frame with a second partner gene, creating novel fusion pro-
teins (MLL-FPs). MLL-AF9 is the most common MLL-FP in AML. Despite much
progress in the overall management of AML, patients carrying MLL-rearrange-
ments still have a poor survival prognosis and limited response to existing ther-
apy. This is in part due to the low therapeutic indices and narrow therapeutic
windows of current chemotherapeutic agents, therefore underscoring the need
to develop improved, targeted therapies. MYB is a direct downstream target of
MLL-AF9. Recent studies indicate that MLL-AF9 leukemia cells are more affect-
ed by MYB knockdown compared to normal hematopoietic stem progenitor
cells. This is despite the fact that MYB is known to be essential for the estab-
lishment of definitive hematopoiesis. This suggests that a therapeutic window
may be achieved through targeting MYB. Therefore, by understanding more
about the role of MYB in MLL-AF9 leukemia and the network it regulates, we
maybe able to exploit this knowledge to target MYB directly by interfering with
its function or indirectly via its downstream targets.
Aims: To understand the molecular function of MYB in MLL-AF9 leukaemia.
Methods: We performed genome-wide MYB, MLL-AF9, H3K27ac, H3K4me3
and H3K4me1 chromatin immunoprecipitation sequencing (ChIP-seq) and
Assay for Transposase-Accessible Chromatin with high throughput sequencing
(ATAC-seq) in two MLL-AF9 leukemia models to identify putative regulatory
regions of MYB and those of a direct MYB gene target, BCL2. The chromatin
conformation capture technique, Capture-C (one vs all) was used to further
characterize interactions from the MYB promoter. We then performed siRNA
knockdown of MYB and assessed the effect of MYB loss on its downstream
druggable target BCL2, using RT qPCR, Western blotting and ChIP qPCR.
Results: We identified MLL-AF9 binding to novel putative enhancers of MYB
as defined by regions co-bound by H3K27ac, H3K4me1 and marked by open
chromatin on ATAC-seq. Furthermore, Capture-C from the MYB promoter iden-
tified novel putative enhancer-promoter interacting domains 100-200kb apart
that are co-bound by MYB but not MLL-AF9. This suggests long-range autoreg-
ulation of MYB. Next, siRNA knockdown of MYB results in loss of MYB binding
at the BCL2 promoter and its downstream enhancer by ChIP qPCR. There is
a corresponding loss of BCL2 mRNA and protein expression in MYB knocked-
down cells compared with control, confirming that BCL2 is directly regulated
by MYB.
Summary/Conclusions: We have identified for the first time, regulation of
MYB by MLL-AF9 via putative enhancers, and also an autoregulatory role of
MYB involving long-range cis-interactions. Furthermore, we confirm that BCL2
is directly regulated by MYB in MLL-AF9 leukemia, suggesting a molecular
rational for using BCL2 inhibitors in MLL-AF9 leukemia therapy.
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CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN
ACUTE MYELOID LEUKAEMIA
S. Chitre1,*, J. Gaken1, A. Venuso1, G. Mufti1
1Haematological Medicine, Kings College London, London, United Kingdom
Background: Acute myeloid leukaemia (AML) is a heterogeneous disease
characterized by clonal evolution of myeloid precursors in bone marrow and
peripheral blood resulting in accumulation of leukemic blasts and severe impair-
ment of normal haematopoiesis. Despite advances in our understanding of
AML biology, development of novel therapies has been limited with 43% relapse
rate and 18% of patients never attaining clinical remission (CR) with frontline
induction treatment. Chimeric antigen receptor (CARs) T cells specific for
tumour-associated antigens are emerging to be an effective form of
immunotherapy for AML. A small number of in vitro and in vivo studies have
evaluated the efficacy and specificity of CAR T cell immunotherapy in AML by
targeting interleukin three receptor alpha (IL3RA; CD123), a molecule over
expressed on AML blasts and leukaemia stem cells (LSC) compared to normal
haematopoietic stem cells (HSCs).
Aims: In this study, we investigated the efficacy of a second generation CAR
expressing six single-chain variable fragments (scFv) with different affinities
for CD123 and evaluated the cytotoxic effect of different co-stimulatory domains
(CD28 versus 41BB) using a co-culture assay. Furthermore, we also evaluated
the cytotoxic effects of a dual targeting CAR (against CD123 and CD33) using
the same assay conditions.
Methods: Six lentiviral constructs (two high, two moderate & two low affinity)
were transduced (MOI 1:5) into peripheral blood mononuclear cells (PBMCs)
from healthy donors and their cytotoxicty was examined by flowcytometry on
leukaemic cell lines; KG1 (CD123+, CD34+, CD33+) [Fig:1a], Kasumi-1
(CD123+, CD34+, CD33+), U937 (CD123+, CD34-, CD33+), K562 (CD123-,
CD34-, CD33+) and AML mononucelar cells (MNCs).
Results: Flowcytometric analysis confirmed the expansion of T cells from PBM-
Cs and the cytotoxicity of the six CARCD123 constructs against CD123+ve
cells. The high affinity CARCD123 (4nM kD & 4nM kD K136Q) T cells demon-
strated enhanced cytotoxicity compared to moderate (56nM kD, 56nM kD
A105G) and low affinity (101nM kD, 101nM kD V24G) CARCD123 in both
leukaemic cell lines and also in allogenic AML MNCs. Both the highest affinity
CARCD123 constructs were also tested in cell lines using increasing effector:
target ratios (1:2, 1:4 & 1:10) displaying consistent cytotoxicity and were also
effective against autologous AML MNCs (target cells) and PBMCs (effector
cells) from two patients. T cell activation was confirmed by ELISA and showed
increased IFN-γ (500-2000 fold) and TNF-α (150-200 fold) levels. Previous
studies have confirmed the distinction in CAR efficiency using CD28 versus
41BB co-stimulatory domains; CD28 co-stimulation augmented, whereas 4-
1BB co-stimulation reduced T cell exhaustion induced by continuous CAR sig-
naling. To confirm persistence of the CAR cytoxicity, we constructed a high
affinity CAR substituting CD28 with a 4-1BB co-stimulatory domain and obtained
similar cytotoxicity results on K562 and U937 cell lines. Furthermore, a novel
a dual targeting CAR in which the activation domain (CD3ζ) is directed against
CD33 and the costimulatory domain (CD28) directed against CD123 enhanced
the specificity of the CAR towards leukaemic cells; reducing “on-target but off-
organ effects”. Results obtained in co-culture assay against KG1 [Fig:1b] and
K562 cell lines [Fig:1c] with varying effector: target ratios were demonstrated
results similar to the high affinity single targeting CAR.
Figure 1.
Summary/Conclusions: In conclusion, we demonstrate the importance of the
scFv on CAR T cell cytoxicity and have constructed and validated the efficacy
of a dual targeting CAR vector in the context of AML.
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TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR
PALBOCICLIB IN AML
I. Uras1,*, P. Valent2,3, V. Sexl1
1Institute of Pharmacology and Toxicology, University of Veterinary Medicine,
Vienna, 2Department of Internal Medicine I, Division of Hematology and Hemo-
staseology, 3Ludwig Boltzmann Cluster Oncology, Medical University of Vienna,
Vienna, Austria
Background: Acute myeloid leukemia (AML) is a clonal hematologic disorder
marked by clinical and biological heterogeneity. AML remains incurable for a
significant proportion of adult patients while no therapeutic option exists for
patients with relapsed and refractory AML. Mutations of the fms-like tyrosine
kinase 3 (FLT3) gene are among the most frequent events in AML and usually
involves internal tandem duplication (ITD) of the juxtamembrane domain coding
region or point mutations of the tyrosine kinase domain. There have been con-
siderable efforts to develop FLT3 tyrosine kinase inhibitors (TKI). The clinical
impact of FLT3-TKI has been limited as resistant clones have emerged rapidly.
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We have recently discovered that FLT3-ITD+ AML cells are highly sensitive to
the FDA-&EMA-approved CDK4/6 kinase inhibitor palbociclib (IBRANCE by
Pfizer). The effect is ascribed to the transcriptional activity of CDK6 on FLT3
and PIM1- a feature not shared by CDK4.
Aims: FLT3-TKI treatment provides short-term disease control but relapse
invariably occurs within months. Acquired resistance on FLT3-D835Y tyrosine
kinase domain is an emerging clinical problem. The focus of our study is to
investigate the potential of palbociclib treatment in FLT3-D835Y+ cells and to
identify critical downstream effectors of CDK6 to open a novel, clinically appli-
cable therapeutic window.
Methods: Ba/F3 cells transformed with FLT3-D835Y were exposed to single
agents and drug combinations. Viability was measured by the CellTiter-Glo
ATP-based assay and FACS stainings after 3 days of treatment. Validation
was performed by in vivo xenograft models and by studies with primary human
FLT3-D835Y+ AML biopsies.
Results: Palbociclib impaired the viability of murine Ba/F3 cells with FLT3-
D835Y at low concentrations. The effect extended to primary FLT3-D835Y+
patient samples and to xenograft models, where palbociclib treatment effec-
tively repressed FLT3-D835Y driven tumor formation in vivo at clinically relevant
concentrations. Besides FLT3 itself, which is regulated by CDK6, transcriptional
targets of CDK6 in AML included Aurora kinases (AURK) and AKT. Thus CDK6
inhibition lead to decreased expression of AURK and AKT in mutant Ba/F3
cells, two signalling nodes critical for survival of tumor cells. Dual targeting with
palbociclib and AURK or AKT inhibitors resulted in synergistic cytotoxicity.
Summary/Conclusions: Palbociclib represents a viable therapeutic option for
use in treatment of resistant clones in FLT3-D835Y+ AML. Inhibitory effects
are caused by cell cycle inhibition as well as by transcriptional activity of CDK6
on important signalling pathways including Aurora kinases and AKT. Our find-
ings provide the basis for the design of synergistic combination therapies with
a CDK4/6 inhibitor which could be readily translated to patients with AML.
P543
CANNABINOIDS DERIVATIVES MODIFY THE PATTERN OF SPHINGOLIPIDS
IN ACUTE MYELOID LEUKEMIA CELLS AND PRODUCE A POTENT
ANTI-LEUKEMIC EFFECT
M. Medrano1,*, M.V. Barbado1, N. Campillo2, F.J. Hidalgo3, T. Caballero1,
I. Alvarez1, O. Lopez1, J.I. Piruat1, J.A. Pérez-Simón1
1Instituto de Biomedicina de Sevilla, Seville, 2CIB/CSIC, Madrid, 3IG/CSIC,
Seville, Spain
Background: Endocannabinoid system is a set of ligands, receptors and
endogenous enzymes which modulate a variety of physiological effects. There
are two well-characterized cannabinoid receptors, CB1 (mainly expressed in
Central Nervous System) and CB2 (mainly in hematopoietic cells). Here, we
tested the effect of the cannabinoid WIN-55 212-2 in acute myeloid leukemia
(AML) in vitro and in vivo and studied the molecular signaling pathways involved
in this effect, specially the role of sphingolipids. Moreover, we synthesized a
new family of twelve cannabinoids that are specific to CB2 receptor.
Aims: - Development of new compounds derived from cannabinoids with CB2
selectivity and evaluation of their anti-tumor effect in AML in vitro and in vivo.
To deepen in the knowledge of lipid metabolism in AML. 
Methods: For the design and synthesis of new cannabinoids, computational
techniques of docking, analytical and spectroscopic techniques such as mass
spectrometry (MS) were used. To assess the anti-leukemia effect of the different
cannabinoids, we analyzed cell viability by MTT and flow cytometry using six
human AML cell lines, primary cells from healthy donors (hematopoietic pro-
genitor cells (HPC) and lymphocytes) and blasts from AML patients. Mitochon-
drial damage was analyzed by flow cytometry using TMRE and by MitoSOXTM
Red. In addition, we performed western blot and immunocytochemistry assays
to determine the expression of different proteins to elucidate the molecular sig-
naling pathways involved in the effect of these drugs.Moreover, we analyzed
the ceramide levels, a membrane lipid associated with death/survival cell
processes, and other sphingolipids by LC-MS/MS and immunohistochemistry.
Finally, NOD/scid/IL-2R gammae null (NSG) mice were xenotransplanted with
HL60 cell line. We confirmed disease infiltration in bone marrow (BM) by BM
aspirates and flow cytometry assays. Once the presence of leukemic cells was
confirmed, treatment with vehicle, WIN-55 cannabinoid at a dose of 5mg/kg/day
or citarabine (ARA-C) at 50mg/kg during 5 days was administered. Also we
tested the effect of these compounds on normal hematopoiesis by treating
healthy BALB-C mice and the levels of sphingolipids in cell and plasma were
studied in mice models.
Results: Cannabinoids induced a potent proapoptotic effect on AML cell lines
and on primary leukemic cells, which was not observed in normal HPC and
lymphocytes from healthy donors. Fragmentation of PARP and activation of
caspases 2, 3, 8 and 9 were confirmed by Western Blot. The proapoptotic
effect of cannabinoids on AML cells was abolished upon co-culture with either
CB2 receptor antagonists or with pancaspase inhibitors. Other proteins involved
in the effect of cannabinoids were p-AKT, p-ERK 1/2, p-38 and p- JNK. Also
studies on p-PERK, p-IRE1 and CHOP confirmed an increased endoplasmic
reticulum stress upon exposure to cannabinoids. Also we confirmed a very
early mitochondrial damage in leukemic cells which was not observed in normal
hematopoietic progenitor cells. Remarkably, we observed significant differences
in the amounts of certain sphingolipids in untreated versus treated leukemic
cells. More specifically in ceramide C16:0, C18:0 and C18:1. Also we observed
a significantly increased survival among mice treated with WIN-55 cannabinoid
as compared to both the control group and the group treated with ARA-C and
we confirmed that cannabinoids did not affect the viability of the different pop-
ulations of hematopoietic progenitors and, moreover, an increased platelet
count was observed in treated mice.
Figure 1.
Summary/Conclusions: Our findings indicate that cannabinoids display a
highly selective proapoptotic effect against leukemic cells. Several pathways
are involved in this effect, the modification in the sphingolipids pattern playing
a main role.
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PROFILING THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID
LEUKEMIA AT RELAPSE AFTER CHEMOTHERAPY AND ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION.
E. Sala1,2,*, F. Biavasco1,2, G. Bucci2,3, C. Toffalori2, L. Zanotti2, D. Biancolini3,
E. Antonini4, M.G. Carrabba1, B. Gentner1,5, C. Tresoldi4, M. Bernardi1,
D. Lazarevic3, G. Tonon3, F. Ciceri1, L. Vago1,2
1Hematology and Bone Marrow Transplantation Unit; Division of Regenerative
Medicine, Stem Cells and Gene Therapy, 2Unit of Immunogenetics, Leukemia
Genomic and Immunobiology; Division of Regenerative Medicine, Stem Cells
and Gene Therapy, 3Center for Translational Genomics and Bioinformatics,
4Immunohematology and Transfusion Medicine Unit; Division of Regenerative
Medicine, Stem Cells and Gene Therapy, 5Translational stem cell and leukemia
research Unit; SR-TIGET, Division of Regenerative Medicine, Stem Cells and
Gene Therapy, San Raffaele Scientific Institute, Milano, Italy
Background: Acute Myeloid Leukemia (AML) is a clinically and biologically
heterogeneous disease that is known to dynamically evolve over time. Unrav-
eling its genetic profile may provide relevant insights into the inception, prop-
agation, and recurrence of the disease, and deliver new rationales for precision
medicine approaches: still, whereas a comprehensive description of AML muta-
tions at disease presentation is now available thanks to large-scale studies, a
satisfying genomic characterization of AML at relapse, particularly after allo-
geneic stem-cell transplantation (allo-HSCT), is still needed.
Aims: To characterize the genetic profile of relapsed AML, highlighting the
evolutionary trajectories in the two different settings of relapse after chemother-
apy (CT) and after allo-HSCT
Methods: For our custom-designed targeted Next Generation Sequencing
panel we took advantage of the HaloPlex High Sensitivity (HS) technology,
allowing a more precise definition of mutations and clonal architecture through
a molecular barcoding system. We included in our panel 192 genes and miR-
NAs known to be involved in the pathogenesis of myeloid malignancies (n=112),
in the DNA damage response (n=50), or in immune-related processes (n=30).
Sequencing was performed on an Illumina HiSeq2500n instrument. Variant
calling was performed using a pipeline based on the FreeBayes algorithm, and
FLT3-ITD status was inferred using Pindel. 
Results: We sequenced a total of 138 AML samples, including 79 diagnoses,
36 relapses after CT and 23 relapses after allo-HSCT. Sequencing yielded uni-
form and consistent coverage of all target amplicons and a 612x mean depth-
of-sequencing, resulting on average in 117 unique barcodes for each region.
Among the 79 diagnosis samples we identified 293 mutations (204 of which
definable as oncogenic), with a median of 3 oncogenic mutations per patient
(range 0-8), and mutation frequencies in line with the largest published dataset
(Papaemmanuil, N Engl J Med, 2016; r2=0.83). In relapses after CT and after
allo-HSCT the median number of oncogenic mutations per patient was 3 (range
0-4) and 2 (range 0-6), respectively. Comparing mutation frequencies at relapse
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with the Papaemmanuil dataset, we observed a weaker correlation for relapses
after CT (r2=0.69) and an even more marked deviation for post-transplant
relapses (r2=0.45). This difference was mainly explained by the enrichment in
both relapse cohorts for FLT3-ITD (25% in diagnoses vs 55% and 48% at
relapses after CT and allo-HSCT, p <0.01 for both comparisons) and WT1
mutations (5% vs 25% and 22%, p <0.01 for both comparisons). For 24 cases
it was possible to longitudinally compare the mutational profile of AML at diag-
nosis and relapse in the same patient: we observed higher stability in relapses
after CT, with 50% of cases carrying the same pattern of mutations present at
diagnosis, whereas at relapses after allo-HSCT changes were more frequent,
with 70% of patients displaying new gains or losses.
Summary/Conclusions: Taken together, our data evidence that the genomic
landscape of AML at relapse can be significantly different from the one docu-
mented at diagnosis, suggesting that the selective pressure mediated not only
by intensive chemotherapy, but also by the graft-versus-leukemia effect, can
be potent drivers of clonal evolution. From the practical standpoint, the pattern
of emergence of novel mutations that we documented should be taken into
account not only for targeted salvage approaches, but also for the design of
post-remission strategies aiming to prevent relapse. 
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AML PATIENTS AGED ≥75 YEARS ENROLLED INTO AMLCG TRIALS: DO
GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD,
INTENSIVELY TREATED PATIENTS?
V. Prassek1,*, M. Rothenberg-Thurley1, M.C. Sauerland2, S. Amler2, D. Goerlich2,
T. Herold3, H. Janke1, S. Schneider1, M. Subklewe1, U. Krug4, A. Faldum2,
W.E. Berdel5, B. Woermann6, J. Braess7, W. Hiddemann3, K. Spiekermann3,
K.H. Metzeler3
1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Uni-
versity of Munich, Munich, 2Institute of Biostatistics and Clinical Research, Uni-
versity of Muenster, Muenster, 3Laboratory for Leukemia Diagnostics, Depart-
ment of Internal Medicine III; German Cancer Consortium (DKTK), partner site
Munich; German Cancer Research Center (DKFZ, Heidelberg), University of
Munich, Munich, 4Department of Internal Medicine III, Hospital Leverkusen,
Leverkusen, 5Department of Medicine A, Hematology and Oncology, University
of Muenster, Muenster, 6Department of Medicine, Hematology, Oncology,
Tumor Immunology, Charité University Medicine Berlin, Berlin, 7Department of
Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Ger-
many
Background: Acute myeloid leukemia (AML) is a disease of the elderly (median
age at diagnosis ~68 years). The prognosis of elderly patients (pts) is poor.
Advanced age often leads to the judgement that pts are unfit for induction
chemotherapy, although several trials have revealed a positive impact of inten-
sive induction therapy in terms of sustained remissions and long-term survival
in a subset of elderly pts.
Aims: We sought to validate existing risk classification systems and identify
genetic factors associated with clinical outcomes in very old AML pts who
received induction chemotherapy.
Figure 1.
Methods: We identified 151 AML pts aged ≥75 years who received intensive
induction therapy in the AMLCG-1999 trial with suitable material for genetic
haematologica | 2017; 102(s2) | 209
Madrid, Spain, June 22 – 25, 2017
analyses. 81% of pts had de novo AML, 15% secondary AML, 3% therapy-
related AML and 2% high-risk MDS. Recurrent gene mutations in AML were
studied from bone marrow aspirates or peripheral blood using a targeted
leukemia genotyping assay covering 68 genes. We analyzed known mutational
hotspots or the entire coding sequence of the genes by multiplexed amplicon
sequencing (Agilent Technologies, mean target coverage of 460 x). We studied
associations between cytogenetics, gene mutations and other potential prog-
nostic factors which might influence the clinical outcome.
Results: The median age in the total cohort was 76 years (y) (range: 75-86 y).
44% of pts reached complete remission (CR) and 4% CR with incomplete blood
count recovery (CRi). The median overall survival (OS) was 6 months with a
3-year OS of 21%. According to the ELN 2010 classification, 20% of pts were
in the favorable, 39% and 25% in the intermediate I or II group, respectively,
and 15% in the adverse group (ELN 2017 data will be presented at the meet-
ing). Pts in the favorable and intermediate I/II groups had significantly longer
OS compared to the adverse group (median OS 6.3 vs 1.2 months, p=.002,
Figure). Likewise, pts in the favorable and intermediate MRC cytogenetic risk
categories had longer OS than those in the adverse category (median OS 6.5
vs 1.2 months, p=.001). By targeted sequencing, we detected 622 leukemia-
associated mutations in 66 genes. The median number of mutated genes per
patient was four. The most commonly mutated genes were TET2 (42%),
DNMT3A (35%), NPM1 (32%), SRSF2 (25%) and ASXL1 (21%). Both NPM1
or EZH2 (5%) mutated pts showed a non-significant trend towards longer OS
(NPM1: p=.09; EZH2: p=.065). FLT3-ITD mutations were identified in 29 pts
(19%), but had no impact on OS (p=.297). The NPM1mutated/FLT3-ITDnegative
genotype also did not associate with OS. Notably, none of the 13 IDH1 mutated
pts (9%; all within the ELN favorable/intermediate groups) reached CR, and
consequently the OS in this group was significantly shorter than for IDH1 wild-
type pts (p<.001; Figure). The positive impact of mutated NPM1 on OS was
reversed when it co-occurred with IDH1 mutations (p=.014).
Summary/Conclusions: Among very old (≥75 y), intensively treated AML pts,
adverse-risk cytogenetics predict inferior survival. On the other hand, 3-year
OS was 24% for MRC/ELN favorable and intermediate-risk pts, suggesting
that even in this age group, selected pts without medical contraindications ben-
efit from intensive induction chemotherapy. The spectrum of driver gene muta-
tions in elderly pts differs from that in younger pts. While NPM1 and FLT3-ITD
mutations had no significant impact on OS in intensively treated pts aged ≥75
y, our data imply IDH1 mutations as a novel marker for chemorefractory disease
and inferior prognosis in this age group.
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GMI-1271, A POTENT E-SELECTIN ANTAGONIST, IN COMBINATION WITH
CHEMOTHERAPY IN RELAPSED/REFRACTORY AML: A NOVEL,
WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE
D.J. DeAngelo1,*, B.A. Jonas2, J.L. Liesveld3, M.E. O’Dwyer4, D.L. Bixby5,
A.S. Advani6, P. Marlton7, J.L. Magnani8, H. Thackray8, P.S. Becker9
1Dana-Farber Cancer Institute, Boston, 2UC Davis Comprehensive Cancer
Center, Sacramento, 3Univ of Rochester James P Wilmut Cancer Ctr,
Rochester, United States, 4National University of Ireland, Galway, Ireland, 5Uni-
versity of Michigan Comprehensive Cancer Center, Ann Arbor, 6Cleveland Clin-
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Cancer Research Center, U of Washington, Seattle, United States
Background: Expression of the adhesion molecule E-selectin (E-sel) in the
vasculature of the bone marrow is associated with infiltrative disease, relapse,
and poor survival in AML. GMI-1271 is a novel antagonist of E-sel that down-
regulates cell survival pathways and enhances chemotherapy response with
improved survival compared to chemotherapy alone (Becker ASH 2013; Win-
kler ASH 2014). Protection from common toxicities (neutropenia and mucositis)
has been observed in preclinical models, also affording survival benefit (Winkler
ASH 2013).
Aims: We assessed GMI-1271 plus salvage chemotherapy with mitoxantrone,
etoposide, and cytarabine (MEC) for the treatment of patients (pts) with
relapsed/refractory (R/R) AML.
Methods: A Phase (Ph) 1 trial in pts with R/R AML escalated GMI-1271 across
pharmacologically active doses from 5-20mg/kg combined with MEC to eval-
uate safety, tolerability and anti-leukemia activity. MEC consisted of mitox-
antrone 10mg/m2/d, etoposide 100mg/m2/d, and cytarabine 1000mg/m2/d IV
for 5 days; supportive care was given as per institutional guidelines. Dose lim-
iting toxicity (DLT) was defined as either persistent neutropenia and/or throm-
bocytopenia beyond day 42 in the absence of disease or any Grade 3 (Gr3)
non-hematologic toxicity that did not resolve to Gr2 by day 42. After confirming
safety and tolerability, a Ph 2 study of GMI-1271 at 10mg/kg plus MEC salvage
chemotherapy was initiated; responders to salvage could receive consolidation
with GMI-1271 plus reduced dose MEC (4 days). GMI-1271 was given 24 hrs
prior, then every 12 hrs during and for 48 hrs post induction/consolidation. Eli-
gible pts had an ECOG score 0-2, received ≤2 prior inductions, had WBC <20K
(<40K after 2 dose levels), no active CNS disease, and adequate renal/hepatic
function. Baseline E-sel ligand expression on leukemic blasts in the bone mar-
row (CD45/SSC by flow) was assessed, as were plasma levels of soluble E-
sel (sE-sel).
Results: To date, 47 pts have enrolled (Ph 1=19; Ph 2=28 of planned 47). The
recommended Ph 2 dose is 10mg/kg based on drug exposure, time over IC50
for E-sel binding, evidence of on-target effect (reduction in sE-sel), lack of DLT
at any dose level, and clinical outcomes. Ph1/Ph2 combined median age was
55yrs (range 26-84) with 70% male pts. Prior AML history included 26% primary
refractory, 36% CR1<6 mos; 17% prior SCT; 52% unfavorable cytogenetics
(by SWOG). Common Gr 3/4 AEs were febrile neutropenia (36%), sepsis
(26%), bacteremia (13%), hypoxia (13%). Oral mucositis (≥Gr 2) developed in
12% of pts. The 30 and 60 day mortality rates were 0 and 7%, respectively;
induction mortality was 0%. The remission rate (CR/CRi) was 45% (19/42) with
an ORR (CR/CRi/MLFS/PR) of 50% (21/42). Observed/expected remission
(CR/CRi) ratio was >2.75 (Estey, Blood 1996). With a median follow-up of 11
mos, the Ph 1 median Disease Free Survival was not reached and Overall
Survival was 7.6 mos. The median E-sel ligand expression at baseline was
35% (range, 1-75%) of blasts in the bone marrow, and was higher in those
achieving remission.
Summary/Conclusions: The addition of GMI-1271, a novel E-sel antagonist,
to MEC chemotherapy is well tolerated; oral mucositis, commonly severe with
MEC, is observed at low severity in this study. Clinical outcomes include a high
ORR and remission rate (CR/CRi), low induction mortality, and promising sur-
vival outcomes in pts with R/R AML. Furthermore, the baseline expression of
E-sel ligand in this population suggests relevance of the target and is predictive
of response. 
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BST 236, A NOVEL CYTARABINE PRO-DRUG ALLOW, FOR THE FIRST
TIME, THE DELIVERY OF HIGH CYTARABINE DOSES FOR OLDER OR
UNFIT PATIENTS WITH ACUTE LEUKEMIA. RESULTS OF AN ONGOING
PHASE I/IIA STUDY
T. Zuckerman1,2,*, S. Gengrinovitch3, R. Ram4, L. Flaishon3, R. Ben Yakar3,
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Background: Acute myeloid leukemia (AML) is associated with poor outcome
in older patients and in patients unfit for standard induction therapy. Therapy
of AML has not changed significantly since the 1970s and still relies on cytara-
bine as the first-line treatment. However, cytarabine therapy is associated with
severe side effects, such as cerebellar toxicity, bone marrow suppression, and
infections, leading to high treatment-related mortality rates. Hence, while the
incidence of AML increases with age, advanced age and comorbidities may
preclude the administration of intensive therapy altogether.
Aims: BST-236 (Astarabine) is a new compound of cytarabine covalently
bound to asparagine. It acts as a pro-drug of cytarabine, enabling delivery of
high cytarabine doses to target cells with lower systemic exposure to the free
drug and relative sparing of normal tissues. As such, BST-236 may serve as
an ideal therapy for leukemia, particularly for delivering high doses of cytarabine
to medically unfit or older adults. The aim of this study was to evaluate the
safety and optimal dose of BST-236 in refractory/relapsed or newly-diagnosed
AML patients unfit for standard induction therapy.
Methods: A Phase I/IIa prospective open label study enrolled adult
relapsed/refractory or newly-diagnosed acute leukemia patients unfit for stan-
dard therapy. Patients are enrolled into 6 BST-236 escalating-dose cohorts
(0.3-6 g/m2/d), each composed of 3-6 patients. Treatment was administered
as 1-hour daily infusion for 6 days.
Results: To date, treatment of cohorts 1-5 is completed, with 18 patients treated
with up to 4.5 g/m2/day, median age 77 (27-90): 6 relapsed/refractory AML
patients, median age 64 (27-81), and 12 newly-diagnosed patients, unfit for
standard chemotherapy (7 secondary AML; 5 de novo AML/ALL), median age
79 (70-90). BST-236 treatment was well-tolerated. Only 6 SAEs in 4 cases
were assessed by the treating physician as possibly/probably related to BST-
236, all “on-target” hematological toxicity events or bacterial infections derived
from it. No neurological or grade >2 typical cytarabine events such as gas-
trointestinal, mucositis, or alopecia were reported during BST-236 treatment
or within 30 days of follow up. Response to the treatment was observed in 6 of
the 12 newly-diagnosed patients, 4 of whom had a continuous complete remis-
sion (CR) and 2 had a partial remission (PR). The median overall survival (OS)
of the responding (CR+PR) and of the CR patients was 7 and 10 months,
respectively. The median OS of the newly-diagnosed non-responders was 2.5
months. No remission was reached in the 6 patients suffering from relapse or
refractory AML and their median OS was 2.3 months.
Summary/Conclusions: BST-236 is safe and very well tolerated, enabling
delivery of high dose cytarabine to older and unfit patients, resulting in overall
response and CR rates of 50% and 33%, respectively, and a 3-fold increase in
median OS of the responding compared to the non-responding newly-diag-
nosed patients. Notably, 67% of the responding patients had secondary AML,
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refractory to hypomethylating agents. To the best of our knowledge, this is the
only experimental drug permitting high-dose cytarabine, considered a corner-
stone of leukemia therapy, to be given to a population of patients that currently
do not have this option. A phase II study is planned to confirm these encouraging
results.
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FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE
DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE
IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID
MALIGNANCIES 
C. Haferlach1,*, N. Nadarajah1, M. Meggendorfer1, A. Stengel1, W. Kern1,
T. Haferlach1
1MLL Munich Leukemia Laboratory, Munich, Germany
Background: Gene fusions are frequent genetic abnormalities in myeloid
malignancies. The impact of the detection of such gene fusions is rising due to
an increasing number of drugs targeting them as has been impressively shown
for e.g. BCR-ABL1 and PML-RARA. Further, they can be used as biomarkers
for disease monitoring.
Aims: Evaluation of targeted RNA sequencing for the detection of recurrent
and novel fusion transcripts.
Methods: 102 cases with myeloid malignancies harboring 105 translocations
identified by chromosome banding analysis were selected. Recurrent fusion
genes had been confirmed by FISH and/or RT-PCR. In cases with suspected
novel fusions the rearrangement of one partner gene had been confirmed by
FISH. The following recurrent rearrangements identified by standard diagnostic
procedures were present: PML-RARA (n=11), RUNX1-RUNX1T1 (n=7), CBFB-
MYH11 (n=3), KMT2A-ELL (n=4), KMT2A-MLLT1 (n=4), KMT2A-MLLT10 (n=3),
KMT2A-MLLT3 (n=3), KMT2A-MLLT4 (n=2), BCR-ABL1 (n=3), NUP98-NSD1
(n=3), DEK-NUP214 (n=1), and KAT6A-CREBBP (n=1). Further, cases har-
boring rearrangements involving KMT2A (n=14), RUNX1 (n=21), ETV6 (n=10),
PDGFRB (n=10), RARA (n=2), NPM1 (n=2) and NUP98 (n=1) were included.
Targeted RNA sequencing was performed using the TruSight RNA Fusion panel
(Illumina, San Diego, CA) consisting of 7690 probes covering 507 genes known
to be involved in gene fusions. Library was prepared according to manufactur-
er’s protocol with ~50ng RNA extracted from fresh/frozen samples. Sequencing
was performed on the NextSeq instrument (Illumina) and analysis with the
RNA-Seq Alignment App (BaseSpace Sequence Hub) using Star for Alignment
and Manta for gene fusion calling with default parameters (Illumina).
Results: In 42/45 (93%) cases with a recurrent rearrangement identified by
standard diagnostics, RNA sequencing detected the respective fusion transcript.
In addition, RNA sequencing was able to identify known and novel fusions in
the remaining 57 cases. For KMT2A these were the following partner genes:
MLLT1 (n=5), ELL (n=3), ITPR2, FLNC, ASXL2, DCP1B, MAML1 and
ARHGEF12. Seven different partner genes were identified in RUNX1 translo-
cated cases: PLAG1 (n=2), PRDM16, MECOM, ZFPM2, MAN1A2, N6AMT2,
and KIAA1549L. Five different partner genes were identified in ETV6 rearranged
cases: ABL1, CCDC126, ERG, FOXO1 and CFLAR-AS1. Most strikingly was
the identification of the ETV6-ABL1 fusion, which could not be suspected by
cytogenetics as the 5’ ETV6 FISH signal was located on chromosome 17. In
7/10 PDGFRB rearranged cases the partner genes were identified. These were
WDR48, CCDC88C, MPRIP, TNIP1, TPR, NFIA and ZBTB11. Further the fol-
lowing fusions were found: NPM1-RPP30, NPM1-SETBP1, NUP98-ING3,
IRF2BP1-RARA, and ZBTB16-RARA. Thus, RNA sequencing identified 39
fusions in 57 (68%) cases in which standard diagnostics had identified only
one of the partner genes. Failure to detect gene fusions should initiate improve-
ments in calling algorithms and may also have biological reasons. It was report-
ed that genomic rearrangements of RUNX1 occur, which do not lead to RUNX1
in frame fusion transcripts but to termination of transcription.
Summary/Conclusions: 1) RNA sequencing was able to detect recurrent gene
fusions with high accuracy and to characterize rare gene fusions providing the
basis for the design of RT-PCR based assays for monitoring MRD. 2) Targeted
RNA sequencing may be a valuable tool in routine diagnostics for patients with
rearrangements unresolved by standard techniques. 3) These findings may
have consequences for targeted treatment approaches.
P550
COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE
ACUTE LEUKEMIA (MPAL)
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Background: Mixed phenotype acute leukemia (MPAL) is a rare subgroup of
acute leukemia characterized by blasts that show immunophenotypes of both
myeloid and lymphoid lineages and therefore not traceable to single lineage of
origin. Diagnosis of MPAL is challenging due to the possible discrepancy
between immunophenotype and morphology. Clinically, MPAL has poor prog-
nosis and poses therapeutic challenges. Genetic basis of MPAL is not well
understood.
Aims: To clarify the underlying pathogenesis of MPAL and provide clue on
future personalized therapy in MPAL, we performed comprehensive molecular
characterization of adult MPAL.
Methods: We studied 31 patients with adult MPAL (median age 53) that met
2008 WHO classification criteria. Pre-treatment bone marrow samples were
studied by targeted capture exome sequencing of 295 genes that are recurrently
mutated in hematologic malignancies (median 393x coverage, N=31), RNA
sequencing (N=24), and Infinium methylation EPIC array (Illumina, N=31).
Mutational landscape was compared to that of 194 AML, 71 B-ALL, and 6 T-
ALL cases of which pre-treatment samples were sequenced internally with the
same platform. Promoter CpG methylation pattern was compared to the data
from 194 AML (data derived from The Cancer Genome Atlast Project), 505 B-
ALL and 101 T-ALL cases (data shared by Nordlund et al. Genome Biology.
2013). Copy number variation was inferred from methylation array data.
Results: Among 31 MPAL cases, 18 (58%) had myeloid-T and 13 (42%) had
myeloid-B phenotype. Four cases had Philadelphia chromosome, 1 had 11q23
abnormality, and 8 had complex karyotype. MPAL had similar numbers of muta-
tions (median 2 [range: 0-6]) with AML (median 3 [range: 0-7], P=0.79) or T-
ALL (median 3 [range: 1-4], P=0.92) but had significantly higher number of
mutations than B-ALL (median 0 [range: 0-4], P<0.001). Consistent with the
mixed immunophenotypic features, MPAL had both AML-type and ALL-type
mutations. However, NPM1 mutation was specific to AML and was not found
in MPAL cases. Myeloid-T and myeloid-B showed distinct patterns of somatic
mutations. Genes in which mutations were enriched in myeloid-T than in
myeloid-B included DNMT3A (33% vs 8%), IDH2 (33% vs 8%), NOTCH1 (39%
vs 0%), IL7R (17% vs 0%), and FBXW7 (6% vs 0%). Genes in which mutations
were less frequently observed in myeloid-T than in myeloid-B included RUNX1
(6% vs 46%), ASXL1 (0% vs 23%), TET2 (0% vs 15%), SRSF2 (6% vs 23%),
and FLT3 (11% vs 23%). Myeloid-T and myeloid-B showed distinct patterns of
promoter CpG methylation. Overall, myeloid-T had more hypermethylated CpG
loci than myeloid-B in all different CpG locations (island, shore, shelf, and oth-
ers). Genes that are essential in T-cell receptor (TCR) signaling (CD3D, CD7,
CD247, LCK, PRKCQ, CCR9, and TCL1A) were differentially methylated and
consequently differentially expressed between myeloid-T and myeloid-B. Copy
number analysis showed that DLL1, one of the essential NOTCH pathway
genes, was amplified and was overexpressed. RNA sequencing revealed sev-
eral known translocations such as NSD1-NUP98 and KMT2A-MLLT4, in addi-
tion to the novel translocations such as FOXP1-DNAJC15, FLI1-IFT46, and
ITPR2-ARID5B. Unsupervised hierarchical clustering of all MPAL, AML, B-ALL
and T-ALL by promoter CpG methylation pattern revealed that myeloid-T con-
sistently showed similar methylation pattern with T-ALL, while myeloid-B
showed random similarity with either B-ALL or AML.
Summary/Conclusions: MPAL is genetically heterogeneous disease and
myeloid-T and myeloid-B shows distinct patterns of mutation landscapes,
methylation and gene expressions. Therapy for MPAL may need to be person-
alized based on genomic profiles.
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ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA COMPARED TO
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Background: Standard remission induction chemotherapy for adult acute
myeloid leukemia (AML) which consists of anthracycline for 3 days plus cytara-
bine for 7 days was first introduced in 1970’s and has been used for a long
time. Several modification or intensification for this conventional regimen did
not prove the effect for higher complete remission (CR) rate or lower relapse
rate which led to superior overall survival (OS) rate.
Aims: We tried to find out possible benefit of early intensification of standard
induction chemotherapy in adult AML patients.
Methods: This single center retrospective study enrolled 1195 adult AML
patients from 2002 to 2013. All patients were initially treated with idarubicin
(12mg/m2) plus cytarabine (100mg/m2) or BHAC (300mg/m2) induction
chemotherapy (3+7), and among them, 731 (61.2%) patients received additional
early augmentation using cytarabine 3 days (3+10, n=363) or anthracycline 2
days plus cytarabine 3 days (5+10, n=368). The decision for augmentation was
based on the follow-up BM blast counts on the 7th day of 3+7 chemotherapy;
totally 3+10 for blast counts 5~20% and 5+10 for blast counts >20% (early
intensified group). The rest 464 with blast counts < 5% finished with 3+7 regi-
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men (standard group). Re-induction and consolidation therapy was performed
according to a consistent strategy and post-remission therapy was mainly
based on hematopoietic cell transplantation. 
Results: Early intensified group was consisted of younger patients (median
age, 37 years old [range 17-69] vs 45 years in 3+7 vs 43 years in 3+10 sub-
group) and larger proportion of t(8;21) (n=102 [27.7%] vs 3+7 [n=33, 7.1%] vs
3+10 [n=47, 12.9%], P<0.001). Also, initial BM blast counts were higher in two
intensified groups (73.3% in 5+10 and 70.1% in 3+10) compared to 3+7 sub-
group (66.8%, P<0.001). Early death rate at 8 weeks was higher in patients
older than 55 years (10.8% vs 3.7%, P<0.001) especially when they were treat-
ed with intensified chemotherapy (21.7% in 5+10 and 15.7% in 3+10 vs 6.3%
in 3+7, P=0.038). CR rate after induction was higher in young patients espe-
cially in 3+10 subgroup (79.8%, P<0.001) and we also found that patients with
favorable to intermediate-risk karyotype might benefit with intensified
chemotherapy in the context of CR rate (79.7% vs 68.3% P<0.001), although
final CR rates became similar after re-induction. Next, we found that pre-HCT
relapse rate was lower in patients younger than 55 years (9.4% vs 18.0%,
P=0.002) and favorable to intermediate-risk group (8.9% vs 20.2%, P<0.001)
after intensified induction. In young patients with favorable to intermediate-risk
karyotype, intensified group showed superior 5-year OS (55.0% vs 45.5%,
P=0.010) and lower long-term relapse rate (32.2% vs 39.0%, P=0.084), but
multivariate analysis revealed no effects for both OS and CIR. In patients older
than 55 years, intensified group showed inferior 5-year OS (19.2% vs 22.8%,
P=0.014) with higher early death rate (17.6% vs 6.3%, P=0.015), and multi-
variate analysis also showed intensified induction was related inferior OS
(HR=1.89, 95%CI; 1.14-3.15, P=0.013).
Table 1.
Summary/Conclusions: Our data revealed that intensified induction
chemotherapy was not influential for poor-risk karyotype, while higher post-
induction CR rate and low pre-HCT relapse was shown in young patients with
favorable to intermediate-risk karyotype although it was not influential for final
OS and CIR rate. In elderly patients, intensified induction chemotherapy was
related with higher early death rate which finally showed poor OS. 
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VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY
CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT
PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML
E. Wang1,*, R. Stone2, R. Collins3, T. Agrawal4, V. Urity4, M. Tallman5
1Department of Medicine, Roswell Park Cancer Institute, Buffalo, 2Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, 3The University
of Texas Southwestern Medical Center, 4Arog Pharmaceuticals, Inc., Dallas,
5Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer
Center, New York, United States
Background: Patients (pts) with FLT3-internal tandem duplication (ITD) and
FLT3-D835 mutant AML have a high relapse rate. These relapses are typically
due to outgrowth of mutant FLT clones. Previously available PCR-based tests
only checked for presence of FLT3-ITD and FLT3-D835/I836 mutations. Whole
genome sequencing of 799 pediatric AML samples from COG trials have shown
novel FLT3 variants in not only the tyrosine kinase domain but also the jux-
tamembrane (JM) and transmembrane domains in 7.6% of these samples (Tar-
lock et al. ASH 2015). Some of these mutations result in autophosphorylation
of FLT3 and therefore may be oncogenic.
Aims: Identify novel FLT3 mutations in pts with FLT3 mutant AML and further
investigate whether these novel clones are sensitive to induction chemotherapy
plus a potent pan-FLT3 inhibitor, crenolanib.
Methods: Pts with newly diagnosed FLT3 mutant AML were enrolled and treat-
ed with cytarabine/anthracycline/crenolanib induction followed by high dose
cytarabine (HiDAC) consolidation. Crenolanib 100mg TID was started on day
9 of induction and continued till next chemotherapy. Crenolanib was given fol-
lowing consolidation and allogeneic stem cell transplantation. Bone marrow
samples were collected at baseline and at the time of remission assessment.
Sequencing of the entire FLT3 gene was performed through FoundationOne
Heme panel (n=18) and MSKCC multigene panel (n=5). Sequencing of exons
14,15,16, and 20 was performed through the Rapid Heme Panel at Dana-Far-
ber Cancer Institution in additional 6 pts.
Results: Out of 29 newly diagnosed FLT3 mutant AML patients with full/partial
FLT3 gene sequencing performed, 4 pts were found to have novel variant FLT3
mutations consisting of V491L, V592L, D593H, A680V, and N841I/T/K (Table
1). The majority of these novel mutations were located at the JM, kinase domain
1 and the activation loop (kinase domain 2). The allele fractions of these FLT3
variants ranged as high as 29% (higher than that of FLT3-ITD in pt3), suggest-
ing that some of these clones may have been potentially driving clinical
leukemia progression in some pts. All 4 pts had NPM1 mutations, and two also
had DNMT3A mutations. All 4 pts achieved CR with full count recovery (3/4 pts
achieved CR after just one cycle of cytarabine/anthracycline/crenolanib induc-
tion). The pt with FLT3-D835Yand N841T achieved a CR after cytarabine/
anthracycline/crenolanib induction and one cycle of HiDAC consolidation. All
pts became FLT3-ve and have remained FLT3-ve. 3 out of 4 pts received 1-4
cycles of HiDAC consolidation followed by crenolanib maintenance. Only one
pt underwent allo SCT. With a median follow up of 13 months, one pt relapsed
(at 8.4-month following treatment). This 61F pt was found to have FLT3-ITD,
D593H and I836del FLT3 abnormalities at the time of diagnosis. A full Founda-
tionOne gene panel done at the time of relapse, showed no residual FLT3
mutant clones.
Table 1.
Summary/Conclusions: This abstract reports multiple novel variant FLT3
mutations in adult pts with newly diagnosed FLT3-ITD or FLT3-D835 mutant
AML. The allelic burden of these FLT3 variant mutations can sometime be
higher than that of FLT3-ITD. Detailed FLT3 analyses in this subset of pts sug-
gests that crenolanib in combination with standard induction chemotherapy
has the ability to eradicate variant FLT3 clones. All 4 pts treated with chemother-
apy followed by crenolanib showed clearance of FLT3-ITD, TKD, as well as
other novel variants. To achieve maximal clinical benefit, a potent pan-FLT3
inhibitor with the ability to inhibit ITD, D835, as well as other activating mutations
maybe beneficial.
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PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO HAVE MUTATIONS
IN IDH1 OR IDH2 RESPOND WELL TO INDUCTION CHEMOTHERAPY
WITH “7+3” DESPITE THE PRESENCE OF COMPLEX KARYOTYPE OR
FLT3-ITD
D.M. Gupta1,*, D.S. Devlin2, D.M. Tallman2, D.E. Stein2
1Mount Sinai Hospital, 2Memorial Sloan Kettering Cancer Center, New York,
United States
Background: Mutations in isocitrate dehydrogenase isoforms 1 and 2
(IDH1/IDH2) occur in 8-12% of patients with acute myeloid leukemia (AML).
Mutant IDH enzymes catalyze the conversion of alpha ketoglutarate to beta
hydroxyglutarate. Increased concentrations of intracellular 2-HG lead to histone
hypermethylation and a block in cellular differentiation and may also lead to
suppression of homologous recombination. Previous studies of outcomes in
patients given induction chemotherapy are limited by the heterogeneity of
induction regimens. In this study, we investigated the outcomes of patients giv-
en induction chemotherapy with daunorubicin and cytarabine (7+3), the most
common regimen used in the United States.
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Aims: To delineate the complete remission rate in AML patients with IDH1 or
IDH2 mutations who receive standard 7+3 induction chemotherapy.
Methods: After receipt of IRB approval, an institutional database of genomic
abnormalities in all patients with AML was queried for patients with IDH1 or
IDH2 mutations between the years of 2010 and 2016. Pathology records of
patients identified as having an IDH1/IDH2 mutation were reviewed to confirm
the presence of an IDH mutation. After confirmation of IDH mutational status,
all patients who received standard induction chemotherapy with 7+3 were
included in this retrospective chart review.
Results: Between 2010 and 2016, 82 patients with IDH1/IDH2 mutations who
had been treated with “7+3” induction chemotherapy were seen at MSKCC. Of
these, 33 (40.2%)had IDH1 mutations and 49 (59.8%) had IDH2 mutations. Of
those with IDH2 mutations IDH2 R140Q mutations were present in 34
(69.3%)and IDH2 R172K mutations were present in 15 (30.6%). The median
age of all patients treated was 63. 56 patients (68%) had de novo AML, 16
(20%) had AML with myelodysplasia related changes, 5(6%) had a a known
prior history of MDS and 5 (6%) had therapy related AML. Nearly half of the
patients (49%) had karyotypic abnormalities. Of the 82 patients who received
induction chemotherapy with “7+3”, 51 achieved a complete remission (CR)
after 1 cycle and 16 after 2 cycles for a CR rate of 82%. The strongest predictor
of response to induction chemotherapy was the presence of an NPM1 mutation.
There was a trend towards decreased response to induction chemotherapy in
patients with a complex karyotype (p=.079) that did not reach statistical signif-
icance. The presence of an IDH2 R172K mutation was predictive of non-
response to one cycle of (7+3) of 7+3 but when two cycles of induction
chemotherapy were given, response rates were equivalent to patients with
R140Q mutations. Co-occurring mutations in FLT3 (ITD or TKD), DNMT3A or
NRAS were not predictive of responses to induction chemotherapy. 
Summary/Conclusions: Induction chemotherapy with 7+3 leads to a robust
CR rate of 82% in patients with AML that harbor and IDH1 or IDH2 mutation.
CR is not affected by IDH2 isoform (R172 or R140), although more patients
with R172 mutations required two cycles of chemotherapy to achieve a remis-
sion. Karyotypic abnormalities did not influence the response to induction
chemotherapy, nor did the presence of co-occurring FLT3-ITD, FLT3-TKD or
NRAS mutations. For AML patients with IDH mutations who are eligible for
induction chemotherapy “7+3” is a reasonable induction regimen regardless of
the presence of FLT3 mutations, or karyotypic abnormalities.
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VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID
LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL
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Background: Treatment of Acute Myeloid Leukemia (AML) is limited to few
different treatments in each clinical trial group guideline, but integrating current
and previous guidelines, and clinical trial publications, there are up to 45 drug
combination treatments among approved chemotherapy drugs in Europe and
USA. There is a need for Precision Medicine (PM) tests to identify which of
these different treatments maybe optimal for each individual patient, independ-
ently of where he/she lives.
Aims: To provide actionable data to improve disease management with existing
treatments with a PM test to guide the hematologist among all possible treat-
ments to achieve a CR.
Methods: AML bone marrow (BM) samples from adult patients were received
at the laboratory within 24 hours from extraction and incubated for 48h in 96-
well plates containing single drugs or combinations representing up to 45 dif-
ferent treatments that are currently given in the clinical practice. The analysis
is performed in the automated flow cytometry PharmaFlow platform. 72 hours
after the extraction of the sample, an encrypted report is sent to the hematologist
before the patient begins treatment. Pharmacological responses were calcu-
lated using pharmacokinetic population models. Induction response was
assessed according to the Cheson criteria (2003). Patients attaining a CR/CRi
were classified as responders and the remaining as resistant, excluding early
deaths. Final scores and treatments ranking is based on a therapeutic algorithm
that integrates ex vivo activity; monotherapy dose responses quantified by the
area under the curve (AUC) with limits such as Cmax values, and synergism
calculated measuring 8 concentration ratios requiring consistency in their results
in a 3D surface (so called alpha factor synergism). The PM Test attempts to
identify at least one treatment, among all evaluated alternatives, predicted sen-
sitive for each patient; conversely, if sensitive treatments can be identified the
PM Test can provide the hematologist with valuable guidelines for individualized
treatment.
Results: (Figure 1) The scoring method was tested using ex vivo results from
samples obtained in an observational clinical trial with Spain´s PETHEMA group
from a cohort of 123 samples from de novo diagnosed AML patients, treated
with the standard PETHEMA 1st line guideline 3+7 with CYT+IDA. The score
predicts sensitive patients with 90% accuracy. This accuracy can be compared
with an independently derived 92% accuracy in identifying sensitive patients in
a statistically significant clinical correlation study (EHA Poster 2016 Montesinos
et al.). The score is a simplified version of such correlation algorithm. Both
methods identify a similar % of all clinically sensitive patients (67% vs 71%).
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However, the correlation is only valid for CYT-IDA while the PM Test is applied
to up to 45 treatments. Any such treatment identified as sensitive means the
PM Test can provides a valuable guideline to hematologists. This means the
PM Test can suggest sensitive treatments for the vast majority of patients.
Figure 1.
Summary/Conclusions: We have developed a novel ex vivo PM test for induc-
tion treatment in AML patients to guide hematologists selecting the right treat-
ment to achieve CR in individual patients leveraging up to 45 different validated
chemotherapeutic regimes. Assuming a similar response rate for all these treat-
ments, our test could estimate a net prediction for sensibility to AML treatment
higher than 80% in 1st line. This PM Test will be evaluated in an interventional
clinical trial on relapse/refractory patients that is expected to begin in the next
few months in collaboration with the PETHEMA group from Spain.
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RESPONSE-ADAPTED AZACITIDINE AND INDUCTION CHEMOTHERAPY
IN PATIENTS >60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE
FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF
THE EAST GERMAN STUDY GROUP
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Background: AML treatment in elderly patients (pts) >60 years (y) with intensive
chemotherapy (IC) or azacitidine (AZA) are not necessarily mutually exclusive.
Aims: Results of the multicenter DRKS00004519 (RAS-AZIC) study of the East
German Study Group (OSHO) which evaluated first-line treatment with AZA fol-
lowed by response-based AZA or IC in pts >60y with AML are presented.
Methods: pts >60y with newly diagnosed AML (n=112) were included. Recruit-
ment was completed in May, 2016. In the phase I part, safety of upfront AZA
(75mg/m2/day s.c) for 7 days followed by IC (mitoxantrone 10mg/m2/day on
day (d) 1-3 and cytarabine 1g/m2/BID on d 1, 3, 5, 7) on d17 was established
through a 3+3 design. In the multicenter phase II part (figure), upfront AZA was
sequentially followed by AZA or IC based on d15 bone marrow (BM) blasts
(<45 vs ≥45%) and CR/CRi on d56 which were both previously identified as
early predictors for long-term response to AZA in AML (Al-Ali et al. Leuk Lymph
2012). The primary endpoint was response (OR) [CR/CRi, and PR] at d90
according to the International Working Group criteria. Based on the optimal
two-stage design (Simon. Control Clin Trials 1989), protocol treatment was
non-inferior to standard IC if, on an intention-to-treat basis, an OR of 61% was
reached. Adverse events (AEs) were reported according to the NCI CTCAE
4.03. All pts gave written informed consent.
Results: Median age was 70y (52% males). de novo AML was present in 65%
of pts. Median BM blasts and WBC were 50% and 4.4x109/L respectively.
Genetic risk was high in 30%, intermediate in 55%, and favorable in 15%. FLT3
and NPM1 were mutated in 12% and 22% respectively. All pts received first-
line AZA. Only lower baseline blasts correlated with blasts <45% on d15
(p<0.0005). Yet, 40% of pts with baseline blasts >50% reached this goal. Pro-
tocol assigned treatment on d15 was applied to 101 (90.2%) pts (54.5% con-
tinued with AZA; 46.5% received IC). Of 152 AZA cycles given till d56, 33.6%
were applied in an outpatient setting. Until d90, one IC cycle was needed in 77
(68.8%) pts. In the intention-to-treat cohort (n=112), OR and mortality at d90
were 62.5% [CR/CRi (n=43%/15%); PR (4.5%)] and 8.9% respectively. The
probabilities of achieving CR/CRi with AZA alone, two AZA cycles + one IC,
and one AZA cycle + one IC were 28.3%; 53.3%, and 58.3% respectively. Age,
WBC, and type of AML had no impact on response in the three treatment sce-
narios. Similarly, response was not influenced by baseline BM blasts. CR/CRi
was lower in high risk genetics (48%) compared to other risk categories (78%)
(p=0.007). This negative association was particularly marked in pts with high-
risk genetics and d15 BM blasts >45% [CR/CRi 38.5% vs 84% in other genetic
categories (p=0.009)]. Interestingly, the impact of genetics on OR was not seen
in the two AZA cycles + one IC cohort (p=1.0). CR with AZA alone was remark-
ably high (70%) in pts with favorable genetics including those with
NPM1mut/FLT3wt (p=0.003). Protocol therapy was generally well tolerated.
Constipation grade 1+2 was the most frequently reported AE under AZA (48%).
The most frequent grade 3+4 non-hematologic AE was infection [IC (47%);
AZA (20%)].
Figure 1.
Summary/Conclusions: Sequential response-based epigenetic and
chemotherapy in elderly pts with AML is safe, associated with low mortality,
and yields non-inferior responses compared to repeated cycles of IC. Marrow
blasts d15 after the first AZA cycle and genetics could guide treatment-decision.
The follow-up of this trial will scrutinize the impact of this approach on survival.
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OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS
WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID
LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY
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Background: Therapy-related acute myeloid leukemia (tAML) may occur as
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a late complication of cytotoxic or radiation therapy and is associated with a
poor prognosis. CPX-351 is a liposomal formulation that delivers a synergistic
5:1 molar ratio of cytarabine and daunorubicin. In a randomized, open-label,
controlled phase 3 trial in patients aged 60 to 75 years with newly diagnosed,
secondary AML (eg, tAML or AML after myelodysplastic syndrome), CPX-351
significantly improved overall survival (OS) versus cytarabine/daunorubicin
(7+3).
Aims: The current analysis of this phase 3 study evaluated outcomes in the
subgroup of patients with tAML.
Methods: Enrolled patients were randomized 1:1 to receive induction with 1 to
2 cycles of CPX-351 (100 units/m2 [cytarabine 100mg/m2 + daunorubicin
44mg/m2] on Days 1, 3, and 5 [2nd induction: Days 1 and 3 only]) or 7+3
(cytarabine 100mg/m2/day x 7 days [2nd induction: x 5 days] + daunorubicin
60mg/m2 on Days 1, 2, and 3 [2nd induction: Days 1 and 2 only]). Patients who
achieved complete remission (CR) or CR with incomplete platelet or neutrophil
recovery (CRi) could receive up to 2 cycles of consolidation therapy. Note, the
study was not powered for this subgroup analysis.
Results: A total of 304 patients were enrolled and received study treatment,
including 62 (20%) patients with tAML (CPX-351 arm, n=30; 7+3 arm, n=32).
Characteristics of tAML patients were similar between the CPX-351 and 7+3
arms: median age was 69.0 versus 67.5 years, and 47% versus 53% were
male. Prior treatment in patients with tAML included prior non-anthracycline
chemotherapy alone (26%), radiation alone (26%), non-anthracycline
chemotherapy + radiation (32%), non-anthracycline + anthracycline chemother-
apy (5%), and non-anthracycline + anthracycline chemotherapy + radiation
(11%). CPX-351 was associated with a significant OS benefit versus 7+3 in
older tAML patients and numerically longer event-free survival and remission
duration (Figure). Additionally, a greater proportion of tAML patients in the CPX-
351 arm versus the 7+3 arm achieved CR+CRi (47% vs 36%, respectively;
odds ratio=1.33 [95% CI: 0.47, 3.81]) and proceeded to stem cell transplantation
(37% vs 27%; odds ratio=1.54 [95% CI: 0.53, 4.49). Serious treatment-emer-
gent adverse events (TEAEs) were reported for 18/30 (60%) of tAML patients
in the CPX-351 arm and 12/32 (38%) of tAML patients in the 7+3 arm; the
observed difference in serious TEAEs in this subpopulation appeared to pri-
marily be due to the incidence of febrile neutropenia (n=6/30 [20%] vs n=0/32
[0%]). Three (10%) patients in the CPX-351 arm and 5 (16%) patients in the
7+3 arm experienced a TEAE that resulted in death during the treatment period;
there was no pattern in the individual TEAEs that led to death.
Figure 1.
Summary/Conclusions: CPX-351 is associated with improved efficacy and a
safety profile comparable to 7+3 in older patients with newly diagnosed tAML.
Outcomes in the tAML subgroup mirrored the overall study population, indicat-
ing CPX-351 may represent a new therapeutic option for this difficult to treat
population.
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HYPERFERRITINEMIA IS AN INDEPENDENT POOR PROGNOSTIC
FACTOR IN ACUTE MYELOID LEUKEMIA
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Background: The prognostic impact of ferritinemia has been studied in
myelodysplastic syndromes and acute myeloid leukemia (AML) patients under-
going allogeneic stem cell transplantation (SCT). In this context, high levels of
serum ferritin have been correlated to a shorter overall survival (OS) and an
increased relapse risk.. We have previously shown that hyperferritinemia at
diagnosis has a strong prognostic impact in a cohort of 162 AML patients with
intermediate cytogenetic risk and younger than 60.
Aims: We now extend the analysis to all age and cytogenetic risk, in order to
confirm the impact of hyperferritinemia in AML.
Methods: This study included 525 adult AML patients (excluding acute promye-
locytic leukemia) treated by intensive chemotherapy in Toulouse and Lyon Uni-
versity Hospitals between January 1st, 2005 and December 31st, 2014 who
had ferritinemia documented at AML diagnosis. Ferritin level was measured by
spectrophotometry. Primary outcome was disease-free survival (DFS). To avoid
the loss of information and the reduction in power introduced by the catego-
rization of ferritinemia and to deal with the non-linearity in the relationship
between outcomes and ferritinemia, we explored the relationship between fer-
ritinemia and outcomes using restricted cubic spline.
Results: Median age at diagnosis was 59.4 years (interquartile range [IQR],
47.8-66.4); 303 of them (57.7%) were men. Disease status was de novo in
83.2% (N=437). Median white blood cell count (WBC) was 10.0x109/L (IQR,
2.5-41.5). Cytogenetic risk was favorable, intermediate and adverse in 9.2
(N=48), 71.8 (N=374) and 19% (N=99) respectively; ELN classification was
favorable, intermediate-I, intermediate-II, adverse and unknown in 21.0
(N=110), 25.5 (N=134), 22.3 (N=117), 18.9 (N=99) and 12.4% (N=65) respec-
tively. Median ferritinemia at AML diagnosis was 715 µg/L (IQR, 372-1304),
ranging from 34µg/L to 70759 µg/L (upper normal limit [UNL]: 300µg/l). 421
patients achieved complete remission (CR; 80.2%). Early death and treatment
failure rates were 7.8% (N=41) and 12% (N=63) respectively. 169 patients
underwent allogeneic HSCT in first CR (32.2%). Median DFS was 19.8 months
(IQR, 8.4-Not Reached). Ferritinemia had a significant impact on DFS: median
DFS was 21.2 months in patients with ferritinemia ≤2100 µg/L (7-fold UNL),
and 12.7 months with ferritinemia >2100 µg/L (HR, 1.6 [95%CI, 1.1-2.3],
p=0.0253). After adjustment for age, AML status and cytogenetics or ELN clas-
sification, relapse or death rate significantly (p=0.0122) increased from fer-
ritinemia superior or equal to 2141 µg/L (Figure 1). Ferritinemia had also a sig-
nificant impact on early deaths, CR rate, EFS and OS after adjustment (≥4-fold
UNL, p<0.0001; ≥7-fold UNL, p=0.004; ≥3-fold UNL, p<0.0001 and ≥3-fold UNL,
p<0.0001 respectively).
Figure 1.
Summary/Conclusions: In conclusion, hyperferritinemia is a prognostic mark-
er independent from well-acknowledged factors, such as cytogenetics and
molecular abnormalities. Ferritinemia should be included at AML diagnosis
workup as it provides reproducible information on short and long-term outcome
for AML patients of any subgroup. The putative link between hyperferritinemia,
inflammation and chemoresistance should be investigated.
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NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML
PATIENTS TREATED WITH AZACITIDINE–IMPACT OF AGE ON MUTATIONAL
LOAD
L. Pleyer1,2,3,*, F.J. Gassner1,2, S. Burgstaller4, H. Wedler5, T.N. Hartmann1,2,3,
B. Jansko1, D. Neureiter6, J. Thaler4, R. Greil1,2,3
1Oncologic Center, Paracelsus Medical University, 2Salzburg Cancer Research
Institute (SCRI), Center for Clinical Cancer and Immunology Trials, 3Cancer
Cluster, Salzburg, 4Department of Internal Medicine IVDepartment of Internal
Medicine IV, Klinikum WelsGrieskirchen, Wels, 5Qiagen Genomic Services,
Qiagen GmbH, Hilden, 6Institute of Pathology, Paracelsus Medical University,
Salzburg, Austria
Background: Recent publications have shown the prognostic value of per-
forming molecular analyses in patients (pts) with acute myeloid leukaemia
(AML) (Papaemmanuil et al, NEJM 2016). While recent data has been pub-
lished on pts with myelodysplastic syndromes (MDS) and AML treated with
decitabine, (Welch et al, NEJM 2016; Duncavage et al, Blood 2017) data on
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AML pts treated with azacitidine (AZA) has only been presented in abstract
form thus far (Tang et al, ASH 2016). Data on the impact of age on mutational
load in AML are scarce.
Aims: To assess the mutational landscape in elderly AML pts treated with AZA;
specifically, whether age has an impact on mutational load.
Methods: We analysed 474 bone marrow FFPE specimens from 157 AML pts
in the Austrian Registry of Hypomethylating Agents from two centres (Salzburg,
Wels-Grieskirchen) using a 53-gene panel (all exons). NGS was performed by
Qiagen. Minimum coverage: 1.500x. All mutations were checked against COS-
MIC-v79, ClinVar, ICGC, DoCM, dbsnp and Varsome databases. For compar-
ison of categorial variables Chi-squared test was used, for comparison of
means Students T-test was used.
Results: The rate of secondary (s)AML was significantly lower in pts <75
(n=85), vs ≥75 years (n=54) (66.0 vs 77.8%, P<0.001). There was no significant
difference in the rate of adverse cytogenetics or monosomal karyotype before
AZA treatment between pts < vs ≥75 years, respectively (data not shown).
Mutational load (average number of mutated genes and mutations per pt)
assessed at/before initiation of AZA, was significantly higher in pts <75 vs pts
≥75 years (10.2 vs 8.6 mutated genes/pt; P=0.030 and 12.9 vs 10.5
mutations/pt; P=0.012; Figure 1A). This also held true when mutational load
was assessed at any timepoint during the course of AML (including during/post-
AZA treatment) (Figure 1B). In total, 139 pts had more than one marrow sample
with NGS results. Analysis of paired samples revealed that mutational load
was significantly higher during/post-AZA vs before AZA in both age groups
(Figure 1C-D). In total, 60.4%, 15.8%, 8.6%, 3.6% and 11.5% of pts acquired
0, 1, 2, 3, 4-13 additional mutations, respectively. No relevant differences
between pts < vs ≥75 years were found (data not shown). When comparing
the delta of mutations before vs during/after AZA according to age group, no
significant difference was found (Figure 1E).
Table 1.
Summary/Conclusions: The observed mutational load per pt in our cohort is
higher than that observed by others using targeted re-sequencing methods,
which report an average of only 2-4 mutations per pt (Duncavage et al, Blood
2017; Conte et al, Leuk 2013; Au et al, Diagn Pathol 2016; Grove & Vassiliou,
Dis Model Mech 2014). It seems however, that a higher mutational load (aver-
age: 13-14 [range 1-51]) per pt can be found using whole genome/whole exome
sequencing (The Cancer Genome Atlas Research Network, NEJM 2013; Mer-
levede et al, Nat Commun 2016). We hypothesize that the higher observed
number of mutations in our study may be due to the high coverage (minimum
1.500x) we used (most previous publications had a median/average coverage
of ≤500x). While age <75 years seems to coincide with a higher mutational
load both before AZA start and during/after AZA in our cohort, it does not seem
to predispose to the acquisition of more mutations during/after AZA. Higher
mutational load in AML pts <75 years did not go hand in hand with a higher
rate of known/presumed adverse prognostic baseline factors such as adverse
cytogenetics, monosomal karyotype, or sAML at AZA start. We thus hypothe-
size that the biology of the disease may generally be more aggressive in
younger pts. Correlation analyses of age and mutational load with response
and survival will be in our final presentation.
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PROGNOSTIC VALUE OF EARLY WT 1 RESPONSE IN AML PATIENTS
UNDERGOING INTENSIVE CHEMOTHERAPY
S. Machherndl-Spandl1,*, T. Vockenhuber1, M. Binder1, O. Zach1, M. Girschikofsky1,
P. Bettelheim1, A. Weltermann1
1Internal Medicine I, Ordensklinikum Elisabethinen Linz, Linz, Austria
Background: Monitoring minimal residual disease based on quantitative PCR
represents an important risk stratification tool in acute myeloid leukemia (AML)
and enables the prediction of impending relapse. Besides common fusion
genes and mutated genes, Wilms tumor 1 (WT1) gene is widely used to follow
de novo AML.
Aims: The aim of our study was to evaluate the relevance of WT1 expression
for the prognosis of patients with AML in a real life population.
Methods: Bone marrow samples from 174 consecutive adult AML patients
(18-85 years) were used for WT1 mRNA quantification. APL patients were
excluded. Of 143 patients with WT1 overexpression at diagnosis, those treated
with intensive induction chemotherapy and achieving haematological remission
after the first cycle of therapy were included in the retrospective follow-up analy-
sis (n=129).
Results: The extent of WT1 expression at diagnosis had no prognostic rele-
vance. In contrast, achievement of low WT1 levels after induction chemother-
apy was associated with a significant better overall (OS) and disease free sur-
vival (DFS) as compared to persistent high WT1 expression at hCR1: 5 years
OS 54% vs 0% (p<0.001); DFS 44% vs 0% (p<0.001). Additionally, compared
with patients with a low WT-1 reduction (<5 log) at hCR1, the relative risk of
death was 0.32 (95% CI 0.1-0.7) in patients with intermediate WT-1 reduction
(5-8 log) and 0.15 (95% CI 0-0.05) in patients with high WT-1 reduction (>8
log), after adjustment for age, ELN-risk group, and stem cell transplantation in
CR1. The corresponding 5-years OS for patients with low, intermediate and
high WT-reduction were 10%, 42% and 71% (p<0.001), respectively. Even
though numbers of patients were small (n=33), SCT at CR1 seems to overcome
the adverse risk of persistent WT1 expression: DFS 5.3 years (0-12.9) for
patients with SCT and 0.7 years (0.6-0.9) for patients without SCT (p=0.004).
Summary/Conclusions: Persisting WT1 expression in AML patients achieving
a CR1 after induction chemotherapy is a strong, independent predictor for DFS
and OS in patients with AML. Since 80–90% of AML patients exhibit WT1 over-
expression at diagnosis, this marker is widely applicable for early risk re-eval-
uation and corresponding therapy adaption.
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EVALUATION OF THE IMPACT OF SIGNAL RATIO ON OVERALL
SURVIVAL IN FLT3-MUTATION-POSITIVE RELAPSED/REFRACTORY
ACUTE MYELOID LEUKEMIA FOLLOWING ONCE-DAILY TREATMENT
WITH GILTERITINIB
M. Levis1,*, J. Altman2, A. Perl3, J. Cortes4, C. Smith5, M. Litzow6, J. Hill7,
R. Larson8, C. Liu7, E. Ritchie9, S. Strickland10, E. Wang11, A. Neubauer12,
G. Martinelli13, E. Bahceci7
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tatsklinikum Giessen und Marburg, Marburg, Germany, 13Seragnoli Institute
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Background: Fms-like tyrosine kinase 3 (FLT3) internal tandem duplications
(ITD) in acute myeloid leukemia (AML) are associated with early relapse and
short survival, particularly in the context of high allelic burden. Patients with
high FLT3-ITD signal ratio are particularly sensitive to FLT3 inhibitors but the
clinical effects of allelic burden on survival have not been validated in trials of
these drugs. Gilteritinib is a highly specific, potent FLT3/AXL inhibitor with
demonstrated activity against both FLT3-ITD and tyrosine kinase domain (TKD)
mutations. A recent Phase 1/2 study (CHRYSALIS; NCT02014558) demon-
strated that FLT3 mutation-positive (FLT3mut+) patients with relapsed/refractory
(R/R) AML treated with gilteritinib had high clinical response rates and pro-
longed overall survival (OS), especially at doses ≥80mg/d.
Aims: To evaluate the effect of FLT3-ITD and FLT3-TKD signal ratios on OS
in FLT3mut+R/R AML patients who had received gilteritinib doses ≥80mg/d.
Methods: Signal ratios were assessed in adult FLT3mut+R/R AML patients who
had received gilteritinib doses ≥80mg/d. Genomic DNA extraction and PCR
with fluorescent primers were used to generate transcripts of FLT3 alleles con-
taining ITD and TKD mutations. FLT3 alleles containing ITD mutations gener-
ated transcripts >330 bp in length. For TKD mutations, primers on either side
of the TKD region were used to amplify the target region and an EcoRV endonu-
clease digest was performed. FLT3 alleles containing TKD mutations generated
shorter (130 bp) transcripts due to the lack of an EcoRV restriction site typically
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present in the wild-type allele. Differential fluorescence detection enabled iden-
tification of the specific transcripts. Median ITD signal ratio (ie, FLT3-ITD:wild-
type FLT3) was calculated from patients with ITD mutations (with/without con-
comitant TKD mutations); median TKD signal ratio (i.e., FLT3-TKD:wild-type
FLT3) was calculated from all patients with a TKD mutation. Median OS esti-
mates were derived and stratified based on ITD and TKD signal ratios that fell
above or below median signal ratio values reported for the trial.
Results: Signal ratio was assessed in 152 patients with FLT3-ITD and -TKD
mutations who had received ≥80mg gilteritinib. Of these patients, 136 had FLT3-
ITD mutations with or without concomitant TKD mutations, and 16 had FLT3-
TKD mutations only. Median ITD and TKD signal ratios were 0.84 and 0.5,
respectively. Patients with FLT3-ITD signal ratios that were above or below the
median ITD signal ratio had OS durations of 216 and 213 days, respectively.
No significant difference in median OS was observed between patients in the
highest and lowest FLT3-ITD signal ratio quartiles (Figure 1). Patients with
TKD signal ratios that were above the median value (0.5) had a median OS of
202 days; those with TKD signal ratios below the median value had significantly
shorter median OS of 33.5 days (P=.0004; Figure 1).
Figure 1.
Summary/Conclusions: These data show that FLT3-ITD signal ratio has little
impact on survival in patients with FLT3-ITD mutations who received gilteritinib.
In the small number of patients with FLT3-TKD mutations only, high TKD signal
ratio was associated with a longer OS, similar to that observed in patients with
FLT3-ITD mutations. These data suggest a possibility that oncogene addiction
in FLT3-TKD+ R/R AML requires a high allelic burden and clonal dominance.
Also, it is possible that FLT3-TKD signal ratio in R/R AML may contribute to the
response rate in patients with FLT3-TKD mutations only. Further investigation
is warranted.
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CLINICAL OUTCOME OF HYPOCELLULAR AML AND AML WITH
MYELODYSPLASIA-RELATED CHANGE (MRC) COMPARED TO DE NOVO
ADULT AML WITH NORMAL CELLULARITY AFTER HEMATOPOIETIC
CELL TRANSPLANTATION
D.-H. Kwak1,*, J.-H. Yoon1, H.-J. Kim1, S.-S. Park1, S.-E. Lee1, B.-S. Cho1,
K.-S. Eom1, Y.-J. Kim1, S. Lee1, J.-W. Lee1, W.-S. Min1
1Department of Hematology, Catholic Blood and Marrow Transplantation Cen-
ter, Leukemia Research Institute, Seoul St. Mary’s Hospital, College of Medi-
cine, The Catholic University of Korea, Seoul, Korea, Republic Of
Background: Hypocellular acute myeloid leukemia (hypo-AML) and AML with
myelodysplasia-related change (AML-MRC) accounts for small proportion of
adult AML. As the characteristics and outcomes are not well recognized.
Aims: We tried to analyze these specific groups and compared to normocellular
AML.
Methods: After exclusion of secondary AML, therapy-related AML, and AML
M3, we retrospectively analyzed 1593 AML cases between 2002 and 2013.
We found 101 (6.3%) patients with hypo-AML and 164 (10.3%) patients with
de novo AML-MRC. Hypo-AML was diagnosed with blast counts ≥20% within
hypocellular (<20%) bone marrow (BM) which was identified with at least two
biopsy specimens and age-related correction was considered. De novo AML-
MRC was defined with multilineage dysplasia ≥10% for each lineage with blast
counts ≥20% without history of antecedent hematologic disease. Patients
(n=20) with both AML-MRC and hypo-AML were distributed in AML-MRC group.
Results: Patients with hypo-AML were older (p<0.001) and significantly pre-
sented lower leukocyte and PB/BM blast counts (p<0.001). Patients with AML-
MRC were older and lower hemoglobin level with lower PB/BM blast counts
(p<0.001) compared to normocellular de novo AML. In both groups, the risk of
karyotype was poorer. In untreated group (n=207), hypo-AML showed longer
survival outcome compared to normocellular de novo AML and AML-MRC. In
treated group (n=1386), hypo-AML and AML-MRC both showed higher relapse
rate and inferior survival outcome compared to normocellular AML, and hypo-
AML showed higher therapy-related mortality (TRM) rate. However, multivariate
analysis showed that there were no significant differences between the three




Summary/Conclusions: The long-term outcome of hypo-AML and AML-MRC
were poorer than normocellular de novo AML, mainly due to older age and
large proportion of adverse-risk karyotype which caused unavailable condition
for HCT.
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INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A
CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL
DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR
REFRACTORY AML
J. Cortes1,*, D. DeAngelo2, E. Wang3, C. Arana-Yi4, P. Zweidler-McKay5,
M. Munteanu5, C. Andreu-Vieyra5, H. Erba6, W. Blum7, E. Traer8
1MD Anderson Cancer Center, Houston, 2Dana-Farber Cancer Institute,
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Cancer Center, Albuquerque, 5ImmunoGen, Inc., Waltham, 6University of Ala-
bama at Birmingham, Birmingham, 7The Ohio State University, Columbus,
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Background: Acute myeloid leukemia (AML) accounts for the highest number
of leukemia deaths in the United States annually. IMGN779 is an ADC that
binds with high affinity and specificity to CD33, a validated therapeutic target
in AML. IMGN779 comprises a humanized anti-CD33 antibody attached via a
cleavable linker to the novel DNA-interacting payload DGN462. Once released
within the target cell, DGN462 exerts potent antitumor activity via DNA alkyla-
tion, without cross-linking, resulting in cell cycle arrest and apoptosis.
Aims: This Phase I study is designed to establish the maximum tolerated dose
(MTD) and determine the recommended phase 2 dose (RP2D) of IMGN779
when administered to patients with CD33+ AML. Evaluation of the safety, toler-
ability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-
tumor activity of IMGN779 are secondary objectives.
Methods: Adult patients (≥ 18 years) with relapsed or refractory CD33+ AML
(defined by ≥20% of AML blasts expressing CD33 by flow cytometry) were eli-
gible for enrollment. Informed consent was obtained from all patients. Dose-
escalation, which follows a standard 3+3 design, began with a starting dose of
0.02mg/kg. IMGN779 was administered intravenously once every 2 weeks on
days 1 and 15 as part of a 28-day cycle. Adverse events (AEs) were evaluated
using NCI-CTC v4.03.
Results: As of February 2017, a total of 17 patients (9 female, 8 male) with a
median age of 62 years have received IMGN779 treatment. Five dose levels
have been completed, with escalation proceeding from 0.02–0.26mg/kg. AEs
were as expected for this relapsed/refractory AML population including cytope-
nias and constitutional symptoms. No relationship between frequency or sever-
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ity of AEs and IMGN779 dose level was observed. The most common AEs
were nausea (41%), febrile neutropenia (29%), and rash (29%); pneumonia,
respiratory failure, and constipation were additional AEs reported in 4 or more
patients (≥ 24%). The most common serious adverse events (SAEs) were
grade 3 febrile neutropenia (29%) and pneumonia (24%). No dose limiting tox-
icities (DLTs) have been reported. Importantly, no safety signals regarding liver
or hematopoietic toxicity have been observed in laboratory assessments. In
general, plasma concentrations (Cmax) of IMGN779 increased relative to dose.
In the highest cohort examined thus far (Cohort 5, 0.26mg/kg), sustained expo-
sure (AUC) was observed in all patients through 48 hours post-infusion. A phar-
macodynamics (PD) assay demonstrated consistent saturation of residual free
CD33 in all Cohort 5 patients past 48 hours, consistent with the PK results. Ini-
tial response data will be presented.
Summary/Conclusions: This is the first clinical experience of the next gener-
ation CD33-targeting ADC, IMGN779, in AML patients. No DLTs have been
noted to date. AEs were generally consistent with the underlying disease. PK
and PD are favorable and dose escalation is continuing.
Aggressive Non-Hodgkin lymphoma -
Relapsed/refractory
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COMBINATION OF TGR-1202, UBLITUXIMAB, AND BENDAMUSTINE IS
SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND
FOLLICULAR LYMPHOMA
M.A. Lunning1,*, P. Bierman1, G.R. Bociek1, M.T. Schreeder2, T. Siddiqi3,
S. Blumel1, K. Cutter2, E.K. Pauli2, D. Bui3, P. Sportelli4, H.P. Miskin4, M. Purdom4,
M.S. Weiss4, J.M. Vose1
1University of Nebraska Medical Center, Omaha, NE, 2Clearview Cancer Insti-
tute, Huntsville, AL, 3City of Hope National Medical Center, Duarte, CA, 4TG
Therapeutics, Inc., New York, NY, United States
Background: TGR-1202 is a next generation, once daily, PI3Kδ inhibitor, active
in patients (pts) with rel/ref hematologic malignancies that has demonstrated a
notably differentiated safety profile, including in long-term follow up (Burris,
2016). Ublituximab (UTX) is a novel glycoengineered mAb targeting a unique
epitope on the CD20 antigen. Bendamustine (Benda) is an active chemotherapy
agent in pts with lymphoma. The combination of UTX + TGR-1202 is tolerable
and active in pts with rel/ref hematologic malignancies and is under Phase 3
testing for patients with CLL and Phase 2b testing for patients with DLBCL.
Aims: This Phase 1 trial evaluates the safety and efficacy of UTX + TGR-1202
+ Benda in pts with advanced Diffuse Large B-cell Lymphoma (DLBCL) and
Follicular Lymphoma (FL).
Methods: Eligible pts had rel/ref DLBCL or FL with an ECOG PS ≤2 w/o limit
to number of prior therapies. ANC of >750 and Platelets >50,000 was permitted.
Pts refractory to prior PI3Kδ, Benda, or anti-CD20 therapy were eligible. UTX
was dosed on Days 1, 8, 15 of Cycle 1, Day 1 of Cycle 2-6, followed by Cycle
9 & 12. TGR-1202 was started at 800mg QD with a -1 dose reduction cohort
at 600mg if not tolerated in ≥2/6 pts. Benda was dosed at 90mg/m2 on Days 1
& 2 of Cycles 1-6 only. Primary endpoints included safety and efficacy (Cheson
2007).
Results: Twenty-three pts were evaluable for safety: 15 diffuse large B-cell
(DLBCL) and 8 follicular (FL). Med age 68 yo (range 31-81); 12 M/11 F; median
prior treatment regimens=2 (range 1-6); 12 pts (52%) were refractory to their
immediate prior treatment and to prior CD20 therapy, and 7 patients had pro-
gressed post-transplant. ECOG PS 0/1/2 (3/18/2). Initially 2/4 pts at 800mg
TGR-1202 experienced AE’s in Cycle 1 that led to treatment interruption (rash,
neutropenia) thus the 600mg dose of TGR-1202 was explored. No additional
Cycle 1 treatment delays were reported at the 600mg dose level, which was
later expanded and the 800mg TGR-1202 dose is now being evaluated with
stricter eligibility criteria to require an ANC of ≥ 1.0, and the use of growth factor
support in cycle 1 is now encouraged. The most common AE’s included diar-
rhea (39%; G3/4 4%), decreased appetite (35%; G3/4 4%), nausea (30%; G3/4
4%), asthenia (26%; G3/4 4%) and neutropenia (22%). The only Grade 3/4 AE
reported in >10% of pts was neutropenia (22%). Two pts had a TGR-1202
dose reduction. Nineteen pts (11 DLBCL/8 FL) were evaluable for efficacy:
ORR amongst all pts was 79% (15/19) with 42% (8/19) achieving a complete
response (CR), of which 5 were DLBCL and 3 FL. ORR in the respective groups
as follows: 
Table 1.
Median follow-up time on study is 6 mos for all pts (range 1–14+ mos).
Summary/Conclusions: The combination of UTX, TGR-1202, and bendamus-
tine has exhibited manageable toxicity with significant activity in advanced
DLBCL and FL pts including an encouraging 42% CR rate (45% in DLBCL and
38% in FL). Enrollment continues at the 800mg TGR-1202 dose level with the
use of growth factor prophylaxis. Safety and efficacy data for all pts will be
updated at the meeting. Based upon the early activity of the triplet, future reg-
istration directed studies are being planned.
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VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-
HODGKIN LYMPHOMA (NHL)
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Background: VEN is a selective orally bioavailable BCL-2 inhibitor. The dose-
escalation Phase 1 study of VEN in 106 patients (pts) with relapsed/refractory
NHL reported an ORR of 44%. Most pts had diffuse large B-cell/follicular lym-
phoma. 
Aims: We report on updated results in pts with less common NHL subtypes. 
Methods: VEN was administered and continued until progressive disease
(PD)/unacceptable toxicity, in dose cohorts ranging from 300-1200mg. Adverse
events (AEs) were assessed by NCI-CTCAE v4.0 and response by 2007 Che-
son IWG response criteria, utilizing CT scans beginning at wk 6.
Results: 35 of 106 pts had mantle cell lymphoma (MCL, n=28), marginal zone
lymphoma (MZL, n=3) or Waldenström macroglobulinemia (WM, n=4). Most
common all grade treatment emergent AEs were nausea (51%), diarrhea (49%)
and fatigue (34%); grade 3/4 AEs in >10% of pts were neutropenia and anemia
(17% each). Laboratory TLS was reported in a single pt (bulky MCL). MCL pts
(median age: 72 years) had received a median of 3 (1–7) prior treatments (tx).
Median time from start of prior tx to start of VEN was 13 mo (2–148) and time
on VEN was 11 mo (0.2-42). ORR was 75%, 6 pts (21%) achieved CR and
remain on study (DORs: 25-40 mo). One pt with a PR proceeded to elective
allogeneic stem cell transplant and remained disease free at last protocol
defined follow-up (24 mo after coming off study). Median PFS was 11 mo and
DOR was 15 mo. MZL pts (median age: 63 years) had received a median of 4
(2-6) prior tx. Time from start of prior tx to start of VEN was 8, 14, 73 mo and
time on VEN was 5, 1, 35 mo. One pt (6 prior tx) received VEN for <1 mo due
to progressive cytopenias; 1 pt (4 prior tx) achieved a PR with VEN at wk 6 but
had PD at wk 16; 1 pt (2 prior tx) achieved PR at wk 6 and is the only pt to
remain on study (DOR:32 mo). WM pts (median age: 67 years) had a median
of 4 (3-5) prior tx. Time from start of prior tx to start of VEN was 5, 18, 33, 67
mo and time on VEN was 42, 17, 54, 20 mo. All pts achieved PR (at wks 6
[n=2], 16 and 36), with DORs of 11, 12, 38 and 50+ mo (latter is ongoing and
remains on study).
Summary/Conclusions: VEN monotherapy has a tolerable safety profile in
MCL, MZL and WM pts. ORR were high and most responses durable; median
PFS and DOR suggest significant activity in MCL pts. Further investigation of
VEN in each disease is indicated.
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WHOLE BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING
IS A GOOD PREDICTOR OF TREATMENT OUTCOME AFTER ONE CYCLE
OF IMMUNOCHEMOTHERAPY IN AGGRESSIVE LYMPHOMA
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Background: Early identification of non-Hodgkin lymphoma patients not
responding to therapy may enable treatment adaptation which might impact on
the prognosis and reduces exposure to ineffective drugs. Interim fluo-
rodeoxyglucose-positron emission tomography/computed tomography (FDG-
PET/CT) after 2-4 cycles of immunochemotherapy has prognostic value shown
for some lymphomas, but its role in treatment adaption is still considered exper-
imental. Disadvantages of this technique are the significant amount of false
positive results due to a rituximab-induced inflammatory response as well as
substantial patient radiation exposure. 
Aims: To evaluate the use of whole body diffusion-weighted magnetic reso-
nance imaging (WB-DWI/MRI) as an radiation-free imaging technique to predict
treatment outcome in NHL after one cycle of ICT (2-3 weeks).
Methods: Forty-six patients with aggressive NHL (35 diffuse large B-cell lym-
phoma (DLCBL), 2 primary mediastinal B-cell lymphoma (BCL), 1 unclassifiable
BCL, 1 Burkitt lymphoma, 4 Mantle cell lymphoma (MCL), 2 peripheral T-cell
lymphoma (TCL) and 1 extranodal natural-killer TCL) were consecutively
enrolled between 2011 and 2015. All patients had baseline and interim WB-
DWI/MRI (after 1 cycle immunochemotherapy), and end-of-treatment FDG-
PET/CT; 38/46 had an interim FDG-PET/CT. Additional International prognostic
index (IPI), immunohistochemical markers Ki-67, Bcl-6 and Bcl-2 were evalu-
ated for their predictive value. WB-DWI/MRI were assessed quantitatively with
histogram analysis (both on high b-value signal intensity (b1000) and apparent
diffusion coefficient (ADC)), and calculation of parameter changes between
baseline and interim scan (Δpar). Statistical analysis consisted of Kaplan-Meier
survival analysis univariate and multivariate Cox regression analysis with dis-
ease-free-survival (DFS) as outcome measure.
Results: Median follow-up time was 43 months (4-70 months). Thirty-three
patients achieved complete remission (CR), 4 progressed and 9 had recurrent
disease. Patients were non-responders according to WB-DWI/MRI in case of
an ADCmean decrease for lymphoid tissue or less than 10% b1000mean
decrease in bone or a b1000kurt increase of less than 6% in extranodal lesions.
WB-DWI/MRI predicted DFS correctly in 45/46 (96%) [p<0.001; hazard ratio
(HR) 66.6, (CI 95% 8.5-523.2)]; end-of-treatment FDG-PET/CT was predictive
in 37/46 (80%) [p=0.004; HR 5.1, (CI 95% 1.7-15.4)], and interim FDG-PET/CT
in 27/38 (71%) [p=0.042; HR 3.5, (CI 95% 1.0-11.5)]. Nor IPI score neither his-
tological or immunohistochemical parameters demonstrated a significant pre-
dictive value. Multivariate analysis revealed WB-DWI/MRI as the only inde-
pendent prognostic factor (p<0.001).
Summary/Conclusions: WB-DWI/MRI can accurately predict treatment out-
come in aggressive NHL after only one cycle of immunochemotherapy (2-3
weeks) without the burden of radiation exposure.
Reused with permission from the American Society of Clinical Oncology
(ASCO). This abstract was accepted and previously presented at the 2017
ASCO Annual Meeting. All rights reserved.
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CLINICAL OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA,
FOLLICULAR LYMPHOMA AND RICHTER’S TRANSFORMATION
PATIENTS TREATED WITH IBRUTINIB: A REAL-WORLD EXPERIENCE OF
OFF LABEL, IBRUTINIB USE.
K. Isaac1,*, K. Kennard2, S. Schuster2, D. Landsburg2, M. Hughes2, J. Svoboda2,
S. Nasta2, T. Latorre2, W. Surkis1, C. Dorsey2, M. Fanning2, E. Chatburn2,
C. Daniel3, C. Timlin2, J. Gill2, A. Mato2
1Lankenau Medical Center, Wynnewood, 2Abramson Cancer Center, Hospital
of the University of Pennsylvania, 3Hospital of the University of Pennsylvania,
Philadelphia, United States
Background: Ibrutinib (IBR), a Bruton’s Tyrosine Kinase (BTK) inhibitor, is
FDA approved for chronic lymphocytic leukemia, Waldenstrom macroglobu-
linemia, marginal zone lymphoma and mantle cell lymphoma. Despite its limited
data, IBR is increasingly being utilized as a treatment option for patients with
relapsed/refractory (RR) diffuse large B-Cell lymphoma (DLBCL) and follicular
lymphoma (FL). 
Aims: To further characterize the efficacy of IBR in patients with RR DLBCL,
Richter’s transformation (RT) or FL.
Methods: We conducted a retrospective cohort study of DLBCL, RT and FL
patients consecutively treated with IBR. Data collected included patient demo-
graphics, stage, IPI, genetic characteristics, prior treatments, IBR dose and
duration, reasons for discontinuation, and response. PFS and OS were esti-
mated using the Kaplan Meier method and survival analysis by the log rank
(LR) test.
Results: 44 patients were identified (DLBCL: n=24, 54.5%; FL: n=12, 27%,
RT: n=8, 18%) who received IBR monotherapy in the RR setting. Baseline char-
acteristics included age (range 19–80), 61% male, 95% ECOG 0 - 1, 71% stage
IV, 62% elevated LDH, and 48% R-IPI ≥ 4. DLBCL sub-types (Hans criteria)
were 25% non-GC (n=11), 16% GC (n=7), and 14% unclassifiable (n=6). In the
FL subgroup, 8% were grade 1, 58% were grade 2, 33% were grade 3a. Median
number of prior therapies was 5 (range 1-11). All RT patients were not treated
with IBR previously for CLL. The three most common reasons for IBR discon-
tinuation were progression (35%), toxicity (20%), and bridge to CAR-T (10%).
PFS and OS data are shown in Table 1. In DLBCL, cell of origin (IHC) did not
impact outcomes (p=0.97, LR test). Patients with RT had better PFS as com-
pared to de novo DLBCL (p=0.03, LR test).
Table 1.
Summary/Conclusions: In the largest single-center, real-world experience of
IBR use in DLBCL, RT and FL, we validate findings reported in clinical trials. In
FL, responses appear to be durable (median PFS of >10 months). Outcomes
are extremely poor in DLBCL and use of IBR as monotherapy is not recom-
mended. Perhaps IBR is best used as a short-term bridge to more definitive
therapies. Cell of origin by immunohistochemistry does not predict PFS and
should not be used to preferentially select non-GC DLBCL patients for IBR.
Patients with RT appear to have more durable responses (vs DLBCL) suggest-
ing differing dependence on BTK signaling for tumor survival.
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PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS
IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS
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Background: Activating mutations in CD79B and MYD88 are important molec-
ular drivers of a subset of diffuse large B-cell lymphomas (DLBCLs), activating
the B-cell receptor and toll-like receptor pathways, respectively. Interestingly,
the frequency of these mutations differs greatly among DLBCLs at different
anatomical sites, with a remarkably high prevalence at immune-privileged (IP)
sites (central nervous system and testis). Recent studies suggest that these
mutations are associated with an unfavorable prognosis. However, the prog-
nostic value in relation to the site of presentation has not yet been explored.
Aims: To investigate if mutations in MYD88 and CD79B are independent prog-
nosticators for overall survival (OS) in DLBCL, particularly in patients with lym-
phomas at IP sites, for which a high prevalence of these mutations was reported.
Methods: In this retrospective study, we investigated a large clinically anno-
tated cohort of 189 consecutive primary DLBCLs, including primarily nodal
(N=64), primarily extranodal (N=74) and IP localizations (N=51). Patients were
diagnosed between 1990-2015 at the Academic Medical Center, (University of
Amsterdam) or other Dutch hospitals. The vast majority was treated with (R-)
CHOP (N=143) or other immune-chemotherapies (N=16). Detailed clinical char-
acteristics of all patients were collected. For all patients BCL2, BCL6, and MYC
translocations, Epstein Bar Virus (EBV) status and the mutational status of
MYD88 and CD79 were assessed, employing methods described previously
(Kraan et al., BCJ 2013).
Figure 1.
Results: Translocations in BCL2, BCL6 and MYC were identified in 14, 32 and
13 patients, respectively and 23 EBV-positive cases were found. MYD88 and
CD79B mutations were identified in 51 patients and 19 cases, respectively.
Interestingly, there was hardly any overlap between the presence of transloca-
tions (BCL2, BCL6 and MYC) or EBV and that of MYD88 and/or CD79B muta-
tions, indicating that these tumors represent distinct DLBLC subgroups. In
accordance with previous studies, the incidence of MYD88 mutations was
increased at IP sites (67%, Chi-square P=0.001), compared to nodal (13%)
and other extranodal localizations (12%). In patients harboring a MYD88 muta-
tion, we frequently found a coexisting CD79B mutation (N=14). Patients with a
MYD88 mutation demonstrated a significantly inferior 5-years OS compared
to DLBCL with wild-type MYD88 (Log Rank test (LR) P=0.001, Figure-1A). This
prognostic significance was also found for DLBCLs with IP sites (Figure-1B,
LR P=0.029). Coexistence of a CD79B mutation did not impact the prognostic
significance of MYD88. Multivariable Cox regression analysis, including clinical
and molecular characteristics (i.e. age, translocations, EBV, CD79B, etc.) iden-
tified MYD88, Ann Arbor Stage and localization (IP, nodal and extranodal) as
independent prognostic parameters with Hazard ratios 1.8, 1.5 and 2.6, respec-
tively (95% Confidence intervals: 1.0-3.6, 1.0-2.8 and 1.3-4.9, respectively).
Summary/Conclusions: Our study demonstrates that mutated MYD88 is an
independent unfavorable prognostic factor for OS, in particular in DLBCL
patients presenting at IP sites. These patients with MYD88 mutations display
a relatively high prevalence of coexisting CD79B mutations. Interestingly, a
recent study by Wilson et al. (Nat. Med. 2015), indicates that these patients
are more sensitive to treatment with Bruton’s Kinase inhibitors. Our study high-
lights the importance of investigating the mutational status of MYD88 and
CD79B in larger prospective clinical trials with molecularly targeted agents,
particularly in DLBCL patients with IP localizations. 
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HIV-INFECTED PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA
(NHL) OR HODGKIN LYMPHOMA (HL): RESULTS FROM THE GERMAN
HIV-RELATED LYMPHOMA COHORT STUDY
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Background: The outcome of HIV-associated lymphoma has undergone sig-
nificant improvement in recent years beginning with the widespread use of
combination antiret roviral therapy (ART). However, among AIDS-related
deaths, non-Hodgkin lymphoma (NHL) is the most frequent event. HIV-positive
patients (pts) with relapsed NHL or Hodgkin lymphoma (HL)) should be treated
in a manner similar to immunocompetent pts.
Aims: To analyze the outcome of pts with HIV-related lymphoma who experi-
enced a relapse after having achieved a complete response to first line therapy.
Methods: This prospective multicenter cohort study includes adult HIV- 1 infect-
ed pts with biopsy or cytologically proven HIV-related lymphoma diagnosed at
32 participating centers in Germany and Austria since January 2005. Data on
HIV-infection and lymphoma characteristics, treatments and outcomes were
recorded. Pts with indolent lymphomas and primary central nervous system
lym phomas were excluded from the present analysis.
Results: Of 499 pts (463 males, 36 females) 394 had aggressive NHL and
105 HL. The median age at lymphoma diagnosis was 45.6 yrs (range, 22–
74.7). 344 pts (69%) were diagnosed with advanced stage (III/IV) lymphoma
and the median CD4-cell count was 271/μl (266/µl in NHL and 287/µl in HL).
As of June 2015, 311 of 499 pts (62%) achieved a documented CR, 235 (60%)
with NHL and 76 (72%) with HL. After a median follow-up of 17 months for
NHL and 30 months for HL pts, 31 of 235 NHL (13%) and 8 of 76 HL (11%)
experienced a relapse. Incidence of relapse was 6.9/100 patient years (PY)
within the 1st year after primary diagnosis and 1.3/100 PY thereafter
(P=0.0062). Median time to relapse was 7.3 months in NHL and 18.0 months
in HL. Relapses beyond 12 months occurred in 6 of 31 NHL cases (19%) and
in all 8 HL cases (100%) (P=0.045). Median overall survival (OS) of all relapsed
pts was 29.0 months (95% CI 14.1-44.2 months) after primary lymphoma diag-
nosis. In pts with HL, OS was not reached, whereas it was 15 months in pts
with NHL (P=0,024). Regarding the entire cohort of 311 pts with a documented
CR, the 2-year OS rate was 57% in pts with relapse as compared to 97% in
those without (P<0.001). The majority of relapsed pts died of lymphoma (68%).
Summary/Conclusions: Relapses from CR are relatively rare in pts with HIV-
associated NHL and HL. In pts with NHL the majority of relapses occur within
the first year after primary diagnosis, whereas in HL most relapses occur
beyond 12 months. Overall, pts with relapsed HIV-related NHL have a worse
outcome than pts with relapsed HL.
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Background: Nodal peripheral T-cell lymphomas (PTCLs) are a heterogeneous
group of neoplasms, which include PTCL not otherwise specified (PTCL-NOS),
angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-cell lymphoma-
anaplastic lymphoma kinase positive (ALCL-ALK+), and ALCL-ALK-. Clinical
assessments before and after treatment are essential to predict survival in
nodal PTCL. However, limited data is available regarding the prognostic rele-
vance of National Comprehensive Cancer Network International Prognostic
Index (NCCN-IPI) and post-treatment PET-CT scan.
Aims: The study investigated the prognostic significance of baseline NCCN-
IPI and post-treatment PET-CT scan, assessed by Deauville score, in patients
with nodal PTCL. The primary aim was to establish a risk model for nodal PTCL
patients based on NCCN-IPI, a clinical tool, and post-treatment PET-CT scan
indicating tumor viability.
Methods: In this retrospective cohort study, patients with newly diagnosed
nodal PTCL were consecutively enrolled from 11 hospitals in South Korea.
Patients were eligible if they were histologically diagnosed with nodal PTCL
from Jan 2005 to June 2016, received systemic chemotherapy, and had the
results of PET-CT scan at the time of diagnosis and at the end of treatment.
Post-treatment PET-CT was assessed using 5-point Deauville score. The study
excluded ALCL-ALK+ due to well-known better survival.
Results: A total of 396 patients were screened for eligibility. Seventy patients
were excluded from the analysis due to following reasons: unavailable pre- or
post-treatment PET scans, no systemic treatment, uncertain histology, and
ALCL-ALK+. Thus, 326 patients were analyzed. The median age was 61 years
(range, 18-86) and 209 (64%) were male. PTCL-NOS (N=172, 53%) was the
most common subtype included, and AITL (N=111, 34%) and ALCL-ALK- (N=43,
13%) followed. Three-fourths of patients (N=242) had stage III/IV. Majority of
patients received anthracycline-based therapy. Patients were categorized into
low (N=42, 13%), low-intermediate (LI, N=108, 33%), high-intermediate (HI,
N=136, 42%), and high (N=40, 12%) risk groups according to NCCN-IPI. Based
on the Deauville criteria, post-treatment PET scan was scored as 1 (N=130,
40%), 2 (N=47, 14%), 3 (N=60, 18%), 4 (N=27, 8%), and 5 (N=62, 19%).
Because the number of progression in Deauville score 3 (40/60, 67%) was sig-
nificantly different from score 2 (21/47, 45%; P=0.023) and 4 (24/27, 89%;
P=0.030), we categorized patients into 3 groups: Deauville score 1-2, 3, and 4-
5. With a median follow-up of 54.7 months (IQR, 30.2-84.5), 5-year PFS rate
was 35.7% (95% CI, 30.0-41.4) and OS rate was 47.1% (95% CI, 40.8-53.4).
NCCN-IPI risk and post-treatment PET-CT scan were independently associated
with PFS in the multivariate analysis (for LI NCCN-IPI, hazard ratio [HR] 1.615,
95% CI 0.838-3.113; HI NCCN-IPI, HR 3.063, 95% CI 1.626-5.769; high NCCN-
IPI 4.475, 95% CI 2.231-8.977; P<0.001: for post-treatment Deauville score 3,
HR 1.895, 95% CI 1.281-2.801; score 4-5, HR 6.916, 95% CI 4.948-9.667;
P<0.001). We stratified patients into 5 groups based on risk of progression: a
low (low NCCN-IPI and Deauville score 1-2), INT-1 (low NCCN-IPI and Deauville
score 3, or LI NCCN-IPI and Deauville score 1-2), INT-2 (HI NCCN-IPI and
Deauville score 1-2), high (high NCCN-IPI and Deauville score 1-2, or LI to high
NCCN-IPI and Deauville score 3), and very high (Deauville score 4-5). The risk
model showed a strong association with PFS and OS (Figure 1).
Figure 1.
Summary/Conclusions: This study proposes a new risk stratification model
incorporating baseline NCCN-IPI in combination with post-treatment Deauville
score on PET-CT scan in patients with newly diagnosed nodal PTCL.
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Background: Anaplastic large cell lymphoma (ALCL) is an aggressive disease
with over 60% ALK-tyrosine kinase (TK) receptor positivity due to oncogenic
fusions proteins containing ALK, mainly NPM-ALK. Crizotinib, an ALK inhibitor,
proved to be effective in ALK positive tumors and in particular in ALK+ ALCL,
with Objective Response Rates (ORR) in the 80-90% range. Long-term data
on the safety and efficacy of crizotinib are lacking.
Aims: In this work, we analysed long-term clinical outcomes in 16 patients
treated with crizotinib for ALK positive ALCL and we evaluated the presence of
TK domain-point mutations in patients who relapsed during crizotinib treatment.
Methods: 16 patients were treated at the Clinical Research Unit, S. Gerardo
Hospital, Monza (Italy) from June 2010 to December 2015 with a median follow
up of 7.3 months (range 2.4-72 months). Survival curves were obtained using
GraphPad Prism 5; differences were evaluated with Mantel-Cox test and
Gehan-Breslow-Wilcoxon test. In 4/7 relapsed patients the TK domain of ALK
were amplified from peripheral blood samples obtained at the time of crizo-
tinib-relapse and subjected to deep sequencing. Subsequently we profiled in-
vitro the activity of 2nd/3rd generation ALK inhibitors (brigatinib, alectinib, ceritinib
and lorlatinib) with a murine BaF3 cell model and obtained their level of sensi-
tivity/resistance to the drugs.
Figure 1.
Results: Median age at diagnosis was 25.5 years (range 16-38 years) and
8/16 patients were male. Median previous line-therapies were 2.5 (range 1-5).
In the Intention-To-Treat population which includes 1 patients who died after
the first crizotinib dose, 13/16 patients (81.25%, 95% CI 53-95%) and 8/16
patients (50%, 95% CI 25-75%,) achieved an OR and a complete response
(CR) after 1 month of therapy, respectively. Median overall survival and pro-
gression free survival (PFS) were 7.53 months and 4.57 months respectively
(fig 1a). Median time to progression was 50 days (range 47-137 days). OS and
PFS at 1 and 3 years from treatment were 44%. At the last follow up 7 patients
were still on treatment and in CR (median treatment duration 44 months [range
15-72 months]). There was a significant difference in 3 years PFS between
patients in whom CR was obtained after 4 weeks of crizotinib and those who
didn’t (PFS at 3 years 87.5% vs 0%, p<0.001-fig 1c); patients with less than 2
previous lines of therapy showed a borderline better 3 years PFS (66% vs 33%,
p=0.08-fig 1b). Crizotinib was well tolerated and there were no cumulative
adverse events (AEs) over this long-term follow-up. The only G3 AEs reported
were transient neutropenia and creatine-kinase elevation. The deep sequencing
of 4 NPM-ALK in relapsed patients demonstrated the presence in 2/4 samples
of ALK mutations G1269A and C1156Y, which were not present in samples
before crizotinib treatment. The level of in vitro resistance of these mutations
showed a high level of resistance to crizotinib (resistance index for C1156Y
and G1269A: 9.59-15.4 respectively). The sensitivity in vitro of these mutations
to ALK-inhibitors was also evaluated: all inhibitors, except alectinib for G1269A,
were active with a therapeutic index (TI) >20 (fig 1d). TI values, as previously
reported by Mologni L. et al (Oncotarget. 2015 Mar 20;6(8):5720-34), provide
a view of the therapeutic impact of a mutation: the bigger the value, the more
targetable is the mutation with the inhibitor.
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Summary/Conclusions: Crizotinib confirmed to be an effective and safe ther-
apy for advanced relapsed ALK+ ALCL, with durable responses up to 6 years
after treatment initiation and no relapse later than 4 months. These results rep-
resent the longest available safety record for crizotinib. ALK point mutations
can develop and 2nd/3rd generation inhibitors may be a therapeutic opportunity
for patients who develop resistance to crizotinib.
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Background: Tipifarnib is a potent and selective inhibitor of farnesyltransferase
(FT). FT catalyzes post-translational attachment of farnesyl groups required
for localization of signaling molecules to the inner cell membrane. CXCL12 is
a chemokine that is essential for hematopoietic stem cell (HSC) homing to the
bone marrow and lymphoid organs and for maintenance of HSCs and immune
cell progenitors. CXCL12 is known to signal in part through HRAS, a signaling
protein that is uniquely farnesylated. Tipifarnib has previously been shown to
be well tolerated and to have a 41% response rate (7 responses out of 17
patients) in patients (pts) with T-cell Non-Hodgkin Lymphoma, including 4 objec-
tive responses in 8 pts with peripheral T-cell lymphoma (PTCL) (Witzig et al,
2011). Building on this prior experience, we report herein the preliminary effi-
cacy, safety and biomarker data from our ongoing Phase 2 study in PTCL.
Aims: This Phase 2 study is a multi-institutional, single-arm, open-label, two-
stage (11+7) study designed to determine the efficacy and safety of tipifarnib
in pts with relapsed/refractory (R/R) PTCL.
Methods: Pts with R/R PTCL after prior cytotoxic systemic therapy, aged ≥ 18
years old, and with a performance status of 0-2 were eligible. Informed consent
was obtained. The following subtypes of PTCL were eligible for enrollment:
PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lym-
phoma (AITL), ALK-positive and -negative anaplastic large cell lymphoma
(ALCL), hepatosplenic T-cell lymphoma, enteropathy-associated T-cell lym-
phoma (EATL), extranodal natural killer (NK) T-cell lymphoma, nasal type and
subcutaneous panniculitis-like T-cell lymphoma. The primary endpoint of the
study is overall response rate. Secondary endpoints include safety and toler-
ability, duration of response (DOR) and progression free survival (PFS). Based
on activity observed in the first 18 pts in the study, the protocol has been amend-
ed and enrollment is ongoing to an expansion cohort in AITL (N=12). Enrolled
pts are treated with tipifarnib 600mg administered orally twice daily on days 1-
7 and 15-21 of 28-day treatment cycles until progression of disease or unac-
ceptable toxicity. Biomarker studies included gene expression profiling of pre-
treatment tumor biopsies by RNASeq and DNA next-generation sequencing
(NGS). Clinical trial information: NCT02464228.
Figure 1.
Results: At data cut-off (2/15/2017), 18 pts (2 AITL, 1 ALK- ALCL, 15 PTCL-
NOS) were treated with tipifarnib. Most common treatment-related AEs (grade
≥ 3) were myelosuppression, including neutropenia (61%), anemia (39%) and
thrombocytopenia (39%). 3 pts achieved a partial response (2 AITL; 1 PTCL-
NOS) and 3 additional pts experienced stable disease >6 months. Tumor DNA
from 16 pts was sequenced using NGS. A high rate of CXCL12 3’UTR single
nucleotide variation (SNV) was observed. Seven of 16 pts carried the
rs2839695 variant while an additional patient carried a novel variant. The pres-
ence of 3’UTR SNVs was associated with low levels of CXCL12 gene expres-
sion and disease progression (Figure) while all pts deriving clinical benefit from
tipifarnib carried reference (wild type) 3’UTR CXCL12 and had tumors that
expressed high levels of mRNA for this chemokine. Testing of circulating
CXCL12 levels is ongoing.
Summary/Conclusions: Although this study is ongoing, these preliminary
data indicate that tipifarnib is generally well-tolerated and has antitumor activity,
particularly in pts with AITL histology, absence of 3’UTR CXCL12 SNV and
high levels of CXCL12 gene expression.
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FOR LYMPHOMA: A RETROSPECTIVE STUDY ON BEHALF OF THE
FRANCOPHONE SOCIETY OF BONE MARROW TRANSPLANTATION AND
CELLULAR THERAPY (SFGM-TC)
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Centre Léon Bérard, Lyon, 8Service d’hématologie, CHU d’Angers, Angers,
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Background: High-dose chemotherapy before autologous stem cell transplan-
tation (ASCT) is a therapeutic option as a consolidation in primary or relapsed
lymphoma. BEAM conditioning is generally used. Alternative conditioning reg-
imens have been published but few data are available. 
Aims: To evaluate tolerance and efficacy of the BAM (Busulfan, Aracytin and
Melphalan) conditioning before ASCT. 
Methods: We conducted a retrospective study in 188 French patients treated
between 2000 and 2015. Data were retrospectively collected from the Promise
database. Informed consent was obtained from all patients. 
Results: Indications for ASCT were diffuse large B-cell lymphoma (n=54, 29%),
mantle-cell lymphoma (n=42, 22%), Hodgkin’s disease (n=33, 18%), low-grade
non-hodgkin lymphoma (n=26, 14%), T-cell lymphoma (n=17; 9%), Burkitt’s
lymphoma (n=8, 4%) and B-cell lymphoma (n=8, 4%). Median age at diagnosis
was 50.9 years (35.7-59.9). Time between diagnosis and ASCT was 295 days
(176-777). Patients received 1 (n=82, 44%), 2 (n=83, 44%), 3 or more (n=18,
10%), unknown (ND) (n=5, 2%) treatment lines before ASCT. Among the 138
B-cell lymphoma patients, 132 received rituximab before ASCT. Only 20
patients received prior radiotherapy. In all patients, ASCT was the first trans-
plantation. In 11 patients, ASCT was planned as part of a multiple graft protocol.
At the time of transplantation, 116 (62%) patients were in complete remission,
54 (29%) in partial remission, 13 (7%) in relapse or progression, and 5 (2%)
ND. ASCT was documented in 186 (99%) patients. Median time to neutrophil
and platelet (>50 Gigal/L without transfusion) recovery was respectively 11
days [10-12] and 19 days [14-32]. Infectious complications were found in 153
patients. One hundred (53%) patients had undocumented fever, 19 (10%) had
sepsis, 150 (80%) had grade 1-4 mucositis during neutropenia with a WHO
toxicity grading of 2 (42%), 3 (39%) and 4 (19%). Colitis with a median duration
of 7 days [5-10], was reported in 73 patients, with a maximum toxicity grading
of 1-2 (n=43, 59%), 3 (n=21, 29%) or 4 (n=4, 6%) and ND in 5 patients. Only
2 (1%) patients had non-fatal hepatic sinusoidal obstruction syndrome. Pul-
monary toxicity was reported in 33 (17.6%) patients with 8 cases of respiratory
distress syndrome. Respiratory distress was fatal in one patient but occurred
more than 6 months after ASCT and salvage treatment. Seven (3.7%) patients
reported secondary cancers (all were solid tumors except one acute leukemia).
Median follow-up was 17.1 months [11.3-29.5]. At the time of the study, 47
(25%) patients had relapsed. Cumulative incidence of relapse was 6.24% at 3
months and 17.31% at 12 months. At the end of the follow-up, 149 (79%)
patients were alive. The main causes of death were relapse (n=15, 41%) and
toxicity (n=16, 43%). Median overall survival (OS) was not reached and pro-
gression-free survival was 71.5 months [47-NR]. Relapse-free mortality was
1.66% at 3 months and 4% at 12 months. In the univariate analysis, the number
of treatment lines (1 or 2) before ASCT and previous use of monoclonal anti-
bodies positively impacted the OS. Conversely, the multiple graft protocol had
an unfavorable impact on OS. 
Summary/Conclusions: BAM conditioning before ASCT for lymphoma helps
to control disease activity without excessive toxicity. It may be a suitable alter-
native to BEAM in case of drug shortage. However, comparative studies are
needed to confirm these findings.
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ANALYSIS OF MICRORNAOME, PROTEOME AND METABOLOME OF
EXOSOMES FROM PATIENTS WITH PAROXYSMAL NOCTURNAL
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R. Teruel-Montoya1,2, G. Luengo-Gil2, F. Vallejo3, J. E. Yuste3, N. Bohdan2, S. Espín2,
N. García-Barberá2, C. Martínez2, J.C. Espín3, V. Vicente1,2, I. Martínez1,2,*
1Grupo de Investigación CB15/00055, Centro de Investigación Biomédica en
Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII),
Madrid, 2Servicio de Hematología y Oncología Médica, Hospital Universitario
Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia,
IMIB-Arrixaca, 3Research Group on Quality, Safety and Bioactivity of Plant
Foods, CEBAS-CSIC. 30100, Campus de Espinardo, Murcia, Spain
Background: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a clonal disease
caused by the lack of glycosyl inositol phosphatidyl anchored proteins at the
cell membranethat leads to intravascular hemolysis upon complement activa-
tion. Patients have intravascular haemolysis with high risk of thrombosis, and
a variable degree of bone marrow failure. Treatment with Eculizumab reduces
intravascular hemolysis and also the thrombotic risk. The mechanism of throm-
bosis in PNH is still unknown. Exosomes are extracellular vesicles released by
cells and whose secretion is closely related with the inflammatory status. Exo-
somes participate in cell communication by activating signaling pathways and
transferring genetic material, i.e. miRNA, and proteins to host cells. 
Aims: To describe the microRNAome, proteome and metabolome of exosomes
from PNH patients to identify potential biomarkers of the disease and to inves-
tigate its relationship with the mechanism of thrombosis in these patients. 
Methods: Plasma exosomes were isolated from 5 healthy controls and from 9
PNH patients(6 with Eculizumab, 3 with thrombosis –ET- and 3 without throm-
bosis –ENT-, and 3 without Eculizumab) using Total ExosomeIsolation kit (Ther-
moFisher).MiRNAsfrom exosomeswere purified using Nucleo Spin miRNA Plas-
ma Kit (Macherey-Nagel).miRNA expression was evaluated by plasma/serum
focus miRNAs PCR panel V4 (Exiqon). Proteomic analysis of exosomes was
performed at the OMICs core facilities. Untargetted metabolomic analysis was
performed by using combination of gas chromatography and liquid chromatog-
raphy (LC) with mass spectrometry (MS). Additionally; latest advances were
used combining LC-MS-solid phase extraction-nuclear magnetic resonance
(UPLC-QTOF_SPE_NMR) ‘on line’ for unequivoque structural elucidation of
unknown metabolites. 
Results: Mir-16-5p and miR-451a had lower levels in patients vs controls.
Eculizumab treatment increased their expression, particularly in the group with
thrombosis. Eculizumab also decreased miR-223-3p (the most abundant miR-
NA in platelets and that has been associated with its reactivity)and increased-
miR-15a-5p levels (0.50- and 3.12-fold respectively). Those proteins differen-
tially expressed in patients and controls were related with the complement sys-
tem and the immune response. We identified an increase in the plasma hemo-
globin levels in patients vs controls (4.9-fold), which is related with platelet acti-
vation. It is also noteworthy the decrease (1.5-fold) of the anticoagulant Protein
S in patients vs controls. When the analysis was performed among the 3 groups
of patients, only Ig heavy chain V-I region HG3 increased in 3.9-fold in the
Eculizumab group vs without Eculizumab group, which could be related with
the treatment. We identified quite few metabolites inside the exosomes, all of
them associated with cell toxicity or immune response. The levels of Choles-
terol, HydroxyTerbinafine-glucuronide and Diacyl-glycerol decreased in 17.3,
17.6 and 19.4-fold, respectively in patients treated with Eculizumab. Interest-
ingly, the Aminoethylphosphonicacid, Cholesterol and PGF2 increased 16.7-;
21- and 19.4-fold in patients with thrombosis. 
Summary/Conclusions: Our study supports that exosomes contain material
that may influence the pathological status of the PNH patients. In concordance,
most of the proteins, miRNAs and metabolites are related with the complement
system or the inflammatory response. In future experiments, some of the pro-
teins, miRNAs and metabolites should be validated to define whether they




SEVERE CHRONIC NEUTROPENIA: THE ROLE OF PRIMARY
IMMUNODEFICIENCY AS CAUSATIVE AGENTS. A SINGLE CENTER DATA 
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Background: Severe Chronic Neutropenia may be a primary disease, usually
defined as congenital (CN), or a condition mainly secondary to autoimmune
disturbances (SN) (1,2). CN rises in early infancy, has a marrow block at
pro/myelocyte, classically carries genes ELANE/HAX1 mutations in 70% of
cases and is G-CSF dependent. SN is accompanied by extrahaematological
signs and/or positivity of autoimmune markers; bone marrow has a normal mor-
phology or is “left shifted”. In spite of these categorization many cases do not
fit either group and share features of both of them. These “Ovelap Neutropenia”
(ON) patients are a diagnostic and management challenge.
Aims: Investigate the genetic backgroud of this ON from a cohort of chronic
neutropenia subjects screened at Hematology Unit of Gaslini Hospital and char-
acterize their clinical phenotype.
Methods: Patients with severe chronic neutropenia were seen prospectively
in our center and diagnosed/followed-up according to published guidelines(3,4).
Genetic diagnosis includes classical Sanger technique foe commonest severe
chronic neutropenia genes and an enlarged NGS panel including also those
gene responsible for PID.
Results: From 2008 to 2016, 24 patients (13 males) with median age at last
follow of 18yrs (range 28 mo-51y) had a complete work up for severe chronic
neutropenia (Table 1). Ten/24 subjects (43%) were diagnosed as classical CN
with ELANE mutation found in the majority (80%) of cases. Seven/24 (29%)
were diagnosed as SN and the remaining 7/24 (29%)as ON.A PID genes muta-
tion was found in a total of 8/24 patients (30) with 5 patients belonging to 7 SN
subjects (71%) and 3 to the 7 ON subjects (42%).Table 1 shows clinical hema-
tological characteristic of the 3 categories of patients.
Summary/Conclusions: A considerable portion (30%) of subjects affected
with severe chronic neutropenia have been identified as PID. In the group of
ON subjects a mutated PID gene was found in 3/7patients and muations of
ELANEin 2/7 patients. No mutation was found in the remaining 2.The phenotype
of ON subjects is characterized by extra-hematological autoimmune symptoms,
by maturation block and by the frequent involvement of more than one
hematopoietic lineage. This phenotype my suggest to access to an enlarged
genetic panel including PID genes for genetic diagnosis. An accurate immuno-
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Background: Acquired aplastic anemia (AA) is a rare disease characterized
by bone marrow failure. First-line treatment is either an allogeneic stem cell
transplantation (alloSCT) or intensive immunosuppressive therapy (IST) con-
sisting of Anti-Thymocyte globulin (ATG) and ciclosporin. Based on studies
from the National Institute of Health, the Dutch guidelines for diagnosis and
treatment of aplastic anemia recommend horse-derived ATG (ATGAM) as the
preferred type of ATG. Patients who are refractory after first-line treatment
with IST can be treated with second-line alloSCT or rabbit-derived ATG (Thy-
moglobulin). Eltrombopag, a Thrombopoietin-mimetic, is registered for sec-
ond-line treatment of AA since May 2016. In order to evaluate the guidelines,
a national registry was started in 2014 in which seven university hospitals and
two large non-academic hospitals collect data on all consecutive adult aplastic
anemia patients, including those that received ATGAM and ciclosporin as first-
line treatment.
Aims: To evaluate the safety and efficacy of first line treatment using ATGAM
and ciclosporin in adult patients with acquired aplastic anemia in the Nether-
lands.
Methods: Data on adults with acquired aplastic anemia who received ATGAM
as first-line treatment was collected in the LUMC, AMC, UMCG, UMCU, VU-
MC, UMCN, Erasmus MC, Medisch spectrum Twente and Antonius Ziekenhuis
Nieuwegein. The data included baseline-characteristics and follow-up data at
3, 6, 9 and 12 months. After 12 months, follow-up data was collected at least
yearly. All patients received first-line treatment with ATGAM (40mg/kg for 4
days intravenously) and ciclosporin. Response was defined as complete in
case of normalization of blood values and as partial in case of transfusion inde-
pendency and neutrophil count >0.5 x 109/L. Overall survival was evaluated
with the Kaplan-Meier method.
Results: In October 2016, 70 patients were registered in the NVvH registry.
Median age at start of treatment was 53 years (18-79) and median follow-up
time was 18 months. Overall survival probability after 18 months was 87%.
Fifty-nine patients were evaluable for a response at 6 months after treatment.
Response was seen in 36 patients (61% (CI 49-73%)). Patients with a response
at 6 months, had an overall survival probability of 94% at 12 months thereafter.
After initial response at 6 months, aplastic anemia relapsed in 4 patients and
1 patient developed AML. From the 23 non-responding patients, 7 patients
continued ciclosporin after 6 months without additional treatment. Five of these
7 patients became transfusion independent up to 16 months after treatment
with ATGAM. Sixteen of the patients without a hematological response 6
months after ATGAM received second-line treatment consisting of alloSCT
(n=8), Thymoglobulin (n=4), Eltrombopag (n=3) or Danazol (n=1). From the 16
patients that received second-line treatment, 10 patients eventually had a
hematological response. Patients without a response at 6 months, had an over-
all survival probability 12 months thereafter of 84%. One patient developed
secondary AML after second-line treatment with Thymoglobulin.
Summary/Conclusions: Six months after treatment with first-line ATGAM,
61% of the adult patients with acquired aplastic anemia is transfusion inde-
pendent. Half of the remaining patients becomes transfusion independent after
rescue treatment or after continuation of ciclosporin beyond 6 months. 
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Background: Acquired severe aplastic anemia (SAA) is a rare disease that is
characterized by bone marrow failure that results in pancytopenia and
hypoplastic bone marrow. Hematopoietic stem cell transplantation (SCT) is
one of the main treatment strategies for SAA. In recent years, for patients who
require transplantation, but have no human leukocyte antigen (HLA) matched
donors, haploidentical SCT (haplo-SCT) is an important alternative option.
Delayed immune reconstitution (IR) after haplo-SCT played a crucial role in
infections and graft-versus-host disease (GVHD) and was considered a barrier
to the wider application of haplo-SCT in SAA. The assessment of immune
reconstitution may provide tools to better predict and modulate adverse out-
comes and subsequently improve survival after transplantation. However, the
kinetics of immune recovery in patients with SAA after haplo-SCT have not
been studied systematically.
Aims: We aim to provide the kinetics for immune reconstitution in SAA patients
who receive haplo-SCT, investigate the factors that may affect immune recovery
and assess the impact of immune cell subset recovery on transplant outcomes.
Methods: In this study, we examined immune cell subset counts and
immunoglobulins in 81 SAA patients from day 30 to day 365 after haplo-SCT.
The immune cells analyzed in this study including lymphocyte, monocyte, CD3+
T cell, CD8+ T cell, CD4+ T cell, CD4-CD8- T cell, CD8+CDC28+Tcell,
CD4+CD28+Tcell, CD4+ memory T cell and CD4+ naïve T cells. Simultaneously,
we determined which factors influence immune reconstitution and analyzed
the effects of immune cell subsects on transplant outcomes.
Results: (i) The reconstitution of different immune cell subsets occurred at dif-
ferent rates after haplo-SCT. Monocytes were the first to recover, followed by
CD8+ T and CD19+ B cells, and finally CD4+ T cells. Early CD4+ T cell recovery
occurred at the expense of memory cells, whereas naïve CD4+T cells rose
only 9 months after SCT. (ii) In the multivariate analysis, lower recipient age,
female gender, high mononuclear cell counts and CD4+ T cell counts in the
graft were associated with improved immune recovery after transplant. (iii) A
CD4/CD8 ratio less than 0.567 on day 30 post-transplantation was associated
with lower treatment related mortality and higher overall survival after haplo-
SCT in SAA patients.
Summary/Conclusions: We provided the kinetics for immune recovery in SAA
patients who received haplo-SCT. In general, our study demonstrated that the
recovery of monocyte and CD8+ T cells was fast in SAA patients, whereas the
recovery of the CD4+ T cell subset was delayed. In addition, our data suggested
that the CD4/CD8 ratio may be useful for predicting transplant outcomes in
SAA patients after they complete haplo-SCT. Our results may be useful for
making better predictions and modulating the IR of SAA patients, which would
subsequently improve the outcomes after transplantation.
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Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal
hematopoietic stem cell disorder that manifests with hemolytic anemia due to
uncontrolled complement activation, bone marrow failure, and thrombosis.
Diagnosis is essential because PNH is a progressive disorder associated with
substantial morbidity and mortality. The protean clinical manifestations of PNH
complicate diagnosis, and subsequently the diagnosis is often delayed or
missed. Although national diagnostic guidelines are available, international
expert consensus on PNH screening and diagnosis is lacking. 
Aims: An international panel of PNH experts was assembled to develop a clin-
ically relevant, consensus-driven screening and diagnostic algorithm for PNH.
Figure 1.
Methods: An expert advisory committee of 4 PNH experts from North America,
Europe, and Japan was assembled. Using a modified Delphi methodology,
consensus was gained on the symptoms and signs of PNH and the laboratory
tests required for screening and confirmation of diagnosis. Globally represen-
tative Delphi panelists were identified through a double-blinded screening
process and asked to complete 2 rounds of web-based questionnaires. The
questionnaires were developed by the expert advisory committee and present-
ed to the Delphi panel in a case-based format. In the first round, Delphi panelists
were given 5 blinded case studies—each including details on clinical presen-
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tation and past medical history—and were asked to provide their differential
diagnosis and the tests they would order to establish the diagnosis in free-text
format. To reduce bias, Delphi panelists were blinded to the fact that the study
was focused on PNH. Responses mentioned by ≥50% of Delphi panelists in
the first round were included in the second-round questionnaire. For each case
in the second-round questionnaire, Delphi panelists were presented with a
series of consensus statements regarding potential diagnoses and the need
for specific tests/data from a multiple-choice list and asked to respond with
their level of agreement on a 4-point Likert scale. Consensus in the second
round was attained if ≥80% of Delphi panelists agreed on a given screening or
diagnostic approach.
Results: Twelve Delphi panelists from 6 countries, all of whom were clinicians
with expertise in PNH, were recruited. Consensus was reached on 22 of 23
PNH screening and diagnostic decision points identified by the Delphi panelists.
Specifically, consensus was gained on the core symptoms and signs of PNH
at presentation, including hemolysis, bone marrow dysfunction, and thrombosis.
Consensus was also reached for 36 of 38 specific screening and diagnostic
tests required at each decision point to narrow the differential diagnosis and to
confirm the diagnosis of PNH. The level of agreement on screening and diag-
nostic decision points and tests was sufficient to enable the development of a
screening and diagnostic algorithm (Figure) that is consistent with the published
literature and with the real-world experience of the international expert advisory
committee.
Summary/Conclusions: The modified Delphi methodology facilitated devel-
opment of a consensus-based, clinically relevant PNH screening and diagnostic
algorithm. This algorithm provides clinicians with varying levels of expertise
detailed guidance on how to screen for and diagnose PNH.
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Background: Diamond-Blackfan anemia (DBA) is a rare genetic disorder, char-
acterized by bone marrow failure (anemia), congenital anomalies and a pre-
disposition for malignancies. DBA is characterized by a highly heterogeneous
nature, both clinically and genetically. Most of our understanding of this disorder
stems from molecular studies combined with extensive data-input from inter-
national patient registries. 
Aims: The aim of our retrospective study was to create an overview of the
pediatric DBA population in the Netherlands.
Methods: Forty-four patients (age 0-18yr) diagnosed with DBA from all Dutch
pediatric hospitals were included in this study and their clinical and genetic
characteristics were collected from patient records. 
Results: Congenital malformations were present in 19/41 patients (46,3%),
varying from craniofacial and cardiac defects to urogenital and developmental
disorders. An underlying genetic defect was identified in 23 patients (56,1%),
the majority of which were found in the RPS19 gene (n=10; 45%). No significant
diversities in malformations, course of disease or response to treatment were
observed when comparing patients with or without identified genetic defects.
In agreement with previous reports, two patients harboring defects in RPL11
displayed a more severe phenotype, including craniofacial malformations,
thumb abnormalities, and cardiac defects. In contrast, our patient with a muta-
tion in RPL5 has no associated congenital abnormalities, while previous studies
reported a very high frequency (83%) of associated congenital defects. Fur-
thermore we observed a relatively high number (12/23) of novel mutations in
well-known ‘DBA-genes’, defined as novel variants. In addition, we have iden-
tified a novel ‘DBA-candidate’, describing a genetic defect in RPL9, in a patient
with multiple congenital abnormalities (craniofacial defects, cardiac defects,
colitis) in addition to severe anemia. Thirty-four (34/44) patients were treated
with glucocorticoids, of which in thirty-one (31/34) patients a complete response
was observed (91,2%). However, in 29% discontinuation was prompted by
high-dosage-dependence, side effects, a weaning response, or a combination
of these factors. Five patients (12,2%) were successfully transplanted with
hematopoietic stem cells from either matched sibling donors (n=3) or matched
unrelated donors (n=2), including two cases after the age of 10 years. Eleven
patients (26,8%) were treatment-independent, defined as acceptable hemo-
globin values without any therapy. No malignancies were thus far reported.
Summary/Conclusions: In line with previous reports, the Dutch pediatric DBA
population is both clinically and genetically heterogeneous, with RPS19 being
the most frequently mutated gene. Interestingly, the majority of mutations in
our cohort have not been described before, probably further underlining clinical
heterogeneity. In addition, we have identified a novel DBA-candidate gene
(RPL9), associated with a more severe phenotype, based on multiple associ-
ated congenital defects. While we created a comprehensive overview of the
Dutch pediatric DBA population, limitations of our study include a relatively
small number of patients, and the lack of complete genetic analysis (for all DBA
candidate genes) in a relevant number of patients. Overall, to increase our
understanding of genotype-phenotype correlation in DBA, and underlying
pathophysiological mechanisms more generally, it crucial to further extend our
genetic, and functional analysis of DBA-candidate genes, as well as compare,
and share data from international registries. 
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NEXT GENERATION SEQUENCING IN BONE MARROW FAILURE
SYNDROMES
E. Galvez1,*, E. Sebastian1, L. Madero1, A. Catalá2, C. Belendez3, C. Diaz de Heredia2,
A. Galera4, D. Plaza3, I. Badell2, E. Vallespin5, P. Lapunzina5, R. Perona5,
J. Surralles6, J. Bueren5, J. Sevilla1
1Hospital Infantil Niño Jesus, Madrid, 2Grupo fallos medulares SEHOP,
Barcelona, 3Grupo fallos medulares SEHOP, Madrid, 4Grupo fallos medulares
SEHOP, Valencia, 5CIBERER, Madrid, 6CIBERER, Barcelona, Spain
Background: Inherited bone marrow failure syndromes (IBMFSs) are a het-
erogeneous group of genetic disorders, with similar clinical presentations,
resulting in complex diagnosis. Molecular characterization is essential in order
to establish diagnosis, treatment and prognosis. Next-generation sequencing
(NGS) techniques seem to be a useful platform for genetically defining different
IBMFSs.
Aims: To design a NGS panel with the objective of making a specific, fast and
cost-effective diagnosis for these pathologies.
Methods: We developed a NGS panel of 164 genes involved in different IBMF-
Ss. A total of 120 samples have been processed. Patients were classified into
two groups based on the clinical presentation: classified IBMFS (CBMFS) for
those with a clinical picture typical os some of these disorders, and unclassified
IBMFS (UBMFS) for the others. For the NGS study the NextSeq platform of
Illumina (Roche) has been used. Bioinformatic analysis has been oriented to
the identification of point polymorphisms (SNPs) and insertions / deletions of
small DNA fragments.
Results: Of the 120 samples processed, 10% (12/120) was not suitable for
analysis. A total of 108 patients were studied. In 59,3% (64/108) causal muta-
tions were detected. From the total samples analyzed (108), 75% (81/108)
were included in the CBMFS patient group, obtaining a diagnostic yield of
64,2% (52/81). The remaining 27 patients (25%) were included in the UBMFS
group and we found causal mutation in 37% (10/27). Therefore, it remains a
percentage of patients without a genetic diagnosis, which seems more evident
in the UBMFS group. This could be explained by the fact that the causal gene
has not been described or due to the limitations of the technique.
Summary/Conclusions: NGS techniques are a fast and cost-effective option
for the diagnosis of IBMFSs patients. In our series, we have reached a diagnosis
rate of 59,3%, coinciding with that described in the literature. Undiagnosed
patients should be included in new research projects.
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APLASTIC ANEMIA PATIENTS WITH MONOCYTE-DOMINANT PNH
CLONES HAVE A UNIQUE PRESENTATION AND ARE LESS RESPONSIVE
TO IMMUNOSUPPRESSIVE THERAPY
E. Nevill1,*, D. Sanford1, D. Forrest1, D. Hogge1, Y. Abou Mourad1, R. Broady1,
M. Barnett1, M. Power1, C. Toze1, K. Song1, S. Nantel1, S. Narayanan1,
A. Gerrie1, H. Sutherland1, B. Dalal2, T. Nevill1
1Leukemia/BMT Program of BC, 2Division of Hematopathology, Vancouver
General Hospital, Vancouver, Canada
Background: Aplastic anemia (AA) is a bone marrow failure syndrome that
can be successfully treated with either immunosuppressive therapy (IST) or
allogeneic bone marrow transplantation (BMT). In ~50% of patients (pts) with
AA, a clone deficient in glycosylphophatidyl inositol (GPI)-linked antigens–a
paroxysmal nocturnal hemoglobinuria (PNH) clone–can be detected (Young,
Blood, 2006). In recent years, highly sensitive techniques have been developed
to test for PNH clones that have primarily focused on evaluating peripheral
blood white cells. Neutrophils are routinely tested for expression of GPI with
fluorescent aerolysin (FLAER); monocytes may also be analyzed but are not
always evaluated in PNH testing. Our centre has previously reported that 60%
of PNH positive tests show a higher monocyte clone than granulocyte clone
and that there was >10% difference in 20% of these discrepant results (Razavi,
ISLH Proceedings, 2015). Whether pts with discordant monocyte and granulo-
cyte PNH clones have different clinical characteristics and/or response to IST
has not been reported to date. 
Aims: To compare the granuloyte and monocyte PNH clones in pts with AA to
determine whether there are differences in clinical presentation and/or response
to IST for pts with discordant clone sizes. 
Methods: A retrospective review was performed on all patients >age 16 treated
for AA with IST at VGH, the tertiary referral centre for the Province of BC,
between 11/09 and 10/15. All patients had central pathology review and
metaphase cytogenetic analysis that confirmed a diagnosis of AA. High-sensi-
tivity flow cytometry testing with a sensitivity of 0.1% was done on all patients
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to detect the presence of a PNH clone. Granulocytes, monocytes and erythro-
cytes were interrogated with multi-colour flow panels including CD59 and
FLAER. The criteria for determining discordant granulocyte and monocyte
clone sizes was dependant upon the absolute size of the smaller clone. For
clones 0.1-10%, discordance was defined as when the larger clone was either
≥2 x the smaller clone or at least 1% (absolute value) greater. For smaller
clones >10%, the larger clone had to be ≥110% its size. IST was uniform -
Cyclosporine (CSA, 2.5mg/kg p.o. b.i.d.), anti-thymocyte globulin (ATG; ATGAM
40mg/kg IV daily x 4 days) and (Methylprednisolone 1mg/kg/day x 10 days).
CSA doses were adjusted to maintain whole blood trough CSA level of 200-
300 ug/L for 12-months followed by slow taper based upon hematologic
response. Non-responders at 6 months were eligible to proceed to either a
second cycle of ATG or BMT, if a suitable donor was available. Severity of AA
[very severe (VSAA), severe (SAA) or non-severe (NSAA)] and response to
IST [(none, partial (PR) or complete (CR)] were determined according to pub-
lished criteria (Marsh, Br J Haematol, 2009). Statistical comparisons were done
using a standard Chi square analysis.
Results: 30 pts with AA and a PNH clone were identified, 18 females and 12
males with median age of 50.5 years (range 17-71). There were 14 pts with
NSAA, 13 with SAA and 3 with VSAA. Responses were seen in 20/30 pts
(66.7%) including 13 PR and 7 CR. Six pts relapsed with CSA tapering and 5
responded to intensified IST; 2 pts required Eculizumab after evolving to a clas-
sic PNH phenotype. Six pts underwent BMT for primary non-response and 4
pts have died (2 post-BMT, 1 from complications of AA and 1 from breast Ca);
26 pts remain alive and well with a median follow-up of 48 mos (15-86). There
were 17 pts (56%) with concordant granulocyte and monocyte clone sizes
(Group 1), 4 pts (13%) had granulocyte-dominant disease (Group 2) and 9 pts
(30%) had monocyte-dominant disease (Group 3). Group 3 pts were signifi-
cantly more likely to have NSAA and showed a trend toward an inferior
response rate to IST (Table 1).
Table 1.
Summary/Conclusions: Flow cytometry for a PNH clone is routinely done in
AA although it may be important to evaluate both granulocyte and monocyte
clone sizes. Pts with a larger monocyte than granulocyte clone size more fre-
quently have NSAA and appear to have a lower response rate to IST. This may
have therapeutic implications and could identify a population of pts requiring a
unique therapeutic approach.
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RESPONSE TO ANTI-THYMOCYTE GLOBULIN (ATG) IN PATIENTS WITH
APLASTIC ANEMIA (AA): A SINGLE-CENTRE EXPERIENCE OVER THE
LAST 28 YEARS
M. Oelmüller1,*, F. Alashkar1, D. Herich-Terhürne1, U. Dührsen1, A. Röth1
1Department of Hematology, University Hospital Essen, Essen, Germany
Background: Aplastic anemia (AA) is a rare, usually acquired disorder char-
acterized by bone marrow failure with bi- or pancytopenia and marrow hypopla-
sia. The classification into the three main subtypes is of prognostic and thera-
peutic relevance. Depending on disease severity, patient’s age, and the avail-
ability of a potential HLA-identical donor, different therapeutic strategies are
favored. Immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG)
and cyclosporin (CsA) is considered the initial standard treatment. A hemato-
logic recovery is seen in up to 60-70% of the pts following horse-ATG (hATG)
treatment, compared to 35-53% in rabbit-ATG (rATG) treated pts, considering
hATG as first-line therapy in AA pts.
Aims: As response rates vary according to the different studies and the source
of ATG being used, our aim was to retrospectively evaluate response rates in
pts with AA receiving IST at the Department of Hematology at the University
Hospital of Essen between 1988 until 2015.
Methods: In this single-center, retrospective analysis, approved by the institu-
tional review board of the University Hospital of Essen, individual response rates
to ATG, according to criteria reported by Camitta et al. 1975, were evaluated in
67 pts with AA (52% (35/67) females; median age 48 years (range 17-89 years))
being treated or monitored at the Department of Hematology between 1988
until 2015. 73% of the pts (49/67) were treated with hATG (ATGAM® (44/49)
and Lymphoglobulin®). ATGAM® was administered at a dose of 40mg per kilo-
gram (kg) body weight (BW) per day for 4 days and rATG (Thymoglobulin®) at
a dose of 3.5mg/kg BW per day for 5 days, respectively. Pts in both arms simul-
taneously received CsA (5mg/kg BW) and prednisone (day 1-29).
Results: Following six months after primary ATG therapy, a hematologic recov-
ery was seen in 66% of the pts (44/67). The hematologic response rate at 6
months was 75% (37/49) for hATG and 39% (7/18) for rATG (p=0.005). Irre-
spective the source of ATG we observed no significant difference in respect to
gender (females: 71% (25/35) vs males: 59% (19/32)) or in the presence of a
PNH clone (GPI-deficient granulocytes (FLAER) 67% (14/21) vs 79% (19/24)
in pts with no detectable PNH clones), whereas in pts ≤50 years (yrs) a statis-
tically higher rate in hematologic recovery was observed (≤50 yrs: 84% (31/37)
vs >50 yrs: 43% (13/30); p<0.001). In primary refractory pts (34% (23/67))
(52% (12/23) in first-line treated hATG pts vs 48% (11/23) rATG treated pts) a
second course with either hATG (3/9) or rATG (6/9) was initiated, achieving an
overall hematologic recovery at 6 months in 3 pts (33% (1/3) hATG vs 33%
(2/6) rATG treated pts). A disease relapse (median: 13 months after primary
ATG therapy) was seen in 11 out of the 44 pts with primary hematologic recov-
ery (25%) (82% (9/11) in first-line treated hATG pts vs two rATG treated pts).
A salvage therapy with rATG was initiated in two pts, whereas in one other pt
a second course with hATG was started. An overall response following relapse
therapy was observed in 33% of the pts (1/3). Four refractory as well as
relapsed pts were treated with eltrombopag respectively (final results are still
awaited). A secondary HSCT (hematopoietic stem cell transplantation) was
performed in 11 out of the 67 pts (16%), either being primary refractory or due
to a disease relapse.
Summary/Conclusions: Our data are able to independently confirm the find-
ings of previous studies concerning hematologic recovery rates in pts with
acquired AA following IST with ATG by providing further evidence that rATG
plus CsA is inferior to hATG plus CsA when administered as a first-line treat-
ment. In addition, we were able to observe in pts ≤50 yrs, irrespective gender,
an overall higher hematologic recovery. For this reason, it remains unclear why
ATGAM® is still not approved in Germany as first-line therapy in pts with AA,
as the only hATG product registered in Europe (Lymphoglobulin®) was with-
drawn from the market in 2007.
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NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE
CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF
NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS
F. Pozzo1,*, T. Bittolo1, E. Vendramini1, R. Bomben1, P. Bulian1, F.M. Rossi1,
A. Zucchetto1, E. Tissino1, M. Degan1, G. D’Arena2, F. Di Raimondo3, F. Zaja4,
G. Pozzato5, D. Rossi6, G. Gaidano7, G. Del Poeta8, V. Gattei1, M. Dal Bo1
1Clinical and experimental Onco-hematology unit, Centro di Riferimento Onco-
logico, Aviano, 2Onco-Hematology Department, Centro di Riferimento Onco-
logico della Basilicata, Rionero in Vulture, 3Division of Hematology, Ferrarotto
Hospital, Catania, 4Clinica Ematologica, Centro Trapianti e Terapie Cellulari,
Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, 5Department
of Internal Medicine and Hematology, Maggiore General Hospital, University
of Trieste, Trieste, Italy, 6Hematology, Institute of Oncology Research and
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, 7Division
of Hematology–Department of Translational Medicine, University of Eastern
Piedmont, Novara, 8Division of Hematology, S.Eugenio Hospital and University
of Tor Vergata, Rome, Italy
Background: Stabilizing mutations of NOTCH1 have been identified in about
10% of chronic lymphocytic leukemia (CLL) cases at diagnosis, with a higher
frequency in unmutated IGHV (IGHV-UM), immuno-chemorefractory or
advanced disease phase CLL, and have been associated with particularly
unfavourable prognosis (Rossi et al, Blood, 2012; Del Poeta et al, Br J Haema-
tol, 2013; Stilgenbauer et al, Blood, 2014). In CLL, all NOTCH1 mutations dis-
rupt the C-terminal PEST domain and cause an accumulation of an active
NOTCH1 isoform, resulting in a sustained pathway activation.
Aims: To identify molecular/biological features of NOTCH1 mutated CLL
Methods: The presence of NOTCH1 mutations was investigated by NGS. Gene
expression profile (GEP) was performed by a one-color labeling strategy using
the 4x44K platform. Specific gene/protein validations were performed by QRT-
PCR, western blotting, flow cytometry and immunofluorescence. CLL-like MEC-
1 cell line was transfected with a vector containing a NOTCH1 intracellular
domain (NICD) or with a control vector. Cell proliferation was evaluated by Cell-
Trace assay. Cell size was estimated by flow cytometry from Forward Scatter
(FSC) values.
Figure 1.
Results: i) A GEP comparing purified cells of 10 IGHV-UM CLL cases (5
NOTCH1-mut; 15%>37% of NOTCH1 mutated alleles) selected nucleophos-
min-1 (NPM1) and genes codifying for several ribosomal proteins (RNPs) as
significantly up regulated in NOTCH1-mut cases. A higher expression of NPM1
and RNPs in NOTCH1-mut cases was validated in a wider independent series
of 188 cases by QRT-PCR (76 NOTCH1-mut cases). In CLL, NPM1 expression
was previously found higher in IGHV-UM cases (Rees-Unwin, Br J Haematol,
2009). In our series, no significant difference in NPM1 transcript expression
was found by comparing IGHV-UM and IGHV-M cases, but NPM1 transcript
expression was confirmed significantly higher in NOTCH1-mut than in
NOTCH1-wt cases in the IGHV UM subgroup. ii) Western blotting in 11 CLL
cases (5 NOTCH1-mut) confirmed a higher NPM1 protein expression in
NOTCH1-mut cases, with a direct correlation with NOTCH1 expression
(r=0.814). In NOTCH1-mut cases, the NPM1highsubpopulation, isolated by cell
sorting, showed a higher NOTCH1 mutational load than the NPM1low subpop-
ulation. iii) EDTA treatment of 12 CLL cases (6 NOTCH1-mut) activated
NOTCH1 signaling (Rand et al, Mol Cell Biol, 2000), as from HES1 and DTX1
induction, and up-regulated NPM1 and other RNPs. The same results were
confirmed by co-culture of CLL cells with the JAGGED1-expressing M2-10B4
stromal cells. Inhibition of NOTCH1 signaling by gamma-secretase-inhibitor L-
685,458 or by siRNA for NOTCH1 reduced NPM1 expression (Fig. A). iv) Pre-
vious studies identified MYC as a direct transcriptional target of NOTCH1
(Palomero et al, PNAS 2006) and, in turn, a transcriptional activator for both
NPM1 and RNPs. ChIP assays on MEC1-cells, transfected with exogenous
NICD, revealed increased NICD binding to the MYC promoter, along with higher
expression of MYC, NPM1 and RNPs. Of note, after 48h culture, NOTCH1-
mut CLL cases showed increased MYC transcript levels than NOTCH1-wt cas-
es. MYC expression was further increased upon NOTCH1 activation by EDTA
or by stromal cells co-cultures (Fig. B). MYC silencing by siRNA efficiently
reduced NPM1 transcript and protein expression. Moreover, CpG-ODN/IL-2
treatment, to induce MYC overexpression, also increased NPM1 transcript and
protein levels in CLL cells. iv) NPM1 silencing by siRNA was able to reduce
proliferation rates and cell size of both NICD-transfected cells and control cells.
In keeping with a NOTCH1-driven regulation of cell growth/ protein biosynthesis,
activation of NOTCH1 signaling in 12 CLL cases (6 NOTCH1-mut) by EDTA or
stromal cells co-culture, induced an increase in cell size.
Summary/Conclusions: NOTCH1 mutations in CLL are associated with the
overexpression of MYC and MYC-related genes involved in protein biosynthesis
including NPM1, which are allegedly responsible for cell growth and/or prolif-
eration advantages of NOTCH1-mut CLL.
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CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT
INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP
I. Criado1,*, A. Rodríguez-Caballero1, L. Gutierrez1, C.E. Pedreira1, W.G. Nieto1,
C. Teodosio1, V. Herraez1, A. Romero-Furones2, P. Fernández-Navarro3,
J. Almeida1, A. Orfao1
1Department of Medicine, Center for Cancer Research, 2Centro de Atención
primaria de Salud Miguel Armijo, 3Centro de Atención Primaria de Salud de
Ledesma, Salamanca, Spain
Background: The presence of very low numbers of clonal B cells in peripheral
blood (PB) of otherwise healthy individuals (low-count monoclonal B lympho-
cytosis -MBLlo-) is a common finding in the general population. Since the vast
majority of clonal B cells from MBLlo subjects show a phenotype overlapping
with CLL (chronic lymphocytic leukemia) cells, the former might represent either
the normal counterpart of CLL or the earliest stages of the disease. Little infor-
mation exists about both the clinical outcome of MBLlo subjects and the biolog-
ical features of their B-cell clones over time.
Aims: To gain insight into the biological and clinical significance of the presence
of CLL-like MBLlo clones, we re-evaluated the biological features of clonal B
cells and the clinical outcome of MBLlo individuals after 7 years of follow-up.
Methods: The baseline study was constructed in 2008, when 80 out of 639
(12.5%) healthy individuals (>40y) were found to carry at least one PB CLL-like
clonal B-cell population, using high-sensitive flow cytometry. A subset of them
(n=49) has been followed for a median period of 84 months (range: 67-95
months). Besides physical examination and flow cytometry analyses, the most
frequent CLL-related cytogenetic alterations [del13q14.3(D13S25), trisomy 12,
de11q(ATM) and del17q(TP53)] were studied at baseline and at follow-up.
Results: A total of 64 CLL-like MBLlo clones (median size: 0.44 cells/ul, range:
0.027-66 cells/ul) were detected in PB of the 49 subjects at recruitment (in 15
cases ≥2 B-cell clones were detected in the same subject). In all subjects, B-
cell clones persisted at reevaluation, phenotypically identical vs baseline. Inter-
estingly, we found a near-3-fold overall increase in the size of CLL-like B-cell
clones after a 7y follow-up vs baseline (median size: 1.22 cells/ul, range: 0.046-
789 cells/ul; p:<0.001); in line with this, most clones (45/64; 70%) increased
their size, while the remaining 30% maintained stable or slightly decreased
numbers compared to time 0. From the genetic point of view, only 8/32 (25%)
clones tested carried one cytogenetic alteration at baseline, del13q(D13S25)
being present in 7/8 cases and trisomy 12 in the remaining one. Strikingly, re-
evaluation after 7 years showed 36/56 clones (64%; p<0.01 vs baseline) with
cytogenetic alterations; again, the most common abnormality was
del13q(D13S25) (34/36) followed by trisomy 12 (1/36) and del 17p(TP53)
(1/36). No statistical association (p>0.05) was found between the change over
time in the size of these clones and the presence of cytogenetic lesions. Three
subjects developed lymphocytosis (median: 5.3x109lymphocytes/l; range:
4.1x109-5.9x109/l) after 7 years; in these cases the clone size increased sub-
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stantially over time and showed (2 of them) del13q14.3. Despite this, only 1/3
subjects evolved to more advanced stage of disease, who showed 5.9x109lym-
phocytes/l with >500 clonal B cells/ul (thus reaching MBLhi) and del13q14.3. 
Summary/Conclusions: Our results suggest that CLL-like MBLlo is not a tran-
sient condition, as all clones detected at recruitment were systematically pres-
ent also at follow-up with an increase frequency of cytogenetic lesions. Despite,
B-cell clones slightly increased in size and even acquired cytogenetic abnor-
malities, the likely to progress into an over CLL seems to be extremely rare.
Further research is needed to better understand the significance of CLL-like
B-cell clones in healthy individuals and to clearly identify those MBLlo subjects
at risk to evolve to MBLhi/CLL.
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NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND
PROGRESSION OF B CELL MALIGNANCIES
T. Klymenko1, J. Bloehdorn2, J. Bahlo3, S. Robrecht3, J. Wang1, K. Fischer3,
G. Akylzhanova1, J. Edelmann12, S. Estenfelder2, J. Strefford4, T. Wojdacz4,
M. Hallek3, S. Stilgenbauer2, M. Cragg4, J. Gribben1, A. Braun1,*
1Queen Mary University of London, London, United Kingdom, 2University of
Ulm, Ulm, 3University of Cologne, Cologne, Germany, 4University of Southamp-
ton, Southampton, United Kingdom
Background: The nuclear periphery, containing the IgH and IgK gene clusters,
is a unique compartment comprised of inner nuclear membrane proteins and
nuclear lamina. Previous genome-wide and cytological studies revealed the
regulatory role for some of these nuclear proteins in higher level genome organ-
isation and gene regulation. In particular, Lamina Associated Domains (LADs)
were identified at the nuclear periphery as transcriptionally silent, gene-poor
domains associated with Lamin B1. More recent studies however revealed an
important role of LADs in the regulation of gene expression and recombination. 
Aims: Given the apparent topological coincidence between LADs and Ig vari-
able clusters, we hypothesised that nuclear lamina might play a paramount
role in the dynamics of Ig-encoding variable genome domains. In particular,
here we tested whether Lamin B1, a principal LAD-associated component of
the nuclear envelope, had any restrictive role on somatic hypermutation (SHM)
and the expression of Ig genes. Due to the strong involvement of IgV mutations
in the pathogenesis of B-cell malignancies, we also tested whether nuclear
lamina is involved in the pathogenesis of germinal centre lymphomas and
chronic lymphocytic leukaemia (CLL).
Methods: We used BL2 and naïve B cells as in vitro and ex vivo models for
somatic hypermutation. ChIP-Seq, ChIP-PCR and ImageStream analyses were
performed to establish Lamin B1 genome and nuclear binding dynamics in
resting and activated BL2 and B cells. LMNB1 RNAi was used to obtain the
functional evidence of the involvement of Lamin B1 in SHM in vitro. For in vivo
studies, OVA immunised mice were used to study Lamin B1 dynamics in de
novo formed spleen germinal centres. From a translational perspective, paired
tissue microarray samples of diagnostic and transformed follicular lymphoma
were analysed using immunohistochemistry and image analysis. Finally, com-
prehensive statistical analysis of CLL8 cohort patients was performed to test
the impact of LMNB1 expression on various clinical parameters in CLL. 
Results: We have found that genome binding of Lamin B1, a component of
the nuclear envelope involved in epigenetic chromatin regulation, is reduced
during B cell activation and formation of lymphoid germinal centres. ChIP-Seq
analysis showed that kappa and heavy variable immunoglobulin domains were
released from the Lamin B1 suppressive environment when SHM was induced
in B cells. RNAi-mediated reduction of Lamin B1 resulted in spontaneous SHM
as well as kappa-light chain aberrant surface expression. Finally, Lamin B1
expression level correlated with progression-free and overall survival in chronic
lymphocytic leukaemia, and was strongly involved in transformation of follicular
lymphoma.
Summary/Conclusions: In summary, here we report that Lamin B1 is a neg-
ative epigenetic regulator of SHM in normal B-cells and a “mutational gate-
keeper”, suppressing the aberrant mutations that drive lymphoid malignancy.
P586
MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1)
RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL)
S. Bossio1, C. Tripodo2, A. G. Recchia3, L. De Stefano4, N. Caruso5, A. Palummo6,
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Background: The PD1 pathway is involved in the inactivation of immune effec-
tors with potential reactivity against neoplastic cells in the tumor microenviron-
ment (TME). PD1 binding to its ligand PDL1 inhibits proliferation, cytokine pro-
duction, and cytotoxic activity of T-cell effectors. T-cells from CLL patients exhib-
it defective immunity, including impaired effector function leading to T-cell
exhaustion. PDL1 checkpoint blockade restores immune dysfunction and
impairs leukemia growth in the Eμ-TCL1 transgenic CLL mouse model.
PD1/PDL1 ligation also affects BCR signaling, and because PD1 is also
expressed on CLL cells, PD1 interference might directly influence tumor growth
and proliferation directly. The PD1/PDL1 axis may be a therapeutic target,
preferably in combination with BCR inhibitors (BCRi).
Aims: To investigate (1) expression of PD1 and PDL1/2 and their correlation
with time to first treatment (TFTT); (2) the role of the TME in controlling the
expression of the PD1 axis; and (3) the role of ibrutinib (IB) in the expression
of PD1 and ligands.
Methods: CLL patients were prospectively enrolled at diagnosis (O-CLL1 pro-
tocol, clinicaltrial.gov identifier: NCT00917540). Gene expression (GE) analysis
was performed using the GeneChipVR Gene 1.0 ST Array (Affymetrix) according
to the manufacturer. Flow-cytometry (FC) was used to evaluate cellular pheno-
type (BD Biosciences) in an independent subset of patients. Lymph node sam-
ples from CLL patients were subjected to in situ immunolocalization analyses.
Autologous T-cells (AAT) were obtained by in vitro exposure of patient T-cells
with anti-CD3/CD28 and rIL2 in co-culture with CLL cells. Cultures were moni-
tored daily until substantial clumping occurred and then tested for PD1 and lig-
and expression by FC. In selected experiments IB was added to cell culture.
Results: We evaluated GE of PD1 and PDL1/2 in 211 early-stage CLL patients.
The impact of GE of PD1 and PDL1/2 on clinical outcomes in CLL cases
[(n=211, median follow-up=39 months, range 6−82 months] indicated a signif-
icantly shorter TTFT in cases with higher levels of PDL2, while no significant
impact was detected based on differences in PD1 or PDL1 gene levels. A Cox
multivariate model showed that higher PDL2 gene expression retained an inde-
pendent prognostic power (HR=1.9, 95%CI 1.1–3.4, P=0.022) in predicting
TTFT together with IGHV-UM status, B-lymphocytosis≥5000/mm3 (P=0.020)
and CD38 expression (P=0.021). In situ immunolocalization analysis of CLL
tissue infiltrates indicated variable expression of PD1 mostly characterized
small lymphoid elements,while PDL1 and PDL2 (with PDL2>PDL1) mostly
characterized larger medium-sized elements within proliferation centers. Co-
localization studies revealed PD1 co-expression on CD20+ CLL cells and in
scattered CD3+ cells. Both ligands were variably expressed in CD20+CLL cells
and few T-cells and macrophages showed expression of either ligand. AAT co-
culture experiments showed a higher percentage of PD1+,PDL1+, and PDL2+
B-cells. Evaluation of T-cells detected an increase of CD3+, CD4+,and
CD8+cells bearing both PD1 and PDL1,but not PDL2. IB (1uM) reduced the
size of activated B- and T-cell clusters as well as PD1/PDL protein expression
on CLL B-cells and only on the CD8+ T-cell subset.
Summary/Conclusions: Our findings indicate that expression of PDL2 char-
acterizes a subset of high-risk early stage CLL patients. The expression of
PD1/PDL1/PDL2 proteins is also characteristic of the CLL TME whereby, co-
stimulatory signals derived from activated T-cells and/or the TME may modulate
the PD1 axis, which is counteracted by IB.
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Background: B cell receptor (BCR) mediated signalling is crucial for the patho-
genesis of chronic lymphocytic leukemia (CLL). Drugs such as ibrutinib and
idelalisib which inhibit BCR associated kinases have proved effective for the
treatment of CLL but only suppress the disease without being curative. Some
patients have developed resistance to these drugs following mutations,
progress on therapy for unknown reasons, or cannot tolerate these drugs due
to adverse events. We have shown that microenvironmental signals (e.g., IL-
4) can increase BCR expression and signalling, and can partially reverse the
effects of BCR-kinase inhibition. GAB1, PTPN22 and FOXP1 can positively
regulate BCR signalling in CLL; but the effect of IL-4 on these proteins has not
previously been studied. Insight into how IL-4 promotes BCR signalling may
allow the development of novel drugs that overcome resistance to kinase
inhibitors. Cerdulatinib (cerd) is an inhibitor of both Syk (pivotal to BCR sig-
nalling) and JAK1/3 (integral for IL-4 signalling). Inhibition of Syk has been
shown to induce apoptosis of CLL samples resistant to ibrutinib. Cerd is cur-
rently in phase II clinical trials in patients with relapsed/refractory B cell malig-
nancies including CLL.
Aims: To investigate the effect of IL-4 on the regulation of BCR signalling in
CLL and how this is modified by cerdulatinib
Methods: Eighteen primary CLL samples were treated with IL-4 +/-cerd (1μM)
and expression of FOXP1, GAB1, PTPN22, SOCS1 and SOCS3 assessed by
immunoblotting. The effect of cerd on apoptosis was assessed by flow cytom-
etry and PI/Annexin V staining.
Results: Primary human CLL cells treated with IL-4 for 24hr significantly
increased expression of positive regulators of BCR signalling FOXP1 and GAB1
in CLL samples with un-mutated IGHV (U-CLL); no change in expression in
FOXP1 or GAB1 was seen in CLL samples with mutated IGHV (M-CLL). There
was a 40% increase in PTPN22 expression in IL-4-treated U-CLL samples vs
no change in M-CLL. Cerd, at therapeutic concentrations, blocked IL-4 medi-
ated increases in FOXP1, GAB1 and PTPN22 and pSTAT6 (a positive control
for IL-4 signalling). After 24hr IL-4 selectively increased expression of the neg-
ative regulators of IL-4 signalling, SOCS1 and SOCS3 in U-CLL, but not M-
CLL cases, and this could be blocked by cerd. Cerd potently inhibited the sig-
nalling of other cytokines known to play a role in CLL biology (IL-6, IL-10, IL-
15, IL-21 and IFNγ) which utilise either JAK1 or JAK3 for activation of STAT
proteins. IL-4, CD40L and BCR ligation signals to CLL cells in lymph nodes
can promote resistance to therapies such as the BCL2-inhibitor venetoclax.
We have shown that cerd can overcome IL-4/CD40L induced expression of
pro-survival proteins MCL1 and BCLxL and that cerd in combination with vene-
toclax induced apoptosis in a synergistic manner in the presence of IL-4/CD40L.
We now extend these results to assess the important effect of this drug com-
bination in the presence of BCR stimulation. The combination of cerd and vene-
toclax in the presence of either BCR signalling (bead immobilised anti-IgM)
alone, or combined with IL-4 and CD40L, induced synergistic killing, with greater
CLL cell death than with either drug alone.
Summary/Conclusions: These results provide evidence that IL-4 may
increase BCR signalling by upregulating the expression of positive regulators
of BCR signalling in U-CLL and that this can be overcome by cerd. These
results support the continued use of cerd in clinical trials for the treatment of
CLL, alone or in possible combination with venatoclax. 
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INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN
IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING
CD49D: CLINICAL RELEVANCE
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Background: VLA-4 (CD49d/CD29), a key molecule mediating cell microen-
vironmental interactions, can be activated via inside-out by BCR triggering in
normal B cells. In chronic lymphocytic leukemia (CLL), nothing has been so far
reported regarding the VLA-4 activation mechanisms and their modulation by
ibrutinib, a drug that is known to determine an impairment of microenvironmen-
tal interactions with consequent shrinkage of tumor masses, and efflux of CLL
cells into the blood stream.
Aims: To investigate in CLL the influence of VLA-4 expression/activation on
ibrutinib response in-vivo.
Methods: VLA-4 activation was assessed by flow cytometry using conformation
sensitive anti-CD29 mAbs (HUTS-21) and LDV-containing VLA-4 ligands, and
measured as VLA-4 receptor occupancy (RO) (Chigaev et al. J Biol Chem,
2009). BCR engagement was performed using goat F(ab)2 anti–human IgM.
In-vitro studies were carried out on purified VLA-4+ CLL cells exposed in-vivo
to ibrutinib. The clinical impact of VLA-4/CD49d expression on ibrutinib treat-
ment was evaluated by measuring the kinetics of absolute lymphocyte count
(ALC), the reduction of lymphadenopathy measured as sum of products of the
diameters (SPD) % reduction from baseline, and the clinical outcome, as
defined by progression free survival (PFS) in CLL patients treated with ibrutinib
single agent in the context of name patients program, clinical trials, and real
world (n=97).
Results: BCR stimulation (n=27) induced VLA-4 activation (mean RO control
vs stimulated: 0.40 vs 0.52, p=0.0006), and increased cell adhesion (stimulat-
ed/control: 4.7 vs 7.5; p=0.0002). By comparing day 30 (t30) in-vivo ibrutinib-
treated CLL cells with pre-treatment (t0), we show that the ibrutinib-dependent
BCR signaling impairment, although reducing the constitutive VLA-4 activation
(mean RO t0 vs t30: 0.40 vs 0.30, p=0.02) and CLL cell adhesion (mean adhe-
sion t0 vs t30: 4.7 vs 2.1, p=0.013), was overcome by exogenous BCR trigger-
ing, which re-activated VLA-4 at levels similar to those of ibrutinib naïve cells
(mean RO: 0.49 at t30 vs 0.52 at t0). ALC data were available at pre-treatment
and at days 30-60-90-120 on ibrutinib in 97 patients (52 CD49d+) (Fig.1A);
CD49d+ CLL showed no ALC rise, whereas CD49d- CLL showed the typical
ibrutinib-induced ALC peak. At day 30 median % ALC change from baseline for
CD49d- and CD49d+ CLL were 126.8% and -4.4% (p=0.0002). When compar-
ing the extent of nodal response, available for 57 cases (30 CD49d+), a signif-
icantly minor % SPD reduction from baseline was observed in CD49d+ versus
CD49d- CLL: 70.5% vs 83% (p=0.033) at 6 months and 81.5% vs 92.0%
(p=0.019) at 12 months (Fig.1B). The impact of CD49d expression on patient
outcome was evaluated in the whole cohort (median follow-up, 24.5 months).
PFS was inferior in CD49d+ compared to CD49d- CLL (median PFS 39.3
months, vs not reached; p=0.004), even when considering the concomitant
presence of TP53 disruption and CD49d+ expression (Fig.1CD). A multivariate
Cox regression analysis confirmed the relevance of CD49d, along with TP53
disruption and UM IGHV mutational status, as independent predictor of shorter
PFS in ibrutinib-treated CLL.
Figure 1.
Summary/Conclusions: Altogether, these data suggest that during ibrutinib
treatment CD49d+ CLL cells residing in tissue sites keep receiving BCR-medi-
ated BTK-independent stimuli that, by inducing inside-out VLA-4 activation,
result in enhanced cell retention, with consequent reduced lymphocytosis, rel-
atively lower and/or slower nodal response, eventually leading to inferior out-
come for CD49d+ CLL patients.
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Background: Ibrutinib is an oral Bruton tyrosine kinase (BtK) inhibitor which
has advanced the clinical management of CLL. Ibrutinib binds irreversibly to
the cysteine 481 residue of the BtK protein, rendering it inactive. Btk inhibition
affects the phosphorylation of other intracellular kinases resulting in an imme-
diate redistribution of CLL cells and subsequent apoptosis. We investigated
the impact of ibrutinib on the phosphorylation of upstream and downstream
kinases in the B-cell receptor pathway in real time in the IcICLLe study
(ISRCTN12695354).
Aims: The IcICLLe trial was a single arm, multi-centre feasibility study of ibru-
tinib in two cohorts of CLL patients: (A) 20 treatment-naïve (TN) requiring treat-
ment (according to IWCLL criteria); and (B) 20 relapsed/refractory (RR). All
patients received continuous oral therapy with ibrutinib (420mg once daily)
from registration until disease progression. The primary endpoint of the trial
was the proportion of patients achieving minimal residual disease (MRD) neg-
ative remission (depletion of CLL ≤0.01% in peripheral blood (PB) & bone mar-
row (BM)) within 6 months of trial treatment. Exploratory endpoints included
the assessment of phosphorylation of intracellular kinases in the B-cell receptor
pathway.
Methods: A panel of markers was assessed on PB & BM taken at screening,
and 1 & 6 months. PB was also taken at baseline (0 hours), 4 & 24 hours, 7 &
14 days, and 2, 9 & 12 months. The phosphorylation of SyK pY348, BtK pY551,
ERK1/2, AkT S473 was assessed in 4 conditions at each time point: unstimu-
lated +/- ibrutinib, and stimulated with IgM/IgD +/- ibrutinib. 1x106leukocytes
were tagged to extracellular antibodies (CD3/CD19) conjugated to fluo-
rochromes. Ibrutinib (10uM) was added to the cells for 30 minutes at 37ºC fol-
lowed by anti-IgM/IgD stimulation (10ug/ml). The BD phosflow protocol was
followed to lyse/fix/permeate the CLL cells. Antibodies to BtK pY551, Syk
pY348, ERK1/2 pT204/pY204, Akt pS473 were used tagged to fluorochromes
(from BD Biosciences). Cells were acquired on a BD Fortessa flow cytometer.
Results: The phosphorylation of BtK, Syk, Akt and ERK1/2 was analysed in
cells at the specified time points and conditions for 20 TN and 20 RR CLL
patients. Baseline phosphorylation of all kinases was similar in both PB & BM.
Phospho-BtK showed no stimulation on addition of IgM/IgD 4h after initiating
therapy. There was a strong (2-4 fold) increase in phosphorylation of Syk kinase
with IgM/IgD even in the presence of ibrutinib in vitro. This effect was profound
in the first 2 months of ibrutinib therapy with a general decrease in phosphory-
lation after 6 months. Baseline stimulation of ERK1/2 gave a 1.5-2 fold increase
in phosphorylation but the effect was abrogated within 1 month of ibrutinib ther-
apy. Akt S473 phosphorylation was maintained after 6-12 months of therapy
although the degree of phosphorylation decreased at later time points. Syk,
AkT and ERK1/2 phosphorylation was unaffected by the addition of ibrutinib in
vitro. The pattern of phosphorylation was found to be relatively consistent in
responding patients. One patient with progressive CLL had sustained phos-
phorylation in all markers despite ibrutinib therapy.
Summary/Conclusions: The effect of ibrutinib on the phosphorylation of var-
ious kinases in the B-cell receptor pathway was analysed in real time. Syk con-
tinued to be phosphorylated over the course of treatment, which is logical as
this kinase is upstream of BtK. That the degree of phosphorylation declined
over time (even with stimulation) suggests a general inhibitory effect of ibrutinib
on CLL cells. ERK1/2 phosphorylation is effectively blocked and there is partial
reduction of phosphorylation of AKT S473. Combinations of BtK inhibitor with a
Syk or PI3 kinase inhibitor may result in complete BCR blockade. Phosphory-
lation patterns may also act as an adjunct to ascertain the response to therapy.
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Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease
with survival ranging from months to decades. CLL patients harboring TP53
alterations are well known to be refractory to standard therapies; however,
recent studies indicate that ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor,
suppresses the B-cell receptor (BCR) signaling pathway and is an effective
treatment option for these patients. Unfortunately, many patients with TP53
alterations will ultimately fail ibrutinib-based therapies. Similarly, we have used
a mouse model of refractory p53 mutant CLL (Eμ-TCL1;p53R172H), and report-
ed that while ibrutinib is effective in reducing the CD5+CD19+ population and
extending survival, these mice eventually succumb to the disease (Lee HJ,
BCJ 2016). These incomplete therapeutic responses indicate that ibrutinib pro-
vides only a temporary respite for this refractory disease, and highlights our
need to develop more potent and targeted combinations. 
Aims: Ibrutinib is effective in delaying (but not eliminating) leukemic progres-
sion in p53 mutant CLL, suggesting that combinational therapies that inhibit
BCR signaling and activate apoptotic programs may be effective therapeutic
strategies. Thus, agents that do not require activation of p53 but are effective
in blocking oncogenic pathways (BTK and BCL-2) are attractive options. Cur-
rently, ibrutinib and ABT-199 meet this criteria and thus, we hypothesize that
simultaneous inhibition of the BTK- and BCL-2-pathways will be an effective
strategy in treating p53 mutated CLL. 
Methods: To test this, we used RNA-Seq to examine expression changes in
B-cells from Eµ-TCL1 mice carrying either wild type or a single p53R172H hot-
spot mutation (corresponding to p53R175H in humans) following ibrutinib treat-
ment. qRT-PCR and IHC were used to validate expression of key targets within
pathways amenable to combinational therapy. Hematopoietic tissues were sub-
jected to combinational therapies to interrogate efficacy. 
Results: We have shown that ibrutinib downregulates the BTK- and ERK-
pathways regardless of p53 status. However, less is known in regards to global
expression changes in p53 mutant CLL following BTK inhibition. To investigate
this, we performed RNA-Seq analyses using malignant B-cells from untreated
and ibrutinib treated Eμ-TCL1;p53R172H and Eμ-TCL1 mice. Pathway analyses
revealed that CLL cells harboring a single p53 mutant allele retained a partial
ability to activate p53-dependent programs. qRT-PCR revealed robust activa-
tion of p53-dependent anti-proliferative targets like p21, but only modest acti-
vation of pro-apoptotic targets (e.g.; PUMA), suggesting these p53 mutant CLL
cells have a diminish capacity to activate apoptosis or overcome apoptotic
inhibitors. To explore this altered bi-modal p53 activation, we performed IHC
and observed that apoptotic activation was hampered by increased BCL-2
expression. To examine whether this BCL-2-dependent inhibition could be over-
come, malignant B-cells were treated with ibrutinib alone, ABT-199 (a BCL-2
inhibitor) alone, or in combination. Here, we observed that ABT-199 was suffi-
cient to activate apoptosis, regardless of p53 status, and that its use in combi-
nation with ibrutinib drastically reduced cell viability.
Summary/Conclusions: Together, these data indicate that patients with a par-
tially attenuated p53 pathway may retain the ability to activate apoptosis if
molecular barriers are removed (e.g.; BCL-2 via ABT-199). Furthermore, these
results suggest that combinations with BTK- and BCL-2 inhibitors may be ther-
apeutically beneficial for patients with mutated TP53.
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THE DNA REPLICATION PATHWAY HAS POTENTIAL PREDICTIVE VALUE
FOR TKI RESPONSE AND THERAPEUTIC INTERVENTION IN CHRONIC
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Background: Chronic myeloid leukaemia (CML) is a myeloproliferative disease
which arises in a haemopoietic stem or multipotent progenitor cell with the
t(9;22)(q34;q11) chromosomal translocation.Tyrosine kinase inhibitors (TKIs)
were developed to target the constitutively active oncoprotein BCR-ABL, which
is expressed as a result of this translocation. TKI therapy has significantly
improved patient survival, however predicting response to therapy is one of
the unmet clinical challenges in CML. Moreover, TKIs are unable to target the
leukaemic stem cells (LSCs) which drive the disease; persistence of LSCs
therefore remains a major obstacle to curing CML. Understanding the mecha-
nisms that LSC employ to survive TKI treatment is necessary to design essential
therapeutics to eliminate CML in the future.
Aims: To identify genes with predictive value for TKI response and to determine
the efficacy of drug targeting one of the key pathways identified.
Methods: Microarray, Fluidigm, Real-time PCR, FACS based cell cycle and
Annexin V apoptosis analysis, Trypan blue exclusion cell counts. 
Results: Analysis of bulk CML patient microarray data (GSE 47927) identified
323 deregulated genes either in the stem cell population or during disease pro-
gression, important for self-renewal, DNA damage and repair, cell cycle and
survival. These genes were validated in 60 samples from the SPIRIT 2 clinical
trial [a multicentre phase III randomised trial comparing the TKI imatinib (400mg
daily) versus Dasatinib (100mg Daily)] with 18 months follow-up data regarding
molecular response to TKI treatment. Patients were stratified as good/interme-
diate/poor responders to TKI and the gene signature significantly differentially
expressed was identified. These data highlighted the DNA repair genes as hav-
ing potential predictive value, in particular, the minichromosome maintenance
(MCM) protein and origin of replication (ORC) family of genes, involved in DNA
replication and cell cycle regulation. Single cell analysis of CD34+ cells across
the patient cohort identified considerable heterogeneity of expression of MCMs
and ORCs, with ORC3, in particular, exhibiting a different expression profile in
good/intermediate/poor responders (n=3 of each). In addition single cell analysis
highlighted a significant difference in the expression of MCM2, -4, -7 & ORC2
in the most primitive LSC (CD34+38-90+93+) compared to CD34+38-90+93-
cells. Next, we investigated the ability of heliquinomycin (HQ), a potent helicase
inhibitor of MCM on its own and in combination with IM to target the CML cell
line K562. Our extensive dose and time response studies followed by FACS-
based apoptosis and cell cycle analysis prove the potency of HQ and its syn-
ergistic action in combination with imatinib. We also investigated the changes
in a panel of cell cycle and DNA damage response genes at the transcript level
in response to HQ and imatinib in the K562 cell line. Overall the data generated
indicates that targeting the MCM pathway in combination with BCR-ABL inhi-
bition is a rational approach for future therapeutic intervention in CML.
Summary/Conclusions: Global ‘omics’ experimental approaches are valuable
for identifying novel pathways deregulated in CML. This combined with single
cell ‘omics’ studies enables the heterogeneity of gene expression and the
response of individual LSCs to TKI to be evaluated. Our data indicate that the
DNA replication pathway plays an important role in CML, with levels of MCMs
and ORCs having potential predictive value in TKI response and are a promising
drug target in CML.
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Background: Signal transducing adaptor protein (STAP) -2 was cloned as a
c-fms binding protein. Previously, we have demonstrated that STAP-2 binds to
BCR-ABL, which is constitutively activated in chronic myeloid leukemia (CML),
via its SH2-like domain and enhances BCR-ABL activity leading to activation
of downstream molecules, including ERK, STAT5, BCL-xL and BCL2. The family
of STAPs includes STAP-1, identified as a c-kit interacting protein, and STAP-
2. While STAP-2 is expressed ubiquitously, STAP-1 has hematopoietic-specific
expression in mice. It is still unknown whether STAP-1 plays a role in CML,
although STAP-1 is expected to have similar functions based on the structural
homology between STAP-1 and STAP-2.
Aims: To elucidate the role of STAP-1 in CML using mouse model and human
samples.
Methods: We generated STAP-1 deficient mice of the C57BL/6J genetic back-
ground. For establishment of CML mouse model, we isolated Lineage (Lin)−
Sca-1+ c-kithigh (LSK) fraction of bone marrow (BM) cells from STAP-1+/+ and
STAP-1−/−mice, infected them with retrovirus carrying MSCV-BCR-ABL-ires-
GFP, and transplanted into congeneic recipients, that were named Wild type
(WT) and STAP-1−/−CML mice, respectively. Human BM samples were collect-
ed after informed consent, using protocols approved by the Investigational
Review Board of Osaka University Hospital. 
Results: Using Western blot and immunoprecipitation assay, we confirmed
that STAP-1 binds to BCR-ABL. CML mice model was then employed to analyze
the role of STAP-1. We found that STAP-1−/− CML mice showed significantly
longer survival than WT CML mice (Fig. 1). STAP-1−/− CML mice displayed
less severe splenomegaly and lung hemorrhages compared to WT, suggesting
that loss of STAP-1 attenuates CML progression. To investigate how STAP-1
regulates CML progression, we evaluated leukemic stem cells (LSCs) in CML
mice. The absolute numbers of STAP-1−/− LSCs (GFP+ LSK) in BM and spleen
were significantly lower than those of control (WT vs STAP-1−/−; 2090.3 ±
694.07 cells vs 412.57 ± 114.07 cells in BM, p=0.0291; 12.9 ± 1.75 ×104 cells
vs 4.09 ± 0.72 ×104 cells in Spleen, p=0.0009). In colony-forming assay in vitro,
STAP-1−/− LSCs generated less colonies in the first and second plating com-
pared to WT LSCs. These data indicated that deletion of STAP-1 would impair
self-renewal capacity of LSCs. When we transplanted 5,000 LSK cells from
STAP-1+/+ or STAP-1−/− mice without BCR-ABL transduction in the presence
of competing BM cells, deletion of STAP-1 had no effects on engraftment at 28
days after transplantation. Furthermore, we measured the expression of STAP-
1 in BM cells derived from patients in the chronic phase of CML. As a result,
STAP-1 mRNA was abundant in the LSC (CD34+ CD38− Lin−) compartment. 
Figure 1.
Summary/Conclusions: In this study, we utilized CML mouse model and
showed that STAP-1 is required for progression of CML. Our findings indicate
that STAP-1 has an indispensable role in LSC maintenance, while normal
hematopoietic stem/progenitors were not affected by STAP-1 deficiency.
Although a majority of patients have a durable response to BCR-ABL tyrosine
kinase inhibitors, the outcome of patients who fail the treatment due to primary
or acquired resistance is still miserable. Our findings in mice and human sug-
gests that STAP-1 could be a therapeutic target for CML. Further analysis will
be needed to clarify the molecular mechanisms by which STAP-1 regulates
the progression of CML and maintains survival of LSCs. 
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TELOMERE SHORTENING IN CD34+38- BCR-ABL POSITIVE BONE
MARROW CELLS FROM NEWLY DIAGNOSED PATIENTS WITH CML
CORRELATES WITH THE CLONE SIZE OF THE LEUKEMIC STEM CELL
COMPARTMENT
A.-S. Bouillon1,*, M. Ventura Ferreira1, S.A. Awad2, J. Richter3, H. Hjorth-Hansen4,
S. Hummel1, M. Schemionek1, S. Mustjoki2, F. Beier1, T.H. Brümmendorf1
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Sweden, 4Department of Hematology, St Olavs Hospital, Norwegian University
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Background: Chronic myeloid leukemia (CML) is a clonal stem cell disorder
characterized by the BCR-ABL translocation. Previous work provides evidence
that based on the size of the leukemic stem cell (LSC) clone within the
CD34+38- population at diagnosis, chronic phase (CP) of CML can be stratified
into early and late CP. Patients in late CP have a higher LSC burden going
along with an inferior response to TKI therapy. Telomeres shorten with each
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cell division and telomere length (TL) in peripheral blood cells has been shown
to correlate with disease stage, response to treatment and duration of CP in
CML patients. However, the use of TL as a routine clinical biomarker in CML
has been complicated by considerable inter-individual, mostly genetic variability
in TL ideally requiring non-clonal control cells. 
Aims: Based on these considerations, we used a modified Q-FISH technique
in order to be able to separately study TL directly in BCR-ABL+ LSC vs BCR-
ABL- control cells within the CD34+38- hematopoietic stem cell compartment
of diagnostic patients with CML in CP.
Methods: 15 patients (median age: 59 years, range: 41- 72 years) diagnosed
with CML in CP of the NCT00852566 study (Nordic CML Study Group) were ret-
rospectively analyzed. Of the patients studied, clinical data were available for 14
patients. Of those, 2 (14%) belonged to the Sokal high risk group, 5 (36%) to
intermediate and 7 (50%) to the low risk group. CD34+38- cells sorted from bone
marrow samples were tested with the standard FISH method using dual fusion
dual color BCR-ABL1 probe following standard procedures. After capturing the
BCR-ABL staining using confocal microscopy, samples were re-processed for
TL analysis by Q-FISH using established protocols. TL staining was analyzed in
all previously captured cells allowing the identification of BCR-ABL+/- cells within
the same sample. Analysis and quantification of BCR-ABL FISH staining and TL
measurement by Q-FISH were performed in blinded fashion.
Results: Overall, we observed significantly shortened TL in the BCR-ABL+
compared to BCR-ABL- cells (-4.9 arbitrary units (a.u.) range: -53.7 to 16.9
a.u., p=0.04). Next, we correlated the clone size (i.e. the proportion of BCR-
ABL+ positive cells within the CD34+38- compartment) with the degree of
telomere shortening in LSC. Mean clone size of the patients was 59.9 ± 32.0
% S.D. Of note, we found a significant negative correlation (R²=0.36, p=0.02)
between TL and clone size strongly supporting the notion that increased expan-
sion of the BCR-ABL+ LSC pool leads to accelerated telomere shortening.
Correlation with clinical prognostic data such as Hasford (R²=0.07, p=0.41) or
Sokal (R²=0.04, p=0.38) score did not reveal any statistically significant corre-
lation with the degree of telomere shortening probably due to the small sample
size analyzed in this pilot study.
Summary/Conclusions: In this study, we provide further evidence for accel-
erated telomere shortening in BCR-ABL+ LSC as compared to their normal
CD34+CD38- counterpart in CP CML samples at diagnosis. Interestingly, the
degree of TL shortening linearly correlates with the clone size of the BCR-
ABL+ LSC compartment. Thus, this retrospective study (now on the LSC level)
further supports a role of TL as a prognostic and predictive biomarker in newly
diagnosed patients with CML pending confirmation in prospective trials.
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GENOMIC CHARACTERIZATION OF CML AT DIAGNOSIS REVEALS
PREEXISTING SOMATIC MUTATIONS THAT MAY PREDICT PROGRESSION
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Background: Blastic phase of chronic myeloid leukemia (BP-CML) remains
mostly incurable even with newer generation tyrosine kinase inhibitors (TKI)
and represents an unmet clinical need. Although in recent years a dramatic
reduction in the transformation of chronic phase (CP-CML) to BP-CML has
been observed, still up to 5% of patients will progress to BP-CML despite treat-
ment with TKI. Prospective identification of such patients may have a significant
clinical impact. There are only few reports to date which use next-generation
sequencing (NGS) to look for somatic mutations - other than those affecting
kinase domain of BCR/ABL1 - at the time of diagnosis (Dx) which could have
a prognostic/predictive value.
Aims: We analyzed the spectrum of somatic mutations in two groups of CML
patients with clinically different disease course: first group (BP) comprised of
11 patients who progressed to BP-CML despite treatment with TKI and/or allo-
HSCT (one patient) and died (paired samples from Dx and BP were analyzed);
second group (MMR) included Dx samples from 36 patients who achieved
major molecular response (MMR) on TKI within 6 months and remained in
MMR for at least 48 months from Dx.
Methods: Targeted enrichment strategy using custom designed capture probes
(SeqCap EZ, Roche NimbleGen) followed by NGS on Illumina platform was
employed. More than 1200 genes implicated in human cancer were included.
Common variants (>1%) gathered in large genomic databases and our internal
database were filtered out and the subsequent analysis was focused on puta-
tive protein damaging variants, supported by variant effect prediction tools such
as PolyPhen-2, SIFT or CHASM. All reported variants were reconfirmed by
Sanger sequencing.
Results: BP group comprised of paired samples from 11 CML patients who
progressed to BP and died despite treatment with TKI. Median age at diagnosis
was 53y (range 26 -77), median time to progression for 9 patients (2 were
diagnosed in accelerated phase or BP) was 17,5 months (mo) (range 4-108)
and median survival was 22 mo (range 10 -116). None of those patients har-
bored BCR/ABL1 mutation at the time of Dx and progression to BP-CML, 4
patients had additional chromosomal alterations at progression to BP including
two frequent (trisomy 8 and monosomy 7). Targeted enrichment followed by
NGS allowed us to achieve deep coverage (>80% ge50). Median number of
rare variants was 26 (range 18-38) and 29 (range 23-32) for Dx and progression
samples respectively. In majority of patients upon progression (72%, 8/11) we
detected new and previously described mutations in selected genes, which
are frequently mutated in myeloid malignancies, namely in RUNX1 (36%, 4/11),
DNMT3A (27% 3/11) IDH1/IDH2 (18%, 2/11) and ASXL1 (18%, 2/11). In six
patients (54%, 6/11) mutations in these genes (excluding IDH2, detected only
in BP sample) were preexisting at the time of Dx. These results were compared
to second, control group that comprised of diagnostic samples from 36 patients
(median age at diagnosis 53y, range 23 -75) who were optimal responders to
TKI and remained in MMR for at least 48mo (median time in MMR: 73mo;
range 48-128). In MMR group, the median number of rare variants was lower
than in BP group in Dx samples (21, range 14-32). However, in 2 patients (2/36,
5%) frameshift mutation in ASXL1 (p. Gly643_Gly644fs) was detected, identical
as in one of BP patients. Additionally, one patient harbored RUNX1 mutation
(p. Arg201Gln) which was not detected in the BP group.
Summary/Conclusions: Our results provide new insights into the already
complex genomic landscape of blastic phase of CML. We suggest that a sig-
nificant number of patients with poor disease outcome may harbor preexisting
mutations in DNMT3A, RUNX1 and IDH1. In contrast, mutations in ASXL1
may be present at Dx in patients who will remain in long-term remission.
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INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY
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Background: Indoleamine 2,3 dioxygenase (IDO1) is the rate-limiting enzyme
in the metabolism of the essential amino acid tryptophan (TRP). IDO1 is
induced mainly by interferons during infection and inflammation. Strong IDO1
activity depletes tryptophan, which results in reduced T cell activation and pro-
liferation as well as expansion of immunosuppressive regulatory T cells. Dereg-
ulation of IDO1 activity has been linked to cancer immune evasion, but its role
in chronic phase (CP) CML has not been investigated in detail.
Aims: Determination of IDO1 levels and activity in plasma CML-CP patients in
the course of tyrosine kinase inhibitor therapy and their correlation with clinical
and immunological parameters as well as molecular response. 
Methods: A large panel of circulating cytokines and components of the IDO-
pathway (soluble IDO1=sIDO1 and kynurenine/tryptophan ratio=KYN/TRP as
a product of IDO1 activity) as well as various leukocyte populations such as
plasmacytoid dendritic cells (pDC) were analyzed alongside the prospective
pan-european ENEST1st clinical study (NCT01061177). This substudy includ-
ed 52 nilotinib-naïve chronic phase (CP)-CML patients that were subsequently
treated with 300mg BID nilotinib and longitudinally analyzed at months 6 and
12 of therapy. Molecular responses were quantified in central EUTOS reference
laboratories. 
Results: Soluble IDO (sIDO1) levels and KYN/TRP ratio are significantly up-
regulated in newly diagnosed CP-CML and drop during nilotinib therapy. sIDO1
levels significantly correlate with increased KYN/TRP, suggesting increased
IDO1 activity at diagnosis. Increased sIDO is linked to a pro-inflammatory status
in CML patients, as it positively correlates with increased serum neopterin
levels as well as to various other pro-inflammatory markers, such as IFN-g, IL-
8, IL-10, IL-17A, sVEGF-A, sVCAM-1 and sTNFR-1. Albeit being an IFN-reg-
ulated gene, IDO1 activity (KYN/TRP) negatively correlates with the proportion
of pDC, the main producers of IFN-α. Interestingly, a higher KYN/TRP is linked
to superior molecular response, as demonstrated by a significant correlation
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of the KYN/TRP ratio to BCR-ABL transcript levels. Patients having a high
KYN/TRP ratio (> mean +2SD of post therapy levels) reach deep molecular
response rates (i.e. MR4.5) significantly earlier and at higher rates. Moreover,
combining KYN/TRP with sCD62L levels, a recently identified predictive bio-
marker, resulted in a score robustly predicting the odds of achieving deep
molecular response. 
Summary/Conclusions: CML diagnosis in CP is linked to an increased inflam-
matory status, as shown by increased levels of sIDO and its metabolites kynure-
nine leading to an increased KYN/TRP ratio. In solid cancer increased IDO
expression/activity is linked to inferior outcome by favoring immune evasion. In
contrast, in CML an increased KYN/TRP ratio is associated with improved
molecular outcome during nilotinib 1st-line therapy. One reason could be that
IDO activity may reflect endogenous IFN-α production, a known factor favoring
immune-mediated CML-control. The predictive potential of KYN/TRP is cur-
rently verified in an independent cohort.
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Background: Despite the dramatic improvement of prognosis in CML patients
due to the introduction of tyrosine kinase inhibitors (TKIs), resistance to therapy
occurs in a considerable proportion of patients. The best-characterized mecha-
nism of resistance is the acquisition of mutations in the BCR-ABL1 tyrosine kinase
domain (TKD) affecting TKI binding. The third-generation TKI ponatinib exerts
strong anti-neoplastic effects even in advanced CML stages and is capable of
suppressing the kinase activity of BCR-ABL1 carrying any single mutation includ-
ing T315I. Nevertheless, resistance to ponatinib can evolve in sub-clones carrying
BCR-ABL1 variants with two or more mutations on the same allele, if the IC50
values for this TKI exceed the maximum achievable effective plasma levels
(efCave). These co-called compound mutations (CMs) are associated with
increased oncogenic potential in comparison to individual mutations, and repre-
sent a powerful mechanism of potential resistance to all currently available TKIs.
The occurrence of compound mutations has been linked particularly to sequential
treatment with different TKIs, and the identification of their responsiveness to
ponatinib is of paramount importance for the subsequent clinical management.
Aims: 1. To determine the spectrum of highly TKI-resistant CMs. 2. Measure
the responses of BCR-ABL1 CMs to ponatinib
Methods: We have established a BCR-ABL1 protein model facilitating assess-
ment of the presumptive impact of 27 different CMs involving important functional
sites of the BCR-ABL1 TKD, and including constellations expected to display
high resistance to ponatinib. To assess the anticipated responses to ponatinib
in vitro, we have introduced all BCR-ABL1 CMs into Ba/F3 cells using a recently
published transposon-mediated approach (Byrgazov et al., Oncotarget 2016,
7(47):78083-78094), and IC50 values of ponatinib were determined.
Results: Most CMs involving sites with no previous evidence for implication in
resistance to ponatinib displayed IC50 values below 10 nM. This efCave is read-
ily achievable even with the 15mg daily dose of ponatinib. CMs revealing ele-
vated resistance to ponatinib in vitro almost invariably included T315I or F317L
mutations. While most CMs involving T315I revealed very high IC50 values,
some of the predicted compound mutations containing F317L displayed an
IC50 for ponatinib in the range of the efCave achievable only with a daily dose
of 45mg. These observations are supported by clinical findings in the PACE
trial which revealed impaired responses of patients with CMs involving F317L
who had received average daily doses of ponatinib below 45mg (Deininger et
al., Blood 2016, 127(6):703-12).
Summary/Conclusions: Current strategies that aim at decreasing the dose of
ponatinib to prevent severe side effects should carefully consider the presence
and type of mutations in the BCR-ABL1 TKD to enable effective treatment. It
would be highly desirable, therefore, to implement testing of the effective plasma
drug concentrations and monitoring the kinetics of mutant subclones covering
also compound mutations in the routine diagnostic surveillance to provide a
basis for optimized clinical management of patients treated with ponatinib.
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Background: Immune surveillance refers to a process whereby the innate and
adoptive immune systems recognize and eliminate cancer cells on the basis of
cancer-specific or related antigens or other molecules. Substantial data support
the concept of immune surveillance in rodents but data in humans are less
convincing and apply mostly to virus-induced cancers. However, considerable
data indicate a strong anti-leukaemia effect in persons with chronic myeloid
leukaemia (CML) receiving an allogeneic haematopoietic cell transplant. Most,
if not all, of this anti-leukaemia effect is confounded with graft-versus-host dis-
ease (GvHD) and whether there is a allogeneic or host specific anti-leukaemia
effect distinct from GvHD is controversial. Another interesting observation is
about 40 percent of persons with CML and a deep molecular response to tyro-
sine kinase-inhibitors (TKIs) remain in molecular remission when TKI-therapy
is stopped. Because TKI-therapy is very unlikely to eradicate every CML cell,
some ascribe this therapy-free remission (TFR) a result of immune surveillance.
Immune surveillance refers to a process whereby the innate and adoptive
immune systems recognize and eliminate cancer cells on the basis of cancer-
specific or related antigens or other molecules. Substantial data support the
concept of immune surveillance in rodents but data in humans are less con-
vincing and apply mostly to virus-induced cancers. However, considerable data
indicate a strong anti-leukaemia effect in persons with chronic myeloid
leukaemia (CML) receiving an allogeneic haematopoietic cell transplant. Most,
if not all, of this anti-leukaemia effect is confounded with graft-versus-host dis-
ease (GvHD) and whether there is a allogeneic or host specific anti-leukaemia
effect distinct from GvHD is controversial. Another interesting observation is
about 40 percent of persons with CML and a deep molecular response to tyro-
sine kinase-inhibitors (TKIs) remain in molecular remission when TKI-therapy
is stopped. Because TKI-therapy is very unlikely to eradicate every CML cell,
some ascribe this therapy-free remission (TFR) a result of immune surveillance.
Immune surveillance refers to a process whereby the innate and adoptive
immune systems recognize and eliminate cancer cells on the basis of cancer-
specific or related antigens or other molecules. Substantial data support the
concept of immune surveillance in rodents but data in humans are less con-
vincing and apply mostly to virus-induced cancers. However, considerable data
indicate a strong anti-leukaemia effect in persons with chronic myeloid
leukaemia (CML) receiving an allogeneic haematopoietic cell transplant. Most,
if not all, of this anti-leukaemia effect is confounded with graft-versus-host dis-
ease (GvHD) and whether there is a allogeneic or host specific anti-leukaemia
effect distinct from GvHD is controversial. Another interesting observation is
about 40 percent of persons with CML and a deep molecular response to tyro-
sine kinase-inhibitors (TKIs) remain in molecular remission when TKI-therapy
is stopped. Because TKI-therapy is very unlikely to eradicate every CML cell,
some ascribe this therapy-free remission (TFR) a result of immune surveillance.
Immune surveillance refers to a process whereby the innate and adoptive
immune systems recognize and eliminate cancer cells on the basis of cancer-
specific or related antigens or other molecules. Substantial data support the
concept of immune surveillance in rodents but data in humans are less con-
vincing and apply mostly to virus-induced cancers. However, considerable data
indicate a strong anti-leukaemia effect in persons with chronic myeloid
leukaemia (CML) receiving an allogeneic haematopoietic cell transplant. Most,
if not all, of this anti-leukaemia effect is confounded with graft-versus-host dis-
ease (GvHD) and whether there is a allogeneic or host specific anti-leukaemia
effect distinct from GvHD is controversial. Another interesting observation is
about 40 percent of persons with CML and a deep molecular response to tyro-
sine kinase-inhibitors (TKIs) remain in molecular remission when TKI-therapy
is stopped. Because TKI-therapy is very unlikely to eradicate every CML cell,
some ascribe this therapy-free remission (TFR) a result of immune surveillance.
Immune surveillance refers to a process whereby the innate and adoptive
immune systems recognize and eliminate cancer cells on the basis of cancer-
specific or related antigens or other molecules. Substantial data support the
concept of immune surveillance in rodents but data in humans are less con-
vincing and apply mostly to virus-induced cancers. However, considerable data
indicate a strong anti-leukaemia effect in persons with chronic myeloid
leukaemia (CML) receiving an allogeneic haematopoietic cell transplant. Most,
if not all, of this anti-leukaemia effect is confounded with graft-versus-host dis-
ease (GvHD) and whether there is a allogeneic or host specific anti-leukaemia
effect distinct from GvHD is controversial. Another interesting observation is
about 40 percent of persons with CML and a deep molecular response to tyro-
sine kinase-inhibitors (TKIs) remain in molecular remission when TKI-therapy
is stopped. Because TKI-therapy is very unlikely to eradicate every CML cell,
some ascribe this therapy-free remission (TFR) a result of immune surveillance.
Immune surveillance refers to a process whereby the innate and adoptive
immune systems recognize and eliminate cancer cells on the basis of cancer-
specific or related antigens or other molecules. Substantial data support the
concept of immune surveillance in rodents but data in humans are less con-
vincing and apply mostly to virus-induced cancers. However, considerable data
indicate a strong anti-leukaemia effect in persons with chronic myeloid
leukaemia (CML) receiving an allogeneic haematopoietic cell transplant. Most,
if not all, of this anti-leukaemia effect is confounded with graft-versus-host dis-
ease (GvHD) and whether there is a allogeneic or host specific anti-leukaemia
effect distinct from GvHD is controversial.
Aims: Another interesting observation is about 40 percent of persons with CML
and a deep molecular response to tyrosine kinase-inhibitors (TKIs) remain in
molecular remission when TKI-therapy is stopped. Because TKI-therapy is very
unlikely to eradicate every CML cell, some ascribe this therapy-free remission
(TFR) a result of immune surveillance. 
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Methods: To test these hypotheses, we studied whether there was an
increased incidence in CML in persons receiving immune suppression after
solid organ transplants. IF immune surveillance is important in CML we would
expect an increased incidence in this setting. We used a dataset from the Col-
laborative Transplant Study (CTS) which collects information on recipients of
solid organ trans plants beginning in 1985 from >300 transplant centers world-
wide. Cancer incidence data were checked annually by questionnaire. Data
for expected CML incidence were obtained from a cohort of identical size
matched for age and sex from Cancer Incidence in Five Continents monitored
for the same duration as the transplant cohort. Data collection and processing
were approved by the Data Protection Agency in Germany and all participating
centers complied with local ethical and privacy regulations.The CTS dataset
consisted of 441,332 recipients of kidney (N=355,606), liver (N=47,846) and
heart (N=37,880) transplants. Amongst kidney transplant recipients the stan-
dardized incidence ratio (SIR) for developing CML was 1.54 (95% confidence
interval, 1.1, 2.1; p=0.01) representing 39 cases in 1,682,491 person-years at-
risk vs. 25 expected (14 excess cases). Amongst liver transplant recipients the
SIR was 1.72 (0.6, 4.0; P=0.34) representing 5 cases in 182,833 person-years
at-risk vs. 3 expected (2 excess cases). Amongst heart transplant recipients
the SIR was 3.47 (1.8, 6.1; p=0.0005) representing 12 cases in 173,015 per-
son-years at-risk vs. 3 expected (9 excess cases). Data from recipients of kid-
ney and liver transplants suggest immune-suppression does not increase risk
of developing CML or does so very slightly. The increase in SIR in kidney graft
recipients is generally-attributed to increased cancer surveillance including
blood testing. Although the SIR of CML was substantially-increased after heart
transplants, these persons receive high doses of ionizing radiations for diag-
nostic radiological procedures such as computer tomography (CT)-angiogra-
phy. Ionizing radiations are a proved cause of CML which might explain the
increased SIR.
Results: Our data, 25 excess cases of CML in 2,038,339 person-years at-risk
observation suggest the magnitude of immune-surveillance do not support the
hypothesis immune surveillance operates to an important extent to prevent
CML in humans. 
Summary/Conclusions: Consequently, the anti-leukaemia effect associated
with allotransplants and the TFR observed after stopping TKI-therapy is unlikely
to result from effective immune surveillance against CML.
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SEQUENCING BASED ON NANOPORE MINION TECHNOLOGY
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Background: In newly-diagnosed chronic phase (CP)-CML patients, 15–30%
who start first-line tyrosine kinase inhibitors (TKIs) therapy will not reach an
optimal response, and a BCR-ABL1 kinase domain (KD) mutation will be
detectable in 25–50% of patients with treatment failure with an increased fre-
quency of these mutations observed in accelerated phase and blast crisis
patients. Currently, Sanger sequencing (SS) technique analyzing BCR-ABL1
is considered the gold standard for mutation detection knowing that this assay
has a sensitivity of around 20 %, and therefore is unsuitable for identifying low-
level variants (<20 % variant frequency). Recently next generation sequencing
(NGS)-based assays have been reported for detecting BCR-ABL1 KD muta-
tions; although these NGS strategies are more accurate and precise than SS,
they are burdened by costs related to the initial investment, that is the
sequencer purchase, the preparation of specific targets libraries, and the
required reagents. MinION is a single molecule sequencer connected to a lap-
top through a USB3.0 interface, based on nanopore technology; it works by
connecting two strands of DNA molecules by a hairpin, and sequencing them
consecutively.
Aims: We describe a third- generation sequencing assay on MinON for detect-
ing BCR-ABL1 KD mutations and compare the results to a SS-based test in 24
Ph+ leukemia cases.
Methods: Overall, 24 patients were included; among them, 12 (11 CML and 1
ALL cases) developed treatment resistance during the TKI’s treatment course
(Group 1) and 12 were at diagnosis (7 CML and 5 ALL cases) (Group 2). For
ABL1 amplification and barcoding the total cellular RNA was extracted from
peripheral blood cells. MinION library preparation, sequencing and data analy-
sis were performed. All cases included in the study were analyzed by SS and
MinION sequencing in blinded manner.
Results: Two sequencing runs were performed with the two different pools of
patients: the first lasted eight hours and was carried out on the Group 1, whereas
the second run included the Group 2 and lasted 24 hours to achieve a deeper
sequencing. Sequencing results showed that 100% of ABL1 from exon 2 to 10
was covered and that the mean of the sequencing depth was around 150x and
1000x for Group 1 and 2, respectively. In any case, the depth of sequencing
was never found below 50X. We found 10 BCR-ABL1 KD mutations in 9 patients
belonging to the Group 1 (one case showed compound mutations). Notably,
almost all mutations had a high allelic ratio. Despite a high depth of sequencing,
MinION data analysis on the Group 2 was able to detect mutation only in a ALL
case. Results from MinION and SS showed 92% concordance in all cases
included in this study. Notably, mutations that were initially undetectable by SS
became evident thanks to the indications coming from MinION analysis.
Summary/Conclusions:. Our findings demonstrate multiple advantages by
using MinION approach, first of all the sensitivity: our comparison of MinION
to SS identified mutations below the detection limit of SS (generally stimated
around <20%) in 2 (22%) among the mutated cases, including mutations known
to be clinically important. Another point on the side of the nanopore technology
is the costs profile. Therefore, the main advantage of this technology is to allow
a more efficient and sensitive analysis than SS at very competitive costs. In
conclusion, we demonstrated that MinION is suitable for employment in hema-
tology laboratory for detecting BCR-ABL1 KD mutation in Ph+ leukemias.
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Background: The chronic myeloid leukemia (CML) is characterized by the
presence of the Philadelphia chromosome and the BCR-ABL1 fusion gene.
The introduction of tyrosine kinase inhibitors (TKIs) significantly improved the
survival, but 15% of patients don’t reach the optimal responses at the defined
end-points or develop secondary resistance. The 2013 ELN guidelines identi-
fied as fundamental the early molecular response (BCR-ABL1/ABL1 % ≤10%
IS), the MR3 (<0.1%) and the deep molecular response (MR4<0.01%,
MR4.5<0.032%, and MR5 <0.001%). Consequently, the molecular monitoring
plays a crucial role in the clinical management of CML patients, with a conse-
quent research of sensitive and standardized molecular techniques. The auto-
mated methods offer advantages in terms of reduced time for analysis,
decreased manual steps, and reduction of possible errors and contamination.
Aims: We compared the automated technique GeneXpert “Ultra” (Cepheid,
Maurens-Scopont, France) with the “Labnet” method that includes the “classi-
cal” manual real-time PCR techniques standardized in the Italian network (57
centers), according to the European guidelines [Cross N, 2015]. We compared
the sensitivity of the two methods (based on the number of ABL1 detected
copies), the classification of molecular responses, with particular attention to
the deep molecular one.
Methods: We assessed the BCR-ABL1 transcript in 86 patients afferent to
laboratories of Pisa, Napoli, Torino, and Bologna (Italy). For statistical analysis,
the t-, the Pearson’s and the Cohen’s K test were adopted. Because our
patients presented different transcript levels (from the >10% to the 0% (MR4,
MR4.5, MR5) the two techniques have been compared in the different molec-
ular subgroups. 
Results: Firstly we compared the number of detected ABL1 copies, that are
fundamental for definition of the molecular response categories, especially for
defining the degree of deep response (32,000 for MR4.5, 100,000 for MR5).
By the “LabNet” method, 51 (81%) samples exceeded the 100,000 copies of
ABL1, while by the automated method 81 samples (94.2%) reached >100,000
ABL1 copies. Then, we compared the two methods in discriminating positive
and negative samples (K Cohen=0.690; p <0.02): 77 samples were concordant
(89.5%) and only 9 (10.4%) were discordant. Of the 18 negative samples with
the “LabNet” method, 2 (11.1%) were in MR4.0, 10 (55.5%) in MR4.5 and 6
(33.4%) in MR5.0. On the other hand, of the 19 negative samples with the
method “Ultra”, 1 (5.3%) was in MR4.5 and 18 (94.7%) in MR5.0, confirming
the higher sensitivity of the automated method. In the cohort of positive cases
by the two methods, the median values of transcript expression were superim-
posable (p=0.55) and the linear regression coefficient was very satisfying (Pear-
son’s r=0.9399; p-value <0.0001). Finally we compared the results produced
by the two methods according to the “molecular classes” (MR1 vs MR2+MR3
vs MR4+MR4.5 vs MR5). This comparison showed a good concordance
between the two methods (Cohen’s k=0.78–good correlation). Variation analy-
sis demonstrated high concordance between “Ultra” and “LabNet” methods
using assay comparison criteria proposed by Müller et al. [Leukemia 2009]
(Table 1).
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Table 1.
Summary/Conclusions: In a huge series of patients the automated and man-
ual molecular methods, applied in 4 different laboratories, resulted comparable
in terms of classification of patients in “molecular classes”. The advantage of
the “Ultra” technique is represented by the higher number of detected ABL1
copies and the easier standardization. 
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Background: Cell response to stress is a central component of genomic sta-
bility. The integrity of signaling pathways involved in cell cycle arrest, chromatin
remodeling and DNA repair, are critical for the maintenance fidelity of replicated
DNA. In this context, Gadd45 proteins function as stress sensors and gene
transcription regulators. Gadd45a, in particular, intervenes in G2/M checkpoint
induction and DNA repair, and it is required for efficient coordination of centro-
some duplication hence preventing abnormal mitosis and aneuploidy. Such
evidences let assume a putative role of Gadd45a in cancer development and
progression. Interestingly, Gadd45a interacts with Aurora Kinase A (AK A), a
key component of centrosome cycle and polar spindle assembly required for
regulated progression from G2 tom and throughout M.
AK A is a member of a serine-threonine kinase family active during mitosis and
it is frequently overexpressed in human cancers where correlates with a poor
prognosis. Notably, AK A overexpression is always associated with defects in
centrosome duplication, bipolar spindle and chromosomal segregation and
aneuploidy, suggesting that it may enhance other oncogenic events by pro-
moting genomic instability, one major trait of chronic myeloid leukemia (CML).
Our results support the hypothesis that AK A cooperates with the constitutive
TK activity of Bcr-Abl fusion protein by increasing DNA damage, promoting the
occurrence of additional genomic alterations and driving TKIs resistance and
disease progression to blast crisis.
Aims: Here we investigated AK A and Plk1 role in CML hematopoietic progen-
itor survival as potential targets to eradicate the transformed clone.
Methods: K562 cell line is a human cell line generated from a CML patient in
blast crisis. Drug resistance was induced in K562 cell line by the exposure to
progressively increasing doses of Imatinib (IM). It was validated by dose-
response curves showing a significant difference in LD50 of IM-sensitive and
IM–resistant cells. By mean of cytofluorimetric and immunofluorescence micro-
scope analyses we investigated the events leading to AK/Plk1 deregulation.
Protein expression and activation were detected by western blotting and
immunoprecipitation. Apoptotic cell death was measured by using an Annexin
V/PI staining; cell cycle distribution was observed by PI staining and subsequent
cytofluorimetric analysis.
Results: Preliminary experiments were aimed to determine whether IM resist-
ance in a BCR-ABL1 cell context is associated with the over-expression and
hyper-activation of AKA/PLK1 axis. In our in vitro model drug resistance was
associated with increased expression and phosphorylation of AK A (Y282) and
Plk1 (T210). 24h exposure to IM significantly reduced expression and phos-
phorylation of both proteins in parental K562, but not in IM-resistant K562, indi-
cating that AK A and Plk1 activation is only partly dependent on BCR-ABL1 TK
activity. Subsequent experiments showed that the inhibition of AK A and PLK1
in response to specific inhibitors (Danusertib and Volasertib respectively) was
associated with:
• significant increase of gadd45 a expression levels;
• reduction of cell survival;
• G2/M checkpoint arrest.
The findings support the role of AK A/PLK1 inhibition in restoration of signals
involved cell growth control and apoptosis.
Summary/Conclusions: The advantage of using AK and Plk1 inhibitors in
CML therapy mostly arises from effects independent from TK activity of Bcr-
Abl protein. We proved that the AK and Plk1 inhibitors induce growth arrest
and apoptosis in IM sensitive and resistant cell lines.
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Background: ENESTfreedom (NCT01784068) is evaluating the ability to stop
NIL and remain in TFR in pts with a sustained deep molecular response (DMR)
on frontline NIL. Previous results from ENESTfreedom showed that 51.6% of
pts (98/190) who attempted TFR remained off treatment and in major MR
(MMR; BCR-ABL1 ≤ 0.1% on the International Scale [IS]) at 48 wk.
Aims: To analyze updated TFR data and predictive factors for remaining in
TFR in ENESTfreedom.
Methods: Eligible pts had CML-CP with b2a2 and/or b3a2 BCR-ABL1 tran-
scripts, ≥2 y of frontline NIL, and MR4.5 (BCR-ABL1IS ≤0.0032%) prior to enroll-
ment. All pts provided informed consent. After enrollment, pts continued NIL for
1 y (consolidation phase). MR was assessed every 12 wk during the 1-y con-
solidation phase; pts with no assessment worse than MR4 (BCR-
ABL1IS≤0.01%), ≤2 assessments between MR4 and MR4.5, and MR4.5 in the
last assessment were eligible to enter TFR. Loss of MMR during TFR triggered
reinitiation of NIL. To investigate potential predictors for remaining in TFR, pts
were grouped according to Sokal risk score at diagnosis or depth of response
prior to attempting TFR (based on response assessments in the consolidation
phase), and 48-wk TFR rates in each subset were calculated. The current analy-
sis was conducted when all pts who entered TFR had completed 96 wk of TFR,
reinitiated NIL, or discontinued from the study (data cutoff, 31 Oct 2016).
Results: Of 190 pts who entered TFR, 93 (48.9% [95% CI, 41.6% - 56.3%])
remained in MMR and off treatment at wk 96, including 88 (46.3%) who were
in MR4.5. Three pts who were in TFR at 48 wk lost MMR by 96 wk, and 2 addi-
tional pts discontinued from the study between 48 and 96 wk without losing
MMR. Among pts with low, intermediate, or high Sokal risk at diagnosis, 39/62
(62.9% [95% CI, 49.7% - 74.8%]), 25/50 (50.0% [95% CI, 35.5% - 64.5%]),
and 9/28 (32.1% [95% CI, 15.9% - 52.4%]), respectively, remained in TFR at
wk 48 (Sokal risk scores were missing for 50 pts). Among pts with MR4.5 in all
assessments during the consolidation phase, 90/170 (52.9% [95% CI, 45.2%
- 60.6%]) remained in TFR at wk 48 vs 8/20 (40.0% [95% CI, 19.1% - 63.9%])
who had ≥1 assessment between MR4 and MR4.5 during the consolidation
phase. Overall, of 88 pts who reinitiated NIL due to loss of MMR, 87 (98.9%)
regained MMR and the remaining pt left the study 7.1 wk after NIL reinitiation
without regaining MMR; 81 of 88 pts (92.0%) regained MR4.5 by the data cutoff.
Among pts remaining in TFR for >48 wk (n=100), adverse events (AEs) were
less frequent during the second vs the first 48 wk of TFR; 2 (2.0%) and 1 (1.0%)
of these pts had cardiovascular AEs during the first and second 48 wk of TFR,
respectively; 34 (34.0%) and 9 (9.0%), respectively, had AEs in the predefined
musculoskeletal pain grouping.
Summary/Conclusions: The majority of pts in TFR at 48 wk remained in TFR
at 96 wk, and they reported fewer AEs during the second 48 wk of TFR than in
the first 48 wk, affirming the durability and safety of TFR following NIL. No strong
predictors for remaining in TFR were identified. Pts with low Sokal risk and pts
with continuous MR4.5 in the consolidation phase tended to have higher TFR
rates than other pts, although these results must be interpreted with caution due
to the small number of pts in some subsets and the wide 95% CIs. Additionally,
the biological explanation for an association between Sokal risk score at diag-
nosis and a subsequent ability to remain in TFR is unknown. These results sup-
port TFR as a valuable option for pts in sustained DMR on frontline NIL.
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Background: The t(9;22) translocation in chronic myeloid leukemia (CML)
generally occurs in intron 12 or 13 of the BCR gene resulting in two different
transcripts, the e13a2 or e14a2. It has been suggested that the two variants
represent separate disease entities and that the transcript variants hold a prog-
nostic value regarding treatment response, where e14a2 predicts a faster and
deeper treatment response. However, no difference in overall survival has been
observed and the issue remains controversial. Reverse transcription quantita-
tive PCR (RT-qPCR) using the Europe Against Cancer (EAC) qPCR assay has
been the gold standard for determining the levels of BCR-ABL1 transcripts.
The assay use common primers for amplification of the two variants resulting
in a PCR product for the e14a2 variant that is 75 base pairs longer than the
e13a2 variant. Under suboptimal PCR conditions, amplicons may be amplified
with different efficiencies, which can result in an underestimation of especially
the amount of longer qPCR products.
Aims: To study the accuracy of the EAC assay in quantifying the e13a2 and
e14a2 transcripts.
Methods: Patient samples were screened for BCR-ABL1 e13a2 and e14a2
transcript variants using either PCR with agarose gel separation or a droplet
digital PCR (ddPCR) assay measuring the amount of e13a2 and e14a2 tran-
scripts. The BCR-ABL1 level was determined by qPCR using the QuantStudio
instrument (Life Technologies) and expressed in the International Scale (%IS)
using the EAC primers and assay conditions with GUSB and BCR as reference
genes. Samples were re-measured by digital droplet PCR (ddPCR) on a Quan-
taLife instrument (Bio-Rad) using modified EAC primers multiplexed with GUSB
and BCR as reference genes and expressed as %IS.
Results: Transcript levels from 124 BCR-ABL1 positive patient samples were
determined using the EAC qPCR assay (median: 0.08% IS, range: 0.001–
159% IS) and ddPCR (median: 0.01% IS, range: 0.0002–124% IS). These
included 59 samples with the e13a2 variant and 65 with the longer e14a2 vari-
ant. Comparing the expression levels obtained by the two techniques revealed
ddPCR/qPCR ratio differences for e13a2 (median: 0.68, range: 0.35 - 3.2) and
e14a2 (median: 3.43, range: 0–8.8), and a consistent 4.5 fold (>0.5 log) under-
estimation of the levels of the e14a2 compared to e13a2 when using qPCR
(figure 1).
Figure 1.
Summary/Conclusions: When we compared the BCR-ABL1 levels using
qPCR and ddPCR, we observed a discrepancy between the e13a2 and e14a2
breakpoint variants. Since ddPCR is an endpoint measurement and not sen-
sitive to variations in primer efficiencies, the most likely explanation for the dis-
crepancy is a decreased qPCR efficiency of the longer e14a2 variant compared
to e13a2 variant. Thus in qPCR analyses using the EAC protocol this may, at
least on some analysis platforms, result in a consistently underestimation of
the e14a2 level resulting in an appealingly better treatment response. A more
than 0.5 log underestimation in a large subgroup of patients could have con-
sequences in clinical decision-making e.g. by miss-grouping patients at different
time points or when considering TKI discontinuation. Since many clinical lab-
oratories uses the BCR-ABL1 EAC protocol, the underestimation of the e14a2
variant could potentially be a widespread issue. We are presently working on
an optimized BCR-ABL1 qPCR protocol where the e14a2 underestimation is
eliminated.
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Background: Ponatinib is an oral tyrosine kinase inhibitor (TKI) approved for
pts with CP-CML or Philadelphia chromosome–positive acute lymphoblastic
leukemia (Ph+ ALL) for whom no other TKI therapy is indicated, or for pts with
T315I. The ponatinib PACE trial (NCT01207440) enrolled pts with CML or Ph+
ALL resistant/intolerant to dasatinib or nilotinib, or with T315I. Long-term results
in these heavily pretreated pts provide value in informing treatment decisions.
Aims: To report 5-yr efficacy and safety, and the association of early landmark
responses with survival outcomes at 4 yrs past landmark, in heavily pretreated
pts with CP-CML from PACE.
Methods: Ponatinib starting dose was 45mg/day. Dose reductions were
instructed in Oct ‘13 to manage risk of arterial occlusive events (AOEs)
observed with longer follow-up. Outcome measures were: 5-yr efficacy (n=267)
and safety (n=270); post hoc landmark analysis (n=267) of the association of
molecular responses (BCR-ABLIS ≤0.1% [major molecular response (MMR)],
>0.1–1%, >1%–10% and >10%) and cytogenetic responses (major [MCyR]
and complete [CCyR]) at 3-, 6- and 12-mos with progression-free survival (PFS)
and overall survival (OS) 4 yrs past landmark (log-rank P values). Data cutoff:
3 Oct ’16.
Table 1.
Results: Baseline characteristics of the CP-CML pts included: median time
from diagnosis, 7 yrs (range, 0.5–27 yrs); median age, 60 yrs (18–94 yrs);
median %Ph+, 100% (2.5–100%); ≤10% Ph+, 20 pts (7%); 60% of CP-CML
pts received ≥3 prior TKIs. At initiation of study closure, 99 pts (37%) were
ongoing; among these pts, minimum follow-up was 52 mos, and most (78%)
had 15mg/d as their last ponatinib dose. In efficacy-evaluable CP-CML pts,
cumulative response rates as of the data cutoff were: MCyR, 60%; CCyR, 54%;
MMR, 40%; and MR4.5, 24%. Among pts who achieved MCyR (n=148) or MMR
(n=108), the Kaplan-Meier (KM) estimated probability of remaining in response
at 5 yrs was 74% (95% CI, 62–83) and 61% (95% CI, 51–70), respectively.
Maintenance of response was high regardless of dose reductions in Oct ’13.
KM estimated 5-yr rates for PFS/OS were 49%/77%. Among pts with 3-, 6-
and 12-mo landmark assessments, MCyR/CCyR was achieved in 48%/39%,
62%/52% and 71%/56%, respectively, and MMR achieved in 14%, 29% and
39%, respectively. Achievement of cytogenetic response and deep reductions
in BCR-ABL1 levels (Table) at most landmark time points was associated with
improved PFS and OS 4 yrs past landmark. Deeper responses at all landmarks
were associated with achievement of MR4.5 over time. Treatment-emergent
adverse events (AEs) in ≥45% of CP-CML pts were rash 47%, abdominal pain
46%, and thrombocytopenia 46%. Most newly occurring AEs were observed
within the first yr. The incidence of any AOE/serious AOE for CP-CML pts was
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29%/23%. Among CP-CML pts with no prior AOEs who had a prospective dose
reduction, 17% (11/63) had a first AOE occurring after Oct ‘13.
Summary/Conclusions: Long-term 5-yr results from PACE demonstrate that
irrespective of dose reductions, ponatinib continues to show deep, lasting, clin-
ically meaningful responses over time in heavily-pretreated pts with CP-CML.
Achieving early cytogenetic response and deep reduction in BCR-ABL1 levels
was associated with improved survival 4 yrs past landmark, demonstrating the
prognostic value of early and deep response to ponatinib.
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Background: Very elderly (>75 yrs) people are a substantial proportion of
chronic myeloid leukemia (CML) patients that sometimes receive Imatinib (IM)
at reduced doses based on physicians’ judgment. However, data on long-term
follow-up of these patients are still lacking. 
Aims: To investigate the treatment response and outcome in a cohort of very
elderly patients with newly diagnosed CML in chronic phase.
Methods: We revised in a retrospective database 263 CML patients aged ≥ 75
years and diagnosed from 2/2002 to 1/2016 and treated with IM frontline; among
these, 121 patients (46%) were older than 80 yrs.
Results: Median age at diagnosis was 78.5 yrs [interquartile range (IQR) [76.3–
81.3]. Sokal Risk at diagnosis was low in 1 patient (0.4%), intermediate in 171
(68.4%), high in 78 (31.2%) and not evaluable in 13 patients. As regards comor-
bidities, 63 patients had no or 1 concomitant disease, 147 patients 2 or 3 and
53 patients (20.1%) 4 or more. Median interval from diagnosis to IM start was
0.8 month (IQR 0.3–1.6): the initial IM dose was 400mg/day in 180 (68.4%),
300mg/day in 67 (25.5%) and <300mg/day in 16 (6.1%) patients. According to
WHO, grade 3-4 haematological and extra-haematological toxicities were
reported in 57 (21,7%) and 51 (19.4%) patients, respectively. As regards cumu-
lative response, 13 patients (4.9%) discontinued IM due to early toxicity, 4
(1.5%) were resistant and 2 (0.8%) died from unrelated causes early after IM
initiation; 250 patients (92.8%) achieved a complete haematological response
(CHR). Among these, 208 (79% of all 263 patients) achieved a cytogenetic
response (CyR), which was partial in 18 patients and complete (CCyR) in 190
(72.2% ) after a median period of 6.1 months since IM initiation (IQR 3.4-9.1).
Among the 190 patients in CCyR, 148 (56.2%) achieved a molecular response
(MMolR) (ratio < 0.1) after a median period time of 13.7 months (IQR 9.0-22.3).
Eleven patients (4.2%) developed a blastic phase (myeloid in 8 and lymphoid
in 3 cases). After a median follow-up of 45.0 months from IM start (IQR 22.3–
72.0), 93 patients have died (9 from disease progression and 84 from unrelated
causes), 144 are alive and 104 of them are still in treatment with IM, while 8
discontinued for prolonged deep molecular response and 22 switched to 2nd
generation TKI. Five-years event-free survival (EFS) and overall survival (OS)
were 51.2% (CI95% 44.8-57.6) and 70.9% (CI95% 64.6-77.2), respectively. At
univariate analysis Hb level at diagnosis (≥ 12 vs ≤ 12g/dl, p=0.021) and the
initial dose of IM (400 vs ≤300, p=0.048) were significant predictive factors for
CCyR achievement, while PLT count at diagnosis (>500 vs < 500 x 109/l,
p=0.006) and female gender (p=0.046) were significant predictive factors for
MMolR achievement. Multivariate analysis for EFS and OS are described in
Table1.
Table 1.
Summary/Conclusions: The long term follow-up of very elderly CML patients
treated with IM suggests that any effort to treat these patients with standard
doses should be made, in order to achieve cytogenetic and molecular respons-
es as in younger subjects.
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Background: Nilotinib has shown better efficacy compared to imatinib, but it
has been associated to a higher incidence of arterial thrombotic events (ATEs).
Little is known on the impact of ATEs on the outcome of nilotinib treated patients.
Aims: To investigate the characteristics of ATEs and their impact on the long-
term outcome of CML patients treated with nilotinib first-line. 
Methods: We analyzed 345 patients ≥ 18 years of age with CP CML enrolled
in clinical trials of the GIMEMA CML WP investigating nilotinib as first-line treat-
ment. Patients were treated with: nilotinib 400mg BID (n=73); rotation of nilotinib
400mg BID / imatinib 400mg OD (3-month periods for each drug)(n=123); nilo-
tinib 300mg BID (n=149). The median follow-up was 58 (22-82) months. The
median age at CML diagnosis was 53 (18–86) years. We analyzed the rate,
type, management, and outcome of ATEs; moreover, we compared the molec-
ular response rates and the long-term outcome of patients with or without ATEs.
Definitions: ATEs: peripheral arterial obstructive disease (PAOD), coronary syn-
dromes, significant carotid stenosis and ischemic stroke, or other significant
ischemic events; major molecular response (MMR): BCR-ABL ≤0.1% (IS), with
>10.000 ABL copies; MR4: BCR-ABL≤0.01% (IS), with >10.000 ABL copies.
Results: Overall, 30/345 (8.7%) patients had ATEs during treatment with nilo-
tinib. The median age at CML diagnosis of these patients was 64 (43-85) years,
and the median age at ATEs was 67 (47-89) years. The median duration of
nilotinib treatment at ATE was 25 (1-78) months. ATEs were: 14 coronary dis-
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ease (including 7 acute myocardial infarction), 8 PAOD, 4 carotid stenosis
(asymptomatic), 2 avascular necrosis of femoral head, 1 optic artery ischemia,
1 atherosclerosis of aorta/right iliac artery. Overall, 21 patients were hospitalized
for the management of ATEs; 15 patients received medical treatment only,
while the remaining required invasive interventions: 9 coronary angioplasty
with stent positioning, 3 lower limbs amputations, 2 peripheral vascular by-
passes, and 1 prosthesis of femoral head. No patient died for ATEs. Overall,
24 patients (80% of patients with ATEs, and 7% of the whole cohort) perma-
nently discontinued nilotinib because of ATEs. The median follow-up after ATE
was 15 (1–58) months. Of the 30 patients with ATEs, 26 (87%) achieved a
MMR and 18 (60%) obtained a MR4, during nilotinib treatment. These rates
were comparable to those observed in patients without ATEs (MR3: 260/315,
83%; MR4: 113/315, 64%). The 5-year progression-free survival and overall
survival were similar in patients with or without ATEs (PFS: 96% vs 92%,
p=0.55; OS: 96% vs 93%, p=0.79).
Summary/Conclusions: After a median follow-up of 58 months, 8.7% of
patients treated front-line with nilotinib had ATEs, being coronary disease and
PAOD the most common. ATEs were more frequent in elderly patients (median
age at ATEs: 67 years). Half of the patients required invasive procedures,
including major surgeries in 6 patients. The other patients were successfully
managed with medical treatment. Importantly, no patients died for ATEs, and
ATEs did not affect the rates of MMR, MR4 and 5-year PFS and OS, which
were all comparable to those observed in patients without ATEs. Taken togeth-
er, these data suggests that ATEs, despite being sometimes associated with
significant morbidity, did not significantly impact on response rates and on long-
term outcome of CML patients treated with nilotinib front-line.
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Background: Long-term use of tyrosine kinase inhibitors (TKIs) may lead to
chronic renal injury.
Aims: To evaluate the incidence of chronic kidney disease (CKD) in patients
with chronic myeloid leukemia (CML) in the chronic phase (CP) receiving TKIs,
and to identify the factors associated with the onset of CKD.
Methods: Data of CML-CP patients treated with TKIs as first-line or second-
or third-line therapy for at least 3 months were analyzed. Glomerular filtration
rate (GFR) was followed from the initiation of TKI-therapy. CKD was defined
as persistent GFR less than 60 ml/min/1.73 m2 or persistent more than 30%
GFR reduction from baseline. CKD-free survival was used to evaluate the onset
of CKD. Patients’ characteristics and TKI used were analyzed to identify the
factors associated with the onset of CKD by Cox regression model in those
receiving first-line and second- or third-line TKI-therapy, respectively.
Results: 587 patients were included in this study. 383 (65%) were male. Medi-
an age was 40 (17-84) years.
464 patients received imatinib (n=363), nilotinib (n=88) or dasatinib (n=13) as
first-line TKI-therapy. With a median follow-up of 35 months (range, 3-185
months), 136 of 416 (33%) patients with normal GFR at baseline developed
CKD. Probabilities of CKD-free survival at 4 years were 62%, 78% and 100%
in the patients receiving imatinib, nilotinib and dasatinib, respectively (p=0.004).
Multivariate analysis showed that imatinib use (HR=2.4, 95% CI 1.4-4.3,
p=0.002), male gender (HR=2.0, 95% CI 1.4-2.9, p=0.001), increasing age
(HR=1.2, 95% CI 1.1-1.4, p=0.003) and prior administration of hydroxyurea,
interferon or chemotherapy (HR=1.7, 95% CI 1.1-2.8, p=0.010) were factors
associated with incident of CKD. In 48 patients with abnormal GFR or prior
CKD before first-line TKI-therapy, 8 of 42 (19%) developed ≥30% GFR reduc-
tion from baseline during imatinib-therapy, while none of 6 during nilotinib- or
dasatinib-therapy. In 123 patients receiving nilotinib (n=59) or dasatinib (n=64)
as second- or third-line TKI-therapy after imatinib-failure, 13 of 110 (12%) with
normal GFR at baseline developed CKD with a median follow-up of 19 months
(range, 3-149 months). Probabilities of CKD-free survival at 3 years were 74%
and 90% in those receiving nilotinib and dasatinib, respectively (p=0.059). Mul-
tivariate analysis showed that nilotinib use (HR=3.6, 95% CI 1.0-13, p=0.047)
and a history of diabetes mellitus, hypertension or other renal diseases
(HR=3.8, 95% CI 1.3~11.6, p=0.019) were factors associated with incident of
CKD. 3 of 13 (23%) patients with abnormal GFR or prior CKD before second-
or third-line TKI-therapy developed ≥30% GFR reduction from baseline during
nilotinib (n=1) or dasatinib (n=2) therapy.
Summary/Conclusions: Our study showed that nilotinib and dasatinib were
associated with less chronic renal injury compared with imatinib as first-line
TKI-therapy, while dasatinib was related to less loss of renal function compared
with nilotinib as second- or third-line TKI-therapy after imatinib-failure in CML-
CP patients.
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Background: Quantification of BCR-ABL1 transcript by qPCR is mandatory
to monitor the response to TKIs therapy in CML patients. The achievement of
Major or Deep Molecular Response (MMR or DMR) with TKIs is crucial for
long-term survival and for treatment free remission (TFR). Currently, up to 30-
40% of CML patients treated with TKIs can achieve DMR, but 50-60% of deep
responders who discontinue the treatment loose their DMR and re-challenge
continuous TKIs therapy. qPCR has some intrinsic limitations and it does not
appear to be an optimal assay to select the best candidates to TKIs discontin-
uation. Digital PCR (dPCR) can give an absolute quantification of target nucleic
acids by partitioning the PCR reaction mix over a large number of wells, each
containing a single copy or no copies of the target region.
Aims: The aim was to comparatively monitor the BCR-ABL1 transcript levels
by dPCR and qPCR in 57 CML patients treated with TKIs and achieving MMR
or DMR in at least 3 time points.
Methods: Using qPCR and dPCR (QS3D Digital PCR System by Life Tech-
nologies), we comparatively analyzed 228 peripheral blood samples from 57
CML patients with MMR (n°14) or DMR (n°43). qPCR analysis were performed
according to the last International Guidelines while absolute quantification of
BCR-ABL1 transcript were obtained by dPCR and results were expressed as
number of BCR-ABL1copies/ul of reaction. Patients were divided into 3 groups
corresponding to the MR classes at the first time point: MR3.0, MR4.0 and
MR4.5-5.0 groups. dPCR Positive Predictive Value (PPV) was also preliminary
evaluated in 14 patients undergoing TKI discontinuation.
Figure 1.
Results: Analyzing comparatively the time course of MR in the patients of the
three groups (MR3.0,MR4.0 and MR4.5-5.0) it was observed a similar trend,
but the dPCR allowed to appreciate that, at the time of starting the monitoring
the patients showed different levels of BCR-ABL1 copies/ml. Furthermore,
those patients with MR4.5-5.0 undetectable by qPCR resulted with detectable
BCR-ABL1 transcript levels when assessed by dPCR. Secondly, while MRD
quantitations measured by qPCR appear to be more homogeneous, nearly
due to a normalization effect of qPCR, the quantitations of MRD measured by
dPCR appear to be more heterogeneous because of the high sensitivity and
accuracy of dPCR. Therefore, dPCR values, reflecting the great heterogeneity
of MRD level in patients belonging to the same MR group, suggest a higher
accuracy in patients stratification (Figure 1a). dPCR value of 0,468 copies/ul,
previously reported as value discriminating between major responders and
deep responders, was used as threshold for dPCR data analysis. Patients with
absolute value of BCR-ABL1 lower than 0,468copies/ul at the first time point
presented more stable disease levels than the patients with absolute value of
BCR-ABL1 higher than 0,468copies/ul (Figure 1b). In 14 CML patients who
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discontinued TKIs, a preliminary analysis showed that 80% of patient with BCR-
ABL1<0,468 copies/ul at discontinuation, maintained stable TFR (PPV of 80%).
Summary/Conclusions: This study suggests that dPCR is more precise and
sensitive than qPCR when detecting levels of BCR-ABL1 transcript and that
dPCR seems to be more robust and accurate for CML patients stratification.
Larger and prospective studies are warranted to confirm the higher sensitivity
and accuracy of dPCR and its usefulness to better select the candidates for
TFR.
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Background: Primary goal of management in chronic myeloid leukemia (CML)
is to prevent disease progression to blast phase CML (BP-CML). Current notion
for management of BP-CML usually involves initiation of intensive chemother-
apy regimen with addition of tyrosine kinase inhibitor (TKI). Despite treatment
with intensive induction chemotherapy, outcome remains dismal. 
Aims: We aimed to describe our experience with management of BP-CML and
its outcome.
Methods: We included 58 patients from Moffitt Cancer Center from 2001 till
2016 with diagnosis of BP-CML and performed a retrospective chart review.
Data elements including age, gender, peripheral blood and bone marrow param-
eters, phase of CML, treatment, cytogenetics and vital status were collected.
Survival analysis using Kaplan-Meier method with log-rank test to determine
significance by calculating two-sided p values was performed.
Figure 1.
Results: The overall survival (OS) of our cohort was 31.87 months (mo). For
patients with progression to BP-CML from previously known diagnosis of CML,
median time to progression was 19.1 mo (range: 3.0-221.2 mo). The median
OS from the diagnosis of BP-CML in this cohort was 10.8 mo, compared to de
novo CML-BP cohort OS of 11.03 mo (p value=0.62). Myeloid blast phase CML
had worse OS compared to lymphoid blast phase cohort but was not statistically
significant (9.17 vs 17.5 mo, p=0.32).  We further compared the treatment
strategies of BP-CML including single agent TKI (n=21) and conventional
chemotherapy regimens in combination with a TKI (n=36). The median OS of
the cohort with single agent TKI was not statistically different from the combi-
nation with chemotherapy arm (12.83 mo vs 10.87 mo, p=0.73) as shown in
Figure 1A. Additionally, combination of chemotherapy with TKI compared to
single agent TKI did not have significant survival impact in either myeloid (9.17
vs 9.13 months, p=0.32) or lymphoid (14.47 vs 18.27 mo, p=0.24) BP-CML.
Total of 26 patients (44.8%) proceeded to allogeneic bone marrow transplant,
26% (n=6) of which only received TKI prior to transplant compared to 76.9%
(n=20) who received chemotherapy in combination with TKI. Use of single
agent TKI rather than TKI in combination with chemotherapy prior to allogeneic
transplant had a trend toward improved OS (128.5 vs 24 mo, p=0.23) (Fig 1B).
Choice of TKI in combination with chemotherapy in treatment of BP-CML also
did not identify any TKI combination resulting in superior survival (Figure 1D).
Overall survival of the cohort stratified by presence of standard Philadelphia
chromosome in comparison to additional cytogenetic aberrations did not detect
difference in overall survival (10.87 vs 12.1 mo, p=0.51). Further evaluation of
cytogenetic aberrations revealed monosomy 7 to be present in greater frequen-
cy in lymphoid blast phase compared to myeloid blast phase (35.71% vs 6.25%,
p=0.02).
Summary/Conclusions: Our data suggest no survival difference when BP-
CML is treated with a single agent TKI compared to a combination therapy,
regardless of histology type. Therefore, single agent TKIs should be considered
as an effective frontline therapy option for BP-CML, which may prevent the
potential toxicity associated with chemotherapy. These findings need further
validation in a larger prospective cohort.
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Background: European LeukemiaNet (ELN) recommendations (2013) advised
closely monitoring for patients with late warning response (patients with com-
plete cytogenetic response without major molecular response after 12 months
of treatment). Our trial, DASAPOST, has been the first one evaluating efficacy
and safety of dasatinib in patients with late warning responses, and preliminary
results have been reported (Garcia-Gutierrez et al, ASH 2016; P5450). Besides,
many studies suggest that dasatinib may augment responses due to its
immunomodulating effect. Although NK and CD8 cells seem to be involved,
the specific mechanism remains to be clarified.
Aims: To evaluate the efficacy and safety of switching change to dasatinib in
patients treated with imatinib first line during at least 18 months and having a
late warning response, and to study the association between response to dasa-
tinib and immune robustness, both baseline and during the therapy, and dasa-
tinib-induced lymphocyte “mobilization”.
Methods: Phase II, open, multicenter DASAPOST study (NCT01802450).
Patients previously treated with imatinib after at least 18 months, with CCyR but
without MMR, were included. All BCR-ABL/ABL (IS) measurements were cen-
tralized in a EUTOS laboratory. Patients not molecularly analyzed at a given time
point were considered as non responders, Lymphocyte counts, subpopulations
and migration studies were done at baseline ( 1st day of dasatinib), and every 3
months, and they were done both previous to the dose, and 2 hours after.
Table 1.
Results: From April 2013 to May 2015, 18 patients were enrolled in 12 centers.
Median age was 59 years (39-77). The ratio of men to women was 13/5, and
the Sokal risk groups were 48%, 30% and 22% for low, intermediate and high
risk, respectively. Median time from diagnosis to switch to dasatinib was 2.6
years (1.6-23) and median time while on imatinib to achieve CCyR 1.4 years
(0.2-12). Median exposure to imatinib was 2.4 years (1.6-14). Eight patients
(44.4%) obtained MMR at 3 months, and 12 (66.7%) obtained MMR at 6 and
12 months. Of interest 9/18 patients (50%) achieved MR4 by 12 months. There
were 3 study discontinuations because of toxicity (16%). Table 1 shows the
median number of the most relevant lymphocyte populations in the pre-dose
sample at baseline. Table 2 shows that the absolute number of CD8 cells was
significantly superior at baseline in those patients having a MMR at 3 months,
with a trend in the same direction of absolute lymphocyte count and percentage.
There were no significant associations with response when considering CD4 T
cells, NK cells, or the degree of mobilization after dasatinib dose either in total
lymphocyte numbers or in subpopulations. Besides, lymphocyte number or pro-
portions at 3 or 6 months were not associated with MMR at 6 or 12 months
(data not shown).
Table 2.
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Summary/Conclusions: Our study shows that in patients treated with imatinib
and with late warning responses, switching to Dasatinib induced MMR in 2 out
every 3 patients, and MR4 in half of the patients, with a good safety profile.
Contrarily to other group reports, we have not found any significant association
between response and lymphocyte mobilization in any point studied. Interest-
ingly, the absolute number of CD8 at baseline was significantly associated with
the early obtention of MMR at 3 months, a finding which underscore the prog-
nostic importance of baseline immune status, the relevance of CD8 cells in the
antileukemic effect,and which suggest that this quite simple variable must be
included in future studies with dasatinib in second line.
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Background: Impaired fasting glucose (IFG) and type 2 diabetes (T2D) rep-
resents adverse events in Chronic Myeloid Leukemia (CML) patients treated
with the second-generation tyrosine kinase inhibitor (TKI) nilotinib. A genetic
risk score (uGRS) for the prediction of insulin resistance, consisting of 10 mul-
tiple single-nucleotide polymorphisms (SNPs), has been proposed. 
Aims: We evaluated the uGRS predictivity in 45 CML patients treated with
nilotinib.
Methods: Patients were genotyped for IRS1, GRB14, ARL15, PPARG, PEPD,
ANKRD55/MAP3K1, PDGFC, LYPLAL1, RSPO3, and FAM13A1 genes. The
uGRS was based on the sum of the risk alleles within the set of selected SNPs. 
Results: MR3.0 and CMR were achieved in 91% and 84% of the patients,
respectively.Before treatment, none of the patients had abnormal blood glu-
cose. During treatment and subsequently follow-up of 84.4 months (range 1-
298), 5 patients (11%) developed diabetes requiring oral treatment, after a
median of 11 months (range 3-95) since nilotinib. Nine patients (20%) devel-
oped prediabetes. Prediabetes/diabetes-free survival was significantly higher
in patients with an uGRS below 10 compared to higher scores (100% vs 18%,
p=0.004) (Figure). Each increment of 1 unit on the uGRS caused a 42%
increase in the prediabetes/diabetes risk (HR=1.42; CI: 1.04-1.94; p=0.026).
Figure 1.
Summary/Conclusions: Although nilotinib is not associated with a higher inci-
dence of TD2 compared to a general population, it could be an early “high-
lighter” of genetic predisposition to the disorder. The presence of more than 10
allelic variants associated to insulin secretion, processing, sensitivity and clear-
ance is predictive of prediabetes/diabetes developing. In clinical practice uGRS
could help tailor the best TKI therapy.
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Background: The quantitative PCR of BCR-ABL transcript has been the most
useful technique for monitoring therapy in CML patients for over a decade. The
numerous standardization projects have been undertaken in order to harmonize
the molecular response results in laboratories all over the world. However, our
data suggest that using the most common protocol may lead to overestimation
of e13a2 transcript.
Aims: The goal of the study was to verify the observation that e14a2 transcript
amplifies less efficiently than e13a2. The secondary goal was to validate the
modification of Europe Against Cancer (EAC) protocol developed in 2011 which
corrects observed artifacts.
Methods: The BCR-ABL measurements acquired using EAC and in-house
modified EAC protocol have been compared with results from SA Pathology in
Adelaide. The Adelaide protocol (Branford and Hughes 2006) consists of sep-
arate, optimized reactions for e13a2 and 14a2 transcripts, therefore it should
be considered free of any PCR efficiency-related artifacts. The data originated
from four independent sample batches exchanged between Poznan and Ade-
laide since 2009.
Results: The analysis of retrospective EAC protocol data showed that when
e13a2 and e14a2 samples entered the exponential phase at the same time,
the latter would cross the threshold approximately 2.2 cycles after the first one.
Re-analysis of data from sample exchanges from 2009 revealed that after
establishing a conversion factor (CF), all of the e14a2 measurements in Poznan
were underestimated according to Adelaide. At the same time, almost all of
e13a2 samples were overestimated (fig. 1). Still, the bias between methods
was acceptable and a valid conversion factor (CF) was calculated. The method
modification introduced 2011 eliminated this difference and increased concor-
dance between laboratories. The last sample batch revealed significant differ-
ence between non-modified and modified EAC protocols in e13a2 measure-
ments: 4,56 (+/- 0.96). Reanalysis of sample batch from 2009 (presented on
fig.1) using 4.57 (2x2.28) factor (e13a2 results divided by 2.28, e14a2 results
multiplied by 2.28) resulted in almost perfect data alignment. The results of
modified EAC protocol, after CF recalculation, showed very good concordance
with Adelaide (100% results of e14a2 and 88% of e13a2 within 2-fold of refer-
ence laboratory).
Figure 1.
Summary/Conclusions: In the EAC protocol, the e14a2 transcript amplifies
less efficiently than e13a2. Since commonly used plasmids, including ERM-
AD623, are based on e14a2, the standard curve is being shifted towards the
latter cycles. It leads to overestimation of e13a2 by mean factor of 4.5 (over
0.5 log), which could be clinically significant. The reports of worse outcome of
e13a2 patients are probably caused by this artifact, which can be easily elim-
inated by implementing an additional forward primer to EAC protocol. This
overestimation cannot be detected in case of lab to lab validation when two
centers are using EAC protocol. In case of method validation in Adelaide, those
differences were not as obvious as well. The shift of 4.5 (fig. 1) means that
results are 2.25 times different from the perfect concordance line and could
easily fit into accepted 2-fold and 3-fold compartments. The CF calculated by
Adelaide would depend on the percentage of each transcripts among the
exchanged samples. The observed artifact should be also taken into consid-
eration in clinical trials that rely on surrogate endpoints such as molecular
response level at certain time points. Uneven transcript variant distribution
between compared groups may lead to improper conclusions.
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Background: Congenital sideroblastic anemia (CSA) is an inherited microcytic
anemia characterized by the presence of bone marrow ring sideroblasts, reflect-
ing excess mitochondrial iron deposition. The most common form of CSA is X-
linked sideroblastic anemia (XLSA), which is attributed to mutations in the X-
linked gene erythroid-specific 5-aminolevulinate synthase (ALAS2). ALAS2
resides on chromosome X and encodes the enzyme that catalyzes the first
and rate-limiting steps in the heme biosynthesis pathway in erythroid cells. This
pathway converts glycine and acetyl-coenzyme A to 5-aminolevulinic acid
(ALA), which requires pyridoxal 5’-phosphate (PLP) as a cofactor. Although
PLP has been used for treating XLSA, a marked proportion of patients with
XLSA remain refractory to treatment (Ohba et al. Ann Hematol 2013). Thus,
there is a need to establish a model of XLSA to reveal the detailed molecular
mechanism contributing to RS formation as well as to explore novel therapeutic
strategy for XLSA.
Aims: We explored to establish a novel model of XLSA by CRISPR/Cas9-
based genome editing.
Methods: We targeted the GATA-1-binding region of intron 1 of the human
ALAS2 gene based on both in vivo mice and human induced pluripotent stem
cell-derived erythroid progenitor (HiDEP) cells (Kurita et al. PLoS One 2013).
The mutation diminished the binding of transcription factor GATA-1, which would
lead to decreased transcription of the ALAS2 gene, thereby causing XLSA
(Kaneko et al. Haematologica 2014). Western blotting and quantitative chro-
matin immunoprecipitation (ChIP) analysis were performed using antibodies
against GATA-1 (D52H6, Cell Signaling Technologies) and TAL1 (C-21, Santa
Cruz). For transcription profiling, Human Oligo chip 25K (Toray) was used.
Gene ontology (GO) analysis was performed with Genecoids
(http://genecodis2.dacya.ucm.es/).
Results: We first generated a founder female mouse lacking the intron 1
enhancer region of Alas2, including the GATA binding domain (Alas2Δint1/X).
Whereas the heterozygous Alas2Δint1/X mice were viable and did not show
anemic phenotype, hemizygous deletion (Alas2Δint1/Y) in male mice led to an
embryonic lethality, suggesting that this sequence is indispensable in the con-
text of mice. As an alternate approach, we established a clonal line with HiDEP
cells, which harbored 19-bp deletion within the intron 1 enhancer region of
ALAS2, including GATA binding domain. Whereas wild-type HiDEP cells exhib-
ited red color, the XLSA clone appeared pink/pale color, which were accompa-
nied by the significantly decreased intracellular heme concentration. Despite
no obvious change in the expression of GATA-1 protein in the XLSA clone,
quantitative ChIP analysis demonstrated that the chromatin occupancies of
GATA-1 and its cofactor TAL1 were significantly abrogated by the deletion of
the GATA binding motif at intron 1 enhancer of the ALAS2 gene. Quantitative
real-time–polymerase chain reaction (RT–PCR) analysis demonstrated signif-
icant downregulation of ALAS2 as well as globin genes (HBA, HBG, and HBB)
in the XLSA clone. Microarray analysis revealed >2-fold up- and down-regula-
tion of 619 and 274 genes caused by the 19-bp deletion, respectively. The
downregulated gene ensemble included globins (HBZ, HBG, HBE, HBD, HBM,
and HBQ) as well as genes involved in iron/heme metabolism (ALAS2, trans-
ferrin receptor: TFRC, coproporphyrinogen oxidase: CPOX, and mitoferrin 1:
MFRN1). GO analysis revealed significant enrichment of cellular iron ion home-
ostasis (p=0.018), regulation of transcription (p=0.0021), and innate immune
response (p=0.0018), implying that heme was involved in various biological
processes in erythroid cells. Interestingly, ALA treatment significantly improved
compromised heme production as well as downregulation of globin genes
observed in the XLSA clone, suggesting that ALA may represent a novel ther-
apeutic option for PLP-refractory XLSA.
Summary/Conclusions: The XLSA model established from HiDEP cells can
be used as an important tool for clarifying the molecular etiology of XLSA and
to explore novel therapeutic strategies.
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BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY FOR COLD
AGGLUTININ DISEASE: RESULTS OF A PROSPECTIVE NORDIC TRIAL
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Background: Primary cold agglutinin disease (CAD) is an autoimmune
hemolytic anemia in which a well-defined clonal lymphoproliferative bone mar-
row disorder (LPD) causes production of monoclonal cold agglutinins. Major
clinical manifestations are anemia and, in most cases, cold-induced circulatory
symptoms. Pharmacological therapy, although not indicated in patients with
very mild disease, seems required in a majority of cases. Corticosteroids are
ineffective. Rituximab monotherapy has resulted in approximately 50%
response rate and 1-year median response duration. Fludarabine and rituximab
combination therapy showed 70% response rate (20% complete responses)
and very long response duration, but considerable toxicity.
Aims: We wanted to investigate whether bendamustine and rituximab combi-
nation therapy can result in favorable response rates and duration with an
acceptable toxicity profile.
Methods: We conducted a prospective, uncontrolled multicenter trial with 16
participating hospitals from Norway, Finland and Denmark. Essential inclusion
criteria were verified CAD with symptomatic anemia and/or severe cold-induced
circulatory symptoms. Eligible patients received 4 cycles of rituximab 375mg/m2
day 1 and bendamustine 90mg/m2 day 1-2 with 28 days interval. Outcomes
were classified into complete response (CR), partial responses (PR) and non-
response (NR). The definition of CR included normalization of hemoglobin (Hb)
levels with no hemolysis, complete histologic resolution of the bone marrow
LPD and disappearance of monoclonal serum protein. The criteria for PR includ-
ed increase in Hb levels by at least 2.0 g/dL or to the normal range, transfusion
independence, at least 50% reduction of IgM and improvement of any circula-
tory symptoms.
Results: Forty-four patients (19 men and 25 women) were included, with a
median age of 74 years (range, 48-86) and median disease duration 4 years
(range, 0-18). Seventeen patients had received previous therapy. At baseline,
median Hb level was 9.5g/dL (range, 4.5-14.8), bilirubin 45micromol/L, lactate
dehydrogense (LDH) 468 U/L, haptoglobin undetectable, IgM 4.1g/L (1.0-27.2),
CA titer 2048 (64-65536). Monoclonal IgM kappa was detected in 38 patients,
IgG kappa in 1 and IgA kappa in 1. We observed CR in 16 patients (36%), PR
in 15 (34%), while the remaining 13 (30%) were non-responders. Hb levels
increased by a median of 4.0g/dL in the responders; 4.4g/dL in patients achiev-
ing CR and 3.9g/dL in those achieving PR. Median post-therapy Hb levels were
14.2g/dL (CR), 12.5g/dL (PR) and 10.5g/dL (NR). Acrocyanosis and Raynaud
symptoms resolved completely in 16 patients and improved in 11 (47% and
32%, respectively, of those with such symptoms at baseline). Histologic regres-
sion of the LPD was complete in 17 patients (39%), partial in 5 (11%) and not
evaluable in 18 (41%). Median time to response was 2 months (0.5-12). Only
3 responders experienced relapse; 2 after PR and 1 after CR. Median observed
response duration was 32 months (range, 1-62) during median 32 months fol-
low-up from response, consistent with a much longer expected response dura-
tion. Neutropenia grade >3 occurred in 14 patients (32%), of which 8 (18%)
had grade 4. Three patients (7%) experienced 1-3 episodes of febrile neutrope-
nia, which was readily manageable. Non-hematologic toxicity occurred in 17
patients (39%), mostly consisting of mild nausea or rash. Three non-neutropenic
serious adverse events (SAE) were recorded; 1 was considered probably ther-
apy related.
Summary/Conclusions: Bendamustine and rituximab combination therapy
resulted in high response rates, a high rate of CR, long response duration and
few relapses during the observation period, with a favorable safety profile. It
might be considered in the first line for reasonably fit patients with CAD requiring
therapy.
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EX VIVO TREATMENT OF RED BLOOD CELLS FROM 15 PYRUVATE
KINASE (PK)-DEFICIENT PATIENTS WITH AG-348, AN ALLOSTERIC
ACTIVATOR OF PK-R, INCREASES ENZYMATIC ACTIVITY, PROTEIN
STABILITY AND ATP LEVELS.
B. van Oirschot1, P.A. Kosinski2, J. Hixon3, K. Johnson2, V. Chubukov2, L. Dang2,
G. Pasterkamp1, S. van Straaten14, C. Kung2, R. van Wijk1,*
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Utrecht, Netherlands, 2Agios Pharmaceuticals, Inc., 3KSQ Therapeutics, Cam-
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Background: Pyruvate kinase (PK) deficiency is a rare hereditary disorder
affecting red blood cell (RBC) glycolysis. It is caused by mutations in the PKLR
gene. PK-deficient RBCs are characterized by changes in metabolism associ-
ated with defective glycolysis, including a build-up of the upstream metabolite
2,3-disphosphoglycerate, and deficiency in the PK product ATP. It is hypothe-
sized that insufficient energy production affects red cell homeostasis, promoting
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premature removal of PK-deficient RBCs from the circulation. Affected patients
display chronic hemolytic anemia of variable severity. Treatment of PK-deficient
patients is generally supportive, focusing on the anemia and iron overload
state, and there are no approved drugs that directly target mutated PK. AG-
348 is an allosteric activator of the RBC isoform of PK (PK-R) and in clinical
development for the treatment of PK deficiency
Aims: To evaluate the ex vivo effect of AG-348 treatment on PK-R enzymatic
function, RBC metabolism and deformability
Methods: Observational case-control study, approved by the Institutional
Review Board. All patients gave informed consent. Enrolled patients (N=15)
were adults, transfusion-independent and compound heterozygous or homozy-
gous for mutations in PKLR. Baseline metabolic profiling was performed by
LC-MS/MS. Purified RBCs from patients and healthy control subjects were
incubated with AG-348 (up to 10 μM) for 24 hours at 37°C. After 6 and 24 hours
PK-R activity, ATP levels and RBC deformability (by Lorrca) were measured.
For determination of PK-R thermal stability, RBC lysates were incubated for 2
hours with 2 μM AG-348 (37°C) prior to testing. Baseline protein levels of PK-
R were assessed using antibodies against PK-R
Results: Baseline patient characteristics show strongly reduced PK-R activity
in all patient cells, in particular taking into account the degree of reticulocytosis
(Table 1). Distinct metabolic changes were consistent with a block of glycolysis
at the PK-R step. Treatment of PK-deficient RBCs with AG-348 resulted in
increased enzymatic activity in all patient cells after 24 hours (mean increase
1.8-fold, range, 1.2-3.4). Similar increases were observed in control cells (mean
fold increase 2.3, range, 1.2-7.1). ATP levels in PK-deficient cells increased
upon AG-348 treatment (mean increase 1.5-fold, range: 1.0-2.2) similar to con-
trol cells (mean increase 1.6 fold, range, 1.4-1.8). Generally, PK-R thermal sta-
bility was strongly reduced in PK-deficient patient cells, illustrated by a mean
loss of activity of 72% (19% for control cells) after incubation at 53 °C for 60
minutes. Ex vivo treatment with AG-348 prior to incubation resulted in residual
activity 1.4 to >10-fold higher than residual activity of vehicle-treated samples.
Baseline protein level analyses suggests that a certain level of PK-R protein is
required for cells to respond to AG-348 treatment ex-vivo, as treatment effects
were minimal in patient cells with very low or undetectable levels of PK-R. In
approximately half of the patients, ex vivo treatment with AG-348 was associ-
ated with an increase in RBC deformability, although there doesn’t appear to
be a clear correlation with enzymatic or metabolic response.
Table 1.
Summary/Conclusions: These data support the hypothesis that drug inter-
vention with AG-348 effectively upregulates PK-R enzymatic activity and
increases stability in PK-deficient RBCs over a broad range of PKLR genotypes.
The concomitant increase in ATP levels suggests that glycolytic pathway activity
may be restored. AG-348 treatment may represent an attractive way to correct
the underlying pathologies of PK deficiency
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IDENTIFICATION OF NEW PATHOGENIC MUTATIONS IN PATIENTS WITH
RED BLOOD CELL MEMBRANE DISORDERS USING NEXT-GENERATION
SEQUENCING
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Background: Red blood cell (RBC) membrane proteins deficiency or structural
alterations lead to RBC membrane disorders such as hereditary spherocytosis,
hereditary elliptocytosis or hereditary xerocytosis among others. Genetic analy-
sis of these patients was not usually performed before next-generation
sequencing due to the laborious task it consisted to sequence by Sanger the
several membrane related genes, considering that they all contain a high num-
ber of coding regions. 
Aims: The aim of this study is to perform the molecular diagnosis of the patients
included in the study as well as to identify new pathogenic mutations leading
to RBC membrane disorders.
Methods: 116 patients from 74 unrelated families were studied with a next
generation sequencing (NGS) based panel that contained genes already
described as disease causing for RBC membrane disorders (ANK1, EPB41,
EPB42, SLC4A1, SPTA1, SPTB, PIEZO1, KCNN4, RHAG) as well as for enzy-
mopathies (ADA, AK1, ALDOA, BPGM, CYB5A, G6PD, GCLC, GPI, GSR,
GSS, HK1, NT5C3A, PFKM, PGK1, PKLR, TPI1), hemoglobinopathies (HBA1,
HBA2, HBB) and congenital diseritrhopoietic anaemias (CDAN1, C15orf41,
SEC23B, KLF1, GATA1, KIF23). The patients analysed were oriented as hered-
itary spherocytosis (63 patients), hereditary elliptocytosis or piropoikilocytosis
(8 patients) and hereditary xerocytosis (3 patients). There were also 42 patients
were the combination of phenotypic laboratory results was suggestive of mem-
branopathy but it didn’t suggest any specific RBC membrane pathology.
Results: A total of 74 pathogenic variants leading to RBC membrane disorders
were identified, of which 14 had already been reported as disease causing. Of
the remaining 60 variants, 42 had never been identified neither by 1000G or
ExAC projects and therefore are novel mutations. Beta-spectrin, ankyrin and
alpha-spectrin were the proteins that gathered most part of the mutations, we
identified 23 variants in SPTB, 20 variants in ANK1 and 16 variants in SPTA.
48% (36/74) of the identified variants were missense changes, mostly from
SPTB gene (11 variants), while a 38% (28/74) of the variants were nonsense
changes or frame shifting mutations, mostly from ANK1 (12 variants) and SPTB
(9 variants). Of special interest, only 2 variants were identified in more than
one unrelated family: 1) SPTB c.647G>A, leading to spherocytosis, was iden-
tified in 8 patients of 2 unrelated families, 2) SPTA1 c460_462dupTTG, leading
to ellyptocytosis, was identified in 6 patients from 5 different unrelated families.
Finally, with the NGS panel results, the genetic diagnosis of 89% (103/116) of
the included patients could be determined and only in 11% (13/116) the muta-
tion was not identified or the variant correlation with disease was not clear. It
is worthy to highlight that 10 of the 13 undiagnosed patients had been oriented
as unclear membranopathy. 
Summary/Conclusions: According to the results, there is a high genetic het-
erogeneity in patients with RBC membrane disorders, as almost each family
carries a unique mutation that is not observed in any other no related family.
The present study reveals the usefulness of NGS panel, which allows the
molecular diagnosis of almost the 90% of the patients and it would avoid mis-
diagnosis that could lead to splenectomy in contraindicated cases such as in
hereditary xerocytosis. Moreover, the 11% of undiagnosed patients will be ana-
lyzed through a second NGS gene panel including potential new genes leading
to chronic haemolysis and/or sequenced by whole exome sequencing with the
aim to identify new disease causing genes.
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ANEMIA: PROGNOSTIC IMPACT OF HEMOGLOBIN LEVELS, AUTOANTIBODY
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Background: Autoimmune hemolytic anemia (AIHA) is greatly heterogeneous,
from mild/compensated to life-threatening, due to autoantibody class/thermal
amplitude, efficiency in activating complement, activity of the reticuloendothelial
system, and efficacy of bone marrow compensatory response.
Aims: Here we analysed predictors of first relapse, complications, and fatality
in a large AIHA series.
Methods: We retrospectively studied 378 patients (135m and 243 F, median
age 61 yrs, range 19-100) from 10 sites, followed-up for 4.3 yrs (range 0.5-
27). Patients were classified in warm (w)AIHA (DAT positive for IgG and IgG+C),
cold agglutinin disease, CAD (C), mixed (IgG+C with high titer cold agglutinins)
and atypical (DAT-, IgA+, wIgM). Cases were also grouped in very severe
(Hb<6 g/dl), severe (Hb 6-8 g/dl), moderate (Hb 8-10 g/dl) and mild (Hb>10
g/dl). LDH was expressed as fold increase upper the limit of normality (ULN),
and reticulocytes as absolute count and reticulocyte index. The following ther-
apy lines were considered a) steroids +/-IvIg, b) rituximab c) splenectomy, d)
immunosuppressive drugs (azathioprine, cyclophosphamyde, cyclosporin), and
e) transfusions, plasma exchange, erythropoietin.
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Results: Table 1 shows clinical and laboratory characteristics of AIHA cases at
onset and distribution of thermal types. Hb values were significantly lower in
IgG+C wAIHA and atypical cases (p<0.001), LDH higher in IgG+C wAIHA,
mixed and atypical forms (p=0.01), and Hb and LDH values were negatively
correlated (r= -0.25, p<0.001). Absolute reticulocytes were reduced in CAD,
mixed and IgG+C wAIHA (p<0.001) together with inadequate reticulocytosis
(p=0.01). Moreover, the reticulocyte index was lower in cases with Hb<6 g/dL
(65 vs 98, p<0.001), along with more frequent inadequate reticulocytosis (87
vs 70%, p=0.01). First line therapy was administered in almost all cases but 25
CAD. A second therapy line was mostly required in IgG+C wAIHA, mixed, and
to a lesser extent in CAD (p=0.005). The ultra-refractory cases requiring 4 or
more lines of therapy were mainly mixed, atypical and CAD. Considering ane-
mia severity, patients with Hb<8 g/dL more frequently required treatment after
first-line (51 vs 33%, p=0.004; p=0.03), or even 3 or more therapy lines (52/71,
73% vs 19/71, 26%, p<0.001). The following hazard ratios (HR) emerged from
multivariate Cox regression analysis: HR 3.2 (95% CI 1.4-7), 2.9 (1.4-6.2), 3.4
(1.6-7.5), for Hb <6, 6-8, and 8-10 g/dL compared to patients with Hb >10,
respectivelyAs regards complications, infections were observed in 14% of cas-
es, mostly mixed AIHA (p=0.02); thrombosis occurred in 10% and acute renal
failure in 3% of patients, with no relationship with AIHA type/Hb values. Evans’
syndrome was more frequent in mixed or atypical cases (p=0.04) and in severe
forms (74% with Hb<8 g/dL vs 26%, p=0.005), and was associated with higher
relapse risk (HR 2.3, 95% CI 1.4-3.9). Seventy patients died during the follow-
up, and 12 because of AIHA-related acute complications. Higher mortality was
observed for infections (HR 5.8, 95% CI), acute renal failure (HR 7.6, 95% CI)
and Evans’ syndrome (HR 8.3, 95% CI).
Table 1.
Summary/Conclusions: In conclusion, we found that severity of anemia at
onset was the major determinant of relapse risk. The lowest Hb levels were
observed in patients with IgG+C WAIHA and atypical cases along with higher
LDH levels and inadequate reticulocytosis, advising strict clinical observation
in these patients.
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HEME BINDS ANNEXIN-A5 DURING HEMOLYSIS AND PREVENTS ITS
INTERACTION WITH CELL MEMBRANE PHOSPHATIDYLSERINE DURING
SICKLE CELL DISEASE
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Background: Intravascular hemolysis, such as in sickle cell disease (SCD), is
characterized by red blood cell damage, high levels of cell-free heme and extra-
cellular vesicles in plasma, along with inflammation and tissue injury. Stressed
leukocytes, platelets, endothelial and red blood cells shed microparticles (MP)
that bear externalized phosphatidylserine (PS) at their surface and promote
tissue injury. Conversely, intracellular annexin-A5 acts as an inhibitor of exter-
nalized PS at the surface of cells and MP. Annexin-A5 is thought to orchestrate
vesicle trafficking, promote cell membrane repair, protect against PS-mediated
effects and enforce anti-inflammatory and anti-thrombotic control.
Aims: We investigated a possible functional relationship between intravascular
hemolysis and annexins. We hypothesized that annexins, and annexin-A5 activ-
ity in particular, is blocked by extracellular heme as it is released in plasma
during intravascular hemolysis.
Methods: In order to test the heme-annexin-A5 relationship, we measured PS-
, PS+, CD235a+ and annexin-A5+ circulating MP in adult SCD patient and
matched control plasmas. We explored annexin-A5 expression in plasma and
blood cells by Western blots and ELISA, and also quantified the PS-binding
functionality of plasma annexin-A5 using a self-designed immunocapture assay
and purified PS+ MP. Moreover, we investigated molecular interactions between
purified heme and recombinant human annexin-A5 by surface plasmon reso-
nance (BiaCore and Proteon), absorbance shift assay and protein autofluores-
cence quenching. Finally, we put forward a model of heme-annexin-A5 docking
by 3D molecular rendering. 
Results: Immunocapture of plasma annexin-A5 revealed an association with
heme (Abs398 nm signature) during SCD, especially during acute hemolytic
events. In SCD plasma, we found increased total annexin-A5, but virtually unde-
tectable levels of functional annexin-A5, contrary to controls. This implied a
greatly reduced ratio of functional annexin-A5/circulating PS+ MP. Moreover,
purified heme bound readily to annexin-A5 with relatively high affinity in vitro, as
demonstrated using absorbance shift, autofluorescence quenching and plasmon
surface resonance assays, with human serum albumin and hemopexin in com-
petition tests. Annexin-A5 autofluorescence was partly quenched by heme addi-
tion, which also produced a significant red-shift in heme absorbance wave-
lengths, implying that a tight and direct molecular interaction was possible.
Hemoglobin and heme also triggered annexin-A5 aggregation in vitro, producing
high molecular weight and heat-resistant multimers, observed by western blot.
Surface plasmon resonance studies revealed that annexin-A5 contains several
sites for heme binding, some with very low affinity, while others are estimated
with a Kd in the 10-6m range, rather similar to that of albumin. Part of the heme
bound to annexin-A5 remained in place, even in the subsequent addition of the
high-affinity heme-scavenger hemopexin. 3D molecular docking rendering sug-
gested that heme may bind to the PS-binding groove of annexin-A5, thereby
preventing further interactions with PS. Finally, heme completely prevented the
binding of exogenous annexin-A5 to purified PS+ MP and plasma MP, as well
as their subsequent detection by flow cytometry.
Summary/Conclusions: Together, our data suggest that PS-neutralizing
annexin-A5 is inhibited by cell-free heme. This heme-mediated inhibition of
annexin-A5 may display physiopathological relevance, contribute to the accu-
mulation of PS+ MP in plasma during intravascular hemolysis, and more specif-
ically of RBC MP during SCD which can participate to the degradation of the
vascular function.
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USE OF PEGYLATED-CARBOXYHEMOGLOBIN BOVINE FOR THE TREATMENT
OF SICKLE CELL DISEASE ASSOCIATED LEG ULCERS: RESULTS FROM
A PHASE 2 SAFETY STUDY
J. Valentino1, H. Misra1,*, L. Lopez2, G.M. Paulino3
1Prolong Pharmaceuticals, Prolong Pharmaceuticals, South Plainfield, United
States, 2Hematology, Centro Hemato-Oncológico Paitilla, Royal Center, Pana-
ma, 3Hematology, Hospital General Plaza de la Salud, Santo Domingo, Domini-
can Republic
Background: Leg ulcers are a common complication of sickle cell disease
(SCD). The pathophysiology of SCD leg ulcer is complex and may include
obstruction of blood vessels by sickled red cell, chronic anemia, depleted nitric
oxide bioavailability (resulting in impaired endothelial function), infection, throm-
bosis and excessive vasoconstriction. These events lead to progressive periph-
eral de-vascularization and tissue necrosis, such that even minor lower-leg
wounds can become persistent ulcers, with no tendency to heal after months
of appropriate treatment. PEGylated-Carboxyhemoglobin bovine (PEG-COHb;
SANGUINATE) is an oxygen carrying agent with anti-inflammatory activity. A
study of safety and effectiveness was undertaken in SCD patients with chronic
leg ulcers to determine the safety of this investigational drug administered in
as a once weekly infusion for either 4 or 6 weeks. 
Aims: To assess the safety and efficacy of repeated doses of PEG-COHb on
SCD leg ulcers.
Methods: The study was an escalating, repeated-dose, open-label, Phase 2
study to test PEG-COHb at 320mg/kg (8 mL) in subjects suffering from leg
ulceration associated with SCD. It was conducted in Panama and the Domini-
can Republic. All enrolled subjects underwent a 3-week Run-In Period, during
which they received standard of care treatment for wound management. During
the Treatment Period, subjects were assigned sequentially to Cohort 1 or Cohort
2. Cohort 1 received 4 once-weekly doses by 2-hour intravenous infusion of
SANGUINATE. Following the completion of Cohort 1, the safety findings were
reviewed prior to initiating Cohort 2. Cohort 2 received 6 once-weekly infusions.
In addition to the study drug, subjects continued to receive standard of care
during the Treatment Period. One week after the end of Treatment, subjects
returned to the study center for a Final Visit. The following assessments were
done: safety: Safety was assessed by recorded adverse events (AEs), labora-
tory assessments (hematology, chemistry, and urinalysis), vital signs, concomi-
tant medications, and 12-lead electrocardiograms (ECGs), efficacy: Wound
pain, wound appearance and condition, wound size, wound vascular status
(Venous Clinical Severity Score; VSCC), quality of Life: Quality of life was
assessed using the Short Form-12 v2 Health Survey (SF-12).
Results: The administration of once-weekly infusions of PEG-COHb was well
tolerated. Treatment emergent adverse events (mild pyrexia, moderate wors-
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ening anemia) considered related to study drug were report in 2/10 patients.
Increases in mean arterial pressure were anticipated due to the oncotic effects
of this colloidal drug, but with no consistent pattern to the changes. Changes
in ECG intervals were seen in a few subjects, but those changes were not con-
sidered clinically meaningful. There were no clinically meaningful changes in
laboratory values, physical examinations, or concomitant medications. There
were no statistically significant changes from Baseline in leg ulcer pain and
wound surface area for either Cohort. All of the wound assessments remained
relatively consistent throughout the study. There were slight decreases in total
VCSS at most time points, indicating slight improvement in vascular status.
Results were similar for the individual scores.
Summary/Conclusions: The administration of 4 or 6 once-weekly infusions
of PEG-COHb at a dose of 320mg/kg was generally well tolerated. Slight
improvements in total and individual VCSS are promising and may warrant fur-
ther study with prolonged repeated doses of PEG-COHb. 
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NON-RENAL DETERMINANTS OF ENDOGENOUS ERYTHROPOIETIN
LEVELS IN SICKLE CELL DISEASE
K. Gardner1,2,*, C. Sharpe3,4, M. Awogbade1
1Haematological Medicine, King’s College Hospital, 2Molecular Haematology,
King’s College London, 3Renal Medicine, King’s College Hospital, 4Renal Med-
icine, King’s College London, London, United Kingdom
Background: Sickle cell disease (SCD) is characterized by chronic hemolysis
and inflammation. Elevated levels of erythropoietin (EPO) drive expansion of
erythropoiesis to compensate for increased red cell destruction. EPO is pro-
duced in response to anemia and tissue hypoxia. Previous studies in SCD
suggest that EPO is inappropriately low for the degree of anemia but the rea-
sons are unclear.
Aims: To perform a retrospective analysis of data collected as part of routine
clinical care to examine the relationship between serum EPO and degree of
anemia, HbF levels, oxygenation status, hemolytic rate, alpha globin status,
inflammation, serum ferritin and renal function. 
Methods: King’s College Hospital (London, UK) has a large SCD population.
All patients with HbSS or HbSβ0 thalassemia who had a serum EPO level
measured between 2007 and 2013 were included. Sickle genotype, alpha
genotype, “baseline” HbF (no hydroxycarbamide, transfusion or pregnancy)
and demographic data were recorded. Other clinical variables were obtained
from the same day as EPO levels (medications, laboratory values and oxygen
saturation). Serum EPO was measured by chemiluminescence immunoassay
(Siemens Immulite XPi). Exclusion criteria were: active vaso-occlusive crisis,
transfusion within 8 weeks, chelation, erythropoiesis stimulating agent therapy,
home oxygen, pregnancy and renal disease (eGFR<60mls/min or urine albumin
creatinine ratio>30). Data analysis was performed in IBM SPSS Statistics 22.
Skewed variables were log transformed and estimated GFR was calculated
using the MDRD formula. Normalized variables were correlated with Ln EPO
using Pearson’s correlation, ordinal variables using one way ANOVA, and bina-
ry variables using independent samples 2-tailed t-test. Multivariate linear
regression using Ln EPO as the outcome was performed.
Results: 245 adult (≥17 years) SCD patients (all of African or African-Caribbean
origin) met the inclusion criteria. Of the 245, 241 had HbSS and 4 HbSβ0, 100
were male and 145 female, and mean age was 31.2 +/- 11.6 years. 221 had
known alpha globin status: 21 α-/α-, 81 αα/α-, 118 αα/αα, 1 αα/ααα. Univariate
analysis revealed a weak/moderate negative association between Ln EPO and
Hb (r=-0.383, p<0.001). Significant associations were also seen between Ln
EPO and: negative correlation with PCV, oxygen saturations, Ln HbF; and pos-
itive correlation with Ln CRP, LDH, STFR, Ln uACR, cystatin C. One way ANO-
VA showed alpha globin status to be associated with EPO (higher EPO with
more alpha chains). There was no significant association between EPO and:
age, sex, eGFR, white cell count, and use of hydroxycarbamide. Multivariate
linear regression (N=175) revealed alpha globin status, Hb, CRP and HbF
remained independently associated with Ln EPO level, see table.
Table 1. Multivariate analysis of EPO.
where alpha= 0 if aa/aa; 1 if aa/a-; 2 a-/a-
Summary/Conclusions: In our SCD cohort without renal dysfunction EPO
was elevated. Unlike the non-sickle setting where Ln EPO is very strongly
(negatively) correlated with Hb levels, in our SCD cohort we have found only
a mild/moderate correlation. Instead, additional associations were seen
between EPO and alpha globin status, CRP and HbF. Our findings suggest
that in addition to Hb, other SCD severity markers influence EPO production.
This may provide explanation for relative EPO deficiency, and have implications
for considering therapeutic EPO in SCD.
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THE PHARMACOKINETICS (PK) OF GBT440 ARE SIMILAR IN
ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE (SCD)
C. Washington1,*, R. Savic2, A. Inati3, J. Estepp4, G. Woods5, E. Fong1,
A. Hutchaleelaha1, M. Tonda1, G. Balaratnam1, J. Lehrer-Graiwer1
1Global Blood Therapeutics, South San Francisco, 2University of California,
San Francisco, United States, 3Rafic Hariri University Hospital, Beirut, Lebanon,
4St. Jude Children’s Research Hospital, Memphis, 5Children’s Mercy Hospital,
Kansas City, United States
Background: Sickle cell disease (SCD) is caused by polymerization of Hemo-
globin S (HbS), resulting in hemolysis and vaso-occlusion. Currently, no therapy
achieving pancellular, direct inhibition of HbS polymerization is available for
adults or children with SCD. GBT440 is a novel small molecular inhibitor which
increases hemoglobin oxygen affinity, thereby preventing HbS polymerization
and red blood cell sickling. This study represents the first evaluation of GBT440
in a pediatric population.
Aims: This study was designed to evaluate the safety and PK of GBT440 fol-
lowing a single and multiple doses in adolescents. In addition a population PK
(PPK) model, based on data derived following single doses of GBT440, was
developed to support the identification of future GBT440 dosing regimens for
pediatric populations with SCD.
Methods: This is an ongoing, open-label, Phase 2a study in adolescents (12
to 17 years) with SCD (HbSS or HbS β0thalassemia). Participants were enrolled
after obtaining written informed consent/assent. This study is being conducted
in 2 parts: Part A, single-dose, and Part B, multiple-dose for 24 weeks. The pri-
mary objective of Part A is PK and the primary objectives of Part B are safety
and efficacy. PK samples to measure whole blood and plasma GBT440 con-
centrations were collected up to 15 days following single dose administration.
Separate PPK models were developed to describe the concentration versus
time profiles of GBT440 in whole blood and plasma using non-linear mixed
effects modeling (NONMEM, version 7.3). The allometrically scaled adolescent
PPK model was also used to estimate the appropriate single dose for subse-
quent evaluation in pediatric participants (6 to 12 years).
Results: Part A has been completed; 7 adolescents (3 males/4 females)
received a single dose of GBT440 600mg. The median age of participants was
16 years (range 14 to 16 years) and the mean weight was 52.8 kg (range 44.6
to 65.8kg). GBT440 was well tolerated; there were no drug-related ≥Grade 3
adverse events (AE) or serious adverse events and the most common AE was
Grade 1 nausea. A 2-compartment model with first order absorption best
described the PK of GBT440 and is the same model structure as previously
used for adults with SCD. GBT440 PK parameters (Table 1) are comparable
to those derived in adults, suggesting that GBT440 PK in adolescents and
adults are similar. Model validation confirmed this result with good agreement
between the observed adolescent PK data and simulated profiles based on
the adult GBT440 PK model.
Table 1.
Summary/Conclusions: This is the first study used to develop a GBT440 PPK
model in adolescent participants with SCD. Data suggests that similar GBT440
doses can be used in adolescents and adults. Part B has been initiated to eval-
uate multiple doses of GBT440 in adolescents. This PPK model can potentially
be used to estimate individual PK parameters (e.g., AUC) to support future
GBT440 dose selection for evaluation in the pediatric population.
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DEVELOPMENT OF TAX-REDIRECTED T-CELL IMMUNOTHERAPY FOR
ADULT T CELL LEUKEMIA
K. Kawamura1,*, Y. Tanaka1,2, Y. Ishihara1, H. Nakasone1, S. Kako1, S. Kobayashi2,
T. Ohmori3, K. Uchimaru4, S. Okamoto5, J. Mineno5, H. Shiku6, S. Nishimura7,
Y. Kanda18
1Division of Hematology, Saitama Medical Center, Jichi Medical University,
Saitama, 2Division of Molecular Therapy, Institute of Medical Science, The Uni-
versity of Tokyo, Tokyo, 3Department of Biochemistry, Jichi Medical University,
Tochigi, 4Department of Computational Biology and Medical Sciences, Gradu-
ate School of Frontier Sciences, The University of Tokyo, Tokyo, 5Center for
Cell and Gene Therapy, Takara Bio Inc, Shiga, 6Department for Immuno-Gene
Therapy, Mie University Graduate School of Medicine, Mie, 7Center for Molec-
ular Medicine, 8Division of Hematology, Department of Medicine, Jichi Medical
University, Tochigi, Japan
Background: Adult T cell leukemia/lymphoma (ATL) is an aggressive peripheral
T-cell neoplasm caused by HTLV-1 virus infection and its prognosis remains
very poor. Tax, which is the most important regulatory protein of HTLV-1, is
associated with aggressive proliferation of host cells and is also a major target
antigen for CD8+ cytotoxic T-cells (CTLs). We previously analyzed the Tax-
specific T-cell receptor (TCR) repertoire, phenotypes and functions of Tax-spe-
cific CTLs at the single-cell levels in HLA-A24+ ATL patients who underwent
allogeneic stem cell transplantation (allo-SCT). We found that a particular amino
acid sequence motif (PDR) in the CDR3 region of TCR-ß was conserved in dif-
ferent patients and also within the same patient before and after allo-SCT, and
the PDR(+) Tax-specific CTL clone selectively expanded in ATL long-term sur-
vivors as less-differentiated effector memory CTLs. Actually, the PDR(+) CTL
showed not only strong binding activity for the Tax-tetramer but also strong
killing activity against patients’ HTLV-1-infected T-cells without any reaction
against normal cells.
Aims: Currently, we are planning a redirected T-cell immunotherapy using the
PDR(+) TCR genes for ATL. Therefore, we prepared donor-derived PDR(+)
TCR-transduced T-cells and evaluated their cytotoxic efficiency against HTLV-
1-infected T-cells and ATL-cells both in vitro and in vivo mouse model.
Methods: HLA-A24:02 restricted and Tax301-309-specific TCR-ɑ/β genes were
cloned from an established PDR(+) CTL clone and integrated into a retroviral
siTCR vector (Tax-siTCR vector) encoding small-interfering RNAs (siRNAs) to
knockdown endogenous TCR genes for the efficient expression of therapeutic
TCRs. Then, CD8+ T-cells of healthy volunteers were transfected with Tax-siT-
CR vector (Tax-siCTLs). First, cytotoxicity and cytokine production capability
of the Tax-siCTLs against HTLV-1 infected T-cells or ATL-cells were evaluated
using calcein-AM-based assay and flow-cytometric analysis, respectively. Next,
to evaluate the in vivo anti-ATL effects by the Tax-siCTLs, the bioluminescence
assay (in vivo imaging system) was performed. We generated a luciferase-
gene transduced HLA-A24+HTLV-1 infected cell-line, MT-2 (Luc-MT-2), and
injected 1×106Luc-MT-2 cells into six-week-old NOD/Shi-scid,IL-2RγKO Jic
(NOG) mice intraperitoneally. After the 3 weeks, 2×106Tax-siCTLs were admin-
istered via the tail vain weekly, for a total of 3 times. For comparison, non-inte-
grated T-cells (Mock) were administered in the same way. These mice were
monitored for tumor growth using IVIS system weekly.
Results: Tax-siCTLs showed specific and strong killing activity against both
HTLV-1 infected T-cells and patients’ ATL-cells without any reaction against
control normal-cells. In addition, Tax-siCTLs produced a sufficient amount of
cytokines such as IFN-γ, TNF-ɑ, and IL-2 against HTLV-1 infected T-cells. In
mice experiments, the bioluminescence of Luc-MT-2 in the mice treated with
Tax-siCTLs had started to reduce gradually after 7 weeks, and finally became
undetectable after 9 weeks. In addition, macroscopic anatomical findings in the
treated mice were normal after 12 weeks. In contrast, the amount of biolumi-
nescence in the mice treated with Mock or in the control mice without treatment
had rapidly increased and all mice died by 9 weeks.
Summary/Conclusions: We confirmed that Tax-siCTLs could exert a strong
anti-ATL effect without significant reaction against normal cells both in vitro and
in vivo. The therapy using this PDR+ Tax-siCTLs has a potential to be a novel




NHEJ-BASED GENE EDITING: A NOVEL GENE THERAPY APPROACH IN
FANCONI ANEMIA HEMATOPOIETIC STEM AND PROGENITOR CELLS
F.J. Roman-Rodriguez1,2,*, B. Diez1,2, L. Alvarez1,2, C. Risueño1,2, R. Torres-Ruiz3,
M. Corton2, C. Diaz de Heredia4, J. Sevilla5, C. Ayuso2, J. Bueren1,2, P. Rio1,2
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2Advanced Therapies Unit, IIS-Fundacion Jimenez Diaz (IIS-FJD, UAM), 3Mol-
ecular Cytogenetics Group, Human Cancer Genetics Program, Centro Nacional
de Investigaciones Oncologicas, Madrid, 4Department of Haematology and
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Pediatrica, Hospital del Niño Jesus, Madrid, Spain
Background: Allogenic transplantation of hematopoietic stem and progenitor
cells (HSPCs) is the only current curative treatment for the bone marrow failure
of patients with Fanconi Anemia (FA). However, the risks of GVHD and increased
incidence of subsequent cancer, and the limited availability of matched donors
hamper the application of this therapy in FA patients. For this reason correction
of patients’ HSPCs by gene therapy is considered a promising therapeutic alter-
native for these patients. In this context, gene editing constitutes a new step in
the development of safe gene therapy approaches. Since non-homologous end
joining (NHEJ) is the preferred DNA repair mechanism in HSPCs, and given
that this mechanism has been reported to be enhanced in FA cells, we have
tested the efficiency of a NHEJ-mediated gene editing approach to generate
compensatory mutations that can restore the FANCA protein function in HSPCs
from FA patients, mimicking reversions observed in mosaic patients.
Aims: To demonstrate the feasibility of using a NHEJ-based gene editing strat-
egy to correct FA-A HSPCs as a result of the insertions and deletions (INDELs)
generated in edited FANCA sequences in these cells.
Methods: Two different FANCA mutations from FA-A patient-derived lym-
phoblastic cell lines (LCLs) and primary HSPCs were targeted by the
CRISPR/Cas9 system. INDELs generated as a consequence of the NHEJ
repair were analyzed at different time points.
Results: Initial studies conducted in a FA-A LCLs carrying the biallelic c.295C>T
point mutation that generates a premature stop codon (p.Q99X) showed tar-
geting efficiencies around 20%. Next Generation Sequencing (NGS) not only
revealed the generation of frame-restoring repair events, but also that these
corrective NHEJ events conferred a marked in vitro proliferative advantage to
the edited cells. Moreover reversion of the characteristic MMC hypersensitivity
and restoration of the FANCD2 foci formation were observed in these cells. In
addition, western-blot analysis confirmed the stable expression of FANCA pro-
tein. To further demonstrate the feasibility of the approach, a second FANCA
associated mutation was targeted (c.3558insG, producing a frameshift and a
premature stop codon -p.R1187EfsX28-) with even higher gene targeting effi-
ciencies. Finally similar studies were conducted in three HSPCs samples from
FA-A patients harboring the c.295C>T mutation, that showed targeting efficacies
up to 36%. Moreover, NGS detected the presence of corrective NHEJ-repair
events immediately after editing and evidenced up to 50-fold expansion of cor-
rected cells after nine days in culture, confirming the functionality and prolifer-
ative advantage conferred by the frame restored alleles.
Summary/Conclusions: Our results demonstrate for the first time that NHEJ
gene correction is feasible in FA HSPCs. The high efficacy of the NHEJ repair
pathway in HSPCs together with the simplicity of the strategy, make this
approach clinically relevant for the future treatment of the hematopoietic defects
in FA patients.
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NOVEL, ENHANCED AND DUAL TARGETING CAR INVARIANT NKT
CELL-BASED IMMUNOTHERAPY FOR CD1D+ B CELL MALIGNANCIES
A. Rotolo1,*, O. Dubois1, K. Goudevenou1, K. Petevi1, G.W. Cheung2, M. Pule2,
J. Maher3, A. Karadimitris1
1Medicine, Imperial College London, London, UK, 2University College London,
3King’s College London, London, United Kingdom
Background: Anti-CD19 chimeric antigen receptor T cell (CART19)
immunotherapy has shown promising clinical potential in relapsed/refractory
mature B cell malignancies. However, only about half of patients benefit, high-
lighting the need for more effective CAR-based strategies. iNKT cells are rare
but powerful immunoregulatory and cytotoxic T lymphocytes, playing a pivotal
anti-tumor role. iNKT cells are restricted by CD1d, a non-polymorphic, phos-
pho-/glycol-lipid-presenting HLA I-like molecule. We previously showed that
CD1d, as well as on normal B cells, is also expressed on malignant CD19+ B
cells in mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and
chronic lymphocytic leukaemia (CLL).
Aims: We tested the hypothesis that bi-specific CARiNKT19 cells, targeting
simultaneously CD19 and CD1d via the CD19-specific CAR and their natural
invariant TCR respectively, would be more effective than CART19 cells against
CD19+CD1d+ B cell malignancies.
Methods: We optimized a novel protocol for manufacturing 2nd (CAR2) and
3rd (CAR3) iNKT cells expressing CAR19. Their in vitro reactivity was assessed
in cytotoxicity (flow cytometry-based) and cytokine and cytotoxic granule
release assays (intracellular staining and Luminex technology). in vivo reactivity
was assessed in NSG xenograft assays, with monitoring of C1RCD1d tumour
cell growth by bioluminescence imaging.
Results: Our optimised protocol for selection, lentiviral transduction and clinical
scale expansion of CARiNKT cells within 3 weeks is suitable for frozen and
fresh lymphocytes, derived from either healthy donors or cancer, including lym-
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phoma patients. The manufacturing process consistently allows high CAR
transduction efficiency of iNKT and T cells (75.31%±4.294 and 76.95%±14.76
respectively, n=8) and ensures the preservation of CD4− iNKT cells, which
have been associated with a higher cytotoxic potential and anti-tumour activity.
In vitro validation, using singly- or dual-positive CD1d and CD19 targets,
demonstrated that CARiNKT19 cells are CD19-specific, retain their natural
CD1d-restricted reactivity, and exert additive dual-specific cytotoxicity against
CD1d+CD19+ targets. Additional functional dissection showed that activated
CARiNKT19 cells, both fresh and cryopreserved, have the ability to produce
cytotoxic granules and IFNγ faster and in larger amounts than same donor
activated CART19 cells. Likewise, CAR2- and CAR3-iNKT cells are equally or
more effective than their CART counterparts in killing CD19+CD1d+ lymphoid
cell lines (B-lymphoblastoid C1RCD1d and lymphoma-derived Farage cells)
and consistently more effective against primary MCL, MZL and CLL cells. Final-
ly, in an in vivo NSG xenograft model of lymphoma, while survival of T- and
NKT cell-treated animals was the same as that of untreated animals (P=0.23),
both CART19 and CARiNKT19 cell-treated animals had significantly and com-
parably improved overall survival (P<0.001). However, compared to CART19,
CARiNKT19 immunotherapy led to a better disease control, with earlier, more
profound and sustained responses resulting in a significantly improved tumour
free-survival (P=0.03).
Summary/Conclusions: In our pre-clinical in vitro and in vivo lymphoma mod-
els, CARiNKT19 are more effective than CART19 cells against CD19+CD1d+
B cell malignancies. Further, dual targeting by CARiNKT19 cells may mitigate
against CD19-focused tumour escape after CAR immunotherapy, while the
previously demonstrated role of donor iNKT cells in protection from aGVHD
supports the development of CARNKT19 cells for ‘off-the-shelf’ use.
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A NOVEL CHIMERIC ANTIGEN RECEPTOR ENDOWS T CELLS WITH NK
CELL-LIKE SPECIFICITY AND ATTACKS A WIDE RANGE OF
HEMATOLOGICAL MALIGNANCIES AND CANCERS
Y. Kasahara1,*, C. Shin1, M. Imamura1, N. Kubo1, T. Takachi1, H. Iwabuchi1,
S. Yoshida1, A. Saitoh1, C. Imai1
1Department of Pediatrics, Niigata University Graduate School of Medical and
Dental Sciences, Niigata, Japan
Background: Engineered T-cells expressing CD19-specific chimeric antigen
receptors (CARs) have shown high response rates against relapsed and refrac-
tory B cell acute lymphoid leukemia (ALL). However, similar success has not
yet been demonstrated in solid tumors, and the reasons for this are currently
being investigated. One major obstacle is the difficulty in determining appro-
priate surface antigens that are effectively targeted by CAR-transduced immune
cells. NKp44 is an activating receptor on human NK cells that is only expressed
when the NK cells are activated, and which confers a marked increase in cyto-
toxicity against various tumors. Ligands for NKp44 have been reported to be
expressed in various types of cancers, but not in healthy cells. Effective use of
the ligand-binding domain of this receptor as an antigen recognition site of a
CAR would thus allow a wide range of cancer cells to be attacked.
Aims: To determine the optimal CAR construct including the NKp44
immunoglobulin domain as a ligand-binding domain (NKp44-based CAR), with
a view to developing effective CAR-T therapy against hematological malignan-
cies and solid cancers.
Methods: We created several NKp44-based CAR constructs. Human T cells
from healthy donors were stimulated with anti-CD3/CD28 beads and recombi-
nant interleukin-2. Human NK cells were stimulated using K562-mb15-41BBL
feeder cells, as previously reported (Imai C, 2005). Activated T cells or NK
cells were then subjected to retroviral transduction with the CAR gene and the
phenotypic and functional characteristics of CAR-T cells engrafted with the
various NKp44-based CARs were compared. We determined if NKp44-ligands
were present on the cell surface of various types of malignant cell lines using
recombinant human NKp44 Fc chimeric protein.
Results: Surface expression of ligands for NKp44 was confirmed in a wide
range of tumor cell lines including acute myeloid leukemia (AML; KG-1, THP-
1, U937, K562, Kasumi-1, Kasumi-6), T-cell ALL (MOLT-4, HSB2, Peer, Jurkat),
B-cell ALL (OP-1), Burkitt’s lymphoma (Raji), osteosarcoma (NOS-10, NOS-1,
NOS-2, SaOS-2, U2OS,mg-63), rhabdomyosarcoma (RMS-YM, Rh28), and
neuroblastoma (NB1, NB16, IMR-32, SK-N-SH). Different expression levels of
CAR were observed among the NKp44-based CARs created in this study, in
which the major CAR domains, except for the ligand-binding domain, were
derived from various components including NKp44, CD8α, CD28, or CD3ζ. A
combination of the hinge domain from NKp44, transmembrane domain from
CD28, and intracellular signaling domain from CD3ζ yielded the highest surface
expression of CAR on both T cells and NK cells. T cells transduced with this
CAR showed enhanced cytotoxicity against various target cells including AML,
T-cell ALL, and B-cell ALL, but did not attack normal T cells. CAR-T cells also
showed increased production of interferon-gamma and granzyme B. The hinge
domain of NKp44 has been suggested to play a role in ligand binding (Koch J,
2013), but the details are poorly understood. Intriguingly, replacement of the
hinge domain from NKp44 significantly reduced cytotoxic function, though CAR
expression levels remained similar.
Summary/Conclusions: T cells transduced with NKp44-based CARs show
enhanced activities against various tumor cells. The extracellular hinge region
of NKp44 appears to play an important role in ligand binding and/or recognition.
NKp44-based CARs may represent a promising candidate for novel immune
therapies targeting a wide range of cancers.
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NKP30-CAR REDIRECTED HUMAN T LYMPHOCYTES INDUCE POTENT
ANTITUMOR IMMUNITY TO LEUKEMIA CELL LINES AND
PATIENT-DERIVED ACUTE MYELOID LEUKEMIA IN NSG XENOGRAFT
MODELS
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versity Medical Center Mainz, Mainz, Germany
Background: Adoptive cellular therapy (ACT) of chimeric antigen receptor
(CAR)-redirected T cells has evolved as a highly effective individualized
immunotherapy for leukemia and solid cancer. In particular, clinical trials using
CD19 CAR expressing T lymphocytes to combat CD19+ lymphomas have
revealed compelling results. However, suitable antigens for an effective and
specific CAR-mediated therapy to acute myeloid leukemia (AML) are still war-
ranted as e.g. CD33 and CD123 CAR expressing T cells induce potent immune
responses not only to AML blasts but also recognize normal hematopoietic
stem cells (HSC). In contrast, B7H6, a member of the B7 family, is frequently
expressed on various tumor cells including AML blasts while not detectable on
normal tissues, and is recognized by the natural killer (NK) cell activating recep-
tor NKp30. Moreover, NKp30 recognizes human leukocyte antigens (HLA)-B-
associated transcript 3, a nuclear factor that is secreted and translocated to
the cell surface in stressed and transformed cells.
Aims: In the current study, we thus explored the use of human T cells redirected
to express a NKp30-CAR for inducing effective antileukemic immunity in vitro
and in vivo to the erythrogenic leukemia line K562 and primary AML blasts in
NSG xenograft mouse models following ACT. 
Methods: PBMCs or MACS® purified human T cells were polyclonally stimu-
lated and reprogrammed with a CAR composed of the extracellular region of
the NKp30 receptor fused to the CD3ζ chain signaling domain (kindly provided
by Dr. S. Klobuch, Dept. of Internal Medicine 3, Medical University Regensburg,
Germany) by retroviral gene transfer. Transduced T cells were further selectively
expanded utilizing puromycin resistance present on the retroviral backbone,
and NKp30 expression was determined by flow cytometry. IFN-γ ELISPOT
analyses and cytotoxicity assays were performed to assess antileukemic
responses to leukemia lines and primary AML blasts in vitro and in vivo using
NSG xenografts and adoptive transfer of redirected T cells. Expression of B7H6
in target cells was confirmed by RNA-based RT PCR. 
Results: Following transduction and puromycin selection ≥90% of CD3+ T cells
expressed the NKp30 CAR. In addition, most T cells displayed an effector-mem-
ory phenotype. Upon coculture with the B7H6 expressing targets such as K562
and HL-60 (myelogenous leukemia cell lines), NALM 16 (pre-B-ALL) and patient-
derived AML samples (e.g. MZ506 and MZ987) NKp30-redirected T cells elicited
potent IFN –γ release and exhibited cytolytic activity to both leukemia lines and
primary AML blasts in vitro. These responses were specific as e.g. no reactivity
to the B7H6 negative myeloma line U266 was observed. We then evaluated
antitumoral responses of NKp30-redirected T cells in vivo. Upon adoptive trans-
fer of NKp30-CAR T cells into NSG mice engrafted with K562 significant reduc-
tion of tumor burden was observed. Moreover, injection of 1 - 5x106 HLA-
matched, NKp30-CAR redirected CD3+ T cells into NSG mice showing up to
5% engraftment of patient derived AML blasts and thus resembling a clinically
relevant minimal residual disease status at time of ACT resulted in clear leukemia
regression. Further experiments e.g. to elaborate to what extent CD4+ and CD8+
T cells contribute to this antileukemic immunity are in progress.
Summary/Conclusions: These studies demonstrate that human T lympho-
cytes can be successfully redirected to acute leukemia by NK cell activating
receptor based CARs such as the NKp30-CAR. As its ligand B7H6 has not
been reported to be expressed on CD34+ HSC, this antigen might be an inter-
esting target for adoptive immunotherapy to AML.
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PRECLINICAL TESTING OF ADOPTIVE T-CELL RECEPTOR GENE TRANS-
FER IN COMBINATION WITH CHECKPOINT INHIBITORS AS A NOVEL
THERAPY FOR MULTIPLE MYELOMA
H. Echchannaoui1,2,*, E. Amann1,2, E. Antunes1, M. Theobald1,2,3
1Third Department of Medicine (Hematology, Oncology and Pneumology), Uni-
versity Medical Center Mainz, Mainz, 2German Cancer Consortium (DKTK),
partner site Frankfurt / Mainz, German Cancer Research Center (DKFZ), Hei-
delberg, 3Research Center for Immunotherapy (FZI), University Medical Center
Mainz, Mainz, Germany
Background: Adoptive cellular therapy (ACT) based on T-cell receptors (TCR)
or chimeric antigen receptor (CAR)-engineered T cells has achieved tremen-
dous success in the treatment of cancer, especially B-cell malignancies. The
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impressive therapeutic results recently obtained with checkpoint inhibitors have
opened a new era in the field of cancer immunotherapy. Yet, clinical responses
are still often observed either transiently or in a minority of patients. This under-
scores the need for an improved understanding of underlying factors limiting
the efficacy of T cell-based immunotherapy and its wide application.
Aims: We explored an immunotherapeutic combination strategy to unleash
the full anti-tumor response of adoptively transferred antigen-specific T cells.
We propose to target multiple myeloma (MM) tumor cells in our established
xenograft in vivo adoptive cell therapy model by T cells equipped with two opti-
mized TCRs specific for HLA-A2.1-restricted MDM2 and p53 epitopes in com-
bination with checkpoint inhibitors.
Methods: Human T cells from healthy donors were retrovirally transduced with
MDM2- and p53-specific TCRs and expression levels were analyzed by flow
cytometry. MDM2 and p53 protein expression in MM cell lines was determined
by Western blot. The therapeutic efficacy of adoptive TCR transfer was evaluated
in NOD-scid IL2R gamma chainnull(NSG) mice engrafted (s.c) with HLA-A2.1-
expressing NCI-H929 MM cell line. In the combination checkpoint inhibitor
approach, mice were treated (i.p) with anti-PD-1 (Nivolumab). Tumor growth was
monitored and intratumoral alterations (in particular expression of relevant tumor
and T cell antigens) in ex-vivo tumors were analyzed by flow cytometry. Tumor-
infiltrating lymphocytes (TILs) were also characterized by flow cytometry.
Results: Adoptive transfer of dual MDM2/p53-specific TCR equipped T cells
showed a superior anti-tumor response in vivo compared to single TCR treat-
ment, demonstrating the need to target multiple MM antigens to circumvent
tumor escape mechanisms associated with down-regulation of antigen. Yet,
we observed a strong up-regulation of PD-L1 expression in tumor cells in vivo
and enhanced PD-1 expression in TILs which may limit the efficacy of antigen-
specific TILs. Accordingly, in vivo ACT experiments combined with anti-PD-1
inhibitor, demonstrated the synergistic therapeutic potential of this approach
as compared to single agent. Yet, it does not result in complete tumor eradica-
tion suggesting that targeting one single immune checkpoint receptor is not
sufficient to drive a full anti-tumor response.
Summary/Conclusions: Combination checkpoint inhibitor approach has
demonstrated synergistic potential in our ACT experimental MM model and
forms the basis for a novel multi-modal immunotherapeutic combination treat-
ment for multiple myeloma.
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ENGINEERED T CELLS TOWARDS BAFF RECEPTOR: A NOVEL STRATEGY
TO EFFICIENTLY TARGET B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
N. Turazzi1,*, G. Fazio1, V. Rossi1, A. Rolink2, G. Cazzaniga1, A. Biondi3,
C.F. Magnani1, E. Biagi1
1M. Tettamanti Reserach Center, Department of pediatrics, University of Milano
Bicocca S.Gerardo Hospital/Fondazione MBBM, Monza, Italy, 2Department of
Biomedicine, University of Basel, Basel, Switzerland, 3M. Tettamanti Reserach
Center, Department od pediatrics, University of Milano Bicocca S.Gerardo Hos-
pital/Fondazione MBBM, Monza, Italy
Background: B-cell Acute Lymphoblastic Leukemia (B-ALL) is most common
in children (80%), but it has also a peak of incidence in adult age. Immunother-
apeutic approaches targeting the CD19 molecule paved the way for the treat-
ment of relapsed and refractory lymphoblastic leukemia, which remains a major
therapeutic challenge. Recently, the emergence of relapses with CD19-epitope
loss in 10-30% of treated patients has been reported1. This newly identified
escape mechanism has been recently shown to be related to the combination
of deleterious mutations and emergence of alternatively spliced RNA isoforms,
as effect of selective pressure2. B-cell Activating Factor (BAFF) Receptor is a
transmembrane protein which is fundamental for B-cell maturation and survival.
Moreover, the expression of this receptor is restricted to mature B cells and,
interestingly, is not present on bone marrow B-cell precursors3. Recent studies
reported the over-expression of BAFF Receptor (BAFF-R) in various B-cell
malignancies such as B-ALL, B lymphoma, chronic lymphocytic leukemia and
myeloma4,5. In the context of B-ALL leukemic cells express both BAFF and
BAFF-R suggesting the presence of an autocrine signalling loop6. BAFF is also
expressed in bone marrow microenvironment by endothelial cells which support
the proliferation and the survival of primary B-ALL blasts4. 
Aims: In the current study, we aimed to develop a chimeric antigen receptor
(CAR)- mediated immunotherapeutic approach targeting the BAFF-R molecule.
Methods: We characterized the expression of BAFF-R in B-ALL primary sam-
ples. As immunotherapeutic approach to target BAFF-R molecule, we devel-
oped six anti-BAFFR.CARs that differ for the inversion of the VH and VL and
the length of the spacer domain (herein long, intermediate and short according
to the presence of entire CH2CH3 domain, of CH3 only or complete absence).
Cytokine-induced Killer (CIK) cells, an heterogeneous populations of CD3+
effector lymphocytes with acquired NK-like cytotoxicity enriched in highly effi-
cient cytotoxic CD3+CD56+ cells, were engineered using an improved Sleeping
Beauty (SB) transposon platform and used as effector population.
Results: Here we showed that BAFF-R is highly expressed in B-ALL primary
samples at the onset and relapse. In order to develop a chimeric antigen receptor
(CAR) approach targeting BAFF-R molecule, six anti-BAFFR CAR genes that
differ for the inversion of the VH and VL and the length of the spacer domain
have been generated. Cytokine-induced Killer (CIK) cells, engineered using an
improved Sleeping Beauty (SB) transposon system, stably expressed anti-BAF-
FR.CARs, and maintained their characteristic phenotype. Among the newly con-
structed CARs, the shortest VHVL anti-BAFFR.CAR exerted the highest anti-
leukemic activity towards target cells, such as NALM-6, with an in vitro killing
activity of 60%. We also evaluated later effector functions in terms of cytokine
release by intracellular staining (8,9±2% of IFN-γ and 16,4±5,5% of IL-2 pro-
ducing cells). Importantly, we also detected a specific cytotoxic activity towards
primary B-ALL blasts (average 65,6±4,5%, n=9). Combining the INVsh.CAR
with CD19.CAR we detected a superior antitumor activity towards ALL targets
(78,1±6,9% and 72,2±2,9% of tumor lysis respectively vs NALM6 and primary
B-ALL blasts) compared to single population per se. Furthermore, by using a
sample collected from a patient relapsed with CD19 negative disease, we
demonstrated the ability of the INVsh.CAR to lysate CD19-negative blasts.
Summary/Conclusions: Taken together, these findings make this receptor a
safe and attractive target for a second line B-ALL immunotherapy in case of
relapse after CD19-targeting therapies or for a double targeted approach. Being
restricted to mature B cells, but absent on precursors and plasmablasts, our
strategy could have an inferior toxicity concerning the emergence of B-cell apla-
sia observed in patients treated with anti-CD19 CAR-modified T cells.
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EXPLORING HUMAN TCR- AND CAR-REDIRECTED INKT CELLS FOR
ADOPTIVE CELLULAR THERAPY
B. Mir1, S. Khan1, M. Theobald1, U. Hartwig1,*
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Background: T cell receptor (TCR) - or chimeric antigen receptor (CAR) redi-
rected T cells have substantially improved adoptive cellular therapy (ACT) for
acute leukemias and show great promise for solid cancer. However, functional
heterogeneity and advanced differentiation of ex vivo expanded redirected lym-
phocytes limits their therapeutic potential and consistent efficacy. Invariant (type
I) natural killer T (iNKT) cells have been demonstrated not only to promote
effector functions of dendritic cells (DC), natural killer (NK) cells and T cells but
also to localize to tumors and have inherent antitumor properties. Moreover, as
these cells are further restricted to the monomorphic, HLA class I-like CD1 mol-
ecule expressed only on a few cell types with limited alloreactive potential, all
these features make iNKT cells as attractive alternative carriers for redirected
immunotherapy. 
Aims: In the current proof of concept study we therefore explored human, AML-
reactive TCR- and CD19 CAR-redirected iNKT cells for their potential to induce
antitumoral responses to leukemia cell lines as well as patient derived, primary
AML blasts.
Methods: iNKT cells expressing the invariant TCR composed of the
Vα24Jα18/Vβ11 chains were immuno-magnetically isolated from PBMC derived
from adult healthy donors using Vβ11-Ab (6B11)-conjugated, anti-iNKT
microbeads (Miltenyi Biotec) and expanded in vitro upon coculture with autolo-
gous, α-galactosyceramide (α-GalCer) loaded DC in the presence of low
amounts of interleukin (IL)-2. iNKT cells were retrovirally transduced on day 6
after stimulation and selected for TCR or CAR expression utilizing a virally trans-
duced puromycin resistance. While phenotypic analyses on iNKT markers and
on the percentage of redirected cells were performed by flow cytometry functional
assays such as IFN-γ ELISPOT and cytotoxicity assays were carried out using
CD19+ NALM-16 (pre B-ALL) and primary AML (MZ653) cells as targets.
Results: Following isolation of 0.7 - 0.8 x 106Vα24/Vβ11+ iNKT cells from
PBMC we achieved on average a 120-fold expansion 21-28 days after stimu-
lation with GalCer loaded, irradiated autologous DC and 25 U IL-2. Additional
use of lenalidomide to promote expansion as described previously had no
effect. Expanded iNKT cells were mainly CD4+(83%) and about 80% of cells
expressed the natural killer receptor CD161 described as iNKT maturation
marker but showed limited or virtually no expression of typical NK markers
such as CD56 and CD16. Following retroviral transduction and selection for 6
days >80% of TCR (5B2)- and CD19 CAR-redirected iNKT cells were obtained.
Subsequent functional analyses revealed that both iNKT cells expressing the
AML-reactive TCR 5B2 as well as CD19-CAR iNKT cells demonstrated sub-
stantial release of IFN-γ and elicited potent antileukemic responses to AML
MZ653 and NALM-16 in vitro. Studies to examine their cytotoxic potential poten-
tial in vivo using NSG xenograft models are currently in progress.
Summary/Conclusions: These studies demonstrate that purified human
Vα24/Vβß11+ iNKT cells expanded from PBMC can be successfully redirected
to acute leukemia both by TCR and CAR expression. Engineered iNKT cells
might therefore be promising alternative carriers for redirected ACT or beeing
used in combination with redirected T cells as combined immunotherapy. 
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SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF
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Background: Acute Myeloid Leukemia (AML) is an aggressive malignancy
still associated with high relapse rates when treated with conventional
chemotherapeutic and hematopoietic transplantation regimens. In search for
alternative strategies, great interest has been posed on antigen-specific
immunotherapies and in particular on T cells redirected with Chimeric Antigen
Receptors (CARs) that have shown exciting results in cancer therapy, espe-
cially in the context of B-cell malignancies. CD33 is the only validated target in
AML so far and represents a suitable antigen to be targeted with CAR-T cells,
being broadly expressed on AML blasts.
Aims: The aim of the present study is to preclinically evaluate the efficacy and
safety profiles of CD33 CAR redirected Cytokine Induced Killer (CIK) cells
alone and in combination with standard chemotherapeutic agents.
Methods: Here we proved the feasibility of harnessing Cytokine Induced Killer
(CIK) effector cells with a third generation anti-CD33.CAR through the non viral
Sleeping-Beauty transposon system, starting from fresh and frozen healthy
mononuclear cells (PBMCs) and also from frozen primary AML samples. The
in vitro anti-AML activity of CD33.CAR-CIK cells is assessed by means of cyto-
toxicity, proliferation and cytokine production assays upon challenge with AML
cell lines and primary samples. The in vivo efficacy of CD33.CAR CIK cells is
evaluated in NSG mice transplanted with AML cell lines (MA9-NRas cells) and
primary samples. Moreover, to investigate the potential benefit of CD33.CAR
CIK cell immunotherapy in combination with standard-of-care treatments,
xenograft chemotherapy models is exploited, by using standard AML induction
therapy drugs (Ara-C and doxorubicin).
Results: CD33.CAR-CIK cells were able to induce a potent anti-leukemic activ-
ity as compared to unmanipulated CIK cells, in terms of specific killing (up to
70%), proliferation (up to 40% of Ki67+CAR-CIK cells) and cytokine production
(up to 30% for both IL-2 and IFN-gamma producing CAR-CIK cells) when chal-
lenged with both AML cell lines and primary leukemic cells. By treating MA9-
NRas cell grafted mice with the already established “5+3” induction chemother-
apy protocol, we confirmed that chemotherapy is able to significantly reduce
the leukemic burden from around 20% to 0.1% in the bone marrow. Since the
AML disease is not totally eradicated, this model will be therefore suitable to
further investigate the efficacy of the CD33.CAR-CIK cells immunotherapy on
the chemotherapy resistant/residual AML cells.
Summary/Conclusions: Having demonstrated the significant in vitro anti-
leukemic activity of SB-modified CD33.CAR-CIK cells we next aim to assess
their efficacy in vivo, particularly against the resistant/residual AML cells that
were not eradicated by standard chemotherapy treatment. Moreover, envisag-
ing a safer clinical translation of this immunotherapeutic approach, a transient
CAR expression, by using CD33.CAR coding mRNA, is under investigation, in
order to limit the potential myelotoxicity due to the long-term off-target effect
on normal hematopoietic stem/myeloid progenitor cells. Finally, if successful,
our results will provide the preclinical validation of CD33.CAR-CIK cell
immunotherapy, supporting its development to the clinic.
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UPDATE ON THE FIRST PATIENTS WITH SEVERE HEMOGLOBINOPATHIES
TREATED WITH LENTIGLOBIN GENE THERAPY
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Background: Insertion of an anti-sickling β-globin gene variant into hematopoi-
etic stem cells (HSCs) could reduce or eliminate symptoms of severe sickle
cell disease (SCD) and transfusion requirements in transfusion-dependent β-
thalassemia (TDT). LentiGlobin Drug Product (DP) contains autologous CD34+
cells transduced with the BB305 lentiviral vector, which encodes a human β-
globin gene containing a single point mutation (AT87Q) designed to confer anti-
sickling properties similar to γ-globin. We recently (ASH 2016) reported 23
months of follow-up for a patient with SCD, and 12−34 months of follow-up for
4 patients with TDT.
Aims: To evaluate the safety and efficacy of LentiGlobin gene therapy for
severe hemoglobinopathies. 
Methods: Patients 5-35 years old with severe SCD (e.g., ≥2 acute chest syn-
drome episodes or ≥2 vaso-occlusive crises [VOC] in the preceding year) or
TDT (≥100 mL/kg of packed red blood cells [RBCs] per year) were enrolled.
After informed consent, autologous CD34+ cells were collected and transduced
with the BB305 vector. Patients underwent myeloablative conditioning with
busulfan prior to infusion of transduced cells. Patients were then monitored for
hematologic engraftment, vector copy number (VCN), genetically engineered
hemoglobin (HbAT87Q) levels, and adverse events (AEs). Disease-specific
assessments included transfusion requirements for TDT, or VOCs and hospi-
talizations for SCD.
Results: As of 9 September 2016, 1 patient with severe SCD (male; 13 years
old) and 4 patients with TDT (2 male, 2 female; 16−19 years old) have received
LentiGlobin DP in Study HGB-205. The median DP cell dose was 8.9 (range
5.6-13.6) x106 CD34+ cells/kg with a DP VCN of 1.2 (range 0.8−2.1) vector
copies/diploid genome. Median post-infusion follow-up was 22.9 months
(range 11.6-33.5). All subjects engrafted successfully with median time to neu-
trophil engraftment of 17 (range 14-38) days. Within patients, VCN in periph-
eral blood remained generally consistent from Month 3 (range 0.3−3.3 at last
measurement). The toxicity profile was consistent with myeloablative condi-
tioning with single-agent busulfan, with no ≥Grade 3 DP-related AEs or serious
AEs and no evidence of clonal dominance reported to date. The patient with
severe SCD who, prior to study enrollment, received regular RBC transfusions,
experienced no clinical symptoms or complications of SCD in the 21 months
since treatment. At Month 21, his total Hb was 13.1 g/dL, with 6.2 g/dL
HbAT87Q (48%) and 6.5 g/dL sickle Hb (HbS: 50%); in addition, their uncon-
jugated bilirubin, lactate dehydrogenase and reticulocyte count had dropped
by 56%, 58%, 26%, respectively, compared to screening. Of the 4 patients
with TDT, 3 have β0/βE genotypes and 1 is homozygous for a severe β+ muta-
tion (IVS1 nt 110 G>A). Two of the β0/βE patients have completed their 2-year
primary follow-up and entered a long-term follow-up study. They have been
without RBC transfusions for 33 and 30 months, with total Hb of 10.9 and
13.5 g/dL, and HbAT87Q of 7.7 and 10.1 g/dL, respectively. The third patient
with a β0/βE genotype has 12 months follow-up and has not required transfu-
sions since 4 days post-LentiGlobin DP infusion, with total Hb 11.3 g/dL and
HbAT87Q of 8.6 g/dL. The patient with the IVS1 genotype has 15 months of
follow-up and has been free of transfusions for 11.6 months, with total Hb 8.3
g/dL and HbAT87Q of 6.7 g/dL. Since September 2016, 2 more patients with
severe SCD have received LentiGlobin DP.
Summary/Conclusions: Data to date from this ongoing Phase 1/2 clinical
study suggest that treatment with LentiGlobin DP elicits sustained HbAT87Q
levels, which alleviate the clinical and biochemical effects of severe SCD and
TDT, with safety consistent with myeloablative conditioning. Follow-up data on
the 5 previously reported patients and early results from the 2 recently treated
patients will be presented.
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A SINGLE INSTITUTIONAL EXPERIENCE OF 261 PATIENTS WITH LARGE
GRANULAR LYMPHOCYTIC LEUKEMIA
M. Van den Bergh1,*, L. Isenalumhe1, E. Wang2, B. Schaible1, Z. Ma1, L. Zhang1,
L. Sokol1
1H. Lee Moffitt Cancer Center & Research Institute, 2University of South Florida,
Tampa, United States
Background: Large granular lymphocytic leukemia (LGLL) is a rare clonal lym-
phoproliferative disorder of post-thymic T-cell or natural killer (NK)-cell lineage
associated with cytopenias, splenomegaly, autoimmune disorders, and recur-
rent mucocutaneous infections. Treatment is dictated by the presence of these
manifestations and consists of immunosuppressive therapy.
Aims: The main aim of this study is to evaluate clinical features, hematological
parameters, and survival data of patients with LGLL. The secondary aim is to
assess response rates and duration of response to various first line immuno-
suppressive therapies in LGLL.
Methods: This is a retrospective analysis of clinical and laboratory features,
treatment modalities, and outcomes of LGLL patients evaluated at Moffitt Can-
cer Center between January 1, 1995 and May 1, 2016. Continuous and cate-
gorical variables were tested via Kruskal-Wallis ANOVA and Fisher’s Exact
Test, respectively. Kaplan-Meier curves were used for overall survival (OS). P-
values were two-sided with significance set at <0.05.
Results: We identified 261 patients with LGLL (91.6% T-cell, 8.4% NK-cell).
Median age was 66 years [21-90] and M:F ratio was 1.2:1. Median follow up
was 3.07 years [0-21.88]. 42.9% of LGLL patients presented with anemia,
37.1% with neutropenia, 30.7% with thrombocytopenia, 29.1% with bicytopenia
and 6.9% with pancytopenia. Transfusion dependence was noted in 20.3%,
splenomegaly in 27.2% and bone marrow involvement in 69.3%. 24.9% had
autoimmune diseases and 9.2% had autoimmune cytopenias. 45.6% were
observed while the remainder required at least one line of therapy. 5-year and
10-year OS were 75.0% and 63.1%, respectively. There was no statistically
significant difference in OS, complete response rate or duration of response
based on first line agent (methotrexate, cyclophosphamide, cyclosporine A).
However, there was a statistically significant improved partial response with
methotrexate versus other therapies (p=0.01). A marginally significant associ-
ation between severe anemia/transfusion dependence and poor overall
response rate (p=0.075) to any immunosuppressive therapy was noted. There
was no statistically significant difference in OS based on absolute LGL count.
Mean number of therapies was 1.08 (range 0-6) and was higher in patients
with LGL count <0.5 k/μL (p=0.0078), bone marrow involvement (p<0.0001),
and splenomegaly (p<0.0001). 
Summary/Conclusions: In this large retrospective study, we described the
frequency of LGLL-associated manifestations and their impact on the course
of LGLL. Severe anemia/transfusion dependence, lower LGL counts, bone mar-
row involvement, and splenomegaly were suggestive of more aggressive dis-
ease. We confirmed that there is no difference in overall survival among first
line immunosuppressive therapies.
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ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA
INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/
REFRACTORY B-CELL MALIGNANCIES (CITADEL-101)
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Background: Signaling networks mediated by PI3Kδ have been implicated in
proliferation, migration, and functioning of B-cells. INCB050465 is a novel,
potent, and selective inhibitor of PI3Kδ (≥19,000-fold more selective for PI3Kδ
vs other isoforms). INCB050465 demonstrated linear pharmacokinetics (PK)
and achieved exposure levels several-fold greater than the IC90 for PI3Kδ inhi-
bition at the recommended phase 2 dose (ASH 2016; Abstract 4195).
Aims: To evaluate INCB050465 in patients with relapsed or refractory B-cell
malignancies enrolled in an ongoing phase 1/2 study (NCT02018861)
Methods: In this phase 1/2 study, eligible patients (≥18 years of age) had
relapsed/refractory lymphoid B-cell malignancies (excluding Burkitt’s lymphoma
and precursor B-cell lymphoblastic leukemia/lymphoma), Eastern Cooperative
Oncology Group performance status score ≤2 (≤1 during dose escalation), nor-
mal liver and kidney function, and had not received autologous hematopoietic
stem-cell transplant (HSCT) within 3 months or allogeneic HSCT within 6
months of screening. The protocol was initiated with a single-patient cohort,
treated with oral INCB050465 5mg QD. Subsequent cohorts used a 3+3 design
and evaluated doses of 10–45mg QD. Based on PK/pharmacodynamics, the
20 and 30mg QD cohorts were expanded. Responses were assessed every 9
weeks using the Lugano Classification or International Working Group on
Chronic Lymphocytic Lymphoma (CLL) criteria.
Results: As of the data cutoff (Nov 1, 2016), 52 patients were treated (median
age, 65 years [range, 30–88]). Baseline disease subtypes included diffuse large
B-cell lymphoma (DLBCL; n=14), follicular lymphoma (FL; n=10), Hodgkin lym-
phoma (HL; n=9), marginal zone lymphoma (MZL; n=8), CLL (n=6), and mantle
cell lymphoma (MCL; n=5). Sixty-two percent (n=32) of patients had >3 prior
systemic regimens; 31% (n=16) had prior HSCT. Median duration of therapy
was 3.3 months (range, 0.6–13.4); no DLTs were identified. Sixty-seven percent
of patients discontinued therapy, most commonly due to disease progression
(31%) and AEs (25%). Thirty-three percent of patients had dose interruption
and 4% had dose reduction. Most common nonhematologic AEs (all grade;
grade ≥3) were nausea (38%; 0%), diarrhea (31%; 6%), and vomiting (25%;
0%). Grade ≥3 hematologic AEs included neutropenia (21%), lymphopenia
(17%), thrombocytopenia (10%), and anemia (4%). Forty-percent of patients
had serious AEs (SAEs), most frequently colitis, diarrhea, and hypotension (all
n=3). One patient had grade 3 pneumonitis; none had Pneumocystis jirovecii
pneumonia (PJP) or grade ≥2 elevated transaminase. Objective responses
occurred at all doses (Table 1), except 5mg QD; 90% of the objective responses
were observed at the 9-week disease assessment.
Table 1.
Summary/Conclusions: In patients with relapsed/refractory B-cell malignan-
cies, INCB050465 demonstrated manageable toxicities with no clinically mean-
ingful transaminitis or PJP. Objective response rates were generally high and
most responses (90%) were observed at the 9-week disease assessment. Dif-
ferent dosing regimens/schedules, long-term safety, and disease-specific
cohorts are being evaluated.
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PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB
(R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN
PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF
FOLLICULAR LYMPHOMA PATIENTS
J.M. Burke1,2,*, D.J. Andorsky2,3, A. Yacoub4, J. Melear2,5, M. Coleman6,
K. Kolibaba2,7, H. Brooks2,8, J. Bitran9, S. Fanning10, F. Lansigan11, J.L. Ricker12,
K. Foon12, M. Llorente12, J. Li12, J. Sharman2,13
1Rocky Mountain Cancer Centers, Aurora, CO, 2The US Oncology Network,
The Woodlands, TX, 3Rocky Mountain Cancer Centers, US Oncology
Research, Boulder, CO, 4University of Kansas Cancer Center, Westwood, KS,
5Texas Oncology, Austin, TX, 6Weill Cornell Medicine, New York, NY, 7North-
west Cancer Specialists PC, Vancouver, WA, 8Oncology and Hematology Asso-
ciates, US Oncology Research, Roanoke, VA, 9Oncology Specialists, SC, Park
Ridge, IL, 10Greenville Health System, Greenville, SC, 11Dartmouth Hitchcock
Medical Center, Lebanon, NH, 12Celgene Corporation, Summit, NJ,
13Willamette Valley Cancer Institute and Research Center, US Oncology
Research, Springfield, OR, United States
Background: Lenalidomide is an immunomodulatory agent with direct and
immune-mediated mechanisms of action, and clinical activity in indolent non-
Hodgkin lymphoma (NHL). Recent studies in frontline and relapsed/refractory
(R/R) iNHL show tolerability and high activity for the combination of lenalidomide
plus rituximab (R2) and support further study of R2.
Aims: The current study evaluates the efficacy and safety of R2 induction in
patients with R/R follicular lymphoma (FL).
Methods: MAGNIFY (NCT01996865) is a Phase IIIb, multicenter, open-label
study of R/R NHL patients, including grades 1-3b and transformed follicular
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lymphoma (tFL). Upon informed consent, patients receive 12 cycles of R2
induction (lenalidomide 20mg/d, 21 of 28 d; rituximab 375mg/m2 weekly cycle
1 [d1, 8, 15, 22], then d1 of odd cycles). Responders to induction (≥SD) are
randomized 1:1 to maintenance with either R2 or rituximab alone (18 cycles);
following R2 maintenance, optional single-agent lenalidomide (10mg/d, 21 of
28 d) can be given until PD. The primary endpoint is progression-free survival
(PFS).
Results: As of April 14, 2016, 106 patients with R/R FL have been enrolled,
including 103 with grade 1-3a FL, 2 with tFL, and 1 unknown grade. Median
age of patients with FL was 66 y (range, 41-91); most had ECOG PS of 0-1
(99%) and stage III/IV disease at study entry (80%). Patients received a median
of 2 prior therapies (>2, 30%); 103 (97%) patients had received prior ritux-
imab-containing treatment, of which 35% were rituximab refractory (defined as
best response of SD/PD to rituximab/rituximab-containing regimen or a CR/PR
of <6 mo after the last rituximab dose). The most common prior regimens were
rituximab alone (40%), R-CHOP/R-CHOP–like (38%), and bendamustine plus
rituximab (35%). Premature discontinuation of lenalidomide and/or rituximab
occurred in 39 (37%) patients during the induction period, mainly due to AEs
(n=20); the most common treatment-related AE leading to early discontinuation
in the induction period was neutropenia in 6 patients. Four (4%) patients dis-
continued the study. Common grade 3/4 treatment-emergent AEs during induc-
tion in the FL safety population (n=104) were 27% neutropenia, 7% leukopenia,
and 6% fatigue. At a median induction duration of 23 weeks (range, 0.4-51),
83 FL patients were evaluable for response with an overall response rate (ORR)
of 65%; those who were not rituximab refractory had improved ORR compared
to rituximab-refractory patients (70% vs 55%; Table 1). The median time to
response during induction was 2.8 mo. Twenty patients have completed 12
cycles of induction and 16 proceeded to maintenance (n=6 R2, n=10 rituximab
alone). Enrollment is ongoing.
Table 1.
Summary/Conclusions: R2 induction therapy shows favorable activity and a
tolerable safety profile in patients with advanced-stage, R/R FL. The study is
ongoing to determine the effect of R2 vs rituximab maintenance in FL patients,
and updated results will be presented.
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A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY
AND SAFETY OF CT-P10 TO INNOVATOR RITUXIMAB IN COMBINATION
WITH CVP IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED
FOLLICULAR LYMPHOMA
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Background: CT-P10 is the first biosimilar of innovator rituximab (RTX),
approved for all indications by the European Medicines Agency. CT-P10 has
demonstrated pharmacokinetics (PK) and efficacy equivalence in patients with
rheumatoid arthritis (Yoo, ACR 2016) and PK equivalence in patients with
advanced follicular lymphoma (AFL) (Coiffier, ASH 2016).
Aims: This study aimed to demonstrate non-inferiority (NI) of efficacy and PK
equivalence between CT-P10 and RTX in patients with newly diagnosed
advanced follicular lymphoma (AFL) (NCT02162771).
Methods: A total of 140 patients were randomized in a 1:1 ratio to receive CT-
P10 or RTX (375mg/m2 intravenous) plus CVP (cyclophosphamide, vincristine,
and prednisone) therapy every 3 weeks over 8 cycles. Overall response rate
(ORR) based on best overall response over 24 weeks was assessed by the
independent review committee, according to the 1999 International Working
Group criteria.
Results: Therapeutic NI of CT-P10 to RTX has been demonstrated in terms of
ORR over 8 cycles (Table 1). The ORR difference between two treatment
groups was 4.3% in per-protocol (PP) population and 5.7% in intent-to-treat
(ITT) population. Considering the statistical Non-Inferiority test using confidence
interval (CI) approach with the exact binomial CI for the difference of ORR
between two treatment groups, the lower bound of 95% CI lies on the positive
side of -7% NI margin (-4.25% in PP population and -3.41% in ITT population).
The pre-defined non-inferiority criterion has been met with the descriptive point
estimate difference approach and the formal statistical NI test with a 5% sig-
nificance level. Median number of B-cells decreased to the lower limit of quan-
tification (LLoQ) after the 1st infusion and remained at the LLoQ over 8 cycles
in both groups. Overall safety profile of CT-P10 was consistent with that of
RTX (Table 2). No progressive multifocal leukoencephalopathy or Hepatitis B
virus reactivation were reported in either groups. The proportion of patients
with positive anti-drug antibody were similar between both groups (4.3% and
2.9%) over 24 weeks in the induction period.
Table 1. Summary of Efficacy [Number (%) of patients].
* Difference was calculated using percentages not the round off values. 
Table 2. Summary of Treatment-emergent adverse event (TEAE) related
to the study drug [Number (%) of patients].
Summary/Conclusions: This study demonstrates therapeutic non-inferiority
of CT-P10 to RTX combined with CVP therapy in previously untreated AFL.
CT-P10 was well-tolerated and the safety profile including immunogenicity of
CT-P10 was comparable to that of RTX over 8 cycles in induction period.
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DURABLE DISEASE CONTROL OF EARLY MYCOSIS FUNGOIDES
PATIENTS TREATED WITH LOW-DOSE INTERFERON-ALPHA2B AND
PUVA
S. Rupoli1,*, G. Goteri2, G. Micucci1, I. Federici1, L. Canafoglia1, F. Giantomas-
si2, I. Cataldi3, A. Giacchetti4, G. Tucci4, L. Morresi4, A. Bettacchi5, M. Nicolini6,
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Background: Early stage Mycosis Fungoides (MF) has an indolent, relapsing
course, with patients frequently undergoing multiple therapies. Current guide-
lines consider the utility of combination therapies (skin-directed therapies plus
systemic biologic response modifiers) to increase the therapeutic efficacy.
Recently, time to next treatment (TTNT) was applied as a new relevant measure
of the durability of response of PUVA, interferon-alpha (IFN-α) and retinoids
as monotherapies in early MF (Hughes et al, Blood 2015; Hanel et al, AJH
2016), but it has not been yet investigated in combination therapies. 
Aims: We aimed to evaluate TTNT together with the usual time-to-event meas-
ures (OS and EFS) in the series of 89 early MF patients treated for 14 months
with low-dose IFN-α2b (6-18 MU weekly) and PUVA, which was first reported
in 2005 (Rupoli et al, EJH 2005). The follow-up was prolonged up to October
2016, in order to evaluate prospectively the regimen activity and influence on
the further course of the disease. 
Methods: The design, rationale, safety and efficacy results for this protocol
were previously published. Clinical stages IA-IIA patients who had received no
previous treatment, or had been submitted to a 4-month wash-out after sys-
temic therapy or a 4-week wash-out after topical therapy, were included in the
study. Survival curves for each efficacy endpoint were calculated according to
Kaplan-Meier.
Results: Eighty-nine patients (56 men and 33 women) with a median age of
60 years (range, 17-80) were recruited. Disease stage was IA in 22 patients,
IB in 55, IIA in 11, and IIB in 1 patient. The majority of patients had generalized
skin disease (75% T2 vs 25% T1). The protocol proved to be highly effective,
well tolerated and able to induce complete clearing of skin lesions in 84% of
patients and an overall response in 98%. The median follow-up time was 175
months (range 4-259). Updated data showed that the median overall survival
(OS) was not reached, whilst the median event-free survival (EFS) was 142
months (95% C.I. 130-153). Estimated OS rates at 1, 2, 5, 10, 15 and 20 years
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were 99%, 98%, 92%, 89%, 78% and 51%; at 1, 2, 5, 10, 15 and 20 years
98%, 97%, 88%, 67%, 19%, 0%, were free from events. Median TTNT was not
reached thus indicating clinical benefit with IFN-α and PUVA. Kaplan-Meier
estimated rates of 97% at 1 year, and 91% at 2 years, respectively whereas 5-
, 10-, 20-year TTNT remained almost unchanged with 62% of patients that still
had not required further treatment. 
Summary/Conclusions: There has been an ongoing debate about whether
patients would benefit from adding PUVA to IFN-α in the treatment of early stage
MF. We chose to initiate the combination treatment of MF as early as possible
in the course of the disease to induce a permanent remission or even a cure. In
our experience, this regimen set the realistic goal of achieve high rates of com-
plete clearing and durable responses (median TTNT not reached) with only 38%
of patients requiring a subsequent systemic treatment within 20 years. Here, we
suggest a synergistic or additive effect between PUVA and IFN-α compared with
either agent alone. With respect to Hughes et al, (Blood 2015), our combination
treatment provide a longer TTNT than PUVA or IFN-α monotherapy (36.3 months
and 8.7 months respectively). At 2 years, 91% of patients receiving PUVA plus
IFN-α were free from further treatment as compared to 54.2% and 29.1% treated
with PUVA or IFN-α monotherapy, respectively.
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PHASE 3 ALCANZA STUDY OF BRENTUXIMAB VEDOTIN (BV) OR PHYSICIAN’S
CHOICE (PC) OF METHOTREXATE (MTX) OR BEXAROTENE (BEX) IN
CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA (CTCL):NUMBER
NEEDED TO TREAT ANALYSIS
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R. Dummer7, J. Scarisbrick8, P. Quaglino9, P.L. Zinzani10, P. Wolter11,
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Background: CTCL is a generally incurable, relapsing disease associated with
a significant symptom burden, including disfiguring lesions, debilitating pruritus
and frequent skin infections. ALCANZA is a Phase 3 study of BV vs PC (MTX
or Bex) for the treatment of CD30-positive (CD30+) CTCL (NCT01578499). BV
was associated with significantly improved rate of objective response lasting
≥4 months (ORR4; 56% vs 13%; p<0.0001), longer median progression-free
survival (PFS; 16.7 vs 3.5 months; p<0.0001), and decreased symptom burden
measured by Skindex-29 ( 27.96 vs -8.62; p<0.0001), compared with PC. BV’s
safety profile was consistent with previous reports, with all-grade and grade 3
peripheral neuropathy of 67% and 9%, respectively. Number needed to treat
(NNT), defined as the number of patients (pts) that need to be treated to prevent
one outcome event relative to the comparator therapy, is an effective method
to assess the benefit-risk of BV in a clinically relevant manner. NNT values of
3–28 have been previously reported, at various time points, in hematologic
malignancies (multiple myeloma, B-cell non-Hodgkin lymphoma) to prevent
one disease progression event or death. Data from the Phase 3 AETHERA
study demonstrated that, at various time points, and dependent on risk group,
one in 3–8 Hodgkin lymphoma pts treated with BV consolidation therapy post-
autologous stem cell transplant will benefit by avoiding disease
progression/death, compared with placebo.
Aims: To determine the NNT with BV to avoid one additional event of disease
progression or death compared with PC in the ALCANZA trial.
Methods: The NNT with BV was calculated as the inverse of the absolute risk
reduction (ARR); ARR was the PFS event rate per independent review facility
(IRF) assessment in the PC arm minus the event rate in the BV arm. PFS was
defined as the time from randomization until progressive disease/death due to
any cause, counting all events despite two or more missed visits or starting of
subsequent anticancer therapy (European Medicines Agency [EMA] criteria).
ALCANZA recruited adults (≥18 years) with previously treated CD30+ mycosis
fungoides or primary cutaneous anaplastic large cell lymphoma. Pts were ran-
domized 1:1 to receive BV 1.8mg/kg IV, once every 3 weeks, for up to 16 three-
week cycles, or PC of MTX 5–50mg PO, once weekly, or Bex 300mg/m² (target
dose) PO, once daily, for up to 48 weeks. All pts gave informed consent.
Results: The intent-to-treat (ITT) population comprised 128 pts (median age
60 yrs [range 22–83]; 55% male) who received BV (n=64) or PC (n=64). Fewer
PFS events per IRF assessment per EMA criteria were experienced by pts in
the BV arm vs PC arm (Table). The NNT with BV to prevent a disease progres-
sion/death ranged from 2.00 (95% CI 1.59, 3) to 3.76 pts (95% CI 2.5, 8.44)
over 24 months (Table). At 24 months, the NNT to prevent a disease progres-
sion/death was 3.37 pts (95% CI 2.26, 7.67).
Table 1. NNT analysis per IRF assessment of PFS in the ALCANZA ITT
population.
Summary/Conclusions: ALCANZA data suggest that, at various time points,
one in every 2–4 pts treated with BV will benefit by avoiding disease progres-
sion/death. This further demonstrates BV’s clinical benefit in CD30+ CTCL pts
requiring systemic therapy. This is, to our knowledge, the first report of an NNT
analysis for a treatment in the CTCL setting.
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PRIMARY OCULAR ADNEXAL LYMPHOMA OF ALL HISTOLOGIC
SUBTYPES: SURVIVAL OUTCOMES AND RISK FACTORS IN LARGE
COHORT OF PATIENTS AND LONG-TERM FOLLOW-UP
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Background: Although the recent reports show that interest in ocular adnexal
lymphomas (OAL) and their biologic and clinical characteristics have been
increased, the most OAL-related clinical study is still limited in the small number
with insufficient follow-up period, result in retrospective studies with non-repro-
ducible. Moreover, because the majority of OAL were in the low-grade histologic
subtypes as primary ocular adnexal MALT (mucosa-associated lymphoid tissue
) lymphoma, there is few comparative analysis study of all histologic subtypes
in OAL patients especially for non-MALT type OAL in large cohort OAL.
Aims: So our purposes of this study were to identify a correlation between
histopathological diagnosis and significant parameters associated with clinical
outcomes of patients with OAL in patients with diverse histologic subtypes.
Methods: We evaluated the consecutive 207 primary OAL patients who diag-
nosed at Catholic University Lymphoma Group (CULG) of Catholic Bone Mar-
row Center, Seoul between January 2004 to April 2015. Clinical information
and parameters were gathered from the electronic medical records such as
geographic status, complete blood count (CBC) with blood chemistry, the status
of BM involvement, primary therapeutic modalities, response to initial therapy,
and treatment-related complications with survival outcomes.
Figure 1.
Results: In OAL of all histologic subtypes, 10-year lymphoma-specific OS and
PFS were 89.3% and 71.0% respectively. 182 patients achieved CR (87.9%).
CR rate according to primary therapy was 90.4% (n=103) in T1N0M0, 95.2%
(n=40) in T2N0M0, 100% (n=7) in T3N0M0, 83.3% (n=5) in T4N0M0, and 71.1%
(n=27) in TxN1-4M0/ TxNxM1. Multivariate analysis in OAL of all histologic sub-
types showed that the risk factors-associated PFS were positivity of BM involve-
ment and non-MALT lymphoma subtype (hazard ratio; HR=5.98, p <0.001 and
HR=2.96, p=0.025, respectively), the risk factors-related OS was only non-
MALT lymphoma subtype (HR=9.18, p=0.013). Then, subgroup analysis
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according to histopathologic subtypes, BM involvement alone was regarded
as a statistically significant factor in the group of MALT lymphoma (HR=3.99,
p=0.013) and there were no statistically significant factors in the group of non-
MALT lymphoma. Although there were no risk factors with statistical signifi-
cance, the BM involvement and advanced TNM stage showed a trend toward
statistical significance about affecting to the failure of PFS (BM involvement of
HR 5.19, p=0.054 and advanced TNM stage of HR 3.06, p=0.056). The median
time-to-progression (TTP) was from 3 to 3.5 years after initial therapy in relapse
or dead patients (range from 4.6 to 109.6 months).
Summary/Conclusions: Our study confirmed that OAL of all histologic sub-
types also represented the indolent nature and localized behavior with favorable
survival outcomes. Although BM involved OAL consisted of a small number, it
was associated with poor survival outcomes. Also, relapse and lymphoma-
related mortality had long-term delayed TTP, so we suggested that BM biopsy
might be a necessary study for initial staging at least in all OAL and long-term
follow-up is required for patients with all histologic type of OAL. 
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CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN
(CBL-MZ): A PROSPECTIVE REGISTRATIONAL STUDY ON 96 CASES
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Background: Clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ)
has been recognized as a provisional entity in the WHO classification. Despite
diagnostic similarities with SMZL, the exact relation between them has not
been established yet. AIM: To describe the main features of CBL-MZ and to
further elucidate its relation to SMZL.
Aims: To describe the main features of CBL-MZ and to further elucidate its
relation to SMZL. 
Methods: 96 CBL-MZ were analyzed. Staging at diagnosis included CBCs,
blood morphology and immunophenotype, biochemistry, viral test for hepatitis
C and B, serum immunoglobulin levels and immunofixation as well as whole
body CT scan. BM biopsies were available in 78 cases which were studied
with the following panel of moAbs: CD20, DBA44, CD23, CD5, CD25, CD38,
CD27, s/cIgM/D, TCL-1, MNDA, T-bet and IRTA-1. Gastroscopy with multiple
biopsies was performed in 56 cases. FISH analysis for del7q was done in 13
pts, and detection for MYD88 mutation in 60.
Table 1.
Results: A synoptic presentation of the main characteristics of CBL-MZ is given
in the table. The median age was 70 y without sex predilection. By definition,
no case presented with cytopenia, lymphadenopathy, splenomegaly or any
other organ involvement. Median ALC and clonal B-cell counts were 5098/μL
and 2880/μL, respectively. 47% had paraproteinemia, mainly of the IgM type.
H.pylori (+) gastritis was evident in 30%. Hp eradication had no influence on
the lymphocyte counts. The percentage of BM infiltration was highly variable,
ranging from 10% to 85%, with an intrasinusoidal pattern in 31%. TCL-1, T-
bet, IRTA-1, and MNDA were invariably negative. MYD-88 mutation was detect-
ed in 18% and was significantly associated with IgM paraproteinemia. 6 cases
were lost to follow-up. At a median follow-up time of 41 months, the majority of
the cases had no disease progression (90%): 61% had stable CBCs, 20%
solely an increase in ALCs and 7% an increase in paraproteinemia only, while
in 2% lymphocytosis regressed. A total of 9 (10%) pts progressed and required
treatment: 5/9 due to cytopenias caused by extensive BM infiltration without
splenomegaly, 1 due to bulky splenomegaly,1 due to lymphadenopathy,1 devel-
oped autoimmune thrombocytopenia, while in one due to high IgM levels in a
MYD-88(-) case. A total of 5 (6%) pts developed splenomegaly after a median
time of 78 mos (48-151).
Summary/Conclusions: After a median follow up time of 4y we demonstrated
that CBL-MZ, although displaying many diagnostic similarities with SMZL, it
rarely evolves to it. Most cases remain stable, while few develop cytopenias
due to an extensive BM infiltration. These latter cases apparently represent a
distinct MZL category which requires further investigation.
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SAFETY OF SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB DURING
THE FIRST-LINE TREATMENT OF PATIENTS WITH NON-HODGKIN
LYMPHOMA: THE MABRELLA STUDY
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Background: Intravenous (IV) rituximab is the mainstay of treatment for CD20+
B-cell non-Hodgkin lymphoma (NHL). A subcutaneous (SC) formulation of rit-
uximab has been approved in Europe and other countries that reduces health-
care resource burden and improves patient (pt) satisfaction and convenience
compared with rituximab IV. MabRella is a global umbrella study comprising
three local open-label, single-arm, Phase IIIb studies of rituximab SC, which
share a core protocol and primary endpoint but have flexibility for exploratory
endpoints (NCT01889069; NCT01987505; NCT02406092). Data from partici-
pating countries are pooled for predefined global analyses.
Aims: To evaluate the safety of first-line (1L) rituximab SC in follicular lym-
phoma (FL) and diffuse large B-cell lymphoma (DLBCL) with a focus on admin-
istration-related reactions (ARRs).
Methods: Eligible pts were aged 18–80 years with grade 1–3a FL/DLBCL and
ECOG performance status ≤3. All pts had received ≥1 full dose of rituximab IV
as 1L induction/maintenance before study entry, and were expected to receive
≥4 additional induction cycles (FL/DLBCL) or ≥6 additional maintenance cycles
(FL). Informed consent was obtained. For induction, pts received rituximab SC
1400mg every cycle (14, 21 or 28 days) for 4–7 cycles, plus standard
chemotherapy. FL pts undergoing maintenance treatment received single-agent
rituximab SC 1400mg every 2 months for 6–12 cycles. The primary endpoint
was incidence of ARRs, i.e. all adverse events (AEs) occurring within 24 hours
of administration, considered related to study drug by the investigator. Sec-
ondary endpoints included grade ≥3 AEs and serious AEs (SAEs). The safety
analysis included all pts who received ≥1 dose of study treatment. Safety data
were not collected for rituximab IV, as pts entered the trial after switching to
SC. Updated data are presented (data cut-off February 7, 2017).
Table 1.
Results: The safety population comprised 421 pts: 160 Italy; 140 Spain; 121
North Africa (Tunisia, Morocco and Algeria). Median age was 58 years (range
19–80); 49% of pts were male; 225 pts had FL and 196 had DLBCL. Of the pts
with FL, 97 completed ≥1 cycle of rituximab SC induction (45 completed 7
cycles) and 204 completed ≥1 cycle of maintenance (175 completed 6 cycles;
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73 completed 12 cycles). Among DLBCL pts, 99 completed 7 cycles of induc-
tion. Overall, 342 pts (81%) experienced an AE during treatment (Table). Com-
mon AEs (≥10% of pts) were neutropenia, anemia, asthenia, erythema and
pyrexia. ARRs were observed in 92 pts (22%); the most common (≥2% of pts)
were erythema (10%), injection-site erythema (4%), neutropenia (3%) and
leukopenia (2%). Grade ≥3 AEs occurring in ≥5% of pts were neutropenia (22%)
and febrile neutropenia (6%). Grade ≥3 ARRs were observed in 4 pts (1%).
SAEs were reported in 29% of pts (7% drug-related). Of 16 grade 5 (fatal) AEs,
2 were considered related to treatment (Klebsiella infection and sepsis). The
safety profile of rituximab SC was generally comparable between FL and DLB-
CL, although neutropenia and anemia (any grade) were more prevalent in DLB-
CL pts, and erythema (any grade) was more common in FL pts. The AE profile
in FL pts was similar during induction and maintenance, but the intensity and
seriousness of events was lower during maintenance.
Summary/Conclusions: In line with previous reports, rituximab SC is well tol-
erated during the 1L treatment of pts with NHL. The safety profile of 1L rituximab
SC is similar to reports for IV administration, with the exception of an expected
increase in ARRs, the majority of which are mild or moderate in intensity, and
resolve spontaneously.
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REAL-WORLD EXPERIENCE WITH RITUXIMAB-FLUDARABINE (RF) AND
DEXAMETHASONE, RITUXIMAB, CYCLOPHOSPHAMIDE (DRC) IN
WALDENSTROM MACROGLOBULINEMIA : A RETROSPECTIVE STUDY
FROM 163 PATIENTS
C. Protin1,*, L. Oberic1, P. Bories2, G. Laurent1, F. Despas3, L. Ysebaert1
1Hematology, 2Oncomip regional cancer network, IUC Toulouse-Oncopole,
3Clinical Pharmacology, University of Toulouse, Toulouse, France
Background: symptomatic Waldenstrom macroglobulinemia (WM) may be
managed with various regimens. After the 8th IWWM congress, experts rec-
ommended the use of rituximab-based regimens. Two phase II trials supported
DRC (n=72, 1L) and RF (n=43, one-third having received chlorambucil alone,
+/- steroids/rituximab before), with published long-term follow up of 95 and 40
months, respectively. Mature data from larger cohorts confirming trials’ results
in real-life practice are lacking.
Aims: Mature data from larger cohorts confirming trials’ results in real-life prac-
tice are lacking. Indeed, outside clinical trials, patients are older and experience
potentially more long term side effects.
Methods: We report data from a retrospective study in 163 symptomatic WM
treated as first-line treatment (or second-line after chlorambucil, n=47) with RF
(n=56) or DRC (n=108) between January 01, 2005 and december 31, 2015.
Results: Median follow up for the entire cohort is 5 years, median age at diag-
nosis 68.6y and at therapy 71.2y, 75% being above 65y at treatment. Significant
differences between DRC/RF cohorts were: median age 74/64y, high IPSS
score 63%/26%, B2M>3mg/l 74%/56%. DRC cohort: median PFS/Time To Next
Therapy and Overall Survival were 33mo, 45.8mo and 78% at 5 years, respec-
tively. Dose reductions>20% had no impact on these outcomes, but age>65y
and anemia<11.5g/dl decreased PFS. Previous CLB therapy increased the risk
for delayed toxicities (infections 39% vs 16%, myelodysplasia 13% vs 3.8%),
but not second cancers including Richter transformation. IPSS scoring system
predicted PFS and OS with good accuracy. RF cohort: median PFS/Time To
Next Therapy and Overall Survival were 53mo, 65mo and 90% at 5 years,
respectively. Previous CLB had no impact on outcomes, but dose reduc-
tions>20% adversely impacted TTNT. IPSS scoring system did not improve
prognostication. Long-term follow-up: 22% of patients had second solid cancers.
RF significantly increased the risk of Richter, and CLB exposure the risk of
myelodysplasia. Second PFS upon salvage (PFS2) was available in 72 patients:
47 DRC (PFS2 47mo), and 25 RF (PFS2 66mo), not significantly different. Only
two parameters decreased the duration of PFS2 with immunochemotherapy:
anemia and B2M>3mg/l, suggesting future trials should focus on this subgroup
to challenge standard R-based regimens with ibrutinib.
Summary/Conclusions: We conclude that clinical trials results of DRC and
RF are reproduced in our real-life cohort despite older ages, and high IPSS
scores. Long-term toxicities are also seen, at similar rates and second cancers
monitoring should be part of physician’s practice in these WM patients.
Infectious diseases, supportive care
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MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL
ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL
T. Oyake1,*, N. Sugawara1,2, Y. Fujisawa1,3, R. Sasaki2,3, W. Izumida1,4,
T. Mine5, M. Asahi1, Y. Suzuki1, Y. Okano1, Y. Fujishima1, Y. Tsukushi1,3,
Y. Aoki1, S. Kowata1, I. Hanamura6, K. Murai7, S. Ito8, Y. Ishida1
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Prefectural Ohfunato Hospital, Ohfunato, 5Division of Hematology, Department
of Internal Medicine, Morioka Red Cross Hospital, Morioka, 6Division of Hema-
tology, Department of Internal Medicine, Aichi Medical University School of
Medicine, Nagakute, 7Division of Hematology, Department of Internal Medicine,
Iwate Prefectural Central Hospital, 8Department of Medical Oncology, Iwate
Medical University School of Medicine, Morioka, Japan
Background: Invasive fungal infections (IFIs) incur significant morbidity and
mortality in neutropenic patients with hematological malignancies (HEM) after
chemotherapy. The risk for these infections is related to the intensity and dura-
tion of neutropenia, and varies from 2% to 40%. Mortality rates associated with
documented IFIs are considerable, reportedly ranging from 30% to 60%. Empir-
ical antifungal therapy is the standard care for neutropenic patients with HEM,
who remain febrile despite broad-spectrum antibacterial treatment. Several
antifungal agents including voriconazole (VRCZ) or liposomal amphotericin B
(L-AMB) have been studied as empirical therapy for febrile neutropenia (FN).
However, limited data are available concerning the efficacy and safety of mica-
fungin (MCFG) in FN patients with HEM.
Aims: We conducted a randomized, cooperative group, open-label trial com-
paring MCFG (150mg once daily) with L- AMB (2.5mg/kg once daily) as first-
line empirical antifungal treatment for FN patients with persistent fever of HEM.
Methods: 138 hospitalized FN patients with persistent fever of HEM (AML 78,
APL 4, ALL 13, MDS (RAEB) 7, NHL 28, MM 5, other hematological malignancy
3 cases) were randomized to each drug group (MCFG, 72; L-AMB, 66). The
efficacy end point was a favorable overall response, as determined by a five-
component end point according to the criteria of Walsh et al (N Engl J Med
2004; 351: 1391).
Results: At the time of enrolment, there were no significant differences in the
demographics or baseline characteristics between the two groups. The mean
treatment duration for MCFG and L-AMB was 13.8 and 16.4 days, respectively.
The efficacy rates of MCFG and L-AMB were not significantly different (38/72
cases (52.8%) vs 26/66 cases (39.4%), p=0.115*), evaluated based on: (1)
successful treatment of baseline fungal infection (3/4 cases (75.0%) vs 0/1
case (0%), p=0.170*), (2) absence of breakthrough fungal infection (65/72 cas-
es (90.3%) vs 65/66 cases (98.5%), p=0.112*), (3) survival for ≥7 days after
study completion (66/72 cases (91.7%) vs 59/66cases (89.4%), p=0.855*), (4)
absence of premature study drug discontinuation due to poor efficacy or drug-
related adverse events (54/72 cases (75.0%) vs 47/66 cases (71.2%),
p=0.615*), and (5) resolution of fever during neutropenia (45/72 cases (62.5%)
vs 33/66 cases (50.0%), p=0.258*). However, discontinuation due to drug-relat-
ed adverse events occurred less frequently in the MCFG group (1/72 cases
(1.4%) vs 9/66 cases (13.6%), p=0.006*). In safety evaluation, adverse events
of creatinine increase and hypokalemia were less often in the MCFG group
than in the L-AMB group (6/72 cases (8.3%) vs 19/66 cases (28.8%), P=0.001*,
14/72 cases (19.4%) vs 34/66 cases (51.5%), P=0.0001*). *: Chi square test. 
Summary/Conclusions: MCFG was as effective as L-AMB, and better toler-
ated than L-AMB as an empirical antifungal therapy in FN patients with HEM.
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ANTIFUNGAL DRUGS INFLUENCE NEUTROPHIL EFFECTOR FUNCTIONS
IN VITRO AND MODULATE PULMONARY DAMAGE IN INVASIVE
ASPERGILLOSIS
F. Ries1, A. Hasibeder1, P. Aranda Lopez1, M. Theobald1, H. Schild2, M. Radsak1,
D. Teschner1,*
1Department of Hematology, Medical Oncology, & Pneumology, 2Institute of
Immunology, University Medical Center of the Johannes Gutenberg University,
Mainz, Germany
Background: Antifungal agents like azoles, echinocandins or polyenes sub-
stantially contribute to reduced morbidity and improved survival of high risk
patients in hematology. However, besides their well-known antifungal activity
there is a growing body of evidence for immunomodulatory side effects on dif-
ferent effector cells of the immune system.
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Aims: The aim of our study is to clarify the immunomodulatory capacity of dif-
ferent antifungal drugs on the effector functions of polymorphonuclear neu-
trophils (PMN) and on the clinical course of invasive pulmonary aspergillosis
(IPA).
Methods: Firstly, isolated PMN from healthy donors were preincubated with
different antifungals in vitro. Here, we used the azoles fluconazole (FLU),
voriconazole (VOR), posaconazole (POS), and isavuconazole (ISA), as well
as the echinocandins caspofungin (CAS) and micafungin (MIC), and the poly-
enes amphotericin b (AmB) and liposomal amphotericin b (LAmB). Further-
more, PMN were simultaneously stimulated with lipopolysaccharides (LPS) or
zymosan. Afterwards, PMN were analyzed by flow cytometry regarding activa-
tion, degranulation, and phagocytosis. Additionally, a dichlorofluorescein assay
was used to detect reactive oxygen species (ROS). IL-8 synthesis was meas-
ured by enzyme-linked immunosorbent assay (ELISA). Secondly, a murine
model was used to investigate the influence of MIC and POS on the clinical
course of IPA in vivo. Therefore, mice were treated with antifungals and inoc-
ulated intratracheally with A. fumigatus conidia. Afterwards, mice were analyzed
concerning fungal burden and pulmonary damage (albumin ELISA) with neu-
tropenic animals serving as controls.
Results: In vitro, pretreatment with POS lead to enhanced activation (CD62L:
44% +/- 8 vs 13 +/- 2, *; mean +/- SEM; p value ≤0.05 considered to be signif-
icant [*]), increased degranulation, and intensified generation of ROS (26880
rfu +/- 2834 vs 8528 +/- 161, *), whereas zymosan triggered IL-8 synthesis
was reduced by trend. In contrast, ISA pretreated PMN showed decreased
expression of activation markers. Moreover, ISA impaired degranulation and
LPS triggered generation of ROS (6980 rfu +/- 1338 vs 28730 +/- 6893, *).
FLU and VOR did not show a significant influence on PMN effector functions
in vitro. MIC pretreatment resulted in enhanced expression of activation marker
CD62L but reduced expression of CD11b, and decreased degranulation. Addi-
tionally, phagocytosis (27% +/- 4 vs 44 +/- 1, LPS, *) as well as generation of
ROS (22660 rfu +/- 3286 vs 41190 +/- 2584, zymosan, *), and IL-8 synthesis
were substantially impaired. CAS showed an increased phagocytosis (75% +/-
6 vs 44 +/- 5, LPS, *), whereas degranulation and LPS triggered generation of
ROS were reduced by trend. Pretreatment with conventional AmB resulted in
activation of almost all effector functions besides impaired phagocytosis (43%
+/- 3 vs 59 +/- 3, LPS, *). In contrast, LAmB did not significantly alter any
effector functions. Regarding IPA, treatment with POS resulted in reduced fun-
gal burden as expected but lead to reduced albumin concentration in BAL (111
ng/ml +/- 46 vs 380 +/- 31, *) indicating a decreased pulmonary damage.
Despite significant influence on PMN effector functions in vitro, MIC did not
affect clinical course IPA in vivo.
Summary/Conclusions: AmB and POS induce PMN activation, whereas ISA
and MIC inhibit PMN effector functions in vitro. CAS shows variable modification
on PMN. Possibly independent from its antifungal effects, POS reduces pul-
monary damage in mice suffering from IPA in vivo. Further studies are needed
to distinguish the obviously multidimensional immunomodulatory effects of dif-
ferent antifungal agents and to clarify their relevance in clinical practice.
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CHARACTERISTICS AND OUTCOME OF PULMONARY INFILTRATES IN
ACUTE LEUKEMIA CLASSIFIED ACCORDING TO EORTC/MSG CRITERIA
OF INVASIVE FUNGAL INFECTION: A PROSPECTIVE STUDY BY THE
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Background: In acute leukemia (AL) patients (pts) pulmonary infections may
be severe and worsen the final outcome of AL. They have been recently shown
to adversely affect the outcome of bloodstream infections (BSI) in AL pts (Cat-
taneo et al, 2016). The radiologic characteristics of PI belong, according to the
EORTC/MSG Study Group, to the diagnostic criteria of a pulmonary invasive
fungal infection (IFI).
Aims: In order to better define the clinical and prognostic significance of PI in
AL pts in a real-life setting, we have analyzed all PI diagnosed during consec-
utive febrile/infectious episodes developing over a 26 months period in pts
admitted to 9 hematological institutions within the Rete Ematologica Lombarda
(REL) network.
Methods: From Dec-12 to Jan-14, all febrile/infectious episodes were recorded
and data concerning PI extracted. PI were classified as specific and aspecific
for IFI according to radiologic criteria. 
Results: During 1086 episodes, 256 PI were diagnosed in 195 AL pts (M/F
124/71; median age 60y; AML/ALL 163/32). PI incidence was similar during
induction and relapse (28.8% and 29%, respectively), but significantly lower in
complete remission (14.2%, p<0.0001). Overall, PI were detected in 57% of
cases during AML induction/reinduction and in 44.5% during posaconazole
prophylaxis. Posaconazole was not responsible for a decreased sensitivity of
serum galactomannan (GM), which was positive in 18.4% and in 18.6% pts
with specific PI receiving posaconazole or not, respectively. Aspecific PI were
observed in 157 cases (61.3%). In the remaining 99 cases (38.3%) the specific
radiologic criteria for suspecting IFI were met, but in 70 of them (27.3%) just in
the context of a diagnosis of possible (poss) IFI. Probable/proven (prob/prov)
IFI criteria were met in 29 PI (11.3%). The characteristics of the three subgroups
of PI are listed in Tab 1. Prob/prov IFI PI were associated with lack of posacona-
zole prophylaxis in comparison with poss IFI (72.4% vs 57.1%, p=0.0074).
Aspecific PI did not differ from poss IFI except for their lower frequency during
neutropenia, particularly if ≥15d (80.3% vs 92.9%, p=0.0164, and 56.1% vs
80%, p=0.0005, respectively), and higher frequency in patients on Fluoro-
quinolone (Fq) prophylaxis (57.3% vs 22.9%, p<0.0001). Multivariate analysis
confirmed that aspecific PI were less frequent during prolonged neutropenia
(HR 0.382, IC 0.189-0.772), and poss IFI during Fq prophylaxis (0.344, 0.159-
0.742). All but two specific PI were treated with systemic antimold therapy.
Thirty-day mortality was observed in 41 cases (16%). It was similar for aspecific
and poss IFI (15.9% and 10%), but significantly higher in prob/prov IFI (31.3%,
p=0.0192). Multivariate analysis confirmed a prob/prov IFI (3.277, 1.243-8.644)
predictive for death, as well as relapsed/refractory AL (2.45,1.092-5.498) and
BSI (2.383, 1.056-5.377).
Table 1.
Summary/Conclusions: Among PI occurring in AL patients IFI could be sus-
pected according to EORTC/MSG Study Group criteria in nearly 40% of cases
but only 11% of PI met the criteria for prob/prov IFI. Posaconazole did not affect
serum GM sensitivity and was protective against prob/prov PI, which had a
higher risk of death. On the other hand, PI associated with a diagnosis of poss
IFI had a similar outcome compared to aspecific PI, although they occurred
more frequently during neutropenia and outside from Fq prophylaxis. These
findings may be relevant in the context of a reevaluation of the criteria for sus-
pecting IFI in AL patients with PI as well as for a more appropriate antimicrobial
stewardship.
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ANTIFUNGAL PROPHYLAXIS WITH CD101 IN IMMUNOSUPPRESSED
MOUSE MODELS OF CANDIDIASIS, ASPERGILLOSIS, AND PNEUMOCYSTIS
PNEUMONIA (PCP)
V. Ong1,*, K. Bartizal1, M. Cushion2, L. Miesel3, S.R. Lopez4
1Cidara Therapeutics, Inc., San Diego, 2Cincinnati VAMC; Univ of Cincinnati
Coll of Med, Cincinnati, United States, 3Eurofins Panlabs, Taipei, Taiwan,
Republic of China, 4TransPharm Preclinical Solutions, Jackson, United States
Background: Fungal infections continue to carry high morbidity and mortality.
Disease- and treatment-related immunosuppression in patients with hemato-
logical diseases increase the risk of opportunistic infection caused by Candida
spp., Aspergillus spp., and Pneumocystis spp., and antifungal prophylaxis is
an important consideration. Agents currently used for prophylaxis, voriconazole
and TMP/SMX, carry safety and tolerability concerns. CD101 is a novel
echinocandin in phase 2 clinical development that has demonstrated preclinical
efficacy in treatment of invasive fungal infections and has physical and phar-
macokinetic attributes that enable once-weekly IV dosing and subcutaneous
(SC) administration.
Aims: To evaluate CD101 as antifungal prophylaxis in neutropenic mouse
models of candidiasis, aspergillosis, or PCP.
Methods: Candidiasis model: ICR mice (5/grp) were rendered neutropenic
by cyclophosphamide (cpm) on day -4 (150mg/kg) and day -1 (100mg/kg) and
challenged (day 0) with Candida albicans ATCC SC5314 (IV, 100 µL, 105
CFU/mouse). One dose of CD101 5, 10, or 20mg/kg SC was given prior to
challenge on day -5, -3, or -1. Kidneys were removed for CFU enumeration 24
h postchallenge. Aspergillosis model: ICR mice (6/grp) were rendered neu-
tropenic by cpm on days -3 (6mg/mouse), +1 and +4 (2mg/mouse) and then
challenged (day 0) with Aspergillus fumigatus ATCC 13073 (IV, 100µL, 104
CFU/mouse). One dose of CD101 5, 10, or 20mg/kg SC was given prior to
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challenge on day -5, -3, or -1. Survival was monitored for 14 days. PCP model:
C3H/HeN mice (10/grp) were immunosuppressed by dexamethasone (4mg/L)
in acidified drinking water and inoculated with Pneumocystis murina (intranasal-
ly, 2 x 106/50 µL). CD101 0.2, 2, or 20mg/kg intraperitoneally was given at the
time of inoculation and 1x or 3x/wk for 6 wks. TMP/SMX 50/250mg/kg/3x/wk
was used as positive control. At 6 wks, lungs were processed for quantification
of trophic and asci (cyst) forms of P. murina.
Results: Candidiasis: Kidney CFU decreased with higher doses of CD101
and shorter times between prophylaxis and challenge. At 20mg/kg, there was
complete clearance of CFU burden regardless of treatment day in all animals
except one (prophylaxis on day -3). There was complete clearance in all animals
given 10mg/kg on days -3 and -1 and significant decreases in CFU in those
given 5mg/kg on days -3 and -1. Aspergillosis: Survival rates significantly
increased following CD101 5, 10, and 20mg/kg prophylaxis on day -5, -3 or -1
compared with vehicle. Prophylaxis closer to challenge increased the rate of
survival in the 5mg/kg group. All animals given higher doses survived regardless
of day of prophylaxis. PCP: Trophic nuclei counts were significantly reduced
versus untreated controls in all CD101 groups except 0.2mg/kg/1x/wk, and effi-
cacy in 3 different CD101 groups was comparable to TMP/SMX (no nuclei
observed microscopically). Asci counts also were significantly reduced in all
CD101 groups versus untreated controls. There was no difference in efficacy
between TMP/SMX and CD101 in all but the lowest dose group
(0.2mg/kg/1x/wk), with no asci observed microscopically.
Summary/Conclusions: CD101, a novel echinocandin, was protective against
fungal challenge in immunosuppressed mouse models of candidiasis,
aspergillosis, and PCP. These data suggest that CD101 may provide benefit
as antifungal prophylaxis in patients with hematological diseases at risk for
infection. The efficacy of SC-administered CD101 demonstrated in the candidi-
asis and aspergillosis models suggests potential utility in the outpatient setting
for treatment or prophylaxis.
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LEUKAEMIA PATIENTS–EXPERIENCE FROM A LARGE TERTIARY
CENTRE IN SOUTH-EAST ASIA
C. Nagarajan1,*, Y.C. Tan1, T.T. Tan2, W. Hwang1, Y.C. Linn1, A. Ho Yew Leng1,
A.L. Ang1, R. Yiu Cheung1, N.F. Grigoropoulos1, B.H. Tan2, G.C. Wong1
1Department of Haematology, 2Department of Infectious Diseases, Singapore
General Hospital, Singapore, Singapore
Background: Invasive fungal infections (IFI) are a major cause of morbidity
and mortality in patients undergoing chemotherapy or stem cell transplantation
for acute leukaemias. Though optimised antifungal therapy might be effective,
in selected patients, surgical interventions might be an useful tool both for diag-
nostic and therapeutic reasons. However due to the nature of the disease and
circumstances, prospective data of Surgical interventions in these situations is
very difficult and the evidence is usually from small cohorts often from single
centers.
Aims: The purpose of this study is to report our single center experience of
surgical interventions for IFI in acute leukaemia patients.
Table 1.
Methods: A retrospective review of our Hospital’s Leukaemia database (IRB
approved) was made for clinical characteristics and outcomes in surgically
managed IFI patients diagnosed between Jan 2005 and Dec 2015. IFI was
defined by EORTC/MSG 2008 criteria.
Results: Among 795 acute leukaemia patients diagnosed during this period,
we found 19 patients with IFI who had undergone surgical interventions (15
proven, 1 probable and 3 possible IFI). The details of the IFI, surgical interven-
tions, antifungal treatments and perioperative complications are summarized
in Table 1. Most commonly performed surgical intervention was either open
thoracotomy or video assisted thoracoscopic surgery for wedge resection or
lobectomy. Nine of the 15 proven IFI patients had overall benefit from the pro-
cedure through optimization of antifungal therapy with MIC/sensitivities, arrest
of aspergilloma related massive bleeding and/or complete resolution of the IFI
allowing further chemotherapy or transplantation. Of these, 7 patients were
alive and well at the time of data collection and 2 had died. Among the survivors,
the mean duration of the survival post-surgery was 57.7months (range 9–118.3
months). The 2 patients who died also had benefitted from the procedure and
had survived for 6.5 and 47 months post-surgery but both succumbed to septic
events unrelated to the IFI during subsequent chemotherapy. Of the remaining
6 patients (out of the 15 proven IFI), 3 had temporary clinical and/or radiological
improvement only but succumbed 2 to 6 months post-surgery due to unrelated
septic events, 2 died due to progression of the IFI despite treatment and 1
lacked information to draw any conclusions. The patient with probable IFI diag-
nosed during induction was able to proceed with further chemotherapy post-
surgery but succumbed to CNS relapse of leukaemia 8 months later. Of the 3
patients with possible IFI, 2 were able to proceed with transplantation and 1
with chemotherapy post-surgery, but all the 3 patients succumbed to leukaemia
and/or unrelated septic events.
Summary/Conclusions: Major surgical interventions are feasible in selected
leukaemia patients with IFI. In carefully selected patients they can yield valuable
information to guide anti-fungal therapy or enable therapeutic outcomes allowing
patients to proceed with curative chemotherapy and stem cell transplantation.
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INFECTIONS IN MULTIPLE MYELOMA ARE FREQUENT AND PREDOMINANTLY
CAUSED BY BACTERIA: RESULTS OF A 12-YEAR SURVEY FROM A
SINGLE CENTER
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O. Yomade1, A. Klink1, K. Schilling1, A. Hochhaus1, A. Brioli1, L.O. Mügge3
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Background: The outcome of patients with multiple myeloma (MM) has
improved dramatically in the past years, mainly due to a better control of the
disease. However, it is not clear what influence this has on treatment- or dis-
ease-related complications like infections. Recent data even suggested an
increased rate of infections in patients with MM, possibly associated with the
use of novel drugs.
Aims: To determine the rate and the type of infections in MM patients undergoing
treatment and to evaluate possible disease- or treatment-related risk-factors.
Methods: All patients with MM treated at our institution between 2003 and
2014 were included in this retrospective analysis after approval by the institu-
tional review board. Data on age, sex, diagnosis, comorbidities, treatment
modalities, and infectious complications were recorded. Each type of therapy
(e.g. high-dose therapy versus conventional therapy) defined a patient-case
(duration per patient-case: beginning of therapy until the beginning of another
type of therapy) and infections were recorded per case. To determine risk-fac-
tors, generalized estimating equations comparing cases were used.
Results: Four-hundred seventy-nine patients (male: 272, 57%) accounted for
1690 cases (median number of cases per patient 3, range 1-15). At presentation
in our institution, median age was 62 (35-89) years, and most patients had
advanced disease (Stage III according to Salmon-Durie classification in 364
patients, 76%) and an IgG-paraprotein (255 patients, 53%). Type of therapy
given were as follows: 534 (32%) conventional long-term chemotherapy, 514
(30%) induction-type chemotherapy, 237 (14%) chemotherapy for stem-cell
mobilisation, 310 (18%) high-dose melphalan with stem-cell transplantation
and 95 (6%) supportive care only. One-hundred sixty-six patients (35%) with
295 patient cases never experienced an infection including 25 cases with high-
dose melphalan. However, the majority of patients experienced at least one
episode of infection throughout their treatment, accounting for 773 infections in
627 patient cases (37% of all patient cases). Most (559, 72%) infections were
of bacterial origin including 156 cases with pneumonia (9% of all patient cases).
Herpes zoster was noted in 37 patient cases. Relapse (OR 1.9, 95% CI 1.5-
2.5, p<0.001) and high-dose chemotherapy (OR 11.3, 95% CI 8.4-15.3,
p<0.001) were associated with a higher risk of infection whereas time of treat-
ment (2003-2008 versus 2009-2014) or use of novel drugs did not influence
the rate of infection.
Summary/Conclusions: More than 60% of MM patients experience at least
one episode of infection during their course of treatment. These infections are
mostly of bacterial origin and strongly associated with high-dose chemotherapy
or relapse. Novel drugs do not seem to influence the rate of infection. Unfortu-
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nately, despite the general improvement in the care of patients with MM, no
difference in the rate of infections could be detected in recent years.
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Background: In neutropenic patients with acute myeloid leukemia (AML) bac-
terial infections and sepsis are a leading cause of mortality. Several studies
propose a contribution of individual single nucleotide polymorphisms (SNPs)
of the innate immune system to the course of infections. Human ficolins rep-
resent recognition molecules of the lectin complement pathway whereas espe-
cially ficolin-2 (L-ficolin) is emerging as an important component of the lectin
pathway in the circulation. Ficolins share structural and functional characteris-
tics with C1q from the classical pathway of the complement that acts with Pen-
traxin 3 (PTX3) that helps the innate immune system targeting pathogens like
bacteria or viruses. In the context of hematopoietic stem cell transplantation
polymorphisms of PTX3 have been identified as an individual risk factor for
developing pulmonary aspergillosis.
Aims: We sought to investigate the impact of L-ficolin and PTX3 SNPs on the
occurrence of infectious events such as sepsis and pneumonia, including invasive
fungal disease (IFD), in 186 adult patients with newly diagnosed AML following
anthracycline-based induction chemotherapy. In addition to our studies on mem-
brane receptors, this work represents an important extension on soluble mole-
cules of the innate immune system and their potential implication on infections.
Methods: Genotyping of L-ficolin and PTX3 SNPs (rs17514136, rs17549193,
rs1800450 and rs3816527, rs2305619, rs1840680) was performed by TaqMan
assay. Multiple logistic regression analyses were applied to evaluate the asso-
ciation between the polymorphisms and the occurrence of infectious events.
Results: Two L-ficolins SNPs were identified as risk factors for developing
sepsis and/or pneumonia. Patients harboring rs17514136GG/AG or GG (n=100
or 22) revealed a significantly higher risk for developing sepsis (odds ratio
(OR): 1.88; 95% confidence interval (CI): 1.01–3.37, p=0.039) or pneumonia
(OR: 2.79; 95% CI: 1.1–6.9, p=0.033). A similar risk profile could be demon-
strated for patients carrying rs17549193TT/CT or TT. No association was found
between SNPs of the PTX3 gene and the analysed infectious events.
Summary/Conclusions: To our best knowledge, this study represents the first
analysis demonstrating that polymorphisms of human L-ficolin (rs7309123,
rs17549193) represent an independent risk factor of developing sepsis and/or
pneumonia in patients with AML undergoing induction chemotherapy. Interest-
ingly, no association of PTX3 SNPs and infectious events such as IFD was
found in this non-transplant setting. In conlusion, a genetic risk profile based
on membrane bound and soluble molecules of the innate immune system might
be helpful in identifying patients prone for infectious events.
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Background: Whereas erythropoiesis stimulating agents (ESA) are indicated
in the management of chemotherapy-induced anemia (CIA), their use in clinical
practice is a matter of controversy with regards to some meta-analyses, opin-
ions released by regulatory institutions and available international guidelines.
However, supportive care is an area of high importance in onco-hematology
thus justifying to study the use of ESA in cancer patients in the real-life setting.
Aims: The PIVOINE study aims to provide a better knowledge about the use
of epoetin theta for the treatment of CIA in onco-hematology in the real-life set-
ting and to identify predictive factors of response to ESA.
Methods: Multicenter, observational, prospective study conducted with 136
oncologists or onco-hematologists on adult patients suffering from non-myeloid
malignant tumors, treated with chemotherapy and initiating epoetin theta treat-
ment according to standard medical practice.
Results: From November 2014 to October 2015, 1379 evaluable patients were
followed in the study (mean age 68.3 ± 11.3 years, 47.2% men). Overall, 21.8%
of patients presented with hematological malignancies, 19.9% with digestive
tumors, 18.2% with lung cancer and 40.1% with other solid tumors. The majority
had a good performance status (75.2% ECOG 0-1). More than 90% of patients
had never received ESA prior to enrolment in this study and 45.2% benefited
from first-line chemotherapy. Median Hb level at inclusion was 9.7 g/dL. Epoetin
theta was initiated at a weekly dose of 20 000 IU for 76.1% of patients and
12.3% of patients benefited from dose adaptation during follow-up, mainly dose
increase (90.5%). Overall, 18.5% of patients received blood transfusion during
the study. Five-hundred and sixty-three patients (45.2%) achieved complete
response (CR) (i.e. Hb level increased by at least 2 g/dL) within 12 weeks after
epoetin theta initiation. According to Kaplan-Meier analysis, the probability of
CR was 12.7% at 4 weeks, 35.8% at 8 weeks and 52.4% at 12 weeks. Multi-
variate analysis showed that the lower the Hb level at baseline, the greater the
chance of complete response (OR 0.4 IC95% [0.335;0.478]). Moreover, good
performance status (ECOG 0 or 1), hematological malignancies (vs. solid
tumor) and the absence of blood transfusion are independent predictive factors
for complete response (OR 1.577 IC95% [1.186;2.098], OR 1.946 IC95%
[1.459;2.597], OR 1. 969 IC95% [1.411;2.747] respectively). Overall, only 27
patients (2%) experienced treatment-related adverse events, 2 of them (0.1%)
presenting with a serious one (non fatal pulmonary embolism).
Summary/Conclusions: The PIVOINE study confirms that the response rate
to epoetin theta varies considerably among patients treated similarly. This obser-
vational study conducted on a large population could help targeting the patients
that could positively benefit from such treatment to prevent CIA, mainly patients
with hematological malignancy, with good performance status and with low initial
Hb level. The safety results confirmed the safety profile of epoetin theta.
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Background: Hepatic VOD/SOS, which may be unpredictable and potentially
life-threatening, is typically considered a complication of hematopoietic stem
cell transplantation (HSCT); however, VOD/SOS can occur after chemotherapy
without HSCT. VOD/SOS with multi-organ dysfunction (MOD) may be associ-
ated with >80% mortality. Defibrotide is approved to treat severe hepatic
VOD/SOS post-HSCT in the European Union and to treat hepatic VOD/SOS
with renal or pulmonary dysfunction post-HSCT in the United States.
Aims: To perform an exploratory post hoc analysis of the impact of timing of
initiation of defibrotide after VOD/SOS diagnosis in patients developing
VOD/SOS after primary chemotherapy without HSCT (off label).
Methods: In an expanded-access protocol for patients with VOD/SOS post-
HSCT or chemotherapy, with or without MOD (renal and/or pulmonary dys-
function), defibrotide 25mg/kg/d (4 divided doses of 6.25mg/kg) was given a
recommended ≥21 days after patients provided informed consent. In this post-
chemotherapy subgroup, survival was analyzed post hoc from the day
VOD/SOS was diagnosed (days 0–30 after start of chemotherapy) through fol-
low-up, which was collected for 100 days post-chemotherapy. For these
exploratory analyses, survival rates in the post-chemotherapy subgroup were
examined by time from VOD/SOS diagnosis to start of defibrotide for (1) all
patients before/after days 1, 2, 3, 4, 7, and 14, using Fisher’s exact test and
(2) patients starting defibrotide on a particular day: 0, 1, 2, 3, 4, 5, 6, 7, 8–14,
and ≥15, by Cochran-Armitage test for trend across days. Causes of treatment
delay were not assessed.
Results: In the final dataset, 137 patients developed VOD/SOS after primary
chemotherapy. Of these, 87 patients (41 with MOD) developed VOD/SOS by
day 30 after the start of chemotherapy. In the latter group, 79.3% (69/87) were
aged ≤16 years. In 26.4% (23/87) of post-chemotherapy patients, defibrotide
was started the day of diagnosis; in 89.7% (78/87), by Day 7. In the popula-
tion-wide analysis of initiation before/after days 1, 2, 3, 4, 7, and 14 post-diag-
nosis in both the overall group and MOD subgroup (Figure), earlier initiation
was associated with higher Day +100 survival rates for all days, which was
significant at a number of timepoints. The trend test for particular initiation days
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also showed a significant trend over time for higher Day +100 survival with ear-
lier defibrotide initiation post-diagnosis in both the overall group and MOD sub-
group (P<.05). In the overall post-chemotherapy population, adverse events
(AEs) and serious AEs occurred in 66% and 40% of patients, respectively.
Aside from multi-organ failure, the most common AE of any severity was
hypotension (9.5%). Possibly related AEs lead to discontinuation in 7.3%; most
common was gastric hemorrhage (3.7%).
Figure 1.
Summary/Conclusions: In this exploratory analysis of final study data in the
subgroup of patients developing VOD/SOS after chemotherapy, earlier defi-
brotide initiation post-VOD/SOS diagnosis was associated with improved Day
+100 survival, confirmed by the Cochran-Armitage test (P<.05), even in the
small MOD subgroup. This time-dependent relationship was consistent with
that found in the HSCT subgroup from this study. No specific day appears to
provide a clinically meaningful cutoff for better Day +100 survival, suggesting
that later intervention retains value if treatment must be delayed.
Support: Jazz Pharmaceuticals
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MODEL OF INVASIVE PULMONARY ASPERGILLOSIS
A. Hasibeder1,*, S. Prüfer2, K. Ebner3, S. Reuter1, P. Aranda Lopez1, I. Scharrer1,
F. Banno4, M. Stassen2, H. Schild2, K. Jurk3, M. Bosmann3, H. Beckert1,
M. Radsak1
1IIIrd Dept. of Medicine, 2Institute for Immunology, 3Center for Thrombosis and
Hemostasis, Johannes Gutenberg-Universitiy Medical Center, Mainz, Germany,
4Department of Molecular Pathogenesis, National Cerebral and Cardiovascular
Center, Suita, Japan
Background: Von Willebrand factor (VWF) is produced as multimers of various
sizes and is secreted as an acute phase protein during inflammation. The main
mechanism regulating the size and prothrombotic activity of VWF is the specific
proteolytic activity of ADAMTS-13 (a disintegrin and metalloprotease with
ThromboSpondin type 1 repeats-13) which is diminished under several patho-
logical conditions.
Aims: To determine the relevance of this regulatory pathway for the innate
inflammatory response by polymorphonuclear neutrophils (PMN), we employed
a mouse model of invasive pulmonary aspergillosis (IPA) where PMN function-
ality is crucial for fungal clearance and survival.
Methods: IPA was induced by intratracheal application of Aspergillus fumigatus
(A. f.) conidia in wildtype (129/Sv/Pas) or ADAMTS-13 deficient (Adamts13-/-)
mice, and VWF deficient (Vwf-/-) mice or respective controls (B6). Some mice
were sacrificed 24 h after infection. Fungal load was assessed as colony form-
ing units (CFU) after plating and culturing lung homogenates on Sabouraud
agar plates. For histological analysis paraffin sections of the lungs were stained
with H&E, mouse complement component C3d and VWF antibody. Broncho
alveolar lavage fluid (BALF) was analyzed for cell count (bead-based by flow
cytometry or by an animal blood counter), ELISA was performed for albumin
amount and cytokines were analyzed by a multiplex assay. Bone marrow-
derived PMN were isolated by magnetic cell sorting using biotin labeled Ly6G/C
specific antibody. PMN functions were analyzed for degranulation, oxidative
burst activity and CD62L shedding by flow cytometry. Fungal killing of PMN in
vitro was assessed by a XTT assay. Chemotactic properties of A.f.-activated
and control serum from wildtype and knock-out mice was evaluated by migration
of purified human PMN, isolated by dextran sedimentation and Histopaque®
centrifugation, in a transwell assay.
Results: While infected neutropenic mice developed lethal IPA, all wildtype
mice survived the infection. Interestingly, Adamts13-/- mice displayed more
severe signs of disease with a lethal course in about 24% of the animals. Exam-
ination of the lungs revealed a higher fungal burden along with increased signs
of acute lung injury and levels of pro-inflammatory cytokines in ADAMTS-13
deficiency. Histology sections demonstrated a more pronounced perivascular
leukocyte infiltration in support of a dysregulated inflammatory response in
Adamts13-/- mice. Importantly, we observed no general defect in the activation
of neutrophil effector functions in response to conidia or hyphae in vitro. Fur-
thermore, innate inflammatory response to IPA was not altered in VWF deficient
(Vwf-/-) mice compared to wildtype (B6) control.
Summary/Conclusions: Therefore, we conclude that the proteolytic regulation
of VWF by ADAMTS-13 or ADAMTS-13 by itself is an important mechanism to
control PMN recruitment in acute inflammatory processes, such as fungal pneu-
monias. 
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Background: Myelodysplastic syndromes (MDS) are hematopoietic disorders
characterized by the ineffective production of mature blood cells of one or more
lineages and by the risk of evolution to acute myeloid leukemia. The current
standard of care for MDS patients is the treatment with hypomethylating agents
(HMA); however, response to drugs from this family occurs in just about half of
the patients and is accompanied by high rates of therapy failure. Failure to
HMA in MDS is a poorly understood process associated to increased risk of
disease progression and to a dismal prognosis and cannot be, thus far, pre-
dicted or prevented.
Aims: Given that MDS are stem cell disorders, our aim was the identification
and molecular characterization of the specific hematopoietic stem/progenitor
cell (HSPC) population in which the relapse-driver clones arise. This is an
essential step for the development of effective monitoring and early intervention
protocols for HMA failure.
Figure 1.
Methods: Using flow cytometry immunophenotyping, we quantitatively ana-
lyzed the different cell subpopulations within the CD34+CD38- and
CD34+CD38+ HSPC compartments in 122 sequential MDS bone marrow sam-
ples obtained from 93 patients at different stages of HMA treatment. 
Results: In line with earlier reports suggesting the presence of alterations in
myeloid progenitor frequencies in MDS, our flow cytometry data stratified
untreated patient samples in two groups representative of two abnormal differ-
entiation patterns, which were independent of the IPSS risk classification. The
“CMP pattern” group (12 samples, 34%) was characterized by an increased
frequency of the common myeloid progenitors (CMP) (2.6-fold; p<10-4), where-
as the “GMP pattern” group (23 samples, 66%) was characterized by the
increased frequency of the granulo-monocytic progenitors (GMP) (1.7-fold;
p<10-3) within the HPC compartment, when compared to those from healthy
individuals. Importantly, these two patterns were not caused by the expansion
of the aforementioned populations, but by the depletion of other progenitors
within the same compartment, which points to the existence of selective differ-
entiation defects in upstream HSC or multipotent progenitors (MPP). For
instance, decreased numbers of long-term (LT)-HSC (-5.1-fold, p=0.001) and
increased counts of the GMP precursors, lymphoid-primed multipotent progen-
itors (LMPP) (4.7-fold, p=0.016), were observed in GMP pattern patients but
not in CMP pattern patients. These data suggest that each abnormal differen-
tiation pattern arises from defects in different HSC populations and has a dif-
ferential impact in the number and functionality of downstream progenitor cells
(Figure 1). In agreement, a deeper immunophenotypic analysis of recently
defined HPC functional fractions showed decreased erythroid and megakary-
ocytic potential in CMP (-2-fold each, p<0.05) and megakaryocytic-erythroid
progenitor (MEP) populations (-3.8-fold erythroid, -7.6-fold megakaryocytic;
p=0.07, p=0.04, respectively) from CMP pattern patients but not in GMP pattern
patients. HSPC frequency-monitoring of 69 samples collected from 36 patients
throughout therapy showed persistence of both abnormal differentiation pat-
terns even during clinical remission. Furthermore, specific HSC populations
were differentially expanded upon HMA failure with leukemic progression in
the two groups of patients. In CMP pattern MDS, LT-HSC frequency significantly
increased after relapse (10.4-fold; p<10-4), whereas the LMPP frequency
sharply increased (8-fold; p<10-4) in GMP pattern patients. The fact that a pro-
liferative switch occurred in different HSC subpopulations confirmed that the
two subgroups are distinct entities with different hierarchical origins. 
Summary/Conclusions: Overall, our data provide evidence of the existence
of biologically different MDS subtypes which are caused by separate differen-
tiation defects and progress through the expansion of characteristic HSC pop-
ulations. 
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Background: Our previous studies showed that RUNX1 and ASXL1 mutations
were frequently co-existed in chronic myelomonocytic leukemia (CMML) (EHA
2015) and clonal evolution of RUNX1 and/or ASXL1 occurred most frequently
in chronic myeloid leukemia (CML) with myeloid blastic crisis (EHA 2016). The
molecular pathogenesis of cooperation of RUNX1 and ASXL1 mutations has
not been reported yet. 
Aims: We aimed to determine the functional role of collaborative association
of RUNX1 and ASXL1 mutations for secondary acute myeloid leukemia (sAML)
transformation.
Methods: For in vitro study, we overexpressed RUNX1-WT/MT (R135T) in
K562 cells which harboring ASXL1-MT (Y591X) and co-expressed with ASXL1-
WT/MT (R693X) in murine 32D cells. After stable expression, functional prop-
erties were examined by using immunoblot, co-immunoprecipitation, quantita-
tive RT-PCR, flow cytometry, cell proliferation, colony formation and gene
expression microarray analyses. C57BL/6 mice were used for bone marrow
transplantation (BMT) experiments for in vivo study.
Results: We found that RUNX1-MT augmented cell proliferation, colony for-
mation, HOXA gene expression and inhibited megakaryocytic differentiation in
ASXL1-MT K562 cells compared to RUNX1-WT or empty vector control. The
cooperation of RUNX1 and ASXL1 mutations or the knocked down of ASXL1
cooperating with RUNX1-MT inhibited apoptosis and impaired differentiation
in 32D cells. Nine months post BMT mice with the combined RUNX1 and
ASXL1 mutations, but not RUNX1-MT or ASXL1-MT alone, developed disease
characterized by marked splenomegaly, hepatomegaly, and leukocytosis with
a shorter latency. We found that RUNX1-MT stabilized hypoxia-inducible factor
1α (HIF1-α) and increased its target gene expression such as ID1 (inhibitor of
DNA binding 1). Clinical samples analyses showed that ID1 expression
increased in both RUNX1-MT and ASXL1-MT or the combined mutations of
RUNX1 and ASXL1 compared to control samples. We also examined the
impact of RUNX1 and ASXL1 mutations on sAML-free survival of 104 Patients
with CMML in whom 11 had co-occurrence of RUNX1 and ASXL1, 39 had
either mutated ASXL1 or RUNX1 and 54 patients were negative for both muta-
tions. We found that patients carrying co-existed mutations had a shorter sAML-
free-survival (median 16.1 months, 95% CI 0.0-60.1 months) than those car-
rying either mutated gene alone (median 23.0 months, 95% CI 17.8-28.2
months) or negative for both mutated genes (median not reached, 59.2% ±
8.8%% at 5 years) (P=0.023). 
Summary/Conclusions: The present study demonstrated that clinical and
functional evidence for a collaborative association of RUNX1-MT and ASXL1-
MT for sAML transformation. We identified HIF-1α targeting a new pathway
which may be critical for leukemic progression of RUNX1/ASXL1-mutated
myeloid malignancies.
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Background: The cytidine analog 5’-Azacitidine (AZA, Fig. A), a DNA demethy-
lating agent, is the primary drug for the treatment of high-risk Myelodysplastic
Syndrome (MDS) and Chronic Myelomonocytic Leukaemia (CMML), and
response is associated with improved survival benefits. However, only ~50%
of treated patients will ever respond to AZA and the molecular basis for poor
response is poorly understood. It is unclear whether non-responders to therapy
have different rates of AZA uptake into their cells and/or AZA incorporation into
nucleic acids compared to AZA responders, nor whether these might relate to
DNA methylation in vivo.
Aims: We aimed to develop an analytical method capable of simultaneously
detecting all the subcellular fractions of AZA (Fig B) within the bone marrows
of patients undergoing AZA therapy, while also assessing DNA and RNA methy-
lation levels. This would provide the most comprehensive snapshot of the intra-
cellular pharmacokinetics of AZA therapy in vivo as a first step towards better
understanding AZA resistance.
Methods: We have developed a new method utilising mass spectrometry to
accurately quantify all the different subcellular fractions of AZA within the same
sample (Fig C). Using an Orbitrap mass spectrometer with very high mass res-
olution, we have achieved the first mass separation of DAC and AZA from all
naturally occurring isotopes of deoxycytidine and cytidine respectively (a differ-
ence of less than 1 Da), thus enabling accurate quantification. We utilised sub-
cellular fractionation to obtain purified quantities of DNA- and RNA-incorporated
nucleotides, as well as free unincorporated nucleotides present in the cytoplasm.
We developed a reduction reaction to reduce the spontaneous hydrolysis of
AZA and DAC, thereby greatly improving the sensitivity of detection.
Results: Using our new method, we report for the first time direct simultaneous
quantification of: (1.) DNA-incorporated DAC, (2.) intracellular, free DAC, (3.)
methyl deoxycytidine in DNA, (4.) RNA-incorporated AZA, (5.) intracellular, free
AZA, and (6.) methyl cytidine in RNA within the same sample. We demonstrate
an inverse correlation between the amount of DAC incorporated into DNA and
DNA methylation. However, no such correlation was observed between AZA
incorporation and RNA demethylation (Fig D). The sensitivity and resolution of
our method also enabled, for the first time, a comprehensive survey of the total
intracellular pharmacokinetics of AZA in vivo in patients undergoing a standard
cycle of treatment. We discovered that the bone marrow cells of AZA responders
(n=4) incorporated more DAC into DNA compared to non-responders (n=4).
DAC incorporation was also inversely proportional to DNA methylation levels,
with greater DNA demethylation observed in the responders compared to non-
responders. Furthermore, we observed two patterns in AZA non-responders,
with DAC-incorporation and DNA demethylation occurring in some individuals
(n=2), while other non-responders (n=2) showed low or no DAC incorporation
and no DNA demethylation (Fig E). Our method also enabled us to directly
prove that low DAC incorporation was not a result insufficient AZA accumulation
intracellularly, as cytoplasmic measurements of unincorporated AZA and DAC
were highest in the non-responders with the lowest levels of DNA-incorporated
DAC. Additionally, in these non-responders, there was also concomitant
increase in AZA incorporation into RNA.
Figure 1.
Summary/Conclusions: We have developed a new method that has enabled
the first comprehensive analysis of the intracellular pharmacokinetics of AZA
therapy in vivo. Our results have revealed that while AZA responders incorpo-
rated AZA efficiently into DNA, leading to DNA demethylation, there were two
modes of primary AZA resistance: in some non-responders, low levels of AZA
incorporation into DNA likely derives from cell cycle quiescence, resulting in
low amounts of DNA demethylation. However, in other non-responders who
showed DAC incorporation into DNA and demethyltion, resistance arises from
as-yet-unknown mechanisms not connected with AZA metabolism. 
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Background: Myelodysplastic syndromes (MDS) are a heterogeneous group
of clonal hematological disorders at high risk of progression to acute myeloid
leukemia (sAML). Due to recent high-throughput sequencing studies, the muta-
tional dynamics and clonal evolution underlying disease progression have just
begun to be understood. However, large longitudinal sequencing genomic stud-
ies are still required.
Aims: To analyze the relationship between the dynamics of gene mutations
and cell pathways they are involved in with the progression from MDS to sAML
in order to study the mechanisms underlying disease evolution.
Methods: Sixty-eight serially collected samples from 34 MDS/CMML patients
evolving to sAML were studied by a combination of whole-exome sequencing
(WES) and targeted-deep sequencing (TDS). Each patient was studied at two
different time-points: at the time of diagnosis (MDS/CMML stage) and after
sAML progression (disease evolution, leukemic phase). At initial presentation
of the disease, diagnoses were as follows: 18 RAEB-1/2, 9 RCMD and 7 CMML.
Initially, WES was carried out on 40 diagnosis/progression-matched samples.
Driver mutations were identified, after variant calling by a standardized bioin-
formatics pipeline, by using the novel tool “Cancer Genome Interpreter”
(https://www.cancergenomeinterpreter.org). Secondly, in order to validate muta-
tions and precise variant allele frequencies (VAFs) estimation, TDS using a
custom MDS/AML-related capture enrichment panel (Illumina ®) of 117 genes
was performed in 30 out of 40 of the initial cohort. Moreover, a total of 28 paired-
samples from a cohort of 14 patients were analyzed by TDS.
Results: Combining both WES and TDS approaches, a total of 143 mutations
in 50 different genes were identified at the sAML stage, with most of them (118
mutations) already present at the MDS stage, at clonal or subclonal levels.
The most recurrently mutated genes were SRSF2 (41%), TET2 (41%), STAG2
(28%), SF3B1 (21%), ASXL1 (21%), TP53 (21%) and NRAS (21%). However,
it should be noted that 68% genes were mutated only in less than 10% of the
patients, highlighting the great heterogeneity that exists in the mechanisms of
disease evolution. To study the mutational dynamics during disease progression
we compared VAFs of mutations detected at both time-points (sAML to
MDS/CMML stage) in each patient. We identified 4 different clonal dynamics:
mutations that were initially present but increased VAF (type-1), decreased
(type-2), were newly acquired (type-3) or persisted with similar allelic burden
(type-4) at sAML stage. Interestingly, most of type-1 mutations were detected
in STAG2 gene. Thus, mutational burden of STAG2 were markedly increased
(6/8 patients) at sAML progression. Moreover, type-3 mutations, only detected
at the sAML-stage, were predominantly identified in FLT3 (3/4) and NRAS (5/6).
Conversely, type-4 mutations were present in MDS-related genes such as
SRSF2 (9/12), SF3B1 (3/6) and TET2 (8/12). Most of mutations in these genes
showed no changes during progression to sAML.
Summary/Conclusions: Progression from MDS to sAML could be explained
by different mutational processes, as well as by the occurrence of unique and
complex changes in the clonal architecture of the disease during the evolution.
Mutations in genes such as STAG2, FLT3 or NRAS could play an important
role during disease progression.
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Background: Progression of myelodysplastic syndromes (MDS) to acute
myeloid leukemia (AML) associates with acquisition of genetic aberrations.
Similar aberrations may occur in the development of primary AML, particularly
in the context of a clonal hematopoiesis of indeterminate potential. Thus, in-
depth knowledge of the genetics and clonal composition of MDS and paired
AML samples allows insights into MDS progression in particular and AML devel-
opment in general.
Aims: Here, we assessed mutations in serial samples of patients with MDS
and progression to AML by next generation (NGS) and single-cell sequencing
to identify mutations and clonal changes associated with AML development. 
Methods: Mononuclear cells from 21 bone marrow (BM) samples of 8 patients
with MDS and progression to AML were studied for mutations by an NGS panel
(Agilent HaloPlex, Illumina MiSeq) comprising 98 genes relevant in hematologic
neoplasms, and for copy number variations (Affymetrix CytoScan HD). All AMLs
had normal karyotype, except one with del(5q). Samples were collected during
MDS, at AML diagnosis and under treatment. Variants were verified by Sanger-
and pyrosequencing or fragment analysis in BM and CD3+ cells (germline).
Clonal assignment of variants was verified by single-cell mutation analysis
using a Single-Cell Printer.
Results: Applying predefined criteria and verifying variants by orthogonal meth-
ods in blasts and CD3+ cells, a median of 3 variants (range, 1-6) in the MDS
and 4 (range, 1-6) in the AML samples were deemed pathogenic. During MDS,
all patients except one had mutations in genes involved in RNA-splicing
(SF3B1, SRSF2, ZRSR2, U2AF1) or epigenetic regulation (TET2, IDH1,
DNMT3A, ASXL1, EZH2). Additional mutations existed in FLT3, NRAS, PTEN,
STAG2, CEBPA, RUNX1 or WT1. Subclonal mutations (i.e. variant allele fre-
quency (VAF) <10%) were present in only two MDS samples. Towards AML,
patients acquired a median of 1 (range, 0-2) new mutation in FLT3, CSF3R,
KRAS, NRAS, PHF6, IDH1 or WT1. The VAF shifts from MDS to AML indicated
cooperativity of mutations on clonal outgrowth, e.g. gain of CSF3R p.T618I
was accompanied by a chromosome 19q-loss resulting in hemizygosity of a
preexisting CEBPA mutation; or acquisition of a FLT3-TKD mutation was asso-
ciated with outgrowth of a RUNX1 mutation. Changes in mutations or VAFs
also occurred under treatment, e.g. in one patient, AML progressed under
decitabine treatment by gaining two distinct FLT3 mutations. In another patient,
who achieved complete remission after induction chemotherapy, but relapsed
with MDS, which again progressed to AML, mutations were lost or gained,
while a STAG2 mutation was detectable at all time. Interestingly, identical genes
were recurrently mutated in different clones within single patients, e.g. pro-
gression to AML associated with acquisition of a WT1 mutation in an NRAS
mutated MDS clone and with the generation of further subclones harboring
distinct combinations of different WT1 and NRAS mutations. The co-occurrence
of the specific WT1 and NRAS mutations in the different clones was demon-
strated by mutation analyses of 72 single patient cells. 
Summary/Conclusions: Mutations in MDS are few in number, but enriched
in genes involved in RNA-splicing or epigenetic regulation; gain of single driver
mutations leads to clonal outgrowth and thus, AML. Subsequent treatment can
change the mutational and clonal profile. Mutations in identical genes occur in
different clones, as confirmed by single-cell analyses; this suggests a fertile
ground (e.g. microenvironment) for such mutations in a patient and may lead
to (a therapeutically exploitable) competition of clones. 
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Background: Myelodysplastic syndromes are a heterogeneous group of clonal
hematopoietic stem cell disorders with diverse phenotypes, characterized by
ineffective hematopoiesis and bone marrow morphological dysplasia with vary-
ing risk of leukemic transformation. Over the last decade, there has been sig-
nificant progress in understanding the pathogenesis underlying the MDS.
Notably, patient derived xenograft (PDX) models offer the most advanced pre-
clinical opportunity to capture the complexities of this myeloid malignancy. A
number of different animal models have been proposed but the more promising
to date are the NSG and the NSG-S (humanized with SCF, GM-CSF and IL-3).
Aims: Here we have used bone marrow cells from 39 MDS patients, covering
all risk groups, to generate a preclinical in vivo and in vitro model, which could
be used to study clonal evolution and test targeted therapies.
Methods: We have used NSG and NSG-SGM3 mice to assess the scid-repop-
ulating capacity of the MDS stem cells in presence or absence of mesenchymal
stromal cells (MSCs). Moreover we have developed an in vitro 2D co-culture
system as an alternative/complementary tool to in vivo studies.
Results: Our data showed promising results with the injection of mononuclear
cells obtained from patient BM, however the co-injection of mesenchymal stro-
mal cells (MSCs) did not improve the level of engraftment. To address the
question of the becoming of MSCs once injected, we tracked them back into
the mice BM and showed that they disappeared after a week of engraftment.
With a 2D in vitro system, we showed that we could co-culture CD34+ cells
from MDS patient BM, on auto- and allo-genic MSCs, over 4 weeks with a fold
expansion ranging from 50 to 600 times. More importantly those cells con-
served their clonal architecture and chromosomal aberrations.
Figure 1.
Summary/Conclusions: Although the in vivo model cannot be replaced, the
low level of engraftment of most of the patients is a limit in the study of MDS.
Here we have demonstrated the value of the 2D co-culture system using MSCs
(or murine MS5) as an alternative model to study MDS. This ex vivo culture
system, which lasts for only 4 weeks and requires low number of human CD34+
cells, provides a robust preclinical assessment model to test therapeutic effects
of different drugs and other approaches on the MDS clonality and autologous
MSCs prior to treatment of MDS patients.
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CHARACTERIZED BY A SWITCH FROM OXIDATIVE PHOSPHORYLATION
TO GLYCOLYSIS AND THIS DEFECT IS PARTIALLY RESTORED BY IRON
CHELATION. A FISM STUDY
D. Cilloni1,*, S. Ravera2, C. Calabrese1, V. Gaidano1, F. Sabatini2, V. Giai Via1,
P. Niscola3, E. Balleari4, C. Finelli5, M.T. Voso6, A. Poloni7, D. Vallisa8, M. Crug-
nola9, S. Fenu10, A.M. Pelizzari11, F. Salvi12, V. Santini13, M. Podestà2, F. Fras-
soni2
1Dept of Clinical and Biological Sciences, University of Turin, Orbassano, 2Stem
Cell laboratory, G.Gaslini Institute, Genova, 3Division of Hematology, Sant’
Eugenio Hospital, Rome, 4Dept of Internal Medicine, IRCCS AOU San Marti-
no-IST, Genova, 5Dept of Hematology, Seragnoli Institute, Bologna, 6University
Tor Vergata, Rome, 7Dept of Hematology, University of Ancona, Ancona, 8Dept
of Hematology, Piacenza Hospital, Piacenza, 9Dept of Hematology, University
of Parma, Parma, 10Dept of Hemaotogy, San Giovanni Hospital, Rome,
11Ospedale Civili di Brescia, Brescia, 12Dept of Hematology, SS. Antonio e
Biagio Hospital, Alessandria, 13dept of Hematology, University of Florence,
Florence, Italy
Background: Myelodysplastic syndromes (MDS) are a heterogeneous group
of diseases characterized by a clonal and ineffective hematopoiesis, as well
as the tendency to develop iron overload, mainly due to red blood cell transfu-
sions. Iron overload has been described to increase ROS production and pro-
gressively worsen hematopoiesis. In mitochondria, iron is a fundamental com-
ponent of cytochromes belonging to the oxidative phosphorylation (OXPHOS),
which is considered the main source of cellular energy. Mitochondria are also
the main site of ROS production.” In this regard, cancer energetic metabolism
is an emerging issue that could represent an attracting therapeutic target.
Aims: The aim of the study was to investigate the energetic metabolism in
MDS patients and to understand the impact of iron overload on the energy
production.
Methods: We selected 37 samples from patients with MDS with or w/o iron
overload (7 RA, 5 RARS, 9 RCMD, 4 RAEB-I, 2 RAEB II and 10 s-AML). In
addition we analyzed 86 samples from healthy subjects stratified according to
age (20-103 years) and 4 samples from beta thalassemia with iron overload.
In all these samples, we evaluated the ATP/AMP ratio, as marker of energy
status, the OXPHOS activity, in term of oxygen consumption and ATP synthesis,
the lactate dehydrogenase (LDH) activity, as marker of anaerobic glycolysis,
and malondialdehyde (MDA), as marker of lipid peroxidation. The same param-
eters have been analyzed also after iron chelation with deferasirox (DFX) and
after incubation of the cells with DFX and DFO
Results: Our study clearly demonstrated that mitochondrial function is altered
in MDS, leading to a strong energetic defect and an increase in oxidative stress,
far beyond the expected paraphysiological decrease resulting from ageing.
The OXPHOS efficiency is highly reduced in MDS compared to controls, deter-
mining an impairment of the ATP/AMP ratio, which is 2.4 in young controls,
0.75 in elderly controls and it is 0.2 in b-thalassemia and MDS patients. By
contrast, LDH activity increased in the MDS patients (6mU/mg) with respect
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the controls (88 mU/mg), suggesting an attempt to compensate the energy
unbalance with the increment of anaerobic glycolysis. MDA level, which reflects
the lipid peroxidation, is 1mM in young subjects, 9mM in elderly subjects, 9mM
in b-thalassemia and 15mM in MDS. In vitro iron chelation partially restored
this abnormalities in MDS patients: ATP/AMP ration increases from 0.2 to 0.6
in MDS and b-thalassemia, by contrast it is reduced in healthy subjects from
2.4 to 1.6. Anaerobic glycolysis is reduced after DFX incubation, in fact LDH
decrease from 88 to 77 in MDS. By contrast, in healthy samples the iron chela-
tion determined a reduction of OXPHOS activity, with a consequent impairment
of ATP/AMP ratio and an increment of anaerobic glycolysis flux. Lipid peroxi-
dation is significantly reduced of 28% with DFX and 23% with DFO (p value
<0.001 for both). Similar reduction is observed in b-thalassemia. By contrast
MDA levels increased in healthy subjects incubated with DFX. Curiously, all
these abnormalities are more pronounced in MDS with IOL compared to MDS
w/o IOL and are significantly worse in MDS without IOL compared to elderly
normal subjects. Finally, in vivo treatment of patients with DFX reproduces sim-
ilar findings as in vitro incubation.
Summary/Conclusions: In summary OXPHOS activity and the energetic sta-
tus are highly impaired in MDS compared to elderly subjects. MDS cells used
O2 to produce ROS instead of ATP. This is typical of ageing but is significantly
increased in MDS compared to elderly controls and it is further increased by
IOL. DFX is able to restore mitochondrial activity and ATP production in all the
patients analyzed after in vivo or in vitro treatment. 
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V-SET AND IMMUNOGLOBULIN DOMAIN-CONTAINING 4 (VSIG4)
EXPRESSED ON MONOCYTES INCLUDING TUMOR-ASSOCIATED
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Background: In myelodysplastic syndromes (MDS), blast cells increase with
clonal proliferation during disease progression, while immune cells in the bone
marrow (BM) microenvironment become less efficient. The V-set and
immunoglobulin domain-containing 4 (VSIG4) molecule is a new B7 family-
related protein and strong negative regulator of T-cell proliferation. However,
the role of VSIG4 in tumors including hematological malignancies remains
unknown. 
Aims: We investigated the expression and functions of VSIG4 in MDS.
Methods: 1) Peripheral blood (PB) and BM samples were obtained from 39
patients with acute leukemia transformed from MDS (AL-MDS, N=21), MDS
(N=13), and chronic myelomonocytic leukemia (CMML, N=5) and from healthy
controls (N=14). The expression of VSIG4 in mononuclear cells (MCs) from
the samples and MDS cell lines (F-36P and SKM-1) was analyzed with real-
time PCR and flow cytometry (FCM). 2) After cultivation with BM stromal HS-5
cells, its culture supernatants (HS-5 sup.), immunomodulatory drugs (lenalido-
mide [LEN] and pomalidomide [POM]), and anti-MDS agents (cytarabine and
azacitidine), VSIG4 expression on cells was determined using FCM. 3) The
proliferative potential was examined by BrdU incorporation using FCM and the
MTT assay. 4) The cytotoxic activity of natural killer (NK) cell line NK-92MI
against target cells was determined by measuring lactate dehydrogenase activ-
ity in culture supernatants. The production of IFN-γ from donor T cells was
measured in the cell culture supernatants using ELISA. 
Results: 1) VSIG4 mRNA expression in PBMCs from patients with AL-MDS
was significantly higher than in those from controls. Cell-surface VSIG4 expres-
sion on CD14+CD11b+ monocytes from MDS and AL-MDS patients was higher
than in those from controls, but VSIG4 expression was not detected on CD34+
blasts. In CD14+CD11b+ monocytes of MDS and AL-MDS patients, VSIG4 was
strongly expressed on CD68+CD206+ tumor-associated macrophages (TAMs).
Furthermore, the expression levels of VSIG4 on CD14+ monoblasts from CMML
patients were significantly upregulated in comparison with those from controls.
2) Two MDS cell lines expressed both VSIG4 mRNA and its cell-surface protein.
VSIG4 expression on MDS cell lines, and on monocytes and monoblasts from
MDS and CMML patients, respectively, was significantly upregulated by co-
cultivation with HS-5 sup, LEN, and POM, but not with cytarabine or azacitidine.
3) VISG4+ MDS cells had higher proliferative potential than VISG4– cells, and
the proliferation of VSIG4+ cells was suppressed by VSIG4-specific small inter-
fering RNA. 4) LEN-treated K562 cells, which induced high VSIG4 expression,
were more resistant to NK-mediated cytotoxicity than untreated K562 cells.
The cytotoxic activity of NK cells was inversely correlated with the expression
levels of VSIG4 on target cells. CD45-mediated ADCC activity of NK92-MI cells
against LEN-treated MDS cells was inhibited in comparison with untreated
cells. Moreover, the production of IFN-γ from donor T cells co-cultivated with
LEN-treated MDS cells was suppressed compared with control cells. 
Summary/Conclusions: Our study demonstrated that VSIG4 was highly
expressed on monocytes including TAMs in MDS and AL-MDS patients, and
on monoblasts in CMML patients. VSIG4-expressing monocytes and
monoblasts may suppress antitumor immune responses and be associated
with disease progression in MDS and CMML. The results will allow us to eluci-
date the function of VSIG4 in MDS pathophysiology and lead to the develop-
ment of new immunotherapy.
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Background: Though genetic instability is a hallmark of myeloid disorders, the
lack of recurrent somatic mutations, inarguably pathogenic, in the DNA repair
machinery have precluded a predominant interest in this pathway. However,
the recent discovery of non classical leukaemogenesis by splicing defects, the
paramount influence of epigenetic anomalies, and the development of of unbi-
ased high-throughput sequencing approaches oblige us to revisit those routes
in blood cancers.
Aims: To perform improved massive RNA-seq in chronic myelomonocytic
leukemia (CMML) samples to identify neoplasm-specific targets for a synthetic
lethality therapeutic aproach. To validate the candidates through a direct strat-
egy in an extended cohort of CMML, myelodisplastic sydromes (MDS) and
acute myeloid leukemia (AML) patients.
Methods: We performed enhanced RNA-seq on 27 CMML bone marrrow sam-
ples at diagnosis and 10 healthy BM samples We validated those DEGs by
RT-PCR in an extension cohort of 73 additional CMML patients and assessed
their potential singular pattern in this disease by analyzing 80 MDS and 90
AML patients. We further chose 13 of the diferentially expressed genes for val-
idation and characterization through the myeloid spectrum based on clinical
considerations: i) druggable oncogenes found to be highly overexpressed in
our cmml patients or allowing for the inhibition of an specific DNA repair pathway
(i.e. XPA, XRCC4, MSH4): ii) oncogenes infra-expressed in our cohort but with
inhibitory molecules already being tested in myeloid neoplasms (i.e.
PARP1).Global pattern of DNA repair gene expression was compared with
MDS and AML MILE study data.
Results: Of 27 CMML patients and 10 healthy donors, the expression of 18
genes was significantly different between the two groups (p-value<0.05) with 6
genes up-regulated and 12 genes down-regulated in CMML patients compared
with donors. Defects on genes predominantly unique to a single strand breaks
repair pathway included: NEIL1 and OGG1 in base excision repair (BER), XPA
and MSS19 in nucleotide excision repair (NER) and MSH4 in Mismatch Repair
(MMR). Only XRRC4 overexpression was found as a significant defect in genes
associated exclusively to double strand break repairs. We found different direc-
tions of misregulation in our DNA repair genes candidates in CMML when we
validated them by RT-PCR in an extended cohort of 73 CMML, 80 MDS and
90 AML patients (i.e. PARP1 is down-regulated in our CMML and up-regulated
in our complex-karyotype AML subset). To validate this, we extracted the DNA
repair transcriptional components from a large dataset of 206 MDS, 47 complex
karyotype AML (AMLcx) and 73 healthy donors bone marrow from the MILE
study. Surprisingly, MDS misregulation was characterized for a predominance
of upregulated genes (14 out of the 20 misregulated targets) while AMLcx
showed a global defect with a predominance of downregulation (37 out of 50
misregulated targets). Of note, some genes showed opposite sense of misreg-
ulation according to the myeloid disorder: TDP1 was upregulated in CMML cas-
es and downregulated in AMLcx, and viceversa for BAP1. CDK1 and EXO1
were upregulated in MDS cases and the opposite effect was found among AML
cases.
Summary/Conclusions: Using an unbiased and massive DNA repair tran-
scriptome assessment, we have identified a series of candidate targets for a
synthetic lethality approach in CMML. In addition, the different sense of mis-
regulation of these and other targets within the myeloid diseases, some of them
already being targeted in the clinical trial setting, emphasize the need of a neo-
plasm-personalized test of DNA repair modulators.
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DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYN-
DROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY
ANALYSIS USING A MYELOID MATURATION DATABASE 
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Background: The diagnosis of myelodysplastic syndromes (MDS) is based
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on cytomorphological characteristics, but it remains a challenge in some
patients who do not fulfil diagnostic criteria. Flow cytometry (FC) immunophe-
notyping can be in an important tool for MDS diagnosis, but a lack of standard-
isation and subjectivity of the analysis hinder its applicability.
Aims: To develop a methodology for FC immunophenotyping that allows us to
stablish the differential diagnosis between MDS patients and non-clonal cytope-
nias using a myeloid maturation database.
Methods: Bone marrow samples from 55 MDS patients, and 51 controls with
cytopenias of several origins (immune disease, hypersplenism, drug toxicity)
were analysed by FC. We elaborated a Myeloid Maturation Database using
the Infinicyt® v1.7 software (Cytognos, Spain). From all bone marrow controls,
we merged files stained with a 4-colour combination (CD16-FITC/CD13-PE/
CD45pCP/ CD11bAPC). We selected myeloid population from the merged file
and drew a maturation path. We obtained a maturation diagram that displays
the fluorescence intensity of each parameter measured along the maturation
stages. Then, for patients and controls, we obtained the fluorescence intensities
whose median values exceeded ±2SD range in comparison with the stored
database values (Figure 1). We elaborated a score, considering the relevant
changes in fluorescence intensities (deviations) in the four markers analysed
(CD16, CD13, CD45, CD11b) and in the four maturation stages, with a punc-
tuation from 0 to 16.
Results: We found a mean of 1.9 deviations (fluorescence intensities values
exceeded ±2SD) in controls, and a mean of 4.5 deviations in patients. Our test
resulted reliable for differential diagnosis between controls and patients (curve
ROC analysis, AUC=0.748; p= 0.016). We found that with a cut-off of 4.5 devi-
ations, we obtained a high specificity in the diagnosis of MDS (100%) but a
low sensitivity (45%). With a high suspicion of MDS (specificity 90%), we can
consider patients with scores above 3.5, thus achieving higher sensitivity (59%).
Additionally, the number of immunophenotyping changes correlated well with
prognostic risk. We confirmed that the higher the risk, the greater impact on
deviations from the normal pattern (average of 3.7 at low risk, 4.5 at interme-
diate risk; 6.8 at high risk) (Figure 2).
ù
Figure 1.
Summary/Conclusions: The maturation database (using the maturation
analysis from Infinicyt® software) was useful to discriminate between MDS
patients and non-clonal cytopenias, proving to be a reliable diagnostic test,
also with prognostic implications. The application of this database as a diag-
nostic tool has the advantage that the result is independent of the observer.
Inclusion of more myeloid markers and incorporation of erythroid parameters
could increase sensibility in differential diagnosis.
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OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE
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Background: Treatment options are limited and prognosis is poor for patients
(pts) with relapsed or refractory myelodysplastic syndromes (R/R MDS), those
who relapse after or fail to achieve complete response with hypomethylating
agents (HMAs). Atezolizumab (atezo) is a humanized IgG1 monoclonal anti-
body that binds programmed death-ligand 1 (PD-L1), disrupting the immune
activation checkpoint. The role of PD-L1 blockade in hematologic disorders is
not yet established. Immune evasion via the PD-L1/PD-1 pathway may play a
role in MDS resistance to HMA treatment (Yang et al. Leukemia. 2014). Upreg-
ulation of PD-L1 expression seen in pts during and after HMA treatment sug-
gests that atezo could provide benefit in HMA-exposed pts as a single agent
or in combination with an HMA.
Aims: To determine the safety and clinical activity of atezo alone and in com-
bination with azacitidine (aza) in an open-label Phase Ib clinical trial
(NCT02508870).
Methods: Pts with R/R MDS were eligible for Cohorts A and B, excluding those
with prior solid organ or allogeneic hematopoietic cell transplant. Pts in Cohort
A received atezo 1200mg intravenously (IV) on day 1 of each 21-day cycle for
up to 17 cycles. Pts in Cohort B received aza 75mg/m2 on days 1 through 7
and atezo 840mg IV on days 8 and 22 of each 28-day cycle for 6 cycles, fol-
lowed by single-agent atezo 1200mg IV on day 1 of each 21-day cycle for up
to 8 cycles. Primary endpoints were safety and tolerability. Secondary endpoints
included overall response rate, time to AML progression, PFS, OS and changes
in transfusion rate. Blood and bone marrow samples were collected for PK
evaluation and biomarker analysis.
Results: At the time of data cutoff, 10 pts in Cohort A and 6 pts in Cohort B
were safety evaluable. The median age was 76 years (range, 63-89 years); 4
of 16 pts (25%) had ≥2 previous lines of therapy. All pts were previously
exposed to aza, and 2 of 16 pts (13%) were also exposed to decitabine. 15 of
16 pts were refractory to prior therapy. All pts experienced ≥1 treatment-emer-
gent adverse event (AE). The most common Grade 3-4 AEs were febrile neu-
tropenia (31%) and decrease in neutrophil count (25%). One pt died on study
of an unknown cause. The median duration of treatment was 101 days (range,
70-275 days) in Cohort A and 92.5 days (range, 39-144 days) in Cohort B.
Four of 10 pts in Cohort A and 3 of 6 pts in Cohort B remained on study as of
16 Sep 2016. All 10 pts in Cohort A and 5 of 6 pts in Cohort B were evaluable
for response. No pt achieved an objective response; 6 of 10 pts (60%) in Cohort
A and 3 of 5 pts (60%) in Cohort B had stable disease. Compared with pre-
treatment, a trend toward decreased RBC transfusions was observed in pts in
Cohort A, especially in those who remained on therapy beyond 12 weeks. Pre-
liminary PK analysis showed that exposure to atezo as a single agent or in
combination with aza was comparable to historical data in pts with solid tumors.
Summary/Conclusions: Early evaluation of atezo alone and in combination
with aza suggests that the safety profile is consistent with that expected in the
study population. Additionally, the duration of therapy observed is encouraging
in this R/R population with no standard-of-care options. Updated safety, efficacy
and survival data will be presented. Emerging correlative biomarker information
will also be discussed.
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EPIGENETIC DRUG TREATMENT GLOBALLY INDUCES CRYPTIC
TRANSCRIPTION START SITES ENCODED IN LONG TERMINAL REPEATS
(LTRS)
M. Daskalakis1,*, D. Brocks1, C.R. Schmidt1, D. Li2, J. Li2, H.S. Jang2, B. Zhang2,
S. Laudato1, D.B. Lipka1, J. Schott3, H. Bierhoff4, Y. Assenov1, M. Helf1,
A. Ressnerova1, M.S. Islam1, A.M. Lindroth5, S. Haas6, M. Essers6,
C.D. Imbusch7, B. Brors7, I. Oehme8, O. Witt8, M. Lübbert9, J.-P. Mallm10,
K. Rippe10, R. Will11, D. Weichenhan1, G. Stoecklin3, C. Gerhäuser1, C.C. Oakes12,
T. Wang2, C. Plass1
1Division of Epigenomics and Cancer Risk Factors, German Cancer Research
Center, Heidelberg, Germany, 2Department of Genetics, Center for Genome
Sciences and Systems Biology, Washington University School of Medicine, St.
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Louis, United States, 3Center for Molecular Biology of Heidelberg University,
Heidelberg, 4Department of Genetics, Friedrich Schiller University, Jena, Ger-
many, 5Graduate School of Cancer Science and Policy, National Cancer Center,
Goyang-si, Korea, Republic Of, 6Heidelberg Institute for Stem Cell Technology
and Experimental Medicine (HI-STEM), 7Division of Applied Bioinformatics,
8Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Cen-
ter, Heidelberg, 9Department of Medicine, Division of Hematology/Oncology,
University of Freiburg, Medical Center, Freiburg, 10Research Group Genome
Organization & Function, German Cancer Research Center and Bioquant Hei-
delberg, 11Genomics and Proteomics Core Facility, German Cancer Research
Center, Heidelberg, Germany, 12Division of Hematology, Department of Internal
Medicine, The Ohio State University, Columbus, United States
Background: Epigenetic drugs are currently used for the treatment of several
hematologic malignancies, but their pharmacological mechanism remains poor-
ly understood. For DNA methyltransferase and histone deacetylase inhibitors
(DNMTi and HDACi) several mechanisms of action have been proposed, mainly
based on candidate gene approaches. However, less is known about their
genome-wide transcriptional and epigenomic consequences.
Aims: To investigate the effects of epigenetic treatment on transcription and
chromatin, we profiled genome wide transcription start sites (TSS) activities
and associated chromatin changes following the treatment with inhibitors
against DNMTs, HDACs, or both.
Methods: Genome wide analysis of transcription start sites (TSS) (Cap analysis
of gene expression (CAGE) sequencing), methylation status (whole-genome
bisulfite sequencing) and chromatin dynamics (Chromatin-immunoprecipitation
(ChIP) sequencing) were done by using a previously described reporter cell
line model. Functional assays were used to investigate the mechanisms of LTR
reactivation, a neuroblastoma mouse xenograft model to confirm the LTR reac-
tivation in vivo.
Results: Following the treatment with inhibitors against DNMTs, HDACs, or
both, we observed the activation of thousands of cryptic, currently non-anno-
tated transcription start sites (treatment-induced non-annotated transcripts,
TINATS). These TINATs arose most commonly from LTR12 elements, particu-
larly LTR12C (ca. 50% of all TINATs). The resulting transcripts frequently splice
into protein-coding exons and encode truncated or chimeric open reading
frames which translated into currently uncharacterized protein isoforms with
predicted abnormal functions or immunogenic potential, the last one based on
their foreign sequence and capability of being presented on MHC-class I mol-
ecules. TINAT transcription after DNMTi coincided with DNA hypomethylation
and gain in H3K4me3, H3K9ac, and H3K27ac, and further activating histone
marks, while HDACi specifically induced a subset of TINATs in association with
H2AK9ac, H3K14ac, and H3K23ac. Despite this mechanistic difference, both
inhibitors convergently induced transcription from identical sites since TINATs
are encoded in solitary long-terminal repeats of the endogenous retrovirus-9
family, epigenetically repressed in virtually all normal cells. Moreover, we found
a consensus GATA2 binding motif which strongly distinguished LTR12Cs with
TINATs from LTR12Cs without TINATs, supporting that GATA2 is likely the
upstream transcription factor responsible for TINAT activation. Knock-down of
GATA2 resulted in a reduced LTR12C expression despite epigenetic drug treat-
ment. Overexpression of LTRs in our cell line model showed reduced cell via-
bility in 3 out of 10 TINAT candidates. The reactivation of LTR12C elements
upon epigenetic drug treatment could be confirmed in other malignant cell lines
as well. Importantly, treatment with several chemotherapeutic agents did not
affect LTR12C transcript levels, suggesting that their induction is a specific
effect of epigenetic modulation rather than a general consequence of cellular
stress. Additionally, we measured the transcription of LTR12C transcripts after
SAHA treatment in a neuroblastoma mouse xenograft model, thereby confirm-
ing LTR12C induction in vivo.
Summary/Conclusions: DNMTi and/or HDACi induce de novo transcription
of LTRs (LTR12 family), resulting in numerous fusion transcripts that encode
novel protein isoforms which partly have the potential to influence cell prolifer-
ation, might explain the priming effect of epigenetic therapy and will be further
investigated regarding their role as potential marker for epigenetic treatment
response. Other future experiments will include proteomic approaches com-
bined with T-cell cytotoxicity assays to further shed light on the interaction
between epigenetic and immune therapy and the role of ERV-derived antigen
presentation.
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LYMPHOPENIA IS AN INDEPENDENT RISK-FACTOR IN PATIENTS WITH
LOW-RISK MDS ACCORDING TO THE IPSS-R
T. Silzle1,*, E. Schuler2, B. Hildebrandt3, S. Blum4, R. Haas2, U. Germing2
1Oncology/Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland,
2Department of Haematology, Oncology and Clinical Immunology, 3Institute of
Human Genetics, University Hospital Düsseldorf, Düsseldorf, Germany,
4Département d’oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland
Background: Lymphopenia is associated with an increased mortality in differ-
ent medical conditions, including solid tumours and lymphoma. Little is known
about its prognostic impact in myelodysplastic syndromes (MDS).
Aims: To clarify the prognostic impact of lymphopenia in MDS in addition to
the Revised International Prognostic Scoring System (IPSS-R)
Methods: The Düsseldorf MDS-registry was searched for patients with a com-
plete differential blood count at diagnosis. Patients having received allografting
or with an absolute lymphocyte count >5.0 G/l were excluded. The influence of
the absolute lymphocyte count at diagnosis on overall survival was determined
by Kaplan-Meier analysis. Multivariate Cox regression analyses were per-
formed.
Results: 2035 patients (RA n=182, RCMD n=978, RARS n=170, MDSdel5q
n=92, RAEB-1/2 n=613) with a median follow-up of 23 months (mo) were iden-
tified. Data were sufficient for IPSS-R calculation in 651 patients. The mean
absolute lymphocyte count (ALC) in the whole population was 1402/μl (95% CI
1368-1437, range 0.12-4972) with no significant differences between the IPSS-
R groups (very low-risk [n=77] mean 1471/μl, low-risk [n=255] mean 1406/μl,
intermediate-risk [n=154] mean 1244/μl, high-risk [n=96] mean 1419/μl, very-
high risk [n=69] mean 1255/μl, p=0.067). 688 patients (34%) were lymphopenic
(ALC < 1000/μl) with a significantly shorter survival (median 33.7 versus 26.4
months, Log Rank p < 0.001). After stratification according to IPSS-R, survival
of lymphopenic patients was not significantly different in the very-low, interme-
diate or (very) high risk group. Within the low risk group the survival difference
was of borderline significance (median 67 vs 47 months, Log Rank p=0.1, Bres-
low p=0.039). With an ALC above the first quartile of the whole population
(850/μl) as discriminator, the survival difference between lymphopenic and non-
lymphopenic patients within the IPSS-R low-risk group reached statistical sig-
nificance (survival median 67.4 versus 43.0 months, Log Rank p= 0.002). This
was not the case in the other IPSS-R subgroups. In multivariable analyses, an
ALC <850/μl retained its independent prognostic value for the IPSS-R low risk
group after inclusion into a Cox regression model together with age <>70 and
LDH <> normal value (240 U/l) (p= 0.039 ). Patients with an ALC <850/μl had
significantly lower platelet (median 97 versus 150 G/l, p<0.001) and neutrophile
(median 1478 versus 1971/μl, p <0.001) counts but similar haemoglobin levels
(median 9.1 versus 9.4 g/dl, p=0.052).
Summary/Conclusions: An absolute lymphocyte count < 850/μl is an inde-
pendent risk factor in patients with low risk MDS according to the IPSS-R.
Whether lymphopenia in MDS is a direct consequence of the underlying
haematopoietic stem cell defects or arises from immune-modulating stimuli
related to the disease or to other host conditions remains to be elucidated. The
lower levels of platelets and neutrophils in lymphopenic patients observed in
our cohort point towards an association of lymphopenia with marrow insuffi-
ciency. In addition, further studies with larger patient cohorts are necessary to
define the lymphocyte count most suitable for prognostication.  
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IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY
OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND
CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH
HYPOMETHYLATING AGENTS 
A. Alfonso Pierola1,*, G. Montalban-Bravo1, K. Takahashi1, E.J. Jabbour1, T. Kadia1,
F. Ravandi1, J. Cortes1, C. DiNardo1, N. Daver1, G. Borthakur1, N. Pemmaraju1,
M. Konopleva1, C. Bueso-Ramos2, S. Pierce1, H. Kantarjian1, G. Garcia-Manero1
1Leukemia, 2Hematopathology, MD Anderson Cancer Center, Houston, United
States
Background: The concept of marrow complete response (mCR) was included
for the first time in the 2006 International Working Group (IWG) response criteria
in MDS. mCR is defined as a reduction to ≤5% myeloblasts and decrease by
≥50% compared to baseline with persistent cytopenias. However, their inclusion
in the response criteria remains controversial as it is not known how it affects
the natural history of MDS.
Aims: The aim of our study was to describe the impact of mCR in survival out-
comes in patients with MDS treated with hypomethylating agents (HMA).
Methods: We retrospectively reviewed 713 patients diagnosed with MDS or
CMML and treated with frontline HMA between 2004 and 2015 at a single insti-
tution. Clinical and demographic data were obtained from an electronic data-
base. Response was assessed by modified 2006 IWG criteria. Statistical analy-
ses were performed with the IBM SPSS Statistics 23.0 software. All tests were
2-sided with significance set at p<0.05.
Results: 444 (62.3%) patients from the initial cohort achieved at least hema-
tologic improvement (HI) as best response and were included in the analysis.
162 (37%) patients were female. Median age at diagnosis was 68 years (range
17-91). Following the 2016 WHO classification: 30 patients (7%) were MDS-
SLD, 50 (11%) MDS-MLD, 20 (5%) MDS-RS, 230 (52%) MDS-EB, 10 (2%)
MDS-U and 104 (23%) CMML. According to the International Prognostic Scor-
ing System (IPSS), 37 patients (8%) belonged to the low risk group, 176 (40%)
to the intermediate-1 risk group, 198 (45%) to the intermediate-2 risk group,
and 31 (7%) to the high risk group. 200 (45%) patients received azacitidine-
based therapies and 244 (55%) decitabine-based therapies. Responses includ-
ed: 238 (33% of the total population) complete responses (CR), 61 (9%) mCR,
2 (<1%) partial responses (PR) and 143 (20%) stable disease (SD). HI was
observed in 410 (58% of the total population) of the patients. The median time
to response was 3 cycles (range 1-24). Median overall survival (OS) since the
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start of treatment was 21 months (95%CI=19-24): CR: 25 months (CI95%=20-
30); PR: 27 months; mCR: 20 months (CI95%=20-30); and SD: 17 months
(CI95%=14-19) (p=0.006). We compared OS between mCR vs CR (p=0.193,
HR 0.796 [95%CI=0.765-1.122]), mCR vs PR (p=0.572; HR =0.564
[95%CI=0.078-4.105]) or mCR vs SD (p=0.243; HR=1.242 [95%CI=0.863-
1.788]), without any statistical difference (Fig. 1A). Median progression-free
survival (PFS) was 14 months (95%CI=13-16): CR: 16 months (CI95%=13-
21); PR: 11 months; mCR: 10 months (CI95%=5-15); and SD: 10 months
(CI95%=9-12) (p=0.013). No statistical differences were observed between
PFS in patients who achieved mCR vs PD (p=0.410; HR 1.816 [95%CI=0.439-
7.512]) and SD (p=0.7743; HR 1.059 [95%CI=0.752-1.491], but PFS was
increased in those patients who achieve CR when compared to mCR (p=0.013;
HR 0.665 [95%CI=0.482-0.918]) (Fig. 1B).
Figure 1.
Summary/Conclusions: Although mCR and CR result in the same OS, PFS
is increased in patients achieving CR when compared with mCR. These data
indicate that mCR should be considered as a valid endpoint in clinical trials.
P666
LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFU-
SION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC
SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS
STUDY
A. Giagounidis1,*, U. Germing2, K. Götze3, P. Kiewe4, T. Wolff5, K. Mayer6,
J. Chromik7, M. Radsak8, D. Wilson9, X. Zhang9, A. Laadem10, M.L. Sherman9,
K.M. Attie9, P.G. Linde9, U. Platzbecker11
1Marien Hospital Düsseldorf, 2Universitätsklinikum Düsseldorf, Düsseldorf, 3Ill.
Department of Medicine, Hematology and Medical Oncology, Technical Uni-
versity of Munich, Klinikum rechs der Isar, Munich, 4Onkologischer Schwer-
punkt am Oskar-Helene-Heim, Berlin, 5OncoResearch Lerchenfeld UG, Ham-
burg, 6University Hospital Bonn, Bonn, 7Universitätsklinikum Frankfurt, Goethe
Universität, Frankfurt/Main, 8Johannes Gutenberg-Universität, Mainz, Ger-
many, 9Acceleron Pharma Inc, Cambridge, 10Celgene Corporation, Summit,
United States, 11Universitätsklinikum Carl Gustav Carus, Dresden, Germany
Background: Management of anemia is a common therapeutic challenge in
patients (pts) with MDS. Luspatercept (ACE-536), a fusion protein containing
modified activin receptor type IIB, is being developed for treatment of anemia
in lower-risk MDS. Luspatercept binds to select TGF-β superfamily ligands
(such as GDF11) reducing aberrant Smad2/3 signaling and promoting late-
stage erythroid differentiation and increased hemoglobin (Hgb) levels (Suragani
R, Nat Med, 2014; Attie K, Am J Hematol, 2014).
Aims: This ongoing, phase 2, multicenter, open-label study followed by a long-
term extension (ext) study evaluates the effects of luspatercept in pts with low-
er-risk MDS. Endpoints include long-term safety and tolerability, erythroid
response (IWG HI-E), RBC transfusion independence (RBC-TI, ≥8 weeks),
duration of HI-E, pharmacodynamic and iron metabolism biomarkers, and pt-
reported quality of life (QoL).
Methods: Inclusion criteria: MDS IPSS low or int-1, age ≥18 yr, Hgb <10 g/dL
(if <4U RBC/8 weeks), no prior HMA, and no current lenalidomide or erythro-
poiesis-stimulating agent (ESA). The dose-escalation phase of the study is
completed. An expansion cohort of up to 56 patients was added to this phase
2 study to evaluate response to luspatercept in pts who would not qualify for
the phase 3 MEDALIST trial (for regularly transfused ring-sideroblast positive
[RS(+)] patients with EPO >200 U/L). These include pts with low transfusion
burden (LTB, <4U RBC/8 weeks) and either 1) RS(+) (≥15% in bone marrow)
with baseline EPO ≤200 U/L or 2) RS(-) and any EPO level. RS(-) pts were
allowed up to 6U RBC/8 weeks. Pts are treated every 3 weeks subcutaneously
for up to 5 doses (titration up to 1.75mg/kg) in the base study (NCT01749514)
and are then eligible for long-term treatment up to 5 additional years
(NCT02268383).
Results: Data (as of 09Sept2016) were available for 73 base and 42 ext study
pts. 32 base and 22 ext pts were LTB; 41 base and 20 ext pts were high trans-
fusion burden (HTB, ≥4U RBC/8 weeks). Median (range) age (yr) was 72 (27-
90), 53% pts had prior ESA, 51% pts had baseline EPO <200 U/L. Median
(range) Hgb (g/dL) for LTB pts was 8.6 (6.4-10.1). Median (range) RBC trans-
fusion burden (U/8 weeks) for HTB pts was 6 (4-18). 71% base and 86% ext
pts were RS(+). IWG HI-E response rates for pts treated with ≥0.75mg/kg in
the base and ext studies, respectively, were 62% (18/29) and 83% (19/23) for
RS(+) pts with EPO <200 U/L and 46% (5/11) and 88% (7/8) for RS(+) pts with
EPO 200-500 U/L. RBC-TI rates for pts treated with ≥0.75mg/kg in the base
and ext studies, respectively, were 68% (13/19) and 71% (10/14) for RS(+) pts
with EPO <200 U/L and 33% (3/9) and 60% (3/5) for RS(+) pts with EPO 200-
500 U/L. Preliminary RS(-) response rates (IWG HI-E and RBC-TI) by subgroup
will also be presented at the meeting. Luspatercept was well tolerated, with
related grade 3/serious adverse events (in 3 pts) as of 28Nov2016 of blast cell
count increase, myalgia, and worsening of general condition. The most com-
mon related AEs (≥2 pts) were diarrhea, fatigue, headache, hypertension,
arthralgia, bone pain, injection site erythema, myalgia, and peripheral edema. 
Summary/Conclusions: Lower-risk MDS patients treated long-term with lus-
patercept demonstrated robust and sustained increases in Hgb and decreases
in transfusion burden and a high rate of RBC-TI. A Phase 3 study of luspater-
cept in regularly-transfused RS(+) patients with lower-risk MDS according to
IPSS-R is ongoing (MEDALIST study; NCT02631070).
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RATE AND CAUSES OF 5-AZACYTIDINE DISCONTINUATION AND
SUBSEQUENT THERAPEUTIC OPTIONS IN 418 MDS PATIENTS FROM
THE ITALIAN MDS REGISTRY OF FONDAZIONE ITALIANA SINDROMI
MIELODISPLASTICHE (FISM)
M. Clavio1,2,*, D. Gioia2, M. Ceccarelli2,3, C. Monagheddu2,3, E. Balleari2,4,
M. Miglino1,2, A. A. Di Tucci2,5, B. Allione2,6, A. Poloni2,7, C. Finelli2,8, C. Aguzzi2,9,
C. Selleri2,10, P. Danise2,11, D. Cilloni2,12, V. Gaidano2,13, M. Cavaliere2,14,
T. Calzamiglia2,15, R. Freilone2,16, G. Cametti2,17, A. R. Conconi2,18,
M. Mezzabotta2,19, R. Goretti2,20, P. Musto2,21, G. Gaidano2,22, F. Pane2,23,
E. Angelucci2,24, A. levis2, V. Santini2,25
1Clinic of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, IRCCS AOU San Martino-IST, Genova, 2Fondazione Italiana Sindromi
Mielodisplastiche, (FISM), Alessandria, 3Unit of Clinical Epidemiology, AOU
Città della Salute e della Scienza di Torino, Torino, 4Division of Internal Medi-
cine, IRCCS AOU San Martino-IST, Genova, 5Hematology and Bone Marrow
Transplantation Unit, Ospedale Oncologico di Riferimento Regionale “Armando
Businco”, Cagliari, 6Division of Hematology, AOU Città della Salute e della
Scienza di Torino, Torino, 7Division of Hematology, Ospedali Riuniti Università
Politecnica delle Marche, Ancona, 8Division of Hematology, Institute of Hema-
tology and Medical Oncology Policlinico S Orsola Malpighi, Bologna, 9Division
of Hematology, University of Turin, AOU Città della Salute e della Scienza di
Torino, Torino, 10Hematology and Transplant Center, University of Salerno,
AOU Ospedale San Giovanni di Dio Ruggi d’Aragona, 11Division of Internal
Medicine and Onco-Hematology, Hospital Umberto I, Salerno, 12Division of
Internal Medicine 2 and Hematology, University of Turin, S Luigi Hospital Orbas-
sano, 13Division of Hematology, Mauriziano Hospital, Torino, 14Division of Inter-
nal Medicine, San Paolo Hospital, Savona, 15Division of Internal Medicine,
Ospedale San Remo, Sanremo, 16Service of Oncology and Hematology, Sta-
bilimento Ospedaliero Ciriè, Torino, 17Division of Internal Medicine, Ospedale
Maggiore di Chieri, Chieri, 18Division of Internal Medicine, Ospedale degli Infer-
mi Biella, Biella, 19Division of Hematology, Ospedale Ordine Mauriziano, Torino,
20Division of Internal Medicine, Ospedale di Pietra Ligure, Pietra Ligure,
21Department of Onco-Hematology, Centro di riferimento Oncologico della
Basilicata, Rionero in Vulture Potenza, 22Department of Translational Medicine,
Division of Hematology Amedeo Avogadro University of Eastern Piedmont,
Novara, 23Division of Hematology, AOU Federico II Napoli, Napoli, 24Division
of Hematology, Azienda Ospedaliera Universitaria S Martino - IST, Genova,
25Division of Hematology, University of Florence, Florence, Italy
Background: Azacytidine (AZA) is the current standard of care for patients
with high-risk myelodysplastic syndrome (MDS) in Europe. AZA has shown a
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survival advantage when compared with conventional therapies and has also
shown activity in IPSS lower-risk patients. However, about 40% of patients do
not respond and most patients loose response within 2 years. Treatment options
for MDS patients failing hypomethylating agents therapy are scarce and overall
survival (OS) is extremely short. 
Aims: Objectives of this study were to describe in a cohort of real life MDS
patients treated with AZA, the reasons causing treatment discontinuation, and
to evaluate the clinical outcome after the end of AZA therapy. 
Methods: Unselected patients recorded in the MDS Registry of Fondazione
Italiana Sindromi Mielodisplastiche (FISM) and treated with AZA from January
2009 to June 2014 were considered for the analysis. All types of conventional
published schedules of AZA were allowed. Clinical response, cause of discon-
tinuation, salvage treatments and OS from discontinuation of AZA were the
major end points.
Results: Between January 2009 to June 2014 1799 newly diagnosed MDS
patients were enrolled in the Registry, and 418 received AZA; 269 as 1st line
treatment (64%), 115 as 2nd line treatment (28%), and 34 as a line ≥3rd (8%).
Median age was 73 years (range 18-91); 260 patients (62%) were male. WHO
diagnosis was RA or RARS (n=27, 6%), RCMD with or without RS (n=62, 15%)
AREB-1 (n=126, 30%), AREB 2 (n=189, 45%), other subtypes (n=15, 4%). At
start of AZA therapy IPSS score was low in 14 (3.4%), int-1 in 97 (23.2%), int-
2 in 183 (43.8%), high in 67 patients (16%), and not available in 57 patients
(13.6%). Patients received a median of 7 courses of treatment (range 1-63).
Seventy-three % of the whole cohort (418 pts) were alive at 1 year from begin-
ning of AZA therapy and median OS was 23 months, (25 for IPSS lower-risk
MDS and 21 for IPSS higher risk MDS). OS after discontinuation of AZA was 8
months. Clinical responses according to IWG criteria were available in 344/418
patients (82%): 45 (13%) patients achieved a complete hematological response,
77 (22%), a partial response, 86 (25%) had stable disease while 136 (40%) did
not respond. Response was achieved after a median of 6 cycles. After a median
follow up of 16 months (range 7-35) in 37 (9%) patients AZA therapy was still
ongoing while in 381 (91%) the treatment has been discontinued. Interruption
of treatment was due to loss of response in 59 (16%) patients, AML evolution
in 154 (40%), death in 43 (11%), toxicity or poor compliance in 39 (10%), allo-
geneic transplant (HSCT) in 12 (3%), other reasons in 22 (6%), not reported in
52 patients (14%). Of the 381 patients who discontinued AZA, 15 (4%)were
managed with intensive AML-like chemotherapy, 22 (6%), received an allo-
geneic HSCT, 27 (7%) low-dose chemotherapy (7%), 22 (6%) erythroid stimu-
lating agents,18 (5%) other treatments and 277(72%) patients no further treat-
ment or only supportive therapy.
Summary/Conclusions: Our data confirm that AZA therapy is effective for
MDS patients, both with higher and lower IPSS risk disease. Response rate is
consistent with what previously reported, with a median OS of 23 months. Inter-
estingly, at 16 months, 91 % of patients had discontinued treatment, either for
progression or loss of response and only in 10% of cases for reported toxicity.
Only 28% of patients received any kind of salvage therapy and overall survival
after AZA discontinuation was poor (8 months).
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COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT
GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN
WITH SUSPECTED MDS
E. Louka1,*, A. Hamblin2, G. Buck1, H. Dreau2, P. Ware2, P. Ancliff3, S. Baird4,
N. Bhatnagar5, H. Campbell6, M. Caswell6, P. Connor7, B. Gibson8, G. Hall5,
J. Motwani9, A. Norton9, D. O’Connor3, K. Patrick10, F. Pinto8, R. Wynn11,
A. Vora310, I. Roberts1, A. Mead1, A. Rao3
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gow, Glasgow, 9Paediatric Haematology Department, Birmingham Children’s
Hospital, Birmingham, 10Paediatric Haematology Department, Sheffield Chil-
dren’s Hospital, Sheffield, 11Paediatric Haematology Department, Manchester
Children’s Hospital, Manchester, United Kingdom
Background: Paediatric Myelodysplastic Syndromes (MDS) are a rare and het-
erogeneous group of disorders distinct from adult MDS. They may present with
symptomatic anaemia, life threating infection or evolving leukaemia; however,
they may also present as unexplained cytopenias or with multisystem disease
of unclear aetiology. Diagnosis can represent a huge challenge for clinicians,
even in highly specialised centres and this can delay the delivery of the most
appropriate treatment. Hence an accurate diagnosis is crucial in selecting the
most appropriate management, including surveillance and follow up.
Aims: To devise a clinical grade diagnostic targeted NGS panel and combine
the results with extensive clinical phenotypic information to obtain a diagnosis
in children referred with suspected MDS. 
Methods: Children (0- 18yrs) were referred from 14 UK centres with a diagnosis
of suspected MDS and/or sustained cytopenias with morphological features of
myelodysplasia. Extensive phenotypic information including family history,
detailed clinical examination and disease course details were collected and
captured on an online database using the Human Phenomiser tool. A cus-
tomised targeted NGS panel was designed using the Illumina design studio
containing 32 genes, 916 amplicons and 301 exons; selected through literature
reports and well described mutations in Paediatric MDS and potential overlap
Bone Marrow failure syndromes (BMFS). Coverage of each base within target
regions was assessed for every sample on each sequencing run using Covermi
software. Library preparation was performed using an Illumina Truseq Custom
Amplicon panel, followed by sequencing on an Illumina MiSeq. Data analysis
was performed using our established bioinformatic pipelines (Hamblin A: Blood
2014 124:2373) 
Results: In total 59 patients (females= 29, males 30) have been screened and
3 subgroups identified based on the original suspected clinician diagnosis at
presentation: MPN/JMML (n= 15), de novo MDS (n=9) and idiopathic cytope-
nias of undetermined significance, (ICUS) with some features of dysplasia (n=
35). Mutations were detected in 24/59 patients (40%, Table 1). Of these, NGS
results confirmed the original clinical diagnosis in 15 cases (62.5%); established
the diagnosis for the first time in 6 cases (25%); and led to a change in diagnosis
(from autoimmune neutropenia to Shwachman-Diamond Syndrome) in 1 case
leading to a significant change in patient management. In two already known
cases, it allowed monitoring of the disease molecular signature. As expected,
RAS pathway mutations were common in the JMML/MPN (100%) and de novo
MDS patient subgroups (33%). Additional mutations in epigenetic modifiers,
splicesome mutations as well as second RAS pathway hits were also detected
in 40% of JMML patients and in one case within the de novo MDS group; this
finding was associated with poor outcome. Within the heterogenous ICUS
patient group, pathogenic mutations were identified in 5/35 (14.3%) cases with
BMFS genes (SBDS, ELANE, TP53). In contrast to the other MDS/MPN cases,
in this group, no RAS pathway mutations were detected.
Table 1.
Summary/Conclusions: Targeted NGS together with detailed phenotyping is
a useful tool for the diagnosis of suspected MDS and unexplained cytopenias
in children, with 40% of patient showing a disease-associated mutations.
Results were available within 6-8 weeks in most cases enabling both rapid
initial diagnosis and, in some cases, appropriate molecular markers for moni-
toring of clonal evolution and response to therapy. For the children who remain
without a clinical diagnosis, whole genome sequencing (WGS) may identify
pathogenic mutations and this is currently underway. 
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OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH
OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE
IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH
DEFERRED ASCT (PADIMAC)
K. Yong1,*, R. De Tute2, D. De-Silva1, E. Phillips3, N. Counsell3, J. Cavenagh4,
C. Roddie1, R. Owen2, M. Streetly5, S. Schey6, M. Koh7, J. Crowe8, M. Quinn9,
S. D’Sa10, A. Virchis11, G. Cook12, C. Crawley13, G. Pratt14, M. Cook15,
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Background: The role of autologous stem cell transplantation (ASCT) as first
line therapy for newly diagnosed (ND) patients with multiple myeloma (MM)
remains under evaluation given the deep responses to novel induction regi-
mens. Outcomes for those not proceeding to ASCT following induction remain
unclear, likely to be influenced by genetic risk and response depth. This study
was designed to evaluate a stratified approach to ASCT, investigating if patients
in CR/VGPR to induction may safely be assigned to delayed ASCT.
Aims: This single arm phase 2 clinical trial conducted at 13 UK sites aimed to
determine the progression free survival (PFS) for patients who achieved
≥VGPR to induction therapy with no further treatment. Here we report the pri-
mary endpoint, PFS at 2 years in the patients not proceeding to ASCT, and the
influence of MRD status on PFS.
Methods: NDMM patients eligible for ASCT received PAD (bortezomib
1.3mg/m2 IV or SC days 1, 4, 8, 11; doxorubicin 9mg/m2 days 1-4, dexam-
ethasone 40mg days 1-4 (and days 8-11 and 15-18 for cycle 1 only)) for 4-6
cycles. Those achieving <PR were off protocol; all others had PBSCH followed
by restaging including MRD assessment on bone marrow using multi-parame-
ter flow cytometry. Those in PR were stratified to ASCT (no maintenance)
whereas those achieving ≥VGPR stopped treatment. Responses were
assessed at 100 days post PBSCH (including MRD), and at monthly intervals
for up to 2 years. High risk disease was defined by the presence of one or
more adverse FISH lesions (t(4;14), t(14;16), t(14;20), del(17p13), +1q21).
Results: Between April 2011 and January 2014 153 patients were enrolled
(median age 55, range 28-71 years), 139 (91%) received 4-6 cycles of PAD.
The majority (88.2%) received SC bortezomib, 18 (11.8%) received at least 1
cycle IV. FISH data was available for 132 patients, 89 (67.4%) patients were
standard and 43 (32.6%) adverse risk. 51 (33.6%) patients were ISS I, 67
(44.1%) ISS II and 34 (22.4%) ISS III. The overall response rate to PAD was
82.4% (≥VGPR: 41.2%). Responses were similar irrespective of ISS or genetic
risk (standard: ≥VGPR 37.5%, PR 40.9%, adverse: ≥VGPR 53.5%, PR 34.9%).
Post-PBSCH, 63 (41.2%) patients achieved ≥VGPR, and 44 (28.8%) patients
achieved PR of whom 36 proceeded to ASCT. After a median follow-up of 45.4
months from registration, median overall PFS was 22.5m (95% CI: 18.1-25.3).
For those who achieved ≥VGPR, median PFS from PBSCH was 8.9m (95% CI:
4.6-13.3) and 25.7m (95% CI: 13.7-37.6) for MRD+ (N=25) and MRD- (N=16)
patients at D100 post-PBSCH respectively, 2y-PFS 28.0% (95% CI: 10.4-45.6)
and 56.3% (95% CI: 32.0-80.6) respectively. PR patients proceeding to ASCT
had a median PFS of 17.2m (95% CI: 14.2-20.2) and 23.1m (95% CI: 16.8-
29.4) for those who were MRD+ (N=20) and MRD- (N=7) at D100 respectively,
2y-PFS 15.0% (95% CI: 0-30.7) and 42.9% (95% CI: 6.2-79.6) respectively.
Summary/Conclusions: This is the first study to report outcomes of patients
stratified to ASCT by depth of response. The overall PFS for the study is shorter
than other published trials, most likely due to the inferior outcome for MRD+
patients not proceeding to ASCT. The median PFS for ≥VGPR patients who
are MRD- and stopped therapy was similar to that in PR patients achieving
MRD- status post-ASCT. The PFS for ASCT was relatively short, reflecting
selection of those only achieving PR. Response rate alone is not sufficient to
identify patients who would benefit from ASCT and use of MRD to stratify treat-
ment is now being investigated.
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PROPORTION AND COMPOSITION OF BONE MARROW LYMPHOCYTE
POOL AT BASELINE CORRELATES WITH OUTCOME IN MM PATIENTS
AFTER RVD AND ASCT
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Background: In multiple myeloma (MM) the interactions between malignant
plasma cells and the bone marrow (BM) microenvironment are important for
treatment outcome. There is limited data on the effects of lenalidomide (LEN)
on the BM immune profile and its therapeutic predictive value. The FMG-MM02
study (NCT01790737) was designed to explore the response to LEN, borte-
zomib and dexamethasone (RVD) induction, followed by a single autologous
stem cell transplantation (ASCT) and LEN maintenance as a first-line therapy
for MM patients (n=80). The primary endpoint was achievement of an
immunophenotypic remission. Here we report the results of one of the sec-
ondary endpoints; composition of lymphocyte subsets at baseline and during
LEN maintenance.
Aims: The aim of this study was to assess the proportion of different lympho-
cyte subsets at baseline and after ASCT and correlate lymphocyte composition
with patient outcome.
Methods: Flow cytometry (FC) panel included antibodies against CD38,
CD138, CD45, CD19, CD56, CD27, CD28, CD81, CD117, intracytoplasmic
kappa and lambda. Sequential analyses (at baseline, after induction and at 3,
9 and 16 months after ASCT) were performed in 37/80 patients who achieved
at least near complete remission (nCR) and/or minimal residual disease (MRD)
negativity by FC. In addition to MRD the samples of these patients were ana-
lyzed for mature B-cells (CD19+/CD45++), B-cell progenitors (CD19+/CD81++/
CD38+/CD45+), B-cell blasts (CD19+/CD81++/CD38+/CD45dim), NK/T-cells
(CD45++/CD56+), T-cells (CD45++ lymphocytes other than B-cells and T/NK-
cells) and CD38+ activated T-cells as calculated per total bone marrow nucle-
ated cells (TNC). The results were compared between two different response
cohorts: the good cohort (n=26) defined by persistent stringent complete remis-
sion/FC negativity, or PCR negativity (≤ 0.006%) and the control cohort (n=11),
who only achieved nCR or had early relapse within one year of ASCT.
Results: At baseline, markers for disease burden, such as the percentage of
myeloma cells in BM or paraprotein levels did not differ between the response
cohorts. No differences were noted in R-ISS or ISS risk stratification either, but
there were more IMWG high risk patients in the control cohort (p=0.048). The
median percentage of total lymphocytes (15.4 vs 11.9; good vs control), T-cells
(9.6 vs 7.8), CD19+ B-cells (1.6 vs 1.3), and CD38+ T-cells (0.9 vs 0.5) in BM
were all higher in the good response cohort at baseline. In particular, the median
proportion of mature B cells in BM was significantly higher in the best cohort
at baseline (1.32 vs 0.91; p=0.02), after induction (0.27 vs 0.13; p=0.002) and
16 months after ASCT (1.73 vs 0.56; p=0.008) (Figure).
Figure 1.
Summary/Conclusions: Composition of the BM lymphocyte pool at treatment
baseline may have an influence on treatment outcome in multiple myeloma.
More detailed subtyping of the lymphocyte phenotypes is ongoing and may
reveal potential predictive biomarkers for immunomodulatory drugs such as
lenalidomide and checkpoint inhibitors.
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VALUE OF THE 18F-FDG PET-CT IN THE IDENTIFYING BONE
INVOLVEMENT EITHER AT DIAGNOSIS OR DURING FOLLOW-UP OF
PATIENTS AFFECTED BY MULTIPLE MYELOMA
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Background: Lytic lesions occur in the majority of patients with multiple myelo-
ma (MM) and represent one of the criteria for starting therapy. In the past,
whole-body X-ray (WBX) represented the method of choice for detecting skele-
ton abnormalities; today, magnetic resonance imaging (MRI), positron emission
tomography (PET) and computed tomography (CT) have been adopted for their
higher power in detecting extra-medullary localizations and their higher sensi-
tivity. Nevertheless, which technique would be really the best one is still matter
of debate.
Aims: Our single-center retrospective study was designed to compare PET-
CT with other imaging techniques (WBX, vertebral column CT and MRI) at the
diagnosis and during the follow-up of MM patients. Finally, we assessed a pos-
sible predictive/prognostic role of the PET-CT in terms of quality of response
and survival.
Methods: We enrolled 160 patients with diagnosed symptomatic (N=149) or
smoldering multiple myeloma (N=11) observed at the AOUP, Pisa, Italy, between
January 1996 and December 2015. Eighty-three were male and 77 female; the
median age was 70 years (range, 28-85), and half of them presented with low
ISS risk score. Forty-five subjects were not eligible to high-dose therapy; 64%
of them received bortezomib- and 23% melphalan-based regimens. Patients
eligible to high-dose therapy received VAD, TAD or VTD and then one (88%)
or two (12%) autologous transplants. At the relapse, lenalidomide (57%) or
anthracyclines (40%) were administered. 
Results: Overall, we compared 160 PET-CT, 233 WBX, 106 CT, and 85 MRI
exams. At diagnosis, PET-CT allowed detecting skeletal involvement in 18% of
cases negative by WBX, in 37% of those CT-negative, and in 10% of those
MRI-negative. Sensitivity of PET-CT was superimposable to that of MRI (90%),
and higher than that of WBX (60%) and CT (73%). Nevertheless, the specificity
was lower for PET-CT and MRI (40%) in respect of CT (51%) and WBX (71%).
Analogously to that observed at diagnosis, PET-CT during follow-up showed
distinct advantages in terms of sensitivity compared to X-rays (83% vs 60%,
respectively). In contrast, PET-CT sensitivity was comparable to that of CT and
MRI. As at diagnosis, the specificity was higher for WBX (70%) than for CT,
RM and PET-CT (40% for all of these). When PET-CT was correlated to the
quality of response, it was significant only in the not transplanted cohort (>PR
rate in PET-negative cases=67% vs 23% in the PET-positive group; p=0.016).
Nevertheless, PET-CT positivity either at diagnosis or during follow-up did not
impact on long-term OS and PFS.
Summary/Conclusions: Our study showed that PET-CT and MRI would rep-
resent the techniques of choice in the assessment of bone involvement in MM
patients in view of their high and comparable sensitivity. Moreover, PET-CT
gives the possibility of a “whole body” analysis in exchange for higher “biologic”
cost.
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INITIAL PHASE 2 RESULTS OF IBRUTINIB COMBINED WITH
BORTEZOMIB/DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS
WITH MULTIPLE MYELOMA
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Background: Bruton’s tyrosine kinase (BTK) is overexpressed in, and has
been implicated in the growth and survival of multiple myeloma (MM) cells,
providing a rationale for evaluating BTK inhibitors in MM (Yang Cancer Res
2015; Tai Blood 2012). Yang 2015 demonstrated that BTK overexpression (OE)
contributes to blunted responses in MM cells when treated with widely used
MM drugs (ie, bortezomib [BTZ], etoposide and doxorubicin). Increased activity
of the ABC transporter efflux pump and expression of the ABCB1 transporter
protein was seen in BTK OE cells, and subsequent inhibition led to a restoration
of BTZ sensitivity in these cells. Ibrutinib (ibr), a first-in-class, once-daily oral
inhibitor of BTK, is approved in the US and EU for the treatment of various B-
cell malignancies. In the EU, regimens containing BTZ and corticosteroids are
a standard of care in MM treatment. A previous study of ibr+carfilzomib±dex-
amethasone (dex) demonstrated an ORR of 58% in relapsed/refractory MM
patients (pts) with a median of 3 prior therapies and 88% refractory to their
most recent therapy (Chari ASH 2015), warranting further investigation of ibr
with proteasome inhibitors.
Aims: To evaluate safety and efficacy of combination ibr+BTZ/dex in previously
treated MM pts.
Methods: In this phase 2, open-label, multicenter, European study (PCYC-1139),
eligible pts received 1-3 prior therapies and demonstrated disease progression
on or following the most recent therapy. Prior BTZ use was permitted provided
pts were sensitive (ie, no progression ≤60 days after having achieved minimal
response or better). All pts provided informed consent. For cycles 1-8 (21-day
cycles), pts received ibr 840mg once daily with BTZ 1.3mg/m2 subcutaneously
twice weekly (Days 1, 4, 8, 11) and dex 20mg on day of and after BTZ. For cycles
9-12 (42-day cycles), BTZ was dosed weekly (Days 1, 8, 22, 29). The primary
endpoint was PFS with secondary endpoints including safety, ORR, PFS at land-
mark points, duration of response, and time to progression (TTP).
Results: As of November 21, 2016, 20 pts were enrolled (Table). Median age
was 68.5 years (range, 49-86). Median number of prior therapies was 1, with
50% refractory to the most recent therapy and 70% previously exposed to BTZ.
Gene expression profiling (GEP) in initial pts indicated high-risk GEP in 35% of
pts. Virtual fluorescent in situ hybridization identified 40% of pts with high-risk
cytogenetics. Median treatment duration was 2.1 months (range, 0.5-3.7). All
pts experienced at least one treatment-emergent adverse event (AE) of any
grade. The most common all-grade nonhematologic AEs occurring in >15%
(>3 pts) were diarrhea (50%), upper respiratory tract infection (30%), and asthe-
nia, peripheral edema, hypocalcemia and hypokalemia (20% each). The most
common Grade ≥3 AEs occurring in ≥10% (>1 pt) were thrombocytopenia
(25%), asthenia and pneumonia (15% each), and hyponatremia, abnormal
hepatic function, infection, and bone pain (10% each). Three deaths were
reported (sudden death in a pt with cardiac history, pneumonia, and myocardial
infarction). With early follow-up, 19 pts are evaluable for response with an ORR
of 47%, including MR or better in 68%. Updated data will be presented.
Table 1.
Summary/Conclusions: The initial data indicate promising clinical potential
for the combination of ibr+BTZ+dex. Treatment was generally well tolerated
without any unexpected safety signals noted for the combination. The prelimi-
nary ORR of 47% after a minimum 2 treatment cycles is encouraging with fur-
ther follow-up needed.
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PROGNOSTIC SIGNIFICANCE OF CLONAL CIRCULATING PLASMA
CELLS BY MULTI-PARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH
LIGHT CHAIN AMYLOIDOSIS UNDERGOING AUTOLOGOUS STEM CELL
TRANSPLANTATION
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Background: Presence of circulating plasma cells (cPCs) prior to autologous
stem cell transplant (ASCT) is an adverse prognostic factor in patients with
multiple myeloma (MM). Prognostic value of cPCs prior to ASCT in patients
with light chain amyloidosis (AL) is not known.
Aims: The aim of our study was to evaluate if the presence of cPCs by multi-
parametric flow cytometry (MFC) prior to ASCT is prognostic in patients with AL.
Methods: We retrospectively analyzed 130 patients diagnosed from 2008–
2015 with AL who had cPCs analyzed by MFC prior to ASCT, and categorized
them as follows: a) Group 1: patients proceeding directly to ASCT without induc-
tion therapy and b) Group 2: patients who received induction therapy before
ASCT. 
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Results: There were 78 patients in Group 1 and 52 patients in Group 2.
Patients in Group 2 had higher baseline dFLC, bone marrow plasma cells
(BMPC), Mayo stage and were more likely to have active MM compared to
patients in Group 1. Table 1 lists baseline characteristics of the patients in
Groups 1 and 2. Patients in Group 1 had higher rate of renal involvement.
cPCs were detectable in 22% (n=28) of patients at the time of ASCT. More
patients in Group 1 had detectable cPCs than in Group 2 (31% vs 8%;
p=0.002), likely due to clearance of cPCs with treatment. Data on cPCs at
diagnosis in the induction group was available in 14 patients, of whom 57%
(n=8) had detectable cPCs vs 31% in the direct ASCT group (p=0.06). 6 of the
8 (75%) patients cleared cPCs with induction therapy. There were no significant
differences in patients who had detectable and undetectable cPCs before trans-
plant, including organ involvement, baseline dFLC, BMPC, and Mayo Stage
(data not shown).
In Group 2, both progression free survival (PFS) (10.5 months vs 58 months,
p <0.0001) and overall survival (OS) (16 months vs not reached, p <0.0001)
were worse in patients who had detectable cPCs compared to those without
cPCs (Figure 1). This difference was not seen in Group 1 (OS: not reached vs
98 months, p=0.96; PFS 43 vs 52 months, p=0.74). In multivariate analysis,
adjusting for Mayo Stage and induction chemotherapy, there was a trend
towards worse OS in patients with detectable cPCs (p=0.06).
Table 1.
Figure 1.
Summary/Conclusions: cPCs are cleared after induction treatment in majority
of AL patients. Patients who have detectable cPCs prior to proceeding to ASCT
after induction have worse PFS and OS than patients without cPCs. On the
other hand, presence of cPCs was not found be an adverse prognostic factor
in patients proceeding directly to ASCT. This may be due otherwise excellent
prognosis in this group, with absence of other high-risk features that are seen
in patients who require induction. A limitation of our study is lack of data on
cPCs at diagnosis in all patients who received induction therapy.
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Background: Renal impairment (RI) is a poor prognostic factor in multiple
myeloma (MM). Analysis of disease characteristics, therapy & outcomes can
improve treatment & prognosis.
Aims: To assess (1) characteristics of patients with RI at diagnosis - severity
of RI, age, risk factors, high risk features, stage, disease manifestations & per-
formance status, and (2) treatment including induction therapy & autologous
stem cell transplant (ASCT) and outcomes.
Methods: Data from newly diagnosed MM patients enrolled in the Australian
and New Zealand Myeloma Registry from 1 Feb 2013 to 31 Dec 2016 were
analysed.
Results: Of 867 patients, 775 had eGFR available at diagnosis: 34% (267/775)
had eGFR <60ml/min (22% at 30-60ml/min; 6% at 15-30ml/min; 6% at <15
ml/min). Mean age of patients with RI (<60 ml/min) was 72 vs 64 yrs without
RI. Diabetes mellitus (DM), a major cause of chronic kidney disease (CKD),
was more prevalent in patients with RI: 17% of patients with eGFR <30 ml/min
compared with 8% >30ml/min. Patients with RI (<30ml/min) and DM had a
similar response to first-line therapy compared to RI without DM (≥PR, 75% vs
82%, p=0.56), with no difference in OS (26 vs 37 mths, p=0.68) or PFS (24
mths, p=0.82). High risk features of FISH (del17p, t(4:14), t(14;16), amp1q21,
del13q) & high LDH were more prevalent in RI (55% vs 46%, p=0.02), as was
advanced stage (ISS III) (66% vs 12% p<0.001). Anemia was more prevalent
in RI (44% vs 14 %, p<0.001), but bone lesions were less prevalent (52% vs
65% p=0.001). There was no difference in ECOG performance status. Most
patients (87%) received Bortezomib-based therapy in first line (81% RI vs 91%
no RI, p<0.001), with no difference with or without ASCT. Response rates (≥PR)
were the same in patients with eGFR <60ml/min compared with normal renal
function (84% vs 85%, p=0.87). PFS & OS decreased with reduction in eGFR
(Fig 1). However, patients with eGFR<15ml/min had better OS & PFS com-
pared with eGFR 15-30ml/min; dialysis in eGFR <15ml/min may be a factor.
Using age 70 yrs as a common age limit for ASCT, we analysed the effect of
ASCT in patients <70 yrs with & without RI. While a smaller proportion of RI
patients received ASCT (21% vs 79%, p<0.07), it was performed at all levels
of renal function including eGFR <15ml/min. In patients with eGFR <60ml/min,
those who received ASCT had a longer PFS (HR 0.37, 95%CI 0.16-0.88,
p=0.03) & OS (HR 0.28, 95%CI 0.08-1.01, p=0.05) compared with no ASCT.
The improvement was also seen in severe RI (<30ml/min), with a longer PFS
(HR 0.21, 95%CI 0.05-0.86, p=0.03) & OS (HR 0.10, 95%CI 0.01-0.82, p=0.03)
with ASCT.
Figure 1.
Summary/Conclusions: RI occurred in one-third of newly diagnosed MM.
DM, an underlying risk factor for CKD, was more common in RI patients, but
not associated with a difference in outcome. Advanced stage & high risk fea-
tures were more prevalent in RI patients, but bone disease was less common.
RI patients had a shorter PFS and OS, overall correlating with eGFR. However
patients with eGFR <15ml/min had a better OS than 15-30 ml/min, for which
dialysis may be a factor. In transplant-eligible patients assessed by age <70
yrs, ASCT was performed in 21% of RI patients, at all levels of renal function.
Patients with RI who underwent ASCT had a superior PFS and OS than those
who did not have ASCT, including those with severe RI (eGFR <30ml/min),
supporting the benefit of ASCT in MM patients with RI.
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Background: Venetoclax (VEN), an orally available selective small-molecule
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BCL-2 inhibitor, induces cell death in multiple myeloma (MM) cells, particularly
those with the t(11;14) translocation.
Aims: The objectives of the study are to evaluate safety, PK, recommended
phase two dose, and preliminary efficacy of VEN monotherapy in
relapsed/refractory (R/R) MM.
Methods: Patients (pts) with relapsed/refractory (R/R) MM received VEN
monotherapy in this phase 1 study. Daily VEN was given at 300–1200mg in
dose escalation cohorts and 1200mg in the safety expansion. Pts with disease
progression (PD) on VEN monotherapy could receive VEN plus dexametha-
sone and remain on study.
Results: As of 19Aug2016, 66 pts were enrolled. Median age was 63 years
and 30 (46%) pts had t(11;14). Median number of prior therapies was 5 (range:
1–15); 46 (70%) pts were refractory to bortezomib, 20 (30%) to carfilzomib, 51
(77%) to lenalidomide, 35 (53%) to pomalidomide, and 52 (79%) were refractory
to the last prior therapy. Median time on VEN monotherapy was 2.5 months
(range: 0.2–23); 17 pts received VEN plus dexamethasone after PD for a medi-
an of 1.4 months (range: 0.1-13). Fifty-five (83%) pts discontinued, with 41 due
to PD. Common adverse events (AEs) were nausea (47%), diarrhea (36%),
vomiting (21%) and grade 3/4 hematologic toxicities [thrombocytopenia (32%),
neutropenia (27%), anemia (23%), leukopenia (23%)]. Common serious AEs
were pneumonia (8%), sepsis (5%), cough, hypotension, pain, and pyrexia (3%
each). There were no events of TLS. Six deaths were reported due to PD, and
1 each due to lung disorder and brain hemorrhage following trauma. Overall
response rate (ORR) for all pts on VEN monotherapy was 21% (14/66); 10
(15%) achieved very good partial response (VGPR) or better [2 stringent com-
plete response (sCR), 3 CR, 5 VGPR]. For all pts, median time to progression
(TTP) and duration of response (DoR) were 2.6 and 9.7 months, respectively.
A clear difference in responses was seen among pts with t(11;14) vs without
[ORR, 40% vs 6%; ≥VGPR, 27% vs 6%]. For pts with t(11;14), median TTP
was 6.6 months [vs 1.9 months for pts without t(11;14)] and median DoR was
9.7 months. A high BCL2:BCL2L1 (BCL-XL) gene expression ratio was
observed in 10/44 (23%) baseline tumor samples, enriched in pts with t(11;14)
compared with non-t(11;14) (38% vs 5%) and associated with clinical response;
80% (8/10) of pts [all t(11;14)] with a high BCL2:BCL2L1 ratio achieved ≥PR
with a median TTP of 11.5 months. Among pts with t(11;14) who were refractory
to the last therapy, ORR was 42% (11/26); for t(11;14) pts refractory to both
bortezomib and lenalidomide, or who were refractory to bortezomib, carfilzomib,
lenalidomide, and pomalidomide, ORR was 40% (8/20) and 50% (3/6), respec-
tively. No difference was seen in ORR for t(11;14) pts with high-risk del(17p)
versus those without the deletion [40% (2/5) vs 40% (10/25)].
Summary/Conclusions: VEN has an acceptable safety profile with promising
single-agent anti-myeloma activity in pts with R/R MM positive for t(11;14) who
failed multiple prior lines of therapy.
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AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB
COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE
(KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
(MM)
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Background: The combination of daratumumab with standard of care regimens
has demonstrated significantly prolonged progression-free survival (PFS),
deeper responses, and a manageable safety profile versus standard of care
alone in patients with relapsed or refractory MM.
Aims: To determine the tolerability and efficacy of daratumumab in combination
with KRd in patients with newly diagnosed MM.
Methods: This open-label, phase 1b study enrolled patients with newly diag-
nosed MM regardless of transplantation eligibility. Patients received daratu-
mumab 16mg/kg qw for Cycles 1-2, q2w for Cycles 3-6, and q4w thereafter,
with all patients receiving the first dose split over 2 days. Carfilzomib was given
on Days 1, 8, and 15 of each 28-day cycle (20mg/m2 on Cycle 1 Day 1, 36 or
70mg/m2 thereafter, based on tolerability of first dose) for up to 13 cycles or
elective discontinuation for autologous stem cell transplantation (ASCT).
Lenalidomide 25mg was administered on Days 1-21, and dexamethasone 20-
40mg per week. The primary endpoint of the study was tolerability. Overall
response rate (ORR; defined as partial response or better) was a major sec-
ondary endpoint.
Results: A total of 22 patients were enrolled in the study; median (range) patient
age was 60 (34-74) years, and 95% had an ECOG score of ≤1. At a median
(range) follow-up duration of 7.4 (4.0-9.3) months, the majority of patients
remained on treatment and had received a median of 8 (1-10) treatment cycles.
Six patients discontinued treatment, 1 due to an adverse event (AE; pulmonary
embolism), 1 due to progressive disease, and 4 due to “other” (all ASCT). The
dose of carfilzomib was increased to 70mg/m2 in 19 patients by Cycle 1 Day
15. Serious treatment-emergent AEs (TEAEs) occurred in 46% of patients,
14% and 18% of which were at least possibly related to daratumumab or carfil-
zomib, respectively. Eighteen (82%) patients had a grade 3/4 TEAE, most com-
monly (>10%) lymphopenia (50%) and neutropenia (23%). One (5%) patient
experienced a grade 3 cardiac TEAE (congestive heart failure) which resolved;
the patient was able to resume study treatment at a reduced carfilzomib dose.
There were no grade 5 TEAEs. Six (27%) patients had daratumumab-associ-
ated infusion-related reactions, and all were grade ≤2 in severity. ORR with
daratumumab in combination with KRd was 100% among the 21 response-
evaluable patients: 18 (86%) patients achieved a very good partial response or
better and 1 patient (5%) achieved a complete response. Median duration of
response has not been reached. With only 1 PFS event having occurred at the
time of follow-up, 6-month PFS rate was 100%, and median PFS has not been
reached.
Summary/Conclusions: Daratumumab in combination with KRd was well tol-
erated, with an overall safety profile consistent with previous reports for KRd.
No additional toxicity occurred with the addition of daratumumab, and deep
and durable responses were achieved. Preliminary results from this ongoing
study support continued investigation of daratumumab plus KRd as a first-line
treatment regimen for patients with newly diagnosed MM. Updated data based
on longer follow-up will be presented.
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GENE EXPRESSION CLASSIFIER EMC92/SKY92 AND REVISED ISS
ROBUSTLY IDENTIFY HIGH-RISK MULTIPLE MYELOMA IN ELDERLY
PATIENTS OF THE HOVON-87/NMSG-18 STUDY
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Background: Multiple myeloma (MM) affects mostly elderly people with a medi-
an age of 69 years at diagnosis, with 35-40% of patients older than 75. Overall
survival (OS) is variable: of patients aged 66-79, 9% survive less than 3 months
and 23% survive longer than 10 years. 
Recently the revised ISS (rISS) has been proposed as a prognostic marker
that incorporates ISS, FISH and LDH. Another marker, the SKY92 prognostic
gene classifier (published as the EMC92 classifier) was developed in younger,
transplant eligible multiple myeloma (MM) patients who were included in the
HOVON-65/GMMG-HD4 trial. The SKY92 classifier was thoroughly validated
in eight independent cohorts, at the time of its initial publication, and since.
Aims: Here, we validated the SKY92 gene expression classifier and rISS in
elderly, non-transplant eligible patients included in the HOVON-87/NMSG-18
trial (Zweegman et al. Blood 2016;127(9):1109-1116).
Methods: In this trial, melphalan, prednisone, thalidomide (MPT) plus thalido-
mide maintenance was compared with melphalan, prednisone, lenalidomide
(MPR) plus lenalidomide maintenance. The MMprofiler™ CE IVD assay was
used to obtain SKY92 scores, classifying a patient as high-risk or standard-
risk. In addition, the international staging system, LDH, FISH and rISS were
analyzed.
Results: The 178 patients in the analysis for which enough bone marrow was
available to perform GEP, had a median age of 73 years. At the time of data
analysis, the median follow up was 34 months. The SKY92 classifier identified
25 of 178 patients as high-risk (14%). The median OS for the 25 patients clas-
sified as SKY92 high-risk was shorter than the median OS of standard-risk
patients: SKY92 high-risk 21 months versus SKY92 standard-risk 53 months
(hazard ratio (HR)=3.0, 95% confidence interval (CI)=1.7-5.3; p <.001; Figure
1a). The proportion of patients with stage rISS-III was 8% which is comparable
to the 10% identified in the initial report of the rISS. Interestingly, the proportion
of SKY92 high-risk patients is larger (14%), whereas the median OS associated
with these patients is shorter (21 vs 25 months). The SKY92 classifier performed
better compared to the rISS as high-risk marker for OS. The 2-year OS rate
was 48% in the SKY92 high-risk patients versus 58% for rISS-III. (Figure 1).
The 2-year progression free survival (PFS) rate was similar for SKY92 high-
risk and rISS-III (16% and 17%, respectively). In the multivariate analysis,
SKY92, rISS and deletion of 13q were independently associated with OS. Inde-
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pendent association with PFS was found for SKY92, rISS, deletion of 13q and
t(11;14) (Table 1). A bidirectional stepwise selection procedure was applied
excluding covariates with the highest p-values until only significant covariates
remain. Initially included covariates were SKY92, r-ISS, gain(1q), del(17p),
del(13q), t(4;14), t(11;14), LDH and age. ISS could not be included as it was
highly correlated with other covariates (i.e. co-linear); t(14;16) was excluded
due to the minimal number of present instances. HR: hazard ratios relative to
the lowest risk category with 95% confidence intervals (CI), p: likelihood ratio
p-value indicating the association of each covariate with OS.
Table 1. Multivariate survival analysis in the HO87/NM18 trial.
Figure 1.
Summary/Conclusions: Here, we compared the SKY92 classifier with revised
ISS staging and FISH. These data validate the SKY92 classifier as a robust
marker to identify high-risk patients in non-transplant eligible MM patients. In
these IMiD treated patients, the SKY92, the revised ISS, and FISH markers
such as deletion of 13q retain independent prognostic value.
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MULTIPLE MYELOMA AND COMORBIDITY: A POPULATION-BASED
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Background: The number of multiple myeloma patients has grown with aging
populations, and with increasing age the number of comorbidities increases
as well. Clinically, it is well known that comorbidity in multiple myeloma patients
decreases performance status, increases risk of therapy-related complications
and may lead to life-threatening conditions. Currently, the literature on comor-
bidity in multiple myeloma is very limited and based on small case series. Clin-
ical trials rarely include elderly, frail patients due to eligibility criteria. Popula-
tion-based studies provide valuable information on survival outcomes in relation
to presence/absence of comorbidities in newly diagnosed real-life multiple
myeloma patients in the general population.
Aims: To evaluate the prevalence of comorbidities and to study the impact of
comorbidities on survival among patients with newly diagnosed multiple myeloma.
Methods: All newly diagnosed patients with multiple myeloma from January
1st 1990 to December 31st 2013 in Sweden were included in the study. Using
the Swedish Patient Registry, all discharge diagnosis and discharge listings
were gathered from each patient from January 1st 1985. Comorbid conditions
were defined as chronic illnesses which demand life-long treatment or follow-
up. Only those diagnoses made prior to multiple myeloma were used. Using
ICD 8, 9 and 10 codes, comorbid diseases were identified. Kaplan-Meier curves
were used to estimate survival. Risk of death was compared among multiple
myeloma patients with a comorbid condition to those without a comorbidity,
using Cox’s proportional hazards regression (adjusting for age, gender, year
of diagnosis, and other comorbid conditions).
Results: A total of 13,718 patients with multiple myeloma were included in the
study and 21 groups of comorbidities were identified. The most common dis-
eases were cancer, hypertension, heart failure, ischemic heart disease and
atrial fibrillation. Among all patients, 55% had no prior history of comorbidity,
23% had one comorbidity, 12% had two comorbidities, and 10% had three or
more comorbid conditions. Survival was negatively influenced by the number
of comorbidities (Figure 1). The risk of death was significantly increased in
patients with atrial fibrillation (HR=1.08; 95% CI 1.00-1.16), heart failure
(HR=1.50; 95% CI 1.40-1.61), stroke (HR=1.20; 95% CI 1.11-1.30), psycho-
logical disease (HR=1.27; 95% CI 1.16-1.39), chronic lung disease (HR=1.22;
95% CI 1.12-1.32), diabetes (HR=1.14; 95% CI 1.04-1.36), peripheral vascular
disease (HR=1.26; 95% CI 1.12-1.42), cancer (HR=1.10; 95% CI 1.04-1.16),
dementia (HR=1.65; 95% CI 1.38-1.99), paralysis (HR=1.44; 95% CI 1.15-
1.80), inflammatory bowel disease (HR=1.38; 95% CI 1.08-1.74), end stage
renal disease (HR=1.57; 95% CI 1.03-2.04), and cirrhosis (HR=1.64; 95% CI
1.10-2.43).
Figure 1.
Summary/Conclusions: In this large, population-based study including almost
14,000 patients, we have shown that comorbidities are common among newly
diagnosed multiple myeloma patients and that comorbidities are associated
with an inferior survival. Importantly, the number of comorbidities showed a
dose-response relationship with inferior overall survival. For example, the medi-
an overall survival for patients with 3 or more comorbidities was reduced by
more than 50% compared to patients without comorbidities. The importance of
comorbidities should be taken into account when evaluating patients and decid-
ing on treatment strategies for individuals with multiple myeloma.
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DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS
ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA
PATIENTS
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Background: Multiple myeloma (MM) is a genetically complex disease, char-
acterized by the presence of multiple clones with differing degrees of drug sen-
sitivity at the time of diagnosis. Consequently, therapeutic response of MM
patients is unpredictable and extremely variable, and although the treatments
introduced over the last decade have significantly improved the outcome of
these patients, most patients eventually relapse. Deep sequencing methods
have contributed to increase the knowledge about the clonal heterogeneity of
the disease and helped to stablish the three evolution patterns at relapse: linear
and branching clonal evolution, and no clonal changes. 
Aims: To analyze the diversity and relative dominance of different clones and
their evolution throughout the course of disease by NGS of the immunoglobulin
repertoire in MM patients. To evaluate if the presence of different clones is
associated with increased risk.
Methods: Immunoglobulin repertoire was analyzed by NGS in bone marrow
samples from 180 MM patients included in three GEM clinical trials
(NCT00461747, NCT00443235 and NCT01237249). The two first clinical trials
involve patients younger than 65 years old, and were analyzed with ClonoSeq
methodology, the later one involve patients older than 65 years old, and were
analyzed with a local NGS method recently validated (Martinez-López et al,
Laukemia 2017). A clonotype was identified when at least 400 identical
sequencing reads were obtained, or it is present at a frequency of >1%.
Results: Of the 180 MM patients studied, 57 (32%) shows the presence of
more than one clone throughout the clinical the course of the disease. The
identification of new evolving clones was only possible in the GEM10 clinical
trial with the Local NGS method; in this clinical essay, 6% (4/71) of patients
shows the development of different clones during treatment. We show that the
frequency of the predominant clone at diagnosis of these four patients
decreased with treatment, but the frequency of the new ones increased and
the patients progressed. When more than one clone is present at diagnosis,
the relative dominance of the clones varies throughout the course of disease
in an independent manner. There were no differences in median MRD values
between patients with one clone or more than one clone (0.0082% and 0.0055%
respectively). The presence of more than one clone was not associated with
high-risk cytogenetics. The presence of more than one clone at diagnosis does
not condition the prognosis in any of the patients and treatments analyzed.
Median PFS was 38 and 58 months for patients with one clone or more one
clone, respectively (HR=1.136, p= 0.563). Median OS was not reached for
patients with one clone, and was 81 months for patients with more than one
clone (HR=1.43, p=0.28).
Summary/Conclusions: The analysis of the IG repertoire by the local NGS
method during treatment is able to identify and quantify new emerging clones
during the treatment that were not detectable at diagnosis. The new clones
contributed to increase the MRD levels in the follow-up samples.The presence
of of different clones at diagnosis is not associated with higher risk of progres-
sion, high risk cytogenetics or higher MRD values.
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Background: In the era of increased use of 1st-line and maintenance lenalido-
mide (LEN), there is growing need for effective ≥2nd-line therapies (tx) for LEN-
refractory pts. The combination of carfilzomib (CFZ), pomalidomide (POM),
and dexamethasone (DEX) has shown promising activity in advanced RRMM,
including for pts refractory to LEN (Shah et al. Blood. 2015).
Aims: In this Ph 1/2 study, KPd was evaluated in RRMM, with a focus on pts
who are LEN-refractory but proteasome inhibitor (PI)-naïve/sensitive.
Methods: LEN-refractory disease was required for 2nd-line KPd and LEN-
refractory/exposure for ≥3rd-line. Ph 1 dose escalation to determine maximum
tolerated dose (MTD) followed the TITE-CRM design with 40 pts receiving 3–
4mg POM PO (days [d] 1–21), 20–36mg/m2 CFZ (IV d1, 2, 8, 9, 15, 16 in cycles
[C] 1–8, and d1, 2, 15, 16 in C9+), and 40/20mg DEX PO weekly (C1–4/5–8;
for all dose levels [DLs]) in 28-day cycles. CFZ was started at 20mg/m2 for d1,
2 of C1 for all DLs. Per design, 30 PI-naïve/sensitive pts were to be enrolled at
MTD across Ph 1/2, with partial response (PR) rate after C4 as 1º efficacy end-
point.
Results: As of 12/1/16, 65 pts have been enrolled, with efficacy and safety
data available for 64 pts: 4 at DL1 (20mg/m2 CFZ, 3mg POM), 29 at DL2
(20mg/m2 CFZ, 4mg POM), 32 at DL3 (20/27mg/m2 CFZ, 4mg POM), 0 at DL4
(20/36mg/m2 CFZ, 4mg POM). Median age was 63 y, median time from diag-
nosis 5.1 y, median prior tx lines 2, and 94% had refractory disease. Cytogenetic
data were available for 59 pts; 33% were high risk per IMWG. There were 9
dose-limiting toxicities, all asymptomatic cytopenias: 8 pts with grade (G) 3
neutropenia and 1 with G4 thrombocytopenia. The MTD was established at
DL3. In 64 pts, G3/4 hematologic toxicities included neutropenia (25%) and
lymphopenia (14%), and non-hematologic toxicities (all grades) included fatigue
(51%), dyspnea (42%), and gastrointestinal (45%). PRs were rapid with a ≥PR
rate of 63% after 1 cycle and 77% after 4 cycles. After a median of 20.9 cycles
(range, 1–49), ≥minimal response was 95%, ≥PR 84%, ≥very good PR 52%,
and ≥near complete response (nCR) 20%. In the 1º population (N=55, 51 LEN-
refractory, 28 progressing on LEN maintenance), ≥PR was 84% with 30 treated
at MTD. After median follow-up of 21 (1–49) mo, median progression-free sur-
vival (PFS) for all 64 pts enrolled was 16.8 mo and 2-y overall survival (OS)
was 76.8% with 20 pts remaining on treatment. For standard-risk (n=38) vs
high-risk pts (n=21), ≥PR was 89% vs 81%, ≥nCR was 24% vs 10%, median
PFS was 22.3 vs 10.6 mo, and 2-y OS was 90.8% vs 56.0%.
Summary/Conclusions: KPd is well tolerated and highly active (≥PR 84%)
with encouraging PFS (median 16.8 mo) in an RRMM pt population that was
mostly LEN-refractory and PI-naïve/sensitive. The results support planned eval-
uation of KPd with daratumumab in RRMM, particularly for high-risk pts.
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Background: Immunotherapy with the anti-CD38 monoclonal antibody (mAb)
daratumumab is increasingly being utilized in myeloma patients with
relapsed/refractory (R/R) disease after prior treatment with immunomodulatory
drugs (IMiDs) and proteasome inhibitors (PIs). However, the efficacy of dara-
tumumab is limited by low CD38 expression on myeloma cells. Here, we inves-
tigate the use of the histone deacetylase inhibitor (HDACi) panobinostat to
modulate target antigen expression on myeloma in favor of potent mAb-medi-
ated recognition and destruction. We show that panobinostat augments CD38
expression specifically on myeloma cells and demonstrate powerful synergy
with anti-CD38 mAb daratumumab.
Aims: Determine the impact of panobinostat on upregulation of CD38 expres-
sion on myeloma cells in order to enhance the efficacy of daratumumab. 
Methods: Myeloma cells were treated with titrated doses of panobinostat (0,
10, 25 nM) and expression of CD38 and a panel of additional target molecules
including SLAMF7, as well as accessory ligands analyzed by flow cytometry at
24, 48 and 72 hours. Antibody-dependent cellular cytotoxicity (ADCC) against
panobinostat treated and untreated myeloma cells was analyzed at 4 and 20
hours after addition of PBMC at an effector to target ratio of 25:1 in the presence
of daratumumab or an isotype control antibody.
Results: We treated primary myeloma (n=12 patients) with panobinostat (10
vs 25 nM) and observed a uniform increase in CD38 expression in each case
by flow cytometry. Upregulation of CD38 was already detectable after 24 hours,
peaked after 48 hours of exposure to panobinostat and was higher at the 25
nM compared to the 10 nM dose. At 48 hours, the mean fluorescence intensity
(MFI) for CD38 expression was 4 (10nM) and 6-fold (25 nM) higher in panobi-
nostat-treated compared to untreated myeloma (p<0.01). The increase in CD38
was equal in patients with previously untreated (n=5) and R/R myeloma (n=7);
and could be confirmed in a panel of myeloma cell lines, including MM1.S and
OPM-2. The panobinostat-induced upregulation of CD38 was rapidly reversible
after drug withdrawal. Further, the increase in CD38 expression after panobi-
nostat treatment was specific for myeloma and neither observed this phenom-
enon in a panel of leukemia and lymphoma cell lines, nor on primary CD8+
and CD4+ T cells that we isolated from peripheral blood of several donors
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(n=3). Interestingly, expression of SLAMF7 was not increased after panobino-
stat treatment at all tested concentrations and time points in both cell lines and
primary myeloma. Next, we were interested in determining whether the increase
in CD38 expression enabled superior antimyeloma activity of the anti-CD38
mAb daratumumab. Thus, we treated primary myeloma cells from patients
(n=4) with panobinostat for 48 hours at 10 nM, as this is the serum level achiev-
able with currently approved dosing regimens. We observed a significant
increase in ADCC against panobinostat-treated compared to untreated myelo-
ma in all patients. On average, 78% of panobinostat-treated primary myeloma
cells were eliminated by daratumumab within the 4-hour ADCC assay, whereas
only 51% myeloma cells were eliminated without panobinostat treatment
(p<0.01). The synergistic anti-myeloma efficacy of panobinostat and daratu-
mumab was confirmed with a panel of myeloma cell lines.
Summary/Conclusions: Our data demonstrate that the HDACi panobinostat
induces upregulation of CD38 on myeloma and a subsequent dramatic increase
of daratumumab-mediated ADCC. These data suggest that panobinostat could
be used synergistically with daratumumab in a clinical setting to increase
response rates and extend duration of responses to daratumumab.
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Background: The anti-apoptotic proteins BCL-2 and MCL-1 have been shown
to promote multiple myeloma (MM) cell survival. Venetoclax (VEN) is a potent,
selective, and orally bioavailable small-molecule inhibitor of BCL-2. Bortezomib
(BTZ) is a proteasome inhibitor that can inhibit MCL-1 activity by increasing
the MCL-1 antagonist, NOXA. 
Aims: Results presented herein describe correlative biomarker analyses in
the ongoing phase 1b study of VEN in combination with BTZ and dexametha-
sone in patients with relapsed/refractory (R/R) MM (NCT01794507).
Methods: As of 19 Aug 2016, 66 patients were enrolled on study. Baseline
bone marrow aspirate samples were available from 52 patients, of which 45
were evaluable for BCL-2 family gene expression by droplet digital PCR in
CD138-selected tumor cells. Correlation between BCL2 (BCL-2), BCL2L1
(BCL-XL) and MCL1 (MCL-1) mRNA expression (log2-transformed copies/ul
normalized to housekeeping gene) and preliminary efficacy [overall response
rate (ORR), time to disease progression (TTP) and duration of response (DoR)]
were examined by Log-rank and Wilcoxon tests for binary biomarkers, and by
risk ratio from Cox proportional hazard model for continuous biomarkers.
Figure 1.
Results: The ORR was 68% (44/65) for all evaluable patients and 89% (31/35)
in patients who had 1-3 prior therapies (31/35). A broad range of BCL2, BCL2L1
and MCL1 expression was observed, however higher BCL2 levels were detect-
ed in patients who achieved a partial response (PR) or better (median: 3.01 vs
0.87, p<0.01). Additionally, higher BCL2 levels were observed in patients who
had 1–3 prior lines of therapy compared to 4 or more lines of therapy (median:
3.03 vs 0.94, p<0.01). In contrast, no association was observed between
BCL2L1 or MCL1 gene expression and response or number of prior therapies.
Bootstrapping and aggregating thresholds from trees was used to estimate a
threshold value for BCL2 expression that would provide optimum selection of
patients likely to have a response. Overall, seventeen of 18 patients with high
BCL2 expression (≥3.0) achieved at least a PR (ORR 94%), with 12 patients
(66%) achieving VGPR or better (Figure 1). Sixteen of 27 patients with low
BCL2 expression achieved at least a PR (ORR 59%), with 6 patients (22%)
achieving a VGPR or better. Median TTP (11.6 vs 5.7 months) and DoR (10.2
vs 7 months) were longer for patients with high versus low BCL2 expression.
Responses in high BCL2 expressors were independent of cytogenetic status
as determined by interphase FISH analysis, including t(11;14), t(4;14), del(13q)
and del(17p).
Summary/Conclusions: Targeting BCL-2 and MCL-1 with the combination of
VEN, BTZ and dexamethasone provides a unique approach for MM treatment.
Efficacy results in tumors expressing high BCL2 levels, including 94% ORR,
provide supportive evidence for the evaluation of this combination regimen in
the ongoing phase 3 study (NCT02755597) in R/R MM.
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Background: Renal insufficiency is common at presentation in patients with
multiple myeloma (MM) and associated with a poor survival. Approximately
10% of the patients require dialysis. Studies have shown that the novel agent
bortezomib has a positive effect on recovery of renal function in MM patients
with renal insufficiency.
Aims: The aim of this study is to determine the effect of the revised guideline,
including the introduction of bortezomib as first line treatment in MM patients
with dialysis dependence, on renal function recovery.
Methods: All patients on renal replacement therapy (RRT) in the Netherlands
are registered in the Dutch registry Renine. Data on age, gender, start date of
RRT, type and switches of RRT or hospitals, primary renal diagnosis, date of
death and cause of death are collected. In this nationwide population-based
study, we selected all patients with MM registered in Renine between January
2002 and January 2016. No information regarding therapy of MM is provided
in Renine. In March 2010, bortezomib was advised as first-line treatment in
patients suffering from MM with renal impairment in the Dutch guidelines.
Therefore, we divided our cohort in two periods: before the bortezomib guideline
(January 1, 2002 till March 29, 2010) and after introduction of the bortezomib
guideline (March 29, 2010 till January 1, 2016). Kaplan-Meier and Cox propor-
tional hazards modelling were used to identify significant indicators for dialysis
independency.
Results: A total of 700 patients were included in the study (422 patients pre-
bortezomib and 278 after bortezomib introduction). In the period after the intro-
duction of bortezomib 15% of patients became dialysis independent compared
to 8% in the pre-bortezomib period (HRadj.=2.1 (95% CI 1.3–3.3), Fig. 1). In
addition, patients who started dialysis in the period after bortezomib was intro-
duced became dialysis independent more rapidly than in the pre-bortezomib
period (1.2 compared to 1.7 years; p < 0.001). Age < 75 years (vs. ≥ 75 years)
and light chain deposition disease (LCDD) as the primary renal disease (vs.
amyloidosis) were significantly associated with achieving dialysis independence
(HRadj.=2.1 (95% CI 1.0–4.2) and HRadj.=5.7 (95% CI 2.5–13.2), respectively).
Figure 1.
Summary/Conclusions: In this nationwide population-based study, covering
all patients with MM and concomitant renal failure, almost a two-fold increase
of patients becoming dialysis independent occurred in the period after the intro-
duction of bortezomib compared to the pre-bortezomib period. This was even
more prominent when age was < 75 years and LCDD was the primary renal
disease.
P684
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Background: The immunomodulatory agent pomalidomide is active in patients
with relapsed/refractory multiple myeloma, including those who failed prior
lenalidomide and bortezomib. Phase II clinical trials showed that pomalidomide
is also effective in primary AL amyloidosis. After this drug was marketed for
multiple myeloma (in Italy since September 2015), it became routinely acces-
sible also to patients with myeloma-associated AL amyloidosis, a particularly
fragile population.
Aims: Aim of this study is to report the efficacy of pomalidomide and dexam-
ethasone in patients with multiple myeloma-associated AL amyloidosis.
Methods: The databases of the Pavia Amyloid Research and Treatment Center
was searched for patients with a diagnosis of multiple myeloma and AL amyloi-
dosis treated with pomalidomide and dexamethasone (PDex). The patients
received 28-day cycles of pomalidomide (4mg from day 1 to 21) and dexam-
ethasone (20/40mg weekly). All patients gave written informed consent for their
clinical data to be used for research purposes, in accordance with the Declaration
of Helsinki. Thirty patients were treated to date. Hematologic and organ response
were assessed according to the International Society of Amyloidosis criteria.
Results: Median age was 65 years (range: 34-85 years) and 22 (73%) patients
were man. Heart involvement was present in 13 patients (43%) and kidney
involvement in 18 (60%). Four (13%) patients were in Mayo Stage I, 17 (57%)
in stage II and 9 (30%) in stage III. Fifteen (50%) subject were in renal stage I,
8 (27%) and 3 (23%) were in renal stage II and III respectively and 5 (16%)
patients were on dialysis at the time of PDex initiation. Median bone marrow
plasma cell infiltrate was 20% (range: 12-90%). Twenty-three (76%) patients
were refractory to all previous lines of therapy. Median time from diagnosis to
treatment initiation was 71 months [interquartile range (IQR): 25-120 months].
Adverse events were observed in 5 (17%) of subjects: skin rash and confusion
in one patient each and mild increase in serum creatinine in 3 (10%, resolved
with the decrease of the dose of pomalidomide). The median number of prior
treatments was 3 (range: 2-5 cycles). All patients previously received lenalido-
mide and an alkylating agent, only 3 patients were not exposed to bortezomib,
due to severe peripheral nervous system involvement, 10 (33%) underwent
autologous stem cell transplant and 9 (30%) received previous thalidomide-
based regimens. The median number of PDex cycles performed was 4 (range:
1-11). Median follow-up of living patients was 8 months (IQR: 3.5-16 months)
and 13 (43%) patients died due to progressive disease. Fourteen patients (47%)
achieved at least partial response, with 1 complete remission (CR), and very
good partial responses (VGPR) in 2 cases (6%). Cardiac responses were
observed in 1 of 5 patients with measurable NT-proBNP (20%), but this can be
underestimated due to the pomalidomide-related increase of NT-proBNP, and
renal response in 3 of the 11 evaluable patients (27%).
Summary/Conclusions: The combination of pomalidomide and dexametha-
sone is well tolerated and effective in multiple myeloma-associated AL amyloi-
dosis and can be a valuable rescue option in this high-risk population.
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Background: AL amyloidosis is a free light chain (FLC) deposition disease that
can affect the heart. To identify the specific subtype is essential for treatment
and prognosis.99mTc-DPD scintigraphy (SC) has shown high sensitivity and
specificity for detecting TTR cardiac amyloidosis, although some cases have
been described with AL amyloidosis and DPD uptake. An intense biventricular
uptake (Perugini score 2-3 (PS)) is highly suggestive of TTR amyloidosis.
Aims: Our objective is to describe the characteristics of patients with AL amy-
loidosis and myocardial DPD uptake.
Methods: We reviewed all SC performed at our center in the last 50 months.
Indication was ventricular hypertrophy of unknown etiology. We have correlated
the image findings with the clinical and/or pathological diagnosis. AL amyloidosis
diagnosis was based on histological demonstration of amyloid by Congo Red
staining and immunohistochemistry (IHC) in any tissue and confirmation by
proteomics (mass spectrometry (MS)) when indicated.
Results: We performed 704 SC for different indications during the study period.
41/61 patients (67.2%) with AL amyloidosisand cardiac involvement underwent
a SC: 27 were negative (66%), 7 (17%) showed some degree of uptake (PS
score<2 and focal or univentricular uptake) and 7 (17%) had biventricular uptake
(PS 2-3). Patients with PS<2 (7): 5 patients underwent an endomyocardial
biopsy (EMB). In 4 cases IHC confirmed AL amyloidosis, while in 1 case IHC
was not diagnostic and MS confirmed AL amyloidosis. The two remaining
patients were diagnosed of AL amyloidosis by IHC unequivocally in other tis-
sues. Patients with PS 2-3 (7): 5 patients underwent an endomyocardial biopsy
(EMB). Among them, 3 were diagnosed of AL amyloidosis, both by IHC and
MS. Two patients, both of them with a M-spike and abnormal free light chains
ratio in serum and increased clonal plasma cells in the bone marrow, showed
TTR and faint light chain deposition but MS confirmed the diagnosis of TTR
amyloidosis (TTR gene non mutated). The two remaining patients were diag-
nosed of AL amyloidosis by IHC unequivocally in other tissues. Mean value of
NT-proBNP (N-terminal-natriuretic peptide) in patients with AL amyloidosis was
7730 pg/ml for those with a positive uptake in the scintigraphy and 9990 pg/ml
for those with a negative result.
Summary/Conclusions: Cardiac 99mTc-DPD SC has been described as a
useful technique in the differential diagnosis between AL and TTR amyloidosis.
However, up to 30% of cases of AL amyloidosis show some degree of uptake
and 10% show a pattern consistent with TTR amyloidosis (biventricular uptake
and PS 2-3). Cases have been described with myocardial deposit of both TTR
and light chain and up to 10-15% of the population >75 years may show a MC
in serum, so it is essential to type accurately amyloid in patients with suspected
AL amyloidosis and myocardial uptake in SC. MS is not routinely available in
most centers and IHC results may be ambiguous. We consider that MS is
mandatory in cases of cardiac amyloidosis with abnormal FLC ratio and positive
biventricular 99mTc-DPD uptake. We did not find any correlation between positive
uptake in the SC and NT-proBNP values, as it has been recently suggested.
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Background: It was recently shown in both clinical and population-based series
that unperformed cytogenetics (UPCs) in intensively treated patients with acute
myeloid leukemia was independently associated with poor prognosis, as com-
pared to patients with performed cytogenetics.
Aims: Therefore, we set out to assess whether UPCs is associated with poor
outcome in young patients with symptomatic multiple myeloma (MM) who have
received induction chemotherapy. 
Methods: We identified 358 newly diagnosed patients with MM <66 years in
2014 from the nationwide population-based Netherlands Cancer Registry
(NCR). UPCs was used to indicate that no sample was sent in for cytogenetic
analysis. Performed cytogenetics were grouped by Revised International Stag-
ing System (R-ISS), i.e. high-risk (presence of translocations (4;14) or (14;16)
or deletion 17p) or standard-risk (presence of other aberrations or no aberra-
tions). Only patients treated with induction chemotherapy, defined as treatment
with VCD, PAD, BD or TAD +/- subsequent high dose melfalan and autologous
stem cell transplantation (ASCT), were included for analyses. In total, 319
(89%, median age 60 years, 62% male) were treated with induction chemother-
apy, 39 patients otherwise or had no therapy. The primary endpoint was pro-
gression-free survival (PFS), defined as time from start of first line induction
chemotherapy to progression or death, whichever comes first. Patients alive
without progression were censored at February 1st, 2016.
Results: In 220/319 (69%) MM patients treated with induction chemotherapy,
cytogenetics was performed and 63 of these patients (29%) were cytogeneti-
cally high-risk. No statistical significant differences were observed in CRAB cri-
teria or ISS between patients with or without performed cytogenetics. The pro-
portion of patients undergoing ASCT was similar in different cytogenetic groups
(standard-risk 85%, high-risk 83% and UPC 77%, p=0.77). Achieving partial
response or better was higher, although not statistically significant, in the stan-
dard-risk group as compared to the high-risk and UPC groups (93% vs 89% vs
85%, p=0.92). Response outcome was unknown for 9% of the UPC group, 5%
in high-risk group and 4% in the standard-risk group. Median follow-up time
was 516 days. PFS for patients in the standard-risk group was highest, as com-
pared to patients in the high-risk or UPCs groups after one year of follow-up
(88% vs 81% vs 74%, p=0.0003).
Summary/Conclusions: Our data show that cytogenetic testing is performed
in almost 70% of MM patients <66 years. Although response rates were similar
for patients in the UPC, standard- and high-risk groups, PFS was better in the
standard-risk group. Patients with unperformed cytogenetics had the poorest
outcomes. The reasons are unclear, but a plausible explanation for not per-
forming cytogenetics could be the patients’ worse clinical condition at presen-
tation which requires immediate treatment. For the abovementioned outcome
measures, data of calendar year 2015 will be added and presented at the Euro-
pean Hematology Association.
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Background: To contextualize the benefit of novel agents such as daratu-
mumab (DARA) monotherapy for the treatment of patients with heavily pre-
treated and highly refractory multiple myeloma (MM), it is critical to understand
the real-world outcomes of this patient population on current standard of care
(SOC) therapies. To determine the comparative effectiveness of DARA vs real-
world SOC, an adjusted comparison was conducted1 utilizing data from the
DARA monotherapy trials2 and the International Myeloma Foundation (IMF)
chart review.3
Aims: The objective of this analysis is to update the adjusted comparison to
include additional Swedish patients from the IMF chart review.
Methods: Data for patients treated with DARA 16mg/kg monotherapy were
available from clinical trials MMY2002 (n=106) and GEN501 (n=42), while
patients treated with SOC therapies were derived from the IMF chart review of
patients with MM who had ≥3 prior lines of therapy and were double refractory
to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) (n=550,
original 510, additional Swedish patients 40). Patients from the IMF-cohort who
moved into further treatment lines after the line therapy where they fulfilled inclu-
sion criteria, contributed information to the analysis for multiple lines of therapy,
with baseline defined as the date of initiation of the actual treatment line, resulting
in a sample size of 963 treatment lines from 550 patients. The relative treatment
effect of DARA versus SOC was estimated using multivariate Cox regression
analyses. The methodology utilized individual patient data to compare overall
survival (OS). The covariates included were age, gender, prior lines of therapy,
albumin, beta-2 microglobulin, prior exposure to pomalidomide and carfilzomib,
and PI/IMiD refractory status. Clustering of observations at the treatment-line
level within patients was controlled for using the robust sandwich estimate for
the covariance matrix. Statistical significance testing was performed using a
two-tailed P-value of <0.05, and all comparisons between treatment groups
were reported with hazard ratios (HRs) and 95% confidence intervals (CIs).
Results: After adjustment for differences in baseline characteristics included
in the multivariate model between the DARA and SOC groups, results showed
a significant improvement in favor of DARA compared with SOC for OS
(HR=0.42 [95% CI 0.31–0.57]). When limiting the comparative analysis to Euro-
pean patients from the IMF cohort (n=341), results for OS are very similar
(HR=0.40 [95% CI: 0.28-0.58]).
Summary/Conclusions: Findings from the regression analyses using the
updated IMF dataset were consistent with results from the previous analysis3
and suggest that DARA is associated with significant gains in OS compared
with SOC therapies for patients with heavily pre-treated and highly refractory
MM. Findings for a European subset from the IMF dataset were similar to
results from the entire cohort.
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Background: Multiple Myeloma (MM) is predominantly a disease of the elderly
and the outcome of these patients is poorer than that of transplant candidates.
It is well stablished that those considered frail or unfit have a dismal prognosis,
however, even within fit patients, such as those included in clinical trials, there
is substantial proportion of early deaths (within the first 2 years after diagnosis).
Identification of this “high-risk” fit elderly patients could contribute both to the
design of innovative clinical trials, and to avoid the emotional and economical
burden of repetitive unsuccessful therapies.
Aims: To analyze the factors associated with early death (within first 2-years)
due to active MM in elderly newly diagnosed (NDMM) patients fit enough to be
included in clinical trials with optimized therapy with proteasome inhibitors and
IMIDs. 
Methods: 497 NDMM not transplant candidates treated in two prospective
GEM-PETHEMA trials were included in the study: GEM05MAS65 (n=260) used
frontline treatment with either bortezomib-melphalan-prednisone (VMP) or
bortezomib-thalidomide-prednisone followed by maintenance with bortezomib,
thalidomide or bortezomib, prednisone; the GEM2010MAS65 (n=239) com-
pared induction with sequential or alternating cycles of VMP + lenalidomide-
dexamethasone. The event was defined as death related to active MM within
2 years from diagnosis, either because of disease progression or early death
due to absence of response.
Table 1.
Results: From the 497 patients included, 77 (15%) patients died within 2 years
from diagnosis due to active MM. When we compared this latter cohort with
the remaining patients, the profile of the high risk group was characterized
(Table 1) by a higher proportion of patients >75 years, advanced ISS and R-
ISS stage, higher β2-microglobuline (β2-M) levels (>3.5 and 5.5mg/dl) and
abnormal LDH; increased incidence of high-risk cytogenetic features (HR CA),
CD45- clonal plasma cells, and lower incidence of CD27+ MM phenotype.
Patients dying in <2 years were also characterized by a higher proportion of
non-responding patients as well as unstained responses (unsR). The multi-
variate analysis showed that the risk of early death due to active MM was relat-
ed to four independent prognostic factors: age >75y (p=0.008), abnormal LDH
(p=0.000), ISS 3 (p=0.008), and presence of HR CA (p=0.019. These four vari-
ables enabled the definition of a scoring system composed of 6 categories (0-
5) (age>75 y=1 point, ISS 3=1, LDH>normal=2, HR CA= 1). Using a cut-off
point of ≥4 the positive predictive value (PPV) was 57.9%, negative predictive
value (NPV) was 87.4% and the positive likelihood ratio 7.9. Upon adding the
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unsR (duration of response (≥PR) <6 months) to the baseline score we were
able to build a new score in which the unsR had a 3 points weight. A score
punctuation ≥5 segregates a subgroup of patients with poor outcome (PPV:
83.3%, the NPV: 84.02%).
Summary/Conclusions: The risk of early death due to active disease in elderly
patients was related to four independent prognostic factors: age >75y, high
LDH levels, advanced ISS, and presence of HR CA. A score ≥ 4 identify a sub-
group of patients with high probability of death within 2 years despite optimized
treatment. 
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Background: Myelofibrosis (MF) may be caused by various pathogenic mech-
anisms, such as elevated circulating cytokine levels, cellular interactions, and
genetic mutations. However, the underlying mechanism of MF remains
unknown. A recent study showed that the neoplastic clone of fibrocytes, spin-
dle-shaped fibroblast-like blood cells derived from monocyte lineage, was
essential in primary MF pathogenesis; serum amyloid P, which suppressed
fibrocyte differentiation, markedly improved survival and MF in a murine
xenograft model (J Exp Med 2016; 213: 1723-1740). Regarding cytokines, the
thrombopoietin (TPO) signaling pathway was assumed to be closely associated
with promoting MF. Mice transplanted with TPO-overexpressing bone marrow
cells showed symptoms such as MF and splenomegaly (Blood 1997; 90: 4369-
4383). Romiplostim (Rom), a TPO-receptor agonist, induced MF in rats and
some immune thrombocytopenic purpura patients (Blood 2009; 114: 3748-
3756). Fibrocytes and TPO played certain roles in MF pathogenesis, but the
nature of their relationship remains unknown.
Aims: We investigated the relationship between myeloproliferative leukemia
protain (MPL; TPO receptor) activation and fibrocyte differentiation in promoting
MF. The secondary goal was to discover a unique fibrocyte marker in monocyte
or macrophage population.
Methods: Murine fibrocyte cell lines were established from transgenic mice
harboring the temperature-sensitive large T-antigen gene of simian virus 40
under IL-13 and M-CSF conditions. Murine fibrocyte cell lines and human
peripheral blood mononuclear cells (PBMCs) were cultured with or without Rom
to evaluate if MPL activation promoted fibrocyte differentiation, and the ratio of
spindle-shaped cells was calculated. Rom was administered on day 1 and 8 to
induce an MF-like phenotype in C57BL/6J mice, and clodronate liposomes
(CLs; day −4, −1, 4, and 7) were used to eliminate monocytes and
macrophages.
Results: Flow cytometric analysis revealed that all murine fibrocyte cell lines
stained positive for fibrocyte cell markers, including collagen I, CD45, CD34,
CD11b, and CD68. Murine fibrocyte cell lines expressed MPL and responded
to Rom or murine TPO to differentiate into mature fibrocytes, specifically with
a longer spindle shape and stronger collagen I expression than when cultured
with IL-13 and M-CSF alone. Rom also increased the number of mice spleen
cell fibrocyte colonies in the presence of IL-13 and M-CSF. The administration
of 1mg/kg of Rom once a week induced an MF-like phenotype in all mice within
2–3 weeks and increased the number of fibrocytes in the spleen. Treatment
with CLs eliminated fibrocyte precursors and prevented severe MF and
splenomegaly. Human cultured fibrocytes also expressed MPL, and Rom
increased the number of spindle-shaped fibrocytes induced from human PBM-
Cs. The SLAMF7high MPLhigh subpopulation was clearly separated from the
SLAMF7low MPLlow population in human CD14+ monocytes. A significantly
higher frequency of fibrocyte differentiation was observed in the SLAMF7high
MPLhigh population. The number of SLAMF7high MPLhigh cells was significantly
greater in MF patients than in healthy donors. Conversely, their numbers did
not increase in MF patients treated with ruxolitinib.
Summary/Conclusions: MPL activation directly induced fibrocyte differentia-
tion from monocytes and macrophages expressing MPL, and the elimination
of these cells reversed the MF phenotype. Our findings confirmed a link
between fibrocytes and the TPO/MPL signaling pathway and indicated that the
combination of MPL and SLAMF7 could be a useful fibrocyte marker in mono-
cytes or macrophages.
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ENGRAFTMENT OF PRIMARY MYELOFIBROSIS BONE MARROW-DERIVED
CD14+ MONOCYTES IN NOD-SCID-g MICE
T. Manshouri1,*, Z. Estrov1, D. Pilling2, C.E. Bueso-Ramos3, S. Prijic1,
K.J. Newberry1, S.M. Post1, X. Zhang1, Y. Zhang1, H.M. Kantarjian1,
S. Verstovsek1
1Leukemia Department, The University of Texas/ MD. Anderson Cancer Center,
Houston, 2Department of Biology, Texas A&M University, College Station,
3Department of Hematopathology, The University of Texas/ MD. Anderson Can-
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Background: Progressive bone marrow (BM) fibrosis in patients with PMF is
thought to arise from non-hematopoietic stromal cells stimulated by overpro-
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duced growth factors. However, in other tissues and organs, fibrosis is asso-
ciated with monocyte-derived fibrocytes, which express markers of both
hematopoietic and stromal cells. Recently, we have reported that clonal neo-
plastic fibrocytes play a role in the induction of BM fibrosis in primary myelofi-
brosis (PMF) (Verstovsek, J Exp Med. 2016). We demonstrated that the BM of
PMF patients harbors more neoplastic, functionally distinct fibrocytes and fewer
MSCs than hematologically normal bone marrow (BM). In addition, we detected
an overabundance of fibrocytes in the BM and spleen of an established PMF
mouse model and a xenograft mouse model of PMF created using BM-derived
low-density cells from patients with PMF.
Aims: Fibrocytes, which make up <1% of BM cells, differentiate from a sub-
population of CD14+ monocytes and are recruited to sites of organ damage
where they regulate tissue repair. We hypothesized that clonal neoplastic
CD14+ monocytes may play a role in the induction of BM fibrosis in PMF
Methods: To test this hypothesis, we transplanted NSG mice (NOD/Scid
(NoD.Cg-prkdcscid //2rgtm1wjl/SZJ) with sorted CD14+ monocytes from
patients with JAK2V617F-positive PMF or donors with hematologically normal
BM. 
Results: Here, we show that BM-derived CD14+ cells from patients with
JAK2V617F-positive PMF or donors with hematologically normal BM engrafted
in NSG mice. Transplanted NSG mice with PMF BM-derived CD14+ monocytes
developed a myelofibrosis-like phenotype with reticulin fibrosis and abundant
neoplastic (JAK2V617F) fibrocytes in the BM and spleen. Two months after
transplantation, we detected a subpopulation of hCD45+ and hCD68+ cells
within the HLA+ population of BM cells. In addition, we found dysplastic
megakaryocytes in the BM and spleen of the PMF CD14+ transplanted mice.
Immunohistochemistry staining of paraffin embedded BM sections did not
detect hCD3, hCD19 or hCD34 cells. However staining with anti-human CD42b
antibodies detected human megakaryocytes, suggesting that the dysplastic
megakaryocytes detected in PMF CD14+ transplanted NSG mice are human-
derived. 
Summary/Conclusions: Taken together, our data suggest that neoplastic
CD14+ monocytes contribute to the induction of BM fibrosis in PMF. What role
CD14-derived megakaryocytes play in the pathogenesis of PMF remains to
be determined.
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MEGAKARYOPOIESIS BY CALRETICULIN MUTATION IN HUMAN CELLS
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Background: Somatic mutations on calreticulin (CALR) gene are found in a
majority of patients with JAK2-unmutated Philadelphia-chromosome negative
myeloproliferative neoplasms (MPNs). We and other groups have recently
shown that mutant CALR activates the downstream pathway of thrombopoietin
(TPO) receptor MPL, which induces factor-independent growth in human and
murine cells. However, roles of mutant CALR in human hematopoietic cell dif-
ferentiation remain largely elusive.
Aims: We aimed to recapitulate the MPN phenotypes and examine the impact
of CALR ins5 on human hematopoietic cell differentiation in vitro.
Methods: We employed iPS cells (iPSC) established from an essential throm-
bocythemia (ET) patient and a healthy individual harboring a 5-base insertion
mutant (CALR ins5) and wild type (CALR wt) CALR gene, respectively.
Hematopoietic progenitor cells (HPCs) were produced from iPSC by “iPS-Sac”
method. HPCs were then cultured to induce megakaryocytic cells (MKs) and
erythroid cells defined by CD42b and CD235a, respectively. The mechanism
of skewed differentiation was assessed by measuring the mRNA expression
of lineage determinant genes such as FLI1 and KLF1. To demonstrate the
established assay system for the use of compound screening, CALR ins5-
dependent megakaryopoiesis was examined by therapeutic compounds.
Results: The number of CD34+ HPCs produced from iPSC was unchanged
between CALR ins5 and CALR wt genotypes, implying that CALR ins5 did not
affect the establishment of HPC from iPSC. As expected from constitutive acti-
vation of MPL by mutant CALR, MKs were induced from CALR ins5-HPC even
in the absence of TPO in either semi-solid or liquid culture systems, which was
not evident with CALR wt-HPC. Unlike megakaryopoiesis, both CALR ins5 and
CALR wt HPCs required EPO for the production erythroid cells. However, the
number of erythroid cells induced from CALR ins5 HPC was significantly
decreased compared to that from CALR wt HPC, implying that CALR ins5 inter-
fered the erythroid cells differentiation from iPSC-derived HPC. This interfer-
ence was seemingly caused by a premature expression of FLI1 that blocked
KLF1 expression required for the erthroid cell differentiation in CALR ins5 cells.
Finally, we showed that the treatment of ruxolitinib greatly reduced megakary-
ocytic differentiation in both CALR ins5 and wt HPCs, demonstrating that rux-
olitinib does not possess preferential targeting of CALR ins5 cells.
Summary/Conclusions: We have established an in vitro model system that
recapitulates the megakaryocytosis caused by mutant CALR, which should be
useful tool for the examination of therapeutic strategies against MPN patients
harboring CALR mutation.
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QUANTITATIVE PROTEOME HETEROGENEITY IN MYELOPROLIFERATIVE
NEOPLASM SUBTYPES AND ASSOCIATION WITH JAK2 MUTATION
STATUS
N. Socoro Yuste1,*, C. Vladan P2, J. Mondet1, I. Plo3, P. Mossuz1,4
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Background: Apart from well-known genetic abnormalities, several studies
have reported variations in protein expression in Philadelphia negative (Ph-)
Myeloproliferative Neoplasm (MPN) patients that could contribute towards their
clinical phenotype.
Aims: In this context, a quantitative mass spectrometry proteomics protocol
was used to identify differences in the granulocyte proteome with the goal to
characterize the pathogenic role of aberrant protein expression in MPNs. 
Methods: LC MS/MS (LTQ Orbitrap) coupled to iTRAQ labeling showed sig-
nificant and quantitative differences in protein content among various MPN
subtypes [polycythemia vera (PV), essential thrombocythemia (ET) and primary
myelofibrosis (PMF)], and according to the genetic status of JAK2 (JAK2V617F
presence and JAK2V617F allele burden).
Results: A number of differentially expressed proteins were identified with the
most frequent being members of the RAS GTPase family and oxidative stress
regulatory proteins. Subsequent analysis found that calreticulin (CALR), known
to be involved in calcium homeostatsis and apoptotic signaling, was overex-
pressed in JAK2V617F granulocytes compared with JAK2 wild-type and inde-
pendently of the JAK2V617F allele burden. Finally it was demonstrated, in a
Ba/F3 cell model, that increased calreticulin expression was directly linked to
JAK2V617F and could be regulated by JAK2 kinase inhibitors. 
Summary/Conclusions: In conclusion, these results reveal proteome alter-
ations in MPN granulocytes depending on the phenotype and genotype of
patients, highlighting new oncogenic mechanisms associated with JAK2 muta-
tions and overexpression of calreticulin.
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THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS
GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING
MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH
SYSTEMIC MASTOCYTOSIS
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Austria, 3Laboratoire de Biologie et Pharmacologie Appliquee, CNRS UMR
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Background: Systemic mastocytosis (SM) is a myeloid neoplasm defined by
abnormal growth and pathologic accumulation of neoplastic mast cells (MC) in
various internal organs. The indolent variant of SM (ISM) is associated with an
almost normal life expectancy. By contrast, the prognosis in advanced SM,
including SM with an associated hematologic neoplasm (SM-AHN), aggressive
SM (ASM), and MC leukemia (MCL) is poor with short survival times. Most
patients with SM express the D816V-mutated variant of KIT, which confers
resistance against several tyrosine kinase inhibitors (TKI), including imatinib.
DCC-2618 is a novel switch control inhibitor that has been described to block
the kinase activity of KIT D816V.
Aims: The aims of this study were to evaluate the effects of the switch control
inhibitor DCC-2618 on proliferation and survival of neoplastic MC and other
neoplastic and non-neoplastic cell types that may play a role in advanced SM
and often expand in AHN patients. 
Methods: For our in vitro studies we used different human MC lines (HMC-
1.1, HMC-1.2, ROSAKITWT, ROSAKITD816V, ROSAKITK509I, MCPV-1.1, MCPV-
1.2, MCPV-1.3 and MCPV-1.4) and primary neoplastic MC obtained from
patients with SM. In addition, the acute myeloid leukemia (AML) cell lines
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MOLM-13, MV4-11, KG-1 and U-937, the eosinophilic leukemia cell line EOL-
1, human cultured umbilical vein endothelial cells (HUVEC), the microvascular
human endothelial cell line HMEC-1 and primary neoplastic cells obtained from
patients with AML, chronic myelomonocytic leukemia (CMML) and (clonal or
reactive) hypereosinophilia were used. Cell proliferation was quantified by 3H-
thymidine uptake. Apoptosis was determined by flow cytometry and light
microscopy. The phosphorylation-status of KIT and BTK was analyzed by West-
ern blotting. The effects of DCC-2618 on histamine secretion in basophils (BA)
were analyzed by histamine release assay. 
Results: DCC-2618 was found to block the proliferation of all MC lines tested,
with lower IC50 values measured in KIT D816V-negative HMC-1.1 cells
(12.3±3.7 nM) and ROSAKITWTcells (41±5 nM) than in KIT D816V-positive
HMC-1.2 cells (123±36 nM), ROSAKITD816V cells (168±65 nM), and the multi-
resistant MC line MCPV-1. The DCC-2618-metabolite DP-5439 showed com-
parable growth-inhibitory effects in all cell lines tested. DCC-2618 was also
found to inhibit proliferation of primary neoplastic MC obtained from patients
with ISM, ASM or ASM-AHN and MCL (IC50: 83-460 nM). DCC-2618 induced
apoptosis and blocked tyrosine phosphorylation of KIT in all MC lines tested.
We were also able to show that DCC-2618 inhibits proliferation and survival in
the eosinophilic leukemia cell line EOL-1 (IC50 1.8±1.3 nM) and the FLT3 ITD-
mutated AML cell lines MV4-11 (IC50 147±88 nM) and MOLM-13 (IC50 132±95
nM). In addition, DCC-2618 was found to block proliferation in primary leukemic
cells in patients with monoblastic AML and CMML which are the most prevalent
types of AHN in advanced SM. DCC-2618 was also found to inhibit growth of
cultured human vascular endothelial cells, suggesting that the drug may also
counteract SM-related angiogenesis. Finally, DCC-2618 was found to inhibit
anti-IgE-induced histamine release from normal BA in a dose-dependent man-
ner (IC50: 1-10 µM).
Summary/Conclusions: DCC-2618 is a new potent switch control TKI that
counteracts growth and survival of neoplastic MC, leukemic monocytes, AML
blasts, eosinophils, and endothelial cells in vitro. Whether DCC-2618 is able to
block growth of neoplastic MC and other involved lineages in patients with
advanced SM is currently being ascertained in a clinical trial (NCT02571036).
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ACCORDING TO CLONAL HEMATOPOIESIS IN ESSENTIAL
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Background: Essential thrombocythemia (ET) and polycythemia vera (PV)
are clonal myeloid disorders that originate from a multipotential hematopoietic
stem cell. Although most women with PV and ET have mutations in JAK2V617F,
CALR or MPL, the proportion of patients presenting clonal hematopoiesis by X
chromosome inactivation patterns (XCIP) is variable and its relationship with
the presence of non-driver mutations is not well known. 
Aims: To study the distribution and dominance of driver and non-driver muta-
tions in the development of clonal hematopoiesis.
Methods: One hundred and twenty-six women (PV n=33, ET n=93) with an
informative result of XCIP based on HUMARA assessment were included in
the study. HUMARA analysis was performed by studying the degree of methy-
lation of exon 1 in granulocytes and lymphocytes. Somatic mutations were
studied in DNA extracted from granulocytes by NGS using a panel of 51
myeloid-related genes.
Results: Median age of patients at the time of HUMARA analysis was 64 years
(range:21-92). Mutations in JAK2 were present in 62% of them, CALR in 11%,
MPL in 8%, and 14% were triple negative (TN). Non-driver mutations were
detected in 45 patients (17 PV and 28 ET). The most frequently mutated genes
were TET2 (16%), DNMT3A (8%), ASXL1 (5%), SF3B1 (5%), EZH2 (2%) and
RUNX1 (2%).The mutation with the highest variant allele frequency (VAF) was
considered the dominant mutation and it corresponded to a driver mutation in
92 patients (JAK2 n=70, CALR n=13, MPL n=8) and a non-driver mutation in
9 patients (3 TN cases with TET2 mutations, 1 TN patient with TP53 mutation
and 4 JAK2-mutated patients with mutations in TET2, CBL, DNMT3A or EZH2).
In 12 cases the VAF of the driver mutation (JAK2 n=9, CALR n=1, MPL n=2)
was similar to the non-driver mutation, being TET2 the codominant mutation in
6 of them. HUMARA analysis was clonal in 66 patients and polyclonal in 60
patients. Clonality was more frequently observed in PV (76%) than in ET (44%,
p=0.002). Clonal HUMARA was observed in 90% of MPL-mutated patients in
comparison with 58% in JAK2-mutated, 42% in CALR-mutated and 11% in TN
(p<0.0001). Two patients with TN ET showing clonal hematopoiesis had TET2
mutations. In JAK2-mutated women, the mutant allele load was significantly
higher in clonal than in polyclonal cases (43% vs 23%, p=0.02) and in PV than
in ET (76% vs 47%, p=0.01). Eighty percent of patients with non-driver muta-
tions showed HUMARA clonality vs 37% of patients without non-driver muta-
tions (p<0.0001). The mutated genes significantly associated with a higher fre-
quency of clonal hematopoiesis were TET2 (p=0.007) and SF3B1 (p=0.029).
Age was significantly associated with clonal hematopoiesis and with the pres-
ence of non-driver mutations (median age of 55 and 68 years for polyclonal
and clonal HUMARA respectively, p<0.0001 and 57 and 71 years for patients
without and with additional mutations respectively, p<0.0001). Patients in which
the driver mutation was dominant were younger than those in which the non-
driver mutation was dominant or codominant (median age 61 vs 71 years,
p=0.01). In the multivariate analysis, the variables that were associated with a
higher probability of clonal hematopoiesis were the presence of non-driver
mutations (OR:4.2, 95%CI: 1.6-10.6, p=0.003), age> 65 years (OR:2.7, 95%CI:
1.2-6.5, p=0.02), MPL genotype (OR:10.9, 95%CI: 1.2-98.9, p<0.0001) and
PV diagnosis (OR 3.6, 95%CI: 1.3-9.7, p=0.01).
Summary/Conclusions: The presence of non-driver mutations is associated
with clonal hematopoiesis regardless of age and type of disease.
Elderly patients with clonal hematopoiesis often show non-driver mutations
coexisting in equal or greater proportion than the driver mutation suggesting
that MPN has originated on preexisting clonal hematopoiesis.
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RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING
NOVEL TREATMENT FOR MYELOFIBROSIS
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Background: Myelofibrosis (MF) is the myeloproliferative neoplasm chromo-
some Phi- negative with worst prognosis. MF is characterized by stem cell-
derived clonal myeloproliferation and reactive cytokine-driven inflammatory
bone marrow fibrosis. Ruxolitinib is the first line treatment for MF. It was asso-
ciated with significant reduction in symptomatic splenomegaly and improved
constitutional symptoms. In a previous work (Arenas et al. Blood Volume 122,
Issue 21 (ASH Annual Meeting Abstrat)) we identified a set of promising syn-
ergistic drugs combinations for a ruxolitinib. Nilotinib and prednisolone were
selected from them. 
Aims: The aim of this work is the study the effect of the combination of ruxoli-
tinib, nilotinib and prednisolone in hematopoietic progenitor cells from patients
with MF.
Methods: A ruxolitinib, nilotinib and prednisolone dose-response curves and
synergistic studies were performed in hematopoietic progenitors CD34+ from
five MF patients. We studied the molecular effect of single drugs and in com-
bination on SET2 cell line with western blot. To adress the antifibrogenic activity
of the drugs and their combinations, we pre-incubated HS27 cultures with
100nM of ruxolitinib, 1 µM of nilotinib, 1 µM of prednisolone or their combination
during 1 h. After that, we added 2ng/mL TGF-β during 24h to induce fibroge-
nesis. Finally, the collagen I expression was evaluated by immunocytochem-
istry (ICC).
Figure 1.
Results: The effects of ruxolitinib, nilotinib and prednisolone resulted in an
EC50 value of 55nM, 6.6µM and 13.1µM, respectively. A combination index (CI)
of less than 1 indicated synergy. All combination had a synergistic behavior
(Table 1); moreover, there were two combinations whose CI from all samples
indicated synergy: 32nM ruxolitinib, 8 µM Nilotinib plus 0.8 µM prednisolone
(CI=0.25±0.11) and 32nM ruxolitinib plus 0.8 µM prednisolone (CI=0.45±0.11).
The JAK/STAT signaling pathway was inhibited: the phosphorylation of STAT5
was inhibited by ruxolitinib in 83.2±10.8 % (p-valor<0.05) regarding to control
at 30 min and it was maintained at 3 hours (p-valor<0.05). The combinations
32nM ruxolitinib plus 1.6 µM nilotinib (RN) and 32nM ruxolitinib, 1.6µM nilotinib
plus 0.8µM prednisolone (RNP) inhibited more than 50% of the phosphorylation
of STAT5 at 30 min and maintained at 3 hours. The MAPK signaling pathway
was inhibited at 30 min, the phosphorylation of ERK was inhibited in 77.7±16.4
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% (p-value<0.05) by ruxolitinib, 42.6±14.4 % by RN and 70.8±11.2 % by RNP
(p-valor<0.001). The inhibition was maintained at 3 hours by ruxolitinib
(71.3±18.9%) (p-value<0.05). The Akt/PI3K signaling pathway seemed to begin
to inhibit at 3 hours by ruxolitinib (57.5+25.2%), nilotinib (38.4±26.8%), RN
(30.5±24.03%) and RNP (37.4±16.5%). Then, the antifibrogenic activity of the
drugs and their combinations were studied. Nilotinib reduced the mRNA expres-
sion of COL1 (39.8±0.9 %) (p-value<0.05). Its combination with ruxolitinib (RN:
48.1±2.9% (p<0.05) and prednisolone (RNP: 37.8±1.9% (p-value<0.05). These
results were corroborated by ICC: the inhibition of expression of collagen I was
more intense if the HS27 were treated with nilotinib or RN (figure 1).
Summary/Conclusions: In conclusion, ruxolitinib, nilotinib, prednisolone and
their combinations had a synergistic behavior to control the proliferation of
myeloid cells in MF patients; moreover, they had anti-fibrotic activity in fibroblast
cells. For these reasons, the combined ruxolitinib/nilotinib/prednisolone could
be a promising therapy to MF and support an ongoing clinical trial in MF patients. 
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Background: Next-generation sequencing (NGS) technology is being imple-
mented in clinical practice for assessing the mutational status of myeloid neo-
plasms. The Working Group on Molecular Biology from the Spanish Society of
Hematology has performed an interlaboratory assessment of gene mutation
analysis by targeted NGS.
Aims: To assess the technical performance of mutation detection by targeted
NGS using myeloid panels.
Methods: The technical comparison was established on two rounds with sam-
ples previously analysed using NGS panels, Sanger sequencing and/or frag-
ment analysis. First, four DNA samples (S1-S4) from AML patients were shared
among 6 laboratories. In a second round, five samples (S5 to S9) were shared
among 14 laboratories. The center of origin had previously characterized and
confirmed: for the first round, 14 relevant mutations in 10 genes; and for the
second round 17 relevant mutations in 7 genes. Each center performed library
preparation, sequencing and blind variant analysis following their own routine
practice. Detected variants and data regarding main methodological parame-
ters were collected. Detection rate was calculated as the number of laboratories
with positive detection out of the number of laboratories that sequenced the
particular gene region.
Results: Eight different gene panels were used for library preparation (pre-
designed in 10 labs and custom in 4). The predominant approach was amplicon
enrichment (11/14, 78.6%) and only 3/14 laboratories (21.4%) used capture-
based methods. Sequencing was performed with Illumina devices in 9/14 lab-
oratories and Ion Torrent platforms in 5/14. Alignment and variant calling was
performed with MiSeq Reporter (n=3), Torrent Suite (n=4) or panel-adjusted
analysis pipelines. The median coverage was 2353 reads (range 275-17096).
Results are summarized in the table. Overall, most variants were detected by
≥80% of the laboratories. None of the participants was able to detect all the
previously characterized mutations using only NGS myeloid gene panels. Vari-
ants with lower detection rates can be classified in 3 groups: a) Medium-long
insertions/deletions. FLT3-ITD was not detected by NGS. CALRL367fs and
ASXL1E635fs were detected in only 67% and 31% of laboratories, respectively.
However, a SRSF2 24bp deletion with similar characteristics showed a 90%
detection rate. b) Mutations with low variant allele frequency (VAF). CBLY371N
(VAF 5.24%) and SF3B1K700E (VAF 4.09%) were less detected/reported. c)
ASXL1G646fs. This mutation caused by a guanine duplication in a homopoly-
meric region is technically challenging and there is controversy as previous
reports have considered this alteration as an artifact. The reported VAFs were
similar for SNVs whereas for indels higher differences were observed (mean
coefficient of variation of 11.91%, and 26.04%, respectively).
Table 1.
Summary/Conclusions: Gene mutation analysis by targeted NGS in myeloid
malignances is highly reproducible between laboratories and allows a com-
prehensive characterization of the molecular profile. However, medium-long
indels, low frequency mutations (<10%), ASXL1G646fs detection and variant
categorization are critical points that have to be addressed to improve the
results. Test system validation is crucial for the implementation of NGS tech-
nology.
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Background: Myeloproliferative Neoplasms (MPNs) result from genetic and
epigenetic dysregulation. Epigenetic therapies, such as Vorinostat (SAHA, MK-
0683), a histone deacetylase inhibitor, have been tested as a therapeutic strat-
egy in these patients. Examining the epigenetic landscape in MPN may provide
new insights into predicting therapeutic response and therefore enhance the
clinical utility of these agents. Probably the best described epigenetic mecha-
nism is DNA methylation (DNAm); in which methyl groups are added to DNA
at CpG sites regulating chromatin compaction and gene expression/repression.
DNAm is known to be altered by ageing and can reflect the effect of diet,
lifestyle or disease on cellular processes. Therefore ‘methylation age’ (MA)
may be a more accurate reflection of disease than ‘chronological age’ (CA),
which is merely a description of how long a person has been alive. Weidner et
al (Genome Biology, 2014) described how the measurement of DNAm levels
at CpGs within 3 genes, ASPA, ITGA2B, PDE4C enabled the determination of
a reliable MA that reflected CA in normal individuals.
Aims: The aim of our study was correlate MA with disease status, mutational
profile and therapeutic response in a cohort of MPN patients treated with
Vorinostat.
278 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Methods: MA was calculated following pyrosequencing of bisulfite converted
DNA from 40 MPN patients on an investigator initiated non randomised open
label phase II multicentre study of Vorinostat (EudraCT #2007-005306-49). Paired
samples were analysed at trial entry and after 3 months of therapy to calculate
their individual MA scores. Validation of methods used and ageing signature cal-
culation was carried out using cell line and healthy volunteer material.
Results: Samples from 18 Essential Thrombocythaemia (ET) and 22 Poly-
cythaemia Vera (PV) patients (23 F/17 M) with a mean age of 62 years (range
29-81) were assessed. JAK2V617F was detected in 77.5% (n=31/40). Com-
plete clinical response (CR) was achieved in 8 patients, partial (PR) in 17, and
no response (NR) in 15 patients. MA was on average 8.3 years younger than
CA (range -43.4 to +41.6) at time of trial entry and 8.2 years younger (range -
36.5 to +33.3) after therapy. This difference between MA and CA was greater
in ET patients compared to PV, both at trial entry (-14.0 years vs -3.7) and after
therapy (-13.0 years vs -4.3). A statistically significant link between JAK2 allele
burden and MA was seen: compared to patients with low or no JAK2 allele bur-
den, patients with high JAK2 (>60% at baseline) had an older MA at trial entry
(64.2 years vs 44.5, p=0.0007) and after therapy (64.3 years vs 44.6, p=0.0015).
This difference was also seen when PV or ET patients were examined sepa-
rately. Patients with a high JAK2 allele burden tended to have a MA closer to
their CA at trial entry (-0.6 years vs -15.3, p=0.0122) and after 3 months therapy
(-0.5 years vs -15.2, p=0.0072). Although the cohort size was small, within the
ET group, NR compared to PR was associated with a younger MA after therapy
(41.4 years vs 56.3, p=0.0156). Within PV, NR compared to PR was associated
with a MA that was older than CA both before (+9.2 years vs -14.2 years,
p=0.0346) and after therapy (+7.4 years vs -13.9, p=0.0347).
Summary/Conclusions: This study suggests a link between MA and JAK2
mutant allele burden in MPN patients, suggesting that allele burden not only
has a role in clinical phenotype and disease evolution but in the overall methy-
lation landscape of the mutated cells. However, the role of MA with respect to
therapeutic response needs to be clarified with further studies required to show
its full impact.
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Background: The number of detectable somatic mutations increase with age,
but this increase is surpassed by the rise in the incidence of cancer in older
people. The underlying mechanisms for this disparity remain to be elucidated.
Myeloproliferative neoplasm (MPN) is an ideal malignancy model disease to
study clonal hematopoiesis, disease initiation and progression during natural
aging because the majority of the relevant mutations (such as JAK2 V617F)
are catalogued, the disease evolves and progresses slowly allowing the col-
lection of serial samples, and an inducible transgenic mouse models for the
disease have been established. Nonetheless, the prevalent occurrence of such
clonal events in aged individuals brings up the question, which age-associated
factors contribute to initiate hematologic malignancies and what are the rate
limiting steps attributable for age-induced myeloid malignancies? We hypoth-
esize that aging induced alterations provides a context that favors acquisition
of new mutations, selection for pre-malignant clones, and that activation of
mutant JAK2 further augments these changes for increased MPN incidence in
aged individuals. Thus, delineation of age associated cellular and molecular
mechanisms attributable for increased prevalence of myeloid malignancies will
be essential for the development of strategies for early detection and therapeutic
targeting of myeloid malignancies.
Aims: The goal of this proposal is to identify age associated hematopoietic
cell-intrinsic and cell-extrinsic factors that determine initiation and progression
of MPN at young versus old age in mouse models carrying a JAK2-V617F or
JAK2-exon12 mutation
Methods: To assess the effcet of aging on MPN initiation and progression we stud-
ied the young and aged inducible transgenic mouse models of MPN. Integreated
omics analysis was peroformed on MPN initiating stem and progenitor cells.
Results: Our results suggest that age related changes in expression patterns
resembling MPN can be found in aged wildtype mice. The mutational profiles
in patients with pediatric MPN appear to be less complex than in older MPN
patients. We are currently investigating the relative contributions and collabo-
rations of age-associated cell intrinsic and extrinsic changes in HSCPs and
BM niche in the course and severity of MPN in mouse models carrying a JAK2-
V617F mutation, and in naturally aged donors and recipients of bone marrow
transplantations.
Summary/Conclusions: Our study provided novel molecular and cellular
mechanisms underlying increased incidence of MPN manifestation in old
age.The implications of this work goes beyond the MPN malignancy and the
comprehensive data sets generated in study will serve as a model to the wider
scientific community to study other types of malignancies. This knowledge ulti-
mately will help to define novel strategies to delay or target the onset of MPN
in an aging individual.
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Background: MF is a life-threatening hematologic malignancy characterized
by splenomegaly, debilitating constitutional symptoms, and progressive cytope-
nias. The approved JAK inhibitor ruxolitinib reduces splenomegaly and symp-
toms in pts with MF, but is associated with dose-limiting cytopenias and not
indicated for pts with platelets <50,000/µL. Red blood cell (RBC) transfusions
are the core treatment strategy for anemia in many pts. PAC is an oral kinase
inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R. In 2 phase 3 stud-
ies (PERSIST-1, PERSIST-2), PAC has demonstrated significant and sustained
spleen volume reduction (SVR) and symptom control vs best available therapy
(BAT), regardless of baseline (BL) platelet count.
Aims: This analysis is focused on anemia (at BL and treatment-emergent [TE])
in pts from PERSIST-2, a phase 3 trial of PAC vs BAT, including ruxolitinib, in
pts with MF and BL thrombocytopenia.
Methods: Pts with MF and BL platelet count ≤100,000/µL were randomized
(N=311) 1:1:1 to PAC 400mg once-daily (QD), PAC 200mg twice-daily (BID),
or BAT (including ruxolitinib). The co-primary endpoints were the rates of pts
achieving ≥35% SVR (by MRI/CT) and ≥50% reduction in total symptom score
(TSS; MPN-SAF TSS 2.0) at week 24. Efficacy analyses used the intent-to-
treat efficacy population, which included all pts with randomization date allowing
them to contribute data for a week 24 end point. The safety population included
all pts who received any PAC or BAT (including those who had watchful waiting
only). Clinical improvement in hemoglobin (hgb) was defined based on IWG
criteria and RBC transfusion end points were defined according to Gale criteria
(Table 1).
Table 1.
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Results: At BL, 59% of pts had anemia (hgb <10 g/dL); pts with BL anemia
were more likely at BL to have platelet count <50,000/µL (51% vs 38%), primary
MF (71% vs 57%), and high DIPSS score (41% vs 14%). For those with BL
anemia regardless of whether RBC transfusion-dependent (TD), PAC did not
worsen hgb levels and the rate of clinical improvement in hgb was higher for
pts in the PAC BID arm (25%) vs PAC QD (13%) or BAT (12%) arms (Table).
For the 49% of pts not RBC-transfusion independent (TI) at BL, reduction in
RBC transfusion-dependency was achieved at higher rates with PAC QD (19%)
and PAC BID (22%) vs BAT (9%); 2 PAC and 0 BAT pts achieved RBC-TI by
week 24. In PAC pts, SVR ≥35% and TSS reduction ≥50% were observed
regardless of BL anemia or RBC-TD (Table). At BL, 16% of pts in the safety
population had grade 3 anemia. Incidence of TE anemia was highest during
the first 16 weeks of PAC (20% and 9% weeks 1-8, 9% and 13% weeks 8-16
for QD and BID, respectively) and first 8 weeks of BAT (10%). For pts with BL
hgb <10 vs ≥10g/dL, incidence of grade 3/4 TE anemia was similar with PAC
QD (26% vs 28%, respectively), and lower in pts with BL hgb ≥10 g/dL with
PAC BID (26% vs 16%) and BAT (20% vs 7%). All instances of TE serious
anemia with PAC or BAT (Table) were in pts with BL hgb <10g/dL. Dose mod-
ifications or discontinuations due to anemia were uncommon (Table). No expo-
sure-response relationship was evident for grade ≥2 TE anemia.
Summary/Conclusions: In pts with MF and BL thrombocytopenia, PAC treat-
ment demonstrated SVR and symptom control, regardless of BL anemia or
transfusion burden. PAC treatment led to clinical improvement in hgb and
reduction of RBC transfusion needs vs BAT. Serious anemia, and dose modi-
fications due to anemia were uncommon. PAC provides a treatment option for
pts with MF, including those with BL thrombocytopenia and anemia, for whom
available options are limited.
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Background: Therapeutic options to address anemia in patients (pts) with
Myelofibrosis (MF) are limited. In our MPNSG-0109 trial investigating poma-
lidomide (POM) in MF with cytopenia, anemia was improved in 14-29% of pts
treated with 0.5-2mg POM once daily (QD) (Schlenk RF, Stegelmann F et al.,
Leukemia 2016). 
Aims: To evaluate synergistic effects of POM plus ruxolitinib (RUX), we are
currently investigating the combination therapy within the MPNSG-0212 trial
(NCT01644110).
Methods: MPNSG-0212 is designed as multicenter, single-arm phase-Ib/II trial
with a target population of 38 pts in the first cohort. Primary endpoints are
response rate after 12 cycles (28 days each) according to IWG-MRT (Tefferi et
al., Blood 2006) and red blood cell (RBC) transfusion independence criteria
(Gale et al., Leuk Res 2011). Secondary endpoints are safety, quality of life,
progression-free, and overall survival. Main inclusion criterion is MF with ane-
mia (Hb <10 g/dL and/or RBC transfusion dependency). While POM is given
at the fixed dosage of 0.5mg QD, RUX is started at 10mg twice daily (BID) with
dose modifications being allowed. 
Results: Safety and efficacy data from 38 pts are presented. Median age of
the pts is 73 years (range, 49-83); 19 pts (50%) previously received hydrox-
yurea, RUX, EPO, POM, and/or corticosteroids. Median hemoglobin (Hb) level
at study entry was 8.6 g/dL (range, 5.4-11.7); 11 pts (29%) were RBC-transfu-
sion-dependent. Median spleen size by ultrasound was 17.9 cm (range, 12.6
- 28). At baseline, 30 pts (79%) had constitutional symptoms. Mutations of
JAK2, MPL, and CALR were present in 28 (74%), 3 (8%), and 7 (18%) pts,
respectively; 26 (68%) were intermediate-2 risk and 9 (24%) high-risk according
to the DIPSS (Passamonti et al, Blood 2010). Median time on treatment was
12 cycles (range, 2-33). In total, 881 adverse events (AE) CTCAE °1-5 were
recorded. Worsening of anemia within the first 6 cycles was the most frequent
AE occurring in 13 pts (34%) followed by fatigue in 12 (32%). Treatment inter-
ruptions were rare. There were 29 serious AE (SAE) CTCAE °2-5: most fre-
quently, leukemic transformation (n=4), pneumonia (n=3), thoracic pain (n=3),
abdominal pain (n=2), cardiac decompensation (n=2) and septic shock (n=2)
occurred in 13 pts (34%) of which 5 were fatal (cardiac decompensation, pneu-
monia, AML and septic shock [n=2]); 5 SAE (Hb, °4; neuropathy, °3, hepato-
toxicity, °3; fatigue, °3; and cardiac decompensation, °3) were considered study-
related. 16 pts (42%) are currently on study treatment; 22 (58%) discontinued
because of AE (n=6), withdrawal of consent (n=5), stable disease (SD) without
objective response after 12 cycles (n=4), leukemic transformation (n=4) or
death (n=3); 13 pts (34%) responded with spleen reduction (n=9) or ≥2 g/dL
Hb increase / RBC transfusion independence (n=4). Of note, mean Hb
increased continuously from 8.7 g/dL at baseline to 9.2 g/dL at the end of cycle
12; 12 pts (31%) continued treatment beyond cycle 12 because of response
or SD plus clinical benefit (Hb increase <2g/dL, prolongation of transfusion
intervals and/or improvement of symptoms); 6 pts (16%) stayed on treatment
for >24 cycles.
Summary/Conclusions: In our study in advanced MF, combination of POM
plus RUX was feasible with an objective response rate of 34%. Approximately
one third of pts was treated beyond cycle 12 due to sustained therapeutic ben-
efit. Based on the favourable safety profile and on results from our MPNSG-
0109 trial, a step-wise increase of the POM dosage is intended for the 2nd
study cohort to further improve anemia response.
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Background: MF is a life-threatening hematologic malignancy characterized
by splenomegaly, debilitating constitutional symptoms, and progressive cytope-
nias (anemia and thrombocytopenia). Currently, JAK1/2 inhibitor RUX is the
only approved therapy for pts with MF. Although RUX has been shown to reduce
splenomegaly and symptoms in pts with MF, it is associated with dose-limiting
cytopenias and is not indicated for pts with platelets <50,000/µL. PAC is an
oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R. In the
phase 3 PERSIST-2 study of PAC vs BAT (including RUX) in pts with MF and
BL thrombocytopenia, PAC was significantly more effective in terms of spleen
volume reduction (SVR; P=0.001) and appeared to have a better benefit/risk
profile vs BAT. 
Aims: This analysis examines outcomes for pts with MF treated with RUX in
the phase 3 PERSIST-2 study. 
Methods: Pts with MF and BL platelet count ≤100,000/µL were randomized
(N=311) 1:1:1 to PAC 400mg once-daily (QD), PAC 200mg twice-daily (BID),
or BAT. BAT included any physician-selected treatments for MF, as well as
symptom-directed treatment, or no treatment. The co-primary endpoints were
the rates of pts achieving ≥35% SVR (by MRI/CT) and ≥50% reduction in total
symptom score (TSS; MPN-SAF TSS 2.0) at week 24. Efficacy analyses used
the intent-to-treat efficacy (ITT-E) population, which included all pts with ran-
domization date allowing them to contribute data for a week 24 endpoint.
Crossover from BAT to PAC was allowed after week 24 or splenic progression.
Results: RUX was the most commonly received active BAT; 44 (45%) BAT pts
received RUX (Figure) and 32 (33%) received only RUX. Of the 44 pts who
received RUX on study, 17 (39%) had BL platelet counts <50,000/µL and would
not have been candidates for RUX by approved indication (or study protocol).
Around half of PAC (46%) and BAT pts (51%) had received prior RUX, including
32/44 (73%) pts treated with RUX on study. One (3%) and 6 (19%) RUX pts
(n=32 in ITT-E population) achieved SVR ≥35% and TSS reduction ≥50% at
week 24, respectively, vs 11 (15%) and 13 (17%) PAC QD and 16 (22%) and
24 (32%) PAC BID pts. For PAC pts with prior RUX, SVR and TSS endpoints
were achieved in 6% and 10% with QD, and 13% and 32% with BID, vs 20%
and 23% with QD, and 28% and 33% with BID for PAC pts without prior RUX.
Grade 3/4 adverse events (AEs) were reported in 76%, 70%, and 45% of PAC
QD, PAC BID, and RUX pts, most commonly (≥9% in any arm) thrombocy-
topenia (31%, 32%), anemia (27%, 22%), and neutropenia (9%, 7%) with PAC
QD and BID, respectively, and thrombocytopenia (16%) anemia (9%), and neu-
tropenia (2%) with RUX. Dose reductions due to AEs occurred in 20%, 12%,
and 11% of pts treated with PAC QD, PAC BID, and RUX, respectively, though
the majority of RUX-treated pts began with 5mg dosing (Figure). Discontinua-
tions due to AEs occurred in 19%, 15%, and 16% of pts treated with PAC QD,
PAC BID, and RUX, respectively. Half (22/44) of RUX-treated pts crossed over
to PAC treatment, at a median of 26.1 (95% CI 25.3-27.3) weeks. Of those 22,
19 pts remained on PAC treatment at the time of data cut-off, 7 for ≥24 weeks
of PAC treatment (Figure 1).
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Figure 1.
Summary/Conclusions: In the phase 3 PERSIST-2 study of PAC vs BAT in
pts with MF and BL thrombocytopenia, although 19% of RUX-treated pts
achieved a 50% reduction in TSS, RUX-treated pts rarely achieved SVR ≥35%
at week 24. Rates of grade 3/4 AEs were higher with PAC vs RUX treatment,
though the majority of RUX-treated pts began with 5mg dosing. Rates of dose
reductions and discontinuations due to AEs with PAC BID and RUX were similar.
Following crossover to PAC in 22 RUX-treated pts, 19 remained on treatment
at the time of data cut-off. 
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Background: RUX is a potent JAK1/JAK2 inhibitor that has led to reductions
in splenomegaly and symptoms in patients (pts) with MF. Although few studies
have assessed RUX in elderly pts, a recent analysis including 100 pts >75 y
showed that RUX was safe and effective in these pts, with safety and efficacy
outcomes similar to those in younger pts (Latagliata et al. Blood.
2016;128:4251). JUMP, a large (N=2233), phase 3b, expanded-access trial
assessed safety and efficacy of RUX in pts with no access to RUX outside a
clinical trial and included a cohort of pts ≥75 y.
Aims: To assess the safety and efficacy of RUX in pts aged ≥75 y.
Methods: Pts with high- or Int-2–MF, or Int-1–risk pts with a palpable (≥5 cm)
spleen, were eligible. RUX starting doses were based on baseline platelet (PLT)
counts (5mg bid [≥50 to <100×109/L], 15mg bid [100 to 200×109/L], or 20mg
bid [>200×109/L]). Pts were ≥18 y; there was no maximum age limit. The pri-
mary endpoint was safety and tolerability of RUX. Secondary endpoints includ-
ed changes in spleen length and symptoms. 
Results: This analysis includes 416 pts (primary MF, 66%) who were ≥75 y
and started treatment ≥1 y before data cutoff (01 Jan 2016). Baseline charac-
teristics (median) were age, 78 y (range, 75-89 y); male, 57%; spleen length,
10 cm (0-35 cm); blast count ≥1%, 30.3%; hemoglobin, 101 g/L (<100 g/L,
46.9%); PLT count, 249×109/L (<100×109/L, 6.3%); ECOG PS <2, 84.9%. At
data cutoff, more than half of pts remained on treatment or completed treatment
per protocol (52.6%). As expected, a greater proportion of elderly pts discon-
tinued RUX due to adverse events (AEs; 23.6%) or death (8.7%) than pts in
the overall study (17.7% and 4.1%, respectively). Overall, 72.4% of pts had
dose modifications (AEs, 58.4%), and 33.9% had an interruption (AEs, 31.5%).
Safety of RUX in elderly pts was consistent with that in the overall population.
Median exposure was 11 mo; mean average daily dose was 26.8mg (SD, 10.6).
The most common hematologic grade 3/4 AEs were anemia (43.8%; overall,
34.1%) and thrombocytopenia (22.1%; overall, 16.3%). AEs (all grade [grade
3/4]) in >10% of pts included asthenia (18.3% [2.6%]), pyrexia (18.0% [2.6%]),
dyspnea (14.4% [4.3%]), diarrhea (13.5% [1.9%]), fatigue (11.8% [2.4%]),
peripheral edema (10.8% [0.2%]), and pneumonia (10.1% [7.2%]). Infections
in >5% of pts included pneumonia (10.1%), urinary tract infection (7.0%), and
bronchitis (5.1%). Herpes zoster occurred in 3.9% of pts. At wk 24, 56.4%
(124/220) of pts had a ≥50% reduction from baseline in spleen length (overall,
56.6%), and 19.1% (42/220) had 25%-50% reductions (overall, 23.3%); rates
were similar at wk 48 (54.6% [65/119] and 19.3% [23/119]; overall, 61.6% and
18.9%). Most pts (64.2%) achieved a ≥50% reduction at any time (Figure 1),
similar to the overall population (70.2%). Pts also experienced significant
improvements in symptoms. From wk 4 to 48, 42%-48% and 50%-57% of pts
achieved a clinically meaningful response on the FACT-Lym TS and FACIT-
Fatigue, respectively.
Figure 1.
Summary/Conclusions: This analysis included the largest cohort of elderly
pts with MF treated with RUX to date. Consistent with the study by Latagliata
et al, RUX was safe and effective in pts ≥75 y, with pts achieving reductions in
splenomegaly and symptoms similar to those in the overall population, with
comparable rates of AEs. Additionally, findings from our study were consistent
with those of the COMFORT studies, which included few pts ≥75 y. Overall,
our study provides further evidence that RUX is safe and effective in elderly
pts with MF.
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Background: Accurate disease risk stratification is crucial for transplant deci-
sion-making in myelofibrosis (MF). Although several prognostic models are
available, it is unknown if they are equivalent in the way they distribute patients
into risk groups and in their discriminatory power to predict survival.
Aims: We have compared the performance of the International Prognostic
Scoring System (IPSS), dynamic IPSS (DIPSS), DIPSS-plus, and Rumi’s score
in a series of 544 MF patients aged 70 years or younger at time of diagnosis.
Methods: The Spanish Registry of Myelofibrosis is a nationwide, longitudinal
registry contributed by centers associated to the Grupo Español de Enfer-
medades Mieloproliferativas Filadelfia negativas (GEMFIN). From January 2000
to January 2016, a total of 544 adult patients aged ≤ 70 years with primary MF
(n=335) or secondary MF (n=209) had been included in the registry. Cases of
the prefibrotic form of MF were not considered. Comparison of the relative power
of each prognostic model to discriminate levels of risk was estimated by means
of the Harrell’s concordance index (C-index) and the R2explained variation. All
the statistical analyses were performed with IBM SPSS 22.0 and Stata 11.
Results: At the study closing date, median follow-up from diagnosis of MF was
3.35 years, 177 patients (33%) had died, and the remaining were censored
alive. Sixty-nine patients (13%) had been submitted to allogeneic stem cell
transplantation, after a median time of 20 months from MF diagnosis. The
median projected survival of the overall series was 9.46 years (95% confidence
interval: 7.44-10.59). Median survival was not reached for the low risk category
of all classifications (and Rumi’s very low risk category). The projected survival
for patients in the intermediate-1 group (intermediate in the Rumi’s score) and
in the high risk group (very high risk in the Rumi’s score) was comparable in
the four models. By contrast, the Rumi’s high risk group had a projected median
survival of 9.2 years, whereas that of the intermediate-2 categories by the
IPSS, DIPSS, and DIPSS-plus models was 6.6 years, 5.6 years, and 6.5 years,
respectively. The number of patients in the intermediate-2 and high risk cate-
gories was smaller in the DIPSS than in the IPSS or the DIPSS-plus. Overall,
the Rumi’s score yielded the highest power to discriminate between risk cate-
gories as measured by the concordance index and the R2 explained variation.
However, the IPSS and DIPSS-plus were the best models to discriminate
between the intermediate-1 and intermediate-2 risk categories, which is the
critical cut-off point for patient selection to transplant.
Summary/Conclusions: In our contemporary series of MF patients only the
highest risk categories of the current prognostication systems have a median
survival below the 5-year threshold recommended for considering transplan-
tation. Patient selection for transplant is quite dependent on which prognosti-
cation model is used for disease risk stratification.
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Background: A common therapy for essential thrombocythemia (ET), hydrox-
ycarbamide (HC), has mutagenic properties and there is potential for leuke-
mogenicity and secondary cancers with this agent. In the EXELS study, we
reported higher event rates for acute myeloid leukemia (AML) and other malig-
nancies in HC-treated patients compared with those treated with anagrelide
(ANA). However, there were large age differences between groups. Here, we
account for age difference by estimating standard incidence ratios (SIRs) using
country-specific cancer registration data.
Aims: To assess the risk of AML and non-hematological malignancies in
patients treated with HC or ANA in the EXELS study.
Methods: Previous exposure to ANA and HC was based on patient history.
SIRs were calculated using background rates retrieved from Cancer Incidence
in Five Continents (CI5). Risk of AML after study enrolment was estimated by
cumulative incidence. Minimum exposure time of 180 days was used to account
for disease progression as a confounding factor. Informed consent was
obtained before the start of the study.
Results: Overall, 3460 patients were exposed to HC, ANA or both at registra-
tion; 481 patients had ANA treatment, 2305 had HC treatment and 674 had
been exposed to both drugs. The median age in ANA patients was 51 years,
and 71 years in HC patients. One hundred and seventy four cases of non-
hematologic cancer, including 35 cases of skin cancer, were recorded. SIRs
for all malignancies were close to 1 for all treatment groups, indicating similar
risks to the background population. For all skin cancers, including melanoma,
the SIR for patients with HC treatment was higher than expected for the normal
population and patients on ANA (1.15 vs 0.45). When melanoma was excluded,
the figures changed only marginally. However, due to the low number of events,
the CIs were wide, and no statistically significant difference was found between
treatments. Sixty seven AML cases were reported; 39 AML cases were found
in the HC group (person-years 8970, SIR 39.7), with another 20 AML cases in
the group who switched from HC to ANA (person-years 2934, SIR 91.5). The
risk ratio for AML developing in patients who switched from HC more than dou-
bled (RR 2.30-2.52), irrespective of minimum exposure time. In contrast, no
AML case was observed in the ANA-only group (person-years 1905, SIR 0)
and there were only 3 AML cases in the group who switched from ANA to HC
(person-years 802, SIR 68.5). Since the number of AML cases in the ANA
group was 0, no statistical comparison could be made. Five AML cases were
excluded from analysis since there was uncertainty about which drug was used
first.
Table 1.
Summary/Conclusions: ET patients have a substantially increased risk for
AML development; the SIR for AML was 40-fold higher than expected with HC
exposure. In patients who switched from HC to ANA the SIR was approximately
90-fold higher, with 20 AML cases observed versus the expected 0.22 cases.
The number of AML cases was much lower (n=3) in patients who switched
from ANA to HC. It has been proposed that exposure of ET patients failing HC
therapy to a second potentially leukemogenic agent should be avoided; yet
these data suggest that even after switching to a non-leukemogenic agent,
HC-treated patients still have an over 90-fold increased risk of AML. Our data
reinforces concerns of a leukemogenic effect of HC, with a markedly higher
risk in patients failing HC and switching to another drug, even if that drug is
ANA. The caution advocated in the use of HC seems well advised.
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Background: Infectious complications represent one of most frequent cause
of morbidity and mortality in Myelofibrosis (MF), the most severe of myelopro-
liferative neoplasms. Ruxolitinib (RUX), the first approved JAK1/2 inhibitor, sig-
nificantly ameliorates disease-related splenomegaly and constitutional symp-
toms. Prospective controlled studies observed a high rate of infectious compli-
cations including opportunistic and unusual infections, probably due to its
immune-suppressant activity. However, risk factors for infections in MF patients
(pts) treated with RUX are still to be investigated.
Aims: To evaluate characteristics, incidence and risk factors for infections in
RUX-exposed MF pts.
Methods: Clinical and laboratory data of MF pts treated with RUX were retro-
spectively collected from the database of 21 Italian Hematology Centers. Infec-
tions were defined according to the CTCAE.
Figure 1.
Results: Overall, 373 pts received RUX between June 2011 and June 2016.
At RUX start the clinical features were (median): age 68 years (27-89), ≥65y,
62%; male, 57%; Hb, 10.8g/dL (7-16.7); Hb <10g/dL, 40%; PLT, 246×109/L
(33-1887); PLT <100×109/L, 10%; spleen enlargement, 97%; spleen length
≥10cm, 66%; constitutional symptoms, 52%. International Prognostic Score
System (IPSS) was intermediate-1 (15%), intermediate-2 (46%), high (39%).
JAK2V617F mutation was detected in 255 out of 313 evaluated pts (81%). Kary-
otype was unfavorable in 15 out of 203 evaluable pts (7%). Previous infectious
complications were recorded in 31 pts (8%). After a median RUX exposure of
20 months (range, 1-56), 101 pts (27%) experienced 129 infectious events
(³grade 3, 33%), for an incidence rate of 14.9 cases for 100 pts/year. The rate
of infections tended to decrease over time: 54% occurred within 6 months of
therapy, 15% between 6 and 12 months, 9% between 12 and 18 months
(p<0.0001). Respiratory tract infections were more frequently observed (73
events, 57%). Cutaneous, urinary tract and gastrointestinal infectious events
were diagnosed in 15%, 10% and 7% of cases, respectively. In 14 cases fever
of unknown origin was recorded (Figure 1). Etiological agents were isolated in
14 cases (11%): bacteria in 9 cases (gram+ 56%, gram- 22%, C. difficile diar-
rhea 22%) and fungi in 2 cases (pulmonary aspergillosis and oesophageal can-
didiasis); Mycobacterium tuberculosis was isolated in 3 cases. Herpes-virus
reactivations occurred in 12 cases (9%). No patients reactivated hepatitis B
virus. At last follow-up, 88 pts (24%) have died, in 10 cases (11%) due to infec-
tious complication. Among baseline features, age≥65 years at RUX start
(p<0.0001), previous infection (p=0.001), primary vs secondary MF (p=0.021)
and high IPSS (p=0.029) significantly correlated with higher infectious risk.
Notably, no differences were observed according presence of large (≥10cm)
splenomegaly, higher (>20) total symptoms score, presence of cytopenias,
Charlson comorbidity index (>2) and body mass index (<21 and >30). In mul-
tivariate analysis, PMF diagnosis (HR 1.6 CI95% 1.07-2.5), age≥65 years (HR
2.1 CI95% 1.3-3.3) and previous infection (HR 3 CI95% 1.7-5.4%) confirmed
their negative prognostic association. Interestingly, RUX dosage, spleen
response and hematological toxicities during treatment were not associated
with infectious risk.
Summary/Conclusions: Infections occurred in around one-third of RUX-treat-
ed pts; the rate of infections tended to decrease over time, and were fatal in
11% of the cases. Advanced age, a previous infectious event and diagnosis of
PMF seem to be the main contributors to infectious risk.
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Background: Patient (pts) with myeloproliferative neoplasms (MPNs), including
myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia
(ET), experience a substantial disease burden. Pts are managed with watchful
waiting or therapy, including aspirin, hydroxyurea (HU), and other drugs. The
international MPN LANDMARK survey evaluated the patient-reported impact
of MPNs in pts in 6 countries and identified current management strategies in
these pts.
Aims: To analyze treatment strategies used by physicians and pts to manage MPNs.
Methods: This cross-sectional, internet-based survey was conducted in Australia,
Canada, Germany, Italy, Japan, and the UK and was administered to pts with
MPNs and to physicians treating pts with MPNs. Pts and physicians were recruited
independently. We describe disease-management strategies in these pts.
Figure 1.
Results: Overall, 699 pts (MF, n=223; PV, n=174; ET, n=302) and 219 physi-
cians completed the survey. In line with treatment guidelines, main therapies
used by pts were ruxolitinib (54%), aspirin (40%), and HU (28%) in MF; phle-
botomy (PLB; 70%), aspirin (66%) and HU (42%) in PV; and aspirin (73%), HU
(48%), and anagrelide (15%) in ET (Figure 1.). Most physicians reported pre-
scribing the following: ruxolitinib (76%), transfusion (54%), and HU (53%) in
MF; aspirin (79%), HU (77%) and PLB (67%) in PV; and aspirin (80%), HU
(67%), and anagrelide (52%) in ET. Many physicians (51% MF, 47% PV, 49%
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ET) chose watchful waiting to manage >25% of their pts at diagnosis; 22% of
untreated pts had moderate to high (quartiles 3-4) overall symptom burden.
Physicians primarily recommended treatment for pts experiencing severe
symptoms (72% MF, 68% PV, 72% ET) or symptomatic splenomegaly (71%
MF, 61% PV, 39% ET). PLB was mainly used to treat pts with PV. Of those
who received PLB (n=155), 71% were very or somewhat satisfied; 25% were
very or somewhat dissatisfied and felt that PLBs had a negative impact on
their QOL. Similarly, 37% of physicians felt that PLB had a negative impact on
pt QOL; PLB alone was insufficient for disease control in 38% of pts. Pts
stopped PLB because physician deemed it no longer necessary (62%), pts felt
worse after treatment (10%), and visit frequency was inconvenient (8%). Physi-
cian-reported reasons for stopping PLB were that visit frequency was incon-
venient (38%), pts felt worse after treatment (35%), and lack of intravenous
access (33%). HU use was assessed in pts with PV or ET. Of those who
received HU (PV, n=95; ET, n=145), 78% and 74%, respectively, continued to
receive HU; 19% and 22% were dissatisfied with HU therapy. Main reasons for
stopping HU were lack of efficacy (29% PV, 13% ET) and toxicity (19% PV,
27% ET). Overall, 78% of physicians reported that up to 25% of their pts
showed inadequate efficacy or intolerance of HU. Main measures of treatment
success among pts were physician feedback (73% MF, 75% PV, 75% ET) and
blood counts (72% MF, 67% PV, 74% ET). Lack of efficacy, side effects, and
disease progression were key reasons for changing therapies.
Summary/Conclusions: Many pts with MPNs are managed with watchful wait-
ing at diagnosis. Although most of these pts have a low symptom burden, 22%
have a moderate to high burden, highlighting the need for proactive and stan-
dardized symptom assessments at diagnosis and over the course of treatment.
Interestingly, a proportion of physicians and pts felt that phlebotomy had a high
negative impact on pt QOL. Overall, pts consider physician feedback and blood
counts to be important indicators of treatment success.
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Background: Ropeginterferon alfa-2b is a novel long-acting monopegylated
interferon alpha (IFNa) with Orphan designation in Europe and the U.S.
Reduced dosing frequencies and favorable tolerability accompanied by robust
clinical responses in patients with polycythemia vera (PV) have been reported
over the first few years of treatment. Successful long-term, potentially life-long
maintenance with high rates of adherence, compliance and treatment outcome
remain important goals to be elucidated.
Aims: PEGINVERA phase I/II (NCT: 2010-018768-18), is a prospective, open-
label, multicenter study investigating efficacy and safety of ropeginterferon alfa-
2b in long-term treatment of patients with confirmed diagnosis of PV, pre-treated
or naïve to cytoreductive therapy.
Methods: All patients responding well to the initial bi-weekly administration
schedule and participating in the study for longer than one year, had the option
to switch to a “once every 4 weeks”-schedule. The 2-week regimen (defined
as the time period when all criteria for switching were fulfilled but the patient
continued the 2-week regimen) was compared to the 4-week regimen (for a
duration of 6 months after switch). The present analysis was focused on main-
tenance of efficacy.
Results: Data from the last available analysis include 29 patients remaining
on study with a median treatment duration of 213 weeks. All 29 patients have
completed at least 2 years of treatment (5 patients are in the 3rd year, 7 in the
4th year, 10 in the 5th year and 7 in the 6th year of treatment). Baseline char-
acteristics of the study cohort during short-term treatment and two year safety
and efficacy follow-up data were already presented earlier (Gisslinger et al.
2015). All of the 29 patients were switched to dosing once every 4 weeks.
Median treatment duration at time of switch was 104 weeks (Q1-Q3: 69-124
weeks). All 29 patients remained on the 4-week schedule with a median obser-
vation duration of further approx. 2 years for this analysis, reflecting the excel-
lent safety and tolerability profile of ropeginterferon alfa-2b in this setting. The
percentage of patients maintaining their best haematological response accord-
ing to ELN before (i.e. after median 104 weeks of treatment) and 6 months
after switching to the 4-week regimen was consistent at 51.7%. Further, need
for phlebotomy during the 6 months after switching did not increase (consistent
7/29 patients). Changes in haematological parameters and spleen size were
minimal and without clinical relevance. Similarly, the percentages of patients
maintaining their best molecular response were 62.1% and 58.6%, respectively
(non-significant). Importantly, the majority of patients on ropeginterferon alfa-
2b long-term treatment, developed a sustained reduction of mutant JAK2 allele
burden to below 10%, a feature that can only be achieved by IFNa based ther-
apies.
Summary/Conclusions: In summary, all patients remaining on ropeginterferon
alfa-2b after a median of 2 years of initial treatment were successfully switched
to a more convenient monthly long-term maintenance schedule, thereafter no
patients discontinued, and all patients could be maintained on this schedule
for currently another 2 years (trial still ongoing). These data underscore the
expected long-term efficacy with regard to haematological, clinical and molec-
ular parameters and the excellent safety/tolerability of ropeginterferon alfa-2b.
Long-term maintenance treatment of PV patients using ropeginterferon-alfa
2b monthly is feasible, efficacious and well tolerable. Continuous patient-indi-
vidual adaption of dosing regimen, including dose and dosing schedule, is rec-
ommended.
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Background: The outcome of patients with Philadelphia negative myelopro-
liferative neoplasms (MPN) who transform to acute leukemia is abysmal. There
have been no advances in targeted therapy for this cohort of patients or indi-
vidualized treatment based on genomic information. Furthermore, no large
studies have investigated the impact of molecular profiling on clinical outcome
in patients with accelerated or blast phase of MPN.
Aims: To describe the clinical outcomes of patients with MPN who transform
to accelerated or blast phase and evaluate the impact of genomic alterations
on outcomes.
Methods: Eligibility criteria included: Prior diagnosis of Philadelphia negative
MPN according to WHO 2008 criteria; evidence of transformation to accelerated
(10-19% blasts in peripheral blood or bone marrow) or blast phase (≥20%
blasts) and seen at Princess Margaret Cancer Center between January 1998
and February 2017. The primary endpoint was overall survival (OS): defined
as the time from transformation to death or last follow-up. Secondary endpoints
included survival based on curative versus non-curative approach and treat-
ment over time. In addition the impact of mutations will be correlated with
clinical outcomes and survival.
Figure 1.
Results: One hundred and eighty-seven patients who transformed to acceler-
ated or blast phase with a prior diagnosis of MPN were identified at our insti-
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tution. Twenty-nine patients were excluded: 17 for myelodysplastic/myelopro-
liferative overlap (MDS/MPN), six for insufficient information, five for not meeting
criteria for accelerated or blast phase and one patient for a diagnosis of systemic
mastocytosis. Of the 158 patients included in the study, the median age at the
time of MPN diagnosis and leukemic transformation was 59 and 67 years
respectively. Prior MPN diagnosis was: polycythemia vera (PV; n=25, 16%),
essential thrombocythemia (ET; n=21, 13%), primary myelofibrosis (n=50, 32%),
post ET myelofibrosis (PET MF; n=27, 17%), post PV myelofibrosis (PPV MF;
n=24, 15%) and MPN-unclassifiable (n=11, 7%). One hundred and forty-two
(90%) patients met the criteria for acute myeloid leukemia, thirteen (8%) had
accelerated phase and 3 (2%) patients were diagnosed with myeloid sarcoma.
Sixty-four (41%) patients were treated with curative intent including 27 (42%)
patients who proceeded to hematopoietic cell transplantation, while 94 (59%)
received non curative approach including low dose chemotherapy, hypomethy-
lating agent, clinical trial or best supportive care. The median OS for the entire
cohort was 6.5 months (95% CI: 5.06-8.01). In patients treated with curative
intent median OS was 8.8 versus 3.2 months (p=0.003) for patients with non-
curative intent. There was no difference in OS between historical controls treat-
ed between 1998 and 2011 when compared to a more recent cohort of patients
(6.5 vs 7.3, p=0.34; see Figure 1). In 105 (67%) patients, NGS molecular pro-
filing of 54 genes (39 hotspot region; 15 complete coding region coverage) was
performed on peripheral blood or bone marrow samples using the TruSight
Myeloid Sequencing Panel. Mutational data will be correlated with clinical out-
comes and will be presented at the EHA annual conference (profiling completed,
analysis ongoing).
Summary/Conclusions: Despite advances in systemic therapies and support-
ive care, there has been no significant improvement in survival for MPN patients
who transform to accelerated or blast phase, confirming that current treatment
approaches are ineffective. Results of molecular profiling may provide valuable
insights and clues as to how to develop an individualized treatment approach
for this cohort of patients.
Other Non-malignant hematopoietic disorders
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SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM
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Background: Masitinib, a selective oral tyrosine kinase inhibitor targeting wild-
type KIT, LYN and FYN, was the first drug to demonstrate efficacy in a phase
3 setting (study AB06006) for treatment of patients with severe indolent systemic
mastocytosis (ISM) who are unresponsive to existing, optimal symptomatic
treatments. In The Lancet (Feb 11;389(10069):612-620), Lortholary and col-
leagues reported a significant and clinically meaningful treatment benefit for
masitinib (6mg/kg/day over 24-weeks) versus placebo, with primary analysis
based on cumulative response (≥75% improvement from baseline, timeframe
weeks 8-24, comprising 5 visits at 4-week intervals) in at least one of four
severe baseline symptoms (pruritus, flushes, depression, or fatigue) using
repeated measures methodology for rare diseases (i.e. a longitudinal analysis
with respect to symptoms as opposed to patient response rate at a single point
in time). Eligible patients were aged 18–75 years and had ISM according to
inclusion criteria that were slightly broader than the WHO classification.
Aims: To aide interpretation of this study’s prospectively declared primary endpoint
via comparison with additional efficacy analyses based on a cohort restricted to the
WHO classification of ISM and more conventional patient-centric response endpoints.
Methods: Randomized, placebo-controlled, phase 3 study that included 135 severe-
ly symptomatic ISM patients, including the subvariant smoldering systemic masto-
cytosis (71 masitinib, 64 placebo), 80% of whom satisfied the WHO classification.
Results: Masitinib showed a significant improvement over placebo according to
its pre-specified primary endpoint (mITT population), with a cumulative response
of 18.7% versus 7.4%, respectively, odds ratio (OR) of 3.6 [95%CI 1.2-10.8],
P=0.008 (with re-randomization). This outcome was confirmed in the WHO patient
subgroup: 17.8% versus 8.0%, respectively, OR=3.25 [0.97-10.88], P=0.0317.
Computing the primary analysis (mITT) according to cumulative response per
patient (GEE model) was also positive: 26.7% versus 12.8%, respectively, OR=2.48
[1.16-5.31], P=0.0212; as was analysis according to individual patient response
(Pearson chi-square): 40.3% versus 24.2%, respectively, P=0.0062. Response
(per patient) on all severe baseline symptoms for at least one visit was: 16.4% ver-
sus 1.6%, respectively, P=0.0062. Finally, analysis of sustained response in all
severe baseline symptoms over multiple visits was highly discriminatory between
treatment-arms: for patients with 3 severe baseline symptoms masitinib generated
a 12.5% response rate (≥75% improvement in each symptom) for 3 out of 5 visits,
versus no response for placebo; and for patients with 2 severe baseline symptoms
masitinib generated a response rate of 21.1%, 15.8% and 10.5% over at least 1,
2, and 3 visits, respectively, versus no response for placebo.
Summary/Conclusions: These post-hoc analyses confirm the clinical rele-
vance, durability, and generalizability of the positive primary endpoint from
study AB06006. Findings therefore support the conclusion that masitinib gen-
erates a significant therapeutic benefit in patients with severely symptomatic
ISM who were unresponsive to optimal symptomatic treatments.
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Background: Hemophagocytic lymphohistiocytosis (HLH) is a devastating dis-
order of uncontrolled immune activation characterized by clinicopathological
evidence of extreme inflammation. Hematological malignancy-associated HLH
(hM-HLH) has the worst outcome in comparison with any other form of HLH.
hM-HLH can occur as the first manifestation of an occult malignancy, before
start or during the treatment of known malignancy, or as the sign of a malig-
nancy relapse or transformation to the more aggressive disease form.
Aims: The aim of the present study was to analyze the response to HLH ther-
apy and overall survival of adult patients with hM-HLH.
Methods: From 2008 and onwards, data on adult patients referred to the
Hematology Center Karolinska with suspected HLH were prospectively col-
lected. Review concerned records of 142 adults with suspected HLH, hospital-
ized between Jan 2009 and Dec 2016. Of those, 71 patients with hematological
malignancy were diagnosed with HLH and included to the present study. Hema-
tological malignancy was defined as a neoplasm of lymphoid or myeloid origin.
In all studied patients, the diagnosis of HLH was based on the HLH-2004 cri-
teria. Infection as a possible additional trigger of HLH was carefully studied in
all our hM-HLH patients. EBV and CMV DNA were routinely examined in whole
blood, using RT quantitative PCR; other viruses (e.g. adenovirus, HSV, VZV,
HHV6, influenza) were studied based on indications. Blood and urine cultures
were performed in order to reveal any bacterial or fungal infections. Tests for
fungal antigens, tuberculosis, and parasites were also performed if indicated.
HLH treatment categories have included proapoptotic chemotherapy (etopo-
side) and immunosuppressive drugs, targeting hyperactivated macrophages
(etoposide, corticosteroids, IVIG) and T cells (corticosteroids, cyclosporine A).
Figure 1.
Results: Seventy-one adults, aged 22–84 years, were diagnosed with aggres-
sive hM-HLH during the 8-year period. Lymphoid malignancy was diagnosed
in 42 patients and myeloid malignancy in 29 patients. Fifty-four (76%) patients
developed HLH as a first manifestation of an unknown malignancy, during pro-
gressive disease, or malignancy relapse. The remaining 24% patients devel-
oped HLH during chemotherapy. In 14 patients, HLH therapy started before
confirmation of HLH diagnosis, based on suspicion of HLH (mean 6.7±8.4
days; median 2 days; range 1-31 days). Seventeen patients started HLH ther-
apy at the day of HLH diagnosis. In 36 patients HLH therapy started after con-
firmation of HLH diagnosis (mean 15.9±41.3 days; median 5 days; range 1–
242 days). Forty of 71 (56%) patients with active HLH died, of which 20 had
signs of progressive malignancy, 16 patients had generalized infection (bacte-
rial - 12 patients, viral - 3 patients, fungal - 4 patients; some patients had more
than one type of infection), and 2 patients experienced central nervous system
bleeding. Thirty-one (44%) patients responded to HLH therapy and achieved
remission of HLH. However, only 13 of 71 (18%) patients with hM-HLH were
still alive after a median follow-up time of 50 months, despite the attempted
treatment in 67 (94%) cases. The probability of overall survival (OS) from 6,
12, 24 and 60 months after HLH diagnosis were 39, 20, 15 and 15%, respec-
tively. The patients who developed hM-HLH with concomitant infection during
chemotherapy had significantly longer OS (p=0.03) compared to patients who
had HLH solely attributed to malignancy (Figure 1).
Summary/Conclusions: HLH in the context of malignancy is still considered
a challenge of adult hematology. hM-HLH is a highly lethal disorder in adults.
The patients who develop hM-HLH with concomitant infection during
chemotherapy show better survival than those who had HLH solely attributed
to malignancy. Although poor outcome in some patients with M-HLH is related
to malignancy progression, in some patients the lack of effective M-HLH therapy
may further impede adequate treatment of malignancy.
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Background: Next generation sequencing is rapidly becoming the main diag-
nostic tool for precise identification of gene defects in human diseases. Apart
from the identification of novel causal genes and pathogenic variants, the main
research goal for now is to assess the impact and strategy of whole exome
sequencing (WES) use in routine clinical evaluation.
Aims: We aimed to evaluate the benefits and drawbacks of using WES as a
diagnostic method in patients with chronic early-onset autoimmune hemolytic
anaemia (AIHA), idiopathic thrombocytopenic purpura (ITP) and immune neu-
tropenia, or their combination (Evans syndrome). Most of these patients pre-
sented with additional symptoms of immune dysregulation, e.g. common vari-
able immunodeficiency (CVID), lymphoproliferation, autoimmune disorders
(diabetes mellitus 1, thyreoiditis).
Methods: 30 patients (age 0-39) were evaluated after an examination by a
clinical geneticist and signing an informed consent. Sequencing libraries were
prepared from peripheral blood DNA using Agilent SureSelectXT Human All
Exon V5/6+UTR kit and sequenced with the Illumina NextSeq 500 system with
a mean coverage of at least 30x.
Results: In 10 patients (33%) we were able to find likely causative mutations.
In 3 patients (siblings) we identified a novel variant leading to CTLA4 deficiency,
another novel variant in CTLA4 was identified together with an additional path-
ogenic variant in TSC1, causing a mixed phenotype. The genetic diagnosis of
CTLA4 deficiency allowed for the use of CTLA4 agonist (Abatacept) treatment
in 1 patient that led to improvement of his symptoms and disease stabilisation.
However, after 6 months, the patient had developed agranulocytosis that led to
hematopoietic stem cell transplantation. In 1 patient we were able to identify a
gain-of-function variant in STAT3 that was recently described in immune dys-
regulation. In 3 patients we observed variants in genes typically described in
connection with antibody deficiency (TACI, CD40L, and IKBKG). In 1 patient
with chronic AIHA and ITP we found a novel heterozygous variant in TERT gene
related to dyskeratosis congenita. In 1 patient with multiple congenital abnor-
malities and Evans syndrome we discovered a heterozygous variant in KMT2D
gene causing Kabuki syndrome. The remainder of our patients harboured vari-
ants that posed a diagnostic challenge. In 4 of these cases we identified variants
in genes involved in the pathogenesis of immune dysregulation, which are
observed at lower frequencies also in healthy people (CASP10, PIK3CD). 12
patients (36%) had either only one hit in the genes reported causal in autosomal
recessive diseases (e. g. ITK, LRBA) or we have not yet found any relevant
aberration. In 4 patients we were able to identify novel variants in genes related
to immune dysregulation. However, these variants require extensive validation
studies, using patients’ primary cells or manipulating established in-vitro or ani-
mal models with gene editing techniques, in order to prove the causality.
Summary/Conclusions: WES is a highly useful method that helps to identify
the genetic cause of the disease in approximately one third of patients and enables
targeted therapy. While targeted sequencing can further reduce costs and make
analysis more straightforward, gene panels are quickly becoming obsolete as
new causal variants are discovered in the rapidly evolving field of primary immun-
odeficiencies. Because of the heterogeneity of genetic causes of immune cytope-
nias, we recommend to use WES over targeted gene panel sequencing.
Support: NV15-30626A, 16-32568A, P302/12/G101.
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Background: : Erythrocytoses are characterized by an elevated red cell mass.
The most widely studied disease is Polycythemia Vera (PV), however, other
types of erythrocytoses can be either inherited (Congenital Erythrocytosis-CE)
or diagnosed in adult patients with no family history (Idiopathic Erythrocytosis-
IE). CE/IE are not associated with myeloproliferation but they can be associated
with severe thrombo-embolic or haemorrhagic events, pulmonary arterial hyper-
tension and, rarely, tumours (hemangioblastoma, pheochromocytoma). The 8
genes identified so far as causing CE are involved (i) in the regulation of the
hypoxia pathway, PHD2 (also called EGLN1), HIF-2A (EPAS1), VHL, (ii) in pro-
liferation and differentiation of erythroid progenitors (EPOR), or (iii) in mature
cell function, haemoglobins (HBB, HBA1, HBA2) or bisphosphoglyceratemutase
(BPGM). However, in 80% of cases the cause remains unknown meaning that
no proper diagnosis can be made, no prognosis or advice can be provided to
CE/IE patients and their families, and no curative treatment exists
Aims: to (i) identify, (ii) collect and (iii) analyze the genomic abnormalities in
patients suspected of CE
Methods: We created and developed a national network in France to analyze
the genomic abnormalities in patients suspected of CE. The selection of patients
was performed in order to exclude patients with Polycythemia Vera or obvious
secondary erythrocytosis related to lung, cardiac or renal disorder. Next gen-
eration sequencing (NGS) has been used to analyse the presence of mutations
in 28 genes (enlarged hypoxia pathway and other candidate genes).
Results: To date, samples from 140 patients have been recorded, among
whom 46 have been tested using NGS approach. Variants in 14 (30%) patients
[13 males and 1 female; median age 50 y. (12-71)] with unknown significance
have been detected, including 4 in PHD genes, 5 in HIF genes, 4 in LNK genes
(SH2B3) and 1 in JAK2 gene. In patients with variants, a familial history of ery-
throcytosis was noted in 3. No independent thrombotic complication was report-
ed in the 15 patients. In 2 patients (one with a PHD2 and one with a JAK2 vari-
ants), the erythropoietin was low, whereas for the others, the erythropoietin
was normal. Of note, the median age of the patients was surprisingly high, sug-
gesting that the diagnostic was not previously performed due to the absence
of available tests. Functional studies were performed on PHD2 variants: a sig-
nificant decrease in the hydroxylase activity was noted for one variant, but not
for the others. On the other hand, a decrease in the stability along time of the
PHD2 protein was observed for two variants, underscoring the different mech-
anisms involved in the impairment of the PHD2 activity
Summary/Conclusions: NGS is a useful tool to explore mutations in CE, but
identifies genetic variants in only 30% of patients with such disorder. Further
exams including whole exome sequencing are planned to achieve a right diag-
nosis in the 70% remaining CE patients. In vitro, in cellulo and in vivo (including
zebrafish model) functional studies are currently performed to validate the clin-
ical relevance of the variants identified in the hypoxia pathway. They are com-
pared to variants identified in the development of tumors in order to dissect the
molecular mechanisms of this finely tuned pathway
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Background: Recent studies show that most systemic mastocytosis (SM)
patients, including indolent SM (ISM) with (ISMs+) and without skin lesions
(ISMs-), carry the KIT D816V mutation in PB leukocytes.
Aims: To investigate the potenctial association between the degree of involve-
ment of BM hematopoiesis by the KIT D816V mutation and the distribution of
different maturation-associated compartments of bone marrow (BM) and periph-
eral blood (PB) CD34+ hematopoietic precursors (HPC) in ISM, and identify
the specific PB cell compartments that carry this mutation.
Methods: The distribution of different maturation-associated of BM and PB
CD34+ HPC from 64 newly-diagnosed (KIT-mutated) ISM patients and 14
healthy controls was analyzed by flow cytometry. In 18 patients distinct FACS-
purified PB cell compartments were also investigated for the KIT mutation.
Results: ISM patients showed higher percentages of both BM and PB MC-
committed CD34+ HPC vs controls, particularly among ISM cases with MC-
restricted KIT mutation (ISMMC); this was associated with progressive blockade
of maturation of CD34+ HPC to neutrophil lineage from ISMMC to multilineage
KIT-mutated cases (ISMML). Regarding the frequency of KIT-mutated cases
and cell populations in PB, variable patterns were observed, the percentage of
KIT-mutated PB CD34+ HPC, eosinophils, neutrophils, monocytes and T-cells
increasing from ISMs-MC and ISMs+MC to ISMML patients.
Summary/Conclusions: Positivity for the KIT D816V mutation in PB of ISM is
usually associated with (early) involvement of circulating CD34+ HPC and mul-
tiple myeloid cell populations, KIT-mutated PB CD34+ HPC potencially con-
tributing to disease dissemination already at very early stages.
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Background: Hemophagocytic Lymphohistiocytosis (HLH) is a life-threatening
disease of children and adults caused by an impaired cytotoxic function of NK
and CTL cells leading to a potentially fatal hyperinflammatory condition. Biallelic
mutations in genes involved in the cytotoxic pathway are responsible for the
familial form of the disease (FHL). Monoallelic mutations in the FHL-related
genes have been reported in association with HLH and other diseases but their
role remains to be understood.
Aims: To describe clinical, functional and genetic features of patients referred to
the Italian HLH Registry, harboring monoallelic mutations in FHL-related genes.
Methods: Patients with complete or partial HLH diagnostic criteria and monoal-
lelic mutations in at least one of the FHL-related genes were selected from the
Italian Registry. Clinical data were collected by specific forms. Perforin expres-
sion and NK-cell degranulation measured as CD107a expression were per-
formed by flow-cytometry. Molecular analysis was performed by Sanger or Next
Generation sequencing.
Results: Of the 600 patients reported to the Registry, 54 (9%) were found to
have monoallelic mutations in FHL-related genes. Their median age was 5 years
(quartiles: 1.7, 3, 13, 50 years). Twenty-nine of the 54 patients (54%) fulfilled at
least 5 of the 8 diagnostic criteria: fever (n=49/52; 94%), splenomegaly (n=37/50,
74%), cytopenia (n=43/50, 86%), hypertriglyceridemia (n=28/47, 60%), hypofib-
rinogenemia (n=1/46, 0.02%), hyperferritinemia (n=47/50, 94%; quartiles: 1.454,
7.937, 17.050, 140.000 ng/ml), hemophagocytosis (n=28/45, 62%), central nerv-
ous system involvement (n=12/41, 29%). Five patients died; of 8 who reactivated,
4 underwent bone marrow transplantation. An associated/underlying disease
was reported in 34/54 (62%): rheumatologic/autoimmune disorder, 22 (11 Juve-
nile Idiopathic Arthritis, 2 Kawasaki disease, Systemic lupus erythematosus,
Cogan Syndrome, colitis ulcerosa; 6 undefined); lymphoproliferative disease, 5
(2 acute lymphoblastic leukemia, 2 non-Hodgkin and 1 Hodgkin lymphoma),
infectious diseases, 6 (2 EBV, 1 CMV, 1 parechovirus, 1 osteomyelitis, 1
myocarditis) and 1 pigment deficiency disease. Functional tests were performed
in 32/54 (60%), showing impaired degranulation in 42% (n=13/31) and defective
perforin expression in 43% (n=16/37). The genetic study revealed 31 monoallelic
variants in PRF1 (n=10), UNC13D (n=9), STX11 (n=5), STXBP2 (n=12), LYST
(n=1) and Rab27A (n=1). Four variants were reported as polymorphism. Of the
25 remaining, 23 were missense (9 predicted as benign and 14 as probably
damaging), 1 STOP and 1 frameshift both predicted as probably damaging. Two
patients had mutations in 2 different genes.
Summary/Conclusions: 9% of patients reported to the Italian HLH Registry
carries monoallelic variants in at least one FHL-related genes, including 37%
being probably damaging. Altogether these patients are characterized by later
onset, partial/milder disease, and partial functional defect. Thus, monoallelic
mutation in one FHL-related gene defines a predisposing factor for HLH.
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Background: Erythrocytosis, (i.e. increased levels of hemoglobin /hematrocit
(Hb/Htc) >95percentile for age and sex), is rarely found in pediatric or adoles-
cent age. Presence of familial cases, presentation at birth or presence of known
mutations, as well as exclusion of secondary causes identifies primary (PE) or
congenital secondary forms (CE). However, many cases still lack evident eti-
ological definition (Idiopatic E.). Moreover, natural course and treatment are
still anecdotally reported.
Aims: Here we present our experience in a large and heterogeous series of
children with absolute erythrocytosis. The aims is to identify a possible clinical
and diagnostic approach to children with erythrocytosis
Methods: All children with E. who lacked evidence of reactive origin were con-
secutively referred to our laboratory for molecular evaluation. Molecular analy-
sis of the main involved genes (VHL, HIF2A, EPOR, JAK2, PHD2) was per-
formed by allele specific PCR, PCR on direct DNA sequencing. Erythopoietic
Colony Essay (EEC) was performed on peripheral blood with and without
cytokines. Clinical features and treatment choices were reported by referring
clinicians (table 1).
Table 1.
Results: Patients were group according to the definitons of absolute Eryhtro-
cytosis. A total of 44 pediatric cases were identified (less than 18 years old).
There were 7 families, where 5 adults were also found polyglobulic. However,
in only 4 families a defect was identified (2 VHL, and 2 Hb variants). One HIF
positive case was found sporadic. Most Hb variants were not symptomatic,
while all other familiar cases had splenomegaly and vascular symptoms.Among
non familial, non genetic cases, 5 children were affected by Down Syndrome;
4 children had severe renal or cerebral disease. In one 4 year old girl, with a
polymorphic VHL variant, who presented with arterial hypertension, a small
size ganglioneuroma was found after a 5yrs follow-up. In 21 cases non causes
could be identified. They were mostly male (n18); presented at adolescent age
with advanced puberal status (n17); many were symptomatic (6). Only one 9
year old girl was diagnosed with Polycytemia vera (JAK2V617F positive). Treat-
ment varied according to physician decisions and presence of vascular symp-
toms, 6 children received ASA and 11 were phlebotomysed. In two older
patients severe vascular complications were observed (arterial thrombosis),
even with Htc<45%.
Summary/Conclusions: This series shows the heterogeneity of Eryhtrocytosis
as found in pediatrics. Extensive clinical and genetic analysis are required but
still a large number of cases lack clear definitions. The usefulness of antiag-
gregation and phlebotomy is not proved.
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HEMOLYTIC AUTOIMMUNE ANEMIA OF CHILDREN: DESCRIPTION,
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Background: Neurological involvement is poorly described in autoimmune
cytopenias (AIC), containing immune thrombocytopenia (ITP), autoimmune
hemolytic anemia (AIHA) and Evans syndrome (ES). This association suggests
an underlying primary immunodeficiency (PID).
Aims: To describe neurological involvement observed in autoimmune cytope-
nias, evolution under treatment and PID profiles in these patients.
Methods: OBS’CEREVANCE is a French nationwide prospective cohort includ-
ing children with an AIC since 2004. Patients with a neurological involvement
were analyzed excluding neurological symptoms related to a traumatism or
isolated febrile seizures. Clinical, radiological and biological data were collected
from primary centers. Centralized radiological review was performed. Genetic
analyses were performed by Sanger gene sequencing or gene-panel based
next generation sequencing.
Results: On October 2016, among the 1,167 patients of the cohort (371 AHAI,
615 ITP, 181 ES), a significant neurological involvement was observed in 8
patients from 7 centers. With a median (range) follow-up of 12 years (6-26.5),
7 children had ES (including autoimmune neutropenia in 5) and 1 child had
isolated AIHA. Median age at initial cytopenia was 11.5 years (1.6-15.8). At the
last follow-up point, AIC were in partial or complete remission for all patients.
Neurological symptoms appeared with a mean delay of 6 years (2.5-18) after
AIC onset. The symptomatology was: seizures (n=4), cranial nerve palsy (n=2),
Brown-Sequard syndrome (n=2) and / or sensory neuronopathy (n=1). No
infectious pathogens were identified. MRI showed multiple (n=6) or unique
(n=2) inflammatory lesions with hyperintense T2 signal in all patients, gadolin-
ium-enhancing lesions in 7 and perilesional edema in 5. Five patients had a
total of 8 biopsies, which confirmed the inflammatory process with macrophagic
(n=3) or lymphoplasmocytic (n=5) infiltrates. In 4 cases, a lymphocytic menin-
gitis was associated. Non-neurological organ involvement was present in all
patients, mainly pulmonary nodules (n=6) and lymphoproliferation (n=4). All
patients had an abnormal immunophenotype, with T-cell (n=7) or B-cell (n=3)
deficiency and hypogammaglobulinemia was present in 7 of the 8 cases.
Patients have been given steroids (n=6), intravenous immunoglobulins (n=2)
or immunosuppressive treatment (n=3, Ciclosporin, Mycophenolate Mofetil and
Methotrexate), improving symptomatology and MRI for all. Five patients
relapsed and 3 patients had an asymptomatic radiological progression. At the
last follow up point, all patients had neurological sequels and 7 persisting radi-
ological abnormalities. Four out of the 6 patients analyzed had a PID: 22q11.2
microdeletion (n=1), heterozygous CTLA mutation (n=2) or homozygous LRBA
mutation (n=1).
Summary/Conclusions: Neurological involvement is a rare and severe late
event in the course of childhood ES, or exceptionally AHAI, that may reveal var-
ious underlying PID. Complete imaging and pathology examination highlight a
causative immune dysregulation and could guide specific therapeutic strategies.
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Background: The most frequent Autoimmune Neutropenia (AIN) in childhood
is the primary type (p-AIN), whereas in adults AIN is mostly represented by
secondary neutropenias, which can be associated to infection, drug adminis-
tration, immunodeficiency, neoplasms, bone marrow transplantation or other
autoimmune disorders.
Aims: To describe clinic and laboratory findings in children affected by AIN
secondary to other autoimmune diseases (s-AIN).
Methods: This registry study analyzes 26 patients affected by s-AIN enrolled
in the Italian neutropenia registry of A.I.E.O.P. (Associazione Italiana di Onco-
Ematologia Pediatrica) over a 15-year time-span: this cohort, the largest ever
described, was compared to 263 patients affected by p-AIN enrolled in the
Registry in the same period.
Table 1.
Results: Specific characteristics of s-AIN patients are presented in Figure 1.
The prevalence of former preterm babies among p-AIN (and not s-AIN) patients
was significantly higher than in a cohort of 487 consecutively hospitalized chil-
dren (p=0.008362). The median age of onset of AIN was 0.77 year and 10.07
year in p-AIN and s-AIN respectively (p=1.105e-12). The prevalence of selected
IgA deficiency was 3% in p-AIN and 13.6% in s-AIN children: both prevalences
were significantly higher than that (0.21%) of a group of 470 controls (p=0.0009
in p-AIN and p=7.239e-12 in s-AIN). Median value of neutrophils was lower in
p-AIN (0.45 x 109/L) than in s-AIN 0.63 x 109/L (p =0.03); median value of lym-
phocytes was significantly reduced (p=6.29e-11) in s-AIN (1.58 x 109/L) vs p-
AIN (4.36 x 109/L) group. Leucopenia (p=1.80e-07) and severe infections
(p=0.0001) occurred more frequently in s-AIN; monocytosis (p=0.039) and
spontaneous remission (p=3.21e-11) in p-AIN. GCSF was used in 6.9% of the
p-AIN and 23.1% of the s-AIN patients (p=0.0045). Neutropenia appeared con-
temporarily to other autoimmune manifestations in 11/26 s-AIN patients
(42.3%), appeared firstly in 8/26 patients (30.7%) (median and mean time of
appearance of other autoimmune signs: 440 and 987 days respectively) and
later in 7/26 patients (26.9%) (median and mean time of appearance of s-AIN:
558.5 and 865.3 days respectively). Evans Syndrome (ES) and autoimmune
thyroiditis (AT) were the most common secondary autoimmune diseases (11
and 7 patients, respectively), whereas 7 s-AIN patients presented not previously
reported associations: 3 with GH deficiency, 2 with coeliac disease (CD), 1 with
autoimmune hepatitis (AH) and 1 with autoimmune encephalitis. In 6 children
s-AIN was associated with more than one defined autoimmune disease and in
4 children with undefined autoimmune signs characterized by arthralgia and
ANA positivity. Finally, only 2/26 patients presented spontaneous remission: a
boy who recovered from ES and one patient, affected by both AT and CD who,
after starting gluten-free diet, recovered from s-AIN (and not from AT). A third
girl suffering from both AH and bi-lineage ES (thrombocytopenia + AIN) has
been maintained, 30 months after the stop therapy, a stable remission from AH
and thrombocytopenia (but not from s-AIN).
Summary/Conclusions: p-AIN is in the vast majority of cases a benign and
self-limiting disorder typically occurring under 2-3 years old whereas s-AIN is
a more severe disease, usually appearing after the first 5 years of life, usually
associated to lymphocytopenia and with a highly frequent tendency to become
chronic.
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Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a life-threatening
disorder with a high risk of thrombosis. Targeted therapy radically changed the
prognosis in PNH. Therefore issues of reproductive health in PNH patients are
becoming very important. Recently the management of PNH during pregnancy
has been challenging because of the high risk of maternal morbidity and fre-
quent pregnancy loss. The combination of targeted therapy with eculizumab
and anticoagulants made it possible not only to increase the survival rate, but
also to improve the quality of life
Aims: We compared the pregnancy outcomes in PNH patients on eculizumab
treatment and retrospective data of pregnancies on symptomatic therapy only.
Methods: Since 1999 we have analyzed 32 pregnancies in PNH patients. 17
patients (group 1) from 2013 exposed to eculizumab during pregnancy with
anticoagulants. Other 15 women (group 2) received only symptomatic therapy.
The median of PNH granulocyte clone at that time was 74,7% (23-99). PNH
diagnosed before the pregnancy in all cases. 64,3% of them had previously
received immunosuppressive treatment of aplastic anemia. 18,7% patients reg-
istered venous thromboses before conception. 92,9% of patients had been
using eculizumab prior to becoming pregnant, mean duration of therapy was
21 months (4-44). Anticoagulation with low molecular weight heparin was used
in 85,7% pregnancies.
Results: Clinical manifestations of hemolysis significantly regressed during
eculizumab treatment: normalization of LDH was registered in 76,5% patients.
Without eculizumab LDH level increased in all pregnant patients. No maternal
death and thrombotic events have been observed. 42,9% of patients required
a dose adjustment due to breakthrough hemolysis (a dose increase and/or
more frequent use of eculizumab). Pregnancy complications were less frequent
with eculizumab: abortion threat 35,3% vs 85,7%, fetal growth retardation syn-
drome 7,1% vs 21,4%, preeclampsia 5,9% vs 14,3%. Transfusion rate was
higher without eculizumab (86,7% vs 41,2%). Pregnancies resulted in the birth
in 100% patients exposed eculizumab and 42,9% on supportive treatment.
Mean birth weight 2560 g (450-3550). Most of newborns (87,5%) are healthy,
83,3% of them received breastfeeding without complications both on eculizum-
ab and without it.
Summary/Conclusions: We can conclude that pregnancy outcomes in PNH
patients with eculizumab are much better than with symptomatic therapy only.
Our data demonstrate the possibility of safe therapy with eculizumab in preg-
nant women. Pregnancy does not worsen the prognosis of PNH in the case of
targeted and adequate supportive therapy. There is no difference in health
between infants born by mothers with PNH and the newborns from general
population.
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Background: In Gaucher disease type 1 (GD1), deficient lysosomal acid β-
glucosidase activity leads to accumulation of glucosylceramide, primarily in
macrophages (Gaucher cells), which deposit in the spleen, liver, and bone
marrow, leading to thrombocytopenia, anemia, hepatosplenomegaly, and skele-
tal disease. Hematologists often identify and manage the disease. Intravenous
enzyme replacement therapy (ERT) with recombinant acid β-glucosidase has
been the mainstay of therapy for GD1. Eliglustat is an oral substrate reduction
therapy approved as first-line treatment for adults with GD1 with poor, interme-
diate, or extensive CYP2D6-metabolizer phenotypes (>90% of patients). Phase
3 trials demonstrated safety and efficacy of eliglustat in naïve patients (Mistry
et al. JAMA. 2015) and safety and stability in patients switching from long-term
ERT (Cox et al. Blood. 2017). We report the final 8-year results of an open-
label Phase 2 trial (NCT00358150, Sanofi Genzyme) in previously untreated
adults with GD1. These data build on 1-, 2-, and 4-year data showing sustained
improvements in hematologic parameters, organ volumes, disease-related bio-
markers, and measures of bone health (Lukina et al. Blood Cells Mol Dis.
2014).
Aims: Report long-term efficacy and safety after long-term eliglustat treatment.
Methods: Adult GD1 patients who had splenomegaly with thrombocytopenia
and/or anemia received 50 or 100mg eliglustat tartrate (equivalent to 42 or
84mg eliglustat) twice daily, dosed by plasma trough levels. Efficacy outcomes
included changes in hemoglobin, platelets, spleen and liver volumes, disease-
related biomarker levels, skeletal manifestations, and achievement of thera-
peutic goals for anemia, thrombocytopenia, splenomegaly, and hepatomegaly
(Pastores et al. Semin Hematol. 2004; Lukina et al. Blood. 2010). 
Results: Of 26 enrolled patients, 19 completed the trial and 7 withdrew: 2 on
the first day of treatment due to asymptomatic nonsustained ventricular tachy-
cardia detected during routine monitoring (plasma levels of eliglustat were
undetectable); 1 after 1 year due to progression of a bone lesion (retrospectively
identified at baseline); 1 chose to withdraw after 2 years; and 3 due to preg-
nancy. After 8 years of eliglustat, mean (±SD) hemoglobin level and platelet
count increased by 2.1±1.7 g/dL (from 11.3±1.6 to 13.4±1.3 g/dL) and 110%
(from 67.5±21.1 to 130.7±59.8 x109/L), respectively. Mean spleen and liver
volumes (multiples of normal, MN) decreased by 68% (from 17.3±10.4 to
5.1±3.5 MN) and 31% (from 1.6±0.5 to 1.1±0.3 MN), respectively. All patients
met ≥3 of 4 long-term therapeutic goals (spleen, 100% of patients; liver, 100%;
hemoglobin, 93%; platelets, 53%) by 7-8 years. Median chitotriosidase levels
decreased by 84%, CCL-18 by 82%, and glucosylsphingosine (Lyso GL-1) by
88%; plasma GL-1 normalized. Total mean lumbar spine bone mineral density
increased by 0.12 g/cm2; mean Z-score increased by 0.88 (from -1.27±1.02 to
-0.39±1.13) and mean T-score by 0.95 (from -1.64±1.07 to -0.69±1.31). Eliglu-
stat was well-tolerated. All quality of life measures (SF-36, fatigue severity
score, Gaucher disease severity score) showed improvement over time. Most
adverse events in this long-term trial were mild or moderate in severity (98%,
342/348) and considered unrelated (94%, 328/348) to treatment.
Summary/Conclusions: After 8 years of treatment with eliglustat, clinically
meaningful improvements in hematologic, visceral, biomarker, and bone param-
eters continued or were maintained among patients in this Phase 2 trial. No
new safety concerns emerged.
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Background: Immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by isolated thrombocytopenia, with platelet counts <100x109/L.
Eltrombopag is an oral small-molecule nonpeptide thrombopoietin-receptor
agonist that has shown to increase platelet production. It is approved for the
management of patients with chronic ITP (aged ≥1 year) who are refractory to
other treatments (eg, corticosteroids, immunoglobulins). The recommended
eltrombopag dose in patients with chronic ITP is 25mg once daily, OD (East
Asians, 12.5mg OD or 25mg every other day) in pediatrics aged 1-5 years,
and 50mg OD (East Asians, 25mg OD) in adults and pediatrics aged 6-17
years at initiation, followed by dose adjustment to a maximum of 75mg OD
based on platelet counts. REVIEU study was conducted in accordance with
risk management plan in five European Union (EU) countries to document
eltrombopag utilization patterns in real-world practice. Here, we report the
eltrombopag data on the subset of adult patients (aged ≥18 years) with ITP as
primary diagnosis.
Aims: To evaluate the real-world data to determine drug utilization patterns
among adult patients with ITP receiving eltrombopag within five EU countries.
Methods: REVIEU study was a multinational, multicenter, retrospective, med-
ical chart review in patients with a documented past treatment with eltrombopag
between the period immediately after first approval/launch in May 2010 and
September 2014 (ie, dispensed at least once by the pharmacy and patient
received at least one dose) for whatever reason. Patients who participated or
were participating in a randomized eltrombopag clinical trial were excluded.
Table 1.
Results: Overall, 287 adult patients with ITP (chronic [>12 months], 75.3%;
persistent [3-12 months], 10.8%; acute [<3 months], 13.6%; unknown [n=1])
were included, majority in Spain (n=128) followed by Italy (n=67), Greece
(n=36), France (n=29), and Germany (n=27). Eltrombopag was the first treat-
ment with no prior ITP therapies in 12 (4.2%) [acute, 10.3%; persistent, 6.5%;
chronic, 2.8%] patients. A total of 99 (34.6%) patients received one prior therapy
(corticosteroids, 79 [27.6%]), 128 (44.8%) patients received two prior therapies
(corticosteroids+immunoglobulin, 114 [39.9%]), and 47 (16.4%) patients
received three prior therapies (corticosteroids, immunoglobulins, and splenec-
tomy). In total, the majority of patients received at least one prescription of cor-
ticosteroids (252, 88.1%) followed by immunoglobulins (180, 62.9%), and
splenectomy (64, 22.4%) prior to eltrombopag initiation. Patients received an
average daily dose of eltrombopag 45.6mg (chronic ITP, 44.6mg; persistent
ITP, 43.1mg; acute ITP, 53.0mg) during the study. Overall, dose changes were
reported in 749 adult ITP prescriptions (down-titration, 53.7%; up-titration,
43.7%; no change in dose, 2.7%). 49.1% of dose changes were reported during
the first 6 months of treatment (35% in first 3 months). The main reasons for
dose change included: disease improvement (30.4%), no treatment response
(26.8%) and others (27.1%). Disease improvement accounted for down-titration
in 51.2% (206/402) and up-titration in 4.6% (15/327), and no treatment
response for up-titration in 54.4% (178/327) and down-titration in 5.0% (20/402)
of adult patients with ITP. Proportion of patients with platelet counts by ITP dis-
ease phase, and by eltrombopag dose are reported in Table 1.
Summary/Conclusions: The majority of adult patients with ITP (75.3%) were
diagnosed with chronic ITP, and were treated with eltrombopag as second-line
or greater therapy after corticosteroids and immunoglobulins, in line with the
approved indication. Eltrombopag was also prescribed in 24.4% of adult patients
with acute and persistent ITP. The starting dose followed the summary of product
characteristics (SmPC) recommendations in the majority of cases and dose
modifications were generally according to platelet counts. Data from REVIEU
study have shown that eltrombopag use in the real world setting is largely con-
sistent with the EU label and is considered part of ITP medical therapies.
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Background: A previous study has suggested a mechanism of Fcγ receptors
(FcγR)-independent platelet clearance in immune thrombocytopenia (ITP) (1).
Antibody-mediated platelet desialylation may lead to platelet clearance in the
liver via hepatic Ashwell–Morell receptors, providing a potential explanation for
refractoriness to classical therapies (steroid, IVIG and splenectomy).
Aims: The aim of this study was to analyze the biological features of ITP
patients refractory to conventional therapies.
Methods: We performed a prospective study in 8 patients with primary ITP not
responding to standard therapies (coticosteroids, IVIG and/or splenectomy) as
well as in 8 patients with non-refractory ITP (control group). Mean platelet size,
surface expression of platelet glycoprotein (GP) IIb,and the activation marker
CD62 were examined by flow cytometry (FC) analysis, as well as desialylation
of platelet membrane GPs using fluorescein-conjugated Ricinus Communis
Agglutinin I (RCA-1), a lectin that binds to galactose residues underlying sialic
acids. Patients’ sera was also incubated with normal human platelets to analyze
their ability to induce desialylation in normal platelets. Analysis of desialylation
of plasma proteins was performed by Western blot (FXI, FXII) and HPLC (trans-
ferrin). The specificity of platelet autoantibodies was assessed by a solid-phase
modified antigen capture ELISA test (MACE). FC results are expressed as ratio
of mean fluorescence intensity (MFI) compared to that of a control.
Results: The characteristics of the patients according to the response to con-
ventional treatments (A, no responsers; B, responders) are summarized in
Table 1. Non responders exhibited lower platelet counts (p=0.006), higher
expression of GPIIb (p=0.049) and loss of platelet sialic acids (p=0.005). Addi-
tionally, those who did not respond not only to traditional therapies (corticos-
teroids, IVIG and splenectomy) but also to thrombopoietin receptor agonists
(TPO-RA) (n=5) displayed higher platelet size and alpha-granule secretion.
Furthermore, TPO-RA refractory patients’ sera desilylated normal platelets, but
not plasma proteins. MACE assay revealed that unique positivity for anti-GPIbα
antibodies was only detected in those patients classified as non-responders to
conventional ITP therapies, including TPO-RA.
Table 1.
Summary/Conclusions: This study shows a significant higher platelet desia-
lylation in ITP patients who are non-responders to conventional therapies, par-
ticularly if they are also refractory to TPO-RA. According to a previous study
(1), these results seem to be associated to platelet activation mediated by anti-
platelet specific antibodies.
Reference
1. Li J et al. Nat Commun. 2015;6:7737.
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Background: ITP is a disorder characterized by thrombocytopenia resulting
from both increased immune-mediated platelet clearance and inappropriate
thrombocytopoieis. TPO-RAs–romiplostim (R) and eltrombopag (E) - offer a
new opportunity of treatment with high response rates. However, a small fraction
of pts does not respond or loses response - i.e. desired platelet (plt) count
achieved but not sustained over time - during long-term follow-up, which can
not be resumed even if dosage is increased over time, or experience wide fluc-
tuations in plt counts with either agent. Moreover, adverse events (AE) may
necessitate treatment discontinuation. Finally, patient’s preference may be an
important issue considering the different route and timing of administration of
the two agents and the alimentary restrictions needed for proper E absorption.
Availability of two TPO-RAs for clinical use, with different molecular structure
and site of binding within the TPO receptor, has prompted trials of TPO-RA
switching with the aim of overcoming treatment limitations of either agent result-
ing in reported overall response rates of approximately 80% in poor responders
to 1st TPO-RA.
Aims: To present the results of a multicenter survey on TPO-RA switch policies
and outcome.
Methods: Charts of ITP pts receiving TPO-RAs at 17 collaborating Haematol-
ogy Centers were reviewed; demographic and clinical data were collected in a
dedicated case report form. Pts were grouped and analyzed based on the clin-
ical setting prompting the switch (Table 1). The study was approved by the
Hospital Review Board of each participating Center.
Table 1.
haematologica | 2017; 102(s2) | 291
Madrid, Spain, June 22 – 25, 2017
Results: A total of 546 pts received either R or E between Dec 2009 and Dec
2015. Of these, 106 (19.4%) underwent TPO-RA switch. Table 1 summarizes
outcome after switch. Overall 69/106 (65%) of pts achieved, regained or main-
tained response upon switching. Either one TPO-RA switch sequence was
equally effective (p=0.682). Outcome was not associated with gender, age at
1st TPO-RA treatment, splenectomy status. However, number of lines of previous
therapies was associated with lower response rates (p=0.020): each additional
line of therapy yielded a 30% increase in the odds of being a non responder; a
trend toward lower probability of response was observed in pts with longer last-
ing disease before 1st TPO-RA administration (p=0.066). Adverse events (AE;
16/106 pts) were generally mild and reversible upon discontinuation of either
one TPO-RA; 1 arterial (managed with thromboendarterectomy) and 1 venous
(standard anticoagulation) thrombotic events were observed which did not recur
after switching. AE were characteristic of older pts: each additional year increase
in pts age determined a 5% increase in the odds of developing AE.
Summary/Conclusions: Approximately 20% of TPO-RA treated pts were felt
by their attending physicians to potentially benefit from a switching policy. Expo-
sure to the 2nd TPO-RA was more effective in pts who had lost response to 1st
TPO-RA (80% responders) compared to those who were non responders to
1st TPO-RA (49% responders, p=0.001). It could be speculated that lack of
response to either one of the two available TPO-RA identifies a subgroup of
pts least likely to respond when switched to the second available TPO-RA. Pts
switched for non-efficacy reasons are more likely to maintain a response upon
switch (p=0.030). The so far unexplained and unprecedented phenomenon of
wide plt fluctuation appears to be linked to the removal of the spleen, the phys-
iological plt reservoir organ
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Background: EPAG is an oral thrombopoietin receptor agonist approved for
treatment of previously treated patients (pts; eg corticosteroids, immunoglob-
ulins) with cITP aged ≥1 yr. The EXTEND study, a global, open-label, extension
study of pts with cITP who received EPAG or placebo in prior EPAG studies,
evaluated long-term safety and tolerability of EPAG. In EXTEND, 19 (6.3%)
pts receiving EPAG experienced a total of 24 thromboembolic events (TEEs;
Saleh et al. Blood 2016;128:1368), which is similar to TEE incidence in cITP
pts receiving romiplostim (Kuter et al. Br J Haematol 2013;161:411–23) and to
one estimate in the general cITP population (Sarpatwari et al. Haematologica
2010;95:1167-75).
Aims: To describe management and outcomes of TEEs occurring during EPAG
treatment in the EXTEND study.
Methods: Adult pts with cITP received EPAG starting at 50mg/day, with titration
to 25–75mg per day or less as required, based on individual platelet count
responses (target range ≥50–200x109/L). Maintenance dosing continued after
minimization of concomitant ITP medication and optimization of EPAG dosing.
Pts could remain on EPAG either for 2 yrs in countries where EPAG was com-
mercially available, or for >2 yrs until EPAG became commercially available.
The EXTEND primary objective included detection and documentation of AEs,
including investigator-reported TEEs.
Results: 302 pts were enrolled and received ≥1 EPAG dose: 67% female;
38% splenectomized; 49% aged 18-49 yrs. Median exposure duration was 2.4
yrs (range, 2 days to 8.8 yrs) and mean daily dose was 50.2 (range, 1-
75)mg/day. Overall, 259/302 (86%) pts achieved platelet counts of ≥50×109/L
at least once and 126/248 (51%) pts maintained continuous platelet counts
≥50×109/L for ≥31 weeks. TEEs during EPAG treatment (n=24 events) included
deep vein thrombosis (DVT; n=8), myocardial infarction (MI; n=5), cerebral
infarction (CI; n=4), transient ischemic attack (TIA; n=3), others (n=4) [Table].
Where available, platelet counts prior to TEE were <150×109/L in eight pts and
≥150×109/L in nine; 6 pts experienced the TEE at or shortly after achieving
their maximum platelet count. Most TEEs resolved with intervention; 15 pts
received anticoagulant therapy for 16 TEEs (treatment not recorded, n=3; no
anticoagulation, n=5). EPAG was discontinued after a TEE (DVT, n=4; CI, n=3;
MI, n=1; other, n=2) in 10 pts (n=9/10 TEE resolved). Seven pts continued to
receive EPAG after a TEE (MI, n=3; TIA, n=3; CI, n=1; DVT, n=1; other, n=2;
TEE resolved, n=8/10); in two cases, EPAG was continued with no anticoag-
ulant therapy (TIA; both resolved), and in four, anticoagulants were given con-
comitantly with EPAG (TEE resolved, n=2/4); one of these also underwent per-
cutaneous transluminal coronary angioplasty (MI, resolved). EPAG was inter-
rupted during treatment for TEEs in two pts, one pt had two DVTs and acute
MI (n=3/3 TEEs resolved), the other had a DVT (not resolved). TEE risk factors
were not recorded for all pts; risk factor effect on the treating physician’s man-
agement could not be analyzed.
Table 1.
Summary/Conclusions: This analysis shows that most pts who experienced
a TEE had resolution of the event after medical/surgical treatment, most com-
monly anticoagulant therapy, regardless of whether EPAG was discontinued,
interrupted or continued. The decision to restart EPAG following a TEE should
be made on a case-by-case basis, with caution (including frequent platelet
count monitoring) and only if the benefit is expected to outweigh any risk. If
anticoagulation therapy is instituted (as in most cases), it is possible the bleed-
ing risk may shift the risk-benefit to maintenance of EPAG treatment.
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Background: Primary immune thrombocytopenia (ITP) is often diagnosed in
the elderly. The elderly patients have been reported to have a higher incidence
of severe bleeding manifestations and a higher ITP-related mortality. Nonethe-
less, few data exist on the characteristics and long-term prognosis of elderly
patients with severe bleeding.
Aims: We retrospectively evaluated elderly patients with ITP who had severe
bleeding to determine characteristics, response to therapy and long-term out-
come.
Methods: We reviewed the medical records of 517 ITP patients over 60 years
of age diagnosed at our center (192 men and 325 women) between 1991 and
2012. Therapy was started at diagnosis or during follow up. Bleeding severity
was assessed by the Mazzucconi’s bleeding assessment. Logistic regression
analysis was used to determine which presenting features were associated
with the risk of severe bleeding. Cox regression analysis was used to estimate
rate ratios(RR) for no remission and mortality.
Results: Among 517 patients with ITP, 10 (1.9%) presented intracerebral hem-
orrhage(ICH) and 74 (14.3%) presented severe (non-ICH) bleeding during ITP.
According to multivariate analysis, risk of severe bleeding in patients was
increased with platelet count <10×109/L (P=0.001, OR=1.682, 95% CI 1.271-
2.234), female patients (P=0.010, OR=2.148, 95% CI 1.200-3.844), complica-
tion of pulmonary disease (P=0.001, OR=4.724, 95% CI 1.845-12.092), gum
or oral mucosal bleeding (P<0.001, OR=2.941, 95% CI 1.658-5.216) and epis-
taxis (P=0.027, OR=1.865, 95% CI 1.074-3.238). Compared to severe (non-
ICH) bleeding, ICH was more likely incurred in severe bleeding patients with
hypertension (P=0.031, OR=2.750, 95% CI 1.266-5.974). Of 103 patients sim-
ply observed after diagnosis, 7(6.7%) patients presented severe (non-ICH)
bleeding and 3(2.9%) patients presented ICH during ITP. Of 222 patients who
had bleeding after treatment, 31 patients (13.9%) presented severe (non-ICH)
bleeding and 4(1.8%) patients presented ICH. Compared to observation, treat-
ment did not significantly reduce the risk of severe bleeding (χ2=1.889,
P=0.169). The total response rate (CR+R) to initial treatment in patients who
presented severe bleeding was 58.1% (43/74), which was lower than that in
patients without severe bleeding (70.2%, 238/340, χ2=4.014, P=0.045). The
response to steroids, IVIG or combination had no significant difference among
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patients with severe bleeding. At the end of follow-up, the estimated 10-year
cumulative rate of no remission among patients with severe bleeding was higher
than that among patients without severe bleeding (P=0.017, RR=1.608, 95%CI,
1.052-2.456). The estimated 10-year cause-specific mortality related to fetal
bleeding in patients with severe bleeding was higher than that in patients without
severe bleeding (P<0.001, RR=9.886, 95% CI, 1.806-54.098). The estimated
10-year mortality among ICH patients was higher than that among severe (non-
ICH) patients (P<0.009, RR= 4.543, 95% CI, 1.317-15.668).
Summary/Conclusions: Platelet count <10×109/L, female patients, complica-
tion of pulmonary disease, gum or oral mucosal bleeding and epistaxis are sig-
nificant predictive factors for severe bleeding in the elderly. Severe bleeding in
elderly ITP was associated with more failure of response to treatment, increased
long-term risk of no remission and mortality related to fetal bleeding.
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Background: Immune thrombocytopenia (ITP) is generally considered to be
an autoimmune disorder characterized by increased peripheral platelet destruc-
tion and reduced platelet production. Corticosteroids represent the standard
first-line therapy achieving responses in around 80% of patients. However, for
those corticosteroid-resistant ITP patients, who exhibit either no response (NR)
to corticosteroids or corticosteroid-dependent, the pathogenesis remains poorly
understood and the management is challenging. Emerging evidence from
mouse studies has suggested that the cross-talk between megakaryocytes
(MKs) and endothelial progenitor cells (EPCs) in the bone marrow (BM)
microenvironment regulates MKs maturation and thrombopoiesis. We recently
reported that the impaired BM EPCs, which could be quantitatively and func-
tionally improved by atorvastatin in vitro, induced the occurrence of poor graft
function following allo-transplant (Blood, 2016,128:2988-2999). However, little
is known about the functional role of BM EPCs and how to improve impaired
BM EPCs in patients with corticosteroid-resistant ITP.
Aims: To determine whether quantitative and/or functional abnormalities of BM
EPCs are involved in the occurrence of corticosteroid-resistant ITP. Moreover,
to investigate the effects of atorvastatin and N-Acetyl-L-cysteine (NAC, a ROS
scavenger) on the number and function of cultivated BM EPCs derived from
patients with corticosteroid-resistant ITP and its underling molecular mecha-
nisms. Finally, to evaluate the efficacy and safety of atorvastatin and NAC to
adult patients with corticosteroid-resistant ITP.
Methods: Twenty-three patients with corticosteroid-resistant ITP, 30 patients
with newly diagnosed ITP and 17 healthy donors (age 18-55) were enrolled
from 2016 to 2017 at Peking University Institute of Hematology. BM EPCs were
cultured as previous reported. Atorvastatin and NAC were administrated to the
5-day cultivated BM EPCs in corticosteroid-resistant ITP patients until tested
on day 7. The number and function of BM EPCs were evaluated pre- and post-
treatment by cell counting, DiI-Ac-LDL and FITC-lectin-UEA-1 double staining,
migration, cell proliferation, tube formation, levels of reactive Oxygen Species
(ROS) and apoptosis. Proteins expressions for p38, ERK, JNK, Akt were meas-
ured by flow cytometry and western blot. Subsequently, a single-center pilot
study was performed to evaluate the efficacy and safety of atorvastatin and/or
NAC in corticosteroid-resistant ITP patients. The primary end points were com-
plete response (CR), response(R), and overall response (OR). Secondary end
points were time to response (TTR) and adverse events. 
Results: Human bone marrow EPCs were demonstrated as the spindle shape
and the similar expression of CD34, VEGFR2 and CD133 at day 7 of cultivation
among the enrolled three cohorts of subjects. Decreased and dysfunctional
BM EPCs, which were characterized by impaired proliferation, migration, angio-
genesis, and higher levels of ROS and apoptosis, were revealed in corticos-
teroid-resistant ITP patients compared to those in newly diagnosed ITP. Acti-
vation of p-P38 was detected in BM EPCs from corticosteroid-resistant ITP
patients. Furthermore, the number and function of BM EPCs derived from cor-
ticosteroid-resistant ITP patients were enhanced by atorvastatin or NAC treat-
ment in vitro through down-regulation of the p38 mitogen-activated protein
kinase (MAPK) pathway. In the single-center pilot study, a total of 12 corticos-
teroid-resistant ITP patients were recruited to receive either the combination of
atorvastatin and NAC or alone. As a result, the CR, R and OR rates were 25%
(3/12), 41.7% (5/12) and 66.7% (8/12), respectively. In patients who achieved
CR and R, the median (range) TTR was 24 days (7-51 days), with no apparent
adverse events.
Summary/Conclusions: The number and the function of BM EPCs were
impaired in corticosteroid-resistant ITP patients. Treatment with atorvastatin
and NAC in vitro and in vivo quantitatively and functionally improved BM EPCs
derived from corticosteroid-resistant ITP patients through down-regulation of
the p38 MAPK pathway. Although the sample size of clinical study is small,
with a relatively short follow-up period by now, our data suggest that atorvastatin
and NAC are effective and safe in the management of corticosteroid-resistant
ITP patients. Therefore, further prospective multicenter randomized clinical
trials with larger sample size are needed in the future.
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Background: Sepsis is a systemic, deleterious host response to infection lead-
ing to severe sepsis, and possibly septic shock as defined by the Surviving
Sepsis Campaign guidelines. Thrombocytopenia is a common finding in sepsis.
Studies in murine models suggested that platelet desialylation was an important
mechanism of thrombocytopenia during sepsis. Desialylation-induced platelet
removal could possibly be circumvented by adding sialidase inhibitors during
sepsis. Oseltamivir, also known as Tamiflu, is a viral sialidase inhibitor that pre-
vents the release of progeny virions. Several studies suggests the feasibility
that oseltamivir can be used for the treatment of infection-associated thrombo-
cytopenia.
Aims: To determine whether thrombocytopenia is associated with increased
platelet desialylation in septic patients, and whether oseltamivir is an effective
treatment to increase platelet counts in severe sepsis.
Methods: We first performed a prospective, multicenter, observational study
that enrolled septic patients with or without thrombocytopenia to determine the
association between platelet desialylation and thrombocytopenia in patients
with sepsis. Next, we conducted an open-label, randomized controlled trial in
which the patients who had severe sepsis with thrombocytopenia (platelet
counts ≤50×109/L) were randomly assigned to receive antimicrobial therapy
alone (control group) or antimicrobial therapy plus oseltamivir (oseltamivir
group). The study flowchart is shown in Fig. 1. Both groups received appropriate
antimicrobial agents and standard medical support based on the guidelines
issued by the Surviving Sepsis Campaign. The oseltamivir group additionally
received 5 full days of oseltamivir therapy. The oseltamivir was administered
orally or through a feeding tube at a dose of 75mg once every 12 hours. Time
from randomization to the administration of oseltamivir was less than 24 hours.
The antimicrobial agents were continuously administered until 3 days after the
resolution of the physiological abnormalities related to the systemic inflamma-
tory response syndrome (SIRS). The primary outcomes were platelet desialy-
lation level at study entry, and overall platelet response rate within 14 days
post-randomization. Secondary outcomes included platelet recovery time, the
occurrence of bleeding events, and the amount of platelets transfused within
14 days post-randomization. The percentages of platelets positive for Ricinus
communis agglutinin I (RCA-I), Erythrina cristagalli lectin (ECL) or Succinyl
Triticum vulgare lectin (sWGA) analyzed by flow cytometry represented the lev-
els of platelet desialylation. Platelet response was defined as platelet counts
returning to or above 100×109/L. Platelet recovery time was calculated as the
date of randomization to the date when platelet counts were >100×109/L. Writ-
ten informed consents were obtained from the study participants prior to inclu-
sion in the study.
Figure 1.
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Results: The platelet desialylation levels increased significantly in the 127 sep-
tic patients with thrombocytopenia compared to the 134 patients without throm-
bocytopenia. A platelet response was achieved in 45 of the 54 patients in the
oseltamivir group (83.3%) compared with 34 of the 52 patients in the control
group (65.4%; P=0.045). The median platelet recovery time was 5 days
(interquartile range 4-6) in the oseltamivir group compared with 7 days
(interquartile range 5-10) in the control group (P=0.003). The amount of
platelets transfused decreased significantly in the oseltamivir group compared
to the control group (P=0.044). The multivariate analysis by Cox proportional
hazards models showed that the Sequential Organ Failure Assessment (SOFA)
score and platelet recovery time were independent indicators of oseltamivir
therapy.
Summary/Conclusions: Thrombocytopenia was associated with increased
platelet desialylation in septic patients. The addition of oseltamivir could signif-
icantly increase the platelet response rate, shorten platelet recovery time and
reduce platelet transfusion. Chinese Clinical Trial Registry, ChiCTR-IPR-
16008542.
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Background: Children with ITP for ≥6 months who completed a romiplostim
phase 1/2 or phase 3 parent study could enroll in this open label long term
extension study
Aims: To evaluate the safety and efficacy of long-term romiplostim in children
with ITP.
Methods: Patients enrolled at 28 sites in the US, Canada, Spain, and Australia.
All patients received SC romiplostim once weekly. The initial dose was the final
dose from the parent study or 1 µg/kg for patients previously receiving placebo;
dose was then adjusted from 1-10 µg/kg to target platelet counts of
50−200×109/L. Incidence of adverse events (AEs) was the primary endpoint.
Figure 1.
Results: As of 24 Feb 2016, 66 patients entered this study; 65 received romi-
plostim for up to 6.2 years. At baseline, median (min–max) age was 11 (3–18)
years; 56% were female; 61% were white, 14% African American, 14% His-
panic/Latino, 9% Asian, and 3% other; 9.1% had prior splenectomy. Median
(min–max) baseline platelet count was 27.5 (2–458)×109/L.  Median (min–
max) treatment duration was 100 (5–321) weeks. Median (min–max) average
weekly romiplostim dose was 4.8 (0.1–10.0) µg/kg, which included escalation
to a stable dose. After ~week 200 (n ≤8 patients), the median dose was
observed to fluctuate. All 65 patients received their doses per protocol >90%
of the time; 18 patients missed ≥1 dose due to noncompliance for a total of 41
times. Reasons for discontinuing treatment (n=22, 33%) included consent with-
drawn (n=8), required other therapy (n=4), noncompliance (n=3), administrative
decision (n=3), per protocol (n=1), and AE (n=2) (asthenia, headache, dehy-
dration, and vomiting in one patient and anxiety in the other, per investigator,
none of the AEs were treatment-related); 43 (65%) patients continued in the
study. Fifty-two serious AEs occurred in 17 patients, 3 deemed treatment-relat-
ed (anemia, epistaxis, and thrombocytopenia). Bleeding AEs occurred in 56
patients; 5 deemed treatment-related (gingival bleeding, petechiae, injection
site bruising, injection site hematoma, and epistaxis). No thrombotic events
were reported. There were no peripheral blood abnormalities warranting a bone
marrow examination. No patients had anti-TPO neutralizing antibodies. From
week 2 on, median platelet counts remained >50×109/L; platelet counts were
>100×109/L at most timepoints, despite an observed decrease in the median
dose from 4-5 μg/kg to 2-3 μg/kg around week 160 (Figure). Nearly all (94%,
61/65) patients had a platelet response (median platelet counts for a month
≥50×109/L). Nine (14%) patients (5 boys and 4 girls, none with prior splenec-
tomy) entered remission (Table), defined here as platelet counts ≥50×109/L for
24 weeks with no ITP treatments. Twenty-three (35%) patients received rescue
medications.
Summary/Conclusions: Over 6 years of data from this ongoing open-label
extension study of romiplostim in children with ITP show that >90% of children
achieved a platelet response with romiplostim. The safety profile was overall
tolerable, similar to that in past studies. Some children (9/66) with longstanding
ITP entered remission after receiving romiplostim.
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IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF CLL PATIENTS
RELAPSED/REFRACTORY TO B-CELL RECEPTOR (BCR) SIGNALING
PATHWAY INHIBITOR TREATMENT
W. Wierda1,*, K. Sail2, J. Potluri2, L. Noe2, R. Kamalakar2, J. Gdovin2,
R. Humerickhouse2, M. Verdugo2
1The University of Texas MD Anderson Cancer Center, Houston, 2AbbVie Inc,
North Chicago, United States
Background: The prognosis for patients with CLL after B-Cell Receptor inhibitor
(BCRi) failure is very poor. Patients with R/R CLL who discontinue and/or
progress on BCRi treatment tend to have poor clinical outcomes. Venetoclax
(VEN) is an oral BCL-2 inhibitor that has demonstrated deep and durable
responses in relapsed/refractory (R/R) CLL patients. 
Aims: To assess whether VEN has an impact on health related quality of life
(HRQoL) among CLL patients R/R to BCRi treatment and receiving VEN
monotherapy.
Methods: The study enrolled patients with CLL who had previously received
treatment with ibrutinib and/or idelalisib, have relapsed on treatment, or expe-
rienced progression after discontinuation of either agent. Patients are to receive
VEN monotherapy for up to two years, or until discontinuation due to disease
progression, unacceptable toxicity, or any other reason. Patient-reported
HRQoL measures included the EORTC QLQ-C30 and EORTC QLQ-CLL16,
which were assessed at Baseline (BL), Week 24, and every 12 weeks there-
after. Mean change from BL to each assessment through Week 48 are reported
here. Clinical relevance was based on minimum important difference (MID) of
values from BL to each assessment. A change of 5-10 points is considered a
“small” change on the EORTC-QLQ-C30. The lower bound of 5 points was
used for MID acceptance on both measures. 
Results: Clinically meaningful improvements from BL were observed early and
were sustained through week 48 in VEN treated patients in the EORTC-QLQ-
C30 global health status and the role, social, and emotional functioning scales.
Furthermore, early and sustained improvements in fatigue through week 48
were seen in both EORTC-QLQ-C30 and EORTC-QLQ-CLL16 (Table 1).
Table 1.
Summary/Conclusions: This interim analysis provides preliminary evidence
that demonstrates CLL patients R/R to BCR inhibitors receiving VEN monother-
apy experienced improvement in several key aspects of functioning and
HRQoL. These results may be important to consider when making therapeutic
choices in R/R CLL following relapse or progression on BCRi inhibitors.
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THE ROLE OF PSYCHOLOGICAL VARIABLES FOR TYROSINE KINASE
INHIBITORS (TKI) DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA
(CML) PATIENTS: IMPLICATION FOR MEDICAL DECISION MAKING
PRACTICE
S. Riva1,*, A. Cortelezzi2, I. Cutica1, E. Orlandi3, E. Chiara3, C. Bucelli2, A. Iurlo2,
G. Pravettoni1
1Department of Oncology and Hematology, University of Milan, 2Hematology-
BMT Unit, IRCCS Ca’ Granda Policlinic Foundation Hospital, Milan, 3Depart-
ment of Oncology Hematology,, IRCCS Policlinic San Matteo Foundation Hos-
pital, Pavia, Italy
Background: Treatment-free remission (TFR) is an emerging goal for CML
patients (pts) that reach a sustained deep molecular response (DMR), as it can
reduce the risk of long-term toxicities that impair quality of life, and mitigate the
costs associated with long-term TKI therapy. Therapy discontinuation may rep-
resent a great challenge for patients and different factors (not only clinical) may
play a role in medical decision, such as psychological and emotional variables.
In this respect, it is essential to consider pts’ concerns and preferences regard-
ing the discontinuation option.
Aims: This study was aimed at investigating psychological (emotional and cog-
nitive) and clinical factors related with the attitude to opt for discontinuation of
therapy in CML pts. 
Methods: This is an observational, prospective, no-drug related study con-
ducted in 3 Italian centers with large experience in CML treatment. A detailed
battery of questionnaires focusing on health behaviour, risk taking and person-
ality was administered.
Results: One hundred and twenty pts were enrolled (56% males; mean
age=50, SD=1.2). Median duration of the disease was 8 years (range 1-39y).
62/120 pts were receiving Imatinib first line. The idea of stopping TKI is appeal-
ing for the 81.6% of pts if there is a chance of long-term stable disease and a
high probability of response upon restarting a TKI. Pts are more likely to stop
their TKI if the risk of relapse is no more than 30% (% Mean=33.62; SD=33.46).
Main worries related with the choice to stop TKI are fear of possible disease
recurrence, (60.5%), fear of drug resistance if the disease relapses (44.5%)
and fear to disappoint family or friends (26.9%). Older pts (>40 years) are more
concerned about relapse and subsequent lack of response than younger
(x2=9.65, p=0.02). Finally, pts with higher passive risk taking attitude (who are
more reluctant and undecided in everyday-life decisions) seemed to be more
afraid to lose disease control in CML. ANOVA showed a significant difference
between the two groups (F=5.46; p=.021).
Summary/Conclusions: Many studies have confirmed the feasibility and safe-
ty of stopping TKI therapy in selected pts, with the potential to drastically modify
clinical practice in CML management in the next future. TKI discontinuation
appears appealing and challenging at the same time for many CML pts. This
study, for the first time, analyses how and when pts would consider this option
including implications for health care providers in clinical practice, using both a
clinical and psycho-cognitive perspective.
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BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR
THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28
EU MEMBER STATES
F. Rencz1,2,*, L. Gulácsi1,2, P. Baji1,2, M. Péntek1,2, V. Brodszky1,2
1Department of Health Economics, Corvinus University of Budapest, 2HTA Con-
sulting Budapest, Budapest, Hungary
Background: In December 2016, the European Medicines Agency’s Commit-
tee for Medicinal Products for Human Use has recommended granting market-
ing authorization to biosimilar rituximab (CT-P10) in all indications of the refer-
ence product, including chronic lymphocytic leukaemia (CLL). Compared to
the originator rituximab, significant price reductions are expected offering a
more affordable treatment option for CLL patients across Europe.
Aims: To assess the budget impact of the introduction of CT-P10 into the treat-
ment of CLL in the 28 EU member states. Moreover, we provide an estimation
for the number of additional CLL patients that can be treated with CT-P10 from
the cost savings.
Methods: A budget impact analysis was performed to evaluate the one-year
cost outcomes under two scenarios with and without the availability of CT-P10.
The budget impact was calculated as the difference in costs between the two
scenarios. For the major European markets, five-year cost savings were also
estimated. Market uptake of CT-P10 was assumed to be 30%. A third party
payer’s perspective was adopted, and only drug costs were considered. Based
on expert opinion, it was assumed that when CT-P10 is entering the market it
will be at 50-70% of the official list price of originator rituximab in each country.
Costs of administration and monitoring were not incorporated in the calculations,
as it can be assumed that these are equal for the reference product and CT-
P10. The initial number of patients treated with rituximab was estimated from
IMS sales data on total annual consumption of originator rituximab in 2016.
Other model parameters such as patients’ average body surface area and treat-
ment rate of rituximab among CLL patients, were derived from the published
literature. One-way sensitivity analysis was undertaken to test the robustness
of model assumptions.
Results: Over a one year time horizon, the cumulative budget impact of adopt-
ing CT-P10 is estimated to be €17.80 million in the 28 EU member states (30%
discount in drug prices compared to the originator rituximab). Countries respon-
sible for the majority of the cost savings are Germany (€4.06 million), Italy
(€3.15 million), France (€2.41 million), Spain (€1.50 million), the UK (€1.34 mil-
lion), Poland (€0.80 million), Austria (€0.66 million), the Netherlands (€0.59 mil-
lion), Finland (€0.49 million) and Sweden (€0.43 million). If the cost savings
were used to treat additional CLL patients with CT-P10, a total of 1,624 patients
could be treated annually throughout Europe. The potential cost savings are in
a direct correlation with the price and market uptake of CT-P10. Applying a
40% and 50% discount in drug prices compared to the originator rituximab,
cost savings are projected to €23.73 and €29.67 million, from which further
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2,526 and 2,706 CLL patients could be treated with CT-P10, respectively. Over
five years, the total cost savings are expected to reach €29.81 million in Ger-
many, €23.10 million in Italy, €17.65 million in France, €10.98 million in Spain
and €9.83 million in the UK.
Summary/Conclusions: Biosimilar rituximab has the potential to improve the
affordability of CLL treatments and easing the burden of healthcare costs in
Europe. The cost savings might be even larger in case of a higher price discount
for CT-P10. Using the cost savings to treat additional patients would substan-
tially increase the access to better cancer medications, and thus contribute to
a longer survival as well as better quality of life outcomes in CLL.
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AN INVESTIGATION INTO THE NEEDS AND PRIORITIES OF PATIENTS
WITH MULTIPLE MYELOMA DURING REMISSION–IMPLICATIONS FOR
RE-DESIGNING PATIENT-CENTRED HEALTHCARE SYSTEMS.
D. De-Silva1,*, J. Land2, M. Heinrich2, J. Galinsky3, Y. Reyal4, N. Rabin5,
A. Mehta5, K. Yong1
1UCL Cancer Institute, 2Department of Behavioural Science and Health, Uni-
versity College London, London, 3Myeloma UK, Edinburgh, 4Haematology, St
George’s Hospital, 5Haematology, University College London Hospital, London,
United Kingdom
Background: Therapeutic advances in multiple myeloma (MM) mean that
patients have extended periods of remission without need for active anti-myelo-
ma therapy. This provides an opportunity to review how these patients are
managed and design patient-centred healthcare systems. Remote monitoring
systems have been implemented for other cancer patients in remission. 
Aims: We aimed to explore patient needs during stable remission from MM
and the influence of these on acceptability of remote monitoring.
Methods: Patients with stable MM in a treatment-free interval selected from
outpatient clinics at a tertiary centre completed a survey which explored the
acceptability of various methods of remote monitoring. Subsequently semi-
structured interviews were conducted by an independent researcher to inves-
tigate factors influencing this preference. Interviews were carried out until sat-
uration of themes, transcribed verbatim and thematic analysis was performed
using open coding by a doctor, physiotherapist and psychologist.
Results: 78 patients were surveyed; the most acceptable alternative was a
telephone clinic (with doctor 77%, nurse 69%). 19 interviews were conducted
exploring suitability of a nurse-led telephone clinic (TC) replacing current face
to face (FTF) consultations with a doctor. Median age was 61years (range 46-
76), and 9 were male. 18 patients were in 1st remission; 16 had most recently
received high dose therapy and autograft, 3 had post autograft consolidation.
The centre was not the local hospital for 18 patients interviewed. The majority
were accepting of TC as an alternative to FTF clinics due to the burden of
travel, associated cost and clinic waiting times. These affected patients’ physical
and psychological well-being, with TC perceived as less burdening. Patients
acknowledged reduced needs during remission compared to treatment phase
and felt TC would benefit redistribution of consultant time for patients on active
therapy. Some patients suggested this service change would be more beneficial
for healthcare resourcing rather than them personally. Interpretation of blood
results by clinicians was regarded as central to monitoring disease, and for
some who were unaware of clinical symptoms, the only way a relapse would
be detected. General preference was for bloods to be done locally, leading to
concerns about availability of results for TC. Patients were unsure how to mon-
itor their own MM, hence valued the knowledge of their medical team. Doctors
were perceived to have more expertise than nurses and this influenced pref-
erences regarding who undertook TC. As a result, patients sought reassurance
they could see a doctor if they had any concerns after TC with a nurse. Patients
valued continuity under the centre where they were treated due to prior positive
experience and the importance of being seen at a tertiary centre renowned for
its expertise in MM. This influenced acceptability of TC as long as they remained
under the centre’s care with preference for continuity of staff involved. Whilst
TC was acceptable for patients in remission, some were concerned about how
relapse would be managed and expressed preference for FTF when being told
they had relapsed.
Summary/Conclusions: Nurse led TCs are an acceptable alternative to FTF
consultations for monitoring patients in remission from MM. Design of health-
care systems incorporating TCs need to have robust systems for accessing
blood test results, for managing relapse, ready access to doctors and reassur-
ance about the competence and knowledge of practitioners involved.
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COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF
CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE
LYMPHOBLASTIC LEUKEMIA
J. Nam1, M. Geirnaert2, R. Milenkovski1, K. Paulson3,4, S. Yunger1, M. Seftel3,4,*
1Hoffmann-La Roche Limited, Mississauga, 2Provincial Oncology Drug Pro-
gram, 3Haematology and Medical Oncology, CancerCare Manitoba, 4Internal
Medicine, University of Manitoba, Winnipeg, Canada
Background: In The Group for Research on Adult Acute Lymphoblastic
Leukemia Rituximab (GRAALL-R) study, the addition of the anti-CD20 mono-
clonal antibody rituximab to standard chemotherapy for Philadelphia chromo-
some negative, CD20-positive, B-cell precursor Acute Lymphoblastic Leukemia
(CD20+ Ph- BCP-ALL) resulted in improved clinical outcomes. However, the
cost-effectiveness of rituximab for this indication has not been previously eval-
uated. We examined this question in the context of the Canadian publicly fund-
ed health care system.
Aims: To determine the economic impact in Canada of the addition of rituximab
to standard of care (SOC) chemotherapy vs SOC alone in newly diagnosed
CD20+ Ph- BCP-ALL.
Methods: Standard of care consisted of the two most widely used chemother-
apy regimens for adults with ALL in Canada: hyper-CVAD or the Dana Farber
Cancer Institute (DFCI) ALL consortium. A decision analytic model included
the following health states over a 15-year time-horizon: event-free survival,
relapsed/resistant disease, cure (death from causes other than ALL, given ≥5
years EFS) and death. Event-free survival, overall survival and serious adverse
event (SAE) rates were taken from the GRAALL-R randomized controlled trial
by Maury et al. Costs of the model included: first-, second- and third-line treat-
ment and administration; disease management; palliative care; and SAE-relat-
ed treatments. Model inputs were sourced from public data, literature and
provincial cancer agency input.  Results are presented using probabilistic sen-
sitivity analysis and Monte Carlo simulation incorporating uncertainty around
all model inputs. 
Results: Life years increased by 1.33 years (95%CI: 0.10-2.63 years) with rit-
uximab in addition to SOC vs SOC alone. Quality-adjusted life-years (QALYs)
increased by 1.15 QALYs (95%CI: 0.34-1.93 QALYs) with rituximab in addition
to SOC. The incremental cost of rituximab plus SOC was C$46,624 (95%CI:
C$28,881-C$64,515), chiefly due to the drug acquisition costs of rituximab.
Superior relative EFS associated with rituximab in addition to SOC drove lower
second-line treatment and palliative care use, resulting in modest cost savings. 
The resulting mean Incremental Cost-Effectiveness Ratio (ICER) was
C$40,505/QALY. At a willingness-to-pay threshold of C$100,000/QALY, the
probability of being cost-effective was 96%. Decision outcomes were robust to
the probabilistic and deterministic sensitivity analyses, including the SOC back-
bone as either hyper-CVAD or DFCI.
Summary/Conclusions: For adults with CD20+ Ph- BCP-ALL, rituximab in
addition to SOC is a cost-effective intervention compared to SOC alone, from
a Canadian public payer perspective. Rituximab is associated with increased
life years and increased QALYs at a reasonable incremental cost.
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THE THERAPEUTIC UTILITY OF A SYSTEMATIC PROTOCOL FOR GERIATRIC
ASSESMENT IN ONCOHEMATOLOGIC PATIENTS
C. Terán 1,*, A. Hormigo 2, R. Cordoba 1, M. Jarana3, M. Perez3, C. Plaza3,
P. LLamas1
1Hematology, 2Geriatrics, 3Oncohealth, Fundacion Jimenez Diaz, Madrid,
Spain
Background: The prevalence of hematological malignancies has increased
overtime especially in the older population. In the era of immunochemotherapy
and targeted therapy, it is important to have a multidimensional and comprehen-
sive assessment that allows the identification of those subsidiaries to intensive
therapeutic measures or a more conservative approach. To choose the best
treatment for these patients, a geriatric hematology program has been launched.
Aims: Evaluate the utility of the comprehensive geriatric assessment (CGA) in
patients with hematologic malignancies on the initial therapeutic decision mak-
ing. Determine frailty prevalence and short - mid term prognostic impact using
a screening tool for its identification.
Methods: Patients diagnosed with hematological malignancies were followed
prospectively. Patients age 70 and over were referred to hematological nursing
consultation. G8 screening tool was used to identify frailty risk. Patients with
G8 score <14 were referred for a complete medical consultation in Geriatric
Oncology Clinic for carrying out the CGA. In the comprehensive geriatric
assessment, the clinical information obtained included: physical, mental, social
and nutritional assessments, as well as an additional screening on geriatric
syndromes. The regular medication was reviewed based on the STOPP/START
criteria. The patients were classified in 3 categories according to the Balducci
classification: 1) Fit, 2) Fragile and 3) Poor prognostic.
Results: We have included 32 patients in the last 9 months, with an average
age of 81 (71-89) years. 56% of the sample was female. The main hematolog-
ical malignancy referred was high grade non-Hodgkin lymphoma (59%). At the
time of the evaluation, 87% had ECOG 1 and 56% EuroQoL score of 80. The
social, functional and mental profiles are shown in Table 1. According to
polipharmacy and comorbidities, data are shown in Table 2. The distribution of
patients by frailty scales, are described in Table 3. 56% of the patients were
classified as robust, 35% fragile and the rest with poorly prognosis. After the
evaluation we recommended nutritional measures, control of the polypharmacy
and physical exercise. Of the included patients, 22 had been reviewed at 6
months staying alive 95%. 24% required hospitalization after the initial assess-
ment and 13% went to the emergency department.
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Summary/Conclusions: Our population had a high score of comorbidity and
polypharmacy with a high median age. Nevertheless, 9% of the patients ben-
efited from the treatment. In 34% of the cases, the treatment was adjusted
because of the frailty criteria. 95% were alive and without clinical impairment.
All these findings support the importance of the comprehensive geriatric assess-
ment in the inicial evaluation of elderly patients with hematological malignan-
cies.
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RADIATION EXPOSURE FROM CT IMAGING AND CHILDHOOD
LEUKEMIA: A NATIONWIDE CASE-CONTROL STUDY
A. Nikkilä1,*, J. Raitanen2,3, O. Lohi4, A. Auvinen2,4,5
1Faculty of Medicine and Biosciences, 2Faculty of Social Sciences, University
of Tamepre, 3UKK Institute for Health Promotion, 4Tampere Center for Child
Health Research, Tampere University Hospital and University of Tampere, Tam-
pere, 5STUK - Radiation and Nuclear Safety Authority, Helsinki, Finland
Background: Pediatric CT imaging offers significant benefits in clinical practice.
However, children are more sensitive to carcinogenic effects of ionizing radiation
than adults and red bone marrow is especially radiosensitive tissue type. The
risk estimates of low doses of ionizing radiation are mainly1,2 based on extrap-
olated results of studies done with substantially higher radiation doses and
there exists a need to assess the risks of low doses with a more direct approach. 
Aims: We assessed the leukemia risk in children after computed tomography
imaging studies with high-quality Finnish register data and data from hospital
databases.
Table 1.
Methods: We used nationwide, register-based case-control study design to
investigate the role of CT imaging in the etiology of childhood leukemia. We
identified all childhood (0-15 years) leukemia cases from 1990 to 2011 (N=1093)
in Finland and randomly selected thrice as many controls (N=3279) from the
Population Registry, individually matched by gender and year of birth. The
cases were 81% (N=885) acute lymphoblastic leukemias and 13% (N=142)
acute myeloid leukemias. We collected data on all pediatric CT scans from
1975–2011 from the databases of all five university hospitals in Finland and
two large central hospitals. In total, we identified 46 CT scans to our subjects.
We approximated that this approach covers 81% of all pediatric CT scans per-
formed in Finland from 1975 to 2011. We used a two-year latency period to
avoid reverse causation. Conditional logistic regression analyses were adjusted
for birth weight (large for gestational age) to control confounding. Cases with
Down syndrome were excluded from the analyses.
Results: Overall, 13 cases (1.2%) and nine controls (0.3%) had a record indi-
cating at least one CT examination. Of the relevant CT scans, 50% were per-
formed on the head region and 41.3% the thorax region. The median age at
CT scan was 8.12 years (7.46 years for cases and 10.0 years for controls). 
In a conditional logistic regression analysis adjusted for birth weight, a signifi-
cantly increased leukemia risk (OR=4.75, 95% CI 1.55, 14.5) was found for
any CT examination (one or more) at least two years prior to leukemia diagno-
sis. When comparing one CT examination and two or more CT examinations
with no examinations the ORs were respectively 2.78 (95% CI 0.73, 10.5) and
16.9 (95% CI 1.91, 150).
Summary/Conclusions: In our preliminary analyses we observed a substantial
increase in childhood leukemia risk related to pediatric CT scans. The risk esti-
mates are materially higher than in two earlier studies1,2 and need to be inter-
preted with caution. We will seek to estimate radiation doses to the red bone
marrow, based on limited data available on CT examinations (body part and
examination type).
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HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO
PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED,
DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/
REFRACTORY MULTIPLE MYELOMA (RRMM)
P. Hari1,*, H.M. Lin2, Y. Zhu2, D. Berg2, P. Richardson3, P. Moreau4
1Medical College of Wisconsin, Milwaukee, 2Millennium Pharmaceuticals Inc.,
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Background: Treatment paradigms for RRMM have evolved in recent years
with the approvals of multiple novel agents and evidence of benefits for using
triplet vs doublet therapy and continuous treatment until progression. With more
complex regimens and longer treatment duration, costs of treatment and health-
care resource utilization (HRU) are expected to increase, with IV agents having
a greater impact on treatment burden than oral agents. The oral proteasome
inhibitor ixazomib is approved in the US, EU, and multiple countries worldwide,
in combination with lenalidomide-dexamethasone (Rd), for the treatment of
RRMM patients (pts) following at least 1 prior therapy. Approval was based on
the phase 3 TOURMALINE-MM1 study of ixazomib-Rd vs placebo-Rd, which
demonstrated significantly improved progression-free survival (PFS; median
20.6 vs 14.7 months, HR 0.74) with ixazomib-Rd, with limited additional toxicity
and no adverse impact on patient-reported quality of life (QoL; Moreau et al, N
Engl J Med 2016).
Aims: HRU was an exploratory endpoint of the TOURMALINE-MM1 trial. The
aim of this analysis was to compare HRU with ixazomib-Rd vs placebo-Rd,
incorporating all non-protocol additional medical care encounters such as inpa-
tient and outpatient admissions and their duration, as well as time lost from
work or other activities by pts and their caregivers.
Methods: 722 RRMM pts with 1-3 prior lines of therapy received ixazomib 4mg
(n=360) or matching placebo (n=362) on days 1, 8, and 15, plus lenalidomide
25mg on days 1-21 and dexamethasone 40mg on days 1, 8, 15, and 22, in 28-
day cycles until disease progression or unacceptable toxicity. The primary end-
point was PFS. HRU was assessed on day 1 of each cycle prior to treatment
and every 4/12 weeks during PFS/overall survival follow-up. After a median
follow-up of ~23 months, pts had received a median of 17 (range 1-34) and 15
(1-34) cycles of ixazomib-Rd and placebo-Rd, respectively; HRU data are
reported from this analysis time point.
Table 1.
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Results: Overall, 152 (42%) pts on the ixazomib-Rd arm had 316 hospitaliza-
tion events, compared to 156 (43%) pts (335 events) on the placebo-Rd arm.
Exposure-adjusted hospitalization rates (0.530 and 0.564 per pt-year [ppy],
respectively) and mean length of stay (10 and 10.8 days) were similar between
the ixazomib-Rd and placebo-Rd arms (Table 1). Rates of outpatient visits
were also similar between arms; 217 (60%) pts on the ixazomib-Rd arm had
1971 visits (median 4) compared to 198 (55%) pts and 1994 visits (median 5)
on the placebo-Rd arm. Exposure-adjusted outpatient visit rates were 3.305
and 3.355 ppy, respectively (Table 1). On the ixazomib-Rd arm, 46 (13%) pts
missed a total of 527 (median 7) days of work or other activity, compared to 51
(14%) pts and 580 (median 8) days on the placebo-Rd arm. Similarly, 16 (4%)
pts’ caregivers missed 128 (median 5) days of work or other activity on the ixa-
zomib-Rd arm, compared to 24 (7%) pts’ caregivers and 110 (median 4) days
on the placebo-Rd arm.
Summary/Conclusions: The ixazomib-Rd triplet regimen did not add to the
HRU burden compared to the placebo-Rd doublet, while prolonging PFS.
These findings are consistent with the limited additional toxicity burden and
the reported lack of an adverse impact on QoL with ixazomib-Rd. In contrast
to findings reported for injected agents (Armoiry et al, J Clin Pharm Ther 2011;
Gaultney et al, J Clin Pharm Ther 2013; Baz et al, Support Care Cancer 2015),
this all-oral triplet regimen did not increase time lost from work, caregiver bur-
den, or the number of inpatient/outpatient visits.
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G. Scerbo6, O. Annibali1,*
1UOC Ematologia Trapianto di Cellule Staminali, University Campus Bio-
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Background: Lymphoproliferative disorders (LD) represent a major burden of
hematologic malignancies generally treated and followed in Hematological Day
Hospital (DH). Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lym-
phoma (FL) are among the most frequent LD treated with chemo-immunother-
apies. These therapies are time consuming and costing and may affect the
Quality of Life (QoL) of these patients because of their prolonged stay in DH.
Aims: To evaluate, in patients with DLBCL and FL, the economic and social
impact of subcutaneous Rituximab administration.
Methods: From March 2016 to December 2016, we investigate in DLBCL and
FL, the management advantages of subcutaneous rituximab administration
compared to the intravenous formulation. During one week we evaluate in 40
patients the time of intravenous and subcutaneous administration, the type of
treatment (rituximab combined or subsequent to chemotherapy, or in monother-
apy) and the time required by the pharmacy to prepare each formulation. More-
over, we collected and analyzed data about patients’ time expenditure in DH
until discharge. Collected data have been categorized as follows: time and
human resource employment; drug waste; safety for patient. In order to meas-
ure the effect on QoL of subcutaneous formulation, we administered a ques-
tionnaire of satisfaction to the patients affected by DLBCL and FL, and their 40
caregivers. Furthermore, we evaluated its role in the optimization of DH man-
agement in terms of time, professionals and economic expenditure and in
improving patients’ safety.
Results: Among the 40 patients, 55% were affected by DLBCL and 45% by
FL, 64% were males and 36% females; as for age 68% were over 60 years.
The questionnaire examined patient’s emotions and perceptions during ritux-
imab administration (anxiety, fear and pain), time required for infusion and
interference with daily activities. Overall, 98% of interviewed patients preferred
subcutaneous administration because less scared by this formulation and
because of the lower waste of time. Among the 40 interviewed caregivers 68%
were workers. They considered advantageous the subcutaneous formulation
because of the lower waste of time (90%) and the reduced number of workdays
lost (80% of workers). With the subcutaneous formulation, we observed a
reduction of 38% (equal to 17.5 hours) of time spent at hospital per cycle. How-
ever, nurses needed 23% lesser time to handle a patient per cycle (from 144
minutes to 111 minutes), earning 33 minutes/patient per cycle. Furthermore,
pharmacy spent 53% lesser time for drug preparation (from 40 minutes to 19
minutes), earning 21 minutes/patient per cycle. Finally, we observed a reduction
of clinical risk. As for the cost, using subcutaneous formulation, we saved
€254.25 for each dose, with a final saving of €61.021 in a year. Considering
that patients who underwent subcutaneous administration of rituximab did not
require DH admission, we saved additional for €24.000 for 2016, and caregivers
spared 112 work days.
Summary/Conclusions: Our investigation shows that subcutaneous formu-
lation of rituximab requires a lower psychological effort for both patients and
caregivers because of a reduced time of administration. In addition, it reduces
healthcare professionals and pharmacist’s workload, ensures a major safety
for patients, and allows an optimized use of DH armchairs. This brings to an
increased satisfaction of patients and caregivers. Moreover, the costs analysis
demonstrates a significant spending reduction improving planning of therapy
sessions and organization.
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EFFECT OF IMPROVEMENTS OF SURVIVAL, POPULATION AGING AND
IMWG´14 CRITERIA ON INCIDENCE AND PREVALENCE OF MULTIPLE
MYELOMA
V. Martínez-Robles1,*, B. Ballina1, S. Cerdá1, N. de las Heras1, M. Fuertes1,
L. Villalobos1, J.A. Rodríguez-García1, E. Fernando1
1Hematología, Complejo Asistencial Universitario de León, LEON, Spain
Background: There are some variables that can modify Multiple Myeloma
incidence of New Diagnosed (NDMM) and prevalence over the time: Past
decade shows a new demographic data in our society: the increment of
expectancy of life and an excellent performance status. In the last years we
have assisted to an amazing improvement in the management and expectancy
of life of Multiple Myeloma (MM) patients. Recent changes in criteria recom-
mendation by IMWG´14 to begin treatment in NDMM patients can increment
its incidence. New expensive but very effective and well tolerated antimyeloma
(antiMM) agents are in the center of attention of Hematologic and Public
Healthcare Systems. There are data of improvement of survival that can incre-
ment of prevalence.
Aims: We have analysed our data base and calculate incidence by sex, age
and three 5-years periods of time at diagnosis and obtain tendencies to get
ready for next decade of ageing people with best antimyeloma agents. We
have analysed prevalence of MM patients on last 7 years with cutoff date on
1st of November (2010 to 2016).
Methods: We retrospectively analysed the incidence of patients with new diag-
nostic of Multiple Myeloma (NDMM) from 1998 to 2012. (Fig.1). Then we divide
the cohort in several groups: sex and age at diagnosis (3 groups: <65, 66-75
and 75y) and in four 5-year (quinquennium) period of time (1998-2002, 2003-
07, 2008-12, 2013-NOV2016). (Fig. 2). We have calculated the incidence per
100000 inhab/year using census data of our Local Registry of Tumours of our
Public Health Area. Characteristics of patients:  n= 346. M/F: 206/140. Median
age at diagnosis: 74 years (Range: 39-100).
Results: A) INCIDENCE RATES (see Table). In the past IMW (Roma-
14#PO197) we reported incidence rates form 1998 to 2012. We observed a
constant increase of Annual Average of incidence from 4.57 cases/100000
inhabitants/ year from the 1st period to 6.15 in the last. Adjusted by Age Inci-
dence also increase from 14 to 18.5 cases in the O65 group. From 2013 to
Nov-2016 global and adjusted by age incidence remains similar to last years
data with 80 new cases in the 4 year-period (5,9 cases for global population
and 17,2 cases for over65 population). After IMWG´14 criteria to begin treat-
ment in NDMM the incidence was similar to the last 7 years (2008-12 period
plus 2013-14) Incidence with 37 NDMM cases (25 O65y group).
B) PREVALENCE RATES (PrevR):
• 2010. 74 patients alive. PrevR: 21.25 /100000 inhabit;
• 2012. 77 pats alive. PrevR: 22.2 /100000 inhabit;
• 2014. 84 pats alive. PrevR: 24.4/100000 inhabit;
• 2016. 103 pats alive. PrevR: 30.3 / 100000 inhabit.
Table 1.
Summary/Conclusions: Although we don´t observe substantial changes on
incidence rates of NDMM, we have noted an important rise on prevalence rates
of more than 40% from 2010 to 2016 (21.2 to 30.3 pats alive /100000
inhabit.) Several new antiMM drugs are available in the therapeutic arsenal
and probably increases the prevalence rates.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ISOLATED
EXTRAMEDULLARY RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA
IN CHILDREN
M. Gabelli1,*, C. Messina1, M. Zecca2, A.M. Rovelli3, F. Fagioli4, E. Lanino5,
C. Favre6, M. Rabusin7, A. Prete8, M. Ripaldi9, A.P. Iori10, G. Basso1, F. Porta11,
M. Caniglia12, P. Di Bartolomeo13, P. D’Angelo14, A. Bertaina15, F. Locatelli15
1Oncoematologia Pediatrica, Università di Padova, Padova, 2Oncoematologia
Pediatrica, Policlinico San Matteo, Pavia, 3Ematologia Pediatrica, Ospedale
San Gerardo, Monza, 4Oncoematologia Pediatrica, Ospedale Regina Margheri-
ta, Azienda Ospedaliero Universitaria, Torino, 5Centro Trapianti Midollo Osseo,
I.R.C.C.S. Giannina Gaslini, Genova, 6Oncoematologia Pediatrica, Azienda
Ospedaliero Universitaria Meyer, Firenze, 7Oncoematologia Pediatrica,
I.R.C.C.S. materno infantile Burlo Garofalo, Trieste, 8Oncologia ed Ematologia
pediatrica “Lalla Seragnoli”, Policlinico Sant’Orsola Malpighi, Bologna,
9Trapianto di Midollo Osseo, Azienda Ospedaliera Santobono Pausilipon,
Napoli, 10Reparto di Trapianto Allogenico, Divisione di Ematologia, Università
La Sapienza, Roma, 11Oncoematologia Pediatrica e Trapianto di Midollo Osseo
Pediatrico, Spedali Civili di Brescia, Brescia, 12Oncoematologia Pediatrica,
Azienda Ospedaliera di Perugia, Perugia, 13U.O.C. Ematologia Clinica,
Ospedale di Pescara, Pescara, 14Oncoematologia Pediatrica, A.R.N.A.S. Civi-
co, Di Cristina e Benfratelli, Palermo, 15Oncoematologia Pediatrica, I.R.C.C.S.
Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background: Although most children affected by Acute Lymphoblastic
Leukemia (ALL) are cured with current protocols, relapses still occur in the
bone marrow as well in extramedullary sites, mainly the central nervous system
(CNS) and the testis.
Aims: Optimal treatment for isolated extramedullary relapse (iEMR) is still con-
troversial. To address this issue, we collected data of patients treated with
hematopoietic stem cell transplantation (HSCT) for ALL iEMR from 19 centers,
members of the Italian Pediatric Onco-Hematology Association (AIEOP).
Methods: From 1990 to 2015, 281 children (1-18 years) underwent HSCT for
ALL iEMR in Italy. Informed consent was obtained from parents or legal
guardians. Treatment protocols were based on Berlin-Frankfurt-Münster (BFM)
Study Group concept, as well as definitions of iEMR, CNS relapse, and time of
relapse (very early/ early/ late). HSCT was performed in second complete remis-
sion (CR2) or subsequent remission (CR>2), even patients transplanted with
disease were included in the analysis. If a matched familiar (MFD) or a matched
unrelated donor (MUD) was available, HSCT was performed from one of these;
if not, the single center decided to perform autologous HSCT (Auto HSCT) or
haploidentical HSCT (Haplo HSCT).
Results: Of the 281 patients (203 male, 78 female) 167 presented relapse
confined to CNS, 73 to testis, 14 to mediastinum,11 to CNS + other sites and
18 to other organs. Thirty one percent of children experienced a late relapse,
34.5% an early relapse, 31% a very early relapse, for 3.5% the time of relapse
is not known. Ninety-seven patients underwent auto HSCT, 79 MFD HSCT, 75
MUD HSCT and 30 Haplo HSCT. At transplantation 72.6% of children were in
CR2, 21.0% in CR>2 and 6.4% were not in remission Total body irradiation
(TBI) was part of 83.6% of conditioning regimens. Overall survival (OS) for the
entire cohort was 56% at 10 years and was not influenced by sex, lineage,
age, site of relapse, length of first remission, HSCT type (Auto vs MFD vs MUD
vs Haplo). Patients transplanted in CR2 had the better OS (64%), those in
CR>2 showed an OS of 44%, those transplanted with disease had an OS of
11% (p<0.0001). For HSCT performed before 2000 the OS was 45%, after
2000 was 63% (p 0.0009). TBI containing regimen yielded a better OS (59%)
then regimens without TBI (40%) but this difference was not statistically signif-
icant (p 0.069). TRM for the entire cohort was 10% at 100 days, 11% at 6
months and 1 year and 16% at 10 years, with no difference between HSCT
types. Multivariate analysis was conducted after exclusion of patients with active
disease at HSCT: the only factors influencing outcome were number of CR and
year of transplantation. Patients in CR>2 have a risk of death 2.3 times greater
than those in CR2. Children treated after 2000 have half the risk of death then
those treated from 1995 to 2000.
Summary/Conclusions: In this study we present the largest series of patients
with ALL iEMR treated with HSCT with a very long follow up. Comparison with
published chemo/radiotherapy approaches is favorable, especially for early
and very early relapse: in fact the use of HSCT seems to abrogate the impact
of some “classical” negative risk factors. Our results suggest that both autolo-
gous and allogenic HSCT are efficient treatments for ALL iEMR. Data from con-
temporary treatment protocols, that include MRD assessment to better stratify
the patients, will further clarify the role of HSCT in the treatment of
extramedullary relapses.
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PREDICTIVE FACTORS FOR DEVELOPING VENO-OCCLUSIVE DISEASE
IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH
INOTUZUMAB OZOGAMICIN FOLLOWED BY ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
P. Kebriaei1,*, R. Saliba1, W. Wallis2, R. Garris3, C. Ledesma1, G. Rondon1,
U. Popat1, A. Alousi1, S. Ahmed1, B. Oran1, E. Shpall1, S. Ciurea1, F. Ravandi3,
K. Rezvani1, D. Marin1, R. Champlin1, H. Kantarjian3, E. Jabbour3
1Stem Cell Transplantation and Cellular Therapy, 2Pharmacy Clinical Programs,
3Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, United
States
Background: Inotuzumab ozogamicin (IO) is a CD22 monoclonal antibody
attached to calicheamycin and targets B lymphocytes in early stages of devel-
opment. In a randomized study of IO compared with conventional salvage ther-
apy in patients with refractory relapsed B-ALL, patients treated with IO had
higher complete response rates (81% vs 29%, p<0.001), and a greater propor-
tion of patients proceeded to allogeneic hematopoietic stem cell transplantation
(SCT) (41% vs 11%, p<0.001). However, patients treated with IO prior to SCT
were also noted to have higher rates of veno-occlusive disease (VOD) com-
pared to the SCT group without IO exposure (11% vs 1%) (Kantarjian NEJM
2016).
Aims: In efforts to further investigate this finding, we reviewed transplant out-
comes for patients with and without IO exposure.
Methods: We performed a nested control comparison of patients transplanted
during the years when they were being treated with IO on a number of clinical
trials at our institution.
Results: Between 6/2010 and 10/2016, 251 patients with B-ALL with a median
age of 35 years (range, 4-70 years) received an allogeneic matched sibling
(n=85), matched- or 1-antigen mismatched unrelated (n=90), haplo-identical
(n=38), or cord blood donor SCT (n=38) in CR1 (n=103), CR2+ (n=105), or
with active disease (n=43). Patients received largely myeloablative regimens
(82%) that were busulfan- (64%), fludarabine- (29%) or total body irradiation-
based (TBI) (7%). 19% of patients received double alkylator regimens consist-
ing of cyclophosphamide-TBI, fludarabine-melphalan-thiotepa, or busuflan-clo-
farabine-thiotepa. IO was administered to 69 (27%) patients prior to SCT. A
median of 3 cycles of IO were administered (range, 1-5 cycles) at a median of
35 days from SCT (range, 11-254 days). Patients were heavily pre-treated,
including 18 who had a prior allogeneic SCT. VOD was noted in 21 patients
overall (8%) with median onset 19 days following SCT (range, 7-230 days);
fatal VOD was noted in 5 patients (2%). VOD was noted in 11 patients treated
with IO (16%), and it was fatal in 2 patients (3%). Factors noted to be significant
in contributing to VOD in univariate analysis were prior exposure to IO (HR
3.05, 95% C.I. 1.3-7.2, p=0.01) and receiving a busulfan-based transplant
preparative regimen (HR 3.4, 95% C.I. 1.02-12, p=0.05); not receiving a prior
SCT was significantly protective (HR 0.3, 95% C.I. 0.1-0.8, p=0.02). Number
of IO cycles, time from IO to SCT, age, and donor relation were not found to be
significant factors for developing VOD. In efforts to predict the risk for VOD in
a patient who has received prior IO, we performed a classification and regres-
sion tree analysis (CART) and noted that the combination of IO and a double
alkylator preparative regimen was significantly associated with the risk for devel-
oping VOD (HR 5.9, 95% C.I. 1.9-18, p=0.002).
Summary/Conclusions: Fatal VOD is a rare occurrence. However, IO expo-
sure prior to SCT increases the risk for any VOD. Furthermore, IO exposure
followed by a double alkylator preparative regimen increases this risk nearly 6-
fold, and should be avoided in these patients.
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DEFIBROTIDE EFFICACY AND SAFETY IN PATIENTS WITH HEPATIC
VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME
(VOD/SOS) DIAGNOSED AFTER DAY 21: ANALYSIS OF FINAL DATA
FROM AN EXPANDED-ACCESS PROGRAM
P. Richardson1,*, A. Smith2, B. Triplett3, N. Kernan4, S. Grupp5, J. Antin6,
L. Lehmann7, S. Giralt8, R. Ryan9, R. Hume9, W. Tappe9, R. Soiffer7
1Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy,
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Med-
ical School, Boston, 2Division of Pediatric Blood and Marrow Transplantation,
University of Minnesota, Minneapolis, 3Bone Marrow Transplantation and Cel-
lular Therapy, St. Jude Children’s Research Hospital, Memphis, 4Pediatric BMT
Service, Memorial Sloan Kettering Cancer Center, New York, 5Pediatric Oncol-
ogy, The Children’s Hospital of Philadelphia, Philadelphia, 6Stem Cell/Bone
Marrow Transplantation Program, Division of Hematologic Malignancy, Depart-
ment of Medical Oncology, Dana-Farber Cancer Institute, 7Center for Stem
Cell Transplantation, Division of Hematologic Malignancy, Department of Med-
ical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston,
8Memorial Sloan-Kettering Cancer Institute, New York, 9Jazz Pharmaceuticals,
Inc., Palo Alto, United States
Background: Hepatic VOD/SOS is a potentially life-threatening complication
of conditioning for hematopoietic stem cell transplant (HSCT). VOD/SOS with
multi-organ dysfunction (MOD) may be associated with >80% mortality.
Although VOD/SOS typically begins <21 days post-HSCT (per Baltimore/mod-
ified Seattle criteria), late-onset VOD/SOS has been reported in 15%>20% of
cases, sometimes after hospital discharge. The European Society for Blood
and Marrow Transplantation (EBMT) proposed new criteria for adults including
late-onset VOD/SOS (>21 days post-HSCT) by Baltimore criteria, histological
evidence of VOD/SOS, or a version of Baltimore criteria using ≥2 of: bilirubin
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≥2mg/dL, painful hepatomegaly, weight gain >5%, or ascites—plus mandatory
hemodynamic/ultrasound evidence of VOD/SOS. Defibrotide (DF) is approved
to treat severe hepatic VOD/SOS post-HSCT in the EU, and for hepatic
VOD/SOS with renal or pulmonary dysfunction post-HSCT in the US.
Aims: This is an analysis of DF efficacy and safety in patients (pts) with late-
onset VOD/SOS using final data from an expanded-access study.
Methods: The original expanded-access protocol required VOD/SOS per Bal-
timore criteria or biopsy by Day+35 post-HSCT, with MOD (renal/pulmonary)
by Day+45. The study was amended to include pts with later-onset VOD/SOS,
with or without MOD; VOD/SOS per modified Seattle criteria; and VOD/SOS
after chemotherapy alone. Pts provided informed consent and received DF
25mg/kg/d (6.25mg/kg q6h) for a recommended ≥21 days. “Late-onset” in this
post-hoc analysis was defined as diagnosis >21 days post-HSCT; hemody-
namic/ultrasound data (EBMT criteria) were not available.
Results: Of 1000 HSCT pts with a confirmed diagnosis of VOD/SOS and receiv-
ing ≥1 dose of DF, 264 (26.4%) had late-onset VOD/SOS, of whom 139 (52.7%)
had MOD. By age group, 95/264 (36.0%) were pediatric (aged ≤16 years; 51/95
[53.7%] with MOD) and 169/264 (64.0%) were adults (aged >16 years; 88/169
[52.1%] with MOD). Kaplan-Meier estimated survival at Day +100 (Figure) was
52.8% (95% CI, 46.5%–58.7%) across all HSCT pts and 43.9% (95% CI,
35.4%–52.0%) for pts with MOD; for pediatric pts, this was 60.4% (95% CI,
49.5%–69.7%) overall and 45.4% (95% CI, 31.0%–58.6%) for pts with MOD;
for adults, Day +100 survival was 48.7% (95% CI, 40.9%–56.0%) overall and
43.0% (95% CI, 32.5%–53.0%) for pts with MOD. Adverse events (AEs)
occurred in 75.4% of the total group (80.6% with MOD); 70.5% of pediatric pts
(76.5% with MOD); 78.1% of adults (83.0% with MOD). Treatment-related AEs
(TRAEs) occurred in 20.8% overall (23.7% in those with MOD); 21.1% of pedi-
atric pts (23.5% with MOD); 20.7% of adults (23.9% with MOD). The most com-
mon TRAEs (>3%) were epistaxis, pulmonary hemorrhage, gastrointestinal
hemorrhage, and hematuria (each in <5% of pts). For TRAEs leading to study
discontinuation (n=25) or death (n=10), the most common was pulmonary hem-
orrhage.
Figure 1.
Summary/Conclusions: In this study, diagnostic criteria requiring onset by
day 21 would exclude >26% of pts with VOD/SOS, with more than a third of
these being pediatric pts. This highlights the importance of including late-onset
VOD/SOS in diagnostic criteria. With DF, 52.8% were estimated to survive to
Day +100 (60.4% of pediatric and 48.7% of adult pts). TRAEs for these sub-
groups were similar to the overall study results. Factors contributing to survival
in these pts is a potential area for future exploration.
Support: Jazz Pharmaceuticals.
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ALLO-HCT FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA-12
YEARS OF EXPERIENCE
M. Markiewicz1,*, M. Dzierzak-Mietla1, M. Rybicka-Ramos1, A. Koclega1,
K. Bialas 1, E. Mendek-Czajkowska2, S. Kyrcz-Krzemien1
1Hematology and Bone Marrow Transplantation, MEDICAL UNIVERSITY OF
SILESIA, Katowice, 2Hematology Department, Institute of Hematology and
Transfusiology, Warsaw, Poland
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired
clonal abnormality of hematopoietic stem cell leading to lack of phosphatidyli-
nositol glycoproteins, sensitizing cells to complement-mediated lysis. Despite
the efficient symptomatic treatment of hemolytic PNH with eculizumab, allo-
HCT is the only curative treatment for the disease, although outcomes pre-
sented in the past were controversial.
Aims: The aim of this study was to evaluate the safety and effectiveness of
allo-HCT in PNH.
Methods: We report 41 allo-HCTs: 37 from MUD and 4 from MRD performed
for PNH in 2004-2016. Median age of recipients was 29(20-62) years and
donors 30(19-53), median time from diagnosis to allo-HCT was 16(2-307)
months. Median size of PNH clone was 80% granulocytes (0.5%>100%). Indi-
cation for allo-HCT was PNH with aplastic/hypoplastic bone marrow (19 pts),
MDS (2 pts), overlapping MDS/aplasia (3 pts), severe course of PNH with
hemolytic crises and transfusion-dependency without access to eculizumab
(17 pts). Additional risk factors were Budd-Chiari syndrome and
hepatosplenomegaly (1 pt), history of renal insufficiency requiring hemodialyses
(2 pts), chronic hepatitis B (1 pt) and C (1 pt). The preparative regimen con-
sisted of treosulfan 3x14 g/m2 plus fludarabine 5x30mg/m2 (31 pts) or treosul-
fan 2x10 g/m2 plus cyclophosphamide 4x40mg/kg (10 pts). Standard GVHD
prophylaxis consisted of cyclosporine-A, methotrexate and pre-transplant ATG
in MUD-HCT. 2 pts instead of cyclosporine-A received mycophenolate mofetil
and tacrolimus. Source of cells was bone marrow (13 pts) or peripheral blood
(28 pts) with median 6.3x108NC/kg, 5.7x106CD34+cells/kg,
24.7x107CD3+cells/kg. Myeloablation was complete in all pts with median 9(1-
20) days of absolute agranulocytosis <0.1 G/l. Median number of transfused
RBC and platelets units was 9(0-16) and 8(2-18).
Results: All pts engrafted, median counts of granulocytes 0.5 G/l, platelets 50
G/l and Hb 10 g/dl were achieved on days 17.5(10-33), 16(9-39) and 19.5(11-
34). Acute GVHD grade I,II and III was present in 16, 7 and 3 pt, limited and
extensive chronic GVHD respectively in 11 and 3 pts. LDH decreased by
73%(5%>91%) in first 30 days indicating disappearance of hemolysis. 100%
donor chimerism was achieved in all pts. In 1 patient donor chimerism
decreased to 81% what was treated with donor lymphocytes infusion (DLI). 3
patients died, 1 previously hemodialysed pt died on day +102 due to nephro-
toxicity complicating adenoviral/CMV hemorrhagic cystitis, two other SAA
patients with PNH clone<10% died on days +56 due to severe pulmonary infec-
tion and +114 due to aGvHD-III and multi organ failure. Complications in sur-
vivors were FUO (10 pts), CMV reactivation (13), VOD (1), neurotoxicity (1),
venal thrombosis (1), hemorrhagic cystitis (4) and mucositis (8). 38 pts (92.7%)
are alive 4.2 (0.4-12) years post-transplant and are doing well without treat-
ment. Complete disappearance of PNH clone was confirmed by flow cytometry
in all surviving pts.
Summary/Conclusions: We conclude that allo-HCT with treosulfan-based
conditioning is effective and well tolerated curative therapy for PNH.
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A COMPARISON OF CLINICAL OUTCOMES BETWEEN MATCHED
SIBLING DONOR (MSD) AND UNRELATED DONOR (URD) STEM CELL
TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA
S.H. Shin1,*, S.S. Park2, Y.W. Jeon2, J.H. Yoon2, S.A. Yahng3, S.E. Lee2,
B.S. Cho2, K.S. Eom2, Y.J. Kim2, S. Lee2, C.K. Min2, H.J. Kim2, S.G. Cho2,
D.W. Kim2, W.S. Min2, J.W. Lee2
1Hematology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic
University of Korea, 2Hematology, Catholic Blood and Marrow Transplantation
Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University
of Korea, 3Hematology, Incheon St. Mary’s Hospital, College of Medicine, The
Catholic University of Korea, Seoul, Korea, Republic Of
Background: Allogeneic stem cell transplantation (SCT) using HLA-matched
unrelated donor (URD) has been usually regarded as a subsequent option in
patients with severe aplastic anemia (SAA), who have failed to immunosup-
pressive treatment (IST). However, recent improved outcomes of URD SCT
lead to its extended role for treating those lacking HLA-matched sibling donor
(MSD).
Aims: Through this study, we intended to verify the possibility of URD SCT as
a front-line treatment for SAA patients.
Methods: We compared outcomes of consecutive SAA patients who received
SCT from 8/8 well-matched URD (WM-URD; n=61) and partially (6/8 or 7/8)
matched URD (PM-URD; n=33) with 8/8 matched MSD (n=126) at our institu-
tion between Mar 2002 and Dec 2016. Patients receiving MSD and URD SCT
were conditioned with fludarabine (180mg/m2) / cyclophosphamide (100mg/kg
IV) plus rabbit ATG (10mg/kg IV), and total body irradiation (fractionated
800cGy)/ cyclophosphamide (100-120m/kg IV) with/without rabbit ATG
(2.5mg/kg IV), respectively. 
Results: Median age of the WM-URD and the PM-URD groups were signifi-
cantly lower compared to that of the MSD group (29 yrs, 31 yrs, and 39 yrs; P
<0.01), with a high proportion of those experiencing IST failures before SCT
(80.3%, 90.9%, and 33.3%; P<0.01). Median days to neutrophil engraftment
of the MSD group was significantly shorter compared to those of the WM-URD
and the PM-URD groups (12 days, 16 days, and 16 days; P<0.01). The inci-
dences of acute and chronic GVHD of the WM-URD and PM-URD groups were
significantly higher compared to those of the MSD group (42.6% and 63.6% vs
9.5%; P<0.01, and 44.6% and 33.3% vs 8.9%; P<0.01, respectively). When
we compared the incidence of transplant-related mortality (TRM; 10.7% vs
7.4% at 6 yrs; P=0.53) and overall survival rate (OS; 89.3% vs 92.5% at 6 yrs;
P=0.52) between the WM-URD and the MSD groups, there were no significant
difference. However, trends of higher TRM incidence (18.2% vs 7.4% at 6 yrs;
P=0.05) and lower OS rate (81.8% vs 92.5% at 6 yrs; P=0.05) were observed
between the PM-URD and the MSD groups. There was no primary graft failure
in either group. Incidence of secondary graft failure of both WM-URD (0% vs
18.3%; P<0.01) and PM-URD (0% vs 18.3%; P=0.02) groups were significantly
lower compared that of the MSD group. When we adjusted other clinical and
transplant-related factors, which include age and IST failure, using multivariate
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analysis, the OS rate of the WM-URD group was not significantly different (HR
1.45, 95% CI; 0.52-4.09; P=0.48), whereas that of the PM-URD group was sig-
nificantly lower (HR 2.85, 95% CI; 1.01-8.02; P=0.04), compared to that of the
MSD group.
Summary/Conclusions: Our study showed that there was no significant dif-
ference in OS rate between the WM-URD and the MSD groups. As high inci-
dence of GVHD remains as a problem in the former group, strategies to reduce
it are needed in future protocols.
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HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT IN SEVERE
THALASSEMIA PATIENTS
S. Hongeng1,*, S. pakakasama1, U. anurathapan1, B. Andersson2
1Pediatrics, Ramathibodi hospital, Mahidol University, Bangkok, Thailand,
2Stem cell transplantation, MD Anderson Cancer Center, Houston, United
States
Background: Thalassemia free survival after allogeneic stem cell transplanta-
tion (SCT) is about 80–90% with either matched related or unrelated donors.
However, the probability of finding a HLA-compatible donor is less than 50%.
We explored the use of a mismatched related (“Haplo-”) donor.
Aims: To evaluate the outcome of SCT with Haplo donors in severe thalassemia
patients
Methods: All patients received two courses of pre-transplant immunosuppres-
sion therapy (PTIS) with fludarabine (Flu) 40mg/m2/d together with dexam-
ethasone (Dxm) 25mg/m2 for 5 d to facilitate engraftment. After two courses of
PTIS, a reduced-toxicity conditioning regimen of rabbit anti-thymocyte globulin
(ATG) 1.5mg/kg/d on days SCT -12,-11,-10, Flu 35mg/m2 on days SCT -7,-6,-
5,-4,-3,-2 and IV Busulfan (Bu) 130mg/m2 on days SCT
-7,-6,-5,-4 was given followed by T-cell replete peripheral blood progenitor cells
(PBPC). GVHD prophylaxis consisted of cyclophosphamide (Cy) 50mg/kg on
days SCT +3 and +4 (Post-Cy), and on day SCT +5 tacrolimus or sirolimus
was started together with a short course of mycophenolate mofetil.
Results: Fifty-one patients underwent haplo-SCT. Their median age was ten
years (range, 2 to 28 years). Forty-nine patients engrafted with 100% donor
chimerism. Two of five patients with high titers of donor-specific anti-HLA anti-
bodies suffered primary graft failure. Median time to neutrophil engraftment
was 14 days (range, 11 to 18 days). Eight patients developed mild to moderate,
reversible veno-occlusive disease, while twelve patients developed acute
GVHD grade II, that quickly responded to steroid therapy. Only seven patients
developed limited chronic GVHD. Projected overall and event-free survival
rates at two years are 95% and 94%, respectively. The median follow up time
is 18 months (range;10 to 50 months).
Summary/Conclusions: This haplo-SCT protocol may yield excellent out-
comes for thalassemia patients, and provide a treatment option for patients
lacking a HLA-matched donor.
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AUGMENTATION OF FLUDARABINE AND BUSULFAN-BASED
MYELOABLATIVE REGIMEN WITH THIOTEPA IMPROVES OUTCOMES
WITH NO ADDED TOXICITY IN ALLOGENEIC STEM CELL TRANSPLANTATION
FOR ACUTE MYELOID LEUKEMIA
V.S. Sheth1,*, N. Boaz1, S. Grisariu1, B. Avni1, R. Or1, M. Shapira1
1Stem cell transplant, HADASSAH, Jerusalem, Israel
Background: Allogeneic stem-cell transplantation (HSCT, allo-SCT) is the most
effective way to control leukemia relapse for patients with acute myeloid
leukemia (AML). Busulfan and Cyclophosphamide (Bu/Cy),the current standard
of care, in allogeneic transplant for acute myeloid leukemia (AML), is limited by
increased treatment related mortality. Myeloablative doses of Busulfan
(12·8mg/kg) with Fludarabine (160mg/m2) (Flu-Bu), has reduced toxicity, how-
ever with the limitation of increased relapses. We have tried to improve outcome
of Flu-Bu regimen by augmentation with Thiotepa (10mg/kg).  Here we com-
pared outcomes of 45 such patients (getting augmented regimen, Flu-Bu with
the addition of Thiotepa, (group 2), to 44 patients who received Fludarabine,
Busulfan myeloablative reduced toxicity regimen (group 1), during the same
period.
Aims: The primary objective of the report was to compare the toxicity and inci-
dence of relapse between the two regimens. Secondary objective was to com-
pare overall survival (OS), and disease-free survival (DFS), the non-relapse
mortality (NRM), engraftment kinetics, incidence of acute and chronic graft ver-
sus host disease (GVHD), and comparison between high and low-risk patients
amongst the two groups.
Methods: 89 patients with AML were retrospectively analyzed. 44 patients were
conditioned with Flu-Bu (group 1) and 45 patients augmented with Thiotepa
(Flu-Bu-TT, group 2). The transplant conditioning regimen, (augmented mye-
loablative) consisted of 30mg/m2 intravenous Fludarabine for 5 days (total dose
150mg/m2), for matched related donors or for 6 days (180mg/m2), for unrelated
or mismatched donors, intravenous Busulfan (3.2mg/kg/day for 4 days, total
dose 12.8mg/kg), and intravenous Thiotepa 5mg/kg for 2 days (10mg/kg). The
conventional myeloablative regime was identical, however without the addition
of Thiotepa.
Results: Toxicities were comparable, with mucositis in 7 patients (15%) in
group 1 and 8 patients (17%) in group 2, (p=1.0), severe sepsis in 4 (9%) in
group 1 and 3 (6%) in group 2, (p=0.7), severe venocclusive disease in 2% of
group 1 and 4% of group 2, (p=1.0) and comparable non- relapse mortality
(NRM), (p=0.7). 5-year disease free survival (DFS), (median follow up of 5
years), was significantly better in group 2, 38% for group 1, and 62% in group
2, (p=0.02) and 5-year overall survival showed trend towards benefit in group
2 (62% vs 42%, p=0.06). 14/30 (46%) patients in group 1 relapsed, as com-
pared to 4/31 patients, (12%, p=0.005) in group 2, considering NRM as com-
peting risk.
Figure 1.
Summary/Conclusions: In conclusion, the outcome of augmented regimen
(DFS and OS) is superior Flu-Bu regime, mainly due to reduction in relapses,
with comparable toxicities and could eventually replace Bu/Cy.
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PROGNOSTIC TOOLS CAN PROVIDE PERSONALIZED OUTCOMES
PREDICTION AFTER ALLOGENEIC HCT IN PATIENTS WITH HEMATOLOGIC
MALIGNANCIES
C. Cho1,*, S. Devlin2, P. Hilden2, M. Maloy1, M. Horowitz3, J.D. Rizzo3,
B. Logan3, P. Barba4, R. O’Reilly5, S. Giralt1, M.-A. Perales1
1Adult Bone Marrow Transplant Service, Department of Medicine, 2Department
of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center,
New York, NY, 3Medical College of Wisconsin and Center for International Blood
and Marrow Transplant Research, Milwaukee, WI, United States, 4Department
of Hematology, Hospital Vall d’Hebrón, Universitate Autònoma de Barcelona,
Barcelona, Spain, 5Bone Marrow Transplant Service, Department of Pediatrics,
Memorial Sloan Kettering Cancer Center, New York, NY, United States
Background: Current prognostic indices for allogeneic HCT (alloHCT) out-
comes often focus on a limited set of factors, be they patient characteristics,
disease features, or transplant approaches. We sought to evaluate two com-
prehensive prognostic models in a large sample of patients undergoing alloHCT
with CD34 selection (CD34 alloHCT).
Aims: To evaluate two comprehensive prognostic models: The first combining
the HCT-Comorbidity Index (HCT-CI) and Disease Risk Index (DRI); the second
applying the Center for International Blood and Marrow Transplant Research
(CIBMTR) One Year Survival Outcomes Calculator, which uses large-scale
multicenter data reported to the CIBMTR to provide patient-specific predictions
on survival 1 year after first alloHCT.
Methods: This retrospective analysis included adult recipients of first alloHCT
with CD34+ selected PBSCs from 7/8 or 8/8 donors for AML, ALL, or MDS at
a single center between 1/2000 and 12/2015. The Kaplan-Meier (KM) method
estimated OS and RFS. The cumulative incidence method for competing risks
estimated relapse and nonrelapse mortality. We evaluated univariate associa-
tion between variables of interest and OS/RFS using the log-rank test. Cox
regression models assessed the adjusted effect of covariates on OS/RFS. We
then determined predicted 1 year OS for each patient using the CIBMTR Cal-
culator. Patients were divided into groups based on predicted OS probability,
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in intervals of 5% +/- 2% (e.g. 65 +/-2% probability of survival at 1 year). Cor-
responding observed 1 year OS was then estimated for each group by the KM
method. A kernel smoother was used to visually display the average of
observed 1 year survival estimates over the continuous range of predicted OS.
Results: 506 patients with AML (n=290), ALL (n=72), or MDS (n=144) were
included. Of these, 470 patients (AML=263, MDS=141, ALL=66) had full data
available for the CIBMTR Calculator. On univariate and multivariate analyses,
DRI, HCT-CI, and age correlated with significant differences in OS/RFS, while
donor HLA match correlated with a significant difference in OS. Stratifying
patients based on a composite of DRI (low/intermediate vs high/very high) and
HCT-CI (0-2 vs 3+) revealed significant differences in OS/RFS between the 4
groups (Fig. 1). Compared with a reference group of patients with both low/inter-
mediate DRI and low HCT-CI, those with high DRI and low HCT-CI were at
greater risk of death (HR 2.30; 95% CI 1.39-3.81) and relapse or death (HR
2.50; 95% CI 1.55-4.05), more so than patients with a higher HCT-CI but still
low/intermediate DRI (HR death 1.80; 95% CI 1.34-2.43; HR relapse/death
1.68; 95% CI 1.26-2.24). When comparing predicted and observed survival,
KM estimates of 1 year OS fell within range of that predicted by the CIBMTR
Calculator in almost all groups (Fig. 1). In one group, patients had lower
observed 1 year OS than predicted (76%, 95% CI 62-93%, vs 85 +/- 2%,
p=NS). In this group, 29/30 patients (97%) had intermediate or high DRI; 59%
had poor prognostic AML/ALL by NCCN criteria (n=12, 44%) or other adverse
features such as minimal residual disease pre-HCT (n=4, 15%).
Figure 1.
Summary/Conclusions: Based on a large cohort of patients who underwent
CD34 alloHCT for acute leukemia or MDS, we demonstrate that DRI is a major
determinant of outcome. The CIBMTR Survival Outcomes Calculator predicts
1 year prognosis with relative precision, though some disease-risk features
not reflected in the Calculator may affect outcomes in patients with otherwise
good prognosis. Taken together, these prognostic models can assist in pre-
dicting outcomes and identifying patients most likely to benefit from CD34 allo-
HCT. Furthermore, applying the CIBMTR calculator analysis in individual cen-
ters may help identify patients with worse outcomes than predicted and guide
patient and/or HCT selection.
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THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION: IS THERE A PROTECTIVE ROLE FOR
URSODEOXYCHOLIC ACID?
R. Parody1,2,*, O. Lopez- Godino3, F. J. Marquez-Malaver4, I. García-Cade-
nas5, C. Martinez6, J.L. Piñana7, L. Lopez-Corral8, A. Esquirol9, R. Martino9,
F. Fernandez-Avilés6, M. Rovira10, C. Solano11, D. Caballero8, J.A. Perez-
Simón4
1Clinical Hematology, H.Universitario Virgen del Rocío, Seville, 2Clinical Hema-
tology, ICO-Duran i Reynals, Barcelona, 3Clinical Hematology, H.Universitario
de Salamanca, Salamanca, 4Hematology, H.Universitario Virgen del Rocío,
Seville, 5Hematology, H Santa Creu i Sant Pau, 6Hematology, H.Clinic,
Barcelona, 7Hematology, H.Clinico, Valencia, 8Hematology, H.Universitario de
Salamanca, Salamanca, 9Hematology, H.Santa Creu i Sant Pau, 10Hematol-
ogy, Hospital Clinic, Barcelona, 11Hematology, H.Clínico, Valencia, Spain
Background: Thrombotic microangiopathy (TMA) after allogeneic stem cell
transplantation (alloSCT) may be a severe complication associated with high
mortality. Since there is no standard treatment it would be helpful to have effi-
cacious prophylactic measures. Some data support the beneficial effect of
ursodeoxycholic acid (UDA) to prevent endothelial-cell damage.
Aims: We retrospectively analysed a total of 671 patients undergoing to
reduced intensity conditioning (RIC) alloSCT, comparing the occurrence of
overall TMA according with the use or not of UDA. 
Methods: Both uni and multivariate analysis were performed including patient
and transplant-related variables at the moment of transplant to analyse the
risk of developing TMA.
Results: Cumulative incidence for overall TMA was 4.8 (3.4-6.6) at 1 month,
10.1 (7.9-12.5) at 100 days, and 12.7 (10.3-15.4) at 180 days (figure 1). On
univariate analysis, TMA was more frequent in lymphoid malignancies, Flu-
darabine-melphalan based conditioning, unrelated donor, mismatched donor,
prophylaxis with sirolimus-tacrolimus (SRL/TKR), prior transplant and non-UDA
patients. The probability of overall TMA at 180 days in UDA patients was 9.6%
(95% CI: 5.9-14.3), versus 14.7% (95% CI: 11.7-18.1) in non-UDA patients.
On multivariate analysis the risk factors which remained statistically significant
were unrelated donor and the use of SRL/TKR, whereas the use of UDA sig-
nificantly decreased the risk of TMA (HR:0.4, 95% CI:0.2-0.8, p:0.01). Moreover,
in the subgroup of SRL/TKR, 100 days-cumulative incidence of TMA was 11.8%
(95% CI: 6.9-18.1) versus 25.6% (95% CI: 17.9-33.9) depending on the use or
not of UDA, respectively (p: 0.005), whereas in the subgroup of CNI/MTX 100d-
Cumulative incidence of TMA was 3.4%(95% CI: 0.6-10.6) vs 12.1(95% CI:7.1-
18.6) with and without UDA, respectively (p:0.05). 
Summary/Conclusions: In conclusion the use of UDA decreases the risk of
TMA after alloSCT regardless of type of immunoprophylaxis.
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FACTORS PREDICTING GRAFT VERSUS HOST DISEASE-FREE,
RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION.
COMPARISON ATTENDING TO TWO DIFFERENT DEFINITIONS AND
BENEFICT OF HAPLOIDENTICAL DONOR
O. Lopez Godino1, E. Pérez López1,*, S. Alonso Álvarez1, Ó. Ferré1, F. López
Cadenas1, N. Arratibel1, L. Vázquez1, M.D. Caballero1, L. López Corral1
1Hematology department, Hospital Universitario de Salamanca, Salamanca,
Spain
Background: Disease free survival is the most common used endpoint for
clinical research on allogeneic stem cell transplantation (HSCT), but it doesn’t
include morbidity endpoints or those which affect their quality of life as graft
versus host disease (GVHD). Recently, Blood and Marrow Transplant Clinical
Trials Network has proposed a composite endpoint: GVHD-free, relapse-free
survival (GRFS) for HSCT outcomes. This endpoint includes as event: III-IV
acute GVHD (aGVHD), relapse, death or chronic GVHD (cGVHD) requiring
systemic treatment. In 2016 EMBT annual meeting a redefinition of this end-
point was proposed changing cGVHD event from those patients with cGVHD
requiring systemic treatment (the original one) to those with just severe cGVHD
(the redefined one).
Table 1.
Aims: We had generated two composite endpoints: in both III-IV aGVHD,
relapse or death were considerated events but we defined GRFS1 as the one
with cGVHD event including those who required systemic treatment (as the
original one) and in GRFS2 just those with severe cGVHD (the EBMT redefined
one) and we had compared both. 
Methods: We retrospectively analysed 616 patients transplanted (1995-2016)
excluding non-malignant diseases, second allo-SCT and those <16 years old age.
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Results: Characteristics of patients are shown in table 1. With a median follow
up for patients alive of 39 months (3-221), the median estimated survival in
months and the % at +1 year and +2 years was: 114 months, 70% and 62%
overall survival (OS); 23 months, 57% and 49% event free survival (EFS); 6
months, 35% and 26% GRFS1; 11 months, 46% and 38% GRFS2. 147 (24%)
and 218 (35%) hadn’t any event in GRFS1 and in GRFS2 respectively. In
GRFS1, event’s incidence was: 90 (15%) for III-IV aGVHD, 170 (27%) for
cGVHD, 152 (25%) for relapse and 57 (9%) for death; In GRFS2 was 90 (15%),
65 (11%), 174 (28%) and 65 (11%) respectively. Considering those patients
with cGVHD as event in GRFS1, 105 of them hadn’t the event as cGVHD at
the same time in GRFS2 (since they had cGVHD requiring systemic treatment
but not severe cGVHD). For these patients, the alternative event in GRFS2
was: 72 without any event, 22 relapsed and 11 died. In the multivariate analysis,
factors associated with better outcomes were:for GRFS1 diagnosis (p=0,04;
benefit in NHL/HL/CLL p=0.02, HR 0.71; CI95% 0.53-0.95), >4 prior lines
(p=0.03, HR 1.5, CI95% 1.04-2.04,), early EBMT stage (p<0,001 with early as
reference; intermediate p=0,002, HR 1.5, CI95% 1.2-1.9; advance p<0,001,
2.0, 1.5-2.6), in vivo T-cell depletion (p=0.02, 0.6, 0.39-0.92) and haploidentical
donor (p=0.04 with HLA identical as reference, no significance 1 or 2 mismatch
[p=0.18], haploidentical p=0.02, 0.43, 0.25-0.74). Only early EBMT disease
stage maintained significance in GRFS2 (p<0,001 with early as reference; inter-
mediate p=0,005, 1.5, 1.1-1.9; advance p<0,001, 1.9, 1.4-2.6).
Summary/Conclusions: In our study the percentage of the GRFS endpoint
was similar to previously reported. Comparing both proposed definitions, the
GRFS2 endpoint define a higher population of patients without any event; so
that it is possible that t morbidity is misdiagnosed. The EBMT disease score
was the factor with more impact in both; it is interesting to point that although
the group is smaller, haploidentical donor is associated with better GRFS1. 
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EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF
HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYN-
DROME FOLLOWING HEMATOPOIETIC STEM CELL
TRANSPLANTATION: FINAL SUBGROUP RESULTS
P. Richardson1,*, A. Smith2, B. Triplett3, N. Kernan4, S. Grupp5, J. Antin6,
L. Lehmann7, S. Giralt8, W. Liang9, R. Hume9, W. Tappe9, R. Soiffer7
1Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy,
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Med-
ical School, Boston, 2Division of Pediatric Blood and Marrow Transplantation,
University of Minnesota, Minneapolis, 3Bone Marrow Transplantation and Cel-
lular Therapy, St. Jude Children’s Research Hospital, Memphis, 4Pediatric BMT
Service, Memorial Sloan Kettering Cancer Center, New York, 5Pediatric Oncol-
ogy, The Children’s Hospital of Philadelphia, Philadelphia, 6Stem Cell/Bone
Marrow Transplantation Program, Division of Hematologic Malignancy, Depart-
ment of Medical Oncology, Dana-Farber Cancer Institute, 7Center for Stem
Cell Transplantation, Division of Hematologic Malignancy, Department of Med-
ical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston,
8Memorial Sloan-Kettering Cancer Institute, New York, 9Jazz Pharmaceuticals,
Inc., Palo Alto, United States
Background: Hepatic veno-occlusive disease/sinusoidal obstruction syndrome
(VOD/SOS) is a potentially life-threatening complication of conditioning regi-
mens for hematopoietic stem cell transplant (HSCT) and may also occur fol-
lowing chemotherapy without HSCT. VOD/SOS with multi-organ dysfunction
(MOD) may be associated with >80% mortality. Diagnosis has traditionally been
based on the Baltimore criteria or modified Seattle criteria. Defibrotide is
approved for treating severe hepatic VOD/SOS post-HSCT in the European
Union and for treatment of hepatic VOD/SOS with renal/pulmonary dysfunction
post-HSCT in the United States. The defibrotide expanded-access protocol
was designed to provide access to defibrotide prior to its approval in the United
States and to collect additional data on safety and efficacy in a broader patient
population, including those with and without MOD, and following HSCT or
chemotherapy without HSCT.
Aims: This is an analysis of defibrotide efficacy and safety in the subgroup of
patients developing VOD/SOS following HSCT, using final data from the
expanded-access protocol.
Methods: The original expanded-access protocol required VOD/SOS diagnosis
by Baltimore criteria or biopsy post-HSCT, with evidence of MOD (renal/pul-
monary dysfunction). The study was amended to also include patients without
MOD (off-label), with VOD/SOS per modified Seattle criteria, and/or with
VOD/SOS following chemotherapy without HSCT (off-label). After patients pro-
vided informed consent, defibrotide treatment (25mg/kg/d in 4 divided doses of
6.25mg/kg) was recommended ≥21 days.
Results: This analysis of final data is based on 1000 patients enrolled from
2007–2016 who had confirmed VOD/SOS following HSCT and had received
≥1 dose of defibrotide. Of these patients, 512 (51.2%) had MOD. The median
age was 14 years (range 0.10–77.0), with 570 patients (57.0%) aged ≤16 years,
(281 [54.9%] of whom had MOD) and 430 patients (43.0%) aged >16 (231
[45.1%] of whom had MOD). Among pediatric patients, 28.2% were aged <1–
23 months, 52.5% aged 2–11 years, and 19.3% aged 12–16 years. Primary
diseases in ≥10% of the overall HSCT group were acute lymphocytic leukemia
(19.8%), acute myelogenous leukemia (26.1%), and neuroblastoma (10.5%).
Kaplan-Meier estimated Day+100 survival was 58.9% (95% confidence interval
[CI], 55.7%–61.9%) in the overall HSCT group (Figure), with rates of 49.5%
(95% CI, 45.0%–53.8%) in patients with MOD and 68.9% (95% CI, 64.5%–
72.9%) in patients without MOD. In patients aged ≤16 years, Kaplan-Meier esti-
mated Day +100 survival was 67.9% (95% CI, 63.8%–71.6%) and 47.1% (95%
CI, 42.3%–51.8%) in patients aged >16 years (Figure). In the overall HSCT
population, 210 patients (21.0%) had ≥1 treatment-related adverse event
(TRAE). TRAEs occurring in ≥2% of patients were pulmonary hemorrhage
(4.6%), gastrointestinal hemorrhage (3.0%), epistaxis (2.3%), and hypotension
(2.0%).
Figure 1.
Summary/Conclusions: This final analysis of the defibrotide expanded-access
protocol demonstrates favorable Day +100 survival (58.9%) in patients with
confirmed VOD/SOS following HSCT, and 49.5% in those with MOD, a compli-
cation typically associated with dismal outcomes. Survival and safety findings,
consistent with prior clinical trials, provide supportive evidence for the clinical
utility of defibrotide for treatment of VOD/SOS in patients with and without MOD.
Support: Jazz Pharmaceuticals.
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GENERATION OF IMMORTAL MURINE HEMATOPOIETIC STEM/PROGENI-
TOR CELL LINES FROM TRANSGENIC MICE
E. Doma1,*, A. Hölbl1, V. Sexl1
1Pharmakologie und Toxikologie, Veterinärmedizinische Universität Wien,
Wien, Austria
Background: Research on hematopoietic and leukemic stem cells (LSCs) is
currently limited as these cells are infrequent and their immortalization is hardly
achieved.
Aims: We aimed to establish a long term ex-vivo culture system that allows
maintenance and expansion of LSK (lin-, Sca-1+, c-Kit+) cells.
Methods: We adapted a technique described by the L. Carlsson lab and trans-
duced high-purity sorted murine LSKs with Lhx2, a LIM-homeobox transcription
factor, which has been reported to facilitate ex vivo expansion of immature
hematopoietic cells.
Results: Lhx2 expressing- hematopoietic progenitor cell (HPCLSK) lines require
SCF (stem cell factor) and IL-6 and they can be maintained in a feeder-inde-
pendent culture for more than 6 months. They preserve LSK markers despite
continuous proliferation. HPCLSK cells repopulate lethally irradiated mice and
re-feed the entire hematopoietic cell pool. HPCLSK cell lines were established
from a range of transgenic mice, underlining the overall applicability of this
model. Using this system, we established LSC lines that express BCR/ABLp210,
MLL-AF9;NrasG12D or Flt3-ITD; NrasG12D. These LSCs home to the bone mar-
row, differentiate into all lineages and drive myeloid leukemia in mice.
Summary/Conclusions: We created a robust method of expanding
hematopoietic stem/progenitor cells. They are immortailized and can be
expanded indefinitely. This tool allows analysis of the molecular mechanisms
controlling self-renewal in hematopoietic and LSCs as well as drug screening.
Our system may represent a breakthrough in (cancer) stem cell biology and
assist in the development of new therapeutic avenues to combat LSCs.
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INHIBITING BCL2 AND NK CELLS IMPROVES STEM CELL TRANSPLANT
OUTCOMES.
J. Davis1,2,*, Y. Jiao3,4,5, R. Koldej1,2, N. Huntington3,5, D. Ritchie1,2,6
1The ACRF Translational Research Laboratory, The Royal Melbourne Hospital,
2Department of Medicine, The University of Melbourne, 3Department of Molec-
ular Immunology, The Walter and Eliza Hall Institute, Melbourne, Australia,
4School of Medicine, Tsinghua University, Beijing, China, 5Department of Med-
ical Biology, The Walter and Eliza Hall Institute, 6Department of Clinical Oncol-
ogy and Haematology, The Royal Melbourne Hospital, Melbourne, Australia
Background: Allogeneic haematopoietic stem cell transplantation (alloHSCT)
is the most effective means of preventing relapse of blood cancers, in particular
AML. The curative potential of alloHSCT is largely due to the immune mediated
graft-versus-leukemia (GVL) effect, which in turn is dependent on the stable
engraftment of donor immunity. The dual challenge of alloHSCT is therefore to
allow sufficient donor engraftment for haematopoietic and immunological recon-
stitution that drives the GVL effect while limiting the toxicity of conditioning and
the onset of graft-versus host disease (GVHD). 
Aims: Optimize the use of BCL2 inhibitors to modify recipient NK cell function
in models of alloHSCT in order to minimize GVHD severity and onset.
Hypothesis: Therapeutic targeting of recipient NK cell frequency or function
pre-transplant will allow reduced intensity conditioning (RIC) and promote both
donor T cell engraftment and GVL whilst reducing the risks of GVHD.
Methods: We used a MHC-mismatched mouse model of alloHSCT, where
donor BM and T cells from BALB/c (H2Kd) mice were injected into irradiated
C57BL/6 (H2Kb) recipients. On day 0, C57BL/6 WT, or Bcl2fl/fl (Bcl2 deleted
in NKp46+NK1.1+ cells) recipients were irradiated with either a standard dose
of 2 x 600 rad, or 2 x 400 rad, before iv injection of 7.5e6 BALB/c BM + 1e6 T
cells. C57BL/6 WT mice were also treated on day -2 and -1 by oral gavage
with 100mg/kg ABT-199 or vehicle, before receiving alloHSCT. Mice were mon-
itored for onset of GVHD and tested for early engraftment (day 7-14 post-trans-
plant), and late engraftment (up to day 50). 
Results: We utilized genetic and pharmacological models of BCL2 deficiency
to establish the role of recipient NK cells as regulators of donor T cell engraft-
ment and GVHD. Conditional deletion of Bcl2 in NK cells results in a 90% loss
of NK cells in vivo. Bcl2fl/fl alloHSCT recipients showed robust donor engraft-
ment, but absence of the pro-inflammatory cytokine storm and substantially
less GVHD as determined by clinical scores and gut histology, with RIC com-
pared to WT recipients. Pharmacological inhibition of BCL2 in WT recipients
recapitulated the transplant findings in Bcl2fl/fl recipients. We found that BCL2
inhibition by Venetoclax (ABT-199), a BCL2 antagonist approved in the treat-
ment of AML, resulted in NK cell apoptosis in human cells. We extended our
observations in Bcl2fl/fl recipients to show that pharmacological inhibition of
BCL2 in WT mice with just two doses of ABT-199 resulted in rapid depletion of
NK cells. Our preliminary data indicates that alloHSCT WT recipient mice pre-
treated with ABT-199 develop full donor engraftment even in the setting of sig-
nificant RIC, with minimal GVHD.
Summary/Conclusions: Recipient NK cell inhibition may therefore represent
a means by which to deliver alloHSCT more safely by reducing conditioning
intensity and GVHD. 
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MESENCHYMAL STROMAL CELL IRRADIATION INTERFERES WITH THE
ADIPOGENIC/OSTEOGENIC DIFFERENTIATION BALANCE IMPROVING
THEIR HEMATOPOIETIC-SUPPORTING ABILITY
S. Preciado Pérez1,*, S. Muntion1, A. Rico1, R. Ortega1, I. Misiewicz-Krzeminska1,
L.A. Perez Romasanta1, J. Borrajo1, T. Ramos1, L.A. Corchete1, C. Rodriguez1,
M. Diez-campelo1, M. López-Parra1, A. Redondo1, L.I. Sanchez Abarca1,
M.C. Del Cañizo1, F. Sánchez-Guijo1
1IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain
Background: Mesenchymal stromal cells (MSC) are precursors of adipocytes
and osteoblasts in the bone marrow (BM) niche, and key regulators of the
hematopoietic process. After HSC transplantation, MSC remain of host-origin.
Total body irradiation has been widely used in conditioning regimen and MSC
are shown to be radio-resistant. Nevertheless, the functional effects of irradia-
tion on BM-MSC have not been extensively explored. 
Aims: The main objective was to evaluate the effects of irradiation on the MSC
in their hematopoietic-supporting capacity. 
Methods: Ten BM samples were obtained from healthy donors after informed
consent. MSC were obtained and characterized following standard procedures
until third passage. Then, one aliquot was gamma-irradiated with a single dose
of 2,5Gy whereas non-irradiated MSC from the same sample were used as
controls. MSC were characterized following ISCT criteria (flow cytometry and in
vitro differentiation stainings). Apoptosis was evaluated by flow cytometry using
annexinV/7AAD staining. Expression microarrays of irradiated and control-MSC
were performed using Human Gene 2.0 ST Array platform (Affymetrix). RT-PCR
of key genes involved in the hematopoietic supporting capacity as well as in the
differentiation of MSC into osteoblasts and adipocytes was performed in both
experimental groups. Finally, long term BM cultures (LT-BMC) were performed
as functional assays to test the hematopoietic-supporting ability of irradiated
and control MSC. For the latter experiments, CD34+ cells were isolated from
leukapheresis and seeded on stromal layers from non-irradiated or irradiated
MSC. CFU-GM colonies derived from the LT-BMC were scored weekly.
Results: Flow cytometric characterization of irradiated MSC was comparable
to that of control MSC. Similarly, there were no differences in the percentage
of viable cells between both experimental groups neither at one hour nor at
72h post irradiation, confirming once more the radio-resistance of MSC. In
addition, expression arrays did not show any statistically significant differences
in genes involved in hematopoiesis maintenance. However, upon comparing
the differentiation ability we interestingly observed that irradiated-MSC differ-
entiation was skewed towards osteogenesis whereas adipogenesis was
impaired. In this regard, irradiated-MSC had significantly higher SPP1 expres-
sion (involved in late osteogenic differentiation) and lower CBPA and PPAR-
gamma (both genes involved in adipogenesis) compared to control MSC. After
inducing in vitro differentiation, there were no differences in ALP and Alizarin
Red staining but the number of adipocytes per field at days 7, 14 and 21 was
significantly lower in irradiated MSC (p=0,018 p=0,046 and p=0,018). In addi-
tion, angiopoietin and SDF-1, key genes implicated in maintenance of
hematopoiesis, were significantly overexpressed in irradiated-MSC (p=0,043
and p=0,028, respectively). Finally, in the functional evaluation of the
hematopoietic-supporting ability of MSC by LT-BMC, we observed that the
number of CFU-GM colonies generated by the culture was significantly higher
in the irradiated group after 4 and 5 weeks (p=0.046 and p=0.018, respectively)
compared to the non-irradiated group. Furthermore, the number of adipocytes
per field was significantly reduced in the LTBMC.
Summary/Conclusions: Irradiation of MSC with 2,5Gy improves their
hematopoietic supporting ability and modifies their differentiation capacity,
increasing the osteogenesis and decreasing the adipogenesis.
Funding: PI12/01775 (ISCIII, Spain). Santander-USAL grant to SP.
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DYSFUNCTION OF BONE MARROW MESENCHYMAL STEM CELLS
FROM PATIENTS WITH PROLONGED ISOLATED THROMBOCYTOPENIA
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
CAN BE IMPROVED BY N-ACETYL-L-CYSTEINE
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Background: Prolonged isolated thrombocytopenia (PT), is a serious compli-
cation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and
defined as the engraftment of all peripheral blood cell lines other than a platelet
(PLT) count ≤20×10E+9/L or dependence on PLT transfusions for more than
60 days after allo-HSCT. Several clinical risk factors have been proposed to be
associated with PT after allo-HSCT. However, the underlying mechanisms
remain to be elucidated. Emerging evidence from mouse studies has suggested
that effective hematopoiesis depends on a particular bone marrow (BM)
microenvironment in which hematopoietic stem cells reside. MSCs represent
a key cellular component of the BM microenvironment, which are potential pro-
genitors for osteoblasts, adipocytes, chondrocytes, and marrow stromal cells.
The processes of megakaryocytopoiesis and thrombocytopoiesis result from
the interactions between hematopoietic progenitor cells, cytokines, and marrow
stromal cells derived from MSCs or MSCs directly. However, the functional role
of BM MSCs in the patients with PT has never been reported. Moreover,
approaches for improving the dysfunction of BM MSCs in patients with PT are
lacking.
Aims: To evaluated the number and function of BM MSCs in patients with PT
post-allotransplant. Moreover, to investigate the approach to enhance the num-
ber and function of BM MSCs derived from patients with PT and its underling
molecular mechanisms in vitro.
Methods: Three cohorts were included: patients with PT (N=25), patients with
good graft function (GGF, N=12), defined as persistent successful engraftment
after allotransplant, and transplant donors as normal controls (N=10). BM MSCs
were cultured as previous reported. All experiments were carried out using BM
MSCs derived from passages 2–4. The number and functions of BM MSCs
were evaluated by fibroblasts colony-forming unit (CFU-F) assay, cell prolifer-
ation assay and senescence-associated β-galactosidase (SAβ-gal) assay.
Reactive oxygen species (ROS) levels were evaluated by flow cytometry. Pro-
tein expression for p-p38, p38, p-p53, p53 was measured by flow cytometry
and western blots. To further investigate the potential effect for repairing the
dysfunctional BM MSCs, N-Acetyl-L-cysteine(NAC, a ROS scavenger) and
SB203580 (p38 inhibitor) were administrated to the BM MSCs from PT patients.
After 2 days in vitro culture, the number of SAβ-positive cells was counted, the
intracellular levels of ROS and p-p38 were evaluated in BM MSCs by flow
cytometry.
Results: Human BM MSCs were demonstrated as spindle shape and typical
immunophenotype of MSCs at day 21 of cultivation among subjects with PT,
GGF and normal controls. Cultures from all normal BM samples produced con-
fluent layers of adherent cells composed of spindled shaped cells. 2 of the 12
GGF BM and 15 of the 25 PT BM failed to produce any adherent layers within
3 weeks of culture. BM MSCs derived from PT patients expanded more slowly
and appeared flattened and larger. Proliferative capacity and CFU-F counts of
BM MSCs from PT patients were significantly reduced compared to those of
GGF patients and normal controls. Moreover, increased levels of ROS, which
was associated with increased number of SAβ-positive cells, were identified in
BM MSCs from PT patients. Intracellular p-p38 level was significantly elevated
in PT patients compared to those in GGF patients. After NAC treatment in vitro,
the proliferative capacity was increased significantly, whereas the number of
senescent cells, the intracellular levels of ROS and p-p38 were reduced
markedly in BM MSCs from PT patients. 
Summary/Conclusions: In summary, the current study demonstrated the num-
ber and the function of BM MSCs were abnormal in PT patients following allo-
HSCT. Moreover, NAC treatment in vitro can partially decreased the ROS level
and reversed the senescence phenotype through down-regulation of the p38
MAPK pathway. Our results indicate that the dysfunctional BM MSCs may play
an important role in the pathogenesis of PT following allo-HSCT and NAC rep-
resents a promising therapeutic approach for repairing the impaired BM MSCs
in PT patients post-allotransplant. 
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INHIBITORS OF APOPTOSIS PROTEINS (IAPS) MODULATE GASTROIN-
TESTINAL GVHD IN MURINE EXPERIMENTAL BMT MODELS
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Background: The two Inhibitors of apoptosis proteins (IAPs), X-chromosome-
liked linked IAP (XIAP) and cellular IAP1 (cIAP1), inhibit apoptosis and play an
important role in regulating innate and adoptive immunity. However, the role of
IAPs in allogeneic immune responses is not known.
Aims: We determined the role of IAPs in GVHD.
Methods: We utilized clinically relevant, well-characterized murine models of
allogeneic BMT. To chemically target IAPs, we utilized AT406 (SM-406), a
SMAC mimetic that actively antagonizes all IAPs.
Results: We first utilized AT406 which regulates TNFα in vitro. Given the GVHD
potentiating effects of TNFα, we hypothesized that AT406 will mitigate GVHD.
After we confirmed that AT406 reduced expression of IAPs in T cells or host
target tissues, we utilized B6→BALB/c MHC-mismatched BMT model. BALB/c
recipients were lethally irradiated and transplanted withsyngeneic or allogeneic
T cells along with bone marrow (BM). Both groups received either AT-406 or its
diluent. Contrary to our hypothesis, allo-recipients receiving AT-406 showed
worse GVHD. To understand the role of IAPs, we next utilized B6 background
XIAP and cIAP1 deficient animals. When donor T cells from B6-cIAP-/- or XIAP-
/- animals were compared to B6-WT T cells, the allo-recipients (BALB/c) showed
similar GVHD. Same results were also observed in another B6→F1 model.
Furthermore, in vitro studies showed that XIAP-/-and cIAP-/- T cells had com-
parable proliferation and cytokine secretion as WT-T cells. These data sug-
gested that increase in GVHD mortality following treatment with AT-406 is not
due to its effects on donor T cells. To further dissect the increased mortality
after AT-406 treatment, we hypothesized that the absence of IAPs in hosts may
impact on GVHD. To test this, cIAP-/-, XIAP-/- and WT-B6 animals were lethally
irradiated and transplanted with syngeneic (B6) or allogeneic (BALB/c) T cells.
Compared to WT recipients, both XIAP-/- and cIAP-/-recipients showed
increased mortality (p<0.001) and worse gastrointestinal (GI) GVHD. To explore
whether IAPs regulate GVHD through their expression exclusively in host
hematopoietic cells, we generated [B6→B6Ly5.2], [cIAP-/-→B6Ly5.2] and
[XIAP-/-→B6Ly5.2] chimeras and utilized them as recipients in 2nd allo-BMT in
BALB/c->B6 models. Both [cIAP-/-→B6Ly5.2] and [XIAP-/-→B6Ly5.2] showed
equivalent GVHD mortality to [B6→B6Ly5.2] chimeras. Consistently, dendritic
cells (DCs) from XIAP-/- and cIAP-/- animals showed similar functions as WT-
B6 in vitro, suggesting that IAP expression in host hematopoietic cells is not
critical. Next, to test the role of IAPs in non-hematopoietic GVHD target tissues,
we made the reverse chimeras, [B6Ly5.2→B6], [B6Ly5.2→XIAP-/-] and
[B6Ly5.2→cIAP1-/-], where IAPs are absent only in the non-hematopoietic host
cells. The allogeneic [B6Ly5.2→XIAP-/-] and [B6Ly5.2→cIAP1-/-] animals
demonstrated a significantly worse survival compared to WT [B6Ly5.2→B6]
recipient (p<0.01). To determine the potential mechanisms for exacerbating
GVHD, we tested tunel staining, and the expression of anti- and pro-apoptotic
genes (Bcl-2, BIM, BAL) and autophagy (LC3) in the CD326+ intestinal epithelial
cells from KO and WT animals after allo-BMT. The cIAP-/- and -XIAP-/- animals
showed increased number of tunel positive cells and significantly reduced
expression of anti-apoptotic protein Bcl-2 and LC-3 but equivalent expression
of pro-apoptotic proteins. In addition, the expression ratio of BIM or BAX to
Bcl-2 in allo-XIAP-/- animals was significantly increased. 
Summary/Conclusions: These data suggest that enhanced apoptosis in the
target tissues in the absence of IAPs contributes to greater GVHD severity.
Thus expression of functional IAPs in host target tissues is crucial for reducing
the damage from GVHD.
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GRAFT-VERSUS HOST DISEASE (GVHD) DEVELOPMENT AFTER BONE
MARROW TRANSPLANTATION IS NOT INFLUENCED BY TH9 CELLS
T. Reisser1, S. Muche1, J. Scheurer1, K.-M. Debatin1, G. Strauss1,*
1Department of Pediatrics and Adolescent Medicine, University Medical Center
Ulm, Ulm, Germany
Background: Th9 cells are a recently defined subset of T helper cells (Th)
characterized by the massive production of IL-9. Th9 cells mediate immune
responses against helminth infections, exhibit anti-tumor immunity against solid
tumors and mediate allogeneic transplant tolerance but they also contribute to
immunopathology in allergy and autoimmunity.
Aims: Currently, the role of Th9 cells for GVHD induction and the graft-versus-
tumor effect is largely unknown. Therefore, we first explored, whether Th9 cells
are induced during GVHD development in two different MHC-mismatched bone
marrow transplantation (BMT) models and secondly analyzed, whether trans-
plantation of in vitro-generated Th9 cells mediates GVHD.
Methods: We transplanted allogeneic BM and spleen cells from B6-SJL mice
(CD45.1, H-2b) in B6D2F1 mice (CD45.2, H-2bxd) or in B6.bm12 mice (CD45.2,
I-Abm12) differing either in 50% of MHC class I and II molecules or only in one
MHC class II molecule and analyzed the induction of Th9 cell during GVHD
development. To clarify whether in vitro-generated Th9 cells mediate GVHD,
we induced Th9 cells in vitro from isolated, naïve CD4+ T cells on anti-CD3/28
coated plates by TGF-b, IL-4, anti-IFNg and recombinant TL1A and co-injected
the Th9 cells together with allogeneic BM in irradiated recipient mice and sub-
sequently monitored GVHD induction.
Results: In both MHC mismatched models used, the transplantation of allo-
geneic spleen cells and BM leads to GVHD characterized by a time-dependent
strong increase of Th1-specific cytokines TNF-a and IFN-g in the serum of the
recipient mice. IL-9, however, was undetectable. Additionally, no IL-9 producing
allogeneic T cells were identified in the spleen, liver and lung of GVHD-devel-
oping animals until 29 days after transplantation, while TNF-a and IFN-g pro-
ducing cells were strongly increased indicating that Th9 cells are not induced
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during GVHD. After in vitro differentiation of Th9 cells from naïve T cells we
obtained more than 60% of IL-9 producing cells after 5 days of culture. Th9
cells differ in their cytokine profile (IL-9+, IFN-g-, IL-13-) from Th1 and Th2
cells. Transplantation of in vitro-generated Th9 cells together with allogeneic
BM cells did not induce GVHD in the MHC-disparate recipient mice, while the
transplantation of unselected T cells or in vitro-generated Th1 cells induced
GVHD and mediated death in about 60% of the animals. Although no GVHD
development was detected, Th9 cells migrated into lymphoid organs and GVHD
target organs such as spleen and lung. Surprisingly, when the cytokine pheno-
type of the transplanted Th9 cells were analyzed after ex vivo isolation from
spleen and liver at different time points after transplantation, the cells lost their
IL-9 production but produced TNF-a and IFN-g pointing to a plasticity of Th9
cells after adoptive transfer. Systemic increase of TNF-a and IFN-g in the serum
of mice receiving Th9 cells, however, was not detected.
Summary/Conclusions: Th9 cells are not induced during GVHD development
and the adoptive transfer of in vitro-generated Th9 cells does not induce GVHD.
However, the transplanted Th9 cells home to spleen and GVHD target organs
and start to produce TNF-a and IFN-g without strong systemic increase in these
cytokines. Since TNF-a and IFN-g are cytokines associated with an anti-tumor
cytotoxicity and Th9 cells are known to eliminate solid tumors, future experi-
ments will define, whether in vitro-generated Th9 cells can be used as a cellular
therapy for anti-tumor responses in BM-transplanted hosts.
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IMPROVED HSC ENGRAFTMENT IN A MOUSE MODEL OF HEMATOPOIETIC
STEM CELL GENE THERAPY MEDIATED BY MSCS
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Innovative Therapies, Instituto de Investigación Sanitaria Fundación Jiménez
Díaz (IIS-FJD, UAM), Madrid, Spain
Background: Co-transplantation of human mesenchymal stromal cells (hMSC)
has been reported to reduce the risk of graft failure and improve hematopoietic
stem cells (HSC) engraftment in xenogeneic and determined allogeneic trans-
plants. In addition, we have demonstrated that the co-infusion of MSCs with
low numbers of purified HSCs significantly improve the short- and long-term
hematopoietic reconstitution in an autologous HSCT experimental model with
sublethal conditioning (5Gy).
Aims: The aim of this study is to analyze the effect of MSCs on HSC engraft-
ment in a clinically relevant model of hematopoietic gene therapy.
Methods: We have studied the effect of MSCs co-infusion in a mouse model
of HSC gene therapy with risk of engraftment failure in Fanconi anemia mice
(Fanca-/-).
Results: In these experiments, the infusion of low numbers of WT LSK cells
(1,500 LSK) in Fanca-/- mice resulted in 30% graft failure, which was prevented
when 6.105 Ad-MSCs were co-infused. Furthermore, when 1,500-3,000 Fan-
ca-/- LSK cells transduced with a therapeutic lentiviral vector (PGK-FANCA-
wPRE*) were transplanted, the infusion of similar cell doses resulted in more
than 50% of engraftment failure, which decreased to 30% only when more
than 10,000 gene-corrected LSK were infused. Once again, Ad-MSCs co-infu-
sion prevented graft failure in after the infusion with the same number of gene-
corrected LSK cells.
Summary/Conclusions: Taken together, our results demonstrate the potential
of Ad-MSCs to avoid graft failure in a clinically relevant model of hematopoietic
gene therapy with risks of engraftment failure.
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EFFECT OF POMALIDOMIDE ON T CELL POLARIZATION IS MEDIATED
THROUGH EPIGENETIC MODIFCATIONS. 
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J.A. Pérez Simón1
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Background: There is conflicting evidence regarding the potential use of IMIDs
and particularly pomalidomide after allogeneic stem cell transplantation (allo-
HSCT). It has been well described that IMIDs polarize naïve T cells towards a
Th1 phenotype increasing IFN-γ cytokine production via the augmentation of
T-bet transcription factor. This effect might increase the risk of GvHD after allo-
HSCT. Nevertheless, a recent trial has reported a potential benefit on the use
of pomalidomide as GVHD treatment. 
Aims: In the current study, we have analyzed the effect of pomalidomide in
the polarization of CD45RA+ cells and the epigenetic mechanisms that might
be involved in this effect.
Methods: Isolated CD45RA+ T cells from healthy donor’s Buffy Coats weres-
timulated with anti-CD3 plus anti-CD28 in the presence of several cytokines to
polarize towards Th1 (IL-12, INF-γand anti-IL4) or Th2 (IL-4, IL-2, anti-IFN-γ
and anti-IL-12) for 5 days. Pomalidomide at two different doses (10 and 100
nM) were added into the culture and the effect on T cells polarization was ana-
lyzed by flow cytometry after staining with anti-CD25, anti-IFNγ, anti-CD4 and
anti-IL2 for Th1 cell polarization and anti-CD25, anti-IL10, anti-CD3 and anti-
IL4 for Th2 cell polarization. In addition, the release of cytokines (IL-2, IL-4, IL-
6, IL-10, TNF-α and IFN-γ) in cell culture supernants were measured with BD
Human Th1/Th2 Cytokine CBA kit (BDBiosciences) and T-bet and GATA-3
expression were analyzed by Western Blot. Chromatin immunoprecipitation
(ChIP) assays were performed to assess the trimethylation of H3K4 (associated
with gene activation) and the trimethylation of H3K27 (associated with gene
repression) in the TBET and GATA-3 gene promoters.
Results: Pomalidomide increased the expression of INF-γ and IL-2 as deter-
mined by flow cytometry in Th1 cell culture conditions. By contrast, in the pres-
ence of Th2 promoting cytokines, we observed an increase for both IL-10 and
IL-4 upon adding pomalidomide to the culture. In addition, the exposure to
pomalidomide increased the levels of TNF-α, INF-γ and IL-2 in the Th1 polar-
izing culture while, under Th2 promoting conditions, an increased concentration
of IL-4 and IL-2 in supernatant was observed after exposure to pomalidomide.
Furthermore, exposure to pomalidomide led to an increased expression of T-
bet as assessed by western-blot in naïve CD45RA+ cells activated with anti-
CD3 plus anti-CD28 and supplemented with IL-12, INF-γ and anti-IL4. By con-
trast, in Th2 polarization conditions, pomalidomide increased GATA-3 expres-
sion.We next studied whether or not the effect of pomalidomide in T cell polar-
ization might be mediated by epigenetic mechanisms: in the presence of Th1
promoting conditions there was a significant increase of the activation marker
H3K4me3 at the TBET promoter and a significant decrease in H3K27me3 upon
exposure to the drug while, under Th2 promoting conditions, a significant
increase in H3K4me3 at the promoter of GATA-3 gene was observed among
T cells exposed to pomalidomide.
Summary/Conclusions: Pomalidomide favours both Th1 and Th2 cell differ-
entiation of CD45RA+ cells depending on the cytokines present in the medium.
Treatment of naïve T cells with pomalidomide induces epigenetic modifications
during T cell polarization which might favour the process of differentiation of
the naïve T cells.
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MESENCHYMAL STEM CELLS (MSCS) ATTENUATE CUTANEOUS
SCLERODERMATOUS GRAFT-VERSUS-HOST DISEASE (SCL-GVHD)
THROUGH INHIBITION OF IMMUNE CELL INFILTRATION IN A MOUSE
MODEL
J.-Y. Lim1,*, D.-B. Ryu1, S.-E. Lee1, G. Park2,3, C.-K. Min1,3
1Department of Internal Medicine, 2Department of Pathology, Seoul St. Mary’s
Hospital, The Catholic University of Korea, 3Leukemia Research Institute, The
Catholic University of Korea, Seoul, Korea, Republic Of
Background: Human chronic graft-versus-host disease (CGVHD) shares clin-
ical characteristics with a murine sclerodermatous GVHD (Scl-GVHD) model
that is characterized by skin thickening and lung fibrosis.
Aims: This study investigated the therapeutic effect of mesenchymal stem
cells on the development of Scl-GVHD according to each target organ.
Methods: A B10.D2 → BALB/c transplant model of Scl-GVHD was used to
address the therapeutic effect of mesenchymal stem cells (MSCs) on the devel-
opment of CGVHD. M210B4 cells were administered after allo-HSCT at a dose
of 3 x 105 cells/mouse on days 3, 5 and 7.
Results: The clinical and pathological severity of cutaneous Scl-GVHD was
significantly attenuated in MSC-treated recipients relative to Scl-GVHD controls.
After MSC treatment, skin collagen production was significantly reduced with
consistent downregulation of TGF-β expression. Effects of MSCs on molecular
markers implicated in persistent TGF-β signaling and fibrosis, such as phos-
phatase and tensin homolog (PTEN), phosphorylated Smad-2/3 and matrix
metalloproteinase-1 (MMP-1), were observed in skin tissue. MSCs neither
migrate to the skin nor affect the in vivo expansion of immune effector cells,
but inhibited their infiltration into skin via downregulation of CCR4 and CCR8
expression on CD4+ T cells and CCR1 on CD11b+ monocyte/macrophages.
MSCs diminished expression of chemokines such as CCL1, CCL3, CCL8,
CCL17, and CCL22 in skin. MSCs were also dependent on stimulated spleno-
cytes to suppress fibroblast proliferation.
Summary/Conclusions: Our findings indicate that MSCs attenuate the cuta-
neous Scl-GVHD by selectively blocking immune cell migration and downreg-
ulating chemokines and chemokine receptors.
P758
C57BL/6 SUBTRAINS SHOW DIFFERENCES IN HEMATOPOIETIC
REPOPULATION
A. Morales Hernandez1,*, A. Martinat2, S. McKinney-Freeman2
1Hematology, St Jude Children’s Research Hospital, 2Hematology, St Jude
Children’s Research Hospital, Memphis, United States
Background: C57BL/6 mice are one of the most studied in-bred mouse strains.
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Although C57BL/6N (N) and C57BL/6J (J) mice are derived from the same
parental C57BL/6 strain, there are key genotypic and phenotypic differences
between these sub-strains. However, more than 58% of studies published
involving C57BL/6 mice do not indicate the specific sub-strain employed. J
mice have a five-exon deletion in the Nicotinamide nucleotide transhydrogenase
(Nnt) gene that results in a non-functional protein. NNT is involved in the res-
olution of oxidative stress in the mitochondria. Hematopoietic stem cells (HSCs)
can reconstitute the entire hematopoietic system after transplantation into hosts
whose hematopoietic compartment has been ablated. This is clinically exploited
as HSCs transplantation (HSCT) to treat hematologic diseases and represents
the only curative therapy for many disorders. During HSCT, HSC are subject
to dramatic increases in both intra and extracellular reactive oxygen species
(ROS), which compromises their self-renewal, differentiation, and survival. The
absence of a functional Nnt gene in J-HSC may curtail their ability to resolve
elevated ROS post-transplant.
Aims: As elevated oxidative stress compromises hematopoietic stem and pro-
genitor cell (HSPC) function, here we thoroughly interrogated the frequency
and function of HSPCs in J and N bone marrow (BM).
Methods: N and J peripheral blood (PB) and BM (n=9) was interrogated by flow
cytometry for the absolute frequencies of all major hematopoietic lineages and
HSPC compartments, respectively. 5000 J or N CD45.2 HSPCs (Lin-Sca-1+c-
Kit+ cells) were transplanted along with 5000 competitor CD45.1 HSPCs into
lethally irradiated mice to test for competitive in vivo hematopoietic repopulating
activity and ROS levels post-transplant. The lineage potential and repopulating
activity of multi-potent progenitors (MPP2: Lin-Sca1+cKit+Flt3-CD48+CD150+,
MPP3: Lin-Sca1+cKit+Flt3-CD48+CD150-, MPP4: Lin-
Sca1+cKit+Flt3+CD48+CD150-) was also tested by transplanting 2000 MPPs
from J or N mice into sub-lethally irradiated mice and examining the PB of recip-
ients every 3-4 days for 34 days post-transplant. Sensitivity of HSPCs to oxida-
tive stress was tested by examining ROS levels and the in vitro colony forming
unit (CFU) potential of HSPCs isolated from N and J mice treated with pI:pC.
Results: The frequency of the major PB lineages and bone marrow HSPC
compartments was identical in J and N mice. However, J-HSPCs displayed
compromised short-term (4-12 weeks post-transplant) hematopoietic repopu-
lating activity relative to N-HSPCs that was driven by a delay in lymphoid recon-
stitution. No differences were found in donor contribution to bone marrow HSPC
compartments at 20 weeks post-transplant. However, donor-derived MPPs and
CLPs displayed a two-fold increase in ROS levels in recipients of J-HSPCs
versus N-HSPCs at 20 weeks post-transplant. MPPs are responsible for repop-
ulation of the hematopoietic system during this early window post-transplant.
Different MPP subpopulations can be defined (MPP2, MPP3 and MPP4)
according to their self-renewal potential and specific lineage potential. MPP3s
and MPP4s are the first MPP subpopulations to reconstitute the lymphoid lin-
eage after transplant. J-MPP3s and J-MPP4s displayed less in vivo repopula-
tion activity than N-MPP3s and N-MPP4s. It is known that pI:pC treatment
increases ROS levels in HSPCs. We found about two-fold higher ROS levels
in HSPCs isolated from pI:pC treated J mice than N mice with the exception of
the myeloid progenitor compartments (CMP, GMP and MEO). J-HSPCs also
generated fewer and smaller CFU than N-HSPCs when isolated from pI:pC
treated mice. These data indicate that J-HSPCs cannot resolve oxidative stress
as efficiently as N-HSPCs, which may be due to lower self-renewal potential
after exposure to oxidative stress. Short-term J-lymphoid-biased progenitors
(e.g. MPPs and CLPs) were especially sensitive to increasing ROS, which very
likely drives the short-term loss of in vivo repopulating activity. 
Summary/Conclusions: Based on these data, we hypothesize that loss of the
Nnt gene in C57Bl/6J mice sensitizes HSPCs to oxidative stress, which com-
promises their short-term in vivo hematopoietic repopulating activity.
Thrombotic disorders
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GWAS RESULTS IN RED BLOOD CELL PHENOTYPES AND THEIR
RELATIONSHIP WITH THROMBOSIS
N. Vilalta1, S. Lopez2, A. Perez-Martinez2, R. Angel F.3,*, M. Sabater-LLeal4, P.
Sarda3, N. Pujol-Moix5, A. Ziyatdinov2, J. Remacha3, J. Fontcuberta1,
J. Nomdedeu3, A. Hamsten4, J.C. Souto1, J.M. Soria2
1Thrombosis and Hemostasis Unit, Hospital de Sant Pau, 2Unit of Genomics
of Complex Diseases, Institut d’Investigació Biomèdica Sant Pau. (IIB-Sant
Pau), 3Hematology, Hospital de Sant Pau, Barcelona, Spain, 4Cardiovascular
Medicine Unit, Department of Medicine,, Karolinska Institutet, Stockholm, Swe-
den, 5Medicine Department, Universitat Autònoma de Barcelona, Barcelona,
Spain
Background: Venous thromboembolism (VTE) is a complex and multifactorial
disease with a estimated heritability of 60%. Intermediate phenotypes of VTE
have been used to identify genetic risk factors. We previously reported a genetic
correlation of 5 erythrocyte phenotypes with VTE1.
Aims: To identify single nucleotide polymorphisms (SNPs) influencing the phe-
notypic variance of erythrocyte parameters, especially those related to VTE, in
Spanish families from the Genetic Analysis of Idiopathic Thrombophilia (GAIT2)
Project. 
Methods: Genome-wide association analyses (GWAS) with ~10M SNPs were
performed for eighteen erythrocyte phenotypes in 935 subjects belonging to
35 extended families with thrombosis of GAIT2. The erythrocyte phenotypes
evaluated were: Hemoglobin (Hb), red blood cell count (RBC), hematocrit (Ht),
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean
corpuscular hemoglobin concentration (MCHC), red blood cell distribution width
(RDW), reticulocyte (RET), low fluorescence reticulocyte (LFR), middle fluo-
rescence reticulocyte (MFR), high fluorescence reticulocyte (HFR), reticulocyte
fluorescence index (IRF), haptoglobin (HP), serum iron (Fe), total iron binding
capacity (TIBC), saturation index (SI), serum ferritin (FT) and serum transferrin
receptor (TFR).
Results: We identified 12 SNPs showing association with the 5 erythrocyte
phenotypes previously related to VTE (Table 1). Interestingly, the rs56036145
that showed association with TFR is an intronic variant located in the gene tis-
sue factor pathway inhibitor 2 (TFPI2), which encodes a protein that inhibits a
variety of serine proteases of blood coagulation, such as activated factor VII
(FVIIa/TF), FXa, plasmin and plasma kallikrein. These data reinforce our pre-
vious report of genetic correlation of TFR with VTE. The most significant SNP-
associations were reported.
Table 1. Top SNP-associations with erythrocyte phenotypes related to
VTE from GWAS in GAIT2.
G: genetic correlation with VTE; Chr: Chromosome.
Summary/Conclusions: Several genetic variants involved in the variance of
erythrocyte phenotype levels were identified by GWAS. Of note, TFR was asso-
ciated with a SNP in TFPI2 that might influence the variance of both TFR levels
and VTE risk. These data could be useful to investigate genes related to red
blood cell parameters and VTE.
Reference
1. Remacha A et al. Erythrocyte-related phenotypes and genetic susceptibility
to thrombosis. Blood Cells Mol Dis. 2016;59:44-8.
This work was supported by RIC RD12/0042/0032, FIS PI12/00612 and FIS PI
15/0269 grants
P760
ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV)
PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAM-
IC MODEL OF PLATELET ADHESION
A. Vignoli1,*, F. Marchesi1, M. Marchetti1, S. Gamba1, C. Giaccherini1, C. Verzeroli1,
L. Russo1, S. Tessarolo1, G. Finazzi2, P.E. van der Meijden3, F. Swieringa3,
H. ten Cate4, J.W. Heemskerk3, A. Rambaldi2, A. Falanga1
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1Department of Immunohematology and Transfusion Medicine, 2Department
of Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy, 3Department of
Biochemistry, 4Department of Internal Medicine, CARIM, Maastricht University,
Maastricht, Netherlands
Background: ET and PV are characterized by a high incidence of arterial and
venous thrombosis. Platelet (PLT) count is not an independent risk factor for
thrombosis in these conditions. However, no information is available on patient
PLT qualitative properties, i.e. the PLT thrombus formation capacity in a dynam-
ic condition.
Aims: We wanted to evaluate, in a group of ET and PV patients, the PLT throm-
bus formation capacity by an ex-vivo dynamic model of PLT adhesion under
flow conditions, and to establish the influence of JAK2-V617F/Calreticulin
(CalR)/MPL mutations, hematological parameters, and ongoing therapies.
Methods: One hundred-thirty patients, i.e. 78 ET (32 M/46 F; median age=61
years, range 28-86) and 52 PV (26 M/26 F; median age=65 years, range 38-
87), and 32 healthy controls (16 M/16 F; median age=44 years, range 27-61)
were enrolled after informed consent. For the adhesion assay, peripheral
venous whole blood was drawn in sodium citrate, recalcified in the presence
of heparin, and perfused over a collagen-coated surface for 4 min. at a shear
rate of 1,000 s-1. PLTs were then stained with an anti-CD62P (P-selectin)-FITC
antibody to evaluate PLT activation, and annexinV-AlexaFluor647 to detect
pro-coagulant phosphatidylserine expression. After staining, phase contrast
and fluorescence images of adherent PLTs were taken in random fields using
an EVOS® microscope. Results are expressed as the mean±SEM of the % of
area covered by all PLTs (% coverage), or as the % of adherent PLTs positive
for either P-selectin or phosphatidylserine. Main hematological parameters,
therapies, and mutational status were recorded.
Results: PLT adhesion was significantly (p<0.01) greater in either ET
(45.3±1.7%) and PV patients (48.9±1.6%) compared to healthy controls
(37.5±1.7%), while no difference was found between ET and PV patients. The
analysis according to the mutational status shows that ET PLT adhesion was
highest in JAK2-V617F mutation carriers (n=41; coverage: 47.7±2.4%, p<0.001
vs controls), followed by CalR-positive patients (n=21; coverage: 45.5± 3.2%,
p<0.05 vs controls, p=n.s. vs JAK2-V617F), while, PLT adhesion of MPL-pos-
itive (n=3; coverage: 32.1±2.1%) or triple negative (n=13; coverage: 42.6±2.5%)
ET patients was not statistically different from controls. In PV, no statistically
significant difference was observed between subjects with >50% versus those
with <50% JAK2-V617F allele burden. According to treatment, we observed
that ET patients treated with the combination of aspirin+hydroxyurea presented
the lowest PLT adhesion, while in PV no significant difference was observed
between different therapeutic regimens. PLT count correlated (p<0.01) with
PLT adhesion only in CalR-positive ET patients. The analysis of adherent PLT
surface markers shows no difference in P-selectin expression between whole
patients and controls. Differently, phosphatidylserine expression was signifi-
cantly reduced (p<0.01) in both ET and PV compared to healthy subjects.
Summary/Conclusions: ET and PV platelets show an increased PLT throm-
bus formation potential, particularly in patients carrying the JAK2-V617F muta-
tion. On the basis of these results, it is worth to include a dynamic PLT adhesion
assay in risk prediction models to evaluate the predictive value of thrombotic
events in ET and PV patients. [Project funded by “AIRC-IG2013” grant Nr.
14505 of the “Italian Association for Cancer Research” (A.I.R.C.)].
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DOAC ASSOCIATED MAJOR GASTROINTESTINAL BLEEDING: REAL
LIFE EXPERIENCE FROM A UNIVERSITY TEACHING HOSPITAL, UK
B. Badugama1,*, S. Mcdermott1, A. Mrray2, A. Barua2, P. Gupta2, D. Gallagher2,
D. Sutton1, D. Chandra1
1Staffordshire Thrombosis & Anticoagulation Centre, 2Haematology, Royal
Stoke University Hospital, Stoke on Trent, United Kingdom
Background: Direct acting oral anticoagulants (DOAC) use is increasing
amongst patients requiring anticoagulation for AF or VTE. The incidence of
major gastrointestinal (GI) bleeding in DOAC patients from clinical trials is
reported to be similar or lower than those on warfarin. There is paucity of real
life data confirming this important safety measure.
Aims: We investigated our database on patients using DOAC over a 3 year
period to identify major GI bleeding events during this period. The objective
was to ascertain the incidence of major GI bleeding and identify demographic
and clinical risk factors in these patients.
Methods: all patients issued, apixaban, dabigatran or rivaroxaban between
April 2013 - July 2016 were identified from the hospital pharmacy records. Hos-
pital admission data was investigated to identify patients who were diagnosed
of a major GI bleeding during this period. Records of patients with major G.I.
Bleeding were then individually studied for demographic and clinical risk factors.
Major bleeding was defined as per the ISTH criteria.
Results: 2611 patients were identified to have received DOAC treatment
between April 2013- July 2016. Of these 1601 (61%) received; apixaban, 722
(27%) rivaroxaban and 288 (11%) dabigatran.18 patients (0.7%) suffered from
a major GI bleeding equating to annual risk of major GI bleeding of 0.23% per
patient/ year. This is a much lower incidence than reported data from clinical
trials in patients on DOAC. Patients who suffered from a major GI bleeding did
so on average 143 days (range 8-576) after starting the DOAC. Of all patients
with major GI bleeding, 14 were taking apixaban (0.8% of all pt on apixaban),
3 (0.4% of all pt on rivaroxaban) rivaroxaban and 1 (0.3% of all pt on dabigatran)
on dabigatran). The numbers were too small to identify any statistical difference
between the 3 different DOAC drugs. 
Summary/Conclusions: The risk of major GI bleeding in our cohort of over
2500 patients over 3 years was noted to be significantly lower than trial data.
Since this is a retrospective review from patient hospital database there is a
risk of reporting bias and under-reporting of bleeding events. A prospective
phase IV study to identify bleeding risk in patients on DOAC is required. Majority
of patients with major GI bleeding had other risk factors such as concurrent
use of anti- platelets, peptic ulcer disease, alcohol abuse, oesophageal varices,
diverticular disease, and bowel malignancy which would increase their bleeding
risk on any anticoagulation. Further sub group analysis of this cohort and efforts




INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING
LOWER LIMB SURGICAL REVASCULARIZATION: IS THROMBOPROPHYLAXIS
WARRANTED?
A. Baranwal1, S. Singh1, A. Yanamadala1, P. Smith1,*, E. Colaiuta1
1MacNeal Hospital, Berwyn, United States
Background: The incidence of postoperative deep vein thrombosis (DVT) or
consequential pulmonary embolism (PE) in patients undergoing lower extremity
surgical revascularization procedures is not well studied. The need for routine
anticoagulation for DVT/PE prophylaxis after the lower limb surgical revascu-
larization remains controversial.
Aims: The purpose of this study is to retrospectively evaluate the incidence of
postoperative DVT/PE in patients undergoing lower limb surgical revascular-
ization.
Methods: Charts for patients undergoing lower limb surgical revascularization,
from 01/01/2010 to 12/31/2015, were evaluated for DVT/PE. DVT/PE within
three months of the revascularization was considered to be a postoperative
DVT/PE. Patients undergoing multiple procedures were counted as different
cases if they were on different days. Multiple procedures on a patient on the
same day were considered a single case. Patients with hypercoagulable states
or previous history of DVT were excluded. Descriptive statistics and t-test was
used to analyze incidence of DVT/PE and assess the importance of postoper-
ative thromboprophylaxis.
Table 1.
Results: Between 1/1/2010 to 12/31/2015, 360 patients were found to have
undergone lower extremity surgical revascularization. Study population includ-
ed 200 males and 160 females. Mean patient age was 69.54 years. One patient
had a previous history of DVT and was excluded. Overall, of the 359 patients,
five (1.4%) were recognized to have a new DVT/PE within 3 months of the sur-
gery. One patient developed DVT in the contralateral limb, and one developed
it in the arm. Patients were recognized to have a new DVT/PE, on an average,
at 7.6 days after the surgery. A one sided t-test demonstrated that the average
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postoperative day for recognition of DVT/PE was significant greater than 3.5
(7.6 vs 3.5, t-value=2.17, p=0.048). Patients developing DVT/PE did not differ
by obesity or age when compared with non-DVT/PE population.
Summary/Conclusions: There have been only a few studies to assess the
incidence of DVT/PE in patients undergoing lower limb surgical revasculariza-
tion. In our study population, 1.4% of patients had evidence of DVT/PE. This
constitutes a low risk of venous thromboembolism. The 2012 American College
of Chest Physicians (ACCP) guidelines for prevention of venous thromboem-
bolism in nonorthopedic surgical patients (Chest 2012; 141(2)(Suppl):e227s-
e277s), recommends the use of pneumatic compression devices (PCDs), over
no prophylaxis, to prevent DVT/PE in low risk patients. Since, patients with
lower limb surgeries are not a good candidate for PCDs, pharmacological
thromboprophylaxis with low dose heparin may be warranted. Given that bleed-
ing is a potential complication in these patient, it might be prudent to start throm-
boprophylaxis 3.5-4 days after the surgery. Further studies are needed to
assess the bleeding risks of postoperative thromboprophylaxis after surgical
revascularization procedures.
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THE ROLE OF INFLAMMATION IN THROMBOEMBOLISM IN RESECTABLE
RENAL CELL CARCINOMA PATIENTS
H. Park1,*, D.-Y. Shin1,2, Y. Koh1,2, S.-S. Yoon1,2, S. Park1,2,3, C. Kwak1,2,
I. Kim1,2
1Seoul National University Hospital, 2Cancer Research Institute, Seoul National
University, Seoul, 3Inje University Haeundea Paik Hospital, Busan, Korea,
Republic Of
Background: Renal cell carcinoma (RCC) may increase the risk for venous
thromboembolism. However, only a few reports have described the clinical fea-
tures and risk factors for thromboembolism.
Aims: This study aimed to elucidate the clinical features of thromboembolic
events and to identify prognosis in patients who experienced thromboembolism
events.
Methods: We retrospectively reviewed medical records of patients who under-
went nephrectomy at our institution between February 1998 and August 2015.
We evaluated the data including pathologic stage, gender, age, smoking history,
underline disease, preoperative laboratory findings and survival outcomes.
Results: A total of 3099 patients were included in the study. Among them, 208
thromboembolic events (6.7%) were identified in pathologic and image studies
during median follow-up duration of 40 months. Patients who have increased
preoperative platelet levels ((≥400x103uL), neutrophil lymphocyte ratio (NLR)
(≥1.86) and c-reactive protein (CRP) (≥0.12mg/dL) experienced significantly
more thromboembolic events than those with lower value according to multi-
variable analysis (hazard ratio [HR], 2.22 [95% CI, 1.01–4.85], P=0.047 for
platelet levels; HR, 3.39 [95% CI, 1.67–6.90], P=0.001 for NLR;HR, 3.38 [95%
CI, 1.67–6.80], P=0.001 for CRP). Moreover, patients who experienced throm-
boembolism showed poor overall survival (OS 195 vs 67 months HR 1.95,
P=0.007).
Summary/Conclusions: Preoperative inflammation markers including NLR,
CRP and platelet cout can be the risk factors for venous thromboembolism in
RCC patients who experienced nephrectomy. Thromboembolism also has a
significant role on the the prognosis of RCC patients.
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GENETIC AND ENVIRONMENTAL RELATIONSHIP BETWEEN VITAMIN
B12, FOLATE AND HOMOCYSTEINE AND SUSCEPTIBILITY TO THROMBOSIS
IN THE GAIT 2 PROJECT. RESULTS OF A GWAS ANALYSIS
R. Angel F.1,*, A. Perez-Martinez2, N. Vilalta3, S. Lopez2, M. Sabater-LLeal4, P.
Sarda1, N. Pujol-Moix5, A. Ziyatdinov2, J. Remacha1, J. Fontcuberta3,
J. Nomdedeu1, A. Hamsten4, F. Blanco-Vaca6, J.C. Souto3, J.M. Soria2
1Hematology, Hospital de Sant Pau, 2Unit of Genomics of Complex Diseases,
Institut d’Investigació Biomèdica Sant Pau. (IIB-Sant Pau), 3Thrombosis and
Hemostasis Unit, Hospital de Sant Pau, Barcelona, Spain, 4Cardiovascular
Medicine Unit, Department of Medicine,, Karolinska Institutet, Stockholm, Swe-
den, 5Medicine Department, Universitat Autònoma de Barcelona, 6Biochemistry,
Hospital de Sant Pau, Barcelona, Spain
Background: Venous thromboembolism (VTE) is a common disease involving
genetic and environmental risk factors. Earlier studies have estimated that the
heritability of the risk of VTE is 60% and we have demonstrated that erythro-
cyte-related phenotypes are good candidates for risk factor of thrombosis
(Genetic Analysis of Idiopathic Thrombophilia 2, GAIT 2, Project).
Aims: To replicate the estimates of the heritability, and to evaluate the role of
intermediate phenotypes as VTE risk factors.
Methods: Thirty-five Spanish extended families were recruited in the GAIT 2
Project. The sample consisted of a set of 935 individuals. Inclusion criteria were
similar to GAIT 1. Levels of serum vitamin B12 (B12), serum folate (SF), red
cell folate (RCF) and homocysteine (HCY) were evaluated using commercial
automated methods. Heritability (h2) estimates were obtained using the vari-
ance component method. The correlations between a given pair of traits were
calculated using a multivariate variance component model. By studying these
traits in extended families we estimated both the genetic (ρg), and the environ-
mental (ρe) correlations between traits. All of the statistical analyses were per-
formed employing the Sequential Oligogenic Linkage Analysis Routines
(SOLAR, version 6.6.2, official). Then a GWAS analysis was carried out.
Results: The h2 of VTE was 0.67. All parameters showed significantly high h2,
and environmental (especially in the case of HCY) factors were also related to
these parameters (table 1). In addition, VTE was correlated with B12 (0.34.
p=0.027). Moreover, B12 was related to autoimmunity (0.5. p= 0.03) and RCF
with malignancy (-0.58, p=0.05). The GWAS analysis detected numerous sig-
nals (table 2). Some of these signals have been reported (B12 and FUT2, SF
and Hcy and MTHFR).
Table 1. Values, heritabilities, household effect and significant covariates
effects.
Values expressed as Mean±standard deviation, in brackets maximum and min-
imum values. B12: serum vitamin B12; SF: Serum folate; RCF: Red cell folate;
HCY: Homocysteine.
Table 2. Suggestive signals detected by GWAS.
Summary/Conclusions: In the GAIT2 study, genetic and environmental factors
were related to B12, SF, RCF and HCY. Moreover, a relationship was observed
between B12 and VTE. In the GWAS analysis some signals were previously
reported (FUT2 and B12 or MTHFR with SF and HCY). New signals were found
that need to be clarified, especially their possible relationship with susceptibility
to thrombosis.
This work was supported by RIC RD12/0042/0032, FIS PI12/00612 and FIS PI
15/0269 grants.
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CELLULAR ORIGIN OF CIRCULATING MICROPARTICLES (MP) ACCORDING
TO SOMATIC MUTATIONS IN PATIENTS WITH MYELOPROLIFERATIVE
NEOPLASMS (MPN)
C.J. Tartari1,*, M. Marchetti1, R. Lacroix2, L. Russo1, S. Gamba1, A. Vignoli1,
G. Finazzi3, A. Rambaldi3, A. Falanga1
1Department of Immunohematology and Transfusion Medicine, Hospital Papa
Giovanni XXIII, Bergamo, Italy, 2Department of Hematology and Vascular Biol-
ogy, Hospital La Conception, Marseille, France, 3Department of Hematology,
Hospital Papa Giovanni XXIII, Bergamo, Italy
Background: Essential thrombocythemia (ET) and polycythemia vera (PV)
are MPN characterized by a high rate of thrombotic complications. We previ-
ously demonstrated increased plasma levels of procoagulant MP in ET (Mar-
chetti et al. A.J.H. 2013). 
Aims: Aim of this study was to extend the analysis of MP to PV patients and to
characterize the cellular origin of plasma MP in both ET and PV patients. The
influence of somatic mutations [i.e. JAK2V617F, calreticulin (CalR), thrombopoi-
etin receptor (MPL)] and concomitant cytoreductive or antiplatelet therapies
was also evaluated.
Methods: Thirty-seven ET (19 JAK2V617F, 9 CalR and 2 MPL mutation carri-
ers), 35 PV patients (all JAK2V617F carriers) and 36 healthy control subjects
were included into the study. Flow cytometry was performed to characterize
MP phenotype in platelet free plasma samples. To define MP cellular origin,
anti-CD31 (endothelial cell marker), anti-CD41 (platelet marker), anti-CD11b
(leukocyte marker), and anti-CD235 (erythrocyte marker) monoclonal antibodies
were used. Annexin V (AnnV) staining was used to evaluate the expression of
procoagulant phosphatidylserine on MP.
Results: ET and PV patients displayed significantly higher MP levels compared
to controls (p<0.05). The majority of circulating MP (90%) were AnnV positive,
indicating the expression of phosphatidylserine on their surface. In healthy con-
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trols, 71% of MP was positive for platelet (P-MP), 24% for erythrocyte (E-MP),
4% for endothelial cell (EC-MP) and 1% for leukocyte (L-MP) specific markers.
In ET and PV patients, the percentage of P-MP was significantly higher (80%;
p<0.05), while E-MP level was significantly lower (15%; p<0.05) than controls.
L-MP and EC-MP values were comparable between patients and controls. The
absolute counts of P-MP and L-MP were higher in both ET and PV versus con-
trols. Overall, no significant correlations were found between the levels of MP
derived from platelet, leukocytes or erythrocytes and the corresponding cell
counts. The analysis according to patient mutations, revealed significantly high-
er levels (p<0.05) of both P-MP and E-MP concentration in patients carrying
JAK2V617F mutation as compared to JAK2V617F negative patients. In addi-
tion, ET patients positive for CalR mutation displayed lower levels (p<0.05) of
P-MP compared to JAK2V617F carriers. No influence of concomitant therapies
on MP levels or composition was observed.
Summary/Conclusions: Our data confirm the presence of high levels of cir-
culating MP in MPN, which support the role in the known hypercoagulable state
of these patients. The MP cellular origin has a different distribution profile
according to the presence of different mutations. Importantly, the lack of cor-
relation found between the total and subtype-specific MP counts with the cor-
responding cell of origin counts suggests an active stimulation of MP formation. 
Project funded by AIRC-IG2013 N.14505 of the Italian Association for Cancer
Research (AIRC).
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ARE WE TESTING APPROPRIATELY FOR THE LUPUS ANTICOAGU-
LANT?
J. Sharif1,*, C. Humphrey1, I. Earnshaw1, J. Thachil1
1Haematology, Central Manchester University Hospitals, Manchester, United
Kingdom
Background: The diagnosis of antiphospholipid syndrome (APS) requires the
presence of thrombosis or defined pregnancy morbidity in addition to the pres-
ence of antiphospholipid antibodies on at least 2 occasions. Patients should
be tested for antiphospholipid antibodies if they fulfil the required clinical criteria.
Lupus anticoagulant may also be tested for when investigating a prolonged
activated partial thromboplastin time which does not correct on mixing studies.
Aims: The aim of our study was to examine retrospectively the frequency of
lupus anticoagulant (LA) testing in our institution, which we suspected to be
high, and the incidence of positive results leading to a diagnosis of APS. 
Methods: A total of 914 requests for LA were received over a 5 month period
between 1st of May and 30th September 2014. We examined which depart-
ments were requesting the tests and the clinical indications for testing. 
Results: Over 90% (829) of LA tests were negative. Nine percent (85) of tests
demonstrated a positive LA. 33 patient had experienced arterial (11) or venous
(22) thrombosis. There were 3 patients who fulfilled the clinical criteria for preg-
nancy morbidity in APS. A total of 6 patients experienced miscarriage before
10 weeks gestation; however none of these patients had the defined 3 miscar-
riages. There was one preterm delivery at 25 weeks due to pre-eclampsia. A
further 3 patients had a still birth, one of which had an identifiable cause. In
total, of the 85 positive results, 12 patients had a confirmed diagnosis of APS;
a further 25 patients had the clinical manifestations fitting the clinical criteria
for APS. Fourty eight patients had a positive LA but did not fit the clinical criteria
for a diagnosis of APS. The clinical specialities requesting the majority of tests
were obstetrics and gynaecology (231), rheumatology (179) and clinical haema-
tology (118). Of these, clinical haematology had the highest yield of positive
results (16%) compared to 3% in obstetrics and gynaecology. 
Summary/Conclusions: Our results highlight a high frequency of LA testing
in our institution with a low yield of positive results (9%), resulting in a total of
1% of patients being diagnosed with APS. Our results demonstrate that the
majority of tests for LA are not of clinical significance and often requested in
patients not fitting the clinical criteria for APS. Further education for all practi-
tioners would help to ensure only appropriate patients are tested. Indeed if a
patient fits the clinical criteria for APS they should be tested for all antiphos-
pholipid antibodies namely anti-cardiolipin and anti-β2-glycoprotein I as well
as the lupus anticoagulant. 
P768
RESULTS OF USING BRIDGING THERAPY WITH SODIUM BEMIPARIN AT
THERAPEUTIC-DOSE 
M.A. García Ruiz1,*, E. Morente Constantin1, P. Romero Garcia2, M. Gómez
Morales1, M. Jurado Chacón1
1Servicio de Hematología y Hemoterapia, Complejo Hospitalario Universitario
de Granada, Granada, 2Unidad de Cuidados Intensivos, Complejo Asistencial
de Soria, Soria, Spain
Background: Bridging therapy consists of the administration of a fast-acting
anticoagulant such as the low-molecular-weight heparin (LMWH) during the
period of cessation of oral anticoagulant therapy. The decision to continue with
anticoagulant therapy or to discontinue the treatment with the establishment
of the Bridging therapy have been carried out carefully and on an individual
basis. While taking this decision, we have taken into account three factors: the
urgency of surgery or invasive process, the risk of bleeding and thrombotic
risk for the patient. In recent decades, there have been multiple studies sup-
porting the LMWH treatment, at least as safe and effective and more cost-
effective than unfractionated heparin (UFH) in the prophylaxis and treatment
of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and
pulmonary embolism (PE). Therefore, the LMWH is considered as the drugs
of choice in the prevention of venous thromboembolism.
There are several types of commercialized LMWH, with different pharmaco-
logical properties, such as molecular weight, anti-Xa/IIa ratio and average life.
The sodium bemiparin is the LMWH with greater anti-Xa/IIa ratio, which implies
a lower risk of bleeding. In addition, it has shown a low incidence of VTE and
bleeding in actual clinical practice.
Aims: There are few published data from bridging therapy at therapeutic doses
in patients treated with oral anticoagulants (AVK) and perioperative manage-
ment. It is intended to assess the efficacy (recurrence of thrombosis) and safe
use of sodium bemiparin at anticoagulant doses on the bridging therapy and
possible thrombotic and / or hemorrhagic complications (major and minor bleed-
ing) resulting from this use.
Methods: We have analyzed 975 bridging therapies at full dose in our clinic in
the last year. They were made to a total of 650 patients (315 men and 335
women) with CHADSVASC >2, aged between 15 and 92, with an average age
of 69 years old. The reasons of anticoagulation in our patients were atrial fib-
rillation, mechanical prostheses, DVT, pulmonary embolism and recurrent
thrombosis in patients with thrombophilia. In 70% of the cases, there were
comorbidities, such as heart failure, chronic obstructive pulmonary disease,
anemia, kidney failure, liver disease and long-term aftereffects of stroke. The
bridging therapy has consisted on suspending AVK 4 (acenocumarol) to 6 days
(warfarin) before the procedure, and replacing it by sodium bemiparin at full
doses <50 kgr: 5,000 IU/24h, 50 to 70 kgr: 7,500 IU/24 h, 70-100 kgr: 10,000
IU/24 h and >100 kgr: 12.500 IU/24 h, and administration of a prophylactic
dose of 3,500 IU, 12 hours before the procedure, and another dose 6-12 hours
after the procedure, depending on the risk of bleeding of the intervention and
the thrombotic risk of the patient’s disease. The bridging therapy has been per-
formed in 225 cases of major surgery (orthopedic surgery, ophthalmological
procedures, valvular replacements etc), 340 cases of minor surgery (removal
of nevus, complex dental extractions, dental implants), 295 cases of invasive
procedures (colonoscopies, endoscopies..), 50 cases of bleeding caused by
AVK (epistaxis, petechiae and bruises, hemoptysis, menorrhagia and gastroin-
testinal bleeding), 30 cases of hospitalization with INR decompensation with
various causes (infectious endocarditis, pneumonia, uncompensated heart fail-
ure...) and 35 cases for thrombophilia study.
Results: As complications of using bemiparin sodium, there have been: 40
cases of hematomas at the needle puncture sites. There was neither cases of
major bleeding nor cases of thrombosis.
Table 1.
Summary/Conclusions: Sodium bemiparin administered at therapeutic doses
(115 IU/kg/24h) in the perioperative period, according to the scheme described
above, it is associated with a low incidence of recurrence of VTE and bleeding.
The complications presented in our sample have been very few, in patients
with associated co-morbidities. In our study, sodium bemiparin has shown to
be safe and effective with minimal bleeding complications. Treatment should
be administered on an individual basis according to each patient and factors
related to surgery. Further studies will confirm our results.
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IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC
LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE
STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP
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Background: Ibrutinib is a first-in-class, once-daily oral inhibitor of Bruton’s
tyrosine kinase. Ibrutinib as a single agent is indicated by the EMEA and US
FDA for the treatment of adult patients with CLL and allows for treatment without
chemotherapy. The phase 3 RESONATE trial in patients with relapsed CLL
showed superior efficacy of ibrutinib compared with ofatumumab (Byrd NEJM
2014). 
Aims: We report updated safety and efficacy results of the RESONATE trial
with up to 4 years of follow-up.
Methods: Eligibility criteria included ≥1 prior therapy, ineligibility for treatment
with a purine analog, and ECOG performance status 0-1. Informed consent
was obtained from all patients prior to study initiation. Patients received oral
ibrutinib (420 mg once daily) until disease progression or unacceptable toxicity
or intravenous ofatumumab (300 mg week 1; 2000 mg weekly for 7 weeks and
then every 4 weeks for 16 weeks) for up to 24 weeks. At the interim analysis
(median follow-up of 9 months), the data monitoring committee declared supe-
riority of ibrutinib vs ofatumumab for progression-free survival (PFS) and overall
survival (OS), and access to ibrutinib was recommended for all patients in ofa-
tumumab arm who had disease progression. Long-term follow-up of efficacy
endpoints are per investigator assessment. Patients randomized to ofatumum-
ab were censored at crossover for OS.
Results: A total of 391 patients were randomized to receive ibrutinib (n=195) or
ofatumumab (n=196). The median age was 67 years, with 40% age ≥70 years,
and Rai stage III/IV in 57% of patients. At a median follow-up of 44 months (max-
imum 53 months) for the ibrutinib arm, PFS was significantly longer for ibrutinib
vs ofatumumab (median NR vs 8 months, [HR 0.133; P<0.0001]). The 3-year
PFS was 59% for ibrutinib vs 3% for ofatumumab. A significant PFS benefit was
observed across baseline subgroups. In the ibrutinib arm, PFS for the del11q
subgroup trended to have the most favorable outcome; however, PFS outcomes
were not statistically different for patients with del17p or del11q or patients without
these FISH abnormalities. At time of analysis, with the majority of patients ran-
domized to ofatumumab (68%) crossing over to receive ibrutinib therapy, OS
was longer for ibrutinib vs ofatumumab (median OS NR for either arm). The 3-
year OS rate for ibrutinib was 74%. The ORR for ibrutinib was 91% with a CR/CRi
rate that increased over time (currently 9%). Baseline cytopenias improved with
extended ibrutinib therapy for hemoglobin (85% of patients), platelet (95% of
patients), and absolute neutrophil counts (95% of patients). The adverse event
(AE) profile of ibrutinib was consistent with previous reports. During a follow-up
of up to 4 years, major hemorrhage occurred in 6%, grade ≥3 atrial fibrillation
occurred in 6%, and grade ≥3 hypertension occurred in 8% of patients. The inci-
dence of most grade ≥3 AEs decreased from year 1 vs year 2-3: neutropenia:
18% vs 8%; pneumonia: 11% vs 4%; atrial fibrillation: 4% vs 2%, respectively.
The most frequent reasons for treatment discontinuation were progressive dis-
ease (27%) and AEs (12%). At analysis, 90 patients randomized to ibrutinib (46%)
continue to receive ibrutinib.
Summary/Conclusions: In this international phase 3 RESONATE study with
median follow-up of up to 4 years, long-term treatment with ibrutinib showed a
favorable tolerability profile with sustained PFS and OS benefit regardless of
high-risk cytogenetics. The results in relapsed del17p and del11q patients com-
pared favorably to those previously reported in phase 2 studies.
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THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY
COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY
CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY
INDICATIONS OF EFFICACY
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Background: Ibrutinib (IBR) is an oral BTK inhibitor with high response rates in
CLL. Venetoclax (VEN) is a potent, highly selective, orally bioavailable small-
molecule BCL2 inhibitor. Both IBR and VEN are approved by both the FDA and
EMA as single agents for chronic lymphocytic leukaemia (CLL). IBR leads to a
rapid nodal response with re-distribution of CLL into the peripheral blood whereas
VEN leads to depletion of CLL cells to levels in some patients where they cannot
be detected. Two of the key cellular processes that are abnormal in CLL are pro-
liferation and apoptosis. The combination of IBR with VEN is therefore logical as
biologically the two drugs would be expected to be synergistic. The eradication
of minimal residual disease (MRD) from blood and bone marrow is associated
with improved outcome in any treatment of CLL where it has been reported.
Aims: The CLARITY trial (ISCRTN: 13751862) is a feasibility study to investi-
gate the safety and efficacy of IBR combined with VEN in patients with
relapsed/refractory CLL. Here we report for the first time the safety of the com-
bination as well as early signs of potent synergy.
Methods: After 8 weeks of IBR monotherapy (420mg/day), VEN was added
initially at a dose of 10mg/day with weekly escalations to 20mg, 50mg, 100mg,
200mg to a final dose of 400mg/day. After the initial 3 patients when there was
no sign of tumour lysis syndrome (TLS) the starting dose of VEN was amended
to 20mg/day. The primary end-point of the trial is MRD eradication (defined as
less than 1 CLL cell in 10,000) in the bone marrow after 12 months of IBR+VEN.
Key secondary end-points are MRD eradication from the bone marrow after 6
and 24 months of combined IBR and VEN as well as the safety of the combi-
nation. Important safety events that were considered critical were the incidence
of laboratory and clinical TLS. All patients were given prophylactic treatment
with uric acid reducing agents beginning at least 72 hours prior to their initial
dose of VEN. Over the first three months of combined therapy the level of CLL
in the peripheral blood was monitored weekly during VEN escalation and then
monthly thereafter. 50 participants will be treated in total.
Results: A total of 35 patients have been recruited between May 2016 and Jan-
uary 2017. To date 21 patients have completed the dose escalation period of
VEN in combination with IBR. To date there has been only a single case of lab-
oratory TLS in a patient whose phosphate (1.21 to 1.48mmol/l) and creatinine
(75 to 146 umol/l) both increased when VEN was increased from 100mg to
200mg. Dosing of VEN was interrupted for 7 days (due to the logistics of clinic
closure periods over the Christmas break) and IBR for 24 hours. The biochemical
abnormalities resolved within 24 hours and the patient subsequently escalated
to 400mg/day of VEN with no further TLS. As yet there have been a total of 5
SAEs and 22 AE’s of special interest with notably lung infection (n=3) and neu-
tropenia (n=11) occurring on more than one occasion. All SAE’s resolved with
appropriate management and all patients remained on therapy. No SUSAR’s
have been reported and no AE’s have been fatal. The level of CLL in the peripheral
blood increased during the 8 weeks of IBR monotherapy at 420mg/day from a
median of 50 x 109/l (range: 0 to 330) to 55 x 109/l (range: 0 to 237) and then fell
during the first 8 weeks of combined IBR with VEN (4 weeks dose escalation fol-
lowed by 4 weeks at 400mg/day) from a median of 55 x 109/l to a median of
0.017 x 109/l (range; 0 to 3.1). The rate of fall is rapid in all patients with a median
of 3 log reduction in CLL level after 8 weeks of combined therapy.
Summary/Conclusions: The combination of IBR with VEN is well tolerated in
relapsed, refractory CLL with to date only a single case of laboratory TLS. The
rapid reduction in the peripheral blood CLL level even during the escalation
phase of VEN with IBR is promising and suggests a potent synergy between
the drugs. The initial bone marrow responses are expected after 6 months of
combination therapy.
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VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC
LEUKEMIA WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL
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Background: Venetoclax monotherapy in patients (pts) with relapsed/refrac-
tory CLL harboring deletion 17p (del17p) resulted in an ORR of 79% with a CR
rate of 7% as determined by an independent review committee at the initial
analysis of the pivotal M13-982 trial (n=107). Subsequently, 51 additional pts
were enrolled in a safety expansion cohort. 
Aims: To present results from the full trial, including minimal residual disease
(MRD) status by both flow cytometry and next generation sequencing (NGS). 
Methods: Pts received venetoclax 400 mg daily after initial standard ramp-up
until PD or discontinuation due to other reasons. CT scan was mandatory at
week 36, after which disease assessment was by clinical evaluation. MRD
assessment was performed beginning with the first clinical assessment of CR
or PR with nodes <2 cm and then every 12 weeks until MRD negativity (defined
at 10−4 sensitivity). MRD was assessed by NGS and multicolor flow cytometry
and the best response was reported. Data cutoff date was 10 June 2016.
Results: Pts (N=158) had a median age of 67 (range, 29–85) years; a median
of 2 prior therapies (range, 0–10); 32% were fludarabine refractory; 11% had
previously received a B-cell receptor signaling inhibitor (BCRi); 48% had nodes
≥5 cm; and 78% had unmutated IGHV. The median duration of venetoclax
therapy was 16.7 (range 0–34.4) months. Primary reasons for discontinuation
(50.6% of pts) were PD (31.0%), adverse events (AEs) (12.6%), withdrawal of
consent (2.5%), stem cell transplant (2.5%), and other (1.9%). For all 158 pts,
the investigator-assessed ORR was 77% and CR rate was 18%. The 24-month
estimates for progression-free survival (PFS) and overall survival (OS) were
52% and 72%, respectively. The safety expansion cohort included 5 pts with
previously untreated del(17p) CLL. These pts had an ORR of 80%, CR rate of
40%, and all 5 were alive and progression-free 1 year after the start of study
treatment. Among the 18 pts with prior BCRi treatment, ORR was 61% and CR
was 11%, with 12-month PFS and OS estimates of 50% and 72%, respectively.
The most commonly reported AEs were neutropenia (42%), nausea (37%),
diarrhea (37%), anemia (24%), and fatigue (22%). The most common grade
3–4 AEs were neutropenia (39%), thrombocytopenia (15%), and anemia (14%).
Infection rate (77% all grades, 22% grade 3–4) and spectrum were consistent
with the underlying disease. The rate of laboratory tumor lysis syndrome (TLS)
was 5%, with no cases of clinical TLS. Of 101 pts with evaluable blood MRD
by flow cytometry, 76 also had MRD data by NGS. From the full trial cohort of
158 pts, 42 (27%) demonstrated blood MRD negativity at 10-4 by flow cytom-
etry, and 28 had a contemporaneous NGS sample. MRD negativity (10−4 sen-
sitivity) was confirmed by NGS in 20 pts (71%), and 8 pts (29%) were MRD-
positive by NGS. MRD negativity by NGS (≤10−4) was observed in 22 pts in
blood; 9 pts were also negative in the marrow although not necessarily at the
same time. One pt negative by NGS did not have a matching flow cytometry
assessment and 1 pt was positive by flow cytometry (0.008% vs 0.02%). Pts
who achieved blood MRD-negative CR by flow cytometry (n=19) had a 24-
month PFS estimate of 100%, compared with 78.5% pts who had blood MRD-
negative PR (n=23). Similar results were obtained when assessed by NGS.
Summary/Conclusions: Venetoclax monotherapy resulted in a high response
rate that was durable in this high-risk population, including among pts who had
previously received a BCR inhibitor. MRD negativity by either flow cytometry
or NGS correlated with outstanding outcomes. 
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CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB,
AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS
WITH ADVANCED CLL AND NHL
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Background: Novel targeted agents are emerging for B-cell malignancies, but
few studies have safely combined these agents. Ublituximab (UTX) is a novel
glycoengineered mAb targeting a unique epitope on the CD20 antigen. TGR-
1202 is a next generation, once daily, PI3Kδ inhibitor, demonstrating a favorable
safety profile compared to prior inhibitors, including in long-term follow up (Bur-
ris, 2016). 
Aims: This Ph 1 trial evaluates the safety/efficacy of the triplet combination of
a novel anti-CD20 mAb+PI3Kδ+BTK inhibitor (ibrutinib) in pts with B-cell malig-
nancies.
Methods: Eligible pts had CLL or rel/ref NHL w/o limit to prior therapies, includ-
ing those ref to prior PI3Kδ or BTK inhibitors. UTX dosed on D 1, 8, 15 of C 1,
D 1 of C 2-6, and C 9 & 12. TGR-1202 dose escalated (400/600/800mg QD),
ibrutinib dosed at 420mg (CLL) or 560mg (NHL), both on C1D1.
Results: 38 pts were enrolled: 20 CLL/SLL and 18 NHL, including 6 follicular (FL),
6 DLBCL, 4 mantle cell (MCL) and 2 marginal zone (MZL). Med age 65 yrs (range
32-85); 29 M/9 F; med prior tx=3 (range 0-6). 2 pts ref to prior PI3Kδ /2 prev
treated with ibrutinib (1 ref/1 rel). MTD was not reached. Most common (>20%)
all causality AE’s were fatigue (42%), diarrhea (39%), dizziness (34%), nausea
(32%), neutropenia, pyrexia, rash, infusion reaction, insomnia (each at 29%),
thrombocytopenia, cough (each at 26%), anemia (24%) and sinusitis (21%). GR
3/4 AE’s (all causality) were minimal, the only event >10% was neutropenia (16%).
ORR amongst 36 evaluable pts is shown in the following Table 1.
Table 1.
53% of evaluable CLL pts had high-risk cytogenetics and 4/6 DLBCL pts were
non-GCB. One CLL pt (17p/11q del) ref to PI3Kδ and ibrutinib achieved a CR.
Med time on study is 10 mos (range 1-27 mos). Med DOR not reached (range
3-24 mos).
Summary/Conclusions: This is the first known triplet combination of an anti-
CD20 mAb+PI3Kδ+BTK inhibitor. The combination of UTX, TGR-1202, and
ibrutinib has been well tolerated with activity observed across heavily pre-treat-
ed and high-risk B-cell malignancies. Expansion cohorts at the highest dose
(800mg TGR-1202+full dose ibrutinib) are underway. Future trials for the triplet
are warranted.
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THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES
COMPLETE INHIBITION OF SYK AND JAK AND RAPID TUMOR
RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH
RELAPSED/REFRACTORY B CELL MALIGNANCIES
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Background: Subsets of B cell malignancies are addicted to B cell antigen
receptor (BCR) signaling for survival. Co-stimulation of the BCR with IL-2 or
IL-4 in normal B cells significantly enhances cellular activation relative to BCR
or cytokine stimulation alone, and combining SYK selective and JAK selective
inhibitors synergize to suppress this response (Coffey et al., 2013). Hence,
BCR/SYK and cytokine JAK/STAT signals cooperate to control B cell activation.
This cooperation appears to be relevant to B cell malignancies as well. IL-4
promotes the survival of CLL cells in culture via up-regulation of MCL1 and
BCLXL, protecting the tumor from death induced by fludarabine and chloram-
bucil (Steele et al., 2010) and by idelalisib and ibrutinib (Aguilar-Hernandez et
al., 2016). Also, unlike ibrutinib, combined SYK and JAK inhibition by cerdula-
tinib induces apoptosis in primary CLL cells and leads to down-regulation of
MCL1 and BCLXL (Blunt et al., 2015) and induces apoptosis in cells from ibru-
tinib-resistant CLL patients (Guo et al., 2017). It also induces apoptosis in pri-
mary DLBCL and DLBCL cell lines that carry BCR pathway mutations resistant
to ibrutinib (Ma et al, 2015). Combined SYK/JAK inhibition may therefore rep-
resent a powerful strategy to control B cell malignancies. A phase I dose esca-
lation study of cerdulatinib in 43 patients with relapsed/refractory CLL and NHL
was recently completed (Hamlin et al., EHA Congress 2016). Inhibition of both
BCR/SYK and JAK/STAT signaling pathways by >90% in peripheral blood
assays was well tolerated. Durable PRs and 1 CR were observed in CLL and
FL, including in patients who had relapsed on prior BCR inhibitor therapy. No
consistent hepatic toxicity, anemia, thrombocytopenia or neutropenia was
observed. Two grade 3 dose limiting toxicities were observed at 45 mg BID
(fatigue, pancreatitis). 35 mg BID was identified as the Phase 2 dose based on
Phase 1 data and on PK/PD modeling. 
Aims: The primary aim of the study was to understand the safety and activity
of cerdulatinib in B-cell malignancies.
Methods: This is an open-label study with 28-day cycles. Twice daily (BID; 30
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mg and 35 mg) dosing was evaluated. Pharmacokinetics (PK), pharmacody-
namics (PD), and safety were monitored, as well as an assessment of efficacy.
Clinical response was assessed by standard criteria. Potency and specificity
for SYK and JAK pathway inhibition were measured in whole blood assays by
monitoring signaling responses following ligation of the BCR and receptors for
IL-4. Serum markers of inflammation, minimal residual disease (MRD) and
apoptosis in CLL patients were also measured.
Results: A phase 2 study was initiated in May 2016 to enroll up to 40 patients
in each of three cohorts; 1) relapsed/refractory CLL/SLL, 2) relapsed/refractory
indolent NHL, and 3) relapsed DLBCL, MCL and transformed FL. As of March
1, 2017, 37 patients have been enrolled, 17 with CLL/SLL, 15 with indolent NHL
(10 FL, 4 MZL, 1 WM), and 5 with aggressive NHL (3 DLBCL, 1 MCL, 1 tFL).
Median patient age is 70 years (range, 51-93). The median number of prior ther-
apies is 3 (range 1–7). 11 patients had prior BTK or PI3K inhibitor therapy. The
safety profile has been similar to what was seen in the Phase 1 study. However,
3 patients at 35 mg BID achieved higher than expected drug concentrations and
had SAEs (2 grade 5 infections, 1 grade 3 pancreatitis). The starting dose was
reduced to 30 mg BID and a PK monitoring and dose reduction strategy has
been implemented. To date, this has resulted in a better safety profile without
PK outliers. The most common AEs of any grade have been diarrhea (27%),
fatigue (27%) and nausea (24%). Grade 3+ AEs occurring in more than 1 patient
are infection (5 patients), abdominal pain (3 patients) and hypertension (3
patients). As seen in phase 1, significant inhibition of SYK and JAK signaling
pathways in peripheral blood is observed. Evidence for tumor cell mobilization
to peripheral blood in CLL/SLL is consistently observed following one week of
therapy. PRs have been seen in all 3 cohorts including 10 of 13 (77%) CLL/SLL
and 3 of 6 (50%) FL patients evaluated. Of these 13 PRs, 12 are still on drug
with 4 patients in response for greater than 6 months. In addition, PRs have
been seen in patients who relapsed on ibrutinib (FL patient, 8+ months) and
venetoclax (SLL patient, 7+ months) therapy. As demonstrated preclinically, we
have seen evidence of apoptosis (Annexin V+ B-cells) in 6 CLL patients. 5 of
these patients had a PR at the end of the 2nd cycle (Figure 1).
Figure 1.
Summary/Conclusions: Cerdulatinib demonstrates clinical activity in heavily
pretreated patients with CLL/B-cell NHL and is generally well tolerated. Con-
sistent activity is seen in patients with CLL and FL. Accrual is proceeding; updat-
ed PK/PD, safety and efficacy will be presented.
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COMPARISON OF CONTRAST-ENHANCED CT-BASED RESPONSE WITH
PET ASSESSMENT AFTER FIRST-LINE THERAPY FOR FOLLICULAR
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Background: Published data show 18F-FDG PET-CT (PET) is predictive after
first-line immunochemotherapy in advanced-stage symptomatic FL, and PET
is now the recommended modality for response assessment. However, no
large-scale prospective comparison of the value of standard contrast-enhanced
CT vs PET response has been performed.
Aims: To compare CT and PET response assessment for FL pts in the prospec-
tive Phase III GALLIUM study, which evaluated chemotherapy plus obinutuzum-
ab (G-chemo) or rituximab (R-chemo) induction followed by maintenance anti-
body therapy (Marcus 2016).
Methods: PET scans, introduced after an early protocol amendment (July
2011), were performed at baseline and end of induction (EOI; all pts gave
informed consent) and assessed by the investigator (INV) and an independent
review committee (IRC) comprising two radiologists, with a third adjudicator;
final response was determined by a clinician. Response was assessed by CT
and PET plus bone marrow biopsy, applying the revised International Working
Group (IWG) criteria (Cheson 2007, Juweid 2007). Complete remission (CR)
status at EOI for each assessment, CT-CR and PET-CR, was compared with
pt characteristics, PFS and OS.
Results: Among 1202 ITT pts with FL enrolled in GALLIUM, IRC-assessed CT
showed a CR in 330 pts (27.5%), PR in 747 (62.1%), SD in 20 (1.7%), PD in
35 (2.9%), unavailable (NA) in 48 (4.0%) and unevaluable (NE) in 22 (1.8%).
Of 609 pts with a baseline PET scan, 595 had detectable lesions, and 535 also
had an evaluable PET at EOI. Baseline demographics and disease character-
istics were similar in PET and non-PET populations. Pts with NA (n=52) or NE
(n=8) scans were considered non-responders; these pts and those with PD
prior to EOI were excluded from landmark PFS analyses. At EOI, 390/595
(65.5%) pts achieved a PET-CR according to IRC, comprising 212/297 (71.4%)
G-chemo pts and 178/298 (59.7%) R-chemo pts. However, for these 390 pts,
evaluable CT responses were 161 CR (41.3%), 216 PR (55.4%) and 5 SD/PD
(1.3%; Table 1). Conversely, PET assessment showed a PET-CR in 161/177
(91.0%) of pts achieving a CT-CR, and PET-PR in only 117/362 (32.3%) of pts
with CT-PR. Concordance between CT and PET assessment was 52.6% for
IRC and 54.1% for INV. Concordance between INV and IRC evaluation was
71.9% for CT and 68.6% for PET. After a median follow-up of 34.5 mo (range
0–54.5), IRC-PET status was highly predictive of PFS (PET-CR vs PET non-
CR: HR 0.39; 95% CI 0.25–0.60; p<0.0001) and OS (HR 0.41; 95% CI 0.19–
0.86; p=0.018). 2.5-yr PFS from EOI was 87.6% (95% CI 83.5–90.8) for PET-
CR pts compared with 70.9% (95% CI 61.3–78.6) for PET non-CR pts; corre-
sponding OS was 96.6% (95% CI 94.1–98.1) vs 90.9% (95% CI 84.7–94.6)
(Figure 1). 
Table 1. CT and PET clinical response assessment by IRC at EOI 
Summary/Conclusions: This large prospective analysis confirms EOI PET as
an early predictor of PFS and OS in FL, with good concordance between INV
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and IRC PET evaluation. Comparison of PFS based on CT-response and re-
analysis of PET scans applying the now recommended 5-point scale for PET
response assessment will be presented. Pooled analyses of these and data
from other studies with longer follow-up may determine PET response as a
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Background: The Phase III GALLIUM study (NCT01332968) showed that
obinutuzumab (GA101; G) significantly prolonged PFS in previously untreated
FL pts relative to rituximab (R) when combined with chemotherapy (chemo;
CHOP, CVP or bendamustine [B]). Grade 3–5 and serious AEs were more
common with G-chemo.
Aims: To explore outcomes by immunochemotherapy regimen.
Methods: Pts were aged ≥18 yrs with documented, previously untreated FL
(grades 1–3a), advanced disease (stage III/IV or stage II with tumor diameter
≥7cm), ECOG PS 0–2, and requiring treatment according to GELF criteria.
Chemo regimen was allocated by center. Pts were randomized 1:1 (stratified
by chemo, FLIPI-1 group and geographic region) to R 375mg/m2 on day (D)
1 of each cycle (C) or G 1000mg on D1, 8 and 15 of C1 and D1 of C2–8, for
6 or 8 cycles depending on chemo. Pts with CR or PR at EOI (per Cheson
2007) continued to receive R or G every 2 months for 2 yrs or until progres-
sion. The cut-off date for this analysis was September 10 2016. All pts gave
informed consent.
Results: 1202 FL pts were randomized. Baseline characteristics were gen-
erally similar across chemo groups, although B and CVP pts had relatively
more comorbidities, e.g. GI and vascular disorders, than CHOP pts. After
41.1 months’ median follow-up, investigator (INV)-assessed PFS remained
superior for G-chemo relative to R-chemo (HR, 0.68; 95% CI 0.54–0.87;
p=0.0016) with consistent HRs across chemo groups (Figure 1). HRs for
secondary time-to-event endpoints were supportive of the primary analysis.
Difference in frequency of grade 3–5 AEs between arms was highest with
CHOP and CVP (Table 1). Rates of second neoplasms and grade 3–5 infec-
tions were similar in G and R arms for CHOP and CVP but not for B. In all
chemo groups, SAEs were more frequent with G than R, and AEs causing
treatment discontinuation and fatal AEs were similar. Reductions in T-cell
counts were more pronounced and prolonged in the B group than CHOP or
CVP groups.
Figure 1.
Table 1. Safety summary (number (%) of FL pts* with ≥1 AE).
Summary/Conclusions: In treatment-naive FL pts, PFS was superior with G-
chemo relative to R-chemo with consistent effects across chemo regimens.
Some differences were seen in safety profiles between chemo regimens, but
comparisons may be confounded by the lack of randomization.
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Background: Follicular lymphoma (FL) is the most common indolent non-
Hodgkin lymphoma (iNHL) subtype, yet treatment options in the relapsed/refrac-
tory setting are limited. Copanlisib is a potent and selective pan-class I PI3K
inhibitor with predominant activity against the δ- and α-isoforms.
Aims: We report results from the FL subset of a large phase II study in iNHL
patients (NCT01660451, part B).
Methods: Patients with histologically confirmed indolent indolent FL (grade 1-
3a) relapsed/refractory to ≥2 prior lines of treatment were treated with copanlisib
(60 mg IV infusion) administered on days 1, 8 and 15 of a 28-day cycle until
disease progression or unacceptable toxicity. The primary endpoint was objec-
tive response rate (ORR) as assessed by independent radiology review accord-
ing to the response criteria for lymphoma (Cheson et al, JCO 20:579, 2007).
Secondary endpoints included progression-free survival (PFS) and duration of
response (DOR), safety and tolerability. 
Results: A total of 141 patients with iNHL were treated in the phase II study,
including 104 patients with FL. The FL subset was characterized as: 52%
male, 83% white, median age 62 yrs, 62% ECOG 0, 63% refractory to last
therapy, median time from most recent progression 8 wks (range 1-73) and
median prior lines of therapy 3 (range 2-8). At the time of primary analysis
the ORR was 58.7%, comprising 15 patients (14.4%) with complete response
and 46 (44.2%) with partial response. Stable disease was observed in 35
(33.7%) patients and progression of disease as best response in 2 patients.
The median duration of response was 370 days (range 0-687), with 43
responders censored at data cut-off. Median duration of treatment was 22
wks (range 1-105); 33 (32%) patients remained on treatment. Per investigator
assessment, 87 of 96 evaluable patients (91%) had some degree of tumor
shrinkage as best response, and 58/96 (60%) had >50% tumor shrinkage
(Figure 1). For all patients in the phase II study, the most common treatment-
emergent AEs occurring in >25% of patients included (all grade/grade 3+):
diarrhea (34%/5%), reduced neutrophil count (30%/24%), fatigue (30%/2%),
and fever (25%/4%). Hyperglycemia (50%/41%) and hypertension (30%/24%)
were transient. The incidence of pneumonitis (8%/1.4%), hepatic enzymopa-
thy (AST 28%/1.4%; ALT 23%/1.4%), opportunistic infection (1.4%) and colitis
(0.7%) were low. Six deaths were observed, 3 of which were attributed to
copanlisib: one lung infection, one respiratory failure, and one thromboem-
bolic event.
Figure 1.
Summary/Conclusions: Copanlisib was highly active as a single agent in
heavily pretreated relapsed/refractory FL patients and resulted in responses
in the majority of patients, with a median duration of response exceeding one
year. Toxicities were manageable, with a low incidence of severe AEs asso-
ciated with other PI3K inhibitors, especially hepatic enzymopathy, opportunis-
tic infections, and colitis.
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Background: Duvelisib is an oral, dual inhibitor of PI3K-δ,γ in development for
the treatment of hematologic malignancies. DYNAMO is a Phase 2 study to
evaluate the safety and efficacy of duvelisib monotherapy in a double refractory
iNHL population, which included a majority of patients (pts) with follicular lym-
phoma (FL).
Aims: The primary objective was to evaluate the antitumor activity of duvelisib
monotherapy in pts whose disease is refractory to rituximab and to either
chemotherapy or RIT, with an additional objective to further characterize the
safety of duvelisib.
Methods: DYNAMO is an open-label, single-arm, safety, and efficacy study in
patients (pts) with FL, small lymphocytic lymphoma (SLL), or marginal zone
lymphoma (MZL), whose disease is double-refractory to rituximab (monother-
apy or in combination) and to chemotherapy or radioimmunotherapy. Pts
received duvelisib 25 mg BID in 28-day treatment cycles until disease progres-
sion or unacceptable toxicity. The primary endpoint is overall response rate
(ORR) as assessed by an independent review committee (IRC) per revised
IWG criteria. Secondary endpoints include duration of response (DoR), pro-
gression-free survival (PFS), overall survival (OS), time to response (TTR),
adverse events (AEs) and other safety parameters. Pneumocystis jiroveci pneu-
monia (PJP) prophylaxis was mandated for all pts.
Results: 129 pts with iNHL were treated on study. Of these, 83 pts with FL
received duvelisib with a median duration of exposure of 6 mo. (range: 0.4 -
24). Median age was 64 years; 68% were male. Most FL pts had an ECOG
performance status score at baseline of 0 (51%), followed by 1 (42%) and 2
(7%). Most FL pts (65%) had a FLIPI score at baseline ≥3, and most had
either Stage 3 (46%) or Stage 4 (39%) disease. Median time from last anti-
cancer therapy to first dose of duvelisib was 3.2 months. FL pts received a
median of 3 prior anticancer regimens (range: 1 - 10); 65% of pts received
≥3 prior regimens, 17% ≥6 prior regimens. The ORR was 41% (CI: 30, 52),
all of which were PRs. 36% of pts had SD as best response, and 17% had
PD as best response. 6% of pts were not evaluable, as they only had a base-
line scan. Median TTR was 1.9 mo. (range: 1.6 - 11.7). 80% of FL pts expe-
rienced a reduction in nodal target lesions after treatment with duvelisib.
Among the 34 FL pts with a response per IRC, the median DoR was 9.2
months. The median PFS for all FL pts was 8.3 months, while the median OS
was 11.1 months. Among all pts treated on study (n=129), AEs were mostly
Gr 1-2. Most common ≥Gr 3 AEs were transient cytopenias [neutropenia
(23%), anemia (12%), and thrombocytopenia (10%)] and diarrhoea (15%).
17% of pts discontinued duvelisib due to an AE. Opportunistic infections
occurred in <5% of pts, none were fatal, and included 1 pt (0.8%) with pneu-
mocystis and 3 pts (2.3%) with CMV infections. Six pts had an AE with a fatal
outcome. 
Summary/Conclusions: In DYNAMO, duvelisib showed clinical activity in a
double-refractory FL population (41% ORR, median DoR 9.2 mo., 80% with
reduction in target lesions). Duvelisib was generally well tolerated, with a man-
ageable safety profile with appropriate risk mitigation. Duvelisib monotherapy
has a favorable benefit-risk profile in double-refractory iNHL, and may represent
an important treatment option. Updated clinical data will be available at the
time of presentation. 
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Background: Between March 2000 and May 2005 a multicenter randomized
trial comparing frontline use of CHOP-R vs R-HDS with autograft has been
performed on 134 Follicular Lymphoma (FL) patients, selected for age less
than 60 yrs. and poor prognostic features according to age-adjusted IPI (2-3)
and IIL-score (3 or greater). Results at 4-yr follow-up were previously published
(Ladetto M et al, Blood 2008), showing superior disease control with R-HDS
without any survival advantage.
Aims: We have recently performed a long term update and the results at a
median follow-up of 13 yrs are here presented.
Methods: The long-term outcome has been updated for 119 out of the original
134 randomized patients (56 CHOP-R and 63 R-HDS arms). Main features
of the updated patients included: median age 51 yrs. (22-60), M/F ratio 68/51,
aaIPI 2-3 90%, high LDH 43%, bulky disease 60%, B-symptoms 46%, BM
involvement 86%; no significant differences were observed in clinical pres-
entation between the two arms, as previously reported. Treatment schedule
consisted of: i. CHOP-R arm: 6 courses of
cyclophosphamide/doxorubicin/vincristine/prednisone followed by 4-weekly
rituximab courses; ii. experimental R-HDS arm: rituximab with high-dose
sequential chemotherapy followed by autografting. The analysis was intention
to treat with event-free survival as the primary endpoint. Minimal residual
disease (MRD) was evaluated post treatment in 56 patients with a bcl-2/IgH
MBR or mcr translocation confirmed at diagnosis by nested PCR. The trial
was registered at www.clinicaltrials.gov, no. NCT00435955. The long-term
outcome has been updated in January 2017 by 27 out of 30 participating
Centers, on 119 patients (88% of the whole series).
Results: Complete remission (CR) was achieved by 86 (72%) patients, includ-
ing 32 (57%) with CHOP-R and 54 (85%) with R-HDS (p <.001); Molecular
Remission (MR) was achieved in 37 out of 56 (66%) evaluable patients. At a
median follow-up of 13 yrs., 74 patients (63%) are alive. Overall, 22 patients
died for lymphoma progression (13 CHOP-R, 9 R-HDS), 12 died for secondary
malignancy (3 in the CHOP-R, 9 in the R-HDS arms), 11 patients died for other
causes, including four early toxic deaths. The overall survival (OS) for the whole
series is 63% at 13 yrs, as shown in Figure 1A. No significant differences in
the long-term OS were observed between the two arms, with 13-yr survival of
65% and 61% for CHOP-R and R-HDS, resppectively (p=0.51). At 13 years,
the event free survival is 35%, whereas the disease-free survival (DFS) is of
53%, as shown in Figure 1B. Response to induction therapy had a major impact
on the OS, with 13 yr survival of 75% for patients achieving CR vs 33% for
those with less than CR (p <.001). Similarly, Molecular Remission (MR)
achievement was associated with prolonged OS, with 13 yr survival of 81% for
patients in MR on BM cells, and of 47% for those with positive MRD (p=.02)
(Figure 1C).
Figure 1.
Summary/Conclusions: i. poor risk FL may have a prolonged survival, with
63% of patients alive at 13 yrs.; ii. no survival differences between CHOP-R
and R-HDS can be detected even at 13 yrs of follow-up; iii. achieving CR is
still crucial for the long-term survival; iv. the MRD analysis has a prognostic
impact not only on progression-free but also on OS; v. lymphoma progression
remains the major cause of death, while secondary neoplasms represent the
second cause of treatment failure; vi. a subgroup of advanced-stage FL may
experience a prolonged DFS lasting at least 13 yrs: this raises the issue of the
potential curability of FL.
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Changing the strategy of therapy in
multiple myeloma
S779
PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE,
AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE
MYELOMA
I. Ghobrial1,*, A. Caola1, P. Henrick1, A. Savell2, J. Cappuccio1, B. Rivotto1,
K. Reyes1, C. Paba-Prada1, R. Schlossman1, J. Laubach1, P. Richardson1,
K. Noonan1, N. Munshi1, C.-J. Liu1, M. Bustoros1, A. Badros3, J. Matous4,
J. Rosenblatt5, A. Yee6, R. Maegawa7, S. Usmani8, J. Vredenburgh9,
A. Boruchov9, O. Nadeem10, D. Bhutani11, A. Jakubowiak 12, M. Bhutani8,
K. Salem1, S. Manier1, J. Park1
1Multiple Myeloma, Dana-Farber Cancer Institute, 2Blood Cancer Research Part-
nership, Boston, 3Multiple Myeloma, University of Maryland Greenebaum Cancer
Center, Baltimore, 4Multiple Myeloma, Colorado Blood Cancer Institute, Denver,
5Multiple Myeloma, Beth Israel Deaconess Medical Center, 6Multiple Myeloma,
Massachusetts General Hospital, Boston, 7Multiple Myeloma, Eastern Maine
Medical Center, Bangor, 8Multiple Myeloma, Levine Cancer Institute, Charlotte,
9Multiple Myeloma, St. Francis Hospital, Hartford, 10Multiple Myeloma, Newton-
Wellesley Hospital, Newton, 11Multiple Myeloma, Barbara Ann Karmanos Cancer
Institute, Detroit, 12Multiple Myeloma, University of Chicago Medical Center,
Chicago, United States
Background: This study aimed to determine the benefit of early therapeutic
intervention with the combination of elotuzumab, lenalidomide, and dexam-
ethasone in patients with high-risk smoldering multiple myeloma (SMM).
Aims: The overarching objective of this trial is to determine progression free
survival to symptomatic myeloma (MM). Furthermore, the study examined
whether genomic studies can help in determining patients who would benefit
the most from this early therapeutic intervention.
Methods: Patients enrolled on study met eligibility for high-risk SMM based on
the newly defined criteria proposed by Rajkumar et al, Blood 2014. Patients
were administered weekly elotuzumab (10 mg/kg) on days 1, 8, 15, and 22 for
the first two 28-day cycles while receiving lenalidomide on days 1-21. For cycles
3-8, patients were administered elotuzumab infusions on days 1, 8, and 15.
Dexamethasone (40mg) was given on days 1, 8 and 15 for 40 of the 50 patients
enrolled. After 8 cycles or best response, patients were given the option to
mobilize with either cyclophosphamide or plerixafor and collect stem cells for
future transplant. Patients were then allowed to continue on maintenance ther-
apy where they were administered elotuzumab (20 mg/kg) on day 1, in combi-
nation with lenalidomide days 1-21 of a 28 day cycle. Bone marrow samples of
33 patients were obtained before starting therapy for baseline assessment and
whole exome sequencing (WES) of plasma cells.
Results: In total, 50 patients were enrolled on this study from January 2015
to date, with the participation of eight sites. The median age of patients
enrolled was 62 years (range 29 to 79) with 18 males (36%) and 32 females
(64%). Interphase fluorescence in situ hybridization (iFISH) detected high
risk cytogenetics in 20 patients. The median number of cycles completed is
12 (range 1 to 24). Therapy related grade 3 toxicities included hypophos-
phatemia (30%), neutropenia (14%), infection (12%), anemia (2%), pulmonary
embolism (2%), rash (4%), and diarrhea (2%). Therapy related grade 4 toxi-
cities included thrombocytopenia (2%), neutropenia (2%) and one instance
of cholecystitis (2%). Stem cell collection was successful in all patients col-
lected to date. Of the 31 evaluable patients that completed the first 8 cycles
of therapy, the overall response rate was 84%, including 2 complete respons-
es (7%), 11 very good partial responses (36%) and 13 partial responses
(42%), and a clinical benefit rate of 100%. None of the patients showed pro-
gression to overt MM to date. WES was performed on 25 samples at the time
of initiation of therapy. Recurrent mutations in the MAPK pathway (KRAS,
NRAS) and tumor suppressor gene, TP53, were detected in 32% of the cases
(16% each), while mutations in NF-KB and plasma cell differentiation path-
ways were present in 10% of patients. CCND1 gene mutation was seen in 1
patient and was associated with t(11:14) as reported in the previous WES
studies of MM. CNAs were called based on WES: 1q amplification, 13q, 17p,
and 1p deletions were identified in 28, 20, 16, and 12% of cases, respectively.
Interestingly, in 6 patients, high-risk CNAs were not reported in iFISH but
were detected by WES. Finally, we assessed the correlation between neoanti-
gen load and clinical response.
Summary/Conclusions: The combination of elotuzumab, lenalidomide, and
dexamethasone is well tolerated and demonstrates a high response rates with
no progression to overt MM to date. Correlation with genomic studies can help
define patients who benefit the most from this early therapeutic intervention.
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Background: Addition of a proteasome inhibitor to a doublet backbone therapy
has been shown to improve efficacy in newly diagnosed multiple myeloma
(NDMM) patients (San Miguel et al, N Engl J Med 2008, Durie et al, Lancet
2017). Data from two phase 1/2 studies indicate that the combination of ixa-
zomib plus lenalidomide-dexamethasone (IRd) is feasible and active in patients
with NDMM, with weekly and twice-weekly ixazomib dosing having been inves-
tigated (Kumar et al, Lancet Oncol 2014; Richardson et al, Blood 2013).
Aims: This phase 1/2 study (NCT01383928) evaluated twice-weekly ixazomib
plus Rd as induction therapy, followed by maintenance therapy with single-
agent ixazomib. We report long-term efficacy and safety data in patients who
did not withdraw from the study in order to receive SCT. 
Methods: Patients with NDMM (SCT-eligible or SCT-ineligible) received twice-
weekly oral ixazomib (3.0 or 3.7 mg on days 1, 4, 8, and 11) plus lenalidomide
(25 mg on days 1–14) and dexamethasone (20 mg [10 mg in cycles 9–16] on
days 1, 2, 4, 5, 8, 9, 11, and 12) for up to sixteen 21-day cycles, followed by
maintenance therapy with single-agent twice-weekly ixazomib. Patients
received therapy until disease progression or toxicity. Those who proceeded to
SCT did not receive further ixazomib therapy. Response/progression was
assessed per IMWG criteria after cycles 1, 2, 3, 4, and then every 2 cycles dur-
ing induction and maintenance.
Results: Of the 64 enrolled patients, 40 continued on study treatment without
early withdrawal for SCT; long-term follow-up of these 40 patients is reported
here. The median age of patients was 66 years (range 34–82), and
45%/38%/18% of patients had ISS disease stage I/II/III. At a median follow-up
of 47.0 months, the overall response rate (ORR; ≥partial response [PR]) in the
response-evaluable population was 95%, the complete plus very good partial
response (CR+VGPR) rate was 68%, and the CR rate was 32%. Median time
to first response was approximately 1 cycle (0.72 months). Median time to a
best response of ≥CR was 4.2 months. Patients received a median (range) of
14 (1–75) treatment cycles. Median progression-free survival (PFS) for patients
not proceeding to SCT was 24.9 months. Median overall survival (OS) was not
estimable; the 2-year Kaplan-Meier estimate for OS was 92%. A total of 78%
of patients had grade ≥3 treatment-related adverse events (AEs); the most
common treatment-related grade ≥3 AEs and serious AEs are shown in the
Table 1. After completing induction therapy with IRd, 18 patients went on to
receive maintenance with single-agent ixazomib on a twice-weekly dosing
schedule. Patients who went on to maintenance received a median (range) of
31.5 (17–75) treatment cycles. Among the patients who received maintenance
treatment, the ORR (≥PR) was 94%, the CR+VGPR rate was 89%, and the CR
rate was 44%. Two (11%) patients improved their responses during mainte-
nance (1 VGPR to stringent CR, and 1 VGPR to near-CR). Five (28%) patients
who received maintenance therapy had an onset of a grade ≥3 treatment-relat-
ed AE in cycle 17 or beyond. Rash (aggregate term) was infrequent with sin-
gle-agent ixazomib during maintenance (1 patient, 6%).
Table 1.
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Summary/Conclusions: In patients with NDMM, twice-weekly ixazomib plus Rd
resulted in exceptional response rates in patients who did not receive a SCT and
who received maintenance therapy. The responses were deep and durable, with
long PFS and a high 2-year OS estimate. The majority of AEs had an onset during
induction, and the incidence of AEs during maintenance was infrequent. 
S781
LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR
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Background: Immunomodulatory agents are effective therapies for multiple
myeloma (MM) acting via the modulation of cereblon. Lenalidomide (Len) has
fewer side effects than Thalidomide (Thal), whilst retaining the benefits of oral
administration, enabling long-term treatment that has been associated with
better disease control. Combinations of agents induce deeper, longer remis-
sions by targeting different clonal populations, with triplets outperforming dou-
blets. The optimum immunomodulatory-based induction combinations and
maintenance regimens are unknown.
Aims: The UK NCRI Myeloma XI study compared triplet induction regimens of
Len vs Thal and examined the role of post-ASCT maintenance Len vs observation,
enabling us to explore the interaction of Len induction with Len maintenance.
Methods: Myeloma XI is a multicenter, open-label, parallel group, randomised
controlled trial for newly diagnosed MM patients of all ages, with pathways for
transplant eligible (TE) and non-eligible patients. For TE patients the induction
question compared Len or Thal plus cyclophosphamide and dexamethasone
(CRD vs CTD) continued for a minimum of 4 cycles and to maximum response.
For patients with a suboptimal response there was a subsequent randomization
to a proteasome inhibitor containing triplet or no further therapy, prior to high-
dose melphalan and ASCT. A maintenance randomisation at 3 months post ASCT
compared Len till disease progression with observation. High risk disease was
defined as the presence of at least one of t(4;14), t(14;16), del(17p) or gain(1q).
2042 TE patients underwent the induction randomization (CRD 1021, CTD 1021).
After a median follow up of 36.3 months, 965 PFS and 415 OS primary endpoint
events had occurred. Secondary endpoints include response and toxicity. 
Results: In TE patients, CRD induction was associated with deeper responses
than CTD (≥VGPR: CRD 60% vs CTD 53%), a finding which persisted post
ASCT (≥VGPR CRD 82% vs CTD 77%). This was associated with a signifi-
cantly improved median PFS. Patients receiving CRD achieved a median PFS
of 35.9 months compared to 32.9 for those who received CTD (HR 0.85, 95%CI
[0.75, 0.96], p=0.0116). This also translated into an overall survival benefit, 3
year OS: CRD 82.9% vs CTD 77.0% (HR 0.77, 95%CI [0.63, 0.93], p=0.0072).
There were higher rates of PN and constipation with CTD vs haematological
toxicity with CRD. Maintenance therapy with Len was associated with a signif-
icantly longer median PFS compared to observation (TE HR 0.47, 95%CI 0.38,
0.60). This finding persisted across all subgroups including patients with high-
risk disease. Exploratory analysis across the TE pathway suggested that CRD
induction with Len maintenance was optimum: 60 month PFS CRD-R 50.2%,
CTD-R 39.1%, CRD-obs 18.5%, CTD-obs 23.4%.
Summary/Conclusions: In TE patients CRD was associated with deeper
responses than CTD and with a PFS and OS benefit. The best outcomes were
associated with Len induction plus Len maintenance. Our findings support con-
tinuing Len therapy through induction until disease progression.
On behalf of the UK NCRI Haemato-oncology CSG.
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Background: Multiple myeloma is characterized by osteolytic bone disease,
with up to 80% of pts presenting with detectable lesions. Myeloma bone disease
is mediated by osteoclast activating factors such as RANKL, increasing the
risk of skeletal-related events (SREs) and impacting morbidity and mortality.
DMB, a human monoclonal antibody that targets and binds to RANKL, can be
administered subcutaneously (SC) to pts regardless of renal function.
Aims: This study evaluates the efficacy and safety of DMB compared with ZA
in newly diagnosed myeloma pts.
Methods: Adult pts were randomized 1:1 to DMB 120mg SC Q4W or ZA 4mg
IV (adjusted) Q4W along with anti-myeloma therapy. Key stratification factors
included type of first-line therapy (novel or non-novel) and previous SRE. Pts
with renal insufficiency were excluded if baseline creatinine clearance
(CrCl)<30mL/min. The primary endpoint was non-inferiority of DMB to ZA with
respect to time to first on-study SRE. Secondary endpoints included superiority
of DMB for time to first on-study SRE and first-and-subsequent on-study SRE,
and overall survival (OS). Progression-free survival (PFS) was an exploratory
endpoint. Safety was also assessed.
Results: A total of 1718 pts were randomized, 859 to each arm. Baseline demo-
graphics and disease characteristics were balanced, with 66.0% of DMB and
67.2% of ZA pts reporting prior SRE history; CrCl≤60mL/min was reported in
26.7% of pts. During the primary blinded treatment period (median follow-up 17.4
months [m]), 43.8% DMB pts and 44.6% ZA pts had a first on-study SRE. The
median time to first on-study SRE was similar between DMB (22.83 m) and ZA
(23.98 m) pts. DMB was non-inferior to ZA (P=0.01) in delaying time to first on-
study SRE (HR[95%CI]=0.98[0.85,1.14]). Superiority was not demonstrated for
time to first on-study SRE (P=0.82) and time to first-and-subsequent on-study
SRE (P=0.84). In this high-risk study population the effect of antiresorptive therapy
may only be evident later in the treatment course. A post-hoc, landmark analysis
at 15 m for time to first SRE demonstrated a
HR(95%CI)=0.66(0.44,0.98),P=0.039 (Figure 1) between DMB and ZA. OS was
similar between DMB and ZA (HR[95%CI]=0.90[0.70,1.16],P=0.41), with fewer
deaths with DMB (121[14.1%]) than ZA (129[15.0%]). PFS yielded a
HR(95%CI)=0.82(0.68,0.99), descriptive P=0.036, with median times of 46.09m
(95%CI:34.3,NE) for DMB and 35.38m (95%CI:30.19,NE) for ZA. The most com-
mon TEAEs(>25%) for DMB and ZA were diarrhea and nausea. The rates of
SAEs (DMB,ZA [%];46.0,47.3), hypocalcemia (16.9,12.4; serious:0.9,0.2), and
positively adjudicated ONJ (4.1,2.8) were comparable to known safety profiles.
Fewer DMB pts (%) compared with ZA pts had AEs potentially related to renal
toxicity (10.0,17.1;P<0.001), most notably in pts with baseline CrCl≤60mL/min
(12.9,26.4). TEAEs led to IP discontinuation in 12.2% of all pts (12.9,11.5).
Figure 1.
Summary/Conclusions: DMB demonstrated non-inferiority to ZA in delaying
time to first on-study SRE in myeloma pts, meeting the primary endpoint of
the study. A landmark analysis at 15 m suggests a significant benefit for DMB
with respect to time to first SRE. The rates of renal AEs were significantly
lower in DMB pts while the overall rates of AEs, including hypocalcemia and
ONJ, were consistent with the known DMB safety profile. The results of the
landmark analysis and possible prolongation of PFS with DMB therapy is
promising.
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SONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE
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Background: Pembrolizumab (pembro) is a humanized, highly selective, high-
affinity IgG4/κ antibody that blocks the interaction between programmed death
1 (PD-1) and its ligands PD-L1 and PD-L2, activating antitumor immunity. Pem-
bro plus lenalidomide (len) and low-dose dexamethasone (dex) may provide
synergistic antitumor activity in relapsed/refractory multiple myeloma (RRMM).
Biomarkers indicative of response, pharmacodynamic activity, and/or mecha-
nism of action to combination therapies are also needed.
Aims: To determine the maximum tolerated dose (MTD) and safety and toler-
ability of pembro plus len and low-dose dex in patients with RRMM. Additionally
PD-L1 and PD-L2 expression in bone marrow (BM), immune profiles in circu-
lating lymphocytes, and gene expression in blood were evaluated.
Methods: This open-label, phase 1 KEYNOTE-023 (NCT02036502) study of
pembro plus len and low-dose dex enrolled patients with RRMM previously
treated with ≥2 prior therapies, including both a proteasome inhibitor and an
immunomodulatory drug. Patients received pembro 200 mg IV every 2 weeks
(Q2W), len 25 mg orally on days 1-21, and dex 40 mg orally weekly on each
28-day cycle. Primary end points were safety and determination of the MTD.
ORR was assessed by IMWG 2006. Exploratory biomarker analyses included
analysis of PD-L1 and PD-L2 on CD38+CD138+ cells in BM aspirate samples
obtained at screening, or before the first dose of study drug. Absolute and/or
relative numbers of circulating lymphocytes (by flow cytometry [FC]) and gene
expression profile (GEP) (by Nanostring) were evaluated in predose; cycle 1,
day 1 (C1D1); and cycle 2, day 1 (C2D1) blood samples.
Results: MTD was determined as pembro 200 mg IV Q2W plus len 25 mg and
dex 40 mg. Median (range) age was 61 years (46-77); median (range) number
of prior lines of therapy was 4 (1-10); 38 (75%) patients were len-refractory,
and 27 (53%) were double refractory. Most common grade ≥3 treatment-related
AEs (TRAEs) were neutropenia (33%), thrombocytopenia (18%), and anemia
(12%). 2 patients (4%) died because of TRAEs (hepatic failure, ischemic
stroke). Immune-related AEs occurred in 5 (10%) patients. No pneumonitis was
reported. ORR in the efficacy population was 20/40 (50%) (1 sCR, 5 VGPR, 14
PR); 1 patient had progressive disease. ORR was 38% (11/29) and 33% (6/18)
for len- and double-refractory patients, respectively. The disease control rate
(sCR+CR+ VGPR+PR+SD) was 39/40 (98%) in the efficacy population and
28/29 (97%) in the len-refractory population. 35/40 (88%) patients had a reduc-
tion in M protein or free light chains. In 16/32 patients with FC-evaluable BM
aspirate with >100 CD38+CD138+ cells, all were PD-L1+, while PD-L2 expres-
sion was variable. At C2D1, proportion of circulating HLA-DR+, central
(CD45RO+CCR7-), and effector memory (CD45O+CCR7+) CD8+ T cells signif-
icantly increased and naive (CD45RA+) CD8+ T cells significantly decreased;
all with multiplicity adjusted P values ≤0.01.
Summary/Conclusions: The combination of pembro, len, and low-dose dex
has an acceptable safety profile and antitumor activity in patients with heavily
pretreated RRMM, including len-refractory and double-refractory patients. PD-
L1 was expressed in all patients evaluated by FC, whereas PD-L2 expression
was variable. Pembro plus len and low-dose dex induced immune activation in
the periphery and a phenotypic shift in effector CD8+ T cells among the circu-
lating T-cell pool in blood.
Old and new drugs in MPN
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Background: Polycythemia vera (PV) is characterized by hyperproliferation of
erythroid/myeloid/megakaryocytic components in the bone marrow, cardiovas-
cular complications, and high symptom burden. Treatment (Tx) in patients (pts)
with PV is focused on maintaining hematocrit (HCT) level <45%. RESPONSE-
2 study evaluated the efficacy and safety of ruxolitinib (RUX) vs best available
therapy (BAT) in hydroxyurea (HU)-resistant/intolerant pts with PV ≥18 years
without splenomegaly and with phlebotomy [PBT] requirement to control HCT.
At week (wk) 28 (primary analysis), HCT control was reported in 46/74 pts in
the RUX arm vs 14/75 pts in the BAT arm.
Aims: This preplanned analysis of RESPONSE-2 evaluated the durability of
efficacy and safety of RUX vs BAT, after all pts reached 80 wk into the study or
discontinued the study.
Methods: Pts were randomized 1:1 to RUX 10 mg twice daily or BAT. Primary
end point was the proportion of pts who achieved HCT control at wk 28
(absence of PBT eligibility [HCT >45%, ie, ≥3 percentage points from baseline,
or HCT >48%] from wk 8 to 28, with ≤1 PBT eligibility from wk 0 to 8). Key sec-
ondary end point was the proportion of pts who achieved complete hematologic
remission at wk 28 (CHR: HCT <45%, WBC ≤10 x 109/L, platelet count ≤400 x
109/L). Durability of HCT, CHR, and safety was evaluated at wk 80 (data cutoff,
September 26, 2016). Additional end points included assessment of patient-
reported outcomes (MPN-SAF TSS) and change in JAK2V617F allele burden
over time. BAT pts could cross over to RUX from wk 28.
Results: Baseline demographics were comparable among RUX (N=74) and BAT
(N=75) arms. When last pt reached wk 80 time point, 69 pts randomized to RUX
were still receiving Tx; while 5 pts discontinued Tx (adverse events [AEs]=3 pts,
physician’s decision/pt withdrew consent=1 pt, each). In BAT arm, 58 pts crossed
over to RUX (crossover data to be included in presentation) with remaining pts
either ongoing follow-up (f/u [n=5]) or having discontinued Tx (completed f/u per
protocol, n=7; death, n=1; other reasons, n=4). Median exposure was 93.6 wk in
RUX vs 28.4 wk in the BAT arm. At wk 80, durable HCT control was achieved in
35 pts (47%) in RUX vs 2 pts (3%) in BAT arm. Of those who achieved a HCT
response at wk 28, Kaplan-Meier estimate of maintaining response up to wk 80
was 78.37% in the RUX arm. Durable CHR was achieved in 18 pts (24%) in RUX
vs 2 pts (3%) in the BAT arm. Total number of PBT was higher in the BAT arm vs
RUX arm (Figure 1). At wk 80, 45% of pts randomized to RUX continued to
achieve a ≥50% of reduction in the MPN-SAF TSS. At wk 80, mean percentage
change from baseline in JAK2V617F allele burden was −9.7% in the RUX (n=65)
vs +0.3% in the BAT arm (n=3). AEs observed were consistent with those gen-
erally reported with RUX (primarily low grade [G]). Most common AEs (all G,
exposure-adjusted rate per 100 pt-years) were anemia (14.3), weight increase
(10.6), arthralgia (9.1), and pruritus (9.1) in the RUX arm vs pruritus (37.5),
headache (16.9), and thrombocytopenia (15.0) in the BAT arm. Rate of throm-
boembolic events (Standardized MedDRA Query, exposure-adjusted) was RUX
(1.5) vs BAT arm (1.9). No pt in the RUX arm had disease progression vs 2 pts
in the BAT arm. No deaths were reported in the RUX arm vs 3 pts in the BAT arm
(septic shock/disease progression/study indication=1 pt, each).
Summary/Conclusions: RUX provided durable HCT control, durable CHR,
reduction in PBT requirement, improved symptom burden, and was generally
well tolerated with >90% of pts still receiving Tx at wk 80. RUX Tx provided a
modest reduction in allele burden over time. Findings from both RESPONSE
studies suggest that RUX should be considered as a standard of care for sec-
ond-line Tx in this inadequately controlled pt population with PV.
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Background: Momelotinib (MMB), an investigational oral JAK inhibitor (JAKi),
has been shown in early trials to reduce spleen volume, improve disease asso-
ciated symptoms and improve red blood cell (RBC) transfusion requirements
in patients with myelofibrosis (MF). 
Aims: To test the non-inferiority of MMB vs ruxolitinib (RUX) in splenic volume
reduction and symptom amelioration, and superiority in transfusion require-
ment, in JAKi naïve patients with primary myelofibrosis, and post-polycythemia
vera or post-essential thrombocythemia myelofibrosis.
Methods: Eligibility included primary myelofibrosis or post-polycythemia
vera/essential thrombocythemia myelofibrosis; International Prognostic Scoring
System (IPSS) high risk, intermediate-2 risk, or intermediate-1 risk associated
with symptomatic splenomegaly; palpable spleen ≥5cm; platelets ≥50 K/μl; no
Grade ≥2 peripheral neuropathy. Informed consent was obtained. Stratification
was by transfusion dependency and platelets (<100K, 100K-200K, and
>200K/μl). Patients were randomized 1:1 to 24 weeks of MMB 200 mg qd+RUX
placebo or RUX 20 mg bid (or modified per label)+MMB placebo, after which
all patients could receive open label MMB. Assessments: spleen volume by
MRI, and patient reported symptoms using a daily eDiary of modified MPN-
SAF Total Symptom Score (TSS). The primary endpoint was splenic response
rate (SRR; ≥35% reduction in volume from baseline) at 24 weeks. Secondary
endpoints, evaluated sequentially at 24 weeks, were rates of TSS response
(≥50% reduction from baseline), RBC transfusion independence and RBC
transfusion dependence, and rate of RBC transfusion.
Results: 175 of 215 (81%) and 201 of 217 (93%) patients randomized to MMB
and RUX, respectively, completed the 24 week double blind phase. Efficacy
results are shown in the Table 1. The most common Grade ≥3 adverse events
in the double blind phase with MMB were thrombocytopenia (7%) and anemia
(6%), and with RUX were anemia (23%), thrombocytopenia (5%) and neu-
tropenia (5%). Grade ≥3 infections occurred in 7% of MMB and 3% of RUX
patients. Treatment emergent peripheral neuropathy occurred in 22 (10%) of
MMB (all Grade ≤2) and 10 (5%) of RUX (9 Grade ≤2, 1 Grade 3) patients in
the double blind phase, none discontinuing study drug for this problem. Overall,
adverse events led to study drug discontinuation in 13% of MMB and 6% of
RUX patients in double blind phase.
Table 1.
aTest for non-inferiority; bTest for superiority, all values nominally significant.
Summary/Conclusions: In patients with JAKi naive myelofibrosis, 24 weeks
of momelotinib is non-inferior to ruxolitinib for spleen response but not for symp-
tom response. Momelotinib treatment is associated with a reduced transfusion
requirement. NCT01969838
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Background: Momelotinib (MMB), an investigational oral JAK inhibitor, has
been shown in early trials to reduce spleen volume, improve disease associated
symptoms and improve red blood cell (RBC) transfusion requirements in
patients with myelofibrosis.
Aims: Test the superiority of MMB versus best available therapy (BAT) in
splenic volume reduction, symptom amelioration, and transfusion requirement
at 24 weeks in patients with primary myelofibrosis (PMF), post-polycythemia
vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) who
were previously treated with ruxolitinib.
Methods: Eligibility included PMF or post-PV/ET MF; Dynamic International
Prognostic Scoring System (DIPSS) high risk or intermediate-2 risk, or inter-
mediate-1 risk associated with symptomatic splenomegaly; currently or previ-
ously treated with ruxolitinib for at least 28 days who either required transfusions
or dose reduction to <20 mg BID with at least one of Grade ≥3 thrombocytope-
nia, anemia, or bleed; palpable spleen ≥5cm; and no Grade ≥2 peripheral neu-
ropathy. Informed consent was obtained. Stratification was by transfusion
dependency and baseline TSS (modified MPN-SAF Total Symptom Score) <18
or ≥18. Patients were randomized 2:1 to 24 weeks of open-label MMB 200 mg
QD or BAT. Assessments included spleen volume by MRI, and patient-reported
symptoms using a daily eDiary for TSS. Primary endpoint was splenic response
rate at 24 weeks (SRR24; ≥35% reduction in volume from baseline). Secondary
endpoints, evaluated sequentially, were rates of TSS response (TSS RR; ≥50%
reduction from baseline), RBC transfusion, RBC transfusion independence (TI)
and RBC transfusion dependence (TD).
Results: 73 of 104 (70%) and 40 of 52 (77%) patients receiving MMB or BAT,
respectively, completed the 24 week randomized treatment phase. BAT for
88% of patients included ruxolitinib, and 27% of patients were on ruxolitinib in
combination with other drugs. Efficacy results are in Table 1. The most common
treatment-emergent adverse events in MMB patients were diarrhea (33%),
asthenia (19%), nausea (19%), and cough (17%), and in BAT patients, asthenia
(21%), fatigue (19%), anemia (15%), diarrhea (15%), and abdominal pain
(15%); the most common Grade ≥3 adverse events in MMB patients were ane-
mia (13%) and thrombocytopenia (7%), and in BAT patients, anemia (13%),
thrombocytopenia (6%) and abdominal pain (6%). Treatment emergent periph-
eral neuropathy occurred in 11 (11%) of MMB (1 Grade 3) and in no BAT
patients; MMB was discontinued in 3 patients due to neuropathy.
Table 1.
ap-values nominally significant.
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Summary/Conclusions: In previously ruxolitinib-treated patients with myelofi-
brosis, 24 weeks of momelotinib was not superior to best available therapy for
splenic response, but significantly better in improving disease related symptoms
and transfusion independence. NCT02101268.
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Background: Interferon alfa (IFNa) has been successfully used to treat myelo-
proliferative neoplasms (MPN) for many years and several phase 2 studies
have independently shown high rates of hematological and molecular respons-
es assessed by the quantification of mutant JAK2 allele burden (%JAK2V617F)
in peripheral blood. However, direct in vivo studies investigating the impact of
IFNa treatment on proliferation of bone marrow (BM) normal and malignant
hematopoietic progenitors are lacking.
Aims: We took advantage of the randomized controlled phase III trial (PROUD-
PV) comparing the novel, long-acting Ropeginterferon alfa-2b (AOP2014) with
hydroxyurea (HU) in polycythemia vera (PV) patients (pts) to assess correlation
between evolution of %JAK2V617F in peripheral blood and the impact of ther-
apy on malignant clones by functional assays testing mutant BM hematopoietic
progenitors in the French study population.
Methods: Randomized, controlled, multicenter phase 3 trial comparing efficacy,
safety and tolerability of hydroxyurea and Ropeginterferon Alfa-2b in PV pts
(NCT01949805). The primary endpoint was non-inferiority of AOP2014 vs HU
at 12 months (mos) of therapy in terms of complete hematological response
(CHR) according to ELN criteria and normal spleen size. As important second-
ary endpoint the effect of treatment on %JAK2V617F was assessed as rate of
complete and partial molecular response (C/PMR) according to modified ELN
criteria. In the group of pts enrolled in France, we could study BM progenitors
clonogenic potential by cultures with or without Erythropoietin (EPO) at baseline
and after 12 months of therapy. The presence of colonies without EPO, namely
Endogenous Erythroid Colonies (EECs) is a hallmark of PV. After 14 days, ery-
throid colonies were enumerated and picked for molecular analyses.
Results: A total of 257 pts were randomized in 13 European countries including
13 pts in France. Non-inferiority of AOP2014 versus HU regarding CHR could
be demonstrated in the whole study population (43.1 vs 45.6%). In the subgroup
of French pts (54% males, mean age 55 years) CHR at 12 mos was 40% in pts
receiving AOP2014 (n=5) and and 50%, in those receiving HU (n=8).
%JAK2V617F at baseline in the AOP2014 and HU arms were 39.4% and
46.5%, respectively, reduced to 29.1% and 25.8% after 6 mos, and 13.8% and
33.2% at 12 mos. No complete MR was achieved at 12 mos, but PMR was
observed in 40% and 25% of pts in AOP2014 and HU arms (p= ns), respectively.
BM progenitors could be studied in 10/13 French pts, 3 treated with AOP2014
and 7 with HU. AOP2014 treatment induced an important decrease of the pro-
portion of EEC (median decrease 64%) between samples collected at baseline
and after 12 months of therapy compared to HU (median decrease 25%). In
addition, clonal architecture studies showed that the % of JAK2V617F mutant
colonies before and after treatment profoundly decreased in all AOP2014-treat-
ed pts (mean ratio of mutant vs wild type JAK2 colonies decreased from 96%
at baseline to 46% at 12 mos). Among HU-treated pts, only 1 experienced a
decrease in the % of mutated colonies while mean ratio of mutant vs wild type
JAK2 colonies didn’t significantly decrease (from 87% at baseline to 79% after
12 mos).
Summary/Conclusions: In this phase 3 trial comparing Ropeginterferon
alfa-2b versus HU, we found a different impact of both drugs on hematopoietic
cells. Although both treatment induced a decrease of JAK2 mutant allele bur-
den at 12 mos in peripheral blood, BM clonogenic assays suggest that
AOP2014 is able to specifically target JAK2 mutant progenitors, an effect not
seen in HU treated pts. Such targeted impact of AOP2014 may account for
the strikingly different kinetics in allele burden reduction and suggests that
sustained long-term molecular response may only be achieved with IFNa
based treatment.
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Background: AdvSM (ie, aggressive SM [ASM], SM with an associated hemato-
logic neoplasm [SM-AHN], and mast cell leukemia [MCL]) comprises rare hema-
tologic neoplasms with a poor prognosis. KIT D816V mutations occur in a majority
of patients with advSM. Midostaurin is a multitargeted kinase inhibitor that blocks
wild-type and D816V-mutated KIT. Two single-arm phase 2 studies
(D2201+A2213) evaluated the safety and efficacy of midostaurin in advSM. Over-
all, 60% and 69% of patients in D2201 and A2213, respectively, achieved the pri-
mary endpoint of partial or complete normalization of SM-related organ damage.
Aims: We compared pooled data from these studies with data from a patient
registry to determine the effects of midostaurin on overall survival (OS).
Methods: Data from the midostaurin studies, in which patients received
midostaurin 100 mg twice daily until progression or toxicity, were pooled. His-
torical control data were obtained from a contemporary patient registry based
at University Medical Centre Mannheim, Germany. Although the primary analy-
sis did not include matching for patient selection, subgroup analyses, and mul-
tivariate analyses were performed to assess whether baseline patient charac-
teristics affected OS and estimated HR. Propensity scoring was used for sup-
portive analyses to match the patients in the registry. Patients were evaluated
for OS based on time from diagnosis to death; patients in the pooled analysis
with known dates of diagnosis were included in the primary analysis. A sensi-
tivity analysis to compensate for potential bias in patient selection was con-
ducted using the start date of last treatment to death.
Results: The primary analysis of OS in patients with advSM included 89
patients from the midostaurin pooled analysis for whom the date of diagnosis
was available (77% of the entire pooled cohort) and all 46 patients from the
German registry who had not been treated with midostaurin. SM subtypes
among patients from the pooled analysis and registry were similar; 66% of
patients in the pooled cohort and 63% in the registry had an AHN (Table 1).KIT
D816 mutations were present in 82% of patients in the pooled analysis and
96% in the registry. More patients in the registry (67%) vs the pooled analysis
(42%) were aged >65 y. Median follow-up (time from diagnosis to data cutoff
for the analyses) was similar for the 2 patient groups: registry, 54.9 (range, 1.9-
150.4) mo and midostaurin, 53.6 (range, 31.6-215) mo. Patients in the
midostaurin pooled analysis had a clinically relevant improvement in OS vs
historical controls (HR=0.62 [95% CI, 0.39-0.98]; P=.0204; Figure 1). Median
OS was 42.6 (95% CI, 31.0-53.9) mo in the pooled analysis vs 24.0 (95% CI,
13.0-39.5) mo in the registry. Multivariate Cox regression analysis after adjusting
for covariates was consistent with the primary analysis: HR=0.51 (95% CI,
0.30-0.88); P=.0147. Data using propensity score for matched pairs (n=44)
were also consistent (HR=0.381 [95% CI, 0.169-0.960]; P=.101). Subgroup
analyses of OS showed HR in favor of midostaurin for all subgroups analyzed
(age [≤65 y vs >65 y], KIT D816V status, number of prior therapies [≤1 vs >1],
and SM subtype) except MCL. Subgroup analysis data should be interpreted
with caution due to the small patient numbers in the German registry. Sensitivity
analysis of OS from date last treatment received (pooled analysis, n=115; reg-
istry, n=42) was consistent with the main analyses (HR from the multivariate
analysis=0.38 [95% CI, 0.22-0.65]; P=.0004).
Table 1.
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Figure 1.
Summary/Conclusions: Midostaurin was associated with a 38% lower risk of
death vs historical controls. Benefit was generally consistent across key sub-
groups.
Childhood and more intensive treatment of AML
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Background: Approximately 10% of the children with Down syndrome are
diagnosed with transient myeloproliferative disorder (TMD) within the first days
of life. Previous studies have shown that TMD patients face an around 20%
risk of early death and a 20% to 30% risk to develop myeloid leukemia during
the first 4 years of life (ML-DS).
Aims: The aim of the AML-BFM TMD Prevention 2007 trial was to analyze the
outcome of patients diagnosed with TMD and to evaluate whether the applica-
tion of a low-dose cytarabin treatment can prevent the progression to ML-DS.
Methods: The AML-BFM TMD Prevention 2007 trial is a multi-center, non-ran-
domized, historically controlled study. Patients with TMD were prospectively
enrolled. They received a low-dose cytarabin treatment (1.5 mg/kg i.v./s.c. daily)
for one week respectively if they met the following criteria: TMD-related symptoms
(e.g. hyperleucocytosis, hepatopathy) at diagnosis, MRD-positivity (FACS≥10-3
or qPCR≥10-4) eight weeks after diagnosis. Patients could receive cytarabin-
treatment up to three weeks in case of failure to respond to the cytarabin-treat-
ment (morphologic detection of blasts between week four and eight after diag-
nosis and/or MRD-positivity after treatment in week ten after diagnosis).
Results: Here we report a cohort of 108 patients (male: 60, female:48) diag-
nosed with TMD. The median age at diagnosis was 4 days. As common in chil-
dren with Down syndrome, many of the patients presented with comorbidities
(cardiac defects: 68%, other malformations: 15%); 36% were delivered preterm.
45 patients received low-dose cytarabin treatment, 57 patients did not receive
this treatment. Overall, patients in this trial do not show a significantly better
event-free survival (EFS; 72±4% vs 63±4%, p=0.15) and overall survival (OS;
91±3% vs 85±3%, p=0.15) than the historic control group (n=146). The cumu-
lative incidence (CI) of death was lower, (8±3% vs 15±3%) albeit not signifi-
cantly (p=0.09). The CI of ML-DS was also similar (19±4% vs 22±4%, p=0.88).
Patients that presented with TMD-related clinical symptoms (n=43; symptoms:
hyperleucocytosis [WBC>100,000], hepatopathy, ascites, hydrops fetalis) had
a tendency for a better EFS (59±8% vs 44±8%, p=0.097), OS (80±6% vs
67±7% p=0.10) and CI of death (20±7% vs 33±7%, p=0.10) than patients with
those symptoms in the historic control group (n=45). For the progression to
ML-DS there is no significant difference between the two groups (21±7% vs
23%±7%, p=0.91). For patients that do not show any of the TMD-related symp-
toms (n=59), no significant differences were observed regarding EFS (81±5%
vs 71±5%, p=0.27), OS (98% vs 93±3%, p=0.16) and CI of ML-DS (19±6% vs
22±4%, p=0.95) compared to patients without these symptoms in the historic
control (n=101). 
Summary/Conclusions: The consequent treatment with low-dose cytarabine of
symptomatic patients results in a trend towards reduced CI of death as compared
to the historic control. However, progression to ML-DS remained unchanged sug-
gesting that the treatment with low-dose chemotherapy does not seem to prevent
the development of subsequent leukemia in TMD-patients. Therefore, a general
preventive chemotherapeutic treatment of children diagnosed with TMD cannot
be recommended. However, children with TMD-related symptoms should receive
low-dose cytarabine to reduce disease-related mortality.
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Background: AML is a heterogeneous disease based on genetic characteris-
tics with impact on prognosis. So, it becomes necessary to treat patients accord-
ing to risk-adapted therapies.
Aims: To analyze the results of intensive induction and post-remission treatment
in 868 patients with the novo AML enrolled into the CETLAM-03 trial between
2003 and 2012 with a prolonged follow-up (results reported at 10 years).
Methods: Patients received 1 or 2 induction chemotherapy courses of IDICE-
G (idarubicin, intermediate cytarabine (IDC), VP-16 and priming with G-CSF)
followed by mitoxantrone and IDC as consolidation therapy. Further treatment
was assigned according to the CETLAM risk groups as follows: Favorable risk
(FR) defined as favorable cytogenetics according to MRC: autologous stem
cell transplantation (ASCT) if leukocyte index [LI=leucocytes x (BM blasts/100)]
≥20 or high dose cytarabine (HDAC) (one course) if LI <20. Intermediate risk
(IR), defined as patients in CR after a single induction course, <50x10E9/l white
blood cells at diagnosis, normal karyotype and absence of FLT3 internal tandem
duplication (FlT3-ITDwt) and no MLL rearrangement: ASCT . Adverse risk (AR),
patients not included in FP or IP: ASCT or allogeneic stem cell transplantation
(allo-SCT) depending on donor availability (HLA-identical sibling or unrelated
donor if high risk of relapse).
Results: There were enrolled 868 patients. Median age was 53 years-old (16-
70). According to MRC cytogenetics, available in 802 patients, 99 belonged to
the favorable (12%), 581 (73%) to the intermediate and 122 (15%) to the
adverse groups. 66 patients with no metaphases. FLT3-ITD was present in 128
patients with normal karyotype (36%). Four patients died before treatment and
864 patients received induction therapy. 77% of patients achieved a CR (88%
with a single course), 11% were refractory and 12% died during induction. CR
rate was 92% in CBF leukemia, 91% in NPM1 mutation without FLT3-ITD, 77%
in intermediate cytogenetic and no mutations, 74% if FLT3-ITD, 70% in adverse
cytogenetics and 62% if monosomal karyotype was present (p<0.001). The
multivariate analysis showed that mutational status (adverse cytogenetics,
FLT3-ITD and absence of NPM1 mutation) had an adverse impact on CR
achievement. Overall survival (OS), event free survival (EFS) and cumulative
incidence of relapse (CIR) of the whole series at 10 years were: 36±2%, 29±2%
and 44±5% respectively. Post-remission results of OS, EFS and CIR according
to the different CETLAM risk groups at 10 years follow up were: FR (n=85,
14%): 85±4%, 70±6% and 22±1%; IR (n=99, 17%): 64±6%, 51±5% and 47±2%;
AR (n=417, 69%): 41±3%, 33±3% and 52±16% respectively. In FR there were
no differences in OS, EFS and CIR depending if intention to treat was HDAC
or ASCT. In AR statistical differences were observed at 10 years in EFS and
CIR when comparing ASCT vs allo-SCT (27±4% vs 39±4%, p=0.026 and
66±6% vs 39±1%, p<0.001). In IR intention to treat was ASCT, but in 21% mobi-
lization failed and most of them received HDAC. Forty-nine patients received
an ASCT and 21 relapsed, 9 of them were rescued with an allo-SCT.
Summary/Conclusions: In this large cooperative experience CR rate was above
75%, in most cases after a single course. In patients with favorable MRC cyto-
genetics, the adverse impact of high LI observed in our previous protocol was
abrogated with autologous transplantation. In IR group, a remarkable proportion
of patients allocated to ASCT had mobilization failure. In HR group, allo-SCT
improves the outcome compared to ASCT. In our experience, molecular charac-
terization and MRD studies are helpful to decide post-remission therapy.
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Background: Azacitidine (AZA) represents an important therapeutic advance
in patients with acute myeloid leukaemia (AML) and high risk myelodysplasia
(MDS) ineligible for intensive chemotherapy. However disease progression
appears inevitable and a number of strategies aimed at improving outcome,
including co-administration of histone deacetylase inhibitors such as vorinostat
(VOR), have been proposed. Leukaemic stem/progenitor cells (LSC) have been
postulated to represent a reservoir of resistant disease but the impact of AZA
based therapy on LSC numbers has not been studied. An additional factor lim-
iting the rational use of AZA based therapy in AML and MDS is imprecision in
the identification of patients likely to achieve a significant clinical benefit and
molecular predictors of outcome would improve the rational utilisation of thsi
important new agent. 
Aims: We wished to study the impact of AZA based therapy on LSC numbers
aswell as identify molecular predictors of outcome in patients treated on the
recently completed UK Trials Acceleration Programme RAVVA randomised Phase
II trial which compared AZA monotherapy with AZA/VOR combination therapy.
Methods: The RAVVA trial randomized 259 adults with AML (n=217) and MDS
(n=42) to receive AZA monotherapy (AZA (75 mg/m2) x 7 days every 28 days)
or AZA combined with VOR (300 mg bd days 3-9) po for a minimum of 6 cycles.
Next generation sequencing was performed on 42 genes commonly mutated
in AML and MDS in 250 patients treated on the RAVVA trial and correlated with
response. Separately serial immunophenotypic quantitation of leukaemic
stem/progenitor cells (LSC) was performed in 44 patients. 
Results: Co-administration of VOR did not increase overall survival (OS) (1
year OS AZA 43% versus 41% p=0.32) as previously reported (Blood 2016
Absract No 1065). The mean number of mutations per patient in the 250 geno-
typed patients was 3.4. The presence of mutations in CDKN2A (p=0.0001),
IDH1 (p=0.004) and TP53 (p=0.003), NPM1 (p=0.037) and FLT3-ITD (p=0.04)
were associated with reduced OS in univariate analysis. In multivariate analysis
adjusted for all clinical variables mutations in CDKN2A, IDH1 and TP53
remained predictive of decreased OS. No mutations were associated with
improved OS. The presence of ASXL1 (p=0.035) and ETV6 (p=0.033) mutations
were found to be associated with a reduced duration of response. AZA based
therapy had no significant impact on LSC numbers in patients who failed to
achieve a CR. LSC numbers were reduced but not eradicated in patients
achieving a CR and observed to expand at relapse.
Summary/Conclusions: In this, the largest such study reported to date, the
demonstration that mutations in CDKN2A, IDH1 and TP53 are associated with
a decreased OS in patients treated with AZA not only can inform patient risk
stratification but also provides insights into the mechanism of action of AZA.
Specifically, the observation that mutations in the cell cycle regulator CDKN2A
was associated with a markedly decreased overall survival is consistent with
the hypothesis that induction of cell cycle arrest represents at least one of the
mechanisms by which AZA exerts an anti-tumour activity. Furthermore our data
identify serial quantitation of LSC populations as a potentially important bio-
marker of response to AZA based therapies which may assist in the evaluation
of novel treatment combinations. 
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Background: The fms-like tyrosine kinase 3 internal tandem duplication (FLT3-
ITD) mutation is a genetic alteration found in approximately 30% of patients
with acute myeloid leukemia (AML). Although patients with FLT3-ITD AML
achieve remission rates similar to those with FLT3 wildtype status with induction
chemotherapy regimens; patients with FLT3-ITD have significantly shorter
remission durations and increased rates of relapse. Even though allogeneic
SCT improves outcomes, patients still have higher rates of relapse compara-
tively with poor prognosis post relapse. Sorafenib(SFB) is a TKI with activity
against RAF, VEGF and FLT3-ITD and its use as maintenance therapy after
allogeneic SCT has been shown as a promising approach to decrease relapse.
Several studies report that SFB maintenance post SCT provides durable com-
plete responses; however, there are also descriptions of sorafenib post SCT
triggering acute GVHD, cytopenias, rash and diarrhea. 
Aims: To assess the outcomes, including progression free survival (PFS) and
overall survival (OS), in patients with FLT3-ITD mutated AML who receive SFB
maintenance after allogeneic SCT. 
Methods: We analyzed adult patients (age≥18) with a diagnosis of FLT3-ITD
mutated AML who received an allogeneic SCT between 1/1/2010 and 10/28/16
at our institution. Using a case control analysis and matching patients who
received maintenance SFB (maintenance group) with control patients, FLT3-ITD
mutated AML who did not receive maintenance post SCT(control group); we
matched each case to two control patients accounting for disease status, type of
conditioning, donor type, cytogenetic risk factors and age. To be considered as
maintenance, SFB had to be started within 101 days of the SCT. To reduce bias
from disease risks and transplant-related mortality (TRM), all patients were
required to be in complete remission (CR) at study entry - defined as the date of
SFB initiation for cases and the same time point after SCT for their matched con-
trols without maintenance. Actuarial OS and PFS were estimated from study
entry using Kaplan-Meier method. OS and PFS were compared between cases
and controls using log rank test and cox proportional hazards regression analysis.
Patient-, transplant- and disease characteristics were compared between cases
and controls using chi square and Fisher exact tests.
Results: Among the 214 AML patients with FLT3-ITD mutation that underwent
SCT during study period, we identified 13 cases (maintenance) and 26 controls
(no maintenance). Median follow-up of survivors were 12 months and 30
months for maintenance and control group respectively. Disease and transplant
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characteristics were comparable between groups as presented in Figure 1.
Patients were classified by the European Leukemia Net (ELN) classification
and 23% in both groups were categorized as adverse risk while 77% were
intermediate risk. All patients received myeloablative conditioning and diseases
status at SCT was first/second complete remission (CR1/2) with or without
count recovery (Cri/p) in 69% while it was active disease in 31%. PFS at 24
months post SCT was 82% in the maintenance and 45% in control group HR
0.3; 95% CI (0.1-1.3) p=0.1. Overall survival at 24 months was also higher in
SFB cases as 100% compared with 60% in control group p=0.035. Only, 2
patients relapsed post SCT on SFB maintenance, one with new TP53 mutation
at relapse, and other received only <30 days of SFB. However, more than half
the patients had disease progression within the control period. The most com-
monly administered dose was 400 mg daily (5 patients) for 28 days cycle; only
2 patients tolerated higher doses and 6 patients received SBF as 300mg daily
or less. There were delays in subsequent cycles in 10 of 12 patients, and the
most common reasons for delays included cytopenias, liver function test abnor-
malities, and fatigue.
Figure 1.
Summary/Conclusions: Sorafenib maintenance is safe and can produce long
term durable remissions after allogeneic stem cell transplant in a high risk pop-
ulation with FLT3-ITD mutated AML.
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A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB
TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY
DIAGNOSED ACUTE MYELOID LEUKEMIA
M.Y. Levy1,*, A.S. Stein2, S. Vasu3, M.B. Maris4, A.S. Advani5, A.T. Fathi6,
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Background: For patients <65 yrs with newly diagnosed AML, standard induc-
tion treatment is continuous infusion of cytarabine for 7 days and an anthracy-
cline for 3 days (7+3). Although a high percentage of patients achieve a CR by
morphologic criteria, some requiring a 2nd induction, many are resistant to
treatment or achieve a morphologic CR with evidence of minimal residual dis-
ease (MRD). Vadastuximab talirine (SGN-CD33A; 33A) is a CD33-directed
antibody conjugated to 2 molecules of a pyrrolobenzodiazepine dimer. Com-
bining 33A with 7+3 could result in enhanced and deeper (MRD negative)
remissions, resulting in reduced relapse rates and improved OS.
Aims: This phase 1b study (NCT02326584) evaluated the safety and
antileukemic activity of escalating doses of 33A on 2 schedules: split dose (D1
and 4) or single dose (D1) with 7+3 induction therapy (cytarabine 100 mg/m2
and daunorubicin 60 mg/m2).
Methods: AML patients must be eligible for induction therapy. Response
assessments occur on D15 and 28. Second induction and post-remission ther-
apies were per investigator choice and did not include additional 33A. MRD
was assessed centrally by bone marrow exam by a multiparametric flow at
D15 and D28.
Results: Split-dose cohort: 42 patients (median age 45.5 yrs [range, 18-65])
were treated with 33A on D1 and 4 (10+10 [n=4] or 20+10 [n=38] mcg/kg) with
7+3. Most patients had intermediate (50%) or adverse (36%) cytogenetic risk.
19% had secondary AML. 2 patients had hematologic DLTs (lack of recovery
of platelets [25K] and/or ANC [500] by D42) and 20+10 mcg/kg was determined
to be MTD. The median time to count recovery from D1 of therapy in patients
who achieved CR/CRi was 4.9 wks for ANC (≥1K) and 5.1 wks for platelets
(≥100K). No non-hematologic TEAEs ≥G3 were reported in >10% of patients;
non-hematologic TEAEs of any grade occurring in ≥25% of patients were nau-
sea (62%), diarrhea, and constipation (38% each). Of the 42 efficacy evaluable
(EE) patients, best responses included 25 CR (60%), 7 CRi (17%), and 5 mor-
phologic leukemia-free state (mLFS; 12%) with a CR+CRi (CRc) rate of 76%;
23 of 25 (94%) responses were achieved in the 1st cycle. Of the patients with
blast clearance (CR+CRi+mLFS), 73% (27/37) achieved MRD negative status.
Single-dose cohort: To date, 25 patients (median age 58 yrs [range, 38-65])
were treated with 33A on D1 only (30 [n=14] or 40 [n=11] mcg/kg) with 7+3.
Patients had intermediate (48%) or adverse (36%) cytogenetic risk. 16% had
secondary AML. The median time to count recovery from D1 of therapy was
4.1 wks for ANC (≥1K) and 5.9 wks for platelets (≥100K) in patients who
achieved CR/CRi. Four patients had hematologic DLTs, 1 at 30 and 3 at 40
mcg/kg. Non-hematologic TEAEs were consistent with those seen in the D1
and 4 schedule. Of the 24 EE patients, best responses included 12 CR (50%),
6 CRi (25%), and 3 mLFS (13%) with a CRc rate of 75%, achieved in 1st cycle.
Of the evaluable patients with blast clearance, 89% (17/19) achieved MRD
negative status. The CRc rate at the 40 mcg/kg dose level was 91% (10/11);
all 11 patients had blast clearance and 90% (9/10) of evaluable patients
achieved MRD negative status. Across schedules (N=67), the CRc rate was
76%; 79% (44/56) of evaluable patients with blast clearance achieved MRD
negativity. The 30- and 60-day mortality rates were 1% and 7%, respectively.
Median OS is not reached for either schedule and 52 patients (78%) were alive
at the time of analysis.
Summary/Conclusions: 33A can be safely combined with 7+3 with acceptable
count recovery in this population at the doses and schedules studied.
Extramedullary AEs, including hepatotoxicity, and induction mortality rates were
similar to reported rates for 7+3 alone in this AML population. A high remission
rate with the 1st induction cycle was observed, the majority of which were MRD
negative.
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21-COLOR FLOW CYTOMETRY REVEALS IMMUNOPHENOTYPES
ASSOCIATED WITH RESPONSE IN ACUTE GRAFT-VERSUS-HOST
DISEASE PATIENTS TREATED WITH THE JANUS KINASE INHIBITOR
INCB039110
K. Staser1,*, J. Choi1, J. Khoury2, M. Jagasia3, H. Ali4, G. Schiller5,
M. Arbushites6, P. Delaite6, Y. Yan6, K. Rhein6, Y.-B. Chen7, M.-A. Perales8,
L. Gehrs1, J. Ritchey1, J. DiPersio1, M. Schroeder1
1Washington University in Saint Louis, Saint Louis, 2Emory University School
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Background: Although ~50% aGVHD patients respond to steroids, no con-
sensus second-line treatment exists. Recent preclinical models, retrospective
studies, and this prospective trial have demonstrated safety and efficacy of
JAK inhibitors (e.g. ruxolitinib, INCB039110) in steroid-refractory aGVHD. 
Aims: Here, we present 21-marker FACS analysis of blood from patients
enrolled in a prospective, randomized, parallel-cohort, open-label phase 1 trial
of the potent and selective JAK1 inhibitor INCB039110 for aGVHD
(NCT02614612). Preliminary results were previously presented at ASH 2016
(Schroeder et al).
Methods: Patients (n=30) were >18 years old undergoing first alloHSCT from
any source with steroid-refractory or treatment-naïve grades IIB-IVD aGVHD,
randomized 1:1 to 200 or 300 mg oral daily INCB039110 combined with corti-
costeroids. Peripheral blood, obtained at treatment days 7, 14, 28, 56, 100,
and 180, was analyzed by 21-color FACS quantifying >30 cell types, including
B, CD4+ and CD8+ T, memory T, T regulatory (Treg), Th1, Th2, Th17, T follicular
helper (Tfh), Th9, Th22, ThGM-CSF cells, granulocytes, monocytes, mono-
cyte-derived suppressor cells (MDSCs), natural killer cells (NKs), and monocytic
and plasmacytoid dendritic cells (DCs). Patients were stratified by treatment
response (e.g. complete response (CR), partial response (PR), mixed response
(MR)).
Results: During INCB039110 treatment, overall B, T, and myeloid proportions
did not correlate with response. However, the CR group showed increased NK
cells (CD3-CD20-CD14-HLADR-CD56+), mDCs (CD3-CD20-CD14-
HLADR+CD11c+), and memory CD4+ T cells (CD3+CD4+CD45RA-). Among
CD4+ memory cells, the CR group showed significant or trend-toward-signifi-
cant increases in Tfh (CCR10-CXCR5+), Th1 (CXCR5-CCR6-CCR10-
CXCR3+), Th2, Th17 (CXCR5-CCR6+CCR4+CXCR3-CCR10-), ThGM-CSF
(CXCR5-CCR6-CCR10+CXCR3-), and Th22 (CXCR5-CCR6+CCR4+CXCR3-
CCR10+) cells. Tregs (CD4+CD25+CD127-) trended toward a ~2-fold increase
in the CR group. Within the monocyte subgroup (CD3-CD20-CD14+), the CR
group skewed toward classical monocytes (HLADR+CD16-) (64.7% vs 36.0%,
CR vs PR/MR, p=0.0078) and away from MDSCs (HLADR-CD16-) (30.0% vs
58.4%, CR vs PR/MR, p=0.0139) during treatment. Interestingly, the NK-to-
MDSC ratio was a sensitive and specific predictor of CR vs all other responses,
a finding consistent for both CD16+ and CD16- NK cells (Figure 1 a, b). Before
treatment, decreased naïve CD8+ T cells (CD45RA+CCR7+) predicted CR
versus PR/MR (12.6% vs 32.3% of CD8+ cells, CR vs PR/MR, p=0.0047) with
a similar trend toward decreased naïve CD4+ T cells (13% vs 24.4% of CD4+
cells, CR vs PR/MR, p=0.0749). While naïve T cells did not correlate with pre-
treatment aGVHD grade, grades III-IV aGVHD demonstrated increased Th2
cells (CD45RA-CXCR5-CCR6-CCR10-CXCR3-) and activated CD8+ cells
(CD38+HLADR+) as compared to grade II aGVHD. Further correlation with
serum cytokines, JAK-STAT signaling, and pharmacology will be available at
time of presentation.
Figure 1.
Summary/Conclusions: Decreased pre-treatment naïve T cells may predict
better outcomes in INCB039110-treated aGVHD. During treatment, increased
DCs, NKs, and memory T cell subsets correlated with better response. Sur-
prisingly, increased MDSCs associated with poorer response, suggesting
MDSC expansion during persistent inflammation. The NK-to-MDSC ratio may
be an important clinical marker to track treatment progress. Finally, this study
establishes a novel FACS-based 21-marker immunophenotyping method with
superior throughput, sample preservation, and flexibility as compared to cytom-
etry time of flight (CyTOF) methods.
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GUT COLONIZATION BY MULTI-DRUG RESISTANT BACTERIA IS AN
INDEPENDENT RISK FACTOR FOR DEVELOPMENT OF INTESTINAL
ACUTE GRAFT-VERSUS-HOST DISEASE
Z. Peric1,2,*, N. Durakovic1,2, L. Desnica1, V. Rezo Vranjes3, I. Marekovic3,
R. Serventi-Seiwerth1, J. Bilinski4, G. Basak4, R. Vrhovac1,2
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Background: Research has recently highlighted the importance of healthy gut
microbiota in the prevention of graft-versus-host disease (GVHD). Gut decon-
tamination and the use of broad-spectrum antibiotics have led to the loss of
natural microbiota diversity and the overgrowth of opportunistic pathogens with
emerging antimicrobial resistence. However, the role of multi-drug resistant
(MDR) bacteria in development of GVHD needs to be elucidated.
Aims: Our aim was to evaluate the impact of gut colonization with MDR bacteria
on the acute GVHD and related outcome.
Methods: Retrospectively we evaluated 145 adult patients who consecutively
underwent allogeneic stem cell transplantation (allo-SCT) in our institution
between 2011 and 2014. All patients were weekly screened by cultivating stool
specimens for gut colonization by the following MDR bacteria: vancomycin-
resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus
(MRSA) and multidrug-resistant Gram-negative bacilli (MDR-GNB). Univariate
and multivariable proportional hazards models using the Fine and Gray
approach were considered to evaluate the variables for acute GVHD, treating
death as competing event.
Results: Our study population included 88 male and 57 female patients who
underwent allo-SCT at a median age of 46 years (range 18-64). Among them,
most patiens were treated for myeloid malignancies (70%), while the rest had
lymphoproliferative disorders and one patient had aplastic anemia. The donors
were unrelated in 74 cases, related in 67 patients and haploidentical in 4
patients. Most of the patients (70%) received peripheral blood stem cells after
a reduced-intensity conditioning regimen (56%). At the time of allo-SCT 37%
patients were colonized with MDR bacteria, while another 19% became colo-
nized in the early postransplantation period. Among colonized patients, 12%
patients were colonized by VRE, 1% by MRSA, 43% by extended-spectrum β-
lactamase (ESBL)-producing Enterobacteriaceae, 27% by carbapenem-resis-
tant Enterobacteriaceae (CRE), 9% by MDR Acinetobacter baumannii and 58%
by MDR Pseudomonas aeruginosa. 36% patients were colonized with more
than one MDR pathogen. The cumulative incidence (CI) of severe (grade III-
IV) acute GVHD was significantly higher in patients colonized with MDR-GNB
(27%, 95% CI, 19-39%) than in non-colonized patients (14%, 95% CI, 7-23%)
(p=0.04). Moreover, MDR-GNB colonized patients had significantly more gas-
trointestinal (GI) GVHD CI as opposed to non-colonized patients (28% (95%
CI, 20-41%) vs 14% (95% CI, 7-23%), p=0.02) and more acute GVHD-related
mortality (16%, (95%CI, 9-26%) vs 7% (95%CI, 3-15%), p=0.10). A substantial
and independent role of gut colonization with MDR-GNB on the development
of GI GVHD was confirmed by multivariate analysis using time-dependent
covariate functions for high risk disease, myeloablative conditioning, peripheral
blood stem cells, unrelated donor (hazard ratio 2.14; 95%CI, 0.99-4.68,
P=0.05), older age (hazard ratio 2.15; 95%CI, 1.00-4.59, P=0.04) and MDR-
GNB gut colonization (hazard ratio 2.26;95% CI, 1.05-4.83, P=0.03).
Summary/Conclusions: In summary, this report shows a significant role of
MDR-GNB in the pathogenesis of severe acute GVHD. To our knowledge, we
are the first to show that gut colonization with MDR-GNB represents an inde-
pendent risk factor for GI GVHD. With growing resistance and lack of efficient
antibiotics, decolonization strategies as fecal microbiota transplantation become
an attractive strategy for restoration of healthy gut flora and prevention of severe
acute GVHD.
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IMPACT OF HLA DISPARITY ON OUTCOME IN HLA-HAPLOIDENTICAL
BONE MARROW TRANSPLANTATION FOLLOWED BY HIGH DOSE
POST-TRANSPLANT CYCLOPHOSPHAMIDE
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Background: By definition “haplo-identical” donors share genotipically 4/8 anti-
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gens with recipients. However, casual phenotypical homozygosity in the non-
shared haplotype makes the real degree of disparity less than 4/8 in a few
donor/recipient couples.
Aims: Since 2010, patients who lacked a HLA-identical donor have been trans-
planted from a haploidentical donor in our two Italian institutions. In this large
series of patients we aim to verify the real degree of antigen disparity between
donors and recipients and whether it impacts on transplantation outcome.
Methods: All haplotransplants performed in two Italian istitutions from August
2010 to July 2016 (n =318) were included. All patients received a myeloablative
regimen (MA) followed by unmanipulated bone marrow and high dose post-
transplant cyclophosphamide (PT-CY), combined with cyclosporine and
mycophenolate. Donors and recipients were typed, until 2015, using DNA
method (SSO and SBT) for HLA A, B, C, DRB1, DQ and DPB at a high reso-
lution level, as defined by EFI standards and by NGS at allelic level in 2016 for
the same loci. When applicable (72,3% of patients) members of the immediate
family where typed to definitively establish HLA genotype and haplotype identity.
Differences at loci A, B, C, DRB1 in both GvH and HvG direction were evalu-
ated. We evaluated overall survival (OS) and non-relapse mortality (NRM)
according to the amount of overall mismatches; also, we analyzed cumulative
incidence of grade II – IV aGVHD, moderate-severe chronic GvHD and relapse
(CIR) according to the degree of HLA mismatches in the GVH direction and
graft rejection rate according to the degree of HLA mismatches in the HVG
direction. For analysis purpose, the whole patient population was divided into
2 groups: 0-1-2 antigen mismatches versus 3-4 antigen mismatches. The same
distinction was mantained when analyzing only GVH or HVG directed mis-
matches. Acute GvHD was calculated at day 100, the other parameters were
calculated at the second year of follow up. OS was estimated using the Kaplan-
Meier approach while cumulative incidence was calculated for aGvHD, cGvhD,
relapse and NRM.
Results: Median age of patients was 48 years (17-74). Diagnoses included
acute myeloid leukemia (130), acute lymphoblastic leukemia (64), lymphoid
and plasma cell malignancies (43), myeloproliferative neoplasms (48) and
myelodisplastic syndrome (33). 144 patients (45%) were transplanted in
advanced phase of disease. With a median follow up of 562 days (range 6-
2241 days), 2-year OS was 55,7%. Concerning the proportion of “true” hap-
loidentical D/R pairs, 231 out of 318 (72%) couples showed 4/8 mismatches at
HLA A, HLA B, HLA C and HLA DRB1 loci. Neither OS nor NRM showed sig-
nificant correlation with the degree of overall mismatches at 2 years (0-2 mm:
54.2% vs 3-4 mm:58.8%, p=0.58 and 0-2 mm:18.2% vs 3-4 mm:19.1%, p=0.93,
respectively). Considering only GVH directed mismatches, no difference was
highlighted between low or high HLA mismatch burden in cumulative incidence
of aGVHD (12.6% vs 23.9%, p=0.13), cGVHD at 1 year (12.2% vs 14.8%,
p=0.84) and relapse (33.3% vs 24%, p=0.26). In this series graft rejection rate
was 6.6%; no correlation was observed with the amount of HLA mismatch in
the HVG direction.
Summary/Conclusions: In this series, about one third of haploidentical
donor/recipient pairs differ for less than 4 /8 HLA antigens. Furthermore, in the
setting of a MA conditioning with PT-CY the real degree of HLA mismatching
observed had no impact on OS, NRM, CI of Relapse and acute and chronic GvHD.
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Background: Allogeneic hematopoietic stem cell transplantation (alloHCT) is
widely used for the treatment of adults with acute lymphoblastic leukemia (ALL).
Although the choice of pre transplantation conditioning has never been a sub-
ject of a randomized trial, results of many retrospective studies suggested
advantage of total body irradiation (TBI)-based over chemotherapy-based reg-
imens. TBI is most frequently administered in combination with either
cyclophosphamide (Cy/TBI) or etoposide (Vep/TBI).
Aims: The goal of this study was to retrospectively compare the outcome of
alloHCT using Cy/TBI or Vep/TBI as conditioning.
Methods: Adult patients with Ph-negative ALL (n=1498) treated with alloHCT
from either HLA-identical sibling (n=696) or unrelated donor (n=802), in CR1
(n=1186) or CR2 (n=312), between year 2000 – 2015, were included in the
analysis. Peripheral blood was used as a source of stem cells in 62% of the
patients, while bone marrow in 38% of the patients, respectively. Conditioning
was myeloablative in all cases (the median TBI dose was 12Gy); 1346 patients
were treated with Cy/TBI while 152 patients with Vep/TBI. Patients in the
Vep/TBI group were younger (median 28 y. vs 30 y., p=0.04), treated in more
recent period (median year of HCT: 2009 vs 2007, p=0.009) and treated more
frequently in CR1 (87% vs 78%, p=0.001).
Results: In a univariate analysis, as compared to Cy/TBI, the use of Vep/TBI
was associated with significantly reduced incidence of relapse (17% vs 30%
at 5 years, p=0.007), increased rate of leukemia-free survival (LFS, 60% vs
50%, p=0.04) as well as improved “GVHD and relapse-free survival” (GRFS,
43% vs 33%, p=0.04). No significant effect could be observed in terms of the
incidence of non-relapse mortality, acute or chronic GVHD. In a multivariate
model the use of Vep/TBI was associated with reduced risk of relapse
(HR=0.62, p=0.04) while the effect on other study end-points was no longer
significant. Among other factors, recipient age (HR=1.17 per every 10 years,
p=<0.0001), year of alloHCT (HR=0.97 per every year, p=0.001) and disease
stage (HR=2.14 for CR2, p<0.0001) had significant influence on the risk of
treatment failure, either relapse or non-relapse mortality. The risk of relapse
was additionally increased for sibling vs unrelated donor transplants (HR=1.47,
p=0.01) and donor/recipient gender combination other than female/male
(HR=1.37, p=0.04).
Summary/Conclusions: Conditioning regimen based on etoposide combined
with TBI appears more effective than the cyclophosphamide TBI combination
for adult patients with Ph-negative ALL treated with alloHCT. Further, prospec-
tive studies are needed to confirm our observation and potentially discriminate
subgroup of patients who are most likely to benefit from the use of etoposide.
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Background: High-risk acute myeloid leukemia (AML) is mainly defined by
the presence of determined poor-risk cytogenetic abnormalities and is a stan-
dard indication for allogenetic stem cell transplantation (SCT). Nevertheless,
high-risk AML is a very heterogeneous group including several abnormalities
with different levels of prognostic impact. Deletion 5q or monosomy 5 (-5/5q-)
has been part of the high-risk group of AML for many years. SCT seems to
improve their outcomes but the additive effects of other high-risk cytogenetic
features on survival have never been thoroughly studied.
Aims: To evaluate the role of SCT in -5/5q- AML with additional cytogenetic
abnormalities such as complex karyotype (CK), monosomal karyotype (MK),
monosomy 7 (-7), or 17p abnormalities (abn(17p)).
Methods: We included adult patients (pts) with AML with -5/5q- reported to the
EBMT registry as having their first SCT between 2000 and 2015.
Results: Five hundred and one pts, 21% of them with secondary AML, have
been allocated. Median age at SCT was 55 year-old (range, 18-75) and median
follow-up was 21 months (range, 2-173). At time of SCT, 338 pts (67%) were
in first remission (CR1), 21 pts (4%) were in subsequent remission and 142
(28%) had active disease. Two hundred seventy-seven pts (55%) were trans-
planted from an unrelated donor (UD) and 224 from a sibling donor. A mye-
loablative conditioning (MAC) was administered in 45% of the pts and a
reduced-intensity conditioning (RIC) in 55% of them. The 2-year probabilities
of overall survival (OS) and leukemia-free survival (LFS) were 27% and 20%,
respectively. The 2-year probality of treatment-related mortality (TRM) was
20%. The cumulative incidence of grade II-IV acute graft-versus-host disease
(GvHD) was 29% and the 2-year cumulative incidence of chronic GvHD was
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27%. The main cause of death was disease-related. In multivariate analysis,
active disease correlated strongly with worse OS, LFS and NRM. The other
factors influencing outcomes were UD with increased NRM, and age with
decreased OS and LFS.
Based on the frequencies of the different additional cytogenetic abnormalities,
we identified 4 groups within our cohort. Group 1 (None) included 47 pts with -
5/5q- but without CK, MK or abn(17p). Group 2 (CK) included pts with -5/5q-
and CK but no MK or abn(17p) (N=90). Group 3 (MK) included 169 pts with -
5/5q- and MK but no abn(17p). Finally, group 4 (17p) included pts with -5/5q-
and abn(17p) (N=193). The 4 groups were quite similar in term of characteris-
tics. The 2-year probablity of LFS was 39% for group 1, 25% for group 2, 20%
for group 3 and only 13% for group 4 (p<0.001). OS decreased also significantly
from group 1 to group 4 (p<0.001). NRM was similar across the groups. In mul-
tivariate analysis, factors associated with worse OS and LFS were active dis-
ease, age, MK and abn(17p). The corresponding 2-year probability of GvHD
and relapse-free survival was 27% for group 1, 17% for group 2, 14% for group
3 and 7% for group 4 (Figure 1).
Figure 1.
Summary/Conclusions: SCT in -5/5q- AML provides a durable response for
approximately 20% of pts. Active disease at time of transplantation was the
most powerful predictor of an inferior outcome. The presence of -5/5q- without
CK, MK or abn(17p) was associated with a significant better survival and the
addition of MK or abn(17p) translated into worse outcomes. We confirmed
the deleterious effect of the combination of -5/5q- and abn(17p) on SCT out-




IDENTIFICATIONS OF NOVEL RECURRENT PU.1 FUSIONS WITH HIGHLY
AGGRESSIVE PHENOTYPE IN PEDIATRIC T CELL ACUTE LYMPHOBLASTIC
LEUKEMIA
M. Seki1,*, S. Kimura2, T. Isobe1, K. Yoshida3, H. Ueno3, H. Suzuki3, Y. Shiozawa1,
K. Kataoka3, Y. Fujii3, Y. Shiraishi4, K. Chiba4, H. Tanaka4, T. Shimamura5,
L. Lin6, M. Takagi6, C. Wang7, A. Iwama7, K. Ohki8, M. Kato8, Y. Arakawa9,
K. Koh9, R. Hanada9, H. Moritake10, M. Akiyama11, R. Kobayashi12,
T. Deguchi13, Y. Hashii14, T. Imamura15, A. Sato16, N. Kiyokawa8, A. Oka1,
Y. Hayashi17, A. Manabe18, A. Ohara19, K. Horibe20, M. Sanada20, H. Mano21,
S. Miyano4, S. Ogawa3, J. Takita1
1Department of Pediatrics, The University of Tokyo Hospital, Tokyo, 2Depart-
ment of Pediatrics, Hiroshima University, Hiroshima, 3Department of Pathology
and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto,
4Laboratory of DNA Information Analysis, Human Genome Center, Institute of
Medical Science, The University of Tokyo, Tokyo, 5Division of Systems Biology,
Nagoya University Graduate School of Medicine, Nagoya, 6Department of Pedi-
atrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo,
7Department of Cellular and Molecular Medicine, Graduate School of Medicine,
Chiba University, Chiba, 8Department of Pediatric Hematology and Oncology
Research, National Research Institute for Child Health and Development,
Tokyo, 9Department of Hematology/Oncology, Saitama Children’s Medical Cen-
ter, Saitama, 10Division of Pediatrics, Faculty of Medicine, University of Miyaza-
ki, Miyazaki, 11Department of Pediatrics, The Jikei University School of Medi-
cine, Tokyo, 12Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo,
13Department of Pediatrics, Mie University Graduate School of Medicine, Tsu,
14Department of Pediatrics, Osaka University Graduate School of Medicine,
Suita, 15Department of Pediatrics, Kyoto Prefectural University of Medicine,
Graduate School of Medical Science, Kyoto, 16Department of Hematology and
Oncology, Miyagi Children’s Hospital, Sendai, 17Gunma Children’s Medical
Center, Shibukawa, 18Department of Pediatrics, St. Luke’s International Hos-
pital, 19Department of Pediatrics, Toho University, Tokyo, 20Clinical Research
Center, National Hospital Organization Nagoya Medical Center, Nagoya,
21Department of Cellular Signaling, Graduate School of Medicine, The Univer-
sity of Tokyo, Tokyo, Japan
Background: T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL)
accounts for 10% to 15% of newly diagnosed cases of childhood acute lym-
phoblastic leukemia (ALL), arising from the malignant transformation of
hematopoietic progenitors primed toward T cell development, as result of a
multistep oncogenic process. However, since the prognostic significance of
these genetic alterations in pediatric T-ALL is not clear, genetic basis which
contributes aggressive phenotype or progression of pediatric T-ALL is still to
be elucidated.
Aims: To discover driver genetic events, which involved in the aggressive phe-
notype of pediatric T-ALL and to identify its novel prognostic markers, we per-
formed integrated genetic analysis in a large cohort of T-ALL case.
Methods: Our cohorts included samples from Tokyo Children’s Cancer Study
Group (TCCSG) and Japan Association of Childhood Leukemia Study (JACLS).
Whole transcriptome sequencing (WTS) was performed in 123 cases. Whole
transcriptome sequencing (WTS) was performed in 123 cases.
Results: Representative recurrent fusion genes were as follows, SIL-TAL1
(n=25), MLL-ENL (n=5), PICALM-MLLT10 (n=5), and NUP214-ABL1 (n=2).
Intriguingly, novel recurrent in-frame PU.1 fusions (STMN1-PU.1 n=2; TCF7-
PU.1 n=5) were detected, and RT-PCR analysis in additional 60 cases revealed
other 2 TCF7-PU.1 fusions. Thus, PU.1 fusions accounted for 4% of pediatric
T-ALL/LBL. Expression data of WTS revealed cases with PU.1 fusion showed
significantly higher expression of PU.1 compared to cases without PU.1 fusion,
implicating that aberrant high expression of PU.1 involved in leukemogenesis.
Using consecutive two-step unsupervised consensus clustering, we obtained
5 stable clusters. Among these, 4 clusters largely recapitulated distinct T-ALL
subtypes characterized in previous studies by an early T-cell precursor (ETP)
signature (ETP-ALL), 2 clusters of high TAL1 expression (TAL1-RA and -RB -
ALL), and mutually exclusive expression of, TLX1, and TLX3 (TLX-related-
ALL). However, the remaining one was newly identified and exclusively con-
sisted of the 7 PU.1 fusion-positive cases. Compared to ETP-ALL, these PU.1
fusion cases typically showed a reduced expression of the phase I genes impli-
cated in early T-cell development, except for PU.1, which was ectopically up-
regulated by the relevant gene fusions. All cases with PU.1 fusion were grouped
into PU.1 high cluster. Moreover, PU.1 high cluster had distinct genetic features
with mutations of transcription factors, such as GATA3, RUNX1, and EVT6. Of
note, significant poor outcome was confirmed by multivariate analysis in cases
with PU.1 high cluster (p=0.048). Consistently, we defined PU.1 overexpression
cases as outliers of PU.1 expression, which resulting in extremely poor prog-
nosis (3-year OS 21%, log-rank p=6.9 ×10-7).
Summary/Conclusions: PU.1 fusions expressing cells expanded and they
remained at an immature stage, implicating a potential leukemogenic activity
of these fusions. Not only the cases with PU.1 fusions, but also the cases with
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high PU.1 expression without fusions showed extremely poor prognosis, sug-
gesting the prognostic value of aberrant PU.1 expression in pediatric T-ALL.
Although it remains unclear, why cases with PU.1 fusions/high PU.1 expression
have a poor prognosis, our results indicate that these cases are genetically
distinct subgroup from other pediatric T-ALL.
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Background: The outcome of Ph+ acute lymphoblastic leukemia (Ph+ ALL)
has drastically improved since the introduction of tyrosine kinase inhibitors
(TKI). At present however, well-defined prognostic markers, beyond the mon-
itoring of minimal residual disease (MRD) during follow-up and to a lesser
extent IKZF1 deletions, are lacking.
Aims: To identify genomic lesions of prognostic value, we evaluated copy num-
ber aberrations (CNA) by SNP arrays, confirmed them by multiplex ligation-
dependent probe amplification (MLPA) and we set up a droplet digital PCR
(ddPCR) assays for additional lesions. Furthermore, we correlated the lesions
identified with MRD monitoring, outcome and biological features, such as the
type of fusion protein (p190 or p210). Finally, in a subset of patients gene
expression profiling (GEP) was carried out.
Methods: Genomic DNA of 116 newly diagnosed adult Ph+ ALL patients
enrolled in 4 consecutive GIMEMA trials, namely 0201B, 0904, 1205 and 1509,
was evaluated. All the trials were based on an induction with steroids and TKI,
the first 2 with imatinib and the remainders with dasatinib. For CNA, the
Cytoscan HD Arrays (Affymetrix, Santa Clara, CA) were used. The lesions
were confirmed by MLPA on all samples using the Salsa MLPA P335-A3 ALL-
IKZF1 kit (MRC-Holland, Amsterdam, The Netherlands). ddPCR was used to
validate lesions targeting MEF2C. In 42 cases, GEP experiments were per-
formed using the HGU133 Plus 2.0 gene chips (Affymetrix, Santa Clara, CA). 
Results: We found a similar load and type of lesions across the 4 trials, one of
which included elderly. The majority of lesions targeted IKZF1 (84%), PAX5 (36%)
and CDKN2A/B (32%). In our cohort, IKZF1 deletions alone did not affect com-
plete molecular response (CMR) achievement or disease-free survival (DFS),
while patients harboring CDKN2A/B and PAX5 deletions had a significant inferior
outcome (p=0.004, p=0.003 respectively). In line with this, a worse DFS was
observed for the so-called “IKZF1 plus” cases, i.e. concomitant deletions of IKZF1
and CDKN2A/B and/or PAX5 (46% vs 24% at 36 months, p=0.005). MLPA con-
firmed the incidence of these deletions and allowed the study of IKZF1 isoforms.
Among IKZF1 deleted cases, patients carrying the ∆4-7 isoform (25%) had a
worse DFS (p=0.02) than patients harboring other IKZF1 isoforms. Importantly,
SNP arrays highlighted novel genomic lesions targeting MEF2C in 13% of cases,
which were associated to the achievement of a CMR (p=0.05) and had a signif-
icant impact on DFS (62% vs 32% at 36 months, p=0.02). The association with
CMR was not affected by the trial (p=0.76) or the TKI used (p=0.57). This result
was confirmed by ddPCR. Unsupervised hierarchical clustering of GEP experi-
ments identified 3 subgroups: the first comprised mainly patients who reached a
CMR, the second one patients who had IKZF1 alone, and the last one comprised
“IKZF1 plus” patients. ANOVA analysis showed an overexpression of genes
involved in cell communication and protein modification process in PAX5 deleted
cases, suggesting that these genes could be contributing factors in BCR/ABL1-
driven leukemogenesis. 
Summary/Conclusions: In adult Ph+ ALL, IKZF1 deletions have a prognostic
impact only if associated with other lesions. Among IKZF1 deletions, only the
∆4-7 deletion has a deleterious effect. MEF2C lesions carry prognostic impli-
cations, being significantly associated with a better prognosis. This study paves
the way to design a prognostic model for adult Ph+ ALL that includes these
findings and more conventional features, in order to better stratify patients at
diagnosis and to further optimize treatment.
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Background: Amplicon-based next generation sequencing (NGS) of
immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements can be
used to identify suitable markers for subsequent quantification of minimal resid-
ual disease (MRD) in acute lymphoblastic leukemia (ALL). Within the Euro-
Clonality-NGS Consortium we established and validated a standardized quality
controlled amplicon-based NGS application to detect clonally rearranged IGH,
IGK, TRB, TRG and TRD genes in lymphoid disorders.
Aims: 1) to test EuroClonality-NGS IG / TR NGS assays within an international
multi-laboratory pilot for their suitability to identify clonal markers in ALL at diag-
nosis, and 2) to compare these NGS results with conventional Sanger sequenc-
ing (SS) of Genescan or Heteroduplex peaks/bands local multiplex PCRs
Methods: Within the EuroClonality-NGS Consortium, V, D, and J gene-spe-
cific primers tailed with universal and T7-linker sequences, were designed to
amplify complete and incomplete IGH, IGK, TRB, TRG or TRD gene
rearrangements employing eight different multiplex PCR assays. PCR pro-
tocols were standardized in a common NGS workflow for all targets. NGS
assays were tested in a European multi-laboratory pilot run in five institutes
(Kiel, Bristol, Prague, Monza, Paris). Diagnostic DNA (100ng) from 10 ALL
patients per centre were amplified in each institute using the EuroClonality
NGS primer sets, and subsequently sequenced on the Illumina MiSeq
(2×250bp v2 kit). Defined copy numbers of clonal reference DNAs were
spiked into all samples for calculation of clonotype copy numbers. A standard
polytarget quality control (QC) DNA was used to monitor inter- and intra-lab
NGS reproducibility. Results of NGS based marker identification were com-
pared to results of routine SS results.
Results: Fifty ALLs (29 BCP-ALL and 21 T-ALL) were analysed. A total of
480 libraries were deep sequenced, leading to 47 M high quality reads (ᴓ
9.2 M/lab). Pre-processing, identification and immunogenetic annotation of
target sequences, quality control and copy number calculations, were per-
formed with ARResT/Interrogate, using IMGT germline sequences – further
analyses and verifications were performed with Vidjil and IMGT/V-QUEST.
Overall, 339 clonal IG / TR sequences were identified, with a mean of 6.3 (2-
13)/sample using NGS vs 5.0 (2-13)/sample using SS. A total of 228/339
(68%) clonal sequences were concordant between both methods. NGS iden-
tified additional clonal rearrangements in 88 (26%) libraries, whereas 23 (7%)
clonal markers were only detected by SS. NGS primers covered possible IG
/TR rearrangement types more completely compared to local multiplex PCR
sets and enabled sequencing of bi-allelic rearrangements and weak PCR
products. Currently discrepant cases are analysed in more detail using allele-
specific PCR assays. Assay performance was analysed by standardized eval-
uation of QC samples and showed high intra- and inter-lab consistency with-
out statistically significant differences between the labs.
Summary/Conclusions: The IG / TR NGS panel, as established by the Euro-
Clonality-NGS Consortium, allows for quality controlled high-throughput detec-
tion of clonal IG /TR rearrangements in ALL. Compared to low throughput meth-
ods more clonal MRD markers are identified, sensitivity is increased, process-
ing time is reduced and labour intensive conventional methods to resolve mixed
sequences in case of bi-allelic rearrangements or background are avoided.
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Background: Reduced intensity conditioned allogeneic haematopoietic stem
cell transplant (RICalloHCT) enables HCT to be performed in older patients.
The UK NCRI UKALL14 study of adult acute lymphoblastic leukaemia (ALL)
considers patients ≥41 years “high risk” and recommends a RICalloHCT where
there are high quality donors. Other “high risk” factors are high WBC at pres-
entation, t(9;22), t(4,11), hypodiploidy/near triploidy, complex karyotype and
positive minimal residual disease (MRD) after completing induction therapy.
The presence of MRD at this time-point predicts poor outcome after conven-
tional chemotherapy. There is evidence that myeloablative alloHCT can over-
come this risk, but the benefit of RICalloHCT is uncertain.
Aims: To determine whether RICalloHCT mitigates the high relapse risk pre-
dicted by MRD positivity after induction therapy.
Methods: Protocol treatment: patients receive a steroid pre-phase before 2
cycles of induction chemotherapy. At the end of induction, patients are
assigned subsequent therapy on the basis of risk. All patients over 41 years
are allocated RICalloHCT, conditioned with fludarabine, melphalan and alem-
tuzumab. Post HCT, escalating doses of donor lymphocyte infusions were
given for T-cell mixed chimerism +/- MRD persistence or relapse. MRD
assessment: BCR/ABL1 or Ig/TCR MRD was assessed and analysed per
EuroMRD guidelines. MRD is negative (undetectable with an assay quanti-
tative range of 1x10-4 or less), positive (≥1x10-4), positive outside quantitative
range (POQR)(<1x10-4) or indeterminate (undetectable but assay quantitative
range ≥5x10-4). Patients with indeterminate MRD were excluded from this
analysis.
Results: There are 736 patients randomised to date, of whom 184 received a
RICalloHCT; of these, 115 had analysable MRD. The following Table 1 shows
patient characteristics.
Table 1.
At 2 years post transplant, overall survival (OS) was 63.1% in the 115 patients
with evaluable MRD and 62.7% in the 184 patients receiving RICalloHCT;
event free survival (EFS) was 55.2% and 55.9% respectively. By contrast, in
the 38 of 115 patients with positive MRD after induction, OS and EFS were
40.6% and 28.4% respectively. Twenty eight of the 115 patients relapsed,
with a 2 year actuarial relapse risk of 31.5% (22.2-43.5). We assessed the
association of the following factors; age, sex, immunophenotype, presenting
WBC, BCR/ABL1, other cytogenetics, post-induction MRD and donor type
with the risk of relapse. Among this population of high risk patients, post-
induction MRD was the only independent prognostic factor for relapse (uni-
variable HR: 3.82 (1.59–9.16), p 0.001 (see Figure 1) and multivariable HR:
4.14 (1.61-10.65), p= 0.003). The relapse rate of the MRD+ patients was
57.2% at 2 years post HCT.
Figure 1.
Summary/Conclusions: The 2-year OS of 62.5% in UKALL14 participants
over 41 years old after RICalloHCT is greater than would be expected with
chemotherapy alone. However, MRD positivity after induction is associated
with significantly lower OS, EFS and a higher risk of relapse, which is not abro-
gated by RICalloHCT.
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Background: Blinatumomab (Blin) is a bispecific monoclonal antibody, acti-
vating autologous effector T-cells and redirecting them against CD19-positive
malignant cells. This leads to polyclonal effector T-cell expansion which is the
necessary component of its antitumour mechanism. Recent reports indicated
promising antitumour activity of Blin in relapsed/refractory (r/r) B-cell precursor
acute lymphoblastic leukemia (BCP-ALL). However, approximately half of these
patients do not achieve minimal residual disease (MRD) response.
Thanks to recent advances in next generation sequencing (NGS) of
immunoglobulin and T-cell receptor gene rearrangements the deep and com-
prehensive evaluation of expanded T-cell repertoire on Blin treatment is now
possible.
Aims: To compare the differrences in TRB repertoire diversity and composition
between two groups of patients with r/r ALL: 1) responders: reaching MRD neg-
ativity at the latest at day 29 of 1. Blin cycle (C1D29), and 2) persisters: with
quantifiable MRD positivity (>0.01%) at C1D29, or with MRD >1% at cycle 1
day 15 (C1D15) if C1D29 sample is not available.
Methods: We used NGS to investigate TRB repertoire in bone marrow samples
(114× at time of screening (scr), 74× C1D15, 98× C1D29) of 114 r/r Ph-negative
BCP-ALL patients (median age: persisters 47; responders 42; p-value=0.81).
Patients received Blinatumomab within the phase II trial (MT103-211). Sequenc-
ing libraries were prepared using 100ng of DNA via 2-step PCR and sequenced
on the Illumina MiSeq (2 x 250bp) with a median coverage of 117,563 reads
(range 59.512 - 447.767 reads) per sample. In the first PCR virtually all TRB
rearrangements present in the investigated sample were amplified using uni-
versal V(D)- and J-regions primers. In the second step, sequencing adaptors
and sample-specific barcodes were added. Annotation of V (D)- and J-regions
of TRB sequences was performed using ARResT/Interrogate (Bystry, Bioinfor-
matics, 2016). Diversity of TRB repertoire within patient groups and time points
was expressed as the Shannon index, using the R-package vegan. Analysis of
variance was employed to assess statistically significant differences in diversity
between groups and time.
Results: Diversity of TRB repertoire (Figure 1) was significantly higher in
responders at time of scr (p=0.02) and at C1D29 (p=5.47E-6). Patients in the
persisters group had significantly higher blast counts, which is in accordance
with previously published data (Topp, The Lancet Oncology, 2015). The
increase of diversity between scr and C1D29 of Blinatumomab treatment was
sharp and highly significant in responders (p=3.96E-6), but not statistically sig-
nificant in persisters (p=0.4).
Figure 1.
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Summary/Conclusions: We showed that Blin responders have significantly
higher TRB repertoire diversity at scr compared to persisters and that the reper-
toire expansion during Blin treatment is sharper in responders. Other repertoire
characteristics did not differ significantly between groups. Further studies on
larger patient cohorts are necessary in order to elucidate whether the response
to treatment can be predicted by repertoire diversity at scr.
Amplicon NGS is a useful tool for monitoring of T-cell repertoire. Development,
standardization, and validation of TRB primer sets is in progress within Euro-
Clonality-NGS Consortium.
Research Support: Amgen.
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Background: In neutropenic patients with unexplained fever the classical
approach is maintaining the empirical antibacterial therapy (EAT) until neu-
trophil recovery. This strategy may result in unnecessarily prolonged EAT favor-
ing bacterial resistance, organ toxicity and damage to microbiota. Nevertheless,
the available scientific evidence supporting the alternative approach of stopping
EAT before neutrofile recovery is moderate. 
Aims: To investigate if a clinical approach (based on apyrexia and clinical
recovery) is better than and as safe as the standard criteria (recovery from
neutropenia) to decide the discontinuation of EAT.
Methods: After local Ethical Committee approval, a randomized, controlled,
multicenter, open-labeled phase IV clinical trial was performed (EudraCT: 2011-
005152-34). Study period: May-2012 to May-2016. Inclusion criteria: a) Adult
patients (≥18 years); b) Hematologic malignancy or autologous or allogeneic
hematopoietic stem cell transplantation (SCT) recipients; c) High risk febrile
neutropenia (FN) d) Informed consent signed. Exclusion criteria: etiological
diagnosis of FN. Patients were randomized 72 hours after fever onset to: 1.
Experimental group (EG): EAT discontinuation if a) apyrexia ≥72 h, plus b) clin-
ical recovery ≥72 h (independently of neutrophil count) or 2. Control group
(CG): EAT discontinuation if a) apyrexia ≥72 h, plus b) clinical recovery ≥72 h,
plus c) >0.5x106/L neutrophils. Follow-up: 28 days from EAT. Primary (efficacy)
end-point was number of EAT-free days. Secondary (safety) end-points were
total days of fever and crude mortality. 
Results: One hundred and fifty seven patients were included (EG 78 and CG
79). There were no differences in baseline characteristics or clinical presenta-
tion between groups. The most frequent underlying conditions were
induction/re-induction chemotherapy for acute leukemia (n=42, 26,7%), autol-
ogous SCT (n=42, 45,8%), and allogeneic SCT (n=14, 8,9%). The most fre-
quent clinical presentation was non-focused FN (n=63, 40,1%), abdominal
focused FN (n=34, 21,6%) and mucositis (n=31, 19,7%). Days with fever, and
neutropenia duration and EAT-free days difference between groups are detailed
in Table 1. Recurrent fever frequency was 14,3% (EG) and 17,9% (CG) (p=ns)
and crude mortality was 1,3% (EG) and 3,8% (CG) (p=ns).
Table 1.
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Summary/Conclusions: In hematological patients with febrile neutropenia of
unknown origin the discontinuation of empirical antibacterial therapy after 72
hours of apyrexia and clinical recovery regardless of neutrophils count is safe
and reduces unnecessary exposure to antibiotics.
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CONJUGATED PNEUMOCOCCAL VACCINE TRIGGERS A BETTER
IMMUNE RESPONSE THAN POLYSACCHARIDE PNEUMOCOCCAL
VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA A RAN-
DOMIZED STUDY BY THE SWEDISH CLL GROUP
T. Svensson1,*, M. Kättström2, Y. Hammarlund3, D. Roth4, P.-O. Andersson5,
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Background: Patients with CLL have an increased risk for infection and Strep-
tococcus pneumoniae is one of the most common pathogens with high mor-
bidity. Patients with CLL are known to respond poorly to the traditionally used
polysaccharide vaccines. Conjugation of polysaccharide to protein carriers ren-
ders a thymus-dependent, memory-inducing and more immunogenic vaccine.
In patients with CLL, there is no consensus on a recommendation for pneumo-
coccal vaccination, due to a lack of comparative studies.
Aims: To determine if patients with untreated chronic lymphocytic leukemia
(CLL) benefit from vaccination with a 13-valent conjugated pneumococcal vac-
cine (PCV13), Prevenar13®, compared with a 23-valent capsular polysaccha-
ride vaccine (PPSV23), Pneumovax®, in terms of immune response.
Methods: 128 treatment naïve CLL patients from eight hematology clinics in
Sweden were randomized to vaccination with PCV13 (n=63) or PPSV23 (n=65)
after stratification by IgG levels and CLL clinical stage (Rai). Blood samples for
evaluation of immune response were obtained at baseline, at one and at six
months after vaccination. Analyses for each of the 12 pneumococcal serotypes
common for PCV13 and PPSV23 were performed by opsonophagocytic assay
(OPA) and enzyme-linked immunosorbent assay (ELISA).
Results: PCV13 elicited a superior immune response than PPSV23 in 10/12
serotypes one month after vaccination and in 5/12 serotypes six months after
vaccination, measured as OPA geometric mean titers (GMTs). Geometric
mean concentrations of serotype-specific IgG antibodies elicited by PCV13
as measured by ELISA, were higher than those elicited by PPSV23 in half of
the common serotypes, both after one and six months. The proportion of
patients with good response (defined as response in 8 of 12 common
serotypes according to predefined response criteria) was higher in PCV13
recipients than in PPSV23 recipients after one month (40% vs 22%, p=0.034)
as well as after six months (33% vs 17%, p=0.041). Never did PPSV23 trigger
a better immune response for any of the serotypes, than PCV13, regardless
of analysis. For two of the serotypes, OPA GMTs were lower at the six months
than at the one-month follow up. Negative predictive factors for vaccination
response were hypogammaglobulinemia and long disease duration. Both
vaccines were well tolerated.
Summary/Conclusions: In patients with previously untreated CLL, the efficacy
of PCV13 in terms of immune response is superior to PPSV23 for many
serotypes common for the two vaccines. PCV13 should be considered as a
part in vaccination programs against Streptococcus pneumoniae for these
patients and administered as early as possible during the course of the disease. 
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INFECTION-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION: AGE, CMV AND PRE-TRANSPLANT
LEVELS OF IGA/IGM PREDICT IRM IN A NEW CLINICO-BIOLOGICAL
SCORING SYSTEM 
A. Forcina1,*, P. Rancoita2, V. Marasco1, R. Greco1, M.T. Lupo Stanghellini1,
M. Carrabba1, M. Marcatti1, C. Di Serio2, M. Bernardi1, J. Peccatori1, C. Corti1,
A. Bondanza1, F. Ciceri1
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Milan, Italy
Background: Infection-related mortality (IRM) is a major challenge after allo-
geneic hematopoietic stem cell transplantation (allo-HSCT). 
Aims: The aim of this study was to develop a scoring system predicting IRM
based exclusively on pre-transplant data.
Methods: A total of 589 adult patients receiving allo-HSCT were studied (Jan
2009 - Nov 2016). In a training set of patients (n=273, Jan 2012-May 2015) the
ROC curve analysis defined the optimal cut-offs predicting 100-day IRM for
continuous data. All clinical and biochemical variables were challenged in a
multivariate analysis and a 3-tiered weighted score was elaborated and tested
firstly in a retrospective validation set (n=219, Jan 2009-Dec 2011) and then in
a prospective validation set (n=97, Jun 2016-Nov 2016).
Results: Median follow-up was 43 months (range 1-85). Acute leukemia was
the main indication to transplant, accounting for 60% (n=356) of patients. The
majority of the patients received an alternative-donor transplant (44% a HLA-
haploidentical, 37% a matched unrelated donor). Forty-seven percent (n=277)
of patients had advanced diseases. Multivariate analysis revealed age >60 yrs
(P=0.003), CMV host/donor serostatus different from negative/negative
(P<0.001) and pre-transplant levels of IgA <1.11 g/L (P=0.004) and IgM <0.305
g/L (P=0.028) as the only independent predictors of increased IRM. Noticeably,
these associations were independent from disease type or status, donor type,
intensity of conditioning, in vivo T or B-cell depletion or from previous coloniza-
tion by multidrug-resistant bacteria. According to the proposed IRM score,
patients were divided into 3 classes: low (<10.17 points), intermediate (10.17-
11.11 points) or high-risk (>11.11 points). In the training set, 100-day and 2-yrs
IRM were 5% (95% CI 2-10) and 9% (95% CI 4-16) for low-risk, 11% (95% CI
5-18) and 23% (95% CI 14-33) for intermediate-risk, and 16% (95% CI 16-37)
and 41% (95% CI 28-53) for high-risk patients, respectively (P=0.001). In the
retrospective validation set, 100-day and 2-yrs IRM were 7% (95% CI 3-14)
and 14% (95% CI 8-22) for low-risk, 17% (95% CI 10-26) and 23% (95% CI 15-
33) for intermediate, and 28% (95% CI 15-42) and 33% (95% CI 19-4) for high-
risk patients, respectively (P= 0.044), with a c-index of 0.608 (Figure 1). In the
prospective validation set, only 100-day IRM was calculated due to a shorter
follow-up, being of 0%, 3% (95% CI 0-13) and of 14% (95% CI 3-33) for low,
intermediate and high-risk patients (P=0.003). Additionally, in both training and
retrospective validation sets (n=492), the 2-yrs OS was different among the 3
groups, being 59% (95%CI 52-67), 50% (95%CI 43-59) and 37% (95%CI 29-
48) for low, intermediate and high-risk groups, respectively (P=0.0001). In the
prospective validation set, only 100-day OS was evaluated, being of 95%
(95%CI 88-100), 91% (95%CI 82-100) and 80% (95%CI 65-100), respectively
(P=0.03). Out of a total of 129 infection-related deaths, 94/129 (73%) were
attributed to bacteria, 22/129 (17%) to viruses, 11/129 (8%) to fungi and 2/129
8 (2%) to parasites.
Figure 1.
Summary/Conclusions: This new clinic-biological score based on age, CMV
serostatus and levels of IgA and IgM, may contribute to the prompt identification
of patients at higher risk of fatal infections prior to allo-HSCT, thus promoting
post-transplant personalized intensive active surveillance strategies and
immune-intervention approaches to improve the overall outcome of transplant.
A multicentric Italian study in currently on the way for the external validation of
these results
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LETERMOVIR FOR PREVENTION OF CYTOMEGALOVIRUS INFECTION
IN ADULT CMV-SEROPOSITIVE RECIPIENTS OF ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
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Background: CMV remains a common complication of HCT, yet no antiviral
drug suitable for prophylaxis is available in HCT. LET is a first-in-class drug
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that inhibits the CMV terminase complex. A dose-escalation phase 2 trial
showed that LET prophylaxis for up to 12 weeks post-HCT was effective with
a safety profile similar to placebo.
Aims: To compare LET prophylaxis to placebo for the prevention of clinically
significant CMV infection (CS-CMV), defined as CMV disease or CMV viremia
leading to preemptive treatment (PET) in a Phase III randomized, double-blind,
placebo-controlled trial.
Methods: CMV seropositive HCT recipients 18 years or older who had unde-
tectable plasma CMV DNA within 5 days of randomization were eligible (full
eligibility at clinicaltrials.gov, NCT02137772). Subjects had to start treatment
by Day+28 post-HCT. Subjects were randomized 2:1 to receive LET or placebo
PO or IV through Week 14 (Day +100) post-HCT, stratified by study site and
high or low CMV disease risk. LET was dosed at 480 mg/d (or 240 mg/d if on
cyclosporine due to drug-drug interaction). Subjects were assessed weekly
through Week 14, biweekly through Week 24, and every other month through
Week 48 after HCT. Plasma obtained at each visit was assayed for CMV DNA
in a central laboratory. Subjects who developed CS-CMV discontinued study
drug and received anti- CMV treatment. Local CMV assay results could be
used to start PET. The primary endpoint was the stratum-adjusted proportion
of subjects with CS-CMV through Week 24 post-HCT among subjects with
undetectable CMV DNA at randomization; subjects who discontinued the study
for any reason or with missing data at Week 24 were considered failures. All
adverse events (AEs) were analyzed through 14 days after the last dose of
study drug.
Results: From June 2014 to March 2016, 565 randomized subjects received
study treatment; 31% were at high CMV disease risk. 50% subjects received
myeloablative conditioning, 35% received ATG. Donors included 14% mis-
matched unrelated, 13% haploidentical and 4% cord blood. Study arms were
balanced. Subjects began study drug a median of 9 days post-HCT; 37% had
engrafted prior to start. Of 495 treated subjects with undetectable CMV DNA
at randomization, fewer subjects developed CS-CMV or were considered fail-
ures in the LET arm (122/325, 38%) compared to placebo (103/170, 61%;
p<0.0001) by Week 24 post-HCT. Figure 1 shows the time to CS-CMV analysis.
The most common AEs (LET, placebo) were GVHD (39%, 39%), diarrhea (26%,
25%), and nausea (27%, 23%). More frequent vomiting (19%, 14%), edema
(15%, 9%), atrial arrhythmias (10%, 5%), and ALT levels >5xULN (4%, 2%)
was noted in LET-treated subjects; no increased myelotoxicity or nephrotoxicity
was observed. The Week 24 all-cause mortality was 10% for LET recipients
and 15% for placebo recipients.
Figure 1.
Summary/Conclusions: Letermovir prophylaxis was effective in reducing clin-
ically significant CMV infection, was overall well tolerated, and provides a new
approach to CMV prevention after HCT.
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EFFICACY AND SAFETY OF DEFIBROTIDE TO TREAT HEPATIC
VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME
POST-CHEMOTHERAPY: A POST HOC ANALYSIS OF FINAL DATA OF AN
EXPANDED-ACCESS PROTOCOL
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Background: Hepatic VOD/SOS, which may be unpredictable and potentially
life-threatening, is typically considered a complication of hematopoietic stem
cell transplantation (HSCT), and VOD/SOS with multi-organ dysfunction (MOD)
may be associated with >80% mortality. Defibrotide is approved to treat severe
hepatic VOD/SOS post-HSCT in the European Union and to treat hepatic
VOD/SOS with renal or pulmonary dysfunction post-HSCT in the United States.
However, VOD/SOS can occur after chemotherapy without HSCT.
Aims: To perform a post hoc analysis of final data on safety and response to
defibrotide in patients developing VOD/SOS after primary chemotherapy with-
out HSCT (off label).
Methods: In an expanded-access protocol for patients with VOD/SOS post-
HSCT or chemotherapy, with or without MOD (renal and/or pulmonary dys-
function), defibrotide 25 mg/kg/d (4 divided doses of 6.25 mg/kg) was given a
recommended ≥21 days after patients provided informed consent. Post-
chemotherapy subgroup survival was analyzed post hoc from the day defi-
brotide was started (days 0–30 after start of chemotherapy) for 70 days
(because follow-up data were collected for 100 days post-chemotherapy).
Results: Of 1154 VOD/SOS patients receiving defibrotide, 137 (12%) devel-
oped VOD/SOS post-chemotherapy without HSCT. Among the 82 patients (38
with MOD) treated with DF by day 30 after start of chemotherapy, median age
was 7.5 years (range, 0–68 years) and 66 (81%) were pediatric patients (≤16
years of age). Among pediatric patients, 15% were age 0-23 months, 74%
were 2-11 years and 11% were 12-16 years. Most common primary diseases
were acute lymphocytic leukemia (51%), acute myeloid leukemia (13%), and
neuroblastoma (6%). Kaplan-Meier estimated survival at Day +70 was 74%
overall (95% CI, 63–82%); 66% (49–79%) in patients with MOD and 81% (66–
90%) in patients without MOD. By age subgroup, Kaplan-Meier estimated sur-
vival at Day +70 was 80% (95% CI, 68–88%) in pediatric patients (Figure 1)
and 50% (95% CI, 25–71%) in adults. Adverse events (AEs) were reported in
54/82 patients (66%). Hemorrhagic AEs (≥2%) were pulmonary (6%), epistaxis
or mouth (4%), and hematochezia (2%). There were 22 (27%) patients with
AEs assessed as being at least possibly related to defibrotide, the most com-
mon (≥2%) were pulmonary or mouth hemorrhage (4% each) and hema-
tochezia, nausea, encephalopathy, epistaxis, or hypotension (2% each). Relat-
ed AEs led to discontinuation in 6 patients and were associated with 1 death
(pulmonary hemorrhage, hypotension).
Figure 1.
Summary/Conclusions: The 74% survival rate at Day +70 in patients with
VOD/SOS receiving defibrotide within 30 days of starting chemotherapy (81%
in patients ≤16 years) is clinically encouraging. Of note is the 66% survival rate
in patients with MOD. The defibrotide safety profile was consistent with that
previously reported in the overall population of this expanded-access protocol.
Support: Jazz Pharmaceuticals.
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Iron: Deficiency and overload
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LACK OF THE FERROPTOSIS INHIBITOR GPX4 IN ERYTHROID CELLS
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Background: GPX4 is a selenoprotein belonging to the family of the glutathione
peroxidases, a class of enzymes involved in cellular defence against oxidative
stress. This enzyme is essential for life since it is the only peroxidase able to
use lipid peroxides as substrate. Mice constitutively lacking GPX4 die at embry-
onic stage while tissue-specific ablation in neurons and T-cells cause neurode-
generation and impaired immune response. Recent studies have identified
GPX4 as the main regulator of ferroptosis, an iron-dependent ROS-mediated
form of nonapoptotic cell death. Erythrocytes are highly specialized cells that
utilize a large amount of iron to bind and deliver oxygen to all tissues. Being
constantly exposed to oxygen, erythroid cells need to continuously fight against
oxidative stress by expressing a variety of antioxidant enzymes, including
GPX4. Iron availability for erythropoiesis depends on systemic iron levels which
are regulated via the hepcidin/ferroportin regulatory system. Hepcidin binding
to the iron exporter ferroportin reduces systemic iron export regulating body
iron levels. In hypoxic conditions the erythroid hormone ErFe suppresses hep-
cidin synthesis to provide iron for the elevated erythropoietic demand.
Aims: The aim of this study is to identify how the lack of GPX4 in the hemato-
logical compartment affects iron homeostasis.
Methods: Lethally irradiated C57BL/6 female mice were reconstituted with bone
marrow cells from Gpx4fl/fl; Rosa26-CreERT2 or Gpx4wt/wt; Rosa26-CreERT2 and
allowed to recover for 8 to 10 weeks. Gpx4 deletion in the hematopoietic system
was induced by feeding tamoxifen citrate for 3 weeks and blood and organs were
drawn at 3 and 6 weeks after terminating the tamoxifen-containing diet. Erythroid
cells have been analysed in FACS. Serum iron levels have been assessed using
the SFBC and UIBC iron kits (Biolabo). Gene expression analysis has been per-
formed using SYBR-green qRT-PCR. Circulating Hepcidin has been measured
with a specific murine ELISA kit (Intrinsic Lifesciences). Tissue iron levels have
been measured with a colorimetric assay. All animal experiments were approved
by and conducted in compliance with institutional guidelines
Results: Compared to GPX4wt/wt;CreERT2 controls, GPX4fl/fl;CreERT2 trans-
planted mice lacking GPX4 in the haematological compartment show a
decrease in the number of red blood cells, haemoglobin and haematocrit. Retic-
ulocyte count measurement revealed a strong increase in this population, sug-
gesting that the erythropenia could be due to a block in the reticulocyte matu-
ration. Reticulocyte FACS characterization revealed a shift towards a more
immature population while electron microscopy analysis showed an accumu-
lation of unphagocytosed vesicles containing remnants of mitochondria. Analy-
sis of the spleen revealed extramedullary erythropoiesis. The anemia and the
erythropenia trigger a hypoxic signature hallmarked by an increase in circulating
EPO and increased ErFe expression. However, both hepatic mRNA analysis
and circulating protein measurement failed to show alteration in hepcidin pro-
duction. Analysis of the liver showed an increase in non-heme iron content and
in the lipid peroxidation causing an elevated mRNA and protein expression of
heme oxygenase 1. Hepatic ferritin and ferroportin are also increased as a con-
sequence of the increased iron content. 
Summary/Conclusions: Our data show for the first time that the presence of
GPX4 in the haematological compartment is essential for the proper hepcidin
downregulation upon ErFe stimulation. This finding opens new insights in the
mechanism that regulate hepcidin during hypoxia.
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IDENTIFICATION OF GUANOSINE 5ʹ-DIPHOSPHATE AS POTENTIAL IRON
MOBILIZER: PREVENTING THE HEPCIDIN-FERROPORTIN INTERACTION
AND MODULATING THE INTERLEUKIN-6/STAT-3 PATHWAY
S. Angmo1,*, N.K Singhal2
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India
Background: Anemia of inflammation (AI) is one of the most common mani-
festations of iron deficiency in the patients with inflammatory conditions. AI is
responsible for hypoferremia, with consequent iron-restricted erythropoiesis
with high level of hepcidin, which stimulate the internalization of ferroportin
(FPN) transporter. Therefore, inhibiting hepcidin-mediated FPN degradation
can be an important strategy to ameliorate AI.
Aims: To increase iron bioavaibility we selected a Novel compound against
hepcidin action through natural compound libraries that might provide a new
alternative approach to increase iron absorption for prevention of hepcidin-
mediated FPN internalization and to ameliorate turpentine-induced anemic
state with different insilico, invitro and invivo studies.
Methods: A systematic approach involving in silico, in vitro and in vivo studies
was employed to identify hepcidin inhibiting agents. To identify a potent hep-
cidin-binding agent, natural compounds were screened using molecular docking
and dynamics simulations and further investigated on cell lines (GFP-FPN,
Caco-2, HepG2) using flow cytometry and western blotting. Normal or turpen-
tine induced anemic mice were used in the associated studies.
Results: The virtual screening via molecular modelling showed that GDP as a
potent hepcidin-binding agent as shown in the (Figure 1A). In vitro studies
revealed that GDP significantly increased ferroportin stabilization in GFP-FPN
cell lines (Figure 1C) and In vivo results showed that co-administration of GDP
and ferrous sulphate (FeSO4) significantly improved the turpentine-induced
anemic state with increase in haemoglobin level (Figure 1B).
Figure 1.
Summary/Conclusions: AI is a normocytic anemia, common among patients
with chronic infection and inflammatory disorders. We found that GDP molecule
have higher contribution to the stability of hepcidin-GDP complex and thus
blocks its interaction with FPN. The results support the novel hypothesis that
GDP along with iron supplement regime can overcome the binding of hepcidin
from interaction with FPN that would be an effective treatment for AI.
S811
UNRAVELING THE MOLECULAR PATHOGENESIS OF INEFFECTIVE
ERYTHROPOIESIS IN CONGENITAL DYSERYTHROPOIETIC ANEMIA
TYPE II: IN VITRO EVALUATION OF RAP-011 TREATMENT
G. De Rosa1,*, I. Andolfo1, F. Manna1, A. Gambale1, R. Marra1, B. E. Rosato1,
A. Iolascon1, R. Russo1
1Molecular Medicine and Medical Biotechnology, CEINGE - Biotecnologie Avan-
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Background: Congenital Dyserythropoietic Anemias (CDAs) are subtypes of
bone marrow failure syndromes, hallmarked by ineffective erythropoiesis. The
most common form is CDAtype II (CDAII), showing moderate/severe anemia,
relative reticulocytopenia, jaundice, and iron overload. It is inherited as auto-
somal recessive disorderdue to loss-of-function mutations inSEC23B gene.
More than 300 CDAII cases and 80 causative mutationshave been described
so far. Despite this high allelic heterogeneity, two variants, R14W and E109K,
represent more than 50% of the mutational events. To date, treatments for
CDAII patients consist of supportive therapy, such as erythrocyte transfusions,
or bone marrow transplantation or splenectomy in transfusion-dependentcas-
es.Recently, members of TGF-β superfamily have been studied as potential
regulators of erythropoiesis,especially the growth differentiation factor 11
(GDF11). Through the binding of specific receptors, GDF11 leads to an inhibited
late-stage erythropoiesis. Indeed, two GDF11 inhibitors, ACE-011 and ACE-
536,have been associated to an improvement of hematologic parameters. Stud-
ies with the mouse counterpart of ACE-011, RAP-011, on mouse model of β-
thalassemia showed increased differentiation of erythroid cells, improvement
of anemic condition and reduced iron overload in treated mice.
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Aims: The main aim of our study is to assess the effects of RAP-011 on different
cellular models of CDAII.
Methods: We measured circulating GDF11 levels in CDAII patients and healthy
controls(HC) bywestern blot(WB). To assess the effectiveness of RAP-011(pro-
vided by Celgene Corporation)in vitro, we established two different cellular
models of CDAII: (i) K562 cells stably silencedfor SEC23B by Sh-RNA carried
in GIPZ lentiviral vectors; (ii) K562 stably overexpressing SEC23B-WT and the
two variants, R14W and E109K. In vitro treatment has been performed at 0, 3,
and 6 days of erythroid differentiation by hemin+GDF11 in presence or absence
of RAP-011 in K562 cells stably silencedfor SEC23B.
Results: WB and subsequent densitometric analysis showed an increase of
GDF11 levels in serum samples from 18 CDAII patients compared to 18 HC
(p=0.02). Stable silencing of SEC23B in K562 cellsled to the establishment of
two different clones, Sh-70 and Sh-74, showing amarkedreduction of
SEC23Bexpression compared to Sh-CTR (85-90% and 60-65%, respectively).
At 3 and 6 days of K562 erythroid differentiation by hemin, we observed an
increased expression of pSMAD2 in GDF11-treated cells compared to non-
treated ones; interestingly, a reduction of pSMAD2 in RAP-011+GDF11-treated
cells was observed.
Summary/Conclusions: We firstly demonstrated the increased levels of
GDF11 in CDAII patients. Thus, we used a combined treatment with
hemin+GDF11 in SEC23B-silenced K562 stable clones, in order to repro-
ducethe pathologic phenotype of the disease, andto make K562 cells suitable
for RAP-011 treatment, as attested by the increased expression of pSMAD2 in
GDF11-treated cells. The reduced pSMAD2 in RAP-011+GDF11-treated cells
suggests that RAP-011treatment leads to repression of ActRIIA/B pathway,
which in turn should increase nuclear levels of GATA1 transcription factor. This
action should lead to an increased expression of GATA1-activated genes
involved in erythroid development. The evaluation of GATA1 activation is ongo-
ing, as well as the in vitro treatment of K562 stably overexpressing SEC23B-
WT,SEC23B-R14W and -E109K.
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WITHOUT ERYTHROPOIESISSTIMULATING AGENTS FOR CANCER
PATIENTS WITH ANAEMIA: A SYSTEMATIC REVIEW AND NETWORK
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1Cochrane Haematological Malignancies, University Hospital Cologne,
Cologne, Germany, 2Institute of Social and Preventive Medicine, University
Bern, Bern, Switzerland, 3Institute of Medical Statistics, Informatics and Epi-
demiology, University Hospital Cologne, Cologne, Germany
Background: A widely prevalent complication in patients suffering from cancer
is the deficiency of haemoglobin-containing red blood cells, referred to as
anaemia. While many patients develop anaemia due to an involvement of
malignant bone marrow cells, others suffer from so called chemotherapy/radio-
therapy-induced anemia. Erythropoiesis-stimulating agents (ESAs) stimulate
the production of red blood cells within the bone marrow and have shown to
increase Hb levels in anaemic patients. Uncertainties remain regarding the
effect of iron supplementation on the fatal consequences of ESA-treatment.
Aims: The aims of this systematic review and network meta-analysis are to
evaluate benefits and risks of ESAs and iron for the treatment of disease-
related as well as therapy induced anaemia in cancer patients.
Methods: Based on an a-priori Cochrane protocol, we developed sensitive
search strategies for Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, databases of ongoing trials and conference proceedings
(search date 12/2016). We included only randomized controlled trials (RCTs)
including anaemic patients of any age with solid and/or haematological malig-
nancy undergoing chemotherapy, radiotherapy or no anti-cancer therapy. We
excluded studies including anaemic cancer-patients as a result of surgery or
due to haemolysis. Two authors independently assessed studies for eligibility,
extracted data and assessed quality of trials. The primary outcome was on-
study mortality. Secondary outcomes included number of red blood cell trans-
fusions and thromboembolic events. For binary outcomes, we used risk ratios
(RRs) with corresponding 95% confidence intervals (CIs) to evaluate the treat-
ment effects. We performed a random-effects meta-analysis for direct com-
parisons. For network meta-analyses, we used the frequentist graph-theoretical
approach. Treatment hierarchy was obtained giving P-scores on a scale from
0 (worst) to 1 (best).
Results: We identified a total number of 105 eligible studies, including 25.722
patients. The network analysis of the primary outcome, on-study mortality,
included 69 studies and 8 treatments. As the given network was not fully con-
nected, we performed pairwise comparisons on the four subnetworks with 2
treatments each. Statistically significant treatment disadvantages were shown
in the direct comparison of ESA plus iron supplementation (given if necessary)
compared to placebo/no treatment plus iron supplementation (given if neces-
sary) (RR 1.14 (95% CI 1.03-1.25), including 41 studies). Network meta-analy-
sis on the need for red blood cell (RBC) transfusions showed the treatment of
ESA plus iron supplementation to have the most positive effect compared to
ESA alone (RR: 0.70 (95% CI 0.53-0.92) P-score: 0.87). No relevant hetero-
geneity was found within the analysed network of four treatments (I²=18.4%).
Inconsistency could not be tested statistically as no closed loop was included.
Thromboembolic events occurred most often in patients treated with ESAs,
irrespective of iron supplementation (ESA plus iron vs no treatment/placebo
plus no iron: RR 1.79 (95% CI 0.74-4.32) P-score: 0.22, ESA plus no iron vs
no treatment/placebo plus no iron: RR 1.90 (95% CI 0.96-3.75) P-score: 0.16).
Subgroup analysis regarding type of iron, as well as route of administration
will be presented at the EHA-congress (Figure 1).
Figure 1.
Summary/Conclusions: While our analyses show that ESA use increases
mortality and risk for thromboembolic events, there is no evidence that iron
supplementation alters these risks. However, addition of iron to ESA does fur-
ther decrease the need for RBC-transfusions compared to ESA alone. Further
investigation, with regards to iron type and route of administration may yield
further distinct results.
This project was funded by the Federal Ministry of Education and Research,
grant number: 01KG1405
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DIFFERENT IRON SOURCES AND ACQUISITION PATHWAYS SHAPE
MACROPHAGES TOWARDS OPPOSING FUNCTIONAL PHENOTYPES
F. Vinchi1,*, R. Sparla1, E. Tolosano2, U. Platzbecker3, M.U. Muckenthaler1
1Molecular Medicine Partnership Unit (MMPU), University of Heidelberg &
EMBL, Heidelberg, Germany, 2Molecular Biotechnology Center, University of
Turin, Turin, Italy, 3University Clinic Dresden, Dresden, Germany
Background: Iron homeostasis and macrophage biology are closely intercon-
nected. On the one hand, reticulo-endothelial macrophages are central for the
regulation of iron homeostasis. The phagocytosis and degradation of senescent
red blood cells (RBC) by macrophages enable efficient recycling of iron and
the maintenance of systemic iron balance. On the other hand, iron exerts mul-
tiple effects on macrophage polarization and functionality. Macrophages exhibit
a remarkable functional plasticity, reflected in their capacity to integrate diverse
signals from the microenvironment and acquire distinct phenotypes.
Macrophage polarization has been shown to dictate the expression of iron-
regulated genes and determine cell iron handling.
Aims: Increasing evidence shows that iron availability itself has significant
effects on immune effector functions and macrophage polarization. However,
it is still unclear how different iron sources and acquisition pathways affect
macrophage phenotypes.
Methods: To investigate this aspect, we analyzed both in vivo and in vitro, and
compared the phenotypic switching of macrophages induced by different iron
sources, including heme and iron, as well as hemolytic or intact RBCs.
Results: Hemolytic RBCs, free heme and iron-dextran treatment in mice shape
macrophage polarization towards an M1-like pro-inflammatory phenotype.
Splenic and hepatic macrophages from treated mice show iron deposition and
increased expression of iron-related genes (ferroportin, ferritin, HO-1). More-
over, in these cells, the expression of M1 markers such as MHCII, CD86 and
pro-inflammatory cytokines (TNFa, IL-6, IL-1b) is strongly increased, whereas
the expression of M2 markers such as CD206, Arg-1 and IL-10 was significantly
suppressed. Consistent results have been obtained treating bone marrow-
derived macrophages with hemolytic RBCs, free heme and Fe-NTA. Impor-
tantly, the addition of the heme scavenger hemopexin and the iron carrier trans-
ferrin or the chelator deferoxamine fully abolish the ability of free heme and
iron to trigger M1 polarization. On the contrary, RBC transfusions in mice shape
macrophages towards an M2-like anti-inflammatory phenotype. After three
transfusions, serum iron and hepcidin levels significantly rise, and tissues as
well as macrophages are heavily iron loaded. Macrophages show a drastic
suppression of M1 markers and inflammatory cytokines, and induction of M2
markers. Interestingly, repeated transfusions result in extensive macrophage
cell death and new monocytes recruitment in both liver and spleen.
Summary/Conclusions: Collectively, these results suggest that the source
and route of iron acquisition have a key role in shaping macrophage phenotype,
and demonstrate a dynamic role of iron overload in determining macrophage
polarization and function. When iron is provided in the form of free heme or
non-transferrin bound iron, it exerts a clear pro-inflammatory effect on
macrophages; whereas when provided via a controlled physiological acquisition
pathway such as erythrophagocytosis, it dampens macrophage immune effec-
tor functions, being its clearance activity more active. 
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Our findings have potential implications, on one side, for hemolytic diseases,
where RBC hemolysis and elevated circulating heme might promote a detri-
mental chronic inflammatory state, and, on the other one, for infectious dis-
eases, where free heme and iron, released upon cell damage, might boost
inflammation and enhance resistance to infections. Conversely, accelerated
RBC clearance, by suppressing macrophage pro-inflammatory response, is
rather expected to promote infections in transfused individuals.
Gene therapy, cellular immunotherapy
and vaccination 2
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A PHASE 3 STUDY TO EVALUATE SAFETY AND EFFICACY OF
LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT
Β-THALASSEMIA IN PATIENTS WITH NON-Β0/Β0 GENOTYPES: THE
NORTHSTAR-2 (HGB-207) TRIAL
M. Walters1,*, A. Thompson2, S. Hongeng3, J. Kwiatkowski4, F. Locatelli5,
J. Porter6, M. Sauer7, A. Thrasher8, I. Thuret9, E. Yannaki10, A. Petrusich11,
M. Asmal11
1UCSF Benioff Children’s Hospital and Research Center, Oakland, 2Lurie Chil-
dren’s Hospital , Chicago, United States, 3Ramathibodi Hospital, Bangkok,
Thailand, 4Children’s Hospital of Philadelphia , Philadelphia, United States,
5IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 6University College
London Hospital, London, United Kingdom, 7Medizinische Hochschule Han-
nover , Hannover , Germany, 8Great Ormond Street Hospital, London, United
Kingdom, 9Hôpital d’enfants de La Timone, Marseille, France, 10General Hos-
pital of Thessaloniki, Thessaloniki, Greece, 11bluebird bio, Cambridge, United
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Background: Standard treatment for transfusion-dependent β-thalassemia (TDT)
includes regular red blood cell (RBC) transfusions and management of iron over-
load. Successful allogeneic hematopoietic cell transplantation (HCT) can eliminate
RBC transfusions and, eventually, chelation. However, due to transplant-related
risks such as graft-versus-host disease (GVHD), as well as donor constraints,
HCT is rarely an option for TDT patients. By transferring a functioning copy of the
β-globin (HBB) gene into hematopoietic stem cells (CD34+ cells) and re-infusing
the modified cells, gene therapy may be an alternative one-time treatment avail-
able to all patients with TDT, without risks of GVHD. LentiGlobin gene therapy is
an investigational treatment consisting of autologous CD34+ cells transduced
with the BB305 lentiviral vector. The Northstar (HGB-204) phase 1/2 clinical study
of LentiGlobin gene therapy for TDT included 18 patients who received LentiGlo-
bin drug product (DP). As of September 2016, all patients in Northstar with non-
β0/β0 genotypes and at least 12 months of follow-up stopped transfusions (median
total hemoglobin [Hb] 11.2 [range 9.4−12.2] g/dL) and there was >60% reduction
in transfusions in patients with a β0/β0 genotype. The safety profile was consistent
with autologous HCT. In this initial study, the average number of therapeutic gene
copies per CD34+ cell in the DP (i.e.DP vector copy number per diploid genome
or DP VCN; median 0.7, range 0.3 to 1.5) correlated with peripheral HbAT87Q
(genetically engineered hemoglobin) expression at 6 months (ASH, 2016). In an
effort to optimize the proportion of patients able to discontinue blood transfusions
to achieve “transfusion independence” in all patients and increase unsupported
Hb levels after treatment, the manufacturing process for LentiGlobin DP was
modified to increase the DP VCN and the proportion of genetically modified cells.
Northstar-2 (HGB-207) is a recently initiated phase 3 study using this new man-
ufacturing process in patients with TDT and a non-β0/β0 genotype.
Aims: To evaluate safety and efficacy of autologous HCT with LentiGlobin DP
in patients with TDT and a non-β0/β0 genotype.
Methods: After providing informed consent, patients 12 to 50 years of age
(N=15) will have CD34+ cells collected via mobilization and apheresis. After
individualized DP manufacture and satisfaction of release criteria, the patient
will receive myeloablative conditioning with single-agent busulfan (starting dose
3.2 mg/kg/day for 4 days, with target AUC 4500 [range 4000−5000] µM*min)
followed by infusion of LentiGlobin DP. Patients will be followed for engraftment,
safety and efficacy endpoints for 2 years after infusion; patients will then have
the option to enroll in a 13-year follow-up study. The primary endpoint is the
proportion of patients who achieve transfusion independence after DP infusion,
defined as total Hb ≥9g/dL without RBC transfusions for a continuous period of
≥12 months. Secondary endpoints include time to neutrophil engraftment,
adverse events, and biological parameters including VCN in peripheral blood
and levels of HbAT87Q over time.
Results: As of March 1, 2017, two 20-year-old females with β0/βE genotypes
have been treated with LentiGlobin DP in the Northstar-2 trial. The DP VCN
was 2.9 and 2.4 copies per diploid genome, respectively. Outcomes in all evalu-
able patients will be presented.
Summary/Conclusions: Results from the Northstar-2 study will provide data
on safety and demonstrate the extent to which an increase in LentiGlobin DP
VCN yields normalization of total Hb and consistently achieves transfusion
independence in patients with TDT of non-β0/β0 genotypes. Optimizing DP
VCN has the potential to improve outcomes across all TDT genotypes treated
by investigational LentiGlobin gene therapy.
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CIS IS A POTENT CHECKPOINT IN NK CELL ANTI-LEUKEMIA IMMUNITY
N. Huntington1,*
1Molecular Immunology, Walter and Eliza Hall, Parkville, Australia
Background: The detection of leukemia by natural killer (NK) cells is controlled
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by the integration of signals from activating and inhibitory ligands and from
cytokines such as IL-15. 
Aims: We set out to identify the negative regultors of NK cell function in order
to understand why immunogenic tumours and leukemia can evade or overcome
NK cell detection and killing.
Methods: We used a multidisciplinary approach including RNAseq, Mass
Spectrometry, Structual biology, kinase enrichment and activity assays, NK
cell in vitro analysis, biochemistry and de novo/experimental tumor/leukemia
in vivo models.
Results: We identified cytokine-inducible SH2-containing protein (CIS, encoded
by Cish) as a critical negative regulator of IL-15 signaling in NK cells. Cish was
rapidly induced in response to IL-15, and deletion of Cish rendered NK cells
hypersensitive to IL-15, as evidenced by enhanced proliferation, survival, IFN-
gamma production and cytotoxicity toward tumors. This was associated with
increased JAK-STAT signaling in NK cells in which Cish was deleted. Corre-
spondingly, CIS interacted with the tyrosine kinase JAK1, inhibiting its enzymatic
activity and targeting JAK for proteasomal degradation. Cish−/− mice are resistant
to leukemia in vivo, and this was independent of MHC-I expression.
Summary/Conclusions: Our data uncover a potent intracellular checkpoint
in NK cell–mediated tumor immunity and suggest possibilities for new cancer
immunotherapies directed at blocking CIS function. 
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GENERATION OF MEMORY STEM T CELLS MODIFIED WITH A NOVEL
OPTIMIZED CD30-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR THE
TREATMENT OF CD30+ T-CELL MALIGNANCIES
L. Escribà-Garcia1,*, C. Alvarez-Fernández1, J. Wegner2, J. Rydzek2,
M. Tellez-Gabriel1, J. Sierra1, H. Einsele2, J. Briones1, M. Hudecek2
1Hematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain,
2Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg,
Germany
Background: Peripheral T-cell lymphomas (PTCL) represent the most aggres-
sive form among non-Hodgkin lymphomas with a very poor prognosis (5-year
survival of 30%), demanding innovative novel treatment strategies. Adoptive
immunotherapy with chimeric antigen receptor (CAR) engineered T cells has
demonstrated its therapeutic potential in advanced hematological malignancies.
However, its application to PTCL remains a formidable challenge mainly due
to a lack of truly tumor-specific antigens that are not expressed on normal T
cells. Anaplastic large T-cell lymphomas (ALCL) and several other subtypes of
PTCL express CD30, which is expressed by activated normal T cells but no
other healthy tissues. Indeed, brentuximab vedotin, an anti-CD30 antibody-
drug conjugate, has shown some clinical efficacy in PTCL and ALCL patients
although duration of responses is short in the majority of cases. Here, we devel-
oped a refined CD30-CAR T-cell approach to target CD30+ PTCL as a potential
novel therapeutic strategy. We selected a novel targeting domain that is unaf-
fected by soluble CD30 protein to prevent blockade of the CD30-CAR in vivo.
Moreover, we optimized the therapy by using memory stem T cells (TSCM) to
promote engraftment and persistence of CD30-CAR Tc ells after transfer, and
we have included an EGFRt depletion marker as a safety feature.
Aims: We evaluated the antitumor effect of memory stem T cells (TSCM) genet-
ically-modified with a novel CD30-specific CAR that recognizes a membrane-
proximal epitope in the CD30 molecule in a CD30+ T-cell lymphoma model.
Methods: A second generation CD30-41BBz-EGFRt CAR was generated using
a scFv that recognizes a tumor-cell membrane-proximal epitope of CD30 protein
(Nagata S et al. Clin Cancer Res, 2002). Naive T cells from healthy donors were
activated with anti-CD3/CD28 beads in presence of IL-7, IL-15 and IL-21 during
10 days to obtain a TSCM-enriched population (Alvarez C et al. J Transl Med,
2016); on day 2 of culture, cells were transduced with a third-generation lentiviral
vector encoding the CD30-CAR. The anaplastic large T-cell lymphoma cell line
Karpas 299 was used as tumor model. Cytotoxicity assay was performed at 4
hours at 10:1, 5:1, 1:1 and 1:5 effector/target (E/T) ratios, and the tumor cell
death was detected by flow citometry. Cytokines (IFN-γ and IL-2) were analysed
at 24 hours in a 5:1 E/T ratio culture using Luminex technology.
Results: TSCM were the most prevalent T-cell subset at day 10 of culture, rep-
resenting 84 ± 3.1% of total cells, and the CD30-CAR expression in these cells
was 76.9 ± 1.0% in CD4+ TSCM and 77.3 ± 2.0% in CD8+ TSCM. Although CD30
protein was detected in a fraction of activated T cells in culture (CD4+ T cells:
32.4 ± 2.1%; CD8+ T cells: 59 ± 4.3%), lentiviral transduction of TSCM with our
CD30-CAR did not compromise their ex vivo expansion (CD4+ CD30-CAR
TSCM: 96.0 ± 3.2 fold expansion; CD8+ CD30-CAR TSCM: 109.0 ± 4.2 fold
expansion). CD8+ CD30-CAR TSCM conferred specific cytolytic activity and
lysed Karpas 299 cells in vitro (tumor cell death 1:1 ratio: 92.6 ± 2.4% vs 0%
with untransduced TSCM; p<0.001), while control CD30- target cells (Raji) were
not recognized. In addition, CD30-CAR TSCM secreted IFN-γ and IL-2 after
stimulation with Karpas 299 cells (IFN-γ: 126.6 ± 18.12 pg/ml vs 5.03 ± 0.16
pg/ml with control targets, p=0.002; IL-2: 20.47 ± 2.3 pg/ml vs 4.06 ± 0.24
pg/ml, p=0.002, respectively).
Summary/Conclusions: Collectively, our data demonstrate the potential to
generate CD30-CAR T cells with enhanced functional attributes against CD30+
PTCL. TSCM cells can be efficiently transduced and ex vivo expanded with a
novel CD30-CAR and confer potent antitumor efficacy against CD30+ PTCL in
vitro. Our findings suggest the potential to improve outcome of patients with
CD30+ PTCL through adoptive therapy with CD30-CAR modified T cells.
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MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF
STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE:
FACTORS INFLUENCING CLINICAL RESPONSES
A. Galleu1,*, S. Deplano2, R. Szydlo3, D. Milojkovic2, A. Bradshaw2, R. Wynn4,
D. Marks5, D. Richardson6, K. Orchard6, E. Kanfer2, E. Tholouli4, M. Saif4,
P. Sivaprakasam5, S. Lawson7, A. Bloor8, A. Pagliuca9, J. Snowden10,
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11Sheffield Children’s Hospital, Sheffield, 12Heart of England NHS Foundation
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Background: The immunosuppressive activity of mesenchymal stromal sells
(MSC) have been extensively tested for the treatment of steroid-resistant acute
graft versus host disease (aGvHD). However, the factors affecting clinical
responses are poorly understood.
Aims: We assessed the impact of MSC treatment on clinical outcomes and
investigate factors influencing the response to MSC.
Methods: Data collected from a cohort of 60 patients treated with MSC
between May 2008 and December 2014 in the UK were analyzed. Clinical
grade MSC were generated from bone marrow aspirates collected from the
iliac crest of healthy donors and expanded using platelet lysate. All patients
received MSC for the treatment of steroid-resistant aGvHD, defined as failure
to respond to high-dose steroids (2mg/Kg methyl-prednisolone) after 6 days.
Informed consent was obtained from all patients in accordance with the local
ethics committee requirements. Clinical responses to MSC were assessed 1
week after MSC infusion. Patients were defined as: a) Responders when an
improvement of at least 50% in at least one organ affected by aGvHD was
observed, or b) Non-Responders if they had stable or progressive disease.
Results: Patient characteristics are summarized in Table 1.
Table 1.
aGvHD was biopsy proven in 45 patients, while in the remaining patients the
diagnosis was clinical and based on the exclusion of alternative causes. 10,
16 and 1 patients had skin, gut and liver involvement only, respectively. 16
patients exhibited gut and skin, 11 skin, gut and liver, 3 skin and liver and 3 gut
and liver. 34 patients received 1 dose, while 19, 6 and 1 were treated with two,
three and four doses, respectively. No side effects were observed. 36 patients
(60%) responded to MSC. Amongst patients who received multiples doses
(26), subsequent doses did not change the status after the first dose (24
responded, 1 did not respond), except from one patient who, although respond-
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ing to the first dose, failed to respond to the second one. When we evaluated
potential factors for response, organ involvement, age at transplant and the
cumulative dose of MSC infused were found statistically significant. Response
rate was 67% among patients with involvement of gut, skin or both, but only
22% among those with involvement of the liver (alone or in combination with
skin and/or gut). Patients younger than 20 years fared better, with 88% of them
responding. Conversely, only 30% and 42% of those aged 20-50 years or older
than 50 responded, respectively. Lastly, higher cumulative MSC dose
(>3.0x106/Kg) was associated with a response in 76%, while none of those
receiving less than 1.5x106/Kg responded. All 3 factors remained significant in
multivariate logistic regression analysis. Patient gender, pre-MSC therapy, inter-
val from transplant or aGvHD diagnosis to MSC treatment and grade of aGvHD
did not affect response. The impact of achieving a response 1 week after MSC
had a profound impact on the overall survival at 18 months accounting for 59%
in responders and 17% in non-responders (log-rank test, p<.001).
Summary/Conclusions: In our cohort of patients, MSC treatment was safe and
well tolerated. We conclude that the presence of a response at one week highly
impacted on the survival of patients with an otherwise very poor prognosis. Impor-
tantly, younger age at the transplant, absence of liver aGvHD involvement and
use of higher MSC doses were strong predictors of a response. 
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CARD9 CONTROLS DECTIN-1-INDUCED T-CELL CYTOTOXICITY AND
TUMOR GROWTH IN MICE
T. Haas1,*, S. Heidegger1, H. Poeck1, J. Ruland2
1Klinik und Poliklinik für Innere Medizin III, 2Institut für Klinische Chemie und
Pathobiochemie, Klinikum rechts der Isar, TU München, München, Germany
Background: Activation of the C-type lectin receptor Dectin-1 by beta-glucans
triggers multiple signals within dendritic cells (DCs) that result in activation of
innate immunity. While these mechanisms can potently prime CD8+ cytotoxic
T cell (CTL) responses without additional adjuvants, the Dectin-1 effector path-
ways that control CTL induction remain unclear. 
Aims: Aims of this study were: To define details of the intracellular signalling
pathway responsible for cross-priming of a CTL response after activation of
the C-type lectin receptor Dectin-1. To analyze whether identified signalling
molecules were indispensable for antitumor immunity. To analyze whether NK
cells played a role in antitumor immunity after Dectin-1-mediated CTL induction. 
Methods: We used in vitro coculture between DCs (wildtype vs gene deficient)
and CD8 T cells to define signalling components of Dectin-1 induced CTL cross-
priming. We used WT and gene-deficient mice to define the signalling pathway
of Dectin-1 induced CTL crosspriming in vivo and to test the role of this pathway
for antitumor immunity by challenging mice with B16-Ova tumor cells intravenous-
ly, with or without depletion of CD8 T cells or NK cells, respectively.
Results: Here we demonstrate that Dectin-1-induced CTL cross-priming in
mice does not require inflammasome activation but strictly depends on the
adapter protein Card9 in vitro. In vivo, Dectin-1-mediated Card9 activation after
vaccination drives both expansion and activation of antigen-specific CTLs,
resulting in long-lasting CTL responses which are sufficient to protect mice from
tumor challenge. This Dectin-1-induced antitumor immune response was inde-
pendent of natural killer (NK) cell function and completely abrogated in Card9-
deficient mice. Thus, our results demonstrate that Dectin-1-triggered Card9
signaling but not inflammasome activation can potently cross-prime antigen
specific CTLs, suggesting that this pathway would be a candidate for
immunotherapy and vaccine development (Figure 1).
Figure 1.
Summary/Conclusions: We identify Card9 as central regulator of Dectin-1-
induced cross-priming of cytotoxic T cells (CTLs) in mice. These antigen specific
CTLs mediate potent antitumor immunity independent of inflammasome activity
and NK cells. This pathway is a candidate for immunotherapy and vaccine
development.
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PRECLINICAL COMBINATION OF A NOVEL IRE1 RNASE INHIBITOR
MKC-8866 AND TYROSINE KINASE INHIBITION ACTS SYNERGISTIC IN
ACUTE LYMPHOBLASTIC LEUKEMIA
M. Vieri1,*, A. Salimi1, J.B. Patterson2, A. Samali3, E. Chevet4, T.H. Brümmendorf1,
I. Appelmann1, B. Kharabi1
1Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Uni-
versity Hospital RWTH Aachen, Aachen, Germany, 2MannKind Corporation,
Valencia, United States, 3 Department of Biochemistry, National University of
Ireland, Galway, Ireland, 4Centre de Lutte Contre le Cancer Eugène Marquis,
Université Rennes 1, Rennes, France
Background: The role of the Unfolded Protein Response (UPR) in BCR-ABL1+
Acute Lymphoblastic Leukemia (ALL) has been extensively studied, proving
the IRE1-XBP1 branch to be required for leukemic cell survival. However, a
therapeutic strategy involving UPR inhibition that possesses translational
impact is yet to be identified.
Aims: In this study we aim to identify a potential synergistic effect of simulta-
neous pharmacological inhibition of IRE1 and BCR-ABL1 in BCR-ABL1+ ALL.
Methods: To study the link between IRE1-XBP1 axis of UPR and BCR-ABL1
we utilized both pharmacological and genetic approaches. 1) We tested the
effect on proliferation and viability of pharmacological IRE1 inhibition (using
MKC-8866) alone and in combination with Tyrosine Kinase Inhibitors (TKI,
using Imatinib or Nilotinib) on BCR-ABL1+ human ALL cell lines, SUP-B15 and
TOM-1. The cell lines were also co-cultured with immortalized tertMSCs to test
the chemo-protective effect of bone marrow stromal cells (BMSCs) on leukemia
cells. 2) We tested whether genetic knock-down of XBP1 could sensitize cells
towards the effect of Imatinib and Nilotinib. To this end, primary murine pre-B
cells from conditional XBP1fl/+mice were transduced with BCR-ABL1 construct,
and with either inducible cre or empty vector.
Results: IRE1 inhibitor MKC-8866 (MKC) in combination with either Imatinib
(IM) or Nilotinib (NL) showed enhanced capacity to arrest proliferation and to
induce cell death in BCR-ABL1+ALL cell lines compared to single treatments,
after 3 days incubation (Viable SUP-B15: MKC 30µM 94.9%±0.1, IM 10µM
78.4±0.4, Combination 17.0±1.4; MKC 30µM 94.1±0.07, NL 5µM 64.2±0.6,
Combination 20.0±0.8. TOM-1: MKC 30µM 85.0±0.9, IM 10µM 89.9±0.4, Com-
bination 17.6±0.07; MKC 30µM 94.6±0.1, NL 5µM 71.0±0.9, Combination
30.6±3.6). Using Bliss independence formula, we confirmed a striking synergistic
effect. Successively, to exclude any possible off-target effect at the basis of the
observed synergism, we used a genetic approach to block IRE1-XBP1 signaling
in vitro. B-cell precursors from Xbp1fl/+ mice, instead of Xbp1fl/fl, were used in
order to warrant a basal signal of XBP1, as present during pharmacological
inhibition. After transductions with BCR-ABL1, and either cre or the empty vector,
we could observe that heterozygous deletion of Xbp1, induced by 4OHT, signif-
icantly increased TKI-induced cell death, after 3 days incubation (4OHT 1µM:
47.5%±13.0, IM 1µM: 70.8±1.7, IM+4OHT: 18.3±2.7, NL 0.5µM: 65.2±0.3,
4OHT+ NL: 6.87±1.2). Finally, we showed whether the tested drugs combina-
tions were still effective in presence of BMSCs. It´s know that BMSCs are a crit-
ical component to escape TKI-induced cell death in Ph+ leukemia and that IRE1-
XBP1 is responsible for chemoresistance in many different cancer types,
although this role has never been confirmed in BCR-ABL1+cells. To shed light
on this aspect we co-cultured either SUP-B15 or TOM-1 cells with tertMSCs,
and while the stroma was capable to block Nilotinib-induced cell death, after 5
days incubation (in SUP-B15, NL 5µM in standard culture 28.7%±1.9, NL 5µM
in co-culture 74.9±0.1; in TOM-1, 29.1±2.8 vs 78.7±0.4), this protective activity
was partially abrogated upon treatment with IRE1 inhibitor. On the other hand,
MSCs were not able to reverse IM effect on cell viability.
Summary/Conclusions: Overall, our data demonstrate that simultaneous inhi-
bition of BCR-ABL1 and IRE1 branch of UPR exerts a potent effect in vitro, by
acting synergistically on BCR-ABL+ ALL cells. This provides basis for a pre-
clinical application of a combined targeted therapy.
E820
HIGH-THROUGHPUT COPY NUMBER PROFILING IN PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA USING MULTIPLEX LIGATION-DEPENDENT
PROBE AMPLIFICATION IN COMBINATION WITH NEXT-GENERATION
SEQUENCING
D. Alpar1,*, P.A. Kiraly1, A. Benard2, I. Haltrich3, H. Piko4, K. de Groot2,
J. Schouten2, S. Savola2, C. Bodor1
1MTA-SE Lendulet Molecular Oncohematology Research Group, 1st Depart-
ment of Pathology and Experimental Cancer Research, Semmelweis Univer-
sity, Budapest, Hungary, 2MRC-Holland, Amsterdam, Netherlands, 32nd
Department of Pediatrics, Semmelweis University, 4Department of Molecular
Genetics and Diagnostics, National Center of Public Health, Budapest, Hungary.
Background: Development, progression and resistance of pediatric acute lym-
phoblastic leukemia (pALL) are widely associated with recurrent copy number
abnormalities (CNAs). Multiplex ligation-dependent probe amplification (MLPA)
is an established technique to screen CNAs, thus providing valuable information
for risk assessment in pALL; however, the number of simultaneously analyzable
genomic loci is limited to 55-60.
Aims: To introduce and test a high-throughput, high-resolution and compre-
hensive disease-relevant CNA profiling approach applicable to all subtypes of
pALL.
Methods: A new digitalMLPA (dMLPA) technique has been developed which
combines the advantages of MLPA and next-generation sequencing (NGS),
massively extending the number of genomic targets that can be analyzed for
their copy number in a single reaction. Bone marrow samples from 58 patients
with pALL were analyzed using this novel assay targeting ~470 genomic loci.
dMLPA probes contain sample-specific barcodes as well as Illumina adapters.
After sequencing, copy number status of each target sequence was assessed
by relative read count quantification. Leukemic cell purity (mean: 81%, range:
60-99%) measured by flow cytometry was considered at the interpretation of
copy number changes. Results were compared to conventional MLPA, cyto-
genetic and FISH data.
Results: CNAs directly indicating structural or whole chromosome aberrations
or indirectly referring to gene fusions were detected in 93% of patients, in 44/48
pre-B ALL and 10/10 pre-T ALL cases. Among patients with CNAs, recurrent
aberrations specifically affecting putative driver genes varied between 0 and 11
(mean: 3.1, total: 175). ETV6 and CDKN2A/B were the most frequently altered
genes in pre-B and pre-T ALL, respectively; followed by CDKN2A/B, PAX5,
RB1, VPREB1, MLLT3, CD200/BTLA, TBL1XR1, IKZF1, CASP8AP2, PTEN,
RUNX1, BTG1, TP53, IKZF2, EZH2, NF1, NR3C2, RAG2 and the PAR region
genes in pre-B ALL cases and PTEN, MLLT3, PTPN2, PHF6, LEF1, CASP8AP2,
MYB, RB1, TP53 in pre-T ALL patients. STIL-TAL1 and NUP214-ABL1 gene
fusions were also observed in T-ALL cases while in one BCR-ABL1+ pre-B ALL
patient, the copy number profile correctly indicated the presence of an extra
Ph-chromosome. dMLPA results showed a congruency of 99.3% with those of
MLPA mixes containing probes with different ligation sites for a subset of the
genes. The increased resolution of dMLPA (i) allowed the detection of subclonal
aberrations with an improved efficacy and confidence as compared to conven-
tional MLPA and (ii) enabled a more patient-specific characterization of CNAs,
e.g. by revealing 15 different deletion patterns across 23 samples harboring
del(9p). In addition to genomic lesions specifically influencing putative or proven
clinically relevant genes, 24 structural and 134 whole chromosome aberrations
were detected genome-wide which was strongly facilitated by the inclusion of
~200 digital karyotyping probes covering each chromosome arm.
Summary/Conclusions: A novel NGS-based method has successfully been
introduced for high-resolution profiling of CNAs in pALL. dMLPA is a robust,
fast and cost-effective technique; its input DNA requirement (≥20ng) is similar
to those of other low-input NGS protocols and lower than the requirement for
MLPA. Due to its targeted approach, data analysis is computationally less
demanding as compared to most NGS methods. The number of genomic sites
analyzed in our study was an order of magnitude higher than that achievable
with conventional MLPA. Due to its specific probe composition, dMLPA allows
both high-resolution analysis of genomic driver regions and a genome-wide
detection of aneusomies and large CNAs.
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CRITICAL ROLE FOR NOTCH SIGNALLING IN B-CELL PRECURSOR
ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) DRUG RESPONSE
P. Takam Kamga1,*, G. Dal Collo1, M. Midolo1, A. Adamo1, A. Gatti1,
R. Carusone1, M. Bonifacio1, M. Krampera1
1Medicine, University of Verona, Verona, Italy
Background: B-cell precursor acute lymphoblastic leukemia (B-ALL) is the
leading cause of cancer-related death in children and young adults. There is
still a need of more efficient therapies for the subset of refractory patients. Our
group has previously shown that Notch-3 and Notch-4 promote human B-ALL
cell survival in presence of stromal cell support. However, the prognosis value
of Notch signalling as well as its contribution in vitro and in vivo to chemotherapy
has not yet been investigated.
Aims: In this study we used B-ALL cell lines and samples from new diagnosed
B-ALL patients to analyse the contribution of Notch signalling to B-ALL patho-
genesis in terms of prognosis, proliferation survival and drug response in vitro
and in mice xenograft models of B-ALL. 
Methods: B-ALL cell lines were obtained from ATCC, while B-ALL primary
cells were obtained from bone marrow or peripheral blood of 30 B-ALL patients.
Flow cytometry and western immunoblotting were used to study the expression
of Notch receptors and ligands. Drugs used were Cytarabine (Ara-C), Dexam-
ethasone (Dexa) and Doxorubicin (Doxo) alone or in combination with Notch
modulators including anti-Notch blocking antibodies, gamma secretase
inhibitors (GSIs), and Notch transcription factor inhibitor (SAHM1). Mice
xenograft model of B-ALL were obtained by injecting the B-ALL line RS4;11 in
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NOD/Shi-scid/IL-2Rγnull mice (NOG). Cell viability was evaluated by Annexin-
V/PI and MTT assay; proliferation was assessed through CFSE dilution.
Results: Western blot and flow cytometric analysis showed that B-ALL cell
lines as well as primary blast cells displayed the same Notch expression pattern
consisting in low expression levels of Notch2 and Jagged1, high expression
levels of Notch1, Notch3, Notch4, Jagged2, DLL3 and DLL4. Notably, in primary
blast cells deriving from patients, the expression of Notch3, Notch4, Jagged2,
DLL3 and DLL4 was significantly higher in the cases refractory to treatment as
compared to patients achieving complete remission, thus suggesting that Notch
signalling could be involved in the response to chemotherapy. In line with this
hypothesis, we found that the treatment in vitro of B-ALL cell lines with Ara-C
or Dexa down regulates the expression of Notch receptors. This down regula-
tion was also observed in human CD19+ blast cells isolated from bone marrow
of recipient mice treated with Ara-C compared to cells isolated from not treated
mice. In addition, Notch inhibitors significantly improved in vitro the cytotoxicity
of Ara-C, Dexa and Doxo towards B-ALL cell lines. Finally, we observed that
the administration to mice of a pan Notch inhibitor, i.e. the GSI XII, significantly
lowered the CD19+ leukemic burden in the bone marrow of recipient mice,
potentiating anti leukemic effect of ARA-C.
Summary/Conclusions: In this study we used both in vitro and in vivo assays
to highlight the prognostic value of Notch expression in B-ALL as well as its
critical role in B-ALL cell survival and response to chemotherapy. We also
demonstrated that Notch inhibitors were able to improve Ara-C-mediated reduc-
tion of blast cells in bone marrow, revealing that Notch signalling is a possible
therapeutic strategy to eradicate minimal residual disease in B-ALL. 
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REGULATION OF NOTCH AND WNT SIGNALING PATHWAYS BY NRARP
IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
I. Pinto1, M. L. Oliveira1, J. T. Barata1, R. Fragoso1,*
1JBarata Lab, Instituto de Medicina Molecular, Lisboa, Portugal
Background: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
hematological malignancy. Although the outcome of T-ALL patients has
improved over recent years, the poor prognosis of patients with resistant or
relapsed disease is still a major concern. Even though NOTCH is a known
driver in T-ALL, its inhibition cannot be efficiently achieved with the drugs cur-
rently available, due to their weak therapeutic effects and severe toxicity. We
have shown that loss of mir-181ab1 blocks Notch-induced T-ALL development
partly by de-repressing the expression of NRARP (NOTCH regulated ankyrin
repeat protein) a negative regulator of NOTCH signaling. Importantly, NRARP
over-expression in murine hematopoietic stem cells impairs T-cell development
suggesting that de-regulation of NRARP expression can contribute to the patho-
genesis of T-ALL. 
Aims: To investigate the role of NRARP in human T-ALL cell growth and survival
and its therapeutic potential in T-ALL. 
Methods: mRNA and protein expression were determined by real time-PCR
and western blot analyses. in vitro functional evaluation of NRARP in T-ALL
cell lines was performed by flow cytometry analysis of proliferation and viability
upon NRARP overexpression using lentiviruses. 
Results: We started by characterizing NRARP expression in human T-ALL
cells and compared it with the expression of NRARP in human thymocytes.
We found that NRARP protein levels are significantly increased in T-ALL cells.
This result, although consistent with the fact that NRARP is a transcriptional
target of NOTCH, suggests that NRARP is not sufficient to block NOTCH onco-
genic signals. To test this hypothesis, we overexpressed NRARP in human T-
ALL cell lines. Curiously, NRARP overexpression blocks the expansion of the
T-ALL cell lines that display NOTCH1-activating mutations but promotes the
expansion of the T-ALL cells without NOTCH1 mutations. Although in both cell
types (WT and NOTCH1-mutated) NRARP overexpression blocks NOTCH sig-
naling, in NOTCH1-WT T-ALL cells we observe an increase in c-Myc expres-
sion. Consistent with these results, NOTCH1-WT NRARP overexpressing cells
are more sensitive to JQ1, a small-molecule bromodomain inhibitor that targets
c-Myc. NRARP is known to positively regulate LEF1, a DNA binding transcrip-
tion factor acting downstream of WNT. Thus we sought to investigate the impact
of NRARP in this signaling pathway. Very interestingly, our results show that in
NOTCH1-mutant cell lines NRARP overexpression results in the down-regula-
tion of the WNT signaling pathway while in NOTCH1-WT T-ALL cells results in
its up-regulation.
Summary/Conclusions: Taken together our results suggest that NRARP may
play a dual role in T-ALL pathogenesis, regulating both NOTCH and WNT path-
ways, with opposite functional effects on leukemia cells depending on NOTCH
mutational status and signaling levels. This dual role may have important bio-
logical and therapeutic implications.
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ETV6/RUNX1-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA: A NOVEL B-
CELL PRECURSOR LEUKEMIA SUBTYPE IDENTIFIED BY THE CD27/CD44
IMMUNOPHENOTYPE
M. Zaliova1,2,3, M. Kotrova1,2,3, S. Bresolin4, J. Stuchly1,3, J. Stary1,2,
O. Hrusak1,2,3, G. te Kronnie4, J. Trka1,2,3, J. Zuna1,2,3, M. Vaskova1,3,*
1Department of Paediatric Haematology and Oncology, Second Faculty of Med-
icine, Charles University, 2University Hospital Motol, 3CLIP - Childhood
Leukaemia Investigation Prague, Prague, Czech Republic, 4Department of
Women’s and Children’s Health, University of Padova, Padova, Italy
Background: We have shown previously that ETV6/RUNX1-positive acute
lymphoblastic leukemia (ALL) is distinguishable from other ALL subtypes by
CD27pos/CD44low-negimmunophenotype. During diagnostic immunophenotyp-
ing of 573 childhood B-cell precursor ALL (BCP-ALL), we identified eight cases
with this immunophenotype among “B-other ALL” (BCP ALL cases negative for
hyper-/hypodiploidy, ETV6/RUNX1, TCF3/PBX1 and BCR/ABL1 fusion genes
and KMT2A-rearrangements).
Aims: We aimed to characterize their genetic and biological background, to
reveal to what extent they resemble ETV6/RUNX1-positive ALL and to elucidate
whether they belong to the recently described ETV6/RUNX1-like ALL (Lilljebjörn
et al., Nature Communications 2016). 
Methods: We utilized microarrays to study the gene expression profile (GEP)
and biological similarity of the BCP-ALL subtypes. Five ETV6/RUNX1-positive
and five hyperdiploid ALL cases were analyzed using microarrays in parallel to
seven CD27pos/CD44low-neg B-other cases with available material. Microarray
data from all 17 BCP-ALL cases were combined with data from an independent
Italian cohort of 291 BCP-ALL cases (including ETV6/RUNX1-positive,
BCR/ABL1-positive, TCF3/PBX1-positive, KMT2A-rearranged, hyperdiploid
and B-other ALL cases) whose specimens were analyzed using the same
microarray. To study the genomic background, we performed comprehensive
profiling using single nucleotide polymorphism (SNP) arrays and whole exome
and whole transcriptome sequencing (WES and RNAseq).
Results: In the hierarchical clustering based on GEP all five ETV6/RUNX1-
positive cases and 5 of 7 CD27pos/CD44low-neg B-other cases clustered within
the ETV6/RUNX1-positive cluster. These B-other cases were thus classified
as ETV6/RUNX1-like ALL. We identified multiple regions of acquired copy num-
ber aberrations (CNA)/ uniparental disomies (5 to 27 per case) and point muta-
tions (10 to 41 per case) in all 7 cases and 3 in-frame fusion transcripts each
in one patient. The most important findings are summarized in Figure 1. All 5
ETV6/RUNX1-like cases harbored a deletion of the ETV6 gene, resulting in an
in-frame ETV6/BORCS5 fusion in one of them. The deletion of ARPP21 was
found in 3 cases, and the deletions of PAX5, ATP10A, BTG1 and the gain of
RUNX1 were found in 2 cases each. The ARPP21 deletions displayed a strik-
ingly uniform character and were highly enriched in ETV6/RUNX1-like ALL.
Using WES and RNAseq, no recurrently mutated gene and no in-frame fusions
were found, respectively, except for the ETV6/BORCS5. Integrating data from
all platforms, we identified IKZF1 as another recurrently affected gene; a dele-
tion, a nonsense mutation and an IKZF1-involving out-of-frame fusion were
each found in one case. The P2RY8/CRLF2 fusion and the TCF3/ZNF384
fusion (the former co-occurring with two activating JAK2 mutations) were found
in 2 CD27pos/CD44low-neg B-other cases that were closer to other BCP-ALL
subtypes than to ETV6/RUNX1-positive ALL as indicated by GEP.
Figure 1.
Summary/Conclusions: We showed that similarly to ETV6/RUNX1-positive
ALL, ETV6/RUNX1-like ALL is also associated with CD27pos/CD44low-neg
immunophenotype. We identified deletion of ARPP21 to contribute to the spe-
cific genomic profile of ETV6/RUNX1-like ALL in addition to lesions of ETV6
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and IKZF1. In conjunction with the single published study, our study establishes
the ETV6 lesion as the only common genetic aberration and thus the most
likely key driver of ETV6/RUNX1-like ALL.
Supported by AZV 15-30626A, AZV 15-26588A, UNCE 204012, NPU I nr.





GENETIC ALTERATIONS IN CHILDREN WITH T-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA IN TAIWAN
D.-C. Liang1,*, T.-C. Yeh1, H.-C. Liu1, T.-H. Jaing2, S.-H. Chen2, J.-Y. Hou1,
Y.-J. Huang3, H.-W. Yao1, T.-Y. Huang3, T.-H. Lin3, C.-P. Yang3, L.-Y. Shih2
1Mackay Children’s Hospital and Mackay Medical College, Taipei, 2Chang
Gung Memorial Hospital and Chang Gung University, 3Chang Gung Memorial
Hospital, Taoyuan, Taiwan, Republic of China
Background: The leukemogenesis of T-cell acute lymphoblastic leukemia (T-
ALL) involves multistep processes of genetic alterations.
Aims: We aimed to determine the genetic alterations including common fusion
transcripts, overexpression of T-cell transcription factor oncogenes and deletion
or mutations of targeted genes in pediatric T-ALL in Taiwan as well as their
impact on outcomes in those treated with TPOG-ALL-2002 protocol.
Methods: Between 1995 and 2015, bone marrow samples from 102 children
(<18 years old) consecutively diagnosed with T-ALL were examined. SIL-TAL1,
MLL-ENL, and CALM-AF10 transcripts were detected by RT-PCR assays. RQ-
PCR with TaqMan assays were used to measure the expression of HOX11,
TAL1, and LYL1 oncogenes expressed as normalized copy number (NCN) to
ABL internal control gene. TAL1 overexpression was defined as NCN > the
lowest level of SIL-TAL1 positive patients. Overexpression of HOX11 and LYL1
was defined as NCN > the upper limits of the 50 normal bone marrow controls.
Mutations of NOTCH1, FBXW7, PHF6, JAK1, JAK2, RUNX1, WT1, NRAS,
and KRAS genes were analyzed by PCR-based assays followed by direct
sequencing. P16 deletion was determined by RQ-PCR or multiplex ligase probe
amplification (MLPA), PTEN and PHF6 deletions, MYB duplication and
NUP214-ABL1 were detected by MLPA.
Results: The frequency of SIL-TAL1 fusion transcript was 16.2%, MLL-
rearranged 5.1%, CALM-AF10 1.0%. and no NUP214-ABL1. The frequency of
NOTCH1 mutations was 46.9%, FBXW7 13.0%, RUNX1 5.2%, WT1 6.3%,
NRAS 6.2%, KRAS 2.1%, and no JAK1 or JAK2 mutations. P16 deletion was
present in 56.2%, PTEN in 11.1%, PHF6 deletion/mutation in 13.4%, and MYB
duplication in 4.8%. Overexpression of TAL1 was present in 46.5%, 22% for
LYL1, and 9% for HOX11. The correlation among the genetic alterations showed
that LYL1 overexpression occurred more frequently in P16 wild-type compared
with P16-deleted patients (P=0.0003) and absence of SIL-TAL1 transcript was
significantly associated with LYL1 overexpression (P=0.018). A comparison of
outcomes was made according to the status of each genetic abnormality.
NOTCH1 mutations conferred a favorable overall survival (OS) (P=0.025). PHF6
deletion/mutation conferred an inferior OS (P=0.030). PTEN deletion was asso-
ciated with shorter relapse-free survival (RFS) (P<0.0001) and OS (P<0.0001).
Status of other gene mutations, deletion or duplication did not influence the RFS
or OS. TAL1 overexpression predicted a higher risk of relapse (37% vs 21%,
P=0.006), an inferior RFS (P=0.002) and OS (P=0.025) whereas HOX11 or
LYL1 overexpression had no prognostic impact. By multivariate analysis,
NOTCH1 mutation did not reach statistical significance for an independent pre-
dictor of OS (HR 0.167, P=0.112), PHF6 deletion/mutation was an independent
unfavorable predictor for OS (HR 4.596, P=0.006), and PTEN deletion was also
an independent predictor for both RFS (HR 29.493, P=0.007) and OS (HR
15.830, P=0.003). TAL1 overexpression was an independent risk factor for both
RFS (HR 3.699, P=0.014) and OS (HR 2.701, P=0.047). 
Summary/Conclusions: The present study showed that LYL1 overexpression
was negatively associated with SIL-TAL1 or P16 deletion. PHF6 deletion/muta-
tion, PTEN deletion, and TAL1 overexpression were the independent predictors
of adverse outcomes. (Grants support: CORPG3C0201, MMH-E-105-09, NSC-
101-2314-B-195-004-MY2, and Terry fox Foundation) 
E826
COMPUTATIONAL METHODS TO FIND NEW THERAPEUTIC TARGETS IN
ALL, SYSTEMATICAL IDENTIFICATION OF ESSENTIAL GENES
L. Ekdahl1,*, M. Pertesi1, A. Palm1, L. Järvstråt1, E. Johnsson1, U. Gullberg1,
A.-K. Wihlborg1, B. Nilsson1
1Division of Hematology and Transfusion Medicine, Lund University, Lund,
Sweden
Background: Deletion of chromosomal material is a hallmark of cancer
genomes. While these lesions primarily target tumour suppressor genes, neigh-
bouring genes are frequently co-deleted en passant. Loss of one copy(haploin-
sufficiency) of a neighbouring gene that is essential for the survival of the cancer
cells may constitute potential therapeutic targets in that the cancer cells may be
selectively sensitive to further suppression of the function of that gene. Identifying
such vulnerabilities is one of the current challenges in cancer genomics. We
show that vulnerabilities in cancer cells can be identified computationally by
applying pattern recognition techniques to a copy-number dataset. This
approach will identify genomic regions with potential essential genes. Genes in
these regions can be evaluated downstream by genome editing techniques to
find novel targets for treatments. Using pattern recognition techniques to find
essential genes is a straight-forward, easily applied and non time-consuming
method compared to genome wide experimental approaches.
Aims: Develop a computational framework to find regions with potential essen-
tial genes from copy-number data, with a primary focus on hematological malig-
nancies and in particular ALL.
Methods: Our computational framework first selected regions of the tumour
genome with heterozygous, but not homozygous, deletion. In sections flanking
these regions we scanned for linear increases in homozygous deletion fre-
quency. Genes near the start of these increases that have more than one case
with homozygous deletion are discarded. Remaining genes were scored by
calculating a line of best fit using the least square method towards the nearby
peak in homozygous deletion. We sorted the results by settings cut-offs for the
slope, amplitude and correlation coefficient of the linear regression line. Genes
with the highest scores were then manually evaluated by comparing to known
mean copy-number loss dependence score from other data-sets, by graphical
visualisation and by investigation of their known function. The data set we
analysed contains copy-numbers from tumour samples matched to normal
blood samples or normal tissue from the same donor. To validate the essen-
tiality of genes in the discovered regions we used pooled CRISPR/Cas9 editing
in ALL cells with and without a deletion of the driving tumour suppressor.
Results: Our framework identified several regions with potential essential
genes around well-known tumour suppressors. The strongest signals in the
data set were located around the tumour suppressor CDKN2A. Downstream
analysis with pooled CRISPR/Cas9 editing in ALL cells with and without a
CDKN2A deletion provided evidence for the essentiality of several genes in
this identified region, including one gene that was essential only in CDKN2A-
deleted cells.
Summary/Conclusions: In conclusion, we explored a computational approach
to identify regions with essential genes in copy-number datasets. Application
of our approach to real data showed several regions with essential gene can-
didates around well-known tumour suppressors, indicating the framework
works. Downstream genome-editing experiments in model cell-lines provided
further evidence for the essentiality of some genes found in such identified
regions. While we cannot yet draw conclusions on whether some of these
genes are viable therapeutic targets it allows for informed guesses on limited
sets of genes for further focused analysis in hematological model cell-lines.
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TARGETING ANTIOXIDANT ENZYMES FOR THE TREATMENT OF B-CELL
ACUTE LYMPHOBLASTIC LEUKEMIA
K. Fidyt1,*, K. Szczygiel1, A. Pastorczak 2, A. Graczyk-Jarzynka1, E. Patkows-
ka3, E. Lech-Maranda3, J. Golab1, M. Firczuk1
1Department of Immunology, Medical University of Warsaw, Warsaw, 2Depart-
ment of Pediatrics, Oncology, Hematology and Diabetology, Medical University
of Lodz, Lodz, 3Department of Hematology, Institute of Hematology and Trans-
fusion Medicine, Warsaw, Poland
Background: B-cell acute lymphoblastic leukemia (B-ALL) is a genetically het-
erogeneous disease characterized by abnormal expansion of B cell precursors
and is mainly affecting children and adolescents. The backbone of the treatment
is chemotherapy providing high cure rates in pediatric ALL (> 85%) but much
worse treatment response is observed in adolescents and adults (< 50%).
Patients who relapse develop refractory, chemotherapy resistant disease and
remain a clinical challenge. Growing body of evidence suggests that distur-
bance of redox homeostasis is a promising anticancer approach. Due to high
metabolic demands and proliferation rate cancer cells elevate their antioxidative
capacity to overcome excessive ROS production and depend on these antiox-
idants for their survival. One of the oxidative stress protectors are peroxiredox-
ins (PRDXs) that next to thioredoxins (TXNs) belong to the TXN-family and
are the key components of TXN antioxidant system. PRDXs are enzymes
involved in scavenging peroxides. TXNs are responsible for cysteine-thiol disul-
fide exchange in numerous protein substrates.
Aims: To investigate the potential of targeting the TXN antioxidant enzymes
as a novel pro-oxidative strategy in B-ALL treatment.
Methods: We have used three different cell lines representing distinct cytoge-
netic subgroups of B-ALL: BV-173 (BCR-ABL), SEMK-2 (MLL-AF4) and NALM-
6 (complex cytogenetics). ROS levels were measured using Cell ROX assay.
RNA and protein levels of TXN-family enzymes were measured by quantitative
PCR and immunoblotting, respectively. Downregulation of PRDX1 was estab-
lished by a novel CRISPR/Cas9 gene editing system. We have employed lenti-
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CRISPR v2 plasmid to produce lentiviral vectors encoding PRDX1-specific
sgRNA and Cas-9 and used them to generate BV-173 cells with PRDX1 genom-
ic deletion. Proliferation rate was evaluated by trypan blue exclusion method.
Cytostatic/cytotoxic effects of TXN-family enzymes inhibitors, such as adenan-
thin (ADE), auranofin (AUR) and SK053 were assessed by MTT viability assay
and by detection of propidium iodide-positive cells in flow cytometry.
Figure 1.
Results: We have found that B-ALL cell lines exhibit significantly higher levels
of ROS as compared to normal B cells isolated from human tonsils (Fig.1A). In
accordance with this observation, our analysis of TXN antioxidant enzymes gene
expression in B-ALL cell lines showed their upregulation (Fig.1B). Analysis of
deposited data revealed that PRDX1 expression level is the highest in B-ALL
among the other types of leukemia (Fig.1C). Moreover, we have observed ele-
vated expression of PRDX1 in malignant lymphoblasts derived from pediatric
patients at both RNA and protein levels. Genomic deletion of PRDX1 in BV-173
cells leads to suppression of their proliferation rate, comparing to parental cells
and cells transduced with mammalian non-targeting sgRNA. These results allow
us to suspect that PRDX1 may play growth-supporting role in these cells. Tar-
geting TXN-family enzymes was also performed with the use of various small
molecule inhibitors. Both B-ALL cell lines and primary cells are sensitive to PRDX
and TXN inhibitors, which reduce cell viability in dose-dependent manner.
Summary/Conclusions: All the above results suggest that targeting TXN
antioxidant system may exert desirable anticancer effects in the treatment of
B-ALL. Inhibitors of TXN-family enzymes can be considered as putative agents
to use in combination with classical drugs and improve existing therapeutic
approaches. Further studies are underway.
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RNA-BINDING PROTEIN IGF2BP1 PROMOTES SURVIVAL OF ETV6/
RUNX1 LEUKEMIA CELLS
M. Stoškus1,*, G. Vaitkevičienė2, A. Eidukaitė3,4, L. Griškevičius1,5
1Hematology, Oncology and Transfusion Medicine Center, Vilnius University
Hospital Santariškių Klinikos, 2Center for Pediatric Oncology and Hematology,
Children’s Hospital, Affiliate of Vilnius University Hospital Santariškių Klinikos,
3Department of Laboratory Medicine, Children‘s Hospital, Affiliate of Vilnius
University Hospital Santariškių Klinikos, 4Department of Immunology, State
Research Institute Centre for Innovative Medicine, 5Faculty of Medicine, Clinics
of Internal, Family Medicine and Oncology, Vilnius University, Vilnius, Lithuania
Background: The IGF2 mRNA binding protein 1 (IGF2BP1, other aliases IMP-
1 (IMP1), CRD-BP (CRDBP), ZBP-1 (ZBP1), and VICKZ1) belongs to a family
of regulatory RNA-binding proteins with an oncofetal expression pattern.
IGF2BP1 has also been identified to be exclusively specific for ETV6/RUNX1-
positive acute lymphoblastic leukemia (ALL) but biological significance of
IGF2BP1 overexpression has not been thoroughly investigated to date (Ander-
sson, Olofsson et al. 2005; Stoskus, Gineikiene et al. 2011). We have recently
contributed by reporting that ETV6/RUNX1 transcript is a target of RNA-binding
protein IGF2BP1 in t(12;21)(p13;q22)-positive ALL, suggesting a role of
IGF2BP1 in ETV6/RUNX1-mediated leukemogenic events (Stoskus, Vaitkevi-
ciene et al. 2016).
Aims: To define the biological significance of IGF2BP1 overexpression in
t(12;21)(p13;q22) ETV6/RUNX1-positive ALL.
Methods: In this study we have used stable sublines with downregulated
IGF2BP1 from our previously published study (Stoskus, Vaitkeviciene et al.
2016). Dynamics of viable cell population was assessed by flow cytometry
using 7-AAD staining (BD Biosciences) following 72 hrs culture in complete
medium. An EdU flow assay (Thermo Fisher Scientific, TFS) was used to assay
DNA replication in proliferating cells. Spontaneous and doxorubicin (Doxo),
staurosporine (STS), and STAT3 selective inhibitor S3I-201 (all from Santa
Cruz Biotechnology) induced cell death rates were determined by Annexin V
(TFS) and 7-AAD staining. All samples were analyzed on Accuri C6 cytometer
(Accuri Cytometers) using CFlow Plus and FCS Express software (De Novo
Software). IGF2BP1, ETV6/RUNX1, and STAT3 RT-qPCR was performed
essentially as reported previously (Stoskus, Gineikiene et al. 2011). Statistical
analyses performed using GraphPad Prism software (GraphPad Software).
Results: Downregulation of IGF2BP1 by 2-fold have rendered into approxi-
mately 2-fold lower population growth rate, increasing levels of spontaneous
cell death in dynamics, and modest yet statistically significant attenuation of
cell cycle progression (35.13% vs 40.40%, p<0.0001). Data from treatment
with 50 nM of Doxo, 250 nM of STS suggest that IGF2BP1 downregulation has
no effect on pharmacological effectiveness of these drugs. In contrast,
IGF2BP1-downregulated cells are more sensitive to pharmacological inhibition
of STAT3 even upon treatment with suboptimal 25 µM concentration of S3I-
201. Lastly, we have probed if STAT3 transcript levels could be sustained by
IGF2BP1 protein as in agreement with previously reported (Stohr, Kohn et al.
2012) and our unpublished insights from anti-IGF2BP1 RNA immunoprecipita-
tion datasets. Correlation analysis of RT-qPCR data have confirmed these
assumptions as downregulation of IGF2BP1 expression have resulted in a
decrease of ETV6/RUNX1 mRNA (r2=0.8253, p<0.001, slope 0.9459) and also
STAT3 transcript levels (r2=0.7709, p=0.002, slope 0.6436). These data sug-
gest that STAT3 transcript is also a potentially regulated by RNA-binding protein
IGF2BP1 in t(12;21)(p13;q22)-positive ALL model cells (Fig 1).
Figure 1.
Summary/Conclusions: We provide evidence that IGF2BP1 promotes survival
of t(12;21)(p13;q22)-positive ALL model cells through cell cycle progression
and preventing spontaneous cell death. Potentiation of ETV6/RUNX1®STAT3
signaling axis is one of the possible mechanisms responsible for this phenotype
as IGF2BP1 maintains appropriate levels of primarily ETV6/RUNX1 and also
STAT3 mRNAs. Further studies are clearly warranted to further delineate the
role of IGF2BP1 in t(12;21)(p13;q22)-positive ALL (Stoskus, Eidukaite et al.
2016).
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6-MERCAPTOPURINE PROMOTES ENERGETIC FAILURE IN LEUKEMIC
T-CELL LINE JURKAT
A.A. Fernandez Ramos1,2,*, C. Marchetti-Laurent1,2, V. Poindessous1,2,
S. Antonio2,3, P. Laurent-Puig1,2,4, S. Bortoli2,3, M.-A. Loriot1,2,4, N. Pallet1,2,4
1INSERM UMRS-1147, 2Université Paris Descartes, 3INSERM UMR-S 1124,
4Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou,
Paris, France
Background: 6-Mercaptopurine (6-MP) is a thiopurine drug with antiprolifera-
tive effects by blocking purine synthesis. 6-MP is largely prescribed for the
treatment of childhood acute lymphoblastic leukemia (ALL). Recent evidence
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suggest that 6-MP inhibits the phosphatidylinositol 3 kinase (PI3K)/ mammalian
target of Rapamycin (mTOR) signaling pathway and modulates the transcrip-
tional activity of hypoxia inducible factor 1 α (HIF-1α). As mTOR and HIF-1α
are key mediators of metabolic reprogramming in cancer and normal T cells
we hypothesized that 6-MP can impact cellular metabolic remodeling through
its action on nucleotide synthesis. Metabolic reprogramming fosters glycolysis,
glutaminolysis, and biosynthesis of lipids and nucleotides to sustain cell growth
and proliferation, a key feature of cancer cells. This metabolic switch is regu-
lated by metabolic checkpoints, including mTOR, AMP-activated protein kinase
(AMPK) and the oncogenes Myc and HIF-1α.
Aims: Our objective is to study the impact of the antiproliferative molecule 6-mer-
captopurine (6-MP) on proliferating T-leukemia cells metabolic reprogramming.
Methods: In vitro experiments were performed in a Jurkat T cell line. Cells
were incubated with 6-MP from 6h to 72h. We used RT-PCR, Western Blot,
glucose uptake and glycolytic and glutaminolytic flux to evaluate the metabolic
effects of 6-MP. 
Results: Our results showed that 6-MP reduces ATP content as early as after
2 hours of treatment and this decrease is maintained up to 72 hours. As AMPK
is an energetic sensor activated with low ATP content, we studied AMPK acti-
vation after 6-MP treatment. We observed that 6-MP treatment activates AMPK
after 6 and 48 hours of treatment. Moreover, 6-MP significantly modifies the
transcriptional reprogramming of genes implicated in glycolysis, glutaminolysis
and nucleotide synthesis after 24, 48 and 72 hours of treatment. In addition, 6-
MP inhibits the expression of the metabolic checkpoints mTOR, HIF-1α and
Myc after 24, 48 and 72 hours of treatment. 6-MP also decreases glucose and
glutamine oxidation after 48 hours of treatment by 60% and 35%, respectively,
suggesting that 6-MP inhibited TCA (tricarboxylic acid cycle) and OXPHOS
(oxidative phosphorylation). The production of lactate, a marker of aerobic gly-
colysis, is significantly decreased by 30% after 6-MP treatment for 48 hours,
meaning that aerobic glycolysis is also inhibited. However, 6-MP has no effect
on glucose uptake or on glucose transporters (Glut1 or Glut3, SLC2A1 or
SLC2A) protein expression, suggesting that 6-MP metabolic effects are not
linked to glucose uptake. 
Summary/Conclusions: In conclusion, our findings offer new insights on the
cellular effects of 6-MP treatment by promoting an early energetic stress that
influence proliferation and raise apoptosis in leukemia T cells. Interestingly,
the inhibition of the metabolic checkpoints (mTOR, HIF-1α, Myc) and the
diminution of glycolytic and glutaminolytic fluxes by 6-MP treatment provide an
original approach to better understand the cellular effects of 6-MP treatment. 
E830
GENETIC ABERRATIONS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
AND THEIR IMPACT ON CLINICAL OUTCOME
K. Takahashi1,*, F. Wang2, K. Patel2, C. Bueso-Ramos2, X. Song2, J. Zhang2,
C. Gumbs2, L. Latasha2, S. Tippen2, T. Kadia1, F. Ravandi1, G. Garcia-Manero1,
N. Short1, N. Jain1, M. Konopleva1, H. Kantarjian1, A. Futreal1, E. Jabbour1
1Leukemia, 2UT MD Anderson Cancer Center, Houston, United States
Background: Genetic alterations have prognostic impact on pediatric patients
with B cell acute lymphoblastic leukemia (B-ALL). Genomic landscape and its
impact on clinical outcome is less understood in adults with B-ALL. 
Aims: To describe the landscape of genomic aberrations and analyze the cor-
relation with clinical characteristics and prognostic impact in adults with B-ALL.
Methods: We assessed bone marrow specimens from 64 consecutive adults
with a median age of 51 years (range 18 to 80) with previously untreated B-
ALL between 2012 and 2015. The cohort included 23 Philadelphia chromosome
(ph)-positive and 41 Ph- negative B-ALL. Sixty patients (94%) were treated
with Hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxoru-
bicin, and dexamethasone alternating with high-dose methotrexate and cytara-
bine)-based regimen; 23 of them received additional tyrosine kinase inhibitor
for Ph-positive disease (dasatinib [N=4] or ponatinib [N=19]). Four patients
(6%) were treated with augmented BFM (Berline-Frankfurt-Munster) regimen.
Genomic DNA extracted from pre-treatment bone marrow specimens were
sequenced by targeted capture exome sequencing of 295 genes that are recur-
rently mutated in hematologic malignancies (median 280x coverage). The panel
included more than 1000 cytoSNP position evenly distributed among the
genome that allowed estimation of copy number variations (CNVs). Point muta-
tions were called by modified Mutect/Pindel algorithm. 
Results: Among the 64 patients, we detected 70 point mutations in 40 genes
in 38 patients (54%). Ph-positive ALL had significantly less point mutations than
Ph-negative ALL (median number of mutations/patient 0 [range: 0-2] versus 1
[range: 0-6], P=0.002). The most frequently mutated genes were TP53 (17%)
followed by DNMT3A (9%), JAK2 (6%), NRAS (6%), NF1 (5%), PAX5 (5%),
RUNX1 (5%), and TET2 (5%). TP53 mutations were strongly associated with
Ph-negative B-ALL (P=0.004) and low hypoploidy (P=0.009). Recurrent CNVs
involved loss/deletion in genes such as PAX5 (38%), TCF3 (38%), IKZF1 (31%),
CDKN2A/2B (31%), BTLA (25%), CD200 (22%), ETV6 (22%), RB1 (20%),
mir15-a/16-1 (15%), ERG (14%), and MLLT3 (11%), whereas gain/amplification
was detected in NR3C2 (18%), ERG (15%), RUNX1 (15%), and LEF1 (14%).
MLLT3 loss/deletion was specific to Ph-negative- ALL (0% for Ph-positive versus
17% for Ph-negative, P=0.036) and Mir15-a/16-1 loss/deletion had non-statis-
tically significant association with Ph- BALL (4% versus 22% respectively,
P=0.06). In this cohort, 78% and 100% of the Ph-negative and Ph-positive ALL
achieved complete remission, respectively. None of the point mutations or CNVs
were associated with differential response to therapy. Survival analysis was
stratified by Ph status. Complex karyotype had trend toward worse event-free
survival (EFS) (median EFS 3.6 months versus 26.3 months, P=0.06) in Ph-
negative ALL. None of the point mutations or CNVs were associated with
EFS/overall survival (OS) in Ph-negative ALL. Notably, TP53 mutation nor low
hypoploidy did not affect EFS/OS in the current cohort. In Ph-positive BALL,
IKZF1 deletion/loss was associated with a trend toward worse EFS (median
EFS 3.6 months versus 21.3 months, P=0.07) but it did not affect OS.
Summary/Conclusions: Genetic analysis highlights the molecular hetero-
geneity of adult B-ALL. Adult B-ALL is frequently associated with CNVs and
point mutations are less frequent. Prognostic impact of genetic alteration in
adult B-ALL appears to be limited except for IKZF1 deletion/loss, which may
predict worse EFS in Ph-positive BALL.
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PROFILING OF RECURRENT COPY NUMBER ALTERATIONS IN
RELAPSED ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC
LEUKEMIA
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M. Batlle3, M. Cabezón1,3, S. Marcé1,3, D. Dominguez1,3, I. Granada1,3,
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L. Escoda6, F. Vall-Llovera7, J. Martinez Lopez8, M. Tormo9, J. Esteve10,11,12,
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5Catalan Institute of Oncology at Duran i Reynals Hospital, Hospitalet de Llo-
bregat, 6Catalan Institute of Oncology at Joan XXIII Hospital, Tarragona,
7Mutua de Terrassa, Terrassa, 8Doce de Octubre Hospital, Madrid, 9Clinic Hos-
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Background: The survival rate of relapsed adult acute lymphoblastic leukemia
(ALL) is around 10%.
Aims: We looked for recurrent Copy Number Alterations (CNA) in relapsed
adult B cell progenitor ALL (BCP-ALL) to shed light into the molecular mecha-
nisms of relapse.
Methods: BM or PB samples with at least 30% of blasts from 31 adult BCP-ALL
patients at 1st relapse and, of them, 21 paired diagnosis and relapse samples
were analysed by MLPA (MRC-Holland, The Netherlands). 19 out of these 21
paired samples were analysed by SNP array with CytoScan HD chips (Affymetrix,
Santa Clara, California, USA). True CNA were considered when encompassed
a minimum of 25 markers, and 25 markers and ≥20Mb for CN-LOH.
Table 1.
342 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Results: With a median follow up of 12.43 [2.4;30.3] months, the median OS
of the 31 patients at first relapse was 7.9 months, [2,4;13,5]. The OS of patients
at first relapse was significantly lower in those having more than 3 CNA by
MLPA (median ≤3 CNA 9.7 months [0-20.7] vs median >3 CNA 4.2 months
(0.6-7.8), p=0.042). CDKN2A/B deletion was the most common CNA observed
at relapse (16/31, 52%) and most of these deletions were homozygous (12/16,
75%). Comparing paired CDKN2A/B deletions, homozygous were more fre-
quent at relapse (from 8 heterozygous CDKN2A/B deleted patients at diagnosis,
7 became homozygous at relapse, p=0.070). SNP arrays detected 554 CNA
(409 DEL, 125 DUP and 20 LOH) in 34 samples of 19 patients. At diagnosis
(n= 16 patients) the mean number of CNA was 12.3 (9.6 DEL, 2.3 DUP and 0.4
LOH) while in first relapse (n=13 patients) was 17.8 CNA (12.6 DEL, 4.2 DUP
and 1 LOH) and in second relapse (n=5 patients) was 21 CNA (14.6 DEL, 6.4
DUP and 0 LOH)(p=0.007). All matched diagnosis and first relapse samples
(available for 10 patients) showed common CNA. In 6/10 cases some of CNA
were retained from diagnosis while others were acquired or lost at relapse (sug-
gesting evolution from an ancestral clone), 3/10 shared all CNA from diagnosis
and acquired new CNA at relapse (indicating an evolution from diagnosis clone)
and 1/10 showed the same CNA signature at relapse (suggesting a primary
resistance of the diagnosis clone). Gene ontology analysis showed a significant
enrichment of gene deletions involving B cell differentiation, activation and pro-
liferation, and regulation of cytokine-mediated signaling pathway at relapse
(Benjiamini Hochberg test, p<0.01). Table 1 summarizes the frequencies of the
most retained or acquired CNA at relapse in at least 4 out of 15 patients.
Besides the high genetic heterogeneity observed, some recurrent CNA could
be identified such as 9p, 11q, 12p, 22q and 7p deletions and 1q, 8q, 17q, 21+
and Xp duplications. In addition, deletions in important tumor suppressor genes
such as TP53, FOXO1, FOXO3 or RB1 were detected in 3 patients.
Summary/Conclusions: BCP-ALL has a high genetic heterogeneity at relapse,
with most of the genetic alterations playing important roles for disease progres-
sion. This heterogeneity points out the need for search of personalized treat-
ments for patients depending on their molecular alterations. Financial support:
Instituto de Salud Carlos III, Ministerio de Economía y Competividad, Spain,
Red Temática de Investigación Cooperativa en Cáncer (RTICC, FEDER)
(RD12/0036/0044); Sociedad Española Hematología y Hemoterapia; 2014
SGR225 (GRE) Generalitat de Catalunya; Fundació Internacional Josep Car-
reras, Celgene Spain and “la Caixa” Foundation.
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IGF1R/IRS PHARMACOLOGICAL INHIBITION REDUCES CELL PROLIFERATION
AND MIGRATION IN ACUTE LYMPHOBLASTIC LEUKEMIA CELLS
A.P.N. Rodrigues Alves1,*, J. Machado-Neto1, R. Scopim-Ribeiro1, J.C. Fernandes1,
B.A. Fenerich1, F.B. Da Silva1, P.S. Scheucher1, B.P. Simões1, E.M. Rego1,
A.J. Ridley2, F. Traina1
1Internal Medicine, University of Sao Paulo at Ribeirao Preto Medical School,
Ribeirao Preto, Brazil, 2Randall Division of Cell and Molecular Biophisics, King’s
College London, London, United Kingdom
Background: A recurrent clinical complication of the acute lymphoblastic
leukemia (ALL) is the infiltration of lymphoblast into central nervous system.
The IGF1/IGF1R signaling pathway is initiated through binding of the ligand
(IGF1) to its transmembrane receptor (IGF1R), and the subsequent activation
of its substrates, IRS1 and IRS2, which transmit mitogenic and antiapoptotic
signals, mainly through the modulation of the PI3K/AKT/mTOR and MAPK sig-
naling pathways. These signaling pathways play an important function in cell
proliferation, survival and migration of leukemia cells. We have previously
noticed that NT157 (IRS1/2 pharmacological inhibitor) significantly decreased
cell viability and induced apoptosis in T-ALL (Jurkat and MOLT-4), and in B-
ALL (Namalwa and Raji) cell lines and in primary ALL cells (T-ALL [n=2] and B-
ALL [n=2]), although did not presented citotoxicity in peripheral blood mononu-
clear cells (PBMC) from healthy donors. In addition, NT157 was able to induce
the p21 (CDKN1A) expression, which is a cell cycle arrest-related gene. We
also observed that OSI-906 (IGF1R/IR pharmacological inhibitor) significantly
reduced cell viability, but did not induce apoptosis in ALL cell lines tested, and
did not modulate viability and apoptosis of primary ALL cells and normal PBMC.
The molecular mechanism by which leukemia cells break the blood-brain bar-
rier, allowing the infiltration of the central nervous system and causing serious
complications remains poorly understood.
Aims: We herein aimed to investigate the impact of the pharmacological
IGF1R/IR and IRS1/2 inhibition on cell proliferation and migration in ALL cells.
Methods: T-ALL Jurkat and B-ALL Namalwa were used. Cell lines were treated
or not with NT157 at 0.2, 0.4, 0.8, 1.6 and 3.2µM, or with OSI-906 at 1, 5, 10
and 20µM for 24 and 48 hours. After drug exposure, cell lines were evaluated
for cell proliferation (Ki-67 assay), migration (Time-Lapse microscopy analysis)
and cell adhesion (using human umbilical vein endothelial cells HUVEC mono-
layer). Statistical analyzes were performed by the ANOVA. P value <0.05 was
considered statistically significant.
Results: In Jurkat and Nalmawa cells, NT157 strongly reduces cell proliferation
in a dose-dependent manner (p<0.05) after 24 hours of treatment. OSI-906
was not able to reduce cell proliferation in these cell lines. The 24 hours treat-
ment with 10µM OSI-906 decreased accumulated distance (µm) and velocity
(µm/min), while 0.4µM NT157 reduces only the accumulated distance of Jurkat
cells under migration assay into fibronectin monolayer, after being filmed by
time-lapse microscopy for 3 hours; the images were captured every 1.5 minutes.
Although there is a trend for reduction, cell adhesion between Jurkat and Nal-
mawa leukemia cells and the human endothelial cell monolayer was not signif-
icantly modulated by treatment with both inhibitors.
Summary/Conclusions: The reduction on cell proliferation found during IRS/2
pharmacological inhibition reaffirms the important role of these proteins on
malignant phenotype of ALL cells. Migration analysis indicated that NT157 and
OSI-906 are potential inhibitors of transendothelial migration in ALL cell lines
and contribute with new perspectives on the participation of the IGF1R/IRS1
pathway in the break of the blood-brain barrier.
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LEUKEMIA-PROPAGATING CELLS DEMONSTRATED DISTINCTIVE GENE
EXPRESSION PROFILES COMPARED WITH THE OTHER CELL FRACTIONS
IN PATIENTS WITH DE NOVO PHILADELPHIA CHROMOSOME-POSITIVE
ALL
H.-Y. Zhao1,*, Y. Song1,2, X.-N. Cao1, Y.-Z. Qin1, Y.-Y. Lai1, H. Jiang1, Q. Jiang1,
Y. Kong1, X.-J. Huang1,2
1Peking University People’s Hospital, Peking University Institute of Hematology,
2Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisci-
plinary Studies, Peking University, Beijing, China
Background: Relapse remains one of the major obstacles in Philadelphia chro-
mosome-positive acute lymphoblastic leukemia (Ph+ALL) even after allogeneic
hematopoietic stem cell transplantation (allo-HSCT). Relapse of Ph+ALL may
result from the persistence of leukemia-propagating cells (LPCs), which are
defined by their ability to initiate human leukemia and self-renew in immuno-
compromised mice. In acute myeloid leukemia, higher LPCs frequencies and
a gene expression profile typical of LPCs at diagnosis are predictive of unfa-
vorable clinical outcomes. In Ph+ALL, we recently reported that LPCs are
enriched in the CD34+CD38−CD58− fraction using a xenograft assay. Moreover,
our cohort study indicate that the LPCs phenotype at diagnosis is an independ-
ent risk factor for relapse in Ph+ALL. However, little is known about the differ-
ential gene expression profiles between LPCs and the other cell fractions in de
novo Ph+ALL patients.
Aims: To identify the potential molecular basis of LPCs-mediated relapse, the
gene expression profiles of the sorted LPCs and other cell fractions from
patients with de novo Ph+ALL were compared.
Methods: Twenty patients with de novo Ph+ALL were enrolled for this study at
Peking University Institute of Hematology from 2015 to 2016. The LPCs
(CD34+CD38-CD58-) and other cell fractions (including CD34+CD38-CD58+,
CD34+CD38+CD58-and CD34+CD38+CD58+) were sorted from the bone mar-
row mononuclear cells of de novo Ph+ALL patients (N=3) using a FACS Aria II.
Differential expression analysis between LPCs and the other cell fractions were
performed using RNA sequencing (RNA-Seq) and the DESeq R package
(1.10.1), Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of
Genes and Genomes (KEGG) analysis. RNA-Seq results were partially validated
by a TaqMan-based real-time quantitative polymerase chain reaction (qRT-PCR)
technique. Moreover, cell cycle status was compared between LPCs and other
cell fractions in de novo Ph+ALL patients (N=20) by flow cytometry.
Results: 1021 genes (301 up-regulated and 720 down-regulated), 1245 genes
(354 up-regulated and 891 down-regulated) and 1228 genes (248 up-regulated
and 980 down-regulated) were differentially expressed between LPC1 and Oth-
er Cell1 (patient No 1), LPC2 and Other Cell2 (patient No 2), and LPC3 and
Other Cell3 (patient No 3), respectively. Most of differential expression of genes
(DEGs) are related to the regulation of cell cycle and metabolism. GO analysis
identified enriched terms of biological functions in DEGs including ATP binding
process, ribonucleotide binding process, nucleoside binding process, DNA repli-
cation process, primary metabolic process, etc. KEGG analysis showed signif-
icantly enriched signaling pathways involved in DEGs including cell cycle, DNA
replication, nucleotide metabolic pathways, biosynthesis of amino acids, glu-
tathione metabolism, p53 signaling pathway, etc. Consistent with RNA-Seq
results, mRNA levels of the cell cycle-related genes, such as CDK4 and
HMGB1, were significantly lower in LPCs fraction than those in other cell frac-
tions. Moreover, the frequencies of quiescent cells in LPCs were significantly
higher than those in other cell fractions.
Summary/Conclusions: Distinctive gene expression profiles and cluster, which
are mostly related to the regulation of cell cycle and metabolism, were demon-
strated between LPCs and other cell fractions in patients with de novo Ph+ALL.
Therefore, our data indicate that it would be of value to develop LPCs biomark-
ers to contribute to personalized leukemia therapy and the need to identify ther-
apeutic targets directed toward LPCs in Ph+ALL.
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Background: T-cell leukemia is a collection of aggressive disorders with unfa-
vorable outcome, in which targeted treatments are still at a preliminary phase.
The RAS/MAPK pathway is crucial for TCR signaling of T-cells and it is dereg-
ulated in T cell acute lymphoblastic leukemia/lymphoma (T-ALL). Farnesyl
transferase inhibitors (FTIs) block the localization of some RAS proteins to
the intracellular membrane, thereby inhibiting their activation. Tipifarnib is a
potent and specific FTI with a prominent anti-proliferative effect in some RAS
mutated cells.
Aims: This study test tipifarnib in T-cell lines for in vitro sensitivity and for bio-
marker discovery, both genomic and immunohistochemical.
Methods: We selected those cell lines with available genomic data from COS-
MIC, CCLE or generated by our group. The MAPK, NFAT, NFKB and JAK/STAT
pathways were tested by immunohistochemical analysis over FFPE-cell lines
at baseline. The range of drug concentrations to perform IC50 analysis was
established between 0-10,000 nM (ten points). Cell proliferation analyses were
performed using CellTiter-Glo® Luminescent Cell Viability Assay kit from
Promega (Madison, WI, USA), following manufacturer´s instructions at 0h, 48h
and 96h. All experiments were done in sextuplet and all numerical data were
expressed as the average of the values ± the standard error of the mean. IC50
analyses were performed with GraphPad Prism v5. Clinically-relevant drug
sensitivity was defined as IC50 <100nM at 96h. Targeted sequencing was per-
formed in 16 genes known to play a potential role in tumorigenesis in T-cell
leukemias.
Results: 59.1% (n=13) of cell lines were sensitive to tipifarnib at concentrations
which are readily achievable in the clinic (i.e. IC50 <100nM at 96h). 45.5%,
50% and 27.3% of cell lines harbored mutations in RAS, RAS-guanine
nucleotide exchange factors (GEFs) and RAS-GTPase activating proteins
(GAPs) genes, respectively. The mutational state of RAS (p=0.38), RAS-GEFs
(p=0.192) and RAS-GAPs (p=1.0) genes were not associated with drug sen-
sitivity. Strikingly, the mutational state of NOTCH1 was associated with tipifarnib
sensitivity. The activation of the MAPK pathway biomarker, ERK, was signifi-
cantly associated (p=0.046) with drug sensitivity. Conversely, RelB (NFKB path-
way) was associated with drug resistance (p=0.007). The same findings were
observed with the presence of mutations in RAS-GEFs genes and NOTCH1
and ERK activation (p=0.015 and p=0.023) and the absence of RelB (p=0.02
and p=0.017).
Summary/Conclusions: This study shows tipifarnib as a potential therapeutic
option in T-cell leukemias. The mutational state of NOTCH1 could constitute a
predictor of sensitivity in T-cell leukemias. Furthermore, p-ERK and RelB could
serve as potential biomarkers of tipifarnib sensitivity and resistance, respec-
tively.
Acute lymphoblastic leukemia - Clinical
E835
HOSPITALIZATION FOR PATIENTS IN THE U.S. AND EU TREATED WITH
INOTUZUMAB OZOGAMICIN VS STANDARD OF CARE FOR
RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN A
GLOBAL PHASE 3 TRIAL
Y. Su1,*, I. Van Oostrum2, E. Vandendries1, V. Welch1, F.R. Loberiza1
1Pfizer Inc, New York, United States, 2Ingress-health Netherlands, Rotterdam,
Netherlands
Background: Inotuzumab Ozogamicin (InO), an anti-CD22 antibody-
calicheamicin conjugate, with its once a week one-hour infusion schedule, has
demonstrated lower hospital utilization, in association with a clinically mean-
ingful improvement in overall survival, high rate of complete remission, favor-
able patient-reported outcomes (PRO), and generally manageable safety profile
versus standard of care (SOC, intensive chemotherapy) for relapsed/refractory
acute lymphoblastic leukemia (R/R ALL) in the phase 3 INO-VATE trial.
Aims: This study aims to determine the regional-specific hospitalization days
per patient in the INO-VATE trial.
Methods: Patients receiving study treatment (safety population) and recruited
from the US and the EU were included in the analyses. The total number of
days hospitalized for each patient was calculated. Hospital days prior to ran-
domization and those after the end of study treatment were excluded. Due to
different durations of treatment for InO and SOC (median 1 vs 3 cycles), cal-
culations were reported for cycle 1 treatment period (randomization to end of
cycle 1) and for the entire treatment period (all cycles - randomization to end
of treatment).
Results: A total of 264 patients from the safety population of the phase 3 INO-
VATE trial were available for the analyses. 149 were from the US, and 115
from 11 of the EU countries. The percentage of patients requiring hospitalization
was lower for InO compared to SOC (Table). The median and mean hospital-
ization days were shorter for patients in the InO arm compared to the SOC
arm across both regions. The difference between the two treatment arms
appears to be greater in the US compared to the EU. Hospitalizations in the
US appear to be shorter than in the EU, particularly for patients receiving InO.
Table 1. Hospitalizations in R/R ALL patients from the INO-VATE trial.
Summary/Conclusions: InO treatment in R/R ALL is associated with less hos-
pitalization across both the US and EU compared to SOC, consistent with InO’s
better efficacy, tolerability, PRO and dosing schedule. The finding that US has
lower hospitalization than the EU might be explained by different patient care
practices in the two regions. Given that hospitalization is the biggest cost driver
in cancer care, the data suggest both EU and US could benefit from cost-sav-
ings of less hospitalization with InO treatment.
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NON-INTENSIVE BUT NON-INTERRUPTIVE TREATMENT WITH FEWER
ALLO-HSCT IS EFFECTIVE STRATEGY FOR ADULT PH-NEGATIVE
B-CELL PRECURSOR (BCP-) ALL: OUTCOME OF THE RUSSIAN
PROSPECTIVE MULTICENTER ALL-2009 STUDY
E. Parovichnikova1,*, V. Troitskaya2, A. Sokolov2, O. Gavrilina2, S. Bondarenko3,
O. Baranova4, Z. Akhmerzaeva2, G. Kliasova5, L. Kuzmina1, E. Gribanova2,
G. Baskhaeva2, I. Piskunova2, T. Obukhova6, M. Rusinov7, S. Kulikov7,
V. Savchenko1
1BMT department, 2Haematology department, National Research Center for
Hematology, Moscow, 3BMT department, Rаisa Gorbacheva Memorial
Research Institute for Pediatric Oncology, Hematology and Transplantation,
St. Petersburg, 4Haematology department, N.N. Blokhin Russian Cancer
Research Center, 5Scientific clinical laboratory of clinical bacteriology, mycology
and antibiotic therapy, 6Сytogenetics laboratory, 7Department of biostatistics,
National Research Center for Hematology, Moscow, Russian Federation
Background: As Ph-negative-BCP-ALL in adults remains less favorable in
prognosis than T-ALL, and by expert opinion needs intensive protocols with
high portion of allo-HSCT, the results of treatment based on the different
approach: de-escalated but non-interruptive treatment with low numbers of allo-
HSCT- may be of interest and can provide new insights to the common view.
Aims: to evaluate survival data and risk groups in Ph-neg-BCP-ALL pts in the
RALL-study.
344 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Methods: The ALL-2009 (NCT01193933) was initiated in Apr2009. The treat-
ment plan was identical for all risk groups with allo-HSCT indicated only for
very high-risk BCP-ALL (t(4;11), t(1;19); WBC >100). Since Apr 2009 till Dec
2016, 329 Ph-negative ALL pts (m.age 28 y (15-55), f/m 147/182) were recruit-
ed. Phenotype was unknown in 6 pts, biphenotypic AL was diagnosed in–1,2%
(n=4), T-ALL/LBL–in 38,7% (n=125), BCP-ALL-in 59,1% (n=194). Among BCP-
ALL there were 54 early pre-B ALL (27,8%), 101 common-ALL (52%), 39 pre-
B ALL (20,2%). In BCP-ALL pts m.age was 27 y (15-54), f/m 99/95, initial WBC
-9,4*109/l (0,4-899,0), LDH 901 IU (31-13059), CNS leukemia- in 17 pts (8,7%),
mediastinal mass- in 3 (1,5%), splenomegaly– in 111 (57,2%). Standard cyto-
genetics was done in 124 pts (64%), 11 had no mitosis, so information is avail-
able in 58,2% (n=113). 43,4% of BCP-ALL (n=49/113) pts had normal karyotype
(NK); 7,9% (n=9) and 1,8% (n=2) - had t(4;11) and t(1;19) respectively; other
abnormalities were detected in 53 (46,9%), including p53 (3,2%), +8 (6,3%),
complex karyotype (7,9%), high hyperploidy (16%), delp16 (22,2%), etc. 9 BCP-
ALL patients (n=4,7%) were not qualified by the risk in the data-base; 68,1%
(n=126) were attributed to the high risk (HR) group (WBC ≥30; EGIL BI,
LDH>2N; late CR; t(4;11)-pos). The analysis was performed in Feb 2017. 191
pts were available for induction outcomes, DFS and relapse probability (RP),
and all pts – for overall survival (OS).
Results: CR rate in 191 pts was 87,4% (n=167), induction death occurred in
8,9% (n=17), resistance was registered in 3,7% (n=9). Late responders consti-
tuted 13,6% (n=26). Death in CR on chemotherapy was 6,3% (n=12) and 1
death after alloHSCT. All-HSCT was performed in 13 (6 – matched related
donor, 7 MUD) of 176 patients who survived induction (7,4%), 11 of them – in
1CR. Totally 59 pts (34,9%) had relapsed. At 7y OS for the whole cohort con-
stituted – 54,3%, DFS– 56.5%, RP– 35,4%. In a multivariate analysis for BCP-
ALL among common risk factors (age >30y, initial risk group, WBC >30,
LDH>2N, immunophenotype, late CR >35d, CNS leukemia, cytogenetics) age,
WBC, t(4;11) became statistically significant for OS, DFS and RP. We developed
a new threshold for the most valuable risk factors. New risk groups stratification
demonstrated 7y OS=79%, DFS=71%, RP=23% in the standard risk (SR) group
(age <27y,WBC <75*109/l, no t(4;11)) and 46%,45%,47%, respectively, in the
HR group (age >27y,WBC>75*109/l, t(4;11)).
Figure 1.
Summary/Conclusions: Our data demonstrate that non-intensive but non-
interruptive treatment with fewer allo-HSCTs is rather effective in adult BCP-
ALL producing more than 50% OS at 7 years, though the RP is high. In our
study among common risk factors only age, initial WBC and t(4;11) - remained
the most valuable markers of poorer prognosis, while immunophenotype, time
to CR, CNS involvement, and other cytogenetic markers did not matter. So
RALL protocol without intensive highly myelosuppressive consolidation courses
and high portion of allogeneic HSCT, may become an alternative and repro-
ducible approach for adult Ph-negative ALL.
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POST-INDUCTION MINIMAL RESIDUAL DISEASE RESPONSE DETERMINED
BY MULTICOLOR FLOW CYTOMETRY IS A POWERFUL INDICATOR OF
EVENT-FREE-SURVIVAL IN THE CHILDHOOD T-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA
P. Tembhare1,*, G. Chatterjee1, I. Sanyal1, P. Devre1, S. Ghogale1, N. Patkar1,
G. Narula2, B. Arora2, N. Deshpande1, Y. Badrinath1, S. Gujral1, S. Banawali2,
P. Subramanian1
1Hematopathology Laboratory, Tata Memorial Centre, Mumbai, Navi Mumbai,
2Medical Oncology (Paediatrics), Tata Memorial Centre, Mumbai, Mumbai,
India
Background: Minimal residual disease (MRD) is a powerful predictor of event-
free survival in acute leukemia including T-cell acute lymphoblastic leukemia
(T-ALL). Due to lower incidence of T-ALL, MRD studies are limited and restricted
to a small cohort of patients. Moreover, flowcytometry based MRD (FC-MRD)
studies in T-ALL are very few. AIEOP-BFM group showed that late (Day-78)
MRD response determines overall risk-of-relapse and event-free-survival (EFS)
using RQ-PCR. However, a larger study by COG (Brent Wood et al. ASH, 2014)
showed that post-induction (Day-29) FC-MRD was more relevant in the pre-
diction of EFS. This indicates that the best time for MRD evaluation for the risk
stratification in T-ALL is still not clear and need more studies. We investigated
the value of post-induction FC-MRD response in an assessment of EFS in
childhood T-ALL. It is a first T-ALL MRD study from India.
Aims: To investigate the value of 10-color flow cytometry based MRD response
in the assessment of EFS in childhood T-ALL
Methods: We studied post-induction (Day-35) MRD (PI-MRD) & post-consol-
idation (Day-78) MRD (PC-MRD) in bone marrow samples from 100 patients
of T-ALL treated under modified MCP-841 protocol between 2014 & 2016. In
T-ALL with early-thymic-precursor (ETP) immunophenotype, patients received
dexamethasone in place of prednisolone. MRD was performed using 10-color
FC-MRD assay on Navios flow-cytometer (Beckman Coulter, BC) and MRD
analysis was performed with Kaluza software v-1.3 (BC). Any detectable level
of MRD (≥20 events) was defined as MRD-positive. Events included relapse &
disease related deaths. Statistical analysis was performed using SPSS v.16. 
Results: The median age of patients was 11.5 years (range 2–16 y; M:F–4.6).
Based on the immunophenotypic criteria, 13 patients were diagnosed as
ETPALL & remaining 87 as not-ETPALL type. PI-MRD was positive in 58/100
(58%) with the median level of 0.23% (range, 0.002% to 6%). PC-MRD was
not performed in 71.4% (30/42) of PI-MRD-negative & 1.2% (6/58) PI-MRD-
positive patients. PC-MRD was available in 64 patients (30/42 of PI-MRD-neg-
ative & 6/58 of PI-MRD-positive). PC-MRD was positive in 28% (18/64) (median,
0.2% &range, 0.009% to 4%). PI-MRD positivity was significantly high in
ETPALL as compared to non-ETPALL (93% vs 53%; p=0.01). Median follow-
up of all patients was 14 months (3-38 months). Patients were categorized
MRD standard-risk (MRD-SR) if PI-MRD was negative and MRD high-risk
(MRD-HR) if PI-MRD was positive with any level. Thus, 42% were categorized
as MRD-SR & 58% as MRD-HR. Twenty patients relapsed & of them, six died
(2 were ETPALL & 18 non-ETPALL; 3 MRDSR & 17 MRD-HR) within 26
months. Median EFS of MRD-HR patients was significantly inferior as compared
to MRD-SR (26 months vs did not reach; & 70.67% vs 92.86%; p=0.0017)
(Kaplan-Mayer curve shown in Figure 1). Interestingly, there was no difference
in EFS for PI-MRD <0.01% vs >0.01%, suggesting any level of PI-MRD positive
indicated inferior EFS. Furthermore, the PC-MRD response was not found to
be significant over PI-MRD (P-value=0.17). ETP vs non-ETP status was also
not found to be associated with EFS (P-value=0.85).
Figure 1.
Summary/Conclusions: We concluded that 10-color FC-based post-induction
MRD response is a powerful indicator of EFS in childhood T-ALL. The frequency
of PI-MRD positivity was significantly high in ETPALL indicating a lower tumor
clearance rate. There was no difference in the EFS based on the level of PI-
MRD-positivity indicating even a low level (<0.01%) PI-MRD is important in
risk-stratification of childhood-TALL.
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SMAC MIMETICS - A NOVEL THERAPEUTIC APPROACH IN CHILDHOOD
ACUTE LYMPHOBLASTIC LEUKEMIA
M. Meyer1,*, J. Zinngrebe1, L.-H. Meyer1, K.-M. Debatin1
1Department of Pediatrics and Adolescent Medicine, University Medical Center,
Ulm, Germany
Background: Pediatric acute lymphoblastic leukemia (ALL) is one of the most
common malignancies in childhood. Survival rates have increased enormously
over the past decades, but the prognosis for patients with relapsed ALL or ALL
resistant to conventional chemotherapy remains poor. Thus, novel therapeutic
options are urgently required. The family of inhibitor of apoptosis proteins (IAPs)
has been shown to play an important role in the prevention of cell death, and
to mediate gene activation important for cell survival. Many of the cellular
processes regulated by IAPs are deregulated in cancer. Thus, IAPs represent
a promising target in anticancer therapy. IAP antagonists, also known as Smac
Mimetics (SMs), were developed to counteract IAPs’ function. SMs have been
shown to induce cell death in a number of different cancer entities, amongst
them B cell precursor (BCP)-ALL. In BCP-ALL, SM-induced cell death was
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shown to depend on autocrine TNF secretion. Of note, only a subset of BCP-
ALL cell lines and primografts showed sensitivity to SM treatment. Little is
known about the underlying molecular mechanisms conferring resistance to
SM treatment. 
Aims: Evaluation of the efficacy of different SMs in inducing cell death in BCP-
ALL and T-ALL cell lines. Identification of the underlying molecular resistance
mechanisms to SM treatment in BCP-ALL and T-ALL cell lines. 
Methods: Cell death induced by SMs AT406 (Debiopharm Int.), LCL161 (Novar-
tis), Birinapant (Medivir) and BV6 (Genentech) was evaluated by FSC/SSC in
the BCP-ALL cell lines Nalm6, Reh, UoCB6 and RS4;11 and in the T-ALL cell
lines ALL-SIL, CEM, Jurkat and Molt4. Expression of cellular inhibitor of apop-
tosis proteins (cIAPs) 1/2 and X-linked inhibitor of apoptosis protein (XIAP) in
presence and absence of different SMs was assessed in the above-named cell
lines by Western blot. The mode of cell death was assessed using inhibitors of
Caspase activity (zVAD) and receptor-interacting protein 1 kinase (RIP1K) activ-
ity (Nec-1). Dependency of SM-induced cell death on TNF secretion was
assessed by application of Etanercept, a TNFR2-Fc fusion protein.
Results: BCP-ALL cell lines Reh and UoCB6 and T-ALL cell lines ALL-SIL and
CEM were identified to be sensitive to SM-induced cell death with half maximal
inhibitory concentration (IC50) values below 1 micromolar. Interestingly, we
found that the bivalent SMs Birinapant and BV6 are up to 100x more effective
in killing ALL cell lines than the monovalent SMs AT406 and LCL161. SM treat-
ment resulted in efficient and rapid degradation of cIAP1 and 2 in both, sensitive
and resistant cell lines. Interestingly, all tested SMs were equally efficient in
degrading cIAPs indicating that the resistance mechanisms are likely to be
downstream of cIAPs. Next, we assessed the mode of SM-induced cell death
in the sensitive cell lines by using zVAD or Nec-1 in order to block activity of
Caspases or RIP1K, respectively. These experiments showed that Reh and
UoCB6 cells die by apoptosis whilst CEM cells die by necroptosis upon stim-
ulation with SMs. SM-induced cell death in ALL-SIL cells was neither blocked
by zVAD nor Nec-1 nor the combination thereof. These results are substanti-
ated by the fact that SM treatment induced typical hallmarks of apoptosis, i.e.
cleavage of Poly-(ADP-ribose-)Polymerase (PARP), Caspase 8 and 3, in the
SM-sensitive BCP-ALL cell lines whereas no Caspase cleavage was detectable
in the sensitive T-ALL cell lines following stimulation with different SMs. In addi-
tion, the bivalent SMs BV6 and Birinapant more effectively induced cleavage
of PARP and Caspases than the monovalent SMs in Reh and UoCB6 cells. In
addition, we found that SM-induced cell death in Reh and UoCB6 cells is par-
tially dependent on autocrine TNF-secretion. Interestingly, we identified ALL-
SIL cells to die in a TNF-dependent manner, whilst CEM cells die independently
of TNF. This strongly suggests that TNF is not the only driver of SM-induced
cell death in ALL cells.
Summary/Conclusions: We identified a subset of both, BCP- and T-ALL cell
lines to be sensitive to SM-induced cell death with IC50 values below 1 micro-
molar. Monovalent SMs are less effective than bivalent SMs in killing ALL cell
lines. SMs induce differential modes of cell death with a variable dependency
on autocrine TNF secretion in the sensitive ALL cell lines. In-depth molecular
characterization of resistance mechanisms of ALL cells to SM-induced cell
death is required to identify patients that will benefit from a SM-based treatment
regimen.
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SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED/REFRACTORY
(R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): A SINGLE-ARM
PHASE II STUDY
R. Klisovic1,*, M. Winderlich2, S. Ambarkhane2, E. Jabbour3
1Department of Internal Medicine, Division of Hematology & Oncology, The
Ohio State University, Columbus, OH, United States, 2MorphoSys AG, Planegg,
Germany, 3Department of Leukemia, Division of Cancer Medicine, The Uni-
versity of Texas MD Anderson Cancer Center, Houston, TX, United States
Background: CD19 is a type I transmembrane glycoprotein that is expressed
throughout B-cell development until terminal plasma cell differentiation. CD19
is also broadly and homogeneously expressed across different B-cell malig-
nancies, including B-ALL. MOR208 is a CD19 monoclonal antibody with an
enhanced Fc region, which leads to a potentiation of antigen-dependent cell-
mediated cytotoxicity and antigen-dependent cell-mediated phagocytosis.
Aims: To investigate the efficacy and safety of single-agent MOR208 in the
treatment of patients with R/R B-ALL.
Methods: This is a single-arm phase II study of MOR208 in patients aged ≥16
years with histologically confirmed R/R B-ALL with progression after at least
one prior therapy. Patients with Philadelphia-chromosome-positive (Ph+) B-
ALL could be included only if they were intolerant or refractory to at least one
tyrosine kinase inhibitor. MOR208 was administered at 12mg/kg IV, weekly,
over two 28-day cycles, with a loading dose on day 4 of cycle 1. Patients with
a partial response (PR) could receive a further 2 cycles of MOR208; patients
with a complete response (CR) or CR with incomplete count recovery (CRi)
after 2–4 cycles could receive extended MOR208 therapy until progression.
The primary endpoint was the overall response rate. The trial was prematurely
terminated due to insufficient evidence of single-agent activity leading to slow
recruitment.
Results: 22 patients were enrolled; median age was 52 years (range 16–79),
12 (55%) patients were male, 6 (27%) patients had previously received an allo-
geneic stem cell transplant (SCT), the most common disease subtype was
pre-B-ALL (15, 68%) and 2 (9%) patients had Ph+ B-ALL. 6 (27%) patients
received ≥2 cycles of MOR208 and had a subsequent response assessment.
Responses were seen in 2 patients; and included a CR and a CRi, giving an
overall response rate of 9%. These 2 patients received extended MOR208
treatment. A further 3 (14%) patients did not fulfil the criteria for PR but did not
progress; 16 (73%) patients withdrew before completing cycle 2, in most cases
due to progressive disease (PD). The patient in CR met the criteria for allo-
geneic SCT, but declined this at the time; response duration was 8 weeks, with
subsequent PD. The patient with the CRi had a response duration of at least
4 weeks, but discontinued due to a treatment-emergent adverse event (TEAE),
sclerosing cholangitis. For 12 out of 13 patients with available data, MOR208
treatment led to a rapid reduction in blast/B-cell counts in the peripheral blood;
in most cases a reduction of >90% within 1 week of treatment initiation was
seen (bone marrow counts were not available). The most common grade ≥3
TEAEs were febrile neutropenia, thrombocytopenia, neutropenia, sepsis and
hyperglycemia (each 5 [23%] patients). Infusion-related reactions were reported
in 13 (59%) patients; all occurred on day 1 of cycle 1 and were mostly grade 1
or 2, with one grade 3 event; all patients recovered on the same day. Pharma-
cokinetic data were comparable with previous clinical studies and anti-MOR208
antibodies were not detected.
Summary/Conclusions: MOR208 showed signs of clinical efficacy with rapid
reductions in peripheral blood blasts in most patients with R/R B-ALL, but the
durability and frequency of achieving CRs was suboptimal, which was not unex-
pected given the complexity of R/R B-ALL. However, since the safety profile of
MOR208 was consistent with previous studies and favorable, further develop-
ment as a part of a combination treatment in R/R B-ALL remains a promising
approach.
E840
UPDATED RESULTS FROM ZUMA-4: A PHASE 1/2 STUDY OF KTE-C19
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN PEDIATRIC
AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY ACUTE
LYMPHOBLASTIC LEUKEMIA
D.W. Lee1,*, A.S. Wayne2, V. Huynh3, R. Handgretinger4, P.A. Brown5,
R. Pieters6, A.C. Dietz2, M.A. Pulsipher2, J. Rossi7, A. Mardiros7, Y. Jiang7,
L. Navale7, J. Aycock7, S. Stout7, J. Wiezorek7, R. Jain7
1Division of Pediatric Hematology/Oncology, Department of Pediatrics, Uni-
versity of Virginia, Charlottesville, 2Children’s Center for Cancer and Blood
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plantation, Children’s Hospital Los Angeles, USC-Norris Comprehensive Can-
cer Center, Keck School of Medicine, University of Southern California, Los
Angeles, 3Division of Oncology, Blood and Marrow Program, CHOC Children’s
Hospital, Orange, United States, 4Department of Pediatric Hematology and
Oncology, University Children’s Hospital, Eberhard Karls University, Tuebingen,
Germany, 5Pediatric Leukemia Program, Sidney Kimmel Comprehensive Can-
cer Center, Johns Hopkins University School of Medicine, Baltimore, United
States, 6Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands,
7Kite Pharma, Santa Monica, United States
Background: Acute lymphoblastic leukemia (ALL) exhibits a bimodal age dis-
tribution with 60% of cases occurring in children and adolescents (<20 y) and
25% in older adults (>45 y; http://seer.cancer.gov/csr/1975_2013/) and is the
most common childhood malignancy (Hematol Rep 2014;6:5554; Front Oncol
2014;4:63). ALL has an incidence of 1.2 to 1.4 per 100,000 per year in Europe
(BMC Cancer 2015;15:771). As many as 20% of children relapse after initial
therapy, with subsequent poor clinical outcomes (Front Oncol 2014;4:63).
Promising results were observed with KTE-C19, an anti-CD19 chimeric antigen
receptor (CAR) T cell therapy, in B cell malignancies, including refractory,
aggressive non-Hodgkin’s lymphoma in the ZUMA-1 trial (Blood 2016;128:LBA-
6). Here, we present updated results from the phase 1 portion of ZUMA-4, a
phase 1/2 trial of KTE-C19 in pediatric and adolescent patients with
relapsed/refractory (R/R) ALL.
Aims: The aim of the phase 1 study is to evaluate the safety of KTE-C19 in
pediatric and adolescent patients with R/R ALL.
Methods: Pediatric and adolescent patients (aged 2-21 y) with high burden
R/R ALL (>25% marrow blasts), adequate renal, hepatic, pulmonary and car-
diac function received 2×106 CAR T cells/kg after low-dose conditioning
chemotherapy consisting of cyclophosphamide (900mg/m2 once) and fludara-
bine (25mg/m2/d for 3 days) (CyFlu). The primary endpoint of phase 1 is the
incidence of dose-limiting toxicities. Secondary endpoints include efficacy out-
comes and biomarker assessments.
Results: As of 19 Jan 2017, 5 patients have enrolled and 4 have been treated
with KTE-C19 at 2×106 CAR T cells/kg. KTE-C19 was successfully manufac-
tured in a centralized, streamlined 6-8-day process for all patients across a
range of baseline absolute lymphocyte counts (0.21–1.0×109/L) except in 1
patient who had disease progression with white blood cells 150,000/µL at
apheresis and <0.2% T cells in the apheresis collection. All 4 treated patients
had high disease burden with a median marrow lymphoblast content of 57%
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(range, 41–99%). All 4 patients received bridging chemotherapy during the
manufacturing period before conditioning chemotherapy and KTE-C19. No
patient experienced a dose-limiting toxicity. One patient had a grade 5 adverse
event of disseminated mucormycosis which was not related to KTE-C19.
Cytokine release syndrome was reported in all 4 patients (all ≤ grade 3); neu-
rologic events were reported in 1 patient (grade 3). All cytokine release syn-
drome events resolved with tocilizumab, corticosteroids, and/or siltuximab plus
other supportive care with a median duration of 8.5 (range, 4-16) days. Minimal
residual disease-negative remission was observed in all 4 patients. One patient
received stem cell transplant post-remission, which is allowed per protocol at
investigator discretion. Peak expansion of CAR T cells occurred 1-2 weeks
post-KTE-C19 infusion. Updated data with additional patients, different dose
of KTE-C19, earlier tocilizumb use, and biomarkers will be presented.
Summary/Conclusions: KTE-C19 after low-dose CyFlu has been tolerable
and appears safe for further analysis in pediatric and adolescent patients with
R/R ALL. No dose-limiting toxicities were observed with KTE-C19 at the 2×106
cells/kg dose in patients despite high leukemic burden. All patients receiving
KTE-C19 achieved a minimal residual disease-negative remission. Based on
these results, ZUMA-4 continues to enroll (NCT02625480).
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COMPARISON OF 8-COLOR FLOW CYTOMETRY AND PCR-BASED METHODS
IN MEASUREMENT OF MINIMAL RESIDUAL DISEASE IN ADULT ACUTE
LYMPHOBLASTIC LEUKEMIA
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Internal Medicine – Hematology, University Hospital and Charles University,
Faculty of Medicine Hradec Kralove, 4Department of Military Internal Medicine
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Background: The presence of minimal residual disease (MRD) is the most
important prognostic factor in adult acute lymphoblastic leukemia (ALL). MRD
monitoring is routinely performed by flow cytometry (FCM) and real-time quan-
titative polymerase chain reaction methods (RQ-PCR). 
Aims: We conducted a retrospective analysis comparing these MRD meas-
urement methods in ALL patients treated in three Czech hematology/oncology
centers within the CELL group (Czech Leukemia Study Group for Life).
Methods: Adult patients (age 18-55) with both Ph-negative and positive ALL
were enrolled in the study, all treated consecutively between 2008 and 2016
according to a pediatric-inspired CELL ALL protocol. Samples for MRD evalu-
ation were acquired from bone marrow on day 26 of induction (D26) and in the
11th week of treatment before the first consolidation (W11). We divided RQ-
PCR MRD positive and negative groups using three different cut-off values and
analyzed them separately: 1) 1.0×10-3, 2) 1.0×10-4, 3) every RQ-PCR positive
result considered MRD positive even below 1.0×10-4. Cut-off value 1.0×10-3
was used for FCM MRD. Results were statistically analyzed by the Kaplan-
Meier method and log-rank (Cox-Mantel) test.
Figure 1.
Results: Total number of 103 patients was evaluated. Nine of them (8.7%)
who did not reach a hematological remission on D26 were excluded from the
study. The median follow-up of the final cohort was 36.9 months. MRD evalu-
ation was carried out by 8-color FCM (N=73) and RQ-PCR of immunoglobulin
heavy chain (IgVH, N=62) or T-cell receptor (TCR, N=3) clonal rearrangements
and BCR-ABL (N=24), MLL-AF4 (N=4) and E2A-PBX1 (N=1) fusion genes.
Methods with strongest sensitivity for OS prediction on D26 were RQ-PCR with
1.0×10-3 cut-off (4-year OS: 76.6% vs 48.8%; median OS: not reached vs 39.1
months; p=0.012) and FCM (4-year OS: 78.3% vs 30.3%; median OS: not
reached vs 27.4 months; p=0.016). The most sensitive method in W11 was
RQ-PCR with every positive result considered MRD positive (4-year OS: 79.6%
vs 53.1%; median OS: not reached vs 46.5 months; p=0.013). Flow cytometry
and PCR with other cut-offs were not sufficiently sensitive. The sub-analysis of
Ph-negative patients has shown the same results for RQ-PCR (p<0.01).
Summary/Conclusions: Our analysis has shown both RQ-PCR and FCM to
be suitable methods for MRD assessment on D26 of induction in adult ALL
patients receiving an intensive treatment. Furthermore it seems convenient to
take any RQ-PCR positivity (even below 1.0×10-4) into account in W11 and
later stages of treatment. FCM can be used for MRD assessment on D26, but
it is not sufficiently sensitive in later stages of treatment. We suggest using RQ-
PCR as a method of choice for MRD assessment in adult ALL while reserving
FCM as a backup method for patients without applicable RQ-PCR target or
when faster MRD evaluation is needed.
Supported by MUNI/A/1106/2016 grant of Masaryk University, Czech Republic
and the Czech Leukemia Study Group for Life.
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QUALITY-ADJUSTED LIFE YEARS (QALY) FOR INOTUZUMAB OZOGAMICIN
VS STANDARD OF CARE FOR RELAPSED/REFRACTORY ACUTE
LYMPHOBLASTIC LEUKEMIA (R/R ALL)
I. van Oostrum1,*, Y. Su2, B. Heeg1, T. Wilke3, A. Smith4, F.R. Loberiza2
1Ingress-health Netherlands, Rotterdam, Netherlands, 2Pfizer Inc, New York,
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Background: Inotuzumab Ozogamicin (InO), an anti-CD22 antibody-
calicheamicin conjugate, has demonstrated superior clinical activity versus
standard of care (SOC; intensive chemotherapy), including clinically meaningful
improvement in overall survival (OS), high rates of complete remission (CR)
and potentially curative hematopoietic stem cell transplantation (HSCT), and
favorable patient-reported outcomes for R/R ALL in the phase 3 INO-VATE trial.
Quality of life (QoL) is an important consideration for R/R ALL patients in both
short- and long-term survival.
Aims: This study aimed to estimate mean overall survival adjusted for QoL
(QALY) for patients treated with InO vs SOC.
Methods: A Markov model was developed with five health states - No CR, CR,
post-HSCT, progression, and death. Lengths and transition probabilities
between health states and mortality rates were based on the InO-VATE trial.
These rates were extrapolated to a lifetime horizon using parametric survival
curves fitted to available OS data, and published literature for survival beyond
available data. Utilities (QoL valuations) for each health state were based on
the patient-reported EQ-5D scores collected in the InO-VATE trial and a litera-
ture review for health states not captured in the trial. Disutilities from adverse
events experienced during and after treatments, including adverse events as
a result of subsequent HSCT such as veno-occlusive disease (VOD), were tak-
en into account in overall QoL. Outcomes were discounted at 1.5% and half-
cycle corrected. 
Results: The estimated mean LY and QALY in each health state for InO and
SOC and their differences are shown in Table. Most gains in LY and QALY for
InO over SOC were from Post-HSCT. These gains are greater in the InO arm
as more patients achieved a CR and could undergo a HSCT. Additionally, a
“tail-of-the-curve” survival gain Post-HSCT is observed in InO but not SOC.
Table 1.
*Increment values may not always correspond to differences between LYs and QALYs due to
rounding
Summary/Conclusions: This analysis taking into account both quantity and
quality of life estimates shows that InO offers an average of nearly 2 more
years of QALY compared to SOC in R/R ALL, based on higher CR and HSCT
rates, “tail-of-the-curve” survival gains, and better QoL. This can help inform
patients, physicians and payers in decision making.
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A COST-EFFECTIVE, HIGH SENSITIVITY 10-COLOR SINGLE TUBE FLOW-
CYTOMETRY BASED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC
LEUKEMIA MINIMAL RESIDUAL DISEASE (MRD) ASSAY WITH STUDY OF
ARTIFACTS AND MIMICS
G. Chatterjee1,*, D. Dhaliwal1, S. Ghogale1, B. Yajamanam1, N. Deshpande1,
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1Hematopathology, Tata Memorial Hospital, Mumbai, Mumbai, India
Background: Minimal residual disease (MRD) has been proven to be the most
important indicator of relapse in BCPALL. Recently, flow-cytometry based MRD
has been shown to achieve a sensitivity of <10-5 using a standardised panel
with high number of event acquisition. However, high-sensitivity BMRD analysis
is based on experience and acquisition of high number of events also includes
other rare BM cellular elements and artifacts.We present a study of the cost-
effective high-sensitivity 10-color single tube FC-MRD assay in BCPALL along
with description of rare BM cellular elements and artifacts causing interference
in analysis.
Aims: 1. To study the applicability and sensitivity of a 10-color high event single
tube FC-MRD assay for BCPALL; 2. To document the rare BM cellular elements
and artifacts causing interference in high-sensitivity FC-MRD assay for BCPALL
and describe their prevalence and immunophenotypic features.
Methods: We studied 230 BCPALL MRD samples.FC-immunophenotyping
was performed on Navios flow-cytometer using bulk-lysis-and-stain method
and data was analyzed with Kaluza-software. MRD was monitored using 10-
color single tube FC-MRD assay including CD45, CD10, CD19, CD20, CD34,
CD38, CD58, CD86, CD123 and CD25/CD73 with an additional 4-color nuclear-
dye (SYTO13) tube. Samples with cluster of ≥20 and ≥2 leukemia associated
phenotypes (LAIPs) were called MRD-positive. High number of events were
acquired for MRD-assay (1.5 to 6 million). To evaluate the applicability of assay,
number of LAIPs were determined in diagnostic and MRD samples. In addition,
the frequency and antigen expression pattern of mimics and artifacts were
studied.
Results: We studied 230 BCPALL MRD samples. High number of events was
acquired for MRD-assay with median-events 3427000 (range, 1678000 to
6052800). We determined the limit of detection (LOD=10 events) and limit of
quantitation (LOQ=30 events) by performing dilution assay. MRD was positive
in 107 (46.5%) samples with median of 0.135% and range of 0.0003% to
48.3%. We categorized positive MRD results into samples with MRD
<0.001%,0.001- <0.01%, 0.01- <0.1%, 0.1- <1.0% and >1% and they were
respectively 1.74%, 10.43%, 13.48%, 5.65% and 10.00%. Furthermore, in 24
samples with MRD-positive ≤0.01% and >1.5 million acquired-events, the
results were compared between time-gated initial 500000-events, 1000000
events and all events acquired. Sixteen samples among these were found to
be negative in initial 500000-events and eight in initial 1000000-events high-
lighting the importance of acquisition of >1.5 million cells. Further, we catego-
rized different rare cellular events and artifacts in the following way: 1) CD34+
mature B cells; 2) CD10+ mature B cells; 3) CD73+ mesenchymal stromal/
stem cells and endothelial cells; 4) CD123+ CD19+ ?PDC precursors; 5)
CD86+ CD58+ B cell precursors (BCP); 6) CD19+ NK cells (Table 1). We also
described their immunophenotypic features highlighting the differentiating fea-
tures from MRD and B cell precursors (Figure 1).
Table 1.
Figure 1.
Summary/Conclusions: We established a cost-effective 10 color single tube
FC-MRD assay with high sensitivity ofatleast 1 in 105 and applicability in >97%
BCPALL MRD samples. We also described the frequency and extent of different
cellular events and artifacts that can interfere with high-sensitivity BCPALL FC-
MRD analysis. The knowledge regarding presence and antigen expression
pattern of these cellular events and artifacts are critical to avoid potential false
positive results.
E844
SPECKLE TRACKING ECHOCARDIOGRAPHY IN PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY STUDY
M. Belloni1,*, G. Biddeci1, G. Bordin2, E. Varotto1, M. Pillon1, G. Geranio1,
G. Basso1, B. Buldini1, A. Todesco1, B. Castaldi2, M.C. Putti1
1Clinic of Pediatric Hemato-Oncology - Department of Woman and Child
Health, 2Pediatric Cardiology Unit - Department of Woman and Child Health,
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Background: Children with acute lymphoblastic leukemia (ALL) are at risk for
late-onset anthracycline-related cardiotoxicity. Left ventricular Global Longitu-
dinal Strain (GLS) by Speckle Tracking Echocardiography has been recently
used to identify preclinical late-onset heart failure in both adult and pediatric
ALL patients. Nonetheless, efficient strategies for the early diagnosis and man-
agement of cardiac toxicity during chemotherapy are still not defined.
Aims: We prospectively studied LV function in ALL patients treated at our Cen-
tre, according to AIEOP-BMF ALL 2009 protocol, measuring both GLS and M-
Mode Left Ventricular Ejection Fraction (LVEF).
Methods: Out of 42 consecutively examined ALL patiets (pts), 32 (76%) under-
went prospective follow-up (Table). At basal evaluaton, 19 pts had Hb<9 g/dl,
7 pts had fever, 7 pts had hyperleukocytosis, 2 had BMI>25. The influence of
there factors on cardiological parameters could not be evaluated due to low
numbers. Echocardiography was performed with Vivid E9 ultrasound system
(GE Medical System) and M5Sc probes at the following time points (TP): diag-
nosis (TP0), after induction phase (anthracycline cumulative dose 120mg/m2,
TP120), at the end of anthracycline exposure (TP240 in standard risk-SR-pts;
TP320 in high risk-HR-pts). HR pts underwent intermediate controls before
each re-exposure (TP150, TP210, TP270). GLS values>-19% (or GLS drop
>15% from basal value) and LVEF values<55% (or LVEF drop >10% from
basal value) were considered as abnormal. Statistical analysis was performed
using Student’s t-test.
Table 1.
Results: Basal evaluation was performed on 26 SR and 16 HR pts. Three SR
pts with severe anemia (<7g/dl) and/or BMI>25 showed altered GLS at TP0.
At the succeeding evaluation, 2 patients recovered, while one obese adolescent
confirmed GLS and LVEF alterations. Follow-up after induction therapy (TP120)
was performed on 10 SR pts and on 11 HR pts: GLS was altered in 3/10 SR
pts (30%) and in 7/11 HR pts (63.6%). Two SR pts showed alterations in both
GLS and LVEF values, while one child had isolated GLS impairment. Out of
the 7 HR pts, one had both GLS and LVEF impairment and 3 worsened in
LVEF at TP150. The 3 remaining HR pts subsequently recovered in GLS value.
In 2 additional HR pts both GLS and LVEF were altered at a late evaluation
(TP150, TP270). After the induction phase, we found an early 10% increase in
mean GLS value (p=0,002), while mean LVEF value was reduced only by 6%
(p=0,052), a non-significant difference even by clinical criteria. Thus, according
to the recent literature, the combination of GLS and LVEF demonstrated to be
able to identify children at risk for LV impairment, as proved later by LVEF fall
in 5 cases. Globally, 12 (37%) pts showed GLS impairment at different TP.
After the induction therapy, 2/10 SR (20%) and 6/11 HR (54%) pts were con-
sidered having significant LV function impairment, even if not clinically evident
yet. In 4 patients with GLS impairment, the LVEF never reached pathological
values. Eight patients underwent cardiological therapy. We chose to treat them
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with b-blockers, as they could limit anthracycline toxicity by their heart rate-
lowering activity and antioxidant effect. All the 8 patients subsequently improved
in both GLS and LVEF values, despite the occurrence of one episode of mild
hypotension in 2 patients.
Summary/Conclusions: ALL children, even if exposed to low doses of anthra-
cycline, show early signs of LV impairment. Overt drop in LVEF, when present,
mostly follow GLS alterations. Alterations seem more frequent in HR pts, pos-
sibly due to the higher burden of both leukemia itself and HR treatment. Further
studies on wider series are needed to confirm the relevance of the early diag-
nosis of LV preclinical dysfunction in pediatric ALL patients.
E845
NUDT15 VARIANT CAUSING HEMATOPOIETIC TOXICITY WITH LOW
6-TGN LEVEL IN KOREAN CHILDREN WITH ACUTE LYMPHOBLASTIC
LEUKEMIA
H. Hoe Koo1,*, E. Sang Yi2, Y. Bae Choi3, N. Hee Lee4, J. Won Lee1, K. Hee
Yoo1, K. Woong Sung1, R. Choi5, S.-Y. Lee5
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College of Medicine, 3Department of Pediatrics, Chung-Ang University Hospital,
Seoul, 4Department of Pediatrics, Cha Bundang Medical Centre, Cha Univer-
sity, Seongnam, 5Department of Laboratory Medicine and Genetics,
Sungkyunkwan Univ School of Medicine, Samsung Medical Center, Seoul,
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Background: NUDT15 polymorphism has been recently identified as a deter-
minant of thiopurine intolerance. 6-thioguanine nucleotides (6-TGN) is moni-
tored to prevent hematopoietic toxicity in acute lymphoblastic leukemia (ALL).
Aims: This study intended to evaluate the impact of NUDT15 polymorphism
on thiopurine intolerance and 6-TGN level in Korean children with ALL.
Methods: Genotyping of NUDT15 was performed in 258 children with ALL who
were registered in Samsung Medical Center. According to NUDT15 diplotype,
patients were classified into low risk (LR, wild-type), intermediate risk (IR, het-
erozygous variant), or high risk (HR, homozygous or compound heterozygous
variant). Total of 182 were fianlly included after 76 patients were excluded for
TPMT variation or lack of information during maintenance therapy; LR (n=131),
IR (n=46), and HR (n=5).
Results: The least 6-mercaptopurine (6-MP) dose (mg/m2/day) were adminis-
tered in HR (HR 8.9 vs. IR 25.9 vs. LR 31.8, p<0.01). HR experienced the
longest days of therapy interruption (HR 167 vs IR 30 vs 15, p<0.01) and days
of leukopenia (HR 131 vs IR 92 vs LR 59, p<0.01). The lowest WBC and platelet
counts and hemoglobin level were observed in HR. 6-TGN level (pmole/8x108
RBC) divided by 6-MP dose (mg/m2) was the lowest in HR group (HR 4.4 vs.
IR 13.3 vs HR 14.7, p<0.01).
Summary/Conclusions: Patients with NUDT15 variants encountered signifi-
cant thiopurine intolerance even with low level of 6-TGN. This concurs with the
existing hypothesis that NUDT15 protein may prevent incorporation of thiop-
urine active metabolites into DNA. Therefore 6-TGN monitoring is not useful to
predict hematopoietic toxicity for patients with NUDT15 variant.
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USING NEXT GENERATION SEQUENCING TO DETECT CLONAL TRG AND
TRB GENE REARRANGEMENTS 
P. Shah1,*, Y. Huang1, K. Hutt1, T. Stenzel1, J.E. Miller1
1Invivoscribe Technologies, Inc., San Diego, United States
Background: During early T-cell development, somatic rearrangements occur
within T cell receptor beta (TRB) locus that bring together, sequentially, the
joining of D and J gene segments, followed by joining of a V segment to the DJ
pair. This process of random combinatorial selection, coupled with N-region
diversity, generates rearrangements that are unique in both length and
sequence. Since T cell malignancies arise from transformation and clonal
expansion of a single cell, over-represented TRB rearrangements can be readily
identified, in the majority of alpha-beta T cell malignancies. The T cell receptor
gamma (TRG) locus rearranges prior to TRB, combined use of TRG + TRB
assays identify the vast majority of T-cell, as well as some B-cell malignancies.
The current gold standard for identifying these clonal rearrangements is to use
PCR assays to amplify all rearrangements, and then identify clonal products
on the basis of their uniform size following size separation using capillary elec-
trophoresis (CE). These PCR-CE assays are quite sensitive, but they provide
limited information; most notably they don’t identify the sequence information
required to allow tracking of residual disease during the course of treatment.
Recently, next-generation sequencing (NGS) based approaches for immune
receptor genes have been developed to both improve the sensitivity of clonal
detection and identify the specific V-(D-)J DNA sequences required to track
clones in follow-up testing. We have developed such an NGS-based TRG +
TRB clonality assay formatted for the Illumina® MiSeq® platform.
Aims: To develop an NGS-based TRG + TRB clonality assay for the MiSeq®
platform.
Methods: Rearranged products from within the TRG and TRB locus were gen-
erated by PCR using proprietary multiplex master mixes with consensus primers
targeting all TRG and TRB V and J exon families, synthesized with MiSeq spe-
cific adapter and individual barcode ID sequences. The PCR products were
purified, quantified and pooled into equimolar library. The final library was
sequenced on the MiSeq. The sequencing data FASTAQ output file was ana-
lyzed using Invivoscribe’s LymphoTrack® software. The software generated
frequency distributions for the top 200 rearranged sequences, identified the
DNA sequences, generated V-J assignments and V-J usage. Cell line DNA
known TRG and TRB V-J rearrangements was tested for the analytical per-
formance. DNA from different clinical sample type (FFPE, PB, and BM) was
used to assess the clinical performance.
Results: This NGS assay was able to correctly detect all known TRB and TRG
rearrangements from cell line DNA. The on-target reads per sample were 90%
- 100%. Excellent linearity (R2>0.90), sensitivity of 2.5% for clonality, and repro-
ducibility (<20% CV) were demonstrated with serial dilutions of contrived cell
line DNA. The clinical performance of the LymphoTrack® TRG + TRB NGS
assays was evaluated on different clinical samples that have also been tested
using the PCR-CE TRG and TRB assays. Assessment of clonality using the
LymphoTrack® MiSeq and PCR-CE assays for TRG and TRB demonstrated
good concordance.
Summary/Conclusions: This combo NGS assay provides a fast, simple, and
accurate method to detect clonality. In combination with the LymphoTrack soft-
ware, the TRG +TRB MiSeq assay can identify clonal TRG and TRB V(-D)-J
rearrangements and the specific V(-D)-J region DNA sequences required to
track clones in follow-up testing. Excellent clinical concordance in detecting
clonality with specific rearrangements was demonstrated between Lympho-
Track® MiSeq and PCR-CE method.
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DETECTION OF CLONALITY IN CLINICAL SPECIMENS FROM SUSPECTED
B-CELL MALIGNANCIES USING COMPREHENSIVE IGH LYMPHOTRACK®
MISEQ® AND PGM® ASSAYS
Y. Huang1,*, K. Hutt1, J. Panganiban1, A. Jacobsen1, N. Wong1, D. Duong1,
R. Bob2, S.A. Pileri3, L. Bernard3, E. Gerbino3, T. Stenzel1, J.E. Miller1
1Invivoscribe Technologies, San Diego, United States, 2Institute for Pathodi-
agnostik, Berlin, Germany, 3Haematopathology Unit at European Institute of
Oncology, Milan, Italy
Background: PCR-based capillary electrophoresis (PCR-CE) methods target-
ing immunoglobulin heavy chain (IGH) framework 1, 2, 3 (FR1, FR2, FR3), and
joining regions (J) are the current gold standard for clonality testing in suspected
B-cell malignancies. Recently, next-generation sequencing (NGS) based
approaches for immune receptor genes have been developed that improve
sensitivity and identify the specific V-(D-)J DNA sequences required to track
clones in follow-up testing. We developed comprehensive LymphoTrack® IGH
(FR1, FR2, & FR3) Assays for both the Illumina® MiSeq® and ThermoFisher
Scientific® Ion PGM™ platforms, which detect the vast majority of rearrange-
ments in a single NGS run. In this pilot study, we compared the performance
of both LymphoTrack® IGH MiSeq and PGM Assays to the IGH PCR-CE assay
by testing in 59 anonymized, blinded clinical samples.
Aims: To assess the clinical performance of LymphoTrack® IGH MiSeq and
PGM Assays
Methods: LymphoTrack® IGH Assay has been developed for both the MiSeq
and PGM platforms. Proprietary consensus primers targeting the V and J gene
segments of IGH were designed to include both platform specific adapter
sequences and individual barcodes so multiple independent PCR products
could be combined and sequenced together on the MiSeq or PGM platforms.
MiSeq IGH FR master mixes were individually manufactured with 24 indices to
allow analysis of 22 samples with 2 controls. PGM IGH FR master mixes were
manufactured with 12 indices to allow analysis of 10 samples with 2 controls.
DNA was extracted from 21 PB, 37 FFPE and 1 BM clinical samples. Single
step PCR amplification of 50 ng DNA input was followed by amplicon purifica-
tion. Equimolar amounts of purified amplicons were pooled and loaded onto
the MiSeq or PGM instruments. The sequencing data was analyzed using Lym-
phoTrack® software, which first sorted the sequences by both index and frame-
work region; then generated frequency distributions, V-J usage, identified spe-
cific sequences for top sequencing reads, and determined the somatic hyper-
mutation rate of FR1 amplicons.
Results: The analytical performance of the LymphoTrack® IGH Assay on both
NGS platforms was evaluated using dilutions of contrived samples with known
V-J rearrangements. Both NGS assays demonstrated excellent linearity
(R2>0.90), sensitivity to detect 2.5% clonality, and reproducibility (<20% CV).
The clinical performance of the LymphoTrack® IGH NGS assays was evalu-
ated on 59 clinical samples that have also been tested using the PCR-CE IGH
assay. Only samples that met the specimen and data acceptance criteria for
both methods were evaluated to determine concordance. Assessment of clon-
ality using the LymphoTrack® IGH MiSeq and PCR-CE assays demonstrated
95% (42/44) concordance. Concordance was 98% (40/41) comparing results
tested using the LymphoTrack IGH PGM and PCR-CE assays. Concordance
in clonality calls between the LymphoTrack® IGH PGM and MiSeq assays was
100% (51/51).
haematologica | 2017; 102(s2) | 349
Madrid, Spain, June 22 – 25, 2017
Summary/Conclusions: Comprehensive IGH Assays have been developed
for both MiSeq and PGM platforms. These assays identify clonal IGH V-J
rearrangements and provide the clonal DNA sequences of the tumor-specific
clonotypes required to perform follow up testing to detect residual disease.
Combining FR1, FR2 and FR3 improved the overall clonality detection rate to
96%. Both NGS-based IGH assays have demonstrated excellent concordance
in detecting clonality regardless of whether clonality was determined using a
PCR-CE method or with assays formatted for the MiSeq and PGM platforms.
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CORRELATION BETWEEN A 10-COLOR FLOW CYTOMETRIC MINIMAL
RESIDUAL DISEASE (MRD) ANALYSIS AND MOLECULAR MRD IN ADULT
ACUTE LYMPHOBLASTIC LEUKEMIA
J. Singh1,*, M. Gorniak1, G. Grigoriadis1,2, D. Westerman3, M. McBean3,
N. Venn4, R. Sutton4, S. Morgan 1, S. Fleming1,2
1Laboratory Haematology, Alfred Pathology, 2Clinical Haematology, Monash
Health, 3Pathology, Peter MacCallum Cancer Centre at the Victorian Compre-
hensive Cancer Centre, Melbourne, 4Children’s Cancer Institute, Lowy Cancer
Research Centre, UNSW, Sydney, Australia
Background: Minimal residual disease (MRD) monitoring in Acute Lymphoblas-
tic Leukemia (ALL) is an accepted standard of care in both adult and pediatric
patients as one of the strongest predictive factors for disease outcome and as a
stratification tool for treatment intensification and allogeneic stem cell transplant.
The currently accepted standard of molecular monitoring with either immunoglo-
bin heavy or kappa chain (IG) or T-cell receptor (TCR) quantitative PCR (qPCR)
in Philadelphia negative ALL allows for sensitive monitoring of MRD, but requires
a high degree of expertise, and factors such as cost and turnaround time may
limit generalized applicability of this technique. Flow cytometric MRD monitoring
is utilized in many centers, with increased sensitivity seen with implementation
of multi-parameter flow cytometry at 8-colours or more.
Aims: We sought to compare a 10-color flow cytometry assay for detecting
MRD in B-ALL with standard molecular monitoring.
Methods: To facilitate rapid identification of MRD in patients with B-ALL, we
developed a 10-colour single tube flow cytometry assay utilizing CD19, CD22,
CD20, CD38, CD58, CD13/33, CD66c, CD10, CD45 and CD34 as markers.
These markers were selected to provide at least two targets for identification
of B-lineage cells, and to include the most frequently aberrant markers in pre-
cursor B-lineage ALL. Samples were subject to bulk ammonium chloride lysis
to maximize cell yields with a target of 1 x 106 events. Once normal maturation
patterns were established, patient samples were analyzed in parallel to stan-
dard of care molecular monitoring with either IG/TCR qPCR in Philadelphia
negative (Ph-) disease and BCR-ABL qRT-PCR in Philadelphia positive (Ph+)
disease. Statistical correlation was performed in Graphpad Prism version 7.0
for linear regression and calculation of correlation co-efficient.
Figure 1.
Results: 33 samples at different time points from 13 patients were analyzed
by flow cytometry. 9 samples from 9 patients were taken at diagnosis. Whilst
an informative MRD phenotype was identified by flow cytometry in all 9 patients,
a molecular assay was not able to be developed in one patient due to lack of
an identifiable marker. 24 samples from 13 patients were tested for MRD by
flow cytometry. The median lower limit of detection was 0.0078% (range
0.0016% to 0.028%) with a median lower limit of quantification of 0.018%
(range 0.002% to 0.07%). A sensitivity of <0.01% was attained in 21 of 24 sam-
ples (88%). 20 samples from 11 patients were tested concurrently for MRD by
both molecular and flow cytometric methods. 11 samples were in Ph- disease
and 9 were in Ph+ disease. MRD was detected by both molecular and flow
cytometry in 11 samples and not detected by both methods in 8 samples. In
one sample, MRD was detected only by molecular at an unquantifiable level.
There was a strong correlation co-efficient between molecular and flow cyto-
metric MRD analysis (R2=0.905, p<0.001). Correlation was strong with both
IG/TCR based molecular analysis (R2=0.949, p<0.001) and BCR-ABL based
molecular assays (R2=0.993, p<0.001).
Summary/Conclusions: 10-color flow cytometric minimal residual disease
analysis with bulk lysis attains a high degree of sensitivity in minimal residual
disease determination in precursor B-lineage Acute Lymphoblastic Leukemia.
There was a strong correlation with molecular MRD monitoring for both quan-
tification of MRD and determination of MRD negative status. Flow cytometric
methods may also permit MRD monitoring in patients where a suitable molec-
ular assay cannot be developed.
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HYPOGLYCEMIC EVENTS DURING TREATMENT OF PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA: OBSERVATIONS FROM TRIAL AIEOP-BFM
ALL 2009
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Background: Hypoglycemia has been reported as a rare side effect in children
and adolescents treated for acute lymphoblastic leukemia (ALL). It has been
associated to purine nucleoside analogues (PNA), but potential relationship
with asparaginase has also been described. Despite these reports, clinicians’
awareness of this risk seems to be limited. 
Aims: Descriptive evaluation of symptomatic hypoglycemic events during ALL
treatment.
Methods: Hypoglycemic events were analyzed among 3293 patients treated
in the trial AIEOP-BFM ALL 2009 in four of the participating countries (Germany,
Switzerland, Czech Republic, and Australia) between 06/2010 and 08/2016.
PNA were administered during induction-consolidation, the second part of the
reintensification phase (reinduction-consolidation) and during maintenance
(MT). Pegylated asparaginase (PEG-ASP) was given in induction, first part of
reintensification, as well as high-risk blocks. Additionally, the benefit of inten-
sified PEG-ASP was tested during induction-consolidation in the high-risk
group, and during reinduction-consolidation/MT in the medium-risk group.
Adverse events were generally captured in a targeted approach by means of
defined events assessed as clinically relevant, not including hypoglycemia.
Thus, data collection of these events was based on proactive reporting by the
investigators. For analysis, clinical severity of the events was retrospectively
graded according to patients’ capacity of action and reaction.
Results: In total, 28 hypoglycemic events were reported in 26 of the 3293
patients. 25 events in 23 patients were described as symptomatic, to which
further analysis was restricted (22 precursor B- and one T-ALL; 8 standard-
risk, 12 medium-risk, and 3 high-risk). Age of patients ranged between 1.7 and
15.5 years at occurrence of symptomatic hypoglycemia. Balanced ratio
between both sexes can be observed (13 male, 10 female), median age was
essentially similar (male 3.2 y, female 4.1 y). Hypoglycemic events occurred in
induction treatment (n=1), induction-consolidation (n=8), reinduction-consoli-
dation (n=4; one in standard reinduction, 3 in reinduction with intensified PEG-
ASP treatment), high-risk block (n=1), and in MT (n=11; 4 events during stan-
dard MT, 6 events during MT with intensified PEG-ASP treatment, and one
event 4 weeks after last PEG-ASP during MT). Seven events were reported
with mild symptoms, 6 patients showed moderate symptoms, and in 12 events
patients showed severe symptoms (loss of consciousness, seizure-like).
Summary/Conclusions: In accordance with previous reports, hypoglycemic
events accumulated in PNA containing treatment phases, but not exclusively.
Considering that 324 patients of the total cohort were treated with intensified
PEG-ASP in reinduction-consolidation/MT, an additive effect of PEG-ASP and
PNA in triggering a hypoglycemic metabolic condition may be assumed
although a similar effect was not seen in induction-consolidation with intensified
PEG-ASP. However, numbers are small and reporting bias of the present data
is probable, as hypoglycemic events were not captured systematically. Inves-
tigators’ attention to adverse reactions and proactive reporting might be higher
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in experimental arms as well as in case of preceding hypoglycemic events in
other patients of the respective trial center. Despite these analytical limitations,
our data suggest that hypoglycemia during ALL treatment is a relevant and
probably underestimated clinical problem. Further investigation including pos-
sible identification of predisposing metabolic conditions is required to avoid
harm to patients by this preventable complication.
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NUDT15 VARIANT IN KOREAN CHILDREN WITH ACUTE LYMPHOBLASTIC
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Background: Acute lymphoblastic leukemia (ALL) is the most prevalent pedi-
atric cancer with cure rates approaching 90% with current therapy. Patient with
ALL require long-term maintenance therapy. The combination of weekly
methotrexate and daily 6-mercaptopurine (6-MP) consisted with the backbone
of ALL maintenance regimens. Genetic polymorphism in thiopurine methyl-
transferase (TPMP) is well known to affect the 6-MP tolerance. However preva-
lence of non-function variant of TPMT is rare in Far East. Recently, a study has
identified a variant of the NUDT15 gene associated with intolerance of 6-MP. 
Aims: We examined the association between NUDT15 polymorphism and clin-
ical data of Korean pediatric ALL. 
Methods: NUDT15 genotyping and collection of clinical data was performed
for 74 Korean pediatric ALL patients from two different hospital. For NUDT15
genotyping, DNA was extracted from whole blood/or bone marrow sample and
Sanger sequencing was performed for exon 1 and 3 of NUDT15 gene. 6-MP
dose intensity, defined as the ration of prescribed 6-MP dose over protocol
planned dose. 
Results: We found two kinds of variants, c.55_56insGAGTCG(rs869320766)
in exon 1 from 8 patients and c.415C>T(rs116855232) in exon 3 from 14
patients. Of them, 7 patients had both variants and all variants were heterozy-
gote. Patients could be divided to four distinct groups according to combinations
of genotype (Table 1). 6-MP dose intensity in wild type was higher than three
other genotypes during maintenance therapy (p=0.003) (Fig 1). The number of
hospitalized days in wild type is small compared to other three genotypes
(p=0.017). Frequency of febrile neutropenia, hepatotoxicity, cumulative days
of antibiotics use and overall survival did not significantly differ by NUDT15
genotype. 
Table 1. Treatement outcome of children with acute lymphoblastic
leukemia according to NUDT15 genotypes.
Figure 1.
Summary/Conclusions: Genotyping of NUDT15 could be beneficial to predict
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KOREAN ADOLESCENTS AND YOUNG ADULTS
H.Y. Ju1, Y.A. Kim2, D.H. Lee2, K. Park2, N.Y. Lee2, H. Lee3, B.-K. Park1, H.J. Park1,*
1Center for Pediatric Oncology, 2National Cancer Control Institute, 3Hemato-
logic Oncology Clinic, National Cancer Center, Goyang-si, Gyeonggi-do, Korea,
Republic Of
Background: The outcome of acute lymphoblastic leukemia (ALL) has marked-
ly improved for last centuries, but the improvement was mainly observed in
children under 10 years old. In contrast, the treatment outcomes of ALL in ado-
lescents and young adults (AYA) still lag beyond those of younger children. 
Aims: We conducted this study to investigate the treatment outcome of AYA
ALL in Korea, and to define any patterns of care related to the treatment out-
come of AYA ALL.
Methods: Clinical data of 10-29 years old ALL patients diagnosed between
2002 and 2010 were extracted from Korean national health insurance service.
Data about patients’ diagnosis, age, gender, mainly treated department (internal
medicine vs pediatrics), usage data of medications (L-asparaginase, 6-mer-
captopurine, vincristine, prednisolone or dexamethasone), hematopoietic stem
cell transplantation (HSCT), radiotherapy, survival, and follow-up duration were
collected. Patients who were treated with steroid over 2 weeks, and L-asparag-
inase at least once in initial 2 months were considered to be treated as pediatric
protocol, and who did not fulfill this criteria were considered to be treated as
adult protocol.
Results: Total 1,223 ALL AYA patients were diagnosed between the 2002 and
2010, and excluding those who never treated, 1,208 patients underwent ALL
treatment. Among them, 665 (55%) patients were treated with pediatric protocol,
and the other 543 (45%) patients were treated with adult protocol. Radiotherapy
was done in 278 (41.8%) and 186 (34.3%) in each group, and HSCT was done
in 205 patients (30.8%) and 216 patients (39.8%) in each group, respectively.
Pediatric protocol group showed significantly better overall survival compared
to adult protocol group in total age (65% vs 43%, P<0.0001), 10-13 year old
(76% vs 57%, P<0.0001), and 20-24 year old patients (51% vs 31%, P=0.0116).
In univariable analysis, patient age (younger), treatment protocol (pediatric), L-
Asparaginase, 6-mercaptupurine, and steroid over 2weeks in initial 2 months
were associated with better overall survival (P<0.0001 for each).
Summary/Conclusions: The overall survival rates in Korean AYA ALL were
comparable with previous studies done at other countries. Patients treated with
pediatric protocol tended to result better overall survival rate when compared
to patients treated with adult protocol. Radiotherapy and early HSCT were wide-
ly used in the 2000s, and further study is needed to follow up the recent trend
of treatment, and outcome as a result. 
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AUTOLOGOUS TRANSPLANTATION AS TIME-DEPENDENT FACTOR FOR
SURVIVAL OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC
LEUKEMIA: STUDY DATA AND SIMULATION MODEL
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1Biostatistics, 2Hematological Oncology and BMT, National Research Center
for Hematology, Moscow, Russian Federation
Background: The role of autologous hematopoietic stem cells transplantation
(aHSCT) for patients with T-cell ALL is still being discussed. The resent Russia
study of ALL shows the promising effect of aHSCT but there is a skepticism as
the study was not randomized. The possible bias was referred to the “time
selection” factor. 
Aims: It’s need to prove that time selection can not explain the magnitude of
the effect of aHSCT on patient’s survival. 
Methods: We have developed SAS macros time-depend graphical and analytic
procedures for time dependent factors: Land Mark (LM) methods, Mantel-Bayr
test, Cox regression model (CM) and also a base for simulation all end points
and study events like remission, transplantation, relapse and death are well
approximated by a mixture of exponent distributions. Non-constant (dropping)
hazard rate exists in real study data. The consequence of violation of constant
hazard assumption as most possible source of biases was tested on our sim-
ulation model in different situations. Real data multicenter study of ALL was
used to fit simulation model parameters. Russian ALL study group held a
prospective multicenter trial RALL-2009 in the treatment of Ph-negative adult
ALL patients based on non-intensive but non-interruptive treatment
(NCT01193933). The therapy was unified for all Ph-negative ALL pts, but in T-
cell ALL/LBL autologous hematopoietic stem cell transplantation (auto-HSCT)
after non-myeloablative BEAM conditioning was scheduled as late intensifica-
tion (+3-4 mo of CR) followed by prolonged 2 years maintenance. From Jan
2009 till Jul 2016, 30 centers enrolled 107 T-ALL/LBL pts. Median age was 28
years (15-54 y), 34 f / 73 m; early T-cell (TI/II) phenotype was verified in 56
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(52.3%), mature (T-IV) - in 10 (9.4%), thymic (TIII, CD1a+) ALL – in 41 pts
(38.3%). T-lymphoblastic lymphoma (T-LBL= <25% b/m blasts) was diagnosed
in 22 pts (20,5%). Autologous HSCT was performed in 35, allogeneic-in 7 pts. 
Results: The survival analysis of real data shows 4-fold dropping hazard rate.
The effect of aHSCT was confirmed by LM analysis, Mantel-Bayr test -
PMB=.0004, Cox model output: 1/HR=15.9, P=0.008. (Fig.1). Simulation model
for remission consists of 3 fractions: early (α=10%, τ=0.05 m, δ=0.2 m), normal
(α=57%, τ=0.28 m, δ=1 m) and late remission (α=33%, τ=1.31 m, δ=2.2 m),
for survival consists of 2 fractions: short life (α=59%, τ=22 m), long life (α=41%,
τ=600 m). (Fig.2). The first simulation experiment was performed in preposition
that transplantation has no effect (HR=1). To exclude the random effect the
sample size was N=4000. Mantel-Bayr and Cox model show no significant
(PMB=.50, PCM=.50, HR=.93) but LM plot demonstrates recognizable bias in
transplanted patient group (Fig.3). The second experiment supposed that the
existed effect of aHSCT (HR=0.5), N=500. Mantel-Bayr and Cox model would
show significance, but hazard ratio was underestimated (PMB=.03, PCM=.03,
HR=.70 (0.50-0.97)). More experiments were done for repeated simulation,
which demonstrated a very good agreement of Mantel-Bayr and Cox methods
and their robustness.
Figure 1.
Summary/Conclusions: The effect of autologous HSCT in T-cell ALL was
confirmed by usual analysis and by simulation experiments. It was shown that
potential bias caused by no constant hazard rate cannot explain the magnitude
of HSCT effect demonstrated on real data. LM plot could express small bias.
Mantel-Bayr and Cox Model analytical methods are robust against violation of
constant hazard assumption and give very concordant outputs. Cox model
underestimates the effect of time-depending factor in case of dropping hazard.
Simulations model is a good instrument for testing tests in situations of deviation
from theoretical assumptions.
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INDUCTION WITH TYROSINE KINASE INHIBITORS, CONSOLIDATION
WITH FLUDARABINE, ARA-C AND DAUNOXOME FOLLOWED BY
ALLOGENEIC STEM CELL TRANSPLANT IS AN EFFECTIVE AND FEASI-
BLE STRATEGY FOR PH+ ALL PATIENTS
N. Di Felice1,*, P. Minetto1, F. Guolo1, M. Clavio1, N. Bisso1, G. Pastori1,
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Background: The prognosis of Philadelphia positive (Ph+) acute lymphoblastic
leukemia (ALL) patients has improved since the introduction of tyrosine kinase
inhibitors (TKI). Following TKIs treatment almost all patients rapidly achieve com-
plete hematologic remission (CR). However, only a minority of patients obtain
complete molecular response and mot of all will eventually relapse without further
treatment. On the other hand, the concomitant combination of TKIs to conven-
tional chemotherapy regimens greatly increases complete molecular responses,
but at the price of significant toxicities and high rates of deaths due to toxicity.
Aims: We present here the preliminary results of a sequential therapeutic strat-
egy starting with TKI (Dasatinib) as single agent induction until CR is achieved.
Fludarabine (Flu), Cytarabine (Ara-C), Lyposomal Daunorubicine (DNX, FLAD
regimen) and Dasatinib were given as consolidation therapy, in order to max-
imize efficacy and reduce toxicity. Allogeneic stem cell transplantation (HSCT)
was planned for all patients in MRD negative CR.
Methods: Dasatinib was given in association with steroids at the dosage of
140mg /die until the achievement of CR. FLAD regimen consisted of a three-
days administration of Flu 30mg/sqm followed by Ara-C 2000mg/sqm and DNX
100mg/sqm. Dasatinib was administered again from the end of chemotherapy
and G-CSF was given to all patients starting from day 4 until complete hema-
tological recovery. FLAD was administrated for up to two cycles. Minimal resid-
ual disease (MRD) was evaluated in all patients after each FLAD either by
multicolor flow cytometry (MFC), RQ-PCR for VDJ rearrangements, and RQ-
PCR for BCR/Abl.
Results: From January 2008 to December 2016, 8 Ph+ ALL at diagnosis (medi-
an age 52 years) have been enrolled in this protocol. The median follow-up
was 27 months. All patients received 70 days induction with Dasatinib +
Steroids and achieved CR with complete hematological recovery. In all patients
but one, however, BCR/Abl was still positive both on day 33 and on day 70.
Two patients were MFC MRD positive on day 33 (one on day 70 also), whereas
five patients achieved MFC MRD negativity on day 33. After the first FLAD
course all patients achieved MFC MRD negativity, with four patients achieving
also negativity for VDJ rearrangements and BCR/Abl transcript. FLAD was
very well tolerated, with a median ANC and platelet recovery of 7,5 and 4 days,
respectively. No patient experienced relapse so far and 5/8 patients proceeded
to HSCT. Two patients are currently waiting for transplant. Overall, 6 patients
are alive and in MRD negative CR at the time of analysis. One patient died at
day +289 after SCT due to non-relapse mortality and one has died after the
first FLAD in molecular CR because of an unrelated event.
Summary/Conclusions: This therapeutic strategy proved to be well tolerated
and extremely effective for Ph+ ALL patients. Administering FLAD in patients
who had already achieved complete hematological response with Dasatinib +
steroids allowed us to reduce the period of neutropenia and thrombocytopenia
compared to what is reported after combined TKI and chemotherapy treatment
given at diagnosis. Most patients underwent HSCT in molecular CR.
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BONE MARROW MRD EVALUATION ON DAY 7 OF STEROID TREATMENT
OF MODIFIED ST JUDE TOTAL XV THERAPY IN STANDART/LOW RISK
PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
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D. uckan1, F. gumruk1
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Background: In the recent years it was cleary shown that levels of minimal
residual disease (MRD) studied by flowcytometry during treatment reflect the
overall response to the chemotherapy and give a chance to individualize treat-
ment and improved outcome.
Aims: To determine the clinical significance of MRD on day 7 of initial steroid
treatment in patients with childhood ALL we analyzed data from 173 patients
treated with modified St Jude Total XV therapy between 1 January 2008 and
31 December 2015.
Methods: According to our previous succesfull results with high dose methl-
prednisolone (HDMPX) we add 7 days of HDMPX to the modified St Jude Total
XV as an initial treatment and randomized patients at doses of 10mg/kg/d or
20mg/kg/d HDMPX: not exceeding at maximum 1000mg methylprednisolone.
After the end of 7th day of steroid concomittant chemotherapy was given and
the doses were tapered gradually to 5mg/kg/d and 10mg/kg/d in each group
respectively. By the 3rd week of treatment steroid dose was tapered to
2mg/kg/d in both groups and continued with this dose till the end of 3rd week
of induction phase. MRD levels were studied at the 15th, 22nd and 42nd days
of induction according to the protocol. However we also analyse steroid
response rate by the peripheral smear on day 7. Moreover, patients were asked
to obtain simultaneously optional bone marrow aspiration after getting informed
consents to show whether there will be any concordance with the steroid
response and/or whether it can give any idea of the outcome. 
Results: Steroid response rate on day 7 by peripheral smear was 91% (n=158)
for the whole group. However simultaneously bone marrow MRD measurement
was done in 22 of the 173 patients.There were 13 female and 9 male patient
with a median initial WBC count of 6400/mm3 (1100-55300/mm3),all were
Calla+ pre B cell ALL (17 low risk ALL, 6 standart risk and 1 high risk ALL),all
were in complete remission and all except one is alive at the time of the analy-
sis. There were 10 patients receiving 10mg/kg/d HDMPX and 12 patients were
in the group of 20mg/kg/d HDMPX. MRD levels were not statistically different
on day 7 between these two groups. Furthermore all patients except 2(one in
each group) were steroid responsive by means of peripheral absolute blast
count <1000/mm3. Bone marrow MRD on day 15th and 42nd there were no
statistically significant difference in each group(P>0.05).Although some of those
patients in each group have high levels of MRD on day 7, interestingly they
were all steroid responsive.
Summary/Conclusions: Our preliminary results suggest to think that MRD
level on day 7 in a small group of low/standart ALL patients may not predict
outcome.
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PONATINIB (PON) IN PHILADELPHIA CHROMOSOME (PH)-POSITIVE
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PRELIMINARY REPORT OF
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Background: PON, a third-generation tyrosine-kinase inhibitor (TKI), displays
activity in de novo Ph-positive (Ph+) ALL and chronic myeloid leukemia (CML)
in lymphoid blastic phase (LyBP), as shown when given as single agent in 42
patients (pts) with resistant disease in the PACE trial (Cortes, NEJM 2013), or
combined to first-line chemotherapy in 58 pts (Jabbour, Lancet Oncol 2015;
Sasaki, ASH 2016 ).
Aims: Because data are still limited to few selected pts, we analyzed the out-
come of pts treated with PON in the real-life setting (OPAL observatory).
Methods: Pts were recruited if aged ≥ 18 years; with de novo Ph+ ALL or CML-
LyBP, treated by PON alone or in combination for at least 1 treatment day, for
relapsed or refractory disease, between Apr 2012 and Dec 2014 (Expanded
Access Program). Twenty-one pts were analyzed (16 men and 5 women; 17
de novo ALL and 4 LyBP-CML), with a median age of 60 years (22-73). Time
from first ALL or CML-LyBP diagnosis was 6 months (1-123). At PON initiation,
1 pt had primary refractory ALL, 15 pts were in first salvage (1 in second com-
plete remission [CR] after chemotherapy, 3 in molecular relapse only), 2 in sec-
ond salvage, and 3 in third salvage or beyond. Numbers of patients who had
previously received 1, 2, 3, or 4 other TKIs were 4, 15, 1 and 1, respectively
(14 imatinib, 17 dasatinib, 5 nilotinib, 1 bosutinib). Six pts had previously under-
gone hematopoietic stem cell transplantation (HSCT). Of the 18 pts screened
for BCR-ABL mutations, 5 had none, 3 had T315I, 3 had other PON-sensitive
mutations, while 5 had compound mutations (known to be resistant to all TKIs
including PON) and 2 had E255V (of intermediate sensitivity to PON). PON
was administered alone in 13 pts, combined to low-intensity chemotherapy in
6 pts, intensive chemotherapy or monoclonal antibody in 2 pts. Dose at initiation
was 45mg in 17 pts and 30mg in 4 pts.
Results: Median duration of PON therapy was 3 months (5 days-30 months+).
Out of the 19 pts who received PON for ≥ 4 weeks, 5 pts failed to reach CR,
while 14 (78%) reached or maintained it. Molecular response was not reported
uniformly. During induction by PON, 5 grade 3-4 events occurred in 4 pts (1
pulmonary infection; 1 acute renal failure; 1 pancreatitis; 1 hepatitis; 1 venous
thrombo-embolic event; no arterial occlusive event). Post-induction therapy
consisted in PON-based therapy in most pts. HSCT was performed in 5 pts.
Out of 14 pts in CR on PON, 1 pt died in CR from HSCT toxicity, 1 had a CNS
relapse at 8 months, and 11 pts ultimately experienced bone marrow relapse,
all of them within 6 months after PON initiation, except 2 who relapsed at 13
and 27 months after HSCT. Two patients are alive in CR at 14 and 30 months,
1 after salvage therapy, 1 on PON.
Summary/Conclusions: Our series of resistant pts is comparable to the PACE
study population by initial characteristics and high frequency of BCR-ABL muta-
tions. CR was achieved in most pts, suggesting the role of PON as a bridge-
to-transplant with a favorable risk-benefit ratio. Effective post-induction combi-
nations of PON to chemo/immunotherapy have to be tested in pts not eligible
for HSCT. Because global outcome of this very high-risk population remains
poor, earlier introduction of PON in the course of the disease is warranted, as
underlined by the excellent results of the hyperC-VAD-PON combination in the
first-line setting.
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Background: JL1 is a novel epitope of CD43, which is known to be specifically
expressed depending on the differentiation stages of hematopoietic cells. JL1
antigen is expressed on tumor cells of T, B, and myeloid lineage in >80% of
acute leukemia patients, and its expression is limited in normal multipotent
hematopoietic cells. The antigen is not expressed on mature peripheral blood
cells or other normal tissues. Thus, the clinical phase 1 test of a therapeutic
agent for leukemia targeting JL1 is being conducted, and when anti-JL1 anti-
body was combined with a toxic substance, its therapeutic effect was found
earlier in preclinical trials. 
Aims: This study aims to examine JL1 expression of leukemic cells in childhood
acute leukemia.
Methods: Between December 2014 and January 2016, a total of 71 patients
younger than 21 years with acute myeloid leukemia (AML, n=25), and acute
lymphoblastic leukemia (ALL, n=46) were enrolled in this study. Expression of
JL1 was examined using FACSCanto II (Becton-Dickinson, Sunnyvale, CA,
USA) based flow cytometry, and an expression of 20% or above was defined
as positive JL1 expression. Pathologic and immunophenotypic characteristics,
and clinical outcomes of the patients were analyzed.
Results: Positive JL1 expression was observed in 16 (64.0%) patients with
AML, and 27 (58.7%) with ALL. In AML patients, positive JL1 group showed
higher expressions than negative JL1 group in CD 14 (P=0.043), CD7
(P=0.026), CD56 (P=0.016) and lower expressions in CD65 (P=0.05). With
regard to ALL patients, CD 20 (P=0.002) and CD2 (P=0.005) expressions were
significantly higher in JL1 positive group than JL1 negative group. Positivity of
JL1 expression did not show significant difference between B-lineage ALL and
T-lineage ALL (P=0.671). Positivity of JL1 expression was not significantly asso-
ciated with overall survival in 71 patients with newly diagnosed childhood acute
leukemia (P=0.570).
Summary/Conclusions: 60.5% of childhood acute leukemia displayed positive
JL1 expression. This finding is similar to 61.2% of JL1 expression in adult AML
and 57.9% of expression in adult ALL reported previously. The JL1 expression
was significantly associated with some immunophenotypic features, but was
not significantly associated with clinical outcome. These findings demonstrates
that anti-JL1 antibody might be used in childhood acute leukemia patient show-
ing JL1 expression
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Background: Dysregulated production of cytokines and adhesion molecules
has been implicated in the onset and progression of various types of leukemia.
Further knowledge gained from multiple cytokine and adhesion molecule eval-
uation could help to improve treatment outcomes.
Aims: The aim of this study was to evaluate baseline levels of cytokines,
cytokine receptors and adhesion molecules in newly diagnosed acute lym-
phoblastic leukemia (ALL) patients and to assess their correlation with baseline
characteristics and prognostic factors.
Methods: A total of 30 newly diagnosed ALL patients (median age 46, range 22–
75 years, 20 males) were included in this study. We evaluated serum levels of 31
analytes, specifically 21 cytokines, 4 soluble cytokine receptors, 5 soluble adhesion
molecules and Matrix Metalloproteinase-9. From cytokines, we measured Inter-
leukins (IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-
15, IL-23), Epidermal Growth Factor (EGF), Granulocyte Macrophage Colony
Stimulating Factor (GM-CSF), Interferon-γ (IFN-γ), Macrophage Inflammatory Pro-
tein-1α (MIP-1α), Monocyte Chemotactic Protein-1 (MCP-1), Tumour Necrosis
Factor-α (TNF-α), Vascular Endothelial Growth Factor (VEGF) and soluble recep-
tors for IL-2 (sIL-2Rα), IL-6 (sIL-6R), TNF-α type I and II (sTNFR-1,2). From soluble
adhesion molecules, we measured E-Selectin (E-SEL), L-Selectin (L-SEL), P-
Selectin (P-SEL), Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell
Adhesion Molecule-1 (VCAM-1). All analytes were measured by biochip array
technology on Evidence Investigator analyzer (Randox). Serum levels of tested
analytes were correlated with baseline characteristics and prognostic factors, such
as age, sex, risk group according to GMALL (SR 9, HR 9, VHR 12 patients), full
blood count parameters (including percentage of blasts), biochemical parameters
(LDH, CRP), response to induction therapy (CR rate after induction), progression-
free survival (PFS) and overall survival (OS). Statistical evaluation was done by a
professional statistician using software R 3.3.2 (R Core Team 2016).
Results: Comparing analytes with baseline characteristics, we found significant
negative correlations between IL-7 and leukocyte count (r=-0.633; p=0.032), per-
centage of blasts in peripheral blood (r=-0.695; p=0.004) and LDH (r=-0.604;
p=0.075). Furthermore, we found significant positive correlations between IL-7
and platelet count (r=0.801; p<0.0001), VCAM-1 and LDH (r=0.664; p=0.012).
Correlations with baseline risk stratification according to GMALL did not reach sta-
tistical significance. In the study population, CR rate after induction was 86% (MRD
negative in 29%), 1-year PFS 68% and 1-year OS 73% (2 patients died during
induction therapy). Higher levels of EGF were associated with failure to achieve
CR after induction therapy (r=0.686; p=0.073). So far, no significant correlations
between baseline analyte levels and inferior PFS or OS were found. In newly diag-
nosed ALL patients, we found statistically significant correlations between sTN-
FR-1 and sTNFR-2 (r=0.805; p<0.0001), IL-1α and IL-4 (r=0.700; p=0.008), sTN-
FR-2 and MIP-1α (r=0.657; p=0.037), sTNFR-2 and VCAM-1 (r=0.652; p=0.044).
Other correlations between analytes did not reach statistical significance.
Summary/Conclusions: Our findings show that serum levels of IL-7 and
VCAM-1 are associated with some baseline characteristics of newly diagnosed
ALL patients and EGF with response to induction therapy. Better understanding
of leukemia microenvironment is essential for development of new treatment
approaches. Further studies in this field are warranted.
The work was supported by a long-term organization development plan 1011
(FMHS) and by MH CZ – DRO (UHHK, 00179906).
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IMATINIB VS. DASATINIB FOR OUTCOMES AFTER ALLOGENEIC STEM
CELL TRANSPLANTATION FOR PATIENTS WITH PH+ ACUTE
LYMPHOBLASTIC LEUKEMIA
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Background: The survival of the patients with Philadelphia chromosome pos-
itive acute lymphoblastic leukemia (Ph+ALL) who received allogeneic stem
cell transplant (allo-HSCT) has improved over the development of tyrosine
kinase inhibitors (TKIs). Currently, Imatinib (IMA) and Dasatinib (DAS) are
widely used for the treatment for Ph+ALL. However, there has been no data
comparing the outcomes between the patients who received allo-HSCT and
the two distinctive TKIs respectively.
Aims: We conducted a retrospective analysis for comparing the two TKIs for
the outcome after allo-HSCT.
Methods: Clinical data of patients were retrospectively collected from Hokkaido
University Hospital and Sapporo Hokuyu Hospital. The patients’ eligibility were
as follows: diagnosed as Ph+ALL, aged more than 16 years, and received allo-
HSCT between 1990 and 2016 and first time for SCT.
Results: Sixty-six patients were eligible for the study. Fifty-six out of the 66
were administered TKIs (TKI group) and the remaining ten who developed
Ph+ALL in the earlier years were treated without TKIs (non-TKI group). Overall
survival was not different between the two groups. Of the 56 patients in the
TKI group, 39 received IMA (IMA-pts), and the remaining 17 received DAS
(DAS-pts). Compared with DAS-pts, IMA-pts received allo-HSCT in relatively
older years of age, more frequent myeloablative conditioning regimen, and
cyclosporine-containing, not tacrolimus-, regimen for GVHD prophylaxis more
frequently. Other characteristics, such as age, disease status at HSCT, or stem
cell source were not significantly different between the two groups. Incidences
of Neutrophil engraftment and acute GVHD incidence were not statistically dif-
ferent between IMA-pts and DAS-pts. Incidence of chronic GVHD was margin-
ally increased in IMA-pts (IMA; 63%, DAS; 33%, P=0.08). At the median fol-
low-up days of 531 after SCT (range: 14-4402 day), overall survival was not
different between the two groups by univariate analysis (Logrank, P=0.16).
However, by multivariate analysis using Cox regression model for adjusting
confounding factors, including, overall survival was superior for IMA-pts [Hazard
ratio; 0.32 (0.11-0.94), P=0.04]. Incidences of transplant-related mortality and
relapse were not different between the groups, even though relapse rate tended
to be increased in DAS-pts (IMA; 16.1%, DAS; 47.1%, Gray P=0.2).
Summary/Conclusions: Our analysis suggests that overall survival may be
superior for the Ph+ALL patients treated with allo-SCT and IMA compared with
those with DAS. There are some limitations for our analysis due to retrospective
fashion and relatively small number of the patients analyzed. Therefore,
prospective study comparing survival of the Ph+ALL patients treated with the
two distinctive TKIs before HSCT is needed.
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IS OLDER AGE AN EXCLUSION CRITERION FOR ALLOGENEIC
HEMOPOIETIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH
PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA?
O. Gavrilina1,*, E. Parovichnikova1, V. Troitskaya1, A. Sokolov1, L. Kuzmina2,
S. Bondarenko3, V. Lapin4, T. Obukhova5, A. Sudarikov6, K. Zarubina1,
S. Kulikov7, M. Rusinov7, V. Savchenko1
1Chemotherapy and BMT, 2Bone marrow transplantation, National Research
center for hematology, Moscow, 3BMT, Institute of the Pediatric Hematology
and Transplantology, Saint-Petersburg, 4Hematology, Regional hospital,
Yaroslavl, 5Cytogenetic, 6Molecular hematology, 7Statistic, National Research
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Background: Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
is diagnosed more often in older than in younger patients. This type of the
acute lymphoblastic leukemia is characterized by very aggressive course of
the disease. All clinical recommendations for such conditions indicate allogenic
bone marrow transplantation after achieving complete remission. The addition
of tyrosine kinase inhibitors (TKI) to chemotherapy has dramatically improved
the long-term outcome in Ph+ acute lymphoblastic leukemia patients. Never-
theless whether to administer chemotherapy at all and if yes – how intensive
it should be, is still the matter of debate. We have conducted two consecutive
trials in Ph+ ALL aiming to evaluate the efficacy of more and less intensive
chemotherapy approaches in combination with constant non-stop 600 mg Ima-
tinib. All patients in both protocols with suitable donors underwent hemopoietic
stem-cell transplantation (HSCT).
Aims: To analyze the effectiveness of RALL–2009+TKI and RALL–2012+TKI
protocols in Ph+ ALL patients with or without HSCT. To analyze the efficacy of
treatment with or without transplantation regarding the patient’s age.
Methods: From 2010 January to 2017 January, 35 new Ph+ ALL cases were
diagnosed in 3 centers of the RALL–group. From 2010 to 2012, 12 Ph+ ALL
pts were treated according to RALL–2009 protocol (ClinicalTrials.gov;
NCT01193933) with concurrent administration of Imatinib. This protocol
includes 8 cytostatic drugs and no intervals between treatment phases. Since
2012 till now 23 pts were included in ongoing RALL–2012 protocol, based
mainly on 600 mg Imatinib with prednisolone, VNCR, L-asp, followed by 6-MP
and MTX. Both protocols suggested the shift to Dasatinib (100-140mg) after
non-achievement of MolCR on day 70 of treatment. MolCR was stated if bcr/abl
chimeric transcript was <0,01% by PCR with 10-4 sensitivity. All patients were
considered as candidates for allogeneic HSCT if HLA-identical donor was avail-
able. 13 pts (37%) underwent all0-HSCT as the first-line therapy: 1 autologous,
5 matched related and 7 matched unrelated.
Figure 1.
Results: MolCR on day 70 was achieved in 36% and 59% in RALL–2009 (n=4)
and RALL–2012 (n=13) respectively. Death on therapy (within 2 months of
induction/consolidation) was registered in 2 cases on less intensive RALL-
2012 protocol and 2 cases on RALL–2009. Hematological CR was achieved
in 30 (85,7%) of 35 pts (except four early deaths and 2 refractory cases). There
was one autologous HSCT in MolCR on the first protocol. Allo–HSCT was car-
ried out in 5 of RALL–2009 protocol pts and in 9 of RALL–2012. The major
issue is the non-relapsed mortality after unrelated allo–HSCT in 3 older pts
(49, 56 and 59 years old) who were included in RALL–2012 (aGVHD and
severe infections, at a median +4 months after HSCT and more than 12 months
of CR duration).
The 5y overall survival (OS) and relapse-free survival (RFS) for all 35 pts con-
stituted 54,6% and 40,4% respectively. The long-term outcome on both proto-
cols (RALL–2009 and RALL–2012) was similar: OS – 62,8% vs 49,4% (p=0,6),
RFS – 55,7% vs 45% (p=0,7), respectively. In order to evaluate the impact of
allogeneic HSCT we performed a comparison of transplanted and non-trans-
planted patients by a landmark analysis. The land mark was chosen as the
median time from CR to allo-HSCT – 4,3 mo (3-16 mo). So, the 5y OS from
land mark was 53,3% for non-transplanted patients and from day of HSCT -
65,6% in transplanted (p=0,18), and RFS was 25% vs 62,5 (p=0,19), respec-
tively. OS for older pts (>45 y) was 40% vs 25% in transplanted vs non-trans-
planted group of the pts, and RFS was 25% vs 66,6%, respectively. OS in
younger (£45 y) pts was 83,3% vs 58,9% for transplanted vs non-transplanted
pts, EFS was 77,1 vs 21,4%, respectively.
Summary/Conclusions: The results very pessimistic in older (>45 years)
patients who received HSCT. The contrary was observed in younger adult
patients with very good results after HSCT – OS was 83,3% and EFS 77,1%.
We conclude that patients aged>45y should continue chemotherapy without
allogeneic HSCT or may be we could apply autologous HSCT for that group of
the patients.
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TARGETABLE BLINATUMOMAB + TYROSINE KINASE INHIBITORS
TREATMENT IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC
LEUKEMIA PATIENTS: CLINICAL EFFECTIVENESS AND PERIPHERAL
LYMPHOCYTES SUBPOPULATIONS KINETICS
A. Sokolov1,*, E. Parovichnikova1, V. Troitskaya1, I. Galtseva1, L. Kuzmina1,
J. Davidova1, N. Kapranov1, I. Lukyanova1, T. Lobanova1, K. Zarubina1,
E. Usikova1, V. Savchenko2
1National Research Center for Hematology of the Ministry of Healthcare of the
Russian Federation, Moscow, Russian Federation, 2Chemotherapy of hemo-
blastoses and bone marrow depression and bone marrow transplantation,
National Research Center for Hematology of the Ministry of Healthcare of the
Russian Federation, Moscow, Russian Federation
Background: Blinatumomab is a bispecific monoclonal anti-CD3/CD19 anti-
body which has clinical activity in relapsed/refractory Ph-positive acute lym-
phoblastic leukemia (ALL) as monotherapy. Combination of Blinatumomab with
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tyrosine kinase inhibitors (TKI) is the promising approach in treating Ph-positive
ALL. Some other rearrangements like IKZF1 in Ph-like ALL, FLT3 and JAK2 in
Ph-negative ALL are the potential targets to some TKIs.
Aims: To demonstrate effectiveness and toxicity profile of Blinatumomab+TKI
treatment. To evaluate peripheral blood lymphocytes subpopulations kinetics
during blinatumomab treatment.
Figure 1.
Methods: From October 2015 to February 2017 10 patients (pts) aged from
24 to 42 (median 31), 7 female and 3 male, with relapsed/refractory ALL were
treated in our center. The diagnosis was relapsed ALL in 8 pts (7 – overt hema-
tological, 1 – cytogenetic relapse) and persistent/increasing minimal residual
disease of ALL in 2 pts. All pts had strong CD19 positivity. 8 pts was diagnosed
as Ph-positive ALL (p190), 1 – Ph-like ALL (IKZF1 rearranged), 1- FLT3+ ALL.
Two pts has T315I ABL mutation. In all pts blinatumomab continuous infusion
+ TKI therapy was started. Blinatumomab dose during 1st week of 1st cycle
was 9 mcg/day, 28 mcg – subsequent three weeks. Blinatumomab dose in sub-
sequent 4-weeks cycles was 28 mcg/day. 7 pts were treated with TKI Dasatinib,
1 – Bosutinib (Dasatinib/Nilotinib intolerant), 1 – Ponatinib (T315I), 1 – Sorafenib
(FLT3+). ATRA was added to Dasatinib in 1 pt with IKZF1rearranged Ph-like
ALL. 1 pt received 1 cycle of 4 weeks blinatumomab, 1 pt – 2 cycles, 6 pts - 4
cycles, 2 pts – 5 cycles. TKIs were administered continuously in all pts. T-
helper, T cytotoxic, T-regulatory and NK cells were measured by flow cytometry
in every week during all cycles of blinatumomab treatment.
Results: No one pt has neurological toxicity of any grade. All pts has significant
decrease of normal IgG level and all of them received intravenous human nor-
mal immunoglobulin replacement. Palmar-plantar syndrome in one pt on
sorafenib completely resolved after temporarily TKI discontinuation. Diarrhea
in 1 pt on dasatinib/nilotinib completely resolved on bosutinib. 8 pts achieved
molecular remission (MolCR), one pt – cytogenetic remission and one pt with
T315I progressed to overt hematological relapse. T-helper and T-regulatory
lymphocytes subpopulations were on or below of lower limit of normal range.
T-cytotoxic and NK subpopulations gradually returned into normal range (Fig.
1). AlloBMT was performed in 4 pts. Three pts are awaiting alloBMT and three
are continuing Blinatumomab + TKI treatment.
Summary/Conclusions: Lowering toxicity in non-chemotherapy treatment has
its significance in such a heavily pretreated patients with relapsed ALL. The
treatment has high MolCR rate and low toxicity profile. Treatment effectiveness
correlated with T-helper and T-regulatory subpopulations exhausting. T-cytotoxic
and NK cells subpopulations restoring also correlated with clinical effectiveness.
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VERY VERY LATE RELAPSES OF CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA, A CASE SERIES 
M. Baka1, D. Doganis1, M. Nikita1,*, A. Pourtsidis1, M. Servitzoglou1,
D. Bouhoutsou1, M. Varvoutsi1, K. Kapetaniou1, H. Dana1, V. Douna2,
T. Anastasiou2, H. Kosmidis1
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Background: Recurrence of acute lymphoblastic leukemia (ALL) during child-
hood usually occurs within the first six years after initial diagnosis. 
Aims: The aim of this study is the identification of all relevant characteristics
and outcomes in a group of patients with childhood ALL, who relapsed more
than six years after initial diagnosis or more than three years after bone marrow
transplantation (BMT).
Methods: All children diagnosed with a first relapse of ALL in our Department,
from January 1992 till December 2010 were included in this study.
Results: During this period, a total number of 353 patients with childhood ALL
were treated in our Department, according to BFM protocols. Recurrence
occurred in 86 patients (24.4%, 56 male - 30 female - median age: 4,83 years),
within 3 to 184 months from initial diagnosis. Very very late recurrence was
noted in 3,1% of our relapses (8 male - 3 female) at 53, 72, 82, 83, 84, 87, 108,
112, 116, 120 and 184 months from initial diagnosis. In 9 patients recurrence
involved the bone marrow, in 1 both bone marrow and central nervous system
(CNS) and in 1 only the testicles. Two children had received allogeneic BMT
from a matched related donor in first complete remission (CR1) and they had
a bone marrow relapse 4 and 5 years later, respectively. The mean WBC, Hb,
Blasts and PLT values at diagnosis were 29260/mm3, 5.6g/dl, 21360/mm3 and
18000/mm3, respectively. All of them were B-cell ALL except for 1 who had
CD33 and CD13 co-expression. Regarding the immunophenotypical profile of
the disease at recurrence, it remained almost identical to the initial. Regarding
cytogenetic characteristics of the patients at diagnosis, 3 of them had high
hyperdiploidy, one del(6)(q12), one BCR-ABL fusion and one 47,ΧΥ,+13(9),
idem,del(12(p13?); none had MLL rearrangement or ETV6-RUNX1. In 9 cases,
the cytogenetic profile remained identical at recurrence, while in 1, trisomia 13
was not detected and another had heterozygous absence of IKZF1, PAX5,
EBF1, CDKN2A and CDKN2B genes. On Day 8, nine of 11 patients were Pred-
nisone Good Responders. On Day 15, nine children had bone marrow M1, one
M2 and one M3, and on Day 33 only one had M2. Two patients were classified
as low risk, 6 as intermediate risk and 3 as high risk. Second remission (CR2)
was achieved in 9 children with very very late recurrence. The other 2 died
from disease progression. Six of nine patients are still alive and well 6, 8, 10,
10, 11 and 20 years after initial diagnosis. One of 9 patients died from second
recurrence and the last two had a second allogeneic BMT and died due to
severe infection, 2 and 10 months following that BMT. Interestingly, 3 out of 5
patients who finally died, had the very very late recurrence (10, 10 and 15 years
after initial diagnosis) and had been treated with adult type protocols.
Summary/Conclusions: The rate of very very late B-cell ALL recurrence was
only 12.8% of all recurrences. The prognosis is worse in patients, older than
18 years, treated with adult type protocols.
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NOVEL CRLF2 MUTATIONS AND CLINICAL SIGNIFICANCE IN ADULT
ACUTE LYMPHOBLASTIC LEUKEMIA
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Background: Cytokine receptor-like factor 2 (CRLF2) plays an important role
in the development of normal B lymphocytes, which can mediate early B cell
proliferation and survival. CRLF2 overexpression and rearrangement have
been observed in acute lymphoblastic leukemia (ALL); and they are reported
to contribute to oncogenesis and unfavorable outcome in ALL. We reported
that CRLF2 overexpression in the patients without CRLF2 rearrangement, indi-
cating the reason other than CRLF2 rearrangement is responsible to the CRLF2
overexpression. There is few reported CRLF2 mutations in adult ALL. 
Aims: This study is to investigate the mutations of CRLF2 and its clinical sig-
nificance in adult ALL without CRLF2 rearrangement.
Methods: The 129 patients’ BM samples (95 B-ALL, 33 T-ALL and 1T-/B-ALL)
were collected between April 2010 and Jan 2015 at the First Affiliated Hospital
of Nanjing Medical University. The ALL diagnosis was made according to the
cytogenetic, morphologic, Immunophenotypic and molecular criteria of WHO
Diagnosis and Classification of ALL (2008). Mutational analysis of CRLF2 exons
1-6 was performed. Genomic DNA was isolated and DNA fragments spanning
the aforementioned CRLF2 exons were amplified by PCR using AmpliTaq Gold
kit (Applied Biosystems, USA) and the exon-specific primers. The resulting
PCR products were purified and sequenced by The Beijing Genomics Institute
(BGI; Beijing, China).The frequency, positions, types and clinical significance
of CRLF2 mutations were analyzed. For qualitative parameters, overall group
differences were analyzed using a χ2 test. All statistical analyses were per-
formed using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was
considered to indicate statistical significance.
Results: Six novel CRLF2 mutants were detected in the 129 patients without
CRLF2 rearrangement, which were L86I (0.8%), R186S (7.8%), P224L (8.5%),
W255C (0.8%), and two silent mutations F232F (0.8%) and A11A (12.4%). The
overall rate of CRLF2 mutation was 26.6%. Exon6 is a hot spot exon, detected
three types of mutants. The incidence of A11A in B-ALL was significantly higher
than that in T-ALL (14.7% vs 2.4%, P=0.037), whereas R186S was only detect-
ed in B-ALL. Exon1, exon5 and exon6 mutations were detected in B- and/or T-
ALL patients; but no mutations were detected in exon2 and exon4. None of
these mutations were reported in the COSMIC and SNP databases. The patents
with R186S, P224L mutations showed significant differences with that of non-
mutant patients in sex, age, white blood cell count, hemoglobin level, and
platelet count. The median neutrophil count in the patients with P224L mutation
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was lower than that of non-mutation (8.53x109/L vs 28.9x109/L, P=0.032). The
positive rate of Ph chromosome in patients with R186S was lower than that
without the mutant (10.0% vs 31.8%, P=0.018). In addition, the incidence of
splenomegaly in patients with R186S and P224 L mutants was lower than that
in non-mutant patients (0.0% vs 29.5%, P=0.026; 0.0% vs 29.7%, P=0.034,
respectively). The B-ALL patients with L86I mutant had myeloid antigen expres-
sion, high white blood cell count (248.4×109/L) and low platelet count
(10×109/L), and relapsed in two months after the first induction chemotherapy;
and the overall survival was only 2 months. The patient with W255C mutation
did not achieve complete remission (CR) with the first induction chemotherapy.
Interestingly, the patient with silent mutation, A11A showed higher age (46 vs
30 years, P=0.033), higher HLA-DR (100% vs 75.3% P=0.035), CD22 (83.3%
vs 47.4% P=0.020) than those without the mutation; and the patient with F232F
mutation relapsed in 6 months.
Summary/Conclusions: Six novel CRLF2 genetic mutations were identified
in adult ALL patients and may associate with clinical outcome, such as CRLF2
R186S indicating favorable, while L86I and W255C indicating poor outcome.
Our data indicated that the CRLF2 mutations may be new prognostic markers
and play an important role on oncogenesis in ALL.
Acute myeloid leukemia - Biology
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THE MUTATIONAL SPECTRUM OF T(8;21)(Q22;Q22) POSITIVE ACUTE
MYELOID LEUKEMIA DETERMINED BY HIGH-THROUGHPUT TARGETED
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Background: Recently, comprehensive genetic profiling of pediatric and adult
core-binding factor (CBF) AML revealed a variety of cooperating events in a
cohort of 85 t(8;21) AML patients (Faber et al. Nat Genet 2016). These muta-
tions comprised alterations in genes encoding for proteins in tyrosine kinase
(TK) signaling, epigenetic regulation (ER), and in the cohesin complex (CC).
Aims: To validate and to further extend our recent findings by comprehensive
characterization of the mutational landscape of t(8;21) positive AML using a
high-throughput targeted sequencing (HTS) approach.
Methods: The HTS panel comprised the entire coding region of 244 genes
that are involved in hematological malignancies. Pretreatment blood (n=23) or
bone marrow specimens (n=72) of 95 additional adult t(8;21) positive AML
patients (pts) (median age: 51 yrs, range 18-72 yrs) were analyzed. 92/95 pts
were enrolled in one of seven prospective AMLSG treatment trials. Libraries
(total probes size: 1.359 Mbp) were prepared using SureSelectXT custom solu-
tions (Agilent). Paired-end sequencing was carried out on a HiSeq 2000 (Illu-
mina). The variant allele frequency (VAF) cutoff for reporting mutations was
set at ≥0.05.
Results: The median coverage per pt was 900x. Mutations were detected with
an average of 5.1 (SD: ±2.6) per pt with 99% of all pts harboring at least 1
mutation and 87% ≥ 3 mutations. Consistent with previous studies, mutations
in TK signaling pathways were common events: KIT mutations were found in
22/95 pts (23%) followed by mutations affecting NRAS (16/95; 17%), FLT3
(11/95; 12%; point mutations only), and KRAS (4/95; 4%). A significant enrich-
ment of mutations was also observed in genes involved in epigenetic regulation,
ASXL1 (15/95; 16%), ASXL2 (12/95; 13%), KDM6A (11/95; 12%), CREBBP
(8/95; 8%), SRCAP (8/95; 8%), EZH2 (7/95; 7%), SETD2 (5/95; 5%), TET2
(12/95; 13%) and DNMT3A (5/95; 5%), highlighting their contribution in altering
the epigenetic state of this leukemia subtype. Moreover, mutations affecting
members of the CC were found with a high frequency: RAD21 (13/95; 14%),
SMC1A (5/95; 5%), STAG2 (3/95; 3%), and SMC3 (2/95; 2%). Of note, muta-
tions in CC genes were almost mutually exclusive. We also identified additional
mutations in previously detected cooperating genes such as mutations clus-
tering in exon 2 of the ZBTB7A gene (15/95; 16%), encoding for a transcription
factor involved in hematopoietic lineage fate. Recurrent mutations were also
observed in CCND2 (9/95; 9%), that plays an important role in regulation of
hematopoietic cell proliferation, as well as DHX15 (6/95; 6%) being involved in
spliceosome function and ribosome biogenesis. With respect to the clonal archi-
tecture we found that the median VAF in genes belonging to ER and CC (0.30;
range 0.03-0.91; 0.31, range 0.05-0.73; respectively) was higher than in genes
associated with TK signaling (0.19, range 0.05-0.53). These data suggest that
alterations affecting the epigenetic state and differentiation occur earlier than
those in signaling during t(8;21) leukemogenesis.
Summary/Conclusions: Using a comprehensive, deep sequencing approach
we could further characterize the mutational landscape of t(8;21) positive AML.
Here, mutation clusters in genes involved in TK signaling, ER and CC were
confirmed as well as novel CBF-associated gene mutations that play an essen-
tial role in regulation of hematopoietic cell proliferation and differentiation. Fur-
ther analyses in terms of sample size extension as well as correlation of findings
with clinical parameters are ongoing.
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NFKB PATHWAY PROMOTES TUMOR PROGRESSION THROUGH
BRUTON’S TYROSINE KINASE IN MLL+ ACUTE MYELOID LEUKEMIA
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Background: Mixed Lineage Leukemia’s (MLL’s) are characterised cytoge-
netically by reciprocal translocations of the MLL gene and clinically by
unfavourable outcomes. Evidence indicating that MLL leukemia’s are resistant
to apoptosis encourages the identification of novel drug targets. 
Aims: Using cord blood (CB) CD34+ cells (control) and CB CD34+ cells
expressing MLL-AF9, we sought to determine the potential role of BTK in the
development and progression of MLL+ leukemia. We further aimed to uncover
possible downstream target/s of BTK, improving the therapeutic efficacy of the
drugs used.
Methods: Experiments were performed using control and MA9.3 cells and
leukemic blasts from 3 AML (MLL+) patients. Signalling events were evaluated
by immunoblotting. p65 mediated BTK expression was determined by promoter
assays. Cells were treated with specific inhibitors of BTK (Ibrutinib (IBR): 0.25,
0.5, 1.0 and 2µM) in combination with Daunorubicin (DAU 5nM) or RAC (NSC
23766 (NSC): 5, 10, 15 and 20µM) for 48 hrs and cell viability was assessed
using Annexin V/ Sytox-Blue based flow cytometric analysis.
Results: To determine the relevance of BTK as a therapeutic target in
MLL+AML, we examined the whole cell lysates (WCL) from control cells, two
clones of CB expressing MA9 (MA9.3 and .6) and leukemic blasts from the 3
AML patients. Activated BTK (pY223) was detectable in both the clones of MA9
and MLL+AML samples. Interestingly, the cells demonstrated activation of p65
(pS536) but not in control cells. To address if activated p65 could potentially
drive BTK expression, we performed BTK promoter assays with reporter con-
struct and empty vector. MA9.3 cells electroporated with test construct demon-
strated significantly higher transcriptional activity. At the protein level, p65
inhibitor treatment (MG132 or Bay 11-7082) reduced total BTK expression, indi-
cating the involvement of activated p65 in the expression of BTK. Treatment of
control and MA9.3 cells with various concentrations of IBR for 48 hrs induced
a dose-dependent reduction of cell viability (Annexin V and Sytox blue nega-
tive). We further sought to determine if the use of IBR in combination with
Daunorubicin would further sensitize MA9.3 cells. The apoptotic rate of the
cells with combination treatment was significantly higher than that of cells treat-
ed with IBR or DAU alone. The coefficient of drug interaction (CDI) values indi-
cated that IBR-DAU combination synergistically reduced cell viability (CDI >1.0-
antagonistic; <1.0 synergistic and =1 additive effect). Recent studies suggested
RAC-GTPase signaling may also represent a target in AML, particularly in the
context of MLL gene rearrangements (Wei J et al., Cancer Cell 2008 and B
Mizukawa et al., Blood 2011). This intrigued us to test if BTK is possibly
upstream of RAC. We measured activation of the GTPase RAC via active RAC
pull down assay. Interestingly, treatment with IBRU significantly reduced RAC
activation, positioning BTK upstream of RAC. In line with observations reported
earlier; we also observed that MA9.3 cells are responsive to RAC inhibitor,
NSC. This effect of NSC on cell viability was further potentiated in combination
with IBR (0.5µM). CDI values once again indicated that the drugs together have
a synergistic effect on reducing the cell viability.
Summary/Conclusions: Taken together, our data support a biological link
between NFκB, BTK and RAC pathways in the modulation of cell survival in
MLL-rearranged AML cells. Aberrantly active p65 drives the expression of BTK
and contributes to the progression of the AML. Combination treatment using
IBR-DAU and IBR-NSC might be a promising therapeutic strategy, minimizing
high drug dose-related side effects but increasing the therapeutic efficacy.
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A PRECISION MEDICINE PLATFORM FOR ACUTE MYELOID LEUKEMIA
TO HELP UNRAVELING THE MOLECULAR ADDICTIONS OF FLT3-ITD-
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Background: Acute myeloid leukemia (AML) is an aggressive disease with
poor prognosis (Tzelepis et al. 2016). No single driver mutation is present in all
cases of AML, making its treatment a challenge (The Cancer Genome Atlas
Research 2013). Current standard of care for AML is an aggressive cytostat-
ics-based treatment that has remained unchanged for the past 30 years (Longo
et al. 2015). Weak or elderly patients might not be eligible for intensive treat-
ment, leading to poor survival rates. Many such patients are labeled as “untreat-
able”, although a portion of them could benefit from specific, individualized
treatment. A precision medicine strategy can help to find the specific treatment
for these ‘untreatable’ AML patients. 
Aims: Drug-driven personalized medicine aims to directly test the sensitivity of
primary cancer cells taken from individual AML patients to a selection of targeted
cancer drugs, compare these results with drug sensitivities of healthy donor
samples and select the most effective drug for each patient. This approach
considers any combination of mutations or epigenetic changes that might not
be found in the standard sequencing panels, an advantage when dealing with
such a heterogeneous disease. Proof of principle of this strategy was recently
demonstrated by FIMM (Helsinki, Finland) (Pemovska et al. 2013), not only
providing immediate clinical benefit to leukemia patients, but also identifying
drugs that can potentially be repurposed for future treatment of patients.
Methods: We have established a drug-driven personalized medicine platform
for AML where we check the ex-vivo drug sensitivity and resistance of bone
marrow primary cells to a panel of around 400 drugs and drug combinations
covering the standard of care treatments, cancer chemotherapeutics as well
as many clinically available and emerging molecularly targeted compounds.
We calculate the IC50 values for all the drugs for each individual donor or
patient, and then the differential drug sensitivity scores, selecting the drugs
that affect preferentially the cancer cells when compared with healthy cells. To
date we have successfully processed 6 healthy donors and 66 AML samples
identifying subgroups of patients who respond with a similar dynamic to certain
classes of drugs, as the subgroup of cells carrying internal tandem duplications
in the receptor tyrosine kinase FLT3 (FLT3-ITD).
Results: FLT3 activating mutations, particularly FLT3-ITD, have been observed
in approximately 30% of AMLs (The Cancer Genome Atlas Research 2013),
and are associated with increased risk of relapse and poor clinical outcome
(Abu-Duhier et al. 2008). The cellular pathways that support FLT3-ITD-driven
cell proliferation and survival remain poorly understood. We discovered that
FLT3-ITD-expressing AML blasts show an enhanced sensitivity to HSP90
inhibitors such as Ganetespib compared to healthy donors and any other sub-
groups of leukemia. In addition, HSP90 inhibitors specifically sensitize FLT3-
ITD-expressing bone marrow-derived cells to TKIs, whereas cells derived from
healthy donors are unaffected. HSP90 inhibitors also preferentially eradicate a
population of patient-derived FLT3-ITD+ AML cells expressing leukemic stem
cell markers.
Summary/Conclusions: In summary, our study reveals a molecular basis for
HSP90 addiction of FLT3-ITD-driven AML and provides a rationale for treatment
of this form of AML with HSP90 inhibitors.
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SECRETION OF SOLUBLE FACTORS BY AML CELLS INFLUENCE
CD33/CD3 BITE® ANTIBODY MEDIATED CYTOTOXICITY AND T-CELL
PROLIFERATION
M. Costanzi1,2,*, C. Krupka1,2, R. Kischel3, P. Kufer3, T. Köhnke1,2,
K. Spiekermann2,4, W. Hiddemann2,4, M. Subklewe1,2,4
1Laboratory for Translational Cancer Immunology - Gene Center, 2Department
of Internal Medicine III, Hospital of the Ludwig-Maximilians-University (LMU)
Munich, 3AMGEN Research GmbH, Munich, 4German Cancer Consortium
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Background: In our previous work, we showed that the CD33/CD3 BiTE® anti-
body construct (AMG 330) is able to recruit autologous, residual T cells and
induce cytotoxicity against primary AML cells ex vivo. However, as described
previously (Mussai et al, Blood 2013) primary AML cells are able to secrete
soluble factors, which might not only influence T-cell proliferation but also neg-
atively impact AMG 330 mediated cytotoxicity.
Aims: In this study we characterized the influence of soluble factors secreted
by primary AML cells on AMG 330 mediated cytotoxicity.
Methods: We used plasma samples (from heparinized serum tubes or after
density gradient centrifugation) from newly diagnosed and relapsed AML
patients in AMG 330 cocultures of healthy donor (HD) T cells and AML cell
lines. In flow cytometry based experiments we determined the influence of AML
plasma in comparison to fetal calf serum (FCS, heat inactivated) on AMG 330
mediated cytotoxicity and T-cell proliferation. In transwell experiments using
primary AML cells physically separated from AMG 330 cocultures, we evaluated
if AML cells are the source of soluble factor secretion. 
Results: The influence of AML plasma from bone marrow (BM) of AML patients
on AMG 330 mediated cytotoxicity and T-cell proliferation was heterogeneous:
In 15/30 samples, AMG 330 mediated cytotoxicity was significantly reduced
compared to cultures containing FCS (mean% specific lysis FCS vs BM: 72.8
vs 25.1). This was accompanied by a reduction in T-cell proliferation (mean%
proliferation FCS vs BM: 27.7% vs 9.5%). The degree of immunosuppression
could not be correlated to percentage of bone marrow blasts. Interestingly, the
effect was not observed in AML plasma samples from peripheral blood (PB)
(mean% specific lysis FCS vs PB: 84.7 vs 83.5;% proliferation FCS vs PB 32.2
vs 36.5, n=19). In the remaining 15 plasma samples from AML BM no influence
on AMG 330 mediated T-cell function was observed (mean% specific lysis FCS
vs BM: 82.1 vs 78.3;% proliferation FCS vs BM: 25.7 vs 26.8). In control cultures
plasma from AML patients in complete remission (CR) or from HD BM was
used which did not negatively impact AMG 330 mediated cytotoxicity (mean%
specific lysis FCS vs CR: 95.6 vs 94.4, n=5; FCS vs HD: 89.6 vs 90.5, n=6), or
T-cell proliferation (FCS vs CR: 76.6 vs 68.2; FCS vs HD: 58.9 vs 65.4). To fur-
ther explore the influence of soluble factors from primary AML cells, we per-
formed transwell experiments. Primary AML cells were cultured in the previously
described long term culture system (Krupka et.al, Leukemia 2016) and HD T
cells and MOLM 13 cells were placed in transwell devices (3µm). In analogy to
our findings with AML BM plasma, we observed a strong reduction in AMG 330
mediated cytotoxicity and T-cell proliferation in 7/14 experiments (mean% spe-
cific lysis control vs AML: 95.0 vs 70.8;% proliferation control vs AML 78.6 vs
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41.8, n=7). In the remaining 7 primary AML samples, no immunosuppressive
effect was observed (mean% specific lysis control vs AML 98.9 vs 98.2;% pro-
liferation control vs AML 82.8 vs 77.7, n=7).
Summary/Conclusions: In summary we demonstrated that BM derived plas-
ma from AML patients at primary diagnosis or relapse reduced T-cell prolifer-
ation and AMG 330 mediated cytotoxicity in half of the samples tested. The
immunosuppressive factors were secreted by primary AML cells as demon-
strated by transwell experiments. Unraveling mechanisms of resistance to
BiTEÒ antibody mediated cytotoxicity will allow the exploitation and usage of
enhanced strategies to increase response rates.
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CLONAL EVOLUTION OF FLT3-ITD POSITIVE AML AT DIAGNOSIS AND
RELAPSE IN PATIENTS TREATED WITHIN THE CALGB 10603 (RATIFY)
AND AMLSG 16-10 TRIALS
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Background: Internal tandem duplications (ITD) in the receptor tyrosine kinase
FLT3 occur in about 22% of patients (pts) with acute myeloid leukemia (AML)
and confer a poor prognosis depending on the mutational load. The multi-tar-
geted tyrosine kinase inhibitor (TKI) midostaurin has been shown to improve
outcome in FLT3-ITD positive (FLT3-ITDpos) and FLT3-TKD mutated (FLT3-
TKDmut) pts in combination with intensive chemotherapy [CALGB 10603 (RAT-
IFY) trial], thus representing a promising targeted treatment approach. How-
ever, a significant number of pts relapse after initial response due to yet
unknown mechanisms.
Aims: To study the clonal evolution in FLT3-ITDpos pts treated in the AMLSG16-
10 (NCT01477606) or CALGB 10603 (RATIFY, NCT00651261) trial in paired
samples obtained at diagnosis (Dx), complete remission (CR) and relapse (Rel)
by whole exome sequencing (WES).
Methods: WES was performed in 17 FLT3-ITDpospts using the Nextera Rapid
Capture Exome kit (Illumina) for library preparation followed by sequencing on
a Illumina HiSeq2000. 6 pts were treated in the RATIFY trial receiving either
midostaurin or placebo combined with intensive chemotherapy during induction
and consolidation; 11 pts were treated in the AMLSG16-10 trial, which includes
treatment with midostaurin combined with intensive chemotherapy during
induction and consolidation followed by a one-year maintenance therapy with
midostaurin; 4 pts in the AMLSG16-10 trial received allogeneic hematopoietic
cell transplantation. The presence of FLT3 and NPM1 mutations (mut) and the
allelic ratio (AR) of FLT3-ITD were analyzed according to standard protocols.
Results: The median AR of FLT3-ITD was 0.51 (0.10-18.94) and 0.54 (0.07-
26.31) at Dx and Rel, respectively. Loss of FLT3-ITD was observed in 5 pts;
changes of the ITD clone at Rel occurred in 7 pts. Of those, 5 pts had a change
of the insertion site and 1 pt gained an additional ITD clone at Rel. 3 pts had a
D835Y FLT3-TKDmut that was lost at Rel. 6 pts had a NPM1mut that persisted
at Rel in all pts. Using WES, 301 mut (226 missense, 24 nonsense, 41 indels,
6 splice sites, 4 unknown) were identified. The average coverage was 125
(186-67) among all samples. 131 (43%) mut were present at both time points
(Dx and Rel). 83 (28%) mut were found only at Dx or only subclonal at Rel. 73
(24%) mut were detected only at Rel and 14 mut with only 1 read at Dx. Besides
FLT3-ITD, the average number of mut per sample (Dx or Rel) was 13. Mut
were most frequently observed in genes related to signaling (23%), transcription
(20%), DNA methylation (5%), chromatin-cohesin (4%), components of the
membrane (4%) and ubiquitin-proteasome (4%). Pre-leukemic mut (DNMT3A,
TET2, IDH1/2) were detectable in 10 pts at both time points and persisted at
CR in 7 pts. Recurrent mut in transcription related genes occurred in 8 pts at
Dx and Rel, with WT1 mut being most frequent (n=7). Mut in signaling related
genes present at both time points included NRAS (G12V/D) and NF1 mut. At
the time of Rel, gene mut frequently referred to signaling (34%) including a
KRAS (G13D) and a KIT (D816V) mut, both in pts with loss of FLT3-ITD at Rel.
Summary/Conclusions: Analyzing the clonal evolution of FLT3-ITDpos AML,
known pre-leukemic mut were stably detectable at Dx and Rel in most pts,
whereas known signaling related gene mut were also acquired at Rel. To further
investigate more comprehensively pathways underlying therapy resistance
with a focus on TKI treatment, larger cohorts of pts are currently analyzed for
the detection of recurrent mutational patterns.
E869
MICROENVIRONMENT SECRETED PROTEINS MEDIATE RESISTANCE TO
TARGETED THERAPY IN PRIMARY AML CELLS 
A. Dokal1,*, J. Gribben1, P. Cutillas1
1Haemato-Oncology, Barts Cancer Institute, London, United Kingdom
Background: The bone marrow stromal microenvironment (BMSM) plays an
important role in the pathophysiology of acute myeloid leukemia (AML). This
is demonstrated by primary AML blasts dependence on stromal conditioned
media to survive  long-term in culture. Although some of the components of
the stromal secretome (the totality of secreted proteins by biological cells) that
augment AML survival are known, the precise molecular mechanisms of the
stromal-blast interactions are not fully defined.
Aims: i) Identify proteins secreted by bone marrow stromal cells that mediate
AML survival; ii) Investigate global changes in signalling pathway activity
induced by stromal factors in primary AML; iii) Validate the functional signifi-
cance of these interactions through targeted inhibition of BMSM activated sig-
nalling pathways.
Methods: We used primary AML cells and established cells lines. Four different
human AML lines were grown individually or in co-culture with a mouse bone
marrow stromal line (MS-5). The resulting conditioned medium from these
experiments (4 AML lines alone, 4 AML lines + MS-5, MS-5 alone) was purified
to obtain the secretome (in triplicate). Proteins in these secretomes were quan-
tified using Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS).
Peptide sequence searches against both mouse and human proteomes
allowed for discrimination between the mouse stromal and human AML pro-
teins. Guava EasyCyte Flow Cytometry was used to measure the viability and
proliferation of these cell populations, assessing the capabilities of the identified
factors above on primary AML cells (n=6) as well as the effects of kinase
inhibitors Torin-1, Trametinib, Tofacitinib and Midostaurin over 72hrs with and
without stromal conditioned media (n=10). Label-free LC-MS/MS based phos-
phoproteomics quantified >5,000 phosphorylation sites in primary AML patient
cells treated with identified stromal factors individually and combined in tripli-
cate. Commercial (MASCOT) and in-house (PESCAL, KSEA) software were
utilised to identify and quantify proteins, determine kinase activities and interpret
intracellular signalling.
Results: Initially by comparing secretomes of the four AML lines (on their own
or in MS-5 co-culture) we identified 520 bone marrow stromal proteins and 293
AML blast proteins. From these, six stromal proteins were selected (including
S100-A11, connective tissue growth factor [CTGF] and bone morphogenic pro-
tein-1 [BMP-1]) based on their ability to effect growth and likely signalling capac-
ity in AML cells. These six proteins were used in varying combinations to deter-
mine their effect on growth of  primary AML cells from patients (n=6). We also
analysed the phosphoproteomes of primary AML cells displaying the maximal
effects on growth in response to the six factors above to determine the under-
lying biological mechanisms. These studies  have shown that several different
pathways are activated as a result of secretome treatment including mTOR
and MAPK. Primary AML cells were sensitive to targeted inihibition of these
pathways. However, the inclusion of stromal secreted factors to the same AML
cells would induce sensitivity towards another kinase inhibitor and insensitvity
towards the previously effective inhibitor.
Summary/Conclusions: This proteomic approach has allowed identification
of a panel of key proteins (including S100-A11, CTGF, BMP-1) secreted by the
stromal cells that modulate cell signalling and cell fate in AML blasts. Using a
proteomic  approach to study growth factor effects we were able to dissect the
factor specific effects on AML signalling. Subsequent survival assays and tar-
geted inhibition studies demonstrate that despite heterogeneity in patient
response to these factors, activity in key signalling pathways such as MAPK
and mTOR switch under stromal influence. These observations suggest that
resistance to targeted therapies in vivo in part may arise from changes that
AML cells induce in the microenvironment.
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Background: Internal tandem duplications (ITD) and mutations (mut) in the
tyrosine kinase domain (TKD) of the receptor tyrosine kinase FLT3 occur in
about 25% of acute myeloid leukemia (AML) patients (pts). FLT3-ITD is asso-
ciated with an unfavorable prognosis in particular in pts with a high allelic mutant
to wildtype ratio (AR;>0.5) as well as localization of the ITD in the beta1-sheet
of the receptor. FLT3is targetable by tyrosine kinase inhibitors (TKI) and the
combination of chemotherapy with the TKI midostaurin has been recently inves-
tigated within the CALGB 10603 RATIFY trial and is still under investigation
within the AMLSG 16-10 trial.
Aims: To study the FLT3mut status at the time of diagnosis (Dx), refractory dis-
ease (RD) and relapse (Rel) in AML pts treated within the CALGB 10603 (RAT-
IFY, NCT00651261) and AMLSG 16-10 (NCT01477606) trial with regard to AR
of FLT3-ITD and FLT3-TKDmut, loss of FLT3-ITD and FLT3-TKDmut and change
of ITD clones (ITD insertion site, length, number of clones).
Methods: FLT3-ITD and FLT3-TKDmut were detected using Genescan-based
fragment-length analysis according to standard protocols. In the randomized
phase-III RATIFY study, FLT3mut pts were treated with induction (daunorubicin/
cytarabine) and consolidation (high-dose cytarabine) plus midostaurin or place-
bo, followed by maintenance therapy with midostaurin or placebo for 1 year.
The phase-II AMLSG 16-10 trial evaluates midostaurin in induction, consolida-
tion (allogeneic hematopoietic cell transplantation or high-dose cytarabine) and
maintenance therapy in FLT3-ITD positive pts.
Results: In total, 83 pts were analyzed, of which 33 were treated in the RATIFY
and 50 within the AMLSG 16-10 trial. 36 pts had RD and 47 pts had relapsed.
FLT3-ITDwas present at diagnosis in all pts treated in the AMLSG 16-10 trial;
one pt had an additional FLT3-TKDmut. Pts entered in the RATIFY trial had
either a FLT3-ITD (n=22), a FLT3-TKDmut (n=9), or both (n=2). The median AR
of FLT3-TKDmut at Dx was 0.82 (0.07-2.66) and the majority of pts showed
loss of FLT3-TKDmut at RD or Rel (n=9/12; 75%). In relapsed pts, loss of FLT3-
ITD occurred in 14 (36%) pts. There was no significant difference between the
median FLT3-ITD AR at Dx [0.62 (0.10-18.94)] and Rel [0.65 (0.07-38.75);
p=.98]. A shift of the ITD clone was found in 14 (36%) pts at Rel, with switch of
the ITD insertion site or length in 8 (21%) pts. 8/14 pts with change of the ITD
clone at Rel had multiple ITD clones at Dx. For 35 FLT3-ITDpositive pts with
refractory AML, FLT3-ITD loss was observed in 17 (49%) pts. The median AR
of FLT3-ITD was significantly lower at the time of RD [0.29 (0.05-2.37)] com-
pared to Dx [0.58 (0.05-8.91); p=.002]. The ITD clone changed in 5 (14%) pts
with RD. In pts with shift of the ITD clone at RD (n=5) or Rel (n=14), no signif-
icant difference of the median ITD length was observed (p=.84).
Summary/Conclusions: Comparing the FLT3-ITD status at Dx, at the time of
RD or Rel, we found a lower median AR of FLT3-ITD in pts at RD compared to
Dx, whereas no significant change of AR was observed at Rel. In addition, loss
of FLT3-ITD was observed in 49% of pts at RD and in 36% of pts at Rel. These
findings suggest that the FLT3-ITD clone can be targeted in a significant number
of pts and other clones might mediate resistance to treatment. We also
observed a switch of the ITD clone in about 20% of pts with Rel, indicating the
presence of ITD subclones at the time of Dx that might confer resistance to
treatment. Despite the small number of TKD mutations in our study, it was
remarkable that most of the TKDs (75%) were lost at the time of RD or Rel.
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A NOVEL PML-RARG FUSION IN ACUTE PROMYELOCYTIC LEUKEMIA
J.-S. Ha1,*, C.-S. Ki2, C. Lee3, D.-H. Kim1, Y.-R. Do1, W.-M. Lee1, N.-H. Ryoo1,
D.-S. Jeon1
1Keimyung University School of Medicine, Daegu, 2Sungkyunkwan University
School of Medicine, 3Samsung Genome Institute, Seoul, Korea, Republic Of
Background: Acute promyelocytic leukemia (APL) is a unique subtype of acute
myeloid leukemia (AML) characterized by specific translocation involving
retinoic acid receptor alpha (RARA) locus. Retinoic acid receptor (RAR) is a
member of nuclear receptor family, and has three types of isoforms such as
RARA, reinoic acid receptor beta (RARB) and retinoic acid receptor gamma
(RARG). These RARs share high structural homology (90%). Although the
oncogenic properties of the artificial PML-RARG fusion gene was observed in
an in vitro study, there has been no report on the PML-RARG fusion in human
APL patients. 
Aims: We report here a novel PML-RARG rearrangement in a patient with AML
displaying suitable morphologic and immunophenotypic features of the classic
hypergranular APL.
Methods: Whole genome sequencing (WGS) and further analysis of mRNA
and gDNA were performed to clarify the atypical gene rearrangement observed
by karyotyping and FISH. 
Results: Laboratory, morphology and immunophenotypic analysis results sug-
gested the classic APL with hypergranular type. A clonal translocation
t(12;15)(q13;q22) was identified by karyotyping. No evidence of fusion of PML-
RARA was detected by RT-PCR and PML-split was found on FISH analysis
using PML-RARA dual color dual fusion probes. WGS analysis performed to
clarifying the partner gene of PML located on chromosome 12q13 strongly sug-
gested a PML-RARG fusion. RT-PCR following sanger sequencing were per-
formed to verify the presence of PML-RARG fusion transcript, then two kind of
transcripts was detected, one with the fusion of PML exon 3 and the middle
part of exon 1 of RARG and the other with the fusion of PML exon 3 and exon
2 of RARG. The breakpoint of DNA was clarified on intron 3 of PML and 5’
region of RARG. Despite of ATRA treatment for 9 days, cell count did not show
any response. Then induction chemotherapy composed of idarubicin and
cytarabine was combined on ATRA. ATRA was finally stopped after 18 days,
then cytogenetic remission was acquired day 36 after induction therapy.
Summary/Conclusions: We first report the presence of PML-RARG fusion in
a human APL patient. This report supports the possibility of a new molecular
mechanism involving RARG not RARA in APL and suggests the need of differ-
ent therapeutic approach for this variant case showing the potential ATRA resist-
ance. 
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COOPERATION OF MLL-PTD WITH DNMT3A OR RUNX1 MUTATIONS IN
AML LEUKEMOGENESIS
H.-W. Kao1,*, R. Bera2, Y.-J. Huang2, J.-F. Fu2, D.-C. Liang3, L.-Y. Shih1
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Background: Our previous study showed that DNMT3A or RUNX1 mutations
were frequently coexisted in the MLL-PTD AML patients (Oncotarget 2015).
Aims: We aimed to investigate the role of coexisted DNMT3A or RUNX1 muta-
tions in leukemogenesis of MLL-PTD AML. 
Methods: After lentiviral-mediated over-expression of RUNX1 or DNMT3A
mutants in MLL-PTD mouse bone marrow (BM) cells or human MLL-PTD+ AML
cell lines, colony formation, cell proliferation, differentiation and apoptosis
assays were carried out. Interaction of RUNX1, HIF-1α, and MLL-PTD were
evaluated by co-immunoprecipitation assay. Differential genes and protein
expression, histone modifying protein expression, and enrichment of histone-
4 acetylation (H4Ac) were assessed by RT-qPCR, Western blot, and ChIP-
qPCR, respectively. For BM transplantation assays in mice, MLL-PTD+ BM
cells over-expressing DNMT3A-wild type (Wt)/mutants and empty vector (EV)
control were injected into C57BL/6 mice via tail vein.
Results: We observed that MLL-PTD mouse BM cells with RUNX1 mutants
lacking C-terminal VWRPY sequence (H377fsX and V425fsX576) had increased
self-renewal, proliferation, increased HIF-1α and its downstream gene expres-
sion. In addition, the interaction of HIF-1α and MLL-PTD was disrupted in the
cells transduced with C-terminal truncated RUNX1 mutants or RUNX1 shRNA.
Compared with those expressing DNMT3A mutants, over-expression of
DNMT3A-Wt reduced cell growth, colony formation and self-renewal activities
of EOL-1 and MLL-PTD+ BM cells. All DNMT3A mutants impaired Na-butyrate-
induced differentiation, but only R882H mutant impaired ATRA-induced differ-
entiation in vitro. DNMT3A mutations were associated mostly with up-regulation
of homeobox B (HOXB) genes. The expressions of BCL2A1, AREG, PRKCA,
HLX, hBEGF and MCL1 were increased in the DNMT3A-mutant cells compared
to those of DNMT3A-Wt. Cells with DNMT3A mutants showed a reduction of
H4Ac enrichment at the HOXB and HOXC12 promoter regions compared to the
control cells or the cells with DNMT3A-Wt. DNA methylation microarray analysis
identified both hypo- and hypermethylation features in different regions through-
out the whole genome of DNMT3A mutants-transduced EOL-1 cells. Up-regu-
lated genes including HLX and hBEGF were hypomethylated in the EOL-l cells
transduced with DNMT3A mutants. In vivo study showed that white blood cells
including neutrophils, lymphocytes and monocytes increased significantly
(P<0.03) in the DNMT3A-mutants mice compared to EV or Wt- mice at 10
months post-BM transplantation.
Summary/Conclusions: The present study showed that both RUNX1 and
DNMT3A mutants dysregulated self-renewal, proliferation and apoptosis in the
mouse MLL-PTD BM cells. Disruption of MLL-PTD-RUNX1-HIF-1α complex in
the RUNX1-mutant and aberrant methylation in the DNMT3A-mutant cells might
play an important role in AML pathogenesis. Our results showed that coopera-
tive RUNX1 or DNMT3A mutations had impact on leukemogenesis of MLL-
PTD AML.
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AML BLASTS INDUCE A SENESCENT PHENOTYPE IN THE BM-MSC
THROUGH THE UPREGULATION OF P21
E. Forde1,*, A. Abdul-Aziz1, T. Mehta2, F. Di Palma2, C. Ingham3, M. Lawes4,
K. Bowles14, S. Rushworth1
1Norwich Medical School, University of East Anglia, 2Earlham Institute, 3Depart-
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Background: Acute myeloid leukaemia (AML) is a heterogeneous clonal dis-
order that arises from the haematopoietic myeloid progenitor cells within the
haematologica | 2017; 102(s2) | 359
Madrid, Spain, June 22 – 25, 2017
bone marrow microenvironment (BMM). Survival of patients with AML is
presently poor; two-thirds of younger adults and 90% of older adults die of their
disease. Even in patients who achieve remission with chemotherapy, relapse
is common and occurs from minimal residual disease sequestered in protective
niches in the BMM. Reciprocal interactions between that of the AML and bone
marrow mesenchymal stromal cells (BM-MSC) are central to the survival and
progression of the leukaemic blasts through micro-environmental promotion
of quiescence in malignant cells as well as the activation of anti-apoptotic and
pro-survival pathways.
Aims: To investigate how BM-MSC are programmed by AML to generate a
pro-tumoural environment.
Methods: Primary AML and BM-MSC were isolated from the pelvis of AML
patients following informed consent and under approval from the UK National
Research Ethics Service (LRCEref07/H0310/146). Low input RNASeq of 10
AML BM-MSC and 10 healthy BM-MSC (taken from the pelvis of patients
undergoing elective hip replacement surgery) was performed following CD271
MicroBead selection. Primary AML blasts 1x106 were co-cultured on confluent
primary BM-MSC for 48 hours (h), 72h and 168h. Real-time PCR was used to
verify the RNA sequencing data and Western Blot analysis to confirm protein
expression. Lentivirus mediated knockdown was used to target gene expres-
sion in the BM-MSC. Senescence was assayed by β-Galactosidase staining.
Results: Results from the RNA sequencing carried out to compare 10 healthy
and 10 AML BM-MSC show that 1125 genes were differentially expressed, with
924 down-regulated in AML derived BM-MSC and 201 up-regulated. From this
analysis, we found that CDKN1A (p21) is up-regulated in BM-MSC from AML
patients (7.406 logFC) compared to BM-MSC from patients with normal bone
marrow. Further analysis of p21 mRNA expression confirmed an increase in
AML BM-MSC compared to normal BM-MSC. In-vitro experimentation showed
that p21 mRNA and protein expression is increased in BM-MSC when co-cul-
tured with primary AML. Furthermore, we show that AML increased senescence
β-Galactosidase staining in BM-MSC and that p21 knockdown in BM-MSC
reversed the senescent phenotype. Finally, primary AML cultured on p21 knock-
down BM-MSC had reduced survival compared to control BM-MSC.
Summary/Conclusions: We have identified that AML induces a senescent
BM-MSC niche via the p21 mediated pathway which in turn promotes survival
and proliferation of AML. Silencing of p21 within the BM-MSC reduces AML
survival. In identifying this novel microenvironment feedback loop in AML we
highlight a potential new target for future AML therapies.
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HYPOXIA DRIVES AML PROLIFERATION IN THE TUMOR
MICROENVIRONMENT THROUGH HIF1Α/MIF SIGNALLING
A. Abdul-Aziz1,*, M. Shafat1, C. Marlein1, R. Piddock1, S. Robinson2,
D. Edwards1, Z. Zhou1, A. Collins3, K. Bowles1,3, S. Rushworth1
1Norwich Medical School, 2School of Biological Sciences, University of East
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Background: The bone marrow microenvironment is hypoxic and furthermore
hypoxia contributes to the development and maintenance of acute myeloid
leukemia (AML) cells within the bone marrow microenvironment. The hypoxic
state is principally maintained by members of the hypoxia-inducible factor (HIF),
in particular HIF1a and its target genes, including MIF. We have previously
shown that AML cells express constitutively high macrophage migration inhibito-
ry factor (MIF) which drives IL-8 expression by the BM-MSC which in turn sup-
ports AML cell survival and proliferation (Abdul-Aziz et al, 2017).
Aims: The aim of the present study is to determine the role of hypoxia in reg-
ulating MIF signalling in AML.
Methods: Primary AML were isolated from the bone marrow and peripheral
blood of AML patients following informed consent and under approval from the
UK National Research Ethics Service (LRCEref07/H0310/146). Differential
expression analysis of RNA sequencing data (GEO ID: GSE49642) was used to
compare hypoxia-associated gene expression of BM AML blasts with AML blasts
obtained from the peripheral blood (PB). AML cell lines and primary AML blasts
were cultured under normoxic (20% oxygen) or hypoxic conditions (1% oxygen).
MIF mRNA expression was determined by RT-PCR and protein was determined
using target specific ELISA. HIF1a protein expression was determined by western
blotting. Lentiviral-knockdown of MIF and HIF1a were performed on AML blasts
prior to in-vivo xenograft mouse model injection. Finally, in-vivo analysis of the
MIF inhibitor, ISO-1, was performed in the AML xenograft model.
Results: Our results show that MIF gene expression was significantly higher
in AML samples from the BM compared to those from PB. To determine If MIF
is regulated by HIF1a in AML cells, we mimicked the hypoxic conditions of the
BM using CoCl2, DFO and a hypoxic chamber. We found that 1% O2, CoCl2
and DFO upregulate MIF transcription and protein expression in OCI-AML3
cell lines and in primary AML blasts. Lentiviral mediated KD of HIF1a decreased
MIF expression in human AML cells and significantly reduced leukaemic pro-
liferative capacity. Moreover, KD of HIF1a in OCI-AML3 significantly increased
survival of NSG mice compared to control-KD. Finally, in-vivo lentiviral mediated
knockdown of MIF and pharmacological targeting of MIF using ISO-1 signifi-
cantly increased survival of AML xenografts.
Summary/Conclusions: The results reported here suggest that hypoxia sig-
nificantly affects the expression of the pro-tumoural cytokine MIF in AML blasts
and that this hypoxia regulated HIF1a/MIF axis supports AML blast survival in
the bone marrow niche.
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BONE MARROW ECOLOGICAL COLLAPSE IN ACUTE MYELOID
LEUKEMIA IS MEDIATED BY REMODELING OF ENDOSTEAL VESSELS
D. Duarte1,2,*, E.D. Hawkins1, O. Akinduro1, H. Ang1, K. De Filippo3, M. Hal-
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Institute, 3National Heart & Lung Institute, Imperial College London, London,
United Kingdom, 4Hamilton Institute, Maynooth University, Dublin, Ireland,
5Institute of Clinical Sciences, Imperial College London, London, United King-
dom, 6Stem Cell Regulation Unit, St Vincent’s Institute of Medical Research,
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Background: Bone marrow vascular niches have been proposed to support
acute myeloid leukemia (AML) growth. However, anti-angiogenic therapies do
not improve patient outcome suggesting that a complex relationship between
AML cells and the microenvironment influences the disease process.
Aims: We aim to study the complex vascular remodelling occuring during AML
progression.
Methods: Using a murine model of AML we performed intravital microscopy to
investigate leukemia behavior in the bone marrow. 
Results: We show AML is an invasive species causing highly localized disrup-
tion of the endosteal stroma and outcompeting non-malignant cells. Particularly
affected are endosteal microenvironments containing osteoblastic cells and
type H endothelium, typically associated with hematopoietic stem cells (HSCs).
In contrast, splenic endothelial cells expand, suggesting de novo niches in the
spleen could potentially support extramedullary hematopoiesis in leukemia.
Intravital microscopy further revealed that the endothelium in AML is more
adhesive and permissive to transendothelial migration of hematopoietic cells.
Pharmacological intervention known to induce type H endothelium preserved
HSCs in endosteal areas of diseased mice.
Summary/Conclusions: Together, these data suggest that AML-induced vas-
cular damage contributes to cell egress from the bone marrow, and that new
therapeutic approaches aiming to normalize bone marrow vasculature may
support normal hematopoiesis.
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CLONAL HETEROGENEITY IN PATIENT-DERIVED XENOGRAFT OF
ADULT ACUTE MYELOID LEUKAEMIA
F. Gonzales1,2,*, P. Peyrouze2, T. Boyer2,3, S. Guihard2, N. Helevaut3,
J. Preudhomme3, S. Geffroy3, C. Roumier3, B. Quesnel2,4, C. Preudhomme2,3,
M. Cheok2
1Service d’hématologie pédiatrique, CHU Lille, 2UMR-S 1172, Inserm, 3Labo-
ratoire d’hématologie, 4Service des Maladies du Sang, CHU Lille, Lille, France
Background: Acute myeloid leukaemia (AML) is the most common leukaemia
in adults. Currently, despite intensive chemotherapy and bone marrow trans-
plantation, outcome is still dismal. In particular, therapeutic stratification remains
suboptimal, which is largely attributed to the clinical and molecular heterogene-
ity of AML.
Aims: To better characterize and study this heterogeneity, we developed an in
vivo model of AML using patient derived xenografts (PDX).
Methods: Blasts cells obtained from bone marrow of 45 de novo AML were
intravenously injected into NOD-scid gamma (NSG) mice. Engraftment was
surveyed by chimerism of CD45 (human versus murine) by flow cytometry. At
sacrifice (peripheral blast count greater than 70% or clinical sign of illness),
cells collected from bone marrow and spleen were used to perform targeted
sequencing (AmpliSeq, Thermo Fisher Scientific®) and gene expression analy-
ses (HG-U133 Plus 2.0 microarray, Affymetrix®). Bone marrow cells were seri-
ally transplanted into secondary and tertiary animals. We then compared muta-
tional and gene expression profiles of patient samples at diagnosis and corre-
sponding PDX samples.
Results: Eighteen out of 45 injected samples (40%) successfully engrafted
into mice with a median delay of 2.5 months (range : 26-154 days). Leukaemia
infiltration into bone marrow was concordant with peripheral blood and spleen
infiltration. Successful xeno-engraftment was linked to younger age (50 vs 61
years, p=0.04) and elevated white blood cell counts at diagnosis (132 vs 35
G/L, p=0.001). No association was found between engraftment and karyotype
or ELN classification. Relapse free survival (RFS) was worse for patients with
successful PDX (0.3 vs 0.9 years, p=0.017). Despite previous reports suggest-
ing better engraftment of AML harbouring FLT3-ITD mutations, we did not find
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a preferential engraftment in the presence of FLT3-ITD mutation (9 of 18). Fur-
thermore, we found that the mutational fraction of 3 out of 4 patients harbouring
a FLT3-ITD mutation enriched for this mutation in the primary PDX and then
remained stable in subsequent xenotransplantations. Similarly, eight PDX with
respective primary AML were analysed by next-generation sequencing (NGS)
of 27 AML relevant genes. We found stable variant allele fractions (VAF) among
the primary and serial PDX bone marrows and spleens for 50 mutations (6
mutations on average per patient); except for DNMT3A and NRAS mutations,
which were lost each for one AML sample at the secondary PDX. Concordantly,
gene expression profiles were stable between primary patient sample and serial
PDX samples up to the tertiary xenograft.
Summary/Conclusions: NSG mice xenotransplantation may be a clinical rel-
evant model for in vivo studies of clonal heterogeneity in AML and may be used
as preclinical model to test novel therapies.
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ANTIBODY CONSTRUCT MEDIATED T-CELL ACTIVATION
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Background: The CD19/CD3 BiTE® antibody construct, blinatumomab, has
been approved in Ph-, relapsed/refractory B-cell precursor Acute Lymphoblastic
Leukemia (ALL). Despite the promising response rate of 43% in heavily pre-treat-
ed ALL patients, reasons for resistance have not been determined. In contrast to
classical T-cell activation, BiTE® antibody construct mediated T-cell activation
relies solely on binding to the CD3ε chain of the T-cell receptor (TCR) complex.
Resolving the exact mechanism of BiTE® antibody construct mediated T-cell acti-
vation is a prerequisite for our understanding of mechanisms of resistance.
Aims: In the present study we characterized the role of costimulation on intra-
cellular signalling in CD33/CD3 BiTE® antibody construct (AMG 330)-mediated
T-cell activation.
Methods: We generated a murine cell line stably expressing human CD33 and
devoid of human costimulatory molecules (B33). In in vitro cocultures, cytotox-
icity against B33 cells and the AML cell line MOLM-13 was evaluated by flow
cytometry. Activation of downstream signalling pathways was assessed by a
phospho-flow cytometry protocol for T-cell recruiting antibodies.
Results: Coculture of B33 cells with CD3+ healthy donor T cells (n=4) resulted
in AMG 330 mediated mean cytotoxicity of 58.3%. In contrast, MOLM-13 cells
were completely lysed (% specific lysis relative to control B33 vs MOLM-13:
58.3±32.9 vs 99.9±0.1, n=4), despite comparable CD33 expression levels (CD33
median fluorescence intensity (MFI) ratio: B33 116.1 vs MOLM-13 67.6). How-
ever through the addition of an anti-CD28 antibody or recombinant human IL-2,
cytotoxicity against B33 cells could be restored (% specific lysis AMG 330 vs
AMG 330 + anti-CD28 vs AMG 330 + IL-2: 58.3±32.9 vs 82.6±11.1 vs 91.3±9.0).
At lower E:T ratios (1:4) the additional costimulatory signal also increased AMG
330 mediated cytotoxicity against MOLM-13 cells (mean MFI Ratio of CD80 and
CD86 on MOLM-13 cells: 1.4±1.2 and 3.0±1.0 respectively, n=3) (% specific
lysis AMG 330 vs AMG 330 + anti CD28: 65.1±19.7 vs 80.7±16.1, n=3). We
next analysed intracellular Akt and Erk phosphorylation levels of T cells after
stimulation with AMG 330 or a control BiTE® antibody construct (cBiTE®) and
MOLM-13 cells. Crosslinked anti-CD3/anti-CD28 antibodies served as positive
control. In the presence of target cells, AMG 330 induced significantly lower Akt
and Erk phosphorylation (mean% phosphorylated (p)Akt and pErk 7.9 and 7.6,
n=3-5) compared to crosslinked CD3/CD28 antibodies (mean% pAkt and pErk
43.0 and 34.6). However, the combination of AMG 330 and CD28 increased the
amount of phosphorylated proteins (mean% pAkt and pErk 11.6 and 11.1), but
not to the level achieved by CD3/CD28 stimulation. In the absence of target
cells, no Akt phosphorylation was observed upon incubation with AMG 330, sug-
gesting a highly target cell dependent T-cell activation (mean% pAkt with vs
without target cells: 0.8 vs 7.9).
Summary/Conclusions: Our data support the hypothesis that costimulation
influences the susceptibility of target cells to lysis by T-cell recruiting antibody
constructs. Currently, we are validating our results in a larger cohort using T
cells from healthy donors and patients with AML. Furthermore, we will analyse
the phosphorylation pattern within different T cell subsets and upon knock out
of B7 molecules in MOLM-13 cells. Our results will contribute to the under-
standing of BiTE® mediated activation of T cells, which is a prerequisite for
clinical responses.
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ESTABLISHING SINGLE CELL WHOLE EXOME SEQUENCING ANALYSIS
AS A DISCOVERY TOOL IN NPM1/FLT3 POSITIVE PEDIATRIC ACUTE
MYELOID LEUKEMIA
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Background: AML is a rare hematological disorder in children and adolescents
caused by distinct genetic aberrations, which are relevant for leukemogenesis,
prognosis and therapy. Although major players in the molecular landscape and
clonal evolution of AML have been identified in adults, it remains a major tech-
nical challenge to genetically characterize the few leukemic stem cells (LSCs)
cells against a noisy background of AML blasts and normal hematopoietic cells.
Aims: The aim of this study was to establish a simple workflow for reliable
genetic analysis of single LSCs in pediatric patients with AML, where often lim-
ited research material is available.
Methods: For three pediatric AML patients with mutations in the genes NPM1
and/or FLT3, we performed single cell sorting for CD34+ CD38- AML blasts by
FACS and subsequently whole genome amplification (WGA) using the REPLIG
single cell kit (Qiagen). The amplified single cell DNA and additionally the DNA
of the corresponding bulk bone marrow was analysed by exome sequencing
(WES). Bulk DNA was additionally evaluated by an amplicon-based sequencing
approach targeting 54 genes (TruSight Myeloid Panel, Illumina) associated
with myeloid malignancies.
Results: The analysis revealed that the median read coverage obtained in the
WES of the five DNAs amplified from the single CD34+ CD38- cells and in the
corresponding bulk DNAs from the bone marrow of all three patients was com-
parable for three out of the five single cells. For three amplified single cell
genomes, between 92 and 98% of all reads could be mapped to the human
genome, however the median coverage for the two failed single cells was 0.
For validation of the WGA quality from single LSC DNA, data from 50 out of 54
genes genes analyzed by both sequencing approaches, WES and TSM Panel,
were available for all three patients. The majority of variants detected in the
WES bulk data could consistently be found at a comparable variant frequency
in the TSM panel data. The variant frequencies in the single cell data from WES
were more variable and more variants could not be detected in the TSM panel
data derived from bulk DNA. We were able to detect n=79 (66%) out of n=121
somatic variants (SNVs, InDels) present in the patients’ AML blasts with all
three sequencing approaches. WES readily identified n=103 (85.1%) and n=93
(76.9%) of all 121 variants in the bulk and single cell DNA, respectively. Only
n=4 (3.3%) variants were not detected by WES at all. We were able to retrace
the NPM1 and FLT3 mutations for each of the three patients in the targeted
sequencing approach. However the NPM1 mutations and one FLT3 ITD could
not reliably be called in the WES approach due to insufficient coverage.
Summary/Conclusions: In summary, WES of amplified single cell DNA is an
excellent discovery tool also in pediatric AML for detecting unique changes in
potential LSCs that should be validated by targeted sequencing approach with
sufficient read counts for finding of rare events.
E879
RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN THE DEVELOPMENT
OF MYELOID SARCOMA
V. Caraffini1,*, S. Schauer2, K. Kashofer2, A. Wölfler1, G. Hoefler2, H. Sill1,
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Background: Myeloid sarcoma (MS) is a subgroup of acute myeloid leukemia
(AML), where leukemic cells invade non-hematopoietic tissues and form solid
tumor masses. It may occur as isolated event or simultaneously with leukemic
infiltration of the bone marrow (BM). Loss of RAF kinase inhibitor protein (RKIP),
a negative regulator of RAS signaling, has recently been described as a fre-
quent event in AML and to be functionally involved in leukemogenesis. Although
RKIP has been shown to inhibit the formation of metastases in solid tumors
previously, its role in the development of MS is currently unknown.
Aims: In this study, we aimed to delineate the role of the metastasis-suppressor
RKIP in the development of MS. 
Methods: RKIP protein and mRNA expression was evaluated in formalin-fixed
paraffin-embedded biopsies of MS and BM by immunohistochemistry and quan-
titative real-time PCR (qPCR). Sequence analysis of MS biopsies defined as
RKIP loss was carried out from 40ng of total DNA employing Ion Torrent Next
Generation Sequencing (NGS). For functional assays, both RKIP overexpres-
sion and knockdown was performed in THP-1 AML cells by lentiviral transduc-
tion of a FLAG-tagged RKIP expression construct and by RKIP shRNA, respec-
tively. Subsequently, these cells were tested in migration and invasion assays
using the Transwell-methodology.
Results: This study comprised 14 patients with MS (MS-group) and 14 patients
with AML without any evidence of extramedullary involvement (BM-AML group).
Of the 14 cases within the MS-group, MS occurred as isolated event in three
cases and concomitantly with systemic AML in eleven cases. Both groups were
age- and sex-matched and clinical as well as laboratory values were compa-
rable between them. Most importantly, however, when we measured the protein
expression of RKIP in leukemic tissues of these patients (MS biopsies in the
MS-group and leukemic BM biopsies in the BM-AML group), we observed a
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significant increase of specimens exhibiting loss of RKIP expression in the MS-
group (7/14 vs 1/14; P=0.0329). Interestingly, RKIP loss in MS specimens of
cases with concomitant systemic AML was also present in the corresponding
leukemic BM samples, thereby excluding a geographical clonal heterogeneity
during MS formation in respect to RKIP expression. We then analyzed RKIP
mRNA levels by qPCR and observed that RKIP loss correlated with decreased
expression of its mRNA (P=0.041). To gain more insight into the molecular
landscape of MS patients with and without RKIP loss, we performed NGS of
39 genes that are recurrently mutated in AML. Interestingly, five out of six (83%)
MS patients with RKIP loss demonstrated mutation(s) affecting the RAS-path-
way, suggesting a potential functional synergism between these events. Con-
sequently, we performed stable overexpression and knockdown of RKIP in the
RAS-mutated THP-1 AML cell line and subsequently studied these cells in
functional migration and invasion assays. Importantly, RKIP knockdown
increased both migration (relative ratio to control cells [rrtcc] of 193%,
P=0.0097) and invasion (rrtcc of 171%, P=0.0197), whereas RKIP overexpres-
sion had the opposite effects (rrtcc of 56%, P=0.0036 for migration; rrtcc of
35%, P=0.0037 for invasion).
Summary/Conclusions: Loss of the metastasis-suppressor RKIP is associ-
ated to MS and to mutations affecting the RAS signaling cascade. In functional
assays employing RAS-mutated AML cells, RKIP knockdown increased both,
migration and invasion, thereby indicating a role of RKIP in the development
of this condition.
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INHIBITING MIR-10A OVERCOMES CYTARABINE-RESISTANCE IN ACUTE
MYELOID LEUKAEMIA
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Background: Chemoresistance is the principle cause of treatment failure in
acute myeloid leukaemia (AML) despite a promising response to induction
chemotherapy. Emerging evidence suggest the roles of autophagy, a self-
eating process contributing to chemoresistance of leukaemia cells. We previ-
ously demonstrated that miR-10a, highly expressed in a subgroup of AML har-
bouring Nucleophosmin1 mutations, promotes cell survival by inhibiting non-
canonical cell death pathway, suggesting its function in autophagy and thus
chemoresistance in AML. 
Aims: We aim to demonstrate evidence that miR-10a, a regulator of autophagy,
plays important roles in chemoresistance in acute myeloid leukaemia.
Methods: Apoptosis and proliferation in miR-10a inhibited and overexpressed
leukaemia cells after cytarabine treatment was measured by Annexin V binding
and MTT assay. Autophagy was measured by monitoring the levels of
LC3I/LC3II proteins, autophagy-related proteins via Western Blotting and mono-
dansyl-cavaradine (MDC) staining (flow cytometry).
Results: First, we observed a decreased expression of miR-10a in the leukaemia
cells after the exposure to stress induced by serum starvation. Overexpressing
miR-10a in miR-10a low MV4-11 cells decreased apoptosis induced by nutrient
starvation and resulted in the resistance to cytarabine. In contrast, its inhibition
in OCI-AML3 cells, which express high miR-10a constitutively, resulted in the
induction of apoptosis and increased chemosensitivity towards cytarabine. miR-
10a was shown to directly downregulate key members of the p53-mediated
tumour suppressor gene network, including the CDKN1A (p21) inhibitor Tran-
scription Factor AP2-gamma (TFAP2C). The inhibition of either miR-10a itself or
CDKN1A by siRNA treatment inhibited autophagy induced by serum starvation,
treatment with autophagy inducer,mg132 or p53 stabiliser, Nutlin3a.
Summary/Conclusions: The data suggests miR-10a as an important regulator
of autophagy via modulation of the p53-p21 tumour suppressor signalling axis
in subtypes of AML. It also emphasizes the significance of autophagy in
chemoresistance in AML, supporting the targeting of the autophagy pathway
as a potential therapeutic approach for AML.
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BY AN MCL-1-DEPENDENT MECHANISM, ALVOCIDIB POTENTIATES THE
ACTIVITY OF CYTARABINE AND MITOXANTRONE WHEN ADMINISTERED
IN A TIME SEQUENTIAL REGIMEN IN AML
H. Haws1, M. Livingston1, W. Kim1, R. Mangelson1, A. Siddiqui-Jain1, P. Peterson1,
C. Whatcott1, S. Weitman1, D. Bearss1, S. Warner1,*
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Background: Treatment with alvocidib has shown significant improvements
in the complete remission rates in newly diagnosed acute myeloid leukemia
(AML) patients when administered before cytarabine and mitoxantrone (ACM
regimen) in a randomized Phase 2 study compared to 7+3. Although the mech-
anism of alvocidib action as a single agent is documented, the mechanism
underlying synergy found in the ACM regimen is not fully understood. The ACM
regimen was originally developed based on the perceived benefit of a time-
sequential regimen starting with cell-cycle arrest (alvocidib), followed by release
of the cells from arrest and inhibition of DNA replication (cytarabine/mitox-
antrone) during S-phase. However, recent reports suggest that the transcrip-
tional repression of key anti-apoptotic proteins (eg., MCL-1) mediated by alvo-
cidib’s CDK9 inhibition, may contribute to the activity in the ACM regimen.
Aims: We hypothesized that MCL-1 transcriptional repression constitutes the pri-
mary mechanism for the synergism observed with the ACM treatment regimen.
Methods: Following treatment, cell viability and caspase activation, an indicator
of apoptosis, were assessed using CellTiter-Glo and Caspase-Glo assays,
according to manufacturer protocol. mRNA levels were assessed using RT-
PCR. Protein levels were assessed using standard immunoblotting technique. 
Results: In this study, we demonstrate that treatment with alvocidib, followed
by treatment with cytarabine and mitoxantrone, synergized in vitro and correlated
with the downregulation of MCL-1 protein and mRNA expression. Indeed, the
ACM regimen resulted in a 2.4 or 3.4-fold increase in caspase activity relative
to any single agent within the combination in MV4-11 or OCI-AML3 cells, respec-
tively. As has been previously reported, we also observed that increased activity
of cytarabine in alvocidib-treated cells corresponded with progression into the
S-phase of the cell cycle, following the washout of alvocidib. However, this
observation accounted for only a small portion of the inhibition of cell prolifera-
tion. This was further confirmed by the observation that CDK4/6 (cell cycle) spe-
cific inhibitors, such as palbociclib, did not show synergistic increases in caspase
activity following treatment in the same setting. In various AML cell lines treated
with MCL-1 siRNA, followed by cytarabine and mitoxantrone treatment, we also
observed a synergistic increase in the inhibition of cell proliferation.
Summary/Conclusions: Considering our earlier work showing that MCL-1
dependence predicts AML patient response to the ACM regimen, we propose
that MCL-1 repression is the primary mechanism of alvocidib’s clinical activity.
As MCL-1 also confers resistance to cytarabine, the current study provides
additional rationale for the inclusion of alvocidib in the treatment of AML, and
in the ACM regimen specifically. Taken together, this data suggests that the
ACM regimen may be an effective regimen in treating patients with high-risk
AML, because of alvocidib’s inhibition MCL-1.
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DYSREGULATION IN KEY REGULATOR GENES OF AUTOPHAGY AS A
MECHANISM OF THERAPY RESISTANCE AND POOR PROGNOSIS IN
ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM MICROARRAY
ANALYSIS ON 148 PATIENTS
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Background: To date, there are no clear evidences if autophagy can lead to
therapy resistance or favor apoptosis in cancer. Autophagy can function as a
pro-apoptotic mechanism, or can improve stresses survival clearing damaged
mitochondria and proteins accumulation. Levels and activity of pro-apoptotic
and anti-apoptotic proteins, particularly BCL-2 and p53, high levels of cAMP,
and a complex made by PINK/PARK could play as fulcrum of this yin and yang
effect of autophagy.
Aims: Our study aims to define the role of PI3P pathways in AML, and to estab-
lish if autophagy could reduce the patients’ chance to respond to induction,
and to worsen OS.
Figure 1.
Methods: We analyzed 148 consecutive newly diagnosed non M3 AML patients
treated with induction chemotherapy regimens containing at least one dose of
anthracycline. We screened all patients for TP53, FLT3, NPM1 mutations. In all
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patients, we perform Microarray-based High-Throughput Technology with
Affymetrix SNP array 6.0 or Cytoscan HD. Survival data were collected prospec-
tively from the time of diagnosis, with a median follow-up of 18 months. Survival
analysis was performed with Kaplan Meyer method using log rank test. Univari-
ate and multivariable regression and Cox Hazard Ratio (HR) model was per-
formed. Correlation between variables was assessed with Fisher’s exact test.
Results: Autophagy alteration (gene group 1: ULK1 CHR11; ULK1 CHR17;
BECN1; ATG14; AMBRA1; UVRAG; ATG9A; ATG9B; PIK3C3; PIK3R4) were
related to lower Complete Remission rate (CR%) after induction in univariate
(p<.001) and multivariable regression with age, karyotype, secondary AML,
TP53 mutation (p=.014). Autophagy alteration showed to confer worst OS
(p<.001) and was significantly associated with complex karyotype and TP53
mutation (p<.001). We detected significant differences in term of survival inde-
pendently both in Copy Number (CN) Gain and CN Loss in group 1 genes
(p<.001). Furthermore, we investigated genes in AMPK pathway (group 2:
SESN1; PRKAA1 CHR 3; PRKAB1: PRKAA1 CHR 1: PRKAG1 CHR11; PRK-
AG1 CHR 7; PRKAG3; PRKAB1) and other genes that could be related to a
switch from a physiological role of autophagy to a resiliency mechanism
(group 3: CCND1; BCL2; PINK1; PARK2; TP53; MDM1; MDM4): alterations in
those genes were shown to confer worst OS (p<.001 in both groups). Alteration
in group 2 and group 3 were related to lower CR% after induction (p<.001 in
both groups). Whole Exome Sequencing on 56 patients in our set did not found
any significant mutation in genes we analyzed with the exception of TP53.
Summary/Conclusions: Our work investigates for the first time with a genomic
approach the role of autophagy in AML. We found that both CN gain and CN
loss in autophagy key regulator genes are associated with poor prognosis and
therapy resistance. A CN loss in autophagy could enhance proliferation and
block apoptosis, a CN gain could give cell resiliency, favoring cytoplasm
turnover, damaged mitochondria elimination, and neutralizing oxidative dam-
ages. Further fucntional studies will be necessary in order to confirm these
results.
Acknowledgements: ELN, AIL, AIRC, PRIN, Progetto Regione-Università 2010-
12, FP7 NGS-PTL project, HARMONY. 
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NO EVIDENCE FOR MICROSATELLITE INSTABILITY (MSI) IN 1,394
PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML)
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Background: MSI is the addition or loss of bases within repetitive DNA
sequences called microsatellites (MSs), caused by defects in DNA mismatch
repair. MSI is most often observed in endometrial and colorectal carcinomas,
and pts with MSI-positive (MSI+) solid tumors have shown promising responses
to therapy with immune checkpoint inhibitors. MSI’s existence in AML has been
examined in several studies, but the results are equivocal, with some reporting
a total absence of MSI and others finding as many as 20% of de novo AML pts
are MSI+. These studies tested for MSI using polymerase chain reaction (PCR)
of small numbers of MSs (usually 5-7), and typically examined <100 pts. To our
knowledge, the largest published AML cohort studied for MSI contained 132 pts.
Aims: To screen 1,394 AML pts for MSI.
Methods: Diagnostic DNA samples from 1,371 pts (1,364 with de novo AML
and 7 with therapy-related AML [t-AML]) and 86 paired germline DNAs were
sequenced for 80 genes using amplicon-based next-generation sequencing
(NGS). Variants were detected by MuTect and Varscan with variant allele frac-
tion cut-offs of 0.30, and considered mutations if not reported in 1000 Genomes
or dbSNP142. NGS-based MSI detection was performed similar to mSINGS
(Salipante et al., Clin Chem. 2014;60:1192) combined with a MS variant caller
we previously developed (Walker et al., Hum Mutat. 2016;37:1004). Briefly, 18
MSs with >50 reads in all samples and that were not polymorphic in germline
DNAs were selected from the target panel; then the number of different length
MSs (alleles) each AML sample had was calculated for each of the 18 MS loci.
Outlier samples with elevated allele counts were flagged for each locus. Based
on previously established mSINGS crtieria, samples flagged in ≥20% of MSs
(4 out of 18) were considered MSI+. Paired DNAs were separately screened
for MSI by comparing the alleles in each AML sample to its paired germline
DNA, using the 2xn version of Fisher’s exact test to determine significance.
The MS PCR analysis system (Promega) was used on any pairs with significant
P-values (P<0.05). 23 additional t-AML cases were screened using PCR-based
detection of 4 MSs (BAT25, BAT26, D2S123 and D17S250).
Results: The NGS-based MSI screen showed that 1,303 samples did not have
elevated allele counts for any of the MSs, 67 samples had elevated counts for
one MS and one sample had elevated counts at 2 MSs. Because none of the
samples met the criterion of ≥4 MSs with elevated allele counts, these data
indicate that none of the samples are MSI+. Comparison of alleles between the
86 paired AML and germline samples showed no differences in 78 pairs, and
small but statistically significant differences in 8 pairs. However, subsequent
assessment of these 8 pairs with the MS PCR analysis system proved that
none of them were MSI+. Because MSI+ tumors have 10-100 times as many
mutations as MS stable (MSI-negative) tumors, we examined the mutation
counts in the 1,371 AML samples for the 80 genes on the target panel. Most
samples (64%) had 2-4 mutations and the 2 most highly mutated samples had
only 9 mutations each. Since any putative MSI+sample would harbor tens if
not hundreds of mutations, these data support the absence of MSI in all sam-
ples. Finally, because it has been proposed that t-AML might be more prone to
MSI than de novo AML,we performed PCR-based MSI detection on an addi-
tional 23 t-AML cases, and found all were MS stable.
Summary/Conclusions: The absence of even a single MSI+ case within this
large cohort provides strong evidence that MSI is non-existent in AML.
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SY-1425, A POTENT AND SELECTIVE RARΑ AGONIST, REPROGRAMS
AML CELLS FOR DIFFERENTIATION ALONG DISTINCT LINEAGES,
UNCOVERING PD MARKERS FOR CLINICAL STUDIES
M. Mckeown1,*, C. Fiore2, K. Austgen2, E. Lee1, D. Smith2, M.L. Eaton2,
A. Volkert3, C. Murphy3, K. Stephens3, C. Fritz2, T. Lodie2, E. di Tomaso1,
E. Olson2
1Translational Medicine, 2Biology, 3Clinical, Syros Pharmaceuticals, Cam-
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Background: SY-1425 (tamibarotene) is a potent and selective agonist of the
retinoic acid receptor alpha (RARα) transcription factor (TF), currently in a bio-
marker directed Ph2 clinical study in AML and MDS patients (NCT02807558).
A subset of AML and MDS has been found to have RARα pathway activation
characterized by a large enhancer at the RARA locus (RARA-high) and/or
upregulation of IRF8, a TF associated with RARα signaling, forming the basis
of SY-1425 sensitive tumor identification.
Aims: We sought to understand how SY-1425 agonism of RARα acts to pro-
mote maturation and halt proliferation of AML blasts locked into an immature
cell state by the cancer circuitry. This characterization could further inform clin-
ical pharmacodynamics markers.
Methods: We analyzed the epigenomic and transcriptional landscape of 66
non-APL AML patients and normal primary myeloid cells by RNA-seq and ChIP-
seq for the enhancer mark H3K27ac. AML cell lines were profiled by RNA-seq,
ChIP-seq for H3K27ac and RARα, and ATAC-seq with or without SY-1425 treat-
ment. Cell surface marker changes were assessed by flow cytometry.
Results: A subgroup of the patient samples was defined by an SE driving RARA,
which co-occurred with SEs driving FOS and JUNB, or IRF8. FOS and JUNB
form the AP-1 heterodimeric TF known to promote an immature cell state and
the interferon regulatory factor 8 (IRF8) pathway has been implicated in AML
pathogenesis. Previously reported crosstalk between INF and retinoic acid sig-
naling was supported by the strong induction of interferon gene sets by SY-1425
in IRF8-high AML models. We found that each AML cell line had distinct com-
positions of lineage factors consistent with cancer initiation from different stages
of myeloid development. SY-1425 induced maturation features associated with
monocytic, macrophage, dendritic, and granulocytic cell types. While APL has
well characterized and specific granulocytic differentiation, we found that
RARA/IRF8-high AML could follow multiple differentiation paths depending on
the initial state of the AML model, necessitating different marker panels to capture
full cell typing. Functional validation confirmed surface marker changes consis-
tent with the observed epigenomic alterations including CD11b, CD11c, CD66b,
and CD38 upregulation. We integrated epigenomic data, DNA accessibility, and
SY-1425 response to understand RARα agonist perturbation to cell circuitry.
Enhancer elements directly bound by RARα were associated with greater
response to SY-1425 as were enhancers bound by other TFs involved in myeloid
differentiation. The accessibility of RAR elements and IRF motifs were increased
and their associated TFs were upregulated. The target genes of known imma-
ture/proliferative state drivers, such as RUNX1 and CEBP, were downregulated.
Importantly, the FOS/JUN circuit, identified as a component of the oncogenic
RARα circuit in patient samples, was found to be suppressed.
Summary/Conclusions: As in normal myelopoiesis, RARα and associated
cell state TFs play a critical role in the differentiation of AML. SY-1425 pertur-
bation of this circuitry leads to differentiation toward multiple potential lineage
paths depending on the initial state of the cancer. These pharmacodynamic
changes can be assessed clinically and combined with common AML/MDS
assays, such as blood and marrow aspirate smears or white blood cell differ-
entials, to support the differentiation mechanism of action and offering the
potential for early biologically relevant data to inform current and future clinical
studies.
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ED AML PATIENTS AND THE EFFECT OF TET2 AND GATA2 MUTATIONS
ON OUTCOME
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Background: Mutations in the CEBPA gene are detected in about 10% of
patients (pts) with cytogenetically normal (CN) acute myeloid leukemia (AML).
CEBPA mutations can either be biallelic (bi) or monoallelic (mo). Only pts with
biCEBPA mutations have favorable outcomes when compared to other CN-
AML pts. biCEBPA mutations are rarely associated with other prognostic muta-
tions like internal tandem duplications (ITD) or mutations in the tyrosine kinase
domain (TKD) of the FLT3 gene or mutations in NPM1. There is a specific asso-
ciation of biCEBPA mutations with mutations in the transcription factor GATA2.
Aims: In this study we aimed to characterize the mutational spectrum of CN-
AML pts with mo- and biCEBPA mutations. We further analyzed the effect of
TET2 and GATA2 mutations on outcome in pts with biCEBPA mutations.
Methods: Targeted amplicon resequencing (Agilent Haloplex, target region:
63kbp) was used to analyze 42 target genes or hotspots known to be mutated
in AML or other hematologic neoplasms.
Results: In 48 biCEBPA and 32 moCEBPA we found mutations in 20 and 26
different genes respectively. MoCEBPA pts had significantly more additional
mutations compared to biCEBPA pts (mean: 3.9±1.7 vs 2.2±1.5; p<.001). We
also compared the mutational profile of moCEBPA and biCEBPA pts with a
cohort of 287 wildtype (wt) CEBPA pts. Eight genes with a mutation frequency
of ≥5% were significantly associated with one or more groups. We confirmed
the mutual exclusiveness of biCEBPA and NPM1 and the association between
GATA2 and biCEBPA (35.4%). TET2 was frequently mutated in both mo-
(43.8%) and biCEBPA pts (41.7%), but not in wtCEBPA (16.3%; mo- vs wtCEB-
PA p<.001; bi- vs wtCEBPA p<.001). Mutations in TKD1 or TKD2 of FLT3 were
frequently identified in moCEBPA (25%) and wtCEBPA pts (17.8%) but not in
biCEBPA pts (2.1%). The FLT3-TKD1/2 mutation frequency in biCEBPA sig-
nificantly differs from moCEBPA (p=0.002) and wtCEBPA (p=0.004). There
was a significant difference in the frequency of FLT3-ITD in biCEBPA (20.8%)
vs wtCEBPA pts (40.8%; p=.009) but not in comparison to moCEBPA pts
(43.8%). IDH2 was found mutated only in wtCEBPA (21.6%) and moCEBPA
(18.8%). In 48.8% of wtCEBPA pts DNMT3A was mutated, this significantly
differs from biCEBPA pts (14.3%; p<.001) but not from moCEBPA patients
(28.1%). CSF3R was frequently mutated only in biCEBPA (10.4%) but not in
wtCEBPA (0.35%; p<.001) or moCEBPA (3.1%; ns). STAG2 was associated
with moCEBPA (25%), while STAG2 mutations were significantly less frequent
in biCEBPA (6.3%; p<.001) and wtCEBPA pts (6.27%; p=.002). TET2 mutations
had a negative prognostic impact on overall survival (OS) in biCEBPA pts, but
not in moCEBPA pts. OS (HR: 3.1; 95% CI: 1.2-8.2; p=.023) was significantly
worse in biCEBPA pts with a TET2 mutation, but relapse free survival (RFS)
and cumulative incidence of relapse (CIR) was not different depending on TET2
mutational status. In biCEBPA pts we also evaluated the clinical impact of
GATA2 mutations. For 30 of 48 biCEBPA pts survival data was available, 15 of
these pts had a GATA2 mutation. We found no significant difference with
respect to RFS (p=0.216), OS (p=0.479) and CIR (p=0.059). In a combined
analysis, the GATA2mut and TET2wt genotype was associated with a lower
relapse risk and a trend towards a higher RFS compared to the GATA2wt and
TET2mut genotype.
Summary/Conclusions: biCEBPA, moCEBPA or wtCEBPA pts show a distinct
profile of co-occurring mutations that might explain the biological differences
between these groups. TET2 mutations were found in 40% of all CEBPA mutat-
ed pts and might have a prognostic impact in biCEBPA pts.
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MECHANISMS OF SYK-MEDIATED SUPPRESSION OF DIFFERENTIATION
AND APOPTOSIS IN ACUTE MYELOID LEUKEMIA (AML)
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Background: Spleen tyrosine kinase (SYK) is a critical mediator of integrin b3
signaling in AML, leading to leukemia cell growth and disease initiation upon
transplantation into healthy recipients. Genetic or pharmacologic inhibition of
SYK leads to increased differentiation, reduced proliferation and apoptosis.
However, the comprehensive description of mediators and effectors of SYK
signaling in AML is lacking. 
Aims: To identify key downstream mediators of SYK signaling in AML respon-
sible for differentiation block, proliferation and leukemic stem cell (LSC) main-
tenance.
Methods: AML cell lines (KG1, MOLM14) or bone marrow primary AML blasts,
were incubated 24h with R406 (1uM, 4 uM) or vehicle. Activity of SYK, ERK,
STAT5 was assessed by western blot and/or intracellular phospho-flow. Prolif-
eration, apoptosis and clonogenic potential were assessed by MTS, PI staining
and methylcellulose colony-forming assay. Differentiation was assessed by
Giemsa-Wright staining, quantitative NBT, CD14/CD15 staining and qPCR.
Constitutively active form of MEKDD and STAT5A1*6 were retrovirally trans-
duced to KG1. Activity toward LSC was assessed using leukemia cell line with
stem cell properties, TEX. ROS level, mitochondrial mass were assessed by
DCF, MitoTracker Green FM staining. Expression of MYC, TFAM, NRF1, NRF2,
EF-Tu were assessed by western blot and/or q-PCR.
Results: To identify downstream mediators of SYK in AML, we assessed the
activity of key signal molecules in KG1 and MOLM14. AML cells exhibited basal
level of pSYK, pERK and pSTAT5. R406 decreased phosphorylation of these
proteins, reduced proliferation, clonogenic potential, induced myeloid differen-
tiation and apoptosis. Since ERK can block maturation, we assessed impact
of this pathway on differentiation arrest downstream of SYK in KG1 transduced
with MEKDD. R406 induced morphological evidence of differentiation and
increased expression of myeloid differentiation genes in control cells, whereas
in MEKDD transduced cells, R406 had no effect. Given the role of STAT5 in
self-renewal of HSC we next assessed impact of this factor on clonogenic
potential. R406 reduced clonogenic potential of control cells, while in cells
expressing STAT5A1*6, clonogenic potential was maintained. Moreover,
STAT5A1*6 cells had significantly higher cell surface expression of an LSC
marker, CD25, and R406 reduced CD25 level only in control cells. Since activity
of SYK is required for LSC survival, and R406 induced differentiation and
reduced CD25 expression, we decided to explore the mechanism of LSC deple-
tion following R406. R406 reduced proliferation, clonogenic potential and
induced dose-dependent apoptosis in LSC-enriched TEX cells. Since high
pSYK is associated with overexpression of MYC and increased expression of
MYC and its targets that drive mitochondrial biogenesis is a characteristic fea-
ture of LSC, we hypothesized that R406 deplete LSC by reducing mitochondrial
biogenesis/oxidative phosphorylation (OXPHOS). In TEX and primary CD34+
AML blasts R406 reduced expression of MYC, transcription factors associated
with mitochondrial biogenesis (NRF1, TFAM, EF-Tu, NRF2), and lowered cel-
lular mitochondrial mass.
Summary/Conclusions: Taken together, we found that SYK inhibition obviates
differentiation arrest imposed by ERK activity, and reduces clonogenic potential
via decreased STAT5 activity. Moreover, we show that pSYK is required to sus-
tain MYC expression and mitochondrial biogenesis/OXPHOS, a key features
of LSC in AML.
This work was supported by NCN grant#2013/11/N/NZ5/03704.
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Background: Although the fusion oncogene PML-RARA is known to initiate
acute promyelocytic leukemia (APL), other cooperating mutations have also
been implicated in the disease pathogenesis. However, the spectrum of muta-
tions of APL patients within the relapse-risk groups, based on patient leukocyte
and platelet counts at diagnosis, are not yet known
Aims: 1)To identify genetic alterations that might cooperate with PML-RARA
in the leukemogenic process within the three APL relapse-risk groups. 2)To
find mutations at diagnosis responsible for poor outcome by comparing patients
who experiment relapse vs. patients who do not relapse in each group.
Methods: We performed multi-amplicon targeted deep sequencing on bone
marrow samples of 91 patients diagnosed with APL (PETHEMA LPA99/
2005/2012) with a median follow-up of 2.8 years (range 0.2-10) (Table 1). APL
patients were classified into relapse-risk groups according to initial leukocyte
(WBC) and platelet counts (Score Sanz et al. 2000). Libraries were prepared
by using the TruSight Myeloid Sequencing Panel (Illumina) that assesses 54
myeloid related genes. Paired-end sequencing runs were performed on a MiS-
eq (Illumina) genome sequencer. Minimum depth for reliable analysis was fixed
in 100x and minimum variant allele frequency (VAF) in 5%. FLT3-ITD mutations
were analyzed by fluorescent PCR and capillary electrophoresis. Sequences
obtained were analyzed with the Variant Studio v2.1 software (Illumina) and
the Integrative Genome Viewer (Genome Browser).
Results: Distribution of 91 patients in the 3 relapse-risk groups was: 28 in low-
risk group (31%), 48 in intermediate-risk (53%) and 15 in high-risk (16%). We
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found 150 mutations in 31 genes, in 73 out of the 91 patients included (a median
of 1 mutation per patient (range: 0-5) with a mean read depth of 10360x. Eight-
een patients remained wild-type for all analyzed genes (Figure 1).Only one of
this patients suffered relapse (5%). In the global series, no single mutation or
functional category showed an association with clinical variables or prognostic
impact in terms of overall survival or relapse free survival (RFS). There were
no differences in the mean number of mutations per patient in each risk APL
group (p>0.05). Patients who lack mutations belonged to the intermediate
(13/48, 27%) and low risk (4/28,14%) groups, except for only one patient (1/15,
6%) in high-risk group. FLT3 was the most frequently affected gene in high risk
APL subgroup (10 out of 15): 8 patients carried an FLT3-ITD mutation and 2
patients had amino acid substitutions at codon 835. Seven patients assigned
to intermediate-risk relapsed (7/38, 18%). All but one carried mutations that
have been reported as unfavorable in AML (FLT3, PTEN, ASXL1, CUX1 and
WT1). By contrast, patients who remain in complete remission in this group,
lack mutations with a greater frequency (12/31, 39%). Finally, within the low-
risk group 3 patients suffered relapse (3/27; 11.5%) and all of them presented
missense mutations in the Ras domain of NRAS at diagnosis (p.Ser65Arg &
p.Gln61Arg). Therefore, we could identify a small subgroup of patients at a
very high risk of relapse (RFS at 5 years, 25% vs 100%, p<0.001).
Figure 1.
Table 1.
Summary/Conclusions: In summary, the present study shows that the muta-
tional status of NRAS and FLT3 genes could be used as genetic markers for
prognosis in APL, especially in the intermediate and low-risk groups, allowing
a more accurate patient risk classification. Our data suggests the need to search
for new mutations required for progression in APL, in order to benefit from a
change in post-remission therapy.
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ANALYSIS OF THE PD-1/PD-L1 AXIS POINTS TO ASSOCIATION OF
UNFAVORABLE RECURRENT MUTATIONS WITH PD-L1 EXPRESSION IN
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Background: Programmed death ligand-1 (PD-L1) is regulated through miR-
34a molecules in AML patients. Moreover, Cortez et al. for the first time identified
novel, complete mechanism of PD-L1 regulation by p53 via miR-34a in non-
small cell lung cancer (NSCLC). 
Aims: In this study, our comprehensive analyses of PDCD1 (PD-1), CD274
(PD-L1), TP53 and miR-34a expression in AML patients shed new light on the
complex regulation of PD-1/PD-L1 axis during development of this disease.
Methods: We performed analysis of TP53, CD274 and miR-34a expression in
197 AML patients available from The Cancer Genome Atlas (TCGA) database.
Moreover, we assessed mRNA expression of PDCD1 in independent cohort of
54 AML, 62 MDS and 8 s-AML patients samples using qRT-PCR method. For
miRNA analysis, CD33+ cells from 29 AML patients were isolated and miR-
34a expression was analysed. We also characterized several SNP for PDCD1
that demonstrate relevant associations with a higher risk of developing autoim-
mune diseases: PD-1.1 (rs36084323), PD-1.3 (rs11568821), PD-1.5
(rs2227981), PD-1.6 (rs10204525), PD -1.7 (rs41386349), PD-1.9 (rs2227982)
in 54 AML, 62 MDS and 100 HVs samples.
Results: We observed significant differences in PDCD1 expression in groups
of 54 AML, 62 MDS, 8 s-AML patients compared to HVs. TCGA data analysis
showed that CD274 expression was elevated in group with TP53 mutations
compared to unmutated TP53 group (p<0.001). We also found negative corre-
lation of TP53 and miR-34a expression with CD274 expression (p=0.02 and
p=0.005, respectively). The expression of miR-34a tended to be elevated in
group with high expression of TP53 compared to group with low TP53 expres-
sion (p=0.17). We have not found any differences in CD274 expression between
groups with or without following mutations: IDH1, TET2, RUNX1, NRAS, CEB-
PA, PTPN11, KIT, KRAS, FLT3, DNMT3, NPM1 and IDH2. Patients with more
than 4 recurrent mutations were characterized with higher expression of CD274
compared to group of patients with 0-3 recurrent mutations. We also found that
patients with >14 of all mutations had elevated expression of CD274 compared
to group 0-13 mutations (p=0.06). We observed significant differences in
PDCD1 expression level regarding to PD-1.1.5 polymorphism. Moreover, analy-
sis of a PD-1.1.3 polymorphism in HVs and MDS groups revealed that genotype
GG was associated with nearly fivefold lower risk of disease (OR=4.93,
p=0.009). We observed significant differences in OS in AML patients in case of
presence of certain genotypes of PD-1.1.6. Genotype AA was significant asso-
ciated with higher risk of shorter OS compared to the rest of the genotypes (58
vs 333 days, HR=35; p=0.0188).
Summary/Conclusions: Our analyses indicate that p53 might specifically mod-
ulate the tumor immune response by regulating PD-L1 via miR-34a which direct-
ly binds to the PD-L1 3’ UTR and blocks its expression. Moreover, we found
that high CD274 expression is associated with the higher numbers of recurrent
and all mutations as well as poor cytogenetic and molecular risk groups of AML
patients. We found significant differences in PDCD1 expression in AML patients
compared to HVs that might indicate deregulation of a signal transduction
through the PD-1/PD-1L axis. While our SNP analysis in AML patients sug-
gested a prognostic impact of PD-1. 6 polymorphism, further studies are war-
ranted to evaluate the impact of the PD-1/PD-L1 Axis in AML.
This work was supported by National Centre for Science Grant HARMONIA
(UMO-2013/10/M/NZ5/00313).
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DISSECTING THE DYNAMICS OF SINGLE-TUMOR-CELL-LINEAGES THAT
UNDERPIN RELAPSE OF AML
F. Caiado1, D. Maia-Silva1, C. Reforço1, R. Faria1, B. Silva-Santos1, H. Norell1,*
1Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lis-
boa, Lisbon, Portugal
Background: Cancers kill primarily via disease recurrences after transient
treatment responses. The emergence of therapy-resistant tumor escape vari-
ants is fueled by intra-tumor heterogeneity, underpinned by interference and
Darwinian evolution across continuously developing sub-clones in the residual
tumor. Several non-genetic factors add significant variation, on top of the diver-
sity provided by the often complex intra-tumor genetic landscape, resulting in
an extremely heterogenous and dynamic tumor cell population that can drive
disease under many conditions. The relapse of human acute myeloid leukemia
(AML) is a prime clinical example of how evolving sub-clonal dynamics can fre-
quently drive treatment-resistant cancer recurrence after initially potent thera-
peutic responses.
Aims: We aimed to understand how sub-lineage interference is regulated in
AML in response to standard and emerging treatments - and clarify how this
impacts the development of therapy resistance. Specifically, we aimed to dissect
if relapse from each drug regimen was driven by predetermined or stochastically
selected sub-lineages and determine the functional impact of such differences.
Methods: We dissected the intra-tumor population dynamics of relapsing AML,
beyond the genetic level, by performing single-cell lineage-tracing through cel-
lular barcoding technology (lentivirus-integrated non-coding DNA-tags). We
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specifically evaluated the impact of in vitro exposure of a barcoded AML cell
line (HEL) to chemotherapy regimens (doxorubicin (DOX) and/or cytarabine
(CYT)) and/or the hypomethylating agent decitabine (DCT) by comparing the
barcode composition of the tumor population recurring after each therapy, ver-
sus non-treated (NT) controls. By comparing the barcode architectures between
parallel replicate cultures for each therapy, we could further delineate whether
AML relapse was driven by predetermined (if recurrent barcodes found in mul-
tiple replicates) or stochastically selected (if mainly diverse barcodes in each
replicate) cells in response to each treatment regimen.
Results: Only treatment regimens containing DOX caused marked decreases
in HEL cell numbers and barcode architectures diverging strongly from the
non-treated control cultures. Replicate AML cultures regrowing after treatment
with DOX all converged to a very similar barcode architecture, reflecting that
relapse following this mono-therapy was driven by predetermined single-cell
lineages. Combination of DOX with CYT increased the degree of overall cell
elimination by ~10-fold, while addition of DCT to either chemotherapy regimen
had minimal quantitative impact (i.e. yielded similar cell number reductions and
re-growth kinetics). Interestingly, DCT additions nevertheless qualitatively
changed which sub-lineages that regrew - specifically making replicates more
divergent from each other, indicating a more stochastic selection of the cells
emerging when DCT had been added to the respective chemotherapy regi-
mens. Importantly, this effect was accompanied by the reversion of resistance
to chemotherapy re-treatment, which the DOX-containing treatment regimens
potently induced in the absence of DCT.
Summary/Conclusions: The development of curative treatment combinations
requires deep understanding of how non-genetic factors synergize with cancer
genetics to drive intra-tumor heterogeneity, which is key for tumor escape/ dis-
ease recurrence. Our detailed analyses of the heterogenous dynamics among
single-cell lineages in AML, following different treatment regimens with appar-
ently similar global impact, represent an important step in dissecting kinship-
dependent aspects that go beyond the genetic level. Critically, these studies
directly provide the rationale for combining standard chemotherapy with admin-
istration of hypomethylating drugs to target AML. The mechanism is prevention
of the development of chemotherapy resistance (mediated by selective relapse
of a specific set of predetermined sub-lineages) - by partially randomizing which
sub-lineages that emerge to drive relapse when DCT is added to the
chemotherapies. Maintaining the chemosensitivity of relapsing AML would rep-
resent a paradigm shift, turning the currently often lethal recurrences into sur-





MRD ANALYSIS BY NEXT-GENERATION SEQUENCING APPROACH FOR
ACUTE MYELOID LEUKEMIA FOLLOW-UP
E. Onecha De La Fuente1,2,*, I. Rapado1,2, T. Cedena1,2, M. Llops3, Y. Ruiz-
Heredia1,2, J. A. Garcia Vela4, J. Perez Oteyza5, A. Figuera6, F. J. Peñalver7,
E. Barragan8, M. Gallardo1,2, J. Martinez-Lopez1,2, R. Ayala1,2
1Hematologia traslacional, Hospital 12 de Octubre, 2Haematological Malignan-
cies Clinical Research Unit, CNIO, Madrid, 3Instituto de Investigación Sanitaria
La Fe, Valencia, 4Hospital Universitario de Getafe, 5Hospital Universitario HM
Sanchinarr, 6Hospital de la Princesa, 7Hospital Universitario Fundación Alcor-
cón, Madrid, 8Clinical Pathology Service, Hospital Universitari i Politècnic La
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Background: Sensitive detection of molecular marker of minimal residual dis-
ease (MRD) in acute myeloid leukemia (AML), could improve prognostication
of a possible relapse during the remission. Traditional methods for measuring
minimal residual disease (MRD) in AML, such as real time PCR and multipara-
metric flow cytometry (MFC) are associated with high technical complexity, low
applicability and laborious standardization. However, some patients who
achieve a negative MRD become to relapse and several MRD+ patients have
a long survival, which indicates that the sensitivity and specificity of traditional
techniques for MRD assessment can be improved. 
Aims: To detect minimal residual disease in AML follow-up sample using high-
throughput sequencing as a standard and accurate technique. 
Methods: We studied 54 gDNA bone marrow follow-up samples (27 after induc-
tion, 10 after first consolidation, 17 after second consolidation) from 30 AML
patients treated according PETHEMA AML clinical protocols and with DNA sam-
ple at diagnosis. All patients had achieve CR at the moment of MRD assess-
ment. We developed a custom-targeted sequencing panel of 32 genes (Ion Tor-
rent Proton System-Thermo Fisher) for mutation (SNV and/or InDels) detection
at diagnosis sample; From the 32 genes, we use specific primers to amplify the
specific region of the four most frequent alterations at diagnosis (Samples at
follow-up: FLT3no-ITD n=2, NPM1n=46, IDH2 n=9 or IDH1 n=7). We analysed
and detected at diagnosis and at follow-up (after induction, first consolidation or
second consolidation), and sequenced with high-throughput approach. We
achieve a technical sensibility around 10-4for point mutations and 10-5for Indels
mutations according our specificity and sensitivity calibration curves.
Results: We analyse the results of assessing MRD by NGS, and the presence
or absence of MRD was established at a cut-off level of 0.0017 (between 10-
4and 10-5technical sensibility) by ROC curve with a sensibility of 0.5 for DFS
and 0.571 for OS, and a specificity of 0.92 for DFS and 0.897 for OS; thereby
a result above this level was considered as MRD positive. DFS (Disease Free
Survival) and OS (Overall Survival) rates in this group were 29.9% and 24.1%,
respectively; positive MRD sample was independent marker associated with
shorter DFS (p=0.002, HR=0.33, 95% CI:1.60-33.51) and OS (p=0.002, HR=
8.33, 95% CI:1.87-37.15) (see figure 1). These results support the usefulness
of MRD evaluation in patients with AML by NGS in the context of molecular
biology studies.
Figure 1.
Summary/Conclusions: High-throughput NGS is a technique with the capacity
to measure, identify and classified MRD levels. In fact, NGS MRD evaluation
has a better DFS and OS prediction than other traditional methods. Implemen-
tation of NGS technique on MRD detection could help to anticipate to disease
progression.
This study was funded by Instituto Carlos III (PI13/02387).
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THE ROLE OF MYELOID-DERIVED SUPPRESSOR CELLS-LIKE BLASTS
WHICH SUPPRESS T CELL PROLIFERATION IN LEUKEMIC CELL
GROWTH
S. Y. Hyun1,*, J. I. Lee1, E. J. Na1, J.-W. Cheong2
1Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, 2Inter-
nal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic
Of
Background: Myeloid-derived suppressor cells have an ability to suppress T-
cell function and have been known to facilitate tumor growth. We elucidated
the immune suppressive function of leukemic blasts which resembled MDSC
phenotype and their role in the growth of leukemic cells.
Aims: We elucidated the immune suppressive function of leukemic blasts
which resembled MDSC phenotype and their role in the growth of leukemic
cells.
Methods: CD11b+CD33+HLA-DR-blast (MDSC like blast) were isolated using
flow-cytometry from bone marrow mononuclear cells of primary acute myeloid
leukemia (AML) patient samples. CD14, CD15, Arg1 and iNOS expression
were checked by flow-cytometry to identify the phenotype of MDSC like blast.
To evaluate the ability of MDSC like blasts to suppress T cell proliferation,
CD8+ T cells from healthy donor and MDSC like blasts were co-cultured with
a ratio of 1:1 with/without phytohemagglutinin A 10ug/ml. T-cell proliferation
was measured by carboxyfluorescein diacetate succinimidyl ester dilution
assay after 3 days of culture. Then, various leukemic cell lines were co-cultured
with jurkat T cells and/or MDSC like blasts at a leukemic cell line:jurkat T cell:
MDSC like blast ratio of 4:4:1. The effect of jurkat T cells and MDSC like blasts
on the proliferation of leukemic cells was assessed by the CCK-8 assay after
1 and 3 days of culture.
Results: MDSCs like blast can be divided into two subtypes, monocytic sub-
group expressing CD14 and granulocytic subgroup expressing CD15, and
CD14 expression was more frequent than CD15 (67.5% vs 39.3%). MDSC-
like blasts showed higher expression of Arg1 (77.1% vs 38.5%, P<0.001) and
iNOS (33.0% vs 1.1%, P<0.0001) compared to non-MDSC-like blasts. CD8+T
cell proliferation induced by PHA was significantly suppressed when co-cultured
with MDSC-like blasts compared to without them. Among the various leukemic
cell lines, the proliferation of NB4 cells were significantly suppressed when co-
cultured with jurkat T cells on day 3 (NB4 23.49±6.26% of control, NB4+jurkat
12.62±3.92%, P<0.01). The decreased proliferation of NB4 cells was partially
recovered after 3 days of co-culture with MDSC-like blasts (NB4+jurkat
12.62±3.92%, NB4+jurkat+MDSC like blast 18.71±6.19, P=0.022).
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Summary/Conclusions: CD11b+CD33+HLA-DR- MDSC-like blasts subpopu-
lation which expressed the iNOS and Arg1 existed in AML, and showed ability
to suppress the T cell proliferation. MDSC-like blasts partially restored the sup-
pressed leukemic cell growth of NB4 cells by jurkat cells. MDSC-like blasts
might play a certain role in immune-escape mechanism of AML. 
E893
GENERATION OF NEW CELLULAR MODELS FOR THE STUDY OF
PEDIATRIC NON DOWN SYNDROME ACUTE MEGAKARYOBLASTIC
LEUKEMIA BASED ON HUMAN PLURIPOTENT STEM CELLS
J. Domingo-Reinés1,*, F. González-Pozas1, L. Morales-Cacho1, M. Vogel-Gonzalez1,
G. Rodriguez-Real1, J. Olmedo-Pelayo1, R. M. Montes1, V. Ayllón1, V. Ramos-
Mejía1
1Genyo, Granada, Spain
Background: Acute megakaryoblastic leukaemia (AMKL) is a rare and com-
plex type of Acute Myeloid Leukaemia (AML), more frequent in children than
in adults, characterized by the accumulation of immature megakaryoblasts
and thrombocytopenia. Paediatric AMKLs are classified in Down Syndrome
AMKL (DS-AMKL) with a good prognosis; and AMKL non-related to Down
Syndrome (non-DS-AMKL), a more aggressive disease with a mortality rate
close to 80%. There is a limited amount of research done on infant non-DS
AMKL due to its low frequency and the heterogeneity of the gene mutations
linked to it. Among the genetic alterations found in non-DS-AMKL, approxi-
mately half of the patients carry the chromosomal translocations t(1;22) and
t(11;12), that generate the fusion proteins RBM15-MKL1 and NUP98-JARID1
respectively, and the inversion of chromosome 16, that originates the fusion
protein CBFA2T3-GLIS2.
Aims: It is essential to establish new human models to provide enough biolog-
ical material for functional and molecular studies. As the genetic alterations
that drive infant leukaemia occur in the developing fetus, we propose that
human pluripotent stem cells (hPSCs) are ideal models to study non-DS AMKL,
as these cells allow us to mimic human embryonic hematopoietic development.
In this project, we aim to use human hPSCs expressing non-DS AMKL-asso-
ciated fusion oncogenes as cellular models for this leukaemia, to study the
molecular and cellular pathways involved in the development of pediatric non-
DS-AMKL.
Methods: Generation of human models of non-DS AMKL using hPSCs: 1. Gen-
eration of hPSCs with the oncogenic fusion proteins RBM15-MKL1, CBFA2T3-
GLIS2 and NUP98-JARID1 using transduction with lentiviral vectors. 2. Gen-
eration of hPSCs with the chromosomal translocations t(1;22)(p13;q13)
RBM15-MKL1 and t(11;12)(p15;p13) NUP98-JARID1 using the CRISPR/Cas9
system. Once the non-DS AMKL hPSC cell lines are generated, we confirm
that they preserve their pluripotency by checking expression of pluripotency
markers by flow cytometry and PCR. We also confirm their ability to differentiate
into the three germ layers forming embryoid bodies. Using an in vitro differen-
tiation system that recapitulates early human haematopoiesis, we compare
non-DS-AMKL hPSCs and control hPSCs in order to determine at which point
of the differentiation fails and the molecular mechanisms underlying. We
analyse by multicolour flow cytometry the generation and evolution over time
of different cell populations: mesodermal cells, hemato-endotelial progenitors,
hematopoietic progenitors and megakaryocytic precursors. We use colony-
forming assays (CFU) to determine the generation and functionality of
hematopoietic progenitors.
Results: Here we report the generation and characterization of human non-
DS AMKL models based on pluripotent stem cells that express oncogenic fusion
proteins RBM15-MKL1, NUP98-JARID1 and CBFA2T3-GLIS2. 
Summary/Conclusions: These models will serve as platforms to discover and
understand the cellular and molecular alterations caused by these oncogenes,
and their impact in the generation of hematopoietic cells during development.
With this information we will have a better understanding of the origin and devel-
opment of paediatric non-DS AMKL, so we will be able to design new thera-
peutic approaches for these children.
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CHARACTERIZATION OF HEMATOLOGIC MALIGNANCIES WITH
ANCHORED MULTIPLEX PCR AND NEXT-GENERATION SEQUENCING
L. Johnson1, M. Bessette1, A. Berlin1, J. Haimes1, D. Fugere1,*, L. Griffin1,
K. Trifilo1, N. Manoj1, H. Wang1, R. Ryan2, M. Hussaini3, B. Kudlow1
1ArcherDX, Boulder, CO, 2Massachusetts General Hospital, Boston, MA, 3Mof-
fitt Cancer Center, Tampa, FL, United States
Background: Hematologic malignancies can be driven by a diversity of muta-
tion types, including single nucleotide variants, copy number variants, gene
fusions, insertions and deletions and changes in gene expression profiles. How-
ever, comprehensive detection of these mutation types from a single clinical
sample is challenging, as specific assays are required to detect each mutation
type. Next-generation sequencing (NGS) enables comprehensive detection of
all mutation types from whole genomes and transcriptomes. However, low
detection sensitivity, high input requirements and high costs render these
approaches impractical for routine detection of mutations from clinical sample
types. Anchored Multiplex PCR (AMP™) is a target enrichment strategy for
NGS that uses molecular barcoded (MBC) adapters and unidirectional gene-
specific primers (GSPs) for amplification.
Aims: Our goal was to develop AMP-based NGS assays to simultaneously
detect multiple mutation types from DNA and RNA, as well as relative gene
expression levels and copy number alterations (CNA) relevant in hematologic
malignancies. In particular, we sought to develop methods to detect novel gene
fusions, internal tandem duplications (ITDs) and mutations in CEBPα.
Methods: We developed AMP-based Archer® VariantPlex™ and FusionPlex®
assays to enable NGS-based detection of mutations from DNA and RNA,
respectively. Open-ended amplification permits identification of novel gene
fusions with FusionPlex and complex mutation types such as ITDs with Vari-
antPlex assays. MBC adapters ligated to RNA and DNA fragments prior to
amplification enable relative gene expression and CNA analysis.
Results: We show instances of gene fusion detection from open-ended ampli-
fication in RNA, including a novel fusion, RUNX1-G6PD, in a case of acute
unclassifiable leukemia. Furthermore, unidirectional GSPs provided bidirec-
tional coverage of a BCR-ABL1 fusion, which was detected with reads origi-
nating from ABL1 as well as BCR. Using our optimized bioinformatics algorithm
and the VariantPlex assay, we accurately and reliably detected ITDs of varying
sizes and insertion points, with simultaneous point mutation detection, in AML-
positive blood samples. Furthermore, we show multiple mutations in various
AML-positive sample types, including mutations in CEBPα. Finally, MBCs used
in AMP enabled NGS-based expression profiling for identification of Diffuse
Large B-Cell Lymphoma subtypes in a small cohort of samples.
Summary/Conclusions: Our results demonstrate that AMP-based NGS
enables comprehensive detection of multiple mutation types as well as gene
expression levels relevant in hematologic malignancies. Importantly, AMP
enables identification of known and novel gene fusions at nucleotide resolution,
detection of ITDs and characterization of relative gene expression levels and
CNAs.
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ASXL1 MUTATIONS IN AML ARE ASSOCIATED WITH SPECIFIC CLINICAL
AND CYTOGENETIC CHARACTERISTICS
K. Kakosaiou1, F. Panitsas2, A. Ioannidou1, M. Pagoni2, P. Apostolou3, A. Daraki1,
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Background: Mutations of ASXL1 are considered early founder events in AML
leukemogenesis. They are included in the definition of the “chromatin-splice-
some” genomic class of AML and among the high risk genetic prognosticators
in the 2017 ELN recommendations.
Aims: We aimed to study the frequency of ASXL1 mutations in a cohort of
newly diagnosed AML patients and to look for correlations with conventional
cytogenetic findings and baseline characteristics. 
Methods: Three hundred and sixty AML patients diagnosed between 2005 and
2014 were studied. Conventional cytogenetic analysis was performed on
unstimulated bone marrow cells cultured for 24 and 48 hours. Molecular analy-
sis of ASXL1 exon 12 mutations was performed by PCR and subsequent direct
Sanger sequencing in diagnostic bone marrow or peripheral blood samples. 
Results: Median age of the whole cohort was 63 years (11-95) and 56% of
patients were male. Eighty two patients (22.8%) had secondary AML (sec-AML)
with prior diseases being MDS (63), CMML (4), PV/ET (9), MF (2) and CML
(4). Karyotypic analysis was successful in 352 (97.7%) AML samples of which
252 (71.6%) exhibited clonal karyotypic abnormalities. ASXL1 mutations were
detected in 52 patients (14.4%). The most common mutation was c.1934 dupG
in 44/52 (84.6%). ASXL1 mutated patients were significantly older with median
age 72 vs 61.5 years in the unmutated (p=0.0001). Three of 61 patients (4.9%)
aged ≤40, 10/97 aged 41-60 (10.3%) and 39/198 aged >60 (19.7%) were mutat-
ed (p=0.005). ASXL1 mutation frequency was similar in male (15.4%) and
female patients (13.2%). ASXL1 mutations were significantly more frequent in
sec-AML patients (32.9%) than in de novo AML (9%, p<10-3). ASXL1mut cases
tended to have higher peripheral white cell count at diagnosis (median 29 vs
11.5 x109/L). Frequency of ASXL1 was similar in patients with normal (13%)
and abnormal karyotypes (15.5%) (p=0.55). No association with complex (16.7
vs 14.3, p=0.63) or monosomal karyotypes (16.4 vs 14.5%, p=0.72) was found.
ASXL1 mutations were less common in patients with WHO defined MDS-related
cytogenetic abnormalities (10.5% vs 16.6%, p=0.14). Moreover, we observed
an inverse relationship of ASXL1 mutations with -7/del(7q) or -5/del(5q) as a
group (8.9% vs 16.8%, p=0.07). ASXL1 mutations were significantly more fre-
quent among cases with trisomy 8 (25% vs 12.8%, p=0.02) and patients with
chromosome 11 aberrations (23.7% vs 13.7%, p=0.1).None of the 12 patients
with inv(16)/t(16;16) was mutated while 2/16 (12.5%) with t(8;21) had ASXL1
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mutations. Moreover, ASXL1 mutations were detected in 3 of 12 patients with
aberrations of 3q (25%), 2/9 (22%) with trisomy 13, 2/11 (18%) with t(9;22)
and only 1 of 22 patients with t(15;17). Multivariate logistic regression showed
that independent predictors of the presence of ASXL1 mutations were older
age (OR 1.43 per decade, 95% CI 1.13-1.79), chromosome 11 aberrations
(OR 2.69, 95% CI 1.09-6.63), and sec-AML (OR 4.44, 95% CI 2.3-8.57), where-
as -7/del(7q) or -5/del5q predicted for lower frequency (OR 0.32, 95% CI 0.13-
0.75).
Summary/Conclusions: Our results support the association of ASXL1 muta-
tions in AML with advancing age and sec-AML. Association with trisomy 8 did
not retain significance in multivariate analysis. Chromosome 11 aberrations
emerged as an independent predictor. Despite the strong link with secondary
AML (majority of cases post MDS), our data show inverse relationship with -
7/del(7q) or -5/del5q. In addition, ASXL1 mutations were not positively associ-





A COMPREHENSIVE DNA TEST FOR THE DETECTION OF TRANSLOCATIONS
IN ACUTE LEUKEMIA
E. Van Den Berg-De Ruiter1,*, M.Z. Alimohamed1, L.F. Johansson1,2,
E.N. de Boer1, E. Splinter3, P. Klous3, A.G. Bosga1, M. van Min3, A.B. Mulder4,
E. Vellenga5, R.J. Sinke1, R.H. Sijmons1, B. Sikkema-Raddatz1
1Genetics, 2Genetic Coordination Center, UMCG, Groningen, 3Cergentis B.V.,
Utrecht, 4Laboratory Medicine, 5Hematology, UMCG, Groningen, Netherlands
Background: Patients with acute leukemias carry a wide range of chromosomal
abnormalities, which affect their prognosis and treatment options. Currently,
over 500 different translocations are reported to be involved in the disease pro-
gression. Traditional methods to detect chromosomal abnormalities involve a
combination of techniques such as karyotyping, FISH, array and RT-PCR. How-
ever, these methods are laborious and at times inadequate. Targeted Locus
Amplification (TLA), a new targeted next generation sequencing technology can
overcome these shortcomings. It is based on proximity ligation (crosslinking) of
DNA and outward oriented probes for enrichment and can therefore identify
chromosomal translocation partners regardless of their identities.
Aims: Here we present a TLA multiplex panel in combination with next gener-
ation sequencing as a first tier screening tool in detecting translocations in
acute leukemias.
Methods: A multiplex TLA panel was designed using primer sets covering
known break-point regions of the 17 most frequently reported genes involved
in acute leukemia’s. TLA was performed on five different cell lines carrying
translocations detectable by our panel. [t(12;21), t(6;11), t(11;19)t(8;13), t(6;9),
t(17;19)]. Various combinations of cell line mixtures in multiple dilution series
were used to determine the specificity and sensitivity of the panel, and to set
sample quality thresholds during analysis. Samples were processed using
standard TLA protocol (de Vree et al, 2014). Targets were enriched by PCR
amplification with the multiplex panel and subjected for sequencing on Illumina
Nextseq 500. To facilitate an easy analysis workflow a semi-automated data
analysis was developed. This includes a quality control step, labelling samples
with no coverages at the anchor regions after filtering at more than half the
number of target regions as failed. These were not interpreted. Only peaks
outside other anchor regions were considered as false positive peaks. Peaks
present in other anchor regions were interpreted as possible artefacts and
labelled as needing extra confirmation. In these series until now, up to 10%
aberrant cells were detected with no false positives as no translocations other
than expected for cell lines were detected. Bone marrows of 36 patients sus-
pected of acute leukemia were taken for routine genetic diagnosis (Karyotyping,
FISH and or RT-PCR) and TLA. Sample analysis was performed randomized
and blinded. TLA outcome was then compared with results from routine genetic
testing.
Results: From a total of 36 patients three samples did not meet the required
sample quality for further analysis. In the remaining 33 patients our TLA multi-
plex panel confirmed the presence of translocations on 16 samples. This
includes a cryptic translocation involving the ETV6-RUNX1 fusion gene,
t(12;21)(p13;q22) in five pediatric ALL samples, not detected with karyotyping
but RT-PCR, confirming the TLA findings. In fifteen samples no translocation
was detected, concordant to (cyto)genetic findings. Three translocations were
missed due to insufficient sequence reads on the partner chromosome. In addi-
tion, in one sample one translocation partner was also missed, located in the
telomeric region of the chromosome and therefore resulting to nonspecific
mapping of the sequence reads. An additional finding, involving a three way
translocation t(9;22;11), missed by cytogenetics was detected by our panel.
Two new findings have yet to be confirmed with FISH.
Summary/Conclusions: Our TLA panel showed concordant results for 29 out
of the 33 successful sequenced samples. No false positives were found, while
an additional translocation was detected. Our panel is able to detect (cryptic)
translocations without prior knowledge of the fusion partner Therefore, the TLA
multiplex panel is suited as a first tier screening tool in acute leukemia. A
prospective study, comparing the diagnostic yield of the TLA panel with current
tests, can establish whether the TLA panel is applicable as a routine procedure.
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ALTERATIONS IN NECROPTOSIS PATHWAY AFFECT PROGNOSIS OF
PATIENTS WITH ACUTE MYELOID LEUKEMIA
S. Lo Monaco1,*, G. Marconi1, M.C. Fontana1, C. Papayannidis1, E. Ottaviani1,
E. Franchini1, A. Ferrari1, A. Padella1, G. Simonetti1, S. Paolini1, G. Martinel-
li1
1University of Bologna, Bologna, Italy
Background: Necroptosis is a type of necrotic cell death involving several
genes transcription and activation of molecular mechanisms as death recep-
tors, interferon, toll-like receptors, intracellular RNA and DNA sensors. The
process is leading by the family of receptor-interacting protein kinase (RIPK3,
RIPK2, RIPK1) and the MLKL substrate. Losses of RIPK3 or MLKL, as well as
deficiency in apoptosis, could allow tumor cells to escape the immune-mediated
cells death (ICD).
Aims: We want to investigate the role of necroptosis deficiency in correlation
with chemotherapy resistance and its impact as prognostic factor in AML.
Figure 1.
Methods: We performed SNP Arrays (Cytoscan HD and SNP 6.0, Affymetrix)
on a cohort of 300 non-M3 AML patients at diagnosis and we analyzed the
Overall Survival (OS) of our patients with deficiency on necroptosis pathways.
Survival was analyzed with Kaplan-Mayer method and Log-Rank test. We fur-
ther analyze the relevance of different prognostic factors by the use of COX-
Hazard Ratio statistical analysis.
Results: We found that 18 patients presented a loss of RIPK1 or MLKL (nobody
presented losses in RIPK3/RIPK2) and 13/18 patients were older than 65 years
old. The Overall Survival (OS) of patients with alterations in these genes is sig-
nificantly lower than control group, with a median OS of 3 vs 6 month respec-
tively (p<.0.001). With Fisher Exact Test we further demonstrate that copy num-
ber loss of RIPK1 or MLKL are associate to loss of TP53 or FANCA genes,
complex karyotype and advanced age. COX-Hazard Ratio model with RIMK1
or MLKL loss, BRCA1 loss, TP53 mutation, FANCA loss, secondary disease
and diagnosis karyotype considered as categorical variable show that necrop-
tosis deficiency (HR 1.98, CI 95% 1.04-3.78) TP53 mutation, and secondary
AML are independent negative prognostic factors in an optimal model.
Summary/Conclusions: Our study shows that losses in necroptosis pathways
are an uncommon alteration in AML, prevalent in old population. Moreover, we
hypothesize that the loss of genes involved in necroptosis could be a real
mechanism of tumor immune-escape and could be a rational to select patients
that high probability to be resistant at chemotherapy promoting ICD mecha-
nism.
Acknowledgment: ELN,AIL,AIRC, progetto Regione-Università 2010-12, FP7
NGS-PTL project,HARMONY.
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NGS ANALYSIS AND IMPACT OF VARIANT ALLELIC FREQUENCY AT
RELAPSE AND REFRACTORINESS STATUS IN AML PATIENTS
E. Onecha De La Fuente1,2,*, I. Rapado1,2, M. Llops3, Y. Ruiz-Heredia1,2,
T. Cedena1,2, E. Barragan3,4, M. Gallardo1,2, J. Martinez Lopez1,2, R. Ayala1,2
1Hematologia traslacional, Hospital 12 de Octubre, 2Haematological Malignan-
cies Clinical Research Unit, CNIO, Madrid, 3Instituto de Investigación Sanitaria
La Fe, 4Clinical Pathology Service, Hospital Universitari i Politècnic La Fe,
Valencia, Spain
Background: A high number of patients with acute myeloid leukemia (AML)
present resistance at treatment, which is associated with clonal persistence or
evolution. The generation of high-depth sequencing data allowed to quantify
variant allelic frequencies (VAF) and permitting estimation of the size of tumor
clonal populations in each AML sample, and to perform an estimation of clonal
evolution at relapse or refractory case according at diagnostic. 
Aims: To evaluate the predictive impact of the fluctuation Variant Allelic Fre-
quency in resistance to treatment cases in AML.
Figure 1.
Methods: We performed a custom-targeted sequencing panel of 32 genes (all
coding regions) implicated in leukemia prognosis, including ASXL1, CBL,
DNMT3A, EPOR, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2, KDM6A, KIT,
KRAS, LNK, MLL, MPL, NRAS, PHF6, PRPF40B, PTEN, RUNX1, SF1, SF3A1,
SF3B1, SRSF2, TET2, TP53, U2AF35, VHL, ZRSR2 and CALR, by Ion Torrent
Proton System-Thermo Fisher. Primary tumor-refractory (n=8) and primaty
tumor-relapsed (n=17) samples pairs from 25 AML patients treated according
PETHEMA AML clinical protocols were sequenced; in addition FLT3-ITD was
detected by GENSCAN and NPM1 mutation was detected by PCR. We analyse
the evolution of level of VAF, to measure the prevalence of somatic mutations
between diagnosis and resistance status (relapse or refractory). 
Results: Mutations in signalling pathway (EPOR, FLT3, JAK2, KIT, LNK or/and
MPL) and GTPases pathway (KRAS, NRAS, HRAS) present significant ΔVAFs
increases in relapse samples, p=0.05 and p=0.039 respectively. See figure 1.
Furthermore, mutations in IDH2, JAK2 or KRAS show ΔVAF trend increases.
Also, mutations in signalling pathway shows significant ΔVAF decrease in pri-
mary refractory samples, p=0.015; mutations in JAK2, KMT2A or SF3A1 shows
ΔVAF trend decreases. Regarding to mutational profile we found significant
differences in the VAF evolution in relapse samples, with VAF increment in
IDH1 (p=0.031), KDM6A (p=0.018), KIT (p=0.000), PRPF40B (p=0.019), SF1
(p=0.033) and SF3A1 (p=0.044). Also, we found significant differences in the
VAF evolution of primary refractory samples, reduced in KMT2A (p=0.016),
RUNX1 (p=0.000) and the methylation pathway (DNMT3A, EZH2, KMD6A,
MLL, TET2, IDH1 and IDH2; p=0.043). Mutations in TET2, U2AF1 or SF3A1
show VAF trend decreases. No correlation was found between VAF and%
blasts, nor did VAF fluctuation with blasts fluctuation.
Summary/Conclusions: These results show VAF increases of specific muta-
tions as KIT correlates with relapse status. However, in this cohort new specific
mutations were not found neither VAF increases, even the opposite being as
VAF decreases of specific mutations as RUNX1 correlates with primary refrac-
toriness status. Furthermore, the variable frequency signalling pathway (EPOR,
FLT3, JAK2, KIT, LNK or/and MPL) play a critical role in resistance status,
increasing variant allelic frequencies of mutations in relapse and decreasing in
refractoriness.
This work was supported by the grant: PI13/02387.
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PRECLINICAL EVIDENCE THAT TRAMETINIB ENHANCES THE RESPONSE
TO TYROSINE KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA
M.L. Morales1,*, M. Linares1, A. Arenas1, I. Zagorac2, R. Ayala2, N. Castro1,
I. Rapado1, M. Quintela-Fandino2, J. Martinez-Lopez1
1Servicio de Hematologia, Hospital Universitario 12 de Octubre, 2Unidad de
Proteomica, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
Background: Acute Myeloid Leukemia (AML) is the most common type of
acute leukemia in adults and the second in children in whom overall survival is
less than 35% and 60% respectively. Activating mutations of FLT3 are now rec-
ognized as the most common molecular abnormality in this disease, and the
poor prognosis of patients harboring these mutations renders FLT3 an obvious
therapeutic target. Although different tyrosine kinase inhibitors (TKI) have been
used for this purpose, their ability to extend progression-free and overall survival
is limited by drug resistance. This strategy could be improved by rationally com-
bining TKIs with other agents. In this work, we have explored bone marrow
samples from a FLT3-AML patient before and after TKI treatment by phospho-
proteomics and observed enhanced activity of Ras-Raf-MEK-ERK1/2 pathway
as a possible mechanism for TKI resistance. 
Aims: To validate the role of ERK1/2 during TKI resistance in vitro and ex vivo
and to search suitable combinations that allow overcome/avoid resistances in
preclinical models of the disease.
Methods: Resistance mechanisms were studied in vitro in MOLM13
(FLT3WT/ITD) after generating resistance by two different methods: by subcul-
turing with increasing doses of sorafenib or by treating them with high doses of
sorafenib, and recollecting alive proliferative (resistant) cells after CFDA and
Anexinn labeling. Phosphoproteomic analyses were carried out by LC-MSMS
after IMAC enrichment or by western blot techniques. Drug sensitivity assays
with trametinib (MEK inhibitor) and three TKIs (sorafenib, pazopanib, midostau-
rin) were read after 48 hours or 72 hours of treatment in vitro or ex vivo respec-
tively. The efficacy of the combinational treatments was characterized by the
cell viability assay using WST8, and analyzed with Graphpad Prism software.
Synergy effects were measured with Calcusyn software.
Figure 1.
Results: As it is presented in figure 1, ERK1/2 pathway was more activated
after TKI treatment in the FLT3-AML patient during sorafenib-resistance devel-
opment. The same fact was confirmed in MOLM13 sorafenib-resistant culture
and in living proliferative cells recollected after sorafenib treatment. Different
doses of trametinib, sorafenib, pazopanib and midostaurin in monotherapy
were tested in MOLM13 cell line determining their IC50 values. Sinergy effects
of combining trametinib with the three TKIs were analyzed with Calcusyn soft-
ware and normalized isobolograms were represented. All combinations showed
CI values less than 0.5 (Ci<0.5). The inhibition levels of four pathways (PI3K,
STAT5, ERK1/2 and MAPK14) implicated in TKIs resistance were studied by
western blot and the combination of midostaurin plus trametinib was the only
one that inhibited all of them. Trametinib efficacy in the MOLM13 sorafenib-
resistant culture was evaluated and confirmed that remained effective. Trame-
tinib plus midostaurin combination was tested in OCI AML-3 cell line
(FLT3WT/WT) showing high efficacy and strong synergy (CI<0.5) too. Finally,
we have assayed these drugs ex vivo in three AML samples showing the same
effectiveness as in vitro, with IC50 values ranging from 0.2µM to 0.9 µM for
midostaurin and 3 nM to 29 nM for trametinib and Ci values less than 0.5.
Summary/Conclusions: In conclusion, we provide preclinical evidence that
combining a TKI, especially midostaurin, with a MEKI, such as trametinib, is a
rational and efficacious treatment regimen for AML. As trametinib has previously
shown good results when combined with pazopanib in clinical trials for other
kind of tumors, we expect similar results in AML.
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IDENTIFICATION OF NOVEL THERAPEUTIC DRUGS IN DISTINCT
PEDIATRIC AML SUBTYPES BY TARGETING EPIGENETIC REGULATORS
C. Wiggers1,2,*, D. Lelieveld3, D. Egan3, M. Bartels1
1Pediatrics, University Medical Center Utrecht, 2Hubrecht Institute, 3Cell
Screening Core, Cell Biology, University Medical Center Utrecht, Utrecht,
Netherlands
Background: Treatment protocols for pediatric acute myeloid leukemia (AML)
are chemotherapy-based, including high-dose cytarabine. While >90% of
patients reach clinical remission, there is still a high relapse rate of ~30%, with
overall survival rates of 60-70%. Therefore, better risk-classification at diagnosis
and alternative treatment strategies are warranted. There is increasing evidence
that epigenetic deregulation is involved in the initiation and progression of can-
cers, including AML. Epigenetic processes are required for hematopoiesis and
epigenetic regulators are frequently translocated (MLL) or mutated (EZH2) in
AML. Following this, deregulated epigenetic pathways could be used for targeted
therapy and provide an alternative approach to improve pediatric AML therapy.
Aims: To identify new therapeutic drugs in pediatric AML by using an 80-com-
pound screen containing inhibitors of epigenetic regulators, including histone
writers (which deposit post-translational modifications (PTMs) on histones),
readers (binding of PTMs) and erasers (removal of PTMs).
Methods: Cell lines used in this study are THP-1 (t(9;11)), Kasumi-1 (t(8;21))
and CMK (Down’s syndrome with GATA1 mutation), reflecting distinct pediatric
AML entities and a differential response to treatment with cytarabine. Cells
were treated for 72hrs followed by analysis of cell viability and apoptosis based
on Hoechst, Draq7 and Calcein Green staining. The effect of three candidate
compounds were further investigated in triplicates at several concentrations
for their effect on cell viability (Annexin V/PI staining), cell cycle, morphology,
and apoptosis in the cell lines, normal myeloid precursor cells derived from
cord blood, and pediatric AML patient cells representing distinct AML subtypes.
Results: From the 80 epigenetic compounds tested in THP-1, Kasumi-1 and
CMK cells, we observed significant effects following treatment with the HDAC
4/5 inhibitor LMK235, the pan-HDAC inhibitor NSC3852, and the pan-bromod-
omain inhibitor Bromosporine. Dose-response curves showed differential cyto-
toxicity of the compounds and suggested LMK235 as most effective. Cell pro-
liferation was inhibited by LMK235 at an IC50 of 0.1uM, 0.13uM and 0.425uM
in Kasumi-1, CMK and THP-1, resp. While inhibition by LMK235 resulted in an
immediate response of apoptosis, Bromosporine-treated cells retained in G1
before undergoing apoptosis and, interestingly, NSC3852 treatment resulted in
an increase of cells in S-phase and G2/M. Among the differential effects of the
compounds in the cell lines, we also observed differences in sensitivity. In line
with previous studies, THP-1 cells were more resistant, illustrated by a 10-fold
increase in concentration required for NSC3852-induced apoptosis. Interestingly,
upon treatment with Bromosporine, Kasumi-1 and CMK cells showed a similar
response, while Kasumi-1 cells were significantly more sensitive to NSC3852-
induced effects. These data are currently validated in pediatric AML patient cells.
Summary/Conclusions: Treatment of three distinct pediatric AML cell lines with
the epigenetic compounds LMK235, NSC3852 and Bromosporine resulted in cell
line-specific effects, regarding compound sensitivity, and compound specific
effects, including cell cycle regulation and induction of apoptosis. Our data sug-
gests a potential role for epigenetic compounds, with specificity for molecular sub-
types, in the treatment of clinically and biologically distinct pediatric AML subtypes.
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ALVOCIDIB SYNERGIZES WITH CYTARABINE AND DAUNORUBICIN (7+3)
IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA
W. Kim1, H. Haws1, R. Mangelson1, P. Peterson1, C. Whatcott1,*, A. Siddiqui-Jain1,
S. Weitman1, D. Bearss1, S. Warner1
1Discovery Biology, Tolero Pharmaceuticals, Inc., LEHI, United States
Background: Although survival of patients with acute myeloid leukemia (AML)
has increased in the years 1975-2011, the 5-year, overall survival of patients
with AML remains unacceptably low at an estimated 26% (2011). ‘7+3’ treat-
ment (cytarabine 100-200mg/m2 + anthracycline [daunorubicin 60-
90mg/m2/day or idarubicin 12mg/m2/day]) remains the standard induction ther-
apy in AML patients, and has persisted largely unchanged for more than 30
years. There is a significant unmet clinical need for improved therapeutic
options in patients with AML. Alvocidib is a CDK9 inhibitor currently in devel-
opment for the treatment of patients with AML. Alvocidib has previously been
studied as part of the ACM regimen, a combination regimen incorporating the
time-sequential (TST) administration of alvocidib, cytarabine, and mitoxantrone,
in multiple Phase 1 and 2 clinical trials. The ACM regimen has achieved sig-
nificant improvements in complete response (CR) rates versus 7+3 in previ-
ously untreated intermediate and high-risk AML patients. The rationale for time-
sequential administration of the ACM regimen was developed with an incom-
plete understanding of alvocidib’s mechanism of action. TST was based on
the expectation that alvocidib would synchronize cells, capitalizing on the S-
phase specific activity of cytarabine in the combination. However, rather than
cell-cycle inhibition, alvocidib potently induces apoptosis by inhibiting the
expression of key anti-apoptotic proteins via CDK9/RNA polymerase II, includ-
ing MCL-1. With this understanding, we reasoned that alvocidib would also
enhance the activity of the 7+3 regimen. 
Aims: These studies sought to interrogate the preclinical activity of alvocidib
in the context of the 7+3 regimen in models for AML.
Methods: CellTiter-Glo and Caspase-Glo was used for all cell viability and
apoptosis assays interrogating alvocidib and 7+3 activity in cell lines, following
manufacturer’s protocol. We used RT-PCR to measure mRNA expression of
MCL-1 and other markers in response to drug treatment. Protein levels were
interrogated using standard immunoblotting techniques. To determine the effi-
cacy of an alvocidib/7+3 combination on tumor growth in vivo, we performed a
MV4-11 xenograft mouse study.
Results: Single agent IC50 values of alvocidib, cytarabine, and daunorubicin
range in AML cell lines from 2.2 nM to as high as 567 nM in viability assays. In
apoptosis (Caspase-Glo) assays, however, we observed modest induction with
single agent cytarabine, and good induction with single agent daunorubicin or
alvocidib. In the combination, however, we observed very strong synergy with
more than two-fold enhanced induction of apoptosis in some treatment groups.
As has been previously described, we report here too that alvocidib treatment
reduced the expression of MCL-1 protein and mRNA in a time and concentra-
tion-dependent fashion in AML cells. We observed this in the 7+3 treatment
context as well. In an MV4-11 xenograft model, we observed 21.1 and 48.5%
tumor growth inhibition (%TGI) following single agent treatment of daunorubicin
or cytarabine, respectively. 1.25mg/kg alvocidib yielded 60.0%TGI. The com-
bination of alvocidib, cytarabine, and daunorubicin, however, resulted in tumor
regression, yielding a 116.2%TGI. 
Summary/Conclusions: Though multiple clinical studies have demonstrated
the increased efficacy of the ACM regimen over 7+3 in AML, these studies
cannot correctly capture the clinical contribution of alvocidib alone as they do
not offer a direct comparison. The current study attempted to interrogate the
contribution of alvocidib to the 7+3 induction regimen, in preclinical models.
These results provide a clear rationale for a clinical study directly comparing
the triple combination to 7+3 alone. Taken together, our results suggest that a
combination of alvocidib, cytarabine, and daunorubicin might be a potential
clinical regimen in treating frontline AML, offering patients additional treatment
options in treating their disease.
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COMBINATION OF INTERFERON-ALPHA AND VALPROIC ACID IN ACUTE
MYELOID LEUKEMIA CELLS IN VITRO AND IN VIVO
R.B. Forthun1, A. Sulen1, G. Sjøholt2, Ø. Bruserud3,4, E. Mc Cormack 1,
B.T. Gjertsen1,3,*
1Centre for Cancer Biomarkers (CCBIO), University of Bergen, 2Department
of Biomedical Laboratory Sciences and Chemical Engineering, Bergen Uni-
versity College, 3Department of Internal Medicine, Haematology Section,
Haukeland University Hospital, 4Department of Clinical Science, Leukemia
Research Group, University of Bergen, Bergen, Norway
Background: Interferon alpha (IFNα) monotherapy is effective in selected
myeloid neoplasias and is proposed to act through mechanisms that may be
additive to the action of valproic acid (VPA), a histone deacetylase (HDAC)
class I and IIA inhibitor with effect in approximately 20% of acute myeloid
leukemia (AML) patients. Both drugs are found to have direct anti-cancer effects
targeting apoptosis, differentiation and proliferation, as well as indirect effects
targeting the immune system.
Aims: As several IFNα formulations are commercially available, we wished to
explore the differences between two such drugs, recombinant IFNα-2b and
human IFNα-Le, in relevance to AML treatment. 
Methods: Flow cytometry and Hoechst staining was used to investigate apop-
totic potential of the IFNα therapeutics, whilst phospho-flow cytometry and dif-
ference gel electrophoresis in combination with mass spectrometry unraveled
IFNα signaling pathways. For in vivo effectivity analyses two orthotopic rodent
models were implanted with leukemic cells and treated with VPA, IFNα-Le or
both drugs.
Results: To investigate the anti-leukemic effects of IFNα we combined the two
therapeutics with VPA in vitro using the human MOLM-13 cell line (wild type
for FLT3 ITD and TP53). Results showed that IFNα-Le was more efficient com-
pared to IFNα-2b in inducing apoptosis, whilst both were synergistic in combi-
nation with VPA. Investigating IFNα signaling pathways using phospho-specific
flow cytometry we found IFNα-2b and IFNα-Le to have an identical stimulation
profile in MOLM-13 cells, except from p-STAT6 Y641 that was higher expressed
by IFNα-2b. The phospho-proteome was further explored using difference gel
electrophoresis (DIGE) and mass spectrometric analyses to find a potential
explanation to the difference in apoptosis-inducing effects between the two
drugs. Here we found protein folding (LCP1, HSPA8, TCP1, CCT6A), cell stress
(AKR1B1, HSP90AB1) and cell death (PKM2, PARK7, HSPB1, HSPA5,
ANXA5, PRDX2) to be differently regulated between IFNα-2b and IFNα-Le,
and also identified the presence of a dose-dependent effect on protein expres-
sion by IFNα-2b and IFNα-Le. Further, we investigated the potential synergistic
anti-leukemic effects of VPA and IFNα-Le in vivo using a MOLM-13Luc+immun-
odeficient NOD/Scid IL2 g-/- orthotopic xenograft mouse model, and the
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immunocompetent brown Norwegian myeloid leukemia (BNML) syngeneic rat
model. VPA mono-treatment increased survival from a median of 34 days to 38
days in the MOLM-13Luc+mouse model, and from 21 days to 50 days in the
BNML rat model. Additionally, the IFNα-Le (0.8x106 IU/kg) and VPA (400mg/kg)
combination treatment indicated a tendency to increased survival in the BNML
model. However, IFNα-Le monotherapy (1x106 IU/kg) decreased survival in
the MOLM-13Luc+ model.
Figure 1.
Summary/Conclusions: IFNα does not add beneficial effects to VPA treatment
in the two in vivo orthotopic models tested, possibly due to immune constitution
and tumor load. 
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KEVETRIN: PRECLINICAL STUDY OF A NEW COMPOUND IN ACUTE
MYELOID LEUKEMIA
R. Napolitano1, S. De Matteis1,*, S. Carloni1, G. Simonetti2, G. Musuraca3,
A. Lucchesi3, D. Calistri1, A. Cuneo4, K. Menon5, G. Martinelli2
1Bioscience Laboratory, IRCCS, Istituto Scientifico Romagnolo per lo Studio e
la Cura dei Tumori (IRST), Meldola, 2Department of Hematology and Oncolog-
ical Sciences, L. and A. Seragnoli, Bologna, 3Hematology Unit, IRCCS, Istituto
Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola,
4Department of Medical Sciences, University of Ferrara-Arcispedale Sant’Anna,
Ferrara, Italy, 5Cellceutix Corporation, Beverly, United States
Background: Acute Myeloid Leukemia (AML) is a heterogeneous disorder
defined by clonal expansion of immature myeloid cells that infiltrate bone mar-
row and other tissues. AML therapeutic strategies remain unchanged since
1970 and the majority of patients often eventually relapse and die due to dis-
ease progression. Tumor protein p53 transcription factor is a key regulator of
several cellular pathways, such as DNA repair, cell cycle, apoptosis and angio-
genesis. It is mutated in 8-14% of AML cases and its mutations are commonly
associated with a complex karyotype. Kevetrin is a new molecule compound,
proposed by Cellceutix, with the ability to target both wild type and mutant p53
tumors.
Aims: The aim of this project is to explore cellular and molecular alterations
induced by Kevetrin, focusing on its role in the p53 pathway.
Methods: Kevetrin was kindly provided by Cellceutix, dissolved and stored at
4°C in sterile water in a 600 μg/ml stock solution, and diluted in medium imme-
diately before use [concentration range in use 15-60μg/ml]. Cell lines, MOLM-
13 and KASUMI-1, were cultured in RPMI 1640 supplemented with 20% heat
inactivated fetal bovine serum, 2mM L-glutamine, 100 U/ml penicillin and 100
μg/ml streptomycin. After 24 and 48 h of treatment MTS, Annexin-V, TUNEL,
JC-1 and Active Caspase-3 assays were performed according to manufacturer’s
instructions. Proteins were separated by polyacrylamide gel electrophoresis
and transferred to 0.2 μm polyvinylidene fluoride membranes. Quantitative
analysis was performed with Quantity One software. Statistical analysis was
carried out using the paired and unpaired two-tailed Student’s t tests. p values
<0.05 were considered as significant.
Results: Our data indicate that Kevetrin exposure induces cell growth arrest,
a great drop of mitochondrial membrane potential and a remarkable increment
of Caspase-3 cleaved form, features that contribute to apoptotic cell death in
the two cell lines. Cellular changes can be associated with a dose and time-
dependent effect in the TP53 mutated cell line (KASUMI-1) but not in the wild
type one (MOLM-13), in which we can observe an activity only after 48 h at the
higher concentration. Regarding molecular alterations in KASUMI-1 we found
a great p53 down-regulation, probably due to Hsp90 reduction, resulting in a
less marked formation of the Hsp90-p53 oncogenic complex. We also found a
down-regulated p53 active form (Ser15), a reduced expression of p53 targets,
p21 and PUMA, and a down-regulation of SIRT-3, that cannot exert its inhibitory
activity on p53. The MOLM-13 cell line showed a great p53 reduction, probably
related to SIRT-3 up-regulation and Hsp90 down-regulation. Regarding p53
active form, we noticed slight variations in protein expression, suggesting a
physiological response of the protein to cellular damage. In accordance with
p53 activity, we observed a great up-regulation of p21, probably associated
with a drug resistance mechanism; in contrast, PUMA protein was highly down-
regulated, suggesting a p53-independent mechanism of action or a feedback
regulation of the apoptotic process, after Caspase-3 activation (Figure 1.). In
order to better understand drug’s mechanism of action we are performing gene
expression profiling after 48h of treatment with Kevetrin 60μg/ml.
Figure 1.
Summary/Conclusions: Our results suggest Kevetrin is a promising new drug
in AML patients treatment, both in wild type and, even more, in TP53 mutated
tumors, through different molecular mechanisms, giving more therapeutic alter-
natives in the treatment of this disease.
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CLEARANCE OF ‘DRIVER-COSMIC’ MUTATIONS POST CR1 WITH
PERSISTING RUNX1_L56S IS UNLIKELY TO CONTRIBUTE TOWARDS
DISEASE PROGRESSION IN AML
L. Rai1,*, T. Boneva2, D. Brazma2, R. Dunn2, C. Grace2, E. Nacheva2,3
1Onco-Cytogenomics, 2OncoGenomics, HSL Analytics LLP, 3Cancer Research
Institute, UCL, LONDON, United Kingdom
Background: Clinical significance of gene variants in AML is well established
(Papaemmanuil E et al, NEJM 2016) and is increasingly being implemented
into routine diagnostic algorithms. Although 80% of patients achieve morpho-
logical remission after induction chemotherapy, long-term relapse free survival
is a meagre 50% (Walter RB et al, JCO 2010. Monitoring of disease kinetics,
is therefore, very critical. 
Aims: To study the kinetics of gene variants post-induction chemotherapy in
AML patients.
Methods: 130 follow-up samples from 45 de novo AML patients [median age-
60 yr & median FU period- 18.6 mo] were screened for gene variants using
TruSight Myeloid panel (Illumina, CA, USA) covering 54 genes with relevance
in myeloid diseases. Gene variants at Variant allele frequency (VAF) of ≥10%
at diagnosis and VAF of ≥1.5% during follow-up; both with target coverage of
≥300 reads were considered. Bone marrow (BM) or peripheral blood (PB) was
obtained at presentation (BM:44; PB:1) and follow-up (BM-130). Gene variants
in 95 samples from 40 MDS patients were also evaluated for progression to
secondary AML. Public databases-Catalogue of Somatic Mutations In Cancer
(COSMIC), dbSNP and 1000 genome (>2%) were used to classify gene vari-
ants as either Drivers (D), variants of unknown significance (VUS) and germline
polymorphisms (SNP). P-value was generated with 2-tailed Fisher Exact
(GraphPad Software, Inc, USA).
Results: Of 45 AML patients 19 achieved complete morphological remission
(CR), 21 had a relapse and 5 had refractory disease with a median of 4 muta-
tions/patient in each subgroup. Driver mutation was identified in 38 patients;
82% of who had persistence until clinical end-point. While 17 of 18 relapse
patients retained a driver only 9 of 15 patients in remission retained it (Table
1). 8 of the 9 patients had a ‘driver with COSMIC and SNP’ (D-C/S) reference
that persisted, while all ‘driver with COSMIC only’ (D-C) disappeared post-
induction. This suggests that drivers with both COSMIC and SNP reference
may not always contribute towards disease progression. We also found that D-
C mutations persist in 85.7% of relapse pat.ients compared to only 11% of
patients in remission (P-value: 0.001). Additionally, D-C mutations were retained
in all 13 relapse patients with intermediate risk cytogenetics while complete
clearance was observed in all 6 patients who were in sustained remission (P-
value: 0.001). Further investigation of genes with D-C/S mutation in the remis-
sion cohort (8x) revealed that 4 patients had persistent DNMT3A-25457242, 1
had DNMT3A-25457243, 2 had RUNX1-36259324/L56S and 1 had CBL-
119149011. As DNMT3A mutations are considered to occur in pre-leukemic
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stem cells contributing to clonal haematopoiesis (Askush et al, Nature 2014;
Genovese et al, NEJM 2014); this led us to study the distribution of RUNX1
gene variants in an additional 119 AML diagnostic samples. 34 patients (21%)
harboured RUNX1 mutation, of which 5 had RUNX1_L56S that were often
associated with D-C mutations (4 of 5 cases). Finally, we evaluated kinetics of
D-C in 40 MDS cases of which 34 had chronic MDS and 6 had secondary AML
(sAML). No significant difference was observed in the number of patients with
persistent D-C mutation in the 2 subgroups (chronic MDS: 16 of 19 (84.2%);
sAML: 5 of 5 (100%); P-value: 1.000).
Table 1.
Summary/Conclusions: Clearance of ‘Driver-COSMIC only’ mutations while
RUNX1_L56S persists is unlikely to contribute towards disease progression in
AML.
Acute myeloid leukemia - Clinical
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PROGNOSTIC SIGNIFICANCE OF FLT3 STATUS, CYTOGENETIC, ECOG
AND 50% BLAST DECREASE IN PRIMARY REFRACTORY OR EARLY
RELAPSED AML PATIENTS BEFORE SALVAGE THERAPY
P. Sesques1, S. Bertoli2, M. El-Hamri1, S. Ducastelle1, G. Salles1, C. Recher2,
X. Thomas1, E. Paubelle1,*
1hematology, Chu Lyon Sud, Pierre Benite, 2hematology, Oncopole Toulouse,
Toulouse, France
Background: Prognosis of relapsed/refractory acute myeloid leukemia (R/R
AML) is unfavorable with a long term overall survival around 10%. Thus, man-
agement of R/R AML represents one of the most difficult challenges. Because
allogeneic-Hematopoietic Stem Cell Transplantation (allogeneic-HSCT) is con-
sidered as the best treatment for this category of patients, to determining which
patient will benefit from this cumbersome strategy is a crucial issue. A better
understanding of the mutational status, cytogenetic, histological and clinical
findings of early R/R AML patients and their outcomes could help treatment
decisions, particularly for those who allogeneic-HSCT is considered as the
best therapeutic option.
Aims: The objective of this study is to determine prognostic factors and develop
a prognostic score using usual mutational status, cytogenetic, histological and
simple clinical variables in R/R AML patients before salvage treatments. 
Methods: In this retrospective study in two hematological departments (Hos-
pices Civils de Lyon and CHU of Toulouse), we evaluated clinical, biological,
histological, cytogenetic and current mutational status of early R/R non APL
AML patient between age from 18 to 70 years. Univariate and multivariate
analysis were performed and we developed a prognostic score based on the
independent prognostic parameters from Cox model.
Results: From January 2009 to May 2016, 58 patients presenting early relapse
and primary refractory AML were analyzed. Overall Survival (OS) and Progres-
sion Free Survival (PFS) median were 9 and 2 months respectively. In univari-
ate analysis, cytogenetic findings (unfavorable groups), unfavorable ECOG
(>2), FLT3 positive status and <50% blast decrease (between induction and
R/R assessment) independently predicted poor OS and were identified as sig-
nificant prognostic parameters of OS (p=.037, p=.0084, p=.0452, p=.0071
respectively). In multivariate analysis, these last four criteria confirmed their
worst prognostic impacts (p=.015, p=.017, p=.026, p=.015 respectively) and
were used to create a five groups prognostic score. Better OS were statistically
observed for patient with score 0 or 1 compared to 2, 3 or 4 (2-years OS 48%
and 11% respectively, p= 0.0104) using a log-rank regression. When data were
censored to allogeneic HSCT, the scoring system revealed a relevant difference
with favorable OS for those with a score 0-1 compared to score 2-3-4 (2-years
OS 64% and Not Reached respectively, p=.001) (Figure 3).
Figure 1.
Summary/Conclusions: Our prognostic score based on simple and usual
data: FLT3 status, cytogenetic, ECOG and percentage blast decrease found
distinct groups with statistically different outcomes. Basically, the higher is the
score, the worst is the OS. This new score is a valuable, simple and useful
score for the therapeutic salvage management of AML patients presenting
early relapse and primary refractory.
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PRELIMINARY RESULTS FROM A PHASE 1 STUDY EXAMINING THE NOVEL
BCL-2 INHIBITOR S55746/BCL201 AS SINGLE AGENT IN PATIENTS WITH
ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC
SYNDROME
A. Wei1,*, A. Bajel2, N. Boissel3, I. Kloos4, C. Delifer4, S. Banquet4, X. Thomas5,
N. Vey6
1Department of Clinical Haematology, The Alfred Hospital and Monash Univer-
sity, 2Department of Haematology & Bone Marrow Transplantation, The Royal
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Background: Novel and effective therapeutic options for patients (pts) with
advanced acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
are limited. Targeting the prosurvival molecule BCL-2 is clinically efficacious in
various hematological malignancies. S55746/BCL201 is a novel, selective and
potent inhibitor of BCL-2, with demonstrated antileukemic activity in preclinical
models.
Aims: To evaluate the safety, recommended phase 2 dose (RP2D), pharma-
cokinetic (PK), pharmacodynamic (PD) and preliminary activity of
S55746/BCL201 in patients with AML [relapsed/refractory (R/R) or ≥65 years
unfit for intensive chemotherapy (IC)], or MDS failing prior therapies.
Methods: A phase I study (EUDRACT 2014-002559-24, NCT02920541) is
underway to investigate S55746/BCL201 as a single agent in 5 European and
Australian centers. S55746/BCL201 was initially administered in fasting condi-
tions, once daily (21-day cycles), until disease progression, unacceptable tox-
icity, or investigator’s or patient’s decision. Pts giving informed consent received
S55746/BCL201 at escalating dose levels according to a modified continual
reassessment method for dose allocation.
Results: As of 23 February 2017, 34 pts have received S55746/BCL201 at
doses ranging from 100 to 1300mg/day (median time on treatment: 43 days,
range 1 to >374); 28 pts were R/R AML, 2 pts were elderly AML unfit for IC, and
4 pts had MDS failing prior therapies. Median age was 70 years (range 19-80),
median number of prior therapies 2 (range 0-6), ECOG ≤2, and median WBC
3 G/L (range 0-30). Among the AML cohort, European LeukemiaNet risk (Döh-
ner 2010) was adverse in 53%, intermediate-I in 20%, and intermediate-II in
17%. Preliminary PK results in fasting pts showed that exposure increased lin-
early but with some inter-individual variability. Most common (≥20% of pts) non-
hematological adverse events (AEs), all grades, included diarrhea (27%),
hypokalemia (27%), nausea (21%), and vomiting (21%). The most frequent
grade ≥3 AEs were hematological [anemia (35%), thrombocytopenia (32%),
febrile neutropenia (21%), and neutropenia (18%)], hypokalemia (18%), and
sepsis (15%). Of 12 pts (38%) with AEs possibly related to study drug, the most
frequent were diarrhea (3 pts), muscle spasms, thrombocytopenia, and anemia
(2 pts each). One 74-year-old pt had grade 5 cardiac failure considered drug-
related after 6 cycles of treatment (900mg). Non-related fatal AEs were reported
in 7 pts (including sepsis, hemorrhagic stroke, pneumonia, and disease pro-
gression). There were no reported episodes of clinical or laboratory TLS. No
DLT was reported and MTD has not been reached. Of 26 AML pts evaluable
for response (at least 1 cycle completed), one achieved a CRi (complete remis-
sion with incomplete blood count recovery lasting 10 months) and one a PR
(partial remission lasting 3 months before proceeding to allogeneic stem cell
transplant). In MDS, 4 out of 4 pts had stable disease (lasting 1 to >7 months).
Bone marrow blasts decreased in 50% of all evaluable pts, with the nadir
reached (87%) within the first two cycles (Figure 1).
Figure 1.
Summary/Conclusions: Initial findings suggest that S55746/BCL201 has
acceptable tolerability and clinical activity in advanced AML and MDS. Based
on non-compartmental pharmacokinetic food interaction results from another
study, demonstrating that S55746/BCL201 Cmax and AUC increased about 6-
fold with food, dose escalation has started in patients with drug intake during a
meal.
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Background: Acute Myeloid Leukemia (AML) with mutations of the gene
encoding Nucleophosmin-1 (NPM1) identifies a subgroup of patients with favor-
able prognosis according to the 2008 WHO classification. However, recent evi-
dences (Papaemmanuil, NEJM 2016) suggest that the coexistence of additional
gene mutations (e.g. DNMT3A, IDH1, IDH2R140 and TET2) may determine an
inferior clinical outcome as compared to favorable risk AML and precludes a
reliable outcome prediction. The presence of minimal residual disease (MRD),
as determined by quantization of NPM1 mutated transcripts, provides powerful
prognostic information independent of other risk factors (Ivey, NEJM 2016). 
Aims: The aim of our study was to investigate if detection of MRD by multi-
parametric flow cytometry (MFC) might represent an alternative tool to discrim-
inate different prognosis within the NPM1 mutated AML group, in a setting
where an extensive gene profiling at diagnosis or a quantitative determination
of NPM1 transcripts in remission would not be available.
Methods: We analyzed a series of 69 AML patients with NPM1 mutations; all
the patients were in complete remission (CR) after intensive induction cycle of
EORTC-GIMEMA protocols. The frequency of NPM1 mutated cases was not
different among patients below (48/142, 34%) or above (21/61, 34%) the age
of 60 years, respectively. Twenty out of 65 patients (31%) carried a concomitant
FLT3-ITD mutation; 51/66 (77%) NPM1 mutated cases had a normal diploid
karyotype. Upon full hematological recovery after consolidation cycle, counting,
by MFC, ≥3.5x10-4 (0.035%) residual leukemic cells (RLCs) in the bone marrow
(BM) was regarded as a condition of MRD positivity.
Results: Among NPM1 mutated patients, the rate of MRD negative CR was
significantly lower (5/69, 7%) as compared to NPM1 WT ones (39/134, 29%),
respectively (p<0.001). Although there was not a statistically significant differ-
ence, probably due to the low numbers, MRD negative/NPM1mut patients had
a lower Cumulative Incidence of Relapse (CIR) as compared to MRD
negative/NPM1wt (25% vs 60%). We also evaluated the impact of autologous
(AuSCT) or allogeneic (ASCT) transplantation on the outcome of MRD
positive/NPM1mut patients. The overall survival (OS) was significantly higher for
patients submitted to ASCT (no=14) as compared to those (no=15) submitted
to AuSCT (93% vs 33%, p=0.011). This was confirmed even after excluding
from the analysis FLT3-ITDmutpatients. When all the meaningful clinical variables
were challenged in multivariate analysis (MRD, type of transplant, age >60 yrs,
karyotype), the type of transplant (ASCT vs AuSCT) was the only variable that
significantly influenced OS and DFS (p=0.001 and 0.003, respectively).
Summary/Conclusions: In conclusion, although quantitative RT-PCR repre-
sents the gold standard, MFC determination of MRD also confirms that the
quality of remission is critical to discriminate patients with a different outcome
among NPM1mut patients. In fact, these patients have a low chance to become
MFC MRD negative and in a situation of MRD positivity, a very poor outcome
can be substantially improved only by a timely use of an allogeneic procedure.
E909
EXPRESSION OF IMMUNE CHECKPOINT MOLECULES (PD-1, PD-L1, AND
PD-L2) ON BONE MARROW T CELLS IN ACUTE MYELOID LEUKEMIA
E. You1,*, C.-J. Park1, Y.-U. Cho1, C.H. Yoon1, S. Jang1, H.J. Im2, J.J. Seo2, J.-
H. Lee3, K.-H. Lee3
1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan
College of Medicine, 2Department of Pediatrics, Asan Medical Center Children’s
Hospital, University of Ulsan College of Medicine, 3Department of Hematology,
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea,
Republic Of
Background: Immune checkpoints constitute a mechanism by which tumors
escape from the host immune system and involve the programmed death-1
(PD-1) receptor and its ligands, PD-L1 and PD-L2. In a tumor microenviron-
ment, overexpression of PD-1, an inhibitory receptor on the surface of T cells,
can lead to dysfunction of antitumor effector cells. Recently, investigators have
detected overexpression of PD-1 for patients with acute myeloid leukemia
(AML) who experienced relapse following allogeneic stem cell transplantation
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(SCT). However, evidence regarding T cell phenotypes for patients with AML
is sparse.
Aims: The authors evaluated patients with AML to determine expression levels
of checkpoint molecules (PD-1, PD-L1, and PD-L2) according to diagnosis and
treatments (chemotherapy [CTx] and SCT). The purpose of this study was to
identify optimal candidates for checkpoint blockade therapy for AML.
Methods: Bone marrow (BM) samples were obtained from 195 AML patients
in different stages of the disease. Samples were stratified by at time of diagnosis
(n=69) and treatment response (complete remission [CR] after CTx, n=30; per-
sistence after CTx, n=29; relapse after CTx, n=7; normocellular marrow with
trilineage regeneration [NMTR] after SCT, n=19; persistence after SCT, n=18;
and relapse after SCT, n=23). BM samples also were collected from 23 patients
with no evidence of hematologic malignancies (control group). Flow cytometric
analysis of PD-1 expression on T cells and PD-L1/PD-L2 expression on
leukemic cells was performed by means of a FACSCanto II system (Becton-
Dickinson, Sunnyvale, CA, USA).
Results: There were no differences in levels of PD-1 expression on CD8+ and
CD4+ T cells at time of AML diagnosis, compared with controls. However, PD-
1 expression levels on CD4+ T cells were significantly correlated with time
since diagnosis. For patients at time of diagnosis, PD-1 expression on CD8+
and CD4+ T cells was significantly different compared with patients who expe-
rienced relapse after SCT (P=.017 and P<.0001), persistence after SCT
(P=.025 and P<.0001), and NMTR after SCT (P<.0001 and P<.0001). In con-
trast, no difference in PD-1 expression was observed between patients at time
of diagnosis and patients after CTx (Figure 1). For CD4+ T cells, a significant
difference was found between SCT and CTx groups, and PD-1 expression lev-
els of groups that experienced relapse (P<.0001) or persistence (P<.0001)
after SCT were significantly higher than those of patients in the CTx groups.
PD-L1 and PD-L2 expression on leukemic cells at time of diagnosis was higher
in secondary AML transformed from myelodysplastic syndrome than in de novo
AML (P=.0001 and P=.039). Although PD-L1 and PD-L2 expression levels for
patients at time of AML diagnosis did not differ from groups that experienced
relapse or persistence after SCT, PD-L1 and PD-L2 levels for diagnosed
patients did differ from those of patients who experienced persistence after
CTx (P=.038 and P=.023).
Figure 1.
Summary/Conclusions: The present study suggests that the PD-1/PD-L1
pathway may constitute an immune-escape mechanism in AML. PD-1 expres-
sion in CD4+ T cells increased with time since diagnosis. Patients who under-
went SCT exhibited overexpression of PD-1, which suggests that SCT and/or
chronic stimulation of leukemic cells might induce more PD-1 expression by T
cells. Blockade of the PD-1 immune checkpoint may represent an immunother-
apeutic strategy for patients with AML relapse or AML persistence after SCT.
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Background: Data on HIV patients with acute leukemia (AL, acute myeloid
leukemia (AML) or non Burkitt acute lymphoid leukemia (ALL)) are very poor
especially on their outcome. Treatment of acute leukemia usually depends of
patient-related prognostics factors and disease related prognostic factors.
Because HIV patients are considered frail, they are always excluded of thera-
peutics protocols. There are no guidelines for their treatments. 
Aims: Our aim was to precise the epidemiology, the best therapeutic strategies
as well as patient’s prognostics, and to compare their outcome to those of
seronegative patients with AL. 
Methods: We conduct a retrospective national multicentric study. HIV positive
patients with a diagnosis of AML or non Burkitt ALL between January 2000 and
February 2016 were included. We compared HIV patients’ outcome to those
of seronegative patients with AL after a propensity score matching. 
Results: 47 HIV patients with a diagnosis of AL (42 AML and 5 ALL) were
included. AL incidence in HIV patients (HIVP) is not different than in general
population but AL occurred earlier (49.29 years [44.21 ; 57.47]) and secondary
AL are more frequent (42.55%). With a global and multidisciplinary approach
these patients can be treated with intensive chemotherapy resulting on good
efficiency (complete remission (CR)=84.38%)) and tolerance. Based on a mul-
tivariable model, only absence of CR was associated with hazard of death
(p=0.01). 8 patients (17,02% ; 7 AML and 1 ALL) received an hematopoietic
stem cell transplantation. HIVP with AL 2 years overall survival (OS) was 29%
CI95% [15 ; 54] for AML and 40% CI95% [14 ; 100] for ALL. There was no dif-
ference in OS between our HIVP and seronegative controls with AL after
propensity score matching (HR=1.347 [0.6486-2.796]; p=0,42).
Table 1.
Summary/Conclusions: Our study shows that HIV status has no prognostic
impact on AL patient’s outcome. HIV patient with acute leukemia should thus
be included in clinical trials to improve and standardize their therapeutic man-
agement.
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Background: Currently, there is no consensus regarding optimal treatment for
older patients with acute myeloid leukemia (AML). Decitabine for 5 consecutive
days produced a complete remission (CR) rate of 17.8% in older patients with
newly diagnosed unfit AML. Ten-day regimen of decitabine induces a higher
response in newly diagnosed older patients with AML considered unfit for inten-
sive chemotherapy. But this 10-day regimen has not been tested in older fit
AML before.
Aims: To investigated the efficacy and safety of the10-day decitabine regimen
in older fit AML prospectively.
Methods: Twenty-one older patients (>60 years old) with newly diagnosed inter-
mediate or adverse cytogenetic risk group AML, considered fit for intensive
chemotherapy, were enrolled in a prospective clinical trial. These patients refused
to take intensive chemotherapy. All patients were treated with at least one course
of 10-day decitabine (20mg/m2 daily ). Patients who achieved less than 5%
bone marrow blasts were subsequently treated with 5-day decitabine courses
as maintenance therapy. Median age was 64 (range 60-74) years. There are
was 5 patients with (23.8%), 10 (47.6%), 6 (28.6%) in favorable, intermediate
and, poor-risk group, respectively, based on the NCCN guideline. All patients
had an Eastern Cooperative Oncology Group performance status of 1.
Results: The overall response rate (ORR) was 57.1%, including 52.4% CR.
There are no significant differences between responders and non-responders,
in the following parameters, including age, LDH, DNMT3a mutation, white blood
cells count in peripheral blood, or bone marrow blasts percentage. Nineteen
patients experienced neutropenia during induction regimen. The lowest median
white blood cell count and neutropenic time is 0.02´109(0-3.05 ´109), 15(0-24)
days, respectively. The common non-hematologic toxicities were febrile neu-
tropenia and infections. Median overall survival (OS) of all patients was 20.7
months. One-year and two-year OSrate were 71.4% and 45.4%, respectively.
Patients who responded to treatment had significantly longer OS than non-
responders.
Summary/Conclusions: This indicates that the 10-day decitabine regimen
may be an optimal management for older AML patients who are in intermediate
or adverse cytogenetic risk group and fit for chemotherapy.
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Background: AML cells can acquire immune evasion and tolerance through
overexpression of indoleamine 2,3-dioxygenase (IDO), which exerts
immunomodulatory effects through tryptophan (Trp) catabolism and kynurenine
production. By degrading Trp, IDO shifts the balance from a Trp-rich environ-
ment, which encourages T-cell proliferation and activation, to a Trp-poor envi-
ronment leading to immune system suppression. We hypothesized that incor-
poration of indoximod, an inhibitor of the IDO pathway, into conventional remis-
sion induction and consolidation would be well tolerated without adding signif-
icant toxicity and may improve clinical outcomes of patients (pts) with newly
diagnosed AML.
Aims: The primary objective of the phase 1 portion of the trial is to characterize
the regimen limiting toxicities (RLT) as well as the recommended phase 2 dose
(RP2D) of indoximod in combination with standard of care (SOC) chemotherapy
for frontline AML treatment. A key secondary objective is to determine the min-
imal (or measurable) residual disease (MRD) status, as measured by multi-
color flow cytometry, in pts with AML who receive indoximod in combination
with SOC at the end of induction, after completion of the 1st cycle of consolida-
tion, and before maintenance or proceeding to allogeneic stem cell transplan-
tation (allo-HSCT).
Methods: This is a phase 1b / randomized phase 2a trial of indoximod in com-
bination with 7+3 remission induction consisting of cytarabine (100mg/m2/day
continuous infusion for 7 days) and idarubicin (12mg/m2/day for 3 days) and
high dose cytarabine (HiDAC) consolidation, as SOC, in pts with newly diag-
nosed AML (NCT02835729), with a 3+3 design for the phase 1 portion. Indoxi-
mod is given orally every 8 hours starting on day 8 of induction onward. Indox-
imod is held on days that pts receive HiDAC consolidation, and it is discontinued
4 weeks prior to allo-HSCT. The phase 1 consists of 4 dose levels [400mg (-1),
600mg (0, starting dose), 1000mg (1), 1200mg (2)] in combination with SOC.
Results: Twelve pts have been enrolled, as of March 1, 2017. Median age is
53 (range 18-69) years, and 4 pts are female. According to 2017 European
Leukemia Net risk stratification, 9 had favorable risk (3 with DNMT3A and 2
with low allelic ratio (<0.5) of FLT3-ITD) and 3 had adverse risk. No RLT was
observed with the 1st and 2nd dose levels. The most frequently reported adverse
events (regardless of attribution), were febrile neutropenia, diarrhea, nausea
and vomiting, dyspnea, hypotension, and hypoxia. Three pts are no longer on
study: 1 (dose level 0) due to inability to swallow indoximod after hypoxic res-
piratory failure during induction, 1 (dose level 1) withdrew consent for personal
reasons after only 2 doses of indoximod, and 1 (dose level 2) was taken off
due to eligibility. The remaining 9 pts are still on study; 3 pts in dose level 2 are
currently receiving induction and are not evaluable. Five of 6 (83%) evaluable
pts in dose levels 0 and 1 achieved complete remission (CR) after induction.
All 5 pts demonstrated no evidence of MRD at levels <0.02% (MRD-neg) post-
induction and remained MRD-neg post cycle 1 of HiDAC. One pt in dose level
1 with favorable risk (normal karyotype, mutations in DNMT3A/NPM1/NRAS)
had primary refractory disease. The pt who was unable to swallow indoximod
had favorable risk (normal karyotype, mutations in DNMT3A/NPM1) and
achieved morphologic CR but had MRD at the end of induction, and ultimately
relapsed after 2 cycles of HiDAC consolidation.
Summary/Conclusions: Indoximod does not appear to add significant toxicity
to standard remission induction and consolidation in pts with newly diagnosed
AML. Initial data suggest a high rate of MRD-neg after one cycle of induction
chemotherapy.
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Background: Activation of the mitogen-activated protein kinase (MAPK) sig-
naling (RAS/RAF/MEK/ERK pathway) promotes growth and inhibits apoptosis
of hematopoietic cells. Inhibition of MEK/MAPK pathway has shown antiprolif-
erative effects in acute myeloid leukemia (AML) cell lines and AML blasts. MEK-
162 is an oral, potent, selective allosteric, ATP non-competitive inhibitor of
MEK1 and 2.
Aims: To study the efficacy and safety of MEK-162 in patients with advanced
myeloid malignancies.
Methods: Patients with relapsed/refractory AML, not candidates for intensive
chemotherapy, and patients with high risk myelodysplastic syndrome (MDS)
who were resistant/intolerant to standard treatment including stem cell trans-
plant were treated with MEK-162 twice daily every 28 days. Patients in the
expansion phase had to be RAS mutated. The primary endpoint was overall
response rate (ORR=CR + CRi) after 1 cycle of therapy. Survival was estimated
using the Kaplan-Meier method. Safety analysis included all patients who had
received at least 1 dose of MEK-162. MEK-162 dose escalation followed a 3+3
design; phase 2 had built in futility/toxicitiy boundaries. 45mg twice daily is the
final dose level for expansion phase. 
Results: Sixteen patients were treated (escalation=7; expansion=9): 14 AML
and 2 MDS. Median age was 62 years (31-85). 56% were male; 94% had a
performance status of 1-2. Median number of prior therapies was 4 (1-6). 3/16
(19%) patients had complex karyotype. 11/16 (69%) patients were RAS mutat-
ed. 10/16 patients completed a minimum of 1 cycle of MEK-162 therapy and
were evaluable for response (3 at 30mg and 7 at 45mg dose). ORR was 10%
(CRi in 1/10 patients). Median number of cycles administered were 2 (1-4).
Median duration on therapy was 1.1 months (0.1-3.4). Median overall survival
is 3.2 months (0.3-7.6). Common G3/4 toxicity included neutropenia (56%),
fatigue (13%), nausea/vomiting (13%) and electrolyte abnormalities (19%). No
dose limiting toxicity was reported.
Summary/Conclusions: MEK-162 shows a tolerable safety profile with an
ORR of 10%. The study is currently on-going. Additional studies involving com-
bination of MEK-162 with RAF and PI3 kinase inhibitors are ongoing.
E914
HAPLOIDENTICAL TRANSPLANTATION IS SAFE AND EFFECTIVE FOR
OLDER PATIENTS WITH AML/MDS
S. Ciurea1,*, R. Saliba1, M. Shah1, S. Gaballa2, G. Rondon1, J. Chen1, A. Gulbis1,
W. Wallis1, B. Oran1, A. Alousi1, Q. Bashir1, S. Ahmed1, D. Marin1, K. Rezvani1,
E. Shpall1, M. Qazilbash1, U. Popat1, I. Khouri1, C. Hosing1, P. Kebriaei1,
N. Daver3, M. Konopleva3, N. Pemmaraju3, F. Ravandi3, J. Cortes3, H. Kantarjian3,
R. Champlin1
1Stem Cell Transplantation, The University of Texas MD Anderson Cancer Cen-
ter, Houston, 2Thomas Jefferson University, Philadelphia, 3Leukemia, The Uni-
versity of Texas MD Anderson Cancer Center, Houston, United States
Background: Acute myeloid leukemia (AML) is more common in the older pop-
ulation. Haploidentical stem cell transplantation (haploSCT) is a potentially cur-
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ative treatment option for patients with AML and allows transplantation for
patients without an HLA matched donor. Recently, the use of post-transplant
cyclophosphamide-based (PTCy) GVHD prophylaxis has improved outcomes
of haploSCT; however, outcomes of haploSCT in older patients remain unclear. 
Aims: Here we evaluated outcomes of older patients with AML/MDS who
underwent haploSCT. 
Methods: We retrospectively analyzed outcomes of all 43 patients ³55 years
with AML/MDS who underwent a haploSCT at our institution after year 2009.
All patients were treated with fludarabine-melphalan (FM)-based conditioning
regimen (melphalan 100 or 140mg/m2) plus thiotepa 5mg/kg or 2GyTBI. Char-
acteristics of these patients are presented in Table 1.
Figure 1.
Results: Median age was 61 years (range 55-69), 22 patients (51%) were in
CR1/2, 16 patients (37%) had poor-risk cytogenetics, and median HCT-CI was
2 (range 0-11). Reduced melphalan regimen (100mg/m2) was used in 29 pts
(67%). Donors were children in 35 (81%) or siblings 10 (19%) patients.
Median follow-up was 19 months (range 6-49). One patient died prior to engraft-
ment. Forty-two patients engrafted the donor cells (100%). Median time to neu-
trophil and platelet engraftment was 19 (13-28) and 28 (15-117) days. Day 30
chimerism was 100% donor in 38 patients (88%). The cumulative incidence
(CI) of grade 2-4 and 3-4 aGVHD at 6 months post-transplant was 35% and
5% while CI of cGVHD at 2 years post-transplant was only 9%. The 2-year
overall survival (OS) and progression-free survival (PFS) was 42%, and relapse
rate was 24%. Cumulative non-relapse mortality (NRM) was 21%, 30% and
34% at day 100, 1 year, and 2 years post-transplant. Patients in CR1/2 had 2-
year NRM and relapse rate of 23% and 14%, and OS was 61%. The 2-year
OS for patients in CR1/2 with intermediate/favorable-risk cytogenetics was
73%. In multivariate analysis, favorable predictors for OS were CR1/2 (HR:0.4,
p=0.05), good /intermediate cytogenetics (HR:0.2, p=0.01), and donor age
greated than 40 (Figure 1).
Table 1.
Summary/Conclusions: HaploSCT with PTCy-based GVHD prophylaxis is
safe and effective for older AML/MDS patients. Lack of an HLA matched donor
is not a contraindication to proceeding to a haploidentical transplant in older
AML/MDS patients. In addition to remission status and cytogenetics, we found
that younger donor age was significantly associated with improved survival in
older AML/MDS patients undergoing haploidentical transplantation.
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Background: Among Acute Myeloid Leukemia (AML) patients achieving hema-
tological complete remission (CR) the persistence of detectable disease
assessed with highly sensitive techniques as Multicolor-Flow-Cytometry (MFC)
or PCR-based molecular analysis retains a negative prognostic value. However,
a consensus on the most informative time-points (TP) and sensitivity cut-offs
for MRD assessment has not been reached. 
Aims: The aim of the present study was the evaluation of the prognostic impact
of MFC and molecular MRD assessment by identifying TP, MFC positivity cut-
off values and molecular MRD markers with the highest prognostic impact.
Methods: One hundred and ten consecutive AML patients treated in our center
between 2004 and 2014 were retrospectively analyzed. As previously
described, all patients had received a fludarabine-containing induction.Median
age was 47 years (range 18-65). Median follow up was 59 months. Three dif-
ferent MRD TP have been considered: TP1, after induction I; TP2, after induc-
tion II; TP3, after consolidation therapy for patients who did not undergo
hematopoietic stem cells transplantation (HSCT). For patients who underwent
HSCT, TP3 coincided with pre-transplant MRD evaluation. MFC-MRD evalua-
tion had been performed through 4-colour MFC analysis (and 8-colour from
2013). To define MFC-MRD positivity two cut-offs were compared: a threshold
of 2.5×10−4residual leukemic cells (>0,025%) or a threshold of 1 x 10-3 residual
leukemic cells (>0.1%). For patients carrying NPM1-gene mutation NPM1
expression levels at TP1, TP2, TP3 (NPM-MRD) were analyzed. A reduction
>3.5 log of NPM1 transcript at TP1 was considered optimal as per our published
experience. For patients presenting WT1 over-expression at diagnosis WT1-
MRD was evaluated at TP1, considering WT1 negativity with a cut-off of WT1
copies/104 ABL lower than 250.
Results: CR rate after induction I and II was 82.7 and 85.5%, respectively. The
percentage of MFC-MRD neg<0.025 and<0.1% increased from TP1 to TP2.
The probability of achieving MFC-MRD negativity at TP2 was only influenced
by ELN risk group (p <0.05). In the whole cohort, 2 years OS was 60.2% (median
not reached). Multivariate Cox-Proportional Hazard model showed that MFC-
MRD >0.1% at TP2 was the strongest predictor of higher risk of death, whereas
MFC-MRD <0.025 at TP1 was the strongest predictor of long survival (Figure
1, a-b). However, patients with MFC-MRD >0.025 at TP1 displayed a heteroge-
neous outcome. In this subgroup WT1-MRD at TP1 was able to identify patients
with the higher risk of death (Figure 1c). Thirty-five patients carried NPM1-muta-
tion. Two-years OS for NPM1-mut patients showing more or less than 3.5 log
transcript reduction at TP1 was 94.1% vs 58.3%, respectively (p 0.039); 2 years
OS for patients achieving NPM1-MRD negativity at TP2 was 90.5% vs 42.9%
(p 0.003). MFC MRD analysis in the NPM1-mut cohort led to results comparable
with the whole cohort. Multivariate analysis showed that NPM1-MRD at TP1
was the strongest predictor for OS in this group.
Figure 1.
Summary/Conclusions: Our data show that MRD assessment at different
time-points during treatment retains a strong prognostic impact in AML and
that different cut-offs at different time-points can give different and useful prog-
nostic information that may drive post-induction therapy. MFC MRD evaluation
at TP2 with 0.1% cut-off is the most useful for patients risk stratification. How-
ever, the evaluation of MFC-MRD at TP1 with 0.025% cut-off can early identify
a group of patients with a significantly low risk of relapse. At the same TP, MFC
and WT1 MRD integration allows a better risk stratification. MFC MRD is accu-
rate also in NPM1-mut patients; however, in this cohort NPM1-based MRD
evaluation is the most accurate predictor of prognosis.
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THE NUMBER OF CD34+CD38+CD117+HLA-DR+CD13+CD33+ CELLS
INDICATES POST-CHEMOTHERAPY NEUTROPHIL RECOVERY IN
PATIENTS WITH ACUTE MYELOID LEUKEMIA
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Background: Hematopoietic recovery is considered to associated with the
number of multipotent hematopoietic stem cells in the bone marrow, as
observed in functional assays involving stem cell transplantation. However,
there is little evidence related to hematopoietic recovery in non-transplantation
settings, which is accomplished by endogenous hematopoietic cells. A recent
study suggested that progenitors are the main contributors during this steady-
state hematopoiesis, which differs from exogenous transplantation. And our
previously data revealed that, CD34+CD38+CD117+HLA-DR+CD13+ CD33+
cells (P cells), a kind of progenitor cell, is significantly decreased in patients
with delayed neutrophil recovery after chemotherapy compared with that without
delayed count recovery.
Aims: To further examine a potential impact of P cells percentage on
hematopoietic recovery.
Methods: The data of 223 patients diagnosed with de novo AML was analyzed
retrospectively. All these patients enrolled in our previously registered prospec-
tive randomized clinical trial AML 2010-01(201002024). We reviewed the data
from bone marrow flowcytometry before the first and second course of consol-
idation therapy, in which the CD34+CD38+CD117+HLA-DR+CD13+CD33+ pro-
genitor cell percentage in the bone marrow was analyzed. Platelet recovery
time and time of neutropenia were counted for the evaluation of hematopoietic
recovery ability after chemotherapy. 
Results: We found that less P cell percentage was significantly associated
with prolonged neutropenia recovery time after the first and second courses of
consolidation chemotherapy (p=0.001; p=0.028, respectively). We also
observed similar results regard to platelet recovery time after the first course
of consolidation chemotherapy (p=0.001). Univariate analysis showed that P
cell percentage, rather than gender, age, WHO classification and cytogenetic
subgroup, were associated with neutrophil recovery after chemotherapy. Mul-
tivariate analysis demonstrated that P cell percentage is an independent factor
affecting neutrophil recovery capability for both first and second courses
(p=0.015; p=0.036, respectively).
Summary/Conclusions: Our results indicate that CD34+CD38+CD117+HLA-
DR+CD13+CD33+ cells before each course of chemotherapy is associated
with chemotherapy related hematopoietic reconstitution capacity independently.
These findings may help better understand endogenous hematopoietic recon-
stitution and modify future chemotherapy regimens based on progenitor cell
percentages.
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MICRORNAS (MIRS) IN HIGH RISK PEDIATRIC ACUTE MYELOID
LEUKEMIA (AML) AS PREDICTION TOOLS FOR RELAPSE INCIDENCE
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M. Pigazzi4, G. Basso4, R. Rota1, A. Bertaina1
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Genetics, 3Genomic Shared Resources, Ohio State University, Columbus (OH),
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Background: Despite recent progresses made in the treatment of acute
myeloid leukemia (AML) of childhood, the cure rates of high-risk subtypes
remain low. Indeed, patients harboring FLT3-ITD mutations or 11q23 translo-
cations (MLL rearrangements) are still characterized by a poor prognosis, main-
ly due to leukemia recurrence. Since microRNA (miRs) are small RNA mole-
cules controlling normal hematopoiesis whose deregulation is fundamental in
leukemia’s pathogenesis, a possible role as predictors of relapse should be
considered.
Aims: Our purpose is to identify, at time of diagnosis, significant miRs signa-
tures able to predict the risk of relapse for patients with high-risk AML, such as
FLT3-ITD and MLL mutated. Moreover, these signatures would help us in iden-
tifying new molecules for novel targeted therapy and to deeply characterize
different deregulated pathways among FLT3-ITD and MLL rearranged patients.
Methods: A total of 20 AML bone marrow (BM) derived samples collected either
at diagnosis (ND) and at relapse (RL) together with 8 healthy controls (HCs)
were studied (total: N=48). Informed consent has been obtained from either
parents or legal guardians according to the Declaration of Helsinki. RNA was
extracted, cleaned up and Nanostring microRNA profiling was performed. Sta-
tistical and bioinformatics analysis were performed using nSolverTM (NanoS-
tring Technologies; Seattle, WA, USA) and R-based software. All the presented
results imply a P<0.05 where not mentioned.
Results: Comparing all AML samples with HCs, we found 16 up- and 509
down-regulated miRs. Similarly, FLT3-ITD (n=11) vs HCs, showed 17 up- and
361 down- regulated miRs, while MLL-rearranged (n=9) vs HCs showed 16
and 428 up- and down- regulated miRs, respectively. A trend towards down-
regulation of the whole cohort was detected and a block in miRs maturation
occurring in the 2 molecular subsets was supposed. Finally, a FLT3-ITD vs
MLL-rearranged analysis produced a signature in which 20 miRs were up- and
18 down- regulated, a putative signature which could characterize high-risk
AML. ND vs HCs analysis identified 17 up- and 397 downregulated miRs, con-
firming a tendency toward downregulation, as well as in RL vs HCs analysis,
in which we found 12 and 374 up- and down- regulated miRs, respectively. RL
vs ND comparison showed a total of 16 up- and 15 down- regulated miRs. In
the attempt to identify a signature predictive of recurrence at time of diagnosis,
we compared ND and RL samples, revealing 301 miRs that maintained their
deregulation in the 2 subgroups, while 113 and 85 were uniquely found in ND
vs HCs and RL vs HCs, respectively. Remarkably, miR-34a-5p (P<0.0001) was
the recurrent and most statistically significant upregulated miR in both ND and
RL samples. Moreover, upregulated miR-10a-5p and miR-99a-5p (P<0.0001),
and downregulated miR-9-5p (P<0.0001) were the most statistically significant
miRs in the FLT3-ITD and MLL-rearranged sets respectively, underlying putative
unique elements distinguishing the two clinical subsets.
Summary/Conclusions: Our results suggest the presence of different microR-
NA signatures in pediatric AML carrying FLT3-ITD and 11q23 translocations
[t(9;11) and t(10;11)]. The identifications of new targets linked to this miRs would
be useful for further studies focused on finding molecular-based therapy. Inter-
estingly, miR-34a-5p was recurrently found upregulated either in ND and RL
groups, but not in the comparative analysis between ND vs RL, suggesting a
potential involvement in the mechanisms at the base of both onset and relapse
in these subtypes of high-risk AML.
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CYTOKINE RECEPTORS AND SOLUBLE ADHESION MOLECULE LEVELS
ARE ASSOCIATED WITH PROGNOSIS OF NEWLY DIAGNOSED AML
T. Kupsa1,2, P. Zak2, L. Jebavy1,2, J. M. Horacek1,2,*
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Background: The outcomes of acute myeloid leukemia (AML) treatment are
beleaguered by the high resistance of malignant clones to therapy. Cytokines
and adhesion molecules have been studied as markers of immune system acti-
vation in many diseases including AML. Further knowledge gained from base-
line cytokine levels assessment may help to improve treatment outcomes.
Aims: The aim of this study is to evaluate baseline levels of selected cytokines,
cytokine receptors and adhesion molecules and their relationship with prognosis
in newly diagnosed AML patients.
Methods: A total of 75 AML patients, age 52.9±13.0 years, median 58.5 years,
44 female, were studied in the period 2010-2015. Only patients with minimal
follow-up of 1 year were included. All patients were induced with “3+7” induction
chemotherapy consisting of Cytarabin 100mg/m2 per day for 7 consecutive
days and Daunorubicin 90mg/m2 for the first 3 days of therapy in younger
patients. Since the beginning of 2015, the induction dose of Daunorubicin used
has been 60mg/m2 even in younger patients, according to recent evidence-
based data modifications. Those who failed to achieve CR were given FlAG-
Ida salvage followed by allogeneic stem cell transplantation in younger and fit
patients. In CR, the patients were treated either with HiDAC consolidations
alone, or followed by allogeneic stem cell transplantation in indicated cases. A
total of 39 patients underwent allogeneic stem cell transplantation. We evalu-
ated serum levels of the following 29 analytes: interleukins (IL-1α,IL-1β,IL-2,IL-
3,IL-4,IL-5,IL-6,IL-7,IL-8,IL-10,IL-12,IL-13,IL-15), Epidermal Growth Factor,
Granulocyte Macrophage Colony Stimulating Factor, Interferon-γ, Macrophage
Inflammatory Protein-1α, Monocyte Chemotactic Protein-1, Tumor Necrosis
Factor-α (TNF-α), Vascular Endothelial Growth Factor, E-selectin (E-SEL), P-
selectin (P-SEL), Intercellular Adhesion Molecule-1 (ICAM-1), Vascular Cell
Adhesion Molecule-1 (VCAM-1), Matrix Metalloproteinase-9, soluble IL-2 recep-
tor-α (sIL-2Rα) and soluble receptors for IL-6 (sIL-6R) and TNF-α type I and II
(TNFR-1,2). All biomarkers were measured by biochip array technology on Evi-
dence Investigator analyzer (Randox). Associations of these markers with com-
plete remission (CR) achievement, 1 year progression-free survival (PFS), and
1 year overall survival (OS), were evaluated. Statistical analysis was performed
in STATISTICA 2.0.
Results: CR by induction therapy was achieved in 53 cases (70.7%). Those
who failed to achieve CR by induction therapy had higher IL-7 levels, which
was not significant after Bonferroni correction (P=0.0913). Inferior PFS was
associated with higher sIL-2Rα (P=0.0525). Inferior OS was significantly asso-
ciated with higher P-SEL (P=0.0003), higher sIL-2Rα (P=0.0029), higher age
(P=0.0356) and possibly with higher TNFR-1 (P=0.0611). Age has not correlated
with any evaluated analyte. TNFR-1 correlated with TNFR-2 (P<0.0001), but
not with TNF-α. The sIL-2Rα did not correlate with IL-2. Only IL-6 and ICAM-1
were significantly influenced by CRP levels.
Summary/Conclusions: Better understanding of the cancer microenvironment
is a sine qua non for development of new treatment approaches. Our results
show that P-SEL, sIL-2Rα and TNFR-1 may be associated with treatment out-
come and thus should be further investigated as possible therapeutic targets.
The work was supported by a long-term organisation development plan 1011
(FMHS) and by MH CZ – DRO (UHHK, 00179906).
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MRD-DRIVEN CHOICE OF CONSOLIDATION AND MODULATION OF
INDUCTION AND CONSOLIDATION INTENSITY RESULTED IN A
SIGNIFICANTLY IMPROVED OUTCOME OF YOUNGER AML PATIENTS IN
THE LAST THREE YEARS
M. Clavio1,*, F. Guolo1, P. Minetto1, M. Miglino1, F. Ballerini1, D. Guardo1,
E. Coviello1, R.M. Lemoli1, M. Gobbi1
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Genoa, IRCCS AOU San Martino-IST, Genova, Italy
Background: In the last decades no effective new drugs have been introduced
and AML induction therapy is still based on a combination of an anthracycline
and cytarabine. The MRC group has, however, reported a progressive increase
of cure rates in younger patients. Our group has recently showed that the out-
come can be improved by a fludarabine-containing induction (FLAI5, with flu-
darabine administration in first course only), followed by a risk- adapted con-
solidation.
Aims: The aim of the present study was to evaluate if the disease free survival
(DFS) and the overall survival (OS) of younger (<65 years) AML patient treated
in our center had shown any modification in four consecutive periods of treat-
ment (< 2008; 2008-2010; 2011-2013; 2014-2016) and to recognize factors
possibly leading to this result.
Methods: We reviewed the outcome of 145 consecutive AML patients aged
65 or less and uniformly treated according to the above mentioned strategy.
Minimal residual disease (MRD) evaluation was performed by flow cytometry
(MFC), assessment of WT1 expression levels and, where applicable, evaluation
of recurrent abnormalities such as NPM1 mutation.
Figure 1.
Results: The cohorts of patients treated in the four periods had a comparable
age and risk distribution. Notably, although the median follow up of the 4 cohorts
of patients is different, patients treated in the last 3 years showed a significant
improvement in DFS (Fig 1), in comparison with previously treated patients.
When we reviewed our experience, we found that some changes we introduced
in the therapeutic management, possibly contributed to improve outcome.
Beside classical risk factors, the time from hematological recovery after the
first induction (induction 1) and the start of the second induction course (induc-
tion 2) proved to be significantly related to DFS and OS probability. An interval
shorter than 15 days resulted in significantly higher toxicity, whereas a time
longer than 25 days was associated with an increased relapse probability.
Patients being treated in the last three years had a median time from recovery
after induction 1 to start of induction 2 of 17 days, compared to 22 days in the
other cohorts (p<0.05). Furthermore, after 2013, MRD information after induc-
tion 1 was added as a prognostic factor and ELN low and intermediate risk
patient with negative MRD after induction 1 were no more scheduled for early
allogeneic stem cell transplant (HSCT), but received an higher dose of Ara-C
in each of the three consolidation cycles (12g/sqm cumulative dose vs 8g/sqm).
Among 8 intermediate risk patients who were MFC MRD negative post FLAI
and did not proceed to HSCT in first complete remission (CR1), only one
relapsed whereas among 5 intermediate risk patients who underwent HSCT in
CR1 because of MRD positivity no relapses have been observed. Starting from
2014, patient in CR1 not scheduled for HSCT who showed MRD reccurrence
underwent salvage therapy before overt hematologic relapse, followed by
HSCT consolidation. MRD-directed therapy allowed all treated patients to
achieve MRD negative remission before HSCT. Finally, the improved outcome
may be associated with a reduced incidence of invasive fungal infections (IFI)
due to the introduction of prophylaxis with posaconazole. The lower rate of IFI
contributed to the reduction in the delay between chemotherapy courses.
Summary/Conclusions: Our experience shows that, even without the contri-
bution of new drugs, more appropriate utilization of HSCT, tailored on early
MRD assessment, MRD directed salvage therapy and posaconazole prophy-
laxis of IFI led to a relevant improvement of outcome.
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EFFECTIVENESS OF TREATMENT ACUTE MYELOID LEUKEMIA IN THE
ELDERLY USING CLADRIBINE WITH LOW-DOSE ARAC
M. Wątek1,*, T. Gromek2, A. Pluta3, K. Budziszewska4, D. Majowicz2, E. Sierlecka1,
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Background: Treatment of acute myeloid leukemia(AML) in the elderly, unfit
patients is a challenge for clinical hematologists. Therapeutic management in
this group of patients causes intolerance and numerous complications including
early deaths. A standard treatment of low dose cytarabine (LD-AraC) or using
hypomethylating therapy is not satisfying enough. Polish Adult Leukemia
Group’s (PALG) studies showed, that addition of cladribine to daunorubicine
and cytarabine increases the complete remission rate and improves overall
survival in younger patients with AML. We also proved effectiveness of cladrib-
ine combined with high dose AraC and mitoxantron in relapsed and refractory
AML (1, 2). Cladribine, enhances the concentration of Ara-CTP, an active
metabolite of Ara-C in leukemic cells (3). Recent data indicate that cladribine
has also hypomathylating properties.
Aims: The aim of our study was to evaluate the efficacy and toxicity of cladrib-
ine in combination with LD-AraC in older AML patients.
Methods: Patients with newly diagnosed AML (excluding APL), older than 60
years, unfit for standard induction chemotherapy, were enrolled to our study. The
patients were given two cycles of cladribine 5mg/m2 i.v on days 1-5 and low-
dose cytarabine 40mg/m2 s.c on days 1-10 every 28 days followed by 2 cycles
of cladribine 5mg/m2 i.v on days 1-2 with LD-AraC (40mg/m2 s.c 1-10 days).
Responding patients were treated with a prolonged maintenance consisting of
LD-AraC (40mg/m2 1-10 day). The treatment was continued until progression.
Results: Twenty-four patients have been enrolled with median age 70 years
(range 62-84). In our cohort 20 patients had newly diagnosed AML, 3 secondary
and 1 therapy related AML. Cytogenetic risk: good risk 5 patients, intermediate
12, poor risk 3 patients, 4 patients were unclassified. The overall response rate
(CR+PR) was 84%. 13 out of 24 (54%) patients achieved complete remission
(CR) and 7 (30%) achieved partial remission (PR). The median number of
cycles to obtain CR was 2 (range 1-3). 16% of patients do not responded to
treatment. The regiment was well tolerated without 4-week and 8-week mor-
tality. The main reason of death were: heart failure (n=2), renal failure (n=1)
and progressive disease (n=4). We didn’t observe grade 3. and 4. nonhema-
tologic adverse events. With a median time of follow-up 14 months, the median
overall survival was 12 months.
Summary/Conclusions: The combination of cladribine plus low dose AraC is
effective and well tolerated regiment in elderly AML patients unfit for standard
chemotherapy.
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SMALL CUSTOMIZABLE NGS BASED TARGET CAPTURE PANELS
DETECT VARIANTS IN CLINICAL SPECIMENS AT FREQUENCIES AS LOW
AS 0.5%
L. Chamberlain1,*, A.R. Carson1, V. McClain1, B. Patay1, O. Kiya1, W. Huang1,
D. Hubbard2, D. Caguioa2, Z. Xie1, J. Thornes2, T. Stenzel1, J.E. Miller1
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Background: The use of large scale hybridization panels in early stages of
clinical trials for novel therapies elicits a plethora of information for targeted bio-
markers. However, as theraputic targets are further characterized large panels
generate an overly broad set of data, compromising sensitivity in the selected
biomarker subset. Therefore, once biomarker targets are identified, the use of
smaller hybridization panels can facilitate specific variant detection by analyzing
specific genomic regions of interest with greater sensitivity than larger gene
panels and greater breadth than that available via PCR-based assays. Modifi-
cations of laboratory methods for small scale panels allow for the maintenance
of high analytic quality with finely targeted panels. Our small panels (~10kb)
focus on 1-4 genes, allowing for high-multiplexing of samples on sequencers,
and reduced costs/processing times without compromising accuracy.
Aims: To demonstrate the sensitivity, linearity, concordance with other assays,
and clinical applications of small NGS target capture panels.
Methods: Two separate next generation sequencing-target capture assays
were developed with bioinformatics software under ISO13485 design control.
One panel contained 3 genes, including fms related tyrosine kinase 3 (FLT3);
the second covers only CD274 (PD-L1). Libraries were made, hybridized with
baits, and sequenced using the Illumina MiSeqDx. Validation was carried out
by spiking in fixed amounts of mutant DNA into wild type DNA to establish the
linearity and sensitivity of the assays. Sequencing libraries were generated by
capturing with baits from either one or both panels. Sequencing data was ana-
lyzed using proprietary software developed by Invivoscribe. Eight AML clinical
samples were cross validated for FLT3 mutations by this small panel, amplicon
based NGS assay, and capillary electrophoresis (CE) assay.
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Results: DNA from 24 cell lines was assessed using both panels, confirming
variants previously detected using other methods. A validation was run on the
3-gene panel using a series of contrived samples generated from cell lines
containing between 0.5% and 25% variant allele frequencies for expected vari-
ants. Initial validation indicates that these small panel assays can detect muta-
tions down to 0.5% variant allele frequencies. Assay linearity for FLT3/TKD
detection from 0.25% to 12.5% or for FLT3/ITD detection from 0.5% to 25% is
excellent (R2= 0.996 and 0.998, respectively). Average sequencing coverage
was high, ranging from 5,265x to 7,680x. Comparison of FLT3 analysis of the
small panel to amplicon based NGS assay and CE, FLT3-ITD showed complete
concordance in clinical samples - and showed a strong linear relationship
between calculated VAFs,and detected ITD sizes. There was also complete
concordance for FLT3-TKD mutations in clinical samples. 
Summary/Conclusions: Small hybridization panels are cost effective in detect-
ing low-frequency variants from smaller subsets of genes while using far less
DNA than individual PCR-based biomarker assays would require. Additionally,
preliminary data shows great accuracy on clinical samples. These smaller
assays focus on the most pertinent genes for a targeted therapy, and have the
potential to greatly assist in understanding the molecular backgrounds of
responders, super-responders, and non-responders, information which can
help improve patient outcomes. Developing these assays with bioinformatics
using the international ISO13485 design control standards makes them suitable
for regulatory approval worldwide.
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EFFICACY BY OUTPATIENT VS INPATIENT ADMINISTRATION OF
CONSOLIDATION: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF
CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED,
HIGH-RISK ACUTE MYELOID LEUKEMIA
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Background: The CPX-351 liposomal formulation delivers a synergistic 5:1
molar ratio of cytarabine and daunorubicin preferentially to leukemia cells. CPX-
351 has demonstrated significantly improved overall survival (OS) versus
cytarabine/daunorubicin (7+3) in a randomized, open-label, phase 3 study in
patients aged 60 to 75 years with newly diagnosed, high-risk AML (Lancet, et
al. ASCO 2016). In contrast to the 7+3 regimen, which includes cytarabine con-
tinuous infusion for 7 days, CPX-351 is administered as a 90-minute infusion
and thus has the potential to be given in the outpatient setting.
Aims: The current analysis of the phase 3 trial assessed the number of patients
getting treated in the outpatient setting and their outcomes.
Methods: Enrolled patients were randomized 1:1 to receive 1 to 2 induction
cycles of CPX-351 or 7+3; patients with complete remission (CR) or CR with
incomplete platelet or neutrophil recovery (CRi) could receive up to 2 consoli-
dation cycles (CPX-351: 65 units/m2 [cytarabine 65mg/m2 + daunorubicin
28.6mg/m2] on Days 1 and 3; 7+3: cytarabine 100mg/m2/day x 5 days +
daunorubicin 60mg/m2 on Days 1 and 2). The site of administration was not
protocol defined.
Table 1.
Results: Few patients received induction as outpatient therapy (CPX-351
n=3/153 and 7+3 n=1/151 in each cycle). A total of 49/153 patients in the CPX-
351 arm and 32/151 patients in the 7+3 arm received consolidation. In contrast
to the induction cycles, a substantial proportion of patients received consolida-
tion with CPX-351 in the outpatient setting (consolidation 1: n=25/49 [51%];
consolidation 2: n=14/23 [61%]) compared with the 7+3 chemotherapy arm
(n=2/32 [6.2%] and n=0/12 [0%], respectively). For the CPX-351 arm, this result-
ed in a reduction in the mean number of treatment days spent in the inpatient
setting (consolidation 1: 1.4 days; consolidation 2: 1.2 days) compared with
7+3 (5.3 and 5.5 days, respectively), and a reduction in the mean percentage
of time spent by patients treated with CPX-351 consolidation in the inpatient
setting (consolidation 1: 47.6%; consolidation 2: 39.1%) compared with the 7+3
arm (93.8% and 100%, respectively). CPX-351 consolidation was associated
with numerical improvement in median OS versus 7+3, irrespective of admin-
istration in the inpatient or outpatient setting (Table). Median OS was not dimin-
ished when CPX-351 was administered in the outpatient (consolidation 1: 25.43
months; consolidation 2: 26.32 months) versus inpatient setting (consolidation
1: 14.72 months; consolidation 2: not reached). CPX-351 was associated with
a manageable safety profile that was generally comparable to that of 7+3
chemotherapy, with no clinically meaningful differences in the rates of grade
≥3 treatment-emergent adverse events, including febrile neutropenia (68% vs
71%, respectively) and infections (55% vs 51%).
Summary/Conclusions: Some patients can successfully receive CPX-351
consolidation as outpatients without diminished efficacy, potentially reducing
hospitalizations associated with treatment administration.
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MOLECULAR GENETIC TESTING PATTERNS FOR PATIENTS WITH
NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) ENROLLED IN
THE CONNECT® MDS/AML DISEASE REGISTRY
D. Pollyea1,*, T. George2, K. Foucar2, H. Erba3, M. Thompson4, G. Roboz5,
D. Landau6, J. Pagel7, K. Seiter8, C. Cogle9, M. Nifenecker10, A. Swern10,
P. Kiselev10, M. Sugrue10
1University of Colorado Cancer Center, Aurora, 2University of New Mexico,
Albuquerque, 3University of Alabama at Birmingham, Birmingham, 4Aurora
Research Institute, Aurora Health Care, Milwaukee, 5Weill Cornell College of
Medicine, New York, 6University of Florida Health Cancer Center–Orlando
Health, Orlando, 7Swedish Cancer Institute, Seattle, 8New York Medical Col-
lege, Valhalla, 9University of Florida, Gainesville, 10Celgene Corporation, Sum-
mit, United States
Background: Recurrent mutations in AML-associated genes have prognostic
value and may help guide treatment decisions. Molecular genetic testing pat-
terns for AML in clinical practice are largely unknown. Previous results of the
CONNECT MDS/AML Disease Registry (George et al. ASH 2016; abstract
3548) showed suboptimal adherence to WHO 2008 recommendations for AML
diagnosis in a cohort of patients with newly diagnosed AML in clinical practice.
Aims: To report a detailed analysis of patterns of molecular genetic testing in
patients with newly diagnosed AML in community and academic settings.
Methods: The CONNECT MDS/AML Disease Registry (NCT01688011) is a
US prospective, observational cohort study of patients with newly diagnosed
AML (≥55 years) or myelodysplastic syndrome (MDS). All clinical decisions are
made by the treating clinicians. Data are collected, using an electronic data
capture system, at screening, enrollment, and approximately quarterly through-
out the duration of the patient’s participation in the registry. All patients provided
informed consent. Enrollment is ongoing. The current analysis evaluated the
percentage of patients with AML who had undergone molecular genetic testing
recommended by NCCN guidelines (NPM1, FLT3-ITD, CEBPA, IDH1, IDH2,
DNMT3A, and KIT). Chi-square tests evaluated effects of several variables on
likelihood of molecular genetic testing. 
Results: Between 12 Dec 2013 and 8 Dec 2016 (data cutoff), 259 patients
with AML were enrolled at 86 sites. Molecular genetic testing was reported in
67% (173/259) of patients. Likelihood of testing varied, respectively, for aca-
demic vs community sites (76% [70/92] vs 62% [103/167], P=.018), normal vs
abnormal karyotype (77% [79/103] vs 59% [79/133], P=.006), age <65 vs ≥65
(83% [65/78] vs 60% [108/181], P=.0003), and Medicare vs other insurance
(61% [83/137] vs 74% [90/122], P=.025). In patients who had undergone molec-
ular genetic testing (n=173), the mutations tested varied substantially. All of the
NCCN-recommended molecular genetic tests were reported in 9% (15/173) of
patients, including 8% (6/79) of those with normal karyotype. Of the seven
NCCN-recommended tests, NPM1 (77%) and FLT3-ITD (76%) were most often
reported and DNMT3A least often (16%). 
Summary/Conclusions: Early data from the CONNECT MDS/AML Disease
Registry reveal that despite molecular testing reported in 67% of patients with
newly-diagnosed AML, a majority do not receive guideline-recommended test-
ing. This prospective registry is uniquely positioned to capture changes in test-
ing patterns as guidelines are established. 
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PHASE 1, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE
EFFECT OF CYTOCHROME P450 (CYP) 3A4 INHIBITION ON THE PHAR-
MACOKINETICS (PK) AND SAFETY OF QUIZARTINIB (Q) AND ITS ACTIVE
METABOLITE, AC886
J. Li1,*, M. Kankam2, D. Trone3, G. Gammon3
1Daiichi Sankyo, San Diego, CA, 2Vince & Associates, Overland Park, KA, 3for-
merly Daiichi Sankyo, San Diego, CA, United States
Background: Q is a potent, selective FMS-like tyrosine kinase 3 (FLT3) inhibitor
currently being investigated in Phase 3 studies in AML patients (pt) with FLT3
internal tandem duplication (ITD) mutations. Early studies showed concentration
(conc)-dependent QTc prolongation and identified conc of Q, but not its active
metabolite, AC886, was a significant predictor of the QTc prolonging
effect(Levis, et al. ASH 2016). Q and AC886 are both primarily metabolized by
CYP3A4. Because CYP3A4 inhibiting drugs are frequently required in the
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course of AML treatment, a drug interaction study was performed to assess
PK when Q is co-administered with CYP3A4 inhibitors.
Aims: The primary aim was to determine the effect of ketoconazole (K), a
strong CYP3A4 inhibitor, and fluconazole (F), a moderate CYP3A4 inhibitor,
on PK of Q and AC886. The secondary aim was to assess the tolerability and
safety of Q co-administered with K or F.
Methods: This was an open-label, randomized, parallel-group study. Healthy
subjects (HS) age 18 -55 years (yr) who provided informed consent were ran-
domized 1:1:1 to receive K 200mg twice daily (BID), F 200mg BID, or placebo
(P) BID on Days(D) 1-28. A single 30mg dose of Q was administered to all HS
on D8. Plasma Q and AC886 conc were measured D8-28, using a validated
liquid chromatography-tandem mass spectrometry method. PK parameters
were determined using noncompartmental analysis. Steady-state (SS) drug
conc, following repeated once daily dosing, were predicted using non-para-
metric superposition. An analysis of variance (ANOVA) was performed to
assess the CYP3A4 inhibitory effect of K and F on the PK.
Results: 93 HS were enrolled (31 per arm), and 89 received Q. 75% were
male, median age 32 yr (18-53). Relative to Q+P, co-administration of Q+K or
Q+F increased the geometric mean (GeoMean) Cmax of Q by 17% and 11%,
and GeoMean AUC0-inf by 94% and 20%, respectively (Table 1 below). The
GeoMean Cmax and AUC0-inf of AC886 were decreased by 60% and 15%,
respectively, for Q+K, and were increased by 3% and 14%, respectively, for
Q+F. Apparent clearance (CL/F) of Q was 50% lower and t1/2 of Q and AC886
were 46% and 96% longer, respectively in Q+K vs Q+P. CL/F of Q was 17%
lower and t1/2 of Q and AC886 were 10% and 28% longer, respectively, in Q+F
vs Q+P. AC886 is a minor component in circulation relative to Q (approximately
25%). An increase of 86% in simulated SS Q Cmax and 96% in SS Q AUC0-24
was predicted following repeat daily dosing of 30mg Q+K vs Q+P, while a mod-
est decrease in AC886 exposure (<20%) was predicted. The most common
(≥5%) adverse events were headache (7.5%) and diarrhea (5.4%), with the
majority being Grade 1/2. There were no clinically significant hematology, clin-
ical chemistry, QTc, or vital sign observations, and no deaths or serious adverse
events.
Table 1.
Summary/Conclusions: Co-administration of Q with K or F was well tolerated
and safe. Overall, there was an approximate 2-fold increase in Q exposure
when Q was co-administered with K, which is considered clinically significant.
The increase in Q exposure when Q was co-administered with F was within
20% and is not considered clinically relevant. Given the relationship between
Q conc and QTc prolongation, these results support reducing Q doses by
approximately one-half when taken concomitantly with a strong CYP3A4
inhibitor. No dose reduction is needed when Q is co-administered with a mod-
erate or weak CYP3A4 inhibitor. This approach has been implemented in two
ongoing Phase 3 trials of Q in FLT3-ITD mutated AML.
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SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF
GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING
AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR
INTENSIVE CHEMOTHERAPY
A. Forsythe1,*, B. Arondekar2, G. Tremblay1, G. Chan2, Y. Su2
1Purple Squirrel Economics, 2Pfizer Inc, New York, United States
Background: In a randomized phase 2 study, glasdegib (GLAS), an oral,
smoothened inhibitor, combined with Low Dose ARA-C (LDAC), showed sig-
nificantly better overall survival (OS) vs LDAC alone in previously untreated
acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy
(NIC). Hypomethylating agents (HMAs), azacitidine (AZA) and decitabine
(DEC) are considered current standard of care in this population. 
Aims: To conduct an indirect treatment comparison (ITC) comparing OS for
GLAS+LDAC vs AZA and DEC, respectively.
Methods: Embase, MEDLINE, Cochrane database, and conference abstracts
(ASCO, ESMO and ASH) were systematically searched through 12/2016 for
relevant randomized controlled trials (RCTs) of GLAS, AZA and DEC in AML
patients ineligible for IC. Classical frequentist ITC using the Bucher method
was used to indirectly compare OS hazards ratios with 95% confidence inter-
vals (CI) using LDAC as the common comparator. 
Results: Four studies met inclusion criteria: two studies comparing AZA to
LDAC: Fenaux 2010; Dombret 2015; one study comparing DEC to LDAC: Kan-
tarjian 2012, and one study comparing GLAS+LDAC to LDAC: Cortes 2016
(Table). Fenaux 2010 study was excluded due to population differences: base-
line median bone marrow blasts at 23% in Fenaux 2010 vs 49% in Cortes
2016. The remaining AZA and DEC studies were generally comparable in
patient baseline characteristics to the GLAS study: age and cytogenic risk: age
75/73/76 years old, poor cytogenic risk 34%/37%/39%, in AZA/DEC/
GLAS+LDAC, respectively. In the ITC, with LDAC as the common comparator,
GLAS+LDAC compared favorably with indirect HR for OS vs AZA and DEC
being 0.51 and 0.56, respectively, (Table 1).
Table 1.
Summary/Conclusions: Using ITC, treatment with GLAS+LDAC showed sig-
nificantly better OS HR than AZA and DEC in previously untreated AML patients
ineligible for treatment with IC. Limitations of current analysis include mixed IC
& NIC population for the AZA trial, and mixed comparator arm of both LDAC
and BSC for the DEC trial. Analyses using patient-level data matching baseline
characteristics across studies may enable more robust ITC. 
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CLINICAL OUTCOMES OF CHILDHOOD ACUTE MEGAKARYOBLASTIC
LEUKEMIA: THE CHILDREN CANCER HOSPITAL EGYPT 57357 EXPERIENCE
N. Maarouf1,*, S. Mahmoud1,2, R. Abdelaziz1,2, L. Lehmann3, K. Shaaban4,5,
S. Fahmy5,6, S. Ibrahim4,5, O. Hassanain7, N. Nader7, A. Elhaddad1,2
1Pediatric Oncology, 57357 CCHE, 2Pediatric Oncology, National Cancer Insti-
tute, Cairo, Egypt, 3 Pediatric Stem Cell Transplant, Dana Farber Cancer Insti-
tute, Boston, United States, 4Department of Clinical Pathology CCHE, 57357
CCHE, 5Department of Clinical Pathology, National Cancer Institute, 6Depart-
ment of Clinical Pathology, 7Department of Research CCHE, 57357 CCHE,
Cairo, Egypt
Background: Acute megakaryoblastic leukemia is a rare subtype of pediatric
AML occurring in both Down and non-Down syndrome patients. Down syn-
drome patients with M7 subtype have an excellent prognosis while non-Down
syndrome patients have poor outcomes. Heterogenous cytogenetic abnormal-
ities have been described with M7 AML and the impact of different prognostic
factors on outcomes is yet to be determined.
Aims: To evaluate the prognostic significance of various cytogenetic abnormalities
and minimal residual disease (MRD) by flow cytometry after induction I and correlate
them with the clinical outcomes of patients with acute megakaryoblastic leukemia.
Methods: We retrospectively analyzed the data of 80 non-Down syndrome
patients diagnosed with M7 AML treated at CCHE between January 2007
through December 2016. Three treatment protocols were used.
Results: The median age at diagnosis was 1.7 years (range 0.2-15). The medi-
an time to diagnosis was 1 month. The overall (OS), event free survival(EFS)
and cumulative incidence of relapse at 2 years were 53.4%, 42.9% and 28.4%
respectively. Sixty one patients had abnormal cytogenetic abnormalities includ-
ing Trisomy 19 (n=20), 13q (n=3), Trisomy 8 (n=12), Complex karyotype (n=28),
t(1;22) (n=12), MLL gene rearrangement (n=9), Trisomy 21 (n=24) but none of
these had an impact on outcomes. Out of the 80 patients 56 were in complete
remission post induction I. Twenty two patients had MRD<0.1% after induction
I. In the univariate analysis patients with MRD <0.1% post induction I had a
better OS and EFS with a lower cumulative incidence of relapse however these
findings did not reach a statistical significance.
Summary/Conclusions: Acute megakaryoblastic leukemia in non-Down syn-
drome patients have poor outcomes irrespective of any cytogenetic abnormal-
ities. Future direction to determining tumor biology based on molecular path-
ways in this disease is being considered.
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IDENTIFICATION OF RESISTANCE ASSOCIATED CPG METHYLATION
CHANGES IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING
INDUCTION CHEMOTHERAPY
C. Niederwieser1,*, C. Rohde1, H. Serve2, W. Berdel3, G. Ehninger4, S. Göllner1,
L. Müller1, C. Müller-Tidow1
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Frankfurt am Main, 3Medizinische Klinik A, Universitätsklinikum Münster, Mün-
ster, 4Medizinische Klinik und Poliklinik I, Universitätsklinikum der Technischen
Universität Dresden, Dresden, Germany
Background: Acute myeloid leukemia (AML) is a heterogeneous disease asso-
ciated with epigenetic alterations that can be targeted with demethylating agents
to induce CR in a subgroup of patients. However, there are currently no pre-
dictive markers that reliably distinguish responder from non-responder patients.
In this analysis we assessed DNA methylation changes in a group of refractory
patients with AML treated either with the hypomethylating agent azacytidine
followed by intensive chemotherapy or with intensive chemotherapy alone in
order to identify the alterations and genes involved.
Aims: The exploration of whole genome methylation changes of azacytidine
and chemotherapy treatment in refractory patients with AML guides treatment
refinement.
Methods: Patients from the AML-AZA trial of the Study Alliance Leukemia were
randomized to receive either azacytidine followed by chemotherapy or
chemotherapy alone. Cells were harvested at baseline and 15 days after
chemotherapy from 16 of the 105 patients receiving the combination and from
four of the 109 patients randomized to receive chemotherapy only. Genome
wide DNA methylation was analysed using a 450K Illumina array (Illumina, San
Diego, USA). With a signature derived by differential blasts within diagnosis to
day 15, patients with a reduction of blasts clustered together by methylation of
all the selected CpG sites, as did those with an increase of blasts on both day
0 and 15, besides paired samples of day 0 and day 15 frequently clustering
together as well. This led us to refine blast independent analyses. We excluded
methylation changes correlating with the percentage of blasts (p=0.14,
exploratory regression among blast change and median methylation change
day 0 to day 15, each), since these are likely to reflect the increased lymphocyte
counts on day 15 in the unsorted samples used for analysis. Motifs most strong-
ly impacted by methylation changes were detected using the Homer software
(Salk institute, San Diego, USA). Methylation changes were compared between
the two groups to identify the changes associated with the use of azacytidine
prior to chemotherapy. 
Results: In the Azacytidine plus Chemotherapy treated group, a total of 389
differentially methylated regions (DMRs), most of which were single CpGs,
were identified, 176 of which were hypermethylated and 213 hypomethylated.
The most highly represented hypermethylated loci were INSM1 (p=1e-17,
6.25% of 176 DMRs), KLF13 (p=1e-14, 7.95%), HIC2 (p=1e-11, 5.11%), while
those most commonly hypomethylated were NRF1 (p=1e-15, 2.82% of 213
DMR’s), MYB (p=1e-14, 3.76%) and STAT1 (p=1e-14, 1.88%). The chemother-
apy alone group yielded 7181 DMRs, 5752 of which were hypermethylated and
1429 hypomethylated. The genes most commonly hypermethylated in these
patients were EHF(ETS) (p=1e-226, 32.79% of 5752), CEBPE (p=1e-90,
10.34%), and Jun-AP1 (p=1e-45, 6.10%), while those most commonly
hypomethylated were RUNX1 (p=1e-24, 28.34% of 1429 DMRs), TCF4 (p=1e-
21, 8.40%) and SMAD3 (p=1e-17, 1.05%). Median overall survival did not differ
between the two treatment groups, with 153 days for chemotherapy and 143
days for azacytidine/chemotherapy patients.
Summary/Conclusions: Methylation changes associated with azacytidine and
chemotherapy of refractory patients were particularly found in genes previously
associated with cancer and AML. DNA hypermethylation was more common
after chemotherapy alone. This finding suggests that DNA hypermethylation of
specific loci may be associated with therapy resistance. Hence, the methylation
levels were detected from the most resistant cells. Of note, upon Azacytidine
treatment more hypomethylated loci were observed. This potentially indicates
DNA hypomethylation in vivo.
E928
OVER-EXPRESSION OF ZEB2-AS1 LNCRNA PREDICTS POOR
OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
X. Shi1,2,*, J. Li1, L. Ma1, L. Wen1, Q. Wang1, H. Yao1, C. Ruan1, D. Wu1,2, S. Chen1
1The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, 2Institute of Blood and Marrow Transplantation,Collaborative Innovation
Center of Hematology, Soochow University, Suzhou, China
Background: Acute myeloid leukemia (AML) is a fatal hematopoietic malig-
nancy with poor clinical outcomes characterized by blasts infiltrated in tissues.
Aims: To determine whether the antisense lncRNA namely ZEB2-AS1 would
be associated with clinical outcomes, we assessed its expression in retrospec-
tive cohort with 62 de novo AML cases.
Methods: Relative quantitative real-time PCR analysis was employed for
detecting levels of ZEB2-AS1. SYBR Green RT-PCR was performed, followed
by obtaining relative threshold cycle normalized to reference GAPDH gene.
Cell migration, invasion, proliferation and apoptosis tests were used to analyze
biological phenotypes of AML cells after knocking down ZEB2-AS1 lncRNA by
small interfering RNAs.
Results: Results showed that expression of ZEB2-AS1 lncRNA was promi-
nently high and closely correlated with adverse clinical outcomes in AML
patients, based on either modified MRC or ELN risk stratification system. Uni-
variate analyses indicated that patients with higher expression of ZEB2-AS1
lncRNA had significant shorter 3-year overall survival (OS) (0% vs 68.2%,
p=0.036) and disease-free survival (DFS) (25.0% vs 69.8%, p=0.039). In addi-
tion, Patients with higher expression of ZEB2-AS1 lncRNA had significant lower
complete remission (CR) rate in response to induction chemotherapy (75.0%
vs 27.3%, p=0.031). In patients with low levels of ZEB2-AS1 lncRNA, patients
treated by allogenic hematopoietic stem cell transplantation had significant
longer OS (3-year OS, 75.8% vs 28.6%, p=0.037) and DFS (3-year DFS, 81.8%
vs 28.6%, p=0.049) compared to that of chemotherapy.
Summary/Conclusions: Moreover, knockdown of ZEB2-AS1 lncRNA could
effectively inhibit invasion and migration in AML cells, which was closely asso-
ciated with down-regulation of ZEB2 and up-regulation of E-cadherin. Collec-
tively, although independent prognostic value for survivals was not rigorously
determined, ZEB2-AS1 lncRNA may serve as candidate to improve conven-
tional risk stratification system and contribute to evaluating therapeutic respons-
es in AML. Furthermore, ZEB2-AS1 lncRNA could effectively modulate leukemic
phenotypes of invasion and migration which may be the potential for targeted-
therapy in AML.
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INTENSIFICATION OF ANTHRACYCLINE DURING INDUCTION AND
CONSOLIDATION IS SAFE AND WELL TOLERATED IN OLDER PATIENTS
WITH ACUTE MYELOID LEUKAEMIA
J. Loh1, S. Avery1, S. Patil1, P. Walker1, A. Spencer1,2, A. Wei1,2, S. Fleming1,*
1Department of Haematology, Alfred Hospital, 2Australian Centre for Blood Dis-
eases, Monash University, Melbourne, Australia
Background: AML in the elderly is more susceptible to treatment failure. Treat-
ment related mortality in elderly patients with AML is decreasing over time, and
receiving chemotherapy of adequate intensity is important in treating AML in
these patients. The optimal induction and consolidation approach for patients
in this age group is yet to be established, however data from the HOVON group
has demonstrated the benefit of anthracycline intensification during indcution
in patients aged 60-65 years, while locally the Australian AML12 study demon-
strated the value of anthracycline intensification during consolidation in younger
adults. We have implemented a novel combination of intensified anthracycline
in combination with infusional cytarabine (AraC) during induction and in com-
bination with intermediate-dose AraC during consolidation.
Aims: To demonstrate the safety and tolerability and provide preliminary effi-
cacy evidence for anthracycline intensification during induction and consolida-
tion in older adults with Acute Myeloid Leukaemia.
Methods: A retrospective pilot study was done on 76 consecutive patients above
the age of 55 years with newly diagnosed AML between January 2010 to June
2016 at Alfred Hospital, Melbourne, Australia. All received the 7+3 induction
regime (AraC continuous infusion at dose of 100mg/m2/day on days 1 to 7, and
idarubicin at a dose of 12mg/m2/day on days 1 to 3), with a planned consolidation
with IDAC+2 (AraC 1000mg/m2 twice daily Day 1, 3, 5, and idarubicin
12mg/m2/day Day 1-2). Outcomes were assessed according to the Cheson cri-
teria with cytogenetic risk assessed by the refined Grimwade MRC criteria.
Table 1.
Results: 76 patients, with a median age of 62 years (range 55.4-70.6 years)
received the 7+3 induction with a median overall survival of 590 (range 6-1996)
days and overall response rate was 52 patients (68.4%). The event-free survival
median is 109 days (range 6-1988) and the relapse-free survival median is 314
days (range 4-1947). There were 9 treatment-related deaths (11.8%) within 30
days following 7+3 induction. Of 41 patients who attained complete morpho-
logical remission after induction, 29 patients (70.7%) received the planned
IDAC+2 consolidation with 17 (41.5%) receiving two consolidation cycles. Of
those not receiving IDAC+2, 10 patients (24.4%) received an alternative con-
solidation regimen and 2 patients (4.9%) did not receive consolidation. Of those
receiving IDAC+2 25 (86.2%) were intermediate cytogenetic risk and 3 (10.7%)
were adverse. No treatment-related deaths occurred during consolidation with
IDAC+2. 20 patients (26.3%) from the whole cohort received an allogeneic
stem cell transplant (SCT), and 8 patients (27.6%) of those who received the
IDAC+2 consolidation regimen proceeded to an allogeneic SCT. In all IDAC+2
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consolidation cycles, the median days to neutrophil recovery was 26 days
(range 18-72), platelet recovery 32 days (range 17-75), and the ICU admission
rate was 12.8% (range 2-10 days). 18 patients (62.1%) receiving IDAC+2 con-
solidation suffered disease relapse. For patients receiving IDAC+2 consolida-
tion the median OS was 727 days (range 113-1614 days) with an EFS of 388
days (range 109-1614 days). For patients aged 60-65 years the remission rate
and survival outcomes were similar to those published by Lowenberg et al.
Summary/Conclusions: Anthracycline intensification was well tolerated with
low treatment related mortality and rates of ICU admission along with accept-
able time to count recovery. In patients aged 60-65 outcomes were similar to
published data with high-dose daunorubicin. Despite this intensive post-remis-
sion therapy approach rates of disease relapse were high highlighting the need
for novel therapeutic approaches in this patient group.
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PROGNOSTIC IMPACT OF IDH1 AND IDH2 MUTATIONS IN LOW AND
INTERMEDIATE RISK AML: A MULTICENTER RETROSPECTIVE STUDY
F. Lessi1, M. Riva1,*, M. Gottardi2, F. Mosna2, B. Luca3, C. Minotto4, R.
Bertorelle5, G. Semenzato1
1Department of Medicine, University of Padua, Hematology and Clinical
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Ospedale Santa Maria di Ca’ Foncello, Treviso, 3Education and Training
Department, Azienda Ospedaliera di Padova, Padova, 4Division of Oncology,
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Background: Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2)
genes are common in acute myeloid leukemia (AML) but, although investigated
in several studies, their prognostic significance still remains controversial.
Aims: To evaluate the prevalence and prognostic impact of IDH1 and IDH2
mutations in adult AML patients with low and intermediate-1 and 2 risk (Euro-
pean Leukemia Net, ELN 2010). 
Methods: We retrospectively evaluated IDH1 and IDH2 mutations in 99 low
and intermediate risk patients with new diagnosed AML who underwent inten-
sive induction chemotherapy in three Italian centers.
Results: Median age for all patients was 60 years. IDH mutations were detect-
ed in 25% of our patients. 7% were IDH1 R132, 16% were IDH2 R140 and 2%
R172. Median WBC count was 12,66x109/L in IDH wild-type, and 24,71 x109/L
in IDH mutated. Absolute neutrophil count was 3,1x109/L in IDH wild-type and
0,9x109/L in IDH mutated, and the difference was statistically significant
(p<0,001). Median bone marrow blasts, platelets count, and LDH did not differ
significantly. Cytogenetic risk group according to ELN 2010 showed favorable
risk in 31,4%, and intermediate (I and II) risk in 68,6%. In favorable risk group
IDH mutated patients were 12%, and 13% in the intermediate risk group. IDH
expression was significantly correlated neither with NPM1 mutation nor with
FLT3 mutation. There were no significant differences between induction ther-
apies in IDH mutated and unmutated patients (overall 3+7 “like” regimens in
57 patients, FLAI like regimens in 42). There were not significant differences
in CR rate after induction therapy, OS and PFS between IDH mutated and
unmutated patients. Median OS was 595 days in IDH mutated and 467 in IDH
wild-type (p=0,67) Median PFS was 319 days in IDH mutated and 406 days in
unmutated (p =0,157). We further analyzed the impact of IDH mutation in dif-
ferent cytogenetic risk groups: OS and PFS were not significantly different
between mutated and unmutated low cytogenetic risk patients. In intermediate
I and II risk patients PFS was significantly different (177 days in IDH mutated
vs 406 days in IDH wild type, p= 0.002), but OS was not. We then evaluated
patients with normal karyotype and mutated NPM1: IDH mutations had no
impact on OS and PFS.
Summary/Conclusions: In this multicenter retrospective study we found that
lower absolute neutrophil count at diagnosis is significantly correlated with IDH
mutations as already confirmed by other groups. In terms of prognosis we only
demonstrated an advantage in PFS for umutated intermediate risk patients,
suggesting a negative prognostic impact of the mutations which need to be
confirmed in further studies.
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DECITABINE COMBINED WITH HAAG REGIMEN IS AN EFFECTIVE
SALVAGE TREATMENT FOR ADVANCED ACUTE MYELOID LEUKEMIA
W. Cui1,2, Z. Jin1, A. Sun1, H. Qiu1, M. Miao1, J. Cao1, D. Guo1, D. Wu1,2,
X. Tang1,2,*
1The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, 2Institute of Blood and Marrow Transplantation,Collaborative Innovation
Center of Hematology, Soochow University, Suzhou, China
Background: As relapsed or refractory acute myeloid leukemia (AML) are
known to have poor prognosis, achieving complete remission (CR) and long-
term survival become extremely challenging for these patients. Reasons for
the dismal prognosis rely on more frequent resistance to conventional
chemotherapy and higher treatment-related mortality. Therefore, novel thera-
peutic approach to treat these patients were developed.
Aims: To evaluate the clinical efficacy and safety of decitabine (DAC) in com-
bination with HAAG regimen [homoharringtonine (HHT), cytarabine (Ara-C),
doxorubicin (Acla) and recombinant human granulocyte colony stimulating fac-
tor (G-CSF)] for advanced patients with AML.
Methods: hirty-six patients with advanced AML receiving DAC combined with
HAAG chemotherapy in our center from December 2012 to August 2015 were
enrolled in this study. Eighteen of them were refractory or relapsed AML, and
another 18 patients were those who didn’t achieve CR after a course of induc-
tion chemotherapy. The therapeutic responses, side effects and long-time sur-
vival were retrospectively analyzed.
Results: After a course of treatment, the rate of CR and partial response (PR)
was 58.3% (21/36) and 22.2% 8/36 respectively, while the overall response
rate (ORR) was 80.6% (29/36) in the cohort. For the patients with refractory or
relapse AML, CR was 61.0% (11/18), PR was 22.2% (4/18), and ORR was
83.3% (15/18). While for the other not getting CR after a course of induction
chemotherapy, CR was 55.6% (10/18), PR was 22.2% (4/18), and ORR was
77.8% (14/18). Grade 4 hematological toxicities were observed in all patients,
and 72.2% cases experienced infection. And all non hematological side effects
were mild and well-tolerated. With a median follow-up of 7.5 (0.5-33.3) months,
the 1-year overall survival (OS) rate was 43.3%, 24.2% for the refractory or
relapsed AML patients, and 61.6% for those not achieving CR after a course
of induction chemotherapy. The difference was significantly (P=0.01).
Summary/Conclusions: DAC combined with HAAG regimen is safe and effec-
tive salvage treatment for advanced stage AML patients.
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LESS-INTENSIVE TREATMENT LEADS TO DECREASED SURVIVAL IN
UNMARRIED ACUTE MYELOID LEUKEMIA PATIENTS AND PATIENTS
LIVING ALONE. A DANISH NATIONAL POPULATION-BASED COHORT
STUDY
L.S.G. Østgård1,2,*, M. Nørgaard2, B.C. Medeiros3, L.S. Friis4, M. Severinsen5,
C. Schöllkopf6, C.W. Marcher7, J.M. Nørgaard1
1Department of Hematology, 2Department of Clinical Epidemiology, Aarhus
University Hospital, Aarhus, Denmark, 3School of Medicine, Stanford University,
Stanford, United States, 4Department of Hematology, Copenhagen University
Hospital, Copenhagen, 5Department of Hematology, Aalborg University Hos-
pital, Aalborg, 6Department of Hematology, Herlev University Hospital, Herlev,
7Department of Hematology, Odense University Hospital, Odense, Denmark
Background: Marital status has been found to affect leukemia survival. Still,
lack of individual-level socioeconomic data, cohabitation status, and treatment
information prevented further investigation of underlying mechanisms. As treat-
ment is changing towards outpatient-care, effects of social support may become
even more important.
Aims: We investigated whether and how cohabitation and marital status affect
chance of intensive remission-induction chemotherapy and allogeneic stem
cell transplantation (HSCT), treatment response, and survival in acute myeloid
leukemia (AML) patients using individualized socioeconomic and clinical data
from Statistics Denmark and The Danish National Acute Leukemia Registry.
Figure 1.
Methods: We conducted a nationwide population-based cohort study and
included all AML patients >25 years diagnosed in Denmark between 2000-
2014 (follow-up ended Feb 2016). We compared chance of intensive
chemotherapy, complete remission (CR) and chance of alloHSCT in CR1 by
cohabitation and marital status (logistic regression, odds ratios; ORs). We used
Cox regression (Hazard ratios; HRs) to compare survival. To help explain
underlying mechanisms, results were given sequentially adjusted for: age, sex,
income, education and occupation, and, additionally for clinical prognostic
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markers. Results were given overall and stratified by age (<60/≥60 years) and
sex. Kaplan Meier curves and Cox regression (Hazard ratios; HRs) was used
to compare survival by cohabitation (living with someone, living alone) and
marital status (married, divorced, widowed, unmarried).
Results: The study included 3243 AML patients. Patients living with someone
(n=2056) were younger, more likely to be married, male, to be working, and to
have a higher education than patients living alone. Comorbidity, white blood
cell count, lactate dehydrogenase, and blast counts did not differ between
groups, however patients living with someone tended to have better perform-
ance status at time of diagnosis. Patients living with someone were more likely
to receive intensive chemotherapy than patients living alone when aged 60
years or older (41.2% versus 22.8%, adjusted OR 0.61 (CI=0.46-0.81)). In
patients <60 years, never-married patients were less likely to receive intensive
therapy (adjusted OR 0.43 (CI=0.19-0.99)) than married patients. In patients
<70 years achieving CR, the chance of alloHSCT was reduced when living
alone (11.8%, adjusted OR 0.47 (CI=0.28-0.78)), versus 19.0% in patients living
with someone. In divorced/widowed, the chance was also reduced (7.6%,
adjusted OR 0.38 (CI=0.20-0.74)) compared to married patients (19.3%). Crude
survival by cohabitation is shown in Figure 1. Overall survival was inferior in
patients ≥60 years living alone (adjusted HR 1.21 (CI=1.09-1.33)) and unmar-
ried patients (never-married: adjusted HR 1.29 (CI=1.06-1.57), divorced/wid-
owed: adjusted HR 1.11 (CI=1.00-1.23)) compared to married patients. In con-
trast, cohabitation and marital status did not affect treatment response (living
with someone: CR 70.6%, living alone: CR 72.8%) or overall survival (adjusted
HR 1.08 (CI=0.81-1.23)) in intensive therapy patients only.
Summary/Conclusions: Our study results indicate, that the effect of cohabi-
tation and marital status on AML outcome, especially in patients ≥60 years, is
explained by social support rather than by differences in income and occupation.
Patients living alone do not present with more advanced disease or higher
comorbidity burden than patients living with someone. Still, patients living alone
and never-married patients are less likely to receive intensive chemotherapy
affecting overall survival. Increased focus on what drives treatment decisions
in patients lacking social support is important to improve survival in these
patients.
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TREATMENT OF MOLECULAR RELAPSE IN ACUTE MYELOID LEUKEMIA
WITH MUTATED NPM1 REDUCES TOXICITY OF SALVAGE TREATMENT
AND IMPROVES DISEASE CLEARANCE
F. Guolo1,*, P. Minetto1, M. Clavio1, D. Guardo1, E. Coviello1, N. Colombo1,
F. Ballerini1, M. Miglino1, R.M. Lemoli1, M. Gobbi1
1Clinic of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, IRCCS AOU San Martino-IST, Genova, Italy
Background: Acute Myeloid Leukemia with mutated NPM1 (NPM-AML) is char-
acterized by a favorable prognosis. Most patients achieve hematological com-
plete remission (CR) and are not considered eligible for an early allogeneic stem
cell transplantation (HSCT). The importance of longitudinal NPM1 minimal resid-
ual disease (MRD) monitoring in NPM-AML is well recognized but no data are
currently available on MRD-directed therapy in this AML subset. Since 2004 we
have prospectically evaluated NPM1 MRD at precise time points to evaluate
response to therapy and predict the risk of hematological relapse (HR).
Aims: The aim of this study was to set a standardized operative definition of
molecular relapse and to evaluate the efficacy and feasibility of MRD-directed
salvage therapy.
Methods: From January 2004 to January 2014, 36 consecutive younger inten-
sively treated patients with NPM-AML achieving CR were included in the study.
MRD assessment was performed on bone marrow (BM) samples after 1st and
2nd induction cycle, after each of the three consolidation cycles and then every
three months for five years. If MRD positivity was found, a new analysis was to
be repeated in 15 days. NPM1 mutation was measured on BM samples using
MutaQuant® kit Ipsogen® from Qiagen. All Real-Time PCR were performed on
DNA Engine Opticon 2. Until 2014 our policy included the treatment of leukemia
in hematological relapse (HR). Salvage chemotherapy consistied in two MEC
cycles and then patients proceeded to HSCT, if feasible. From January 2015
we decided to use a pre-emptive strategy, treating the molecular relapse. Four
consecutive NPM-AML patients who showed MRD relapse received MRD-
directed therapy so far, which consisted of one cycle of MEC.
Results: Among 36 patients, 13 showed HR, after a median of 24 months
(range 14-52). All relapsing patients showed NPM MRD reccurrence prior to
HR, with a median time of 4.5 months (range 1-8.4) from the first recurrence.
Based on these data we defined MRD relapse as the reccurrence of NPM1
mutation, confirmed in 3 consecutive bone marrow samples repeated every 15
days, with a total increase of NPM1 expression levels of at least 2 logarithms
(i.e at least from 0 to 100/104Abl). All patients who fulfilled criteria for MRD
relapse progressed to HR within 3 months (range 1.5-3). All 13 patients treated
in HR received two cycles of MEC. Eight (62%) patients obtained hematological
CR, and one patient died during therapy. Complete NPM-MRD clearance was
achieved in 4/13 patients (31%). Starting from January 2015, 4 patients who
met the MRD relapse criteria received pre emptive therapy, consisting of a sin-
gle course of MEC. Four consecutive patients have been treated so far. Pre-
chemotherapy and post-therapy disease burden, assessed by NPM levels, was
significantly lower than in patients treated in HR (p <0.001, Figure 1). Both
hematological and non-hematological toxicity was significantly lower than in
patients treated in HR. Notably, all patients were able to achieve complete MRD
clearance before HSCT and are alive and well at the time of the analysis.
Figure 1.
Summary/Conclusions: Despite the good overall prognosis, a significant pro-
portion of NPM-AML patients will relapse. Our preliminary data strongly support
the feasibility and efficacy of MRD-directed therapy in NPM-AML. This strategy
reduces the toxicity related to re-inductin and increases the proportion of
patients achieving a MRD negative CR.
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MINIMAL RESIDUAL DISEASE AND LAIP CHANGES BY FLOW CYTOMETRY
IN DE NOVO ACUTE MYELOID LEUKEMIA DURING CHEMOTHERAPY
AND CLINICAL OUTCOMES
T. Lobanova1,*, I. Galtseva1, Y. Davydova1, N. Kapranov1, V. Troitskaya1,
E. Parovichnikova1
1Hematological Oncology and BMT, National Research Center for Hematology,
Moscow, Russian Federation
Background: Minimal residual disease (MRD) detection by multicolor flow
cytometry (MFC) in acute myeloid leukemia (AML) is widely explored by differ-
ent researchers and it is an additional independent factor in clinical outcomes.
The prognostic value of leukemia associated immunophenotype (LAIP)
changes in not explored enough.
Aims: To investigate the amount and clearance of MRD reduction and LAIP
changes in de novo AML during chemotherapy and compare the results with
clinical outcomes. 
Methods: In clinical prospective study since March 2016 till February 2017 50
patients (pts) de novo AML (f/m 32/18 m. age 44 (17-85)) were included. 14 pts
by this moment completed basic chemotherapy (ChT) courses: «7+3» 2 induc-
tion and 2 consolidation. Among them favorable cytogenetics was in 4pts
(t(16,21)-1, 16q22-1, t(8,21)-2pts), intermediate-7 (6-with normal caryotype, 1-
t(17,22)), poor–3 (complex karyotype-2, 11q23-1pt). Bone marrow samples
were studied in standardized panel with most common antibodies by 6-color
MFC (BD FACSCanto II, USA) before the treatment, after 1st and 2nd courses
of induction and after 2nd consolidation. Any amount of MRD >0 was assumed
as MRD positivity. Besides MRD status we also explored LAIP changes in
patients with CMR after 2nd ChT and in drug resistant cases.
Results: Leukemia associated immunophenotype (LAIP) was detected in all
monitored patients at the diagnosis. Molecular markers were detected in 28,5%
(2pts-with NPM1+FLT3+CEBPA+, 1-with FLT3+, 1-NPM1+). 2 pts had resistant
AML after 2 courses (DR). 3 pts out of 7 with complete morphological remission
(CMR) after 1st course had MRD positivity (0,03%, 1,61%, 8,3%), and these pts
became MRD-negative after 2nd course. CMR was achieved after 2ndcourse in
5 more pts and MRD positivity was detected in 3 pts (0,033%, 0,523 and 3,9%)
with intermediate cytogenetic risk. By the end of 4th course 11 pts stayed in
CMR and we diagnosed 1 morphological relapse (patient with MRD-negativity
and CMR after 2nd ChT). Two early relapses were also traced: both with persist-
ent MRD during all period of ChT and CMR after the second ChT. All pts with
MRD-negative status after first course are alive and in CMR (8 months from
diagnosis). While monitoring, LAIP changes were distinguished in 7 pts. One
from two with resistant AML lost CD65, another one acquired CD11b. 5 pts were
in CMR after the second course and during ChT one of them gained CD56 and
CD13, 2nd- lost CD65 and CD11b, 3rd – gained CD65, 4th gained CD11b after
2nd ChT, the last one didn’t change LAIP. We detected relapse in 3 pts from this
group and one – with increasing MRD after 4th course and cytopenic syndrome.
We may suggest that LAIP changes during ChT reflect selection of more
chemoresistant leukemia clone, followed by subsequent relapse.
Summary/Conclusions: 1. The most favorable group consisted of MRD neg-
ative pts after 1st course 2. LAIP changes are common in pts with less favorable
prognosis.
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LENALIDOMIDE MAINTENANCE IN PATIENTS WITH HIGH RISK ACUTE
MYELOID LEUKEMIA
T. Kadia1,*, J. Cortes1, F. Ravandi1, N. Daver1, E. Jabbour1, A. Ferrajoli1,
N. Pemmaraju1, K. Naqvi1, S. Pelletier1, M. Brandt1, Z. Estrov1, H. Kantarjian1
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Background: New drug combinations and higher intensity therapy have led to
significant improvements in complete remission (CR) rates for patients with acute
myeloid leukemia (AML). However, relapsed disease remains a major source of
failure. With the exception of allogeneic stem cell transplant (SCT), there are few
options for post-consolidation maintenance of remission in high-risk patients. NK
cells as part of the immune microenvironment are important mediators of immune
surveillance in AML. Lenalidomide has demonstrated single-agent activity in AML
and enhances NK cell activity and immune synapse formation in leukemia.
Aims: We designed a phase II clinical trial studying the efficacy of lenalidomide
as maintenance therapy in AML patients with high-risk disease in remission,
who were not being considered for SCT.
Methods: AML patients ≥18 years with a high-risk feature in 1st CR (CR1) or
any patient in 2nd CR (CR2) who had received induction and at least 1 consol-
idation cycle were eligible for enrollment. Patients should be within 12 months
of achieving CR, have PS ≤3, adequate kidney/liver function, ANC >0.5 and
platelets ≥30. Patients were treated continuously with lenalidomide 10mg PO
daily on D1-28 of a 28 day cycle for up to 24 cycles. All pts had baseline cyto-
genetic and molecular testing, and minimal residual disease (MRD) assessment
by flow cytometry. After cycle 1, stepwise dose escalations were allowed to
20mg daily in pts who were tolerating their dose and have presence of minimal
residual or morphologically detectable disease.
Figure 1.
Results: A total of 14 patients have been enrolled with a median age of 57.5
years (range, 23-67). All pts were in CR at the time of enrollment, with 12 pts
(86%) in CR1 and 2 (14%) in CR2. Baseline pt characteristics are outlined in
table 1. AML-related mutations detected at start of therapy include: CEBPA
(n=5), NPM1 (3), FLT3 (3), IDH2 (2), NRAS (2), DNMT3a (2), and 1 each of
JAK2, TET2, and EZH2. High risk features at the time of enrollment were as
follows (some are overlapping): 5 (36%) with history of prior myeloid neoplasm
or therapy related AML, 4 (29%) persistent MRD, 4 (29%) adverse mutational
profile, 2 (14%) adverse karyotype, 1 (7%) primary refractory disease, and 2
(14%) CR2 status. Patients have received a median of 9 cycles (1-24) cycles
of therapy. With a median followup of 19+ months (8.5-39), the 6- and 12-
month estimated RFS were 100% and 69%, respectively. The 6- and 12-month
estimated OS were 100% and 90%, respectively (Figure 1). The regimen was
well tolerated. Cytopenias were mild and managed with dose adjustments. The
most common grade 3 (no grade 4 toxicity) non-heme toxicities were 1 each
of rash, fatigue, cough, and nausea, vomiting, and stroke.
Table 1.
Summary/Conclusions: Lenalidomide is a safe and feasible maintenance
strategy in high-risk AML patients who are not candidates for SCT. The study
continues to surpass the pre-specified expected rate of relapse-free survival
of high-risk patients based on a historical cohort. Studies evaluating dynamics
of MRD on study are ongoing.
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POSTREMISSION THERAPY FOR AML WITH INTERMEDIATE RISK
CYTOGENETICS IN FIRST COMPLETE REMISSION
J. Vydra1,*, C. Šálek1, J. Schwarz1, P. Cetkovský1, P. Žák2, J. Novák3,
V. Petečuková3, J. Mayer4, Z. Ráčil4
1Institute of Hematology and Blood Transfusion, Prague, 24th Department of
Internal Medicine - hematology, Charles University, University Hospital Hradec
Králové, Hradec Králové, 3Dept. of Hematology, Charles University, University
Hospital Královské Vinohrady, Prague, 4Department of Internal
Medicine/Haemato-Oncology, University Hospital Brno, Brno, Czech Republic
Background: Postremission therapy of AML with intermediate risk cytogenetics
in first CR is based on chemotherapy with high dose cytarabine (HIDAC) or
hematopoietic cell transplantation (HCT). Evidence from single trials with
regards to optimal postremission therapy has been inconclusive, metaanalyses
suggest a survival benefit of allogeneic HCT in first CR, except for patients
with mutation of NPM1 without concomitant FLT3/ITD. 
Aims: We analyzed retrospectively data from patients with AML with intermediate
risk cytogenetics in CR1 with the aim to determine rates of completion of postre-
mission therapy, rates and risk factors for early relapse and non relapse mortality
(NRM), overall survival (OS) and relapse free survival (RFS) according to postre-
mission treatment and describe causes of and risk factors for treatment failure.
Methods: Data on 304 patients in CR1 treated with curative intent between 2007
and 2016 in four centers participating in Czech Leukemia Study Group for Life
were analyzed. All patients signed informed consent with data collection, analysis
and publication. Cox regression was used to determine risk factors for OS and
RFS, using time dependent covariates for postremission therapy. Age, WBC
count, number of induction cycles, NPM1 mutation, FLT3/ITD, performance sta-
tus, BMI, previous malignancy and extramedullary disease were included in mod-
els. Postremission therapy was completed after HCT or after three cycles of
HIDAC without HCT in patients <= 60 years or two cycles of intermediate dose
cytarabine (IDAC) in patients>60 years. Competing risk cumulative incidence
estimates were calculated for NRM and relapse. Early relapse and NRM were
defined as relapse/NRM before completion of postremission therapy.
Figure 1.
Results: Median age was 52(18-74) years. Median follow up time was 481(31-
3384) days. Early relapse rate (RR) and NRM were 11.01% and 5.29%, respec-
tively. Median OS after early relapse was only 128 days. Presence of FLT3/ITD
mutation and high body mass index were associated with increased risk of
early relapse on multivariate analysis (HR 14.88, 95%CI 3.24-68.43 and 2.34,
95%CI 1.3-4.2, respectively). Age increased risk of early NRM (HR 5.13, 95%CI
1.5-17.58 for age 55:35 years). 76% of patients completed therapy: 42%
received allogeneic HCT in CR1, 21% completed three cycles of HIDAC and
13% completed two cycles of IDAC. 3-year OS and RFS of the whole cohort
were 53.68% and 40.26%, respectively. OS was 67% in a group of patients
who completed HIDAC, 34% in IDAC group and 64% in HCT group
(p=0.28469). Cumulative incidence of NRM and RR 3 years after completion
of therapy were 23% and 20% after HCT, 7.13% and 51% after HIDAC and
16.8% and 66.4% after IDAC, respectively, differences among groups were
significant (p=0.00947 and p<0.00001). HCT reduced the risk of relapse in
comparison to chemotherapy (HR 0.51, 95%CI 0.3-0.85). RFS was adversely
influenced by concomitant FLT3 ITD/NPM1 mutation (HR 2.17, 95%CI 1.06-
4.45). Increasing age had negative effect on OS (HR 1.65, 95%CI 1.13-2.42
for age 55:35 years). After HCT, HLA mismatch and TBI based myeloablative
conditioning were associated with increased NRM [HR 6.32 (95%CI 1.89-
21.14) and 6 (95%CI 1.88-19.2), respectively] in comparison to transplantation
from HLA matched donors and busulphan based myeloablative conditioning.
Summary/Conclusions: The majority of patients within intermediate cytoge-
netic group in our analysis received allogeneic HCT. Patients who relapsed
before completion of treatment had dismal outcome with very short OS. Allo-
geneic HCT decreased risk of relapse but led to increased NRM, reducing pos-
itive effect of HCT on OS. Risk of NRM was increased after TBI based mye-
loablative conditioning and after HCT from mismatched unrelated donors.
Supported by Ministry of Health of the Czech Republic, grant nr. 15-25809A.
All rights reserved.
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LONG TERM FOLLOW UP OF PATIENTS OVER 60 YEARS TREATED WITH
INTENSIVE CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA AND
MYELODYSPLASTIC SYNDROMES
S. Blum1,*, E. Schuler2, B. Hildebrandt3, A. Kuendgen2, A. Giagounidis4,
G. Kobbe2, R. Haas2, C. Aul5, N. Gattermann2, U. Germing2
1Haematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzer-
land, 2Haematology, 3Cytogenetics, University clinics Duesseldorf, 4Haema-
tology, Marien Hospital, Duesseldorf, 5Haematology, Helios Klinikum, Duisburg,
Germany
Background: More and more data on patients over the age of 60 years treated
with intensive chemotherapy are emerging, however, long term data with patient
outcome after the initial 2-5 years are lacking. In 2007, we published a single
center study on patients over the age of 60 years, suffering from acute myeloid
leukemia (AML) or high risk myelodysplastic syndrome (MDS), treated with
intensive chemotherapy (Knipp et al. Cancer 2007, 110:345-52). We now pres-
ent long term follow up data of these patients, the first patient being treated in
1991, meaning 26 years ago.
Aims: To characterize the longterm outcome of elderly AML and high risk MDS
patients treated with intensive chemotherapy after the usual 2-5 year follow up
period.
Methods: We treated 160 patients aged 60 years or more suffering from high
risk MDS and AML with intensive chemotherapy regimen between 1991 and
2004. None of the patients underwent allogeneic stem cell transplantation after-
wards. We now performed a follow up of the surviving patients 10 years after
publication of the initial study.
Results: In the initial study median survival from the start of induction therapy
was 9.5 months (10 days to 157 months), with the median survival from diag-
nosis of 14 months (1 day to 157 months). At publication of the study in the
year 2007, 20 patients were still alive, 18 of them presented with a low risk
karyotype. 13 of these patients were in complete remission and 7 patients had
relapsed. Since then 11 of the 13 patients who were in CR relapsed and died
of their leukemia. One patient died of other causes and only one patient is still
alive and well, currently at the age of 84. This patient initially presented with a
normal karyotype, too. As a result the rate of long term survivors 5 years after
treatment is 5.6% only.
Summary/Conclusions: Long term follow up data of elderly patients treated
for AML and MDS with intensive chemotherapy is scarce. Our data show, that
induction chemotherapy not followed by allogeneic stem cell transplantation
does not result in a meaningful improvement of outcome. In addition, morbidity
and lack of quality of life has to be taken into account. More data and studies on
this subject are urgently needed in an aging population. In our population of 160
treated patients, 158 died of their leukaemia, only one patient died of another
cause and only one single patient is still alive and well over a decade later.
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FLAG-IDA FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA:
A SINGLE CENTRE 5-YEAR STUDY
C. Agbuduwe1,*, G. Follows1, J. Craig1, B. Uttenthal1, C. Crawley1,
P. Krishnamurthy1
1Haematology, Cambridge University Hospitals NHS Trust, Cambridge, United
Kingdom
Background: The treatment of relapsed/refractory Acute Myeloid Leukaemia
(AML) remains a formidable challenge as the therapeutic options are limited.
The regimen most commonly used in this setting, FLAG-Ida (Fludarabine,
cytarabine, G-CSF and idaurubicin) is considered more toxic than standard
Daunorubicin plus Cytarabine (DA) regimen, often associated with prolonged
periods of bone marrow suppression and predisposition to severe infections.
Aims: In this study, we present a single tertiary centre experience in the use of
this regimen with a view to identifying predictive factors for survival following
FLAG-ida chemotherapy. The secondary aim of this project was to assess its
efficacy and safety profile in the routine clinical setting.
Methods: We conducted a retrospective chart review of patients treated with
FLAG/FLAG-ida chemotherapy regimen for relapsed or refractory acute myeloid
leukaemia (including secondary AML) between 2011 and 2016 in a large tertiary
hospital. Patients treated with FLAG/FLAG-ida as first line therapy were exclud-
ed. Important prognostic variables including age, cytogenetics, performance
status, previous chemotherapy regimen, complete response rate and overall
survival were collected in an anonymized format. Informed consent was
obtained as part of routine clinical care. 
Results: Fifty-four patients met the criteria for inclusion in this study. The medi-
an age of the patients was 53 (10-69) years. Eighteen percent (18%) received
FLAG/FLAG-ida for primary refractory AML while the remainder were treated
having relapsed after at least 1 previous regimen. The median time to relapse
was 15 months. Complete remission was achieved in 70% of patients and 81%
of these patients proceeded to have an allogeneic stem cell transplant. The
median overall survival following FLAG/FLAG-ida chemotherapy was 16
months with 1-year and 2-year survival rates of 59% and 46% respectively.
Approximately 6% therapy-related mortality was observed. The median overall
survival in patients with early relapse (<12 months) was significantly shorter
than those with late relapse (>12 months): 6 months and 20 months respectively
(log-rank test p value: 0.04) (Figure 1). Complete remission rates were similar
between relapsed and primary refractory AML patients.
Figure 1.
Summary/Conclusions: FLAG-ida is an effective salvage regimen in patients
with refractory or relapsed AML allowing the achievement of complete remission
in the majority of cases. In this single-centre cohort, early relapse, within 12
months, from first line therapy was associated with an inferior survival following
salvage therapy with FLAG-ida.
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A MULTICENTER, RETROSPECTIVE ANALYSIS OF ELDERLY PATIENTS
WITH ACUTE MYELOID LEUKEMIA WHO WERE TREATED WITH
DECITABINE
J.H. Yi1,*, S. Park2, J.H. Kim3, Y.-W. Won4, D.H. Lim5, B.R. Han6, J. Uhm7,
H.S. Kim8, C.W. Jung2, J.H. Jang2
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Medical Center, Seoul, 4Hematology-Oncology, Hanyang University Guri Hos-
pital, Guri, 5Hematology-Oncology, Dankook University College of Medicine,
Cheonan, 6Hematology-Oncology, Hallym University Medical Center, Hallym
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versity College of Medicine, 8Hematology-Oncology, VHS Medical Center,
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Background: While acute myeloid leukemia (AML) is the disease of the elderly,
treatment options has been limited for elderly patients. Decitabine is widely
accepted as the treatment options for them. However, the efficacy has yet been
evaluated in Asian population where difference of clinical manifestation or cyto-
genetics had been noted 
Aims: In the current study, we conducted a multicenter, retrospective analysis
on elderly AML patients from 8 tertiary institutes in Korea who were treated
with decitabine in order to confirm whether the clinical outcomes of this agent
are also acceptable in this population, and to provide further understanding of
the disease nature of AML arisen in elderly patients.
Methods: Patients diagnosed with AML from 2013 to 2016 were included in the
analysis. The inclusion criteria were as follows: (1) 65 or older patients with
newly diagnosed, histologically confirmed AML (myeloid blast ≥20% either in
the bone marrow or peripheral blood); (2) Treated with decitabine in a schedule
of 20mg/m2 for five days every 4 weeks in patients. The primary end-point of
the study was OS. We compared our data to the data from another Korean ret-
rospective analysis, in which elderly patients with AML were treated with best
supportive care or intensive chemotherapy. (Int J Hematol 2014; 100: 141-151).
Results: A total of 80 patients were eligible for the analysis. The median age
of patients was 74 years (range, 64 to 86 years) and 49 patients (61.3%) were
male. Regarding the risk group, 6 (7.5%), 49 (61.2%), and 25 (31.3%) cases
were classified as favorable, intermediate, and poor risk group, respectively.
The patients had received median 3 (range 1-27) cycles of treatment and the
median OS for all patients was 10.2 months. The median OS durations accord-
ing to the cytogenetic risk group are as follows; 12.4 months (95% CI 11.4-
13.4) for favorable risk group (N=6), 13.6 months (95% CI 8.7-18.5) for inter-
mediate risk group (N=49), and 5.5 months (95% CI 1.4-9.6) for poor risk group
(N=25) (p=.001). And when we categorized our cohort into two groups, that is
ECOG-PS 0~2 vs. ECOG-PS 3 & 4, those with good performance status
demonstrated improved survival (11.5 months (95% CI 6.6-16.4) vs 4.4 months
(95% CI 2.4-6.4), p=.004). The OS curves according to prognostic factors are
provided in figure 1. Next, we compared our data to another Korean retrospec-
tive analysis dealing with elderly AML patients who were treated with either
best supportive care or intensive treatment. Although our cohort contains more
patients with poor performance status and elderly patients, it seems that out-
comes of decitabine treatment are fairly better than that of best supportive care
(OS 3 months) and comparable to intensive chemotherapy (12.1 months).
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Figure 1.
Summary/Conclusions: While the treatment options for elder AML patients
have been limited, our real world data suggest that decitabine could be an
effective treatment of choice also in Asia
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DRUG-DRUG INTERACTION POTENTIAL OF GILTERITINIB IN HEALTHY
SUBJECTS AND PATIENTS WITH RELAPSED/REFRACTORY ACUTE
MYELOID LEUKEMIA
M. Levis1,*, C. Smith2, M. Litzow3, A. Perl4, J. Altman5, A. James6, T. Kadokura6,
B. Sargent6, G. Yuen6, Z. Lu6, C. Liu6, I. Nagase6, E. Bahceci6
1John Hopkins University, Baltimore, 2University of California San Francisco,
San Francisco, 3Mayo Clinic, Rochester, 4University of Pennsylvania-Abram-
son Comprehensive Cancer Center, Philadelphia, 5Robert H. Lurie Compre-
hensive Cancer Center of Northwestern University, Chicago, 6Astellas Pharma
US Inc, Northbrook, United States
Background: Gilteritinib (ASP2215), a highly selective FLT3/AXL tyrosine
kinase inhibitor with activity against both FLT3-ITD and FLT3-D835 mutations,
is currently in development for the treatment of acute myeloid leukemia (AML).
in vitro data suggest that gilteritinib is a CYP3A substrate as well as an inducer
and weak inhibitor of CYP3A. 
Aims: To evaluate drug-drug interaction potential with gilteritinib in healthy
subjects and patients with relapsed/refractory (R/R) AML. 
Methods: The effects of CYP3A4 inhibitors (itraconazole [ITZ] and fluconazole
[FLZ]), as well as a CYP3A4 inducer (rifampin [RIF]), on the gilteritinib phar-
macokinetic (PK) profile were assessed in an open-label, parallel-group study
conducted in 81 healthy subjects. Gilteritinib was administered as a single
10mg dose alone on Day 6, or in combination with 200mg ITZ administered
twice daily on Day 1 and once daily on Days 2–28, or in combination with once
daily 400mg FLZ on Day 1 and 200mg FLZ on Days 2–28. When given con-
comitantly with ITZ or FLZ, gilteritinib was administered on Day 6. In an addi-
tional cohort, RIF 600mg was administered on Days 1–21 and gilteritinib was
administered as a single 20-mg dose on Day 8. Additionally, the potential
inhibitory effects of gilteritinib on the PK profile of a CYP3A4 substrate (mida-
zolam) was assessed in a cohort of patients with R/R AML (n=9) in the Phase
1/2 CHRYSALIS study (NCT02014558). Patients received oral gilteritinib
(300mg/d) and single oral midazolam (2mg) doses. Gilteritinib was adminis-
tered on Cycle 1 Day 1 and continued once daily in 28-day cycles; midazolam
was administered on Day -1 and Cycle 1 Day 15. Furthermore, in patients with
R/R AML, gilteritinib trough concentration data for patients on strong (eg,
voriconazole or posaconazole) or moderate (eg, FLZ) CYP3A4 inhibitors were
compared with those for patients not using CYP3A4 inhibitors.
Figure 1.
Results: In healthy subjects, gilteritinib exposure (expressed as Cmax and
AUC24) was higher (2.2-fold increase) in subjects who were coadministered
gilteritinib with a strong CYP3A4 inhibitor (ITZ) than in subjects who were
administered gilteritinib alone. Coadministration of gilteritinib with RIF, a strong
CYP3A4 inducer, resulted in an approximate 70% decrease in gilteritinib expo-
sure in healthy adult subjects (Figure 1). In patients with R/R AML, midazolam
exposure was approximately 10% higher when administered with gilteritinib
compared to midazolam alone as reflected by the geometric mean ratio and
90% confidence intervals of midazolam Cmax (111.64%; 69.54%–179.25%)
and AUC24 (109.46%; 49.82%–240.48%). Additionally, a <2-fold increase in
gilteritinib exposure was observed in patients who were taking concomitant
medications that were moderate or strong CYP3A4 inhibitors relative to patients
who did not use a CYP3A4 inhibitor. The increased exposure in these patients,
however, did not translate to differences in the incidence of drug-related safety
events when compared across groups.
Summary/Conclusions: These data suggest limiting concomitant use of
strong CYP3A4 inducers, such as rifampin, with gilteritinib. Furthermore, these
data suggest coadministration of CYP3A substrates with gilteritinib is unre-
stricted. A comprehensive review of safety data in patients with R/R AML did
not suggest that dose adjustment is warranted when gilteritinib is coadminis-
tered with strong CYP3A inhibitors. Although concomitant use of gilteritinib with
strong CYP3A inhibitors (eg, ITZ or FLZ) may be permissible, precaution is
warranted.
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A FLUDARABINE-BASED ACUTE MYELOID LEUKEMIA INDUCTION IS
WELL TOLERATED UP TO 75Y OF AGE ALLOWS EARLY CONSOLIDATION
AND LONG TERM SURVIVAL. A SINGLE CENTRE EXPERIENCE OF 136
CONSECUTIVE PATIENTS 
E. Zappone1, L. Aprile1, M. Defina1, G. Papini1, V. Candi1, G. Bartalucci1,
C. Zuanelli Brambilla1, S. Ciofini1, M. Bocchia1,*
1Hematology Unit, University of Siena, Siena, Italy
Background: For decades no effective new drugs or better anthracyclin cytara-
bin combinations other than the standard 3 + 7 regimen have been available
for AML induction treatment. Fludarabine-based regimens have shown good
efficacy in relapsed patients but raised concern about toxicity in the induction
setting (Burnett JCO 2013, PMID 23940227) a modified regimen has shown
better tolerance and good results in patients younger than 60 years (ys) (Guolo
AJH 2016, PMID 27084986)
Aims: We report a single center, real life experience of unselected 136 consec-
utive AML patients treated since 2002 in our center with Fludarabine, Aracytin,
Idarubicin with or without Etoposide: FLAIE up to 65ys or FLAI up to 75ys.
Methods: Patients were treated with the FLAIE or FLAI regimen followed by
Idarubicin plus Aracytin as 2 step induction. Exclusion criteria for treatment
were: acute promyelocytic leukemia, poor performance status and severe
comorbidity. Post remission treatment included up to three cycles of high dose
Aracytin, autologous (Auto) or allogeneic (Allo) stem cell transplantation accord-
ing to cytogenetic and molecular risk stratification (CMR, Döhner Blood 2010
PMID 19880497) aiming for a curative strategy for all our AML patients.
Figure 1.
Results: Median age at diagnosis was 55ys (18-75ys), median follow up was
18 months (range 3-172 months), 75% of patients (102/136) had de novo AML
while 25% (34/136) had secondary AML mostly from myelodisplastic syndrome.
19% of patients (26/136) had good CMR risk disease, 45% of patients (61/136)
had intermediate risk and 36% of patients (50/136) had high risk disease. Com-
plete remission (CR) rate was 68% and was comparable to the majority of pub-
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lished trial data, considering the proportion of high CMR risk (36%) and
leukemia of secondary origin (25%) and the relatively high median age: 36%
of patients (49/136) were above the 60ys old age limit of most AML protocols.
In multivariate analysis CR rate was significantly affected by age below 50ys:
p=0,011; good/intermediate CMR risk: p=0,011 and de novo AML: p=0,008.
The induction death rate was 4% in line or slightly lower than published results,
showing that the treatment was well tolerated; grade 3-4 non hematologic tox-
icity incidence was 9,6% allowing to proceed to consolidation in more than 70%
of CR patients. Overall 80/136 patients (59%) were beyond 50ys, intensive
condolidation with Allo or Auto was done in 34/80 patients (43%) confirming
the feasibility of this therapeutic strategy. The Kaplan-Meier median probability
of overall survival (OS) for the whole cohort was 28 months and factors signif-
icantly affecting OS were age below 50ys p<0,0001; de novo AML p<0,0003;
good-intermediate CMR risk p<0,0002; intensive consolidation with Allo or Auto
transplant p<0,0001 compared to chemotherapy alone. The mean probability
of Leukemia free survival (LFS) was 88 months (median not reached). Patients
above 50ys of age had worse outcome, the median probability of OS and LFS
were 16,4 and 23,4 months respectively, this compares favorably with many
published results. Chen Medicine 2016 PMID: 27472687 reported a median
OS of 10,3 months in a large cohort of patients of similar age treated with inten-
sive induction. Morevover we did not found a significant difference between
the 50-59ys and 60-75ys age groups: median OS was 20,8 and 14 months
(p=0,12) and median LFS was 15,9 and 23,6 months (p=0,71) respectively.
Summary/Conclusions: In our real life experience the FLAIE/FLAI regimen
combined with intensive consolidation demonstrated good long term results
both in terms of OS and LFS in patients younger than 50ys, this regimen was
also feasible and manageble in patients beyond age of 60ys a difficult popula-
tion to treat with a curative intention mainly because of concern of high toxicity
of intensive induction regimens and higher incidence of poor risk prognostic
factors.
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OVEREXPRESSION OF SOX4 CORRELATEDS WITH POOR PROGNOSIS
OF ACUTE MYELOID LEUKEMIA
C.-Y. Hu1,*, H.-A. Hou2, C.-Y. Chen2, H.-F. Tien2, L.-I. Lin1
1Clinical Laboratory Sciences And Medical Biotechnology, National Taiwan Uni-
versity, 2Department of Internal Medicine, National Taiwan University Hospital,
Taipei, Taiwan, Republic of China
Background: The SOX4 belongs to the SOX (Sry-related high-mobility group
box) family and has been characterized as a transcription factor. Over the past
decade, multiple functions of SOX4 have been unveiled, and the protein is now
known to play important roles in embryonic development, cell fate decision,
and cellular differentiation. Overexpression and amplification of SOX4 have
been implicated in various cancers and are correlated with poor prognosis. In
mouse models, previous studies demonstrated that the upregulation of Sox4
can be induced by and then cooperate with the aberrant expression of AML1-
ETO, NUP98-DDX10, and PML-RARa; the overexpression of HOXA9, CREB,
and Evi1, and the haplosufficiency of PU.1 to trigger leukemogenesis. Further-
more, a previous study that employed retroviral transduction of Sox4 and bone
marrow transplantation techniques revealed that increased Sox4 expression
may cooperate with the deregulation of Mef2c expression to induce myeloid
leukemia in recipient mice. Sox4 gene was also reported to be as a direct target
of C/EBPα. C/EBPα is known to inhibit the self-renewal of leukemic cells and
to restore cellular differentiation. The overexpression of Sox4 that results from
C/EBPα inactivation contributes to the development of a type of leukemia that
is characterized by a distinct leukemia-initiating cell (LIC) phenotype. This work
further indicated that Sox4 is a key oncogenic target and critical mediator of
C/EBPα mutants in acute myeloid leukemia (AML), which suggests a potential
novel therapeutic approach to the treatment of this disease. However, the clin-
ical implications of SOX4 expression and its role of AML leukemogenesis are
not well understood.
Aims: To evaluate the relationship between bone marrow (BM) SOX4 expres-
sion and clinicopathological parameters of de novo AML and to evaluate the
prognostic value of SOX4 expression for AML patients.
Methods: From Mar 2009 to Dec 2011, a total number of 112 adult AML patients
were enrolled in this study. This study was approved by the Institutional Review
Board (IRB) of the National Taiwan University Hospital (NTUH) and written
informed consent was obtained from all participants in accordance with the
Declaration of Helsinki. Immunocytochemical staining was used to assess
SOX4 expression in bone marrow leukemic cells. All statistical analyses per-
formed for this study involved two-tailed Student’s t-tests, Mann-Whitney U
tests, one-way ANOVA, Chi-square test or Fisher’s exact test and multivariate
analysis with Cox proportional hazards regression models. Kaplan-Meier esti-
mation techniques were used to plot survival curves and log-rank tests.
Results: We divided AML patients into two groups according to the intensity
and extent of SOX4 expression as follows: low expression group (score 0-2,
n=62) and high expression group (score 3-4, n=50), respectively. The various
clinical manifestations of AML did not show significant differences in terms of
SOX4 expression. However, AML patients with low SOX4 expression tended
to have favorable-risk cytogenetic (P=0.0866). We did not observe significant
differences between the high and low expression groups in terms of age, gen-
der, hemograms, NPM1 mutation and FLT3/ITD. Additionally, of the 112 AML
patients that underwent conventional intensive induction chemotherapy, 85
(75.9%) achieved complete remission (CR), and the high and low expression
groups showed similar probabilities of achieving first CR (36/50, 72% vs 49/62,
79%, P=0.3219). However, high SOX4 expression were associated with
increased relapse rates compared to low SOX4 expression (19/36, 52.8% vs
13/49, 26.5%, P=0.028). Furthermore, with a median follow-up period of 46.7
months (range: 0.3 to 70.9 months), SOX4 expression was associated with
overall survival (OS) and disease-free survival (DFS) in all patients with de
novo AML (P=0.008 and P=0.013, respectively), patients with non-M3 subtypes
(P<0.001 and P=0.001, respectively), patients with intermediate-risk cytoge-
netics, (P=0.001 and P=0.005 respectively), or even in those with normal kary-
otype profile (P=0.022 and P=0.111, respectively). In multivariate analysis, high
SOX4 expression was found to be an independent poor prognostic factor of
OS (RR 1.924, 95% CI 1.020-3.628, P=0.043) irrespective of age, WBC count
at diagnosis, karyotype profile and NPM1/FLT3-ITD status. A meta-analysis
that we conducted using an on-line data cohort retrieved from PrognoScan (a
database for meta-analysis of the prognostic value of genes; http://www.abren.net/
PrognoScan/) revealed similar findings.
Summary/Conclusions: In the current study, we found that AML patients with
low BM SOX4 expression had higher remission rates and longer overall survival
than those with high SOX4 expression, regardless of age, WBC count at diag-
nosis, karyotype profile and NPM1/FLT3-ITD status. Our results also reveal
that SOX4 is an independent prognostic factor of AML. In conclusion, we reveal
that BM SOX4 expression could serve as an informative new biomarker for the
clinical prognosis of AML patients.
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AN OPEN-LABEL, MULTICENTER, PROSPECTIVE, RANDOMIZED STUDY
OF RECOMBINANT HUMAN THROMBOPOIETIN AS AN ADJUNCT AFTER
INTENSIVE CONSOLIDATION CHEMOTHERAPY IN ACUTE MYELOID
LEUKEMIA
X.-H. Sui1,*, Y. Li1, X. Wang2
1Hematology department of Shandong provincial hospital affiliated to Shandong
University, 2 Hematology departmentof Shandong provincial hospital affiliated
to Shandong University, Shandong University school of medicine, Jinan, China
Background: Thrombocytopenia is a common problem in the management of
patients with acute myeloid leukemia (AML) receiving induction and consolida-
tion therapy. AML patients with platelet count of less than 20×109/l might have
a high risk of bleeding complications and had to take dose modifications instead
of intensive chemotherapy leading to increased disease-free survival and over-
all survival. Platelet transfusions have a short therapeutic effect and are asso-
ciated with all types of transfusion reactions. Recombinant human thrombopoi-
etin (rhTPO) has been shown to improve the megakaryocyte and platelet devel-
opment in solid tumor patients and immune thrombocytopenia (ITP) patients
refractory to glucocorticoid. We conducted this study to determine the availability
of rhTPO in the platelet recovery after intensive consolidation chemotherapy
with AML patients. 
Aims: The aims of this study were to identify the effectiveness and safety of
rhTPO in supportive care in patients with AML receiving consolidation
chemotherapy.
Methods: Patients: Patients were eligible if they were 1570 years of age who
achieved completing remission after one course of IA induction therapy, and
had platelet counts of less than 50×109/L after induction therapy, with an East-
ern Cooperative Oncology Group (ECOG) performance status of 0~3. Patients
with FAB M3 (acute progranulocytic leukemia) and FAB M7 (acute megakary-
oblastic leukemia) were excluded from the study. All patients provided written
informed consent according to protocol guidelines approved by the institutional
review boards at their individual institutions. Study design: Patients received
consolidation chemotherapy with DA, MA and intermediated-dose arabinosyl-
cytosine(Ara-C), et al. When the platelet counts were less than or equal to
50×109/L, patients in study group received 15000u/day of rhTPO (trade name:
TPIAO) administration subcutaneously and patients in control group not
received rhTPO therapy. The administration of rhTPO continued until the
platelet count was more than 100×109/L or for the maximum of 21 days. Sta-
tistical analysis: Baseline of patients’ characteristics was summarized by using
independent samples test and chi-square test. Other statistical data analyses
were performed using the two-tailed Student’s t test and were represented as
means±SD of values. All differences were considered to be statistically signif-
icant when the P value was less than 0.05.
Results: There was no significant difference was observed in the main initial
characteristics between study group (n=49) and control group (n=36), including
age, gender and other baseline characteristics. No patient withdrew. Platelet
transfusion and time required for platelet recovery were shown in Table 1.
Platelet transfusions: The mean number and days of platelet transfusions for
patients in study group were less than those in control group, but there were
no significant differences of statistic status between the patients. Platelet recov-
ery: 1. rhTPO might reduce the duration of platelet count less than or equal to
20×109/l and 30×109/l after chemotherapy. 2. rhTPO could increase the maxi-
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mal and minimal platelet count after chemotherapy. 3. rhTPO might shorten
the days of platelet count recover to at least 20×109/l from its nadir. The inci-
dence of side effects were similar in both groups of the study.
Table 1.
Summary/Conclusions: rhTPO, administered as dose of 15000u/day when
platelet count less than or equal to 50×109/l, might improve the recovery of throm-
bocytopenia of patients with acute myeloid leukemia in CR after consolidation
chemotherapy. While there was no significant difference between study group
and control group, there was a decreasing trend of platelet transfusion number
and shorter time required for platelet transfusion for patients in study group.
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TREATMENT-ASSOCIATED SURVIVAL RATES IN OLDER PATIENTS WITH
ACUTE MYELOID LEUKEMIA (AML): A SYSTEMATIC LITERATURE
REVIEW
J. Bell1,*, A. Galaznik2, R. Huelin3, M. Stokes4, D. Faller5, R. Fram6
1Global Outcomes Research, 2Millennium Pharmaceuticals, Inc., a wholly
owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge,
3Meta Research, Evidera Inc., Waltham, United States, 4Retrospective Obser-
vational Studies, Evidera Inc,, Dorval, Quebec, Canada, 5Oncology Clinical
Research, 6Takeda Oncology, Cambridge, United States
Background: AML patients ≥60 years old are more likely to experience com-
plications following intensive induction chemotherapy and are at higher risk of
unfavorable outcomes compared with younger patients. Information regarding
optimal treatment approaches for older AML patients is limited.
Aims: Summarize outcomes associated with therapies among older AML
patients, with a focus on treatment patterns and overall survival (OS) as report-
ed in the literature.
Methods: Searches were conducted in Medline and Embase (Jan 2014–May
2016) and supplemented by conference abstracts (2015–2016). Eligibility
included studies in English reporting on treatment regimens and outcomes
associated with older AML patients or subgroups thereof, and conducted in
the US, EU 5 (United Kingdom, Germany, France, Spain, Italy), or Japan. Only
studies enrolling ≥50 patients were included.
Results: Twelve studies (in 19 publications) reporting on OS among older AML
patients were included. Participants in most studies were newly diagnosed with
AML; ages ranged from 60 to 93 years. Five non-comparative studies exam-
ining the effects of various treatment modalities were identified. Median OS in
studies examining azacitidine (AZA) ranged from 10 to 12 months, whereas in
studies examining induction chemotherapy or reduced intensity conditioning-
hematopoietic stem cell transplantation, the median OS ranged from 6.85
months (95% CI: 3.7–13.5) to 16.4 months (95% CI: 12.6–24.6), respectively.
Six comparative observational studies assessed the efficacy of different treat-
ment regimens. Intensive chemotherapy (IC) was generally associated with
longer median OS compared to other regimens. In one study, median OS for
patients receiving IC, lower-intensity therapy (low dose cytarabine [LD-AraC])-
(AZA, decitabine), or best supportive care (BSC) was 12.4 months (95% CI:
8.5–17.4), 11.5 months (95% CI: 9.2–13.9), and 2.6 months (95% CI: 1.9–3.1),
with 3-year OS rates at 27%, 17% and 6% (p<0.0001), respectively. Another
study assessed the efficacy of LD-AraC relative to IC, hypomethylating agents
(HMA), and BSC. Patients appeared to have longer OS when receiving IC
compared to LD-AraC (median OS: 12.4 vs 9.6 months; 3-year OS: 27% vs
12%; p=0.07), and those receiving LD-AraC compared to BSC had significantly
improved OS (median: 9.6 vs 3.4 months, p=0.001). In this same study, while
OS was longer with HMA than LD-AraC, this difference was not significant
(median OS 16.1 vs 9.6 months; 3-year OS 22% vs 12%, respectively;
p=0.1).Two studies assessed the efficacy of AZA vs moderate-IC, LD-AraC, or
palliative therapy, alone or in combination. AZA had a significantly better survival
rate vs LD-AraC in poor prognosis patients (p=0.015). Furthermore, 1-year
survival was higher for AZA-treated patients (67.8%) compared to those not
treated with AZA (36.9%) (p=0.004). The efficacy of AZA relative to other con-
ventional care regimens (CCRs) including BSC, LD-AraC, or standard IC was
also examined in a randomized clinical trial (n=488). Median OS at 1-year was
significantly higher for AZA relative to CCR (10.4 vs 6.5 months). Results also
showed that 1-year median OS was higher with AZA than CCR in all cytogenetic
risk groups, normal risk (14.1 vs 10.0), intermediate risk (13.0 vs 10.1), and
high risk (6.4 vs 3.2), respectively.
Table 1.
Summary/Conclusions: Among older AML patients, IC tended to be associ-
ated with improved OS compared with other CCRs. However, evidence from
this review indicates that AZA could be an alternative treatment option for older
AML patients, whether fit or unfit for IC.
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SYSTEMATIC REVIEW OF HEALTH STATE UTILITY VALUES FOR
ECONOMIC EVALUATION OF ACUTE MYELOID LEUKEMIA
A. Forsythe1,*, V. Bal 2, M. Dolph 3, S. Patel 4, G. Tremblay5
1Purple Squirrel Economics, New York, 2Novartis Pharma, East Hanover, Unit-
ed States, 3Purple Squirrel Economics, Montreal, Canada, 4Novartis Pharma-
ceuticals UK Limited, Surrey, United Kingdom, 5Purple Squirrel Economics,
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Background: Cost-utility analyses undertaken to inform decision making
regarding acute myeloid leukemia (AML) require a set of health state utility
values (HSUVs) so that the time AML patients spend in different health states
can be aggregated into quality-adjusted life-years (QALY). 
Aims: This study reviews AML-related HSUVs that could be used in economic
evaluation and assesses their advantages and disadvantages with respect to
valuation methods used and AML clinical pathways.
Methods: Embase, MEDLINE, Cochrane database, and conference abstracts
(ASCO, ESMO and ASH) were systematically searched from Jan 2000 through
Nov 2016 for relevant studies that reported quality of life (QOL) and HSUV in
AML. Identified relevant EORTC Quality of Life Core Questionnaire QLQ-C30
values were mapped to HDUV using previously published algorithm by Crott,
et al. 2010. HSUV for induction, consolidation, complete remission (CR),
relapse, stem cell therapy (SCT) treatment, SCT recovery and CR post SCT
were identified. 
Results: Ten relevant studies were identified. Six were cost effectiveness
analyses utilizing HSUVs for calculation of Quality Adjusted Life years (QALY),
one effectiveness analysis (incremental QALY), two QOL studies reporting spe-
cific AML utilities (either collected or mapped from QLQ-C30). An additional
study reported QOL for patients undergoing SCT. Since no study reported
HSUV for relapse, values from study of secondary AML patients who failed
prior treatment for Myelodysplastic Syndrome, were used. Where multiple HSU-
Vs were available, priority was made for collected values vs assumption. Iden-
tified HSUV are presented in Figure. AML treatment (both induction, consoli-
dation and SCT) was associated with decreased HSUV, while post-treatment
CR lead to increased HSUV. 
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Figure 1.
Summary/Conclusions: There are relatively few methodologically robust
HSUVs that can be directly used in economic evaluations concerned with AML.
Careful interpretation of published values is advised considering difference in
studies methodologies and patient populations. There is need to develop new
HSUVs which improve on those currently available either by utilizing time trade
off studies or by making greater use of condition-specific data and further use
of mapping algorithms. 
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ITALIAN REAL LIFE EXPERIENCE OF DECITABINE IN ELDERLY ACUTE
MYELOID LEUKEMIA PATIENTS: INTERIM ANALYSIS OF MULTICENTRIC
OBSERVATIONAL DEA65 STUDY.
L. Aprile1,*, V. Sammartano1, G. Alunni2, E. Capochiani3, V. Pavone4, G. Fontanelli5,
A.M. Liberati2, C. Biagiotti6, M. Rondoni7, B. Scappini6, L. Schiattone1, S. Ciofini1,
V. Federico4, G. Bartalucci1, P. Bernardeschi5, M. Defina1, P. Galieni8,
A. Mianulli9, M. Petrini10, A. Bosi6, M. Bocchia1
1Hematology Unit, University of Siena, Siena, 2Unit of Oncoematologia con
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tology, Azienda Ospedaliera Careggi, Firenze, 7Unit of Hematology, AUSL della
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Unit, University of Pisa, Pisa, Italy
Background: Acute Myeloid Leukemia (AML) has a higher incidence among
the elderly population. Older patients (pts) with AML have a worse prognosis
and limited treatment options. Hypomethylating agent decitabine was recently
approved by FDA and EMEA as first line treatment in AML pts older than 65 yrs
and unfit to receive standard cytotoxic chemotherapy. Decitabine showed to
be superior to supportive care or low dose cytarabine in controlled randomized
clinical studies (Kantarjian, JCO 2012; Cashen, JCO 2010). 
Aims: In July 2016 we approved a retrospective and prospective multicentric
observational study to investigate efficacy and tolerability of decitabine at the
approved schedule of 20mg/m2 daily for 5 days of a 4-week cycle in real life
(DEA65 study). The primary objective was the assessment of overall survival
(OS). Secondary objectives were evaluation of adverse events (AEs) and
response rate: complete remission (CR), CR with incomplete platelets or white
blood cells (WBCs) count recovery (CRi), partial remission (PR) and hemato-
logical improvement with transfusion independence. We here present an interim
analysis of the first 56 pts enrolled. 
Methods: AML pts older than 65 yrs treated in first line with decitabine were
enrolled in the study. At diagnosis and during follow-up, cytogenetic and molec-
ular assessment was performed by each center according to local guidelines
for AML management in elderly pts. 
Results: Biologic and clinical data of 56 pts, with a median age of 73 yrs (range
65-90 yrs) are reported. Thirty-one patients (55,3%) had a secondary AML and
13/31 (42%) were progressed MDS previously treated with 5-azacitidine. Medi-
an WBCs count was 3050/µL (range 770-131500/µL) with 13/56 (23%) pts with
WBCs>10000/µL. Cytogenetic analysis was performed in 52/56 pts, and in
24/56 (43%) molecular analysis including FLT3 and NPM1 mutations was per-
formed. According to prognostication, 50% of pts had a high risk, 34% an inter-
mediate risk, 9% a low risk AML and in 4/56 (7%) pts risk was unknown. Median
OS was 7 months (range 1-19 months) with 34/56 deaths (60,7%) and a median
of 6 cycles (range 1 to 19) of decitabine. Overall response rate was 60,7%
(34/56 pts), of which 7/56 (12,5%) CR or Cri; 17/56 (30,4%) PR and 10/56
(17,8%) improvement of transfusion needs. According to response, median OS
was 9,5 months (range 4-19) and 4 months (range 1-15) in responder vs not
responder pts. Table 1 shows response rate according to pts characteristics.
At present time 18/22 alive pts are still on treatment with decitabine. Regarding
toxicity, 23/56 (41%) pts manifested a grade ≥3 AEs although severe comor-
bidities (cardiovascular and metabolic) pre-existed in 14/23 (60,9%). A total of
35 hospitalization episodes due to toxicity were recorded and 10/56 pts (17.8%)
died due to serious AEs. Overall the most common non-hematologic AEs were
pneumonia and fever.
Table 1.
Summary/Conclusions: This interim analysis of the use of decitabine in real
life showed a superimposable OS to controlled international clinical trials. Safety
profile was acceptable considering setting of pts and incidence of important
comorbidities. Despite a similar OS, the comparison between our data and
Cashen study (56 vs 55 pts) showed in our cohort, a poorer rate of CR+CRi
with a negative impact of secondary AML, previous 5-azacitidine therapy, WBC
>10000/µL as well as high cytogenetic risk. This apparent contradiction supports
the idea that in elderly pts recovery of peripheral blood cells counts (PR+hema-
tological improvement) is probably the most important factor influencing OS
(Ferrara, Hemat 2016).
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ASPARAGINASE ERWINIA CHRYSANTHEMI EFFECTIVELY DEPLETES
PLASMA GLUTAMINE, HAS CLINICAL ACTIVITY, AND IS WELL TOLERATED
IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE
MYELOID LEUKEMIA 
A. Emadi1,2,3,*, E.T. Strovel4, R.G. Lapidus1,2, L.J. Jeng2,4,5, M. Lee1,
M.G. Blitzer4, B.A. Carter-Cooper1, D. Sewell2, I. Van Der Merwe1, M. Imran1,
S.L. Yu1, H. Li1, P.C. Amrein6, V.H. Duong1,2, E.A. Sausville1,2,3, A.T. Fathi6, Z.
Singh5, M.R. Baer1,2, S.M. Bentzen1,7
1University of Maryland Greenebaum Comprehensive Cancer Center, 2Medi-
cine, 3Pharmacology, 4Pediatrics, 5Pathology, University of Maryland, Balti-
more, 6Massachusetts General Hospital Harvard Medical School, Boston, 7Epi-
demiology and Public Health, University of Maryland, Baltimore, United States
Background: Asparaginase-induced glutamine (Gln) depletion demonstrates
anti-leukemic activity in preclinical studies of AML. We hypothesized that admin-
istration of asparaginase Erwinia chrysanthemi (Erwinaze) would lead to effec-
tive plasma Gln reduction and may be a feasible therapeutic approach for AML,
because myeloblasts may be addicted to Gln.
Aims: The primary aim was to determine the dose of Erwinaze inducing plasma
Gln levels ≤120μmol/L, with an acceptable safety profile, 48 hours (h) after the
first intravenous (IV) dose and before each subsequent dose administered thrice
weekly for 2 weeks in patients (pts) with relapsed or refractory (R/R) AML.
Methods: This was a phase 1, single-arm, pharmacokinetic investigator-initi-
ated trial (NCT02283190, funded by Jazz Pharmaceuticals), with a 3+3+3
design with dose de-escalation/escalation rules that incorporate both safety
and biochemical activity (nadir plasma Gln levels) of IV Erwinaze. There was
no intrapatient dose adjustment. For safety, a 3rd cohort of three pts was to be
added if 2 of 6 pts in the 1st and 2nd cohorts experience a dose limiting toxicity
(DLT) at a certain dose level. If ≥3 of 9 patients experienced DLT, the trial was
to be terminated. To evaluate Gln reduction ability of Erwinaze, the dose could
be increased based on 48h trough plasma Gln in cohorts of 3, 6, or 9 pts per
dose level. Correlative studies measured plasma Gln, glutamate (Glu) and
asparagine (Asn) levels, plasma asparaginase activity and plasma and urine
2-hydroxyglutarate (2-HG) levels.
Results: Five pts were enrolled on study. Enrollment was then halted due to
Erwinaze supply manufacturing complexities. Median age was 69 (range 20-
83) years, 4 were male, 2 had prior MDS or CMML, 3 had high risk abnormal
karyotype, 3 had isocitrate dehydrogenase (2 IDH1, 1 IDH2) mutations, and 3
had been treated with ≥2 lines of prior treatment. Erwinaze was administered
IV (25,000 IU/m2, dose level 0) for 6 doses MWF for 2 weeks to all pts. No DLT
was observed. Anemia and electrolyte abnormalities were the most common
adverse events. Plasma asparaginase activity ≥0.1 IU/mL was achieved in all
pts at 48h trough, but in 3 pts it decreased to zero on day 8 (72h trough).
Median trough plasma Gln, Asn and peak Glu levels (μmol/L) at 48h were 27.6
(range <12.5-227), 0 (range 0-0), and 704 (range 474-754), respectively. Asn
remained undetectable for the entire 2 weeks. Gln levels increased significantly
on day 8 (72h trough) compared to day 5, p<0.001. Four of 5 pts (80%, lower
limit of 1-sided 95% CI: 34%) achieved at least one nadir Gln value <120
μmol/L. The fold reduction (FR) in Gln level at 3 days, relative to baseline, was
0.16 (p<0.001 for rejecting FR=1). One pt achieved partial remission (PR) and
one achieved hematologic improvement (HI) after 6 doses of single agent
Erwinaze. Both pts had plasma Gln levels <85 μmol/L on days 5, 10 and 12.
Off study, after completion of Erwinaze, they have been treated with azacitidine.
Both pts are still alive in complete remission (CR) and CR with incomplete
count recovery (CRi) 13.3 and 13.4 months after the on-study date. Plasma
and urine 2-HG levels did not change significantly. The 3 pts with IDH mutations
tended to have higher plasma 2-HG levels (p=0.10).
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Summary/Conclusions: To the best of our knowledge, this is the first clinical
report demonstrating that an asparaginase product is capable of not only
decreasing plasma Gln level to ≤120μmol/L but also depleting it to undetectable
(i.e. <12.5μmol/L) levels in pts with AML. Two of 5 patients with R/R AML had
clinical responses and are alive in remission. Given clinical activity of asparag-
inase in AML, we are to investigate mechanistically-designed asparaginase
combination therapies.
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PROGNOSTIC SIGNIFICANCE OF SOX2, SOX3, SOX11, SOX14 AND
SOX18 GENE EXPRESSION IN DE NOVO ACUTE MYELOID LEUKEMIA
(AML) PATIENTS
N. Tosic1,*, M. Virijevic2, I. Petrovic3, N. Kovacevic Grujicic3, S. Davidovic3,
N. Suvajdzic Vukovic2, S. Pavlovic1, M. Stevanovic3
1Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and
Genetic Engineering, University of Belgrade, Serbia, 2Clinic of Hematology
Clinical Centre of Serbia, University of Belgrade Faculty of Medicine, 3Labora-
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Background: Members of the SOX (SRY-related high mobility group (HMG)
box) gene family encode a group of transcriptional factors with important func-
tions in embryonic development. Also, SOX genes are aberrantly expressed in
different types of cancer. However, their role in hematological malignancies,
especially in acute myeloid leukemia (AML), remains elusive.
Aims: The aim of this study was to investigate the expression level of SOX2,
SOX3, SOX11, SOX14 and SOX18 genes in de novo AML patients, and to
evaluate their potential as prognostic markers.
Methods: Fresh bone marrow (BM) samples were collected from 50 non-APL
AML patients at diagnosis (27 male, 23 female, median age 52.5 years, range
22-73) and from 8 healthy donors. Relative quantification analysis of SOX
genes expression level was performed by RQ-PCR methodology, with GAPDH
gene as endogenous control, and using comparative ddCt method with healthy
controls as calibrator.
Results: The median expression level of SOX2, SOX3, SOX11, SOX14 and
SOX18 in AML patients was 0.46 (0.01-226.13), 0.81 (0.01-1210.00), 0.35
(0.01-177.29), 0.98 (0.02-469.51) and 3.53 (0.18-332.00), respectively. This
was not significantly different from the levels detected in healthy controls where
the expression levels were 1.01 (0.32-2.54), 1.00 (0.45-5.73), 1.00 (0.19-2.83),
1.04 (0.38-2.38) and1.00 (0.48-12.29), respectively. As a cut-off value above
which the patients were considered to be positive for SOX2/3/11/14/18 gene
expression we used median expression level of each SOX gene in healthy
controls + 2SD. The percentage of patients who were positive for the expres-
sion of the studied genes ranged from 14% (SOX2+ and SOX11+), 20%
(SOX3+ and SOX18+) to 28% (SOX14+). A significant association with the
presence of FLT3-ITD and NPM1 mutations was detected in all but SOX14+
patients. The same result was found concerning association with higher leuko-
cyte count. There were no significant associations with any other presenting
clinical parameters. As for the impact that SOX expression positive status that
any of the analyzed genes had on the prognosis and outcome of the disease,
we detected higher relapse rate in SOX14+ patients (p=0.045). Significantly
shorter disease-free-survival (DFS) was detected among SOX2+, SOX11+ and
SOX18+ patients (p<0.001; p=0.001; p=0.017, respectively). Although all of
the SOX+ patients had shorter overall survival (OS) time compared to SOX-
patients, the most prominent influence has been detected for the SOX2+
patients (p=0.034).
Summary/Conclusions: This is the first study focused on examining the
expression level of SOX2/3/11/14/18 in AML patients. We have found that these
genes are seldom overexpressed among patients in comparison with normal
BM. However, in some patients, the expression of these genes is highly
increased, and associated with a negative prognostic factors such as the pres-
ence of FLT3-ITD mutations and higher leukocyte count. Also, increased
expression of these genes has been clearly associated with shorter DFS and
OS. Although the exact function of these genes in the pathogenesis of AML is
not yet known, our preliminary results show that their overexpression can have
prominent prognostic significance in AML patients and therefore should be the
subject of further investigation.
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ACUTE ANTHRACYCLINE INDUCED CARDIOTOXICITY IN PATIENTS
WITH ACUTE MYELOID LEUKEMIA
O. Pasvolsky1,*, O. morelli1, U. rozovski1, M. vaturi1, O. wolach1, I. amitai1,
I. vaxman1, R. ratzon1, M. yeshurun1, Z. Iakobishvilli1, R. kornowski1, P. raanani1
1Beilinson Hospital, Petach Tikva, Israel
Background: Chemotherapeutic agents are associated with a wide range of
cardiotoxic adverse effects. Anthracyclines and related drugs are some of the
most implicated agents, with a well-recognized potential for the development
of cardiomyopathy and heart failure. Chronic anthracycline induced cardiotox-
icity can lead to cardiomyopathy, which may develop several years after treat-
ment. Acute and subacute anthracycline induced cardiotoxicity is considered
relatively uncommon, described mostly in patients treated for solid tumors or
lymphomas. While anthracycline based regimens have been used to induce
remission in newly diagnosed patients with acute myeloid leukemia (AML) for
more than four decades, relatively little is known about the acute cardiotoxic
effect of anthracyclines in this setting. Since many of these patients are candi-
dates for hematopoietic stem cell transplantation (HSCT), an intensive inter-
vention usually reserved for fit patients, even transient decrease in cardiac
function might render them ineligible for this intervention, or might increase
their transplant related morbidity.
Aims: To study the short-term outcomes of anthracycline exposure on cardiac
function in patients with AML who are candidates for allogeneic HSCT. Because
current AML-induction regimens use anthracyclines (most commonly daunoru-
bicin) at a relatively high dose between 45 and 90mg/m2/day for three consec-
utive days, we hypothesized that the incidence of post-induction cardiac injury
in patients with AML might be high.
Methods: The medical records of 55 consecutive patients who had received
induction chemotherapy and had undergone HSCT in our medical center were
reviewed. Patients included in the study were those with echocardiographic
data both prior to and post induction therapy. Median age at diagnosis was 59
years (range: 18-73) and 49% were males. Approximately half of the patients
had de novo AML (N=29, 53%). 26 patients (47%) had either therapy related
AML or AML secondary to a previous hematological disorder. Induction treat-
ment included 7 days of cytarabine at a dose of 100mg/m2/day and 3 days of
daunorubicin at a dose of 45mg/m2/day (N=2, 3.6%), 60mg/m2/day (N=34,
61.8%) or 90mg/m2/day (N=15, 27.3%).
Results: Selected patient characteristics are summarized in Table1. Post-
induction echocardiogram studies demonstrated a significant cardiac deterio-
ration in left ventricular ejection fraction (EF) (defined as 10% or more absolute
decrease from baseline EF) in 25.5% of the patients (N=14). Higher doses
(90mg/m2/day) of anthracyclines were associated with higher rates of cardiac
function deterioration (odds ratio: 4.1, 95%, confidence Interval: 1.06 to 15.7).
Patients with cardiovascular risk factors and male patients tended to develop
cardiotoxicity at higher rates, whereas age, white blood cell counts at diagnosis
and AML type (de novo vs. secondary) had no impact on cardiotoxicity. The
decrease in cardiac function was temporary in 10.9% of the patients (N=6)
with subsequent normalization of left ventricular EF in those patients.
Table 1.
Summary/Conclusions: The use of daunorubicin at a dose of 60mg/m2/day
or less is associated with significantly lower rates of acute cardiotoxicity. Our
findings should be taken into consideration when choosing the anthracycline
dose, particularly in male patients with cardiovascular risk factors who are can-
didates for HSCT.
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AN INTEGER WEIGHTED GENOMIC MUTATION SCORING (IWGMS) USING
THE TRUSIGHT MYELOID SEQUENCING PANEL SHOWS HIGHER MOR-
TALITY IN PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID
LEUKEMIA- A RETROSPECTIVE STUDY
Q. Qin1,*, X. Nan1, C. Gentille Sanchez1, M. Greenwood2, Y. Xing3, A. Zieske2,
I. Ibrahim3, K. Baker3, L. Rice3, B. Merritt4, S.R. Pingali3, R. Olsen 2, S. Iyer3
1Internal Medicine, Houston Methodist Hospital, Weill Cornell Medical College,
2Laboratory and Genomic Medicine, Houston Methodist Hospital, 3Hematology,
Houston Methodist Cancer Center, 4Baylor Miraca Genetics Laboratories, Bay-
lor College of Medicine, Houston, United States
Background: AML is currently classified by European LeukemiaNet into favor-
able, unfavorable, and intermediate prognosis based on cytogenetic aberra-
tions. Although favorable and unfavorable categories have good prognostic
values, the intermediate category encompasses the majority of patients and
offers unclear prognosis. The development of Cancer Genome Atlas (TCGA)
opens new windows for the incorporation of next generation sequencing (NGS)
into cytogenetics to enhance prognostic risk stratification. However, few studies
explore the combination of cytogenetics and NGS in prognostic predictions.
Aims: Here we have developed a system of Integer Weights for the Genomic
Mutation Score (IWGMS) for a quantifiable stratification of the prognostic risks
associated with a combination of cytogenetic aberrations and genomic muta-
tions. Our next step is validating the scoring system through its application to
data obtained from other institutions.
Methods: Patient data at Houston Methodist Hospital was queried from
Methodist Environment for Translational Enhancement and Outcomes
Research (METEOR), a clinical data warehouse that integrates research data-
bases and national registries. The diagnosis of AML was queried along with
patient demographics, cytogenetics, NGS and OS. The resultant patients were
divided into three categories based on their MRC cytogenetic risks- favorable,
intermediate, and poor. Using the TruSight Myeloid Sequencing Panel (Illumi-
na), mutations in 54 genes associated with myeloid disorders were tested in
NGS. A scoring system was developed that assigned each of the nine TCGA
mutation categories (Transcription- Factor Fusion, Nucleophosmin (NPM1),
Tumor Suppressor Genes, DNA-Methylation related genes, Signaling Genes,
Chromatin Modifying Genes, Myeloid Transcription Factor Genes, Cohesion
complex Genes and Spliceosome-complex genes) a score between -2 (good
risk) and +2 (poor risk). The IWGMS for each patient was calculated by the
sum of the individual mutation scores. A IWGMS score greater than 3 was con-
sidered significant as a poor prognostic factor. Statistical analysis was done
using Chi-Square, Mann Whitney U test and multivariate logistic regression
analysis. Data from other institutions will be analyzed in a similar fashion for
the confirmatory portion of the project.
Results: A hundred of the 1200 AML patients met the criteria for having both
cytogenetic and NGS data availability. The two-year mortality rates were 43%,
52%, and 51% respectively for the favorable, intermediate, and poor cytogenetic
groups. In the intermediate cytogenetic group, high IWGMS score (>3) was
associated with higher mortality when compared to low IWGMS score (80% vs
44%, p=0.045, Fig 1). A look at the gene mutation distribution in the intermediate
risk cytogenetic group also showed a general correlation between known favor-
able gene mutations with low IWGMS scores and unfavorable ones with high
IWGMS scores. We thus hypothesize the IWGMS scoring system can be uti-
lized to divide the intermediate cytogenetic group into higher and lower mortality
subgroups based on a combination of cytogenetic and genetic mutations. We
expect similar results with data from other institutions.
Figure 1.
Summary/Conclusions: Most studies in current literature focuses on the indi-
vidual contributions of cytogenetic aberrations or genetic mutations to risk strat-
ification and treatments risk stratification and treatment response. However,
prognosis varies widely in the heterogeneous, intermediate cytogenetic class,
where 60% of the AML patients belongs. We propose a systematic approach
that integrates cytogenetics with genetic mutations in stratifying prognostic out-
comes with a focus on the intermediate cytogenetics group. The ability to dif-
ferentiate in this specific group opens great potentials for targeted therapies
and improving outcomes.
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SUCCESSFUL IDENTIFICATION OF SPECIFIC AMINO ACID-DEPENDENCE
IN ADULT T-CELL LEUKEMIA / LYMPHOMA (ATL) AND PRECLINICAL
APPLICATION FOR NEW THERAPY
T. Ishigaki1,2,*, S. Yamazaki3, Y. Taya1, K. Uchimaru4, A. Tojo5, H. Nakauchi1,6
1Division of Stem Cell Therapy, 2Department of Laboratory Medicine, Research
Hospital, 3Project Division of Advanced Regenerative Medicine, The Institute
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The University of Tokyo, 5Department of Hematology and Oncology, Research
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Background: Adult T-cell leukemia / lymphoma (ATL) is highly aggressive
malignancy caused by human T-cell leukemia virus type 1 (HTLV-1). As
leukemia/lymphoma cells are often resistant to combination chemotherapy and
recent antibody therapy, new strategies should be developed. Our laboratory
recently found that proliferation and survival of hematopoietic stem cells are
critically dependent on the amino acid valine (Science, 2016).
Aims: We here aimed to assess amino acid-dependence of lymphoma and
leukemic stem cells, and tried to establish a novel therapy by utilizing the dif-
ferences in amino acid-dependence between normal and leukemic stem cells.
Methods: First, primary ATL cells were sorted from samples of 7 typical acute-
type ATL patients by 12-color flow cytometry, and serially passaged on stromal
cells. Then passageable ATL cells from 3 patients were transduced with GFP-
expressing lentivirus for tracking and counting by image cytometry. Using com-
plete medium and twenty different culture media each lacking a single amino
acid, we examined amino acid dependency of ATL cells. Amino acids vital for
ATL cells were screened by co-culture with stromal cells. Effects of these media
on normal lymphocytes of healthy volunteers were also examined. Finally, the
effectiveness of amino acid restriction was evaluated in vivo by xeno-trans-
plantation of ATL cells into NOG mice. Mice were fed with different diets lacking
specific amino acids at 6 weeks after transplantation, and sacrificed at 10 weeks
for analysis of peripheral blood, organs, and lymphoma size.
Results: In vitro studies revealed that ATL cells have dependency on specific
amino acids: cysteine, methionine, and valine. As 2-weeks restriction of the former
two amino acids damaged stromal cells or normal lymphocytes, valine was picked
up for further analysis. Proliferation of ATL cells was dramatically inhibited by
valine restriction while the influence on normal cells was limited. Interestingly,
valine restriction did not effect a significant change in the proportion of normal
CD4+ populations, such as Treg, naïve, central memory, effector memory, and
effector T-cells. Moreover, 4-week restriction of valine succeeded in eradicating
ATL cells in vitro and no recurrence was observed after refilling valine although
2-weeks restriction was insufficient for extermination. In-vivo model also showed
that 4-weeks restriction of valine could dramatically reduce ATL tumor size. Valine-
depleted diet did not significantly reduce hemoglobin or platelet count, and there
were no significant organ damages as far as examined macroscopically.
Summary/Conclusions: We discovered that proliferation and survival of adult
T-cell leukemia / lymphoma cells were dependent on valine. ATL cells could be
eradicated by 4-weeks of valine in vitro. In-vivo model also showed that the
growth of ATL cells was significantly inhibited by dietary restriction of valine.
Massive lymphoma cells, which are known to be resistant to antibody therapy,
were also vulnerable to the valine restriction. There were no severe complica-
tions such as anemia, thrombocytopenia, and organ damages which are often
seen in chemotherapy recipients. These data demonstrate that valine restriction
may potentially provide a new option for leukemia/lymphoma therapy.
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VEGF AND VEGFR2 POLYMORPHISMS ARE INVOLVED IN AGGRESSIVENESS
AND PROGNOSIS OF DIFFUSE LARGE B-CELL LYMPHOMA
A. Borsarelli Carvalho Brito1,*, M. Torresan Delamain2, C. Antonio de Souza2,
J. Vassallo3, C. Silvia Passos Lima1
1Department of Internal Medicine, 2Haematology and Haemotherapy Centre,
3Laboratory of Molecular and Investigative Pathology, University of Campinas,
Campinas, Brazil
Background: Angiogenesis (AG), with participation of the vascular endothelial
growth factor (VEGF) and its receptor (VEGFR2), plays a key role in clinical
features and outcome of patients with diffuse large B cell lymphoma (DLBCL).
The ability to induce AG is variable in humans, once that VEGF and VEGFR2
genes have several single nucleotide polymorphisms (SNPs) described with
distinct proteins production. The wild-type alleles of VEGF -2578 C/A
(rs699947), -2489C/T (rs1005230), -1154G/A (rs1570360), -634G/C
(rs2010963), -460C/T (rs833061), 936C/T (rs3025039), and VEGFR2 -271G/A
(7667298) and -604T/C (rs2071559) SNPs determine higher production, tran-
scriptional activity or binding efficiency of VEGF/VEGFR2.
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Aims: Since the roles of these SNPs in clinical aspects, response to therapy
and prognosis of DLBCL treated with R-CHOP- are still unknown, these were
the aims of the present study.
Methods: Our analysis included 168 consecutive DLBCL patients at diagnosis
seen at University Hospital from July 2009 to September 2014. Genotypes
were identified in DNA of peripheral blood by real-time polymerase chain reac-
tion, using a Taqman SNP Genotyping Assay. Replicates were performed in
10% of the reactions, achieving 100% of concordance. Chi-Square test, Fish-
er’s Exact test, and multivariate analysis, using the logistic regression model,
served to assess associations between genotypes and clinical aspects. Kaplan-
Meier analysis was used to evaluate the effect of clinical features and geno-
types on the cumulative probability of event free survival (EFS) and overall
survival (OS). EFS and OS were calculated from the date of diagnosis to first
event date (relapse, progression or death by disease) or last seen date and
death by any cause or last seen date, respectively. The Cox proportional haz-
ards regression model was used to evaluate the effects of clinical features and
genotypes of the above mentioned SNPs on PFS and OS, and the results of
analysis were presented as hazard ratios (HRs) with their corresponding 95%
confidence intervals (CIs). First, these associations were examined using uni-
variate Cox proportional hazards regression. In a second step, all variables
with P<0.10 were included in a multivariate Cox regression. All reported P val-
ues were two-sided, and P<0.05 was considered to indicate statistical signifi-
cance.
Results: Concerning clinical features, the frequency of the wild-types VEGF -
1154G allele and VEGF -634GG genotype were more common in stage III or
IV patients. The wild-type VEGFR2 -604TT genotype was more common in
high intermediate and high international prognostic index (IPI) patients. Con-
cerning response rate, patients with the wild-type VEGF 936CC genotype was
associated with higher complete response (CR). These patients had 2.65 more
chances of achieving CR to therapy than others. The median follow-up time of
168 DLBCL patients enrolled in the study was 43 months (range: 1-105). The
estimated probabilities of 60-months EFS and OS were 58.8% and 66.0%,
respectively. At 60 months of follow-up, patients with the variant VEGF 1154 A
and 936 T alleles had 1.52 and 1.82 more chances of presenting disease
relapse or progression, and 1.47 and 1.60 more chances of evolving to death
in univariate analysis, respectively. After correction with other classical prog-
nostic factors in DLBCL (IPI and GCB subtype), only the VEGF 1154 G/A SNP
was associated with PFS and OS: patients with the variant VEGF 1154 A allele
had 1.88 and 1.83 more chances of having an event.
Summary/Conclusions: Our data present, for the first time, preliminary evi-
dence that inherited abnormalities in AG pathway, related to the VEGF -
1154G/A, -634GG and 936C/T, and VEGFR2 -604T/C, influence clinical fea-
tures, response to R-CHOP and outcome of DLBCL patients.
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BONE MARROW BIOPSY SUPERIORITY OVER PET/CT IN PREDICTING
PROGRESSION FREE SURVIVAL IN A HOMOGENOUSLY-TREATED
COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA
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Background: Recently, several studies have reported uneven results when
evaluating the role of bone marrow biopsy (BMB) and PET/CT in the staging
of diffuse large B cell lymphoma (DLBCL). The retrospective nature of the stud-
ies and the heterogeneity of the inclusion criteria might explain part of these
discrepancies. Given the lack of a “gold-standard” to examine the most accurate
test to assess BM involvement (BMI) at diagnosis, the prognostic value of each
technique emerges as a key factor to determine the correct management at
baseline.
Aims: The main aim of this study was to evaluate the prognostic impact on
progression free survival (PFS) of BMI at baseline, assessed by means of BMB
or PET/CT, in DLBCL with a priority in narrowing the heterogeneous inclusion
criteria used in most reports to date.
Methods: This is a retrospective multicenter study including patients older than
17 years, with a BMB and a PET/CT performed simultaneously as part of the
routine pre-therapy staging for newly diagnosed DLCBL. Patients had not
received either chemotherapy or corticosteroids and no concomitant malig-
nancy was known to be present at the time of both procedures. Only patients
treated with R-CHOP as first line therapeutic strategy were included. Only vari-
ables with a p<0.150 in univariate analysis were included in the multivariate
Cox regression for outcome predictors.
Results: A total of 271 DLCBL patients were initially identified; we excluded:
31 patients who received low intensity chemotherapy regimens (R-COP, Mini-
CHOP-R, monotherapy with steroids) due to advanced age, comorbidities or
fragility, and 35 patients enrolled in clinical trials including standard regimens
plus new agents (Bortezomib, Lenalidomide, Ibrutinib) or non-standard regi-
mens (R-CHOP/14, Da-EPOCH-R, MACOP-B, Mega-CHOP, Hyper-CVAD)
In the homogeneously treated (R-CHOP/21) 205 DLBCL patients subset, the
median age at diagnosis was 61 y.o. (range 18-85), with a balanced gender
distribution (103 females/ 102 males). Twenty-six of these patients (12.7%)
had BMI on BMB, whereas 43 (21%) had BMI according to PET/CT finding.
Fifty-three patients (25.9%) had BMI according to either BMB or PET/CT. Con-
cordant BMI by means of both techniques was present in 16 (7.8%) patients.
With a median follow-up of 25 months (15-47 months, p25-p75), 50 patients
(24.4%) progressed or relapsed and 41 (20%) died. The 3-year estimated pro-
gression-free survival (PFS) and overall survival (OS) were 70%, and 78%,
respectively. By univariate analysis, factors associated with a shorter PFS, with
a p<0.150, were: female gender, IPI≥3, abnormally elevated B2-microglobulin
levels, PET/CT-BMI(+) and BMB-BMI(+). In multivariate analysis only two fac-
tors, BMB-BMI(+) (HR: 3.27, 95%CI 1.58-6.78; p=0.001) and IPI≥3 (HR: 1.96,
95%CI 1-3.76; p=0.04) were independently associated with a shorter PFS. By
univariate analysis, factors predictive of a shorter OS, with a p<0.150, included:
IPI≥3, abnormally elevated B2-microglobulin levels, PET/CT-BMI(+). In multi-
variate analysis only IPI ≥3 (HR: 2.6, 95%CI 1.13-5.14; p=0.006) was inde-
pendently associated with a shorter OS.
Summary/Conclusions: In our DLBCL cohort, treated with a uniform first-line
chemotherapy regimen, BMI by BMB complemented IPI in predicting those
patients with a higher risk for relapse or progression, while IPI defined a subset
of patients with a worse survival. In this cohort, BMI by PET/CT could not inde-
pendently predict a shorter PFS and/or OS. 
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THE PROGNOSTIC SIGNIFICANCE OF CD11B+CX3CR1+ MONOCYTES
IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL
LYMPHOMA
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Background: Interest in the role of myeloid-lineage cells, including monocytes
and their precursors, has been increasing in prognosis of lymphoma. It has
been shown that the circulating monocyte count at the time of diagnosis shows
prognostic significance in diffuse large B-cell lymphoma (DLBCL), suggesting
the role of specific subset of monocyte in prognosis of DLBCL. Recent studies
suggest CD11b+ monocytes expressing CX3CR1 promote angiogenesis and
suppress anti-tumor immunity through the interaction with fractalkine (CX3CL1),
the only ligand for CX3CR1. However, limited data is available regarding the
prognostic significance of CD11b+CX3CR1+ monocytes in DLBCL patients.
Aims: The study investigates the prognostic significance of peripheral blood
(PB)- and bone marrow (BM)- CD11b+CX3CR1+ monocytes on progression-
free survival (PFS) and overall survival (OS) in newly diagnosed DLBCL
patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine,
and prednisone (R-CHOP) therapy.
Methods: The prospective cohort study was conducted in two Korean institu-
tions from May 2011 to August 2015. Patients were eligible if they were newly
diagnosed DLBCL, treated with R-CHOP, and provided informed consents.
Percentages of CD11b+CX3CR1+ cells in total mononuclear cells (>50,000
cells) were measured by flow cytometric analysis using fresh PB and BM aspi-
rate samples before treatment.
Results: Eighty-nine patients (male, 52) were enrolled. The median age was
65 years (range, 19-88). 37 patients (41.6%) were classified as high-interme-
diate (HI) or high risk according to National Comprehensive Cancer Network
International Prognostic Index (NCCN-IPI). CD11b+CX3CR1+ monocytes were
detectable in all PB and BM samples analyzed. The median percentage of
CD11b+CX3CR1+ cells was 3.31% (range, 0.21 to 21.66%) in PB and 3.09%
(range, 0.20-20.01%) in BM. Patients were categorized into high (PB- or BM-
CD11b+CX3CR1+ cells >median) and low (<= median) groups. High PB-
CD11b+CX3CR1+ cell group was significantly associated with unfavorable
parameters including age >=60 years, advanced stage, elevated serum LDH
level, and extranodal involvement (P<0.05), which were clinical factors asso-
ciated with higher risk NCCN-IPI (P=0.004). However, BM-CD11b+CX3CR1+
cells were not associated with clinical variables. With a median follow-up of
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27.7 months (IQR, 14.6-46.1), low PB-CD11b+CX3CR1+ cell group had signif-
icantly better PFS (3-year, 77.1% vs 58.7%; P=0.006) and OS (3-year, 86.6%
vs 58.4%; P=0.004) than high PB group. No significant survival differences
were observed between high and low BM-CD11b+CX3CR1+ cell groups. Uni-
variate analyses demonstrated that age, ECOG performance status, B symp-
toms, extranodal involvement, NCCN-IPI, and PB-CD11b+CX3CR1+ cell group
were significantly associated with OS. However, HI or high risk NCCN-IPI was
an only independent prognostic factor for reduced OS (hazard ratio, 4.41; 95%
confidence interval, 1.17-16.59) in the multivariate analysis. In subgroup analy-
sis according to the NCCN-IPI, 3-year OS of high PB-CD11b+CX3CR1+ mono-
cytes was significantly inferior to that of low group (34.0% vs 77.9%; P=0.026)
in DLBCL with HI to high risk NCCN-IPI. In contrast, PB-CD11b+CX3CR1+
monocytes failed to predict OS (3-year, 91.7% vs 96.7%; P=0.878) in the low
to low-intermediate risk NCCN-IPI subgroup.
Summary/Conclusions: Our study represents PB-CD11b+CX3CR1+ mono-
cytes can be used in differentiating patients with high risk for early death and
are associated with risk stratification by the NCCN-IPI, possibility of potential
therapeutic target in DLBCL.
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RARE NON-HODGKIN LYMPHOMAS (R-NHLS) IN CHILDREN: THE AIEOP
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Background: Clinical management of pediatric rare non-Hodgkin lymphomas
(r-NHL) (<1case/1million) is unclear.
Aims: To characterize children with r-NHLs in AIEOP centers. Performing a
retrospective analysis of r-NHLs AIEOP case records, describing main epi-
demiologic, clinical and histopathological parameters. To review the histopatho-
logical case records according to WHO 2008 classification. Evaluation of treat-
ment response - chemotherapy or wait and see (W&S) in terms of overall sur-
vival (OS) and of complete remission (CR), relapse and resistance cases, sec-
ondary neoplasias and deaths.
Methods: Data from the AIEOP database were collected between 1997 and 2015.
Results: The incidence of r-NHL in AIEOP registry was 6.5% (67 pts). Forty-
eight were male and 19 female, median age was 11 years (0.3-21 years). Clas-
sification according to St.Jude stage was: stage I n=36; II n=13; III n=11; IV
n=7. Bone marrow (BM) involvement was diagnosed in 7 cases; central nervous
system (CNS) in one case. Patients who presented LDH >500 UI were 18. B-
rNHLs accounted for approximately 49% (33 pts) of the entire population
analysed, T-rNHLs for another 40% (27 pts), the remaining 11% (7 pts) of the
population under study being categorized as “others” (other than those deriving
from B or T/NK-cells). The most common histological subtypes were: follicular
lymphoma (FL) amongst B-rNHLs; peripheral T-cell lymphoma (PTCL) n.o.s.,
mycosis fungoides (MF), subcutaneous panniculitis T-cell lymphoma (SPTCL)
and lymphomatoid papulosis (LP) amongst T-rNHLs; histiocytic sarcoma (HS)
amongst “others” category. A similar proportion for both B and T/NK NHL under-
went either W&S approach only or active treatment (AT): 45% and 55% were
W&S and AT approach, respectively. Patients in “others” category were almost
actively treated (71%). Therapy was based on AIEOP B-, T/NK-NHLs and ALCL
protocols +/- RT, and/or immunotherapy. Surgical resection has been performed
in case of localized disease B-rNHLs only, followed by a W&S strategy, with
100% 3-yr OS. It has been seen that B-rNHLs have a more favorable prognosis
and very few events (development of resistance to therapy, relapse, secondary
malignancy, death). Amongst T/NK rNHLs-related events, death remained the
most likely to occur, differently than B-rNHLs which showed a slight prevalence
of relapses; as for the category “others”, no relative preponderance has been
registered for any of the above-mentioned events. The 3-year OS has shown
to be significantly higher for B-rNHLs than for T/NK-NHL (94% vs 69%, p-value
0.024), as illustrated in Figure 1. Regarding the treatment, the 3-year OS was
100% for the patients underwent a W&S approach whereas 75% for treated
patients (p-value 0.037). FLs show favourable clinical course and outcome,
limited stage at diagnosis. Differently from adults, pFLs have a higher 3-years
OS with respect to that of other histological pediatric NHLs subtypes (100% vs
75%, p-value 0.049).
Figure 1.
Summary/Conclusions: The incidence of AIEOP pediatric rNHLs is in line
with the literature. In case of localized disease, a W&S approach was success-
fully applied; of these, the T/NK rNHLs being most often registered and with
best prognosis are the cutaneous lymphomas (i.e. LyP, MF). Patients’ prognosis
varies greatly depending on the histological subtype. The better survival was
observed in the B-rNHLs compared to other categories. An international col-
laboration is warranted, in order to create new guidelines or protocols for an
appropriate management of pediatric rNHLs.
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Background: T cell lymphoma(T-NHL) is a rare and heterogeneous group of
lymphoid malignancies with mostly poor outcome with conventional
treatment.Recent studies have suggested that Hematopoietic stem cell trans-
plantation(HSCT) has a better curative effect and is superior to traditional
chemotherapy.
Aims: To investigate the effect of HSCT in the treatment of T cell lymphoma.
Methods: The clinical data of 110 patients with T cell lymphoma treated by
HSCT from January 2006 to August 2016 in our center were retrospectively
analyzed.
Results: (1)110 T-NHL patients, 70 males and 40 females, aged 7-64 years
(median age 26 years). Disease subtypes: 35 cases of T-cell lymphoblastic
lymphoma(T-LBL), 23 cases of NK / T cell lymphoma(NK/TCL), 24 cases of
peripheral T-cell lymphoma (PTCL, NOS), 24 cases of variable large cell lym-
phoma (ALCL), 3 cases of subcutaneous panniculitic T cell lymphoma(SPTCL)
and 1case of hepatosplenic T cell lymphoma(HSTCL).Transplantation type: 56
cases of autologous hematopoietic stem cell transplantation (auto-HSCT), 54
cases of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The
follow-up was ended in December 2016, the duration of following-up ranged
from 2 to 130 months (median follow-up time was 22 months). (2)56/110
patients with auto-HSCT, 3 year overall survival (OS) and disease-free survival
(EFS) were 76.5% and 60.9%, respectively. (3)54/110 patients with allo-HSCT,
3 year EFS and OS of allo-HSCT were 61.7% and 58.9%, respectively. (4)36/56
patients with CR1 status before auto-HSCT, 3 year OS and EFS were 87.3%
and 68.7% respectively. 20/56 patients with non-CR1 status before auto-HSCT,
3 year OS and EFS were 60.6% and 40.2%. The OS and EFS of the two groups
were significantly different (P=0.001).(5)45/110 cases were young and high-
risk patients (age<60 years, IPI score ≥3).25/54 cases treated with allo-HSCT,
the 3 year OS and EFS were 62.8% and 60.8%. 20/56 cases treated with auto-
HSCT, the 3 year OS and EFS were 47.6% and 36.9%. The OS and EFS of the
two groups were also significantly different (P=0.001).
Summary/Conclusions: HSCT can improve the efficacy of T cell lymphoma.
Auto-HSCT in first complete remission (CR1) enables T-NHL patients with
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greater benefit. Allo-HSCT can cure some T-NHL patients, which can be con-
sidered for the treatment of young and high-risk T-NHL patients.
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PROLONGS PROGRESSION FREE SURVIVAL TO MORE THAN 9 YEARS.
SINGLE CENTER EXPERIENCE
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Background: Mantle cell lymphoma (MCL) is considered an incurable disease
with an historical median overall survival around 3-4 years with short progres-
sion free survival (PFS) periods. Regimens that include high dose cytarabine
and consolidation with autologous stem cell transplant (ASCT) have become
standard therapy for fit patients. The median PFS reported after 4-6 cycles
HyperCVAD followed by ASCT consolidation is 4.5 years (Ahmadi et al, BMT
2012). Nevertheless, toxicity is high and many patients cannot obtain stem
cells for transplant. In this setting, some groups use 6-8 cycles R-HyperCVAD
without ASCT consolidation, achieving the same median PFS of 4.6 years
(Romaguera et al, Br J Hematol 2010). Based on this we have review our expe-
rience using a short course of HyperCVAD followed by transplant consolidation. 
Aims: To analyze our experience treating fit patients with MCL in first line with
a short course of 2 cycles of R-HyperCVAD followed by consolidation with ASCT.
Methods: from January 2002 to August 2016, the patients diagnosed with MCL
treated in first line with a short course of 2 cycles of R-HyperCVAD and ASCT
were included in this retrospective analysis. International working group
response assessment criteria were used, PFS was calculated from the date of
start therapy until date of relapse/progression or last contact.
Results: During the study period 85 MCL patients were registered: 7 (8.2%)
did not receive immediate therapy, 44 (52.4%) were not eligible for intensive
therapy due to comorbidities or age and 33 (39.3%) were treated with R-Hyper-
CVAD. Clinical characteristics at diagnosis of these 33 patients were: M/F ratio:
26/7 (78.8%/21.2%), median age: 63 y.o (limits: 40-73), ECOG 0-1: 26 (86.7%),
Ann Arbor stage III-IV 28/31 (90.3%), MIPI score: low risk: 5 (16.7%), interme-
diate risk: 17 (56.7%), high risk: 8 (26.7%). Thirty (90.9%) patients completed
the 2 cycles of R-HyperCVAD. Reasons for discontinuation were: 2 deaths for
sepsis and 1 CNS progression. Intention to treat response rate was: CR 26
(78.8%), PR 2, (6.0%), progressive disease 3 (9.0%), not evaluable 2 (6.0%).
Among the 28 patients in CR / PR considered eligible for consolidation with
ASCT, 8 patients were not transplanted: 4 (14.3%) had harvest failure (all
before plerixafor availability), 2 had persistent toxicity (prolonged neutropenia
and severe mucositis) and were not longer considered for ASCT, 1 rejected, 1
unknown cause. Conditioning regimen was BEAM/LACE in 18 (90%) patients
and cyclophosphamide-TBI in 2 (10%). One patient died 10 days after infusion
for sepsis. With a median follow-up of 35 (1-131) months, the median PFS
was 73.0 (95%IC 38.2-107.8) months (6.08 years) for the whole group, 114
(47.3-180.7) months (9.4 years) for the transplanted patients vs 21 (3.1-38.9)
months (1.8 years) for the not transplanted group. The median OS was 123
(31.9-214.1) months, median OS was not reached for transplanted group vs
31.0 (7.5-54.6) months for not transplanted.
Figure 1.
Summary/Conclusions: A short course of R-HyperCVAD achieves a very
high remission rate in fit patients with MCL. Stem cells could not be obtained
in a small proportion of patients, all of them before the use of plerixafor. Two
thirds of the patients could complete the planned therapy with ASCT consoli-
dation, and those patients have an excellent outcome, with a PFS of more than
9 years. 
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PET/CT SCANS IN PATIENTS WITH LYMPHOMA AND THE ASSOCIATED
CLINICAL IMPLICATIONS
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Background: PET/CT imaging has a well-established role in the investigation
of malignant lymphoma. Given the widespread clinical applications, unexpected
findings are occasionally identified. Whilst there is substantial information per-
taining to additional primary cancers identified on PET/CT in patients with solid
organ malignancy, there is a relative paucity of data in patients with lymphoma.
Aims: The primary aim was to identify the frequency of incidental second malig-
nancies detected by PET/CT scans in patients with lymphoma. Qualitative data
related to histological diagnosis and staging, interruptions or obstacles to lym-
phoma therapy, therapy for the second malignancy and the overall impact upon
prognosis were also reviewed.
Methods: A total of 550 PET/CT images were performed in 298 patients at
The Prince of Wales Hospital, Sydney Australia between January 2013 – March
2016. Patients with both Hodgkin’s and Non-Hodgkin’s lymphoma, with PET/CT
imaging performed for all medicare-approved indications were included. All
PET/CT reports suggestive of an incidental second malignancy prompted fur-
ther review of electronic medical records, MOSAIC cancer database and paper
medical records. Where a clear diagnosis of second malignancy was confirmed,
information regarding histological findings and staging, as well as the implica-
tions of this diagnosis related to treatment of the underlying lymphoma and
impact on overall prognosis was collected.
Results: 510 PET/CT scans in 259 patients had confirmed diagnoses of lym-
phoma. Patients aged 17 to 96 were included in the study, with a median age
of 62 years. Of the 259 patients included (M=155; F =104), 55 patients had a
diagnosis of Hodgkin’s lymphoma and 204 patients a diagnosis of Non-
Hodgkin’s lymphoma. A total of 33 out of 259 patients with a diagnosis of malig-
nant lymphoma had PET/CT findings suspicious for an underlying second
malignancy (12.7%). Of the 33 patients, 19 underwent further invasive inves-
tigation, with a total of 8 patients having a biopsy proven histological diagnosis
of a second malignancy (3.1%). Qualitative information was gathered regarding
the patients who did not have further investigation.
Summary/Conclusions: The frequency of incidental malignancies detected
by PET/CT imaging in patients with lymphoma was found to be comparable to
other similar international retrospective studies. The majority of incidental sec-
ond malignancies were early stage and gastrointestinal in origin. Further ret-
rospective as well as prospective data may assist in the establishment of guide-
lines, to address a standardized diagnostic approach to investigating incidental
lesions discovered on PET/CT imaging that are suggestive of a second malig-
nancy.
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Background: The acquisitions of additional chromosomal abnormalities are
generally accompanied by the emergence of therapeutic resistance and even-
tually lead to poor treatment outcome in cancers. However, the actual clinical
impact of karyotypic evolution on prognosis differs depending on the type of
hematologic malignancy. Although several prognostic indexes, including the
International Prognostic Index (IPI), revised IPI (R-IPI), National Comprehen-
sive Cancer Network (NCCN)-IPI, and Kyoto Prognostic Index (KPI) which we
have developed (Kobayashi T. Blood Cancer J 2016), have the determinants
for prognosis, little is known concerning the prognostic impact of karyotypic
evolution in diffuse large B cell lymphoma (DLBCL), the most prevalent subtype
of non-Hodgkin lymphoma.
Aims: We in this study investigated the clinical impact of karyotypic evolution
on the treatment outcome of DLBCL.
Methods: We retrospectively examined the medical records of 465 DLBCL
patients who were diagnosed and treated with either rituximab, cyclophos-
phamide, doxorubicin, vincristine, and prednisolone (R-CHOP) or with a R-
CHOP-like regimen at three independent institutes in Kyoto, Japan, between
January 2006 and April 2014. We analyzed the relationship between the num-
ber of subclones and prognosis utilizing the Kaplan-Meier curve and Cox pro-
portional hazards regression analysis. We also utilized Fisher’s exact test to
investigate the correlation between the number of subclones and the conven-
tional prognostic indexes, i.e. R-IPI, NCCN-IPI, and KPI. This study was con-
ducted in accordance with the ethical principles of the Declaration of Helsinki
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and was approved by the institutional review boards of all participating insti-
tutes.
Results: Among the 465 DLBCL cases, karyotypic analyses by G-banding
were performed on biopsied tumor specimens before the start of treatment in
181 patients. Among the 181 patients, metaphase spreads were available for
G-banding in 120 patients. Neither overall survival (OS) nor progression free
survival (PFS) was statistically significantly different between the patients with
available metaphase and no available metaphase spreads. Based on the result
of G-banding, we next divided the 120 patients with available metaphase
spreads into two groups, i.e., patients with karyotypic abnormalities accompa-
nied by ≥2 subclones and patients with 0-1 subclones. We found that the pres-
ence of ≥2 subclones was significantly associated with poor OS (3 year OS
rates of patients with ≥2 subclones and 0-1 subclones were 67.6% and 82.8%,
respectively (p=0.035), and tended to associate with a shorter PFS. Among
the 120 patients with available metaphase spreads, the R-IPI-defined high-risk
patients and KPI-defined high-risk patients were significantly more frequent in
the group of patients with ≥2 subclones. Ages and genders were not significantly
different between patients with ≥2 and with 1-2 subclones.
Summary/Conclusions: DLBCL is a cytogenetically and molecularly heteroge-
nous disease entity. No specific chromosomal abnormality has been associated
with the shorter survival, except double or triple hit lymphomas. However, in
this study, it was possible to divide DLBCLs into two groups based on karyotypic
evolution, i.e., DLBCLs with 0-1 subclones and with ≥2 subclones, because
the OS was the most markedly different between these two groups. In our
study, more subclones were associated with poor prognosis, suggesting the
significance of karyotypic evolution in DLBCL. In conclusion, our study suggests
that more advanced cytogenetic clonal evolution underlies the development of
high-risk disease feature in DLBCL.
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Background: Despite effective combination antiretroviral therapy for HIV, there
remains an increased incidence of HIV related B-cell Non-Hodgkin lymphomas
(NHL). The introduction of early antiviral therapy and effective chemotherapy
have led to improved outcomes overall. Regimen intensification (RI) in HIV
associated B-cell NHLs has shown improved survival, especially in the rituximab
era (Barta et al, Blood 2013). 
Aims: To examine the effect of RI on the overall survival (OS) and progression
free survival (PFS) compared to CHOP based chemotherapy according stan-
dard risk stratification. 
Methods: Patients with HIV associated aggressive B-cell NHL were identified
between 2001- 2015 at Moffitt Cancer Center. Patients with primary central
nervous system lymphoma, T-cell NHL and indolent NHLs were excluded.
Patients received R-CHOP or intensive chemotherapy (IC) including DA-
EPOCH, hyperCVAD or CODOX/IVAC as initial treatment. Data collected
included patient demographics, disease baseline characteristics, CD4 count,
HIV viral load, treatment regimen, response, and outcomes including relapse
and OS. The IPI score was calculated, and patients were divided into two
groups: lower risk group (low and low-intermediate IPI risk) and higher risk
group (high-intermediate and high). Descriptive statistics were used for baseline
characteristics. Kaplan Meier method was used to estimate PFS and OS, and
the log-rank test was used to compare OS and PFS between lower and higher
risk groups.
Results: A total of 83 patients were included. The M:F ratio was 9.4. Median
age was 45 years (y) (range 25 – 65). Two thirds of patients were Caucasian.
The median time from HIV to NHL diagnosis was 29 months (range 0 – 284).
Eighty two percent presented with stage III/IV disease. Bulky disease was pres-
ent in 27%, elevated LDH in 66%, and CD4 count<100/mL at diagnosis in 22%
patients. Fifty percent of patients were on HAART therapy at time of lymphoma
diagnosis. Chemotherapy regimens included: RCHOP (n=30, 36%), CHOP
(n=12, 15%), DA-EPOCH-R (n=27, 33%), DA-EPOCH (n=1, 1%), hyperCVAD
(n=11, 13%) and CODOX/IVAC (n=2, 2%). The median follow up was 2.7 y
(95% CI 2.0-3.4). The median OS and PFS for the whole cohort was 5.9 and 4
y, respectively. The median OS was 4 y (95% CI 1.5-6.5) for patients who
received CHOP based regimen and was not reached (NR) for patients who
had IC (p=0.44). Based on the IPI, the median OS was NR for the lower risk
group compared to 1.8 y in higher risk group (p=0.025). Among patients who
received CHOP, the median OS for those with lower risk disease was NR com-
pared to 1.8 y in patients with higher risk disease (p=0.07). For patients who
received IC, the median OS was NR among both lower and higher risk groups
(p=0.2). Among patients who received CHOP, the median PFS for those with
lower risk disease was NR compared to 1 y in patients with higher risk disease
(p=0.05). For patients who received IC, the median PFS was NR among lower
and 1.4 y higher risk groups (p=0.34).
Summary/Conclusions: The IPI score remains prognostic in HIV related B-
cell NHLs. There was a trend for improved OS and PFS using IC regimens.
CHOP treatment remained associated with worse outcome among higher risk
patients while IC regimens may overcome the higher risk features based on
the IPI. 
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EPSTEIN-BARR VIRUS LATENT MEMBRANE PROTEIN 1-MEDIATED
OVEREXPRESSION OF MYC AND BCL2 CAN PREDICT POOR PROGNOSIS
IN PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE
J.-H. Wang1, X.-W. Bi2, Z.-J. Xia1, W.-Q. Jiang2, H.-Q. Huang2, L. Wang1,*
1Hematologic Oncology, 2medical oncology, Sun Yat-sen University Cancer
Center, Guangzhou, China
Background: Recently double-hit lymphoma or double protein expressor lym-
phoma has been identified as a distinct group of diffuse large B cell lymphoma
with poor prognosis. However, the expression status, clinical and prognostic
effect of combined overexpression of MYC and BCL2 in extranodal NK/T-cell
lymphoma, nasal type (ENKTL) are not known.
Aims: This study aims to explore the clinical and prognostic effect of combined
overexpression of MYC and BCL2 in ENKTL.
Figure 1.
Methods: Paraffin-embedded lymphoma samples from 53 patients with newly
diagnosed ENKTL were studied using immunohistochemistry for MYC and
BCL2, and fluorescent in situ hybridization (FISH) for MYC and BCL2 were
done on 5 tissue sections with highest percentages of both MYC and BCL2
positive lymphoma cells.
Results: The median percentage of MYC-positive lymphoma cells and BCL2-
positive lymphoma cells were 20% (range, 5% >45%) and 70% (10% >95%),
respectively. Using median scores as cutoffs, we assigned each patient an IHC
double-hit score (DHS) that ranged from 0 to 2. Using this DHS, 15 patients
(28.3%) had a DHS of 0, 24 patients (45.3%) had a DHS of 1, and the remaining
14 patients (26.4%) had a DHS of 2. FISH analysis was performed on 5 tissue
sections with DHS of 2, and none of them had MYC or BCL2 rearrangement.
The DHS was not associated with patients’ age, gender, disease stage, LDH
level, B symptoms, performance status, or local tumor invasiveness. However,
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patients with tumor localized in extranasal sites seemed to have higher expres-
sion of BCL2 and higher DHS than nasal lesions (p=0.014 and 0.042, respec-
tively). In univariate survival analysis, either high expression of MYC or BCL2
was significantly correlated with inferior PFS and OS (p<0.05). According to
the DHS, patients with ENKTL could be divided into three significantly different
risk groups for PFS and OS (3-year PFS rate for DHS of 0, 1, and 2 was 60%,
41%, and 21%, respectively, p=0.008; 3-year OS rate for DHS of 0, 1, and 2
was 79%, 49%, and 33%, respectively, p=0.015). In multivariate survival analy-
sis, it was found that DHS was an independent prognostic factor for both PFS
and OS (p=0.006 and 0.011, respectively).
Summary/Conclusions: Our study demonstrated that DHS can help identify
patients with newly diagnosed ENKTL who are at a high risk for a poor clinical
outcome, which needs to be validated in prospective clinical trials with patients
treated uniformly.
E962
SOLUBLE INTERLEUKIN-2 RECEPTOR AS A PREDICTIVE MARKER FOR
SPONTANEOUS REGRESSION OF OTHER IATROGENIC IMMUNODEFI-
CIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS; A
RETROSPECTIVE STUDY
Y. Nakajima1,*, S. Fujisawa2, C. Nigauri2, A. Matsumura1, T. Ando2, T. Suzuki2,
E. Ogusa2, Y. Ishii2, K. Miyashita2, H. Takahashi1, T. Miyazaki1, K. Motohashi2,
M. Hagihara1, K. Matsumoto1, E. Yamazaki3, H. Nakajima1
1Department of hematology and Clinical Immunology, Yokohama City University
Graduate School of Medicine, 2Department of Hematology, Yokohama City
University Medical Center, 3Clinical Laboratory Department, Yokohama City
University Graduate School of Medicine, Yokohama, Japan
Background: Patients treated with immunosuppressive drugs (ISD) for autoim-
mune diseases are at an increased risk of developing other iatrogenic immun-
odeficiency-associated lymphoproliferative disorders (OI-LPD). Some patients
with OI-LPD shows spontaneous regression after withdrawal of ISD, but some
requires chemotherapy. The factors that are associated with spontaneous
regression and outcomes of chemotherapy remain uncertain.
Aims: The aims of our retrospective study are to assess the clinical factors
that predict spontaneous regression of lymphoma after ISD withdrawal in
patients with OI-LPD and to evaluate the outcomes of patients who underwent
chemotherapy without spontaneous regression.
Methods: We collected data from all patients with autoimmune disease who
were pathologically diagnosed with OI-LPD between January 2002 to October
2016 at Yokohama City University Hospital, and Yokohama City University
Medical Center.
Figure 1.
Results: The patients included 12 males and 28 females, with a median age
at diagnosis of 65 years (range 30-81). Methotrexate (MTX) was administered
to all patients at any point of the clinical course before OI-LPD. The median
time from diagnosis of autoimmune disease to OI-LPD development, and the
median duration of MTX administration were 129 months (range 11-564), and
89 months (range 4-297), respectively. The histological findings of OI-LPD
were diffuse large B-cell lymphoma (DLBCL) in 26 patients, follicular lymphoma
in 1, MALT in 2, peripheral T cell lymphoma, not otherwise specified in 3,
Hodgkin lymphoma in 4, and LPD in 4. EBER in situ was examined in 30
patients:17 positive, and 13 negative. The median observation period in the
surviving patients was 34 months (range 3-119). The 2-year progression-free
survival (PFS) and overall survival (OS) rates for all 40 patients were 69% and
79%, respectively. A total of 18 patients (45%) had spontaneous regression
after ISD withdrawal. The median time from ISD withdrawal to spontaneous
regression was 4 months (range 1-13). Among the 18 patients with sponta-
neous regression, 3 relapsed. Of the 22 patients without spontaneous regres-
sion, 20 subsequently underwent chemotherapy: 18 underwent CHOP/CHOP-
like ± rituximab, and 2 underwent other regimens. In total, 7 patients died: all
died from lymphoma progression. Compared to those without spontaneous
regression, patients with spontaneous regression had clinical stages I-II
(P=0.021), performance status of 1-2 (P=0.028), normal levels of LDH
(P=0.026), and lower levels of sIL-2R (P=0.005). The ROC curve analysis
showed the appropriate cut-off of sIL-2R levels to be 2400 U/mL for predicting
spontaneous regression (AUC, 0.74; sensitivity, 0.81; specificity, 0.67). On mul-
tivariate analysis, only an sIL-2R level of <2400 U/mL was associated with
spontaneous regression (odds ratio, 0.03; 95% CI, 0.002-0.39; P=0.007). Thir-
teen patients with DLBCL who did not have spontaneous regression received
CHOP/ CHOP like ± R therapy. The CR rates, and 2-year PFS and OS of these
13 patients were 38%, 68.3%, and 82.1%, respectively.
Summary/Conclusions: Our study revealed that an sIL-2R level of <2,400
U/mL was significantly associated with spontaneous regression in patients with
OI-LPD. Because CR rates with chemotherapy in patients without spontaneous
regression are low, evaluation of sIL-2R in patients with OI-LPD may be useful
for an early withdrawal of ISD, resulting in a higher chance of spontaneous
regression.
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PROGRAMMED DEATH-1 PROTEIN EXPRESSION AND ITS RELATION
WITH HISTOLOGIC AND CLINICAL VARIABLES IN MYCOSIS FUNGOIDES
C. Vasquez1, S. Novelli2,*, A. Mozos1, P. Garcia Muret3, A.C. Caballero2,
J. Sierra2, J. Briones2
1Pathology, 2Hematology, 3Dermatology, Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain
Background: Mycosis fungoides (MF) is a T-cell malignancy with affinity for
the skin. In early stages,treatment directed to the skin can induce long-lasting
remissions. However, advanced stages are characterized by short-duration
remissions and progressive disease. The programmed death cell surface pro-
tein-1 (PD-1) is expressed on activated T cells. Interactions between PD-1 and
its ligands control the induction and maintenance of peripheral T-cell tolerance
during the normal immune response. These interactions may also play a role
in the immune evasion of tumors in which PD-1 ligand is overexpressed.
Aims: To described histologic characteristics and the proportion and intensity
of PD1 expression by tumor cells, as well as the presence of PD1 positive lym-
phocytes in the epidermis in patients with MF. To identify histologic variables
that might have an impact in clinical outcome.
Table 1.
Figure 1.
Methods: Histological preparations of 85 patients diagnosed with with MF
were evaluated. Survival analysis was performed with the Kaplan-Meier
method. A univariate analysis was performed with clinical variables (stage and
age) and anatomopathological variables (i.e. intensity of the inflammatory infil-
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trate, epidermotropism, cellular atypia, tumor density, presence of folliculotro-
pism and phenotypic alterations) and the proportion and intensity of PD1
expression by tumor cells, the presence of PD-1 positive lymphocytes in the
epidermis. Likewise, a Pearson correlation analysis was performed between
the degree of atypia and the ratio of PD-1 expression, PD-1 intensity, and loss
of CD7 expression in tumor cells. Statistical analysis was performed using the
IBM SPSS Statistics version 21.0.
Results: The median follow-up was 125 months (range 6-450 months). Char-
acteristics of patients are in table 1. The overall survival (OS) at 10 years was
81%. OS in the early stages was 85% vs.64% in advanced stages (p<0.05).
The OS for patients <60 years was 85%, and 75% for patients ≥60 years
(p<0.05). Regarding istologic findings, the degree of atypia was the only variable
that had an impact in OS.(see Figure 1) The presence of atypia grade +1 had
an OS of 88%, grade +2 of 75%, and grade+3 of 50% (p<0.05). We performed
a correlation analysis between degree of atypia and the ratio of PD-1 expres-
sion, PD-1 intensity, and loss of CD7 expression. A positive correlation was
detected, however it was weak (r<0.5).
Summary/Conclusions: MF tumoral cells express PD-1 protein in a high pro-
portion of cases being a potential therapeutic target. Advanced disease, age ≥60
years and the degree of atypia of the tumoral infiltrate had an impact on survival.
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CIRCULATING MICRORNAS AS BIOMARKERS IN DIFFUSE LARGE
B-CELL LYMPHOMA: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL
STUDY
C. Bouvy1,*, A. Wannez12, C. Chatelain1, J.-M. Dogne1
1Department of Pharmacy, University of Namur, Namur, 2CHU UCL Namur,
Université Catholique de Louvain, Yvoir, Belgium
Background: Diffuse large B-cell lymphoma (DLBCL) is highly heterogeneous
in terms of phenotype and treatment response in patients. These characteristics
make the prognosis difficult to establish and hinder the use of new personalized
treatments in clinical practice. In this context, there is currently a necessity to
define new biomarkers enabling a better definition of DLBCL subtypes, prog-
nosis evaluation and an overview of the resistance to chemotherapeutics. We
decided here to focus on circulating microRNAs that are found in all biological
fluids. This accessibility makes them good candidates for biomarkers studies.
Aims: This research aims at studying microRNAs found in plasma from DLBCL
patients and at investigating their potential as biomarkers of survival in these
patients. For this purpose, a plasma biobank was created with samples from
DLBCL patients at different times of their treatment. This follow-up of microR-
NAs level during the course of treatment is particularly innovative in this study.
Methods: A plasma biobank from DLBCL patients was set up at the Centre
Hospitalier Universitaire (CHU) UCL Namur Yvoir, Belgium (ethical agreement
number B039201419613). Informed consents of all patients were obtained. In
this way, blood samples from patients were taken before any treatment (C0), at
the administration of the second and the fourth chemotherapeutic cure (C2 and
C4) and at the remission review (Cf). In the case of an autograft, a sample was
taken at the post-graft review (Cpg). The first step of this study was the selection
of the microRNAs that will be quantified in all the samples of the biobank and
that could potentially be used as biomarkers. To this end, a quantification of
377 microRNAs was performed by TaqMan® Low Density Array on the plasma
samples of two selected DLBCL patients and one healthy donor with no history
of cancer. These DLBCL patients were selected based on their highly different
response to treatment. One of them obtained a complete remission after a R-
CHOP treatment, while the other presented a refractory disease to the same
treatment. Thereafter, we determined some criteria to use in a scoring system
to evaluate their potential as biomarkers. In this way, one point was given to a
microRNA each time it meets the criteria enabling it to be defined as a potential
diagnostic, prognostic and/or remission biomarker, biomarker of a disease pro-
gression, biomarker of an inherent resistance to treatment, and/or biomarker
of an acquired resistance to treatment. 
Results: On the 377 microRNAs quantified into the plasma of the 3 selected
donors (2 DLBCL patients and 1 healthy donor), 81 microRNAs were detected.
Three microRNAs obtained the highest score of 5 points: miR-197, miR-20a
and miR-451. Four points were attributed to miR-122, miR-19b and miR-19a.
Two additional microRNAs were also selected: let-7e, for its prognostic value
at C0, C2 and C4 and miR-21, for its numerous citations in the literature.
Summary/Conclusions: miR-197, miR-20a, miR-451, miR-122, miR-19a, miR-
19b, let-7e and miR-21 have been selected in this study and are currently quan-
tified into the plasma of the entire biobank. Since then, 19 patients have been
included in the study and the potential of these microRNAs as biomarker are
statistically evaluated. 
E965
COMBINED CHEMOTHERAPY PLUS RADIATION THERAPY IS MORE
EFFECTIVE IN LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA OF
THE TONSIL
S.-N. Lim1,*
1Internal Medicine, Haeundae Paik Hospital, Busan, Korea, Republic Of
Background: Primary extranodal non-Hodgkin’s lymphomas of the head and
neck account for 10-20% of all non-Hodgkin’s lymphomas. Primary tonsillar
lymphoma accounts for less than 1% of head and neck malignancies, although
the tonsil is the most common primary extranodal site of head and neck non-
Hodgkin’s lymphomas.
Aims: The purpose was to evaluate the prognostic factors and treatment out-
come of patients with diffuse large B-cell lymphoma (DLBCL) of the tonsil.
Methods: In all, 114 patients with DLBCL of the tonsil with stage I or stage II,
treated at multicenter in Korea, from September 1995 to April 2011, were includ-
ed. The median age was 59 years and the majority of patients (61%) were male.
Systemic symptoms were present in 6% of patients. International prognostic
index (IPI) score was 0 in 54 patients (48%), 1 in 40 (35%), 2 in 14 (12%), and
3 (3%). Ten patients (8%) showed elevated level of lactate dehydrogenase
(LDH). Treatment consisted of a combination of chemotherapy (CTx) and radio-
therapy (RTx) for 38 patients (34%) and 72 patients (65%) received CTx only.
Among those receiving RTx, the median RTx dose was 39 Gy.
Results: After median follow-up of 32 months (range,0.4-106 months), event
free survival (EFS) and overall survival (OS) were 25.9% and 42.5%, respec-
tively. Significant prognostic factors included: age (≥ 60 year-old vs <60 year-
old), LDH level (> upper normal limit and ≤upper normal limit), IPI score (0-1 vs
2-3), and treatment (CTx plus RTx vs CTx only). On multivariate analysis; LDH
level (hazard ratio [HR], 10.522; 95% confidence interval [CI], 2.548-43.449,
p=0.001) and treatment (HR, 12.393; 95% CI 2.151-71.410) were independent
prognostic factor of EFS and age (HR, 8.920; 95% CI 1.089-73.053, p=0.043),
LDH (HR, 8.316; 95% CI 1.914-36.127, p=0.005), and treatment (HR, 8.943;
95% CI 1.089-73.425) retained statistical significance in OS.
Figure 1.
Summary/Conclusions: LDH level and age significantly influence outcome. A
combined modality treatment, consisting of CTx and RTx, results in a satisfac-




SEQUENTIAL TREATMENT WITH BENDAMUSTINE, RITUXIMAB AND
DEXAMETHASONE FOLLOWED BY RITUXIMAB CONSOLIDATION AND
LENALIDOMIDE MAINTENANCE FOR FRAIL ELDERLY PATIENTS WITH
AGGRESSIVE B-NON HODGKIN LYMPHOMA
L. Pezzullo1, L. Mettivier1, A. Bruno1, R. Bianco1, S. Annunziata1, R. Fontana1,
B. Serio1, C. Martorelli1, R. Guariglia1, R. Rosamilio1, B. Marcelli Graziosi1,
C. Selleri1,*
1Hematology, AUO San Giovanni di Dio e Ruggi D’Aragona, Salerno, Italy
Background: Frail elderly patients with aggressive B non-Hodgkin Lymphoma
(a-B-NHL) in most cases show comorbidities such as to preclude the use of
antracycline-based standard regimen. Although significant advances have
recently been achieved in the therapy of older patients with a-B-NHL, there is
still need for treatment strategies able to overcome the impact of drug toxicity
in elderly frail patients. 
Aims: The safety and efficacy of bendamustine and rituximab plus dexametha-
sone (RD-Benda) regimen were prospectively investigated in 14 elderly and
frail patients with newly diagnosed a-B-NHL.
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Methods: Fourteen (4 female, 10 male) consecutive frail elderly patients (medi-
an age: 79 years; range 68-86 years) with a-B-NHL (11 DLBCL, 1 Burkitt NHL,
1 Burkitt-like NHL and 1 Mantle cell lymphoma) were enrolled in a phase II
study with bendamustine 70mg/m2 i.v. on days 1 and 2, rituximab 375mg/m2
i.v. on day 1and oral dexamethasone 20mg total dose on days 1-4 for four
cycles. Frailty criteria were age > or =80 years, or age > or =70 years associated
with three or more grade 3 comorbidities or at least one grade 4 comorbidity
according to the cumulative illness rating scale (CIRS), as well as not self-suf-
ficient or the presence of geriatric syndromes.
Results: Patients who showed complete (CR) or partial response (PR) after
the fourth induction cycle of RD-BENDA started a consolidation course with
four weekly doses of rituximab (375mg/m2 i.v.) followed, in the case of persist-
ence of CR or PR, by a maintenance treatment with monthly courses of
lenalidomide (10mg/m2, days 1-21). All patients performed G-CSF prophylaxis
to avoid febrile neutropenia. Patients with progressive disease after RD-BENDA
started maintenance therapy with monthly courses of full dose lenalinomide.
PET-CT scans were performed for the assessment of therapy response after
RD-BENDA induction course and after rituximab consolidation. After a median
follow-up of 6 months (range 2-18), the overall response rate was 81%, with
CR and PR of partial response rates of 63 (n=7) and 21% (n=2) respectively.
Two patients died due to multiple organ failure and disease progression after
1 and 8 months from diagnosis, respectively. In our frail and elderly patient
cohort, the sequential treatment strategy was well-tolerated. After R-BENDA
cycles, grade II infectious disease was observed in 2/11 patients (18%) and
DNA-CMV reactivation was detected in other 2 additional patients (18%). How-
ever, 2 out of five patients who started maintenance lenalidomide treatment
discontinued therapy for renal and hematological grade 3 toxicity. At the time
of analysis, the estimated median 18-month progression free survival (PFS)
and overall survival (OS) were 75 and 66%, respectively.
Summary/Conclusions: Our preliminary data show that sequential treatment
with RD-BENDA followed by four weekly doses of rituximab and finally by
lenalidomide maintenance is a feasible and safe therapy option in frail elderly
a-B-NHL patients, but needs to be assessed in a larger subsequent trial.
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CLINICAL RELEVANCE OF SARCOPENIA IN DIFFUSE LARGE B-CELL
LYMPHOMA - TWO ARE BETTER THAN ONE
S.-I. Go1, M.J. Park2, G.-W. Lee1,*
1Internal Medicine, 2Radiology, Gyeongsang National University School of
Medicine, Jinju, Korea, Republic Of
Background: Sarcopenia is known to be associated with poor clinical outcome
in patients with diffuse large B-cell lymphoma (DLBCL). There is no consensus
concerning the optimal method to define sarcopenia in DLBCL.
Aims: In this study, given the uncertainty about the optimal SMI to define clin-
ically meaningful sarcopenia in DLBCL, we compared the characteristics and
clinical outcome between sarcopenic patients determined by L3 skeletal muscle
index (L3-SMI) and those determined by pectoralis muscle SMI (PM-SMI) who
were treated with standard front-line R-CHOP therapy. Furthermore, the syn-
ergistic role of L3- and PM-SMIs as prognostic markers was also investigated.
Methods: We retrospectively reviewed 193 DLBCL patients treated with ritux-
imab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) therapy. Sarcopenia was classified by the region where the pretreat-
ment skeletal muscle index (SMI) was measured.
Results: Both the sarcopenia-L3 and sarcopenia-pectoralis muscle (PM)
groups had increased incidences of severe treatment-related toxicities and
treatment discontinuation compared with the non-sarcopenia-L3 and non-sar-
copenia-PM groups, respectively. The sarcopenia-L3 and non-sarcopenia-L3
groups had 5-year overall survival (OS) rates of 40.5% and 67.8% (p<0.001),
respectively. The sarcopenia-PM and non-sarcopenia-PM groups had 5-year
OS rates of 35.9% and 69.0% (p<0.001), respectively. When the sarcopenia-
L3 alone and sarcopenia-PM alone groups were compared, there were no dif-
ferences in baseline characteristics, treatment toxicity, or survival. In multivari-
ate analysis, when compared with the non-sarcopenia-both group, OS was
significantly worse in the sarcopenia-both group (HR, 2.480; 95% CI, 1.284-
4.792; p=0.007), but not in patients with either sarcopenia-L3 alone or sar-
copenia-PM alone (p=0.151).
Summary/Conclusions: L3- and PM-SMIs are equally useful to define sar-
copenia, which is related to intolerance to R-CHOP therapy and to worse sur-
vival in patients with DLBCL. More prognostic information can be obtained
when these two SMIs are combined to define sarcopenia.
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INTENSIFIED TREATMENT REGIMENS IMPROVE EVENT-FREE AND
OVERALL SURVIVAL IN YOUNGER NEWLY DIAGNOSED HIGH-RISK
PATIENTS WITH B-LARGE CELL LYMPHOMA; A RETROSPECTIVE
OBSERVATIONAL STUDY OF KROHEM
S. Basic-Kinda1,*, M. Lucijanic2, I. Hude1, Z. Prka2, Z. Mitrovic2, I. Radman1,
T. Valkovic34, D. Radic-Kristo56, D. Lozic7, D. Nemet8, V. Pejsa29, I. Aurer19
1Division of Hematology, Department of Internal Medicine, University Hospital
Centre Zagreb, 2Division of Hematology, Department of Internal Medicine, Uni-
versity Hospital Dubrava, Zagreb, 3Division of Hematology, Department of Inter-
nal Medicine, University Hospital Centre Rijeka, 4Medical School, University
of Rijeka, Rijeka, 5Division of Hematology, Department of Internal Medicine,
University Hospital Merkur, Zagreb, 6Medical School, University of Osijek, Osi-
jek, 7Division of Hematology, Department of Internal Medicine, University Hos-
pital Centre Split, Split, 8KroHem, 9Medical School, University of Zagreb,
Zagreb, Croatia
Background: Standard therapy for newly diagnosed B-large cell lymphoma
(B-LCL) is R-CHOP. Patients with high-risk disease have unsatisfactory out-
comes. Non-randomized trials have suggested that intensified regimens, such
as R-CHOEP14 and DA-R-EPOCH, improve treatment results in younger
patients. 
Aims: We performed this analysis to compare response rates, event-free (EFS)
and overall survival (OS) rates of newly diagnosed patients with high-risk dis-
ease treated with R-CHOP21 and more intensive regimens (R-CHOEP14 and
DA-R-EPOCH).
Methods: Outcomes of B-LCL patients younger than 60 with aaIPI ≥2 treated
at two different centres with R-CHOEP14 and DA-R-EPOCH were collected ret-
rospectively from patient files and compared to outcomes of patients with same
characteristics treated with R-CHOP21 from the registry of KroHem, the Croatian
Cooperative Group for Hematologic Diseases. All three regimens were admin-
istered according to standard guidelines for 6-8 cycles. Patients in PR or with
initial bulky disease were irradiated after the end of systemic treatment. Twelve
patients treated with DA-R-EPOCH were autografted in 1st remission.
Results: 54 patients were treated with R-CHOP21, 40 with R-CHOEP14 and
22 with DA-R-EPOCH. R-CHOEP14 and DA-R-EPOCH treated patients did
not differ in response rates, EFS and OS and were grouped together for further
analysis. R-CHOP treated patients had less frequently bulky disease (25% vs
49%, P=0.007) than more intensively treated patients; there was no difference
in age, gender, stage, elevated LDH or PS ≥2. Patients receiving R-CHOP had
similar response rates as those receiving more intensive regimens (80% vs
85%, P=0.405), but inferior EFS (HR 2.12, 95% C.I. [1.09-4.12], P=0.028) and
OS (HR 2.15, 95% C.I. [1.07-4.3], P=0.034) (Figure 1). 5-year EFS rates were
58% and 78% and 5-year OS rates 60% and 80% for R-CHOP21- and more
intensively treated patients, respectively. Differences in outcomes between R-
CHOP and intensified regimens remained significant in a multivariate Cox
regression model adjusted for age, gender and presence of bulky disease (HR
2.45, 95% C.I. [1.11-5.4], P=0.026 for OS and HR 2.46, 95% C.I. [1.16-5.24],
P=0.019 for EFS).
Figure 1.
398 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Summary/Conclusions: Our data suggests that the addition of etoposide to
R-CHOP and increase in dose-intensity improve EFS and OS of younger
patients with newly diagnosed high-risk B-LCL. R-CHOEP14 and DA-R-EPOCH
seem to be similarly effective in this setting.
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HIGH COMORBIDITY INDEX ALONG WITH HIGH NCCN-IPI STRONGLY
INFLUENCE SURVIVAL OF DIFFUSE LARGE B CELL LYMPHOMA
PATIENTS: SERBIAN LYMPHOMA GROUP EXPERIENCE
J. Jelicic1,*, D. Antic2, M. Todorovic Balint2, B. Andjelic2, O. Markovic3,
I. Petkovic4, V. Nikolic5, J. Bila2, V. Djurasinovic2, A. Sretenovic1, V. Vukovic1,
M. Smiljanic1, S. Sretenovic6, B. Mihaljevic2
1Clinic of Hematology, Clinical Center of Serbia, 2Clinical Center of Serbia, Uni-
versity of Belgrade, Clinic of Hematology, 3Clinical Hospital Center “Bezanijska
Kosa”, University of Belgrade, Belgrade, 4Clinic of Oncology, University Clinical
Center Nis, 5Clinic of Hematology, Clinical Center Nis, Nis, 6Clinic of Hematol-
ogy, Clinical Center Kragujevac, Kragujevac, Serbia
Background: A few studies have validated the prognostic significance of the
NCCN International Prognostic Index (NCCN-IPI) so far. However, some
patients with low risk according to NCCN-IPI have poor survival, and thus clin-
ical parameters, that might better characterized patients within risk groups,
need to be analyzed. 
Aims: The aim of this study was to evaluate prognostic significance of current
indexes such as International Prognostic Index (IPI), NCCN-IPI, and the influ-
ence of comorbidities on the overall survival (OS) of patients with newly diag-
nosed diffuse large B cell lymphoma (DLBCL). 
Methods: A total of 708 patients (363 males/345 females) with the median age
of 58 years (range 18-89) were included in the study. Majority of patients
received R-CHOP (Rituximab, Cyclophosphamide, Doxorubicine, Vincristine,
Prednisone) protocol, 652 (92.1%), while 29 (4.1%) received R-EPOCH (Rit-
uximab, Etoposide, Cyclophosphamide, Doxorubicine, Vincristine, Prednisone),
and 27 (3.8%) received R-CVP (Rituximab, Cyclophosphamide, Vincristine,
Prednisone). 
Results: According to the Ann Arbor classification, stage I and II had 332
patients (46.9%), while stage III and IV had 376 patients (53.1%). Bulky disease
was present in 201 patients (28.4%), and B symptoms in 437 patients (61.7%).
Poor European Cooperative Oncology Group (ECOG) performance status (≥2)
had 145 patients (20.5%). Bone marrow involvement was present in 97 patients
(13.7%). At least one comorbid condition had 309 patients (43.6%), while high
Charlson Comorbidity Index (CCI) had 44 patients (6.2%). Majority of patients
had cardiovascular disorders (223, 31.5%), endocrinological (63, 8.9%), neu-
rological (20, 2.8%), reumatological (19, 2.7%), previous malignancy (19, 2.7%),
pulmonary (18, 2.5%), psychiatric (13, 1.8%), nephrotic (8, 1.1%), autoimmune
(6, 0.8%), and other (13, 1.8%). According to IPI, low, low intermediate, high
intermediate and high risk had 332 patients (46.9%), 174 (24.6%), 132 (18.6%),
and 70 (9.9%), respectively, while according to NCCN-IPI, 139 (19.6%) patients
had low risk, 335 (47.3%) low intermediate, 198 (28.0%) high intermediate,
and 36 (5.1%) high risk. Overall treatment response (ORR) was achieved in
615 patients (86.9%). Disease relapse was confirmed in 116/615 patients
(18.9%). The patients with B symptoms (Log Rank=18.50, p<0.0001), and bulky
disease (Log Rank=14.79, p<0.0001) had inferior OS compared to those with-
out B symptoms or bulky disease. All parameters incorporated in IPI, as well
as in NCCN-IPI, were significantly associated with OS (p<0.01). Moreover, the
patients with at least one comorbidity had inferior OS (Log Rank =5.41, p=0.20),
as well as those with high CCI ≥2 (Log Rank =7.59, p=0.006). Regarding OS,
IPI (Log Rank=97.36, p<0.0001), and NCCN-IPI (Log Rank=102.29, p<0.0001)
confirmed its prognostic significance. Furthermore, the patients with high CCI
had significantly inferior median OS in the high risk group according to IPI (19
months vs 37 months), and NCCN-IPI (12 months vs 19 months).
Summary/Conclusions: NCCN-IPI represents useful prognostic index in DLB-
CL patients, and can better describe patients within risk groups, compared to
IPI. Moreover, comorbidities contribute to inferior survival through frailty, drug
dose reduction and poorer tolerability. 
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SUBSTITUTING DOXORUBICIN WITH ETOPOSIDE IN R-CHOP RESULTS
IN A REGIMEN WITH SIMILAR EFFICACY FOR TREATMENT OF NEWLY
DIAGNOSED ELDERLY PATIENTS WITH B-LARGE CELL LYMPHOMA
(B-LCL)
I. Hude1,*, S. Basic-Kinda1, I. Radman1, S. Dotlic2, M. Kralik3, M. Vodanovic1,
P. Roncevic1, L. Galunic-Bilic4, M. Dobrenic56, A. Ostojic1, D. Dujmovic6,
I. Aurer16
1Division of Hematology, Department of Internal Medicine, 2Department of
Pathology and Cytology, 3Department of Radiology, 4Department of Oncology,
5Department of Nuclear Medicine, University Hospital Centre Zagreb, 6Medical
School, University of Zagreb, Zagreb, Croatia
Background: R-CHOP is standard front-line treatment for B-LCL. However,
anthracycline-induced cardiac toxicity limits its use in elderly and patients with
preexisting heart disease. R-CEOP, in which doxorubicin is substituted with
etoposide, has been suggested as a potential solution of this problem, but
reports on the efficacy of this regimen vary substantially, especially in patients
with non-GC DLBCL. We have been using this regimen regularly for front-line
treatment of patients with B-LCL and preexisting heart disease and present
here our experience.
Aims: To compare outcomes of newly diagnosed patients with B-LCL treated
at a single institution with R-CEOP and R-CHOP.
Methods: We performed a retrospective analysis of all newly diagnosed B-
LCL patients treated with R-CEOP at our centre from 2011 to 2016 and com-
pared them to patients 60 years or older treated during the same period with
R-CHOP, the standard regimen used at our centre for non-frail elderly without
significant cardiac comorbidities. The dose of etoposide in R-CEOP was
50mg/m2 iv or 100mg/m2 orally daily for 3 days. Both regimens were given
every 3 weeks for 6-8 cycles. Patients with initial bulky disease or in PR after
systemic treatment were irradiated.
Results: 31 patients, 15 male and 16 female, received R-CEOP and 48, 25
male and 23 female, R-CHOP. Patients in the former group were older (median
age 77 y, range 58-87 vs median age 66 y, range 60-83), had more often low
performance status (81% vs 31%) and advanced disease (84% vs 54% stage
3 and 4) resulting in a significantly higher proportion of patients with IPI 3-5 (74%
vs 40%, p=0.019). Proportions of patients with increased LDH were similar
between the groups. There were no significant differences in frequency of grade
3-4 toxicity between the regimens; 48% of patients in both groups required emer-
gency hospitalization; thrombocytopenia or anemia occurred in 16% of R-CEOP
and 23% R-CHOP treated patients, infections in 32% and 31% and cardiovas-
cular events in 16% and 21%. However, 7 patients (23%) in the R-CEOP group
died during treatment due to adverse effects in comparison to 4 (8%) in the R-
CHOP group. Efficacy was similar, 65% responded to R-CEOP and 79% to R-
CHOP. After a median follow-up of survivors of 27 mo, 3y-OS was 55% in the
R-CEOP group and 52% in the R-CHOP group; 3-y EFS was 50% and 50%,
respectively (figure). Outcomes of patients with GC and non-GC DLBCL cate-
gorized according to Hans’s algorithm were similar irrespective of treatment.
Figure 1.
Summary/Conclusions: Long-term outcomes of newly diagnosed B-LCL
patients treated with R-CEOP seem as good as those achieved with R-CHOP
irrespective of cell of origin. Observed differences in treatment-related mortality
were most probably caused by differences in age, comorbidities and perform-
ance status. R-CEOP should be considered as a regimen of choice for B-LCL
patients with cardiac contraindications for anthracycline treatment.
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POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: A SINGLE-
CENTER CASE SERIES
C. De Miguel1,*, B. Navarro1, J. Martín2, P. Martín2, G. Anze1, A. Alarcón1,
R. Forés1, C. Bellas2, J.R. Cabrera1
1Hematology, 2Pathology, Hospital Universitario Puerta de Hierro Majadahon-
da, Majadahonda, Spain
Background: Post-transplantation lymphoproliferative disease (PTLD) is a
complication of both solid organ transplant (SOT) and haematopoietic cell
transplant (HCT) and represent a very heterogeneous group.
Aims: The objective of this study is to evaluate the epidemiology, clinical fea-
tures, characterization and therapeutic management of this disease.
Methods: We evaluated a total of 52 patients diagnosed between May 1995
and February 2017. We analyzed the following data: type of transplantation,
immunosuppression time from transplantation to lymphoma diagnosis, clinical
stage, response to treatment and survival. We classified them morphologically
according to the WHO criteria (2016 revision), using immunohistochemical and
molecular techniques and their relationship with the Epstein-Barr virus (EBV)
by studying the expression of EBERs. We correlated clinical data with mor-
phological, immunohistochemical and molecular results.
Results: Among the 52 patients, 31 were men (59.6%) and 21 women. PTLD
after SOT were 45 (86.5%), of which 16 were after liver transplant (35.6%), 14
cardiac (31.1%), 9 pulmonary (20%), 4 renal (8.9%) and 2 double (cardiac-
pulmonary and cardiac-renal) (4.4%). There were 7 PTLD after HCT, 2 identical
HLA family donor, 2 unrelated donor, 2 dual umbilical cord blood and 1 autol-
ogous. Of the 52 PTLD, 48  were B lymphomas (92.3%), of which 26 were dif-
fuse large B-cell lymphomas (DLBCL) (54.2%), 7 polymorphic (14.6%), 7 low-
grade (14.6%), 4 Burkitt lymphomas (8.3%), 1 Hodgkin’s lymphoma (2.1%)
and 3 were non-classifiable. Other 4 PTLD were T lymphomas (6.7%), 2
anaplastic, 1 T/NK lymphoma, and 1 gamma/delta T lymphocytosis. 35/52
PTLD were EBV + (67.3%). The median time of immunosuppression was 123
months in renal transplant, 93 months in liver, 85.5 months in cardiac, 51
months in lung and 3 months in HCT. Histologically, it was 96 months in T lym-
phomas and 80 months in B lymphomas, being 51 months in EBV + and 124
months in EBV-. Fifty percent of Burkitt lymphomas were diagnosed after lung
transplant, while 85% of low-grade lymphomas were diagnosed after liver trans-
plant. Clinical stage was III/IV in 73% of the patients (38). Among the 52, 45
received treatment (86.5%), 37 with immunochemotherapy (82.2%) and 8 with
Rituximab (17.8%). Three patients responded to reduction of immunosuppres-
sion (5.8%) and 3 did not receive any treatment for early death (5.8%). At the
time of writing, 19 patients remain alive (36.5%) and 33 have died. The median
survival of these patients was 19.5 months (0-198).
Summary/Conclusions: PTLD constitute a very heterogeneous group. Its
appearance is much earlier in the HCT than in the SOT and, within this latter
group, it is earlier after lung transplant and later after renal transplant. The
most common type in our series is DLBCL. The majority are related to EBV, so
post-transplant monitoring is essential, and its diagnosis is earlier than in EBV-
. Most low-grade lymphomas appear post-liver transplant, either in relation to
virus C or with autoimmune diseases. Survival is significantly lower than in
other primary LPS. :AR-SA’>We analyzed the following data: type of trans-
plantation, immunosuppression used in both induction and maintenance,
immunosuppression time from transplantation to lymphoma diagnosis, clinical
stage, response to treatment and survival. We classified them morphologically
according to the WHO criteria (2016 revision), using immunohistochemical and
molecular techniques and their relationship with the Epstein-Barr virus (EBV)
by studying the expression of EBERs. We correlated clinical data with mor-
phological, immunohistochemical and molecular results.
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SURVIVAL OUTCOMES AFTER FIRST-LINE THERAPY IN DIFFUSE LARGE
B-CELL LYMPHOMA (DLBCL) USING A UNITED STATES (US) ELECTRONIC
MEDICAL RECORD (EMR)-BASED COHORT
A. Galaznik1,*, J. Bell1, L. Hamilton2, A. Ogbonnaya2, A. Raju2, K. Hennenfent2,
M. Eaddy2, Y. Shou1
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Phar-
maceutical Company Limited, Cambridge, 2Xcenda LLC, Palm Harbor, United
States
Background: In the rituximab era, the recommended first-line therapy (1LT) in
DLBCL patients who can tolerate combination therapy is rituximab combined with
chemotherapy. For refractory/relapsed disease, high-dose chemotherapy with
stem cell transplant, combination chemotherapy, or single-agent rituximab are
considered. While the efficacy of rituximab has been shown in clinical trials, few
studies have evaluated survival outcomes in patients seen in routine clinical care.
Aims: We evaluated survival outcomes in a US population of newly diagnosed
DLBCL patients seen in routine clinical care.
Methods: In this retrospective study, adult patients ≥18 years old with newly
diagnosed DLBCL were identified from the Humedica, a large US electronic
medical record database, between 01/01/08 and 07/31/15. DLBCL diagnosis
was determined by the presence of ≥1 inpatient record or ≥2 outpatient records
with DLBCL diagnosis codes; the first DLBCL record served as the index date.
Following the index date, initiation of 1LT for DLBCL was required. For the
assessment of the survival outcomes, patients were evaluated from the date of
treatment initiation until death, loss to follow-up, or end of study (09/30/15).
Median progression-free survival (PFS) (defined as initiation of second-line ther-
apy, evidence of supportive care >30 days after the end of a line of therapy, or
death), median overall survival (OS), and PFS and OS rates at 2 years following
initiation of 1LT were evaluated using unadjusted Kaplan-Meier analyses.
Results: 1,436 newly diagnosed DLBCL patients who initiated 1LT met the
patient selection criteria. 54.0% were male, and the mean age was 66.4 years
(SD: 13.7). At baseline, 27.4% of patients had a Charlson Comorbidity Index
of ≥2, and the most common comorbidities were diabetes (20.3%), chronic
pulmonary disease (15.5%), and moderate to severe renal disease (9.5%). In
1LT, 92.1% of patients received combination therapy, with R-CHOP (63.5%)
being the most common combination therapy. 7.9% of patients received
monotherapy upfront, with rituximab (77.2%) being the most commonly used
single agent. At 2 years following initiation of 1LT, the Kaplan-Meier OS and
PFS were 79.2% and 67.3%, respectively. Median OS was not reached, and
median PFS was 53.9 months (95% confidence interval: 45.2, 61.5). OS and
PFS were also compared among patients receiving monotherapy vs combina-
tion therapy in unadjusted analysis. At 2 years, OS was 80.2% for patients
receiving combination therapy vs 67.4% (P=0.0093) for patients receiving
monotherapy. Also at 2 years, PFS was 68.3% for patients receiving combina-
tion therapy vs 55.1% (P=0.0051) for patients receiving monotherapy. 
Summary/Conclusions: In this population of patients with newly diagnosed
DLBCL receiving 1LT, survival outcomes at 2 years were significantly improved
for patients treated with combination therapy vs monotherapy. Future analysis
will explore the differences in clinical characteristics of patients treated with
monotherapy vs combination therapy in the 1LT setting.
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AN EXPERIENCE WITH LONG ACTING FACTOR VIII PROPHYLAXIS IN
PAEDIATRIC AND YOUNG ADULT PATIENTS WITH HAEMOPHILIA A
S. Verma1, A. Tripathi1,*, G. Suri1, N. Kumar1, R. Kushwaha1, A. Kumar1, P. Kumar1
1K G. Medical University Lucknow, Lucknow, India
Background: Hemophilia is an X linked inherited bleeding disorder. Recurrent
Joint bleeds and muscle bleeds are the commonest manifestations leading to
long term comorbidities in hemophilia. High dose factor prophylaxis has been
proven to be very effective in preventing joint problems in western world. We
look for a cost effective and feasible way for Indian patients in terms of reduced
dose and frequency of factor infusion. Data on prophylaxis with low dose long
acting factor infusion on twice weekly dosing schedule is limited.
Aims: To study the efficacy and safety of long acting factor VIII (Eloctate) for
tertiary prophylaxis in pediatric and young adult patients with moderate and
severe haemophilia A.
Methods: Thirty eight patients with moderate and severe haemophilia A without
inhibitors and age range from 1 to 25 years were included in this study. Patients
were initially observed for 4 months during which they received therapeutic
doses of long acting factor VIII, ELOCTATE ( Factor VIII with Fc Fusion Protein)
on episodic basis after clinical bleed. In next 4 months they received prophy-
lactic ELOCTATE, given intravenously at doses of 20 unit/kg body weight on
twice weekly schedule. Annual bleeding rates, school absenteeism, emergency
visits, aspects of quality of life and joint scores were compared during obser-
vation and prophylaxis period. 
Results: Total number of bleeds during observation and prophylaxis period was
607 and 90 respectively. Annual bleeding rate was 47.9 during observation
period and 7.1 during prophylaxis. There was 85.1% reduction in bleeding rates
on prophylaxis. School/college absenteeism was 3.1 days/ month and 0.84
days/month during observation and prophylaxis respectively. Emergency visits
were significantly more during observation. None of the patients developed
inhibitors and two patients had superficial thrombophlebitis during prophylaxis.
Quality of life assessment using KIDSSCREEN QOL questionnaire showed
moderate to marked improvement in quality of life domains during prophylaxis.
Summary/Conclusions: Low dose, twice a week, long acting factor VIII pro-
phylaxis can be a reasonable option for patients with haemophilia A in devel-
oping countries. It significantly reduces joint bleeds, school absenteeism, Joint
scores significantly without risk of inhibitor formation and also improves all
domains of quality of life.
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NOVEL MUTATIONS IN THAI CHILDREN WITH CONGENITAL FACTOR VII
DEFICIENCY
D. Sosothikul1,*, T. Pusongchai1, R. Ittiwut1, P. Komvilaisak2, C. traivaree3,
K. Suphapeetiporn1
1Department of Pediatrics, Chulalongkorn University, Bangkok, 2Department
of Pediatrics, Khon Kaen University, Khon Kaen, 3Department of Pediatrics,
Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
Background: Congenital factor VII (FVII) deficiency is a rare autosomal reces-
sive coagulation disorder resulted from mutations in the FVII gene (F7). The
disease severity is not correlated with FVII levels but might be determined by
molecular defects in F7. 
Aims: To delineate the phenotypic and genotypic characteristics of patients
with congenital FVII deficiency
Methods: We described demographic data, clinical manifestations, and out-
come of patients with congenital FVII deficiency. F7 mutation analysis was per-
formed by PCR-direct sequencing.
Results: Of the ten patients diagnosed with FVII deficiency, five (50%) were
males. The median age (range) at diagnosis was 19 days old (1-730). Consan-
guinity was found in 50% of the patients. Of the nine patients (90%) classified
as severe, six patients presented with intracerebral hemorrhage within the first
month of life, two presented with gastrointestinal bleeding and one presented
with hemarthrosis. There were eight different alterations identified. Four have
been previously reported (c.1091G>A (p.R364Q), c.1238G>A (p.R413Q),
c.1256C>T (p.T419M), and c.681G>T (IVS6+1T)). Four were novel (c.1192G>T
(p.D398Y), c.1313G>T (p.G420V), c.291+2T>C (IVS3+2T>C), and IVS6-2A>G)
and associated with major bleeding especially during infancy.
Summary/Conclusions: This study reported Thai children with congenital FVII
deficiency presented with life-threatening bleeding especially in the first year
of life. Pathogenic including newly identified variants in the F7 gene were detect-
ed in all cases. Genetic counseling can be appropriately provided to reduce
the risk of disease recurrence in the families at risk.
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RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF
A-HYPO-FIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS
C. Santoro1,*, F. Massaro1, E. Baldacci1, G. Ferrara1, A. Ferretti1, R.C. Santoro2,
S. Pasca3, G. Castaman4, F. Peyvandi5, R. Foà1, M.G. Mazzucconi1
1Cellular Biotechnology and Hematology, Hematology Sapienza University,
Rome, 2Oncohaematology Department, Haemostasis and Thrombosis Serv-
ice- Pugliese-Ciaccio Hospital, Catanzaro, 3Center for Hemorrhagic and Throm-
botic Diseases, University Hospital of Udine, Udine, 4Center for Bleeding Dis-
orders, Careggi University Hospital, Florence, Florence, 5Angelo Bianchi Bono-
mi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplan-
tation, University of Milan, Milan, Italy
Background: Afibrinogenemia (AF) and hypo-fibrinogenemia (HF) patients
(pts) experience hemorrhages or thromboses, and the clinical management
can be difficult.
Aims: To obtain information on AF/HF clinical phenotype and management.
Methods: This is a spontaneous, retrospective, multicenter national study. Data
are collected from clinical records.
Results: 2 AF and 12 HF pts have been enrolled (6M, 8F). Median follow-up:
39 months (1-553). Median fibrinogen activity/antigen level: 78mg/dL (0-
150)/73mg/dL (0-140). Five pts experienced epistaxis, hematomas, ecchi-
moses, menometrorrhagia, intra-abdominal bleeding, gum bleeding, hemarthro-
sis. Fresh frozen plasma, fibrinogen concentrate (FC), cryoprecipitate, whole
blood, tranexamic acid were administered in the majority of these events. One
ischemic stroke, 1 lower limb arterial and 1 cerebral sinus thrombosis, 1con-
comitant aortic and inferior vena cava thrombosis occurred: 3 events during
FC therapy, 1 during puerperium. Heparin, low molecular weight heparin
(LMWH), anti-platelet agents, fibrinolytic agents, warfarin were then adminis-
tered. One gastrectomy, 1 lower limb amputation, 5 gynecological, 1 otorhino-
laryngological and 1 plastic surgery were performed in 2AF and 3 HF pts: in AF
pts, FC or FFP prohylaxis was administered while in HF pts was not. Bleeding
was observed after 2 surgeries performed without prophylaxis. Eight pregnan-
cies were initiated in 3 HF women. Two spontaneous deliveries (SD) and 2
cesarian sections (CS) were performed; 4 abortions occurred. FC prophylaxis
and LMWH were administered during pregnancy in 3 and 4 cases, respectively.
One venous thrombosis, 2 hemorrhages, 1 DIC and 4 complicated pregnancies
were recorded. FC was administered at delivery and LMWH during puerperium,
for the 2 CS. No complications at delivery occurred.
Summary/Conclusions: AF and severe HF pts experience severe hemor-
rhagic/thrombotic events. The intervening clinical situations are difficult to man-
age. Further large scale data collections are necessary in order to provide
useful information to better characterize and manage patients suffering from
these rare diseases.
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RETROSPECTIVE REVIEW OF FOUR DAYS OF VON WILLEBRAND’S
FACTOR AS SURGICAL PROPHYLAXIS IN VON WILLEBRAND’S DISEASE
S. Bal1,*, M.K. Riaz1, D. Peters1, J. Palascak1, S. Girnius1
1Hematology and Oncology, University of Cincinnati Medical Center, Cincinnati,
United States
Background: Von Willebrand disease (vWD) is the most common inherited
bleeding disorder that manifests as easy bruising, mucocutaneous bleeding
and excessive hemorrhage with invasive procedures. In 2007, Humate-P, a
lyophilized concentrate of purified VWF and FVIII, was approved in the United
States for treatment and prophylaxis. Current guidelines per National Heart,
Lung, and Blood Institute (NHLBI) Expert Panel recommend 40-60 U/kg pre-
operatively, followed by maintenance dose of 20-40 U/kg for 7-14 days for
major surgery and 5 days for minor surgery. Here, we report a single-institution
experience of a short course of Humate-P as surgical prophylaxis.
Aims: To assess if an abbreviated schedule of Humate-P given as perioperative
dose of 40 U/Kg for 2 days (one dose pre-op and one post op) for extensive
dental procedures and for 4 days (one dose pre-op and for 3 days post-op) for
minor and major surgical procedures as surgical prophylaxis would result in
equi-efficacious hemostasis without compromising patient outcomes.
Methods: We retrospectively identified 202 patients with known diagnosis of
VWD at our institution that underwent surgical procedures requiring prophylaxis
between 2002-2017. Ninety elective surgical events occurred among these
patients that required peri-operative prophylaxis with Humate-P. These patients
were treated with peri-operative dose of 40 U/Kg on D0-1 for extensive dental
procedures and for D0-3 for minor and major surgery. The definition of bleeding
risk was based on NHLBI guidelines.
Results: Eighteen (20%) were males and 72 (80%) were females. Type I VWD
constituted 94.4% (85/90). 84.4% Caucasian patients, 8.8% African American,
1.1% South Asian. Twenty-nine (32.2%) procedures were categorized as major
surgeries, 51 (56.6%) were minor and 2 (2%) uncomplicated dental procedures.
Eighty-four (93.3%) achieved excellent hemostatic efficacy defined as clinical
hemostasis within normal limits. Six (6.6%) surgeries had good hemostatic effi-
cacy defined as slight oozing. Five (6%) patients required blood transfusions
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(1-3 units packed red blood cells). 100% excellent-good outcomes similar to
longer factor replacement schedules were noted. No deaths or thromboembolic
events were noted. One patient required re-admission for post-op hematoma
following gynecologic procedure. Thirty-four (37.7%) patients were discharged
either same day or after overnight observation. Von Willebrand factor (VWF)
is necessary to form a platelet plug by recruiting Factor VIII and platelets to
damaged vessels walls. We believe that four days is sufficient time for the for-
mation a stable platelet plug and further downstream hemostasis is presumably
VWF-independent. Here, we demonstrate safety and efficacy of a two to four
day regimen of Humate-P, with only one person requiring re-admission for a
post-operative hematoma. Current guidelines for surgical prophylaxis of VWD
are based on expert opinion and lack level 1 evidence. Prolonged exposure
may place patients at risk for unnecessary side effects, including thromboem-
bolism and protracted hospitalization, and also causes financial toxicity. One
unit of Humate-P costs 1.2 USD, which translates to enormous cost savings.
Cumulatively, we were able to save ~1.5million USD in these 90 surgical events
using our abbreviated schedule.
Summary/Conclusions: Perioperative dose of 40U/Kg for 2 days (one dose
pre-op and one post op) for extensive dental procedures and for 4 days (one
dose pre-op and for 3 days post-op) for minor and major surgical procedures
are associated with excellent hematologic outcomes and significant cost sav-
ings. However, this is single institutional data with limited number of patients
and there remains a need for further studies to better define the exact dosing
and duration of surgical prophylaxis. 
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AUDIT ON MANAGEMENT OF HIGH INTERNATIONAL NORMALIZED
RATIO (INR) IN WARFARINISED INPATIENTS
H. Hendra1, V. Gorur1,*, W. Nagi1
1Haematology, Broomfield Hospital, Chelmsford, United Kingdom
Background: Warfarin is the commonest used oral anticoagulant with an effec-
tive antidote. The British Committee for Standards in Haematology guidelines
recommend administration of 25-50µg of four factor Prothrombin Complex Con-
centrate (PCC) and intravenous (IV) Vitamin K 5mg for patients with major
bleeding, 1-3mg of Vitamin K intravenously for those with minor bleeding and
1-5mg of Vitamin K orally for patients with INR >8 and who have no signs of
bleeding.
Aims: The aim of this audit was to compare our hospital’s performance against
the above guidelines. 
Methods: A total of 76 patients admitted between 01/08/2015-31/01/2016 were
analysed retrospectively. 
Results: There were 103 incidents with INR level 5-8 and 24 with INR >8 in
these 76 inpatients. Bleeding was documented in 18/127 cases, which included
6 incidents of major and 12 incidents of minor bleeding. In major bleeding, war-
farin was withheld and Vitamin K administered. However, 4/6 (66.7%) of these
patients got a dose different to 5mg advocated. Also, PCC was prescribed in
only 50% of these patients. While 9/12 (75%) patients with minor bleeding
received Vitamin K, only 3 of these 9 patients received the recommended dose
of 1-3mg IV. Vitamin K was unnecessarily given to 9/83 (10.8%) non-bleeders
with an INR between 5-8. Additionally, the recommended dose and route of
administration of Vitamin K 1-5mg PO was followed only in 7/16 (44%) of non-
bleeders with INR >8. 
Summary/Conclusions: Our audit highlighted that there is less than 100%
compliance in the recommended dose and route of vitamin K administration.
A flowchart containing the guidelines will be designed to improve the manage-
ment of high INR. To increase the awareness of this issue, teaching sessions
for junior doctors and nursing staff are planned. A re-audit will be conducted
once these steps are in place. 
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NOVEL AND RECURRENT F7 MUTATIONS IN KOREAN PATIENTS WITH
COAGULATION FACTOR VII DEFICIENCY
H. Kim1,*, K.-Y. Yoo2, K.-O. Lee3, S.-H. Kim1, H.-J. Kim1
1Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan
University School of Medicine, 2Korea Hemophilia Foundation, 3Samsung bio-
medical Research Institute, Seoul, Korea, Republic Of
Background: Coagulation factor VII deficiency is one of rare hereditary bleed-
ing disorders with relatively limited clinical and genetic data.
Aims: This study aimed to characterize F7 gene mutational patterns of Korean
patients with coagulation Factor VII deficiency including their clinical and lab-
oratory variability.
Methods: F7 gene mutations of total 16 unrelated Korean patients with Factor
VII deficiency were identified by direct sequencing analyses of all exons and
flanking intronic sequences. Variants were assigned according to the recently
released criteria of 2015 ACMG standards and guidelines.
Results: A total of 14 mutations (pathogenic or likely pathogenic) were detected
including four novel mutations (Glu66Lys, c.681+3A >T, Glu66Alafs, Ile290del).
Six (38%) patients have 2 mutant alleles and three mutations were recurrently
identified. The most frequent mutation detected in this study was Cys389Gly
detected in 37% (11/30) patients, validating the data of our previous patient
cohort. 
Summary/Conclusions: Correlation of genetic data with coagulation labora-
tory and clinical findings suggested the presence of modifiers, which warrants
further investigation in a larger cohort of patient for better clinical prediction
and management in this rare bleeding disorder.
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UTILITY OF CD157 IN A FLAER BASED SINGLE TUBE FIVE COLOR
COMBINATION FOR SCREENING OF PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA CLONE
K. Rahman1,*, R. Gupta1, S. Harankhedkar1, T. Gupta1, M. Sarkar1, S. Nityanand1
1Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Luc-
know, India
Background: Fluorescent Aerolysin (FLAER) based flow cytometric analysis
of polymorphs and monocytes is the gold standard for the screening of parox-
ysmal nocturnal hemoglobinuria (PNH) clone. In recent years CD157 has been
identified as a PNH marker which targets both polymorphs and monocytes. It
can be used in a single tube five color combination to screen polymorphs and
monocytes simultaneously.
Aims: The objective of this study was to analyse the utility and advantage of
CD157 in the PNH screening along with its ability to replace CD24 and CD14.
Methods: Our routine protocol for PNH screening included single tube six color
antibody cocktail in following combination: FLAER-AF488, CD24-PE, CD15-
PerCPCy5.5, CD14-PeCy7, CD64-APC, CD45-APC H7. We assessed the utility
of single tube 5 color combination of FLAER-AF488, CD157-PE, CD15-Per-
CPCy5.5, CD64-APC, CD45-APCH7 for PNH screening and compared the
results with the routinely used 6 color panel. Laboratory cutoff for CD157 was
defined by running 10 samples from healthy individuals. Sensitivity analysis
was assessed in spiking experiments by diluting a PNH positive sample with
large clone size in a serial 10 fold dilution. Inter assay and intra assay precision
analysis was done by running samples in triplicates across different clone size
range and calculating the coefficeint of variance (CV). Correlation of PNH clone
size obtained from CD24/CD14 and CD157 was assessed by analysing a total
of 30 samples across a wide range of PNH clone size (0.06-97.3%).
Results: CD157 was sensitive at the level of 10-4 and better. Frequency of
cells with PNH phenotype in normal samples were found to be <0.002%. The
CVs of intra-/interassay precision analysis ranged from 0.9/2.6% to 3.2/4.64%
for granulocytes and 1.9/2.5 to 5.3/8.9% for monocytes. The PNH clone size
as obtained by CD157 based analysis was highly comparable to those obtained
by CD24/CD14 based assay (R2>0.993). CD157 was found much better than
CD24/CD14 in identifying the type II PNH clones. There was no false positive
or false negative result. The cost of analysis was found to be approximately
15% lesser than the routinely used 6 color assay.
Figure 1.
Summary/Conclusions: CD157 is a robust, reliable and potentially useful uni-
versal marker for PNH screening. Its inclusion in a single tube five color FLAER
based panel is a cost effective approach which is ready to replace CD24/CD14
from routine PNH screening.
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IMMUNOPHENOTYPIC DYSPLASTIC FEATURES IN PATIENTS WITH
APLASTIC ANEMIA
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A. Kohno1, L. Kuzmina1, V. Troitskaya1, Z. Fidarova1, T. Moiseeva1, V. Savchenko1
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of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Fed-
eration
Background: Multicolor flow cytometry (MFC) of bone marrow (BM) is a prom-
ising additional approach to the diagnosis of myelodysplastic syndromes (MDS).
Aplastic anemia (AA) as MDS characterizes by cytopenias and dysplastic fea-
tures in BM by morphology are absent. It is well known that up to 15% of AA
transformed in MDS over time. It is possible to suggest that in some cases of
AA immunophenotypic abnormalities can also be identified. 
Aims: To study and compare the presence of dysplastic features by MFC in
AA and MDS without excess of blasts.
Methods: The study included 14 patients with AA (8m, 6f, median age 33), 28
patients with MDS de novo without excess of blasts by morphology (13m, 15f,
median age 59). MDS group included 3 patients with 5q-syndrome, 4 - RCUD,
3 - RARS, 18 - RCMD. 20 patients with cytopenias constituted the control group
(4m, 16f, median age 42) due to B-12 deficiency anemia, iron-deficiency ane-
mia, Fanconi anemia, hemolytic anemia, β-thalassemia, ITP, hepatitis C, mul-
tiple myeloma, Burkitt’s lymphoma. BM of 33 healthy donors were analyzed for
the reference values . MFC was performed according to International Leukemi-
aNet by 6-color cytometer BD FACSCanto II. We enumerated the proportion of
CD34+ myeloid cells from CD45+ cells (normally <2%), the proportion of CD19+
(B-cell progenitors) from CD34+ cells (normally >5%), the expression of CD34,
CD45, CD117, CD7, CD56 on CD34+ myeloblasts. Among granulocytes we
analyzed: their proportion, granularity, CD14, CD64, CD10, CD56 expression
and patterns CD16vsCD13, CD16vsCD11b, CD13vsCD11b. Among of mono-
cytes we measured: their proportion, CD64, CD56 expression and analyze pat-
terns CD14vsCD36, CD11bvsCD13, CD11bvsHLA-DR. The final MFC conclu-
sion was done by scale Ogata/Wells (van de Loosdrecht, 2013): A - does not
correspond to MDS; B - reveales some features which commonly appears in
MDS; C - results are consistent with MDS.
Results: Among MDS patients without excess of blasts assessment “B” and
“C” scores were obtained in 78.6% (sensitivity). Increased proportion of CD34+
myeloblasts was in 35.7% of cases, increased CD56 and CD7 - in 42.9%. The
most common abnormalities were: increased CD56 (53.6%), abnormal patterns
(39.3%), low granularity (35.7%) in granulocytes; increased proportion (21.4%)
and abnormal patterns (28.6%) in monocytes. 64.3% (n=9) patients with AA
were assessed as “A”, 21.4% (n=3) - “B” and 14.3% (n=2) - “C”. In cases with
“C” abnormal expression of CD117 and expression of CD56 on CD34+ cells
were seen. AA patients with “B” and “C” showed increase expression of CD56,
CD64 and decrease CD10 expression on granulocytes. Abnormal patterns
were less common than in MDS patients. The increased proportion and CD56
expression in monocytes were more frequent than in MDS patients.
All patients not diagnosed with AA, MDS were assessed as “A” (specificity-
100%). But some MFC abnormalities were found in them: abnormal expression
of CD34 (35%) and CD45 (30%) on CD34+ myeloblasts, and increased CD64
expression (20%) on granulocytes (pic.).
Table 1.
Summary/Conclusions: Flow cytometry MDS study with Ogata/Wells scale
has a high sensitivity and specificity. Immunophenotypic abnormalities charac-
terizing dysplastic features can also be found in AA patients up to 35% of cases.
Increased expression of CD56 on CD34+ myeloblasts, granulocytes and mono-
cytes is commonly found in AA patients. Perhaps the appearance of MFC dys-
plastic features foreshadows the MDS-transformation of AA, but requires further
prospective studies.
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SURGICAL MANAGEMENT OF PATIENTS WITH PAROXYSMAL NOCTUR-
NAL HEMOGLOBINURIA (PNH) – DATA FROM THE SPANISH PNH REG-
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Background: Patients with PNH often need surgery due to disease-related
complications. However, surgery, anesthesia, and possible surgical complica-
tions, including inflammation and acidosis, can trigger complement activation,
making surgery an important risk factor for hemolysis (Ando K, et al. Ann Hema-
tol 2012;91:1987-8; van Bijnen ST, et al. Eur J Haematol 2011;87:376-8).
Aims: Here we report data on the clinical management and treatment results
of patients with PNH undergoing surgery. 
Methods: We collected data on 14 surgical interventions of 11 patients (8
males; age, 25-76 years). All patients had a high prevalence of PNH clone
cells (55-99% in PMN) and were receiving eculizumab (ECU). Types of surgery
were: 6 laparoscopic cholecystectomies, a transjugular intrahepatic portosys-
temic shunt, a distal splenorenal shunt, a laparoscopic Achilles allograft liga-
mentoplasty, a gastrectomy, an emergency appendectomy, and 3 urologic inter-
ventions. Ten patients received ECU 900mg, while one (patient E, surgery 6)
received 1200mg since he had developed hemolysis at a previous surgical
intervention (surgery 5). In two cases (patient G, surgery 8; patient H surgery
11), an additional dose of ECU was administered before surgery. Patient H
(surgery 11) had developed hemolysis at previous surgical interventions (surg-
eries 9 and 10). In most cases, either the date of the ECU dose was taken into
account when scheduling surgery or the ECU dose was moved forward to coin-
cide with the date of surgery. The time between the last ECU dose and surgery
was normally one day (range, 1-8).
Results: In nine cases, transfusions were required due to hemorrhagic compli-
cations. Patient I (surgery 12) had a thrombotic event leading to acute myocar-
dial infarction one week after surgery. Increased hemolysis was observed
(increased LDH and/or presence of hemoglobinuria) in five cases (patients E,
H, I and K; surgeries 5, 9, 10, 12 and 14) during the week following surgery.
Two of these patients (patients E and H) later underwent additional surgery
(surgery 6, and surgeries 10 and 11, respectively). The pre-surgical ECU dose
was increased in surgery 6 (patient E) and an extra dose was administrated in
surgery 11 (patient H) and no hemolysis was observed. (See Table 1).
Table 1.
Summary/Conclusions: Our findings lead us to recommend to perform the
intervention within 24 hours of the administration of Ecu in programmed surgery
for which it is necessary to program the dose. While in urgent surgical inter-
ventions put a new dose on the day of the intervention independently of the
previous dose. Also the normal ECU dose could be increased or an extra dose
be administered in order to minimize the risk of hemolysis in high-risk patients
or in those with a previous history of surgery-related hemolysis.
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BINURIA (PNH) PATIENTS WITH OR WITHOUT APLASTIC ANEMIA;
PROSPECTIVE STUDY OF KOREAN PNH COHORT
C.W. Choi1, J.H. Jang2,*, J.S. Kim3, D.-Y. Jo4, J.-H. Lee5, S.-H. Kim6,
Y.-K. Kim7, J.-H. Won8, J.S. Chung9, H. Kim10, J.H. Lee11, M.K. Kim12,
H.-S. Eom13, S.Y. Hyun14, J.-A. Kim15, J.W. Lee16
1Internal Medicine, Korea University Guro Hospital, 2Samsung Medical Center,
Sungkyunkwan University School of Medicine, 3Yonsei University College of
Medicine, Seoul, 4Chungnam National University, Daejeon, 5Asan Medical
Center, Seoul, 6Dong-A University Hospital, Busan, 7Chonnam National Uni-
versity Hwasun Hospital, Hwasun, 8SoonChunHyang University Hospital,
Seoul, 9Pusan National University Hospital, Pusan, 10Ulsan University Hospital,
Ulsan, 11Gachon University Gil Medical Center, Incheon, 12Youngnam Univer-
sity Hospital, Daegu, 13National Cancer Center, Goyang, 14Yonsei University
Wonju College of Medicine, Wonju, 15St. Vincent Hospital, The Catholic Uni-
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Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a hematopoietic
stem cell disease characterized by the intravascular lysis of red blood cells.
PNH patients often have underlying bone marrow failure (BMF), with aplastic
anemia (AA) as the most frequently associated type. Eculizumab, a humanized
monoclonal antibody that binds specifically to human complement protein C5,
has been used in Korea since 2012.
Aims: The purpose of this study was to determine whether eculizumab-treated
patients show clinical benefit and reduced risk of complications regardless of
concomitant AA in a Korean population.
Methods: Forty-six PNH patients ≥18 years of age diagnosed by flow cytometry
and treated with eculizumab for more than 6 months were analyzed in the
prospective Korean PNH registry. Patients were categorized into two groups:
PNH patients with concurrent AA (PNH/AA) and without (classic PNH). Patients
with severe AA/PNH were excluded. Biochemical indicators of intravascular
hemolysis, hematological laboratory values, transfusion requirement, and PNH-
associated complications assessed by the treating physician were reported
every 6 months after enrollment.
Figure 1.
Results: The median age of the study population was 49 years (range, 18-73
years) at eculizumab initiation and the median duration of eculizumab treatment
was 34 months (range, 6-44 months). Median LDH fold x upper limit of normal
was 7.29 (range 2.4-23.7) and GPI-deficient granulocytes was 92.8% (range,
15.7-100%) at the time of eculizumab treatment. PNH-related signs and symp-
toms were thromboembolism (TE, n=19), renal failure (n=20), pulmonary hyper-
tension (n=5), and severe/recurrent abdominal pain requiring opioids (n=17).
Of 46 total patients, 12 (26%) were classified as having PNH/AA and 34 with
classic PNH. There were no substantial differences in laboratory findings, trans-
fusion requirement, or clinical signs and symptoms at baseline between the
two groups. Treatment with eculizumab induced a rapid inhibition of hemolysis.
At the time of 6 month follow-up, LDH level decreased to near normal levels in
all patients and this effect was maintained until 36 months follow-up regardless
of concomitant AA. Mean hemoglobin level significantly increased from the first
6 months of eculizumab treatment, and the effect (hemoglobin above 10 g/dL)
was sustained throughout 36 months in both groups. Transfusion-indepen-
dence was achieved by 54.3% within the first 6 months of treatment and 86.4%
by the last 36 months (83.3% in PNH/AA vs 87.5% in classic PNH). The mean
number of RBC units transfused was significantly reduced from 8.5 units during
the previous 6 months to 1.6 units for the first 6 months in total PNH patients
(Fig). There were no significant differences in clinical outcomes (ie, LDH and
transfusion unit per every 6 months) with eculizumab between the two groups.
All TE (n=19) patients in whom 6 received concomitant anticoagulation therapy
were resolved on the eculizumab; one classic PNH patient had recurrence of
TE at the same site after discontinuation of anticoagulation therapy while on
eculizumab. Among 9 patients who had baseline eGFR less than 60
ml/min/1.73m2, 5 patients (56%) showed improvement of eGFR during the
eculizumab treatment and 4 patients stabilized eGFR.
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Summary/Conclusions: Clinical outcomes with eculizumab were significantly
improved compared with the baseline in patients with both PNH/AA and classic
PNH. This study demonstrated that eculizumab has a beneficial role in the
management of patients with PNH/AA, similar to that of classic PNH, by inhibit-
ing hemolysis and reducing transfusion requirements, thus resulting in the
improvement of clinical signs and symptoms.
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DIAGNOSIS AND FOLLOW-UP OF THE CLONES OF PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA BY FLOW CYTOMETRY
S. Oukid1,*, S. Taoussi1, N. Rekab1, M.T. Abad1
1Hematoloy, EHS ELCC CAC, Blida, Algeria
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a very rare chron-
ic disease associated with a clonal expansion of one or several hematopoietic
stem cells carrying acquired somatic mutations of PIG-A gene resulting in GPI-
AP deficient blood cells and great susceptibility to complement mediated cell
lysis. Diagnostis of PNH is of importance and flow cytometry (FC) is a required
tool for this. We report 33 cases of PNH diagnosed and monitored by FC.
Aims: To show the interest of flow cytometry for the diagnosis and follow-up of
PNH clones in some risky haemopathies.
Methods: A PNH clone has been researched in 234 patients since August
2009 to January 2017. The PNH clone was investigated for bone marrow apla-
sia with or without haemolysis, regenerative hemolytic anemia with negative
direct coombs test (DCT), myelodysplasia (MDS), unexplained cytopenia and
thrombosis. The search for the PNH clone by FC is based on the analysis of
the following monoclonal antibodies: Flear and CD59 with gating on CD45 for
neutrophils, Flear and CD14 with gating on CD64 for monocytes and CD59
with gating on Glycophorin A for red blood cells. We judged that the patient has
an PNH clone when the deficiency is >05% on at least two markers highlighted
on two different lines. FC surveillance is provided in the absence of a deficit or
in the case of a very moderate or single-line deficit.
Results: Out of 234 cases analyzed, 201 cases (85%) showed absence of
PNH clone and 33 cases (14%) had a PNH clone. There are 14 women and 19
men; Sex ratio (M/F) = 1.35, mean age = 42.27 years (17-73). Among patients
that should be screened for positive PNH clone we have bone marrow failure:
25 positive (21,9%) of 114 cases screened, hemolytic anemia with negative
direct coombs test: 4 positive/63 cases (6.34%), thrombosis: 2 positive/28
(7.14%), one negative case of AML2, myelodysplasia with 02 (11.2%) posi-
tive/18 cases and cytopenias: 0 positive/13 cases. The types of PNH was type
II in 3 cases (9%), type III in 24 cases (72.8%) and mixed deficits in 6 cases
(18.2%). The mean degree of CD59 deficiency was 29.4% (5-82) on red blood
cells 48.21% (5-95) on neutrophil (N); the mean degree of Flear was 55.33%
(6-99) on N in 22 cases ; the mean degree of CD14 deficiency on monocytes
was 44% (7-97) in 17 cases, the mean degree of Flear (8 cases) was 51.8%
(12.9-92). During surveillance, PNH clone appeared in 02 cases and clone size
increase in 08 cases (initially less than 2%) and in one case the clone doubled
in size from 54% to 98% and 6 months after the patient developed extensive
thrombosis. In 44 cases, a moderate deficiency <5% was noted on a single
line either N or red blood cells, thus monitoring by FC.
Summary/Conclusions: In our study the clone PNH was noted in 11.2% of
cases of MDS which joins the literature were the rate is 10 to 23%. (1). In the
group where a moderate deficit was observed, there are no biological signs of
haemolysis ; in these cases, the indication of a follow-up of the size of the PNH
clone is then necessary and must include a haemolysis report repeated with
LDH assay; this is verified in our study since in 8 cases of increase in the size
of the clone a thrombosis developed in one case. The follow-up of clone sizes
is important given that there are 8 cases of increase in clone size, and in 01
case the increase was accompanied by thrombosis. This interest was confirmed
by the study of B. Höchsmann who demonstrated in 155 cases of followed
PNH, a significant increase of the clone in 28% of the cases and in 9% of the
cases a new clone appeared. (2). The application of flow cytometry enabled us
to make the diagnosis and to determine the phenotypic profile of PNH clones
and to specify their sizes as well as to follow up the patients. 
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COMPLETENESS AND OTHER CHARACTERISTICS OF REMISSION IN
PATIENTS WITH APLASTIC ANEMIA
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Background: Immune-mediated dysregulation of hemopoiesis is the basis for
pathogenesis of aplastic anemia (AA). Dysbalance of T cell subsets, especially
Th1 and Th2 and produced by them cytokines serves as a possible mechanism
of this phenomenon. It is suggested, that NK-T cells play an important role in
regulation of Th1:Th2 balance. The role of NK-T cells in development of aplasia
of hemoiesis in AA now is broadly studied. Nevertheless, up to this moment,
the features of balance of T lymphocyte subsets, and, especially NK-T cells
during stable and prolonged remission are not characterized yet.
Aims: To evaluate the association of T-, B-, NK и NK-T cell levels of AA patients
with the duration of remission, its completeness, duration of period free of
immunosuppressive therapy (IST) and the size of PNH-clone.
Methods: The studied group included 36 patients with AA in remission, refer-
ence group – 20 patients with primary diagnosed AA. Level of T-, B-, NK and
NK-T cells in peripheral blood (PB) and bone marrow (BM) was evaluated using
5-color flow cytometry (Beckman Coulter, FC-500).
Results: Group of AA patients in remission was divided into subgroups in four
variants: 1) according to the remission duration (<12 months, 12-24 months,
24-36 months, >36 months); 2) completeness of remission: partial (PR) and
complete (CR); 3) duration of IST-free period (<1 year, ≥1 year); 4) PNH-clone
size (0,1-1%, 1-10%, >10%). Levels of Т-, В- and NK cells in AA patients with
remission varied broadly in different subgroups, but there were not revealed
any clear tendency of their dynamics in all assigned subgroups, except for NK-
T cells. In primary AA patients the level of NK-T cells in PB and BM exceeded
normal level 1,8- and 2,2-fold, respectively. In remission lasting less then 12
months NK-T cell level decreased significantly; then, along with increase of
remission duration (24-36 months), it normalised, and in patients with remission
≥36 months it significantly decreased both in PB and BM (data presented in
table 1). In patients with PR, as compared with primary AA patients, NK-T cells
decreased 2,8- and 1,9-fold, respectively, and further in CR this tendency per-
sisted. Duration of IST-free period less than 1 year and ≥1 year was also accom-
panied by a significant and stable decrease of NK-T cells in PB and BM. It is
known that PNH-clone presence is a favourable factor for treatment response
of AA patients. Therefore, it was of interest to study the association of NK-T cell
level in AA remission with the size of PNH-clone. In subgroup with small PNH-
clone (0,1-1%) NK-T cell level was decreased as compared to primary AA
patients, and it significantly decreased further along with growth of PNH-clone
size.
Table 1. NK-T cell level (%) in patients with AA in remission according to
subgroups.
Summary/Conclusions: Thus, in patients with AA the decrease of NK-T cell
level was observed along with recovery of hemopoiesis in all the subgroup vari-
ants. Previously we have shown that the decrease of NK-T cells accompanies
the decrease of TNFα and increase of IL-4. This pattern, taking into consider-
ation our earlier obtained data, may be the evidence of the role of NK-T-cells
in regulation of balance Th1:Th2 and produced by them cytokines.
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A NOVEL DUAL-REAGENT SINGLE TUBE FLOW CYTOMETRIC ASSAY
TO SCREEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
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Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired
hematopoietic stem cell disorder resulting from loss of membrane-bound gly-
cosyl phosphatidy linositol (GPI) anchor protein. The disease is characterized
by heterogeneous clinical phenotypes including intravascular hemolysis,
cytopenia(s), bone marrow hypoplasia and atypical site thrombosis. Screening
guidelines recommend documentation of the lack of at least two GPI-liked anti-
gens on at least two cell lineages. Alexa fluor 488 conjugated fluorescent
Aerolysin (FLAER-AF488) has become a mandatory component in FCM based
PNH assays.
Aims: We have analyzed the feasibility of a novel dual-reagent assay for a
simplified, single tube, cost-effective approach for PNH screening. 
Methods: EDTA anti-coagulated peripheral blood of patients referred to depart-
ment of Hematology with clinical suspicion of classical-PNH/ aplastic anemia,
was tested with a single tube panel of FLAER-AF488/CD33APC. Simultane-
ously, the routine two tube flow cytometry assay (established sensitivity of 0.1%)
used in our lab for PNH screening (FLAER/ CD15/ CD24 for granulocytes and
FLAER/CD33/CD14 for monocytes) was performed in the same sample. Each
tube was run till a minimum of 50,000 granulocytes were acquired or till the
tube ran dry. A cluster of at least 20 FLAER negative events was considered
for reporting PNH-clone positivity in both granulocytes and monocytes. The
granulocyte and monocyte PNH positivity and the respective clone sizes detect-
ed by both the strategies were compared.
Results: A total of 33 patients and 7 healthy controls were analyzed by both
dual-reagent and conventional strategies. Among the thirty-three patients,
twelve patients concurrently showed the presence of PNH clones by both meth-
ods (36%). The rest twenty-one patients were negative for PNH clones in gran-
ulocytes and monocytes by both strategies, indicating complete concordance
at a sensitivity of 0.2% (Chi Square p=0.000). Of the PNH positive cases, the
mean PNH clone sizes among the granulocytes by dual-reagent and conven-
haematologica | 2017; 102(s2) | 405
Madrid, Spain, June 22 – 25, 2017
tional methods were 3.79% (range, 0.2-18.2) and 3.60% (range, 0.1-18.6),
respectively. The mean PNH clone sizes among the monocytes by dual-reagent
and conventional methods were 7.30% (range 0.2-29.4) and 7.32% (range
0.1-28.8), respectively. There was no significant difference in the granulocyte
and monocyte PNH clone sizes determined by both the methodologies
(p=0.000). There were significant correlations between the granulocyte PNH
clone sizes (Pearson’s r=0.993, p=0.000) and the monocyte PNH clone sizes
(Pearson’s r=0.991, p=0.000) detected by both the analysis strategies. 
Summary/Conclusions: This pilot study demonstrates the practical feasibility
of a simple, cost-effective and widely applicable dual-reagent, single tube PNH-
screening assay at a sensitivity of 0.2%.The study needs to recruit patients of
various hematological disorders besides healthy controls, and although seems
effective for analyzing classic and subclinical PNH, the strategy has to be
further standardized to achieve a sensitivity of 0.01%.
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TREATMENT OF REFRACTORY APLASTIC ANEMIA WITH ELTROMBOPAG:
EXPERIENCE OF A CENTER
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Background: Eltrombopag, a thrombopoietin receptor agonist, was approved
in 2008 for the treatment of immune thrombocytopenic purpura. More recently,
benefits demonstrated in the proliferation and maintenance of hematopoietic
stem and progenitor cells (HSTC) led to its use and approval in the treatment
of severe aplastic anemia (AA) refractory to immunossupressive therapy.
Aims: In this report, we evaluated response to eltrombopag in patients with
refractory AA and associated side effects.
Methods: Retrospective analysis of six patients with a diagnosis of aplastic
anemia and thrombocytopenia (platelet count ≤30.000/uL), refractory to
imunossupressive therapy and ineligible for allotransplant, treated with eltrom-
bopag. Patients characteristics, response, clinical evolution and adverse effects
were evaluated.
Results: Four patients were female and median age at diagnosis was 66 years
(36-76). Previous treatments included horse antithymocyte globulin (1),
cyclosporine (4), intravenous immunoglobulin (1), corticosteroids (4) and dana-
zol (1). Treatment with eltrombopag was associated to cyclosporine in four
patients; two cases had chronic renal failure and consequent contraindication
to cyclosporine. The median duration of treatment with eltrombopag at the time
of this analysis was 7 months (3-12). At 3 months, all patients had platelet
counts >30.000/uL (median increase, 16.500/uL). Five patients improved hemo-
globin levels (median increase, 2.2g/dL); 3 of them were previously dependent
on red cell transfusions, and no longer needed transfusions. Four patients
increased neutrophil counts (median increase, 1110/uL). All but one patient
received a maximum dose of 150mg per day. Only one patient needed tempo-
rary discontinuation due to hepatic abnormalities, that were rapidly resolved.
One other patient had mild elevation of liver enzyme levels. No other relevant
side effects occurred.
Summary/Conclusions: Treatment with eltrombopag was associated with
hematologic response of one or more hematopoietic lineage, independence of
blood transfusions and improved quality of life of patients with refractory severe
AA. Except for infrequent and reversible hepatic abnormalities, tolerability was
excellent. Thus, eltrombopag might be used in situations where other measures
have failed in patients who have no indication for allogeneic stem cell trans-
plant. A caution, however, should be taken on the risk for clonal evolution that
should be carefully screened and surveilled.
Chronic lymphocytic leukemia and related
disorders - Biology
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DECREASED EXPRESSION OF ADHESION MOLECULES IN CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) CELLS OF PATIENTS TREATED WITH
IBRUTINIB
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Background: The B-cell receptor (BCR) pathway in CLL plays a well recog-
nized role in the onset and progression of the disease and the resulting devel-
opment of mechanism-driven drugs is revolutionizing the therapeutic manage-
ment. Ibrutinib is a BTK inhibitor that plays an important role in the BCR path-
way and induces several alterations in CLL cells.
Aims: The modulation of the expression of adhesion molecules on the surface
of CLL cells from patients treated with ibrutinib has been evaluated to analyze
the effect of treatment on the relationship between the microenvironment, that
promotes cell survival and proliferation, and the leukemic cells with the conse-
quent cell mobilization and increased drug exposure.
Methods: In a cohort of 101 CLL patients treated with ibrutinib (420mg/die)
and rituximab (375mg/m2/week) in the GIMEMA LLC1114 trial, we evaluated,
before and after 15 days of therapy, the surface expression on leukemic cells
of several adhesion molecules. In detail, using 8 color antibody combinations
(all from Becton Dickinson, BD, San José, CA) we evaluated the MIF expres-
sion (using the FACSCanto II, BD) of CD11a, CD18, CD38, CD40, CD43,
CD44, CD49d, CD62L, CD69, CD80, CD81, CD86, CD154, CD184, CD185
on CD5/CD19+ leukemic cells.
Results: The number of CD5/CD19+ did not increase after 15 days of treatment
(52.8±58.8 vs 53.4±51.5 x 109/L; p=0.36) probably because of the concomitant
rituximab administration, which ‘masks’ the mobilization effect induced by ibru-
tinib. We observed a significant down-modulation of CD62L (461±435 vs
171±146; p<0.0001), a molecule (L-selectin) that has been reported as the key
factor controlling the binding of CLL cells to the endothelial walls in vivo. CD69
expression resulted also significantly decreased (744±784 vs 438±716;
p<0.0041), is expressed on CLL cells in the tissue microenvironment, both in
the bone marrow and in lymph nodes. We observed the significant down-mod-
ulation of the expression of CD43 (3285±2282 vs 2515±1826; p<0.0063); this
antigen is utilized in CLL for the detection of minimal residual disease (MRD)
and does therefore not seem a reliable marker in patients treated with ibrutinib.
On the contrary, CD81 expression, another antigen utilized for MRD detection,
resulted unchanged after 15 days of treatment. CD185 expression was signif-
icantly decreased (1502±1327 vs 804±687; p<0.001), while we unexpectedly
observed the up-modulation of CD184 (2244±2022 vs 3182±1877; p<0.003);
both antigens participate in the BTK signaling pathway. CD40, that interacts
with activated CD4+ T cells, resulted down-modulated (722±467 vs 395±262;
p<0.0001). CD38 and CD49d, when expressed in >20% of the leukemic cells,
resulted significantly (p<0.028 and p<0.021) down-modulated: both molecules
have a role in the crosstalk between the leukemic cells and the microenviron-
ment. No significant changes were detected in the expression of CD11a, CD18,
CD44, CD80, CD86 and CD154.
Summary/Conclusions: Within an ancillary biologic study of the GIMEMA
LLC1114 protocol we observed a significant down-modulation in the expression
of several adhesion molecules on the surface of CLL cells of patients treated
with ibrutinib. Since these molecules promote the binding of the leukemic cells
with the microenvironment, these results help to elucidate the mobilization
process of CLL cells from the different compartments observed with ibrutinib
and support its progressive efficacy over time in controlling the disease. A fol-
low-up clinical analysis will define a possible correlation between these findings




CLL CELLS UNDERGO METABOLIC REPROGRAMMING AND UTILIZE
FREE FATTY ACIDS AS THEIR PRIMARY ENERGY SOURCE
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Background: The gene expression profile of chronic lymphocytic leukemia
(CLL) cells revealed a homogeneous phenotype related to memory B cells
accompanied by an aberrant expression of several proteins. For example,
lipoprotein lipase (LPL), typically expressed in adipocytes, is readily detected
in CLL cells. However, unlike their normal counterparts which are resting cells,
CLL cells do proliferate. What energy source CLL cells use and which metabolic
pathway they recruit is currently unknown. Because the gene expression profile
of CLL cells is skewed towards that of adipocytes, and because they proliferate
at similar rates, we hypothesized that like adipocytes CLL cells utilize free fatty
acids (FFA).
Aims: (A) Determine whether CLL cells are capable of utilizing FFA for energy
production. (B) Determine whether lipid metabolism in CLL is LPL dependent.
(C) Determine why LPL is aberrantly expressed in CLL cells.
Methods: Peripheral blood (PB) and bone-marrow derived lymphocytes were
obtained from previously untreated patients with CLL. Imaging of CLL cells was
done by electron microscopy, and PB lymphocytes were stained for Oil red O.
Confocal microscopy studies helped in determining the cellular localization of
LPL. To study the capacity of CLL cells to utilize FFA we developed an assay
that measured the oxygen concentration in the sera of cultured CLL cells prior
to and after adding FFA. In addition we measured the oxygen consumption of
CLL cells derived from ibrutinib-treated patients. We used chromatin immuno-
precipitation (CHIIP) and luciferase assays to study the binding of STAT3 to
the LPL promoter.
Results: To study whether CLL cells are capable of utilizing FFA we cultured
freshly isolated CLL cells from 20 patients and measured the concentration of
cultured media-dissolved O2 (dO2) prior to and after adding FFA, assuming
that if the cells oxidize the acid, dO2 levels will drop. Indeed, after 48 hours
incubation with FFA dO2 levels were markedly reduced as compared with the
dO2 media levels of CLL cell incubated without FFA. Remarkably, unlike cul-
tured CLL cells, dO2 media levels of cultured normal B cells did not changed.
Intriguingly, the levels of dO2 remained unchanged if CLL cells were incubated
in the presence of FFA and ibrutinib. Similarly, the dO2 levels of CLL cells
obtained from ibrutinib-treated patients remained constant, suggesting that
ibrutinib disrupts the capacity of CLL cells to utilize FFA. Oil Red O staining of
CLL bone marrow smears detected lipid deposits and electron microscopy con-
firmed the presence of lipid vacuoles in the cytoplasm of peripheral blood CLL
cells but not in normal B cells, suggesting that like adipocytes, CLL cells store
lipids in intracytoplasmic lipid vacuoles. Similar to adipocytes CLL cells express
LPL which mediates the uptake of lipid particles into the cells and catalyze the
hydrolysis of triglycerides into FFAs. Indeed, we detected LPL in the cell mem-
brane and in the cytoplasm of CLL cells. Furthermore, using small interfering
RNA (siRNA) we knocked-down LPL mRNA levels and found that LPL-siRNA
reduced the capacity of CLL cells to utilize FFA, suggesting that the lipid metab-
olism in CLL is LPL-dependent. Because STAT3 is constitutively active in CLL
cells, and because the LPL gene harbors STAT3 binding sites, we sought to
determine whether STAT3 activates the LPL gene. Indeed, transfection of
luciferase reporter gene constructs driven by LPL promoter fragments into MM1
cells revealed that STAT3 activates the LPL promoter. In addition, ChIP con-
firmed that STAT3 binds to the LPL promoter. Furthermore, transfection of CLL
cells with STAT3-shRNA downregulated LPL transcripts and protein levels, con-
firming that STAT3 activates the LPL gene.
Summary/Conclusions: Our data suggest that CLL cells undergo metabolic
reprograming and use strategies normally utilized by adipocytes. This process
is driven by constitutively activated STAT3 and is inhibited by ibrutinib.
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INHIBITION OF ARGININE UPTAKE VIA HUMAN CATIONIC AMINO ACID
TRANSPORTER-1 (CAT-1): A NOVEL APPROACH FOR CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) THERAPY
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Background: Interference with cancer metabolism by specifically restricting
extracellular nutrients is a rapidly emerging field of research. A variety of tumor
entities depend on the availability of the amino acid arginine since they have
lost the ability to synthesize it endogenously. The systemic depletion of arginine,
induced by the arginine-metabolizing enzymes arginine deiminase or arginase
is currently explored clinically in phase I-II studies. An alternative, largely unex-
plored strategy to restrict nutrient availability for cancer cells would be to target
the specialized cell membrane transporter proteins. Arginine uptake into cells
is mediated by members of different solute carrier families (hCAT-1, hCAT-2A,
hCAT-2B, hCAT-3; y+LAT1, y+LAT2, ATB0,+and b0,+AT), which differ in expres-
sion and regulation between individual cell and tissue types.
Aims: We wanted to clarify (i) if CLL cells depend on exogenous arginine, (ii)
which transporter is responsible for arginine transport in human CLL cells and
(iii) if the reduction of arginine availability via knockdown of this transporter
inhibits CLL cell growth and viability.
Methods: Experiments were performed with both, primary human CLL cells,
isolated from highly leukemic peripheral blood, and immortalized CLL cell lines.
Primary CLL cells were left unstimulated or were stimulated via Toll-like receptor
9. The expression levels of arginine transporters were determined by quantita-
tive RT-PCR and Western Blot. Arginine uptake was measured by [3H]-arginine
import, cell proliferation by [3H]-thymidine DNA incorporation and cell viability
by Annexin-V + propidium iodide staining in flow cytometry. The expression of
hCAT-1 was downregulated in HG3 CLL cells using lentiviral shRNA technology.
HG3_hCAT-1_knockdown cells were injected s.c. in NOD/SCID/gcnull mice and
tumor growth was monitored. 
Results: We show that primary CLL and immortalized CLL cell proliferation
depends on the availability of extracellular arginine. Screening a large panel of
individual CLL patient samples and different immortalized CLL cell lines demon-
strated that hCAT-1, y+LAT1 and y+LAT2 are the predominantly expressed argi-
nine transporters. Upon activation the expression level of hCAT-1 further
increased significantly. Arginine uptake both, in primary CLL cells and in the
CLL cell lines, was inhibited by the CAT inhibitor N-ethylmaleimide. Lentiviral
downregulation of the hCAT-1 transporter in HG3 CLL cells resulted in a signif-
icant reduction of arginine uptake, associated with an inhibition of cell prolifer-
ation and viability in vitro. The corresponding in vivo data of tumor growth upon
hCAT-1 knockdown in a murine xenograft model will be presented at the con-
ference.
Summary/Conclusions: Our results demonstrate that the hCAT-1 transporter
is a potential pharmacological target structure in CLL cells. Development of
small molecule- or antibody-based inhibitors of hCAT-1 might lead to a novel
therapeutic approach for CLL.
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FCMR IS A NEGATIVE REGULATOR OF B-CELL RECEPTOR SIGNALING
IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
S. Gobessi1,*, B. Sasi1, G. Pozzato2, I. Innocenti3, L. Laurenti3, D. Efremov1
1Molecular Hematology, International Centre for Genetic Engineering & Biotech-
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Background: Chronic lymphocytic leukemia (CLL) cells frequently display fea-
tures of anergic B cells, including reduced B-cell receptor (BCR) signaling
capacity and downregulation of membrane IgM (mIgM). These features are
particularly evident in freshly isolated peripheral blood (PB) CLL cells belonging
to the indolent, M-CLL subset (Lanham S et al, Blood. 2003). The mechanism
responsible for this phenomenon is still unclear, but chronic stimulation with
autoantigens has been considered as a possible explanation because of the
observation that BCR signalling capacity and mIgM expression can sponta-
neously recover in CLL cells following prolonged in vitro culture (Mockridge CI
et al, Blood. 2007). An alternative explanation for this phenomenon is that these
anergic features are induced by soluble IgM molecules, which are absent from
standard cell culture media, and could interact in vivo with the leukemic BCRs
through recently described intermolecular immunoglobulin interactions or by
binding to the Fcμ receptor (FcμR). The latter is highly overexpressed in CLL
cells, particularly those belonging to the M-CLL subset (Li FJ et al, Blood. 2011). 
Aims: Investigate the role of the FcμR in regulating BCR signaling in CLL cells.
Methods: CLL cells were isolated from PB or lymph nodes (LNs) using standard
procedures. FcμR stimulation was done using pentameric human Fcμ fragment,
whereas BCR stimulation was done using goat anti-human IgM or anti-human
Ig light chain F(ab’)2 fragments. FcμR knockdown was done by RNA interfer-
ence using the Nucleofector system and solution V/C-009 program. Surface
FcμR and IgM levels were measured by flow cytometry on gated CD19+/CD5+
cells.
Results: We recently reported that FcμR stimulation results in activation of
certain downstream BCR signaling pathways and increased CLL cell survival
in vitro (Gobessi S et al, ASH 2016, abstract 2015). To investigate whether
FcμR regulates BCR signaling capacity, we analyzed activation of downstream
signaling molecules in CLL cells that had been pretreated for one hour with
Fcμ and then stimulated with an anti-Ig light chain antibody. Decreased phos-
phorylation of SYK, AKT and ERK was detected in the Fcμ-treated samples,
suggesting that FcμR negatively regulates BCR signaling in CLL cells. Consis-
tent with this finding, we also observed that FcμR knockdown by RNA interfer-
ence resulted in greater activation of SYK, AKT and ERK in anti-IgM stimulated
primary CLL cells. Because IL-4 was recently shown to increase BCR signaling
capacity and surface IgM expression on CLL cells (Aguilar-Hernandez MM et
al, Blood. 2016; Guo B et al, Blood 2016), we next investigated whether it will
have an opposite effect on FcμR expression. Stimulation of CLL cells (n=7) for
48 hours with IL-4 resulted in a mean 2.4 fold reduction in surface FcμR expres-
sion and a 3.9 fold increase in surface IgM expression compared to unstimu-
lated cells (P<0.001 and P=0.016, respectively). Since IL-4 is produced by T
cells, which typically interact with CLL cells in LNs, we next compared surface
FcμR and IgM expression in two paired LN and PB CLL samples. Interestingly,
in both cases the levels of surface FcμR were lower on LN than PB CLL cells,
whereas no difference was detected in the expression of surface IgM. To further
understand the mechanisms through which IL-4 regulates BCR signaling, we
compared BCR signaling capacity of CLL cells cultured for 48 hours in the pres-
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ence or absence of IL-4. Most of the investigated samples in this series showed
reduced surface FcμR expression and increased surface IgM expression after
IL-4 treatment, but a few cases showed only reduced FcμR expression and no
change in IgM expression. Interestingly, these samples also showed greater
anti-IgM induced phosphorylation of SYK, PLCγ2, AKT and ERK, suggesting
that downregulation of FcμR is the primary mechanism through which IL-4 reg-
ulates the BCR signaling capacity of CLL cells. 
Summary/Conclusions: These data show that FcμR is a negative regulator
of BCR signaling in CLL cells. Overexpression of FcμR could be at least in part
responsible for the reduced BCR signaling capacity of PB CLL cells. FcμR is
downregulated by IL-4 and shows reduced expression in LN CLL cells, which
could represent a mechanism to allow CLL cells to respond more effectively to
stimulation with antigen encountered in the appropriate context.
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TRANSCRIPTION FACTORS AND CHECKPOINT INHIBITORS EXPRESSION
WITH AGE: MARKERS OF IMMUNOSENESCENCE?
L. Dang1, K. Willard-Gallo2, S. Garaud2, H. Duvillier1, J.-N. Lodewyckx2,
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1Clinical and Experimental Hematology, 2Molecular Immunology, 3Anatomo-
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Background: Aging is characterized by a progressive decline in immune sur-
veillance that favors tumor development in older patients. One mechanism
used by malignant cells to escape immune surveillance is the upregulation of
immune checkpoint inhibitors. Another process associated with aging is genetic
or epigenetic modifications of tumor suppressor genes (TSGs). 
Aims: We previously reported a correlation between 6q deletion and progres-
sion into a T cell lymphoproliferative disease, identifying the BACH2 gene as
a candidate TSG. We thus examined the expression of specific transcription
factors (BACH2 and PRDM1) and checkpoint inhibitors (PD-1 and PD-L1) in
the major lymphocytes subsets for their potential role in immunosenescence.
Methods: Peripheral blood mononuclear cells were isolated from whole blood
using Lymphoprep (Stemcell Technologies) density gradient centrifugation.
Lymphocyte subsets (CD19+, CD3+CD4+; CD3+CD8+) were isolated for sub-
sequent molecular analyses using the MACS Technology (Miltenyi), with the
purity of each lymphocyte subpopulation between 95%>99%. PD-1 (PDCD1),
PD-L1 (CD274), IL4, IFNG, BACH2 and PRDM1 mRNA transcripts were quan-
tified using qRT-PCR. BACH2 and BLIMP1 (PRDM1) protein expression were
examined by Western blotting. 
Results: Blood samples were obtained from 60 healthy volunteers and 41
untreated B-cell chronic lymphocytic leukemia (B-CLL) patients (median: 67yo).
Healthy donors (HD) between the ages of 20 to 90 years subdivided into <50
yrs (median: 36yo) and ³50 yrs (median: 65yo). BACH2 mRNA expression in
the HD groups is significantly down-regulated in CD4+, CD8+ T cells and
CD19+ B cells from the older HD group (p=0.0012; 0.0045 and 0.0367, respec-
tively). BACH2 expression was further reduced in CD4+, CD8+ T cells and
CD19+ B cells from CLL patients compared to HD well balanced for age
(p=0.001; <0.0001 and 0.0043). PRDM1 mRNA expression was inversely cor-
related with BACH2 in CD4+, CD8+ T cells and CD19+ B cells (r=0.61; 0.71
and 0.65, respectively). Curiously, PRDM1 was – as expected - significantly
up-regulated in CD4+ and CD8+ T cells (p=0.0034; p=0.0017) from B-CLL
patients but not in their leukemic B cells. Western blotting analysis demon-
strated that BACH2 and BLIMP1 (PRDM1) protein expressions in the T and B
cell subpopulations were significantly correlated with transcript expression.
BACH2-deficient mice have been shown to have an increased numbers of IL4-
producing CD4+ T cells. We also observed that BACH2 down-regulation is cor-
related with increased IL-4 mRNA expression (r=0.67) but not IFNγ in CD4+ T
cells. These observations suggest that BACH2 down-regulation in CD4+ T cells
could enhance the expression of effector memory-related genes, particularly
Th2, such as IL-4 and PRDM1. PD-1 mRNA expression was up-regulated in
CD4+, CD8+ T cells (p=0.0153 and 0.0214) in the older HD group and also up-
regulated in the T cells from B-CLL patients (p=0.0014 and 0.0023) when com-
pared to age-matched HD population. High PD-L1 mRNA expression was cor-
related with increased age in HD B cells (p=0.04) with a further increase detect-
ed in leukemic B cells (p=0.001). We also observed an inverse correlation
between BACH2 and PD-1 in CD4+, CD8+ T cells (r=0.62 and 0.68); and
between BACH2 and PD-L1 in CD19+ B cells (r=0.66).
Summary/Conclusions: These data suggest that down-regulation of
BACH2/PRDM1 and up-regulation of PD1/PD-L1 mRNA expression in major
lymphocyte subsets from CLL patients and older healthy controls are signifi-
cantly correlated with the aging immune cells and could be part of the
immunosenescence process.
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T-CELL EXHAUSTED PHENOTYPE IS ENHANCED DURING DISEASE
PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
I. Jiménez1,*, S. Bobillo2, P. Abrisqueta2, C. Palacio2, J. Carabia1, M.J. Terol3,
M. Crespo1, F. Bosch1
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Background: The different biological mechanisms leading the clinical progres-
sion of CLL from early stages are currently not fully elucidated. Different prog-
nosis factors that correlate with a higher probability of progression, such as
IgHV mutational status, ZAP70 or CD49d expression, or TP53 defects, are still
not able to identify an important proportion of patients that eventually progress.
Clinical progression from early stages to an advanced CLL is associated with
a certainly reduced acquisition of molecular changes that are not able to explain
the fifty percent of the CLL cases progressing. CLL cells are dependent on
survival and proliferative signals from the microenvironment and are able to
evade immune anti-tumoral responses using different mechanisms, which is a
crucial feature for cancer development. T-cell dysfunction is one of the main
sources of impaired anti-tumor immunity. In CLL, T cells show functional defects
and have increased expression of the exhaustion markers PD1, CD244 and
CD160 compared to T cells from healthy individuals. Taking this into account,
we hypothesize that changes in the microenvironment, and particularly in T-
cell exhaustion component, are contributing to the clinical progression of CLL.
Aims: In order to explore the role of the immune system in the progression of
CLL we studied the immunophenotype of T cells from CLL patients using paired
samples at diagnosis and progression.
Methods: A total of 14 CLL patients (median age, 69 years; median time to
progression of 29,5 months) and 6 patients diagnosed with CLL that did not
experience clinical progression during a median follow up of 34 months were
included in the study. Multicolor flow cytometry was performed in matched sam-
ples at two time-points: diagnosis and progression before treatment or diagno-
sis and follow-up. We studied T-cell differentiation status based on CD45RA
and CCR7 expression and the inhibitory receptors PD1, CD244, CD160, LAG3,
TIM3 and CTLA4. We also analyzed the expression of the transcription factors
T-bet and Eomes.
Results: We observed a significant increase in CD8+ absolute numbers
(P=0.0107) and a significant decrease of the CD4:CD8 ratio (P=0.0012) with
progression. T cells increased their effector memory (EM) CD45RA- CCR7-
phenotype during progression (EM CD4+ P=0.0353; EM CD8+ P=0.0023). PD1
expression was significantly increased during progression in absolute numbers
on both CD4+ and CD8+ T cell subsets (P=0.0166), as well as in the PD1+ EM
subset (EM PD1+CD4+; EM PD1+CD8+ P=0.0024). Interestingly, we did not
observe these changes in CLL patients that did not progress where the absolute
numbers of cells expressing PD1 were either diminished or maintained during
the follow-up, pointing out an important role of PD1 in regard to CLL progres-
sion. We observed that the percentages of CD8+ cells expressing CD244 and
CD160 were higher at the time of progression, especially for CD244
(P=0.0078). Moreover, the co-expression of these markers with PD1 was found
on CD8+ T cells and its percentage was increased during progression
(P=0.0078). Among the differentiation subsets, the EM and EM CD45RA+
(TEMRA) CD8+ T cells expressed the highest percentages of CD244 and
CD160. We did not observe changes in LAG3, TIM3 and CTLA4. T-bet and
Eomes are essential to regulate T-cell differentiation and their expression has
also been associated with a progenitor (T-bethi PD1int) or a terminal (Eomeshi
PD1hi) exhausted phenotype in chronic viral infections. The percentage of
CD8+ T cells expressing Eomes and co-expressing Eomes and PD1 were sig-
nificantly increased during progression (P=0.0186 and P=0.0286, respectively)
whereas T-bet expression was more stable.
Summary/Conclusions: T cells from patients with progressed CLL show a
more severe exhausted phenotype compared to diagnosis, which is charac-
terized by an effector memory subset with higher expression and co-expression
of PD1, CD244 and CD160, as well as higher levels of the transcription factor
Eomes, indicating that the terminal exhausted phenotype (Eomeshi PD1hi) is
predominant. These changes may contribute to the immune evasion that facil-
itates the progression and to the immunosuppresive scenario that dominates
advanced CLL stages. Functional assays to explain why this T cell subset is
enhanced during progression are currently ongoing.
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EARLY SPECIFIC INCREASED EXPRESSION OF SURFACE IGM BUT NOT
OF OTHER ASSOCIATED MOLECULES APPEARS TO REFLECT ANTIGEN
DISENGAGEMENT IN CLL PATIENTS ON IBRUTINIB THERAPY
S. Drennan1,*, G. Chiodin1,2, A. D’Avola1, P.W. Johnson3, L. Trentin2,
G. Packham3, A.J. Steele3, F.K. Stevenson3, F. Forconi1,4
1Haematology Oncology Group, Cancer Sciences Unit, University of
Southampton, Southampton, United Kingdom, 2Padua University School of
Medicine, Department of Medicine, Hematology and Clinical Immunology
Branch, University of Padua, Padua, Italy, 3Cancer Sciences Unit, University
of Southampton, 4Haematology Department, University Hospital Southampton
NHS Trust, Southampton, United Kingdom
Background: B cell receptor (BCR) signaling through surface IgM (sIgM) is
key to the survival and proliferation of normal and chronic lymphocytic leukemia
(CLL) cells, and can be targeted effectively by the BTK inhibitor ibrutinib. Chron-
ic exposure of the BCR to (super)antigen leads to downmodulation of sIgM,
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but not of sIgD, levels and signaling capacity. This is evident in the circulating
CLL B-cells which are characterized by variably reduced sIgM levels/signaling.
The variability influences outcome and cases with relatively higher sIgM
levels/signaling capacity, but not sIgD, have more rapid progression, likely due
to a larger proliferative component.
Aims: The aim of this study was to investigate the effect of ibrutinib in vivo on
the dynamics of expression and function of sIgM and of other surface molecules
associated with the BCR complex on the circulating CLL cells of patients during
the early phases of therapy (first 3 months).
Methods: Peripheral blood mononuclear cells were collected from 12 CLL
patients prior to (pre-) and at 1 week, 1 month and 3 months following com-
mencement of single agent ibrutinib therapy. Expression of BCR-complex asso-
ciated sIgM, sIgD, CD19 and other surface markers was assessed by flow
cytometry. Signaling capacity following sIgM stimulation was measured by
immunoblotting. Following biotinylation of cell surface proteins, the N-glycosy-
lation pattern of the µ chain was assessed by immunoblotting as a readout of
sIgM status. Informed consent was obtained from all patients (REC: H228/02/t).
Results: At week 1 of ibrutinib therapy, there was a dramatic increase in the
expression of sIgM on the circulating CLL cells (mean fold increase 1.6,
P=0.001), while expression of sIgD and CD19 remained constant. At this time
point, increased sIgM expression associated with full N-glycan maturation of
sIgM heavy-chain, indicative of recovery from antigen engagement at tissue
sites. Also, the sIgM levels correlated with increased anti-IgM mediated SYK
phosphorylation (r=0.64, P=0.03), to indicate functionality upstream of BTK.
Sequential assessment at month 1 and 3 revealed that sIgM levels were similar
to that observed prior to therapy, with preserved upstream signaling ability. In
marked contrast, the other BCR complex associated molecules sIgD, CD19
and CD20 all reduced expression (P<0.001). Reduction of these markers was
also accompanied by reduction of cell size and of other surface markers while
overexpression of autophagy marker LC3B2 was documented.
Summary/Conclusions: Our data point to two major events dissociating sIgM
expression and function from other BCR-complex associated molecules. In the
initial phase, the increased sIgM expression and maturation, with no changes
of other BCR-associated molecules, appears consequent to lack of antigen
encounter, likely due to inhibition of chemokine-mediated entry to tissue sites.
In the later phases the circulating CLL cells will suffer lack of tissue derived
pro-survival stimuli. In their absence, CLL cells will reduce expression of several
markers and cell size, possibly explained by autophagocytic mechanisms aim-
ing to protect the circulating CLL cells from death unless ibrutinib therapy is
withheld.
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TRB REPERTOIRE PROFILING OF TCL-1 TRANSGENIC MICE USING NOVEL
NGS TECHNOLOGIES REVEALS OLIGOCLONAL EXPANSIONS:
SIMILARITIES WITH CHRONIC LYMPHOCYTIC LEUKEMIA
A. Agathangelidis1,2, A. Rovida2, S. Bonfiglio2, E. Vlachonikola1, L. Scarfò2,*,
A. Hadzidimitriou1, K. Stamatopoulos1, P. Ghia2
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Background: Findings from independent studies reported that the BcR path-
way and antigenic stimulation occupy a central spot in the development of
leukemia in the Eµ-TCL-1 transgenic (tg) mouse, as in the case of chronic lym-
phocytic leukemia (CLL). Recently, the detailed characterization of the T-cell
receptor beta chain (TRB) gene repertoire in patients with CLL revealed gene
expression biases and oligoclonality. These characteristics strongly suggested
that not only leukemic B cells, but also T cells are selected by antigenic ele-
ments. In this context, very little is known regarding the T cell compartment in
Eµ-TCL-1 mice.
Aims: Here, we sought to: (i) obtain a comprehensive view of the TRB gene
repertoire in TCL-1 mice, and (ii) assess from an immunogenetic standpoint
the extent of similarity between TCL-1 mice and CLL patients. 
Methods: In total, we analyzed 18 samples from 16 TCL-1 mice that were cat-
egorized into 3 distinct groups, based on disease stage: (i) 6 mice with a clone
size of <20% (group 1), (ii) 6 mice with a clone size of 30-55% (group 2) and
(iii) 6 mice with a clone size of >60% (group 3). Clone size was measured as
the percentage of CD5+/CD19+ B cells in the blood. Two different mice were
studied longitudinally: one belonged originally to group 1 and progressed to
group 2, while the other animal progressed from group 2 to 3. Five C57BL/6
wild-type (wt) mice were also analyzed as controls. TRBV-D-J gene rearrange-
ments were amplified using the immunoSEQ® mouse T-cell receptor beta
(mmTCRB) Kit from Adaptive Biotechnologies® and sequencing was performed
using the MiSeq® Reagent Kit v3. Data were analyzed using the immunoSEQ®
software.
Results: Only productive, in-frame TRBV-D-J rearrangements were included
in the analysis that, in total, concerned 383,951 sequences (median 14,239
sequences). The TRB gene repertoire was almost identical in all groups, includ-
ing the wt mice. In detail, 5 different genes: TRBV13-02, TRBV19-01, TRBV03-
01, TRBV13-03, TRBV05-01, TRBV02-01 accounted for almost 50% of the
total repertoire. Concerning the TRBJ gene repertoire, the TRBJ02-07 gene
was the most frequent gene in all groups. The analysis of the CDR3 length
showed the same distribution in all groups with the mean and median CDR3
length being 12 amino acids. Expanded clones were observed in all samples
with the average size of the 10 largest clones being: 9.8% for group 1, 18.3%
for group 2, 12.9% for group 3 but only 0.4% for wt mice. Comparison of the
TRBV repertoire in the expanded clones versus the general cohort revealed
significant differences with genes TRBV12-01, TRBV12-02, TRBV16-01 and
TRBV20-01 being frequent only in the former group. Shared or public clono-
types (identical CDR3 sequences) were only observed in longitudinal samples
from the same mice, which also concerned some of the largest clones. Scan-
ning the 10 largest clones of each sample for the existence of highly similar
clones led to the identification of 48 clusters that contained 91/180 clonal
sequences.
Summary/Conclusions: Overall, the TRB gene repertoires of TCL1 mice were
characterized by oligoclonal expansions that could persist over time. The TRB
gene repertoire of expanded clones was more restricted than that of the general
cohort, whereas comparisons between different samples revealed the existence
of identical and highly similar clonotypes. These findings argue that (ongoing)
selection by antigenic elements may shape the T-cell compartment in TCL-1
mice, similar to human CLL. These results further support the notion that this
mouse model closely resembles CLL, at least from an immunogenetic perspec-
tive.
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ROLE OF THE COMBINATION MEK1/2 INHIBITOR BINIMETINIB AND AKT
INHIBITOR MK2206 IN CLL
S. Sandhu1,2,*, S. Mulligan2,3, G. Best2
1Acute Medical Unit, Royal Melbourne Hospital, Parkville, 2Northern Blood
Research Centre, Kolling Institute of Medical Research, 3Haematology, Royal
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Background: Clinical trials of ibrutinib and idelalisib demonstrate the efficacy
of B-cell receptor-targeted therapies for CLL. We sought to investigate the effi-
cacy of targeting both the BCR and the MAPK-ERK1/2 signaling pathways.
Aims: To evaluate the role of targeting the Ras-Raf-MEK1/2-ERK1/2 together
with the Pi3K-AKT pathways as a potential novel approach in treating chronic
lymphocytic leukemia. In particular, assessing the efficacy of MEK1/2 inhibitor,
binimetinib (MEK162), in combination with either a Pi3K inhibitor, idelalisib or
an AKT inhibitor, M2206.
Methods: All experiments conducted on primary CLL cells were co-cultured
with CD40L-expressing stroma which mimics the support conferred by the
tumour environment. Firstly, the effects of MK2206 and idelalisib at doses vary-
ing from 1 to 40µM were tested on primary CLL cells. Secondly, binimetinib
and MK2206 were tested as single agents and in combination at 20µM against
primary CLL cells. Thirdly, binimetinib at 20µM combined with varying doses of
idelalisib on primary CLL cells. The mechanisms underlying the effects of
binimetinib in combination with MK2206 in primary CLL cells were investigated
by western blotting with changes in the expression of phosphorylated and total
forms of AKT, MCL-1, and ERK1/2 assessed. Expression of B-actin was used
as a loading control.
Figure 1.
Results: MK2206 is effective against CLL cells co-cultured with stromal cells
in a dose dependent manner. It was also observed that the primary CLL cells
co-cultured with the CD40L-expressing stroma were significantly more sensitive
to MK2206 than to idelalisib (Figure 1A). No cytotoxic effects of binimetinib
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were observed while the combination with MK2206 was significantly more
effective than either drug alone, suggestive of synergy between the two drugs
(Figure 1B). The analysis of binimetinib at 20µM with idelalisib failed to demon-
strate any additive effects or suggestion of synergy between the two drugs
(Figure 1C). Binimetinib treatment led to an increase in the activity of AKT and
a decrease in ERK1/2 phosphorylation. MK2206 completely abrogated the
activity of AKT and MCL-1 phosphorylation when combined with binimetinib
(Figure 2A). Although we observed a reduction in AKT phosphorylation following
idelalisib alone, it had no effect on the levels of AKT activity induced by binime-
tinib or the levels of phosphorylated MCL-1 protein. This result was irrespective
of the dose of idelalisib used (Figure 2B). We explored the possibility that pro-
tein kinase C (PKC) may also be involved in the binimetinib-induced AKT activ-
ity. Using the pan-PKC inhibitor GF109203X (GFX), we demonstrated that inhi-
bition of PKC significantly reduces binimetinib-induced phosphorylation of AKT
with no effect on the activity of ERK1/2-MAPK (Figure 2C). These data suggest
a role for PKC in the regulation of AKT activity in CLL cells.
Summary/Conclusions: The combination of binimetinib and MK2206 in vitro
has been shown to be effective strategy to treat primary CLL cells. The western
blot data reinforce that the increased activity observed in AKT activity in CLL
cells following binimetinib treatment is independent of the idelalisib and totally
abrogated by MK2206. This PI3-kinase independent regulation may be regu-
lated by protein kinase C and is likely to play a significant role. 
Dual inhibition of MAPK-ERK1/2 and AKT signaling may be effective at target-
ing the proliferative/drug-resistant compartment of CLL that resides in the
tumour microenvironment.
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TARGETING HIF-1Α AND ITS REGULATORY PATHWAYS AS A STRATEGY
TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN
CHRONIC LYMPHOCYTIC LEUKEMIA
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Background: The CXCL12/CXCR4 axis has a fundamental role in the microen-
vironment-mediated protection of chronic lymphocytic leukemia (CLL) cells
from spontaneous and drug-induced cell death. The binding of CXCL12 with
CXCR4 activates multiple intracellular pathways, including RhoA- and Ras-
dependent signaling. We have previously shown that co-culture with stromal
cells (SC) induces in CLL cells the activation of RhoA/RhoA kinase and
Ras/ERK1-2 signaling, the upregulation of Akt, and an increased activity of the
transcription factor HIF-1α (Rigoni et al., Oncotarget 2015).
Aims: The purpose of this study was to identify new potential pharmacological
targets involved in the CXCL12/CXCR4 axis in order to impair the protection exert-
ed by SC towards spontaneous and fludarabine-induced apoptosis in CLL cells.
Methods: Peripheral blood was collected from 62 patients with CLL. In selected
experiments, the M2-10B4 murine SC line and the HS-5 human SC line were
used. Patient-derived bone marrow SC were generated from 12 patients with
CLL. Where indicated, cell cultures were treated with recombinant CXCL12
(100 ng/ml), CXCR4 inhibitor AMD3100 (5 μg/ml), fludarabine (F-ara-A, 10
μM), simvastatin (1 μM), ERK1-2 kinase inhibitor PD98059 (10 μM), HIF-1α
inhibitor BAY87-2243 (1 μM), and PI3K inhibitor idelalisib (10 μM). RhoA and
Ras activities were evaluated by an ELISA based assay and by pull-down
assay, respectively. ERK1-2, HIF-1α amount in whole cell extracts and in
nuclear fraction, and HIF-1α phosphorylation were evaluated by Western Blot.
RhoA kinase, Akt and HIF-1α activities were measured with specific immunoas-
say kits. CXCL12 was quantified by ELISA. Cell viability was determined by
Annexin-V/propidium Iodide immunostaining and flow cytometry analysis.
Results: The exposure of CLL cells to recombinant CXCL12 led to the activa-
tion of RhoA- and Ras-dependent signaling, and to the downstream upregula-
tion of HIF-1α. The CXCR4 antagonist AMD3100 completely abrogated the
positive regulation exerted by both CXCL12 and SC, thus unveiling the key
role of the CXCL12/CXCR4 axis in the SC-induced modulation of these sig-
naling pathways. The inhibition of Ras and RhoA activity by simvastatin, and
the inhibition of ERK1-2 and HIF-1α by PD98059 and BAY87-2243 effectively
blocked the SC-induced expression and activity of HIF-1α, significantly impair-
ing the SC-mediated protection of CLL cells, both in absence and presence of
fludarabine. Similar effects were observed by targeting the PI3K/Akt pathway
with idelalisib. We then investigated whether targeting RhoA- and Ras-depen-
dent signaling could modulate HIF-1α also at the SC level. Simvastatin and
BAY87-2243 effectively inhibited HIF-1α expression both in SC lines and in
patient-derived SC. Moreover, simvastatin significantly reduced the secretion
of CXCL12, which is a known transcriptional target of HIF-1α.
Summary/Conclusions: Our data demonstrate that the targeting of HIF-1α
and its regulatory pathways, both at the tumor cell and at the SC level is an
appealing strategy to overcome the microenvironment-mediated protection
toward spontaneous and fludarabine-induced apoptosis in CLL cells. 
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THE ROLE OF GENETIC-BASED PROGNOSTIC FACTORS IN PREDICT-
ING MINIMAL RESIDUAL DISEASE NEGATIVITY IN CHRONIC LYMPHO-
CYTIC LEUKEMIA PATIENTS TREATED WITH FLUDARABINE,
CYCLOPHOSPHAMIDE AND OFATUMUMAB
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Background: Chemoimmunotherapy with fludarabine, cyclophosphamide and
rituximab (FCR) is the optimal front-line treatment for fit chronic lymphocytic
leukemia (CLL) patients. IGHV mutations and FISH lesions are predictive mark-
ers of response and progression-free survival after FCR. Minimal residual dis-
ease (MRD) is the single best post-treatment predictor of long-term outcome
after FCR, independent of biologic prognostic markers.
Aims: To explore whether conventional biologic markers (i.e. IGHV mutations,
FISH lesions) and TP53, NOTCH1, BIRC3 and SF3B1 mutations can predict
the obtainment of a MRD negativity after first-line treatment of CLL patients
with FC and ofatumumab (FCO).
Methods: Eighty young (≤65 yrs) and fit CLL patients from 15 Italian centers
were enrolled in the GIMEMA LLC0911 first-line trial and treated with 6 cycles
of FCO. CLL diagnosis, treatment requirement and response were defined
according to the 2008 iwCLL guidelines. MRD was evaluated in responding
patients by 8-color flow cytometry in the peripheral blood (PB) and bone marrow
(BM) 2 months after the end of induction (month +8), and every 6 months there-
after; flow negative cases were analyzed by RQ-PCR, according to the guide-
lines. The association between CLL biologic markers and MRD clearance after
FCO was tested by Fisher’s exact test; logistic regression models were used
to estimate the risk values in univariate and multivariate analyses.
Table 1.
Results: Sixty-five responding patients underwent MRD evaluation at month
+8; their biologic features are reported in the Table. By flow cytometry, 25/65
cases (38%) resulted MRD+ in the PB and/or BM, while the remaining 40 (62%)
showed no residual CLL cells. The absence of del17p/TP53mut/del11q was
associated with the achievement of MRD negativity: 37 MRD- (74%)/13 MRD+
among patients with trisomy 12/negative FISH/del13q/TP53WT vs 2 MRD-
(14%)/12 MRD+ among del17p+/TP53mut/del11q+ (p=0.0001). Interestingly,
when patients were stratified into high (n=6), intermediate (n=22), low (n=21)
and very-low risk (n=15) groups by integrating FISH and gene mutations (Rossi
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et al, 2013), the high and intermediate risk groups (del17p/TP53/BIRC3+ or
del11q/NOTCH1/SF3B1+) showed a significantly lower probability of achieving
a MRD negativity (36%, 10/28) than the low and very-low risk groups (+12/neg-
ative FISH/del13q/WT for 4 genes: 81%, 29/36) (p=0.0003). The 40 flow cytom-
etry MRD- cases were also evaluated by RQ-PCR: 22 (55%) were reclassified
as MRD+. By combining the two methods, 47/65 cases (72%) were MRD+ and
18/65 (28%) MDR- at the end of FCO. Mutated (M)-IGHV status was signifi-
cantly associated to a molecular MRD- (12 MRD-/15 MRD+, 44%) compared
to unmutated (UM)-IGHV cases (5 MRD-/32 MRD+, 13%) (p=0.0092). More-
over, when M-IGHV status is reinforced by the absence of del17p/
TP53mut/del11q, the association with a deep MRD negativity got stronger (12
MRD-/13 MRD+, 48% vs 5 MRD-/33 MRD+, 13%; p=0.0036). A multivariate
model including FISH lesions, gene and IGHV mutations supports the inde-
pendent role of FISH and IGHV profile in predicting MRD negativity by flow
and RQ-PCR, respectively.
Summary/Conclusions: In CLL patients treated with the FCO combination
(LLC0911 Gimema trial), MRD negativity by flow cytometry (62%) can be pre-
dicted by the FISH profile: 74% in patients without del17p/del11q vs 14% in
del17p+/del11q+ cases. A deeper MRD negativity by RQ-PCR (28%) can be
anticipated by the IGHV status (44% M vs 13% UM) or by combining IGHV and
FISH. A longer follow-up will determine whether these parameters can identify
patients who maintain over time a good quality of response.
E1001
ISOCHROMOSOME 17Q, UNBALANCED TRANSLOCATIONS AND 8Q
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Background: Chromosomal abnormalities are present in about 80% of CLL.
Among them, the loss of the short arm of the chromosome 17 (17p-), uncom-
mon at diagnosis (<10%), is frequent in relapsed or refractory patients (up to
50%) and is associated with short survival. Loss of 17p results from various
chromosomal abnormalities, including unbalanced translocations, deletions,
rings or isochromosomes. All these aberrations lead to the loss of one copy of
the TP53 gene, the remaining allele being generally mutated. In addition, 17p-
is frequently accompanied by genomic complexity. Patients with 17p- typically
progress quickly and are refractory to most conventional therapies.
Aims: We evaluated if the type of chromosomal abnormality leading to 17p-
and the additional aberrations could influence the prognosis.
Methods: We collected data from a multicentric and retrospective cohort of
195 CLL patients harboring a TP53 deletion detected by FISH, with an inform-
ative conventional karyotype (K). All the K were reviewed by the members of
the Groupe Francophone de Cytogénétique Hématologique. Overall survival
(OS) and time to first treatment (TTFT) were calculated from diagnosis to death
or first-line treatment, respectively, or last follow-up. The log-rank test was used
to compare Kaplan-Meier curves. Cox regression models were used for multi-
variate analyses.
Results: The ratio H/F was 1.9. At diagnosis of CLL, the median age was 63
years [33-88], 59% were Binet stage A, 28% B, 12% C. IGHV genes were
unmutated in 38/47 (81%) patients tested. The median follow-up was 70 months
[0-401]. The majority of the patients was treated (87%), with a median TTFT of
13 months and a median of 2 lines of treatment [1-10]. In 28/124(23%) cases,
the 17p- was not present at diagnosis and occurred after the first therapy, with
a median time of 77.5 months [22-291] from the diagnosis. Karyotype was com-
plex in 141/195(72%) patients, and monosomal in 90/195 (46%). The 17p- was
the sole abnormality detected by K in 28/195(14%) cases. A total of 240 17p
abnormalities were found in the 195 patients. In the majority of cases, loss of
17p was the consequence of an unbalanced translocation (n=167/240, 70%),
with various chromosome partners, the most frequent being the recurrent
der/dic(17;18)(q10;q10) (n=32, 13%), followed by translocations involving chro-
mosomes 8, 13, 14, 21, 15. Unbalanced translocations involving 17p and chro-
mosome 8 (n=26, 11%), lead either to del8p (n=17), gain8q (n=6), or del8q
(n=3). The other 17p abnormalities were: deletion 17p (n=45, 19%), monosomy
17 (n=15, 6%), isochromosome 17q [i(17q)] (n=9, 4%) and ring of chromosome
17 (n=4, 1%). Among the additional abnormalities accompanying the 17p-,
unbalanced translocations were found in 121/195(63%) of patients. Combining
FISH and K, del13q was detected in 71/118(60%) of cases, del8p in
40/189(21%), tri12 in 30/195(15%), gain8q in 13/105(12%), and del11q in
20/161(12%). By univariate analysis, the paramaters which were associated
with significantly shorter OS were: age ≥65 years, stage B/C, unmutated IGHV,
i(17q) (69 months vs 179, p=.0375), the presence of unbalanced translocations
in addition to 17p- (153 vs 223 months, p=.03), and gain8q (74 vs 123 months,
p=.0014). Monosomy 17, a total number of abnormalities ≥6 and gain8q pre-
dicted a shorter TTFT. By multivariate analysis, age ≥65 years, stage B/C and
gain8q remained significant for OS.
Summary/Conclusions: Among the high risk group of 17p- CLL, i(17q) confers
a shorter OS than the other 17p abnormalities. In addition, the gain8q aggra-
vates the outcome as well as the presence of additional unbalanced transloca-
tions. These results confirm that patients with 17p- CLL have a variable clinical
course and highlight the relevance of conventional karyotyping to identify the
alterations that modulate the prognosis within these patients.
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THE MICROENVIRONMENT REGULATES THE EXPRESSION OF MIR-21
AND TUMOR SUPPRESSOR GENES PTEN, PIAS3 AND PDCD4 THROUGH
ZAP-70 IN CHRONIC LYMPHOCYTIC LEUKEMIA
J. Carabia1,*, C. Carpio2, P. Abrisqueta2, I. Jiménez1, N. Purroy1, E. Calpe1, C.
Palacio2, F. Bosch1, M. Crespo1
1Experimental Hematology, 2Hematology, Vall d’Hebron Institute of Oncology,
Barcelona, Spain
Background: Microenvironment found in bone marrow and lymph nodes sup-
ports survival, proliferation and drug resistance in chronic lymphocytic leukemia
(CLL). Indeed, CLL cells are highly dependent on interactions with the microen-
vironment. The BCR is one of the key players involved in the crosstalk between
CLL cells and the microenvironment. Furthermore, it has a critical role in patho-
genesis and prognosis of CLL. Accordingly, different factors related to increased
BCR signaling are adverse prognostic factors in CLL, such as IGHV genes,
high expression of ZAP-70 and increased serum levels of CCL3. Expression
of ZAP-70 in CLL cells has been related to enhanced response to BCR stimu-
lation, as well as to increased response to diverse migrative and survival stimuli
from the microenvironment. MiR-21 is an oncogenic microRNA that has been
found to be overexpressed in a wide variety of neoplasms where it participates
in oncogenic events such as proliferation, resistance to treatment, and metas-
tasis; its overexpression in CLL has been associated to refractoriness to flu-
darabine and to shorter overall survival and higher probability of progression. 
Aims: In order to further elucidate the molecular mechanisms defining bad
prognosis CLL by further elucidation of the role of ZAP-70 in the crosstalk
between CLL cells and the microenvironment, we studied the relationship
between ZAP-70 protein and miR-21 and how it is influenced by the microen-
vironment.
Methods: Peripheral blood mononuclear cells (PBMC) from 48 patients diag-
nosed with CLL were isolated by Ficoll-Paque Plus density gradient centrifuga-
tion. Ramos B-cells stably transfected with a vector encoding for ZAP-70 protein
fused with Green fluorescent protein (GFP) or GFP only as a control were treat-
ed with Akt (LY294002), MAPK (PD98059) and STAT3 (JSI-124) inhibitors for
1 hour. BCR was stimulated with F(ab)2 anti-IgM. PBMC were co-cultured with
bone marrow stromal cells with CD40L and CpG to mimick the microenviron-
ment found in proliferation centers. After 48 hours CLL cells were harvested to
analyze cell viability, cell proliferation and mRNA expression. Expression levels
of primary miR-21, miR-21, PTEN, PDCD4 and PIAS3 were measured by QRT-
PCR. 
Results: First, we observed that miR-21 expression was significantly higher in
patients with high expression of ZAP-70. Subsequently, using stably transfected
Ramos B-cells with ZAP-70 protein we found that pri-miR-21 and mature miR-
21 expression were significantly increased upon BCR crosslinking, which was
enhanced by ectopic expression of ZAP-70. We also observed that inhibition
of both MAPK and STAT3 pathways impairs the regulation of miR-21 expression
after ZAP-70 activation. Moreover, the induction of miR-21 expression after
ZAP-70 activation also induced downregulation of the tumor suppressor genes
PTEN, PDCD4 and PIAS3, targeted by miR-21 in malignant cells. The co-cul-
ture of primary CLL cells induced ZAP-70 and miR-21 expression, as well as
downregulation of the putative miR-21 targets. Interestingly, the increase in
miR-21 after co-culture was significantly impaired by ibrutinib, indicating that
the BCR signaling pathway is involved in its regulation in primary CLL cells.
Finally, co-culture-induced increased CLL survival correlated with miR-21 upreg-
ulation.
Summary/Conclusions: In conclusion, stimuli from the microenvironment are
capable of regulating expression of miR-21 and tumor suppressor genes
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(PTEN, PDCD4 and PIAS3) via a signaling pathway involving ZAP-70, MAPK
and STAT3 transcription factor. 
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Background: Regimens consisting of rituximab and DNA-damaging drugs
represent an important therapeutic option for patients with chronic lymphocytic
leukemia (CLL). Up-to-date studies including clinical trials agreed upon the
adverse outcome of TP53-defective patients that should be provided alternative
treatment approaches. Additionally, mutations in NOTCH1 gene were connect-
ed with a lack of benefit from rituximab added to chemotherapy. A potential
impact of other mutations commonly occurring in CLL patients remains less
clear, namely regarding a role in relapse development. 
Aims: (a) to assess impact of mutations in ATM, SF3B1, NOTCH1 and BIRC3
genes on progression-free survival (PFS) in CLL patients treated with front line rit-
uximab-based regimens, and (b) to analyze clonal evolution of mutations in relapse.
Methods: We analyzed 53 CLL patients administered first line regimens FCR
(fludarabine, cyclophosphamide, rituximab) or Q-FCR (FCR with reduced dos-
es) or BR (bendamustine, rituximab); all harbored intact TP53 gene as
assessed by FISH and the yeast functional analysis; 46/53 (87%) had unmu-
tated IGHV. The next generation sequencing using MiSeq (Illumina) was done
in 53 pre-therapy samples and 41 relapsed samples using three separate pan-
els: ATM (exons 2-63; median coverage (MC) 6100), SF3B1/NOTCH1/BIRC3
(exons 14-16, part of 34, and 7-10, respectively, MC 11200), and TP53 (exons
2-11; MC 31500). Functional impact of ATM mutations was verified by SIFT
and PolyPhen online tools. Only mutations present in ˃ 10% of reads were con-
sidered for the PFS analysis (log-rank (Mantel-Cox) test); the interval was cal-
culated from therapy completion to clinical progression (as defined by the iwCLL
recommendations). 
Results: In the pre-therapy analysis, we identified 23 patients with one dis-
rupted gene and 7 patients with two disrupted genes; the rest of the cohort
(n=23) was devoid of the mutations (wt). The most frequently affected gene
was ATM (15 cases; only mutations with predicted functional impact consid-
ered), followed by SF3B1 (10 cases; hot-spot mutations), NOTCH1 (7 cases;
all deletion c.7541_7542) and BIRC3 (5 cases; frame-shift mutations). We did
not observe significant differences in PFS among the employed regimens: the
medians were 16.5 months (m) for FCR (used in 30 patients; median: 4 cycles);
15 m for Q-FCR (15 patients; 4 cycles); and 14 m for BR (8 patients; 3.5 cycles);
P=non-significant (ns). In univariate analyses of individual affected genes, we
did not observe an adverse impact of mutations on PFS: ATM-mut median 19
m vs 14 m in wt patients; SF3B1-mut 19.5 m vs 16 m; NOTCH1-mut 32 m vs
15.5 m; BIRC3-mut 16 m vs 16 m (all analyses P=ns). In a more detailed analy-
sis structured according to the type of ATM defect, patients with sole 11q- (the
other ATM allele intact; n=13) manifested the shortest PFS of 11 m, followed
by ATM-mutated patients (n=15; 19 m; P=0.1) and wt patients (n=24; 24 m;
P=0.041). Analysis of clonal evolution in patients who relapsed (41 paired sam-
ples) revealed the following significant events: selection of TP53 mutations in
two cases (from 2.3% to 77%, and 5.4% to 64.5%) and ATM mutations in two
cases (8% to 15% and wt to 18%), as well as more complex changes involving
both increase and decrease of mutations in BIRC3 gene in three patients.
Summary/Conclusions: Our pilot analysis with limited number of samples
does not indicate adverse impact of studied mutations in rituximab-based reg-
imens. Some relapsed samples showed quite distinct mutation profile. Sup-
ported by projects AZV 16-32743A, MUNI/A/1106/2016 and FNBr, 65269705.
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BCR SIGNALLING PROFICIENT CHRONIC LYMPHOCYTIC LEUKAEMIA
B CELLS ARE PRONE TO RITUXIMAB MEDIATED ELIMINATION IN VIVO
G. Pavlasova1,2,*, M. Borsky2, V. Svobodova1,2, K. Musilova1,2, K. Cerna1,2,
V. Seda1,2, J. Osickova2, Y. Brychtova2, M. Doubek2, S. Pospisilova1,2,
J. Mayer2, M. Mraz1,2
1Molecular Medicine, CEITEC MU, 2Department of Internal Medicine - Hema-
tology and Oncology, University Hospital Brno and Faculty of Medicine,
Masaryk University, Brno, Czech Republic
Background: Anti-CD20 monoclonal antibody rituximab (RTX) has improved
clinical outcome of patients with CD20-positive B-cell malignancies, including
chronic lymphocytic leukaemia (CLL). However, despite the fact that RTX has
been clinically used for 20 years, the exact mechanism of its action remains
largely unclear.
Aims: The aim of this study was to determine susceptibility of CLL cells’ sub-
populations to RTX.
Methods: Peripheral blood samples from CLL patients (N=17) were obtained
and analysed before (day 0) and 24 hours (day 1) after RTX administration
(375mg/m2, single agent).
Results: It was described that CLL cells that interacted with stromal cells in
vivo can be characterised by relatively weak cell-surface expression of
chemokine receptor CXCR4 and high expression of activation marker CD5
(CXCR4dimCD5brightcells) (Calissano et al., 2011). We showed that these cells
also have higher CD20 expression than CLL cells circulating in the peripheral
blood without contact with immune niches (CXCR4brightCD5dim; Pavlasova et
al., 2016). We hypothesised that the higher levels of CD20 on
CXCR4dimCD5bright cells make them the primary target for RTX in vivo, since
the cell surface CD20 expression associates with the RTX efficacy (Golay et
al., 2001). We analysed blood samples obtained from CLL patients treated
with RTX as a single agent and indeed, we observed that RTX preferentially
and nearly completely eliminates the CXCR4dimCD5bright subpopulation after
the first RTX dose (8.3% pre-RTX vs 2.1% post-RTX, P<0.0001). We further
analysed BCR signalling proficiency of the CXCR4dimCD5brightCD20bright sub-
population, since CD20 was proposed to play a role in BCR signalling. We
observed that CXCR4dimCD5bright CLL cells have higher immunoglobulin (IgM)
expression (~2-fold, P<0.005) which was coupled with higher responsiveness
to BCR crosslinking with anti-IgM (P=0.005). Moreover, CXCR4dimCD5bright
cells also have higher levels of CD19 (1.8-fold, P<0.0001), which is an important
component of BCR complex that augments signal transduction. Furthermore,
we demonstrated that CXCR4dimCD5bright cells have higher phosphorylation
of several proteins involved in PI3K/BCR/NFkB signalling pathway (P<0.05)
compared to CXCR4brightCD5dim cells obtained from the same patient. This
led us to hypothesize that CD20 up-regulation on CXCR4dimCD5bright cells is
likely of physiological importance for PI3K/BCR signalling. Indeed, we observed
significant reduction in phosphorylation of tyrosine-protein kinases associated
with PI3K/BCR signalling after silencing of CD20 by siRNA in B cells.
Summary/Conclusions: We showed that CXCR4dimCD5bright CLL subpopu-
lation in peripheral blood of CLL patients has the highest surface levels of
CD20 and is therefore preferentially and effectively eliminated by RTX. These
CLL cells likely represent the most “aggressive” subclone of CLL cells since
they have relatively high proliferative and BCR signalling capacity.
Supported by: the Ministry of Education, Youth and Sports of the Czech Repub-
lic under the project CEITEC 2020 (LQ1601); Czech Science Foundation (pro-
ject No. 16-13334Y); the Ministry of Health of the Czech Republic, grant No.
16-29622A. All rights reserved. The European Union’s Horizon 2020 research
and innovation programme under grant agreement No. 692298. This study
reflects only the author’s view and the Research Executive Agency is not
responsible for any use that may be made of the information it contains. MH
CZ-DRO (FNBr, 65269705); MUNI/A/1106/2016; GAMU MUNI/H/0865/2016,
and G.P. is a city of Ostrava scholarship holder. 
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REGULATION OF BCR SIGNALLING IN CHRONIC LYMPHOCITYC
LEUKEMIA: ROLE OF E3 UBIQUITIN LIGASE C-CBL
V. Martini1,2, R. Molfetta3, F. Severin1,2, V. Trimarco1, F. Frezzato1,2, F. Raggi1,2,
L. Martinello1, A. Visentin1, E. Scomazzon1, M. Facco1,2, G. Semenzato1,2,
R. Paolini2,3, L. Trentin1,*
1Department of Medicine, University of Padua, 2VIMM, Venetian Institute of
Molecular Medicine, Padua, 3Department of Molecular Medicine, University of
La Sapienza, Rome, Italy
Background: In normal B cells, the E3 ubiquitin ligase Cbl (c-Casitas B-lineage
lymphoma) is involved in the ubiquitin-dependent Lyn degradation and in the
down-regulation of BCR signalling. c-Cbl is activated by phosphorylation that
releases c-Cbl from its autoinhibited structure by triggering a conformational
change that leads to an enhanced transfer of ubiquitin from the E2 enzyme to
the substrate proteins. Mutations in this RING/Linker region result in the loss
of ubiquitin E3 ligase activity thus prohibiting lysosomal or ubiquitin/protea-
some-mediated degradation of tyrosine kinases and thereby unleashing tyro-
sine kinase signaling. We reported that in Chronic Lymphocityc Leukemia (CLL)
Lyn is over-expressed and is in an active conformation as integral component
of an aberrant cytosolic multiprotein complex, associated with several proteins,
such as Hsp90, HS1 and SHP-1L. In particular, Hsp90 appears tightly bound
to cytosolic Lyn, thus stabilizing the aberrant complex and converting individual
transient interactions into stable ones.
Aims: The accumulation of clonal B lymphocytes in CLL is mostly due to apop-
tosis resistance but also to proliferative activity. Abnormalities of molecules
involved in signal transduction pathways are connected to CLL pathogenesis
and a critical role has already been ascribed to B-cell receptor (BCR)-Lyn axis.
Here, we investigated the expression and the role of c-Cbl in CLL B cells since
in normal B cells is involved in the ubiquitin-dependent Lyn degradation and in
the down-regulation of BCR signaling.
Methods: Blood samples were collected from 30 CLL patients and 15 controls.
Untouched peripheral blood B cells were purified using the RosetteSep isolation
kit for human B cells. We characterized c-Cbl total protein level and c-Cbl(Y700)
by Western blotting. To evaluate the interaction between c-Cbl and Lyn in CLL
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B cells we performed a co-immunoprecipitation assay, followed by Western
blotting analysis, at steady state and after IgM (10µg/ml) stimulus. We also
evaluated the interaction between c-Cbl and Lyn after treatment with 17-DMAG
(500nM), a potent HSP90 inhibitor.
Results: We demonstrated that c-Cbl is overexpressed (p<0.001, Student’s t
test in CLL B lymphocytes with respect to normal B cells. We found that in neo-
plastic B cells c-Cbl did not co-immunoprecipitate with Lyn neither after BCR
trigger. We obtained similar results when we treated neoplastic B lymphocytes
with 17-DMAG to dissociate the Lyn-Hsp90 complex: after 1h, 2h and 4h of
treatment we immunoprecipitated Lyn demonstrating that neither before nor
after IgM stimulation c-Cbl interacts with this kinase. These results support the
hypothesis that c-Cbl is not involved in Lyn turnover. Data obtained from 10
independent experiments showed that in CLL neoplastic cells the phosphory-
lation on Y700 increased after 5’ and 10’ of IgM stimulus, highlighting the
involvement of c-Cbl in BCR signaling.
Summary/Conclusions: These preliminary results prompt us to investigate
the role of c-Cbl in the development of neoplastic clone. In CLL cells c-Cbl is
overexpressed with respect to normal B cells, and upon BCR engagement it
undergoes Y700 phosphorylation. However, c-Cbl is unable to stably interact
with Lyn suggesting an altered c-Cbl function that contribute to affect cell home-
ostasis.
E1006
ACTIVATION OF SHP-1/PP2A PATHWAYS TRIGGERS APOPTOSIS IN
CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
F. Severin1,2, E. Tibaldi3, M.A. Pagano4, F. Frezzato1,2, V. Trimarco1,2,
V. Martini1,2, F. Raggi1,2, L. Martinello1, M. Facco1,2, G. Zagotto4, G. Ribaudo4,
V. Pavan4, L. Bordin3, A. Visentin1,2, F. Zonta5, G. Semenzato1,2, A.M. Brunati3,
L. Trentin1,2,*
1Department of Medicine, University of Padua, 2Venetian Institute of Molecular
Medicine (VIMM), 3Department of Molecular Medicine, 4Department of Phar-
maceutical and Pharmacological Sciences, 5Department of Biomedical Sci-
ences, University of Padua, Padova, Italy
Background: CLL B cells inability to reach programmed cell death is due to
intrinsic defect and extrinsic factors. Among the intrinsic fault there is the mis-
regulation of the phosphorylation pattern. Reversible protein phosphorylation
is a fundamental post-translational modification by which virtually all cellular
events are regulated. The crucial players involved in this dynamic process are
protein kinases and protein phosphatases, which are placed at the different
levels of cellular signaling. The Src Family Kinase (SFK) Lyn is a key factor in
the dysregulation of survival and apoptotic pathways of malignant B cells in
CLL. One of the effects of Lyn’s action is the spatial and functional segregation
of the tyrosine phosphatase SHP-1 into two pools, one beneath the plasma
membrane in an active state promoting pro-survival signals, the other in the
cytosol in an inhibited conformation and unable to counter the elevated level of
cytosolic tyrosine phosphorylation.
Aims: Because CLL is characterized by a high level of Lyn-dependent tyrosine
phosphorylation in the cytosol, we focused our attention on compounds capable
of directly or indirectly driving the activation of SHP-1 which in turn could counter
the action of Lyn and induce cell demise. The goal is to discover new therapeutic
strategies to defeat a still incurable disease as CLL.
Methods: B cells were collected from 37 CLL patients. Freshly isolated CLL
cells incubated with increasing concentrations of nintedanib (0-24 μM) and
MP07-66 (2,2-diethoxyethyl{[4-(hexyloxy)phenyl]methyl})amine) for 24 and 48
hours with/without a layer of Mesenchymal Stromal Cells (MSCs). Caspase
dependence was demonstrated using the pan-caspase inhibitor z-VADfmk.
CLL B cells viability was tested by Flow Cytometer with Annexin V/PI test. SHP-
1 and PPP2Ac expression and phosphorylation were evaluated by Western
Blotting.
Results: We performed in vitro phosphatase activity assays on the cytosolic
pool of SHP-1 in the presence of increasing concentrations of nintedanib, a
receptor tyrosine kinase inhibitor recently shown to trigger SHP-1 activity.
Nintedanib treatment could activate the phosphorylated (at Ser591), and inhib-
ited, form of SHP-1 and to induce apoptosis, depending on the caspase acti-
vation, after 24h and 48h at marked level. Interestingly, we recently demon-
strated that Ser591 phosphorylation of SHP-1 could be dephosphorylated by
PP2A. In this scenario, the restoration of PP2A activity by a fingolimod analogue
devoid of immunosuppressive action, called MP07-66, and the subsequent
dephosphorylation of PP2A substrates, was shown to trigger apoptosis, like
nintedanib, in a caspase-dependent manner. Since our data suggest that the
activation of either PP2A or SHP-1 triggered by specific small molecules caused
stimulation of each other’s activity, we treated CLL cells with nintedanib and
MP07-66 together demonstrating an improved effect when used in combination.
Similar results, in all the conditions, were obtained in presence of a MSC layer,
showing the capability of these treatments to counteract the protective action
of tumor microenvironment.
Summary/Conclusions: In conclusion, our findings indicate that phosphatase
activators may represent a new weapon against this form of leukemia. Overall,
these data corroborate the hypothesis that the inhibition of PP2A is central to
CLL cell viability and that its activation is facilitated by the supportive action of
SHP-1, as demonstrated by the effect produced by the simultaneous use of
the respective activators.
E1007
TARGETING NANOPARTICLES TO CHRONIC LYMPHOCYTIC
LEUKAEMIA: EXPLOITING THE PROPERTIES OF CXCR4
C. Mccallion1,*, A. Booth2, J. Adams3, K. Rees-Unwin3, A. Peters1, A. Pluen4,
S. Webb1, J. Burthem3
1School of Chemistry, University of Manchester, Manchester, 2School of Chem-
istry, University of Leeds, Leeds, 3Institute of Cancer Sciences, 4School of
Pharmacy, University of Manchester, Manchester, United Kingdom
Background: Nanoparticle carriers of therapeutic agents (“drug delivery vehi-
cles”) can be used to deliver drugs to specific cells through the incorporation
of a “targeting ligand”. Targeting provides the therapeutic benefit of achieving
high local drug concentrations while reducing off-target effects against other
cells; the combined ligand/delivery vehicle system can also be manipulated to
determine the uptake pathway or modulate biological effects. The CXCR4
chemokine-receptor is an attractive target for drug delivery vehicles. It is over-
expressed in cancers including chronic lymphocytic leukaemia (CLL) (Doman-
ska et al., 2013) and binding to its ligand (CXL12) may induce proliferation,
survival or entry into protective cellular niches (Ganju et al., 1998). Targeted
nanoparticles that can bind and antagonise CXCR4 could therefore allow spe-
cific drug delivery to cancer cells while simultaneously blocking CXCL12-
induced chemoprotection. 
Aims: A drug-design strategy was developed to synthesise and evaluate a
novel CXCR4 targeting motif (BAT1) with structural similarity to Plerixafor, a
CXCR4-antagonist in clinical use. A key design principle was to incorporate a
polyethylene glycol (PEG) tether with a functional end-group to provide an
attachment point for cargoes, particularly liposomes. The evaluation aim was
to assess the effectiveness of BAT1 to deliver a chemotherapy cargo to CLL
cells within an ex vivo culture system.
Methods: A three-step synthesis was used to generate BAT1 (Figure 1A); its
structure and purity was confirmed using NMR, MS and HPLC. Bioactivity test-
ing employed primary CLL lymphocytes. Assessments tested: CXCR4 bind-
ing-affinity (flow cytometric competition assays), cell-binding characteristics
(immunocytofluorescence) and blockade of CXCL12-induced signalling
(immunoblot). Initial targeting assessment used a fluorescent label (Cy5) con-
jugated to the functional PEG tether. Cholesteryl chloroformate was then select-
ed to conjugate BAT1 to PEGylated liposomes. 
Results: The binding affinity of BAT1 (Figure 1B) was demonstrated using
competition assays (CXCL12, anti-CXCR4 ab, and the bis(cyclam) drug Pler-
ixafor). The studies confirmed BAT1 had high affinity for CXCR4 receptors
expressed on primary CLL cells. Immunocytofluorescence comparison with its
native ligand confirmed binding of BAT1 to the CLL cell surface, while
immunoblotting demonstrated blocking of CXCL12-induced downstream sig-
nalling (Figure 1C and 1D). The fluorescent moiety Cy5 was covalently linked
to the PEG moiety as a test-cargo, demonstrating that binding affinity was
retained in the presence of a cargo and that the drug competed for CXCR4
binding with related bis(cyclam) drugs. This work has been extended to attach
BAT1 to liposomes, with present work optimising liposome characteristics for
binding and uptake by CLL and the delivery of cytotoxic payload.
Figure 1.
Summary/Conclusions: A novel bis(cyclam) CXCR4 antagonist and targeting
ligand – BAT1 – has been synthesised. BAT1 demonstrates high affinity for the
CXCR4 receptor, supporting targeted delivery to CLL cells. Receptor binding
is associated with simultaneous blockade of CXCL12-mediated signal initiation
and effect, and therefore biological modulation of target cell behaviour. BAT1
haematologica | 2017; 102(s2) | 413
Madrid, Spain, June 22 – 25, 2017
is readily attached to liposomes through the PEG moiety, which will allow
chemotherapy delivery using stealth-liposomes (Allen and Cullis, 2013). Lipo-
some size and composition will be used to drive pathway-specific uptake to
different intracellular compartments. BAT1 therefore offers significant potential
to enhance therapy in CLL.
E1008
THE ROLE OF THROMBOPOIETIN AS A TOOL OF IMMUNE MODULATION
IN CHRONIC LYMPHOCYTIC LEUKEMIA
S. Ringelstein-Harlev1,*, M. Fanadka2, N. A. Horowitz1, T. Katz1
1Department of Hematology and Bone Marrow Transplantation, Rambam
Health Care Campus, 2Bruce Rappaport Faculty of Medicine, Technion, Israel
Institute of Technology, Haifa, Israel
Background: Thrombopoietin (TPO) is the major regulator of platelet produc-
tion, synthesized mainly by liver cells. The TPO receptor (TPO-R) is known to
be expressed on platelets, megakaryocytes and CD34+ cells. It has been report-
ed that patients with immune thrombocytopenic purpura, treated with TPO-R
agonists, developed alterations in the T-cell repertoire and pattern of cytokine
secretion from B- and T-cells. Thus, clinical activity of these agents could be
attributed in part to immune modulation. In chronic lymphocytic leukemia (CLL),
characterized by aberrant T-cell responses, high TPO serum levels coexist with
low levels of TPO gene transcripts in the malignant cells. These observations
could imply that TPO acts as an immune modulator in CLL.
Aims: The aim of the current study was to explore the role of TPO in T-cell
modulation in CLL. 
Methods: B-cells and CD4+T-cells were isolated from peripheral blood mononu-
clear cells (PBMCs) of untreated CLL patients (Rai stages 0-IV) and healthy
donors. TPO-R (CD110) expression on CD4+ T-cells was estimated by FACS.
CD4+ T-cells were incubated with low-dose IL2 and TPO for 5 days and the
percentage of CD4+CD25hiFOXP3+ cells (Tregs) was assessed. T-cell prolifer-
ation was evaluated using CFSE staining after stimulation with anti-CD3/CD28
antibodies, high-dose IL2 and TPO for 5 days. Percentage of cells retained in
G0 (non-proliferating pool) was assessed. CLL B-cells were activated with a
TLR9 agonist (ODN) and TPO expression was assessed by Q-PCR.
Results: CD4+ T-cells of CLL patients expressed significantly higher levels of
TPO-R (CD110) compared to T-cells of healthy donors, with a mean fluorescent
intensity of 764±148 and 498±206, respectively (p<0.05; n=6). Stimulation of
patient-derived CD4+ T-cells with TPO led to a 12% increase in the number of
cells retaining in G0 (from7.5%±5.4 to 8.5%±6.4; p<0.05; n=8), whereas pro-
liferation of healthy donor T-cells remained unaffected by TPO (11.5%±5.7 and
11.4%±5.7 of cells in G0; p=NS; n=6). Additionally, TPO stimulation resulted in
a 24% increase of Treg levels in patient T-cells (from 2.1%±1.7 to 2.6%±1.7%;
p<0.01; n=8). However, the Treg levels were not altered in healthy donor T-
cells subjected to TPO (0.74%±0.7 and 0.74%±0.8; p=NS; n=5), which is similar
to their proliferation response to this growth factor. To determine whether CLL
cells could be the TPO source in this disease, TPO mRNA expression in the
malignant cells was assessed, demonstrating a baseline ct value of 721±296,
which significantly increased to 1033±342 (p<0.05; n=6) upon ODN activation.
Summary/Conclusions: In the current study, TPO is found to affect immune
properties of CLL patient T-cells, inhibiting their proliferation and increasing
Treg levels. These effects have been observed in patient T-cells only, which
could be partly explained by higher levels of TPO-R expression revealed on
patient T-cells compared to healthy donor cells. The elevated TPO mRNA
expression in CLL B-cells could point to them as one of the possible sources
of this growth factor in patient serum. Activation of TPO-R may represent a
novel mechanism of T-cell inhibition in CLL. 
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TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION
IN CLL CELLS
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1CMBGT, Department of Internal Medicine – Hematology and Oncology, Uni-
versity Hospital Brno and Faculty of Medicine, Masaryk University, 2Central
European Institute of Technology (CEITEC), Masaryk University, 3Department
of Internal Medicine – Hematology and Oncology, University Hospital Brno and
Faculty of Medicine, Masaryk University, 4Institute of Experimental Biology,
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Background: Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1)
expression on malignant B-cells is considered a promising target for therapy
of CLL and other lymphoproliferative disorders. Recently published data sug-
gest that combination of BCR inhibitor ibrutinib with ROR1 antibody cirmtuzum-
ab can enhance treatment efficacy in CLL. Nevertheless, the variability in ROR1
expression during disease progression, therapy administration and relapse
remains unknown.
Aims: In our study we aimed to i) detect ROR1 in CLL cells during different
stages of the disease using flow cytometry and qRT-PCR with focus on patients
undergoing therapy; ii) analyse changes in ROR1 expression within individual
patients during the disease course.
Methods: CLL cohort consisted of 96 CLL patients (152 samples): 23 patients
with stable disease, 16 patients with active disease prior first therapy interven-
tion, 6 patients during first therapy, 13 patients in progression before second
line treatment, 3 patients in complete remission, 10 refractory patients, 9
patients treated with ibrutinib, 16 patients treated with idelalisib. To monitor
changes in ROR1 expression we tested serial samples from 5 CLL patients
(median follow up 76 months (66-131), median number of sampling points 12
(5-18)). For surface ROR1 protein analysis we used 8-colour flow cytometry
(modified MRD protocol: CD45/CD3/CD19/CD5/CD81/CD79b/CD22/ROR1) in
all samples. To quantify ROR1 mRNA expression changes within individual
patients we performed qRT-PCR in separated CLL cells (>95% CD19+CD5+).
CLL cells from samples in remission were separated immunomagneticaly
(Whole Blood Anti-ROR1 MicroBead Kit, Miltenyi Biotec).
Results: Using multicolour flow cytometry we confirmed ROR1 antigen/protein
presence on CLL cells in each analysed sample. The ROR1 antigen was
detectable on residual CLL cells during disease remission with the ability to
distinguish malignant population from healthy B-cells. Using qRT-PCR we
detected significantly higher levels of ROR1 mRNA in samples of treated
patients (p<0.01). This observation was supported by analysis of ROR1 mRNA
expression in five patients tested consecutively in several time-points. We
detected ROR1 mRNA expression increase in disease progression before ther-
apy and further increase during therapy administration. In case of remission
induction we observed decrease of ROR1 mRNA level. In patients treated with
ibrutinib or idelalisib we observed steep increase of ROR1 expression com-
pared to patients treated with FCR regimen.
Summary/Conclusions: ROR1 protein remains detectable on CLL cells during
disease course even in complete remission. ROR1 mRNA levels are highly
influenced by therapy administration especially in the case of treatment with
BcR inhibitors.
Supported by grants AZV-MZ-ČR 15-29793A, 15-31834A, and 15-30015A,
MUNI/A/1106/2016 and CEITEC 2020 (LQ1601) MŠMT ČR.
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NORMAL SERUM PROTEIN ELECTROPHORESIS IDENTIFIES AN
EXCELLENT PROGNOSIS GROUP AMONG IGHV MUTATED PATIENTS
WITH CHRONIC LYMPHOCYTIC LEUKEMIA, WITH A MEDIAN TFS OVER
18 YEARS
J. Chauzeix1,2,*, N. Bargues1, M.-P. Laforêt1, M. Deveza1, V. Combeau1,
V. Renat1, E. Guérin1, F. Trimoreau1, N. Dmytruk3, J. Feuillard1, N. Gachard1,
D. Rizzo1
1Service d’hématologie biologique, CHU Limoges, 2UMR7276, Université de
Limoges, 3Service d’hématologie clinique, CHU Limoges, Limoges, France
Background: Approximately 36% of patients with chronic lymphocytic leukemia
(CLL) have abnormal serum protein electrophoresis (SPE), either with hypogam-
maglobulinemia or with monoclonal immunoglobulin (Ig) peak. In this study, we
compared locally recruited patients with normal and abnormal SPE.
Aims: The aim was to identify prognosis parameters.
Methods: A total of 189 patients (132 abnormal SPE and 57 normal SPE) were
studied. Diagnoses were performed between 1980 and 2015. Prognosis param-
eters investigated were IGHV mutation status, presence of SF3B1, NOTCH1
or BIRC3 mutations (determined by high throughput and Sanger sequencing),
and cytogenetic abnormalities such as del17p, del11q, del13q and trisomy 12
(assessed by standard caryotype, FISH analysis and QMPSF).
Results: In this series, 73%, 19% and 8% of patients were at Binet stage A, B
and C respectively, and 30% had a normal SPE at diagnosis. Ninety six percent
of patients with normal SPE were at Binet stage A, versus 63% of patients with
abnormal SPE (Chi2 test : p<10-4). Median lymphocytosis at diagnosis was
lower in patients with normal SPE (12,82 G/L versus 19,54 G/L in abnormal
SPE, Fisher test : p=0,00169). Regarding genetic prognosis factors, we found
that 58% of cases with normal SPE had a good prognosis profile (mutated
IGHV and/or isolated del13q, with no other genetic abnormality detected),
meanwhile 65,2% of patients with abnormal SPE exhibited at least one poor
prognosis marker (unmutated IGHV, mutation of SF3B1, NOTCH1, del17p,
del11q or trisomy 12, Chi2 test : p<10-4). In patients with normal SPE, only
3,5% cases were SF3B1 mutated against 15,2% in case of abnormal SPE
(Chi2 test : p=0,002). Among other strong differences, 10,5% patients with nor-
mal SPE had a trisomy 12 against 18,2% for abnormal SPE. Isolated del13q
was found in 38,6% and 21,2% of cases with normal and abnormal SPE
respectively. Mutated IGHV status was found in 65% in normal SPE and 56%
with abnormal SPE. Compared to the whole series, IGHV repertoire analysis
shows bias in IGHV1-2, and IGHV4-34 rearrangements, with decreases usage
of IGHV3-21 and IGHV3-48. Treatment free survival was markedly increased
in patients with normal SPE (median of 10,0 years versus 3,0 years for normal
and abnormal SPE respectively, log rank test : p<0,0001). Moreover, while
patients with mutated IGHV had a median TFS of 8 years (against 3 years for
unmutated patients), those with normal SPE and mutated IGHV had a median
TFS over 18 years. Patients with mutated IGHV and abnormal SPE had a
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median TFS of 4 years (log rank test : p=0,0003). Thus, patients with normal
SPE and IGHV mutated status constitute a group with excellent prognosis.
Summary/Conclusions: In conclusion, normal SPE was associated with good
outcome with decreased accumulation of side genetic events (in particular,
SF3B1 mutations). This analysis shows a bias in IGHV repertoire according to
SPE status. These results also clearly suggest that patients with a normal SPE
and mutated IGHV have an extremely quiet CLL natural history. This could be
either due to the weaker activity of the disease and/or to the absence of adverse
consequences of a concomitant paraprotein.
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HSP70 EXPRESSION IS MODULATED BY ITS MASTER REGULATOR HSF1
VIA MAPKS AND PI3K/AKT/MTOR PATHWAYS IN CHRONIC LYMPHOCYTIC
LEUKEMIA
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Background: The search for molecules involved in apoptosis resistance/
increased survival of B cells from Chronic Lymphocytic Leukemia (CLL) is still
ongoing since this disease remains not definitively understood. We recently
found that the Heat Shock Protein of 70kDa (HSP70), expressed in response
to a wide variety of stress signals and allowing cells to survive to lethal condi-
tions, was particularly overexpressed in neoplastic B cells from CLL. Moreover,
the Heat Shock Factor 1 (HSF1), the major responsible for the transcription of
HSP70, is itself overexpressed in CLL and strictly correlated to HSP70. In
response to stress, HSF1 becomes phosphorylated, forms homotrimers, binds
DNA and activates heat shock gene transcription. HSF1 is regulated by a fine
balance of activatory/inhibitory phosphorylations mediated by kinases belonging
to pathways triggered by RAS (i.e. PI3K/AKT/mTOR and RAF/MEK/ERK).
Aims: Since HSP70 is overexpressed in CLL neoplastic B cells and most of
“HSF1-phosphorylating actors” belong to signalling pathways taking part from
RAS, being the PI3K/AKT/mTOR and the RAF/MEK/ERK pathways, we are
herein aimed at gaining information and dissecting this network in CLL B cells.
Methods: In a Reverse Phase Protein Array (RPPA) study, previously per-
formedin B cells from 57 CLL patients and 11 healthy subjects, we assessed
the activation/expression of key signalling proteins. Herein, we focused on
HSP70, AKT-Ser473, mTOR-Ser244, GSK3a/b-Ser21/9, CDK2, CREB-Ser133,
MEK1/2-Tyr217-221, ERK1/2-Thr202/Tyr204, NFkB-Ser536, p38MAPK-
Thr180/Tyr182, SAPK-JNK-Thr183/Tyr185 and PDK1-Ser241. Cluster and sep-
arated analyses have been performed. 
Results: We divided our patients in HSP70-high and HSP70-low considering
as cut-off the value of the median of HSP70 expression levels calculated by
RPPA and demonstrated that the examined proteins behave in a different way
between patients expressing high or low levels of HSP70. HSP70-high patients
present high Akt-Ser473, an inhibitor of GSK3a/b that, in the inhibited form,
prevents HSF1 inhibition. By contrast, HSP70-low patients have high MEK1/2-
Ser217/221 and ERK-Thr202/Tyr204, known to negatively regulate HSF1.
Intriguingly, p38MAPK-Thr180/Tyr182 which has been described to both acti-
vate and inhibit HSF1 at different sites, is overexpressed in those patients pre-
senting low levels of HSP70.
Summary/Conclusions: These data would suggest that, in CLL, HSP70
expression is regulated by the modulation of HSF1 activity through the activation
of one or the other way triggered by RAS. In particular, an activation of the
PI3K/AKT/mTOR pathway leads, as result, to a higher expression of HSP70
while an activation of the RAF/MEK/ERK signalling rather results in HSP70
down regulation. The dissection of signalling pathways connected to HSP70-
HSF1 axis in CLL will contribute to define the biology and understand the patho-
genesis of this disease. 
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THE INTERPLAY BETWEEN TH17 AND TREGS: A NEW IMMUNOSUP-
PRESSIVE INSIGHT IN CHRONIC LYMPHOCYTIC LEUKEMIA
S. De Matteis1,*, R. Napolitano1, A. Lucchesi2, D. Cangini2, A. Cuneo3,
G.M. Rigolin3, E. Volta3, G. Musuraca2
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Background: Chronic lymphocytic leukemia (CLL) is the most frequent
leukemia in the Western world and it is characterized by the clonal expansion
of CD5 positive B cells. In CLL, different T cells dysfunctions have been
described, probably related to the interaction with malignant B cells. TH17 and
regulatory T cells (Tregs) are subpopulations of T lymphocytes which play a
fundamental part in inflammatory response and immune tolerance. However,
their role in the immunopathogenesis of CLL has not yet been fully clarified.
Aims: The aim of this study is to clarify the interplay between TH17 and Tregs
in the pathogenesis of CLL.
Methods: After obtaining the patient’s informed consent, peripheral blood was
collected from 30 untreated CLL patients and 30 age-matched healthy volun-
teers (HV). Cytokine production was evaluated before and after a 48 h culture
of CD4+ T cells in complete medium with IL-6 (o/n), followed by a 5 h stimulation
with PMA, Ionomycin and Monensin (PIM), or with Candida Albicans. For
cytokine secretion analysis, stimulated CD4+ T cells were analyzed by human
IL-17 and IL-10 secretion assay. IL-23 plasma levels were evaluated by ELISA.
For the analysis of Tregs and their subsets, stimulated PBMCs were stained
with anti-CD4 FITC, anti-CD25 APC-Cy7, anti-FoxP3 APC and anti-Tbet PE or
anti-RORγt PE or anti-GATA-3 PE. Statistical analysis were carried out using
the paired and unpaired two-tailed Student’s t tests and confirmed with the non
parametric Wilcoxon signed-rank test.
Results: In CLL patients we observed a reduced production of IFN-y and IL-4,
respectively from TH1 and TH2 and an increase of IL-17A from TH17, compared
to HV. All the observed differences were statistically significant. We also eval-
uated the ability of CD4+ T cells to secrete IL-17A, IL-10 or both. We reported
a statistically significant increase in the frequency of CD4+ IL-17A-producing
cells in CLL patients compared to HV, whereas the percentage of IL-17A+/IL-
10+ cells remained unchanged. In order to evaluate the functional effects of
the observed alterations, we analyzed IFN-γ+ CD4+ T cells-mediated response
after stimulation with C. Albicans for 48 h, with or without depletion of IL-17A-
secreting cells. The frequency of IFN-γ-producing T cells resulted statistically
significant increased in patients than HV before IL-17A-secreting T cells deple-
tion. Conversely, after IL-17A+ CD4+ T cells depletion, we didn’t observe sig-
nificant differences in term of IFN-γ production. We also observed increased
IL-23 plasma levels in patients compared to HV. In addition our data highlighted
a significantly higher frequency of CD4+ CD25highFoxP3+ cells (Tregs) in CLL
samples, with a statistically significant increase in Tbet+ Tregs, RORγt+ Tregs
and GATA-3+ Tregs subpopulations (Figure 1).
Figure 1.
Summary/Conclusions: Our results reported a down-regulation of IFN-y and
IL-4 producing T cells, associated to an increased frequency of Tregs and their
subsets in CLL patients, probably trying to overcome the deficit of effector T
cells. On the other hand, we observed a rise in IL-17A secreting T cells related
to the increased IL-23 production by dendritic cells in order to restore TH17
pool, without changing the percentage of IL-17A+/IL-10+ cells. These data sup-
port the idea of the protective function of TH17 that show an effector and not a
regulatory T phenotype. Starting from these observations, this study could pave
the way to further researches and applications in the comprehension of the
biological and regulatory mechanisms of TH17 and Tregs, supporting the study
of a pioneering anticancer therapy in CLL.
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LOW EXPRESSION OF CD25 IN CHRONIC LYMPHOCYTIC LEUKEMIA
NOTCH1-MUTATED CASES INDEPENDENT OF CDK4/6 MISREGULATION
T.H. Chen Liang1,*, A.M. Hurtado1, M. Castillo1, J. Muñoz-Ballester1,
B. Przychodzen2, M.D. García-Malo1, F. De Arriba1, F.J. Ortuño1, J.P. Maciejewski2,
V. Vicente3, A. Jerez1
1Hematology and Oncology Department, Hospital Morales Meseguer,Centro
Regional de Hemodonación. Universidad de Murcia, IMIB, Murcia, Spain,
2Translational Hematology and Oncology Research Department, Cleveland
Clinic, Cleveland, United States, 3Hematology and Oncology Department, Hos-
pital Morales Meseguer,Centro Regional de Hemodonación. Universidad de
Murcia, IMIB,CIBERER, Murcia, Spain
Background: Recently, it has been shown that CDK6-mediated repression of
CD25 is required for induction and maintenance of NOTCH1-induced T-cell
acute lymphoblastic leukemia. 
Aims: The aim of this study was to identify the NOTCH1 mutational status
detected by deep sequencing in a cohort of 138 CLL patients and to correlate
it with the immunophenotypic profile and CDK4 and CDK6 expression.
Methods: We performed targeted NGS sequencing of blood samples, collected
at diagnosis, from 138 CLL patients. We designed a TruSeq Custom Amplicon
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containing 13 genes and covering 28.099 bases. Paired-end sequencing was
performed with MiSeq v2.2 chemistry, and a mean depth of 998 reads/base
was obtained. Every patient underwent, at baseline, a flow cytometry charac-
terization with a panel including (sIg)λ, (sIg)κ, CD19, CD5, CD11b, CD81,
CD10, CD79b, CD29, CD38, FMC7, CD22, CD45, CD103, CD11c, CD25,
ZAP70, CD11a, and CD24. CDK4 and CDK6 expression levels were quantified
by RT-qPCR.
Results: With a median age of 66 y.o. (range, 31-89) and a slight male pre-
dominance, the median follow up time of our cohort was 43 months (24-104).
We found that 38/138 (28%) patients harbored at least one mutation, with
NOTCH1 (n=16, 12%), ATM (n=12, 9%), TP53 (n=9, 7%), and SF3B1 (n=8,
6%), as the most frequently mutated genes. Those patients with a NOTCH1
mutation showed a lower CD25 expression (24 mean fluorescence intensity
units (MFIu)) than those without a mutation (43 MFIu), p=0.03. We could not
validate the recently reported association between the presence of NOTCH1
mutations and a low expression of CD20. In our cohort, the MFI expression in
NOTCH1 mutated and non-mutated patients was 163 and 146 units, respec-
tively (p>0.05).We measured CDK4 and CDK6 expression in the CD19+ sorted
fraction RNA of 7 NOTCH1 mutated cases and 11 non mutated cases, without
finding significant differences (0.26 vs 0.27 for CDK6, 0.025 vs 0.022 for CDK4;
p>0.5 in both cases).
Summary/Conclusions: We found a significant inferior expression of CD25
when activating NOTCH1 mutations are present in CLL patients. The relation-
ship found between these two variables, with an inversed direction to that found
in physiological conditions, has also been shown in the setting of NOTCH1-
mutated T acute lymphoblastic leukemia. In CLL cases, it seems to be inde-
pendent of CDK4/6 expression, prompting further studies assessing CDK4 and
CDK6 regulators.
E1014
GENE MUTATIONS ANALYZED BY NEXT-GENERATION SEQUENCING
ALLOW US TO DEFINE THE PROGNOSIS OF CHRONIC LYMPHOCYTIC
LEUKEMIA PATIENTS WITH EARLY-STAGE DISEASE AND 13Q DELETION
M. Hernández-Sánchez1,*, M. Quijada1, C. Robledo1, A.E. Rodríguez1, A. Montaño1,
A.-Á. Martín1, R. Benito1, M.-J. Vidal-Manceñido2, J. Galende3, J.-M. Alonso4,
J.-A. Queizán5, I. De la Fuente6, C. Aguilar7, A. García de Coca8,
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Background: Next-Generation sequencing (NGS) studies have revealed a
number of recurrently mutated genes in chronic lymphocytic leukemia (CLL).
It is reasonable to argue that evaluation of the newly gene mutations as prog-
nostic markers would help to improve prognostication of CLL patients. Inter-
estingly, gene mutations could help us to refine the prognosis in the group of
CLL patients with other prognostic markers associated with good prognosis.
Aims: To analyze the presence of mutations of a panel of genes by NGS and
its prognostic impact in patients with CLL, focusing in the groups of patients
with good prognosis characteristics.
Methods: Amplicon-based-NGS was performed using 454 platform in 147 CLL
patients to evaluate the mutational status of 6genes (TP53, NOTCH1, SF3B1,
XPO1, FBXW7 and MYD88). Samples were obtained at diagnosis or before
treatment in all cases. 70.1% were Binet A and 53% had 13q deletion (13q-).
A cut-off 2% was applied to define variants. All the mutations were validated.
Results: 1. NGS analysis showed that 37.4% of CLL patients (55/147) showed
mutations in any of the analyzed genes. The frequency of mutations was 16.3%
for NOTCH1, 10.2% for SF3B1, 6.8% for TP53, 4.8% for XPO1, 3.4% for
FBXW7, and 1.4% forMYD88.The presence of mutations in any of these genes
except to MYD88 (mutated CLL) was significantly associated with clinical pro-
gression (60.0% for mutated CLL vs. 38.2% for unmutated CLL; P=0.05). Inter-
estingly, mutated CLL patients showed a shorter time to first treatment (TFT)
than unmutated CLL patients (30 months vs. 88 months; P=0.006). By contrast,
MYD88 mutations were detected in CLL with mutated IGHV and 13q-. 2. Of
note, 23.6% of the mutations had a mutational load of ≤15% and thus would
not have been detected by capillary Sanger sequencing. CLLs with mutations
in ≤15% of cells had also a shorter TFT than patients without mutations (18 vs.
88 months; P=0.018), and similar to CLL patients with mutations in >15% of
cells (P=0.370). In addition, 14.5% of mutated CLL patients showed 2muta-
tions.Patients with more than one mutation had a shorter TFT than CLL patients
with one mutation (7 months vs 31 months). 3. In the group of CLL patients
with Binet stage A, 32.8% of them showed mutations in any of the analyzed
genes. Interestingly, CLL patients Binet A with mutations (except to MYD88)
showed a shorter TFT than CLL patients without mutations (31 vs 131 months,
P<0.001). Besides this, CLL with 13q- as the sole cytogenetic alteration and
gene mutations had also a shorter TFT that unmutated 13q- CLL patients
(P=0.002).
Summary/Conclusions: 1) CLL patients with mutations in TP53, NOTCH1,
SF3B1, XPO1 and FBXW7 show a worse prognosis than CLL patients without
mutations. 2) Gene mutations in TP53, NOTCH1, SF3B1, XPO1 and FBXW7
in a low percentage of the cells are associated with a shorter TFT. 3) Among
CLL patients with good prognostic characteristics (Binet A and 13q-), gene
mutations help us to define the prognosis of the patients.
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ALTERED COMPLEX C5 IS ASSOCIATED WITH COMPROMISED
COMPLEMENT ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA
A. Braester1,2,*, M. Barhoum1, R. Michelis1
1Haematology, Galilee Medical Center, Naharyia, 2Faculty of Medicine, Bar-
Ilan University, Safed, Israel
Background: The therapeutic monoclonal antibodies used for the treatment
of Chronic lymphocytic leukemia (CLL) mediate anti-tumor effects through sev-
eral mechanisms: complement-mediated cytotoxicity (CDC), antibody-depen-
dent cell-mediated cytotoxicity (ADCC), and phagocytosis. CDC efficacy thus
depends on the expression level of the target B-cell antigen, the integrity of
apoptotic cascades within tumor cells, the functional capacity of effector cells,
and the availability and activity of the complement (C) system. Published data
indicate deficiency of one C protein or more in most CLL patients, as well as
additional factors that may affect C activity. The role of structural abnormalities
of C complexes in affecting C function has not been investigated.
Aims: To study the structural integrity of circulating C complexes, focusing
mainly on C5, and to establish its importance for C activity in CLL.
Methods: Blood samples were collected from 36 naïve CLL patients and 10
healthy controls (HC). Biochemical and haematological parameters, and CLL
staging were recorded. The isoforms of two key C components, C3 and C5
were studied by Western blot analysis. The activity of the C system before and
after in-vitro activation via the classical or alternative pathways was followed
by the levels of C5b-9, the terminal product of C activation. C activation was
also studied in combination with C5-deficient serum or after supplementation
with normal C5. In-vitro activation data were associated with the presence of
C5 isoforms.
Results: Differences in C5 pattern were found in some of the CLL patients.
Specifically, the C5 complex that exists as a single protein band in all HC and
in 56% of CLL patients appeared in 44% of the patients as a clear double-
band. No clear differences were observed in C3 pattern in the patients. Higher
basal levels of C5b-9 were found in CLL patients with abnormal pattern of C5
(3946±758 SEM ng/ml) compared with both HC (682±158 SEM ng/ml) and
CLL patients presenting normal C5 pattern (2363±655 SEM ng/ml). In-vitro C
activation via the classical pathway was inversely correlated with basal activity,
and was significantly lower (p<0.03) in the CLL patients with altered C5 com-
pared to HC and CLL patients with normal C5. In-vitro activation via the alter-
native pathway was similar in all subjects’ groups. C activity in C5-deficient
serum supplemented with 33% sera from patients with abnormal C5 was sig-
nificantly lower compared to the activity observed after supplementation with
serum from HC or from patients with normal C5. Activity after supplementation
with normal C5 (commercial) was significantly lower in sera from CLL patients
with abnormal C5 pattern compared to sera from the other subjects’ groups.
Summary/Conclusions: The data indicate a possible link between the acti-
vation potential of the C system in CLL patients and alterations in the complex
structure of C5. The differences in C activation via the classical and alternative
pathways may indicate disturbance in the classical pathway in patients with
abnormal C5. The exact mechanisms by which abnormal C5 distracts the C
activity need further clarification. Yet, the appearance of abnormal C5 in CLL
patients with disturbed C activity bears the potential to develop a marker which
will assist in identifying patients who are likely to be less responsive to future
immunotherapy treatment due to compromised CDC. Development of such a
marker may assist clinicians in refining and personalizing the immunothera-
peutic approach, improving CDC and consequently the therapy results.
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ASSOCIATIONOF CPG-STIMULATED KARYOTYPE WITHTIME-TO-FIRST
TREATMENT FOR CLL
F.P. Tambaro1,*, N. Jain2, A. Ferrajoli2, C. Criscuolo3, J. Burger2, P.A. Thompson2,
H. Kantarjan2, M. Keating2, M. Ripaldi1, Z. Estrov2, M.R. D’Amico1, S. O’Brien4,
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1Bone Marrow Transplantation, Ospedale Pausilipon, Napoli, Italy, 2Leukemia,
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Background: Prognostic factors correlate with clinical outcomes, independent
of treatment. B cell receptor (BCR) signaling pathway inhibitors can nullify the
prognostic impact of some markers, such as IGHV mutation status.CpG-stim-
ulated metaphase karyotype can identify clonal cytogenetic abnormalities in
CLL that may not be seen with standard non-stimulated karyotype or by FISH.
Complex cytogenetics, defined as 3 or more chromosome abnormalities in 2
or more metaphases was the highest-risk feature for shorter progression-free
and overall survival in patients receiving ibrutinib for relapsed/refractory CLL.
Complex karyotype is not uncommon among relapsed/refractory CLL cases,
particularly those who previously received genotoxic chemotherapy.
Table 1. Continuous and Categorigal Patients Characteristics.
Figure 1.
Aims: The aim of this study is to report the incidence and the impact of CpG-
stimulated karyotype in the treatment of naive CLL.
Methods: We evaluated 501 treatment-naïve patients with CLL at MDACC
between July 2013 and June 2016. CpG-stimulated metaphase karyotype of
CLL cells from blood or bone marrow was performed by culture of mononuclear
cells for 72 hrs in media containing CpG-685 (20ug/ml), phorbol 12-myristate
13-acetate (PMA; 0.04ug/ml) and Pokeweed mitogen (PWM; 0.1ug/ml). Banding
and analyses were by standard laboratory procedures. Twenty metaphases
were analyzed per culture and patients were categorized as having diploid kary-
otype, a single, 2 or 3 or more(complex) clonal chromosome abnormalities pres-
ent in more than 1 metaphase by CpG-stimulated karyotype.The frequency and
distribution of chromosome abnormalities with other prognostic factors and time-
to-first treatment from diagnosis (TTFT) were analyzed (Table + Firgure).
Results: The majority (69%) of patients had diploid cytogenetics. Higher-risk
prognostic features such as del17p, del11q, unmutatedIGHV and ZAP70
expression were associated with presence of complex karyotype abnormalities.
Shorter TTFT from diagnosis was associated with 1, 2, and complex clonal
chromosome abnormalities compared to diploid karyotype (p=.0005). A model
was developed, which identified patient characteristics independently associ-
ated with shorter TTFT including: 1 or more clonal chromosome abnormality
by CpG stimulated karyotype; unmutatedIGHV; 3 involved lymph node sites;
and CD38 expression (>30%).
Summary/Conclusions: In conclusion, CpG-stimulated karyotype identified 1
or more clonal chromosome abnormality in nearly a third of untreated patients
and was a significant independent prognostic factor for TTFT. Models for TTFT
may be useful in identifying patients at high-risk for needing treatment sooner
and thereby useful for early intervention clinical trials.
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COMPARISON OF THE CHRONIC LYMPHOCYTIC LEUKEMIA INTERNATIONAL
PROGNOSTIC INDEX (CLL-IPI) WITH THE BARCELONA-BRNO
PROGNOSTIC MODEL: ANALYSIS OF 1299 NEWLY DIAGNOSED CASES
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Background: In the last two decades, a plethora of clinical, serological and
biological markers have been identified that are significantly associated with
the prognosis of chronic lymphocytic leukemia (CLL) patients. Recent research
has focused on the development of scoring systems capable of integrating the
major prognostic parameters. A recent prognostic index called CLL International
Prognostic Index (CLL-IPI), built on clinical, serological, and biological param-
eters (TP53 deletion and/or mutation, IGHV mutational status, β2M, clinical
stage, and age) has been proposed and validated. Recently, a Barcelona-Brno
CLL group, with the aim of simplifying the CLL-IPI, proposed a prognostic model
comprising only two biomarkers (IGHV mutational status and FISH cytogenet-
ics).
Aims: We performed a comparison of the CLL-IPI with the Barcelona-Brno
prognostic model in an independent series of Italian and United States (U.S.)
patients.
Methods: Databases from 4 Italian and 1 U.S. centers including roughly 3700
newly diagnosed CLL patients were used to compare the CLL-IPI with the
Barcelona-Brno prognostic model. Baseline data regarding age, Rai stage,
IGHV mutational status, β2M and fluorescence in situ hybridization (FISH)-
detected cytogenetic abnormalities were available for 1299 cases. Del17p was
used as the sole marker of TP53 status. The CLL-IPI and the Barcelona-Brno
prognostic model were calculated using the methods proposed. The accuracy
of the prognostic models was assessed by the Harrell C index (an index of dis-
crimination), the explained variation in mortality (an index combining calibration
and discrimination), and the Akaike information criterion (AIC, an index com-
paring two non-nested prognostic models). The lower the AIC, the higher the
prognostic accuracy of a predictive model.
Results: The median age of the 1299 patients was 63 years (range 27-92)
with 61.3% males. The majority of patients had Rai stage 0 (57.9%). According
to the CLL-IPI, 51.3% of patients were classified as low-, 28.7% as intermedi-
ate-, 16.2% as high-, and 3.8% as very high-risk. The 5-year OS probabilities
were: 95% for low-risk, 89.9% for intermediate-risk, 70.1% for high-risk, and
32.8% for very high-risk cases (P<0.0001; Harrell C index=73%;P<0.001) (Fig-
ure 1A). According to the Barcelona-Brno prognostic model, 58.1% of patients
were classified as low-, 31.8% as intermediate-, and 10.1% as high-risk. The
5-year OS probabilities were: 92.2% for low-risk, 83.6% for intermediate-risk,
and 68.2% for high-risk cases (P<0.0001; Harrell C index=65%; P<0.001) (Fig-
ure 1B). The AIC showed the superiority of the CLL-IPI compared to the
Barcelona-Brno prognostic model in predicting OS (CLL-IPI, AIC=3432.167
versus Barcelona-Brno prognostic model, AIC=3549.492). Accordingly, the
explained variation in mortality provided by the CLL-IPI was 42% (P<0.001), a
figure higher than that due to the Barcelona-Brno prognostic model
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(21%,P<0.001), indicating that the CLL-IPI had a higher prognostic accuracy
for mortality compared to that of the biomarkers-only prognostic model. Then,
we also compared the ability of the two scores to predict TTFT in newly diag-
nosed patients. The Harrell C-index of the Barcelona-Brno prognostic model
was 0.70 (P<0.001), lower than that of the CLL-IPI score (0.73,P<0.001). The
AIC showed the superiority of the CLL-IPI compared to the Barcelona-Brno
prognostic model in predicting TTFT (CLL-IPI, AIC=5960.503 versus biomark-
ers-only prognostic model, AIC=6010.929). Accordingly, the explained variation
provided by the CLL-IPI was 33% (P<0.001), a figure higher than that achieved
by the Barcelona-Brno prognostic model (28%,P<0.001), indicating that the
CLL-IPI had a higher prognostic accuracy for predicting TTFT as compared to
that of the Barcelona-Brno prognostic model.
Figure 1.
Summary/Conclusions: Our results confirm the validity of both scores (CLL-
IPI and biomarkers-only prognostic model) to predict survival and TTFT among
patients with previously untreated CLL. Moreover, we have demonstrated that
the CLL-IPI which combines clinical and serological data with biological param-
eters has a higher accuracy for predicting prognosis and TTFT of CLL patients
than the Barcelona-Brno biomarkers-only prognostic model.
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PHARMACOKINETICS
V. Ribrag1,*, M. Wermke2, F. Morschhauser3, S.T. Lim4, G. Salles5, I. Kloos6,
M. Becquart6, A. Derreal6, L. Kraus-Berthier6, S. Pennaforte6, J.-M. Michot1,
S. Stilgenbauer7, J. Walewski8, S. Le Gouill9
1Institut Gustave Roussy, Villejuif, France, 2Universitätsklinikum Carl Gustav
Carus, dresden, Germany, 3CHRU - Hôpital Claude Huriez, Lille, France,
4National Cancer Centre, Singapore, Singapore, 5Hematology, Hopital Lyon
Sud, Lyon, 6Servier, SURESNES, France, 7University of Ulm, Ulm, Germany,
8Lymphiod Malignancies, Maria Sklodowska-Curie Memorial Institue and
Oncology Centre, Warszaw, Poland, 9Hematology, CHRU Nantes, Nantes,
France
Background: BCL-2 is an anti-apoptotic protein overexpressed in chronic lym-
phocytic leukemia (CLL). BCL-2 is responsible for apoptosis machinery dys-
regulation and contributes to chemotherapy resistance. S55746/BCL201 is a
novel, oral, selective BCL-2 inhibitor.
Aims: The current first-in-human study evaluates the safety and aims to estab-
lish the recommended phase 2 dose; main secondary objectives include eval-
uation of pharmacokinetics (PK), food effect, pharmacodynamics and prelimi-
nary activity in patients (pts) with relapsed or refractory CLL.
Methods: S55746/BCL201 as single agent is being investigated in a phase I
(EUDRACT, NCT02920697), open label, multicenters, international dose esca-
lation trial. S55746/BCL201 was initially administered in fasting condition, once
daily (in 21-day cycle) until progressive disease (PD) or unacceptable toxicity.
A tumor lysis syndrome (TLS) prevention protocol was implemented. After giv-
ing informed consent pts could receive 50 to 2000mg according to a modified
version of the Continual Reassessment Method for dose allocation process. In
the food effect part of the study, 7 non-Hodgkin’s lymphoma patients received
a film coated 200mg tablet under fasting condition (i.e. after 10-hour fasting
period) and after a calibrated moderate meal the day after.
Results: As of February 2017, 12 CLL pts have been treated (median age 67
years [range 52-82]). On these 12 pts, 5 presented a bulky disease, 1 a 17p13
deletion, 4 a 11q deletion, and 1 a p53 mutation. CLL pts were dosed up to
700mg, with a median duration on treatment of 79 days. Median number of
prior regimens in CLL pts was 4 (range 2-5). Preliminary PK results in fasting
pts showed that exposure increased linearly but with some inter-individual vari-
ability. The most frequent (≥2 pts) grade 3/4 adverse events (AEs) were neu-
tropenia (n=2) and thrombocytopenia (n=2). AEs possibly related to the study
drug were reported in 4 pts: neutropenia (n=2), neutrophil count decrease
(n=1), fatigue (n=1), dyspnea (n=1), gingival bleeding (n=1) and left ventricular
ejection fraction (LVEF) decrease (n=1). No clinical or laboratory TLS were
reported. One patient in the 700mg cohort experienced a DLT (asymptomatic
LVEF decrease grade 2 recovered within 2 weeks). At 700mg, a decrease in
lymphocytes count from baseline (>50%) was observed in 3 out of 4 patients
associated with a decrease in the sum of the product of the diameters of lymph
nodes (from 23% to 40%). This decrease in lymphocytes count, started from
cycle 1, and may be correlated with an induction of apoptosis in CLL cells (4
hours post first dose), detected by flow cytometry in CD19+/AnnexinV+ cells.
Two CLL pts are ongoing after having completed their 3rd cycle; 10 pts have
withdrawn from the study: 7 due to PD, 1 for lack of efficacy and 2 due to AE.
The non-compartmental pharmacokinetic analysis of the food effect cohort (5
assessable pts) demonstrated that S55746/BCL201 PK is modified by the
ingestion of a moderate meal (400-500 kcal with fat contributing to 150 kcal).
The median Tmax was delayed from 1.5h to 4h when administered with food.
Compared with fasting condition, Cmax and AUC increased by approximately
6-fold following a moderate meal. Based on these results, a protocol amend-
ment to the clinical trial has been implemented in order to further investigate
the administration with food in a new dose escalation.
Summary/Conclusions: S55746/BCL201 monotherapy showed first signs of
activity across the tested dose levels with an acceptable safety profile so far.
Based on PK food interaction results, dose escalation in the fed state has start-
ed.
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INCREASED VIRUS-SPECIFIC IMMUNE RESPONSES PARALLELED BY
A PNEUMOCOCCUS-SPECIFIC-IMMUNODEFICIENCY STATE AND
HYPOGAMMAGLOBULINEMIA: ALREADY EMERGE IN HIGH-COUNT
MONOCLONAL B LYMPHOCYTOSIS PRIOR TO CLL
I. Criado1,*, S. Muñoz-Criado2, A. Rodríguez-Caballero1, W.G. Nieto1,
A. Romero-Furones3, P. Fernández-Navarro4, M. Alcoceba5, T. Contreras6,
M. González5, A. Orfao1, J. Almeida1
1Department of Medicine, Cancer Research Center (IBMCC, CSIC-USAL),
2Service of Microbiology, University Hospital of Salamanca, 3Centro de Aten-
ción Primaria de Salud Miguel Armijo, 4Centro de Atención Primaria de Salud
de Ledesma, 5Service of Hematology, 6Service of Biochemistry, University
Hospital of Salamanca, Salamanca, Spain
Background: Patients diagnosed with chronic lymphocytic leukemia (CLL)
display a high incidence of infections, due to an associated immunodeficiency
state that includes hypogammaglobulinemia. Even more, it has been recently
shown that the earlier stages of disease, i.e. high-count monoclonal B lympho-
cytosis (MBLhi), subjects also have increased risk for infection.
Aims: To evaluate the status of the humoral immune response in CLL at dif-
ferent disease stages, as well as in pre-leukemic MBLhi and MBL low count
(MBLlo) cases, vs healthy controls, through quantitation of soluble plasma
levels of specific antibodies against ubiquitous and pulmonary infection-asso-
ciated pathogens.
Methods: A total of 249 subjects (119 males/130 females; aged 68±11y) includ-
ing 91 healthy donors, 71 CLL-like MBLlo, 29 CLL-like MBLhi and 58 CLL cases
(32 Binet A, and 26 Binet B/C patients) were studied. Detection of clonal CLL(-
like) B cells was performed by high-sensitive 8-color flow cytometry. Quantifi-
cation of plasma antibody isotypes and specific immunoglobulins against CMV
(cytomegalovirus), EBV (Epstein Barr Virus), influenza virus and S.pneumoniae
were performed by nephelometry and commercial ELISA kits, respectively.
Individuals who had received vaccination against Influenza and/or Pneumococo
were excluded from the analysis of the immunoglobulin-specific titers against
the corresponding pathogen, respectively. Plasma CMV and EBV DNA load
was measured using commercial kits.
Results: Total immunoglobulin (Ig) titers tended to decrease with disease pro-
gression, independently of the isotype. In contrast, specific IgM and IgG titers
against CMV, EBV and Influenza virus did not vary among groups, with the
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exception of VCA-EBV IgG titers, that were higher in CLL vs the other groups.
Strikingly, the IgG levels for the three viruses tended to gradually increase,
from healthy individuals to stage B/C CLL. These findings were more pro-
nounced (p<0.05) for IgG and to a lesser extend also for IgM, when the ratios
between the virus-specific Ig/total Ig titers of the same isotype were calculated,
except for Influenza-specific IgG, that showed the same trend but without sta-
tistical significance. Regarding CMV DNA load, only 3/177 individuals -1 MBLhi
and 2 CLL- were found to be positive (below the limit of quantitation), while
EBV DNA load was detected in plasma from 7/191 (all being Binet A CLL) at
median levels of 3.6 copies/ul. In contrast to the virus-specific Igs, IgG plasma
levels against S.pneumoniae progressively diminished through progression of
the disease, in parallel to the overall lower gammaglobulin levels.
Summary/Conclusions: Both MBLhi and CLL patients present relatively high
levels of specific Ig against human host viruses in parallel to progressively
lower levels of anti-S.pneumoniae antibodies, which might reflect (asympto-
matic) chronic reactivation of humoral immune responses against host viruses
and progressively decreased protection against other microorganisms, denoting
a severe pathogen-specific humoral immunodeficiency state not reflected by
the overall plasma immunoglobulin levels. Alternatively, these results might
point out a potential role of ubiquitous viruses in the pathogenesis of the dis-
ease. Further analyses are necessary to establish the potential relevance of
such asymptomatic humoral immune responses against host viruses in the
expansion of the tumor B-cell clone and progression from MBL to CLL.
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AN EXTENSIVE MOLECULAR CYTOGENETIC CHARACTERIZATION IN
HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IDENTIFIES
KARYOTYPE ABERRATIONS AND TP53 DISRUPTION AS PREDICTORS
OF OUTCOME AND CHEMOREFRACTORINESS
G.M. Rigolin1,*, L. Formigaro1, M. Cavallari1, F.M. Quaglia1, E. Lista1, A. Urso1,
E. Guardalben1, S. Martinelli1, E. Saccenti1, C. Bassi2, L. Lupini2, A. Bardi1,
E. Volta1, E. Tammiso1, A. Melandri1, M. Negrini2, F. Cavazzini1, A. Cuneo1
1Scienze Mediche, Azienda Ospedaliero Universitaria Arcispedale S. Anna,
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Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease,
running an indolent course in some patients and a clinically aggressive course
in others. Risk assessment is important in clinical practice and prediction of
outcome and response to treatment is very useful in an era in which several
chemoimmunotherapy combinations and effective mechanism-driven treat-
ments are available.
Aims: We investigated whether an extended genetic characterization including
mutational screening by next generation sequencing (NGS) and karyotype
analysis could allow for a refinement of our capability to predict outcome in
newly diagnosed CLL patients with high-risk features, as defined by the pres-
ence of unmutated IGHV gene and/or 11q22/17p13 deletion by FISH and/or
TP53 mutations.
Methods: 101 patients were included in this study. TP53 disruption was defined
by the presence of 17p13 deletion by FISH and/or TP53 mutation by NGS.
Cytogenetic analysis was performed using CpG-oligonucleotide DSP30. Each
patient was categorized according to the following classification: favorable
group (isolated 13q14 deletion or normal karyotype), unfavorable group (dele-
tions of 11q22 or 17p13, or complex karyotype, ie, at least 3 chromosome aber-
rations); intermediate group (all other karyotypic abnormalities). A cut-off of
98% homology to the germline sequence to discriminate between IGHV mutat-
ed and unmutated cases. Mutational screening was performed with Ion Torrent
PGM NGS platform on 20 CLL-related genes by using a 5% cut off.
Results: Cytogenetic analysis showed favorable findings in 30 patients, unfa-
vorable in 34 cases and intermediate in 36 cases. A complex karyotype was
present in 21 patients. By NGS, 95 somatic mutations were observed in 56/101
(55.4%) cases; 80 missense mutations, 5 nonsense mutations and 10 frameshit
deletions. 16 cases (15.8%) showed mutations in the TP53 gene, 11 (10.9%)
in the NOTCH1 gene, 11 (10.9%) in the SF3B1 gene, 8 (7.9%) in the ATM
gene, 5 (4.9%) in the BIRC3 gene, 5 (4.9%) in the PTEN gene, 4 (4.0%) in the
MYD88 gene, 4 (4.0%) in the BRAF gene, 4 (4.0%) in the POT1 gene, and 18
(17.8%) cases in the remaining 11 genes. 26/56 (46.4%) mutated patients pre-
sented two or more mutations. The presence of mutations was associated with
unmutated IGHV status (p=0.040) and the complex karyotype (p=0.047). TP53
disruption correlated with the presence of ≥2 mutations by NGS (p=0.001) and
a complex karyotype (p=0.012). By multivariate analysis an advanced Binet
stage (p<0.001) and an unfavorable karyotype (p=0.001) predicted for a shorter
time to first treatment (TTFT), while TP53 disruption (p=0.019) and the unfa-
vorable karyotype (p=0.028) predicted for a worse overall survival (OS). A short-
er time to chemorefractoriness (TTCR) was associated with TP53 disruption
(p=0.001) and unfavorable karyotype (p=0.025). Patients with both unfavorable
karyotype and TP53 disruption presented a dismal outcome (median OS and
TTCR of 28.7 and 15.0 months respectively).
Summary/Conclusions: A comprehensive analysis of chromosomal aberra-
tions and gene somatic mutations in high-risk CLL showed that the cytogenetic
profile was independently associated with a shorter TTFT, OS and TTCR. Since
karyotyping using novel mitogens may contribute to the refinement of prognosis
in high-risk CLL patients, the introduction of this technique in future CLL trials
seems warranted to identify those patients that could be ideal candidates for
consolidation treatment or novel treatment combinations.
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SHOULD CLL-IPI BE USED TO ASSESS OVERALL SURVIVAL OF EVERY
CLL PATIENT? A SYSTEMATIC REVIEW AND META-ANALYSIS
S. Molica1,*, D. Giannarelli2, R. Mirabelli1, L. Levato3
1Hematology-Oncology Department, Azienda Ospedaliera Pugliese-Ciaccio,
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Background: A weighted grading approach based on five independent prog-
nostic factors (i.e, TP53 status, IGHV mutational status, ß2-microglobulin, clin-
ical stage and age) has been used by an international Working Group to gen-
erate the chronic lymphocytic leukemia international prognostic index (CLL-
IPI). Although the robustness of CLL-IPI has been confirmed in independent
validation studies it remains unclear whether CLL-IPI has the greatest validity
and should be preferred to guide clinical decision in CLL. 
Aims: To shed light on this important research question, we conducted a sys-
tematic review which includes all published studies which used CLL-IPI to prog-
nosticate overall survival (OS) in CLL.
Methods: A comprehensive MEDLINE search using “CLL-IPI” as Medical Sub-
ject Headings (MESH) allowed to identify at the cut-off time of February the 28,
2017 “seven hits” with only “four” citations considered pertinent. The search
extended to the conference proceedings of annual meetings of ASH, EHA and
ASCO of last two years recognized “three” additional citations.
Results: Overall 6720 patients from seven evaluable studies were suitable for
the present analysis aimed at assessing the impact of CLL-IPI on OS. The
majority of patients (4953 or 73.7%) came from studies of external validation
of CLL-IPI while 17% (1192) and 8.5% (576) had been used to generate (train-
ing set analysis) and to internally validate the model. Patient distribution into
the four risk categories of CLL-IPI was heterogeneous thus reflecting the CLL
phase (i.e., at diagnosis, at time of first treatment and at relapse) of patients
within different studies. Accordingly, patients diagnosed as having low-, inter-
mediate-, high- and very high-risk CLL-IPI ranged respectively between 9%
and 58%, 25% and 39%, 14% and 52% and 2% to 9%. Next we evaluated the
5-year OS of patients stratified into each of the four CLL-IPI risk groups using
either “Q” or “I2” test to assess the heterogeneity across different studies. The
5-year survival probability was 91% for low-risk group (95% CI, 90-91%;
Q=55.2; P< 0.00; I2, 87%), 80% for intermediate-risk group ( 95% CI, 79-82%;
Q=49.36; P<0.00; I2, 86%), 60% for high-risk group (95% CI, 57-62%; Q=42.78;
P<0.00; I2, 84%) and 32% for very high-risk group (95% CI, 27-38%; Q=18.1;
P=0.01; I2, 67%).
Figure 1.
Summary/Conclusions: In this comprehensive review and meta-analysis of
studies thus far published on CLL-IPI we confirmed the value of this novel
model to predict OS whatever the CLL phase (fig 1). The prognostic impact of
CLL-IPI needs an extensive validation in patient cohorts receiving therapy with
B-cell receptor or bcl-2 inhibitors. Nonetheless, in a study of relapsed/refractory
CLL included in this analysis the PI3K-inhibitor idelalisib was not able to over-
come the impact of CLL-IPI risk categories on OS.
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Background: Oral anticancer medications (OAMs) present several advantages
compared with intravenous cytotoxic chemotherapy, including greater conven-
ience for the patient. However, OAMs require that a patient be actively involved
in regular drug administration over an extended period of time (Schneider SM,
et al. Semin Oncol Nurs. 2011;27(2):133-141). Adherence to OAMs significantly
impacts patient outcomes; poor adherence may result in inferior survival and
outcomes, higher hospitalization rates, treatment resistance, and increased
healthcare costs (McCue DA, et al. Pharmacotherapy. 2014;34(5):481-494).
The Canadian YOU&i™ patient support program (PSP) was developed to
improve adherence to long-term ibrutinib therapy using research-proven tech-
niques for promoting positive behavioral changes, i.e. cognitive behavioral ther-
apy, psycho-social support, and a nurse coaching component. Results from
the program are presented below.
Aims: To evaluate patient adherence to ibrutinib, and patient and physician
satisfaction with the YOU&i™ PSP
Methods: Using evidence-based literature reviews and global/local market
research, various patient-centered barriers to treatment adherence were iden-
tified. Risk for non-adherence was calculated using the Morisky Medication
Adherence Scale© score, which informed nurse coaching frequency. Adherence
was delineated by prescription refill compliance. Patient and physician ques-
tionnaires were used to gauge satisfaction with the YOU&i™ PSP.
Results: As of 20 January 2016, a total of 903 patients with CLL were enrolled
in the YOU&i™ PSP. A total of 552 patients were included in the adherence
analysis. Of these, 86% opted in to receive the nurse coaching component. At
2 months from treatment initiation, patients who received nurse coaching
demonstrated an adherence rate of 92.3%, as compared with 63.5% for
patients who did not receive nurse coaching (95% CI, 17.5-41.0; p <0.0001).
At 3 months the adherence rates were 89.9% vs 60.8% (95% CI, 17.5-41.4; p
<0.0001). By 9 months, adherence rates were 81.7% vs 71.1% (95% CI, -4.4
to 28.4; p =0.141). At study conclusion, 12 month adherence rates were 76.6%
vs 72.2% (95% CI, -18.9 to 32.4; p =0.715). Discontinuation rates were similar
in all patients, regardless of nurse coaching status at 9 and 12 months. Patients
reported satisfaction rates of >90% in surveys conducted at both 3 months
and 12 months of program enrollment. Of physicians surveyed at 3 months,
96% reported that the YOU&i™ PSP was helpful in supporting patient needs.
Figure 1.
Summary/Conclusions: The current analysis provides insight into adherence
patterns of patients on long-term ibrutinib treatment. These results are consis-
tent with the literature showing that PSPs like the YOU&i™ PSP can help to
improve adherence rates (Schneider SM, et al. J Adv Pract Oncol.
2014;5(3):163-172). The information obtained from long-term adherence data
can help to inform future trials examining patterns of adherence with OAMs.
Nurse coaching may be helpful in supporting early adherence by addressing
side effects that occur more frequently at treatment initiation. Moreover,
changes in disease or health status that arise over the first 12 months of therapy
may provide information that allows a PSP to adapt to patients’ evolving needs
over the treatment journey. A better understanding of long-term adherence pat-
ters may allow programs such as the Canadian YOU&i PSP™ to target adher-
ence support more precisely, thereby optimizing patient outcomes.
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TREATMENT AND 17P DELETION TESTING PATTERNS IN COMMUNITY
PRACTICE FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
(CLL) IN THE UNITED STATES
T. Kapustyan1,*, H. Keim1, B. Meissner1, L. Zhang1, D. Jiang1
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Background: CLL is the most common type of leukemia in adults in the US.
Traditionally, chemotherapy - and chemo-immunotherapy (CIT) have been the
treatment mainstay. Historically, CLL patients (pts) with high-risk genetic fea-
tures (e.g., 17p deletion (del(17p)) have poor prognosis and few treatment
options. Over the past few years, oral-targeted therapies have been approved
in the US for CLL pts, including those positive for del(17p).
Aims: This study used an electronic health record database to characterize
treatment and del(17p) testing patterns in the first 2 lines of therapy (LoT) for
CLL pts initiating treatment between 2011–2016. The association between
del(17p) testing and utilization of targeted therapies was also explored.
Methods: This was a retrospective observational study in CLL utilizing a large,
longitudinal, demographically and geographically diverse database of US can-
cer pts (Flatiron Health 12/2016). An analytical cohort of pts treated at commu-
nity practice sites who initiated 1st LoT after Jan 2011 was developed. Two
sub-cohorts of pts who initiated 1st LoT before and after 2014 were also iden-
tified reflecting the approval timeline of oral-targeted therapies in the US.
Results: As of Dec 2016, 3,140 pts with CLL were included in the broad Flatiron
Health CLL cohort. The results of this analysis are based on the analytical
cohort that included 1,700 pts who initiated 1st LoT during 2011–2016, of which
1,134 (66.7%) pts initiated therapy after 2014. Second LoT was initiated in 622
pts during 2011-2016, with 472 (75.9%) initiations occurring after 2014. Average
age at CLL diagnosis was 66.9 years; 63.2% of pts were male; 70.2% were
Caucasian. Over 2011–2016, the rate of genetic testing by cytogenetics or flu-
orescence in situ hybridization (FISH) before initiation of 1st LoT was 67.4%.
The rate of del(17p) specific testing before 1st LoT was 59.1% (an increase
from 38.9% in 2011 to 64.4% in 2016). Among those who were tested before
1st LoT, 12.5% tested positive for del(17p). In the sub-cohort of pts who initiated
1st LoT after 2014, ibrutinib monotherapy replaced fludarabine, cyclophos-
phamide and rituximab (R) combination as the 3rd most frequent (13.0%) 1st
LoT in pts with CLL, after bendamustine/rituximab (BR) combination (29.8%),
and rituximab (R) monotherapy (17.7%). In contrast, ibrutinib became the most
common (43.9%) 1st LoT in newly diagnosed CLL pts with del(17p), followed
by BR (24.5%) and R (7.1%). 36.6% of pts initiated 2nd LoT by December
2016. The three most common treatment sequences from 1st LoT to 2nd LoT
were CIT to B-cell receptor pathway inhibitor containing therapy (16.4%), CIT
to CIT (14.0%), and immunotherapy (IT) to IT (12.4%). Overall, the utilization
of oral-targeted therapies has steadily increased since 2014, and multivariate
analyses indicate that the presence of del(17p) is strongly associated (OR=8.7
and 2.8 for 1st and 2nd LoT, respectively) with this choice once these agents
became available in 2014.
Summary/Conclusions: Considerable treatment pattern changes were
observed for CLL pts in the US community practice due to the adoption of
newly approved targeted therapies. Presence of del(17p) is strongly associated
with choosing a targeted therapy regardless of LoT. Future research is needed
to determine how differences in pt and disease characteristics and cytogenetic
testing patterns influence treatment decisions and associated outcomes.
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PATIENTS WITH TREATMENT-NAÏVE (TN) CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL): AN ADJUSTED COMPARISON OF RESONATE-2™ WITH
THE CLLEAR AND LYON-SUD DATABASES
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G. Salles2
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Background: The phase 3 RESONATE-2™ study demonstrated significant
improvement of progression-free survival (PFS) and overall survival (OS) with
ibrutinib (ibru) vs chlorambucil (chl) in TN (aged ≥65 years) CLL patients. In
the absence of direct comparison of single-agent ibru with other frequently
used treatments in this patient population, additional comparative evidence
against standard of care as observed in clinical practice can provide useful
insights on the relative efficacy of ibru.
Aims: To investigate the relative treatment effect on PFS and OS for ibru vs
real world (RW) treatment in daily clinical practice in TN CLL patients by adjust-
ed comparison of patient-level data from RESONATE-2™ vs RW data from
the CLLEAR (Chronic Lymphocytic Leukemia Registry) and Lyon-Sud data-
bases.
Methods: CLLEAR holds medical records for CLL patients from seven aca-
demic centers across the Czech Republic. Lyon-Sud database holds medical
records for CLL patients from the academic French hospital Lyon-Sud. Patients
initiated on CLL frontline therapy were selected from CLLEAR and Lyon-Sud
using the same inclusion-exclusion criteria as for RESONATE-2 (excluding
patients with age<65 and with del17p positive status). PFS and OS were com-
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pared between ibru and RW treatment using patient-level data from RES-
ONATE-2™ (n=136) and pooled patient-level data from the two cohorts. To
adjust for differences in patient characteristics between the trial population and
both cohorts, a multivariate Cox proportional hazards model was fitted on
patient-level data to estimate the hazard ratio (HR) for ibru vs RW treatment,
with age, sex, disease stage (based on RAI/BINET), and deletion 11q pres-
ence/absence included as covariates.
Results: Median age at treatment initiation for CLLEAR (n=418) and Lyon-Sud
(n=110) was 73 and 71 years, respectively, vs 73 for Ibru patients from RES-
ONATE-2™. The proportion of male patients was 63% in CLLEAR and 57% in
Lyon-Sud vs 65% in RESONATE-2™. The median follow-up was 35.7 months
(mo) for Lyon-Sud and 16.8 mo in CLLEAR vs 28.1 mo for RESONATE-2™.
Adjusted HR for ibru vs physician choice in CLLEAR and Lyon-Sud were 0.23
[95% CI: 0.14, 0.39] and 0.25 [0.14, 0.43] for PFS, and 0.29 [0.11, 0.79] and
0.39 [0.18, 0.83] for OS, respectively. Fludarabine+cyclophosphamide+ritux-
imab (FCR; n=117), bendamustine+R (BR; n=91), Chl alone (n=43), Chl+R
(n=45), and other R-containing regimens (n=154) were the most commonly
used treatment regimens across both RW cohorts. Older age, male gender,
advanced disease stage and del11q positive status were independent risk fac-
tors for PFS and OS. The adjusted HRs (pooled estimates) for ibru vs the two
most commonly used regimens were 0.30 [0.17-0.53] (FCR) and 0.33 [0.16-
0.68] (BR) for PFS, and 0.44 [0.20-0.95] (FCR) and 0.33 [0.13-0.83] (BR) for
OS (Figure 1). Estimates of HR vs regimens in the cohorts were consistent
across both databases.
Figure 1.
Summary/Conclusions: This adjusted comparison of patient-level data from
RESONATE-2™ with RW data from CLLEAR and Lyon-Sud demonstrates ibru
to be more effective compared with RW treatment, with a 4.1-fold improvement
in PFS and a 3-fold improvement in OS. When comparing ibru with the most
commonly used RW treatments, statistically significant benefits for ibru were
consistently observed vs all treatment regimens on PFS and for most compar-
isons on OS. These results further support the existing evidence that ibru sig-
nificantly improves PFS and OS vs common regimens used in TN CLL settings,
and has important implications for clinical practice.
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Background: People over 80 years are the fastest growing age group in west-
ern populations. Clinical management of ≥80 year old patients (pts) with CLL
remains a challenge due to the very limited amount of data currently available
for this age segment. Two retrospective studies reported observational data on
characteristics, treatment, and outcomes of ≥80 year old pts not enrolled in a
clinical trial (Bairey et al., Meunier et al.). Comparably little is known about ≥80
year old pts who were treated for CLL within clinical trials, however.
Aims: To study the characteristics, treatment, and outcomes of pts aged ≥80
years who received their first therapy within prospective trials of the German
CLL Study Group (GCLLSG).
Methods: Trial populations of seven clinical trials of the GCLLSG (CLL1, CLL5,
CLL7, CLL8, CLL9, CLL10, CLL11; total N=3552) were reviewed and screened
for pts ≥80 years at frontline treatment. Clinical, laboratory, and genetic data of
identified pts were pooled. Time-to-event data were analysed by Kaplan-Meier
methodology. Independent prognostic factors for survival were identified by
multivariate analysis using Cox regression modelling with stepwise selection
procedures.
Results: Among 3552 reviewed GCLLSG trial participants, 152 were aged ≥
80 years at initiation of firstline treatment. A majority of these pts were identified
from CLL11 (n=132) while the remaining were from CLL1 (n=3), CLL5 (n=1),
CLL7 (n=3), CLL8 (n=2), CLL9 (n=9), and CLL10 (n=2). Median age was 82
years (range 80-90). Concomitant diseases were present in 99% of the pts and
median cumulative illness rating scale (CIRS) score was 8 (0-18). Median cre-
atinine clearance was 46 mL/min (range 17-99 mL/min). Identified genomic
aberrations were 13q deletion as a sole abnormality in 27%, trisomy 12 in 18%,
11q deletion in 9%, and 17p deletion in 16% of pts. IGHV was unmutated in
69% of the pts. Distribution of CLL-IPI risk groups was as follows: 6% low, 19%
intermediate, 61% high, and 14% very high. Most pts had Binet stage B (36%)
or C (43%). Chemoimmunotherapy with chlorambucil plus obinutuzumab (CLB-
OB) or chlorambucil plus rituximab (CLB-R) was administered to 61 (40%) and
56 (37%) pts, respectively. Remaining pts received chlorambucil alone (CLB,
n=19), fludarabine (F, n=10), fludarabine/cyclophosphamide (FC, n=1), fludara-
bine/cyclophosphamide/rituximab (FCR, n=2), or bendamustine/rituximab (BR,
n=3). Rates of grade 3 or 4 neutropenia and infections were 35% and 13%,
respectively. Premature treatment discontinuations occurred in 15% of cases
and were mostly due to adverse events. The total overall response rate was
92% with 13% complete remissions. Median observation time for all pts was
40.7 months. Median progression-free survival (PFS) and treatment-free sur-
vival (TFS) were 17.2 and 32.3 months, respectively. A total of 47 pts (31%)
received at least one further line of treatment. Median overall survival (OS)
was 48.3 months, with adverse events (22%) and progressive CLL (16%) being
the most frequent causes of death. Standardized mortality ratio was calculated
and showed a 1.99 (CI 1.54-2.53) increased risk of death as compared to an
age- and sex-matched general population. Independent prognostic factors for
OS were 17p deletion and elevated serum thymidine kinase.
Figure 1.
Summary/Conclusions: Findings suggest that antileukemic therapy (including
chemoimmunotherapy) is feasible and efficacious in ≥ 80 year old pts with CLL.
However, such pts are stll highly underrepresented in clinical trials and even
with modern treatment live shorter than age-matched controls of the general
population. Broader recruitment of these pts to prospective trials and evaluation
of targeted therapies therefore appears imperative to improve outcome of CLL
in this age segment.
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THE ROLE OF CD200 IN THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC
LEUKEMIA
A. Mora1,2,*, E. P. Vicente1,2, C. Cuellar1,2, R. Bosch1,2, L. Blanco3, R. Martino2,
J. M. Ubeda3, J. Sierra1,2, C. Moreno1,2, J. Nomdedeu3
1Laboratory of Oncology/Hematology and Transplantation, Institute of Biomed-
ical Research, IIB Sant Pau, 2Department of Hematology, 3Laboratory of Hema-
tology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Background: Clinic, morphologic, immunophenotypic and genetic features are
the basis for the diagnosis of B-cell malignancies. It is considered that the diag-
nosis of CLL requires the presence in peripheral blood of >5x109/L monoclonal
B lymphocytes with a distinctive immunophenotype (i.e. SmIgweak, CD5+,
CD19+, CD23+). Based on immunophenotypic characteristics, Matutes et al
devised in 1994 a immunophenotypic score based on a few markers (CD5+,
CD23+, FMC7-,SmIgweakand CD22weak) each one of them receiving a score of
1 if present or 0 if absent. A total score of 4 or 5 is typical of CLL whereas those
cases scoring 0 or 1 correspond to other B-cell malignancies, mostly lym-
phomas. Nevertheless, clinical and immunophenotypic features of CLL may
overlap with other B-cell malignancies. CD200 has been described as a marker
potentially useful to distinguish CLL from other CD5+B-cell malignancies.
Aims: The aim of this study was to analyze whether the addition of CD200 to
the Matutes score improves the diagnostic accuracy of CLL.
Methods: We prospectively assessed the immunophenotype of 99 peripheral
blood samples of patients with suspected lymphoproliferative disorders
between November of 2015 and January of 2017. Immunophenotyping was
performed using a Canto Flow Cytometer (Becton Dickinson) and samples
were stained with routine combinations plus CD200. The Matutes Score was
calculated as follows: FMC7, CD22 and CD79b were considered score 1 in
CLL when the positive cells were <30%, CD5 and CD23 were considered
score 1 when the positive cells were ≥30%. The cut-off used for CD200 was
calculated by Receiver Operating Characteristics (ROC). CD200 was scored
as 1 when the positive cells were >96%. Mean Fluorescence Intensity Ratio
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(MFIR) was calculated as a relative expression between MFI positive popu-
lation and MFI negative population. McNemar´s test was used to assess sta-
tistical significant differences in accuracy among individual markers and scor-
ing systems. The treating physician made the final diagnosis of the different
B-cell malignancies according to IWCLL and WHO criteria. Logistic regression
including sensitivity, specificity and accuracy values, were used to evaluate
statistical differences in diagnosis precision between different combinations
of markers as well as individual markers.
Results: Flow cytometry analysis was performed in 99 patients, including 62
cases with a diagnosis of CLL (62.6%) and 37 cases with a “non-CLL” diagnosis
(37.4%). Matutes score was 4-5 in all CLL cases and ≤3 in “non-CLL” cases.
CD200, CD23 and CD5 were the most consistent markers for CLL (90.3%,
96.8% and 100.0% of sensitivity respectively). Moreover, CD79b and FMC7
had also a good discriminant value (80-85% sensitivity). For “non-CLL” cases
the most reliable markers were SmIg, FCM7 and also CD200. The analysis of
the accuracy is shown in the table. Of note, CD200 as a single marker was
found to be a reliable marker for distinguishing CLL and “non-CLL” cases
(90.9%; p<0.001; 90.3% sensitivity, 91.9% specificity) showing a significantly
higher accuracy than CD5, CD23 and SmIg as individual markers (p<0.001).
The accuracy of CD200 did not vary when comparing% of positive cells and
MFIR. In contrast, the accuracy for SmIg significantly increased from 67.7% to
78.8% when using MFIR values (according to the cut-off established by ROC
curves), being lower in CLL than in “non-CLL” cases (71.0% vs 86.5%,
p<0.001). Finally, the addition of CD200 to the Matutes score system and using
a cut off ≥4, improved its accuracy from 88.9% (95% CI: 88.2-95.6) to 98.0%
(95% CI: 94.7-100.0) and showed a better sensitivity.
Table 1.
Summary/Conclusions: These results confirm CD200 as a valuable marker
in the diagnosis of CLL
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COMPARISON OF CHROMOSOME BANDING ANALYSIS AND GENOMIC
MICROARRAY TECHNIQUES FOR THE DETECTION OF COMPLEX
KARYOTYPES IN CHRONIC LYMPHOCYTIC LEUKEMIA
A. Puiggros1,2,*, A. Gómez-Llonín1,2, S. Ramos1,2, M. J. Calasanz3, L. Blanco4,
R. Collado5, M. Á. Piñán6, M. Ortega7, M. J. Larrayoz3, A. Batlle8, E. Abella9,
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Background: Well-established poor prognostic factors in chronic lymphocytic
leukemia (CLL) include deletions in 11q22 and 17p13 (delATM and delTP53)
by FISH. Genomic complexity detected by either chromosome banding analysis
(CBA) or genomic microarray techniques, but underestimated by FISH, predicts
an impaired outcome in CLL. Of note, none of these techniques is still routinely
performed and standard criteria for risk stratification based on genomic com-
plexity are lacking.
Aims: 1. To assess the complexity detected by genomic arrays in patients with
complex karyotype by CBA; 2.To compare both methods regarding the number
and type of aberrations detected in order to categorize patients based on
genomic complexity.
Methods: A total of 24 CLL patients with complex karyotype (≥3 abnormalities,
CK) by CBA were included [Median age: 73; 15 males (63%)]. Median time
from diagnosis to CBA/microarray analysis was 3 months (range, 0-160), and
4 patients (16%) had received prior treatment. The cohort was enriched in
delATM and delTP53 (37% and 42%, respectively). DNA from peripheral blood
mononuclear cells or CD19+ lymphocytes was hybridized to Cytogenetics
Whole-Genome 2.7M (n=2) or CytoScan HD (n=22) array, results were ana-
lyzed with Chromosomal Analysis Suite Software (Affymetrix). Number, size
and type of aberrations detected were compared between techniques.
Results: A median of 3.5 aberrations (range: 3-9) were detected by CBA, being
significantly lower than the copy number abnormalities (CNA) identified by
microarrays (median 5, range: 1-28; P=0.018). The median size of the CNA
was 5.4Mb (range: 0.1-174Mb). Current recommendations for microarray analy-
ses suggest that only CLL known abnormalities and CNA >5Mb should be con-
sidered for clinical interpretation (Schoumans et al, 2016). When applying this
cut-off, 42% of the initially detected CNA (74/177) were omitted and no signif-
icant differences in the number of abnormalities by each technique were found
(P=0.334). CNA <1Mb did not involve any chromosomal altered region in the
corresponding karyotype. Thus, their omission probably would not affect the
stratification based on complexity. In contrast, most of the CNA between 1 and
5Mb involved small CNA associated to apparently balanced translocations by
CBA, and in some cases revealed a higher genomic instability than the previ-
ously recognized by CBA (i.e. multiple deletions defined as a single one or a
monosomy by CBA). Indeed, four cases showed chromothripsis not detected
by CBA which has been associated with impaired outcome (Salaverria et al,
2015). Of note, genomic microarrays failed to detect some balanced translo-
cations or subclonal aberrations by CBA, which probably were represented in
a minor proportion of the sample but expanded during CBA culture. Thus, eight
patients (21%) could only be considered complex by CBA, as by microarray
analyses <3 CNA were detected. The present study is ongoing; additional
cases have been collected in order to statistically assess the clinical impact on
survival of the complexity detected by microarrays.
Summary/Conclusions: 1. The number of chromosomal abnormalities detect-
ed in CLL patients differs if assessed by CBA or genomic microarrays. 2. The
current 5Mb cut-off to define clinically relevant CNA should be revised, as it
could underscore genomic instability (contiguous small deletions, chromoth-
ripsis). 3. More studies should be performed to establish standard criteria for
prognostic stratification of CLL patients based on genomic complexity consis-
tent with the results from both techniques.
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ABNORMAL SERUM FREE LIGHT CHAINS RATIO ASSESSMENT IN
CHRONIC LYMPHOCYTIC LEUKEMIA: A SIMPLE YET POWERFUL TEST
CORRELATING WITH CLINICAL OUTCOME AND MINIMAL RESIDUAL
DISEASE
F. Durrieu1,*, M. Le Bouar1, F. Bijou2, A. Schmitt2, J. Blanchi1, G. Etienne2
1Laboratory of hematology, 2Hematology Department, Institut Bergonie, BOR-
DEAUX, France
Background: An abnormal serum Free Light Chain (sFLC) ratio has been
shown to be significantly associated with poor outcome in chronic lymphocytic
leukemia (CLL) Yegin ZA et al, Eur J Haematol 2010, suggesting that this
parameter may discriminate different biological subgroups.
Aims: As the technic is easily implementable in routine lab and cost effective,
we evaluated the sFLC levels (kappa + lambda) and kappa/lambda (K/L) ratio
in CLL patients in this prospective study. The relationship between abnormal
sFLC levels (K+L) and/or K/L ratio, minimal residual disease (MRD) assessed
by flow cytometry (FCM) and disease evolution was evaluated.
Methods: Diagnosis was confirmed by 10-color FCM immunophenotyping of
blood lymphocytes on a Navios (Beckman Coulter). Serum FLC kappa and
lambda chains were measured by nephelemetry using the Freelite™
immunoassay. The normal free kappa chains level was defined as within the
range of 3.3-19.4mg/L, and the normal lambda chains level within the range of
5.71-26.30mg/L. A normal sFLC kappa/lambda (K/L) ratio was therefore defined
as between 0.26 and 1.65 (a ratio above 1.65 indicating an excess of kappa
light chain, and a ratio below 0.26 indicating an excess of lambda light chain).
The cumulative level of kappa plus lambda (K+L) was also evaluated. Most
patients received combined chemo-immunotherapy or entered clinical trials
whenever possible. The ROC methodology was used to establish the best cut-
off value of sFLC ratio level to discriminate treated patients from those who
remained treatment-free.
Figure 1.
Results: Main patients characteristics are detailed [N=147, M/F:75/72, 111 in
early stage disease, Del 17p in 11 patients and Del11q in 15]. Median age was
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69 years (range 34 to 86). Ninety patients were untreated during the follow-up
period. Median follow-up duration was 30 months (range 0 to 101). Furthermore,
sFLC measurement was assessed in 57 patients who progressed during the
study and required treatment according to international guidelines. ROC curve
analysis determines cut-off level of K/L ratio at 1.88. Abnormal sFLC was
observed at diagnosis in 50.9% (N=29) of all treated patients. The mean ± SD
ratio of sFLC in the untreated patients group and in the treated patients group
was 1.51±2.08 and 2.80±3.75 respectively (p=0.0082). Considering the sFLC
levels (kappa + lambda), the mean±SD in the untreated patients group and in
the treated patients group was 29.1±17 and 53.0±41.9 respectively (p<0.0001).
Treatment systematically induced a modification of the sFLC K/L ratio. Inter-
estingly, after treatment completion, the persistence of an abnormal sFLC K/L
ratio was associated with positive MRD determined by FCM with a 82% speci-
ficity and a 95% positive predictive value. Moreover, median time to treatment
income for patients in early stage disease with ratio >1.88 was 12 months while
it is not reached in those with ratio ≤1.88 (p<0.0001) (figure 1).
Summary/Conclusions: In this study we confirm the value of sFLC K/L ratio
determination as a technically simple, standardized and cost-effective test to
improve risk stratification of patients with low risk CLL at diagnosis, at the end
of the treatment and during follow-up. Determination of the sFLC K/L ratio
during the follow-up of treated patients provides additional information regarding
the response to therapy in patients with an abnormal K/L ratio. In this study,
persistence of an abnormal sFLC K/L ratio after treatment was strongly asso-
ciated with positive MRD and could serve as a predictive as well as a prognostic
biomarker for residual disease detection and clinical outcome. 
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PLATELET FUNCTION ASSAYS FOR STRATIFICATION OF BLEEDING
RISKS IN CLL PATIENTS ON IBRUTINIB TREATMENT
E. Nikitin1,*, E. Dmitrieva1, A. Ignatova2, A. Poletaev2, D. Polokhov2, A. Fedotov2,
E. Seregina2, A. Pshonkin2, M. Panteleev2, V. Ptushkin1
1Outpatient department for hematology oncology and chemotherapy, S.P.Botkin
hospital, 2Molecular hemostasis laboratory, National Scientific and Practical
Center of Pediatric Hematology, Oncology and Immunology named after Dmitry
Rogachev, Moscow, Russian Federation
Background: Ibrutinib therapy in chronic lymphocytic leukemia (CLL) is asso-
ciated with frequent bleeding complications, explained by inhibition of BTK,
which mediates downstream signaling of GPVI and GPIb receptors in platelets.
Detailed characterization of platelet functional impairment can help predict and
possibly prevent severe bleeding on ibrutinib. Here we investigate platelet func-
tional activity in CLL patients before initiation of ibrutinib and at different time
points during treatment.
Aims: A longitudinal study on the impact of ibrutinib on platelet function, severity
and frequency of bleeding.
Methods: Forty-three patients with relapsed and refractory CLL and 10 healthy
donors were included in the study. Platelet functional activity was characterized
by flow cytometry before and after activation with SFLLRN plus collagen-related
peptide. Levels of CD42b, CD61, CD62P, PAC1, annexin V binding, and
mepacrine release were determined. Aggregation with collagen, ADP and ris-
tocetin were measured. All tests were performed before initiation of treatment,
at weeks 2, 4, 8 and at 6 months. Bleeding complications were scored using
ITP-specific Bleeding Assessment Tool.
Results: Among 43 CLL patients, 29 (67%) were men, the median age was 65
(range 31 to 83 years). Four patients with del (17p) received ibrutinib as a first
line. In 39 previously treated patients the median number of prior treatments
was 3 (range, 1-6). Del17p or TP53 mutation was found in 11 (25%) patients.
Only 1 patient received anticoagulant and antiplatelet drugs. Median duration of
ibrutinib treatment was 8.2 months (range 2.2-10.9). At least one bleeding
episode occurred in 23 patients (53%). Among patients with bleeding, 14 (61%)
had grade 1 events, 7 (30%) had grade 2 and two (9%) had grade 3 events.
Bleeding frequency decreased with time on ibrutib; only 4 patients still had bleed-
ing complications after 6 months. The patients with bleeding had significantly
lower mean platelet count that those without (120 versus 170 thousands per
microliter, P<0.0001) and higher lymphocytosis (74 versus 45, P<0.05). Their
activation of integrins in response to stimulation was greatly impaired (9% versus
26%, P<0.0001; while the 95% confidence interval for healthy controls 63-137%),
and there was significant difference in procoagulant activity as well (2% versus
5%, P<0.01; normal range is 7-35%). Importantly, the integrin activation allowed
risk stratification: a person with more than 9% integrin activation had less than
10% risk to develop bleeding while the one with less than 9% integrin activation
had a risk of more than 40%. There was no difference in dense- or alpha-granule
release between the patient groups, and these indicators remained in their nor-
mal ranges. There were also significant differences in aggregation assay with
ADP (25±16% versus 36±18% for bleeding and non-bleeding patients, p<0,001),
collagen (38±19% versus 53±20%, P<0.001), and ristocetin (53±22% versus
62+20%, P=0.02). Interestingly, the patients with bleeding had negative corre-
lation of the ADP-induced aggregation with leukocyte level.
Summary/Conclusions: Both classic aggregation assays and flow-cytome-
try-based techniques demonstrate impaired platelet function in the bleeding
CLL patients compared with non-bleeding ones. The level of integrin activation
appears to be the most sensitive and able to identify patients with different
bleeding risks.
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HYPOGAMMAGLOBULINEMIA IS A STRONG PREDICTOR OF TIME TO
FIRST TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
G. Reda1, R. Cassin1,*, G. V. Levati 2, B. Fattizzo2, V. Mattiello2, D. Giannarelli3,
W. Barcellini1, A. Cortelezzi2
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Background: Management of chronic lymphocytic leukemia (CLL) dramatically
improved since the introduction of novel therapies. Rarely patients requires
treatment at diagnosis and approximately a third of patients will never require
therapy. Predictive and prognostic factors are well known (IGHV, del11q, del17p,
TP53); CLL-IPI score including age, clinical stage, beta2microglobulin, IGHV
and deletion 17p and/or TP53 mutation has been recently validated. It identifies
4 risk groups with significantly different time to first treatment (TTFT) and overall
survival (OS). Hypogammaglobulinemia (HYPO) is a typical feature of CLL,
with an incidence of 20-60% at diagnosis and a relationship with infections
occurrence. Prognostic significance of HYPO at diagnosis has not been exten-
sively evaluated in terms of OS and TTFT. Only IgG serum levels have been
reported to be associated with TTFT but no data are available on other
immunoglobulin classes (Ig).
Aims: To evaluate the impact of HYPO and single Ig classes on TTFT in a ret-
rospective cohort of CLL patients and to assess the relationship between HYPO
and CLL-IPI.
Methods: We retrospectively evaluated 698 consecutive CLL patients diag-
nosed at our Institution from 1983 till 2016. Data from laboratory, biological
analysis and clinical stage were collected. We also evaluated immunoglobulin
(Ig) status (i.e. IgG, IgM and IgA) at diagnosis and calculated CLL-IPI. HYPO
was defined basing on our laboratory cut-offs (IgA 70mg/dl, IgG 700mg/dl, IgM
40mg/dl). However, as no recognized prognostic/predictive Ig cut off has been
reported to date, we aimed to identify a prognostic threshold for each Ig class. 
Results: From 698 patients assessed, 410 cases were evaluable for Ig values
at diagnosis. IgA levels were lower than 70mg/dl in 17,4%, IgG lower than
700mg/dl in 22,2%, and IgM lower 40mg/dl in 33.7%. Forty-six percent of
patients presented deficit of at least one Ig class, while 7.8% of patients had all
Ig low. Each Ig deficit was related with a shorter TTFT with the following hazard
ratios (HRs): 2.09 (1.45-3.03) for IgA (P<0.0001), 1.58 (1.10-2.27) for IgG
(P=0.008) and 1.52 (1.09-2.13) for IgM (P=0.01) (Figure 1, A-B-C). However,
only IgA deficit maintains statistical significance in multivariate analysis [HR
1.59 (1.08-2.35)]. A prognostic threshold for each Ig class was identified max-
imizing the differences in TTFT and the following values were obtained: 80mg/dl
for IgA, 410mg/dl for IgG and 18mg/dl for IgM (Figure 1, D-E-F). Considering
CLL-IPI, 186 patients presented IPI 0-1, 99 had IPI 2-3, 32 patients IPI 4-6,
and 12 patients had IPI 7-10. Even in our series, CLL-IPI separated four risk
groups with different TTFT and OS, suggesting that our cohort may be suitable
to evaluate new prognostic factors. As regards the relationship between HYPO
and CLL-IPI, we observed a correlation with IgA levels, using our laboratory
cut-off. Moreover, we found a relationship among CLL-IPI and both IgA and
IgM values, when using the newly validated Ig cut-off. Finally, CLL-IPI was a
stronger prognostic factor for TTFT than HYPO in our analysis. However, the
addition of IgA deficit to CLL-IPI appears to further improve CLL prognostica-
tion.
Figure 1.
Summary/Conclusions: In conclusion, HYPO significantly impacts on CLL
prognosis. Moreover, even if CLL-IPI has a stronger prognostic value for TTFT
compared to HYPO, the addition of IgA deficit appears to further improve CLL
prognostication.
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CLL: IS LYMPHOCYTE DOUBLING TIME (LDT) A RELEVANT PROGNOSTIC
PARAMETER IN THE ERA OF PROGNOSTIC BIOMARKERS?
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Background: In CLL, tumor doubling time is reflected by the pace at which
lymphocytes increase in blood (lymphocyte doubling time or LDT). However,
since LDT is rarely available at the time of diagnosis, its role in assessing prog-
nosis in patients in CLL is controversial.
Aims: To reassess the prognostic significance of LDT in a large series of
patients.
Methods: Retrospective single-center study based on 629 patients diagnosed
with CLL/SLL. LDT was measured at the time of diagnosis if prior WBC counts
were available or calculated after diagnosis by linear regression analysis, usually
over a treatment-free period of 2 months and including at least three WBC counts.
Results: 140 patients displayed short LDT (≤12 months) and 489 long LDT
(>12 months). The median follow-up up was 13.4 years (6.1-22.5) and 11.2
years (2.2-30.9), respectively. Patients with short LDT were younger (p=0.005),
had more advanced clinical stage (p<0.001), higher ALC (p<0.001), as well as
increased serum LDH (p<0.001) and B2-microglobulin (B2M; p=0.035) levels
and also a tendency towards lower levels of Hb and platelet counts. A short
LDT was also associated with an increased expression of ZAP70 and CD38,
unmutated IGHV (all p<0.001) and poor FISH cytogenetics (del17p, del11q)
(p=0.002). Additionally, patients with a short LDT presented more frequently
mutations in NOTCH1 (p=0.008), ATM (p=0.029), TP53 (p=0.035) and a ten-
dency to more mutations in SF3B1 (p=0.102). The proportion of patients treated
in each group was markedly different [80% vs 46%] as it was the median time
to treatment (TTT, 1.4 vs 9.4 years; p<0.001). Type of treatment (mainly,
chemo[immuno]therapy) did not significantly differ between both groups and
there was no significant differences in response rates (ORR 59% with 29% CR
vs 69% with 29% CR; p=0.253). Overall survival (OS) was shorter in the group
with short LDT (median: 7.2 vs 12.2 years; p<0.001). Univariate analysis
demonstrated a significant correlation between OS and advanced clinical stage,
age >70 years, increased B2M and LDH (p<0.001), short LDT, increased
ZAP70 and CD38, unmutated IGHV, and high-risk FISH genetics (del17p,
del11q) (all p<0.001). Likewise, mutations in NOTCH1 (p<0.001), SF3B1
(p=0.027), ATM (p=0.028) and TP53 (p<0.001) were associated with OS. In a
multivariate analysis including clinical stage, age, LDT, IGHV, ZAP70, FISH
cytogenetics and TP53 mutations (NOTCH1 and SF3B1 mutations were not
included in the analysis because of the small number of patients in whom these
markers were available), a short LDT maintained its prognostic value for OS
(HR 2.7 (95% CI: 1.6-4.7), p<0.001) along with age >70 years (HR 5.2 (95%
CI: 3.2-8.5), p<0.001), high-risk FISH (HR 2.2 (95% CI: 1.3-3.6), p=0.003),
unmutated IGHV (HR 2.4 (95% CI: 1.5-4.0), p<0.001), and presence of TP53
mutation (HR 2.0 (95% CI: 1.0-3.9), p=0.041).
Summary/Conclusions: This study shows that LDT continues being an inde-
pendent prognostic parameter for OS in the era of biomarkers. In contrast,
LDT did not correlate with response to therapy and, accordingly, cannot be
regarded as a response predictor to chemo(immuno) therapy. Finally, LDT war-
rants investigation in the setting of novel therapies. 
E1032
INDICATIONS FOR TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA:
CLINICO-BIOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPACT
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Background: Chronic lymphocytic leukemia (CLL) is characterized by the pro-
gressive accumulation of monoclonal CD5+ B cells in the bone marrow and
lymphoid tissues. International guidelines recommend initiation of treatment
only in case of infiltrative cytopenia, progressive splenomegaly or lym-
phadenopathy, short lymphocyte doubling time (LDT), B symptoms and/or
refractory immune cytopenia (IC). These criteria are based on experts’ con-
sensus and considered equally relevant for treatment initiation, even though
little evidence exists concerning the relative value of each individual criterion.
Aims: To describe the clinico-biological characteristics and prognosis of CLL
patients according to the criteria that prompted the initiation of first-line treatment.
Methods: We identified 530 consecutive patients with CLL who required front-
line therapy from 1978 to 2014 and had their indication(s) for treatment (IfT)
recorded. Massive/progressive lymphadenopathy and massive/progressive
splenomegaly were grouped together as lymphoid mass (LM). Infiltrative ane-
mia and thrombocytopenia were categorized as marrow failure (MF). As 505
patients (95%) initiated therapy due to LM, MF or both, we decided to focus on
these two groups. Patients whose IfT was both LM and MF were classified as
MF following the logic behind Rai and Binet staging systems.
Results: Median age of the whole cohort was 62 years (range 22-93), and
63% of patients were male. Median follow-up from first-line therapy was 64
months (range, 1-433). Half of the patients had a single IfT, while the other half
had two or more. IfT were LM in 72% patients, MF in 31%, short LDT in 29%,
B symptoms in 19%, and IC in 3%. Compared to patients from the LM group,
patients from the MF group were significantly older, had a significantly higher
β2-microglobulin level (probably due to an age-related impaired renal function),
and were more frequently treated with alkylating agents than purine analogues.
Conversely, patients treated due to LM had more frequent adverse prognostic
characteristics, such as higher ZAP70 expression, unmutated IGHV genes,
and 11q deletion. The median OS of the entire population was 77 months (95%
confidence interval [CI]=71-83) from first-line therapy and 108 months (95%
CI=102-118) from diagnosis. Indication for treatment was significantly associ-
ated (p<0.001) with a shorter OS from first-line therapy: 63 months in the MF
group (95% CI: 48-72), compared to 89 months in the LM group (95% CI: 80-
106). This association remained significant after adjusting for age and β2-
microglobulin concentration.
Figure 1.
Summary/Conclusions: All IfT are still regarded as equally important,
although no solid evidence exists to support such statement. In our series,
infiltrative cytopenia and/or progressive lymphadenopathy/splenomegaly con-
stituted the IfT in most (95%) CLL patients. In spite of being enriched in favor-
able biological prognostic factors (mutated IGHV genes, low ZAP-70 expression
and favorable-risk cytogenetics), MF patients had a shorter age-adjusted OS
from first-line therapy compared to LM patients. Further studies should address
whether this result also applies to patients treated with novel agents.
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UNCOVERING PRIMARY TP53-DELETED CLONES WITH FISH THROUGH
FACS-SUPPORTED PURIFICATION OF CHRONIC LYMPHOCYTIC
LEUKEMIA LYMPHOCYTES
G. Marques1, M. Pereira2,3,*, J. Lima1, R. Reis1, A. Coelho1, L. Jorge1,
S. Pedreiro4, L. Ribeiro2, A. Paiva4, F. Rodrigues1
1Clinical Pathology Department, 2Clinical Hematology Department, Coimbra
University Hospital Centre, 3Faculty of Medicine, University of Coimbra, 4Flow
Cytometry Unit, Coimbra University Hospital Centre, Coimbra, Portugal
Background: The presence of TP53-inactivation in chronic lymphocytic
leukemia (CLL), namely through the deletion of all or part of the chromosomal
region containing its locus, is a well-established marker of poor prognosis and
chemoresistance to traditional chemotherapeutic agents. Fluorescence in situ
hybridization (FISH) is a useful tool for the detection of the deletion. Neverthe-
less, its sensitivity is influenced by the number of blood-cell lineages that carry
the aberration; the absolute count of deletion-positive cells; and the proportion
of deletion-positive neoplastic cells relative to deletion-negative neoplastic cells
and non-neoplastic cells, in the whole blood or bone marrow sample. The latter
issue can be minimized by purifying the sample through the selection and sep-
aration of tumor cells, using techniques such as fluorescence-activated cell
sorting (FACS).
Aims: In this study, we aim to evaluate the benefit of using purified samples of
neoplastic CLL lymphocytes for the detection of TP53-deletion by FISH, when
compared to full samples.
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Methods: We reviewed all CLL samples that were submitted for the investiga-
tion of TP53-deletion through FISH, in our Lab, between January 1st 2011 and
February 28th 2017. Results obtained on tests performed on whole mixed cel-
lularity samples were compared with results obtained directly in FACS purified
CLL clonal lymphocytes.
Results: We analyzed 410 samples tested for the deletion of TP53 in our Lab
during the study period. The majority of patients (63.2%) were male. Although
FACS separation of neoplastic cells was only introduced within the last two
years of the study period, it accounted for 39.0% of all tested samples. This
poor prognostic aberration was identified in 15.8% of patients in the overall
cohort, with no differences in the incidence of a positive finding between mixed
cellularity samples and FACS purified samples (15.6% vs 16.2%, respectively,
p=NS). In contrast, the average proportion of positive cells within a positive
sample was markedly different between mixed cellularity samples and FACS-
processed samples, increasing nearly three-fold through the purification of the
sample, from 24.0±15.9% to 62.9±33.3%, p<0.001. In fact, in 57.7% of all
patients who were tested after FACS separation of CLL cells, the TP53-deleted
clone was larger than 50% of neoplastic clonal lymphocytes, making it the pri-
mary clone.
Summary/Conclusions: We observed that the pre-processing of the sample
through the FACS-supported purification of CLL neoplastic lymphocytes
revealed that the TP53-deleted clone was nearly three-fold larger than sug-
gested by the mixed cellularity sample, increasing from an average of a quarter
of all cells, to nearly two-thirds. This finding uncovered that the TP53-clone
was, in fact, the primary major clone within the neoplastic lymphocyte population
in the majority of patients. Considering the poor prognosis conferred by the
aberration, and its impact on current treatment decisions, it is quite significant
to correctly identify a primary deletion-positive clone, instead of mislabeling it
as a secondary minor clone.
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PRIMARY PEGFILGRASTIM PROPHYLAXIS VERSUS FILGRASTIM GIVEN
“ON DEMAND” FOR CLADRIBINE - INDUCED NEUTROPENIA IN HAIRY
CELL LEUKEMIA
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Beer-Sheva, 13Department of Hematology,, Hadassah University Hospital,,
Jerusalem., 14Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel
Background: Major advances in the treatment of patients with HCL were made
in the 1980’s after the introduction of two purine analogues: pentostatin and
cladribine. Both these agents dramatically altered the clinical course and out-
come of this disease and induced high response rates of 75-90%, with durable
remissions and subsequent median relapse-free survival of up to 15 years.
The major significant short-term toxicity of therapy with cladribine are neutrope-
nia and neutropenic fever (NF). Based on the script data: 71% of patients expe-
rience grade 4 neutropenia (absolute neutrophil count [ANC] <500x109/l), and
42% develop NF. The latter complications may result in life - threatening infec-
tions, as well as hospitalization.
Aims: In this retrospective study, we compared the incidence and duration of
neutropenia, NF and hospitalization in patients with HCL treated with cladribine
followed by pegfilgrastim as primary prophylaxis versus daily filgrastim given
“on demand “according to the absolute neutrophil count.
Methods: The study population included 202 patients with HCL, diagnosed
and followed in 12 medical centers in Israel during 1985-2015. Patients were
treated with cladribine, for 5-7 days given either sub-cutaneously or via intra-
venous infusion. Medical records were evaluated for details of disease at diag-
nosis, including date of diagnosis, age, sex, ethnicity,complete blood count
results, and spleen size at diagnosis. The efficacy of pegfilgrastim and filgrastim
was assessed by evaluating the incidence of neutropenia (defined as ANC
<1000x109/l), number and length of hospitalizations due to NF, severity of infec-
tions and the number of days from the last day of therapy until recovery of ANC
to >1000x109/l.
Results: Mean follow up was 7.5 years (0.1-40), with 5 and 10 years’ survival
of 96% and 90.62% respectively. The median age at diagnosis was 53 years,
and 81.8% were males. First line therapy with cladribine was given to 159
patients (80.7%) and of these 50.3% required hospitalization for the adminis-
tration of broad-spectrum antibiotics due to NF. The risk factor to develop NF
was WBC< 0.6 109/l, and ANC<0.3109/l. Twenty eight patients were treated
with pegfilgrastim as primaryprophylaxis 24 hours after the last day of therapy
with cladribine, while 75 patients received filgastrim “ on demand “due to neu-
tropenia.Median hospitalization days, and Nadir duration was 8 and 18 days
respectively in both groups (p=0.71, p=0.44).
Table 1.
Summary/Conclusions: Infectious complications post cladribine treatment,
remains high, with an incidence of 50.3%. For all parameters analyzed, includ-
ing the percentage of febrile patients, number of febrile days, and NADIR dura-
tion the results of primary pegfilgrastim prophylaxis and filgrastim given on
demand were similar.Accordingly, we conclude that it remains the treating physi-
cian’s choice to decide on which type of filgrastim to use and when to administer
it.
E1035
REDUCED HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH
CHRONIC LYMPHOCYTIC LEUKEMIA ACHIEVING COMPLETE
REMISSION TO FIRST-LINE THERAPY
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A. Rokito3, G. Gauthier2
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Background: Most targeted therapies in the management of chronic lympho-
cytic leukemia (CLL) lead to high overall response rates but complete remis-
sions are rare. Achieving complete remission (CR) is associated with improved
clinical outcomes such as longer time to progression; however little is known
about the economic benefits associated with achieving CR. 
Aims: The objective of the study was to compare healthcare resource utilization
among CLL patients initiated on first-line treatment who achieved CR versus
those who did not. 
Methods: This was a retrospective chart review study. From July to August
2016, 93 US oncologists/hematologists provided data abstracted from medical
charts of their CLL patients who initiated a first-line CLL treatment between
January 2010 and December 2014. The study collected patient demographics,
clinical characteristics, response to first-line therapy, and the number of all-
cause hospitalizations between first-line therapy initiation and end of the data
follow-up (i.e., patient’s date of death, end of care, or data collection date,
whichever occurred first). Patients were selected based on their best response
to first-line therapy (i.e., CR, partial remission [PR], stable disease [SD] and
progressive disease [PD]) as defined by the physician according to iwCLL 2008
criteria. The targeted number of patients in each category was a priori deter-
mined based on rates of response observed in clinical trials. The incidence of
all-cause hospitalization was compared between patients who achieved CR
and those who did not (including patients with PR, SD or PD) using univariate
and multivariate generalized linear models with a Poisson distribution. As
patients had different follow-up, incidence rates were reported per-patient-per-
month (PPPM). Multivariate regression models were adjusted for age, gender,
selected comorbid conditions, time from CLL diagnosis to first-line initiation,
and Eastern Cooperative Oncology Group (ECOG) status.
Table 1.
Results: Patient-level data was collected for 179 patients who achieved CR
and 151 patients who did not achieve CR (120 patients with PR, 25 with SD,
and 6 with PD). Average time from CLL diagnosis to first-line initiation was 8.4
months for patients who achieved CR and 13.3 months for those who did not.
The majority of patients were male (65%), the average age was 63 years, and
80% of patients had an ECOG of O or 1 at first-line therapy initiation. The medi-
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an follow-up after first-line therapy initiation was 30 months. Over that period,
patients who did not achieve CR had statistically significantly higher incidence
of all-cause hospitalization compared to patients who achieved CR (0.021 vs
0.006 PPPM; unadjusted incidence rate ratio [IRR]=3.30, p<0.05). After adjust-
ing for potential cofounders, the incidence of all-cause hospitalization was 2.4
times higher for patients who did not achieve CR compared to those who did
(IRR=2.44, p<0.05).
Summary/Conclusions: Results from this study showed that achieving CR to
first-line therapy (vs. not achieving CR) is associated with reduced frequency
of all-cause hospitalizations. This suggests that, in addition to the clinical benefit
associated with CR achievement, treatment strategies in CLL that improve CR
may help reducing the economic burden of CLL management for both patients
and payers.
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RITUXIMAB (R) USED AS A SINGLE AGENT FOR AUTOIMMUNE
HEMOLYTIC ANEMIA (AIHA) IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL) PATIENTS INDUCES ALSO SIGNIFICANT DISEASE
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Background: There are very few effective treatment options for steroid refractory
AIHA of CLL or for CLL patients(pts) that are unable to receive corticosteroids.
R has been noted to be active in certain autoimmune hematologic disorders
while experience with single-agent R in untreated CLL pts is very limited.
Aims: To report our experience concerning the use of R as a treatment of AIHA
occurring during the clinical course of treatment naïve CLL pts by analyzing
concomitantly its efficacy and safety as a single agent in CLL therapy
Methods: 15 pts diagnosed with CLL who received R due to AIHA were includ-
ed in this study. Staging was performed at diagnosis (Binet system). Pts were
placed on R at the standard dose I.V of 375mg/m2 once weekly for 6 consec-
utive weeks because of contraindication of corticosteroids administration
Results: Pts’ median age was 60 y(range, 42-83 y), (8 out of 15, males), 10
having disease stage A and 5 B. Two were presented with splenomegaly and 1
with B-symptoms. 12 pts (83%) had leukemic lymphocyte counts of more than
50x109/L. Median time from diagnosis, the AIHA diagnosis and to 1st R infusion
was 59 mos. All 15 pts completed the 6-week course of R and were assessable
for response. The median WBC and the median absolute lymphocyte
count(ALC) before R administration and after the end of 6-week course are
shown in the Table. Resolution of the AIHA effect was achieved in all pts whereas
in 4 there was a persistence of positive DAT without evidence of active hemol-
ysis. After the end of 6 weekly R infusions 13 out of 15 pts (86%) showed also
disease response. 12 pts experienced PR (80%) and 1 CR (6%). All pts with
advanced disease also responded entering PR. Resolution of splenomegaly
was documented in both splenomegalic pts. After a median follow up of 84, 5
mos from CLL diagnosis, 14 pts are alive, 9 maintain their disease response
while 5 were in need of therapy due to CLL progression, after a median time of
10 mos from the last R infusion. Among them 4 were placed on FCR (2CR,
2PR) and 1 on R-Bendamustine(PR). Median PFS has not reached. All pts
received the entire first dose on day 1 of treatment. There was only a grade 3
infusion related reaction in a patient with WBC>400x109/L without need for hos-
pitalization. None of the pts experienced severe tumor lysis syndrome, pul-
monary insufficiency, myelosuppression or opportunistic infections.
Table 1.
Summary/Conclusions: A) R is an effective agent for AIHA treatment with
concomitant significant activity against CLL and therefore could be the standard
of care for CLL pts with AIHA, especially for the cohort of pts with comorbidities.
B) We confirm previous data that: 1) single-agent R induces significant respons-
es in treatment naïve CLL pts 2) R is well tolerated and its administration is not
associated with myelosuppression or immunosuppression 3) R as a single
agent could be an excellent first-line treatment option for pts who are very eld-
erly or who have a poor performance status
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ATTAINMENT OF COMPLETE REMISSION IS SIGNIFICANTLY ASSOCIATED
WITH LONGER SURVIVAL OUTCOMES IN RELAPSED/REFRACTORY
(R/R) CLL: A META-ANALYSIS
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S.J. Snedecor1
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Background: Chronic lymphocytic leukemia (CLL) is an incurable neoplasm
of B lymphocytes, associated with a heterogeneous clinical course. Complete
response (CR) with/without minimal residual disease in first-line chemoim-
munotherapy has been associated with more favorable progression-free sur-
vival (PFS) and overall survival (OS). However, patients (pts) with R/R CLL
and/or those with TP53 abnormalities (ie, 17p deletion and/or TP53 mutation)
are less likely to achieve deep responses and experience poorer outcomes.
Therefore, less is known about the relationship between CR and survival out-
comes in R/R CLL pts.
Aims: To quantify this association, we generated meta-analytic estimates of
PFS and OS reported in clinical trials using the proportion of study patients
with CR as a predictor variable.
Methods: We performed a systematic literature review of PubMed/EMBASE
up to Nov 2014 and congress abstracts 2012‒2014. Randomized controlled
trials and observational studies evaluating any treatment in R/R CLL pts were
eligible for inclusion. Data were extracted from publications as median survival,
the proportions of pts surviving at specific follow-up times, or individual event
or censoring times from reported Kaplan-Meier (KM) curves, along with the
proportion of pts with CR. Data were synthesized to estimate overall OS and
PFS including population-level CR as a covariate using a Weibull proportional
hazards model within a Bayesian meta-analysis framework. 
Results: 74 published studies of treatment outcomes in R/R CLL pts were
identified from the peer-reviewed literature and congress abstracts. 56 of these
studies reported the proportion of CRs together with either OS or PFS out-
comes and were included in the analysis. Individual pt data were extracted
from KM curves of 29 studies generating 5176 individual pt OS and PFS data
points in addition to 54 study-level data points including 3638 pts. There were
no clinically meaningful differences in study or pt characteristics among the
included studies that were not also associated with CR, our variable of interest.
The hazard ratio (HR; and 95% credible interval, the Bayesian analog to con-
fidence intervals) of survival for each 10% increase in CR among a study pop-
ulation was estimated to be 0.64 (0.60, 0.68). Estimated median OS for hypo-
thetical populations with 0% CR, 25% CR, or 50% CR were 20.4 mo, 44.7 mo,
and 61.9 mo. Corresponding median PFS estimates were 10.0 mo, 21.9 mo,
and 30.3 mo. (Figure 1).
Figure 1.
Summary/Conclusions: The attainment of CR is significantly associated with
longer OS and PFS outcomes in R/R CLL at the study level. Moreover this can
be expressed linearly, with each 10% increase in CR rate corresponding to a
36% reduction in the risk of progression or death. To our knowledge, this is the
first meta-analysis to quantify the relationship between CR and survival out-
comes in R/R CLL pts. It must be noted that these results reflect the study
(population) level CR versus survival association and therefore do not neces-
sarily represent the expected survival gain associated with an individual achiev-
ing CR. Further, CR is less likely to be achieved in pts with TP53 abnormalities,
a factor not explicitly considered in our analysis. These results synthesize data
from 56 clinical trials and strongly support the importance of achieving CR to
improve long-term outcomes in R/R CLL pts. In particular, given the negative
association between CR and TP53 abnormalities, treatments focused on
improving the likelihood of CR in these hard-to-treat pts are likely to confer the
greatest impact on survival outcomes.
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APLICATION OF THE CLL-IPI AND THE MDACC PRGNOSTIC INDEXES IN
A LOCAL COHORT OF CLL PATIENTS
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M.A. Foncillas1, J.M. Hernández-Rivas2, J.Á. Hernández1
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Background: New prognostic scores have been developed in order to better
discriminate the clinical course of CLL patients, along with Rai and Binet clinical
staging systems. These scores, such as that proposed by the MDACC group,
and recently the CLL-IPI combine clinical and biological variables with prog-
nostic value.
Aims: In this study we investigated the validity and reproducibility of these
scores in a local cohort of patients with CLL.
Methods: We made a retrospective analysis including 650 unselected CLL
patients newly diagnosed and previously untreated from a single institution.
The final analysis has been limited to the 486 cases with complete data to
apply the MDACC score, and to the 258 cases with complete data to apply the
CLL-IPI score.
Results: Median age was 67 years old (25-90). With a median follow-up time
of 46 months, 394 patients were alive, and 187 had received any treatment for
CLL at the moment of the analysis. Median overall survival (OS) of the whole
series was 173 months (127-220), and median time to first treatment (TTFT)
106 months (82-130). The MDACC score was applied to 486 cases giving 0 to
9 points to each case according to: age, b2-microglobulin levels, absolute lym-
phocyte count, sex, Rai stage, and number of involved lymph node groups. As
shown in the Table, stratification of patients using the MDACC score allowed
the prediction of prognosis for both TTFT (P=0.000) and OS (P=0.000). 162
patients were classified as low risk, 302 as intermediate risk, and 21 as high
risk. Due to missing data, the CLL-IPI score could only by applied to 258
patients giving 0 to 10 points to each case according to 17p deletion, IGHV
mutational status, β2-microglobulin, clinical stage, and age. As shown in the
table, 126 patients were classified as low risk, 79 as intermediate risk, 46 as
high risk, and 7 as very high risk. We also found significant differences in terms
of OS (P=0.000) and TTFT (P=0.000) using this score.
Table 1.
Summary/Conclusions: In this study we confirm that both scoring systems
are able to discriminate patients in different prognosis subgroups. Both scores
are also easily applicable in clinical practice. The new CLL-IPI score is able to
distinguish subgroups of patients with worse prognosis including new factors
(17p deletion and mutational status of IGHV).
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Background: Prognostication is a key component in the management of
patients with chronic lymphocytic leukemia (CLL). Prognostic factors however
may change as a result of the introduction of more effective therapies.
Aims: To investigate whether the prognostic value of classical parameters has
changed over time.
Methods: Retrospective single-center study of prognostic factors and outcome
in patients with CLL diagnosed before (n=454) and after (n=903) 1995 when
purine analogs and subsequently chemoimmunotherapy (CIT) were introduced
in CLL treatment at the Hospital Clínic, Barcelona.
Results: The median follow-up up was 8.3 years (0.1-33.0) for the overall
series and 24.9 years (21.9-33.0) and 7.8 years (0.1-21.3) for patients diag-
nosed before and after 1995, respectively. Patients diagnosed before 1995
were older (p<0.001), had more advanced clinical stage (p<0.001), higher ALC
(p<0.001), shorter LDT (p<0.001), and more often anemia (p=0.028), thrombo-
cytopenia (p<0.001) and increased serum LDH levels (p=0.019) than those
diagnosed thereafter. There were no differences in B2-microglobulin (B2M) lev-
els and ZAP70 or CD38 expression. Mutated IGHV was more frequently detect-
ed in patients diagnosed before 1995 (75% vs 55%; p<0.001). The proportion
of patients receiving treatment did not differ between groups [42% (38-47%) vs
46% (42-49%) at 6 years; p=0.08]. The type of therapy given to patients diag-
nosed before and after 1995 was: alkylating agents (91% vs 34%), purine
analogs (4% vs 27%), CIT (0% vs 31%), other (5% vs 8%) (p<0.001). The
response rate was lower in patients diagnosed before 1995 (57% with 9% CR
vs 67% with 36% CR; p<0.001) and overall survival (OS) was shorter (median;
8.0 vs 10.1 years; p<0.001). The median OS in patients diagnosed before and
after 1995 broken down by clinical stage was: stage A: 10.1 vs 10.9 years
(p=0.1); stage B: 4.5 vs 9.2 years (p<0.001); stage C: 3.8 vs 3.8 years (p=0.2).
In both groups of patients univariate analyses demonstrated a correlation
between OS and clinical stage (both p<0.001), age >70 years (both p<0.001),
B2M (both p<0.001), short lymphocyte doubling time (LDT) (both p<0.001),
unmutated IGHV (both p<0.001), and ZAP70 (p=0.015 and p<0.001). High-risk
FISH correlated with OS in patients diagnosed after 1995 (p<0.001). In patients
diagnosed before 1995, the number of subjects with available FISH was too
small for a meaningful analysis. In multivariate analysis (age >70 years,
advanced clinical stage short LDT increased B2M, diagnosis before 1995) only
age (HR 2.7 (95% CI: 2.1-3.4), p<0.001), LDT (HR 2.5 (1.9-3.2), p<0.001) and
B2M (HR 2.8 (2.2-3.6), p<0.001) showed independent prognostic significance
for OS. IGHV mutational status, ZAP70 and high-risk FISH cytogenetics corre-
lated with OS but these variables were not included in multivariate analyses
because of the many patients with missing information.
Summary/Conclusions: Survival of patients with CLL in intermediate-risk
(stage B) disease has dramatically improved over the last years. In contrast,
the outcome of patients with either low (stage A) or high (stage C) stage has
not been significantly modified, indicating the need for more effective therapies
in these patients. Importantly, the prognostic significance of classical prognostic
variables has not changed after the introduction of more effective therapies.
Finally, similar studies are warranted in patients treated with novel agents.
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AN OBSERVATIONAL STUDY EVALUATING THE USE OF BENDAMUSTINE
AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA
IN RUSSIA
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1Almazov Federal North-West Medical Research Centre, Saint Petersburg,
2Clinical Trial Support, Smolensk, Russian Federation, 3Astellas Pharma
Europe, Middle East and Africa, Chertsey, United Kingdom
Background: Bendamustine has gained footing as a component of first-line
therapy for chronic lymphocytic leukemia (CLL) due to its efficacy and favorable
toxicity/tolerability profile for most patient types. There is a dearth of data on
the effectiveness of bendamustine as first-line therapy in the Russian CLL
patient population, which is needed to support drug cost reimbursement
processes.
Aims: Evaluate effectiveness of first-line therapy with bendamustine for CLL in
the Russian Federation.
Methods: This was a prospective, multicenter, observational study
(NCT02110394) in adults (>18 yr) diagnosed with CLL who were receiving, or
were scheduled to receive, first-line therapy with bendamustine plus rituximab.
Patients who had prior CLL treatment (eg, chemotherapy, radiation) or had con-
traindications to bendamustine were excluded. Each subject was required to
have 2 to 8 study visits, where Visits 2–6 reflected treatment cycles; total number
of treatment cycles for each patient was determined by the study investigator.
Interim and final evaluations were performed after 3 and 6 treatment cycles,
respectively. Primary endpoints were overall response rate (ORR, patients
achieving complete remission [CR] plus those achieving partial remission [PR]).
Secondary endpoints were time to therapeutic failure, time to progression, pro-
gression-free survival (PFS), relapse or death after CR or PR, quality-of-life (EQ-
5D questionnaire), and frequency of adverse drug reactions (ADRs).
Results: Of the 196 patients who enrolled between June 2012 and August
2015, 191 were included in the Safety Population (patients who received ≥1
dose of study drug) and 149 were included in the Full Analysis Set (FAS;
patients in the Safety Population who had ≥1 response evaluation). Most
patients in the FAS were male (59.7%); mean age was 61.5±8.9 yr. Overall,
35.6% of patients were ≥65 yr old and 80.5% had ≥1 comorbidity such as
decreased renal function. The ORR was 83.2%; CR and PR rates were 59.7%
and 23.5%, respectively. Generally, response rates were slightly higher than
those reported in the Phase 3 pivotal trial (Knauf et al. J Clin Oncol. 2009).
Eradication of minimal residual disease was achieved in 23 of the 84 evaluable
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patients (27.4%). Overall, 80.3% of FAS patients did not experience therapeutic
failure and 85.9% did not experience disease progression during the 2-year
observation period. By the end of the study, median PFS had not been reached;
2-year PFS rate was estimated as 85.9%. Improvements from baseline were
observed after 6 cycles of treatment across all EQ-5D domains. No relapses
or deaths occurred in the FAS; however, 2 subjects in the Safety Population
experienced fatal serious ADRs (myocardial infarction [n=1]; acute pneumonia,
infections and toxic shock, and atrial fibrillation [n=1]). In concurrence with the
Phase 3 trial results, hematologic disorders (19.9%; anemia, neutropenia,
thrombocytopenia), most of which were Grade ≤2 in severity, were the most
common ADRs (Safety Population; Table 1).
Table 1. Hematologic ADRs by CTCAE Grade.
Summary/Conclusions: First-line therapy with bendamustine plus rituximab
was well tolerated in this Russian CLL population, including elderly patients
and patients with renal dysfunction or other comorbidities. Additionally, combi-
nation therapy resulted in high rates of treatment response in the CLL. These
data confirm the value of bendamustine as a first-line agent for CLL in routine
clinical practice in Russia.
Chronic myeloid leukemia - Biology
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MUTAGENESIS OF BCR-ABL1 IS REQUIRED FOR RESISTANCE
DEVELOPMENT IN DE NOVO CHRONIC MYELOID LEUKEMIA KCL-22
CELLS BUT NOT IN RELAPSED KCL-22 CELLS EXPRESSING BCR-ABL1
INDEPENDENT RESISTANCE
N. Curik1,2, V. Polivkova1,3, T. Kalina4, V. Kanderova4, J. Linhartova1, F. Savvulidi2,
O. Toman1, K. Srutova1, S. Ransdorfova1, J. Brezinova1, H. Klamova1,5,
K. Machova Polakova1,5,*
1Institute of Hematology and Blood Transfusion, 2Institute of Pathological Phys-
iology, First Medical faculty, Charles university, 3Faculty of Science, Charles
University, 4Department of Paediatric Haematology and Oncology, Univ. hos-
pital Motol, 5Institute of Clinical and Experimental Hematology of the 1st Med-
icine Faculty, Charles University and Institute of Hematology and Blood Trans-
fusion, Prague, Czech Republic
Background: BCR-ABL1 kinase domain (KD) mutations are an important
mechanism of resistance of chronic myeloid leukemia (CML) patients devel-
oping during the tyrosine kinase inhibitors (TKI) treatment. However, mecha-
nisms underlying KD mutation acquisition in TKI-resistant CML cells are not
yet well understood.
Aims: We studied an acquisition of mutations in the KD after an exposure of
de novo and relapsed (grown in optimal growing medium for 24 months) KCL-
22 cells to imatinib (IM). In addition, we examined kinetics of mutated sub-
clones in established IM-resistant KCL-22R culture after dose-reduction of IM.
We also studied changes in the expression profile of KCL-22 cultures early
after exposure to IM.
Methods: The occurrence and kinetics of expansion of BCR-ABL1 mutant sub-
clones were studied using next-generation deep sequencing in KCL-22 cells
treated with 0.4 µM IM and in established IM-resistant KCL-22R cells at 4 µM
IM. In other set of experiments, KCL-22R cells were sorted according to the
CD38 expression to explore whether CD38 is associated with the acquisition
of BCR-ABL1 mutations as suggested by Wang et al. (2014). A protein array
was used allowing analysis of 576 proteins per sample. DNA damage path-
way-RT Profiler PCR arrays were applied for gene expression analysis.
Results: No BCR-ABL1 KD mutations were detected in de novo untreated
KCL-22 cells, however T315I and E255K appeared after the exposure of the
cells to 0.4 µM IM. PCR array revealed increased expression of SUMO 1 ligase
and ERCC2 involved in the nucleotide excision repair pathway. Notably, we
also found a significant decrease of G2/M-checkpoint protein GADD45A whose
deficiency is associated with mutagenesis (Hollander et al., 2001). During the
first culture period, T315I slowly emerged whereas E255K was not detectable.
Later, E255K-bearing cells also became detectable and increased over time.
A similar time-dependent expansion of mutant-bearing sub-clones was seen
in the KCL-22R cells growing at 4 µM IM. Interestingly, a mutant-clone switch
from T315I to E255K in KCL-22R was accelerated after IM reduction from 4
µM to 1 or 2 µM. Moreover, the emerging of E255K sub-clone was accompanied
by rapid decrease of CD38 expression in KCL-22R cells. Profiling of transitional
KCL-22R culture, carrying both T315I and E255K sub-clones, revealed that
T315I transcripts were expressed only in the CD38+ subpopulation, while
E255K was detected only in CD38- cells. Unlike to de novo KCL-22 cells, BCR-
ABL1 mutations were repeatedly not detected in relapsed KCL-22 cells up to
follow-up of 60 days after the cells exposure to 0.4 µM IM. Neither BCR-ABL1
upregulation nor gene amplification was detected in these cells. We identified
considerably upregulated (D7, DTX3, ETV6, GLUL, HCLS1, HIF1α, IGF1R,
MAP2K7, MYH11, TP53) or downregulated (BAD, BID, MCL2 NOTCH3,
PDKPK1) proteins early, 4 weeks after the exposure to IM. Increased expres-
sions of HIF1α and IGF1R proteins are known to ensure proliferation, while
decreased expressions of pro-apoptotic proteins BAD and BID enhance sur-
vival of CML cells in the presence of TKIs.
Summary/Conclusions: Our observation suggests the ability of KCL-22 cells
to survive and proliferate early after the exposure to IM. BCR-ABL1 mutations
development seems to be related to a mutagenesis of imatinib on de novo
KCL-22 cells, but not on relapsed KCL-22 cells that activated signaling path-
ways ensuring their survival and growing in the presence of tyrosine kinases
inhibitor.
Supported by the project no. 00023736 and AZV 15-31540A of MZCR and
ERDF OPPK CZ.2.16/3.1.00/28007.
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FLOW-CYTOMETRY DETECTION OF CD26+ LEUKEMIA STEM CELLS IN
PERIPHERAL BLOOD: A SIMPLE AND RAPID NEW DIAGNOSTIC TOOL
FOR CHRONIC MYELOID LEUKEMIA
D. Raspadori1, S. Sirianni1, L. Aprile1,*, E. Abruzzese2, A. Iurlo3, A. Sicuranza1,
S. Galimberti4, L. Schiattone1, A. Gozzini5, P. Pregno6, G. Caocci7, G. Papini1,
I. Ferrigno1, B. Mecacci1, M. Bocchia1
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Background: Diagnosis of Chronic Myeloid Leukemia (CML) implies docu-
menting in bone marrow (BM) or in peripheral blood (PB) Philadelphia (Ph)
chromosome by cytogenetics, molecular BCR-ABL1 fusion by FISH or BCR-
ABL1 rearrangement by RT-PCR. In clinical practice, at the earliest, 24-72 hrs
are needed to confirm CML by any of these assays. Lately, characterization of
CML leukemia stem cells (LSCs) from BM samples of CML patients (pts)
showed a specific co-expression of dipeptidylpeptidaseIV (CD26) within the
CD34+/CD38─/Lin─ stem cell fraction and CD26 appeared a robust biomarker
for identifying CML LSCs within the normal BM compartment. We recently
demonstrated that CD34+/CD38-/CD26+ LSCs can be easily identified by flow-
cytometry also in PB during treatment with tyrosine kinase inhibitors.
Aims: We investigated accuracy and specificity of flow cytometry PB
CD34+/CD38-/CD26+ LSCs identification as a new tool for the diagnosis of CML.
Methods: Pts with clinical suspicion of CML entered the study after written
informed consent and all were evaluated for CD26+LSCs, cytogenetics, FISH
and/or BCR-ABL1 RT-PCR analysis. CD34+/CD38-/CD26+ population was
investigated in PB and when possible simultaneously in BM samples using a
flow-cytometry 4-color staining procedure. 2.0x106leucocytes were incubated
with BD Pharmigen CD45V500 (c.2D1), CD34FITC (c.581), CD38APC
(c.HIT2), CD26 (c.M-A261) and negative controls. Acquisition and analysis of
at least 1.0x106 CD45+ cells were done by FACSCanto II with DIVA 8 software
(BD, Biosciences). CD26+ cells were identified by sequential gate. CD45+ and
CD34+ gates were performed on viable cells identified by FSC/SSC light prop-
erties and CD34+/CD38- population was gated applying a narrow gate excluding
all CD38+ cells (Fig.1).
Results: PB samples from 107 pts with myeloproliferative features were eval-
uated for CD26+LSCs. Leucocytes median value was 52x109/L (range 5-
408x109/L). In 83/107 (77.5%) pts we showed CD34+/CD38-/CD26+ LSCs in
PB and in 83/83 (100%) the diagnosis of CML was confirmed by cytogenetics,
FISH and RT-PCR analysis. Median value of circulating PB CD26/µL was 14
(range 0,27-698) and a positive correlation with leukocyte count (p<0.01) was
found. In 53/107 (49,5%) pts analysis was performed contextually in BM sam-
ples. All CD26+ PB-BM matched pairs (49/53) showed superimposable results
in terms of absolute number of CD26+LSCs/µL (19,18 and 18,73 respectively)
while the percentage of CD26+ cells within the CD34+/CD38- fraction appeared
lower in BM than in PB samples (median 28,18 and 37,33; range 0,87-77,14
and 5,59-99,57 respectively). In 24/107 (22.5%) PB samples and in 4/53 BM
samples CD26+ LSCs were not detected and none of these samples was found
Ph or BCR-ABL1 positive. Pts with CD26 neg PB/BM samples were subse-
quently diagnosed as Idiopathic Myelofibrosis (12 pts), Myelodysplastic/Myelo-
proliferative disorders (7 pts) benign neutrophilia (5 pts). Of note, we additionally
studied 4 PB+BM samples of 4 Ph+ acute lymphoblastic leukemia and all
scored negative for CD26+LSCs.
Figure 1.
Summary/Conclusions: Flow-cytometry evaluation of PB CD34+/CD38-
/CD26+LSCs is a feasible, very rapid (about 3 hrs from sample handling to
results) and highly specific alternative/complementary diagnostic tool for CML.
To validate these data in a larger cohort of patients we are developing a pre-
titrated lyophilized antibody mixture (lyotube, BD Biosciences) to maximize
sensitivity and to optimize standardization and working time, with the further
aim to monitor stem cells minimal residual disease in CML patients.
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LIPID PEROXIDATION AND INFLAMMATORY STATUS DURING TKI TREAT-
MENT IN CHRONIC MYELOID LEUKEMIA PATIENTS: INTERIM ANALYSIS
OF A PROSPECTIVE MULTICENTER STUDY
A. Sicuranza1,*, L. Aprile1, E. Abruzzese2, A. Iurlo3, S. Galimberti4, A. Gozzini5,
N. Sgherza6, L. Puccetti1, G. Papini1, D. Cattaneo3, F. Stagno7, F. Di Raimondo7,
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Background: Evidences of increased cardiovascular (CV) events, mostly
atherothrombotic, in Chronic Myeloid Leukemia (CML) patients (pts) treated
with some Tyrosine Kinase inhibitors (TKIs) prompted physicians to carefully
evaluate CV risk factors (CVRFs) in the choice of TKI. However, the pathogen-
esis behind CV events during TKIs is still largely unknown and even pts without
overt CVRFs incur in CV events. We retrospectively showed that an induced
“inflammatory status” during nilotinib treatment, together with genetic pro-
atherothrombotic predisposition, may partly explain the increased incidence of
CV (Bocchia, Oncotarget 2016). These data provided the rationale to start a
multicentric “Prospective study of TKI induced pro-AtherothROmbotic status
in CML. KIARO study” (Grant support: AIRC-ITT) including Chronic Phase CML
pts treated with any first line approved TKI in which clinical, genetic and bio-
chemical pro-atherothrombotic profiles were evaluated at diagnosis and during
treatment.
Aims: This prospective study aims to confirm the possible role of genetic pre-
disposition and behavior of specific pro/anti-inflammatory biochemical param-
eters in the atherosclerotic pathogenesis during TKIs treatment.
Methods: Enrolled pts were prospectively evaluated for: presence of traditional
CVRFs, atherothrombotic episodes, presence of Single Nucleotide Polymor-
phisms (SNPs) associated to CV risk (Cardiokit) and plasma levels of several
pro and anti-inflammatory cytokines. In this first interim analysis we focused on
levels of LDL, oxidated-LDL (oxLDL), TNFα, IL-6 and IL-10 and the presence
of SNPs of LDL-R (rs1122608), LOX-1 (rs3736235), and IL-10 (rs1800896)
genes.
Results: 12 Italian Hematology Units participated to the study and up to date
95 CML patients were enrolled. We here report data from the first 43 patients
on TKI treatment for at least 12 months (15 nilotinib, 14 imatinib and 14 dasa-
tinib,. No CV events were recorded to date. At diagnosis, levels of LDL
(143.5±13.2), ox-LDL (237.4±99.5), TNFα (3.91±2.51), IL-6 (1.96±0.99) and
IL-10 (0.34±0.15) were evaluated for the whole cohort and according to the
TKI treatment. No statistically significant differences were found in the expres-
sion of these variables between the 3 groups of treatment (p>0.096). Consid-
ering the genotype frequency, we confirmed in the whole cohort a correlation
between basal levels of LDL, oxLDL and IL10 with the presence/absence of
the detrimental G/G allele of LDL-R (H.R. 2.11, p<0.01), LOX-1 (H.R. 2.86,
p<0.01) and IL10 (H.R. 1.85, p<0.05) polymorphisms. During TKIs treatment
we observed increased levels of LDL (p<0.05) and oxLDL (p<0.05) only in the
nilotinib cohort at 3 and 12 months of treatment, regardless of the concomitant
use of CV medications. No differences in TNFα and IL6 levels during the first
12 month of treatment were detected in the 3cohort (p<0.079). Interestingly,
IL-10 levels were significantly higher at 3 and 12 months of treatment in the
imatinib and dasatinib cohort (p<0.01) respect to nilotinib (p=0.094). 
Summary/Conclusions: This interim analysis, although still very preliminary,
suggests that in nilotinb patients the high levels of LDL and oxLDL in combina-
tion with low levels of IL10, could induce a persistent pro-inflammatory/oxidative
status potentially favoring atherothrombotic events. Additional biochemical and
genetic data as well as prolonged clinical observation are needed to confirm
this hypothesis. Patients enrolment and monitoring is ongoing.
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TRANSCRIBED ULTRACONSERVED NONCODING RNAS (T-UCRS) IN
CHRONIC MYELOID LEUKEMIA: EXPRESSION PROFILES ASSOCIATED
WITH MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE
INHIBITORS
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Background: Transcribed ultraconserved regions (T-UCR) are a novel class
of long noncoding RNAs. Many classes of noncoding RNAs have been impli-
cated in human tumorigenesis. In addition to the different expression profiles
of T-UCRs that could be used to distinguish human leukemias and carcinomas,
they have also been reported to have direct interactions with miRNA with an
important regulatory effect in disease development such as chronic myeloid
leukemia (CML).
Aims: In this study, we aimed at the correlation of T-UCR and miRNA:T-UCR
pairs in CML, according to tyrosine kinase inhibitor (TKI) therapy, clinical risk
scores and molecular response.
Methods: We analysed peripheral blood samples from 45 CML patients and
15 healthy controls. Two panels of 481 T-UCR and 752 miRNA probes were
used for RT-qPCR analysis. Differential expression was evaluated using the
Mann-Whitney test followed by Benjamini-Hochberg multiple testing correction.
Results: CML samples presented significantly different expression of uc.164
(p<0.01), uc.118 (p<0.01), uc.125 (p<0.01), uc.391 (p<0.01), uc.153 (p<0.01),
uc.141 (p<0.01), uc.143 (p<0.05) and uc.145 (p<0.05), when compared to
healthy controls. This latter T-UCR (uc.145) was associated with development
and immune regulation pathways. We analysed Sokal, Hasford and EUTOS
risk scores and found uc.236 (p<0.0001), uc.39 (p<0.05) and uc.7 (p<0.05) to
be associated with EUTOS low risk. Concerning therapy, dasatinib was corre-
lated with uc.187 (p<0.005). For imatinib doses, uc.4 (p<0.05) and uc.3 (p<0.05)
inversely correlated with 400 and 800mg daily, respectively. Molecular response
in CML samples presented a signature including uc.187 (p<0.001), uc.107
(p<0.05), uc.409 (p<0.05), uc.198 (p<0.05), uc.309 (p<0.05), uc.102 (p<0.05),
uc.294 (p<0.05) and uc.361 (p<0.05). Major molecular response was identified
by the altered expression of uc.198 (p<0.05), uc.215 (p<0.05) and uc.210
(p<0.05). The negative regulation of T-UCRs by miRNAs, involving T-UCR:miR-
NA interaction, was associated with upregulated (miR-720, miR-886-3p, miR-
1274a, miR-101 and miR-129) and downregulated (miR-489 and miR-1973)
microRNAs.
Summary/Conclusions: In the present study, we identified T-UCRs signatures
and T-UCR:miRNA pairs associated with CML, risk scores, TKI therapy and
molecular response. The expanded knowledge of RNA biology in general,
together with the recent interest in the multitude of newly discovered elements
such as T-UCRs, could help to improve CML therapy.
Financial Support: FEDER (Programa Operacional Factores de Competitivi-
dade – COMPETE) and FCT (Fundação para a Ciência e Tecnologia) through
project PEst-C/SAU/LA0001/2013-2014.
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MAINTENANCE OF LEUKAEMOGENIC POTENTIAL OF BCR/ABL+ CELLS
REQUIRES PAK2 BUT NOT PAK1
A. Hoelbl-Kovacic1,*, A. Berger1, L. Edlinger1, I. Menzl1, G. Hoermann2,
E. Grundschober1, Z. Bago-Horvath3, V. Sexl1
1Institute of Pharmacology and Toxicology, Veterinary University of Vienna,
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Background: p21-activated kinases (PAKs) are key nodes in oncogenic sig-
nalling pathways that control growth, survival, and motility of cancer cells. Their
activity is increased in many human cancers and the increase is associated
with a poor prognosis. To date, PAK deregulation has mainly been studied in
solid tumours, where PAK1 and PAK4 are the main isoforms deregulated.
Aims: We aimed at identifying deregulations of PAKs in haematopoietic tumors
and the potential contribution of individual PAKs to tumorigenesis.
Methods: We used a combination of in silico analysis of publicly available data
of haematological patients, shRNA-mediated knockdown and in vitro transfor-
mation assays. In parallel, we analysed the tumorigenic potential of leukemic
cells in vivo after knockdown of individual PAKs.
Results: We show that PAK1 and PAK2 are frequently deregulated in
haematopoietic tumors, particularly in BCR/ABL+ leukemia. In suspension,
BCR/ABL+ leukaemic (KU812) cells deficient for PAK1 and PAK2 undergo
apoptosis, while the loss of either protein is well tolerated. When leukaemic
cells are challenged to grow towards an extracellular matrix, the loss of PAK2
alone abrogates cell growth. PAK2-deficient cells fail to form colonies in growth-
factor free methylcellulose and do not induce lymphomas in vivo.
Summary/Conclusions: PAK2 is the critical isoform in a BCR/ABL-driven dis-
ease. This finding suggests that the PAK2 isoform represents a promising
target for the treatment of haematological diseases.
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MIRNA PROFILING OF CIRCULATING EXTRACELLULAR VESICLES IN
CML PATIENTS WITH MUSCULOSKELETAL PAIN ASSOCIATED WITH
DISCONTINUATION OF TYROSINE KINASE INHIBITORS
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Background: Clinical trials of TKI discontinuation are still ongoing, approxi-
mately 60% of CML patients who achieved a deep molecular response for
more than 2 years maintained a major molecular response after discontinuation
of imatinib. However, the long-term prognosis and/or adverse events after TKI
cessation remain unclear. Recent reports showed that transient musculoskele-
tal pain without consistent biochemical abnormalities occurs in approximately
30% of CML patients after stopping imatinib.
Aims: Recent evidences suggest that extracellular vesicles (EVs) that contain
genetic element such as DNA, RNA, and miRNA, are important mediators of inter-
cellular communication. We therefore studied molecular study to ascertain the
possible correlation between musculoskeletal pain and EV-miRNA expression.
Methods: We investigated circulating EV-miRNAs in five CML patients who
did not experience musculoskeletal events and five patients with musculoskele-
tal pain after stopping TKIs, as well as three healthy individuals. Peripheral
blood was obtained approximately 3 months after successful TKI cessation in
CML patients. Exosomes were extracted by using Total Exosome Isolation
Reagent (Invitrogen, Carlsbad, CA, USA) and EV-miRNA profiling was per-
formed with a TaqMan Low-Density Array (Thermo Fisher Scientific, Carlsbad,
CA, USA), as reported previously. The relative expression level of each gene
was calculated by using the comparative thresholds cycle (Ct) method. Syn-
thetic spike control (ath-miR-159; Hokkaido System Science, Hokkaido, Japan)
was used as an invariant control for EV-miRNA. This study was approved by
the institutional review board of Tokyo Medical University (no. 930 approved
24 June 2008 and no. 3052 approved 9 June 2015).
Results: Three-way analysis of variance (ANOVA) performed for healthy con-
trols and CML patients with and without musculoskeletal pain revealed EV-
miR-140-3p to be the most significant value (P=0.00778). A t-test analysis using
R software identified 10 differentially expressed EV-miRNAs for CML patients
with and without musculoskeletal pain: seven miRNAs were upregulated (miR-
107, miR-145, miR-140-3p, miR-539, miR-495, miR-299-5p, miR-425) and
three were downregulated (miR-122, miR-218, miR-523) in CML patients with
musculoskeletal pain. The up-regulated EV-miR-140-3p in all CML patients
decreased after release of musculoskeletal pain.
Summary/Conclusions: CML patients with increased EV-miR-140-3p
achieved levels similar to those of healthy controls after relief from muscu-
loskeletal pain. It has been reported that there is an association between mus-
culoskeletal pain and inflammatory indicators in some CML patients who
stopped TKIs; however, we did not find any positive association. Although the
number of CML patients in this study is too small to draw definite conclusions,
further research should investigate whether upregulation of EV-miR-140-3p
expression in peripheral blood is correlated with musculoskeletal events in
CML patients after TKI cessation.
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CHECKPOINTS AND CHRONIC MYELOID LEUKEMIA: CORRELATIONS
WITH MOLECULAR RESPONSE AND TYROSINE KINASE INHIBITOR
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Background: Blockade of immune checkpoints seems to unleash the potential
of the antitumor immune response in a fashion that is transforming human can-
cer therapeutics. Soluble and membrane-bound receptor–ligand immune
checkpoints are the most druggable forms using agonist antibodies (for co-
stimulatory pathways) or antagonist antibodies (for inhibitory pathways).
Although its implications in immune response during chronic myeloid leukemia
are obvious, literature regarding chronic myeloid leukemia (CML) and immune
checkpoints is scarce.
Aims: This study aimed at the analysis of lymphocyte subsets expression and
plasmatic levels of immune checkpoint inhibitors during tyrosine kinase inhibitor
(TKI) therapy in CML and its correlation with molecular response.
Methods: Peripheral blood samples from chronic phase CML patients (n=55),
divided according to molecular response to imatinib, dasatinib, nilotinib, bosu-
tinib, ponatinib and Interferon-alpha 2b (IFN-α 2b) therapy, were included in
this study. Multi-parametric flow cytometry was used for the analysis of the
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expression of several immune checkpoint inhibitors (BTLA, GITR, LAG-3, PD-
1, PD-L1, PD-L2, TIM-3, CD137/4-1BB) by different T, B NK, monocyte and
dendritic cell subsets. A 14-plex panel including BTLA, GITR, HVEM, IDO, LAG-
3, PD-1, PD-L1, PD-L2, TIM-3, CD28, CD80, CD137 (4-1BB), CD27, and
CD152 (CTLA-4) was analyzed by xMAP technology (Luminex®).
Results: Expression of CD137 by several lymphocyte subsets and PD-1 by
regulatory T cells (Tregs) and natural killer (NK) cells were found significantly
altered in CML patients under TKI therapy. These associations were observed
for the cell population frequency expressing the receptor, and also for density
of these molecules. Increased plasmatic levels of BTLA, HVEM, PD-1, PD-L1,
and CD137 were associated with good molecular response to therapy. PD-1,
PD-L1, TIM-3 and CD137 were found increased in patients that achieved
MR4.5.
Summary/Conclusions: Some immune checkpoint inhibitors seem to be
affected by TKI therapy in CML and their cell expression and plasmatic levels
correlates to molecular response. Similar observations were described for other
types of cancers, including solid tumors. Soluble and membrane-bound recep-
tor–ligand immune checkpoints could represent interesting targets for future
therapeutic monitoring and for pharmacologic interventions in CML.
Financial Support: FEDER (Programa Operacional Factores de Competitivi-
dade – COMPETE) and FCT (Fundação para a Ciência e a Tecnologia) through
project PEst-C/SAU/LA0001/2013-2014.
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TYROSINE KINASE INHIBITORS SIGNIFICANTLY CHANGE THE EXPRESSION
OF POLYCOMB GENES IN CHRONIC MYELOID LEUKEMIA
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M. Vangeli5, S. Salehzadeh5, M. R. Metelli5, S. Pellegrini2, F. Ricci4, C. Baratè4,
V. Mariotti2, M. Petrini4, A. Di Paolo3, S. Galimberti4
1Medical Biotechnologies, University of Siena, Siena, 2Clinical and Experimen-
tal Medicine, Clinical Biochemistry and Molecular Biology, University of Pisa,
3Clinical and Experimental Medicine, section of Pharmacology, University of
Pisa, 4Clinical and Experimental Medicine, Hematology, University of Pisa,
5Clinical and Experimental Medicine, Hematology Molecular Laboratory, AOUP,
Pisa, Italy
Background: It has been reported that, notwithstanding their clinical success,
tyrosine kinase inhibitors (TKIs) are not able to eradicate the leukemic stem
cell (LSC) in patients with chronic myeloid leukemia (CML). Different mecha-
nism have been hypothesized, especially those linked to the niche (increased
osteoblastic differentiation, angiogenesis, hypoxia...). The epigenetic control
seems to be relevant, and our group previously identified a correlatio between
the expression of some polycomb genes (PcGs) and response to TKIs, with
BMI1 resulting a good predictive molecular marker (Crea, 2015).
Figure 1.
Aims: In order to better understand the role of the PcGs genes in CML patients
receiving TKIs, we analyzed the expression of 86 PcGs at baseline and after 6
months of therapy.
Methods: Buffy coats obtained from peripheral blood samples of 6 patients (5
receiving imatinib and 1 dasatinib) have been used for the RNA extraction;
these RNAs were used for quantifying the BCR-ABL1/ABL1 ratio%IS, according
to the European guidelines, and the expression of the chosen 86 PcGs by real-
time PCR (PrimePCR pathway kit, Biorad, Milan, Italy) at diagnosis and after
6 months of treatment. Expression values were calculated using the 2DDCt
method.
Results: At the sixth month of treatment, 5 patients were in optimal response
and one was “warning”, according to the 2013 ELN guidelines. After therapy,
55% of the tested PcGs resulted up-regulated and 23% of them in the majority
of patients; whereas 3 genes (DNMT3B, SCML2, CBX2) were down-regulated
in at least half of samples. The expression of 5% of PcGs was “mixed”, up- or
down-regulated in different samples. Among the up-regulated genes, some could
be relevant from a biological point of view: 1) HLTF, a target for RUNX1, whose
low expression in acute leukemia is correlated with poor outcome; 2) PHC2, able
to silence the HOX genes, overcoming the multidrug resistance in myeloid mod-
els; 3) PCGF5, that is a marker of normal hematopoiesis; 4) MOV10, that has
been reported to have an anti-viral activity, increasing levels of gamma interferon.
This up-regulation is particularly interesting, because concerns all assessed sam-
ples and could explain our previous observation that Torque Teno virus replication
does not occur in CML patients during TKIs therapy; 5) in the only “warning”
patient, the up-regulation of SIRT1 was observed: this is in line with the observa-
tion that its up-regulation increases the oncogenic ability of K562 cells in a murine
model. Among the down-regulated genes, could be relevant: 1) CBX2, that bind-
ing P16/p19 promotes the cell cycle progression; its down-expression could
induce apoptosis; 2) DNMT3B, whose high levels have been reported in stem
cells, and whose reduction could characterize the differentiation process; 3)
ZBTB16, whose reduction could be a sign of the reduced osteoblastogenesis,
one of the mechanisms responsible for the LSC preservation in the niche; 4)
SMARCA1, it too correlated to the cell cycle progression. Finally, BMI1 levels
resulted unmodified in 3 cases and increased in other 3.
Summary/Conclusions: We demonstrated that PcGs de-regulation occurs in
CML patients during the treatment with TKIs, with possible pathogenetic impli-
cations. Huger series of patients will improve the biological suggestions coming
from these preliminary data.
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CHRONIC MYELOID LEUKEMIA USING NEXT GENERATION SEQUENCING
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Background: Chronic Myeloid Leukemia (CML) is 20% of all leukemias diag-
nosed every year. Discovery of Imatinib Mesylate has brought a paradigm shift
in treatment of Chronic Myeloid Leukemia, despite 15% - 20% patient showing
resistance to this TKI. Therefore, it is important to identify susceptibility and
prognostic markers, which can help us in predicting occurrence and prognosis
of CML. We did Clinical Exome Sequencing, a panel of more than 4800 clinically
important genes, in CML patients
Aims: To identify prognostic and susceptibility genetic markers in CML
Methods: Enrolled CML patients (n=18) were segregated as responders (n=10)
and failures (n=8) as per ELN, 2013 guidelines. Healthy controls (n=5) were
also enrolled. DNA from blood of subjects was subjected Next Generation
Sequencing (NGS). Mutations present in one patient group and absent in oppo-
site group were considered as prognostic markers, whereas rare mutations,
present in more than 50% of enrolled patients and absent in healthy controls,
were considered as susceptibility markers
Results: We discovered mutations in genes associated with cancer or cancer
related functions in different patient groups as markers. Five of them:
rs116201358, rs17882014, rs4014596, rs52897880 and rs2274329 in C8A,
HLA-DRB1, UNC93B1, APOH and CA6 genes respectively, were present in
responders; rs4945 in MFGE8 was present in failures. Mutations in HLA-DRB1
(rs17878951, rs11554462, c.239C>G), HLA-DRB5 (rs137863146), RPHN2
(rs193179333), CYP2F1 (rs116958555), KCNJ12 (rs76684759), FUT3
(rs151218854), BMO1 (rs28370522) and PRSS1 (rs144422014) were present
in half or more patients
Summary/Conclusions: We discovered potential genetic markers, which can
help in predicting response to IM as frontline therapy. Susceptibility markers
can be used as panel for to configure individuals prone to CML
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Background: Chronic myeloid leukemia (CML) is the most common myelo-
proliferative disorder characterized by the reciprocal translocation t (9; 22),
(q34; q11), leading to the formation of chimeric oncogene BCR-ABL on the
22q-chromosome. It is known that the protein products of the genes of
cytochromes ensure homeostasis at the cellular and tissue level, carrying out
the metabolism of toxic compounds that can damage the genome of the cells.
Prognostic value of certain genotypic variants of these genes in the formation
of a number of neoplastic diseases, including leukemia. In individuals with
weakened functional genotypes of A2455G polymorphism of CYP 1A1 gene
expression of this enzyme and, consequently, inactivation of xenobiotic must
occur very slowly, thus creating conditions for adverse action of harmful
metabolites in the genome of the cells. Currently, the scientific literature dis-
cusses the role of the negative allele A2455G polymorphism of CYP 1A1 gene
in the development of hematological malignancies. However, the adverse roles
of genotypic variants for this gene in oncogenesis of BCR-ABL-positive patients
with CML have studied not enough.
Aims: Evaluation the role of А2425G polymorphism of CYP1A1 gene in the
formation the mutant clone of tumor and the development of CML.
Methods: The work is performed on DNA samples isolated from the peripheral
blood of the patients in the clinic of scientific research Institute of Hematology
and blood transfusion in Uzbekistan. We studied 146 patients with CML. The
control group was formed from 217 individuals of Uzbek nationality, without of
any cancer disease. The diagnosis of CML verified in accordance with the
International nomenclature ISCN. Standardized PCR with detection in real-
time was carried out on a thermal cycler Rotor-Gene 6000 (Corbett Research,
Australia), using a set of reagents “AmpliSens® Leucosis quantum M-bcr-
FRT”(InterLabServis, Russia). Testing А2425 polymorphism of CYP1A1 gene
was performed on a programmable thermal cycler of the company “Applied
Biosystems” (USA) using test systems company “Litech” (Russia) according
to the manufacturer’s instructions. Statistical analysis of results was carried
out using the statistical software package “2009 OpenEpi, Version 2.3”. 
Results: The frequencies of allele A and G are as follows: 87.7% and 12.3%
in patients with CML, and 93.3% and 6.7% in the control group, respectively.
The frequency distribution of genotypes A / A, A / G and G / G were as follows:
76.7%, 21.9% and 1.4% - in CML patients, and 86.6%, 13.4% and 0.0% - in
the control group. Observed frequencies of genotypes in the studied groups
was consistent with the theoretically expected and were in equilibrium with
hardy-Weinberg equilibrium (Р>0.05). There was a statistically significant
decrease in carriage of the adverse alleles in the population sample comparison
group patients (1.4% vs 6.7%, respectively; χ2=6.8; Р=0.01; OR=2.0; 95% CI
1.17- 3.282). Also detected significant association of heterozygous genotype
A/G in patients with CML, compared with the control group (21.9% vs 13.4%,
respectively). The risk of mutant formation of the tumor clone in carriers of this
genotype was 1.8 times significantly higher compared with patients not having
it (χ2=4.6; Р=0.03; OR=1.8; 95% CI 1.046-3.166). The homozygous genotype
G/G in the group of patients was significantly more compared to the control
group (1.4% vs 0.0%), but due to the small number of carriers of this genotype
differences in the results did not reach statistical significance (Р>0.05). Func-
tionally favorable genotype A/A was found with high frequency in a population-
based sample of 86.6% vs 76.7% cases of patients. At the same time, the dif-
ferences reached the threshold level of significance (χ2=6.0; Р=0.01; OR=0.5;
95% CI 0.29-0.88), that is evidence of a favorable protective effect of this geno-
type against the development of CML.
Summary/Conclusions: Our results suggest that the G allele and the het-
erozygous genotype A/G А2425G polymorphism of CYP 1A1 gene are impor-
tant markers of increased risk in formation of malignant tumor cells and devel-
opment of CML in Uzbekistan (Р<0.05). In this case, homozygous genotype
A/A of А2425G polymorphism of CYP 1A1 gene has a protective character in
relation to risk of CML.
Chronic myeloid leukemia - Clinical
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HEMATOLOGIC TOXCITIY GRADE III-IV IS ASSOCIATED WITH LOWER
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Background: TKIs introduction in the treatment of chronic myeloid leukemia
(CML) has offered an outstanding improvement in survival outcomes. These
results were obtained from clinical trials but little is known about long-term tox-
icity and their translation to real life. In addition, clinical trials results are mainly
based on the analysis of the therapy of interest (experimental or control), but
the descriptions of the subsequent treatment sequences due to failure or intol-
erance are normally lacking.
Aims: To analyze the long-term toxicity of patients outside clinical trials in clin-
ical trials. The setting was a multicentric, hospital-based registry.
Methods: Toxicity grade III-IV and survival and their potentially associated
variables were studied.
Figure 1. Evolution of hematologic toxicity grade 3-4 with time (all treat-
ments sequences included).
Results: Demographics, risk and treatment distribution: 893 patients (533 men,
360 women) with a median age at diagnosis of 52 y (14-94y) were included
with a follow up of 85±7 months (m) from diagnosis, 78±6.6 m from first treat-
ment, and 69±6 m from first TKIs. 151 patients (16,9%) were over 70y. The
risk distributions were as follows: Sokal: low (L) 48%, intermediate (I) 37% and
high (H) 14%; Euro score: L 50%, I 45% and H 5%; EUTOS L: 92% and H 8%;
EUTOS LT: L 70%, I 23% and H 7%. Treatment groups were the following:
Group 1: IFN alpha and then imatinib or 2º GTKIs (221 patients); Group 2:
imatinib only (404 patients); Group 3: imatinib and then nilotinib, dasatinib or
both due to failure or intolerance (177 patients) and Group 4: 2ºGTKIs in first
line (93 patients).Hematologic toxicity grade III-IV: Figure 1 shows the incidence
through the years (all group of treatments). From 800 patients treated with
imatinib (first o second line) 67 (8,3%) had grade III-IV toxicity, and 26 had to
switch treatment due to toxicity. From 166 patients treated with dasatinib (29
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in1st line, 114 in 2nd, 56 in 3rd) only 13 had hematologic toxicity and 6 had to
switch, 14 had pleural effusion grade III-IV and 9 had to switch. From 115
patients treated with nilotinib (49 in 1st line and 66 in 2nd) only 10 had hema-
tologic toxicity and 10 switched treatment. Survival: Estimated survival by 10
years was 80%. Variables associated with survival: In the univariate survival
analyses (log rank test) either from diagnosis, first therapy or first TKIs, the
Sokal, Eutos, Euro and EUTOS LT scores, as well as age over 70y were the
only statistically significant variables associated with survival. Hematology tox-
icity grade III-IV was associated with lower PFS or OS (figure 1). In the multi-
variate analysis (Cox model), only hematology toxicity grade III-IV and age
over 70y were independent variables.
Summary/Conclusions: 1.These results show that the probability of survival
by 10 years is roughly 80%, and extend the findings of our previous work show-
ing that this probability is not different across different sequential treatments
(imatinib 1st line or post-IFN, or switched to 2ªGTKis due to intolerance o failure)
(1). This fact emphasizes the rescue potential of available TKI therapies. 2.
Hematologic toxicity grade III-IV in the first two years identified a group of
patients with worse survival outcome. 3. Patients over 70 years have shorter
survival due to reasons different than progression. 4 Second GTKIs showed
better hematologic toxicity profile. 
Reference
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5-YEAR EFFICACY OF DASATINIB AND IMATINIB IN NEWLY DIAGNOSED
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Background: Multiple dosage strengths are approved for dasatinib (DAS), per-
mitting dose-optimization strategies for patients who experience adverse events
(AEs). In a 2-year retrospective analysis of DASISION, efficacy was maintained
in DAS- and imatinib (IM)-treated patients with dose reductions or interruptions
to manage AEs (Jabbour ASH 2011); cytogenetic and molecular response rates
were higher for patients given DAS vs IM, even when daily doses were modified.
Longer term follow-up is needed to fully understand the potential impact of
dose reductions on efficacy.
Aims: To evaluate the effect of dose reduction for any AE and for pleural effu-
sion on efficacy in DAS- or IM-treated patients from DASISION.
Methods: Treatment-naïve patients with CML-CP in DASISION
(NCT00481247) were randomized to receive either DAS (100mg once/day;
N=259) or IM (400mg once/day; N=260). Dose reductions for AEs (up to 2)
were allowed: DAS: 80mg, then 50mg; IM: 300mg, then 200mg. Five-year
molecular and cytogenetic response rates in all patients were assessed retro-
spectively.
Table 1.
Results: Patients on DAS maintained higher molecular response rates than
patients on IM, whether or not they had dose reductions for an AE; these rates
were similar in patients with and without dose reductions in each arm (table). 95
(37%) DAS- and 44 (17%) IM-treated patients had dose reductions at any time
due to AEs. Median time to first DAS dose reduction was 289 days (range: 22-
2123), and median time to first IM dose reduction was 160 days (range: 31-
2052). For patients with reductions due to any cause, median average daily
dose was DAS 83mg and IM 328mg; for DAS patients with reductions due to
pleural effusion, median average daily dose was 82mg. Median duration of treat-
ment (excluding interruptions) was 54 months (range: 3-70) for patients who
had a DAS dose reduction and 57 months (range: 2-71) for patients who had an
IM dose reduction. Changes in level of response were tracked for patients who
achieved complete cytogenetic response (CCyR) or major molecular response
(MMR) before or after the first dose reduction (table). Many patients maintained
or increased to CCyR or MMR following dose reductions for any AE. Hemato-
logical toxicity (9%) was the most common AE resulting in dose reduction for
IM, and pleural effusion (12%) was the most common for DAS.
Summary/Conclusions: Reducing DAS doses to 80mg or 50mg was a safe
and effective means of managing patients who experienced AEs in this 5-year
retrospective analysis of DASISION. These results were consistent with previ-
ous reports and continued to show that efficacy was not affected by dose reduc-
tions for any cause, including pleural effusion. Notably, there was no loss of
CCyR following dasatinib dose reductions. Molecular responses remained high-
er for DAS vs IM irrespective of dose reductions due to AEs.
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EFFECT OF PLASMA TROUGH CONCENTRATION OF NILOTINIB AND
POLYMORPHISMS OF DRUG TRANSPORTER GENES ON THE FREQUENCY
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1Hematology, AKITA UNIV., 2Pharmacy, AKITA UNIV. HOSPITAL, Akita, Japan
Background: STAT trials (STAT1 and STAT2) are multicenter, phase II, sin-
gle-treatment arm, open-label clinical studies designed to evaluate the efficacy
and safety of two-year consolidation by nilotinib (NIL) for achieving a deep
molecular response (DMR) or successful treatment-free remission (TFR) in
patients with chronic phase chronic myeloid leukemia (CML). 
Aims: In this report, we focus on the adverse events (AEs), especially anemia
and liver dysfunction observed in the STAT trials. Additionally, we analyzed the
relationship between laboratory abnormalities and pharmacokinetics (PK)/ phra-
macogenetics (PGx) of NIL.
Methods: AEs were assessed according to the Common Terminology Criteria
for Adverse Events (CTCAE) v4.03. Safety evaluations were conducted
throughout the study. Plasma trough concentrations of NIL were determined
with high-performance liquid chromatography (HPLC) at 1 month (1M), 3M,
6M, 12M, and 24M in the STAT trials. Genotyping of CYP3A5*3 [6986A>G
(rs776746)], ABCB1 [3435T>C (rs1045642)], ABCG2 421C>A (rs2231142),
and UGT1A1*6, *27, and *28 was performed using polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP). All genotype frequen-
cies were tested for Hardy-Weinberg equilibrium.
Figure 1.
Results: Between July 2011 and December 2012, CML patients were recruited
in the STAT trials. NIL was administered twice daily (600mg/day) for 2 years
according to the study protocol. A total of 76 and 96 patients were analyzed as
a safety data set in STAT1 and STAT2, respectively. In STAT1, 18 patients who
achieved a confirmed DMR were switched from STAT1 to STAT2. These
patients entered both trials, but safety data had not been collected in STAT1
after entering STAT2 to avoid double counts. The PK/PGx data of 147 of 154
patients were available and were evaluated in this study. Median trough con-
centrations of NIL were 1265 ng/ml at 1M, 1154 ng/ml at 3M, 974 ng/ml at 6M,
735 ng/ml at 12M, and 781 ng/ml at 24M. Although any-grade AEs were report-
ed in 43 patients in STAT1 and 55 patients in STAT2, the most common drug-
related hematological and non-hematological AEs were elevated total bilirubin
(28.6%), anemia (24.5%), elevated ALT (21.1%), and elevated AST (18.4%).
The incidence of these AEs, except for anemia, was significantly associated
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with high trough concentration of NIL (Figure1). There were statistically signif-
icant correlations between median concentrations of NIL and the grades of
each AE. Based on the results of the analysis using Cox proportional-hazards
model, the trough concentration of NIL [hazard ratio=1.001 (1.000-1.002),
P=0.004] and ABCG2 421A/A [hazard ratio=3.044 (1.155-8.027), P=0.024]
were independent factors for the elevated ALT. Similarly, the trough concentra-
tion of NIL [hazard ratio=1.001 (1.000-1.002), P<0.001] and UGT1A1 *1/*1
[hazard ratio=0.475 (0.246-0.919), P=0.027] were independent factors for the
elevated total bilirubin.
Summary/Conclusions: In this study, we identified the relationship between
NIL trough concentration and liver dysfunction. Our finding suggests that ther-
apeutic drug monitoring might help avoid drug interruption and discontinuation
because of AEs, especially liver dysfunction.
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Background: In BCR-ABL1 tyrosine kinase inhibitor (TKI) treated chronic
phase chronic myeloid leukemia (CP-CML), early molecular response (EMR)
at 3 month is currently identified as being one of the most important prognostic
factors. Sokal risk score and dose intensity during first 3 months were strongly
associated with achievement of EMR. As dasatinib is a novel, oral tyrosine
kinase inhibitor with improved potency, identification of very early molecular
response (VEMR) would be beneficial.
Aims: We evaluated the possibility of the VEMR at 1 month predicting long-
term outcomes in newly diagnosed CP-CML patients treated with dasatinib.
Methods: In this multi-center, observational, open-label study, 102 patients
with CP-CML were enrolled to receive dasatinib at a dose of 100mg once daily.
The primary end point was complete molecular response (CMR) by 18 months.
Secondary end points including molecular response (MR) by 1, 3, 6, 12, 18,
24 month, time to and duration of MMR and CMR, and safety were tested. A
receiver operating characteristic (ROC) curve from BCR-ABL1 transcript level
on Day+28 was calculated to predict EMR and MMR at specific timepoints.
Results: Median age was 49 years (19-81 years) and 61 patients were male.
With median follow-up duration of 28 months (0.9-33.8 months), 80 (78.4%)
out of 102 patients were still on dasatinib treatment and 22 patients discontin-
ued due to disease progression (n=2) or treatment failure (n=3) or adverse
events (n=8) or other reasons (n=9). The BCR-ABL1 mutations, assessed in
10 patients after dasatinib discontinuation, were detected in 3 patients which
were all T315I mutation. The cumulative CMR by 18 months and MMR by 24
months were 20.5% and 79.6% respectively. In safety analyses, grade 3/4
thrombocytopenia (30.3%) was most common. Pleural effusion occurred in six-
teen (15.6%) patients which were mostly grade 1/2. The cut-off value of BCR-
ABL1 transcript on Day+28 was 40% by ROC curve analysis. Among 95
patients who had available molecular data of both D+28 and 12 months, fifty
nine (62.1%) patients had less than 40% of BCR-ABL1 transcript (VEMR) on
Day+28. Among them, 49 (83.1%) patients achieved MMR at 12 months. How-
ever, only 27.8% (10 out of 36 patients) of patients without VEMR achieved
MMR (p<0.0001). Among 85 patients who had available molecular data of both
D+28 and 24 months, fifty two (61.2%) patients achieved VEMR. In 52 VEMR
patients, 46 (88.5%) patients achieved MMR at 24 months. However, only
48.5% (16 out of 33 patients) of patients without VEMR achieved MMR
(p=0.0001). Overall survival (OS) & progression-free survival (PFS) rates by
24 months were 98.0% and 95.1% respectively. PFS rates by 24 months for
VEMR and no VEMR group were 98.4% vs 88.8% respectively (p=0.04).
Summary/Conclusions: Our study shows that VEMR at 1 month can be a
strong predictor for further molecular responses as well as long-term outcome.
Therefore it would be helpful to monitor BCR-ABL1 transcript level at 1 month
in patients who treated with more potent TKIs.
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SURVIVAL OUTCOMES IN PATIENTS WITH CHRONIC-PHASE CHRONIC
MYELOID LEUKEMIA (CP-CML) RECEIVING THIRD- OR SUBSEQUENT
LINE (3L) TREATMENT PRIOR TO THE AVAILABILITY OF PONATINIB
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Background: PACE was a phase 2 single-arm trial of ponatinib, a 3rd-gener-
ation tyrosine kinase inhibitor (TKI), in 449 highly-refractory patients with CML
or Philadelphia-chromosome positive (Ph+) acute lymphocytic leukemia (ALL)
or who had the BCR-ABL T315I mutation. Overall survival (OS) for 3L CP-CML
patients in PACE at 1, 2, 3 and 4 years was estimated to be 91%, 83%, 80%,
and 79%, respectively. Expected survival for 3L CP-CML patients prior to the
availability of ponatinib has not been documented.
Aims: To estimate OS in patients with CP-CML receiving 3L treatment prior to
ponatinib via a systematic literature review.
Methods: Studies were identified from a review by Lipton et al. (2015), updated
with studies identified from searches of electronic databases (MEDLINE,
EMBASE, Cochrane Libraries) and abstract databases of key conferences. Land-
mark and median survival were extracted from study reports. Pseudo-individual
patient data (IPD) for survival outcomes were derived from digitized Kaplan-
Meier (KM) survival curves then pooled and analyzed using KM methods.
Results: Fifteen studies (717 patients) were identified that reported median,
landmark, or KM curves for survival outcomes for CP-CML patients receiving
3L treatment without ponatinib. KM curves for OS were obtained for 6 arms (3
nilotinib and/or dasatinib; 3 other TKIs). OS at 1, 2 and 3 years based on the
pooled IPD is reported in the Table. To avoid confounding of OS from post-pro-
gression treatment with ponatinib, 1 study was excluded that included follow-
up after the date of ponatinib’s approval.
Table 1.
Summary/Conclusions: Estimated OS in patients with CP-CML receiving 3L
treatment prior to ponatinib appears to be shorter than that observed among
ponatinib-treated patients in PACE: 4-year survival probability in PACE is higher
than estimated 2-year survival probability prior to ponatinib. Further analyses
are needed to identify and adjust for potentially confounding factors.
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DETECTION AND MONITORING OF BCR-ABL1 KINASE DOMAIN
MUTATIONS IN CML AND ALL PATIENTS BY NEXT GENERATION
SEQUENCING AND DROPLET DIGITAL PCR, A BELGIAN PROSPECTIVE
STUDY
C. De Rop1,*, H. Devos2, P. Vannuffel1, F. Nollet2
1Molecular Biology, IPG, Gosselies, 2Laboratory Medecine, AZ Sint-Jan,
Bruges, Belgium
Background: Among myeloproliferative diseases, development of chronic
myeloid leukaemia (CML) is associated with the emergence of the fusion onco-
gene BCR-ABL1 resulting from a t(9,22) chromosomal translocation (Philadel-
phia chromosome). This chimeric transcript is also present in all acute lym-
phoblastic leukaemia (ALL) patients bearing a Philadelphia chromosome (Phi+
ALL). Mutations of the BCR-ABL1 kinase domain constitute a major cause of
treatment failure in CML and Phi+-ALL patients receiving first or second gen-
eration tyrosine kinase inhibitor (TKI) treatment. So far, the gold standard pro-
cedure to detect BCR-ABL1 kinase domain (KD) mutations is the conventional
Sanger Sequencing, endowed with an analytical sensitivity of 15-20%. Recent
studies on the implementation of Next Generation Sequencing (NGS) for detec-
tion of BCR-ABL1 KD mutations showed a significant dropping down of the
sensitivity level (1-5%), improving patient’s treatment management.
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Aims: Both NGS and droplet digital PCR (ddPCR) were used in this prospective
study. NGS screened all known mutations in the BCR-ABL1 KD and ddPCR
targeted only the 3 most common mutations, T315I, E255K and Y253H, which
represent approximatively 75% of the ABL1 mutations. Patients eligible for the
study were i) CML patients with failure or warning to all lines of TKI therapy
according to the 2013 ELN-guidelines, with no suspected lack of adherence
and ii) Phi+ ALL patients at diagnosis and/or molecular relapse. Monitoring was
performed when clinically appropriate.
Methods: Total BCR-ABL1 RNA was transcribed into a long range cDNA cov-
ering the kinase and the regulatory and the SH2/SH3 domains of either p190
or p210 BCR-ABL1 transcripts (exons 4 to 10). For NGS, primers designed
with the AmpliseqTM Designer Software generated a set of 10 amplicons. Bar-
coded libraries, constructed according to the AmpliSeqTM protocol, were
sequenced on the Ion Torrent PGM platform (sensitivity of 2.5%). For ddPCR,
cDNA was analysed for the presence of one of the 3 main mutations (T315I,
E255K and Y253H) on the Bio-Rad QX200 platform (sensitivity of 1%). 
Results: The participation of more than 20 Belgian centres allowed the inclusion
of 60 samples on a 9 months period (54 CML and 6 Phi+ ALL). The overall
number of BCR-ABL1 mutated samples was 18 (15 CML and 3 Phi+ ALL), rep-
resenting 30% of the cases. Among these samples, 27 mutations were found.
9 samples presented with one mutation: T315I (2), E255K (3), G250V (1), F359I
(1), M237T(1) and E255A (1) and 9 harboured compound mutations: T315I +
E255K (6) and T315I + Y253H (3). A high frequency (85%) of T315I, E255K
and Y253H mutations was also observed (23/27). As far as these 3 mutations
are concerned, reproducibility to determine mutational burden was found to be
very high between NGS and ddPCR.
Summary/Conclusions: Advances in sequencing technologies and further
lowering sensitivity levels contribute to optimal management of CML and Ph+
ALL patients and improve treatment outcome. The earlier a mutation in the
kinase domain is detected, the earlier an informed choice can be made regard-
ing optimal subsequent TKI treatment.
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CLINICAL AND IMMUNOLOGICAL EFFECTS OF NILOTINIB IN COMBINATION
WITH PEGYLATED INTERFERON-Α2B IN PATIENTS WITH SUBOPTIMAL
MOLECULAR RESPONSE ON IMATINIB (NORDDUTCHCML009)
I. Geelen1,*, U. Olsson-Strömberg2, S. Mustjoki3,4, J. Richter5, N. Blijlevens6,
W. Smit7, B. Gjertsen8,9, T. Gedde-Dahl10, B. Markevärn11, M. Koppes12,
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Background: The ability to “cure” a proportion of chronic myeloid leukemia
patients (CML) makes treatment free remission (TFR) an important treatment
goal which requires sustained deep molecular response on TKI therapy. Unfor-
tunately, not all patients achieve deep molecular responses on their first line
treatment. Novel treatment strategies to increase the proportion of CML patients
eligible for a TKI stop attempt are therefore needed.
Aims: The primary objective of the NordDutchCML009 study was to assess if, in
CML patients who did not achieve an MR4.0 or better to imatinib could attain this
MR4.0after a switch to nilotinib with pegylated interferon-α2b (pegIFN-α2b) com-
bination treatment for at least 12 months. Assessment of safety, tolerability and
immunological effects of the combination treatment were additional study goals.
Methods: In a phase II, single arm, multicenter trial, patients with BCR-ABL1
levels above 0.01% (IS) after at least two years of imatinib treatment were
switched to nilotinib 300mg BD (Nilo). PegIFN-α2b (Peg) 25 µg/week was intro-
duced after three months, increased to 40 µg/week at month 6 if tolerated and
continued until month 12. Adverse events were assessed according to CTCAE
version 3. Flow cytometry assessments of T-, NK- and B-cell populations, acti-
vated T-cells, myeloid-derived suppressor cells (MDSCs) and regulatory T-cells
(Tregs), cytotoxicity assays of NK-cells against K562 target cells, IFN-γ pro-
duction analysis of stimulated CD3+ cells (Elispot), and Granzyme B staining
of T-cells were performed at baseline (imatinib), 3 months (nilotinib) and 6
months (nilotinib + pegIFN-α2b) after inclusion and compared using a repeated
measures ANOVA with multiple comparisons.
Results: In total 16 patients were enrolled in the study. Recruitment of patients
was difficult and the study was prematurely closed for this reason. Confirmed
MR4.0 at 12 months was achieved by 50% (7/14) of the patients. Two patients
discontinued nilotinib treatment within the first 3 months due to hepatotoxicity
and lipase elevation (grade 4). Five patients did not tolerate PegIFN-α2b com-
bination treatment, mainly due to mood disturbances. Finally, only 56% of
patients completed the scheduled Nilo/Peg combination treatment for the first
12 months. We found a reduction in the proportion of CD56+ NK-cells after
addition of PegIFN-α2b to the nilotinib treatment (P=.046), but no significant
changes in the other immunological parameters. In the subgroup analysis this
finding only demonstrated as a trend for a decreased NK-cell count after
PegIFN—α2b administration in patients who attained confirmed MR4.0 at 12
months (p=0.063), and was not established in patients who did not attain con-
firmed MR4.0 at 12 months. In those patients who did not attain confirmed MR4.0
at 12 months, we observed an increased number of stimulated CD3+ cells pro-
ducing IFN-γ after introduction of PegIFN-α2b (p=0.026). These results from
the subgroup analysis need to be interpreted with caution due to low statistical
power.
Summary/Conclusions: Despite relatively poor tolerability of the scheduled
Nilo/Peg combination treatment in the current study, CD56+ NK cells were sig-
nificantly modulated and more than half of the patients achieved a sustained
MR4.0, which would allow for a TKI stop attempt. The discontinuation rate sug-
gests that the PegIFN dose was too high in combination with nilotinib treatment
in our study population.
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ANALYSIS OF VASCULAR ADVERSE EVENTS IN TKI TREATED JAPANESE
CML PATIENTS: RETROSPECTIVE LARGE COHORT STUDY OF CML
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Background: Chronic myeloid leukemia (CML) is a disease of hematopoietic
stem cells resulting from oncogenic chromosome translocation that leads to
the formation of the BCR-ABL1 fusion gene.Treatment of chronic phase (CP)
CML has dramatically changed since the emergence of the first-in class tyrosine
kinase inhibitor (TKI) imatinib, and treatment based on TKI has improved the
outcome in the majority of CP-CML patients. Nowadays, second generation
TKIs are available and brought about faster and deeper clinical responses, and
lower disease progression rate than imatinib. On the other hand, longer treat-
ment duration and the increased types of TKIs gave rise to various kinds of
unexpected adverse events (AEs). In 2011, drug-induced peripheral artery
occlusive disease (PAOD) was first reported, followed by vascular AEs (VAEs)
including ischemic heart disease (IHD) and cerebral infarction (CI). Further-
more, it became clear that the incidence of VAEs increased with the dose and
treatment duration, therefore VAEs are considered a more fatal complication
of TKI treatment. However, there is no available data about the incidence of
VAEs in Japanese patients.
Aims: We investigated the vascular safety issue and estimated the 1000 per-
son-years risk of developing VAEs during TKI treatment, including imatinib,
nilotinib, and dasatinib, using 3 risk assessment tools among 320 Japanese
patients who were enrolled in the CML Cooperative Study Group.
Methods: A surveillance data of 320 patients enrolled in the CML Cooperative
Study Group was conducted in this analysis. Briefly, the study included patients
who were diagnosed with CML-CP from April 2001 to January 2016, whose medi-
an age was 57 years old (15-80) and median time of follow up was 64.2 months.
Patients in the accelerated or blastic phase (AP/BP) were excluded. The study
was approved by the research ethics boards of each institutions and was con-
ducted in accordance with the Declaration of Helsinki. All patients who developed
VAEs were analyzed using 3 risk assessment tools (SCORE chart, Framingham
risk score, Suita-score) to estimate the patients’ 10-year risk of VAEs.
Results: Among the 320 newly diagnosed CML-CP patients, 16 (5.0%) cases
of VAEs were reported during the study period. Seven cases were treated by
imatinib, 3 cases by nilotinib, 1 case by dasatinib, 4 cases were a switch from
imatinib to nilotinib, and 1 case was a switch from dasatinib to nilotinib. The
VAEs were 9 IHD, 5 CI, and 2 PAOD cases. Results from the 3 risk assessment
tools are as follows: SCORE (2 low, 9 moderate, 1 high, 4 very high risk), Fram-
ingham score (3 low, 5 moderate, 7 high risk), and Suita-score (13 low, 1 inter-
mediate, 1 high risk). The incidence rate of IHD and CI per 1000 person-years
were 5.26 and 2.92 in the enrolled CML-CP patients, 4.65 and 2.33 in the ima-
tinib-treated patients, 14.34 and 10.75 in the nilotinib-treated patients, 4.08 and
no case in the dasatinib-treated patients, and 1.787 and 3.342 in the age-
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matched general population, respectively. Among the 320 newly diagnosed
CML-CP patients, 16 (5.0%) cases of VAEs were reported during the study peri-
od. Seven cases were treated by imatinib, 3 cases by nilotinib, 1 case by dasa-
tinib, 4 cases were a switch from imatinib to nilotinib, and 1 case was a switch
from dasatinib to nilotinib. The VAEs were 9 IHD, 5 CI, and 2 PAOD cases.
Results from the 3 risk assessment tools are as follows: SCORE (2 low, 9 mod-
erate, 1 high, 4 very high risk), Framingham score (3 low, 5 moderate, 7 high
risk), and Suita-score (13 low, 1 intermediate, 1 high risk). The incidence rate
of IHD and CI per 1000 person-years were 5.26 and 2.92 in the enrolled CML-
CP patients, 4.65 and 2.33 in the imatinib-treated patients, 14.34 and 10.75 in
the nilotinib-treated patients, 4.08 and no case in the dasatinib-treated patients,
and 1.787 and 3.342 in the age-matched general population, respectively.
Table 1.
Summary/Conclusions: The incidence rate of IHD per 1000 person-years
were higher in the nilotinib- and lower in imatinib- and dasatinib-treated CML
patients, and the patients showed almost the same rate of CI as compared with
the age-matched general population, even though the incidence of VAEs were
lower in Japanese as compared to the European cohort. More patients were
estimated to have very-high and high risk of VAEs in the SCORE and Framing-
ham risk score assessment tools as compared with the Suita-score tool.
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PROSPECTIVE FOLLOW-UP REGISTRY OF PATIENTS WITH CHRONIC
PHASE CML WITH A HIGH PROBABILITY OF OBTAINING A DEEP
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Background: Since the introduction of Tyrosine Kinase Inhibitors (TKI), many
patients diagnosed of Chronic Myeloid Leukemia (CML) in chronic phase
achieve a deep molecular response. Around 50% of these patients are expect-
ed to maintain their molecular responses even after discontinuation of their
TKI treatment. Several clinical trials are exploring the best way of stopping TKI
therapy and evaluating patient and disease characteristics that could predict
relapse after treatment discontinuation.
Aims: This is an update of the CMRegistry study aimed at collecting clinical
data and molecular information from spanish CML patients that have achieved
a series of molecular milestones to any of the tyrosine kinase inhibitors in order
to monitor their progress and the achievement of a stable deep molecular
response: >MR4 (IS).
Methods: CMRegistry is an observational, multi-center and prospective study.
CML patients treated with any of the tyrosine kinase inhibitors who are likely to
achieve, or have already achieved, a deep molecular response (>MR4.0 (IS))
are included. This likelihood of achieving >MR4 is defined, for the purposes of
the study, as a bcrabl/abl ratio of: 1) ≤1% at 3 months from start of TKI therapy;
2) ≤0.1% at 6 months from start of TKI therapy; or 3) ≤0.01% any time point
during treatment. Clinical data have been collected using a specific CRF. All
data were registered in an anonymous manner. The BCR-ABL ratios in the IS
have been provided by standardized labs in Spain.
Results: From June 2014 to Februay 2017, 976 patients were registered in
the study. Median age was 51 years (15-88). The Sokal risk groups were as
follows: 345 patients low risk, 307 intermediate risk and 129 high risk. Eutos
classification yielded 714 patients in the low risk and 79 in the high risk cate-
gories. The majority of patients received first-line treatment with imatinib (626
patients), dasatinib (39 patients) or nilotinib (87 patients). Of note, 5 patients
received bosutinib, 1 patient ponatinib and 74 patients were treated with Inter-
feron previous to TKI administration. So far 14 patients have died of non-CML
related conditions such as carcinoma (2 patients), ischemic heart disease, res-
piratory failure and sepsis. Interestingly, 2 patients developed progression of
their CML to accelerated phase and blast crisis (1 patient each) with no deaths.
At present, 104 patients (11%) have achieved a MR4.0, 174 patients (18%) a
MR4.5 and 123 patients (13%) have obtained a complete molecular remission
(undetectable bcr-abl transcripts with a sensitivity of at least 10-5).
Summary/Conclusions: Almost one thousand CML patients have been includ-
ed in this spanish prospective study owing to their promising molecular
response that would predict for a sustained deep molecular remission. Four
hundred and one patients have already achieved a deep molecular response
(>MR4 (IS)) and could be enrolled in prospective discontinuation studies.
E1060
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Background: Patients with CML often have comorbidities, which may influence
treatment-related decisions and impact response and survival. In a retrospective
analysis of 1-year data from the phase 3 DASISION study, the overall safety or
response in dasatinib- or imatinib-treated patients was not substantially impacted
by baseline comorbidities, although certain adverse events (AEs) trended higher
in patients with ≥1 vs 0 comorbidities (Khoury ASH 2010). Further analysis is
warranted to determine how comorbidities may impact long-term outcomes.
Aims: To evaluate the impact of baseline comorbidities and patient age on 5-
year safety and efficacy in dasatinib- or imatinib-treated patients from DASI-
SION.
Methods: In DASISION (NCT00481247), patients were randomized to receive
dasatinib 100mg/day (N=259) or imatinib 400mg/day (N=260). For this retro-
spective analysis, patients were grouped as having 0 or ≥1 baseline comorbid-
ity, by baseline disorder (diabetes mellitus, hepatobiliary disease, hyperlipi-
demia, cardiovascular disorder, or pulmonary condition), or by age group (<46
years, 46–65 years, >65 years). Safety (treatment-related AEs in ≥10% of
patients) and efficacy (response rates by 5 years and median times to
response) were assessed for each group and treatment.
Table 1.
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Results: The number of patients with 0 or ≥1 comorbidity was similar in the
dasatinib (66 [25%]; 193 [75%]) and imatinib (67 [26%]; 193 [74%]) arms, respec-
tively; most (>90%) patients were <65 years old. In patients with 0 or ≥1 baseline
comorbidity, the median average daily dose was comparable within arms and
discontinuation rates (36%–39%) were similar within and across arms (table).
The overall safety profiles were comparable in the 0 and ≥1 comorbidity groups
in both arms, other than specific AEs, which had a ≥2 times higher frequency in
patients with ≥1 vs 0 comorbidities; the majority of these were grade 1/2 AEs
(table). The incidence of peripheral edema increased with patient age for both
imatinib and dasatinib (<46 years: 5% each; 46–65 years: 12% and 10%; ≥65
years: 21% and 20%). In this analysis, the increased incidence of pleural effusion
(PE) in dasatinib-treated patients was most highly associated with increased
age: <46 years (16%) vs 46–65 years (37%) vs >65 years (60%). PE incidence
did not appear to be related to baseline pulmonary comorbidity and was similar
in dasatinib-treated smokers (33%) vs nonsmokers (27%). Within each arm,
patients with 0 or ≥1 comorbidity (table) and across age groups had similar
response by 5 years, although rates were numerically higher for patients with
≥1 vs 0 comorbidities in both arms (MR4.5 on dasatinib: 46% vs 32%; MR4.5on
imatinib: 36% vs 22%). Median time to response (months) for patients with 0 or
≥1 comorbidity did not differ within each arm, but was numerically shorter for
dasatinib (MR4.5; 36 or 35) vs imatinib (MR4.5; 42 or 47).
Summary/Conclusions: The superior efficacy of dasatinib over imatinib was
shown in previous studies. Response rates and times to response were com-
parable in patients with 0 or ≥1 comorbidity and trended in favor of dasatinib vs
imatinib. Although a few AEs (most grade 1/2) appeared to occur at a higher
frequency in patients with ≥1 vs 0 comorbidities in either treatment arm, the
overall incidence of AEs and discontinuation rates at 5 years in patients who
were treated with first-line dasatinib or imatinib did not appear to be substantially
affected by baseline comorbidities.
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Background: Introduction of second-generation TKIs (2GTKIs) provided addi-
tional options to treat CML patients effectively. Patient compliance is crucial to
achieve good outcomes of TKI therapy. The recommended dose of nilotinib –
potent 2GTKI in a second-line treatment is 400mg twice daily. The drug’s admin-
istration might be more challenging for patients as compared to other TKIs. Nilo-
tinib should be taken twice daily approximately 12 hours apart, and must not be
taken with food. No food should be consumed two hours before and at least
one hour after the drug is administered. Recent studies comparing adherence
to the second-line CML treatment with nilotinib and dasatinib reported conflicting
results. It has been reported that the therapy with TKIs might have an adverse
effect on the quality-of-life (QOL). To date the majority of the research on QOL
among patients treated with TKIs has been focused on imatinib.
Aims: The aim of this study was to assess the adherence to nilotinib used as
a second line therapy and to evaluate the quality-of-life (QOL) in patients with
chronic myeloid leukemia in a chronic phase (CML-CP), as well as to analyze
the correlation between QOL and drug compliance, the correlation between
patient’s and physician’s assessment of drug compliance and to evaluate the
relationship between drug compliance and dosing schedule (twice daily, once
daily), patient’s age, educational and marital status, satisfaction with medical
care and the QOL.
Methods: The study was designed as a multicenter prospective observational
trial. The enrollment period lasted from June 2010 to June 2012. The duration
of the observation of an individual patient was 12 months. 177 patients were
recruited in 23 centers in Poland and evaluated during the study at six time
points. Nilotinib is not reimbursed in Poland as a first-line therapy. Therefore,
eligible were patients suffering from CML-CP, treated with nilotinib as a second
line therapy due to the ineffectiveness or intolerance of first line therapy. The
adherence to the therapy was assessed using the 4-item Morisky Medication
Adherence Scale (MMAS) and reported by patients and their physicians at 1,
3, 6, 9 months and at the completion of the observation. The QOL was evalu-
ated with the standard Core Quality of Life (EORTC QLQ-C30) questionnaire.
Basic descriptive statistics were used to present results of the study.
Results: 83.2% of patients assessed themselves as highly compliant at their
first visit and 93.4% at the 5th visit. Males were less compliant to nilotinib than
females. Patients who live with families were more compliant than those who
live with a partner or live alone. Low compliant patients represented 1.7% of
total during visit 1; none of the patients assessed themselves as low compliant
since the 4th visit. At the first visit 85.3% of patients were categorized by their
physicians as highly compliant and 96.0% during the last three visits. Patients
and physicians assessments were significantly correlated. No significant dif-
ferences in drug compliance in patients treated once daily vs twice daily were
found in all groups of patients. The average QOL expressed as QL2 parameter
in patients that have completed the study was significantly higher during the
last visit (69.4±17.4) than at the start of the study (59.1±18.8; p<0.001).
Summary/Conclusions: The adherence to the treatment was high and the
QOL among patients on nilotinib administered as a second-line therapy was
very good. Both have been improved during the study. The efficacy and safety
of the drug were confirmed in the real-life setting.
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RADOTINIB TREATMENT IN CHRONIC PHASE CHRONIC MYELOID
LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO
BCR-ABL1 TKIS: 36 MONTHS UPDATE OF RADOTINIB PHASE 2 STUDY
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Background: Radotinib is an orally active, selective BCR-ABL1 tyrosine kinase
inhibitor (TKI), approved for the first-line and second-line treatment of chronic
phase chronic myeloid leukemia (CP-CML) patients in Korea. Earlier 12 and
24 month results demonstrated that radotinib is effective and well tolerated in
CP-CML patients with resistance and/or intolerance to BCR-ABL1 TKIs.
Aims: We update the long-term outcome of radotinib treatment in patients
failed to BCR-ABL1 TKIs with a minimum follow-up of 36 months.
Methods: Ph+ CP-CML patients who failed prior TKI therapy were enrolled
between July 2009 and November 2011. All patients were treated with radotinib
400mg twice daily. Cytogenetic and molecular assays were performed at base-
line, every 3 months, and at treatment failure. Safety parameters were also
analyzed. Probabilities of overall survival (OS) and progression free survival
(PFS) were calculated using Kaplan-Meier method. 
Results: A total of 77 CP-CML patients (18 years of age or over) were enrolled.
This analysis includes data from last enrolled patient who received at least 36
months of radotinib therapy. With a median follow-up of 45.7 (range 0.9-65.7)
months, 31 patients (40.3%) completed 36 months treatment, and 46 patients
(59.7%) discontinued the treatment before 36 months. Main reasons of dis-
continuation were abnormal laboratory test (n=18), adverse events (n=4), treat-
ment failure including disease progression and lack of response (n=18), death
(n=2), and other reasons (n=4). Median duration of radotinib exposure was
19.5 (0.3-60.9) months. Cumulative incidence of complete cytogenetic response
(CCyR) by 36 months was 90.0% and of patients achieving CCyR, 45.0%
(18/40) achieved MMR. The drug-related safety profiles were consistent with
those previously reported and new safety issues have not been observed after
12 months. Most drug-related AEs have developed within 12 months, and have
shown minimal increase compared with rates at 12 months follow-up. Estimated
OS and PFS at 36 months were 87.6% and 85.7%, respectively.
Figure 1.
Summary/Conclusions: The 36 months data supports radotinib treatment in
TKI failed CML-CP patients maintains the effective response and high rates of
OS & PFS rate. Thus, radotinib demonstrated a promising alternative treatment
for patients with TKIs failure.
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100 YEARS OF CHRONIC MYELOID LEUKEMIA PREVALENCE IN FRANCE
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Background: The success of imatinib and other rationally designed tyrosine
kinase inhibitors (TKI) in the treatment of chronic myeloid leukemia has dras-
tically improved the fate of CML patients. From a couple of years in median
survival in the 70’s, a majority of patient now achieve a near normal life
expectancy with lifelong treatment though. This new paradigm where CML can
be regarded as a chronic disease has mechanical consequences on the dis-
ease prevalence and overall costs for health care systems. The success of
imatinib and other rationally designed tyrosine kinase inhibitors (TKI) in the
treatment of chronic myeloid leukemia has drastically improved the fate of CML
patients. From a couple of years in median survival in the 70’s, a majority of
patient now achieve a near normal life expectancy with lifelong treatment
though. This new paradigm where CML can be regarded as a chronic disease
has mechanical consequences on the disease prevalence and overall costs
for health care systems.
Aims: We present here a fully detailed and comprehensive analysis of the
French CML prevalence over a century from 1960 to 2060.
Methods: Prevalence of CML was estimated using a cohort component-based
model fromestimates of incidence rate of the disease by age and sex, population
and demo-graphic projection from the National Institute of statistics and Eco-
nomics Studies, and various hypotheses on the relative survival of CML patients.
Prevalence of CML was estimated using a cohort component-based model fro-
mestimates of incidence rate of the disease by age and sex, population and
demo-graphic projection from the National Institute of statistics and Economics
Studies, and various hypotheses on the relative survival of CML patients. The
number of CML patients is estimated over time and the resulting CML prevalence
expressed as a number of CML patients per 100,000 inhabitants.
Results: The CML prevalence in France, expressed in cases per 100,000
inhabitants, was estimated to be around 3 before the 80’s, 6 before the 2002,
17 in 2016, 25 in 2030 where the tendency inflects, and 30 after 2040. Consid-
ering the 100% relative survival hypothesis, a target CML prevalence were
defined, the level of which will be nearly reached by 2060. By simulation, we
showed that given constant incidence rates and high relative survival hypothe-
ses, the CML prevalence will be driven by population aging, and that the target
prevalence, defined as the maximum CML prevalence, should be nearly
reached by 2050 to levels above 30 per 100,000 in-habitants. By simulation,
we showed that given constant incidencerates and high relative survival
hypotheses, the CML prevalence will be driven bypopulation aging, and that
the target prevalence, defined as the maximum CMLprevalence, should be
nearly reached by 2050 to levels above 30 per 100,000 inhabitants.
Figure 1.
Summary/Conclusions: Due to high rates of relative survival observed after
introduction of imatinib, the trajectory of the CML prevalence in France, as in
other western countries, has changed. Given particular hypothesis on the CML
incidence rates, this trajectory will bring the CML prevalence by the mid century
to levels fully determined by population aging. For France, we have estimated
this level above 30 cases per 100,000 inhabitant. Due to high rates of relative
survival observed after introduction ofimatinib, the trajectory of the CML preva-
lence in France, as in other westerncountries, has changed. Given particular
hypothesis on the CML incidence rates,this trajectory will bring the CML preva-
lence by the mid century to levels fullydetermined by population aging. For
France, we have estimated this level above30 cases per 100,000 inhabitant.
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Background: Chronic myeloid leukemia (CML) is characterized by the pres-
ence of BCR-ABL fusion gene. This molecular event becomes the main ther-
apeutic target with Imatinib as first-line treatment. In spite of the continued clin-
ical success of Imatinib on CML treatment, the emergence of resistance to
tyrosine kinase inhibitors (TKIs) had stimulated the research of the mechanisms
involved. These included those related with target changing (e.g. the presence
BCR-ABL gene mutations and amplifications) and with intracellular drug con-
centrations (e.g. the abnormal levels of influx and efflux transporters such as
OCT1/OCNT2 and PgP/BCRP, respectively). MicroRNAs (miRNA) are impor-
tant regulators of both mechanisms, and so, could influence TKIs response. 
Aims: In this context, we investigated the role of miR-203, miR-21, miR-519c,
miR-451 and miR-26 expression levels in TKI response in CML patients, and
correlated them with TKI sensitivity, BCR-ABL levels, and disease progression,
among other clinical and laboratory data.
Methods: To this end, we assessed the expression levels of miR-203, miR-
21, miR-519c, miR-451, miR-26 and miR-16 (endogenous control) by TaqMan
MicroRNA Assays in peripheral blood cells from 31 patients with CML at fol-
low-up examinations. We also studied 4 CML cell lines, K562 a cell line sensi-
tive to Imatinib, LAMA-84 a cell line with 4 copies of chromosome Philadelphia
(Ph), and 2 Imatinib resistant cell lines models created in our lab (K562-RC
and K562-RD). K562-RC cells, generated by continuous exposure to Imatinib,
present an IC50 8x times higher than the parental cell line (K562); in K56-RD
cells (created by discontinuous exposure), the degree of resistance is 18x.
Statistical analysis was performed with ANOVA and multiple comparison tests,
with significance levels of 95% (p<0.05).
Results: The miR-203 and miR-519c expression was not detected in any cell
line or CML patient. First, we correlated miRs expression with BCR-ABL levels.
Higher levels of tumor suppressor miR-451 were associated with a higher
reduction of BCR-ABL levels (lower than 0.01%) in CML patients and patients
with higher BCR-ABL present lower levels of expression of miR-451. This miR
was also down-regulated in LAMA-84, K562-RC and K562-RD comparing with
sensitive cell line (K562; p<0.05). On the other hand, patients with more BCR-
ABL content (between 1.0% and 0.1%) present higher expression of the
oncomiRs, mir-21 and miR-26. These miRs were also up-regulated in resistant
cell lines. MiR-21 was more relevant for K562-RC cells (4-fold higher than
K562). LAMA-84 and K562-RD cell lines showed almost 2 times more expres-
sion of miR-26. Next we analyzed if treatment options affected miRs expres-
sion. CML patients under Imatinib treatment showed higher levels of miR-451
associated with less expression levels of miR-21 and miR-26. Imatinib had
been described to be able to block the BCR-ABL negative feedback on miR-
451, increasing miR function. Since miR-21 and miR-26 were also lower
expressed, more PTEN is available to block PI3K-AKT-mTOR pathways,
decreasing this survival signaling. Opposite profile was observed in patients
that changed treatment to a second generation TKI suggesting a different effect
of this TKI on microRNA expression.
Summary/Conclusions: Our preliminary results suggested the involvement
of miRNAs in BCR-ABL levels regulation and in TKI response, supporting the
search of a miRNAs TKI response profile that could predicts the response in
CML patients. This information could act as powerful tool for the stratification
and selection of the best therapeutic approach (lower toxicity and cost effec-
tive), contributing to higher survival rates and better quality of life in CML
patients.
Work supported by the Faculty of Medicine of the University of Coimbra and
Santander Totta Bank, grant reference FMUC-BST-2016-214. 
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IMPACT OF ABCB1 AND ABCG2 POLYMORPHISMS ON RESPONSE TO
IMATINIB AND 2G-TKIS THERAPY IN PATIENTS WITH CHRONIC PHASE
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Background: Overexpression of multidrug resistance proteins ABCB1 and
ABCG2 confers resistance to anticancer drugs, including tyrosine kinase
inhibitors (TKIs). Various ABCB1 and ABCG2 single nucleotide polymorphisms
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(SNPs) affect the transporter activity, but their impact on clinical response to
imatinib in chronic myeloid leukemia (CML) is discordant; even less is known
on their role in patients treated with second generation (2G) TKIs dasatinib and
nilotinib.
Aims: To investigate the role of the most common ABCB1 and ABCG2 genetic
polymorphism in chronic phase CML patients treated with imatinib and 2G-TKIs.
Methods: We analysed four polymorphisms of ABCB1 (129T>C, 1236C>T,
2677G>T/A and 3435C>T) and two polymorphisms of ABCG2 (34G>A and
421C>A) in 196 CP-CML patients, of whom 139 treated with imatinib (114 in
first line and 25 after interferon failure) and 57 treated with dasatinib or nilotinib
(22 in first line and 35 after imatinib failure), We compared the rates of optimal
response at 3 months (defined as BCR/ABL <10%), at 6 months
(BCR/ABL<1%) and at 12 months (BCR/ABL<0.1%), progression-free survival
(PFS) and time to treatment failure (TTF) according to the different protein
genotypes. TTF was calculated from the start of therapy to any of the followings:
progression to accelerated or blastic phase (ABP), death for any cause at any
time, treatment discontinuation for primary or secondary resistance or intoler-
ance. PFS was calculated from the start of TKI to ABP or death.
Results: A total of 196 patients with CP-CML (median age 57 years, range 21-
84) were included in the analysis. Frequency of ABCB1 and ABCG2 SNPs
expression is summarized in Table 1. Considering response to therapy, either
in imatinib-treated patients and in those receiving a 2G-TKI, we did not find
any significant difference in terms of optimal response at the various timepoints,
TTF or PFS for ABCB1 C1236T, G2677T and C3435T and of ABCG2 G34A
and C412A polymorphism, even if there was a trend for a worse PFS in the few
patients (n=3) with 1236 allele A treated with imatinib. Conversely, we found a
lower rate of optimal response at 3 (p=0.1), 6 (P=0.05) and 12 (p=0.2) months
in imatinib-treated patients with TC genotype of ABCB1 T129 SNP, though the
small number of patients (7) had probably and impact on statistical significance.
However, TTF was shorter for ABCB1 129T>C patients, both receiving imatinib
(P=0.05) and 2G-TKIs (P=0.07), and also PFS was significantly shorter in this
cohort (P=0.003).
Table 1.
Summary/Conclusions: With the limits of the low expression rates of some
SNPs, our data suggest a lower response in patients harboring 129T>C poly-
morphism, at least in those receiving imatinib. Other ABCB1 and ABCG2 geno-
types do not seem to impact on response to TKI treatment.
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Background: The discovery of tyrosine kinase inhibitor (TKI) imatinib has rev-
olutionized the conception of chronic myeloid leukemia (CML) as a mortal dis-
ease to a long-term controllable disease. The European Treatment and Out-
come Study (EUTOS) score is a clinical tool that utilizes imatinib-based objec-
tives to predict treatment response and progression free survival (PFS) in
patients with CML in chronic phase (CP). However, it is currently unknown
whether the introduction of second generation TKIs (2nd TKIs) affects prognostic
score of patients with CML-CP, particularly among those considered high-risk
according to EUTOS score.
Aims: Our study aims to highlight the critical role of the introduction of 2nd TKIs
on patient prognosis as determined by EUTOS score.
Methods: Patients data was obtained retrospectively from patients enrolled in
the CML Cooperative Study Group. Patients with CML-CP who were treated
with any TKIs as first line therapy between April 2001 and January 2016 were
enrolled to the study and were classified according to date of diagnosis. Those
who were diagnosed with CML-CP before March 2009 were classified into the
imatinib group, and those diagnosed after April 2009 were classified into the
2nd TKI group, as these patients were able to be treated with 2nd TKIs. The
study was approved by the research ethics boards of each institution and was
conducted in accordance with the Declaration of Helsinki.
Results: There were 308 patients newly diagnosed with CML-CP during the
study period. Of these patients, 104 (34%) were assigned to the imatinib group
and 204 (67%) were assigned to the 2nd TKI group. With respect to EUTOS
score, 223 patients were classified as low-risk, of which 69 were in the imatinib
group and 154 were in the 2nd TKI group. Forty-six patients were considered
high-risk, of which 19 were in the imatinib group and 27 were in the 2nd TKI
group. EUTOS score was unavailable in 39 patients. With regard to initial TKI,
all patients were treated with imatinib in the imatinib group. Among patients
assigned to the 2nd TKI group, 149 (73%) were initially treated with any TKI.
The median follow-up period for all patients was 48 months (range: 1–185
months). Among patients in the 2nd TKI group, CML-associated death rates
were significantly lower than those in the imatinib group. EUTOS high-risk
patients score exhibited significantly worse outcomes in EFS, PFS, and CML-
associated death compared to those considered low-risk. Most importantly, risk
stratification by EUTOS score was predictive of risk-associated clinical out-
comes in patients assigned to the imatinib group; however, EUTOS score failed
to predict risk-associated clinical outcomes of patients assigned to the 2nd TKI
group (see Figure). The EUTOS high-risk patients in the imatinib group showed
worse clinical outcomes than those in the 2nd TKI group (hazard ratio [HR]
6.35, 95% confidence interval [CI] 1.79 – 22.6, p=0.0042). However, prognostic
effect was less in the 2nd TKI group (HR 3.21, 95% CI 0.59 – 17.6, p=0.18).
Out of 308 patients, 9 progressed to AP/BP, of which 8 transformed during ima-
tinib therapy and 1 transformed during dasatinib therapy.
Figure 1.
Summary/Conclusions: Among patients assigned to the imatinib group, risk
stratification by EUTOS score was predictive of clinical outcomes in that those
considered high-risk experienced considerably more adverse events (EFS,
PFS, or CML-associated death) than those considered low-risk. Our results
support the use of 2nd TKIs in treating high-risk patients with CML-CP in order
to avoid disease progression. Future large-scale studies are necessary to eval-
uate the clinical significance of EUTOS scoring in the accurate prediction of
prognosis among patients with CML-CP treated with 2nd TKIs.
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Background: Chronic myeloid leukemia (CML) diagnosed at pregnancy is a
serious challenge. Treatment by tyrosine kinase inhibitors (TKI) today is con-
sidered harmful for fetus due to possible teratogenicity. On the other hand TKI
delay is dangerous for disease progression as no other options have compa-
rable to TKI effectiveness. Pregnancy termination by abortion may be crucial
for desired pregnancies as further childbirth is postponed for years until stable
deep molecular response (DMR). Due to limited number of cases and ethical
issues there is no consensus on how to behave in such delicate cases.
Aims: To describe pregnancy outcomes and therapy tactics for CML diagnosed
at pregnancy.
Methods: Information regarding CML diagnosed at pregnancy was collected
within the database of countries participating in the observational study of Euro-
pean LeukemiaNet (ELN Pregnancy Registry). The data included CML clinical
characteristics at diagnosis, cytogenetic and molecular parameters, information
of therapy, pregnancy outcomes and data of newborns.
Table 1.
Results: Thirty one women with median age 26 years (range 20-39) were diag-
nosed with Ph-positive chronic phase CML during pregnancy. That was 11% of
all 282 pregnancy cases. In certain countries (Russia) up to 21% of women with
CML and pregnancy had the synchronistic onset of these events (table 1). Sokal
low/intermediate/high and EUTOS low/high risk score was in 22/5/3 and 28/2
patients correspondingly, no data for risk score was in 1 patient. CML was diag-
nosed in 1st/2nd/3rd trimester in 18/7/6 females correspondingly. Induced abor-
tion was done before CML therapy was started in 10 (32%) around 10 obstetri-
cian week (range 6-17), spontaneous abortion happened in 1 woman (at week
8th). Pregnancy was prolonged by consistent desire or religious reasons in 20
females: 2 pregnancies are ongoing now and 18 have ended in childbirth. No
treatment till labor was in 5 women. Treatment of CML during pregnancy was
initiated in 15 of 20 patients. Interferon alpha (IFN) was given to 5 women and
3 of them were switched to imatinib (IM) 400mg daily in 2nd-3rd trimester due to
insufficient control of complete blood count. IM 400mg daily in 1st line was also
taken by 9 women since 2nd-3rd trimester. In summary 12 women got IM from
Me 22nd week (range 16-36). One woman got hydroxyurea (HU) from 3rd
trimester till labor and 3 got HU shortly for 5-7 days before any other treatment
in 1st-2nd trimester. Nineteen healthy newborns (including twins in 1 case) were
born: 14 at term, 5 by preterm delivery at week 35-37. There were no birth
abnormalities in 10 newborns exposured to IM in 2nd-3rd trimester. Two preg-
nancies under IM exposure are currently at week 17 and 31, developing nor-
mally. Four infants had low birth weight (<2500 g): 3 of them were exposed to
IM and 1 for HU at pregnancy. Follow-up of children was uneventful with Me
observation time 47 months (range 9-192) and Me observation time 38 months
(range 9-63) for 10 infants exposed to IM in 2nd-3rd trimester. Twenty nine of 31
women with CML diagnosed at pregnancy are alive and continue TKI treatment,
2 women unfortunately died: 1 patient with postponed switch from IFN to IM
during pregnancy progressed to blast crisis after labor and had furher bone
marrow transplant failure while 1 patient after induced abortion developed rapid
blast crisis with BCR-ABL compound mutations including T315I.
Summary/Conclusions: This is the first report of a large database of women
diagnosed with CML during pregnancy. Management of this very delicate sub-
set of patients is a challenge especially when a woman refuses from abortion.
Individual treatment approach may differ considering pregnancy terms and
clinical status. Although normal childbirth is possible using IM after 2nd-3rd
trimester, the risks of pregnancy prolongation remain still not well defined. To
get the most safe prognosis for mother and child pregnancy in CML should be
planned in a stable DMR.
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Background: The BCR-ABL1 tyrosine kinase inhibitors (TKIs) dramatically
improved long-term survival of the patients with chronic myeloid leukemia
(CML). As increased NK cells during TKI therapy positively correlate with better
outcome, antitumor immunity by NK cells may contribute to the effects of TKIs.
However, the response to TKIs depends on each case, and the determinants
of it remain to be elucidated.
Aims: Given that NK cell function is regulated depending on the interaction
between killer immunoglobulin-like receptor (KIR) and human leukocyte antigen
(HLA) class I molecules, we hypothesized that polymorphisms of KIR and HLA
play important roles on the responses to TKIs. Then we performed allele geno-
typing of KIR and HLA with deep sequencing in CML patients, and here report
their clinical impacts.
Methods: KIR and HLA high resolution typing were performed on peripheral
blood DNA from 76 CML patients in chronic phase (CML-CP) using Scisco
Genetics typing kit (Scisco Genetics Inc., Seattle WA) and MiSeq as platform
by NGS. Therapeutic effects of TKIs were evaluated based on bcr-abl mRNA
levels measured by real-time quantitative (RQ)-PCR compensated according
to international scale (IS) and/or transcription mediated amplification (TMA)
method. Major molecular response (MMR) was defined as 3-log reduction
(MR3) in RQ-PCR (IS) or BCR-ABL transcript level of less than 50 copy/0.5 µg
RNA in TMA method. We also defined DMR as 4-log reduction (MR4.0) in RQ-
PCR (IS), which is similar to undetectable of BCR-ABL transcript level in TMA
method. The Cox proportional hazards model was used in the time-to-event
analysis. A p value<0.05 was considered statistically significant.
Results: Second generation TKIs as first-line therapy (n=46) and female (n=29)
sex were strongly associated with superior DMR at the 2-year of therapy (sec-
ond generation TKIs as first-line treatment, HR 7.305, 95% CI, 3.377 to 15.803;
p<0.001; female sex, HR, 1.709; 95% CI, 1.028 to 2.842; p=0.039). After adjust-
ment with these two factors, several KIR alleles positively correlates with supe-
rior DMR at the 2-year; KIR2DL4*008 or 011/00501 (HR 1.942, 95%CI 1.160
to 3.250, p=0.012); KIR2DS4*00301 or 007/010 or 015 (HR 2.811, 95% CI,
1.590 to 4.968, p<0.001); KIR3DL1*00501 (HR 3.634, 95% CI 1.884 to 7.013,
p<0.001). Interestingly, KIR3DL1*00501 for the patients has more strong link-
age to KIR2DL4*008 or 011/00501, and 2DS4*00301 or 007/010 or 015 than
other KIR3DL1 alleles. (Fisher’s exact test, p<0.001).
Summary/Conclusions: KIR3DL1*00501 and several KIR2DL4 and 2DS4
alleles positively correlate with better therapeutic effects of TKIs, and they may
be form the same KIR haplotype. Our data indicate that these KIR alleles rep-
resent strong anti-CML immunity by NK cells, and consequently may associate
with long-term outcome and treatment-free remission in CML.
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Background: Recent reports have demonstrated that tyrosine kinase inhibitors
(TKIs) discontinuation can be employed in chronic phase chronic myeloid
leukemia (CP CML) patients with sustained deep molecular responses after
enough TKI therapy. Consequently, treatment-free remission (TFR) has been
a new therapeutic goal. Although 50-70% of patients experienced molecular
relapse by several imatinib (IM) discontinuation studies, the most of patients
resumed molecular responses (MR) following restart of IM.
Aims: Though the Korean multicenter prospective study (Korean Imatinib Dis-
continuation Study; KID Study), we have explored molecular kinetics after the
first IM discontinuation and after IM resumption for molecular relapse. In patients
regaining durable UMRD with IM resumption, we tried second IM discontinuation
and compared molecular kinetics between the first IM stop and second IM stop.
Methods: CP CML patients who were treated with IM for more than 3 years
and had undetectable levels of BCR-ABL1 transcripts determined by quantita-
tive reverse transcriptase polymerase chain reaction (PCR) for at least 2 years
were eligible for KID study and in cases of MMR loss after 2 consecutive
assessments, IM treatment was re-introduced. After IM resumption for MMR
loss, the molecular response was evaluated every month until MMR was re-
achieved and every 3 months thereafter. The second stop was permitted in the
patients who were in second UMRD for at least 2 years.
Results: Among patients who lost MMR in 2 consecutive analyses and
resumed IM in the KID study, 12 patients (6 men and 6 women) with a median
age of 45 years (range, 25-59 years) entered into a second IM discontinuation
after maintaining UMRD at least 2 years. Prior to first discontinuation, the medi-
an duration of IM therapy was 68.9 months (range, 38.5-115.1 months) and
the duration of sustained UMRD was 32.9 months (range, 24.8-64.5 months).
After first attempt of IM discontinuation, they relapsed after a median duration
of 3.7 months (range, 1.8-13.1 months) and re-achieved UMRD at a median of
6.7 months (range, 3.3-13.6 months) after IM resumption. After sustaining a
second UMRD for a median of 25.5 months, IM therapy discontinued for a sec-
ond time. After a median follow-up of 8.8 months (range, 0.3-38.1 months) after
second IM discontinuation, 10/12 patients (83%) and 8/12 patients (67%) lost
UMRD and MMR, respectively. Among two patients who lost UMRD but not
MMR, one patient showed fluctuation of BCR-ABL1 transcript under the level
of 0.1% on IS for 9.4 months and another patient have shown gradually increas-
ing BCR-ABL1 transcripts under the level of 0.1%. Eight patients who experi-
enced second relapse (MMR loss) after a median 2.9 months (range, 1.9-30.7
months). The patients who lost MMR, except one patient, were retreated with
IM for a median of 7.1 months (range, 0.8-24.8 months); five patients re-
achieved MMR at a median of 1.8 months (range, 1.0-10.2 months) and one
re-achieved UMRD at 5.5 months.
Summary/Conclusions: Our data demonstrated that a second attempt might
be possible and the median time to MMR loss after second discontinuation
was similar to those of the first discontinuation. But the molecular kinetics after
second IM resumption needs longer follow-up with more patients. Further stud-
ies on the predictors to select patients for a trial of second TFR and novel
strategies such as intermittent therapy will be warranted.
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Background: BCR-ABL1 transcripts ≤1% after 6 months was an effective pre-
dictor. Also, radotinib showed that optimal molecular responses at landmark
time point 3, 6, and 12 month were significantly higher than imatinib group.
Aims: We evaluated the impact of molecular response by 24 months for molec-
ular level after 3 months (BCR-ABL1 transcript level ≤10%) and 6 months (BCR-
ABL1 transcript level ≤1%) of radotinib 300mg twice daily (bid) approved for
first-line use in Korea or imatinib treatment in newly diagnosed CML-CP.
Methods: Based on baseline demographics and Sokal risk score, 241 patients
were randomized 1:1:1 to radotinib 300mg bid (n=79), radotinib 400mg bid
(n=81), or imatinib 400mg once daily (qd) (n=81). 157 patients with available 3
months qRT-PCR on study therapy [radotinib 300mg bid (n=79), and imatinib
400mg qd (n=78)] were evaluated. And, total of 151 patients who received
radotinib 300mg bid (n=77), and imatinib 400mg qd (n=74) were evaluable at
6 months. Molecular response was assessed by RQ-PCR at baseline and every
3 months. BCR-ABL1 transcript level was measured by RQ-PCR, standardized
according to international scale (BCR-ABLIS). Major molecular response (MMR)
was defined by BCR-ABL1/ABL1 ratio ≤0.1%IS and MR4.5 was defined as ≥4.5
log reduction in BCR-ABL1 transcript levels from standardized baseline or BCR-
ABL1/ABL1 ratio ≤0.0032%IS.
Results: In two study groups, early molecular response (EMR) at 3 months
were observed in 86.1% of patients in the radotinib 300mg bid group and 67.9%
in the imatinib group (P=0.0179). More patients treated with radotinib 300mg
bid who had EMR at 3 months achieved MMR and MR4.5 by 24 months: 73.5%
and 38.2% in the radotinib 300mg bid group and 63.6% and 29.1% in the ima-
tinib group, respectively. At 6 months, 73.4% of patients in the radotinib 300mg
and 53.1% patients in imatinib group (P=0.0246) achieved 6 months EMR. The
patients who had EMR at 6 months in radotinib 300mg bid group were signifi-
cantly higher MMR and MR4.5 compared with the patients who were not
achieved EMR (P<0.0001), which they achieved MMR and MR4.5 by 24 months:
86.2% and 44.8%, respectively and imatinib group achieved 81.4% and 39.5%,
respectively. By 24 months, overall survival (OS) and progression-free survival
(PFS) according to 3 months or 6 months were not significantly different in two
groups.
Summary/Conclusions: With minimum 24 months follow-up, early responses
at 3 months or 6 months can predict better outcomes in newly diagnosed chron-
ic myeloid leukemia patients treated with radotinib or imatinib. But, to evaluate
the significant long-term prognostic value such as overall survival and progres-
sion-free survival by EMR, longer follow-up are needed. 
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HYDROXYUREA SUPPRESSES BCR-ABL1 T315I+ CML CLONES IN VIVO
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Background: In chronic myeloid leukemia (CML), BCR-ABL1T315I leads to
resistance against most BCR-ABL1 tyrosine kinase inhibitors (TKI). Long-term
therapy with ponatinib, which suppresses BCR-ABL1T315I, is problematic
because of side effects. In addition, resistance against ponatinib may develop
due to occurrence of compound mutations in BCR-ABL1. Therefore, alternative
therapies have to be considered. Hydroxyurea (HU) has been used for (pallia-
tive) treatment of CML over decades. However, the effects of HU on TKI-resis-
tant sub-clones have not been examined so far. 
Aims: The aim of this study was to evaluate the effects of HU on CML sub-
clones carrying BCR-ABL1T315I mutations (isolated or in compound-configura-
tion) in vitro and in vivo and to explore cooperative effects between HU and
ponatinib.
Methods: Four BCR-ABL1T315I+ CML patients were treated with HU (1-3 g/day)
for 2 to 18 months. White blood counts (WBC), differential counts, and BCR-
ABL1 transcript levels were reported. The BCR-ABL1T315I/BCR-ABL1 ratio was
determined by mutation-specific, ligation-dependent, PCR and next generation
sequencing. In in vitro studies, primary CML cells, the CML cell lines K562,
KU812, KCL-22, and KCL-22T315I as well as Ba/F3 cells expressing BCR-
ABL1WT (Ba/F3p210WT), or mutant BCR-ABL1 (Ba/F3p210T315I,
Ba/F3p210T315I/E255K, Ba/F3p210T315I/F311L, Ba/F3p210T315I/F359V,
Ba/F3p210T315I/G250E) were examined. Cell proliferation was quantified by 3H-
thymidine uptake. Apoptosis was determined by flow cytometry. Drug effects
on competitive clonal growth were analyzed by mixing Ba/F3p210WT (labeled
with GFP) with Ba/F3p210T315I/F359V or Ba/F3p210T315I/E255V (labeled with
tdTomato) at a ratio of 1:1. Then, cells were exposed to HU, pontinib, or
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HU+ponatinib for 72 hours, and the percentage of viable cells in each sub-
clone was analyzed by flow cytometry. 
Results: HU treatment resulted in WBC stabilization in 3 of 4 patients, but
failed to induce a molecular response. However, surprisingly, the percentage
of BCR-ABL1T315Idecreased significantly in all 4 patients during HU treatment
and was no longer detectable in 3 of 4 cases. Stem cell transplantation could
be performed in 2 patients after 2-3 months. In one patient, stable disease
over 18 months was obtained with HU-therapy. In one patient, the disease pro-
gressed rapidly despite temporary suppression of BCR-ABL1T315I. In in vitro
studies, HU was found to block the growth in all cell lines tested and in all pri-
mary cell samples (n=7) examined, with IC50 values ranging between 50 and
250 µM. Interestingly, cell lines exhibiting mutant BCR-ABL1 were more sen-
sitive against HU than cell lines expressing BCR-ABL1WT. HU and ponatinib
were found to synergize in inhibiting growth of all cell lines tested, including
cells expressing BCR-ABL1T315I or T315I-including compound mutations.
Cooperative drug effects were also confirmed in primary CML cells (n=4). In
cell mixing experiments, ponatinib was found to supress Ba/F3p210WT cells
but not Ba/F3p210T315I/F359V or Ba/F3p210T315I/E255V cells, whereas HU was
found to exert stronger effects on cells expressing mutant BCR-ABL1, and the
drug combination resulted in complete suppression of all sub-clones. 
Summary/Conclusions: Our data show that HU exerts strong, sub-clone spe-
cific, anti-neoplastic effects in TKI-resistant CML cells in vivo and in vitro. In
addition, HU and ponatinib produce synergistic growth-inhibitory effects on TKI
resistant CML cells. Clinical studies are now warranted to define the exact
value of the drug combination ponatinib+HU in TKI resistant CML.
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Background: The inhibition of BCR-ABL1 kinase with tyrosine kinase inhibitors
(TKIs) has markedly improved the prognosis of chronic myeloid leukemia (CML).
Recently, it has been recognized that some CML patients with deep molecular
response (DMR) can maintain treatment-free remission (TFR) after TKI cessation.
However, no predictive prognostic factor for successful treatment cessation has
yet been identified. BCL2L11 (BIM) deletion polymorphism (intron 2) has been
reported to be associated with an inferior response to TKI (Ng et al. Nature Med-
icine, 2012). We have previously reported that BIM deletion polymorphism may
predict relapse after TKI discontinuation (Katagiri et al. Br J Haematol, 2013).
Aims: To further clarify the role of predictive biomarkers in molecular relapse
after TKI cessation, we performed a long-term follow-up of CML patients with
DMR after TKI cessation.
Methods: Patients with DMR receiving TKI treatment were included. Molecular
relapse was defined as a loss of the major molecular response (MMR). The
genomic DNA of patients was obtained from their whole blood samples using
the EZ1 DNA Blood 350 l kit (Qiagen, Valencia, USA). Deletion polymorphism
was detected by Q-Invader assay using primers designed to detect a deletion
site (2,903 bp) (Ohyashiki et al. J Hematol Transfus, 2014).
Results: Forty-six CML patients (29 men;17 women; median age, 58.5 years)
were included in this study (Sokal category; low: 32, intermediate: 10, and
high: 2). Thirty-three patients discontinued imatinib, five discontinued nilotinib,
and eight discontinued dasatinib. Ten patients were treated with IFNα before
TKI treatment. The median duration from TKI initiation to cessation was 85.0
(range: 22–177) months; the median duration of DMR before TKI cessation
was 43.0 (range: 5–131) months. Treatment-free remission was estimated to
be 66.5% at 12 months, 61.5% at 24 months, and 58.5% at 36 months. Thir-
ty-six CML patients were analyzed for the presence of BIM deletion polymor-
phism of which six exhibited BIM deletion polymorphism. All patients with BIM
deletion polymorphism relapsed within 12 months after TKI cessation. A signif-
icant difference was observed only in BIM deletion polymorphism between the
patients who maintained and those who lost MMR (p=0.0000528). No patient
died during the follow-up period. No significant difference was observed in the
second TKI therapy, prior IFNα therapy, and time to DMR between relapsing
and non-relapsing patients.
Summary/Conclusions: The analysis of BIM deletion polymorphism in CML
patients is expected to be useful for predicting their early molecular relapse
after TKI treatment discontinuation.
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Background: The ability to consistently detect low levels of BCR-ABL tran-
scripts in patients with chronic myeloid leukemia (CML) is important in the
assessment of treatment outcomes in patients on tyrosine kinase inhibitor (TKI)
therapy. Particularly, BCR-ABL assays that are sensitive in the measurement
of deep level response may aid in the identification of potential candidates for
treatment discontinuation. Xpert® BCR-ABL Ultra detects the most common
BCR-ABL transcripts below MR4.5 (Molecular Response at 4.5-log reduction)
or 0.0032%, which is widely accepted as the clinical threshold that defines
candidates who can safely discontinue TKI therapy.
Aims: The present studies were designed to verify the limit of detection (LoD)
for the Xpert® BCR-ABL Ultra assay below MR4.5 on the international Scale
(IS) in clinical samples for both the b3a2 and b2a2 transcripts.
Methods: To overcome the challenge of testing numerous replicates requiring
large volumes of patient samples,, serial dilutions ranging from BCR-ABL/ABL
levels of 10% to <0.001% (IS) were prepared as contrived samples using CML
patient blood with initial BCR-ABL level >10% (IS) and pooled blood from CML
negative patients, ranged from 10% to <0.001% (IS). Twenty-one replicates of
each dilution were measured for%BCR-ABL/ABL (IS). Determination of the
LoD was performed by the statistical analysis to identify the lowest concentra-
tion of%BCR-ABL/ABL (IS) per test that can be reproducibly distinguished from
negative samples with 95% confidence. The acceptable precision for%BCR-
ABL/ABL (IS) is defined as the ability to detect at least a 3-fold difference for
all concentrations tested.
In addition, analytical LoD studies were performed using spike-in CML cell lines
and cell-line derived RNAs, carrying either b3a2 or b2a2 transcripts. Further-
more, the clinical sensitivity study was conducted using blood from twelve low
BCR-ABL transcripts level CML patients on TKI therapy, who had achieved
and maintained MMR (Major Molecular Response) [0.1% (IS)] with reporting
below 0.05% (IS).
Results: Consistent results were observed in the both the diluted CML patient
blood and spike-in CML cell lines or cell-line derived RNA studies for both the
b3a2 and b2a2 transcripts, demonstrating an assay LoD of MR4.5 and below
with a less than 2-fold difference at the LoD levels. With the clinical sensitivity
study, eleven out of twelve low CML subjects were detected in at least 19 out
of 20 replicates tested per subject over a range of 0.038% (IS) (SD=~0.17 Log)
to 0.0011% (IS) (SD=~0.4 Log). The overall ABL copy number present in clinical
samples in each study was at least 5-10 times the required minimal ABL copy
number of ≥32,000 to support a claim of MR4.5 and ≥100,000 for MR5.0.
Summary/Conclusions: These LoD evaluations demonstrate that the Xpert®
BCR-ABL Ultra assay complies with the international guidelines for assay sen-
sitivity achieving MR4.5 with 5-10 times more than the required ABL copies to
confidently identify candidate patients that may benefit from the discontinuation
of TKI therapy.
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IDENTIFICATION OF INCIDENTS CASES OF GAUCHER DISEASE IN
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Background: Gaucher disease (GD) varies greatly in severity and organ
involvement. Clinical characteristics are usually nonspecific and lead to late
diagnosis with irreversible complications. Splenomegaly and thrombocytopenia
are the two most common manifestations (Gaucher Registry, 2008), which
reported 86% cases with moderate to severe splenomegaly and 60% throm-
bocytopenia at the time of diagnosis, thus demonstrating why patients are
referred to hematology. A diagnosis of GD is considered after other diagnostic
hypotheses have been ruled out. The consensus of international experts on
the management of patients with GD established a diagnostic algorithm that is
particularly intended for specialists (Mistry, 2010). Straightforward implemen-
tation of diagnostic algorithms to support medical specialties in Latin America
for early diagnostic testing of GD is required.
Aims: To identify new cases of GD in a selected population with splenomegaly
and/or thrombocytopenia referred to Hematology, Pediatric Hematology, Pedi-
atrics, Genetics and Internal Medicine, using a selection algorithm for the gen-
eral population (Mistry, 2010).
Figure 1.
Methods: Multicenter, descriptive study, in active recruitment process with non-
probabilistic sampling by convenience. Currently, the study has 51 specialized
medical centers in Hematology, Pediatrics and Internal Medicine in Colombia,
approved by Ethics Committee (EC). The study has an expected duration of
24 months since EC approval for each center. Eligible subjects are those with
three documented criteria: thrombocytopenia <150,000/cc plus anemia (hemo-
globin <12g/dL in men and <11 g/dL in women) plus/or bone pain plus/or Mon-
oclonal Gammapathy of Unknown Significance plus/or Polyclonal Gammapathy
in subjects aged 30 years and older; and/or splenomegaly defined as palpable
spleen ≥1cm below the costal rib or diagnosed by imaging, and/or Splenectomy
by splenomegaly with no known cause. Subjects with prior diagnosis of GD,
splenomegaly due to portal hypertension, hematologic malignancy, hemolytic
anemia and thalassemia were excluded. Informed consent was obtained for all
included subjects. Clinical information was collected from their medical history.
The enzymatic activity of the β-glucocerebrosidase was performed in peripheral
blood, using dried blood spots (DBS) and/or leukocytes. In subjects with
reduced enzymatic activity in DBS, confirmatory β-glucocerebrosidase enzy-
matic activity in leucocytes was determined. GBA1 gene was analyzed.
Results: Since Feb/14 to Nov/16, 400 subjects have been included (51.3%
men) with a median age of 28.79 years (range, 0.01 to 91.67). Reduced enzy-
matic activity of β-glucocerebrosidase was identified in 14 subjects (50%
women) with a median age of 12.68 years (range, 0.9 to 74.85). All subjects
were non-Ashkenazi origin, with 82.8% thrombocytopenia, 49.5% splenomegaly
and 4.33% splenectomy. Detailed population description is on Figure 1.
Summary/Conclusions: This study suggests that selection algorithm could
be implemented in Colombia, supporting specialists in making decisions on
diagnosis of Gaucher Disease. Further characterization of the population is
ongoing.
Acknowledgements: This study was funded by Sanofi Genzyme Colombia and
coordinated by Caimed Colombia.
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Background: Several anemias are associated with oxidative stress, namely,
sickle cell anemia, β-thalassemia, glucose-6-phosphate dehydrogenase defi-
ciency and hereditary spherocytosis. Red blood cells (RBC) are continuously
exposed to oxidative stress, mainly due to their primary function as oxygen
carriers; therefore, the erythrocytes are equipped with an efficient antioxidant
system, however, when its capacity is overwhelmed, the cell is exposed to
reactive oxygen species (ROS), triggering oxidative modifications. The antiox-
idant system includes several enzymes, such as peroxiredoxin 2 (Prx2), glu-
tathione peroxidase (GPx) and catalase (CAT); in spite of their roles in cell
defense being known, the interplay between these peroxidases is still unclear.
The recent report of conoidin A, as a specific Prx2 inhibitor, offers the possibility
to further explore the roles and contribution of these enzymes to antioxidant
defense.
Aims: We aimed to study the importance of Prx2, GPx and CAT inhibition on
defense against oxidative stress in normal erythrocytes. 
Methods: We performed in vitro assays (n=3) with RBCs from healthy volun-
teers, inhibiting Prx2, GPx and CAT, either individually, two-by-two or all three;
conoidin A, mercaptosuccinic acid and sodium azide were used as specific
inhibitors of Prx2, GPx and CAT, respectively. Since the RBC membrane is a
major target of ROS, we evaluated membrane lipoperoxidation (LPO) and mem-
brane bound haemoglobin (MBH), as well as, cytosol’s total antioxidant status
(TAS), by spectrophotometric methods.
Results: Concerning TAS we found a trend towards decreasing values with
enzyme inhibition (one or more); the lowest value of TAS was observed when
all three enzymes were inhibited and, when only two enzymes were inhibited,
the lower values were obtained for pairs that included CAT inhibition; when
only one enzyme was inhibited, GPx inhibition showed the lowest TAS. Regard-
ing LPO, a trend towards increasing values with enzyme inhibition was
observed; the lowest value was obtained when all enzymes were active, and
the highest when all of them were inhibited; when only one enzyme was inhib-
ited, CAT inhibition showed the highest LPO value and when two enzymes
were inhibited, LPO was highest for the pairs that included GPx. MBH was
increased for all enzyme inhibitory conditions, when compared to the condition
with all enzymes active, excepting when CAT was inhibited.
Summary/Conclusions: In conclusion, inhibition of these antioxidant enzymes,
either alone or simultaneously, leads to oxidative stress modifications within
the RBC, as showed by the increase in MBH and membrane LPO, and by the
decrease in cytosolic TAS. Moreover, the inhibition of CAT or GPx (either alone
or with other enzymes) presented more impact on oxidative modifications than
Prx2 inhibition. Our data strengthens the importance of these enzymes in RBC’s
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antioxidant homeostasis, and suggests that inhibition or injury to one (or more)
compromises erythrocytes, which might influence clinical presentation in oxida-
tive stress associated anemias.
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Background: Recently we have identified a new form of transfusion dependent
hemolytic anemia due to KLF1 mutations causing a trans-acting deactivation
of pyruvate kinase genes (PKLR). Mutations of PKLR per se can affect red
blood cells metabolism and cause a wide range of clinical manifestation from
fetal anemia leading to hydroptic fetus, severe neonatal jaundice requiring mul-
tiple exchange blood transfusions, chronic to fully compensated hemolytic ane-
mia. Understanding of the molecular basis of pyruvate kinase deficiency (PK
def.) might be useful to predict clinical phenotypes and suggest appropriate
clinical management of future patients. Moreover, an interaction of PKLR and
KLF1 mutations in such patient has not been explored.
Aims: This study aim to identify the mutation of patients with PK def. for the
first time in Southeast Asian populations.
Methods: Seven unrelated patients; 6 from Thailand and 1 from Indonesia
have been enrolled after inform consent. We have measured the PK activity of
all patients and their parents and siblings using a standard biochemical tech-
nique as we have described earlier. A complete genomic analysis of all PKLR’s
exons (NM_000298.5) including exon-intron boundaries were selectively ampli-
fied and followed by direct Sanger sequencing.
Table 1.
Results: Seven index PK def. patients as confirmed by enzyme activities, age
range 9-35 yrs old, were identified (Table 1). Three patients presented with
severe hemolytic anemia and required regular blood transfusion; every 3-4
weeks in two (PK-1 and PK-3) and every 10-12 weeks (PK-2) in which one
patient (PK-1) has been successfully treated with bone marrow transplantation
and became transfusion-free. Three patients (PK-5, -6 and -8) had moderately
severe hemolytic anemia and required blood transfusion occasionally. Only
one patient (PK-7) from Indonesia had well-compensated anemia and never
required blood transfusion. All but one had PK activities lower than 50% of nor-
mal range but these activities did not correlate with clinical severity. We found
11 different mutations in 5 compound heterozygotes and 1 homozygote as
shown in Table 1. Four mutations appeared to be novel as they were not been
reported in any public databases (c.1269+3A>G; c.353A>G =p.N118S;
c.865C>T =p.R289W; c.1618G>T =p.G540X). One mutation (c.941T>C=p.I314T)
seemed to be recurrent since it was found in two families; one homozygous
and one compounded with N118S. Beside nucleotide mutations, we found a
5006 bp deletion from intron 3 to exon 10 affecting PKLR gene. To detect these
mutations in family members and further cases, we developed a long range
GAP-PCR analysis to amplify the breakpoint fragment and directly sequenced
to determine deletion extends and also ARMS-PCR (C.1641T>TA), PCR-RFLP
(c.941T>C), mismatched PCR-RFLP for c.1403C>G, c.1463G>A and
IVS9(+3)A>G). Interestingly, one index patient (PK-4) was found with only one
known missense mutation (R488Q), however we could not find any mutation
in KLF1 of this patient suggesting that she might have other unidentified cis
mutation involved gene regulation of PKLR. Due to a limited number of patients,
there was no clear genotype-phenotype correlation found in our studied pop-
ulation.
Summary/Conclusions: Seven confirmed cases of PK def. are reported here-
in. They showed a wide variation of clinical severity. Molecular basis of PKLR
mutations was proven to be beneficial to provide a definitive diagnosis of PK
def. and might help suggesting clinical presentation in future cases.
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Background: Gaucher disease (GD) is an autosomal recessive lysosomal
storage disease characterized by the deficient activity of beta-glucocerebrosi-
dase (GBA). GBA deficiency results in the accumulation of glucosylceramide
in different organs, causing tissue damage. Typical GD features are spleno-
hepatomegaly, peripheral blood cytopenias (mostly thrombocytopenia and/or
anemia), growth retardation, bone involvement, gammopathies, increased risk
of malignancies and, in some patients, neurological manifestations. Since
symptoms are non-specific, the diagnosis can be delayed for years or missed.
Enzyme replacement therapy (ERT) with recombinant β-glucocerebrosidase
is safe and effective in preventing and/or reversing many clinical manifestations.
However, if the diagnosis is delayed for years, major complications cannot be
reversed. A useful screening method for GD is based on measuring enzyme
activity on a Dried Blood Spot (DBS), while the gold standard test is still con-
sidered GBA activity in cellular homogenates. A pediatric algorithm has been
proposed to promote timely diagnosis and early access to ERT (figure 1).
Figure 1.
Aims: Since pediatric patients with splenomegaly and cytopenias are usually
referred to pediatric hematologists, we have designed the GAU-PED study to
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evaluate the prevalence of GD among children referred to the haematology
paediatric units and selected according to the above mentioned diagnostic
algorithm. Here, we report a preliminary analysis of GAU-PED trial.
Methods: The GAU-PED study involves 53 centers in the context of the AIEOP
Study Group, the Italian clinical research consortium in paediatric hematology
and oncology. Patients referring to the pediatric hematology and oncology units
for splenomegaly with or without hepatomegaly and cytopenia (thrombocytope-
nia and/or anaemia), where other causes of splenomegaly has been excluded,
are tested for GBA activity though a DBS sample. Only patients with DBS show-
ing a GBA activity below normal values are recalled to confirm GBA enzyme
deficiency using the gold standard GBA analysis in cell omogenate. For every
tested patient, clinical information are also collected.
Results: After parental consent, a total of 25 DBS have been collected from 11
centers, in the first 12 months of study accrual. DBS values under 4.4
pmol/punch_1/h_1were found in 9/25 patients (36%). These patients have been
recalled for the conventional enzymatic test. The diagnosis of GD has been
confirmed in 5/9 patients (55%), with a prevalence of GD of 20% (95% CI, 8.8-
39.1%) equal to 5/25 patients in the tested population. In all 5 patients the
genetic analysis has been consistent with GD. Three patients were males and
2 females. The mean age at diagnosis was 8 years (range 2-13 years). The
median time from the initial clinical presentation and diagnosis has been 12
months (range 6-50 months), while the mean time between the DBS test and
the diagnosis has been 2 months. ERT has been started in all GD patients.
Summary/Conclusions: Our preliminary results support the use of DBS as
screening test for GD in a selected population of children with splenomegaly
and/or thrombocytopenia considered at increased risk for the disease. The use
of an appropriate diagnostic algorithm is useful to increase awareness of GD
among pediatric hematologists and to shorten the time to diagnosis. Taking
into consideration the long life expectancy of pediatric GD patients, the early
diagnosis will have a strong impact on health and quality of life.
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Background: Microparticles (MPs) are small particles budding from cells, which
contain variable amounts of proteins, miRNA and cytosol from the parental cell.
MPs play a role both in physiological and pathological conditions such as signal
transduction, cell activation, thrombosis and cancer. Thrombotic events are a
possible complication of haemolytic conditions, both congenital and acquired.
Elevated levels of circulating MPs have been described in several haemolytic
conditions, including sickle cell anaemia, thalassemia intermedia, haemolytic
uremic syndrome, and thrombotic thrombocytopenic purpura.
Aims: To evaluate platelet MPs (PMP), tissue factor expressing MPs (TFMPs),
endothelial MPs (EMPs) and microparticles expressing single antigens (CD41,
CD144 or CD142) levels in in other haemolytic anaemias, such as hereditary
spherocytosis (HS), elliptocytosis (HE), stomatocytosis (HSt), red cell enzymatic
defects, congenital dyserithropoietic anaemia (CDA), autoimmune haemolytic
anaemia (AIHA), and paroxysmal nocturnal haemoglobinuria (PNH).
Methods: To determine MPs, whole blood was collected into 0.109 M sodium
citrated vacutainer tubes. Platelet Free Plasma (PFP) was prepared by double
centrifugation at 2500 g for 15 min and stored frozen at -80°C until assayed.
For MPs analysis 25 µl of PFP was incubated with annV-APC, CD41-FITC,
CD142-PE and CD144 PerCp-Cy5.5 in Hepes buffer in the presence of 15 mM
CaCl2 and 1 u/ml of r-Hirudin for 30 min. Samples were diluted with 500 µl
Annexin V binding buffer and 25 µl of Flow-Count fluorospheres were added to
express MP count as absolute numbers. MPs analyses were performed on a
BD FACS Canto cytometer using Megamix-Plus SSC to define the MPs gate.
Results: MPs levels were evaluated in plasma of 43 patients followed-up for a
median time of 9 years (range 2-34) and compared with normal controls. The
median age of patients (15 male and 28 female) was 53 years (range 22-87),
9/43 (21%) had been splenectomized and 13/43 (30%) were treated at the
moment of the study (steroids/immunosuppressors for AIHA, and eculizumab
for PNH). Table shows Hb levels, PLT and WBC counts of the different
haemolytic conditions, along with LDH and reticulocyte values. In AIHA, the
number of EMP was negatively correlated with Hb levels (p<0.05), and PMPs
positively with reticulocytes and LDH (p<0.05 for both); CD41+ MPs, CD142-
PE+ MPs, PMPs, TF-MPs, and EMPs positively correlated with disease duration
(p<0.05). In membrane defects the following positive correlation were observed:
CD41+ MPs and PMPs with platelet values and EMPs with LDH (p<0.05 for
all). In PNH, annV APC and CD144+ MPs were positively correlated with retic-
ulocyte counts (p<0.05). In CDAs, the number of annV APC and PMPs nega-
tively correlated with Hb (p<0.05). Finally, the number of annV APC was
increased in PKD compared with controls (p=0.023), and positively correlated
with disease duration (r=0.999, p<0.001); PMPs and TF-MPs were elevated
too, although not significantly. The number of MPs here investigated were com-
parable between splenectomized and not splenectomized, and between naive
and treated cases.
Table 1.
Summary/Conclusions: These preliminary results suggest that MPs levels
are abnormal in both congenital and acquired haemolytic conditions. MPs levels
correlate with the degree of anaemia and haemolysis and with the duration of
disease.
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Background: The population of people aged ≥60 years is growing rapidly. Ane-
mia represents a common condition among the elderly, however its prevalence
and causes are not well known.
Aims: The aim of the study was to evaluate the prevalence, severity and etiol-
ogy of anemia in the population aged ≥60 years. Risk factors for the develop-
ment of anemia including concomitant diseases and treatment, were analysed.
The association between anemia and hospitalization or all-cause mortality dur-
ing follow-up was determined.
Methods: Retrospective analysis was performed on 981 Caucasian, outpatient
patients aged ≥60 in Poland over 2013-2014 (median age 68, range 60-99
years, 60% females). The prevalence of anemia, defined according to WHO
criteria, by gender, age groups (60-69, 70-79, and ≥80) and anemia etiology
were studied. Data on the incidence of common comorbidities (coronary artery
disease, heart failure, diabetes, chronic obstructive pulmonary disease, chronic
kidney disease, chronic liver diseases, cancer, thyroid diseases), hospitaliza-
tion, treatment used and all-cause mortality were analysed.
Results: The prevalence of anemia in the studied population was 17.2% and
was higher in men than women (20.4% vs 15.2%, p=0.038). Anemia was pres-
ent in 10.3% of patients aged 60-69, in 20.1% of those aged 70-79 and in
35.6% of patients ≥ 80 years. Incidence rates of anemia increased significantly
with age (60-69 vs 70-79 years, p<0.001; 60-69 vs ≥80 years, p<0.001, 70-79
vs ≥80 years, p<0.001). Anemia was mild in 69.8% of patients, but a severe
form was found significantly more often among men aged ≥80 years (p=0.03).
Analysis of the etiology of anemia revealed three predominant types: anemia
of chronic disease (33.1%), unexplained anemia (28.4%) and deficiency anemia
(22.5%, including iron deficiency 13%). In comparison to patients without ane-
mia, those with anemia were older (p<0.001), had a higher prevalence of comor-
bidities (p<0.001) and were more often hospitalized (p<0.001). In the multivari-
ate logistic regression model, factors increasing the risk of anemia were: age
≥80 years (OR=2.29; 95%CI 1.19-4.42; p=0.013), the number of comorbidities
(2 diseases OR=2.85; 95%CI 1.12-7.30; p=0.029, 3 diseases OR=6.28; 95%CI
2.22-17.76; p=0.001, 4 diseases OR=4.64; 95%CI 1.27-17.01; p=0.021) and
the number of hospitalizations (OR=1.34; 95%CI 1.13-1.58; p=0.001). At the
end of the 2-yr follow-up, the cumulative survival among patients without anemia
in relation to the group with anemia was 90.76% vs 78.08% and the difference
was statistically significant (p<0.001). In multivariate model, factors that signif-
icantly increased the risk of death in study population were anemia (HR=3.33;
95%CI 1.43-7.74; p=0.005), cancer (HR=3.31; 95%CI 1.47-7.49; p=0.004) and
heart failure (HR=2.94; 95%CI 1.33-6.51; p=0.008).
Summary/Conclusions: In patients ≥60 years the incidence of anemia increas-
es with age and male gender, number of comorbidities and frequency of hos-
pitalization. The high rate of unexplained anemia indicates the necessity for
detailed hematologic diagnosis. The occurrence of anemia among people aged
≥60 years has an adverse impact on survival.
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WHEN THE PHENOTYPE IS BEYOND HAEMOLYTIC ANAEMIA
D. Mota1,*, S. Marini1, T. Nascimento1, P. Bernardo1, L. Relvas1, A. Oliveira1,
E. Cunha1, J. Ribeiro1, C. Bento1, T. Magalhães Maia1, M.L. Ribeiro1
1Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra,
Coimbra, Portugal
Background: Piezo proteins are integral membrane proteins with many trans-
membrane domains broadly expressed, including erythrocytes (RBCs). PIEZO1
proteins play an important role as an osmoreceptor, maintaining RBCs ionic
homeostasis, functioning as a mechanically activated cation channels. Mutated
PIEZO1 proteins have been linked to hereditary xerocytosis (HX), which is
characterized by RBCs dehydration with mild to moderate compensated
haemolytic anaemia and iron overload. As these clinical features are present
in many different clinical conditions, the diagnosis always needs a high level
of suspicion. Nowadays, besides peripheral blood smear (PBS) observation,
molecular analysis, searching for mutations in PIEZO1 gene, became a tool in
the diagnosis of HX.
Aims: Describe 26 patients with HX associated with PIEZO1 mutations belong-
ing to 13 unrelated families, raising awareness of the highly variable phenotype
of this patients, and the need of a highly grade of suspicion along with the mor-
phologic evaluation of the PBS.
Methods: Collection of clinical and laboratory data on our 26 patients with HX
and hyperferritinemia due to 10 different identified mutations in PIEZO1. Sanger
sequencing was used to identify mutations affecting PIEZO1, encoded by
FAM38A gene, and to confirm transmission according to the presence of dis-
ease phenotype. In all patients were excluded other known causes of hyper-
ferritinemia (HF) and haemolytic anaemia.
Results: Of the 26 patients identified as having PIEZO1 mutations, 13 were
probands and 13 were identified by family studies. Median age at diagnosis
was 43 years (1-80), with female predominance (n=14; 53.9%). 4/13 probands
had family history of HX (n=1) or HF (n=2). The common feature of our entire
cohort of patients was the presence of xerocytes in PBS. 13/26 patients had
reticulocytosis with a median reticulocyte count of 101x109/L (28.1-557.3),
18/26 patients have HF with a mean value of ferritin of 556ng/mL (161-6617)
and 9/26 had both. Of the 26 patients, four had splenomegaly and six gallblad-
der lithiasis (5/6 cholecystectomized), two of them have both. Only 5 patients
presented with anaemia (Hb <12g/dL), 2 macrocytic and 3 normocytic. One
patient was microcytic because he also was a β-thalassemia carrier. We detect-
ed heterozygous missense mutations in all 26 patients.
Summary/Conclusions: HX is a dominant disorder of RBCs dehydration pre-
senting a great phenotypic variability. As shown in our cohort of patients, the
anaemia may not be the main feature, in fact, the presence of xerocytes in
PBS and HF were the most frequent characteristics of our patients. We would
like to emphasise that in the genomics era the identification of xerocytes in the
PBS keeps playing an important role for this diagnostic. Not only because,
unlike other haemolytic anaemias, in HX there is a contraindication to splenec-
tomy due to the increased risk of thrombotic events, but also because this
patients present an iron overload that is not proportional to the degree of hemol-
ysis. This iron overload may be related to a defective iron homeostasis depend-
ent on PIEZO1 function not strictly related with Xerocytosis.
E1081
MODELLING PYRUVATE KINASE DEFICIENCY IN HUMAN PROGENITORS
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Background: Pyruvate Kinase Deficiency (PKD) is an autosomal recessive
disorder caused by mutations in the PKLR gene. PKD produces chronic non-
spherocytic hemolytic anemia, which can be fatal during early childhood and
may result in lifelong transfusion dependence that in some instances persists
despite therapeutic splenectomy. Although not considered a standard-of-care,
allogeneic bone marrow transplantation has been curative in a limited number
of cases. These findings, and the evidence that PKLR gene mutations are
likely the sole etiology of the disorder, make PKD a candidate for gene therapy.
We developed a gene therapy strategy in a PKD mouse model using a lentiviral
vector (LV) carrying a codon-optimized version of the PKLR cDNA (coRPK).
This vector has been recently designated as Orphan Drug for the treatment of
PKD by the EMA and FDA (EMA: EU/3/14/1330; FDA: DRU-2016-5168).
Aims: To test the efficacy of the therapeutic LV, we have proposed an alterna-
tive to patient-derived PKD-hematopoietic progenitors. In particular, we have
generated CRISPR/Cas9 system tools to knock-out the PKLR gene in healthy
hematopoietic progenitors from healthy cord blood samples
Methods: Up to six different gRNAs were specifically generated to cleave the
exons 8, 9 and 11 of the PRLR gene. All gRNAs contain at least 3 mismatches
with the coRPK present in the therapeutic LV, to avoid the cleavage of the ther-
apeutic transgene. Two gRNAs cleaved the PKLR gene both in 293T cells and
primary CD34+ cells. In order to identify and select edited cells, Cas9-gRNAs
components were cloned into a Cas9-2A-ZsGreen1 plasmid.
Results: Cord Blood CD34+ cells were electroporated, sorted and differentiated
in vitro along the erythroid lineage. Significantly, the pyruvate kinase activity in
ex vivo differentiated erythroid cells was impaired in gene edited cells as com-
pared to non-edited samples. 
Summary/Conclusions: Gene edit of wt CD34+ progenitors allow us to gen-
erate cells with RPK impaired. The decrease of PK activity validates this
approach as a human model for PKD.
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Background: Dehydrated hereditary stomatocytosis, also called hereditary
xerocytosis (HX) is a dominant non-spherocytic chronic hemolytic anemia char-
acterized by an increased cation leak through the red cell membrane, associ-
ated with dehydration and shortened red cell survival. Clinically, most patients
present a totally compensated hemolysis, with a normal hemoglobin level con-
trasting with a high reticulocytosis. In most cases, HX is caused by missense
mutations activating Piezo1, a mechanosensitive ion channel. However, the
pathophysiology of this compensated hemolysis remains largely unclear.
Aims: We studied the hemoglobin oxygen affinity parameters in HX patients
and in hereditary spherocytosis (HS) subjects as controls.
Methods: Fourteen patients from 5 described and 4 unreported families with
a HX diagnosis and 15 HS subjects were included. Diagnosis was based on
ektacytometry and EMA assay. PIEZO1 and KCNN4 coding regions were ana-
lyzed by Sanger sequencing in all HX patients. Hemoglobin oxygen affinity
was evaluated using p50 measured on venous blood on a Hemoxanalyser or
a Radiometer blood gas analyzer. 2,3 diphosphoglycerate (2,3 DPG) levels
were measured using a commercialized kit and expressed as a molar ratio 2,3
DPG/hemoglobin.
Results: All the 14 HX patients carried one or two missense mutations in
PIEZO1, no gene variation was identified in KCNN4. Five families (9 subjects)
have already been reported, with identified mutations in exon 18, 21, 42 or 51.
Five subjects from 4 new families carried new mutations in exons 14, 16 and
29 and 51 for which bioinformatic softwares showed a high likelihood of path-
ogenicity. For all HX patients, p50 values were under the normal range (mean
21,1, range 19,7-23,4, normal range 25-29 mmHg), contrasting with HS patients
for whom p50 was found to be in the normal range (mean 26,1, range 24,6-
28,8 mmHg). This indicated a significant increase in the hemoglobin affinity for
oxygen restricted to PIEZO1 mutated HX. Of note, p50 was not correlated with
the Hb level (mean 139, range 112-180 g/L in HX patients versus 125, range
93-142 g/L in HS patients). Intracellular red cell 2,3 DPG level could be meas-
ured in 7 HX patients from 4 families, it was found decreased in all of them
(0,43+/-0,06, normal 0,9+/-0,19), providing a pathophysiological basis for the
increased hemoglobin oxygen affinity we observed.
Summary/Conclusions: The increased hemoglobin affinity for oxygen
observed in HX patients reflects the decrease in the 2,3 DPG level. This may
be a consequence of a high ATP requirement and an increased glycolytic activ-
ity in HX red cells at the expense of the 2,3DPG shunt in order to maintain the
cell ion homeostasis. High hemoglobin affinity for oxygen may induce a relative
tissue hypoxia and consequently a high reticulocytosis, providing a clue to
explain the compensated hemolysis frequently observed. However, the links
between PIEZO1 mutations, red cell enzymatic activity and erythropoiesis need
to be clarified and a proteomic and a metabolomic approach is under investi-
gation. Of interest, on a clinical point of view, HX diagnosis is sometimes difficult
and this low p50 value, easily measured on venous blood, represents a useful
new diagnosis tool for HX.
446 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Gene therapy, cellular immunotherapy and
vaccination
E1083
SAFETY AND EFFICACY OF MULTI-PATHOGEN-SPECIFIC T CELLS IN A
HUMANIZED MODEL OF INVASIVE ASPERGILLOSIS: A PROOF OF
CONCEPT STUDY
A. Papadopoulou1,*, K. Koukoulias12, M. Alvanou1, E. Athanasiou1,
N. Savvopoulos1,2, T. Vyzantiadis3, E. Siotou1, M. Gounis1, P. Kaloyannidis4,
M. Yiangou2, A. Anagnostopoulos1, E. Yannaki1
1Gene and Cell Therapy Center- Hematology Dpt- BMT Unit, George Papani-
colaou Hospital, 2School of Biology, Department of Genetics, Development and
Molecular Biology, 3School of Medicine, 1st Department of Microbiology, Aris-
totle University of Thessaloniki, Thessaloniki, Greece, 4Adult Hematology &
Stem cell Transplant, King Fahad Specialist Hospital, Dammam, Saudi Arabia
Background: Viral infections, most commonly by cytomegalovirus (CMV),
Epstein-Barr virus (EBV), polyoma virus type I (BK), and fungal infections, main-
ly by Aspergillus Fumigatus (Asp), are leading causes of transplant-associated
mortality in patients undergoing allogeneic hematopoietic stem cell transplan-
tation. Standard treatment with antiviral and antifungal pharmacological agents,
is often ineffective or toxic and may lead to resistance. Due to these limitations,
adoptive immunotherapy with antigen-specific T cells has emerged as an attrac-
tive alternative. Towards unleashing its full potential and treat multiple viral and
fungal infections by a single T-cell product, we developed a rapid, simplified
and minimally laborious protocol for the generation of multipathogen-specific T
cells (mp-STs) that simultaneously target CMV, EBV, BK and Asp, from healthy
donors. 
Aims: Due to the lack of mouse models recapitulating the clinical condition of
multiple opportunistic infections in transplanted hosts, we here aimed to test
the in vivo safety of produced mp-STs and provide a proof of concept of their
efficacy in a humanized model of invasive aspergillosis (IA).
Methods: mp-STs were generated from healthy donors by pulsing
1.5x107mononuclear cells with viral (CMV: IE1, pp65; EBV: EBNA1, LMP2,
BZLF1; BK: Large T, VP1) and Asp pepmixes (Crf1, Gel1, SHMT) and culturing
for 10 days. The specificity of mp-STs was analyzed by IFN-γ Elispot. A total of
1.5x107of immunomagnetically isolated CD3+cells (donor lymphocyte infu-
sions-DLI) or mp-STs were infused in myelo/immuno-ablated NSG mice which
had been intranasally inoculated with Asp conidia or left uninfected. Mice were
evaluated by a 5-parameter sickness score and at sacrifice, tissues were
assessed by histology and immunohistochemistry.
Results: We generated 23±5x107 cells mp-STs (12-fold expansion). All cell
lines were polyclonal expressing central and effector memory markers and spe-
cific against Asp [spot forming cells (SFC)/2x105cells: 315±82] and the targeted
viruses, if derived from seropositive donors [SFC/2x105cells, CMV: 637±267;
EBV: 744±158; BK: 578±118). To first address the safety issue, we asked
whether mp-STs can induce acute graft-versus-host disease (aGvHD) in
myelo/immuno-ablated mice. While DLI-treated mice developed clinically and
histologically confirmed aGvHD and succumbed by day 20, mp-ST-mice sur-
vived free of aGvHD until the day of sacrifice (d28). To assess the in vivo func-
tionality of mp-STs against IA, conditioned and Asp-inoculated mice, received
mp-STs (n=5), DLI (n=4) or were left untreated (IA control, n=6). All IA- and
DLI-mice succumbed to histologically evidenced IA at a median day 6, whereas
60% of mp-ST-mice survived until sacrifice, at day12. While the day-12 survivors
presented high T-cell engraftment in the lung (% CD3+/CD45+: 14±7) with no
histological evidence of IA, the two mp-ST-non-survivors died from IA in the
absence of T-cell engraftment. Non-specific DLI failed to control IA despite T-
cell presence in 3/4 DLI-mice (%CD3+/CD45+spleen: 58±12, lung: 3±1) which
succumbed early, before aGvHD development. 
Summary/Conclusions: Overall, engrafted mp-STs effectively controlled IA
without evidence of alloreactivity. Based on the robust specificity of our mp-
STs against all targeted pathogens and the clinical efficacy of virus-specific T-
cells, we expect that our “four in one” T-cell product has the potential to also
fight the targeted viruses and become a powerful tool for the treatment of mul-
tiple, life-threatening post-transplant infections.
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DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH HEMATOLOGICAL
MALIGNANCIES LEADS TO DIVERSITY OF LEUKEMIA-ASSOCIATED-
ANTIGENS-SPECIFIC T CELL RESPONSES AND TO REDUCTION IN
REGULATORY T CELL FREQUENCY
S. Hofmann1, M. Schmitt1, M. Götz2, H. Döhner2, M. Wiesneth3, D. Bunjes2,
J. Greiner2,4,*
1Clinic for Internal Medicine V, University of Heidelberg, Heidelberg, 2Clinic for
Internal Medicine III, University of Ulm, 3Institute of Clinical Transfusion Medi-
cine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service
Baden-Württemberg–Hessen and Institute of Transfusion Medicine, Ulm,
4Department of Internal Medicine, Diakonie Klinikum, Stuttgart, Germany
Background: Cytotoxic T-cell (CTL) responses against malignant cells play a
major role in maintaining remission and prolonging overall survival in patients
with hematologic malignancies after allogeneic stem cell transplantation (allo-
SCT) and/or donor lymphocyte infusions (DLI). Graft versus leukemia (GvL)
effects after allogeneic stem cell transplantation and/or DLI are considered to
be T cell-mediated. Many groups described specific T-cell responses against
several leukemiaassociated antigens (LAA) in different hematological malig-
nancies. However, T cell responses after allo-SCT and DLI are not well char-
acterized.
Aims: In this study, we analyzed LAA-specific T cell responses after allo-SCT
and DLI. To this end, we assessed the frequency and diversity of LAA-specific
CD8+ T cells using ELISpot analysis and tetramer assays in 12 patients (5
patients (pts) with acute myeloid leukemia, 2 pts with chronic myeloid leukemia,
3 pts with multiple myeloma and 2 pts with chronic lymphatic leukemia) before
and after DLI. Epitopes derived from PRAME, NPM1mut, RHAMM, WT-1 and
other LAA were tested. Moreover, the frequency of regulatory T (Treg) cells
was measured and the course of cytokine profiles before and after DLI was
analyzed. These immunological findings were correlated to the clinical course
in the respective patients.
Methods: In ELISpot and tetramer assays, an increase in frequency and diver-
sity of LAA-specific T cells was observed in all patients. Cytokine assays using
ELISA for the detection of more than 10 cytokines before and after DLI were
employed.
Results: Importantly, there was a significant increase from 0 to 7 LAA-derived
T cell epitopes (P=0.03) in clinical responders (R) when compared to non-
responders (NR). These positive results in R versus NR where confirmed by
tetramer-based flow cytometry assays, where an increase in frequency from
0.5 to 2.3% in the R group of LAA-specific T cell/all CD8+ T cells was observed.
Interestingly, the frequency of Tregs in clinical responders decreased signifi-
cantly from a median 72,9% to 54,6% (P=0.008) while the frequency of Tregs
stayed stable over time in non-responding patients. T cell subset analysis did
not reveal significant differences before versus after DLI administration. In
cytokine assays using ELISA we found a significant increase of IL-4 after DLI.
Summary/Conclusions: Taken together, we detected an increase of specific
CTL responses against several LAA after allogeneic stem cell transplantation
and donor lymphocyte infusion. Moreover, this study suggests that broader
LAA epitope-specific T cell responses as well as decreasing numbers of Tregs
contribute to clinical outcome of patients treated with DLI.
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GENE-MODIFIED NK-92MI CELLS EXPRESSING A CHIMERIC CD16/CD64-
BB-Ζ RECEPTOR EXHIBIT ENHANCED CANCER-KILLING ABILITY IN
COMBINATION WITH THERAPEUTIC ANTIBODY
Y. Chen1,*, F. You1, J. Li1, X. Tang2, G. An1, H. Meng1, L. Yuan3, L. Yang1
1The Cyrus Tang Hematology Center, 2Department of Hematology, Soochow
University, Suzhou, Jiangsu, 3Department of Hematology, Aerospace Center
Hospital, Beijing, China
Background: Natural killer (NK) cells play a pivotal role in monoclonal anti-
body-mediated immunotherapy through an antibody-dependent cell-mediated
cytotoxicity (ADCC) mechanism. NK-92MI is an interleukin-2 (IL-2)-independent
cell line, which was derived from NK-92 cells with superior cytotoxicity to a
wide range of tumor cells in vitro and in vivo. However, the Fc-receptor (CD16),
which usually mediates ADCC, is absent in NK-92 and NK-92MI cells.
Figure 1. NK-92MIhCD16 and NK-92MIhCD64 functional validation in vitro
and characterization. A. Schematic representation of the CD16-BB-ζ and
the CD64-BB-ζ receptor constructs. B. Exogenous CD16 or CD64 expres-
sion on surfaces of NK-92MI cells are shown. C. Immunoblot analysis of
CD3ζ fusion protein expression in NK-92MIhCD16 or NK-92MIhCD64 cells.
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Aims: To apply NK-92MI cell-based immunotherapy in cancer, we designed
and generated two chimeric receptors which can bind the Fc portion of human
immunoglobulins in NK-92MI cells.
Methods: The construct included the low-affinity Fc receptor CD16 (158F) or
the high-affinity Fc receptor CD64, with the addition of the CD8a extracellular
domain, CD28 transmembrane domains, two costimulatory domains (CD28
and 4-1BB), and the signaling domain from CD3ζ. The resulting chimeric recep-
tors, termed CD16-BB-ζ and CD64-BB-ζ, were utilized to generate chimeric
receptor-modified NK-92MI cells, which were named NK-92MIhCD16 and NK-
92MIhCD64 cells, respectively. 
Results: We found that NK-92MIhCD16 and NK-92MIhCD64 cells significantly
improved cytotoxicity against CD20-positive non-Hodgkin’s lymphoma (NHL)
cells in the presence of rituximab.
Summary/Conclusions: These results suggest that the chimeric receptor-
modified NK-92MI cells could potentially enhance the clinical responses medi-
ated by currently available anticancer monoclonal antibodies (mAbs).
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A NOVEL IN VITRO METHOD TO QUANTIFY THE PHARMACOLOGY
ACTIVITY OF BISPECIFIC ANTIBODIES IN HEMATOLOGICAL SAMPLES
D. Primo1, P. Hernandez1, P. Ghia2, J. de la Serna3,4, J. M. Ribera5, S. Vives5,
J.M. Bergua6, J. Perez de Oteyza7, J. Serrano8, J. Gorrochategui1,
M.L. Vicente1, C. Gomez1, G. Martinelli9, G. Simonetti9, P. Ranghetti10,
L. Scarfo10, D. Martinez-Cuadron11, P. Montesinos11, J. Martinez34,
J. Ballesteros1,*
1ViviaBiotech, Madrid, Spain, 2Strategic Research Program on CLL and B Cell
Neoplasia Unit, Università Vita-Salute San Raffaele and IRCCS Istituto Scien-
tifico San Raffaele, Milan, Italy, 3Hospital Universitario 12 de Octubre, Madrid,
Spain, 4Hospital Universitario 12 de Octubre, Madrid, 5Hospital Universitari
Germans Trias i Pujol, Badalona, 6Hospital San Pedro de Alcántara, Caceres,
7Hospital Universitario Sanchinarro, Madrid, 8Hospital Universitario Reina
Sofía, Cordoba, Spain, 9Department of Experimental, Diagnostic and Specialty
Medicine, University of Bologna Institute of Hematology “L. e A. Seràgnoli,
Bologna, 10Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico
San Raffaele, Milan, Italy, 11Hematology, Hospital Universitari i Politècnic La
Fe de Valencia, Valencia, Spain
Background: The PharmaFlow automated flow platform has achieved 85%
clinical correlation with AML samples with its novel Native Environment assay.
Recently, novel Bi-specific antibodies (BsAbs) or analogous constructions act-
ing through the formation of an immunologic synapse between T-cells (CD3)
and a tumor-associated surface antigen (TAA) have been used as immunother-
apy leading to T-cell activation and serial lysis of tumor cells.
Aims: The aim of the present study is develop and in vitro assay with multiples
variables to better quantify the activity of bispecific antibodies and reflect the
interpatient variability.
Figure 1.
Methods: For this purpose, different fresh whole Bone Marrow (BM) or Periph-
eral Blood (PB) were tested with their corresponding BsAbs at 8 different con-
centrations in different time points (24h-144h). In this sense, we tested 31 AML
BM samples (5 paired BM and PB) with the CD123XCD3 (Creative Biolabs)
and 7 CLL and 3 B-ALL samples with Blinatumumab (Amgen). When appro-
priate, basal quantification of TAA was performed by flow cytometry (FCM).
The PharmaFlow platform efficiently count by FCM how many tumor cells are
killed by every activated T-cells, here called effective E:T ratio. For each sample,
8-colour FCM staining was performed to simultaneously analyze the leukemic
population, activated CD4 and CD8 T-cells and the residual normal cells. EC50
or Emax was calculated to evaluate potency or efficacy. Kinetics of activity was
measured repeating the dose response curves in 3 different days.
Results: Most of the samples present both T-cell activation (CD25+) and an
effective lysis of tumor cells after BsAbs exposure in a time and dose dependent
manner (Figure 1), even starting with low basal E:T ratios (<1:100). For AML,
basal quantification of CD123 by FCM density does not reflect a correlation
with the in vitro response. By contrast, differences in T-cell cytotoxicity or
leukemic immunoresistance were observed between samples in terms of EC50
or Emax, even more marked between CLL samples. The integration of effective
E:T ratios, EC50, Emax, and kinetics allow us to generate an in vitro response
model and select those samples with higher T-cell cytotoxicity after the different
BsAbs exposure. Interestingly, many of the samples for all the BsAbs leave a
significant proportion of live cells, even at the higher BsAb concentrations or
with a remarkable expansion of activated T-cells that suggest the use of
immunecheckpoint to unblock this immnunoresistant status.
Summary/Conclusions: We have developed an automated flow cytometry
assay for bispecific antibodies screening that keep intact both basal effector to
target (E:T) ratios and Native environment using whole blood or bone marrow
samples. In this context, the PharmaFlow platform selects different in vitro T-
cytotoxicity effects across patients identifying best patient candidates for adop-
tive antitumor immunotherapy with BsAbs. The integration of Effective E:T
ratios and pharmacological parameters better predict the in vitro response of
BsAbs. Because of the high capacity of the PharmaFlow platform, additional
antibodies constructions alone or in combinations with immunomodulatory
agents could be tested to identify the better agents or immunotherapeutics
combinations in hematological diseases.
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HUMANIZED CD7 NANOBODY-BASED IMMUNOTOXINS EXHIBIT PROMISING
ANTI-T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA POTENTIAL
Y. Yu1,*, J. Li1, X. Zhu2, X. Tang3, Y. Bao4, Y. Huang1, L. Yuan5, L. Yang1
1The Cyrus Tang Hematology Center, Soochow University, Suzhou, 2Depart-
ment of hematology, The Affiliated Hospital of Nanjing University of Chinese
Medicine, Nanjing, 3Department of Hematology, The First Affiliated Hospital of
Soochow University, Suzhou, 4Binhu Hospital, the First People’s Hospital of
Hefei Group, Hefei, 5Department of Hematology, Aerospace Center Hospital,
Beijing, China
Background: Nanobodies, or named as VHHs, are derived from heavy-chain-
only antibodies that circulate in sera of camelids. Their exceptional physico-
chemical properties, possibility of humanization and unique antigen recognition
properties make them excellent candidates for targeting delivery of biologically
active components, including immunotoxins. In our previous efforts, we have
successfully generated the monovalent and bivalent CD7 nanobody-based
immunotoxins, which can effectively trigger the apoptosis of CD7 positive malig-
nant cells. 
Aims: To pursue the possibility of translating those immunotoxins into clinics,
we humanized the nanobody sequences (designated as dhuVHH6), as well
as further truncated the Pseudomonas exotoxinA (PE) derived PE38 toxin to
produce a more protease-resistant form which is named as PE-LR, by deleting
majority of PE domain II.
Methods: Three new types of immunotoxins, dhuVHH6-PE38, dVHH6-PE-LR,
and dhuVHH6-PE-LR, were successfully constructed. These recombinant
immunotoxins were expressed in E. coli and showed that nanobody immuno-
toxins have the benefits of easy soluble expression in a prokaryotic expression
system. 
Results: Flow cytometry results revealed that all immunotoxins still maintained
the ability to bind specifically to CD7-positive T lymphocyte strains without bind-
ing to CD7-negative control cells. Laser scanning confocal microscopy found
that these proteins can be endocytosed into the cytoplasm after binding with
CD7-positive cells, and that this phenomenon was not observed in CD7-neg-
ative cells. WST-8 experiments showed that all immunotoxins retained the
highly effective and specific growth inhibition activity in CD7-positive cell lines
and primary T-cell acute lymphoblastic leukemia (T-ALL) cells. Further in vivo
animal model experiments showed that humanized dhuVHH6-PE38 immuno-
toxin can tolerate higher doses and extend the survival of NCG mice trans-
planted with CEM cells without any obvious decrease in body weight. Further
studies on NCG mice model with patient-derived T-ALL cells, dhuVHH6-PE38
treatment significantly prolonged mice survival with around 40% survival
improvement. However, it is also noticed that despite dhuVHH6-PE-LR showed
strong anti-tumor effect in vitro, its in vivo anti-tumor efficacy is disappointed. 
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Summary/Conclusions: We have successfully constructed a targeted CD7
molecule modified nanobody (CD7 molecule improved nanobody) immunotoxin
dhuVHH6-PE38 and showed its potential for treating CD7-positive malignant
tumors, especially T-cell acute lymphoblastic leukemia.
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STATINS MAY IMPROVE CAR-NK IMMUNOTHERAPY IN MM BY PREVENTING
LOSS OF BCMA EXPRESSION ON MM CELLS
G. Suñe1,*, L. Perez-Amill1, A. Urbano-Ispizua1, B. Martín-Antonio1
1Hematology, Hospital Clinic/IDIBAPS/Josep Carreras Leukemia Research
Institute, Barcelona, Spain
Background: Chimeric Antigen Receptor (CAR) modified immune cells tar-
geting BCMA against multiple myeloma (MM) has appeared as a feasible
immunotherapy strategy to treat MM patients. However, high doses of CAR
immune cells are required to achieve a response. Cord blood derived NK cells
(CB-NK) is a feasible source of obtain NK cells to modify with a CAR against
BCMA. We previously observed that MM cells exposed to CB-NK are able to
transfer MM proteins, such as BCMA, both to CB-NK and to adjacent MM cells
non-exposed to CB-NK. Furthermore, statins, which are toxic for MM cells, by
altering the lipid composition of tumor cell membrane are involved in cell-cell
communication. We hypothesized that statins could prevent the loss of BCMA
expression which occurs in MM cells after CB-NK exposure, allowing infusing
a lower CAR immune cell dose in MM patients
Aims: To evaluate the effect of statins on MM cell proliferation, on the CB-NK
immune response against MM, and on BCMA expression in MM cells after CB-
NK exposure.
Methods: The cytotoxicity of statins against MM cells was determined in vitro
and in vivo in a murine MM model; furthermore, their impact in CB-NK cytotoxicity
against MM was also determined in vitro. BCMA expression on MM cells after
CB-NK exposure was analyzed by confocal microscopy and by flow cytometry.
FACS sorting experiments were performed to analyze BCMA transfer between
CB-NK exposed MM cells to neighboring non-exposed CB-NK MM cells.
Results: Atorvastatin and Fluvastatin treatment (1µM) decreased MM cell line
(ARP1, RPMI, KMM1) proliferation. No effect was detected for U266 MM cells
and for K562 non-MM cells. In vivo studies, showed that mice treated for three
days I.P with Fluvastatin (1mg/kg) showed significant decreased MM disease
progression. Blocking of BCMA decreased CB-NK cytotoxicity against MM cells.
Furthermore, pretreatment of MM cells with Fluvastatin (3 µM) increased CB-
NK cytotoxicity against all MM cell lines; no impact was observed against K562
non-MM cells. Co-culture experiments showed that, as soon as 30 minutes, CB-
NK exposure led to a BCMA transfer from MM cells to CB-NK and to the extra-
cellular milieu leading to a loss of BCMA expression on MM cells. Fluvastatin
pretreatment prevented loss of BCMA expression. After two days of co-culture,
alive MM cells still showed decreased BCMA surface expression, and surpris-
ingly, increased intracellular BCMA expression. Fluvastatin pretreatment partially
avoided the loss of BCMA surface expression and the increased intracellular
BCMA expression. Furthermore, FACS sorting experiments showed that MM
cells exposed to CB-NK, transferred BCMA to neighboring non-CB-NK exposed
MM cells which was partially inhibited with Fluvastatin pretreatment.
Summary/Conclusions: Our findings show that besides the anti-MM activity
of statins alone, they avoid the loss of BCMA expression on MM cells after
immune cell exposure. Preventing loss of BCMA expression on MM cells might
improve the efficiency of CAR immunotherapy against BCMA, suggesting the
potential of statins as an adjuvant in CAR-NK immunotherapy against MM
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DENDRITIC CELL VACCINATION COMBINED WITH LENALIDOMIDE AND
PROGRAMMED DEATH-1 (PD-1) BLOCKADE HAS SYNERGISTICALLY
INDUCED A MARKED TUMOR REGRESSION IN A MURINE MYELOMA
MODEL
S.-H. Jung1,*, M.-C. Vo2, H.-J. Lee2, T.J. Lakshimi2, S. Yang2, H.-J. Kim1, J.-J. Lee1
1Department of Hematology-Oncology, 2Research Center for Cancer
Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun-Eup,
Korea, Republic Of
Background: There is an emerging evidence that the maximal benefit of den-
dritic cell (DC)-based cancer immunotherapy may be achieved by combination
with other therapies that act to immunomodulation and tumor microenvironment. 
Aims: In this study, we tried to obtain the best efficacy of immunotherapy using
DC vaccination in combination with lenalidomide and PD-1 blockade in a murine
myeloma model.
Methods: After establishing myeloma-bearing mice, five treatment groups were
designed to be a mimic protocol as like treatment in clinics as following: 1) PBS
control, 2) DCs, 3) DCs + lenalidomide, 4) DCs + PD-1 blockade, and 5) DCs
+ lenalidomide + PD-1 blockade. After treatment, preclinical response and in
vitro immunological responses were evaluated.
Results: DCs combined with lenalidomide and PD-1 blockade showed the best
tumor regression among the study groups. These anti-tumor effects have mean-
ingfully related to the decrease of immuno-regulatory populations, such as
myeloid-derived suppressor cells (MDSCs), M2 macrophages, and regulatory
T cells (Treg) and the increase of effector immune cell populations, including
CD4+ and CD8+ T cells, natural killer (NK) cells, and M1 macrophages, accom-
panied with the activation of cytotoxic T lymphocytes (CTLs) and NK cells in
the splenocytes from the treated mice. Moreover, the level of immunosuppres-
sive cytokines, such as TGF-β and IL-10, was significantly reduced in tumor
microenvironment.
Summary/Conclusions: DC vaccination in combination with lenalidomide plus
PD-1 blockade has synergistically induced a strong antitumor immunity by mod-
ulating tumor microenvironment in a murine myeloma model. This protocol will
become a promising translational approach to improve the efficacy of
immunotherapy in the field of MM.
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B- AND T-CELL IMMUNE REPERTOIRE PROFILING WITH ANCHORED
MULTIPLEX PCR AND NEXT-GENERATION SEQUENCING
J. Eberlein1, T. Harrison1, J. Sims2, I. McKittrick1, M. Wemmer1, D. Fugere1,*,
L. Griffin1, B. Culver1, L. Johnson1, B. Kudlow1
1ArcherDX, Boulder, CO, 2Q2 Solutions, EA Genomics, Morrisville, NC, United
States
Background: NGS-based analysis of the immune repertoire (IR) is a powerful
tool to monitor disease, adaptive immune responses to disease, vaccination
and therapeutic interventions. IR characterization by NGS usually requires large
primer panels to cover its extensive combinatorial diversity, and a complex sys-
tem of synthetic controls to account for differential amplification efficiency across
segment combinations. Anchored Multiplex PCR (AMP™) uses molecular bar-
coded (MBC) adapters and gene-specific primers (GSPs), enabling NGS-based
immune chain mRNA interrogation from a single side. This eliminates the need
for opposing primers that bind within the highly variable V-segment, eliminating
clone dropout due to somatic hypermutation.
Aims: Our goal was to develop an NGS assay based on AMP that would enable
IR characterization utilizing a minimal set of unidirectional GSPs and to reduce
amplification bias through the use of MBC adapters.
Methods: Upon developing our AMP-based NGS assay, we validated its quan-
titative reproducibility and sensitivity using mRNA isolated from PBMCs of
healthy donors, B-cell chronic lymphocytic leukemia donors and formalin-fixed
paraffin-embedded (FFPE) tissue.
Results: We developed the AMP-based NGS assays, Immunoverse™ IGH
and TCR, for B-cell and T-cell receptor sequencing, respectively. Both assays
demonstrated high reproducibility between replicates with quantitative clone
tracking down to 0.01%. The ability to determine isotype, clonotype and IGHV
mutational status in a single assay was demonstrated. Preliminary TCR assay
data indicates that CDR3 sequence capture is possible from FFPE tissue with
clonotype calling being driven by input quantity, T-cell content, and, to a lesser
degree, mRNA quality.
Summary/Conclusions: AMP-based NGS with MBC quantification and error-
correction is a powerful method to characterize the immune repertoire.
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SYNERGISTIC ANTITUMOR IMMUNITY BY DENDRITIC CELLS IN
COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN A
MURINE MYELOMA MODEL
S.-H. Jung1,*, S. Yang2, H.-J. Lee2, M.-C. Vo2, T.J. Lakshimi2, H.-J. Kim1,
J.-J. Lee1
1Department of Hematology-Oncology, 2Research Center for Cancer
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Background: Pomalidomide (Pom) plus dexamethasone (Dex) could be con-
sidered one of the new treatment options in patients with relapsed and/or refrac-
tory multiple myeloma (MM). Recently, several diverse agents would be com-
bined to improve the therapeutic efficacy of immunotherapy. 
Aims: In this study, we investigated the preclinical efficacy of combined therapy
with dendritic cells (DCs) and Pom-Dex in a murine myeloma model.
Methods: After establishing myeloma-bearing mice, four treatment groups were
designed to be a mimic protocol as like treatment in clinics as following: 1) PBS
control, 2) DCs, 3) Pom + Dex, and 4) DCs + Pom + Dex. After vaccination,
preclinical and in vitro immunological responses were evaluated.
Results: Among four treatment groups, DC combined with POM and DEXA
strongly inhibited tumor growth, compared with other groups. in vitro immuno-
logical analyses revealed that these enhanced anti-tumor effects were closely
associated with the decrease of regulatory cell populations, such as regulatory
T cells (Tregs) and type 2 macrophages (M2), and the increase of effector cell
populations, including activated CD4 T cells, and type 1 macrophages (M1),
accompanied with the activation of cytotoxic T lymphocytes (CTLs) and natural
killer (NK) cells in the splenocytes from vaccinated mice.
Summary/Conclusions: This study suggested thay DC combined with POM
and DEXA synergistically enhance the anti-tumor immunity in a murine myelo-
ma model, by skewing immuno-suppressive status toward immuno-supprotive
status in tumor microenvironment.
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ALTERATIONS IN T-CELL SUBPOPULATIONS AFTER CO-CULTURING
WITH MSCS DERIVED FROM DIFFERENT DONORS
N. Kapranov1,*, Y. Davydova1, I. Galtseva1, N. Petinati1, N. Drize1, L. Kuzmina1,
E. Parovichnikova1, V. Savchenko1
1Research Center for Hematology of the Ministry of Healthcare of the Russian
Federation, Moscow, Russian Federation
Background: Study of interactions between lymphocytes and mesenchymal
stromal cells (MSCs) in vitro revealed increase of HLA-DR expression on T-
cells after co-cultivation with some MSCs samples. On lymphocytes derived
from one donor the elevation of HLA-DR was observed after co-cultivation with
half of MSCs samples (group A), on the others the HLA-DR expression level
did not change (group B). MSCs were divided into two groups based on HLA-
DR rise on lymphocytes. Study of T-cell subpopulations after interactions with
MSCs could explain ineffectiveness of some MSCs as an immunomodulating
agent in clinical applications.
Aims: The aim of the study was to discriminate variations in T-cell subpopula-
tions, co-cultured with MSCs from two groups.
Methods: MSCs were isolated from bone marrow of 13 donors for allogeneic
hematopoietic cells transplantation and cultured by a standard method. MSCs
were seeded 105 cells per flask, and then 106 allogeneic lymphocytes from
single donor were added to all MSCs cultures. For lymphocytes activation
5mg/ml phytohemagglutinin (PHA) was added to half of these cultures. Lym-
phocytes were removed from MSCs. Than MSCs were removed from the bot-
tom of the flask by trypsin and expression of HLA-DR on their surface was
measured by flow cytometry. Activation markers CD25, CD38, CD69, HLA-DR
and PD-1 were studied by flow cytometry as well as distribution of naïve and
effector T-cells were analyzed on 4th day of cultivation. p<0.05 was considered
statistically significant; all data are presented as medium ± SEM.
Table 1.
Results: Expression of HLA-DR on lymphocytes after 4 days of cultivation
without MSCs did not change compared to 1st day. When lymphocytes were
co-cultured with some MSCs samples expression of HLA-DR was higher. Ele-
vated percentage of HLA-DR positive cells correlates between CD4+ and CD8+
cells (R2=0.932). Thus samples of MSCs were divided into two groups: in group
A proportion of HLA-DR lymphocytes were 3 times greater than in group B.
Subpopulations of lymphocytes co-cultured with MSCs from group A and B
were compared. Subpopulations which significantly differed between groups A
and B are presented in the table. In lymphocytes co-cultured with MSCs there
were higher number of naïve cells compared to control (47.4±3.5% and
54.9±2.0% for group A and B vs 36.9±1.4% for lymphocytes cultured without
MSCs, p<0.001). Group B showed lower number of EM and TM cells. Differ-
ences between groups were more pronounced when lymphocytes were acti-
vated. In group B proportion of HLA-DR CD4+ and CD8+ cells was significantly
lower, compared to group A and control samples. At the same time the number
of CM and PD-1+ CD4+ cells was lower in group B, but number of TE was
increased. Investigation of HLA-DR expression on MSC after co-culturing with
lymphocytes showed higher level of fluorescence signal (MFI) in group A then
in group B (635±130 vs 289±18, р=0,03). These data indicated that MSCs from
group A had become more immunogenic after interaction with lymphocytes
and could not show immunomodulating properties in same way as MSCs from
group B.
Summary/Conclusions: The immunomodulatory properties of MSCs depend
on the donor. This could explain why administration of MSCs is not always
successful. Preliminary study of MSCs prior to their administration may be
used to predict their efficiency in the future.
The materials are supported by grant from the Russian Science Foundation,
Project № 16-15-00102.
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GRANULOCYTE COLONY STIMULATING FACTOR AND ERYTHROPOIETIN
ENTERALLY GIVEN FOR NEONATES RECOVERING FROM GIT SURGERIES:
RANDOMIZED CONTROLLED TRIAL
G. Gad1, R. El-Farrash1,*, H. Abdelkader2, S. Fahmy3
1Pediatrics Department, 2Pediatric Surgery Department, Faculty of Medicine-
Ain Shams University, 3Ministry of Health, Cairo, Egypt
Background: Feeding intolerance is a common problem among neonates
recovering from surgery for congenital abnormalities of the gastrointestinal
tract (GIT) such as small bowel atresia, omphalocele or gastroschisis. Feeding
intolerance is a multifactorial process, but one of the important reasons is con-
genital maldevelopement of the small bowel villi. Disuse atrophy of the small
bowel mucosa following several days of post-operative enteral fasting is one
factor that can contribute to feeding intolerance. The human fetus swallows
over 200 ml/kg/day of amniotic fluid and such swallowing is essential for normal
small bowel development. Growth factors found in the amniotic fluid have been
shown to promote proliferation of fetal intestinal cells. These growth factors
include epidermal growth factor, granulocyte colony stimulating factor (G-CSF)
and erythropoietin (EPO). We postulated that infants recovering from surgeries
for congenital obstructive bowel abnormalities could be provided with physio-
logic quantities of recombinant human G-CSF and EPO by the intermittent oro-
gastric or nasogastric administration of 20 mL/kg/day of sterile isotonic solution
that contained cytokine concentrations comparable to what they would have
ingested from amniotic fluid in utero. 
Aims: is to test a hypothesis suggesting that feeding tolerance could be
improved in neonates recovering from surgeries for congenital obstructive bow-
el abnormalities by enterally administering recombinant human G-CSF and
EPO included within simulated amniotic fluid solution.
Methods: This double-blinded randomized controlled clinical trial was con-
ducted on 40 neonates recovering from GIT surgeries for congenital bowel
abnormalities. Hemodynamically unstable babies, and those with any con-
traindication to enteral feeding were excluded. Neonates were randomly divided
postoperatively into 2 groups; 20 neonates received the test solution (called
Simulated Amniotic Fluid-like solution given Enterally; SAFE); 20 neonates
enterally received distilled water (control). Treatment was started postoperative
and the test solution (or distilled water) was discontinued when enteral intake
reached 100cc/kg/day. Feeding tolerance and adverse effects of treatment (if
any) were assessed.
Results: All the studied neonates tolerated the received solution well without
side effects that could be attributed to its intake. The study group showed better
feeding tolerance as reflected by earlier achievement of 50, 100, 120 and full
enteral feeds with higher enteral caloric intake 7 days after SAFE administration
and higher rate of weight gain (p<0.05). No significant increase was found in
the level of WBCs count, hemoglobin and hematocrit values either pre-initiation
or 7 days after administration of SAFE (p>0.05). 
Summary/Conclusions: This study provides further insights on the improve-
ment of neonatal outcomes and help to decrease morbidities from post-oper-
ative malnutrition and feeding intolerance. Enteral administration of rhG-CSF
and rhEPO may play a critical role in preventing villous atrophy, thereby, reduc-
ing feeding intolerance in neonates recovering from surgeries for congenital
bowel abnormalities.
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GENE EDITING OF HUMAN HEMATOPOIETIC PROGENITORS TO
CORRECT PYRUVATE KINASE DEFICIENCY
S. Fañanas-Baquero1,2,*, I. Orman1,2, A. Gouble3, R. Galetto3, L. Poirot3,
J.A. Bueren12, O. Quintana-Bustamante1,2, J.C. Segovia1,2
1Division of Hematopoietic Innovative Therapies, Centro de Investigaciones
Energéticas Medioambientales y Tecnológicas/Centro de Investigación Bio-
médica en Red de Enfermedades Raras (CIEMAT/CIBERER), 2Advanced
Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz
(IIS-FJD, UAM), Madrid, Spain, 3CELLECTIS, Paris, France
Background: Pyruvate Kinase Deficiency (PKD) is a rare erythroid metabolic
disease caused by mutations in the PKLR gene which encodes the erythroid
specific Pyruvate Kinase (RPK) enzyme. The defective enzyme fails to produce
normal ATP levels and consequently, erythrocytes from PKD patients show an
energetic imbalance and are susceptible to hemolysis. Site-specific hematopoi-
etic stem cell gene therapy would be the safest approach to treat PKD patients.
In this study, different gene editing approaches have been explored to correct
PKD, either by the Knock-in of a PKLR cDNA sequence in the second intron
of the gene, or by the site-specific correction of specific mutations. 
Aims: In the Knock-in system, that previously showed to correct the PKD phe-
notype of PKD-iPSC lines, a recombination matrix carrying codon optimized
exons 3-11 of the PKLR cDNA and a puromycin selection cassette was inserted
in the second intron of the PKLR gene assisted by TALEN nucleases.
Methods: Thus, the therapeutic matrix together with specific TALENs as DNA
plasmid or mRNA, for the second intron of PKLR were electroporated in purified
CD34+ cells from healthy cord bloods. Cells were then expanded and
puromycin selected to enrich the population for gene edited ones. 
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Results: Although a high toxicity and low efficiency were observed with the
electroporation technique used, up to 96% colony forming units showed the
specific integration. Experiments directed to improve efficacy and reduce toxicity
were then conducted. A high percentage of gene edited HPCs were detected
by shortening the cell expansion and puromycin selection periods. Importantly,
gene edited HPCs were detected after infusion in immunodeficient (NSG) mice.
More recently, site-specific correction has been developed aiming at the cor-
rection of PKD patient’s specific mutations. 
Summary/Conclusions: Overall, we showed that gene editing in engraftable
HPCs is feasible, although the efficiency of the procedure should be further
improved prior to consideration of these strategies in the clinic.
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BLAST KINETICS AFTER NON-ENGRAFTING HAPLOIDENTICAL
MICROTRANSPLANTATION IN PATIENTS WITH REFRACTORY ACUTE
MYELOID LEUKEMIA
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University, 3Clinical Hematology Unit, Oncology Center, Mansoura University,
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Background: Multiple trials have showed that granulocyte colony-stimulating
factor (G-CSF) –mobilized donor peripheral-blood stem cells (GPBSCs) based
on allo-graft can be effective in mediating graft-versus-leukemia (GVL) effects
and promote hematologic recovery without triggering of acute GVHD.
Aims: To analyze the safety and efficacy of non-engraftment haploidentical
cellular therapy for patients with refractory acute myeloid leukemia by assess-
ment of bone marrow blast and hematopoietic cells percent kinetics.
Methods: Seven patients (4 males 57.1%, 3 females 42.9%) with refractory
acute myeloid leukemia were enrolled into this Phase I/II study. They were
treated with chemotherapy including fludarabine 30mg/m2, cytarabine 1gm/m2,
etoposide 100mg/m2, endoxan 750mg/m2 followed by infusion of haploidentical
unmanipulated GPBSCs 24 hour after last chemotherapy infusion. Morphologic
assessment of bone marrow blast kinetic by bone marrow aspiration conducted
before therapy, D14 and D30 after therapy. Hematopoietic cells percent kinetics
(Hematologic recovery) was assessed by Complete blood count every day till
Day 40.
Figure 1.
Results: At day +30, 6 patients were evaluable for response and one patient
had died. One patients out of 7 showed PR, then developed CR after a second
microtransplantation and the patient who died showed PR at D14 marrow eval-
uation (8% blast). So collectively objective response rate was 28.6%. The
patient who developed CR was consolidated with an HLA-matched sibling trans-
plant at day +75 from the 1st microtransplantation (day +50 from 2nd micro-
transplantation).Three patients attain neutrophil recovery with median time 29
(range, 13-40) days, while the other four patient did not. Two patients attain
platelet recovery with median time 34.5 (range, 29-40) days, while the other
five patient did not. The cellular therapy did not elicit statistically significant
changes in bone marrow blast% over time, F(2, 10)=1.558, p=.258, partial
η2=.238., with bone marrow blast% decreasing from pre-infusion blast%
(M=60%, SD=22.4%) to D14 blast% (M=39.5%, SD=24.47%) then increased
to D30 blast% (M=54.8, SD=33.5%), in that order. Less than four previous
chemotherapy, fludarabine-free previous chemotherapy and response naïve
patients are the factors associated with good response to microtransplantation.
There was a strong positive correlation between patient age (statistically sig-
nificant), CR1 duration (statistically non-significant) and blast% at D30, r=.842
and .693, p=.036 and p=.307 respectively. There was a moderate negative
non-statistically significant correlation between CD34+ cell dose and blast% at
D30, r=-.498, p=.315.
Summary/Conclusions: The use of G-CSF primed halo-identical microtrans-
plantation appears to be a biologically active therapy in patients with refractory
AML, especially in patients received less than four previous chemotherapy, flu-
darabine-free previous chemotherapy, response naïve and young age patients.
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ALTERATIONS IN T-CELLS SUBPOPULATIONS AFTER CO-CULTIVATION
WITH MULTIPOTENT MESENCHYMAL STROMAL CELLS
Y. Davydova1,*, N. Kapranov1, I. Galtseva1, N. Petinati1, N. Drize1, L. Kuzmina1,
E. Parovichnikova1, V. Savchenko1
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Background: Lymphocyte population depends on immunological state of
organism and varies in different diseases and during treatment. Multipotent
mesenchymal stromal cells (MSCs) are widely used for cell therapy due to their
immunomodulatory properties. Administration of MSCs is not always effective.
Immunomodulatory properties of MSCs could be induced by different cytokines,
e.g. IFN-γ. After injection MSCs interact with activated and non-activated lym-
phocytes. Changes in lymphocytes subpopulations characterize the influence
of MSCs on immunological state.
Aims: The aim of the study was to determine the distribution of naïve and effec-
tor cells in lymphocytes co-cultured with MSCs.
Methods: MSCs were derived from bone marrow of 13 donors (7 male and 6
female aged 22 to 62 years, median 27 years). MSCs were co-cultured with allo-
geneic lymphocytes in a ratio of about 1:10 for 4 days and their basic properties
were analyzed over time. Lymphocytes were activated by adding to the culture
medium 5mg/ml of PHA (PHA-lymphocytes). Some MSCs were treated for 4
hours with 500 U/ml IFN-g (gMSCs). Activation markers CD25, CD38, CD69,
HLA-DR and PD-1 were studied by flow cytometry as well as distribution of naïve
and effector cells were analyzed on 1st, 2nd, 3rd and 4th days of cultivation.
Results: By the fourth day of incubation the proportion of naive CD4+ cells
reduced by 30% (from 47.5±3.0% to 32.8±3.3%) in cultured lymphocytes. It
did not happen in lymphocytes co-cultured with MSCs and gMSCs (p=0.001).
At the same time in cultured lymphocytes to the fourth day the number of CD4+
effector memory cells increased in 1.8 times from 19.5±1.9% to 34.6±4.2%,
which did not occur when co-cultured with both MSCs and gMSCs (p=0.001).
Thus, co-culturing with MSCs or gMSCs prevented naive T-lymphocytes tran-
sition into effector cells. The proportion of CD4+/PD-1+ cells increased from
8.2±1.1% to 10.9±0.7% by the 4th day of cultivation. When co-cultured with
MSCs and gMSCs the proportion of these cells did not change (p=0.0125).
The proportion of HLA-DR+ both on CD4+ and CD8+ cells in lymphocytes
remained unchanged for 4 days. When co-cultured with MSCs and gMSCs for
4 days there was a consistent increase in the proportion of CD4+/HLA-DR+
(6.1±0.7% to 15.6±1.1%, p=0.005) and CD8+/HLA-DR+(from 9.7±0.8% to
26.0±3.7%, p=0.024). So allogeneic MSCs induced peptide presentation on
lymphocytes. The proportion of CD4+ central memory cells increased in PHA-
lymphocytes from 37.4±4.4 at 1st day to 68.2±6.5 at 4th day. MSCs inhibited
this increase - the proportion CD4+ central memory cells increased from
24.4±2.7% to 46.6±4.5% (p=0.047). Thus the interaction of PHA-lymphocytes
with MSCs inhibited their activation and preserved naïve state.
Summary/Conclusions: The composition of lymphocyte population changes
during cultivation. The proportion of naive cells reduced, while the number of
effector cells and the proportion of PD-1+ increased, indicating lymphocyte
activation probably due to the presence of xenogeneic serum in the culture
medium. Co-cultivation with MSCs maintained lymphocytes in not activated
state. The interaction of activated lymphocytes with MSCs inhibits their activa-
tion and preserves naïve state. IFN-γ priming did not enhance MSCs inhibitory
effect on lymphocyte activation. It is shown that MSCs both support naïve lym-
phocyte condition and have an inhibitory effect on their activation.
The materials are supported by grant from the Russian Science Foundation,
Project № 16-15-00102
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OPTIMIZATION OF TRANSDUCTION CONDITIONS WITH GMP LIKE
LENTIVIRAL VECTORS FOR THE GENE THERAPY OF PYRUVATE KINASE
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Background: Pyruvate kinase deficiency (PKD) is an autosomal recessive dis-
order caused by mutations in the PKLR gene. PKD is the most common erythroid
inherited enzymatic defect causing chronic nonspherocytic hemolytic anemia.
PKD is associated with reticulocytosis, splenomegaly and hepatic iron overload,
and may be life-threatening in severely affected patients. To-date, allogeneic
bone marrow transplant represents the only curative treatment for severely
affected patients but has been employed infrequently. Splenectomy confers
reduced transfusion-dependence in many patients, but 10-15% of PKD patients
remain transfusion-dependent despite splenectomy, which confers increased
lifelong susceptibility to systemic infections. Preclinical gene therapy studies
conducted in pyruvate kinase deficient mice have shown the safety and the effi-
cacy of a new CPcoRPKW-17 therapeutic lentiviral vector that has been granted
orphan drug designation (EMA: EU/3/14/1330; FDA: DRU-2016-5168).
haematologica | 2017; 102(s2) | 451
Madrid, Spain, June 22 – 25, 2017
Aims: In order to develop a gene therapy clinical trial for PKD we are optimizing
transduction procedures compatible with a clinical application 
Methods: Using a GMP-grade lentiviral vector production according to manu-
facturing process of the CMO VIVEbioTECH (www.vivebiotech.com) using a
solid phase bioreactor iCLELLis. These viral batches have been tested for
transduction efficiency in healthy cryopreserved cord blood CD34+ cells com-
paring different viral concentration and one or two transduction rounds.
Results: Increased doses of virus concentration revealed, as expected,
increasing levels of transduction that ranged 40-90% both by scoring trans-
duced colony forming units and by flow cytometry analysis in hematopoietic
progenitors maintained for 15 days in liquid culture. Analysis of vector copy
number (VCN) by qPCR ranged from 0.5 to 3 VCN/cell, demonstrating good
transduction efficiency, compatible with a clinical application. Two cycles of
transduction showed an increased level of transduction at limiting concentra-
tions of the viral vector, improving the VCN up to 2-fold. 
Summary/Conclusions: Transduction optimizations are being carried out in
order to reduce the amount of viral vector needed to achieve optimal transduc-
tion efficiencies.
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Background: Multipotent mesenchymal stromal cells (MSCs) are widely used
for cell therapy of autoimmune diseases and graft-versus-host disease. MSCs
have long been reported to be hypoimmunogenic or ‘immune privileged’. The
treatment of MSCs with interferon-g (IFNg) increases their immunomodulating
properties, but induce HLA-DR expression on their surface. When administered
intravenously MSCs interact with activated and non-activated lymphocytes. It
is impossible to follow the fate of MSCs in the recipient’s organism. The only
way to study the changes in the properties of MSCs after intravenous admin-
istration is in vitro model.
Aims: The aim of the study was to investigate the properties of MSCs after
interaction with lymphocytes.
Methods: MSCs were isolated from 13 bone marrow samples used for allo-
geneic hematopoietic cells transplantation and cultured by a standard method.
MSCs were seeded 105 cells per flask and a day later 500 units/mL of IFN-g
were added for 4 hours to half of the cultures (gMSCs). Some cultures were
seeded with 106 allogeneic lymphocytes, to half of these cultures 5mg/ml phy-
tohemagglutinin (PHA) was added for lymphocytes activation (PHA-Lympho-
cytes). For each of the MSCs cultures the mean fluorescent signal intensity
level (MFI) of CD90 PE, CD54 APC, HLA-DR APC was measured. Relative
expression level (REL) of IDO1, CFH, PTGES, IL6, CSF1, ICAM-1 was ana-
lyzed in MSCs by RT-PCR. MFI and REL were investigated on the 1st, 2nd, 3rd
and 4th days of cultivation.
Results: HLA-DR expression on MSCs increased when co-cultured with lym-
phocytes and after IFNg treatment. PHA-lymphocytes induced HLA-DR expres-
sion significantly greater than IFNg licensing. IFNg increased the viability of
MSCs when co-cultured with lymphocytes. Immunomodulating properties of
MSCs were amplified both after IFNg priming and interaction with lymphocytes,
so did not dependent on IFNg source (exogenous or secreted by lymphocytes).
The elevated expression ICAM1 on manipulated MSCs may indicate an
increase in their adhesive properties. IFNg treatment and interaction with lym-
phocytes induced in MSCs the increase in relative expression level (REL) of
factors involved in immunomodulation (IDO1, CFH, PTGES, IL6, CSF1).
Summary/Conclusions: The data suggest that IFNg treatment enhances the
immunomodulatory effects of MSCs in the case of intravenous injection into
the body. Interaction with lymphocytes of the recipient causes the same change
in the properties of MSCs as their pre-treatment of IFNg. However, this treat-
ment stabilizes the MSCs, while maintaining their viability. Based on the results
of this work it can be recommended to use: 1. autologous or obtained from the
donor hematopoietic cells MSCs; 2. the short-term pre-treated with IFNg MSCs
for cell-based therapy for immune modulation in order to increase MSCs sur-
vival.
The materials, supported by grant from the Russian Science Foundation, Proj-
ect № 16-15-00102.
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Background: Hematopoietic stem cells (HSCs) arise from hemogenic
endothelial (HE) precursors between embryonic day 10.5 (E10.5) and E12.5
of murine development, primarily in the aorta-gonad-mesonephros (AGM)
region and the umbilical (UA) and vitelline arteries (VA). The window of spec-
ification of HE has not yet been defined in any mammalian system.
Aims: To determine the precise window of specification of HE hematopoietic
precursors and interrogate at the single cell level their functional heterogeneity.
Methods: Dams pregnant with Cdh5+/ERT2-CreROSA26Confetti/+embryos were
treated with tamoxifen (TAM) at E7.5, E8.5, E9.5, E10.5 or E11.5. Here, TAM
induces the permanent and random labeling of endothelial cells and their prog-
eny with one of the Confetti allele fluorescence reporters (YFP, GFP, CFP or
RFP). The blood of resulting adult Cdh5+/ERT2-CreROSA26Confetti/+offspring
was then examined for the presence of Confetti+ cells by flow cytometry. Clonal
ex vivo assays: VE-Cadherin+CD45- cells, which contain HE, were isolated by
FACS from E9.5, E10.5 or E11.5 embryos and co-cultured at limiting dilution
ex vivo with either OP9 stromal cells (OP9) or AGM-derived endothelial cells
engineered to express Myr-AKT (AA-ECs), which both support hematopoietic
output from HE ex vivo. Co-cultures were scored for hematopoietic colony for-
mation, which were then analyzed for hematopoietic re-plating activity and by
flow cytometry for hematopoietic cell surface markers.
Results: To estimate the temporal window of TAM activity, CD45.2+
ROSA26ERT2-Cre/Confetti bone marrow (BM) cells were transplanted into
CD45.2+CD45.1+ recipients treated with TAM three, two, one or zero days
before transplant. Only the PB of recipients treated on the same day of trans-
plant showed Confetti+cells, indicating that TAM actively labels cells for less
than 24 hours. Analysis of 10 weeks old Cdh5+/ERT2-CreROSA26+/Confetti mice
revealed that only mice exposed to TAM in utero at E8.5 and E9.5 had Confetti+
blood. Thus, specification of HE begins at E8.5 and is complete by E10.5. Next,
E11.5 AGMs isolated from CD45.2+ Cdh5+/ERT2-CreROSA26+/Confetti embryos
exposed to TAM at E10.5 were cultured as explants for three days under con-
ditions that preserve ongoing HSC specification from HE, dissociated, and then
transplanted into CD45.2+CD45.1+ mice. Remarkably, although the CD45.2+
chimerism was high (≈80%) in the blood of recipients, all CD45.2+ blood was
negative for the Confetti label, further indicating that HE recruitment is complete
by E10.5 and cannot be reactivated during explant culture. Limiting dilution co-
culture of E9.5, E10.5, and E11.5 VE-Cadherin+CD45- endothelium revealed
the frequency of functional HE to be 0.1, 1.1 and 0.19% at these time-points,
respectively. Phenotypic analysis of primary hematopoietic colonies revealed
heterogeneity in the hematopoietic output of individual HE, with only 9% of
colonies producing phenotypic HSCs in AA-EC co-cultures. These data suggest
the presence of HE precursors with distinct functional output or the existence
of a continuum of HE at different stages of maturation.
Summary/Conclusions: We have defined the window of mammalian HE spec-
ification. The abrupt loss of ongoing HE recruitment at E10.25 suggests an
active mechanism that terminates this process. We also observed large phe-
notypic and functional variability amongst individual HE precursors examined
throughout ontogeny.
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C-TYPE LECTIN-LIKE RECEPTOR 2 SPECIFIES A FUNCTIONALLY DISTINCT
SUBPOPULATION OF MEGAKARYOCYTE-BIASED LONG-TERM
HEMATOPOIETIC STEM CELLS
T. Kumode1,*, H. Tanaka1, R. Fujiwara1, K. Sano1, K. Serizawa1, Y. Taniguchi1,
S. Rai1, I. Matsumura1
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Background: Recent studies have supported the model in which hematopoi-
etic stem cell (HSC) compartment consists of functionally distinct subsets with
discrete self-renewal and differentiation potentials. However, their immunophe-
notypes and the functional diversities remain poorly understood. We previously
reported that the authentically identified HSC population includes a subset of
cells expressing the C-type lectin-like receptor 2 (CLEC2), which efficiently
give rise to megakaryocyte progenitors (MkPs) and megakaryocytes bypassing
the pathway from common myeloid progenitor (CMP) to megakaryocyte/ery-
throcyte progenitor (MEP) (21th Congress of EHA, # P356, 2016).
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Aims: In this study, we analyzed in vivo dynamics of CLEC2high HSCs to clarify
their functional roles in adult hematopoiesis.
Methods: In this experiment, we defined Lin-Sca1+Kithigh CD150+CD34- cells
as HSCs and Lin-Sca1-Kit+CD150+CD41+ as MkP, respectively. We performed
transplantation assays using HSCs isolated from EGFP transgenic (CAG-
EGFP) mice to trace donor-derived HSCs and their progeny excepting enucle-
ated erythrocytes. In reconstitutional analysis, 5x102EGFP+CLEC2high and
CLEC2low HSCs were transplanted into lethally irradiated mice, respectively.
Chimerism and lineage distribution of donor-derived cells were evaluated peri-
odically by tracing EGFP. Secondary transplantation was performed by trans-
ferring 1x107 BM cells from the recipient mice 16 weeks after the 1st trans-
plantation.
Results: Bone marrow analysis revealed that both EGFP+CLEC2highand
CLEC2low donor-derived HSC populations were detected for up to 12 weeks
after transplantation. Also, these subsets were capable of generating all line-
ages of cells in transplanted mice. Interestingly, CLEC2high HSCs generated
CLEC2low HSCs in the recipient mice as observed in the steady-state BM, and
vice versa. Consistent with these reciprocal transition, both types of HSCs could
effectively reconstituted hematopoiesis in the secondary recipients. However,
CLEC2high HSCs showed significantly reduced repopulating activity than
CLEC2low cells, especially at 12 weeks after transplantation (mean of EGFP+
HSC proportion in the primary recipients with CLEC2high HSCs vs CLEC2low
HSCs (each n=5): 21.1% vs 66.1% at 4 weeks (p=0.054); 2.14% vs 48.3% at
12 weeks (p<0.05). In addition, the recipient mice transplanted with CLEC2low
HSCs kept high chimeric levels of EGFP+ CMP and MEP, while these levels
decreased in the recipients with CLEC2high HSCs. On the other hand,
CLEC2high HSCs yielded 2.8-fold more MkPs than CLEC2low HSCs in short
term grafts (1 to 2 weeks after transplantation) (p<0.05). Consistent with this
finding, CLEC2high HSCs yielded more CD41+ platelets than CLEC2low HSCs
by 6.0-fold at 1 week after transplantation (p<0.05), which peaked 10 weeks
earlier than in CLEC2high-recipient mice. These platelets yielded through the
transient expansion of MkPs were detected at a certain level 12 weeks after
transplantation. Furthermore, treatment with fostamatinib (R788), a Syk kinase
inhibitor that is an indispensable component for CLEC2 signaling, blocked more
potent and rapid megakaryopoiesis in the CLEC2high-recipients, indicating that
CLEC2 signaling is essential for rapid and enhanced megakaryopoiesis from
CLEC2high HSCs.
Summary/Conclusions: Here, we showed that CLEC2 expression on HSCs
demonstrates their oscillation for serving as a potent source of megakary-
opoiesis, and found that CLEC2/Syk signaling would be involved in differential
regulation between CLEC2high and CLEC2low HSC subtypes.
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Background: Poor graft function (PGF) is a serious complication after allo-
geneic hematopoietic stem cell transplantation (allo-HSCT). PGF is defined as
complete donor hematological chimerism with no residual or recurrent leukemia,
but a hypo- or aplastic bone marrow (BM) with 2 or 3 of the following: (1) neu-
trophils ≤0.5×109/L; (2) platelets ≤20×109/L; and/or (3) hemoglobin concentra-
tion ≤70 g/L for at least 3 consecutive days after day +28 post-HSCT. The exact
pathogenesis of PGF remains unclear. Mouse studies suggest that endothelial
progenitor cells (EPCs), one of the major components in BM vascular microen-
vironment, modulate the proliferation, self-renewal and differentiation of
hematopoietic stem cells(HSCs). In this regard, we previously reported that
PGF patients had impaired BM EPCs post-HSCT (BBMT 2013; BMT 2016).
Moreover, we recently reported that the impaired BM EPCs post-HSCT, which
could be quantitatively and functionally improved by atorvastatin in vitro, may
induce the occurrence of PGF (Blood, 2016). However, whether the BM EPCs
in subjects with PGF are impaired pre-HSCT and the reconstitution kinetics of
BM EPCs post-HSCT remains to be elucidated.
Aims: To investigate whether the BM EPCs in subjects with PGF are impaired
pre-HSCT. To compare the reconstitution kinetics of BM EPCs, HSCs and their
ROS levels in subjects with PGF and good graft function (GGF) post-HSCT.
Methods: A total of 115 patients who will receive allo-HSCT were prospectively
recruited and randomly selected as training group (n=32) and validation group
(n=83). The percentage of BM CD45-CD34+VEGFR2+ EPCs, CD34+ HSCs,
and reactive oxygen species (ROS) levels in EPCs and HSCs were evaluated
in all of the enrolled patients pre-HSCT by flow cytometry. Furthermore, 59
patients were monitored for the frequency and ROS levels of BM EPCs and
HSCs at +1, +2 month post-HSCT by flow cytometry. In order to identify risk
factors for PGF, pre-HSCT risk factors with a P<0.10 on univariate logistic
analysis were included in the multivariate logistic regression analysis, and fac-
tors with a P <0.05 were considered independently associated with PGF.
Results: A total of 18 patients including 5 patients in training group (15.63%)
and 13 subjects in validation group (15.67%) developed PGF post-HSCT. Both
in training group and validation group pre-HSCT, significantly reduced percent-
age of BM EPCs were observed in PGF patients than those in GGF patients,
whereas no significant differences were found in the percentage of BM HSCs
between PGF and GGF patients. Meanwhile, similar ROS levels were demon-
strated in BM EPCs and HSCs between PGF and GGF patients. Although there
was no difference in transplanted CD34+ cell dose between the PGF and GGF
groups, significantly lower percentages of BM EPCs and HSCs, whereas
remarkably higher ROS levels were observed in BM EPCs and HSCs in PGF
patients than those in GGF patients at +1 month and +2 month after allo-HSCT.
Moreover, inverse correlations were observed between BM EPCs frequency
and their ROS levels post-HSCT, as well as BM HSCs frequency and their
ROS levels post-HSCT. Multivariate analyses revealed that the reduced BM
EPCs and the disease status pre-HSCT were independent risk factors for the
occurrence of PGF following allo-HSCT.
Summary/Conclusions: We identified that patients with impaired BM EPCs
pre-transplant were at a high risk for the occurrence of PGF post-allotransplant.
Moreover, persistent low percentage and high levels of ROS in post-transplant
BM EPCs may hamper the hematopoietic reconstitution of engrafted donor
HSCs in patients with PGF. Therefore, strategies to repair the impaired BM
EPCs appear to be a promising therapeutic approach in patients with PGF after
allo-HSCT.
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Background: The Warts, Hypogammaglobulinemia, Infections and
Myelokathexis Syndrome (WS) is a rare immunohaematological disorder char-
acterized notably by a chronic lymphopenia. It is mostly caused by inherited
heterozygous autosomal gain-of-function mutations in CXCR4, which engender
a distal truncation in the C-tail domain and lead to a desensitization-resistant
receptor. Given that CXCR4 is widely expressed on non-hematopoietic cells
and virtually on all leukocytes at multiple stages of development, one possibility
could be that the WS-associated peripheral blood lymphopenia is a conse-
quence of skewed production, differentiation or distribution of lymphocytes relat-
ed to altered CXCR4-mediated signaling. Recently, we have been able to repli-
cate the hematologic phenotype of WS using a knock-in mouse strain that har-
bors the WS-linked heterozygous CXCR4S338X mutation causing a distal trun-
cation of the last 15 residues of the C-tail domain (Balabanian et al., Blood,
2012). Mutant mice displayed lymphocytes with enhanced migration to Cxcl12,
phenocopied severe lymphopenia and failed to maintain antibody titers after
immunization (Biajoux et al., Cell Reports, 2016). First-line analyses of +/1013
mice suggested developmental defects at the pro/pre-B cell stage in the bone
marrow (BM) and during the early double-negative stages of thymocyte matu-
ration. However, whether impaired lymphopoiesis stems from an upstream cell-
intrinsic hematopoietic defect remains to be established.
Aims: We took advantage of our relevant knock-in model and the access to
blood samples from WS patients to investigate the impact of CXCR4 desensi-
tization on BM and extra-medullary splenic hematopoiesis and recirculation of
hematopoietic stem and progenitor cells (HSPCs).
Methods: The global hematopoietic development, including quiescence, cycling
and survival properties of HSPCs, was examined in non-manipulated and BM-
chimeric mice using flow-cytometric- and clonogenic-based assays. Cxcr4
expression and function were assessed using internalization, chemotaxis, in
vivo homing and AMD3100-promoted mobilization experiments. Both multipo-
tency and self-renewal abilities of HSPCs have been assessed using serial BM
transplantation experiments. Immunophenotypic and clonogenic analyses of
HSPCs were performed from blood samples of five WS patients and age-, sex-
matched healthy donor volunteers.
Results: We showed that Cxcr4 desensitization is required for quiescence/
cycling balance of murine short-term HSCs and their differentiation into multi-
potent (MPPs) and downstream lymphoid-biased progenitors (i.e. LMPPs and
CLPs). Alteration in this negative feedback mechanism resulted in dramatic
decrease of circulating HSPCs in five patients with WS. This was also evi-
denced in WS mice and mirrored by accumulation of HSPCs in the spleen,
where enhanced extramedullary hematopoiesis occured.
Summary/Conclusions: Efficient Cxcr4 desensitization is critical for the lym-
phoid differentiation of HSPCs and its impairment is a key mechanism under-
pinning the lymphopenia observed in mice and likely in WS patients.
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Background: GATA4 is a transcription factor expressed in mesoderm and
endoderm during development. Members of the family such as GATA1-3, but
not GATA4, are critically involved in hematopoiesis. An enhancer (G2) of the
mouse Gata4 gene directs its expression throughout the lateral mesoderm and
the allantois, beginning at E7.5, becoming restricted to the septum transversum
by E10.5, and disappearing by midgestation (Rojas et al., Development, 2005,
132:3405). Our previous work has shown that inactivation of Gata4 using this
G2Cre driver is lethal by midgestation (Delgado et al., Hepatology, 2014,
59:2358). The anemia observed in the G2Cre;Gata4flox/flox embryos was attrib-
uted to a failure in the expansion of the hematopoietic progenitors in the fetal
liver. Interestingly, a small population of hepatic YFP+ cells from
G2Cre;R26REYFP embryos was positive for leukocyte and megakaryocyte mark-
ers, suggesting that a lineage of hematopoietic cells could derive from GATA4-
expressing progenitors. 
Aims: To study in our murine models the origin and properties of the hematopoi-
etic lineage derived from progenitors expressing GATA4 under control of the
G2 enhancer.
Methods: We analyzed hematopoietic organs of G2-Gata4Cre;R26RYFP mice,
adults and embryos, by flow cytometry, RT-PCR and confocal microscopy.
Cells obtained from different tissues were cultured and transplanted to analyze
in vitro and vivo potential.
Results: YFP+ cells represented about 20% of the hematopoietic system of
adult mice and contributed in the same proportion to the lymphoid, myeloid
and erythroid lineages. Adult YFP+ hematopoietic stem cells (Figure 1) consti-
tuted a long-term repopulating, transplantable population. Fetal YFP+
hematopoietic progenitors were much more abundant in the placenta than in
the aorta-gonad-mesonephros area. These placental YFP+ progenitors were
clonogenic in the MethoCult assay and fully reconstituted hematopoiesis in
myeloablated mice (Cañete et al., Haematologica. doi: 10.3324/haema-
tol.2016.155812. [Epub ahead of print]).
Figure 1.
Summary/Conclusions: A lineage of adult hematopoietic stem cells in mice
is characterized by the expression of GATA4 in their embryonic progenitors
and probably by its extraembryonic (placental) origin. Both lineages basically
showed similar physiological behavior in normal mice, but this finding raises a
number of questions, for example: Does this hematopoietic stem cell subpop-
ulation show a different response in physiopathological conditions? Does this
subpopulation show a differential profile of gene expression? Does a similar
heterogeneity exist in human HSCs? We are currently investigating the tran-
scriptome of the G2-GATA4 linage HSC in order to answer these questions.
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Background: GATA-1 is a hematopoietic zinc-finger transcription factor, which
controls the development of erythrocytes and megakaryocytes. Numerous pro-
teins have been reported to be associated with GATA-1 to alter its activity. Among
them, Friend of GATA-1 (FOG1), a nine-zinc finger protein, is expressed in a tis-
sue-specific pattern that overlaps markedly with that of GATA-1. FOG1 is an
essential coregulator of GATA-1 during hematopoiesis, which mediates transcrip-
tional activation and repression of GATA-1 target genes; yet, the mechanisms by
which FOG1 exerts its activating and repressing functions remain unknown.
Aims: We explored a novel role of FOG1 by forcibly expressing FOG1 in the
human K562 erythroleukemia cells.
Methods: FOG1 mRNA was cloned into Flexi HaloTag vector (Promega) and
pBABE-puro retrovirus vector (Addgene), and FOG1 was overexpressed in
K562 cells. Quantitative ChIP analysis was performed using antibodies against
GATA-1, GATA-2, TAL1, FOG1, histone H3 acetylated-K4 (H3K4ac), H3K9ac,
H3 trimethylated-K4 (H3K4me3), and H3K27me3. PU.1 regulatory element
was cloned into luciferase plasmid (pGL4.10, Promega) and mutation within
the cis-element was introduced using a site-directed mutagenesis kit (Agilent).
TAL1 loss-of-function analysis was conducted with specific siRNA. For tran-
scription profiling, Human Oligo chip 25K (Toray) was used.
Results: Forced FOG1 expression in K562 cells induced the expression of
erythroid genes (HBA, HBB, and SLC4A1), whereas repressed that of GATA-
2, which have been reported to be FOG1-dependent GATA-1-target genes
(Lee et al, Mol Cell 2009). On the other hand, FOG1 overexpression did not
affect the expression of master regulators of erythropoiesis, such as GATA-1
and TAL1. Next, we conducted microarray analysis to comprehensively char-
acterize FOG1-regulated gene ensemble. The analysis demonstrated that 942
and 180 genes were upregulated and downregulated (> 2-fold), respectively,
in the FOG1-overexpressed cells. Noticeably, we found that the expression of
PU.1, known as a myelo-lymphoid-promoting transcription factor, was strongly
downregulated by FOG1 overexpression, indicating that PU.1 is another FOG1-
dependent GATA-1 target. Because GATA-1 ChIP sequencing analysis identi-
fied a GATA-1 peak in the PU.1 promoter (Fujiwara et al, Mol Cell 2009), which
contained evolutionally conserved consensus GATA-binding motif (AGATAG),
we performed a transient luciferase promoter analysis to test whether FOG1-
mediated transcriptional repression of PU.1 could be regulated at the GATA
site located at its promoter. Co-transfection of the FOG1 expression vector sig-
nificantly reduced the promoter activity of PU.1, and this effect was clearly
diminished by disruption of the GATA motif, suggesting that this motif has an
important role in FOG1-mediated transcriptional repression of PU.1. Quantita-
tive ChIP analysis demonstrated increased GATA-1 chromatin occupancy at
both FOG1-activated (globins, SLC4A1) as well as FOG1-repressed (GATA-2,
PU.1) gene loci. However, while TAL1 chromatin occupancy was significantly
increased at FOG1-activated gene loci, it was significantly decreased at FOG1-
repressed gene loci. When FOG1 was overexpressed in TAL1-knocked down
K562 cells, FOG1-mediated activation of HBA, HBG, and SLC4A1 was signif-
icantly compromised by TAL1 knockdown, suggesting that FOG1 may require
TAL1 to activate GATA-1 target genes. To estimate the molecular mechanisms
by which FOG1 confers transcriptional repression, we evaluated the epigenetic
landscape at FOG1-repressed gene loci. Quantitative ChIP analysis demon-
strated that activating marks (H3K4ac, H3K9ac, and H3K4me3) were signifi-
cantly decreased, whereas repressive H3K27me3 was not affected, by FOG1
overexpression.
Summary/Conclusions: Our results provide important mechanistic insight into
the role of FOG1 in the regulation of GATA-1-regulated genes and suggest that
FOG1 has an important role in inducing cells to differentiate toward the erythroid
lineage rather than the myelo-lymphoid one by repressing the expression of
PU.1.
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Background: The stem cell zinc finger 1 (SZF1) / ZNF589 protein, a member
of the family of Krüppel associated box domain-zinc finger (KRAB-ZNF) tran-
scription factors, has an isoform exclusively expressed in CD34+ hematopoietic
stem/progenitor cells (HSPCs), suggesting its role as epigenetic regulator of
specific genes involved in hematopoiesis. The SZF1/ZNF589 gene exhibits a
human-specific evolutionary nucleotide DNA-change leading to a complex
molecular organization and to a protein structure peculiar for humans, as com-
pared to all other primates, potentially conferring human-specific functional
properties. SZF1/ZNF589 has recently been shown to control cell viability in
the hematopoietic system. It is regulated by the HIF-1α hypoxia-induced tran-
scription factor and is differentially expressed in a cytokine-dependent manner
during hypoxia in CD34+ HSPCs (Venturini et al., Exp Hematol 2016; 44: 257-
268). Thus, SZF1/ZNF589 may play a role in the maintenance of hematopoietic
stem cell quiescence and survival, known to be influenced by the hypoxic state
in the bone marrow niche.
Aims: We studied the effects of SZF1/ZNF589 overexpression in vitro and
evaluated its tumor suppressor potential in vivo.
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Methods: K562 (BCR-ABL positive chronic myeloid leukemia in blast crisis)-
Luciferase-control or K562-Luciferase-SZF1/ZNF589 cells were directly injected
into the femurs of NSG mice and tumor development was monitored by biolu-
minescence. Furthermore, K562 cells with or without SZF1/ZNF589 overex-
pression were studied by proliferation assay, cytomorphology, flow cytometry,
cell cycle analysis, cyclin B1 expression and beta-galactosidase assay.
Results: K562-dependent tumor growth was efficiently inhibited in NSG mice
transplanted with K562-Luc-SZF1/ZNF589-cells as compared to mice trans-
planted with K562-Luc-control-cells, leading to significantly prolonged survival,
demonstrating a strong tumor suppressive potential of SZF1/ZNF589 in vivo.
In vitro, overexpression of SZF1/ZNF589 dramatically inhibited proliferation of
K562 cells which, instead of dying, became giant and dysplastic, without other
significant morphological changes and in absence of polyploidy. Cell cycle
analysis revealed a blockade in G2/M phase, with cyclin B1 accumulation char-
acteristic for mitotic arrest. As suggested by morphology and beta-galactosidase
assay, these cells were entering premature senescence.
Summary/Conclusions: SZF1/ZNF589 controls survival of hematopoietic cells
mediated by mitotic arrest and premature senescence, exhibiting tumor sup-
pressing functions in vivo.
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Background: DNA methyltransferase 3A (DNMT3A) plays a pivotal role for de
novo DNA methylation (DNAm) during development. It seems to be of particular
relevance in hematopoietic differentiation because it is frequently mutated in acute
myeloid leukemia or clonal hematopoiesis. So far, it is unclear how DNMT3A gov-
erns the multitude of lineage-specific DNAm patterns – it is conceivable that this
can at least partly be attributed to alternative splicing of DNMT3A.
Aims: In this study, we followed the hypothesis that specific splice variants of
DNMT3A impact on hematopoietic differentiation or DNAm patterns. Therefore
we addressed the role of specific splice variants of DNMT3A in hematopoietic
stem and progenitor cells (HSPCs).
Methods: Expression of DNMT3A splice variants was modulated in HSPCs:
transcript 1+3 (Tr.1+3), transcript 2 (Tr.2), or transcript 4 (Tr.4) of DNMT3A
were either knocked down by short hairpin RNA or constitutively overexpressed
by lentiviral infection. Expression changes were validated by qRT-PCR. Sub-
sequently, we evaluated the impact on colony formation potential (CFU assay),
proliferation (CFSE assay), and the immunophenotype (CD34+ and CD133+).
Global DNAm profiles were generated with the Infinium HumanMethylation450
BeadChip platform and gene expression profiles with the Human Affymetrix
Gene ST1.0 platform.
Results: Downregulation of either Tr.2 or Tr.4 reduced the proliferation rate of
HSPCs significantly (n=3, p<0.05). HSPCs maintained CD34 expression for a
higher number of cell divisions upon knockdown of Tr.2 (n=3; p<0.05). In colony
forming unit (CFU) assays downregulation of Tr.4 resulted in a clear bias
towards erythroid colonies (n=3, p<0.05). Overall, CFU frequency was reduced
by knockdown of DNMT3A transcripts, whereas it was increased by overex-
pression. Subsequently, we analyzed the impact of specific DNMT3A variants
on the DNAm patterns: several CpG sites revealed significant differences in
DNAm levels upon knockdown of Tr.2 and Tr.1+3 (8,905 and 352 CpGs, respec-
tively; n=3, adjusted p-value <0.05). Notably, these patterns were regulated in
the opposite direction upon overexpression of the same transcripts. Knockdown
of Tr.4, which does not have the DNA-methyltransferase domain, did not evoke
significant changes in DNAm. Furthermore, modulation of DNMT3A splice vari-
ants resulted in transcript-specific gene expression changes, which may at
least partly be attributed to the DNAm changes.
Summary/Conclusions: Our results demonstrate that the various splice vari-
ants of DNMT3A have different functional sequel on HSPCs. Knockdown and
overexpression resulted in opposite and transcript-specific DNAm changes.
Thus, alternative splicing of DNMT3A is relevant for site-specific epigenetic
modifications in hematopoietic development.
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Background: Erythropoietin (EPO) is a crucial kidney-derived hormone respon-
sible for erythropoiesis; however, its extra-erythroid effects are substantial and
correlate with EPO receptor (EPO-R) expression in both hematopoietic and
non-hematopoietic tissues. Bone turnover is regulated by the coupled actions
of osteoblasts, the bone-forming cells, and monocyte-derived osteoclasts, which
mediate bone resorption. In this regard, we have recently reported that EPO
directly stimulates bone resorption via activation of EPO-R signaling in the
monocytic lineage (Hiram-Bab et al., 2015). Monocyte differentiation into osteo-
clasts relies on monocyte-macrophage colony-stimulating factor (M-CSF) and
the receptor activator of nuclear factor kappa B ligand (RANKL). B cells are
also known to regulate bone metabolism, chiefly via paracrine signals. Osteo-
clasts and B cells arise from distinct myeloid and lymphoid progenitors, respec-
tively, which are downstream of a common multipotent progenitor cell.
In the bone marrow (BM), Pro-B cells sequentially differentiate into Pre-B and
immature B cells. Whether BM B cells can transdifferentiate into osteoclasts
remains controversial, since osteoclast differentiation from residual monocytic
precursors in the cultures was not excluded in earlier studies.
Aims: We set to determine whether B cells can transdifferentiate to osteoclasts
and to assess the effect of EPO on this process.
Methods: Experiments were conducted on C57BL/6J or CD19-Cre;R26R-EYFP,
8-12-week-old female mice in accordance and with the approval of the Institu-
tional Animal Care and Use Committee of Tel-Aviv University (M-14-043). BM
cells were flushed from femurs, tibias, and pelvic bone and red blood cells were
lysed. Cells were stained with labelled anti-mouse antibodies: PE-B220, FITC-
CD19, PerCP-IgM, PeCy7-CD43, and APC-M-CSF receptor/CD115; and sorted
by flow cytometry. Cells were then cultured in α-MEM containing 10% fetal bovine
serum, M-CSF and RANKL. Multinucleated osteoclasts were stained for tar-
trate-resistant acid phosphatase (TRAP) and pit resorption was assessed.
Figure 1.
Results: B cells isolated from BM of CD19-Cre:R26R-EYFP mice cultured with
M-CSF and RANKL differentiated into TRAP+ multinucleated osteoclasts that
were also positive for EYFP, thus tracing back their B cell origin (Figure 1A).
Next, we dissected which B cell precursor subtype possesses this osteoclas-
togenic capacity and found that only Pro-B (B220+CD19+CD43HighIGM-), but
not Pre-B (B220+CD19+CD43LowIGM-) nor immature B cells (B220+CD19+
CD43-IGM+) could transdifferentiate into osteoclasts (16%±3.7 vs. 0.79%±0.28
and 0.48%±0.13 osteoclasts’ area, respectively). Moreover, among the Pro-B
cells, only those expressing M-CSF receptor (CD115) could transdifferentiate
into functional osteoclasts (18%±6.55 vs. 0.11%±0.05 osteoclasts’ area, respec-
tively, Figure 1B and C). Using an anti-EPO-R specific antibody we detected
EPO-R on the surface of B cells and noted that EPO enhanced the differenti-
ation of the Pro B cells into osteoclasts by as much as 70% (p=0.04) (Figure
1D). Figure 1: Osteoclastogenesis in vitro from sorted B cells. (A) Transd-
ifferentiation of 180,000 cells/well CD19-Cre;R26R-EYFP into osteoclasts.
DRAQ5 (blue) and anti-GFP (green) for CD19-Cre;R26R-EYFP and CD19-Cre
cells. Bottom - TRAP staining. Confocal images (x20 magnification) (B) TRAP
staining of osteoclasts derived from the indicated sorted cells from BM (10,000
cells/well) and cultured with M-CSF and RANKL. Left – Pro-B cells expressing
CD115 (B220+CD19+CD43HighIgM-CD115+). Right – Pro-B cells not expressing
CD115 (B220+CD19+CD43HighIgM-CD115-). Data are mean±SEM of osteoclast
area, n=5 mice in each group; *p<0.05. (C) Pit resorption area from the indicated
sorted cells cultured on calcium phosphate-coated plates. (D) TRAP staining
of osteoclasts derived from sorted Pro-B cells (B220+CD19+CD43HighIgM- cells;
180,000cells/well)±5U/ml EPO, n=7 mice in each group. Data are% osteoclasts
of a representative image; EPO versus Control was 70% increase, p<0.05.
Summary/Conclusions: Taken together, our data suggest a new physio-patho-
logical role for BM B-cell precursors in bone metabolism via their capacity to
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Background: Notch signaling is a highly conserved pathway important in mul-
tiple developmental processes. Canonical signaling through all Notch receptors
converges on the Csl transcription factor recombination signal binding protein
for immunoglobulin kappa J region (Rbpj). In haematopoiesis, Notch is critical
for the emergence of definitive hematopoietic stem cells (HSCs) in the embryo
and in thymic T cell development. Contrastingly, canonical Notch signaling has
been shown to be dispensable for HSC homeostasis in the adult bone marrow
(aBM). Recent studies have however suggested a role of Notch in promoting
megakaryocyte (Mk) and erythroid (E) progenitor cell development as well as
in suppressing granulocyte-macrophage (GM) progenitor expansion and acting
as a tumor-suppressor in myeloid malignancies. However, these findings were
largely made through genetic approaches potentially also affecting regulatory
pathways distinct from canonical Notch signaling.
Aims: To unambiguously investigate the role of canonical Notch signaling in
aBM myelopoiesis, in steady-state and following transplantation.
Methods: B6-SJLCD45.1, Rbpjfl/fl, Mx1-Cre, Vav-Cre and Vwf-eGFP BAC
mice were used. Flow cytometry (FACS) was applied for phenotypic analyses.
Gene expression levels were measured by real-time reverse transcription-
PCR. Mk/E and GM in vitro colony forming potentials were applied in mouse
colony assays. For transplantation study, lethally irradiated recipients were
competitively transplanted (1:1) and reconstitution assessed 7-9 weeks after
transplantation.
Results: FACS staging of GM, Mk and E progenitors in aBM of loxP-flanked
Rbpj mice crossed to both Mx1-Cre and the pan-hematopoietic Vav-Cre strains
was applied. As expected, HSCs were unaffected. Not previously investigated,
FACS analysis of distinct stages of GM, Mk and E progenitors revealed no
defects, at any progenitor stage, in Rbpj-deficient mice. To demonstrate that
this lack of a phenotype was not due to BM cells escaping Rbpj deletion, we
FACS purified HSCs and all GM, Mk and E progenitor stages from Rbpj-defi-
cient mice and verified a virtually complete deletion of Rbpj in all populations.
In further agreement with canonical Notch signaling not being required for
steady-state generation, maintenance or stepwise differentiation of adult GM,
Mk and E progenitors, the number of GM, E and Mk colonies generated from
unfractionated aBM cells as well as circulating platelet counts were also unaf-
fected in Rbpj-deficient mice. We next sought to address whether we could
uncover a role of the Notch pathway in regulation of GM, Mk and E progenitors
by establishing BM chimeras in which Rbpj-deficient progenitors compete with
wild type (WT) progenitors for replenishment and differentiation in lethally irra-
diated recipients. No deficiencies were observed in the replenishment of HSCs
and any stages of GM, Mk and E progenitors in mice competitively transplanted
with Rbpj-deficient as compared to control WT BM cells. Moreover, transplanted
Rbpj-deficient and control progenitors contributed equally well to platelet recon-
stitution. We next investigated whether loss of canonical Notch signaling might
nevertheless impact on expression of genes for key regulators the Mk and E
lineages at distinct progenitor stages for these lineages, as previously impli-
cated. Notably, transcript levels of genes encoding key Mk/E regulators were
unaffected in Rbpj-deficient Mk/E progenitors. In previous studies, expression
of Notch target genes in Mk and E progenitors in aBM has been implicated as
reflecting activation through Notch signaling. However, since the expression
of Notch targets might also be regulated by other pathways besides Notch
pathway, we investigated whether the expression of key Notch target genes
(Hes1, Hes5, Nrarp and Gata3) in Mk/E progenitors in aBM was dependent on
canonical Notch signaling. Neither in HSCs or any Mk/E progenitor was the
expression of these Notch genes negatively affected by Rbpj-deficiency,
demonstrating that their low expression levels in aBM HSCs and Mk/E is inde-
pendent of canonical Notch signaling.
Summary/Conclusions: Studies implicating canonical Notch signaling as a
critical regulator of aBM Mk, E and GM progenitors potentially failed to target
only canonical Notch signaling. Herein, we demonstrate that canonical Notch
signaling is dispensable for generation and replenishment of Mk, E and GM
progenitors in aBM in steady-state as well as following BM transplantation.
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IDENTIFICATION OF NOVEL HUMAN HEMATOPOIETIC STEM CELL
SUBPOPULATIONS VIA COMPREHENSIVE SURFACE MARKER ANALYSIS
T. Jiromaru1,*, K. Miyawaki1, Y. Mori1, H. Iwasaki1, T. Maeda1, K. Akashi1
1Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan
Background: All hematopoietic cells are derived from hematopoietic stem
cells (HSCs), which exhibit capacities for multilineage differentiation and long-
term self-renewal. Human HSCs can be isolated by Fluorescence-activated
cell sorting (FACS) with the combination of several surface markers, such as
CD34, CD38, CD45RA and CD90. The HSC fraction reportedly consists of
functionally heterogeneous subpopulations, including multi-potent and/or line-
age-biased progenitors {Notta:2016hj} and HSC-like populations with reduced
self-renewal capacity {Notta:2011bg}; however, prospective isolation of bona
fide human HSCs is still challenging due, at least in part, to the lack of specific
markers.
Aims: The goal of this study is to identify a novel HSC-specific surface
marker(s) that enables prospective isolation of functionally-distinct HSC sub-
populations.
Methods: We examined expression levels of 342 cell surface markers in the
HSC fraction (Lin-CD34+CD38-CD45RA-CD90+) by FACS using commercial-
ly-available antibodies. Single-cell gene expression profilings of isolated sub-
fractions were performed using Fluidigm C1 system in combination with Bio-
mark. Differentiation potential of each HSC fraction was assessed by single-
cell colony assays in methylcellulose. in vitro lineage tracing in liquid culture
were performed to determine hierarchical relationships among subfractions.
Results: Among 342 cell surface proteins examined, only CD35, CD115 and
CD215 were detected in the HSC fraction. We focused on CD35, which is also
known as complement receptor type 1 (CR1), as its expression was most dis-
tinct among the three markers. CD35-positive population accounted for
15~50% of the human HSCs, defined as Lin-CD34+CD38-CD45RA-CD90+
cells, in adult bone marrow and cord blood. HSCs exhibited multi-lineage recon-
stitution capacity without lineage-biased differentiation in a single-cell colony
assay regardless of the CD35 levels. CD35+HSCs gave rise to CD35-HSCs in
lineage tracing experiments, suggesting that CD35+HSCs reside upstream of
CD35-HSCs in the hierarchy of hematopoietic differentiation. Single-cell gene
expression profiling of CD35-positive or -negative HSCs indicated that
CD35+HSCs, but not CD35-HSCs, are phenotypically homogenous, express-
ing cell cycle-related genes and lineage-specific markers at low levels. 
Summary/Conclusions: Our data suggest that HSCs can be further subdi-
vided into subfractions based on CD35 levels. CD35 might be a useful marker
to prospectively isolate the most primitive human HSC fraction. in vivo functional
assays using xenotransplantaion models are currently underway, and the
results will be discussed at the meeting.
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DEVELOPMENT OF A 3-DIMENSIONAL CULTURE TO MIMICK THE BONE
MARROW MICROENVIRONMENT AND RECAPITULATE DRUG
RESISTANCE FOR IN VITRO STUDY
M. Karimpoor1,*, E. IIlangakoon1, A. Reid2, J. Khorashad2, M. Edirisinghe1
1Biomechanical engineering/Pharmacy, University College London, 2Depart-
ment of Medicine, Imperial College London, London, United Kingdom
Background: Chronic myeloid leukemia (CML) is a haematological malignancy
caused by acquisition of the BCR-ABL1 oncogene. Demonstration of the central
role of BCR-ABL1 kinase activity in CML pathogenesis led to the development
of imatinib, an ABL1-specific tyrosine kinase inhibitor. Most patients on imatinib
attain good clinical and molecular responses, despite the persistent presence
of a low level of therapy-refractory leukaemia stem cells (LSCs), which reside
in the bone marrow niche. However, in a significant minority of patients these
cells eventually provide a reservoir for disease relapse and subsequent malig-
nant progression. A greater understanding of the biology of imatinib-resistant
LSCs could therefore be of significant clinical benefit. One of the proposed
mechanisms of drug resistance in CML LSCs is close contact with the sur-
rounding microenvironment, however an in-vitro model of the bone marrow
matrix is currently lacking.
Aims: Development of a 3-Dimnsional culture using fibre scaffolds to mimick
bone marrow microenvironment in order to study the mechanism of resistance
to anti-leukaemia agents 
Methods: Scaffold production: PMMA solution was prepared by dissolving
PMMA in chloroform and adding appropriate amount of hydroxyapatite to poly-
mer solution followed by pressurized gyration and collection of the PMMA fibres
using a rod - collector. 2 Dimensional (2D) Cell culture: K562 and HL60 cell
lines were cultured and treated with or without imatinib or doxorubicin respec-
tively.3D Cell culture: The same experiment was performed in the presence
of scaffolds. Co-culture of HS-5 with HL60 or K562 cells: GFP+ stromal cells
HS-5 cells were added to PMMA-HA scaffold. K562 and HL60 cells were treat-
ed in the presence or absence of imatinib and doxorubicin in HS-5 cells plus
scaffold environment respectively and were investigated for proliferation and
viability 72h later.
Results: We produced a PMMA-based 3D scaffold and compared the growth
of CML and AML cell lines grown in this scaffold in the presence and absence
of cytotoxic or targeted therapy to that of cells grown in 2D culture. PMMA-HA
scaffold was not toxic to the leukaemia cells as primary AML cells and also
K562 cells grew in the presence of scaffold and also concentrated around the
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fibres. Treatment of K562 or HL60 cells with imatinib or doxorubicin respectively
resulted in a lower level of apoptosis in cells grown on the 3D scaffold compared
to those grown in 2D culture. Further development of this 3D culture by adding
stromal cells HS-5 to the scaffold reduced even further the sensitivity of K562
or HL60 to imatinib or doxorubicin, respectively. 
Figure 1.
Summary/Conclusions: The relative resistance to either imatinib or doxoru-
bicin that we observed in cells grown in 3D culture supports a role for the bone
marrow matrix in the protection of leukaemic cells against chemotherapeutic
agents. A combination of the PMMA-HA with HS-5 cells made this system more
similar to the bone marrow microenvironment as this is a model in which all the
basic components of the bone marrow microenvironment such as scaffold, stro-
mal cells and cytokines (secreted by HS-5) are present. The results of this
study show adding extra complexity to the microenvironment changes the sen-
sitivity of the cells to therapeutic agents, better recapitulating the situation
observed in-vitro. Three dimensional cultures using the PMMA-HA/HS-5 model
may prove useful in the investigation of therapy resistance in leukaemia and
for the discovery of new agents capable of eradicating quiescent leukaemic
stem cells.
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WHOLE EXOME SEQUENCING REVEALED SEQUENTIAL GAIN OF
MUTATIONS IN TWO CASES OF DONOR CELL HAEMATOLOGICAL
MALIGNANCY AFTER HEMATOPOIETIC TRANSPLANTATION
J. Suárez González1,2,*, C. Martínez-Laperche2,3, M. Kwon2,3, G. Rodríguez-
Macías3, A. Figuera4, A. Balas5, N. Martínez6, P. Balsalobre2,3, D. Serrano2,3,
M.Á. Piris6,7, J.L. Vicario5, J. Gayoso2,3, J.L. Díez23, I. Buño1,2,3
1Genomic Unit, Instituto de Investigación Sanitaria Gregorio Marañón y Hospital
General Universitario Gregorio Marañón, 2Instituto de Investigación Sanitaria
Gregorio Marañón, 3Department of Hematology, Hospital General Universitario
Gregorio Marañón, 4Department of Hematology, Hospital de la Princesa,
5Departament of Histocompatibility, Madrid Blood Centre, Madrid, 6Cancer
Genomics, IDIVAL, 7Department of Pathology, Hospital Marqués de Valdecilla,
Santander, Spain
Background: The leukemic transformation of otherwise healthy donor stem
cells provides a useful in vivo model to study the mechanisms involved in leuke-
mogenesis. 
Aims: We report two cases of donor cell derived haematological malignancy
in which whole-exome sequencing (WES) was performed in bone marrow (BM)
samples from recipient at different times after allogeneic hematopoietic stem
cell transplantation (allo-HSCT) in order to study the dynamics of emergence
of mutations that precede the development of donor cell leukemia (DCL) and
donor cell myelodysplastic syndrome (DC-MDS).
Figure 1.
Methods: Case 1: A 43-year-old female diagnosed with lymphoblastic leukemia-
B t(1;19), who developed acute myeloid leukemia (AML) with normal karyotype,
NPM1+of donor origin 16 months after unrelated cord blood transplantation
(UCBT). Case 2: A 65-year-old male diagnosed with mantle cell lymphoma, who
developed MDS 45,XX,-7,del(12)(p12) of donor origin, 57 months after allo-
geneic BM transplantation from his HLA-identical brother. WES (SureSelect-XT
Human-exon 50Mb) was performed by next generation sequencing (Hiseq) on
donor stem cells (SCs) infused as well as on BM samples from recipient after
allo-HSCT. The exome of donor SCs and 5 BM samples, from case 1, were
aligned to the human reference genome (GRCh 37/hg19) and donor SCs and
9 BM samples were aligned to GRCh 38/hg38 in the second case.
Results: WES analysis revealed progressive emergence of multiple somatic
mutations probably related to the development of leukemia in bone marrow
samples post allo-HSCT (Figure 1). Both SCs showed alterations that may be
involved in leukemogenesis. (Case 1: SH2B3 and case 2: KMT2C, KMT2A,
ARHGAP26 and monosomy 7). Somatic mutations, acquired over time, fall into
genes that play well-established roles in signalling pathways. Mutations in
leukemic subclones that disappear after chemotherapy were indentified, as
well as the acquisition of new mutations in resistant subclones. We propose a
possible model of leukemogenesis in these cases (Figure 2).
Summary/Conclusions: The present study reveals a process of sequential
clonal expansions, promoted by the acquisition of additional somatic mutations
in donor hematopoietic cells. Detection of heritable or acquired gene mutations
in donor associated with predisposition to haematological malignancies could
have clinical implications for the patients undergoing to allo-HSCT. Although
the cause of donor cell derived haematological malignancy onset seems to be
multifactorial, the infusion of a SCU with pre-leukemic potential in a context of
residual toxicity in recipient as a result of pre-transplant chemotherapy, a post-
transplant environment characterized by a decreased immune surveillance may
well have played role in these cases. The study of a greater number of DCL
cases by next generation sequencing could help to understand this process
and to detect new mutations involved in the emergence of AML.
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LEUKEMIC STEM CELL-RELATED MRNA EXPRESSION ANALYSIS USING
A NOVEL FLOW CYTOMETRY-BASED ASSAY
B. Depreter1,2,*, K. Vandepoele3, B. De Moerloose4, B. Denys3, J. Philippé1,3,
T. Lammens2
1Department of Clinical Chemistry, Microbiology and Immunology, 2Department
of Paediatric Haematology-Oncology and Stem Cell Transplantation, Ghent
University, 3Department of Laboratory Medicine, 4Department of Paediatric
Haematology-Oncology and Stem Cell Transplantation, Ghent University Hos-
pital, Ghent, Belgium
Background: Gene expression analysis of protein-coding (mRNA) and non-
coding RNA in paediatric and adult acute myeloid leukaemia (AML) has become
of paramount importance for therapeutic decision-making, revealing prognostic
information and for the identification of novel therapeutic targets. AML is a clin-
ically, phenotypically and molecularly heterogeneous haematological malig-
nancy, with different leukemic cell populations organized in a hierarchical fash-
ion, and leukemic stem cells (LSCs) residing at the apex herein. Unfortunately,
gene expression profiling is commonly performed on unfractionated bulk sam-
ples, leading to ‘expression averaging’ of these heterogeneous leukemic cell
populations. Multicolor flow cytometry (FCM) is capable of distinguishing het-
erogeneous cell populations based on the phenotypic characterization at a sin-
gle-cell level. However, fluorochrome-conjugated antibodies are not available
for intracellular RNA targets.
Aims: To evaluate the applicability of a novel flow cytometry-based technique,
PrimeFlow™ RNA assay, to measure cell-of-interest RNA expressions in het-
erogeneous AML samples. 
Methods: Technical assessment was performed using six neuroblastoma cell
lines with varying levels of MYCN gene amplification. Correlation to expression
data obtained by the gold standard RT-qPCR, performance in rare (0.1%) cell
populations, effects of cryopreservation and off-target effects were evaluated.
Next, diagnostic material of de novo AML patients was used to measure target
gene (Wilms’ tumor 1 (WT1)) and reference gene (RPL13a, GAPD) expression.
Expression analysis was performed in unfractionated bulk leukemic cells as
well as blasts and rare subsets of leukemic cells, e.g. LSCs. FCM analyses
were performed on a FACSCanto II (BD Biosciences) with set-up according to
EuroFlow guidelines. Infinicyt™ (Cytognos®) was used for data analysis and
mean fluorescence intensities (MFI) values (with/without normalisation) were
interpreted. P-values < 0.05 were considered significant.
Results: mRNA expression quantified by PrimeFlow™ significantly correlated
with data obtained by RT-qPCR and remained detectable in rare (0.1%) cell
populations. WT1 expression was shown to be statistically significantly higher
in bulk leukemic cells of those patients characterized by WT1 overexpression,
as defined by RT-qPCR, showing a mean 52% MFI upregulation by Prime-
Flow™ if WT1 overexpression was present, as shown by the gold standard
RT-qPCR. Moreover, WT1 overexpression could be detected within heteroge-
neous cell populations, e.g. the CD34+CD38+ cell population and the LSC
(defined as CD34+CD38-), showing a 63% and 45% MFI upregulation, respec-
tively, compared to patients with normal WT1 expression levels, although only
statistically significant in the former population. GAPD and RPL13a expression
differed intra- and interpatient in the bulk (defined as CD34+) and both of the
aforementioned populations. Interestingly, reference gene expression was con-
sistently higher in CD34+/CD38+ cells compared to LSCs.
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Summary/Conclusions: Key mRNA target expressions in AML, e.g. WT1
gene expression, could be evaluated using PrimeFlow™ RNA assay, including
rare and heterogeneous cell populations herein, e.g. LSCs. This study demon-
strates that PrimeFlowTM is a technique of interest for the discovery of novel
LSC-specific targets.
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POTENTIAL PREDISPOSING GERMLINE MUTATIONS IN PATIENTS WITH
CONCOMITANT MYELOID AND LYMPHOID MALIGNANCIES
F. Asmar1,*, M. Munk Johansen1, T.C. El-Galaly2, H.E. Johnsen2, C. Westmose
Yde3, D. El Fassi4, K. Grønbæk1
1Department of Hematology, Rigshospitalet, Copenhagen, 2Department of
Hematology, University hospital of Aalborg, Aalborg, 3Center of Genomic Med-
icine, Rigshospitalet, Copenhagen, 4Department of Hematology, University
Hospital Herlev and Gentofte, Herlev, Denmark
Background: Recent findings have suggested that mutations predisposing
the development of either acute myeloid leukemia (AML) or chronic lymphocytic
leukemia (CLL) may arise in pre-leukemic hematological stem cells. In addition,
genes involved in epigenetic regulation, such as TET2, and RNA processing,
such as SFB31, are mutated in both myeloid and lymphoid malignancies. This
could indicate a possible genetic link between myeloid and lymphoid malig-
nancies. Therapy related AML (t-AML) is a known complication to treatment
with cytotoxic drugs such as alkylating agents and topoisomerase inhibitors.
The susceptibility of developing t-AML has been associated with variation in
DNA-repair pathways, drug metabolism and transport.
Aims: In this study, we aimed to investigate a possible common genetic origin
of hematological cancers in patients with concomitant CLL and de novo AML
or myelodysplastic syndrome (MDS) and in patients with concomitant therapy-
related AML (t-AML) and CLL.
Methods: The presence of concomitant lymphoid and myeloid malignancies
in patients is rare, however we managed to include 3 patients with de novo
AML and CLL, one patient with MDS and CLL, one patient with chronic
myelomonocytic leukemia(CMML) and CLL, and two patients with t-AML and
CLL. The patients’ diagnoses were based on the evaluation of the morhophol-
ogy, immunohistochemsitry, cytogenetics, and flowcytometry analysis in accor-
dance to the WHO classification. For each patient mononuclear cells (MNCs)
from blood or bone marrow were isolated using Ficoll gradient centrifugation
and used for fluorescence activated cell sorting (FACS) of the malignant clones
and the T-cells. Paired end exome sequencing (2x150) aiming for an average
coverage of 50-100x was performed using either the HiSeq2500 or NextSeq500
platforms from Illumina. Raw sequencing data was processed using CASAVA-
1.8.2. Mapping to the human genome (hg19/GRCh37 UCSC) was performed
using CLC Biomedical Genomics Workbench (Qiagen) mapping cell software.
Variants with a frequency of 5% or above were called.
Results: We identified possible pre-disposing germline mutations in all 7
patients by comparing variants between the myeloid malignant clone, CLL
cells, and T cells, as well as using saliva to aid in characterizing the mutations
as either germline or only present in the hematological compartment. In all the
patients except one with de novo AML and CLL, we identified a potential dam-
aging germline variant in a DNA-repair related gene, such as ATM (387dupA,
D130fs*4), SMARCAL1 (2114C>T, T705I), HELQ (393_397delAGGTG,
G132fs*16), SWI5 (652C>T, R218*), LIG1(2168A>G, Q761R) and
PRKDC(902G>A, C301Y). In the remaining patient with concomitant de novo
AML and CLL, we identified a potential damaging germline variant in an epi-
genetic regulator believed to play a role in normal and malignant hematopoiesis,
KDM2B(44delC, P15fs*92). Furthermore, we identified the somatic mutational
landscapes of the malignant clones using T-cells as germline tissue for the
patients with concomitant de novo AML/MDS/CMML and CLL and for the two
patients with t-AML and CLL. The somatic mutational landscapes of the malig-
nant clones in the de novo concomitant cases and the cases with CLL and t-
AML were quite similar to what has previously been reported in isolated cases
of disease. The myeloid and lymphoid malignant clones did not share any of
the mutations, indicating development of two independent malignancies.
Summary/Conclusions: Our results suggest a possible role of germline vari-
ations in the susceptibility to development of concomitant de novo hematolog-
ical cancers as well as t-AML. However, further studies including more patients
are needed to confirm this hypothesis.
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THE MUTATIONAL LANDSCAPE OF DNMT3A MUTATIONS IN CLONAL
HAEMATOPOIESIS OF INDETERMINATE POTENTIAL. CHIPPING AWAY
AT THE PROBLEM
S. Chaudry1,*, T. Chevassut1
1Brighton and Sussex Medical School, Brighton, United Kingdom
Background: Dysfunction of epigenetic modifiers contributes significantly to
the pathogenesis of acute myeloid leukaemia (AML). One frequently mutated
gene involved in epigenetic modification is DNMT3A (DNA methyltransferase-
3-alpha). Approximately 22% of de-novo AML and 36% of cytogenetically nor-
mal AML are found to have DNMT3A mutations and around 60% of these muta-
tions affect the R882 codon. In particular, the R882H mutation has been asso-
ciated with a poor prognosis and survival outcomes for patients. A large number
of DNMT3A mutations are present in clonal cells in healthy individuals with no
characteristics of haematological malignancy and is termed as clonal
haematopoiesis of indeterminate potential (CHIP).
Figure 1.
Aims: We aimed to compare here the locations and types of mutations iden-
tified in AML and in CHIP in the DNMT3A gene by several different studies.
Methods: To review the mutations found in CHIP and AML, we carried out an
extensive literature search of CHIP studies and AML studies that had mapped
a large number of mutations in this gene. Mutations were collated to form sev-
eral diagrams illustrating and comparing these findings.
Results: When DNMT3A mutations in CHIP were compared to mutations in
AML the R882 residue was still found to be the most frequently mutated residue
in both CHIP and AML. Figure 1 clearly illustrates the mutations in comparison
to AML. However, only 13% of all reported mutations were found at the R882
residue in CHIP, while in AML 60% DNMT3A mutations are found at the R882H
mutations.
Summary/Conclusions: Analysis of the mutational landscape of CHIP has
clearly highlighted the role of DNMT3A mutations in clonal haematopoiesis in
older healthy individuals, the significance of such preleukaemic clones is yet
to be determined.
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NEXT-GENERATION REFERENCE INTERVALS FOR PEDIATRIC
HEMATOLOGY
J. Zierk1,*, J. Hirschmann2, D. Toddenroth2, F. Arzideh3, T. Streichert4,
R. Haeckel5, H.-U. Prokosch2, M. Rauh1, M. Metzler1
1Department of Pediatrics and Adolescent Medicine, University Hospital Erlan-
gen, 2Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-
Nuremberg, Erlangen, 3Department of Statistics, University of Bremen, Bre-
men, 4Department of Clinical Chemistry, University Hospital of Cologne,
Cologne, 5Bremer Zentrum für Laboratoriumsmedizin, Klinikum Bremen Mitte,
Bremen, Germany
Background: Interpretation of hematology analytes in children is challenging
due to extensive changes in hematopoiesis with age leading to pronounced
sex- and age-specific dynamics. To facilitate clinical decision making based on
quantitative hematology test results, reference intervals are used to classify
samples according to upper and lower limits, and age-related change is rep-
resented using reference intervals partitioned into separate age groups. How-
ever, this approach can only approximate the continuous physiological dynam-
ics of hematological analytes in childhood and does not enable appropriate
quantification of test results in relation to the reference distribution. Conversely,
percentile charts as used in anthropometric quantities (e.g. pediatric weight-
for-age charts) would allow adequate appreciation of pediatric hematology test
results. However, the ethical and practical challenges unique to pediatric ref-
erence intervals have restricted the creation of such percentile charts, and lim-
itations in current approaches to laboratory test result display prevent their
integration into clinical decision making.
Aims: To create percentile charts for hematology analytes from birth to adult-
hood using a data-mining approach and to demonstrate their integration into
clinical care with benefits in clinical decision making.
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Figure 1.
Methods: We applied a data-mining algorithm to generate percentile charts
for hematology analytes using laboratory data collected during the clinical care
of patients. A total of 9,517,245 samples from 343,463 patients (72,614–337,011
samples per analyte) from 8 German tertiary care centers and 2 German lab-
oratory service providers were examined. Percentile charts were calculated
using an established statistical approach which extracts the proportion of sam-
ples from healthy individuals from the unfiltered input dataset containing both
non-pathologic and pathologic samples. To evaluate the clinical benefit of hema-
tology test result interpretation using percentile charts, accuracy and speed of
pediatricians assessing eight different predefined clinical situations were meas-
ured in comparison to conventional test result representations.
Results: We created percentile charts for hematology analytes in girls and
boys from birth to 18 years which can be used as common reference intervals.
Results are provided for hemoglobin, hematocrit, red cell indices, red cell count,
red cell distribution width, white cell count, and platelet count, example charts
for hemoglobin, mean corpuscular volume, and platelet count are shown in the
accompanying figure. A web application at www.pedref.org/hematology demon-
strates hematology test result interpretation using percentile charts and z-scores
with special consideration of pediatric dynamics. Comparison of pediatricians’
decision times when assessing different clinical scenarios using percentile
charts and conventional representations shows more correct decisions (75.9%
vs 68.4%, p<0.01) which are made in shorter time (2.7 s vs 3.8 s, p<0.01) when
using percentile charts.
Summary/Conclusions: The created percentile charts enable the appropriate
differential diagnosis of changes in hematology analytes due to disease and
changes due to physiological development. Integration of suitable forms of
result reporting using the provided percentile charts into clinical decision making
improves assessment of the unique dynamics in pediatric hematology.
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GROWTH FACTOR INDEPENDENCE 1 (GFI1) REGULATES THE AML
SUPPORTING FUNCTION OF MESENCHYMAL STROMAL CELLS
Y. Al-Matary1,*, L. Botezatu 1, A. Thivakaran 1, R. Köster1, J. Schütte 1,
J. Göthert 1, U. Dührsen1, B. Opalka1, C. Khandanpour1
1University Hospital of Essen/ West centre of tumor, Essen, Germany
Background: Mesenchymal stromal cells (MSCs) harbor and support the func-
tion of normal hematopoietic stem cells. Less is known about their interaction
with leukemic cells, e.g. in acute myeloid leukemia (AML). The prognosis of
AML, a clonal malignant disease of the bone marrow (BM), is still poor with
only 25% of patients living longer than 5 years.
Aims: In the current study, we investigated the interaction between MSCs and
AML cells. and we also investigated the underlying molecular mechanism.
Methods: We used cell cultures using primary cells from human and mice and
cell lines of MSCs and AML cells. Different Mouse models of human AML were
used in our study to confirm the results obtained from human sample. MSCs
were characterized by differentiation assay, flow cytometry and RT-PCR.
Matrigel test was also applied in this study.
Results: MSCs from AML patients called AML-associated MSCs (AMSCs) or
from murine models of human leukemia enhance significantly in vitro the growth
of leukemic cells compared to AML cells growing without MSCs or in presence
of MSCs from non-leukemic patients or mice. Among other, AMSCs increased
entry of leukemic cells into the cell cycle, and at the same time protected the
leukemia cells against exogenous toxic events such as chemotherapy or irra-
diation. The interaction between AMSCs and leukemia cells is dependent on
cell-to-cell contact. In vivo, absolute and relative numbers of AMSCs and other
stromal cells, i.e. endothelial cells and osteoblast lineage cells were highly
expanded in the BM of mice modeling of human AML. AMSCs showed a higher
efficiency of capillary tube formation in the matrigel assay than normal MSCs
which gives an additional indication that AMSCs were polarized by leukemia
cells towards a tumor-supporting state. On a molecular level, the polarization
of MSCs towards an AML-supporting state depends on upregulated expression
of the transcription factor Growth factor independence 1 (Gfi1). Loss of Gfi1
diminished the tumor-supporting state of AML-associated MSCs. 
Summary/Conclusions: We conclude that leukemia cells polarize AMSCs
towards a leukemia-supporting state in a Gfi1-dependent manner, which could
open the way to new therapeutic approaches.
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BASELINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME
IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
PATIENTS TREATED WITH PD1 INHIBITION
I. Hude1,2,*, S. Sasse2, P.J. Broeckelmann2, B. von Tresckow2, J. Momotow2,
A. Engert2, S. Borchmann2
1Department of Internal Medicine, Division of Hematology, University Hospital
Center Zagreb, Zagreb, Croatia, 2German Hodgkin Study Group (GHSG), First
Department of Internal Medicine, University Hospital Cologne, Cologne, Ger-
many
Background: Despite encouraging efficacy of anti-PD1 antibodies in relapsed
or refractory (r/r) classical Hodgkin lymphoma (cHL), not all patients achieve a
lasting response, with few complete remissions (CR) observed. Thus, identifi-
cation of predictive biomarkers is important. Recently, two models using readily
available differential blood count parameters have been suggested to predict
outcome in melanoma patients treated with immune checkpoint inhibition. 
Aims: In this study, we aimed to identify baseline differential blood count param-
eters associated with response and progression free survival (PFS) in r/r cHL
patients treated with anti-PD1 antibody nivolumab.
Methods: We retrospectively investigated baseline differential blood count
parameters and their association with response and progression free survival
(PFS) in 30 r/r cHL patients treated with the anti-PD1 antibody nivolumab. All
30 patients had previously received multiple lines of treatment, including treat-
ment with high dose chemotherapy followed by autologous stem cell transplant
(ASCT) for r/r disease; the median number of prior treatment lines was 5 (2-
11) and 21 patients received prior brentuximab vedotin. To investigate the asso-
ciation of baseline blood count parameters (white blood cell count (WBC), rel-
ative monocyte count (RMC), relative neutrophil count (RNC), relative lympho-
cyte count (RLC) and relative eosinophil count (REC)) with outcome after PD1
inhibition, we used the last differential blood count performed immediately prior
to the first received dose of nivolumab.
Results: RMC, RNC and RLC did not have a prognostic impact on PFS, where-
as higher WBC ≥ 7.78x10³/µl and lower REC<1.7% were associated with worse
PFS in both univariate and multivariate analysis. We constructed a simple
score to prognosticate PFS. By adding 1 point each for WBC ≥ 7.78x10³/µl
and REC<1.7% to the score, we could clearly differentiate a low (score=0),
intermediate (score=1) and high risk (score=2) group for disease progression
(p<0.001). Only one PFS event occurred in the best prognostic group (n=10,
median PFS (days): NA]) whereas 5 out of 11 patients in intermediate (median
PFS (days): 365 [129-NA]) and 7 out of 9 patients in high risk group progressed
(median PFS (days): 197 [50-NA]). Evaluation of best response achieved
according to the initial risk score showed a trend towards higher CR-rates in
low risk group, but was not significant.
Figure 1.
Summary/Conclusions: Our simple prognostic model, mainly characterized
by a normal to high REC, robustly discriminates three risk groups for PFS.
Almost all patients in the low risk group achieved a durable remission without
disease progression throughout the study period, despite often achieving just
a partial response. In contrast, high-risk patients often progressed quickly
despite initially achieving a partial or complete response. Further validation of
this score which is easily available from routine clinical parameters in a larger
cohort of patients and further investigation of its potential predictive impact is
needed. Moreover, efforts to clearly understand a possible mechanistic role of
eosinophils in cHL patients treated with PD1-inhibiton are warranted.
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Background: The prognosis of HL primarily depends on clinical stage (CS) as
well as limited-stage risk classification schemes and the International Prog-
nostic Score (IPS), both of which delineate further prognostic subgroups within
stages. B2m is a well-established prognostic factor for several hematologic
malignancies, but its role in HL is yet controversial. Between 1993 and 2016,
several reports from other groups have yielded heterogenous results in small-
to-medium-sized patient series of no more than 220 patients, frequently under
variable treatment.
Aims: Our aim was to investigate the prognostic significance of serum b2m
levels in HL.
Methods: We analyzed 864 patients with HL treated with ABVDeq CT/CMT
(1990-2016) and selected solely based on the availability of pretreatment b2m
levels. B2m [P1] levels (upper normal limit 2.4mg/L) were analyzed according
to other baseline features and prognostic factors as well as according to the
outcome: Freedom From Progression (FFP) was defined as time between
treatment initiation and treatment failure (primary refractoriness, PR with switch
to alternative CT or relapse); deaths of unrelated causes were censored. Over-
all Survival (OS) was measured from treatment initiation to death of any cause.
ROC curves and sequential cut-offs (1.8-3.5 by 0.1 increments) were used to
explore the potential impact of b2m on FFP and OS.
Results: The median follow-up for currently living patients was 88 months.
Univariate Analysis: FFP was significantly inferior in patients with higher b2m
at all tested cut-off points. At 2.4mg/L (normal versus elevated) the 10-year
FFP was 81% vs 71% (p=0.003). However, the best cut-off was the observed
median value of this series, calculated at 2.1mg/L, with 10-year FFP rates of
84% vs 71% (p<0.0001). In early stages (IA/IIA) significant results were
obtained at cut-offs between 1.8 and 2.1mg/L. The best cut-off was 1.9mg/L,
a close approximation of the median b2m level of early stage patients, with 10-
year FFP of 89% vs 78% (p=0.003). In advanced stages, none of the cut-offs
yielded statistically significant results (borderline at 2.0mg/L; 10-year FFP 77%
vs 67%, p=0.057). Multivariate Analysis: B 2m levels remained significant for
FFP after adjustment for IPS factors, ESR and B-symptoms at both 2.1mg/L
and 2.4mg/L cut-offs [hazard ratio (HR) 1.78, p=0.001 and 1.41, p=0.04 respec-
tively) in the whole series of 864 patients. In early stages, b2m was a significant
predictor of FFP at the cut-offs of 1.9mg/L and 2.1mg/L (HR 2.00, p=0.01 and
1.83, p=0.02 respectively), but only borderline at the cut-off of 2.4mg/L (HR
1.65, p=0.07). In advanced stages, b2m emerged as an independent prognostic
factor for FFP at the cut-off of 2.2mg/L (HR 1.59, p=0.046 despite the lack of
significance in univariate analysis), but was not significant at the 2.4mg/L cut-
off. The 10-year OS was lower in patients with high b2m levels (10-year rates
91% vs 76%, p<0.0001).
Summary/Conclusions: Higher serum b2m emerged as a significant inde-
pendent predictor of FFP at the cutoff of 2.0mg/L for the whole series and
1.9mg/L for early-stage patients. The prognostic significance in advanced
stages was weaker (best cut-off 2.2mg/L). Serum b2m was also highly predic-
tive of OS. This is by far the largest report on the prognostic significance of
b2m in HL, highlighting the significance of the cut-off used to define “high”
levels. Its significance is more pronounced in early stage disease. The optimal
cut-off for the evaluation of serum b2m in HL may be stage-dependent and
appear to lie between 1.9 and 2.2mg/L, thus performing better than a “normal
versus high” evaluation (cut-off 2.4mg/L). 
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Background: Hodgkin lymphoma (HL), a disease of mostly young patients,
also peaks in the elderly. Despite the profound improvement in the clinical out-
come of young patients, in the elderly, 5 year overall survival (OS) is estimated
at only 40-55%. Interim PET-CT (iPET), known to be highly predictive for pro-
gression free survival (PFS) in young patients with HL, has not been sufficiently
validated in elderly patients, nor have many other outcome predictors in HL of
the elderly.
Aims: The objective of the present study was to evaluate the significance of
iPET in elderly patients with HL.
Methods: All consecutive patients (age ≥60) diagnosed with HL between 1998-
2016 were retrospectively reviewed in this multi-center study. Baseline charac-
teristics as well as PET-CT results at diagnosis, interim analysis and end of
treatment (EOT) were recorded and analyzed. PET-CT results were classified
as no evidence of disease (NED), partial response (PR), stable disease (SD)
and progressive disease (PD).
Results: Ninety five patients from 5 centers were identified. Median age was
71 (range 60-89) years. Subtype was nodular sclerosis in 48% and mixed cel-
lularity in 23%. Sixty three (69%) patients had advanced disease and mean
international prognostic score (IPS) was 3.5±1.4. Fifty nine (63%) patients
received first line treatment with ABVD, in 13 (14%) chemotherapy was followed
by involved field radiotherapy. At EOT, sixty seven (82%) patients achieved
CR, 6 (7%) achieved PR, 10 (11%) were primary refractory and 2 (2%) died
during treatment. Fifteen (16%) patients experienced relapse. Five year PFS
and OS were 56% and 78%, respectively. ABVD treated patients had 5 year
PFS and OS of 59% and 82% as opposed to 48% and 68% for all other regi-
mens, but these differences were not statistically significant. Seventy two (76%)
patients had undergone both iPET and EOT-PET. 50 patients had NED on
iPET, 20 had PR, 1 SD and 1 PD. NED EOT-PET was achieved in 47/50 (94%)
patients who had NED iPET, 12/20 (60%) patients who had PR iPET and none
of the patients with SD/PD iPET (p<0.01). In patients with either NED or PR on
iPET, relapse occurred in 11 (15%) patients and 5 year PFS and OS were 62%
and 85%, respectively. The 5 year PFS of these patients differed according to
the depth of response on iPET - 69% vs 45%, (p=0.02, fig.1) in patients achiev-
ing NED vs PR, while 5 year OS did not reach statistical significance, 90% vs
71% (p=0.08). Restricted analysis, evaluating only 59 patients who were treated
with ABVD, showed similar results with 94% of NED iPET vs 45% of PR iPET
achieving NED on EOT-PET (p<0.01). Outcome differed according to the depth
of response in iPET with 5 year PFS rates of 74% vs 34%, in patients achieving
NED vs PR, respectively (p<0.01). 5 year OS rates were 92% vs 76%, in
patients achieving NED vs PR (p=0.1).
Figure 1.
Summary/Conclusions: We present a cohort of elderly patients with HL, most
were treated with ABVD. Outcome was comparable or even superior to previ-
ously published cohorts. Traditional outcome measures for HL have not been
extensively validated in the elderly. iPET and EOT-PET, known to be highly
predictive for PFS in young HL patients, appeared to be highly predictive in
elderly individuals. The improved prognosis, suggested by our results, may be
related to the high rate of iPET which was used in this cohort. The importance
of this tool in HL in the elderly is emphasized by the diminished prediction power
of the traditional outcome measures in elderly HL patients.
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HIGH-DOSE BENDAMUSTINE PLUS BRENTUXIMAB COMBINATION IS
EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREAT-
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Background: The management of patients with refractory or relapsed Hodgkin
lymphoma (HL), especially after autologous stem cell transplantation (ASCT),
remains controversial. Bendamustine has demonstrated efficacy in several lym-
phoproliferative disorders but limited data are available regarding the schedule
in patients with HL, in particular its dosage and the possible combinations for
a synergistic effect. Brentuximab Vedotin is a CD30-directed antibody-drug
conjugate, currently approved for the treatment of relapsed or refractory HL. 
Aims: The objective of this retrospective observational trial was to evaluate
efficacy and safety of salvage cytotoxic regimens in patients with refractory
and/or relapsed HL. Three different regimens were evaluated. 
Methods: From May 2011 to December 2016, 32 consecutive patients (19
M/13 F) with a median age of 31.7 years (range, 16-73) received a salvage
regimen after failure of ASCT. Patients were by chance assigned to one of
these three arms: standard dose bendamustine (90mg/sqm) days 1 and 2 plus
standard DHAP schedule (every 4 weeks) x 3 cycles (Arm A, n= 10 cases),
brentuximab single agent 1.8mg/kg (every 3 weeks) x 4-8 cycles (Arm B, n= 11
cases), high dose bendamustine (120mg/sqm) days 1 and 2 plus brentuximab
1.8mg/kg (day 3) x 4-6 cycles (Arm C, n= 11 cases). Each cycle in arm C was
repeated every 28 days and growth factor support was systematically admin-
istered, in association with antimicrobial prophylaxis. The treatment efficacy in
each arm was evaluated according to Revised Response Criteria for Malignant
Lymphoma by Cheson et al. Any adverse event occurred was recorded and
classified for type and grade using NCI-CTCAE criteria (v 4.0). 
Results: In arm A, the overall response rate (ORR) was 40% (4/10 patients),
with 4 (40%) complete remission (CR) and 6 (60%) progressive disease (PD).
Hematological toxicity was grade 3 thrombocytopenia in 4 patients (40%) and
bone marrow aplasia in 1 patient (10%); extra-hematological toxicity was gas-
trointestinal toxicity of grade 2 in 6 patients (60%) and grade 1 in 3 patients
(30%), In arm B, ORR was 63.6% (7/11 patients), with 5 (45%) CR, 2 (18%)
partial response (PR) and 4 (36%) PD. Hematological toxicity was grade 2 neu-
tropenia in 4 patients (36%), extra-hematological toxicity was grade 3 neuropa-
thy in 2 patients (18%), In arm C, ORR was 100% (11/11 patients), with 11 CR
followed by SCT (second autologous transplant, 6 cases; and haploidentical
transplant, 5 cases) with persistence of complete remission in all patients at a
median follow-up of 33.4 months (range, 12-60). Hematological toxicity was
grade 3 thrombocytopenia in 4 patients (36.3%); extra-hematological toxicities
were increase of transaminase (grade 2) in 3 patients (27%) and
cytomegalovirus (CMV) reactivation in 2 patients (18%), treated successfully
with valganciclovir. Three patients had fever during infusion at first cycle, togeth-
er with a skin rash, managed with corticosteroid injections, and a successful
antihistamine plus corticosteroid prophylaxis in the next cycles of treatment.
Figure 1.
Summary/Conclusions: High-dose bendamustine plus brentuximab has
shown relevant efficacy and a relatively good safety profile in a setting of heavily
pretreated patients with HL. Adequate monitoring of CMV reactivation is rec-
ommended. This combination could be considered as a bridge to second autol-
ogous or allogenic SCT. However, these results should be validated by con-
trolled and prospective studies involving larger number of patients.
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Background: In the last decades, Hodgkin and Non-Hodgkin Lymphoma (HL-
NHL) therapies have resulted in high cure rates and increased survival. How-
ever, younger patients (< 50 years), experienced severe late toxicities, such
as, gonadal toxicity that can result in permanent sterility. 
Aims: to evaluate different aspects of fertility (menstrual status, pregnancy,
and menopause) in women with HL and NHL in reproductive age before and
after chemotherapy.
Methods: By a phone interview we administered a questionnaire to the
patients. The interview was composed of questions concerning reproduction
(pregnancies, menses and abortion) and also menopausal status. The analyses
were made using data collected in a cohort 109 women patients from two Italian
hematologic centers. Statistical analysis was carried out in Graphpad® system,
data were compared by the chi-square (P value <0.05 was consider to be sta-
tistically significant)
Results: the median age (in years) at the time of the treatment was 31 (range
16-49), 69/109 (63%) had HL and 40/109 (37%) NHL, 74/109 [ES1] (64%) of
the patients had a stage I-II. All HL patients were treated with ABVD, whereas
the remaining NHL patients were treated with R-CHOP (20%) or similar regi-
mens (16%), respectively. Radiotherapy was delivered to the 62/109 (57%) of
the sample. Complete Remission (CR) was obtained by the 101/109 (93%)
and only 16/101 (16%) relapsed. Considering the gynecologic history of the
patients there were no statistically significance difference between the regularity
of menses and the event of an abortion pre and post treatment. As for preg-
nancies, 35% of patients had children before therapy and 17% after. Among
these 109 patients, 68/109 (62%) received gonadotropin-releasing hormone
(GnRH) analogues and/or oral contraception, while 41 (38%) were not treated
with hormonal therapy. Among the 68 patients who received hormonal therapy
regular menses recovered in 61/68 (90%) while in those of the control group a
recover of menses was observed in 20/41 (48%). This difference was statisti-
cally significant (P<0.05). The same was observed as for early menopause. In
this case excluding patients who had a natural menopause, a lower cases of
early menopause was observed in those who received hormone therapy (8/65,
12% vs 23/38, 61%; P<0.05). Considering only the 81/109 (74%) patients who
had regular menses after chemotherapy, 61/81 (75%) received hormonal ther-
apy and 20/81 (25%) were not treated with hormonal therapy. Before treatment
for lymphoma, 16% of patients belonging to the hormonal group had pregnan-
cies versus 45% of the control group (P<0.05). Following therapy, pregnancies
were observed in 23% of those receiving hormonal therapy vs 5% of the control
group (P<0.05).
Summary/Conclusions: The use of hormonal therapy is fundamental not only
to favor of pregnancies and motherhood but in particular to avoid the conse-
quences of an irregular cycle or an early menopause with its symptoms and
clinical implications.
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Background: Vitamin D has pleiotropic effects on cellular differentiation, pro-
liferation, apoptosis and angiogenesis in addition to maintaining serum calcium
and skeletal homeostasis. Several studies suggest that low serum 25(OH)D
levels may be associated with inferior outcome in solid tumors as colorectal
and breast cancer, and in Non-Hodgkin lymphomas [Drake et al, J Clin Oncol
2010; 28:4191] as diffuse large B cell lymphoma [Bittenbring et al, J Clin Oncol
2014; 32:3243], and follicular lymphoma [Kelly et al, J Clin Oncol 2015;
33:1482]. 25(OH)Vitamin D levels have not been reported for Hodgkin Lym-
phoma (HL).
Aims: To evaluate vitamin 25(OH)D levels in patients with HL and analyze for
associations with clinical characteristics and clinical outcome.
Methods: We studied 76 patients with cHL (40 females, 36 males, median
age 33 years), diagnosed at our Institution between 2014 and 2016. Treatment
consisted in ABVD (66 patients), BEACOPP d.e. (7 patients), and COPP (2
patients). One patient received only radiotherapy. Serum samples for vitamin
D quantification were collected before the first day of chemotherapy. 25(OH)D
was measured in patients’ sera using a standardized clinical assay, the DiaSorin
LIAISON 25-OH Vitamin D TOTAL. 25(OH)D levels were defined according to
three conditions: deficient (<10 ng/ml), insufficient (10-30 ng/ml), and sufficient
(>30 ng/ml). 
Results: The median 25(OH)D level at diagnosis was 20.6 ng/ml (range: 5.5 to
42.3 ng/ml). 25(OH)D levels were considered normal in 8 (10.5%) patients,
insufficient in 59 (77.5%) patients, and deficient in 9 (12%) patients. Looking at
patient characteristics, 25(OH)D levels were lower in patients with age over 60
years (p=0.002), reduced performance status (ECOG>1) (p=0.01), stage IV dis-
ease (p=0.01), and IPS (Hasenclever) score >2 (p=0.002). Furthermore levels
were lower in patients with hemoglobin below 10,5 g/dl (p=0.06). No association
was found with gender, albumin level, B symptoms. In addition, there was a sig-
nificant seasonal variation, with 25(OH)D levels to be lowest in the first quarter
and highest in the third quarter (p=0.03). FDG-PET evaluation after 2 cycles of
chemotherapy according to the 5-point Deauville scale was available in 66
patients. Vitamin D levels were not associated with interim PET response. With
a median of 12 months follow-up of patients is still short. Patients with deficient
levels (n=9) had a significantly worse PFS than patients with higher levels (n=67)
(p=0.002). The probability of progression-free survival at 12 months was 87%
(95% C.I., 75-94%) in patients with 25(OH)D levels>10 ng/ml, while patients
with levels<10 ng/ml had a 12 months PFS of 47% (95% C.I., 12-76%). We
included 25(OH)D levels, IPS (that includes age, stage and hemoglobin level),
ECOG and season in a multivariate Cox analysis. Deficient 25(OH)D level had
a borderline significance (HR 5.65, 95% C.I.,0.98-32.55; p=0.05).
Summary/Conclusions: 25(OH)Vitamin D serum levels are frequently low in
patients with Hodgkin Lymphoma and are associated with patient-related and
disease-related characteristics. Our preliminary analysis suggests that low
25(OH)D levels might be associated with worse prognosis.
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Background: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
is a rare variant of Hodgkin’s lymphoma (HL), that only accounts for 5% of all
HL. Due to its rarity, consolidated and widely accepted guidelines of treatment
still lack for this type of HL. Due to NLPHL cells expression of CD20, targeted
therapy with Rituximab (R), a chimeric anti-CD20 monoclonal antibody, has
been explored as a treatment option.
Aims: This study analyzed two different risk-adapted therapeutic strategies to
cure patients newly diagnosed with NLPHL. The aim was to compare the effi-
cacy and safety of the conventional chemotherapy plus irradiation versus the
R-including treatment of patients with NLPHL.
Methods: Within a retrospective study, we collected the medical records of 24
consecutive adult patients with NLPHL, taken from the total of 484 patients
with HL, who referred to our institution from 1 October 2001 to 31 July 2014.
According to our institutional guidelines, the 12 patients diagnosed from Octo-
ber 2001 to November 2007 received a treatment based on ABVD with/without
involved-field radiotherapy (IFRT). Treatment was modulated according to the
stage. The 9 patients with stages I and II received 4 courses of ABVD plus
IFRT, while 3 patients in stages III or IV received 6 cycles of ABVD. The sub-
sequent 12 patients (diagnosis from December 2007 to July 2014) received R
(375mg/m2) alone or combined with ABVD. The stage-adapted strategy of ther-
apy was applied for these patients, as well. The 5 patients with early favourable
disease, according to the stage and baseline EORTC risk factors, received R
as single agent (once per week for four consecutive weeks) followed by R
maintenance (MR) (once every three months for 2 years); the 2 patients with
early unfavorable stage were treated with R (once per month on day 1) plus 4
cycles of ABVD, while the remaining 5 advanced stage patients received R
(on day 1 and 15) plus ABVD for 6 cycles. The primary end-point was DFS
rate, and secondary end-points were ORR and treatment-related toxicity eval-
uation.
Figure 1.
Results: At final restaging, 4 weeks after the cycle of treatment or completion
of IFRT, 23/24 patients (95.8%) were in CR while one patient showed refractory
disease and was addressed to rescue therapy with autologous hematopoietic
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stem cell transplantation (ASCT). Patients treated with R alone or R+ABVD
had better DFS (p=0.04) than those treated with ABVD with/without IFRT.
Specifically, the year Kaplan-Meier estimates for DFS were 100% for the R
treated group versus 50% for those treated with ABVD with/without IFRT. Four
patients in the latter group, showed insufficient response to the therapy: 1
refractory disease in the early stage group and 3 recurrent diseases in the
advanced stage group were recorded. The median follow-up time of the entire
cohort of patients was 4.3 years (range, 0.5-8.2 years). Over the study period,
one patient died for infectious pneumonitis due to severe neutropenia following
the last cycle of R-ABVD. Of the 9 patients treated with addition of IFRT, adverse
events regarded mainly thyroid (4), bone (2), lung (1) and salivar glands (1).
Nobody developed a secondary malignancy.
Summary/Conclusions: Our results confirm the value of R in NLPHL and
show that R induction and maintenance combined with chemotherapy only in
the presence of risk factors or in more advanced stages give excellent treatment
results respect the conventional radio-chemotherapy either in term of ORR and
of DFS while sparing long term toxicity usually seen in patients affected by
classical HL who receive chemo and irradiation.
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CASE-BASED LEARNING IN CONTINUING EDUCATION: IMPROVING
HEMATOLOGIST/ONCOLOGIST EVIDENCE-BASED DECISIONS FOR
PREVENTING HOGDKIN LYMPHOMA POST-TRANSPLANT RELAPSE
P. Repetto1,*, C. Moskowitz2
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Background: Several prognostic factors have been identified as associated
with a higher rate of relapse after autologous stem cell transplant (ASCT) for
patients with Hodgkin lymphoma (HL). Due to the rarity of this disease, many
hematologists/oncologists (hem/oncs), especially those in the community set-
ting, lack experience in correctly identifying patients who may be at risk of post-
transplant relapse. Proper risk assessment and understanding of treatment
options in the pre- and post-transplant setting are critical to ensure optimal
longer progression-free survival for qualified patients.
Aims: Underlying clinical practice gaps and educational needs were identified
and a study was conducted to determine whether an online, case-based edu-
cational intervention could improve knowledge, competence, and confidence
of hem/oncs in managing patients with HL.
Methods: The educational format presented patient case scenarios (2) followed
by a series of 4-5 questions that “tested” learner knowledge and competence
before delivering the education focused on the optimal approach to the case
using evidence-based medicine. Case questions assessed degree of patient
risk for disease relapse or progression prior to ASCT and consolidation strate-
gies, taking into consideration patients’ prior received therapies. To assess edu-
cational effectiveness, participants served as their own controls by responding
to a sample of same questions again after (post-assessment) exposure to the
content. For all questions combined, the McNemar’s chi-square test assessed
differences from pre- to post-assessment. P values are shown as a measure
of significance; P values <.05 are statistically significant. Cramer’s V calculation
determined the change in proportion of 184 participants who answered ques-
tions correctly from pre- to post- assessment and who qualified for the study.
Results: At post-assessment, there was a large effect to the education
(V=0.442), indicating a sizable improvement in evidence-based choices and
significant improvement in knowledge, competence, and confidence related to
managing patients with HL, including: 138% relative improvement regarding
the implications of type and number of prognostic factors on risk of HL relapse
and benefit of consolidation brentuximab vedotin after ASCT (P<.001); 101%
relative improvement in knowledge that a higher rate of relapse after ASCT is
associated with a CR duration of less than 1 year, extranodal disease at relapse,
and the presence of symptoms at relapse (P<.001); 5% relative improvement
in knowledge regarding the efficacy of brentuximab vedotin in relapsed/refrac-
tory HL after ASCT (P<.001); Responses to a self-efficacy question indicated
that 42% of hematologists became more confident in managing a patient on
consolidation therapy for HL after participating in the education.
Summary/Conclusions: This study demonstrated the success of an online,
case-based format using a predisposing pre/post assessment was effective in
improving the evidence-based practice patterns of hem/oncs in the manage-
ment of patients with HL. Despite the marked improvement in knowledge, com-
petence, and confidence, hematologist education needs specific to accurate
risk assessment, treatment selection, and adverse effect monitoring remain.
The education gaps uncovered during this intervention and the evolving treat-
ment landscape outside of the United States lay a foundation for future global
education initiatives to bridge education gaps in HL.
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QUANTITATIVE PET PARAMETERS PREDICTS OUTCOME IN PATIENTS
WITH HODGKIN’S LYMPHOMA
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Background: Positron emission tomography [18F] fluorodeoxyglucose (FDG-
PET) has emerged as the standard response assessment after 1st line therapy
for classical Hodgkin’s lymphoma (HL). Quantitative PET parameters are not
well established as a predictive factor for disease progression in HL. 
Aims: Thus, the aim of this study was to test the hypothesis that tumor burden
characterized by mean standardized uptake value (SUVmean), maximum SUV
(SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG)
could be independent prognostic factors.
Methods: We analyzed the relation of absolute value PET parameters, negative
predictive value (negative PET scan and no treatment failure, NPV) and positive
predictive value (positive PET scan and treatment failure, PPV) with event-free
survival (EFS) or overall survival (OS). Quantitative PET parameters of the
baseline (PET-1), interim (PET-2) and end of treatment (PET-3) PET-CT scans
were investigated in the retrospective study. MTV was computed by using the
41% maximum SUV thresholding method, and the optimal cut-off for survival
prediction was determined. 
Results: Thirty one patients with HL with a stage I-II–51.6%, III-IV–48.4% con-
secutively admitted from April 2009 to December 2016, by 5 Ukrainian hema-
tological centers were included in the analysis. Patients were staged at baseline,
after 2-4 cycles of chemotherapy with PET/CT and at the end of chemotherapy.
All patients were treated with ABVD, BEACOPP-14/esc. All 31 patients achieved
CR or PR and 67,7% had a negative PET-2, while 16,3% had a positive PET-
2. Patients with negative PET-2 and positive PET-2 had CR rates of 64,5% and
12,1%, respectively, which yielded a PPV of 26% and NPV of 74%. ROC analy-
sis revealed that PPV and NPV are an important markers associated with EFS
in patients with HL (Se=100%; Sp=100%; AUC=1.0). 3-year EFS was 100%
for NPV patients and 12% for PPV patients, which was statistically significant
(p<0.01). 3-year OS was 100% and 75% for NPV and PPV patients, respec-
tively (p<0.01). Quantitative parameters at PET-1 and PET-2 were not statisti-
cally significant in predicting clinical outcome in this study. This may be due to
the small sample size in our study. PET-3 was negative in 67,7% cases. ROC
analysis showed that ∑MTV at PET-3 is an important marker associated with
reduced EFS in patients with HL (Se=75%; Sp=100%; AUC=0.97, p<0.0001).
3-year EFS was 89% and 25% in patients with ∑MTV <4.75 and ∑MTV >4.75,
respectively (p=0.005). Also, ROC analysis revealed that TLG at PET-3 was
associated with decrease EFS in patients with HL (Se=75%; Sp=100%;
AUC=0.97, p<0.0001). Multivariate analysis confirmed ∑MTV and TLG at PET-
3 were the only significant variables for EFS with HRs of 1.07 [95% confidence
interval(CI) 1.0–1.15, p=0.003] and 2.9 [95% (CI)0.9-1.03, p=0.05), respectively.
The PET-3 SUVmax and SUVmean were not statistically significant in predicting
EFS. 
Summary/Conclusions: Quantitative PET parameters may play a predictive
role for identifying patients at high risk of treatment failure. These results should
be evaluated prospectively in larger cohorts with longer follow-up.
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Background: Ibrutinib, a first-in-class, oral, covalent inhibitor of Bruton’s tyro-
sine kinase, has demonstrated robust clinical activity and is approved in various
B-cell non-Hodgkin’s lymphomas. To assess the efficacy and safety of ibrutinib
in patients (pts) with follicular lymphoma (FL), the DAWN study (FLR2002,
NCT01779791) investigated single-agent ibrutinib in chemoimmunotherapy
(CIT)-refractory FL pts. Ibrutinib may exert immune-modulatory effects on T-
cell activity via inhibition of ITK, a key regulator of T-cell activity, possibly through
inhibition of T-helper 2 (Th2)-polarized CD4 T-cells and activation of Th1 cells
(Dubovsky, et al. Blood 2013). Here, we describe the effect of ibrutinib treatment
on T-cells and cytokines in pts in the DAWN study.
Aims: To determine the effect of ibrutinib on circulating T-cells, chemokines,
and cytokines in ibrutinib-treated CIT-refractory FL pts.
Figure 1.
Methods: The DAWN study was an open-label, multicenter, single-arm, phase
2 study of ibrutinib in pts with CIT-refractory (i.e., ≥2 prior lines of therapy and
progressive disease [PD] ≤12 months after last dose of a CIT regimen). All pts
received ibrutinib (560mg QD) on a 21-day cycle until PD or unacceptable tox-
icity. The primary end point was Independent Review Committee (IRC)-
assessed overall response rate (ORR) (complete response [CR] + partial
response [PR]). Flow cytometry assessed T-cell subsets in peripheral blood at
baseline (C1D1) and at cycle 3 (C3D1) for 57 pts (14 responders and 43 non-
responders); cytokine and chemokine analyses were performed at C1D1 and
at cycle 2 (C2D1) for 50 pts (21 responders and 29 nonresponders).
Results: Results from the DAWN study have been presented previously (Gopal
A, et al. ASH 2016). Briefly, 110 pts with a median age of 61.5 years and a
median of 3 prior therapies were enrolled. Ibrutinib achieved an ORR of 20.9%
(CR rate, 10.9%) and a median duration of response of 19.4 months. Flow
cytometry analysis revealed significant downregulation of CD4+CD25+CD127-
Tregs at C3D1 in 14 responders (CR + PR, mean decrease 17 to 12.9% CD4,
p=0.02) but not in 43 nonresponders (SD + PD, 11.5 to 10.4% CD4, p=0.17).
From a large panel of inflammation-related cytokines and chemokines, some
of the most significant changes at C2D1 were the Th1 cytokines interferon
(IFN)-γ and interleukin (IL)-12, both of which were increased in responders but
decreased in nonresponders (p=0.0025 and p=0.035, respectively; Figure 1).
Conversely, the chemokines IFN-γ-induced protein 10 (IP-10) and monocyte-
chemotactic protein 3 (MCP-3) were decreased in responders but increased
in nonresponders (p=0.022 and 0.016, respectively).
Summary/Conclusions: Here we show immunomodulatory effects of ibrutinib
in pts with CIT-refractory FL, which may be related to response to therapy. In
responding pts at early time points, downregulation of Tregs was observed,
along with increases in Th1-associated cytokines IFN-γ and IL-12. This shift in
T-cell population may be linked to the antitumor response; in nonresponders,
these cytokines were decreased but Tregs were not. Chemokine changes
observed also indicate variation in chemoattraction of T-cells and monocytes/
macrophages. These data suggest that immunomodulatory effects of ibrutinib
could play a role in its antitumor activity in FL, so combinations with other
immune-oncology therapies may prove beneficial.
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Background: Duvelisib is an oral, dual inhibitor of PI3K-δ,γ in development
for the treatment of hematologic malignancies. DYNAMO is a Phase 2 study
to evaluate the safety and efficacy of duvelisib in a double refractory iNHL pop-
ulation, which included 28 patients (pts) with small lymphocytic lymphoma
(SLL).
Aims: The primary objective was to evaluate the antitumor activity of duvelisib
monotherapy in pts whose disease is refractory to rituximab and to either
chemotherapy or RIT, with an additional objective to further characterize the
safety duvelisib.
Methods: DYNAMO is an open-label, single-arm, safety, and efficacy study in
patients (pts) with FL, small lymphocytic lymphoma (SLL), or marginal zone
lymphoma (MZL), whose disease is double refractory to rituximab (monother-
apy or in combination) and to chemotherapy or radioimmunotherapy. Pts
received duvelisib 25mg BID in 28-day treatment cycles until disease progres-
sion or unacceptable toxicity. The primary endpoint is overall response rate
(ORR) as assessed by an independent review committee (IRC) per revised
IWG criteria. Secondary endpoints include duration of response (DoR), pro-
gression-free survival (PFS), overall survival (OS), time to response (TTR),
adverse events (AEs), and changes in safety laboratory values. Pneumocystis
jiroveci pneumonia (PJP) prophylaxis was mandated for all pts.
Results: 129 pts with iNHL were treated on study. Of these, 28 pts with SLL
received duvelisib with a median duration of exposure of 9 mo. (range 6.5-12).
Median age was 65 years; 68% were male. Most SLL pts had an ECOG per-
formance status score at baseline of 0 (43%), followed by 1 (54%) and 2 (4%).
Most SLL pts had either Stage 3 (25%) or Stage 4 (61%) disease at baseline.
Median time from last anticancer therapy to first dose of duvelisib was 3 months.
SLL pts received a median of 3 prior anticancer regimens (range: 1-18); 43%
of pts received ≥4 prior anticancer regimens, 29% ≥6 regimens. The ORR for
SLL pts was 68% (95% CI: 48, 84) per IRC assessment. All responses (19)
were PRs. Four (14%) pts had a best response of SD and 3 (11%) pts had a
best response of PD. 2 pts were unevaluable for response. Per Investigator
assessment, the ORR was 79% (including 1 CR). Median time to IRC response
was 1.9 months (range 1.4-5.5). 93% of pts had a reduction in nodal target
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lesions. Among the 19 SLL pts with a response per IRC, the median DOR was
9.9 months. The median PFS among all SLL pts was 11.3 months, while the
median OS was not reached. The estimated probability of survival at 12 months
was 83.9%. Among all pts treated (n=129), AEs were mostly Gr 1-2. Most com-
mon ≥ Gr 3 AEs were transient cytopenias (neutropenia [23%], anemia [12%],
and thrombocytopenia [10%]), and diarrhoea (15%). 4 SLL pts had SAEs that
led to discontinuation of duvelisib: NSCLC, neuroendocrine carcinoma of the
skin, pseudomembranous colitis, and pneumonia. Two SLL pts has a fatal AE,
1 pneumonia and 1 viral infection.
Summary/Conclusions: In DYNAMO, duvelisib showed clinical activity in a
double-refractory SLL population (68% ORR, median DOR 9.9 mo., 93% with
a reduction in target lesions). Duvelisib was generally well tolerated, with a
manageable safety profile with appropriate risk mitigation. Duvelisib monother-
apy appears to have a favorable benefit-risk profile in double refractory SLL.




WALDENSTROM MACROGLOBULINEMIA: UK REAL WORLD EXPERIENCE
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1Cancer Division, University College London Hospital (UCLH), 2Peripheral
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Background: There are few randomised controlled trials in Waldenström
macroglobulinaemia (WM) due to its rarity and indolent nature. As a result,
there is no standard treatment approach and management is variable.
Aims: The aim of this retrospective study was to review “real world” manage-
ment of WM in the UK and correlate this with survival outcomes.
Methods: All patients with a diagnosis of WM seen at ULCH between
01/07/2002 and 31/12/2016 were included. Patient characteristics, presenting
features, lines of treatment, responses and overall outcome were recorded.
IPSSWM where available, was calculated at time of first treatment. Survival
was estimated using Kaplan-Meier analysis from time of first treatment and P
values calculated using the log-rank test.
Figure 1.
Results: A total of 211 patients were identified (116 M/ 95 F), median age 60
yrs (range 34-89). Presenting symptoms included anaemia, n=33; neuropathy,
n=19; fatigue, n=18; hyperviscosity symptoms, n=13; lymphadenopathy; n=5;
progression frommgUS, n=5; B symptoms, n=5; other, n=28; unknown, n=55.
Mutated MYD88 was seen in 59 of 72 cases analysed (82%). Of these 59 cas-
es, 13 were CXCR4 mutated. IPSSWM was known in 150 cases of whom 64
were in low, 63 intermediate and 23 high risk groups. Median follow-up from
first appointment was 64 months (range 0-394). The median number of lines of
therapy was 2 (range 0-9). Dexamethasone, rituximab and cyclophosphamide
(DRC) was given to 62 patients upfront, 52 had other cyclophosphamide con-
taining regimens e.g. CHOP +/- rituximab, 29 had Chlorambucil-based regimen,
14 R-bendamustine, 15 fludarabine-based with a minority getting R-cladribine
(5) or R-bortezomib (4), 9 patients had no treatment at data cut-off. Notably,
DRC was given to 1 patient before 2009, 28% of patients between 2009 and
2013, and 41% from 2013. In the 149 cases with known responses to first line
treatment, 11% achieved a CR (7 patients with R-CHOP, 4 DRC, 2 fludarabine
containing regimen, and 3 patients other treatment), 63% PR/ VGPR, 21% no
response or PD and 5% stopped due to toxicity. For the 52 patients who had
DRC chemotherapy, median PFS was 61 months. Of those patients who had
at least 3 lines of chemotherapy (n=62), median time between 1st and 2nd line
treatment was 10 months and 3 months between 2ndand 3rd line. Transplants
were performed on 28 patients after a median of 2 lines of chemotherapy. Medi-
an overall survival (OS) has not been reached in the 195 patients with available
data. Stratifying by IPSSWM shows median OS for the low risk group has not
been reached, 11 years for the intermediate risk and 9 years for the high risk
group, P=0.29 (Figure). Patients had a significantly reduced OS if they devel-
oped Bing Neel syndrome or high grade transformation compared to other
known complications of WM. Despite differences in chemotherapy strategies
over the past two decades, there was no difference in outcome in patients treat-
ed before 2005, between 2005-2009, 2009-2013 and 2013 onwards. Of the 34
deceased patients, the cause of death was unknown in 3 cases, due to PD in
16 and other causes in 15 cases.
Summary/Conclusions: The management of patients with WM in this large
case series reflects the variability of treatment given over time and also geo-
graphically. UCLH treats both a local and tertiary referral patient population,
thus it is not completely typical. Survival data confirms the IPSSWM is likely to
still differentiate patients into prognostic groups but the overall prognosis is bet-
ter than when first published. With the advent of targeted therapies, it is imper-
ative to perform randomised controlled trials and to collect data prospectively
in order to elucidate the optimal management. To this end, a WM Biobank and
Registry has been set up at our centre.
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Background: According to the WHO classification (2008) hepatitis C virus is
one of the causesof non-Hodgkin lymphoma. The incidence of chronic hepatitis
C (HCV) in patients with indolent B-cell non-Hodgkin’s lymphoma (IL + C) is
15%. Diagnosis of hepatitis C related lymphoma (IL + C) is established in cases
where the tumor tissue of patients express proteins of hepatitis C virus. These
proteins could idefined by immunohistochemistry (IHC).
Aims: The aim of this work was evaluation of the results of treatment of IL
associated with hepatitis C in comparison with a control group of patients with
IL without viral hepatitis markers.
Methods: The study included 107 patients with indolent lymphoma who were
identified in the blood markers of hepatitis C.
Results: Histological types were follicular lymphoma - 74%, marginal zone
lymphoma - 32%. The age of patients ranged from 28 to 82 years (median 50).
Men / women ratio was 1: 1. Stage I + II were in 3%, III stage was in 24% of
patients, IY stage was at 73% of patients. Primary extranodal lymphoma was
diagnosed in 33% of patients. Extranodal lesions: splenic lesion -in 53% of
patients, liver injury - 21% of the patients, the bone marrow - 62% of patients.
LDH ≥ 450 IU / l was at 76% cases, ALT ≥40 IU / l was at 82% of cases, albumin
<35 g / l was at 31% of patients. 57 patients were treated with interferon and
Ribavirinum as a first-line treatment. Treatment lasted for 2 years after reaching
the antitumor effect. 50 patients were treated with immunochemotherapy (R-
CHOP, R-CVP) as a first-line treatment. Antiviral therapy was effective in 88%
patients, immunochemotherapy was effective in 64% of patients. Median pro-
gression-free survival in patients with IL + C treated with antiviral treatment
was 42 months, in patients with IL + C treated with immunochemotherapy - 19
months (p=0.00001). Five-year overall survival was 67% and 32%, respectively
(p=0.0003). It was diagnosed disease relapses after immunochemotherapy in
39 patients. All the patients in the second-line was received antiviral treatment.
Response to the ongoing antiviral therapy was achieved in 77% of cases. Medi-
an progression-free survival in relapsed lymphoma was 31 months.
Summary/Conclusions: Antiviral therapy in first-line and relapse of disease
surpasses all the indicators of efficiency of treatment IL + HCV. In this category
of patients preferred option is to conduct anti-viral treatment.
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Background: Follicular lymphoma (FL) accounts for around 22% of all non-
Hodgkin lymphomas. His natural history is characterized by multiple relapses
and progressively shorter response durations after every new line of therapy
for this is desirable to offer the best first-line approach to each patient. In the
current guidelines several first line options are included: immunotherapy (Rit-
uximab (R) x4 or Lenalidomide+/- R), immunochemotherapy (CHOP, RCVP,
Bendamustine + R), radioimmunotherapy for elderly patients. Moving forward,
the consolidation with radioimmunotherapy or extended dose immunotherapy
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(R every 8 weeks for 4 or 12 doses) still appears as an optional part of the
therapy (NCCN V3.2016). Radioimmunotherapy with 90Yttrium-ibritumomab
tiuxetan (90Y-IT) is available in our institution since 2006 and more than 100
patients have been treated with RIT since then. Here an institutional analysis
focus in their use as consolidation is presented
Aims: To analyze the experience with 90Y-IT as a consolidation therapy in
patients in CR after first-line therapy.
Methods: A retrospective analysis was performed including all the patients
that have received RIT with 90Y-IT. Inclusion criteria were: patients 18 years
or older with a grade 1-2a follicular lymphoma, RIT was received as a consol-
idation therapy in complete response (CR) after a first-line therapy. Demo-
graphic and follow-up data were included. International working group (IWG)
criteria of response was used. Progression free survival (PFS) was calculated
from the date of RIT to the date of a confirmed relapse according IWG criteria,
overall survival (OS) was calculated from the FL diagnosis to the last contact.
Results: A total of 31 FL patients have received 90Y-IT been in CR after a
first-line of therapy and were included for the study. Mean age at diagnosis
was 61.2 (29-86) years with a female predominance (19, 61.3% vs 12, 38.7%).
80.6% (26) with ECOG 0-1 and 19.4 ECOG 2. A third of them (10, 32.3%) were
diagnosed with low tumor burden (stage I-II), 2 (9.7) of them presented extra
nodal infiltration (subcutaneous and gut) and 12 (38.7%) showed bone marrow
infiltration demonstrated by flow cytometer or biopsy. There were no patients
with bulky disease. Stages: I: 7 (22.6%), II: 3 (9.7%), III: 9 (29.1%), IV: 12
(38.7%). As first-line therapy the patients received: Rx4: 11 (35.5%) cases, R-
Cyclophosphamide vincristine prednisone (COPx4): 3 (9.7%) cases and 17
(54.8) R-cyclophosphamide doxorubicin, vincristine and prednisone (R-
CHOPx4-6). The median follow-up was 58.0 (10-107) months. During this time
only 5 (16.1%) of patients have relapsed and need another therapy. None of
the patients that have received R-CHOP+90Y-IT have relapsed; the relapsed
patients received Rx4 (4) and R-COP (1). The median PFS after 90Y-IT has
not reached, the mean was 83.3 (71.7-94.98) months, see Fig 1. Four (12.9%)
patients have died, none of them were relapsed and the mortality was due
other causes. The median OS was not reached, the mean was 95.8 (85.6-
106.1) months. As long-term events one 82 years old patient developed a colon
cancer after 67 months of RIT, one 72 years old female a breast cancer after
17 months of RIT and one 71 years patient amgUS after 24 months of RIT,
none of them related with mortality events.
Figure 1.
Summary/Conclusions: The use of immunotherapy with rituximab or com-
bined schedules with immunochemotherapy (R-COP and R-CHOP) followed
by consolidation with 90Y-IT remains as a valid option for follicular lymphoma
patients. After ~6 years of follow-up: 63.6% (Rx4+RIT), 66.7% (R-COP+RIT)
and 100% (R-CHOP+RIT) of patients continue with complete response and
off of therapy. 
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Background: By contrast, with follicular lymphoma (J Clin Oncol
2015;33:2516) or other chronic hematological malignancies (Blood
2009;114:1299; Blood 2016;128:902), few reports attempted to decipher the
evolution of pts with WM, a disorder associated with delayed response to ther-
apy in some pts.
Aims: To assess the prognostic role during the clinical course of initial interna-
tional prognostic index (IPSSWM), response and progression (according to 6th
International Workshop criteria).
Methods: We took advantage of our continuously updated clinical database
for reviewing a series of 114 symptomatic WM pts treated in our 2 institutions
between 1993 and 2016 (median age 70, male/female ratio=1.91, high,
low/intermediate and unavailable IPSSWM in 57, 36 and 21 pts respectively).
Response rate after 1st line therapy was 70%. Sixty-two, 37 and 19 pts received
a 2nd a 3rd and 4 to 6 lines of therapy respectively according to the 2nd Inter-
national Workshop guidelines. Monitoring of serum monoclonal immunoglobulin
concentration (SMIC) throughout the evolution of the disease was available in
106 pts. Informed consent was obtained according to the protocol submitted
to the Institution Review Board
Results: Median survival after 1st line was estimated 79 months. It was esti-
mated 69 and 65 months after 2nd line and 3rd line respectively. High IPSSWM
(hIPSSWM vs low/intermediate) retained prognostic value for survival after 1st
treatment initiation (SAFTI, p=0.0005). However, plot of hazard function showed
a decrease of hazard ratio over time with a departure from the proportional
hazard hypothesis (Grambsch and Therneau test: p=0.053). Consequently,
Dxy concordance index obtained in multiple landmarks analyses decreased
from 0.27 to 0.12, during the first 6 years of follow-up. In Cox model of SAFTI
with time dependent covariate, onset of response (whatever cut-off in SMIC)
had no prognostic value. By contrast, onset of progression and initiation of 2nd
line therapy, retained prognostic values for SAFTI (p=0.0038 and p=0.004
respectively). Only 2 thresholds in SMIC defined a response status (observed
between onset of response and progression) of prognostic value for SAFTI:
namely >25% reduction in SMIC (i.e. minor response or better: p=0.041) and
50% (i.e. partial response or better: p=0.056). In similar Cox models with hIPSS-
WM, onset of progression (p=0.0034) and 2nd treatment initiation (p=0.0031)
retained independent prognostic value beside hIPSSWM (p<=0.0026). Times
elapsed from the initiation of 1st line therapy to 1st progression and to the initi-
ation of 2nd line therapy had no prognostic value for subsequent survival. In
similar Cox model of survival after 2nd line therapy with time dependent covari-
ate no threshold in SMIC were found to be associated with a significant value
of onset of response or response status. Neither onset of progression nor next
treatment initiation had significant prognostic value. Similar results were
observed after the 3rd line of therapy. 
Summary/Conclusions: The prognostic value of initial IPSSWM decreased
in part during the first 6 years of evolution. Onset of progression and 2nd treat-
ment initiation provided additional prognostic information for predicting SAFTI.
Therefore progression-free survival or time to next treatment may be satisfac-
tory surrogate endpoint of SAFTI in WM. Further international collaborative
studies are mandatory for this purpose. Assessing response in more advanced
phase of the disease may require specific tools.
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TIME TO NEXT TREATMENT ANALYSIS FOR EARLY AND ADVANCED
STAGES OF MYCOSIS FUNGOIDES /SEZARY SYNDROME TREATED
WITH BEXAROTENE AND PUVA IN COMBINATION
S. Rupoli1,*, G. Goteri2, G. Micucci1, I. Federici1, L. Canafoglia1, P. Leoni1,
G. Brandozzi3, F. Giantomassi2, G. Mozzicafreddo4, R. Alterini5, M. Simonacci6,
L. Bugatti7, S. Serresi4, R. Santilli4, A. Campanati3, N. Pimpinelli8
1Clinica di Ematologia, 2Istituto di Anatomia Patologica, 3Clinica di Dermatolo-
gia, Ospedali Riuniti Umberto I- Salesi-Lancisi di Ancona, 4Clinica di Derma-
tologia, I.N.R.C.A. Ancona, ancona, 5Clinica di Ematologia, AOU Ospedale
Careggi di Firenze, Firenze, 6Clinica di Dermatologia, Ospedale di Macerata,
Macerata, 7Clinica di Dermatologia, Ospedale di Jesi, Jesi, 8Clinica di Derma-
tologia, AOU Ospedale Careggi di Firenze, Firenze, Italy
Background: Bexarotene is a syntetic retinoid effective in early and advanced
stages of Mycosis Fungoides (MF)/Sezary Syndrome (SS) both in monotherapy
and combination schemes. Time to next treatment (TTNT) seems to be a clin-
ically meaningful endpoint that incorporates both symptom control and disease
progression. It has been investigated in few retrospective studies focusing on
retinoids in monotherapy both in limited-stage and advanced stage MF, but up
to now no data are available concerning the use of retinoids in combination. 
Aims: We aimed to evaluate TTNT together with the usual time-to-event meas-
ures (OS and EFS) in our series of 21 refractory and/or relapsed patients with
MF and SS treated with Bexarotene and PUVA in combination, that we recently
published (Rupoli et al, EJD 2016). The follow-up of these protocols was pro-
longed up to February 2017.
Methods: We recruited patients with stages I-IV MF who had failed PUVA (early
disease) or several systemic regimens (early and advanced disease). We
designed “mini” and “standard” protocols in which Bexarotene dose and PUVA
administration were individually titrated, and tailored during induction and main-
tenance according to previous therapy, disease stage and toxicity. Survival
curves for each efficacy endpoint were calculated according to Kaplan-Meier.
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Results: We enrolled 21 patients, 12 males and 9 females, with median age
of 67 years (range, 30-77), of which 15 affected by early MF (13 with stage IB,
2 with stage IIA) and 7 by advanced disease (2 with stage IIB, 2 with stage IIIA,
1 with stage IIIB and 1 with stage IVA). Six patients had previously received
PUVA therapy only, while fifteen patients had received other therapies.The pro-
tocol proved to be effective, well tolerated and able to induce an overall
response of 85.6% at the end of induction phase (93.4% of early stage patients
and 66.6% of advanced stage patients) and of 76.2% at the end of maintenance
phase (86.7% of early stage patients and 14.2% of advanced stage patients).
Median follow up for all patients was 85 months (6-118) with respectively 98
months (21-118) for early stages and 46 months (6-102) for advanced stages.
For the entire cohort, median OS, PFS and TTNT was not reached; mean val-
ues of OS, PFS and TTNT were respectively, 90, 92 and 72 months and median
EFS was 33 months. For the early stage MF cohort, the median OS, PFS and
TTNT were not reached; mean values of OS, PFS and TTNT were respectively,
105, 103 and 79 months, and median EFS was 58 months. For advanced stage
patients, median OS, PFS, EFS and TTNT were 32, 29, 18 and 39 months
respectively. 
Summary/Conclusions: Our combination treatment seems to have superior
TTNT compared to data published in the literature for PUVA and bexarotene
used in monotherapy. When considering early and advanced MF, 66% of our
patients are estimated to be free from further treatment at 2 years, a higher per-
centage compared to the results of Hughes et al. (Blood, 2015) for patients treat-
ed with PUVA (54.2%) or bexarotene (36.8%) as single agents. Moreover, TTNT
seems to be longer in our study than in the study by Hanel et al (AJH 2016) on
patients treated by retinoids in monotherapy, respectively 79 vs 60 months (mean
TTNT values) in the early stages and 39 vs 9 months (median TTNT values) in
the advanced stages. We believe that our results strongly suggest a synergistic
or additive effect between PUVA and bexarotene compared to either agent alone
in the treatment of both limited-stage and advanced stage MF.
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PERIPHERAL BLOOD INVOLVEMENT IN PATIENTS WITH ADVANCED
STAGE FOLLICULAR LYMPHOMA: CLINICAL-BIOLOGICAL CHARACTERISTICS
AND PROGNOSTIC IMPACT
A. Rivas-Delgado1,*, L. Magnano2, P. Mozas1, I. Dlouhy 1, J. Rovira1,
A. Martinez-Trillos 1, O. Balague3, A. Martínez3, E. Gine1, T. Baumann1,
J. Delgado1, N. Villamor2, E. Campo3, E. Matutes2, A. Lopez-Guillermo1
1Hematology department, 2Hematopathology Unit, 3Pathology department,
Hospital Clinic, Barcelona, Spain
Background: Follicular lymphoma (FL) is a clinically heterogeneous indolent
lymphoma. The majority of patients have a non-aggressive clinical course, but
a small percentage shows a rapidly progressive disease, including histological
transformation in some cases. Although disseminated disease and bone mar-
row infiltration are common, only a small percentage of FL patients have periph-
eral blood (PB) involvement. The clinical significance of the PB involvement is
unclear.
Aims: To describe the clinico-biological characteristics and to determine the
prognostic impact of blood involvement in patients with advanced FL.
Figure 1.
Methods: We selected 304 patients in stage IV out of 654 patients diagnosed
with FL between 1991 and 2014 in a single institution. Patients with a diffuse
large B-cell lymphoma component, histological grade 3b and primary cutaneous
FL were not included. Fifty-six (18%) had PB expression (PB+) defined by the
presence of circulating FL cells by morphology, further confirmed by
immunophenotype. The main clinical and biological characteristics, response
to treatment and outcome were analyzed.
Results: Patients with PB+ more frequently had splenic involvement, anemia,
elevated β2-microglobulin and LDH and high FLIPI score than those without
PB involvement (PB-) and differences were statistically significant. There were
no differences concerning the proportion of patients undergoing a watchful wait-
ing approach (7% vs 9%), type of treatment, or overall response rate (83% vs
88%) and complete response rate. Overall, 149 patients had refractory disease
or relapsed, including 34/52 (65%) PB+ and 115/225 (51%) PB-. The median
follow-up was 7 years (range 0.7 - 22.2 years). The 5-year progression-free
survival (PFS) of treated patients in PB+ group was 28% (95% CI: 14-42%)
compared with 48% in the PB- (95% CI: 41-55%) (p=0.013). However, when
the analysis was restricted to patients receiving rituximab combination regimen,
5-year PFS was 45% (95% CI: 24-66%) vs 64% (95% CI: 54-74%) (p=NS).
Ninety-six patients died during the follow-up (19 PB+ and 77 PB-), with a 5-
year overall survival (OS) of 68% (95% OR: 54-82%) in the PB+ group and of
81% (95% CI: 76-86%) in the PB- group (p= NS) (Figure). Finally, there was no
difference in the risk of histological transformation or second malignancies.
Summary/Conclusions: Peripheral blood involvement in FL is associated with
particular clinical features, higher tumor burden load and shorter PFS, although
in the short-term it appears that has not impact on overall survival.
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TREATMENT PATTERNS OF PATIENTS WITH FOLLICULAR LYMPHOMA
IN A LARGE US-INSURED DATABASE FROM 2010 TO 2014
M. Mehra1,*, N. Monga1, B. Schenkel2, R. Potluri3, L. Parisi1
1Janssen Research & Development, LLC, Raritan, NJ, United States, 2Janssen
Scientific Affairs, Horsham, PA, United States, 3SmartAnalyst Inc., New York,
NY, United States, United States
Background: Follicular lymphoma (FL) is the second most common type of
non-Hodgkin’s lymphoma. While there are therapeutic options for patients with
FL, it remains an incurable disease with conventional therapies. Furthermore,
real-world treatment patterns for patients with FL are not well characterized in
the literature.
Aims: To characterize the real-world treatment patterns by line of therapy (LOT)
for patients with FL in a large US-insured database.
Methods: Using the Optum integrated database, patients with FL were identi-
fied and included if 1) they were diagnosed with the International Classification
of Diseases, Ninth Revision (ICD-9) codes 202.0 or 202.00 to 202.08 between
January 2010 and December 2014; 2) their age was ≥ 18 years at the index
date (defined as date of FL diagnosis); 3) they did not have any other primary
cancers during the period from 3 years prior to index date up to 1 month post-
index date; and 4) they had continuous insurance coverage for 365 days prior
to index date. All reporting was done using descriptive statistics.
Table 1.
Results: A total of 2569 patients with FL met the inclusion criteria and were
included in the analysis. In this cohort, the mean age was 60 years; 51% were
male; 72% were Caucasian, 5% African American, 2% Asian, and 20% other.
The median duration of follow-up was 610 days. Across all LOTs, 1180 patients
(46%) had at least one National Comprehensive Cancer Network (NCCN)
guideline-recommended treatment for FL, and 153 patients (6%) had steroids
only in their follow-up. Across all LOTs, rituximab monotherapy (RTX) was the
most frequently used regimen (26%; average duration of therapy [DOT]: 96
days), followed by rituximab-cyclophosphamide-doxorubicin-vincristine-pred-
nisolone (R-CHOP) or R-CHOP-containing regimens (19%; average DOT: 75
days) and bendamustine-rituximab (BR) (12%; average DOT: 128 days). These
regimens represented 21%, 16%, and 14% of the first LOT, and 27%, 16%,
and 11% of the second LOT, respectively. Across all LOTs, the use of other FL
treatments was very low, including rituximab-cyclophosphamide-vincristine-
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prednisolone (R-CVP) (2%) and obinutuzumab (< 1%). Utilization trends of R-
CHOP-containing regimens and RTX increased in successive LOTs, while all
the other regimens remained unchanged or declined, particularly in later LOTs.
RTX-containing regimens were used in 69.5% of regimens across all LOTs.
The share of regimens used in different LOTs and overall are described in
Table 1.
Summary/Conclusions: The use of NCCN guideline-recommended treat-
ments in less than half of this cohort of patients with FL suggests that many
patients with this form of indolent lymphoma are not adequately treated. As
expected, rituximab was found to be the mainstay of treatment. Further
research is needed to examine the relationship between LOT and long-term
outcomes in patients with FL.
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A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS
(PK) OF VENETOCLAX (VEN) IN JAPANESE PATIENTS (PTS) WITH
NON-HODGKIN LYMPHOMA (NHL) AND MULTIPLE MYELOMA (MM)
K. Yamamoto1,*, K. Hatake2, N. Fukuhara3, S. Kusumoto4, H. Nagai5,
Y. Kobayashi6, T. Kakihara7, M. Shintani7, A. Roberts8, P. Maciag8, S.K. Agarwal8,
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Background: The antiapoptotic protein BCL-2 is commonly overexpressed in
hematologic malignancies. VEN is a potent, selective, orally bioavailable BCL-
2 inhibitor that has demonstrated acceptable safety and antitumor activity in
NHL and MM pts.
Aims: To evaluate the safety, PK profile, and preliminary antitumor activity of
single-agent VEN in Japanese pts with NHL or MM.
Methods: Phase 1 open-label, dose-escalation study of VEN in Japanese pts
with relapsed or refractory (R/R) NHL or MM (NCT02265731). Dose escalation
followed a 3+3 design. After a 2-week ramp-up period with weekly dose esca-
lation, VEN was administered daily at final doses of 300, 600, 900, or 1200mg
on 21-day cycles until progression. All pts received tumor lysis syndrome (TLS)
prophylaxis (allopurinol, hydration, hospitalization and monitoring) starting at
least 72 hours before the first VEN dose and before each dose escalation.
Adverse events (AEs) were assessed by NCI CTCAE v4.0. Dose-limiting tox-
icities (DLTs) were determined during the ramp-up period and during cycle 1.
Responses were assessed by 2007 IWG (NHL) or 2006 IMWG (MM) criteria.
Informed consent was obtained from all pts.
Results: As of January 19, 2017, 20 pts (50% male; median age 65 years
[39–81]) have been enrolled: 3 pts in the 300-mg, 7 pts in the 600-mg, 7 pts in
the 900-mg, and 3 pts in the 1200-mg VEN dose cohorts. Eighteen (90%) pts
had NHL (stage III/IV, n=14), including 11 with follicular lymphoma (FL), 6 with
diffuse large B-cell lymphoma (DLBCL), and 1 with concurrent FL+DLBCL; 2
(10%) pts had MM at diagnosis. Treatment-emergent AEs (all grades) in >20%
pts were lymphopenia (80%), neutropenia (60%), leukopenia (50%), and ane-
mia (25%), and non-hematologic toxicities including nausea (55%), vomiting,
diarrhea, and nasopharyngitis (30% each). Grade ≥3 treatment-related AEs
were lymphopenia (45%), neutropenia (40%), and leukopenia (30%). One pt
in the 600-mg dose cohort experienced grade 3 pemphigus as DLT after receiv-
ing 2 doses of 100-mg VEN on day 2 of the dose ramp-up period. One DLBCL
pt died while on study due to disease progression. No TLS events were report-
ed. Steady-state VEN exposures were nearly dose proportional across 300-
mg to 900-mg doses. At the 1200-mg dose, exposures to VEN increased less
than dose proportionally, which is consistent with non-Japanese subjects. VEN
exposures were comparable between Japanese and non-Japanese pts at the
300-mg dose. At higher doses, individual exposures were generally within the
range observed in non-Japanese pts but mean exposures were 30–100% high-
er. OR was seen in 8/19 (42%) pts evaluable for efficacy. Among pts with NHL,
8/17 (47%) had an OR (CR+PR), including 2 (12%) CR (both pts with FL) and
6 (35%) PR; 6/17 (35%) pts had SD and 3/17 (18%) pts progressed while on
treatment. The 2 (100%) pts with MM (1 with t[11;14]) had PD. Time on study
for all pts ranged from 2 to 795 days; at data cutoff, 7/20 (35%) pts were still
on study, with treatment duration ranging from 98 to 795 days.
Summary/Conclusions: VEN monotherapy has a tolerable safety profile in
Japanese pts with R/R NHL or MM, with most common toxicities being hema-
tologic. Individual exposures were generally within the range observed in non-
Japanese pts but mean exposures were 30–100% higher. Overall, the OR rate
was high, with nearly half the pts with NHL achieving an OR. Further evaluation
of VEN in Japanese pts with hematologic malignancies is ongoing.
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A SIMPLIFIED APPROACH IN THE ASSESSMENT OF T-CELL CLONALITY
BY FLOW CYTOMETRY
M. Sartor1,*, E. Lau1, V. Luu1, Z. Timbol1, S. Wong1, S. Deo1, L. Pasalic1,
D. Brown2, E. Tegg1, D. Gottlieb3
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Background: T-cell lymphoprolferative disorders are amongst the most chal-
lenging diagnoses in haematology. Flow cytometric T-cell receptor (TCR)-V(β)
repertoire analysis (TCR-V(β)-R) is a sensitive method for detection of T-cell
clonality; however, the assay is cumbersome owing to the required eight-part
analyses that limit its clinical utility. 
Aims: Here we describe a simplified flow cytometric method utilising a mono-
clonal antibody Jovi-1 that targets the T-cell receptor β constant domain 1
(TRBC1). The α/β TCR is a pan T-cell antigen, expressed on >90% of T-cell
lymphomas and all normal T-cells. A feature of the TCR is that the β-constant
region comprises 2 functionally identical genes: TRBC1 and TRBC2. Each T-
cell expresses only one of these. Consequently, normal T-cells will be a mixture
of individual cells expressing either TRBC1 or 2, while a clonal T-cell disorders
will exclusively express TRBC1 or 2.
Methods: Using multiparameter flow cytometry we assessed the expression
of Jovi-1 in normal donors (n=19), T-cell leukaemia cell line (n=1), T-LGL (n=9),
T-NHL (n=3), Sezary syndrome (n=3) and patients with reactive lymphocytosis
(n=20). A comparison of Jovi-1 and TCR-V(β)-R was also performed to compare
the two approaches.
Results: Jovi-1expression within the CD4 and CD8 compartments of T-cells
in normal donors was a median of 42.6% (range 33.7%> 49%) and 36.4%
(range 22.3%> 48.5%) respectively. The T-cell line, Jurkat was exclusively pos-
itive for Jovi-1. Of the 9 patients with T-LGL, 7 patients shared a common T-
cell phenotype CD3+/CD8+/CD4-, one patient was predominantly CD4+ and
the other patient was dual negative for CD4 and CD8. Jovi-1 expression within
the abnormal T-cell population of this group of patients was >90% restricted to
one compartment; these findings were confirmed by TCR-V(β)-R analysis. Sim-
ilar results were also obtained in each case of T-NHL and Sezary syndrome,
more than 90% of T-cells from the population with an abnormal phenotype
(CD3dim/CD4+/CD8-, CD3+/CD4+/CD8+, CD3+/CD4+/CD8- and
CD3+/CD4+/CD7- respectively) were either positive or negative for Jovi-1.
Patients with persistent lymphocytosis were also assessed for Jovi-1 expres-
sion. Within this group all patients had Jovi-1 positive and negative compart-
ments within CD4 and CD8 T-cells.
Summary/Conclusions: In summary we have demonstrated a novel approach
in the assessment of T cell clonality by targeting T-cell receptor β constant
domain 1 (TRBC1). The addition of Jovi-1 in routine practice could improve
the clinical evaluation of abnormal T-cell populations by flow cytometry.
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A HIGHER AMOUNT OF LILOTOMAB PRE-DOSING INCREASES THE
ACTIVITY-ADJUSTED AUC AND HAS A PROTECTIVE EFFECT AGAINST
MYELOSUPPRESSION OF LUTETIUM (177LU)-LILOTOMAB SATETRAX-
ETAN IN INDOLENT NHL PATIENTS
A. Kolstad1,*, U. Madsbu1, C. Stokke2, J. Blakkisrud2, A. Muftuler Løndalen1,
J. Dahle3, L. Baylor Curtis3, Å. Østengen3, K. Brustad Melhus3, S. Turner3,
M. Erlanson4, T. Illidge5, H. Holte1
1Radiumhospitalet, 2Oslo University Hospital, 3Nordic Nanovector, Oslo, Nor-
way, 4Norrland University Hospital, Umea, Sweden, 5University of Manchester,
Manchester, United Kingdom
Background: lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) is a novel
CD37-binding murine IgG1 antibody radionuclide conjugate (ARC), in a ready-to-
use formulation currently in Phase 1/2 clinical development for the treatment of
indolent non-Hodgkin lymphoma (iNHL). Previously, pharmacokinetic (PK) data
have been reported from 2 treatment arms of the ongoing LYMRIT-37-01 study.
In this abstract PK data from 4 treatment arms are presented for the first time.
Aims: This PK sub-study in iNHL patients (pts) was designed to determine the
PK profile of 177Lu-lilotomab when administered after four different pre-dosing
schedules.
Methods: Patients with relapsed incurable indolent NHL, with platelet counts
≥150 x109/L and <25% bone marrow involvement were eligible for inclusion in
the study. All pts received either one or two doses of rituximab to deplete normal
B cells. In addition, prior to 177Lu-lilotomab administration pts also received:
- 40mg lilotomab prior to 10, 15 or 20 MBq/kg 177Lu-lilotomab;
- no pre-dosing prior to 10 or 15 MBq/kg 177Lu-lilotomab;
- 250 or 375mg/m2 rituximab prior to 15 MBq/kg 177Lu-lilotomab;
- 100mg/m2 lilotomab prior to 15 or 20 MBq/kg 177Lu-lilotomab.
PK samples were collected at 0 and 5 minutes, then after 1, 2, and 20 hours
and at 2, 3, 4, 7, 14 and 21 days post-177Lu-lilotomab administration. The
patients were followed with weekly blood counts for 12 weeks post-treatment. 
Results: A total of 22 pts were enrolled into this PK sub-study, 19 with follicular
lymphoma, 2 with mantle cell and 1 with marginal zone histologies. The number
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of prior therapies ranged from 1 to 7, median body weight was 79 kg (range:
58-118kg).The administered activity across all treatment groups ranged from
746 to 1982 MBq. The table below shows a summary of the median PK and
haematology safety results for 177Lu-lilotomab by treatment group. The activi-
ty-adjusted AUC0-∞ of 177Lu-lilotomab increased with 100mg/m2 of lilotomab
compared to the other pre-dosing regimens (p<0.001 compared to 40mg lilo-
tomab). The median volume of distribution and clearance were both reduced
with 100mg/m2 of lilotomab compared with the other pre-dosing regimens.
However, activity adjusted Cmax was similar. Smaller percentage post-treat-
ment reductions in platelet and neutrophil counts were observed in patients
receiving 100mg/m2 lilotomab. Most common grade 3/4 AEs were hematolog-
ical and were transient and reversible.
Table 1.
#15 MBq/kg only. N=3 for each arm except with no pre-dosing n=2
Summary/Conclusions: A higher pre-dose of lilotomab increases the activi-
ty-adjusted AUC and decreases the volume of distribution and clearance rate
of 177Lu-lilotomab in iNHL pts. Despite the increase in AUC the percentage
reductions in neutrophil and platelet counts were smaller, indicating that a higher
dose of lilotomab may have a protective effect against the myelosuppression
associated with 177Lu-lilotomab. Further characterisation of 20 MBq/kg dose
of 177Lu-lilotomab with 100mg/m2 of lilotomab pre-dosing is ongoing and will
be presented.
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PHARMACOKINETICS AND TOLERABILITY OF OFATUMUMAB AND
BENDAMUSTINE IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN’S
LYMPHOMA
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Background: Anti-CD20 antibody rituximab (R)-based immunochemotherapy
is the standard treatment for untreated or relapsed indolent B-cell non-Hodgkin
lymphoma (iNHL). Due to the inevitable relapse of patients with iNHL, an unmet
need remains for active and well-tolerated novel therapies. Bendamustine
(BEN) is approved for the treatment of refractory iNHL, and the combination
therapy BEN-R showed efficacy in the treatment of relapsed iNHL. Ofatumumab
(OFA) is an anti-CD20 human monoclonal antibody (mAb) with high binding
affinity and slower dissociation from a distinct membrane-proximal epitope on
both small and large loops of CD20. OFA is indicated for the treatment of chronic
lymphocytic leukemia (CLL) and is being investigated for the treatment of iNHL.
The combination of OFA and BEN may provide additional clinical benefit in
patients with iNHL and therefore the potential for drug-drug interaction was
investigated. 
Aims: The study aimed to evaluate the pharmacokinetics (PK) of OFA and
BEN alone and in combination, along with the safety and tolerability assess-
ments in patients with previously untreated or relapsed iNHL.
Methods: In this Phase I open-label, multicentre study, patients (aged ≥18
years) with previously untreated or relapsed iNHL were randomized 1:1 to Arm
A (OFA + BEN) or Arm B (OFA alone) to receive at least four cycles and up to
eight cycles of treatment (cycle length 28 days). All patients provided informed
consent. Arm A patients received single-sequence treatment of BEN, then OFA
+ BEN, BEN (90mg/m2) on days 1 and 2 every 28 days for up to 8 cycles, and
OFA (1000mg) on day 1 of weeks 2, 3, and 4 of cycle 1 and on day 1 of cycles
2-8. Patients in Arm B received OFA alone at same dosing schedule. Blood
samples including all end-of-infusion (EOI) PK samples were collected for plas-
ma concentration over time. The primary PK parameters Cmax, AUClast, AUCinf
were derived using non-compartmental analysis. All adverse events (AEs) and
severe AEs (SAEs) were recorded for safety assessments.
Results: Thirty two patients were randomized (15 in Arm A and 17 in Arm B),
3 patients in Arm A discontinued study treatment due to consent withdrawal (2
patients) and infusion related AE (1 patient). All 32 patients were included for
safety and PK concentration analysis while 30 patients (15 in each arm) were
included for PK parameters. Patient and disease characteristics were similar
between treatment arms; the majority of patients from both arms did not receive
prior NHL therapy. PK concentration profiles and PK parameters of OFA were
comparable when administered alone or co-administered with BEN (Table 1).
As compared to OFA alone, there was a decrease of 14% in Cmax and 15% in
AUClast when OFA was co-administered with BEN, which was not considered
relevant (Table 1). BEN PK concentration profiles and PK parameters were
comparable with or without OFA co-administration (Table 1). 
All patients reported AEs. The most frequent treatment-related AEs were infu-
sion related reaction in 53% and 47%, nausea in 33% and 35%, fatigue in 33%
and 18% patients in Arm A and Arm B, respectively. The percentages of patients
with grade 3/4 AEs were higher in Arm A (53%) compared to Arm B (24%).
Cytopenias were present in 40% of patients in Arm A and 6% in Arm B. Four
SAEs were related to study treatment in Arm A while none in Arm B.
Table 1.
Summary/Conclusions: No relevant drug-drug interaction between OFA and
BEN was observed in this study. OFA alone or in combination with BEN exhib-
ited manageable safety profile in patients with iNHL.
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ASSESSMENT OF INTERNATIONAL CONSENSUS GROUP FOR
HEMATOLOGY (ICGH) SMEAR REVIEW RULES FOR AUTOMATED
PLATFORMS IN THE DETECTION OF MALARIA
J. Vaughan1,2,*, E. Benade1,2, S. Havyarimana1,2, N. Alli1,2
1Haematology, National Health Laboratory Services, 2Molecular Medicine and
Haematology, University of the Witwatersrand, Johannesburg, South Africa
Background: Peripheral blood smear review (SR) is a useful adjunct to the
full blood count (FBC) and differential white cell count (DWCC), but is labor
intensive and time consuming. For this reason, the international consensus
group for hematology (ICGH) published guidelines to reduce SR rates in clinical
laboratories using rules based on a combination of blood parameters and instru-
ment suspect flags. These rules have reduced SR rates in many laboratories,
but adjustment is often required to accommodate for local pathology/clinician
preferences. As malaria is common in Johannesburg (JHB) (although not
endemic), this study was undertaken to retrospectively evaluate the perform-
ance of modified ICGH SR rules for detection of malaria at the Chris Hani
Baragwanath Academic Hospital Laboratory (CHBAH) (part of the National
Health Laboratory Service (NHLS) network) in JHB, South Africa. 
Aims: To assess the performance of the CHBAH NHLS SR rules in the detec-
tion of malaria.
Methods: Malaria test results (P. falciparum antigen & thick/thin SR) were
extracted from the laboratory information system and corresponding FBCs
assessed in those with parasitemia. All ICGH rules were applied to patients
with both a FBC and DWCC requested, while only the parameter related rules
were applied to patients with only a FBC performed. Samples were processed
using a Sysmex XE-5000 analyser (Sysmex, Kobe, Japan), and the rules vio-
lated for each FBC recorded. As a retrospective laboratory based study,
informed consent was not obtained. However, the study was approved by the
Human Resarch Ethics Committee of the University of the Witwatersrand. 
Results: Of the 153 samples included, all had P. falciparum parasitemia and
37 were collected from patients with severe malaria. A FBC with a DWCC was
performed in 72/153(47.1%) patients, and a FBC alone in 81/153(52.9%). SR
rules were triggered in 132(86.3%) patients (68(84.0%) in those with only a
FBC performed and 64(88.9%) in those with a FBC and DWCC). The throm-
bocytopenia (platelets (Plt) <100x109/l) and anemia (Hb <7g/dl) rules were the
most common, triggering in 105(79.5%) and 24(15.7%) patients respectively.
Common analyzer morphology flags included those querying the presence of
atypical lymphocytes, immature granulocytes and blasts, but 1/more of these
triggered in the absence of parameter flags in only 5(7.9%) patients with a
DWCC requested. There were 21(13.7%) unflagged (false negative (FN)) sam-
ples, of which 20(95.2%) had a Hb level ≥10g/dl, 14(70.0%) had both a Hb
≥10g/dl and a plt count >120x109/l and 8(38.1%) had a Hb ≥10g/dl and a plt
count >150x109/l. On SR, malaria parasites were missed in a further 13.0% of
cases, predominantly when the parasitemia was low (median 0.35% in those
missed vs 3.1% in those with parasites identified). Reassuringly, SR rules were
triggered in all the patients with severe malaria, and the parasites identified in
90.5% of these. 
Summary/Conclusions: ICGH SR rules are FN in 13.7% of patients with
malaria, largely in those with near-normal blood counts. Furthermore, SR failed
to identify the parasites in a further 13.0% of cases (particularly those with very
low parasitemia). Elimination of a proportion of FN samples is thus not likely to
be possible, and clinical vigilance for this condition is required. Reassuringly,
SR rules were flagged in all patients with severe malaria, thus increasing the
likelihood of this entity being diagnosed if not tested for specifically. 
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A PROSPECTIVE MULTICENTER STUDY OF CANDIDEMIA IN NEUTROPENIC
PATIENTS WITH HEMATOLOGICAL DISEASES: INCIDENCE, RISK
FACTOR AND OUTCOMES
C.H. Yan1,*, D.-P. Wu2, J.-D. Hu3, H. Huang4, M. Jiang5, J. Li6, M. Hou7,
C. Wang8, Z. Shao9, T. Liu10, Y. Hu11, X.-J. Huang1
1Peking University People’s Hospital, Beijing, 2The First Affiliated Hospital of
Soochow University, Suzhou, 3Fujian Medical University Union Hospital,
Fuzhou, 4The First Affiliated Hospital of Medical School of Zhejiang University,
Zhejiang, 5he First Affiliated Hospital Of Xinjiang Medical University, Wulumuqi,
6The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 7Qilu Hos-
pital of Shandong University, Jinan, 8Shanghai General Hospital, Shanghai,
9Tianjin Medical University General Hospital, Tianjin, 10West China Hospital of
Sichuan University, Chengdu, 11Wuhan Union Hospital, Wuhan, China
Background: Candidemia is one of the most common nosocomial bloodstream
infections and is associated with high morbidity and mortality, especially
amongst the immunocompromised population. Several articles focus on the
epidemiology of candidemia, but most of them were from cancer patients,
patients with hematological malignancies, patients receiving solid organ trans-
plant, or patients receiving hematopoietic stem cell transplantation (HSCT).
Only 3 retrospective studies from single center described the clinical and micro-
biological features of candidemia in neutropenic patients with hematological
malignancies.
Aims: A prospective, multicenter, observational study was designed to inves-
tigate the incidence, risk factors and outcomes of candidemia in neutropenic
patients with hematological diseases.
Methods: This study was conducted in 11 hematological centers in China over
a five-month period. From October 20, 2014 to March 20, 2015, consecutive
patients of any age were included in this prospective study if they met the fol-
lowing criteria: (1) had hematological disease; (2) experienced at least one
episodes of neutropenia during hospitalization.
Results: A total of 1139 concecutive cases were enrolled in this study. Out of
1139 neutropenic cases, 8 developed candidemia. The median time from neu-
tropenia to diagnosis of candidemia was 18 days (range: 9-20 days). Among
the 8 causative strains, 5 were C. albicans and other 3 were C. Tropicalis. The
cumulative incidence of candidemia in neutropenic patients with hematological
diseases was 0.00% [95% confidence interval (CI): 0.00, 0.00%] at 7 days,
0.26% (0.00, 0.65%) at 14 days, 2.24% (0.67, 3.81%) at 21 days and 2.24%
(0.67, 3.81%) at 28 days after neutropenia, respectively. Among 8 casese with
candidemia, 3 were from patients receiving HSCT, other 8 were from patients
who had acute myeloid leukemia (AML) and receiving induction chemotherapy.
The cumulative incidence of candidemia in patients with AML and receiving
induction chemotherapy was also significantly higehr than that in patients
receiving HSCT and other patients (5.45% vs. 3.1%9 vs. 0.00%, P=0.023). In
addition, multivariate analysis suggested that gastrointestinal mucositis
(OR=26.038; P=0.003), central venous catheterization (OR=12.904, P=0.027),
duration of neutropenia >17 days (OR=11.649, P=.028) and diabetes
(OR=12.435, P=0.037) were the risk factors of candidemia in neutropenic
patients with hematological diseases. Based on the risk factors, 1139 cases
were stratified into low-risk group (0-2 risk factors), intermediate-risk group (3
risk factors), and high-risk group (4 risk factors). The cumulative incidence of
candidemia was higher in high-risk group than that in intermediate-risk group
and low-risk group (100.00% vs. 25.84% vs. 0.27%, P<0.0001). Besides, the
antifungal agents used when candidemia developed were itraconazole (3 cas-
es), voriconazole (2 cases), caspofungin (2 cases), and amphotericin B (1
case). All patients were treated effectively and no one died of candidemia.
Summary/Conclusions: This study provided a description for the epidemio-
logical study of candidemia in neutropenic patients with hemotological dis-
eases. This study defined the risk factors associated with candidemia in these
patients, and confirmed that based on the risk factors, risk-stratification could
identify the patients with a high-risk of candidemia. 
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BRONCHOALVEOLAR LAVAGE AS SYSTEMATIC APPROACH FOR EARLY
DIAGNOSIS OF LUNG INFILTRATES AND INVASIVE PULMONARY
ASPERGILLOSIS IN HEMATOLOGIC PATIENTS: A PROSPECTIVE SINGLE
INSTITUTION STUDY
F. Marchesi1,*, A. Spadea1, F. Pimpinelli2, G. Prignano2, M.G. Paglia3, D. Forcella4,
S. Gumenyuk1, D. Renzi1, F. Palombi1, A. Vulcano3, F. Pisani1, A. Romano1,
E. Papa1, F. Facciolo4, F. Ensoli2, C. Girmenia5, A. Mengarelli1
1Hematology and Stem Cell Transplant, Regina Elena National Cancer Insti-
tute, 2Molecular Virology, Pathology and Microbiology Laboratory, San Galli-
cano Dermatological Institute, 3Microbiology and Infectious Diseases Biorepos-
itory Laboratory, National Institute of Infectious Diseases “L. Spallanzani”, 4Tho-
racic Surgery Unit, Regina Elena National Cancer Institute, 5Hematology Unit,
Sapienza” University, Rome, Italy
Background: The best diagnostic approach of lung infiltrates (LI) remains to
be established. Despite bronchoscopy with bronchoalveolar lavage (BAL)
appears to be useful for LI diagnosis, hematologists and thoracic surgeons
often have qualms in performing bronchoscopy in this difficult patient population
at high-risk of procedure-related complications. A proper diagnostic approach
at LI seems to be particularly relevant in neutropenic patients and/or in patients
with an unfavorable clinical response to broad-spectrum antibiotics, in which
the cause of LI are often filamentous fungi, as Aspergillus spp.To date, there
is not a general consensus regarding the diagnostic panel to apply in hemato-
logic patients undergoing bronchoscopy for LI.
Aims: To evaluate the feasibility of bronchoscopy with BAL as systematic diag-
nostic approach at LI in hematologic patients, focusing on its role to diagnose
invasive pulmonary aspergillosis (IPA).
Methods: Bronchoscopy was performed in all hospitalized patient with diag-
nosis of acute leukemia and LI at onset of disease before therapy start, and in
any other hematologic patient in any phase of disease with LI requiring hospi-
talization because of concomitant febrile neutropenia and/or respiratory distress
not responding to broad-spectrum antibiotics. Criteria for not response to broad-
spectrum antibiotics were defined as persistent (> 48 h) fever and/or persistent
respiratory distress. In all cases we performed the same diagnostic work-up
including blood-swabs cultures, serum galactomannan (GM) assessment (in
three consecutive checks), serum beta-D-glucan, serum PCR for CMV; BAL
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fluid was studied by bacterial and fungal cultures, GM and PCR for Streptococ-
cus pneumoniae, Legionella pneumophila, Chlamidophila pneumoniae,
Mycoplasma pneumoniae, Bordetella pertussis, Bordetella parapertussis,
Haemophilus influenziae, respiratory virus including CMV, Pneumocystis jirove-
ci, Mycobacterium tuberculosis complex, Nocardia spp., Lysteria monocito-
genes and Aspergillus spp. Available commercial kits were used according to
manufacturer’s instructions.
Results: Out of 769 patients consecutively admitted in our ward, 85 had LI
and 47 of them underwent BAL (total amount: 51 procedures). A causal agent
of LI was detected in 33 cases (65%) allowing to modify the ongoing anti-micro-
bial treatment in 25 of these ones (76%). Twelve cases of probable IPA, accord-
ing to standard criteria, were diagnosed. Seven cases of LI fulfilling the radio-
logic criteria for IPA, though presenting only a positive Aspergillus PCR on BAL,
were detected and treated as probable IPA. One life-threatening post-procedure
complication was observed.
Summary/Conclusions: BAL seems a safe approach for an early diagnosis
of LI in hematologic patients. The assessment of a broad diagnostic panel
allowed the detection of a putative agent in 65% of cases. Assessment of
Aspergillus by PCR on BAL proved useful for probable IPA diagnosis.
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ESCAPE DRUG-RESISTANT INFECTIONS IN HEMATOLOGICAL
MALIGNANCIES. DARE TO REVIEW!
C. Gentille Sanchez1,*, K. Sun1, P. Teegavarapu1, Q. Qian1, P. Mamta2,
S. Wong2, I. Ibrahim1, L. Rice3, S.R. Pingali1, S. Iyer1
1Houston Methodist Cancer Center, 2Houston Methodist Research Institute,
3Houston Methodist Department of Hematology, Houston Methodist Hospital,
HOUSTON, United States
Background: Patients with hematological cancers are at a high risk for increas-
ingly resistant and severe infections. The Infectious Diseases Society of Amer-
ica has defined commonly resistant bacteria as ESKAPE (Enterococcus,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter, Pseudomonas
aeruginosa, Enterobacter). As suggested in recent literature, other common
and difficult-to-treat infections such as Clostridium difficile and Enterobacteri-
aceae organisms (E. coli, Proteus) can be added to this group and change the
acronym from ESKAPE to ESCAPE.
Aims: We performed a retrospective review of the rate of ESCAPE infections,
resistance profile, and outcomes in patients with various hematological malig-
nancies at the Houston Methodist Hospital from 2006 to 2015. 
Methods: The patient data was obtained from METEOR (Methodist Environ-
ment for Translational Enhancement and Outcomes Research), a clinical data
warehouse that contains records dating back to January 1, 2006, with over 3
million patients and over 10 million unique patient encounters. We queried for
leukemia (AML, CML, ALL, CLL), amyloidosis and myelodysplastic syndrome
(MDS) along with hospitalizations due to bacterial infections. Baseline demo-
graphics and overall outcomes were also obtained.
Table 1.
Results: Out of 6017 patients with Hematological Malignancies, 660 patients
with 684 malignant diagnoses were found; 235 had MDS, 174 had AML, 105
had CLL, 77 had amyloidosis, 44 had CML, 39 had ALL, and 10 had an unspec-
ified hematological cancer. Of 1132 infectious events, 62% were ESCAPE infec-
tions. The bacteria most frequently isolated were Enterococcus (23.4%),
Staphylococcus aureus (18.5%) and Pseudomonas (16.9%). Bacteremia was
the most predominant type of infection (41.9%) followed up by urinary tract
infections (38.2%). Patients with MDS (39.6%) and AML (25.3%) were mainly
affected. A prevalent resistance to levofloxacin was detected in gram positives
and gram-negative organisms (29-54%). Pseudomonas, E. coli, Proteus and
Klebsiella pneumoniae showed a significant resistance to broad-spectrum
antibiotics including aztreonam (23-34%), cefepime (7-23%), and imipenem
(22%). Proteus had the highest mortality rate (45.2%), followed by Enterococ-
cus (44.2%), and Pseudomonas (36.7%).
Summary/Conclusions: Hematological cancers with risk for neutropenia such
as MDS and AML were the most affected by ESCAPE. Bacteremia was fre-
quently seen. Gram-negative pathogens had an increased resistance to broad-
spectrum antibiotics and higher mortality rates. A significant resistance to lev-
ofloxacin, a prophylactic antibiotic, was also noted. New strategies for reducing
ESCAPE in MDS and AML are required. Further statistical review of this data
set will be presented at the EHA Meeting, Madrid 2017.
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PROPOSED PEGIFLGRASTIM BIOSIMILAR CHS-1701 DEMONSTRATES
PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY TO MAR-
KETED PEGFILGRASTIM IN A RAT NEUTROPENIA MODEL AND IN
HEALTHY SUBJECTS
P. O’Connor1,*, H. Tang1, F. Civoli1, B. Finck1, V. Vexler1
1Coherus BioSciences, Inc., Redwood City, United States
Background: CHS-1701, a proposed biosimilar of pegfilgrastim, is being devel-
oped to decrease infection in patients receiving myelosuppressive anticancer
drugs associated with febrile neutropenia.
Aims: The aim of the preclinical study was to compare pharmacokinetic (PK)
and pharmacodynamic (PD) effects of CHS 1701 and marketed pegfilgrastim
(MP) in a rat model of cyclophosphamide (CPA)-induced neutropenia. Since
pegfilgrastim has the same mechanism of action in humans and rats, preclinical
models of CPA-induced neutropenia are considered to be pharmacologically
and clinically relevant models of chemotherapy-induced neutropenia in cancer
patients. The aim of the clinical program was to demonstrate the PK and PD
bioequivalence of CHS-1701 to MP in a multi-center, randomized, single-blind,
3-sequence, 3-period, crossover study in healthy subjects.
Methods: In the rat model, a single SC dose of CHS-1701 or MP was admin-
istered at 24 hours after CPA administration, when the peripheral neutrophil
counts had been reduced by ~60-70% from baseline. Doses from 30 to 1000
µg/kg were evaluated in order to provide a broad range of exposures to pegfil-
grastim and allow for the comparison of CHS-1701 and MP dose response in
a steep part of the PD dose response curve. The PD response was evaluated
in the blood by analyzing time-dependent changes in absolute neutrophil counts
(ANC) and calculating ANC AUC0-last and in the bone marrow by analyzing
pegfilgrastim-induced expansion of myeloid cells and calculating the myeloid
to erythroid cell (M:E) ratio. In the clinical PK/PD study, healthy subjects (n=122)
were randomized to 1 of 3 treatment sequences; each included 1 therapeutic
dose of CHS-1701 (6-mg) and 2 doses of MP (6-mg) separated by ≥28 days.
Bioequivalence of CHS-1701 to pegfilgrastim was demonstrated for PK (Cmax,
AUC0-∞) if the 90% confidence interval (CI) for the geometric mean ratio (GMR)
was within 80-125% and for PD (ANCmax and ANC AUC0-last) if the 90% CI for
the GMR was within 80-125%.
Results: In the rat model, CHS-1701 and MP demonstrated similar time- and
dose-dependent changes in the number of peripheral neutrophils and in the
proliferative response in the bone marrow. No differences between CHS-1701
and MP in PD (Fig. 1) or PK were observed across the tested dose range.
In the clinical study, PK bioequivalence criteria were met for Cmax (GMR=105.0;
90% CI 95.5, 115.4) and AUC0-∞ (GMR=97.5; 90% CI 88.6, 107.2). Pre-spec-
ified PD bioequivalence criteria (90% CI) and more stringent criteria (95% CI)
were met for ANCmax (GMR=99.6; 90% CI: 96.2, 103.2; 95% CI: 95.5, 103.9)
and ANC AUC0-last (GMR=96.7; 90% CI: 92.2, 101.4; 95% CI: 91.4, 102.4).
The two treatments displayed similar safety profiles. Investigator-designated
treatment-related AEs occurred in 71.9%, 71.2%, and 62.8% of subjects during
the CHS-1701, first MP, and second MP dosing periods, respectively, and most
commonly included back pain (46.9%, 42.3%, 30.8%), headache (29.2%,
36.9%, 29.5%), and arthralgia (8.3%, 13.5%, 7.7%). There were no treatment-
related serious AEs.
Figure 1.
Summary/Conclusions: The dose-dependent changes in the neutropenia
model were consistent with the PD effects of pegfilgrastim in humans and
demonstrate that CHS-1701 results in comparable neutrophil recovery and time
course compared to marketed pegfilgrastim. The clinical study demonstrates
highly similar PK, PD, and safety profiles in humans for CHS-1701 and mar-
keted pegfilgrastim. Overall, preclinical and clinical results suggest that CHS-
1701 would provide similar PK, PD, safety, and efficacy to marketed pegfil-
grastim in patients with chemotherapy-induced neutropenia.
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A RETROSPECTIVE REVIEW IDENTIFYING RESISTANT MICROBIAL
STRAINS, ANTIMICROBIAL SENSITIVITIES AND RISK STRATIFICATION
OF FIRST LINE ANTIBIOTIC USE IN ADULT CANCER PATIENTS WITH
NEUTROPENIC SEPSIS
A. Danga1,*, Y.M.T. Hui2, K. Lazarus3, T. Sugai4
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Madrid, Spain, June 22 – 25, 2017
1Haematology, North West London NHS Trust, 2Haematology, West Middlesex
University Hospital, 3Renal Medicine, Imperial College Healthcare NHS Trust,
4Haematology, Hillingdon Hospital NHS Trust, London, United Kingdom
Background: Neutropenic sepsis remains a leading cause of morbidity and
mortality in both haemato-oncology and general oncology patients on cytotoxic
treatment. In 2012, UK NICE published guidelines on the empirical use of beta
lactam monotherapy in suspected neutropenic sepsis, discouraging the use of
aminoglycosides, in view of potential toxicities. Increasingly in clinical practice
it becomes evident that our patient population is incredibly heterogeneous and
with the emergence of multi drug resistant strains of micro-organisms, high-
risk individuals need to be identified early and first line antimicrobial treatment
regimens tailored according to patient factors alongside local antibiogram.
Aims: To retrospectively review appropriate antibiotic use, microbial identifi-
cations and antibiotic sensitivities amongst adult cancer patients with neu-
tropenic sepsis. To identify if any patient or disease characteristics are associ-
ated with adverse outcomes, that would support the upfront usage of amino-
glycoside containing antibiotic treatment regimes.
Methods: A retrospective review of patients treated for neutropenic sepsis was
conducted for the period between 1/4/2015 to 11/10/2016. Analysis of potential risk
factors including primary disease, age, sex, treatment regimen, albumin, neutrophil
and lymphocyte count to assess potential association with adverse outcomes.
Results: There were 116 episodes of neutropenic sepsis in 92 patients in this
period. Of these, 61 were haemato-oncology patients and 31 general oncology.
42 of 76 positive cultures identified gram-negative organisms. 40 patients
received single agent Tazocin and 71 patients (61.2%) received Tazocin and
an aminoglycoside as first line antimicrobial treatment. Fourteen isolates
demonstrated resistance, including 2 cases of stenotrophomonas maltophilia
and 12 cases of enterobacteriaceae. 13 of the 14 resistant isolates were found
in haemato-oncology patients. Nine of these cases were resistant to single
agent Tazocin but sensitive to an aminoglycoside. The mean age of cases with
resistant bacteria isolated was 54.2 years (range 25-84 years). There was no
difference in sex or degree of neutropenia/lymphopenia in the cases that con-
tracted resistant bacterial strains compared to those that were culture negative.
Of the 4 fatal cases with resistant bacteria, 3 had low albumin (mean 25.5g/L
cf. mean of 34g/L in resistant bacteria cases surviving).
Summary/Conclusions: This retrospective analysis supports the use of com-
bination antimicrobials up front as first line treatment in high-risk patients with
neutropenic sepsis. The study has demonstrated that the patient cohort most
at risk of developing drug resistant bacteraemia are patients with high-risk or
relapsed haemato-oncological disorders like AML or high-grade lymphoma,
requiring multiple cycles of intensive chemotherapy. Of the patients who isolate
resistant bacteria, identifying low albumin early may be a potential marker for
adverse outcome in terms of morbidity and mortality. Of interest only one oncol-
ogy patient isolated a resistant strain of bacteria, furthermore only 25% of gen-
eral oncology patients treated with neutropenic sepsis had positive cultures
compared to 79.8% of haemato-oncology patients. When comparing these
findings to UK NICE recommendations it is clear that first line use of Tazocin
in general oncology patients may well suffice in initial treatment of neutropenic
sepsis. However with haemato-oncology patients early or up front consideration
for the additional usage of an aminoglycoside is essential to optimize favourable
outcomes in high-risk patients. From this small study, the proposed risk factors
of isolating resistant strains of bacteria leading to adverse outcomes would be
aggressive haematological malignancies, receiving more intensive cytotoxic
therapy, multiple lines of treatment and low albumin. Further analysis in a multi
centre prospective study in this patient population alongside close collaboration
between clinicians and microbiologists is essential in providing optimal antimi-
crobial therapy algorithms in neutropenic patients.
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PRELIMINARY RESULTS FROM A LONG-TERM REPEAT DOSE TOXICITY
AND TOXICOKINETIC STUDY OF ANF-RHO, A NOVEL ANTI-NEUTROPENIC
FACTOR
J. Valentino1, H. Misra1,*, J.A. Newmark2
1Prolong Pharmaceuticals, Prolong Pharmaceuticals, South Plainfield, 2Toxi-
cology, Toxikon, Bedford, United States
Background: ANF-Rho is a novel polyethylene glycol-modified granulocyte
colony stimulating factor that has biophysical and biological properties that pro-
duce a prolonged pharmacokinetic and pharmacodynamic profile as compared
to pegfilgrastim (Neulasta®). As such, it has potential applications in chemother-
apy induced neutropenia and chronic idiopathic neutropenia. These disorders
require prolonged administration of G-CSF agents to treat neutropenia. There-
fore, long term toxicology, genotoxicity and Juvenile studies were conducted
with ANF-Rho.
Aims: A 13-week study was conducted in Sprague Dawley rats and cynomol-
gus primates to assess various safety and pharmacokinetics of ANF-Rho as
compared to Neulasta® (pegfilgrastim). 
Methods: The study design used 288 rats, divided into 5 dosage groups: con-
trol, 100, 300, 1000 (high) and 1000 (positive) µg/kg. A total of 58 monkeys
were also divided into 5 dosage groups: control, 75, 250, 750 (high dose) and
750 (positive) µg/kg of ANF-Rho. Doses were administered by weekly subcu-
taneous injections on Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85 and
92 at a dose volume of 5 mL/kg. Genotoxicity assessments were evaluated
using Salmonella typhimurium and Escherichia coli reverse mutation assay,
rodent blood micronucleus assay and chromosomal aberration assay. Toxicol-
ogy assessment included clinical observations, body weight change, food con-
sumption, ophthalmic examination, function observational battery (motor activ-
ity, behavioral changes, coordination and sensory/motor reflex response), organ
weight, bioanalytical and toxicokinetic analysis, immunogenicity, gross necrop-
sy and histopathology. 
Results: No observed clinical signs seemed to be related to ANF-Rho admin-
istration. There were no related effects in body weight changes or food con-
sumption. Observed ophthalmic effects were considered procedural related
due to low incidence. No biologically meaningful findings were noted during
the function observational battery assessment. Preliminary analysis showed a
dose related increase in spleen weight in rats and a dose dependent decrease
in kidney weight in primates. Genotoxicity studies found no signs of mutagenic-
ity, clastogenicity or cytotoxicity.
Summary/Conclusions: The results from this preliminary toxicology studies
are unremarkable and consistent with those of an earlier 28-day study. Results
from the 28-day rat neutropenia dosage model found that the blood pharma-
codynamics parameters of ANF-Rho were significantly superior to PEG-filgras-
tim. Both PK and PD data demonstrate relatively predictable systemic expo-
sures and activity following SC or IV dose levels in both rat and primate. It is
anticipated that this long terms 13-week study will provide evidence of safety
sufficient to support advancement of ANF-Rho into Phase II clinical studies in
chemotherapy-induced neutropenia and chronic idiopathic neutropenia in
Europe, USA and India.
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USE OF MICAFUNGIN IN PROPHYLAXIS IN ONCO-HEMATOLOGY:
RESULTS OF AN OBSERVATIONAL, MULTICENTER, PROSPECTIVE
FRENCH STUDY (OLYMPE)
J. El-cheikh1,*, J.-H. Dalle2, S. Ducastelle-Leprêtre3, J.-B. Quiniou4, P. Ceballos5,
R. Herbrecht6
1American Hospital, Beirut, Lebanon, 2Hôpital Robert Debré, Paris, 3Hospices
Civils, Lyon, 4Medical Affairs, Astellas pharma France, Levallois-Perret, 5Centre
Hospitalo-Universitaire, Montpellier, 6Centre Hospitalo-Universitaire, Stras-
bourg, France
Background: Antifungal prophylaxis is being used increasingly.
Aims: The therapeutic arsenal is extensive and requires a better understanding
of micafungin use in onco-hematology where most-at risk patients of invasive
fungal infections (IFI) are managed.
Methods: This observational study was conducted in 18 onco-hematology
units in adult patients and children treated with micafungin in prophylaxis with
a 3-months follow-up period.
Results: 150 patients (95 adults, 55 children) were included and represent the
analysis population. In total, 15 patients (10%) presented an IFI during mica-
fungin treatment. Among them, 11 presented a probable or proven IFI. The
rate of IFI was higher in children (15%, n=8) than in adults (7%, n=7) and seem
to have been influenced by the type of hemopathy and if the patient was allo-
grafted or not: 13% (n=8) in allografted patients, 9% (n=4) in patients with AML
or SMD and 7% (n=3) in other patients. Median time to infection was 24 days
(1 to 68 days) and was longer in adults (25 days, 4 to 68 days) than in children
(16.5 days, 1 to 68 days). Twelve patients (8 children and 4 adults) presented
at least one clinical or radiological sign of suspected IFI. Fungus was identified
in 8 patients (62%), mostly in blood cultures (50%, n=4): candidiasis in 4
patients, aspergillosis in 3 patients and infection related to Rhisopus in 1 patient.
Incidence rate of IFI (10%, 5 patients) was inferior to prophylaxis failure rate
(23%, 34 patients). Prophylaxis failure rate takes in account patients who
switched to empirical treatment besides patients who switched to preemptive
or curative treatment. After the end of prophylaxis, 4 patients (3%, 3 adults
and 1 child) presented a proven IFI. Median time to infection after the end of
treatment was 10,5 days in adults (7 to 24 days) and 52 days in children. Mica-
fungin was overall well tolerated: only 10 patients (7%, mostly children) pre-
sented grade 1 to 4 adverse events related to micafungin, including 5 patients
(3%à with grade 3 or 4 adverse events.
Summary/Conclusions: Effectiveness and safety profile of micafungin in pro-
phylaxis are similar to what was observed in previous studies. Incidence IFI
rate of 10% confirms the clinical effectiveness of micafungin in prophylaxis in
high risk patients. The low rate of serious adverse events confirms micafungin
safety profile, in children included.
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OUTBREAK OF MULTI-DRUG RESISTANT PSEUDOMONAS AERUGI-
NOSA (MPA) IN A HAEMATOLOGY WARD (HW): MANAGEMENT AND
INFECTION CONTROL MEASURES
D. Armiento1,*, E. Cerchiara1, O. Annibali1, M. Becilli1, E. Circhetta1, S. Ferraro1,
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Background: Pseudomonas Aeruginosa (PA) is a gram negative, ubiquitous,
opportunistic pathogen. Its intrinsic resistance to many antibiotics and the selec-
tive pressure exerted by empiric antimicrobial use, led to the emergence of
MPA in hematologic units, with high mortality and morbidity rates among infect-
ed immunocompromised patients (pts). Considering our MPA incidence of 9%
in 2007/08, an outbreak developed at the HW of “Campus Bio-Medico” Univer-
sity Hospital of Rome, from 2009, despite the measures employed from the
previous 2 years (health personnel sensitization, regular air and water filters
changing, isolation precautions). 
Aims: To describe the MPA outbreak occurred between 2009 and 2013.
Methods: Our HW, opened in 2007, is composed by 7 rooms, each with a pri-
vate WC: 2 single, 1 double and 4 single, positive pressure, each with a fil-
tered-zone, dedicated to stem cell transplanted pts. Retrospective study: From
01/2009 to 04/2013 we hospitalized 415 adult pts; of these, 106, at high infec-
tious risk (HIR) for severe and prolonged expected post-chemotherapy neu-
tropenia, have been routinely screened at admission with microbiological sam-
ples (nasal, pharyngeal and rectal swabs) and additional tests when clinically
indicated. Because, during this period, we observed a dramatic incidence of
MPA isolates, we fulfilled specific sequential measures, to assess potential
reservoirs and breaks in infection control and to manage the outbreak, sum-
marized by the following 4 phases: phase A: closing of HW from 29/04/2013 to
09/06/2013; phase B: serial pre and post-disinfection environmental sampling
from each room: swabs from sink filters, bidet filter, shower filter, flush button,
infusion pump, TV remote control, 70% ethylic-alcohol gel bottle, floor sink,
bedpan and water samples from bedpan automatic washers (BAW); phase C:
room environmental disinfection and microbial decontamination with nebulized
H2O2 solution added with silver cations; phase D: disposal of BAW, introducing
the sole use of disposable bedpans and planning an environmental sampling
and disinfection program.
Results: On 04/2013 we revised retrospective study data: 82 pts carried bac-
terial isolates; of these, 48 (59%) had MPA, classified as colonisation in 13 pts
(mainly detected on rectal swabs) and true infection in 35: 10 pneumonias
(29%), 6 anorectal/perineal (17%), 5 urinary tract (14%), 14 bloodstream infec-
tions (40%). Ten pts died of MPA related infection, with a mortality of 53% (10
on 19 pts) and case-fatality rate of 29% (10 on 35 pts). Phase B defined a
prevalence of PA isolates in 6 out of 7 rooms in different sample types, with 4
MPA isolates identified in 3 different BAW and 1 bedpan after washing cycle.
After phase C, a new phase B demonstrated sterilization of 3 out of 6 PA and
3 out of 4 MPA isolation sites. As a main corrective action, after 41 days we
resumed admissions and approached phase D, resulting into a prompt and
maintained decrease in isolates (Table 1).
Table 1. MPA isolates and mortality rate after phase D.
Summary/Conclusions: We identified the contaminated water residue from
BAW as the main source of MPA spread in our HW, getting a full outbreak con-
trol by improving environmental measures. Pseudomonas contaminates and
survives on many ecological niches, being continuously reintroduced in noso-
comial settings. Our experience highlights the value of environmental and per-
sonal hygiene measures on MPA infections control.
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MONITORING VORICONAZOLE PHARMACOGENOMICS AND PLASMA
CONCENTRATIONS IN THE TREATMENT AND PREVENTION OF INVASIVE
FUNGAL DISEASE FOR HEMATOLOGICAL PATIENTS A SINGLE CENTER
EXPERIENCE
D. Guo1, T. Xu1, Z. Li1, J. Yin1, X. Tian1, D. Guo1, Y. Xu1, X. Zhu1, L. Miao1,
D. Wu1,2, X. Tang1,2,*
1The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, 2Institute of Blood and Marrow Transplantation,Collaborative Innovation
Center of Hematology, Soochow University, Suzhou, China
Background: Voriconazole has been widly used in treatment and prevention
invasive fungal disease for immunodeficiency hematological patients. And the
voriconazole plasma drug levels were associated with its efficacy and toxicity.
The hepatic cytochrome P450 isoenzyme 2C19 plays a important role in
voriconazole metabolism. However if CYP2C19 genetic polymorphism can
result in voriconazole metabolism and drug plasma level in setting of Asian
population especially in hematologic patients is unknown.
Aims: To evaluate the effect of CYP2C19 polymorphism on the voriconazole
(VCZ) plasma concentration of patients with hematological disease and the
value of serial monitoring voriconazole plasma concentrations in the treatment
and prevention of invasive fungal disease(IFD).
Methods: Between January to August 2016, 76 hematological patients who
received voriconazole for the treatment or prevention of invasive fungal disease
were enrolled in this study. The population CYP2C19 polymorphism of voricona-
zole were performed using PCR-Pyrosequencing. The trough plasma concen-
trations of vriconazole (Ctrough) was determined using high-performance liquid
chromatography (HPLC).
Results: Genotyping for CYP2C19 polymorphic isoenzyme variations showed
that 32 subjects (43.42%) for the CYP2C19 wild-type, 43 (56.58%) for the
CYP2C19 no-wild-type. 2. 45 of 76 patients received voriconazole intravenous
administration, Based on the genotype analysis, 45 subjects were identified as
extensive metabolizers’ group for EMs (CYP2C19*1/*1), poor metabolizers’
group for IMs+PMs (CYP2C19 * *1/*2,*1/*3,*2/*3,*2/*2,*3/*3)and there was a
significant difference between Ctrough values in the two groups (1.66±1.86ug/ml
vs 3.30±2.35ug/ml, p=0.00). 3. The Ctrough of the 45 patients were detected for
119 times totally. The medium of the Ctrough 45 hematological patients were
described. Lack of response to therapy was more frequent in patients with
voriconazole levels <1.5mg/L (23.5%) than in those with voriconazole levels
>1.5mg/L (21.4%])(p=0.87). And the risk of adverse events was more frequent
in patients with voriconazole levels >5.5mg/L (40.0%) than in those with
voriconazole levels <5.5mg/L (25.0%) (p=0.49). Furthermore, the Ctrough val-
ues of patients with adverse events is higher than the others(3.21±2.46ug/ml
vs 2.17±2.14 ug/ml, p=0.042).
Summary/Conclusions: The single-center study showed that the mutation of
CYP2C19 was quite common in Chinese hematological patients. Patients with
CYP2C19 wild-type phenotype are extensive metabolizers, their Ctrough of
voriconazole are significantly lower than patients with CYP2C19 non-wild-type
phenotype (poor metabolizers). Appropriate concentrations of vriconazole can
improve the effiency of therapy and safety outcome.
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BACTEREMIA AND SEPSIS FOLLOWING INTENSIVE CHEMOTHERAPY
OF ADULT ONCOHEMATOLOGICAL PATIENTS
S. Bessmeltsev1,*, V. Chebotkevich2, E. Kiseleva2, N. Stizhak2, E. Kaytandzhan2,
V. Burylev2
1Haematilogy, 2Lab. Bacteriology, Russian Institute of Haematology andTtrans-
fusiology, St. Petersburg, Russian Federation
Background: Intensive cytostatic chemotherapy is a standard strategy for
leukemia treatment. Meanwhile, such treatment causes negative effects, including
lymphopenia, granulocytopenia and damage to tissue barriers associated with
significant risks of infectious complications, especially, bacterial sepsis and viremia.
Aims: Our study was aimed for identification of bacteremia in oncohematolog-
ical patients following intensive chemotherapy, and assessment of potential
modifying role of herpesvirus infections. 
Methods: Retrospective review of positive bacterial isolates of blood between
January 1991- December 2015. Prospective study the cases of bacteremia and
sepsis in cohort of 64 patients with hematologic malignancies. Diagnostics of
septic conditions was based on clinical data, bacteremia and systemic inflam-
matory reaction syndrome (SIRS) (registration of, at least, 2 of 4 clinical symp-
toms of SIRS). Bacteriological analyses and identification of micromycetes were
performed by uniform technique over the entire study period, according to the
valid guidelines. For DNA-diagnostics, we used gene-specific PCR with real-
time registration. DNA was extracted from peripheral blood leukocytes The her-
pesvirus panel included Herpes Simplex type 1 and 2 (HSV); Cytomegalovirus
(CMV); Epstein-Barr virus (EBV), and Human Herpesvirus type 6 (HHV6). PCR
techniques were performed according to manufacturer instructions.
Results: Based on the study 4923 blood samples it was shown that the fre-
quency of detection of bacteria was 11.0%. The predominance of Gram-positive
bacteria was demonstrated among pathogens detected in the bloodstream.
However, the ratio of detectable Gram-negative flora was found to be increased
from 23.1% to 39.6% between 2002 and 2015 (p<0.05). Coagulase-negative
staphylococci (CoNS) prevailed among Gram-positive microorganisms, in par-
ticular, S. epidermidis, whereas Enterobacteriaceae, especially, E.coli, dominat-
ed among the Gram-negative bacteria. It is shown that the development of bac-
teremia were significantly more frequently occurs on the background of the
detection of Cytomegalovirus and the Epstein-Barr virus genomes. In recent
years there has been increase the frequency of micromycetes detection in the
blood of patients with hematological malignancies. In present study, аntibacterial
therapy started with β-lactame antibiotics combined with fluoroquinolones,
aminoglycosides, metronidazole. If required, the antimicrobial strategy was
revised 48 to72 hours later as based on clinical and microbiological data, apply-
ing carbapenems also combined with other anti-infectious drugs. When detecting
herpesviruses (EBV, HSC-1/2, HHV6, or CMV) the therapy was accomplished
by antiviral drugs, i.e., Acyclovir or Valacyclovir (for CMV treatment). Sepsis in
accordance with the criteria (SIRS and bacteremia) was diagnosed in 33 of 64
patients. Мortality was higher in patients with Gram-negative sepsis – 8 of 14
patients (57%) whereas in Gram-positive sepsis 2 of 19 patients (11%).
Summary/Conclusions: Our data support a general viewpoint on regular mon-
itoring of infectious pathogens upon intensive chemotherapy of oncohemato-
logical patients prone to both bacterial and viral infections. Severe bloodstream
infectious complications are often associated with fungal invasions, and her-
pesvirus reactivation. In particular, our results suggest that herpesviruses, may
cause immunosuppression, or may serve as additional immunodeficiency mark-
ers predictive for bacterial infections at later terms.
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GLYCOSYLATED FERRITIN MEASURING SIGNIFICANCE FOR SECONDARY
HEMOPHAGOCYTIC SYNDROME DIAGNOSTICS
V. Potapenko1,*, M. Pervakova2, S. Lapin2, A. Klimovich1, O. Mironova1,
N. Petrova1, N. Chernookaya1, N. Skorobogatova1, E. Karyagina3, E. Karev4,
E. Pavluchenko4, N. Potikhonova5, T. Kulibaba6, N. Medvedeva1, B. Afanasyev2
1Municipal clinical hospital №31, 2Academician I.P. Pavlov First St. Petersburg
State Medical University, 3Municipal hospital №15, 4I.I. Mechnikov North-West-
ern State Medical University, 5Russian Scientific Research Institute of Hema-
tology and Transfusiology, 6Saint-Petersburg State University, Saint-Peters-
burg, Russian Federation
Background: Hemophagocytic syndrome (HPS) is a clinicopathologic condi-
tion characterized by systemic inflammatory reaction with cytopenia and tissue
damage. The HPS may be primary (genetic associated) or secondary (SHPS),
caused by different systemic disorders (immune, infectious, neoplastic). The
overall clinical symptoms are similar to sepsis, so it could be difficult to differ-
entiate among these entities. Ferritin levels are high in both cases, but the gly-
cosylated/nonglycosylated ferritin fractions ratio is seems to be indicative.
Aims: The estimation of the ferritin fractions ratio and biochemical profile in
patients with sepsis and SHPS.
Methods: The data from 64 patients were analyzed: 40 pts with diagnosed
SHPS (median age 57, range 8-74 years) and 24 with lethal septic shock (medi-
an age 57.5, range 18-82 years). SHPS in patients with persistent fever refrac-
tory to antibacterial therapy and/or prolonged cytopenia and/or organ (lungs,
CNS) involvement was established after the other conditions had been exclud-
ed. Sepsis diagnostics was based on the confirmed infection site and systemic
inflammation with multiorgan failure. The following serum values were analyzed:
alkaline phosphatase (AlPh), alanine aminotransferase (ALAT), asparagine
aminotransferase (ASAT), lactate dehydrogenase (LDH), bilirubin, creatinine,
INR, C-reactive protein (CRP), procalcitonin (PCT), total ferritin, and glycosy-
lated ferritin percentage. Mann-Whitney U test and ROC-analysis were used
for statistical analyses.
Results: No differences were found in sepsis and SHPS for ALAT, ASAT, AlPh,
LDH, and bilirubin levels. The difference of INR, CRP, PCT, creatinine levels
was significant (p<0.01). The most substantinal difference in SHPS and sepsis
groups had serum concentrations of ferritin, triglycerides, level of ferritin gly-
cosylation (p<0.01) (Table 1). According to ROC-analysis, the area under the
curve for ferritin, triglycerides and percentage of ferritin glycosylation were
0.78, 0.82, and 0.92, respectively.
Table 1.
Summary/Conclusions: The most difference between sepsis and SHPS was
observed for triglycerides, ferritin and percentage of glycosylated ferritin. Per-
centage of glycosylated ferritin fraction seems to be the most indicative, which
may make it useful for SHPS diagnostics and its differentiation from sepsis. 
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SERUM HEPCIDIN QUANTIFICATION IN INFLAMMATORY BOWEL
DISEASES
V. Manolov1,*, V. Vasilev1, K. Tzatchev1, O. Georgiev2, D. Stefanova-Petrova2,
R. Tzrantcheva2, V. Mitev3
1Dept. of Clinical laboratory and clinical immunology, 2Department of
Propaedeutics of Internal diseases, 3Department of Medical chemistry and bio-
chemistry, Medical University, Sofia, Sofia, Bulgaria
Background: Inflammatory bowel diseases (IBD) includes different intestinal
pathologies, most common among them are Colitis Ulcerosa (CU) and Crohn’s
Disease (CD). Pathogenesis of IBD is still unclear, however they are multifactor
diseases, with genetic and autoimmune compounds, in combination of envi-
ronmental factors. One of IBD symptoms is iron deficiency anemia. 
Aims: We aimed to search for connection between serum hepcidin quantifica-
tion and anemia in IBD.
Methods: We included 64 patients with IBD - 29 with Colitis Ulcerosa (CU),
and 35 with Crohn’s Disease (CD). They were diagnosed in University “Alek-
sandrovska” hospital in Clinic of Gastroenterology. Their results were compared
to age and gender matched healthy controls. Laboratory assessments were
analyzed for included groups – iron, ferritin, CRP, IL-6 and hepcidin. AAS,
nephelometric, ELISA and statistical methods were used during analyzes and
obtained results interpretation.
Results: 53 from our patients had with iron deficiency anemia (IDA) and low
hepcidin concentrations (5.9±1.1 µg/L) compared to control group (19.9±2.8
µg/L); P<0.001. 11 of included cases had combination of IDA and anemia of
chronic disease (ACD). Their hepcidin levels were increased (59.9±6.4 µg/L)
in comparison to healthy controls (19.9±2.8 µg/L); P<0.001. In patients with
ACD/IDA, quantified serum hepcidin correlates positively to increased IL-6
(r=0.758, P<0.005) and CRP concentrations (r=0.899, P<0.001). 
Summary/Conclusions: Quantification of serum hepcidin levels in IBD
patients might be a key element in diagnosis and treatment of anemia in these
patients. Serum hepcidin levels are useful marker for differential diagnosis
between iron deficiency anemia and combination iron deficiency anemia/ ane-
mia of chronic disease.
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MUTATIONS IN YARS2 CAUSE CONGENITAL SIDEROBLASTIC ANEMIA
WITHOUT SHOWING EVIDENCES OF MYOPATHY AND LACTIC ACIDOSIS
B. Cadenas1,*, J. Fita1, S. Montesdeoca2, C. Pedro2, M. Sanchez1
1Iron Metabolism: Regulation and Diseases, Josep Carreras Leukaemia
Research Institute (IJC), BADALONA, 2Hematology Service, Hospital del Mar,
Barcelona, Spain
Background: Mutations in the gene YARS2 encoding mitochondrial tyrosyl-
tRNA synthetase have previously been identified as a cause of MLASA2, a
mitochondrial respiratory chain disorder presenting with myopathy, lactic aci-
dosis and congenital sideroblastic anemia (OMIM #610957, ORPHA 2598).
Up to date in the literature it has been reported 9 families with 11 affected indi-
viduals with mutations in YARS2 gene and affected from MLASA2. 
Aims: Here we report a new case with a different clinical presentation.
Methods: We have identified two novel variations in YARS2 gene using Next
Generation Sequencing (NGS) panel containing 10 genes involved in congen-
ital and acquired sideroblastic anemia.
Results: The proband is a young woman aged 24 where we have identified 2
novel variations in YARS2 gene. One pathogenic splicing mutation
NM.001040436.2 c.[1104-1G>A], and a missense variation NM.001040436.2
c.608 G>T; NP_001035526.1: p. Ser203Ile located in the C-core catalytic
domain of the mitochondrial tyrosyl-tRNAsynthetase. None of these two vari-
ations were previously reported in public databases (ExAC, NCBI SNP, Ensem-
bl). Clinical data from the patient showed marked sideroblastic anemia (Hb 91
g/L, 32% ring sideroblasts), but not signs of muscle weakness or myopathy
and no lactic acidosis (lactic acid levels were 1.8mmol/L, normal range: 0.5 -
2.2 mmol/L; creatine kinase 23 UI/L, normal range: 23-170 UI/L), as could be
expected due to previously reported cases in the literature. Functional assays
are on-going to confirm pathogenicity of the novel missense variation. 
Summary/Conclusions: Here, we reported a patient with mutation in YARS2
gene showing congenital sideroblastic anemia but presenting neither lactic aci-
dosis nor myopathy. Therefore, patients with defect in YARS2 gene may pres-
ent with a less severe clinical manifestations only involving congenital sider-
oblastic anemia without other extra-hematopoietic defects. MLASA2 must be
consider in patients presenting with only congenital sideroblastic anemia since
early diagnosis and supportive therapy will be important to prevent complica-
tions.
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IRON CHELATION DATA OF CONGENITAL DYSERYTHROPOIETIC ANEMIA
PATIENTS: A SINGLE CENTER EXPERIENCE
M. Cetin1,*, N. Kalkan1, T. Bayhan1, F. Gumruk1, S. Unal1
1Hacettepe University, Divison Of Pediatric Hematology, Ankara, Turkey
Background: Congenital dyserythropoietic anemia (CDA) is a rare, genetically
heterogenous disorder characterized with ineffective erythropoiesis, and con-
genital malformations in certain types. Patients present with varying degrees
of anemia and some of the patients may have mild disorder wheras others
may be transfusion dependent. The ineffective erythropoiesis and the transfu-
sional iron load puts these patients at risk for iron overloading and there is very
scarce data on the iron loading and chelation types in these patients.
Aims: We aimed to summarize the chelation results of our patients with CDA
from a single center.
Methods: Of the 33 patients with CDA, 11 were initiated iron chelation treat-
ment either for receiving more than 20 packed RBC transfusions previously or
for having serum ferritin levels above 1000ng/ml. 
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Results: Of these 11 patients, 7 were CDA type II. The median age of diagnosis
was 12 months (3-144) months and male to female ratio was 7/4. Median trans-
fusion requirement per year at previous year prior to initiaition of chelation was
12 times (0-17). All of the patients were on chronic transfusion programme at
initiation of iron chelation except for 2 (one receives occasional transfusion, and
the other patient was on chronic transfusion programme but became treansfu-
sion independent after splenectomy). The median age at last visit was 70 months
(32m-40 years). The median value of serum ferritin at initiation of iron chelators
was 822 ng/ml. All of the patients were initiated deferasirox for iron chelation at
a median dose of 24mg/kg/day (10-40) and the median chelation follow-up dura-
tion was 27 months (2-54 months). Three of the patients were evaluated with
cardiac and hepatic T2* assesment prior to and by the end of 1 year of chelation
aand none of the patients were found to have cardiac iron loading at chelation
initiation, wheras 2 had severe and 1 had moderate LIC values. In the subse-
quent assesment under chelation of these 3 patients all still had cardiac T2* val-
ues above 20 ms, wheras 1 had mild and 2 had moderate LIC values. Serum
ferritin levels prior to chelation initiation and by the end of 1 year were compared
and the difference was found statistically insignificant.
Summary/Conclusions: Patients with CDA are at risk for iron loading and
they need to be screened for the iron loading periodically. The prompt chelation
in these patients prevent organ failure risks at long term including cardiac failure,
cirrhosis and endocrinopathies. 
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ORAL IRON CHELATION FOR TREATMENT OF HEREDITARY
HEMOCHROMATOSIS IN CHILDREN
M. Moraki1,*, E. Repousi1, D. Kyriakopoulou1, P. Delaporta1, A. Kattamis1
1Thalassemia Unit,First Department of Pediatrics, National and Kapodistrian
University of Athens, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece
Background: Hereditary hemochromatosis (HH) very rarely presents during
childhood. The most common form of HH in children is Juvenile Hemochro-
matosis (JH), a rare genetic disorder inherited with an autosomal recessive
manner, resulting from mutations in either the hemojuvelin (HJV) (type 2A) or
the hepcidin (HAMP) gene (type 2 B). Early diagnosis and closely monitoring
of iron overload indexes, namely, serum ferritin levels, transferrin saturation
and tissue iron measurement by magnetic resonance imaging (MRI) are essen-
tial in order to prevent permanent organ damage and potentially life threatening
complications (cirrhosis, diabetes mellitus, cardiac dysfunction, and hypogo-
nadism). Therapeutic intervention in children with HH may be problematic, as
eryhtrapheresis is invasive and may not be well tolerated in young children.
Iron chelation therapy can be implemented as an alternative treatment to ery-
throcytapheresis.
Aims: The scope of this study was to evaluate the use of an oral iron chelation
therapy in young children with HH.
Methods: 3 children (2 females and 1 male) were diagnosed with HH at the
aged of 4, 6 and 8 years old, respectively, based on increased ferritin and trans-
ferrin saturation levels and exclusion of other not-iron-overload related causes
of hyperferritinemia. Genetic analysis were performed in all 3 patients and
showed positive results in 2 of them, while on the 3rd no genetic changes could
be identified. All patients were at pre-symptomatic stage of the disease and
they were referred for evaluation after hyperferritinemia was discovered on a
routine screening examination. Liver iron concentration (LIC) and cardiac iron
concentration were evaluated by MRI (table 1). Iron chelation therapy with
deferasirox (DFX) at low dose (of 10mg/kg/24h) was initiated, after evaluation
was completed and permission from regulatory authorities obtained.
Table 1. Clinical characteristics of the patients.
Results: All 3 patients responded promptly to therapy and showed decreased
levels of ferritin, LIC and cardiac iron concentration. Gastrointestinal distur-
bances were noted in 1 patient, which resolved with H2-blockers and with
changing the treatment to 5d/wk (patient 2). Mild increase in serum creatinine
(>33% from baseline but within normal range for her age) was observed in
patient 3, which resolved with temporary cessation of the chelation therapy. 
Summary/Conclusions: HH is very rare disorder in children, most frequently
due to JH. Timely initiation of treatment to prevent iron overload consequences
is essential. Chelation therapy with deferasirox is efficacious with a manageable
toxicity profile and it can be considered as an alternative therapeutic option to
chronic erythrocytapheresis for the treatment of JH.
E1159
NEUTROPHIL HYPERSEGMENTATION IN ADULTS WITH IRON DEFICIEN-
CY: A CASE-CONTROL STUDY
I. Erdogan Ozunal1,*, D. Keskin1, E. Durcan2, Y. Gunay2, S. Bilgin2, S. Berk1,
D. Ozmen1, N. Ozgur Yurttas1, S. Sadri1, A. Salihoglu1, A.E. Eskazan1,
M.C. Ar1, S. Ongoren1, Z. Baslar1, Y. Aydin1, A.L. Yaldiran2, T. Soysal1
1Department of Internal Medicine, Division of Hematology, 2Department of Inter-
nal Medicine, Istanbul Universitiy Cerrahpasa Faculty of Medicine, Istanbul,
Turkey
Background: Neutrophil hypersegmentation (NH) has been accepted as a
hallmark of the macrocytic anaemias associated with the deficiency of cobal-
amin or folate. However, there are a small number of reports stating that NH
might accompany iron deficiency anaemia. The aim of the present study was
to determine the association of NH with iron deficiency (with or without
anaemia). 
Aims: The aim of the present study was to determine the association of NH
with iron deficiency (with or without anaemia) in adults and also to compare
neuthrophil segmentation status in anemia group before and after oral or par-
enteral iron treatment .
Methods: Fifty-six patients with iron deficiency and 20 age and sex matched
controls were included in this prospective, single blind, case-control study
between February-November 2016. Subjects were included if they were ≥ 18
years of age, and had normal serum vitamin B12 and folate levels, liver, thyroid
and renal function tests. Pregnant women and patients with a history of blood
transfusion within last 3 months and/or those with acute renal failure, anaemia
of chronic disease, hypothyroidism, additional cytopenias and infection were
excluded. Patients with iron deficiency were divided into 2 groups being with
iron deficiency anemia (IDA) and iron deficiency without anaemia (ID). Those
with anaemia were further evaluated prior and after iron replacement. Results
of the study groups were compared to age and sex matched healthy controls.
Blinded peripheral blood smear slides were evaluated by a haematologist by
counting 200 neutrophils. Hypersegmentation was defined as reported by Bain
et al.. Iron deficiency was diagnosed based on the findings of iron parameters
including serum iron, total iron binding capacity, and ferritin. Anaemia was
defined according to the WHO recommendation. Cohort characteristics were
given in Table 1.
Table 1.
Results: Hypersegmentation was detected in 25 individuals with iron deficiency
(45%) and 1 healthy control (5%). It was significantly more frequent in the IDA
group (48.8%) than in the ID group (30.7%) [p<0.001]. After iron treatment 3
IDA patients’ peripheral blood smear were checked and with normalization of
iron parameters and hemoglobin, hypersegmentation was undetectable. The
study is still ongoing and rest of the IDA group are still on treatment, their periph-
eral blood smears are to be examined after iron treatment is over.
Figure 1.
Summary/Conclusions: Although the mechanism of neutrophil hypersegmen-
tation in iron deficiency anaemia is not clear, it is thought that iron acts as a
cofactor in folate metabolism and / or DNA synthesis in granulocytes. There
are a limited number of studies dealing with NH associated with IDA in the lit-
erature. However most of these studies were observational and did not include
controls or were not blinded. Our study is the first to demostrate the association
of NH with iron deficiency anaemia in adults in the absence of megaloblastic
anemia. 
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M-TOR INHIBITORS-ASSOCIATED MICROCYTIC ANEMIA AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
R. Angel F.1,*, A. Monter1, A. Esquirol1, R. Martino1, I. Garcia-Cadenas1,
J. Remacha1, S. Payan1, S. Brunet1, J. Sierra1
1Hematology, Hospital de Sant Pau, Barcelona, Spain
haematologica | 2017; 102(s2) | 475
Madrid, Spain, June 22 – 25, 2017
Background: Immunosuppression with mTOR inhibitors (sirolimus or
everolimus) has been associated with development of microcytic anemia after
solid organ transplantation. The prevalence reaches 27 to 57% in the case of
kidney transplantation. This anemia has been attributed to hepcidin increase
induced by the inhibition of mTOR protein1,2.
Aims: To evaluate the prevalence of microcytic anemia after allogeneic
hematopoietic stem cell transplantation in patients receiving mTOR inhibitors.
Methods: 61 consecutive allogeneic stem cell reduced intensity conditioning
(alloRIC) recipients were analyzed. In all cases, a non-related donor was used.
Baseline disease was: 23 acute leukemia (37.7%), 12 non-Hodgkin lymphomas
(19.7%), 10 myelodysplastic syndromes (16.4%), 7 Hodgkin lymphomas 7
(11.4%), 4 multiple myelomas (6,5%),3 chronic lymphocytic leukemia (4.9%),
and 2 myelofibrosis (3.2%). All of them received Fludarabine-based condition-
ing treatment and the combination sirolimus (mTOR inhibitor)-tacrolimus (cal-
cineurin inhibitor) as GVHD prophylaxis. Drug doses were adjusted according
to blood levels and renal function. Levels of Hb, MCV and iron parameters
were systematically evaluated after alloRIC. Microcytosis was considered when
MCV was below 80 fl. 
Results: At 6 months 56 out of 61 (92%) were alive. Anemia was observed in
30 (49%) of them, with only 8 cases (13.1%) showing Hb level below 100 g/l.
Microcytic anemia was diagnosed in 2 of them (3.3%). One patient showed an
iron deficiency anemia due to gastrointestinal bleeding (Hb 94 g/l, MCV 69 fl,
serum ferritin 21 µg/l). However, the second one, a 61-year old male with an
acute leukemia, had a microcytic anemia with iron parameter changes similar
to those observed in kidney transplantation and associated with increased hep-
cidin, (see table).Anemia progressively improved with sirolimus tappering.
Table 1.
Inh: inhibitors. Hb: hemoglobin. MCV: mean corpuscular volume. Fe: iron. TIBC: total iron binding
capacity.%SAT.% transferrin saturation. BM: bone marrow. NV: normal values.
Summary/Conclusions: In contrast to kidney transplantation, microcytic ane-
mia related to immunosuppression with mTOR inhibitors was seldom observed
in alloRIC recipients. However, this association should be taken in account in
this setting, as a rare cause of anemia. In case of microcytic anemia, the eval-
uation of iron parameters and hepcidin provides the diagnosis of this rare type
of anemia. 
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IRON METABOLISM IN PATIENTS WITH PAROXISMAL NOCTURNAL
HEMOGLOBINURIA
E. Lukina1,*, K. Tandilova1, N. Tsvetaeva1, O. Nikulina1, E. Sysoeva1, I. Karpova2,
E. Mershina3, V. Sinitsyn3
1Department of Orphan Diseases, 2Central Clinical Diagnostic Laboratory,
National Research Center for Hematology, 3Radiology Department, Federal
Center of Treatment and Rehabilitation, Moscow, Russian Federation
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired
clonal non-malignant hematological disorder that is associated with hemolytic
anemia, bone marrow failure, thrombosis. At the onset the condition is often inter-
preted as iron deficiency anemia that leads to the prescription of ferrotherapy.
Aims: Study iron metabolism in patients with PNH.
Methods: The study group included 19 patients (11 men and 8 women aged
from 20 to 64 years, median age 43 years) with a diagnosis of PNH, followed
up in our Center between 2014 and 2017. The median hemoglobin level was
8,1 g/dl. The erythrocyte PNH clone size ranged from 17 to 99%, median -
47%. Granulocyte and monocyte PNH clone sizes were 85% and 89%, respec-
tively. The following parameters were studied to characterize iron metabolism:
ferritin, transferrin, iron concentration, total iron binding capacity (TIBC), trans-
ferrin saturation. Ten of 19 patients undergone magnetic resonance imaging
(MRI) of the liver and kidneys to determine iron overload. Five of 10 patients
received treatment with eculizumab.
Results: Iron metabolism parameters varied in wide limits. Iron deficiency was
detected in 4 (21%) patients, 8 (42%) patients had laboratory signs of iron
overload, remaining 7 (37%) patients had normal parameters of iron metabo-
lism. Ferritin rates ranged from 6 to 3050 ng/ml (median – 544ng/ml), transferrin
– from 75 to 452mg/l (median – 238mg/l), TIBC –from 21 to 95 umol/l (median
– 55umol/l), transferrin saturation – from 9 to 92% (median – 43%), iron con-
centration – from 5 to 50 umol/l (median – 22umol/l). MRI (including T2*-weight-
ed images) revealed signs of liver hemosiderosis varying from mild to severe
degree in 7 out of 10 studied patients. Signal intensity of renal cortex was
decreased in 9 out of 10 patients, presumably due to renal hemosiderosis. In
1 patient there were no pathological findings on MRI. Laboratory signs of iron
deficiency were revealed in 2 out of 9 patients with renal hemosiderosis. Signs
of renal hemosiderosis were absent only in 1 out of 10 examined patients. This
patient has been treated with eculizumab for 15 months.
Summary/Conclusions: Evaluation of laboratory parameters of iron metabo-
lism is not sufficient to identify tissue iron overload in transfusion-dependent
patients with PNH. MRI (including T2*-weighted images) revealed signs of
hemosiderosis of liver and kidneys in 7 (37%) and 9 (47%) patients respectively,
indicating the feasibility of this method for diagnosis of post-transfusion iron
overload in patients with PNH and assessment of the need for chelation ther-
apy. Described case of the patient who has no signs of renal hemosiderosis
and receives treatment with eculizumab fortifies the results of clinical studies
showing the efficacy of eculizumab in the prevention of renal failure in patients
with severe PNH.
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ORAL IRON ELEVATES SERUM IRON AND CONSEQUENTLY CHANGES
IRON DISTRIBUTION IN LIVER AND ERYTHROCYTES
Y. Matsuo-Tezuka1,*, M. Noguchi-sasaki1, M. Kurasawa1, K. Yorozu1,
Y. Shimonaka1, M. Hirata1
1Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura,
Japan
Background: For renal anemia patients, there are several therapeutic options
including erythropoiesis-stimulating agents (ESAs), intravenous and oral iron
supplementations. In terms of iron absorption, ESAs were known to activate
iron absorption via down-regulation of hepcidin, a key mediator of iron metab-
olism, and consequent up-regulation of duodenal iron transporters divalent
metal transporter 1 (DMT1) and ferroportin (FPN). On the other hand, in our
previous study, intravenous iron was demonstrated to deactivate iron absorption
system via hepcidin elevation. However, iron absorption under oral iron sup-
plementation have not fully evaluated yet.
Aims: In this study, we investigated the activity of iron absorption under oral
iron supplementation in mice as well as under intravenous iron supplementa-
tion. In addition, we also analyzed iron distribution under intravenous and oral
iron supplementation.
Methods: To load iron orally, a diet including 200 ppm of iron was used as
control and a diet including approximately 5000 ppm of ferric citrate was used
as iron-rich diet. 6-week-old male C57BL/6NCrl mice were divided into 3
groups; control group, intravenous iron (IV iron) group, and oral iron (Oral iron)
group (n=5). Mice in IV iron group were fed a control diet from days 0 and
intravenously administered 0.4mg/mouse of iron-dextran on days 9. Mice in
Oral iron group were fed an iron-rich diet from days 0 and intravenously admin-
istered 0.4mg/mouse of dextran as vehicle on days 9. Mice in control group
were fed a control diet from days 0 and intravenously administered
0.4mg/mouse of dextran on days 9. All mice were euthanized by exsanguination
under anesthesia with isoflurane on days 14. For analyses of iron absorption,
serum hepcidin and iron were measured and expression of duodenal DMT1
and FPN were evaluated immunohistochemically. For analyses of iron distri-
bution, berlin blue staining for liver and hematological indices were evaluated.
Results: Serum hepcidin levels in IV and Oral iron groups were significantly
higher compared with control group. However, serum iron levels were elevated
only in oral iron group. In immunohistochemical analyses, expression levels of
duodenal DMT1 were not detected in all groups and expression levels of duo-
denal FPN in IV and Oral iron groups were significantly lower than control
group. As for iron distribution in liver, iron was accumulated in reticuloendothelial
cells in IV iron group, on the other hand, in Oral iron group iron was accumu-
lated in parenchyma. In hematological analyses, although red blood cell and
reticulocyte count were not significantly different among all groups, Ret-He and
MCH in Oral iron group were higher than IV iron groups.
Summary/Conclusions: It was demonstrated in this study that serum iron
levels were elevated in spite of high hepcidin levels and down-regulation of
duodenal iron transporters under oral iron supplementation. Furthermore, iron
was distributed in liver parenchyma and hemoglobin contents in each reticulo-
cyte and erythrocyte were up-regulated only under oral iron supplementation.
We speculated that high serum iron lead to excess iron uptake into tissues
and erythrocyte fraction. These data might provide an opportunity to rethink
the importance of proper use of iron supplementations.
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Background: Children with haemoglobinopathy and rare anaemias often
require regular red cell transfusions at some stage of their lives. Iron overload
is therefore inevitable and iron chelation is a key component of therapy for chil-
dren in this group. However its use has not been validated especially in children
under two years of age. Deferasirox (Exjade®; Novartis Pharma AG, Basel,
Switzerland) is an iron chelator that is conclusively proven to be effective and
safe in transfusional anaemia such as haemoglobinopathies. 
Aims: We aim to look at the efficacy and safety of Deferasirox in children with
severe anemias.
Methods: We present a case report of 6 children with severe anemias treated
with Deferasirox in a tertiary pediatric hematology centre in London, UK.
Results: Here we report 6 cases where deferasirox has been used in young
children with rare anaemias and sickle cell disease. Patients 1 and 2 presented
within the first year of life with pancytopaenia requiring regular transfusion and
were diagnosed with Pearson syndrome. Deferasirox was started at the age of
30 months and 4 months respectively. Patients 3 and 4 presented with neonatal
anaemia requiring regular transfusion and were diagnosed with Pyruvate
Kinase deficiency. Deferasirox was started at 12 and 19 months consecutively.
Patient 5 presented with pure red cell aplasia at the age of 3 months and was
diagnosed with Diamond Blackfan anaemia. He was initially treated with steroid
but became resistant at around 40 months of age. He was then started on reg-
ular transfusion and was started at deferasirox at 4 years of age. Patient 6 was
diagnosed at birth with sickle cell anaemia. He suffered from stroke at the age
of 8 months and was started on chronic transfusion program. Deferasirox was
started at around at the age of 1. He had a successful maternal haplo-identical
haemopoietic stem cell transplant at the age of 3 years old. Transfusion and
deferasirox were subsequently stopped.
Figure 1.
Summary/Conclusions: All of these children had stabilization or improvement
of ferritin values after initiation of deferasirox as shown in figure 1. Deferasirox
is licensed in Europe to be used in children with thalassaemia older than 6
years of age or older than 2 year of age when desferoxamine therapy is inap-
propriate or inadequate. Deferasirox is preferable in severe anemias due to
better side effect profile on the bone marrow compared to deferiprone; the use
of which can cause agranulocytosis or neutropaenia. Furthermore, its oral
administration improved compliance compared to desferrioxamine that required
prolonged subcutaneous administrations. Deferasirox has been associated with
renal impairment. However, none of patients developed renal or liver impairment
during the use of deferasirox. Furthermore, it is crucial to conduct eye and ear
screening tests both before and after the commencement of deferasirox. None
of our patients had neurological side effects. Three of these children had
deferasirox started at younger than 2 years of age. Hence, we have shown
that deferasirox is safe and efficacious in treating iron overload in very young
children with rare anaemias and sickle cell disease where evidence is sparse.
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MONITORING ORAL IRON THERAPY IN CHILDREN WITH IRON DEFICIENCY
ANEMIA. AN OBSERVATIONAL, PROSPECTIVE, MULTICENTRIC STUDY
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Background: Iron deficiency anemia (IDA) is the most common hematological
disease in infancy and childhood. Oral iron administration is a well-established,
effective, and widely accepted treatment for anemia because of its efficacy,
safety, and cost-effectiveness. Recently new preparations of oral iron com-
pounds were launched, including droplet formulations, i.e. liposomal prepara-
tions and bis-glycinate iron; little is known on their effectiveness in real clinical
practice.
Aims: To evaluate the efficiency of different oral iron preparations in children
with IDA.
Methods: This observational study collected clinical and hematological data
from 12 AIEOP (Associazione Italiana di Ematologia ed Oncologia Pediatrica)
centers. Inclusion conditions for patient enrollment were age 3 months-12 years,
diagnosis of IDA; exclusion criteria were all conditions interfering with iron
absorption such as celiac disease, gastro-intestinal disorders and other chronic
conditions. Local Physicians were free to prescribe any oral iron formulation,
according to their standard practice. A calendar of laboratory test was suggest-
ed, including basal assessment of whole blood count, reticulocytes, iron status,
with subsequent checkpoints at 3 days (WBC and retyculocytes only), 2 weeks,
8 weeks, 6 months. Clinical data regarding compliance to therapy, unwanted
effects, final outcome were recorded.
Results: 112 (M 58) patients were enrolled. Ethnic distribution was: Caucasian
74, African 23, Asian 10, Other 5. The median age at diagnosis of IDA was 1.5
years, with a bimodal distribution with frequency peaks at age 0-3 and 12-14
years. Sixty-eight patients received bis-glycinate ferrous iron 0.45mg/kg, 19
elemental iron (ferrous gluconate/sulfate) 2mg/kg, 12 liposomal iron 0.7-
1.4mg/kg, and 15 other preparations. Eating habits were reported as normal in
48 patients, inadequate weaning in 21, meat/fish restriction in 32, other in 11.
Gastro-intestinal side effects were reported in 9/68 (13%) of the bis-glycinate
iron group, in 3/19 (16%) of the elemental iron group, and in 0/12 of the liposo-
mal iron group. Suspension of therapy due to side effects was needed only in
5 patients, 4 in the bis-glycinate and 1 in the elemental iron group, respectively.
Final outcome was available for 77 patients; it was recorded as solved IDA,
persistent IDA, or lost at follow up. Solved cases were 40/53 (75%) in the bis-
glycinate iron group, 4/11 (36%) in the elemental iron group, and 8/13 (62%) in
the liposomal iron group. Persistent cases were 8/53 (15%) in the bis-glycinate
iron group, 6/11 (55%) in the elemental iron group, and 1/13 (8%) in the lipo-
somal iron group. Lost at follow up were 5/53 (9%) in the bis-glycinate iron
group, 1/11 (9%) in the elemental iron group and 4/13 (31%) in the liposomal
iron group.
Summary/Conclusions: The collected data show that both bis-glycinate and
liposomal iron formulations have a good efficacy/safety profile and offer a sus-
tainable alternative to classic elemental iron preparations.
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AN INVESTIGATION ABOUT WEIGHT GAIN WITH TREATMENT OF IRON
DEFICIENCY ANEMIA: CHANGES OF GHRELIN AND HEPCIDIN LEVELS
WITH TREATMENT
H. C. Kılınç1, B. Onec2,*, K. Onec1, E. Caliskan3, H. Ankaralı4
1Internal Medicine, 2Hematology, 3Medical Microbiology, 4Biostatistics, Duzce
University Faculty of Medicine, Duzce, Turkey
Background: Iron deficiency anemia (IDA) is a global health problem and prob-
lems in compliance with oral iron therapy are frequently seen. It has been
shown that medications are not used regularly or discontinued due to weight
gain during the treatment process. 
Aims: We investigated ghrelin, known as appetite hormone and its relationship
with hepcidin, the homeostatic regulator of intestinal iron absorption, in order
to explain some symptoms of IDA and weight gain during iron treatment.
Methods: A hundred and twenty adult IDA patients, referred to our clinic
between October 2015 and October 2016 were included in the study. The study
was completed with 87 patients, who gave the informed content and a control
group consisted of 50 healthy people. Information about age, gender, weight,
height, body mass index (BMI), waist-hip circumference and blood samples
were taken from the patient and control groups. The treatment of IDA was done
according to the dose and method recommended by the responsible physician,
the researchers did not have any effect on the treatment. Measurements and
blood tests were repeated in the patient group after normalization of the anemia
parameters, not before the third month of treatment. Hepcidin and ghrelin levels
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were examined once in the control group and twice in the patient group, before
and after treatment.
Results: When the patient and control groups were compared, there was no
significant difference in terms of age, sex, height, weight, BMI, waist and hip
circumference. The pretreatment plasma hepcidin and ghrelin levels of the
patient group were significantly lower than those of the control group (80±21
ng/ml vs 179 ng/ml p <0.001 for hepcidine, 152±119 pq / ml vs 213±167 for
ghrelin, p=0.026). There was a significant increase in terms of weight (mean
1.15 kg, p <0.001), BMI (25.86 kg/m2 vs 26.33 kg/m2, p <0.001), waist and hip
circumference measurements (mean 0.81cm in both, p <0.001) after treatment
in the patient group. After treatment, the levels of hepcidine was significantly
increased compared to the pre-treatment levels (80±21 ng/dl vs 92±13 ng/dl,
p<0.001). Although an increase in the plasma ghrelin levels was encountered
after treatment, it was not statistically significant (152±119 pq/ml vs 164±150
pq/ml, p=0.589). When correlations of individual increases in ghrelin levels
were examined, a weak positive correlation was found between increase in
ghrelin levels and weight gain.
Summary/Conclusions: In our study, ghrelin was significantly lower than the
control group in the IDA group, suggesting that it may be the cause of loss of
appetite. Ghrelin is also detected in neurons of hypothalamic arcuat nucleus,
which regulates appetite. The deficiency of iron may cause deficiencies in enzy-
matic activities of iron depended enzymes and it may disturb the function of
these neurons. But the increase with treatment did not reach statistical signif-
icance. This may be due to physiological suppression of levels by weight gain.
When patient-based weight gains were examined, there was a positive but
weak correlation with the increase in ghrelin levels of those people. Hepcidin
was significantly lower in the iron deficiency group than in the control group
and showed a significant increase with treatment, but it was not associated
with weight gain and change of ghrelin levels. More extensive and controlled
studies should be designed in this regard.
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SOMATIC MUTATION DYNAMICS IN HIGH-RISK MDS PATIENTS TREATED
WITH AZACITIDINE IDENTIFIED VIA SERIAL SAMPLING
K. Polgarova1, K. Vargova2, V. Kulvait2, N. Dusilkova2, L. Minarik1, Z. Zemanova3,
A. Jonasova1, T. Stopka1,2,*
1Hematology Clinic, General Hospital, Prague, 2Biocev, Charles University,
Vestec, 3Cytogenetic Center, General Hospital, Prague, Czech Republic
Background: Azacatidine (AZA) is a standard therapy for MDS patients with
higher risk of AML transformation and not eligible to undergo transplantation.
While AZA is well tolerated the responses occuring in upto two thirds of patients
are not durable. Somatic mutations were previously associated with pathogen-
esis of MDS, some of them also with prognosis. Several studies suggested
that MDS patients as they progress may evolve new mutations and loose some
of the clonal architecture detected at preceding stages (Pellagatti, Roy et al.
2016). In addition, there exist gene mutations that are detected in patients sub-
sequently responding to hypomethylating agents (Bejar, Lord et al. 2014), which
implies that there exist variants-bearing clones that persist upon AZA as well
as those that do not.
Aims: To identify variants either persisting or not upon the AZA therapy we
tracked BM samples during AZA treatment. Next, we were interested in deci-
phering their relationship of the dynamics in somatic variants to clinical course
of the analyzed MDS patients. 
Methods: Massive parallel sequencing with high accuracy utilized duplicate
libraries from myeloid cells and included the non- tumorous T-cell controls to
identify somatic mutations in the serial samples before and during AZA therapy.
The tool for detecting the dynamics of somatic mutations was the TruSight
Myeloid Panel that contains 54 gene regions with previously documented muta-
tion recurrence in 439 patients (Bejar, Stevenson et al. 2011). Indeed, 92% of
our MDS cohort bore at least one somatic mutation with mostly 4 mutations
per patient (range 1-9), which indicated that the MDS patients were already at
relatively progressed state (Papaemmanuil, Gerstung et al. 2013).
Results: Analysis of 38 patients treated with AZA (reaching median OS 24
months (Mo) with 60% hematology improvement) revealed 125 somatic vari-
ants with VAF over 5%. Adverse effects of variants in cooperating regulators
of DNA damage and cell cycle were confirmed: TP53 (OS on AZA 14.8 Mo),
CDKN2A (12.3 Mo), EZH2 (11 Mo). Besides the stable variant’s allele frequency
(50%<VAF <200%) there existed four additional VAF profiles. Stable variants’
dynamics precluded putative AZA-resistant clones associated with shorter sur-
vival (19 Mo). In contrast, the patients bearing variants with decreasing VAF,
which supposedly were inhibited by AZA, lived longer (31 Mo). Interestingly,
small group of highly dynamic variants upon AZA therapy formed a subgroup
with longer-lasting complete remissions.
Summary/Conclusions: Our work support the importance of catalogization
of somatic variants to delineate pathogenesis of MDS with a focus on molecular
AZA responsiveness. Several types of variant dynamics during the AZA therapy
were noted by using the massive parallel sequencing approach of the duplicate
libraries per MDS BM samples also utilizing non-tumorous controls and serial
sampling. Stable dynamics was found in variants previously recorded by COS-
MIC and targetting the adverse outcome genes such as TP53, BCORL1,
ASXL1, and EZH2 as well as their combinations with TET2 that may potentially
mediate clonal selection of additional variants mediating progression during
AZA therapy.
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WHOLE GENOME MBD-SEQ REVEALS DIFFERENT CPG METHYLATION
PATTERNS IN AZACYTIDINE-TREATED JUVENILE MYELOMONOCYTIC
LEUKEMIA (JMML) PATIENTS
P.P. Leoncini1,*, P. Vitullo1, F. Di Florio1, V. Tocco1, M.P. Cefalo1, A. Pitisci1,
K. Girardi1, C. Niemeyer2, F. Locatelli1, A. Bertaina1
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Background: Juvenile Myelomonocytic Leukemia (JMML) is a rare and aggres-
sive leukemia of early childhood. Allogeneic hematopoietic stem cell transplant
(HSCT) is the only available curative treatment, but, since disease recurrence is
responsible for treatment failure in at least one third of transplanted patients,
developing alternative therapeutic approaches is desirable. Aberrant DNA methy-
lation is a key molecular feature of JMML, suggesting an important role of epi-
genetic events in the pathophysiology of the disease. Azacytidine (AZA), a mol-
ecule that inhibits DNA methylation in human cells, is under investigation in
JMML.
Aims: Here we report, for the first time, a global evaluation of DNA methylation
status of CD34+ cells deriving from JMML patients before and after AZA treat-
ment and compared the results with those of healthy controls. Identifying dif-
ferentially methylated CpG islands linked to various genes will help us describe
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an epigenetic aberrant paradigm possibly involving transcriptional and transla-
tional regulation in JMML.
Methods: CD34+ cells isolated from 3 JMML patients samples collected at diag-
nosis (t0) and after the third cycle of AZA (t1) were evaluated together with those
of 3 healthy donors (HD). JMML patients have been treated with AZA on a com-
passionate use basis after obtaining signed informed consent. DNA samples
were processed and Ion fragment libraries were prepared. MBD-seq, bioinfor-
matics and statistical analysis were performed by Genomnia srl (Bresso, Italy).
Results: First, we compared t0 JMML cells with HD cells, finding 987 different
transcriptional units corresponding to 714 coding and 273 non-coding
sequences. We also compared DNA methylation between t1 and HD cells. In
this comparison, 644 unique transcriptional units, including 468 coding and 175
non-coding sequences, were found. Hypermethylation in JMML samples com-
pared to HD was detected, but, unexpectedly, t0 vs t1 methylation analysis did
not show any significant result, suggesting a likely unspecific patient-related
pharmacological effect. Notably, 453 coding and 165 non-coding differentially
methylated regions are shared between t0 vs HD and t1 vs HD sets. More in
detail, 261 and 15 coding regions and 107 and 10 non-coding regions were
uniquely found in t0 vs HD and t1 vs HD sets, respectively. However, 439 coding
and 161 non-coding genomic regions preserve their hypermethylated status,
probably due to a mechanism of resistance to AZA treatment. Among non-cod-
ing elements, we found different RNA species, such as microRNAs, splicing
RNAs, lincRNAs/antisense transcripts (AS) and other unknown RNAs. Retro-
transposons, belonging to LINEs and SINEs families, were also screened. We
identified 13 sequences with a significant differential methylation profile in both
t0 and t1 vs HD. Again, a comparison between t0 and t1 groups did not show
any significant difference. Eleven hypermethylated common LINEs were evident
between t0 vs HD and t1 vs HD sets. Two retrotransposons with opposite
methylation patterns were found in t0 vs HD and t1 vs HD sets; while in the first
comparison they included LINEs, in the second one they are 1 hypermethylated
LINE and 1 hypomethylated SINE.
Figure 1.
Summary/Conclusions: In conclusion, the whole genome MBD-seq per-
formed for the first time on JMML CD34+ bone marrow derived cells, showed
a broad genomic hypermethylation both in pre- and post-AZA samples com-
pared to HD, suggesting a patient-specific AZA-effect. Transcription and trans-
lation processes of coding and non-coding genes could be deregulated in mul-
tiple ways, due to heterogeneity of sequences involved in CpG islands hyper-
methylation. Moreover, due to their known ability to insert random mutations in
the genome, retrotransposons should be candidate for further studies in JMML
pathogenesis.
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Background: Flow cytometry (FCM) is one part of integrated MDS diagnostics.
Different well established FCM-scores are applied, as FCSS (Wells et al. 2003),
Ogata-score (Ogata et al. 2012), new iFS (Cremers et al. 2017), and del(5q)-
FCM-score (Oelschlaegel et al. 2015).
Aims: The aim of this prospective study was to test, which of the mentioned
FCM-scores fits best for response monitoring in del(5q) MDS in comparison to
cytogenetics.
Methods: Overall, 245 FCM investigations were performed in 61 patients with
MDS and del(5q) (IPSS-R very low/low: n=26, int: n=13, high/very high n=22)
including 42 patients with isolated del(5q) or one additional cytogenetic abnor-
mality. The majority of analyses were performed in patients receiving lenalido-
mide or azacitidine (n=29 and n=22 patients), or in patients receiving
chemotherapy and/or allogeneic transplantation or growth factors (n=10). Stan-
dardized FCM (lyse-stain-wash) and cytogenetics/FISH procedures were per-
formed according to ELN guidelines at the TU of Dresden, VUMC of Amster-
dam, UH of Guadalajara and UH of Bristol. Cytogenetics/FISH analysis was
considered the gold standard. All of the applied FCM-scores were propagated
by the ELNet iMDS working group. Additionally, hematological improvement of
the erythroid lineage (HI-E) was evaluated (Cheson et al. 2006).
Results: The del(5q)-FCM-score reflected best the disappearance / presence
of the cytogenetic abnormality del(5q) with a sensitivity of 98% and a specificity
of 82%. This was confirmed if only MDS with del(5q) as a single abnormality or
only MDS treated with Lenalidomide were evaluated separately (sensitivity:
98% and 100%; specificity: 85% and 75%). The use of the Ogata-score con-
sidering almost only abnormalities of the myeloid progenitors, ended up with a
slightly lower sensitivity (86%) and specificity (81%). The new iFS analyzing
progenitor cells, granulo-, mono-, and erythropoiesis showed a comparably
high specificity (83%) but a slightly impaired sensitivity (72%). FCSS, analyzing
dyspoiesis of multiple cell lineages, showed a response in less than the half of
all investigations being in cytogenetic CR (sensitivity: 41%), but revealed a high
specificity (91%). The analysis of HI-E was high sensitive (81%) but not as spe-
cific (62%). Next, we investigated the potential prognostic impact of response
monitoring using various FCM-scores compared to cytogenetics. Considering
all del(5q) MDS patients as well as only those patients with del(5q) as a single
abnormality, cytogenetics and all tested FCM-scores showed a significantly
longer OS for MDS responding to therapy. The highest prognostic impact dis-
played the new iFS (p=0.0019) and Ogata-score (p=0.0092), respectively. Eval-
uating only MDS treated with lenalidomide, response monitoring using FCSS
separated best the OS curves (p=0.0080). Finally, we combined the evaluation
of HI-E with cytogenetics or the FCM-scores. This resulted in an even better
OS for MDS fulfilling two response criteria vs none of the criteria with the highest
prognostic impact for the combination of HI-E plus the new iFS (p=0.0010).
Summary/Conclusions: Flow cytometry might serve as a rapid tool for
response monitoring during treatment with disease-modifying drugs. All estab-
lished FCM-scores allowed for an at least similar correctness of response pre-
diction. The prognostic impact of the various FCM-scores seems to be even
higher than that of cytogenetic response evaluation in this MDS subgroup. One
reason might be, that most of the FCM-scores reflect not only the genetic back-
ground of the MDS but dyspoietic alterations in various cell lineages of the
hematopoietic system.
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EVALUATION OF MUTATIONS AT RELAPSE IN MYELODYSPLASTIC
SYNDROME PATIENTS RECEIVING ALLOGENEIC STEM CELL
TRANSPLANTATION
M. Cabrero1,*, J.M. Hernandez-Sanchez1, J.C. Caballero1, C. Chillon1,
M. Martin-Izquierdo1, M. Abaigar1, A. Redondo1, F. Lopez-Cadenas1, E. Perez-
Lopez1, L. Lopez-Corral1, R. Benito1, C. Robledo1, M. del Rey1, M. Gonzalez1,
C. del Cañizo1, D. Caballero1, J.M. Hernandez-Rivas1, M. Díez Campelo1
1Hematology Department, Hospital Universitario de Salamanca-IBSAL, Sala-
manca, Spain
Background: Allogeneic transplant (AlloSCT) is the only curative therapy for
myelodysplastic syndromes (MDS). Unfortunately, relapse is the main cause
of treatment failure. Evaluation of genetic mutations both at diagnosis and
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before AlloSCT is a potent prognostic tool. However, mutational profile at
relapse after AlloSCT has not been widely explored.
Aims: In this study, we evaluate mutational profile at post-AlloSCT relapse in
MDS patients to determine if pre-AlloSCT mutations are still present at relapse,
so we could eventually monitor them as minimal residual disease (MRD) after
AlloSCT.
Methods: From a retrospective cohort of 115 patients, we selected those who
relapsed post-AlloSCT (19/115, 16.5%) with available material at relapse (18
patients). We performed an in-house target-capture panel, sequencing across
selected exons of 117 cancer-related genes previously related to MDS in pre-
AlloSCT samples to identify genetic mutations and we checked the presence
of those mutations in samples at relapse. Six patients were discarded because
lack of pre-AlloSCT mutations, so we selected 12 patients for the sequential
study. DNA was amplified with FastStart High Fidelity PCR System using exon-
specific primers for each mutation. The indexed paired-end library was pre-
pared with Nextera XT DNA Sample Preparation Kit (Illumina) The median cov-
erage per base achieved was 4579 reads range 2401-8573). In a second step,
we explore the possibility of evaluating mutations in both CD34 positive and
the rest of bone marrow cells, to check if we could increase the sensitivity of
the detection.
Results: Median age of relapsed patients was 60 (45-70). Diagnosis were
RAEB 1 (n=4), RAEB 2 (4), dysplasia associated AML (2) and RCMD (2). They
relapse post-AlloSCT after a median of 2.5 months (1-7), and 4 of them are
alive at last follow up after a median of 22 months (9-33). Patients had a median
of 2.5 mutations (range 1-4). TET2 mutations were detected in 4 (33%) of
patients; U2AF1, EZH2, SRSF2, KRAS, JAK2 and RUNX1 in 2 (17%), and
NRAS, TP53, ETV6, PHF6, SMC1A, ZRSR2, BCOR, DNMT3 and SF3B1
mutations in 1 (8%) (Table 1). In 10 out of 12 patients evaluated, we found
same genetic mutations at relapse compared with pre-AlloSCT sample (Table
1). In addition, mutational pattern was similar for all patients except for one in
which dominate mutation at relapse was SRSF2 (present in 14% of cells pre-
Allo and in 3% at relapse) instead of ETV6 (51% pre-AlloSCT and 0.6% at
relapse). In 2 patients, pre-AlloSCT mutations were not detected at relapse
(Patient 8: BCOR and RUNX1. Patient 11: SRSF2, TET2 and RUNX1). In a
second step, we searched for mutations in CD34 positive cells to check its
sensitivity to detect genetic alterations. We selected CD34 positive cells in one
patient with KRAS and IDH2 mutations pre-AlloSCT. KRAS and IDH2 were
present in 40% and 45% of CD34 positive cells and in 37% and 48% of the
bone marrow (CD34 depleted) compartment respectively in pre-AlloSCT sam-
ples. In relapse samples, mutations were present in similar percentage in CD34
positive cells compared to CD34 depleted bone marrow (KRAS 0.63% and
2.23%; IDH2 1.6% and 1.45% respectively).
Table 1.
Summary/Conclusions: Post-AlloSCT relapsing MDS show same genetic
mutations found in pre-AlloSCT evaluation, so they would potentially be used
to confirm clonality and probably MRD assessment after AlloSCT in the near
future. CD34 selection does not provide additional sensitivity to whole bone
marrow cellularity sample.
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RIGOSERTIB COMBINED WITH AZACITIDINE EPIGENETICALLY MODULATES
CHROMATIN AND HEMATOPOIETIC STEM CELL POPULATIONS IN THE
MYELODYSPLASTIC SYNDROME (MDS)
P. Chaurasia1, S.C. Navada1, R. Odchimar-Reissig1, E.P. Demakos1, P. Reddy1,
L.R. Silverman1,*
1ICAHN School of Medicine, Mount Sinai, New York, United States
Background: Azacitidine (AZA) is the standard of care for patients (pts) with
higher-risk MDS, however, only 50% of pts respond and the majority will relapse
within 2 years. All pts ultimately fail treatment due to primary or secondary
resistance. RIGosertib (RIG) is a “ras mimetic” agent that binds to the Ras
Binding Domain of RAF kinases and inhibits the RAS-RAF-MEK and the PI3K
pathways. Initial results of an ongoing Phase I/II study with RIG combined with
AZA, in pts with MDS demonstrated a response rate of: 76% overall; 62% in
pts following hypomethylating agent (HMA) failure and 85% in HMA naïve pts
(Navada et al ASH 2016).
Aims: To Investigate the in vitro effects of RIG combined with AZA or vorinostat
(VOR) on epigenetic and stem cell pathways on two cell lines: AML (BW90),
MDS (MDS-L) and on pt bone marrow samples
Methods: We investigated the in vitro effects of RIG combined with AZA or
vorinostat (VOR) on two cell lines: AML (BW90), MDS (MDS-L) and on pt bone
marrow samples treated on the phase I/II study, obtained prior to and after one
cycle of AZA and RIG.
Results: Treatment with RIG alone altered global histone post-translational
modifications (PTMs) including methylation (H3K4me3, H3K4me2, H3K27me3,
and H3K27me2) and acetylation (H3K9ac, & H3K18ac) levels associated with
transcriptional activation or repression in both the cell lines and pt samples. Q-
PCR studies demonstrated that individual treatment of BW90 and MDS-L with
RIG or combined with AZA or VOR in sequential treatment (AZA/RIG, RIG/AZA,
VOR/RIG or RIG/VOR) altered DNA methyl transferases (DNMT1, 3a and 3b),
the class I, II and IV histone deacetylases (HDACs), and chromatin remodeler
(KDM2a, SET1, JMJD3 and LRWD1) transcript levels in a cell line specific
context. Sequential treatment of RIG with AZA or VOR demonstrated differential
effects on the association of RNA polymerase II (Pol II) with active histone
marks (H3K4me3 and H3K4me2) in both cell lines. An overall decrease in
association of Pol II/H3K4me2 was observed with the combinations (AZA/RIG,
VOR/RIG or vice versa) in MDS-L and BW-90, 10-33% (ANOVA, p=0.0006),
9-20% (ANOVA, p=0.0004), respectively. Significant differences were observed
in association of H3K4me3/Pol II in BW-90 cells (7-30%; ANOVA, p<0.0001).
Similarly, in BM from a pt with MDS after 1 cycle of RIG and AZA treatment
demonstrated a decrease in association of Pol II with H3K4me2 (67%) and
H3K4me3 (28%). Treatment of MDS-L cells with RIG alone or RIG/AZA failed
to induce expansion of CD34+ cells and yielded maximum aldehyde dehydro-
genase (ALDH) activity, a marker of primitive hematopoietic stem and progen-
itor cells (HSCs) (ANOVA, p=0.006), but the RIG/VOR induced 1.9-fold expan-
sion of CD34+ cells (ANOVA p=0.002). A marked decrease in ALDH activity
was observed in AZA or VOR or RIG/VOR, that was inversely proportion to the
expansion of CD34+ cells. In an MDS pt treated with RIG/AZA an expansion
of primitive HPSCs expressing low levels of CD34 appeared with disappear-
ance of a highly expressing CD34 subpopulation that co-existed prior to treat-
ment. Expansion of CD34+ cells led to ≥2 fold increase in pluripotent genes
(SOX2, OCT4, NANOG and ZIC3) expression levels in the BM from MDS pts
after RIG/AZA treatment and 1.7-34 fold increase in the presence of RIG or
RIG/AZA or RIG/VOR in MDS-L. These findings indicate that expression of
pluripotency genes is a consequence of epigenetic reprogramming that favors
expansion of more primitive HSPCs in a pt.
Summary/Conclusions: RIG potentially functions as a chromatin modifying
agent, in combination with AZA and may overcome HMA resistance through
chromatin remodeling. RIG alone and in combinations also leads to epigenetic
reprogramming of HSPC that may manifest in hematological improvements in
the clinical setting.
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UNEXPLAINED CYTOPENIAS IN HOSPITAL: INDICATIONS AND BENE-
FITS OF NEXT-GENERATION SEQUENCING
D. Beauvais1,*, B. Céline1,2, O. Nibourel2,3, C. Preudhomme2,3
1Department of Adult Hematology, CHRU University Hospital of Lille, 2UMR-S
1172, Institute for Cancer Research of Lille, 3Biology and pathology center,
Laboratory of Hematology, CHRU University Hospital of Lille, Lille, France
Background: Unexplained cytopenias (UC) are common problems during hos-
pitalisation, particulary in elderly patients. If there is no evident cause,
myelodysplastic syndrom (MDS) is frequently suggested and a bone marrow
aspiration is performed. Next-generation sequencing (NGS) reveals MDS-asso-
ciated somatic mutations but their significance are discussed. In our centre,
NGS was systematically realized in the context of unexplained cytopenias.
Aims: The objective of this study was to explore results of NGS in practical
routine in the context of UC and to precise if some groups of patients could
more specifically benefit of NGS.
Methods: All patients in our centre with analysis of NGS performed in blood
or in bone marrow in a context of UF were included. Exclusion criteria were:
patients under 18 years, monocytosis >1000/mm3, excess of blasts, history of
hematological malignancy disorder. Patients were included in group “positive
NGS” if at least one significant mutation (no SNP) was found on 25 genes
panel (ASXL1, CBL, DNMT3A, ETV6, EZH2, IDH1, IDH2, JAK2, KIT, KRAS,
MPL, NPM1, NRAS, PHF6, PTN11, RIT1, RUNX1, STBP1, SF3B1, SRSF2,
TET2, TP53, U2AF, WT1, ZRSR2). Clinical and biological criteria were reported
from local database. All patients gave consent.
480 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Results: 156 patients were included between January 2014 and December
2015 with a mean age of 68 years [65.8-70.3] and 47.4% of men. 127 patients
(81.4%) had a bone marrow analysis. 53 patients (34.0%) were reported in the
group “positive NGS” and 103 patients (66.0%) in the group “negative NGS”.
In univariate analysis, significant variable associated with “positive NGS” were
age (p <10-7), no history of auto-immune disease (p=0.002), hemoglobin
<12g/dL (p=0.017), platelets >150000/mm3 (p=0.015), >10% dysplastic cells
in erythroid (p=0.012) and granulocytic lineage (p=0.034). Trend test on dys-
plastic lineage number was significant (p=0.006). Normal karyotype (78.1%)
was comparable in the two groups (p=0.352). Cirrhosis and/or portal hyperten-
sion were comparable in the two groups (14.1%, p=0.092) as well as mean
serum creatinine (p=0.24). In multivariate analysis, age >70 years (p=0.0011)
and platelets >150000/mm3 (p=0.0213) remained significantly associated to
positive NGS (Table 1). In “positive NGS” group, 1 (58.5%), 2 (32.1%), 3 (7.5%)
or 4 (1.9%) mutation(s) were found per patient. Most frequent mutations were
TET2 (25.9%), DNMT3A (17.3%), SF3B1 (12.3%), ASXL1 (12.3%), SRSF2
(8,6%), U2AF1 (4,9%), TP53 (3,7%) and ZRSR2 (3,7%). Other mutations were
reported in less than 3 patients. As expected in this elderly population, if a
unique mutation was found, TET2 and DNMT3A were predominant (35.5% and
25.8% respectively) but interestingly mutation R882 of DNMT3A was found in
only one patient. Sideroblasts were found>15% in 46.2% of patients with a
mutation of SF3B1, SRSF2, U2AF1 or ZRSR2.
Table 1.
Summary/Conclusions: In the context of unexplained cytopenias, a third of
patients had at least one MDS-associated somatic mutation. Age above 70
years and no thrombopenia seems to be good arguments to realize NGS in
this context. Probably thrombopenia is frequently associated to other causes
than MDS. If NGS is positive, aging genes are the most frequently mutated
genes and they can reflect age-related clonal cytopenias. Even if their clinical
significance is uncertain, monitoring is recommended because of an increased




RESISTANCE TO AZACITIDINE IS DETERMINED AT CELLULAR LEVEL
BY LOWER EXPRESSION OF NUCLEOSIDE ACTIVATING ENZYMES UCK1
AND UCK2
E. Masala1,*, A. Valencia1, A. Brogi1, A. Sanna1, M. Torres Martin2, M. Figueroa2,
V. Santini1
1Experimental and Clinical Medicine, University of Florence, Florence, Italy,
2Department of Human Genetics, University of Miami Miller School of Medicine,
Miami, United States
Background: Azacitidine is at present the standard treatment for MDS. We
demonstrated that MDS patients responsive to azacitidine have significantly high-
er intracellular expression of the azacitidine-activating enzyme uridine-cytidine
kinase-1 (UCK1) in bone marrow mononuclear cells (Valencia et al. Leukemia
2014). Correlation of the expression of nucleoside transporter, activating and dis-
activating enzymes with clinical and in vitro response to hypomethylating drugs
azacitidine and decitabine has been suggested by several authors. Yet, the crucial
role of these enzymes has to be ascertained, as well as their possible different
importance in determining resistance to azacitidine.
Aims: To confirm that the cellular expression of nucleoside metabolizing
enzymes plays a major role in cellular resistance and significantly impacts on
clinical response to azacitidine.
Methods: Two cell lines, SKM1 sensitive (SKM1-S) and SKM1 resistant (SKM1-
R) to azacitidine, were analyzed for expression of UCK1, UCK2, hENT1,
hCNT3, RRM1 and RRM2 by quantitative PCR. Corresponding proteins were
quantitated by western blotting in both cell lines. The expression of UCK1 and
UCK2 was blunted by siRNAs in SKM1 sensitive cells to determine their role
in in vitro sensitivity to azacitidine. For UCK1 and UCK2 silencing in SKM1-S,
specific siRNAs were used (OriGene Technologies, MD, USA); cells were cul-
tured at a density of 600x105cells/ml in 5 ml of RPMI 1940 medium. After 72 h
of transfection, cells were treated for further 48h with azacitidine at the con-
centrations of 0,1 and 1 μM. After assessment of effective gene silencing, apop-
tosis and cell cycle arrest were evaluated, respectively by Annexin V test and
Propidium Iodide. In parallel, the percentage of 5-methylcytosine was quanti-
tated by ELISA assay (Global DNA Methylation LINE-1 kit ActiveMotif, CA,
USA). In addition, the expression of nucleoside metabolizing enzymes was
evaluated prospectively in 18 IPSS high risk MDS patients treated with azaci-
tidine 75mg/m2/7 days every 28 days. Furthermore, UCK1 and UCK2 expres-
sion was evaluated in 37 patients (classified as 26 responder and 29 non-
responder) treated with azacitidine, by RNAseq analysis using DEXseq2.
Results: SKM1-R cells did not express UCK1, UCK2, hENT1, hCNT3, RRM1
and RRM2. Corresponding proteins were also not expressed. A reduction of
apoptosis was observed in UCK1-silenced SKM-1 S after azacitidine 0.1 μM
treatment: 35,7%±0,77% Annexine V-positive cells versus 25%±0,35% (P=0.031)
in non-silenced control SKM1-S cultures. We observed a reduction of apoptosis
during UCK2-silencing after azacitidine 0.1 μM treatment too: 31%±0,85% Annex-
in V-positive cells versus 21%±0,35% (P=0.054). Hypomethylation induced by in
vitro azacitidine treatment was also hampered by reduction of expression of
UCK1 and UCK2. Quite surprisingly gene expression of UCK1, UCK2, hENT1,
hCNT3, RRM1 and RRM2 in primary cells did not predict different clinical
response to azacitidine. RNAseq analysis for UCK1 and UCK2 did not find any
differences between responder and non-responder patients.
Summary/Conclusions: We demonstrated that UCK1, UCK2, hENT1, hCNT3,
RRM1 and RRM2 and the corresponding proteins are absent in azacitidine-
resistant cell line SKM1-R suggesting to be the determinant of the induced
resistance to azacitidine. UCK1 and UCK2 silencing induced by synthetic siR-
NAs significantly decreased azacitidine effects. Prospective evaluation of the
predictive role of cellular expression of genes involved in azacitidine metabolism
is ongoing in a larger cohort of MDS patients.
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FAMILIAL TIN2 N-TERMINAL LOSS OF FUNCTION MUTATION IN TELOMERE
SYNDROME
D. Di Giacomo1,*, V. Nofrini1, T. Iannotti1, M. Quintini1, F. Pellanera1, G. Barba1,
C. Matteucci1, S. Ballanti1, R. Piazza2, C. Mecucci1
1Haematology and Bone Marrow Transplantation Unit, University of Perugia,
Perugia, 2Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Background: The shelterin complex protects telomeres from being processed
by the DNA damage repair machinery and regulates telomerase access and
activity (Frank 2015). TINF2 (14q12) is encoding for TIN2, the central compo-
nent of shelterin which interacts with other members of the complex
(TRF1,TRF2 and TPP1), thus contributing to telomere length regulation and
structural integrity (Frank 2015). About thirty TINF2 mutations are known in
Dyskeratosis Congenita (DC) (Savage 2008) and other telomere related phe-
notypes, i.e. aplastic anemia (AA), idiopathic pulmonary fibrosis, liver cirrhosis,
myelodysplastic syndromes (MDS) and acute myeloid leukemia (Armanios
2012). All mutations were missense and heterozygous, clustering in exon 6
encoding for a highly conserved segment at the C-terminus (aa 280–291)
(Frank 2015).
Aims: Precise diagnosis in AA/MDS with clinical features of telomere syndrome.
Methods: AA was diagnosed in a 69-year-old man, with a multisystem disorder,
i.e. psoriasis, nail dystrophy, severe osteoporosis, chronic hepatopathy, mild
chronic kidney failure and hypertension, suggesting a telomere syndrome. Kary-
otype was normal. Patient was unresponsive to immune-suppressive therapy.
DNA from peripheral blood and hair bulbs was analyzed for TERT, TERC and
TINF2 using DHPLC and Sanger sequencing. Q-FISH investigated telomere
length. SNPs were performed following manifacturer’s instructions (Affymetrix).
Paired-end libraries for Whole Exome Sequencing (WES) were generated with
NimbleGen Exome Capture v3 (Roche), according to manufacturer. DNA from
CD3+ population was used for germinal matching. Data were aligned to the
human reference genome (GRCh38/hg38) and analyzed with the in-house
CEQer2 software (Piazza 2013). Mutational analysis and telotype were per-
formed in both proband and familial members. TERF2 and TINF2 coding
sequences were cloned in pGem-Teasy vector and site direct mutagenesis repro-
duced in vitro the mutation. Using expression vectors, respectively pEGFP-C1
and pDsRed-Express-C1, TRF2 and TIN2 wild type or TRF2 and TIN2 mutated
were co-expressed in HEK-293T cell line. Co-immunoprecipitation was per-
formed with anti-GFP antibody and differences in TRF2 binding between TIN2wt
and TIN2mut were revealed by western blotting.
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Results: A new TINF2 germinal variation at exon 2, c.254A>G p.H85A, was
identified in the proband and in two brothers. Screening on 200 healty donors
was negative. Significantly short telomeres were found in proband (p=0,0161)
and brothers (p=0.0082 and p<0,0001), compared to age and sex matched
controls. The proband had a normal SNPs profile and WES identified an addi-
tional somatic variation in TLR1 gene (c. 1859G>A, p.R620Q). Co-immuno-
precipitation experiments showed that the new TINF2 mutation reduced TIN2
binding with TRF2 in vitro.
Summary/Conclusions: A new TINF2 germinal variation at exon 2, c.254A>G
p.H85A, was identified in the proband and in two brothers. Screening on 200
healty donors was negative. Significantly short telomeres were found in
proband (p=0,0161) and brothers (p=0.0082 and p<0,0001), compared to age
and sex matched controls. The proband had a normal SNPs profile and WES
identified an additional somatic variation in TLR1 gene (c. 1859G>A, p.R620Q).
Co-immunoprecipitation experiments showed that the new TINF2 mutation
reduced TIN2 binding with TRF2 in vitro.
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FUNCTIONAL EXPRESSION OF TIM-3 AND CLINICAL SIGNIFICANCE OF
PLASMA GALECTIN-9 LEVELS IN MYELODYSPLASTIC SYNDROMES
T. Asayama1,*, M. Ishibashi1, H. Tamura1, Y. Kuribayashi-Hamada1,
N. Takada-Okuyama1, A. Onodera-Kondo1, K. Moriya1, N. Yokose2, K. Inokuchi1
1Division of hematology, Department of medicine, Nippon Medical School,
Tokyo, 2Division of hematology, Department of internal medicine, Chiba Hoku-
soh Hospital, Chiba, Japan
Background: T-cell immunoglobulin and mucin domain-3 (Tim-3) is an inhibito-
ry immune checkpoint molecule that suppresses adaptive immunity by binding
with galectin-9 (gal-9). The Tim-3−gal-9 pathway is associated with self-renewal
of leukemic stem cells in acute myeloid leukemia (AML), although the function
of the axis in myelodysplastic syndromes (MDS) remains unclear.
Aims: To clarify the expression and function of Tim-3 and clinical impact of its
ligand gal-9 in MDS.
Methods: 1) We evaluated Tim-3 expression on CD45-gating blasts of bone
marrow mononuclear cells (BMMCs) in 20 patients with MDS and AML trans-
formed from MDS (AL-MDS), 12 healthy controls, and 4 MDS cell lines using
flow cytometry (FCM). 2) To investigate Tim-3 induction, MDS cell line F-36P
cells were co-cultured with the culture supernatant of human stromal cells and
MDS-related cytokines. 3) To elucidate the functions of Tim-3 on MDS cells, F-
36P cells were divided into Tim-3+ and Tim-3– fractions with FACS sorting and
their differential gene expression was determined with oligonucleotide microar-
ray analysis. 4) To investigate the proliferative potential of Tim-3 signaling,
intracellular Ki-67 expression in F-36P cells was evaluated using FCM when
co-cultured with/without anti-Tim-3 blocking antibody. 5) Finally, we analyzed
gal-9 concentrations in cell culture supernatants of MDS cell lines and in plasma
obtained from patients with MDS (n=51) and AL-MDS (n=19), and healthy
donors (n=10) using ELISA.
Results: 1) Tim-3 expression was observed on monocytes and CD45-gating
blasts in MDS BMMCs and in all 4 MDS cell lines. In AL-MDS patients, Tim-3
expression levels on blasts were markedly higher than in controls and MDS
patients. 2) Tim-3 expression in F-36P cells was increased by co-culture with
the culture supernatant of human stromal cells and the MDS-related cytokine
transforming growth factor-β1 (TGF-β1). Tim-3 cell-surface protein and mRNA
expression in MDS cell lines was induced by co-culture with TGF-β1. The Tim-
3 induction was abrogated by adding the TGF-β receptor I kinase inhibitor
SD208. 3) Microarray analysis showed 572 upregulated genes (>2-fold differ-
ence) and 304 downregulated genes (<0.5-fold difference) in Tim-3+ F-36P
cells compared with Tim-3– cells, and ingenuity pathway analysis of those
genes revealed upregulation associated with cell proliferation and antiapoptotic
responses in Tim-3+ cells. 4) The blockade by anti-Tim-3 antibody decreased
intracellular Ki-67 expression in F-36P cells, suggesting that Tim-3 signaling
induced MDS cell proliferation. 5) Soluble gal-9 was detected in culture super-
natants of MDS cell lines and PBMCs obtained from AL-MDS patients. Soluble
gal-9 levels and gal-9 mRNA expression were upregulated by MDS-related
cytokines interferon-γ and tumor necrosis factor-α. Plasma gal-9 levels were
higher in MDS and AL-MDS patients than in healthy controls (P<0.0001). When
MDS patients were divided into high (defined as >10 ng/mL) and low
(≤10ng/mL) gal-9 groups, the high group had poorer overall survival compared
with the low group (P=0.001), even in refractory anemia (RA)/RA with ringed
sideroblast patients alone (P=0.0029). Multivariate analysis revealed that a
high gal-9 level was an independent poor prognostic factor (P=0.0017).
Summary/Conclusions: Our data suggest that Tim-3 expression and plasma
gal-9 levels were upregulated in advanced-stage MDS. Tim-3 is associated with
cell proliferation of MDS blasts, and higher plasma gal-9 is a poor prognostic marker
in MDS. These molecules could play a key role in MDS disease progression.
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PROGNOSTIC SIGNIFICANCE OF GENE MUTATIONS IN MDS DEPENDS
ON THE LOCI OF GENE VARIANCES
T. Boneva1,*, L. Rai1, D. Brazma1, R. Dunn1, C. Grace1, E. Nacheva1,2
1OncoGenomics, HSL Analytics LLP, 2Cancer Institute, UCL, LONDON, United
Kingdom
Background: Myelodysplastic syndromes are a collection of clonal hematopoi-
etic disorders with a wide range of clinical manifestations and eventual out-
comes. Predicting the prognosis is of great importance for defining the risk and
select treatment options. Several models of risk stratification exist, all of which
include genetic markers along with other clinical and paraclinical features. The
Revised International Prognostic Scoring System (IPSS-R, Greenberg et al.,
Blood. 2012;120(12): 2454-2465) defines 5 risk levels based on the presence
of specific chromosome abnormalities. These genome aberrations provide evi-
dence for disease although reports of frequent driver mutations (Papemauilie
et al., Blood, 2013) and/or structural variants detected by single nucleotide
polymorphism (SNP) arrays (Tiu et al., Blood, 2011) have shown a potential
for score criteria in the diagnosis of MDS. Recent reports of the presence such
genetic aberrations in disease free individuals makes this approach problematic
(Genovese et al., N Engl J Med 2014; Lichman, Blood 2015, Kwok et al., Blood
2015). A study of patients without evidence for MDS identified a driver mutation
and/or structural gene variants in 91% of pre-diagnostic samples with the muta-
tional spectrum mirroring that seen in MDS population (Cargo et al. Blood,
2015). The presence of mutations with greater median variant allele fraction
(40% vs 9% to 10% in healthy individuals) and occurring with additional muta-
tions (>2 mutations, 64% vs 8%) were shown to define a high-risk group with
a shorter time to disease progression and poorer overall survival.
Aims: To compare the genomic profile of bone marrow from 145 adults, 76 of
whom met the WHO criteria for MDS.
Methods: All samples were screened by chromosome G banding or molecular
karyotyping using 8x60K oligonucleoitiude arrays (Agilent, USA) or screened
by FISH using probes (Cytocell, UK) targeting the most common aberrations
associated with MDS as per IPSS-R classification (Greenberg et al., Blood,
2013). The commercially available target gene panel TruSight on a MiSeq plat-
form (Illumina, USA) was used to screen mutational hotspots in 54 cancer-
related genes relevant in myeloid malignancy. Gene variances were reported
at allele frequencies (VAF) >10% and at minimum read depth of 300 as per
manufacturers criteria. We used the Catalogue of Somatic Mutations In Cancer
(COSMIC), dbSNP and 1000 genome (>2%) to classify gene variants as either
drivers, variants of unknown significance and germline polymorphisms (SNPs).
Results: A total of 145 bone marrow samples from 58 women and 87 men,
aged from 26 to 85 suspected to have myeloid dysplasia were investigated. Of
these only 76 (52%) were found to fulfill the WHO, criteria referred to as MDS
positive, the rest as MDS negative. Gene variances were detected in all but 7
samples (5%). The latter appear to be void of gene mutations. We observed
driver mutations as reported in myeloid malignancies in 68 (47%) samples
whilst 70 (48%) were found to carry the same variances seen in disease free
individuals or of unknown significance. As expected driver variances were not
identified in any of the samples that failed the WHO criteria for MDS. Variances
were detected in all samples for 35 of the 54 genes targeted by the TruSight
myeloid panel. In order of frequency these are TET2, SRSF2, ASXL1, CUX1,
DNMT3A, RUNX1, BCORL1 and HRAS, seen in more that 10% of all samples,
while the rest were less frequently reported. The aberrant genes ASXL1, TET2
and SRSF2 figured prominently in both groups of samples with comparable
frequencies as may be expected from published data and there were in addition
a number of aberrant genes unique to the MDS group albeit at low frequency.
When we examined the distribution of individual variances (rather than genes)
we found a number of unique loci of the genes ASXL at 131022441, U2AF at
144524456 and TET2 at 106197285 to be associated with the MDS positive
group. A more detailed analysis on the significance of these findings will be
presented.
Summary/Conclusions: We compared 145 bone marrow samples from
patents presenting with MDS of which 76 met the WHO criteria. There is little
difference in their genomic profile when comparing the two groups on the basis
of the most highly involved genes (ASXL1, TET2 and SRSF2) but if we compare
the two groups by variance, 9 variances are exclusively associated with MDS
positive disease.
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SUPPRESSION OF DNA METHYLTRANSFERASE ENZYMES BY A NOVEL
HYPOMETHYLATING AGENT, SGI-1027, IN AZACITIDINE- AND
DECITABINE-RESISTANT CELL LINES
E.-H. Hur1,*, D.R. Choi2, B.-K. Goo1, J.H. Moon1, E.-J. Choi1, H.-S. Park 1,
J.-H. Lee1, K.-H. Lee1, J.-H. Lee1
1Hematology, Asan Medical Center, University of Ulsan College of Medicine,
SEOUL, 2Internal Medicine,, Chuncheon Sacred Heart Hospital, Hallym Uni-
versity College of Medicine, Chuncheon, Korea, Republic Of
Background: We established azacitidine- and decitabine-resistant cell lines,
MOLM/AZA-1 and MOLM/DEC-5 from MOLM-13, an acute myeloid leukemia
cell line (Oncotarget in press). DNA methyltransferase (DNMT) 3B was upreg-
ulated in the resistant cell lines.
Aims: We tried to find out clues to overcome the resistance to hypomethylating
agent (HMA).
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Methods: Besides azacitidine and decitabine, three other agents (SGI-1027,
zebularine, and gemcitabine) are known as having hypomethylating effect. in
vitro activities of the 5 HMA’s on HMA resistant cell lines (MOLM/AZA-1 and
MOLM/DEC-5) were tested by cell viability assay using luminescent-based
CellTiter-Glo system. Protein and mRNA levels of DNMT enzymes (1, 3A, and
3B) were assayed before and after treatment of each HMA. Proteosomal degra-
dation and activation of Akt were also determined to see the correlation with
changes of DNMT’s.
Results: Although azacitidine and decitabine could suppress DNMT1 and
DNMT3A in MOLM-13, the agents could not suppress DNMT enzymes in resist-
ant cell lines. Inhibition of proteosomal degradation by bortezomib induced
accumulation of DNMT enzymes in MOLM-13, whereas it did not accumulate
the enzymes in MOLM/AZA-1 and MOLM/DEC-5. Phosphorylated Akt (p-Akt)
was dramatically overexpressed in MOLM/AZA-1 and MOLM/DEC-5. SGI-1027
showed the lowest IC50 values for MOLM/AZA-1 and MOLM/DEC-5, and it
suppressed the protein levels of all three DNMT enzymes. SGI-1027 could also
decrease the level of p-Akt. GDC-0941, a PI3K inhibitor, suppressed DNMT1
and DNMT3A as well as p-Akt, but it could not decrease DNMT3B in
MOLM/AZA-1 and MOLM/DEC-5. Cell viability assay showed the synergistic
effects of combination of GDC-0941 and Nanaomycin A, a specific DNMT3B
inhibitor, in MOLM/AZA-1 and MOLM/DEC-5.
Summary/Conclusions: DNMT levels of MOLM/AZA-1 and MOLM/DEC-5
were not dependent on proteosomal degradation. DNMT1 and DNMT3A might
be regulated via PI3K-Akt pathway, while regulation of DNMT3B might be dif-
ferent from DNMT1 and DNMT3A. SGI-1027 appears to exert inhibitory effects
on MOLM/AZA-1 and MOLM/DEC-5 by inhibition of both p-Akt and DNMT3B.
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MECHANISTIC HIGHLIGHTS OF IMPROVED ERYTHROPOIESIS WITH A
LOW DOSE OF DEFERASIROX IN LOW RISK MYELODYSPLASTIC SYN-
DROMES
M. Mathieu1,2,*, S. Ancelet2, C. Lefebvre3, J. Arnaud4, C. Garrel4, M. Pezet5,
Y. Wang2, P. Faure4, G. Szymanski3, B. Polack3, J. Y. Cahn12, J. M. Moulis6,7,8,
S. Park1,2
1Clinique Universitaire d’hématologie, CHU Grenoble Alpes, 2Equipe TheREx-
laboratoire TIMC, Université Grenoble Alpes, 3Laboratory of hematology, 4Unité
de Biochimie Hormonale et Nutritionnelle, Département de Biologie - Toxicolo-
gie - pharmacologie, CHU Grenoble Alpes, 5Plateforme de Microscopie Pho-
tonique - Cytométrie en Flux, Institut Albert Bonniot, Université Grenoble Alpes,
6LBFA, Inserm U1055, 7CEA-Grenoble, Bioscience and Biotechnology Institute,
8Laboratory of Fundamental and Applied Bioenergetics, and Environmental
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Background: Myelodysplastic syndromes (MDS) are a group of heterogeneous
clonal stem cell disorders leading to ineffective hematopoiesis. Anemia is a fre-
quent cytopenia in MDS and the majority of patients requires red blood cell
(RBC) transfusion resulting in the development of iron overload (IO).
Deferasirox (DFX) became a standard treatment of IO in MDS and seems to
have positive effects on hematopoiesis with a reduced need of RBC transfusion. 
Aims: Decipher the mechanisms of the potential improvement of erythropoiesis
with DFX.
Methods: We report our in vitro data about the proliferation, cell cycle, apop-
tosis, erythroid differentiation, and cell signaling pathways concerning CD34+
hematopoietic stem progenitor cells from low risk MDS samples in a 2-step
erythroid differentiation liquid culture with low dose DFX and iron overload. 
Results: We observed a higher proliferation rate for cultures with 3μM DFX
versus the control condition (p=0.038). In contrast, no increased proliferation
was found with DFX>5μM and with other chelators used in the clinic. The higher
proliferation rate with DFX 3µM was due to the combination of decreased apop-
totic cells at day 10 (D10) (p=0.03) and D14 (p=0.007) and increased cycling
cells at D10 (p=0.0001). Regarding clonogenic assays, there were more CFU-
E colonies with DFX 3µM (p=0,04). Despite the low concentration of DFX, cells
exposed to DFX 3µM had a lower intracellular iron concentration measured by
ICP-MS than control cells (p=0.019). Nevertheless, this decreased iron amount
was not sufficient to activate cellular iron regulation by Iron Regulatory Proteins
suggesting the absence of a direct effect of low dose DFX on iron homeostasis.
Moreover, low dose DFX decreased intracellular and mitochondrial reactive
oxygen species (ROS) at D14 (p=0.048 and p=0.03) and decreased the level
of malonaldehyde (p=0,048), a product of lipid peroxidation. Then, we have
investigated which signaling pathways were sensitive to DFX 3µM. We found
an increased nuclear translocation of NFκB with DFX 3µM (p=0,028) in confocal
microscopy (CM). Using RT-qPCR microarrays, we have analyzed target genes
of NFκB. We found 4 upregulated genes (BIRC3, CASP8, CSF3, IRAK2) and
10 downregulated genes (FASLG, IL1R1, TLR9, PSIP1, CCL2, TRAF2, LTBR,
TICAM2, CD27, TLR4) suggesting an anti-apoptotic and anti-inflammatory pat-
tern. To demonstrate a link between the likely ROS modulation effects of DFX
and the NFκB activation pathway, we have engineered a cellular model of inhi-
bition of thioredoxin (TRX) by siRNA. TRX1 and 2 contribute to the cellular
antioxidant response. Inhibition of TRX1 and 2 in iron overloaded medium led
to increased ROS levels (p<0.0001; p=0.006, respectively) versus mock-trans-
fected cells. In this model of iron overload and in the siTRX1 condition, DFX
3µM triggered activation of NFκB detected by both CM (p=0.04) and luciferase
reporter assay (p=0.03). NFκB activation was absent in the knock-down (KD)
of mitochondrial TRX (siTRX2) condition. Moreover, in non-iron overloaded
medium condition, the level of ROS was not increased, and DFX in the TRX1
KD condition was not associated with NFκB activation. These results suggest
that NFKB activation in this model is linked to TRX1 and regulated by an
extremely fine control of ROS levels with a likely threshold effect.
Summary/Conclusions: Our study describes the pro-proliferative effects of
low dose of DFX on erythroid progenitors in low risk MDS patients. These
results provide a biological rationale for a clinical trial which will propose low
dose of DFX in MDS patients, refractory to erythropoiesis stimulating agents.
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EVALUATING ERYTHROBLAST PAS POSITIVITY IN THE DIAGNOSTIC
APPROACH OF MYELODYSPLASTIC SYNDROME
R. Invernizzi1,*, E. Travaglino1, R. Bastia1, I. Ambaglio1, F. Quaglia1, E. Boveri1,
M. G. Della Porta1, L. Malcovati1, M. Cazzola1
1IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy
Background: According to WHO minimal morphological criteria for myelodys-
plastic syndrome (MDS) diagnosis, at least 10% of bone marrow (BM) cells of
at least one hematopoietic lineage must show unequivocal dysplasia to be
considered as dysplastic. Morphological abnormalities of erythroid cells include
cytoplasmic Periodic acid-Schiff (PAS) positivity, but the diagnostic power of
this cytochemical reaction is not yet fully clear. 
Aims: The aims of our study were to evaluate the diagnostic significance of
erythroblast PAS positivity in MDS and to investigate a possible correlation
between levels of PAS positivity and other morphological and clinical features.
Methods: We retrospectively examined the results of the cytochemical PAS
staining for glycogen in BM smears from 165 patients with MDS, 116 patients
with non-clonal cytopenia and 49 healthy subjects. We developed a PAS score
by counting 100 nucleated cells for the erythroid lineage and classifying them
according to their degree of PAS reactivity. The discriminant power of both PAS
positivity rate and score for MDS identification was evaluated in comparison
with that of the conventional morphological features of dyserythropoiesis; then,
PAS positivity was included into the morphological scoring system we have
previously defined (Leukemia 2015;29:66-75).
Results: PAS positive erythroblasts were observed in 104 (63%) MDS patients,
46 (40%) patients with non-clonal cytopenia, and 12 (24%) non-cytopenic con-
trols, with a significant difference between MDS and non cytopenic controls
(p<0.0001) or non-clonal cytopenias (p=0.0001), but not between healthy con-
trols and non-clonal cytopenias (p=0.09). In MDS, both positivity rates (median
2%, range 0-33) and scores (median 2, range 0-53) were significantly higher
than those in normal and pathological controls (p=0.0001 and p=0.0004 for
rate, p=0.0001 and p=0.0002 for score, respectively), without significant differ-
ence in relation to excess blasts or multilineage dysplasia. MDS patients with
>4% ring sideroblasts (RS) showed lower PAS positivity rates and scores than
MDS patients with<4% RS (p=0.0332 and p=0.0412, respectively). In MDS-
RS, erythroblast PAS positivity was not influenced by SF3B1 mutation status.
In MDS, no significant relationship was detected between erythroblast PAS
positivity and percentage of BM blasts, percentage of BM erythroblasts, dysery-
thropoiesis grading, or Hb levels, whereas an inverse correlation was noticed
between PAS score values and internuclear bridging (r=-0.23, p=0.0395). A
ROC curve analysis allowed us to identify a PAS score value ≥1 (AUC=0.697,
p=0.0008) and a PAS positive erythroblast percentage ≥1% (AUC=0.674,
p=0.0034) as optimal cutoff to discriminate MDS patients from non-clonal
cytopenias. Considering the most discriminant morphological features for
dyserythropoiesis, the weight of both PAS positivity rate and score in the iden-
tification of BM dysplasia was lower than that of ring sideroblasts and mega-
loblastosis, but higher than that of defective hemoglobinisation, nuclear lobu-
lation, multinuclearity, cytoplasmic fraying, pyknosis, and internuclear bridging.
Integrating conventional parameters and PAS results significantly improved
the sensitivity of our morphological scoring system.
Summary/Conclusions: The evaluation of BM erythroblast PAS positivity,
easy to perform and inexpensive, may be useful in the work-up of patients with
suspected MDS, especially if there is only unilinear dysplasia without ring sider-
oblasts or excess blasts. 
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A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND
TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1)
RISK MYELODYSPLASTIC SYNDROMES (MDS)
U. Platzbecker1,*, A. Symeonidis2, E. Oliva3, J. Goede4, M. Delforge5, J. Mayer6,
B. Slama7, S. Badre8, E. Gasal8, B. Mehta8, J. Franklin8
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Hematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria,
Italy, 4Division of Hematology, University Hospital and University of Zürich,
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Background: There is a lack of PBO-controlled data for erythropoiesis-stimu-
lating agents (ESAs) in MDS.
Aims: To evaluate darbepoetin alfa (DAR) in IPSS low/int-1 risk MDS
(EudraCT2009-016522-14, NCT01362140).
Methods: Patients with MDS per WHO 2008 criteria with IPSS low/int-1 risk,
anemia [hemoglobin (Hb)≤10 g/dL], low transfusion burden, no previous treat-
ment with ESAs or biologic response modifiers, and serum EPO≤500mU/mL
were randomized 2:1 to 24 weeks (wk) SC DAR 500 µg or PBO every 3 wk
(Q3W), stratified by IPSS, then 48 wk open label (OL) DAR; follow-up is ongoing.
Doses were withheld for Hb>12g/dL and decreased if Hb increased by >1.5
g/dL in 3 wk. Key endpoints were transfusion incidence and HI-E per IWG 2006.
Results: Randomized patients [N=147] had median Hb of 9.3 (min-max:5.5-
10.6) g/dL and median baseline EPO of 69 (min-max:4.3-497) mU/mL; WHO
classification was RA:15%, RARS:14%, RCMD:44%, del5q:9%, RAEB-1:16%,
and MDS-U/unknown:2%. Transfusion incidence wk 5-24 was significantly
reduced with DAR [DAR:36.1% vs PBO:59.2%, p=0.008]. In the 48-wk OL DAR
period, 50.8% of patients had transfusions. More DAR patients achieved HI-E
in the double blind period [DAR:14.7% (11/75 evaluable) vs PBO:0% (0/35
evaluable), p=0.016]. In the 48-wk OL DAR period, 34.7% (34/98) of patients
achieved HI-E. Improved HI-E and transfusion responses were seen with more
favorable status for IPSS-R but not IPSS. In the 48-wk OL DAR period, dose
frequency increased from Q3W to Q2W in 81% of patients; doses were
held/reduced frequently. Safety results from this trial were consistent with the
previous DAR phase 2 MDS trial, with similar AML rates in PBO and DAR
arms.
Figure 1.
Summary/Conclusions: In this phase 3, randomized, double-blind, PBO-con-
trolled trial in anemic IPSS low/int-1 risk MDS patients, 24 wk of darbepoetin
alfa Q3W significantly reduced transfusions and increased HI-E rates with no
new safety signals. Most patients met criteria to change to Q2W dosing during
the 48-wk OL period, suggesting that Q2W dosing may offer more benefit. The
true clinical benefit of darbepoetin alfa may have been underestimated due to
the nature of IWG 2006 HI-E criteria and trial design (Hb measured Q3W, dos-
ing rules).
E1181
PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV
CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN
LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION
INDEPENDENCY
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Background: Lenalidomide (LEN) is the first choice of treatment in low risk
MDS patients with isolated de(5q) (MDS-del(5q)) and transfusion dependency
(TD). Most of the low risk MDS-del(5q) patients diagnosed with anemia and
independent of transfusions developed TD or needed treatment for symptomatic
anemia early after diagnosis (median of 20 months, abstract 3180 ASH, 2016).
LEN directly targets the del(5q) clone improving anemia, quality of life and sur-
vival in these subset of patients. For these reasons, the use of LEN in patients
with del(5q), anemia and not TD seems to be very attractive. However, data
about the use of LEN in MDS 5q- patients and transfusion independency (TI)
are scanty, some retrospective studies suggest a benefit with the early use of
LEN in this setting, but there is not already available any prospective and ran-
domized study to confirm this likely advantage.
Aims: Our aims were to analyze efficacy and safety at week 12 of treatment
with LEN vs Placebo in this setting of low risk MDS del(5q) patients with anemia
and not in TD at diagnosis
Methods: From 2010 to 2017, 47 patients have been included in the Sintra-
Rev trial, a phase III, multicenter, randomized and double blind study with LEN
(5mg/day) vs placebo [2:1 randomization] in Low – Int-1 risk (IPSS) MDS del(5q)
patients with anemia but TI. Preliminary results of efficacy (according to the
IWG 2006 criteria for erythroid [HI-ER] and cytogenetic response [CyR]) and
safety has been analyzed at week 12. Progression disease (DP) in the trial
was defined as the development of TD.
Table 1.
Results: Main clinical characteristics are summarized in table 1, 85% were
females, median age was 72 years (37-89) and most of patients (95%) had
del(5q) as the only cytogenetic abnormality. Among 47 patients, only 38 were
evaluable at week 12 (5 out of 38 discontinued the study: 3 due to DP, 1 due
to toxicity and 1 for unknown reasons), 7 patients are currently receiving the
first 12 weeks of treatment and 2 patients were excluded (screening failures).
Regarding efficacy (w12), data from 36 patients were available. HI-ER was
observed in 14/36 patients (39%), minor HI-ER (Hb increased<1.5g/dL) in 4/36
(11%), stable disease in 15/36 (42%) and PD (transfusion dependency) in 3
(8%). CyR was available in 30 patients: complete CyR was obtained in 12
(40%), partial CyR in 6 (20%) and no CyR in 12 (40%) patients. Safety infor-
mation in 38 patients demonstrated that most patients (87%) developed any
adverse events (AE) while only 42% of these were relevant (G3-4). Most G3-
4 AE were hematological (neutropenia 38%) being non-hematological only in
5%. Seven serious AE were reported in 5 patients: vestibular neuritis, conges-
tive heart failure, polyarthritis, arterial hypertensive crisis, carpal arthritis, res-
piratory infection and chronic obstructive pulmonary disease exacerbation. All
SAE were not related with the drug of the study (LEN/Placebo).
Summary/Conclusions: In this study we confirm a high rate of erythroid and
cytogenetic responses early after treatment with an adequate safety profile in
the first 12 weeks of treatment with LEN or placebo.
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MYELODYSPLASIA-RELATED MORTALITY REMAINS THE MAIN CAUSE
OF DEATH ALONG DIFFERENT GROUPS OF RISKS: AN ANALYSIS FROM
MDS ARGENTINEAN STUDY GROUP
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Background: Myelodysplastic syndrome (MDS) are the most frequent hema-
tological malignancy in elderly patients. The impact of MDS burden over overall
mortality remains controversial, moreover, after the incorporation of hypometi-
lating agents in the therapeutic armamentarium.
Aims: We aimed to analyze overall mortality and causes of death in our pop-
ulation of patients with MDS.
Methods: A retrospective analysis of patients with MDS reported to Argentinean
MDS registry and a previous study from Academia Nacional de Medicina. Caus-
es of death were classified in: acute myeloid leukemia (AML), infections, bleed-
ing, solid tumor, cardiovascular, transplant related mortality (MRT), others and
unknown. AML, infections and bleeding were considered as MDS-related mor-
tality. Causes of death were analyzed using cumulative competitive events
curves with Gray test and Fine-Gray for proportional hazard regression was
used for the multivariate analysis. 
Results: From 1981 to 2016, 1040 patients with MDS were recorded; 717 out
of 1040 (69%) were diagnosed after 2006. Median age of patients was 70 years
(range: 14-95 years) with 588 (56%) being male. MDS was primary in 974
patients (94%). Median follow-up of 25 months (range: 1-170 months) for the
surviving patients. The cumulative incidence of overall mortality was 20% at 12
months (95%CI 2-22), 37% at 24 months (95%CI 3-40) and 59% at 60 months
(95%CI 5-63). The incidence of overall mortality did not significantly differ along
the years of diagnosis (p=0.291) neither according to age group. Multivariate
analysis for cumulative incidence of overall mortality found Charlson index (HR
1.38; p<0.001), sex (HR 1.45; p=0.014) and IPSS-R (HR 2.79; p=<0.001) as
prognostic variables. The main cause of death was AML accounting for 9% at
12 months (95%CI 7-11), 16% at 24 months (14-19) and 25% at 60 months
(95%CI 22-28) of mortality for all patients. Infection-mortality and bleeding-mor-
tality were the second and the third cause of death respectively. MDS-related
mortality was 16% at 12 months (95%CI 13-18), 29% at 24 months (95%CI 26-
32) and 44% at 60 months (95%CI 40-48); this incidence was not different by
year of diagnosis. MDS-related mortality remained the main cause of death in
all IPSS-R groups and in all Charlson index categories. Multivariate analysis
for cumulative incidence of MDS-mortality found Charlson index (HR 1.29;
p=0.02), IPSS-R (HR 2.88; p<0.001) and sex (HR 1.47;p=0.03) as independent
variable. Age (p=0.034) and IPSS-R (p<0.001) were associated with AML-relat-
ed mortality. A total of 56 patients underwent allogeneic transplant; cumulative
incidence of MRT for all cohort was 0.5% at 12 months (95%CI 0.2-1.2) and
1.4% at 24 months (95%CI 0.8-2.4). Only male sex was associated with a high-
er cumulative incidence of mortality by solid tumor (p<0.001) and a Charlson
index ≥2 was associated with higher cumulative incidence of cardiovascular
mortality (p=0.021). 
Summary/Conclusions: In this large cohort of patient with MDS we demon-
strate that MDS-related causes are the leading cause of death along all IPSS-
R groups. The absence of difference in mortality along the years of diagnosis
highlights the necessity of better treatments for these patients. 
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PROSPECTIVE STUDY OF FLOW CYTOMETRY OF BONE MARROW IN
105 CONSECUTIVE PATIENTS WITH CYTOPENIA AND SUSPICION OF
MYELODYSPLASTIC SYNDROME: STRONG CORRELATION WITH RISK
OF AML-EVOLUTION AND SURVIVAL
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C. Barrenetxea1, A. Blanco1, B. Barreña2, S. Herráez1, I. Capel3, I. Leal1,
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Background: Diagnosis of myelodysplastic syndromes (MDS) remains a chal-
lenge, specially in patients with scant displastic morphology features and/or in
the absence of cytogenetic changes. Multiparametric flow cytometry (MFC)
findings have been recognized as a co-criterion for the diagnosis of MDS and
have also demonstrated prognostic value in some studies. Nevertheless, this
diagnostic tool is not fully implemented for the study of MDS in many centers
and data from real life out of investigational studies are few.
Aims: To prospectively assess the value of MFC in the diagnosis of MDS in
our center and correlate its findings to the clinical outcome of patients in terms
of overall survival, transfusional needings, risk of hospitalization and evolution
to acute leukemia.
Methods: We studied bone marrow samples from 105 consecutive patients
submitted to our hospital between January 2013 and Abril 2015 because of
one or more cytopenia and suspicion of MDS. Cytomorphology of every sample
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was evaluated by at least two morphology experts and a consensus diagnostic
of MDS-confirmed, MDS-suspected or MDS-excluded was emitted. MFC was
performed applying at least five-colour staining and a numerical score was cal-
culated for every patient following criteria defined by Ogata et al (Blood. 2006
Aug 1; 108(3):1037-44), with a score >=2 suggesting MDS. Conventional kary-
otype and FISH employing probes to detect usual 5q-, 7q-, +8, 20q- and
delTP53 were performed in all cases.
Results: Median age of the patients was 73.5 y/o. Patients presented with
anemia in 88 cases (84%), neutropenia in 36 (34%) and thrombopenia in 49
(47%). Cytomorphology was reported as MDS-confirmed (60 pts), MDS-exclud-
ed (22) or MDS-suspected (23). MDS subtypes were Multilineage Dysplasia
(23), Unilineage Dysplasia with Ring Sideroblasts (4), Blast Excess (14), Mul-
tilineage Dysplasia with Ring Sideroblasts (9), del5q Syndrome (3) and Unclas-
sified (2), 4 pts being diagnosed of CMML. MFC score was MDS-suggestive
in 56 cases, MDS-not suggestive (36) and in 13 cases its use was precluded
because of morphology findings. Considering cytomorphology as gold stan-
dard, and excluding those patients with MDS-suspected but not confirmed,
MFC score sensitivity was 77%, especificity 88%, with positive and negative
predictive values of 96% and 56% respectively. Furthermore, MFC-score
showed a significant correlation with single morphologic findings of granulocytic
(p<0.001), erythroid (p=0.001) and megakaryocytic displasia (p=0.002), and a
trend to significant association with del7q by FISH (p=0.085). In the subset of
patients with MDS-suspected but not confirmed by morphology, the presence
of a MFC score >=2 was significantly associated with a poorer overall survival
(log-rank p=0.012), with all MFC score <2 patients alive after a median follow-
up of 35 months. There was also a trend to statistical association between
MFC findings and overall survival in the whole series of patients (log rank
p=0.053). Interestingly, there was a striking difference in risk of evolution to
AML according to MFC findings (log rank=0.013), with a 100% of patients free
from this complication in the group of patients with MFC score <2.
Summary/Conclusions: MFC analysis of the bone marrow provides useful
information in the diagnosis of MDS which can be specially helpful in the subset
of patients with inconclusive morphological findings, showing a strong correla-
tion in this group of patients with clinical outcome in terms of risk of evolution
to AML and overall survival.
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ECONOMIC IMPACT AND HEALTHCARE UTILIZATION IN PATIENTS WITH
HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE
CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE
STUDY
J. Bell1,*, A. Galaznik1, E. Farrelly2, M. Blazer2, H.-C. Shih2, A. Raju2, A. Ogbonnaya2,
M. Eaddy2, R. Fram1, D. Faller1
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Background: Therapy for patients with HR-MDS includes systemic chemother-
apy, stem cell transplant (SCT), and supportive care aimed at improving symp-
toms associated with MDS-related disruption of normal hematopoiesis. How-
ever, the economic impact of these interventions over time for HR-MDS patients
has not been fully examined.
Aims: We evaluated the costs and healthcare utilization (HCU) of US HR-
MDS patients treated during routine care.
Methods: Newly diagnosed adult HR-MDS patients who initiated first-line ther-
apy were identified from Optum, a large US claims database, between 1/1/08
and 10/31/15. HR status was based on ICD coding: ≥1 inpatient claim or ≥2
outpatient claims with ≥1 HR-MDS ICD-9/10 code (ICD-9 code: 238.73; ICD-
10 codes: D46.20, D46.21, D46.22). The first MDS claim served as the index
date. Exclusion criteria included: lack of continuous enrollment in medical/phar-
macy benefits in the 12 months prior to index date (baseline period), presence
of other primary cancer, or receipt of any chemotherapy or SCT during baseline
period. MDS-related and non-MDS-related HCU and costs incurred during fol-
low-up were evaluated. MDS-related HCU and costs were medical claims with
a primary diagnosis of MDS or MDS-related treatment (ie, MDS chemotherapy
as defined by NCCN MDS Guidelines v2.2017 or MDS-directed supportive
care which included hydroxyurea, erythrocyte- and colony-stimulating- growth
factors and erythrocyte/platelet transfusions) and pharmacy claims for MDS
treatment. Proportions of patients with HCU were reported. Costs were calcu-
lated as per-patient-per-month (PPPM) costs adjusted to 2015 US dollars and
reported as mean (standard deviation [SD]). Patients with a capitated payment
plan were excluded from the cost analysis. Patients were followed until death,
progression to acute myeloid leukemia (AML), end of continuous enrollment,
or end of study (12/31/2015).
Results: 209 treated HR-MDS patients were identified. During the follow-up
period, 69.4% of patients had ≥1 inpatient admission, but more patients had
an MDS-related than non-MDS-related admission (Table 1). 56.9% of patients
had ≥1 emergency room visit over the follow-up period; visits were predomi-
nately for non-MDS-related services. The majority of patients had ≥1 physician
office visit (91.9%) and other outpatient visits (99.5%). Over the follow-up peri-
od, the mean PPPM cost was $17,361 (SD: $19,747) (Table 1) and was higher
in Year 1 than in Year 2 ($17,337 [SD: $19,696] vs $12,976 [SD: $14,135]).
The majority of costs overall were for MDS-related medical services ($10,327
PPPM, SD: $11,050). Between Years 1 and 2, MDS-related medical PPPM
costs decreased from $10,557 (SD: $11,164) to $6,530 (SD: $7,406) while
non-MDS-related medical PPPM costs remained fairly constant in both years.
Chemotherapy and supportive care medical services were the main drivers of
MDS-related medical costs, also decreasing from Year 1 to Year 2. Non-MDS-
related costs accounted for a smaller portion of the overall medical PPPM costs
($6,124 [SD: $15,158]); and remained relatively similar in Years 1 and 2.
Table 1.
Summary/Conclusions: The economic impact of HR-MDS is considerable,
with higher costs incurred within the first year of diagnosis. The decrease in
cost between Year 1 and Year 2 was mainly due to decreased MDS-related
medical costs. Consistent with this cost trend, healthcare utilization for MDS-
related services decreased in Year 1 vs Year 2. As treatment of HR-MDS con-
tinues to evolve, economic impact and HCU need to be further investigated in
this patient population.
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INTRAVENOUS IMMUNOGLOBULIN IS AN EFFECTIVE TREATMENT FOR
CYTOPENIAS ASSOCIATED TO CIRCULATING T-CELL CLONES IN
MYELODYSPLASTIC SYNDROMES
F. Schieppati1,*, E.P. Demakos2, R. Odchimar-Reissig2, S.C. Navada2,
L.R. Silverman2
1Hematology, ASST Spedali Civili di Brescia, Brescia, Italy, 2Tisch Cancer Insti-
tute, Icahn School of Medicine at Mount Sinai, New York, United States
Background: Myelodysplastic syndrome (MDS) can be associated with
immunologic disorders, including autoimmune cytopenias and Coombs positive
or negative (C±) hemolytic anemia. Abnormally expanded T-cells can be detect-
ed in these patients, possibly contributing to both bone marrow insufficiency
and peripheral cytopenia, and offer another target for therapeutic intervention.
Aims: To explore the role of intravenous immunoglobulin (IVIG) as a treatment
for immune-related cytopenia in a series of 20 consecutive patients with MDS
at a single institution.
Methods: T-cell clonal expansion in the peripheral blood (PB) was documented
by flow cytometry and PCR. Eighteen patients had a confirmed MDS (16 IPSS
lower-risk, LR). Two suspected MDS were designated as idiopathic cytopenia
of uncertain significance (ICUS). Reasons for IVIG treatment were chronic
hemolysis refractory to corticosteroids (16: 12 LR, 1 higher-risk (HR), 1 ICUS)
or pancytopenia (2 LR and 1 HR refractory to standard therapy, 1 ICUS) asso-
ciated to a T-cell clonal proliferation in the PB. Hematological response was
assessed by IWG criteria 2006. Hemolysis response (HLR) included normal-
ization (CR) or a greater than 50% improvement (PR) of LDH, reticulocytes,
indirect bilirubin and haptoglobin.
Results: Clinical characteristics are shown in the Table. All patients had a
clonal rearrangement of TCR by PCR (10 TCRβ, 8 TCRβ+TCRγ, 2 TCRγ). In
9 cases the clone was characterized by flow cytometry: 6 had a CD3+ T-cell
and 3 had a CD3-/CD16+/CD56+ NK-cell expansion. Associated immunologic
disorders were: ITP (4), neutrophil dermatosis (3), inflammatory bowel disease
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(3), seronegative arthritis (2), connectivitis (2). One patient with hypoplastic
MDS had LGL liver involvement. Coombs test was positive in 4/16 hemolysis
cases. From Jan-’10 to Jan-’17, IVIG was administered at a dose of 500mg/kg
once per week, in cycles of 1 to 4 weeks. The ORR was 75% (15/20): all patients
showed an erythroid hematological improvement (HI) (100%). Platelets and
neutrophil HI was seen in 50% and 80% of responsive cases, respectively.
HLR occurred in 13/16 (81%: 4 CR and 9 PR). Median number of cycles and
duration of treatment were 11 and 12 months (mo), respectively. The HLR-CR
was stable in 7 patients; 4 relapsed from HLR but subsequently responded by
shortening the intervals between administrations of IVIG; 2 were secondary
refractory. Eventually, 6 responders became refractory to IVIG. Response was
more durable with continuous rather than sporadic dosing. Median time to
response was 1 mo. Median duration of response was 39 mo. Corticosteroids
were discontinued in 5/10 patients and reduced in 5/10. Adverse events were:
1 palpitations (G1); 1 hypertension (G1). Responders had lower platelet counts
(p<0.05), but no other clinical differences compared to non-responders. How-
ever, the 5-year OS rate was higher in the responders to IVIG: 53% compared
to 30% (p=0.08).
Table 1.
Summary/Conclusions: Treatment with IVIG of C± hemolytic anemia and
pancytopenia associated with T-cell immune-clones and MDS was safe and
yielded high rates of durable response on all lineages and on hemolysis. Trans-
fusion independency and reduction/discontinuation of corticosteroids for chronic
hemolysis make this drug a valuable option not only in LR but also in HR
patients, although a confirmation on larger cohorts is needed. IVIG at interme-
diate-high dose suppresses proliferation of T-cells and induces immune-regu-
lation. Given the relative rarity of T-cell clones in MDS, further investigational
studies are underway to define their pathogenetic role and the mechanism of
action of IVIG in this specific subset of patients.
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DEVELOPMENT AND EXTERNAL VALIDATION OF A NEW PATIENT-CENTERED
PROGNOSTIC INDEX FOR PATIENTS WITH ADVANCED MYELODYSPLAS-
TIC SYNDROMES
F. Efficace1,*, F. Cottone1, G. Abel2, P. Niscola3, G. Gaidano4, F. Bonnetain5,
A. Anota5, G. Caocci6, A. Cronin2, L. Fianchi7, M. Breccia8, R. Stauder9,
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L. Borin15, A.A. Di Tucci16, H. Zhang17, M. Sprangers18, M. Vignetti1, F. Mandelli1
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Shenyang, China, 18Academic Medical Center/University of Amsterdam,
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Background: The clinical presentation of myelodysplastic syndromes (MDS)
is highly variable, and the ability to accurately predict outcomes is critical. Cur-
rent prognostic systems for these diseases are based on traditional clinical,
pathologic and laboratory indicators.
Aims: We aimed to develop and validate a new prognostic index for advanced
MDS by including self-reported fatigue severity into a well-established clinical
risk classification: the International Prognostic Scoring System (IPSS).
Methods: Untreated patients (n=280) were recruited at the time of diagnosis
of advanced MDS from 37 hospitals in nine countries to create the index. The
index was then applied to an independent cohort including pre-treated MDS
patients from the Dana-Farber Cancer Institute (DFCI) in Boston, Massachu-
setts (USA; n=189). Patients in both the International and DFCI cohorts were
adults with newly-diagnosed intermediate-2 or high-risk MDS (advanced dis-
ease on the IPSS). Patients were enrolled regardless of age, comorbidity, per-
formance status and progression from a lower IPSS category. All completed a
baseline health-related quality of life assessment. Data from international and
DFCI cohorts were independently collected and analyzed. Univariate and mul-
tivariate Cox proportional hazards (PH) regression analyses were performed
to estimate hazard ratios with 95% Confidence Intervals (CIs). Discrimination
and calibration were evaluated for both the development (internal validation)
and independent DFCI datasets (external validation). Statistical significance
for all tests was set as two-sided α=0.05.
Results: A new risk classification was developed, namely, the fatigue (FA)-
IPSS(h). Whereas use of the standard IPSS in more advanced disease dis-
criminates between two risk categories for untreated patients, the new fatigue
FA-IPSS(h) classification was able to distinguish three subgroups of patients
with distinct survival outcomes. Overall survival rates at 6 months, 1 year, and
2 years were markedly different among the three groups. To illustrate, one year
survival was 80.3% (95% CI, 73.4;87.8), 60.5% (95% CI, 52.3;70.0) and 37.6%
(95% CI, 23.9;59.1) for patients classified into Risk-1, Risk-2 and Risk-3 respec-
tively. Median OS in DFCI data by FA-IPSS(h) risk was similar to that of the
development cohort for each of the three risk groups, indicating good external
calibration. Patterns of OS through 2 years were also distinct between risk
groups as in the development cohort of untreated patients, with one exception:
2–year OS was similar for FA-IPSS(h) risk-3 and risk-2. Predictive accuracy of
this new index was higher than the IPSS alone in both the development cohort
(C-statistic, 0.61 vs 0.57) as well as in the independent cohort including pre-
treated patients (C-statistic, 0.58 vs 0.54).
Summary/Conclusions: The FA-IPSS(h) is an additional prognostic tool that
might enhance clinicians’ ability to provide more personalized treatment strate-
gies both in untreated and pretreated advanced MDS patients. This analysis
offers a model for integration of PROs in prognostic systems for patients with
other cancers and advanced illnesses.
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PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF SIGNIFICANT MAR-
ROW FIBROSIS IN COMBINATION WITH P53 OVER-EXPRESSION IN
PATIENTS WITH MYELODYSPLASTIC SYNDROME: A SINGLE CENTRE
STUDY
E. Groarke1,*, S. Maung1, K. Ewins1, M. Jeffers2, B. MacDonagh1, J. McHugh1,
R. Desmond1, H. Enright1
1Department of Haematology, 2Department of Cellular Pathology, Tallaght Hos-
pital, Dublin 24, Ireland
Background: Myelodysplastic syndromes (MDS) are defined in the WHO 2016
classification as a group of clonal bone marrow neoplasms characterized by
ineffective hematopoiesis, morphologic dysplasia in hematopoietic cells and
peripheral cytopenia(s)1. They present as a diverse phenotype with some
patients requiring merely observation while others require more intensive man-
agement due to significant marrow failure and the risk of development of acute
leukaemia. The presence of significant marrow fibrosis has previously been
shown to be a poor prognostic factor in patients with MDS, with reduced overall
survival2. Significant marrow fibrosis has also been associated with both the
presence of the TP53 gene mutation and with p53 over expression, which is a
known adverse prognostic risk factors in MDS patients3.
Aims: To assess the presence of p53 expression in patients with moderate to
severe marrow fibrosis (grade 2-3), observe its effect on overall survival in
patients with marrow fibrosis, and determine whether the use of azacitadine
had any impact on survival.
Methods: We conducted a retrospective study utilizing a hospital database of
247 patients with MDS diagnosed in a single center between 2000 and 2014.
Of these patients, 200 had bone marrow trephine samples adequate for reticulin
stain analysis, which was completed using the European consensus on grading
bone marrow fibrosis (grades 0-3). P53 expression was examined using
immunohistochemistry staining defined according to the modified quick scoring
system. We then looked for an association between degree of marrow fibrosis
and p53 expression. In patients with significant marrow fibrosis and p53 expres-
sion we examined overall survival and response to treatment with azacitadine.
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Results: Overall, no significant correlation was seen between expression of
p53 and degree of fibrosis (p=0.25). However, degree of fibrosis predicted for
overall survival in patients with p53 expression (median overall survival of 4
months in patents with both p53 over expression and significant fibrosis com-
pared with median overall survival of 18 months in patients with p53 over
expression without fibrosis, p=0.001). In patients who received azacitadine,
those with both significant fibrosis and p53 expression had a significantly
increased overall survival compared with those who did not receive azacitadine
(4 month versus 1 month, p=0.002). Azacitadine treatment was not associated
with increased survival in patients with p53 expression without fibrosis but
these patients did have an overall increased survival compared to those with
fibrosis (median survival 12 vs 37 months).
Summary/Conclusions: This study confirms that significant marrow fibrosis
adversely affects overall survival in patients with MDS, including those with
p53 over expression. Patients who received azacitadine had a significant
increase in median survival. Alhough the numbers of patients who received
azacitadine were small, this data suggests that patients with fibrosis may benefit
from the use of azacitadine and larger and randomized studies should be con-
sidered to study this further.
References
1. Arber, Daniel et. al. The 2016 revision to the World Health Organization clas-
sification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):
2391-2405.
2. Della Porta,mg et al. Clinical relevance of bone marrow fibrosis and CD34-
positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol.
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3. Loghavi, S et. al. TP53 overexpression is an independent adverse prognostic
factor in de novo myelodysplastic syndromes with fibrosis. British Journal of
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FACS PURIFICATION OF BLAST CELLS IN MDS IMPROVES THE FISH
DETECTION RATE FOR DEL(5Q) AND DEL(20Q), BUT NOT FOR DEL(7Q)
OR T8
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Background: Prognostication in Myelodysplastic Syndromes (MDS) using val-
idated scores includes the detection of chromosomal aberrations by conven-
tional karyotyping. When the latter is unavailable or unsuccessful, fluorescence
in-situ hybridization (FISH) panels can be used. Although panels vary by lab-
oratory, some of the most commonly used probes include the search for mono-
somy 5 or del(5q), monosomy 7 or del(7q), del(20q) and trisomy 8 (T8). In our
Lab, FISH was historically performed on the whole unsorted patient sample
(Full Sample); since 2015, we have primarily performed the analysis on Fluo-
rescence Activated Cell Sorting (FACS) separated blast cells.
Aims: In this study, we aim to analyze the benefit of using purified samples of blast
cells for FISH analysis in MDS, when compared to full mixed cellularity samples.
Methods: We reviewed all samples analyzed in our laboratory between Jan-
uary 1st 2011 and February 28th 2017 in which a FISH panel was performed
due to a suspicion of myelodysplasia, using probes for del(5q), del(7q), del(20q)
and T8. The proportion of patients positive for the test, as well as the proportion
of positive cells within a positive sample, were compared.
Results: We obtained valid results for 328 samples during the relevant time-
frame, 39.6% of which were collected from female patients. FISH was per-
formed after FACS in one third of samples (35.1%, n=115), starting in 2015.
Considering the overall cohort, nearly a quarter of samples (23.8%) had at
least one aberration in the four probes tested in this study. This proportion of
abnormal findings was nearly double in FACS patients (33.0%) compared to
full sample patients (18.8%, p=0.004). Del(5q) was present in 5.6% of the
cohort; however, positivity was 8-fold higher in FACS patients, compared to
full sample patients (12.3% vs 1.6%, p<0.001). Considering the percentage of
positive cells in each sample, it doubled from 38.7±29.9% in the full sample to
71.8±28.1% after FACS, p=0.08. Del(7q) was similarly present in 5.7% of the
cohort; however, in contrast, there were no relevant differences between FACS
patients, 4.2% of whom had del(7q), and full sample patients (8.1%, p=NS).
There were, however, differences in the percentage of positive cells within the
sample, doubling from 32.1±11.2% in the full sample to 77.6±17.8% after FACS,
p<0.001. Del(20q) was identified in 7.0% of the overall tested cohort; the asym-
metry in results was marked, with a 36-fold higher proportion of positive findings
after FACS (18.7%) compared to full samples (0.5%, p<0.001). The percentage
of positive cells doubled from 15% in the single positive test in the full sample
cohort, to an average of 35.5±22.2% after FACS. Finally, T8 was found in
10.2% of patients, a result which was uninfluenced by the type of sample used
(10.2% in both full and FACS samples, p=NS). The percentage of positive cells
once again doubled from 25.5±14.7% in the full sample to 53.3±28.1% after
FACS (p=0.0008).
Summary/Conclusions: We found that one quarter of all patients who under-
went a FISH panel workup for a suspected diagnosis of MDS presented with
aberrations in at least one of the four selected probes, a proportion which was
significantly lower (one fifth) when a full sample was analyzed, and significantly
higher (one third) in FACS purified blast cells. Although the purification of the
sample through FACS doubled the percentage of positive cells within each sam-
ple for all four probes, the likelihood of obtaining a positive result for del(7q) and
T8 in the cohort was unaffected by the methodology used. In contrast, the use
of a sorted sample greatly increased the proportion of positive findings in del(5q)
and, especially, in del(20q), the two probes for which the basal positivity in full
samples were lowest. The clinical value of this increased rate of detection of
del(5q) and del(20q) remains unclear, since their prognostic utility has only been
established for levels detectable by conventional karyotyping of a full sample.
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COUNTING BONE MARROW BLASTS AS A PERCENTAGE OF NON-ERY-
THROID CELLS PROVIDES SUPERIOR RISK STRATIFICATION FOR MDS
PATIENTS WITH ERYTHROID PREDOMINANCE
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Background: Patients with erythroid predominance (≥50% erythroblasts, MDS-
erythroid) compose a significant proportion of patients with MDS. The ery-
throid/myeloid subtype was divided from the AML category into MDS-erythroid
by the 2016 WHO classification of myeloid neoplasms. At that time, there was
no consensus on a more appropriate way of enumerating bone marrow (BM)
blasts from TNCs or NECs in MDS-erythroid patients.
Aims: To clarify these questions, 1283 MDS patients were retrospectively ana-
lyzed in our center. 
Methods: MDS-erythroid was observed in 27.0% of patients (346/1283), and
these patients had similar clinico-pathological features and overall survival,
with 937 cases of MDS with <50% ENCs.
Results: By calculating the percentage of BM blasts from NECs, 73 of 200
patients (36.5%) with MDS-erythroid who were diagnosed within WHO sub-
types without excess blasts (EB) were moved into higher-risk categories and
showed shorter OS than those who remained in the initial categories (P=0.041).
Recalculating the International Prognostic Scoring System-Revised (IPSS-R)
by enumerating blasts from NECs, 40 of 168 (23.8%) MDS-erythroid patients
with relatively lower risk were re-classified as higher-risk and had significantly
poorer survival than those who remained in the lower-risk category (P=0.030).
This was especially true for the intermediate risk group that was stratified by
IPSS-R (unchanged patients vs shifted patients, P=0.007). However, the impact
of enumerating BM blasts from NECs on classification and prognostication was
not evident in all MDS patients.
Summary/Conclusions: In conclusion, our results suggested that enumerating
the percentage of BM blasts from NECs significantly improved the prognostic
assessment of MDS-erythroid, especially for patients within the intermediate
risk group stratified by IPSS-R.
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SUCCESSFUL TREATMENT WITH DANAZOL FOR MYELODYSPLASTIC
SYNDROMES AND APLASTIC ANEMIA REFRACTORY OR INELIGIBLE TO
STANDARD THERAPY
F. Schieppati1,*, A.M. Pelizzari1, E. Borlenghi1, M. D’Adda1, E. Cerqui1,
D. Marocolo1, G. Rossi1
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Background: The discovery of danazol potential activity on telomere elonga-
tion in bone marrow failure has renewed interest in this drug. The treatment of
cytopenia in myelodysplastic syndromes (MDS) and aplastic anemia (AA)
patients who fail or are ineligible to standard therapies is an unmet medical
need; however only dated reports on danazol use in this setting are available.
Aims: We report the results of treatment with danazol in patients with MDS
and AA at a single institution.
Methods: From Jun-‘11 to May-‘15, danazol was administered to 31 consec-
utive patients (20 MDS and 11 AA). Criteria for treatment were non-severe AA
(8), severe AA ineligible/refractory to immunosuppressive therapy or allogeneic
transplantation (3), transfusion dependent (TD) lower risk MDS refractory to
erythropoietin (11), MDS with isolated thrombocytopenia <50x109/L (6) or with
bone marrow hypoplasia and bicytopenia (3). Diagnosis was defined by WHO
2008 for MDS and according to Camitta (Blood 1975) for AA; response was
assessed by IWG 2006 criteria.
Results: The characteristics of the patients are shown in the Table. All MDS
patients had low-risk disease according to IPSS and IPSS-R, except 2 and 3
patients respectively. Nineteen patients (12 MDS, 7 AA) received danazol at
full dose (600mg daily). A 400mg daily dose was given to 12 patients, due to
toxicity (4 MDS, 4 AA) or comorbidities (4 MDS). Median duration of treatment
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was 19 months (mo) (1-66) in AA and 6 mo (1-60) in MDS. ORR was 73% and
50%, respectively. Age and hemoglobin levels impacted on response in AA.
Hematological improvement was seen on all lineages in 92% of cases, with a
median time to best response of 3-5 mo on platelets and neutrophils and of 8-
12 mo on hemoglobin. Interestingly, duration of response in MDS patients was
significantly longer with a danazol dose of 600mg than with 400mg (p=0.001).
Conversely, dosing did not impact on response to danazol in AA patients. Grade
2-3 toxicity was significantly higher in AA patients (p<0.05), 60% pretreated
with IST. Adverse events included: hepatotoxicity (3 G1, 1 G2, 3 G3), muscle
pain/CPK elevation (3 G1, 2 G2), transient renal impairment (1 G1), hyporexia
(1 G1). Responders to danazol had a better survival in terms of OS and EFS
in both groups (Figure 1).
Table 1.
Figure 1.
Summary/Conclusions: Danazol was proved both effective and safe as treat-
ment of cytopenia in MDS and AA patients refractory or ineligible to standard
therapies. The daily dose of 600mg was more effective for MDS patients, where-
as a lower dose of 400mg may have a better risk/benefit ratio in AA. Younger
AA patients with less severe anemia were more likely to respond. Danazol use
is particularly attractive in thrombocytopenic patients, where responses were
rapid, but delayed responses may be expected also on anemia by using dana-
zol for prolonged periods, when tolerated. Response to danazol is also poten-
tially associated to a survival advantage, although these data should be con-
firmed by larger prospective studies.
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SURVIVAL OUTCOMES IN PATIENTS WITH HIGHER-RISK
MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL
CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY
J. Bell1,*, A. Galaznik1, E. Farrelly2, M. Blazer2, H.-C. Shih2, A. Raju2,
A. Ogbonnaya2, M. Eaddy2, R. Fram1, D. Faller1
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Phar-
maceutical Company Limited, Cambridge, 2Xcenda, Palm Harbor, United States
Background: MDS is composed of multiple and rare hematological stem-cell
disorders, resulting in cytopenias and disease-related complications and deaths.
There are no robust trial data comparing the available treatment options for HR-
MDS patients; and of the approved drugs, only azacitidine has demonstrated a
statistically significant, but modest clinical impact on overall survival (OS).
Aims: We evaluated first-line treatment (1LT) choice and survival outcomes in
a US cohort of HR-MDS patients engaged in routine care.
Methods: Newly diagnosed HR-MDS patients who were ≥18 years old and
who had initiated 1LT were retrospectively identified from Optum, a large US
claims database, between 1/1/2008 and 10/31/2015. HR status was based on
ICD coding: ≥1 inpatient claim with an HR-MDS ICD-9/10 code (ICD-9 code:
238.73; ICD-10 codes: D46.20, D46.21, D46.22), or ≥2 outpatient claims with
≥1 HR-MDS ICD-9/10 code. The first MDS claim served as the index diagnosis
date. Exclusion criteria included: absence of continuous care for 12 months
prior to index date (baseline period), presence of other primary cancer, or receipt
of any chemotherapy or stem-cell transplant (SCT) during the baseline period.
1LT was defined as MDS-specific treatment (MDS-Tx) (NCCN MDS Guidelines
v2.2017)1 and initiated after first HR-MDS claim (index date). Follow-up ended
upon death, end of continuous enrollment, end of study, or progression to acute
myeloid leukemia (AML) (except for OS). Transfusion independence (defined
as ≥60 days with no evidence of erythrocyte [RBC] or platelet [PLT] transfu-
sions) was evaluated in patients with ≥60 days of follow-up. Median progres-
sion-free survival (PFS) (defined as progression to AML, initiation of second-
line therapy, or death) and OS, along with PFS and OS rates at 2 years following
initiation of 1LT, were evaluated using unadjusted Kaplan-Meier analyses.
Results: 209 newly diagnosed HR-MDS patients initiating 1LT MDS-Tx were
identified; mean age was 73 years (standard deviation [SD]: 10.1) and 61.2%
were male. In the 12 months prior to diagnosis, 27.3% of patients used MDS-
directed supportive care (ie, colony stimulating-, erythrocyte-, or thrombopoietic
growth factors; RBC or PLT transfusions; or hydroxyurea). 1LT with hypomethy-
lating agents (HMAs) predominated in 89.5% of patients (azacitidine, 68.9%
and decitabine, 20.6%); 8.6% of patients received an immunomodulator
monotherapy; and 8.6% of patients underwent SCT during follow-up. Of the
169 treated HR-MDS patients with ≥60 days of follow-up on 1LT, 51% achieved
transfusion independence. For all treated HR-MDS patients, median PFS and
2-year PFS rates were 12.5 months (95% confidence interval [CI]: 9.1, 14.9)
and 27.9%, respectively. OS rate at 2 years was 59.1%. Patients who achieved
transfusion independence had a higher rate of 2-year OS (65.2% vs 53.8%)
and PFS (36.3% vs 25.7%), but neither were statistically significant.
Table 1.
Summary/Conclusions: Survival outcomes in routine clinical care were higher
than reported in clinical trials, specifically in HR-MDS trials with azacitidine.2
Among patients able to achieve transfusion independence, a trend toward
increased 2-year PFS and OS rates was observed, although statistical signifi-
cance was not reached. Characteristics that contribute to variations in PFS and
OS outcomes within the HR-MDS population need further investigation.
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DOSE-CONFIRMATION PK/PD STUDY OF ORAL ASTX727, A COMBINATION
OF ORAL DECITABINE WITH A CYTIDINE DEAMINASE INHIBITOR (CDAI)
E7727, IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
G. Garcia-Manero1,*, E.A. Griffiths2, G.J. Roboz3, J. Bergeron4, R. Wells5,
O. Odenike6, D. Steensma7, K.W. Yee8, S. Faderl9, P. Amrein10, L.C. Michaelis11,
H. Kantarjian1, A. Oganesian12, J. Lowder12, P. Taverna12, M. Azab12, M.R. Savona13
1UT MD Anderson Cancer Center, Houston, 2Roswell Park Memorial Institute,
Buffalo, 3Cornell University Medical Center, New York, United States, 4Hopital
Maisonneuve-Rosemont, Montreal, 5Sunnybrook Medical Center, Toronto,
Canada, 6University of Chicago, Chicago, 7Dana Farber Cancer Institute,
Boston, United States, 8Princess Margaret Cancer Center, Toronto, Canada,
9Hackensack University Medical Center, Hackensack, 10Massachusetts Gen-
eral Hospital, Boston, 11Medical College of Wisconsin, Milwaukee, 12Astex
Pharmaceuticals Inc., Pleasanton, 13Vanderbilt University Medical Center,
Nashville, United States
Background: We have previously shown that ASTX727, a combination of oral
decitabine and the oral CDAi E7727, emulates the pharmacokinetics of a one
hour intravenous decitabine infusion (IV-DAC) in a dose-escalation phase 1
study. (Garcia-Manero. Blood 2016 128:114)
Aims: To confirm pharmacokinetic (PK) and pharmacodynamic (PD) compa-
rability of 20mg/m2 IV-DAC administered D1-5 of a 28 day cycle with an entire
cycle of ASTX727 given at the selected dose from phase 1 (35mg decitabine
and 100mg of E7727). 
Methods: Adult patients with Int-1/Int-2 or HR MDS or Chronic Myelomonocytic
Leukemia (CMML) were enrolled in a randomized cross-over Phase 2 study.
Patients were randomized 1:1 to receive in the first 28 day cycle, either 5 days
of IV-DAC or 5 days of ASTX727, followed by a cross-over to the other in Cycle
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2. Cycles 3 forward were with ASTX727. PD were assessed with LINE-1 methy-
lation measured on blood cells at baseline and days 8, 15, 21 and 28 in cycles
1 and 2. Full PK assessments of ASTX727 were performed on Days 1, 2 and
5 with sparse sampling on Days 3 and 4 and on Day 1 of IV-DAC. Modeling of
5 day exposures of ASTX727 and IV-DAC was created for each patient. Safety
and clinical response were assessed on all patients.
Results: 50 patients were randomized, of whom 43 had matched PK and 46
had matched PD sample sets for the first 2 cycles. No significant differences
were seen when comparing the randomized sequences for any parameters,
so all assessments comparing ASTX727 and IV-DAC were performed inde-
pendent of sequence. The geometric mean maximum demethylation was 9.9%
for ASTX727 and 11.2% for IV-DAC [Ratio of oral over IV=0.89, with a lower
limit of 90%CI of 0.804]. The geometric mean AUC for IV-DAC was 161
ng*h/mL. The 5 day total geometric mean of the AUC (ng*h/mL) was 769 for
ASTX727 and 805 for IV-DAC [(Ratio of oral over IV=0.96, with a lower limit of
90%CI of 0.806]. Decitabine Cmax was higher for IV-DAC (189 ng/mL) than
after ASTX727, Day 2 (109ng/mL) and Day 5 (121ng/mL). The most common
adverse events regardless of grade or causality were febrile neutropenia 34%,
neutropenia 28%, thrombocytopenia 16%, fatigue 16%, and hypomagnesemia
16%. There were no reported GI Adverse Events greater than Grade 2 with
ASTX727 regardless of relationship to treatment. 
Summary/Conclusions: Fixed dose oral administration of 35mg decitabine
and 100mg E7727 (ASTX727) emulates the AUC of IV-DAC over the 5-day
treatment cycle and induces a similar degree of demethylation of LINE-1
sequences in blood cells compared to IV decitabine at 20mg/m2 dose. The
preliminary safety profile is similar to what has been reported for IV-DAC and
no increase in GI side effects has been observed. Clinical responses continue
to be evaluated as the study data mature. This combination will be tested
further as an alternative to parenteral administration of decitabine. 
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FACTORS PREDICTIVE FOR INFECTION IN PATIENTS WITH HIGHER- RISK
MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC
LEUKEMIA AND ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE
K. Mądry1,*, K. Lis1, J. Żurawska1, M. Górka1, P. Kacprzyk1, M. Dutka2,
M. Rodzaj3, L. Bołkun4, D. Krochmalczyk5, J. Drozd-Sokołowska1, A. Waszczuk-
Gajda1, W. Knopińska-Posłuszny6, A. Kopińska7, E. Subocz8, A. Masternak9,
R. Guzicka-Kazimierczak10, L. Gil11, R. Machowicz1, J. Dwilewicz-Trojaczek1
1Hematology, Oncology and Internal Diseases, Medical University, Warsaw,
2Hematology and Bone Marrow Transplantation, Medical University, Gdańsk,
3Hematology, Voivodal Specialistic Hospital, Kraków, 4Hematology, Medical
University, Białystok, 5Hematology, Jagiellonian University, Kraków, 6Hematol-
ogy, SP ZOZ WMCO Oncology Center, Olsztyn, 7Hematology and Bone Mar-
row Transplantation, Silesian Medical University, Katowice, 8Hematology and
Internal Diseases, Military Institute of Medicine, Warsaw, 9Hematology, Spe-
cialistic Hospital, Opole, 10Hematology, Pomeranian Medical University,
Szczecin, 11Hematology, Medical University, Poznań, Poland
Background: Hypomethylating agents (HMAs) are the current standard treat-
ment of higher-risk myelodysplastic syndrome (MDS), chronic myelomonocytic
leukemia (CMML) and older acute myeloid leukemia (AML) patients. Severe
infectious complications are common during HMAs therapy and have been
recognized as one of the most important reasons of morbidity and mortality in
MDS, CMML and AML patients especially at the beginning of treatment.
Aims: To evaluate the incidence of and predisposing risk factors for infections
during the first three azacitidine (AZA) cycles treatment
Methods: In this retrospective study we analyzed 282 consecutive patients
with higher- risk MDS (174), CMML (34) and AML with bone marrow blasts
<30% (74) treated with azacitidine in 10 Polish hematologic centers between
the years 2009-2016. Patients who did not complete three AZA cycles and also
did not experience infection were excluded (50 cases).
Results: Median age was 68 (28-93). Median number of AZA cycles was 6 (1-
43). Infectious episodes during the first three cycles of AZA were reported in
94 out of 232 (40%) eligible patients - in 32% of MDS, 30% of CMML and 63%
of AML patients (p<0.05). Among patients with infection, most of them had their
first infection episode during the first cycle -53%, during the second cycle -
29% and during the third AZA cycle -18%. It was found that low neutrophil
count (0,6x109/Lvs 1,2x109/L), low lymphocyte count (1,1x109/L vs 1,3x109/L),
low platelet count (37x109/L vs 63x109/L), high blood ferritin level (1101ng/ml
vs 569 ng/ml), low albumin concentration (3,6 g/dl vs 4,0 g/dl), high bone mar-
row blasts percentage (15% vs 12%), higher IPSS, IPSS-R and WPSS score,
red blood cell transfusion dependency and worse WHO performance status
prior therapy were significantly predictive factors for infection (p<0.05). Factors
like age, gender, hemoglobin concentration, iron, immunoglobulin and creati-
nine blood level, time from diagnosis to beginning of AZA treatment, IPSS and
IPSS- R cytogenetics, coexistence of diabetes mellitus, heart failure, chronic
obstructive pulmonary disease, second cancer, autoimmune disease and cor-
ticosteroids treatment did not have significant impact on infection risk (p>0.05).
Antibacterial, antifungal or antiviral prophylaxis did not significantly reduce the
risk of infection (p>0.05). Median overall survival patients with infection was 5
months and patients without infection 12 months.
Summary/Conclusions: Patients treated with azaciditine (especially AML
patients) are at high risk of infection during the first three AZA cycles. All impor-
tant infection predictive factors should be assessed before therapy. Patients
possessing factors predictive for infection require special approach and pre-
dictive infection model should be developed in further analysis.
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OVERALL SURVIVAL, INITIAL TREATMENT AND TREATMENT DURATION
OF PATIENTS WITH MYELODYSPLASTIC SYNDROME, A DETAILED
POPULATION BASED STUDY
H. Rozema1,2,*, R. Kibbelaar2, N. Veeger2, E. Van Roon1,2, M. Hoogendoorn2
1Pharmacotherapy, -Epidemiology & -Economics, University of Groningen,
Groningen, 2Medical Centre Leeuwarden, Leeuwarden, Netherlands
Background: Population-based studies on myelodysplastic syndrome (MDS)
containing detailed clinical information of patient characteristics, treatment and
follow-up of the disease are scarce. Since 2005, all patients diagnosed with
hematological malignancies in Friesland, a province in the Netherlands, are
prospectively registered and followed by their clinicians in a population-based
registry, the HemoBase. The registry provides representative population-based
data on diagnosis, treatment and outcomes in an era where low-intensity treat-
ment such as hypomethylating agents have become available for the elderly.
Aims: The objectives of this study were to determine the overall survival (OS)
of patients with MDS and the effect of the variables gender, age, comorbidities,
IPSS(-R) score and MDS subtype according to WHO 2016 classification. Fur-
thermore, the leukemia free survival (LFS), the initial treatment and the duration
of first-line treatment were analyzed.
Methods: An observational, population-based study was performed using the
HemoBase registry. The bone marrow biopsies and aspirates of all MDS
patients diagnosed between 01-01-2005 and 31-12-2013 were independently
and blindly reviewed by both the hematologist and hemato-pathologist and
classified according to the WHO 2016. Treatment categories were defined as
intensive chemotherapy (IC) either combined or not combined with allogeneic
stem cell transplantation, the hypomethylating agent azacytidine, the
immunomodalatory agent lenalidomide, hydroxyurea or best supportive care
(BSC) (blood transfusions, erythropoiesis-stimulating agents). Approval was
obtained from the Medical Ethics Review Committee from Medical Centre
Leeuwarden. Statistical analyses were performed with SPSS 19; survival analy-
ses were presented using Kaplan-Meier estimates.
Results: 217 patients (72.4% male, 66.8% >70 years old, median age 75
years, 27.2% Charlson Comorbidity Index (CCI) score ≥3 at diagnosis) were
included with a median follow-up duration of 70.2 months. 15.7% of the popu-
lation had an IPSS score of ≥1.5 and 12.4% of the population had an IPSS-R
score of ≥4.5. In 41.5% no cytogenetic information was available. MDS-RS,
MDS-SLD/-MLD, MDS-EB, MDS-U and CMML were diagnosed in 11.5%,
14.7%, 36.4%, 27.2% and 10,1% of the population respectively. 18.4% showed
progression towards acute myeloid leukemia (AML). IC, azacytidine, lenalido-
mide, hydroxyurea and BSC were the initial treatment in 5.1%, 13.8%, 1.4%,
9.7% and 66.4% of the patients respectively. Within 12 months 78.1% of all
treated patients terminated their first-line therapy because of death (20.0%),
refractory to treatment (18.3%) or disease progression (16.7%). A second treat-
ment was initiated in 10.1% of patients. The median LFS was 18.2 months
(95% CI: 12.6-23.8). The median OS of MDS patients in Friesland was 22.5
months (95% CI: 15.2-29.7). Univariate analysis showed an association
between lower OS and male gender (HR for women: 0.54, p=0.008, 95% CI:
0.34-0.85), age >80 years (HR: 2.7, p<0.0005, 95% CI: 1.6-4.6), CCI score ≥3
(HR: 2.0, p<0.001, 95% CI: 1.3-3.0), IPSS score ≥1,5 (HR: 2.3, p=0,004, 95%
CI: 1.3-4.1), IPSS-R score ≥4,5 (HR: 5.7, p<0.0005, 95% CI: 2.4-2.4) and MDS
subtype MDS-EB (HR: 1.8. p=0.016, 95% CI: 1.1-2.9).
Summary/Conclusions: This study provided complete and representative
population-based data on overall survival and treatment of patients with MDS
in an era of new treatment modalities. Despite the median age of 75 years and
significant comorbidity in this population, a third of the patients received treat-
ment in addition to BSC.
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DANAZOL TREATMENT FOR THROMBOCYTOPENIA IN LOWER-RISK
MYELODYSPLASTIC SYNDROMES: A REAL LIFE EXPERIENCE
M. Riva1, E. Ravano1,*, R. Cairoli1, A. Molteni2
1Hematology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano,
2Hematology Unit, ASST Cremona, Cremona, Italy
Background: Severe thrombocytopenia is an uncommon event in lower-risk
MDS patients, but it may significantly affect the prognosis. In fact, when it
occurs, major bleeding may be a life-threatening complication. No licensed
pharmacologic approach is nowadays available yet for this unmet need in
Europe. Eltrombopag seems to be a very interesting product, but its efficacy
and safety still need to be better demonstrated. Even romiplostim could be
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suitable, but, at present, its safety is questioned in MDS patients. Furthermore,
in clinical practice, danazol, an attenuated androgen, has been reported to
have some ability to increase the platelet count in this context (Wattel 1994;
Chan 2002).
Aims: To asses efficacy and toxicity of danazol employed to improve severe
thrombocytopenia in lower-risk MDS setting.
Methods: We retrospectively reviewed twenty-four patients affected by MDS
and treated with danazol for thrombocytopenia. The initial dose was 600mg/day
for all patients. The IWG criteria of response (Cheson 2006) were adopted.
The outcome was observed every 3 months till 12th month. The overall
response rate and the average platelet count or each time of observation were
described. Progression free survival was estimated with the Kaplan-Meier prod-
uct limit method, followed by the logrank test and by the Cox proportional-haz-
ard regression.
Results: Of the 24 patients, 3 patients had a therapy-related MDS. At the start-
ing time of danazol therapy, the IPSS was “low” in 9, “int-1” in 13 and “int-2” in
2 cases respectively; the IPSS-R was “very low” in 2, “low” in 11, “intermediate”
in 7 and “high” or “very high” in 4 cases. At baseline in 14 patients the platelet
count was lower than 20x10^3/mL, the average was 20x10^3/mL and the max-
imum value was 38x10^3/mL. The median dose was 600mg (range 200-600)
also maintained at least up to 3 months (range 400-600). At 6 and 12 months
the median dose therapy was 400mg (range 400-600 and 200-600 respective-
ly). The response rate was 79.1% (19 responders on 24 treated). The average
count increased as shown in Figure 1, over 60x10^3/mL after 6 months from
the beginning of therapy and so maintained after one year. Only 3 patients lost
the response at 187, 600 and 633 days respectively. The median survival was
not reached in the presented series, and the probability to maintain the
response is over 75% after two years from the beginning therapy in the respon-
der patients (Figure 2). Adverse events recorded were as follows: moderate
(grade 1 and 2) increase in transaminases in 4 cases (with reduction of dana-
zolo to 400mg/day in 2 of these); 1 case of severe but reversible liver toxicity
(grade 3) (with subsequently drug suspension); severe (grade 3) but reversible
renal failure in 1 case (the drug was stopped); moderate (grade 1 and 2)
increasing of serum creatinine in 6 case (with reduction of danazolo to
400mg/day in 2 of these); reversible cutaneous rush in 3 cases; amenorrhea
in 1 case (the only fertile woman in the series); weight loss and loss of appetite
in 1 case, weight gain in 1 case.
Figure 1.
Summary/Conclusions: This series confirms the efficacy of danazol to
improve platelet count in the most of patients with severe thrombocytopenia
due to lower-risk MDS. In all patients with increased platelet count, the response
was clinically significant. The median dose of 600mg should be maintained for
at least 3 months to properly assess the effectiveness of therapy and then
adjusted according to response and toxicity. The response may not be imme-
diate, but seem to be reachable after 3-6 months of treatment. A responsive
patients have short probability to loss the response, that may last for very long
time. The toxicity profile of this drug is low. The mechanism of action of danazol
in MDS patients remains unclear. Waiting for more information on the efficacy
and safety of eltrombopag from the clinical trials in progress, danazol may be
a good therapeutic option for these patients.
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TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELODYS-
PLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE
UNITED STATES (US) – A CLAIMS DATABASE STUDY
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A. Ogbonnaya2, M. Eaddy2, R. Fram1, D. Faller1
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Phar-
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Background: Treatment of patients with HR-MDS includes hypomethylating
agents (HMAs) (azacitidine and decitabine), high-intensity induction chemother-
apy (IC), and stem cell transplant (SCT). Given the rarity of disease, information
available on how these treatments are applied in practice is limited.
Aims: We evaluated the treatment patterns of HR-MDS patients engaged in
routine care within the US.
Methods: Newly diagnosed HR-MDS patients who were ≥18 years old were
retrospectively identified from Optum, a large US claims database between
1/1/2008 and 10/31/2015. HR status was based on ICD coding: ≥1 inpatient
claim or ≥2 outpatient claims with an HR-MDS ICD-9/10 code (ICD-9 code:
238.73; ICD-10 codes: D46.20, D46.21, D46.22). The first MDS claim served
as the index date. Exclusion criteria included: absence of continuous enrollment
in medical and pharmacy benefits for 12 months prior to index date (baseline
period), presence of other primary cancer, or receipt of any chemotherapy or
SCT during the baseline period. First-line therapy (1LT) was defined as an
MDS-specific treatment (as defined by NCCN MDS Guidelines v2.2017)1 initi-
ated on or after the index date. Patients were followed until death, end of con-
tinuous enrollment, or end of study (12/31/2015). For patients with progression
to acute myeloid leukemia (AML), treatment pattern evaluation stopped at AML
diagnosis.
Figure 1.
Results: 335 newly diagnosed HR-MDS patients were identified; 209 (62.4%)
were treated with 1LT with treatment initiated within 1 month of diagnosis (medi-
an: 17 days, interquartile range [IQR]: 9, 35). A higher proportion of untreated
patients (n=126) was ≥75 years of age (71.4% vs 53.1%) and had certain
comorbidities at baseline (congestive heart failure, 23.0% vs 16.3%; renal dis-
ease, 24.6% vs 16.3%; diabetes 31.0% vs 23.4%, diabetes with end organ fail-
ure, 16.7% vs 8.1%) than treated patients. For treated patients, 1LT with azac-
itidine predominated in 68.9% of patients (n=144), followed by decitabine in
20.6% of patients (n=43), and immunomodulators (lenalidomide or thalidomide)
in 8.7% of patients (n=18) (Figure 1). 4 patients had only SCT and an additional
14 had SCT at some point during follow-up. With regard to HMA therapy, median
duration was 4.5 months (IQR: 2.6, 9.5) for azacitidine and 4.8 months (IQR:
2.1, 11.6) for decitabine. A greater proportion of decitabine-treated patients
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received supportive care with colony-stimulating factors (CSFs) (39.5% vs
28.5%) and either erythrocyte or platelet transfusions (69.8% vs 57.6%) during
1LT vs azacitidine-treated patients. Second-line therapy (2LT) was administered
to 30 (14.4%) patients; the HMAs again predominated in 63.3% of patients
(n=19). Of patients not receiving 2LT, 65 (31.7%) progressed to AML, 47
(22.9%) had <30 days of follow-up due to proximity to end of study (38 [80.9%]
of these were on 1LT at end of study date), 33 (16.1%) continued to receive
some supportive care and, 21 (10.2%) died.
Summary/Conclusions: Most HR-MDS patients treated in routine care are
treated according to guidelines, with the HMA, azacitidine, predominating. Under-
lying comorbidities and older age may influence whether or not to treat HR-MDS
patients with 1LT. For treated HR-MDS patients, duration of 1LT did not differ
with azacitidine and decitabine. However, use of certain MDS-related supportive
care treatments varied by choice of HMA, with more decitabine-treated patients
receiving CSFs and transfusions. Further research is needed to determine how
these factors influence both clinical outcomes in a HR-MDS population.
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APPRECI8: A PIPELINE FOR PRECISE VARIANT CALLING INTEGRATING
8 TOOLS
S. Sandmann1,*, M. Karimi2, A. de Graaf3, B. van der Reijden3, E. Hellström-
Lindberg2, J. Jansen3, M. Dugas1
1Institute of Medical Informatics, University of Münster, Münster, Germany,
2Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden,
3Laboratory Hematology, RadboudUMC, Nijmegen, Netherlands
Background: For the use of next-generation sequencing in clinical routine
valid variant calling results are crucial. However, evaluation of eight open-
source variant calling tools on two different real- and simulated data sets has
pointed out that variant calling - even of single nucleotide variants and short
indels - remains challenging. Perfect results could not be obtained with any of
the considered tools. High sensitivity was always accompanied by low positive
predictive value (PPV).
Aims: We aimed at developing a variant calling pipeline with both, high sensi-
tivity and high PPV.
Methods: We developed appreci8, a variant calling pipeline combining the
output of eight open-source variant calling tools: GATK HaplotypeCaller, Platy-
pus, VarScan, LoFreq, FreeBayes, SNVer, SAMtools and VarDict. The pipeline
performs several steps of filtration, including a final automatic characterization
of all reported calls as artifacts, likely polymorphisms and likely mutations. To
train our pipeline, we analyzed two data sets covering data of 54 myelodys-
plastic syndrome (MDS) patients, sequenced on Illumina HiSeq, and 111 MDS
patients, sequenced on Illumina NextSeq. Subsequently, two independent test
sets were analyzed. The first test set covered 237 MDS patients, sequenced
on Illumina HiSeq. The second test set covered 89 MDS patients, sequenced
on Roche 454. In all cases the same target region consisting of 19 genes
(42,322bp) was analyzed. Validation was performed by re-sequencing on the
same platform, on a different platform and expert-based review.
Figure 1.
Results: When analyzing the training sets with only one of the eight variant
calling tools and considering all variants -pathogenic as well as polymorphisms-,
sensitivity ranges between 0.85 and 1.00 in case of set 1 and 0.47 and 0.99
in case of set 2. Although FreeBayes features highest sensitivity regarding
both sets, it consistently features lowest PPV as well (set 1: 0.03, set 2: 0.02).
Combining the output of all variant calling tools leads to perfect sensitivity,
while PPV is 0.03 for set 1 and 0.02 for set 2. Application of our appreci8
pipeline leads to a minor decrease in sensitivity (set 1 and set 2: 0.98), while
PPV is significantly increased (set 1: 0.99, set 2: 0.94). The PPV of the appre-
ci8 output for both training sets is higher compared to each of the individual
tools. Analysis of the independent test set 1 leads to comparable results. Sen-
sitivity of the individual tools ranges between 0.82 and 0.99, while PPV ranges
between 0.02 and 0.91. Combining the output of all variant calling tools leads
to sensitivity of 1.00 and PPV of 0.02. However, application of appreci8 leads
to variant calling results with sensitivity of 0.98 and PPV of 0.99. To test the
robustness of our approach, we analyzed Roche 454 data, although the
pipeline was exclusively trained on Illumina data. Regarding the individual
tools sensitivity ranges between 0.91 and 0.99, while PPV ranges between
0.07 and 0.68. By combining the output of all variant calling tools, sensitivity
increases to 0.99, while PPV is 0.05. Application of appreci8 leads to sensitivity
of 0.98 and PPV of 0.76.
Summary/Conclusions: To consider variant calling results in clinical routine,
it does not seem appropriate to rely on the output of a single tool only. Instead,
combining the output of several tools and applying a set of filters as it is done
by our appreci8 pipeline leads to results with both high sensitivity and PPV.
Nonetheless, variant calling results should, especially at allelic frequencies
below 20%, always be viewed with criticism.
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COMPARISON OF ADMINISTRATION OF HYPOMETHYLATING AGENTS
WITH EFFICIENCY OF ALLOGENEIC SCT IN ELDERLY PATIENTS WITH
ADVANCED MDS
J. Cermak1,*, A. Vitek1, J. Maalouf-Soukupova1, M. Markova-Štastna1,
P. Cetkovsky1
1Clinical Hematology, Institute of Hematology and Blood Transfusion, Praha,
Czech Republic
Background: Hypomethylating agents (HMA) have been introduced as a
promising agent in the treatment of elderly patients with advanced myelodys-
plastic syndromes (MDS) leading to a response in approximately 50% of
patients. However, most of the patients relapse and estimated years survival
is below 10%. Stem cell transplantation (SCT) still represents the only curative
treatment even in elderly patients with advanced MDS and it is connected with
long-term survival in 35-40% despite relatively high risk of transplant related
mortality (25-30%).
Aims: The aim of the study was a retrospective analysis of results of the treat-
ment of 59 elderly patients (50 years of age or older) with MDS RAEB-2 or with
acute myeloid leukemia with multilineage dysplasia with less than 30% of bone
marrow blasts (MDS RAEB-T according to the FAB classification) who received
either HMA or underwent allogeneic SCT. 
Methods: In the HMA group, 34 out of total 38 patients received azacytidine
(Vidaza®) in the dose of 75mg/m2x7 every 28 days and 4 patients were treated
with decitabine (Dacogen®) in the dose of 20mg/m2 x5 every 28 days. Median
number of cycles administered was 10.4 (range 3-31). An age and diagnosis
matched transplanted group consisted of 21 patients, 9 patients were trans-
planted upfront, 12 patients were pretretated either with combination
chemotherapy (10 patients) or with HMA (2 patients) and achieved CR prior to
SCT. Ten patients received myeloablative conditioning and 11 patients were
transplanted after reduced conditioning regimen.
Results: A hematologic response to HMA (CR,PR, hematologic improvement)
was observed in 22 out of 38 patients in HMA group (57.9%), CR was achieved
in 10 patients (31.8%). In SCT group, engraftment was reached in 20 out of 21
patients, 11 patients died after SCT ( 6 on complications related to SCT, 5
patients relapsed). No difference was observed between both the groups in 2
years estimated overall survival (OS), (42% for SCT vs 36% for HMA), a sig-
nificant difference in favour of SCT was present in estimated 3 years and 5
years OS (42% and 38% for SCT vs 9% and 4% in HMA group, P=0.001).
Median OS was 18.7 months in HMA treated group compared to 42.6 months
in SCT group (P=0.02). In a recent analysis performed at 48 months after start-
ing the treatment, 2 patients treated with HMA (5,3%) and 9 transplanted
patients (42.8%) were alive, 23 patients in HMA group and 6 patients in SCT
group relapsed. No significant differences in results and adverse effects of
treatment were observed between patients aged 50-60 years and those older
than 60 years in both HMA and SCT groups.
Summary/Conclusions: Our results confirm previous observations showing
that despite a promising effect of HMA resulting in hematologic response in
more than 50% of elderly patients with advanced MDS, allogeneic SCT still
represents the only potentially curative treatment connected with long-term
survival in a significant number of patients even in elderly MDS patients.
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A MULTICENTER, OPEN-LABEL, PHASE I CLINICAL STUDY: SAFETY,
EFFICACY, AND PHARMACOKINETICS OF ORAL RIGOSERTIB IN JAPAN-
ESE PATIENTS WITH RECURRENT/RELAPSED OR REFRACTORY
MYELODYSPLASTIC SYNDROMES
K. Ishizawa12,*, K. Usuki3, K. Ando4, Y. Ueda5, T. Kiguchi6, N. Uike78, Y. Onishi2,
H. Iida9
1Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yam-
agata, 2Department of Hematology and Rheumatology, Tohoku University Hos-
pital, Sendai, 3Department of Hematology, NTT Medical Center Tokyo, Tokyo,
4Department of Hematology and Oncology, Tokai University School of Medicine,
Isehara, 5Department of Hematology/Oncology, Kurashiki Central Hospital,
Kurashiki, 6Department of Hematology, Chugoku Central Hospital, Fukuyama,
7Department of Palliative Care Medicine, Saga Medical Center Koseikan, Saga,
8Department of Hematology, National Hospital Organization Kyushu Cancer
Center, Fukuoka, 9Department of Hematology, National Hospital Organization
Nagoya Medical Center, Nagoya, Japan
Background: Rigosertib, a novel phosphoinositide 3 kinase pathway inhibitor,
induces G2/M arrest leading to the apoptosis of cancer cells and myeloblasts
and is safe for and well tolerated by pts with low, intermediate-1, intermediate-
2, or high-risk myelodysplastic syndromes (MDS).
Aims: The aims of the study were to assess the safety, efficacy, and pharmaco-
kinetics of oral rigosertib and to determine the recommended dose (RD) for a
Phase II clinical study in Japanese pts with recurrent/relapsed or refractory MDS.
Methods: We conducted a multicenter, open-label, Phase I clinical study of
oral rigosertib. The key eligibility criteria were as follows: recurrent/relapsed or
refractory MDS; age: 20 or older; ECOG PS of 0 to 2; and no major organ dys-
functions. Rigosertib (280 and 560mg BID) was administered orally in one 21-
day cycle (up to cycle 6) that consisted of the 14-day, twice-daily, oral admin-
istration term, followed by 7-day monitoring. The primary endpoint was dose-
limiting toxicity (DLT). The secondary endpoints were 1) safety as assessed
with adverse events (AEs) and laboratory results, 2) efficacy as assessed with
the International Working Group 2006 criteria, and 3) pharmacokinetics.
Results: Between March 2013 and November 2014, 6 male and 3 female pts
(median age: 70; range 52-80) were enrolled. ECOG PS was 0 in 7 pts and
was 1 in 2 pts, and 3 and 6 pts were eventually assigned to the 280 and 560mg
BID arms, respectively. According to the FAB classification, 4, 2, 2, and 1 pts
were categorized to RAEB, RARS, RA, and RAEB-t, respectively. The prog-
nostic factor according to IPSS was Int-1 risk in 4 pts (1 and 3 pts in the 280
and 560mg BID arms, respectively) and was Int-2 in 5 pts (2 and 3 pts in the
280 and 560mg BID arms, respectively). DLT occurred in 1 pt in the 280mg
BID arm and in 2 pts in the 560mg BID arm: the former consisted of type 2 dia-
betes and grade 4 delirium, and the latter grade 5 urinary tract infection and
grade 3 prolonged QT interval. Therefore, the RD for a Phase II clinical study
in Japanese pts was determined to be 560mg BID. On day 11 of treatment, 1
pt in the 560mg BID arm died of grade 5 urinary infection whose relationship
with the investigational drug was rated to “Definite”. The presumed cause of
death for this patient was septic shock caused by urinary tract infection. The
mean counts of leukocytes, neutrophils, lymphocytes, and reticulocytes in the
280mg BID arm did not decrease along with increases in the number of cycles
delivered but decreased slightly in the 560mg BID arm. Any changes of note
were not found in other hematological items. One case of grade 3 neutropenia
developed in the 280mg BID arm, and 1 case each of grade 3 laboratory abnor-
malities—increased alanine aminotransferase, increased aspartate aminotrans-
ferase, prolonged QT interval, neutropenia, and decreased hemoglobin—
occurred in the 560 BID arm. The hematological remission rate was 11.1% (1
marrow CR; 1/9 pts), and the hematological improvement rate was 11.1% (1
HI-P; 1/9 pts). Among the PK parameters, inter-individual variability was
observed in the Cmax and AUC. However, changes suggesting the accumulation
of rigosertib during repeated oral administration (e.g., consistent increases in
the Cmax and AUC) were not found.
Summary/Conclusions: The present chemotherapy regimen of oral rigosertib
was well tolerated. Our study indicates that the RD for a Phase II clinical study
is 560mg BID in Japanese patients with recurrent/relapsed or refractory MDS.
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NON-OVERLAPPING PROMOTER AND SUPERENHANCER DRIVEN
PROCESSES SUPPORT MYELOMA CELL GROWTH AND SURVIVAL VIA
DISTINCT REGULATORY AXES
M. Fulciniti1,*, C. Lin2, M. Samur1, H. Avet-Loiseau3, K. Anderson1, J. Bradner4,
N. Munshi1
1Dana Farber Cancer Institute, Boston, 2Baylor college of medicine, Houston,
United States, 3Cancer research center, Toulouse, France, 4Novartis, Boston,
United States
Background: We have previously reported that E2F1 and its heterodimeriza-
tion partner DP1 promote MM tumor proliferation both in vitro and in vivo; and
observed an inverse correlation between their expression and patient survival
suggesting a role in MM pathogenesis. Moreover, E2F functional impairment
by a dimerization inhibiting stapled peptide significantly affects myeloma tumor
cell growth while sparing effect on normal components of bone marrow as well
as normal plasma cells, suggesting an E2F dependency in MM cells.
Aims: In this study, our aim was to defined the regolatory landscape of E2F in
MM to better understand how E2F1 and DP1 drive myeloma cell proliferation;
and to define the relationship between promoter proximal transcription factor-
associated gene expression and super-enhancer-driven transcriptional programs.
Methods: We integrated genetic perturbation with functional omics to define
E2F role in MM. Global occupancy of E2F1 and DP1 in MM was evaluated by
ChIP-seq analysis. E2F1 and DP1 genomic localizations were then integrated
to MM reference epigenome. Enhancers and super-enhancers were mapped
using ROSE2 (github.com/bradnerlab/pipeline). Read densities were calculated
using bamliquidator (github.com/BradnerLab/pipeline/wiki/bamliquidator). 
Results: Integration of E2F1 and DP1 genomic localization to MM reference
epigenome revealed specific co-occupancy of the factors at promoters of active
genes marked by H3K4me3, with a strong positive correlation between E2F
and RNA Polymerase II (RNA Pol II) binding at transcription start sites. In con-
trast, active enhancers, as defined by promoter distal Mediator (MED1) peaks
and marked by H3K27ac and BRD4, showed virtually no E2F binding. Prompt
by these observations, we explored the transcriptional and functional interrela-
tionship between E2F and BETs to identify their individual contribution to even-
tual functional effect in MM. Unbiased hierarchical clustering revealed distinct
regulatory axes for E2F and BETs, with E2F predominantly localized to active
gene promoters of growth/proliferation genes and BETs disproportionately at
enhancer- regulated tissue specific genes confirming that these factors estab-
lish distinct target gene programs. At the extremes, we found less than 10% of
genes were among the top 500 in BRD4 enhancer signal (i.e. SE-regulated)
and top 500 E2F promoter signal. We hypothesized that the presence of BETs
and E2F in distinct regulatory axes divides active genes in MM into those that
can be selectively influenced by BET inhibition or E2F perturbation, but not
both. In line with this we have observed that dual E2F and BET inhibition is
synergistic for MM cell growth, both in vitro and in vivo. 
Summary/Conclusions: In conclusions, our results highlight the existence of
non-overlapping promoter and super-enhancer-associated dependencies in
multiple myeloma, suggesting a sequestered molecular control that may be
perturbed in cancer with potential for development of a promising therapeutic
strategy.
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ANALYSIS OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA
HIGHLIGHTS NOVEL CANDIDATE PROGNOSTIC MARKERS AND
DISEASE SUBGROUPS 
N. Bolli1,*, G. Biancon2, M. Moarii3, S. Gimondi2, Y. Li4, C. De Philippis2,
F. Maura2, V. Sathiaseelan4, T. Yu-Tzu5, L. Mudie4, S. O’Meara4, K. Raine4,
J.W. Teague4, A.P. Butler4, C. Carniti6, M. Gerstung7, T. Bagratuni8, E. Kastritis8,
M.A. Dimopoulos8, P. Corradini2, K.C. Anderson5, P. Moreau9, S. Minvielle10,
P.J. Campbell4, E. Papaemmanuil3, H. Avet-Loiseau11, N.C. Munshi5
1Department of Oncology and Onco-Hematology, 2University of Milan, Milan,
Italy, 3Memorial Sloan Kettering Cancer Center, New York, United States, 4Well-
come Trust Sanger Institute, Cambridge, United Kingdom, 5Dana-Farber Can-
cer Institute, Boston, United States, 6Fondazione IRCCS Istituto Nazionale dei
Tumori, Milan, Italy, 7European bioinformatics institute, Cambridge, United King-
dom, 8National and Kapodistrian University of Athens, Athens, Greece, 9Centre
Hospitalier Universitaire de Nantes, 10Center for Cancer Research Nantes-
Angers, Nantes, 11Centre de Recherche en Cancerologie de Toulouse,
Toulouse, France
Background: In multiple myeloma (MM), next generation sequencing (NGS)
has expanded our knowledge of genomic lesions, and highlighted a dynamic
and heterogeneous composition. Despite a growing number of cases
sequenced, the full potential of NGS studies has not been exploited so far.
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Aims: We used a custom target pulldown (TPD) approach on a large cohort
of MM samples at diagnosis, with homogeneous treatment and long follow-up,
to further our understanding of the landscape of driver lesions in MM and how
this can be used to improve prognostication and disease classification.
Methods: We used a custom-designed SureSelect pulldown strategy (Agilent
Biotechnologies) to target 246 genes implicated in MM or cancer in general;
2538 single nucleotide polymorphisms; the immunoglobulin heavy chain (IGH)
locus. We sequenced unmatched DNA from CD138-purified plasma cells from
418 patients with a median follow-up of 5.4 years using Illumina Hiseq2000
machines. We applied algorithms developed in-house to detect driver genomic
events, filtering out potential artifacts and germline variants. We then ranked
each mutation on its likelihood of being oncogenic.
Results: We identified 197 driver events including gene mutations, aneuploi-
dies and IGH translocations (IGH-Tx), median of 6 per patient. Gene mutations
where found in >99% of patients. At least one oncogenic mutation of a known
driver gene previously identified (KRAS, NRAS, TP53, FAM46C, BRAF, DIS3,
TRAF3, SP140, IRF4) was found in 64%, with a long tail of infrequently mutated
genes with uncertain significance. Karyotypic class was assigned in 80% of
patients, with 9% of hyperdiploid cases also showing an IGH-Tx (mostly
t(4;14)). IGH-Tx and aneuploidies dominated the MM genomic landscape,
KRAS and NRAS being the only point mutations present in the 15 most frequent
driver events. Multivariate analysis by sparse Cox regression highlighted only
four driver events with significant prognostic impact for both progression-free
(PFS) and overall survival (OS): t(4;14) (HR 1.88, CI 1.25-1.84), amp(1q)
(HR2.63, CI 1.92-3.59), del(17p) (HR2.55, CI 1.66-3.92), and rare mutations
of ATP13A4 (HR 0.08, CI 0.01-0.65, mutated in 1.4% of patients). We found a
significantly worse prognosis for increasing numbers of driver lesions in each
patient (median OS 8.2 vs 3.5 years for <5 and>8 driver events, respectively).
This was only partially explained by instances of additive effect or interactions
between variables, which were very informative but not frequent. To better
investigate these findings in the context of the genomic landscape of each
case, we applied Bayesian clustering algorithms. The large number of driver
events screened led to the identification of three groups: in the largest one,
some hyperdiploid and IGH-Tx cases clustered together, suggesting that sec-
ondary mutations and CNAs required for tumor progression are often shared
between these two subgroups. We then identified two clusters both character-
ized by significantly lower number of mutations, but with opposing features.
One was enriched for IGH-Tx, had the highest number of CNAs overall, showed
higher prevalence of amp(1q), del(13), del(17p), TP53 mutations, and had a
shorter median OS of 5.3 years. The other was mostly composed of hyper-
diploid cases and showed fewest CNAs and mutations, with a good prognosis
(median OS not reached).
Figure 1.
Summary/Conclusions: We report on the first attempt towards the use of
extended tumor genotype for a genomic classification of MM using innovative
clustering algorithms. Despite the heterogeneity of the disease, we could iden-
tify disease subgroups with a distinct spectrum and number of driver events
carrying different prognosis, supporting the introduction of genomics in the clin-
ical approach to MM
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A NOVEL METHOD FOR GENOME-WIDE COPY NUMBER ASSESSMENT
FROM TARGETED SEQUENCING DATA AND CLINICAL APPLICATION IN
PATIENTS WITH MULTIPLE MYELOMA
G. Ryland1,*, J. Markham2, K. Jones1, E. Aydogan1, T. Papenfuss2, M. Chin3,
J. Sive4, K. Yong3, M. Prince5, D. Westerman1, M. Dickinson5, P. Blombery1
1Pathology, 2Research, Peter MacCallum Cancer Centre, Melbourne, Australia,
3UCL Cancer Institute, 4Department of Haemato-Oncology, St Bartholomew’s
Hospital, London, United Kingdom, 5Haematology, Peter MacCallum Cancer
Centre, Melbourne, Australia
Background: Assessment of gene mutations by next generation sequencing
is now standard in patients with haematological malignancy. However, larger
chromosomal aberrations (e.g. exon, gene and chromosome level gains and
losses) also serve as critical prognostic indicators that guide therapeutic deci-
sion making. These larger genetic lesions are typically detected using a sepa-
rate methodology such as conventional cytogenetics/FISH.
Aims: We aimed to develop and clinically validate a novel method for assessing
genome-wide copy number changes using an existing hybridisation-based tar-
geted sequencing panel in order to provide further critical prognostic information
in addition to variant-level data without the need for a separate assay.
Methods: A custom Agilent SureSelect capture panel targeting 313 genes of
relevance in myeloid and lymphoid malignancies was sequenced on an Illumina
NextSeq (paired end 75bp reads) to a mean depth of 700x. An in-house bioin-
formatics pipeline was created to analyse probe counts from on-target and off-
target reads, which also corrects for biases introduced during DNA enrichment
and sequencing by normalisation to a pooled reference comprising 10 normal
controls. Three metrics for copy number calling were tested including a per-
mutation-based statistic from circular binary segmentation, weighted mean and
variance for the bins in each segmented region, and an MLPA-like test using
read count ratios compared to controls. An interactive web-based graphical
user interface was developed to visualise both large-scale and exon level ampli-
fication and deletions.
Results: We validated the approach on 45 samples from patients with multiple
myeloma (predominantly advanced disease) with known copy number status
as determined by conventional cytogenetics, FISH and MLPA. Our novel
method detected numerous copy number changes that were outside the tar-
geted region (through genome-wide mapping and analysis of off-target reads)
such as del(1p) in 12 patients, gain(1q) in 15 patients and MYC amplification
in 5 patients. Moreover our method was able to interrogate and resolve the
complexity of changes on del(1p) including isolated deletions of FAM46C,
CDKN2C and FAF1. Of 25 patients with a TP53 mutation, 20 had concomitant
del(17p) detected by our assay, while 1 case had a del(17p) without mutation;
both monoallelic and biallelic TP53 aberration was associated with poor sur-
vival. Other findings in this cohort include frequent DIS3 mutations in patients
with monosomy 13 and novel oncogenic copy number changes such as the
high level amplification of KRAS in 1 case.
Summary/Conclusions: We have developed and demonstrated utility of a
reliable workflow for genome-wide copy number assessment that can be imple-
mented using existing targeted short read sequencing data, greatly extending
the utility of this technology beyond the identification of mutations in patients
with haematological malignancy. In the context of myeloma this can be used
to report clinically relevant changes including deletions of 1p and 17p, and
gains of 1q and 8q, as well as novel numerical chromosome aberrations.
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THE MULTIPLE MYELOMA GENOME PROJECT: DEVELOPMENT OF A
MOLECULAR SEGMENTATION STRATEGY FOR RISK STRATIFICATION
OF MULTIPLE MYELOMA
K. Mavrommatis1, B. Walker2, M. Samur3, F. Towfic4, C. Ashby2, C. Wardell2,
M. Bauer2, M. Ortiz5, E. Flynt4, Z. Yu4, M. Amatangelo4, M. Trotter5, H. Avet-
Loiseau6, G. Jackson7, K. Anderson3, A. Thakurta4, N. Munshi3, G. Morgan2,*
1Celgene Corporation, San Francisco, 2Myeloma Institute, University of
Arkansas for Medical Sciences, Little Rock, 3Dana Farber Cancer Institute,
Harvard Medical School, Boston, 4Celgene Corporation, Summit, United
States, 5Celgene Corporation, Seville, Spain, 6Centre de Recherche en Can-
cérologie de Toulouse Institut National de la Santé et de la Recherche Médicale,
Toulousse, France, 7Newcastle University, Newcastle, United Kingdom
Background: Segmenting multiple myeloma (MM) into subgroups with distinct
pathogenesis and clinical behavior is critical to implement a targeted therapy
approach and improve prognosis for patients. Current technologies have elu-
cidated major translocation groups and recurrent copy number changes with
varying effects on prognosis. However, minor translocation and mutational
groups remain poorly described due to limited sample numbers and small
datasets. The availability of multiple sets of high quality genomic data associ-
ated with clinical information, cytogenetics, and outcomes provides an oppor-
tunity to create an integrative genomic predictor using mutational, chromoso-
mal, and gene expression alterations to develop a classification system to seg-
ment MM into therapeutically meaningful subgroups. 
Aims: The Multiple Myeloma Genome Project (MGP) is a global collaborative
research initiative that aims to develop a molecular segmentation strategy for
MM to inform development and deployment of clinically relevant tests that could
improve diagnosis, prognosis, and treatment of patients with MM.
Methods: We have established a dataset representing 1766 MM patients for
which whole exome sequencing (WES; n=1367), Whole Genome Sequencing
(WGS; n=779), and expression data from RNA-Seq and Expression arrays
(n=1059) were available. Data were derived from the Myeloma XI trial, Dana-
Faber Cancer Institute/Intergroupe Francophone du Myeloma, The UAMS
Myeloma Institute and the Multiple Myeloma Research Foundation (IA1 – IA9).
Data were investigated for genetic abnormalities following preprocessing with
state of the art methods and algorithms. 
Results: Our analysis is focused on data from newly-diagnosed MM patients
(n=1751), which is the majority of our dataset. We have begun to integrate
genomic dataset with various correlates. Based on our data, we have at least
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80% power to detect gene expression changes and genomic variants associ-
ated in >2% of the study population. WES data identified the main cytogenetic
groups, somatic variants, and significantly mutated genes. 28 significantly
mutated genes were present in newly diagnosed samples (17 genes in >2% of
samples). The main recurrent mutations included KRAS and NRAS, and neg-
ative regulators of the NF-κB pathway; however, novel genes were also iden-
tified. Distinct mutational patterns, proportions, and sites between translocation
subgroups were found and will be presented. In addition, we detected recurrent
copy number abnormalities and examined the interaction with mutations and
fusion gene expression from RNASeq. Preliminary analysis with an integrative
model developed with machine learning methods/approaches using CN, SNV
and structural variants predicted a subset of high-risk patients. Unsupervised
molecular classification is in progress to integrate genomic data and define
subgroups, which will be presented. 
Summary/Conclusions: We have established the largest repository of molec-
ular profiling data in MM associated with clinical outcomes. Integrated analyses
are enabling generation of clinically meaningful disease segments associated
with differing risk that will inform development of clinical tests. ThemgP intends
to build a global network by expanding collaboration with global MM centers to
incorporate additional datasets through current and new collaborations.
*The first 6 authors share co-first authorship. The last 3 authors share co-senior
authorship.
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ALVOCIDIB SYNERGIZES WITH VENETOCLAX IN PRECLINICAL MODELS
OF MULTIPLE MYELOMA
H. Haws1, M. Livingston1, W. Kim1, R. Mangelson1, P. Peterson1, C. Whatcott1,*,
A. Siddiqui-Jain1, S. Weitman1, D. Bearss1, S. Warner1
1Discovery Biology, Tolero Pharmaceuticals, Inc., LEHI, United States
Background: With over 30,000 new cases expected in 2016 (US), new treat-
ments are desperately needed for the treatment of multiple myeloma (MM).
Major developments in the treatment of MM have included introduction of
agents such as lenalidomide, thalidomide, or bortezomib. Bortezomib, an
inhibitor of the proteasome, reduces the degradation of many proteins, including
the pro-apoptotic protein NOXA. However, high levels of MCL-1 and/or low
basal levels of NOXA have been implicated in bortezomib resistance and neg-
ative patient outcomes. The BCL-2-specific BH3 mimetic, venetoclax (ABT-
199), is also being explored in multiple hematologic malignancies, including
multiple myeloma. However, intrinsic resistance to venetoclax treatment
observed in MM patient samples has been attributed to a low BCL-2-to-MCL-
1 gene expression ratio, suggesting a central role for MCL-1 in cell survival in
this context as well. NOXA functions to sequester the anti-apoptotic BCL-2 fam-
ily member, MCL-1. Increased MCL-1 expression is a known resistance mech-
anism to venetoclax treatment in a variety of cell types including chronic lym-
phocytic leukemia and lymphomas. Considering the central role of MCL-1 to
treatment efficacy in MM, we investigated the ability of an MCL-1-lowering
agent, namely the CDK9 inhibitor alvocidib, to potentiate the activity of vene-
toclax in MM. Alvocidib suppresses MCL-1 expression via CDK9-mediated reg-
ulation of RNA polymerase II. Alvocidib has demonstrated robust improvements
in the clinical response rates of high-risk, newly diagnosed acute myeloid
leukemia (AML) patients as part of the time-sequential ACM regimen (alvocidib
+ cytarabine + mitoxantrone).
Aims: We hypothesize that alvocidib would potentiate the activity of venetoclax
in MM through an MCL-1-dependent mechanism.
Methods: CellTiter-Glo and Caspase-Glo were used for cell viability and apop-
tosis assays interrogating alvocidib and venetoclax in cell lines. We performed
RT-PCR to measure mRNA levels of MCL-1 and other genes following treatment.
Protein levels were interrogated using standard immunoblotting techniques. To
determine the efficacy of an alvocidib/venetoclax combination on tumor growth
in vivo, we performed a mouse study in the OPM-2 xenograft model.
Results: In this report, we demonstrate that alvocidib inhibited the protein
expression of MCL-1 in MM cells in a time-dependent fashion, up to 96 hours.
In cell viability assays, the addition of up to 100 nM venetoclax resulted in a
2.8-fold reduction in the IC50 of alvocidib in the cultured OPM-2 cell line. Con-
versely, the potentiation of venetoclax activity with the addition of alvocidib
resulted in a more than 500-fold decrease in IC50 in the relatively venetoclax-
resistant OPM-2 cells. Additional studies are currently underway to investigate
the efficacy of alvocidib and venetoclax in the context of bortezomib resistance
where low NOXA may contribute to enhanced cell survival via MCL-1.
Summary/Conclusions: Taken together, our data suggest that the combination
of alvocidib with venetoclax may constitute a novel therapeutic regimen in the
treatment of MM. Further, it suggests that CDK9-mediated targeting of MCL-1
may offer a clinical route to addressing intrinsic resistance in MM patients.
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NOVEL COMPOUND, OSSL_325096, INDUCES APOPTOSIS IN MULTIPLE
MYELOMA CELLS THROUGH VCP INHIBITION
N. Nishimura1,*, M.O. Radwan2,3, M. Amano1, S. Endo1, S. Ueno1, N. Ueno1,
H. Tatetsu1, H. Hata4, Y. Okamoto2, M. Matsuoka1, M. Otsuka2, Y. Okuno1
1Department of Hematology, 2Department of Bioorganic Medicinal Chemistry,
School of Pharmacy, Kumamoto University, Kumamoto, Japan, 3Department
of Chemistry of Natural Compounds, National Research Center, Cairo, Egypt,
4Graduate School of Health Sciences, Kumamoto University, Kumamoto, Japan
Background: VCP (p97) is an ER-associated protein that belongs to the AAA
ATPase family. It has a variety of cellular functions including ER-associated
protein degradation, autophagy, and aggresome formation. Recent studies
have elucidated emerging roles of VCP and its potential as a therapeutic target
in several cancer subtypes including multiple myeloma (MM).
Aims: We screened approximately 2,000 small molecular compounds to find
out novel small compounds that suppress growth of MM cell lines, and found
that OSSL_325096 has strong anti-proliferative activity on MM cell lines (IC50
100-500nM). In this study, we evaluated anti-MM activity of OSSL_325096
through VCP inhibition, in an ATP-competitive manner.
Methods: OSSL_325096 were purchased from Princeton BioMolecular
Research, Inc. (Princeton, NJ, USA). His-tagged human VCP (hVCP) cDNA
was cloned and utilized to generate hVCP protein in vitro as previously
described [Chou et al., PNAS, 2011, vol. 108(12): 4834-4839] to evaluate the
VCP inhibition by OSSL_325096. For in vivo analysis, MM xenograft model
mice were intraperitoneally administrated with vehicle or 50mg/kg of
OSSL_325096 twice a week.
Results: OSSL_325096 inhibited proliferation of MM cell lines, including one
bortezomib-resistant cell line (Figure 1). OSSL_325096 induces apoptosis in
these MM cell lines and primary MM cells purified from patients but not in PBM-
Cs from healthy donors. OSSL_325096 treatment leads to accumulation of
poly-ubiquitinated proteins, cleavage of caspase-3, and up-regulation of CHOP
in MM cell lines (Figure 2), suggesting this compound induces caspase-medi-
ated apoptosis and ER-stress in MM cells. OSSL_325096 has a chemical struc-
ture similar to several known VCP inhibitors. Therefore, to evaluate the role of
VCP in MM cell lines, we next performed knockdown of VCP. Knock-down of
VCP induced apoptosis in MM cell lines, accompanied with accumulation of
poly-ubiquitinated protein. In-silico protein-drug binding simulation suggests
possible binding of OSSL_325096 to the ATP binding site in VCP’s D2 domain.
Indeed, in the cell-free ATPase assay, OSSL_325096 showed dose-dependent
inhibition of VCP’s ATPase activity (Figure 3). The IC50 of OSSL_325096 on
ATPase activity was 7-10µM, while IC50 of cell survival in MM cells was 0.1-
0.8µM, suggesting that OSSL_325096 may have other anti-myeloma function
in addition to VCP inhibition. RNA-sequencing of MM cells treated with
OSSL_325096 revealed that several pathways including mTROC1 signaling,
TNFα signaling, and unfold protein response, were activated by OSSL_325096.
Finally, OSSL_325096 was administered to xenograft mice with MM cell tumors
and inhibited the tumor growth in vivo (Figure 4).
Figure 1.
Summary/Conclusions: The present data suggest that OSSL_325096 may
be novel anti-myeloma drug candidate partially through its direct inhibition activ-
ity of VCP.
E1206
A NOVEL PREDICTIVE MODEL COMBINING LINCRNAS AND PROTEIN
CODING GENES IN MULTIPLE MYELOMA
M. Samur1,2,*, A. Gulla1, M. Fulciniti1, R. Szalat1, A. Aktas Samur1, M. Shamas1,
F. Magrangeas3, S. Minvielle4, K. Anderson1, G. Parmigiani1, H. Avet-Loiseau5,
N. Munshi1
1Dana Farber Cancer Institute, 2Harvard Medical School, Boston, United
States, 3Centre de Recherche en Cancérologie Nantes, 4Institut de Recherche
Thérapeutique, Nantes, 5Cancer Research Center of Toulouse, Toulouse,
France
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Background: RNA has diverse sets of regulatory functions and a recent analy-
sis of RNA repertoire has identified a large numbers of non-coding transcripts.
One of which, long intergenic non-coding RNA (lincRNA) with transcripts longer
than 200 nucleotides, are located between the protein coding genes and do
not overlap exons of either protein-coding or other non-lincRNA genes. lincR-
NAs have been considered to provide regulatory functions, however, their pre-
cise role in cellular biology remains unclear.
Aims: Here, we have studied lincRNAs using uniformly treated patients to
show their impact on survival outcome in MM.
Methods: We performed RNA-seq on CD138+ MM cells from 360 newly-diag-
nosed patients and 18 normal plasma cells (NPM) and analyzed for lincRNA
and protein coding genes. MM patient data for clinical characteristics, cytoge-
netic and FISH as well as clinical survival outcomes were also analyzed and
correlated with lincRNA data.
Results: Using only the expressed lincRNAs, we developed a risk prediction
signature. The Kaplan-Meier estimates of EFS at 4 years were 53.3% (95%
CI, 45.1% to 63.1%) and 32.6% (95% CI, 25.1% to 42.2%), and OS at 4 years
were 93.2% (95% CI, 88.9% to 97.6%) and 71.1% (95% CI, 62.9% to 80.3%)
in our patients having a low or high risk score. We then combined lincRNA sig-
nature with known expression signatures and improved the risk prediction for
known expression signatures dramatically. We validated our results on inde-
pendent large cohort with newly diagnosed MM RNAseq data. When applied
to patient cohort separated by other risk categorization including minimal resid-
ual disease status (MRD), cytogenetic risk status (del17p, t(4;14) and t(14;16))
and International Staging System (ISS), lincRNA signature was able to further
identify patients with significant differential survival outcomes.
Summary/Conclusions: In summary, we report that lincRNAs have an inde-
pendent effect on survival outcome in MM and provides rational for its use in
risk stratification as well as to understand biological impact. Combined risk
prediction with other risk features improve the prediction power and helps to
create better classification in MM.
E1207
DYNAMIC IMMUNOHISTOCHEMICAL EVALUATION OF MARROW
MICROENVIRONMENT MODIFICATIONS IN PATIENTS WITH SMOLDERING
MYELOMA
A. Mussetti1,*, A. Pellegrinelli2, N. Cieri3, M. Pennisi3, G. Garzone2, F. Dominoni2,
A. Cabras2, P. Corradini4, V. Montefusco1
1Hematology and Adult Bone Marrow Transplantation, 2Department of Pathol-
ogy and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori,
3Università degli Studi di Milano, Milano, Italy, 4Department of Oncology and
Hemato-oncology, Università degli Studi di Milano, Milano, Italy
Background: In most cases, multiple myeloma (MM) is preceded by an asymp-
tomatic status known as monoclonal gammopathy of unknown significance
(MGUS) or smoldering multiple myeloma (SMM). The mechanisms of progres-
sion from SMM to MM are not well understood. Despite an increasing evidence
of an immune system dysregulation in the setting of MM characterized by a
tumor tolerating microenvironment, the immunosurveillance profile in the setting
of SMM has never been investigated.
Aims: Our aim was to identify a progressive dysregulation of marrow microen-
vironment in sequential samples of SMM patients. Secondly, we hypothesized
a difference in the microenvironment of the patients with progressed SMM ver-
sus those with stable SMM.
Methods: We performed extensive immunohistochemical analysis of bone
marrow samples of 16 patients affected by SMM at time 0 (16 samples) and at
+24 months (+/- 4 months, 16 samples). Half of these patients developed MM
at 24 months (progressed SMM), the other half remained asymptomatic (stable
SMM). Immunohistochemical panel comprised the following markers: microen-
vironment cell composition (CD138, CD4, CD8, CD3, CD45, CD56, CD68),
loss of immunogenicity (PDL1, PDL2, PD1, LAG3, CTLA-4, IDO), loss of anti-
genicity (HLA-DR). Immunogenicity and antigenicity markers expression was
described as percentage on the total of marrow plasma cells and non-plasma
cells separately. A first analysis compared the samples of the whole cohort at
time 0 and +24 months (32 samples, paired t-test). A linear correlation was
performed to study the expression of T cell inhibitory ligands on plasmacells
and their respective receptors on marrow non-plasma cells (HLA-DR with
LAG3, PDL1 with PD-1). A second analysis compared, at time 0 and +24
months, the samples of stable SMM versus progressed SMM (16 samples
each analysis, t-test). 
Results: In the first analysis, we found a significant increase between time 0
and +24-month samples of CD4+ (11% vs 17%, p<0.01), CD8+ (15% vs 18%,
p<0.01), CD4/CD8 ratio (0.75 vs 0.94, p<0.01), PDL1 on plasmacells (1% vs
12%, p=0.03), HLA-DR on plasmacells (7% vs 10%, p=0.04), HLA-DR on non-
plasmacells (29% vs 39%, p=0.01), LAG3 on non-plasmacells (4% vs 10%,
p=0.04). Interestingly, we found a significant correlation between LAG3 and its
ligand HLA-DR (r=0.47, p=<0.01). In the second analysis we compared stable
SMM versus progressed SMM at time 0 and at +24 months. At time 0, we
found only an increased CD68-KP1 expression in favor of stable SMM group
(28% vs 23%, p=0.01). At time +24 months, no differences were observed but
an increased plasma cell marrow infiltration in the progressed SMM group
(50% vs 26%, p<0.01). 
Summary/Conclusions: First, we observed an increase in inflamed microen-
vironment markers (increase in CD4+ and CD8+ cell count in favor of CD4+
population and HLA-DR expression on plasmacells and non-plasmacells) during
the course of SMM. Secondly, expression of T cell inhibition markers (PDL1,
LAG3) was significantly augmented during disease progression. For the first
time, we reported a comprehensive analysis of microenvironment modifications
in the setting of SMM with a paired-samples analysis. Features of an immune
dysregulated microenvironment were observed. In particular, increased in PDL1
and LAG3 expression could be of clinical interest due to the current availability
of checkpoint inhibitors drugs targeting these molecules. The results of this
study should be confirmed on prospective studies with larger number of patients.
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IMMUNE CELL PROFILING IN BONE MARROW OF MYELOMA PATIENTS
POST AUTOLOGUS STEM CELL TRANSPLANT SHOWS PRESENCE OF
CYTOTOXIC CD4 AND CD8 CELLS, WITH PROMINENT LAG-3 EXPRES-
SION AND OTHER CHECKPOINT MARKERS
N. Alrasheed1,*, A. Furness1, D. De-Silva1, D. Galas-Filipowicz1, M. Chin1,
L. Lee1, J. Henry1, M. Pule1, S.A. Quezada1, K. Yong1
1UCL Cancer institute, university college london, London, United Kingdom
Background: Multiple myeloma (MM) is a plasma cell malignancy that remains
incurable, despite therapeutic advances. Immunotherapies have recently
shown much promise in this and other cancers, and are under intense inves-
tigation. Autologous stem cell transplantation (ASCT) is standard of care in
young fit newly diagnosed patients. In the post-ASCT setting, the minimal dis-
ease burden and re-constituting immune system may be a favourable context
for immunotherapies, including cellular therapy and checkpoint blockade.
Aims: We aimed to characterise the immune landscape in the bone marrow
(BM) of MM patients post- ASCT, to identify candidate immune checkpoint pro-
teins for therapeutic targeting.
Methods: BM aspirates were obtained from patients with MM at 3months post
ASCT (n=28), and 6-12months post ASCT (n=41) at University College Hos-
pital. Control BM aspirates were collected from healthy volunteers undergoing
BM harvesting with the Anthony Nolan. Immunoﬂuorescence surface staining
was performed using antibodies to CD3, CD4, CD8, LAG-3, PD-1, HLA-DR,
ICOS and the intracellular markers GzmB and Foxp-3. All p-values indicate
differences from normal donors unless otherwise stated.
Results: In the post-ASCT BM, absolute numbers of CD8 cells exceeded CD4
cells as early as 3months post-ASCT, suggesting the BM compartment is rapidly
filled with CD8 cells. Although absolute numbers of CD4 effectors (CD4+Foxp3-
) were either similar (3 months) to or lower (6-12months, p<0.05) than healthy
donors, there was a higher proportion of cytotoxic (GzmB+) CD4 cells (3months
median 30.4%, range 0.2-89.7%, p<0.01 vs control median 2.6%, range 0.2-
33.4% and 6-12months, median17.6%, range 0.4-100%, p<0.05). CD4 effectors
also expressed activation markers: Inducible co-stimulator (ICOS, 3months
median 20.2%, range 2.9-80.6% p<0.05 vs control median 8.6%, range 2-22%
and 6-12months median 33%, range 1.8-80.7%, p<0.01) and HLA-DR (p<0.05),
and high levels of lymphocyte-activated gene-3 (LAG-3, 6-12months median
29.6%, range 12.2-62.1%, p<0.05 vs control median 17.9%, range 8.2-32.4%)
Significant numbers of CD4 effectors co-expressed LAG-3 and GzmB (p<0.05),
as well as LAG-3 and ICOS (p<0.05). Absolute numbers of CD8 effectors
(CD8+Foxp3-) in post ASCT patients were not different from healthy donors.
Similar to CD4 effectors, a significantly higher proportion of CD8 effectors dis-
played cytotoxic phenotype (GzmB+, 3months median 88%, range 15.2-98.3%,
p <0.0001 vs control median 30.3%, range 5.8-71.4% and 6-12months median
81.5%, range 19.4-100%, p <0.0001) as well as increased levels of HLA-DR
(p<0.05) post ASCT. CD8 effectors also displayed high co-expression of LAG-
3 and GzmB (p<0.05), but overall levels of LAG-3 were not significantly higher
than controls. Both CD4 and CD8 effectors expressed PD-1, however, levels
were not significantly higher compared to healthy donors. Patients whose BM
contained higher levels of activated (and cytotoxic) CD4 effectors also had sim-
ilar phenotype of CD8 effectors. We correlated immune checkpoint protein
expression with disease response in patients at 12months post ASCT. Patients
with residual disease (PR) had higher levels of cytotoxic (Foxp-3-GzmB+) CD4
and CD8 effectors (p<0.05) with co-expression of LAG-3 on cytotoxic CD4 effec-
tors, but no differences in PD-1 expression were seen.
Summary/Conclusions: The BM of MM patients following ASCT contains acti-
vated CD4 and CD8 effectors, but high co-expression of LAG-3 suggests that
these cells may be functionally suppressed. Patients with larger amounts of
residual disease have higher numbers of cytotoxic CD4 and CD8 cells, and
the co-expression of the checkpoint protein LAG-3 may provide a rationale for
blockade of this pathway.
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INHIBITION OF EXTRACELLULAR VESICLE SECRETION INDUCES
APOPTOSIS OF BONE MARROW STROMAL CELLS: TOWARDS
SOIL-TARGETED THERAPY IN MULTIPLE MYELOMA
T. Umezu1,*, S. Imanishi2, S. Yoshizawa1, K. Ohyashiki1, J. Ohyashiki2
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Background: Bone marrow stromal cells (BMSCs) interact with multiple myelo-
ma (MM) cells in the bone marrow, and also create a permissive microenviron-
ment for MM cell growth and survival. Recent evidence indicated that MM cell-
BMSC communication via extracellular vesicles (EVs) plays an important role
in the MM microenvironment.
Aims: In this study, we investigated the biological property of EVs and miRNAs
in EVs derived from BMSCs, aiming to establish the emerging strategies to tar-
get MM microenvironment to prevent tumor growth and spread.
Methods: Bone marrow samples were obtained from MM patients (age 56 to
82, n=20) and monoclonal gammopathy of undetermined significance (MGUS)
patients (age 44 to 82, n=13) in accordance with the Declaration of Helsinki
and using protocols approved by the research Ethics Committee of Tokyo Med-
ical University (IRB No. 2648), and BMSCs derived form MM patients (MM-
BMSCs) andmgUS patients (MGUS-BMSCs) were isolated by the classical
adhesion method. EVs were isolated from conditioned medium of BMSCs using
a Exoquick-TC (SBI). The size of EVs was confirmed using a NanoSight LM10
(Malvren). The RNA from cells and EVs was profiled for 381 miRNAs using a
TaqMan low-density array (ABI). For functional analysis of candidate miRNAs,
the miRNA mimics (Ambion) were transfected into BMSCs using HiPerFect
(Qiagen). Cell viability of miRNA-overexpressed BMSCs were determined using
WST-8 (Dojindo), and Apoptosis rates were determined using Caspase-Glo
assays (Promega). To assess the effect of the inhibit on EV secretion, BMSCs
were treated with 10 µM GW4869 (nSMase2 inhibitor, Sigma) for 48h. 
Results: MM-BMSCs andmgUS-BMSCs had a fibroblast-like morphology in
culture, and were homogeneously CD73+, CD90+, CD105+, CD34-, and CD45-.
MM-BMSCs had a higher expression of α-smooth muscle actin (α-SMA) than-
mgUS–BMSCs. The nanoparticle size distribution of EVs derived from BMSCs
was approximately 50 nm. We found high expression of miR-10a in the EVs
derived MM-BMSCs, while the expression of intracellular miR-10a was low in
MM-BMSCs. We therefore hypothesized that low expression of cellular miR-
10a might be important for survival of MM-BMSCs; As a result, miR-10a was
packaged into EVs, and they were released to the extracellular space. To test
the hypothesis, miR-10a mimic was transfected into MM-BMSCs andmgUS-
BMSCs. Of note is that overexpression of miR-10a inhibited cell proliferation
and induced apoptosis of MM-BMSCs, while the cell proliferation and apoptosis
ofmgUS-BMSCs were not affected by the overexpression of miR-10a. We also
found that inhibition of EV release with GW4869 promote the accumulation of
intracellular miR-10a in MM-BMSCs, and EV-release inhibitor also can inhibited
cell proliferation and induced apoptosis of MM-BMSCs.
Summary/Conclusions: Our results provide the possibility that the inhibition
of EV secretion induced apoptosis of MM-BMSCs that can support MM cell
growth and survival in BM microenvironment.
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SINGLE-NUCLEOTIDE POLYMORPHISM IN THE PBK GENE IS CLOSELY
ASSOCIATED WITH MYELOMA CELL PROLIFERATION
I. Hanamura1,*, A. Ota2, S. Karnan2, M. Wahiduzzaman2, S. Mizuno1, K. Uchino1,
J. Kanasugi1, T. Horio1, S. Murakami1, S. Suzuki3, R. Ueda3, S. Tsuzuki2,
H. Konishi2, Y. Hosokawa2, A. Takami1
1Division of Hematology, Department of Internal Medicine, 2Department of Bio-
chemistry, 3Department of Tumor Immunology, Aichi Medical University,
Nagakute, Japan
Background: Elevated expression of PDZ binding kinase (PBK), which
encodes a serine/threonine kinase, has been reported to be associated with a
poor prognosis in a variety of cancers. The public gene expression profiling
data also showed that higher expression of PBK was related with a poor prog-
nosis in myeloma. However, the molecular mechanisms of PBK expression
have never been investigated in myeloma.
Aims: The aim of this work was to elucidate PBK gene functions associated
with myeloma cell growth in vitro and in vivo.
Methods: Eight human myeloma cell lines including ANBL-6, 8226, OPM2,
and KMS-11 were used in this study. The expression levels of mRNA and pro-
tein of PBK were detected by real-time RT-PCR and western blotting, respec-
tively. The genome sequence of the whole PBK gene was determined using
the dye terminator method. Knockout of PBK was performed using CRISPR-
Cas 9 system. A single guide RNA sequence for PBK was in exon 3 and PBK
expression was completely disrupted (Fig. 1). Transfection of the plasmid
expressing PBK to cells was performed using with the Amaxa Nucleofector
system. Cell viability and proliferation were examined by the MTT and colony
formation assay. The KMS-11 cells were subcutaneously injected to mice and
tumor volumes were observed every 3 to 4 days.
Results: High expression of mRNA and protein of PBK was observed in 8/8
myeloma cell lines. Genome sequencing revealed the rs3779620 polymorphism
in the PBK exon 5, in which the A to G transition results in the N107S substitu-
tion. A/A, A/G and G/G were found in 88, 0 and 12%, respectively. Of note,
PBK inhibition by CRISPR-mediated knockout enhanced cell proliferation in
ANBL-6, 8226, and OPM2 cells, all of which carry PBKA/A. Surprisingly, in the
KMS-11 cells carrying PBKG/G, PBK inhibition by CRISPR-mediated knockout
suppressed cell growth in vitro and in xenograft mice (Fig. 2). Moreover, exoge-
nous expression of PBKG/G augmented cell proliferation in the PBK-deficient
OPM2 cells, which carry PBKA/A originally. Furthermore, Thr 9 phosphorylation
on PBK was increased in cells expressing PBKG/G compared with those cells
expressing PBKA/A.
Figure 1.
Summary/Conclusions: Our findings indicate that expression of PBKG/G was
associated with myeloma cell proliferation, while PBKA/A was likely linked to
tumor suppression. Increased phosphorylation of Thr 9 on PBK might contribute
to proliferation in cells with PBKG/G. These results provide a novel insight into
the mechanisms underlying myeloma cell growth and PBK rs3779620 genotype
is a potential stratification and therapeutic target for plasma cell dyscrasias.
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THE HISTONE METHYLTRANSFERASES G9A/GLP REPRESENT NEW
PROMISING TARGETS FOR THE TREATMENT OF MULTIPLE MYELOMA
E. De Smedt1,*, J. Devin2, H. Liu3, A. Maes1, K. Maes1, K. De Veirman1,
E. Menu1, K. Vanderkerken1, J. Moreaux2, E. De Bruyne1
1Department of Hematology and Immunology-Myeloma Center Brussels, Vrije
Universiteit Brussel, Brussels, Belgium, 2Laboratory for Monitoring Innovative
Therapies, Institute of Human Genetics, CNRS, Montpellier, France, 3Depart-
ment of Hematology, Tianjin Medical University General Hospital, Tianjin, China
Background: Multiple myeloma (MM) is a clonal plasma cell malignancy which
mainly resides in the bone marrow. In cancer cells, the epigenetic landscape
is known to be highly disturbed. In line, numerous epigenetic aberrations have
been described in MM, resulting in deregulated gene expression, disease pro-
gression and drug resistance. Targeting deregulated epigenetic modifiers there-
fore represents an interesting therapeutic approach. G9a (EHMT2) and GLP
(EHMT1) are 2 histone methyltransferases which catalyze mono- and dimethy-
lation of histone 3 lysine 9 (H3K9). Importantly, G9a is overexpressed in several
cancers, correlating with a poor prognosis.
Aims: Currently, data about the expression and role of G9a/GLP in MM is lack-
ing. The aim of this study is therefore to investigate the functional role of
G9a/GLP in MM pathogenesis.
Methods: The prognostic value of G9a/GLP in terms of overall survival was
determined in the UAMS-TT2 cohort of newly diagnosed MM patients (n=345,
GSE4581) using Maxstat analysis. In addition, we used a panel of 10 human
cell lines, 3 murine cell lines and 5 primary patient samples to evaluate the
effect of the small molecule inhibitors UNC0638 and BIX01294 on MM cell via-
bility, cell cycle progression and apoptosis. We also assessed the in vitro anti-
MM activity of BIX01294 in combination with bortezomib or ABT-199. The in
vivo anti-MM activity of therapeutic BIX01294 treatment was tested using the
murine 5TGM1 model. Difference in overall survival between groups was
assayed with a log-rank test and survival curves plotted using the Kaplan-Meier
method.
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Results: Here we report that high expression levels of both G9a and GLP are
associated with a worse disease outcome in newly diagnosed MM patients.
Moreover, gene set enrichment analysis of patients with high G9a/GLP expres-
sion levels displayed a significant enrichment of genes involved in pathways
associated with MM disease progression, including the RAS pathway, NF-ĸB
canonical pathway, IRF4 multiple myeloma program and mRNA splicing. Next,
we demonstrated that the specific G9a/GLP inhibitors BIX01294 and UNC0638
significantly and potently reduced MM cell viability in vitro. Moreover, both
inhibitors also induce cell cycle arrest and apoptosis. When comparing between
both inhibitors, BIX01294 was found to be the most potent in induce apoptosis.
Mechanistic studies for BIX01294 furthermore indicated that BIX01294 treat-
ment resulted in autophagic programmed cell death as evidenced by a strong
increase in the formation of LC3B puncta and an increase in LC3II and beclin-
1 protein levels. In addition, we found that BIX01294 sensitizes MM cells to
the proteasome inhibitor bortezomib and the Bcl-2 inhibitor ABT199. Lastly,
therapeutic treatment of 5TGM1 inoculated mice with BIX01294 resulted in a
clear delay in tumor progression, as evidenced by a clear decrease in tumor
burden and a significant increase in the overall survival of BIX01294 treated
mice compared to vehicle treated mice.
Summary/Conclusions: Altogether, our results demonstrate for the first time
the importance of the histone methyltransferases G9a/GLP in MM pathogenesis.
Furthermore, we show that specific targeting of G9a/GLP induces MM cell apop-
tosis, enhances MM sensitivity to ABT- 199 and bortezomib and significantly
delays tumor progression in the murine 5TGM1 model. Thus, G9a/GLP targeting
represents a promising strategy to improve treatment of MM.
E1212
CYTOTOXIC LYMPHOCYTES IN NEWLY DIAGNOSED MYELOMA HAVE
REVERSIBLE FUNCTIONAL AND PHENOTYPIC ABNORMALITIES THAT
MAY OFFER THERAPUTIC OPPORTUNITIES
F. Seymour1,*, J. Cavenagh1, J. Gribben1
1Haemato-Oncology, Barts Cancer Institute, London, United Kingdom
Background: A bi-directional interaction exists between malignant cells and
those of the immune microenvironement. This dynamic relationship results in
gradual loss of clonal control associated with loss of cytotoxic lymphocyte (CTL)
response. Mechanisms of immune escape are varied and include the induction
of immune checkpoint pathways, notably the PD1-PDL1 axis. Multiple myeloma
is a disease characterised by a pre malignant phase which can evolve into
periods of asymptomatic and symptomatic disease. One possible mechanism
for disease progression is progressive loss of immunological control. The malig-
nant plasma cell has multiple potentially immune modifying effects including
the expression of PDL1 and induction of a pro-tumour micro-environment. The
role of CTLs is less well understood.
Aims: To undertake deep immune profiling of the CTL landscape in myeloma
in order to establish whether features of immune dysregulation are present
and to identify potential therapeutic opportunities.
Methods: Cryopreserved bone marrow from 18 patients with newly diagnosed
and untreated myeloma and 9 controls were assessed using a 36 parameter
mass cytometry panel. The panel was designed to assess 9 immune checkpoint
regulators, 5 cytokines, and markers of proliferation and degranulation across
multiple lymphocyte subsets. Samples were stimulated with CD3 and CD28 to
assess functional capacity. Dimensionality reducing clustering algorithmic
analysis was used alongside traditional data analysis techniques to identify
functional subpopulations characterised by expression of multiple markers.
Results: The cytokine profile in newly diagnosed myeloma is shifted towards
a pro-tumour microenvironment with particularly marked elevation of TGFb
throughout resting CTLs (36.4% v. 66.2%, p=<0.0001). IFNg production is
reduced in the resting myeloma effector population (0.33% v. 0.18%, p=0.0099).
Stimulation restores the cytokine profile to match that of controls. Myeloma
CTLs retain the capacity to proliferate and produce the constituents for cytotoxic
granule formation, however elevated PD1 expression alongside other markers
of exhaustion suggests a transition towards an exhausted phenotype is occur-
ring. Strongly PD1 expressing populations in myeloma are larger (26% v.43%,
p=0.05) and have increased rates of co-expression of CTLA4 (32%v. 64%,
p=0.0015), PDL1 (26% v. 47%, p=0.0198) and TIM3 (34% v. 56%, p=0.0241).
Populations of CTLS from myeloma up-regulate expression of the TCR co-
stimulatory receptors DNAM1 (74% total CD8), NKG2D (45% total CD8) and
OX40 (33% total CD8) following stimulation.
Summary/Conclusions: Clear differences can be identified in the functional
and phenotypic features of CTLS in myeloma compared to those of controls.The
partial nature of these defects and the fact that reversibility can be demonstrated
suggests that these cells have not yet reached the stage of irreversible exhaus-
tion. Taken together this data suggests that targeting immune checkpoint regu-
lators at an early disease stage, in order to optimise immunological function
and reverse partial defects, is a viable therapeutic strategy to explore. PD1,
PDL1, CTLA4 and TIM are all potential immune checkpoint targets. In addition
the expression of NKG2D, DNAM1 and OX40 raises the possibility of activating
TCR co-stimulation in order to up-regulate antigen specific CTL activity. Com-
bining immunological blockade with other immune optimising agents may
enhance the benefit, leading to greater malignant cell clearance.
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P53-RESTORING SMALL MOLECULE CP-31398 INDUCES APOPTOSIS
VIA INDUCTION OF REACTIVE OXIDATIVE SPECIES IN HUMAN MULTIPLE
MYELOMA
Y. Arihara1,*, K. Takada1, Y. Kawano1, N. Hayasaka1, H. Nakamura1,
S. Kikuchi1, Y. Kamihara1, K. Murase1, H. Ikeda2, S. Iyama2, T. Sato2, K. Miyanishi1,
M. Kobune2, J. Kato1
1Department of Medical Oncology, 2Department of Hematology, Sapporo Med-
ical University, Sapporo, Japan
Background: Reactive oxygen species (ROS) are normal byproducts of a
wide variety of cellular processes. ROS have dual functional roles in cancer
cell pathophysiology. At low to moderate levels, ROS act as signaling trans-
ducers to activate cell proliferation, migration, invasion, and angiogenesis. In
contrast, high levels of ROS induce cell death. In multiple myeloma (MM), ROS
overproduction is the trigger for apoptosis induced by several anticancer com-
pounds, including proteasome inhibitors. However, no drugs that mainly affect
oxidative stress are currently used for treatment of MM in the clinic. In MM,
p53 status is an independent prognostic marker, since patients harboring p53
abnormalities are highly resistant to standard therapies, and the incidence of
p53 mutations and deletions increases during disease progression. Therefore,
restoration of p53 is an attractive strategy for treating advanced relapsed and
refractory MM (RRMM) patients. CP-31398 (CP) is a small molecule that acti-
vates wild-type p53 or restores tumor-associated p53 mutants to wild type p53
function in multiple human cancer cell lines; this leads to cell cycle arrest and/or
apoptosis. The growth of rhabdomyosarcoma cell lines can be inhibited by
p53-dependent induction of ROS, but it is not clear whether CP-induced cyto-
toxicity proceeds via a similar pathway.
Aims: Our study was aimed at evaluating the anti-myeloma activity of CP.
Methods: MM cell lines (MM1S, RPMI8226, U266, KMS5, OPM2, Delta47,
KMS11) and three primary MM samples were treated for 48 h with CP. Subse-
quently, the inhibitory effect of CP on MM cell line growth was assessed using
a WST-1 assay. In order to elucidate the cytotoxic mechanism of CP,
immunoblotting and flow cytometry analysis were performed. Measurements
of cytosolic and mitochondrial ROS were performed with CellROX Deep Red
or MitoSOX Red. For quantification of ROS, cells were analyzed by flow cytom-
etry and fluorescence microscopy. The therapeutic potential of CP was evalu-
ated by its ability to suppress tumor growth in vivo using the subcutaneous
RPMI8226 murine xenograft model for human MM.
Results: In this study, we have demonstrated that the p53-activating small
molecule CP-31398 effectively inhibited the growth of MM cell lines and primary
MM isolates from patients with IC50 values in the range of 2.51–11.2 µM. CP
also suppressed the growth of MM xenografts in mice. Mechanistically, CP
was found to induce intrinsic apoptosis in MM cells via increasing mitochondrial
and cytosolic ROS production. Interesting, CP-induced apoptosis occurs
regardless of the cells’ p53 status, suggesting that CP has additional mecha-
nisms of action. In addition, we found that CP acted synergetic with the protease
inhibitor carfilzomib (CFZ) in MM cells, providing a framework for further studies
of CP alone and in combination with CFZ to improve the prognosis for MM
patients.
Summary/Conclusions: Our findings indicate that CP could be an attractive
candidate for treatment of MM even in patients with p53 abnormalities; this
would satisfy an unmet clinical need, as such patients currently have a poor
prognosis. 
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TUMOR MICROENVIRONMET TRANSFORMATION FROMmgUS TO
MYELOMA IS ASSOCIATED WITH PRO-TUMORAL ACTIVATION OF MES-
ENCHYMAL STROMAL CELLS (MSC) 
C. Giallongo1,*, D. Tibullo1, N. L. Parrinello1, P. La Cava1, G. Camiolo1, M. Tummino1,
N. Caporarello1, C. Anfuso1, C. Conticello1, A. Romano1, F. Di Raimondo1
1Clinical and Molecular Biomedicine, section of Hematology, University of Cata-
nia, catania, Italy
Background: A well-recognized feature of MM is the intimate relationship
between plasma cells (PC) and bone marrow microenvironment, characterized
by a modified extracellular matrix, enhanced angiogenesis and presence of
cells with immune suppressive activity, including tumor-associated
macrophages and myeloid-derived suppressor cells (MDSC). Recently, we
demonstrated that MM-MSC are able to convert normal immature myeloid cells
in MDSC contributing to immune-escape mechanisms.
Aims: We hypothesize that MSC derived from Smoldering myeloma (SMM)
and MM are in an activated status that promotes tumor growth and and tumor
microenvironment trasformation.
Methods: Human peripheral blood mononucleated cells (PBMC) isolated from
healthy subjects (HC) were cultured with healthy controls (HC-),mgUS-, SMM-
or MM-MSC. After 6 days,. neutrophils (N) were isolated using anti-CD66b
magnetic microbeads and were tested in vitro for their ability to induce angio-
genesis and suppress T cell proliferation.
498 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Results: Only N educated by SMM- and MM-MSC (both from patients at diag-
nosis, relapsed and refractory) significantly up-regulated Arg1, NOS2 and TNFα
and exhibited suppressive effect with a reduction of T cell proliferation
(p<0.001). By co-culturing educated-N with Human Brain Microvascular
Endothelial Cells (HBMEC), we observed increased both tube length and num-
ber of branch points only in conditions where HBMEC were incubated with MM-
MSC or MMref-MSC educated-N (p<0.05). Adding Bortezomib, Lenalidomide
or Pomalidomide during co-culture of PBMC with MM-MSC, isolated N showed
a significant reduction of pro-angiogenic activity but did not lose immunosup-
pressive ability. To examine if PC play a role in MSC “activation”, before per-
forming co-cultures with PBMC, we pre-treated HS-5 or HC-MSC with MM cell
lines. PC pre-treatment drives healthy MSC to activate N in immunosuppressive
and pro-angiogenic cells. Implanting of mixtures of fluorescently labeled MM
cells and healthy- or MM-MSC into zebrafish, animals coinjected with PC and
MM-MSC showed enhanced tumor colonization and growth compared with
those injected with PC and healthy MSC. 
Summary/Conclusions: Tumor microenvironmet transformation frommgUS
to MM is associated with progressive activation of MSC that have a pro-tumoral
activity. Indeed SMM- and MM-MSC polarize N in immunosuppressive and pro-
angiogenic N (N2) in vitro. In addition, MM-MSC facilitate MM growth in vivo
confirming their central role in tumor progression.
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LONG TERM CR MULTIPLE MYELOMA PATIENTS STUDIED WITH NEXT
GENERATION FLOW SHOW PREDOMINANTLY CURED VSmgUS-LIKE
MINIMAL RESIDUAL DISEASE PATTERNS: A STUDY OF THE
GTMM-TUSCAN GROUP FOR MULTIPLE MYELOMA
A. Gozzetti1,*, S. Sirianni1, V. Candi1, D. Raspadori1, C. Nozzoli2, M. Staderini2,
G. Papini1, C. Zuanelli Brambilla1, B. Mecacci1, G. Buda3, R. Caporale4,
A. Bosi2, M. Petrini3, M. Bocchia1
1Hematology Unit, University of Siena, Siena, 2Hematology, Azienda
Ospedaliera Universitaria Careggi, Firenze, 3Hematology, University of Pisa,
Pisa, 4Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
Background: CR is a prerequisite for long term responses, progression free
survivals, and ultimately overall survivals and cure. In the era of novel agents,
many MM patients can achieve stringent CR (sCR), i.e. disease disappearance
at serological, immunoistochemical level plus negativity of free light chains
(FLC). On the other hand most of these patients still will relapse and minimal
residual disease (MRD) detection will play a crucial role in the very next future.
Recently, two 8 colours tubes panel developed by the EuroFlow Consortium
can detect MRD with an increased sensitivity and can be applied as standard-
ized method to study multiple myeloma (MM) patients. 
Aims: While many studies have looked at MRD status sequentially and soon
after autologous or allogeneic stem cell transplantation with flow or molecular
techniques, little is known about long term remission patients (>5-10 years)
and in particular if more sensitive techniques such as NGF or NGS can still
detect minimal disease in those patients. Aim of the study was to analyse
patients with MM in >VGPR with next generation flow at>2 and>5 years of last-
ing remission.
Methods: Clinical assessment definition of CR status included serum and urine
immunofixation, free light chain determination, imaging study with CT-PET,
bone marrow aspirate, bone core biopsy. 56 MM patients (M/F= 30/26), were
studied with NGF at two GTMM centers between February 2016 and February
2017. 28/56 ( 50%) patients were in sCR at the moment of the study at a median
of 40 months after therapy (range 3-140). 28/56 ( 50%) patients were in VGPR
at study analysis according to new IMWG response criteria. N= 12, 25 and 44
patients had a remission disease >5 years, >2 years, and <5 years, respectively.
Two tube assay incorporated 8 antibodies each: CD38, CD56 β2-Microglobulin,
CD19, κ Anti-Kappa Anti-Lambda CD45 CD138, and CD38, CD28, CD27,
CD19, CD117, CD81, CD45 and CD138 (OneFlow™ PCST and PCD, BD Bio-
sciences) and were utilized to detect MRD level with a lyse-wash-and-stain
sample preparation protocol by flow cytometry (FACScanto II, BD, Biosciences).
Accurate identification of BM plasma cells (PCs) and discrimination between
phenotypically aberrant (aPC) and normal PC (nPC) were carried out after
acquisition and analysis of >2 x 106 cells (Diva 8, BD Biosciences).
Results: MRD+ status was detected in 23/56 ( 41%) of the patients. 4/12 (2
33%) were MRD positive at >5 years remission (2 sCR, 2 VGPR) (median 96
months range 72 – 186 months); 20/44 ( 45%) were positive at<5 years of
remission (3 CR; 17 VGPR)(median 9,5 range 3 – 46 months). 9/25 (36%)
were MRD + after >2 years of remission (2 sCR, 7 VGPR) (median 46 months
range 24 – 186 months). As expected being in sCR was correlated with a low
MRD+ status 5/28 (18%) (2 patients after >5 years, 3 patients after <5 years).
Interestingly looking at long lasting remission, i.e. >5 years, the 4/14 patients
that resulted MRD+ displayed anmgUS like –plasmacell immunophenotype
(prevalence of normal plasmacells vs aberrant monoclonal) with a PCn/PCtot
ratio of 48%, 95%, 35%, 30%. CT/PET was positive in 22/56 patients. All
patients in sCR were CT/PET negative.
Summary/Conclusions: In conclusion NGF showed that MM patients with
long remission status can be considered disease free/cured with a high sensi-
tivity method. MM patients that display anmgUS–like phenotype after achieving
a CR can have long lasting remissions meaning disease control. Patients in
sustained CR after 2 years can have high percentage of MRD negativity. Larger
studies are warranted to identify patients who need treatment consolidation or
continuous treatment based on MRD+ status vs others who could stay treat-
ment free with social and economical benefits.
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THE NOTCH PATHWAY IN THE INTERPLAY BETWEEN MYELOMA CELLS
AND ENDOTHELIUM IN THE BONE MARROW NICHE
M.T. Palano1,*, N. Palatonova2, I. Saltarella3, S. Garavelli1, M. Colombo1,
F. Baccianti1, A. Neri2, R. Ria3, R. Chiaramonte1
1Scienze della Salute, 2Oncologia ed emato-oncologia, Università degli Studi
di Milano, Milano, 3Medicina interna e Oncologia clinica, Università di Bari,
Bari, Italy
Background: Angiogenesis is a hallmark of tumors, and it is a peculiar charac-
teristic in bone marrow (BM) of multiple myeloma (MM) patients. MM is a still
incurable disease that strongly depends on interactions with BM microenviron-
ment. Endothelium of MM patients displays malignant behavior as compared to
a healthy counterpart (1). MM displays a dysregulation of the Notch pathway
due to Jagged ligands and Notch receptors overexpression. This condition brings
to the generation of homotypic and heterotypic interaction loops that sustain
MM cells. Moreover, Notch pathway represents a bridge in the dialogue with
BM resident cells, including osteoclast and BM stromal cells (BMSCs), although
its role in the crosstalk of MM and endothelium is still to be clarified.
Aims: The aim of this study is to investigate Notch role in MM crosstalk with
endothelium exploiting 2D assays and 3D organoid systems to mimic tumor
microenvironment (TME).
Methods: The Notch ligands, Jagged1 and 2, were silenced in the MM cell line
RPMI8226 (RPMI8226shJAG1/2 ) using an inducible lentiviral vector carrying
two short hairpin RNAs targeting Jagged1 and 2. To mimic the endothelial com-
partment the human pulmonary arterial endothelial cells (HPAECs) were used
and for the stromal compartment, the GFP+HS5 cell line. Matrigel and wound
healing assays were set up to investigate Notch role in modulating respectively
the angiogenic potential of MM cells co-cultured with HPAECs and HPAEC
motility in response to MM-derived soluble factors. To develop a TME-like sys-
tem, a decellularized extracellular matrix (dECM) was used as a physiologic
scaffold for organoid generation. dECM was produced by treating murine fibrob-
last NIH3T3 with ascorbic acid and was loaded with cells for organoids gener-
ation. We evaluated apoptosis of MM cells in single culture and co-culture with
BMSCs or HPAECs by flow cytometry.
Results: Matrigel assay of HPAEC co-cultured with MM cells showed that direct
contact increased angiogenic potential of HPAEC to form a grid of tubes; this
effect is significantly reduced when HPAECs are co-cultured with
RPMI8226shJAG1/2 cells, indicating a key role of Notch signaling in endothelial
stimulation. Wound healing assay demonstrated that Notch signaling affects
HPAEC motility, since it is reduced when Jagged ligands are silenced. Con-
cerning the 3D-organoid generation, our results indicate that the handcrafted
dECM was a suitable scaffold. Moreover, apoptosis assays indicated that MM
cells displayed an increased survival when cultured in the presence of BMSCs,
that consistently with their recognized protective role; no significant difference
in MM cell apoptosis was observed in the presence of endothelial cells. On the
contrary, we have observed that endothelial cells were protected by MM cells
suggesting that MM cells improve angiogenesis by preventing endothelial cells
apoptosis.
Summary/Conclusions: These results indicate a novel role for Notch pathway
in MM-EC crosstalk suggesting that the Notch pathway activation in MM cells
can increase their proangiogenic potential. 3D-organoid mimics BM microen-
vironment and may be used as a novel tool to recapitulate the interactions of
BM and tumor cells beyond the animal models.
References
1. Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A, et al.
Endothelial cells in the bone marrow of patients with multiple myeloma.
Blood. 2003;102(9):3340-8.
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MIR-101-3P REGULATES BONE MARROW STROMA-INDUCED DRUG
RESISTANCE IN MULTIPLE MYELOMA CELLS BY TARGETING SURVIVIN
AND MODULATING CELL-CELL ADHESION
J. Abdi1,*, Y. Chen1, N. Rastgoo1, H. Chang2
1University Health Network, Toronto, Canada, 2Lab Hematology, University
Health Network, Toronto, Canada
Background: In multiple myeloma (MM), bone marrow stromal cells (BMSCs)
protect MM cells against cell death by direct or indirect interaction. This phe-
nomenon can partly explain de novo or acquired drug resistance in MM. Find-
ings of relevant studies indicate activation of some oncogenic or survival path-
ways including PI3K/mTOR, Ras/MAPK, NFkB and Wnt. However; the potential
regulatory mechanisms and druggable targets have not been clearly elucidated. 
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Aims: To understrand the role of stomal induced drug resistance and to identify
new therapeutic target in myeloma 
Methods: GFP-tagged human myeloma cell lines, 8226, U266 and MM.1s,
were co-cultured with MM patient-derived BMSCs or HS.5 cells with or without
BTZ for 24 h. MM cells in monocultures were used as controls. Co-cultures
were then applied to magnetic cell separation to isolate MM cells for down-
stream analyses including western blotting and mRNA or miRNA qPCR arrays.
Furthermore, percent apoptosis of gated GFP+ cells was determined using
FACS. In other experiments, MM cells were exposed to BMSCs pre-treated
with Brefeldin-A (BFA) or separated with a transwell (TW) insert. For functional
analysis, miR-101-3p was overexpressed using lentiviral transduction and sur-
vivin gene was silenced using siRNA. MM cells were then seeded on BMSCs
in presence or absence of BTZ. GFP fluorescence-based adhesion, cytotoxicity
and annexin-V/PI apoptosis were applied.
Results: qPCR arrays showed that BMSCs up- or down-regulated several
mRNAs and miRNAs in MM cells. Survivin (BIRC5) was confirmed to be con-
sistently upregulated in 3 MM cell lines at both mRNA and protein levels. In
contrast, miR-101-3p was confirmed to be significantly downregulated by stro-
ma in MM cells. Moreover, suppression of miR-101-3p or upregulation of sur-
vivin was reversed partially when BMSCs were pre-treated with BFA but highly
significantly when they were separated from MM cells with a TW insert. The
same rescue pattern was observed in apoptosis FACS analysis indicating that
direct cell-cell adhesion was more effective in BMSC-induced modulations in
MM cells. Next we identified that survivin was a direct target of miR-101-3p,
overexpression of miR-101-3p suppressed survivin mRNA/protein. As indicator
of involvement in stroma-mediated drug resistance, survivin and miRNA-101-
3p were not affected by BTZ in MM cell-BMSCs co-cultures compared to mono-
cultures. Furthermore, miR-101-3p overexpression or silencing of survivin
increased BTZ-induced apoptosis in MM cells in the absence or presence of
BMSCs significantly overcoming stroma-mediated drug resistance. To test
whether miRNA-101-3p could also regulate adhesion of MM cells to BMSC,
we found that miRNA-101-3p significantly reduced adhesion of MM cells to
HS.5 and primary MM BMSCs compared to scrambled control. This finding
suggests that miRNA-101-3p regulates cell adhesion-mediated drug resistance
(CAMDR) by modulation of MM-BMSC adhesion. 
Summary/Conclusions: Our results identify a mechanism whereby BMSCs
induce drug resistance in MM cells by upregulating survivin and downregulating
miRNA-101-3p which directly targets survivin. Overexpression of miRNA-101-
3p or silencing of survivin sensitizes MM cells to BTZ significantly overcoming
stroma-induced drug resistance. These findings disclose a role of survivin-miR-
NA-101-3p axis in regulation of BMSCs-induced BTZ resistance in MM cells,
thus provide a rationale to further investigate the anti-myeloma activity of miR-
101-3p in combination with BTZ as a potential therapeutic strategy in MM.
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ARQ-197, A SMALL-MOLECULE INHIBITOR OF C-MET, REDUCES
TUMOUR BURDEN AND PREVENTS TUMOUR-ASSOCIATED BONE
DISEASE IN A MURINE MODEL OF MYELOMA
A. Chantry1,*, E. Holly1, M. Fisher1, D. Jenny1, L. Michelle1, L. Darren1
1Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom
Background: The receptor tyrosine kinase c-Met, its ligand HGF, and their
signalling pathway, have all been implicated in the pathogenesis of myeloma.
In myeloma patients with elevated levels of HGF their prognosis is known to
be poor. Therefore, targeting these molecules or their pathway in such patients
may be of great benefit. We hypothesised that ARQ-197 (Tivantinib), a small
molecule c-Met inhibitor, would reduce myeloma cell growth and prevent myelo-
ma-associated bone disease in a murine model.
Aims: 1. Assess effects of ARQ-197 on myeloma cell proliferation. 2. Assess
effects of ARQ-197 treatment on tumour burden in murine models of myeloma
and 3. Assess effects of ARQ-197 treatment on myeloma bone disease in
murine models of myeloma.
Methods: In vitro we assessed the effects of ARQ-197 (0.1563 μM - 5 μM) on
myeloma cell proliferation, cytotoxicity and c-Met protein expression in the
JJN3 human cell line. In vivo we intravenously injected NOD/SCID-γ mice with
106 JJN3 cells and 1 week later treated mice with either ARQ-197
(200mg/kg/day, 5 times per week by oral gavage) or vehicle for 2 weeks.
Results: In vitro exposure of JJN3 cells to ARQ-197 (0.625 μM - 5 μM) resulted
in a significant inhibition of cell proliferation (p<0.0001) and an induction of cell
death (p<0.001), probably caused by significantly [SL1] reduced levels of phos-
phorylated c-Met. In vivo ARQ-197 treatment of JJN3 tumour-bearing mice
resulted in a significant reduction in tumour burden (p<0.001), where tumour
infiltration of the bone marrow was reduced by approximately 43% (96±4.9%
vehicle vs 55±20% ARQ-197 treatment). ARQ-197 treatment also significantly
prevented the formation of myeloma-induced bone lesions (P<0.001) and the
loss of trabecular bone (p<0.01) compared to vehicle treated JJN3-tumour
bearing mice. Dynamic histomorphometry showed ARQ-197 treatment pre-
vented significant decreases in the mineralising bone surface (p<0.001), the
mineral apposition rate (p<0.01), the bone formation rate (p<0.01), and pre-
vented complete loss of osteoblasts on the cortico-endosteal bone surface
compared to the vehicle group.
Summary/Conclusions: In summary, these results suggest that ARQ-197
could be a promising therapeutic in myeloma patients who express high levels





THE GENETIC LANDSCAPE OF THE MURINE 5T MODELS FOR MULTIPLE
MYELOMA
K. Maes1,*, B. Boeckx2, K. De Veirman1, E. Menu1, K. Vanderkerken1,
D. Lambrechts3, E. De Bruyne1
1Hematology and Immunology, Vrije Universiteit Brussel, Brussel, 2Department
of Oncology, VIB Center for Cancer Biology, 3Department of Oncology, VIB
Center for Cancer Biology, Leuven, Belgium
Background: Multiple myeloma (MM) is a plasma cell malignancy which
remains incurable in most cases. This is mainly attributed to the large genetic
and clonal heterogeneity between patients and within individual patients. The
mutational landscape of MM patients has led to the discovery of several potential
driver mutations and copy number alterations reflecting this genetic heterogene-
ity. Genetic lesions affecting RAS/MAPK and NF-KB pathways, apoptosis and
cell cycle signaling are the most commonly found in patients. Moreover, muta-
tions disturbing the DNA damage response are linked with poor prognosis.
Aims: The use of suitable murine MM models is important to gain understand-
ing of the functional consequences of the genetic heterogeneity observed in
patients. However, to date, the genetic landscape of murine MM models have
not been analyzed. Our aim of this study is to analyze the genetic landscape
of the 5T murine models for MM.
Methods: In this study, we used the 5T2, 5T33vv and 5TGM1 murine models
for MM. As control samples, we used C57Bl/KaLwRij and C57Bl/6J germline
DNA. We analyzed the copy-number alterations and the mutational landscape
using shallow whole genome sequencing and whole exome sequencing.
Results: Among the tested models, the 5T2 model displayed the most copy
number alterations. Over the entire genome, 11% and 17% showed copy num-
ber alterations for the 5T33vv and 5TGM1 of which 6% is shared reflecting
their clonal relationship. Overall, the copy-number alterations affects genes
involved in RAS/MAPK, PI3K/AKT1 and JAK/STAT signaling, DNA damage
response, cell cycle and epigenetic regulation. Exome sequencing revealed
the presence of 417, 407 and 314 non-synonymous mutations and 8, 14 and
24 indels in the 5T33vv, 5TGM1 and 5T2 models, respectively. Moreover, a
statistically significant overlap of mutated genes between the 5T33vv and 5T2
models and multiple myeloma patients from two large cohorts published by
Lohr et al. and Walker et al. was observed (p<1E-8). Similar to MM patients,
we identified damaging mutations in Trp53, Rb1, Pik3ca, Fat3, Kdm6a and
Nf1.
Summary/Conclusions: In summary, our results show that the disturbed
genetic landscape of the 5T models shows heterogeneity and a partial overlap
with multiple myeloma patients. The genetic defects affect pathways known to
be involved in multiple myeloma cell survival. The 5T models thus represent
reliable models to study the characterized genetic defects.
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CHARACTERIZING THE CONTRIBUTION OF BONE MARROW STROMA-
DERIVED IL-6 TO MYELOMA GROWTH AND RESISTANCE
T. Csikos1,*, H.-J. Prins1, E. Drent1, P. Poddighe2, S. Zweegman1, T. Mutis1,
R. Groen1
1Hematology, 2Clinical Genetics, VU University Medical Center, Amsterdam,
Netherlands
Background: The bone marrow niche is a specialized microenvironment,
which allows for the survival, growth and differentiation of hematopoietic stem
and progenitor cells. This niche also provides the optimal growth conditions for
hematological malignancies, such as multiple myeloma (MM). A complex inter-
action between cytokines, adhesion molecules, cell receptors and their ligands
provides the MM plasma cells with survival signals and contribute to therapy
resistance.
Aims: To unravel the role of the bone marrow mesenchymal stem/stromal cells
(BMMSCs) in MM cell growth, progression and drug resistance.
Methods: Hypothesizing that the interaction between MM cells and the BMMSCs
is bidirectional, we have compared BMMSCs from healthy individuals, mgUS,
and MM patients and used our “humanized” bone marrow-like model to charac-
terize the molecular impact of MM cells on BMMSCs. Finally, we have validated
targets by generating HS-5 knock-out lines using CRISPR/Cas9 targeting.
Results: Analyzing the BMMSCs of healthy individuals,mgUS, and MM
patients, as well as BMMSCs impacted by MM in our humanized bone mar-
row-like model, allowed us to confirm established disease biomarkers (e.g. IL-
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6, HGF, IGF and GDF15) and identify novel mediators of MM disease progres-
sion and bone disease. To further elucidate the role of IL-6 in BMMSC-induced
growth of MM plasma cells and drug resistance, we have established HS5 stro-
mal cell lines that upon CRISPR/Cas9 targeting have reduced or no expression
of IL-6. RNA sequencing analysis of these cells revealed IL-6 to be a master
regulator of cytokine production (e.g. IL-1B, CXCL8, CSF2 and CSF3). Disrup-
tion of the IL-6 gene did not result in a reduced growth rate of the IL-6 deficient
stromal cells as compared to wildtype. Using the compartment specific biolu-
minescent imaging co-culture system, where luciferase gene-marked MM cells
are co-cultured with non-marked stromal cells, we have documented a contri-
bution of the stromal cells to both growth and drug resistance to known
chemotherapeutics (e.g. bortezomib, doxorubicin) of MM cells. Using this same
co-culture system we compared wildtype and IL-6 deficient stroma. Although
disruption of IL-6 in the stromal cells resulted in a reduced proliferation of MM
cells and stromal cell mediated drug resistance, it did not entirely reverse these
stroma-mediated effects.
Summary/Conclusions: Taken together these data suggest that although IL-
6 is one of the most deregulated genes in MM-derived BMMSCs, it certainly is
not the sole contributor to BMMSC-induced MM cell growth and drug resist-
ance.
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THE PAN-PIM KINASE INHIBITOR, PIM447, POTENTLY SYNERGIZES WITH
POMALIDOMIDE PLUS DEXAMETHASONE IN PRECLINICAL IN VITRO
AND IN VIVO MODELS OF MULTIPLE MYELOMA
T. Paíno1,2,*, L. San-Segundo1,2, S. Hernández-García1,2, L. González-Méndez1,2,
E.M. Algarín1,2, M. Martín-Sánchez1, M.-V. Mateos2, M. Garayoa1,2, E.M. Ocio1,2
1Centro de Investigación del Cáncer (CIC-IBMCC), 2Complejo Asistencial Uni-
versitario de Salamanca-IBSAL, Salamanca, Spain
Background: PIM kinases are a family of serine/threonine kinases recently
proposed as therapeutic targets in multiple myeloma. Recent work from our
group has shown the dual antimyeloma and bone-protective effects of the pan-
PIM kinase inhibitor, PIM447, and its in vitro synergism with current standards
of care. Since myeloma remains an incurable disease, the preclinical evaluation
of new drug combinations is of utmost importance, in order to support the devel-
opment of future clinical trials. In this scenario, effective all-oral combinations
are particularly attractive.
Aims: The aim of the present work has been the evaluation of the efficacy and
mechanism of action of the all-oral triple combination PIM447 + pomalidomide
+ dexamethasone in preclinical in vitro and in vivo models of multiple myeloma.
Methods: in vitro cytotoxicity of PIM447, pomalidomide and dexamethasone
alone or in double and triple combinations was evaluated on myeloma cell lines.
The combination index (CI) was calculated with Calcusyn software based on
results from MTT assay. Effects on apoptosis and cell cycle were evaluated by
flow cytometry. Glucose uptake was analyzed by incubation with 2-NBDG. The
mechanism of action was explored by analysis of different protein levels by
western blot. Finally, a plasmacytoma model in CB17-SCID mice was employed
for in vivo studies.
Results: Triple combination PIM447 + pomalidomide + dexamethasone
showed a strong synergism (CI<0.3) in MM1S and RPMI-8226 cell lines. The
clear reduction of cell viability promoted by this combination was due to induc-
tion of apoptosis and cell cycle arrest at G0-G1 phase. Accordingly, cleavage
of caspase 3 and PARP, as well as reduction of cyclin D2 was observed by
western blot. In addition, triple combination inhibited mTORC1 as shown by
decreased levels of p4EBP1 and pS6RP. Interestingly, treatment with PIM447
+ pomalidomide + dexamethasone remarkably reduced the levels of the glucose
metabolism-associated enzime hexokinase II and also reduced glucose uptake
by cells. Finally, the efficacy of this combination was confimed in a plasmacy-
toma model in CB17-SCID mice, where it clearly reduced tumor growth as
compared to single and double treatments. 
Summary/Conclusions: Our preclinical data suggest that myeloma patients
could benefit from treatment with the triple combination PIM447 + pomalidomide
+ dexamethasone and would support future clinical trials with this combination.
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EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC
PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE
USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN
MULTIPLE MYELOMA
F. Costa1,*, D. Toscani1, A. Chillemi2, V. Quarona2, M. Bolzoni1, V. Marchica1,3,
R. Vescovini1, C. Mancini4, E. Martella4, N. Campanini4, C. Schifano5, S. Bonomini5,
F. Accardi1,5, A. L. Horenstein2, F. Aversa1,5, F. Malavasi2, N. Giuliani1,3,5
1Medicine and Surgery, University of Parma, PARMA, 2Medical Sciences and
CeRMS, University of Torino, TORINO, 3CoreLab, 4Pathology, 5Hematology
and BMT Center, Azienda Ospedaliero-Universitaria di Parma, PARMA, Italy
Background: Bone disease is the hallmark of multiple myeloma (MM). It is
known that MM cells express CD38 and that a recently developed human anti-
CD38 monoclonal antibody, Daratumumab (DARA), induces and mediates MM
cell killing. However, the expression of CD38 and other functionally related
ectoenzymes in the bone niche of MM patients and the potential effects of
DARA on bone cells are still unknown. 
Aims: The aim of this study was to define the expression profile of CD38,
CD31, CD39, CD73 and CD203a on MM and bone niche cells. Then, the effect
of DARA on bone cells was evaluated by in vitro osteoclastogenesis.
Methods: In order to evaluate the expression profile of CD38 and the ectoen-
zymes, we firstly performed immunohistochemical analysis on bone biopsies
in a cohort of 37 patients with MM and 14 with monoclonal gammopathy of
uncertain significance (MGUS). The same antigens were analyzed by flow
cytometry on primary MM cells, mesenchymal stromal cells (MSC), osteoblasts
(OB), monocytes and osteoclasts (OC). Then, we tested DARA effects, in the
presence or absence of All-trans retinoic acid, compared with human IgG iso-
type control, on OC differentiation from either CD138- cell fraction or purified
MM bone marrow (BM) CD14+ cells. We also investigated the effect of
microvesicles isolated from a MM cell line treated with DARA or the human IgG
isotype control, on OC differentiation.
Results: MM cells showed a high expression of CD38 and were positive for
CD31, CD39, CD73 and CD203a at variable levels. However, we did not find
any significant difference in the expression of CD38 and related ectoenzymes
between MM andmgUS patients. CD38 was expressed by monocytes and early
OC progenitors but not by OB, mature OC and MSC, that were positive for
CD73 and CD203a. Indeed, CD38 was lost during OC differentiation. Consis-
tently, we found that DARA reacts with CD38 expressed by monocytes and its
binding inhibits early in vitro osteoclastogenesis from total mononuclear cells.
All-trans retinoic acid treatment increased the inhibitory effect of DARA on OC
formation. 
Summary/Conclusions: Our data suggest that DARA inhibits osteoclastoge-
nesis, targeting monocytes and early progenitors. These observations provide
a rationale for the use of an anti-CD38 antibody-based approach as treatment
for MM-induced osteoclastogenesis.
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TRIM33 IS A POTENTIAL TUMOR SUPPRESSOR IN MULTIPLE MYELOMA
C.K. Johnston1,*, L.J. Crawford1, K.I. Mills1, A.E. Irvine1
1Centre for Cancer Research and Cell Biology, Queen’s University Belfast,
Belfast, United Kingdom
Background: Multiple myeloma (MM) continues to be an incurable plasma cell
neoplasm, regardless of recent therapeutic advances. The success of protea-
some inhibitors in MM validates the ubiquitin proteasome system (UPS) as a
therapeutic target. Using a UPS-specific microarray (PIQOR) we identified aber-
rant expression of an E3 ligase TRIM33 (tri-partite motif containing protein 33)
in MM. TRIM33 has previously been identified as a tumor suppressor in chronic
myelomonocytic leukaemia and hepatocellular carcinoma.
Aims: The aim of this study was to examine TRIM33 expression and to inves-
tigate its role as a potential tumor suppressor in MM.
Methods: Western blotting and qPCR were used to analyse TRIM33 expres-
sion at basal level and following knockdown in four MM cell lines representing
a range of MM translocations; JJN3 t(14;16), U266 t(11;14), KMS-18 t(4;14),
OPM-2 t(4;14). TRIM33 knockdown was performed using shRNA pLKO lentivi-
ral plasmids. CellTiter-Glo® was used to determine cell viability following knock-
down and drug treatments. Partek ®Genomics Suite was used to analyse pub-
lically available datasets to look at TRIM33 expression and correlation with sur-
vival in subsets of newly diagnosed MM; GSE19784 (N=320) and GSE2658
(N=551). qPCR was used to validate the changes in expression of the TRIM33
gene signature.
Results: Compared to normal bone marrow, lower expression of TRIM33 was
observed at both gene and protein level (p=0.03) in the t(4;14) cell lines, KMS-
18 and OPM-2. Conversely, expression was found to be high in the non t(4;14)
cell lines, JJN3 (p=0.001) and U266 (p=0.015). Knockdown of TRIM33 expres-
sion did not alter cell viability in the t(4;14) cell lines. However, cell viability was
significantly increased in JJN3 (P<0.04) and U266 (P<0.05). Analysis of a pub-
lically available dataset, GSE19784, showed lower levels of TRIM33 present
in patients with a t(4;14) compared to other MM subtypes, particularly t(6;14)
(p≤0.004) and hyperdiploid cluster (p≤0.03). Low TRIM33 expression has also
been associated with poor overall survival (GSE2658; p=0.00034). Forty-seven
genes associated with TRIM33 expression in non t(4;14) MM were identified;
these genes were analysed using QUADrATiC tools connectivity mapping to
identify FDA approved agents predicted to enhance the TRIM33 gene signature.
One of the top enhancers identified was the tyrosine kinase inhibitor (TKI) Ima-
tinib. The OPM-2 cell line showed greatly increased sensitivity to Imatinib com-
pared to other cell lines (IC50: 0.8 μM vs 20 μM). Similar effects were observed
with second generation TKIs, Dasatinib (IC50: 0.003 μM vs >1μM) and Nilotinib
(IC50: 0.08 μM vs >1μM). An increase in genes associated with TRIM33 expres-
sion in non t(4;14) subtypes was also observed following Imatinib treatment.
Summary/Conclusions: We have shown that TRIM33 exhibits lower expres-
sion in t(4;14) cell lines, compared to non t(4;14) cell lines and that knockdown
of TRIM33 increased the viability of non t(4;14) cell lines. This suggests that
TRIM33 may act as a tumor suppressor in MM and that expression is dysreg-
ulated in a subset of MM. Connectivity mapping identified Imatinib as an
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enhancer of the TRIM33 signature that potently decreased the viability of the
OPM-2 cell line. This study suggests that enhancing the TRIM33 gene signature
could potentiate the tumor suppressive effect of TRIM33 and identify novel
therapies for this subset of MM. 
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Background: Increasing amount of evidence indicates that deregulation of
long non-coding RNAs (lncRNAs) is a common feature of cancer and therefore,
its investigation may uncover new molecular oncogenic mechanisms. In mul-
tiple myeloma (MM), altered expression of small number of lncRNAs has been
associated with decreased disease-free and overall survival, suggesting that
these elements may play a more important role in MM than previously antici-
pated. Nevertheless, an extensive high-throughput analysis that characterizes
the deregulation of lncRNAs in MM has not yet been performed.
Aims: We aim to characterize the lncRNA transcriptome of MM and its hetero-
geneity, and determine whether altered lncRNAs have a functional involvement
in this disease.
Methods: Paired-end strand-specific RNA sequencing (ssRNA-seq) was per-
formed in 38 purified plasma cell (PC) samples from MM patients, as well as
in 5 tonsil PCs (TPCs) and in 3 bone marrow PCs (BMPCs) of healthy donors
as controls. We also performed ssRNA-seq of populations from B cell differen-
tiation (Naïve, Germinal Center, Memory and PC). To study the heterogeneity
of lncRNAs expression we performed sample level enrichment analysis (SLEA),
in which each individual lncRNA was compared to BMPCs. To determine the
epigenetic regulation of lncRNAs we used whole-genome bisulfite sequencing
and CHIP-seq. shRNA-mediated knockdown using 2 different shRNAs and
MTS (cell proliferation) and annexin V (cell death) assays were utilized to study
the functional effect of lncRNA overexpression. 
Results: We identified 40.552 novel lncRNAs in MM samples that were present
in at least 3 of the 38 patients. Principal component analysis demonstrated
that TPCs and BMPCS cluster separately, suggesting that, in spite of being
the same cell type, their transcriptomes are very different. We observed that
the expression of lncRNAs was more heterogeneous than that of coding genes.
More importantly, SLEA showed 11.067 lncRNAs that were overexpressed and
5.601 underexpressed in >40% of patients. Thus, the number of deregulated
genes analyzed by SLEA was much larger than the 70 lncRNAs that appeared
as deregulated when all MM were compared to BMPCs, demonstrating the
relevance of studying the heterogeneity in this disease. To determine the func-
tional role of heterogeneously altered lncRNAs in the biology of MM cells we
focused on the study of LINC-SMILO (Specific Myeloma INtergenic LOng non-
coding RNA), a lncRNA that it is overexpressed in ~ 40% of MM patients and
not at different stages of B-cell differentiation. DNA methylation analysis demon-
strated that CpGs located upstream of LINC-SMILO showed a significant
hypomethylation inmgUS, that was even more pronounced in MM samples.
We also have observed a gain of active chromatin modifications in the promoter
region of LINC-SMILO in MM patient samples. These data suggest that epige-
netic mechanisms, namely DNA hypomethylation and the gain of active histone
modifications, may be the cause of LINC-SMILO overexpression in MM. Knock-
down of LINC-SMILO in 3 different cell lines (MM.1S, MM.1R and KMS-11)
resulted in reduced proliferation and induction of apoptosis, indicating this lncR-
NA is essential for the survival of MM cells.
Summary/Conclusions: All together, these data demonstrate that alteration
of lncRNAs is an important and unexplored feature of MM. Moreover, overex-
pression of LINC-SMILO is required for the survival of MM cells and could rep-
resent a potential therapeutic target for the treatment of this disease.
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Background: The tyrosine kinase Eph receptor A3 (EphA3) has recently
emerged as a potential therapeutic target, since it resulted to be overexpressed
in many cancers, including some hematological malignancies (Keane et al.
2012). Furthermore, EphA3 has been found overexpressed not only in neo-
plastic cells, but also in the microenvironment of different human cancers,
where its targeting inhibits tumor growth by disrupting supportive stroma and
vasculature (Vail et al. 2014).
Aims: Due to the absence of relevant information about the role of EphA3 in mul-
tiple myeloma (MM), we aimed to evaluate the expression of this molecule in pri-
mary bone marrow plasma cells (BMPCs) from MM patients and MM cell lines
compared to healthy controls (HCs). In addition, using a “loss of function” approach
by mRNA silencing and an anti-EphA3 monoclonal antibody (EphA3mAb), we
studied in vitro plasma cells (PCs) viability and movement. Finally, we analysed
the in vivo effects of EphA3mAb in a MM mouse xenograft model.
Methods: EphA3 mRNA and protein where investigated in 15 MM BMPCs, 11
MM cell lines and 10 HCs by qRT-PCR and flow cytometry. The effects of
EphA3 targeting by lentiviral RNA silencing (shRNA) and anti-EphA3mAb on
PC trafficking and viability were studied by adhesion assay on fibronectin and
on bone marrow stromal cells (BMSCs), invasion assays and proliferation MTS
assay, respectively. Gene expression profiling (GEP) was performed in shEp-
hA3 versus shControl cells. Furthermore, the effects of EphA3mAb were
analysed in a MM xenograft model by measuring tumor size and by assessing
angiogenesis, proliferation and apoptosis rate on tumor biopsies using immuno-
histochemistry (anti-CD31, anti-ki67 and TUNEL assay, respectively). Statistical
significance was determined by the t-test or One-way ANOVA analysis.
Results: EphA3 was found overexpressed in primary MM BMPCs and MM
cell lines when compared with HCs (figure 1A-B). The EphA3 loss of function
by siRNA and by EphA3mAb significantly inhibited in vitro the ability of MM
PCs to adhere to fibronectin, to BMSCs and to invade (figure 1C-E), without
affecting cell proliferation and viability (data not shown). GEP showed that
knockdown of EphA3 modulated some molecules that regulate adhesion,
migration and invasion processes. Importantly, the treatment with EphA3mAb
in vivo significantly reduced tumor size and inhibited angiogenesis, as revealed
by decrease of CD31+ vessels at immunohistochemistry (data not shown).
Figure 1.
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Summary/Conclusions: Our findings suggest that EphA3 is a novel regulator
of MM PC trafficking, in part via effects on adhesion and invasion; its targeting
using EphA3mAb inhibits tumor growth, possibly by reducing angiogenesis,
though other possible mechanisms of tumor death cannot be excluded. These
data, together with the favourable clinical properties of a humanized EphA3mAb
reported in a phase I trial on acute myeloid leukemia and myelodysplastic syn-
drome (Swords et al. 2016), support EphA3 targeting as a new potential ther-
apeutic opportunity for MM that would warrant to be further investigated.
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Background: Multiple Myeloma (MM) is a genetically heterogeneous and com-
plex disease with widely diverging survival times from months to years. Ampli-
fication of locus 1q21 (amp1q21) is among the most commonly reported genetic
abnormalities in MM, but its prognostic value remains unclarified.
Aims: To define the frequency of amp1q21 in MM and its correlation with other
chromosomal abnormalities, clinical course and prognosis.
Methods: In 134 patients (pts) with newly diagnosed MM from December, 2009
to March, 2016, 67 male and 67 female, median age 57 years (30-81), we per-
formed FISH with locus-specific and centromere DNA probes (XL 1p32/1q21,
XL IGH plus, XL t(11;14), XL t(4;14), XL t(14;16), XL t(14;20), XL t(6;14), XL
cMYC BA, XL 5p15/9q22/15q22, XL P53 (MetaSystems), D13S25 (Cytocell).
Induction therapy with bortezomib-based courses was initiated for 131 pts, 3
pts with smoldering MM remained under observation. Response was evaluated
according to the IMWG criteria for 127 pts, because 4 pts died in induction. 48
pts were underwent ASCT. The median follow-up of group was 19.3 months
(3,2 – 77,4). Progression was diagnosed in 69 pts, in 12 of them FISH-analysis
was performed also in disease progression.
Results: Chromosomal aberrations were revealed in 133 of 134 (99%) pts.
TIgH/14q32 were detected in 42.5% (57/134), hyperdiploidy in 57.5% (77/134),
hypoploidy in 2.4% (3/134) pts. In 11.2% (15/134) a concurrent tIgH/14q32 and
a trisomy were found. The IgH translocations t(11;14), t(4;14), t(14;16), t(14;20),
t(6;14) were observed at a frequency of 16.4%, 12.7%, 3.7%, 2.2%, 0.7%
respectively, chromosomal partner is not found in 6.7%. Del(13q) was detected
in 40.3% (54/134), del(17p) in 12.7% (17/134), tсMYC/8q24 in 17.2% (23/134).
Amp1q21 was detected in 39.6% (53/134). We identified 3 copies of 1q21 in
32 (60.4%) and>3 copies 1q21 (4-7) in 21 (39.6%) pts. Cases with amp1q21
had a high incidence of del(13q) (OR=2.71 (1.32-5.55); p=0.006) and t(4;14)
(OR=4.49 (1.47-13.51); p=0.005), as well as higher LDH levels (OR=2.27 (1.09-
4.72); р=0.027). From 12 pts investigated in progression amp1q21 was found
in 9 pts (75%): in 2 cases amp1q21 was not found at diagnosis and was
revealed in disease progression only; in 7 cases - amp1q21 was detected at
diagnosis and in progression, and its copy number did not change. The differ-
ence in response after induction between pts with or without amp1q21 was not
statistically significant: CR – 11.8% versus 14.5%; VGPR –39.2% versus 27.6%;
PR –37.2% versus 27.6%; therapy resistance 11.8% versus 30,3% (p=0.07).
Pts with amp1q21 had significantly worse 5-year overall survival (OS) (43.5%
vs 79.4%; p=0.07). According to copy number of 1q21 the 5-year OS pts car-
rying 3 or >3 copies of 1q21 were 67.3% and 20.9% (р=0.0016) (Figure 1). On
multivariate analysis>3 copies of amp1q21 (HR=4.29, p=0.0094), tcMYC/8q24
(HR=6.51, p=0.0082), del(17p) (HR=3.46, p=0.007) were found to be an inde-
pendent adverse predictors of shorter OS.
Figure 1.
Summary/Conclusions: Our results show that amp1q21 has a significant
impact on OS MM pts in cases of more than 3 copies of locus only. In cases of
3 copies of 1q21 OS pts is comparable with OS in group without amp1q21.
Amp1q21 can appear in the course of MM, therefore FISH-analysis of locus
1q21 should be performed at diagnosis, as well as in disease progression.
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Background: Immune paresis is commonly identified in patients with plasma
cell dyscrasias (PCD). Often, in newly presenting multiple myeloma (MM), it is
associated with intractable infections for which the patient first seeks medical
help. Furthermore, recent evidence suggests the importance of assessing levels
of bone marrow (BM) derived B cells for risk stratification of MM patients as
reduced levels of B-cells in the BM have been associated with poorer outcomes
and reduced progression free survival1. This cellular measure of adaptive
immune function (ie: B cell enumeration) is, however, seldom analysed in the
peripheral blood (PB) of patients with PCD.
Aims: This study was designed to examine measures of the adaptive immune
response in PCD patients, by measuring relative and absolute numbers of T, T
cell subset, B, NK and NKT cells at different stages of PCD, and to determine
if the PB B-cell component can act as a surrogate marker for B cell enumeration
in the BM.
Methods: PB and BM lymphocyte subset analysis was performed on samples
obtained from a range of PCD patients (n=70) using directly conjugated mon-
oclonal antibodies (MAB) and multicolour flow cytometry, carried out on a FAC-
SAria III cell sorter (BD, Oxford, UK). Serum protein electrophoresis was per-
formed to identify and quantify paraprotein, and uninvolved Ig levels were quan-
tified immunoturbidometrically. sFLC were estimated using the Freelite assay
on the SPAplus instrument (Binding Site, Birmingham, UK). 
Results: Data is presented on 102 PB samples obtained from 70 PCD patients
at different stages of disease, including monoclonal gammopathy of undeter-
mined significance (MGUS), smoldering myeloma (SMM), and MM at diagnosis
(MMD), throughout treatment (MMT) and at relapse (MMR). Quantification of
circulating lymphocyte subsets showed reduced, absolute, numbers of B cells
(56/102), T cells (19/102), TH cells (32/102), CTLs (17/102), NK cells (32/102)
and NKT cells (72/102). Furthermore, these reduced B cell levels were more
frequently seen in the MMD and MMT groups (50% of samples) compared with
the other PCD groups (10-25% of samples). Lymphocyte subset analysis was
also performed on paired PB and BM samples from 14 patients with MM and
a significant, positive, correlation was seen between relative numbers of B cells
in both PB and BM (p<0.0001, r2=0.94). No clearcut correlations were found
between reductions in uninvolved Ig or sFLC levels, and numbers of cells
involved in the adaptive immune response.
Summary/Conclusions: The results presented here are further evidence of
immune paresis in PCD with specific effects seen at the cellular level. The high-
est frequency of reduction was in B lymphocytes and NKT cells, in keeping
with reduced levels of circulating uninvolved Ig levels, followed by T cells, par-
ticularly TH cells which have a crucial role in B cell Ig production. Relative B cell
levels in BM were significantly correlated with B cell levels in PB and we suggest
that monitoring of B cell levels in the PB of PCD patients may serve as a sur-
rogate assay for enumeration of B cells in BM.
References
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Background: Bone disease is a hallmark of multiple myeloma (MM) and tar-
geting osteoclasts (OCs) to alleviate bone destruction is a component of the
standard care for MM. CD26 is a 110-kDa cell surface glycoprotein with DPPIV
enzyme activity and has well-defined roles in T cell activation and several tumor
developments, including malignant lymphoma. However, little is known about
the role of CD26 in regulating bone remodeling.
Aims: In this study, we examine the CD26 expression in human normal OCs
and OCs of MM patients. We explore the function of CD26 in osteoclastgenesis
(OCG) and investigate the effects of humanized anti-CD26 monoclonal antibody
(CD26mAb) on human OCG. We further define the molecular targets of CD26
signaling cascade in OCG and explore the therapeutic potential of CD26mAb
for treating MM.
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Methods: Human BM-MNCs derived from normal human subjects or MM
patients were cultured with M-CSF plus sRANKL with or without CD26mAb for
OC formation for TRAP staining and functional assay. To assess the mecha-
nisms of action of CD26mAb on OCG, RANK signaling proteins were examined
by immunoblotting. 
Results: CD26 is expressed on normal human OCs and is intensely expressed
on activated OCs in MM. M-CSF and sRANKL induced human OC differentia-
tion, in association with CD26 expression on monocyte-macrophage lineage
cells. CD26 expression was accompanied by increased phosphorylation of
MKK3/6 and p38MAPK, which is crucial for early human OC differentiation with
its downstream activation of microphthalmia-associated transcription factor
(mi/Mitf), which plays an important role in OC functions. CD26mAb decreased
the number of multinucleated OCs (>3 nuclei) by TRAP/CD26 staining and
down-regulated the secretion of TRAP-5b and type 1 collagen. It decreased
the size of OCs and the number of nuclei per OC, with significantly defective
bone resorption activity. It was revealed that in the presence of CD26mAb,
when it bound to CD26 on OC precursor cells, only MKK3/6-p38MAPK phos-
phorylation pathway was specifically, rapidly inactivated and subsequently, its
downstream mi/Mitf phosphorylation was persistently inhibited. Thus, OC mat-
uration with its bone resorption was impaired by suppressing the expression
of TRAP and OC fusion proteins. In contrast, MKK3/6-p38MAPK-mi/Mitf was
not phosphorylated at all in mature OCs after RANKL stimulation, regardless
of the absence or presence of CD26mAb. These results suggest that CD26mAb
blocked RANKL induced p38MAPK phosphorylation in OC precursor cells, but
not in OCs. The activation of other MAPKs including ERK and SAPK/JNK, or
NFκB was rapidly induced in response to RANKL both in OC precursor cells
and OCs, regardless of the absence or presence of CD26mAb. Moreover,
CD26mAb did not directly affect mature OC functions. Next, although
CD26mAb did not demonstrate direct inhibition of proliferation of MM cells, to
further investigate the role of CD26 in MM cells in the BM, co-cultures of 11
MM cell lines with CD26-stained OCs were performed. We examined the
expression of CD26 in MM cells. Although CD26 expression was only slightly
detected in any of MM cell lines in mono-culture, CD26 expression level was
upregulated in all MM cell lines, co-cultured with OCs by flow cytometry and
immunohistochemistry. CD26 protein level in these cell lines was also increased
by immunoblotting or ELISA. To further explore the CD26 expression in the
BM of MM patients, we performed immunohistochemical staining on decalcified
biopsy specimens. CD26/CD138 positive plasma cells were detected around
CD26 positive OCs and certain endothelial vascular cells in several cases.
Anti-myeloma efficacy of CD26mAb on MM cells, co-cultured with OCs was
also revealed.
Summary/Conclusions: Our data imply that the blockade of CD26 signaling
with CD26mAb impairs the development of human functional OCs. Targeting
CD26 in both OCs and MM cells with CD26mAb may be a promising novel
therapeutic strategy in MM-associated bone disease and MM progression.
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Background: IDO is an intracellular enzyme proceed the essential amino acid
tryptophan metabolism. Accumulation of tryptophan derivatives such as kynure-
nine blocks antigen-specific T-cell proliferation and induces T-cell death. A
recent study indicated that kynurenine was an endogenous ligand of aryl hydro-
carbon receptor (AhR), which is a ligand-dependent transcription factor well
known to generate biological responses to dioxins. We previously showed that
both IDO expression by tumor cells and high serum kynurenine levels correlate
with poor prognosis in non-Hodgkin lymphoma patients. We also revealed that
tumor IDO activity can inhibit CD19-specific CAR T-cell therapy through the
action of tryptophan metabolites (Blood. 2015; 125(25): 3905-3916).
Aims: Therefore, we now focus on the AhR in T-cells to escape from IDO-pos-
itive tumor microenvironment.
Methods: We collected PBMCs from healthy blood donors, and bone marrow
(BM) samples from multiple myeloma (MM) patients at first diagnosis. The cells
were activated with anti-CD3 and anti-CD28 Abs. We measured the expression
of AhR in activated T-cells using by flow cytometry. We then studied the effect
of kynurenine on the proliferation and apoptosis of T-cells. To evaluate the
effect of inhibiting AhR in T-cells, we used AhR inhibitor (CH-223191). Next, to
assess the functional effects of tryptophan metabolites on the T-cells, we cocul-
tured T-cells with GFP-transduced wild-type Raji cells or IDO-transduced Raji
cells. After 72 hours, cells were stained with CD8 antibody to distinguish tumor
(GFP+ CD8–) and T-cells (GFP- CD8+).
Results: We found that the range of AhR expression in activated T-cells were
from 4.5% to 38%. We found that kynurenine significantly inhibited the prolif-
eration of T-cells with high expression of AhR. The percentage inhibition with
kynurenine 25µM was 33%. While T-cells with low expression of AhR were not
inhibited with even 50µM of kynurenine. We found that kynurenine was also
associated with increased the apoptosis of T-cells with high AhR, as assessed
by Annexin-V staining (percent Annexin-V positive and 7-AAD negative cells
in 0 and 25 µM kynurenine was 11.8% and 36%, respectively). We found that
CH-223191 could blocked the inhibitory effects of kynurenine on T-cells. We
found that the percentage of T-cells with high AhR in culture with IDO negative
and positive Raji cells was 46.7% and 61.4%, respectively, while the percentage
of T-cells with low AhR was 41.6% and 39.4%. These data showed that only
T-cells with high AhR were inhibited at IDO-positive tumor microenvironment.
Next, we could generated the activated T-cells from 10 of 12 BM samples from
MM patients. We found that there was a positive correlation between the
expression of AhR and the proportion of plasma cells in BM (r=0.76, P=0.04)
and clinical stage of MM. The mean expression of AhR in T-cells of stage2 and
stage3 were 7.3% (3.3-11.6) and 19.5% (11.3-26.6), respectively.
Summary/Conclusions: Kynurenine produced by IDO, induce inhibitory signal
in T-cells through the AhR. Anti-PD-1 and anti-CTLA-4 therapies, which block
directly the inhibitory signal in T-cells, have been getting some clinical benefits
against such as melanoma and Hodgkin lymphoma. Therefore, the AhR in T
cells might be a target for IDO-positive hematological malignancies.
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Background: Due to the immunoglobulin production, multiple myeloma (MM)
plasma cells are dependent on the unfolded protein response process (UPR),
which controls protein production and ensures its proper translation and folding.
A study by Michallet et al (2011) showed that knockdown of one of the three
well-known arms of the UPR, PERK (protein kinase R (PKR)-like ER kinase)
in MM cells resulted in autophagic cell death. This outcome indicated the impor-
tant role of PERK activation for the metabolic shift of plasma cell to myeloma
cell but also its ability to impede the apoptotic effect. In this study we used a
small ATP competitive molecular inhibitor, GSK2606414, that acts by targeting
PERK enzyme activity in its inactive DFG conformation at the ATP-binding
region, while displaying ≥385 fold selectivity over c-kit, Aurora B, BRK and
many other kinases. 
Aims: In this study we aimed to use a small ATP competitive molecular inhibitor,
GSK2606414, that acts by targeting PERK enzyme activity in its inactive DFG
conformation at the ATP-binding region, while displaying ≥385 fold selectivity
over c-kit, Aurora B, BRK and many other kinases. 
Methods: We initially screened 25 CD138+ MM patients and 6 human myelo-
ma cell lines (HMCLs) for PERK mRNA expression. Our results showed that
PERK mRNA is highly expressed in almost all patients (5-10 fold higher than
the mean PERK expression of HMCLs).
Results: To test the effect of GSK2606414 on the proliferation of MM cells, 4
HMCLs were treated with different doses of GSK2606414 at two time points
(24 and 48 hours). Treatment of cells with 3-30μM GSK2606414 resulted in a
dose-dependent inhibition of cell proliferation in all HMCLs ranging for 20-95%
reduction of proliferative activity, thus, indicating the dependency of these cells
on PERK activity. Treatment with GSK2606414 at 20μM in H929 and L363
HMCLs for 24 hours resulted 25% and 15% increase in apoptotic cells by
Annexin-PI staining respectively compared to the untreated cells. However,
the most important finding was a significant synergistic effect of GSK2606414
with bortezomib in these cells. Specifically when H929 and L363 cells were
treated with 5nM bortezomib in combination with 20μM GSK2606414, syner-
gistic effect was seen where apoptotic cells reached 99% and 77% respectively,
compared to bortezomib-treated cells (87% and 42% respectively). In addition,
the effect of GSK2606414 in combination with bortezomib in the proliferation
of H929 and L363 cells was examined. As seen in the apoptosis assay, pre-
treatment with GSK2606414 for 2 hours prior to bortezomib treatment resulted
in 40% and 30% reduced cell proliferation in H929 and L363 respectively com-
pared to bortezomib only treated cells. Under ER stress conditions, the activa-
tion of ATF6 and PERK/eIF2α leads to the induction of ATF4 translation and
results in the upregulation of CHOP. To determine the gene target effects of
GSK2606414, ATF4 and CHOP mRNA expression levels were determined in
H929 cell line after 24 hour of treatment. Treatment with GSK2606414 alone
did not alter the expression levels of CHOP but reduced more than 50% the
expression levels of ATF4. When combined with bortezomib CHOP and ATF4
levels were reduced 20% and 60% respectively while treatment with bortezomib
alone increased the levels of CHOP and ATF4 by 50-100%. Changes in RNA
expression of 84 UPR-related genes were analyzed in H929 cells. Specifically
H929 cells were pre-treated with GSK2606414 and then subjected to ER stress
conditions by treatment with tunicamycin (TM). After 24 hours of treatment, 50
genes were found to be transcriptionally regulated by 5-fold in response to TM-
induce UPR activation. Thirty of these genes (ERN1, ERN2,XBP1, DDIT3,
CEBPB, PPP1R15A, etc.) were downregulsted by >5 fold, whereas 10 of these
genes (HERPUD1, EIF2AK3, CREB3L3, HSPA2, HSPA1B, etc.) were upreg-
ulated similarly.
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Summary/Conclusions: In conclusion, given the on-target pharmacological
effects of PERK inhibitor on MM, development of PERK inhibitors may offer a
therapeutic advantage that would affect MM pathogenesis and treatment.
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ENVIRONMENTAL CONTROL OF PLASMA CELL FITNESS IN MULTIPLE
MYELOMA: MALIGNANT CO-OPTATION OF ARGININE AS NOVEL
IMMUNO-METABOLIC CHECKPOINT
A. Romano12,*, J. M. Garcia Manteiga3, V. Simeon4, L. Parrinello2, L. Canziani1,
E. Milan1, M. Ghizzinardi1, D. Tibullo2, C. Giallongo2, P. La Cava2, F. Cremas-
co1, C. Conticello5, P. Musto4, F. Ciceri6, F. Di Raimondo2, S. Cenci1
1Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano,
2Division of Hematology, Azienda Ospedaliera Policlinico e Vittorio Emanuele
di Catania, Catania, 3Center for Translational genomics and BioInformatics,
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in Vulture (Pz), 5Division of Genetics and Cell Biology, Azienda Ospedaliera
Policlinico e Vittorio Emanuele di Catania, Catania, 6Department of Oncohe-
matology, San Raffaele Scientific Institute, Milano, Italy
Background: The bone marrow (BM) environment plays a crucial role in the
incurable plasma cell (PC) malignancy multiple myeloma (MM). Our previous
work showed that autophagy is essential to sustain long-lived PC fitness, reg-
ulating Blimp-1, immunoglobulin (Ig) production and ATP availability (Pengo,
2013) and that MM is addicted to the autophagy receptor SQSTM1/p62 (Milan,
2015). Among putative pro-tumoral players are immunosuppressive BM-derived
high-density neutrophils (HDNs), but their role in MM is unknown. 
Aims: We hypothesized that in MM HDNs sustain PC fitness sustaining p62
through environmental arginine deprivation.
Methods: We integrated diverse unbiased and hypothesis-driven approaches:
(1) gene expression profiles (GEP) of patient-derived circulating HDNs (60 MM,
30mgUS, 30 healthy controls), (2) metabolomic profiling by UHPLC/GC-MS of
ad hoc-collected BM and peripheral plasma (16 MM, 17 smoldering MM,
30mgUS, 29 controls), and (3) functional and expression in vitro studies on
human MM cell lines. We validated our observations in primary MM cells using
bioinformatic analysis of transcript expression levels detected by RNA sequenc-
ing (RNAseq) available from the open-access, public clinical and molecular
database, the CoMMpass Researcher Gateway (RG, (https://research.themm-
rf.org, v IA8, n=549).
Results: In vitro, selective and progressive arginine deprivation (range 1000-
0 µM) in four MM cell lines (MM.1S, U266, OPM2 and RPMI8826) activated
the GCN2/CHOP axis, resulting in increased p62 and Blimp-1 expression,
increased ATP availability and immunoglobulin production. Conversely, stable
lentiviral p62 silencing significantly reduced Blimp-1 and ATP, and led to com-
plete extinction of MM cell lines within 10 days of culture. Bioinformatic analysis
of MMRF-Encompass trial data showed a positive correlation between p62 and
Blimp-1 expression (r2=0.92, p<0.0001). Both high Blimp-1 and p62 transcripts
predicted shorter progression-free survival at 24 months (4.56 months versus
11.6 months, p<0.0001).
Summary/Conclusions: Taken together, our findings disclose a novel envi-
ronmental circuit co-opted by MM evolution, whereby immunosuppressive
HDNs sustain PC cell fitness through arginine depletion to increase p62 and
Blimp-1 via the GCN2/CHOP pathway.
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ESTIMATED GLOMERULAR FILTRATION (EGFR) CALCULATED BY
CKD-EPI EQUATION COMBINED WITH THE INTERNATIONAL STAGING
SYSTEM PROVIDES A POWERFUL PROGNOSTIC MODEL FOR EARLY
MORTALITY IN MYELOMA PATIENTS 
E. Katodritou1,*, V. Palaska1, E. Giannopoulou1, S. Papadaki1, A. Gerofotis1,
N. Karampatzakis1, K. Keramidioti1, E. Verrou1, K. Kokoviadou2, I. Batsis3,
I. Sakellari3, A. Anagnostopoulos3, M.-A. Dimopoulos4, P. Konstantinidou1,
E. Terpos4
1Hematology Department, Theagenion Cancer Hospital, 2Hematology Depart-
ment, Papageorgiou General Hospital, 3Hematology Department and Bone
Marrow Transplantation Unit, G. Papanikolaou General Hospital, THESSA-
LONIKI, 4Department of Clinical Therapeutics, National and Kapodistrian Uni-
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Background: During the last decades, the introduction of autologous trans-
plantation and novel agents has improved early mortality rates (EM, henceforth
defined as death within one year after diagnosis) in Multiple Myeloma (MM).
However, the incidence of EM remains high. Data relating to prognostic factors
for EM in MM are limited.
Aims: The aim of this study was to explore for possible prognostic factors for
EM, which could be a useful tool for planning treatment strategy in MM.
Methods: We have studied the medical records of 479 patients with MM (M/F:
258/221, median age: 68 years, range 29-88, IgG: 269, IgA: 123, light chain:
72, non-secretory: 15), diagnosed and treated in our Department between Jan-
uary 2001 and January 2016; 86 patients (18%) had EM. Comparisons of
patients’ characteristics between the EM group and the rest of the patients,
were performed with χ2, one-way ANOVA and Mann Whitney U test. Prognostic
factors for EM and overall survival (OS) were studied by using logistic regres-
sion and cox regression analysis, respectively; OS was plotted by Kaplan-
Meier; p<0.05 was considered as statistically significant.
Results: Patients with EM were more often men with a higher median age;
hemoglobin, platelets and albumin were lower whereas β2 microglobulin, lactate
dehydrogenase (LDH) and calcium were higher in the EM group compared to
the rest of MM patients (p<0.05). The percentage of patients with abnormal
estimated Glomerular Filtration (eGFR) calculated by chronic kidney disease
epidemiology collaboration (CKD-EPI) creatinine equation (<40ml/min/1.73m2)
was higher in EM group compared with the rest of the patients (69% vs 17%,
p<0.001). In accordance with the International Staging System (ISS), advanced
MM stage (i.e. ISS3) was observed more often in the EM group compared to
the rest (65% vs 31%, p<0.001). High risk cytogenetics including t(4;14),
t(14;16) and del17p were present in 48% of patients in the EM group vs 21%
of the others (p<0.001). The causes of EM included infection/sepsis: 54%,
relapsed/refractory disease: 26%, other causes: 6%. Univariate logistic regres-
sion analysis demonstrated that ISS, revised ISS (R-ISS), abnormal LDH,
hemoglobin <10g/dl, high risk cytogenetics, and CKD-EPI <40ml/min/1.73m2
were independent prognostic factors for EM. In the multivariate analysis ISS
and abnormal eGFR were the only independent prognostic factors for EM.
When we incorporated ISS and eGFR in a single prognostic model (CKD-
EPI/ISS) we identified 3 distinct prognostic groups: 1) low risk group including
patients with ISS1 and CKD-EPI ≥40ml/min/1.73m2, 2) high risk group including
patients with ISS3 and CKD-EPI <40ml/min/1.73m2 and 3) intermediate risk
group including patients that did not fit in either low or high risk group. The inci-
dence of EM in each group was 8.1% 39% and 15.3%, respectively (OR: 2.8,
95% CI:1.9-4.1, p<0.001). Multivariate cox regression analysis of prognostic
factors for OS in the whole population demonstrated that CKD-EPI/ISS model
was the strongest independent prognostic factor for OS (HzR: 0.38, 95% CI:
0.23-0.6, p<0.001).
Summary/Conclusions: Based on our data, the combination of eGFR esti-
mated by CKD-EPI with ISS (CKD-EPI/ISS) represents a powerful independent
prognostic model for EM and OS, in the era of novel agents. The markers con-
stituting eGFR and ISS are cheap and available for most of MM patients, there-
fore the CKD-EPI/ISS prognostic model may have a wide application. Never-
theless, the establishment of CKD-EPI/ISS model requires further validation.
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ACTIVATED AND EXPANDED NATURAL KILLER CELLS FROM MULTIPLE
MYELOMA PATIENTS DESTROY TUMOR DRUG RESISTANT CELLS AND
CLONOGENIC TUMOR CELLS
A. Leivas1,2,*, I. Rapado1,2, L. Fernández1, A. Pérez-Martínez3, J.J. Lahuerta2,
J. Martínez-López1,2
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Research Center, 2Hematology, Hospital Universitario 12 de Octubre, 3Pedi-
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Background: Multiple myeloma (MM) remains an incurable disease. Novel
therapeutic strategies targeting drug resistant cells (DRC) and clonogenic tumor
cells (CTC) are needed. Our group has conducted a phase I clinical trial with
activated and expanded autologous NK cells (NKAEs) in patients with refractory
MM with a relevant clinical effect. Likewise, it has been possible to discriminate
DRCs in MM by side population (SP) detection. 
Aims: The aim of this study was to characterize DRC and to check the activity
of NKAEs against these DRCs and CTCs while preserving the hematopoietic
progenitor cell.
Methods: Flow cytometry of the side population was performed by Dye Cycle
Violet efflux detection to characterize DRC of MM cell lines and bone marrow
samples from MM patients. The side population was purified by sorting and
characterized by RNAseq. NK cells from MM patients’ peripheral blood were
obtained and cocultured with the genetically modified K562-mb15-41BBL cells
in order to obtain NKAE cells. The activity of NKAE cells against SP was eval-
uated by time lapse microscopy and the activity against CTCs was evaluated
by methylcellulose assay. In vitro safety against CD34+ progenitors was eval-
uated by time-resolved fluorescence cytotoxicity with europium-TDA and cul-
tures of methylcellulose of healthy bone marrow CD34 + progenitors.
Results: SP cells from both cell lines and samples from different stages of MM
showed overexpression of stemness markers. Patient NKAE cells were shown
to have much higher adhesion, migration and detection capacity of MM tumor
cells than NK cells from the same patient. After SP purification by sorting, NKAE
cells were able to detect and destroy the SP cells without significant differences.
NKAE cells were also able to destroy CTCs from different MM cell lines. Cyto-
toxicity studies revealed that NKAE cells did not destroy mononuclear cells from
healthy bone marrow, even at maximum ratios of 32:1 the mean cytotoxicity
was 1.85% (range 0 - 4.47%). Experiments on CD34+ hematopoietic progenitor
cell cultures also showed that NKAE cells do not destroy CD34+ clones from
healthy bone marrow, confirming the safety of NKAEs.
Summary/Conclusions: SP cells have molecular characteristics of the tumor
stem cell compartment in MM. Likewise, NKAE cells from MM patients could
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destroy drug resistant MM cells and clonogenic tumor cells with high efficiency,
preserving CD34+ hematopoietic cells, and thus constitute an effective and
safe therapy against MM.
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UNMASKING THE RETROTRANSPOSON-ORCHESTRATED PRODUCTION
OF SOLUBLE RANKL IN MULTIPLE MYELOMA CELLS
S. Papamichos1,*
1Laboratory of General Biology, Aristotle University of Thessaloniki Medical
School, Thessaloniki, Greece
Background: Growing evidence suggest that production of soluble receptor
activator of nuclear factor-kappa B ligand (sRANKL) directly by myeloma cells
is causally related to generalized bone loss in multiple myeloma (MM). Notably,
sRANKL may be produced either by proteolytic cleavage of membrane-bound
RANKL or by alternative splicing of TNFSF11 gene (TNFSF11 variant 2, sRAN-
KL mRNA). Recent analysis argues against proteolytic processing of the mem-
brane-bound form being the main mechanism of sRANKL production by myelo-
ma cells. Accumulative data indicate that sRANKL mRNA presents a restricted
transcriptional pattern, namely is expressed predominantly in malignant cell
types. Accordingly, sRANKL mRNA (over)expression in primary MM cells and
human MM cell lines has been validated in three independent studies. Fur-
thermore it was recently demonstrated that sRANKL mRNA proximal promoter
and first exon are of retroviral origin, residing within a large genomic cluster of
transposable elements (TEs). 
Aims: To unmask the TE-shaped transcriptional and epigenetic apparatus
impelling the expression of sRANKL mRNA in a cell type- and cell context-spe-
cific manner. 
Methods: RepeatMasker software was used to reveal the presence of inte-
grated TEs in the genomic segment comprising TNFSF11. TNFSF11 RNA-Seq
data, generated by the GTEx project across 51 normal human tissues, were
analyzed via GTEx Portal. TNFSF11 RNA-seq data from 4 bone marrow sam-
ples and 8 white blood cells samples, generated from the PRJEB4337 and
PRJNA182351 BioProjects, were analyzed via the NCBI portal. TNFSF11 tran-
scription factor (TF) ChIP-seq data were downloaded from the UCSC Genome
Browser Database. Data on TNFSF11 proximal promoter methylation status in
63 cell lines were downloaded from the HAIB Methyl450 ENCODE track. 
Results: RNA-Seq data from 51 normal human tissues show that sRANKL
mRNA is expressed exclusively in testis, which is in accordance with the retro-
viral origin of the transcript. Data analysis from the PRJEB4337 and PRJ-
NA182351 BioProjects further validates the null expression of sRANKL mRNA
in normal human bone marrow and white blood cells. Methylation status of
sRANKL mRNA promoter in 5 lymphoblastoid cell lines (LCLs) signifies that
the retroviral promoter remains heavily methylated in these cell types. TNFSF11
TF ChIP-seq data show that 5 of 161 TFs can bind to the TE-derived sRANKL
mRNA promoter region. Four of the five TFs (EBF1, PAX5, IKZF1, and PU.1)
bind to this genomic segment exclusively in LCLs, signifying a cell-type specific
transcriptional regulation. Notably, all 4 TFs are known to play a major role in
normal and/or malignant lymphopoiesis. Furthermore, IKZF1 and PU.1 repre-
sent direct targets of immunomodulatory drugs (IMiDs) for down-regulation.
Summary/Conclusions: Transcription of sRANKL mRNA is driven by a retro-
viral promoter which remains heavily methylated, thereby inactive, in normal
lymphocytes. Epigenetic derepression of this promoter during the course of
myelomatogenesis resulting in the (over)expression of sRANKL mRNA by
myeloma cells represents a plausible scenario. Should the IKZF1 and the PU.1
TFs act as enhancers of sRANKL mRNA expression, directly contributing to
upregulation of sRANKL production in MM, is a tantalizing hypothesis that war-
rants further investigation especially because this type of transcriptional boost
could be intercepted following treatment with IMiDs. That Lenalidomide treat-
ment downregulates the amount of sRANKL in the serum of patients with MM
through inhibiting PU.1 expression (Breitkreutz et al., Leukemia 2008) is in
accordance with the above and further raises the interest on the mechanisms
promoting the anti-osteoclastogenic properties of IMiDs.
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THE RATIO OF PATHOLOGICAL PLASMOCYTES, ASSESSED BY
8-COLOR FLOW CYTOMETRY, PREDICTS OF RISK OF EVOLUTION IN
MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE AND
SMOULDERING MULTIPLE MYELOMA
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Background:mgUS and SM are defined by the presence of a monoclonal
immunoglobulin and bone marrow infiltration by plasmocytes, with no associ-
ated symptoms of Multiple Myeloma (MM). The risk of development of symp-
tomatic MM justifies identification of the factors associated with an increased
risk of evolution. Flow cytometric quantification of the ratio of bone marrow
pathological/total plasmocytes (PP/PT) has been reported to be predictive in
this context (Pérez-Persona E. et al. Blood 2007; 110: 2586–2592).
Aims: We undertook to test this in a single center study.
Methods: All patients undergoing bone marrow evaluation following identifi-
cation of a monoclonal peak (at diagnosis or during follow-up) during a 7.5year
period with a diagnosis ofmgUS (n=154) ou SMM (n=56) and at least 6 months
follow-up were analysed by 8-color FC (including 11 antibodies) from fresh
whole bone marrow. PP/PT ratios ≥95% were considered high risk. Disease
evolution was indicated by a necessity to treat.
Results: The 210 PP/PT ratios were on average 77% (10-100). Amongst the
154mgUS patients, 24 had a ratio >95%, of which 8 (33%) evolved, compared
to 9/130 (7%) with a ratio below 95%. Only 2 of these 8mgUS demonstrated
other high risk factors (a non-IgG monoclonal peak or a peak at >15g/L).
Amongst SMM patients, 22/30 (73%) patients with a high ratio evolved, of
which 9 (41%) had a non-IgG peak, compared to 10/26 (38%) evolution in
SMM with low PP/PT ratios. The risk of evolution to active MM was significantly
higher in patients with a PP/PT ≥ 95%, both in themgUS (p<0.0001) and in the
overallmgUS + SMM group (p<0.0001). The delay to treatment start was sig-
nificantly longer in the PP/PT <95% group, in both themgUS (p<0.0001) and
overall (p=0,0004) groups. There was a discordance between PP/PT ratio and
disease evolution in 11% (17/154)mgUS patients and 23% (48/210) of the over-
all group but no other FC markers associated with an increased risk of evolution
could be identified.
Summary/Conclusions: We confirm the clinical value of a simple, rapid, two-
tubes FC quantification of the proportion of pathological plasma cells in the
evaluation of the risk and kinetics of disease evolution inmgUS and SMM. It’s
use allows identification of patients which require more frequent follow-up.
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ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE
CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION
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Background: The tumor microenvironment is rich in extracellular mono- and
di-nucleotides (ATP, NAD) which are metabolized by cell surface ectoenzymes
to produce adenosine (Ado), a nucleoside involved in the control of inflamma-
tion and immune responses. Multiple myeloma (MM), a plasma cell malignancy
that develops within the bone marrow (BM) niche, overexpresses CD38, a mol-
ecule with complex functions. As a nucleotide-metabolizing ectoenzyme, CD38
catalyzes the initial disassembly of NAD (to cADPR and ADPR), which is fol-
lowed by adenosinergic activity, provided that CD38 is operating in the pres-
ence of other ectoenzymes (CD203a and CD73).
Aims: To demonstrate that adenosinergic pathways contribute to customize
homeostasis in MM.
Methods: Evaluation of the expression of adenosinergic ectoenzymes was
assessed by immunohistochemical and flow cytometric analysis on cell lines,
and primary myeloma cells and BM biopsies from patients with MM or with
asymptomatic monoclonal gammopathies (MGUS and SMM). Having investi-
gated the cell antigenic pattern, the adenosinergic functionality of BM cell pop-
ulations and of microvesicles (MVs) isolated thereof was analyzed by HPLC to
evaluate Ado production.
Results: Using BM plasma aspirates, we showed that NAD within the MM
niche is able to activate a discontinuous (i.e., multicellular) pathway for Ado
production that relies upon CD38, CD203a and CD73 (or TRAP) ectonucleoti-
dases, depending on the environmental pH. Ado production was likely due to
interactions taking place between myeloma and other cells lining the BM niche.
The results of a pilot study revealed a parallel between Ado levels and disease
progression, and patients with symptomatic MM usually have higher levels of
Ado. This is reflected statistically in the International Staging System (ISS) for
MM. Preliminary studies showed that MVs deriving from MM patients are pecu-
liar in that i) they are enriched for CD38, CD203a and CD73 ectoenzymes and
ii) are able to generate Ado. These MVs may adhere or fuse with neighboring
cells, egress the BM niche and eventually reach the bloodstream. Thus, one
aspect of the dynamics of available anti-CD38 antibodies for MM therapy is
the role of polarization and release of the MVs after treatment. In vitro studies
showed that MV/IgG antibody complexes can be captured by Fc receptor-
expressing cells.
Summary/Conclusions: 1) We hypothesize that MM cells deploy the
adenosinergic metabolic strategy to silence immune effectors during the pro-
gression of MM from indolent monoclonal gammopathy to symptomatic overt
disease; 2) While these observations may only be correlative and a reflection
of the tumor burden, Ado levels in the BM plasma may prove to be a useful
marker of myeloma progression; 3) The therapeutic IgG on the surface of
adenosinergic MVs may acts as a link determining the final destination of MVs.
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TREATMENT OPTIMIZATION FOR MULTIPLE MYELOMA: SCHEDULE-
DEPENDENT SYNERGISTIC CYTOTOXICITY OF POMALIDOMIDE AND
CARFILZOMIB ON AN IN VITRO AND EX-VIVO MODEL
E. Borsi1,*, M. Martello2, B. Santacroce2, V. Solli2, R. Termini2, E. Zamagni2,
P. Tacchetti2, L. Pantani2, S. Rocchi2, M. Cavo2, C. Terragna2
1Fondazione Umberto Veronesi (FUV), Milano, 2Department of Experimental
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Background: In recent years significant progress has been made in the under-
standing of Multiple Myeloma (MM) biology. These advances have translated
into the development of new drugs and a different approach to treatment, which
has ultimately translated into an unprecedented rate of complete remissions.
Immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) form the
backbone of modern MM treatment,but new and more targeted treatments are
under development and are being tested in the context of clinical trials.Poma-
lidomide (POM) is a third-generation IMiD with immunomodulatory, antiangio-
genic, and direct anti-MM activities, and greater in vivo potency than its sister
Lenalidomide. Carfilzomib (CAR) is a second generation irreversible PI that is
structurally and mechanistically distinct from Bortezomib. Preclinical study sug-
gested that the timing and dosing schedules of IMiDs in combination with PIs
treatment is critical, proposing a first evidence that established treatment reg-
iments need to be carefully re-evaluated to maximize the anti-tumor effects.
Aims: In this study we tried to optimize the anti-MM therapy using the new
class of agents of IMiDs and new generation PIs, by evaluating a possible syn-
ergistic effect between POM and CAR.
Methods: For the purpose of this study we used five bona fide MM cell lines
(MM1.S, OPM-2, NCI-H929, KMS12.BM and U266), a human bone marrow
stromal (BMS) cell line (HS-5 cells) and primary samples from newly diagnosed
MM patients. Apoptosis analysis was done up to 48h after administration of the
first drug. For each drug, three different concentrations were used: low dose,
intermediate dose and high dose. Since the BM microenvironment is a complex
and active system, with potential contributions of both physical adhesion and
soluble factors, we used three experimental conditions to differentiate these
interactions: 1) MM cells cultured in complete medium, 2) MM cells suspended
in medium conditioned in the prior presence of BMSCs, or 3) MM cells co-cul-
tured with BMSCs in a transwell system.
Results: Using the median effect method of Chou Talalay, we evaluated the
combination indices for simultaneous and sequential treatment schedules, and
we found that the schedule of administration is important to maximize the syn-
ergistic effects. Indeed, schedule-dependent synergistic cytotoxicity was
demonstrated for the combination of IMiDs and PIs and a maximal apoptosis
consistently observed in IMiDs pre-exposure schedule. The superiority of this
schedule was maintained throughout BM microenvironment models. Our data
overall suggest that the administration of IMiDs before PIs can improve efficacy.
Clinical trials are needed to investigate the most effective schedule, which could
be to start the administration of IMiDs a day before PIs to increase cells killing.
Summary/Conclusions: Schedule-dependent synergistic cytotoxicity was
demonstrated for the combination of CAR and POM and a maximal apoptosis
consistently observed in POM pre-exposure schedule. The superiority of this
schedule was maintained throughout BM microenvironment models using low
dosage of both drugs. Whilst the clinical efficacy of CAR and POM combinations
has been demonstrated, the synergistic cytotoxicity may be further exploited
by using optimized schedule. Utilizing such a schedule with IMiDs pre-treatment
may improve the depth and duration of response of MM patients both as upfront
therapy and in the relapsed/refractory setting.
Myeloma and other monoclonal
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ASSESSMENT OF THE IMPACT OF POST-AUTOLOGOUS STEM CELL
TRANSPLANT MAINTENANCE THERAPY ON SURVIVAL OUTCOMES IN
PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE
COMMUNITY-BASED CONNECT MM REGISTRY
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Background: Randomized phase 3 clinical trials have shown that maintenance
therapy after autologous stem cell transplant (ASCT) can extend time to progres-
sion, progression-free survival (PFS) and overall survival (OS) for patients (pts)
with newly diagnosed multiple myeloma (NDMM) (Sonneveld, J Clin Oncol, 2012;
McCarthy, N Engl J Med, 2012; Attal, N Engl J Med, 2012; Palumbo, N Engl J
Med, 2014; Attal, ASCO, 2016). Connect MM is a largely community-based, US
prospective observational cohort study designed to characterize diagnosis, treat-
ment patterns and outcomes in pts with NDMM in clinical practice.
Aims: The Connect MM registry was used to assess impact of maintenance
therapy on survival outcomes in pts with NDMM receiving ASCT.
Methods: Adult pts with NDMM were eligible to enroll in the registry within 60
days of diagnosis. Pts were enrolled in 2 sequential cohorts and were treated
at the clinician’s discretion as per standard of care. Cohort 1 pts receiving induc-
tion and ASCT were included in the analysis and characterized into 4 mainte-
nance regimen subgroups: no maintenance, lenalidomide (LEN)-based main-
tenance, bortezomib (BORT)-based maintenance, and LEN+BORT mainte-
nance. Duration was from 100 days post-ASCT (no maintenance group) or
start of maintenance until progressive disease, death, discontinuation, or data
cutoff of January 7, 2016. End points were PFS, second PFS, OS, and safety.
An exploratory analysis of the impact of baseline characteristics on survival
outcomes was performed.
Table 1.
Results: A total of 1493 pts were enrolled in Cohort 1 from Sep 2009 to Dec
2011; 1450 were treated, 81% (n=1173) in a community setting. Of those, 432
(29%) met analysis criteria. Median follow-up was 39.3 months. Median age
was 60 y (range, 24-78); 60% were men; and 86% were white. A total of 165
pts did not receive maintenance. Of 267 pts receiving maintenance, 213 (80%)
received LEN-based maintenance; 30 (11%) received BORT-based mainte-
nance; and 16 (6%) received LEN+BORT maintenance. Of the maintenance
groups, only data from LEN maintenance is presented; small sample sizes in
the other maintenance groups limited interpretation. The median treatment
duration was 35.2 months for pts who received LEN maintenance and 26.1
months for those who did not receive maintenance. Median PFS was signifi-
cantly longer for pts who received LEN maintenance vs no maintenance (50.3
months vs 30.8 months; hazard ratio [HR]=0.62 [95% CI: 0.46, 0.82); P=.0009;
Table). OS was also significantly improved for pts who received LEN mainte-
nance vs no maintenance (HR=0.54 [95% CI: 0.36, 0.83]; P=.0050). Second
PFS (PFS for second-line treatment) was similar for both LEN and no mainte-
nance groups. Exploratory analyses showed generally similar PFS and OS
improvements across subgroups (age, ECOG status, International Staging Sys-
tem stage, risk group, and induction regimen). No new safety signals were
observed.
Summary/Conclusions: In this observational study, post-ASCT LEN mainte-
nance therapy significantly improved PFS and OS compared to no maintenance.
These improvements appeared to be independent of induction regimen. Pre-
liminary analysis of second PFS suggests no adverse impact of maintenance
treatment on the efficacy of second-line therapy. These data, from a largely com-
munity-based setting, support results from randomized phase 3 trials.
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DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRE-
TREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE
MYELOMA
A. Lakshman1, J. Abeykoon2, S. Kumar1, V. Rajkumar1, T. Kourelis1, F. Buadi1,
D. Dingli1, L. Martha1, W. Gonsalves1, A. Dispenzieri1, R. Kyle1, Y. Lin1,
R. Go1, R. Warsame1, M. Hobbs1, A. Fonder1, Y. Hwa1, S. Hayman1,
S. Russell1, N. Leung1, M. Gertz1, P. Kapoor1,*
1Division of Hematology, 2Internal Medicine, Mayo Clinic, Rochester, United
States
Background: Daratumumab-based Combination Therapies (DCT) with borte-
zomib (V)/ lenalidomide (R)/ pomalidomide (P) and dexamethasone (d) have
shown exceptional activity in relapsed and/or refractory multiple myeloma
(RRMM) in trials. Experience outside of trials since the approval of Daratu-
mumab (D) in 2015 is limited.
Aims: We aimed to review the outcomes of patients who received DCT at our
institution.
Methods: Records of RRMM patients seen at Mayo Clinic, MN from December
2015 –December 2016 were reviewed. Patients who received ≥ 1cycle of DCT
were included. Time-to-event analyses were done from date of starting DCT
using Kaplan Meier method. Common terminology criteria for adverse events
v4.0 were used to grade toxicities.
Results: Of 130 patients, 59% were males and median age at DCT initiation
was 67 (43-93) years, ECOG performance score was ≥2 in 29%. Patients were
classified as mSMART high (22%), intermediate (22%) or standard (56%) risk.
Median time from diagnosis to initiation of DCT was 51.3 (5-156) months, and
median number of prior therapies was 4 (1-14). Eighteen (14%) of patients
were refractory to prior daratumumab monotherapy. Fifty-three (41%), 34 (26%)
and 25 (19%) received DPd, DRd and DVd respectively. Eighteen (14%)
patients received ‘other’ DCT. Median time to first response (≥ PR) was 3.1
months (95% CI 2.1-4.6). Overall response rate was 46%, [complete remis-
sion-2%, very good partial remission-18%, partial remission-26%]. Minimal
response was seen in 17%, with clinical benefit rate of 62%. Median estimated
follow up from initiation of DCT was 5.5 months (CI 4.2-6.1). The median dura-
tion of response was 6.1 months [CI 5.1- not reached (NR)]. Median progres-
sion free survival (PFS) was 5.5 months (CI 4.1-7.8) (figure A) and median
time to next therapy (TTNT) was 5.9 months (CI 4.6-9.4) (figure B). Median
PFS for DPd, DRd, DVd and other DCTs were 4.6 (CI 2.7-NR), 7.8 (CI 5-NR),
3.9 (CI 2.1-NR) and 3.9 (CI 2.8-8.2) months, respectively (p=0.3). Median over-
all survival (OS) from starting DCT was NR (CI 11.4-NR) (figure C). Median
PFS for quadruple refractory (n=28) MM was 2.8 months (CI 2.2-5.3) vs 5.9
months (CI 4.9-NR) for the rest (p=0.008) (figure D). Grade 3 or higher hema-
tological toxicities were seen in 42% of patients. Other toxicities included infec-
tions (37%), fatigue (31%), infusion reactions (16%) and diarrhea (10%).
Figure 1.
Summary/Conclusions: DCT are effective in RRMM, but the PFS remains
short, particularly in quadruple refractory patients, reflecting the challenges
encountered in managing heavily-pretreated, and often less fit patients, in rou-
tine practice. 
E1241
IMPACT OF METFORMIN USE IN THE OUTCOMES OF MULTIPLE MYELOMA
PATIENTS POST STEM CELL TRANSPLANT
N. Duma1,*, J. Vera-Aguilera1, J. Paludo1, Y. Wang1, T. Anagnostou1,
A. Fonder1, F. Buadi1, S. Kumar1, M. Lacy1, S. Hayman1, A. Dispenzieri 1,
M. Gertz1, D. Dingli1
1Hematology, Mayo Clinic, Rochester, United States
Background: Multiple myeloma (MM), a monoclonal plasma cell disorder, is
one of the most common hematologic malignancies in the US. In preclinical
studies, metformin demonstrated plasma cells cytotoxicity. However there is
lack of studies translating the effect of metformin into the clinical setting. 
Aims: Assess the clinical effect of metformin in patients with MM.
Methods: All MM patients who underwent stem cell transplant (SCT) at the
Mayo Clinic Rochester from 2007 to 2012 were reviewed. Patients were
grouped based on metformin use. Initial diagnosis at our institution and ≥12
months of follow up were required. Kaplan-Meier method and Cox regression
were used for time-to-event and multivariate analysis.
Results: Out of 687 patients, 78 (11.4%) patients were using metformin at the
time of MM diagnosis. Baseline characteristics in the metformin and no-met-
formin groups were similar. Median metformin dose was 2000mg daily and
median duration of metformin use from MM diagnosis was 22 months. Patients
on the Metformin group achieved higher rates of complete response after SCT
(41% vs 29% p<0.02). Median progression-free survival (PFS) after SCT was
longer in the Metformin group, 31.3 months (95% CI: 10.4-52.2) vs 16.6 months
in the no-metformin group (95%CI: 14.5-18.7) p<0.04. There was a trend
toward longer overall survival in the Metformin group, but it was not statistically
significant (170 vs 106 months, p<0.10). In a multivariate analysis of metformin
use, age, sex, international staging system (ISS), LDH and cytogenetics/FISH,
the former was an independent predictor of PFS after SCT (OR: 0.38, 95%CI:
0.20-0.68, p<0.001).
Figure 1.
Summary/Conclusions: Metformin use was associated with a better progres-
sion-free survival and higher complete response rates after SCT in our MM
cohort. A trend toward better overall survival was also noted in the Metformin
group. Larger studies are needed to enhance our understanding of the clinic
effect of metformin on MM.
E1242
COMPARING WHOLE BODY MRI WITH PET-CT IMAGING AT DIAGNOSIS
OF MYELOMA
J. Vidler1,*, G. Havariyoun2, G. Vivian3, I. Walker1, M. Streetly1, K. Cuthill1,
R. Benjamin1, N. Mulholland3
1Department of Haematological Medicine, 2Department of Medical Engineering
and Physics, 3Departments of Radiology and Nuclear Medicine, King’s College
Hospital, London, United Kingdom
Background: Imaging in the diagnosis of myeloma is a rapidly developing
field. First line imaging has traditionally been a skeletal survey with plain films,
however new guidelines recommend whole body imaging to aid the diagnosis
of plasma cell disorders. The International Myeloma Working Group recom-
mend low-dose whole body computerised tomography (LDWBCT), PET-CT or
whole body magnetic resonance imaging (WBMRI) as initial imaging modali-
ties.
Aims: To compare WBMRI with PET-CT as initial imaging modalities at diag-
nosis of myeloma or plasmacytoma.
Methods: Both WBMRI and PET-CT were performed at diagnosis of myeloma
or a plasmacytoma in 33 patients presenting to King’s College Hospital, Lon-
don. The scans were reviewed independently by two Consultants in Radiology
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and Nuclear Medicine, looking for focal bone lesions, bone marrow pattern and
incidental findings. Details of the patients’ demographics, myeloma diagnosis
and treatment were collected from the medical records. 
Results: Of the 33 patients, 24 were male. The median age was 64 years(
range=43-86 years). One patient had a solitary plasmacytoma, the other 32
had myeloma (21 IgG, 3 IgA, 2 non-secretory, 4 light chain disease, 2 biclonal
myeloma). Most had ISS stage I disease with a median paraprotein at diagnosis
of 17 (range 0-52.6). 21 patients had a bone marrow plasma cell burden of 10-
60%, 10 patients >60% and 2 were unknown. Sixteen patients were diagnosed
with smouldering myeloma and a ‘watch and wait’ policy was adopted. Eleven
patients were treated with chemotherapy, 4 were entered into a clinical trial,
one was offered palliative care and one was referred to our centre for autograft.
WBMRI identified a focal lesion of disease in 30% of patients compared with
36% by PET-CT. This was not a statistically significant difference (p=0.18). In
addition there was no statistically significant difference between PET-CT & MRI
in detecting <3 or >3 lesions (p=0.705 and p=0.083 respectively). The apparent
diffusion coefficient (ADC) at vertebrae L5 (using diffusion weighted MR imag-
ing) was measured. This showed a strong correlation with the degree of bone
marrow infiltration by plasma cells (r=0.64). An ADC of <600mm2/s had a neg-
ative predictive value of 93% for a bone marrow plasma cell infiltrate of >60%.
There was also a significant difference (p=0.012) in the ADC between those
with smoldering myeloma and those with symptomatic disease. It was noted
that 9 scans resulted in incidental findings including pneumonia, adrenal lesions
and one case of colorectal cancer.
Summary/Conclusions: We have shown no difference in PET-CT and WBMRI
in detecting a myeloma defining focal bone lesion, or providing prognostic esti-
mate of burden of disease. Using MRI, a measure of the ADC at vertebrae L5
has been shown to be a semi-quantitative parameter that correlates with bone
marrow plasma cell infiltration and distinguished between those with smoul-
dering and symptomatic disease. In addition it is noted that whole body imaging
has led to incidental findings of further pathology, including an unrelated malig-
nancy, which may lead to useful clinical information or to further investigations
and imaging which may not be needed.
E1243
PERSISTENCE OF MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER
FLOW CYTOMETRY CAN HINDER RECOVERY OF ORGAN DAMAGE IN
PATIENTS WITH AL AMYLOIDOSIS
P. Milani1,*, M. Massa1, M. Basset1, F. Russo1, P. Berti2, A. Foli1, O. Annibali2,
G. Palladini1, G. Merlini1
1Department of Molecular Medicine, Amyloidosis Research and Treatment Cen-
ter, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia,
2Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular
Therapy, Research Unit, Università Campus Bio-Medico di Roma, Rome, Italy
Background: In multiple myeloma, Minimal Residual Disease (MRD) demon-
strated by multiparameter flow cytometry (MFC) identifies subjects with signif-
icantly shorter survival among those who attain complete response (CR). The
role of MRD in AL amyloidosis has not been assessed so far. 
Aims: In the present study, we assessed the MRD by MFC in patients with AL
amyloidosis who attained CR.
Methods: CR was defined as per current criteria (negative serum and urine
immunofixation and normal free light chain ratio). For flow cytometry studies
bone marrow samples were processed following the Euro Flow Bulk Lysis Stan-
dard Operating Protocol and stained with the EuroFlowIMF MM MRD panel. At
least 5x106 events were measured using a FACSCanto II (USA) instrument.
Data were analyzed using the Infinicyt software (Spain). Patients were identified
as having residual disease if a discreet population of clonal plasma cells com-
prising ≥50 events was identified (10-5 limit of detection).
Results: Twenty-eight patients were tested (7 were found to have relapsed at
the time of MRD assessment with monoclonal components detectable and
MRD+) and 21 satisfied current criteria for CR. Nineteen (90%) had renal and
9 (44%) had cardiac involvement at diagnosis. More than 2 lines of therapy
were required to achieve CR in 7 subjects. Median time to CR was 10 months
(range: 3-82). Five patients (62%) had achieved cardiac response and 9 (50%)
renal response at the time of CR. The median time from CR to MRD was 30
months (range: 6-148), this was not different in the MRD positive vs negative
patients. Flow cytometry identified MRD in 9 patients (43%). A median of 1089
(range 256-2500) corresponding to 0.04% (range 0.02-0.3%) plasma cells with
abnormal phenotype were detected in patients MRD+. No differences in organ
involvement, cardiac and renal stage, type of therapy, number of treatments,
and organ response at the time of CR was found between the two groups.
However, a further improvement of cardiac function compared to the time of
CR was observed in all 5 evaluable MRD- patients and in none of the 2 MRD+
patients (P=0.047). Compared to the time of CR, renal response was obtained
in 7 MRD- subjects (84%) and in 4 (50%) MRD+ (P=0.153). Overall, further
improvement of cardiac or renal function after CR was significantly associated
with absence of MRD (P=0.012).
Summary/Conclusions: This proof-of-concept study indicates that 43% of
patients with AL satisfying current criteria for CR have detectable MRD. MRD
positivity could in part explain persistence of organ damage is patients in CR.
A validation study in a larger cohort is ongoing. The possible impact of MRD
should be considered in trials aiming at increasing organ response rate in
patients in CR.
E1244
RATES OF PERIPHERAL NEUROPATHY (PN) IN PATIENTS WITH
RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED
WITH CARFILZOMIB VS COMPARATORS IN PIVOTAL PHASE 3 TRIALS
R. Niesvizky1,*, V. Hungria2, P.J. Ho3, A. Suvorov4, D. White5, D. Ben-Yehuda6,
L. Zhou7, K. Iskander7, L. Rosiñol8
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Camperdown, Australia, 4Hematology Department, First Republican Clinical
Hospital of Udmurt Republic, Izhevsk, Russian Federation, 5Dalhousie Univer-
sity and QEII Health Sciences Centre, Halifax, Canada, 6Kiryat Hadassah,
Jerusalem, Israel, 7Amgen Inc., Thousand Oaks, United States, 8Institut d’In-
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Background: PN is a doselimiting toxicity for some anti myeloma agents,
such as the proteasome inhibitor bortezomib (V). 
Aims: Carfilzomib (K), a novel irreversible proteasome inhibitor associated with
a low incidence of PN, was evaluated in two recent phase 3 studies in RRMM
patients.
Methods: This analysis evaluated PN rates in ASPIRE (K [27mg/m2] lenalido-
mide [R]-dexamethasone[d] [KRd] vs Rd in relapsed or refractory MM; Stewart
2015) and ENDEAVOR (Kd [K 56mg/m2] vs Vd in RRMM; Dimopoulos 2016).
We evaluated treatment emergent grade ≥2 PN, patient reported outcomes
(PROs; QLQ C30 pain, FACT/GOG neurotoxicity subscales), and progression
free survival (PFS) in patients with a baseline history of PN (patients with
grade ≥3 PN at baseline or grade 2 PN with pain at baseline were excluded
from the studies).
Results: In ASPIRE, grade ≥2 PN rate was low (8.9% [KRd] vs 8.0% [Rd]; Table).
Pain subscale scores were similar between arms. Median PFS was longer with
KRd vs Rd for patients with grade 2 PN at baseline. In ENDEAVOR, grade ≥2
PN rate during the study (prespecified key secondary endpoint) was significantly
lower with Kd vs Vd (6.0% vs 32.0%; Table). Patients had significantly improved
pain and neurotoxicity subscale scores with Kd vs Vd. PFS improved with Kd vs
Vd in patients with baseline history of grade 2 PN (Table 1).
Table 1.
Summary/Conclusions: In ENDEAVOR, the rate of PN was significantly lower
with Kd then with Vd; in ASPIRE, PN rate was similar for KRd and Rd. Improved
pain and neurotoxicity subscale scores with K may be attributed to better dis-
ease control and/or lower PN rates.
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EARLY RELAPSE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT
IN MYELOMA IS A POOR PROGNOSTIC MARKER FOR OVERALL
SURVIVAL AND IS DIFFICULT TO PREDICT AT DIAGNOSIS OR DURING
INDUCTION TREATMENT
I. Walker1,*, A. Coady2, I. El-Najjar 3, K. Wilson4, K. Cuthill1,3, W. Ingram4,
M. Kazmi3, K. Raj1, R. Benjamin1, S. Schey1, A. Pagliuca1, G. Mufti1, M. Streetly1,3,
C. Bygrave4
1Department of Haematology, King’s College Hospital Foundation Trust, 2Guy’s,
King’s and St Thomas’ School of Medical Education, King’s College London,
3Department of Haematology, Guy’s and St Thomas’ NHS foundation Trust,
London, 4Department of Haematology, University Hospital Wales, Cardiff, Unit-
ed Kingdom
Background: High dose chemotherapy followed by autologous stem cell trans-
plant (ASCT) remains the gold standard treatment in myeloma for young
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patients at induction. A number of factors have been shown to correlate with
overall survival (OS) and progression free survival (PFS) including depth of
remission prior to ASCT, Initial ISS stage and high risk cytogenetics. Emerging
evidence has demonstrated that early relapse following ASCT is associated
with reduced OS, and is not correlated with depth of pre-transplant response. 
Aims: To characterise myeloma patients who relapsed within 12 months of
ASCT, through baseline characteristics and transplant engraftment, and assess
the impact of this early relapse on OS and PFS.
Methods: We performed a multicentre retrospective analysis of patients who
underwent ASCT at 3 centres between 01/2009 – 02/20016 (London) and
06/2006 – 03/2013 (Cardiff). Baseline characteristics were reviewed and ASCT
engraftment was assessed by; time to neutrophils 50 x 109/l and platelets >20
x 109/l. Post-transplant PFS & OS was calculated by time (months) from diag-
nosis to progression or death.
Results: 443 myeloma patients were identified, median age was 57 (r 31-73),
56% were male. 41% of patients were ISS stage 1, 34% stage 2, 25% stage 3.
Cytogenetic data was available for 139 patients. 1st-line therapy prior to trans-
plant was immunomodulatory drug (IMiD) based (THAL/LEN) for 318/443
patients & 72/443 were proteasome inhibitor (PI) based (BORT/CARF). In addi-
tion, 11 patients received combination PI and IMiD. Median time from start of
therapy to ASCT was 10 months (r 3-109m). 67 patients progressed within 12m
of ASCT (early progression). No statistical difference was found between <12m
or >12m relapse for: age, gender, 1st line therapy, ISS stage, Hb, LDH, Ca or
cytogenetics, confirming that this group is difficult to predict at baseline. Median
OS from time of diagnosis was 103 months (95% CI 101 -137), median OS
from start of ASCT was not reached, however 5-year OS was 68%. Patients
with progressive disease within 12 months of ASCT, has significantly reduced
median OS from diagnosis: 31 months (95% CI 21- 39) compared to non-pro-
gressive patients (median OS:103m 95% CI 89-117) p<0.0005. Median OS from
ASCT was reduced in early progression median OS:18m (95% CI 14-22m) vs
progression >12 months median OS:89 months (95%CI 79-98m) p<0.0005. 1st
line therapy did not influence likelihood of PFS<12months, with no statistical
difference between patients who received PIs, IMiDs or both 1st line (p=0.484).
A significant difference was observed in median time to platelet engraftment
between the 2 centres. Increased time for platelets to reach >20 x109/l was
associated with reduced OS from ASCT for each centre HR 1.14 & 1.20 (p=
0.046 & 0.03) for Cardiff or London centres respectively (Cox’s Method).
Summary/Conclusions: Early relapse following ASCT is a significant predictor
of inferior OS in myeloma and difficult to predict from standard baseline char-
acteristics. From our analysis; 1st line treatment prior to ASCT did not influence
OS or PFS. There was an association between slow platelet engraftment fol-
lowing ASCT and PFS and OS. Possible explanations include: residual occult
disease, toxicity of chemotherapy or patient stromal factors which facilitate dis-
ease resistance and impair normal haematopoiesis. All of these factors have
been shown to drive relapse. RCTs are required to standardise bone marrow
response assessment post ASCT, quantify remission status (using laboratory
and imaging techniques) and definitively predict early relapse. Additionally,
these studies will investigate further biological or genetic mechanisms driving
early relapse to help identify novel therapeutic approaches in this extremely
poor prognosis group.
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PATIENT-REPORTED OUTCOMES (PROS) WITH IBRUTINIB: SUBSTUDY
OF INNOVATETM FOR WALDENSTRÖM MACROGLOBULINEMIA (WM)
J. Trotman1,*, M.A. Dimopoulos2, A. Tedeschi3, J.V. Matous4, L.T. Heffner5,
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Greece, 3Azienda Ospedale Niguarda Ca’ Granda Hospital, Milan, Italy, 4Col-
orado Blood Cancer Institute, Denver, 5Winship Cancer Institute of Emory Uni-
versity, Atlanta, United States, 6Royal Victoria Hospital at McGill University
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Background: Anemia and fatigue are frequent indications for WM treatment.
To date, patient-reported outcomes (PROs) have not been used to quantify
benefits of any WM treatment. Ibrutinib (ibr), a first-in-class, once-daily inhibitor
of BTK, is indicated in the EU for the treamtent of WM after ≥1 prior therapy or
first-line in patients (pts) unsuitable for chemoimmunotherapy.
Aims: To prospectively collect PROs from the iNNOVATE substudy to assess
patients’ perspectives of the therapeutic beneﬁt of ibr.
Methods: INNOVATE has randomized (ibr+rituximab [RTX] vs placebo+RTX)
and substudy (RTX-refractory) components. Pts in the substudy received oral ibr
420mg daily until progressive disease (PD) or unacceptable toxicity. All pts pro-
vided informed consent. PRO assessments—FACT-An total score (TS) and FACT-
An anemia subscale (AS), and EQ-5D-5L (EQ)—were performed regularly.
Results: Persistent fatigue was the main indication for treatment in 22/31 (71%)
pts. Baseline PRO scores were lower for the substudy vs randomized pts
(Table). With a median of 17 months (mo) of treatment, most pts had clinically
meaningful improvement in TS (≥7 points; 77%), AS (≥6 points; 84%), and EQ
utility scores (≥0.08 points; 68%). Time to clinically meaningful improvement
was prompt (1 mo for TS and AS; 2 mo for EQ), corresponding with a 48%
decline in median IgM (median 20 g/L) after 4 weeks. In pts with baseline ane-
mia (hemoglobin [Hb] ≤110 g/L), sustained Hb improvement increased with
depth of response. At week 65, Hb levels significantly correlated with TS
(r=0.507, P=0.01) and AS (r=0.519, P=0.008), and were marginal for EQ
(r=0.39, P=0.054). Although IgM levels did not significantly correlate with PRO
scores, the benefit was similar in responders regardless of depth of response.
Table 1.
Summary/Conclusions: Clinical response, and associated anemia improve-
ment induced by ibr, correlated with meaningful improvements in the well-being
of heavily pretreated pts with RTX-refractory WM.
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INCIDENCE AND RISK FACTORS OF CARDIOVASCULAR ADVERSE
EVENTS IN A LARGE POPULATION OF NEWLY-DIAGNOSED,
TRANSPLANT INELIGIBLE MYELOMA PATIENTS TREATED WITH
CARFILZOMIB
S. Bringhen1,*, R. Mina1, M.T. Petrucci2, N. Giuliani2, E. Angelucci2, M. Genuardi1,
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M. Offidani2, C. Musolino2, R. Troia1, A.M. Liberati2, L. De Paoli2, S. Ballanti2,
F. Esma1, P. Galieni2, M. Cavo2, C. Conticello2, R. Zambello2, P. Corradini2,
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della Salute e della Scienza di Torino and CPO Piemonte, Torino, Italy, 4Myelo-
ma Unit, Division of Hematology, University of Torino - Currently Takeda Phar-
maceuticals Co., Torino, Zurich, Italy, Switzerland, 5Department of Hematology,
Erasmus Medical Center, Rotterdam, Netherlands
Background: Cardio-vascular (CV) toxicities in patients (pts) with multiple
myeloma (MM) may derive from comorbidities, MM itself and its treatment.
Carfilzomib, an irreversible proteasome inhibitor, is approved as single agent
or in combination with dexamethasone or lenalidomide-dexamethasone for
relapsed MM.
Aims: We conducted an integrated analysis of CV adverse events (AE) in new-
ly diagnosed, transplant-ineligible MM patients treated with Carfilzomib in 3
phase I/II studies (IST-CAR-506, IST-CAR-561, IST-CAR-601).
Methods: All pts were treated with 9, 28-day induction cycles with carfilzomib,
cyclophosphamide (300mg/m2 on days 1,8,15) and dexamethasone (40mg
weekly) (CCyd), followed by carfilzomib maintenance until progression or intol-
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erance. Carfilzomib was administered i.v. at the dose of 36mg/m2 on days 1,
2, 8, 9, 15, 16 in the IST-CAR-506 trial; at 3 dose levels escalated from 45 to
70mg/m2 on days 1, 8, 15 in the IST-CAR-561 trial and on days 1, 2, 8, 9, 15,
16 in the IST-CAR-601 trial. AEs were graded based on NCI-CTCAE v4.
Results: 148 pts with a median age of 72 years were analyzed. At enrollment,
34% of patients had at least 1 cardiovascular risk factor: 20% had peripheral
vascular disease (including hypertension in 13% patients), 19% diabetes and
5% chronic pulmonary disease. After a median follow-up of 21 months, at least
1 any grade CV-AE occurred in 45% of patients; any grade hypertension was
reported in 17% of patients, dyspnea in 9%, and heart failure, arrhythmia and
venous thromboembolism (VTE) in 6% of patients, each. Grade 3-5 CV-AEs
occurred in 15% of patients, the most common being heart failure (4%), hyper-
tension (3%), pulmonary edema (3%) and VTE (3%). Four (3%) fatal CV-AEs
occurred: 1 case of heart failure, pulmonary edema, arrhythmia and VTE,
respectively. No difference in terms of CV-AEs was observed in patients treated
with different doses of carfilzomib. In pts who developed at least 1 CV-AE,
carfilzomib dose reduction (33%) and discontinuation (33%) were more frequent
as compared to those without CV-AEs (12% and 18%, respectively; p<0.0001).
A trend toward a shorter 2-year overall survival (adjusted for age) was observed
among patients who experienced at least 1 CV-AE as compared with those
who did not (74% vs 83%, HR: 0.51; p=0.066). Pts ≥75 years had a higher risk
of any grade (58% vs 36%, p=0.02) and grade 3-5 CV-AEs (34% vs 15%,
p=0.01); major cardiac events of any grade were more frequent in older patients
(29%) than in younger ones (6%; p<0.001). Patients with at least 1 CV risk
factor at enrolment had a 4-fold increased risk (odds ratio: 3.79; p<0.001) of
developing a CV-AE during treatment as compared to patients with no CV risk
factors: in detail, baseline hypertension (odds ratio: 4.12; p=0.012) and periph-
eral vascular disease (odds ratio: 3.75; p=0.002) conferred the highest risk of
developing CV-AEs.
Figure 1.
Summary/Conclusions: Among newly diagnosed MM pts treated with carfil-
zomib, cyclophosphamide and dexamethasone, at least 1 CV-AE occurred in
45% of pts, hypertension and dyspnea were the most common. Pts ≥75 years
of age and those with at least 1 pre-existing CV risk factor were at higher risk
of developing a CV-AEs. The onset of CV toxicity significantly increased the
rate of dose reductions and treatment discontinuation, translating into higher
risk of death. CV toxicity may significantly impact on treatment compliance and
survival. Therefore, to derive maximum benefit from Carfilzomib, all pts - par-
ticularly the elderly - should be carefully assessed to select the most appropriate
treatment.
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POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX)
AFTER SECOND-LINE LENALIDOMIDE (LEN)-BASED TREATMENT OF
RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED
PROGRESSION-FREE SURVIVAL ANALYSIS
D.S. Siegel1,*, G.J. Schiller2, K. Song3, R. Agajanian4, K. Stockerl-Goldstein5,
H. Kaya6, M. Sebag7, F.J. Reu8, E. Malek9, G. Talamo10, J. Mouro11, W. Chung11,
S. Srinivasan11, M. Qian11, S. Rizvi11, A. Thakurta11, N.J. Bahlis12
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Background: Most recent pivotal trials of triple therapy in second- and third-
line treatment excluded patients (pts) whose multiple myeloma (MM) was refrac-
tory to LEN. This is not reflective of the standard of care in first and second line
where LEN is given until progressive disease (PD). To address this, the MM-
014 phase 2 trial enrolled pts with RRMM and second-line LEN-based treatment
failure. Cohort A enrolled pts treated with POM + LoDEX. The study was amend-
ed to include cohort B (pts treated with POM + LoDEX + daratumumab).
Aims: To present updated safety and efficacy analyses only from cohort A, in
which pts received POM + LoDEX immediately after relapsing or being refrac-
tory to second-line LEN-based therapy.
Methods: Pts aged ≥18 years had documented MM, measurable disease, 2
prior lines of treatment, and PD after ≥2 cycles of second-line LEN-based treat-
ment. Pts received 28-day cycles of POM 4mg/day on days 1-21 + LoDEX
40mg/day (20mg/day if>75 years) on days 1, 8, 15, and 22; thromboprophylaxis
was mandatory. The primary endpoint was overall response rate (ORR; ≥ partial
response [PR]) assessed by modified IMWG criteria. Key secondary endpoints
included time to response (TTR), progression-free survival (PFS), secondary pri-
mary malignancies (SPMs), and biomarkers. All pts provided informed consent.
Results: Of 51 enrolled pts in cohort A, 39 (76.5%) discontinued treatment,
mostly due to PD. Median age was 68.0 years, and 92.2% had an Eastern
Cooperative Oncology Group performance status of ≤1. A total of 45 pts (88.2%)
were refractory to their last treatment with LEN, and 37 (72.5%) had prior treat-
ment with bortezomib. Median duration of prior LEN-containing therapy was
24.6 months. With a median follow-up of 13.6 months, ORR was 29.4%, with
1 (2.0%) complete response, 5 (9.8%) very good partial responses, and 9
(17.6%) PRs. Minimal response (MR) was reached in 15.7% of pts. Median
TTR was 1.9 months and 66% of pts had ongoing response at 1 year. Median
PFS was 13.8 months. The 2-year PFS rate was 48.6% for the intent to treat
population, 69.4% for pts with ≥ MR, and 69.1% for pts with ≥ PR. In addition,
pts with ≥ MR had similar treatment durations as those achieving ≥ PR (10.5
vs 11.5 months; Table). Common grade 3/4 adverse events (AEs) included
anemia (25.5%), neutropenia (11.8%), and infections (19.6%; including pneu-
monia [9.8%]). No pts experienced SPMs. In the immune subset analysis, the
proportions of CD3+ and CD3+/CD8+ T cells after treatment were significantly
higher vs baseline (72.6% vs 67.8% and 36.9% vs 32.1%, respectively; P<.05).
Pts with response also had significantly elevated proportions of these T-cell
populations, but pts with no response did not. Relative changes from baseline
for CD3+ and CD3+/CD4+T-cell populations were significantly greater in pts
with response vs those with no response (10.4 vs −0.8 and 4.2 vs −3.5, respec-
tively; P<.05).
Table 1.
Summary/Conclusions: This update confirms the safety and efficacy of POM
+ LoDEX following second-line LEN-based treatment failure in pts with RRMM.
Hematologic AE rates improved, and median PFS was longer with third-line
use than previously reported with POM + LoDEX use in later treatment lines.
In addition, achieving disease control of ≥ MR led to similar PFS rates as reach-
ing ≥ PR.
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“REAL WORLD” DATA ON THE EFFICACY AND SAFETY OF IXAZOMIB IN
COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA: A STUDY OF THE
GREEK MYELOMA STUDY GROUP
E. Terpos1,*, E. Katodritou2, M. Kotsopoulou3, I. Ntanasis-Stathopoulos1,
P. Lampropoulou3, S. Papadaki2, M. Papathanasiou4, D. Stoumbos3,
M. Gavriatopoulou1, P. Repousis3, E. Kastritis1, M.A. Dimopoulos1
1Department of Clinical Therapeutics, National and Kapodistrian University of
Athens, School of Medicine, Athens, 2Department of Hematology, Theagenion
Cancer Hospital, Thessaloniki, 3Department of Hematology, Metaxa Cancer
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tion Unit, G. Papanikolaou General Hospital, Thessaloniki, Greece
Background: The all-oral combination of ixazomib, lenalidomide and dexam-
ethasone (IRd) has been recently approved as a novel standard of care for
relapsed/refractory multiple myeloma (RRMM).
Aims: The aim of this study was to evaluate the efficacy and safety of IRd in
the “Real World” (RW) practice, where data are very limited. 
Methods: This was a retrospective, non-interventional study, which recorded
IRd treatment data from patients with RRMM who participated in the name-
patient program of ixazomib in Greece. The primary endpoint was the evaluation
of overall response rate (ORR), according to IMWG criteria. Secondary end-
points included: treatment duration; time to response; duration of response;
percentage of patients who experienced adverse events (AEs), needed dose
modification or treatment discontinuation; evaluation of PFS and TTP.
Results: Forty-one patients were included in the present study. Of those, 35
(19M/16F, median age 70.5 years (range: 63-79 years) had received at least 3
cycles of IRd on the date of data analysis and thus they were included in the
present report. The median line of previous therapies was one (range: 1-5):
71.4% (25/35) patients had received one prior treatment, while 20.0% (7/35),
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5.7% (2/35) and 2.9% (1/35) had received 2, 3 and 5 prior treatment lines,
respectively. Overall, 82.9% (29/35) of patients had been exposed to protea-
some inhibitors prior to IRd (77.1% to bortezomib and 8.6% to carfilzomib] and
48.6% (17/35) to IMiDs [31.4% (11/35) to thalidomide and 22.9% (8/35) to
lenalidomide]. Autologous transplantation had been given in 42.9% (15/35) of
patients. Median treatment duration was 7.1 months. Among 34 patients with
available data for response, VGPR was recorded in 35.3% (12/34), PR in 32.4%
(11/34), MR in 2.9% (1/34) and stable disease in 26.5% (9/34). The ORR (PR
or better) was 67.6%: 70.8% among those who received IRd in the second line
and 60.0% among those who received IRd beyond the second line;ORR tended
to be higher as the time of exposure to ixazomib increased, with patients
exposed to ixazomib for at least 6, 7 and 8 months, noting ORR rates of 70.8%
(17/24), 76.5% (13/17) and 91.8% (9/11), respectively. Median time to best
response was 1.2 months. Treatment interruptions due to AEs were recorded
for 11.4% (4/35) of patients, while 20.0% (7/35) of patients discontinued treat-
ment. Reasons for ixazomib discontinuation were AEs for 3 patients (an event
of septic shock had fatal outcome), disease progression in 3 patients and
administrative reason (patient could no longer visit the site) in one. Among the
35 patients analyzed, 17.1% (6/35) had experienced disease progression or
death; the 6-month PFS rate was 90.5% and the 6-month TTP rate was 93.2%.
Regarding AEs of interest, 31.4% (11/35) of patients experienced peripheral
neuropathy; of those events, 54.5% (6/11) resolved, while 45.4% (5/11) had
not resolved (three were grade 1, one grade 2, and one of grade 3) at the end
of follow-up. In addition, 31.4% (11/35) of patients developed gastrointestinal
AEs, 11.4% (4/35) experienced pneumonia, 9.4% (3/32) hypertension, 5.7%
(2/35) cataract and herpes zoster, and 2.9% (1/35) deep vein thrombosis; no
cardiac arrhythmia or other cardiac events were recorded, while osteonecrosis
of the jaw developed in 5.7% (2/35) of the patients.
Summary/Conclusions: This study showed that the IRd regimen produces
an ORR of near 68% and a clinical benefit in almost all patients with RRMM
who are treated in RW practice. IRd acts rapidly and has an acceptable toxicity
profile with no cardiac events. 
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Background: EU PASS is an observational, non-interventional study designed
to investigate the safety of lenalidomide (LEN) and other agents in the treatment
of patients with RRMM in a real-world setting. 
Aims: To assess the incidence of adverse events (AEs) of special interest (ie,
neutropenia, thrombocytopenia, venous thromboembolism [VTE], neuropathy,
and second primary malignancies [SPMs]).
Methods: Patients with RRMM initiating LEN treatment were enrolled at the
investigator’s discretion into the LEN cohort (LEN + dexamethasone, the
approved combination for the treatment of RRMM); patients who received ≥ 1
prior therapy initiating a non–LEN-based treatment were enrolled into a back-
ground cohort (all other treatments, including novel agents). Thromboprophy-
laxis was administered per local standard practice. AEs were graded per the
National Cancer Institute-Common Terminology Criteria for AEs, v3.0. SPMs
were defined using MedDRA terms, SPM assessments were to be conducted
up to 36 mos after treatment discontinuation (Protocol amendment 2011). All
patients provided informed consent.
Results: As of March 1, 2016, 3630 patients were included in the safety pop-
ulation. Of these patients, 2151 (59.3%) received LEN, 1187 (32.7%) received
bortezomib (BORT), 137 (3.8%) received thalidomide (THAL), and 155 (4.3%)
received other therapies. The median duration on study treatment was 6.6 mos
(range 0.1-79.9 mos) for patients receiving LEN, 4.1 mos (range 0-61.4 mos)
for BORT, and 4.6 mos (range 0.2-36.9 mos) for THAL. At the time of analysis,
3557 patients (98.0%) had discontinued treatment. Of the 73 patients (2.0%)
who were on treatment, 63 were treated with LEN, 6 with BORT, 0 with THAL,
and 4 with other therapies. Baseline characteristics were balanced across
cohorts. Median age was 70 yrs (range 25-95 yrs) and 54.0% of patients were
male. Of 2985 patients with available ECOG scores, 2865 (96.0%) had an
ECOG score ≤2. The median number of prior therapies was 1 (range 1-6); the
proportion of patients with only 1 prior treatment was lower in the LEN (44.2%)
vs BORT (70.8%) and THAL (56.2%) cohorts. Overall, 1843 patients (50.8%)
had grade 3/4 AEs (Table). All grade neuropathy occurred in 9.8%, 28.2%, and
17.5%, and VTE occurred at 6.0%, 1.3%, and 0% of patients in the LEN, BORT,
and THAL cohorts. The incidence of SPMs per 100 patient-years was 3.87
overall and 3.45, 5.41, 2.73, and 6.51 for LEN, BORT, THAL, and other agents,
respectively. Treatment discontinuation rates due to AEs were similar in each
cohort (LEN: 22.4%; BORT: 20.1%; and THAL: 21.2%). Rates of treatment-
emergent AEs leading to dose reductions were also similar across cohorts,
occurring in 23.9% of patients in the LEN cohort, 21.2% in BORT, and 17.5%
in THAL. Data on long-term responders will be presented at this meeting.
Table 1.
Summary/Conclusions: LEN was generally well tolerated and the safety
results were similar to published data. As expected, the occurrence of neu-
tropenia, TCP, and VTEs were higher in patients in the LEN cohort, whereas
neuropathy was more frequently reported in patients in the BORT cohort. VTEs
were low in all cohorts. The occurrence of SPMs was generally low and com-
parable between cohorts.
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NEW CLINICAL PATHWAYS OF THE CENTERS OF EXCELLENCE
NETWORK IN GERMANY: A NEW CONCEPT FOR STANDARDIZED CARE
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Background: Clinical outcome of multiple myeloma (MM) patients is hetero-
geneous and depends on various prognostic factors and available treatments.
Although tremendous progress has been made in MM, so far, there is no nation-
al or international evidence-based guideline giving recommendations for clinical
practice in the treatment of MM patients. In Germany, 14 Comprehensive Can-
cer Centers (CCC) are funded as ‘Centers of Excellence’ by the German Can-
cer Aid (DKH). All these Centers of Excellence are required to develop and
provide in-house clinical pathways for standards in cancer care. These path-
ways include concise diagnostic and therapeutic instructions, reflecting avail-
able evidence-based recommendations. In addition, ongoing studies (in par-
ticular phase I / II) are part of clinical pathways, so that a rapid transfer of inno-
vation is provided and patients gain access to new therapeutic approaches.
The Centers of Excellence Network working group SOP has the goal to har-
monize these hospital specific in-house clinical pathways differing in format,
content and level of detail of guidance.
Aims: The project’s objective is to harmonize diagnosis, treatment and follow-
up of all MM patients in Germany by providing concise, freely available online
clinical pathways.
Methods: The clinical pathway was prepared according to a methods hand-
book developed by the working group including recommendations for stan-
dardized methodology and evidence processing. Intensive collaboration of clin-
ical and methodological experts in the multi-disciplinary working-group, together
with experts from both German Study Groups Multiple Myeloma and the Ger-
man-speaking Multicenter Myeloma Group ensured clinically relevant and up-
to-date pathway drafts. In a first step, information from all available in-house
clinical pathways was used as a first harmonized draft. Experts from four lead-
ing centers in the field of myeloma research and treatment in Germany
(Cologne, Freiburg, Heidelberg, Wuerzburg) agreed after intense discussion
during face-to-face meetings and after including latest research results from
literature searches into one pathway. The resulting pathway draft was discussed
with experts from all 14 Centers of Excellence during face-to-face meetings,
conference calls and two online surveys until consensus was reached. The
project is funded by the DKH, No. 111493.
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Results: During the development process, a number of similarities and dis-
crepancies between centers as well as evidence gaps were identified. Intense
discussion and literature searches resulted in a concise, harmonized clinical
pathway, released by all 14 Centers of Excellence. This is freely available on
the website ccc-netzwerk.de and provides a very decisive insight according to
the current state of knowledge on the CCC-level (e.g. on the diagnostic algo-
rithm, Fig. 1). The clinical pathway is well suited for informing patients and
physicians about the most up-to-date, comprehensive medical treatment stan-
dards as well as innovative procedures. Furthermore, this project initiated the
idea of developing a national evidence-based clinical practice guideline for MM
in the frame of the German Guideline Program in Oncology.
Figure 1.
Summary/Conclusions: The first clinical MM pathway developed and released
by all 14 German CCCs/Centers of Excellence translates scientific evidence
and expert knowledge into precise suggestions for MM patients in clinical prac-
tice. These harmonized processes might increase the quality of cancer care
throughout Germany. To be up-to-date and to reflect latest research findings
this clinical pathway will be updated every 18 months.
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WT1 HETEROCLITIC EPITOPE IMMUNIZATION FOLLOWING AUTOLOGOUS
STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK
MULTIPLE MYELOMA (MM)
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Background: The Wilms tumor 1 (WT1) protein is a tumor associated antigen
that is a target for anticancer immunotherapy. We had previously demonstrated
overexpression of WT1 in multiple myeloma (MM) cells by IHC, as well as for-
mation of a WT1 peptide fragment (RMFPNAPYL)/HLA-A*0201 complex on
the engagement interface between malignant plasma cells and T-cells in HLA-
A*0201+ MM pts using the high-affinity fully human IgG1 mAb ESK1. We report
initial results from MM pts immunized with the WT1 heteroclitic peptide mixture
galinpepimut-S (GPS) after autoSCT.
Aims: To determine the safety and potential efficacy of the WT1 heteroclitic
peptide immunizer GPS administered in patients with multiple myeloma follow-
ing autologous stem cell transplantation.
Methods: 16 MM pts underwent autoSCT with melphalan conditioning followed
by (f/b) lenalidomide maintenance starting 3 months (mos) post-SCT. 13/16
pts presented with high-risk (HR) cytogenetics [t(4;14), t(14;16), del17p,
1q21/25 gain and/or del13q]. GPS was administered with montanide s.c. start-
ing 2 wks post-SCT and q.2 wks thereafter x 6 initial doses f/b boosters q.4
wks x 6 additional doses. GM-CSF was given on days -2 and 0 of each cycle.
GPS consisted of 4 peptides: WT1-A1: Y*MFPNAPYL; 427-L (long):
RSDELVRHHNMHQRNMTKL; 331-L: PGCNKRYFKLSHLQMHSRKHTG, and
122A1-L: SGQAY*MFPNAPYLPSCLES. 2 of the 4 peptides were mutated at a
single residue (*) to induce stronger HLA-binding/reduce tolerance. WT1-spe-
cific immune responses (IRs) were assessed by intracellular IFN-g analyses
post-challenge with PBMC’s pulsed with a ‘total pool’ of overlapping 15mers
along the entire WT1 protein; or each of the 4 WT1 peptides in GPS; or the
non-mutated (native) WT1 peptides corresponding to the 2 heteroclitic
sequences.
Results: 16 pts underwent auto SCT followed by WT1 heteroclitic peptide
immunization; median follow-up of 18 mos (range: 5-31 mos) for survivors;
median age: 61.6 y. Overall survival (OS) and progression-free survival (PFS)
(95% CI) at 18 mos: 0.88 (0.73-0.99) and 0.62 (0.42-0.97) respectively. Current
median PFS: 23.6 mos (15.2- not reached). No ≥G2 systemic side effects were
observed, however, all pts developed local nodularity at the site of injections
which resolved over 2 – 6 wks. Both CD8+ and CD4+ IRs could be detected at
various levels and were induced not only against the heteroclitic peptides (within
GPS), but also against the corresponding native WT1 peptide sequences as
well as the ‘total pool’ of WT1-derived overlapping peptides. 
Summary/Conclusions: Administration of the novel WT1 heteroclitic peptide
immunizer GPS post-SCT demonstrates favorable safety profile along with an
encouraging mPFS of currently 23.6 mos in this high-risk MM population. This
‘off-the-shelf’ immunotherapeutic is easy to administer and has been specifically
designed to elicit responses across most common HLA Class I and II alleles.
Based on these results, a larger phase II trial is being planned to optimally inte-
grate post-transplant immunotherapeutic strategies to meaningfully delay or
reduce risk of relapse in this challenging clinical setting.
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ANALYSIS OF MULTIPLE MYELOMA PATIENTS WITH PROGRESSIVE
DISEASE AT TIME OF FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION:
PREDICTORS OF PROGRESSIVE DISEASE AND FACTORS AFFECTING
SURVIVAL 
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Background: The impact of response depth at time of autologous stem cell
transplantation (ASCT) on the progression-free and overall survival (PFS and
OS, respectively) of multiple myeloma (MM) patients has been an extensively
investigated area. Rosiñol et el. (2011) reported a significantly worse PFS and
OS in patients with progressive disease (PD) compared to stable disease (SD)
at time of ASCT; Parrish et al. (2015) stated a significantly shorter PFS, but not
OS, in patients with PD in comparison to SD or minimal response (MR) at time
of ASCT.
Aims: Our goal was to characterize MM patients with PD at time of first ASCT.
We aimed to analyze the effects of PD on PFS and OS. Next, we intended to
examine the influence of clinical factors (evaluated at beginning of induction
therapy) as well as use of novel agents in induction therapy, response after 1st
ASCT, and use of maintenance therapy in those patients to identify predictors
for PFS and OS. Furthermore, we aimed to identify clinical/ therapeutic features
predicting the occurrence of PD before ASCT.
Methods: Non-trial MM patients who had undergone a single or tandem ASCT
at the University Hospital of Heidelberg in the years 1992-2014 were analyzed
regarding their response before 1st ASCT (d -100 or, if available, response as
close to the date of ASCT as possible, i.e. until d -4). Of the 874 ASCT-patients,
829 were eligible for a PFS- and 832 for an OS-analysis. In 51 patients, PD
was present at time of ASCT. PFS and OS of those patients were compared
with the survival of patients with at least SD at time of ASCT (non-PD patients).
Furthermore, clinical factors at beginning of induction therapy, including age (<
vs ≥ 65 years), ISS stage, elevated LDH, use of novel agents in induction ther-
apy, high-risk FISH cytogenetics (at least one of the following: del17p, 1q21
gain, t(4;14)); response after ASCT, and maintenance therapy (yes vs no) were
analyzed regarding their impact on PFS and OS of patients transplanted in PD.
We also analyzed clinical factors at beginning of as well as use of novel agents
in the induction therapy regarding their impact on the presence of PD before
ASCT. Response was evaluated according to EBMT-criteria. PFS was calcu-
lated from date of 1st ASCT, except for prognostic impact of response assess-
ment after 1st ASCT, where date of response assessment was used. Start of
maintenance therapy was analyzed as time-dependent factor.
Results: Non-trial patients transplanted in our center between 1992 and 2014
with PD ≤100 days before ASCT had similar PFS and OS as non-PD patients.
Neither the clinical parameters at induction start, response after 1st ASCT, nor
maintenance therapy had a significant effect on PFS in those patients. In the
univariate analysis, high-risk cytogenetics as well as elevated LDH at induction
start had a significantly negative effect on OS in patients with PD before ASCT
(HR= 17.12, p= 0.0017; HR=6.09, p= 0.01, respectively), compared to PD-
patients with no high-risk cytogenetics or with normal LDH. Furthermore, ISS
stage III was a significant predictor (OR= 3.35, p= 0.02)) of occurrence of PD
before ASCT.
Summary/Conclusions: In conclusion, our analysis of 51 patients with PD at
time of ASCT- among 874 ASCT-patients with MM transplanted between 1992
and 2014- shows no significant difference regarding PFS and OS between
patients with PD and other response rates. It was further shown that high-risk
cytogenetics as well as elevated LDH at beginning of induction therapy have a
significant impact on worse OS in patients with PD at time of ASCT. In addition,
ISS stage III is a significant factor for occurrence of PD before ASCT. The
impact response depth at time of ASCT is not entirely clear, especially regarding
the benefit of ASCT in patients with PD at time of ASCT, as reports from other
centers show significantly worse PFS and OS (Rosiñol et al.) or only PFS (Par-
rish et al.) in patients with PD at time of ASCT.
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SEVERE INFECTIONS IMPACTS OVERALL SURVIVAL IN ACTIVE MULTIPLE
MYELOMA PATIENTS
G. Barila’1,*, C. Nicolo’1, A. Liço1, A. Branca1, L. Checuz1, E. De March1,
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Background: Multiple myeloma (MM) represents the second most common
hematological malignancy characterized by the proliferation of monoclonal
plasma cells (PC) in the bone marrow. The natural history of active MM patients
may be complicated in significant fraction by the occurrence of infections that
can be related both to the development of therapy induced neutropenia (mainly
due to high dose chemotherapy used in the setting of autologous stem cell
transplantation or in salvage regimen) or to MM induced secondary immunod-
eficiency. 
Aims: The aim of this study was to analyse the frequency, the type and the major
risks factors of severe infections in our cohort of patients affected by MM and to
understand the impact of these events on MM patient overall survival (OS).
Methods: A cohort of 341 patients affected by MM (104 with smouldering MM
and 237 with symptomatic MM) followed from 1996 to 2016 was retrospectively
studied for the presence of severe infections (si, defined by the need of hospi-
talization) during the natural history of the disease. Infections were classified
as “not neutropenia related” or “neutropenia related” according to the Absolute
Neutrophil Count > or <1,000/ml respectively. International Staging System
(ISS) and Durie-Salmon (DS) were used for MM patients staging.
Results: In our cohort of patients, si were significantly associated to active
MM (28,69% of symptomatic patients vs 3,85% of asymptomatic patients;
p=0.0001, c2=25,318). Among the 138 infective events occurred in 91 active
MM patients, 38 (28%) were neutropenia related while remnant 100 not neu-
tropenia related (72%). Furthermore, almost 44% of these events (61/138)
developed during induction therapy, with 12 out of 61 (20%) being present at
time of the diagnosis. Considering that majority of si was not neutropenia relat-
ed and that these infective events involved most of active MM patients who
developed si (68/91, 75%), our aim was to identify MM patient characteristics
associated to the development of not neutropenia related si. Our results prove
evidence that major features presented at the time of the diagnosis significantly
associated to si were DS stage III (p=0.0004, c2=12,14), ISS stage III
(p=0.0001, c2=21,11), age >70 years (p=0.0195, c2=5,455), bone marrow plas-
ma cells >60% (p=0.034, c2=4,50), acute renal failure (p=0.0003, c2=13,010)
or MM presenting with at least three of CRAB criteria (p=0.0123, c2=6,26). For
what concern the impact of si on the natural history of the disease, patients
who experienced infective event presented a reduced OS towards other
patients (p<0.0001). Among infected patients no significant differences were
reported referring to the number of infections (>1 or =1, p=0.11), while patients
who developed exclusively neutropenia related infective events showed better
OS towards patients who experienced not neutropenia related infections
(p=0.0011).
Figure 1.
Summary/Conclusions: Severe infections represent an underestimated
comorbidity in MM, characterizing all phases of the disease and not only refrac-
tory/relapsed patients receiving multiple lines of therapy. Considering that
severe infections impact OS mostly in the setting of not neutropenia related
infections, immunoglobulin replacement therapy or antibiotic prophylaxis may
possibly have a protective role in high risk old patients characterized by ISS
and DS stage III, bone marrow PC >60% and aggressive disease at the time
of diagnosis.
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EVALUATION OF CARDIOVASCULAR EVENTS ASSOCIATED WITH
DIFFERENT TREATMENT MODALITIES OF MULTIPLE MYELOMA IN THE
REAL-WORLD SETTING IN THE UNITED STATES
D. Lenihan1, R. Potluri2, H. Kanakamedala2, A. Dasgupta2, C. Chen3,*
1Vanderbilt University Medical Center, Nashville, 2SmartAnalyst Inc., New York,
3Bristol-Myers Squibb, Lawrenceville, United States
Background: Multiple myeloma (MM) is a disease of the elderly. The prevalence
of cardiovascular (CV) comorbidities in the MM population is high. Past research
suggests that MM is associated with a range of cardiac risks, and emerging evi-
dence shows that both proteasome inhibitors (PIs) and immunomodulatory
drugs (IMiDs) can have important CV sequelae. The improved efficacy of PI
plus IMiD combination therapy (PI+IMiD) has resulted in its widespread adoption,
which suggests that CV events may become a prominent concern in patients
receiving PI+IMiD as contemporary treatment for MM.
Aims: To assess the risk of developing CV events in patients receiving anti-
MM treatment and to test if a specific treatment modality was associated with
higher risk of a CV event.
Methods: Patients with ≥1 inpatient claim or ≥2 outpatient claims with a primary
diagnosis code for MM who were treated with PI and/or IMiD drugs between
Jul 2012 and Sep 2014 were identified in a large US claims database. The first
claim for a PI or IMiD drug in this period was defined as the index date, which
was preceded by 180-d continuous eligibility with no anti-MM treatment (base-
line). Patients were divided into three cohorts based on the anti-MM treatment
received: PI, IMiD, PI+IMiD. CV events of interest included cardiac arrhythmia,
cardiac failure, venous thromboembolism (VTE), myocardial infarction,
ischemic heart disease, angina, stroke and coronary atherosclerosis, and were
measured during anti-MM treatment. Kaplan–Meier methods were used to esti-
mate the occurrence rate of a CV event, and multivariate Cox regression mod-
els were developed to identify prognostic factors of each CV event among
patients treated with anti-MM therapies.
Results: 4268 patients met the eligibility criteria for inclusion in the study (57%
male, median age 66 y, 41% with Charlson Comorbidity Index ≥2, mean dura-
tion of treatment 192 d; Table), 42% (n=1779) were treated with PIs, 38%
(n=1624) with IMiDs and 20% (n=865) with PI+IMiDs. Patients receiving
PI+IMiD were significantly younger and generally had lower prevalence of CV
comorbidities than those receiving PI or IMiD (Table). Compared with patients
on PI, the risk of developing VTE was 46% greater in patients on PI+IMiD (HR:
1.46; 95% CI: 1.09, 1.96). Compared with those on IMiD, the risk of developing
cardiac failure and cardiac arrhythmia was 33% and 18% greater in patients
on PI+IMiD (HR: 1.33; 95% CI: 1.03, 1.72; HR: 1.18; 95% CI: 1.00, 1.40). After
6 months of treatment, the rates of VTE were 8%, 10% and 11% for patients
on a PI, those on an IMiD and those on PI+IMiD, respectively. The correspon-
ding rates for cardiac failure were 18%, 11% and 11% for PI, IMiD and PI+IMiD
cohorts, and 21%, 16% and 22% for cardiac arrhythmia.
Table 1.
Summary/Conclusions: PI+IMiDs may be associated with incremental occur-
rence of specific CV events during treatment, and may result in specific CV
events earlier during therapy than PIs or IMiDs alone. These highlight a need
for treatments that do not exacerbate CV risks and are appropriate for patients
with pre-existing CV conditions. The lower prevalence of baseline CV comor-
bidities and lower mean age in patients on PI+IMiDs suggest that prevalence
of a CV comorbidity and age influences treatment choice. Further analysis may
be necessary to better understand the impact of baseline CV comorbidities on
choice of MM treatment.
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LENALIDOMIDE PLUS HIGH-DOSEVERSUS LOW-DOSE DEXAMETHASONE
FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE
MYELOMA: A SYSTEMATIC REVIEW 
K. Kupas1,*, I. Kaspar1, V. Baecke2, K. Weisel3
1Bristol-Myers Squibb, Munich, 2Ecker + Ecker GmbH, Hamburg, 3University
of Tübingen, Tübingen, Germany
Background: Lenalidomide in combination with dexamethasone is approved
globally for the treatment of multiple myeloma (MM). Although older pivotal reg-
istrational studies used lenalidomide combined with high-dose dexamethasone
(LD), more recent studies have used lenalidomide plus low-dose dexametha-
sone (Ld) for relapsed/refractory MM (RRMM), as the Ld regimen demonstrated
better survival with lower toxicity for the treatment of newly diagnosed MM
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(NDMM; Rajkumar SV et al. Lancet Oncol 2010;11:29–37). Additionally, all recent
Phase 3 trials establishing new triplet combinations with lenalidomide and dex-
amethasone in RRMM, such as ELOQUENT-2 (study of elotuzumab plus Ld in
RRMM; Lonial S et al. N Engl J Med 2015;373:621–31), used the Ld regimen in
both standard and experimental arms. Although the lenalidomide label includes
Ld for NDMM, there are differences between the approved dose of dexametha-
sone and what is currently used in real-world clinical practice for RRMM.
Aims: We performed a historical comparison based on a systematic review of
literature describing low- vs high-dose dexamethasone in patients with RRMM
to assess effects of Ld vs LD on safety and efficacy outcomes.
Methods: We searched MEDLINE, EMBASE and Cochrane databases and
key clinical trial registries for studies including adults with RRMM who had
received ≥1 prior therapy and had a symptomatic relapse on their last treatment.
Eligible studies evaluated Ld (lenalidomide: 25mg on Day 1–21 of each cycle;
dexamethasone: 160mg/cycle, not pulsated) or LD (Cycles 1–4: 480mg/cycle;
Cycle 5+: 160mg/cycle, pulsated). Only those trials with designs and baseline
patient characteristics similar to ELOQUENT-2 were eligible to ensure compa-
rability. Studies with a follow-up of 16–25 months were evaluated separately
from studies with a follow-up of >30 months; these observation periods approx-
imately align with those of ELOQUENT-2. 
Results: From an initial bibliographic search yielding 5155 non-duplicate results
and 619 registry results, 7 studies (8 publications) met the inclusion criteria (4
Ld studies, 3 LD studies). Data for overall survival and tolerability from 1153
patients in the Ld group and 353 patients in the LD group were analyzed. The
median patient age was 63–68 years. Most patients were white, male and had
an ECOG score of 0-1. Ld was not associated with loss of efficacy vs LD in
terms of overall survival; after >30 months of follow-up, the hazard ratio for LD
vs Ld was 1.04 (95% CI 0.85-1.28). Tolerability was similar for LD vs Ld; after
16-25 months of follow-up, LD was associated with a statistically significantly
increased risk of Grade 3/4 adverse events (AEs; relative risk [RR]: 1.10 [95%
CI 1.01-1.18]). However, after >30 months of follow-up, LD was not associated
with an increase in overall AEs (RR: 1.02 [95% CI 1.01-1.03]), grade ≥3 AEs
(RR: 1.03 [95% CI 0.95-1.12]) or serious AEs (RR: 1.08 [95% CI 0.97-1.20]);
RR for AEs leading to discontinuation was 1.16 (95% CI 0.87-1.54).
Summary/Conclusions: Overall survival and safety are not significantly affect-
ed by different dosing of dexamethasone in combination with lenalidomide;
thus, the use of Ld seems to be reasonable in this patient population. Further
studies may provide additional evidence to inform clinicians and revision of
international guidelines for dexamethasone dosing in RRMM.
Study funded by Bristol-Myers Squibb.
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HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN
NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT – A
REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP
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Background: Three drug bortezomib-based regimens are nowadays generally
recommended standard induction therapy for transplant-eligible patients with
newly diagnosed multiple myeloma (MM). The choice between different regi-
mens depends on drug availability in particular countries, their toxicity profile
and local preferences. Observations from routine practice might have though
significant clinical importance.
Aims: The aim of this retrospective analysis was to evaluate the efficacy and
safety of VTD regimen in newly diagnosed MM patients eligible for
HDT/autoSCT in routine clinical practice. 
Methods: We collected the clinical data of 169 patients qualified to
HDT/autoSCT treated with VTD as an induction regimen in 14 Polish hematol-
ogy/oncology centers. VTD protocol recommended by Polish Multiple Myeloma
Study Group was as follows: bortezomib: 1.3mg/m2 (days 1,4,8,11), thalido-
mide: 100 – 200mg a day (days 1-21), dexamethasone 20mg a day (days: 1,2,
4,5, 8,9, 11,12) or 40mg a day (days 1- 4), every 21 days. Patients were includ-
ed into analysis if ≥1 cycle of VTD was administered. Adverse events (AEs)
were graded according to CTCAE v4.0. The analysis involved also the impact
of VTD regimen on efficiency of stem cells mobilization as well as high dose
therapy/ autologous stem cell transplantation (HDT/autoSCT) procedure.
Results: In the cohort of 169 patients, median age was 59 years (range 36-70).
ISS stage 1 was found in 30.8% of patients, ISS 2 and 3 in 20.7% and 45.5%,
respectively. Median number of VTD cycles was 5. In 81.6% of patients borte-
zomib was administered subcutaneously. Thalidomide dose was 100mg a day
in 85.1% of patients. Bortezomib dose was reduced in 43 patients (25.4%) with
peripheral polyneuropathy as the most common reason (75%). Polyneuropathy
was also the most common grade 3/4 adverse event, observed in 20 patients
(11.8%) and neutropenia was the most common hematologic toxicity, though it
was noted only in 5 patients (3%). Response rate ≥ PR was achieved in 95% of
patients, including 5.6% of sCR, 27.1% of CR and 35.1% of VGPR. So far, stem
cell mobilization was performed in 110 patients, most commonly used protocols
were cyclophosphamide (42.9%) and cytosine arabinoside (36.2%). In 69.3%
of patients one apheresis allowed to obtain the number of stem cells sufficient
for transplantation. Median yield of CD34+ cells was 11 x 106/kg (max
55.7x106/kg) that was sufficient for two transplantations in the majority of
patients. HDT/autoSCT was performed so far in 89 patients with MEL 200 pro-
tocol as conditioning regimen in 77.6% of patients. Median number of trans-
planted CD34+ cells was 4.4 x 106/kg. Median time to reach ANC count >0.5
G/L and PLT count >20 G/L was 11 days and 12 days, respectively. In the eval-
uation of response 100 days after HDT/autoSCT performed in 81 patients, sCR
rate increased from 5.6% to 12.7% and CR from 27.1% to 36.7%.
Summary/Conclusions: VTD regimen allowed allowed to achieve ≥ PR in
95% of patients including ≥ VGPR u 64.8% of patients as compared to 73.5%
≥ PR including 36% of ≥ nCR achieved in patients treated with CTD in our pre-
vious study (Dmoszynska et al. Leuk Res 2010). In 96% of patients subse-
quently undergoing stem cell mobilization sufficient numer of CD34+ cells was
obtain during first procedure. HDT/autoSCT further increased response rate
after VTD induction (≥ CR up to 43.5%, ≥ VGPR up to 83.5%).
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HIGH CUT OFF HEMODIALYSIS FOR RENAL RECOVERY IN PATIENTS
WITH MULTIPLE MYELOMA: FIVE YEARS OF EXPERIENCE
A. Berni Wennekers1,*, M. V. Dourdil Sahun2, E. Bonafonte Arruga2, A. Asensio
Matas2, M.P. Martin Azara1, R. Alvarez Lipe1, L. Palomera Bernal2
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Background: Up to 20% of patients with multiple myeloma (MM) present acute
kidney injury (AKI) as complication and half of them can even require dialysis.
The toxicity of serum free light chains (sFLC) is the main cause of renal damage
in MM.
Aims: Demonstrate that rapid and sustained reduction of sFLC levels by com-
bined chemotherapy and high cut-off hemodialysis (HCO-HD) improves renal
outcome.
Methods: From July 2011 to July 2016, were performed 21 treatments on 19
patients with MM and serum concentrations of FLCs above 500mg/L who had
severe AKI requiring hemodialysis according to KDIGO criteria. The HCO-HD
was initiated immediately after establishing hematology diagnosis and simul-
taneously to bortezomib-based induction chemotherapy. A dialytic protocol was
instated based on the Hutchinson scheme: HCO filter of 2.1m2 (Theralite™ by
Gambro®). Initially daily sessions on 6 consecutive days; afterwards, dialysis
on alternate days until getting levels of sFLC under 500mg/L or recovering a
renal function to avoid dialysis. The duration of every dialysis was 6 hours with
low blood flow between 250-300ml/min, and a bath flow of 500 ml/min (ultrapure
water). Blood monitoring includes renal function, sFLC, calcium, phosphorus,
albumin and ions.
Results: The patients were 12 men and 7 women, aged 60±4 years (37–73
years). 10 patients were diagnosed with lambda FLC MM and 9 with kappa
type. A total of 244 sessions were conducted, with an average of 11.6 sessions
per patient (range 3-27) In all cases reduction of serum FLCs concentration
was successfully achieved. (90% of reduction). At the end of treatment with
HCO-HD, the reduction of lambda and kappa FLCs concentrations was 85%
and 94%, respectively. The average reduction per dialysis session was 65%
for lambda and 60% for kappa. 17 out of the 21 treated cases recovered suffi-
cient renal function to become independent of dialysis (80.9% renal recovery).
Renal recovery appears to be sustained over time. There was a significant
association between the percentage reduction in serum FLCs concentrations
and renal recovery. Our results confirm previous findings on the effectiveness
of FLCs reduction by HCO-HD. Until randomized trials yield results, our highest
percentage of improve renal outcome with respect to published studies leads
us to recommend combined therapy of chemotherapy and HCO-HD in patients
with MM and renal failure.
Summary/Conclusions: In dialysis-dependent AKI secondary to MM, combi-
nation HCO HD with chemotherapy allows a sustained reduction of FLCs levels,
representing an effective therapy in renal recovery.
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IMPACT OF IMMUNOPARESIS IN PATIENTS WITH LIGHT CHAIN
AMYLOIDOSIS
L.G. Rodríguez-Lobato1,*, C. Fernández de Larrea1, M.T. Cibeira1, N. Tovar1,
J.I. Aróstegui2, L. Rosiñol1, M. Elena3, J. Yagüe2, J. Bladé1
1Department of Haematology, 2Department of Immunology, 3Department of
Biochemistry, Hospital Clínic, Barcelona, Spain
Background: The presence of immunoparesis (IP) at diagnosis in several
plasma cell disorders is a risk factor for progression, associated with an unfa-
vorable outcome with reduced progression-free survival (PFS) and overall sur-
vival (OS). However, its impact in light chain (AL) amyloidosis has been eval-
uated only in few series, and when present it was associated with worst
response and survival.
Aims: The aim of this study was to investigate the prognostic impact of IP in
patients with newly diagnosed AL amyloidosis at a single institution.
Methods: We reviewed the clinical records of patients with AL amyloidosis diag-
nosed from January 2006 to December 2016. Sixty-nine patients (32F/37M;
median age at diagnosis 62) with available immunoglobulin (Ig) measurements
were the final study population. Initial baseline demographics, clinical and lab-
oratory data, treatment and follow-up were collected. Median follow-up was 30.2
months. IP was defined as suppression of all uninvolved Ig below the lower ref-
erence value. PFS and OS were calculated from the date of diagnosis.
Results: Forty-three patients (62.3%) were transplant ineligible while 26
(37.7%) underwent an autologous stem cell transplantation (ASCT). The dis-
tribution of the monoclonal protein isotype by immunofixation at diagnosis was
as follows: light chains only (46.4%), IgG (39.1%), IgA (10.2%) and IgM (4.3%).
The predominant light chain isotype was lambda (79.7%). A very good partial
response (VGPR) or better was achieved in 53.6% of patients. Three-year OS
rate was 64.3%. IP was observed in 27.5% of the patients at diagnosis. Patients
with IP had a higher bone marrow plasma cells (BMPC) infiltration (29 vs. 9;
P<0.001). Also a trend towards a higher difference between involved and unin-
volved free light chains was observed in the group of patients with IP (360.2
vs. 221.7; P=0.08). IP was more frequent in those who received an ASCT
(57.9% vs. 42.1%; P=0.03). There were no changes in the frequency of IP
comparing at diagnosis vs. post-ASCT settings (39.13% vs. 34.78%; P=0.4).
Regarding its prognostic value, IP did not influence survival in the whole series.
In the ASCT group, the presence of IP resulted in a significantly shorter PFS
(median: 30.2 months vs. not reached [NR]; P=0.019; Figure 1A) and a trend
in OS (62.5 months vs. NR; P=0.097). In the group of patients with stage I and
II of the Mayo risk stratification system of 2012 (Mayo12), the presence of IP
resulted in a shorter PFS (21.8 months vs. NR; P=0.047; Figure 1B), but not
significantly different in OS. Multivariate analysis restricted to the population of
patients with stage I and II Mayo12, incorporating ASCT, BMPC and IP, indicate
that IP retained its independent prognostic factor for worse PFS (HR=12.06;
95% CI, 1.9-75.7; P=0.008).
Figure 1.
Summary/Conclusions: The presence of IP has a negative impact on survival,
especially in the sub-group of patients in early stages of the disease. The pres-
ence of IP at diagnosis could be an additional powerful discriminatory prog-
nostic indicator in the group of patients without advanced stage of the Mayo
risk stratification system of 2012.
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Background: The introduction of novel agents, such as proteasome inhibitors
(PIs) and immunomodulatory drugs (IMiDs) approved in 2006 and 2010,
respectively, and/or autologous stem cell transplantation (SCT) are associated
with improved overall survival of 60.6 months in Japanese multiple myeloma
(MM) patients (pts) (Ozaki et al. Blood Cancer Journal 2015). However, the
disease still remains incurable with disease relapse being inevitable after front-
line therapy (FLT). Data regarding treatment patterns and duration of treatment
(DOT) of Japanese pts with relapsed and refractory (RR) MM in routine clinical
practice is limited.
Aims: This retrospective study aims to describe the treatment patterns and
DOT of second-line therapy (SLT) with PI- and IMiD-based regimens and to
assess factors that influence treatment choice and DOT of SLT in Japanese
MM pts.
Methods: This is retrospective cohort study in pts with MM diagnoses with
ICD-10-CM (C900) codes between April 2008 and January 2016 in Japan. This
study used Japanese health insurance data provided by Medical Data Vision.
MM pts receiving SLT were included. Index date was defined as the first
observed claim for MM treatment and SLT was defined as switch to another
drug combination>60 days or retreatment following a treatment gap of>90 days
after starting FLT. Pts with salvage SCT were excluded. Observations were
censored at loss to follow up, death or the end of study period. Kaplan-Meier
analyses were performed to calculate DOT from the start of SLT. Welch’s test
was used to test for statistical significance between groups.
Results: Among 585 pts receiving SLT, mean age was 68.8 years of age (yo);
65.3% were ≥65 yo at start of SLT; 54.2% were male. Most pts received
lenalidomide (L)-based SLT (35.4%), followed by bortezomib (B)-based regi-
mens (29.4%) and other regimens not containing novel agents (35.2%); Other
regimens includes thalidomide, cyclophosphamide, etoposide, melphalan, vin-
cristine, (liposomal) doxorubicin, interferon, panobinostat, single-agent steroid;
only 1.2% received B+L combination therapy. L±D and B±D were the most
common (35.2% vs 21.7%) in SLT. Majority of Japanese pts received B-based
regimen in FLT among those receiving L±D and B±D SLT (77.2% vs 55.1%).
Pts with peripheral neuropathy (PN) and renal insufficiency (RI) prior to SLT
were 30.3% and 15.6%, respectively; those with PN were more likely to receive
L±D compared to B±D (35.9% vs 21.3%, P=0.0047), but those with RI was not
independently associated with treatment choice of SLT. Median DOT of L±D
was longer than B±D (13.8 vs 6.9 months, P=0.0001); DOT was similar for
those without a front-line SCT and receiving B±D FLT in both regimens (11.9
vs 11.9 months). PN and RI prior to SLT and age have not shortened the DOT
in SLT. Additionally, 35.4% experienced PN during SLT among pts receiving
L±D and B±D in SLT but there was no statistical significant difference of DOT
between pts with and without PN. Median daily dose of L was 12.0mg; there
was no significant difference of DOT between pts received at least and less
than 12.0mg.
Table 1.
Summary/Conclusions: Among pts in SLT, 65% of Japanese pts obtained L-
and B-based regimens. This observation is similar to the United States
(Romanus et al. EHA 2016) and Europe (Raab et al. EHA 2015). Majority of
pts did not receive triplet-based regimen. Pts experienced PN in FLT were
more likely to initiate L-based therapy in SLT and regimen type in SLT was cor-
related with DOT. Future research is needed to better understand treatment
changes in routine clinical practice and the impact on pts’ outcomes, especially,
after integration of novel agent-based triplet combinations as new standards
of care in RRMM in Japan.
References
1. Ozaki et al. Blood Cancer Journal 2015; Boudreault et al. Expert Rev Hema-
tol. 2017; Raab et al, EHA 2015 abstract: P647; Romanus et al, EHA 2016
abstract: E1287
E1261
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Background: Polyclonal antibodies against the conformational epitopes
between the heavy and light chains (HLC) of immunoglobulin (Ig) have been
recently introduced as diagnostic tool in multiple myeloma (MM) and other mon-
oclonal gammopathies. They separately identify the two different light chain
types of each Ig, allowing the quantification of the monoclonal component. HLC
and HLC ratios may be particularly useful for monitoring the presence of mon-
oclonal component in oligo-secretory MM or when it migrates in the β region,
as frequently observed in IgA MM. The International Myeloma Working Group
(IMWG) has published in 2016 new consensus criteria for assessing response
and minimal residual disease (MRD) in MM, outlining the potential role of HLC
assay in this setting and the need of its further investigation, particularly in
patients achieving complete response (CR) after treatment. 
Aims: We conducted a single center, prospective study of HLC ratio, in compar-
ison with free light chain (FLC) ratio, for the evaluation of MRD and its prognostic
role in MM patients achieving CR after first line treatments including novel agents.
Methods: Twenty-five consecutive patients were evaluated. Mean age was 63
years (range 43-82), fourteen patients were males. Ig isotype was IgG or IgA
in 14 and 11 patients, respectively, with 20 patients showing kappa and 5 lamb-
da light chains. According to International Staging System, seven patients had
stage 1, ten stage 2 and eight stage 3. Fourteen patients not eligible to autol-
ogous stem cell transplantation (AuSCT) received a bortezomib-based treat-
ment, mainly constituted by bortezomib, melphalan and prednisone combination
(VMP), while eleven patients underwent AuSCT after induction therapy with
bortezomib, thalidomide and dexamethasone (VTD). With a median follow-up
of 52 months (range 21-92), overall survival (OS) of the entire cohort was 61
months (95% CI 52-80) and progression-free survival (PFS) was 26 months
(95% CI 12-38). Ig HLC pairs (IgGk/IgGλ and IgAk/IgAλ) and FLC were ana-
lyzed on serum samples at diagnosis and at the time of immunofixation negative
CR (according to 2006 IMWG criteria), using Hevylite and Freelite commercial
kits, respectively, on a SPAplus analyzer (Binding Site); IgGk/IgGλ, IgAk/IgAλ
and k/λ ratios were then calculated.
Results: At CR time, we found seven (28%) samples still showing abnormal
HLC ratio and fourteen samples (56%) with abnormal FLC ratio. Discrepancies
between the two assays occurred in 11 patients. FLC assay normalization in
CR was significantly associated with better PFS (43 months, 95% CI 14-45)
respect to patients with persistent abnormal FLC ratio (12 months, 95% CI 9-
35, p=0,049). In contrast, normalization of HLC ratio had no impact on PFS (26
months, 95% CI 10-38, vs 20 months, 95% CI 10-34, p=0,51), even selecting
IgA MM. Notably, in 9 patients, the negative effect of abnormal FLC ratio at CR
on PFS was not mitigated by concomitant normalization of HLC ratio (19 months,
95% CI 4-35; p=0,022). Neither FLC, nor HLC affected OS. There were no dif-
ferences between patients who received AuSCT and those who did not.
Summary/Conclusions: To the best of our knowledge, this is the first study to
analyze HLC ratios exclusively in MM patients in CR. While our preliminary
data confirm the prognostic usefulness of FLC in this setting, currently they do
not support a role for HLC as putative biomarker of MRD. 
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Background: Emerging resistance to modern antimyeloma agents such as
proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) remains the
main clinical problem in managing multiple myeloma (MM). Daratumumab, a
first-in-class anti-CD38 monoclonal antibody, has been recently approved in
Europe as a monotherapy for patients (pts) with relapsed and refractory multiple
myeloma (RRMM), whose prior therapy included a PI and an IMiD and whose
disease had progressed during this time; based on the SIRIUS clinical trial out-
come (Lonial et al. Lancet 2016). Nevertheless to optimize daratumumab use
in clinical practice, more data on its “real life” activity and safety are still required.
Aims: This observational study of the Polish Myeloma Group (PMG) was aimed
to prospectively evaluate the efficacy and toxicity of daratumumab monotherapy
in RRMM pts treated within the daratumumab compassionate use named
patient program in Poland (DaraCUP).
Methods: Patients were eligible for DaraCUP if they met all the following criteria
a) confirmed diagnosis of RRMM, b) relapse after a minimum of 3 prior lines of
therapy (including PI and IMiD) or were double refractory to PI and IMiD, c)
had a ECOG performance status score 2 or lower. Data on treatment outcomes
and complications were anonymously collected using electronic CRFs. The
IMWG response criteria were applied.
Results: In total 30 patients were qualified to DaraCUP in Poland and all were
enrolled to the PMG observational study. At the time of writing this report, 26 pts
(87%) had received at least one dose of daratumumab and were included in the
safety analysis, while 22 pts (73%) had received at least 2 cycles of daratu-
mumab and were included in the preliminary efficacy analysis. Baseline pts
characteristics are reported in Table 1. Pts were heavily pretreated, with a median
of 4 prior lines of therapy (range, 2-10). Ten pts (38.5%) were double refractory
to both PI and IMiD while 15 pts (58%) were refractory to the last line of previous
therapy. Median time since initial diagnosis to start of treatment with daratu-
mumab was 3.9 years (range, 1.4-12.2 years). At the time of analysis, the median
follow-up time within the study was 5.1 months (range, 0-8 months) and median
daratumumab treatment duration was 4.4 months (range, 0-8 months). Sixteen
pts (61.5%) remain on treatment, while ten pts (38.5%) discontinued therapy as
a result of disease progression (n=7) and adverse events (AEs) (n=3). Overall
response rate (PR or better) was 31.8% including one (4.5%) CR and two (9%)
VGPR (Table 1). Stable disease was reported in 11 (50%) pts. The median PFS
and OS had not been reached. During the time of observation three deaths were
recorded due to disease progression. Regarding daratumumab toxicity, grade 3
or 4 non-haematological toxicities occurred in 8 pts (30.7%) and included: infu-
sion-related reactions (n=2), pneumonia (n=2), other infections (n=2), mandible
inflammation (n=1), dyspnoea (n=1). The most common haematological toxicities
of any grade were anaemia (n=8; 30.7%) and neutropenia (n=6; 23.1%) while
thrombocytopenia occurred in 3 pts; 11.5%. Grade 3 or 4 anaemia and neu-
tropenia were found in 3 (11.5%) and 2 (7.7%) pts, respectively. Updated results
will be presented at the meeting.
Table 1.
Summary/Conclusions: In this first real-world analysis we confirm that dara-
tumumab monotherapy is able to induce response in one third of highly pre-
treated and double refractory RRMM patients. Regarding safety, in contrast to
the SIRIUS trial where no treatment discontinuations due to AEs occured, 3/26
pts (11%) treated with daratumumab in clinical practice had their therapy inter-
rupted due to complications.
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Background: Multiple myeloma (MM) is the second most common haemato-
logical malignancy after non-Hodgkin lymphomas, accounting for 13% of blood
malignancies and 1% of all cancers1. The medical management of multiple
myeloma has changed over the years and is inﬂuenced by multiple factors
(e.g., evidence from clinical trials, drug approval status, level of drug reim-
bursement, guidelines), which vary across Europe. Information describing how
patients are managed in the real world is needed.
Aims: The aim of this analysis was to investigate real-world treatment patterns
and patient characteristics in MM across Europe.
Methods: Physicians in Europe were requested to answer a series of questions
on patient characteristics and treatment regimens of the last eight patients that
they had treated during the month prior to answering the questionnaire, accord-
ing to their patients’ medical charts. The questionnaire was conducted between
January and June 2016. Data on 2564 patients with MM were available and
are presented here. Countries were grouped into regions according to similar
health care systems: Spain, Portugal, Italy and Israel (Southern Region, SR,
n=1099); Austria, Netherlands, Belgium, Norway, Sweden, Switzerland and
Finland (Central and Northern Region, CNR, n=776); Croatia, Estonia, Hungary,
Latvia, Lithuania, Poland, Serbia, Slovakia (Eastern Region, ER, n=689). Analy-
ses were descriptive
Results: Patient characteristics were generally similar across regions, with the
majority being <75 years old (69-76%), receiving frontline therapy at study
inclusion (57-58%), and being ineligible for autologous stem cell transplant
(ASCT) (53-59%). The median time from MM diagnosis to the time that the
physician answered the questionnaire was higher in ER (19.5 months) than
other regions (9.7-11 months) (Table). The majority of frontline regimens con-
tained bortezomib although this was lower in ER (51%) than other regions (66-
70%). The median duration of frontline therapy was longer in ER (4.5 months)
than other regions (3.2 months). This difference was mainly driven by ASCT
eligible patients having longer duration of therapy in ER (4.5 months) than
other regions (2.2 months). The number of bortezomib injections in frontline
therapy, however, was higher in SR and CNR (both 24) than in ER (18). The
majority of second line regimens contained lenalidomide (57-64%) in all regions
except ER, where bortezomib-based regimens were most frequent (38%). The
median duration of second line therapy was shorter in SR and CNR than in ER
(Table). Moreover, for second line therapy, ASCT-eligible patients had shorter
duration of therapy in ER and SR (3.2 months) than in CNR regions (4.5
months). The majority of later-line (3+) regimens were based on therapies that
did not include bortezomib, lenalidomide or pomalidomide for all regions (57-
67%) with the exception of SR where pomalidomide (29.4%), lenalidomide
(12.6%) and bortezomib (14%) were the preferred options. In this analysis con-
ducted in Europe, treatment patterns differed in terms of regimens used and
duration of therapies even though patient characteristics were generally similar
across regions. This may in part be related to differences in healthcare systems.
Further research is required to understand how new therapies can be integrated
into current treatment patterns and how these treatment patterns impact patient
outcomes.
Table 1.
Summary/Conclusions: In this analysis conducted in Europe, treatment pat-
terns differed in terms of regimens used and duration of therapies even though
patient characteristics were generally similar across regions. This may in part
be related to differences in healthcare systems. Further research is required
to understand how new therapies can be integrated into current treatment pat-
terns and how these treatment patterns impact patient outcomes.
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Background: Worldwide, life expectancy continues to rise. The treatment of
elderly people with cancer poses special challenges that should be better
addressed. Frailty is a geriatric syndrome associated with reduced functional
reserve, impairment in multiple physiological systems, and reduced ability to
regain physiological homeostasis.
Aims: To evaluate the impact of the level of frailty on early death and overall
survival of elderly patients with multiple myeloma.
Methods: Retrospective study of a cohort of 150 patients older than 65 years
with a recent diagnosis of multiple myeloma from January 2006 to December
2012. Patients were treated with IMIDs, alkylating or bortezomib based
chemotherapy based on physician preference blind to the geriatric assessment.
A check list for frailty burden measurement was used based on Edmonton
frailty score and included: cognitive impairment, depressive disorder, polyphar-
macy, urinary incontinence, functional impairment, gait disturbance or falls, low
weight or weight loss and previous hospitalization. Level of frailty was scored
as the sum of each area involved. Record of all the variables were obtained
from a retrospective review of the centralized and computerized medical
records by a hematologist and geriatrician, using predefined standardized cri-
teria. Patients were classified as fit (0-1 frailty criteria), vulnerable (2-3 criteria)
or frail (≥ 4 criteria). OS and PFS were estimated using the Kaplan Meier
method using Stata13 program Group differences according to frailty were
investigated using the Cox proportional hazard model accounting for ISS, age,
Charlson comorbidity index and treatment.
Results: From the 150 patients evaluated, 124 patients were included in the
study. The median age was 77 years (range 65-98). Thirty one percent of the
patients were older than 80 years, 51% were female. The median Charlson
Comorbidity index was 2 (range 0-7), 28% had renal failure and 40% of the
patients presented with Myeloma ISS 3. Sixty five percent of patients met at
least one frailty criteria and 31% of patients were considered frail. The most
common findings were polypharmacy, gait and functional impairment. Most
patients were treated with IMIDs (47%); alkylating agents (33%) or borteomib
(14%) based chemotherapy. There was no difference in treatment according
to frailty group (p=0.38). The median overall survival time was 75 months (95%
CI 53-110), 39 months (95% CI 19-64) and 17 months (95% CI 5-37) for fit,
vulnerable and frail patients respectively (log rank p 0,0002). Frailty was spe-
cially associated with early death [OR 8,2 (95% CI 1,9-34) p=0.0007]. In the
multivariate analysis a higher risk of death was observed related to age [ HR
1,07 (95% CI 1,02-1,12) p 0,002], number of frailty criteria [HR 1,13 (95% CI
1 – 1,3) p 0,05] and ISS [HR 2,6 (95% CI 1,8 -3,8) p 0,001]. The frailty criteria
independently associated with death were incontinence polypharmacy and pre-
vious hospital admissions. Frailty was specially associated with early death
[OR 8,2 (95% CI 1,9-34) p=0.0007].
Table 1.
Summary/Conclusions: This study shows that the prevalence of frailty syn-
drome is high and has a profound impact in early death. It is also independently
associated with a worse prognosis. Frailty should be considered as part of the
clinical assessment when treating elderly patients with myeloma.
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PROGNOSIS OF AL AMYLOIDOSIS WITH KIDNEY INJURY
A. Talbot1,*, X. Belenfant2
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Background: AL amyloidosis is a rare disease related to excessive and uncon-
trolled secretion of monoclonal light chains. The consequence of this prolifer-
ation is an alteration of the affected organs due to deposition of free light chains.
Despite therapeutic advances in recent years based, among others, on the
finding of French studies, the prognosis of this disease remains poor in partic-
ular for patients with cardiac disease. Kidney involvement is also frequently
observed at diagnosis in the form of a classical nephrotic syndrome, but at
present the prognosis of chronic renal failure in this context is unknown.
Aims: The study was interested in the prognosis of AL amyloidosis associated
with endstage renal disease on dialysis in the era of treatment with bortezomib.
Methods: A total of 133 patients (61 from Ile-de-France region register and 72
from reference center) were analyzed.
Results: A total of 133 patients (61 from Ile-de-France region register and 72
from reference center) were analyzed. Median survival was 66.7 months com-
pared to 70.6 months for patients without dialysis (p=0.65). Within the group
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of patients on dialysis, there is no significant difference between those receiving
or not bortezomib. Median survival before 2008 was 54.82 months and rose to
82.30 months for patients treated after this date (p=0.95). Age (HR: 0.2819, CI
0.1375 to 0.5782), heart disease (HR: 0.3746, CI 0.1724 to 0.8141) and serum
albumin (HR: 2.500 CI: 1.077 to 5.803) were identified as prognostic factors.
Transplantation is a viable treatment option for good responders.
Summary/Conclusions: Prognosis of AL amyloidosis in dialysis is heteroge-
neous. Prognostic scoring integrating clinical biological data could identify the
patient who may benefit the most dialysis. This results need to be matched by
sex and age with non-dialysis and dialysis for another cause.
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Background: The combination of lenalidomide/dexamethasone (LenDex) is
an established treatment for relapsed/refractory Multiple Myeloma (MM)
patients; however, apart from clinical trials, there is limited data for the efficacy
of this combination as 2nd line treatment. Furthermore, the efficacy of LenDex
when administered before evident clinical manifestations, namely in the case
of biochemical relapse as compared to clinical relapse, has not yet been
assessed.
Aims: In the current study, we evaluated response rates and progression-free
survival (PFS) in patients treated with LenDex in 2nd line and we compared
survival parameters for patients treated with LenDex at biochemical relapse vs
those treated at clinical relapse.
Methods: Medical files of 207 patients with MM diagnosed between 2000-2013
in 18 Greek centers and treated with LenDex as 2nd line treatment from January
1st 2009, up to March 1st 2014, were retrospectively studied. Overall response
and PFS were evaluated for all patients. Additionally, PFS was compared in
patients treated at either biochemical relapse (group A) or at clinical relapse
(group B). The prognostic significance of biochemical relapse adjusted with
important patients’ characteristics was also evaluated. Classical methods were
used for statistical analysis.
Results: Two hundred and seven patient files were recorded and analyzed
(M/F: 112/95, median age: 67.2y, range 31-91y, IgG: 115, IgA: 55, Light chain:
22, non-sectretory: 2, IgD: 5, IgM: 1, unknown: 7, ISS I: 54, ISS II: 74, ISS III:
77, high risk: 13%, standard risk: 87%). First line treatment included borte-
zomib-based regimens (63.3%), immunomodulatory drug-based combinations
(34.8%) and chemotherapy (40.1%); 25% of patients underwent autologous
stem cell transplantation; 2nd line treatment with LenDex was administered at
biochemical relapse in 67.5% (95% CI: 61.1% >73.9%) of patients and at clinical
relapse in 32.5% (95% CI: 26.1-38.9) of patients. The overall response rate
(ORR) was 73.4%; 23.7% of patients achieved very good partial response
(VGPR) and 17.8% complete response (CR). The number of patients that
achieved at least VGPR did not differ between the 2 groups (p>0.05). The medi-
an time to best response was 6.7 months (range 0.6- 51.9). After a median fol-
low-up of 52.8 months, 112 (54.1%) patients are alive and 95 (45.9%) patients
are deceased; 131 patients (63.3%) have relapsed (biochemical relapse:
66.4%, clinical relapse: 33.6%). Median PFS and PFS rate at 12 months was
19.2 months (95% CI: 15.6-25.2) and 67.6% respectively. The median PFS
was 24 months (95% CI: 18.0-34.8) for patients in group A vs 13.2 months
(95% CI: 8.4-19.2) for patients in group B (HR: 0.63, p=0.006). When adjusted
for important prognostic patients’ characteristics (ISS, age, β2 microglobulin,
and LDH), biochemical relapse maintained its prognostic significance for PFS
(p<0.05).
Summary/Conclusions: Our data confirm that Lendex combination as 2nd
line treatment leads to high overall response rates and prolonged PFS. Addi-
tionally, we have shown for the first time in routine clinical practice that MM
patients who receive 2nd line therapy with LenDex at biochemical relapse have
a significantly longer median PFS compared to patients treated at clinical
relapse, underlining the importance of potentially starting treatment before evi-
dent clinical manifestations at the first relapse.
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Background: Dual Time Point (DTP) 18F-FDG PET imaging has been shown
to be useful in differentiating malignant from benign lesions in that increasing
uptake from 1 to 3 hours is a characteristic feature of malignancy in contrast to
inflammation.
Aims: The aim of this study was to evaluate the predictive role of DTP 18F-
FDG PET/CT imaging in assessing response to chemotherapy in multiple
myeloma (MM).
Methods: 23 patients with MM (21 male, aged 53-75 years) underwent 18F-
FDG PET/CT in a prospective study (NCT02187731) before start of treatment
and two months after high dose chemotherapy with stem cell support. All scans
were performed at 60 and 180 minutes after tracer injection at Odense Univer-
sity Hospital and Vejle Hospital. Thirteen patients with ≥ 3 focal lesions of at
least 10 mm were selected for analysis. Images were analyzed using an adap-
tive thresholding algorithm (ROVER software; ABX GmbH, Radeberg, Ger-
many). Focal malignant lesions were localized in pre-treatment scans; maxi-
mum standard uptake value (SUVmax) and mean SUV (SUVmean) and partial
volume corrected SUVmean (pvcSUVmean) were obtained for each lesion.
Lesional response to chemotherapy was classified as complete or partial in
the post-treatment scan. A complete response was defined as a complete res-
olution of the lesion in the post-treatment scan. Lesions with partial response
were present in the post-treatment scan. All statistical analyzes were done in
SPSS 24 using repeated measurements-ANOVA.
Results: Three-five focal lesions were evaluated in each patient. In the pre-
treatment PET studies, the increase in SUVmean from 1 to 3 hours was signif-
icantly higher for lesions with partial response compared to those with complete
response (27.7% vs 11.4%; P=0.050). Additionally, the increase in pvcSU-
Vmean was more significant than the increase in SUVmean (+42.23% vs
+12.0%; P=0.003). The increase in SUVmax of delayed scans was not signif-
icant (P =0.082).
Summary/Conclusions: These preliminary data show that a more significant
increase of FDG uptake in delayed scans of DTP PET before treatment corre-
lates with a poor response of focal malignant lesions to chemotherapy in MM.
The increase in pvcSUVmean is a better index than those of SUVmean and
SUVmax for this purpose.
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Background: Multiple myeloma (MM) is an incurable cancer stemming from
malignant plasma cells. MM is characterized by a strong tropism to the bone
marrow (BM), where tumor cells accumulate and establish complex interactions
with the normal stroma, which in turn promotes tumour survival, drug resistance
and the development of bone disease. The Notch oncogenic pathway provides
a key contribute to the ability of MM cells to shape the BM niche, affecting both
MM cell biology and the interplay with the surrounding normal cells. Recently,
extracellular vesicles (EVs) have been reported as novel mediators in creating
a supportive milieu for MM. Here we investigate the role of the activated Notch
signaling in EV-mediated cross-talk.
Aims: The aim of this work was to further elucidate the role played by the Notch
pathway in the shaping of the BM microenvironment to provide a supportive
milieu for MM cells, with a focus on the contribute of EVs to the crosstalk
between MM cells and the BM stromal cells.
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Methods: We established two MM cell lines stably retaining the doxycycline-
inducible pTRIPZ vector containing anti-Jagged1 and Jagged2 shRNAs and a
BM mesenchymal stromal cell (BMSC) line expressing shRNAs for Notch1 and
Notch2. EVs were isolated by ultracentrifugation and used for functional assays
and molecular analysis. qPCR was performed using SYBR Green. Apoptosis
analysis was performed by flow cytometry; evaluation of protein expression
was achieved by flow cytometry or western blot.
Results: We present evidences that EVs play a crucial role in the dysregulated
interactions of MM cells with the BM microenvironment and that Notch regulates
their release. Indeed, BMSCs knockdown for Notch1/2 results in a decrease
in EVs release and reduce their ability to induce Bortezomib resistance in MM
cells and to stimulate their migration. On the other side, MM-derived EVs are
able to increase the production of pro-tumor factors by BMSCs (i.e. SDF1α),
promoting their ablity to boost tumor growth; interestingly, this effect is lost
when EVs are isolated from MM cells where the Notch pathway was inhibited.
Finally, EVs released by co-cultures of BMSCs and MM cells where the Notch
pathway is blocked display a reduced ability to increase osteoclastogenesis
compared with EVs from the control culture. This is particularly relevant due to
the crucial role played by bone disease in MM progression.
Summary/Conclusions: These new insights in the pathophysiology of the de-
arranged BM niche represent the rationale for a Notch-directerd therapy aiming
to uncouple the crosstalk of MM with the surrounding microenvironment by
inhibiting Notch signaling.
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THE USE OF CARFILZOMIB AND BORTEZOMIB IN ROUTINE CLINICAL
PRACTICE: RESULTS FROM PREAMBLE, AN ONGOING, OBSERVATIONAL
COHORT STUDY IN MULTIPLE MYELOMA
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Background: Multiple myeloma (MM) remains largely incurable despite
improvements in clinical outcomes following the approval of immunomodulatory
drugs (IMiDs) and proteasome inhibitors (PIs) (Rajkumar et al 2010). Previous
findings from PREAMBLE indicated shorter median duration of therapy (DoT)
with PIs and IMiDs (5 and 9 mo, respectively; Palumbo et al 2016) vs clinical
trials (Stewart et al 2014). Understanding real-world use of therapies for
relapsed/refractory (RR) MM is important to determine their position in the
treatment paradigm.
Aims: In this subsequent PREAMBLE analysis, treatment patterns in patients
(pts) with RRMM receiving bortezomib (bort) and carfilzomib (carf) were eval-
uated to better understand the use of PIs in routine clinical practice.
Methods: PREAMBLE (NCT01838512) is an ongoing, observational, interna-
tional cohort study exploring real-world treatment patterns and outcomes in
pts with MM. Eligible pts were aged ≥18 yrs with diagnosis of RRMM, ≥1 prior
therapy and initiated treatment (index therapy) with an IMiD, PI or IMiD+PI
within 90 days before to 30 days after study enrollment. Treatment patterns,
DoT and time to next treatment (TTNT; for pts who switched or died) were
assessed. Informed consent was obtained for all pts. 
Results: At data cut-off (Sept 1, 2016), data were available for 924 pts, of
which 326 (35%) pts had bort-based index therapy and 86 pts (9%) received
carf-based index therapy (63/72 [88%] were enrolled in North America). The
most common bort-based combination was bort + dexamethasone (dex; n=99,
30%). The most common carf-based therapies were carf alone (n=40, 47%),
followed by carf+dex (n=21, 24%). The most widely used bort dose per 21
days for any bort-based therapy was ≤4.0mg/m2 (98/151; 65%). The most com-
mon carf dose per 28 days received for any carf-based therapy was ≤120mg/m2
(28/55; 51%). Switch from carf-based index therapy occurred after a median
(Q1, Q3) DoT of 3.4 (1.9, 9.5) mo (n=34); most pts switched to pomalidomide
(pom)-based regimens (23/34; 68%). Switch rates increased from 17% at 3
mo to 54% at 15 mo, and then to 57% at 24 mo. Median (Q1, Q3) TTNT from
index therapy was 5.6 (2.3, 9.0) mo (n=53). Median (Q1, Q3) DoT (n=113) and
TTNT (n=173) for bort-based index therapy was 4.5 (2.4, 7.1) and 7.0 (3.7,
12.3) mo, respectively; most pts switched to lenalidomide (43/113; 38%) or
pom (33/113; 29%). Switch rates increased from 10% at 3 mo to 57% at 33
mo. Dose reductions on carf-based therapies (6/86; 7%) were mostly deter-
mined by clinical decision (67%), whereas for bort+dex (24/99; 24%) adverse
events (AEs) were the main reason (63%). Discontinuation/switching from carf-
based index therapy was reported for 80% (69/86) of pts, driven mainly by dis-
ease progression (39%) and AEs (14%). Similarly, disease progression (27%)
and AEs (21%) were also the main reasons for pts discontinuation/switching
from bort+dex therapy (84/99; 85%). AEs were reported for 45% (39/86) of pts
with carf-based index therapy, most commonly fatigue (12%) and anemia (9%);
70% (69/99) of pts receiving bort+dex had AEs, most commonly thrombocy-
topenia and diarrhea (each 14%).
Summary/Conclusions: Treatment duration observed for PIs in the real-world
clinical practice setting was shorter than reported in clinical trials. As patient
enrollment and follow-up continues for PREAMBLE, additional analyses will
be conducted to evaluate the impact of these patterns on efficacy outcomes.
Study funding: BMS. 
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ROLE OF SERUM FREE LIGHT CHAIN VS BENCE JONES MEASURE-
MENT IN LIGHT CHAIN MULTIPLE MYELOMA (LCMM) AT DIAGNOSIS,
DURING TREATMENT AND FOLLOW-UP FOR RESPONSE EVALUATION
AND RELAPSE DETECTION
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rence, Italy, 3BMT Unit, Azienda Ospedaliero-Universitaria Careggi, Florence,
Italy
Background: According to IMWG recommendations for response assessment
in multiple myeloma (MM), serum free light chain (sFLC) measurement should
be used to define a “stringent” complete response in symptomatic MM and,
only in cases when Bence Jones protein (BJP) is deemed as not quantifiable
(<200mg/24h), in light chain multiple myeloma (LCMM). However, data are
available suggesting that sFLC could be a more sensitive tool than BJP for
minimal residual disease assessment and an earlier indicator of progressive
disease (PD). BJP measurement requires to perform both urinary electrophore-
sis and immunofixation, it is time-consuming for tecnicians and could be limited
by poor patient compliance.
Aims: Aim of our study was to retrospectively compare sFLC and BJP results
in LCMM patients (pts) at diagnosis, during treatment and follow-up.
Methods: Serum and urine samples were collected from pts affected with plasma
cell dyscrasia referring to the Azienda Ospedaliero-Universitaria Careggi between
1st February 2012 and 31 December 2013. Serum and urine protein elec-
trophoresis was performed using Capillarys II, serum and urine immunofixation
using Hydrasys II (both from Sebia), sFLC were measured on Immage 800 neph-
elometer (Beckman Coulter) using Freelite reagents (The Binding Site).
Results: We analized samples from 387 pts having positive serum and/or pos-
itive urinary immunofixation and/or abnormal sFLC ratio. Among them, 43
symptomatic LCMM pts were identified having both sFLC and BJP measure-
ment at baseline (at MM diagnosis or first relapse). Serum and urine lab tests
results were evaluated at baseline, monthly during therapy and every 3 months
during follow-up. Median duration of laboratory monitoring for the whole group
was 42 months (range 3-120). Autologous stem cell transplantation was per-
formed in 30% of pts previously treated with proteasome inhibitors (81%) and/or
immunomodulating agents (40%) or chemotherapy (9%). sFLC or BJP were
not available in 10% of 872 pair of samples from 43 pts. In 10% of cases
(68/696 pair of samples) sFLC ratio was abnormal with increased involved
FLC without any detectable BJP (FLCr+;iFLC+;BJP-); the opposite (FLCr-
;iFLC-;BJP+) occurred in 1% of cases (8/696 pair of samples). Renal failure
was found in 9% vs 13% of discrepant cases. At baseline, of the 43 LCMM pts,
6 had “measurable disease” only by sFLC due to BJP<200mg/24h and were
therefore considered not evaluable for response assessment. Median time to
BOR was 3 months by both sFLC and BJP (range FLC: 1-11 mesi; range BJP:
1-10 mesi). Among the remaining 37 pts evaluable for best overall response,
6/37 had complete response according to BJP but not to sFLC; interestingly
5/6 progressed after 2-8 months. Twenty-one pts progressed during follow-up:
PD was detected only by sFLC in 4, only by BJP in 1. Both tests were able to
detect PD in 16 pts: at the same time in 5, with sFLC-PD occurring earlier in 7
and BJP-PD occurring earlier in 4 pts.
Summary/Conclusions: Both sFLC and BJP measurement are useful in
LCMM pts for disease monitoring, however, sFLC assessment appears to be
more sensitive in MRD and early relapse identification. These data suggest
that BJP could be substituted by sFLC assessment in LCMM. In our series
only 1 case showed BJP-PD according to IMWG occurring earlier than sFLC-
PD but was considered not clinically significant. On the contrary 5 pts in BJP-
CR clinically progressed within few months without having reached FLC-CR.
Limits of our study are a small number of pts, inhomogeneous duration of ther-
apy and follow-up and retrospective analysis.
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SUPPRESSION OF THE NON-MONOCLONAL PAIR AS NEW BIOMARKER
OF POOR PROGNOSIS IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS
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Background: The outcome for patients with Multiple Myeloma (MM) is highly
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variable. Understanding the prognosis for a particular patient can help when
selecting the intensity of treatment to be used and the frequency of reviews.
The quantification of heavy/light chains pairs by the immunoassay Hevylite
(HLC) allows us a precise measurement of monoclonal and non-monoclonal
immunoglobulins of the same isotype. 
Aims: The aim of the study is to evaluate i) the impact of the “HLC ratio” defined
as monoclonal immunoglobulin over isotype matched non-monoclonal
immunoglobulin (involved/uninvolved HLC ratio or i/u HLC ratio), ii) the sup-
pression on non-monoclonal pair denominated “HLC-matched pair suppression”
and III) the effect of “systemic immunoparesis” at diagnosis and at +100 days
after autologous stem cell transplant (ASCT).
Methods: 85 patients (50 Male:35 Female) with a median age of 70 years (56-
78) were followed (35 IgGK, 18 IgGL, 17 IgAK and 15 IgAL). The median fol-
low-up of the patients was 19 (5-30) months. Sixteen patients (18%) presented
ISS stage I, 15 (28%) with stage II and 54 (64%) with stage III disease. Thirty
patients that reached ASCT were evaluated at +100 days after ASCT.
Immunoglobulin heavy/light chain pairs (HLC) were assessed by Hevylite
assays (The Binding Site). Clinical variables were evaluated for their impact on
patient´s outcome. Overall survival (OS) and progression-free survival (PFS)
were evaluated by Kaplan-Meier method and Cox regression. Statistical analy-
sis was made with Prism 6.0.
Results: The median OS of the 85 patients was 54% and 26 patients deceased
during the study due to MM. The median value of i/u HLC ratio was 80 (31.5-
319.71). At diagnosis, a i/u HLC ratio>80 was significantly associated with worse
OS (48 vs 61%, p=0,005) and shorter PFS (23% vs 42%, p=0,006). Severe
HLC-matched pair suppression (i.e. more than 50% below the lower reference
range) was identified in 68% of the newly diagnosed patients and was associated
with significantly shorter OS (35% vs 81%, p=0,004) and PFS (21% vs 50%,
p=0,013). Severe (>50%) systemic immunoparesis of non-monoclonal
immunoglobulins was identified in 64% of the patients at diagnosis and was
also significantly associated with shorter OS (32% vs 81%, p=0,030) but not
with shorter PFS (26% vs 44%, p=0,306). The evaluation of other clinical vari-
ables on patient´s outcome are shown in table (see Table). In multivariate analy-
sis, severe HLC-matched pair suppression and albumin were found as inde-
pendent risk factors for OS whereas creatinine and i/u HLC ratio >80 were found
as independent risk factors for PFS. In the post-ASCT evaluation of the patients
(n=30), normalization of HLC ratio was observed in 22 patients (73%). An altered
HLC ratio was significantly associated with shorter PFS after ASCT (25% vs
70%, HR: 3,42, 95%CI 1,12-11,97, p=0,039) and with a trend towards a worse
OS (p=0,072). Severe HLC-matched pair suppression was found in 12 patients
(40%) and was predictive of worse OS (0% vs 70%, HR: 10,63, 95%CI: 1,11-
114,11, p=0,023) and shorter PFS (35% vs 71%, HR: 8,87, 95%CI: 1,72-45,92,
p=0,002). On the other hand, the severe systemic immunoparesis observed in
17 patients (57%) was not associated with OS (p=0,644) and PFS (p=0,750).
Table 1.
Summary/Conclusions: Severe HLC-matched pair suppression and i/u
HLC>80 are associated with worse OS and shorter PFS in MM patients sug-
gesting a potential use of these parameters as prognostic biomarkers in newly
diagnosed patients. Severe HLC-matched pair suppression is an independent
risk factor for OS whereas i/u HLC>80 is independently associated with shorter
PFS. In patients after ASCT, severe HLC-matched pair suppression reflects
the persistence of clonal cells that is not associated with severe systemic
immunoparesis.
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Background: Established risk stratification tools in MM, such as the Interna-
tional Staging System (ISS) and the revised ISS, have improved overall survival
(OS) estimates by combining the strongest known predictors of survival at diag-
nosis. There remains, however, a need for tools that use additional data avail-
able at relapse to improve risk stratification. We previously used real-world data
from the Czech Registry of Monoclonal Gammopathies (RMG) to develop a
RSA for estimating risk of death in patients with MM starting second line (2L)
treatment. A multiple Cox regression model identified predictors of OS at 2L
(Table); hazard ratios (HRs) for each predictor were multiplied to obtain an
overall score for each patient. A K-adaptive partitioning for survival (KAPS)
algorithm stratified patients into risk groups based on these scores.
Aims: To investigate how our RSA is affected by: 1) removing cytogenetic
abnormalities (CAs) at diagnosis as an OS predictor, as these are not routinely
measured in practice; 2) adding 2L treatment as a predictor, as 2L treatment
type is likely to affect OS; 3) changing the number of stratification groups.
Methods: The analyses used data for 1418 patients aged ≥18 years who were
diagnosed with symptomatic MM between May 2007 and April 2016 and who
had started 2L. The Cox model was re-run for two sensitivity analyses: excluding
CAs and adjusting for treatment received at 2L (adding bortezomib or lenalido-
mide vs other treatments as a predictor). The impact of different numbers of
risk groups was assessed using KAPS.
Table 1.
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Results: Results are shown in the Table. The model without CAs had similar
HRs and predictors to the original; however, lactate dehydrogenase level at
diagnosis was not identified as a predictor. Kaplan–Meier OS analysis showed
separation between groups (median OS for the lowest [group 1] to the highest
[group 4] risk group: 57.2, 29.4, 14.9 and 4.9 months), but the separation was
weaker than when CAs were included in the model (median OS: 57.2, 28.8,
13.4 and 4.7 months). Despite 81% of patients in the RMG having no CA data,
(‘missing’ CA was treated as a separate level in the original model), the fit of
the model (measured using Akaike’s information criterion; Table) without CAs
was worse than the original, reducing the accuracy of survival predictions.
Adding 2L treatment as a predictor did not affect the model fit, indicating that
OS predictions were not improved. KAPS analysis showed that a model with
three groups for stratifying patients by risk of death was less effective than one
with 4 or 5 risk groups. With group 1 as the reference, the HRs for OS were
2.4 and 8.1 for groups 2 and 3 in the three-group model (all p<0.001), 2.1, 4.2
and 11.1 in groups 2–4 in the four-group model (all p<0.001) and 1.8, 2.8, 4.9
and 10.5 for groups 2–5 in the five-group model (all p<0.001). Using five risk
groups was considered less practical in a clinical setting than the four-group
model, which provides a clearer difference in risk across groups.
Summary/Conclusions: These analyses indicate that our RSA incorporating
data from diagnosis and relapse can identify patient groups with profoundly
different survival expectations, regardless of 2L treatment type. CAs at diag-
nosis is a known OS predictor and, as expected, improves the strength of pre-
dictions. The practicalities of measuring CAs should be considered, but these
data suggest that physicians should be encouraged to assess CAs at diagnosis;
CAs at relapse may also be informative. Further validation of this model is
required using other real-world and clinical trial data.
E1273
REAL-WORLD DATA ON MULTIPLE MYELOMA: A PROSPECTIVE
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Background: The Uruguayan National Myeloma Registry is the first observa-
tional prospective Uruguayan registry designed to document clinical charac-
teristics of newly diagnosed multiple myeloma (MM), treatment and outcomes
in a real-world setting. It collects detailed data from MM patients diagnosed at
all institutions from 2012, nationwide. Analysis of this non-selected data will
allow us to plan strategies to improve our local approach to this disease, reduc-
ing problems derived from extrapolating information from other realities.
Figure 1.
Aims: To document current strategies of clinical characteristics at diagnosis,
management, outcomes and treatment adverse effects of non-selected newly
diagnosed MM patients in a recent period. 
Methods: This registry includes all MM diagnosed from January 2012 in all
institutions, nationwide. Smoldering MM are not included. We present the analy-
sis of the first 3 years of data collection. Information was obtained from medical
records at each institution. Our database includes clinical and laboratory char-
acteristics, treatment, disease-related and treatment-related adverse events,
response, progression free survival, overall survival and cause of death. Sur-
vival is obtained from the Uruguayan Ministry of Health database.
Results: With a 71% institutional coverage, 224 patients were included. Median
age at diagnosis was 66 years (range 33-94 years), 54,5% were male; 10%
were younger than 50 years and 34,5% older than 70 years. Distribution
according Ig subtype was: IgG 50,4%, IgA 23,3%, Light chains 18,7%, non-
secretor 2,2% and IgM <1%. Most patients had advanced disease: 79,6%
Durie-Salmon stageIII (176/221), 48,6% ISS3 (86/177). Anemia (hemoglo-
bin<10 g/dl) was present in 58%, osteolytic lesions in 69%, renal impairment
(creatinine>2mg/dl) in 29,5% and hypercalcemia in 10%. Cytogenetics was
evaluated in 150 patients; high risk features were detected in 6,3% by conven-
tional cytogenetics and 19% by fluorescence in situ hybridization. First-line
treatment included at least one of the new drugs (Thalidomide, Bortezomib or
Lenalidomide) in 92% of patients ≤70 years and in 50% of>70 years. First-line
response was available in 73%. Overall response rate (≥ PR) was 82,3%,
VGPR= 23,2% and CR=15,2%; 9,8% patients achieved stable disease and
7,9% were refractory. (Fig 1.). Comorbidities and treatment-related toxicities
were observed in 43,8% (47% in>70 y vs 41%). Most common adverse events
were recurrent infections (26%), neuropathy (17%), thromboembolic
events(5,4%) and grade 3-4 cytopenias(5%). Sixty out of 146 potential candi-
dates have been transplanted as first line consolidation at the time of this analy-
sis. After a median follow-up of 30 months, overall survival was 62,8% (median
NR in ≤70 years and 32 months in>70 years) and median progression free
survival (PFS) was 17 months.
Summary/Conclusions: This first national registry provides a thorough insight
into the characteristics of MM patients in our country. With a high institutional
coverage, we show MM characteristics at diagnosis are similar to other real-
life reports.(1) MM is detected in advanced stage with a high percentage of
renal impairment. Diagnosis is performed according to international recom-
mendations. First-line treatment is defined by local policies which restrict Borte-
zomib to high-risk cytogenetic features and/or renal impairment and do not
provide Lenalidomide. Reasons for 59% potential candidates not receiving
ASCT should be addressed in future research. This analysis provides relevant
real-life information to plan strategies to improve MM management and perform
high quality population-based research on the field.
Reference
1. Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et
al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol.
Oct 2016;175(2):252-64. 
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Background: Multiple myeloma (MM) accounts for approximately 1% of all
cancers and 10% of hematologic malignancies in the United States (US). MM
occurs in all races but the incidence in African Americans is two to three times
higher than in non-Hispanic whites. Many clinical trials (CT) lack appropriate
representation of specific patients populations, limiting the generalizability of
the evidence obtained.
Aims: Determine the representation of ethnic minorities, the elderly and women
in MM CT.
Methods: Enrollment data from all therapeutic trials reported as completed in
clinicaltrial.gov from 2000 to 2016 were analyzed. CT including other hemato-
logic malignancies and with recruitment outside of the US were excluded.
Enrollment fraction (EF) was defined as the number of enrollees divided by
the 2013 Surveillance, Epidemiology, and End Results (SEER) database MM
complete prevalence. Chi-square test was used to estimate differences in cat-
egorical data.
Results: Out of 177 MM CT, 78 (44%) reported ethnicity with a total of 12,055
enrollees. Out of those 78 CT, 52 (67%) were phase II, 15 (19%) phase III and
11 (14%) phase I. Most of the results were published from 2012 to 2016 (74%).
Distribution by race, gender, age and comparison with the SEER MM preva-
lence data are described on Table 1. Forty-six (59%) trials were sponsored by
industry, 7 (9%) by NCI and 25 (32%) were investigator initiated. Participation
in CT varied significantly across ethnic groups, non-Hispanic Whites (NHW)
were more likely to be enrolled in CT (EF of 0.23) than African Americans (AA)
(EF of 0.08, p <0.0001) and Hispanics (H) (EF of 0.05, p <0.0001). Males had
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a higher recruitment rate than females (58% vs 42%), but this could be
explained by the higher incidence of MM in this subgroup. Enrollee’s median
age was 62 years. Younger pts (<65 years) were more likely to be enrolled in
CT than the elderly (66% vs 34%, p<0.0001). Industry sponsored trials were
less likely to recruit AA compared with investigator initiated trials (7.6% vs 12%,
p<0.0001).
Table 1.
Summary/Conclusions: Despite the higher incidence of MM in African Amer-
icans and the elderly, the former only represented 8.6% of the study participants
and 66% of these were less than 65 years of age, perharps lacking data in the
tolerability of these new agents in our aging MM population. We also observed
industry studies were less likely to recruit AA patients. Future trials should take
extra measures to recruit participants that adequately represent the United
States MM population.
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1Hematology department, Universitary hospital of Sidi Bel Abbés, Sidi Bel
Abbes, Algeria
Background: Peripheral neuropathy (PN) is a major dose limiting and potentially
disabling adverse event of commonly therapeutic drugs used in the management
of multiple myeloma (MM), including the immunomodulatory drugs (IMIDS,
Thalidomide and Lenalidomide), and the proteasome inhibitor (Bortezomib).
Aims: The aims of this study were to (1) perform a psychometric evaluation of
PN and (2) examine the prevalence of this complication and its influence on
physical and role functioning of MM patients.
Methods: The FACT/GOG-Neurotoxicity (Ntx) subscale for assessing treatment
induced PN was evaluated. The 11-item of this questionnaire was administered
to patients with MM treated with IMIDS and/or Bortezomib. The subscale was
evaluated in 32 patients for internal reliability, construct validity, criteria validity,
and compared to NCI grading adverse events (CTCAE version 3). Spearman
rank correlation was calculated to determine the impact of PN on functional,
physical and role functioning of MM patients, assessed by EORTC quality of
life scale (EORTC QLQ-C30). A Cronbach coefficient ≥ 0,8 is good. Spearman
rank correlation is significant if p< 0.05 or r >0, 5.
Results: Cronbach’alpha coefficient for infernal consistency of FACT/GOG-
Ntx subscale was 0, 92, and its correlation with the full CTCAE scale as follows:
P<0, 0001. All the 11 items exhibited high correlations with the NTX subscale
score (r= 0, 65- 0, 79), and the Construct validity of NTX was good. According
to FACT/GOG-NTX and NCI- CTCAE, 24 (75%) patients presented PN sec-
ondary to IMID or Bortezomib. The PN was severe in 14 (43, 7%) patients,
especially those who received Bortezomib associated with IMIDS (71, 4%). PN
did not influence the achievement of a very good response of MM to therapy
neither a complete remission (P=0.6), but patients with high scores of NTX
subscale have reduced functional activities, especially physical and role func-
tioning (P=0.0005, P=0.0001 respectively).
Summary/Conclusions: The 11-item FACT/GOG-Ntx subscale reliably and
validly assesses Bortezomib/IMIDS induced PN. This complication is frequent
and can alter the functional abilities of MM patients.
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Background: Rearrangements of the immunoglobulin heavy chain (IGH) on
chromosome 14 are identified by FISH in about 15-20% of patients (pts) with
newly diagnosed multiple myeloma (MM). Historically there is variation on the
significance on prognosis of these rearrangements: typically, t(4;14), t(14;16)
and t(14;20) have high risk (HR), and t(11;14) have standard risk (SR). A recent
study (Kaufman et al, Leukemia. 2016 30:633-9) suggests that t(11;14) may
confer a worse prognosis.
Aims: To determine the prognostic significance of t(11;14) in a single-institution
MM cohort.
Methods: 87 pts with t(11;14) by CD 138 selected FISH at diagnosis were
identified, pts without symptomatic MM were excluded. Cox regression was
used for statistical analysis. Progression free survival (PFS), and overall sur-
vivals (OS) from diagnosis and post autologous stem cell transplant (ASCT)
were analyzed by Kaplan-Meier.
Results: Median age at diagnosis was 62 years, 45 pts (52%) were male, and
24 pts (27%) had ISS 3. All pts received either a proteasome inhibitor or an
immunomodulatory agent, and 42 (48%) received triplet treatment as induction.
Sixty-nine (79%) pts had ASCT, and overall response rate (ORR, partial
response or better) post ASCT was 73%. For pts with HR FISH (defined as
t(14;16), p53 del, 1q21 gain or 1p del) compared to SR FISH, the ORR post
ASCT was 70% vs 77% (p=0.67). OS from diagnosis was 93% at 3 years, 74%
at 4 years and 51% at 5 years. Seven patients (8%) developed plasma cell
leukemia, and there was no association between HR and SR FISH (p=0.66).
In multivariate analysis, ISS stage was an independent risk factor for mortality;
pts with stage 3 had 7.3 times (CI: 1.16-36.4) and 5.7 times (CI: 1.63-20.0) the
risk of mortality than pts with stage 1 and 2. Having an ASCT reduced mortality
by 87% (CI: 0.04-0.41).
Summary/Conclusions: Despite the use of novel therapies the OS at 5 years
of our pts with MM was not significantly improved compared to SEER data from
1992-2013 (51% vs 48.5%). Pts with t(11;14) who had ASCT had increased
survival compared to those who did not. Our results suggest that t(11;14) may
confer a worse prognosis. Further prospective studies evaluating the risk of
t(11;14) are warranted.
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Background: Maintenance therapy post autologous stem cell transplant
(ASCT) has been shown to improve clinical outcomes, including time to pro-
gression, progression-free survival (PFS), and overall survival (OS) in patients
with newly diagnosed multiple myeloma (NDMM) (Sonneveld, J Clin Oncol,
2012; McCarthy, N Engl J Med, 2012; Attal, N Engl J Med, 2012; Palumbo, N
Engl J Med, 2014; Attal, ASCO, 2016). However, the effect of continued treat-
ment on healthcare resource utilization (HRU) is mostly unknown. Connect MM
is a largely community-based, US prospective observational cohort study
designed to characterize diagnosis, treatment patterns, and outcomes in
patients with NDMM in clinical practice. 
Aims: This analysis used the Connect MM registry to analyze the impact of main-
tenance treatment on clinical outcomes and HRU in a largely community setting.
Methods: Adult patients with NDMM were eligible for enrollment in the registry
within 60 days of diagnosis. Patients who completed induction and single ASCT
without subsequent consolidation and received lenalidomide (LEN)-only or no
maintenance were included in the analysis. HRU (hospitalization rates and
length of stay, surgery/procedures, concomitant medications including growth
factor, bisphosphonate, and neuropathic pain medication) was assessed from
100 days post-ASCT to the end of years 1 and 2. Data cutoff was Jan 7, 2016
and the median follow-up was 39.3 months.
Results: A total of 1493 patients with NDMM were enrolled in Cohort 1 from
Sep 2009 to Dec 2011; 421 patients met the analysis criteria stipulated above.
Of these, 165 did not receive maintenance therapy and 256 received any type
of maintenance therapy. Of those receiving maintenance, 180 (70%) were treat-
ed with LEN-only maintenance. The median age was 60 y (range, 24-78); 60%
were men, and 86% were white. Baseline patient characteristics except serum
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creatinine, calculated International Staging System stage, history of monoclonal
gammopathy of unknown significance, presence of del(17p), and induction
regimen were similar across groups. LEN-only maintenance significantly
extended PFS compared to no maintenance (median 54.5 months vs 30.8
months; hazard ratio [HR]=0.58 [95% CI: 0.43, 0.79]; P=.0005; Table). OS was
also significantly improved with LEN-only vs no maintenance (HR=0.45 [95%
CI: 0.28, 0.73]; P=.001). HRU results are detailed in the Table. The rate of hos-
pitalization/100 person-years (PY) was similar across groups (P=not significant
[NS], all comparisons) at the end of years 1 and 2. The median duration of
hospitalization was numerically longer for patients who received no mainte-
nance. Procedures/surgeries and concomitant medication use were similar
across both groups at the end of years 1 and 2.
Table 1.
Summary/Conclusions: For patients with NDMM, LEN-only maintenance sig-
nificantly improved PFS and OS vs no maintenance with no apparent impact
on HRU.
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Background: Response and follow-up criteria in multiple myeloma (MM) are
still based on the protein electrophoretic (PEP) quantification of the monoclonal
protein (MP) in serum (s) and / or urine (u). Monitoring MP by urine (u) PEP
has a very low sensitivity for evaluating variations of small amounts of MP.
Since 2001, serum free light-chain assays (sFLC) are available, with demon-
strated clinical utility. Dejoie et al. have recently reported the usefulness of
sFLC for evaluating response in LCMM.
Aims: In this work, we try to validate the use of sFLC assay in the context of
GEM/PETHEMA clinical trials in order to evaluate the responses and its advan-
tages in comparison to standard quantification of MP by PEP in serum (s) and
—mainly— urine (u) after treatment, given the usual difficulties to collect and
adequately perform urine studies in the usual clinical praxis.
Methods: We included 169 patients with Bence Jones (BJ) MM with measur-
able urine disease who have being treated according to GEM/PETHEMA clin-
ical trials (GEM05menos65, GEM05MAS65, GEM2010MAS65 and GEM2012
menos65). Serum FLC assays (Freelite®, The Binding Site, Birmingham, UK)
were performed on an automated nephelometer (BNII, Dade Behring /
Siemens, Marburg, Germany). The electrophoretic study of the monoclonal
component (CM) was performed by capillary electrophoresis (V8, Helena Bio-
sciences Europe), and immunofixation was performed for the Ig, γ, κ and λ
chains (SAS-3 and SAS-4, Helena Bioscience Europe).
Results: From a total of 169 patients with LCMM (93 Bence Jones kappa / 76
Bence Jones Lambda), 146 (86%) had FLC data at diagnosis, with 139/146
(95%) evaluable by FLCs [involved sFLC ≥100)]. In addition, 68 of the 169
patients also had detectable MP in serum and 7 of the 169 had non-evaluable
MP in urine (MP <0.200 g/24h). We studied the correlation of both techniques’
MP quantification results (uPEP vs isFLC) and we observed a low correlation
(Pearson’s r 0.293, p =0.003), that should be partly explained by the low prof-
itability and subjectivity of the electrophoresis technique for quantifying para-
protein in urine. [Figure 1A]. The concordance between the classification of
the response by uPEP / immunofixation (IF) and by FLCs (Kappa Index=0.425
p <0.0001) was moderate. The normalization of the sFLC ratio (r) was reached
in 35/98 (36%) patients after treatment, associated to a lower risk of progression
(normal vs abnormal sFLCr: PFS 60 vs 39 months, p =0.038) but without impact
in overall survival in our series.  We also observed that an absolute value of
isFLC greater than 50mg/L after treatment was associated with an increased
risk of progression, regardless of the response achieved (PFS 60 vs 28 months,
p<0.0001). [Figure 1B].
Figure 1.
Summary/Conclusions: There is an acceptable agreement between both
methods for response evaluation. The sFLC assays provide a greater sensitivity
than the urine protein electrophoresis for monitoring low levels of disease in
certain cases with measurable disease at diagnosis (isFLC ≥100) being useful
for its follow-up, and also provide prognostic value as a predictor of progres-
sion.
E1279
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Background: In recent years many novel treatments have been introduced
for Multiple Myeloma (MM), leading to an improved survival. However, this has
also led to a situation where many different treatment combinations are used,
without a clear indication which patient will benefit most from which treatment.
It is increasingly recognized that genetic heterogeneity between tumors influ-
ence treatment response. Patient outcomes may be improved by selecting the
right treatment for the right patient at the moment of diagnosis. This requires
the discovery of predictive markers, for example gene expression signatures,
that can aid in this treatment decision. Here we present TOPSPIN (Treatment
Outcome Prediction using Similarity between PatIeNts), a novel algorithm to
discover such markers from tumor gene expression data. We use it to identify
patients more likely to benefit from bortezomib.
Aims: This algorithm aims to develop a classifier that identifies a subset of
patients that will benefit more from a treatment of interest than similar patients
who receive a different treatment.
Methods: TOPSPIN aims to predict whether a patient will benefit (class 1) or
will not benefit (class 0) from a certain treatment of interest based on the gene
expression profile of the patient. This algorithm relies on the idea that geneti-
cally similar patients who received a different treatment should have a large
difference in survival, given that genetic similarity is defined in a manner that
is relevant to treatment response. This principle is used to identify prototype
patients: patients who received the treatment of interest and have a larger than
expected survival difference with the genetically most similar patients who
received another treatment. Genetic similarity is defined separately for 10 581
gene sets based on Gene Ontology (GO) annotation. These prototype patients
are used to define a classifier: new samples who exhibit a similar gene expres-
sion profile as these prototypes are also expected to benefit more from the
treatment of interest. Here we use TOPSPIN to predict which patients will ben-
efit from the proteasome inhibitor bortezomib. We combine tumor gene expres-
sion data from the Total Therapy 2, Total Therapy 3 and HOVON-65/GMMG–
HD4 phase III clinical trials into one dataset comprising 910 patients, split into
a bortezomib arm (n=407) and a non-bortezomib arm (n=503). Progression
free survival is used as outcome measure. This dataset was split in a training
set (n=606) and a test set (n=304). The test set is not used at any point in the
training procedure and is only used for independent validation. 
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Results: We successfully identify gene sets that enable us to predict which
patients will benefit most from bortezomib. The top 8 performing GO sets based
on Hazard Ratio (HR) were combined to achieve the final classification. In the
training set 28.4% of patients are classified a class 1, resulting in an HR of
0.13 (p=7.1*10-11) between the two treatment arms. More importantly, in an
independent test set an HR of 0.47 (p=0.03) was found, as shown in Figure 1.
Figure 1.
Summary/Conclusions: TOPSPIN is successful in predicting bortezomib spe-
cific survival in independent data. TOPSPIN can be applied to any dataset with
two treatment arms and a continuous outcome measure. In a disease like MM,
where many different treatment are available, selecting the right treatment is
critical and TOPSPIN can aid in this decision. 
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Background: Cardiac amyloidosis is a severe disease that can lead to cardiac
dysfunction and death. Amyloid light chain (AL) amyloidosis, hereditary
transthyretin (hATTR) amyloidosis, and wild-type transthyretin (wtTTR) amy-
loidosis may result in cardiac amyloidosis. AL amyloidosis is caused by an
accumulation of misfolded light chain and often involves organs other than the
heart (eg, kidneys, nervous system). Initial symptoms are often nonspecific
(eg, weight loss, fatigue). Consequently, a diagnosis is frequently made only
after the disease has become advanced. Previous patient-directed research
found that despite patients being initially referred most often to cardiologists
(as opposed to hematologists and nephrologists), cardiologists diagnosed the
condition much less frequently than other specialists.
Aims: To understand delays, errors, and inconsistencies in the diagnostic path-
way for patients with AL cardiac amyloidosis and validate using caregiver
responses.
Methods: An online survey consisting of 36 questions (for patients) and 37
questions (for caregivers) was developed by the Amyloidosis Research Con-
sortium (ARC) and distributed to the patient mailing lists of ARC, the Amyloidosis
Foundation, and Amyloidosis Support Groups in January 2017. The survey
was designed for patients with all forms of cardiac amyloidosis and their care-
givers; however, the present analysis is limited to AL amyloidosis.
Results: In this subanalysis, 137 patients and 115 caregivers completed the
survey. Most patient respondents were >55 years of age (n=111; 81.0%); of
those, 16.1% (n=22) were >70 years of age. Composition of the population
was 81.8% white/Caucasian (n=112), 2.2% Asian (n=3), 4.4% African American
(n=6), 2.2% Latino (n=3), 5.1% other (n=7), and 3.6% unknown (n=5). Most
patients had lived with their diagnosis for >1 year (17.5% [n=24] <1 year; 23.4%
[n=32] 1-2 years; 29.2% [n=40] 3-5 years; 21.2% [n=29] 6-10 years; 8.8%
[n=12] >11 years). A significant percentage of patients had multiorgan involve-
ment (54.7% [n=75] kidney; 29.9% [n=41] nerve; 14.6% [n=20] liver; 43.8%
[n=60] GI; 14.6% [n=20] skin; 22.2% [n=49] other site). Before diagnosis, 43.8%
(n=60) of patients were incorrectly diagnosed with one or more other conditions,
predominantly by cardiologists and general practitioners (Table 1). Furthermore,
more than 75% of patients visited 3 or more different physicians before diag-
nosis. Nearly all misdiagnosed patients (83.3%; n=50/60) reported receiving
treatment for their misdiagnosed condition. Both patients and caregivers report-
ed correct diagnoses being made most frequently by cardiologists and hema-
tologists (Table 1). Caregivers echoed the multitude of distinct physicians visited
before diagnosis (Table 1). Patients reported that biopsy of fat pad, kidney, or
heart was the predominant diagnostic test performed (Table 1). Hospitalization
was prevalent; 55.5% (n=76) patients reported amyloid-related cardiac hospi-
talization. Moreover, 31.3% (n=43) of patients reported the need for air travel
for physician consultation.
Table 1.
Summary/Conclusions: This represents the first survey compiling both care-
giver and patient experiences with AL amyloidosis. Alignment of caregiver with
patient responses validates our patient-directed research. Patients with AL car-
diac amyloidosis frequently receive misdiagnoses and sometimes receive incor-
rect treatment for the misdiagnosed condition. Disease awareness among all
specialists is vital, especially among those to whom patients are initially referred
due to the nature of their initial symptoms. 
E1281
EFFICACY OF DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH
RELAPSED/REFRACTORY MULTIPLE MYELOMA – A SYSTEMATIC
LITERATURE REVIEW AND NETWORK META-ANALYSIS
M.A. Dimopoulos1,*, K. Weisel2, J. Kaufman3, P. Sonneveld4, M. Rizzo5,
Y. Xu6, K. Fahrbach6, M. Gaudig7, M. Slavcev8, L. Dearden8, A. Lam8
1National and Kapodistrian University of Athens, Athens, Greece, 2 Universi-
taetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere
Medizin II, Tuebingen, Germany, 3Hematology and Medical Oncology, Winship
Cancer Institute, Emory University, Atlanta, GA, United States, 4Department of
Hematology, Erasmus MC, Rotterdam, Netherlands, 5Evidera, London, United
Kingdom, 6Evidera, Waltham, MA, United States, 7Janssen-Cilag, Neuss, Ger-
many, 8Janssen Global Services, LLC, Raritan, NJ, United States
Background: Daratumumab is a new monoclonal antibody aimed to improve
outcomes in relapsed or refractory multiple myeloma (RRMM), and has been
investigated in combination with lenalidomide plus dexamethasone (DRd), and
with bortezomib plus dexamethasone (DVd), in randomized controlled trials
(RCTs), POLLUX and CASTOR, respectively. Although DRd and DVd have
been compared against current standard of care (SOC), namely Rd, and Vd, it
is important to assess how daratumumab plus SOC compares with other rou-
tinely used treatment regimens and investigational regimens expecting regula-
tory approvals.
Table 1. NMA Efficacy Results.
*100% probability represent any value above 99.951%
Aims: Therefore, the objective of this analysis is to compare DRd and DVd with
other relevant treatment options via network meta-analysis (NMA) techniques.
Methods: A systematic literature review (SLR) based on searches of Medline,
Embase, and the Cochrane Library was conducted to identify and then assess
RCTs of treatments for RRMM. The specific studies of interest were those that
had investigated the efficacy of other treatment options considered to be com-
parators to DRd or DVd. Data from trials that met the SLR’s inclusion criteria
and the most recent data from POLLUX and CASTOR were extracted and then
included in a Bayesian NMA to allow for the indirect comparison.
Results: Data from RCTs identified by the SLR allowed formulation of two evi-
dence networks. Network 1 included DRd and other immunomodulatory agent
(IMiD)-containing regimens, and Network 2, contained DVd and other
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immunomodulatory agent (IMiD) -free regimens. Analysis using a fixed-effects
model found that DRd compared with other IMiD-containing regimens in Net-
work 1, and DVd compared with other IMiD-free regimens in Network 2 pro-
longed PFS and OS among patients RRMM (see Table 1).
Summary/Conclusions: In the absence of prospective head-to-head trials,
NMA provides potentially important information on comparative effectiveness
of different treatments. This NMA suggests that the combinations of DRd and
DVd are effective in improving PFS in patients with RRMM with similar trends
found for OS when compared with other established and new regimens.
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TRENDS IN TREATMENT PATTERNS AND SEQUENCING IN PATIENTS
WITH MULTIPLE MYELOMA DIAGNOSED 2011-2016 IN THE UNITED
STATES USING AN ENHANCED ELECTRONIC HEALTH RECORDS
DATABASE
B. Ung1, S. Abouzaid1,*, Q. Ni1, K. Parikh1, A. Agarwal1
1Celgene Corporation, Summit, NJ, United States
Background: Over the past few years, the multiple myeloma (MM) treatment
(Tx) landscape has changed considerably. Immunomodulating (IMiD®) drugs
and proteasome inhibitors (PI) have emerged as mainstays of MM Tx. However,
the limitations and lag time of available administrative claims databases make
it difficult to assess current real-world trends in the Tx of MM. 
Aims: The study aimed to describe trends in demographics, Tx patterns, and
sequencing for newly diagnosed MM (ndMM) patients (Pt) in the United States
(US) using an enhanced Electronic Health Records (EHR) database.
Methods: A retrospective observational study of ndMM Pts was conducted uti-
lizing EHR from a nationally-representative database (Flatiron Health). The
Flatiron MM provider network comprises over 260 clinics throughout the US.
Pts with an ICD-9 (203.0x) or ICD-10 (C90.xx) diagnosis of MM between
01/01/2011–12/31/2016 were randomly selected into the study. Pts were
excluded if they did not have ≥2 documented clinical visits during the study
period. Diagnosis of MM was confirmed through review of unstructured chart
data. Index date was defined as the Pt’s date of diagnosis with MM. NdMM Pts
were defined as those without a MM Tx more than 14 days prior to their first
diagnosis date. Start of first-line (1L) therapy was defined as the 1st episode of
an eligible systemic Tx given after or up to 14 days before the index date. Reg-
imens were defined using the 1st eligible drug episode plus other eligible drugs
given within 28 days of each other. A maximum gap of 90 days was allowed
within a given line of therapy (LOT) and was considered concluded the day
before the start date of the next LOT. 
Results: For the 3367 ndMM Pts identified, mean(SD) age was 68.5(11) years
at the time of diagnosis, 45.9% were female, 57.6% were white, 14.7% African
American, and 11.1% other race. The most common immunoglobulin (Ig) class-
es at diagnosis were IgG (51.8%) and IgA (18.9%). Median follow-up time for
ndMM Pts was 15.9 months. During the study period, 1611 received only 1 line
(L), 737 were treated with 2L, 325 with 3L, 252 with 4L+; while 442 (13%)
received no Tx. Mean follow-up time for these groups was 471, 730, 928, 1132,
and 610 days respectively. Among treated Pts, 205 (12.7%), 208 (28.2%), 109
(33.5%), and 98 (38.1%) received at least 1 stem cell transplant (SCT), respec-
tively. Of Pts receiving 1L therapy, 984 (33.6%) received IMiD compound +PI,
715 (24.4%) received PI-based, and 556 (19%) received IMiD compound-
based therapy in 1L. The use of IMiD compound +PI in 1L increased during
the study period for SCT and non-SCT Pts (NSCT) from 40.6% and 21.5% in
2011, to 66.7% and 46.8% in Pts diagnosed in 2016. In Pts who received a
SCT (n=618), the most common 1L regimens were lenalidomide + bortezomib
+ dexamethasone (RVd; n=217, 43.9%), cyclophosphamide + bortezomib + d
(CyBord; n=124, 20.1%), lenalidomide + d (Rd; n=70, 11.3%), and bortezomib
+ d (Vd; n=57, 9.2%). In NSCT Pts (n=2307), the most common 1L regimens
were RVd (n=642, 27.8%), Vd (n=510, 22.1%), and Rd (n=412, 17.9%). Among
the RVd NSCT Pts with a documented 2L (n=189), the most common 2L reg-
imens were CyBord (13.2%), carfilzomib monotherapy (7.4%), pomalidomide
+ d (6.9%), and carfilzomib + d (6.9%). Documented death occurred in 785
(23.3%) Pts during the study period.
Summary/Conclusions: Over time, RVd has become the most common 1L
regimen for SCT and NSCT Pts with ndMM. After a median follow up of 15.9
months, many patients remain in the initial LOT. With a longer follow up time,
we will able to observe sequencing and patterns of treatment in later LOTs. 
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Background: Infection is a major cause of morbidity and mortality in patients
with Multiple Myeloma (MM), responsible for 10-25% of deaths within 6 months
of diagnosis. It is associated with suppression in primary antibody response
(systemic immunoparesis (SI)), which may be aggravated following anti-myelo-
ma therapy. Recently, the suppression of the non-monoclonal immunoglobulin
pair (e.g. IgG-Lambda in IgG-Kappa MM), termed heavy+light chain (HLC) pair
suppression, has been associated with poor prognosis in MM. However, the
impact of HLC pair suppression as a risk factor for bloodstream infections has
not been reported.
Aims: To evaluate HLC pair suppression as a risk factor for bloodstream infec-
tions and early death in MM patients.
Methods: The study retrospectively included 114 consecutive MM patients
with diverse bloodstream infections, identified during investigation into unex-
plained fever and hospitalisation. Bloodstream infection was defined as a pos-
itive blood culture related to a febrile episode. The population consisted of 66
male:48 female patients, with a median age of 68 (56-77) years. The mono-
clonal immunoglobulin isotype was: 49 IgG-K, 26 IgG-L, 21 IgA-K and 18 IgA-
L. In order to explore the impact of HLC pair suppression on bloodstream infec-
tions and early mortality, only events within 6 months (180 days) from diagnosis
were documented. HLC pair suppression was defined as suppression in the
levels of the non-monoclonal pair by >50% below the lower limit of the reference
range. HLC measurements were carried out using Hevylite® immunoassays
(The Binding Site) on a SPAPLUS analyser. SI was defined as levels of the
alternate immunoglobulins (e.g. IgA and/or IgM in an IgG patient) more than
50% below the lower reference range. Association between variables were
analysed by Chi-square test and survival was estimated using Kaplan-Meier
method.
Results: At diagnosis, HLC pair suppression was observed in 72 (63%)
patients, and SI in 52 (45%). The incidence of bloodstream infections during
the study period was 23%; and 20 patients (18%) died within 6 months from
diagnosis. We found a significant association between HLC pair suppression
and both the occurrence of bloodstream infections (OR: 6.10, 95% CI: 1.71-
21.83; p=0.002) and early deaths (OR: 4.02, 95% IC: 1.10-14.66; p=0.03); by
contrast SI had no significant association with either event (p=0.07 and p=0.3,
respectively). Survival analyses demonstrated an association between blood-
stream infections and shorter OS (50% vs 92%, HR: 7.43, 95% CI: 2.96-18.61,
p<0.0001, Figure A). The risk of bloodstream infections was significantly higher
among patients with HLC pair suppression vs those without suppression (34%
vs 7%, respectively; HR: 5.12, 95% CI: 1.54-17.07, p=0.003, Figure B). In line
with this, patients with HLC pair suppression had shorter overall survival (OS)
compared to those without (76% vs 93%, HR: 3.47, 95% CI: 1.02-11.83,
p=0.03). By contrast we found no association between SI and risk of infection
(p=0.08) or survival (p=0.4).
Figure 1.
Summary/Conclusions: HLC pair suppression provides information on
immune status and associates with an increased risk of bloodstream infections
and early deaths in newly diagnosed MM patients. Our findings highlight the
importance of recognising this status at time of diagnosis, and suggest that
HLC pair suppression may help guide clinical decisions about the need for
adequate antimicrobial treatment during myeloma therapy. 
E1284
DARATUMUMAB SIGNIFICANTLY IMPROVED PROGRESSION-FREE
SURVIVAL IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE
IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA
D. Katalinic1,*
1Depatment of Internal Medicine, Faculty of Medicine, J.J. Strossmayer Uni-
versity of Osijek, Osijek, Croatia
Background: Daratumumab is a human IgG1k monoclonal antibody which
binds with high affinity to the CD38 molecule on the surface of multiple myeloma
cells. It induces rapid tumor cell death through multiple immune-mediated
mechanisms and showed encouraging results alone and with lenalidomide and
dexamethasone in a phase 1-2 study involving patients with relapsed multiple
myeloma.
Aims: The primary end point of the study was progression-free survival.
Methods: We enrolled a total of 134 patients (74 male and 60 feemale, mean
age 65.4±18.2 years) with multiple myeloma who had received at least three
lines of therapy to receive lenalidomide with dexamethasone (68 patients, control
group A) or in combination with daratumumab (66 patients, therapy group B).
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Results: At a median follow-up of 9.8 months in a protocol-specified interim
analysis, 67 patients had disease progression or death were observed (in 18
of 66 patients (27.2%) in the group B vs 28 of 68 (41.1%) in the control group
(p<0.001)). A significantly higher rate of overall response was observed in the
group B than in the group A (88.7% vs 62.9%, p<0.001), as was a higher rate
of complete response or better (39.2% vs 16.1%, p<0.001). The most common
adverse events during the treatment was myelotoxicity (neutropenia in 68.6%
of the patients in the therapy group B vs 42.1% of those in the control group A),
anemia (in 21.5% vs 13.6%) and thrombocytopenia (in 13.8% vs 8.7%).
Summary/Conclusions: In patients with relapsed multiple myeloma, the addi-
tion of daratumumab to lenalidomide and dexamethasone appeared active and
resulted in significantly improved progression-free survival. However it was
associated with a higher risk of myelotoxicity.
E1285
COMPARISON BETWEEN IMMUNOFIXATION NEGATIVITY AND NORMAL
FREE LIGHT CHAIN RATIO WITH MULTICOLOUR FLOW CYTOMETRY
FOR RESPONSE ASSESSMENT IN PATIENTS WITH MULTIPLE MYELOMA
WITH VGPR OR BETTER
K. Narita1,*, H. Takamatsu2, Y. Abe1, Y. Usui1, M. Takeuchi1, K. Matsue1
1Department of Medicine, Hematology/Oncology Kameda Medical Center,
Kamogawa, 2Department of Hematology and Respirology, School of medicine,
Institute of Medical, Pharmaceutical and Health Sciences,Kanazawa University,
Kanazawa, Japan
Background: Urine and serum Immunofixation electrophoresis (uIFE and sIFE,
respectively) and free light chain assay (FLC) are widely accepted as standard
tests for diagnosis and monitoring of multiple myeloma (MM). However, there
is significant discordance between the electrophoretic method and FLC test for
response assessment. Despite this discordance, previous studies did not
address the differences in assessment of treatment response between the
intact immunoglobulin MM (IIMM) and light chain only MM (LCMM)/oligosecre-
tory MM (OSMM). uIFE results are poorly correlated with the serum FLC level,
however, treatment response of LCMM has still been recommend to assess by
24-hour uIFE by International Myeloma Working Group guideline. However,
MRD levels on uIFE negativity or normal FLC ratio (rFLC) in patients with var-
ious types of MM have not been studied.
Aims: To explore the relationship between uIFE, sIFE negativity and normal
rFLC for MRD assessment in patients with IIMM and LCMM.
Methods: We initially selected 162 patients with MM (LCMM and OSMM, n =
41; IIMM, n=21) that received treatment at Kameda Medical Center, Kamo-
gawa-shi, Japan and Kanazawa University Hospital, Kanazawa-shi, Japan
between April 2008 and January 2016. Among them, 126 patients
(LCMM/OSMM 40, IIMM 86), who achieve VGPR or better response, were
selected on the basis of the availability of simultaneous serum and urine test,
FLC data, and bone marrow MRD. To explore the relationship between uIFE
and sIFE negativity and normal rFLC, MRD levels were compared by multi-
colour flow-cytometry (MFC) in patients with LCMM/OSMM, and IIMM that
obtained VGPR or better. MRD negativity was defined as MRD <10–4. Complete
response (CR) was divided into conventional CR (cCR, CR but MRD-positive)
and MRD-CR (CR and MRD-negative)
Results: One hundred and fifty-four complete IFE, FLC, and MFC data set of
126 patients (LCMM/OSMM 40, IIMM 86) with ≥ VGPR were analysed. Normal
FLC at VGPR, cCR and MRD–CR was 65.0%, 78.4% and 78.6% in IIMM, and
0%, 21.4% and 100%, respectively, in LCMM/OSMM. The percentages of sam-
ple at MRD levels of MRD ≥10–3, 10–3 ≥MRD >10–4 and 10–4>MRD in
LCMM/OSMM were 12.5%, 50.0%, and 100% for negative uIFE, and 0%, 11.5%
and 100% for normal rFLC, respectively. These figures in IIMM were 23.0%,
41.6%, 81.4% for negative sIFE, and 53.8%, 75.0% and 88.8% for normal rFLC,
respectively. Positive/negative predictive value (PPV/NPV) of uIFE and rFLC
for MRD in LCMM/OSMM was 100%/54.8% and 100%/85.0%, respectively,
while those were 90.6%/45.8% and 88.9%/32.4% in IIMM, respectively.
Figure 1.
Summary/Conclusions: Our observations confirmed that FLC test has greater
sensitivity than uIFE for detection of the monoclonal component, and that nor-
malization of sFLC ratio is highly predictive of MRD negativity in patients with
LCMM/OSMM. The proportion of negative sIFE samples increased with depth
of MRD, but the FLC response did not appear to parallel with the depth of
response in IIMM. We recommend that FLC test should be incorporated into
response assessment in LCMM/OSMM as an alternative to 24-h uIFE, and
both negative sIFE and normal rFLC are still useful for response assessment
of residual clonal PCs in IIMM.
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DARATUMUMAB IS AN EFFECTIVE AND SAFE SALVAGE THERAPY IN
RELAPSED/REFRACTORY PATIENTS WITH MULTIPLE MYELOMA AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
E. Klyuchnikov1,*, U.-M. von Pein1, F. Ayuk1, M. Christopeit1, R. Adjalle1,
A. van Randenbourgh1, C. Wolschke1, N. Kroeger1
1Department for Stem Cell Transplantation, University Cancer Center Ham-
burg-Eppendorf, Hamburg, Germany
Background: Daratumumab is a human monoclonal antibody that targets
CD38, a cell surface protein that is overexpressed on multiple myeloma cells.
The drug became the first monoclonal antibody as single agent therapy
approved by the FDA for the treatment of multiple myeloma. The role of allo-
SCT in myeloma patients (pts) remains unclear; nevertheless, the registry study
of EBMT suggests an increasing rate of allografts in Europe in last years.
Despite the potentially curative potential of this approach, the increased relapse
rate and low PFS remain a central clinical problem. 
Aims: In this single center retrospective analysis, we report on our experience
on the use of daratumumab in relapsed/refractory myeloma pts after allo-SCT.
Methods: A total of 16 pts (male, n=9) with median age of 66 years (39-72)
relapsing after allo-SCTs that had been performed during a period 2008-2015
at the University of Hamburg and received daratumumab as single agent sal-
vage therapy. Before allografting 9 pts received one and 7 pts ≥2 autografts,
respectively. All but one pt received at least 1 salvage therapy line prior to the
allo-SCT. The allografts were performed from unrelated donors (MUD, n=9;
MMUD, n=4) or matched related donors (MRD, n=3). The median number of
salvage lines post-transplant and prior to first daratumumab infusion was 3 (1-
4). The salvage regimens included bortezomib, lenalidomide, pomalidomide
and carfilzomib. Daratumumab infusions were started at a median of 21 months
(0-30) after relapse/progress.
Results: The median number of infusions was 13 (3-22). A total of 16 and 15 pts
were available to safety and efficacy evaluation, respectively. The safety was
assessed according to the Common Toxicity Criteria (CTC). A total of 20 adverse
events were observed in 16 pts: dyspnea (CTC1, n=3; CTC2, n=1), bron-
chospasm (CTC2, n=2) shivering (CTC1, n=3), cough (CTC1, n=1; CTC2, n=1),
musculoskeletal pain (CTC1, n=4), acute coronary syndrome (CTC3, n=1), skin
rush (CTC2, n=1), pressure on eyes (n=1). Two patients developed late onset
infections (pneumonia and infection of urinal tract) followed by temporarily therapy
interruption. We observed a decrease of Tregs (CD4+CD25int/highCD127low) num-
ber from a median of 5,05% at start to 0,65% at day 21 after first daratumumab
infusion in four pts. There were no cases of GvHD. The adverse events appeared
in all pts after the first infusion, with improved tolerance of following infusions.
There were no cases, where the therapy had to be stopped due to adverse
events. Within a median follow-up of 32 months (1-45) from the relapse/progres-
sion 12 of 16 pts remain alive. Two pts died due to progress of myeloma and
another 2 pts died due to severe infection/sepsis. A total of 9 of 15 evaluable pts
responded (60%, PR, n=7, vgPR, n=2). The responses (decrease of paraprotein
and/or free light chains; reduction of extramedullary tumor in 2 pt) occurred at a
median of 7 days (7-75) after the first administration of daratumumab. The median
response duration is 4.5 mo (1.5-8). Six pts show ongoing responses. All respond-
ing and 2 non-responding pts (stable disease) showed clinical improvement of
constitutional symptoms.
Summary/Conclusions: Daratumumab demonstrated encouraging efficacy in
relapsed/refractory pts with myeloma after allo-SCT. The administrations of the
drug in these heavily pre-treated pts were associated with good safety profile
and development mostly non-severe adverse events mostly after the first infu-
sion. Further studies on the use of daratumumab in post-transplant setting are
warranted.
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PROGNOSTIC RELEVANCE OF VEGF AND VEGFR EXPRESSION IN
CD138+/CD19- AND CD138+/CD19+ PLASMA CELLS FROM PATIENTS
WITH MONOCLONAL GAMMOPATHIES
C. Geraldes1,2,*, A.C. Gonçalves2,3, R. Alves2,3, E. Cortesão1,2,3, L. Ribeiro1,
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(CHUC), 2Applied Molecular Biology and University Clinic of Hematology,
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Background: Vascular endothelial growth factor (VEGF) is a potent angiogenic
peptide with biologic effects that include regulation of extracellular matrix remod-
eling and inflammatory cytokine generation with an important role in the bone
marrow microenvironment of multiple myeloma (MM). Angiogenesis is enhanced
in the bone marrow of MM patients in parallel with tumor progression. Myeloma
and stromal cells secrete angiogenic factors that include VEGF. Previous studies
showed heterogeneity in the expression of VEGF between plasma cells (PCs)
from the same MM patient. However, no clear association with expression levels,
phenotypic subtypes of PCs and prognosis was demonstrated.
Aims: The present study aimed to evaluate the expression levels of VEGF
and VEGF receptor (VEGFR) on phenotypic subtypes of PCs in patients with
monoclonal gammopathies and to explore its role as diagnostic and prognostic
biomarkers.
Methods: We include 128 patients with monoclonal gammopathies, 60 patients
with newly diagnosed symptomatic MM and 68 with monoclonal gammopathy
of uncertain significance (MGUS) and also from 11 non-neoplastic controls
(Ctr). We evaluated the expression levels of VEGF and VEGFR by flow cytom-
etry in the two populations of bone marrow PCs, identified by gating
CD138+/CD19- (clonal PCs) and CD138+/CD19+ (non-clonal PCs). The results
are presented as percentage of PCs expressing VEGF/VEGFR and as expres-
sion levels of this antiangiogenic molecules expressed in mean intensity of flu-
orescence (MIF). The effects of these parameters on progression-free survival
(PFS) and overall survival (OS) were analyzed with Kaplan-Meier method. For
statistical analysis, software IBM SPSS Statistics v22 was used. ROC curves
were performed to assess the VEGF and VEGFR accuracy as diagnostic and
prognostic biomarkers.
Results: In our cohort of patients, median age was 70 (39-86) years, 52%
were male. We found increased expression levels of VEGF in CD138+/CD19-
PCs from MM (80±7,5 MIF) compared tomgUS patients (61,7±6,2 MIF)
(p=0,011), and also higher to the observed in CD138+/CD19+ PCs (39,92±1,74
MIF) in both populations of patients (p<0,001 and p=0,02, respectively). No
differences were observed in the expression levels of VEGF in CD138+/CD19+
PCs from MM (39,92±1,74 MIF),mgUS patients (41,18±1,92 MIF) and controls
(32,8±1,5 MIF). However, the percentage of CD138+/CD19+ cells expressing
VEGF was significantly higher inmgUS (39,4±4%) and in MM patients
(46,7±4,5%) compared to Ctr (13,5±0,5%)(p=0,019 and p=0,003, respectively).
The differential expression of VEGFR showed thatmgUS patients with VEGFR
levels higher than 23,5 MIF in CD138+/CD19- PCs have higher probability to
progress to MM [AUC 0,688 (95%CI 0,592-0,784), p<0,0001, 90% sensitivity,
56% specificity, 65% PPV, 84% NPV]. In MM patients, we also found an asso-
ciation between increased VEGF expression levels in CD138+/CD19- PCs
(³175 MIF) and inferior PFS (p=0,002) and OS (p=0,003), irrespective of first
line therapy (bortezomib-based regimens for fit patients or alkylating-based
treatments for unfit patients). Interestingly, we also observed an increased per-
centage of CD138+/CD19+ PCs (³21%) expressing VEGF in MM patients with
a more favorable PFS (p=0,04) and OS (p=0,008).
Summary/Conclusions: The results of our investigation showed that
CD138+/CD19- and CD138+/CD19+ PCs have differences in what concerns
VEGF/VEGFR expression, not only in MM patients, but also inmgUS patients.
The increased expression of VEGF in clonal PCs from MM compared tomgUS
patients evidences the relevance of VEGF in myelomagenesis. We also
demonstrated a negative prognostic impact of an increased VEGF expression
in CD138+/CD19- PCs, highlighting the role of VEGF in the survival and main-
tenance of clonal PCs and as a predictor of outcome in MM progression. The
association between the percentage of CD138+/CD19+ PCs and survival sup-
ports the suggestion that these cells may not be neutral players in the complex
pathogenesis of MM. The results of our study should be further investigated in
larger series of patients.
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RACIAL DIFFERENCES OF FISH ABNORMALITIES IN MINORITIES WITH
MULTIPLE MYELOMA: A SINGLE-CENTER EXPERIENCE
M. Gonzalez Velez1,*, V. Jaramillo Restrepo2, N. Duma3, M. Palascak4,
M. McKenna4, J. Richter5, D. Vesole5, D. Siegel5, N. Biran5
1Internal Medicine, Rutgers NJMS, Newark, United States, 2CES University,
Medellin, Colombia, 3Mayo Clinic, Rochester, 4Saint George University, 5John
Theurer Cancer Center, Hackensack University Medical Center, Hackensack,
United States
Background: Racial disparities of FISH abnormalities in multiple myeloma
(MM) have been well described in whites (W) but partially described in minori-
ties (M) (Paulus et al, ASH 2016, 4432). 
Aims: To explore racial-based differences of FISH abnormalities using the
largest cohort of minorities to date.
Methods: CD-138 selected FISH was done on 799 consecutive patients (pts).
Pts without symptomatic MM, and biopsy >6 months after diagnosis were
excluded. The abnormalities evaluated included standard and intermediate
risk: IGH rearrangements (IGH r), t(4;14), t(11;14), and high risk: t(14;20),
t(14;16), del13q, del 17p, 1q21. Chi-square was used for statistical analysis.
Due to smaller numbers, all M (Hispanic (H), Black (B), Asian (A) and Other
(O)) were included into the same group for statistical analysis. 
Results: 482 pts were eligible, 343 (71%) were W, 52 (10%) H, 50 (10%) B,
19 (3%) A, and 18 (3%) O. Median age was 65 years, 54% were male, and
26% ISS stage 3. There were no were no statistically significant differences in
FISH abnormalities between the M. Overall W had more abnormalities in IGH
r, t(4;14), t(11;14), t(14:20), 1q21 gain compared to M. Most notably W had
more IGH r (39% vs 28%; p=0.019) and t(11;14) (20% vs 12%; p=0.024). There
were no statistically significant differences between W and M in the high risk
FISH abnormalities.
Table 1.
$p-value compares W vs M. * means statistical significant (p-value<0.05)
Summary/Conclusions: W had significant differences in FISH compared to
M. W had more IGH r and t(11;14) than M, and there was no difference in high
risk FISH abnormalities between W and M. This study confirms the biological
racial disparities that exist in minorities with MM. Further studies with more
inclusion of minorities are needed to elucidate these disparities and its effects
on risk stratification and outcomes.
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POMALIDOMIDE ALONE OR IN COMBINATION WITH LOW DOSE
DEXAMETHASONE AS MAINTENANCE FOLLOWING INDUCTION WITH
POMALIDOMIDE AND LOW DOSE DEXAMETHASONE IN RELAPSED AND
REFRACTORY MYELOMA (ALLG MM14)
A. Kalff12,*, N. Kennedy3, J. Reynolds1, H. Quach4, P. J. Ho5, N. Horvath6,
P. Mollee7, J. D’Rozario8, K. Taylor9, J. Estell10, A. Spencer12
1Monash University, 2Alfred Hospital, Melbourne, Australia, 3Haematology
Departmen,, Alfred Hospital, 4St Vincents Hospital, Melbourne, 5Royal Prince
Alfred Hospital, Sydney, 6Royal Adelaide Hospital, Adelaide, 7Princess Alexan-
dra Hospital, Brisbane, 8The Canberra Hospital, Canberra, 9Haematology &
Oncology Clinics of Australia, Brisbane, 10Concord Repatriation General Hos-
pital, Sydney, Australia
Background: Whilst the addition of dexamethasone to upfront therapy with
Immunomodulatory (IMiD®) agents is important to mediate rapid reduction in
disease burden, preliminary findings suggest that the NK stimulatory effects of
IMiD® compounds are best harnessed without the co-administration of dex-
amethasone, and may be especially effective in the setting of minimal disease
burden (in the maintenance setting for example) when some inherent immune
recovery has occurred. However this has yet to be confirmed in a prospective
clinical trial.
Aims: To evaluate the effect of maintenance with POM alone (Arm 1) versus
POM-LoDEX (Arm 2) on progression free survival (PFS), overall survival (OS),
and kinetics of response (overall response rate (ORR)) in relapsed myeloma
(MM) patients refractory to lenalidomide (R-LEN) demonstrating stable disease
(SD) or better following salvage treatment with pomalidomide (POM) and low
dose dexamethasone (LoDEX) induction. 
Methods: Multicentre, open-label, randomized phase 2 study of relapsed R-
LEN patients who had received>2 prior lines of therapy. POM 4mg days 1-21
(28 day cycle) was administered alone or in combination with LoDEX (40mg
weekly) as maintenance following an induction with 4 cycles of POM and
LoDEX. Treatment continued until toxicity or progression. Peripheral blood
samples for immune studies were collected pre-induction and prior to cycles
1, 3, 6 and 10 of maintenance.
Results: 154 patients from 11 sites were enrolled on to the study (M:F 80:74),
with a median age of 67 years (range 35-88). Median number of prior lines of
therapy was 4.5 (2-14). All patients had failed LEN (100%), 127 (82.5%) were
also refractory to bortezomib (double refractory) and 94 (61%) had received a
prior autologous stem cell transplant. 72 (47%) patients achieved SD or better
with POM-LoDEX induction and were randomised, 35 to POM (Arm 1) and to
37 to POM-LoDEX (Arm 2). After a median follow-up of 19 months, median
PFS for all patients from study entry was 4.2m (IQR 2.1 – 8.6m). PFS for ran-
domised patients (from time of randomisation) was 2.7m for POM (arm 1) ver-
sus 5.6 for POM-LoDEX (arm 2) (p=0.39). The PFS hazard rate for Arm 2 was
relatively constant compared to Arm 1 which started with a hazard rate double
that of Arm 2 but dropped to less than half of the rate in Arm 2 by 15 months,
suggesting that with longer follow-up, there may be an emergent advantage to
maintenance with POM versus POM-LoDEX (Figure 1.). Median OS for all
patients from study entry was 13.2m (IQR 6.3-26.8m). For randomised patients,
median OS (from time of randomisation) was 19m for POM (Arm 1) versus
13.7m for POM-LoDEX (Arm 2) (p=0.41). ORR (≥PR) for all patients was 45.5%
[CR=5 (3.3%), VGPR=13 (8.4%), PR=52 (33.8%)]. Clinical benefit rate (CBR)
(≥MR) was 55.2% [MR=15 (9.7%)]. 
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Figure 1.
Summary/Conclusions: In patients with relapsed myeloma, after initial disease
control/debulking is achieved with POM - LoDEX, induction, maintenance with
single agent POM may be more effective for sustaining disease control than
continuation of POM-LoDEX. Correlative studies are currently underway to fur-
ther investigate the immunological mechanisms behind this observation.
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POMALIDOMID IS MORE EFFECTIVE IN REAL CLINICAL PRACTICE THAN
IN RANDOMIZED TRIAL – AN OBSERVATIONAL STUDY OF THE CZECH
MYELOMA GROUP 
L. Pour1,*, L. Brozova2, I. Spicka3, V. maisnar4, J. Minarik5, A. Jungova6,
E. Gregora7, S. Sevcikova8, P. Pavlicek7, T. Jelinek9, J. Radocha4, M. Štork10,
R. Hajek9
1Departement Hematology and Oncology, University Hospital Brno, 2Institute
of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno,
3First internal clinic, 1. medicine faculty Charles univesity prague, Praha, 4Uni-
versity Hospital, Hradec Kralove, Hradec Kralova, 5University hospital Olomouc,
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Vinohrady, Praha, Praha, 8Masaryk university Brno, Brno, 9University Hospital
Ostrava and the Faculty of Medicine, Ostrava, 10University hospital Brno, Brno,
Czech Republic
Background: The combination of pomalidomide and low-dose dexamethasone
(Pom-Dex) is a perspective option for patients with end-stage relapsed/refractory
multiple myeloma (RRMM). We analyzed efficacy and toxicity of Pom-Dex in all
patients from the Czech Republic treated from june 2013 to december 2016.
Methods: Patients were eligible if they had been diagnosed with RRMM and
had failed at least two previous treatments with bortezomib and lenalidomide.
They were treated with start dose of Pom (4mg/day on days 1-21, orally) plus
low-dose dexamethasone (40mg/day on days 1, 8, 15, and 22, orally) until dis-
ease progression or unacceptable toxicity. We analyzed TTP and OS together
with toxicity. Also, univariate Cox proportional hazards model for OS was done
for standard risk factors. One hundred and twenty-two patients with median
age of 67 treated with Pom-Dex were evaluated. Median follow-up was 8.7
months. Median of previous treatment lines was 4.
Results: Median TTP of Pom-Dex treatment was 7.1 months (95% CI 5.3-8.6).
Median OS was 19.0 months (95% CI 13.2-25.8). The most common grade 3-
4 adverse events were neutropenia in 44%, anemia in 22% and thrombocy-
topenie in 24% of patients. Grade 3-4 infection were observed in 10% of
patients. Patients with ECOG worse than 2, B2microglobulin higher than 5, ISS
stage 3, low hemoglobin, low platelet count and presenting extramedullary
mass had worse OS according to univariate Cox proportional hazards model.
Summary/Conclusions: Our analyses show that Pom-Dex treatment of Czech
RRMM patients is effective, well tolerated and had better results than the reg-
istration study. Performance status and tumor burden seem to be main prog-
nostic factors according to our model. Thus, our suggestion for clinical practice
is to start pomalidomide treatment as soon as possible in case of MM relapse.
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UNDERSTANDING THE REAL-WORLD CLINICAL CHARACTERISTICS OF
MULTIPLE MYELOMA PATIENTS IN EUROPE
T. Bacon1,*, M. Gaudig2, T. Ito3, A. Hadfield4, A. Rider4
1Janssen Health Economics & Market Access EMEA, Dublin, Ireland, 2Janssen-
Cilag, Neuss, Germany, 3Janssen Health Economics & Market Access EMEA,
High Wycombe, 4Adelphi Real World, Bollington, United Kingdom
Background: Multiple myeloma is a heterogeneous disease that accounts for
approximately 10% of all haematological malignancies. While European treat-
ment guidelines exist for multiple myeloma, there is limited understanding about
the characteristics of patients with multiple myeloma in Europe and how these
characteristics vary by disease stage. Numerous patient and disease-related
factors can have an impact on treatment choice. Data surrounding these factors
would help to better characterise European patients and inform management
and treatment practices in multiple myeloma. 
Aims: The aim of the current study is to describe multiple myeloma patients
from 5 European countries (France, Germany, Italy, Spain, and the UK) across
the disease continuum. 
Methods: Data were drawn from the Adelphi Real World Multiple Myeloma
Disease-specific Programme (DSP), which was conducted across France, Ger-
many, Italy, Spain, and the UK in Q1 2015. The Multiple Myeloma DSP is a
real-world, cross-sectional survey that involves haematologists and haemato-
oncologists who completed patient record forms for the next 8 multiple myeloma
patients with whom they consulted. Study variables included patient demo-
graphics and background clinical information.
Results: A total of 262 physicians reported on 2,024 patients with multiple
myeloma. Of these patients, 73.2% were receiving first-line treatment; the
remaining 26.8% were receiving second-line treatment or later. The median
age of multiple myeloma patients was 70 years, 58.4% were male, and most
patients (88.5%) were white/Caucasian. Only 4.3% of patients had a family
history of cancer. Patients had a mean height of 168.8 cm, a mean weight of
72.8 kg, and a mean body mass index of 25.5 kg/m2. In terms of performance
status, 79.8% of patients had an Eastern Cooperative Oncology Group (ECOG)
status of 0 or 1, whereas 20.2% had an ECOG status of ≥2. While 12.9% of
patients had smouldering myeloma, 47.5% of patients had advanced stage
(stage III) disease. The most common symptoms experienced by patients were
anaemia (31.0%), bone pain (32.4%), fatigue/weakness (28.4%), and kidney
impairment or failure (12.6%). Furthermore, 34.6% of patients had bone com-
plications at some point in time. Over half (51.1%) of patients had comorbidities;
of these, 22.8% had hypertension and 12.5% had diabetes. Overall, 33.7% of
patients were considered eligible for transplant. Variances in patient character-
istics, both by country and by line of therapy, were observed.
Summary/Conclusions: Results from this analysis provide valuable insight
into multiple myeloma patients in European countries. These findings can help
to inform future treatment practices in Europe.
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EFFECTS ON BONE METABOLISM AND ANGIOGENESIS; FINAL
RESULTS OF A PHASE 2 STUDY OF THE GREEK MYELOMA STUDY
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Background: There is limited published data on the efficacy and safety of the
combination of lenalidomide, adriamycin and dexamethasone (RAD) as induc-
tion therapy for newly-diagnosed myeloma (NDMM) patients who are eligible
for autologous transplantation (ASCT).
Aims: The primary endpoint of this phase 2 study was the assessment of
overall response rate (ORR) after 4 cycles of RAD induction in NDMM patients
who are eligible for ASCT. Secondary endpoints included safety, progression-
free survival (PFS), time to progression (TTP) and overall survival (OS).
Exploratory endpoints included: i) the yield of stem cell collection after RAD; ii)
the effects of RAD on biochemical markers of bone metabolism: CTX, TRACP-
5b, bone-alkaline phosphatase (bALP), P1NP, osteocalcin, soluble RANKL,
osteoprotegerin (OPG) and dickkopf-1 (Dkk-1) and iii) the effects of RAD on
angiogenic cytokines: angiopoietin- (Angp) 1 & -2, angiogenin (Ang), VEGF
and bFGF.
Methods: Lenalidomide was administered at a dose of 25mg, po, daily, on
days 1-21 of a 28-day cycle; dexamethasone was given at a dose of 40mg, po,
on days 1, 8, 15, and 22, while adriamycin was administered as IV bolus infusion
at a dose of 9mg/m2, on days 1-4 of each cycle. Serum levels of the above
markers of bone remodeling and angiogenesis were measured before and after
4 cycles of RAD, using ELISA methodology.
Results: Between November 2014 and February 2016, 45 patients (median
age: 56 years) were enrolled. Osteolytic lesions were present in 33 (73%)
patients, while 3 (6.6%) had hypercalcemia (>11mg/dl). All but one patient com-
pleted 4 cycles of RAD. Best response included one (2.2%) CR, 8 (17.8%)
VGPRs, 21 (46.7%) PRs, for an ORR of 66.7%, while 14 (31%) patients had
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stable disease and one progressed during the 4th cycle of treatment. After
ASCT the ORR was 84.4%: 6 (13.3%) patients achieved CR, 13 (28.9%) VGPR
and 19 (42.2%) PR. Adverse events of grade 3 or 4 included mainly anemia (4
patients, 9%), neutropenia (3, 6.6%) and febrile neutropenia (one patient). After
a median follow-up of 19.1 months (range: 11.0-24.9), 11 patients have pro-
gressed and 4 died (all had achieved less than VGPR post-ASCT). The PFS,
TTP and OS rates at 12 months were 88.6%, 88.6% and 100%, respectively.
Forty (89%) patients had adequate stem cell collection post-RAD induction
(mean±SD: 8.94±6.50 x106/kg CD34+ cells). Patients at baseline had elevated
levels of CTX, TRACP-5b, sRANKL/OPG, Dkk-1, Ang, VEGF, VEGF-A, bFGF
and reduced levels of Angp-1/Angp-2, bALP and P1NP compared to 30 healthy
subjects of similar age and gender (p<0.01 for all comparisons). RAD therapy
resulted in a reduction of circulating CTX (p=0.03), TRACP-5b (p<0.01), Ang
(p=0.02), VEGF (p=0.01) and bFGF (p<0.01). Moreover, RAD increased serum
levels of bALP (p=0.036), P1NP (p=0.028) and Ang-1/Ang-2 ratio (p=0.022).
These alterations occurred irrespective of response, although patients who
achieved at least VGPR tended to have more profound differences in the above
parameters.
Summary/Conclusions: RAD resulted in successful induction for NDMM
patients with an ORR of approximately 67% pre- and 84% post-ASCT. With a
median follow-up of >1.5 year, the 12-month PFS rate and OS rates are high,
as expected. RAD reduced bone resorption and increased bone formation; the
latter has not been previously described with lenalidomide-based regimens.
Furthermore, RAD reduced angiogenic cytokines and this supports the action
of the regimen also through the disruption of the interactions between myeloma
and stromal cells.
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MULTIPLE MYELOMA IN THE REAL WORLD: HOW THERAPEUTIC
LANDSCAPE HAS CHANGED IN THE LAST 15 YEARS
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Background: Therapeutic Multiple Myeloma (MM) scenario has completely
changed in the last 30 years: conventional chemotherapy (CT) has been grad-
ually abandoned and autologous stem cell transplantation(ASCT),proteasome
inhibitors as Bortezomib (Bor) and immunomodulatory drugs as Thalidomide
and Lenalidomide (Len) have become the new actors in MM treatment (Tx). 
Aims: aim was to outline how the management of MM patients (pts) had
changed in the last 15 years reporting the experience of a single center.
Methods: Overall survival(OS) was measured from disease onset to death for
any cause or last follow-up. Progression free survival (PFS) was defined as
the time from first-line tx to disease progression or last-follow-up. The effect of
variables on OS and PFS was evaluated by log-rank test.
Table 1.
Results: We analyzed 584 MM pts diagnosed in our center from 2000 to 2015.
Patients’ characteristics are reported in Table1. Median number of therapy lines
is 2 (1-9). Among pts ≤65 yrs, 242/371 (71.8%)received ASCT as 1st line tx.
Patients >65 yrs were treated as follows: 16(8.5%) received ASCT,53(28.2%)
VMP,21 (11.2%) MPT,45 (23.9%) MP and 53 (28.2%) other therapies. As 2nd
line tx our pts received: 27 ASCT (8.9%), 115 Bor-based tx (38.1%), 48 Len-
based tx (16%), 53 CT(17.5%) and 59 other therapies(19.5%). As 3rd line tx:
5 pts received ASCT (2.8%), 65 Bor-based tx (35.9%), 42 Len-based tx
(23.2%), 39 CT (21.5%) and 30 other therapies (16.6%).The percentage of pts
receiving a new drug in 1st line was 64% (338/525). This percentage was sig-
nificantly different in pts treated before and after 2007 (42% vs 87%, p=0.001).
Similar results were observed in 2nd line, 75% of pts treated before 2007
received a new drug and 90% after 2007(p=0.002). Median PFS in pts >65 vs
≤65 yrs was 1.7 vs 2.4 yrs (p<0.001); median PFS in pts ≤65 yrs receiving or
not ASCT was 3.2 vs 1.9 yrs (p=0.001); of note, PFS was not different when
considering pts undergoing to ASCT after a CT-based or a Bor-based induc-
tion(3 vs 2.5 yrs, p=0.2).Time to next treatment (TTNT) in pts receiving ASCT
or not was 30.1 months ( 5-122.7) vs 10.3 months (0.2-70.5) (p<0.001) from 1st
to 2nd line tx and 11.2 months (0.3-121.9) vs 6.3 months (1-41.6) from 2nd to 3rd
line tx (p=0.026). The early mortality (within the first year) was 5.9% (31/525), in
details only 1/258 of those eligible to ASCT (0.4%) and 30/267 of those not can-
didate to transplant (11.2%). When considering this last group before and after
the 2007, we observed a significant higher incidence of early mortality in the first
period [21 (17.2%) vs 9 (6.2%), p=0.006]. About new drugs toxicity: with Bor-
based tx 30% of pts complaint neurological, 20% gastrointestinal and 18.2%
hematologic toxicity; with Len-based tx 36.4% infective events and 28.9% hema-
tologic toxicity. Median OS in pts ≤65 vs >65 yrs was 7 vs 4.8 yrs (p=0.001), of
note considering pts ≤65 vs >65 yrs treated before 2007 median OS was 5.5 vs
3.1 yrs (p<0.001)and after 2007 median OS was not reached vs 7.5 yrs (p=0.034).
Summary/Conclusions: Our real life data show how MM therapeutic scenario
have changed during the last 15 yrs. The tremendous improvement observed
in this study was mainly evident in older pts with a strong reduction of early
mortality and median OS reaching, in the second time frame after year 2007,
7.5 yrs. For younger pts ASCT confirmed to be of great benefit in term of TTNT
and PFS. Thus, considering the real advantage of new drugs a palliative
approach is not anymore justified even in very old pts.
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Background: Despite the clinical effectiveness of immunomodulatory drugs
(IMiDs) in multiple myeloma (MM), neither their mechanisms of action nor the
biomarkers that could identify patients who would benefit from IMiDs treatment
are yet known. While the identification of the IMiDs action via cereblon (CRBN),
Ikaros (IKZF1) and Aiolos (IKZF3) was a milestone, the role of other pathways
including CRBN and E3 ubiquitin ligase complex proteins (CUL4A, DDB1,
Roc1) are not fully understood so far. 
Aims: The aim of this study was to: 1) evaluate CUL4A, IKZF1, IKZF3, MUM1
and IRF4 expression in bone marrow trephine biopsies obtained from multiple
myeloma patients before treatment with thalidomide, 2) analyze the associa-
tions between the expression of these proteins and clinical characteristics and
outcomes.
Methods: IHC staining for CUL4A, IKZF1, IKZF3, IRF4 and MYC expressions
was performed in trephine biopsies obtained from 25 patients with multiple
myeloma before the treatment initiation. The patients (20 females, 5 males,
median age 68 years) were treated with thalidomide based regimens as a first-
line treatment. The patterns of proteins’ expression were scored independently
by two hematopathologists on a semi-quantitative scale and the cutoff was
defined as ≥ 30% positive cells. Associations between studied proteins’ expres-
sion and clinical parameters were assessed using Fisher’s Exact Test for cat-
egorical variables and Mann-Whitney-Wilcoxon Test U for continuous variables.
Survival (PFS and OS) were estimated using the Kaplan-Meier method and
compared using the log-rank test.
Results: Prior to treatment with thalidomide, 13 patients (52%) showed high
expression (≥ 30%) of CUL4A protein. No associations between expression of
CUL4A and other proteins were seen. Patients with high CUL4A expression
more often presented low disease stage according to Durie-Salmon classifica-
tion (P=0.02), beta-2-microglobulin level within normal ranges (P=0.07) and
higher median platelet count (P=0.003) compared to patients with low CUL4A
expression. Moreover, patients with high CUL4A expression before treatment
showed longer PFS compared to those with low CUL4A expression (P= 0.03).
Additionally, a significant association between high Aiolos expression and high-
er median of CD138+ cells in bone marrow was observed (P=0,01) compared
to low Aiolos expression, however no other associations with clinical course of
MM patients were seen. No associations between IKZF1, IKZF3, IRF4, MYC
expression and patients’ characteristics or outcome were revealed.
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Summary/Conclusions: In conclusion, our results suggest that CUL4A expres-
sion could serve as prognostic marker for patients assigned to IMiDs containing
regimens. Further analysis of the expression of other E3 ligase complex pro-
teins in a larger patient cohort is in progress.
Acknowledgement: This work is funded by a grant No 2014/13/B/NZ5/03160
from National Science Centre.
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DISEASE (MRD)
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Background: MRD-negativity status in patients with MM after autologous stem
cell transplantation (ASCT) directly correlates with higher Relapse-Free Sur-
vival. It remains unclear whereas these patients should all receive maintenance
therapy with it’s toxicity and cost.
Aims: To assess efficacy of maintenance therapy with Bortezomib in patients
with MM, who have achieved complete remission after ASCT with MRD positive
and negative status.
Methods: From January 2014 to February 2016 52 patients with ММ (19 male
and 33 female) ages from 24 to 66 years (median 54 years) who have achieved
complete remission after ASCT were randomized for a year-long maintenance
therapy with Bortezomib. On 100th day after ASCT and after completion of
maintenance therapy samples bone marrow from all patients were assessed
using 6-color Flow Cytometry to detect MRD. We chose Relapse-Free Survival
(RFS) as the indicator of maintenance therapy efficacy. Kaplan-Meier survival
curves were compared using log-rank test. Statistical analysis was performed
using SAS 9.4.
Figure 1.
Results: 2-year Relapse-Free Survival in patients with MRD-negative status
after ASCT was higher (p=0.05) than that in MRD-positive patients - 52,9%
(95% CI: 35,5–70,5%) vs 37,2% (95% CI: 25,4–49,3%). The MRD-positivity
significantly increases the risk of relapse (HR=1,7; 95% CI: 1,2–3,4; p=0,05).
Two year cumulative probability of relapse after ASCT in patients with MRD-
negative status, who had (n=15) and hadn’t received (n=10) maintenance ther-
apy with Bortezomib was not different (р=0,58). Average time of relapse in
MRD-positive patients who received maintenance therapy with Bortezomib was
5 months longer than in the group of patients without maintenance therapy -
17,3 months vs 12,3 months. In the group of MRD-positive patients who did
not completed maintenance therapy, relapse was diagnosed in 6 patients. After
the end of the treatment 42% of MRD-positive patients achieved MRD-negative
status. RFS in this group of patients was significantly higher than in the group
of treated MRD-positive patients who retained that status after maintenance
therapy (MT) - 100% vs 20% (р=0,02, Fig.1).
Summary/Conclusions: In cases when MRD-negative status was achieved
after ASCT, maintenance therapy does not increase the RFS. In comparison –
patients with positive MRD status after ASCT require maintenance therapy to
improve their survival rate. 
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Background: ASCT after induction treatment has been standard of care for
MM for almost 30 years. Some centers routinely perform two transplantation
up-front (so-called tandem transplants), while others advocate postponing the
second transplant until after progression. In recent years novel antimyeloma
agents have significantly improved the prognosis of MM patients, thus casting
further doubts on the value of the more aggressive tandem ASCT approach.
Aims: To describe long-term outcomes of MM patients treated with ASCT (sin-
gle and tandem) in a single centre. alled tandem transplants), while others
advocate postponing the second transplant until after progression. In recent
years novel antimyeloma agents have significantly improved the prognosis of
MM patients, thus casting further doubts on the value of the more aggressive
tandem ASCT approach.
Methods: This was a retrospective analysis of outcomes of 334 MM patients
who underwent 470 ASCT procedures at our center between 1993 and 2014.
During that period treatment policies changed from single to tandem to salvage
second ASCT, as data from different clinical studies became available.
Results: 296 patients received VAD (vincristine, doxorubicin, dexamethasone)
as induction therapy and 38 regimens based on immunomodulatory drugs or
proteasome inhibitors. All received high-dose melphalan for pretransplant con-
ditioning, 32 in combination with total body irradiation. Tandem ASCT (defined
as second transplantation performed within 6 months after the first) was per-
formed in 136 patients, single ASCT in 168 and salvage second (after
relapse/progression) in 30 patients. Transplant related mortality was 1.5%.
Median follow up is 70 months (range 4 – 238). Median overall survival (OS)
for the entire group is 123 months and median progression free survival (PFS)
40 months. Tandem ASCT in comparison to single and second salvage trans-
plantation resulted in superior OS (203 vs 86 vs 68 months respectively,
p<0.0001) and PFS (60 vs 38. vs 25 months respectively, p<0.0001) (figure).
Thirteen percent of patients who underwent tandem ASCT are alive and pro-
gression-free more than 10 years after the procedure. Fourteen patients devel-
oped secondary malignancies.
Figure 1.
Summary/Conclusions: Our results suggest that tandem ASCT is a very effec-
tive treatment modality that can partially substitute for the absence of expensive
novel agents with low long-term and lethal toxicities. Tandem ASCT seems to
result in superior OS and PFS in comparison to single or salvage second ASCT.
More than 10% of patients treated with tandem ASCT experience very pro-
longed PFS.
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EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS
UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION:
CLINICAL IMPACT IN DIAGNOSIS, TREATMENT AND OUTCOME
A. Roque1,2,*, A.L. Pinto1, E. Cortesão1,2, A. I. Espadana1, A.B. Sarmento-
Ribeiro12, C. Geraldes12, L. Ribeiro1
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bra, 2Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Background: Extramedullary disease (EMD) is defined as an infiltrate of clonal
plasma cells outside of the bone marrow. The presence of EMD in multiple
myeloma (MM) patients (pts) at diagnosis is a relatively uncommon presentation
and accounts for about 13% (6-20%) of MM pts. Although several studies
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showed an association of EMD with other adverse prognosis factors and
unfavourable outcomes, reports evaluating EMD role in pts undergoing autol-
ogous hematopoietic stem cell transplantation (aHSCT) are scarce.
Aims: We aimed to evaluate the clinical and laboratorial characteristics of pts
with EMD as well as its impact in outcomes of MM pts submitted to aHSCT
(response to treatment, overall survival [OS] and progression free-survival [PFS]).
Methods: We analysed 155 MM pts submitted to aHSCT in our centre between
January/2007 and December/2015, excluding second procedures. The assess-
ment of response to treatment was based in the International Myeloma Working
Group consensus criteria (2016).
Results: The median age of the cohort was 58 years (27-69), with 58% of
males, and the most common subtype was IgGκ (45%). In our cohort, 46 pts
(29.7%) presented EMD at diagnosis, which was significantly higher compared
to reports in the literature (p<0.001; 95%CI 0.22-0.37). The more common
involved sites were vertebral column (49%), ribs (13%) and pelvis (13%). EMD
occurred more frequently in males (38 vs 18%; p=0.012) and in pts with bone
disease at diagnosis (45 vs 13%; p<0.001). Surprisingly, it was more commonly
observed in pts with lower International Staging System scores (I and II vs III)
(82 vs 64%; p=0.022) and without anaemia at diagnosis (28 vs 11%; p=0.023).
No other significant differences in characteristics at diagnosis were found
between pts with and without EMD. Pts with EMD achieved lower complete
response/ very good partial response (CR/VGPR) proportions previously to
aHSCT (30.4 vs 53.2%; p=0.009), as well as at 100 days after aHSCT (D100)
(41.3 vs 59.6%; p=0.037). However, no differences were found concerning
refractoriness to first line therapy or proteasome inhibitor (PI) treatment, despite
EMD pts received a higher mean number of therapeutic lines previously to
aTPH (1.7 vs 1.4; p=0.025). After a median follow-up of 46.6 months, the medi-
an OS was not reached for global cohort and both groups, and there was no
difference between them (p=NS). The median PFS was 51.3 months for global
cohort, with no differences seen between pts with and without EMD (50.2 vs
54.1; p=NS). Pts with EMD treated with a PI (57%) presented a higher OS (NR
vs 55.2 months, p=0.04), but with no impact in PFS (p=NS), and there were no
differences concerning radiotherapy treatment (72%) or thalidomide mainte-
nance after aHSCT (32%) (p=NS).
Summary/Conclusions: In our cohort, EMD prevalence was significantly high-
er than usually described in the literature. This observation was probably asso-
ciated with a more carefully surveillance of EMD in aHSCT candidates. EMD
was associated with a lower proportion of CR/VGPR previous to aHSCT and
at D100 evaluation, even after a higher number of therapeutic lines, although
we failed to demonstrate that EMD was an independent prognosis factor for
PFS and OS. PI seem also to be the best first-line therapeutic approach for
EMD pts. In conclusion, our study suggests that EMD is underdiagnosed in
MM pts. It is necessary to achieve a better knowledge of the physiopathology
of EMD, in order to define better treatment options that may overcome its neg-
ative impact in therapeutic response.
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Background: Tools such as the International Staging System (ISS) and the
revised ISS (R-ISS) are used to stratify risk of death in patients newly diagnosed
with multiple myeloma (MM), enabling assessment of survival expectations.
These tools are based on factors measured at diagnosis only; understanding
the role of these factors at relapse is less clear. Patient characteristics change
between first-line (1L) and second-line (2L) treatment. Predicting survival using
tools that rely on patient characteristics measured at diagnosis only may, there-
fore, become less relevant than other tools that consider factors measured at
relapse. The Registry of Monoclonal Gammopathies (RMG) is a large hema-
tological disease registry, collecting data from patients in the Czech Republic
and Slovakia. Data from the RMG can be used to explore real-world charac-
teristics of patients with MM throughout their disease course.
Aims: To explore how key characteristics of patients with relapsed MM evolve
between initiation of 1L treatment and initiation of 2L treatment to better under-
stand drivers of disease progression and death.
Methods: This non-interventional, observational, retrospective study used data
collected prospectively from Czech patient charts available in the RMG. Adults
(≥18 years old) initiating 1L treatment for MM between May 2007 and April
2016 were included (N=3027); those with smoldering MM were excluded.
Patient and disease characteristics were extracted at initiation of 1L and of 2L
treatment. Repeated measurements were available only for those who initiated
1L and 2L treatment (1L+2L group; N=1418); patients who did not start 2L
treatment may have been in remission, lost to follow-up or had died.
Results: Patient and disease characteristics are summarized in the table (all
patients starting 1L and those who started 1L+2L). In general, for patients who
received 1L+2L treatment, their health status improved between initiation of
1L and of 2L treatment. At 2L, patients tended to have a lower ISS stage (re-
measured at 2L) than when they started 1L (stage I at 1L: 26.6%; at 2L: 41.1%).
Similarly, the proportion of patients with R-ISS stage III disease was lower at
start of 2L (24.6%) than at start of 1L (31.1%) treatment. Eastern Cooperative
Oncology Group performance status scores were also better for patients when
they started 2L than when they started 1L treatment (stage 3–4 at 1L: 8.7%; at
2L: 5.5%). Laboratory measurements indicated that patients were in better
health at the start of 2L treatment than at initiation of 1L treatment: median M
protein levels decreased from 31.2 g/L at 1L to 17.7 g/L at 2L, and elevated
calcium and creatinine levels were less common at 2L than at 1L. Median lac-
tate dehydrogenase levels were slightly elevated at start of 2L vs start of 1L
treatment (184.4 U/L vs 206.6 U/L).
Table 1.
Summary/Conclusions: Patient health was better at initiation of 2L treatment
than at initiation of 1L treatment. At relapse, patients are likely to be closely
monitored and are able to initiate the next treatment line while in relatively
good health; at initiation of 1L, patients may have experienced deterioration in
health which could have triggered their diagnosis. These findings illustrate how
patient characteristics change over time and indicate that factors influencing
survival may evolve; therefore, restaging patients at relapse may be beneficial
and could contribute to improved predictive tools that can better define survival
estimations at first relapse by considering patients’ experiences at 1L.
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AN EARLY GOOD RESPONSE AFTER BORTEZOMIB-BASED INDUCTION
REGIMENS REPRESENTS A SIGNIFICANT PREDICTOR FOR IMPROVED
PFS IN NDMM PATIENTS
G. Rivoli1,*, M. Cea1, S. Aquino2, A. Dego1, N. Di Felice1, N. Bisso1,
D. Avenoso1, R. M. Lemoli1, M. Gobbi1, L. Canepa1
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Background: Introduction of triplets-based induction regimens containing pro-
teasome inhibitors (PIs) in clinical practice have led to higher response rates
and prolonged life expectancy in newly diagnosed multiple myeloma (NDMM)
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patients. Different studies have linked complete response (CR) with better PFS
(progression free survival), but not always with prolonged overall survival (OS),
most likely due to the impact of novel agents in the management of relapsed-
refractory patients. Overall, these observations suggest PFS as a more reliable
predictor of clinical outcome. Also, the biological aggressiveness is emerging
as a pivotal disease characteristic which affects clinical behavior and response
to therapy. In this context, little is known about the association of response
kinetic with survival outcomes. 
Aims: In order to evaluate whether early achievement of a good quality
response impacts on outcome, we retrospectively analyzed 87 NDMM patients
treated at our institution with bortezomib containing regimens (BRs).
Methods: From 2004 to 2016, 87 patients with NDMM and measurable disease
(serum and/or urine M protein) were treated with BRs. Both patients eligible
and non-eligible to ASCT were included in the study; patients undergoing ASCT
were censored at the time of transplant. Median age was 66 (range 32-87);
males were 51 (59%); 72 (83%) patients were in III stage; median follow up
was 30.7 months; median number of administered courses was 5 (range 2-9).
PFS was defined according to IMWG criteria. Cytogenetic risk evaluation per-
formed by a standardized FISH panel, including del17p, del13q, t(11;14),
t(4;14), was available in 37 patients (42.5%). Among these high risk abnormal-
ities were identified in 20 patients. Early good response (EGR) defined an M
protein reduction ≥75% after 2 courses of therapy. Survival curves were calcu-
lated for PFS and OS by Kaplan Meyer method, using log-rank test. 
Results: PFS and OS were both assessed in patients who achieved EGR as
well as in patients who did not. No significant differences were observed in
terms of OS between the two groups, whilst PFS was significantly longer in
patients achieving EGR (p= 0.036, median PFS 44.7 vs 29 months, respec-
tively). Next, we analyzed patients with high risk cytogenetic. Among these,
EGR vs non-EGR patients reached a PFS of 43.7 and 18.7 months, respec-
tively. Remarkable PFS differences between these two groups were not signif-
icant (p value=0.11).
Figure 1.
Summary/Conclusions: Overall, our data demonstrate a significant impact of
EGR on PFS in NDMM patients after BRs, irrespective of median age at diag-
nosis. In presence of high cytogenetic risk EGR is associated with prolonged
PFS, although not significantly. Ongoing analysis on larger cohort of high risk
patients will confirm the impact of EGR on PFS also in this group of patients.
Based on our data kinetic of response, deriving from EGR assessment, may
provide information on both disease aggressiveness as well as clinical outcome,
thus representing a novel, surrogate marker for an early survival analysis, with
favorable cost-effectiveness characteristics. In summary biological and clinical
information deriving from EGR analysis combined with cytogenetic risk evalu-
ation and patient-related (age, comorbidities) characteristics, may represent a
useful tool to make clinical decisions. Further prospective evaluations are need-
ed to include this marker in clinical practice.
E1300
RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL
TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/REFRACTORY
MULTIPLE MYELOMA
K. Betts1, C. Chen2, M. Zichlin1, A. Brun2, J. Signorovitch1, D. Makenbaeva2,*
1Analysis Group, Inc., Boston, MA, 2Bristol-Myers Squibb, Inc., Plainsboro, NJ,
United States
Background: In combination with lenalidomide (REVLIMID®, R) and dexam-
ethasone (d), elotuzumab (EMPLICITI™, E), carfilzomib (KYPROLIS®, K), and
ixazomib (NINLARO®, N) were recently approved for the treatment of
relapsed/refractory multiple myeloma (RRMM). In randomized controlled trials,
all three drugs showed a significant relative reduction in the risk of disease pro-
gression or death as compared to patients who received Rd. To date, there
have been no head-to-head trials comparing ERd, KRd, and/or NRd.
Aims: To describe the time-specific progression-free survival (PFS) based on
published Kaplan-Meier PFS curves for ERd, KRd, and NRd relative to Rd.
Methods: Individual patient-level data (IPD) were reconstructed from the pub-
lished Kaplan-Meier PFS curves from the ELOQUENT-2 (ERd), ASPIRE (KRd),
and TOURMALINE-MM1(NRd) randomized, controlled, Phase III trials using
digitization software and the methods described by Guyot, et. al. Using the
reconstructed IPD, Kaplan-Meier survival curves were estimated for each arm
within each trial. PFS curves were digitized by two independent researchers
and the reconstructed curves were overlaid with the published data to validate
the IPD. In each trial, the relative PFS benefit over time was calculated as the
difference in the Kaplan-Meier PFS estimate of each triplet regimen and the
Kaplan-Meier PFS estimate of Rd divided by the Kaplan-Meier PFS estimate
of Rd: rPFS(t)=[SXRd(t) - SRd(t)] / SRd(t). Where S(t) denotes the Kaplan-Meier
PFS estimate at time t, and X denotes E, K, or N, respectively.
Results: IPD from the three randomized controlled trials was successfully
reconstructed and validated. Numerically, ERd had the highest relative PFS
over the initial 10 months of treatment and showed sustained benefit from
month 24 onwards (Figure 1). At 12 months, the relative PFS benefit was
17.9% for ERd, 21.7% for KRd, and 9.7% for NRd. At 24 months, the relative
PFS benefit was 45.1% for ERd, 34.3% for KRd and 24.1% for NRd. At 36
months, the relative PFS benefit was 39.9% for ERd and 19.1% for KRd. ERd
had a higher relative PFS than NRd for almost the entirety of RRMM treatment.
At the end of data availability, NRd and KRd showed no additional PFS benefit
relative to Rd, while ERd showed a sustained benefit through 40 months. Data
will be updated for the conference, where available.
Figure 1.
Summary/Conclusions: For the treatment for RRMM, ERd showed an early
and sustained benefit in relative PFS which was maintained through 40 months.
KRd and NRd showed initial benefits which faded by the end of data availability.
E1301
POMALIDOMIDE WITH LOW-DOSE DEXAMETHASONE IN PATIENTS WITH
RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A
PROSPECTIVE ANALYSIS IN A POPULATION-BASED REGISTRY
R. Wester1,*, A. Dinmohamed1,2,3, P. Sonneveld1, A. Broijl1, N. Blijlevens4
1Department of Hematology, Erasmus Medical Center Cancer Institute, Rot-
terdam, 2Department of Research, Netherlands Comprehensive Cancer Organ-
isation (IKNL), Utrecht, 3Department of Public Health, Erasmus University Med-
ical Center, Rotterdam, 4Department of Hematology, Radboud umc, Nijmegen,
Netherlands
Background: Patients with relapsed and/or refractory multiple myeloma
(RRMM) have limited treatment options and a poor prognosis. Previous trials
showed that pomalidomide combined with low-dose dexamethasone is effective
in these patients with improvement in response and survival. These studies
led to the approval of pomalidomide as third line treatment in patients with
RRMM.
Aims: A prospective analysis in a population-based registry was conducted to
assess response and survival in patients with RRMM treated with a pomalido-
mide-based regimen. Also, we defined subgroups who benefit most of this treat-
ment regimen.
Methods: Patients were eligible for pomalidomide if they received ≥2 prior lines
of therapy including bortezomib, lenalidomide and alkylator therapy and devel-
oped progressive disease on their last therapy. This is a prospective analysis
of patients registered at the nationwide Netherlands Cancer Registry. Treatment
consisted of 4mg pomalidomide, day 1-21, combined with corticosteroids. Treat-
ment was discontinued in case of progressive disease or unacceptable toxicity.
Primary endpoint was progression-free survival (PFS). Secondary endpoints
included overall survival (OS), overall response rate (ORR), toxicity, response
per risk group (based on cytogenetics and ISS at initial diagnosis) and response
per age group (≤65 vs >65 years).
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Results: A total of 82 patients (median age 68 years [range: 43-88]) were
included in this analysis. CRAB criteria included anemia in 23 patients (28%),
renal insufficiency in 8 (9.8%), hypercalcemia in 13 (16%) and bone lesions in
54 (66%). Median time from diagnosis to start pomalidomide was 5.75 years
[range: 0.8-18.4], median number of treatment cycles was 3 [range: 1-17]. At
time of analysis 59 patients had stopped pomalidomide treatment: 24 patients
had progressive disease, 10 had unacceptable toxicity, 6 patients were refrac-
tory, 4 patients died during treatment and 15 patients stopped due to various
other reasons. Grade ≥3 hematological adverse events occurred in 11% of
patients, 4% had neutropenic fever. Grade ≥3 non-hematological toxicities
occurred in 57% of patients, including infection in 22%, gastrointestinal disor-
ders in 5% and renal disorders in 5%. Of 69 patients evaluable for response
ORR was 41%, with a partial response (PR) rate and a very good partial
response (VGPR) rate of 36% and 4% respectively. Response based on age
was not significantly different (p=0.426). Median PFS for all patients was 3.8
months (95% confidence interval [CI] 2.3-6.6). Patients >65 years had a longer
PFS of 5.7 months (95% CI 2.3-8.0) versus 2.8 months (95% CI 1.9-6.6) in
patients ≤65, however, this was not statistically significant (p=0.427) (figure 1).
For patients achieving ≥PR, median PFS was 9.6 months (95% CI 5.7-not
reached (NR)). Median PFS in patients diagnosed more than ten years prior
to initiation of pomalidomide treatment was 9.6 months (95% CI 1.8-NR), as
compared to 2.2 months (95% CI 1.9-6.6) among patients treated within 5
years after diagnosis (p=0.05). Data about previous treatment, ISS stage, cyto-
genetics at diagnosis and an update of OS will be presented at EHA.
Figure 1.
Summary/Conclusions: In this analysis the experience in clinical practice of
patients with RRMM treated with a pomalidomide-based regimen is reported.
These data support results shown in clinical trials. Preliminary data presented
here suggest that older patients and patients with a long interval between initial
diagnosis and pomalidomide treatment (indicating a less aggressive multiple
myeloma) may benefit from this treatment.
E1302
INVOLVED/UNINVOLVED HEAVY/LIGHT CHAIN INDEX CAN PREDICT
PROGRESSION IN MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS
PERIPHERAL BLOOD STEM TRANSPLANT. PRELIMINARY EXPERIENCE
M. Espiño Martinez1,*, A. Arteche Lopez2, A. Arriero3, C. Muñoz-Calleja4,
A. Alegre Amor3, M.J. Blanchard Rodríguez5, F.J. López Jiménez5, L.M. Villar1
1Immunology, University Hospital Ramon y Cajal, 2Clinical Analisis, 3Haema-
tology, 4Immunology, University Hospital La Princesa, 5Haematology, University
Hospital Ramon y Cajal, Madrid, Spain
Background: High-dose therapy followed by autologous peripheral blood stem
transplant (APBSCT) has demonstrated to improve overall survival and pro-
gression free survival with a high complete remission rate in multiple myeloma
(MM) patients. However most patients eventually present progression or
relapse (P/R). Detection of P/R is mainly based on a significant increase of
monoclonal protein (MC) or free light chains (sFLC). The identification of new
biomarkers to early predict P/R might be clinically useful for an anticipated
therapy. 
Aims: The aim of our study was to evaluate the potential role of the
Involved/Uninvolved Heavy/Light Chain index (I/Ui) in this setting.
Methods: We prospectively followed 44 MM transplanted patients: 19 with
IgG-kappa isotype, 11 with IgG lambda, 9 with IgA-kappa and 5 with IgA-lamb-
da. They were followed for 29.0±3.8 months (mean±standard error (SE)). Serial
serum samples from each MM patients were collected periodically after APB-
SCT. Relapse or progression was defined according IMWG criteria. To identify
factors that predict disease progression in MM transplanted patients, we studied
heavy/light chains (HLC) pair quantification, sFLC and total immunoglobulins
levels in serial serum samples collected during the follow-up. Involved/unin-
volved index (I/Ui) was calculated using the monoclonal chain (Involved) as
numerator and the polyclonal chain of the same class (Uninvolved) as denom-
inator. The HLC ratio (rHLC) was calculated as IgGκ/IgGλ or IgAκ/IgAλ with
normal reference ranges established in 1.3-3.7 for IgG and 0.7-2.2 for IgA. 
Results: In IgG MM patients, values of I/Ui were significantly increased in pre-
relapse compared to basal samples (8.49±4.01 vs 2.23±0.67 p=0.012). By
contrast, this index remained stable along follow-up in patients in complete
remission (CR) or with a partial response (PR). However, the later showed
higher values of I/Ui ratio, suggesting that the presence of an M-component
induces a moderate immunosuppression of the uninvolved chain of the mon-
oclonal isotype. Regarding IgA MM, we established a cut-off value of 2.0 for
I/Ui that allowed the discrimination of patients at high risk of early progression
(values above 2.0) from those in CR, whose levels of I/Ui are always below 2.0
(p=0.02). 
Summary/Conclusions: Our results show that HLC-pair measurement could
detect progression or relapse and the increase of MC in transplanted MM
patients earlier than other methods. Future studies will need to demonstrate
the real value of the I/Ui index as a biomarker to anticipate progression in MM
patients subjected to APBSCT. 
E1303
MULTIPLE MYELOMA IMMUNOPHENOTYPIC REMISSION IS A SIGNIFICANT
PREDICTOR OF PROGRESSION FREE SURVIVAL AFTER FIRST
AUTOLOGOUS STEM CELL TRANSPLANTATION - PILOT STUDY 
K. Beranova1,*, J. Radocha1, O. Soucek2, K. Machalkova1, J. Hanousek1,
P. Zak1, V. Maisnar1
1IV. interni hematologicka klinika, 2Institute of Clinical Immunology and Aller-
gology, Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic
Background: Minimal residual disease in multiple myeloma assesed by mul-
tiparameter flow cytometry has become an increasingly important predictor of
progression-free survival (PFS).
Aims: Our primary endpoint was to evaluate PFS in myeloma patients after
stem cell transplantation who reached immunophenotypic CR (iCR) versus
those who have not.
Figure 1.
Methods: We prospectively evaluated prognostic importance of minimal resid-
ual disease detection by multiparameter flow cytometry (MFC) in multiple
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myeloma patients who underwent autologous stem cell transplantation from
January 2014 until December 2016. All patients were uniformly treated with
bortezomib based induction therapy followed by high dose chemotherapy (Mel-
phalan 200mg/m2) and autologous stem cell transplantation. Minimal residual
disease (MRD) status was determined by 8-colour MFC 1 month after autolo-
gous transplantation from bone marrow aspirate in all patients who achieved
at least conventional VGPR or CR. 
Results: We identified 56 patients who fulfilled the above mentioned criteria.
30 were males and 26 females, median age was 61. 62.5% of patients (35/56
patients) achieved iCR, 37.5% of patients (21/56) did not. Median follow up of
the cohort was 19 months (6-59). 32.1% of patients (18/56) relapsed during
the follow-up period, 16.1% of patients (9/56) died. 22.9% (8/35 patients) in
iCR and 47.6% (10/21 patients) not in iCR relapsed during the follow up.
Patients in iCR showed significantly longer PFS with median 42 months than
those in less than iCR with PFS median 29 months (p=0.0196, log-rank test).
This was reflected by decreased hazard ratio of relapse (0.3565) for iCR group.
Summary/Conclusions: Achieving immunophenotypic CR is clearly associ-
ated with longer progression free survival compared to conventional CR. Reach-
ing iCR should be a goal of myeloma treatment.
E1304
REGULATION OF NORMAL AND MONOCLONAL IMMUNOGLOBULIN
SECRETION BY CYTOKINES (S- SYNDECAN-1, BLYS & TGF-BETA-1) IN
PATIENTS WITH IG-SECRETING B-CELL DISORDERS AT PRESENTATION.
PROGNOSTIC IMPLICATIONS
E. Koulieris1, P. Papaioannou1,*, E. Nikolaou1, K. Sarris1, D. Maltezas1,
S. Harding2, N. Kafassi3, K. Tsalimalma3, K. Bitsani1, T. Tzenou1, V. Bartzi1,
P. Petsa1, S. Kotsanti1, A. Koudouna1, E. Kastritis4, S. Sachanas5,
M. Angelopoulou1, G. Pangalis5, E. Terpos4, P. Sfikakis1, M. Dimopoulos4,
P. Panayiotidis1, M.-C. Kyrtsonis1
1Hematology Section - 1st Department Of Propaedeutic Internal Medicine,
Laikon General Hospital, Athens, Greece, 2Binding Site Ltd, Birmingham, Unit-
ed Kingdom, 3Immunology Laboratory, Laikon General Hospital, 4Therapeutic
Clinic, Alexandra’s Hospital, 5Hematology Clinic, Medical Center Psychico,
Athens, Greece
Background: The most common neoplastic lymphoproliferative diseases that
secrete paraprotein are multiple myeloma (MM), Waldenstrom’s Macroglobu-
linemia (WM) and chronic lymphocytic leukemia (CLL). The two first entities
secrete paraprotein by definition, while serum free light chains (sFLC) are
increased in 50% of CLL cases. Microenvironmental factors, such as soluble
Syndecan-1 (ssynd-1) and BlyS normally promote lymphoplasmacytic differen-
tiation as well as their secretory activity, whereas others, like TGFbeta1, inhibit
them. Determination of Ig is necessary in MM and WM for diagnostic purposes
and for monitoring patients, while in CLL, sFLC has prognostic value. The total
amount of secreted Ig does not really reflect disease burden. The heavy chain
Ig can be accurately determined with the ‘Heavylite’ method (that measures
separately HLC-IgA, -G, -M kappa or lambda), thus allowing exact quantification
of the amount of pure monoclonal fraction but also the degree of suppression of
polyclonal Igs, both being reflected by the corresponding ratios (HLCR).
Table 1.
Aims: To determine any possible relationship between the amount of Igs secret-
ed and serum sSynd1, BLyS and TGFbeta1, as well as with disease outcome.
Methods: We studied 269 patients: 105 with MM (79 IgG and 26 IgA, of whom
33%, 31%, and 36% were staged ΙSS 1, 2 and 3 respectively), 64 suffering
from WM (44%, 28%, 28% staged WM-IPSS 1, 2, 3 respectively), and 100 with
CLL (67%, 23%, 10% staged Binet 1, 2, 3 respectively). Patients were regularly
followed-up from diagnosis to last visit or death (median follow-up time: 63
months). sFLC/sFLCR and HLC/HLCR were determined by nephelometry
(Freelite™ and Heavylite™, the Binding Site Birmingham, UK) while sSynd1,
BLyS and TGFbeta1 by ELISA, either in fresh or in frozen sera sample drawn
at the time of diagnosis. Statistical analysis was performed by standard methods
using the SPSS v22.0. software. 
Results: The main correlations observed between the Ig levels secreted in the
3 diseases and cytokines studied, as well as their impact, with regard to patients’
outcome, are shown in table.
Summary/Conclusions: sSynd1 in MΜ and BLyS in WM and CLL correlated
with Ig production. By inhibiting both monoclonal and polyclonal Ig, TGFb1 cor-
related in MM with both HLC and FLC ratios and differences. In addition, the
aforementioned variables are prognostic with regard to patients’ outcome.
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PATIENTS WITH MULTIPLE MYELOMA (MM) IN LONG TERM COMPLETE
REMISSION (LTCR) AFTER AUTOLOGOUS TRANSPLANT (APBSCT)
EXPRESS A DISTINCTIVE INMUNE PROFILE WITH POTENTIAL
PROGNOSIS VALUE
A. Arteche-Lopez1,*, A. Alegre Amor2, A. Kreutzmann3, B. Aguado2, M. Espiño
Martinez4, L.M. Villar5, P. Sanz1, A. Arriero2, C. Muñoz-Calleja3
1Clinical Analisis, 2Haematology, 3Immunology, University Hospital La Princesa,
4Haematology, 5Immunology, University Hospital Ramon y Cajal, Madrid, Spain
Background: A small fraction of patients with MM could be considered poten-
tially cured as long as they remain for more than six years in long term complete
remission (MM-LTCR) after autologous transplant (APBSCT). The exhaustive
study of the immune status of these patients could highlight interesting infor-
mation.
Aims: Here we present an observational study that evaluates the numbers and
phenotype of T- and B-cells subsets in the peripheral blood (PB) of MM-LTCR
patients.
Methods: After approval by the ethics committee, we selected 13 patients diag-
nosed with MM, in sCR according to IMWG criteria for at least six years after
APBSCT, and 15 healthy adults (HA) of similar ages as a comparative group.
Group MM: 7 males and 6 females; median age: 61. Median follow up in sCR
after APBSCT was 8 years (range 6-19). Group HA: 5 females and 10 males,
median age 60 (36-78). Immunophenotype characterization was done using a
comprehensive 8-color flow cytometry panel. Subpopulations of CD4+ and
CD8+ T-cells from PB were quantified, including naïve, central and effector
memory, regulatory T-cells, as well as subpopulations of B-cells: naïve, transi-
tional, marginal zone-like, class-switched memory and plasmablasts. In order
to confirm their specific immune signature, the analysis was repeated in the
same LTCR-MM patients one year after the first analysis was done. A Kruskal-
Wallis test was used to evaluate differences among the studied groups. A pos-
teriori test was done to compare the control group with the two patient’s group
(patients and patients +1 year), independently of each other. A Wilcoxon
matched test was used to compare a patient under group “patients” with the
status of the same patient in the second group “patients +1 year”. Statistical
analysis was done using GraphPad Prism software.
Results: The patients had a lower percentage of total CD4+T-cells (p=0.0004)
together with a decrease in the naïve CD4+ T-cells (CD27+CCR7+CD45RA+;
p=0.0004) and an increment of the effector memory CD4+ T-cells (CD27-CCR7-
; p=0.0028), both CD27-CCR7-CD45RA-and CD27-CCR7-CD45RA+ cells. Similar
results were found within the CD8+T-cells. No differences were observed in the
Tregs defined as CD4+CD25highCD127-. The mean percentage of total B-cells in
the patients was within the normal range and no significant differences were
found when compared to HA. However, naïve B-cells (CD27-IgD+IgM+) proportion
was higher in patients and a corresponding reduction of marginal zone-like B-
cells (CD27+IgD+IgM+, p=0.0047) and class-switched memory B-cells
(CD27+IgD-IgM-, p=0.0043) was observed. No differences were observed in the
percentage of transitional B-cells (CD27-CD10+CD38+) or plasmablasts (CD27++
CD38++) in the PB of the two groups. When the analysis was repeated in the
same LTCR-MM patients one year after the first analysis, no changes were detect-
ed neither when analysed as a group nor when analysed individually.
Summary/Conclusions: The MM-LTCR patients seem to express a distinctive
immune “footprint” characterized by a decreased proportion of naïve T-cells
and an increased percentage of effector T cells, which probably exert a com-
petent immune surveillance. Conversely, the increase in naïve B cells may
guarantee the humoral response homeostasis, including the recovery of normal
plasma cells that might compete with myelomatous cells for normal bone mar-
row niches. The precise role of these refined immunological studies in the mon-
itoring and therapeutic decisions in MM patients, and also in the duration of
sCR, should be defined in the future.
Study partially performed with research grants from the spanish Leukemia and
Lymphoma Foundation and Grant PI12/00494P from the Fondo de Investiga-
ciones Sanitarias and FEDER funds.
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IMPACT OF THE AFFORDABILITY OF NOVEL AGENTS IN PATIENTS WITH
MULTIPLE MYELOMA: REAL WORLD DATA ON CURRENT CLINICAL
PRACTICE IN MEXICO
L. Tarin-Arzaga1,*, V. Martinez-Pacheco1, A. Gomez-De Leon1, P. Colunga
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Pedraza1, P. Santana-Hernandez1, G. Sotomayor-Duque1, D. Arredondo-Campos1,
C. De la Cruz-De la Cruz1, O.G. Cantu-Rodriguez1, D. Gomez-Almaguer1
1Hematology, Hospital Universitario Dr Jose Eleuterio Gonzalez Universidad
Autonoma de Nuevo Leon, Monterrey, Mexico
Background: The success of bortezomib and lenalidomide in improving out-
comes as first-line therapies in multiple myeloma (MM) patients has been
achieved at a very high cost. Treatment has become difficult to access for
patients living in low to middle-income countries, as most receive assistance
by public healthcare systems wherein novel drugs are unaffordable.
Aims: To compare the outcomes of MM patients who can afford private insur-
ance and treatment in a private center (PrivC), with those managed in a public
center (PubC), who do not have access to healthcare coverage and are treated
on an out-of-pocket basis. 
Methods: We analyzed records of 148 patients diagnosed with MM in two
health sectors in Monterrey, Mexico, from October 2007 to July 2016; 77 (52%)
from PubC, where the most common induction therapy was cyclophosphamide-
thalidomide-dexamethasone, followed by thalidomide maintenance, and 71
(48%) from PrivC wherein bortezomib or lenalidomide-based induction and
lenalidomide maintenance were used. We compared demographics, disease
stage, response rate and survival among both groups. 
Results: Median age, gender and frequency of immunoglobulin isotype did not
differ significantly between the two groups. Patients treated in PubC were more
likely to be diagnosed with advanced stage disease (ISS III 42% vs 26% p<0.05).
Median follow-up was 36 months (range 3-120 months). Autologous transplan-
tation was performed in 80% of the transplantation-eligible patients in PrivC and
only in 31% of PubC. At least a very good partial response to induction therapy
was achieved more often in the PrivC among transplantation-eligible (65% vs.
42%, p<0.05) and ineligible patients (66% vs. 41%, p<0.05). Overall survival
was significantly higher in PrivC for transplantation-eligible (median 84 vs. 59
months, p<0.05) and ineligible groups (median 79 vs 46 months; p<0.05). After
controlling for disease stage and transplantation factors, the risk of mortality
was still higher in PubC (HR 1.49; 95% CI:1.0-2.2, p<0.05).
Summary/Conclusions: Stage at diagnosis, induction therapy and autologous
stem cell transplantation were contributors to survival disparities between
patients treated in public vs private health care facilities in Mexico. These find-
ings underscore the need for more efforts to improve the affordability of novel
agents and transplantation settings in public health services.
Myeloproliferative neoplasms - Biology
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BASAL CALCIUM, AN IMPORTANT ELEMENT IN THE DEVELOPMENT OF
CALR MUTANT MPNS
M. Morlan Mairal1,*, P. Papadopoulos2, M. Krstic-Demonacos 1, A. Aziz1
1Salford University, Manchester, United Kingdom, 2Hospital Clinico San Carlos,
Madrid, Spain
Background: Calreticulin (CALR) is a calcium (Ca2+) buffering chaperone
mutation of which has recently being associated with essential thrombo-
cythemia and primary myelofibrosis without JAK2 mutations. These mutations
have been suggested to impair the Ca2+buffering activity of Calreticulin due to
a change of the negative charge in its C-terminal domain. Ca2+is known to be
important during megakaryocyte activity; however its role during megakary-
opoiesis and the possible link of CALR mutations and abnormal megakaryocyte
production due to impaired Ca2+ buffering activity in myeloproliferative neo-
plasms (MPNs) remains unclear.
Aims: Here we aim to understand how basal Ca2+fluctuates during normal
megakaryopoiesis and how CALR mutations could affect the basal Ca2+levels
in megakaryocytes in MPNs.
Methods: Ca2+ stainning was performed using Fluo-8 dye and Ca2+ basal lev-
els were measured by flow cytometry. Changes in basal Ca2+during megakary-
opoiesis using two cellular systems, K-562 cells and mouse bone marrow cells,
were measured each 24 hours. Further studies using CALR mutant cellular
models were performed using the same methology.
Results: Our results showed a characteristic behaviour of fluctuations of basal
Ca2+ during this megakaryopoiesis, where Ca2+levels decreasein the last stage
of megakaryocyte formation. These results suggest that Ca2+reduction could
be essential for megakaryopoiesis. In order to understand how CALR mutations
affect basal Ca2+, Marimo cells and Dami cells expressing CALR mutations
were analysed. Here we show a decrease in basal Ca2+in Marimo cells and
DAMI-CALR type2 mutation compared to the controls. Moreover, DAMI-CALR
type1 did not show any significant reduction, suggesting possible differences
in Ca2+behaviour depending in CALR type mutation. We are currently working
in the analysis of basal Ca2+fluctuations during megakaryopoiesis in the pres-
ence of CALR mutations and preliminary results show abnormal basal Ca2+lev-
els throughout all the process of megakaryocyte differentiation.
Summary/Conclusions: Altogether, our findings indicate that basal Ca2+ could
be an important element during megakaryopoiesis and CALR mutations found
in MPN could impair the normal production of megakaryocytes due to changes
in cellular Ca2+. However, further analysis need to be done in order to under-
stand the role CALR mutations and their effect in the Ca2+buffering activity of
CALR in MPNs.
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THE INHIBITION OF JAK/STAT SIGNALING IS COMPENSATED BY
ACTIVATION OF MAPK PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS
T. Subotički1, B. Beleslin Čokić2,*, D. Djikić1, S. Mojsilović3, D. Šefer4, S. Bjelica3,
J. Santibanez3, V. Čokić3
1Laboratory of neuroendocrinology, Institute for Medical Research, University
of Belgrade, 2Clinic for endocrinology, Diabetes and Metabolic Diseases, Clin-
ical Center of Serbia, 3Laboratory of experimental hematology, Institute for
Medical Research, University of Belgrade, 4Clinic of Hematology, Clinical Cen-
ter of Serbia, Belgrade, Serbia
Background: Myeloproliferative neoplasms (MPN) remain incurable regard-
less of advancement in the use of JAK1/2 inhibitor Ruxolitinib, which compe-
tence is unrelated to the JAK2V617F mutation.
Aims: We want to explore JAK1/2 inhibition dependency in correlation with
activated JAK/STAT3 signaling and cell cycle in MPNs.
Methods: The immunoblotting has been used to analyze activation of
JAK/STAT3, PI3K/AKT and MAPK signaling in JAK2V617F mutated HEL cells
and granulocytes of MPN. The cell cycle and apoptosis of granulocytes are
studied by flow cytometry.
Results: Concerning myeloproliferation, JAK1/2 inhibitors reduced the per-
centage of cells in G2M phase and increased apoptosis in JAK2V617F mutated
HEL cells. Comparing to polycythemia vera (PV), the percentage of granulo-
cytes is decreased in S and G2M phases of essential thrombocythemia (ET)
and primary myelofibrosis (PMF) that demonstrated increased apoptosis. Hexa-
bromocyclohexane increased percentage of granulocytes in GoG1 phase of
JAK2V617F positive, but reduced in JAK2V617F negative PMF, the later one
similar to Ruxolitinib. JAK1/2 inhibitors reduced percentage of apoptotic gran-
ulocytes in JAK2V617F positive, but increased in JAK2V617F negative PMF.
JAK1/2 inhibitors could not prevent constitutive activation of JAK/STAT3 sig-
naling in HEL cells as well as in granulocytes of JAK2V617F positive ET and
PMF. Absence of JAK2V617 mutation supported dephosphorylation of
JAK/STAT3 pathway by JAK1/2 inhibitors in ET, but not in PMF. JAK1/2 inhibitor
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Ruxolitinib largely activates MAPK signaling in MPN, while slightly PI3K/AKT
signaling in PV and JAK2V617F negative PMF. Specific JAK2 inhibitor Hexa-
bromocyclohexane activates PI3K/AKT signaling in JAK2V617F positive ET,
but reduced in JAK2V617F negative ET and PMF.
Summary/Conclusions: This observation support cross-talk between exam-
ined pathways, where inhibition of JAK/STAT3 signaling is compensated by
activation of MAPK pathway irrespective of JAK2V617F mutation, while
PI3K/AKT signaling demonstrates JAK2V617F dependence in MPN.
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CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPAR-
TICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE
DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO
RUXOLITINIB?
M. Barone 1, F. Ricci2, D. Forte1, D. Sollazzo1, M. Romano1, M. Spinsanti1,
E. Ottaviani1, M. Cavo1, N. Vianelli1, P. Tazzari2, F. Palandri1, L. Catani1,*
1Department of Experimental, Diagnostic and Specialty Medicine, Institute of
Hematology “L. e A. Seragnoli”, University of Bologna, 2Immunohematology
and Blood Bank Service, Azienda Ospedaliero-Universitaria S. Orsola-Malpighi,
Bologna, Italy
Background: Microparticles (MPs) are small vesicles (0.1-1 micron) deriving
from plasma membrane budding during homeostasis and cell activation. MPs
express antigens and contain constituents from cell of origin and are increased
in conditions that are characterized by high cell turnover or death, particularly
inflammatory, autoimmune and neoplastic diseases. Myelofibrosis (MF) is a
clonal neoplasia of the hematopoietic stem/progenitor cells characterized by
distinctive abnormalities in megakaryocyte (MKC) development and platelet
(PLT) activation. Mutations in 3 genes (JAK2, CALR, MPL) and chronic inflam-
mation are the main pathogenetic drivers of MF. Ruxolitinib (RUX), a JAK1/2
inhibitor, suppresses both clonal myeloproliferation and release of proinflamma-
tory cytokines, reducing splenomegaly and constitutional symptoms in around
50% of patients (pts). We hypothesized that MPs, as mediators of inflammation,
could be overexpressed in MF and possibly predict responses to RUX.
Aims: This study aims to: 1) enumerate circulating MK and PLT-derived MPs
of MF pts; 2) evaluate the effect of RUX on MPs production by PLT and MK; 3)
investigate whether circulating MK and PLT- MPs may be a biomarker of
response to RUX.
Methods: EDTA-anticoagulated peripheral blood from healthy donors (HD, n=10)
and JAK2V617F positive MF pts (n=12) at intermediate-2/high IPSS risk was col-
lected at baseline and 3 and 6 months after RUX therapy and immediately cen-
trifuged. PLT (CD61+CD62P+) and MK (CD61+CD62P-)-derived MPs were
analysed in PLT poor plasma samples by flow cytometry (CytoFLEX, Flow Cytome-
ter-Beckman Coulter). The instrument was calibrated with MEGAMIX Beads
(Beckman Coulter) with various diameters to cover the MPs (0.5 and 0.9μm).
Results: At 3 and 6 months, 5 out of 12 pts achieved a spleen response (R)
according to 2013-IWG-MRT criteria. At baseline, the mean percentage of MK-
derived MPs was significantly decreased (29±6 vs 72±5; p<0.0001) while that
of PLT-derived MPs significantly increased (49±7 vs 11±1; p<0.0001) in MF pts
compared to HD. However, the mean percentage of MK-derived MPs from pts
not achieving a spleen response (NR) was significantly decreased compared
to R (17±6 vs 45±5; p<0.005) and HD (17±6 vs 72±5; p<0.0001). By contrast,
the mean percentage of PLT-derived MPs was significantly increased in NR
compared to R (64±7 vs 37±9; p<0.05) and HD (64±7 vs 11±1; p<0.001). Of
note, NR pts had significantly lower PLT number as compared with R pts
(220±29 vs 422±98 p<0.05). No correlation was observed at baseline between
the percentages of MK/PLT-derived MPs and platelet number, allele burden,
splenomegaly and constitutional symptoms. At 3 and 6 months, RUX did not
significantly modify the mean percentages of MK- and PLT-derived MPs com-
pared to baseline values.
Summary/Conclusions: At variance with HD, the majority of circulating MPs
in JAK2V627F mutated MF pts at intermediate-2/high IPSS risk derived from
PLTs. RUX therapy did not modify the MK/PLT-derived MPs pattern, suggesting
that JAK1/2 inhibition does not seem to affect the pathways of MK/PLT MPs
production or clearance. Most importantly, MPs evaluation at baseline is signif-
icantly associated with subsequent spleen response. Specifically, NR pts had
increased percentages of PLT-derived MPs with a concomitant reduction of
PLT number. This could be related to a state of PLT hyper-activation with hyper-
production of MPs. Further studies are needed to confirm whether MPs may
actually be considered a biomarker of disease activity and response to RUX.
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A COMPARATIVE FUNCTIONAL AND PHENOTYPIC PLATELET ANALYSIS
AMONG GENETIC GROUPS OF ESSENTIAL THROMBOCYTHEMIA
PATIENTS
P. Papadopoulos1,2,*, C. Al Assaf2, S. Smits2, I.M. De Cuyper3, E. Lierman2,
T. Devos4, A. Alvarez5, B. Bellosillo6, C. Besses 5, J.C. Hernández-Boluda7,
L. Gutierrez8, P. Vandenberghe4
1Hematology, IdISCC (HCSC), Madrid, Spain, 2Human Genetics, KU Leuven,
Leuven, Belgium, 3Blood Cell Research, Sanquin Research and Landsteiner
Laboratory, Amsterdam, Netherlands, 4Hematology, UZ Leuven, Leuven, Bel-
gium, 5Hematology, 6Pathology, Hospital del Mar, Barcelona, 7Hematology,
Hospital Clínico Universitario-INCLIVA, Valencia, 8Hematology, IdISCC, Madrid,
Spain
Background: Essential thrombocythemia (ET) is a myeloproliferative neoplasm
(MPN) characterized by a sustained elevation of platelet counts. Patients are
at risk of hemorrhagic or thrombotic complications, and, eventually, of progres-
sion to acute myelogenous leukemia or marrow fibrosis. ET patients are clas-
sified on genetic subgroups based on known driver mutations (i.e. JAK2V617F,
MPL W515K/L, CALR Type I/II). So-called triple-negative patients (TN) do not
bear any of the aforementioned mutations but many other mutations that have
not been hitherto shown to be causative of the disease. Cytoreductive or anti-
platelet treatment is currently being used in the clinic. However, a comprehen-
sive study of platelet properties is lacking in these patients, with updated genetic
classification.
Aims: We aim to characterize platelets of the ET genetic groups and establish a
phenotypic and functional profile that will help us to understand the pathophysi-
ology of the disease and potentially add to a better patient diagnosis/prognosis.
Methods: More than 40 ET patients (from Belgian and Spanish cohorts) and
healthy donors (HD) were recruited. Since treatment with acetylsalicylic acid is
common, a number of HD that had taken the drug 3 consecutive days prior
blood sampling were recruited. Platelets were subjected to a functional assay
(Platelet aggregation) and flow cytometry analysis of surface marker expres-
sion. A novel flow cytometry based platelet aggregation assay (de Cuyper et
al, Blood 2013) has been used to measure kinetics and quantitate the respons-
es to different platelet receptors (CLEC2, GPIIB/IIIA vWF R, and collagen recep-
tors GPVI and GPIA/IIA) upon specific agonist stimulation.
Results: Among the TN cases we identified four MPL S204F/P cases that were
analyzed separately given that part of their hematological parameters (MPV,
RBC counts) were not similar to the rest of the ET cases. Additionally, flow
cytometry analysis also showed that MPL S204F/P platelets are larger and
they have lower expression of surface markers (CD61, CD42b, CD49b, CD31)
as compared to the other ET groups and HD. On the other hand, JAK2 V617F
and CALR type I ET platelets exhibited normal to increased expression density
of these receptors as compared to HD. Variable patterns were observed
amongst the other ET genetic subgroups, with reduced responses especially
upon challenge with Aggretin A or collagen, while platelets from the JAK2 ET
genetic subgroup displayed hyper-reactivity to certain agonists (i.e. Aggretin A
and Ristocetin). MPL S204F/P platelets displayed, in general,decreased aggre-
gation responses.
Summary/Conclusions: These preliminary results suggest that MPL S204F/P
platelets are intrinsically defective (hypo-reactive), in contrast to JAK2 V617F
platelets (hyper-reactive), while in other genetic subgroups, potential defects
are most probably synergistic and/or acquired by treatment. Data suggests that
JAK2 V617F and CALR type I platelets could also undergo basal degranulation
or vesiculation in the circulation. Analysis of the platelets has identified charac-
teristics in different genetic groups of ET that should be further investigated
taking into account the different treatment conditions and using larger cohorts
of patients. When specific functional and phenotypic platelet patterns are estab-
lished they could contribute significantly to a better diagnosis/prognosis of the
disease.
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ASSOCIATION ANALYSIS OF CYTOGENETIC AND GENETIC ALTERATIONS
IN PRIMARY MYELOFIBROSIS
R. Norvilas1,2,*, V. Dirse1,3, E. Gineikiene1, O. Mickeviciute1, S. Pakstyte1,
M. Stoskus1, L. Griskevicius1,3
1Hematology, Oncology and Transfusion Medicine Center, Vilnius University
Hospital Santariskiu Klinikos, 2Department of Innovative Medical Technologies
and Health Resort Science, State Research Institute Centre for Innovative Med-
icine, 3Department of Internal, Family Medicine and Oncology, Faculty of Med-
icine, Vilnius University, Vilnius, Lithuania
Background: A number of genomic abnormalities have been associated to
primary myelofibrosis (PMF). Next-generation sequencing (NGS) and single-
nucleotide polymmorphism array (SNP-A) methods are widely used for PMF
genomic studies and certain cytogenetic and genomic associations have been
determined. To better characterise the genomic landscape of PMF we per-
formed comprehensive analysis of gene mutations and chromosomal aberra-
tions in a population-based cohort of PMF patients.
Aims: To characterize genomic alterations in PMF using SNP-A and NGS meth-
ods.
Methods: PMF peripheral blood samples were screened by Infinium HD whole-
genome genotyping assay with the HumanCytoSNP-12 BeadChips (Illumina
Inc., CA). NGS analysis was performed using TruSight Myeloid 54 gene
sequencing panel (Illumina). SNP-A and NGS data analyses were performed
using Illumina BaseSpace Informatics suite (Illumina). JAK2, CALR, MPL muta-
tions were additionally confirmed with Sanger sequencing while small indels −
with DNA fragment analysis.
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Results: 110 patients diagnosed with PMF according to WHO criteria between
years 2013 and 2014 were included into this study. SNP-A analysis identified
77 chromosomal abnormalities in 61 patients (55,4%). These comprised the
loss of heterozigosity (LOH) (59.7%), hemizygous deletions (23.4%) and copy
number gains (16.9%). The most common aberrations in affected patients
were: 9p LOH (55.7%), 20q deletion (11.5%), 1q duplication (4.9%), 19p dele-
tion (4.9%), 13q deletion (3.2%), 1p LOH (3.2%) and 6q LOH (3.2%). NGS
analysis detected 219 gene mutations (in a total of 27 genes) in 108 patients
(98%). The most frequently mutated genes were: JAK2 (62.9%), CALR
(27.8%), ASXL1 (20.3%), TET2 (16.6%), MPL (7.4%), <5% ZRSR2, EZH2,
DNMT3A, U2AF1, ETV6, SF3B1, IDH1, IDH2. Recurrent specific mutations
were detected in 10 genes. Sixty-two patients (57.4%) had more than one
somatic mutation. Six patients (5.5%) had no JAK2, CALR or MPL mutations
and were defined as “triple-negative”. Previously not described ZRSR2 gene
12 bp insertion was indentified in four patients (3.7%). The correlation analysis
showed significant associations between 9p LOH and JAKV617Fmutation
(p<0.001); 20q deletion and ASXL1 mutations (p=0.011); 19p deletion and
CALR mutations (p=0.004). Notably, the affected genes are located in core-
sponding affected chromosome regions, indicating disruption of both alleles
by different biological mechanisms. KRAS and ETV6 mutations were statisticaly
associated with ASXL1 mutations (p<0.001 and p=0.005, respectively) while
JAK2 and CALR mutations were mutualy exclusive in all cases (p<0.001).
Summary/Conclusions: A number of associations between gene mutations
and chromosomal aberations was revealed in PMF. Co-presence of 9p LOH
with JAK2V617F and CALR mutations with 19p deletion indicate that further
deregulation of these key signaling pathways may take place disrupting the
second allele of the affected genes by different biological mechanism – LOH
or deletion. 
E1312
FREQUENCY OF CONCURRENT BCR-ABL1, JAK2, CALR AND MPL
MUTATIONS IN A COHORT OF 5,545 CASES WITH SUSPECTED MPN BY
A DEEP SEQUENCING APPROACH
S. Jeromin1,*, M. Meggendorfer1, A. Fasan1, C. Haferlach1, W. Kern1, T. Haferlach1
1MLL Munich Leukemia Laboratory, Munich, Germany
Background: Chronic myeloid leukemia (CML) is a myeloproliferative neo-
plasm (MPN) characterized by BCR-ABL1, whereas in about 90% of BCR-
ABL1-negative MPN a mutation in CALR, JAK2 or MPL can be detected. These
genetic alterations are thought to be nearly mutually exclusive, however, an
accurate frequency is still missing.
Aims: To determine the incidence of genetic markers occurring in parallel in a
large cohort of patients with suspected MPN and characterize double mutated
cases.
Methods: From July 2016 till January 2017 5545 samples were sent to our
laboratory with suspected MPN. The male:female ratio was 1:1, and the median
age was 60 years (range: 18-98 years). Median white blood cell count was
9x109/L, hemoglobin level (Hb) was 15g/dl, and platelet count was 328x109/L.
All of these cases were analyzed by an amplicon deep sequencing approach
for mutations in JAK2 (exon12, exon14), CALR (exon9) and MPL (exon10)
with a sensitivity of 1%. 3070 patients were additionally screened for BCR-
ABL1 fusion by a multiplex PCR approach. Samples that were double mutated
for JAK2, CALR and MPL were analyzed by amplicon deep sequencing for
additional mutations in 13 myeloid genes.
Results: In total 1775/5545 (32%) of suspected MPN patients showed JAK2,
CALR and/or MPL mutations. 1438 (26%) were JAK2, 267 (5%) CALR, and 89
(1%) MPL mutated. Of note, the analysis of a subgroup (n=3070) for BCR-
ABL1 fusion identified 123 (4%) as CML cases. The JAK2 mutated cases pre-
sented mainly with Val617Phe (99%) and rarely with JAK2 exon12 mutations
(1%). CALR mutations were primarily type 1 (54%) and type 2 (30%). MPL
mutations were located at amino acid Trp515 in 96% of cases. Double mutated
cases were present in 19/1775 (1%) cases: JAK2/MPL (63%), JAK2/CALR
(32%), CALR/MPL (5%). In nearly all CALR mutated cases (6/7) the CALR
mutation was detected with the higher load, whereas in JAK2/MPL double
mutated cases the ratio was equal. Most of the patients (18/19) had one muta-
tion with a load below 10% and could have been missed by other approaches.
BCR-ABL1 together with JAK2 or CALR mutation was found in one patient,
each (2/123, 2%). Interestingly, out of the 267 CALR mutated cases, 3 patients
had already received treatment for CML but were suspected to have independ-
ent BCR-ABL1-negative MPN. For two of these patients, samples 1 and 6
years prior to diagnosis of CML were available. Both showed CALR mutations
already at this former time-point at high loads. In 10/19 (53%) double mutated
patients 13 additional mutations were detected in 8 different genes. SRSF2
and TET2 were the most frequently mutated ones (n=3, each). No significant
difference in mutation frequency was detected to the overall frequency in MPN
patients with single mutations. The JAK2, CALR and/or MPL mutated vs wild-
type cases showed higher age (mean: 67 vs 56 years, p<0.001) and higher
platelet counts (646 vs 317x109/L, p<0.001). Overall, the mean age was sig-
nificantly different according to the presence of mutations as follows: triple-
negative (56 years), CALR (63 years), JAK2 (67 years), MPL (71 years) and
double mutated (74 years).
Summary/Conclusions: One-third of the cases can be diagnosed having
MPN according to the detection of BCR-ABL1, JAK2, CALR and/or MPL muta-
tion in an unselected cohort with suspected MPN. The frequency of double
mutated JAK2, CALR and MPL cases is 1%. In CML cases BCR-ABL1 fusion
and JAK2 or CALR mutation were detected in 2% of the patients. The impact
of these parallel genetic events on the clinical course of the disease has to be
evaluated in the future.
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A COMPREHENSIVE ASSESSMENT OF MOLECULAR AND CYTOGENETIC
MARKERS OF PROGNOSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
L. Polushkina1,*, I. Martynkevich1, V. Shuvaev1, E. Motyko1, M. Fominykh1,
I. Krivolapov2, Z. Asaulenko2, L. Martynenko1, M. Ivanova1, N. Cybacova1,
D. Shikhbabaeva1, A. Zhernyakova1, S. Voloshin1, S. Bessmelcev1, A. Chechetkin1
1Russian Research Institute of Hematology and Transfusiology, 2North-Western
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Federation
Background: According to resent reports the data of molecular and cytogenetic
analysis (type or absence of driver mutation (DM), mutations in ASXL1, EZH2,
IDH1/2 genes, karyotype) is a promising tool for prediction of survival in primary
myelofibrosis (PMF). Multiple combinations of genomic aberrations lead to clin-
ical course and survival heterogeneity. The aforementioned factors need to be
considered together to evaluate their mutual influence.
Aims: The aim of the study was to evaluate a prognostic impact of DM, muta-
tional status of epigenetic regulation (ER) genes, karyotype and their combi-
nations for overall survival (OS) in PMF patients.
Methods: We have examined 110 patients (pts) with PMF (34.5% males).
Median (Me) age was 59 years (16-82). For all pts the detection of JAK2V617F
was done. JAK2(-) samples were tested for MPL 515 codon mutations and
exon 9 mutations of CALR (direct sequencing). All pts except 4 underwent the
analysis of mutations in ASXL1, EZH2, IDH1/2 genes with high resolution melt-
ing method followed by sequencing of probably mutated samples. Karyotype
research was done for 48 (43.6%) pts.
Figure 1.
Results: DM were detected in 81,8% pts: JAK2(+) - 50%, CALR(+) - 25.5%,
MPL(+) - 6.4% cases. No DM were found in 18.2% pts considered triple-neg-
ative (TN). Mutations in ER genes were detected in 20.8% pts. High risk (HR)
chromosomal aberrations (CA) (unfavorable CA according to DIPSS along with
del(6)(q15), add(6)(p25), del(X)(q22), t(X;7)(p21;q11)) were found in 27.1%
pts. Univariate analysis identified HR karyotype (hazard ratio (HR) 8.2,
p<0.001), the absence of DM (HR 8.1, p<0.001) and nonsense and frameshift
(hereinafter mut) (HR 2.9, p=0.018) but not missense mutations of ASXL1
(p=0.378) as being prognostically detrimental for survival. CALR mutations had
a favorable impact on survival with borderline significance (HR 0.3, p=0.052).
A multivariate analysis included TN, CALR, ASXL1 status and HR karyotype
as covariates revealed an inter-independent prognostic value of HR karyotype
(HR=7.4, р=0.001) and ASXL1mut (HR=2.8, р=0.023). In Cox regression model
considering the same covariates except karyotype TN status (HR=2.4, р=0.050)
and ASXL1mut (HR=3.3, р=0.012) but not CALR mutations (HR=0.3, р=0.075)
were significant for OS. CALR mutations became significant (HR=0.3, р=0.075)
when only ASXL1mut were included as covariate (HR=3.9, р=0.004). When
comparing groups divided by CALR/ASXL1 status the shortest OS was noted
in CALR(-)ASXL1mut pts (Me 2.5 years, p=0.021). CALR(+)ASXL1 wide type
(wt) pts seem to have better OS than CALR(-)ASXL1wt (median not reached
(with follow up period of 10.1 years) and 13.5 years, respectively, p=0.124).
Median OS estimated in pts due to presence/absence of DM and ASXL1 status
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was 0.9 years in TNASXL1mut, 3.6 years in TNASXL1wt, 13.8 years in
DM(+)ASXL1wt and was not reached in DM(+)ASXL1mut (with follow up period
of 10.3 years) group (р<0,0001). Differences in OS depending on the ASXL1
status were statistically significant in the TN (p=0.007) but not for DM(+) group
(p=0.788). The better OS was observed in ASXL1wt pts with low risk (LR) kary-
otype (Me 6.4 years, р=0.0005). There were no differences in OS of ASXL1wt-
HR, ASXL1mut-LR and ASXL1mut-HR pts (1.4 vs 1.6 vs 1.2 years, p=0.493).
Summary/Conclusions: The differences in OS were more statistically relevant
in groups divided by TN/ASXL1 and karyotype/ASXL1 status. The presence of
ASXL1mut significantly worsens OS in the TN group. OS in pts with any of the
findings: HR karyotype or ASXL1mut – was significantly shorter than in cyto-
genetically favorable ASXL1wt counterparts.
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JAK2 HAPLOTYPE 46/1 (GGCC) HAS NO EFFECT ON THE PRIMARY RISK
OF JAK2 V617F MUTATION, BUT IT STRONGLY POTENTIATES THE
PROGRESSION OF GROWN ALLELE BURDEN IN MYELOPROLIFERATIVE
NEOPLASMS
M. Stolyar1,2,*, O. Klimova3,4, M. Ivanov3,4, A. Gorbenko1, S. Titov3,4, I. Olkhovskiy1,5
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Background: Several research groups have determined that the JAK2 46/1
(GGCC) haplotype in multiple ethnic groups is strongly associated with a pre-
disposition to acquiring JAK2 V617F-positive MPNs. The role of the JAK2 46/1
haplotype in the natural evolution of the mutant JAK2V617F allele burden in
PV but not ET or PMF has been shown [Alvarez-Larrán A e.a. Leukemia
Research 2012, 36(3):324-326]. However, the data on the impact of the hap-
lotype on the JAK2 V617F allele burden do not always agree. Using a highly
sensitive test allowed to reveal a high prevalence JAK2 V617F among persons
without symptoms of hematological disorders [Krichevsky S e.a. Blood Cells,
Molecules and Diseases,, doi: 10.1016/ j.bcmd.2017.01.001]. Influence of hap-
lotype 46/1 for such cases is not known. There are two competing hypotheses
of “hypermutability” and “fertile ground” explaining the causes of the higher fre-
quency of mutations of JAK2V617F in haplotype 46/1 carriers. The “hyper-
mutability” hypothesis refers to an increased risk of a primary mutation in car-
riers of haplotype 46/1. In this case, the increasing frequency of the haplotype
in patients with low allelic burden (<5%) must also be observed, including those
individuals without evidence of hematological disorders.
Aims: Studying the relations of haplotype 46/1 and JAK2 V617F allelic burden
Methods: The diagnosis of chronic myeloproliferative neoplasms was based
on the WHO (2008) criteria. The cohort included patients with JAK2 V617F
mutation: 100 patients with PV, 51 with ET, 14 with MF, 41 patients with unclas-
sifiable MPN and 47 patients with asymptomatic V617F+ carriers. Among all
patients, 17 patients were treated with hydroxyurea and 20 were treated with
interferon. The control group included 100 healthy donors without JAK2 V617F
mutation. SNP genotyping of two 46/1 tag SNPs, rs12340895 and rs10974944
(the G-allele, and G-allele tags the JAK2 46/1 haplotypes) was performed by a
polymerase chain reaction (PCR). The JAK2V617F allele burden was evaluated
by a quantitative real-time allele-specific PCR test using “in-house” kit (0.01%
sensitivity). Associations between JAK2 V617F mutation and haplotypes of
JAK2 were assessed using the Chi-squared test. The odds ratio (OR) and 95%
confidence interval (CI) were also calculated for each comparison of JAK2 46/1
haplotype frequency and ranges of allele burden.
Figure 1.
Results: The JAK2 46/1 haplotype (GG and CG) was present in 170 patients
(80.6%) with MPN, in 25 (52%) patients with suspected MPN, in 23 (49%)
asymptomatic JAK2 V617F+ patients and in 42 (42%) cases of control group.
G variant of rs10974944 was more frequent in all JAK2 V617F-positive MPNs,
than in the control population (χ2=46.5, p<0.0001). These results were similar
to findings of previous studies, which have shown that the 46/1 haplotype pre-
disposes to the acquisition of JAK2 V617F mutation. JAK2V617F allele burden
was significantly higher in patients with PV than in patients with ET (p=0.001),
but no differences were observed with from patients with the PMF. 46/1 haplo-
type was closely associated with MPN patients if the allele burden exceeds 5%
(Fig. 1) regardless of the phenotype or the treatment. In this case with an
increase in JAK2V617F allele burden the JAK2 46/1 haplotype frequency sig-
nificantly increased. However, there was no significant difference in the JAK2
46/1 haplotype frequencies between patients with allele burden less than 5%
and the control group.
Summary/Conclusions: No significant differences of the carrier haplotype
46/1 prevalence between control group and patients with minimal allelic burden
(less than 5%) JAK2 2V617F have been observed. This is evidence against
primary “hypermutability” hypothesis. A further increase in allelic load is more
pronounced in carriers of haplotype 46/1 that supports the “fertile ground”
hypothesis. We hypothesize that DNA mutation JAK2V617F repair is down-
graded in 46/1 haplotype carriers.
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MINIMAL RESIDUAL DISEASE MONITORING BY DIGITAL PCR FOR
JAK2V617F DETECTION IN PATIENTS WITH MYELOFIBROSIS (MF) OR
ACUTE MYELOID LEUKEMIA SECONDARY TO MF AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION
S. Salmoiraghi1,*, C. Belotti, M.C. Finazzi, M.C. MIcò1, A. Algarotti1, G. Finazzi1,
M. Mascheroni 1, A. Salvi1, A. rambaldi12, O. Spinelli1
1Hematology and Bone Marrow Transplant, ASST Papa Giovanni XXIII, Berg-
amo, 2Oncology and Hematoncology, University of Milan, Milan, Italy
Background: Myelofibrosis (MF) is one of the BCR-ABL1-negative Chronic
Myeloproliferative Neoplasms (MPNs), characterized by clonal expansion of
abnormal hematopoietic progenitors and gradual replacement of normal bone
marrow with fibrous tissue. MF patients’ prognosis is widely variable and the
median survival can vary from months to many years. At present, Allogeneic
Stem Cell Transplantation (ASCT) is the only curative treatment option for these
patients. The most frequent phenotype-driving mutation in MF is the V617F
mutation in the JAK2 gene. A high sensitive quantification of JAK2V617F muta-
tion load can be useful to assess Minimal Residual Disease (MRD) in treatment
directed to eradicate the malignant clone, such as ASCT. Droplet Digital PCR
(ddPCR) is a quantitative approach for the detection of rare allele characterized
by a high level of sensitivity and specificity. 
Aims: To evaluate the efficacy of ddPCR JAK2V617F mutation detection assay
in monitoring the MRD level at consecutive time-points in a small cohort patients
who underwent an ASCT for MF or MF-derived Acute Myeloid Leukemia (s-
AML). 
Methods: DNA from 9 patients affected by primary, secondary MF or s-AML
were serially collected during the follow-up after ASCT (50-2500 days). These
samples were investigated for hematologic chimerism by PowerPlex System
(Promega, USA) and were also analyzed for JAK2V617F mutation both by con-
ventional allele specific PCR (ASO-PCR) and by a validated ddPCR mutation
detection assay (Bio-rad, USA). Results were expressed as percentage of
JAK2V617F mutated alleles on total evaluated alleles.
Results: The JAK2V617F ddPCR mutation assay was able to detect low muta-
tion load (up to 0.006%), confirming to be much more sensitive than ASO-PCR
(0.5-2%). In 4 patients, early after transplantation, we observed by ddPCR a
low level of MRD that progressively increased during the follow-up and antici-
pated a decrease in donor chimerism level and a worsening of clinical situation.
In 2 patients, who always showed a full donor chimerism and complete hema-
tologic remission of the disease, very low levels of MRD (ranging from 1% to
0.006%) could be detected by ddPCR in the 2 years after ASCT. With a longer
follow-up, a full molecular remission was achieved as demonstrated by ddPCR.
In 2 other patients, we observed a very early achievement of full donor
chimerism and JAK2V617F molecular negativity (within 90 days post HSCT),
also when evaluated by ddPCR. These patients entered a complete hemato-
logic remission of the disease which still persists (after 1 and 5 years after
transplantation, respectively). Interestingly, in one patient whose post-transplant
hematopoiesis proved full donor and negative for JAK2V617F mutation for 2
years, a weak positive signal revealed by ddPCR (0.075%) became apparent
and anticipated an extra-hematologic relapse (skin and bone). A subsequent
second allogeneic transplant from the same sibling donor restored clinical and
molecular remission.
Summary/Conclusions: The ddPCR proved to be a sensitive and accurate
method in detecting JAK2V617F mutation. Therefore, this assay can be a valid
tool for the MRD monitoring in JAK2V617F MPN patients undergone an ASCT.
However, the use of this highly sensitive PCR should be considered with caution
in the clinical management of transplanted patients to avoid inappropriate use
of donor leukocyte infusion (DLI) and tampering of immunosuppression. A large
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number of patients have to be studied with ddPCR to better understand the
clinical significance of low mutation load.
E1316
S100A8/9 ACTIVATION OF MAPK PATHWAY IS SUPPORTED BY ITS
RECEPTORS RAGE AND TLR4 IN POLYCYTHEMIA VERA
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Background: S100 proteins have been shown to regulate cell proliferation,
excessively augmented in myeloproliferative neoplasms (MPN). S100A8/9 is
produced by cells of myeloid origin as mediator of inflammation, while AKT
and MAPK pathways mediate cell proliferation.
Aims: This study analyzed activation of AKT and MAPK pathways by S100A8/9
proteins in healthy controls and MPNs: polycythemia vera (PV), essential
thrombocythemia (ET), primary myelofibrosis (PMF), according to JAK2V617F
and calreticulin (CALR) mutation status.
Methods: S100A8/9 factor is examined in granulocytes of MPN using
immunoblotting, while its influence on cell cycle of granulocytes is determined
by flow cytometry. Mutations of JAK2V617F and CALR exon 9 are analyzed
by DNA sequencing. Besides JAK2V617F+ PV patients, we formed per three
groups of patients: JAK2V617F+, JAK2V617F-/CALR+, and JAK2V617F-
/CALR- for ET and PMF.
Results: S100A8/A9 proteins demonstrated a common significant increase in
plasma of MPN patients, whereas the presence of CALR mutation augmented
S100A8/A9 levels in granulocytes of ET and PMF patients. Activation of AKT
pathway is generally reduced by S100A8/9 factor, further on ameliorated by
inhibition of the receptor for advanced glycation end products (RAGE) in gran-
ulocytes of JAK2V617F+ and JAK2V617F-/CALR+ groups of ET and PMF
patients, while it has been prevented by Toll-like receptor 4 (TLR4) inhibition in
PV patients. MAPK pathway is significantly inhibited by S100A8/9 only in
JAK2V617F+ ET patients and JAK2V617F-/CALR- PMF patients, partially pre-
vented by TLR4 inhibition in PMF. Inhibition of TLR4 reduced S100A8/9 medi-
ated MAPK activation in JAK2V617F-/CALR+ ET. In contrast, S100A8/9 medi-
ated MAPK activation has been significantly augmented by TLR4 and RAGE
inhibition in PV patients. S100A8/9 stimulated granulocyte cycle arrest in G2M
phase has been stopped by JAK1/2 inhibition.
Summary/Conclusions: S100A8/A9 protein levels demonstrated stable ele-
vation in MPNs. Common inhibition of AKT pathway has been controlled by
TLR4, whereas MAPK pathway activation by TLR4 and RAGE in PV, during
treatment with S100A8/A9.
E1317
MUTATIONAL PROFILE STUDY OF DOUBLE-NEGATIVE ESSENTIAL
THROMBOCYTHEMIA BY HIGH-DEPTH NEXT GENERATION SEQUENCING
(NGS)
G. Carreno-Tarragona1,*, I. Rapado1, R. Ayala1, A. Arenas1, J. Martínez-López1
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Background: Essential thrombocythemia is one of the three classical philadel-
phia negative myeloproliferative neoplasms. It is frequently difficult to diagnose
and some molecular markers are used as diagnostic criteria according to WHO
classification. Despite this, a significant proportion of patients do not present a
clonality marker.
Aims: To identify the mutational profile of ET negative for V617F and CALR
mutations and to correlate it with clinical data.
Methods: A cohort of 22 ET negative for mutations in JAK2 (qPCR) and CALR
(GENESCAN) was selected. Median age at diagnosis was 46 years (range:
14-88), male:female ratio 9:13; 2 patients had a record of thrombotic event
prior to diagnosis, 4 patients had symptoms at the time of among diagnosis, 3
patients suffered a thrombotic event after diagnosis, 1 patient suffered trans-
formation to AML. Median Hb, WBC and platelets at diagnosis were respec-
tively 14.75g/dl 8,85 x109/L and 720x109/L. We performed targeted gene
sequencing by NGS (Ion Torrent Proton System–Life Technologies) using a
panel of 33 genes implicated in leukemia prognosis. X2 and t-student tests
were used to find association between mutations and clinical data.
Results: On average, 97.94% of the target sequence showed a mean depth
coverage around 2500. We discovered 17 non-synonymous mutations which
16 were somatic single nucleotide variants (SNVs) and 1 a nucleotide deletion
in coding regions. No mutations were detected in 9 samples (40.9%), 10 sam-
ples presented 1 mutation (45.5%), and the other 3 samples present 2 or more
mutations (13.6%). TET2 was the most frequently mutated gene (18.2% of
patients, mean allele frequency of 24,45%), followed by JAK2 (13.6% V617F
at a low mean allele frequency (5.8%), MPL (9.1%, one W515L, one with two
mutations W515R and S505C, mean allele frequency of 21,95%), SF3B1
(4.5%), DNMT3A (4.5%), KIT (4.5%), VHL (4.5%), CBL (4.5%) and KMT2A
(4.5%). The samples with more than one mutation: one presented a CBL and
two TET2 mutations, one two mutations in MPL and the other one mutation in
TET2 and other in JAK2. No correlation was found between mutational profile
and clinical data.
Summary/Conclusions: In ET, around 60% of patients present the
JAK2V617F mutation, 15-30% show CALR mutations and around 5% present
MPL mutations. In spite of this, there is still a significant percentage of ET
patients without a molecular marker. Our study shows that the use of a NGS
panel allows identifying markers of clonality as for example TET2. NGS also
makes affordable to interrogate whole genes classically associated to ET, to
detect mutations that were not found by traditional approaches. Finally, we can
conclude, as previously described, that ET is an entity with a low mutational
burden in comparison with other MPNs as primary myelofibrosis.
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TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO
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M. Petrini9, M. Mosca6, C. Baldini10
1Clinical and Experimental Medicine, University of Pisa, Hematology, 2Clinical
and Experimental Medicine, University of Pisa, Hematology, 3Hematology
Molecular Laboratory, AOUP, 4Department of Translational Research and New
Technology in Medicine, General Pathology, 5Cardio-Thoracic and Vascular
Department, 6Department of Clinical and Experimental Medicine, University of
Pisa, Rheumatology, 7Department of Informatics, University of Pisa, Pisa,
8GENOMEC doctorate school, Siena, 9Department of Clinical and Experimen-
tal Medicine, University of Pisa, Hematology, 10Department of clinical and
experimental medicine, rheumatology, Pisa, Italy
Background: Hypereosinophilia-associated syndromes are a heterogeneous
group of diseases characterized by sustained and elevated blood eosinophilia
with evidence of eosinophil-induced organ damage. Classically, Eosinophilic
Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome
(HES) present several overlapping clinical and laboratory features, making it
challenging to correctly insert patients in restricted and well-defined categories
with specific and more effective therapeutic approaches in daily practice. There-
fore, great efforts are ongoing searching for novel biomarkers able to differen-
tiate these two disorders. 
Aims: To detect T cell receptor gamma (TCRG) clonal rearrangements in EGPA
and HES, comparing the frequency of distribution of the V and J region segments
in 21 patients afferent to the hematology, rheumatology or pulmonology divisions.
Methods: Consecutive patients with a diagnosis of EGPA and HES were
enrolled into the study. Inclusion criteria were: documentation of a persistent
peripheral eosinophilic count of ≥1.5 x109/L and signs or symptoms of organ
involvement. Clinical and laboratory data of the patients were collected.
Sequence-based determination of the frequency distribution of TCRG Gene
Rearrangements was performed using next-generation sequencing with the
Illumina MiSeq (LymphoTrack TRG assay, Invivoscribe).
Results: We included 21 patients (9 with EGPA and 12 with HES). Four EGPA
patients were MPO-ANCA positive. We detected TCRG clonal rearrangements
in 44% patients with EGPA and in 42% patients with HES. No association was
observed between TCRG clonal rearrangements and ANCA status in EGPA
patients. The following recurrent TCRG gene rearrangements were observed:
Vg10JgP1 (5 cases) and Vg4Jg1/2 (4 cases) were observed in both EGPA
and HES, whereas Vg9Jg1/2 (2 cases) and Vg10Jg1/2 (2 cases) were
observed only in patients with HES. The presence of TCRG rearrangement
was not different according to the symptoms (asthma, vasculitis, skin, heart,
gut, lung involvement, splenomegaly). IL2, IL5, IL4, eosinophil cationic protein
(ECP), absolute eosinophils were measured: IL5 and ECP were higher in the
polyclonal than in the clonal cases (9±2.5 vs 1.7±0.9; p=0.021 and 121.8±61.5
vs 39.5±1.5; p=0.07). On the contrary, no difference was observed in the
absolute eosinophil count. Finally, the presence/absence of TCRG clonality
did not significantly impact on the response to treatment (immunosuppressive
or interferon) and on the progression-free survival length.
Summary/Conclusions: Conclusions: Even if preliminary, this study reveals
a similar T cell receptor gamma repertoire in EGPA and HES, with recurrent
rearrangements, thus suggesting a possible antigen-driven inflammatory
response underlying hypereosinophilia in both EGPA and HES. Interestingly,
this study confirms our previous results showing the TCR delta rearrangement
(assessed by qualitative PCR) in 40% of the EGPA patients. 
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Background: We already demonstrated augmented proinflammatory IL-6 and
angiogenic vascular endothelial growth factor (VEGF), hypoxia inducible fac-
tor-1α (HIF-1α) and endothelial nitric oxide synthase (eNOS) levels in myelo-
proliferative neoplasms (MPN).
Aims: To observe IL-6 activated signaling pathways during stimulation of angio-
genic factors and their JAK-STAT dependence in MPN.
Methods: We analyzed phosphorylation of JAK/STAT3, PI3K/AKT and MAPK
signaling by immunoblotting in HEL 92.1.7 cells (with JAK2V617F mutation)
and granulocytes of MPN. The granulocyte cycle phases have been studied by
flow cytometry.
Results: We demonstrated IL-6 stimulated angiogenic factors in HEL cells and
HEL-derived macrophages, blocked by JAK-STAT inhibition for eNOS and HIF-
1α. IL-6 stimulated JAK-STAT3 and angiogenesis related PI3-AKT signaling
pathways in HEL cells, the later one prevented by JAK1/2 inhibition. Opposite
to primary myelofibrosis (PMF), IL-6 activation of JAK-STAT3 and PI3-AKT
pathways has been prevented and enhanced by JAK1/2 inhibition, respectively
in granulocytes of polycythemia vera (PV). Moreover, IL-6 inhibition of JAK-
STAT3 and PI3-AKT pathways in essential thrombocythemia (ET) has been
prevented by JAK2 inhibitor in JAK2V617F positive ET granulocytes. JAK1/2
inhibitor Ruxolitinib upregulated IL-6 activation of MAPK pathway in MPN, in
contrast to specific JAK2 inhibitor Hexabromocyclohexane. IL-6 mediated
reduction in the percentage of HEL cells in G2M phase was inversed by Rux-
olitinib that potentiated apoptosis and reduced the cell percentage in G0G1
phase both in HEL cells and granulocytes of PMF. It has been detected the cell
cycle arrest of MPN granulocytes in S phase (DNA replication) after treatment
with IL6, completely diminished by JAK1/2 inhibition.
Summary/Conclusions: Therefore, we concomitantly revealed that inflamma-
tion stimulated angiogenic factors and signaling pathways involved in cell pro-
liferation, apoptosis and angiogenesis are regulated by JAK-STAT inhibition.
Myeloproliferative neoplasms - Clinical
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Background: The global MPN LANDMARK survey evaluated the patient (pt)
and physician-reported impact of myeloproliferative neoplasms (MPNs), includ-
ing myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia
(ET), among pts from 6 countries. We present an analysis comparing physician
and pt perceptions of the impact of these MPNs.
Aims: To investigate differences between pt and physician perceptions of symp-
tom burden, treatment goals, and disease management 
Methods: This was a cross-sectional survey of pts with MPNs and physicians
treating pts with MPNs. Respondents completed an online survey measuring
their perception of the impact of MPNs on symptom burden, disease manage-
ment, and treatment goals. Pts and physicians were recruited independently.
Figure 1.
Results: Pts (n=699) from Australia (n=10), Canada (n=64), Germany (n=149),
Italy (n=106), Japan (n=84), and the UK (n=286) completed the survey (MF,
n=223; PV, n=174; ET, n=302). Most pts had been diagnosed within ≤2 years
of experiencing symptoms (73%); 56% were women. Physicians (n=219) were
from the same countries; most were hematologists (54%) or hemato-oncologists
(27%). Overall, 54% of pts reported having a prognostic score; however, 71%
of physicians reported using a prognostic risk classification. Physicians
assessed symptoms by proactively asking pts how they were feeling (43%) or
asking about specific symptoms (37%); 11% waited for pts to mention symp-
toms. Importantly, only 26% of physicians used a validated symptom assess-
ment form; 44% used their own rating method. Pts and physicians both agreed
that pts with MPNs have a high symptom burden and that MF had a higher
degree of burden on daily living. Interestingly, a higher proportion of physicians
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than pts felt that MPN symptoms have an impact on pt quality of life (92% vs
76%) and that pts had a substantial emotional burden associated with their
disease. For instance, 34%, 29%, and 26% of pts with MF, PV, or ET reported
feeling anxious or worried compared with 70%, 46%, and 36% of physicians
reporting that their pts experience substantial anxiety or worry. Some pts did
not recognize that their symptoms could be MPN related; for example, ≈ one-
fifth of pts did not think that their night sweats could result from their MPN (16%
MF, 21% PV, 25% ET). Consistent with this, 60% of physicians indicated that
pts could identify only few or some of their symptoms as MPN related. Pts and
physicians were both concerned about reducing symptoms (pts: 70% MF; 61%
PV; 53% ET; physicians: 80% MF, 55% PV, 60% ET); however, pts were also
concerned about delaying MPN progression (58% MF, 57% PV, 66% ET; physi-
cians: 43% MF, 28% PV, 37% ET; Figure 1). Compared with pts, physicians
indicated a greater focus on prevention of vascular/thrombotic events in PV
(66% vs 48%) and ET (80% vs 60%). Overall, only 27% of physicians felt they
completely agreed with their pts on treatment goals; 66% felt they “somewhat”
agreed. However, most pts (87%) were satisfied with their physician’s disease
management/communication.
Summary/Conclusions: This study revealed a potential disconnect between
physician and pt perceptions relating to communication and disease manage-
ment, and an apparent lack of standardization in symptom assessment. Of
note, some pts did not recognize that their symptoms could be MPN related
and had different treatment goals than their physicians, indicating a need for
improved pt education and pt-physician communication and a treatment plan
that includes standardized monitoring of symptoms and agreement on treat-
ment goals.
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SURVIVAL IN THE MYELOFIBROSIS: KEY INSIGHTS FROM THE
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Background: Quality of life (QOL) is a critical aspect of cancer treatment and
survival. A strong association exists between QOL and overall survival (OS) for
numerous malignancies including breast, gastro-esophageal, colorectal, lung,
prostate, ovarian, and head and neck cancer (Sloan 2012, Montazeri 2009, Nils-
son 2017). Healthcare organizations have used symptom burden as a primary
therapeutic endpoint when assessing the benefit of JAK inhibitors in myelofibrosis
(MF) in clinical trials, although QOL was also considered. To date, little is known
about the association of these items in regards to overall survival in MF.
Aims: To evaluate the prognostic relevance of QOL and symptom burden
among patients with MF from the COMFORT-I study.
Figure 1.
Methods: Data from the COMFORT-I trial of ruxolitinib (Verstovsek 2012) ver-
sus placebo was obtained from Incyte© for independent analysis. Association
of total symptom burden (TSS; divided by the sample quartiles) and QOL (divid-
ed by the sample median) at baseline with OS among MF patients was esti-
mated using the Kaplan-Meier method and tested using log rank tests and Cox
regression. Symptom burden and QOL were assessed using the 5-symptom
MF-SAFv2.0 (Mesa 2009) and EORTC QLQ-C30 Global Health/QOL scale
(Aaronson 1993), respectively. The PROMIS instrument was used to assess
fatigue (Cella 2007).
Results: A total of 309 patients were available for analysis including 155 rux-
olitinib-treated and 154 placebo-treated MF patients. Baseline demographics,
disease-related variables, and calculated overall survival were similar to pre-
vious published results (Verstovsek 2015). Symptom Burden: When comparing
OS by TSS quartiles at baseline, no significant associations in OS were
observed (Figure 1A). Individual symptoms of bone or muscle pain, feeling full,
pain under ribs on left side, abdominal discomfort, itchiness, or night sweats
also did not demonstrate significant associations when comparing OS by quar-
tile symptom score. Baseline fatigue score demonstrated no difference in OS
when stratified by median or quartiles. Global Health Status/QOL: Intention to
treat analysis demonstrated significant survival advantage for patients with
higher QOL at baseline (HR 1.47, p=0.02, Figure 1B). When censoring placebo
patients at crossover, this hazard ratio improved to a HR 1.79 (p=0.008). Cox
Proportional Hazards Modeling: Cox regression for survival analysis reached
significance for items of age (p<0.001), sex (p<0.009), and QOL (p=0.009)
when taking into consideration TSS, IPSS prognostic risk score, age, sex,
COMFORT treatment arm, and QOL. When censoring for placebo patients at
crossover, this analysis demonstrated that the same items remained significant
(age [p=0.001], sex [p<0.001], and QOL [p=0.002]).
Summary/Conclusions: For the patients prospectively evaluated in the COM-
FORT-I trial, pre-treatment QOL is strongly prognostic for overall survival and
remains highly prognostic even when adjusting for symptom burden, disease
risk, age, sex, and treatment. Prior literature has confirmed the importance of
QOL in prognosticating survival in other cancer types. However, this is the first
study that has identified the key correlation among individuals with MF. Neither
individual nor combined symptom scores at baseline appeared prognostic for
overall survival, emphasizing the importance of QOL assessment in addition
to symptom assessment. Weight loss (a prognostic factor for DIPSS scoring)
was not included in this symptom burden assessment and may represent an
independent factor associated with increased survival.
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MYELOFIBROSIS: A POPULATION BASED STUDY
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Background: Myelofibrosis (MF) is a myeloproliferative neoplasm with pro-
found negative effects on health related quality of life and survival. It is char-
acterized by clonal myeloproliferation, ineffective erythropoiesis, bone marrow
stromal changes, hepatosplenic extramedullary hematopoiesis, and aberrant
cytokine expression. Although progress has been made in the understanding
of the pathogenesis and management of MF, there are still unresolved issues
regarding prognosis and causes of death.
Aims: This population-based study characterizes disease and outcomes in
patients (pts) with MF by using the U.S. Surveillance, Epidemiology, and End
Results (SEER) database.
Figure 1.
Methods: We identified a total of 3,367 pts with primary myeloid fibrosis (PMF,
ICD-O-3 morphology code as 9961/3 and primary site code as C420, C421 or
C424) diagnosed between January 2000 to December 2013. Pts with missing
survival status (n=753), pts lost to follow up (n=4), and pts with missing age
record (n=1) were excluded. Kaplan-Meier analysis was performed to deter-
mine overall survival (OS) and cancer specific mortality. The effects of specific
covariates on OS were analyzed using a Cox proportional hazards model.
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Results: The final study cohort comprised of 2,619 PMF pts. Median follow up
period was 28 months (interquartile range (IQR),11-56). Median age at diag-
nosis was 68 years (interquartile range 59-77 years) with 60.6% (n =1,586) ≥
65 years old. More than half of the pts were male (58.5%; n=1,531); 82.2%
(n=2,153) were white, and 16.4% (n=430) were diagnosed between 2012 and
2013. The geographic distribution was as follows: East 14.8%, South 18.4%,
West 54.2% and Midwest 12.6%. Median OS was 42 months (Figure 1). The
hazard ratio of all-cause mortality for age was 1.05 (95% Confidence interval
(CI) 1.04-1.05), for female vs male was 0.72 (CI 0.64-0.80), for nonwhite vs
white 1.01 (CI 0.87-1.16), for unmarried vs married was 1.04 (CI 0.94-1.16),
for patients diagnosed 2012-2013 vs 2000-2011 was 0.95 (CI 0.75-1.20). Com-
pared to West, the hazard ratio of OS for East, South and Midwest was 1.05
(CI 0.90-1.22), 1.28(CI 1.12-1.47), 1.03(CI 0.88-1.19) respectively.
Summary/Conclusions: This population based study showed that the overall
survival of pts with PMF was short. Older and male pts were associated with
higher mortality risk. There were significant differences across geographic
regions of the United States. Although there is a trend of improvement in the
period of 2012 to 2013, the result is not statistically significant, partially due to
short follow up. These findings underscore the continuing need for effective
therapies for pts with MF.
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Background: Albumin is the main protein in human plasma. Serum albumin
(SA) is used as a surrogate marker of nutritional status and inflammation. The
prognostic role of SA has been studied in many diseases, including hematologic
malignancies. In myelofibrosis (MF), ruxolitinib has been shown to improve SA
levels in addition to other metabolic parameters. SA holds particular significance
in MF given its ability to capture both nutritional status and inflammation level
in a disease hallmarked by hyperactive inflammatory pathways and constitu-
tional symptoms.
Aims: We aim to closely evaluate the significance of SA in MF patients as it
pertains to clinical presentation, laboratory correlations, disease genomics,
comorbidities and outcomes.
Methods: We retrospectively reviewed an institutional database of 376 MF
patients who presented to Moffitt Cancer Center between 1/1/1998 and
12/31/2012 and had available SA levels within 30 days of presentation. Labo-
ratory values and prognostic scores were determined at time of first presenta-
tion. Overall survival (OS) was measured from time of first presentation until
date of death or censored at time of last follow-up. Progression free survival
(PFS) was defined as time from first presentation to development of acute
myeloid leukemia (AML).
Figure 1.
Results: Our cohort of MF patients had median age of 67 and 69 at diagnosis
and presentation, respectively. Most patients had primary MF (73%) with 11%
and 16% having post-PV MF and post-ET MF, respectively. First, we looked at
the correlation between SA and other clinical factors. SA was positively corre-
lated with hemoglobin (p<0.01) and platelet count (p<0.01), and negatively cor-
related with age (p<0.01), peripheral blast percentage (p=0.03), ferritin (p<0.01),
prognostic scoring models (p<0.01 for IPSS, DIPPS and DIPSS+) and pack-
year smoking history (p<0.01). SA did not correlate with spleen size or any
specific somatic mutation, but negatively correlated with somatic mutation bur-
den (p=0.03). On univariate regression, SA was associated with inferior PFS
(HR: 0.31 [0.13-0.72]; p<0.01) and OS (HR: 0.25 [0.17-0.36]; p<0.01). Four
cohorts were created based on SA: cohort I=SA 2.5-3.5 g/dL (n=31); cohort
II=SA 3.6-4.0 g/dL (n=99); cohort III=SA 4.1-4.5 g/dL (n=182); and cohort
IV=SA>4.5 g/dL (n=64). OS increased with increasing SA; with median OS (in
months) of 9.34, 25.3, 48.4, and undefined in cohorts I-IV, respectively. On
focused comparison, each cohort was significantly different than all others. On
multivariate analysis, the influence of SA on OS remained significant after con-
trolling for prognostic scores (IPSS, DIPSS, DIPSS+) and comorbidities. For
PFS, SA remained significant when controlling for IPSS and DIPSS, but lost
significance (p=0.08) when controlling for DIPSS+. Multivariate analysis was
performed on a cohort of patients with available molecular data (n=138). SA
significantly influenced OS after controlling for prognostic systems, comorbidi-
ties and mutations of SRSF2 and ASXL1. Lastly, given its independent prog-
nostic value, we incorporated SA into pre-existing prognostic models. For IPSS,
DIPSS, and DIPSS+, patients were assigned 0, 1, 2, and 3 points for low (LR),
intermediate-1 (int-1), intermediate-2 (int-2), and high risk (HR), respectively.
Patients were then assigned -1, 0 and 1 point for SA >4.3, 3.8-4.3, and <3.8
g/dl, respectively. Risk groups were defined as LR (-1-0 points), int-1 (1 point),
int-2 (2 points), and HR (3-4 points). Survival curves and histograms displayed
better capture of LR and HR prognostic groups with median OS similar to stan-
dard prognostic modeling (see figure).
Summary/Conclusions: SA level is independently prognostic in MF and cor-
relates with variables known to hold prognostic value. Its representation of
nutritional status, inflammation, and comorbidities imbues it with special status
in predicting outcome. Its incorporation into known prognostic scoring systems
provides an improved ability to accurately capture low and high-risk subgroups.
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Background: Although Next Generation Sequencing (NGS) has helped char-
acterize the complex genomic landscape of myeloid malignancies, its clinical
utility remains not well defined. Funding for NGS testing by healthcare systems
or third party payers is variable due to the lack of data on its utility in a routine
care setting. At our centre, targeted sequencing (TAR-seq) is offered to all new
patients referred for myeloid malignancies as part of the Advanced Genomics
in Leukemia (AGILE) project. 
Aims: In this study, we evaluate the impact of TAR-seq on the management of
patients with a diagnosis of MPN or post-MPN acute myeloid leukemia
(MPN/AML). 
Methods: All consenting patients referred to the MPN program at the Princess
Margaret Cancer Centre between February 2015 and December 2016 with a
suspected or confirmed diagnosis of MPN were evaluated (n=188). TAR-seq
was performed on DNA extracted from peripheral blood (n=159, 85%) or bone
marrow (n=29, 15%) using the TruSight Myeloid Sequencing Panel (Illumina),
a targeted NGS panel of 54 genes (39 hotspot region; 15 complete coding
region coverage) implicated in myeloid malignancies. Reporting was restricted
to high quality exonic nonsynonymous, intronic splice site, frameshift, nonsense
and known pathogenic synonymous variants. Variants with global mean allele
frequency >1% were identified using multiple population databases (1000
genomes, ESP, ExAC) and excluded. Each patient’s TAR-seq results were
reviewed alongside their clinical information systematically by at least two
hematologists with expertise in MPN, and disagreements were resolved by
consensus. 
Results: 179 patients fulfilled the 2008 WHO diagnostic criteria for MPN: 107
were diagnosed with myelofibrosis (MF), 26 with polycythemia vera (PV), 21
with essential thrombocythemia (ET), 13 with other MPNs including MPN-
unclassifiable and 12 with MPN/AML. In 6 patients with ‘triple negative’ MPN,
who lacked mutations in the driver genes JAK2, CALR and MPL, TAR-Seq con-
firmed clonal hematopoiesis through identifying other mutations. In 61 trans-
plant-eligible patients with MF, 32 (52%) were considered to carry a high molec-
ular risk (HMR) profile based on harboring at least one mutation in ASXL1,
EZH2, IDH1/2, SRSF2 or TP53; or a total of three or more mutations. Of these,
11 patients (34%) were considered for early transplant, three with Intermedi-
ate-1 and eight with Intermediate-2 risk, who were responding well to JAK 1/2
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inhibitor (JAKi) therapy. All high-risk, transplant-eligible MF patients were con-
sidered for transplant irrespective of their HMR status. Nine patients with
low/intermediate-1 risk MF bearing HMR mutations were considered for a clin-
ical trial of early JAKi therapy, and one patient was successfully enrolled. Seven
patients were identified with IDH1/2 mutations (five with MF and two with
MPN/AML), and therefore can be potential candidates for enrolment into clinical
trials evaluating novel IDH 1/2 inhibitors. In PV and ET, TAR-seq identified
HMR profiles in 6/26 (23%) and 5/21 (24%) patients, respectively. These
patients are monitored closely, but no therapeutic decisions were taken based
on their HMR profile. In MPN/AML, TP53 mutations were detected in 4/12
(33%) patients. However, these patients progressed rapidly before their TAR-
seq results became available to inform clinical management. 
Summary/Conclusions: We have determined that TAR-seq improves the
characterization of triple negative MPN patients, refines risk stratification and
decisions related to the timing of transplant in MF, and can potentially identify
candidates for future targeted therapies. Therefore, we suggest that NGS
should be part of the standard of care in MF, and in the investigation of triple
negative MPN. Based on these findings and in conjunction with ongoing studies
in the MPN program, an algorithm integrating NGS in the management of MF
has been developed, and will be evaluated prospectively. 
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Background: Charlson Comorbidity Index (CCI) and body mass index (BMI)
are significantly associated with outcome in patients (pts) who receive continue
treatment with tyrosine kinase inhibitors. Ruxolitinib (RUX) is the first JAK1/2
inhibitor that may induce spleen/symptom responses and improve quality of
life in pts with myelofibrosis (MF). No data are yet available on the impact of
comorbidities and BMI on pts treated with RUX.
Aims: To evaluate the impact of CCI and BMI on overall survival (OS) in a
cohort of RUX-treated MF pts.
Methods: A multicenter observational study on WHO-defined MF treated with
RUX according to standard clinical practice was conducted in 20 Italian Hema-
tology Centers. Response to RUX was evaluated according to 2013 IWG-MRT
criteria. OS was calculated from the date of RUX start to the time of death or
last follow-up. Baseline parameters evaluated for correlation with OS were:
blood cell count, spleen ≥10cm, marrow fibrosis grading, time from MF diag-
nosis to RUX start, transfusion dependency, mutation status, Total Symptom
Score (TSS), CCI, and BMI.
Results: Between June 2011 and Apr 2016, 343 pts with PMF (51.9%), or
post-ET (20.1%) / post-PV (28.0%) were treated with RUX in participating Cen-
ters. At RUX start, median age was 67.6 years (range 36.5-89.0) with a male
prevalence (57.1%); International Prognostic Score System (IPSS) was inter-
mediate (intm)-1 (16.0%), intm-2 (47.5%), high (36.4%). Transfusion depend-
ence and spleen enlargement were present in 23.9% and 97.4% of pts, respec-
tively (62.4% with spleen ≥10 cm). TSS was <20 in 131 pts (38.2%); 62 (18.1%)
pts had a BMI<21 (corresponding to lower quartile). CCI was zero in 105 pts
(30.6%), one in 74 pts (21.6%), two in 58 pts (16.9%) and ≥ 3 in 106 pts
(30.9%). Median follow-up from MF diagnosis was 3.6 yr (range 0.4-25.6) and
median RUX exposure was 21.2 months (3-56.2). In multivariable Cox regres-
sion analysis, factors negatively correlating with OS from RUX start were: trans-
fusion dependence (HR: 2.65; p<0.001), CCI ≥3 (HR: 1.67; p=0.031), BMI<21
(HR: 1.74; p=0.039), and IPSS (intm-2= HR: 3.19; p=0.057; high risk= HR:
6.83; p=0.001). Scoring values were assigned to each factor based on multi-
variable HR values (transfusion dependency=1.5; CCI≥3=1; BMI<21=1; intm-
2=2 and high risk=4) and three different groups were identified: group1 (0-2
points, 137 pts), group2 (3-5 points, 144 pts) and group3 (5.5-7.5, 62 pts). OS
at 3 years was 91.8%, 65.6% and 34.8% in group1, 2 and 3, respectively (log
rank p<0.001) for a median OS of undefined, 56.7 and 22.8 months. Notably,
while 88.7% of high IPSS risk pts clustered in group3, only 60.5% of pts in
group1 were at intm-2 IPSS risk, and 48.6% of pts in group2 were at high IPSS
risk. The achievement of a spleen response at 6 months (39.2% vs 36.4%,
p=0.71) was not influenced by lower BMI. However, pts achieving a spleen
response at 6 months significantly increased OS (Fig. 1A). Also, a higher CCI
did not correlate with lower spleen response at 6 months (44% vs 34% of pts
with CCI<3, p=0.11). The impact of higher CCI on survival was only mildly
affected by the achievement of a spleen response at 6 months (Fig. 1B).
Figure 1.
Summary/Conclusions: Together with transfusion requirement, CCI and BMI
may influence survival in RUX-treated MF pts. Taking into account these addi-
tional parameters may allow to better define survival probability beyond IPSS
risk assessment. Unfavorable CCI and BMI did not hamper responses to RUX;
also, the achievement of a spleen response counterbalanced the negative
prognostic effects of a lower BMI.
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Background: Primary myelofibrosis (PMF) as well as secondary post essential
thrombocythemia (pET)-MF and post polycythemia vera (pPV)-MF are consid-
ered rare diseases associated with significant morbidity. Diagnostics and ther-
apeutic options have significantly improved during the last decade by develop-
ment of novel drugs, improvement of allogeneic stem cell transplantation (SCT)
procedures and supportive care. Whereas the characteristics of PMF, pET-MF
and pPV-MF patients (pts) participating in clinical trials are well analyzed, data
are rare for the general MF population including patients not included in or eli-
gible for clinical trials.
Aims: In order to gain a broader, more comprehensive data set on the general
MF population we performed a questionnaire poll in 35 German hematology
centers gathering characteristics on 845 pts who were currently under care.
Methods: A questionnaire asking for general patient and disease specific data
as symptoms, splenomegaly, prognostic factors, past/ current treatment and
blood count, degree of MF in bone marrow and transfusion frequency was
designed. It was distributed to participating centers (n=35, mostly private
offices) throughout Germany and analyzed centrally. Time period of collection
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was 03/2013-12/2015. 845 pts were included i.e. a median of 20 pts (range 6–
90 pts) per center
Results: Gender was equally distributed (50%/50%). Pts ages at initial diagnosis
were as follows:<50 years (y) (11%), 50–60y (19%), 61-70y (31%), and >70y
(40%). Current age was >65y in 70% of all pts. PMF represented the largest MF
cohort (77%), followed by pET-MF (10%), pPV-MF (7%) and unspecified (6%).
Most pts had a longer disease duration (>5y (36%); 1-5y (48%); <1y (15%);
unknown (1%)). Key current blood values at time of survey included abnormal
thrombocyte counts (<50GPT/l (6%); 50 to <100GPT/l (10%); ≥450GPT/l (28%)
and elevated WBC >25.000/μl (11%). Presence of circulating blasts in the periph-
eral blood was documented in 11% of pts. Hemoglobin [g/dl] was ≥10 (68%), 8–
10.0 (21%), <8 (8%), unknown for 3% of the pts. Constitutional symptoms were
present in 20% of the pts. Common symptoms included splenomegaly (60%),
decreased fitness (41%) and weight loss (16%). Pruritus was present in 5% and
night sweats in 9% of all pts. An individual Dynamic International Prognostic
Scoring System (DIPPS) score was calculable in 495 pts: 19% low risk, 52%
intermediate-1, 23% intermediate-2 and 5% high risk disease. Concomitant dis-
eases were common, most often cardiac (56%). Most common medical treat-
ments included cytostatic (37%), anticoagulation (25%), JAK-inhibitors (23%)
and none (24%). Non-medical treatments were rare: stem cell transplantation
(3%), splenectomy (2%) and spleen irradiation (3%). Only 31% of all pts received
red blood cell transfusions, however 7% had received >50 units.
Summary/Conclusions: Daily practice MF pts share several characteristics
with MF trial cohorts (e.g. COMFORT). As expected the diseases were not as
progressed as in the trials. Interestingly gender was equally distributed in our
study. SCT was a rarely used treatment within this cohort whereas JAK2
inhibitors were frequently used
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Background: “Driver mutations” in Essential Thrombocitemia (ET) involve
JAK2V617F, CALR and MPL genes. The mutation profile affect the hematolog-
ical parameters and the risk of thrombosis being the JAK2V617F mutation the
one associated with the higher risk of thrombosis. Among CALR mutations
there are two main types: type -1 like and type-2 like, but it is not clear if the
mutation type is associated with a different clinical feature
Aims: The objective of this study is to understand the clinical meaning of CALR
mutation type in ET
Methods: We analyzed 309 ET patients from two hospitals: H.C.U. Santiago
and H.U. of Gran Canaria Dr. Negrin. Dates of diagnosis were between 1-11-
90 and 1-10-2016, and the median follow up was of 6.88 years. Patients were
treated according to local protocols. We collected clinical data of patients at
diagnosis and during follow-up as well as events such as thrombosis, transfor-
mation to myelofibrosis (MF) or acute leukemia (AL). Thrombosis associated
with diagnosis refers to those events happening from two years before diagno-
sis until diagnosis. The statistical analyses were performed with R Core Team
(2016) and IBM SPSS 21.0 
Results: JAK2V617F mutation was present in 60.5% of the patients, 1.9% had
MPL mutations, 14.5% were CALR type-1like, 11% were CALR type-2like and
11% were triple negative. In three cases, we were not able to classify CALR
mutation as type-1/2 like. With regard to the clinical events: 21 patients (6.8%)
had thrombosis associated with diagnosis, and 34 (11%) at least 1 thrombosis
since the diagnosis. Twelve patients suffered more than 1 thrombotic event.
MF evolution was found in 18 patients (5,6%) and 2 cases transformed to AL.
In the analysis of hematological parameters according to the mutation type,
when we compared JAK2V617F VS CALR type-1like we observed that
JAK2V617F group showed higher hemoglobin values (mean 13.8g/dL vs 13.26
g/dL; p=0.014) and lower platelet counts (mean 730x109/L vs 884x109/L,
p=0.001) than CALR type-1like group. Confronting JAK2V617F VS CALR type-
2like: the JAK2V617F group showed a higher leucocyte counts (mean
9.39x109vs 8.44x109/L, p=0.039) and higher hemoglobin values (mean
13.8g/dL vs 12.8g/dL, p<0.001)), but lower platelet counts (730x109/L vs
1081x109/L, p<0.001) as compared with the CALR type-2like group. When we
studied CALR type-1like VS CALR type-2like: the CALR type-2like group
showed higher platelet count (1081x109/L vs 884x109/L, p<0.035) than CALR
type-1like group. With regard to the thrombotic events, frequency of first
thrombosis (arterial or venous) was 20.9% (n=39) in the JAK2V617F group,
15.5% (n=7) in the CALR type-1like, and 3% (n=1) in the CALR type-2like
group. Frequency of thrombosis was significantly higher in JAK2V617F than in
CALR group (p= 0.036) and also in JAK2V617F vs. CALR type-2like (p=0.013).
When comparing CALR type-1like vs CALR type-2like the differences were
marginally significant (p=0.06). In a multivariate analysis with the IPSET vari-
ables and CALR subtype, in our series the previous history of thrombosis (p
<0.001) and the JAK2V617F status (p=0.026) were significantly associated
with increased risk of thrombosis, but no the advanced age neither the presence
of cardiovascular risk factors. However, presence of CALR type-2like mutation,
with respect to the JAK2V617F mutation, was a protective factor of thrombosis
(p= 0.06). The five year-thrombosis free survival (TFS) study was as follows:
83%, 85% and 97% for groups JAK2V617F, CALR type-1like and CALR type-
2like (log rank p=0.03)(fig. 1).
Figure 1.
Summary/Conclusions: The type of driver mutation is associated with a dif-
ferent risk of thrombosis. Among the two types of CALR mutantion, patients
have similar clinical characteristics except for the risk of thrombosis which
seems lower in CALR type-2like compared to type-1like. This finding shows
the importance of studying the CALR mutation type in ET.
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Background: Although the reduction of thrombotic risk is a primary goal of ther-
apy in Philadelphia negative myeloproliferative neoplasms (Ph-MPN), even low
risk patients (pts) may experience thrombotic events during the course of the
disease. Some recent studies revealed a correlation between the occurrence of
thrombosis and activation of blood and endothelial cells. However, not many
information is available about influence of therapy on these parameters.
Aims: We prospectively analyzed the levels of leukocyte-platelet (Le-Plt) aggre-
gates, together with levels of soluble selectins, in a group of pts with Ph-MPN
at diagnosis and during therapy. 
Methods: Our study included 90 consecutive de novo Ph-MPN pts (37 poly-
cythemia vera, 27 essential thrombocythemia, 26 primary myelofibrosis), diag-
nosed according to WHO criteria. According to therapy, pts were assigned as:
hydroxyurea (HU 7.8%), aspirin (ASP 55.6%), hydroxyurea+aspirin (HU+ASP
31.1%), although 5.6% of pts were without therapy. Neutrophil-platelet (Neu-
Plt) and monocyte-platelet (Mo-Plt) aggregates were determined in whole blood
samples (EDTA/CTAD) by flow cytometry. Aggregates were estimated as frac-
tion (%) of CD42b+CD61+ neutrophils and monocytes. Plasma levels of E-, L-,
and P-selectins were determined by enzyme immunoassay. All analyses were
performed on diagnosis, and repeated 6-9 months after the start of therapy (for
pts on HU after achievement of partial or complete remission).
Results: In all pts, mean levels of Neu-Plt and Mo-Plt aggregates at diagnosis
were significantly elevated in comparison to control values (22.9% vs 8.9% and
13.0% vs 5.2% respectively, p<0.01). Mean concentration of soluble E-, L- and
P-selectins were also significantly higher in Ph-MPN than in control group (34.2
ng/mL vs 19.0 ng/mL; 2748.7 ng/mL vs 1322.0 ng/mL and 294.0 ng/mL vs 69.8
ng/mL, respectively, p<0.01). Mean levels of Neu-Plt and Mo-Plt aggregates in
response to therapy were significantly reduced compared to baseline levels
(Figure). Significant reductions were observed for E-selectin levels in HU+ASP
group, for L-selectin levels in all three therapy groups and for P-selectin levels
in HU and HU+ASP groups (Table). During the median follow up of 39 months
from diagnosis of Ph-MPN, thromboembolic events occurred in 13.3% of pts
(12/90), particularly: 0/7 on HU, 3/50 on ASP, and 9/28 on HU+ASP. In this
subgroup we observed increased baseline levels of Neu-Plt and/or Mo-Plt
aggregates in 9/12 pts, while all 12 pts had increased at least one soluble
selectin, predominantly P-selectin. Retesting revealed that all 9 pts with throm-
bosis and increased aggregates level at baseline, normalized those levels after
therapy, while only 4/12 pts normalized soluble selectin levels.
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Table 1.
Figure 1.
Summary/Conclusions: We have found elevation of blood and endothelial
cell activation markers at baseline in Ph-MPN. Cytoreductive and antiaggrega-
tory therapy reduced the mean level of Le-Plt aggregates and concentration of
soluble selectins. In subset of pts with thrombosis, therapy lead to normalization
of Le-Plt aggregate levels, with incompletely normalized soluble selectin levels.
Even with normal Le-Plt agregates, observed elevated selectin levels can
explain persistent thrombotic risk due to intrinsic changes in relationship
between blood and endothelial cells as a part of biology of Ph-MPN itself. 
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Background: Increased heat shock protein 27 (HSP27/HSPB1) expression
and phosphorylation were observed in a large number of neoplastic diseases
and they have mostly been associated with aggressive disease features and
poor prognosis. There are only few reports investigating HSP27 in primary
myelofibrosis (PMF), a myeloproliferative neoplasm characterized by high
inflammatory state reflecting in debilitating clinical symptoms.
Aims: To analyze HSPB1 mRNA expression in patients with PMF and sec-
ondary myelofibrosis (SMF) and to correlate it with clinical and hematological
features.
Methods: We analyzed HSPB1 relative expression in bone marrow aspirates
of 26 patients with PMF, four patients with SMF and 13 controls using quanti-
tative real time polymerase chain reaction (RT-PCR). Spleen size was
assessed by palpation. Association with overall survival was analyzed in 27
PMF and SMF patients evaluated at the time of diagnosis. The Kuskal-Wallis
one way analysis of variance, The Mann Whitney U test, the Chi squared test,
the Spearman rank correlation, the log-rank test and the Cox regression analy-
sis were used, cut-off point for survival analyses was determined using the
ROC curve analysis.
Results: Relative expression of HSPB1 differed significantly between diag-
noses (P<0.001); it was significantly higher in patients with PMF and SMF than
in control group (P<0.05 for both comparisons), but did not differ between PMF
and SMF patients (non significant). Increased expression was associated with
increase in the spleen size (P=0.009) and JAK2 V617F mutation (P=0.073).
We did not detect significant associations with other disease specific features.
Lower HSPB1 expression was associated with inferior overall survival in both
univariate (HR 3.2; P=0.04) and multivariate analysis (HR 6.12; P=0.034) where
effect was independent of age (non significant), gender (non significant) and
the International Prognostic Scoring System (IPSS) score (HR 3.31; P=0.033).
Figure 1.
Summary/Conclusions: Both PMF and SMF patients have increased HSPB1
mRNA expression in their bone marrows which is associated with increased
spleen size. Surprisingly, higher expression is also associated with improved
overall survival which is independent of IPSS score. We speculate this to be
due to atheroprotective properties of HSP27.
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NON-DRIVER MUTATIONS IDENTIFIED BY A 190-GENE NEXT GENERA-
TION SEQUENCING PANEL IN PATIENTS WITH PRIMARY MYELOFIBRO-
SIS AND POST-POLYCYTHAEMIC/ESSENTIAL THROMOCYTHAEMIA
MYELOFIBROSIS
B. Li1,*, Z. Xu1, T. Qin1, Y. Zhang1, J. Liu1, Z. Xiao1
1MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital
Chinese Academy of Medical Sciences, Tianjin, China
Background: It is a consensus that the driver mutation is an independent
prognostic factor in PMFs. Moreover, some non-driver mutations are found
associated with initiation, progression and prognosis in PMFs. However, a
recent study from the AGIMM (AIRC- Gruppo Italiano Malattie Mieloprolifera-
tive) group showed that the type of driver mutation did not influence prognosis
in post-PV/ET MF. These observations proved that there were indeed some
differences in these two types of MF. 
Aims: The aim of current study was to describe the non-driver mutation land-
scape and the molecular differences between the patients with PMF and those
with post-PV/ET MF.
Methods: Targeted gene sequencing was carried out at diagnosis. We
sequenced 190 genes across 62 patients, resulting in 229 high-confidence
mutation. The average gene coverage was 99%. The average read depth was
540×. Also, 92% of targeted regions were covered with >20×. Every mutation
identified in this study was then compared against these expected patterns
and categorized into “oncogenic,” “possible oncogenic variants,” or “unknown
significance”. Using copy number-adjusted VAF, we reconstructed the clonal
architecture to establish whether a mutant gene was an ancestral or subclonal
mutation. According to the statistically differences in VAF among gene muta-
tions, subjects were classified as two different clonal architecture, namely
clone+subclone(s) (P<0.05) or clonal. 
Results: In PMFs, 42 (93.3%) patients had at least one non-driver mutation.
Within the 17 patients lacking the driver mutations in JAK2V617F/exon 12,
MPLW515 and CALR, 2 had mutant genes (SH2B3 and PIAS3) involving in
JAK-STAT pathway, 13 had mutations in other genes and 2 had no mutations.
In Post-MFs, non-driver mutations were detected in 16 (94.1%) patients. There
are no differences in the median number of non-driver mutations in PMFs vs.
post-PV/ET MFs (3 vs. 3.18, P=0.885) and PMF patients with vs. without driver
mutations (3 vs. 3.18, P=0.668).  In PMFs, 12 non-driver genes were mutated
in >5% of patients, namely ASXL1 33.3%, U2AF1 22.2%, TET2 15.6%, FAT1
15.6%, SETBP1 13.3%, SRSF2 8.9%, CUX1 8.9%, EP300 8.9%, FAT2 6.7%,
NOTCH3 6.7%, EZH2 6.7%, and GATA3 6.7%. In post-PV/ET MFs, ASXL1
(41.2%) was the most frequent mutation, followed by TET2 (29.4%). U2AF1
and SRSF2 mutations were significantly more frequent in PMF than in post-
PV/ET MF. Moreover, SETBP1 and FAT1 were mutated in PMF more often
and not mutated in post-PV/ET MF. Figure1 A-C show 3 illustrative patients.
Clonal architecture was significantly different between PMFs and post-PV/ET
MFs (Figure 1D). About 50% PMF patients were classified as clonal, however,
most (87.5%) post-PV/ET MF patients were clone+subclone(s). In PMFs, driver
mutation was an ancestral mutation with other non-driver mutations in 14
(31.1%) subjects as 2015-R02413 in Figure 1A. Moreover, driver mutation
even was a subclonal mutation in 9 (16.7%) subjects as 2015-R02406 in Figure
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1B. In post-PV/ET MFs, 11 (64.7%) subjects showed that JAK2 mutation as an
only ancestral mutation as G121517R00701 in Figure 1C.
Figure 1.
Summary/Conclusions: In conclusion, we found that the differences in non-
driver mutation profile and clonal architecture between PMF and post-PV/ET
MF. In addition, by applying a 190-gene panel we demonstrated some variants
classified as of “unknown significance”. And larger sample sizes may enable
some of these to be reclassified in the future. The precise role of each mutation
and their impact on MPN phenotype will require further studies.
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DETERMINING MEANINGFUL CHANGE IN THE MYELOFIBROSIS SYMPTOM
ASSESSMENT FORM (MFSAF) V2.0 USING A COMBINATION OF
DISTRIBUTION- AND ANCHOR-BASED APPROACHES IN THE COMFORT-I
TRIAL
A. Dueck1,*, R. Scherber2,3, H. Kosiorek1, B. Langlais1, L. Padrnos3, J. Palmer3,
S. Verstovsek4, J. Sloan5, G. Holly3, R. Mesa3
1Mayo Clinic, Scottsdale, AZ, 2Oregon Health and Science University, Portland,
OR, 3Mayo Clinic, Phoenix, AZ, 4MD Anderson, Houson, TX, 5Mayo Clinic,
Rochester, MN, United States
Background: Symptom response was defined in the COMFORT-I trial as a
50% improvement from baseline at week 24 in the Myelofibrosis Symptom
Assessment Form (MFSAF) v2.0 total symptom score (TSS; Mesa [J Clin Onc,
2013]; 0 to 60 scale where 60 represents the worse symptom experience imag-
inable) with no minimum score requirement at baseline.
Aims: In this analysis of the phase III placebo-controlled COMFORT-I study
we used distribution- and anchor-based approaches to investigate whether
alternative change scores in the MFSAF v2.0 TSS could be meaningful relative
to patient-reported quality of life (QOL).
Figure 1.
Methods: One third and one half of the pooled standard deviations (SD) of
scores and change scores (raw and percentage change) were used as distri-
bution-based estimates. The anchor-based approach estimated meaningful
changes (raw and percentage change) relative to the patient’s change in global
health status/QOL (GH/QOL; 0=worst, 100=best) as measured by the EORTC
QLQ-C30 where a decrease of 12.1 or more points was considered as deteri-
oration; an increase of 7.6 or more points was considered as improvement;
and all other changes were considered as stable based on change scores
established in a multiple myeloma population (Kvam et al., Eur J Hem, 2011).
Analysis of covariance (ANCOVA) was used to investigate whether estimated
meaningful changes were consistent across the spectrum of observed baseline
TSS. This model of TSS changes at week 24 included a continuous term for
baseline TSS, a 3-level grouping factor for GH/QOL change (deterioration vs
stable vs improvement), and an interaction term between baseline TSS and
the GH/QOL grouping factor.
Results: 301 patients randomized to ruxolitinib [N=149] or placebo [N=152]
completed TSS at baseline (45% female, median age 68 [range 40-91]). Median
baseline TSS was 16.6 (range 0 to 52.7). Pooled SD at baseline and week 24
in TSS was 11.4 and 11.6, respectively, resulting in estimated meaningful
changes of 3.8-5.8 points. For change and percentage change from baseline
at week 24 in TSS, the pooled SDs were 9.8 and 75%, respectively, resulting
in estimated meaningful changes of 3.3-4.9 points or 25%>38%. Among
patients with TSS and QLQ-C30 data at baseline and week 24, 51 (23%)
patients had deterioration, 61 (27%) were stable, and 110 (50%) had improve-
ment based on QLQ-C30 GH/QOL changes. Mean (95% CI) changes in TSS
for the three groups were 0.8 (-2.5 to 4.2), -1.4 (-3.6 to 0.8), and -6.8 (-9.0 to -
4.6), and for percent changes 20% (-6% to 46%), 17% (-11% to 44%) and -
34% (-45% to -22%). ANCOVA revealed that baseline TSS statistically signifi-
cantly impacted meaningful change estimates (p=0.02, Figure 1) resulting in
estimated mean (95% CI) changes in TSS for the improved group of -20.8 (-
26.4 to -15.1), -11.7 (-14.3 to -9.0), and -2.6 (-5.1 to -0.1) for baseline TSS of
50, 30, and 10.
Summary/Conclusions: Distribution- and anchor-based approaches suggest
that changes as small as 3-6 points on a 0-60 scale of the MFSAF v2.0 TSS
may be meaningful to patients. However, estimates of meaningful change
appear to increase in magnitude for higher baseline scores, though in a way
that a static percentage change criterion would either require too much change
for lower baseline TSS or not enough change for higher baseline TSS. All analy-
ses suggest that some changes in symptoms which do not meet a 50%
improvement may still be meaningful to patients.
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ERYTHROPOIESIS STIMULATING AGENTS CAN IMPROVE ANEMIA IN
PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
E. Crisà1,*, C. Daniela2, E.M. Elli3, E. Beggiato1, C. Frairia4, M. Cerrano1,
G. Lanzarone1, M. Marchetti5, M. Mezzabotta6, M. Boccadoro1, D. Ferrero1
1Hematology Division, A.O.U. Città della Salute e della Scienza di Torino,Uni-
versity of Turin, 2Department of Clinical and Biological Sciences, University of
Turin, Torino, 3Hematology Division, Ospedale San Gerardo, ASST Monza,
Monza, 4Hematology, A.O. Ospedale Maggiore di Novara, Novara, 5SOC
Oncologia, Ospedale Cardinal Massaia, Asti, 6Hematology Division, Ordine
Mauriziano - Ospedale Umberto I, Torino, Italy
Background: Anemia is common in patients with myelofibrosis (MF) and it is
one of the main cause of symptoms in this setting. Erythropoiesis stimulating
agents (ESA) have been used in MF but mostly small series and no randomized
trials have been published so far. Anemia response rate ranged between 23
and 60% in different reports (Cervantes et al, BJH 2004;Cervantes et al, BJH
2006;Tsiara et al, Acta Haematologica 2007) and a larger study recently pub-
lished by Cervantes group on 163 patients (Hernandez-Boluda JC. E et al, EJH
2016) showed a response rate of 50%. Ruxolitinib is currently approved for the
treatment of intermediate 2 or high DIPSS/IPSS risk MF and it is highly effective
in reducing spleen size and controlling the symptoms of MF, thus resulting in a
marked improvement in the patients’ quality of life (Verstovsek S. et al, NEJM
2012; Harrison C. et al, NEJM 2012) and possibly a prolonged survival (Cer-
vantes F. et al Blood 2016). However, one of ruxolitinib main side effects is
anemia, which occurs in 40% of the patients and can be a limiting factor for
treatment tolerability and thus compliance and optimal dosage, mostly in the
first weeks of treatment.
Aims: To evaluate the efficacy and safety of combination therapy with ruxolitinib
and ESA.
Methods: We retrospectively evaluated 32 patients who received concomitant
therapy with ruxolitinib and ESA. ESA (epoetin alpha or zeta or darbepoetin)
were given off-label after obtaining patient written consent and local pharmacy
approval. Erythroid response was defined as transfusion independence with
normal haemoglobin (HB), transfusion decrease of >50% or sustained HB
increase of >2g/dl, partial response as a sustained HB increase of 1-2g/dl. 
Results: We included 32 patients diagnosed with MF, 23,1% primary,34,6%
secondary to PV and 42,3% to TE. 20 patients (62,5%) were male and median
age at ESA start was 70 years (range 41-80). 87% of patients were at interme-
diate 2 and 13% at high risk according to DIPSS. Fifty-nine% of patients
received epoetin alpha, 28% darbepoetin and 13% epoetin zeta. Median dose
for epoetin alpha/zeta was 40000 U/week and for darbepoetin 150 mcg/week.
Seven patients had started ESA treatment before ruxolitinib therapy, whereas
twenty-five patients received erythropoietin after ruxolitinib start for persisting
or worsening of anemia. In particular, 5 were already RBC transfusion depend-
ent before commencing ruxolitinib while 13 patients required red blood cell
(RBC) transfusions only after treatment start. Overall ruxolitinib treatment wors-
ened anemia leading to RBC transfusion requirement in 52% of patients. Medi-
an Hb at ESA start was 8 g/dL(range 6,2-10g/dL) and 62,5% of patients were
transfusion dependent. Median basal endogenous erythropoietin level was 58
UI/l (range 8-146 UI/l). Overall response rate was 87,6%, with 68,8% of erythroid
response and 18,8% of partial response. Median time to response and median
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response duration were 4 and 31 months respectively. 23% of patients lost
response after a median time of 16 months. Seventy-five% of patients respond-
ed to ruxolitinib in terms of spleen size, of whom 86,4% also achieved an ery-
throid response to ESA. A spleen increase during ESA treatment in patients
responding to ruxolitinib was observed in 2 patients only.
No thrombotic events and no toxicity were reported over treatment with ESA.
Summary/Conclusions: ESA were effective in improving anemia in MF
patients treated with ruxolitinib. We observed a high response rate in this
patients series without significant toxicities. In particular no thrombotic event e
no negative impact on response to ruxolitinib was reported. This results may
be partially explained by the selection of patients with endogenous erythropoi-
etin level below 250 UI/l, but they could also suggest synergistic activity of ESA
and ruxolitinib.
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COMPARING THE SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN
PATIENTS (PTS) WITH DIPSS LOW/INTERMEDIATE-1–, INTERMEDIATE-2–,
AND HIGH-RISK MYELOFIBROSIS (MF) IN JUMP, A PHASE 3B,
EXPANDED-ACCESS STUDY
F. Passamonti1,*, V. Gupta2, B. Martino3, L. Foltz4, A. Zaritksey5, H.K. Al-Ali6,
R. Tavares7, M. Maffioli8, P. Raanani9, P. Giraldo10, M. Griesshammer11,
C. Bouard12, J. Perez Ronco12, R. Tiwari13, A. M. Vannucchi14
1Universtiy of Insubria, Varese, Italy, 2Princess Margaret Cancer Centre, Toron-
to, Ontario, Canada, 3Azienda Ospedaliera Bianchi-Melacrino’-Morelli, Reggio
Calabria, Italy, 4St. Paul’s Hospital, University of British Columbia, Vancouver,
British Columbia, Canada, 5Federal Almazov Medical Research Center of the
Russian Ministry of Health, St. Petersburg, Russian Federation, 6University
Hospital of Halle, Halle (Saale), Germany, 7Universidade Federal de Goiania,
Goiania, Brazil, 8Ospedale di Circolo e Fondazione Macchi, Varese, Italy,
9Rabin Medical Center, Petah Tikva, Israel, 10Miguel Servet University Hospital
and Centro de Investigación Biomédica en Red de Enfermedades Raras
(CIBERER), Zaragoza, Spain, 11Johannes Wesling Clinic, Minden, Germany,
12Novartis Pharma AG, Basel, Switzerland, 13Novartis Healthcare Pvt. Ltd,
Hyderabad, India, 14CRIMM, Center for Research and Innovation of Myelo-
proliferative Neoplasms, AOU Careggi, Department of Experimental and Clin-
ical Medicine, University of Florence, Florence, Italy
Background: RUX is a potent JAK1/JAK2 inhibitor that led to improvements
in splenomegaly and symptoms and increased overall survival in pts with inter-
mediate (Int)-2– and high-risk MF by the International Prognostic Scoring Sys-
tem (IPSS) in the phase 3 COMFORT studies. JUMP is a large, phase 3b,
expanded-access trial in countries with no access to RUX outside a clinical
trial and includes pts with IPSS Int-1–, Int-2–, and high-risk MF. To further eval-
uate RUX, we conducted an analysis assessing safety and efficacy of RUX by
Dynamic IPSS (DIPSS) prognostic risk. 
Aims: To compare the safety and efficacy of RUX in pts with DIPSS low/Int-1–
vs Int-2– vs high-risk MF 
Methods: Eligible pts had IPSS high- or Int-2–risk MF, or Int-1–risk MF and a
palpable spleen (≥5 cm). Starting dose was based on baseline platelet (PLT)
count (5mg bid [≥50 to <100×109/L], 15mg bid [100-200×109/L], or 20mg bid
[>200×109/L]) and could be titrated during treatment. The primary endpoint
was safety and tolerability of RUX. Changes in palpable spleen length and
symptom scores were also assessed. DIPSS scores were determined using pt
characteristics at baseline.
Results: Based on available pt data, DIPSS status was determined for 1840
of 2233 enrolled pts. JUMP included 893 low/Int-1–, 754 Int-2–, and 193 high-
risk pts (primary MF, 57%, 63%, 62%) who started treatment ≥1 y before data
cutoff (01 Jan 2016). Pts with higher-risk MF were older (62, 68, and 72 y), had
lower Hb (<10 g/dL, 3%, 64%, 100%), and had higher blast counts (≥1%, 18%,
44%, 84.5%). Disease duration (50, 51, and 55 mo) and spleen size (12, 13,
and 14.5 cm) were similar in all 3 groups. Most pts started at 20mg bid (68%,
57%, 59%) or 15mg bid (26%, 32%, 33%). Median exposure was 16, 11, and
9 mo; mean average daily dose was 30, 28, and 29mg. At data cutoff, most pts
remained on treatment or had completed per protocol (70%, 56%, 45%). Main
reasons for treatment discontinuation included adverse events (AEs; 15%,
17%, 27%), disease progression (6%, 11%, 11%), and death (2%, 5%, 11%).
The most common hematologic grade 3/4 AEs were anemia (22%, 44%, 55%)
and thrombocytopenia (11%, 18%, 25%), but these rarely led to discontinuation.
Overall rates of nonhematologic grade 3/4 AEs were ˂ 2%, except for pneumo-
nia (4.5%), pyrexia (2.3%), asthenia (2.2%), and dyspnea (2.2%). Infections in
≥5% of pts were pneumonia (7.3%), urinary tract infection (6.1%), and
nasopharyngitis (5.3%). Herpes zoster was reported in 4.8% of pts. At wk 48,
64% (226/355), 52% (121/232), and 50% (26/52) of pts had a ≥50% reduction
from baseline in spleen length; 19% (68/355), 19% (43/232), and 23% (12/52)
had 25%-50% reductions. Best response in spleen length by wk 72 is shown
in the Figure; 69%, 57%, and 51% of pts achieved ≥50% reductions. Median
time to response was 4.7 wk (2.9-75 wk), 5.3 wk (2.6-80 wk), and 8.1 wk (3.1-
72.3 wk). From wk 4 to 48, 39%-43%, 41%-44%, and 48%-54% of pts achieved
a clinically meaningful response on the FACT-Lym TS; proportions of respon-
ders on the FACIT-Fatigue were 42%-49%, 46%-49%, and 55%-61%.
Figure 1.
Summary/Conclusions: RUX was safe and generally well tolerated. Interest-
ingly, lower-risk pts received higher starting doses yet had lower rates of hema-
tologic AEs. Additionally, lower-risk pts remained on treatment longer than high-
er-risk pts, with fewer discontinuations due to AEs. Lower-risk pts also achieved
slightly better spleen size reductions and symptom improvement than higher-
risk pts, suggesting that earlier RUX treatment may lead to greater benefits in
pts with MF.
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SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH
MYELOFIBROSIS (MF) WHO STARTED TREATMENT AT 10mg BID AND
HAD THE DOSE UPTITRATED IN THE PHASE 3B EXPANDED-ACCESS
JUMP STUDY
L. Foltz1,*, B. Martino2, A. Zaritksey3, R. Tavares4, P. Giraldo5, H.K. Al-Ali6,
P. Guglielmelli7, V. Gupta8, P. Raanani9, C. Bouard10, J. Perez Ronco10,
R. Tiwari11, M. Griesshammer12
1St. Paul’s Hospital, University of British Columbia, Vancouver, British Colum-
bia, Canada, 2Azienda Ospedaliera Bianchi-Melacrino’-Morelli, Reggio Cal-
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abria, Italy, 3Federal Almazov Medical Research Center of the Russian Ministry
of Health, St. Petersburg, Russian Federation, 4Universidade Federal de Goia-
nia, Goiania, Brazil, 5Miguel Servet University Hospital and Centro de Investi-
gación Biomédica en Red de Enfermedades Raras (CIBERER), Zaragoza,
Spain, 6University Hospital of Halle, Halle (Saale), Germany, 7CRIMM, Center
for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi,
Department of Experimental and Clinical Medicine, University of Florence, Flo-
rence, Italy, 8Princess Margaret Cancer Centre, Toronto, Ontario, Canada,
9Rabin Medical Center, Petah Tikva, Israel, 10Novartis Pharma AG, Basel,
Switzerland, 11Novartis Healthcare Pvt. Ltd, Hyderabad, India, 12Johannes
Wesling Clinic, Minden, Germany
Background: JUMP is a phase 3b, expanded-access trial that assessed the
safety and efficacy of RUX in pts with no access to RUX outside of a clinical
trial. Pts received RUX at 5, 15, or 20mg bid per protocol. Increasing evidence
from clinical practice suggests that starting RUX at 10mg bid and subsequently
uptitrating may reduce the risk of cytopenia development. An ad hoc analysis
of a subset of JUMP pts provides information on this approach.
Aims: To assess the safety and efficacy of RUX at a starting dose of 10mg bid
in pts with MF.
Methods: Pts with high-, Int-2–, or Int-1–risk MF were eligible. Int-1–risk pts
had a palpable (≥5 cm) spleen. Protocol starting doses (5, 15, or 20mg bid)
were based on baseline platelet (PLT) counts (≥50 to <100×109/L, 100 to
200×109/L, >200×109/L, respectively). Although not per protocol, some pts
started RUX at 10mg bid. The primary endpoint was safety. Secondary end-
points included changes in spleen length and symptoms. 
Results: A total of 48 pts (primary MF, 60%) started RUX at 10mg bid ≥1 y
before data cutoff (01 Jan 2016). Mean baseline characteristics were: median
age, 65.5 y (range, 20-83 y); male, 44%; spleen length, 12.3 cm; time since
diagnosis, 56.6 mo; hemoglobin (Hb), 112.1 g/L (<100 g/L, 33.3%); PLT count,
351×109/L (<100×109/L, 10.4%). Pt characteristics were similar to those of the
overall population and did not indicate an increased risk of developing cytope-
nias. At data cutoff, most pts remained on treatment or had completed treatment
per protocol (58.3%). Primary reasons for treatment discontinuation included
adverse events (AEs), disease progression, and death (8.3% each). Overall,
41.7% of pts had dose modifications (AEs, 33.3%); 20.8% had interruptions
(all due to AEs). Median exposure was 14.4 mo. The mean average daily dose
was 25.8mg/day (SD, 10.1) and was comparable to those (33.2 and
23.3mg/day) of patients starting at higher doses (20 and 15mg bid; Figure).
The most common hematologic grade 3/4 AEs were anemia (27.1%; overall,
34.1%) and thrombocytopenia (14.6%; overall, 16.3%). Hb and PLT dynamics
were also similar. AEs (all-grade [grade 3/4]) in >10% of pts included pyrexia
(14.6% [4.2%]), asthenia (12.5% [0%]), weight increase (12.5% [0%]), abdom-
inal pain (10.4% [0%]), headache (10.4% [2.1%]), and peripheral edema (10.4%
[0%]). Infections in >2 pts included herpes zoster (8.3%), gastroenteritis,
nasopharyngitis, and septic shock (6.3% for each). At wk 24, 60.9% of pts
(14/23) had a ≥50% reduction from baseline in spleen length and 26.1% (6/23)
had 25%-50% reductions; rates were similar at wk 48 (58.3% [7/12] and 25.0%
[3/12]). Most pts (56.3%) achieved a ≥50% reduction at any time. Pts also expe-
rienced significant improvements in symptoms. From wk 4 to 48, 43%-59%
and 45%-68% of pts achieved a clinically meaningful response on the FACT-
Lym TS and FACIT Fatigue, respectively.
Figure 1.
Summary/Conclusions: A small cohort of pts in JUMP started at 10mg bid,
and had the dose uptitrated during the first 8 wks to a mean average daily dose
comparable to those of pts starting at higher doses, leading to safety and effi-
cacy outcomes consistent with those in the overall JUMP population. This alter-
native approach will be prospectively evaluated in anemic MF pts in the
REALISE study (NCT02966353).
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HYDROXYUREA IS ASSOCIATED WITH SKIN TOXICITY IN MYELOPRO-
LIFERATIVE NEOPLASMS: RESULTS FROM A PROSPECTIVE
NON-INTERVENTIONAL STUDY
F. Stegelmann1,*, K. Wille2, S. Schauer1, H. Döhner1, K. Döhner1, M. Griesshammer2
1University Hospital of Ulm, Ulm, 2University of Bochum, Minden, Germany
Background: Until today, hydroxyurea (HU) remains the most commonly used
cytoreductive drug in patients (pts) with classic myeoproliferative neoplasms
(MPN), i.e. essential thrombocythemia (ET), polycythemia vera (PV), and
myelofibrosis (MF). However, mucosal lesions, cutaneous ulcers, and pre-car-
cinomatous skin alterations such as actinic keratoses are being considered as
potential side effects of HU.
Aims: We sought to investigate the occurrence of skin toxicity in MPN pts
under HU compared to other (non-HU) cytoreductive drugs in routine clinical
practice.
Methods: Classic MPN pts regularly presenting at the outpatient centers of
the University Hospital of Ulm and Johannes Wesling Clinic Minden were includ-
ed in our non-interventional study after having given informed consent. Skin
alterations were evaluated prospectively between December 2010 and Novem-
ber 2016.
Results: In total, 151 MPN pts under cytoreductive therapy were included (ET,
n=55; PV, n=55; MF, n=41). Primary MPN diagnosis was made between 1979
and 2012 at a median age of 55 years (range, 22-82). Median duration of the
disease until baseline of the study was 6.3 years (0-32.6). Median prospective
observation time for the total cohort within the study period was 5.3 years (0.4-
6.2). Most frequently used cytoreductive drugs were HU in 120 pts, followed by
ruxolitinib in 59, anagrelide in 39, and pegylated Interferon-alpha (IFN-a) in 28
pts. Median cumulative HU exposure was 46 months (1-252), while the median
cumulative treatment time for the corresponding drug in the 126 non-HU pts
was 24 months (1-267) [ruxolitinib: 22 months (2-64); anagrelide: 19 months
(1-216); IFN-a: 64 months (1-267)]. Of 120 pts exposed to HU, 52 pts (43%)
presented with skin abnormalities during the observational period occurring
after a total HU treatment time of median 46 months (1-252). Sixteen of 120
pts (13%) discontinued HU due to skin toxicity such as skin ulcers (n=6), pho-
totoxicity / erythrodermia (n=5), actinic keratoses (n=3), dry skin / xerostomia
(n=2). Of note, four malignant skin diseases were reported under HU therapy
(basal cell carcinoma, n=3; malignant melanoma, n=1). Although pts of the HU
cohort were exposed longer to the drug compared to pts of the non-HU group,
numbers of skin events in non-HU treated pts were as following: n=5 under
anagrelide (skin ulcers, n=2; allergic reaction, n=2; basal cell carcinoma, n=1),
n=4 under IFN-a (local reaction after subcutaneous injection, n=3; actinic ker-
atosis, n=1), and none under ruxolitinib. In 3/126 (2%) non-HU treated pts,
occurrence of skin toxicity led to discontinuation of the corresponding cytore-
ductive drug. Interestingly, both skin ulcers as well as the single events ´basal
cell carcinoma´ and ´ actinic keratosis´ occurred under combination therapy with
HU. Taken together, skin alterations occurred more frequently under HU com-
pared to non-HU treatment (52/120 [43%] vs 9/126 [7%]; p=0.0001), and the
same was true for treatment discontinuations due to skin toxicity (16/120 [13%]
vs 3/126 [2%]; p=0.014).
Summary/Conclusions: According to our prospective observation, skin toxicity
was clearly associated with HU treatment compared to other cytoreductive
drugs. This resulted in a higher rate of HU treatment termination due to skin
toxicity. However, median exposure time to HU was longer compared with non-
HU treatment, and controlled clinical trials are necessary to provide more pre-
cise data on the occurrence and severity of skin toxicity under HU.
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THE NEGATIVE PROGNOSTIC IMPACT OF BASOPHILIA, EOSINOPHILIA
AND MONOCYTOSIS AT DIAGNOSIS IN PRIMARY MYELOFIBROSIS
M. Pereira1,2,*, K. Hundarova2, J. Carda1,2, E. Cortesão1,2, R. Guilherme1,2, L.
Ribeiro1, A.-B. Sarmento-Ribeiro1,2
1Clinical Hematology Department, Coimbra University Hospital Centre, 2Faculty
of Medicine, University of Coimbra, Coimbra, Portugal
Background: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm
(MPN) with a variable clinical presentation, from asymptomatic disease to rap-
idly progressive bone marrow failure and/or leukemic transformation; prognostic
stratification using the DIPSS-plus score isolates patient cohorts with median
survivals ranging from 16 months to 185 months. The development of mono-
cytosis during the course of PMF has been associated with a worse outcome,
and absolute monocyte counts have been shown to be of prognostic value in
other MPNs. Basophilia and eosinophilia are frequent findings in BCR-ABL-
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positive MPNs, where they associate with an accelerated phase of disease,
and seem to correlate with worse survival in myelodysplastic syndromes. How-
ever, the impact of these three findings at diagnosis in PMF remains unclear.
Aims: The aim of this work is to evaluate, at diagnosis, the prognostic impact
of basophilia, eosinophilia and monocytosis in patients with PMF. 
Methods: We identified all PMF patients diagnosed and followed-up in our
Center between January 1st 2005 and August 31st 2016 who still fulfill PMF
criteria under the WHO 2016 diagnostic revision, have synchronous bone mar-
row (BM) and peripheral blood (PB) analyses dating from the time of diagnosis,
and have complete charts with no missing data. After the exclusion of reactive
causes, monocytosis was defined as an absolute count (AC) >1.0 G/L,
eosinophilia as an AC>0.6 G/L and basophilia as an AC >0.2 G/L.
Results: We studied 55 evaluable patients (73% male) with a median age at
diagnosis of 70.1±11.7 years old. At diagnosis, 20% of patients had monocy-
tosis, with no significant differences according to gender or age. The median
overall survival (OS) in PMF patients with monocytosis was 27.3 months, and
twice as long (46.4 months) in patients without. In this cohort, a new calculated
cut-off of 0.75 G/L was better able to stratify patients according to survival with
a specificity of 74.1% (95% CI: 53.7-88.9%); 32.7% of patients had an AC
above the cut-off, with a median OS of 27.9 months, compared to 64.4 months
for patients under the cut-off. We identified 12.7% of patients with eosinophilia
at diagnosis, with no differences according to gender or age. PMF patients
with eosinophilia had a five-fold lower median OS compared with patients with-
out (6.1 vs 32.5 months, respectively). We obtained a new cut-off of 0.25 G/L
of eosinophils, which separated patients with a specificity of 77.8% (95% CI:
57.7-91.4%); 29.1% of patients had an eosinophil AC above the cut-off, with a
median OS of 27.3 months, compared to 43.6 months for patients under the
cut-off. A total of 30.9% of patients had basophilia at diagnosis, with no differ-
ences according to gender or age. The median OS in patients with basophilia
was 25.6 months, and 32.5 months in patients without. With a new cut-off of
0.25 G/L of basophils, with a specificity of 88.9% (95% CI: 70.8-97.64%), 20.0%
of patients had a basophil AC above the cut-off and a median OS of 19.7
months, compared to 46.4 months for patients under the cut-off. Considering
the whole cohort, 61.8% of patients had normal monocyte, eosinophil and
basophil ACs; the median OS in these patients was 56.1 months, compared to
28.5 months in patients with an increase in at least one AC. Applying the new
cut-offs, this difference in OS increased to 27.9 vs 64.4 months. Progression-
free survivals were not calculated, since only 2 patients had BM- or PB-docu-
mented progression during follow-up.
Summary/Conclusions: We observed that the presence of monocytosis at
diagnosis in PMF was associated with a halving of the median OS, while
eosinophilia decreased the median survival to one-fifth; basophilia also asso-
ciated with a reduction in survival, of approximately 20%. The application of
specific cut-offs calculated for the cohort improved the differentiation and strat-
ification of patients, with moderate to high specificity, further clarifying the neg-
ative prognostic impact of these three variables, at diagnosis, in PMF. Our
results show that even simple, inexpensive and readily available parameters
can be used to predict survival in PMF patients, and suggest that their integra-
tion into established scores could further increase the prognostic accuracy of
the latter.
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BLAST PHASE IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS:
A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS OF 85 PATIENTS
E. Roncoroni1,*, M. Bellini2, E. Rumi1,2, V. Ferretti1, D. Pietra1, C. Cavalloni1,
M. Ciboddo2, I. Casetti2, P. Zappasodi1, P. Benvenuti2, C. Astori1, M. Cazzola1,2
1Department of Hematology Oncology, Fondazione IRCCS Policlinico San Mat-
teo, Pavia, Italy, 2Department of Molecular Medicine, University of Pavia, Pavia,
Italy
Background: Classic Ph-negative myeloproliferative neoplasms (MPN) include
essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofi-
brosis (PMF). Clonal evolution can lead MPN patients in chronic phase (CP)
to develop acute myeloid leukemia (AML), called blast phase (BP): this event
occurs at rates of approximately 1% in ET, 4% in PV and 20% in PMF over the
first decade from MPN diagnosis.
Aims: To evaluate differences in clinical features and outcome in 85 patients
with MPN in blast phase, according to MPN diagnosis and mutational profile.
Methods: We identified in our database all patients affected with ET, PV and
PMF who developed acute myeloid leukemia according to 2016 WHO criteria
(≥ 20% blasts in bone marrow or peripheral blood) and for whom at least one
DNA sample to define the mutational status of the three MPN driver genes
(JAK2, CALR, MPL) was available. Treatment used in blast phase was classi-
fied as palliation (supportive care only or low intensity chemotherapy) or induc-
tion chemotherapy (de novo AML-like therapy). 
Results: We retrospectively identified among 2902 consecutive patients affect-
ed with Ph-negative MPN 85 patients who progressed to BP, with a known
molecular profile: 26 ET patients of whom 15 presented JAK2 V617F mutation,
8 CALR mutation, 1 MPL mutation, 1 JAK2/MPL mutation and 1 was triple-
negative, 36 PV patients all JAK2V617F mutated, and 23 PMF patients of
whom 17 were JAK2 mutated, 2 CALR mutated, 2 MPL mutated and 2 triple-
negative. Median age at BP was 71,3 years (range 46,3-86), being higher in
PV (median 73 years, range 46,3-84,7) compared to ET (median 68,7 years,
range 54,4-86, P 0,318) and PMF (median 67,9 years, range 48,1-84,9, P
0,016). The complete blood count at leukemic evolution was not influenced by
the initial diagnosis. At the time of BP, 31 out of 44 patients (70%) for whom
cytogenetic analysis was available showed an abnormal karyotype (22 patients
with complex karyotype or high risk aberrations). JAK2 mutated MPN can
evolve into JAK2 wild type AML (9 of 28 patient with blasts DNA available),
while CALR mutation was identified also in AML blasts in all 6 patients for which
DNA was available. Time to leukemic evolution was shorter in PMF (35,3
months, range 3,6-141,1) compared to ET (176,7 months, range 14,4-362,3,
P <0,001) and PV (129,1 months, range 17-367,6, P<0,001). According to
chronic phase driver mutation, time to leukemic evolution was shorter in JAK2
V617F mutated PMF compared to CALR mutated PMF (30,6 vs 138 months,
P 0,024), but not statistically different in JAK2 mutated ET compared to CALR
mutated ET (123,4 vs 203,2 months, P 0,121). Outcome was dismal, inde-
pendently from MPN diagnosis (P 0,278), with a median overall survival (OS)
of 3,9 months (range 3,3-5,6). OS was not influenced by treatment during blast
phase (4,5 months with induction chemotherapy versus 4,6 months with palli-
ation; P 0,865). Of the whole series, only one patient is alive and in complete
clinical and molecular remission, after 11 months from allogeneic bone marrow
transplantation.
Figure 1.
Summary/Conclusions: Clinical phenotype and outcome of BP is not influ-
enced neither by the diagnosis in chronic phase nor by the driver mutation;
moreover the outcome is poor irrespective of treatment. PMF patients have a
shorter time to BP than ET and PV patients; in PMF JAK2 V617F mutation is
associated with a shorter time to BP compared to CALR mutation. The only
potentially curative treatment is represented by allogeneic stem cell transplan-
tation, but only a few patients can actually undergo this procedure.
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TELOMERE LENGTH IS REDUCED IN ESSENTIAL THROMBOCYTHAEMIA
PATIENTS COMPARED TO AGE AND GENDER MATCHED HEALTHY
CONTROLS
S. Alimam1,*, J. Jie2, D. McLornan2, D. Radia1, G. Mufti2, C. Harrison1
1Haematology, Guys and St Thomas’ NHS Foundation Trust, 2Haematology,
King’s College London, London, United Kingdom
Background: Essential thrombocythaemia (ET) is a clonal stem cell disorder,
commonly diagnosed in the 6th or 7th decade of life. ET is associated with risk
of thromboembolic events, hemorrhage, constitutional symptoms, progression
to myelofibrosis and acute myeloid leukemia. In over 85% of patients a clonal
driver can be identified with mutations in JAK2 (50-60%%), Calreticulin (CALR)
(25-30%) or the thrombopoetein receptor (MPL) (3-5%); the remainder of
patients are termed “triple negative” (TN). Telomeres are non-coding regions
of DNA consisting of thousands of repeated sequences (TTAGGG) and are
considered central to chromosomal integrity and genomic stability. In healthy
adults, telomere length (TL) progressively shortens with age; therefore, TL is
considered a marker of aging and genome instability. Hematopoietic cells in
several hematological malignancies have been shown to be characterized by
shortened TL.
Aims: Determine if there is TL shortening in patients with ET when compared
to age and gender matched controls and establish the effects of cytoreductive
on TL in ET patients.
Methods: 100 patients were included in the study (27 with CALR, 35
JAK2V617F and two MPL515W mutations. 36 patients were TN). Most patients
were female (70% 70/100); median age was 45 years (range 20 - 86 years).
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TL was determined in peripheral blood mononuclear cells using a monochrome
multiplex quantitative PCR based on the original methods described by
Cawthon. All results were corrected for age and gender.
Results: Regardless of driver mutation status ET patients had significantly
shortened TL compared with age and gender matched controls, p=<0.0001.
Considering individual mutation status these differences remained significant
e.g. CALR positive, p=0.0009; JAK2V617F positive p=0.007 and p=0.012 in
TN patients. TL appeared more markedly short in the CALR cohort; for the 18
patients, whose TL was below the first centile, 55% (10/18) were CALR positive
vs 28% (5/18) JAK2V617F positive vs 17% (3/18) who were TN. Concerning
the potential impact of therapies 31/100 patients were treated with hydroxycar-
bamide (HC); 24/100 interferon (IFN) (eight of these had prior exposure to HC);
34/100 were not on cytoreductive therapy. Remaining treatments were ruxoli-
tinib (5), busulphan (4), anagrelide (1) and vorinostat (1). Independent of muta-
tion status there was significant TL shortening in untreated patients, p=0.05;
however, upon evaluating the impact of cytoreductive therapy on TL we noted
that ET patients with either current, or prior HC treatment had significantly short-
ened TL, p= 0.0015 and p=<0.0001 respectively. Strikingly, there was no sig-
nificant difference in TL in IFN patients who had no previous exposure to HC,
p=0.2 but those ET patients currently on IFN but with prior HC exposure still
had shorter TL, p=<0.0001. 
Summary/Conclusions: We document for the first time that ET patients, when
compared to age and gender matched healthy controls, have shortened TL.
This shortening is more pronounced in CALR and JAK2 V617F positive patients.
Concerning therapy whilst present in untreated patients TL shortening was
more pronounced in HC treated patients indicating that there may be a therapy
effect as has been observed after HC treatment in sickle cell disease. Of note
IFN treated patients had more normal TL suggesting that the disease related
TL effects may be reversed by this agent. 
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NUTRITION IN MYELOFIBROSIS: CORRELATES FROM THE COMFORT-1
STUDY
R. Scherber1,2,*, H. Kosiorek3, H. Geyer4, S. Verstovsek5, B. Langlais3,
L. Padrnos1, J. Palmer1, A. Dueck3, A. Fleischman6, R. Mesa1
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Medicine, Mayo Clinic, Scottsdale, 5Hematology and Oncology, MD Anderson,
Houston, 6Hematology and Oncology, University of California Irvine, Irvine,
United States
Background: Nutritional status declines in most patients with myelofibrosis
(MF). Sixty-seven percent of patients with MF lose weight over time and 27%
of patients have a BMI decrease of at least one body mass index (BMI) category
(Mesa et al. Blood. 2008;112(11):5224). MF also leads to deficient LDL and
cholesterol levels compared to age matched controls (Mesa R A et al. Blood.
2007;110(11):2548). Both hypocholesterolemia (p<0.001) and weight loss>10%
(p<0.001) have been associated with decreased survival in PMF patients (Mesa
et al. Blood 2009 114:3918) JAK inhibitor therapy has been found to improve
nutritional markers including weight, cholesterol, albumin, and leptin compared
to placebo in the COMFORT-1 study (Mesa et al. Clin Lymphoma Myeloma
Leuk. 2015 Apr; 15(4): 214–221; Verstovsek et al. N Engl J Med 2012; 366:799-
807). However, the corelation of these factors with other disease related vari-
ables and overall survival has not been established.
Aims: To evaluate the correlation, if any, between nutritional markers other
variables collected in the COMFORT-1 study.
Methods: Data from the COMFORT-1 trial of ruxolitinib versus placebo was
obtained from the Incyte for independent analysis. Data was analyzed for cor-
relation with symptom burden and survival along with other variables. Symptom
burden was assessed by the MF-SAF v2.0 (Mesa et al. Leuk Res 2009) for
individual items and total symptom score (TSS).
Results: A total of 309 patients were available for analysis including 155 rux-
olitinib-treated and 154 placebo-treated MF patients. At baseline, the average
BMI was 24.9 (SD=4.5). Baseline demographic and other disease-related vari-
ables can be found in previous publications (Verstovsek et al. N Engl J Med
2012; 366:799-807). Correlatives: Baseline: For all patients at baseline, numer-
ous correlations between baseline nutritional markers and markers of nutrition
(Figure 1) were identified. Total Symptom Scores (TSS) inversely correlated
with albumin, cholesterol, alpha-feto protein, HDL, and serum erythropoietin
levels. Baseline leptin levels correlated with many items including BMI, albumin,
cholesterol, LDL, erythropoietin, insulin and CRP. Placebo: For patients treated
with placebo, changes in BMI inversely correlated with changes in CRP (r=-
0.22, p=0.04). Positive correlations were observed between changes in LDL
with cholesterol (r=0.87, p<0.001) and HDL (0.41, p<0.001). In addition to LDL,
HDL change inversely correlated with TSS score (-0.24, p=0.02), and positively
correlated with changes in bone pain (0.23, p=0.02), abdominal fullness (r=0.22,
p=0.02), erythropoetin levels (0.27, p=0.01) and cholesterol levels (r=0.39,
p<0.001). Ruxolitinib: Most correlations with nutritional and metabolic markers
mirrored with baseline scores (Figure 1b). For ruxolitinib-treated patients,
change in JAK2V617F mutational status inversely correlated with changes in
serum cholesterol (-0.26, p=0.008), leptin (-0.38, p<0.0001), and LDL (-0.23,
p=0.02). CRP changes were inversely correlated with change in cholesterol
levels (-0.18, p=0.03).
Figure 1.
Summary/Conclusions: Nutrition decline remains an unmet need for many
MF patients. JAK2 inhibition represents a potential source to improve symptom
burden in those who qualify for therapy. Leptin closely correlated with many
other nutritional values suggesting this may be a good marker of nutritional
status in MPN patients. CRP was inversely correlated with BMI, suggesting the
importance of inflammation as a contributor to weight loss. Further study into
the unique nutritional needs of myelofibrosis patients is warranted.
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IS THE SURVIVAL OF PATIENTS WITH ESSENTIAL THROMBOCYTEMIA
BETTER IN THE LAST DECADE? RETROSPECTIVE ANALYSIS OF
DATABASE OF LATIAL GROUP FOR THE STUDY OF NMP, PH NEGATIVE
M. Montanaro1, A. Andriani2,*, M. Cedrone3, C. Santoro4, F. Spirito5, S. Leonetti
Crescenzi3, R. Porrini6, A. Di Veroli7, N. Villivà8, A. Spadea9, A. Rago10,
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A. Bagnato15, G. Cimino16, M. G. Mazzucconi17, R. Latagliata18
1Department of Hematology,, Belcolle Hospital,, Viterbo, 2UOSD of Hematology,
ASL Roma1, Ospedale Santo Spirito & Nuovo Regina Margherita, 3Department
of Hematology,, S. Giovanni Addolorata Hospital,, 4Department of Cellular
Biotechnology and Hematology, University of Rome “Sapienza”, 5Department
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Camillo-Forlanini, 6Department of Hematology,, Azienda ospedaliera Sant’An-
drea, 7Department of Hematology, University “Tor Vergata”, 8UOSD of Hema-
tology, ASL Roma1, 9Department of Hematology, Regina Elena National Cancer
Institute, Rome, 10Department of Hematology, Polo Universitario Pontino,, Lati-
na, 11Department of Hematology, Belcolle Hospital, Viterbo, 12Department of
Hematology, Steam Cell Transplantation, Transfusion Medicine and Cellular
Therapy, Campus Bio-Medico University Hospital, 13Department of Cellular
Biotechnology and Hematology,, University “La Sapienza”, 14Department of
Hematology, Azienda ospedaliera Sant’Andrea, Rome, 15Department of Hema-
tology, S. Giovanni Addolorata Hospital, Roma, 16Department of Hematology,
Polo Universitario Pontino, Latina, 17Department of Cellular Biotechnology and
Hematolog,, University “La Sapienza”, 18Department of Cellular Biotechnology
and Hematology, University “La Sapienza”, Rome, Italy
Background: To evaluate the prognosis of patients with Essential Thrombo-
cythemia (ET) in the first decade of the century we assessed retrospectively
the thrombosis free survival (TFS) and the overall survival (OS) of the patients
diagnosed from 01/01/2000 to 31/12/2009 and collected on the database of
our group.
Aims: Diagnosis of ET was performed with PVSG, WHO 2001 or 2008 criteria,
according to the date of the first observation. The whole population of 757
patients was then divided in two groups: the first (group I) with the diagnosis
performed between 01/01/2000 to 31/12/2005 (334 patients), presented a medi-
an follow-up of 111,9 months, the second (group II) diagnosed between
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01/01/2006 to 31/12/2009 (385patients), with a median follow-up of 58,2
months.
Methods: The characteristics of two groups of patients are reported in the
Table 1. No differences could be found between the two groups according age,
gender, platelet and WBC count and Hb level, Cardio-Vascular Risk Factors
(CVRF), spleen enlargement and the occurrence of previous thrombotic events.
The frequency of the JAK-2 V617F mutation resulted significantly different
(49.1% vs 68.4%) but in the group I the search of the mutation was never per-
formed at the diagnosis. TFS and OS were calculated from the date of diagnosis
of ET to the date of event with Kaplan-Meier product limit method; the compar-
ison of proportions and median values was computed with the Chi-squared
and the Mann-Withney tests, as indicated.
Results: No significant differences emerged neither for TFS (p= 0,09, HR 1,42,
95% C.I. 0.89-2.30) nor for OS (p= 0,15, HR 1,34, 95% C.I. 0,87-2,06). We
also evaluated the type of treatment used in the two groups to assess the
potential link between the therapy and TFS or OS (Table 2). No difference
emerged between the two groups as for anti-aggregating (mainly ASA), equally
utilized in both groups, 287/369, 77,8%, and 330/383, 78,3%, respectively
(p=0,95). As for the cytoreductive therapy, Hydroxyurea was used in 74.8% vs
67.9% (p= 0.60) and alkylating agents in 1.9% vs 2.1% (p= 0.85), whereas the
Anagrelide resulted utilized in 10,6% vs 3,9% (p= 0,001) and Interferon in 9,5%
vs 5,2% (p= 0,037), respectively. The more frequent use of Anagrelide and
Interferon in the first group (2000-2005) didn’t modify the prognosis (as for TFS
and OS) of the patients.
Figure 1.
Summary/Conclusions: Unfortunately, no improvement, neither as the TFS
nor the OS was observed (Fig. 1 and 2): more efforts to better identify the
groups at risk and, hopely, the introduction of new drugs as JAK-2 inhibitors
could change the prognosis of ET patients.
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CUTANEOUS INVOLVEMENT IN PHILADELPHIA-NEGATIVE MYELOPRO-
LIFERATIVE NEOPLASMS-SINGLE-CENTER EXPERIENCE
J. M. Sanchez-Raga1,2,*, N. Knöpfel3, M.D.M. Escudero-Góngora3, F. Sartori2,
B. Lopez1,2, I. Herraez2, M.D.C. Ballester2, M. Torres2, A. Martin-Santiago3,
A. Sampol2, M.A. Durán2
1Hematology and Hemotherapy, Fundación de Investigación Sanitaria de las
Islas Baleares Ramon Llull, 2Hematology and Hemotherapy, 3Dermatology,
Hospital Universitari Son Espases, Palma de Mallorca, Spain
Background: Philadelphia-negative chronic myeloproliferative neoplasms
(MPNs) may present clinical dermatological manifestations at the time of diag-
nosis, as well as during the course of the disease. On the other hand, also its
treatments can present skin side effects.
Figure 1.
Aims: We have performed a dermatological review of a cohort of patients we
follow-up at our center with the aim of assessing the cutaneous manifestations.
Methods: A randomized selection of patients with a diagnosis of essential
thrombocythemia and polycythemia vera was performed. We create a specific
consultation in which a detailed history of each patient (sex, age, diagnosis,
signs and symptoms, treatments and its duration) as well as a deep dermato-
logical examination was done. All data was collected in an Excel database and
analyzed using the SPSS system.
Results: 63 patients (54 ET and 9 VP) were reviewed. The most frequent skin
lesions were xerosis and/or keratosis pilaris (76.2% patients), nail changes
(41.3%), actinic keratosis (39.7%), hyperpigmentation of the skin (23.8%), pru-
ritus (23.8%) and non-melanoma skin cancer (22.2%). In figure 1 we detail all
the skin alterations that we have found.
Summary/Conclusions: Cutaneous involvement in MPNs is more frequent
than expected and it is usually underdiagnosed. Some of these lesions could
be prevented with the correct treatment of their pathology and adequate pho-
toprotective measures. The results obtained support the recommendation of
an annual review by a dermatologist in a systematic way, especially in patients
with higher risk factors: low phototype, high sun exposure, past dermatological
history and prolonged cytoreductive therapy.
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HEMOGLOBIN AND WHITE CELL COUNT IN PATIENTS CLINICALLY
SUSPECTED TO HAVE ESSENTIAL THROMBOCYTHEMIA MAY HELP IN
PREDICTING EARLY PRIMARY MYELOFIBROSIS OR UNCLASSIFIABLE
MYELOPROLIFERATIVE NEOPLASM
S. Sirhan1,*, C. Ross2, A. Orazi3
1Jewish General Hospital Montreal, Montreal, 2McMaster University, Hamilton,
Canada, 3Weill Cornell Medical College, New York, United States
Background: Classification of myeloproliferative neoplasms (MPN) in patients
presenting with thrombocytosis can be challenging. Relying only on clinical
features may lead to misclassification of patients in the early stages of primary
myelofibrosis (PMF) as essential thrombocythemia (ET). Although bone marrow
(BM) biopsy examination is the gold standard necessary for accurate classifi-
cation, in clinical practice it might be helpful to identify among patients with a
working diagnosis of ET those most likely to have early PMF or unclassifiable
MPN (MPN-U). To this end, Carobbio et al. (Am J Hematol. 2012;87:203-4)
developed a simple algorithm based on presence of anemia (hemoglobin <120
g/L for females and <130g/L males) and/or leukocytosis (leukocytes ≥13x109/L)
or elevated LDH (>200 mU/mL). For an accurate classification, the clinical and
laboratory features need to be correlated with BM findings, thus collaboration
between hematologists and pathologists is essential. 
Aims: To examine applicability of the Carobbio algorithm in routine practice
and its potential use in identifying among patients presenting with thrombocy-
tosis and clinically suspected to have ET, those with early PMF or MPN-U. To
identify unmet needs in the diagnosis of MPNs in daily practice upon which
further educational initiatives can be built which stress the importance of hema-
tologist-pathologist collaboration.
Figure 1.
Methods: A retrospective Personal Practice Assessment Program was con-
ducted at 8 Canadian institutions. Eight hematology/pathology pairs reviewed
charts of about 20 consecutive examined patients who presented with throm-
bocytosis and suspected to have ET. The first 5 out of 20 cases who met the
Carobbio algorithm were selected for BM evaluation. To avoid the impact of
treatment and/or natural disease evolution on accurate classification, the
requirement was for the BM biopsy to be collected within a year of patient’s
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presentation with thrombocytosis. No central pathology review was planned
for this stage of the study.
Results: A total of 122 patients (58 males and 69 females; 54% >60 years of
age; 65% with LDH ≥200 mU/mL) with a clinical history indicative of ET were
initially assessed. A majority of patients (76%) presented with suspected ET
within the last 5 years, likely because it was more difficult for clinicians to identify
patients with BM biopsy collected within a year of presentation with thrombo-
cytosis if they presented more than 5 years ago. Out of 122 patients, 48 met
the hemoglobin and/or leukocytes criteria outlined in the Carobbio algorithm,
Figure. The BM examination was performed on 33 patients who met pre-spec-
ified criteria for the timing of bone marrow biopsy. About one third of the 33
patients met the WHO classification for ET and one third for PMF. While 2 of
the remaining patients met criteria for PV, the rest were uncertain whether to
represent true ET or early PMF, i.e. represented MPN-U (Figure 1).
Summary/Conclusions: Despite its methodological limitations, this initiative
confirms that in real world clinical practice the Carobbio algorithm can be used
to identify possible cases of early PMF and MPN unclassifiable among patients
clinically suspected to have ET. It suggests a need for educational initiatives
on using diagnostic algorithms to separate ET from PMF. It confirms the impor-
tance of hematologist-pathologist collaboration in reaching a final integrated
diagnosis based on the WHO classification. These findings warrant further
investigation in larger prospective studies. 
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PK/PD MODELING COMPARING DIVIDED DOSING (200mg TWICE-DAILY
[BID]) VS SINGLE DOSING (400mg ONCE-DAILY [QD]) OF PACRITINIB
(PAC) IN PATIENTS WITH MYELOFIBROSIS (MF) ON THE PERSIST-2
PHASE 3 TRIAL
S. Al-Fayoumi1,*, J. Mascarenhas2, R. Hoffman2, M. Talpaz3, A.T. Gerds4,
B. Stein5, V. Gupta6, A. Szoke7, M. Drummond8, A. Pristupa9, H. Zhou1,
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Background: MF is a life-threatening hematologic malignancy characterized
by splenomegaly and debilitating constitutional symptoms. At the present, the
JAK inhibitor ruxolitinib is the only therapy for patients (pts) with MF that has
garnered regulatory approval. Although ruxolitinib has been shown to reduce
splenomegaly and symptoms in pts with MF, it is associated with dose-limiting
cytopenias, and not indicated for pts with platelets <50,000/µL. PAC is an oral
kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R. Using data
from early-phase PAC studies, population PK modeling and simulations pre-
dicted that BID dosing would result in higher steady-state AUC and lower Cmax
vs QD dosing, which may be associated with increased efficacy and comparable
or improved safety. Thus, the phase 3 PERSIST-2 trial of PAC vs BAT (including
ruxolitinib) in pts with MF and platelet counts ≤100,000/µL evaluated both PAC
400mg QD and 200mg BID dosing schedules. Data previously presented (Mas-
carenhas, J. et al. Blood, 128(22), LBA-5.) showed significantly higher spleen
volume reduction (SVR) with PAC (QD and BID pooled) vs BAT (P=0.001);
despite identical cumulative dosing, pts had improved SVR and total symptom
score (TSS) reduction with PAC 200mg BID vs PAC 400mg QD, with numeri-
cally fewer adverse events and a trend towards improved survival.
Aims: Validate the clinical utility of PK/PD modeling to select the PAC 200mg
BID regimen in pts with MF treated in the PERSIST-2 trial.
Methods: Pts with MF and baseline platelet count ≤100,000/µL were random-
ized 1:1:1 to PAC 400mg QD, PAC 200mg BID, or BAT. Blood samples were
collected from PAC-treated pts for PK and PD analysis at a prespecified subset
of trial sites. Blood samples were collected on day 1 of week 1 (4 h post-dose),
week 3 (pre-dose and 4 h post-dose), week 12 (pre-dose), and week 24 (pre-
dose). At the remaining sites, blood samples were collected from PAC-treated
pts for PK analysis only at weeks 12 and 24 (pre-dose).
Results: In total, PK samples were collected up to week 24 from 144 PAC-
treated pts (78 BID, 64 QD). The PK of PAC was described by a 2-compartment
model with first order absorption, first order elimination from the central com-
partment, and an absorption lag time. PAC QD was associated with higher
Cmax and lower Cmin vs PAC BID (Table). Median PAC plasma concentrations
during week 1 were 47% higher with QD vs BID dosing. At steady-state, median
Cmin (Cminss) at weeks 12 and 24 were higher with BID vs QD dosing by 10%
and 15%, respectively. Also, median observed steady-state 4-h concentration
at week 3 (coincides with Cmaxss) was 12% higher with QD vs BID dosing. In
an exposure-response analysis, with QD or BID dosing, no trends were detect-
ed for a relationship between observed Cminss and death, cardiac death, hem-
orrhagic death, hemorrhagic events, thrombocytopenia (grade ≥2 or ≥3), ane-
mia (grade ≥2 or ≥3), or gastrointestinal events (any grade, grade ≥2, or ≥3).
Eleven (15%) and 13 (17%) PAC QD pts achieved SVR ≥35% and TSS reduc-
tion ≥50% at week 24, respectively, vs 16 (22%) and 24 (32%) PAC BID pts.
Treatment with PAC BID but not QD showed a trend of increased SVR vs
Cminss.
Table 1.
Summary/Conclusions: As predicted by PK modeling and simulations analy-
ses, PAC 400mg QD was associated with higher Cmax and lower Cmin vs
PAC 200mg BID in pts with MF from the PERSIST-2 trial. These differences
appear to translate into an improved benefit/risk profile of PAC BID vs QD reg-
imens.
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ZMYM2-FLT3 IS A RARE, RECURRENT, CYTOGENTICALLY CRYPTIC
FUSION IN MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA THAT
IS RESPONSIVE TO FLT3 INHIBITION
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Background: Myeloid/lymphoid neoplasms with eosinophilia are characterised
by diverse tyrosine kinase (TK) fusion genes, many of which can be effectively
targeted by small molecule inhibitors. More than 70 TK fusions have been
described, most of which are associated with visible cytogenetic abnormalities.
However these fusions are rare, and the pathogenesis of the great majority of
cases presenting as myeloproliferative neoplasm with eosinophilia (MPN-eo)
remains unexplained. We hypothesized that some MPN-eo cases may be driv-
en by hitherto undetected cryptic TK fusion genes.
Aims: To screen cases with MPN-eo for TK fusion genes and evaluate the sig-
nificance of any novel fusions
Methods: PolyA RNA extraction from MPN-eo cases, RNA-Seq library prepa-
ration and 100bp paired-end sequencing was performed with multiplexing for
a minimum of 75 million reads/sample using an Illumina HiSeq 2000. Bowtie,
TopHat and TopHat-Fusion were used to align reads, resolve splice junctions,
identify and filter potential TK fusions. Confirmation and screening of fusions
was performed by RT-PCR and Sanger sequencing. 
Results: Of 20 cases tested by RNAseq analysis, just one cryptic TK fusion
was identified: ZMYM2-FLT3, predicted to arise as a consequence of an 8Mb
inversion at 13q12. Unusually, both breakpoints fell within exons (ZMYM2 exon
20 and FLT3 exon 14, respectively) resulting in an in frame fusion. To test if this
fusion might be recurrent, we analysed 105 additional cases by RT-PCR. One
additional positive case was detected, with similar but not identical breakpoints
to the initial case. Case 1, a 48 year old female, presented with leukocytosis
(30x109/L), eosinophilia (2x109/L, elevated serum tryptase (37µg/l),
splenomegaly and a hypercellular bone marrow (BM). Cytogenetics was normal
and FIP1L1-PDGFRA, KIT D816V and JAK2 V617F were all negative and no
pathogenetically relevant mutations were identified by a myeloid NGS panel
(28 genes). After 10 months, she progressed to myeloid blast phase. Because
the disease was resistant to AML-induction chemotherapy (FLAG-Ida), an allo-
geneic PBSCT from an unrelated donor was performed 13 months after diag-
nosis. As a consequence of chronic GvHD and septic shock, the patient died 6
months after allogeneic PBSCT. The ZMYM2-FLT3 fusion gene was identified
post mortem. Case 2, a 47 year old male, presented with eosinophilia
(4.7x109/L, 47%) elevated serum tryptase (42µg/l) and a hypercellular BM Cyto-
genetics was normal and FIP1L1-PDGFRA, KIT D816V and JAK2 V617F were
all negative. There was no response on steroids or hydroxyurea. Following the
finding of ZMYM2-FLT3 positivity, treatment with sunitinib was commenced.
Blood counts started to improve from day 4 and normalized after 3 weeks. Dur-
ing a pause of 3 weeks due to pulmonary infection, leukocytes/eosinophils rap-
idly increased, but normalized again within weeks after restart of sunitinib. The
patient has been maintained on sunitinib for 10 months (since re-start) and
remains in complete hematologic remission.
Summary/Conclusions: ZMYM2 is the fourth gene reported to fuse to FLT3
in myeloid neoplasms but the first FLT3 fusion that is cytogenetically cryptic.
Patients with ZMYM2-FLT3 may be amenable to treatment with FLT3 inhibitors
and thus, although very rare, this fusion should be considered in the work up
of MPN-eo cases. Due to their extensive diversity, we anticipate that RNAseq
will become the method of choice to detect rare TK fusions.
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COMPLETE HEMATOLOGIC AND CYTOGENETIC RESPONSE IN A
PATIENT WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 ACTIVATED
MYELOPROLIFERATIVE NEOPLASM RECEIVING INCB054828
N. Daver1,*, V. Subbiah1, E. Asatiani2, S. Verstovsek1
1MD Anderson Cancer Center, Houston, TX, United States, 2Incyte Europe,
Geneva, Switzerland
Background: Fibroblast Growth Factor Receptor (FGFR) inhibitors have
demonstrated efficacy in solid tumors with FGFR pathway activation.
INCB054828, a novel, highly selective FGFR1, FGFR2, and FGFR3 inhibitor,
is being assessed for the treatment of several advanced malignancies (AACR
2015; Abstract 771). 8p11 myeloproliferative syndrome is an aggressive myelo-
proliferative neoplasm (MPN) associated with FGFR1 translocation on chro-
mosome 8p11.
Aims: To describe the characteristics of a patient with FGFR1 activated MPN
who achieved a complete hematologic and cytogenetic response with
INCB054828 in an ongoing phase 1/2 trial (NCT02393248)
Methods: In this 3-part, phase 1/2 dose-escalation and expansion trial, eligible
adults had any advanced solid tumor (parts 1 and 3) or malignancy with
FGF/FGFR alteration (part 2), had Eastern Cooperative Oncology Group per-
formance status score ≤1 (part 1) or ≤2 (parts 2 and 3), and were refractory to
prior therapy with no known effective standard therapy available to them.
Patients received INCB054828 orally on a 21-day cycle (2-weeks on/1-week
off) starting at 9mg QD and increasing to 13.5mg QD.
Results: This 51-year-old male patient with 8p11 translocated MPN diagnosis
(currently the only patient with MPN enrolled in this trial), presented with abnor-
mal white blood cell (WBC) count (eosinophils, 15%; peripheral blood [PB]
blasts, 4%) and abnormal platelet count (68×109/L). The patient had prior ther-
apy with hydroxyurea. Bone marrow (BM) biopsy at study entry showed 95%
cellularity, 4% BM blasts, decreased megakaryocytes, t(8,9)(11.2,q33) in 19 of
20 metaphases, and European Myelofibrosis Network grade MF-1. After 6
weeks of treatment with INCB054828 at a dose of 9mg QD in part 2 of the
study, WBC count normalized with disappearance of eosinophilia and PB
blasts. BM biopsy demonstrated a normalization of bone marrow differential
with 50% cellularity, 1% BM blasts, adequate trilineage hematopoiesis, MF-1
fibrosis, and a complete cytogenetic response. After 4 months of treatment
the patient was hospitalized for pneumonia and study treatment was held. The
patient progressed to AML shortly after therapy interruption, with BM blasts
increasing to 83% and evidence of clonal evolution (47,XY: +8 t(8,9) (11.2;q33)
[3]/48 idem, +19 [17]). The patient was taken off study at this time (end of cycle
6) and subsequently achieved a complete remission on intensive chemotherapy
with fludarabine, cytarabine, idarubicin, and allogeneic BM transplantation. The
patient is currently alive and in complete remission.
Summary/Conclusions: INCB054828 showed efficacy in this patient with
FGFR1 activated MPN using a 21-day (2-weeks on/1-week off) regimen. Con-
tinuous treatment may be necessary to sustain response and avoid rebound
as has been seen with other kinase inhibitor therapies. A phase 2 trial has
been initiated to evaluate INCB054828 in patients with myeloid/lymphoid neo-
plasms with FGFR1 rearrangement (NCT03011372).
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THE GRADE OF STROMAL CHANGES IMPACTS ON PROGNOSIS IN
PATIENTS WITH PRIMARY MYELOFIBROSIS
U. Gianelli1,*, S. Fiori1, D. Cattaneo2, A. Bossi3, I. Cortinovis3, C. Bucelli2,
N. Orofino2, A. Iurlo2
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Background: Recently, a detailed grading system for the assessment of bone
marrow stromal changes has been proposed in primary myelofibrosis, proved
to be reproducible and adopted by the updated WHO 2016 classification.
Aims: In this study, we aim to evaluate any possible prognostic implications of
this grading system in a series of patients with primary myelofibrosis.
Methods: The study involved 122 consecutive patients with primary myelofi-
brosis diagnosed between 1998 and 2015 at the Oncohematology Division of
the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan,
for which an adequate bone marrow trephine biopsy (more than 1 cm in length)
performed at the time of first observation was available, together with complete
clinical, laboratory and follow-up data.
Results: Reticulin myelofibrosis (MF), collagen deposition (Co) and osteoscle-
rosis (Ost) were evaluated and graded from 0 to 3 in the bone marrow trephine
biopsies for each patient at diagnosis. In detail, the stromal changes were grad-
ed as follows: bone marrow fibrosis: MF-0 in 9 cases, MF-1 in 60, MF-2 in 31
and MF-3 in 22; collagen deposition: Co-0 in 64 cases, Co-1 in 23, Co-2 in 21
and Co-3 in 14; osteosclerosis: Ost-0 in 72 cases, Ost-1 in 24, Ost-2 in 19 and
Ost-3 in 7. Patients’ population was composed of 56 males and 66 females
(M/F=1/1,2) with a median age at diagnosis of 68 years (range 30–85). Clini-
cally, at presentation, anemia with hemoglobin values less than 10 g/dL was
present in 20 (16%) patients, leukocytosis more than 25 x109/L was identifiable
in 4 (3%) patients, and platelets count less than 100 x109/L in 7 (6%) cases.
JAK2V617F mutation was detected in 81 cases (66%). Among the remaining
41 JAK2-negative patients, 4 and 27 carried MPL and CALR mutations, respec-
tively; 10 out of 122 resulted “triple-negative”. According to the International
Prognostic Scoring System, 38 cases were stratified as low risk, 51 as inter-
mediate-1 risk, 21 as intermediate-2 risk, and the remaining 12 as high risk. By
the time of the analysis, 21 (17%) patients had died: leukemic evolution
occurred in 14 (11.5%) patients, whereas thrombotic or hemorrhagic events
occurred in 25 (20.5%). Subsequently, a comprehensive grade of bone marrow
stromal changes ranging from 0 to 9 allows us to distinguish 88 (72%) cases
with low-grade stromal changes (total score: 0-4) and 34 (28%) with high-grade
stromal changes (total score: 5-9). Clinically, patients with high-grade stromal
changes presented more frequently with anemia, thrombocytopenia, leukocy-
tosis, peripheral blood blasts and increased lactate dehydrogenase levels. The
grade of bone marrow stromal changes resulted strictly associated with the
International Prognostic Scoring System and the overall mortality (low-grade:
10 dead out of 88 vs high-grade: 11 dead patients out of 34; p=0.013). Finally,
the grade of bone marrow stromal changes was effective in discriminating the
overall survival of the patients with low-grade and high-grade stromal changes
(Log-Rank test: p=0.0002).
Summary/Conclusions: A detail evaluation of the bone marrow stromal
changes has important prognostic implications and can be used at diagnosis
in the clinical stratification of the patients affected by primary myelofibrosis.
Further studies are needed to test if the prognostic significance of this grading
system remains during the follow-up.
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INCREASED RISK OF INFLAMMATORY BOWEL DISEASE IN PATIENTS
WITH PHILADELPHIA NEGATIVE CHRONIC MYELOPROLIFERATIVE
NEOPLASMS
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Background: Studies reveal that patients with inflammatory bowel disease
(IBD) may have increased risk of haematological cancers. Moreover, Philadel-
phia negative chronic myeloproliferative neoplasms (MPNs) have previously
been associated with autoimmune diseases, including IBD. Nevertheless, to
our knowledge, the risk of IBD has not been investigated in patients with MPN.
Aims: We undertook a nationwide population-based matched cohort study,
and estimated the risk of IBD in patients with MPN.
Methods: We used valid Danish national registries, covering more than 5 mil-
lion individuals, and included all patients diagnosed with either essential throm-
bocythemia (ET), polycythaemia vera (PV), myelofibrosis (MF), or unclassifiable
myeloproliferative neoplasm (MPN-U) between 1994 and 2013. For each
patient, 10 individually age- and sex-matched comparisons were included.
Patients and comparisons were followed until first occurrence of any IBD diag-
nosis (ulcerative colitis or Crohn’s disease), death, emigration or end of 2013.
Patients and comparisons with prior IBD were excluded from the analysis. Haz-
ard ratios (HRs) between MPN patients and comparisons were estimated using
cox regression models, and used as measure of the relative risk. The risk was
only calculated if five or more individuals were diagnosed with IBD.
Results: Of the 8,210 MPN patients, 80 individuals were diagnosed with IBD
during the study period; including 37 ET patients, 28 PV patients, 1 MF patient
and 14 MPN-U patients. During a total risk time of 45,241 years, the rate of
IBD per 1000 person years at risk was 1.8 (95% confidence interval [95%
CI]:1.4-2.2) for the MPN patients. The corresponding rate for the 81,326 com-
parisons was 0.8 (95% CI: 0.7-0.8).The 10-year risks of IBD for MPN patients
and comparisons were 0.8% (95% CI: 0.6-1.0) and 0.4% (95% CI: 0.4-0.5),
respectively. The overall HR of IBD was 2.4 (95% CI: 2.1-2.9) for MPN patients,
with HRs of 2.6 (95% CI: 2.1-3.2) for ulcerative colitis and 2.4 (95% CI: 1.7-
3.4) for Crohn’s disease. The risk of IBD was increased 2 to 3 fold among ET,
PV and MPN-U patients, with HRs of 2.8 (95% CI: 2.1-3.7) for ET patients, 2.1
(95% CI: 1.6-2.7) for PV patients and 2.2 (95% CI: 1.3-3.7) for MPN-U patients.
Summary/Conclusions: Patients with MPN are at increased risk of IBD com-
pared to the general population. The absolute risks of IBD are low, but abdom-
inal discomfort may in few patients be caused by underlying IBD.
554 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
E1348
ESSENTIAL THROMBOCYTHEMIA WITH AQUAGENIC PRURITUS: AN
ENTITY WITH MORE AGRESSIVE CLINICAL AND BIOLOGICAL PROFILE
AT THE DIAGNOSIS AND A HIGH MORBIDITY DURING THE FOLLOW-UP
C. Le Gall-Ianotto1,2,*, R. Le Calloch3, L.-M. Mollard4, L. Misery1, J.-C. Ianotto4
1Service dermatologie, CHU Brest - Hôpital Augustin Morvan, 2laboratory of
interactions epitheliums-neurones, university of Brest, Brest, 3Service Héma-
tologie, CHIC, Quimper, 4Service Hématologie, CHU Brest - Hôpital Augustin
Morvan, Brest, France
Background: Polycythemia vera (PV) and essential thrombocythemia (ET)
are Phi-negative myeloproliferative neoplasms in which arterial or venous
thromboses and phenotypical evolutions (leukemia, myelofibrosis) are the most
recurrent complications. Aquagenic pruritus (AP), induced by water contact, is
a typical symptom of PV. However, we showed recently that ET patients also
suffered from AP with clinical characteristics quite different from those observed
in PV patients. In 2008, the presence of AP was associated with a lower risk of
arterial thrombosis in PV patients. 
Aims: It seemed particularly interesting to analyse the clinical relevance and
the prevalence of the presence of AP in ET patients for such a risk.
Methods: In this study, we used the OBENE observatory (Observatoire Brestois
des NEoplasies myéloprolifératives), a register of MPN patients followed in our
University Hospital in which biological and clinical data of 396 ET patients have
been collected. This register was approved by a local ethical committee and
registered in clinicaltrials.gov (NCT02897297). To avoid masked polycythemia
Vera diagnostics, all JAK2 positive cases were tested for isotopic red mass
cells if appropriate.
Results: Among our 396 ET patients, 42 (10,6%) suffered from AP. Interestingly,
the median age at diagnosis of these patients was lower (51.6 vs 63.8%,
p<0.0001). Furthermore, they presented more symptoms as erythrocytosis,
hyperviscosity, constitutional symptoms and splenomegaly (p<0.01). ET
patients with AP were more proliferative (more polycythemic but less thrombo-
cythemic, p<0.04 each) and were more difficult to treat (2.2 vs 1.1 treatment
lines, p=0.005). Concerning the occurrence of thrombotic events (arterial or
venous) at diagnosis, no significant difference between patients with or without
AP was found. In contrast, the presence of AP induced an increase of throm-
botic events during the follow-up (30.9 vs 17.2%, p=0.03). But surprisingly,
these events appeared in the delayed timing. The arterial/venous rate of throm-
botic events was also different with 50/50 vs 2/3:1/3. Furthermore, we observed
that about one-third of the patients with AP had phenotypic evolutions against
13.3% in the other group (p=0.0007); the most frequent evolutions were PV
and secondary myelofibrosis (16.7 vs 5.4%, p=0.005 and 19 vs 4.8%, p=0.0003,
respectively). Concerning the overall survival of the patients, we have noter
that there was less death in the group with AP than without AP (11.9 vs 32.5%,
p=0.006) in spite of a longest follow-up (12.1 vs 7.7 years, p=0.002).
Summary/Conclusions: AP is classically associated to PV. But we confirmed
here that AP is also present in ET. Furthermore, ET patients suffering from AP
were more proliferative, more symptomatic at diagnosis but had also higher
risk of thromboses and phenotypic evolutions than ET without AP. Despite that
these patients have a higher overall survival. So, the presence of AP in patients
with ET characterizes patients with high risk of morbidity (thromboses, pheno-
typic evolutions).So as in PV, the presence of AP in ET patients at the time of
diagnosis should be systematically identified.
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ANAGRELIDE RESPONSE ACCORDING TO THE MOLECULAR PROFILE:
SOMETHING TO CONCLUDE ON THE MECHANISM OF ACTION OF THE
DRUG IN MYELOPROLIFERATIVE NEOPLASMS (MPN)?
M. Montero1,*, T. Knight 1, M. Domínguez1, E. Carrillo1, F. Márquez1, V. Escamilla1,
P. Guerrero1, M. Suito1, A. Blum1, N. Alkadi1, J. González1, J. Falantes1,
N. Rodríguez1, M. Martino1, I. Espigado1, J. Pérez- Simón1
1Haematology and haemotherapy Service, Hospital Universitario Virgen del
Rocío, Sevilla, Spain
Background: Anagrelide is a useful drug in the control of thrombocytosis in
MPN. Although it is known that in therapeutic levels it primarily influences in
the post-mitotic phase of megakaryocytic development interfering with its com-
plete maturation, its mechanism of action is not well known. 
Aims: The progress in the diagnosis of MPN due to the discovery of driver
mutations (JAK2, calreticulin and MPL) leads us in the present study to correlate
them with the response to anagrelide in a group of patients treated with this
drug, investigating the possible interference in the referred biological pathways.
Methods: a total of 56 patients with MPN diagnosed in our centre between
1993 and 2015 were studied. The median age was 49 years, with 19 patients
older than 60 years. 83% were female and 17% were male. The diagnosis was
initially carried out based on the WHO criteria 2008 and subsequently reviewed
the medical records with the new criteria of 2016. A molecular study on periph-
eral blood samples was carried out using quantitative allele-specific PCR tech-
niques for JAK2, qualitative for MPL (L515V mutation) and Sanger sequencing
of exon 9 for calreticulin. Type 1 mutation was considered at 52 bp deletion
and type 2 at 5 bp insertion. In all patients, the goal of anagrelide therapy was
to control thrombocytosis (platelet count below 600x10e9 /L), with dosage within
the range of efficacy and safety recommended in the datasheet. The results
were analysed with the statistical software SPSS vs 15.0
Results: 80.5% of the patients were diagnosed with ET, 12.5%  of PV, 3.5% of
myelofibrosis and 3.5% of unclassifiable MPS. 59% of the patients had a V617F
JAK2 mutation, with allelic load higher than 20% in 47.5% of the cases. 28.5%
presented mutation in calreticulin; of which 50% were type 1 and 50% type 2.
Only one patient had a mutation in MPL (2%), the remaining 6% being classified
as “triple negative”. The median daily dose of anagrelide received was 1.5mg.
17.5% of the patients required more than 2mg for an adequate control, half of
them being positive for mutations in calreticulin and the other 50% of the muta-
tion V617F JAK2 with allelic load higher than 20%. 26% of the patients received
daily dose of 1mg, being 70% positive for the mutation V617FJAK2 with allelic
load lower than 20%, although there were no statistically significant differences
between the groups according to the mutational profile. 16% of patients dis-
continued treatment due to toxicity, with the most common adverse effects
being mild (headache and palpitations).
Summary/Conclusions: Patients requiring higher doses of anagrelide present
mutations in calreticulin or JAK2 V617F allelic load higher than 20% and
patients with lower allelic load having greater sensitivity to the drug, with no
statistically significant differences. It is possible that the first situation is asso-
ciated with a greater pre-mitotic deregulation in the megakaryocyte where the
drug does not interfere whereas the second one could be related to anagrelide
interference through the JAK2 pathway in post mitotic maturation although larg-
er exploratory studies are required.
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THE DELAYED DIAGNOSIS OF PHILADELPHIA-NEGATIVE MYELOPRO-
LIFERATIVE NEOPLASMS (MPN) IS COMMON AND RESULTS IN A HIGH
INCIDENCE OF POTENTIALLY PREVENTABLE THROMBOTIC COMPLI-
CATIONS
C. Forsyth1,*, C. Tiley2, B. Wylie2, M. Dean2, T. Armytage2, K. Melville2
1Medicine, Wyong Hospital, Kanwal, 2Haematology, Gosford Hospital, Gosford,
Australia
Background: Ph-negative MPNs are a heterogenous group of stem cell derived,
clonal bone marrow disorders characterised by increased production of mature
blood cells. Patients with MPNs are at significantly increased risk of thrombotic
and haemorrhagic complications which are a major cause of morbidity and mor-
tality. The early diagnosis and treatment of MPN may reduce the incidence of
thrombotic complications and the associated morbidity and mortality.
Aims: We performed a study to determine if the delayed-diagnosis of MPN
was common and the implications of any such delay.
Methods: The medical records of patients treated at our centre with a new
diagnosis of MPN between January 2010 and June 2016 were audited. We
determined the duration from first appearance of a full blood count (FBC) abnor-
mality consistent with the diagnosis of MPN until the time of formal diagnosis.
The occurrence of any thrombotic or haemorrhagic complications during this
time was recorded.
Results: 143 patients were diagnosed with MPN; 35 with polycythemia vera,
70 with essential thrombocythemia, 25 with primary myelofibrosis and 13 with
MPN-unclassifiable. Patients with PV had a median diagnosis delay of 456
days (range 0-2650 days) and 26% had potentially preventable events. Patients
with ET had median diagnosis delay of 823 days (range 0-8731 days) and 23%
had potentially preventable thrombotic events including 2 patients with multiple
events. Patients with PMF had a median diagnosis delay of 196 days (range
0-3684 days) and 12% had potentially preventable thrombotic events. In MPN-
U the median diagnosis delay was 1371 days (range 42-3255) and 31% of
patients had potentially preventable adverse events.
Summary/Conclusions: Over 5.5 years we identified 143 patients with a new
diagnosis of Ph-negative MPN within our centre. The overall median diagnosis
delay was 723 days (0-8731) with delays of more than 12 months in ET, PV
and MPN-U, and more than 6 months in PMF. 21% of patients had potentially
preventable thrombotic events and 2.8% had potentially preventable haemor-
rhagic events. Earlier recognition of FBC abnormalities consistent with MPN
should result in earlier referral for specialist haematological management which,
with earlier intervention, would be expected to prevent many thrombo-haemor-
rhagic complications and reduce MPN-associated morbidity and mortality.
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LONG-TERM AND LOW-DOSE BUSULFAN IS SAFE AND EFFECTIVE IN
ELDERLY PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
R. Renso1,*, A. Aroldi1, P. Pioltelli1, C. Gambacorti-Passerini1,2,3, E. M. Elli1
1Hematology Division, 2Clinical Research Unit, Hematology, San Gerardo Hos-
pital, 3Department of Medicine and Surgery, University of Milano-Bicocca, Mon-
za, Italy
Background: Therapeutic options for elderly patients (pts) with Essential
Thrombocythemia (ET) resistant or intolerant to hydroxyurea (HU) are limited.
Busulfan (BU) is a possible second-line treatment, but conventional schedule
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(starting dose of 14mg/week up to obtain the complete hematological response
CHR) is associated with high risk of leukemic transformation and second malig-
nancies.
Aims: We analysed efficacy, toxicity, risk of Myelofibrosis (MF) and leukemic
evolution in 31 of 352 ET pts collected in our database, treated with an alter-
native long-term schedule of BU, defined by low-starting dose (4-6mg/week)
up to CHR (evaluated according to ELN response criteria), followed by dose
de-escalation overtime.
Methods: Non parametric tests, such as Mann-Whitney, Pearson Chi-square
and Fischer’s exact tests, were used for statistical analysis of continuous and
categorical variables. Survival curves were calculated by Kaplan-Meier method
and compared with Log-rank (Mantel-Cox) test.
Results: 27/31 pts were evaluable for analysis (8 male, 19 female). Median
age at diagnosis and at BU start were 71,3 and 79 years (yrs) respectively. We
found these driver mutations: JAK2V617F in 15 pts (55.6%), Calreticulin in 8
pts (29,6%) and MPL in 1 patient (3,7%); 3 pts (11,1%) were triple negative.
IPSET score at diagnosis was low-intermediate in 17 (63%) and high in 10
(37%) pts. 26 pts started BU as 2nd line treatment: 11 (42,3%) were intolerant
and 15 (57,7%) were resistant to HU respectively. Only one received BU as 1st
line treatment. They received BU for a median time of 47,67 months (range:
1,48 – 94,42). The median cumulative BU dose was 453mg (range: 32-1032).
25/27 pts (92,6%) obtained CHR, after a median time of 191 days. 6 pts (22,2%)
presented hematological (5) and extra-hematological (1, cutaneous) side
effects. Overall, 12 pts (44,4%) stopped BU: 4 for hematological toxicity, 4 for
disease progression, 2 for drug intolerance/resistance; the remaining 2 not for
drug-related side effects. After a median follow-up of 9,74 yrs (range: 1,82-
27,05), 9 (33,3%) and 2 (7,4%) pts presented MF evolution and leukemic trans-
formation respectively. The MF-free-survival (MFS) was 48,8% at 15 yrs and
appears to be significantly lower than the entire series of ET pts (77,4% at 15
yrs; p=0,002; figure 1). Median MFS was 12,7 yrs for pts treated with BU,
whereas it was not reached at 15 yrs in the entire series of ET. There were no
statistically significant differences in principal hematological and clinical features
between “evolving-MF pts” and “not evolving-MF pts”, apart from lower hemo-
globin value at BU start (11,5 vs 13,05 g/dl; p=0,05) and lower time of exposition
to BU in MF subgroup (16 vs 53,7 months; p=0,026). Drug cumulative dose
was the same in the two subgroups. Thrombotic complication after BU start
were observed in 3 pts (11,1%). During time of analysis 5 pts (18,5%) died.
Figure 1.
Summary/Conclusions: Our experience with an alternative long-term and
low-dose BU administration is safe and effective in elderly patients with ET.
92.6% of them obtained CHR, with acceptable hematological and extra-hema-
tological toxicity. We noticed a high rate of MF evolution with respect to global
ET population, while the risk of leukemic transformation seems to be limited,
considering that these pts were elderly and previously treated. Predictive factors
for MF evolution should be analysed and confirmed in larger series.
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DIFFERENCES IN JAK2V617F POSITIVE PATIENTS WITH AND WITHOUT
THROMBOSIS ACCORDING TO DIAGNOSIS, AGE, SEX AND V617F
ALLELE BURDEN
I. Horvat1,*, M. Radic Antolic1, P. Roncevic2, R. Serventi Seiwerth2, R. Zadro1
1Department of Laboratory Diagnostics, 2Department of Hematology, University
Hospital Center Zagreb, Zagreb, Croatia
Background: Thrombosis is one of the most frequent events in Ph(-) myelo-
proliferative neoplasms and the reasons for that are still under investigation.
Aims: The aim of this study was to find out if there is difference in frequency
and type of thrombosis in JAK2 V617F positive patients according to their diag-
nosis, age, sex and V617F allele burden.
Methods: One hundred and eighty two JAK2 V617F positive patients diag-
nosed with polycythemia vera (PV) N=63, essential thrombocythemia (ET)
N=83, and primary myelofibrosis (PMF) N=36 were included in the study.
Patients in each group were additionally divided according to sex, age at diag-
nosis and first thrombosis. V617F allele burden was quantified in peripheral
blood granulocyte DNA by real time PCR established by Larsen et al. Br J
Haematol 2007;136:745.
Results: Among 182 patients observed, 66 (36%) experienced thrombosis,
with arterial thrombosis being twice more frequent than venous thrombosis in
all 3 studied groups. In ET group there was statistically significant difference in
sex distribution (proportion of females=0.71), p<0.001. Statistically significant
difference in age at diagnosis was observed between ET and PV/PMF patients
without thrombosis (p<0.001); the youngest patients were those in ET group.
The age at diagnosis of ET patients with thrombosis (65 years, range 23-92)
was statistically different compared to ET patients without thrombosis (50 years,
range 21-83), p=0.002. Our study showed that V617F allele burden in patients
without thrombosis was statistically significantly different between ET (17.2%,
range 4.2-55.2) compared to PV (43%, range 1.7-99.9) and PMF (37.1%, range
1.4-99.7), p<0.001. The same statistically significant difference for V617 allele
burden was established in patients with thrombosis between ET patients (19%,
range 1.4-84.5) and PV and PMF patients (42.5%, range 8.9-97.2 and 48.8%,
range 1.6-99.8, respectively), p<0.001.
Summary/Conclusions: Our results confirm that arterial thrombosis is more
frequent than venous thrombosis in JAK2 V617F positive patients. Female sex
was prevalent only in ET group. The age at diagnosis in all studied groups was
similar except for ET patients without thrombosis. There was no difference in
the frequency and type of thrombosis among ET, PV and PMF patients with
high heterogeneity in V617F allele burden between all studied groups regard-
less of the occurrence of thrombosis.
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PROTECTION AGAINST DEVELOPMENT OF B CELL LYMPHOMA BY
TETRASPANIN CD37
C. de Winde1, S. Veenbergen1, K. Young2, M. van den Brand1, A. van der
Schaaf1, S. Elfrink1, H. van Krieken1, C. Figdor1, S. van Deventer1, B. Scheijen1,
A. Van Spriel1,*
1Radboud University Medical Center, Nijmegen, Netherlands, 2MD Anderson
Cancer Center, Houston, United States
Background: B cell non-Hodgkin lymphoma, worldwide the most common
hematological malignancy, remains a clinical problem. The molecular events
leading to B cell lymphoma are only partially defined. CD37 is a member of the
tetraspanin superfamily that is highly expressed on mature B cells and is
required for optimal GC function and long-lived antibody production.
Aims: We investigated the function of tetraspanin CD37 in the development of
B cell lymphoma.
Methods: A combination of studies was performed in mouse models (CD37/IL-
6-deficient mice), and studies of DLBCL patient material using biochemical,
immunological, genetic and microscopical approaches.
Results: We provide evidence that deficiency of CD37 induces the develop-
ment of B cell lymphoma in vivo. Cd37-deficient mice develop germinal center-
derived B cell lymphoma in lymph nodes and spleen with higher incidence than
Bcl2-transgenic mice. We discovered that CD37 interacts with SOCS3, and
when absent drives tumor development through constitutive activation of the
IL-6 signaling pathway. The importance of the IL-6 pathway was confirmed by
investigating Cd37xIl6 double knock-out strains that were fully protected against
lymphoma development. Our unpublished data shows discovery of inactivating
CD37 mutations in patients with DLBCL. Importantly, loss of CD37 on neoplastic
cells in patients with diffuse large B cell lymphoma (DLBCL) is directly correlated
with activation of the IL-6 signaling pathway and with worse progression-free
and overall survival.
Figure 1.
Summary/Conclusions: Together, this study identifies tetraspanin CD37 as a
novel tumor suppressor that directly protects against B cell lymphomagenesis,
and provides a strong rationale for blocking the IL-6 pathway in patients with
CD37-negative B cell malignancies as therapeutic intervention.
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CONCOMITANT DUAL ABLATION OF BLIMP1 AND P53 IN B-CELLS AS A
NOVEL IN VIVO MODEL FOR HIGH-GRADE B-CELL LYMPHOMA
A. Sacco1, Y. Kawano2, M. Moschetta3, J. Park3, O. Zavidij3, D. Huynh3,
M. Reagan4, Y. Mishima3, E. Morgan5, S. Takagi3, S. Manier3, G. Rossi1,
L. Imberti1, K. Wong3, R. Carrasco3, M. Shipp3, I. Ghobrial3, A. Roccaro1,*
1ASST Spedali Civili di Brescia, Brescia, Italy, 2Kumamoto University, Kumamo-
to, Japan, 3Dana-Farber Cancer Institute, Boston, 4Maine Medical Center, Uni-
versity of Maine, Scarborough, 5Brigham and Women’s Hospital, Boston, United
States
Background: B-Lymphocyte-Induced Maturation Protein-1 (BLIMP-1)- and
p53-inactivation contributes to the pathogenesis of a wide spectrum of malig-
nancies, including diffuse large B-cell lymphomas. Nevertheless, there is lack
of in vivo models that may be used for a better understanding of the biology
and genomics of high-grade B-cell lymphomas characterized by dual loss of
both BLIMP-1 and p53.
Aims: 1) To develop and characterize a transgenic mouse model of BLIMP-
1/p53 dual loss in B cells; 2) To provide an in vivo model that mirrors human
ABC-DLBCL phenotype.
Methods: Cre recombinase under the control of CD19 promoter (C57BL/6
CD19Cre/Cre) mice were crossed with either C57BL/6 BLIMPflox/floxor C57BL/6
p53flox/floxmice to achieve deletion of BLIMP or p53, respectively, in B cells.
Secondly, CD19Cre/Cre BLIMPflox/floxmice were crossed with
CD19Cre/Crep53flox/floxto achieve dual deletion of BLIMP and p53 in B cells
(CD19Cre/CreBLIMPflox/floxp53flox/flox: referred as CD19/Bl-/p53-). Transgenic
experimental mice (CD19/Bl-/p53-) where characterized for clonal B cell infil-
tration using immunohistochemistry, flow cytometry, Southern Blotting, whole
exome sequencing. MTT assay was used to test BTK-inhibitor-dependent cyto-
toxicity using CD19/Bl-/p53-derived B220 cells.
Results: CD19/Bl-/p53- mice presented with diffuse lymphadenomegalies,
splenomegaly, hepatomegaly (100%, 90.3% and 77.4%, respectively). Other
clinical manifestations included presence of ascites and hind lymb paralysis
(12.9% and 19.3%, respectively). The CD19/Bl-/p53- showed worse survival
compared to Bl-/p53- mice non-expressing the CD19/Cre recombinase,
CD19/p53-, or CD19/Bl- (363, 469.5, 460.5, and 770 days, respectively). H.E.
staining of CD19/Bl-/p53—derived lymph nodes, defined a nodal architecture
with a monomorphic population of large sized atypical lymphoid cells, multiple
basophilic medium sized, paracentrally situated nucleoli. A “starry sky” pattern
was also observed. Features were compatible with a high-grade lymphomas.
IHC analysis confirmed positivity for B220 staining (TdT, Bcl6, CD138 and CD4,
CD8 negative). Tumors were confirmed to be B220+/IgM+, with either Igk- or
Ig-lambda-restriction as demonstrated by flow cytometry; and either mono- or
bi-clonal, as demonstrated by Southern blotting. Whole exome sequencing was
performed from B220+ selected cells obtained from pathological lymph nodes
of CD19/Bl-/p53- mice and identified 143 SNVs. Non-synonymous somatic
mutations were mapped on genes involved in the regulation of focal adhesion,
PDGF signaling, p53-downstream pathway, and lipoprotein metabolism. B220+
cells selected from CD19/Bl-/p53—derived lymph nodes were implanted s.q.
into recipient SCID/Bg mice, and presented with 100% engraftment, with a
monomorphic lymphoid infiltration of B220+ and IgM+ cells. B220 positive cells
were selected from the s.q. tumor and intravenous injected into recipient
SCID/Bg (n: 10) and BL/6 mice (n: 10). Engraftment was demonstrated in all
the mice, where hepatomegaly, splenomegaly and hind limb paralysis were
observed. Infiltration of B220+ cells was documented within bone marrow, liver
and spleen. Finally, we found that B220+ cells selected from lymph nodes har-
vested from CD19/Bl-/p53-mice were sensitive to ibrutinib.
Summary/Conclusions: Dual inactivation of p53 and BLIMP in B-cells sup-
ports a novel in vivo model that recapitulates what seen in patients with ABC-
DLBCL, thus providing a novel model for studying high-grade B-cell lymphoma
driven by BLIMP-1/p53 dual loss-induced c-Myc expression.
E1355
IDENTIFICATION AND CHARACTERISATION OF THE LYMPHOMA
INITIATING CELL (LIC) POPULATION IN AN ALCL MOUSE MODEL
S. Kreutmair1,*, C. Klingeberg1, G. Andrieux2, A. Keller1, C. Miething1,
D. Pfeifer1, M. Follo1, H. Busch2, M. Boerries2, J. Duyster13, A.L. Illert13
1Hematology, Oncology and Stem Cell Transplantation, University medical cen-
ter Freiburg, 2Institute of Molecular Medicine and Cell Research, Freiburg,
3German Cancer Consortium (DKTK) and German Cancer Research Center
(DKFZ), Heidelberg, Germany
Background: In 60% of anaplastic large cell lymphoma (ALCL) patients a
translocation t(2;5) (p23;q35) is found, which results in NPM-ALK fusion gene
expression and constitutive activation of the ALK tyrosine kinase. Immunophe-
notypic characterization of human ALCLs revealed highly CD30-positive cells
of T- or Null-cell-origin.
Aims: However, the origin of the lymphoma initiating cell population as well as
NPM-ALK signal transduction in course of the disease remains unclear and
needs to be characterized. 
Methods: In this regard, we established a retroviral murine bone marrow trans-
plantation model resembling human ALCL. Therefore we use an inducible
Cre/loxP system where NPM-ALK expression is restricted to early T-cells. We
infected bone marrow of Lck-Cre transgenic mice with our MSCV-Stop-NPM-
ALK-IRES-EGFP vector and transplanted it into lethally irradiated recipient mice.
With a latency of 4-5 months, mice developed CD30-positive lymphomas and
died from neoplastic T-cell infiltration of lymphatic organs and bone marrow.
Results: Immunophenotypic analysis confirmed T-cell origin of the lymphomas
with a heterogeneous compound of all T-cell stages with mainly CD4-/CD8-
double negative (DN) T-cells including all DN T-cell stages as well as
hematopoietic stem cells and lymphatic precursors. Staining of the T-cell sub-
populations demonstrated high NPM-ALK expression in immature CD4-/CD8-
double negative T-cells and undifferentiated CD4+/CD8+ double positive T-cells
with highest expression of proliferation marker Ki67 as well as the activation
marker CD30 in the CD4-/CD8- double negative T-cells. Interestingly, the CD4-
/CD8- double negative lymphoma population further more aberrantly expressed
the T-cell receptor alpha/beta chain, which may allow these early T-cells to
establish a systemic lymphoma. To further proof this hypothesis and identify
the LIC population we performed secondary transplantations with sorted DN
and T-cell subpopulations. Indeed, only mice transplanted with DN3 and DN4
lymphoma cells could give rise to secondary lymphomas, whereas sorted DN1,
DN2, CD4+, CD8+ or CD4+/CD8+ transplanted lymphoma cells failed to estab-
lished serial lymphomas in recipient mice. Immunophenotypic analyses of sec-
ondary lymphomas caused by transplantation of the DN3 and DN4 lymphoma
subpopulation demonstrated double positive CD4+/CD8+ cells as well as single
positive CD4+ and CD8+ cells next to the DN3/DN4 population. However, we
were not able to detect redifferentiation of the DN3/DN4 cells to more immature
DN1/DN2 lymphoma cells. To substantiate our findings, we performed microar-
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ray analyses. Indeed, heatmap analyses revealed wide pattern similarities in
the DN3 with DN4 lymphoma subpopulation in contrast to the DN1 and DN2
lymphoma cells. Interestingly, DN3 and DN4 cells show different expression
profiles of stemness genes resembling early progenitor cell distribution pat-
terns.
Summary/Conclusions: In summary, our results highlight the existence of a
lymphoma initiating stem-cell-like population originated within the DN3/DN4
lymphoma cell population in a highly relevant NPM-ALK positive CD30-express-
ing ALCL mouse model, thereby giving the opportunity to test the eradication
of the LIC with established and new therapeutical approaches.
E1356
HSP110 SUSTAINS MYD88-DEPENDENT NFKB SIGNALING IN ACTIVATED
B CELL DIFFUSE LARGE B CELL LYMPHOMA
C. Boudesco1, S. Causse1, A. Hamman2, E. Verhoeyen3, L. Martin1, F. Jardin4,
T. Fest5, O. Wolz6, A. Weber6, C. Garrido2, G. Jego1,*
1University of Burgundy, 2INSERM 1231, Dijon, 3INSERM U1111, Lyon,
4INSERM 918, Rouen, 5INSERM 911, Rennes, France, 6University of Tübin-
gen, Tübingen, Germany
Background: Diffuse large B cell lymphoma (DLBCL) is an aggressive lym-
phoproliferative disorder of B lymphocytes accounting for 30% of adult Non
Hodgkin Lymphoma (NHL). Among DLBCL, Activated B Cell – DLBCL (ABC-
DLBCL) is the most aggressive form and has a poor prognosis. Heat-shock
proteins (HSPs) are molecular chaperons highly expressed in cancer cells and
implicated in resistance to radio- and chemotherapy. Therefore, HSPs are envi-
sioned as therapeutic targets in many cancers. Among the different HSPs,
HSP110 has been recently identified as a pro-survival factor in germinal cen-
ter-derived DLBCL (GC-DLBCL), through stabilization of the GC-DLBCL onco-
gene Bcl-6.
Aims: Here, we have explored if HSP110 could also be involved in the survival
of the most aggressive form of DLBCL
Methods: The study was performed with ABC-DLBCL patient samples and
several cell lines. ShRNA specific for HSP110 was introduced through a lentivi-
ral vector designed to infect highly efficiently non-permissive B cell lines.
Results: We observed a high HSP110 expression in all ABC-DLBCL patient
samples, compared to normal reactive lymph nodes by using IHC staining of
ABC-DLBCL tumor sections and transcriptional analysis of ABC-DLBCL patient
tumors. Furthermore, shRNA silencing of HSP110 decreases the survival of
several ABC-DLBCL cell lines, and downregulates the expression of pro-sur-
vival factors such as BcL2 and BcL-XL. SiRNA silencing of HSP110 abrogates
NF-kB signaling, which is the major oncogenic pathway in ABC-DLBCL cell
lines. In accord with these results, over-expression of HSP110 in DLBCL and
non-DLBCL cell lines increases NF-kB signaling, indicating a tight interplay
between HSP110 and the NF-kB pathway. Using immune-precipitation in DLB-
CL cell lines and DuolinkTM assays, we identified an in vitro and in cellulo inter-
action between HSP110 and Myd88, a critical protein of the NF-kB pathway
that bears an activated mutation in many ABC-DLBC patients and that is
responsible for lymphoma aggressiveness. Finally, we demonstrate that
HSP110 stabilizes the wild type as well as the mutated form of Myd88, therefore
facilitating the chronic NF-kB pathway activation in those cells.
Summary/Conclusions: In conclusion, we identified HSP110 as a regulator
of NF-kB signaling through MyD88 stabilization in ABC-DLBCL. This finding
highlights HSP110 as a new potential therapeutic target in DLBCL and poten-
tially in other hematological malignancies driven by mutated MyD88 as Walden-
strom macroglobulinemia.
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STAT3 ACTIVATION MEDIATES CD8+/CD16+/CD56- T-LGLL NEUTROPENIA
THROUGH FAS LIGAND SECRETION
G. Barilà1,2,*, A. Teramo1,2, G. Calabretto1,2, M. Leoncin1,2, C. Vicenzetto1,2,
A. Liço1, A. Cabrelle2, S. Carraro1, V. Trimarco1, M. Facco12, F. Piazza1,
L. Trentin1,2, G. Semenzato1, R. Zambello1,2
1Dept of Medicine, Hematology and Clinical Immunology section, Padua Uni-
versity School of Medicine, 2Venetian Institute of Molecular Medicine, Padua,
Italy
Background: T-cell large granular lymphocyte leukemia (T-LGLL) is a rare
chronic lymphoproliferative disorder characterized by the clonal expansion of
CD3+ Large Granular Lymphocytes (LGL). In addition to the most common
CD8+ T-LGL leukemia, less frequent LGL proliferations with CD4+/CD8-/+dim
phenotype (CD4+ T-LGL leukemia) exist, which are characterized by indolent
clinical course. Somatic STAT3 mutations determining constitutive activation
have been recently reported in a proportion of approximately 40% of patients,
with no clear correlation with the occurrence of neutropenia, whose pathogen-
esis is likely to be multifactorial, comprising both humoral (i.e. soluble FAS lig-
and secretion) and cell-mediated mechanisms.
Aims: The aim of this work was to evaluate whether 1) STAT3 mutations might
be associated with a distinctive LGL immunophenotype and/or indicative for
symptomatic disease and 2) STAT3 activation is directly related to the devel-
opment of neutropenia.
Methods: A cohort of 101 patients affected by T-LGLL according to WHO cri-
teria were screened for STAT3 mutation by Sanger sequencing and PCR ARMS
assay. All the samples were analysed by flow for CD3, CD4, CD8, CD16, CD56
and CD57 antigen. STAT3 tyr 705 levels were studied by Western blot. FAS
ligand mRNA levels were analysed by RT-PCR Assay.
Results: By flow we observed that 68 out of 101 patients (67.3%) were char-
acterized by CD3+/CD8+/CD4- expression (CD8+ T-LGLL), while the remaining
33 patients (32.7%) were CD3+/CD4+/CD8+dim/neg (CD4+ T-LGLL). All STAT3
mutated (n=38) and almost all neutropenic (38 out of 39) patients belonged to
CD8+ T-LGL leukemia (n=68), while among CD4+ T-LGL leukemia (n=33) no
STAT3 mutated and only one neutropenic patient (1 out of 33, 3%) was found.
Among CD8+ T-LGLL, immunophenotypic signature CD16+/CD56- was both
associated to the presence of neutropenia and STAT3 mutation (37 out of 41,
90.2%; c2=49.5, p<0.0001 and 37 out of 41, 90.2%; c2=49.5, p<0.0001 respec-
tively). Furthermore, by western blot we showed that high STAT3 tyrosine phos-
phorylation observed in LGL obtained by CD8+ T-LGLL patients belonging to
CD16+/CD56- subgroup was significantly higher as compared with other
immunophenotypic groups. Provided this relationship between STAT3 muta-
tion/activation and neutropenia, by RT-PCR we analysed Fas ligand expres-
sion, showing higher transcription levels in CD16+/CD56- CD8+ T-LGLL
patients as compared to the not neutropenic patients belonging to the other
immunophenotypes, both CD8+ T-LGLL and CD4+ T-LGLL (7.66±0.87,
2.45±0.22 and 2.35±0.28 arbitrary units, respectively; p<0.01). To confirm this
relationship, in patient’s PMBCs treatment with STAT3 inhibitor Stattic
decreased both STAT3 phosphorylation and Fas ligand transcription as com-
pared to the untreated conditions. In addition, IL-6 and IL-15 stimulation (which
are known STAT3 activator) increased Fas ligand transcription levels (1.59-
and 2.01-fold after IL-6 and IL-15, respectively) which is prevented by con-
comitant Stattic treatment.
Summary/Conclusions: Our results provide evidence that STAT3 mutation
and activation is mostly restricted to neutropenic CD8+ T-LGLL patients
equipped with the CD16+/CD56- signature. The relationship between STAT3
activation and neutropenia FAS ligand related further supports to approach
STAT3 inhibition as therapeutic strategy in symptomatic CD8+/CD16+/CD56-
LGLL patients, obtaining the dual results of inducing apoptosis in leukemic
LGL together with inhibition to FAS ligand mediated neutropenia.
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CYCLIN D2 OVEREXPRESSION RECAPITULATES MANTLE CELL
LYMPHOMA IN MICE
T. Pieters1,*, S. T’Sas1, J. Morscio1, F. Matthijssens1, K. Lemeire1, T. Hochep-
ied1, B. Lintermans1, L. Reunes1, G. Berx1, J. Haigh2, S. Goossens1, P. Van Vlier-
berghe1
1Ghent University, Ghent, Belgium, 2Monash University, Melbourne, Australia
Background: Mantle cell lymphoma (MCL) is a highly aggressive subtype of B-
cell lymphoma that is characterized by a poor response to current treatment reg-
imens. Most MCLs carry a prototypical translocation, t(11;14), which juxtaposes
the CCND1 gene towards the immunoglobulin heavy chain (IGH) locus, resulting
in cyclin D1 overexpression. Notably, a subset of MCL patients are cyclin D1
negative but instead overexpress cyclin D2 (encoded by CCND2) as a conse-
quence of recurrent genomic rearrangements involving the CCND2 locus.
Figure 1.
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Aims: Here, we aim to recapitulate MCL in a mouse model of hematopoietic-
specific overexpression of cyclin D2. Next, we want to use this preclinical mouse
model to evaluate novel therapeutic strategies for the treatment of MCL.
Methods: To evaluate if cyclin D2 could act as a bona fide oncogene in the
pathogenesis of MCL, we developed a conditional R26-driven Ccnd2 overex-
pression mouse model. For this, we used a targeting vector that contained a
floxed stop cassette followed by the Ccnd2 gene and a EGFP/luciferase
reporter, which was subsequently targeted in mESCs using recombinase-medi-
ated cassette exchange (RMCE).
Results: The resulting R26-Ccnd2 mice were crossed to VaviCre mice to
enable biallelic R26-driven overexpression of Cyclin D2 in the entire hematopoi-
etic system. Interestingly, these mice developed large lymphomas starting from
36 weeks of age (Figure 1A), with tumor cells showing characteristic MCL
immunophenotype (CD19+,CD5+,CD23-). Of note, these malignant B-cells
were monomorphic small-sized cells with slightly irregular hyperchromatic nuclei
and disseminated into other organs such liver, spleen and the gastrointestinal
tract (Figure 1B). In addition, the infiltrating B-cell lymphoma cells were SOX11
positive, as evaluated by IHC, suggesting that these tumors indeed reflect a
murine form of MCL. Noteworthy, the MCL cells from this mouse model also
contain a luciferase reporter, allowing accurate in vivo tracing of tumor cells in
xenograft experiments. These xenograft experiments can be used as preclinical
models, in which bioluminescence is used to asses the tumor burden and to
monitor tumor regression upon drug treatment.
Summary/Conclusions: In conclusion, our preliminary data suggest that mod-
eling cyclin D2 in mice, mimicking the elevated cyclin D2 levels of human MCL
patients with translocations involving the CCND2 locus, is sufficient to form MCL.
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HDAC6 INHIBITION INCREASES CD20 LEVEL BY STIMULATING
TRANSLATION OF CD20 MRNA
A. Graczyk-Jarzynka1,*, M. Bobrowicz1, M. Dwojak1, J. Stachura1, E. Berthel2,
B. Pyrzyńska1, M. Siernicka1, N. Miązek1, P. Zapała1, N. Dalla-Venezia2,
J. Gołąb1, M. Winiarska1
1Department of Immunology, Medical University of Warsaw, Warsaw, Poland,
2Centre Léon Bérard – Centre de Recherche en Cancérologie de Lyon, Lyon,
France
Background: HDAC6 (histone deacetylase, isoform 6) is a novel promising
target in hematological malignancies. HDAC6 is an atypical member of HDAC
family that regulates the acetylation status, and thus the functionality of cytosolic
proteins, and has been explored therapeutically for its role in the process of
protein degradation. HDAC6 mediates the transport of protein aggregates to
the autophagic machinery to diminish their cytotoxicity. Thus, the disruption of
the aggresome pathway, similarly to proteasome inhibition, results in a massive
accumulation of misfolded protein aggregates and apoptotic cell death. As this
strategy holds a considerable potential in aggressive B-cell tumors with a high
rate of protein synthesis, HDAC6 inhibitors - are currently being tested in Phase
I and II clinical trials in multiple myeloma and non-Hodgkin lymphoma. The
results of preclinical studies show the increased efficacy of the combination of
HDAC6 inhibitors with proteasome inhibitors in inducing stress-related cell
death. The results of our studies show that HDAC6 inhibition in non-toxic con-
centrations significantly increases CD20 level on a protein level.
Aims: The aim of this study was to elucidate the mechanism of the regulation
of CD20 expression by HDAC6.
Methods: We used qRT-PCR and Dual Luciferase Assays in order to determine
the influence of HDAC6 on CD20 transcription. We used pulse-chase assays
using widely used translation inhibitors – cycloheximide and homoharringtonine.
In order to study the effect of HDAC6 inhibition on global as well as specific de
novo synthesis of CD20 we optimized Click-IT chemistry methods. In order to
study CD20 translation on polysomes we performed polysomes profiling followed
with qRT-PCR. To get an insight into molecular mechanism of increased translation
of CD20 after HDAC6 inhibition we studied the formation of stress granules (SG).
Results: We show that HDAC6 inhibition regulates CD20 level without affecting
its transcription. Moreover, we demonstrate that HDAC6 inhibition increases
translation of CD20 mRNA on polysomes without affecting general synthesis
of novel proteins in the cell. However, our experiments suggest that the
increased translation of CD20 mRNA is not a result of resumed translation of
mRNA stalled in SG.
Summary/Conclusions: Our study shows a new mechanism of the regulation
of CD20 expression by increasing its translation. Moreover, we demonstrate a
new role of HDAC6 protein. This finding has a potential clinical application, as
HDAC6 inhibitor are being widely tested in different hematological malignancies.
Further studies in order to identify other targets for HDAC6 are required.
The work was supported by National Science Center 2013/09/N/NZ3/01407
(MB), 2015/16/T/NZ6/00034 (MB), 2014/13/N/NZ6/02081 (MS), 2015/18/E/
NZ6/00702 (MW), 2013/11/B/NZ5/03240 (BP), Polish Ministry of Science and
Higher Education grant IP2011 060271 (MW), DI2011 021241 (MB), DI
2014007344 (NM) and DI2013 006643 (AD), the Medical University of Warsaw
grant 1M19/PM/112D/14/14 (MB) and 1M19/PM1/16 (AGJ) and Horizon 2020
Programme, project 692180-STREAM-H2020-TWINN-2015 (JG).
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MANTLE CELL LYMPHOMA PATIENTS:RESULTS OF THE LYMA-GENOMIC
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Background: Mantle cell lymphoma (MCL) is an incurable heterogeneous dis-
ease with a median overall survival (OS) of around 4-6 years. There are 3 prog-
nostic groups of patients: a high-risk (HR) group of 15-20% of patients having a
duration of response <1yr after end of treatment (EOT); an intermediate-risk
(IG) group that includes patients remaining in response one year after EOT but
with an incidence of relapse of 10-15%/yr thereafter, other patients defining the
low-risk (LR) group remain in response three years at least. The MIPI score
(age, leukocytosis, PS, stage) helps to classify patients according to their risk
of relapse but it is not currently possible to treat patients according to risk factors.
Investigation of the MCL genomic landscape could help to understand MCL biol-
ogy complexity and build biology-driven medical decisions.
Aims: In the present work, we report a whole-genome copy number analysis
performed with OncoScan® FFPE Assay, a new robust and validated single
nucleotide polymorphism (SNP) array (Foster et al. BMC Med Genomics 2015).
We investigated the prognostic value of somatic recurrent copy number alter-
ations (CNA) detected in 96 young MCL patients treated in the LyMa trial (Le
Gouill et al. Abstract 145, ASH 2016).
Methods: Samples were selected according to material availability. Lymph node
biopsies collected at diagnosis, formalin-fixed and paraffin-embedded were used
to extract DNA, usable even when highly degraded since the OncoScan® FFPE
Assay is optimized for highly degraded FFPE samples. Whole-genome copy
number profiling was analyzed with 50 ng of genomic DNA. TuScan algorithm
(Affymetrix) was used to analyze data. The frequency and prognosis impact of
CNAs were evaluated with univariate analysis of survival data.
Results: Characteristics of the 96 patients were as follow: median age 57y
(41-65), 82% of males, MIPI-low/intermediate/high respectively 19%, 51% and
30%, blastoid morphology in 10%. No significant difference was observed
between these patients and the LyMa patients (n=299). Among the 96 patients,
9 were HR patients with primary refractory disease or early relapse within one
year post-diagnosis while 87 patients remained in response more than one
year after diagnosis (including 64 LR patients who were still in complete remis-
sion more than 30 months after diagnosis). After ASCT, 41 patients (43%) were
randomized in the rituximab maintenance arm and 40 (42%) in the observational
arm. Median follow-up from diagnosis was 61.3 months (1.4-83.2). Overall, 68
recurrently altered regions were observed in 98% of patients. Deletions were
more frequent than amplifications, at 9 vs 3 by patient respectively. HR patients
were associated with TP53del (44%vs14%;p=.04), CDKN2Adel
(56%vs22%;p=.04), 8p11del (44%vs15%;p=.05). Interestingly, we identified in
10 patients duplication of a minimal common region of 5,3 Mb located on chro-
mosome 7p22 and including CARD11. This lesion was associated with low
MIPI (80%vs12%;p<.001), and other gains such as 21q21, 10q11 and 6p21
which together define a favorable subgroup (24% of the cohort). These anom-
alies were significantly more associated with LR patients (87%vs60%;p=.02).
None of the patients with CARD11 duplication (n=10) had relapsed despite the
presence of TP53 in 2 patients or CDKN2A deletion in 3 patients. This translates
into a longer PFS (100%vs70%;p=.02) (fig.).
Figure 1.
Summary/Conclusions: Our study confirms the worse impact of TP53 and
CDKN2A deletion on early relapse in MCL. By contrast, the CARD11 duplication
haematologica | 2017; 102(s2) | 559
Madrid, Spain, June 22 – 25, 2017
is associated with an absence of relapse and thus defines a new group of very
low risk patients. These findings provide important clues for future theranostic-
driven therapies in MCL.
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CLINICOBIOLOGICAL FEATURES OF B-CELL NEOPLASMS WITH CDK6
TRANSLOCATIONS: FREQUENT ASSOCIATION WITH MARGINAL-ZONE
LYMPHOMA, CONTINGENT OF PROLYMPHOCYTIC CELLS AND TP53
ABNORMALITIES. A GFCH STUDY
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Background: Translocation involving the CDK6 gene is a rare but recurrent
abnormality in B-cell neoplasms. Three different translocations have been
described: t(2;7)(p11;q21), which is the most frequent, t(7;14)(q21;q32) and
t(7;22)(q21;q11), leading to juxtaposition of CDK6 gene with IGK, IGH or IGL
locus respectively.
Aims: The Groupe Francophone de Cytogenetique Hematologique (GFCH)
collected 35 chronic B-cell disorders with CDK6 translocation in order to doc-
ument the clinicobiological features of this uncommon aberration.
Methods: Clinical and biological data were gathered at diagnosis when avail-
able. A cytological review was performed by 3 experts in 27/35 cases. FISH
was used to detect IG or TRAD and CDK6 rearrangements, and recurrent
abnormalities frequent in SMZL and CLL (trisomy 3, 12, 18, deletions of ATM,
TP53, 13q14 and 7q22/7q36 loci). TP53 (exons 4-9), NOTCH2 (exon 34), and
IGHV genes were analyzed by Sanger sequencing. Detection of MYD88 L625P
was performed by real-time AS PCR.
Figure 1.
Results: Our cohort included 22M and 13F, with a median age of 71 years.
The involvement of CDK6 was confirmed in all cases. A t(2;7) IGK/CDK6 was
found in 33/35 patients. One case had a t(7;14) IGH/CDK6, and one had a
t(7;14)(q21;q11) involving the TRAD locus. There were 23 (66%) marginal-
zone lymphoma (MZL), including 22 splenic MZL (SMZL) (including the t(7;14)
TRAD), and 1 bronchus MALT type, 7 (20%) unclassified small B-cell lym-
phomas (USBCL) and 5 (14%) chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL) with Matutes score 4/5 (including the t(7;14) IGH). Mor-
phological review showed a contingent of prolymphocytic cells (median: 10%
of lymphoid cells) in 17/27(63%) cases, including 14/19 MZL and 3/4 UBCL
and 0/4 CLL/SLL. The CDK6 translocation was the sole aberration in
9/35(26%). K was complex in 18/35(51%). The most frequent additional abnor-
malities were: del17p (TP53) (51%), del13q (41%), del8p (23%), trisomy 18
(22%), trisomy 3/3q (17%) and trisomy 12 (11%). Deletion of 7q and 11q were
rare (one case of each). TP53 was mutated in 6/22 patients (27%), including
5 with del17p. Overall, 19/29 (66%) tested cases had a TP53 abnormality (del
and/or mutated), which was significantly associated with complex karyotype
(p=0.016) and del13q (p=0.042). MYD88 L625P was detected in 2/22 patients.
No NOTCH2 mutation was found. IGHV analysis showed a preferential usage
of VH4 (8/23, 35%), while VH1 was rare (3/23, 13%, including one VH1-2).
Most carried IGHV with some impact of somatic hypermutation (85%). Median
follow-up was 28 months [0-192]. The median survival was not reached, only
4/32 (12.5%) died. A treatment was undertook in 15/32(47%) cases, with a
median time to first treatment of 13 months. In our series, the CDK6+ MZL
cases differed from classical SMZL by frequent prolymphocytic differentiation
(14/19, 74%), very low incidence of 7q deletion (1/23, 4%), high frequency of
TP53 abnormality (12/23, 52%), absence of NOTCH2 mutation (0/13, 0%),
and a different IGHV repertoire with low frequency of VH1-2 (1/13). The CDK6+
USBCL also had frequently a contingent of prolymphocytes (3/4, 75%), and
showed a genetic profile similar to the CDK6+ MZL (see figure).
Summary/Conclusions: These results, obtained on the largest series to date,
suggest that CDK6 translocation is associated with indolent small B-cell lym-
phomas, mostly SMZL, with distinctive features. However, CDK6 translocations
can also be rarely observed in CLL/SLL. We describe one case involving the
T-cell receptor (TCR) locus, which is a rare event in a B neoplasm. Finally, it is
intriguing that this abnormality involves almost exclusively the IGK locus, and
not the other IG loci, especially IGH which is usually the most frequently
rearranged.
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M.T. Koning1,*, R. Übelhart2, S. van der Zeeuw3, S. Kielbasa3, H. Jumaa2,
M. Vermeer4, R. Willemze4, C. Tensen4, H. Veelken1
1Department of Hematology, Leiden University Medical Center, Leiden, Nether-
lands, 2Department of Immunology, University Medical Center Ulm, Ulm, Ger-
many, 3Sequence Analysis Support Core, 4Department of Dermatology, Leiden
University Medical Center, Leiden, Netherlands
Background: Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
(DLBCL, LT) is a rare and aggressive neoplasm with a primary cutaneous pres-
entation that shares genetic and phenotypic characteristics with DLBCL of acti-
vated B-cell subtype (ABC-DLBCL). Although receptor stereotypes have been
observed, the role of the B-cell receptor (BCR) in DLBCL, LT is largely
unknown. Previous studies on small cohorts suggested that DLBCL, LT
expresses IgM with overrepresentation of IGHV3 alleles and high rates of
somatic mutations. 
Aims: We aimed to elucidate the stereotype of the BCR in DLBCL, LT and to
test for autonomous antigen-independent signaling as described for CLL
(Dühren-von Minden, Nature 2012) and non leg-type ABC-DLBCL (Koning,
AACR 2016 & ASH 2016).
Methods: 8 cases of DLBCL, LT were subjected to RNAseq. Additional
RNAseq data from 6 healthy volunteers (GEUVADIS project), 10 non leg type
DLBCL, and 16 follicular lymphoma were obtained from NCBI publicly available
datasets and collaborators. VDJ/VJ rearrangements and IgM constant regions
were Sanger sequenced for all cases and two granulocyte controls. Lymphoma-
derived, clonal BCR were tested for autonomous signalling activity in the murine
TKO pre-B-cell system (Dühren-von Minden, Nature 2012).
Results: RNAseq analysis demonstrated an IgM isotype in all eight and VJ-kap-
pa in seven DLBCL, LT cases. IGHV3 usage was observed in 7/8 cases; 4 cases
expressed the IGHV3-7 gene. DLBCL, LT BCR were strongly mutated (range:
VDJ 3.1-22.2%; VJ 0.6-13.5%). No intraclonal sequence variation was observed.
Non-synonymous single nucleotide variants (SNV) were observed in the constant
regions of four cases and in IGKC of one additional case, but not in available
granulocyte DNA of two cases with C region mutations or in the other 32 RNAseq
libraries. Constant region mutations were highly specific to DLBCL, LT as com-
pared to other DLBCL (p=0.0018) and follicular lymphoma (p=0.0013). In contrast
to ABC DLBCL, V(D)J BCR of DLBCL, LT on a murine constant region backbone
did not induce antigen-independent calcium flux in TKO cells upon induction of
functionality of the BCR signalling cascade by tamoxifen.
Summary/Conclusions: Our data identify a clearly stereotyped receptor in
DLBCL, LT. In contrast to CLL and ABC-DLBCL, BCR stereotypy was not asso-
ciated with autonomous BCR signalling activity using a murine IgM backbone.
The pathogenic potential of the novel constant region mutations for BCR activity
in DLBCL, LT warrants further functional studies.
E1363
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Background: NR4A1 (Nur77) belongs together with NR4A2 (Nurr1) and
NR4A3 (NOR-1) to the Nur77 family of nuclear orphan receptors. As immediate
early- or stress response genes their expression is diverse as it is the cellular
outcome upon activation. Recently, there has been attributed a pivotal role to
NR4A1 and NR4A3 as tumor suppressors in AML in humans and mice. In our
comprehensive NR4A expression analysis in various lymphoma entities we
demonstrated a significant reduction of NR4A1 expression in aggressive lym-
phomas, which was associated with poor cancer-specific survival. Moreover,
ectopic expression of NR4A1 in aggressive lymphoma cells resulted in induction
of apoptosis.
Aims: In order to better dissect the role of Nr4a1 in lymphoid malignancies, we
used a Myc-driven mouse model of lymphomagenesis and crossed the EµMyc
mouse with the Nr4a1-/- mouse. Survival and tumor formation were monitored
and RQ-PCR was performed on selected tumor specimens, whereby genes,
found to be associated with NR4A1 expression in the publicly available gene
expression data set of DLBCLs generated by Lenz et al., were taken. Moreover,
the driver-function of Nr4a1 in lymphomagenesis at the premalignant stage
was investigated by using apoptotic assays and by carrying out transplantations
of tumor cells into wt recipients.
Methods: Kaplan Meier analysis was performed for survival and tumor forma-
tion in EµMyc Nr4a1+/+ (n=134), EµMyc Nr4a1-/- (n=84) and EµMyc Nr4a1+/-
(n=59), respectively. For RQ-PCR selected tumor specimens from wt and
EµMyc mice with (n=14) and without (n=17) Nr4a1 loss were used. For inves-
tigation of the role of Nr4a1 at the premalignant stage, mice aged 4 weeks (n=4
per genotype) were sacrificed and AnnexinV staining and cleaved-caspase3
assay were performed on cells isolated from the spleen and bone marrow. In
vivo tumor formation was induced by tumors derived from EµMyc Nr4a1+/+
(n=8) and EµMyc Nr4a1-/- (n=11) mice injected into the tail vein of wt mice.
Kaplan Meier analysis was used for monitoring survival and tumor formation,
and FACS analysis for analysis of bone marrow, spleen and tumor, respectively. 
Results: EµMyc Nr4a1-/- mice showed decreased survival with a median of
92 days compared to EµMyc Nr4a1 +/+ with median survival of 123 days
(p<0.001) and tumors developed faster with a median of 45 days for EµMyc
Nr4a1-/-, vs 107 days for EµMyc Nr4a1 +/+; p<0.001. Both, survival (medi-
an=101 days; p=0.037) and tumor formation (median=66 days, p=0.001) gave
intermediate values for EµMyc Nr4a1 +/- mice. Furthermore, EµMyc Nr4a1+/+
exhibited induction of apoptosis in all investigated B cell subpopulations at the
premalignant stage, whereas apoptosis was significantly diminished in EµMyc
Nr4a1-/- mice. RQ-PCR showed that several genes involved in immunoregu-
lation and Nf-κB target genes were upregulated in EµMyc Nr4a1-/- compared
to EµMyc Nr4a1+/+. Last, tumor formation upon i.v. injection showed that
tumors with Nr4a1 loss engraft faster than tumors derived from mice without
Nr4a1 loss (25 days vs 38 days; p=0.009) and lead to a decreased number of
inflammatory cells in the tumor. 
Summary/Conclusions: Our results clearly demonstrate the influence of
Nr4a1 loss on tumor formation and consequently survival in a Myc-driven model
of lymphomagenesis. Importantly, Nr4a1 seems to impact cell death early in B
cell development, even ahead of malignant transformation. Additionally, Nr4a1
seems to be involved in driving immune responses towards an anti.-inflamma-
tory, tolerogenic phenotype, thereby facilitating tumor growth and in altering
the tumor environment. Collectively, these data underpin the tumor suppressive
function of Nr4a1 in aggressive lymphomas.
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Background: Mantle cell lymphoma (MCL) presents as a highly disseminated
B-Cell malignancy, accounting for about 6% of all non-Hodgkin lymphomas.
Genetically, MCL is characterized by the t(11;14)(q13;q32) translocation, leading
to the overexpression of the cell cycle regulator Cyclin D1. The disease is asso-
ciated with short responses to current standard therapies and a great need for
new therapeutic strategies. Interestingly, the PI3K/mTOR pathway has emerged
as a promising therapeutic target in MCL, as cell lines and patients have shown
substantial response rates to rapamycin and analogs.
Aims: The aim of this study is to functionally dissect the role of individual
PI3K/mTOR pathway genes by performing a shRNA-based screen in geneti-
cally defined primary murine MCL tumor cells. Hereby, we want to identify syn-
thetic lethal genes for Cyclin D1 and novel molecular dependencies in Cyclin
D1-driven lymphomagenesis, thereby establishing novel potential therapeutic
targets in MCL.
Methods: We have developed a new mouse model for MCL using Eµ-myc
transgene mice that overexpress the MCL hallmark lesion Cyclin D1, as well
as the reverse tet transactivator for inducible transgene expression. Using pri-
mary MCL tumor cell lines derived from this model as a platform, we performed
shRNA loss-of-function screen entailing a two colored, antibiotic selectable and
tet-inducible retroviral shRNA expression vector system. A shRNA library tar-
geting more than 300 different PI3K related genes was introduced into primary
murine MCL cells. After induction of shRNA expression by addition of Dox,
shRNA representation in knockdown and control cells was deconvoluted by
deep sequencing to identify differentially selected shRNAs.
Results: The shRNA screen identified more than 50 strongly (> than 4 fold)
differentially regulated genes affecting MCL tumor growth and survival. We
identified numerous targets within the PI3K pathway and the molecular depend-
ency on this pathway was in line with the observed high sensitivity of these
cells towards pharmacological mTOR inhibition. Individual shRNA knockdown
experiments confirmed the newly identified candidate genes including compo-
nents of the lipid second messenger system, such as diacylglycerol kinase iso-
form alpha (Dgka) and gamma (Dgkg). Knockdown of these lipid kinases by
three or two different hairpins lead to decreased cell proliferation. Dgka knock-
down was further validated on protein level by Western Blot analysis. Further-
more, two small molecule inhibitors targeting Dgka (R59022 and Ritanserin)
significantly decreased cell viability.
Summary/Conclusions: Using an unbiased shRNA screen of more than 300
genes contained in the PI3K pathway, we were able to identify a range of pro-
teins that significantly impaired cell proliferation and cell viability in Cyclin D1-
driven lymphoma cells. Among the candidate genes were components of lipid
second messenger pathways, such as class I diacylglycerol kinases alpha and
gamma, which could be successfully validated in downstream analyses.
Dependence on these kinases was further demonstrated using two different
small molecule inhibitors, indicating an important role for the diacylglycerol sec-
ond messenger system in MCL growth. Their mode of action on the PI3K path-
way, especially in regard to Cyclin D1, will be further investigated in murine
and human MCL cells. Furthermore, additional newly identified candidate genes
will be further explored to characterize their role in Cyclin D1-driven lymphoma-
genesis, with the aim of identifying novel therapeutic targets in this difficult-to-
treat disease.
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Background: cHL can be cured in the majority of cases. However, ~10–20%
patients die of the lymphoma after relapse or progressive disease. There are
unmet needs for understanding the mechanisms that cause cHL relapses, for
development of new prognostic/predictive markers and effective targeted ther-
apies. Comprehensive genetic characterization and advance in understanding
the molecular pathology of cHL are indispensable to meet those needs. How-
ever, genetic information on cHL is still scarce mainly due to difficulties of iso-
lating malignant HRSC, whose overall frequencies in the affected tissues range
from 0.1-5%. Formalin-fixed paraffin-embedded (FFPE) tissue archives are the
most abundant source of clinically annotated tumor specimens. However, FFPE
tissue usability is limited because of poor DNA quality and difficulty to enrich
neoplastic cells. Therefore, new enrichment techniques are necessary to enable
larger scale comprehensive genetic investigations of cHL.
Aims: Our aims were: 1) to develop a technique for HRSC enrichment from
the archival formalin-fixed paraffin embedded tissue; 2) to reliably detect genetic
aberrations in the genomes of enriched tumor samples and to use this infor-
mation for development of new prognostic and predictive markers as well as
for better understanding of the genetic background of cHL.
Methods: We have developed a new high-throughput method for marker-based
enrichment of archival FFPE tissue-derived HRSC nuclei by fluorescence-assist-
ed flow sorting (FACS). Genomic DNA extracted from sorted nuclei was used for
identification of mutations in 68 genes that are frequently mutated in lymphomas
by targeted high throughput sequencing (HTS). Chromosomal copy number aber-
rations were investigated by the Agilent SurePrint 180k microarray.
Results: Enzymatically extracted FFPE tissue-derived cell nuclei retain their
antigenicity and can be reliably labelled with monoclonal antibodies against
nuclear (MUM1, PAX5) and cytoplasmic/cell surface (CD30) markers. A mean
neoplastic cell purity of 70% (range 40-95%) was achieved by sorting HRSC
cells according to their double expression of MUM1 and CD30 in 11 cHL cases.
Using sorted non-malignant cells as a germline control we detected somatic
singe nucleotide mutations and indels in all investigated samples. Mutations of
STAT6, PIM1, SOCS1, KMT2D occurred in at least 18% (2/11) of cases. Also,
individual cases contained copy number aberrations such as gain of chr2 (CREL
locus), focal deletions of chr4, chr7, chr16 and chr19 affecting genes such as
JAK3, CDKN2D, MAP2K3 and NOTCH3. Taken together our study demon-
strates that DNA extracted from the enriched cell populations is suitable for
wide-scale genetic profiling.
Summary/Conclusions: A novel rare-cell-enrichment technique is suitable for
genetic cHL studies and opens the possibility for the wider use of archived
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FFPE tissue, thus enabling more robust study designs to answer clinically rel-
evant questions in the field.
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Background: The highly conserved JAK-STAT signaling pathway regulates
proliferation, differentiation, apoptosis and immune responses. Activating muta-
tions in STAT3 are considered to drive the development of diffuse large B-cell
lymphomas (DLBCL). STAT1 is a critical counter player of STAT3. Of note, many
STAT1 target genes are frequently altered or mutated in DLBCL patients, such
as SOCS-1, B2M, PDL1, CARD11, CIITA and BCL6. We observed that the loss
of STAT1 suffices to provoke spontaneous haematopoietic tumors in mice.
Aims: We aimed at investigating the underlying mechanisms of spontaneous
hematopoietic tumor formation in STAT1-deficient mice.
Methods: We characterized the spontaneous haematopoietic tumors by FACS
and morphological analysis. To identify the cell of origin for the disease, we
performed bone marrow transplantation assays. We high-purity FACS-sorted
individual cell populations of diseased STAT1-deficient mice and transplanted
them into recipient mice. Ex vivo derived transformed tumor cells were char-
acterized for lineage-specific surface marker expression and identified as B-
cells. Malignant B-lymphoid STAT1-deficient cell lines were established and
expression levels of typical lymphoid-specific tumor- suppressor and promoter
genes were assessed by qPCR. In parallel, Stat1-/- cell lines were used for
RNA-seq analysis to identify the signaling pathways driving disease. RNA-seq
data were compared to publicly available RNA-seq data from different haema-
tological malignancies.
Results: STAT1-deficient mice develop a myeloid hyperplasia that manifests
with an incidence of 60% and is characterized by the absence of RigI. Trans-
plantation of bone marrow unmasked the development of a B-cell malignancy
which can be transferred by CD19+ cells. The malignant B-cells arising in Stat1-
/- mice can be maintained in vitro and display alterations in gene expressions
that are typically found in human DLBCL such as Irf4, Prdm1 and p53. RNA-
seq analysis revealed features shared with human DLBCL: increased reads a
loci of SpiB, Mef2b, Card11 and Cd274 (PDL1) and decreased expression of
Socs-1, Cdkn2a, B2m and Prdm1. Low levels of STAT1 combined with low
levels of p16INK4A correlate with a reduced life expectancy in DLBCL patients.
Summary/Conclusions: Loss of STAT1 in Balb/C mice provokes a myeloid
hyperplasia which masks a B-cell malignancy resembling human DLBCL. DLB-
CL patients with low levels of STAT1 have a poorer prognosis if they lack the
tumor suppressor p16INK4A.
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C.G. Nyvold1
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University Hospital, Aarhus C, 3Department of Clinical Genetics, 4Department
of Pathology, 5Department of Haematology, Odense University Hospital,
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Background: Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma
characterized by t(11;14)(q13;q32) leading to constitutive cyclin D1 overexpres-
sion and cell cycle deregulation. The survival is still poor, especially for patients
resistant to frontline drugs. Although patients are brought in remission, relapses
often occur with disseminated lymphoma, which is more difficult to treat. There
is a need for a better understanding of the clonal heterogeneity of this disease
and to identify new signaling pathways with genes which could be targeted by
novel drugs or be used as biomarkers to predict response to treatment.
Aims: To address the genetic heterogeneity in MCL in paired patient samples
at diagnosis and relapse.
Methods: Highly pure malignant B-cell populations were isolated using fluo-
rescence activated cell sorting in four patients diagnosed with MCL. In addition
T-cells were sorted from the same patients as paired non-malignant control
samples. Exome sequencing was performed on both the malignant B-cell pop-
ulation and paired T-cells (13 samples in total). Mutations were detected in
parallel with CLC Biomedical Workbench 2.5 (Qiagen) and MuTect 1.04 (Broad
Institute) (coverage ≥ 20, population allele frequency<0.01) and evaluated
against the COSMIC (Wellcome Trust Sanger Institute), dbSNP and PubMed
database. Exemption from informed consent was approved by the National
Ethical Committee.
Results: Our data highlighted in each patient persistent gene modifications
between diagnosis and relapse. We confirmed gene mutations already well-
known in B-cell malignancies (e.g. TP53, NOTCH1 and MYD88). Interestingly,
aberrations not previously described in the COSMIC database, were observed
with high allele frequency both at diagnosis and at relapse. This included genes
in B-cell signaling (e.g. transcriptional repressor SPEN associated to NOTCH
pathway regulation and blockage of the precursor B-cell differentiation), inflam-
matory response (e.g. IRG1), genes found in invasive carcinoma (e.g. integrin
β4 subunit) and B-cell malignancies (e.g. PLA2G4D). In addition to common
mutations or hit in putative drivers, new gene modifications as well as loss of
previous ones could be observed at relapse. For example, genes involved in
embryonic development and cell fate (e.g. the transcription factor SOX1) and
genes involved in inflammation (CCL13) were not previously correlated to MCL
and were novel at relapse. This suggests that a modified malignant clone has
evolved and progressed. No gene modification was observed to be shared by
all four patients. However, aberrations in the same signaling pathways were
identified across individuals. From allele frequency distributions detected with
MuTect we could detect discrete clonal or competing subclonal involvement: A
patient harbored one major discrete clone at diagnosis while at relapse two
clearly separated clones were present, whereas another patient presented a
diffuse clonal pattern at diagnosis and a more discrete biclonal pattern at relapse.
Summary/Conclusions: Our work shows examples of molecular progression
from diagnosis to relapse in MCL and supports the heterogenic nature and
genetic complexity of this disease. We confirm mutations in genes already
known as involved in the malignant transformation of MCL and identify new
ones involved in the B-cell signaling pathways. This adds valuable knowledge
to the biological understanding of MCL which is pivotal in the era of precision
medicine.
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NOVEL TARGET GENES OF DEREGULATED MIRNAS IN DLBCL
REVEALED BY ENDOGENOUS AGO2 PAR-CLIP
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Background: Aberrant expression of microRNAs (miRNAs) is a widespread
phenomenon in cancer. However, the functional significance of such deregu-
lation is poorly understood as the target genes of miRNAs (the targetome) are
notoriously difficult to predict computationally and moreover differ according to
cellular context. An alternative approach is to directly sample the targetome
using immunoprecipitation (IP) techniques such as PAR-CLIP. The drawback
however of such techniques is the need for exogenously produced tagged pro-
teins. Diffuse large B-cell lymphoma (DLCBL) is the most common form of
non-Hodgkin lymphoma, typically aberrantly expressing miRNA-155 (Lawrie,
2007). This miRNA is a well known key regulator of lymphomagenesis, needed
for T and B cell function (Rodriguez, 2007; Thai, 2007; Vigorito, 2007), and its
over-expression in pre-B cells or haematopoietic stem cells leads to oncogenic
transformation (Costinean, 2006; O´Connell, 2008). Given their relevance,
DLBCL and miR-155 were chosen as models for the present study.
Aims: We set ourselves to adapt PAR-CLIP technique to allow non-engineered
cells to be used based on IP of endogenous levels of Ago2. In addition, we
also aimed at testing the minimum number of input cells needed for miRNA
target identification.
Methods: Two DLBCL cell lines (ABC-type RIVA, and GC-type SUD-HL10)
were transfected with lentiviral vectors that encoded miR-155. In parallel, we
transfected these cells with an inhibitor of miR-155 or with a scrambled
sequence, as experimental controls (for reducing the number of false positives).
Cells were then stably selected with puromycin, and grown in the presence of
100 uM 4SU for 18 h. Different amounts of these cells (300M, 50M and 10M)
were then irradiated to cross-link the RNA to RNA-binding proteins. PAR-CLIP
was then performed on cell lysates using anti-Ago2 mAbs for IP. The original
protocol (Hafner, 2010) was modified to eliminate radioactive labelling. The
recovered RNA was used for library building using TruSeq Small RNA Sample
Kit v1 and the sequencing performed on an Illumina HiScanSQ system. After
deduplication and alignment, T-to-C variants (indicative of miRNA-dependent
binding sites) were identified, and PAR-CLIP clusters called using wavClusteR
(Comoglio, 2015).
Results: Endogenous Ago2 IP, followed by a radioactive-free modified PAR-
CLIP protocol yielded sufficient RNA for building libraries for NGS irrespectively
of cell input. Samples gave an average ~9.7 x106 aligned reads/library. There
were an average of 7,370 PAR-CLIP clusters mapping to coding genes (range
4,675 - 11,004, correlating with the number of input cells, r=0.82). In all exper-
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imental conditions we found that a number of the captured genes corresponded
to experimentally validated targets of miR-155. Crucially, ontogeny analysis of
the PAR-CLIP-captured genes demonstrated an enrichment of genes involved
in haematopoietic and/or lymphomagenesis pathways.
Summary/Conclusions: To fully understand the role of a particular miRNA in
a specific malignancy, it is essential to identify its target genes in a relevant
cellular context. Using a haematological malignancy model of high clinical inter-
est we have developed an optimised method for interrogating the miRNA:mRNA
interface (targetome) within a cellular system without the need of ectopically
express tagged Ago2, keeping physiological levels of the core component of
the RISC complex unaffected. Moreover, our optimized protocol allowed us to
reduce the number of input cells, therefore opening the exciting possibility of
interrogating the targetome of patient primary samples.
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DARATUMUMAB, A NOVEL HUMAN CD38 MONOCLONAL ANTIBODY FOR
THE TREATMENT OF B-CELL NON-HODGKIN LYMPHOMA
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Background: Daratumumab (DARA) is a first-in-class human monoclonal anti-
body that targets the CD38 epitope and is approved for the treatment of
relapsed/refractory (R/R) multiple myeloma (MM) patients. DARA is currently
being evaluated in phase II clinical trials as monotherapy in patients with R/R
Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL) and Diffuse Large B-
Cell Lymphoma (DLBCL). DARA induces tumor cell death through effector
mediated mechanisms in MM, including Antibody-Dependent Cellular Cytotox-
icity (ADCC), Complement-Dependent Cytotoxicity (CDC) (de Weers M. J
Immunol, 2011) and Antibody-Dependent Cellular Phagocytosis (ADCP)
(Overdijk MB. MAbs, 2015). In Chronic Lymphocytic Leukemia (CLL), DARA
induces killing mainly via ADCC and ADCP (Matas-Céspedes A. Clin Cancer
Res, 2016). Furthermore, immunomodulatory effects (Krejcik J. Blood, 2016)
and modulation of the enzymatic activity of CD38 (Lammerts van Bueren J.
Blood, 2014) have been described to contribute to its antitumor activity.
Aims: To evaluate the activity of DARA on MCL and FL cells as monotherapy
and in combination with current therapies, both in vitro and in vivo.
Methods: ADCC, CDC and ADCP activities were assessed by calcein release
or flow cytometry. Penetration of DARA was analyzed in a 3D model by Selec-
tive Plane Illumination Microscopy (SPIM). Molecules per cell were analyzed
using Qifikit and flow cytometry. In vivo activity was assessed in prophylactic
and therapeutic set ups using SCID mice subcutaneously (sc) or intravenously
(iv) injected with 1x107of MCL or FL cells. Mice were treated (human IgG control
or DARA) with two different schedules: prophylactic (3 doses of 10mg/kg one
dose per week) or therapeutic (20/10/10/10mg/kg, one dose per week). For
the combination regimens in FL, sc injected SCID mice were treated following
the therapeutic schedule in combination with Rituximab (20/10/10/10mg/kg,
one dose per week) and/or CHOP (initial unique dose).
Results: DARA (0.0001-1µg/mL) induced ADCC in a dose-response manner
on MCL (n=6) and FL (n=4) cell lines in the presence of PBMCs in vitro. More-
over, DARA induced significant levels of ADCP at 1µg/mL on MCL (n=6) and
FL (n=4) cell lines in the presence of murine macrophages in vitro. However,
DARA did not induce significant CDC in any of these models due to a high
expression of the complement inhibitors CD46, CD55 and CD59, and insuffi-
cient number of CD38 molecules per cell. In a 3D model of FL, SPIM analysis
revealed a maximum penetration of DARA at 1µg/mL after 48h of treatment. 
We tested DARA activity in vivo in two different mouse models (sc and iv) of
MCL and FL. In the prophylactic setting, DARA completely prevented the out-
growth and induced tumor regression of MCL (n=6) and FL (n=6) subcutaneous
tumors. In the therapeutic setting, DARA significantly increased the overall sur-
vival (OS) of these mice and reduced organ infiltration of tumor cells both in
the MCL (n=10) and in the FL (n=10) systemic xenograft models. In addition,
the combination of DARA with Rituximab/CHOP regimen in FL, resulted in a
synergistic reduction of tumor growth (n=7-10).
Summary/Conclusions: DARA shows encouraging cytotoxic activity in MCL
and FL cells in the presence of external effectors in vitro. In addition, DARA
exerts unique and substantial effects as single agent on MCL and FL tumor
cell growth in different mouse models and contributes to potent therapeutic effi-
cacy in combination with current approved therapies. These results warrant
further studies of DARA in the clinical setting for these conditions.
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ECTONUCLEOTIDASES CD39/CD73 ARE HIGHLY EXPRESSED ON ATLL
CELLS AND RESPONSIBLE FOR GENERATING AMP/ADENOSINE
Y. Nagate1,*, S. Ezoe1, J. Fujita1, M. Ichii1, J. Toda1, K. Oritani1, Y. Kanakura1
1Hematology and Oncology, Osaka University Graduate School of Medicine,
Suita, Japan
Background: Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell neo-
plasm, linked to the human T-cell lymphotropic virus, HTLV-1. Patients with
ATLL are often at the risk of opportunistic infections. It might be possible that
this immunocompromised state could be induced by the function of ATLL cells
having similar phenotypes with regulatory T cells (Tregs). However, difficulties
of in vitro studies using primary tumor cells have hampered the progress of
ATLL research, and it is still controversial whether ATLL tumor cells have the
immunosuppressive characteristics.
Aims: In this study, we analyzed, the roles of molecules expressed in ATLL
cells associated with immunosuppressive functions of Tregs.
Methods: The protocol of this study was approved by the Investigational
Review Board of Osaka University Hospital. Peripheral blood mononuclear
cells (PBMCs) were collected from 8 asymptomatic HTLV-1 carriers and 20
ATLL patients (3 with smoldering type, 5 with chronic type, and 12 with acute
type) after getting informed consent. PBMCs from 3 ATLL patients were sepa-
rated into CD4+CD7-CADM1+ ATLL cells and adjacent CD4+ CD7+CADM1-
normal T cells using Fluorescence-activated Cell Sorter(FACS), and total RNA
sequencing experiments were conducted. And we also examined the expres-
sion patterns of CD39 and CD73 at in HTLV-1 carriers or each type of ATLL
patients.
Results: We compared whole transcriptome of ATLL cells and normal CD4+
cells. Bioinformative analyses showed that many genes associated with immuno-
suppressive functions of Tregs were elevated or downregulated in ATLL cells.
Among these genes we focused on CD39, CD73 and CD26, because recently
it has been reported that extracellular adenosine, which is catalyzed by CD39,
expressed in human Tregs, and CD73, expressed in murine but not in human
Tregs, has strong anti-inflammatory function and plays major role in Treg-medi-
ated immunosuppression. Therefore, we investigated the expression of CD39
and CD73 in ATLL cell lines and primary tumor cells. We found that all of 4 ATLL
cell lines expressed CD39, but not CD73 just as human effector Tregs. In con-
trast, the expression patterns of CD39 in 20 ATLL patients were various (Table)
and interestingly, some ATLL tumor cells express CD73. Also in asymptomatic
carriers, we could detect CD39 and/or CD73 positive on CD7-CADM1+abnormal
fraction of CD4+ cells. CD26, expressed in human naïve but not in effector Tregs,
was negative in all cell lines and primary cells except for abnormal cells in one
smoldering patient. Next, the role of CD39 and/or CD73 in ATLL cells was
assessed. Extracellular ATP is converted into AMP by CD39. As expected,
CD39+ ATLL cells converted significantly more ATP than CD39- ATLL cells, which
was comparable with normal effector Tregs. Conversely, mass spectrometry
analysis of AMP/adenosine concentration indicated the activity of CD73 medi-
ated AMP hydrolysis was very slow; less than 10% of 1mM AMP was converted
to adenosine by CD73+ ATL cells, indicating that the aberrant expression of
CD73 could not efficiently increase adenosine synthesis.
Table 1.
Summary/Conclusions: In this study, we showed that about two thirds of ATLL
samples were CD39+CD26-just as effector Tregs and have comparable level
of ATPase activity as Tregs, which are expected to play some immunosuppres-
sive function in ATL patients. Recently it is also reported that in exhausted CD8+
T cells in cancer patients, CD39 is co-expressed with PD-1. CD39 expression
in ATLL cells may also have some roles in immunosuppression and thus in the




ACTIVATION OF SYK TYROSINE KINASE PLAYS A ROLE IN RESISTANCE
AGAINST THE SELECTIVE BTK INHIBITOR ONO/GS-4059 IN DIFFUSE
LARGE B CELL LYMPHOMA (DLBCL)
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Background: The B-cell receptor (BCR) pathway is implicated in the survival
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and proliferation of several B cell malignancies. BTK is a key regulator of this
pathway. In a preliminary clinical study, the selective BTK inhibitor ONO/GS-
4059 showed therapeutic activity in relapsed/refractory DLBCL of the Activated
B-cell phenotype (ABC-DLBCL) (Walter et al Blood 127pp411-419,2016). How-
ever, median treatment duration in ABC-DLBCL was only 3 months due to pro-
gressive disease and development of resistance. Two acquired resistant muta-
tions BTK C481S and PLCγ2 R665W have been reported as dominant resistant
mechanisms to BTK inhibition in CLL but resistance mechanisms in DLBCL
have not been fully elucidated.
Aims: To determine resistance mechanisms in the ABC-DLBCL TMD8 cell line
and determine new rational combinations to take into the clinic with ONO/GS-4059.
Methods: The BTK inhibitor-sensitive ABC-DLBC cell line TMD8 and cloned
ONO/GS-4059 and Ibrutinib resistant TMD8 cell lines (TMD8RO and TMD8RI)
were used for this study. TMD8RO has PLCγ2 R665W whilst TMD8RI lacks
both BTK C481S and PLCγ2 R665W. Cell viability and apoptosis after com-
pound treatment were assessed using Cell titer Glo assay and Annexin V/ PI
staining. The effect of ONO/GS-4059 on intracellular signaling and expression
of immunoreceptor were assessed by immunoblot and Flow cytometry. The
mutational status of BTK and PLCγ2 in TMD8R was determined by Sanger
sequencing.
Results: ONO/GS-4059 induced apoptosis in TMD8 at nanomolar concentra-
tion and over 72 hours induced classical apoptosis in >80% of cells. Although
ONO/GS-4059 induced rapid reduction in ERK and AKT activation, activation
of ERK and AKT rebounded within 24 hours in surviving cells. Interestingly,
surface immunoglobulin M (sIgM) expression was increased more than three
times in these cells leading to subsequent activation of SYK. The specific SYK
inhibitor GS-9973 combined with ONO/GS-4059 inhibited the downstream ERK
and AKT reactivation and induced synergistic apoptosis in TMD8. On the other
hand, SYK hyper-activation as determined by phospholyration of SYK and its
downstream target BLNK was also observed in the two BTK inhibitor resistant
cell lines. Additionally, expression of CD5 and CD22, which negatively regulate
BCR signalling, was decreased in these cells. The combination of ONO/GS-
4059 and GS-9973 restored sensitivity to ONO/GS-4059 and induced syner-
gistic apoptosis in both resistance cell lines. 
Summary/Conclusions: These data show that SYK is highly activated through
increased sIgM expression and/or downregulated CD5 and CD22 following
BTK inhibitor treatment in ABC-DLBCL. These changes may contribute to not
only the development but also the maintenance of resistance to BTK inhibitor.
The combination of ONO/GS-4059 with SYK inhibitor is therefore a rational
strategy for preventing and overcoming BTK inhibitor resistances.
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STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC)
FOR TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMA (NHL)
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Background: CD74 is a type II transmembrane glycoprotein involved in the
formation and transport of MHC class II protein. CD74 is rapidly internalized
and highly expressed in many B-cell malignancies with limited expression in
normal tissues (Stein R. et al., CCR 2007). STRO-001 is a novel CD74-target-
ing ADC comprised of a p-azido-methyl-phenylalanine (pAMF)-containing anti-
CD74 aglycosylated human IgG1 antibody (SP7219) conjugated to a non-
cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead. Highly
efficient site-specific conjugation enabled by Sutro’s cell-free antibody produc-
tion and click chemistry produced a well-defined homogeneous ADC with a
drug-antibody ratio (DAR) of 2. Due to its limited cell permeability, the major
catabolite released by STRO-001 has 1000X lower cell killing activity on CD74
positive and negative cells compared to a reference cytotoxic maytansine.
Since conjugation sites were selected based on highest stability both in vitro
and in vivo, thereby limiting loss of drug moiety from STRO-001 in circulation,
this novel ADC has potential for improved PK, safety and activity profiles.
Aims: The aim of this study was to investigate the therapeutic potential of
STRO-001 in non-Hodgkin’s lymphoma (NHL) cell lines and xenografts. A dose-
escalating exploratory toxicology study was also conducted in cynomolgus
monkeys.
Methods: Biotinylated SP7219 was used for immunohistochemistry (IHC).
DBCO-Alexa647-conjugated SP7219 and flow cytometry were used for detec-
tion and quantitation of CD74 expression on NHL cell lines and B-cells from
normal human donors. STRO-001 was used to determine the EC50 and percent
span of killing in NHL cell lines. The anti-tumor activity of STRO-001 in SCID
mice bearing NHL tumor cell xenografts was examined. STRO-001 was admin-
istered to cynomolgus monkeys in an exploratory dose-escalating study of
repeat IV doses of 1, 3, 10 and 30mg/kg on days 1 and 15.
Results: Expression of CD74 in different lymphoma subtypes was evaluated
by IHC on duplicate core (matched pair) biopsies. Medium to high CD74
expression in >70% of cells was observed in 86/100 diffuse large B-cell (DLB-
CL), 22/28 follicular lymphoma and 49/78 mantle cell lymphoma (MCL) sam-
ples. In vitro cytotoxicity assays show potent activity of STRO-001 in a diverse
panel of B-cell tumor lines including 9 germinal center B-cell (GCB) diffuse
large B-cell lymphoma (DLBCL), 3 activated B-cell (ABC) DLBCL, and 4 mantle
cell lymphoma (MCL) cell lines with EC50 values ranging from 0.17-13 nM.
STRO-001 has only modest effects on naïve B-cells, but exhibits more potent
cell killing in activated human B-cells that have upregulated CD74 expression
(similar CD74 expression as SU-DHL-6 cell line). CD74 cell surface expression
is required for STRO-001 cytotoxic activity but expression level, as measured
by antibody-binding capacity, does not correlate with in vitro potency
(R2=0.4154). STRO-001 exhibits dose-dependent tumor growth inhibition in
rituximab-resistant SU-DHL-6 xenografts starting at 2.5mg/kg weekly x 3 doses.
The standard of care combination of bendamustine/ rituximab (BR) + STRO-
001 further improves tumor suppression in SU-DHL-6 xenografts compared to
vehicle (p=0.002) or BR alone (p=0.02). Studies with a MCL xenograft model,
Jeko-1, demonstrate potent anti-tumor activity compared to vehicle (p<0.0001)
starting at a single STRO-001 dose of 3mg/kg, with a single 10mg/kg dose
resulting in tumor regression for up to 64 days post treatment. STRO-001 treat-
ment 14 days post tumor inoculation was used to evaluate disease progression
in Mino, a slow growing disseminated MCL xenograft model. Vehicle-treated
animals developed advanced disease with palpable tumors and distended
abdomens, with median survival of 81.3 days. In contrast, Mino xenografts
treated with STRO-001 at 3mg/kg or 10mg/kg exhibited improved survival, with
most animals healthy and disease free at the time of sacrifice 135 days post
inoculation. STRO-001 demonstrated B-cell depletion in cynomolgus monkeys,
confirming the intended pharmacodynamic effect. Myelosuppression was
observed at the highest dose but there was no evidence of off-target toxicity.
Table 1.
Summary/Conclusions: STRO-001 demonstrates potent in vitro cytotoxicity
in NHL cell lines and anti-tumor activity in NHL xenograft models, including
prolonged survival in the disseminated Mino MCL model. STRO-001 depletes
B cells in a dose-dependent manner. Clinical studies of this novel ADC for
treatment of B-cell malignancies are under development.
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DETECTING MALIGNANT B-CELLS IN CEREBROSPINAL FLUID: DOES
THE IDEAL METHOD EXIST?
J. Osman1, S. Tarfi1, M. Armand1, C. Houillier2, S. Choquet3, H. Agnelo1, H. Strub1,
P. Bonnemye1, K. Hoang-Xuan2, M. Le Garff-Tavernier1,*, M. Costopoulos1,
F. Davi1
1Biological Haematology Department, 2Neuro-Oncology, 3Clinical Haematol-
ogy, Pitie-Salpetriere Hospital, Paris, France
Background: Leptomeningeal dissemination (LD) is a relatively rare but often
fatal complication of lymphomas, confirmed by the analysis of the cerebrospinal
fluid (CSF). The diagnosis is suspected in case of neurological symptoms,
parenchymal brain involvement detected with neuroimaging techniques and
confirmed by the analysis of the cerebrospinal fluid (CSF). Cytomorphological
examination (CM) is still considered as the “gold standard” but remains insuf-
ficiently sensitive.
Aims: The aim of our study was to assess the benefit of more sensitive tech-
niques, i.e. immunophenotyping by flow cytometry (FCM) and clonality by PCR,
for the detection of malignant B cells in the CSF of patients with suspected
leptomeningeal dissemination.
Methods: This study was conducted on 326 CSF samples (236 patients)
referred to our laboratory between January 2015 and December 2016. CM,
FCM and PCR results were recorded and classified as positive (+), negative (-)
or suspicious. Immunophenotyping was performed on a FACSCanto II (BD
Biosciences®) using an 8-colour panel. A sample was FCM+ when a cluster of
at least 20 events with neoplastic features was detected. PCR-based analysis
of immunoglobulin heavy (IGH) and light (IGL) chain rearrangements were per-
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formed following the BIOMED-2 design and protocol. All PCR experiments were
done in duplicates, and cases were considered PCR+ when both duplicates
showed the same clonal pattern, ruling out false positivity (pseudoclonal pattern)
often seen in paucicellular samples.
Results: We confirm that FCM and PCR are more sensitive than CM. Indeed,
every CM+ cases (n= 16) was also FCM+ and/or PCR+ while 13 cases were
FCM/PCR+ but CM-. A total of 269 samples showed similar results by FCM
and PCR with presence (n=22) or absence (n=247) of lymphomatous cells
whereas 25 samples were classified as suspicious by at least one technique.
Eleven samples were FCM+ but PCR-. False negative (FN) PCR results can
be explained in part by extensive somatic mutation in IGH genes, preventing
optimal annealing of primers and thus blocking efficient amplification. Other
targets less prone to somatic mutations, such as IGL, should therefore be eval-
uated. Conversely, 21 samples were PCR+ but FCM-. Absence of FCM detec-
tion might have resulted from the presence of very large lymphomatous cells
outside the scope of analysis. Also, rapid cell death is an issue with FCM (pre-
vented by the use of stabilizing reagents) whereas molecular techniques do
not systematically require intact cells. Most of the difficulties encountered with
both methods are due to occult blood contamination and poor cellularity, leading
to low-intensity clonal signals by PCR and inconsistent cluster of events with
FCM. In addition discordant results between FCM and PCR might be explained
by sampling heterogeneity. Considering those limitations, it seems highly advis-
able to choose the best suited method for the follow-up according to the results
at diagnosis.
Summary/Conclusions: Our results suggest that a multimodal investigation
using FCM and PCR is necessary for improved detection of leptomeningeal
dissemination in B-cell malignancies. It seems premature to make clinical deci-
sions based on a single technology. Both methods, which suffer limitations that
need to be acknowledged, are complementary and should be performed at
diagnosis. Specific limitations of each of them should be taken in consideration
for follow-up studies.
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THE SYK INHIBITOR R406 DRAMATICALLY INCREASES THE SENSITIVITY
OF GCB AND ABC DLBCL CELL LINES TO THE BCL-2 INHIBITOR
VENETOCLAX
B. Sasi1,*, S. Turkalj1, D. Efremov1
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nology, Trieste, Italy
Background: The BCL-2 inhibitor venetoclax demonstrated significant single-
agent activity in recent clinical trials of relapsed/refractory chronic lymphocytic
leukemia (CLL). However, results in some other B cell malignancies character-
ized by BCL-2 overexpression have not been equally impressive. This partic-
ularly refers to diffuse large B cell lymphoma (DLBCL), where only 18% of
patients responded to treatment with venetoclax in a recent phase I clinical trial
(Davids MS et al, J Clin Oncol. 2017).
Aims: Investigate whether the SYK inhibitor R406 can increase sensitivity of
DLBCL cells to venetoclax.
Methods: The following cell lines were used: Ly4, Ly1, Ly7, Ly18, DHL4, Toledo
and BJAB (all GCB DLBCL) and U2932, DHL2, Ly3, Ly10, HBL1 and TMD8
(all ABC DLCBL). The percentage of apoptotic cells was determined by Annexin
V/PI staining and flow cytometry analysis. Expression of BCL-2 family members
was determined by immunoblotting or RQ-PCR analysis.
Results: In a recent study, we showed that MCL-1 increases the resistance of
anti-IgM stimulated CLL cells to venetoclax, and that SYK inhibitors can effec-
tively overcome this resistance by blocking B cell receptor (BCR)-mediated
MCL-1 upregulation (Bojarczuk K et al. Blood. 2016). Since constitutive activa-
tion of the BCR pathway has been described in both ABC and GCB DLBCL
(Davis RE et al, Nature 2010; Chen L et al, Cancer Cell. 2013), we investigated
whether treatment with the SYK inhibitor R406 can sensitize DLBCL cells to
venetoclax. Single-agent venetoclax had only modest activity against most
DLBCL cell lines at concentrations ranging up to 0.25 μM (Figure 1). Substantial
apoptosis induction (>20%) was observed in only 2 GCB (Ly1 and Ly18) and
2 ABC (U2932 and Ly10) cell lines. R406 as single agent had almost no effect
on tumor cell viability, with only one cell line showing >20% apoptosis induction
(HBL1). However, addition of R406 to venetoclax resulted in a dramatic increase
in the percentage of apoptotic cells in six of the investigated cell lines (Ly18,
DHL4, U2932, Ly10, HBL1 and TMD8). A synergistic effect was also observed
with Ly1 using a lower concentration of venetoclax, whereas no effect or only
an additive effect was observed in the remaining cell lines (Ly4, Ly7, Toledo,
BJAB, DHL2 and Ly3). Among these, only Toledo expressed similar levels of
BCL-2 as the R406 + venetoclax sensitive cell lines, whereas the levels of BCL-
2 in the other cell lines were extremely low or undetectable. To understand the
mechanisms how R406 increases the sensitivity of DLBCL cells to venetoclax,
we evaluated changes in the expression of MCL-1 and other antiapoptotic BCL-
2 family proteins that have been associated with venetoclax resistance. Five of
the seven R406 + venetoclax sensitive cell lines (Ly1, DHL4, U2932, HBL1
and TMD8) showed a 20-45% reduction in MCL-1 levels following 24 hours
culture with 2μM R406, whereas no changes were observed in Ly18 and Ly10.
However, a substantial reduction in A1 levels was observed in Ly18 and U2932
cells, whereas no substantial changes in A1 and BCL-xL expression were
detected in any of the other investigated cell lines. Finally, we also investigated
the effects of R406 on expression of HRK, which is a propapoptotic BCL-2 fam-
ily member that was recently shown to be induced by SYK inhibition in a subset
of GCB DLBCLs (Chen L et al, Cancer Cell. 2013). A substantial increase in
HRK expression (140-640%) was observed in 5 of the 7 R406 + venetoclax
sensitive cell lines (Ly1, Ly18, DHL4, U2932 and TMD8).
Figure 1.
Summary/Conclusions: These data show that the SYK inhibitor R406 can
significantly increase the sensitivity to venetoclax in the vast majority of BCL-
2 positive DLBCL cell lines. The mechanisms of action require further investi-
gation, but are likely to involve downregulation of MCL-1 and upregulation of
HRK in a substantial proportion of cases.
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VΒ EXPRESSION ASSESSMENT AND CLONALITY DETECTION IN T-CELL
PROLYMPHOCYTIC LEUKEMIA (T-PLL) BY FLOW CYTOMETRY (FCM)
AND NEXT GENERATION SEQUENCING (NGS): A COMPARISON OF
BOTH METHODS
M. Kotrová1,2,*, M. Nováková1,2, S. Oberbeck3, P. Mayer3, A. Schrader3,
H. Knecht2, M. Herling3, M. Brüggemann2
1contributed equally, 2Medical Department II, Unit for Hematological Diagnos-
tics, University Hospital Schleswig-Holstein, Kiel, 3Dept. of Medicine I, Cologne
University, Cologne, Germany
Background: Vβ repertoire analysis can distinguish monoclonal from poly-
clonal (reactive) T-cell proliferations. The molecular quantification of clonal T-
cell receptor (TR) gene rearrangements can also be used to record minimal
residual disease (MRD) in T-cell malignancies. TR clonality can either be
assessed by FCM employing Vβ antibody panels covering ~70% of the normal
human TR Vβ repertoire or by molecular techniques like NGS with primers that
amplify virtually all possible Vβ-Jβ rearrangements. T-PLL is the most common
mature (post-thymic) T-cell leukemia. Clonal TR gene rearrangements are
detected in virtually all T-PLL by FCM or PCR from peripheral blood (PB) or
bone marrow samples.
Aims: To compare the results of parallel TRB-based clonality analyses by FCM
and NGS in T-PLL.
Methods: We investigated diagnostic PB leukocytes of 73 T-PLL patients with
median lymphocytes at 66% (range 13-93; harboring T-cells at 97% (55-100)).
FCM of surface (not intracellular) Vβ expression was assessed by the IOTest
Beta Mark kit (Beckman Coulter). Libraries for NGS were prepared using 100ng
of DNA via a 2-step PCR and sequenced on the Illumina MiSeq (2x250bp, v2)
with a median coverage of 17,908 reads (range 1,125–41,193)/sample. In the
first PCR TRB rearrangements were amplified using TRB BIOMED-2 V- and J-
region primers (van Dongen et al, Leukemia 2003). In the second PCR step,
sequencing adaptors and sample-specific barcodes were added. Annotation
of V, (D)- and J-regions of TRB sequences was done using ARResT/Interrogate
(Bystry et al, Bioinformatics 2016).
Results: In all samples one or two dominant clonal TRB rearrangements were
detected by NGS and represented in median by 83% of reads (range 15-90%).
In 36/73 (49%) of these cases, also FCM demonstrated clonality. Interestingly,
in 8/36 (22%) of cases the dominant Vβ by FCM differed from the molecular
clonotype. In 5 of these cases the discrepancy was most likely accountable to
a non-functional TRB clonotype detected by NGS corresponding to a bi-allelic
TRB rearrangement with the second non-functional allele being preferentially
identified by NGS. In 37/73 (51%) of cases no reactivity with one of the Vβ anti-
bodies was seen. In 16 (43%) of these cases this could be attributed to expres-
sion of a TRB rearrangement for which the appropriate Vβ antibody was not
present in the FCM panel. In another 12 (33%) of these cases a non-productive
TRB rearrangement represented the dominant NGS clonotype. However, in
further 9 cases (24%), the functional TRB clonotype (TRBV 5-6, 6-5, 25-1, 18,
20-1, 27) was not detected by FCM despite theoretical coverage. Of note,
overal 10/73 T-PLL (14%) lacked surface TRα/β chain expression.
Summary/Conclusions: T-cell clonality is detected by TRB NGS in all T-PLL,
whereas FCM-based Vβ repertoire analysis identifies a dominant single Vβ
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domain expression in only 49%. A substantial proportion of such failures of
FCM-based clonality detection can be best explained by lost surface TR expres-
sion and the limited coverage of the Vβ antibody panel. NGS-based clonality
analysis can overcome these limitations, because it detects virtually all TRV
VB-JB rearrangements. On the contrary, NGS is more sensitive and therefore
enables the detection of minor subclones, which has great appeal for MRD
analysis. Nevertheless, flow cytometric Vβ spectratyping is a faster, cheaper,
and less labourious alternative. It has the additional advantage of detecting
the actual TR Vβ chain expression and of visualizing individual T-cell subsets
for quantification of Vβ cell populations.
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IRF4 EXPRESSION IS ASSOCIATED WITH RESPONSE OF MANTLE CELL
LYMPHOMA TO BRUTON’S TYROSINE KINASE INHIBITORS
H.P. Thompson1,*, D.L. Tucker2, S.A. Rule1,2, C.V. Hutchinson1,2
1Institute of Translational and Stratified Medicine, Plymouth University, Penin-
sula Schools of Medicine and Dentistry, 2Clinical Haematology, Plymouth Hos-
pitals NHS Trust, Derriford Hospital, Plymouth, United Kingdom
Background: Mantle cell lymphoma (MCL) responds poorly to conventional
chemotherapy. Inhibitors of Bruton’s tyrosine kinase (BTKi) have unexpectedly
shown significant clinical effect; however despite this success, approximately
one third of MCL patients have primary resistance to the drug, and patients
who initially respond to treatment frequently acquire secondary resistance and
aggressive relapse of the disease. Understanding how BTKi-resistance or sen-
sitivity is mediated can identify new targets for therapy or predictive biomarkers
of response. Using an in vitro model system we have identified the transcription
factor IRF4 as a sensitive indicator for BTKi response in MCL cell lines and pri-
mary cells.
Aims: To identify molecules or pathways responsible for resistance to BTK
inhibitor-drugs in mantle cell lymphoma using cell line models and primary cells.
Methods: Primary cells and validated MCL cell lines (REC-1, G519, JEKO-1,
JVM2) were cultured either alone, or together with murine stromal cells (with
or without CD40L transfection). The BTKi sensitive REC-1 cell line was contin-
uously treated with BTKi to generate an acquired resistance model. Cultures
were treated with BTKi drugs: ibrutinib or acalabrutinib in the presence or
absence of B-cell receptor or CD40L stimulation, and their sensitivity or resist-
ance to treatment was determined using flow cytometry to assess proliferation
(Ki67), apoptosis (Annexin-V), or phosphorylation of BTK (pY223). Changes
affecting downstream proteins were determined by protein expression or phos-
phorylation analysis (immunoblotting) and by mRNA expression (RT PCR).
Following initial experiments the studies focussed on IRF4.
Results: Each MCL cell line showed basal phosphorylation of BTK (Y223) and
its downstream effector molecule ERK1/2 (Y204/187); in each case phospho-
rylation was prevented by BTKi. Of the cell lines tested however, only REC-1
cells showed growth inhibition by BTKi (ibrutinib and acalabrutinib), demon-
strating both dose-dependent apoptosis (p=0.01) and inhibition of proliferation.
Further investigation showed that only the BTKi-sensitive REC-1 cell line down-
regulated IRF4 in response to BTKi; this downregulation was an early and spe-
cific response (mRNA downregulated after 4 hours, and protein expression
after 8 hours). Furthermore in REC-1 cells with acquired partial resistance to
BTKi, the downregulation of IRF4 was significantly less than in the parental
cell line. Finally in vitro co-culture of REC-1 cells with CD40L prevented IRF4
downregulation and protected the cells from BTKi-induced apoptosis. Experi-
ments with primary MCL cells reinforced these findings: in vitro CD40L induced
proliferation, survival, prevented BTKi-induced IRF4 downregulation and pro-
tected the cells from BTKi-induced death. These findings were confirmed using
ex vivo samples from treated patients (n=7) analysed before and during BTKi
treatment: IRF4 was downregulated in 6 samples from patients shown to be
clinically responding to BTKi and was not downregulated in 1 refractory case.
Summary/Conclusions: CD40L encountered in the cellular microenvironment
supports the proliferation and survival of MCL cells, and protects them from
the effects of BTK inhibition. This study has identified that BTKi induces down-
regulation of IRF4 in sensitive but not resistant MCL cells, and that downreg-
ulation is opposed by CD40L. This suggests that the expression of IRF4 fol-
lowing treatment with BTKi might be a biomarker for BTKi-sensitivity in MCL,
and that proteins modulated by IRF4 may play an important role in MCL treat-
ment response.
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LOSS OF TPL2 KINASE ACCELERATES MYC-INDUCED LYMPHOMAGENESIS
E. Stagakis1,2,*, D. Vyrla1, H. Papadaki2, E. Drakos3, A. Eliopoulos1
1Laboratory of Molecular and Cellular Biology, Medical School, University of
Crete, 2Department of Hematology, University Hospital of Heraklion, 3Depart-
ment of Pathology, Medical School, University of Crete, Heraklion, Greece
Background: While MYC t(8;14)(q24;q32) translocation was initially identified
as a hallmark of Burkitt lymphoma, a number of other B-cell neoplasms are
associated with MYC deregulation. These MYC-driven non-Hodgkin lym-
phomas have aggressive clinical behavior and respond poorly to treatment.
However, MYC-dependent lymphomagenesis is believed to require additional
oncogenic alterations, such as deregulation of genes that counteract the
proapoptotic functions of MYC. TPL2 is a MAP3 kinase with an obligatory role
in inflammatory signal transduction on the MEK/ERK axis but little is known
about its involvement in B lymphocyte biology and lymphomagenesis. 
Aims: The aim of this study is to define the impact of and the mechanism by
which TPL2 kinase affects MYC-induced lymphomagenesis. 
Methods: CD19+ positive B lymphocytes were isolated from peripheral blood
of human healthy individuals and mouse B cells from spleens of WT (C57BL/6)
and Eμ-myc transgenic mice engineered to overexpress c-myc in B cell pro-
genitor cells under the control of the IgH chain enhancer. Mouse pre–B lym-
phocytes were isolated from bone marrow by flow cytometric cell sorting. Dif-
ferentiation status of lymphomas was analysed by flow cytometry using B220,
IgM and IgD antibodies. The TPL2 RNA and protein expression levels were
assessed by qPCR and Western blot analysis, respectively. The extent of apop-
tosis was estimated by immunohistochemical evaluation of activated caspase-
3 in paraffin embedded mouse lymphoma tissues and by flow cytometry using
Annexin and 7AAD staining of ex vivo cultured lymphoma cells following
cytokine deprivation. 
Results: TPL2 RNA levels were found dramatically decreased in various
human Burkitt lymphoma cell lines as well as in 7 primary Burkitt lymphoma
biopsies compared to B lymphocytes of healthy individuals. In line with this
finding, both pre-B and B lymphomas derived from Eμ-myc mice express very
low levels of TPL2 both at RNA and protein level, compared to pre-B and
splenic B lymphocytes isolated from WT mice. Interestingly, pre-B and B lym-
phocytes of healthy (premalignant) Eμ-myc mice express TPL2 in comparable
levels to their WT counterparts, suggesting that the reduction of TPL2 expres-
sion in lymphomas is an additional oncogenic alteration. In this regard, genetic
ablation of TPL2 in Eμ-myc mice (Eμ-myc/tpl2-/-) significantly shortened their
survival to 92 days from 140 days of Eμ-myc/tpl2+/+ mice (p<0.005). Eμ-
myc/tpl2-/- mice also displayed a trend to develop more pre-B cell lymphomas
compared to Eμ-myc/tpl2+/+ mice. This may be attributed to the decreased
TPL2 expression in mouse pre-B lymphocytes, while it is upregulated in mature
B lymphocytes. Finally, Eμ-myc/tpl2-/- lymphomas displayed reduced levels of
apoptosis.
Figure 1.
Summary/Conclusions: This study reveals a novel pathway during myc-dri-
ven lymphomagenesis. We show that MYC deregulation imposes selective
pressure in favor of clones with decreased expression of TPL2 kinase. This
process seems to be advantageous for the malignant clone, since genetic abla-
tion of TPL2 in the Eμ-myc mouse model accelerates MYC-induced lymphoma-
genesis likely by contributing to apoptosis resistance. 
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LIQUID BIOPSY: DECIPHERING A SIGNATURE OF CIRCULATING
MICRORNAS AS NOVEL NON-INVASIVE BIOMARKERS IN DIFFUSE
LARGE B-CELL LYMPHOMA
F. Marchesi1,*, G. Regazzo2,3, A. Sacconi2,3, M. Spagnuolo2, S. Donzelli2,
F. Palombi1, M. Marino4, C. Ercolani4, A. Di Benedetto4, G. Blandino2,
A. Mengarelli1, M.G. Rizzo2
1Hematology and Stem Cell Transplant, 2Epigenetic and Oncogenomic Unit,
Translational Research Area, 3Regina Elena National Cancer Institute, Rome,
Italy, 4Pathology Unit, Regina Elena National Cancer Institute, Rome, Italy
Background: Up to 40% of Diffuse Large B-Cell Lymphoma (DLBCL) patients
still experience treatment failure or disease relapse after conventional chemo-
immunotherapy. Therefore, the search of novel non invasive biomarkers able
to early identify these patients is warrant in order to offer a different therapeutic
approach. Recently, bodily fluids have emerged as an important source of infor-
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mation in several diseases analyzable by liquid biopsies, representing minimally
invasive methods for precision diagnostics and prognosis. Blood extracellular
microRNAs (miRNAs) are under investigation as novel biomarkers. While tissue
miRNAs in DLBCL patients have been extensively studied, only few reports,
and limited to a small subset of miRNAs, evaluated the role of circulating/serum
miRNA as potential prognostic factors.
Aims: To identify and validate a serum miRNA signature with prognostic value
in a cohort of newly diagnosed DLBCL patients.
Methods: This is a on-going prospective non interventionist study on a cohort
of newly diagnosed de novo DLBCL patients uniformly treated with six courses
of R-CHOP (Rituximab, Cyclophosphamide, Vincristine, Doxorubicin and Pred-
nisone). Serum samples of patients were collected at diagnosis and after the
end of treatment. Treatment response was evaluated by standard Cheson cri-
teria. The expression profile of selected circulating miRNAs described as asso-
ciated with lymphoid malignancies by us (let-7c/miR-99a/miR-125b cluster) and
by previously published studies (miR-22, miR-18a and miR-20a) was evaluated
by quantitative real time polymerase-chain reaction (qRT-PCR) in serum sam-
ples collected at diagnosis of the first 18 patients enrolled into the study.
Results: Our results showed that the expression level of serum miR-22 as well
as let-7c/ miR-99a/125b cluster was significantly higher at diagnosis, in patients
unresponsive to R-CHOP treatment when compared with responsive patients.
On the contrary, miR-18 and miR-20 levels appeared to be not significantly
associated to treatment response. In addition, a global expression profile of
circulating miRNAs was evaluated in serum samples derived from a smaller
cohort of patients (n=4) after first-line chemo-immunotherapy. Interestingly, we
found a striking difference in miRNA modulation upon treatment between unre-
sponsive and responsive patients. In particular, we found 31 miRNAs signifi-
cantly modulated after R-CHOP in the group of responsive patients, including
miR-22. In contrast, this miRNA subset did not show remarkable expression
changes in unresponsive patients. Moreover, we performed a study interrogat-
ing The Cancer Genome Atlas (TCGA) database about miRNA expression lev-
els in samples of DLBCL patients. We found that the only available data are
relative to the miRNA expression levels in tumor tissue samples of 47 out of 58
DLBCL patients. Kaplan Meier method and log-rank test revealed a signature
of 13 miRNAs with potential prognostic value. Among these we found that miR-
22, also emerged as modulated in our genome-wide analysis, was linked to
risk of disease recurrence.
Summary/Conclusions: These preliminary data suggest that the serum miR-
22 as well as miR-99a/let-7c/miR-125b miRNA cluster are of potential interest
as non–invasive biomarkers to predict therapeutic response in DLBCL patients.
Ongoing experiments in a wider cohort of patients are aimed to confirm these
results and unveil potential miRNA signature with predictive value.
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INTRACELLULAR CALCIUM AND METABOLISM HAVE CRITICAL ROLES
IN DETERMINING ANTI-CD20 ANTIBODY EFFICACY IN DLBCL
E. Vilventhraraja1,*, J. Gribben1, A. Braun1
1Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom
Background: Since the discovery and utilisation of the Type-I anti-CD20 anti-
body Rituximab, many have tried to enhance the efficacy of anti-CD20 anti-
bodies in order to improve first-line treatment of B cell malignancies, leading to
the evolution of Type II humanised anti-CD20 antibodies.To date, the complete
biological role of CD20 and the mechanism of anti-CD20 antibody action
remains unclear. However, CD20 has been shown to be involved in the store
operated calcium (Ca2+) system. This complex has the ability to facilitate mito-
chondrial membrane permeabilisation, resulting in reduced mitochondrial func-
tion. Basal oxidative phosphorylation (OxPhos), ATP production, and maximal
and spare respiratory capacity of cells can be calculated as a measure of mito-
chondrial function.
Aims: i) Assess and compare intracellular calcium concentration following treat-
ment with anti-CD20 antibodies ii) Evaluate mitochondrial function of cells fol-
lowing treatment with anti-CD20 antibodies iii) Assess whether cytotoxicity of
Type-I and Type-II anti-CD20 mAbs can be enhanced by exploiting cellular
metabolism
Methods: We established a panel of four DLBCL cell lines (Karpas422, Pfeiffer,
OCI-LY7 and SUDHL4). Following a 24-hour treatment with one of four anti-
CD20 antibodies [one Type-I (Rituximab) and three Type-II anti-CD20 antibod-
ies (BHH2, Obinotuzomab and Tositumomab)], intracellular calcium concen-
tration was quantified and visualised using imaging flow cytometry. Next, we
used the XF Seahorse Mito Stress Test to reveal bioenergetic profiles of the
cell lines following a 24-hour treatment with the same antibodies. We used Met-
formin to inhibit oxidative phosphorylation (OxPhos) and then characterised
the bioenergetic profile of our panel of cell lines again, this time to assess how
combining each anti-CD20 antibody with an OxPhos inhibitor affected mito-
chondrial function. Metformin was also used to reduce the mitochondrial mem-
brane potential (MMP) across our panel of cell lines. We confirmed MMP reduc-
tion by staining cells with JC-1, a chameleon dye used as an indicator of MMP
and analysed samples using flow cytometry. Under the same conditions, we
conducted clonogenic survival assays to see whether cytotoxicity of anti-CD20
antibodies could be enhanced by manipulating metabolism.
Results: Intracellular calcium concentration was decreased across our panel
of cell lines following a 24-hour treatment with all Type-II anti-CD20 antibodies
in our panel. This decrease was not observed following treatment with the Type-
I anti-CD20 antibody Rituximab. Treatment with anti-CD20 antibodies resulted
in a significant increase in the maximal respiratory capacity of our panel of cell
lines; cells were able to produce more ATP in response to oxidative stress.
Conversely, pharmacological inhibition of OxPhos impaired mitochondrial func-
tion, causing a significant reduction in basal OxPhos and in maximal respiratory
capacity. Under this condition, cells were unable to increase ATP production in
response to oxidative stress. We also show that treatment combining Metformin
with either Type-I or Type-II anti-CD20 antibodies prevents the increase in max-
imal respiratory capacity observed with anti-CD20 antibody treatment alone.
When analysing the clonogenic survival of cell lines, we have found that only
the cytotoxicity of Type-II anti-CD20 antibodies is enhanced by simultaneously
treating cell lines with Metformin. 
Summary/Conclusions: Our data show for the first time that when cells are
treated with Type-II anti-CD20 antibodies, intracellular calcium is decreased.
Intracellular calcium remains unchanged following treatment with Rituximab.
Next, we show anti-CD20 antibody treatment causes cells to increase maximal
mitochondrial respiratory capacity to compensate for reduced basal mitochon-
drial function. We show that inhibition of OxPhos disables the cells from being
able to compensate for the reduced mitochondrial function that is caused by
CD20-antibody treatment. Importantly our data show that combining Metformin
with Type-II CD20 antibodies leads to enhanced cytotoxicity, with a significant
reduction in clonogenicity in our panel of DLBCL cell lines.
E1381
CYCLIN D1 ONCOGENIC OVEREXPRESSION LEADS TO A GLOBAL
TRANSCRIPTIONAL DOWNREGULATION IN MALIGNANT LYMPHOID
CELLS
R. Albero1,*, A. Enjuanes2, S. Demajo1, G. Castellano3, M. Pinyol2, N. Garcia1,
C. Capdevila1, H. Suarez-Cisneros2, K. Karube4, S. Bea1, I. Martin-Subero1,
E. Campo1, P. Jares5
1IDIBAPS, Barcelona, Spain, 2Genomics Unit, IDIBAPS, 3Molecular Biology
Core, Hospital Clinic, Barcelona, Spain, 4University of the Ryukyus, Okinawa,
Japan, 5Hospital Clinic, Barcelona, Spain
Background: Cyclin D1 is an oncogene frequently overexpressed in human
cancers. In hematologicl neoplams, mantle cell lymphoma and multiple myelo-
ma are clear exemples of deregulated cyclin D1 expression. It plays a dual
function as cell cycle and transcriptional regulator, although the latter is widely
unexplored.
Aims: In this study, we investigate the transcriptional role of cyclin D1 in lym-
phoid tumor cells. We aim to study initial cyclin D1 oncogenic overexpression
in B cells as a model of the first steps in MCL oncogenesis.
Methods:
Chromatin immunoprecipitation (ChIP) followed sequencing was performed in
four established MCL cell lines. RNA-Sequencing (RNA-Seq) and information
from histone ChIP-Seq were correlated with genomic intervals displaying cyclin
D1 binding. Transcriptional downregulation was studied through cytometric
RNA total quantification in lymphoblastic cyclin D1-overxpressing models and
RNA Pol II ChIP-Seq.
Results: Endogenous cyclin D1 showed widespread binding to active promot-
ers and its overexpression was responsible for a global transcriptional down-
modulation. Cyclin D1, instead of showing specific gene activation, seems to
globally decrease cell transcription. Mantle cell lymphoma and multiple myelo-
ma cell lines displayed an inverse relation with cyclin D1 quantity. This tran-
scriptional effect was associated with an increased RNA polymerase II pausing
in promoters due to cyclin D1 overexpression.
Summary/Conclusions: This mechanism expands the oncogenic cyclin D1
functions and places the transcriptional machinery as a potential therapeutic
target in cyclin D1 overexpressing tumors.
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MICROENVIRONMENTAL EXPRESSION OF IMMUNOREGULATORY
MOLECULES AND CYTOKINES IN CLASSICAL HODGKIN LYMPHOMA
PROGNOSIS
O. Novosad1,*, N. Svergun2, O. Skachkova2, O. Gorbach2, N. Khranovska2,
I. Kryachok1
1Oncohematology, 2Experimental Oncology, National Cancer Institute, Kiev,
Ukraine
Background: Over the past decade, new biologic insights have revealed a
key role of tumor microenvironment in the pathogenesis of classical Hodgkin`s
lymphoma (cHL). cHL infiltrating cells produce cytokines and growth factors
that provide essential stimulatory signals for survival and proliferation of
Hodgkin`s and Reed–Sternberg cells. Moreover, clinical behavior of cHL may
be directly regulated by the cross-talk between tumor cells and infiltrating
immune cells.
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Aims: The aim of our study was to estimate the role of microenvironment
expression of immunoregulatory molecules (PD-1 ligands, IDO) and cytokines
(TGF-β, IL-13) in clinical outcome of cHL.
Methods: 74 patients (median age: 44, range: 17-71 years; males: 22, females:
52) were included in the study. 55.4% of patients were diagnosed with an early
stages of HL, while 44.6% - with advanced stages. ABVD or BEACOPP
(14/esc) were administered as a 1st-line therapy. 78.3% of patients achieved
remission (CR/PR), while 8.1% had progression of disease during the therapy.
We recorded 14.8% relapses in patients after the 1st line therapy during the
follow-up period (median duration – 36 months; range 6–66 months). PD-L1,
PD-L2, IDO, TGF-β, IL-13 mRNA expression levels were analyzed in fresh
pre-treatment lymph nodes biopsies using qRT-PCR.
Results: Expression of PD-1 ligands was heterogeneous across the samples
and did not depend on histological variant or stage of cHL. Only 12.1% of
patients (9/74) were PD-L1 negative and all but one of those cases had a CR
and a long-term remission. Patients with PD-L1 overexpression tended to have
a higher rate of relapse, comparing to low/absent PD-L1 expression (p=0.1).
We did not find any significant association between PD-L2 expression level
and clinical outcome of cHL. Expression levels of IDO, TGF-β, IL-13 were eval-
uated in 38 cHL samples. 18.4% (7/38) patient were IDO positive and 81.6%
(31/38) - IDO negative. The presence of IDO expression was associated with
a higher risk of relapse in cHL patients (p=0.006). 85.7% (6/7) and 23.3% (7/30)
of relapses were observed during the follow-up period in IDO+ and IDO-
patients, respectively (p<0.05). The patients with double negative expression
of PD-L1 and IDO were noted to have a favourable outcome of cHL. A 5-year
event-free survival (EFS) rate was 80% for double negative PD-L1-/IDO-
patients’ vs 20% for double positive PD-L1+/IDO+ patients (p=0.008). IL-13
was expressed at various levels depending on the stage of cHL with the highest
expression levels in advanced stages. A trend for a higher risk of relapse was
observed for HL patients with increasing level of IL-13, (p=0.23). TGF-β expres-
sion level was not association with histological variant or stage of cHL, however
multivariate analysis showed that TGFβ+ expression is a significant increase
EFS in cHL patients with HRs of 6.7 [95% (CI) 1.3-2.1, p=0.04].
Summary/Conclusions: Our results suggest that tumor microenvironment
plays an important role in clinical behavior of cHL. Hence, better understanding
of molecular mechanisms of interacted between tumor and immune cells prob-
ably can provide us with a novel promising strategy for relapsed/refractory cHL
treatment.
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AN IN VIVO TRACEABLE AND MULTIPLEXING CRISPR/CAS9 GENOME
EDITING SYSTEM
L. Cheng1,*, T. Niu1, Y. Liu2
1Department of Hematology and Research Laboratory of Hematology, 2State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital Sichuan
University, Chengdu, China
Background: Gene gain of function and loss of function mutations, oncogene
overexpression, gene amplification, chromosome deletion and epigenetic
changes, may lead to lymphoma onset.The CRISPR-Cas9 genome editing
system has become a feasible tool for exploring the functions of specific genes
in different contexts.We want to use this technique to screen for lymphoma
suppressor genes.
Aims: Construct an in vivo traceable and multiplexing CRISPR-Cas9 gene
editing system, which is high efficient for studying in vivo functions of both indi-
vidual genes or any given chromosome fragment.
Figure 1.
Methods: Two retroviral vectors were constructed via molecular clone, one of
which contains a locus for tandem U6-sgRNAs and inducible GFP reporter
gene and the other contains Cas9 and tTA genes. This system’s function of
traceable and simultaneously mutate multiple gene efficiencies were validated
in vitro. Eμ-myc HSPCs retrovirally transduced with sgp53 and Cas9 were
transplanted into sublethally irradiated C57/BL6 mouse.
Results: Co-transduced cells can be tracked by the expression of GFP protein
and multiple sgRNA can be efficiently introduced to the GFP-labeled cells for
simultaneously mutating multiple genes or deleting a large chromosome frag-
ment. Further we applied this system for both in vitro and in vivo genome edit-
ing. As an example, we show that Trp53 mutation accelerated Eμ-Myc driven
lymphoma onset in vivo.
Summary/Conclusions: This traceable and multiplexing CRISPR/Cas9 sys-




HDAC6 INHIBITION SENSITIZES TUMOR CELLS TO ANTI-CD20
IMMUNOTHERAPY IN VIVO
M. Bobrowicz1,*, M. Dwojak1, J. Stachura1, M. Angelika1, P. Beata1, S. Marta1,
N. Miazek1, P. Zapala1, J. Golab1, M. Winiarska1
1Department of Immunology, Medical University of Warsaw, Warsaw, Poland
Background: Down-regulation of CD20, a molecular target for monoclonal
antibodies, constitutes a clinically significant issue leading to decreased efficacy
of anti-CD20-based therapeutic regimens. The epigenetic modulation of CD20
coding gene (MS4A1) has been proposed as a mechanism for the reduced
therapeutic efficacy of anti-CD20 antibodies and confirmed previously with clin-
ically available non-specific histone deacetylase pan-inhibitors (HDACis). How-
ever, the identification of particular HDAC isoforms involved in CD20 regulation
seems to be of paramount importance. Since the use of pan-HDACi is associ-
ated with substantial side effects, especially difficult to manage in elderly and
frail patients, the new specific HDAC6 inhibitors are currently being tested in
multiple myeloma and non-Hodgkin lymphoma. They have already been shown
to sensitize tumor cells to proteasome inhibitors and novel kinase inhibitors
e.g. ibrutinib and demonstrated promising results in in vitro studies in chronic
lymphocytic leukemia (CLL). 
Aims: HDAC6 has been known for its regulatory role in protein degradation.
We have previously reported that inhibition of proteasome activity can effec-
tively increase CD20 levels in tumor cells. In our study we tested the hypothesis
that selective HDAC6 inhibition sensitizes tumor cells to immunotherapy with
anti-CD20 monoclonal antibodies (mAbs) by regulating CD20 levels.
Methods: We assessed the influence of HDAC6 inhibition in a panel of different
subtypes of human lymphoma cell lines (Burkitt, DLBCL; both EBV+ and EBV-
cells) on CD20 expression using flow cytometry and Western blotting. We con-
firmed our observations in primary samples from the patients with CLL, known
to express low CD20 levels. Moreover, we performed cytotoxic assays using
flow cytometry in order to assess complement-dependent cytotoxicity (CDC)
as well as apoptosis. We used HDAC6-specific chemical inhibitors (tubacin,
trichostatin A and clinically tested ricolinostat), as well as HDAC6 shRNA assay.
We also performed animal studies using SCID mice injected with Burkitt CD20+
lymphoma cell line s.c. and treated with rituximab i.p. We used both the phar-
macological ( i.p. administration of ricolinostat) and genetic (cells stably trans-
duced with HDAC6 shRNA ) approach.
Results: The results of our studies demonstrate that HDAC6 inhibition signif-
icantly increases CD20 level and sensitizes tumor cells to rituximab- and ofa-
tumumab-induced CDC, as well as to direct cytotoxicity of obinutuzumab. In in
vivo settings HDAC6 inhibition potentiated the efficacy of rituximab by signifi-
cantly reducing tumor size and prolonging the survival of the mice.
Summary/Conclusions: Our results clearly indicate that HDAC6 inhibition
sensitizes tumor B-cells to anti-CD20 immunotherapy. Therefore, we propose
HDAC6 inhibition with specific inhibitors as an effective strategy to be associ-
ated with the therapy with anti-CD20 mAbs. This strategy seems to be highly
promising in CLL patients, often expressing very low CD20 level and do not
fully benefiting from immunotherapy.
The work was supported by National Science Center 2013/09/N/NZ3/01407
(MB), 2015/16/T/NZ6/00034 (MB), 2014/13/N/NZ6/02081 (MS), 2015/18/E/
NZ6/00702 (MW), 2013/11/B/NZ5/03240 (BP), Polish Ministry of Science and
Higher Education grant IP2011 060271 (MW), DI2011 021241 (MB), DI
2014007344 (NM) and DI2013 006643 (AD), the Medical University of Warsaw
grant 1M19/PM/112D/14/14 (MB) and Horizon 2020 Programme, project
692180-STREAM-H2020-TWINN-2015 (JG).
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NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER
IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A
CELAC NETWORK STUDY
M. Cheminant1,2,*, J. Bruneau3, G. Malamut4,5, N. Guegan5, D. Sibon1,2,
A. Trinquand6, L. Lhermitte6, N. Brousse3, L. Frenzel12, R. Delarue1,
A. Marçais1, F. Suarez1,2, E. Macintyre6, V. Asnafi6, F. Lhospice7, C. Bonnafous7,
T. Molina3, B. Meresse5, C. Cellier4, N. Cerf-Bensussan5, O. Hermine1,2
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Background: Primary gastrointestinal (GI) T-cell lymphoproliferations (T-CL)
are heterogeneous entities, which diagnoses are difficult to perform. T-CL
include aggressive lymphoma such as enteropathy-associated T-cell lymphoma
(EATL) as well as indolent monoclonal lymphoproliferations. Refractory coeliac
disease type II (RCDII) is one of the indolent clonal T-CL that complicates coeli-
ac disease (CD) and may evolve toward an overt EATL. The differential diag-
nosis of RCDII from CD and RCDI is difficult and essentially based on negative
expression of sCD3 and CD8 and the presence of a clonal TCR rearrangement.
Lymphocytes from RCDII are dependent for survival on IL-15, which reprograms
T lymphocytes towards a cytotoxic NK phenotype.
Aims: We thus studied the expression of NKp46 on a representative panel of
GI T-CL to assess its diagnosis and prognosis value.
Methods: Using formalin-fixed paraffin-embedded tissue biopsies, we
assessed NKp46 expression by immunohistochemistry (IHC) and investigated
its clinical and biologic significance on 177 intestinal, 11 lymph node and 7
other biopsies from 84 CD or RCD patients (RCDI, n=20; RCDII, n=40), 44 GI
T-cell lymphoma patients (EATL, n=25; monomorphic epitheliotropic intestinal
T-cell lymphoma_MEITL, n=4; indolent T-LPD, n=15), 11 healthy patients and
5 patients with a GI inflammatory environment as controls.
Results: By doing ROC analysis on number of cells expressing NKp46 on GI-
TCL we identify that 25 intra-epithelial lymphocyte (IEL) per 100 epithelial cells
(EC) clearly separates RCDII from CD and RCDI patients, with a good positive
and negative predictive values (100 and 95% respectively). In healthy controls,
CD or RCDI patients, NKp46 was only expressed on scattered IEL (median
3%, 0-15). Based on NKp46 expression the overall survival is poor if over 25%
of IEL are positive for NKp46 (OS-5years 96.4% vs 72.8%, P=0.0004) (Figure
1A). Among patients with GI T-cell lymphoma, we show that NKp46 was
expressed in most of aggressive lymphoma (EATL 80%, n=20/25 and MEITL
100%, n=4/4). On the other hand, NKp46 was never expressed on indolent T-
LPD (n=0/15). The NKp46 expression was also associated with a poor prog-
nosis in GI T-cell lymphoma patients (OS-5years 50.5% vs 5.4%, P=0.0011)
(Figure 1B).
Figure 1.
Summary/Conclusions: The NKp46 expression in more than 25 IEL per 100
EC by IHC analysis can easily identify RCDII from CD and RCDI. Furthermore,
the NKp46 expression is associated with aggressive forms of GI T-cell lym-
phoma. Finally, the NKp46 expression was strongly associated with shortened
survival. Thus NKp46 provides a new biomarker for both diagnosis and prog-
nosis in GI T-CL.
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HIGH EXPRESSION LEVELS OF MIR23A CLUSTER IN DLBCL ANTAGONIZE
INDUCTION OF APOPTOSIS
N. Freytag1, C. Pommerenke2, Y. Merkhoffer1, J. Arribas Arranz1, D. Kube3,
H. Drexler2, H. Quentmeier2, S. Eberth1,*
1Junior Research Group Molecular Cancer Research, 2Department of Human
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ganisms and Cell Cultures, Braunschweig, 3Haematology and Oncology, Uni-
versity Medical Center Göttingen, Göttingen, Germany
Background: The microRNA cluster MIR23A, which encodes for the mature
microRNAs miR-23a, miR-27a and miR-24, was shown to be deregulated in
many different malignancies including subtypes of B cell non-Hodgkin lym-
phoma (B-NHL). Furthermore, high expression of miR-23a was correlated with
poor overall survival in diffuse large B-cell lymphoma (DLBCL) patients (Wang
et al., Med Oncol. 2014) indicating that miR-23a might act as an onco-miR
(tumor promoting microRNA) in this entity. However, both targets and function
of the MIR23A cluster in B-NHL remain unknown.
Aims: This study aims to elucidate the role of the MIR23A cluster as a potential
onco-miR in DLBCL by identification of the lymphoma-specific targetomes of
miR-23a and miR-27a and subsequent analyses of associated functions.
Methods: DLBCL model cell line U-2932 R1, which has a low basal expression
level of MIR23A cluster, was used for the lentiviral-based generation of clones
overexpressing miR-23a, miR-27a, or a scrambled control. Differentially
expressed genes (DEG, fold-change >2, p-value <0.05) between samples were
determined by mRNA sequencing (RNA-Seq). miR-23a and miR-27a targe-
tomes were identified by immunoprecipitation of AGO2-bound mRNA (AGO2-
RIP) followed by RNA-Seq. MicroRNA targets had to be enriched >2-fold with
a p-value <0.05. Validations were performed by qPCR and immunoblotting.
Gene set enrichment analyses (GSEA) and GO-term analyses were applied
on identified targetomes and DEG to predict microRNA associated functions.
Apoptosis was assessed by Annexin-V staining followed by FACS analyses as
well as in immunoblots.
Results: Overexpression of miR-23a and miR-27a, respectively, in a DLBCL
model cell line resulted in global alterations of gene expression (so-called indi-
rect targets) with a substantial overlap of 104 of DEG affected by both microR-
NAs. Using AGO2-RIP, 26 novel direct targets of miR-23a, and 20 novel direct
targets of miR-27a were identified. GSEA and GO-term analyses of direct and
indirect targets indicated that the MIR23A cluster might regulate processes in
apoptosis. Moreover, BBC3 which encodes the pro-apoptotic protein PUMA
was one of the identified direct targets of miR-27a. After etoposide induced
apoptosis, miR-27a overexpressing DLBCL cells failed to induce PUMA on pro-
tein level. Importantly, functional analyses confirmed that miR-23a overexpres-
sion reduces and high levels of miR-27a significantly attenuate the ability of
DLBCL cells to undergo apoptosis in response to DNA damage.
Summary/Conclusions: We demonstrate that high levels of miR-23a and miR-
27a antagonize induction of apoptosis in a DLBCL model cell line. This might
be one possible explanation why DLBCL patients with high miR-23a expression
levels have a worse overall survival rate than patients with low levels. Thus,
future studies should address the suitability of the MIR23A cluster as biomarker
and potential target in DLBCL.
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PLASMA CELLS ARISE FROM DIFFERENTIATION OF CLONAL LYMPHOCYTES
AND SECRETE IGM IN WALDENSTRÖM MACROGLOBULINEMIA
D. Talaulikar1,2,*, J.H. Lim1, J. Wang2, N. Hein2, A. El-Ayoubi2
1Haematology, Canberra Hospital, 2Australian National University, Australian
National University, Canberra, Australia
Background: Waldenström Macroglobulinemia (WM) is an indolent non-
Hodgkin lymphoma characterized by bone marrow infiltration with malignant
cells and hypersecretion of monoclonal immunoglobulin M (IgM). The malignant
infiltrate comprises of two distinct cellular populations: the predominant lym-
phoplasmacytic cells (LPLs), and a smaller number of plasma cells (PCs). 
Aims: In this study, we aimed to characterise the immunophenotype, molecular
genetics and secretory function of PCs in 2 WM cell lines. 
Methods: Using FACS, we identified LPLs as CD45bright/CD38dim/CD138-
/CD19+/CD20+cells and PCs as CD45dim/CD38+/CD138+ cells from 2 cell lines
- MWCL1 (Ansell lab) and BCWM.1 (Treon lab). We used standard PCR and
Sanger sequencing to assess MYD88 (using MYD88 L265P specific primers)
and Immunoglobulin heavy chain (IgHV) (using Biomed2 specific primers for
FR3) status. Finally to determine which population was predominantly responsible
for IgM hypersecretion, isolated PCs and LPLs from both cell lines were kept in
culture for 72 hours and the culture media analysed by ELISA for IgM secretion.
Results: Using a conservative sorting strategy, we analysed 2 WM cell lines
MWCL1 and BCWM.1, and found that MWCL1 had 5~6% PCs and 20-30%
LPLs; while BCWM.1 had 4-5% PCs and 10-20% LPLs. Cells that were
CD38+/CD138- or CD38-/CD138+ were not included. Both cell lines expressed
heterozygous MYD88-L265P mutation in both PC and LPL populations. We
also observed the expression of the same auto-reactive IgHV sequences (VH3-
15*01) in both PCs and LPLs from MWCL-1, suggesting similar clonal origin
and a role for auto-antigens in WM cell survival. We noted VH3-23*01 in the
LPL population of BCWM.1 but not in the PC compartment – the significance
of this remains uncertain. Cell culture studies showed that PCs alone were pri-
marily responsible for IgM production despite the relative lack of proliferation
and eventual cell death in MWCL-1 (~65% plasma cells remained after 72
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hours and produced 8.7 ~ 9.3 X 103 ng/ml of IgM). PCs isolated from BCWM.1
increased to 130% and produced 2.5 ~2.8 X 103 ng/ml of IgM. LPLs from both
cell lines proliferated in culture (~ 130 ~ 140% in MWCL-1 and ~170 ~ 200%
in BCWM.1 at 72 hours), gave rise to the more differentiated PCs (7.5 ~ 9.0%
PCs at 72 hours in MWCL-1 and 1.2 ~ 1.4% PCs in BCWM.1), and secreted
smaller amounts of IgM than PCs (3.5 ~ 5.0 X 103 ng/ml in MWCL-1 and 0.3
~ 0.7 X103 ng/ml in BCWM.1. 
Summary/Conclusions: Our analysis of the 2 WM cell lines provides evidence
to support the common hypothesis that malignant PCs arise from the clonal
malignant LPL population, and are primarily responsible for IgM secretion in
WM.
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LMP-1 MEDIATED UPREGULATION OF IL-2RΑ PROMOTES LYMPHOMA-
GENESIS AND CHEMOTHERAPY RESISTANCE IN NATURAL KILLER/T-CELL
LYMPHOMA AND COULD BE A POTENTIAL THERAPY TARGET
X.-W. Bi1, W.-J. Liu2, Z.-J. Xia2, W.-Q. Jiang1, H.-Q. Huang1, Y. Lu2, L. Wang2,*
1medical oncology, 2Hematologic Oncology, Sun Yat-sen University Cancer
Center, Guangzhou, China
Background: Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus
(EBV)-associated, highly aggressive lymphoma. Treatment outcome remains
sub-optimal, especially for advanced-stage or relapsed diseases. Our previous
study demonstrated the prognostic value of IL-2Rα in NKTCL, but the role of
IL-2Rα in the lymphomagenesis and chemotherapy resistance and its interac-
tions with EBV in NKTCL remain to be investigated.
Aims: This study investigated the mechanism of IL-2Rα expression in NKTCL,
and explored the role of IL-2Rα in lymphomagenesis and chemotherapy resist-
ance as well as the potential role of anti-IL-2Rα treatment in NKTCL.
Methods: Expression of IL-2Rα was measured in NK-92 (LMP-1 weak expres-
sion) and SNK-6 (LMP-1 strong expression) cells by western blot, quantitative
real-time PCR, enzyme-linked immunosorbent assay, and flow cytometry,
respectively. LMP1-harboring lentiviral vectors were transfected into NK-92
cells to examine the correlation between LMP1 and IL-2Rα expression. Proteins
in the downstream pathways of LMP1 signaling were measured in NK-92 cells
transfected with LMP1-harboring or negative control vectors as well as in SNK-
6 cells. Then IL-2Rα-harboring lentiviral vectors were transfected into both NK-
92 cells and SNK-6 cells to examine the cell proliferation by CCK8, apoptosis
by staining with Annexin V and detected by flow cytometry (FCM), cell cycle
distribution by FCM analysis, and IC50 values exposed to three chemotherapy
drugs (adriamycin, gemcitabine, and asparaginase) by MTT. Finally anti-IL-
2Rα antibody was added to investigate its ability of reversal of drug resistance.
Figure 1.
Results: Expression of IL-2Rα was significantly higher in SNK-6 cells than in
NK-92 cells, at both protein and mRNA levels. Expression of IL-2Rα was remark-
ably upregulated in NK-92 cells transfected with LMP1-harboring lentiviral vec-
tors compared with those transfected with negative control vectors. Proteins in
the MAPK/NF-κB pathway were upregulated in LMP1-expressing NK-92 cells
compared with the negative control. Selective inhibitors of those proteins induced
significant downregulation of IL-2Rα expression in LMP1-expressing NK-92
cells as well as in SNK-6 cells. When comparing with those transfected with
negative control vectors, cell growth was significantly increased in both NK-92
and SNK-6 cells transfected with IL-2Rα-harboring lentiviral vectors, and the
cell cycle assay displayed a significant decrease in the percentage of cells in
the G0/1 phase (p<0.05) and an increase in the percentage of cells in the S
phase (p<0.05), while apoptosis was not affected. Subsequent western blot
tests demonstrated that cyclin A, B, D, and CDK1, 4 were involved in the regu-
lation of cell cycle with overexpression of IL-2Rα. The IC50 values to all three
chemotherapy drugs were significantly increased after overexpression of IL-
2Rα (p<0.05), which can be fully reversed by addition of anti-IL-2Rα antibody.
Summary/Conclusions: IL-2Rα expression was upregulated in NKTCL by
LMP-1-mediated activation of MAPK/NF-κB pathway. IL-2Rα can promote NKT-
CL cell proliferation partially through regulation of cell cycles and induce
chemotherapy resistance, which can be reversed by anti-IL-2Rα antibody, indi-
cating the potential role of IL-2Rα as a therapy target in NKTCL. 
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LENALIDOMIDE (LEN) DRIVES PROGRAMMED DEATH-1 (PD1) PATHWAY
UPREGULATION IN A TUMOR MICROENVIRONMENT (TME) MODEL OF
ACTIVATED LOW-GRADE LYMPHOMA CELLS
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19Scientific Direction, IRCCS-A.O.U. San Martino-IST, Genoa, 20Hematology
Department, Annunziata Hospital of Cosenza, Cosenza, Italy
Background: PD1 binding to its ligand PDL1 inhibits TCR/BCR signaling;
impairs activation and effector functions of T- and B-cells; induces a state of T-
cell exhaustion; and ultimately provokes tolerance towards cancer cells. PD1
is expressed on Hodgkin lymphoma (HL) and B-cell non-HLT-cells.The TME
may play an essential role in maintaining PD1-induced immune exhaustion.
LEN is an oral immunomodulator (IMID) with direct antineoplastic activity and
immunologic effects, including stimulation of T-cell– and NK cell–mediated
cytotoxicity in experimental models.Preclinical findings indicate that combina-
tion of IMIDs with immune checkpoints inhibitors may promote therapeutic syn-
ergy and long-term antitumor immunity to improve clinical outcome.
Aims: 1) To better characterize the PD1, PDL1 and the lesser-known PDL2,
phenotype in peripheral neoplastic CD19+ lymphocytes and T-cell subsets in
patients with low-grade B-cell lymphoma; 2)to evaluate the role of the TME in
supporting the PD1 axis; and 3) to determine whether LEN influences PD1 or
cognate ligand expression
Methods: Samples obtained from patients attending participating Hematology
Units were used to determine PD1, PDL1, PDL2 phenotype (%±SEM) by Flow-
cytometry (FC). Autologous activated T-cells (AAT) were obtained by in vitro
co-culture of patient T-cells with anti-CD3/CD28 beads, rIL2 and with PBMCs.
Cultures were monitored daily until sizeable clumping was observed and tested
for PD1 and ligand expression. In selected experiments LEN(provided by Cel-
gene) was added to cell cultures.
Results: Twelve cases of lymphoma were evaluated for PD1, PDL1 and PDL2
expression on malignant B- and T-cells by FC. The expression of PD1 and PDL2
was similarly expressed, while PDL1 was almost undetectable on B-cells. Levels
of PD1 expression on CD3+ cells were variable across samples, however they
were significantly higher than those expressed on malignant B-cells. Significantly
higher PD1 expression and very low levels of ligands were detected inboth
CD4+ and CD8+ cells.Co-culture of lymphoma cells with AAT cells showed con-
sistent formation of B/T-cell clusters. Higher numbers of CD19+CD5-PDL2+
cells were detected than PDL1+ cells compared to baseline cells. PD1 expres-
sion also significantly increased in AAT co-culture on B-cells. PD1 expression
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on CD3+ cells was unaffected by AAT, although the expression of both ligands
increased significantly. Closer analysis of T-cell subsets showed that only in
CD4+ cells, PD1 expression increased significantly following co-culture experi-
ments.Preliminary data on lymphoma-AAT co-culture experiments (n=3) indi-
cated that LEN (0.5/1 uM) did not negatively influence the formation of AAT clus-
ters. After 48 h of co-culture, the expression of CD19+CD5-PDL1+ cells
increased in 2/3 cases following LEN treatment while, PDL2 expression
remained unchanged. PD1 expression gradually increased following exposure
to LEN compared to untreated cells.CD3+ cells showed a significant increase
in PD1 expression by LEN, while the expression of both ligands remained unaf-
fected. Evaluation of activated T-cell subsets showed similar results, with the
exception of stronger induction of PD1 and PDL1 expression by LEN in CD8+
cells.
Summary/Conclusions: Our data provide support for the potential involvement
of the PD1-axis in lymphoma patients. Interestingly, LEN further induces the
expression of PD1 in CD8+ and CD4+ cells and may contribute to reactivate
PD1 signaling under treatment. The PD1 pathway may be potentially targeted
to overcome both the intrinsic and LEN-induced exhaustion phenotype.
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IDENTIFICATION AND DIAGNOSTIC APPLICATION OF GENOMIC NPM-ALK
FUSION SEQUENCES IN ANAPLASTIC LARGE CELL LYMPHOMAS
M. Krumbholz1,*, C. Damm-Welk2, W. Woessmann2, M. Metzler1
1Department of Pediatrics, University Hospital Erlangen, Erlangen, 2Department
of Pediatrics, Justus-Liebig-University, Giessen, Germany
Background: ALK positive anaplastic large-cell lymphomas (ALCL) account
for 10-15% of pediatric Non-Hodgkin lymphomas. Most of these patients carry
the chromosomal translocation t(2;5)(p23;q35) resulting in the NPM-ALK fusion
gene formation. The quantification of NPM-ALK fusion transcripts is a well-
established tool for diagnostic purposes and risk stratification during the course
of treatment.
Aims: Establishment of a PCR based assay to identify patient-specific genomic
NPM-ALK fusion sequences for a DNA based monitoring of minimal residual
disease in ALCL patients. Compared to RNA based methods the quantification
of DNA is independent of the gene expression. Additionally, due to the higher
stability of DNA, cell-free circulating tumor DNA (ctDNA) should be detectable
in the patient´s plasma and may represent a tumor marker for “liquid biopsies”
in ALCL.
Methods: Using a specifically designed multiplex long-range PCR assay,
genomic NPM-ALK fusion sequences were identified in 45 ALCL patients. The
genomic NPM-ALK breakpoints were analyzed concerning fine structure and
breakpoint distribution pattern. Furthermore, the patient-specific genomic NPM-
ALK fusion sequences were evaluated for their use as biomarkers in selected
cases. For this purpose patient´s blood and plasma samples were quantified
using a high sensitive digital droplet PCR assay.
Results: In more than 60% of cases the identified breakpoint was localized
within repeat regions. The genomic breakpoints within the breakpoint cluster
regions of the fusion genes were randomly distributed. Most of the NPM-ALK
fusion sequences were characterized by the occurrence of small insertions or
deletions indicating the involvement of the non-homologous end-joining (NHEJ)
repair system for chromosomal translocation initiation.
Using a DNA based quantification assay in a subset of patients, the genomic
NPM-ALK fusion sequences were detectable in circulating tumor cells in
patient´s blood samples as well as cell-free tumor DNA in plasma samples.
Summary/Conclusions: The established multiplex long-range PCR assay is
a useful diagnostic tool for the identification of genomic NPM-ALK fusion
sequences. This individual tumor maker is independent of gene expression
and can be used for therapy response monitoring and relapse detection.
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ARSENIC TRIOXIDE TARGETS BCL6 FOR DEGRADATION AND INHIBITS
THE PROLIFERATION OF BCL6-DEPENDENT DIFFUSE LARGE B-CELL
LYMPHOMA
E. Tse1,*, K. Yue1, D. Chau2, Y.-L. Kwong1
1Department of Medicine, 2Medicine, The University of Hong Kong, Hong Kong,
Hong Kong
Background: B-cell lymphoma 6 (BCL6) is a transcription repressor and is
frequently over-expressed in diffuse large B-cell lymphoma (DLBCL). It sup-
presses the expression of its target genes ATR, TP53 and CDKN1A, leading to
dysregulation of DNA repair and cell proliferation. It has been shown that BCL6
is an oncoprotein involved in the pathogenesis of DLBCL and represents a
potential therapeutic target. Arsenic trioxide (ATO) targets various oncogenic
proteins, including PML-RARA in acute promyelocytic leukaemia (APL), Tax in
adult T-cell leukaemia/lymphoma (ATLL), cyclin D1 in mantle cell lymphoma
(MCL), and NPM-ALK in anaplastic large cell lymphoma (ALCL), for degradation
through the ubiquitin-proteasome pathway. ATO is now used for the manage-
ment of APL, ATLL and MCL with proven clinical benefit.
Aims: To investigate if ATO targets BCL6 and inhibits the proliferation and
growth of BCL6-dependent DLBCL
Methods: BCL6-dependency of a panel of DLBCL cell lines (i.e. OCI-Ly1,
OCI-Ly7, SU-DHL-6, OCI-Ly18 and Pfeiffer) was determined based on their
sensitivity to proliferation inhibitory activity of the BCL6 inhibitor 79-6 (Cal-
biochem). The effects of ATO and cisplatin as single agent or in combination
on cell viability and apoptosis of DLBCL cells were examined with MTT assay
and flow cytometric analysis. Expression of BCL6 and its target genes was
examined with quantitative RT-PCR and western immunoblotting. The thera-
peutic efficacy of ATO treatment was also examined in a DLBCL (OCI-Ly7)
xenograft mouse model.
Results: OCI-Ly1, OCI-Ly7 and SU-DHL-6 were highly sensitive to inhibitory
activity of BCL6 inhibitor and were designated as BCL6-dependent. Treatment
of DLBCL cells with ATO led to a decrease in BCL6 protein level and an upreg-
ulation of downstream targets of BCL6, including PRDM1, CD44 and CD69.
The effect of ATO on BCL6 protein were abrogated by treatment with protea-
some inhibitormg132, suggesting that ATO targeted BCL6 for degradation
through the ubiquitin-proteasome pathway. Interestingly, ATO also inhibited cell
proliferation and induced apoptotic cell death of BCL6-dependent DLBCL cell
lines, analogous to the effect of BCL6 inhibitor on these cells. In addition, there
was a synergistic inhibitory and cytotoxic activity between ATO and cisplatin.
Finally, ATO treatment suppressed the growth of DLBCL in a xenograft mouse
model.
Summary/Conclusions: ATO targets BCL6 for proteasomal degradation and
inhibits the proliferation and growth of BCL6-dependent DLBCL.
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PROTEOMIC PHOSPHOSITE ANALYSIS IDENTIFIED CRUCIAL NIPA
SERINE RESIDUES FOR NPM-ALK-MEDIATED TRANSFORMATION
A. Gengenbacher1,*, A. Rudorf1,2, T. Poggio1, C. Rummelt1, S. Kreutmair1,
V.I. Dumit3, J. Duyster1,2, A.L. Illert1,2
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Background: Anaplastic large-cell lymphoma(ALCL) is an aggressive non-
Hodgkin lymphoma that occurs mainly in children and younger adults. Patients
typically show an advanced stage disease as well as an aggressive disease
pattern with extralymphatic manifestations. At the molecular-genetic level, 60%
of the patients with systemic ALCL exhibit a translocation t(2;5)(p23;q35), which
leads to the expression of the NPM-ALK fusion protein. Under the control of the
NPM promoter, ALK activation causes increased and autonomous cell prolifer-
ation. Nuclear interaction partner of ALK (NIPA) was first identified as a new
interaction partner of the oncogene NPM-ALK in a yeast-2-hybrid screen which
defines an E3-SCF ligase and is physiologically involved in cell cycle regulation
at the transition from G2 phase to mitosis. It has already been shown in prelim-
inary studies that co-expression of NIPA with the oncogenic tyrosine kinase
NPM-ALK results in the constitutive phosphorylation of NIPA (Illert et al., 2012a).
Until now, the specific signal transduction pathway, the crucial phosphorylation
sites as well as the functional effect of the pathological NIPA phosphorylation in
NPM-ALK-induced lymphomagenesis still remain unclear. Molecular insights
into the activated pathways of the oncogenic tyrosine kinase NPM-ALK may
help to identifiy new drugable targets for therapeutic implications.
Aims: In the present study, we investigated the molecular mechanisms as well
as the functional impact of the NPM-ALK-induced NIPA phosphorylation.
Methods: For this purpose, biochemical methods with ALCL cells were used
to examine functional effects of the constitutive NIPA phosphorylation. More-
over, we performed a “proteomic-phosphosite-analysis” to identify crucial NPM-
ALK specific phosphorylation sites in NIPA. Based on these results, phospho-
deficient NIPA mutants were generated to investigate the functional effect of
this phosphorylation: MTT proliferation- and Softagar- Assays were performed
after retroviral infection of Ba/F3 and primary Nipa-deficient MEF cells with
NPM-ALK and the respective phospho-deficient NIPA to reveal transformation
and growth ability.
Results: It has already been shown, that cell cycle dependent NIPA phospho-
rylation at critical serine residues 354, 359 and 395 leads to dissociation of the
SCF-core complex. Interestingly, we were able to show in our study that con-
stitutive phosphorylation of NIPA by NPM-ALK does not lead to changes in the
SCFNIPA-complex formation. Proteomic-Phosphosite-analyses identified 10 sig-
nificantly upregulated (ratio >2; Log2Fold Change) NIPA phosphosites upon
NPM-ALK expression. Interestingly, 80% of the identified Serine phospho-
residues lie within the NPM-ALK binding region of NIPA. This result was further
substantiated by generation of a AAΔ310-402 mutant, where NIPA phosphory-
lation by NPM-ALK was totally abolished. To further prove biological significance
of the identified residues, phospho-deficient mutants were established and
transformation assays were performed. Here we were able to show drastically
impaired cell proliferation in mutants with silenced serine/threonine residues
338, 344, 370, 381 and 387 upon NPM-ALK expression.
Summary/Conclusions: Taken together, we identified five phosphorylation
sites in NIPA to be highly upregulated upon NPM-ALK expression. However,
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NPM-ALK mediated NIPA-phosphorylation of those sites did neither change
the SCFNIPA-complex formation nor influence the NIPA localization at the
nuclear pore complex, but silencing of these NIPA Serine/Threonine residues
led to significantly reduced proliferation and altered transformation ability of
Ba/F3 and primary MEF cells. Further analyses will shed some light into the
mechanisms underlying these findings and evaluate NIPA as a possible new
treatment option for ALCL.
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APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY
DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B CELL
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Background: Diffuse large B cell lymphoma (DLBCL) can be divided according
to cell of origin (COO) in germinal center B-cell–like (GCB) and activated B-
cell–like (ABC) that have been shown different prognosis. Immunohistochem-
istry (IHC)-based algorithms and recently, Lymph2Cx assay, a digital test based
on the expression of 20 genes, have been developed to facilitate COO assign-
ment in clinical practice. Although the importance of COO is well established
in DLBCL arising in immunocompetent individuals, its applicability on HIV-
infected patients has been scarcely studied.
Aims: To study the characteristics and prognostic impact of COO subtypes in
a series of HIV-related DLBCL using the Lymph2Cx assay and to compare the
results with those obtained with an IHC-based algorithm.
Methods: A series of 55 patients with the diagnosis of HIV-related DLBCL
(N=48), high-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6
rearrangements (N=3), or HGBL NOS (N=4) was studied. The following clinical
parameters were collected from records: age, gender, ECOG, extranodal and
bulky disease, B-symptoms, Ann-Arbor stage, LDH and beta2-microglobulin,
HCV and HBV serology, history of opportunistic infection and of AIDS-defining
illness, onset of combination antiretroviral therapy, CD4-counts and HIV loads.
IHC and FISH studies were performed on tissue microarrays. RNA was extract-
ed from FFPE samples with RecoverAll kit (Ambion, Carlsbad, California) and
digital GEP was determined with the Lymph2Cx assay (NanoString Technolo-
gies, Seattle, WA). Cohen’s kappa was calculated to measure the agreement
between COO given by Hans algorithm and Lymph2Cx assay.
Table 1.
Results: The median follow-up of living patients was 8.5 years. IHC studies
showed that 35.8% of the cases expressed CD10, 61.5% expressed BCL6,
55.8% expressed MUM1, and according to Hans algorithm 56.6% had a non-
GC phenotype. CD30 was expressed in 15.4% of the cases and EBER was
found in 21.2%. The expression of MYC was detected in 32.7% of the cases
and BCL2 in 44%, and 18% were dual expressers. Rearrangements involving
MYC, BCL2 and BCL6 were detected in 26%, 8% and 28%, respectively. The
Lymph2Cx assay assigned a COO to all 55 studied cases, 63.6% were GCB
subtype, 20% were ABC subtype, and 16.4% were unclassified. The only clin-
ical feature significantly associated with a defined COO subtype was B-symp-
toms (ABC=81.8% vs GCB=28.6%, P=0.003) and HIV-load tended to be more
frequently observed in ABC (90%) than in GCB (58.1%, P=0.066). Regarding
IHC and FISH results, MYC rearrangements were only detected in GCB cases
and expression of CD10 and BCL6 tended to be associated with GCB (Table
1). Hans algorithm and Lymph2Cx assay differently assigned COO subtypes
(κ=-0.288, P=0.029) showing that 44.1% of the GCB cases had a non-GC phe-
notype according to Hans. Only patients treated with RCHOP were considered
in survival analyses (N=47). COO subtypes had neither impact on OS nor PFS,
independently of being determined with Hans or Lymph2Cx assay. Features
associated with shorter OS and PFS were history of AIDS-defining illnesses,
HCV-infection and dual MYC and BCL2 expression. Extranodal disease and
increased MYC or BCL2 expression were also bad prognostic factors for PFS.
Summary/Conclusions: In HIV-related lymphomas, COO subtypes were dis-
cordantly assigned with Hans and Lymph2Cx assay and COO subtypes
showed no impact on outcomes, independently of the method applied.
This work was supported by 2014 SGR225 (GRE) from CERCA Programme/
Generalitat de Catalunya, and by funds from Josep Carreras International
Foundation, “la Caixa” Foundation and Celgene Spain.
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CXCR4 AND CXCL12 ARE IMPLICATED IN BONE MARROW INFILTRATION
PROCESS OF AGGRESSIVE B CELL LYMPHOMAS AND THEIR INHIBITION
SUPPRESSES LYMPHOMA CELL GROWTH IN VITRO
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Background: The chemokine receptor CXCR4 together with its prime ligand
CXCL12 plays a pivotal role in tumorigenesis of solid and haematological neo-
plasms. Our comprehensive study on the CXCR4 expression in aggressive
lymphoma demonstrated that high CXCR4 expression was associated with
poor clinical course of aggressive lymphoma patients.
Aims: Therefore, we aimed to comprehensively study the implication of the
CXCR4 - CXCL12 axis in bone marrow infiltration process of aggressive lym-
phoma and to analyse the effects of CXCR4 antagonists on cell growth and
migration of aggressive lymphoma cells in vitro.
Methods: To determine whether CXCR4 and CXCL12 expression have any
effects on the bone marrow infiltration process of aggressive lymphomas, we
performed gene expression analysis on bone marrow biopsies of our diffuse
large B-cell lymphoma patient cohort. Therefore, we used 63 bone marrow
specimens, whereby 52 bone marrow biopsies were taken at time of diagnosis.
Additionally, we generated a novel CXCR4 antagonist -named WK1- by mod-
ification of the side chain of AMD070 - a commercially available CXCR4 antag-
onist. We treated various aggressive lymphoma cell lines (U2932 and RI-1 as
ABC-DLBCL and BL2 and Raji as Burkitt lymphoma lines) with CXCR4 antag-
onists (AMD070 and its derivate WK-1 and the FDA approved CXCR4 antag-
onist AMD3100) and determined cell growth by using the EZ4U assay. Trans-
well migration using the Boyden chamber was used to estimate migration
indices for AMD070 and WK-1.
Results: By correlating CXCL12 expression levels of infiltrated bone marrow
biopsies, we observed a significant positive correlation between CXCL12
expression and the percentage of infiltration levels (Spearman-Rho=0.764;
p=0.001). Furthermore, remission inthe bone marrow after standard
immunochemotherapy was associated with a reduction of CXCR4 expression
(p=0.075). The cell growth of BL2 and RI-1 cell lines -exhibiting strong and
moderated CXCR4 expression- was significantly inhibited by AMD070 and
WK1. Whereas the cell growth of U2932 -exhibiting a weak CXCR4 expres-
sion- was just affected by WK1. AMD3100 did not show any effects on the lym-
phoma cell growth. The transmigration index to evaluate the chemotactic ability
of lymphoma cells was reduced by AMD070 and WK1 treatment, however, the
inhibitory effects of WK1 were lower compared to AMD070.
Summary/Conclusions: These data strongly suggest that CXCR4 and its lig-
and CXCL12 is implicated in the bone marrow infiltration process of diffuse
large B-cell lymphomas. Additionally, our in vitro results indicate that treatment
of lymphoma cells with CXCR4 antagonists might be a promising new thera-
peutic intervention to eliminate lymphoma cells.
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EPSTEIN-BARR VIRUS LOAD IN PLASMA IS AN EARLY BIOMARKER OF
HIV-RELATED LYMPHOMA
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Background: Epstein Barr virus (EBV) has been detected in the tumor cells of
some non-Hodking lymphomas (NHL) and Hodgkin lymphomas (HL) and
detectable EBV loads have been found in the plasma of immunocompetent
patients with HL. In HIV-related lymphomas the importance of EBV load as
potential lymphoma biomarkers has been scarcely studied.
Aims: We aimed to evaluate the usefulness of EBV load in plasma as lym-
phoma biomarker in HIV-infected patients.
Methods: One hundred and fifteen patients with NHL (HIV-infected =57 and
HIV-uninfected=34) and HL (HIV-infected= 16 and HIV-uninfected= 8) were
studied. EBV loads were determined in plasma by means of a commercial real-
time PCR technique (EBV PCR kit, Qiagen GmbH, Hilden, Germany) at lym-
phoma diagnosis and in a group of HIV-infected patients also at one year before
diagnosis (N=11) and at complete response (CR) (N=34). EBER expression
was studied by in situ hybridization in tumor biopsies. The following clinical and
biological parameters were collected from records: age, gender, date of lym-
phoma diagnosis, ECOG score, extranodal and bulky disease, B symptoms,
Ann-Arbor stage, serum lactate dehydrogenase and beta2-microglobulin, Inter-
national Prognostic Index (IPI), HCV and HBV serology, history of opportunistic
infection and of AIDS-defining illness, onset of combination antiretroviral ther-
apy, CD4-counts, HIV loads, type and date of response, relapse date, last follow
up or death date. McNemar’s test and Wilcoxon test were used to compare
quantitative and qualitative variables, respectively. Survival analyses were per-
formed using the Kaplan-Meier method. P-values of less than 0.05 were con-
sidered statistically significant.
Figure 1.
Results: At diagnosis, EBV loads were detectable in more HIV-infected patients
than HIV-uninfected (48% vs 14%, P=0.002) and in more HL cases than NHL
(70% vs 26.3%, P=0.006). In HIV-infected patients, detectable EBV load was
associated with EBER expression, 66.6% of the patients with detectable EBV
loads had EBER-positive tumors and 92% of the patients with undetectable
EBV loads had EBER-negative tumors (P=0.003). All the remaining clinical and
biological features were not associated with detectable EBV load in plasma. In
HIV-uninfected patients, associations between EBV load and EBER expression
(P=0.006) and EBV load and HBV infection (P=0.017) were observed. From
16 out of 34 (47%) HIV-infected patients with detectable EBV loads at lym-
phoma diagnosis, 15 had undetectable EBV loads at CR (P<0.001) (Figure 1).
The exception was one patient with HL whose EBV load substantially decreased
at CR but was still detectable. Moreover, 4 out of 7 HIV-infected patients with
detectable EBV loads at diagnosis had detectable loads one year before diag-
nosis, and no patient with negative EBV loads at diagnosis had detectable
loads before it, pointing EBV load can be used as an early biomarker of lym-
phoma. EBV loads at diagnosis had neither impact on overall survival nor pro-
gression-free survival.
Summary/Conclusions: EBV-load in plasma can be used as early biomarker
of lymphoma in HIV-infected patients since EBV-loads can be detected up to 1
year before lymphoma diagnosis and are virtually undetectable at lymphoma CR.
This work was supported by 2014 SGR225 (GRE) from CERCA Programme/
Generalitat de Catalunya, and by funds from Josep Carreras International Foun-
dation,“la Caixa” Foundation and Celgene Spain.
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Background: T-cell large granular lymphocyte leukemia (T-LGLL) is a rare
heterogeneous T-cell neoplasia whose leukemic cells usually express the αβ
T-cell receptor (TCR); only a small subset of cases expresses the γδ TCR
denoting the TCRγδ LGLL. Currently, among the different LGL diseases, TCRγδ
LGLL remains less studied and several clinical and laboratory data already
described in TCRαβ-LGLL have not yet been explored in TCRγδ-LGLL.
Aims: The aims of this work were 1) to characterize TCRγδ-LGLL defining
STAT mutational pattern and CDR3 repertoire diversity/clonal composition
(clonotype) and 2) to evaluate correlations among LGL phenotype, mutations,
TCR rearrangement and clinical presentations.
Methods: In this work 11 patients affected by TCRγδ-LGLL were included.
Sanger sequencing was used for mutational analysis on hot-spot regions in
the two genes more frequently mutated in LGL disorders, STAT3 and STAT5b.
Immunophenotype of LGL clone was defined by flow cytometer analysis. CDR3
repertoire and frequency distribution of TCR gamma gene rearrangements
were obtained by Next-Generation Sequencing (NGS).
Results: Our results showed that TCRγδ LGLL had a high incidence of STAT
mutations, 9 out of 11 patients carrying STAT3 or STAT5b mutations in a mutu-
ally exclusive pattern. At variance from CD8+ TCR αβ LGLL and CD4+ TCR αβ
LGLL, the first being mostly characterized by STAT3 mutations and the latter
by STAT5b, TCRγδ LGLL patients were characterized by both the mutations.
Thus, TCRγδ LGLL showed features shared by CD8 and CD4 TCRαβ-LGLL.
Consistently, TCRγδ LGLL showed the same correlation between immunophe-
notype and kind of mutation observed in TCRαβ-LGLL: γδLGL patients with
CD16+/CD56- LGL immunophenotype were characterized by STAT3 mutations
(as in CD8+ T-LGLL), while γδLGL patients with CD56+ LGL immunophenotype
by STAT5b mutations (as in CD4+ T-LGLL). Moreover, we observed that
patients with γδLGLs positive for Vδ2 showed usually indolent course, while
Vδ1 was linked to a more symptomatic disease (4 out of 5 symptomatic patients
were Vδ1+), whereas no correlation was found between mutations and clinical
course. By NGS of TCR gamma gene, we observed that all patients were clonal
but two, showing a polyclonal pattern borderline with clonality percentage
defined by sequencing kit criteria. Interestingly, these two last patients were
the only two patients without STAT mutations. As far as the remaining cases
are concerned, among STAT3 mutated patients (n=4), 3 were polyclonal and
one biclonal, while STAT5b mutated patients (n=5) were more frequently mon-
oclonal (4/5 monoclonal and 1/5 biclonal). In terms of clonal rearrangements,
Vg3-Jg1/2, Vg9-JgP and Vg8Jg1/2 were the combination usages most fre-
quently detected. Concerning the clonotype repertoire, CDR3 sequences of
the immunodominant clones were present with low frequency in almost all the
other γδ patients and two different CDR3 sequences were found shared, each
one in two different patients at frequency >10% of the total rearrangements.
Summary/Conclusions: Our data indicate that TCRγδ LGLL can be consid-
ered at the intersection of the two types of TCRαβ-LGLL, sharing CD8 or CD4
TLGLL mutational features. As already described in TCRαβ-LGLL, also in γδ
disease a decreased diversity of TCR repertoire was demonstrated. However,
in these γδLGL patients STAT mutations do not correlate with a symptomatic
clinical behavior while STAT5b mutations seems to be more frequently linked
to monoclonal nature of the LGL lymphoproliferation. Rather, the marker Vδ1
appears to be correlated to symptomatic disease.
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INCREASED EXPRESSION OF IRF8 IN TUMOR CELLS INHIBITS THE GEN-
ERATION OF TH17 CELLS AND PREDICTS UNFAVORABLE
SURVIVAL OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS
Q. Li1,*, W. Zhong1
1Guangzhou First People’s Hospital, Guangzhou Medical University,
Guangzhou, China, Guangzhou, China
Background: The immunological pathogenesis of diffuse large B cell lym-
phoma (DLBCL) remains elusive. Searching for new prognostic markers of
DLBCL is a crucial focal point for clinical scientists. 
Aims: The aim of the present study was to examine the prognostic value of
interferon regulatory factor 8 (IRF8) expression and its effect on the develop-
ment of Th17 cells in the tumor microenvironment of DLBCL patients. 
Methods: Flow cytometry, immunohistochemistry, and quantitative real-time
PCR were used to detect the distribution of Th17 cells and related cytokines
and IRF8 in tumor tissues from DLBCL patients. Two DLBCL cell lines (OCI-
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LY10 and OCI-LY1) with IRF8 knockdown or overexpression and two human
B lymphoblast cell lines were co-cultured with peripheral blood mononuclear
cells (PBMCs) in vitro to determine the effect of IRF8 on the generation of Th17
cells. Quantitative real-time PCR and Western blotting were used to investigate
the involvement of retinoic acid receptor-related orphan receptor gamma t
(RORγt) in the effect of IRF8 on Th17 cell generation. The survival of 67 DLBCL
patients was estimated using the Kaplan-Meier method and log-rank analysis. 
Results: The percentage of Th17 cells was lower in DLBCL tumor tissues than
in PBMCs and corresponding adjacent benign tissues. Relative expression of
interleukin (IL)-17A was lower, whereas that of interferon (IFN)-γ was higher in
tumor tissues than in benign tissues. Co-culture with DLBCL cell lines inhibited
the generation of Th17 cells in vitro. IRF8 upregulation was detected in DLBCL
tumor tissues, and it was associated with decreased DLBCL patient survival.
Investigation of the underlying mechanism suggested that IRF8 upregulation inhib-
ited Th17 cell generation by suppressing the effect of RORγt on CD4+ T cells.
Summary/Conclusions: Our findings suggest that IRF8 expression in the
tumor microenvironment inhibited the generation of Th17 cells through its
antagonistic effect on RORγt in the DLBCL tumor microenvironment, suggest-
ing that it could be a prognostic factor for DLBCL.
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Background: Diffuse large B cell lymphoma (DLBCL) is an aggressive disease
featuring heterogeneous genetic, phenotypic and clinical characteristics.
Recently, a negative prognostic impact of double expression of BCL2 and MYC
(double expressor (DE) lymphoma) has been identified in several studies. SNP
array (SNP-A) studies have already led to the identification of novel genomic
aberrations in ABC and GCB subtypes of DLBCL whereas similar analysis has
not been done in DE and non-DE DLBCL. 
Aims: To characterize the landscape of genomic aberrations in DE and non-
DE DLBCL groups using SNP-A and interphase fluorescence in situ hybridiza-
tion (FISH).
Methods: Immunohistochemical and FISH analysis was performed on tissue
microarray of formalin fixed paraffin embedded (FFPE) tumor tissue samples
using Bcl2 (124, DakoCytomation) and MYC (Y69, Epitomics) antibodies and
FISH MYC (Zytovision), Bcl2 (Abbott/Vysis), Bcl6 (Abbott/Vysis) break-appart
probes and MYC/IgH (Zytovision) double-fusion probe. Infinium HD whole-genome
genotyping assay with the HumanCytoSNP FFPE-12 BeadChip (Illumina Inc.,
San Diego, CA, USA) was performed for genomic analysis of the aberrations.
Results: A cohort of 91 primary DLBCL patients diagnosed between 2004 and
2012 was selected for the study. Immunohistochemical evaluation was inform-
ative in 84 cases, 25 cases (29.8%) were DE. On FISH analysis, 61 cases
were informative for MYC, 56 cases for Bcl6, and 65 cases for Bcl2. 7 cases
(11.4%) were positive for MYC translocation, 14 (25%) for Bcl6, and only 3
(4.6%) were positive for Bcl2. No cases of FISH MYC and bcl2 double positive
DLBCL were identified. Genomic DNA from FFPE tumor tissue for SNP-A was
available in 66 DLBCL cases. SNP-A analysis detected in total 329 genetic
abnormalities not corresponding to known copy number polymorphisms (89%
of all the patients, 59/66). These comprised 164 (50%) hemizygous and 2 (1%)
homozygous deletions, 106 (32%) gains, 41 (12%) trisomies and 16 (5%)
monosomies. The most common aberrations were 1p deletion, 1q gain, 6q
deletion and 3q gain. Complex karyotype (>3 aberrations) was detected in
37/66 (56%) patients. Both DE and non-DE DLBCL groups had equal rate of
aberrations per case (~5 aberr./case) and shared the most common aberrations
– 1p deletion and 1q gain. In contrast, 11q deletion was more common in DE,
while 6q and 17q deletions were more prevalent in the non-DE had group.
Notably, we detected a higher proportion of hyperdiploidic karyotypes in non-
DE group than in DE (16 vs 6 cases, respectively). Cases with MYC positive
(FISH) and MYC gain (SNP-A) had the median number of two chromosomal
aberrations with an exception of two MYC positive cases with complex kary-
otypes. These two cases shared the same 9q, 11q, 14q deletions and the
monosomy of chromosome 19. Finally, of the 7 cases with normal SNP-A kary-
otype, BCL6 FISH-positive marker was detected in 3 patients.
Summary/Conclusions: SNP-A analysis highlights the genomic differences
between the DE and non-DE DLBCL. Our finding of MYC positive (transloca-
tions and/or gains) association with low complexity karyotype status may sug-
gest MYC to be an early initiating genetic event.
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ARQ 531, A REVERSIBLE BTK INHIBITOR, DEMONSTRATES POTENT
ANTI-TUMOR ACTIVITY IN ABC-DLBCL AND GCB-DLBCL
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Background: B-cell receptor (BCR) signaling has emerged as a critical path-
way for B-cell lymphoma development. BTK, a key mediator of BCR signaling
is a major target for ibrutinib. Ibrutinib has demonstrated efficacy in chronic
lymphatic leukemia (CLL), mantle cell lymphoma and Waldenström macroglob-
ulinemia. However, as anticipated by preclinical models, clinical objective
response rates of only 37% in ABC and 5% in GCB diffuse large B cell lym-
phoma (DLBCL) were reported. ARQ 531 is a potent reversible inhibitor of
BTK, highly effective in targeting BCR signaling. Kinase profiling indicated
members of Tec, Src, Trk families as additional targets with especially potent
inhibition of HCK and BLK kinases. ARQ 531 caused significant growth inhibi-
tion (GI50=< 1µM) of hematological malignant cell lines and and showed greater
efficacy than ibrutinib in a CLL mouse model. 
Aims: We aim to assess biological and anti-tumor effects of ARQ 531 in in
vitro and in vivo in DLBCL tumor models.
Methods: Biochemical inhibition and kinase profiling were assessed using
recombinant proteins. The ARQ 531 binding kinetics on BTK were determined
by Surface Plasmon Resonance assay. Anti-proliferative activity of ARQ 531
was tested in a MTS-based assay against a panel of hematological malignant
cell lines. Pathway inhibition assessments, in vivo efficacy and in vivo target
inhibition were performed in TMD8 (ABC-DLBCL) and SUDHL-4 (GCB-DLBCL)
cell lines and xenografts. ADME and pharmacokinetic properties of ARQ 531
were also evaluated in rats, dogs and monkeys. 
Results: ARQ 531 potently inhibited BTK (IC50=0.85 nM) and displayed long
residence time (56 min). ARQ 531 exhibited strong anti-proliferative activity in
TMD8 (GI50=0.13 µM) and SUDHL-4 (GI50=0.2 µM) cell lines. Ibrutinib, while
potent on TMD8 cells (GI50=0.002 µM), had a GI50 of 1.1 µM in SUDHL-4, a
concentration not reached in human blood, consistent with published studies.
Pathway analysis in TMD8 and SUDHL-4 cells showed that ARQ 531 potently
inhibited both upstream activating signals (Src kinase family) and downstream
signaling pathways such as AKT and ERK. Cell cycle analysis indicated that
ARQ 531 inhibited cell growth through G1 phase arrest, similar to ibrutinib. In
the TMD8 xenograft mouse model, ARQ 531 strongly inhibited BTK signaling,
with better efficacy than reported with ibrutinib: tumor growth reduction was
97% after 12 days of dosing, with no re-growth observed for 17 days post dose
interruption. In the ibrutinib-resistant SUDHL-4 mouse xenograft model, ARQ
531 potently suppressed tumor growth (>80% inhibition) compared to the con-
trol group.
Summary/Conclusions: ARQ 531 is a potent reversible inhibitor of BTK. Its
distinct kinase selectivity can be used to target constitutive BCR signaling in
DLBCL primarily resistant to ibrutinib, as demonstrated by the excellent efficacy
in both ABC and GCB DLBCL xenograft models. These data support the clinical
investigation of ARQ 531 in patients with hematological malignancies, expected
to begin in mid-2017. 
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ROLE OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN
DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS
OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY
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Pescia, Pescia, 7Oncologia, Ospedale Lucca, Lucca, 8Oncologia, Ospedale
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Background: Standard chemotherapy represented by the R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone) regimen is successful
in about 60% of patients (pts) with diffuse large B-cell lymphoma (DLBCL). Pts
who do not benefit from this treatment, due to the development of tumor drug
resistance, have a very poor prognosis. Currently, knowledge on reasons of
treatment related failures in DLBCL are scanty and predictive biomarker of
response are largely unknown. 
Aims: We hypothesized that polymorphisms of gene involved in the pharma-
cokinetics and pharmacodynamics of drugs included in R-CHOP regimen may
play a role in predicting the outcome in DLBCL pts. Thus, we designed a mul-
ticentre prospective pharmacogenetic trial aimed at identifying gene polymor-
phisms potentially predictive of drug efficacy/resistance in DLBCL pts treated
with R-CHOP. We are reporting update data of an interim analysis on the first
80 enrolled pts.
Methods: The study includes chemonaive DLBCL pts (Ann Arbour I-IV stages)
candidate to an R-CHOP standard treatment. The Ethical Committee of each
participating centre approved the pharmacogenetic protocol, and all pts signed
a written informed consent. In this interim analysis, the impact of single
nucleotide polymorphisms (SNPs) on R-CHOP efficacy was evaluated by
objective response (OR) rate, progression-free survival (PFS) and overall sur-
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vival (OS).The efficacy of R-CHOP was evaluated according to Cheson criteria
by performing standard hematochemical and instrumental (TC and FDFG-PET)
tests and defining complete remission (CR), partial remission (PR), non
response or progressive disease (PD). Genomic DNA was extracted from
peripheral blood of 80 pts. SNPs analysis was performed by an Affimetrix array.
To date, 21 SNPs from 19 candidate genes (ABCB1, ABCC1, ABCC2, ABCG2,
CYBA, CYP2C9, FCGR2A, GSTP1, IL2, MARCKS, MLH1, NCF4, NQO1,
NQO2, RAC2, TNF, TOP2A, TP53, TUBB) involved in pharmacokinetics and
pharmacodynamics of R-CHOP (www.pharmgkb.org) selected and analysed
in relation to R-CHOP efficacy. Univariate and multivariate logistic regression
analyses were performed to evaluate associations between SNPs and
clinical/pathological characteristics or survival parameters (PFS and OS).
Results: Median age was 63 years. There were 37 men and 43 women. 47.5%
of pts were in stage I-II, 52.5% of pts in stage III-IV. 27.5% of pts had bulky dis-
ease, 43.8% of pts had involvement of extranodal site. 47.5% of pts had patho-
logical LDH value. According to the revised IPI, 15% of pts were in the low risk
group, 58.7% in the intermediate, and 26.3% in the high risk group. Overall,
468 courses of R-CHOP had been administered (mean: 5.85 courses, range:
4-6). 88,7% of pts had CR to R-CHOP whereas the remaining showed PR or
SD (7.5%) or PD (3,8%). Multivariate analysis identified FCGR2A rs1801274
as a predictor of PFS (p=0.045). Pts with HR or RR genotypes showed shorter
PFS than pts with HH genotype (HR: 2.437, CI95% 1.020-5,823). No statistically
significant correlation was found between SNPs and OS.
Summary/Conclusions: Our preliminary data obtained in a limited number of
pts, show an association between a SNP of the low affinity FCGR2A gene
involved in the activity of rituximab and PFS. Further insights will derive from
the completion of pts accrual to reach the planned number of cases at the end
of our study.
This work was supported by a grant from the Associazione Giacomo Onlus,
Castiglioncello (LI), Italy to E.M. and Cassa di Risparmio di Firenze, Firenze,
Italy to S.N.
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CDK4/6-INHIBITION BY ABEMACICLIB INDUCES POTENT EARLY
G1-ARREST IN MCL CELL LINES AND SHOWS SEQUENCE-SPECIFIC
INTERACTIONS WITH CYTARABINE AND IBRUTINIB
L. Fischer1,*, A. Mayer1, M. Irger1, B. Freysoldt1, Y. Zimmermann1, G. Hutter1,
W. Hiddemann1, M. Dreyling1
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Background: Mantle cell lymphoma (MCL) is characterized by t(11;14) result-
ing in a constitutive cyclin D1 overexpression. The cyclin D1-CDK4/6 complex
inactivates Rb through phosphorylation, leading to G1/S-phase transition.
Therefore, inhibition of CDK4/6 is an efficient and rational approach to overcome
cell cycle dysregulation in MCL.
Aims: We evaluated the efficiency of the novel CDK4/6 inhibitor abemaciclib
in various MCL cell lines and in primary MCL cells in combination with cytarabine
(AraC) and ibrutinib.
Methods: MCL cell lines (Granta 519, JeKo-1, Maver-1, Mino) and primary
MCL cells were exposed to abemaciclib alone and combined with AraC or ibru-
tinib. Cells were pretreated with abemaciclib and exposed to AraC or ibrutinib
with or without consecutive wash-out of the CDK4/6 inhibitor. Proliferation and
viability were measured by trypan blue staining and Cell Titer Glo assay. Com-
bination Index (CI) to assess synergy or antagonism was calculated using the
Fractional Product method by Webb (1963). Flow cytometry was applied for
cell-cycle (PI-staining) and apoptosis analysis (Annexin V PE/7AAD-staining).
Protein expression and phosphorylation status of various downstream proteins
was analyzed by Western Blot analysis.
Results: Abemaciclib inhibited cell proliferation by induction of early G1-arrest.
We observed an almost complete and reversible G1-arrest in all sensitive cell
lines by FACS analysis (JeKo-1: G1-phase +51,7%; S/G2-phase -51,7% at
31,25 nM after 24 h; G1-phase +35,4%; S/G2-phase -34,8% after 72 h), where-
as cell viability was not reduced. IC50-values of sensitive cell lines (JeKo-1,
Maver-1, Mino) were <30 nM after 72 h. Western Blot analysis revealed reduced
phosphorylation of Rb on serine 795 without changes in CDK 4 and cyclin D1
expression, in line with reversible cell cycle arrest. Wash-out of abemaciclib
after 24 h resulted in synchronized S-phase entry in all sensitive cell lines (e.g.
Mino: G1-phase -20,4%; S-phase +30,5%). Accordingly, sequential combination
of abemaciclib followed by AraC showed strong synergy in Mino cells (CI=0,22
for 31,25 nM abemaciclib / 3,33 µM AraC). In contrast, simultaneous exposure
to abemaciclib had a protective effect against AraC treatment in all sensitive
cell lines, due to an ongoing G1-arrest (Mino: CI=-0,19 for 31,25 nM abemaciclib
/ 3,33 µM AraC). Sequential administration of abemaciclib and ibrutinib had
synergistic or additive effects in sensitive cell lines (CIs: JeKo-1=0,24; Maver-
1=0,19; Mino=-0,03 for 31,25 nM abe / 2,5 µM ibru), whereas the simultaneous
administration of both showed additive effects at most (CIs: JeKo-1=0,02;
Maver-1=-0,1; Mino=-0,09 for 31,25 nM abe and 2 µM ibru). In primary MCL
cells abemaciclib had no impact on cell death or sensitization since no cell pro-
liferation was observable and cells where resting in G1-phase.
Summary/Conclusions: The novel CDK4/6 inhibitor abemaciclib causes
reversible G1 cell cycle arrest without loss of viability at low nanomolar doses.
Rationale drug combinations exploiting the sequential effect may achieve major
benefits. Pretreatment with abemaciclib might sensitize cells to ibrutinib, result-
ing in synergistic drug effects. In contrast, simultaneous application of Abe-
maciclib protects cells from AraC treatment whereas Abemaciclib-induced S-
phase synchronization sensitizes MCL cell lines to AraC. Further analysis need
to explore the interaction with other targeted approaches (inhibitors of the B-
cell receptor pathway) to better understand the underlying molecular mecha-
nisms.
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CD8+ T-CELL CLONES PERSISTENT IN BONE MARROW AND PERIPHERIAL
BLOOD DURING COURSE OF CD4+ ANGIOIMMUNOBLASTIC LYMPHOMA
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4Faculty of Basic Medicine, Lomonosov Moscow State University, Moscow,
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Background: Angioimmunoblastic T-cell lymphoma (AITL) – peripheral T-cell
lymphoma, characterized by polymorphous infiltration of the lymph nodes, pro-
liferation of high endothelial venules (HEV) and follicular dendritic cells (FDC).
In addition to the lymph nodes, AITL affects spleen, liver, skin and bone marrow.
The disease is almost always associated with Epstein-Barr virus (EBV), sug-
gesting its role in the etiology of AITL. Neoplastic T cells in most cases are CD4+
and express pan T-cell antigens CD3, CD2, CD5, markers of normal follicular T-
helper cells – CD10, CXCL13, PD-1. To confirm the diagnosis and assess dis-
ease dissemination combined morphological, immunohistochemical and molec-
ular studies of affected tissues are being used. We have found that T-cell clones
detected in the tissue of the lymph node (LN), often differ in T-cell receptor gene
rearrangements from those detected in the bone marrow (BM), peripheral blood
(PB) and other tissues. T-cell clonality testing itself may not distinguish between
neoplastic or reactive lymphoproliferation in the BM and PB. Therefore, T-cell
clonality of CD4+ and CD8+ populations of peripheral blood lymphocytes in
patients with AITL had been tested during the course of disease.
Aims: To determine immunological characteristics of persisting in the PB and
BM T-cell clones in AITL patients.
Figure 1.
Methods: The study included 26 patients (15 males and 11 females; age 36-92,
median 67) with the diagnosis of AITL established on the basis of WHO 2008
diagnostic criteria. LN, BM and peripheral blood lymphocytes were tested for T-
cell clonality according to BIOMED-2 protocol with subsequent fragments analysis
on ABI PRISM 3130 (Applied Biosystems). The material was examined at the
diagnosis and at various stages of patient’s treatment. In 5 patients selection of
CD8+ and CD4+ populations of PB lypmphocytes was performed with MidiMACS
and MiniMACS Separators using CD4+, CD8+ MicroBeads (Miltenyi Biotec).
Results: Clonal TCRG and TCRB gene rearrangements in the LN of all AITL
patients were found. In 6 of the 26 patients (23%) clonal products found in LN
matched those from PB and BM. In 8 patients (30%) at least one of the clonal
products isolated from the BM and/or PB mismatched the clonal products iso-
lated from LN. In 12 patients (46%) clonal rearrangements found in the PB and
BM were completely different from those identified for LN. Thus, at the diagnosis
20 patients (76%) had PB and BM T-cell clones distinct from LN T-cell clones.
In 14 of 20 patients T-cell clones of PB and BM were tested repeatedly during
the course of disease treatment. In 7 of 14 patients (50%) clonal products per-
sisted for a long time and do not disappear upon reaching the remission of the
disease. The observation period averaged 12 months (1 to 44 months). No
correlation of T-cell clones persistence and the activity of EBV infection in the
PB was found. Selection of CD4+ and СD8+ T-lymphocyte populations was
performed for 4 patients in remission with persistent T-cell clones. In all cases,
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clonal products, which were originally identified in the BM and PB were shown
to belong to the CD8+ population of cells (Fig.). In one case BM and PB derived-
CD4+ cells also shared a clonal product with LN cells tested at at the diagnosis.
In one case CD4+ population selected from PB cells at the diagnosis carried
clonal rearrangements, fully consistent with that of LN.
Summary/Conclusions: One may conclude that CD8+ T-cell clones identified
in BM and PB, do not match those identified in LN for the majority of patients
with AITL (76%). These clones can persist for a long time (the period of obser-
vation from 1 to 40 months), may not disappear in remission and probably
have reactive nature. Therefore exclusive T-cell clonality in PB and/or BM
should not be threated as minimal disease or relapse in AITL.
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CD5 POSITIVE DIFFUSE LARGE B CELL LYMPHOMA SHOWED
FREQUENT MYC EXPRESSION AND AGGRESSIVE CLINICAL BEHAVIOR 
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Background: Aberrant expression of CD5 distinguishes a unique immunohis-
tochemical subtype of diffuse large B cell lymphoma (DLBCL). This CD5+ DLB-
CLs, either de novo lesions or transformed from preceding low grade lym-
phomas, are characterized by unique molecular pathologic alterations and
aggressive behavior. The incidence of CD5+ DLBCL was variably reported
from 5 - 22% of all DLBCLs in western countries and Japan, however, no exact
data available in Koreans.
Aims: This study aimed to investigate clinicopathologic features of CD5 + DLB-
CL among Koreans.
Methods: A total of 350 cases of DLBCL were reviewed 4 university hospitals
from 2004 to 2012. Review of the histologic features along with immunohisto-
chemical study for BCL1, BCL2, BCL6, CD5, CD10, CD23, CD30, IRF4/MUM1,
MYC, Ki-67 and EBV in situ hybridization was performed. Florescent in situ
hybridization (FISH) for MYC rearrangement and amplification was also per-
formed. The results were compared with DLBCL-NOS (N=195).
Results: Thirty cases of CD5+ DLBCL were retrieved among 350 cases of
DLBCL (8.6%), which showed predominance of female (20/30), elderly (mean
age 64), and extranodal presentation (16/30). Richter transformation was sus-
picious in only one case, and EBV was negative in all. Most cases (22/30)
belong to non-GCB subtype by Hans classifier. Rearrangement of MYC was
found in 2 cases and amplification was found in one. Compared with DLBCL-
NOS, CD5+ cases revealed significantly higher expression of MYC, BCL6,
IRF4/MUM1 and Ki67 (all p<0.05). Double expression of both BCL2 and MYC
was found in 9 of 30 cases (30%). Also, CD5+ DLBCL showed more frequent
bone marrow involvement, advanced stages and high international prognostic
index (all p<0.05). In univariable survival analysis, CD5+ DLBCL revealed sig-
nificantly shorter progression free survival (median 8.2 months) compared with
DLBCL-NOS (median 56.3 months) (p<0.05)
Summary/Conclusions: This is the first collective study of CD5+ DLBCL in
Korea. The incidence, clinical presentation, and pathologic features including
cell of origin coincide with previous reports from western population or Japan-
ese. However, frequent high expression of MYC without chromosomal structural
alteration was a unique finding in our study. Expression of CD5 should be rou-
tinely investigated in DLBCL to find this particularly aggressive subtype. 
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REACTIVE FLORID B-LINEAGE LYMPHOID PROLIFERATIONS IN HIV
INFECTION MAY MIMIC LYMPHOMA
T. Wiggill1,*, J. Vaughan1, E. Mayne1
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Background: Approximately 7 million people are living with Human Immunod-
eficiency Virus (HIV) infection in South Africa (SA) (2015), which is associated
with an increased risk of lymphoma. Although there is limited local information
available, previously published data from the Johannesburg academic complex
of hospitals (SA) showed an HIV prevalence of >90% in patients diagnosed
with high grade B cell non Hodgkin lymphoma (NHL) who were tested for HIV
(n= 568), during the period 2007-2009. The diagnosis of lymphoma with comor-
bid HIV infection is, however, challenging as lymphomas may present with
atypical features and in unusual extranodal sites. In addition, there are reactive
conditions which may mimic lymphoma (such as Tuberculosis (TB)). Within
this setting reactive florid B-lineage lymphoid proliferations (RBLP) in the blood
and bone marrow may raise a differential diagnosis of lymphoma. 
Aims: This study aims to document the clinico-pathological features of florid
RBLP in the setting of HIV infection in order to provide an approach to differ-
entiating reactive and clonal processes. 
Methods: A retrospective database search was performed of the laboratory
information system (National Health Laboratory Service) that screened pathol-
ogy reports for samples referred to the Departments of Molecular Medicine
and Haematology and Anatomical Pathology at the Johannesburg Academic
Complex during 2007-2011, supplemented with results of immunophenotypic
analysis from 2007-2016. Demographic and clinico-pathological findings were
collected for patients identified with florid RBLP who showed no definite evi-
dence of monoclonality. 
Results: During this period, 38 patients were diagnosed with florid RBLP with
up to 70–80% of cells in blood or bone marrow comprising reactive B cells
(including mature B, plasmablasts and plasma cells). All patients tested were
HIV positive, with a median age of 28 years (range 6 months-79 years). There
was a bimodal age pattern with a peak in children <1 year of age (34% of
patients). This is different from the pattern noted in NHL in our centre, where
lymphoma is virtually absent in children under a year of age. Common clinical
presentations included cytopenias (85%); infection (70%) (commonly
Cytomegalovirus (35%), TB (30%) and bacterial septicaemia (22%));
hepatosplenomegaly (42%); and lymphadenopathy (36%). Patients showed
increases in serum total protein levels (reflecting hypergammaglobulinaemia),
with increased inflammatory markers (C-reactive protein and erythrocyte sed-
imentation rate) and evidence of increased cell turnover (high uric acid, B2
microglobulin and lactate dehydrogenase levels). Extremely high HIV viral
loads (VL) were documented (median 1 612 003copies/ml, range 12 000 - 10
000 000). Only one patient was virologically supressed. This is significantly
different from lymphoma patients where median VL ranged from 16 000- 97
000 dependent on subtype. Median CD4 counts were also higher in this sub-
group of patients when compared to patients with lymphoma (see table 1).
Limited follow-up data was available, with only 8 patients documented to be
attending an HIV clinic for long-term follow-up.
Table 1. Comparative data: HIV associated lymphoma and HIV associated
RBLP.
123p-value<0.001, Children excluded from CD4 count analysis.
Summary/Conclusions: In the setting of HIV, reactive conditions may mimic
lymphoma and vigilance is needed in the confirmation of monoclonality.
Patients with RBLP presented at a younger age when compared to their coun-
terparts with lymphoma. They had extremely high VL with higher CD4 counts,
suggesting this may be a feature of early HIV disease and the possibility of a
seroconversion type illness should be considered.
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MICROVESSEL DENSITY IN CD30 POSITIVE DIFFUSE LARGE B-CELL
LYMPHOMAS
F. Gaudio1,*, G. Ingravallo2, T. Perrone1, P. Sindaco1, V. Carluccio1, S. D’agostino1,
M. Di Noi1, F.E. Laddaga1, R. Tamma3, S. Ruggieri3, P. Pedote4, G. Specchia1
1Hematology, 2Pathology, 3Human Anatomy and Histology, 4Radiology, Bari,
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Background: Diffuse large B-cell lymphoma (DLBCL) is the most common
and one of the most heterogeneous lymphomas. Therefore, it is critical to fur-
ther stratify cases of DLBCL into biologically similar and clinically meaningful
subgroups, which will not only guide prognostic assessment and facilitate ther-
apeutic decisions but also stimulate further research to understand the patho-
genesis and develop novel potential treatments. Preliminary reports involving
a number of different kinds of tumors have indicated that microvessel quantifi-
cation may be useful in predicting disease outcome. 
Aims: The aim of this study was to examine the relationship between microves-
sel density (MVD) as a parameter of tumor angiogenesis, and the immunophe-
notype in patients with diffuse large B-cell (DLBC) lymphomas.
Methods: We retrospectively identified cases of DLBCL diagnosed between
January 2010 and January 2016 at our Institution. The following large B cell
lymphoma subtypes were excluded from this analysis: post-transplant lympho-
proliferative disorders with a DLBCL morphology, Primary Mediastinal large
cell lymphoma and unclassifiable lymphomas with intermediate features
between either DLBCL and Burkitt’s lymphoma or DLBCL and Hodgkin’s lym-
phoma. Immunohistochemistry was performed as part of the routine workup
and CD30 was considered positive at ≥30% staining of neoplastic cells.
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Microvessel quantification was performed by immunohistochemical staining,
using monoclonal antibodies against platelet/endothelial cell adhesion mole-
cule-CD31. A total of 82 cases of de novo DLBCL treated with R-CHOP were
included in the training set for further analysis There were 45 men and 37
women, with a median age of 57 years (range, 16-84); 35 patients (43%) pre-
sented with B symptoms, and 49 (60%) had advanced Ann Arbor stages. Most
of the patients had a good performance status (Eastern Cooperative Oncology
Group score 0- 1, 87%), elevated serum lactate dehydrogenase level (61%),
and low or low-intermediate International Prognostic Index (IPI) risk (IPI score
0-2, 63%). Involvement of multiple extranodal sites (>=2) was seen in 22% of
cases, and bulky disease in 32% of cases.
Results: The median follow-up time was 47 months. Among the 82 cases in
the training set, CD30 was positive in 24 cases (29%). No difference in response
rate was observed between CD30 positive and CD30 negative patients.
Patients with CD30+ DLBCL showed a significantly superior OS and PFS com-
pared with CD30– patients. The 5-year OS was 79% in patients with CD30+ vs
59% in CD30– (P<0.05); 5-year PFS was 82% in patients with CD30+ vs 63%
in CD30– (P<0.05). In patients with CD30 positive diffuse large B cell lym-
phomas we found a smaller number of vessels compared with patients CD30
negative (fig.1, p<0.05).
Figure 1.
Summary/Conclusions: CD30 is expressed in approximately 29% of all DLB-
CL and defines a novel subgroup of diffuse large B-cell lymphoma with a more
favorable prognosis. Microvessel density expression is lower in CD30 positive
DLBCL. The advent of brentuximab vedotin and its well-established effective-
ness in other types of relapsed lymphomas has introduced the possibility of its
application in this subset of patients.
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ANTIGEN SELECTION PROMOTES CLONAL CYTOTOXIC T-CELL
RESPONSES: HIGH-THROUGHPUT IMMUNOGENETIC EVIDENCE
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Background: Expansions of T-large granular lymphocytes (T-LGL) with a char-
acteristic CD3+CD8+CD57+ phenotype may be either idiopathic or develop in
the clinical context of several conditions e.g. autoimmunity, viral infections,
post-transplant and in hematologic malignancies. Whether this heterogeneity
reflects a dynamic process of cytotoxic T-cell responses against auto- and exo-
antigens remains to be established. That said, earlier, low-throughput immuno-
genetic studies have implicated antigenic drive in the development of T-LGL
lymphoproliferations. However, due to the inherent limitations of low-throughput
analysis, definitive conclusions were not possible.
Aims: To obtain comprehensive insights into the role of antigen selection in
the pathogenesis of T-LGL lymphoproliferations using next-generation sequenc-
ing (NGS) for in-depth immunoprofiling of the clonotypic T cell receptor beta
chain (TRBV) genes.
Methods: Included in the study were (i) a father and a son with T-LGL leukemia,
the first case of intra-family occurrence; a single blood sample from the father
and 2 samples from the son spanning 5 years were analyzed; and, (ii) a patient
with T-LGL leukemia of donor cell origin developing after allogeneic hematopoi-
etic cell transplantation (allo-HCT) for Philadelphia-positive acute lymphoblastic
leukemia: for this case, the donor blood was analyzed as were two blood sam-
ples, one at the first documentation of clonal T-LGL expansion (at 6 months
post allo-HCT while investigating persistent neutropenia that developed after
Rituximab treatment for EBV reactivation) and a second 3 years later; at both
timepoints, the patient had 100% donor chimerism and tested negative for
BCR-ABL transcripts. TRBV-TRBJ-TRBD rearrangements were amplified on
gDNA and subjected to paired end NGS, covering the CDR3 twice/sequence.
To increase the consistency of results, raw NGS reads were analyzed by a pur-
pose-built bioinformatics algorithm, performing: (i) quality filtering, (ii) merging
of filtered in paired reads and (iii) quality filter of stitched sequences. Filtered-
in sequences were submitted to IMGT/HighV-QUEST, and metadata was
processed by an in-house dedicated bioinformatics pipeline.
Results: Only productive TRBV-TRBD-TRBJ rearrangements were included
in the analysis. Overall, 1,129,289 filtered-in sequences from 6 samples were
evaluated (median 188,095 sequences/sample). Major findings in the familial
cases included: (i) pronounced skewing of the TRBV repertoire; (ii) existence
of more than one immunodominant clonotype; (iii) in the analysis of longitudinal
samples from the son, persisting clonotypes albeit with fluctuating frequencies
(clonal drift); and, (iv) shared (‘public’) clonotypes between father and son. In
the T-LGL leukemia of donor origin, the immunodominant clonotype was detect-
ed amongst the polyclonal donor repertoire and subsequently expanded in the
recipient, persisting over time and accompanied by a few other considerably
expanded, albeit smaller, clonotypes.
Summary/Conclusions: The borders between polyclonal versus oligoclonal
versus monoclonal T-LGL lymphoproliferations are not sharply demarcated,
but rather the transition from a polyclonal cytotoxic response to the development
of T-LGL leukemia is a gradual process. Repertoire restrictions, public clono-
types and clonal drift strongly indicate selection by restricted (perhaps also
shared) antigens in T-LGL leukemia ontogeny and evolution.
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MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN LYMPHOMAS
WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK:
INTER-LABORATORY REPRODUCIBILITY ON BORDERLINE SAMPLES
I. Della Starza1,*, M. Cavalli1, L.A. De Novi1, E. Genuardi2, B. Mantoan2,
D. Drandi2, L. Monitillo2, E. Ciabatti3, S. Grassi4, A. Gazzola5, C. Mannu5,
C. Agostinelli5, P.P. Piccaluga5, S. Galimberti3, A. Guarini16, R. Foà1, M. Ladetto7,
S. Ferrero2, I. Del Giudice1
1Department of Cellular Biotechnologies and Hematology, Hematology, Sapien-
za University, Rome, 2Department of Molecular Biotechnologies and Health
Sciences, Division of Hematology, University of Torino, Turin, 3Department of
Clinical and Experimental Medicine, Division of Hematology, University of Pisa,
Pisa, 4Department of Medical Biotechnologies, University of Siena, Siena,
5Department of Experimental, Diagnostic, and Specialty Medicine,
Hematopathology Section, S. Orsola-Malpighi Hospital, University of Bologna,
Bologna, 6Department of Molecular Medicine, Hematology, Sapienza University,
Rome, 7Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e
Cesare Arrigo, Alessandria, Italy
Background: In B-cell non-Hodgkin lymphomas, minimal residual disease
(MRD) is a highly valuable tool for the direct assessment of the reduction of the
disease burden. In 2009, the four laboratories of the Fondazione Italiana Linfomi
(FIL) - FIL MRD network - started a collaborative effort to harmonize and stan-
dardize their methodologies, performing QC (Quality Control) rounds twice a
year for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD
assessment.
Aims: We evaluated the molecular results of bone marrow (BM) samples analy-
sis performed during the QC rounds, to determine how borderline samples (i.e.
those with a low MRD level) challenge the inter-lab reproducibility and data
interpretation.
Methods: Between February 2010 and November 2016, in the context of 14
QC rounds, the FIL MRD Network labs received 188 BM (114 FL and 74 MCL)
samples; 167 were analyzed by both nested polymerase chain reaction (PCR)
and real-time quantitative PCR (RQ-PCR). BCL2/IGH MBR rearrangement was
analyzed by nested PCR (Gribben, 1993) and by RQ-PCR (Ladetto, 2000).
Clonality assessment was performed using an IGHV multiplex consensus PCR
(Van Dongen, 2003) and RQ-PCR was carried out as described (Ladetto, 2000;
Donoval, 2000). All analyses were conducted and interpreted according to the
“EuroMRD Consortium” guidelines (van der Velden, 2007).
Results: The sensitivity and the accuracy of each molecular analysis was test-
ed, reaching a uniform sensitivity of 10-5 and a quantitative range for RQ-PCR
of at least 10-4. Ninety-three/114 FL BM samples showed a 81% concordance
(75/93) being PCR+/RQ-PCR+ or PCR-/RQ-PCR- in all the 4 labs. The remain-
ing 18/93 (19%) were alternatively positive and negative in the inter-lab evalu-
ations, representing samples with very low MRD levels, thus defined as “bor-
derline” (brd): 6/18 were PCR-brd/RQ-brd, 6/18 were PCR-brd/RQ-positive not
quantifiable (PNQ) and 6/18 were PCR-/RQ-brd. Among the 74 MCL BM sam-
ples, the concordance rate was 86% (64/74; +/+ or -/-). Ten/74 resulted brd
samples: 1 was PCR-negative/RQ-brd, 5 were PCR-brd/RQ-brd, 2 were PCR-
brd/RQ-PNQ and 2 were PCR-brd/RQ-negative. Overall, considering the 167
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samples analyzed by both methods, 83% (139/167) of these were classified
as +/+ or -/- by all the FIL labs. The remaining 28/167 (17%) were the samples
that showed discordant results in the inter-lab assessments: while in 17 cases
the “borderline status” was defined alternatively by only one method, 11 resulted
brd samples by both techniques (11/167, 6.6%) (Fig.). Given that the 167 sam-
ples were tested in three replicates across the 4 labs, a total of 12
replicates/sample were analyzed: 31 brd samples were thus identified, 13 of
which brd by both approaches. Of 156 evaluations performed on the 13 brd,
69/156 (44%) resulted PCR-positive and 87/156 (56%) PCR-negative, 58/156
(37%) were RQ-PNQ and 98/156 (63%) RQ-negative.
Figure 1.
Summary/Conclusions: Despite the high inter-lab reproducibility in the MRD
analysis that can be obtained and maintained by the QC round strategy, sam-
ples with the lowest MRD levels can still represent a challenge: 17% (28/167)
of our series resulted brd, showing discordant results in inter-lab assessments;
39% of them (11/28) remained brd even applying both methods. The results
did not change even increasing the number of replicates/sample. Thus,
although representing a minority, brd samples are still problematic, especially
when a clinically oriented interpretation is required. As the combined use of
standard methods does not totally solve this problem, alternative, novel, meth-
ods such as digital PCR and NGS need to be tested in this context.
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RHOA GLY17VAL MUTATION AND T-CELL CLONALITY ANALYSIS IN
PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Y. Sidorova1,*, N. Chernova2, I. Yakutik1, S. Smirnova1, N. Ryzhikova1,
E. Nikulina1, M. Aleksenko2, O. Glinshchikova1, M. Sinitsyna3, A. Kovrigina3,
E. Zvonkov2, A. Sudarikov1
1Department of Molecular Hematology, 2Department of Lymphoma Chemother-
apy, 3Department of Pathology, National Research Center for Hematology,
Moscow, Russian Federation
Background: Аngioimmunoblastic T-cell lymphoma (AITL) is a rare subtype
of T-cell lymphoma, characterized by generalized lymphadenopathy, hyper-
globulinemia, and autoimmune manifestations. Interpretation of histological
and immunohistochemical data can be difficult due to the small number of
tumor CD4+ T cells, surrounded by abundant polymorphocellular infiltrate. AITL
could often be misdiagnosed as reactive processes and other lymphomas,
including Hodgkin’s lymphoma. T cell clonality assessment plays an important
role in AITL diagnosis. However, ambiguous clonality results may be obtained.
Recently discovered somatic RHOA Gly17Val mutation is present in 53-71%
of angioimmunoblastic T-cell lymphomas. We compared the efficacy of T-cell
clonality testing and quantitative allele-specific PCR RHOA Gly17Val mutation
assay in different tissues for AITL diagnosis.
Aims: To correlate the number of RHOA Gly17Val mutated cells in lymph
nodes, blood, bone marrow and skin of AITL patients with corresponding T cell
clonality results.
Methods: Lymph nodes (LN), skin biopsies, blood and bone marrow (BM)
samples were studied for 40 patients with AITL. The male/female ratio was
25/15, median age was 65 years (36-92). To evaluate T-cell clonality rearranged
TCRG and TCRB gene rearrangements were PCR-amplified according to BIO-
MED-2 standardized protocol and analyzed by capillary electrophoresis on ABI
PRISM 3130 (Applied Biosystems). Sensitivity of T-cell clonality assay was
limited to 10% of clonal Т-cells of the total T-lymphocytes in the sample.
Gly17Val mutation was analyzed by quantitative allele-specific (qAS) TaqMan
Real-Time PCR assay. The detection level of this method was 1% of mutated
cells in the total cell population.
Results: The clonal TCR gene rearrangements in LN were found in 37 of 40
patients (92%). RHOA (Gly17Val) mutation in LN was revealed in 60% (24 of
40) patients. T-cell clonality was detected in 26 of 28 primary samples of BM,
but in 12 of 26 patients (46%) clonal TCR rearrangements were not matched
in length with rearrangements detectable in LN. Number of cells with RHOA
mutation was highest in the LN (in average 26.7% of the total cells), while in
the bone marrow RHOA mutation was undetectable (in 7 patients), or detected
in 10 patients in a small amount (in average 2% of the total cells). Combined
histological investigation, T-cell clonality and RHOA (Gly17Val) testing showed
BM lesion in 76% of patients (13 of 17) with at least one of the methods. Blood
and bone marrow samples examined simultaneously showed slightly higher
numbers of RHOA positive cells in the blood than in the BM in 5 of the 7 RHOA
positive patients. Significant percentage of cells with a RHOA mutation (in aver-
age 25% of the total cells) was revealed in 5 of 6 skin samples from RHOA
positive patients. We have found good correlation (Spearman’s Rho-0,8198,
p-level <0,00001) between T-cell clonality (matching with LN clonal peaks) and
the number of RHOA positive cells in the AITL samples (n 51). Skin, blood and
bone marrow samples with the T cell clonality peaks that differ from those
found in the LN were also negative for the presence of cells with RHOA
(Gly17Val) mutation. 
Summary/Conclusions: RHOA (Gly17Val) point mutation is detected in LN
by allele-specific PCR in 60% of patients with AITL. The percentage of tumor
cells in BM is low (averaging less than 2% of the total cells). However, combined
molecular and histological data suggest that BM may be involved in most
patients. Extent of T cell clonality (matching with LN clonal peaks) correlates
with the amount of cells having a RHOA mutation. T-cell clonality in BM, skin,
spleen, etc. with rearrangements not matching those identified for the LN should
be considered reactive and possibly associated with autoimmune process or
antiviral response.
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USEFULNESS OF CHITOTRIOSIDASE ACTIVITY, CCL18/PARC, 7-KETO-
CHOLESTEROL AND GLUCOSYLSPHINGOSINE CONCENTRATIONS FOR
SCREENING OF LYSOSOMAL STORAGE DISORDERS
P. Irún1,2,*, J.J. Cebolla1,2,3, L. Lopez de Frutos2,4, P. Giraldo1,2,4
1Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBER-
ER), 2Unidad Investigación Traslacional. Hospital Universitario Miguel Servet,
Instituto de Investigación Sanitaria Aragón (IIS Aragón), 3Departamento de Bio-
química, Biología Molecular y Celular, Universidad de Zaragoza, 4Fundación
Española para el Estudio y Terapéutica de la Enfermedad de Gaucher y Otras
Lisosomales (FEETEG), Zaragoza, Spain
Background: Gaucher (GD), Niemann-Pick Type A/B (NPA/B), Niemann-Pick
Type C (NP-C) and the Lysosomal acid lipase deficiency (LALD) are lysosomal
storage diseases (LSDs) difficult to diagnose due to the great heterogeneity of
signs and symptoms, including haematological disorders, sometimes common
to several pathologies, and the consequent alteration of biomarkers.
Aims: To assess the diagnostic utility of Chitotriosidase activity (ChT),
CCL18/PARC, 7-ketocholesterol (7KC) and glucosylsphingosine (Lyso-Gb1)
concentrations in previously mentioned LSDs.
Methods: ChT activity, CCL18/PARC and 7KC concentrations were measured
in 146 plasma samples from subjects with suspected LSD (32 GD, 7 NPA/B,
90 NP-C and 17 LALD) received in our laboratory. In addition, a new biomarker,
the Lyso-Gb1 concentration, was evaluated in 83/146 of previous mentioned
subjects, 19 of them with confirmed LSD diagnosis. ChT was evaluated using
a fluorogenic substrate, CCL18/PARC concentration by ELISA and 7KC and
Lyso-Gb1 by liquid chromatography followed by tandem mass spectrometry.
Results: A total of 9/32 (28%) samples with suspected GD showed high ChT
and/or high CCL18/PARC, 4/9 confirmed GD status; the rest were 1 NPA/B, 1
NP-C and two carriers of NP-C. Only 3/7 (43%) with suspected NPA/B and
altered biomarkers were confirmed. Among the 23/90 (26%) with suspected
NP-C and some elevated biomarker four were diagnosed of NP-C, and two
carriers showed some biomarker higher than cutoff. Of the 8/17 (47%) referred
to LALD suspicion with some elevated biomarker six were affected. All GD con-
firmed patients show high levels of Lyso-Gb1 whereas none of the other cases
showed elevation for mentioned biomarker.
Summary/Conclusions: The screening of three biomarkers: ChT activity,
CCL18/PARC and 7-ketocholesterol concentrations (the latter not applicable
in GD) is a powerful tool to identify patients at high risk of suffering from LSDs
which should undergo confirmatory diagnostic tests. In this line we would have
reduced the number of cases needing confirmatory diagnostic test from 146 to
43 (29%) and 19/43 (44%) were positive for LSDs. Lyso-Gb1 concentration
can allow the unambiguous identification of all the GD patients but is not useful
for the other LSDs. 
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THE VALUE OF SOLUBLE IL-2R APLHA SUBUNIT MEASUREMENT IN CSF
OF CHILDREN WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
(HLH): PRELIMINARY OBSERVATIONS
Y. El Chazli1,*, A. Elsharkawy1, N. Mikhael2, M. Abd El-Maksoud3, W. Shoman4,
H. Assem1
1Department of Pediatrics, Hematology/Oncology unit, 2Department of Clinical
pathology, 3Department of Pediatrics, Neurology unit, 4Department of Pedi-
atrics, Immunology/Rheumatology unit, Faculty of Medicine, Alexandria Uni-
versity, Alexandria, Egypt
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening
clinical syndrome due to a severe hyperinflammatory response. HLH is typically
divided into a primary, genetic form and a secondary, acquired form. It is char-
acterized by a very wide spectrum of clinical findings. Central nervous system
affection “CNS disease” has been frequently described at presentation of HLH,
during course of disease, or as isolated CNS-HLH that could preceed other
systemic clinical manifestations by months to years.
Aims: To study the value of CSF soluble interleukin-2 receptor alpha subunit
(sIL-2Rα) assay as a marker of CNS affection in children with HLH.
Methods: In this descriptive, observational study done at Alexandria University
Children’s Hospital, we analyzed the clinical data of a group of patients diag-
nosed as HLH. After informed consent was obtained, data was collected from
patients who have undergone clinical examination, brain MRI, routine CSF
analysis for evaluation of CNS-HLH, and sIL2Rα measurement in the CSF
(Quantikine Human CD25/IL-2Rα Immunoassay, R&D Systems). Patients were
considered as “CNS-HLH positive” when they had either neurological manifes-
tations, abnormal findings on MRI or routine CSF analysis (elevated proteins
&/or pleocytosis) and as “CNS-HLH negative” when they did not show any of
these findings.
Results: We analyzed the data of 9 HLH patients; 4 females and 5 males.
Their age ranged from 2 months to 13 years with a median of 5 months. Six
patients had genetic diseases predisposing to HLH [Griscelli syndrome type II
(GSII) & Chediack-Higashi syndrome (CHS)], and 3 other patients were diag-
nosed according to HLH-2004 diagnostic criteria and presumed to be of familial
form (FHL). Out of the 9 patients, only 5 patients (55.6%) showed clinically evi-
dent neurological manifestations; 5 patients (55.6%) had elevated CSF proteins
&/or pleocytosis, and 4 patients (44.4%) had an abnormal brain MRI. Overall 7
out of the 9 patients (77.8%) were “CNS-HLH positive” versus only 2 (22.2%)
“CNS-HLH negative” according to classical criteria. Interestingly, the geometric
mean of CSF sIL2Rα in CNS-HLH positive group was lower than in CNS-HLH
negative group (734 vs 1952 pg/ml, p= 0.094). Moreover, CSF protein level
and cell counts did not statistically correlate with CSF sIL2Rα level. Several
patients showed interesting observations. Among the 3 patients with presumed
FHL (6/7 HLH-2004 diagnostic criteria fulfilled, NK cell activity not tested), the
one with the highest observed CSF sIL2Rα level (17329 pg/ml), a 2 months
old infant, was “CNS-HLH negative”, but had severe bilateral papilledema (dis-
covered during workup for suspected autoinflammatory disorder). The second
patient was a 3.5 year old boy, with history of a year of “CNS-HLH positive”
findings and psychomotor regression, he had severe papilledema associated
with high CSF sIL2Rα (3700 pg/ml). The third patient, an 11 months old “CNS-
HLH negative” infant also had a relatively elevated CSF sIL2Rα of 220 pg/ml.
On the other hand, 2 twin sisters evaluated at the age of 3 months for HLH
secondary to CHS (positive family history, grey hair), had no systemic, neuro-
logical or radiological evidence of HLH, but had positive routine CSF analysis
(elevated protein & pleocytosis) and CSF sIL2Rα (600 & 800 pg/ml).
Summary/Conclusions: We hypothesize that routine CSF sIL2Rα level assay
could enhance earlier & better detection of CNS-HLH in children especially in
primary and genetic forms. Moreover, the absence of statistically significant
correlation between serum and CSF levels of sIL2Rα in our patients indicates
that sIL2Rα is locally produced in the CSF secondary to cellular infiltration of
the CNS and could be a valuable biological marker of disease activity. Larger
prospective studies are warranted to confirm these results and determine diag-
nostic and prognostic value of CSF sIL2Rα levels, as well as its value for follow
up of CNS disease.
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GAUCHER DISEASE PATIENTS EXHIBIT A HIGH EXPRESSION OF
LIPOCALINE (LCN2) AS POSSIBLE BIOMARKER OF RESIDUAL DISEASE
ACTIVITY. EXPLORATORY STUDY AND CORRELATION WITH OTHER
CYTOKINES
M. Andrade-Campos1,*, M.P. Garcia Sobreviela2,3, B. Medrano Engay3,
P. Irun1, J. Gervas Arruga3, M. Arbones2,3, P. Giraldo1,4
1Translational Research Unit, IIS-Aragon. CIBERER. IISCIII, 2ADIPOFAT, Insti-
tuto Aragones de Ciencias de la Salud, 3Translational Research Unit, IIS-
Aragon., 4FEETEG, Fundacion Española Estudio y Terapeutica Enfermedad
de Gaucher, Zaragoza, Spain
Background: Gaucher Disease (GD) is characterized by a latent chronic
inflammatory macrophage activation status expressed by an imbalance on pro-
inflammatory cytokines, hyperferritinemia, hypergammaglobulinemia, altered
calcium homeostasis and metabolic syndrome. Even patients under ERT do
not fully revert this status and their risk to develop bone crisis, iron metabolism
alterations, autoimmune disorders and neoplasm remain higher. This observa-
tion leaded to the creation of the minimal-residual-disease-activity concept.
Monitorization of patients through chitotriosidase and CCL18/PARC has
become essential however there are patients whom never normalize while oth-
ers developed bone crisis/ complications after long-time under therapy and
normal values. One of the key features for chronic inflammation is the anemia;
this is characterized by hyperferritinemia a common feature at diagnosis of
GD1 patients. Lipocaline (LCN2), a cytokine released by adipocytes, mononu-
clear cells and neutrophils with expression on endothelial cells, hepatocytes
and other cells, has been involved into the monocyte polarization and perpet-
uation of the inflammatory state. Based on this, we have performed an
exploratory study assessing LCN2 expression in GD1 patients.
Aims: To explore the Lipocaline (LCN2) expression as biomarker for disease
activity in type 1 Gaucher Disease patients under different circumstances.
Methods: We have performed an exploratory study on 18 GD1 patients dis-
tributed in two cohorts. Cohort A was composed by 6 patients: 2 naïve (N)
cases and 4 under miglustat (M) therapy; this patients were part of the clinical
study QUELAFER and sere from baseline and after 4 months on chelation ther-
apy were obtained. Cohort B included 12 patients on enzymatic replacement
therapy (ERT), for this cohort sera samples were obtained for LCN2 determi-
nation and also a panel of cytokines (IL-10, IL-13, IL-4, IL-6, IL-7, Mip1a, Mip1b
y TNFa), ferritin, hepcidin, chitotriosidase and CCL18/PARC were analyzed at
beginning of ERT and after one year on it. Data were incorporated into a data-
base for this porpoise including demographic and clinical available data. All
patients have signed an inform consent for the use of their samples and ethical
approved were obtained form institutional board of FEETEG foundation. 
Results: Compared to reference controls provided by the manufacturer, all the
patients showed increased levels of serum LCN2, the overall mean value for
the initial sample was 171, 88 (66,72-261,72). As cohorts the differences among
individuals were significant (Cohort A, p=0.02 and cohort B, p<0.01). Naïve
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patients exhibit the higher values. In general 9 patients showed a reduction on
LCN2 levels while 7 showed an increase and one the value was stable. All
patients showed a reduction in ferritin and chitotriosidase, however a fully cor-
relation with LCN2 expression were not founded. Globally there were no sta-
tistically differences, but as individual T-test showed a difference between both
measures (p=0.027). A detailed description an analysis will be presented in
case of acceptance.
Summary/Conclusions: Lipocaline expression is increased in GD1 patients
in general, a correlation with other cytokines expression to establish the role
of this biomarker is warranted.
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COMPARISON OF TREATMENT AND OUTCOMES BETWEEN ACQUIRED
PRIMARY AND SECONDARY THROMBOTIC THROMBOCYTOPENIC PURPURA
S.H. Wai1,2,*, H.J. Ng2, T.C. Wen2, J. Quek2, H.T. Mya2
1Monash University, Melbourne, Australia, 2Singapore General Hospital, Sin-
gapore, Singapore
Background: Thrombotic thrombocytopenic purpura (TTP) is a rare disease
that is fatal if untreated. While the main treatment modality is plasmapheresis,
immunosuppressants also play a crucial role in the treatment of TTP.
Aims: Our aim is to compare the clinical characteristics, treatment and outcomes
of patients with acquired primary TTP to those with secondary TTP i.e. autoim-
mune and malignancy/ hematopoietic stem cell transplant (HSCT) related.
Methods: We reviewed all patients with TTP who received plasmapheresis at
our institution from 1st Jan 2008 to 31st Jan 2017. Clinical and laboratory char-
acteristics, treatment, response to treatment and complications were recorded.
Complete remission (CR) was defined as platelet count normalisation, partial
remission (PR) as platelet count doubling and >30 x 109/L and the rest as unre-
sponsive/mortality (UM).
Results: Of 41 cases of TTP, 24% (n=10) was primary, 44% (n=18) was sec-
ondary to autoimmune diseases, 27% (n=11) was secondary to malignancy or
HSCT, 5% (n=2) was related to DRESS syndrome and acute pancreatitis. The
median age was 47(18-86) years and it was predominately female (81%). About
two-thirds of the cases presented with neurological symptoms (66%), renal
dysfunction (56%) and fever (59%). Only 12 patients (29%) had TTP pentad.
Proportionate to incidence of secondary TTP, 85% required immunosuppres-
sive therapy. CR was seen in 51% (n=21) and PR in 15% (n=6). Mortality rate
at end of treatment was 41% (n=17) and at end of follow-up was 46% (n=19).
Comparison of demographics, clinical presentation, treatment and outcomes
between acquired primary TTP and secondary TTP are shown in table below.
Table 1.
Compared to primary TTP using chi-squared for categorial data and non-parametric Mann-
Whitney U Test for continuous data. * P<0.1 **P<0.05.
Summary/Conclusions: Compared to primary TTP, secondary TTP had an
initial poorer response to plasmapheresis. Patients with autoimmune diseases
required more immunosuppressive therapy and rituximab. Although the final
response and mortality rates showed a trend towards poorer prognosis in sec-
ondary TTP, it was not statistically significant. Further studies are needed to
improve the treatment of TTP, both primary and secondary.
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EVANS SYNDROME IN CHILDHOOD: LONG TERM SINGLE CENTER
EXPERIENCE
A. Teli1, E. Farmaki1, A. Taparkou1, D. Adamidou2, M. Economou1,*
1Aristotle Universtity of Thessaloniki, 2Blood Bank, Hippokration General Hos-
pital, Thessaloniki, Greece
Background: Evan syndrome (ES) is a rare entity in childhood, usually pre-
senting with a course that is chronic and refractory to treatment.
Aims: To report on the clinical and laboratory characteristics of pediatric
patients with ES diagnosed and long followed at a single center. 
Methods: Data covering a 15 year period and concerning 14 ES patients were
retrospectively studied. Clinical presentation, laboratory parameters, diseased
severity, therapeutic approaches, number of relapses, presence of complica-
tions, time of follow-up and final outcome were reported. Disease was consid-
ered active when Hb <7g/dl and/or PLT <30,000/mm3 and/or Ν<500/mm3, in
partial remission (PR) when 7-11g/dl and/or PLT 30,000 – 10,0000/mm3 and/or
Ν 500 – 1,000/mm3, in short-term complete remission (SCR) when >11g/dl
and PLT >100,000/mm3 and N >1,000/mm3 when still under or less than 12
months off treatment, and in long-term complete remission (LCR) when labo-
ratory values as in SCR but free of treatment for over 12 months.
Results: Mean age at diagnosis was 5.4 years (18 months-12 years). Recent
history of infection was reported in 3 (21.4%) and positive family history for
autoimmune disease in 5 (35.7%) patients. At disease onset mean laboratory
values and range were: Hb 10.5±3.38 gr/dl (4–14.5 gr/dl), WBC 6,233±3,593
/mm3 (1,700–13,100/mm3), N 3,282±3,166/mm3 (100-9,442/mm3), PLT
22,546±20,970/mm3 (2,800-62,000/mm3), LDH 372±302 U/L (226±1,162U/L),
bilirubin 1.8±1.78mg/dl (0.3-4.8mg/dl). DAT was positive for IgG - IgG/C3d in
13 patients (92.9%) and for IgG/IgA in one patient (7.1%). As to immunology,
5 (35.7%) patients presented with mild IgG and/or IgM hypogammaglobuli-
naimia, 2 (14.3%) patients with decreased CD4/CD8 ratio, 3 (21.4%) with
increased CD3+TCRαβ+CD4-/CD8- double negative T cells and 3 (21.4%)
with persistently low C4. EMA were found positive in 2 (14.3%) and anti-TPO
and/or anti-TG in 3 (21.4%) patients. In 10 (71.4%) cases simultaneous, where-
as in 4 cases (28.6%) sequential cytopenia presence were reported. All patients
presented with thrombocytopenia, all with positive DAT - but only 8 (57.1%)
with Hb<11g/dl-, 7 (50%) with leucopenia and 6 (42.8%) with neutropenia.
Severe presentation was reported at disease onset in 10 (71.4%) patients. All
patients received IVIG (1-6g/kg) and high dose methyl-prednisolone
(30mg/kg/H) – one or more times depending on clinical course. Prednisolone
was administered in 10 (71.4%), cyclosporine in 8 (57.1%) and vincristine in 1
patient. Mean follow-up was 5.4 years (18 months - 13 years), during which 5
(35.7%) patients presented with one or more complications related to treatment:
Cushing syndrome, osteopenia, hypertension, renal dysfunction and/or periph-
eral neuropathy. No severe infection or death was reported during the 15 year
period. Disease relapses (1-3) were reported in 8/14 (57.1%) patients. With
regards to outcome, 8/14 (57.1%) remained in LCR, 1 (7.1%) in SCR, 1 (7.1%)
in PR, 3/14 (21.4%) in active disease, whereas 1 patient was lost to follow-up.
Summary/Conclusions: The rare entity of Evans syndrome in childhood
seems to be associated with various immune manifestations and to carry com-
plications related to treatment. Long term studies are needed to guide optimal
management, which still remains challenging.
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LOW DOSE RITUXIMAB IS A USEFUL ADDITION TO CORTICOSTEROIDS
FOR NEWLY DIAGNOSED PATIENTS WITH WARM AUTOIMMUNE
HEMOLYTIC ANEMIA
A. Gomez-De Leon1,*, P. Colunga Pedraza1, P. Santana-Hernandez1,
G. Sotomayor-Duque1, L.D.C. Tarin-Arzaga1, J.C. Jaime-Perez1, C.H. Gutierrez-
Aguirre1, O.G. Cantu-Rodriguez1, D. Gomez-Almaguer1
1Hematology, Hospital Universitario Dr Jose Eleuterio Gonzalez Universidad
Autonoma de Nuevo Leon, Monterrey, Mexico
Background: Warm autoimmune hemolytic anemia (wAIHA) is an infrequent
autoimmune disorder with a high response rate to corticosteroids, albeit relaps-
es are common. Low-dose rituximab has been used successfully in autoim-
mune cytopenias in an effort to increase response duration, while reducing
adverse effects and costs associated with a traditional rituximab dose and pro-
longed prednisone exposure. 
Aims: To evaluate the safety and efficacy of low-dose rituximab combined with
corticosteroid treatment in newly diagnosed patients with wAIHA.
Methods: We performed a single-center, prospective, single-arm, open-label
study in adult patients with newly diagnosed “primary” or idiopathic wAIHA from
2013-2016 using high-dose dexamethasone (40mg IV days 1-4) followed by
prednisone 1mg/kg PO with slow tapering combined with low-dose rituximab
(100mg total dose, days +1, +8, +15, +22). CR was defined as an increase in
hemoglobin (Hb) ≥12 g/dL, PR was defined as Hb ≥10 g/dL or an increase of
≥2 g/dL. Response was evaluated at day +28, months +6 and +12. Informed
consent was obtained from all participants. 
Results: Eight patients were included, median age was 32 years (range 18-
42), 6 were female. Median Hb at diagnosis was 5.8 g/dL (range 4-8.2 g/dL).
All patients had response at day +28 (50% CR rate); median time to response
was 12 days (range 3-17). During follow-up 7/8 achieved CR (median time to
CR: 30 days, range 15-103), all of which were sustained at 6 months. Median
follow-up was 24 months (range 8-40). One patient remained steroid-dependent
and relapsed after 12 months, achieving a stable PR after re-treatment with
low-dose rituximab. Furthermore, two patients had new-onset immune throm-
bocytopenia (IT; Fisher-Evans’ syndrome), without hemolysis 6.5 and 8 months
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after diagnosis. Two patients were diagnosed with systemic lupus erythemato-
sus during follow-up, they remained in CR. Twelve-month CR rate was 80% (5
evaluable patients). One patient experienced grade 3 neutropenia two months
after the last rituximab infusion that resolved without complications. Estimated
relapse-free survival was 80% at 2 years (60% if IT is considered). No patient
had a splenectomy performed. 
Summary/Conclusions: This small study reports favorable outcomes for
patients with newly diagnosed wAIHA treated with low-dose rituximab, and
adds 8 patients with similar responses to the 7 cases previously published by
the Italian group in 2012 and 2015. These results may be comparable to stan-
dard doses of rituximab, with a lower cost, and deserves further inquiry. The
emergence of additional autoimmune phenomena (SLE, Evans’ syndrome) is
unpredictable and can be an obstacle for appropriate data analysis in prospec-
tive AIHA studies. 
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INFECTIOUS COMPLICATIONS IN PRIMARY AUTOIMMUNE NEUTROPENIA
OF CHILDHOOD
T. Palianopoulos1, A. Gkoutsias1, N. Chaliasos1, A. Makis1,*
1Department Of Pediatrics, University Hospital Of Ioannina, Ioannina, Greece
Background: Primary autoimmune neutropenia (PAN) of childhood is caused
by the action of antibodies against membrane antigens of neutrophils leading
to their peripheral destruction. Despite the low neutrophil counts, it is charac-
terized by minor intercurrent infections with rare severe bacterial episodes,
which can be a significant cause of morbidity.
Aims: The retrospective evaluation of the incidence and characteristics of infec-
tious complications in children with PAN from one reference academic center
in Greece.
Methods: The study included the clinical and laboratory findings of children
with PAN, who were diagnosed in our department in the last eight years (2008-
2016). All children had neutropenia lasting over 3 months with a positive test
for neutrophil antibodies, using the granulocyte immunofluorescence test, the
granulocyte agglutination test and the monoclonal antibody immobilization of
granulocyte antigen test. Laboratory evaluation for nutritional deficiencies, infec-
tions, systemic autoimmune diseases or malignancies was negative. Clinical
data related to the occurrence of bacterial infections and treatment, hospital-
ization and outcome were collected and analyzed.
Results: 48 children with PAN were enrolled; 28 were boys, the median age
was 14.5 months (range 5-96) and median follow-up time was 20 months (range
4-93). 19 children (39.6%) all suffering from severe neutropenia (<0.5 x 109/L)
had to be hospitalized 25 times for bacterial infections; 4 for pneumonia, 7 for
acute otitis media, 1 for mastoiditis, 7 for urinary tract infections, 4 for bacterial
infections of unspecified site,1 for perianal abscess and 1 for cellulitis, all with
good outcome with proper antibiotic treatment. The average number of hospi-
talizations due to infections was 0,52/patient and the rate was 0.56/1000 patient-
days. G-CSF was administered in 2 children due to severe infection, while 8
children received antibiotic chemoprophylaxis.
Summary/Conclusions: Although rare, infections are an important clinical
issue in the management of children with severe PAN, sometimes requiring
hospitalization. Early signs of infection should be promptly recognized and
accordingly treated.
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NEW EPO-RECEPTOR MUTATION IN A -17 YEAR OLD WOMAN WITH
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Background: Erythrocytosis is defined when red cell, hematocrit (Hct) and
hemoglobin (Hb), are elevated above normal limits. Causes of erythrocytosis
can be primary and secondary. Secondary causes are divided into congenital
and acquired. There is a group of patients with idiopathic erythrocytosis.
Aims: We present a case report of a novel EPO-Receptor mutation.
Methods: We present a case report of a 17-year-old woman with erythrocytosis.
In the control blood test she had hemoglobin of 18.6g/dl and hematocrit of 62%.
We contacted the patient and she attended hematology consultations for study
and treatment with phlebotomy.The patient had no known drug allergies or toxic
habits. She didn’t have any known comorbidities or previous treatment. At eval-
uation she referred chronic headache without other symptoms. The physical
examination was normal. At that time, three possible diagnose were suspected.
Firstly, primary erythrocytosis, polycythemia vera (PV). In this disease, the bone
marrow produces many red cells and the JAK2 V617F mutation has been
demonstrated in the majority of patients. Exon 12 mutation has been described
in patients with PV who did not have the JAK2 V617F mutation. The erythro-
poietin (EPO) level is undetectable as a compensatory mechanism. In our
patient, JAK2 V617F mutation and exon12 mutation were negative and the
EPO levels were undetectable (<1.5). The bone marrow aspirate and the bone
marrow biopsy were normal. These results show that this patient doesn´t pres-
ent PV, due to she only fulfilling one diagnosis criteria of PV. Secondly, acquired
secondary erythrocytosis can be produced as a compensatory mechanism,
including: cardiac or pulmonary disease, smoking, renal artery stenosis, sleep
apnea/hypoventilation and malignant tumors. In the patient, pulmonary function
test, abdominal ultrasound and kidney function were normal. Endogenous ery-
throid colonies were positive. Due to the test results, we ruled out the diagnosis
of acquired secondary erythrocytosis. Finally, congenital secondary erythrocy-
tosis. Genetic abnormalities have been identified in congenital causes of ery-
throcytosis. The congenital erythrocytosis are divided into two sets according
to EPO levels. If the EPO levels are normal or increased, the patient could
present high oxygen-affinity hemoglobin because of bisphosphoglycerate
mutase deficiency or mutations in the genes in the oxygen sensing pathway.
However, if the EPO levels are decreased, the patient could present an ery-
thropoietin-receptor mutation. Our patient presented undetectable EPO levels
and the EPO-receptor mutation was requested. The patient has been treated
with phlebotomies and aspirin due to headache with good evolution. In this
moment, she presents hematocrit levels of 46.8%.
Results: The test revealed an EPO-receptor mutation (c.1275_1290dup), which
had never been described before.
Figure 1.
Summary/Conclusions: The study of the patient with erythrocytosis must
begin with a full medical history and confirmation of raised Hb and Hct. In the
study of erythrocytosis, after ruling out primary and acquired causes we should
always consider the possibility of congenital erithrocytosis, which often is under-
estimated. When EPO binds to its receptor a signaling cascade is activated,
which cause red cells to be produced. This process is switched off when suffi-
cient red cells have been produced by binding of SHP-1. EPO-receptor mutation
results in failure of bind of SHP-1, causing uncontrolled production of red cells
and erythrocytosis. We describe a new EPO-receptor (c.1275_1290dup) (fig-
ure1).
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FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN CHILDREN
Z. Salcioglu1,*, G. Aydoğan1, F. Akici1, C. Bayram1, A. Ayçiçek1, G. Özdemir1
1Pediatric Hematology and Oncology Clinic, İstanbul Kanuni Sultan Süleyman
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Background: Familial hemophagocytic lymphohistiocytosis (FHL) is an auto-
somal recessive disorder characterized with uncontrolled activation of T-helper
lymphocytes and macrophages and over-release of inflammatory cytokines.
The only curative treatment is hematopoetic stem cell transplantation (HSCT).
Aims: This study evaluates the clinical and laboratory data of children with
FHL. Thirty five FEL cases followed and treated at our clinic between 2005 and
2017 were retrospectively evaluated in our study.
Methods: Information of patients were retrieved from patient files and from the
records contained in the electronic information processing environment created
after 2005. All patients vere treated with HLH-2004 protocol. HSCT was per-
formed in nine patients.
Results: Twenty one of the cases were boys and fourteen were girls. The age
at presentation for patients was two week-three years (mean 6.2 months).
There was a history of consanguineous marriage in 26 of the families(74%).
Fever, anemia, and hypertriglyceridemia were present in all HLH cases.
Hepatomegaly was detected in 74%. Splenomegaly was more frequent in
patients (85.7%). Hypofibrinogenemia was detected in all patients. All patients
had neutropenia and thrombocytopenia. Hyperferritinemia was present in
94%% of patients. Only nine patients found to have hemophagocytosis in the
cytological evaluation of the CSF(25.7%). Mutation analysis were performed in
18 patients and of these, 10 had PRF1, 5 had UNC13D, and 3 had STX11
gene mutation. All patients vere treated with HLH-2004 protocol. Of the 22 chil-
dren who were placed in first remission. HSCT was performed in 9 patients
(%25.7). The overall mortality rate was 57% (20 cases) in our series. Twenty
children died opportunistic infection (n=10) or of disease progression (n=10).
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Summary/Conclusions: In conclusion, FHL is a disease with high mortalite
rates and the only curative treatment is HSCT. Donor search for HSCT must
be started and HSCT should be performed after the remission.
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ABNORMAL MONOCYTE POPULATIONS IN THE PERIPHERAL BLOOD
OF PATIENTS WITH CHRONID IDIOPATHIC NEUTROPENIA
M. Velegraki1,*, V. Kaliafentaki1, H. Koutala1, A. Damianaki1, M. Ximeri1,
P. Kanellou1, I. Mavroudi1, C. Pontikoglou1, H. Papadaki1
1Department of Haematology, University of Crete School of Medicine, Herak-
lion, Greece
Background: Chronic idiopathic neutropenia (CIN) is an acquired disorder of
granulopoiesis characterized by an unexplained, prolonged reduction in the
number of neutrophils and a generally benign and uncomplicated course. Neu-
tropenia in CIN has been mainly attributed to increased apoptotic death of the
granulocytic progenitor cells due to abnormal production of pro-inflammatory
cytokines and pro-apoptotic mediators. Activated T-lymhocytes with a skewed
oligoclonal/monoclonal profile and myelosuppressive properties have also a
major role in the pathophysiology of CIN.
Aims: Monocyte subpopulations display a prominent role in innate immunity
but also mediate pro-inflammatory responses and T-cell activation. The mono-
cyte subsets have never been studied in CIN. The aim of the present study
was to evaluate the monocyte subsets, namely the classical CD14++/CD16-,
intermediate CD14++/CD16+ and non-classical CD14+/CD16++ cells as well as
the monocytic CD14+/CD15-/DRneg/low/CD33+/CD11b+ fraction of the myeloid
derived suppressor cells (MDSC), in CIN patients.
Methods: We have studied 25 patients fulfilling the well-defined diagnostic cri-
teria for CIN and 10 age and sex-matched healthy individuals. Three-colour
flow cytometry was used to assess the peripheral blood monocytes subsets in
the gate of CD14 positive cells and five-colour flow cytometry for the evaluation
of the myeloid derived suppressor cells in the gate of cells with intermediate/
high FSC/SSC properties.
Results: The mean number of neutrophils and monocytes in CIN patients was
1176±496/μl and 412±130/μl, respectively (range 200-1800/μl and 200-700/μl,
respectively). The proportion of classical CD14++/CD16- cells was significantly
decreased in CIN patients (79.69%±7.60%) compared to the healthy individuals
(87.90%±3.70%) (P=0.0009). In contrast, a significant increase was observed
in the proportion of CD16 positive cells in CIN patients (16.81%±6.75%) com-
pared to the controls (7.97%±3.16%) (P=0.0001). This increase was due to
the higher proportion of the intermediate CD14++/CD16+ but not the non-clas-
sical CD14+/CD16++ monocyte subsets in CIN patients (12.74%±5.28% and
4.05%±2.51%, respectively) compared to controls (7.05%±2.47% and
2.73%±1.39%, respectively) (P=0.0014 and P=0.1383, respectively). Further-
more, the proportion of CD14+/CD15-/DRneg/low/CD33+/CD11b+ MDSCs was
significantly increased in the patients (6.18%±3.92%) compared to the healthy
controls (3.31%±1.74%) (P=0.0412).
Summary/Conclusions: CIN patients display increased proportion of circu-
lating intermediate CD14++/CD16+ monocytes that may have a role in the aber-
rant inflammatory responses commonly seen in these patients. The increased
proportion of the CD14+/CD15-/DRneg/low/CD33+/CD11b+ MDSC in CIN may
simply reflect a compensatory reaction aiming to suppress the T-cell activation.
Isolation of the above cell populations and transcriptome studies are currently
in progress in our laboratory.
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DIAGNOSTIC VALUE OF CELL BOUND AND CIRCULATING ANTI-
NEUTROPHIL ANTIBODY DETECTION IN PEDIATRIC NEUTROPENIA
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Universitaria Policlinico Giovanni XXIII, Bari, 7Department of Clinical Sciences
and Community Health, Milan, Italy
Background: Chronic benign neutropenia (CBN) of infancy includes primary
autoimmune (pAIN) and chronic idiopathic (CIN) neutropenia. A diagnosis of
CIN is supported by the absence of demonstrable anti-neutrophil autoantibod-
ies, which can be detected free in the serum and bound to neutrophils with the
Indirect- and Direct-Granulocyte Immunofluorescence Test (I-GIFT, D-GIFT),
respectively. Conclusive evidence is lacking on the diagnostic value of the D-
GIFT, whose performance requires specific laboratory expertise, may be logis-
tically difficult and hampered by very low neutrophil count in patient samples. 
Aims: This study investigated whether the evaluation of D-GIFT improves the
diagnostic accuracy of pediatric neutropenia.
Methods: I-GIFT and D-GIFT were performed by flow cytometry in 533 children
including 174 (33%), 162 (30%), 81 (15%), 51 (10%) and 65 (12%) cases with
pAIN, CIN, secondary autoimmune (sAIN), post-infection (PIN) and non-autoim-
mune (nAIN) neutropenia referred to this laboratory during 2002-2014, respec-
tively.
Results: Using highly specific median fluorescence intensity cut-off values cal-
culated by ROC curves, a positive D-GIFT was found in 49% of CIN patients,
who showed similar clinical features as those included in the pAIN group. In
44 (27%) of 162 CIN patients I-GIFT was repeated 2-3 times in a year, resulting
positive in 12 (27%) and 2 (5%) patients at the second and third screenings,
respectively. Interestingly, 10 (71%) of the latter 14 patients showed a positive
D-GIFT at the first serological screening. 
Summary/Conclusions: D-GIFT evaluation improves the diagnostic accuracy
of pediatric neutropenia. This can reduce the need for expensive and invasive
investigations in CBN patients.
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INAPPROPRIATE TREATMENT COULD MASK COBALAMIN DEFICIENCY:
ROLE OF METHYLMALONIC ACID EVALUATION
R. Angel F.1,*, P. Sarda2, M. Serra1, J.M. Queralto2, E. Zapico2, J. Remacha1,
S. Payan1, A. Ramos-Aviles2
1Hematology, 2Biochemistry, Hospital de Sant Pau, Barcelona, Spain
Background: Metabolic markers of cobalamin (Cbl) deficiency, such as methyl-
malonic acid (MMA) and homocysteine (Hcy) enable us to diagnose Cbl defi-
ciency1,2. They differentiate Cbl deficient patients from those with low serum
cobalamin levels (LB12), but without a real Cbl deficiency. Hcy evaluation is
fully automated and available in many laboratories, whereas MMA determina-
tion is cumbersome and measured in few laboratories3. Routinely, Hcy is used
to differentiate LB12 patients because a good concordance has been reported
between Hcy and MMA4. However, in a study involving few cases, 26.5%
patients with LB12 and normal Hcy showed high MMA levels4.
Aims: To evaluate the characteristics of patients with LB12 and normal Hcy
and high MMA levels. 
Methods: A prospective study was carried out in our University Hospital. Hcy
levels were determined in LB12 (level <150pmol/l) patients with normal folate
parameters for 18 consecutive months. MMA was assessed in those with nor-
mal Hcy. Serum B12, serum and red cell folate, and Hcy levels were evaluated
using commercial automated methods. Hyperhomocysteinemia was defined
by serum Hcy >17μmol/l. Serum MMA was assessed by using mass spec-
trophotometer and an increase in the MMA level was considered when MMA
was >0.4nmol/l.
Results: A total of 237 patients with LB12 and normal Hcy were observed. In
27 (11.4%) MMA levels could not be determined. MMA levels were normal in
147 (70%). In 63 patients, MMA was increased (30%), including 25 cases
(12%) with MMA levels >0.8nmol/l. In 48 out of 63 patients (76%), data on pre-
vious treatment were available. Of them, 40 (83.3%) patients had previously
received inappropriate treatment (40% receiving folate) and 5 no previous Cbl
treatment (10.5%). Only, 3 patients (6.25%) were treated with an adequate Cbl
dosage. 
Summary/Conclusions: MMA was increased in 30% of LB12 patients with
normal Hcy, demonstrating cobalamin deficiency. Most of these patients (83%)
were erroneously treated, including 40% receiving folate. As a consequence,
in most of these cases this erroneous treatment decreased Hcy levels to normal
values, but cobalamin deficiency was masked and could deteriorate, especially
when folate treatment was used without and adequate cobalamin replacement.
References
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Background: Autoimmune hemolytic anemia (AIHA) is not commonly seen
during childhood, and is extremely rare in infancy. Absence of guidelines ren-
ders management of the disease difficult in children – and even more so in
infants.
Aims: Aim of the report is to present a number of cases of infantile AIHA, refrac-
tory to conventional treatments, demonstrating response in administration of
rituximab.
Methods: The report concerns four infants (3 baby girls and one baby boy)
who presented with AIHA. Data regarding demographics, personal and family
medical history, immunologic assessments, previous treatments and response
to rituximab were studied.
Results: Age at diagnosis of AIHA was 4-6 months. In 3 cases (cases number
1, 2 and 3) personal and family history, as well as laboratory screening at diag-
nosis, did not reveal presence of any other hematologic, autoimmune or
immunologic condition. In case number 4 AIHA followed the diagnosis of giant
cell hepatitis. Hospitalization before rituximab administration ranged between
1 and 4 months, and included multiple transfusions, administrations of intra-
venous immunoglobulin (maximum dose 6g/kg), repeated doses of intravenous
methyl-prednisolone (30mg/kg) followed by oral prednizolone (max 5mg/kg),
all failing to achieve sustained response. Rituximab was administered at
375mg/m2 in 4 weekly infusions. In 3 infants 5 monthly infusions followed. Sta-
bilization of hemoglobin and improvement of hemolysis parameters were
observed after the 3rd-4th weekly infusion in all infants. In 3 patients (no 1,2,3)
CD19+ and CD20+ Β cell assessment before and after rituximab administration
was performed. Complete elimination (<1%) was observed in all patients after
the 1st-2nd infusion. Despite B cells returning to normal 11 months after treat-
ment, infant no 1 remained in clinical remission during follow-up (22 months
post treatment). Infant no 2 remained in clinical remission for the 16 month
post treatment follow-up, despite B cell normalization. Infant no 3 relapsed fol-
lowing B cell normalization, 11 months after rituximab administration. Infant no
4 did not undergo B cell measurements and relapsed one year after completing
rituximab therapy. The 2 patients that relapsed were re-treated with 4 rituximab
infusions: patient no 3 remained well for the 18 month follow-up, whereas
patient no 4 remained well for 10 years – again relapsing and receiving her 3rd
rituximab treatment with good response for the remaining 7 month follow-up.
None of the patients presented with adverse reactions during the infusions or
with severe infections as a result of immunosuppression. However, infant no 1
developed asymptomatic progressive IgG hypogammaglobulinemia 11 months
after initial exposure to rituximab, eventually requiring IVIG administration.
Summary/Conclusions: Rituximab administration in refractory AIHA seems
to be efficacious and safe in infants. However, close follow-up is warranted in
order to ensure absence of long term complications, including the risk of post-
treatment hypogammaglobulinemia, when the drug is administered at such
young ages.
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DIAGNOSIS OF RARE INHERITED ANAEMIAS
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Background: Targeted re-sequencing has recently been adopted for the rapid
diagnosis of anaemia patients whose disease is likely to have a genetic basis,
however, currently results remain inconclusive in 30-60% of cases. Whole-
genome sequencing (WGS), provides more uniform coverage than amplifica-
tion-based panels and is allied to an unbiased approach offering the opportunity
to explore both coding and non-coding regions. It is also possible to use WGS
data to detect copy number variation with good resolution and sensitivity. There-
fore WGS has the potential to offer an accurate molecular diagnosis in a pro-
portion of unsolved anaemia cases and may therefore be a superior initial
approach. Furthermore, WGS is likely to lead to the identification of novel genes
involved in pathogenic and normal erythropoiesis.
Aims: We aimed to undertake WGS in a set of patients in whom targeted re-
sequencing had not been able to identify a molecular cause for the inherited
anaemia, in an attempt to increase the diagnostic yield of the molecular analysis
of such patients and provide novel candidate genes as causative of anaemia.
Methods: We performed WGS of 20 individuals (2 singletons and 6 trios) at
30X coverage where all the probands have a rare anaemia of suspected genetic
origin. Probands were pre-screened with a targeted panel containing ~50 can-
didate genes, none of which had harboured likely causative variants. Analysis
of WGS data involved Stampy for read alignment, Platypus for variant calling
and Ingenuity Variant Analysis (Qiagen) for variant annotation and filtering, fol-
lowed by visual inspection and verification by Sanger sequencing.
Results: Known causative variants in a gene absent from the targeted panel
were detected in two patients (25%), whereas candidate variants in novel genes
not previously associated with anaemia were identified across the other six
cases. Familial segregation and functional studies are underway to provide fur-
ther evidence of causality for these novel variants, of which 60% are in genes
with previous evidence of a role in erythropoiesis and 40% in genes with no
known role in erythroid development.
Summary/Conclusions: These results illustrate the overlap in phenotypic abnor-
malities existing among these conditions and the importance of providing an
accurate molecular diagnosis to enable correct diagnostic and clinical manage-
ment of anaemia patients. We also demonstrate the benefit of using WGS over
targeted resequencing given the difficulty of designing comprehensive gene pan-
els and keeping them up-to-date as new candidate genes are identified.
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Background: Congenital erythrocytosis (CE) is a rare hereditary disorder of
red cell production, characterized by an absolute increase in red cell mass with
elevated hematocrit and hemoglobin levels not accompanied by increased
numbers of white cells and platelets. It can be caused by defects in the EPO-
induced signaling pathway (primary), defects in the control of EPO synthesis
by the oxygensensing pathway (secondary) or sinthesis of high oxygen affinity
hemoglobins. EPO transcription is regulated by Hypoxia Inductable Factor
(HIF). 3 prolyl hydroxylase domain proteins (PHD1, PHD2, PHD3), active in
the presence of oxygen, are able to hydroxylate key prolines in oxygen depe-
dent degradation domains of HIF alpha subunit and it is degradated by the pro-
teosome. Mutations in those proteins are linked to CE.
Aims: Describe a new mutation in PHD2 gene associated to CE.
Methods: Clinical process consultation and search in Blood, European Hema-
tology Association and Pubmed websites of keywords: “congenitalfamilial ery-
throcytosis” “phd2”.
Results: We described a portuguese family followed by hematology service
because of an isolated but sustained erythrocytosis, affecting 3 generations -
grandfather, father (propositus) and son. Propositus referred headache and
presented plecthoric face and hypertension. Analytically, it was confirmed ery-
throcytosis (haemoglobin>18g/dL and hematocrit>50%), without any other
changes, except an indirect hyperbilirubinemia. Secondary causes of erytho-
cytosis was excluded, with normal EPO and partial oxygen pressure. Bone
biopsy only showed an erythroid hyperplasia, no JAK2 mutations identified,
and normal hemoglobins electrophoresis, HBB and EPOR gene sequencing.
We then proceeded to sequencing of gene included in EPO-induced signaling
pathway and it was detected a new mutations in PHD2 gene (F366L), in het-
erozigoty. Despite it has never been described, other mutations in PHD2 were
associated to slightly increased thrombotic potential so patients began
antiplatelet aggregation therapy and phlebotmies. Additionally, they were diag-
nosed with Gilbert syndrome by a mutation in UGT1A1 gene promoter region
[A(TA)7TAA].
Summary/Conclusions: An unknown mutation of PHD2 has been detected in
2 generation of a family with erythocytosis and it was co-segregated with the
erythocytosis phenotype. That gene plays an important role in the regulation of
EPO production and subsequently in erythropoiesis. Futhermore family studies
have to be performed to better understand its pathogeny and management.
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L. Escoda Teigell1
1Hospital Joan XXIII Tarragona, Tarragona, Spain, 2Preventive Medicine Unit,
3Nefrology, 4Intensive Care Unit, Hospital Joan XXIII Tarragona, Tarragona,
Spain
Background: Thrombotic microangiopathies (TMA) are characterized by the
formation of platelet thrombi that obstructs vital organ microcirculation. The
presence of the 5 classic parameters (haemolytic anemia, thrombocytopenia,
fever, oliguria and neurological affection) is rare. ADAMTS13 determination
allows a more accurate diagnosis than the presumption based on clinical and
biochemical parameters.
Aims: To retrospectively analyze 44 TMA patients diagnosed in our centre in
the last 17 years and characterize TTP, HUS and secondary TMA (sTMA) by
revising their clinical data, correlate with ADAMTS13 level and identify predic-
tors for survival and relapse.
Methods: TMA was defined as microangiopathic hemolytic anemia with throm-
bocytopenia under 150x109/L. All cases were classified as: 1. TTP (TMA with
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ADAMTS13 <5% or TMA without baseline cause), 2. HUS (TMA with
ADAMTS13 >5% and high creatinine level or positive E. Coli Shiga-Toxin or
HUS related mutation), 3. sTMA (other TMA with a definite triggering cause).
Clinical and laboratory parameters were analyzed in each group
(TTP/HUS/sTMA) (ADAMTS13 ≤5% or >5%) by a univariate analysis using
chi-square for categorical variables and ANOVA test for continuous variables.
Kaplan Meier and multivariate Cox proportional hazards regression was used
for survival and relapse.
Table 1.
Results: Patient distribution was: TTP 13, HUS 8, sTMA 23. ADAMTS13 was
determined in 28 patients (low 8, high 20). Clinical and laboratory parameters
of each group and univariate analysis are summarised in table 1. All patients
received 1mg/kg/day steroids on admission and started plasma exchange.
Patients in the TTP group showed increased levels of LDH, schistocytes, biliru-
bin and a low platelet count which was associated with bleeding. They also
required a higher number of plasma exchanges to recover. Five patients
relapsed, 4 with low ADAMTS13 level. 4 patients were splenectomized and
received immunomodulators. One patient received only plasma exchanges
when relapsed. One patient died immediately after diagnosis before receiving
plasma exchange. HUS group patients had higher creatinine level which was
associated with oliguria and dialysis requirement. Neurological symptoms were
more frequent as well. Two patients progressed to renal failure and one was
transplanted. Two other patients received eculizumab and 1 relapsed when
treatment was interrupted during pregnancy. sTMA patients showed more car-
diac events and fever. Main triggering causes were: 6 malignant hypertension,
5 systemic lupus erythematosus, 4 neoplasia, 3 pancreatitis, 2 pregnancy, 1
tuberculosis, 1 glomerulonephritis, 1 dermatomyositis. Six patients died (4 can-
cer related). In the multivariate analysis, high LDH level was significantly asso-
ciated with relapse (p=0.012) while the number of schystocytes showed a trend
to statistical significance (p=0.063).
Summary/Conclusions: ADAMTS13 determination is a useful tool in TMA
differential diagnosis. A high LDH level, and also probably the number of schys-
tocytes, could be valuable to predict relapse in TMA patients.
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CHILDREN WITH CHRONIC-REFRACTORY AUTOIMMUNE CYTOPENIAS:
A SINGLE CENTER EXPERIENCE
T.H. Karapınar1,*, E. Durgun1, Y. Oymak1, N. Gülez2, Y. Ay1, F. Genel2, S. Gözmen1,
E. Serdaroğlu3, S. Aydın Köker1, E. Töret1, C. Vergin1
1Pediatric Hematology and Oncology, 2pediatric immunology, 3pediatric
nephrology, Dr. Behcet Uz Children Training and Research Hospital, Izmir,
Turkey
Background: Autoimmune cytopenias are a group of heterogeneous disorders
characterized by immune-mediated destruction of one or more hematopoietic
lineage cells. They can be idiopathic or occur as a manifestation of other under-
lying disorders, such as autoimmune diseases, immunodeficiency, autoimmune
lymphoproliferative syndrome, tumors, medications or infections.
Aims: The aim of this study was to evaluate the clinical course and significance
of autoimmune cytopenias due to immunodeficiency or autoimmune diseases
in children followed up at our hospital.
Methods: A total of 337 files of information belong to patients with chronic or
refractory autoimmune cytopenias were evaluated retrospectively at our hema-
tology department between February 1997 and September 2015. Ultimately,
patients with immune deficiency or autoimmune diseases (23 patients) were
included in this study. Data were analyzed using SPSS 15.0. The results are
presented as the mean, SD, median, absolute number, or percentile.
Results: Twenty-three of the patients with chronic or refractory autoimmune
cytopenias (6.8%) had an immune deficiency or an autoimmune disease. The
median age of diagnosis was 3.1 years (between 6 months-16 years) and the
ratio of male/female was 1.3. The median duration of following was 2.6 years
(between 4 months and 18.5 years). A total of 13 patients (56.5%) had single-
lineage cytopenias and 10 (46.5%) had multi-lineage cytopenias. Shows last
diagnosis of the patients. In 22 of the patients, firstly cytopenias had detected
than the primary diseases were diagnosed after median 2 months (between 0
and 77 months). Only one patient firstly had diagnosed as CVID, cytopenia
has developed after years. All of the patients were treated with corticosteroids
or intravenous immune globulin (IVIG) as first-line treatment. Ten patients need-
ed second or further-line immunosuppressive therapies including rituximab,
mycophenolate mofetil, cyclosporine A, azathioprine, and chloroquine. A total
of 8 patients (34.7%) recovered from autoimmune cytopenias after the treat-
ment of primer disease. That diseases were diagnosed as systemic lupus ery-
thematosus in 4 patients, hypogammaglobulinemia in 3 patients, and celiac
disease in 1 patient. Cytopenias have countinued in 14 of the patients. One
patient with CVID died.
Summary/Conclusions: Cytopenia may be the first finding of an immunode-
ficiency or autoimmune disease and primary disease may be diagnosed in the
clinical course. Early diagnosis is important because of beginning to the early
treatment of underlying disease 
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INHERITED PROTHROMBOTIC RISK FACTORS IN TURKISH CHILDREN
WITH HEREDITARY ANGIOEDEMA. SINGLE CENTER
T. Patiroglu1,*, M. Cansever2, A. Ozcan1, F. Tahan3, Y. Özkul4
1Pediatric Hematology, 2Pedıatric Immunology, 3Pediatric Allergy, 4Genetıcs,
Erciyes University Medical Faculty, Kayseri, Turkey
Background: Hereditary angioedema (HA) is characterized with recurrent
mucocutaneous angioedema, abdominal pain, edema of larynx and extremities.
HA is a life treatening, rare disease, it’s genetic inheritance known as autosomal
dominant. The incidence of the disease ranges from 1/10000 to 1/150000. 3
types of disease were described. Classic HA, is associated with C1 esterase
inhibitor quantitative (type 1) or functional (type 2) defficiency. Type 3 HA is
defined as form of HA which is seen in pregnant women and women use estro-
gen treatment. If plasma C1 inhibitor is deficient, complement, kinin-bradykinin,
coagulation and fibrinolytic systems activate out of control and then vascular
permeability increases and angioedema develops, tendency to thrombosis
increases as well. Futhermore, it is known that acute treatment with C1 inhibitor
concentrate and prophylactic use of danazol and antifibrinolytic drugs may also
stimulate the thromboembolism. Therefore, prothrombotic risk factors are
important in the patients with HA. Hence, we planned to search prothrombotic
risk factors in patients with HA. 
Aims: Hence, we planned to search prothrombotic risk factors in patients with HA.
Methods: Ten patients wih HA who were followed up at the Department of
Pediatric Immunology and Allergy of the Erciyes University Medical Faculty
were included in our study. The type and frequency of attack, use of prophy-
laxy and family story of HA were questioned. Factor V G1691A, prothrombin
G20210A variant, methylenetetrahydrofolate reductase (MTHFR) and plas-
minogen activator inhibitor (PAI) mutations were investigated in all patients.
Results: Among the 10 patients of the study, five of the them were male
(50%) and five were female (50%) and their ages mean was 151,90±48,21
months old (ranged from 75 to 210 months). No one had parental consan-
guinity. Nine patients (90%) had the family history of HA. Patients’ affected
family members were distributed by 5 sibling (50%), 3 mother and aunt (30%),
1 father (10%). One patient had no family story (10%). The mean serum
value of C4 level in diagnosis was 4,71±1,62mg/dl (normal value: ) mean
value of C1 inhibitor level in diagnosis was 50,10±19,22mg/dl (normal value).
It was learned that four patients (40%) had an attack of HA once every week,
three patients had (30%) once per month, one patient (10%)had, once every
2-3 months. Two patients (%20) had no attack. Four patient had abdominal
(40%), four patient had edema of hands, feet and face (40%). None of them
received prophylactic treatment. One patient (10%) had heterozygous F V
G1691A mutation, another one had also heterozygous protrombin G20210A
mutation. The heterozygous MTHFR mutation were identified in seven
patients (70%) and homozygous MTHFR mutation were found two patients
(20%). Furthermore, four patients (40%) had heterozygous and one patient
(%10) had homozygous PAI mutation.
Summary/Conclusions: C1 inhibitor, inhibits activated F XII,thrombin and
plasmin. When the C1 inhibitor is deficient, dermal vascular thrombosis and
systemic coagulation occur due to inhibition of activated FXII, thrombin and
plasmin. Decrease level of PAI1 and PAI2, destructs plasmin activation which
cause FXII activation and it effects prekallikrein and bradykinin cascade, there-
fore increase tendency of thrombosis and HA risk. In the literature, an adult
patient who had heterozygous Factor V leiden mutation and purpura fulminans
was reported. In our study, there is no clinical evidence supporting thrombosis,
nevertheless it was observed that one of our patient with a homozygous PAI
mutation had an attack more frequently. As a conclusion, in the patients, risk
of thrombosis increases because of both HA and related treatment. Hence,
prothrombotic risk factors should be investigate in patients with HA. In HA
patients, known to protrombotic risk factors was crucial to estimate attack fre-
quency-severity and treatment related thrombosis risk.
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FLOW CYTOMETRIC ANALYSIS OF TISSUE SAMPLES IN 42 ADULT
PATIENTS WITH MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC
LYMPHOHISTIOCYTOSIS
M. Klimkowska1,*, C. Arlinde1, K. Kosior1, M. Machaczka2,3
1Department of Clinical Pathology and Cytology, 2Hematology Center, Karolin-
ska University Hospital, Stockholm, Sweden, 3Medical Faculty, University of
Rzeszow, Rzeszow, Poland
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare, potentially
fatal hyperinflammatory syndrome, which in its most common, secondary form,
can be induced by infection, malignancy or autoimmune disease. Diagnosis of
HLH is made when at least five of eight clinical and laboratory HLH-2004 criteria
are met. However, diagnostic criteria were established based on studies from
pediatric patients, and it is debated if they can be applied to adults. Assessment
of these criteria can be subjective (microscopic identification of hemophago-
cytes), time-consuming or not easily available (e.g. molecular analyses, func-
tional tests of NK-cells).
Aims: The aim of the study was to evaluate phenotypic findings from flow cyto-
metric (FC) analyses of bone marrow (BM) and other tissue samples from
patients with hematological malignancies (hM) who developed HLH. The study
was intended to investigate potential utility of a rapid phenotypic screening in
diagnostics of suspected HLH.
Methods: Flow cytometric files for 42 patients with hM were retrieved from
archive of the Department of Clinical Pathology and Cytology, Karolinska Uni-
versity Hospital. The patients were diagnosed and treated for hM-HLH at the
Hematology Center of the same hospital, between 2009 and 2016. Tissue sam-
ples (bone marrow, peripheral blood, lymph nodes) were analyzed according
to standard procedures, using monoclonal antibodies (BD, DAKO, Beckman
Coulter, BioLegend). Cells were acquired using 4-color Canto A or 8-color Canto
II cytometers (BD), and analyzed with BD FACSDIVA software. Neoplastic
clones of myeloid or lymphoid character were excluded from reanalysis for the
purpose of this study. Bone marrow samples were obtained from 31 patients
shortly before and from 24 patients following HLH-diagnosis; in 13 patients
paired BM samples were available.
Results: Patient characteristics are presented in table 1. Bone marrow B-cell
lymphopenia was observed in 67% patients before and 74% after HLH diagnosis.
Decreased amounts of NK-cells were noted in 48% persons at both time points.
T-cell lymphopenia before HLH diagnosis was noted in 60% patients with myeloid
malignancy but in only 25% cases of lymphoid malignancy, whereas in estab-
lished HLH the respective figures were 27% and 46%. CD4/CD8 ratio was
skewed-to-normal in both myeloid and lymphatic tumors before HLH was diag-
nosed. In cases of confirmed hyperinflammation, patients with myeloid tumors
showed dominance of CD4+ cells but no such difference was noted in lymphoid
disease. Loss of lineage specific markers of non-neoplastic T-cells was a con-
stant feature in lymphoid malignancy, whereas aberrant expression of lymphatic
markers (CD2, CD7, CD56) on myeloid cells was uniform in patients with myeloid
tumors. Monocytosis was more often observed in myeloid as compared to lym-
phoid tumors at HLH onset (40% vs 31%), although it was of non-neoplastic
character. However, monocytopenia was also noted in cases of established
HLH, in 10% of myeloid malignancies and 15% of lymphatic malignancy cases.
Table 1.
Summary/Conclusions: In the presented cohort, quantitative shifts could be
observed in BM samples around the time of HLH onset. However, different pat-
terns were observed between patients affected by lymphoid or myeloid malig-
nancies, which may represent disease-specific impact on BM microenviron-
ment. Further study will be carried out to confirm findings in a large, possibly
prospectively collected patient group. Control group of patients with respective
malignancies but without HLH will be included.
Platelets disorders
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BLEEDING IN PRIMARY IMMUNE THROMBOCYTOPENIA: WHO ARE
MOST AT RISK?
U. Doobaree1,*, S. Hodges1, R. Nandigam1, A. Newland1, D. Provan1
1Haematology, Barts and The London School of Medicine and Dentistry, Lon-
don, United Kingdom
Background: Primary Immune Thrombocytopenia is rare disorder in which
patients are at risk of bleeding due to autoimmune-mediated platelet destruction.
Aims: This study focused on describing the prevalence and types of bleeding
events around the time of ITP diagnosis and after, as well as identify any factors
that can potentially influence the risk of bleeding.
Methods: Data from the United Kingdom Immune Thrombocytopenia Registry
were analysed for this study. The registry obtained its data from about 70 cen-
tres around the UK. Descriptive and logistic regression statistical techniques
were used for this study.
Results: This analysis was based on 2365 (57.8% females) participants who
are part of the Registry. The median age at diagnosis was 50 years (IQR 32,
66) and 77% of these patients were of European ethnicity. The commonest
comorbid conditions was hypertension (23%). Median platelet count was 19
(IQR: 5, 53). Eighty percent had a platelet count below 30x109/L around ITP
diagnosis. The most common bleeding events were skin-related (46.5%) and
to the oral cavity (14.4%). About 70% of the cohort experienced at least one
bleeding event at some point after diagnosis. After ITP diagnosis the most com-
mon bleeds were again skin-related (34.3%) and oral cavity bleeding (14.8%).
Epistaxis had risen from 11.6% before diagnosis to 17.7%. Bleeding at other
sites did drop. However, the prevalence of intracranial haemorrhage rose from
0.9% pre-diagnosis to 1.2% after diagnosis. Prednisolone (79%) and IVIg (43%)
remained the most used drugs followed by rituximab (26%) among those were
treated. Romiplostim (15%) and Eltrombopag (9%) are used too but not any-
more than mycophenolate (18%) and azathioprine (22%). Fourteen percent of
the cohort had a splenectomy at some point. Age but not gender or ethnicity
were found to be associated with having a bleeding event around the diagnosis
of ITP. Young adults (18 to 30 years old) are less likely to experience a bleed
than older adults (>70 years), who were most at risk. Platelet counts, expectedly,
was associated with bleeding with those presenting with a platelet of <30x109/L
were at higher risk. No comorbid illness or cotherapies were found to be asso-
ciated with bleeding events.
Summary/Conclusions: The frequency of bleeding decreased for most sites
but for some others a slight increase has been observed since ITP diagnosis.
It is possible that bleeding events may have been recorded more accurately or
observed more closely and over a longer period of time since diagnosis. How-
ever, control of bleeding was an issue after the diagnosis of ITP. Future analysis
statifying its findings by time periods would be beneficial in describing if bleeding
events were better controlled over the last few years, especially after the intro-
duction of new therapeutic agents and the publication of the internal consensus
report on the diagnosis and management of primary ITP.
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A MULTICENTRE, SINGLE ARM, OPEN LABEL STUDY EVALUATING THE
EFFICACY AND SAFETY OF ELTROMBOPAG IN PATIENTS WITH SEVERE
PERSISTENT IMMUNE THROMBOCYTOPENIC PURPURA (ITP) WITHIN
SIX MONTHS OF DIAGNOSIS
H. Tran1,2,*, R. Bird3, S. Chunilal4, T. Brighton5, J. Reynolds6, S. He7, C. Mazis1,
R. Hall1, P. Shuttleworth7, A. Grigg7
1Clinical Haematology, The Alfred Hospital, 2Clinical Haematology, Monash
University, Melbourne, 3Clinical Haematology, Princess Alexandra Hospital,
Brisbane, 4Clinical Haematology, Monash Health, Melbourne, 5Clinical Haema-
tology, Prince of Wales Hospital, Sydney, 6Clinical Epidemiology and Preven-
tative Medicine, Monash University, 7Clinical Haematology, Austin Hospital,
Melbourne, Australia
Background: Patients with acute ITP who fail or are dependent on steroids or
intravenous immunoglobulin (IvIg) are often committed to splenectomy or pro-
longed immunosuppression. Splenectomy is potentially curable but not without
operative risk with many patients reluctant to undergo surgery, while the
response to immunomodulation is often suboptimal with significant side effects.
Although effective, to date, there is no published studies evaluating the benefit
of eltrombopag among steroid dependent or resistant, non-splenectomised ITP
patients diagnosed within 6 months.
Aims: To evaluate the efficacy and safety of eltrombopag in patients with severe
“acute” and persistent ITP within 6 months of diagnosis.
Methods: A multicentre, single arm open label study involving 39 patients with
severe ITP (a) with platelet count of <30x109/L despite a daily dose of pred-
nisolone of 1mg/kg for at least 2 weeks from diagnosis OR (b) requiring pred-
nisolone ≥10mg daily and/or recurrent doses of IvIg to maintain a platelet of
≥30x109/L within 6 months of diagnosis. Prior splenectomy was not a requisite.
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Patients with platelets <10x109/L will commence on eltromobopag 75mg daily
while those with a count ≥10x109/L will commence on 50mg daily. A reduced
dose is used for subjects of East Asian heritage. The dose of eltrombopag can
be progressively increased by 25mg increment every 2 weeks to maximum of
150mg daily (patients of East Asian heritage should have a maximum eltrom-
bopag dose of 100mg daily) if the platelet count remains ≤30x109/L or there is
clinically significant bleeding every 2 weeks. The steroid can be progressively
weaned to zero over the subsequent 6 weeks if clinically appropriate. The pri-
mary endpoint was overall response rate (ORR) at week 12, defined as the
proportion of patients achieving complete response (CR; platelet >100x109/L),
partial response (PR; platelet >50 x109/L) or minor response (MR; platelet
≥30x109/L with ≥50% reduction in the dose intensity of concomitant ITP therapy
compared with screening). The protocol specified a 1-sided 5% level binomial
test of the null hypothesis that ORR at week 12 ≤30% and reporting of a 90%
two-sided confidence interval (CI).
Results: Of the 39 patients enrolled, 46% were women, median (Q1, Q3) age
was 52 (37, 68) years, median (Q1, Q3) time since ITP diagnosis was 2.2 (1.1,
5.4) months, and median (Q1, Q3) screening platelet count was 21(13, 34)
x109/L. Prior treatments included steroids (95%), IVIG (58%), and immuno-
suppresion (28%). 35 patients (90%) completed 12 weeks of treatment, 4 (10%)
discontinued eltrombopag prior to week 12 [3 required new ITP therapy; 1
developed pulmonary embolism (PE)]. The median (Q1, Q3) dose eltrombopag
at week 12 was 50 (50, 100)mg daily. The median (Q1, Q3) dose of steroid at
week 12, zero (0, 5)mg daily. At week 12, the ORR was 64% (p<0.0001; 90%
CI: 51-77%); CR, PR, MR rates were 41%, 15% and 8% respectively and the
median (Q1, Q3) platelet count among responders was 168 (98, 252)x109/L.
At week 26, the ORR was 54% (90% CI 40-67%); CR, PR, MR rates were
28%, 21% and 5% respectively. Two patients had serious adverse events
(SAEs) with two episodes of venous thromboembolism (one deep vein throm-
bosis at platelet 97x109/L; one pulmonary embolism at platelet 240x109/L).
There were no other adverse events or deaths.
Summary/Conclusions: The majority of patients with ITP diagnosed for ≤6
months had a favourable overall response rate to eltrombopag and the drug
was generally well tolerated. Longer-term follow up data (beyond 6 mos) will
be presented at the meeting.
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A NOVEL RUNX1 MUTATION IN FAMILY WITH FAMILIAL PLATELET
DISORDER WITH PREDISPOSITION TO ACUTE MYELOGENOUS LEUKEMIA
L. Krupkova1,*, M. Divoka1, B. Ludikova2, J. Kucerova1, M. Holzerova1,
A. Hlusi1, T. Szotkowski1, T. Papajik1, D. Pospisilova2
1Department of Hemato-oncology, 2Department of Pediatrics, University Hos-
pital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech
Republic
Background: Familial platelet disorder with predisposition to acute myeloge-
nous leukemia (FPD/AML) is a clinically heterogeneous group of rare disorders
with autosomal dominant inheritance. Germline mutations in RUNX1 were iden-
tified as causative lesions in several families with FPD/AML. RUNX1 plays a
key role in megakaryocyte maturation and differentiation but also in ploidization
and platelet formation. In FPD/AML, RUNX1 mutations are very heterogeneous
and often specific to individual pedigrees, most commonly involving exons 3-
5 in the RHD domain near the N-terminus of RUNX1. The presence of RUNX1
mutation in FPD/AML is associated with 30-50% lifetime risk of developing
AML. Clonal hematopoiesis can be detected in >80% of asymptomatic FPD/
AML individuals at the age of 50.
Aims: To analyze mutational status of RUNX1 and clinical and laboratory mark-
ers of the disease in family with hereditary thrombocytopenia including 3 cases
of MDS/AML.
Methods: Platelet aggregation was measured on 4-channel aggregometer
APACT 4004, with platelet rich plasma (PRP) in response to adenosine diphos-
phate (ADP), collagen, epinephrine and agglutination in the presence of risto-
cetin. DNA and RNA were isolated from peripheral blood leukocytes using stan-
dard procedures. Stored DNA from 2 patients who succumbed to AML was
used for analysis. Mutational status of RUNX1 was determined using direct
Sanger sequencing of PCR products on DNA level. Analysis of alternative tran-
script length was performed using PCR with cDNA template, followed by detec-
tion on agarose gel electrophoresis. Sequences of alternative transcripts were
obtained using direct Sanger sequencing. In 3 patients with MDS and/or AML,
standard cytogenetics with G-banding was done, chromosomal changes were
confirmed by fluorescent in situ hybridization (FISH).
Results: 9 individuals (4 adults, 5 children) from 3 generations in one family
with FPD/AML were analysed. Novel hereditary RUNX1 mutation
NM_001754.4:c.509-13C>A was found in 7/9 family members as a likely cause
of FPD/AML. The mutation is located in intron between exons 2 and 3 and dis-
rupts RNA splicing, resulting in formation of alternative transcript with aberrant
length (11 nucleotides longer than its physiological variant). Frameshift and
premature termination of amino acid sequence presumably cause impaired
function of the truncated protein. All family members harboring the mutation
had various degree of thrombocytopenia (range 60-128x109/l) and did not
require treatment in the absence of clinical bleeding. In 6/7 patients with muta-
tion, decreased aggregation with collagen and epinephrine was found. Six of
7 patients with RUNX1 mutation have iron deficiency anemia of unknown origin.
Two women died of AML at the age of 51 and 38 years - the mother had kary-
otype 47,XX,+9[4]/46,XX[16] and her daughter harbored two pathological
clones 45,XX,-7[5]/46,XX,-7,+8[3] and one clone with normal karyotype. The
second daughter is followed due to pancytopenia with myelodysplastic
changes, particularly marked megakaryocytic dysplasia with normal cytoge-
netics but severe aggregation impairment.
Summary/Conclusions: We revealed novel causal RUNX1 mutation in familial
thrombocytopenia. Identification of RUNX1 mutation facilitates proper diagnosis
of FPD/AML and identification of heterozygous carriers can help detect the
development of myeloid malignancy. In the patient with pancytopenia, possible
impact of other somatic mutations acquired during leukemogenesis will be
examined.




PROFILING CIRCULATING MICRORNAS IN PATIENTS WITH IMMUNE
THROMBOCYTOPENIA (ITP) TO EXPLORE THE ROLE OF MICRORNAS
AND POSSIBLE BIOLOGICAL PATHWAYS INVOLVED IN THE PATHOGENESIS
OF ITP
L. Garabet1,2,3,*, W. Ghanima1,4, A. Rangberg1, R. Teruel-Montoya5,6,
C. Martinez5, J.B. Bussel7, P.M. Sandset3,8, C. Monceyron Jonassen1
1Østfold Hospital Trust, Grålum, 2Akershus University Hospital, Lørenskog,
3Institute of Clinical Medicine, University of Oslo, 4Department of Haematology,
Oslo University Hospital, Oslo, Norway, 5Hospital Universitario Morales
Meseguer, 6CB15/00055-CIBERER, Murcia, Spain, 7 New York Presbyterian
Hospital, Weill Cornell Medical Center, New York, United States, 8Department
of Haematology, University Hospital of Oslo, Oslo, Norway
Background: MicroRNAs (miRNAs) are small noncoding RNAs involved in
regulation of gene expression. Dysregulated expression of miRNAs has been
associated with several autoimmune diseases. ITP is an autoimmune disease
characterized by isolated thrombocytopenia and increased risk of bleeding.
The development of autoantibodies against platelets and megakaryocytes
results in increased platelet destruction and insufficient platelet production
remains central to the pathophysiology of ITP. Platelets contain high levels of
miRNAs and a substantial fraction of circulating miRNAs originates from
platelets. Circulating miRNAs are stable and relatively easy to measure and
considered as potential disease biomarkers. The role of miRNAs in the patho-
genesis of ITP has not been well explored. 
Aims: Determine the expression profile of circulating miRNAs in ITP patients in
aim to identify miRNAs that can be used as disease biomarkers and to explore the
potential biological pathways that might be involved in the pathogenesis of ITP.
Methods: Exiqon Serum/plasma Focus microRNA PCR panel was used to
determine the expression profile of 179 miRNAs in plasma acquired from 8 ITP
patients with low platelet count and who failed to respond to various treatment
for ITP, and from 8 age- and sex-matched controls. In addition, next generation
sequencing (NGS) for miRNAs was performed in 2 pooled plasma samples
(pool 1 from 4 ITP patients, and pool 2 from 4 matched controls), on the Illumina
NextSeq 500 system. Statistical analyses were performed with the GenEx soft-
ware and SPSS. Pathway analysis was performed using DIANA-miRPath v3.0
to explore the probable pathways involved in the pathogenesis of ITP. 
Results: Comparing the expression profiling from the PCR panel between ITP
patients and matched controls, 81 circulating miRNAs were differentially
expressed (p<0.05), of those 17 miRNAs had a high statistical significance
(Bonferroni correction). Among those, miR-191-5p and miR-26a-5p were down-
regulated and miR-486-5p and miR-222-3p were up-regulated in ITP compared
to controls. Interestingly, 15 of the 17 differentially expressed miRNAs from
PCR panel were also differentially expressed in NGS. Using the 17 differentially
expressed miRNAs in the miRPath analysis, we uncovered some immune sys-
tem related pathways, including MyD88-independent toll-like receptor signaling
pathway and TRIF-dependent toll-like receptor signaling pathway, as enriched
pathways in target genes of miRNAs differentially expressed between ITP
patients and controls.
Summary/Conclusions: We identified a large number of miRNAs that were
differentially expressed in ITP patients compared to controls that might be
associated with the pathogenesis of ITP. Pathways analysis uncovered some
possible biological pathways that might be involved in the pathogenesis of ITP.
Further validation of these miRNAs in a larger patient cohort and preferably in
comparison to patients with other causes of thrombocytopenia such as aplastic
anemia to explore the role of these miRNAs in the pathogenesis of ITP. Future
studies of these miRNAs in relation to initiation of treatment with defined clinical
outcomes as treatment response/ remission after initiation of treatment will
clarify their potential as biomarkers for treatment response. 
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NORDIC COUNTRY PATIENT REGISTRY FOR IMMUNE THROMBOCY-
TOPENIA (NCPRITP): A COHORT OF PATIENTS WITH CHRONIC IMMUNE
THROMBOCYTOPENIA IN DENMARK, SWEDEN, AND NORWAY
C. Christiansen1, S. Bahmanyar2, W. Ghanima3,*, N. Kristensen1, S. Stryker4,
J. Acquavella1, K. Cetin5, M. Nørgaard1, H. Sørensen1
1Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 2Clinical
Epidemiology Unit & Center for Pharmacoepidemiology, Department of Medi-
cine, Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Øst-
fold Hospital Trust, Fredrikstad, Norway, 4Center for Observational Research,
Amgen Inc, San Francisco, 5Center for Observational Research, Amgen Inc,
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Background: Immune thrombocytopenia (ITP) is a rare disease characterized
by isolated low platelet counts and an increased tendency to bleed. As yet,
there have been no large, multi-country, population-based cohorts established
to describe its long-term clinical course and investigate the effectiveness and
safety of related therapies.
Aims: To describe the establishment of the NCPRITP and the characteristics
of patients enrolled.
Methods: Encompassing Denmark, Norway, and Sweden, the NCPRITP start-
ed as a population-based post-authorization safety study to assess the long-
term safety of romiplostim in treating ITP. It includes patients with prevalent
chronic ITP (cITP – ITP lasting >6 months) as of 04/01/2009 and incident cITP
diagnosed from 04/01/2009-12/31/2014, confirmed through medical record
review. Since the start of the registry, guidelines have changed to define cITP
as ITP lasting >12 months. For consistency, incident cases of ITP for a duration
of >6 months will continue to be accrued through 2019. Through linkage of
data from the national health registries and medical record review, the registry
has rich clinical information for all enrolled ITP patients, such as comorbidities
(including scores according to the Charlson Comorbidity Index [CCI] – a vali-
dated tool developed to predict 1-year mortality), treatments, lab values (e.g.,
platelet counts), and complete follow-up for several clinical outcomes of interest
(e.g., clinically significant bleeding, the need for rescue therapies, and throm-
boembolic/thrombotic events). Additionally, available bone marrow samples are
restained and reexamined for reticulin and collagen content to assess Thiele´s
myelofibrosis (MF) grading. 
Results: The NCPRITP includes 3,749 patients with confirmed cITP (35% Dan-
ish, 51% Swedish, and 14% Norwegian), with a female preponderance (58%)
and median age of 56 years at cITP diagnosis. Forty-one percent of the cohort
was prevalent at study inclusion; 59% represent incident cITP patients. Median
follow-up time thus far is 4.3 years. At study enrollment, 24% had a platelet
count <50x109/L, 16% were splenectomized, and 41% had at least one previous
ITP therapy (mainly oral glucocorticoid steroids). The majority (68%) of the
cohort had no underlying conditions included in the CCI at study enrollment,
but 8% had a CCI score of 3 or higher, indicating severe comorbidity. Of note,
based on hospital diagnoses of specific comorbidities recorded within 5 years
before study enrollment, 8% had a history of a solid tumor, 9% had a history of
diabetes, and 18% had a history of hypertension. Currently, 718 bone marrow
samples from 566 patients have been retrieved.
Summary/Conclusions: The NCPRITP provides an example of how, within
the Nordic countries’ uniform health care systems, registries can be established
to study the clinical course of rare diseases such as ITP and the safety of drugs
used to treat these patients.
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Background: Primary immune thrombocytopenia (ITP) is a rare disease. The
incidence of ITP is not well estimated in Russia and worldwide. Due to WHO
information it varies from 1,6 to 3,9/100 000 person-years in adults. The gender
and age-associated results in Russia and abroad are discussed and differ in
several investigations.
Aims: evaluation of the incidence and demographic characteristics of primary
immune thrombocytopenia in adults in Russia.
Methods: The data source is the Registry of the patients with primary ITP in
Russia (intermediate data during the 2 years period). 1063 adult patients: 254
males (24%) and 809 females (76%), age from 18 to 89 years (median 44
years) with ITP (ICD-10 code D69.3).
Results: 41 region of Russia participated in the Registry formation. In 2016
more than a half of patients (58%) in comparison with 2014 (201 persons) and
2015 (441 persons) entered the Registry. All patient’s mean age at the moment
of diagnostic was 47.2 years, in females - 47.6, in males – 45.9. The gender-
age distribution was following: male: age <30=20% of cases, age 31-40=19%,
age 41-50=12%, age 51-60=19%, age 61-70=22%, age >70=8%. Three regions
of Russia (Republic of Crimea, Irkutsk and Tula Regions) were selected for
assessment of the incidence of ITP because of fully performed registration
process. The number of newly diagnosed cases in these regions was 31, 42
and 56 patients per year respectively. ITP incidence was 1.3/100 000 person-
years in Republic of Crimea, 1.7/100 000 in Irkutsk Region and 3.7/100 000 in
Tula Region. The gender-age distribution was following: male: age <40=37%,
age 41-60=26%, age >60=37%; female: age <40=50%, age 41-60=25%, age
>60=25%. Totally, the ITP incidence rate in females was three times higher
than in male population. Among patients with chronic ITP (82% of the total
number of patients) the disease duration distribution was following: up to 3
years - 50% of the total number of patients, 3-6 years – 18.7%, 7-10 years -
11.6%, >10 years - 19.7%. The mean disease duration was equal to 6.7 years.
Summary/Conclusions: Overall incidence of ITP in three selected regions of
Russia is: 1.3/100 000 person-years in Republic of Crimea, 1.7/100 000 in
Irkutsk Region and 3.7/100 000 in Tula Region. It is compatible to the incidence
in other European countries. Variations in parameters could be due to geo-
graphic location or not fully performed registration process. Our data demon-
strate the rise of incidence rate in males with age and its decrease in female
population. The number of patients included in the study on the epidemiology
of ITP increased 5 times during 2016 in comparison with 2014 and 2015. Geo-
graphical variations of incidence of ITP in different regions of Russia require
further study.
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Background: ITP is an acquired autoimmune disorder characterized by iso-
lated platelet reduction, which is considered chronic when it persists for >12
months. Evidence suggests that age may influence both the hemorrhagic man-
ifestations of ITP and also response and adverse events (AEs) associated with
some therapies. Changes in drug metabolism can contribute to increased AE
rates in patients (pts) ≥65 yrs compared with younger adults. The oral throm-
bopoietin-receptor agonist, EPAG, is approved for the treatment of previously
treated (eg corticosteroids, immunoglobulins) cITP pts, but limited data are
available in pts ≥65 yrs old. The EXTEND study was a global, open-label, exten-
sion study that evaluated long-term efficacy, safety and tolerability of EPAG in
adults with cITP who had participated in prior EPAG studies.
Aims: To describe the efficacy, durability of response, and safety of EPAG use
in pts with cITP aged ≥65 yrs.
Methods: All pts on EXTEND started EPAG at 50mg/day, titrated to 25–
75mg/day or less often as required, based on individual platelet count respons-
es: to achieve counts in the range ≥50–200×109/L. Maintenance dosing con-
tinued after minimization of concomitant ITP medication and optimization of
EPAG dosing. Pts could remain on EPAG either for 2 yrs in countries where
EPAG was commercially available, or for >2 yrs until EPAG became commer-
cially available.
Results: At baseline (BL), 50/302 pts (17%) on EXTEND were ≥65 yrs old
(mean ± SD 73±5 yrs). Among these 50 pts, 24% were splenectomized, 62%
female and 74% had platelet counts <30×109/L. Twenty-four pts (48%) withdrew
early from the study, most commonly because of AEs (n=8, 16%), other reasons
(n=7, 14%) and lack of efficacy (n=5, 10%). Median exposure duration was 2.3
yrs (range, 2 days to 7.9 yrs) and mean daily dose was 49.9 (range, 11–
75)mg/day. Overall, 43 (86%) pts achieved platelets ≥50×109/L without rescue
therapy; 37 (74%) achieved platelets ≥50×109/L for ≥50% of assessments; 26
(52%) maintained platelet counts continuously ≥50×109/L for ≥22 weeks (Fig-
ure). Median time maintaining platelet counts >50×109/L and twice BL values,
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while not receiving rescue treatment, was 78 (range, 0–350) weeks. Incidence
of bleeding symptoms (WHO grades 1–4) decreased from BL (66%) to 1 yr
(15%). AEs were reported in 47 (94%) pts, most frequently nasopharyngitis
(n=13, 26%), constipation (n=12, 24%), fatigue (n=12, 24%), diarrhea, arthral-
gia, urinary tract infection, cataract and cough (all n=11, 22%). Serious AEs
occurred in 24 (48%) pts, most frequently (>5%) cataracts (n=7, 14%), pneu-
monia (n=3, 6%) and urinary tract infection (n=3, 6%). The most frequent AEs
with suspected relationship to study drug were cataracts (n=4, 8%), headache,
fatigue, and increased ALT, AST and bilirubin (all n=3, 6%).
Figure 1.
Summary/Conclusions: The efficacy of EPAG in cITP pts ≥65 yrs was con-
sistent with that seen with the overall EXTEND study population (Bussel et al.
Haematologica 2016;101[s1];S517), with sustained platelet increases and
reduced bleeding. EPAG was well tolerated; AE rates were similar to that report-
ed in the overall EXTEND study population, but an apparent increase in
cataracts was observed in pts ≥65 yrs old (cataract incidence was 7% and
22% in <65 and ≥65 age groups, respectively). Further outcomes in patients
<65 yrs old will be presented. Results should be interpreted with caution as
almost half of the pts withdrew from the study. EPAG is an effective treatment
option for certain cITP pts ≥65 yrs; its use should incorporate baseline cataract
screening and regular monitoring.
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Background: The current American Society of Hematology guideline recom-
mends the use of thrombopoietin receptor agonists, eltrombopag or romiplostim
as one of the second-line therapies for chronic immune thrombocytopenia
(ITP). The efficacy and safety of those drugs have been tested in several clinical
trials. However, the safety profile was not consistent throughout trials and is
not yet well understood. 
Aims: We herein conducted a meta-analysis of randomized control trials to
compare the safety and efficacy of thrombopoietin receptor agonists; eltrom-
bopag and romiplostim versus placebo in patients with previously treated chron-
ic ITP. Our primary outcome was drug-related adverse events greater than
CTCAE grade 3.
Methods: We performed a literature search in MEDLINE, EMBASE, Cochrane
library, and the American Society of Hematology website up to September,
2015 by two independent authors according to PRISMA guideline. We included
only randomized clinical trials comparing eltrombopag or romiplostim versus
placebo. Random-effects model was used to estimate pooled Odds Ratio (OR).
Results: A total of eight trials including 834 participants were included in the
analysis. There was no significant difference of grade 3 or higher adverse events
between placebo and treatment group (OR=1.01, CI 0.57-1.78). Thromboem-
bolism (OR=0.59 CI 0.20-1.73), elevated ALT (OR=0.68 CI 0.26-1.74), headache
(OR=1.26, CI 0.90-1.78), nausea (OR=0.82 CI 0.43-1.55), or fatigue (OR=1.13
CI 0.65-1.91) did not show a significant difference between groups, either. Clin-
ical response, which is defined as platelets ≥50,000/μL at least once on treat-
ment was significantly better in treatment group than in placebo group (OR=0.10
CI 0.07-0.15). Bleeding symptoms (WHO Grades 1-4) were significantly more
frequent in the placebo group (OR=1.6, CI 1.14-2.24) during treatment.
Summary/Conclusions: Although several studies have suggested clinically
significant treatment-related adverse events, such as thromboembolism, this
meta-analysis showed that thrombopoietin receptor agonists are safe, well-tol-
erated, and effective in patients with previously treated chronic ITP.
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Background: Little is known about the management of pediatric ITP in real
life, that is, routine clinical practice. Moreover, the predictive value of these
factors upon disease outcome was explored individually and therefore the con-
founding effect of associated exposures remains unknown.
Aims: With this nationwide prospective cohort study, our objectives were to
explore (1) the factors associated with treatment initiation (vs. watchful waiting)
in children with primary immune thrombocytopenia (ITP) followed in routine
clinical practice and (2) the predictors of chronicity at 12 months.
Methods: Between 2008 and 2013, 23 centers throughout France consecu-
tively included 257 children aged 6 months to 18 years and diagnosed with pri-
mary ITP over a 5-year period. Data on ITP clinical features along with medical
management were collected at baseline and 12 months. Multivariate logistic
regressions were used to determine (1) and (2) as defined above, providing
odds ratio (OR) with 95% confidence intervals (95%CI). 
Results: 137 (53%) children were males, median age was 4.6 years, median
platelet count was 7×109/L, and 214 (81%) patients initiated medication. Fac-
tors independently associated with treatment initiation included platelet counts
<10x109/L (p<0.0001) and mucocutaneous bleeding symptoms at baseline
(p<0.001). At 12 months, data were available in 211 (82%) children, of whom
160 (74%) had recovered. Predictors of chronicity included female gender
(OR=2.2; 95% CI=1.0–4.8), age ≥10 years (OR=2.6; 95% CI=1.1–6.0) and
platelet counts ≥10x109/L (OR=3.2; 95% CI=1.5–6.9). 
Summary/Conclusions: In routine clinical practice, the decision to apply a
watchful-waiting strategy seems to be driven by platelet counts even in the
absence of bleeding symptoms, resulting in treatment being initiated in more
than 80% of the children surveyed. Overall, younger children with ITP showed
good prognosis, with lower platelet counts and, to a lesser extent, male gender
predicting more favorable outcomes.
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Background: The treatment of chronic/relapsing immune thrombocytopenia
purpura (ITP) is not well established due to the lack of evidence-based data,
and is particularly challenging in children who are more at risk of severe side-
effects secondary to prolonged steroid therapies. Sirolimus has been shown
to be effective in patients with ITP secondary to ALPS1and in very few patients
with primary disease or secondary to ALPS-like syndromes2. 
Aims: The aim of this study is to evaluate the outcome and toxicity of patients
with ITP either primary or secondary to ALPS-like syndromes, with or without
involvement of other cell lineages. 
Methods: We retrospectively evaluated charts of patients followed in our Unit
for ITP primary or secondary to ALPS-like syndromes. Patients with ALPS were
excluded. ALPS-like was defined as the presence of at least one absolute or
primary additional criterion for ALPS. Complete response (CR) and partial
response (PR) were defined as a platelet count >/= 100x109/L and >30x109/L
and at least 2 fold increase of the baseline count, respectively.
Results: 23 children aged 0-12 yrs (median 6) with primary ITP (7) or second-
ary to an ALPS-like disorder (16), were treated with Sirolimus. Seven patients
(30%) with ALPS-like also had an Evans syndrome (ES), due to the association
of leukopenia (1), or to the presence of trilinear cytopenia (6). Four patients
with ALPS-like were found to have mutations on PI3KCD, CTLA4, TACI, and
CARD 11 gene. All patients, but one treated in first-line, received Sirolimus as
second (4), third (14) or fourth (4) line treatment, respectively. 18 patients had
previously failed Micofenolatemofetile (MMF) therapy. Overall, 17/23 (74%)
patients achieved a response that was complete and partial in 12 (52%) and 5
(22%) cases, respectively. Patients with ES responded in 6/7 (86%) cases.
Children with mono-linear ITP achieved a response in 11/16 (68%) cases, in
particular 4/7 (57%) and 7/9 (77%) patients with primitive or secondary disease,
respectively. 12 out of 18 (66%) patients who failed MMF therapy responded
to Sirolimus rescue. Three patients (13%) reported toxicity consisting of ovary
cysts (2) and gastrointestinal issues (1) that required the interruption of the
treatment in 2 cases.
Summary/Conclusions: To the best of our knowledge this is the largest cohort
of patients with ITP or ES -other than ALPS -treated with Sirolimus, that showed
to be safe and effective in most cases, including patients who previously failed
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MMF treatment. Therefore, it can be considered as an alternative therapeutic
option in the setting of ITP non only for patients with an underlying diagnosis
of ALPS but also for the ones with primitive disease or with an ALPS-like dis-
order.
References
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Background: A HAT pack was designed as an additional risk minimization tool
to support healthcare providers (HCPs) in selecting patients and training of
patients/caregivers to mitigate medication error risk when self-administering
romiplostim subcutaneously, a thrombopoietin-receptor agonist which is
approved in the European Union (EU) to treat chronic immune thrombocy-
topenic purpura (ITP) refractory to other treatments.
Aims: To estimate the proportion of adult patients and caregivers who admin-
istered romiplostim correctly after HAT pack training.
Methods: This non-interventional, cross-sectional study enrolled 40
patients/caregivers and was conducted at 12 centres in Austria, Belgium,
France, Germany, Greece, The Netherlands, Spain, and The United Kingdom,
from 7 July 2014 to 20 November 2015. HCPs directly observed adults (≥18
years of age) with chronic ITP or caregivers new to administering romiplostim
in the act of product administration at the first standard-of-care (SoC) 4-week
visit after HAT pack training. Correct administration of romiplostim (primary
endpoint) was defined as dose accuracy within 10% margin of error between
prescribed and administered romiplostim doses, and correct romiplostim recon-
stitution and successful injection, and no HCP intervention during administration
to correct patient/caregiver error. All analyses were descriptive and no formal
hypothesis was tested.
Results: At the first SoC visit, 4 weeks (range: 2-8 weeks) after HAT pack train-
ing, 35 patients/caregivers (87.5%) administered romiplostim correctly. The dose
accuracy was within 10% margin of error for all patients. HCP intervention was
required in 5 instances: 1 patient did not ensure all romiplostim was dissolved,
1 patient and 1 caregiver needed verbal encouragement, 1 patient needed nurs-
ing intervention to read the correct dose from the vial due to poor eyesight, and
1 caregiver needed guidance with syringe and vial connection. Further follow-
up data was available for only 2 of these 5 patients/caregivers; they both admin-
istered romiplostim correctly at a voluntary subsequent visit.
Summary/Conclusions: Given that this study was conducted on a conven-
ience instead of random sample of patients, generalizability of the results may
be limited. Direct observation can be susceptible to observation bias and to the
Hawthorne effect with the patients/caregivers acting differently when observed.
Nonetheless, the success of most patients and caregivers in correctly admin-
istering romiplostim after HAT pack training suggests that self-administration
of romiplostim is a feasible option for suitable romiplostim-treated ITP patients.
E1442
FCΓIIA 131 H/R (A>G) RECEPTOR GENE POLYMORPHISM IN PATIENTS
OF PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
A. Tripathi1,*, D. Yadav1, A. Kumar2
1Clinical Hematology, 2K.G. Medical University Lucknow India, Lucknow, India
Background: Primary Immune Thrombocytopenia (ITP) is an autoimmune
hematologic disorder characterized by isolated thrombocytopenia
(<100,000/cmm) in the absence of other causes or disorders that may be asso-
ciated with thrombocytopenia. The predominant mechanism is enhanced
peripheral destruction of autoantibody coated platelets through binding of Fc
portion of antibody with the Fcγ receptors on cells of reticuloendothelial system
mainly monocytes/macrophages.
Aims: This study was aimed to investigate the association of polymorphisms
in FcγIIA 131 H/R (A>G) gene with Primary Immune thrombocytopenia (ITP).
Methods: Genotyping for the FcγIIA 131 H/R (A>G) was performed using poly-
merase chain reaction and restriction fragment length polymorphism (PCR-
RFLP) in 70 ITP patients and 70 healthy controls.
Results: The mean age of patients and control was 29.53± 13.86 yrs and
27.90± 8.89 yrs respectively. Male/Female ratio in patients and control was
1:2. Under additive model, the heterozygous genotype (AG) of the FcγIIA 131
H/R (A>G) polymorphism shows the significant association with ITP, (Odds
Ratio 2.41 (95% CI, Lower - 1.19 Upper 4.90 P- value 0.0149) whereas the
homozygous mutant genotype (GG) had no significant association with ITP
(Odds Ratio 2.47 (95% CI, Lower - 0.63 Upper 9.72 with P- value 0.2979).
Under dominant model, the Odds Ratio was 2.42 (95% CI, Lower - 0.34 Upper
0.94) with the significant P- value 0.0167. Mutant allele (G) frequency was
37.85% in patients and 25.71% in controls (Odds ratio 1.76 1.05-2.93 with the
p-value 0.0397).
Summary/Conclusions: The study shows the association of heterozygous
genotype (AG) of FcγIIA 131 H/R (A>G) with ITP. The dominant model also
shows significant association with ITP. We conclude that mutant allele (G) in
FcγIIA 131 H/R (A>G) gene polymorphism may have impact on susceptibility
to ITP.
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Background: Immune thrombocytopenia (ITP) is an autoimmune disorder
mediated by clearance of antibody-opsonized platelets (plt) by spleen
macrophages. Pulsed high-dose dexamethasone (HD-DXM) has proved to be
effective in adult patients (pts) with primary ITP resulting in controlled studies
in 89% short-term response and a relapse-free survival (RFS) of 58% at 50
months (mos) (Mazzucconi, Blood 2007).
Aims: To assess the short-term and sustained response rates of adult ITP pts
receiving pulsed HD-DXM in everyday clinical practice.
Methods: Charts of pts with ITP - as defined by Rodeghiero, Blood 2009 -
treated with HD-DXM were reviewed. DXM was administered according to the
schedule of 40mg/day for 4 consecutive days to be repeated every 21 days for
a maximum of 6 courses. A reduced-dose schedule of 20mg/day for 4 days
was preferred for elderly/diabetic pts. Pts who had completed at least 3 courses
were included in the analysis. Response to HD-DXM was classified according
to IWP definitions (Provan, Blood 2010); therefore, steroid-dependent pts were
considered as non-responders even if plt counts increased to safe levels during
HD-DXM and were included only in the analysis of short-term response, but
not evaluated for long-term response. Short-term response rate was determined
at completion of the whole course of treatment. Relapse was defined as a plt
count decrease ≤20x10^9/L after initial response achievement and RFS was
defined as the time interval between last course administered and the date of
relapse, censoring pts alive or dead without relapse. Follow-up was defined as
the time between diagnosis and last available assessment. The probability of
RFS was calculated using the Kaplan-Meier method.
Figure 1.
Results: A total of 45 pts (M: 21) were eligible for analysis; median age at treat-
ment was 60 yrs (range 18-87) and median time between diagnosis and treat-
ment start was 3 days (range 0-4686). Pts received a median of 5,15 courses
(range 3-6); 27/45 completed 6 courses: 21/45 received the full dose of
40mg/day (=960mg total dose) while 6/45 received the reduced dose of
20mg/day (=480mg total dose). Median total DXM dose was 800mg; IVIG along
with 1st DXM course were required in 11/45 pts. In between courses, no bleed-
ing complications were observed and no emergency therapies were required.
Short-term response was achieved in 39/45 (87%): complete response (CR) in
28/45 (62%), response (R) in 7/45 (16%); 4/45 (9%) pts were classified as
steroid-dependent ITP and excluded from subsequent analysis. Long-term
response off therapy, lasting for a median time of 28 mos (range 5-80) without
relapses was observed in 25/35 responding pts (71.5%; CR in 18/25, R in 7/25
at last follow-up) with a RFS of 51% at 50 mos (Fig. 1). Median plt count at last
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follow-up was 192x10^9/L (range 54-336). Disease duration of less than 3 mos
prior to therapy start was associated with better outcome (log rank p=0.049,
Fig.2) with a median RFS not reached; median RFS for pts treated after 3 mos
of diagnosis was 31 mos [OR: 3.8 (CI 95% 0.9-16.3), p=0.067]. No significant
association between gender (p=0.67), age at treatment (more or less than 60
yrs) (p=0.85), DTX total dose (more or less than 480mg) (p=0.35) was found.
Summary/Conclusions: Pulsed HD-DXM is a well tolerated and highly effec-
tive first line treatment for ITP in every day clinical practice. The role of a
reduced-dose schedule needs to be explored in a larger cohort of pts. Treat-
ment of newly diagnosed ITP pts - i.e. within 3 mos of diagnosis (Rodeghiero
Blood 2007) - seems to lead to longer RFS.
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EFFECT OF OSELTAMIVIR TREATMENT ON PLATELET COUNTS
N. Revilla1,*, I. Heras2, M.E. de la Morena-Barrio3, P. Iniesta2, J.B. Nieto2,
J. Corral3, V. Vicente3, M.L. Lozano3
1Servicio de Hematología y Oncología Médica, 2Hospital Universitario Morales
Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-
Arrixaca, 3Hospital Universitario Morales Meseguer, Centro Regional de
Hemodonación, Universidad de Murcia, IMIB-Arrixaca. Grupo de Investigación
CB15/00055 del CIBERER, ISCIII, Murcia, Spain
Background: As platelets lose sialic acid during aging and circulation, they
are cleared by the hepatic Ashwell-Morell receptor (AMR) (1). A recent study
suggests that inhibition of sialidase by oseltamivir, a commonly administered
anti-influenza medication that inhibits viral sialidase, could associate with an
increase in platelet counts (2).
Aims: The aim of this study was to analyze the effect of oseltamivir treatment
in platelet counts. 
Methods: We performed a retrospective single-center study. From November
2009 until March 2015, a total of 168 patients from our Hematology Unit were
prescribed oseltamivir due to clinical suspicion of influenza. A total of 120 patients
were excluded because they had received myelotoxic chemotherapy within 30
days (n=82) or platelet count was not available before treatment (n=38). The
direct immunofluorescent antigen test was carried out with nasopharyngeal
aspirate specimens. Those specimens that were negative by the antigen detec-
tion assay underwent RT-PCR testing for influenza virus types A and B. Platelet
count was available before and after treatment (median of 5 days) in 48 patients
and in 44 patients also when the infection was cleared (median of 30 days).
Results: Patients were divided into those with proven influenza (n=34) and
without influenza (n=14). Median age was 58.0 and 59.5 years; respectively.
Treatment consisted of 75mg oseltamivir bid for 5 days, with the exception of 3
patients in the proven influenza group receiving 150mg bid for 10 days (allo-
geneic stem cell transplant recipients). We observed a significant increase in
the mean platelet count after treatment with oseltamivir (170±95 x109/L vs
190±103 x109/L, p=0.04). As in the previous study (2), this effect was independ-
ent of whether influenza was diagnosed (Table 1). In addition, we did not discern
significant fluctuation in platelet counts when treatment was immediately inter-
rupted or after a 30-day time lapse (184±100 x109/L vs 182±91 x109/L).
Table 1.
Summary/Conclusions: Our study confirms the effect of oseltamivir on
increasing platelet counts regardless of influenza infection. Although an
increase in platelet counts related to the viral syndrome healing is not ruled
out, the lack of long-term fluctuations after the end of treatment may indicate
a late inhibition that contributes to reduction in platelet clearance via the hepatic
receptor.
References
1. Grozovsky R et al. Nat Med. 2015;21(1):47-54.
2. Jansen AJ et al. Am J Hematol. 2015;90(5):E94-E95.
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CLINICAL UTILITY OF CARDIAC MRI IN IMMUNE MEDIATED THROMBOTIC
THROMBOCYTOPENIC PURPURA
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Background: Immune Mediated Thrombotic Thrombocytopenic Purpura (TTP)
is a life threatening thrombomicroangiopathy caused by acquired antibody
mediated inhibition of ADAMTS13. Cardiac complications are a common cause
of death and a raised troponin is a recognized risk factor for poor prognosis in
TTP. There is scant evidence on the best investigations for patients suspected
of being at risk of cardiac complications with no evidence on the clinical utility
of cardiac magnetic resonance imaging (MRI) in acute TTP episodes.
Aims: A retrospective review evaluating the value of cardiac MRI scanning in TTP.
Methods: 24 patients underwent cardiac MRI scanning between September
2008 and November 2014 whilst being treated for an acute episode of immune
mediated TTP. All patients had troponin-t measurement on admission and a
transthoracic echocardiogram within 72 hours of presentation. All patients were
treated for their TTP episode with plasmapheresis, steroids and Rituximab.
Two cardiologists reported each MRI scan and only agreed, unequivocal find-
ings were considered.
Results: The median age of patients was 49 (range 13-75), 71% of whom
were women. Two patients had a diagnosis of hypercholesterolemia prior to
TTP diagnosis but otherwise there was no previous cardiac history. 71% of
patients had a raised troponin-t at presentation (normal <14ng/ml). Two patients
developed bradycardia and one atrial fibrillation during their acute admission.
One patient had symptoms of heart failure. Three patients had transient ST
depression suggestive of ischemia on EKG monitoring and a further four had
non-specific T-wave inversion. There were no incidences of cardiogenic shock
or ST elevation myocardial infarction. 33% of patients (n=8) had abnormal car-
diac MRI results. Late gadolinium enhancement (LGE) in the mid-apical
regions, a finding suggestive of focal myocardial fibrosis and usually secondary
to myocardial necrosis, was seen in all 8 patients, subendocardial LGE in six,
transmural LGE in one and one patient had both subendocardial and transmural
LGE. The latter patient was the only one with any abnormality seen on the pre-
ceding transthoracic echocardiogram. LGE seen in combination with regional
wall motion abnormalities (RWMA) suggests irreversible myocardial dysfunc-
tion. No patient was found to have RWMA on transthoracic echocardiogram
but this was seen in five patients on cardiac MRI imaging, all of whom also had
LGE. The median troponin-t was not significantly higher in those with an abnor-
mal cardiac MRI (normal MRI 100ng/ml, abnormal MRI 165ng/ml, p=0.9), nor
was there a significant difference in median age (49 vs 49), symptom duration
(abnormal MRI 7 days, normal 5 days, p=0.39) or presenting anti-ADAMTS13
antibody level (abnormal MRI 41%, normal MRI 40%, p=0.66).
Summary/Conclusions: Cardiac MRI scanning in TTP is a sensitive tool for
detecting ischemic cardiac changes that would otherwise be missed by
transthoracic echocardiogram. Mid-Apical late gadolinium enhancement
appears to be a characteristic finding in TTP. These findings help increase the
understanding of the pathophysiology behind the TTP disease process
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THE FREQUENCY AND CLINICAL SIGNIFICANCE OF MEFV GENE
MUTATIONS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA 
I. Kaygusuz Atagunduz1,*, C. Keklikkiran2, T. Toptas1, O. Kara1, A. Sezgin1,
F. Gecgel1, T. Ozgumus1, T. Firatli Tuglular1
1Hematology, 2Internal Medicine, Marmara University Hospital, Istanbul, Turkey
Background: Immune thrombocytopenia (ITP) is an immune-mediated
acquired disease characterized by transient or persistent decrease of the
platelet counts. MEFV gene mutations are responsible for Familial Mediter-
ranean Fever (FMF) a hereditary autoinflammatory disease characterized by
recurrent febrile inflammatory attacks of serosal and synovial membranes.
MEFV gene’s protein product, pyrin or marenostrin, play an essential role in
the regulation of inflammatory reactions. MEFV gene mutations are associated
with a wide range of auto-inflammatory and autoimmune diseases. Recently,
studies showed that MEFV mutations change the Th1, Th2 balance and
increase the Th17 numbers. Th17 cells may have a key role in neutrophil acti-
vation and autoimmune diseases. ITP is an autoimmune-mediated condition
that results from antibody-mediated destruction of platelets and impaired
megakaryocyte platelet production. ITP is a complex disorder of immune dys-
regulation caused by anti-platelet antibodies produced by B cells. A recently
proposed model for ITP involves antigen-presenting cells, B cells and T cells.
Increased Th1/Th2 ratio and Th17 levels are implicated in the pathogenesis of
ITP, as well. 
Aims: This study addressed the prevalence of MEFV mutations and their effect
on clinical features of ITP. 
Methods: We studied the prevalence of exon 2 and 10 mutations (E148Q in
exon 2, M694V, M694I, M680I, V726A, A744S and R761H in exon 10) in 81
adult ITP patients and 186 healthy controls. Patients were classified in two
subgroups according to the presence of mutations. Demographic and clinical
features were compared between groups to assess possible impacts of these
mutations on clinical severity. 
Results: Female to male ratio was 61/20=3,05 in the study group and
98/88=1,1 in the control group. The median age was 50 (21-79) in the ITP
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group and 56 (24-76) in the control group. Overall MEFV mutation prevalence
was%25.9 (21/81) in the study group and%24.7(46/186)in the control group,
(p=0.963). MEFV mutation distribution prevalence was similar in both gender
groups among ITP patients and their presence did not alter the age of disease
onset, (p>0,05). Similarly, presence of mutations did not change the platelet
count at diagnosis, the number of treatment courses, the rate of patients under-
going splenectomy and primary steroid resistance. Although statistically not
significant, there was a trend towards a better overall response to steroids in
patients carrying MEFV mutations,%94.7 vs%82.8,(p=0,28) respectively. The
median time to loss of response to steroids was 60 (10-124) months in patients
with mutations and 42 (19.2-64.8) months in patients without MEFV mutations,
(p=0.64). The median time to splenectomy was 101 (42.5- 159.5) months in
the MEFV mutation carriers and 51 (46-56) months in the non-carriers, (p=0.48).
Time to loss of response to splenectomy was 38 (12-90.9) months in mutation
carriers and 54 (14.9-93.1) months in non-carriers,(p=0.42).
Summary/Conclusions: To the best of our knowledge, our study is the first to
address a possible effect of MEFV mutations on ITP. MEFV mutation carrier
rates were similar in both ITP and control groups. Although MEFV carrier state
had no affect on clinical features of ITP, mutation carriers tended to have a
better overall response to steroid treatment, stayed longer in remission, had a
longer time to splenectomy and relapsed earlier after splenectomy. 
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PD-1 AND CTLA-4 POLYMORPHISMS AFFECT THE SUSCEPTIBILITY AND
CLINICAL FEATURES OF CHRONIC IMMUNE THROMBOCYTOPENIA
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N. Gotoh1, M. Takizawa3, A. Yokohama4, H. Handa3, T. Saitoh1, H. Murakami1
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Background: The programmed death-1 (PD-1) and cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4) play a central role in immune checkpoint path-
ways. The PD-1 negatively regulates self-reactive T and B cells in peripheral
immune tolerance. The CTLA-4 antagonizes the binding of CD28 to its ligands
including CD80 and CD86, and inhibits T cell activation. Previous studies have
shown the lower expression of serum soluble PD-1 and CTLA-4 mRNA in
patients with chronic immune thrombocytopenia (cITP) than healthy individuals.
Single nucleotide polymorphisms (SNPs) of PD-1 and CTLA-4 have been
reported to be associated with susceptibility of some autoimmune diseases;
however, the possible association between these immune checkpoint SNPs
and cITP risk remain controversial and obscure.
Aims: In order to explore the role of PD-1 and CTLA-4 in the pathogenesis of
cITP, we investigated the impact of PD-1 and CTLA-4 SNPs on the susceptibility
and clinical features of adult cITP.
Methods: We extracted the genomic DNA from 141 cITP patients and 223
healthy controls, and determined, 3 PD-1 SNPs (-606G/A, +7209C/T, A215V)
and 4 CTLA-4 SNPs (-1722T/C, -1577G/A, +49A/G, +6230G/A) by using the
polymerase chain reaction -restriction fragment length polymorphism (PCR-
RFLP) method. The severity of bleeding tendency and thrombocytopenia was
assessed according to the previously described criteria by Han JJ. The
response criteria, ‘corticosteroid dependence’,‘severe cITP’, and ‘refractory
cITP’ were assessed according to the criteria of the ITP International Working
Group. The characteristics and laboratory data of cITP patients with CTLA-4
and PD-1 polymorphisms were compared by using the Mann-Whitney U test
for continuous variables and the chi-square test for categorical variables. This
study was approved by the Institutional Review Board of Gunma University
Hospital (Approval #160007).
Results: The minimum platelet count of all clinical course ranged from 0 to
98×109/L with a median count of 13×109/L. Eighty-six patients (61.0%) had
bleeding tendency and 24 patients (17.0%) had severe thrombocytopenia (<
10×109/L). Eighty-six patients (61.0%) received the treatment with corticos-
teroid, and 38 patients (27.0%) were corticosteroid-dependent. As compared
to healthy controls, the higher frequency of PD-1 +7209 TT genotype (low pro-
ducer) was observed in cITP patients (12.8% vs 4.5%, p=0.004). There were
no significant differences in CTLA-4 SNPs between cITP patients and healthy
controls. In cITP patients, PD-1 +7209 TT genotypes (low producer) was sig-
nificantly associated with high frequency of treated patients, treated patients
with coticosteroid, and steroid-dependent patients compared with CC & CT
genotype (high producer) (94.4% vs 71.5%, 94.4% vs 57.7% and 52.9% vs
23.6%; p=0.043, 0.003 and 0.018, respectively). On the other hand, CTLA-4
+49 AA genotype (high producer) was significantly associated with low bleeding
tendency than AG & GG genotype (low producer) (36.4% vs 65.5%, p=0.010).
CTLA-4 +6230 AA genotypes (high producer) was significantly associated with
low bleeding tendency than AG & GG genotype (low producer) (27.3% vs
63.8%, p=0.017). CTLA-4 -1577 AA genotypes (high producer) was significantly
associated with low frequency of bleeding tendency and steroid treatment than
AG & GG genotype (low producer) (20.0% vs 64.1% and 30.0% vs 64.9%;
p=0.014 and 0.041, respectively). CTLA-4 -1577 AA genotypes was significantly
associated with higher minimum platelet count than AG & GG genotype (22.5
vs 14.0 ×109/L, p=0.048).
Summary/Conclusions: Our findings indicate that PD-1 gene polymorphisms
contribute to the susceptibility of cITP, and PD-1 low producer genotype affects
the severity of cITP. In addition, CTLA-4 high producer genotypes suggest the
good clinical features and a little requirement of treatment in patients with cITP.
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IS THE SPLENECTOMY OUTCOME PREDICTABLE IN PATIENTS WITH ITP?
M. Mitrovic1,2,*, S. Matic2,3, J. Bodrozic1, M. Smiljanic1, J. Jelicic1, D. Antic1,2,
M. Todorovic - Tirnanic2,4, D. Tomin1,2, I. Elezovic1,2, N. Suvajdzic1,2
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Background: Splenectomy may lead to a good response in 60-80% of adults
with corticosteroid refractory immune thrombocytopenia (ITP). However, in the
era of new drugs the proper selection of patients for splenectomy is essential
to optimizing treatment outcomes. Accordingly, it is important to identify pre- or
post-operative parameters that are able to predict the response to splenectomy. 
Aims: To identify the pre- and postoperative parameters predictive of successful
splenectomy in ITP.
Methods: We retrospectively analyzed 130 ITP patients (median age 43 years,
range 19-74; 84/39 female/male; median time from diagnosis to splenectomy
19 months, range 2-132; median number of pre-splenectomy therapies 2, range
1-5; median follow-up from splenectomy 112 months, range 2-364) who under-
went splenectomy between the years 1986 and 2015.Platelet kinetic study with
Indium-111 was performed in 50 patients before splenectomy. Indications for
splenectomy were: unresponsiveness to initial corticosteroid therapy, need for
continuous glucocorticoid therapy to maintain safeplatelet counts and multiple
relapses after discontinuing corticosteroids.Complete response (CR) and partial
response (PR) were defined as platelet count (PC) >100×109/L and 30×109/L
one month after surgery, respectively. The patient was considered refractory if
his PC remained <30×109/L after splenectomy. Relapse was defined as a loss
of CR or PR. 
Results: CR and PR were achieved in 105/130 (79%) and 12/130 (7.5%) of
the splenectomised patients, respectively. However, 13/130 (112.5%) patients
were refractory. Twenty-nine of the 117 (24.8%) responsive patients relapsed.
Predictors of good response after splenectomy identified by univariate analysis
were: initial response to steroids (69.5% vs 22.7%, τ=0.358, p<0.0001), higher
PC on the surgery day (90×109/L vs.37×109/L, ρ=0.353, p<0.0001), on the first
(387×259/L vs 56×109/L, ρ=0.502, p<0.0001) and on the 7thdays after splenec-
tomy (387×259/L vs.25×109/L, ρ=0.522, p<0.0001) and splenic platelet destruc-
tion (86% vs 0%, τ=0.358, p=0.0001). Using ROC analysis, cut-off prognostic
values of PC were reevaluated: PC before splenectomy >47x109/L (AUC 0.864,
sensitivity 63.6%, specificity 83.2%, 95% CI 0.785-0.943, p<0.0001), PC on
the first day after splenectomy >50x109/L (AUC 0.956, sensitivity 44.4%, speci-
ficity 83.2%, 95% CI 0.912-0.999, p<0.0001 ) and PCon the 7thday after
splenectomy >300x109/L (AUC 0.951, sensitivity 91.7%, specificity 45.6%, 95%
CI 0.873-1.000, p<0.0001 ). By multivariate analysis, splenic platelet destruc-
tion, PC >47x109/L on the day of surgery (p=0.043) and PC >300x109/L on the
7thday after splenectomy (p=0.0013) were identified as predictive for favorable
response. Patients who relapsed frequently were older >60 years (31% vs
23%,p=0.030) and had lower PC three months after splenectomy (130x109/L
vs 278x109/L, ρ=0.203, p<0.0001). However, ROC values could not be calcu-
lated. 
Summary/Conclusions: Splenectomy is effective in approximately two thirds
of patients with ITP. Our study suggests that splenectomy might be considered
in the patients younger than 60 years, with splenic platelet destruction and PC
>50x109/L on the splenectomy day. 
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FINAL RESULTS FROM AN OBSERVATIONAL STUDY (PLATEAU) OF
ADULT PATIENTS TREATED WITH ROMIPLOSTIM FOR PRIMARY IMMUNE
THROMBOCYTOPENIA (ITP) IN ROUTINE CLINICAL PRACTICE IN GER-
MANY
M. Reiser1,*, M. Welslau2, K. Josten3, H. Dietzfelbinger4, A. Kuhn5
1PIOH Koeln, Koeln, 2Gemeinschaftspraxis Dr. Klausmann, Dr. Welslau,
Aschaffenburg, 3Hämatologie und Onkologie, Helios Kliniken Praxis, Wies-
baden, 4Haematologisch-onkologische Schwerpunktpraxis, Herrsching,
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Background: In the European Union, the thrombopoietin-receptor agonist romi-
plostim (Nplate®) is recommended since January 2016 for treatment of ITP in
adult patients who are refractory to other treatments (e.g. corticoids,
immunoglobulins).
Aims: The aim of this study was to assess the use of romiplostim in clinical
practice in Germany. 
Methods: This multicentre, prospective and retrospective observational study
(data collected before and after initiation of romiplostim) enrolled ITP patients
≥18 years who received at least one dose of romiplostim in routine clinical prac-
tice, with an observation period of 2 years following romiplostim initiation. End-
points included patient demographics, romiplostim use, platelet counts, adverse
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drug reactions (ADRs), and other clinically relevant parameters. We report
results from a full data set analysis. 
Results: A total of 59 patients were enrolled (49.4% male; 54% aged 65 years
or above) from 38 sites; 22 of them were excluded due to protocol violations
(e.g. incomplete documentation, inclusion criteria not met). Of the 137 remain-
ing patients (the full analysis set, FAS), 102 completed the 2-year observation
period. Reasons for dropping out included loss to follow-up (10 patients), deaths
(6 patients) and ADRs (3 patients). Median (Q1, Q3) time from ITP diagnosis
to romiplostim initiation was 21.7 months (4-85) months in the FAS. 123 FAS
patients received prior ITP therapies; most of them received corticosteroids
(104 [75.9%]). 117 patients (85.4%) were non-splenectomized before romi-
plostim therapy, for reasons such as refusal of splenectomy, comorbidities, or
age. Over the observation period, romiplostim was injected at a median (Q1,
Q3) dose of 3.11 mcg/kg/bw (1.8 – 4.8; FAS) over a median (Q1-Q3) treatment
period of 103 weeks (33-104). The median platelet count rose sharply from
baseline (29.0 x 109/L) to two weeks of treatment (62.5 x 109/L). From week 3
to two years of follow-up, the median count remained in a range between 87.5
x 109/L and 145.5 x 109/L. Since the start of romiplostim therapy, 59 patients
out of 137 (43.1%) received concomitant therapies, mostly corticosteroids (49
patients [35.8%]). The overall number of ADRs was 112 in the FAS, affecting
37 patients (27.0%). The most frequent ADRs were gastrointestinal (10.2%)
and neurological (11.7%) ADRs, followed by constitutional symptoms (10.9%).
Adverse drug reactions pertaining to blood/bone marrow affected 2.9% of
patients (vascular/thrombotic events, bone marrow fibrosis), whereas bleeding
as an ADR was seen in 0.7% of patients. The exposure-adjusted rate of bleed-
ing events (grade 3 or 4) per 100 patient-years in the FAS was 7.2 before treat-
ment initiation vs. 4.0 after starting the treatment. The rate of ITP-related hos-
pitalization per 100 patient-years decreased from 23.3 before the start of ther-
apy to 15.5 since the start of therapy.
Summary/Conclusions: This study of routine clinical practice in Germany
showed that treatment with romiplostim in ITP patients resulted in a rapid
increase in platelet counts to levels maintained between 50 and 250 x 109/L
over time, regardless of the splenectomy status of the patients; most of them
were non-splenectomized. The product was well tolerated and achieved a
decrease in the rate of ITP-related hospitalization. 
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MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
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Background: It is well recognized that neurological manifestations are com-
mon in thrombotic Thrombocytopenic Purpura (TTP) however research into
the neuropsychological impact of the disease is lacking despite evidence sug-
gesting patients who experience critical illnesses are at high risk for long-term
cognitive impairment.
Aims: To review the clinical utility of neuropsychology testing in thrombocytic
thrombocytopenic purpura.
Methods: Between 2010 and 2015, all patients within a single tertiary hematol-
ogy center with a confirmed diagnosis of TTP were reviewed as outpatients
after their acute episode. Those with persisting, non-physical neurological or
psychological symptoms underwent cerebral MRI scanning and were referred
for neuropsychological assessment. The Wechsler Adult Intelligence Scale III
(WAIS-III) IQ test was used to assess factors including verbal IQ and perform-
ance IQs.
Results: 18 patients were included. 89% were female with a median age of 51
(16-67 years). 56% were Caucasian, 33% Afro-Caribbean and 11% of South
Asian ethnic origin. 33% had experienced TIA or stroke-like symptoms during
their acute TTP episode whilst 28% had no neurological symptoms during their
initial presentation. The most common symptom leading to neuropsychology
review was problems with concentration, experienced by 89% of patients. 44%
had problems with memory, 39% felt depressed and 33% had anxiety issues.
The median time from acute TTP episode to neuropsychology review was 29
months (range: 3-99 months). 25% had normal cerebral MRI scans, 50% had
signs of sub-acute infarction on imaging and two patients scans showed both
mature infarcts and microhaemorrhages. The median scores for both verbal
and performance IQs were reduced compared to average (normal 100, range
90-110). The median verbal IQ was 87 (range: 65-122) and the median per-
formance IQ 83 (range: 56-109). Taking all aspects of the WAIS-III review into
consideration, one patient had a normal assessment. 50% (n=9) were found
to have mild cognitive impairment, 33% (n=6) mild-moderate impairment and
11% (n=2) significant impairment. The two cases with significant impairment
had a widespread pattern of dysfunction whilst in the other cases the most
common pattern was of anterior/sub-cortical involvement (44%).
Summary/Conclusions: Persisting psychological symptoms after an acute
TTP episode are highly suggestive of underlying cognitive impairment as a
result of cerebral sub-acute infarction or microhaemorrhages.
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FIVE NEW CASES OF HERMANSKY-PUDLAK SYNDROME: IDENTIFICA-
TION OF NOVEL GENETIC VARIANTS IN HPS4 AND HPS3 ASSOCIATED
TO RELEVANT CLINICAL COMPLICATIONS
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Background: Hermansky-Pudlak syndrome (HPS) is an inherited platelet dis-
order characterized by bleeding diathesis, oculocutaneous albinism and some-
times serious clinical complications. Heterogeneous clinical symptoms and a
large numbers of possible genetic culprits (9 HPS genes, >118 exons) compli-
cate unequivocal HPS diagnosis. 
Aims: To assess the clinical and platelet phenotype in five patients with HPS sus-
picion and to identify their genetic defect by high-throughput sequencing (HTS).
Methods: We studied 5 patients from 3 families (2 Spanish, 1 Turkish) pre-
senting with oculocutaneous albinism. Clinical records were reviewed and
bleeding scored with ISTH-BAT. Platelet phenotyping (only Spanish patients)
included: platelet aggregation, GPs expression and granule secretion, 14C-
serotonin uptake and whole mount electron microscopy. Patients DNAs were
analyzed by HTS using a 71 gene panel. 
Results: Clinical and laboratory findings in these patients are shown in Table
1. The Spanish patients (P1,P2,P5) showed impaired platelet aggregation to
mild agonists and reduced platelet dense granules. In family 1 (F1), HTS iden-
tified a homozygous, potentially harmful, c.2054delC (p.Pro685Leu fs*17) vari-
ant in HPS4. One sister (P1) had Crohn´s disease and severe gastrointestinal
(GI) bleeding. This variant had been reported in a 46yr Asian patient with pul-
monary fibrosis (Bachli EB. Am J Med Genet 2004). A novel missense homozy-
gous HPS4 variant, c.272T>C (p.Leu91Pro), was found in two Turkish siblings
(F2). One had severe GI bleeding requiring colectomy (P4) and the other devel-
oped pulmonary fibrosis. Patient 5, suffering from mild GI bleeding, bears a
heterozygous novel variant in HPS3 (c.2464C>T, p.Arg822X) and, most likely,
an additional unrevealed mutation. 
Table 1.
Summary/Conclusions: HTS facilitates genetic confirmation of HPS diagno-
sis, and may help investigating phenotype-genotype relationships in HPS. The
novel p.Leu91Pro variant in HPS4 associates with severe clinical phenotype.
Funding: JMB: Gerencia Regional de Salud [GRS 1370/A/16]; JR: ISCIII &
Feder (PI14/01956), CIberer CB15/00055, Sociedad Española de Trombosis
y Hemostasia.
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CHARACTERIZATION OF PLATELET ACTIVATION MARKERS IN EARLY
ONSET PREECLAMPSIA
D. Angelov1,2,*, K. Egan1,2, F. Ní Ainle1,2,3,4,5
1UCD Conway SPHERE Research Group, 2School of Medicine, University
College Dublin, 3Department of Haematology, Rotunda Hospital, 4Department
of Haematology, Mater Misericordiae University Hospital, 5School of Biomole-
cular and Biomedical Sciences, University College Dublin, Dublin, Ireland
Background: Preeclampsia is a serious pregnancy complication with poten-
tially life-threatening consequences for both mother and baby, diagnosed when
new onset hypertension and proteinuria develops after 20 weeks gestation.
Early onset preeclampsia (EOP; onset <34 gestational weeks), is associated
with higher maternal and fetal risks than late onset preeclampsia. At the
extreme end of the severity spectrum, HELLP syndrome is characterised by
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hemolysis, elevated liver enzymes, and low platelets. Previous studies have
demonstrated enhanced platelet activation in pregnant women with pre-eclamp-
sia, using cell surface markers and platelet microparticles1. Although severe
pre-eclampsia is associated with increased inflammatory markers in vitro, levels
of platelet activation do not necessarily correlate with severity of disease2.
Aims: To assess the presence, and degree, of platelet activation in a cohort of
patients with early onset preeclampsia (EOP)±HELLP syndrome, and to corre-
late this with evidence of in vivo coagulation activation using D-dimers.
Methods: Plasma samples from patients with EOP were accessed from a clin-
ical biobank. Platelet activation markers were characterized using ELISA assays
measuring platelet factor 4 (PF4), soluble glycoprotein VI (sGPVI) and neu-
trophil activating peptide-2 (NAP-2). Platelet microparticles (CD42a+ micropar-
ticles) were measured by flow cytometry. Platelet activation biomarker levels
were adjusted by platelet count and expressed as /108 platelets/ml). All data
was analysed using GraphPad Prism 7. Parameters were reported as
mean±SEM.
Results: Plasma samples from 19 individual patients were included. Patients
with HELLP syndrome demonstrated significantly greater numbers of CD42a+
microparticles when corrected for platelet count compared with those without
HELLP syndrome (598x103±203x103 versus 297x103±37x103, CD42a +
microparticles/108 platelets/ml p=0.04). Similarly, patients with HELLP syn-
drome demonstrated increased levels of sGPVI than those without HELLP, cor-
rected for platelet count (2.576±0.9667 versus 1.22±0.124 ng/ 108platelets/ml,
p=0.0334). There was no difference in NAP-2 or PF4 levels between those
with HELLP and those without HELLP, nor between severe and moderate pre-
eclampsia patients. Severe pre-eclampsia patients in this cohort had a D-dimer
level of 3.71±0.7742 µg/ml compared with non-severe patients 1.852±0.3501
µg/ml, p=0.0537. There was a significant correlation between sGPVI levels and
D-dimer levels (Spearmann Rank correlation coefficient, r =0.532, p=0.04).
Summary/Conclusions: The results of this study demonstrate a positive cor-
relation between severity of pre-eclampsia and platelet activation, as measured
by levels of platelet-derived microparticles and platelet GPVI expression. A
number of randomised controlled trials have evaluated the role of low-dose
aspirin therapy as prevention for pre-eclampsia, and there is Grade 2B evidence
for its use in those at risk of severe pre-eclampsia3. The evidence of enhanced
platelet activation in our study provides rationale for the efficacy of aspirin in
this setting, and the potential for novel antiplatelet agents to be studied for the
same indication.
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PRIMARY ITP IN ADULTS TREATED WITH ELTROMBOPAG: A
RETROSPECTIVE STUDY USING DATA FROM THE UNITED KINGDOM
ADULT IMMUNE THROMBOCYTOPENIA REGISTRY.
D. Provan1,*, U. Doobaree1, A. Newland1, J. Fleming2
1Haematology, Barts and The London School of Medicine and Dentistry, Lon-
don, 2Haematology, Novartis, Camberley, Surrey, United Kingdom
Background: Primary ITP is an autoimmune disorder associated with a
reduced peripheral blood platelet count. Although many patients are relatively
asymptomatic, many suffer with bruising, mucosal bleeding and quality of life
issues. The first line treatment has remained unchanged for decades and until
recently, second-line therapy has been unsatisfactory, using empirical treat-
ments. The recently approved thrombopoietin receptor agonists eltrombopag
and romiplostim have transformed patient care and these agents are licensed
second-line therapies in adults.
Aims: To describe the adult patients receiving eltrombopag using data from
the UK Adult ITP Registry. In particular we were interested in understanding
the mean dose used, number of prior therapies, median length of treatment
with eltrombopag, median counts at baseline before treatment and at six months
following treatment, and sustained response in patients who have received
eltrombopag.
Methods: The UK Adult ITP Registry involved more than 70 UK collaborating
centres, coordinated by The Royal London Hospital. In this study we analysed
data from all patients receiving eltrombopag and analysed these using various
statistical techniques.
Results: The total number of patients evaluable was 129. The median age at
diagnosis was 49.4 years (26.9-66.4). There were 74 males (57.4%) and 55
females (42.6%). 29 patients (22.4%) had undergone prior splenectomy. The
median age at eltrombopag initiation was 59.5 years (37.0-70.7 years). The
median time from ITP diagnosis to eltrombopag initiation was 1.6 years (0.7-
2.3 years). The majority of patients started eltrombopag between 2013 and
2016 (93%). 10 (8%) and 8 (6%) started eltrombopag within the first 6 months
and between 6 to 12 months of ITP diagnosis, respectively. Most patients had
received prior ITP therapies. Some 10 patients (7.8%) had received one prior
ITP therapy and 99 patients (77%) had received three or more prior therapies
before starting eltrombopag. The commonest prior therapies were corticos-
teroids in 110 patients (87%); IVIg 91 patients (72%); rituximab 68 patients
(54%); romiplostim 47 patients (37%); and immunosuppressants 71 patients
(56%). At baseline, prior to starting eltrombopag, the median platelet count was
21×109/L (10-54) and the majority of patients (64.5%) had platelets less than
30×109/L. The mean platelet count at 6 months was 206.2×109/L and at 1 year
was 288×109/L. The median dose of eltrombopag used was 50mg/day. The
median course length on eltrombopag was 14.7 (IQR: 4, 67) weeks. After initi-
ation, 53 (41%) remained on eltrombopag as a monotherapy whereas 27 (21%)
had other ITP treatment concurrently with eltrombopag. Forty nine (38%)
changed treatment after eltrombopag, of which prednisolone (47%), IVIg (33%),
mycophenolate (18%) and rituximab (14%) were the commonest and 10%
underwent a splenectomy. Response to eltrombopag was assessed for 106
patients with adequate follow up time and platelet counts. 81 (76%) had a
response, of which 54( 51%) were above 100x109/L and 27 (25%) had a partial
response (platelet counts between 30 to 100x109/L). Among those that had a
response, 15 (14%) became unresponsive after some time whereas 2 (2%)
patients were unresponsive soon after a brief episode of response. In short, 64
(60%) had a sustained response to eltrombopag (among patients who remained
or came off eltrombopag).
Summary/Conclusions: The patient characteristics of those receiving eltrom-
bopag appear to be typical of adult ITP. Only 10 patients (7.8%) received eltrom-
bopag as a second line therapy. Three quarters had received 3 or more prior
therapies before starting eltrombopag despite its licence as a second line ther-
apy. As clinicians become more familiar with its use, a greater proportion of
patients are likely to receive eltrombopag as a second line therapy.
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EFFICACY OF TPO-MIMETICS IN PATIENTS WITH IMMUNE THROMBO-
CYTOPENIA 
F. Bacchiarri1,*, V. Carrai1, C. Biagiotti1, A. Bosi1
1Hematology, AOU Careggi, Firenze, Italy
Background: Immune thrombocytopenic purpura (ITP) is an autoimmune dis-
order in which antibodies are produced to circulating platelets. The two currently
available agents (Romiplostim and Eltrombopag) have similar efficacies and
only slightly different safety profiles, being effective in restoring a safe platelet
count in 70%-80% of cases with chronic ITP failing one or more lines of treat-
ment, including splenectomy.
Aims: We evaluated the efficacy of TPO-RAs in patients with ITP.
Methods: From November 2008 and February 2017 65 patients (33 M; 32 F)
were treated with a median follow-up of 29 months (1-96): 39 underwent therapy
with Romiplostim and 26 to Eltrombopag. Median age was 69 years (range 39-
94 years). In the group of patients treated with Romiplostim, 21 had already
received more than 4 lines of therapy, while 18 received 1-2 lines of therapy.
13/26 patients who received Eltrombopag were at the 3nd line of therapy, 1 at
the second, and the others were at least at the 4th line. The median platelet
count was 21x109/L (3-52) at the start of Romiplostim, with a median starting
dose of 1 µg (1-2) and 17x109/L (1-53) in patients treated with Eltrombopag,
with a median starting dose of 50mg (25-50). 
Results: Patients treated with Romiplostim we observed 22 complete respons-
es and 10 responses, with a 82% response rate, while 7 patients were no
responders. In our study 26 (66%) patients stopped Romiplostim after a median
time of 16 months (1-93): 9 for stable response, 5 for no response, 3 for loss
of response; 3 for adverse events (2 for bone marrow fibrosis, 1 for headache
associated to visual disturbances and gastrointestinal disorders), 2 underwent
splenectomy, and 3 patients interrupted the treatment for other causes (es.
diagnosis of cancer). The median platelet count at suspension of Romiplostim
was 91.5 x109/L (3-320). In patients treated with Eltrombopag 16 achieved a
complete response, 5 a response, obtaining response in the 80% of cases; 5
were no responders. 14 (53%) patients stopped Eltrombopag after a median
time of 1,5 months (1-12): 6 for adverse events (2 cases of major cardiovascular
events, liver toxicity, skin rash, pharyngitis), 5 for no response, 1 for loss of
response, 2 patients who achieved a CR interrupted Eltrombopag obtaining a
sustained remission after discontinuation. The median platelet count at sus-
pension was 97x109/L (2-739). Patients who did not interrupted treatment are
still receiving therapy with a median of 29 months (3-96). Several studies report-
ed Romiplostim and Eltrombopag to be highly effective against chronic ITP,
with average immediate responses exceeding 80% in our study. We observed
that therapeutic response was influenced by the starting platelet count. In par-
ticular platelets count before therapy influenced the first response observed. In
particular in patients treated with Romiplostim PLT pre-treatment directly cor-
related with the first response and the mantainance of response during treat-
ment at month 1°, 2° 3° and 6. Patients with a median starting platelet count of
15×109/L obtained a response (CR + R), while almost all patients who started
therapy with PLT<15×109/L at baseline can obtain an initial response, but the
majority is non-responder.
Summary/Conclusions: TPO-mimetics have proved efficacy in patient with
ITP and their use can be applied in several conditions (bridge to splenectomy;
sustained response; switch and discontinuation). Future study on large series
of patients are needed to best correlate baseline platelets with hematological
response. The two currently available agents (Romiplostim and Eltrombopag)
have similar efficacies and only slightly different safety profiles, being effective
in restoring a safe platelet count in 70%-80% of cases with chronic ITP failing
one or more lines of treatment, including splenectomy.
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PREVALENCE AND RISK FACTORS FOR THROMBOSIS IN ADULT ITP
PATIENTS
C. Moret1, A. Tichelli2, A. Wieland-Greguare-Sander3, A. Angelillo-Scherrer3,
A. Rovó3,*
1Faculty of Medicine, University of Bern, Bern, 2University Hospital of Basel,
Basel, 3University Hospital of Bern, Bern, Switzerland
Background: Immune thrombocytopenia (ITP) is characterized by severe
thrombocytopenia due to autoantibody- and cell-mediated peripheral platelet
destruction and attenuated thrombopoiesis. Despite a higher risk for bleeding,
thromboembolic events (TEE) have been observed.
Aims: We aimed to investigate the prevalence and type of TEE and the poten-
tial risk factors in adult ITP patients.
Methods: Retrospective cohort study, including all ITP patients followed in our
clinic between 01/1990 and 05/2016. Information on gender, age, date of ITP
diagnosis, platelets count, type and clinical form of ITP, type of ITP treatments
and its response, severe bleeding and follow up time were collected. Further-
more we evaluated date of first appearance, number and type of thromboem-
bolic events, cardiovascular risk factors, date and cause of death. We assessed
and compared risk factors of ITP patients with and without TEE in univariate
and multivariate analysis.
Results: Medical files of 480 patients registered as ITP were reviewed; 42
patients were excluded from the analysis (not fulfilling the ITP criteria according
to Rodeghiero et al. Blood 2009). In total 438 patients were retained for analy-
sis, 10% out of them (44 patients) presented ≥1 TEE after ITP diagnosis. Within
these patients, in total 54 TEE occurred: 34 venous (61%), 19 arterial (34%)
and 3 arterial and venous (5%) thrombotic events. The most frequent venous
TEE were pulmonary embolism, deep vein thrombosis, and superficial vein
thrombosis; arterial TEE were cerebrovascular insults, myocardial infarction
and peripheral artery thrombosis. At time of TEE, 43% of patients were on
treatment with corticosteroids, 14% with thrombopoietin receptor agonists
(TPO-ra) and 18% were off-treatment. In the univariate analysis, older age at
diagnosis (≥50 years, P=0.015), longer interval since ITP diagnosis (P=0.001),
persistent or chronic ITP (versus acute, P=0.009), ≥2 treatment lines
(P=0.0002), TPO-ra at time of thrombosis (P=0.027), non-response to first-line
treatment (P=0.010), smoking (P=0.011), arterial hypertension (P=0.005), and
obesity (P=0.041) revealed to be significant. The multivariate analysis model
showed that older age at diagnosis (RR, 2.272; 95% CI, 1.167-4.426; P=0.016),
≥2 treatments (RR, 2.539; 95%CI, 1.305-4.941; P=0.006), persistent or chronic
ITP (RR, 3.830; 95% CI, 1.111-13.196; P=0.033), and smoking (RR, 2.622;
95% CI, 1.250-5.499; P=0.011 were independent risk factors for TEE. When
the variable “number of treatments” (<2 versus ≥2) was excluded from the mul-
tivariate model, having a splenectomy increased the risk for TEE. The cumu-
lative incidence of TEE at year 1, 5, 10, 15 and 20 years since diagnosis of ITP
was 6.2% (95% CI, 4.1-9.3), 11.9% (95% CI, 8.3-17.0), 15.8% (95% CI, 11.1-
22.4), 24.2% (95% CI, 16.9-34.7) and 32.8% (95% CI, 22.8-47.3) respectively
(Figure). Death occurred in 7/44 (16%) patients with TEE, and in 12/394 (3%)
patients without TEE (P=<0001). Most frequent causes of death were infection
(32%) and bleeding (21%).
Figure 1.
Summary/Conclusions: Adult ITP patients are at risk for thromboembolic
events. Patients older than 50 years, having a persistent/chronic form of the
disease, requiring two or more lines to treat the ITP, previous splenectomy,
and smokers were more likely to develop TEE. The knowledge about the risk
of thromboembolic events in adults ITP patients could have an impact on man-
agement attitude for patients at risk.
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OSELTAMIVIR FOR THE TREATMENT OF ITP PATIENTS NOT RESPONDING
TO CONVENTIONAL TREATMENT: BIOLOGICAL CHARACTERIZATION
AND CLINICAL RESPONSES
N. Revilla1,*, R.M. Campos2, F. Velasco3, A. Miñano4, I. Fuentes5, J. Rivera6,
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5Hospital Infanta Cristina, Badajoz, 6Hospital Universitario Morales Meseguer,
Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca.
Grupo de Investigación CB15/00055 del CIBERER, ISCIII, Murcia, Spain
Background: Oseltamivir phosphate, a drug that conventionally serves as an
antiviral sialidase inhibitor classically prescribed for the treatment of patients
with influenza, has shown to induce an increase in platelet counts in 2 patients
with primary immune thrombocytopenia (ITP) (1,2). A previous study has sug-
gested a mechanism of Fcγ receptors (FcγR)-independent platelet clearance
in ITP patients with anti-Glycoprotein (GP) Ibα autoantibodies (3). However,
little is known about the exact response mechanism of this drug in ITP.
Aims: To analyze the biological features and clinical responses following
oseltamivir treatment in patients that are non-responders to conventional treat-
ments.
Table 1.
Methods: We performed a prospective study in 4 ITP patients who exhibited
no response to standard therapies (steroid, IVIG and/or splenectomy) and
showing relevant platelet desialylation levels. Patients were given off-label
oseltamivir at the referring physician´s discretion. Desialylation of GP platelet
surface was examined via flow cytometry (FC) analysis, with fluorescein-con-
jugated Ricinus Communis Agglutinin I (RCA-1), which binds galactose
residues only if the terminal sialic acid has been removed. FC data are
expressed as fold change compared to control samples. Additionally, patients’
sera were incubated with normal human platelets to analyze the ability to induce
desialylation of normal platelets. Analysis of plasma proteins was performed
by Western blot (FXI, FXII) and HPLC (transferrin). Platelet autoantibody speci-
ficity was detected by a solid-phase modified antigen capture ELISA test
(MACE). 
Results: Patients’ characteristics are summarized in Table 1. Two patients
achieved complete platelet response (>100x109/L) after oseltamivir treatment.
The oral dose was 75mg twice daily, for a variable duration (5 days in one case
and 4 months in the other showing response criteria since the third week of
from start) combined with low doses of other treatments (azathioprine or romi-
plostim). A sustained platelet response was observed after 4 weeks of the sial-
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idase inhibitor discontinuation. Patients with no response after oseltamivir treat-
ment (n=2) were given similar doses for 5 days. Patients with response had
antibodies directed solely to GPIb and had greater platelet loss of sialic acids.
Moreover, their sera induced significant desialylation of normal platelets. How-
ever, no desialylation in patients’ plasma proteins was detected. Biological
analysis after treatment discontinuation (median of 3 weeks), revealed a sus-
tained sialylation level of platelet glycoproteins over time, particularly in patients
with sustained platelet response.
Summary/Conclusions: Chronic ITP patient with anti-GPIbα autoantibodies
who do not respond to conventional therapies and exhibit significant platelet
desialylation may achieve a complete response to treatment with oseltamivir.
References
1. 1. Alioglu B et al. Pathophysiol Haemost Thromb. 2010; 37:55-58.
2. Shao Let al. Platelets. 2015; 26:495-497.
3. Li J et al. Nat Commun. 2015;6:7737.
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BORTEZOMIB THERAPY IS ASSOCIATED WITH SIGNIFICANT
RESOURCE IMPLICATIONS FOR BOTH PATIENTS AND PROVIDERS:
RESULTS OF A TIME-IN-MOTION STUDY
M. Tatarczuch1, K. Ramasamy1, A. Peniket1,*, M. Sultanova1, G. Vallance1,
F. Panitsas1
1Haematology, Oxford University Hospitals NHS Trust, Oxford, United King-
dom
Background: Bortezomib is a proteasome-inhibitor, which has improved out-
comes in multiple myeloma (MM). Its use is approved within the UK NHS. Borte-
zomib is frequently administered as a subcutaneous injection in a hospital day
treatment unit. Whilst the administration of a subcutaneous injection is brief,
the process for the patient travelling to hospital, assessment and waiting for
the delivery of the injection can take considerable time. From a patient per-
spective, significant amount of time spent without economic activity and travel
costs add up during the course of therapy. From the health-care provider the
process of safely administering bortezomib has significant resource implications
beyond those of drug procurement.
Aims: We set up a time-in-motion study to evaluate the costs to health care
provider and patients during bortezomib therapy to estimate the ‘real-world’
cost of delivering bortezomib therapy.
Methods: Retrospective data collection was undertaken, using electronic pre-
scribing records for patients treated between July 2014 -August 2016. Travel
distance and time was estimated using Google maps and costed using HMRC
mileage (an approved costing of mileage used for taxation purposes). The NHS
schedule of service costs was used to estimate the cost of bortezomib admin-
istration. Cost of delivery of Bortezomib for healthcare providers is a sum of
these individual costs.
Results: We identified 127 patients who incurred a total of 2 134 visits whilst
receiving Bortezomib therapy at the Churchill Hosptial in Oxford during this 2
year period. Median age was 70 years-old (yo) (39-95); Male 74 patients (58%)
53 patients (42%). We restricted the analysis to 110 patients who started and
completed therapy during the study period. Median number of patient visits
was 16 (range 11-52). The median travel distance (return journey) for each
patient was 33 miles (53 km) (range: 1.2-224 mi; 1.9-360 km). Median travel
time was 90 min (range: 8-300 min). The range travel cost per patient was
£8.35-£13.20. Twenty-seven patients (21%) required use of specialist hospital
transport services, which resulted in 295 transport-episodes (14%) in total. In
order to assess the time spent in the day therapy unit, a subgroup of 589 patient-
episodes were analysed to assess time from arrival to administration of Borte-
zomib: the median time from patient registration to bortezomib administration
was 63min (range: 5-433min). Pharmacy cost for preparation of Bortezomib
was £50 per dose. The cost of delivery of bortezomib (not including cost of
drug) was £1,160 per cycle, which equated to a total median cost of £4,640 per
patient (range: £290-£15,080). Drug procurement costs for Bortezomib is esti-
mated at an additional £12,261 per course of therapy (BNF 2016). Delivery
costs therefore added an additional 38% to the procurement costs.
Summary/Conclusions: We provide the first time-in-motion data on myeloma
patients treated with Bortezomib. The ‘real-world cost’ of delivering therapy is
37% higher than the drug-costs alone. In addition the impact on patients is
substantial: over a two year period 127 patients required 2 134 visits with a
median time in the day unit of 63 minutes and a median travel time of 90 minutes
per visit. Our data highlights the burden of both time and economic costs to
patients during therapy. Novel oral proteasome inhibitors offer the potential to
reduce this resource impact in the future. This data could be used by health
care providers and reimbursing agents for economic modeling of the potential
benefits of oral proteasome inhibitors.
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HOSPITAL CARE AT HOME ADMINISTRATION OF SUBCUTANEOUS
AZACITIDINE IS FEASIBLE AND PREFERRED BY PATIENTS COMPARED
TO HOSPITAL ADMINISTRATION: A FRENCH REGIONAL HEMATOLOGY
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Background: In France, azacitidine (AZA) is indicated for the treatment of
adult patients affected by Myelodysplastic Syndrome with intermediate-2 or
high risk according to the International Prognostic Scoring System (IPSS),
Chronic Myelomonocytic Leukemia (CMML) with 10-29% medullary blasts and
Acute Myeloblastic Leukemia (AML) with 20-30% blasts. It’s also a drug treat-
ment of adult AML patients over 65 years with>30% of medullary blasts. Azac-
itidine is a hypomethylating agent administered by subcutaneous route. Though
effective, treatment cycles require frequent hospital visits which could decrease
patient comfort and increase medical personnel workload. Limousin is a region
with the oldest population of France and with a very low population density.
There is one university hospital and two local state-run hospitals each with a
hematology department. In 2009, HEMATOLIM, the Limousin hematology net-
work, set up a protocol called ESCADHEM (externalization and securitization
of injectable chemotherapy at home for malignant hematological diseases) that
facilitates chemotherapy administration via local Hospital at Home (HaH) estab-
lishments, which is an alternative to conventional hospitalization in France
(www.fnehad.fr). The aim was to minimize the frequent hospital visits that these
treatments require. This organization includes the three previously mentioned
hospitals, four HaH structures, and three central pharmacies with an integrated
preparation unit for cancer treatments. From 2009 to 2015, a total of 11 367
infusions were administred at home for 464 pts. In 2016, we demonstrated the
feasibility of ESCADHEM and the medico-economic interest of such care with
Bortezomib, another injectable chemotherapy at home (Touati et al. Support
Care Cancer. 2016 Dec; 24(12):5007-5014). In 2014, we have conducted a
satisfaction survey with a cohort of 84 pts who received treatment in HaH struc-
tures via ESCADHEM (20% pts with AML/MDS were treated by AZA). The
overall satisfaction rate was 95%.
Aims: Our work aimed to demonstrate that HaH administration of AZA is fea-
sible and well preferred by patients compared to hospital administration. 
Methods: Chemotherapy at home obeys to strict rules. The first chemotherapy
cycle (C1) and the first injection (D1) of subsequent cycles were administered
at the outpatient care unit. The following injections were administered at the
patient’s home and carried out by HaH, according to a predefined procedures
(Fig 1) to comply with safety rules essential to the protection of the professional,
the patient, the entourage and the environment. Subcutaneous AZA injections
were administered at a dose of 75mg/m2 for 7 days of each 28-day cycle.
Between 2009 and 2015, 169 patients were treated with AZA by a combination
care in outpatient unit and HaH and were included in the study. In February
2017, we set up a satisfaction survey with an anonymized questionnaire for all
patients alive at the date of dispatch. The aim is to assess several criteria such
as the degree of satisfaction, quality of care, well-being, personal anxiety,
advantages and disadvantages. Each item will be analyzed using a Likert scale
to realize a satisfaction survey. 
Results: From 2009 to 2015, a total of 6369 subcutaneous injections of AZA
were administered at home for 169 pts with AML/MDS received AZA therapy.
Among all pts, 110 were males and 59 females with a median age of 75 years
(range 41-92) there are 88 (52%) MDS patients and 81 pts (48%) with AML.
Patients received a median number of 5 cycles (1-41) and 26 injections of AZA
(1-244) at home. The total duration of HaH management lasted from less than 1
day to more than 3.4 years with a mean of 6.3 months. During the period of HaH
administration of AZA, 101 out of 169 pts (60%) had to return to conventional
hospital for a non programmed rehospitalization: 90% of the time the patient
needed a transfusion, 4% because of infection and 6% for other reasons.
Figure 1.
Summary/Conclusions: This important number of subcutaneous injections
(n=6369) in a large cohort (n=169) over a period of time of 6 years activity show
that home administration of subcutaneous AZA is feasible without serious
adverse event. The first satisfaction survey demonstrates a high rate of satis-
faction by all patients (20% with AML/MDS) treated by injectable chemotherapy
at home. The results of the satisfaction survey, focused on pts treated with sub-
cutaneous AZA, is in process and results will be presented at the EHA meeting.
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USE OF COMBINED ORAL FENTANYL CITRATE (ACTIQ®) AND MIDAZOLAM
AS PREMEDICATION FOR BONE MARROW BIOPSY IN PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED
PATIENT BLINDED CLINICAL TRIAL
C. Cerchione1,*, M. PIcardi1, N. Pugliese1, R. Della Pepa1, A. Gravetti1,
A. Casoria1, L. Catalano1, D. Nappi1, G. Ciancia2, G. Pettinato2, F. Pane1,
V. Martinelli1
1Hematology, Ematologia e trapianto/au federico ii, 2Anatomia Patologica, AOU
Federico II, Napoli, Italy
Background: Bone marrow aspiration and biopsy (BMAB) is a painful proce-
dure, and the commonly adopted local infiltration anesthesia (LIA) with lidocaine
is unable to relieve the pain during the most uncomfortable phases, or the
anticipatory anxiety related to pain recalling thereafter. As there are no formal
guidelines for adding a sedoanalgesic premedication before beginning the
BMAB, many combinations have been adopted by several authors. 
Aims: Our randomized and patient blinded trial aimed to evaluate, as primary
end point, the efficacy and safety of opioid and benzodiazepine agent combi-
nation plus LIA in patients who underwent BMAB for hematological malignan-
cies. Two secondary end points were: 1) define if patients who already under-
went to BMAB without LIA prefer sedoanalgesia; 2) sedoanalgesia can influ-
ence the quality of the biological specimen harvested.
Methods: Patients were randomly assigned into two arms for receiving either
sedoanalgesic placebo plus LIA (standard group, 48,6%) or oral fentanyl citrate
200 mcg plus oral midazolam 5mg in addition to LIA (combo-group, 51,4%) dur-
ing BMAB. Pre-procedural anxiety and procedural pain were assessed accord-
ing to the Numered Rating Scale (NRS: 0-10), dividing the time of the procedure
into five intervals (T0, T1, T2a, T2b, and T3) and evaluating discomfort grade
during each moment of procedure in both groups. Cognitive function was meas-
ured before and 30 minutes after the procedure. Possible side effects were
recorded, as well as the adequacy of tissue samples harvested. A telephone
interview was performed 24 hours later. A total number of one-hundred-sixteen
(n=116, Table 1) were enrolled in the study. Nine (n=9) patients did not meet
inclusion criteria and were excluded. Fifty-two (n=52) patients were randomized
and assigned to standard group and fifty-five (n=55) to combo group.
Results: At T2b and T3 (corresponding to the biopsy time and time after the
biopsy, respectively) there was a significantly lower (p< 0.05) perception of
pain in the patients who received sedo-analgesia (combo-group) compared to
those who did not (standard group). Moreover, 100% of the patients in combo
group who had previously undergone this procedure without premedication,
reported that they would prefer sedoanalgesia for the subsequent procedures,
thus showing the effectiveness of this combination also in relieving anticipatory
anxiety. Finally, the histological specimen was found to be high in quality, as
defined by standards.
Table 1.
Summary/Conclusions: Administration of oral analgesia and anxiolysis is a
safe and feasible option to be used in outpatient setting; sedo-analgesia is very
effective in reducing pain during the biopsy and diminishes the anticipatory anx-
iety related to a painful procedure. Patients should have the possibility to choose
between local anesthesia alone or sedo-analgesia plus local anesthesia.
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ASSESSMENT OF THE ECONOMIC IMPACT OF HORSE-ATG IN SWEDEN
FOR APLASTIC ANAEMIA
R. Desmond1, R. Peffault de Latour2, A. Risitano3, K. Sutton4, E. Remak5,
M. Barra5, V. Katkade6,*, C. Charbonneau7
1Hematology, Tallaght Hospital, Dublin, Ireland, 2Hematology, Saint Louis Hos-
pital, Paris, France, 3Hematology, Department of Clinical Medicine and Surgery,
Federico II University of Naples, Naples, Italy, 4Modeling & Simulation, Evidera,
London, United Kingdom, 5Modeling & Simulation, Evidera, Budapest, Hungary,
6Pfizer, Philidelphia, United States, 7Pfizer, Paris, France
Background: Aplastic anaemia (AA) is a rare, potentially fatal haematopoietic
stem-cell disorder that can either be inherited or acquired. AA is graded accord-
ing to disease severity, from non-severe to very severe and is linked to immune-
related responses such as the destruction of the bone marrow. Cases of severe
and very severe AA are considered to be a haematological emergency requiring
urgent treatment. Extended hospitalisations and the cost of treatments and
disease management are associated with the economic impact of AA.
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Aims: To assess cost-effectiveness of ATGAM (horse antithymocyte globulin)
in comparison to rabbit antithymocyte globulin (r-ATG) in the treatment of mod-
erate to severe aplastic anaemia (sAA) patients in Sweden.
Methods: A semi-Markov state-transition cohort model was developed to esti-
mate longer-term (up to five years) clinical and economic outcomes for patients
with AA receiving either ATGAM or r-ATG as first-line IST treatment. The fol-
lowing key assumptions were included in the model: responders who relapse
are assumed to be re-treated with no expected change in survival. Patients
that do not respond to first-line treatment move onto a second-line treatment
comprised of either IST, IST + eltrombopag or hematopoietic stem cell trans-
plantation (HSCT). Although response rates are lower, those who respond to
second-line treatment are assumed to have the same outcomes as those who
respond to first-line. Patients who continue to not respond receive standard
supportive care with a significant decrease in expected survival. Efficacy data
for ATGAM and r-ATG were obtained from published literature. Adverse events
were not included due to lack of evidence of any difference between the two
comparators. Medication, administration, and disease management costs were
obtained from published literature, publicly available sources and clinical expert
opinion. As resource utilization for disease management changes over time
and differs considerably between responders and non-responders, three distinct
phases have been included in the model: short-term (first 6 months post-IST
administration), medium-term (6-12 months) and long-term (greater 1 year),
for patients in either of the response categories.
Results: Response to treatment was calculated to be seen in 67% of ATGAM
patients’ vs 35% in r-ATG (accounting for mortality). Over 5 years, the model
estimated that patients gained 4.15 life-years (3.28 quality-adjusted) on ATGAM
vs 3.52 (2.56) on r-ATG. Short-term disease management costs were estimated
to be SEK 880,144 (€96,816) in responders vs SEK 1,264,016 (€139,041) in
non-responders. Medium and long-term costs also followed the same pattern.
Overall costs (drug plus disease management), were significantly lower for
patients receiving ATGAM vs r-ATG; making ATGAM cost-saving by being both
more effective and less costly than r-ATG. When considering treatment costs
only (including cyclosporine and HSCT), the model estimated a cost of SEK
107,097/life-year gained (approx. €11,781) and SEK 135,655/quality-adjusted
life-year (approx. €14,922), showing ATGAM is highly cost-effective. The analy-
sis showed that when treatment and disease management costs are consid-
ered, ATGAM dominates r-ATG as the gain in QALYs and LYs are achieved at
a lower cost. Therefore making ATGAM cost-saving with greater health benefits
in comparison to r-ATG.
Summary/Conclusions: Due to improved treatment response, survival, and
quality of life outcomes, the model shows that ATGAM is at least more cost-
effective, if not cost-saving, in comparison to r-ATG for the treatment of patients
with aplastic anaemia.
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NEUROPSYCHOLOGICAL ANALYSIS OF LONG-TERM CONSEQUENCES
OF ANTINEOPLASTIC TREATMENT
A. Nesterova 1, S. Khrushchev2,*, D. Vybornykh2, A. Tkhostov3
1Open Institute - Higher Professional School, 2National Research Institute for
Hematology, 3Lomonosov Moscow State University, Moscow, Russian Federation
Background: Study of long-term consequences of conducted antineoplastic
treatment is becoming on the front burner because of significant increase in
survival rates of Acute Lymphoblastic Leukemia (ALL) and Hodgkin’s Lym-
phoma (HL) patients. Modern therapeutic protocols (cranial irradiation and
chemotherapy) can negatively affect patients’ cognitive functions and conse-
quently decrease patients quality of life. It is therefore necessary to carry out
qualitive and quantative analysis of neuropsychological impairments in patients
conducted antineoplastic treatment.
Aims: The aim of the research to study neuropsychological status (memory and
executive funcions) of adult patients after antineoplastic therapy in childhood.
Methods: Patients in a present clinical remission (5-14 years remission dura-
tion). N=60 (ALL), N=50 (HL). Mean age-14 (ALL), (HL) – 19 years. N=60 con-
trol group. Qualitative, quantitative neuropsychological scales developed in
Luria’s approach methodology (tests for dynamic praxis and memory domains)
and one-way ANOVA on ranks were used.
Results: The main neuropsychological impairments were found in auditory-
verbal memory and auditory-motor coordination (memory narrowing, violations
in selectivity, inertia in mental process, perseverations, contaminations, diffi-
culties in praxis automatisation). 20% of patients didn’t recall all words (audi-
tory-verbal memory tests ) after four representations (3,3% in control group,
p<0,005). 19% of patients failed or had severe difficulties in dymanic praxis
tests (2% in control group, p<0,005). The results point at possible deficits in
temporal and frontal parts of the brain (predominantly posterior frontal and
mediobasal systems).
Summary/Conclusions: Neuropsychological impairments in audioverbal, audi-
tory motor and dynamic praxis spheres, qualitive and quantative analysis
showed deficits in temporal and posterior frontal areas of the left hemisphere,
that can be as a result of antineoplastic therapy in childhood. Such findings
can improve understanding the nature of patients impairments and difficulties
they experience. Rehabilitation programs should take into account patients
neuropsychological changes and cognitive decline. Indeed psychological inter-
ventions are necessary in long-term period after clinical remission.
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A CLINICAL AUDIT OF NUTRITIONAL SCREENING AND SUPPORT OF
HOSPITALIZED PATIENTS WITH HEMATOLOGIC DISEASES
A. Stamou1, A. Liaskas1, I.-G. Tzanninis1, E. Kanioura1, D. Politis1, L. Poulia2,
N.-A. Viniou1, K. Konstantopoulos3, P. Diamantopoulos1,*
11st Department of Internal Medicine, Hematology Unit, Laikon General Hos-
pital, National and Kapodistrian University of Athens, 2Clinical Nutrition Depart-
ment, Laikon General Hospital, 3Hematology Department, Laikon General Hos-
pital, National and Kapodistrian University of Athens, Athens, Greece
Background: Poor food intake is a common problem in patients with hemato-
logic diseases. Recurrent infections and chemotherapy complications are some
of the possible causes. Malnutrition is correlated to slow recovery, prolonged
hospitalization, and higher mortality. Audits about the nutritional support of hos-
pitalized patients may detect significant failures in patient care and help towards
the correct application of the international guidelines.
Aims: We performed a prospective observational audit on hospitalized patients
with hematologic diseases to investigate their nutritional status and whether
they received the appropriate nutritional support.
Methods: The initial population consisted of 122 consecutive patients with
hematologic diseases admitted from March 31, 2016 to June 8, 2016 in two
Hematologic Units of a Tertiary University Hospital in Athens, Greece. We
designed a special questionnaire based on the Malnutrition Universal Screening
Tool (MUST) with additional questions on demographic, somatometric and med-
ical data (Table 1). The questionnaire was applied by 6th-year medical students
to all patients within 48 hours of admission. Patients were classified as high,
intermediate, and low-risk per the MUST score and were reassessed at prede-
fined intervals. During reassessment, we examined the food intake and the
nutritional interventions (nutritional supplements, enteral or parenteral nutrition)
applied.
Results: Ninety-three patients were included in the final analysis (5 refused to
participate, 22 were excluded due to short-term hospitalization, 2 were absent
during reassessment). Forty-one (38%) patients had a MUST score ≥2 (high
risk) but none of them received nutritional supplements. One patient was sup-
ported with parenteral nutrition (Table 1).
Table 1.
Summary/Conclusions: Our audit revealed a lack of nutritional support of the
hospitalized patients. A meeting with the involved health professionals was
organized and an oral presentation of the results and the possible causes (lack
of sensitization of the staff, high regimen cost, shortness of staff) was performed.
Proposals to change the current situation were made such as detection of high
risk patients by medical students and further assessment by a nutritional spe-
cialist. A brief MUST-based questionnaire was also proposed to be used for all
patients upon admission. A re-audit was programmed and is already in
progress.
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ASSESSING REAL-WORLD TREATMENT PATTERNS, OUTCOMES AND
RESOURCE USE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE
MYELOMA (MM) POST AUTOLOGOUS STEM CELL TRANSPLANT
ACROSS EUROPE
J. Ashcroft1, G. Taylor-Stokes2, S. Dhanasiri3, D. Judge2,*
1Mid-Yorkshire Hospitals NHS, Wakefield, 2Adelphi Real World, Bollington,
United Kingdom, 3Celgene International, Boudry, Switzerland
Background: Autologous stem cell transplant (ASCT) is the standard of care
for first line (1L) treatment (tx) for patients (pts) with MM deemed of suitable fit-
ness to safely undergo the procedure. More recently introduced tx options have
significantly increased the life expectancy of pts with MM and continue to pro-
vide further promise for the future in this devastating disease. The increasing
therapeutic armoury across the MM pathway allows for varied tx patterns pro-
viding both potential differences in outcomes and healthcare resource use
(HCRU).
Aims: The aim of the analysis was to determine current management of pts in
the post ASCT setting, assess outcomes of pts and HCRU. 
Methods: A retrospective chart review was conducted in France, Germany,
Italy, Spain and the UK. Data collection took place in Q1 2017. Physicians pro-
vided data on consecutive pts with MM who had undergone an ASCT as part
of 1L tx on or after 1st January 2014, to specifically examine the HCRU post
1L SCT. Data collected pertained to pt characteristics, tx patterns, duration of
tx and outcomes (including time to progression (TTP) and best response
achieved (IMWG updated criteria), HCRU in terms of hospitalizations, additional
supportive drugs prescribed and healthcare professional (HCP) visits. Pt
records included in this interim analysis were completed by Feb 17th 2017,
with data collection continuing in all countries.
Results: 214 record forms have been reviewed to date. Pts’ mean age at diag-
nosis was 59 (±7.8 SD) years; 43% female and 57% male. Mean duration from
diagnosis, to receiving an ASCT was 9.6 months (±13.3 SD). Of the pts included
in the study, 62%, 28% and 8% had received 1st, 2nd and 3rd line tx respectively.
In the 1L setting, 72% of pts did not receive any drug therapy post ASCT, 21%
received consolidation and 8% maintenance therapy. Of the pts who did not
receive maintenance therapy, 42% and 34% went onto receive 2L and 3L drug
therapy respectively; whereas, only 24% of pts who received maintenance
therapy went onto 2L, and none onto 3L. The most frequently prescribed reg-
imens at 1L maintenance were Lenalidomide (82%), Bortezomib (12%) and
Thalidomide (1%). The mean TTP from start of 1L tx was 22.2 months (±11.1
SD) for pts not receiving maintenance and 33.0 months (±8.1 SD) for pts receiv-
ing maintenance. Overall 43% of pts achieved a sCR and CR, 51% achieved
a VGPR and PR. During the period from 1L post ASCT to start of 2L, 54% of
pts required supportive tx (bisphosphonate (55%), blood transfusions (24%),
G-CSF (21%), ESAs (11%), radiotherapy (4%) and dialysis (3%)). 64% of pts
were hospitalized at least once during this period, with a mean duration of 7.2
days (±18.1 SD). The mean number of visits to Hematologists was 7.1 times
in 24.8 months (between start of 1L to start of 2L tx); mean visits to a HCP dur-
ing this period were 17. The mean TTP from start of 2L tx was 11.2 months
(±6.8 SD). 20% of pts achieved a sCR and CR, 52% achieved a VGPR and
PR.
Summary/Conclusions: The sample is reflective of the pt demographics data
reported in Raab et al. 2016. Furthermore, the TTP for pts not receiving any
active ongoing tx post ASCT in this real-world study is comparable to findings
in other studies. Limited or no data exists on HCRU post ASCT. This study
demonstrates that there is ongoing HCRU impact even if pts are not receiving
any active ongoing tx post first ASCT. Prolonging the remission period post
ASCT may therefore spread the marginal cost of HCRU whilst simultaneously
enhancing a pt’s quality of life by deferring future tx lines.
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NUMBER-NEEDED-TO-TREAT (NNT) AND COST OF RESPONSES
ACHIEVED IN TYROSINE KINASE INHIBITOR (TKI) TREATMENT OF
REFRACTORY CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-
CML) IN THE UNITED STATES (US)
M.Y. Levy1,*, L. McGarry2, S. Iannazzo3, H. Huang2, S. Chiroli4
1Baylor University Medical Center, Dallas, TX, 2ARIAD Pharmaceuticals, Inc.,
Cambridge, MA, United States, 3SIHS Health Economics Consulting, Torino,
Italy, 4INCYTE, Epalinges, Switzerland
Background: The emergence of targeted therapies with high efficacy in small
patient populations such as TKI-refractory CP-CML has challenged decision-
makers.
Aims: To demonstrate a simple and intuitive approach to assessing the value
of available TKIs (nilotinib, dasatinib, ponatinib and bosutinib) in this setting.
Methods: Using synthesized efficacy data from a published meta-analysis
(Lipton 2014), we calculated NNT to achieve one additional response, defined
as complete cytogenetic response (CCyR), for CP-CML patients treated with
a TKI after failing ≥2 prior TKIs. NNT represents the expected number of treated
patients required to achieve one additional response—i.e., the multiple of treat-
ed patients to responders. We assumed response is not evaluated prior to 3
months, per National Comprehensive Cancer Network (NCCN) guidelines.
Therefore, the cost of achieving an additional response was estimated as the
product of NNT and 3-month cost, based on US Wholesale Acquisition Costs
(WAC) and recommended dosing for each TKI from US prescribing information
(USPI).
Results: To achieve one expected response, the NNT is 1.7 (95%CrI: 1.5-1.9)
patients for ponatinib, 3.8 (3.1-4.8) for nilotinib, 4.2 (2.2-11.1) for dasatinib, and
4.5 (3.4-6.7) for bosutinib (based on CCyR of 60%, 26%, 24% and 22%, respec-
tively). With a 3-month WAC for ponatinib of $49,683, nilotinib: $33,892, dasa-
tinib: $33,897 and bosutinib: $36,045, the estimated 3-month cost per response
achieved is $82,800 ($73,100-$95,500) for ponatinib, $130,000 ($106,000-
$161,000) for nilotinib, $141,000 ($75,300-$377,000) for dasatinib, and
$164,000 ($124,000-$240,000) for bosutinib.
Summary/Conclusions: Using published, synthesized efficacy estimates, the
NNT to achieve response with ponatinib in TKI-refractory CP-CML is less than
with nilotinib, dasatinib or bosutinib. Despite a higher WAC, ponatinib has the
lowest estimated 3-month cost per response achieved. Therapy choice should,
however, consider both treatment cost and the benefit-risk profile of the indi-
vidual patient.
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THE COST-EFFECTIVENESS OF PEGASPARGASE FOR FIRST-LINE
TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A COST-UTILITY
ANALYSIS
S. Basu1, P.L. Lin2, C. Rowntree3,*, V. Saha4
1Shire, London, United Kingdom, 2Shire, Cambridge, United States, 3University
Hospital of Wales, Cardiff, 4University of Manchester, Manchester, United King-
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Background: Asparaginase is a key component in the multi-agent chemother-
apeutic regimen for the treatment of children, adolescents, and adults with
acute lymphoblastic leukaemia (ALL). Compared to native asparaginase (native
ASP), pegaspargase (PEG-ASP) has a longer half-life, can be given less fre-
quently, and is less immunogenic, which leads to fewer hypersensitivity reac-
tions. In the UK, patients with newly diagnosed ALL are treated with PEG-ASP
followed by Erwinia-derived asparaginase (ERW-ASP) in cases of hypersen-
sitivity, based on the UKALL protocols. Although native ASP is no longer used
as the first choice of asparaginase therapy, it was the standard of care before
PEG-ASP was available. A cost-utility analysis (CUA) was conducted to eval-
uate overall cost-effectiveness of PEG-ASP in comparison to native ASP when
utilized as part of antineoplastic combination therapy for treating newly diag-
nosed ALL in children, young people, and adults.
Aims: To evaluate the cost-effectiveness of a treatment strategy including
PEG-ASP in a multi-agent in patients with newly diagnosed ALL compared to
regimens that include native ASP.
Table 1.
Methods: In line with accepted National Institute for Clinical Excellence (NICE)
methodology, a combined decision tree and health state transition Markov mod-
el was developed to compare treatment sequences starting with PEG-ASP
versus native ASP, followed by ERW-ASP in case of hypersensitivity. Although
ERW-ASP is not used first-line in the United Kingdom, alternative switching
scenarios could be clinically possible, and therefore all scenarios were mod-
elled. Paediatric, young adult (≤25 years), and adult (26-65 years) patients
were modelled separately using the UKALL 2003 and UKALL14 protocols,
respectively. Further splits were made between high-, intermediate-, and stan-
dard-risk patients in the paediatric model, between patients aged ≤40 vs ≥41
years, and patients eligible versus not eligible for transplant in the adult model.
Key model parameters (survival, risk of hypersensitivity) were based on pub-
lished data and clinical expert input. In the base-case analysis, overall survival
and event-free survival were assumed to be equivalent for PEG-ASP, native
ASP, and ERW-ASP, with 1,000IU/m2 dosing (per UKALL protocols) used for
PEG-ASP. In the scenario analyses, the 2,500 IU/m2 dosing (per SmPC) of
PEG-ASP was examined, as well as variations in comparative survival and
hypersensitivity rates. Incremental cost-effectiveness ratios (ICER; defined as
incremental costs/quality-adjusted life years [QALYs] gained) were produced. 
598 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Results: The base-case scenario demonstrated that PEG-ASP followed by
ERW-ASP dominated (i.e., was both less costly and more effective than) native
ASP followed by ERW-ASP in adults, children, and the whole (combined) pop-
ulation (Table). Scenario analyses highlighted the robustness of the cost-effec-
tiveness results. Differences in total QALYs between PEG-ASP and native ASP
were driven primarily by the difference in hypersensitivity rates.
Summary/Conclusions: This analysis demonstrates that PEG-ASP, as part
of multi-drug chemotherapy, is a cost-effective treatment option compared to
native ASP for treating ALL in children, young people and adults with newly
diagnosed ALL.
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IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF PATIENTS WITH
RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS
OF A PHASE 2, OPEN-LABEL STUDY OF VENETOCLAX (ABT-199/
GDC-0199) MONOTHERAPY 
W. Wierda1,*, K. Sail2, L. Noe2, R. Kamalakar2, J. Gdovin2, M. Verdugo2,
S. Kim2, R. Humerickhouse2, S. Stilgenbauer3
1The University of Texas MD Anderson Cancer Center, Houston, 2AbbVie Inc,
North Chicago, United States, 3Department of Internal Medicine III, Ulm Uni-
versity, ULM, Germany
Background: Chronic lymphocytic leukemia (CLL) is associated with reduced
health-related quality of life (HRQoL), with progressive severe fatigue being a
particularly relevant burden. Disease-related symptoms, toxic effects of therapy,
and the awareness of living with an incurable disease can have a profound
impact on HRQoL. Venetoclax (VEN) is an oral BCL-2 inhibitor that has demon-
strated deep and durable responses in relapsed/refractory (R/R) CLL patients. 
Aims: To assess whether Venetoclax has a sustained impact on health related
quality of life among patients with relapsed/refractory CLL based on a second
interim analysis (first interim results through week 24) of patients treated with
VEN monotherapy.
Methods: Patients ≥18 years of age with R/R CLL received VEN monotherapy
until disease progression, unacceptable side effects, or discontinuation for any
other reason. Patient-reported HRQoL measures included the EORTC QLQ-
C30 and EORTC QLQ-CLL16, which were assessed at Baseline (BL), at 4
weeks and every 12 weeks thereafter. Mean change in the HRQoL measures
from BL to each assessment are reported. Clinical relevance was based on
minimum important difference (MID) of values from BL at different assessment
points. The lower bound of 5–10 point changes, considered a “little” change for
EORTC-QLQ-C30 was used for MID acceptance for both measures.
Results: Clinically meaningful improvements from BL were observed early and
were sustained through week 96 in VEN treated patients in the EORTC-QLQ-
C30 global health status and the role, social, and emotional functioning scales.
Improvements in VEN treated patients in EORTC-QLQ-CLL16 disease effects,
social problems, and future health worries scores were statistically significant
and exceeded the MID at all assessment points. Furthermore, early and sus-
tained improvements in fatigue through week 96 were seen in both EORTC-
QLQ-C30 and EORTC-QLQ-CLL16 (Table 1). The changes observed in patient
EORTC-QLQ-CLL16 future health views were considered large (>20 points) at
Weeks 12, 24, and 48.
Table 1.
Summary/Conclusions: These updated interim results suggest that patients
receiving VEN monotherapy experienced early and sustained clinically relevant
improvement in several key aspects of functioning and HRQoL for up to 96
weeks in a very symptomatic and difficult to treat patient population. These
results are important to consider when making treatment decisions in the R/R
settings.
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WHICH HAEMATOLOGICAL CONDITIONS CAN THIRD YEAR MEDICAL
STUDENTS RECOGNISE INTERPRETING FULL BLOOD COUNT
RESULTS?
S. Lovato1,2,*, J. Arnold1,2
1Postgraduate, London North West Healthcare NHS Trust, 2Undergraduate,
Imperial College London, London, United Kingdom
Background: Haematology is often seen by medical students as a niche spe-
cialty, however interpreting full blood count results is a daily job for most hospital
doctors. Furthermore a recent review showed that survival for haematological
malignancies is worse in UK than in other European countries, late diagnosis
being one the possible causes. Educate future doctors in interpreting symptoms
and blood results correctly to suspect haematological condition should be con-
sidered essential. In the UK the Education Subcommittee of British Society for
Haematology wrote the “A Haematology Curriculum for Medical Students” as
a guide to the knowledge of haematology expected from medical students.
Aims: The aim of the study was to evaluate the ability of a group of third year
medical students in recognising ten haematological conditions as indicated in
the curriculum proposed by the BSH. The students had all attended a haema-
tology course during their second year of medical school.
Methods: A multiple choice test “best of four” containing ten clinical cases
including full blood count results was given to the students. According to the
Team Based Learning “TBL” model the students completed the test first indi-
vidually, “i-RAT” and then after discussing the results in small groups “t-RAT”.
The topics and the percentage of correct answers are shown in table 1.
Results: Twenty four students participated. In the i-RAT none of the scenarios
were correctly interpreted by 100% of the students, the scenarios interpreted
correctly by at least 70% of the students were only two: B12/folate deficiency
and iron deficiency; less than 30% of the students could identify CML, NHL
and Multiple myeloma; the remaining topics: thalassemic trait, MDS AML, CLL
and lymphocytosis due to viral infection were correctly diagnosed by a variable
number of students, between 66% and 42%. When the test was repeated after
discussion in small groups “t-RAT” there was an improvement of the percentage
of correct answer with the exception of the topic AML. In the t-RAT 100% of the
groups diagnosed correctly thalassemic trait and MDS, at least 70% of the
groups identified correctly CML, CLL and multiple myeloma in addition to
B12/folate and iron deficiency, there was an improvement in diagnosis of Mul-
tiple myeloma, but still less than 30% of the groups could identify NHL.
Table 1.
Summary/Conclusions: This group of medical students found it difficult to
correctly diagnose some of the haematological conditions presented, even
though they had studied all the conditions before, however the use of a “Team
Based Learning” approach where students could discuss the cases in small
groups did improve their results. Interestingly for two conditions, for CML and
Multiple myeloma the number of correct answers was the same for i-RAT and
t-RAT, possibly the students who responded correctly during the i-RAT were
each in a different group during the t-RAT and worked as peer-to-peer teachers
for the other students. The t-RAT results for AML were actually worse than for
the i-RAT, probably the students who replied correctly in the i-RAT were con-
centrated in fewer groups. To the author’s knowledge this is the first study on
the effect of applying the Team Based Learning method to haematology teach-
ing. This study showed that TBL could be a useful teaching tool to improve
teaching of haematological conditions in medical schools, however the size of
the sample was small and the results should be validated with a bigger study.
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LONGITUDINAL ASSOCIATIONS BETWEEN HEALTH-RELATED QUALITY
OF LIFE AND HEALTHCARE UTILIZATION IN AL AMYLOIDOSIS
M. Bayliss1, T.P. Quock2, S.D. Guthrie2, M.K. White1, K.L. McCausland1,*
1Optum, Lincoln, 2Prothena Biosciences Inc, South San Francisco, United
States
Background: Light chain (AL) amyloidosis is a rare, complex disease associ-
ated with significant organ dysfunction, disability, and death. AL amyloidosis
patients interact with the healthcare system in a myriad of ways; however, few
studies have quantified healthcare utilization (HCU) in this condition. 
Aims: To prospectively examine the association between health-related quality
of life and healthcare utilization among patients with AL amyloidosis.
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Methods: A non-interventional, longitudinal online study was conducted among
patients with AL amyloidosis who were recruited with assistance from patient
advocacy groups. Initial (n=341) and six-month follow-up (n=226) surveys
assessed demographics, disease and treatment characteristics, and health-
related quality of life (HRQoL), measured by the SF-36v2® Health Survey phys-
ical and mental component summary scores (PCS and MCS). HCU (e.g., out-
patient doctors’ visits, emergency room [ER] visits, hospitalizations, and insur-
ance coverage) was measured during the six-month follow-up. Prevalence of
HCU and its bivariate associations with patient characteristics were evaluated.
Multivariable logistic regression models were used to test for associations
between HRQoL and having an ER visit or hospitalization in the past six
months.
Results: Overall, visits with specialists and other healthcare providers during
the previous six months were nearly ubiquitous (92.0% and 94.6%, respec-
tively). Collectively, 56.0% of patients reported having ≥1 ER visit or hospital-
ization. ER visits and hospitalizations were not associated with the numbers or
types of organs affected by the disease or the duration of disease. There were
significant associations between PCS and ER visits (p<0.05) and between both
PCS and MCS and hospitalizations (p<0.05 for all) based on multivariable
analyses.
Summary/Conclusions: There is a lack of real-world evidence regarding HCU
among patients with AL amyloidosis. This research identified longitudinal asso-
ciations between HRQoL and HCU, indicating there is potential for using
HRQoL surveys as screening tools to predict future HCU for AL amyloidosis
patients. The development of prediction models for HCU in AL amyloidosis
should consider incorporating HRQoL, as well as disease staging and treatment
type. 
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SAFETY, FEASIBILITY AND EFFECTIVENESS OF ELECTRICAL MUSCLE
STIMULATION IN HOSPITALIZED PATIENTS UNDERGOING AUTOLOGOUS
OR ALLOGENEIC STEM CELL TRANSPLANTATION AND INTENSIVE
CHEMOTHERAPY
D. Kaddu-Mulindwa1, A. Klostermann1,*, M. Bewarder1, J. Bittenbring1,
M. Pfreundschuh1
1Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany
Background: Autologous and allogeneic stem cell transplantation (HSCT) or
intensive chemotherapy are the only treatment option for many patients with
haematological malignancies. Even after complete remission many patients
are physically and psychologically impaired because of intensive treatment
and weeks of immobilisation. Electrical muscle stimulation (EMS) is a verified
training tool to prevent muscle decline in seniors and helps improving physical
performance in patients with chronic disease.
Aims: This prospective, randomized and controlled study tested the safety, fea-
sibility and efficacy of EMS in 72 patients (EMS=42, control=30) undergoing autol-
ogous HSCT (n=21), allogeneic HSCT (n=17) and intensive chemotherapy (n=34).
Methods: A Myopuls 2000 device (Curatec Services GmbH) was used. Tar-
geted training time was 15 minutes 5 days a week on both thighs and arms
from start of therapy (T1) to time of discharge (T2). Adverse events and treat-
ment adherence were documented. Impact on psychological and physical func-
tioning was evaluated using the Multidimensional Fatigue Inventory (MFI), the
EORTC QLQ-C30, the Short Physical Performance Battery and the 6 Minute
Walking Distance test at T1 and T2.
Results: Seven patients died in the EMS- (n=4) and control-group (n=3). 6 of
42 EMS patients withdrew because of sepsis (n=4) or loss of motivation (n=2).
32 patients from the EMS group completed our study with 22 accomplish-
ing>66% of the pre-set training time. EMS related adverse events were
hematoma (n=1) and muscle pain (n=2). No bleeding events (WHO bleeding
scale>1) or ventricular arrhythmias occurred. Difference in 6-minute walking
distance between both groups was 23 meter (p=0,2). SPPB test results differed
by one point (p=0,08). MFI and EORTC QLQ-C30 both favoured the EMS
group, but showed no statistical significance.
Summary/Conclusions: EMS is feasible and safe in patients undergoing
intensive chemotherapy regimens. It also may improve physical fitness, fatigue
and quality of life, indicated by favourable test results in the EMS group. To
verify positive effects of EMS in patients with haematological malignancies,
further research is needed, with more patients and sham EMS stimulation. 
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MYELOMA PATIENT VALUE MAPPING: A DISCRETE CHOICE EXPERIMENT
J. Galinsky1,*, S. Fifer2, S. Richard1
1Research, Myeloma UK, Edinburgh, United Kingdom, 2Research, Community
and Patient Preference Research, Sydney, Australia
Background: Myeloma is a life threatening haematological cancer. Although
myeloma is responsive to treatments, there remains no cure. In recent years,
there have been improvements in survival due to the use of high dose thera-
pies, stem cell transplant, and other novel therapies. However, while myeloma
patients are living longer, they are also living with symptoms and treatment
side-effects. Therefore, myeloma patients face difficult decisions about the
benefits and risks of treatment. The purpose of this study was to assess myelo-
ma patient preferences for treatment.
Aims: The study aimed to answer the following questions: What treatment attrib-
utes do myeloma patients value? What is the relative importance of different
treatment attributes to myeloma patients and the maximum acceptable risk they
are willing to accept? What risk-benefit trade-offs characterise patients’ decision-
making around treatment options, including not to treat? What, if any, influences
and predictive factors are found in the way patients assess benefits and risk?
Methods: Participants were 475 Myeloma patients in the UK. Data were col-
lected using discrete choice experiments (DCEs) through an online survey.
The DCEs presented patients with a traditional treatment choice experiment
(e.g., treatment A vs treatment B), focusing on the clinical benefits of treatments
and the associated risks. The attributes and levels of the attributes were select-
ed based on previous research, literature review and expert opinion. The DCE
data were modelled using a Latent Class Model (LCM), and the effect of demo-
graphic characteristics were also examined.
Results: Findings revealed two classes (groups) of patients with different pref-
erences for treatment attributes. Patients in class one placed greater importance
on overall survival and mild-to-moderate side effects, whereas patients in class
two placed greater importance on how the treatment was administered and the
average out-of-pocket costs. Patients living with others and those diagnosed in
the last five years were more likely to be to be in class one (those more concerned
with overall survival) than class two (those more concerned with quality of life).
Summary/Conclusions: Findings from this study suggest that not all myeloma
patients value the same treatment features equally. This finding has important
implications for healthcare policy decisions and could be used to guide deci-
sions around the value of new myeloma medicines. For example, to establish
more patient-aligned endpoints in clinical trials or as evidence which is incor-
porated into the Heath Technology Assessment process.
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COST-MINIMIZATION ANALYSIS OF RITUXIMAB SUBCUTANEOUS
FORMULATIONVERSUS INTRAVENOUS ADMINISTRATION OF RITUXIMAB
FOR THE TREATMENT OF NON-HODGKIN’S LYMPHOMA IN THE REPUBLIC
OF MACEDONIA
O. Nikolov1,*, Z. Sterjev2, A. Dimovski2, A. Kapedanovska-Nestorovska2,
Z. Naumovska2, A. Grozdanova2, L. Cevreska3, B. Georgievski4, A. Sto-
janovik5, O. Karanfilski6, S. Genadieva-Stavrik4, S. Trajkova6, A. Pivkova-Vel-
janovska4, T. Sotirova6, M. Pavkovic5, S. Trpkovska-Terzieva6, G. Amzai6, L.
Cadievski4, D. Dukovski6, L. Suturkova2
1Roche Macedonia DOOEL Skopje, 2ISPOR - Republic of Macedonia Regional
Chapter, Faculty of Pharmacy, Ss. Cyril and Methodius” University of Skopje,
3University Clinic of Hematology, 4Stem cell transplantation unit, 5Outpatient
Clinic, 6Clinical department, University Clinic of Hematology, Skopje, Macedo-
nia, The Former Yugoslav Republic Of
Background: Rituximab, an anti-CD20 monoclonal antibody, in combination
with chemotherapy is a standard of care for non-Hodgkin’s lymphoma (NHL),
in a standard dose of 375mg/m2 body surface area (BSA), administered by
intravenous (IV) infusion, or fixed dose of 1400mg administered as subcuta-
neous formulation (rituximab SC). Intravenous infusion of rituximab typically
last for three to four hours, while subcutaneous application last approximately
five to seven minutes. The evidence to support the use of rituximab SC as an
alternative to rituximab IV is primarily based on the phase III, randomised, non-
inferiority, open-label SABRINA study. Recent studies demonstrated therapeutic
and pharmacokinetic non-inferiority of rituximab SC to rituximab IV.
Aims: The aim of the study was to identify and compare the total costs of sub-
cutaneous (SC) vs intravenous (IV) administration of rituximab for the treatment
of NHL patients in the Republic of Macedonia.
Methods: Cost-minimization analysis was used to evaluate pharmacoeconomic
impact of the use of subcutaneous vs intravenous administration of rituximab in
the treatment of NHL patients. The total of 220 NHL patients (mean body surface
area 1.9 m2, middle aged 59.6 years) were enrolled in the study. Evaluated
healthcare resources included drug treatment costs, infusion chair occupying
cost, active Healthcare Professional time cost and consumable disposals.
Results: Direct costs of administering one course of rituximab, including cost
of drug, cost of administration and cost of consumables in all treatment phases
(premedication, medication and post medication), for intravenous administration
of rituximab were 1621€ compared to 1546€ for subcutaneous administration
of rituximab. Average time for intravenous administration is 6 hours, 12 minutes
and 13 seconds, compared to 10 minutes and 13 seconds for subcutaneous
administration. Subcutaneous rituximab incurred less non-drug related costs
than intravenous rituximab under the observed clinical practice: 14.62€ vs
1.76€ regarding active healthcare professional time and 10.10€ vs 1.2€ as
infusion chair occupying cost. 
Summary/Conclusions: Subcutaneous administration of rituximab is a cost-
saving therapy in comparison with intravenous administration of rituximab for
the treatment of NHL patients in the Republic of Macedonia.
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QUALITY OF LIFE AND ABILITY TO WORK OF PATIENTS WITH CHRONIC
MYELOGENOUS LEUKEMIA TREATED WITH THYROSINE KINASE
INHIBITORS
B. Sidi Mohamed El Amine1,*, H. Asma1, Z. Zahia1, M. Naima2, M. Nemra3
1Hematology department, Universitary hospital of Sidi Bel Abbes, Sidi Bel
Abbes, 2Hematology department, Universitary hospital of Tlemcen, Tlemcen,
3Hematology department, Hospital of Mascara, Mascara, Algeria
Background: Thyrosine kinase inhibitors (TKIs) are now standard treatment
for chronic myelogenous leukemia (CML), but little is known about quality of
life (QoL) of the patients.
Aims: The purpose of this study is to evaluate QoL of CML patients receiving
TKIs, a disease requiring strict daily compliance with taking these drugs orally,
as well as regular clinical and biological controls.
Methods: The study included patients with CML followed in three hospitals in
west Algeria between 2004 and 2016. The measure of QoL was performed by
the tool of functional assessment of chronic illness therapy (Functional Assess-
ment of Chronic Illness Therapy, FACIT) for leukemia. We have established
QoL scores given by the questionnaire, FACIT, consisting of three levels: TOI
for leukemia trial outcome index, FACT-G for general score, and FACT-LEU for
the total score of leukemia. Specific areas of the questionnaire were associated
with QoL of patients such as fatigue and ability to work. The correlation between
these data and QoL scores was assessed using Spearman’s test. The test is
significant if p<0.05.
Results: 67 patients with CML have agreed to answer to the questionnaire of
QoL, medications in use, and their side effects. The mean QoL of the patients
was 93.7 (out of 124 total points) for the TOI, 77,2 (out of 108) for the FACT-G,
and 128.9 (out of 176) for the FACT-LEU. Patients who presented with TKIs
side effects had a low score of QoL (p=0.0006), especially when these effects
are severe (p=0.003). Stopping TKIs medication was noted in 41.3% of patients
with severe side effects. Severe fatigue was observed in 14 (22.9%) patients,
having low QoL scores in all scales (p<0.0001). 44 (65.8%) patients were able
to work with higher QoL scores in the three FACIT scales (p<0.0001, Spearman
correlation).
Summary/Conclusions: QoL is an important aspect in the management of
CML, its assessment is necessary and must be regular. The ability to work
and fatigue are important components of QoL of patients receiving TKIs and
should be specifically taken into account during the treatment. Adverse effects
of TKIs can interfere with QoL of patients and can lead to discontinuation of
CML therapy.
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QUALITY OF LIFE AND EMPLOYMENT AFTER AN HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN A MEXICAN POPULATION
L. Rivera-Fong 1, A. Riveros Rosas1, C. Benjet1, L.M. Valero Saldaña2,
R. Robles García1, L. Traeger3, S. Rivas-Vera2,*, J.L. Aguilar Ponce4, O. Galindo
Vázquez5, B.L. Acosta Maldonado2
1Psicología y Salud, Universidad Nacional Autónoma de México., 2Hematology,
National Cancer Institute, Mexico, Mexico City, Mexico, 3Health psychology,
Hardvard University, Massachusetts, United States, 4Oncology, National Can-
cer Institute, Mexico, 5Psicología, Universidad Nacional Autónoma de México.,
Mexico City, Mexico
Background: Hematopoietic stem cell transplantation (HSCT) is a consolida-
tion therapy for multiple hematological malignances and its goal include patients
achieve levels of quality of life (QOL) similar that general population. However,
studies developed in Europe and United States have shown that patients on
long-term follow-up after HSCT reported lower levels of QOL, more unemploy-
ment and lower household income than before the procedure. These relation-
ships have not been examined in Mexican HSCT patients.
Table 1.
Aims: To describe the QOL (EORTC-QLQ), level of employment and household
income in Mexican patients on follow-up after HSCT
Methods: This was a cross-sectional study with patients ≥18 years old with at
least one year of follow up after HSCT at the National Cancer Institute, Mexico.
Results: 30 participants were included, with a median age of 34 years (range
21-65), 56% male, and 41% married. Regarding educational level 68.7% had
basic education, 25% had a college education and 6.3% postgraduate educa-
tion. Mean time after HSCT was 36 months, 10% had active chronic graft versus
host disease (GVHD). Patients reported moderate to high levels of QOL (Table
1). With respect to employment, 52% had a job (56% had a full time job, 13%
work part-time and 31% had an informal job) and 48% were unemployed (50%
could not find a job and 50% did not want to have a job). Finally, 56% had lower
household income than before HSCT.
Summary/Conclusions: Mexican patients showed similar or higher levels of
QOL in comparison with samples from other countries, with the exception of
higher impact in emotional QOL and better social QL in our sample. Additionally,
a substantial minority of patients were unemployed and over half had lower
household income after HCST. More work is needed to identify risks associated
with changes in QOL, employment status and income among long-term sur-
vivors of HCST. 
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ANTHRACYCLINE INCREASES THE RISK OF DEVELOPING DIABETES
IN B CELL LYMPHOMA
H.-C. Lin1,*, W.-L. Hwang1, C.-L. Teng1
1Division of Hematology/Medical Oncology, VTaichung Veterans General Hos-
pital, Taichung, Taiwan, Republic of China
Background: Treatments of R-CHOP (rituximab, cyclophosphamide, doxoru-
bicin, vincristine, and prednisone) or R-CHOP like regimens have made B cell
lymphoma to be one of the most curative hematological malignancies. Among
the effective chemotherapeutic agents in B cell lymphoma treatment, anthra-
cycline plays an important role. However, anthracycline associated bone mar-
row suppression and cardiotoxicity limit its clinical application. Whether anthra-
cycline would further increase the risk of developing diabetes in B cell lym-
phoma remains unclear.
Aims: The aim of this study was to compare the cumulative incidences of dia-
betes in B cell lymphoma patients treated with and without anthracycline. We
also investigated the dose effect of anthracycline on diabetes development.
Additionally, whether anthracycline would increase the severity and complica-
tion of diabetes in B cell lymphoma patients were also studied. 
Methods: We conducted this population-based study by using Taiwanese
National Health Insurance Research Database. From 2004 to 2011, medical
records from a total of 3984 B cell patients were analyzed. To understand
whether anthracycline therapy was associated with more diabetes in B cell lym-
phoma, we compared the cumulative incidence of newly diagnosed diabetes
between patients with (n=3147) and without (n=837) anthracycline treatments.
Impact of anthracycline on diabetes was further studied by multivariate Cox
proportional hazard regressions in a dose-dependent manner. 
Results: Log-rank test did not show the difference of cumulative incidences of
newly diagnosed diabetes between B cell lymphoma patients with and without
anthracycline treatments (p=0.1446). However, anthracycline remained asso-
ciated with more diabetes [hazard ratio (HR): 1.59; 95% confidence interval
(CI): 1.05–2.39; p=0.0278] after adjustment for age, gender, and comorbidities.
Moreover, cumulative anthracycline doses of 253-400mg (HR: 1.94; 95% CI:
1.23–3.05; p=0.0043) and 401-504mg (HR: 1.83; 95% CI: 1.11–3.01; p=0.0180)
increased the incidence density of diabetes in a dose-dependent manner
(p=0.0438). Notably, patients with and without anthracycline treatment had sim-
ilar yearly adapted diabetes complications severity index alteration (0.58±1.89
vs 0.75±1.85; mean±standard deviation), suggesting anthracycline did not dete-
riorate outcome of diabetes in B cell lymphoma patients (p=0.4924).
Figure 1.
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Summary/Conclusions: Anthracycline therapy was responsible for more dia-
betes in B cell lymphoma in a dose-dependent manner. More intensive blood
sugar monitoring and control should be recommended to B cell lymphoma
patients, especially those who received anthracycline treatment.
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THE COST-EFFECTIVENESS OF LENALIDOMIDE PLUS DEXAMETHASONE
FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE
MYELOMA IN CHINA
J. Lu1,*, S. Hu2, P. Xu3, Y. Feng4
1Peking University People’s Hospital, Peking University Institute of Hematology,
Beijing, 2Fudan University School of Public Health; Shanghai Health Develop-
ment Research Center, 3Celgene China, Shanghai, 4Department of Pharmacy,
Beijing Hospital, Beijing, China
Background: The introduction of lenalidomide plus dexamethasone (RD), and
bortezomib-contained regimens, has improved the management of relapsed
or refractory multiple myeloma (rrMM) in China. However due to the absence
of both head-to-head (direct) comparative efficacy and local economic data,
stakeholders still face hard choices to make when choosing one therapy over
another. Indirect treatment comparisons and health economic modeling can
help support local decision-making by enabling the incorporation of country-
specific unit cost data, in the comparison of cost-effectiveness of one treatment
vs another where treatments have not been directly compared in clinical trials.
Aims: To assess the cost-effectiveness of RD relative to bortezomib/dexam-
ethasone (VD) and bortezomib/cyclophosphamide/dexamethasone (VCD) for
rrMM in Chinese patients.
Methods: The Markov-based decision analytic model was constructed to sim-
ulate lifetime health benefits and direct medical costs associated with RD, VD,
and VCD for rrMM in Chinese patients. A systematic literature review was con-
ducted (in both Chinese and English databases, from 2005 to 2016) to obtain
efficacy data of the three treatment regimens. The risk of progressive disease
associated with RD and VD were estimated from available Chinese trials. The
efficacy of VCD and the mortality associated with progressive disease after
treatments with RD and VD were lacking in China, therefore were estimated
from the published international randomized clinical trials. Published quality of
life data was adapted to Chinese rrMM patients with health utility adjustment.
The model took into account (i) drug acquisition costs, (ii) treatment adminis-
tration costs derived from Chinese urban claims data, (iii) serious adverse
events management costs based on a survey of seven MM centers across
China, and (iv) rrMM management costs estimated from a Chinese real-world
hospital setting. Quality-adjusted life years (QALY) and direct medical costs in
the model were discounted at 3% per annum. Base case analysis calculated
incremental cost-effectiveness ratio (ICER) per QALY for RD relative to VD
and VCD, respectively from the Chinese healthcare payer’s perspective. One-
way sensitivity analysis and probabilistic sensitivity (PSA) with 5,000 Monte
Carlo simulations assessed the impact of the model uncertainty on the cost-
effectiveness of RD. A scenario analysis was conducted by meta-analyzing the
published international randomized trials for the efficacy associated with RD,
VD, and VCD, to verify the base case analysis.
Results: Based on the model simulation without discounting survival outcomes
over a lifetime horizon, RD could obtain longer average PFS years than VD
(2.37 vs 0.78) and VCD (2.37 vs 1.36). RD was associated with longer dis-
counted QALY (3.06 vs 1.58 vs 1.41) and more discounted lifetime medical
costs (¥494,060 vs ¥272,135 vs ¥ 244,220) than both VD and VCD. The ICERs
per QALY for RD relative to VD (¥149,706) and VCD (¥150,774) were less
than the cost-effectiveness threshold of China (three times of estimated 2016
China GDP per capital ¥166,920/QALY, ¥1= €0.138). The cost-effectiveness
of RD relative to VD and VCD was mainly driven by the mortality risk associated
with the progressive disease after treatment. The scenario analysis generated
comparable ICER per QALY associated with RD relative to VD (¥120,974) and
VCD (¥117,191), therefore supports the robustness of base case analysis.
Summary/Conclusions: The local data-based health economic model esti-
mates that RD could gain longer PFS and OS with acceptable cost-effective-
ness, when compared to VD and VCD in Chinese rrMM patients.
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DEVELOPMENT OF A NEW HAEMATOLOGICAL MALIGNANT PATIENT-
REPORTED OUTCOME MEASURE FOR USE IN CLINICAL PRACTICE:
HM-PRO
P. Goswami1,*, S. Salek1, T. Ionova2, E. Oliva3, A.K. Fielding 4, M. Karakantza5,
S. Al-Ismail6, G.P. Collins7, S. McConnell5, C. Langton5, D.M. Jennings8,
R. Else9, J. Kell10
1School of Life and Medical Sciences, University Of Hertfordshire, Hatfield,
United Kingdom, 2National Medical Surgical Centre and Multinational Centre
for Quality of Life Research, St Petersburg, Russian Federation, 3Haematology
Unit, Azienda Ospedaliera, Reggio Calabria, Italy, 4UCL Cancer Institute, Lon-
don, 5Leeds Teaching Hospitals NHS Trust, Leeds, 6Singleton Hospital, ABM
University Health Board, Swansea, 7Oxford University Hospitals NHS Trust,
Oxford, 8Royal Surrey County Hospital NHS Foundation Trust, Guildford,
9Patient Research Partner, Milton Keynes, 10Cardiff and Vale University Health
Board, Cardiff, United Kingdom
Background: Health-related quality of life (HRQoL) of patients with haemato-
logical malignancy (HM) is greatly affected by the disease and the treatment and
this has not been captured in a systematic manner in routine clinical practice.
Aims: The aims of this study were to identify issues important to patients with
HM and development of a new patient reported outcome measure for use in
daily clinical practice. 
Methods: A conceptual framework was developed using preliminary literature
search and discussions with physicians and patients. Patients with HM were
then interviewed to produce a comprehensive item pool reported important by
them. The generated items were then discussed in the data definition panel
meeting to be included in the prototype version of the HM-PRO. Subsequently,
a panel of experts and a panel of patients were asked to rate the items of the
prototype HM-PRO for its language clarity, completeness, relevance and scal-
ing followed by cognitive interviews with the patients to pilot test the HM-PRO. 
Results: The preliminary literature search revealed that there is no PRO specif-
ically developed for patients with HM for use in daily clinical practice. The con-
ceptual framework comprised of two main themes: QoL (impact); and symp-
toms. 129 patients (male=76; mean age=61.1 years; SD=15.3; median age
=64.9 years; age range =18-88 years; diagnosis –AML, ALL, CML, CLL, MM,
ANHL, INHL, HL, MPN, and MDS) with mean duration of the HM of 3.6 years
(SD=4.3; and range= 19 days-23 years) from 5 haematology centres were
interviewed to identify the issues important to HM patients. A prototype version
of HM-PRO was developed after data definition panel meeting with 34 items
in impact category (Part A) and 23 items representing disease symptoms (Part
B). Nine- member panel of experts and 7-member panel of patients, rated the
items and discussed them for its language clarity, completeness, relevance
and scaling to reach consensus. 60 patients (male=36; mean age=63.8 years;
SD=16.61; median age =69.2 years; and age range =18-91 years) with mean
duration of the HM of 4.9 years (SD=6.4; and range= 14 days-26 years) were
recruited for the pilot testing where 34 of which were involved in cognitive inter-
views. 92% of the patients reported that the statements were easy to under-
stand and all issues important to them were covered; 95% stated that they
were able to respond spontaneously and expressed their willingness to com-
plete the instrument during their visit to the clinic; 97% reported that the state-
ments were easy to read; 98% did not wish to delete any item; and 88% did
not see the need to add any item. 
Summary/Conclusions: The findings of the content validation, pretesting and
cognitive interviews indicate that HM-PRO possesses a strong content validity
in different HMs, includes all the issues important to these patients and the
statements are easy to read, understand and respond to spontaneously. HM-
PRO will undergo further psychometric testing to support its psychometric prop-
erties across different types of HMs. 
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OVARIAN TISSUE CRYOPRESERVATION IN PEDIATRIC AND ADOLES-
CENT PATIENTS UNDERGOING CANCER CHEMOTHERAPY AND/OR
HEMATOPOIETIC STEM CELL TRANSPLANTATION
A. Kinoshita1,*, R. Ooyama1, D. Keino1, Y. Matsuoka1, Y. Koto1, T. Mori1,
S. Takae2, N. Suzuki2
1Pediatric Hematology/Oncology, 2Department of Obstetrics and Gynecology,
St. Marianna University School of Medicine, Kawasaki, Japan
Background: Ovarian tissue cryopreservation (OTC) and subsequent re-
implantation is the only option available for fertility preservation in prepubertal
females, but this approach remains unestablished in pediatric and adolescent
patients with cancer. After the experience of OTC for more than 200 patients
with primary ovarian failure and more than 50 patients with breast cancer in
our center over 5 years, we have started OTC for pediatric and adolescent
cancer patients since 2015. 
Aims: To define safety and benefits of OTC in pediatric and adolescent patients
with undergoing cancer chemotherapy and/or hematopoietic stem cell trans-
plantation. 
Methods: From December of 2015 to February of 2017, OTC was performed
in 6 girls (median age 14 years, range 11-15): 2 patients with myelodysplastic
syndrome, 2 with lymphoma, 1 with acute lymphoblastic leukemia, and 1 with
primary immunodeficiency. Indications for OTC were 5 hematopoietic stem cell
transplantation and 1 sterilizing chemotherapy. Two patients with myelodysplas-
tic syndrome and 1 with immunodeficiency received no previous chemotherapy
and the other 3 had received prior chemotherapy. Laparoscopy was used to
collect one of a pair of ovarium that was frozen by vitrification method.
Results: Ovarian tissue was successfully collected from the 6 patients studied
without major postoperative complications and this procedure did not delay
chemotherapy or hematopoietic stem cell transplantation. Histological analysis
of ovarian tissue revealed primordial follicles, even in the patients with previous
cancer chemotherapy. No malignant cells were identified. Median post-harvest
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follow-up was 9 months (0-14) and all patients were alive. Hormonal results
were evaluable for 3 patients: 2 patients were in premature ovarian insufficiency.
Re-implantation of ovarian tissue has not yet been performed.
Summary/Conclusions: Although OTC and subsequent re-implantation is
experimental, this approach may be the best method for restoration of ovarium
function and fertility preservation in pediatric and adolescent cancer patients.
A risk of reseeding malignant cells is a problem still to be conquered.
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A MULTI-DISCIPLINARY APPROACH TO CHEMOTHERAPY PRESCRIBING
AT NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST
S. Gabriel1,*, G. Jones2, C. Cox2, S. Blakey2, M. Lannon2
1Northern Centre for Cancer Care- Pharmacy, 2Northern Centre for Cancer
Care-Haematology, Newcastle upon Tyne Hospitals NHS Trust, Newcastle
upon Tyne, United Kingdom
Background: Newcastle Upon Tyne Haematology service has made numerous
changes in recent years to provide streamlined care for patients, focusing on
reduced wait times & improve quality of care. The original pathway was costly
in time, involving several waits for the patient: for urgent venepuncture, physician
consultation, prescribing of chemotherapy, specialist pharmacist screening of
prescriptions & then a separate trip to pharmacy for dispensing. Patients then
returned home & waited for a call from the Clinical Nurse Specialist (CNS) to
confirm if blood results were appropriate for chemotherapy administration. If a
dose adjustment was required the drug was wasted & patients needed to return
to hospital for another prescription. Pharmacy waiting times for oral outpatient
chemotherapy or supplementary medications are approximately 30 minutes.
Aims: We introduced a weekly multi-disciplinary chemotherapy prescribing
meeting in 2013 with the aims of improving prescribing safety; minimising time
spent prescribing in clinic & reducing patient waiting times. Present at each
meeting is a Haematology Specialist Pharmacist, Haematology CNS, Consult-
ant & Specialist Registrar. Chemotherapy is planned a week in advance on
ChemoCare (an electronic chemotherapy prescribing package). Chemotherapy
is prescribed & immediately screened by the pharmacist; oral chemotherapy is
collected from pharmacy by a CNS prior to clinic. All prescription queries are
resolved during this meeting. Deferred oral chemotherapy can be returned to
pharmacy stock, minimising waste. Intravenous chemotherapy is pre-planned
with authorisation on the day of treatment if the patient is fit to proceed.
Methods: In the latest update to the care pathway, we focused on delivery of
care to myeloma patients receiving oral chemotherapy, including setting up a
nurse-led clinic. Data have been collected to assess service impact, particularly
on patient satisfaction. The latter was assessed using a patient survey. Between
July-Dec 2014, 66 patients received oral chemotherapy in the Myeloma Con-
sultant-led clinic, Lenalidomide based regimens accounted for 86% of the oral
regimens prescribed. On average, 7 patients per week were on maintenance
therapy. During this period 8% of chemotherapy courses were deferred due to
low blood counts or side-effects. Drugs were not wasted due to the pharmacy
agreement.
Results: A patient satisfaction survey was undertaken from Jan-June 2015,
post-introduction of the nurse-led clinic paired with the MDT chemotherapy pre-
scribing meeting. Patients were asked about a wide-range of quality parame-
ters. Results showed 89% of patients noted a reduction in wait times & 89%
felt they spent more time in consultations as a result. All patients noted they
spent more time with the nurse specialist & benefited from not attending phar-
macy. All patients rated the service as more efficient.
Summary/Conclusions: The MDT approach to prescribing & dispensing oral
chemotherapy & supportive medication has streamlined our way of working &
led to greater efficiency for both staff & patients. The new model has changed
how patients are seen & assessed and minimised drug wastage, an issue
incurred in the old system. However, it must be noted that during Jan-June
2015 the cost of wasted drug, due to patients being unfit for treatment on the
day, potentially incurred by pre-prescribing was £57,775. It is, therefore, critical
to ensure that medication that has not yet been given to patients can be returned
to pharmacy if this type of pre-prescribing model is to operate efficiently. 
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FINANCIAL TOXICITY OF THE MANAGEMENT OF MULTIPLE MYELOMA
B. Sidi Mohamed El Amine1,*, H. Asma1, O. Fouzia1, S.A. Najet1, Z. Zahia1
1Hematology department, Universitary hospital of Sidi Bel Abbés, Sidi Bel
Abbes, Algeria
Background: Advances in supportive care and the development of novel treat-
ments have helped to double the life expectancy of patients with newly diag-
nosed multiple myeloma (MM). Financial toxicity is increasingly recognized as
adversely affecting the quality of life and medication adherence, and patients
with MM might be particularly vulnerable because of extended treatment dura-
tion.
Aims: Our aim was to measure financial toxicity and its effects on patients
undergoing treatment for MM.
Methods: Between October 2016, and January 2017, we did a cross-sectional
survey of individuals receiving at least 3 months of ongoing treatment for MM
at our department. The survey included the 11-item COST measure (financial
toxicity score range 0-44). A paper survey was offered to eligible patients on
arrival for routine follow-up visits or treatment, and participants were asked to
complete the survey before or after their visit or stay in day hospital. The data
were postponed by two psychologists. The COST questionnaire was validated
with internal consistency (Cronbach’s coefficient) and item correlation (Pear-
son’s r coefficient) tests, especially those of Quality of life (EORTC QLQ 30).
Results: Of 47 patients approached for the study, 44 individuals completed
the survey and 40 (91%) were insured. Analysis of the internal consistency of
the COST questionnaire showed an overall Cronbach’s alpha coefficient of 0,
84. According to COST data, 26 (59, 1%) patients have a score<22. Patients
with financial difficulties have a negative impact on their quality of life (P=0, 02,
r=0, 32), and low scores of physical and role functioning (P<0,001, r >0, 5). 29
(66%) patients feel financially stressed, and 23 (52, 3%) did not control their
financial situation. After a logistic regression, lower household income (P=0,009)
and Poor response to treatment (P=0, 0037) were associated with higher finan-
cial burden as measured with the COST score.
Summary/Conclusions: Despite insurance and free care, financial toxicity is
common in many myeloma patients, especially those with lower income and
refractory disease. Strengthened collaboration among patients and health-care
stakeholders is needed to promote healthcare reforms that promote high value
and affordable myeloma care.
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THE IMPLICATIONS OF NON-PROPORTIONAL HAZARDS FOR THE
MEASUREMENT OF SURVIVAL BENEFIT IN HEALTH TECHNOLOGY
ASSESSMENT: CURRENT APPROACHES AND THE ROLE OF RESTRICTED
MEAN SURVIVAL TIME
G. Monnickendam1,*, J. McKendrick1, M. Zhu1, Y. Su2
1PRMA Consulting, Fleet, United Kingdom, 2Global Health and Value, Pfizer,
New York, United States
Background: Median survival and hazard ratios (HR) calculated from Cox pro-
portional hazard (PH) models for progression-free survival (PFS) and overall
survival (OS) are principal survival endpoints in oncology clinical trials. The
advent of novel agents, including immuno-oncologics, has seen increasing
reports of non-proportional hazards (non-PH). When non-PH are present, it is
challenging to evaluate the true clinical significance of survival differences
expressed as median and HR since these measures do not represent the com-
parative benefit over the full period of observed data. In such situations, addi-
tional metrics such as restricted mean survival time (RMST) may be valuable.
Aims: To determine current methods used by health technology assessment
(HTA) agencies when non-PH are observed in assessments of hematology/
oncology drugs, and the extent to which RMST is accepted as an alternative
measure of treatment benefit in these circumstances.
Methods: Methodological guidelines published by 10 HTA agencies in 8 major
developed countries (Australia, Canada, France, Germany, Italy [Emilia Roman-
ga, Veneto], Spain, Sweden, and the United Kingdom [NICE, SMC]) and by
influencing organizations in the US (including the Institute for Clinical and Eco-
nomic Review, ICER) were reviewed to establish recommended approaches
for presenting survival benefit from clinical trials, particularly the use of RMST
where non-PH were reported. To determine how these guidelines are imple-
mented in practice, published HTA reports were examined across the 8 coun-
tries for 23 oncology agents (including 4 in hematology) approved by the FDA
and EMA since 2014, to identify instances where testing for non-PH was con-
ducted and RMST data reported.
Results: Guidelines from only 2 agencies (PBAC in Australia and NICE in the
UK) described formal testing for non-PH. Testing was reported in 15 (of 23) NICE
assessments and 4 (of 10) PBAC assessments. For the hematology drugs, non-
PH testing was conducted in 3 (of 4) NICE assessments; it did not hold in 2
instances. Of the agencies (from France, Germany, Italy and Spain), which focus
on comparative clinical benefit, only 1 (GENESIS in Spain) discussed the concept
of RMST in their guidelines; 5 (of 45) assessments from these countries included
RMST. Of the agencies (from Australia, Canada, Sweden, and the UK) which
focus on cost-effectiveness, all except the TLV in Sweden include RMST in their
guidelines; RMST was reported in 13 (of 81) HTA assessments from those coun-
tries. Of the 3 hematology drugs where non-PH was tested within the NICE
process, only one (ofatumumab, where there were PH) reported RMST (utilized
during economic model sensitivity analyses). Non-PH is not a widely reported
issue in US guidelines; however, the ICER has acknowledged it and PH testing
was conducted in both ICER reports in oncology.
Summary/Conclusions: Testing for non-PH is not widely reported in clinical
trials or incorporated into assessments by HTA agencies except by UK NICE.
RMST as a metric to assess OS has played a role in assessing clinical benefit
within the context of HTA assessments, although not consistently within coun-
tries (across drugs) or across countries (for the same drug), as was seen with
the hematology agents. As treatments for cancer expand to new classes and
indications, instances of non-PH will likely increase; alternative survival metrics
such as RMST may have an increasingly important role to play in describing
survival benefit in such cases.
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DISEASE SEVERITY AND SLOWER PSYCHOMOTOR SPEED IN ADULTS
WITH SICKLE CELL DISEASE
E. Novelli1,*, D. Jorgensen2, A. Metti2, M. Butters2, C. Rosano2
1Medicine, Vascular Medicine Institute, University of Pittsburgh, BST E1240,
200 Lothrop St., 2University of Pittsburgh, Pittsburgh, United States
Background: Psychomotor slowing is common in children with sickle cell dis-
ease (SCD), but little is known about its severity in adult patients. While the
primary risk factor for psychomotor slowing is stroke, there has been mounting
evidence that cognitive impairment also occurs in patients without a history of
overt or silent stroke. Risk factors for cognitive impairment in patients with SCD
without stroke are, however, not completely known, particularly in relationship
to the SCD genotype.
Aims: We conducted a cross-sectional study to quantify psychomotor slowing,
measured with the Digit Symbol Substitution Test (DSST), a pencil and paper
test of executive function, in relationship with disease severity in adult patients
with SCD attending an outpatient clinic. We also examined whether demo-
graphic, behavioral, physiologic, and pathologic factors that are known to be
related to SCD severity and cognitive function in other settings are also related
to psychomotor speed in these patients.
Methods: Genotype was used to group patients with SCD (n=88, age: 36.3
years, 33 males) in “severe” (homozygous for the mutated sickle hemoglobin
HbS [HbSS], or compound heterozygous with β0 thalassemia [HbS/β0]) or “mod-
erate” groups (compound heterozygous for HbS, with either HbC [HbSC], or
β+thalassemia [HbS/β+]). Standardized DSST scores based on published norms
were used to define mild cognitive impairment, defined as ≤1.5 standard devi-
ations (SD) below the DSST T-score (T-scores had a mean of 50 and SD of 10).
Data on demographics, hematological parameters, hydroxyurea and opiate
intake, stroke (including silent cerebral infarcts (SCI)) and transfusion history
were collected concurrently with DSST. Analyses were repeated after exclusion
of patients with a history of stroke (n=12). Age-adjusted p-value was calculated
with logistic regression for all variables except age (unadjusted) and DSST T-
score (already adjusted for age, sex and education in calculation of T-score).
Results: Among our patients, 56 (63%) had a “severe” genotype and 32 (27%)
had a “moderate” genotype. Mild cognitive impairment was detectable in both
the “severe” and the “moderate” group (30% and 9%, respectively, age-adjusted
p=0.15). Compared to the “moderate” group, those in the “severe” group, had
significantly lower DSST scores (age, sex and education adjusted p val-
ue=0.006), independent of adjustment for factors that differed between groups:
hemoglobin, ferritin, hydroxyurea use, blood pressure parameters and stroke
history. Results were similar after excluding patients with stroke.
Table 1.
Summary/Conclusions: Psychomotor slowing in SCD differs in relationship
to genotype; this difference appears unrelated to history of stroke or severity
of anemia and other risk factors examined cross-sectionally. Although relatively
infrequent, mild cognitive impairment was also detectable in patients with a
less severe genotype. Longitudinal studies of SCD should include all diseases
genotypes, and examine factors that would reduce the risk of cognitive impair-
ment in each subgroup.
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MONITORING OF CHRONIC HEPATIC DAMAGE IN SICKLE CELL DIS-
EASE: LONGITUDINAL OBSERVATION OF A COHORT OF ADULT
PATIENTS
V.M. Pinto1, B. Gianesin1, M. Balocco1, P. Carrara1, G.L. Forni1,*
1Haematology-Centro Microcitemia Anemie Congenite, Ospedale Galliera Gen-
ova, Genova, Italy
Background: Acute vaso-occlusive events (VOCs) in Sickle Cell Disease
(SCD) is an important cause of hepatic damage which can result in catastrophic
consequences as acute hepatic failure and contribute to early mortality. In addi-
tion, sickle hepatopathy may be the consequence of SCD’s treatment as liver
iron overload or viral hepatitis due multiple blood transfusions that these
patients require in their lifetime. Therefore both SCD itself and related therapies
may lead liver to fibrosis/cirrhosis.
Aims: We evaluated liver fibrosis using Transient Elastography (TE) in patients
with SCD, exploring possible correlation with clinical, laboratory and imaging
findings in longitudinal way.
Methods: SCD patients with at least one stiffness evaluation were retrospec-
tively evaluated in the decade 2006-2016 using biochemical markers (liver
damage, cholestatis, liver syntetic capacity, iron overload, viral hepatitis and
hemolitytic index), TE and liver imaging (ultrasound, MRI-R2*).
Results: 37 adult patients were evaluated: 32% HbSS, 68% HbSβ°, median
39yrs, 46% male, median stiffness 6.6 KPa IQR: 5.1-9.1 KPa (Table). There
were not differences of stiffness value for gender, genotype. A positive moderate
correlation was observed between TE and serum ferritin values (Rp=0.43,
p=0.008), ALT (Rp=0.42, p=0.01), AST (Rp=0.49, p=0.0022), conjugated biliru-
bin (Rp= 0.59, p<0.001), ALP (Rp=0.51, P=0.002); a positive strong correlation
was observed between TE and GGT (Rp=0.79, p< 0,001), negative moderate
correlation with the albumin (Rp=-0.47, p=0.0048). We found that the group of
patients on eritroexchange programmes had a value of stiffness lower than
the group transfused (p=0.007). No significant correlation was found between
stiffness and LIC (Rp=0.11, p=0,67). For 24 patients all record were available
at time of first observation until last follow up (f.u.): 75% HbSβ°, median age
39.5yrs, male 42%, median f.u. 6 yrs, median stiffness 7.3 KPa IQR: 5.3-11.9
KPa. At the first evaluation we documented a significative positive-moderate
correlation of TE with serum ferritin (Rp=0.43, p=0,037), AST (Rp=0.54, p=
0,006), conjugated bilirubin (Rp=0.52 values 0,009) and positive-strong corre-
lation with GGT (Rp=0.68, p<0,001); these parameters except of ferritin
(Rp=0.3, p=0.15) and AST (Rp=0.39, p=0.058) have maintained the correlation
with last f.u.; albumin and ALP showed a significant strong correlation only at
f.u. (albumin Rp=-0.64, p=0.004; ALP Rp=0.7, p=0.0017). To remove factors
associated with liver fibrosis we also conducted this analysis in the subset of
patients HCV negative without liver iron overload: 26 patients, HbSβ° 73%,
median age 40.5yrs, male 50%, median f.u. 6 yrs, median values of stiffness
6.1 KPa IQR: 4.6-7.4 KPa. All significant correlations previously described were
confirmed also in this group. Three patients in this cohort presented stiffness
value according to F4 METAVIR since their first evaluation: all these patients
showed pauci-symptomatic disease in terms of VOCs, however they had a
severe hepatic damage due to sickle cell disease.
Table 1.
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Summary/Conclusions: Early identification of chronic hepatic disease some-
times pauci-symptomatic in terms of VOCs but able to lead to advanced stage
and progressive fibrosis is crucial for suitable clinical management to avoid cir-
rhosis in SCD patients. The combination of TE with specific serum markers
(GGT, ALP, albumin) is a valid tool to early detection of sickle hepatopathy.
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MICROSTRUCTURAL ANALYSIS OF RETINO-CHOROID LAYERS USING
OPTICAL COHERENCE TOMOGRAPHY IN ADULT PATIENTS WITH
SICKLE CELL DISEASE
G. Graziadei1,*, L. Dell’Arti2, G. Barteselli3, F. Viola4, L. Riva2, E. Carini5,
S. Francomm3, A. Invernizzi6, L. Duca7, M.D. Cappellini8
1Rare Diseases Center, Internal Medicine Unit, Department of Medicine and
Medical Specialties, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Poli-
clinico, 2Eye Clinic, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Poli-
clinico, Milan, Italy, Milan, Italy, 3Genentech, Inc, South San Francisco, United
States, 4Eye Clinic, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Poli-
clinico, 5Unita` Operativa di Oculistica, Ospedale Fatebenefratelli, 6Eye Clinic,
Luigi Sacco Hospital, University of Milan, 7Department of Medicine and Medical
Specialities, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
8Rare Disease Center, Internal Medicine Unit, Department of Clinical Sciences
and Community Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, University of Milan, Milan, Italy
Background: Retinopathy is one of the ophtalmological complications of
patients with Sickle cell disease (SCD), due to microvascular occlusions; occa-
sionally, proliferative sickle cell retinopathy (PSR) can lead to severe vision loss.
Aims: a. to analyze macular alterations in patients with Sickle Cell Disease
(SCD) by spectral-domain optical coherence tomography (SD-OCT), using the
automated software for retinal segmentation; b. to investigate relationship
between OCT abnormalities and the severity of proliferative sickle cell retinopa-
thy (PSR); c. to elucidate the role of potentially contributory systemic factors
on the development of macular thinning.
Methods: This is a prospective, observational case-control study. Ophthalmo-
logical evaluation, fluorescein angiography and SD-OCT were performed. Cen-
tral and temporal retinal layers were measured by the SD-OCT Automatic Seg-
mentation software. SCD eyes were divided into two groups based on the pres-
ence of visible macular thinning areas. Clinical data and blood samples were
collected.
Results: Thirty consecutive adult SCD outpatients were studied (median age
38.7±9.89 (M:F 12:18), including 9 patients with Sickle Cell Anemia (SCA), 17
with Sickle Cell β°-Thalassemia and 4 HbS/HbC. One HbS/HbC eye was not
considered due to retinal detachment and severe refractive defect. Nineteen
out of 59 eyes (32.2%) and 13 out of 30 SCD patients (43%) were noted to
have patchy areas of macular thinning on SD-OCT, mostly seen temporally to
the fovea. Among these patients, 6 had SCA, 4 had β°-Thalassemia and 3
HbS/HbC. More severe PSR was present in 16/59 eyes (29%); the prevalence
of temporal macular thinning was higher (10/16) in eyes with more severe PSR
(62.5%). Both inner and outer retinal layers thinning of the foveal region and of
the central and temporal macula was found in the overall SCD patients com-
pared with normal controls (p<0.0001). SCD eyes with patchy retinal thinning
showed a significant reduction of inner nuclear layer (INL) and outer plexiform
layer (OPL) in the temporal region. Univariate analysis revealed a significant
correlation between patchy areas of severe retinal thinning on OCT and SCD
need for transfusions, need for chelation, HbF, ferritin, and transferrin saturation
(p-value<0.10). However, the most predictive variables for retinal thinning as
assessed after multivariate regression analysis were the need of chelation
(p=0.0187) and the HbF (p=0.0775). More specifically, the odds of retinal thin-
ning is 94.2% lower when chelation is present, and the odds of retinal thinning
decreases by 12.9% when HbF increases by 1 unit.
Summary/Conclusions: In this study SCD eyes of all patients showed both
inner and outer retinal thinning in the central and temporal macula. Ischemia
caused by chronic occlusion of the deep and superficial capillary plexus could
explain the different retinal layers’ damage and the pattern of thinning. No major
statistical differences were found between the three sickle genotypes because
of small sample. Because severe retinal thinning affects visual function and
can lead to irreversible visual loss, regular ocular checkups are essential for
SCD patients.
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NON ABLATIVE TRANSPLANT CONDITIONING WITH TREOSULFAN IS
CURATIVE IN A MURINE MODEL OF SICKLE CELL DISEASE
D. Devadasan1,*, C.-W. Sun2, T. Townes2, F. Goldman3
1Pathobiology and Molecular Medicine theme, Department of Graduate Bio-
medical Sciences, 2Department of Biochemistry and Molecular Genetics,
3Department of Pediatrics, University of Alabama at Birmingham, Birmingham,
United States
Background: Hematopoietic stem cell transplantation (HSCT) for patients with
sickle cell disease (SCD) is curative, though significant toxicity from myeloab-
lative conditioning is limiting. We have previously developed knock-in mice pro-
ducing normal (AA) or sickle (SS) human hemoglobin recapitulating severe
anemia, hyposthanuria and limited lifespan found in SCD. Reduced-intensity
conditioning regimens decrease transplant toxicity and are preferable in non-
malignant disorders. Novel approaches have been proposed including targeted
depletion of stem cells (ACK2), co-stimulation blockade (anti-CD40L), and com-
bination therapy with less toxic alkylating agents (Treosulfan).
Aims: Optimize non-myeloablative conditioning in a murine model of SCD that
allows for sufficient donor RBC chimerism.
Methods: Control (AA) and SCD (SS) animals were treated with varying con-
ditioning regimens (+/- rescue with AA or SS marrow), including Treosulfan (2-
5g/kg), ACK2 (100-500ug), anti-CD40L, and low-dose radiation, alone or in
combination. Short and long-term toxicities, including survival, were monitored
over a 12 month period. Hematologic effects were determined by assaying
CBCs, reticulocytes, bone marrow (BM) cellularity and RBC chimerism (iso-
electric focusing). Myeloid/lymphoid chimerism was monitored by FACS com-
bined with droplet-digital PCR. Renal tubular function was assessed by meas-
uring urine osmolality, and moribund animals underwent necropsy to assess
organ damage.
Results: Erythroid hyperplasia was noted in the BM of SS, relative to AA mice.
Treosulfan, in a dose-dependent manner, decreased BM cellularity and induced
cytopenia in AA and SS mice. AA mice were able to tolerate Treosulfan at non-
myeloablative doses of 6g/kg. In contrast, SS mice were unable to tolerate dos-
es of 3g/kg unless RBC transfused by d+3. At 3g/kg dose, erythroid engraftment
was transient in SS transplanted mice and most often absent by 2 months post-
transplant, with only 25% of animals having sustained RBC chimerism at one
year. In SS mice achieving 50% AA in peripheral blood, fertility was preserved,
urine osmolality normalized and organ pathology was comparable to age-
matched controls. ACK2, anti-CD40L, or low-dose radiation, in combination
with Treosulfan (3g/kg), failed to improve engraftment. In contrast, increasing
Treosulfan to 3.6g/kg resulted in donor-erythroid chimerism at 3 months post-
transplant in all mice, with improvement in hematologic parameters and nor-
malization of hyposthanuria. These animals are currently being observed for
fertility, organ toxicity and survival.
Summary/Conclusions: SCD mice closely mimic human disease in phenotype
and ablative conditioning intolerance. Treosulfan, at sub-myeloablative dosing,
sustained erythroid chimerism and reversed the SCD phenotype. Our data sug-
gests that pre-transplant conditioning with Treosulfan alone may be permissive
for engraftment, in an allogeneic and gene-corrected autologous clinical trans-
plant setting.
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SILENT CEREBRAL ISCHEMIA AND THROMBOEMBOLIC EVENTS IN
SICKLE CELL DISEASE: ANALYSIS OF COAGULATION PARAMETERS
AND THROMBOELASTOGRAPHY
M. Dimopoulou1,*, M. Politou2, K. Stavroula1, D. Koutsouri2, P. Tsioutsias1,
P. Flevari1, E. Voskaridou1
1Thalassemia and Sickle Cell Disease Center, Laikon General Hospital, 2Hema-
tology Laboratory, Blood bank, Aretaieion Hospital, Athens, Greece
Background: The complications of Sickle Cell Disease (SCD) include stroke
and silent cerebral infarcts (SCI). The increased incidence of thromboembolic
events in SCD has only recently been recognized. Apart from red cell sickling
other pathogenetic mechanisms have been proposed but they have not been
clarified completely. Coagulation factors have been analysed in several studies
in SCD but very limited data exist about global coagulation assays such as
thromboelastography, which evaluates the contribution of platelets, coagulation
factors and cellular elements in clot formation.
Aims: The aim of the present study was to assess the incidence of cerebral
ischemia and TEEs in SCD patients and to investigate their pathophysiology
with analysis of coagulation parameters, including thromboelastography.
Methods: 61 adult SCD patients were included in the study and underwent
brain MRI. Measurements of fibrinogen, D-Dimers, antithrombin III, proteins S
and C were performed (SIEMENS BCS) and thromboelastography ROTEMR
was performed in order to analyse ΝΑΤΕΜ CT(Closure Time), MCF (Maximum
Clot Firmness), EXTEM CT, MCF and FIBTEM CT, MCF. Brain imaging as well
as all clotting assays were performed in steady state and not during the course
of an acute thrombotic or ischemic event
Results: The median age of the patients was 51 yrs (range 27-70), 40 of them
were female and 21 male. Abnormal findings were revealed in the brain MRI of
35/61 patients (57.4%). The findings consisted mainly of microischemic lesions.
Only 5/35 patients had a previous history of overt stroke, 1/5 TIA. In the remain-
ing 30/35 patients ischemic lesions were considered SCIs, in the abscence of
neurologic manifestations. In 3/5 patients with a previous stroke the size of the
infarcts in brain MRI was larger (with maximum diameter up to 4,5 cm). 14/61
patients had a previous history of venous TEE (23%), in 7/14 the event was pul-
monary embolism and 2/14 had recurrent TEE. 14/61 (23%) of patients had a
previous history of acute chest syndrome (ACS). In total 48/61 patients (78.7%)
were already on treatment with hydroxyurea when they underwent the analysis.
Elevated platelets were found in 22/61 patients (36%), elevated fibrinogen in
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4/61 (1.6%), positive D-Dimers in 57/59 (96.6%), decreased protein S in
10/61(16,3%) and decreased protein C σε 13/61 (21,3%). NATEM MCF was
increased in 27/61(44,3%) patients while EXTEM MCF was increased in
31/61(50.8%) patients. Patients with a history of TEE had higher mean values
of NATEM-MCF and EXTEM–MCF and those differences were statistically sig-
nifinact (p=0.023, and p=0.011 respectively). There was a statistically significant
association between the presence of ischemic lesions in brain MRI and the his-
tory of previous TEE (p=0.01). On the contrary the history of ACS was not cor-
related with the presence of ischemic lesions in MRI. Chronic Hydroxyurea treat-
ment did not correlate with the abscence of ischemic findings in brain MRI.
Among patients with ischemic lesions those who were already on chronic
hydroxyurea treatment had a shorter NATEM-CT compared to patients without
treatment. In patients with ischemic lesions in MRI and a history of TEE NATEM-
MCF and EXTEM MCF were higher (p=0.03, και 0.03, respectively).
Summary/Conclusions: The presence of microischemic encephalopathy is
very common in SCD patients and is associated with a history of TEE, which
is also frequent in SCD. There seems to be a permanent activation of the coag-
ulation mechanism in SCD. In SCD patients with SCIs and a histrory of TEE,
apart from clotting factors and natural inhibitors there seems to be a contribution
of platelets and cellular elements, possibly sickle cells. The impact of chronic





INVASIVE BACTERIAL INFECTIONS IN GAMBIAN PATIENTS WITH SICK-
LE CELL ANEMIA IN AN ERA OF WIDESPREAD PNEUMOCOCCAL AND
HAEMOPHILUS INFLUENZA TYPE B VACCINATION
G. Soothill1,*, S. Darboe2, G. Bah2, L. Bolarinde2, A. Cunnington3, S. Anderson2
1Royal Free Hospital, London, United Kingdom, 2Medical Research Council
Unit Gambia, Fajara, Gambia, 3Imperial College London, London, United Kingdom
Background: Bacterial infections cause significant morbidity and mortality in
patients with sickle cell anemia, especially in populations without reliable access
to antimicrobial prophylaxis and treatment. The longstanding use of penicillin pro-
phylaxis and vaccination for Streptococcus pneumoniae and Haemophilus influen-
zae type b in resource-rich settings has minimised the additional risk of invasive
bacterial infections associated with sickle cell anemia. However, these interven-
tions are not routinely implemented in much of Africa, despite this region having
the greatest burden of disease, with over 80% of people with sickle cell anemia
born on the continent. The Gambia has well established vaccination programmes
for pneumococcal and Haemophilus influenzae type b, which is rare in the region.
There is little data on the identity of bacterial infections in African sickle cell anemia
populations, and we believe (until this study) there were no data from countries
with comprehensive vaccination programmes against Streptococcus pneumoniae
and Haemophilus influenzae type b.
Aims: Primary: to determine the predominant pathogens causing invasive bac-
terial infections in a population of sickle cell anemia patients admitted to the
Medical Research Council Unit Gambia. Secondary: to review the character-
istics of this sickle cell anemia population. 
Methods: A retrospective analysis of the clinical and laboratory records relating
to 161 admissions of 126 patients with sickle cell anemia admitted to the Med-
ical Research Council Unit Gambia over a five-year period (between April 2010
and April 2015) when there was high coverage of pneumococcal and
Haemophilus influenzae type b vaccination.
Results: Pathogenic bacteria were cultured from blood in 11 of the 131 admis-
sions which had blood cultures taken (8.4%, 95% CI 4.5-14.1%). The most fre-
quent organism isolated was Salmonella typhimurium (6/11; 54.5%), followed
by Staphylococcus aureus (2/11; 18.2%) and other enteric Gram-negative
pathogens (2/11; 18.2%) and there was one case of Haemophilus influenzae
non-type b bacteremia (1/11; 9.1%). No cases of bacteremia caused by Strep-
tococcus pneumoniae or Haemophilus influenzae type b were identified. The
most common diagnosis causing the admission was vaso-occlusive crisis
(53/161; 32.9%), followed by infective complications including pneumonia
(16/161; 9.9%) and osteomyelitis (12/161; 7.5%). The median length of admis-
sion was five days and the median age of patients was five years (IQR: 2-13
years). A new diagnosis of sickle cell anemia was made during the admission
in just under half of patients.
Figure 1.
Summary/Conclusions: The predominance of non-typhoidal Salmonella and
other enteric Gram-negatives as the causative agents of invasive bacterial
infections in our study is striking. Despite its success in resource-rich settings,
penicillin may not be the optimal prophylaxis for sickle cell anemia patients
already vaccinated for pneumococcal and Haemophilus influenzae type b in
The Gambia. For sickle cell anemia patients with suspected bacterial sepsis,
empirical treatment must be effective against both non-typhoidal Salmonella
and Staphylococcus aureus, and account for local resistance patterns. As other
countries in the region adopt pneumococcal and Haemophilus influenzae type
b vaccination programmes, they may see a change in the spectrum of
pathogens found in sickle cell anemia patient populations. Local research may
be needed to determine appropriate antimicrobial treatment and prophylaxis
regimens for patients with sickle cell anemia.
E1488
THE ASSOCIATION OF IGF-1 AND IGFBP-3 SERUM LEVELS AND GENE
EXPRESSION WITH THE PATHOGENESIS OF INFLAMMATION IN SICKLE
CELL DISEASE
N. basut1, F. karahan2, E. Ak3, S. Ünal3,*
1Pediatri, merisin Üniversity Pediatri, 2Mersin Üniveristy Pediatric Oncology
Department, 3Mersin Üniversity Pediatic Hematology Department, Mersin, Turkey
Background: Sickle cell disease (SCD) is one of the chronic inflammatory dis-
easesSerum markers of inflammation have provided evidence for a state of
chronic inflammation in sickle cell disease (SCD). Inflammation promotes
endothelial adherence to sickle erythrocytes.
Aims:. We aimed to investigate the serum insulin-like growth factor 1 (IGF-1)
and insulin-like growth factor binding protein 3 (IGFBP-3) levels and gene
expression in the pathogenesis of inflammation in sickle cell disease and to
determine its role in painful crises.
Methods: A total of 71 patients aged 2 to 18 years, who were followed with the
diagnosis of SCD in our department, were included in the study between April
2012 and April 2013. Patients were divided into two groups; Group 1: Patients
who had a painful crisis during the study (41 patients, mean age: 11.5 years)
and Group 2: Patients who were in steady state during the study (30 patients,
mean age: 11 years). Blood samples were taken from the patients for complete
blood count, serum levels of C-reactive protein (C-RP), interleukin-1 β (IL-1β),
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), IGF-1, IGFBP-3 and
IGF-1, IGFBP-3 gene expression.
Results: When the patients in both groups were compared in terms of serum
IGF-1 level; serum IGF-1 levels were normal in all patients (100%) in group 2
and 33 patients (80.5%) in group 1, and the difference was considered to be
statistically significant (p <0.001). When the groups were compared in terms
of serum IGFBP-3 level; serum IGFBP-3 level in Group 2 was found to be sig-
nificantly lower in Group 1 (p <0.001). Also, when the patients were examined
for IGF-1 and IGFBP-3 gene expression, no significant difference was found
between the groups (Table 1). A negative correlation was found between leuko-
cyte level and IGF-1 in group 1, and IGF-1 gene expression and CRP in group
2. Serum IGFBP-3 and IL-6 levels were found to be significantly lower in
patients without any painful crisis than those with painful crisis in the last year
(p <0.05).
Table 1.
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Summary/Conclusions: The clinical manifestations of SCD were thought to
be associated only with hemoglobin polymerization for a long time. However,
recent studies have shown that SCD is a chronic inflammatory disease. The
pro-inflammatory cytokines and IGF are in a state of equilibrium in the human
body. It has been reported that IGF-1 plays a major role in the production of
NO, which is produced in the endothelium and causes a vasodilatory response,
and that it increases antioxidant systems and reduces oxidative stress, thereby
decreasing inflammation by reducing pro-inflammatory cytokines. In our study,
we found that the serum levels of IGF-1, an important growth factor that has
not been studied previously in SCD and has recently been evaluated on the
effects of inflammation, decreased in SCD patients with painful crisis compared
to patients in steady state. It was also found that the levels of inflammatory
cytokines, evaluated during the same period, such as IL-6 and TNF-α increased.
In conclusion, IGF-1 was thought to play a role especially in the pathogenesis
of acute inflammation in SCD.
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UNIVERSAL NEWBORN SCREENING FOR SICKLE CELL DISEASE:
PRELIMINARY RESULTS OF THE FIRST YEAR OF A MULTICENTRIC
ITALIAN PILOT PROJECT
M. Martella1, L. Cattaneo2, G. Viola1, S. Azzena1, A. Cappellari1, E. Baraldi3,
C. Zorloni2, N. Masera2, A. Biondi2, G. Basso1, R. Colombatti1,*, L. Sainati1
1Clinic of Pediatric Hematology Oncology, Department of Child and Maternal
Health, Azienda Ospedaliera-Università di Padova, Padova, Italy, Padova,
2Pediatric Clinic, Università degli studi Milano-Bicocca-Fondazione MBBM,
Monza, 3Neonatal Intensive Care, Department of Child and Maternal Health,
Azienda Ospedaliera-Università di Padova, Padova, Italy, Padova, Italy
Background: Sickle cell disease (SCD) is the most common monogenetic dis-
ease worldwide. Although it is most prevalent in Africa, in parts of the eastern
Mediterranean and Asia, as a result of migration, the prevalence is also con-
tinuously increasing in central and northern Europe. It is established that early
detection and appropriate prophylactic measures prevent potentially fatal com-
plications and many European countries have already introduced newborn
screening programs for SCD. In Italy it is estimated that 6.5% of the total pop-
ulation is represented by carriers of hemoglobinopathies1, nevertheless, there
isn’t a national newborn screening program for SCD nor a plan to establish it.
Selective newborn screening programs for SCD are currently active in three
regions of Italy, and a pilot universal newborn was terminated due to lack of
funding2; the benefit of universal newborn screening is still not clear n the Italian
context. Since May 2016 a pilot program of universal newborn screening for
SCD is active at the birth center of the Department of Women and Child- Health
in Padova, which has about 3,500 births a year. In September 2016 the screen-
ing program was extended to San Gerardo Hospital in Monza, also located in
Northern Italy, with centralization in Padova for samples analyses
Aims: To study the feasibility and efficacy of a universal newborn screening for
SCD and to evaluate SCD epidemiology in the areas of Padova and Monza.
To identify S gene carriers and affected newborns for a timely taking in charge
and to provide genetic counseling for the family. To reduce morbidity and man-
agement costs of children with SCD
Methods: Guthrie cards collected after parents’ informed consent, from an
unselected cohort of newborns, are analyzed by HPLC (Variant Newborn
Screening-NBS-BioRad). The abnormal hemoglobin fractions identified by
HPLC are confirmed by molecular analysis of the β-globin gene (HBB) by PCR
and sequencing of the DNA extracted from the dried blood spot. Genetic coun-
selling is offered to the families of infants carriers of the S gene, after notification
of the result; families of all infants with SCD are contacted within two months
for enrollment in comprehensive care.
Results: Over a period of nine months and five months 1364 and dried blood
spots were collected in Padova and Monza respectively. Two families in Padova
and 19 in Monza refused the test. The ethnic origin of newborns was similar in
the two sites: 64.08% were children of Italian couples, 8.21% of mixed couples
and 27.71% of foreign couples in Padova. And 69.45% were of Italian couples,
9.29% of mixed couples and 21.26% of foreign couples in Monza. None of the
collected samples has been excluded from the analysis. The main results are
summarized in Table1.
Table 1. Summary of screening results.
Summary/Conclusions: These preliminary data indicate the feasibility and
effectiveness of a multicentric universal newborn screening program in Italy.
The incidence of S abnormality is in agreement with the only previous Italian
universal newborn screening experience conducted in a single city2. Moreover,
the results confirm the high incidence of other hemoglobin variants such as
HbC, HbD and HbE. The affected children received dedicated medical care
from birth. Our preliminary data confirm and support the need for a universal
newborn screening that should be extended to the whole country.
References
1. Aguilar Martinez et al. Haemoglobinopathies in Europe: health, migration
policy perspectives. Orphanet J Rare Dis. 2014;9:97.
2. Ballardini et al. Universal neonatal screening for sickle cell disease and other
haemoglobinopathies in Ferrara, Italy. Blood Transfus. 2013; 11(2):245-9.
Performed with a grant from Team for Children.
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EXTENDING ACCESS TO CARE FOR CHILDREN WITH SICKLE CELL
DISEASE THROUGH TELEHEALTH 
J. Kanter1,*, J. Mcelligott1
1Pediatrics, Medical University of South Carolina, Charleston, United States
Background: Sickle Cell Disease (SCD) is the most common inherited blood
disorder in the United States and is highly prevalent in South Carolina. Previous
work using administrative databases have shown that 25% of affected individ-
uals live in the more rural PeeDee region and seek acute care from community
hospitals. As a result, many of these patients have to travel >90 minutes for
routine SCD care. Due to the difficulty in travel, many patients from this region
were seen less frequently which made more time-intensive interventions diffi-
cult. Hydroxyurea, the only drug FDA-approved to modify the course of SCD,
requires monthly laboratory assessments in the firstyear and every 3 months
in subsequent years. Thus, in addition to concerns with medication side effects,
the frequency of visits limits this option for individuals in rural areas with SCD.
Aims: The primary aim of this project was to evaluate the feasibility and accept-
ability of using a telehealth clinic to provide SCD care for children living in a
designated rural area. The secondary aims were to improve the clinic adher-
ence for patients living in the rural PeeDee region, decrease the burden of care
and expense of travel for affected families and improve Hydroxyurea accept-
ance and uptake.
Methods: The Medical University of South Carolina (MUSC) Center for Tele-
health agreed to sponsor the necessary equipment including the video com-
munication system, moveable camera and tele-stethoscope. A regional partner
was identified in the target area willing to host the telehealth clinic. Nurses and
Advanced Practice Providers were trained in using the equipment and also
trained in spleen palpation techniques which cannot be performed using the
telehealth system. A local hospital was also identified where routine laboratories
can be performed for children seen in the local clinic. Pediatric patients currently
seen at the central academic center (MUSC) living in this region were contacted
to assess their interest in coming to the telehealth clinic. 
Results: The pediatric SCD telehealth clinic was initiated in November, 2014
and data reflects the first 16 months of practice. There were originally 21
patients identified from MUSC of whom 4 families declined interest in partici-
pating. Two additional children with known SCD were referred from the local
pediatric group for the telehealth clinic who had been designated as “lost to fol-
low up (LTFU).” The clinics were originally scheduled monthly however three
clinics were cancelled during the first 16 months and a total of 13 clinics were
conducted. There were 64 total visits scheduled of which 50 visits were com-
pleted. The overall no-show rate was 14% (range 0-34%) and six clinics had a
no-show rate of 0%. The scheduling rate was 78% (range 60-100%). The pri-
mary aim was to assess the feasibility and acceptability of a telehealth clinic
measured by patients’ and families’ adherence to scheduled appointments. Of
the original cohort of 19 patients, 100% (19) have continued participating in
clinic (defined as attending more than 3 clinics in the 16-month period). Prior
to starting the telehealth clinic, 10 of the 19 patients had only been seen once
in the previous calendar year and 5 of those patients had not been seen in >18
months. Three new patients were started on Hydroxyurea. Two additional refer-
rals to the telehealth clinic were made during the first 13 months (young adults
with SCD who had been LTFU for over 3 years). These young adults were seen
once by telehealth and then referred to MUSC for the young adult clinic. 
Summary/Conclusions: The pediatric SCD telehealth clinic met its primary aim
and has continued monthly operations. Hydroxyurea initiation has improved and
decreased travel has been welcomed by participating families. Challenges have
included equipment issues, difficulties in post-clinic care coordination and assuring
caregivers received discharge information. Future directions include a tele-tran-
scranial Doppler program from children with SCD at risk for stroke and additional
telehealth clinics for adults with SCD that will be utilized for both routine care as
well as acute care through the state sickle cell network, (SC)2. This approach will
both harness the resources of the state to approach SCD and will also use a
technology-based approach to increase education of providers.
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Background: The incidence of the Sickle Cell Disease (SCD) has increased
in Europe because of the high rate of migration from areas in which carriers of
the sickle cell allele account for 19-27% of the entire population. Although SCD
is endemic in Southern Italy, the recent migration fluxes spread SCD all over
Italy with the number of carriers at about 6.5% of the whole population. The
distribution of SCD patients has dramatically changed. The large part of resident
immigrants are young with an high fertility rate. Neonatal screening combined
with timely diagnostic testing, parental education and comprehensive care
markedly reduces morbidity and mortality of SCD. Up to now, a national new-
born screening program for SCD is not active in Italy and only few pilot studies
have been carried out (Ballardini E et al. Blood Transfus. 2013 Apr: 11(2): 245-
9.;Venturelli D et al.. Blood Transfusion 2014; 12: 346-51.; Rolla R et al. Clin
Lab 2014; 60 (12): 2089-93).
Aims: To provide recommendation for newborn screening program for SCD in Italy.
Methods: A panel of experts was identified by Italian Society of Thalassemia
and Hemoglobinopaties (SITE) and Italian OncoHematology Pediatric Associ-
ation (AIEOP).The panel has rigorously revised the literature (from 1990 to
2016), the exhisting recommandations/guidelines of other countries where
newborn screen for SCD already exhists. The GRADE system (Grading of
Recommendations Assessment, Development and Evaluation) was used to
score levels and grades of evidence. The working group produced the draft
guideline, and the final version has been revised by external (international)
reviewers and the national patients association (UNITED).
Results: The recommendations were divided into in five sections according to
the newborn screening program as well as: 1) testing of newborns and specific
screening methods, 2) evaluation of screening results for a definitive diagnosis,
3) enrollment of affected newborns in comprehensive care programs, 4) eval-
uations of the efficacy of follow-up and interventions, and assessment of the
benefit to the patient, family, and society. The on line access for recommenda-
tions will be available for clinicians and healthcare providers. 
Summary/Conclusions: The recommendations for SCD newborn screening
program will be an important tool (i) in discussion of strategical new born
screening panel at national level; (ii) to early identify patients to be treated in
comprehensive SCD centers and (iii) to produce epidemiological data required
for future design of SCD map in Europe.
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GENETIC HEMOLYTIC MARKER IN SICKLE CELL ANAEMIA
P. Pereira Nascimento1,*, L. Souza Torres1, D. Grunig Humberto da Silva 1,
J. Viviane Okumura1, É. Belini Junior2, C. Lopes de Castro Lobo3, C. Regina
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1Departamento de Biologia, Instituto de Biociências, Letras e Ciências Exatas
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Background: The heterogeneity and complexity of the phenotypic profile
among individuals with sickle cell anemia (SCA) its one of the principals focus
of current research. The SCA, a homozygous condition for Hb S, is a hereditary
haemolytic anemia wich severe clinical consequences. The intravascular
hemolysis is a chronic clinical subphenotype and has been associated as an
independent risk factor related to complications such as pulmonary hyperten-
sion, leg ulcer and more recently with progress of vasculopathies. Researches
has already shown that the heterogeneity of the hemolytic profile can be due
to the presence of different beta S-globin gene cluster haplotypes among the
individuals, which suggests the participation of genetic factors in the charac-
terization of this subphenotype. Thus, search for genetic variants has been a
promising strategy to assist in the individualization of treatments, and favoring
clinical evolution. Recent studies showned that the presence of at least one
rs7203560 SNP allele (G) of the NPRL3 gene plays a protective role at hemol-
ysis in individuals with SCA, suggesting this variant as a genetic marker of
hemolysis.
Aims: Our objective were to evaluate the association between different geno-
types of the SNP rs7203560 and the intravascular hemolysis in patients with
SCA.
Methods: We evalueted 76 Brazilian people with SCA, all with a Bantu / Bantu
haplotype profile, and in a steady state. The patients were divided into two
groups: wich with use or without use of hydroxycarbamide (HC): 22 individuals
using (Bantu / Bantu + HC) and 54 without (Bantu / Bantu - HC), respectively.
The plasmatic hemoglobin (cell-free hemoglobin - Hb) was measured by
enzyme-linked immunosorbent assay (ELISA) to evaluated intravascular
hemolysis. The association between categorical variables (with or without use
of HC and diferents SNP genotypes) and cell-free Hb levels was performed by
univariate covariance analysis (GLM), followed by Fisher’s Post Hoc, consid-
ering the gender and age covariables. Statistic software was used and
assumed p <0.05 as significant
Results: Evaluating the recessive model (GG / GT versus TT), we found a sig-
nificant difference between the different genotypic patterns (p=0.026), and not
for HC treatment. Therefore, we performed an analysis to evaluate the participa-
tion of SNP in the variation of cell- free Hb levels and hemolysis markers com-
monly used as hemolysis parameters (relative reticulocytes, the enzymes lactate
dehydrogenase and aspartate aminotransferase and unconjugated billirubin),
and we found that the individuals genotypic profile was responsible for 50.7% of
this variation (Wilk’s λ: 0.507; F: 4.08; p-value <0.001), suggesting that the SNP
may play a role in characterizing the hemolytic profile of our patients with SCA. 
Summary/Conclusions: The SNP here studied is located in the intronic region
of the NPRL3 gene, where the main regulatory elements of the alpha globin
gene cluster (HS-48, HS-30 and HS-33) are also found. Studies have already
suggested that the protective effect of the G allele of the SNP on the hemolytic
profile may be probably related to the role of this genetic variant in the expres-
sion of the alpha globin genes. Its promissing that aditional analyzes in other
ethnic groups and models of hemolytic anemias, such as those of an acquired
character are realized. This is one of our next step in the attempt to suggest
this variant as a genetic marker capable of assisting in the characterization of
the hemolytic and prognostic profile of people with SCA.
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ASSESSMENT OF INTERNATIONAL DAY HOSPITALS/INFUSION UNITS
FOR THE EVALUATION AND TREATMENT OF SICKLE CELL DISEASE
L. De Castro1,*, J. Jonassaint2
1Internal Medicine, University of Pittsburgh Medical Center, 2Internal Medicine,
UPMC, Pittsburgh, United States
Background: A Sickle Cell Disease (SCD) Day Hospital is defined as a ”ded-
icated facility for the treatment of SCD uncomplicated painful crises, operating
on principle-based pain management”. SCD Day Hospital/Infusion Units (SCD-
DH/IU) play a positive role in improving pain management, preventing emer-
gency room visits, hospitalizations, and readmissions. No study to date has
systematically surveyed the availability, organization, diagnostic tools/therapy
provided, and number of SCD patients treated at these facilities as well as
compared these facilities’ practices based on location
Aims: To evaluated and compare availability and characteristics of key SCD-DH/IU
components with the overarching goal of enhancing and standardizing across facil-
ities, guidelines and standard of care and help supporting the development of alike
outpatient-care units at other health care institutions and countries.
Methods: A Web-based survey was developed and link to the survey sent via
email in September 2016 and January 2017, to 120 health care providers (80
in the USA and 40 in other countries) identified via the Global Sickle Cell Dis-
ease Network as caring for individuals with SCD. Responses were collected
between September 4 and February 10, 2017. Data was analyzed by descrip-
tive statistics and T tests using Graphpad. 
Results: Fifty seven surveys were completed (41% response rate) from 51
unique institutions. Responders from the USA sites, 27 (53%) were, mostly,
from long-standing sickle cell institutions in the East, West, and South. Non
USA sites, 15 (29%) included Canada, Oman, France, Kuwait, and England.
Location of nine sites (18%) was not available. Data from only 42 sites showed:
34 (80%) sites reported having a SCD-DH/IU facility. Thirty-one (73%) sites
care for 200 or more individuals with SCD, including 17(40%) caring for more
than 400 SCD patients. Self-standing units accounted for 30% of SCD-DH/IU,
while most (63%) were part of a multi-specialty unit. Only three site operated
24 hours/day, 7 days/week, while 50% of the sites functioned Monday-Friday,
8am-5pm. Half of the SCD-DH/IU sites treat 1-3 SCD patients, 34% treat 4-6
and only 8% treat more than 10 daily. Treatments a vailable at SCD-DH/IU
varied among sites. All performed blood tests, but not all were able to provide
IV hydration, IV pain management, and blood transfusions. SCD-DH/IU data
such as utilization, therapy outcomes, and admissions/readmissions were
tracked by 74% of the sites. Only 44% have standard post-discharge/follow-
up procedures, ¾ of those were Non-USA sites. Most (69%) sites provide indi-
vidualized care plans for pain management. Only 29% use Patient Controlled
Analgesia (PCA). Most 85% allowed direct hospital admissiol for patients ini-
tially evaluated in the SCD-DH/IU. Seven (19%) sites do not have a dedicated
provider (MD/PA/NP) available to triage SCD patients presenting to the SCD-
DH/IU. Twelve SCD-DH/IU sites have both a SW and a psychologist on site to
address patients’ psychosocial issues, 21 sites have only a SW, one has only
a psychologist, and six neither available. When presented with three different
clinical scenarios, sites significantly differed in services availability. Data ana-
lyzed based on geographical location, i.e. USA vs Non-USA showed similar
results independently of location; trends for higher protocols use and data
tracking in the USA sites; but higher availability of triage medical staff in Non-
USA sites. Notably, 50% of Non USA sites, only treated patients 18 years and
younger, p=.003.
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Table 1.
Summary/Conclusions: This is the first study highlighting key healthcare prac-
tice data for the small but significant number of SCD Day Hospital/Infusion
Units around the globe. Our data suggest that among institutions with SCD-
DH/IU there is no consensus regarding clinical practice or data collection. We
conclude that there is a significant need to further evaluate SCD DH/IU patient-
based value, and to develop operational standards / benchmarks to ensure
dissemination, adaptability, and sustainability of these alternative care models
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REDUCED SERUM HAEMOPEXIN LEVELS IN HAEMOGLOBIN SC
DISEASE OCCUR INDEPENDENTLY FROM THE DEGREE OF HAEMOLYSIS
F. Vendrame1,*, L. Marani1, S. Saad1, F. Costa1, K. Fertrin1
1Hematology and Hemotherapy Center, Unicamp, Campinas, Brazil
Background: In intravascular haemolysis, saturation of haptoglobin leads to
haemoglobin oxidation and the release of free haem, whose main scavenger is
haemopexin. In sickle cell mice, excess free haem has been shown to cause
vaso-occlusion that can be reversed by haemopexin, implicating that knowledge
on how haemolysis changes haemopexin production may influence the appli-
cability of clinical use of haemopexin for sickle cell disease and other haemolytic
states. Recent studies have reported reduced haemopexin levels in children
with sickle cell disease (Santiago et al., 2016) and adults with beta thalassemia
(Vinchi et al., 2016) in association with elevated haem levels, thus suggesting
haemopexin decreases due to chronic haemolysis. No data are available in
adults with milder sickling disorder haemoglobin SC (HbSC) disease.
Aims: In this study, we examined haemolytic markers, haem, and haemopexin
levels in samples from HbSC patients with varying degrees of haemolysis in
comparison with healthy subjects with no abnormal haemoglobins (HbAA
group).
Methods: Forty HbSC patients (age range 25-68 years, 15 men) and forty
HbAA controls (age range 18-66 years, 28 men) participated in this study. Exclu-
sion criteria were pregnancy, other cause of haemolysis, history of blood trans-
fusion or sickle cell pain crisis in the past 3 months. Venous blood samples
were collected for complete blood counts (Advia 2120, Siemens) and meas-
urement of lactate dehydrogenase (LDH), bilirubin (Roche Hitachi), haem
(Bioassay Systems), and haemopexin (Abcam) levels. Statistical analysis was
performed with GraphPad Prism v.5 and data are expressed as mean±standard
deviation.
Results: As expected, serum LDH, total and indirect bilirubin, and reticulocyte
counts were increased in HbSC patients (P=0.0001). Despite this, no significant
difference in total circulating haem was found between HbSC and HbAA (39±2.6
vs 35±1.8 μM, respectively, P=0.30), but haemopexin was surprisingly elevated
in HbSC patients when compared to HbAA (15,080±488 vs 8,407±684 ng/mL,
P= 0.0001), contrary to what has been reported in other haemolytic diseases.
Haemoglobin (Hb) was higher in the HbAA group when compared to the HbSC
group (15±0.2 vs 12±0.3 g/dL), and considering World Health Organization def-
initions of anaemia for men (Hb below 13g/dL) and women (Hb below 12g/dL),
20 (50%) patients in our HbSC cohort were not anaemic, thus fulfilling criteria
for compensated haemolysis. HbSC patients with compensated haemolysis
were not significantly different from their anaemic counterparts, with similar
reticulocyte counts, LDH, bilirubin, haemopexin (9,836±948 vs 7,739±813
ng/dL, P= 0.10), and total haem levels (33.92±2.4 vs 37.55±2.9 μM, P=0.30).
We also found an unexpected negative correlation between haemoglobin and
haemopexin, r=-0.42 (Pearson), P=0.007).
Summary/Conclusions: Despite the putative importance of reduced
haemopexin in the pathophysiology of sickle cell disease, HbSC patients do
not always present with haemopexin deficiency, regardless of the intensity of
the haemolytic state, and possibly to due to a lesser importance of intravascular
haemolysis. Our data support that non-anaemic HbSC patients may be equally
affected by haemolysis, but intravascular haemolysis does not predominantly
regulate haemopexin production. We suggest that excessive free haem and
low haemopexin probably represent a lesser contribution to the pathophysiology
of complications found in this subgroup of sickling disorders.
E1495
ASSOCIATION OF TOLL-LIKE RECEPTOR 2 GENE POLYMORPHISM WITH
THE INCIDENCE OF BACTERIAL INFECTIONS IN SICKLE CELL DISEASE
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Background: Despite antimicrobial prophylaxis and immunization, bacterial
infection remains a leading cause of morbidity and mortality in sickle cell disease
(SCD) patients. Functional hyposplenia/asplenia partially explains their sus-
ceptibility, since even young SCD children with functional spleen are at raised
infectious risk. Toll-like receptors (TLR), that recognize pathogen molecular
patterns, are at the forefront of immune protection. The interaction between
TLR and infectious diseases in SCD patients has never been explored. 
Aims: To evaluate if functional polymorphisms in TLR confer susceptibility/resis-
tance to infections in SCD.
Methods: 160 SCD patients followed either in France (n=104) or Senegal
(n=56) with recorded history of infections were tested for SNPs in TLR-1, TLR-
2, TLR-4, TLR-6 and TLR-10 by TaqMan 5’-nuclease assay for their association
with infectious history. Comparisons between groups were evaluated by x² or
Fisher exact T-test with Bonferroni corrections of P-value (Pc); associations
were measured by odds ratio (OR). 
Results: 76 patients were positive for at least one bacterial infectious episode
(IP) and 84 had no infection (NIP). Eleven IP had more than one episode of
infection. Median age was 25 years (range 4-49) for IP and 23 years (range 3-
52) for NIP with no distribution bias in gender (p=0.24). All patients had vacci-
nations against Streptococcus pneumoniae and Haemophilus influenza B, and
patients under 10 years had received penicillin prophylaxis. Etiological agent
was identified in 58 cases with encapsulated bacteria (EB) occurring in 35; the
most common agents consisted of Mycobacterium tuberculosis, Streptococcus
pneumoniae, Salmonella spp, Escherichia coli and Klebsiella pneumoniae.
Sites of infection included respiratory tract (n=24), bone and joints (n=21), blood
stream (n=17), urinary tract (n=11), central nervous system (n=8) and abdom-
inal (n=5). TLR-2 rs4696480 TA genotype was less represented in IP than in
NIP [45% vs 98%, OR=0.02, 95%CI=0.01-0.09, Pc<0.003] and in particular
TLR-2 rs4696480 TA genotype was significantly less frequent in the group of
patients infected by EB as compared to NIP+IP with other known etiological
agents [51% vs 85%, OR=0.19, 95%CI=0.08-0.44, Pc<0.003]. Other TLR
SNPs, genotype and haplotype showed no significant difference between
groups.
Summary/Conclusions: rs4696480 TA genotype apparently confers protection
against infections especially for EB. Given the previously demonstrated asso-
ciation of AA genotype with exacerbated expression of inflammatory cytokines
as well as association of T allele with lower expression of cytokines it is tempting
to postulate that TA genotype can be considered as a compromise between
deleterious effects of over inflammatory response (TLR-2 AA genotype) and
under response (TLR-2 TT genotype) to infectious agents. Such balanced
selection effect is probably reflected by the observed deviation from HWE. 
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HIGH PROGNOSTIC VALUE OF PRE-SCT MOLECULAR MINIMAL RESID-
UAL DISEASE ASSESSMENT BY WT1 GENE EXPRESSION IN AML
TRANSPLANTED IN CYTOLOGIC COMPLETE REMISSION
A. Candoni1,*, M.E. Zannier1, E. Bertoli1, F. De Marchi1, E. Simeone1, C. Fili’1,
D. Lazzarotto1, G. Ventura1, E. Toffoletti1, N. Rabassi1, C. D’Odorico1,
C. Comuzzi1, R. Fanin1
1Division of Hematology and SCT, University Hospital, Udine, Udine, Italy
Aims: We analyzed the outcome of allogeneic Stem Cell Transplantation (allo-
SCT) in AML patients according to molecular Minimal Residual Disease (MRD)
at the pre transplantation (pre-SCT) workup, assessed by the quantitative
expression evaluation of the panleukemic marker Wilms’ tumor gene (WT1),
according to LeukemiaNET validated method. 
Methods: 122 consecutive AML patients received allo-SCT while in cytologic
Complete Remission (cCR), between 2005 and 2016, at our Center. The medi-
an age at SCT was 53 years (18-70). The quantitative analysis of the WT1
gene expression (bone marrow samples) was available in 100% cases, both
at diagnosis (100% overexpressing WT1 with a mean of 8607±8187 copies/104
Abelson) and before allo-SCT (81/122-66% MRD-WT1-negative and 41/122-
44% MRD-WT1 positive cases at the pre-SCT workup). We evaluated post-
SCT Overall Survival (OS), Disease Free Survival (DFS) and Relapse Rate,
according to MRD-WT1 pre-SCT status.
Results: Both post-allo-SCT OS and DFS were significantly better in patients
who were MRD-WT1 negative (WT1<250 copies) at the time of SCT compared
with those who were MRD-WT1 positive (WT1>250 copies), with a median OS
and DFS not reached in the MRD-WT1 negative group and 9 and 8 months,
respectively, in the MRD-WT1 positive group (OS log-rank p<0.0001; hazard
ratio [HR]=3.9, 95% confidence interval [95% CI]=2.0-7.38; DFS log-rank
p<0.0001; HR=3.73, 95% CI=2.0-6.72). The relapse rate after allo-SCT was
15% (12/81) in pre-SCT MRD-WT1 negative cases and 44% (18/41) in MRD-
WT1 positive cases (p=0.00073). At univariate analysis, MRD-WT1 negativity
before allo-SCT and grade <2 acute GVHD were significant prognostic factors
for improved OS and DFS. However, at multivariate analysis, MRD-WT1 neg-
ativity before allo-SCT was the only independent prognostic factors for
improved OS and DFS. 
Summary/Conclusions: These data show that pre-allo-SCT molecular MRD
evaluation through WT1 expression is a powerful predictor of post-SCT out-
come (OS, DFS, relapse rate). Patients with both cCR and a MRD-WT1 neg-
ativity before allo-SCT have a very good outcome with a very low relapse rate
and better survival. The pre-SCT MRD-WT1 stratification in AML is a valuable
tool to identify patients, transplanted in cCR, who are at high risk of relapse
and who could be considered for conditioning regimen intensification and/or
for post-SCT preemptive strategies (donor lymphocyte infusion, tapering of
immunosuppression, azacitidine or new target drugs).
E1497
GOOD IMMUNOLOGICAL RECONSTITUTION IN ADULTS WITH ACUTE
LEUKEMIA AFTER ΑLFA-BETA TCR/CD19+ DEPLETED HAPLOIDENTI-
CAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
L. Prezioso1,*, S. Bonomini1, C. Schifano1, A. Monti1, I. Manfra1, A. Spolzino1,
G. Sammarelli1, L. Craviotto1, M. Sassi2, M. Soli2, F. Aversa1
1Hematology and BMT Unit, 2Immunohematology and Transfusion Unit, Parma, Italy
Background: Haplo-HSCT based on the infusion of high numbers of T cell
depleted (TCD) hematopoietic progenitor cells and no post-transplant immuno-
suppression controls both graft rejection and GvHD in patients with acute
leukemia. One major remaining issue is the delay in the post-transplant
immunological reconstitution because of the minimal residual T lymphocytes
in the graft and in vivo ATG-linked T cell depletion. Current studies are focussing
on rebuilding posttransplant immunity to improve clinical outcomes separating
GvHD from favourable donor immune responses. Selective elimination of αβ+
T cells retains in the graft NK, dendritic cells, monocytes and γδT lymphocytes.
Under this approach, a rapid immunological reconstitution and very promising
outcome have been reported in pediatric patients.
Aims: With the aims of confirming these results in adults, we tested this
approach in adults with acute leukemia.
Methods: Thirty-two patients, median age 51 years (range 19-74), with AML
(n=27) or ALL (n=5) entered to study. Twenty were in CR (12 CR1; 8 CR≥2),
12 in advanced-stage disease at transplant. Conditioning consisted of ATG
1,5mg/kg from day -13 to -10, Treosulfan 12 gr/sqm from -9 to –7, Fludarabine
30mg/sqm from -6 to -2 and Thiotepa 5mg/Kg on days -5 and -4. PBPCs from
haplo-donor (3 mothers, 9 siblings, 13 sons/daughters and 7 cousins) under-
went αβTCR/CD19+ depletion by CliniMACS. No post-transplantation immuno-
suppression was given. Ganciclovir was given over the conditioning regimen
in the 22 patients who were CMV seropositive; L-AmB was used as anti-mold
active prophylaxis over the neutropenic phase
Results: Grafts contained a median of 11x106/kg (range 5-19) CD34+ cells,
4.3x106 CD3+Tcells/kg (range 1-36), 4.9x104/kg (range 0.4-62) αβ+T cells,
4x106γδ+Tcells/kg(range 1-34), 5x104B cells/kg (range 1.5-32) and
22x106CD56+NKcells/kg (range 5-91). All patient achieved a full donor sus-
tained engraftment. Median time to reach 500 neutrophils and 20,000 platelets
was 13 (range 10-18) and 11 days (range 6-30), respectively. Two patients
developed and died from severe acute GVHD. One of them had received the
highest dose of αβ+T cells (3.7x105/kg) and the second one affected by 6GPDH
deficiency experienced a late onset hepatic GVHD. Eight patients had skin lim-
ited grade II aGVHD that required short course steroids. Only two patients
have so far developed mild cGvHD that recovered completely after steroid and
cyclosporin treatment. Tending to confirm our working hypothesis, there was a
rapid, sustained increase in peripheral blood T-cell subpopulations (Fig. 1).
Naïve and memory T-cell subsets increased signiﬁcantly over the ﬁrst year
after transplantation. B-cell reconstitution was rapid and sustained and
immunoglobulin serum levels normalized within 3 months. CMV reactivation
occurred in 9 of the 30 patients who were at risk (only 3 had 2 or more CMV
reactivations). One with unfavorable serology (donor negative into recipient
positive) developed and died of CMV disease 8 months after transplant.
Relapse was the main cause of failure (8/12 in relapse, 3/20 in CR). NRM was
15% (4/12 in relapse, 4/20 in CR), 13 patients survive at a median follow-up of
29 months (range 5-53).
Figure 1.
Summary/Conclusions: The infusion of αβ/CD19-depleted grafts confirmed
a fast immunological reconstitution also in adults. Relapse is still a major con-
cern in patients already in relapse at transplantation.
E1498
UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION CONDITIONING
WITH BUSULFAN, CYCLOPHOSPHAMIDE AND ANTI-THYMOGLOBULIN
FOR ADULT SEVERE APLASTIC ANEMIA: GOOD OUTCOME AND
PROGNOSIS ANALYSIS
Z. Xu1, L. Xu1,*, F. Wang1, X. Mo1, T. Han1, W. Han1, Y. Chen1, Y. Zhang1,
J. Wang1, Y. Wang1, C. Yan1, Y. Sun1, F. Tang1, X. Zhang1, X. Huang1
1Peking University People’s Hospital, Peking University Institute of Hematology,
Beijing, China, Beijing, China
Background: Severe aplastic anemia (SAA) is a life-threatening disorder for
which allogeneic hematopoietic stem cell transplantation (HSCT) is the avail-
able curative approach. Recently, more and more studies have focused on the
feasibility of haplo-identical transplantation in SAA patients because of donor
availability.
Aims: To evaluate the outcomes and prognosis of haploidentical hematopoietic
stem cell transplantation (HSCT) in adult patients with acquired severe aplastic
anemia (SAA), we conducted a retrospective analysis.
Methods: A total of 49 SAA adults received haplo-identical transplantation
without in vitro T-cell depletion between May 2011 and December 2016.
Patients were administered busulfan (BU), cyclophosphamide (CY) and anti-
thymoglobulin (ATG) as conditioning regimens and then bone marrow plus
peripheral blood transplantation.
Results: The patients’ median age was 25 years (ranging from 18 to 45). All
of 47 cases surviving for more than 28 days achieved donor myeloid engraft-
ment. The median time for myeloid engraftment was 13 (range, 10-21) days
and for platelet was 17.5 (range, 7-101) days with the cumulative incidence of
93.88±0.17%. The cumulative incidence of grade II-IV and III-IV acute graft-
versus-host disease (aGVHD) were 20.89±0.35% and 4.17±0.08%, respec-
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tively. For patients who survived more than 100 days, the incidence of chronic
graft-versus-host disease (cGVHD) were 14.94±0.40% and 27.40±0.77%, and
that of extensive cGVHD were 2.57±0.07% and 7.18±0.27% at 1 year and 3
year. With a median follow up of 20.1 (2.1-70.1) months for alive patients, 3-
year estimated overall survival (OS) and failure-free survival (FFS) were both
82.5±5.7%. Multivariate analysis showed hematopoietic cell transplantation-
specific comorbidity index (HCT-CI) score of ≥3 was significantly associated a
worse 3-year survival outcome (86.0% vs 50.0%, P=0.035, Hazard ratio [95%
Confidence interval]: 6.266 [1.139-34.463]).
Summary/Conclusions: Haplo-identical transplantation without in vitro T-cell
depletion conditioning including BU/CY+ATG is a feasible strategy for adult
SAA patients, with successful engraftment, acceptable GVHD, and inspiring
survival outcomes. HCT-CI might be an outcome predictor in these patients.
E1499
PLERIXAFOR EFFICIENTLY AND SAFELY MOBILIZES PERIPHERAL
BLOOD STEM CELLS: HOVON-107 RESULTS IN HLA-IDENTICAL SIBLING
DONORS AND TRANSPLANTED RECIPIENTS
G. De Greef1,*, B. van der Holt1, E. Braakman1, J. Janssen2, E. Petersen3,
V. Vucinic4, N. Thuss1, M. Grootes1, J. Cornelissen1
1Hematology, Erasmus Cancer Institute Rotterdam, Rotterdam, 2Hematology,
Vu University Hospital, Amsterdam, 3Hematology, UMCU, Utrecht, Netherlands,
4Hematology, University of Leipzig, Leipzig, Germany
Background: Plerixafor (PFX) is a reversible inhibitor of stem cell-stroma cell
interactions, by interrupting SDF-1 binding to CXCR4. A single subcutaneous
(sc) injection results in direct release of hematopoietic stem and progenitor
cells (HSPC) with limited side effects and therefore could be of advantage for
allogeneic stem cell donors.
Aims: We set out to address the feasibility of sc PFX in family donors and their
recipients. Feasibility was defined by the percentage of HLA-matched sibling
donors in whom at least 2x 106/kg CD34+ cells/kg recipient weight could be
harvested after 1 or 2 gifts of PFX (320μg/kg).
Methods: Currently, data of 23 donors and 23 transplanted patients are avail-
able, All donors (16 male; 7 female, median age: 47, range: 24-60) received
PFX sc 9-11 hours before stem cell collection. The median age in patients was
50 (21-64), diagnoses included: AML/MDS RAEB (n-9), ALL(n-3), MM (n=4),
Hodgkin/NHL (n=3), CLL (n=2), other (n=2).Transplant conditioning regimen
was non-myeloablative in 17 patients and myeloablative in 6. Grafts obtained
after the first gift PFX were analyzed for the total number of CD34+ cells, CD34
subsets: CD34+/CD45RA-/CD90+ and 90- cells, T-cells and distinct CD4+ T
cell subsets including regulatory T cells (Treg), Th1, Th2, and Th17 cells. Median
cell numbers assessed in 10 G-CSF-mobilized grafts were used as controls.
Results: Criteria for feasibility were met as in 22 out of 23 donors ≥2x 106kg
CD34+ cells were collected. PFX was administered twice in 10 donors. Side
effects CTC grade 2 occurred in 39% of donors and included gastrointestinal
(17%), headache or tingling (17%), fatigue/myalgia (17%). CTC grade 3 fatigue
was observed in 1 donor; in 2 donors grade 3 clotting occurred occurred during
the leukapheresis procedure. All side effects resolved. The median number of
CD34+ cells in the graft was 189 x 106 (range:106-548) after PFX versus 438
x 106 (range:360-840) with G-CSF. Within the CD34+ cells, 31% CD34+/45-
/90+ cells were present after PFX vs 14% after G-CSF. With PFX the median
number of CD3+ cells in the graft was 22.4 (11-57) x109 versus 12.8 (7.6-21)
x109 after G-CSF. CD4/CD8 ratios were similar. The percentages of T-reg within
the CD4+ cells were 6.3% (2.7-10.4) after PFX and 5.8% (2.6-10.9) after G-
CSF. The Th1 cells within the PFX grafts were 24.2% (3-40.7) vs 16.6% (2.5-
27.5) with G-CSF. The Th2 and Th17 cells after PFX and G-CSF were, respec-
tively, 2.5% (0.4-7.5) versus 2.3% (0.5-4.4) and 1.3% (0.2-25.9) versus 1.4%
(0.2-5). The unmanipulated grafts were infused according to local protocol and
contained a median of 3.5x 106/kg CD34+ cells (range:1.9-6.5). All patients
engrafted with prompt recovery of granulocytes >0.5x 109L at a median of 19
days (0-27) and platelet recovery >50 x 109L at day 13 (0-23). Acute graft
versus host disease (GVHD) grade 1-4 was observed in 6 out of 23 patients,
including 2 with grade 3 and no grade 4. Chronic extensive GVHD was
observed in 9 patients.
Summary/Conclusions: Stem cell mobilization by sc PFX is feasible in HLA
identical sibling donors with limited side effects and results in sufficient numbers
of CD34+ cells for transplantation. While absolute numbers of CD34+ cells
were higher after G-CSF mobilization, the subset of phenotypic stem cells was
similar after both types of mobilization. No graft failures were observed and all
23 patients showed prompt recovery of neutrophils and platelets. So far, despite
the infusion of higher numbers of T-cells, no increase of GVHD was apparent.
E1500
A FEASIBILITY STUDY OF THE FULL OUTPATIENT CONDUCT OF
HEMATOPOIETIC TRANSPLANTS IN PERSONS WITH MULTIPLE SCLE-
ROSIS EMPLOYING AUTOLOGOUS NON-CRYOPRESERVED PERIPHER-
AL BLOOD STEM CELLS
G.J. Ruiz Argüelles1,*, A. Leon Peña1, M. Leon Gonzalez1, A.K. Nuñez Cortés1,
J.C. Olivares Gazca1, J. Vargas Espinosa1, E. Medina Ceballos1, Y. Cantero Fortiz1,
J.A. Arizaga Berber1, M.S. Torres Priego1, A. Ruiz Arguelles1, M. Ruiz Arguelles1,
R. Ruiz Delgado1, G. Ruiz Reyes1, M. Priesca Marin1, G. Ruiz Delgado1
1Hematologia, Centro de Hematologia y Medicina Interna, Puebla, Mexico
Background: With the goal of immune system reset, autologous hematopoietic
stem cell transplantations have been done in patients with multiple sclerosis (MS).
Aims: With the goal of immune system reset, autologous hematopoietic stem
cell transplantations have been done in patients with multiple sclerosis (MS).
Methods: 131 consecutive patients with MS were autografted in a single center
using non-frozen peripheral blood stem cells, on an outpatient basis and con-
ditioning with cyclophosphamide (Cy) and rituximab. The protocol was regis-
tered in ClinicalTrials.gov identifier NCT02674217. The PBSC mobilization
schedule was done with Cy and Filgrastim (G-CSF). Intravenous Cy (50mg/Kg)
was delivered on days -11 and -10. Sucutaneous G-CSF (10ug/Kg/BID) was
delivered on days -9 to -1. The apheresis procedure was performed on day -2.
The apheresis objective was to reach at least 1 x 106 viable CD34+ cells/Kg.
As outpatients and after collecting the PBSC, intravenous Cy (50mg/kg) was
delivered over a 120 minute period, on days -2 and -1 followed by MESNA
(1000mg/m2 over a 180 minute period). After the intravenous Cy, oral
ondasetron, oral cotrimoxazole, oral fluconazole and oral acyclovir were used
in all patients until granulocytes were greater than 0.5x109/L. After the recovery
of the granulocytes, patients were given rituximab (375mg/m2 over a 3 h period)
and subsequently rituximab (100mg) every two months over a 12-month period.
The cumulative dose of Cy is 200mg/Kg.
Results: 80 females and 51 males were included; median age was 47 years.
28 have PPMS, 42 RRMS, and 61 SPMS. All procedures were started on an
outpatient basis and two persons were admitted to the hospital during the pro-
cedure. In order to obtain at least 1x106/Kg viable CD34 cells, one to four
apheresis were performed (median 1). Total number of viable CD34+ cells
infused ranged between 1 and 9.6x106/Kg (median 2.2). Patients recovered
above 0.5 x109/L absolute granulocytes on median day 9 (range 6 to 12). Two
individuals needed red blood cells but none needed platelet transfusions. There
were no transplant related deaths and the 125 month overall survival of the
patients is 100%. In a subset of 78 persons followed for 3 months or more the
EDSS (Expended Disability Status Scale) was assessed three months after
the graft and means diminished from 5.2 to 4.9. The EDSS score improved in
33 patients (42.3%), remained stable in 29 (37.17%) and worsened in 16
(20.51%). Best results of EDSS were found in Relapsing Remitting (82%) and
Primary Progressive (80%) type of MS compared to Secondary Progressive
(71.4%).
Figure 1.
Summary/Conclusions: It is possible to conduct autotrasplants for patients
with MS employing non-frozen peripheral blood stem cells and outpatient con-
duction. Additional information is needed to assess the efficacy of these proce-
dures in the treatment of patients with MS. 
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VEDOLIZUMAB IN STEROID REFRACTORY INTESTINAL GRAFT-VER-
SUS-HOST DISEASE
A.E. Myhre1,*, J.D. Kristiansen1, K.E.A. Lundin2, L.T.N. Osnes3, D.J. Warren4,
G.E. Tjønnfjord1, T. Gedde-Dahl1, Y. Fløisand1
1Hematology, 2Gastroenterology, 3Immunology, 4Medical Biochemistry, Oslo
University Hospital, Oslo, Norway
Background: Steroid refractory intestinal graft-versus-host-disease (GvHD) is
a serious complication after allogeneic stem cell transplantation (allo-SCT),
and treatment options are limited. We have previously described successful
treatment of this condition with the antibody vedolizumab, targeting the homing
of allogeneic T-cells to the intestinal mucosa by inhibiting the binding of T-cell
integrin α4β7 to mucosal addressin MadCAM-1.
Aims: Explore outcome of all patients treated with vedolizumab in our department.
Methods: Prospective case series of 13 patients with steroid refractory gas-
trointestinal GvHD. Patients received 300mg of intravenous vedolizumab at
weeks 0, 2 and 6, followed by infusions every 8 weeks if deemed necessary.
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Patients were endoscopically evaluated at time of GvHD diagnosis and follow-
up. Treatment characteristics are provided in table 1.
Results: All 13 patients experienced clinical responses, which were confirmed
by endoscopies and in mucosal biopsies. 10 patients (77%) achieved a clinical
response within 28 days, and half of these were complete responses. At last
follow-up 10 patients (77%) had achieved sustained complete responses, 2
patients (15%) had responded partially and 1 patient (8%) suffered disease
progression. 7 patients (54%) were alive after a median follow up of 35 weeks.
The causes of death were transplantation related toxicity, GvHD in other target
organs and infectious complications. Increased relative counts of CD25++
CD127low regulatory T-cells prior to treatment were observed in peripheral
blood of 7 of 9 evaluable patients, and the relative counts decreased in all 7
patients during follow-up.
Table 1.
Summary/Conclusions: Our results indicate that vedolizumab may effectively
treat steroid refractory cases of intestinal GvHD and is well tolerated. The
mechanism of action is believed to be inhibition of allo-reactive T-cells inter-
acting with intestinal endothelial cells. It is unclear why regulatory T-cells were
initially increased in our steroid refractory GvHD patients and subsequently
normalized. This might initialle reflect a response to the alloreactive inflamma-
tion and subsequent redistribution to affected tissues and/or its resolution after
successful treatment. 
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RISK FACTORS, OUTCOMES AND CHARACTERIZATION OF ‘AUTOLOGOUS
GRAFT VERSUS HOST DISEASE’: THE MAYO CLINIC EXPERIENCE
T. Anagnostou1,*, J. Paludo1, M.M. Patnaik1, M.R. Litzow1, D.A. Gastineau1,
N. Duma1, F.K. Buadi1, L.F. Porrata1, W.J. Hogan1, G. Goyal1, J.S. Lehman1,
S.K. Hashmi1, S.S. Kenderian1
1Hematology/Medical Oncology, Mayo Clinic, Rochester, United States
Background: Graft versus Host Disease (GVHD) is a common complication
of allogeneic stem cell transplantation (SCT) which is caused by the recognition
of recipient antigens by the donor T lymphocytes. Acute GVHD remains a major
cause of morbidity and mortality and half of the cases are refractory to steroids.
The development of GVHD after autologous SCT (ASCT) is a poorly under-
stood phenomenon. While some experts suggest that such an entity does not
exist, some ASCT recipients develop clinical and histo-pathological changes
similar to GVHD after allogeneic SCT.
Aims: In this analysis, we aimed to elucidate the factors that affect the out-
comes of patients with autologous GVHD.
Methods: This is a retrospective analysis of patients that received ASCT at
Mayo Clinic between January 2006 and December 2015. Autologous GVHD
was defined as the development of clinical and histo-pathological findings
indicative of GVHD in ASCT recipients, as determined by pathology review.
Survival was estimated and compared using the Kaplan Meier and Log Rank
tests. The study was approved by the institutional review board.
Results: Between 2006 and 2015, 3,891 consecutive patients underwent
ASCT. Of these, 35 patients (0.9%) developed symptoms suggestive of GVHD
warranting biopsies. In 19 of these 35 patients (54%), the histopathological
changes were consistent with GVHD. The most common underlying disease
in patients who developed GVHD was multiple myeloma (14 patients, 73.7%)
and the most common conditioning regimen used was melphalan (16 patients,
84.2%). The median age at ASCT was 61.9 (range 49.2-72.6) years and the
median time from disease diagnosis to ASCT was 3.1 (0.3-9.6) years. The
median number of prior therapeutic regimens was 2 (range 1-7). GVHD man-
ifested with gut involvement in all 19 patients, skin involvement in 8 patients
(42.1%) and liver involvement in 2 patients (10.5%). The median time to symp-
tom onset was 11 (range 3-80) days and the median time to GVHD diagnosis
was 12 (range 2-162) days. Most patients (14, 73.7%) had grade 3 or 4 GVHD
and the clinical grading correlated with the histopathologic grading in all
patients. All but one patient received steroids with an average dose of 0.6-
2.2mg/kg prednisone equivalents. The median time to symptom resolution was
15 (range 3-162) days and 14 patients (73.7%) achieved a complete resolution
of symptoms. The median overall survival (OS) from the time of ASCT was not
reached and 53% of patients were alive 3 years after ASCT. Of the 19 patients
diagnosed with autologous GVHD, 5 (26.3%) died due to complications of
GVHD or its treatment. Delay in initiation of steroids beyond 1 week was asso-
ciated with lower response rates to treatment (30.8% vs 69.2%, p=0.03), longer
duration of symptoms of GVHD (median 28 vs 4 days, p=0.02), and a trend
towards worse 1-year OS (64.5% vs 83.3%, p=0.1). Higher steroid doses
(>1mg/kg) were associated with a trend towards better complete response
rates (76.9% vs 23.1%, p=0.5), although this difference did not reach statistical
significance.
Table 1.
Summary/Conclusions: Our findings suggest that autologous GVHD is asso-
ciated with significant mortality and early initiation of treatment with steroids
results in improved outcomes. Further studies into the mechanisms of the dis-
ease are warranted.
E1503
CNS DEMYELINATION AFTER HAPLO-HSCT AND ITS ASSOCIATION
WITH THE IGG INTRATHECAL SYNTHESIS INDEX AND ANTI-MYELIN
OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY IN CEREBROSPINAL
FLUID
X. Zhao1, Q. Wang1, J. Zhang1, X. Zhu1, Y. He1, L. Xu1, W. Han1, H. Chen1,
Y. Chen1, F. Wang1, J. Wang1, Y. Zhang1, X. Mo1, Y. Chen1, Y. Wang1,
Y. Chang1, L. Xu1, K. Liu1, X. Huang1, X. Zhang1,*
1Peking University Institute of Hematology, Peking University People’s Hospital,
Beijing, China
Background: Haploidentical haemopoietic stem cell transplant (haplo-HSCT)
is an upfront and effective therapy for haematological patients, but it usually
has many complications such as neurological complications. As one of the
neurological complications following haplo-HSCT, immune-mediated demyeli-
nating diseases of the central nervous system (CNS) seriously affect the patient
quality of life. However, the incidence, risk factors and pathogenesis of CNS
demyelination are not very well understood.
Aims: To analyse the incidence, risk factors, and prognosis of CNS demyeli-
nation after haplo-HSCT.
Methods: A study was conducted in 1,526 patients who underwent haplo-
HSCT between January 2013 and June 2016. The definition of CNS demyeli-
nation during haplo-HSCT was confirmed by neurologic signs, MRI abnormality
corresponding to the neurologic signs, abnormal CSF studies and the presence
of systemic GVHD or the response to immunosuppressive therapy (Grauer O
et al. Brain. 2010; 133(10): 2852-2865, Chronic graft versus host disease.
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Page 243-51, 2009, Thomas’ Hematopoietic Cell Transplantation. Page 766-
75, Fifth Editon, 2016, Polman C H et al. Ann Neurol. 2011; 69(2): 292-302).
Patients who did not meet these criteria and were determined to have CNS
infection (bacterial, fungus, and viruses), neurotoxicity or malignancy relapse,
based on clinical and laboratory findings, were excluded. The CSF immunoglob-
ulin index includes BBB permeability, the IgG index, the CSF IgG intrathecal
synthesis index, CSF and blood myelin basic protein, CSF and blood anti-
myelin basic protein antibody, CSF and blood anti-myelin oligodendrocyte gly-
coprotein antibody.
Results: Thirty patients developed CNS demyelination after haplo-HSCT. The
cumulative incidences of the diseases at 100 days, 1 year and 2 years post
transplantation were 0.6%, 1.6% and 2.3%, respectively. The mean age at the
time of presentation was 26.5 years (range, 10-52 years), and the mean time
from transplant to the onset of neurologic symptoms was 216 days (range, 17-
844 days). Nineteen patients received a corticosteroid pulse, five patients
received immunoglobulin, and six patients received supportive treatment and
an increase in immunosuppressive therapy. The symptoms improved in all
patients. The mean duration from the time of improvement to deterioration was
5 days (±4). In univariate analysis, we found that BBB permeability and the
CSF IgG intrathecal synthesis index were related to the occurrence of CNS
demyelination (p<0.1). In multivariate analysis, the CSF IgG intrathecal syn-
thesis index (OR=1.017, 95% CI: 1.003-1.031, p=0.019) and CSF myelin oligo-
dendrocyte antibody (OR=12.059, 95% CI: 1.141-127.458, p=0.038) were inde-
pendently associated with the onset of CNS demyelination. We also studied
the possible pathogenesis of CNS demyelination. Immune reconstitution (the
cell proportion of CD19+B cells, CD3+T cells, CD4+T cells), the count of leu-
cocytes, lymphocytes, monocytes and platelets, as well as the level of
immunoglobulins A, G and M +30 days, +60 days, and +90 days after HSCT
showed no significant differences between CNS demyelination and no demyeli-
nation (P>0.05). The probabilities of overall survival showed no significant dif-
ferences between patients with and without demyelination.
Summary/Conclusions: The CSF IgG intrathecal synthesis index and CSF
anti-myelin oligodendrocyte glycoprotein antibody are independently risk factors
for the onset of CNS demyelination after haplo-HSCT and have no influence
on long-term survival. Immune reconstitution may not be pathogenesis of CNS
demyelination.
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BASELINE CREATININE CLEARANCE AND ALBUMIN ARE POWERFUL
RISK FACTORS FOR ALLOGENEIC TRANSPLANTATION RELATED
MORTALITY
R. Shouval1,*, N. de Jong2, J. Fein1, E. Braakman2, A. Broers2, J. Kuipers2,
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Background: The course following allogeneic hematopoietic stem cell trans-
plantation (HSCT) varies between individuals. Baseline comorbidities, com-
monly scored by the Hematopoietic Cell Transplantation-Comorbidity Index
(HCT-CI), are important determinants of transplant risk. However, their prog-
nostic utility varies and only partially accounts for transplantation-related mor-
tality (TRM). Standard pre-HSCT laboratory carries objective physiologic infor-
mation which can be used for TRM risk estimation.
Aims: Determine the value of pre-HSCT estimated creatinine clearance (CrCl),
albumin, and alkaline phosphatase (Alk-p) for TRM prediction.
Methods: The study population included 1,217 patients from two European
centers. Indications for transplantation and conditioning regimens were diverse.
Donors were either HLA-matched sibling donors (54%), matched unrelated
donors (30%), or 9/10 HLA-mismatched unrelated donors (15%).The impact of
CrCl, albumin, and Alk-p on TRM was evaluated in a univariate and multivariate
analysis, adjusted for age, HCT-CI, disease status, donor-recipient sex mis-
match, donor type, cytomegalovirus serostatus, and conditioning intensity.
Relapse was considered a competing event for TRM. The predictive benefit of
adding the laboratory markers to the HCT-CI score was estimated by calculating
the area under the receiver operating curves (AUC) of TRM prediction models,
with and without the markers.
Results: Patients had a median age of 55 years and HCT-CI scores of 0 (24%),
1-2 (39%), and >=3 (37%). A cut-off of CrCl<60 ml/min, albumin<3.5 g/dl, and
Alk-p>180 IU/l corresponded with 8.8%, 8.3%, and 6.5% of the population,
respectively. CrCl and albumin were associated with increased risk and higher
cumulative incidence of day-100, 1-year, and 2-year TRM, regardless of
whether they were continuous or categorized (Figure-panel a). A similar pattern
was observed with Alk-p, except for day-100 TRM. In a multivariate analysis, a
CrCl<60 ml/min and albumin <3.5 g/dl were consistently among the top risk
factors for early and late term TRM. Hazard ratios for 2-year TRM of CrCl<60
ml/min and Albumin <3.5 g/dl were 2.00 (1.37-2.95) and 2.329 (1.58-3.43).
Interestingly, age did not meet statistical significance in models incorporating
these biomarkers, suggesting they strongly reflect patients’ physiological status.
Alk-p was dropped out in the multivariate analysis. Prediction models for day-
100 and 2-years TRM, based only on HCT-CI, had AUCs of 56.4 and 58.6,
respectively. The introduction of both albumin and CrCl, separately or combined,
resulted in incremental improvement in AUC, topping at 66.1 (+17% increase)
and 63.2 (+8% increase), for day-100 and 2-years TRM, respectively (Figure-
panel b). The improvement was maintained in all conditioning and donor sub-
groups.
Figure 1.
Summary/Conclusions: Pre-transplantation CrCl and albumin are powerful
risk factors for TRM. Deviations from normal ranges were frequent in our cohort,
making them useful prognostic markers. We report for the first time the role of
CrCl in HSCT prognostication, rather than the traditional HCT-CI cut-off of Cre-
atinine >2mg/dL, which is rare in HSCT population (<1% in our cohort). We
also corroborate albumin’s important prognostic role. Incorporation of these
simple biomarkers can improve pre-transplant risk stratification and potentially
be used as a tool for treatment personalization.
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CYTOGENETIC AND MOLECULAR RISK FACTORS AT DIAGNOSIS ARE
OVERCOME BY WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT
MINIMAL RESIDUAL DISEASE ASSESSMENT IN ADVANCED ACUTE
MYELOID LEUKEMIA PATIENTS
F. Guolo1,*, P. Minetto1, P. Minetto1, M. Clavio1, F. Galaverna2, D. Guardo1,
M. Clavio1, D. Guardo1, E. Coviello1, N. Colombo1, N. Colombo1, F. Ballerini1,
F. Ballerini1, M. Miglino1, C. Di Grazia2, A.M. Raiola2, R.M. Lemoli1, M. Gobbi1,
M. Miglino1, R.M. Lemoli1, M. Gobbi1, A. Bacigalupo2
1Clinic of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, 2Division of Hematology and Bone Marrow Transplantation, IRCCS
AOU San Martino-IST, Genova, Italy
Background: Allogeneic bone marrow transplantation (BMT) offers the only
chance of cure for patients with advanced acute myeloid leukemia (AML). High
levels of pre BMT minimal residual disease (MRD) have been reported to predict
relapse risk in patient transplanted in first complete remission (CR). WT1
expression levels and multicolor flow cytometry (MFC) are the most common
tools to evaluate MRD.
Aims: Here, we analyzed the role of pre-BMT MRD assessment as predictor
for the post-transplant relapse risk in patient transplanted beyond first CR.
Methods: We retrospectively analyzed the outcome of 92 consecutive AML
patients receiving allo-BMT in 2nd (CR2) or 3rdCR (CR3). Pre-BMT MRD was
evaluated by WT1 expression and MFC. Median age at transplant was 45
years. Disease phase was CR2 in 63 patients (68%) and CR3 in 29 (32%).
Risk group according to European Leukemia Net (ELN) at diagnosis was low
in 28 patients (30%), intermediate in 44 (48%) and high in 20 (22%). Sixty-six
patients (71%) received myeloablative conditioning, whereas 26 (29%) were
conditioned with reduced intensity regimen. Stem cell source was HLA-identical
sibling in 18 (20%), haploidentical (HAPLO) in 24 (26%) and alternative donor
in 50 (54%). Median follow-up was 64 months (95% CI 39.8-88.2 months). A
positive MFC MRD was defined by the presence of at least 1x10-3 residual
leukemic cells at four or eight (since 2011) color flow-cytometry. WT1 copy
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number/Abl copy number 250x104 was used as cut-off value for abnormal WT1
expression.
Results: Relapse occurred in 30 patients (33%) and two years non-relapse
mortality was 29%. Three-year estimate of OS was 47.9% (median19 months).
The survival probability was significantly affected by donor source (better for
HAPLO, p<0.05), ELN risk at diagnosis (better for ELN low risk, p<0.01), MRD
status before BMT measured with any method (p <0.01 for WT1-based MRD,
p<0.03 for MFC based MRD) and CR status at BMT (better for CR2, p<0.05).
Specifically patients transplanted in a MRD negative status had comparable
OS irrespectively of ELN risk at diagnosis (2-years OS of 62.2% and 52.7%
among MFC MRD negative patient with ELN risk low or intermediate/high,
respectively, Fig.1). The predictive value of MRD resulted independent from
all other analyzed variables, although patients with positive MRD undergoing
HAPLO BMT had a slightly better outcome. Multivariate OS analysis revealed
that MRD status (evaluated by any method) was the only independent predictor
of OS (p <0.05 for both). Pre BMT MRD was also a strong predictor of cumu-
lative incidence (CI) of relapse in competitive risk analysis (p<0.01 and p<0.03,
respectively, for WT1 and MFC MRD). Multivariate CI of relapse analysis
showed that donor source and MRD significantly influenced relapse risk (p
<0.05 and <0.01, respectively).
Figure 1.
Summary/Conclusions: Pre transplant MRD evaluated by both WT1 and
MFC on bone marrow samples is a reliable predictor of relapse risk and OS
which can overcome the ELN risk stratification at diagnosis. Pre BMT MRD
negative patients had a significantly better OS, compared with MRD positive
ones. MRD positive patients showed an increased risk of relapse, irrespectively
of having a low ELN risk at diagnosis. In patients undergoing BMT beyond
CR1 pre-BMT MRD status confirms its prognostic relevance and may help in
selecting stem cell source. Pre-BMT MRD evaluation may also help in choosing
pre-emptive therapeutic strategies.
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Background: Allogeneic stem cell transplantation (allo-SCT) represents an
increasingly important curative treatment strategy in adults with acute myeloid
leukaemia (AML), consequent upon both the increased availability of unrelated
donors and the advent of reduced intensity conditioning (RIC) regimens.
Although optimal outcomes are achieved in patients transplanted using an
unrelated donor matched at 10/10 HLA A, B, C, DRB1, DQ alleles it remains
the case that many undergo transplantation using a donor matched at only
9/10 HLA alleles.
Aims: There are limited data concerning the impact of specific HLA mismatches
on patient outcome and we therefore interrogated the EBMT database in order
to characterize the impact of mismatch on transplant outcome
Methods: 937 patients with AML in CR1 or CR 2 underwent transplantation
utilizing a RIC regimen using a 9/10 mismatched unrelated donor between
2001-2015. Of these 264 were transplanted using a donor mismatched at HLA-
A, 127 were mismatched at HLA-B, 292 mismatched at HLA-C, 180 mis-
matched at HLA-DQ and 74 mismatched at HLA- DRb1. 85% of patients
received in vivo T cell depletion.
Results: The 2 year leukaemia free survival (LFS) for the whole cohort was
45% and the 2 year overall survival (OS) was 50%. The corresponding non-
relapse mortality was 26% and relapse incidence 29%. 30% of patients devel-
oped Grade 2-4 acute GVHD and 14% chronic extensive GVHD. In Cox analy-
sis age, adverse karyotype and patient CMV seropositivity were correlated with
decreased LFS and OS. There was no significant difference in LFS or OS
between patients transplanted from donors mismatched at HLA-A, B, C, DRB1
or DRQ respectively. Of note mismatch at HLA-C was correlated with a lower
incidence of acute GVHD but this did not translate into a survival difference.
Patient:donor CMV mismatch was associated with a marked increase in trans-
plant related mortality and concomitant reduction in LFS and OS in all groups
studied.
Summary/Conclusions: To our knowledge this is the largest to date studying
the impact of specific HLA mismatch on the outcome of adults undergoing a
RIC allograft from an adult unrelated donor. Recipients of HLA-A, B, C, DRB1
and DQ mismatched allografts demonstrated equivalent outcomes.
Patient:donor CMV disparity is an important adverse prognostic factor in HLA
mismatched transplants. These data have the potential to inform donor selec-
tion in allo-mandatory adults with AML undergoing a RIC allograft who lack a
10/10 matched donor. 
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PRE-EMPTIVE THERAPY WITH IFN-Α-2B FOR ACUTE LEUKEMIA
PATIENTS WITH HIGH RISK OF RELAPSING TENDENCY POST ALLO-HSCT
X. Lin1, A. Wang1, F. Chen1, X. Ma1, A. Sun1, X. Zhu1, H. Qiu1, Z. Jin1,
S. Xue1, D. Wu1,2, X. Tang1,2,*
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Background: Relapse still remains the most frequent cause of treatment failure
and mortality. According to the data of CIBMTR, relapse has become the lead-
ing cause of death following allo-HSCT. The high risk patients with more
advanced disease, have a relapse rate of 40–80%.Therefore, prevention and
treatment of relapse post allo-HSCT is the most likely approach to improve
survival of these patients. It is well known that IFN-α had been widely used in
the field of antitumor. Recently it is shown that IFN-α also play an important
role in immune modulation to enhance the effect of GVL.
Aims: To determine the efficacy and safety of IFN-α-2b pre-emptive therapy
for acute leukemia(AL) patients with relapsing tendencies after allogeneic
hematopoietic stem cell transplantation (allo-HSCT).
Methods: Retrospectively analyzed 986 acute leukemia patients undergoing
allo-HSCT from Jan ,2006 to Mar ,2014 in our hospital. After allo-HSCT, 986
AL patients were periodically monitored the minimal residual disease(MRD)
including: bone marrow smear, leukemia-associated immunophenotype (LAIP),
leukemia specific or related fusion genes, and donor chimerism through mul-
ti-parameter detection to evaluate disease status. Patients were given IFN- a
-2b 3 million units / day by subcutaneous injection for preemptive treatment
once a relapse tendency was detected, such as: increasing proportion of blast
in bone marrow between 3–5%, or MRD>1.0×10-3, or leukemia specific fusion
gene transfrom negative to positive, or dynamic incressing copy number of
WT1 more than 200 copies/104 abl, or decreasing of donor chimerism(≤ 90%).
There were 98 patients who presented increasing tendency of MRD and were
enrolled in this study. Among them, 31 patients received IFN-α-2b pre-emptive
therapy, and 67 patients received non-IFN-α-2b therapy such as: withdraw
immunosupressant, traditional DLI or DC-CIK immunotherapy.
Results: There were no significant differences in disease characteristics
between two groups. For the 31 patients who received IFN-α-2b pre-emptive
therapy(IFN group), the median time of IFN-αtreatment was 60 days (range:
5–720 days), Twenty five patients had responsed to the treatment without pro-
gressing to hematological relapse (response rate 80.6%). 2 patients developed
to hematological relapse again after temporary response; 3 patients had no
response and eventually progressed to hematological relapse. Regarding
67patients who received non-IFN-α-2b therapy(non IFN group), 22 patients
responsed to the treatment (RR 32.8%), 45 patients failed to the treatment and
progressed to hematological relapse at a median time of 35 (range: 6–940)
days, There was significant difference of RR between two group(P=0.000). 31
patients of IFN group tolerate well and no patient terminated therapy due to
side effects. During the treatment of IFN, 18 patients(58.1%) developed GVHD:
6 patients 19.4% with aGVHD and 14-45.2% with limited cGVHD. The median
follow-up time was 21-4.5-78.5 months. 22 of 31 cases of IFN group maintained
disease-free survival. The 5-year overall survival rate (OS) and the leukemia-
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free survival rate (LFS) of IFN group were 47.0%±13.9% and 38.7%±13.1%
respectively. However, the 5-yr OS and LFS of non IFN group were
14.5%±10.7% and12.5%±9.4% respectively.The difference were significantly
(P=0.000,P=0.002 respectively). Patients with GVHD had significantly better
response than patients without GVHD (88.9% vs 53.8%, P=0.043, P <0.05).
Summary/Conclusions: IFN-α-2b pre-emptive therapy can effectively prevent
high-risk patients with relapsing tendencies for disease progression post allo-
HSCT. Further large-scale investigation is warranted.
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Background: Several attempts to predict mortality after autologous stem cell
transplantation (ASCT) have been made, like Hematopoietic Stem Cell Trans-
plant Comorbidity Index (HCT-CI) score, originally described by Sorror for allo-
geneic HSCT. There is no score applicable to the clinical practice that integrates
comorbidities with other patient characteristics.
Aims: To describe a comprehensive score that combines comorbidities with
other factors and analyse the impact of this score in OS and NRM after ASCT
in a cohort of patients transplanted in Argentina.
Methods: We retrospectively reviewed a cohort of 1453 medical records of
adult patients who received an ASCT in our centres between October 2002
and August 2016, for Multiple Myeloma or Lymphoma. We compared NRM and
Relapse with CI, OS with KM and long term MVA with fine-Gray or Cox regres-
sion. We included in the score all the factors that remained significant after
MVA for NRM, and assigned a score of 1 if the Hazard ratio (HR) was around
2 (1.5-2.5) and 2 if it was around 3 (2.6-3.5). 
Results: Mean age was 50.7 years (range 15-74); 57% were male, 52% had
Multiple Myeloma, 29% Non Hodgkin Lymphoma and 19% Hodgkin Lymphoma.
Forty-seven percent were in CR, 50% in PR and 3% SD/PD; 14% received
three or more chemotherapy lines before transplant (heavily pre-treated).
Regarding comorbidities, 62% had low HCT-CI score (score 0), 26% interme-
diate risk (1-2) and 12% high risk (≥3). Median follow up was 1.1 years (range
100 days-12 years). Early NRM (day 100) was 2.8%, long term NRM (1-3 years)
was 4.3-5.8% and OS (1-5 years) was 89-67%. On multivariate analysis risk
factors that showed an independent significant impact with NRM and were
included in the score were: male patients (1 point), age ≥55 years (1 point),
heavily pre-treated (1 point), HCT-CI ≥3 (1 point) and Non Hodgkin Lymphoma
(2 points). One hundred and seventy eight patients (12%) had a score of 0,
469 (32%) 1, 381 (26%) 2, 241 (17%) 3, 137 (9.5%) 4 and 47 (3.5%) ≥5. The
hazard ratio for NRM increased proportionally with the score (1 2.2, 2 3.5, 3
4.6, 4 10.1 and ≥5 32.3). Patients were grouped as low risk (LR) with a score
0 (12%), intermediate risk (IR) score 1-3 (75%) and high risk (HR) >3 (13%).
The score was significantly associated with early NRM (day 100: 1.1% vs 1.9%
vs 9.2 for LR, IR and HR respectively), long term NRM (1-3 years 1.1-1.1% vs
2.9-4.1% vs 15-20%, respectively, p<0.001) (figure 1) and OS (1-5 years 93-
78% vs 91-67% vs 73-50% respectively, p<0.001) (figure 2). No significant
association was observed with relapse rate.
Figure 1.
Summary/Conclusions: We found that GATMO score had a significant asso-
ciation with long term OS due to an increase in NRM. All end-point risks
increased proportionally with the score. This observation should be confirmed
in larger series. 
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A RETROSPECTIVE ANALYSIS OF PATIENT CHARACTERISTICS AND
RISK FACTORS FOR ADMISSION TO THE INTENSIVE CARE UNIT (ICU)
FOLLOWING HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM
CELL TRANSPLANT (HDC-ASCT)
L. Jeyaraj Nallathambi1,*, T. Freeman1, S. Williams1, V. Potter1, R. Benjamin1,
K. Cuthill1, S. Devereux1, P. Patten1, D. Yallop1, S. kassam1
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Background: HDC-ASCT is a standard treatment modality for patients with
myeloma and lymphoma. It carries a low, but significant risk of morbidity and
mortality. Given that the upper age limit for patient selection continues to
increase, it is important to have an objective way of assessing patient suitability
for HDC-ASCT. Admission to the ICU is an ominous clinical event post HDC-
ASCT and carries a high risk of mortality. There are currently no standard
assessment tools to predict the risk of morbidity and mortality. 
Aims: To review the incidence and cause of ICU admission in patients receiving
HDC-ASCT and identify pre-transplant factors that may be predictive of trans-
plant morbidity and mortality.
Table 1.
Methods: All patients receiving HDC-ASCT for myeloma and lymphoma at
King’s College Hospital, London between July 2015 and December 2016 were
included. Data cut off was 1st February 2017. Electronic patient records were
used to collect data on baseline patient characteristics, comorbidities and per-
formance status. The Charlson comorbidity index (CCI) and haematopoietic
cell transplantation comorbidity index (HCTCI) were calculated. Univariate
analysis of variables was performed using Graph Pad Prism version 5.03. A p
value <0.05 was considered significant.
Results: 169 patients received HDC-ASCT. The median age was 58 years
(23-74). Patient characteristics are shown in the table (See Image). Thirteen
patients (7.6%) required ICU admission at a median of 14 days post cell infusion
(range 5-85), with all patients having a neutrophil count <1x109/l. The reasons
for ICU admission included sepsis (n=12), severe mucositis/colitis (n=11), renal
failure (n=7), hypotension and arrhythmias (n=7), respiratory distress (n=4),
liver failure (n=1). The median number of days spent in ICU was 9 (range 2-
16). Five patients required single organ support (non-invasive ventilation, 2;
inotrope support, 2; haemofiltration; 1) and 2 required only management of
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fluid balance. Six patients required multi-organ support (non invasive ventila-
tion/intubation, haemofiltraion and inotropic support) and all died. Four patients
died within 30 days of HDC-ASCT and had not engrafted neutrophils at the
time of death. Two patients died late at day +120 and day +93 post HDC-ASCT.
The latter had both successfully engrafted neutrophils but subsequently
became neutropenic. Causes of death were neutropenic sepsis (3), cerebrovas-
cular event (1), hepatitis E (1) and autologous graft versus host disease (1).
By univariate analysis none of the baseline parameters, comorbidities or con-
ditioning regimens were predictive of ICU admission. The only parameter for
which there was a trend for significance was baseline cardiac ejection fraction
(EF) <50% (p=0.05). Three patients that required ICU has an EF <50% and 2
were on heart failure medications prior to HDC-ASCT. Two of these 3 patients
died.
Summary/Conclusions: In this retrospective series, the risk for ICU admission
and death following HDC-ASCT was 7.6% and 3.5% respectively. All patients
requiring more than one organ support died. The only predictor of ICU admis-
sion may be baseline ejection fraction but this would need confirmation in a
larger series. Patient selection remains challenging with no definite tool to pre-
dict ICU admission or death.
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AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BENDA-EAM
(BENDAMUSTINE, ETOPOSIDE, CYTARABINE, MELPHALAN) IN
AGGRESSIVE NON HODGKIN AND HODGKIN´S LYMPHOMA
T. Noesslinger1, R. Simanek1,*, M. Panny1, E. Koller1, M. Moestl1, F. Keil1
1Hematology and Oncology, Hanusch Krankenhaus, Vienna, Austria
Background: Autologous Stem Cell Transplantation (ASCT) is standard of
care in relapsed diffuse large B-cell lymphoma (DLBCL) and other lymphopro-
liferative disorders (relapsed Hodgkin´s disease, 1st line mantle cell lymphoma
(MCL) or T-cell lymphoma). BCNU, Etoposide, Ara-C, Melphalan (BEAM) is a
standard conditioning regimen, but BCNU is known to be associated with inter-
stitial pneumonia (range 2 to 20%) and an increased risk of death compared
with other regimens.
Aims: Therefore a less toxic conditioning protocol might improve the results in
lymphoma patients. Bendamustine showed promising results in B- and T-cell
lymphoma and dose escalation is safe and feasible. Here we report promising
results with bendamustine replacing BCNU in the BEAM regimen described
as Benda-EAM, previously published in a phase two dose finding study (Visani,
Blood 2011). 
Methods: Fourty-one patients with Hodgkin’s (HL)(n=9) or Non-Hodgkin (n=32)
lymphoma were consecutively treated with Benda-EAM (bendamustine on two
consecutive days at a dose of 200mg/m2 per day). Eleven patients were diag-
nosed with DLBCL, ten patients with MCL, six patients with follicular lymphoma
(FL), three patients with T-cell lymphoma (TCL) and two patients with greyzone
lymphoma (GZL). Twenty-seven patients were male and fourteen female with
a median age of 52 years (range 22-71) and 25% were above the age of sixty.
The median lines of previous therapies were 2 (range:1-4).
Figure 1.
Results: All patients had chemosensitive disease and before transplantation,
34 patients (83%) were in complete (CR) and 7 (17%) in partial remission (PR).
A median number of 4,20*106CD34+ cells/kg (range: 1,60-13,30) were infused.
All patients showed engraftment with a median time to achieve an absolute
neutrophil count >1*109/L of 10 days (range 8-13) and to platelets >20*109/L
of 12 days (range 7-110). The median time of fever was 5 days (range: 0-15).
The median number of days on G-CSF was 7 (range 4-15) and in median 2
units of red blood cells and 5 units of platelets had to be transfused. The median
duration of hospitalization was 25 days.The most common grade 3 and 4 tox-
icity during the whole treatment period were diarrhea (n=10), mucositis (n=7),
infections (n=9) and febrile neutropenia (n=6), followedby nausea (n=4) and
cardiologic toxicities (n=3). No severe pulmonary or renal toxicities were
observed and no transplant related mortality occurred. After a median follow-
up of 43 months 22 patients (56%) are still in CR, while 19 patients (44%)
showed progression after a median time of 7 months after transplantation
(range 2-29 months). Until today nine patients received an additional allogeneic
transplantation. Eleven patients (27%) have died (3 DLBCL, 3 HL, 2 MCL, 1
GZL, 1 TCL and 1 FL), all due to lymphoma progression. Thus the 1- and 2-
year PFS are 73.2% and 57.9% and the 1- and 2-year OVS 85.4% and 79.4%,
respectively.
Summary/Conclusions: In conclusion Benda-EAM is feasible with a quite
promising outcome. Currently an international randomized phase II trial com-
paring Benda-EAM with BEAM is recruiting. So far fifty-five of 110 planned
patients are randomized and first results are expected for 2018.
E1511
THROMBOTIC MICROANGIOPATHY WITH CONCOMITANT AGVHD AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: RISK
FACTORS, SEVERE OUTCOME AND TREATMENT EXPERIENCE
X. Liu1, Q. Wang1, Y. He1, X. Zhu1, J. Zhang1, L. Xu1, W. Han1, H. Chen1,
Y. Chen1, F. Wang1, J. Wang1, Y. Zhang1, X. Mo1, Y. Chen1, Y. Wang1, Y. Chang1,
L. Xu1, K. Liu1, X. Huang1, X. Zhang1,*
1Peking University Institute of Hematology, Peking University People’s Hospital,
Beijing, China
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)-
associated thrombotic microangiopathy (TA-TMA) is a significant complication
after allo-HSCT. acute graft-versus-host disease (aGVHD) is one of the risk fac-
tors for the occurrence of TA-TMA, and some patients may develop both.
Although there has been sufficient information available on aGVHD and TA-TMA,
TMA with concomitant aGVHD after allo-HSCT remains not well understood.
Aims: To explore the possible risk factors for the occurrence and mortality of
TMA with concomitant aGVHD and to investigate outcomes and treatments of
this disorder after allo-HSCT.
Methods: This study was based on patients who underwent allo-HSCT at
Peking University People’s Hospital from January 2008 to December 2016.
We included patients who showed refractory diarrhea and underwent
enteroscopy and biopsy. The diagnosis of TA-TMA and aGVHD were mainly
made based on the probable-TMA criteria (Byung-Sik Cho et al. Transplantation
2010;90:918-926) and endoscopic appearance and histologic findings
(Thomas’ Hematopoietic Cell Transplantation, Fifth Edition, 2016), respectively.
The potential factors affecting TMA with concomitant aGVHD occurrence and
markers associated with the death of these patients were identified using uni-
variate and multivariate Cox analysis. The cumulative incidence of relapse,
non-relapse mortality (NRM), overall survival (OS) and disease-free survival
(DFS) were estimated using the Kaplan-Meier method and were compared by
the log-rank test.
Results: Among all 3,992 allo-HSCT recipients, 276 patients showed refractory
diarrhea and underwent enteroscopy; of these patients, 50 (1.93%) were diag-
nosed with TMA with concomitant aGVHD and were enrolled in the case group,
and 150 (5.80%) were enrolled in the control group. The two groups matched
well with regard to baseline characteristics. Based on the nested case-based
control study, grade III-IV aGVHD (P=0.000), AKI (P=0.033) and hypertension
(P=0.028) were significant independent risk factors associated with the occur-
rence of TMA with concomitant aGVHD. Considering the case group only, our
data suggested that a haptoglobin level below normal (P=0.013), a maximum
volume of diarrhea 2500 ml/d (P=0.015) and bloody diarrhea (P=0.049) were
significant markers for death in both univariate and multivariate analysis. Among
the case group and control group, the 9-year OS rates were 52% and 81%
(P=0.001), respectively; the 9-year DFS rates were 50% and 65% (P=0.345),
respectively; the 9-year cumulative incidence rates of NRM were 44% and
16% (P=0.001), and those of relapse were 6% and 19% (P=0.010), respec-
tively. To further study the treatments of patients with TMA and aGVHD, we
calculated the OS and found that plasma exchange (PE) use (PE=0, 62.5%;
PE 0, 38.9%; P=0.156) had no significant influence on the patient outcome.
Summary/Conclusions: This study demonstrated that patients diagnosed
with TMA with concomitant aGVHD after allo-HSCT had a significantly lower
OS, higher NRM, and a lower incidence of relapse. The risk factors associated
with the occurrence and mortality of TMA with concomitant aGVHD may help
us assess the prognosis of patients. The findings also suggested that PE use
may be ineffective to these patients.
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SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY
QUANTITATIVE RT-PCR IN CORE BINDING FACTOR AML ON TRANS-
PLANTATION OUTCOMES
B. Oran1,*, K. Patel 2, D. Marin1, Q. Bashir1, S. Ahmed1, A. Alousi1, S. Ciurea1,
J. Chen1, K. Rezvani1, U. Popat1, E. Shpall1, R. Champlin1
1Stem Cell Transplantation and Cellular Therapy, 2Hematopathology, The Uni-
versity of Texas MDACC, Houston, United States
Background: Despite the well-defined role of minimal residual disease (MRD)
monitoring in core binding factor (CBF)-AML after intensive chemotherapy,
there has been, to date, a paucity of data assessing the clinical utility of MRD
monitoring before allogeneic stem cell transplantation (HSCT).
Aims: We investigated the prognostic impact of MRD monitoring by real-time
quantitative polymerase chain reaction (RT-PCR) for RUNX1/RUNX1T1 and
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CBFB-MYH11 transcript levels at HSCT on transplant outcomes in AML patients
with CBF abnormalities. 
Methods: We included 61 AML patients with CBF at diagnosis that underwent
their first HSCT in complete remission (CR) from January 2007 through May
2016. Of 61, 19 (31%) had t(8;21) chromosomal translocation and 42 (69%)
inv(16)/t(16;16). Diseae status at HSCT was CR1 in 19 (31%) and CR2 in 42
(69%) patients. Hematopoietic stem cell sources were peripheral blood (n=32),
bone marrow (n=22) and cord blood (n=7). Conditioning regimen was mye-
loablative in 38 (62%) and reduced intensity in 23 (38%) patients. Donors were
matched related (MR) in 24 (38%), matched unrelated (MUD) in 26 (43%), and
haploidentical in 4 (7%). Quantitative real-time PCR analysis was performed
on reverse-transcribed RNA for the CBFB-MYH11(Type A) and RUNX1/
RUNX1T1 fusion transcripts. Fusion (RUNX1/RUNX1T1 and CBFB-MYH11)
and internal control (ABL1) transcript levels were detected simultaneously and
quantitative results were expressed as the percent ratio of fusion to ABL1 tran-
script levels ([fusion/ABL1]×100).
Figure 1.
Results: MRD by RT-PCR at HSCT was evaluable in 43 patients (70%) and
36 of 44 (84%) had evidence of MRD (MRDpos). RT-PCR was <0.1% in 22
patients, ≥0.1% and <1% in 7 and ≥1% in 8 patients. Overall survival (OS) and
leukemia free survival (LFS) at 4-years was 100% and 85.7% in 7 MRDneg
and 65.4% and 61.6% in 37 MRDpos patients respectively (p=0.09 and p=0.3).
The incidence of disease progression was comparable between MRDneg and
MRDpos patients, 15% vs 16% at 4 years. There was no increase in the risk of
progression with higher levels of MRD by RT-PCR (p=0.6). None of the other
variables were prognostic for OS, LFS and disease progression.There was no
transplant-related mortality observed in MRDneg group while the incidence
was 22.6% at 2 years in MRDpos group.
Summary/Conclusions: Durable complete remissions can be achieved in
CBF AML patients with HSCT even if they are MRDpos at HSCT. 
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LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION
IN ADULT SEVERE APLASTIC ANEMIA WITH ABNORMAL CYTOGENETICS
AT DIAGNOSIS
S.-E. Lee1,*, S. S. Park1, Y.-W. Jeon1, J.-H. Yoon1, B.-S. Cho1, K.-S. Eom1, Y.-
J. Kim1, S. Lee1, C.-K. Min1, H.-J. Kim1, S.-G. Cho1, D.-W. Kim1, W.-S. Min1,
J. W. Lee1
1Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of
Korea, Seoul, Korea, Republic Of
Background: Cytogenetic abnormalities (CAs) have been reported at the time
of diagnosis of acquired aplastic anemia (AA), up to approximately 4-15%.
Considering evolution into clonal hematologic disorders and difficulty between
AA and hypoplastic MDS, clinical implications of CAs in AA is important.
Aims: In this study, we investigated long-term outcome of allogeneic stem cell
transplantation (SCT) in adult severe AA (SAA) patients with abnormal CAs at
diagnosis.
Methods: Total of 19 patients with abnormal CAs at diagnosis who underwent
allogeneic SCT at our institution between 2003 and 2015. Morphologically
hypoplastic bone marrow with dysplastic cells was considered as hypoplastic
MDS and excluded. Clonal CAs were defined as 2 or more cells showing the
same chromosomal gain or structural abnormality, or 3 or more cells with the
same chromosomal loss.
Results: The most frequent abnormality was trisomy 8 (n=11), followed by
inversion 9 (n=2). Other CAs included t(3;3), t(5;18), t(1;11), t(1;8), t(1;19), -Y,
+Y, -7, +9. Two patients had two or more CAs. Seven male and 12 female
patients with a median age of 41 years (range, 20-59 years) were included.
Patients had received SCT from HLA-matched sibling (n=12), unrelated (n=5),
or haplo-identical donor (n=2). After a median follow-up of 66.3 months (range
12.3-156.3), the 5-year estimated OS rates were 94.7±5.1%. One patient died
of acute GVHD. All patients engrafted and three patients developed delayed
graft-failure. The incidence of acute GVHD (≥grade II) and chronic GVHD
occurred in 4 (21%) and 2 (11%) patients, respectively. Among 16 patients with
available follow-up data of cytogenetics after transplantation, 14 patients dis-
appeared CAs with donor-type normal chromosome. However, in two patients,
same CAs was observed after transplantation; in one patient with three CAs
[+8, +9, and t(1;19)], same CAs was sustained at the most recent follow-up of
23.1 months without morphologically dysplastic cells. In another patient with
t(5;18), CA did not detected at 39.2 months but reappeared at 67.5 months,
and this CA had disappeared again at 79.6 months. None of patients developed
MDS or AML after SCT.
Summary/Conclusions: This study showed that long-term transplant out-
comes in SAA patients with CAs at diagnosis were excellent. Moreover, CAs
at diagnosis did not affect the clinical outcome including clonal evolution to
other hematologic malignancies after SCT in adult SAA.
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PROGNOSTIC VALUE OF PET/CT PRIOR TO AUTOLOGOUS HCT IN
RELAPSED / REFRACTORY LYMPHOMA
M. Damlaj1,2,*, G. Syed3, G. Gmati1, H. Salama1, K. Abuelgasim1, M. Al-Zahrani1,
S. Ghazi3, A. Hejazi3, A. Alaskar1
1Oncology, King Abdulaziz Medical City, 2King Abdullah International Medical
Research Center (KAIMRC), 3King Abdulaziz Medical City, Riyadh, Saudi Arabia
Background: Positron Emission Tomography /Computed Tomography
(PET/CT) is emerging as a powerful prognostic tool in the management of
Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). A number of
retrospective single center cohorts have reported that a positive PET/CT prior
to autologous Hematopoietic Stem Cell Transplantation (HCT) is an adverse
factor associated with higher relapse risk. However, important heterogeneity is
noted in these studies due to differences in timing of PET/CT prior to HCT as
well as different metabolic activity threshold (i.e. Deauville ≤2 vs ≤3). At our
institution, we perform PET/CT within 4 weeks prior to HCT and after all intend-
ed salvage therapy is administered. 
Aims: We sought to further investigate the prognostic value of PET/CT in
relapsed / refractory lymphoma patients prior to HCT. 
Methods: After due IRB approval, patients who received autologous HCT at
our institution for relapsed / refractory lymphoma between 2010 - 2016 were
identified. All variables were retrospectively extracted. PET/CT reports were
reviewed and metabolic activity was assigned per Deauville criteria. Patients
with primary CNS lymphoma were excluded. Refractory disease indicates dis-
ease progression prior to completing planned first line therapy. Categorical and
continuous variables were compared using Chi-squared and Wilcoxon tests,
respectively. Time to end point analysis was computed using the method of
Kaplan and Meier with log ranks. Competing events were computed using
Grey’s method considering non relapse mortality as a competing event for
relapse. Analysis was computed using JMP software, version 11.
Figure 1.
Results: A total of 53 patients underwent HCT for relapsed / refractory lym-
phoma with 80% of the cohort having HL. Median follow up of the entire cohort
was 26.8 months (0.6-70.5). Cumulative incidence of relapse (CIR), progression
free survival (PFS) and overall survival (OS) at 2 years was 37.9%, 56.1% and
74.8%, respectively. A. PET/CT status pre-HCT: A total of 47 patients had pre-
HCT PET/CT and were evaluable for further analysis. Median time from PET
to HCT was 17 days (6-59). There were no significant differences between the
cohorts based on age at HCT, gender, underlying diagnosis, relapsed/refractory
status, time to relapse, number of salvage regimens, number of salvage cycles,
use of immunotherapy as part of salvage and post HCT immunotherapy use
as maintenance. Considering Deauville ≤3 as complete metabolic response
(CMR), 2-year CIR was 16.7% vs 60.5% for PET negative vs PET positive
patients (p=0.0021). 2-year PFS was significantly higher in PET negative vs
PET positive patients at 72% vs 39.5%, respectively (p=0.035). 2-year OS was
similar irrespective of PET status (p=0.49). Considering Deauville ≤2 as CMR,
there was only a trend towards decreased CIR for metabolically negative scans
(p=0.096). Significance of these results remained unchanged after excluding
NHL cases. B. Relapse post HCT: Median time to relapse post HCT for patients
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was 109 days (55-395) vs 271 days (55-449) for PET positive vs PET negative
patients, respectively. Mortality post relapse was 50% with the remaining
patients achieving long term disease control with immunotherapy alone (57%),
allogeneic HCT (29%) and combination chemotherapy (14%). Median follow
up of patients with long term disease control was 1093 days (177-1271). Caus-
es of death post HCT relapse was progression of disease in all cases.
Summary/Conclusions: Despite inherent limitations of this analysis, we pres-
ent a number of important observations: 1. Deauville score ≤3 is an appropriate
cutoff for metabolic activity pre-HCT and is associated with significantly
decreased relapse and improved PFS. 2. PET positive status will better identify
patients who may benefit from maintenance strategies post HCT. 3. Time to
relapse in PET positive patients is significantly shorter highlighting the need
for early initiation of pre-emptive maintenance therapy. 4. Long term disease
control is possible in a high proportion of patients despite relapse post HCT.
These important observations require further study. 
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COMPARISON OF OUTCOMES AFTER DONOR LYMPHOCYTE INFUSION
WITH OR WITHOUT PRIOR CHEMOTHERAPY FOR MINIMAL RESIDUAL
DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
X.-D. Mo1,*, X.-H. Zhang1, L.-P. Xu1, Y. Wang1, C.-H. Yan1, H. Chen1,
Y.-H. Chen1, W. Han1, F.-R. Wang1, J.-Z. Wang1, K.-Y. Liu1, X.-J. Huang1
1Peking University People’s Hospital, Institute of Hematology, Beijing, China
Background: Minimal residual disease (MRD) can predict impeding relapse
after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thus,
MRD-directed immunotherapy may be a reasonable option for relapse prophy-
laxis. Chemotherapy prior to donor lymphocyte infusion (Chemo-DLI) can further
decrease the tumor burden, and immunotherapy should preferably be started
in patients with leukemia with relatively low tumor burden. However, some
patients who are MRD-positive may refuse or are unable to receive chemother-
apy prior to DLI. Few studies have compared the clinical outcomes of Chemo-
DLI and DLI alone in patients who were MRD-positive after allo-HSCT.
Aims: The efficacy of DLI without chemotherapy was investigated and com-
pared with that of Chemo-DLI in patients who were MRD-positive after allo-
HSCT.
Methods: We enrolled 115 consecutive patients who received either DLI (n=20)
or Chemo-DLI (n=95) during the same period. For each DLI recipient, three
recipients matched for age at the HSCT, underlying diseases, and the year of
the HSCT were randomly selected from the Chemo-DLI cohort (n=60).
Results: The 2-year cumulative incidence of severe acute graft-versus-host
disease (GVHD) and chronic GVHD was comparable between the groups. Fif-
teen (75.0%) and 47 (78.3%) patients in the DLI and Chemo-DLI groups turned
MRD negative, respectively. The 2-year cumulative incidences of relapse and
non-relapse mortality after intervention were 30.7% versus 39.6% (P=0.582)
and 10.3% versus 6.0% (P=0.508) in the DLI and Chemo-DLI groups, respec-
tively. The 2-year probabilities of disease-free, overall, and GVHD-free/relapse-
free survival after preemptive intervention were 58.9% versus 54.3% (P=0.862),
69.3% versus 78.1% (P=0.361), and 44.4% versus 35.1% (P=0.489) in the
DLI and Chemo-DLI groups, respectively. In multivariate analysis, the inter-
vention method did not significantly influence the clinical outcomes.
Summary/Conclusions: In summary, preemptive DLI alone may be effective
for patients who are MRD-positive and may be a potential alternative for
patients who refuse or are unable to receive Chemo-DLI after HSCT.
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DIFFERENTIAL PROGNOSTIC IMPACT OF HEMATOPOIETIC CELL
TRANSPLANTATION SPECIFIC COMORBIDITY INDEX (HCT-CI) ON
TRANSPLANT OUTCOMES BY STEM CELL SOURCES
Y. Adachi1,*, K. Sagou1, Y. Yamaga1, N. Fukushima1, K. Ozeki1, A. Kohno1
1Department of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan
Background: The hematopoietic cell transplantation specific comorbidity index
(HCT-CI) has been proposed to predict the probability of nonrelapse mortality
(NRM) and overall survival (OS) in allogeneic hematopoietic stem cell trans-
plantation (HSCT). However, the impact of HCT-CI on clinical outcomes in sin-
gle unit umbilical cord blood transplantation (UCBT) has not been investigated
extensively.
Aims: The purpose of this single-center retrospective study was to investigate
the validity of HCT-CI in UCBT.
Methods: We retrospectively analyzed a cohort of 144 consecutive adult
patients who received first allogeneic HSCT between July 2008 and December
2016 in our hospital. One patient was excluded from this analysis due to inad-
equate data regarding comorbidities before HSCT. Patients were divided into
the UCBT group (n=90) or the non-UCBT group (n=53). Two-year OS and 1-
year NRM were defined as the primary endpoints.
Results: Pre-transplant parameters, such as gender, diagnosis, and the phase
of disease, were comparable between the two groups. The median follow-up
durations were 562 days and 627 days for the non-UCBT group and the UCBT
group, respectively. The most frequent comorbidity was mild hepatic comor-
bidity (22%), followed by mild or severe pulmonary comorbidities and active
infections (16%). For the non-UCBT group, 2-year OS rates for HCT-CI scores
of 0, 1-2 and ≥3 were 70% (n=43), 63% (n=30), and 31% (n=17), respectively
(P=0.014). For the non-UCBT group, 1-year NRM rates for HCT-CI scores of
0, 1-2 and ≥3 were 10%, 17%, and 35%, respectively (P=0.026). For the UCBT
group, 2-year OS rates for HCT-CI scores of 0, 1-2 and ≥3 were 78% (n=26),
46% (n=13), and 69% (n=14), respectively (P=0.38). For the UCBT group, 1-
year NRM rates for HCT-CI scores of 0, 1-2 and ≥3 were 9.0%, 15%, and 7.1%,
respectively (P=0.75). In multivariate analysis, the HCT-CI score of ≥3 was sig-
nificantly associated with lower OS (p=0.005; hazard ratio=2.8) and higher
NRM (p=0.015; hazard ratio=3.1) for the non-UCBT group, but not for the UCBT
group. There was no significant difference in the cumulative incidences of grade
2 to 4 acute GVHD between the non-UCBT group (41%) and the UCBT group
(33%, P=0.51). Similarly, there was no significant difference in the cumulative
incidences of grade 3 to 4 acute GVHD between the non-UCBT group (6.8%)
and the UCBT group (6.1%, P=0.80). The cumulative incidence of extensive
chronic GVHD was significantly higher in the non-UCBT group compared with
the UCBT group. (38% vs 3.8%, P<0.001) Although not significant, patients in
the non-UCBT group were more likely to have the systemic steroid therapy
compared with those in the UCBT group. (54% vs 34%, P=0.064).
Figure 1.
Summary/Conclusions: UCBT showed good OS with the low incidence of
NRM even in patients with high HCT-CI scores. These results indicate that a
single unit umbilical cord blood might be a promising stem cell source for
patients with multiple comorbidities. Further studies are needed in order to val-
idate these results.
E1517
LOW DOSE POSTTRANSPLANTATION CYCLOPHOSPHAMIDE CAN
ENHANCE THE PROTECTIVE EFFECT OF ATG /G-CSF ON GVHD:
RESULTS OF A PHASE II PROSPECTIVE TRIAL
Y. Wang1,*, Y.-J. chang1, X.-J. huang1
1Peking university people’s hospital, beijing, China
Background: Anti-thymocyte globulin (ATG)/granulocyte colony-stimulating
factor (G-CSF)-represented regimen produces essentially universal engraft-
ment with limited relapse and favorable survival, albeit with relatively high rates
of graft-versus-host disease (GVHD), especially after HCT from maternal donor
or collateral relatives. While use of high-dose, post-transplant cyclophos-
phamide (PT/Cy) results in low rates of GVHD and favorable immune recon-
stitution, although with higher rates of relapse and somewhat high rates of graft
failure. Thus, novel strategies are needed to refine each approach: under Bei-
jing protocol including ATG and G-CSF, reducing GVHD without abrogating
GVL effect is a major priority. 
Aims: In order to benefit patients at high risk of developing GVHD without
abrogating engraftment and GVL effects, we sought to develop a novel proce-
dure in TCR haplo-HCT with intensified conditioning containing ATG and G-
CSF followed by lower-dose of PT/Cy. In addition, the current study attempt to
establish a murine model and focus on Treg cells to clarify the immunological
mechanisms for GVHD prevention by the new strategy. 
Methods: We performed a prospective pilot study of HLA haploidentical cell
transplantation (HCT) from maternal or collateral donors with intensified con-
ditioning including G-CSF and ATG, followed by two lower doses of PT/Cy
(14.5mg/kgx2 doses; designated as Group A). Outcomes were compared with
those of 160 controls from matched-pair analysis who undergone haploidentical
HCT from other donors than mother or collateral relatives at the same time
period (Group B) as well as with those of 46 historical controls who undergone
HCT from mother or collateral relatives at earlier time period (Group C). In
addition, the current study attempt to establish a murine model and focus on
Treg cells to clarify the immunological mechanisms for GVHD prevention by
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the new strategy. Trial registration: The study is registered at www.clinicaltrial.gov
as NCT02412423.
Results: We found that low dose PT/Cy combined with ATG could alleviate
GVHD in mice and could increase the number of Treg cells while have no
effects on CD4+ or CD8+ T cells. A total of 40 patients with myelodysplastic
syndrome (MDS) and leukemia undergoing haploidentical HCT from maternal
or collateral donors were enrolled in the study. The cumulative, 100-day inci-
dence of acute GVHD, grades II-IV, in Group A (17%; 95% CI, 5%>29%) was
significantly lower than both that in Group B (33%; CI, 25%>41%; P=0.04) and
that in Group C (56%; CI, 42%>70%; P<0.001). The 1-year probabilities of
NRM (5%; CI, 0%>12%), OS (84%; CI, 68%>100%), and LFS (83%; CI,
70%>96%) in Group A were similar to that in Group B, but was significantly
lower than that of Group C (28%; CI, 15%>41%; P=0.006; 65%; CI, 51%>79%;
P=0.02; and 65%; CI, 51%>79%; P=0.04; respectively). 
Summary/Conclusions: Low dose PT/Cy can enhance the protective effect
of ATG /G-CSF on GVHD. Conditioning with ATG/G-CSF and low-dose PT/Cy
might be a feasible option for patients undergoing HLA haploidentical, T-cell
replete HCT, in particular for those with high GVHD risk.
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HEPATITIS B REACTIVATION IN HEMATOPOIETIC STEM CELL TRANS-
PLANTED PATIENTS: 22 YEARS EXPERIENCE OF A SINGLE CENTRE
A. Murt1, T. Elverdi2, A. Salihoglu2, A.E. Eskazan2, M.C. Ar2, S. Ongoren Aydin2,
Z. Baslar2, T. Soysal2,*
1Internal Medicine, 2Hematology, Cerrahpasa Medical Faculty, Istanbul, Turkey
Background: Reactivation of inactive viruses is an important complication of
haematopoetic stem cell transplantation (HSCT). Suggestion of strategies to
combat this problem will probably decrease transplant related mortality and
morbidity.
Aims: Aim of this study is to evaluate the clinical progress and risk factors for
reactivation in HSCT patients who were infected with hepatitis B virus (HBV)
with the prospect of developing recommendations for a better clinical care. 
Methods: Patient files and electronic records of 561 patients who received
HSCT between 1994 and 2015 at the Bone Marrow Transplantation Centre of
Cerrahpaşa Medical Faculty were retrospectively evaluated. A total of 66
patients with HBsAg (n=15; 12 autologous, 3 allogeneic) and anti HBc IgG pos-
itivity (n=51; 29 autologous, 22 allogeneic) were included in the study. Cases
were grouped according to transplant types (allogeneic or autologous) and anti-
HBS antibody positivity (anti-HBs positive or negative) to calculate relative risks
and cumulative incidences of HBV reactivation.
Results: Four (%26) of the 15 patients with HBsAg positivity showed HBV reac-
tivation in an average of 13 months following HSCT. While cumulative incidence
of reactivation was 7% at day 60, it went up to 16% and 44% at days 270 and
730 following HSCT, respectively. In Anti HBc IgG positive group, allogeneic
HSCT (n=22) was a higher risk factor for reactivation (31.8%) than autologous
HSCT (n=29, 6.8%). Relative risk of reactivation in the allo-transplanted patients
who were anti-HBc IgG positive and anti-HBs negative was 6,8 when compared
to anti-HBs positive patients (n=9, 55% vs n=13, 15%) (95% CI: 1,3-46,5). Cumu-
lative incidence of reactivation in anti-HBc IgG positive anti-HBs negative patients
(isolated anti HBc IgG positivity) was 11% at day 10 day, 33% at day 133, 50%
at day 400 and going up as high as 75% at day 940.
Summary/Conclusions: The results of our study indicate that HBsAg positive
patients undergoing autologous or allogeneic HSCT should receive antiviral
prophylaxis at least one year posttransplant. Anti-HBc IgG positive patients
carry the risk of reverse seroconversion, with receivers of allogeneic HSCT
having higher risk than those of autologous HSCT. Patients who are anti-HBc
IgG positive and anti-HBs negative should receive prophylaxis for HBV if allo-
geneic HSCT is to be performed. However, close follow-up seems to be accept-
able rather than a prophylactic treatment for anti-HBc IgG positive patients
undergoing autologous HSCT. 
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ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM
HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOS-
PHAMIDE WAS RELATED TO LESS INPATIENT COST COMPARED TO
CORD BLOOD TRANSPLANTATION
N. Kurita1,*, Y. Yokoyama1, T. Kato1, H. Nishikii1, M. Sakata-Yanagimoto1,
N. Obara1, Y. Hasegawa1, S. Chiba1
1Department of Hematology, University of Tsukuba, Tsukuba, Japan
Background: The number of allogeneic HSCT from alternative donors such
as cord blood (CB) and haploidentical donor (haplo) is increasing especially
after introduction of post-transplant cyclophosphamide (PT/CY) as GvHD pro-
phylaxis for haplo. Although comparison of the survival benefit between CB
and haplo with PT/CY has been made by several groups, there is little informa-
tion about the medical cost and the hospitalization period of HSCT from alter-
native donors.
Aims: We evaluated the medical costs and the hospitalization period related
to allogeneic HSCT in order to clarify the impact of donor sources and other
clinical factors on these outcomes.
Methods: Patients (n=134) with hematological malignancies who underwent
allogeneic HSCT between January 2013 and December 2016 in University of
Tsukuba Hospital were included. The days of the initial hospitalization (from
the beginning of the conditioning regimens to discharge), the whole initial inpa-
tient costs and the costs of transfusion during the initial hospitalization was ret-
rospectively analyzed.
Results: The median age of the patients was 46 (range, 16-67) years. The
diagnoses were AML (n=66), ALL (n=31), MDS (n=17), lymphoma (n=11), and
others (n=9). Twenty-seven patients were transplanted from MRD, 37 from
MUD, 22 from haplo with PT/CY, and 48 with single-unit CB. The median initial
inpatient cost was €49179 (IQR, 37030-66923), the median transfusion cost
was €11500 (IQR, 9500-15250), and the median length of initial hospitalization
was 55 (IQR, 44-75) days. CB showed significantly higher inpatient cost (medi-
an, €66852) than haplo (median, €49085, P=0.008 vs CB), MRD (median,
€36998, P<0.001 vs CB), and MUD (median, €39262, P<0.001 vs CB) (Figure).
Also, the transfusion cost was highest in CB (median, €22750) compared with
haplo (median, €12866, P<0.001 vs CB), MRD (median, €12699, P<0.001 vs
CB), and MUD (median, €13118, P<0.001 vs CB). The median hospitalization
days were 67 in CB, 61 in haplo (P=1.0 vs CB), 46 in MRD (P=0.001 vs CB),
and 49 in MUD (P=0.01 vs CB). Among the clinical variables such as diagnoses
(acute leukemia or others), refined disease-risk index (low/int or high/very high),
donor source (MRD, MUD, haplo, or CB), age, first or second HSCT, intensity
of conditioning (RIC or MAC), with or without comorbidity, graft failure, GvHD
III-IV, and admission to the intensive care unit (ICU), multiple regression models
revealed CB (P<0.001), haplo (P=0.003), graft failure (P<0.001), admission to
ICU (P<0.001), and MAC (P=0.05) were the factors that increased the initial
inpatient cost. The transfusion cost was increased by CB (P<0.001), graft failure
(P<0.001), admission to ICU (P<0.001), and MAC (P<0.001). CB (P<0.001),
haplo (P=0.003), and GvHD III-IV (P=0.01) were selected as factors associated
with longer hospitalization period.
Figure 1.
Summary/Conclusions: Although HSCT from alternative donors was related
to the higher initial inpatient cost and longer hospitalization, the impact on those
outcomes was more significant in CB than haplo with PT/CY. The higher inpa-
tient cost of CB was partly attributed to delayed hematological recovery which
lead to its larger demand for transfusion. The strategy to improve hematological
recovery will be needed to reduce the medical cost especially in CB. The larger
scale investigation is necessary for better cost-effectiveness in HSCT.
E1520
THE ROLE OF PPARΓ EXPRESSION IN PATIENTS WITH AGVHD FOLLOWING
ALLO-HSCT
X. Wu12,*, J. Zhang1, S. Ma1, Y. Ji1, J. Xu1, Y. Xie1, Y. Han1, X. Tang1, C. Fu1,
D. Wu12
1The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, 2Institute of Blood and Marrow Transplantation,Collaborative Innovation
Center of Hematology, Soochow University, Suzhou, China
Background: The acute graft versus host disease (aGVHD) is the main com-
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plication after allogenic hematopoietic stem cell transplantation (allo-HSCT).
Peroxisome proliferator-activated receptor (PPAR)-gamma (γ), a potent anti-
inflammatory agentis a transcription factor belonging to the nuclear hormone
receptor super family which may be participating in aGVHD.
Aims: To explore the role of PPARγin aGVHD after allo-HSCT.
Methods: 65 patients under allo-HSCT and 10 healthy controls were enrolled
in study. Peripheral blood (PB) of patients was collected at 15 days, 30 days,
60 days, and 90 days after allo-HSCT. The mRNA expression of PPARγ, IFNγ,
T-bet was detected by the real-time PCR. Furthermore, we conducted mixed
lymphocyte reaction (MLR) to detect the proliferation of active lymphocytes
under different concentration of PPARγ agonist.
Results: Among 65 patients after HSCT, aGVHD occurred in 45 patients.
Expression of PPARγ mRNA in healthy controls were significant lower than
that in patients after allo-HSCT within 90 days (P<0.05). The expression of
PPARγ mRNA hold steady in non-GVHD patients within 90 days after allo-
HSCT, and was significantly lower in GVHD group than in non-GVHD group
(P<0.05). PPARγ expression in severe aGVHD (grade 3 to 4) was lower than
mild aGVHD (grade 1 to 2) patients (P<0.05). The expression of IFNγ and T-
bet increased in aGVHD patients and were negatively correlated with PPARγ
mRNA expression (P<0.05). The experiment of MLR shows that PPARγ agonist
rosiglitazone above concentration of 25μM had dose-dependent inhibition effect
to proliferation of lymphocytes.
Summary/Conclusions: Low expression of PPARγ is associated with aGVHD
occurrence and degree. PPARγ agonist can inhibit the proliferation of lympho-
cytes, which may be a new way to treat aGVHD.
E1521
HAPLOIDENTICAL TRANSPLANTATION WITH MYELOABLATIVE
CONDITIONING REGIMEN COULD SERVE AS AN OPTIONAL SALVAGE
THERAPY FOR YOUNGER PATIENTS WITH REFRACTORY OR
RELAPSED NON-HODGKIN LYMPHOMA
H. Huang1,*, X. Xiao1, Z. Jin1, D. Wu1
1Soochow University, Suzhou, China
Background: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT)
has a well-established role in the treatment of refractory or relapsed (R/R)
aggressive non-Hodgkin lymphoma (NHL). However, whether patients with
R/R aggressive NHL, in the absence of appropriate HLA-matched donors, can
benefit from haploidentical hematopoietic stem cell transplantation (haplo-
HSCT) is yet to be elucidated. Herein, we evaluated clinical outcomes of hap-
lo-HSCT in patients with R/R aggressive NHL.
Aims: To evaluated clinical outcomes of haplo-HSCT in patients with R/R
aggressive NHL.
Figure 1.
Methods: 23 patients with R/R aggressive NHL who had undergone haplo-
HSCT in our center between January 2004 and December 2015 were included,
and data were retrospectively analyzed. 25 patients with R/R aggressive NHL
who received HLA-matched HSCT during the same period constituted the con-
trol group for this analysis. All patients received myeloablative conditioning
(MAC) regimen. Antithymocyte globulin (ATG) was administered to prevent
graft-versus-host disease (GVHD). The median age of patients who underwent
allo-HSCT was 33 years (range, 16-58). Twenty-three patients had received
transplant from haploidentical donors, while twenty-five patients received trans-
plant from HLA-matched donors, of which included 13 ISD and 12 MUD.
Chemoresistant disease at transplantation was more common in the haplo-
HSCT group as compared to that in the HLA-matched HSCT cohort (P= 0.005).
No significant between-group differences were observed with respect to distri-
bution of age and sex, histological subtype, bone marrow involvement, aaIPI
score, chemotherapy regimen and relapse after ASCT.
Results: Median age of patients at allo-HSCT was 33 years (16-58). Over a
median follow-up of 23 months, 27 out of the 48 patients (56%) were alive.
Progression free survival (PFS) rate at 2-years in the haplo-HSCT and HLA-
matched HSCT groups was 52.1% and 56.6%, respectively (P=.75); 2-year-
overall survival (OS) rate was 52.8% and 57.8%, respectively (P=.83). Cumu-
lative incidence of relapse (RI) was 41.7% and 35.5% (P=.37), while non-
relapse-mortality (NRM) was 21.7% and 35.0%, respectively (P=.32). Collec-
tively, these results showed no significant difference with respect to major allo-
HSCT endpoints between the haplo-HSCT and HLA-matched-HSCT groups.
On multivariate analyses, older age (> 45 years), primary chemorefractory dis-
ease, and occurrence of grade III-IV aGVHD were associated with poor prog-
nosis in both groups. Likewise, the most important factors that influenced the
overall survival rate in the haplo-HSCT group were age and occurrence of
grade III-IV aGVHD.
Summary/Conclusions: Haplo-HSCT with MAC regimen could serve as an
optional salvage therapy, with outcomes comparable to those of HLA-matched
HSCT, particularly in younger patients with R/R NHL without appropriate donors.
E1522
OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
HARBORING INV(3)/(Q21;Q26.2)/T(3;3)(Q21;Q26.2)
J. Aoki1,*, K. Ishiyama 2, N. Uchida3, T. Fukuda4, K. Ohashi5, M. Hidaka6,
N. Kobayashi7, T. Sakura8, N. Aotsuka9, H. Okumura10, T. Ichinohe11, J. Tanaka12,
Y. Atsuta13,14, S. Yano15
1Department of Hematology, Kanagawa Cancer Center, Yokohama, 2Depart-
ment of Hematology, Kanazawa University Hospital, Kanazawa, 3Department
of Hematology, Toranomon Hospital, 4Division of Hematopoietic stem cell trans-
plantation, National Cancer Center Hospital, 5Department of Hematology, Tokyo
Metropolitan Cancer and Infectious disease Center Komagome Hospital, Tokyo,
6Department of Hematology, National Hospital Organization Kumamoto Med-
ical Center, Kumamoto, 7Department of Hematology, Sapporo Hokuyu Hospital,
Sapporo, 8Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi,
9Division of Hematology-Oncology, Japanese Red Cross Society Narita Hos-
pital, Narita, 10Department of Internal Medicine, Toyama Prefectural Central
Hospital, Toyama, 11Department of Hematology and Oncology, Hiroshima Uni-
versity Hospital, Hiroshima, 12Department of Hematology, Tokyo Women’s
Medical University, Tokyo, 13Japanese Data Center for Hematopietic Cell Trans-
plantation, 14Department of Healthcare Administration, Nagoya University
Graduate School of Medicine, Nagoya, 15Division of Clinical Oncology and
Hematology, Department of Internal Medicine, Jikei University School of Med-
icine, Tokyo, Japan
Background: Acute myeloid leukemia (AML) with inv(3)/(q21;q26.2)/t(3;3)
(q21;q26.2) [inv(3)/t(3;3)] is categorized as AML with recurrent genetic abnor-
mality in the WHO classification, accounts for approximately 1%-2% of AML,
and is characterized by resistance to chemotherapy and poor outcomes. There-
fore, the presence of this chromosomal abnormality in AML is an indication for
allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, out-
comes of AML with inv(3)/t(3;3) remain unclear.
Aims: We retrospectively examined the impact of inv(3)/t(3;3) on the outcomes
of allo-HSCT in patients with AML.
Methods: Clinical data were collected from the registry database of the Japan
Society for Hematopoietic Cell Transplantation. We selected patients with AML
harboring inv(3) /t(3;3), who were aged ≥16 years and underwent their first
transplantation between January 2000 and December 2014. We analyzed out-
comes such as overall survival (OS), relapse, and nonrelapse mortality (NRM)
for the patients underwent allo-HSCT. OS was estimated using the Kaplan-
Meier method and compared using the log-rank test. Relapse and NRM were
considered as competing risk and were compared using the Gray’s test. In a
multivariate analysis, the Cox proportional hazard model was used to analyze
OS, using the following variables: age, sex, disease status at allo-HSCT, time
taken for allo-HSCT from diagnosis, donor source, conditioning regimen, addi-
tional monosomy of chromosome 7 or partial depletion of long arm of chromo-
some 7 and type of 3q abnormality.
Results: Of 15025 patients with AML who were aged ≥16 years and who under-
went their first transplantation, inv(3)/(q21;q26.2)/t(3;3)(q21;q26.2) was identi-
fied in 66 patients. The median age was 46 years (range, 16-72 years). Of the
66 patients, 10 (15.2%) were in first complete remission (CR1) at allo-HSCT,
54 (81.8%) were in non-CR, and the disease status of two patients was
unknown. The probabilities of 2-year OS, relapse, and NRM were 27.8% (95%
CI, 16.8-40.0), 64.2% (50.4–75.0), and 21.1% (11.8-32.3), respectively. Multi-
variate analysis revealed that an age of ≥50 years (HR, 2.05; 95% CI, 1.06-
3.99; P =0.03) was significant risk factors for poor OS. Non-CR at transplanta-
tion (HR, 2.55; 95% CI, 0.94-6.93; P=0.07), and reduced conditioning intensity
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(HR, 2.03; 95% CI, 0.99-4.14; P=0.05) were risk factor with marginal signifi-
cance for poor OS.
Summary/Conclusions: These findings revealed that AML with inv(3)/t(3;3)
had dismal outcome even after allo-HSCT. Multivariate analysis suggested that
a myeloablative conditioning regimen might improve the transplantation out-
come.
E1523
PHARMACOKINETICS (PK) OF PROPYLENE GLYCOL-FREE MELPHALAN
HCL (PG-FREE MEL) IN MULTIPLE MYELOMA (MM) PATIENTS
UNDERGOING AUTOLOGOUS TRANSPLANTATION (AHCT)
P. Hari1,*, B. Dhakal1, A. D’souza1, R. Thompson1, M. Hamadani1, M. Pasquini1,
S. Chhabra1
1Medical College of Wisconsin, Milwaukee, United States
Background: Melphalan (MEL) is the most commonly used conditioning agent
in AHCT for MM and exhibits a dose response relationship (Nath CE Br J Clin
Pharmacol. 2010 May; 69(5):484). PG-free MEL (EvomelaTM) has longer sta-
bility in solution, results in a slightly higher systemic exposure compared with
standard MEL and eliminates propylene glycol administration during high dose
melphalan-based conditioning. This agent was shown to be bioequivalent to
conventional melphalan leading to successful myeloablation and engraftment
in MM pts receiving AHCT with no transplant related mortality or unexpected
toxicity leading to its FDA approval (Hari P Biol Blood Marrow Transplant. 2015
Dec; 21(12):2100). Published studies thus far have used PG-free MEL in 2
consecutive daily doses of 100mg/m2/day while a single daily conditioning dose
of 200mg/m2 (MEL200) is most commonly used in clinical practice. 
Aims: Determine the safety and PK variability of high dose PG-free MEL
200mg/m2 in patients undergoing AHCT for MM
Methods: Open-label phase II study in which 10 serial blood samples at specific
time points for the PK evaluation of melphalan were collected immediately prior
to and after receiving single 200mg/m2 dose of PG-free MEL on day -2 as a
2mg/ml solution. The primary objective was a descriptive analysis of melphalan
PK while secondary objectives included the response rates, engraftment and
the toxicity and safety profile of PG-free MEL conditioning.
Results: As of Feb 2017, a total of 24 pts. were enrolled (63% male) with a
median age of 67 years (range 46-72), including 23 (96%) who received upfront
AHCT and 1 (4%) after relapse (Figure 1). High-risk cytogenetics was present
in 6(25%) pts 25% were in ISS stage 3. Disease status at transplant was com-
plete remission (CR) in 4 (17%), very good partial remission (VGPR) in 12
(50%) and PR in 8 (33%). AHCT was performed entirely as outpatient in 25%.
PK data are available for the first 12 pts at this time. Wide variability in MEL
exposure was noted with maximum plasma concentration (Cmax) of 10,100
ng/ml, median Cmax 7750ng/ml (range, 5220-10,100) and median area under
the concentration- time curve (AUC) of 561500 ng.min/ml (range, 771000-
254000). Mean AUC was 549000 (±155000). No grade 4 non-hematologic tox-
icities or gastrointestinal toxicities were observed including in patients with
Cmax >10,000 (upper quartile of distribution) or AUC>625000. All patients are
alive and post-transplant responses in those with at least 100 days of follow up
indicate sCR/CR in 60% and VGPR in 30%.
Figure 1.
Summary/Conclusions: PG-Free MEL can be safely administered as a single
200mg/m2 in conditioning with a favorable toxicity profile. Considerable vari-
ability in the PK parameters of high dose MEL indicate that PK directed MEL
dosing could be used to optimize MEL exposure. The safety profile of PG-free
MEL indicates no increase in mucosal toxicity or adverse events seen even in
subjects with highest levels of MEL exposure. For patients in the lowest quartile
of AUC, increased PG-free MEL doses up to 20 to 40% over 200mg/m2 may
be safely attempted without additional toxicity if PK directed dosing is used to
ensure adequate MEL exposure and utilize the dose response effect of MEL.
E1524
IMPAIRED LYMPHOCYTE RECONSTITUTION AFTER AUTOLOGOUS
TRANSPLANT IS ASSOCIATED WITH APOPTOSIS OF CD8+ T CELLS AND
PREDICTS ADVERSE CLINICAL OUTCOME
U. Rozovski1,2,*, B. Tartakovsky3, S. Frank4, E. Zigman-Hofman4, M. Yeshurun5,
S. Trestman3, E. Naparstek6
1Hematology, Davidof Cancer Center, Beilinson Campus, Petah Tikva, 2Tel
Aviv University, 3Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv,
4Shneider Hospital, Beilinson Campus, 5Hematology, Davidof Cancer Center,
Beilinson Campus, Petah Tikva, Petah Tikva, 6Hematology, Assuta Medical
Centers, Tel Aviv, Israel
Background: In patients undergoing autologous stem cell transplantation
(ASCT), faster recovery of the lymphocyte counts has been associated with
longer disease-free survival (DFS) and longer overall survival (OS). We noticed
that the post-transplant lymphocyte counts fluctuated significantly during the
first post-transplant weeks and wondered what the clinical significance of this
observation is, and what dictates the lymphocyte counts over time.
Aims: Describe the kinetics of post-ASCT lymphocyte reconstitution in a single
patient and across patients. Determine whether activation of anti-apoptotic
pathways are associated with faster recovery of the lymphocyte counts.
Methods: We reviewed the medical records of 105 consecutive patients with
lymphoma (Non-Hodgkin’s’ lymphoma and Hodgkin disease) or multiple myelo-
ma who underwent ASCT at Tel-Aviv Sourasky Medical Center and were alive
24 weeks after the transplant. In each patient we documented the absolute
lymphocyte counts (ALC) starting 2 weeks after the transplant until the 24th
post-transplant week. We used flow cytometry to characterize the lymphocyte
sub-populations in lymphocytes derived from 20 randomly selected patients,
assayed apoptosis by DiO6 binding and used fluorescence anti-MO2 mono-
clonal antibody to detect the MO2 epitope by flow cytometry. The probability of
OS and of DFS was estimated by the Kaplan-Meier method. The log-rank test
was used to compare survival distributions.
Results: The ALC was recorded at least once-weekly between the 2nd and 24th
post-transplant weeks for each of the 105 study participants. The median ALC
during the first 2- 16 weeks was 1.4 X103/μL (range: 0.3 to 4.1) and varied con-
siderably in a single patient. After the 16th week, the ALC stabilized and divided
the cohort into those with high (n=54, median =1.9 x103/μL, range: 1.3 to 3.1)
and low (n=51, median=0.9 x103/μL, range 0.15 to 1.25) ALCs. Patients with
low ALCs were slightly younger, but in all other patient or disease characteristics
there were no differences between the two groups. Remarkably, the CD4+ sub-
population was low across all patients, and the difference in ALCs was primarily
in the CD8+ subpopulation which remained low in half of the patients and normal
or above normal in others. Interestingly, patients with prolonged lymphopenia
had higher rates of apoptosis in freshly obtained lymphocytes and the expression
levels of MO2, a CD14-derived epitope that protects the cells from apoptosis
correlated with lymphocyte counts. Patients with high ALCs during 16-24 post-
transplant weeks had longer DFS (P=.07) and OS (P=.04) compared to patients
with low ALCs. In a multivariable analysis low ALC at 16 to 24 post-transplant
weeks was the strongest predictor for shorter OS.
Figure 1.
Summary/Conclusions: The analysis of post-ASCT lymphocyte counts
revealed a unique pattern. It fluctuates during the first 4 post-transplant months
and stabilizes thereafter, dichotomizing the patients into two groups. In all
patients the CD4 subpopulation remained low for at least 6 post-transplant
months. However, in half of the patients upregulation of intracellular anti-apop-
totic signals was associated with recovery of the CD8+ subpopulation. In the
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remaining, both CD4+ and CD8+ subpopulations remained low and these
patients were prone to develop relapse. These findings underscore a putative
function of CD8+ T-cells in eliminating post-transplant residual disease and
maintaining the patients disease free.
E1525
COMPARISON OF TECAM AND BEAM HIGH-DOSE CHEMOTHERAPY
FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN LYMPHOMA: EFFICACY AND TOXICITY
F. Sahin1,*, P. Patir1, N. Akad Soyer1, R. Durusoy2, G. Saydam1, M. Tobu1,
M. Tombuloglu1, F. Vural1
1Hematology, Ege University Hospital Internal Medicine, 2Public Health, Ege
Univeristy, Bornova, Turkey
Background: High-dose chemotherapy conditioning regimens followed by
autologous hematopoetic stem cell transplantation (AHSCT) generally provide
good results in relapsed and refractory lymphomas.
Aims: Limited data are available to guide the choice of conditioning regimen
before AHSCT for patients with lymphoma. We evaluated the efficacy and safe-
ty of TECAM and BEAM regimens as conditioning with autologous stem cell
support in patients with relapsed/refractory lymphomas.
Methods: From July 2011 to October 2016, 64 pathologically confirmed lym-
phoma patients underwent AHSCT with BEAM (n=32) or TECAM (n=32) regi-
mens in Hematology Division of Ege University Faculty of Medicine. Patients
considered as high risk at diagnosis or with relapsed or refractory diseases
were eligible for AHSCT. The two groups were well matched in terms of age,
gender, histology. Patients were conditioned with TECAM (thiotepa [40mg/m2
x four days], etoposide [200mg/m2 x four days], cyclophosphamide [60mg/kg
x one day], cytarabine [200mg/m2 x four days] and melphalan [60mg/m2 x two
days]) or BEAM (carmustine [300mg/m2 x one day], etoposide [200mg/m2 x
four days], cytarabine [200mg/m2 x four days], melphalan [140mg/m2 x one
day]) regimens.
Results: The estimated 22-months overall survival for the TECAM and BEAM
groups were 53% and 63%, respectively (p=0.41). The estimated 22-months
progression-free survival in the BEAM group (59%) was relatively inferior to
the TECAM (74%) group, but the differences were not significant (p=0.98).
Cardiotoxicities were relatively more common in the BEAM group. No differ-
ences were observed in the time to hematopoietic recovery, the duration of
hospitalization, hematological and nonhematological toxicities.
Summary/Conclusions: We conducted a single-center retrospective on lym-
phoma patients undergoing AHSCT, comparing efficacy and toxicity of TECAM
and BEAM conditioning regimens. These two regimens are all optional high-
dose chemotherapy with favorable efficacy and acceptable toxicity. 
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GENETIC MARKERS OF THE NEUTROPENIA DURATION AFTER
AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH
MULTIPLE MYELOMA
E. Nazarova1,*, M. Horobryh2, V. Shardakov1, V. Dem’janova1, N. Zorina2,
N. Minaeva3, I. Paramonov3
1Laboratory of Immunology of Leukemia, 2Department of chemotherapy and
bone marrow transplantation, 3Kirov Research Institute of Hematology and
Blood Transfusion, Kirov, Russian Federation
Background: The successes achieved in the treatment of multiple myeloma
(MM) in the past few years, associated with the use of high-dose chemotherapy,
and with the use of new drugs. Using high-regimes with subsequent autologous
hematopoietic stem cells (auto-HSCT) has increased both overall and progres-
sion-free survival of patients with MM, as well as improved quality of life. In
most cases, patients in the early post-transplant period have severe toxic and
infectious complications of varying severity that requires resource-intensive
supportive care. The duration of the period of hematopoiesis hypoplasia is
dependent on many factors, and an average of 14-16 days. In turn, the attach-
ment of infectious complications in some cases adversely affect the duration
of neutropenia.
Aims: To evaluate the possible association of the immune response genes
mutation status to the duration of neutropenia after autologous transplantation
of peripheral blood stem cells in patients with multiple myeloma.
Methods: The study included 19 patients with multiple myeloma at the age of
32 to 67 years (median - 52 years) who underwent autologous transplantation
of hematopoietic stem cells after conditioning regimen with high-dose melpha-
lan. Among surveyed: 8 men and 11 women. In accordance with staging for
Durie-Salmon (DSS) system in patients following stages of MM were installed:
stage 1A in one patient (5.2%), stage 2A - in 12 patients (63.2%), stage 2B -
in two patients (10.5%) and stage 3A - in four patients (21.1%). In the pre-
transplantation period partial remission of the disease was achieved in seven
patients (36.8%), very good partial remission - in eight patients (42.1%) and
complete response in four patients (21.1%). Genotyping of polymorphisms of
the innate immune response genes TLR2 (rs5743708), TLR3 (rs3775291),
TLR6 (rs5743810), TLR9 (rs5743836), IL1β (rs2856841), IL2 (rs2069762), IL4
(rs2243250), IL6 (rs1800795), IL10 (rs1800871), IL17A (rs2275913), CD14
(rs34424920), TNFα (rs1800629), FCGR2A (rs1801274) was performed by
polymerase chain reaction with allele-specific primers (Liteh, Russia) at the
time of diagnosis.
Results: Depending on the duration of the neutropenia period all examined
are divided into two groups. The first group included 10 patients with MM who
have early observed recovery (within the first 13 days, 11-13 days), the number
of leukocytes ≥1000 cells per ml after auto-HSCT. The second group consisted
of nine patients with agranulocytosis held more than two weeks (≥14 days, 14-
19 days). When comparing the genotyping data found that a longer period of
neutropenia after autologous HSCT was significantly associated with the pres-
ence in genotype of MM patients homozygous wild-type allele A gene IL17A at
position -197 (OR 13.15, 95%CI: 0.60-288.34, p=0.03) and with a predomi-
nance of heterozygous mutant allele C of the gene IL1β at position -31 (OR
8.17, 95%CI: 1.03-67.94, p=0.04).
Summary/Conclusions: Our findings point to immune response genes
involved in the rate of recovery of hematopoiesis in MM patients after autolo-
gous HSCT. Identification of the wild-type allele in intron gene IL17A (G-197A)
and mutant allele in intron gene IL1β (T-31C) will predict the risk of prolonging
the period of agranulocytosis and, consequently, the risk of post-transplant
complications, and develop a personalized strategy of managing them.
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SUCCESSFUL TREATMENT WITH GRANULOCYTE TRANSFUSION AND
EARLY NEUTROPHIL ENGRAFTMENT IN ALLOGENEIC TRANSPLANT
PATIENTS WITH FEBRILE NEUTROPENIA
A. Ünal1,*, L. Kaynar1, N. Keni1, A. Birekul1, E.E. Turak1, S. Sivgin1, B. Eser1,
M. Çetin1
1Erciyes University Medical School, Kayseri, Kayseri, Turkey
Background: Febrile Neutropenia is very severe and urgent early complication
after bone marrow transplantation before engraftment. Infection delays engraft-
ments. In this study we retrospectively evaluated the effect and outcome of
Granulocyte transfusion on febrile neutropenia and neutrophil engraftment in
patients receiving allogeneic transplantation.
Aims: Between 2015-2016, five patients receiving allogeneic bone marrow
transplantation (BMT) were treated with granulocyte transfusion at the time of
febrile neutropenia before engraftment. The reasons for the use of the granu-
locyte transfusion were prolonged febrile neutropenia episode.
Figure 1.
Methods: Five AML patients underwent allogeneic transplantation. Three of
them transplanted from match sibling donors, one from unrelated donor, and
one from (7/10) mismatch mother (haploidentic transplant). They had febrile
neutropenia after transplantation, before engraftment. They were given antibi-
otics. Before the granulocyte transfusion, on the 13th-18th days of transplanta-
tion, their neutrophil counts were 0.03-0.08x10^3/dl.
Results: We started Granulocyte transfusion for three days. Granulocyte was
collected from unrelated and same blood groups donors. Mean infused gran-
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ulocyte counts were 3.6x10^10 (1.3-4.6x10^10)/day. Twenty-four hours after
granulocyte transfusion, mean neutrophil counts were 0.6x10^3/dl (0.4-
0.8x10^3/dl). Neutrophil counts were 2.6 x 10^3/dl, (1.7-2.6x10^3/dl), after 48
hour. After 72 hours, neutrophil counts were 3.4x10^3/dl. (2.1-4.5x10^3/dl).
After 4th days of granulocyte transfusion, neutrophil counts were normal levels
(>0.5x10^3/dl.).
Summary/Conclusions: Granulocyte transfusions during the febrile neutrope-
nia, helped to better-overcome febrile neutropenia periods in allogeneic trans-
plant patients before engraftment. In addition, granulocytes transfusion also
may help early neutrophil engraftments.
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DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC
VENO-OCCLUSIVE DISEASE AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION; A SINGLE CENTER EXPERIENCE
B. Antmen1,*, I. Sasmaz1,2, B. Karagun1, M. Serbest1
1Pediatric Bone Marrow Transplantation Unit, Department of Pediatric Hema-
tology, Adana Acibadem Hospital, 2Pediatric Hematology, Cukurova University,
Adana, Turkey
Background: Hepatic veno-occlusive disease (VOD) is a common and serious
complication of hemotopoietic stem cell transplantation (HSCT) in children. We
aimed to assess prospectively the use of prophylactic defibrotide in pediatric
patients undergoing HSCT.
Aims: We aimed to assess prospectively the use of prophylactic defibrotide in
pediatric patients undergoing HSCT.
Methods: In this study, 113 patients who underwent HSCT were given defi-
brotide prophylaxis as 25mg/kg per day in four divided intravenous infusions
over 2h, starting on the same day as the pretransplantation conditioning regi-
men. The mean duration of use of defibrotide is 25 days as a prophylaxis.
Results: In this study, 113 patients were recruited, 66 male patients and 47
female patients, with the average of 9.1 years, range 1-20; 8% infants, 55%
children and 37% adolescent. There were 50 patients with thalassemia major,
41 patients with leukemia, 11 patients with aplastic anemia, one patient with
Diamond Blackfan anemia, two patients with congenitale dyserythropoetic ane-
mia, one patient with osteopetrosis, four patients with famial hemophagocytic
lymphohistiocytosis, two patienrs with severe immune deficiency and one
patient with Kostman syndrome. All transplants were allogeneic. No serious
side effects were seen. In eight patients developed clinical VOD (Seattle crite-
ria). In these patients, defibrotide dose was increased to a treatment dose of
40-60mg/kg per day. One infant patient with Kostman syndrome died due to
hepatic and pulmonary veno-occlusive disease. After 36 months of follow up,
7 patients who developed VOD are being well and no patient have transplant
related complications.
Summary/Conclusions: Hepatic veno-occlusive disease, which is caused by
hepatocyte and sinusoidal vessel endothelium damage, can ocur early after
HSCT, and in its severe form, may lead tol iver faillure, hepatorenal syndrom,
portal hypertension, and eventually death from multiorgan faillure. In this
prospective study, we demonstrated that the use of defibrotide is safe and effec-
tive in preventing and treating VOD in pediatric patients at high risk. 
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ACUTE RENAL IMPAIRMENT IN ALLOGENEIC STEM CELL TRANSPLANT
RECIPIENTS, A PREDICTOR OF MORTALITY
A.J. Mahdi1,*, D. Foxwell2, G. Scott1, D. Davies1, K. Wilson1, W. Ingram1
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Background: Allogeneic stem cell transplant (ASCT) remains the only curative
option in many malignant and non-malignant conditions. There remains how-
ever a risk of significant morbidity and mortality. One risk, acute kidney injury
(AKI), can result from drug toxicity and/or haemodynamic instability from sepsis
and/or graft vs host disease (GvHD). Existing reports on the impact of AKI have
concentrated on patients undergoing mainly myeloablative (MA) conditioning
alone, whilst those undergoing reduced intensity conditioning (RIC) transplants
have reported outcomes from limited patient numbers.
Aims: To investigate the incidence, causes and consequences of AKI in patients
undergoing ASCT, including survival.
Methods: The prospectively maintained database of the South Wales Blood
and Marrow Transplant programme which serves 77% of the Welsh population,
was interrogated to identify patients undergoing ASCT from January 2010 to
December 2015. Patients received ciclosporin as GvHD prophylaxis to 100
days post ASCT and weaned thereafter in the absence of GvHD. Serum crea-
tinine and derived estimated glomerular filtration rate (eGFR) acted as the main
assessment of renal function. The Acute Kidney Injury Network classification
was used to grade AKI. Causes of AKI were assigned after independent review
of clinical notes and relevant laboratory data. Patients undergoing second ASCT
were excluded. Statistical analysis was carried out using SPSS, version 23
including COX regression and Kaplan-Meier survival analysis.
Results: A total of 229 patients were identified (MA-n=35, 15%; RIC-n=194,
85%). Acute myeloid leukaemia was the most common indication (n=103, 45%).
Mean age at ASCT was 51 years (18-72 years). Median follow up after ASCT
was 2.19 years (range 9 days-6.6 years). Overall survival to 100 and 365 days
was 93% and 74% respectively. Pre-existing renal impairment was uncommon
(mean eGFR 92ml/min, range 45-143ml/min). During the first 100 days, no dif-
ference was seen in mean eGFR in survival vs non-survival groups (75 and
80ml/min respectively, p=0.23). Amongst all patients, AKI incidence in the first
100 days was greater in the non-survival group (93.2% vs 80.6%, p=0.02). On
multivariate analysis, AKI event in the first 100 days and HLA mismatch (<8/8)
were independent factors predicting mortality (p=0.02 and p=0.04 respectively).
Recipient age and gender, ASCT indication, history of hypertension, CMV sta-
tus, donor sex, stem cell source and conditioning regimen (MA vs RIC) were
not statistically significant (p>0.05). Within the first year of ASCT, pre-terminal
AKI was noted in 29% (n=23) of all patients dying (n=59) with sepsis accounting
for the major non-relapse cause of death (n=15). Of the patients alive, only 11
(8%) had chronic renal impairment. Chronic GvHD was associated with these
patients (73%) one of whom was dialysis dependent.
Summary/Conclusions: AKI is very common post ASCT. Chronic renal failure
is uncommon in long-term survivors. AKI is however a prominent event pre-
ceding death. Consistent with other reports AKI and HLA mismatch conferred
inferior outcomes. Poor survival from AKI probably reflects physiological strain
from other complications (e.g. sepsis and GvHD). Early recognition and treat-
ment of AKI are important measures in the supportive care of patients with AKI.
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PREDICTIVE INDEXES FOR ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION, A SINGLE-CENTER EXPERIENCE
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Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is often associated with complications such as graft-versus-host disease
(GVHD), resulting in poor outcome, relapse and death. Introduction of reduced
intensity conditioning (RIC) regimens and improvements in supportive care,
have allowed offering allo-HSCT to more and older patients (pts). A balanced
risk-benefit approach of candidates for allo-HSCT is the key for maximized
chances of cure with acceptable quality of life.
Aims: Compare the potential utility of two pretransplant predictive models:
PAM (pretransplant assessment of mortality; Parimon et al, AIM 2006) and
HCT-CI (HCT comorbidity index; Sorror et at, Blood 2005), in our cohort of pts.
Methods: We retrospectively studied 154 pts, 86 (55.8%) were males with a
median age of 51 years (range: 15-68), who underwent allo-HSCT in our center
between May 2005 and December 2014. Patients’ baseline diseases were:
acute myeloblastic leukemia (24%), multiple myeloma (22.7%), non Hodgkin
lymphoma (11.7%), acute lymphoblastic leukemia (11%), myelodisplasic syn-
drome (9.1%), chronic lymphocytic leukemia (5.2%), Hodgkin lymphoma
(3.9%), aplastic anemia (3.9%), myelofibrosis (3.9%), chronic myeloid leukemia
(1.3%), Waldenströn macroglobulinemia (1.3%) and others (1.9%). Eighty
(51.9%) pts received cells frommatched siblings, seventy (45.5%) from unre-
lated donor and the remainder haploidentical-HSCT (2.6%). Only 43 (27.9%)
pts received RIC regimens. Stem cell source were: peripheral blood (n=86),
bone marrow (n=63) and umbilical cord (n=5). Median and maximum follow-up
were 31 and 228 months, respectively.
Figure 1.
Results: After allografting, 57.1% pts had complications, the most frequent
were: infections (45.5%), followed by nephrotoxicity (25.3%), hepatotoxicity
(12.3%), pulmonary toxicityes (9.7%) and cardiotoxicity (3.9%). Eighty-two per-
tent of pts with high/very high risk group of PAM score presented complications
versus 46% of pts included in low/intermediate risk (p<0.001). Regarding GVHD,
41.6% and 31.2% of pts developed aGVHD (grades II to IV) and cGVHD, respec-
tively. PAM score was a good predictor for aGVHD risk: 38.1% of pts with
low/intermediate risk had aGVHD versus 59.3% of pts with high/very high risk
(p=0.043). Non-relapse mortality (NRM) was 26%. Causes of NRM included
infections (45.8%), hemorrhage (10%), pulmonary toxicities (16%), second neo-
plasia (14.6%), GVHD (6.25%), cardiotoxicity (2%) and hepatic toxicity (2%).
PAM score effectively risk-stratified pts for NRM: 17%, 24.7%, 45.8%, and 50%
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in the low, intermediate, high and very high risk groups, respectively, showing a
clear distinction by categories (p=0.038) (figure 1). Refarding relase, 44 (28.6%)
pts relapsed. Neither PAM nor HCT-CI were good predictors for relapse. How-
ever, HCT-CI was not good predicting complications, GVHD, NRM or relapse.
Summary/Conclusions: In our series of pts, risk-groups based on PAM score
provided much better discrimination of post-HSCT complications, aGVHD (II-
IV) and NRM than HCT-CI model. None of the indixes were acceptable predic-
tors of relapse. Furthermore, correlation between both indexes was poor.
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ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR
HIGH-RISK PERIPHERAL T-CELL LYMPHOMAS
H. Huang11,*, Y. Jiang1, Q. Wang1, T. Xu1, X. Chen1, Z. Jin1, D. Wu1
1Soochow University, Suzhou, China
Background: Peripheral T-cell lymphomas (PTCLs) often carry poor outcomes
with conventional chemotherapy, and hematopoietic cell transplantation (HCT)
can benefit patients with PTCL. Recent retrospective studies have reported
that autoHCT as consolidation can offer a durable survival benefit in high-risk
patients with first complete or partial response, and alloHCT could result in
long-term disease control for relapsed and refractory patients. 
Aims: To explore questions about the optimal timing for stem cell transplanta-
tion and relative efficacy of auto-HCT versus alloHCT. 
Methods: We conducted a retrospective review of 67 patients with peripheral
T-cell lymphoma who underwent autologous HCT (autoHCT, n=43, median
age 40 years) or allogeneic HCT (alloHCT, n=24, median age 36.5 years) from
2004 to 2016.
Results: With a median follow-up of 27 months, 5-year PFS and OS of auto-
HCT patients were 49% and 57%, respectively. Among alloHCT recipients, the
5-year PFS and OS were 54% and 55%, respectively. When considering inci-
dence of disease relapse or progression (CIR) and nonrelapse mortality (NRM),
the 5-year CIR and 1-year NRM of alloHCT recipients were 38% and 18%,
respectively, and 58% and 7% of autoHCT patients, respectively. There were
no differences between autoHCT and alloHCT on 5-year PFS (P=0.499), OS
(P=0.566), CIR (P=0.555) and NRM (P=0.202). When specifically examining
recipients in primary refractory disease, 3-year PFS rates of autoHCT and allo-
HCT were 20% and 49% (P=0.054), 3-year OS rates were 20% and 53%
(P=0.042), respectively.
Figure 1.
Summary/Conclusions: This analysis shows that HCT can benefit patients
with high-risk PTCL in both remission and primary refractory setting. The out-
comes did not differ significantly between autoHCT and alloHCT approaches,
but alloHCT recipients in primary refractory disease resulted in significantly
better outcomes than autoHCT patients. So, we favor proceeding to alloHCT
if patients with PTCL in primary refractory disease.
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IMPACT OF BASELINE BILIRUBIN ON SURVIVAL IN PATIENTS WITH
HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION
SYNDROME RECEIVING DEFIBROTIDE: POST-HOC ANALYSIS OF
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Background: Veno-occlusive disease/sinusoidal obstruction syndrome
(VOD/SOS) is an unpredictable, potentially life-threatening complication of
hematopoietic stem cell transplantation (HSCT) conditioning. VOD/SOS with
multi-organ dysfunction (MOD) may be associated with >80% mortality. Defi-
brotide is approved in the European Union to treat severe hepatic VOD/SOS
post-HSCT and in the United States to treat hepatic VOD/SOS with renal or
pulmonary dysfunction post-HSCT. Prior to approval, defibrotide had been
available in the United States via an expanded-access program.
Aims: A post-hoc analysis of final data from the defibrotide expanded-access
program was used to explore Day +100 survival post-HSCT based on biliru-
bin-level categories at the time of study entry.
Methods: Patients in the defibrotide expanded-access program had VOD/SOS
diagnosed by investigators using Baltimore criteria (bilirubin ≥2mg/dL and ≥2
of: hepatomegaly, ascites, ≥5% weight gain), modified Seattle criteria (≥2 of:
bilirubin >2mg/dL, hepatomegaly, or ascites and/or ≥5% weight gain), or biopsy;
bilirubin >2 was not required for modified Seattle criteria or biopsy. MOD
(renal/pulmonary) was permitted. After informed consent, defibrotide treatment
(25mg/kg/day) was recommended for ≥21 days. Here, Day +100 survival was
explored by bilirubin level at study entry using categories that are part of the
European Society for Blood and Marrow Transplantation (EBMT) proposed
grading scale for adults (≥2 to <3mg/dL, ≥3 to <5, ≥5 to <8, and ≥8), as well as
bilirubin <2mg/dL, which is not part of the scale but has been reported in chil-
dren with VOD/SOS.
Results: There were 1000 HSCT patients enrolled, between December 2007
and September 2016, with a confirmed diagnosis of VOD/SOS and receiving
≥1 dose of defibrotide, 512 patients had MOD. Median age was lowest in
patients with bilirubin <2 (4.5 years; 19% of patients). Median ages were 16
years in the bilirubin ≥2 to <3 group (53.5% of patients) and 13.5 in the ≥3 to
<5 group (20.4% of patients); median age in other groups ranged from 15 to
17 years. Kaplan-Meier estimated Day +100 survival in all HSCT patients was
58.9%, with 85.6% in patients with BR <2; other bilirubin groups were older
and survival estimates decreased (Table 1). In the pediatric (aged ≤16 years)
and adult (aged >16 years) patients, patterns were similar (Table 1). Estimated
survival rates were lower for patients with MOD across all groups. Of all 1000
HSCT patients with confirmed VOD/SOS, 210 (21%) had treatment-related
AEs (TRAEs). The TRAEs in ≥2% of patients were pulmonary hemorrhage
(4.6%), gastrointestinal hemorrhage (3.0%), epistaxis (2.3%), and hypotension
(2.0%).
Table 1. Day +100 Survival (Kaplan-Meier, N=1000).
Summary/Conclusions: This post-hoc analysis found that higher bilirubin lev-
els were generally associated with lower Day +100 survival. These results
should be interpreted with caution, as only 1 EBMT criterion was analyzed.
MOD was also associated with lower Day +100 survival. The results suggest
that diagnosis and treatment of VOD/SOS, before bilirubin becomes markedly
elevated, may be associated with improved outcome.
Support: Jazz Pharmaceuticals.
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CHEMO-IMMUNOTHERAPY WITH AUTOLOGOUS OR ALLOGENEIC STEM
CELL TRANSPLANTATION IN PATIENTS AFFECTED BY PERIPHERAL
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Background: The prognosis of patients with newly diagnosed peripheral T-
cell lymphomas (PTCLs) is very poor following conventional therapy alone with
5-years PFS ranging from 20% to 30%. From 2006 to 2010, we conducted a
multicenter prospective phase II trial to evaluate the efficacy of upfront consol-
idation of clinical response with autologous (auto) or allogeneic (allo) stem cell
transplantation (SCT) in patients at diagnosis. The results were previously
reported (4 year PFS of 70% and 69% for auto and allo SCT, respectively)
(Corradini P. 2014). 
Aims: In this analysis, we extended the follow-up of our trial. 
Methods: Sixty-one patients were enrolled after central review pathology
[Peripheral T-cell Non Hodgkin Lymphomas (PTCL-NOS) n=33, Anaplastic lym-
phoma kinase-negative anaplastic large cell lymphomas (ALCL) n=12, Angioim-
munoblastic lymphomas (AITL) n=14, enteropathy-associated T-cell lym-
phomas (EATL) n=2]. The induction therapy consisted of 2 courses of CHOP
and alemtuzumab followed by 2 courses of high-dose methotrexate, cytarabine
and cyclophosphamide. Patients in clinical remission with HLA identical donors
received allo SCT whereas those without a suitable donor received auto SCT.
Three patients relapsed after auto SCT and were subsequently allografted
(data of last follow-up was censored at date of second transplantation proce-
dure).
Results: Only 37 patients underwent transplantation [autologous SCT (n=14),
allogeneic SCT (n=23] whereas 24 did not for toxicity (n=5), progressive disease
(n=18) or clinical decision (n=1). In intention to treat analysis, at a median fol-
low-up of 78 months, the estimated 7-years progression-free survival (PFS) and
overall survival (OS) for all the patients were 42% (95% CI, 29% >54%) and
41% (95% CI, 28% >53%), respectively. Despite auto or allo SCT consolidation
was chosen based on donor availability, the majority of patients allografted had
a diagnosis of PTCL-NOS [19 of 23 (83%) versus 6 of 14 (43%) autografted,
(p=0.02)]. The PFS and OS were not significant different in patients transplanted
with a diagnosis of PTCL-NOS as compared to others subtypes but numbers
are too small for definitive conclusions [PFS: 48% (95%CI, 32% >62%) versus
33% (16% > 51%) (p=0.26); OS: 50% (95%CI, 33% >64%) versus 30% (13%
>49%) (p=0.36)]. Considering only the patients who underwent a consolidation
with any type of transplant (n=37), the PFS were 48% (95% CI, 18% >73%) and
62% (95% CI, 46% >83%) (p=0.40) in patients autografted and allografted,
respectively. We did not observe a significant difference in OS between auto or
allo consolidation 69% (95% CI ,31% -88%) versus 63% (38% >79%) (p=0.51)],
but 3 patients in relapse after auto SCT were allografted. The main cause of fail-
ure after auto SCT was relapse (6 of 14, last relapse occurring at 81 months
after auto). The Crude Cumulative Incidence of non-relapse mortality and relapse
after allo SCT were 19% (n=4 deaths, one patient died of cardiac complication
62 months after allo SCT) and 17% (n=4 deaths), respectively.
Summary/Conclusions: The long-term outcome of patients receiving any
transplantation strategy remains satisfactory. In the future, biological markers
could help physician to select the better therapeutic option for the patients.
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UNRELATED DONOR ATTRITION AT A LATE STAGE: THE BRITISH BONE
MARROW REGISTRY EXPERIENCE
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Background: The success of searches for unrelated stem cell donors (UDs)
relies on the existence of large international donor registries and the availability
and reliability of donors on the register. Donor attrition at the verification typing
(VT) or later stage results in delay of transplant and can adversely affect patient
outcomes. The British Bone Marrow Registry (BBMR) provides UDs to interna-
tional transplant centres (TCs) and to UK TCs via the Anthony Nolan registry.
Data reported by international registries on donor attrition is scarce and mainly
focused on attrition at the VT stage. BBMR donors are recruited from blood
donors and may differ in their reliability from non-blood donors included in exist-
ing reports.
Aims: To investigate donor attrition rates and causes of cancellation among
finally selected or backup BBMR donors at the post-VT stage. 
Methods: Data on requests for work-ups from April 2002 to December 2016
were extracted from BBMR databases and donor notes and were analysed ret-
rospectively. The reasons for cancellation were categorised: cancellation initi-
ated by TCs, donor reason or mixed reasons. Within donor reasons we distin-
guished 3 categories: donor medical reasons, donor withdrawal on personal
grounds and inability to contact the donor. We examined associations between
cancellations for donor-related reasons and the following factors: donor sex,
age at time of donation/cancellation, time on the register and donor reliability
score. The reliability score relates to blood donation and runs from 1 (best) to
5 (worst), increasing if a donor fails to attend appointments for blood donation.
Results: A BBMR final/backup donor was selected for 3184 stem cell or lym-
phocyte collections. 82% of the requests (n=2613) were completed. Out of the
571 (18%) cancelled cases the reason for cancellation was not available for 5
cases. Overall more than half of the cancellations (n=302, 53%) were activated
by TCs mainly due to patient death, deterioration or alternative donor choice.
Donor reasons accounted for 38% of cancellations (n=216, 6.8% of requested
donors), of which 69% (n=148) happened for medical reasons, 27% (n=59) for
donor pull-out on personal grounds and 4% (n=9) due to uncontactable donors.
The medical reasons for withdrawal were varied but the most frequent health
issues were obesity and cardiovascular disease. Analyses of factors affecting
donor reasons showed that donor sex and time on the register were not asso-
ciated with donor fitness or withdrawal rate. Age had no impact on donor pull-
out, but it was significantly associated with medical eligibility and donors who
failed medically were older (p=0.005). Donor pull-out showed significant asso-
ciation with blood donor reliability score (p=0.029, score 5 vs others). In 48
cases (8%) there were mixed reasons where TCs had other donor options and
pursued them because of issues such as donor availability for ideal dates or
CMV mismatches. 
Summary/Conclusions: In our registry patient-related issues accounted for
more than half of cancellations at a late stage in the stem cell donor pathway.
Cancellations for donor reasons were unusual (6.8% of requested donors),
which figure compares favourably with international data (12.4% of requested
donors, WMDA Annual Report 2015). This is likely due to the fact that most
BBMR donors are regular blood donors: few donors withdrew for personal rea-
sons and very few were uncontactable. Medical conditions were the most fre-
quent cause of cancellation for donor reasons. Further work is underway to
allow earlier or reduced deferral of medically unsuitable donors such as control
of high blood pressure and to explore personal reasons which cause donors to
withdraw. This study should provide reassurance to TCs that BBMR provide
reliable and accessible stem cell donors. 
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Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is the most effective treatment option for certain hematological malignancies.
Cytokines play a well established role in the mechanism of acute GvHD
(aGvHD), which is one of the most significant complications of allo-HSCT. Trans-
forming growth factor B1 (TGFB1) is one of the inflammatory cytokines, which
play a pivotal role in the development of aGvHD.
Aims: The aim of this study was to investigate the role of TGFB1 -1347C>T
polymorphism in the outcome of HSCT.
Methods: We examined the association of recipient and donor TGFB1 -
1347C>T and allo-HSCT outcome in a cohort of 419 adult patients who under-
went first allo-HSCT between January 2007 and December 2013 at our single
center. 217 patients received stem cells from their siblings, 202 patients from
matched unrelated donors (MUD). For identification of TGFB1 rs1800469 from
genomic DNA LightCycler melting curve analysis (LightCycler 480II, Roche
Diagnostics) was performed.
Results: We did not find any association between recipients’ TGFB1 -1347C>T
polymorphism and HSCT outcome. However, in patients whose unrelated
donors carried homozygous TGFB1 -1347TT variant, aGvHD grades III-IV
occurred more frequently (aGVHD grade III-IV: 28.9% vs aGVHD grade 0-II:
9.6%, p=0.006). Similar finding was observed on a subgroup of patients with
acute leukemia: in aGVHD grade III-IV 37.5%, while in grade 0-II 11.5% of
patients had TT genotype (p=0.022). Donor TT genotype did not influence the
relapse rate significantly. Patients with MUD carrying TT genotype had lower
overall survival (OS) that that of donors bearing at least one C variant, but the
difference did not reach the level of significance (OS at 40 month for CC and
CT variant donors: 45.3% and for TT donors: 26.2%). In case of sibling donors,
we did not find association between recipient or donor genotype and aGVHD,
but relapse rate was increased if donor had at least one T variant (n=115, 67.9%
vs 32.1%, p=0.028). Significant differences in OS between the subgroups with
different genotypes were not observed.
Summary/Conclusions: Our findings suggest that TGFB1 -1347C>T poly-
morphism in HSCT donors might influence the development of aGVHD in unre-
lated and the relapse rate in related HSCT.
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MEASLES, MUMPS AND RUBELLA IN PATIENTS GIVEN ALLOGENEIC
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Background: Live-vaccines should be avoided in the early period following
allogeneic hematopoietic cell transplantation (HCT), due to a possible uncon-
trolled proliferation of the attenuated strains. The post HCT immune system is
severely compromised by pharmacological immunosuppression and disruption
of lymphoid tissues by conditioning and donor T cell alloreactivity. Patients fre-
quently lost their antibody-based immunity against measles, mumps, and rubel-
la after receiving allogeneic HCT. 
Aims: Here, we studied the dynamics of antibody (AB) titers against measles,
mumps, and rubella post-HCT. 
Methods: We retrospectively analyzed serial AB titers in 240 patients who
underwent allogenic HCT from related und unrelated HLA-matched donors
from 2002-2014 at our center. AB titers against measles, mumps and rubella
were measured prior to HCT, at 6 months (m), and every year (y) post-HCT.
Results: Most patients had protective AB titers (measles 90%, mumps 86%,
rubella 92%) prior to HCT. AB protection against mumps was lost in a substantial
proportion of patients after HCT (protective AB titers in 72%@1y, 56%@5y,
50%@8y), comparing to AB against measles, which persist more frequently
(protective AB titers in 85%@1y, 74%@5y, 73%@8y). We found a faster lost of
protective AB in the first years for patients given a rmyeloablative condition
(MAC) in comparison to patients with reduced condition (RIC), but the proportion
of seropositive patients became more equal over time (Figure 1 displays the
percentage of seropositive patients to Measles AB given MAC or RIC during 8
years post-HCT). The proportion of patients who retained protective AB titers at
5y post-HCT was higher in recipients of mobilized peripheral blood compared
with bone marrow (BM) grafts (measles p=0.01, mumps=0.06, rubella p=0.08).
For rubella, absolute AB titers were available. Patients with lymphoid malignan-
cies, ongoing GVHD and pharmacological immunosuppression had a steeper
decline of rubella AB titers as compared to patients with myeloid malignancies.
Figure 1.
Summary/Conclusions: We found a marked decline of AB titers post-HCT
with loss of protection in a substantial proportion of patients. Surprisingly, BM
grafts did not provide better AB protection post-HCT, despite their higher con-
tent of (donor) plasma cells. Together with the observations that (i) patients
with lymphoid malignancies (who have received (B-) lymphocyte targeted ther-
apies prior to HCT) had lower AB levels, while (ii) those given reduced intensity
conditioning have a higher percentage of protective AB levels in the first years,
our data suggest, that residual host plasma cells significantly contribute to AB
production during the first years post-HCT. In opposite, the loss of protective
AB levels in later years after transplantation was independent of the toxicity of
the conditioning regime and may be a effect of weakening signaling for host
plasma cells or late donor alloreactivity. 
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MICA AND NKG2D POLYMORPHISMS HAVE A SIGNIFICANT IMPACT ON
GRAFTVERSUS HOST DISEASE AFTER HLA-MATCHED HEMATOPOÏETIC
STEM CELL TRANSPLANTATION.
M.-J. Apithy1,*, A. Charbonnier2, J. Desoutter1, P. Morel2, J.-P. Marolleau2,
N. Guillaume1
1Hematology and Histocompatibility, 2Hematology and cellular therapy, Uni-
versity Medical Center, AMIENS, France
Background: MICA (MHC class I polypeptide-related sequence A) is a highly
polymorphic gene closely linked to the HLA-B locus. It encodes a cell stress
inducible glycoprotein, which mediates an activatory signal towards the NKG2D
receptor expressed on NK-cells, CD8+ T-cells and NKT-cells. MICA polymor-
phisms have been shown to influence NKG2D signaling. Indeed, a methionine
to valine change at position 129 in exon 3 categorized the MICA alleles into
strong (MICA-129 met) and weak (MICA-129 val) binders of NKG2D receptor.
5 repetitions of GCT with 1 additional nucleotide insertion (G) in exon 5
designed the MICA A5.1 alleles with a premature stop codon. Moreover,
NKG2D polymorphisms identified alleles associated with a low (NKC3 C/C and
NKC4 C/C) or high cytotoxic activity (NKC3 G/G and NKC4 T/T).
Aims: In this study, we hypothesized that polymorphisms at the MICA and
NKG2D loci are associated with adverse outcomes in HSCT.
Methods: Here, we evaluated whether recipient MICA and donor NKG2D poly-
morphisms (respectively MICA-129, MICA A5.1 and NKC3, NKC4) could influence
the incidence of acute and chronic graft versus-host disease (GVH), overall sur-
vival (OS) and relapse free survival (RFS) on 124 patients undergoing allogenic
hematopoietic stem cell transplantation using an HLA-matched donor (10/10).
Results: In an univariate model, recipient MICA A5.1 heterozygosity (p=0.030)
and donor NKC4 C/C polymorphism (p=0.013) are associated with the increase
of incidence of acute GVH (grade I to IV). Recipient MICA A5.1 heterozygosity
is also associated with chronic GVH (p=0.04) while Recipient MICA-129 val/val
tends to be a risk factor of chronic GVH without being statistically significant.
These polymorphisms have no significant impact on OS and RFS in our study
(median of follow up=15 months; range 0.2-49 months).
Summary/Conclusions: Our data suggest that a MICA or NKG2D low activity
status can be related to an increase of acute GVH according to a mechanism
that remains to be elucidated, maybe by a low cytotoxic activity on recipient
dendritic cells.
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STEM CELL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING
USING TIMED SEQUENTIAL BUSULFAN IMPROVES OUTCOMES IN
OLDER AML AND MDS PATIENTS
B. Oran1,*, R. Saliba1, S. Ahmed1, A. Alousi1, S. Ciurea1, C. Hosing1, I. Khouri1,
D. Marin1, A. Olson1, Q. Bashir1, Y. Nieto1, K. Rezvani1, P. Kebriaei1,
B. Valdez1, E. Shpall1, B. Andersson1, R. Champlin1, U. Popat1
1Stem Cell Transplantation and Cellular Therapy, The University of Texas
MDACC, Houston, United States
Background: We previously reported 6% 100 day NRM with a MA fludarabine
(Flu) and busulfan (Bu) in older patients with a median age of 60 years. MA
dose of Bu in this timed sequential (TS) regimen was administered over a longer
period of time. To assess its impact on survival, we compared the outcomes of
older patients treated with the TS Bu (TS cohort) or the RIC Flu/Bu regimen,
which is used as standard (ST) for older patients at our center ST cohort.
Aims: To assess its impact on survival, we compared the outcomes of older
patients treated with the TS Bu (TS cohort) and the reduced intensity condi-
tioning with Flu/Bu regimen, which is used as standard (RIC cohort) for older
patientsat our center.
Methods: Patients in the TS cohort received IV Bu 80mg/m2/d on day -13 and
-12 and Flu 40mg/m2/d followed by IV Bu on day -6 to -3, dose adjusted to
achieve a total Bu course AUC of 20,000μmol-min based on PK studies. Patients
in the ST cohort received Flu 40mg/m2 day followed by IV Bu daily for 4 days
(day -6 to -3) dosed to achieve AUC of 16,000μmol-min. Patients with AML or
MDS were eligible for the study if they had adequate organ function, had matched
related or unrelated donor and were treated between Jan 2012 and Se.
Results: Patient characteristics including age, sex, disease status, cytogenetic
risk group, donor type, graft source CMV status and comorbidity were similarly
distributed between the two cohorts. Median age was 66 and 65 years in TS-
MAC and RIC cohorts respectively. Overall survival (OS) and progression free
survival(PFS) were significantly better in the TS -MAC cohort. This was due to
a reduction in the disease progression without any increase in the TRM. After
adjusting for other covariates, the multivariate analysis for PFS confirmed
longer PFS with TS-MAC regimen (HR: 0.36; P=0.003). The benefit was mainly
seen in patients with a comorbidity score ≤3.
Table 1.
Summary/Conclusions: The myeloablative timed sequential Bu regimen
improves survival and appears promising in older patients with AML/MDS. The
myeloablative timed sequential Bu regimen improves survival and appears
promising in olderpatients with AML/MDS.
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HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
WITH DEPLETION OF TCR ΑΒ (+) IN CHILDREN: ERCIYES PEDIATRIC
BMT CENTER
M. Karakukcu1, E. Unal1, E. Yilmaz1, A. Ozcan1, S. Kose1, G. Ucan1, T. Patiroglu1,*
1Department of Pediatrics, Division of Pediatric Hematology Oncology, Erciyes
University, Faculty of Medicine, Kayseri, Turkey
Background: Recently, haploidentical hematopoietic stem cell transplantation
(HSCT) posses an alternative option for patients without a suitable donor.
Erciyes Pediatric BMT Center is the first pediatric center for haploidentical
HSCT with depletion of TcR αβ (+) in Turkey.
Aims: We would like to share our pediatric experience with a follow up period
of more than four years.
Methods: All children who underwent haploidentical HSCT in our center from
December 2012 to February 2017 were included in the study. Total 51 hap-
loidentical HSCT in 44 children (17 relapsed/refractory AML, 9 relapsed/refrac-
tory ALL, 4 SAA, 4 HLH, 2 Fanconi aplastic anemia, 2 Griscelli syndrome, 1
JMML, and 5 SCID) were performed. Transplantation-related mortality (TRM)
was 13.7%. The regimen included ATG, Fludarabine, Thiotepa, Melphalan.
Mycophenolate mofetil (MMF) was given as GvHD prophylaxis if the graft con-
tained>5 x104/kg TcR αβ (+).
Results: The mean of collected CD34 cells were 18,60 (range 3,98-43,66) x
106/kg. The graft had a purity of 99.9% TCRαβ depletion with a median of 0,257
(range 0.003 to 1,47) x 105 TCRαβ cells. The median engraftment days for
myeloid and platelet were both 12th day of HSCT (range 7 to 28, 9 to 33 day)
respectively. Grade II skin GvHD was detected in 8 patients, and treated with
steroids without any further complications. However grade III, and grade IV
gastrointestinal GvHD were observed in three patients. Although the patients
with gastrointestinal GvHD were treated with steroid, budenosid, cyclosporine,
MSC; one patient did not respond and died. MMF was given as GvHD prophy-
laxis in 36 patients and 15 patients did not receive any immune suppressive
drug. The mean day of discharge was 34th day of HSCT. The long term follow
up including immunological reconstructions were performed in 18 patients. The
analysis of the immune reconstitution of the patients transplanted in haploiden-
tical HSCT group showed a rapid immune reconstitution for CD3+ T cells 732
(range 126-2432)/mm3; for CD4+ helper T cells 92 (range 1–419)/mm3; CD8+
T cytotoxic cells 310 (range 95-2235)/mm3 at 28th day of HSCT. Twenty nine
patients are currently alive, with a median follow up of 22 months (range 1 to
49 months). Overall survival was 65,9% in these group.
Summary/Conclusions: Our primary results underline that haploidentical
HSCT with depletion of TcR αβ (+) can be an option in experienced center in
countries which unrelated donor programs are not satisfactory, as in Turkey.
The availability of a haploidentical donor in most families is a potential advan-
tage. Moreover probably more potent graft-versus tumor effect can be induced
with haploidentical HSCT.
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SECONDARY MYELODYSPLASTIC SYNDROME AND/OR ACUTE
LEUKEMIA INCIDENCE AFTER AUTOLOGOUS TRANSPLANTATION FOR
LYMPHOMA PATIENTS IS CONNECTED WITH DECREASE OF
HEMATOPOIETIC RESERVE
M. Trněný1,*, M. Trnkova1, D. Pohlreich1, B. Vackova1, Z. Gasova2, R. Pytlik1,
P. Blahovcova1
1Charles University General Hospital, 2Institute of Hematology and Blood Trans-
fusion, Prague, Czech Republic
Background: Secondary myelodysplastic syndrome and acute myelogenous
leukemia (sMDS/AML) is one of the most important long term complication of
high dose therapy (HDS) with autologous stem cell transplantation (ASCT).
The factors usually described to be associated with sMDS/AML development
are pretreatment, HDS itself, radiotherapy, age and recently the evidence of
TP53 mutations (Wong, Nature 2015) or clonal hematopoiesis (Gibson, JCO
2016) before ASCT. 
Aims: The aim of the study was to analyse the incidence and risk factors for
sMDS/AML after HDT and ASCT for lymphoma. 
Methods: Patients who underwent HDT with ASCT for lymphoma in one centre
since 12/1993 till 7/2016 were analysed. Pretreatment characteristic, graft qual-
ity, engraftment characteristics were included into analysis. Patients were cen-
sored at the time of death or allogeneic stem cell transplant. Pearson, Kaplan
Maier, log-rank and cox regression tests were used. 
Results: Altogether 728 pts underwent ASCT for lymphoma in given time peri-
od. The cohort consists out of 77% B-NHL (n566), 6% T-NHL (n 43) and 16%
HL (n 119), 58% were men, age median at the transplant was 49 years (18-
71). The median of previous lines was 2 (1-9). The stem cell collection was
performed after chemotherapy and G-CSF mobilization in most cases, 19 pts
were mobilized by G-CSF only and bone marrow only was used in 4 pts. The
target CD34 dose was 3x106/kg. The median number of apheresis was 2 (1-
12). At the time of ASCT 90.6% of patients had chemosensitive disease (51.1%
CR) and 9.4% were transplanted for chemoresistant disease. Tandem HDT
and ASCT was used in 36 pts, BEAM was the most frequent HDT regimen
(92.5%, 15 pts received ibritumomab tiuxetan and BEAM), the total body irra-
diation was used only in 4 pts, the rest of the patients received other chemother-
apy regimens (CPB, thiotepa based, ICE and others). All pts except 4 received
peripheral blood progenitor cells (PBPC) with median CD34 dose 8.6x106/kg
(0.4-115.5). BM was used in 22 cases (in 18 together with PBPC). G-CSF was
administered from day +7. Involved or extended field radiotherapy either during
previous therapy or in the period after ASCT was used in 37.7% of pts. With
median follow-up 7.2 years there were observed 19 cases of sMDS/AML. The
cumulative sMDS/AML incidence was at 5, 10 and 15 years 2.7%, 4.0% and
5.3% (figure A) in all lymphoma pts, 3.3% at 5,10 and 15y in HL pts, and 2.6%,
4.3% and 6.3% in NHL pts (figure B). There was significantly increased
sMDS/AML incidence in pts with ³3 previous lines (7.7% vs 1.9% at 5y, HR 3.9,
p 0.005), in pt’s group with chemoresistant disease (8.1% vs 2.3%, HR 3.5, p
0.05), in CD34+ dose<3.0x106/kg (14.3% vs 2.5% at 5y, HR 4.9, p 0.05), in BM
reinfused group (13.7% vs 2.5% at 5y, HR 4.7, p 0.05), in patients with pro-
longed platelet engraftment above 20x109/l - ³15 days vs 11-14 days vs £10
days (5.4% vs 3.0% vs 0.9%, p 0.05). There was no difference between groups
of NHL and HL, with and without radiotherapy, according to the apheresis num-
ber or neutrophil engraftment. In multivariate analysis in the whole cohort the
independent risk factors were number of previous therapy lines, disease status
at ASCT and the speed of platelet engraftment (p <0.05). For NHL only number
of previous therapy lines (p<0.05), for HL number CD34+cell reinfused, use of
BM as the progenitor cell source and disease status (p<0.05).
Figure 1.
Summary/Conclusions: The risk of sMDS/AML was 4.0% at 10y after ASCT
and was connected with heavier pretreatment, which leads to the decrease of
BM reserve, hematopoietic clonal development. The lower dose of CD34+ cell,
the necessity to use BM progenitor cell and prolonged platelet engraftment
could be considered as clinical markers of these biological processes. 
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USE OF DEFIBROTIDE TO TREAT TRANSPLANT-ASSOCIATED THROMBOTIC
MICROANGIOPATHY 
M. Martinez-Muñoz1,*, A. Lario1, G. Bautista1, J. Bueno1, B. Navarro1,
A. De Laiglesia1, J. Cabrera1, R. Duarte1
1Hospital Universitario Puerta de Hierro Majadahonda (Madrid), Majadahonda,
Spain
Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is
a severe early transplant complication which results from endothelial injury and
it exhibits characteristics of an atypical hemolytic uremic syndrome. Beyond
removal or treatment of precipitating factors and, more recently, treatment with
eculizumab, TA-TMA remains a therapeutic challenge. Defibrotide, with marked
protective effects on the endothelium and the potential to restore thrombotic-
fibrinolytic homeostasis in small vessels, may be considered a therapeutic
option for TA-TAM.
Aims: To analyze our center’s experience in the treatment of TA-TMA with defi-
brotide.
Methods: We reviewed all cases of TA-TMA treated with defibrotide in our allo-
geneic transplant recipients between October 2008 and November 2016. All
cases had non-inmune hemolytic anemia with high LDH, low haptoglobin and
negative Coombs test, >2 schistocytes per high-power field and thrombocytope-
nia (<50x109/L or <50% of normal baseline). Cases without signs of renal or
neurological dysfunction were classified as probable TA-TMA [Uderzo C, 2014].
Results: We identified 17 TA-TMA episodes treated with defibrotide in 16 allo-
geneic transplant recipients: 9 men; median age 38 years old (16-57); 10 sin-
gle-cord blood plus third-party donor cells [Bautista G, 2009], 3 HLA-identical
siblings and 3 unrelated donors; 13 myeloablative conditioning regimen, 10
with total body irradiation (Table 1). Concomitant risk factors at the time of TA-
TMA onset were: calcineurin inhibitor treatment in all cases (13 cyclosporin, 4
tacrolimus), acute GVHD grade ≥II/IV in 8 cases, 3 CMV reactivations and 3
severe fungal (1 pulmonary aspergillosis, 1 Scedosporium Prolificans sep-
ticemia) or bacterial (1 E Coli sepsis) infections. Median onset of TA-TAM was
on day +43 after transplant (2-556); 11 cases of early onset (<2 months) and 6
of late onset. Nine episodes were probable TA-TMA without organ dysfunction,
8 had renal failure and 2 presented with concomitant diffuse alveolar hemor-
rhage. First line replacement of calcineurin-inhibitors for basiliximab or other
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drugs for GVHD was performed in all cases. Defibrotide was subsequently
administered as monotherapy in 5 cases, in combination with rituximab and/or
plasma exchange in 7, and with other agents in 5 others (2 vincristine; 1
eculizumab; 1 bevacizumab; 1 mesenchymal stromal cells). Complete resolu-
tion of TA-TMA (CR) was achieved in 11 episodes (65%), and associated with
a reduced all-cause mortality: 18% of CR cases (2/11: 1 multilobar pneumonia
and 1 toxic encephalopathy) versus 83% of cases without CR (5/6, P=0.035;
1 TA-TAM-related diffuse alveolar hemorrhage, 1 lymphocytic encephalitis and
3 severe infections). TA-TMA cases triggered by severe infections had early
(days 4, 11 and 15 after onset) and higher mortality rates (3/3, 100% vs 4/14,
29%; P=0.023). Rates of CR were higher in cases of probable TA-TAM without
renal failure (8/9, 89% vs 3/8, 38%; P=0.027) and early-onset TA-TAM (9/11,
82% vs 2/6, 33%; P=0.046).
Table 1.
Summary/Conclusions: TA-TMA is a severe endothelial dysfunction syn-
drome for which, beyond the complement inhibitor eculizumab, treatment is
not well established. Defibrotide has proven to be safe and effective in sinu-
soidal obstruction syndrome. Here, we provide encouraging evidence suggest-
ing that defibrotide, as monotherapy or in combination with other agents, may
also have a role in the treatment of TA-TMA. Our data show complete resolution
of TA-TMA in two thirds of cases, and even higher in those with early treatment
and early onset forms of the disease. Validation of single-center experience in
prospective controlled studies should be warranted.
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PRE-TRANSPLANT COMORBIDITY AS AN OUTCOME PREDICTOR IN
HEMATOPOIETIC CELL TRANSPLANTATION FOR SEVERE APLASTIC
ANEMIA
S.-N. Lim1,*
1Internal Medicine, Haeundae Paik Hospital, Busan, Korea, Republic Of
Background: In the context of allogeneic hematopoietic cell transplantation
(allo-HSCT), comorbidites are an important risk factor. Use of the hematopoietic
cell transplantation-specific comordigity index (HSCT-CI), which was modeled
to effectively capture comorbidity and predict post-transplant outcomes. HSCT-
CI had been evaluated in a chort of patients with a variety of hamtologic malig-
nancies. However, it was not validated in a cohort of adult patients with non-
hematologic malignancies.
Aims: We performed multi-center retrospective study to validate the prognostic
impact of HSCT-CI on transplant outcomes in a cohort of aplastic anemia
patients undergoing allo-HSCT.
Methods: In this study, we applied the HCT-CI to 140 patients with severe
aplastic anemia (SAA) who underwent allogeneic HCT at the Asan Medical
Center, Seoul, and Haeundae Paik Hospital, Busan, Korea between April 1995
and March 2013. Required data were retrieved from Asan medical center and
Haeundae Paik Hospital BMT Registry Database. We stratified the patients
based on comorbidities, as assessed by HCT-CI. Post-transplant outcomes
were evaluated in terms of overall survival (OS) and event-free survival (EFS).
Event was defined as graft failure including primary and secondary, relapse,
donor lymphocyte infusion, and death.
Results: The median age of including patients was 31 year-old (range, 31-61
year-old) and male was 81 patients (58%). HCT-CI score was 0 in 92 patients
(65.0%), 1-2 in 34 (24.3%), and ≥3 in 14 (10.2%). The most prevalent comor-
bidity captured by the HCT-CI was infection (n=20, 14%) followed by moder-
ate/severe hepatic comorbidity (n=10, 7%). During a median surviving post-
HCT follow-up period of 45.5 months (range, 4.1-178.4 months), 32 patients
(24%) died and 20 (14%) experienced primary or secondary graft failure. The
10-year probability of OS and EFS was 73.4% and 68.3%, respectively. OS
and EFS was significantly different according to HCT-CI score; the OS for HCT-
CI 0, 1-2, and ≥3 at 4 years was 84.1%, 68.6%, and 60.6%, respectively
(P=0.007). The EFS for HCT-CI 0, 1-2, and ≥3 at 4 years was 76.5%, 60.0%,
and 56.3%, respectively (P=0.019). Multivariate analysis after adjustment for
other variables demonstrated that higher HCT-CI score were associated with
increased OS and EFS as judged by increasing hazard ratio compared to
patients with HCT-CI score of 0 (Table 1).
Table 1.
Summary/Conclusions: In conclusion, our data indicate that the presence of
pre-transplant comorgicity assessed by HSCT-CI may predict worse outcomes
after allo-HSCT in severe aplastic anemia.
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EFFICACY AND SAFETY OF FILGRASTIM BIOSIMILAR COMPARED TO
FILGRASTIM ORIGINATOR IN THE STEM CELL MOBILIZATION AND
HEMATOPOIETIC ENGRAFTMENT IN PATIENTS UNDERGOING STEM
CELL TRANSPLANTATION
M. López-Parra1,*, M. Baile1, J. Dávila1, J.C. Caballero1, Á. Veiga1, N. Arratibel1,
F. López-Cadenas1, L. García-Martín1, M. Salinero1, N.C. Gutiérrez1, O. López-
Villar1, M.D. Caballero1, R. García-Sanz1
1Hematology, University Hospital of Salamanca, Salamanca, Spain
Background: Neupogen® is the original Filgrastim used for peripheral blood
stem cell mobilization (PBSC) in patients and donors selected for stem cell
transplantation (SCT). Nivestim® is a Filgrastim biosimilar approved for the
same indications as Neupogen®.
Aims: To evaluate the efficacy and safety of Nivestim® in the PBSC mobilization
for harvesting and hematopoietic SCT.
Methods: Retrospective, controlled, observational study conducted at the Uni-
versity Hospital of Salamanca (Spain) between JAN08 and DEC15.
Results: The study included 365 patients candidates for ASCT and 217 healthy
sibling donors for Allo-SCT who underwent PBSCs mobilization. Neupogen®
(Amgen Europe BV, Breda, NL) was administered for mobilization at standard
doses until SEP2012, while Nivestim® (Hospira, Maidenhead, UK) was used
from that date. Among PATIENTS, 145 were mobilized with Nivestim® and 220
the originator Neupogen®. Patient characteristics between groups were similar,
although lenalidomide was more frequently used in the Nivestim® group, as it
corresponds to more recent transplants. The mean number of CD34+ cells/µl
in the peripheral blood after 4 days of mobilization treatment was not signifi-
cantly different (Neupogen®73.2, SD=113.0; Nivestim® 94.5, SD=166; p=0.15),
but the mean of the total CD34+ collected cells was 4.75, SD=4.41 in the Neu-
pogen® and 6.35±6.42 in Nivestim® group (p=0.01), with a larger number of
apheresis procedures needed in the Neupogen® group (1.39, SD=0.65 vs 1.24,
SD=0.45; p=0.02). The mobilization failure rate was slightly higher with Nives-
tim® (22%) than with Neupogen®(13%, p=0.04), although it was attributed to
a more frequent use of lenalidomide. Most patients underwent ASCT: 87% and
92% patients in the Neupogen® and biosimilar groups, respectively. There
were no statistically significant differences in hematopoietic recovery and trans-
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plant-related toxicity. The median hospitalization time (20, range 14-70 vs 20,
range 14-53, p=0,72) and the consecutive number of re-admissions after dis-
charge (27% vs 35% p=0,35) were also similar between Neupogen® and Nives-
tim® groups. In the group of HEALTHY DONORS, 95 were mobilized with Neu-
pogen® and 122 with Nivestim®. Donor characteristics were equivalent between
groups, and no severe adverse events were registered in any of them. Mean
of CD34+ cells collected/kg of recipient body weight was 7.62x106,
SD=3.45x106 for Nivestim® vs 6.26 x106, SD=2.71x106 Neupogen®(p=0.002),
but the minimal target cell dose (2x106/kg) was collected in all donors. 8.5% of
donors mobilized with Nivestim® failed to achieve the optimal cell dose
(4x106/kg) compared with 13% in the Neupogen® group (p=0.25). All recipients
were successfully transplanted. All donors for haploidentical transplants (N=25)
were mobilized with Nivestim®; none with Neupogen®. There were no other
transplant differences. Platelet and neutrophil engraftment were comparable
between the two groups, as well as transfusion requirements and infectious
complications after transplant. The incidence of grade 1 to 4 acute graft-ver-
sus-host disease was not different (Nivestim®65.5% vs Neupogen® 67.7%;
p=0,7). The hospitalization period was similar in Neupogen® and Nivestim®
groups, (30 days, range 16-102; 30 days, 16-136, respectively).
Table 1.
Summary/Conclusions: Although prospective data are still required, our study
supports that the use of the Filgrastim biosimilar Nivestim® has a similar efficacy
and safety as mobilization agent compared with the originator Neupogen®.
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PERIPHERAL BLOOD STEM CELL DONATION IN OLDER SIBLING
DONORS: IS IT SAFE?
K. Balassa1,*, A. Peniket1, R. Danby1, R. Pawson1
1Department of Haematology, Oxford University Hospitals NHS Foundation
Trust, Oxford, United Kingdom
Background: The introduction of reduced intensity conditioning regimens has
led to an increase in allogeneic haematopoietic stem cell transplantation (HSCT)
in older patients with a consequent increase in age of family members who are
asked to donate HSCs for them. Such donors are expected to have more co-
morbidities than younger donors and careful assessment of their suitability to
donate is required. 
Aims: Our aim was to assess the frequency and nature of issues concerning the
eligibility of related peripheral blood stem cell donors seen at Churchill Hospital,
Oxford between 2012 and 2016. We wished to examine the influence of age and
the nature of any extra interventions required to establish donor suitability.
Methods: For clinical data collection donors’ notes were reviewed and analysed
retrospectively. At our centre the same template was used in all cases for sibling
donor selection and screening. 
Results: During the study period 90 related donors were screened, of whom 1
declined to proceed because of his concerns regarding G-CSF safety, 2 were
excluded due to pre-existing medical conditions and 2 were defined medically
ineligible during work-up, and finally 85 donors donated PBSCs to their relatives
(36% of allogeneic HSCT performed at our centre). The median donor age was
51 years (range 25-71, n=17 over 60). Nearly half of the donors (44%) took
regular medications. Two thirds (67%) suffered from at least one significant
comorbidity (25% hypertension, 24% back problems, 16% asthma, 9% cardio-
vascular conditions, 9% diabetes mellitus, 8% autoimmune disease). The pres-
ence of comorbidities was significantly associated with age (p=0.033). 59%
travelled abroad, of whom 14% visited a malarial area within a year of donation.
Based on donors’ history or examination findings, 47% needed extra blood
tests on top of the mandatory tests before the clearance, including malaria
(31%) and haemoglobinopathy screening (13%). 6% underwent specific
haematology investigations e.g. BMA, molecular studies. Additional imaging
studies were performed in 13%. In 16% specialist opinion was sought from
other specialties with concerns regarding donor fitness or safety. 13 out of 85
cases were handled as planned deviation from our standard eligibility criteria.
Two donors needed central venous access for stem cell collection. The collected
median CD34+ dose was 5.73x106/kg (range 1.76-22.45). Collection was com-
pleted in one day in 54%, in two in 44% and in three in 2%. Male (p=0.017) and
younger donors (p=0.041) were more likely to achieve stem cell yield in one
day collection. The stem cell dose was higher for collections being successful
in one day (median 6.5 vs 5.03, p<0.001). Citrate related toxicity was the most
common complication of the apheresis procedure (52%). The only documented
serious complication affected a 69-year old donor who was hospitalized on 3rd
day of G-CSF treatment with chest and abdominal pain and troponin rise, but
investigations excluded acute coronary syndrome or other significant acute
pathology and she managed to donate successfully with no further issues.
Summary/Conclusions: Peripheral blood stem cell collection seems to be
safe among sibling donors, who are significantly older than unrelated donors.
With careful assessment and planning even individuals with significant co-mor-
bidities can donate successfully. The demographic trend and its implications
should be considered when planning resources in HSCT programmes.
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LONG-TERM RESULTS OF DONOR LYMPHOCYTE INFUSIONS IN
RELAPSED AND MIXED CHIMERISM PATIENTS AFTER ALLOGENEIC
STEM CELLS TRANSPLANTATION
O. Koroleva1,*, E. Parovichnikova1, L. Mendeleeva1, L. Kuzmina1, M. Drokov1,
V. Vasilyeva1, Z. Konova1, E. Mikhalcova 1, D. Dubnyak1, N. Popova1, V. Savchenko1
1BMT, National Research Center for Hematology, Moscow, Russian Federation
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is a potentially curative treatment for patients with hematological malignancies.
However, relapse remains the major cause of treatment failure after allo-HSCT.
Mixed chimerism (MC) can induce immunologic tolerance and lead to relapse.
One of the most effective approaches to treat these patients is donor lympho-
cyte infusion (DLI) with or without chemotherapy.
Aims: To analyze long-term results DLI in early posttransplant MC and in
relapsed patients after allo-HSCT.
Methods: The study included 61 patients of in whom DLI with interleukin 2 (IL-
2) was administered at the National research center for Hematology from 2011
till 2016. DLI with IL-2 was administered for patients with MC, more than 10-
15% recipient DNA (n=26). A median age was 33 years old (19-54 years). Eight
were males, 20 – females. There were AML (n=17), ALL (n=4), MDS (n=2),
CML/MPN (n=3). Before allo-HSCT complete remission had in 20 patients and
6 had relapse/progression disease. Patients received allo-HSCT from related
(n=20) or unrelated (n=6) donor. The intensity of conditioning was mainly
reduced intensity (n=15) rather than myeloablative conditioning (n=11). Bone
marrow (BM) as a graft source was used in 20, PBSC – 6. DLI was started at
low dose 1*107CD 3+ per kg. Every following dose of infusion CD 3+ increased
until 5*107CD 3+ per kg. Number of infusions depended on achievement 100%
donor chimerism. Thirty five patients with relapse after allo-HSCT (AML, n=27,
ALL, n=5, MDS, n=2, CML, n=1) were administered DLI with IL-2. Number DLI
was 1 or 5 in different causes. Complete remission before allo-HSCT had in 25
patients and 10 had relapse/progression disease. 33 patients received
chemotherapy and after chemotherapy on 7 days DLI was using an escalating
dose following infusions. Two patients received DLI with IL-2 without chemother-
apy. A median age was 33 years old (18-60 years). 14 were males, 21 - females.
Stem cell source was BM and (PBSC) in 22 and 13 of the cases, respectively.
Patients were transplanted from related (n=17) and from an unrelated donor
(n=18). Condition regimen was MAC (n=7), RIC (n=28). Bone marrow as a
graft source was used in 22, PBSC – 13.
Figure 1.
Results: A median follow up was 5 months (0,3-63). A median time between
allo-HCST and DLI was 3 months (1,5-64). 100% donor chimerism was
achieved in 17 patients with MC from 26 (65%). A median number of infusions
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was 2 (1-5). There were 5 (19%) graft failures. Acute GVHD appeared in 8
(32%), all of them as grade 3; chronic GVHD occurred in 7 (27%). Patients
with a MC had better overall survival 77,6% than patients with relapse after
allo-HSCT (22%). Remission was achieved in 16 (48%) patients with relapses.
However, 5 patients relapsed again. Acute GVHD was developed in 8 cases
(22%). Nineteen patients died from relapse and 1 patient died from aGVHD in
remission. Event free survival in patients with MC and in patients with relapses
was 78,6% and 26,2%, respectively.
Summary/Conclusions: The prognosis of hematological malignancies is poor
if relapse is established after allo-HSCT. DLI protocol as preventive therapy
must be created for improving long-term results in high risk patients. “Prevention
is better than cure.”
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MEMORY T CELLS DONOR LYMPHOCYTE INFUSIONS AFTER
HAPLOIDENTICAL STEM CELL TRANSPLANTATION AS A SAFE
PROCEDURE TO IMPROVE T-CELL RECONSTITUTION
S. Cortez 1,*, R. De Paz1, M. Gasior1, A. Martínez1, Y. Mozo2, B. Rosich2,
J. Valentin1, A. Sastre2, A. Pérez 2
1Hematology, 2Pediatric Hematology-Oncology, Hospital Universitario La Paz,
Madrid, Spain
Background: Hematopoietic stem cell transplantation (HSCT) is a potential
curative treatment for patients with hematologic malignant diseases. Haploiden-
tical transplantation with extensive ex vivo T cell depletion of the graft, has
demonstrated to prevent graft versus host disease (GVHD), but the major dis-
advantage has been the development of graft failure, relapse and infections
due to delayed immune reconstitution. A selective T cell depletion method that
removes T naïve cells that express CD45RA+ in haploidentical donor lympho-
cytes, which are responsible for GVHD, as well as preservation of memory T
cells CD45RO, is a novel therapy that may provide functional T cells with anti-
infection, anti-leukemia and anti-rejection properties.
Aims: We describe the outcome of CD45RA+ cell depletion of donor lymphocytes
infusions, in patients with hematologic diseases with mixed chimerism, severe
infections and high risk of relapse after hematopoietic stem cell transplantation.
Methods: Patients with hematologic diseases with poor prognosis who lacked
an HLA matched donor were included. The recipients received a CD45RA-
depleted haploidentical transplantation, on day 0 they received a first graft with
a median CD34+ cell dose of 6.44x106/Kg (range 5x106/Kg-9x106/Kg), on day
+1 they received a CD45RA-depleted graft. After transplantation studies of
chimerism, quantification of lymphocyte subsets as well as control for viral
infections were made to all patients.
Results: We present the results of six patients with a median age of 11 years
(range 4 to 15 years), diagnosis included B-Cell acute lymphoblastic leukemia
(n=2), T cell acute lymphoblastic leukemia (n=1), acute myeloblastic leukemia
(n=2), aplastic anemia (n=1), these patients received a selective CD45RA-
depleted haploidentical transplantation. During the follow up after HSCT, three
patients had persistent lymphopenia, four patients developed infections caused
by CMV, norovirus, HHV-6, BK virus and toxoplasma, one patient had increasing
levels of mixed chimerism and one had graft failure. These patients were treated
with infusions of 16 aliquots of cryopreserved CD45RO+ haploidentical donor
lymphocytes, the CD45RA+ cells depletion was made using the cliniMACS sys-
tem. The median dose of CD45RO+ cells was 1,02x107/Kg, starting at a dose
of 1x10e5/Kg until a maximal dose of 2x10e8/Kg, infused every 21 days. The
CD45RA+ cell dose was a median of 0.0045x103/Kg (range: 0-1,6x103/Kg). All
the procedures were well tolerated, neither adverse events nor GVHD were
noticed. After the DLI, a progressive increase in T cells count were observed.
Summary/Conclusions: In our experience DLI enriched for CD45RO+ mem-
ory T Cell is a promising and safe strategy for patients with severe viral infec-
tions and risk of relapse after haploidentical HSCT, these cells has demon-
strated to trigger the CD4 and CD8 T-cell reconstitution, which will help reduce
risk infection with a low risk of GVHD. However further studies are needed in
order to support this therapy.
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FLAG REGIMEN WITH IDARUBICINE AS CYTOREDUCTION THERAPY
BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
IN PATIENTS WITH REFRACTORY ACUTE MYELOID LEUKEMIA
L. Wang1,*, R. Devillier2, X. Fan1, W. Tang1, S. Harbi2, N. Vey2, J. Hu1, D. Blaise2
1Blood and marrow transplantation center, Department of Hematology, Rui Jin
Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,
2Unité Transplantation et de Thérapie Cellulaire, Département d’Hématologie,
Institut Paoli-Calmettes, Marseille, France
Background: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT)
is the only curative option for patients with refractory acute myeloid leukemia
(AML). However, allo-HSCT with standard conditioning regimen could merely
achieve a long-term survival of 20% and the key problem is the high relapse
rate even after transplantation.
Aims: We have evaluated the safety and efficacy of new conditioning regimen
with sequential intensive chemotherapy (FLAG-IDA) followed by conditioning
of Flu-Bu(3).
Methods: The study was designed and developed in two separate transplanta-
tion centers in Rui Jin Hospital (RJH, Shanghai) and Institut Paoli-Calmettes
(IPC, Marseille) respectively. A total of 47 refractory AML patients with median
bone marrow blast of 35% (1~90%) and median age at 42y (16~62) were
enrolled. Thirteen patients received transplantation with mobilized peripheral
blood stem cells (PBSC) from HLA-matched sibling donor while 18 and 16 with
matched unrelated or haplo-identical donors. All patients received FLAG + 3-
days idarubicine (12mg/m2 in RJH or 10mg/m2 in IPC) and then received Flu-
darabine (5 days) with IV Busulfan (3-days) with a 7-day interval. The GVHD
prophylaxis regimens were CsA+MMF±ATG (RJH) or post-cyclophosphamide
(IPC).
Results: With a median follow-up of 8 months (1~70m), a total of 14 patients
relapsed with a median time of relapse at 4.8 months (2.1~18.1) and most of
them (11/14) relapsed within first 6 months after transplantation. A total of 24
patients died due to relapse (n=12) or non-relapsed mortality (NRM, n=12).
The estimated 3-year relapse rate (RR) and NRM were 42.0±9.2% and
25.9±6.5% respectively. The estimated 3-year OS and DFS were 43.6±7.8%
and 42.2±7.8%. In the primary multivariate analysis (including age, cycles of
pre-transplantation chemotherapy, bone marrow blasts, cytogenetics and treat-
ment center), only bone marrow blast ≥35% and age over 40 were associated
with disease-free survival and relapse respectively while there was no signifi-
cant difference between RJH and IPC in terms of transplantation outcome in
uni- and multivariate analysis.
Summary/Conclusions: Our primary data demonstrated a promising outcome
with FLAG-IDA chemotherapy as debulking therapy sequential with Flu-Bu3
conditioning regimen in patients with refractory AML and clinical trial with larger
patients cohort is warranted.
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STUTTER PCR PRODUCTS MAY NOT INTERFERE WITH STR BASED
CHIMERISM MONITORING AFTER ALLOGENEIC BONE MARROW
TRANSPLANTATION
N. Kostritsa1,*, N. Risinskaya2, E. Parovichnikova3, A. Sudarikov2
1School of Medicine, Lomonosov Moscow State University, 2Department of
Molecular Hematology, 32Department of Hematological Oncology and BMT,
National Hematology Research Center, Moscow, Russian Federation
Background: Chimerism analysis is one of the main methods to monitor the
bone marrow engraftment or disease relapse after allogeneic bone marrow
transplantation. Routine test is based on differences in the length of short tan-
dem repeats (STR) from the donor and the recipient. However, chimerism esti-
mation is complicated by stutter PCR peaks appearing due to irregular DNA
polymerase activity. Generally, these sequences are 4 nucleotides shorter than
a specific marker and may concur with a specific sequence of recipient’s DNA
hindering chimerism estimation based on that locus. This problem seems to
be especially serious in case of a sex-matched sibling BMT when most of the
alleles for donor and recipient are the same. One may suggest to limit the use
of these markers for the cases with stutter-bands comparable with donor allele
peak height. Thereby, the absence of “stutter-peaks free” markers hinders
mixed chimerism estimation at the point of low recipient hematopoiesis output.
Aims: To identify the contribution of stutter-bands to the total amount of PCR-
product and to derive universal formulas for the chimerism calculation excluding
stutter percentage.
Figure 1.
Methods: Genomic DNAs of donors and patients were isolated from bone
marrow samples. Chimerism was assessed by the STR-PCR analysis (poly-
merase chain reaction with a panel of primers for loci of short tandem repeats)
with COrDIS Plus multiplex kit for amplification of 19 polymorphic STR-markers
and amelogenin loci. The fragment analysis was performed on a 3130 Genetic
Analyzer. The data processing was accomplished using GeneMapper v.4-0
software. Informative loci were chosen beforehand comparing pretransplant
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patient DNA and donor DNA. The percentage of donor chimerism as well as
stutter percentage was calculated using standard formula.
Results: Fifty transplant cases with stutter peaks were evaluated: 18 homozy-
gous; 15 heterozygous with both alleles showing detectable stutter; 17 heterozy-
gous with one stutter visible only. Stutter percentage and standard deviation
were calculated in each case for donor DNA sample and for four bone marrow
DNA samples from recipient with established complete donor chimerism taken
during the time. It was found that the contribution of the stutter-peaks into the
total amount of product ranges from 1.2% to 11% (SD was no more than 1.5%
for each locus) for markers with appreciable stutter-bands and seems to be
locus-specific constant for each patient. Assuming the stutter percentage as a
locus- and patient-specific constant (for the same PCR conditions) we derived
a formulae for recipient DNA percentage: Actual recipient’s%=(apparent rec./total
DNA ratio - stutter/total DNA ratio):(1-stutter/total DNA ratio)*100% (special for-
mulas for hetero- and homozygous on fig. 1). To test these formulae the panel
of DNA samples with mixed chimerism from 50 to 97% estimated by independent
“stutter free” assay was used. The results of chimerism estimation based on
“stutter-complicated” markers (using proposed formulae) conventional “stutter-
free” markers appeared to be the same (SD<1%).
Summary/Conclusions: The use of formulae described may circumvent the
absence of the “stutter-free” informative markers for mixed chimerism estimation.
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INTRODUCING PLERIXAFOR TO IMPROVE MOBILIZATION IN MULTIPLE
MYELOMA PATIENTS WHO BEHAVE AS POOR-MOBILIZERS IS
COST-EFFECTIVE CONSIDERING THE WHOLE MOBILIZATION AND
TRANSPLANT PROCEDURE
C. Chabannon1,*, A.-G. Le Corroller-Soriano2, R. Touzani2, A.-M. Stoppa3,
C. Lemarie1, M. Debals-Gontier2, B. Calmels1, R. Bouabdallah3, A. Granata3
1Centre de Therapie Cellulaire. Departement de Biologie du Cancer, Institut
Paoli-Calmettes, 2SESSTIM, Inserm, 3Departement d’Oncohematologie, Institut
Paoli-Calmettes, Marseille, France
Background: Plerixafor, a CXCR4-antagonist, is efficient to improve CD34+
cell mobilization and collection in candidates for autologous transplantation
who behave as poor-mobilizers. The cost of the drug is however of concern.
Published medico-economics studies were mostly conducted in the US, and
few including detailed and comprehensive micro-costing of the collection and
transplantation process; conclusions may thus not apply to European countries
where cost structures are different.
Aims: To compare costs and effectiveness of plerixafor-free and plerixafor-
replete management strategies for multiple myeloma patients who behaved as
poor-mobilizers after adequate administration of a standard rhG-CSF mobiliza-
tion regimen.
Methods: Sixty patients diagnosed with multiple myeloma were consecutively
identified during years 2009-2011, immediately before and after EMA granted
marketing authorization for plerixafor. Poor-mobilizers were defined as having
circulating CD34+ cell counts below 20/µL. Plerixafor was introduced or not as
a result of the attending physician’s decision, reflecting progressive changes in
medical practices over this transitional period. The historical and study groups
were matched over four criteria: disease stage at diagnosis, age, gender and
number of chemotherapy treatments received before mobilization. Two cost-
effectiveness analyses (CEA) were conducted; the primary CEA looked at the
criterion “collecting at least 2x106 CD34+ cells”; a secondary CEA looked at
the criterion “successful autologous transplant administered”. Detailed micro-
costing evaluations (2015 figures) did not or did include transplantation costs
for the first and second CEA respectively.
Results: The two groups were similar in terms of age, sex distribution, disease
characteristics or previous treatments. 27/30 and 26/30 patients proceeded to
high-dose melphalan and autologous transplantation in the study and historical
groups, respectively. There was a trend to a higher number of collected
CD34+cells in the control group; however, the proportion of patients who met
the minimal target number of 2x106 collected CD34+ cells/kg was identical
(28/30).Length of hospitalization, times to neutrophil and platelet recoveries,
numbers of PRBC and platelet transfusions were identical in the two groups.
Mobilization and collection costs per patients were more important in the plerix-
afor group that in the historical group (8.757 vs 5.460 €, p<0.0001), and propor-
tionally higher in patients who received plerixafor as part of a remobilization
treatment rather than pre-emptively (10.401 vs 8.162€ respectively). The main
CEA concluded to a 3.237€ increase in costs for the same number of patients
achieving a minimal target number of 2x106 collected CD34+ cells/kg. The sec-
ond CEA found a decrease in the cost of transplant, with 12.724€ in the study
group vs 13.634€ in the historical group (NS). In total, the 2.035€ increase for
the complete procedure cost (22.866€ per successfully autografted patient in
the study group vs 20.831€ in the historical group) was not statistically different.
Summary/Conclusions: Cost-effectiveness arguments should not been used
against the administration of plerixafor in multiple myeloma patients in the Euro-
pean context. Future prospective researches looking at patients reported out-
come criteria and labour organization in apheresis facilities are needed.
This work was supported by a grant from SANOFI S.A.
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PERIPHERAL BLOOD STEM CELL (PBSC) HAPLOIDENTICAL
TRANSPLANTATION VERSUS MISMATCHED UNRELATED DONOR
TRANSPLANTATION: A SINGLE UK CENTRE EXPERIENCE
J. O’Sullivan1,*, K. Parmesar2, D. McLornan2,3, D. L. Hugues2, V. Potter4,
M. Streetly1,4, M. Gallagher4, I. Walker4, M. Kazmi1,2, A. Kulasekararaj4,
J. Marsh4, G. Mufti4, T. Pagliuca4, K. Raj2,3
1Haematology, Guy’s and St. Thomas’ NHS Foundation Trust, 2Haematology,
King’s College Hospital NHS Foundation Trust, 3Haematology, Guy’s and St.
Thomas’ NHS Foundation Trust, 4Haematology, King’s College Hospital NHS
Foundation Trust, London, United Kingdom
Background: Haploidentical (Haplo) and mismatched unrelated donor trans-
plantation (MMUD) are potential alternatives for those without a fully matched
available donor. Recent collaborative and single centre studies suggest that
haploidentical donor outcomes are comparable to unrelated donor outcomes
in the T cell-replete setting.
Aims: In this single centre review, we aimed to compare outcomes of T cell-
replete haploidentical allogeneic stem cell transplantation with mismatched
unrelated donor allogeneic stem cell transplantation.
Methods: From January 2010 to December 2015, 38 patients underwent T
cell-replete HLA-matched haploidentical transplantation with post transplanta-
tion cyclophosphamide given on days +3 and +4 given as graft versus host
disease (GvHD) prophylaxis. These were retrospectively compared with 45
patients underwent single HLA-locus mismatched unrelated donor transplan-
tation with alemtuzumab as GvHD prophylaxis. Data was censored at time of
last contact in 2016. Analysis was performed using SPSS v.23.0 and R 3.3.2
statistical software.
Results: The median recipient age was similar in both groups; 51 (19-69) years
in Haplo and 59 (28-74) years in MMUD transplants, p=0.012; 68.7% of all
patients were male. Non-Caucasian ethnicity comprised 63.2% of Haplo versus
(vs.) 15.6% of MMUD transplants, p<0.001. Myelodysplasia (MDS)/acute
myeloid leukaemia (AML) was the commonest transplant indication in both
groups (60.5% of Haplo and 93.6% of MMUD transplants). The disease risk
index (DRI) in this subgroup was overall low/intermediate in 69.2% and high/very
high in 26.2% (unknown in 4.6%). Reduced intensity conditioning was used in
all but two Haplo (4.6%) and 4 MMUD transplants. Patients were followed up for
a median of 544 days with a similar 2-year overall survival of 61.5% (95% con-
fidence interval, CI, 52.4 – 69.3%) and 58.1% (95% CI 48.8-66%) and 3-year
overall survival of 56.4% (95% CI 45.8 – 65.6%) and 48.9% (95% CI 41 – 56.2%)
in Haplo and MMUD transplants respectively, p=0.67. Overall progression free
survival (PFS) at 2 years was 53.3% (95% CI 44-61%) and 40.1% (95% CI 34-
46%) in Haplo and MMUD transplants respectively, p=0.31. In those with
MDS/AML, the 2-year progression-free survival was 64.2% (95% CI 49-75%) in
Haplo vs 38.5% (95% CI 33-43%) in MMUD transplants, p=0.1. In Haplo and
MMUD transplants, the 3-year cumulative incidences of non-relapse mortality
were 25.5% (95% CI 12-41%) and 31.2% (95% CI 18-45%) respectively, p=0.61
and of relapse were 25.6% (95% CI 12-41%) and 34.8% (95% CI 20-49%)
respectively, p=0.51. Median time to neutrophil engraftment was 18 and 12 days
and for platelet engraftment 21 and 12 days in the Haplo and MMUD transplants
respectively. Engraftment was successful in 89.4% (Haplo) and 95.5% (MMUD)
of patients. The incidence of acute GVHD was 42.1% in Haplo and 35.6% in
MMUD transplants but severe (grade 3/4) acute GvHD only occurred in 7.9%
(Haplo) and 8.9% (MMUD). Chronic GvHD occurred in 15.8% of Haplo and
33.3% of MMUD transplants, p=0.067. Chronic GvHD did not impact overall or
progression free survival in either transplant group.
Summary/Conclusions: T cell-replete haploidentical transplantation when
compared with T cell-deplete mismatched unrelated donor transplantation
showed high engraftment rates, low rates of severe acute and chronic GVHD
and comparable overall survival, non-relapse mortality and relapse rates. We
suggest that T cell-replete haploidentical transplantation is a safe and accept-
able alternative when a matched unrelated donor is unavailable.
E1551
IMPACT OF ABO BLOOD GROUP INCOMPATIBILITY ON THE OUTCOME
OF RECIPIENTS UNDERGOING ALLOGENIC TRASPLANTATION:
EXPERIENCE IN OUR CENTER BETWEEN 2013 AND 2016
G.A. Méndez Navarro1,*, G. Moreno Jiménez1, F.J. López Jiménez1, A. Jiménez
Martín1, S. López González1
1Servicio de Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal.
Madrid, Madrid, Spain
Background: ABO blood group compatibility is not an essential requirement or
priority in the selection of the allogenic bone marrow donor, unlike what happens
in solid organ transplant; thereby, up to 30-50% of allogeneic transpantation
shows ABO incompatibility1, but its clinical impact is controversial. It’s accepted
that it may provoke hemolitic reactions and delayed erytrhocyte engraftment.
Nevertheless, its influence on leukocyte and platelet engraftment, graft-versus-
host disease (GvHD), and overall survival is not fully elucidated yet2.
Aims: To describe the experience in our center in allogenic transplantation with
ABO mismatching and its relation with hemolytic events (HE), red blood cell
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(RBC) recovery, neutrophil and platelet engraftment, pure red cell aplasia
(PRCA), acute GvHD, relapse and overall survival (OS).
Methods: We retrospectively studied allogeneic transplants performed from
January 1, 2013 to December 31, 2016. We collected the baseline variables
reflected in Table 1 and analyzed the incidence of HE, neutrophil and platelet
engraftments, RBC recovery, PRCA (defined as anemia with transfusional
requirement and reticulocytes <1% in day +60 without other cytopenias), acute
GvHD, relapse of the background disease and survival (at 6, 12 and 24 months)
in the ABO compatible groups (ABOc) and in the incompatible (ABOi), the
latest divided into major, minor and bidirectional disparity.
Results: A total of 133 transplants were included, with a mean follow-up time
of 16.4 months. The median age was 52 years and there were 79 males and
54 females. Diagnoses were mainly AML (n=72), ALL (n=19) and NHL (n=11)
(see Table 1). 60 received low intensity and 73 myeloablative regimens. They
were HLA identical (n=44), unrelated donor (n=50), haploidentic (n=38) and
cord (n=1) and, in most cases, hematopoietic progenitors were obtained from
mobilized peripheral blood (90.2%). 44.3% (n=59) presented some type of
ABOi: major (n=26), minor (n=25) and bidirectional (n=8). The product was
processed in order to prevent hemolysis in only 7 cases (red cell depletion in
4 and deplasmatization in 3). There were 23 hemolytic (18 immediate and 5
delayed) -mostly mild- events, which appeared predominantly in patients with
ABO-incompatibility (38.98%)- 50% in major disparity, 28% in minor and 37.5%
in bidirectional- vs ABOc (2.7%) and this difference was statistically significant
(p<0.0001). No differences were observed in the neutrophil graft between the
ABOc group and the ABOi group, nor in the platelet engraftment; in contrast,
we found a statistically significant effect on the time to erythrocyte recovery
(mean: 49.94 days in ABOi vs 24.69 in ABOc; p=0.032). Only 6 cases of PRCA
were documented (all in ABOi). The occurrence of acute GvHD did not differ
significantly among the groups (52% in ABOc vs 53.5% in incompatibles) nor
in its severity. We have not found differences either in the rate of relapse (24.6%
vs 19.6%) nor in the survivals at 6, 12 or 24 months (66.1% vs 78.8%, 48.2 vs
47.2% and 38.4 vs 39.4%, respectively).
Table 1.
Summary/Conclusions: In our study ABO-mismatched transplants have
shown a greater number of hemolytic events and red cell aplasia, as well as a
greater delay in achieving erythrocye recovery. However, we have not found
an association with delayed neutrophil and platelet recoveries, increased acute
GvHD, relapse or worse OS in the ABO incompatible group, in keeping with
most previous reports**, although the absence of effect might be as well be
related to an insufficient study power due to low sample size.
References
1. Mielcarek M, Leisenring W et al. Blood. 2000 Aug 1;96(3):1150-6.
2. Kimura F, Sato K et al. Haematologica. 2008 Nov;93(11):1686-93. Kollman
C, Howe CW et al. Blood. 2001 Oct 1;98(7):2043-51.
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LOW BLOOD CONCENTRATION OF TACROLIMUS CAN BE A RISK OF
GRAFT FAILURE AFTER CORD BLOOD TRANSPLANTATION
A. Fujimoto1,*, T. Ishikawa1
1Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
Background: Cord blood transplantation (CBT) has recently emerged as an
attractive alternative donor. However, graft failure still remains potential threats
for morbidity and mortality. 
Aims: Several biological mechanisms may contribute to graft failure. Immuno-
logical rejection of the graft is known as a major cause of graft failure. Graft
failure may also be caused by septicemia, viral infections, drug toxicity and so
on.These events have been frequently occurred just before engraftment, and
we often experience fluctuation of blood levels of immunosuppressive drugs.
Here, we analyzed an association between blood levels of Tacrolimus (Tac)
before neutrophil engraftment and neutrophil engraftment.
Methods: Between January 2011 and Jury 2016, 76 patients received single-
unit CBT at our institutions. We analyzed 59 patients for whom Tac was used
for GVHD prophylaxis including Tac and Mycophenolate mofetil (MMF) combi-
nation (n=26) and Tac with an additional short Methotrexate (sMTX) (n=33).
Sixteen patients who underwent second or third CBT and a patient for whom
Tac was not used for GVHD prophylaxis were excluded. We also excluded a
patient whose Tac concentration we didn’t check more than two times a week.
Tac was started at a dose of 0.02mg/kg/day by continuous i.v. infusion. Tac
blood concentrations were monitored at least three times a week before engraft-
ment, and dosages were adjusted to maintain serum levels about 10-20 ng/ml. 
Results: Of the 59 patients, 48 patients achieved neutrophil recovery at a
median of 22 (range 13-35) days. Two patients died before engraftment from
severe PIR and active infection. Nine patients (18.6%) experienced graft failure.
Patients who could maintain Tac level above 12ng/ml during the second week
after CBT (Tac high group) had an incidence of graft failure of 4.8%, which was
significantly lower than the 26.3% seen in the other patients (Tac low group)
(p<0.01). Patients for whom Tac and MMF were used (MMF group) had an
incidence of graft failure of 3.8%, which was significantly lower than the 36.4%
seen in the other patients for whom Tac with an additional sMTX (MTX group)
for GVHD prophylaxis (p<0.01). Combined of these factors, the patients of Tac
low group and MTX group had had an incidence of graft failure 40.9%, which
was significantly highest than the 5.4% seen in the other patient including Tac
high group and MMF group even if the patient were included of Tac low group. 
Figure 1.
Summary/Conclusions: Low levels of Tac blood concentration were signifi-
cantly associated with the incidence of graft failure of the patient for whom Tac
with an additional sMTX were used for GVHD prophylaxis. Before engraftment,
frequent checks of the Tac blood concentration and maintaining the drug level
should be considered for these patients. 
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THE EXPRESSION OF TOLL-LIKE RECEPTORS GENES IN PATIENTS
WITH LYMPHOID MALIGNANCIES AFTER AUTOLOGOUS PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION
J. Rybka1,*, B. Jaźwiec1, K. Wicherska-Pawłowska1, R. Poręba2, K. Kuliczkowski1,
T. Wróbel1
1Hematology, 2Internal Medicine, Wroclaw Medical University, Wroclaw, Poland
Background: Peripheral blood stem cell transplantation (PBSCT) is one of
the main strategies for the treatment of malignant hematological diseases. Toll
like receptors (TLRs) are present on various immune cells including natural
killer cells, monocytes, macrophages, T lymphocytes and B lymphocytes. Ten
different TLRs have been evaluated in humans. TLRs play a central role in
immune surveillance and in the initiation of the inflammatory response. The
expression of TLRs genes and their association with outcome in patients treat-
ed with PBSCT remains unclear.
Aims: The objective of the current study was to investigate association between
expression of TLRs genes and hematopoietic recovery and rate of infections
in patients treated with PBSCT.
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Methods: The evaluation of TLRs expression genes were performed in 40
patients who underwent PBSCT. The median age of patients was 54 years
(range: 25-65 years). There were 15 patients with multiple myeloma (MM), 20
patients with non-Hodgkin lymphomas (nHLs) and 5 patients with Hodgkin lym-
phoma (HL). Peripheral blood samples were taken before megachemotherapy
with autolougous stem cell transplantation and at time of hematopoietic recovery
in patients after PBSCT. Relative expression of Toll-like receptors was assessed
by real-time PCR using inventoried TaqMan® Assays from Life
Technologies/ThermoFisher. Beta glucoronidase (GUSB) served as endoge-
nous control. Reaction was performed in 7500 Real Time PCR instrument
(LifeTechnologies) using Gene Expression MasterMix (LifeTechnologies/Ther-
moFisher). Comparative CT method (**) was used to compare expression
among patients and with healthy controls. Statistical analysis was conducted
using STATISTICA 12 software (StatSoft, Polska). For quantitative variables
arithmetic means (X) and standard deviations (SD) of estimated parameters
were calculated in the analysed groups. Distribution of variables was examined
using tests of Lilliefors and W-Shapiro-Wilk. In cases of independent quantita-
tive variables with the normal distribution the statistical analysis took advantage
of t test for unlinked variables. In cases of variables manifesting distribution
distinct than the normal one, for independent quantitative variables U test of
Mann-Whitney was used. For dependent quantitative variables of the normal
distribution, the t test for linked variables was applied. In cases of quantitative
dependent variables with the distribution distinct from normal, the pair sequence
test of Wilcoxon was applied. In order to define a relationships between the
studied variables, correlation analysis was performed. Results at the level of
p<0,05 were assumed to be of statistical significance.
Results: The mRNA expression of TLR2 and TLR9 was significant higher in
patients after PBSCT than before PBSCT procedure (ΔCt TLR2 1,4209±1,0461
vs 1,7877±1,4974 and ΔCt TLR9 117,853±141,0870 vs 289,788±271,98)
(p<0,05). We observed that expression of TLR9 was significant higher in
patients with bacterial and fungal infection after PBSCT in comparison to group
without infection after PBSCT (ΔCt TLR9 117,853±141,087 vs 289,788±271,98)
(p<0,05). Moreover we found significant positive correlation between expression
of mRNA of TLR9 and neutrophil recovery after PBSCT (r=0,4075; p=0,023).
Summary/Conclusions: In conclusion our findings suggest that TLRs could
be useful markers in outcome in patients treated with PBSCT.
This observation should be validated by larger study. 
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TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC
VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME
AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPANDED
ACCESS PROGRAM FINAL DATA
S. Grupp1, P. Richardson2,*, A. Smith3, N. Kernan4, J. Antin5, L. Lehmann6,
S. Giralt7, W. Liang8, R. Hume8, W. Tappe8, R. Soiffer6
1Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia,
2Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy,
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Med-
ical School, Boston, 3Division of Pediatric Blood and Marrow Transplantation,
University of Minnesota, Minneapolis, 4Pediatric BMT Service, Memorial Sloan
Kettering Cancer Center, New York, 5Stem Cell/Bone Marrow Transplantation
Program, Division of Hematologic Malignancy, Department of Medical Oncol-
ogy, Dana-Farber Cancer Institute, 6Center for Stem Cell Transplantation, Divi-
sion of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber
Cancer Institute, Harvard Medical School, Boston, 7Memorial Sloan-Kettering
Cancer Institute, New York, 8Jazz Pharmaceuticals, Inc., Palo Alto, United
States
Background: Hepatic veno-occlusive disease/sinusoidal obstruction syndrome
(VOD/SOS) is an unpredictable, potentially life-threatening complication of
hematopoietic stem cell transplantation (HSCT). VOD/SOS with multi-organ
dysfunction (MOD) may be associated with >80% mortality. Defibrotide is
approved to treat severe hepatic VOD/SOS post-HSCT in the European Union
and to treat hepatic VOD/SOS with renal and/or pulmonary dysfunction post-
HSCT in the United States. Prior to approval in the United States, defibrotide
had been available via an expanded-access program.
Aims: To perform an exploratory post hoc analysis of final data from the
expanded-access program on the impact on Day +100 survival of timing of ini-
tiation of defibrotide after diagnosis of VOD/SOS in HSCT patients.
Methods: In an expanded-access study, patients diagnosed with VOD/SOS
(per Baltimore criteria, modified Seattle criteria or biopsy) with or without
renal/pulmonary MOD after HSCT or chemotherapy received defibrotide
25mg/kg/d in 4 divided doses for a recommended ≥21 days after patients pro-
vided informed consent. For these exploratory analyses, Day +100 survival
rates in HSCT patients were examined post hoc by time from VOD/SOS diag-
nosis to start of defibrotide for (1) all patients before/after days 1, 2, 3, 4, 7, and
14, using Fisher’s exact test and (2) patients starting defibrotide on a particular
day: 0, 1, 2, 3, 4, 5, 6, 7, 8–14, and ≥15, by Cochran-Armitage test for trend
across days. Causes of treatment delay were not assessed.
Results: In the final dataset, timing of initiation date was available for 1000
HSCT patients (512 with MOD) who received ≥1 dose of defibrotide. In 31.0%
of all HSCT patients, defibrotide was started the day of diagnosis; in 92.9%, by
Day 7. In the population-wide analysis of initiation before/after days 1, 2, 3, 4,
7, and 14 post-diagnosis in both the overall group and MOD subgroup (Figure
1), earlier initiation was associated with significantly higher Day +100 survival
rates for all days (P≤.001), except Day 14 (2.6% of patients started defibrotide
after Day 14). The trend test for particular initiation days also showed a signif-
icant trend over time for higher Day +100 survival with earlier defibrotide initi-
ation post-diagnosis in both the overall HSCT group and MOD subgroup
(P<.001). Adverse events (AEs) and serious AEs occurred in 70.8% and 53.4%
of patients, respectively. Other than VOD/SOS and MOD, the most common
AE was hypotension (11.7%) and most common serious AE was respiratory
failure (7.3%).
Figure 1.
Summary/Conclusions: In this exploratory analysis of final study data, earlier
defibrotide initiation post-VOD/SOS diagnosis significantly improved Day +100
survival, confirmed by the Cochran-Armitage test (P<.001). No specific day
provides a clinically meaningful cutoff for better Day +100 survival, suggesting
that later intervention retains value if treatment must be delayed.
Support: Jazz Pharmaceuticals.
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RED BLOOD CELL DISTRIBUTION WIDTH (RDW) AS AN ACUTE GRAFT
VERSUS HOST DISEASE PREDICTOR MARKER IN ALLOGENIC STEM
CELL TRANSPLANTATION
B. Robredo1, F. Sartori1, M.A. Duran1, A. Gutierrez1, A. Sampol1, L. Lo Riso1,
J.M. Sanchez-Raga1, B. Lopez Andrade1,*
1Hematology, Hospital Universitario Son Espases, Palma Mallorca, Spain
Background: The red blood cell distribution width (RDW) is a common param-
eter for measuring anisocytosis in the study of anemia. Recently it has been
regarded as a surrogate marker of inflammation and adverse outcome in sev-
eral diseases. Acute graft-versus-host disease (GVHD) is a common compli-
cation of allogeneic hematopoietic cell transplant (allo-HSCT) which is related
to inflammation in the context of damage of the host tissue and the release of
inflammatory cytokines. We decided to study the utility of this potential inflam-
matory marker in the setting of GVHD in the allo-HSCT.
Table 1.
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Aims: RDW values were evaluated at the day of infusion (RDW 0), we choose
this point in time to evaluate the tissue injury and inflammation secondary to the
conditioning regimen, in order to evaluate if there is a major incidence of GVHD.
Methods: We retrospectively evaluated 103 patients who had underwent allo-
HSCT for different indications at our center, with a median follow up of 12.8
months (0-235) at our center. The population consisted of 59 males and 44
females, the median age was 43.7 years. The RDW was collected from the
hemogram at the day of the HSCT cell infusion, before it was performed (table
1). The IBM SPSS STADISTICS program was used for all statistical analyses.
Differences were considered statistically significant when p<005. The median
of RDW values in our study was of 16.4 (11.2-38.5). The areas under the receiv-
er operating characteristic (ROC) curves of RDW were ≤18.4 and >18.4 for
the selection of the increased RDW cutoff. We evaluated the association of
increased RDW (>18.4) with the development of GHVD. A survival analysis of
the association of different levels of increased RDW was performed. A subgroup
analysis of the Haploidentical HSCT patients (N=13) was also evaluated.
Figure 1.
Results: The presence of increased RDW >18.4 was strongly associated with
an increased risk of developing acute GVHD (p=0.009) being present in 80%
of the patients. In the haploidentical HSCT subgroup an increased RDW >16
was associated with acute GVHD. (p=0.044). There was no association of
chronic GVHD with elevated RDW at day 0 (p=0.563). The survival analysis
didn’t found an association of high RDW levels with mortality or survival
(p=0.301) but a tendency to an increased survival was show between the RDW
level subgroups. (figure2). Where a higher RDW seems to have a better sur-
vival, but this should be evaluated in a wider sample.
Summary/Conclusions: RDW at day 0 is a feasible predictor factor of Acute
GHVD, most likely as a secondary surrogate marker of inflammation secondary
to the conditioning regimen. The presence of other factors contributing to the
RDW increase (secondary to other comorbidities) cannot be ruled out; but by
itself RDW it’s an easy and affordable prognosis marker for aGVHD that should
be further evaluated.
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COMPARISON OF THE BEEAM CONDITIONING REGIMEN AND THE
BEAM CONDITIONING REGIMEN IN THE AUTOLOGOUS TRANS-
PLANATAION FOR HL AND NHL
S. Lozenov1,*, P. Ganeva1, B. Spassov1, Y. Petrov1, G. Arnaudov1, G.
Mihaylov1
1NSHATHD, Sofia, Bulgaria
Background: The BEAM has established itself as a standard of care condi-
tioning regimen in the autologous lymphoma HSCT setting for most transplant
centres in Europe. Yet however various other regimens are being compared
with it in order to achieved better safety profile, better OS and DFS, in order to
improve results with chemoresistant and unfavourable patients. One such reg-
imen is BeEAM (bendamustine, etoposide, cytarabine, melphalan).
Aims: We aimed to compare the efficacy of the BEAM and BeEAM conditioning
regimens and to compare there myelotoxicity profile.
Methods: We evaluated retrospectively 114 patients, receiving auto-HSCT at
the National Specialized Hospital for Active Treatment of Hematological Dis-
eases in Sofia for relapsed/refractory HL or NHL for the period from 1.01.2013
to 1.07.2016 with a follow-up of patients up to 1.11.2016. 92 of the patients
received BEAM and 22 received BeEAM. 2 and 3 year OS and DFS were com-
pared, CR rates and the average time periods to hematological recovery.
Results: The OS at 2 and 3 years respectively was 86.1%, 86.1%, for BeEAM
and 78%, 71% for BEAM, the DFS at 3 years was 76.4% in BeEAM and 73.2%
BEAM, provided that the differences did not have statistical significance. The
CR rate was 63.63% in the BeEAM group versus 50% in the BCNU group.
22.72% of the patients receiving BeEAM in SD or in diseases progression
achieved CR versus 10.86% respectively for the BEAM group. The mean time
to hematological recovery for neutrophils was 11.27 days (BeEAM) versus
10.24 days (BEAM) and 12.64 days (BeEAM) versus 11.12 days (BEAM) for
platelets.
Figure 1.
Summary/Conclusions: BeEAM appears to be a non-inferior alternative con-
ditioning regimen to the standard BEAM, it shows a trend towards higher myelo-
toxicity, but also a trend towards better short-term results in chemoresistant
patients. 
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DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS:
CORRELATION OF ALLELE-LEVEL HLA MATCHING WITH OUTCOME
AND WHICH CORD BLOOD UNIT WILL BECOME DOMINANT
M. Westendorp1,*, D. Hogge1, K. Song1, S. Narayanan1, S. Nantel1, R. Broady1,
M. Barnett1, C. Toze1, A. Gerrie1, Y. Abou Mourad1, D. Sanford1, M. Power1,
D. Forrest1, S. Heather1, N. Thomas1
1Leukemia/BMT Program of BC, Vancouver General Hospital, Vancouver,
Canada
Background: Umbilical cord blood (UCB) has been used for alternative donor
transplantation for the past 3 decades. Graft failure is not uncommon due to
higher degrees of histoincompatibility between recipient and UCB units and
fewer hematopoietic precursors in the product. To improve engraftment rates,
especially in larger (i.e. adult) patients (pts), two UCB units can be used. Double
UCB transplantation (DUCBT) is being utilized at many centres although it has
been noted that, while both units may contribute to engraftment, only one unit
becomes “dominant” – i.e. persists to provide long-term hematopoiesis. A vari-
ety of predictors of which unit will become dominant have been suggested, pri-
marily the unit that is more closely HLA-matched or the unit with the highest
total nucleated cell (TNC) count.
Aims: To determine the likelihood of engraftment, incidence of GVHD, influence
of TNC count and HLA mismatch on survival and selection of the dominant
cord following DUCBT in adults with high-risk hematologic disorders. 
Methods: A retrospective review was performed of adult pts undergoing
DUCBT at the referral centre for British Columbia. Recipients signed informed
consents for all clinical trials in which they participated. HLA typing at A, B, C
and DRB1 loci was done on all pts using high-resolution allele-level testing
(HRT). HRT was available at these 8 loci for both UCB units in 25/31 pts; for
the remaining units, class I typing was done by serology. UCB units selected
had to be ≥4/6 match at A, B (serologically) and DRB1 (by HRT). Combined
TNC count for the units had to be ≥30x106/kg recipient weight. Conditioning
was Fludarabine 40mg/m2 x4 and TBI 150 cGy x9; GVHD prophylaxis was
Tacrolimus/Mycophenolate. Pts received G-CSF 300 mcg s.c. daily from day
+1. Outcomes were compared using Fisher’s exact test.
Results: Between 06/09 and 09/16, 31 pts underwent DUCBT - 11 males, 20
females with median age 50 years (range 19-59). Diagnosis was acute myeloid
leukemia (AML; n=12), acute lymphoid/mixed phenotype leukemia (n=7),
chronic lymphoproliferative disease (n=5), MDS (n=4) or other (n=3). All 31 pts
recovered ANC>0.5x109/L at median of 20 days (range 14-72). Platelet count
reached >20x109/L in 26/31 pts at median of 38 days (range 24-188). Acute
GVHD developed in 26/31 pts (84%) and chronic GVHD in 17 of the 26 pts
(65%) that survived to day +100. Seventeen pts (55%) remain alive, in contin-
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uous remission at median follow-up of 3 years (range 0.5-7.0). Ten pts (32%)
experienced non-relapse mortality from GVHD (5 pts), infection (4 pts) or
unknown cause (1 pt). Four pts (13%) have relapsed at 3, 5, 10 and 12 months.
Outcomes for pts when the best cord unit match was 0-2 antigen-mismatched
(Ag-M/M) were superior (8/12 alive and well) to those pts when the best unit
was 3 Ag-M/M (3/9 alive and well; p=0.20). Unexpectedly, 6/9 pts whose best
unit was ≥4 Ag-M/M are alive and well. Information on the dominant cord was
available on 19 pts (Table 1); in 15/19 pts, the dominant cord was the same or
a better HLA match compared to 4/19 with a dominant cord that was an inferior
HLA match (p<0.001). However, the TNC was of less importance with the lower
TNC unit being dominant as frequently as the higher TNC unit for each HLA
match category (Table1).
Table 1.
Summary/Conclusions: DUCBT is effective in adults with life-threatening
hematologic disorders. With current UCB inventories, conditioning therapies
and supportive care, graft failure is rare - even in adults. HLA disparity between
the UCB unit and the patient is a better predictor than the TNC regarding which
unit will become dominant. Pts receiving well-matched UCB units (0-2 Ag-M/M)
may have better outcomes than pts receiving 3 Ag-M/M units although suc-
cessful outcomes can be seen even with a high degree (≥4 Ag-M/M) of HLA
incompatibility.
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CLINICAL ANALYSIS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR 46 ACTIVE RELAPSED AND REFRACTORY ACUTE PEDIATRIC
LEUKEMIA
L. Yuan1, S. Xue1, J. Wang1,*
1Department of Hematology, Aerospace Center Hospital, Beijing, China
Background: Given the dismal prognosis for relapsed and refractory (R/R)
acute leukemia, many physicians discourage offering hematopoietic stem cell
transplantation (HSCT) to adults patients with bone marrow (BM) blasts over
25%. Therapeutic recommendations for pediatric subjects with a similar situa-
tion are not available. 
Aims: With no significant alternative managing options for these patients, more
data are required to make an informed and patient tailored decision.
Methods: We retrospectively analyzed the preliminary outcome of 46 active
R/R acute pediatric leukemia including 30 AML and 16 ALL receiving trans-
plantation between 2012 and 2016. Median age at HSCT was 13 years. Active
R/R disease was all confirmed by cytogenetics/molecular genetics and aggres-
sive clinical course. Median bone marrow blasts was 46.4% (5-99%). Of note,
27 patients had over 50% blasts in BM. The earliest 13 transplants were con-
ditioned with conventional Bu/Cy or TBI/Cy regimen, thereafter, all received
intensified conditioning including FLAG/TBI (N=21), FLAG/Bu/CY (N=2) and
CLAG/Bu/Cy (N=10). Immuno-suppressive agents withdrawal started since day
30 if no acute GVHD occurred. Variety of post-HSCT intervention including
donor lymphocytes infusion and interleukine-2 injection were performed to
reduce relapse. Median follow-up of the whole cohort is 19 months (3–53
months).
Results: Forty-five (97.8%) achieved CR following HSCT. One died of infection
before engraftment. All 3 death occurred before 90 day due to relapse. Trans-
plant-related mortality at 1 year was 15.2%. Acute GVHD incidence was 49.3%
(grade III 20.4%), chronic 59.5%. Relapse was the major cause of treatment
failure and occurred in 28.3% of patients at a median of 1 year post HSCT.
Two-year overall survival and leukemia-free survival were 44.8±9.5% and
44.6±8.9%, respectively. Survival of AML patients was superior to those of ALL.
Besides, outcomes in patients with primary refractory disease were equivalent
to those with relapsed refractory AML which not seen in ALL. Blast percentage
50% in the BM pre-HSCT, TBI based conditioning and chronic GVHD proved
to be favorable prognostic features.
Summary/Conclusions: This may validate decision making on if this special
group of patients should receive HSCT as salvage treatment.
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POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE AFFECT
T-CELL RECONSTITUTION IN BONE MARROW, BUT NOT IN PERIPHERAL
BLOOD STEM CELLS RECIPIENTS 
E. Mikhaltsova1,*, M. Drokov1, J. Davydova2, L. Kuzmina1, N. Popova1,
D. Dubnyak1, V. Vasilyeva1, O. Koroleva1, Z. Konova1, N. Kapranov2, I. Galtseva2,
E. Parovichnikova1, V. Savchenko1
1BMT department, 2Laboratory of immunophenotyping, National Research Cen-
ter for Hematology, Moscow, Russian Federation
Background: Hematopoetic stem cell transplantation (HSCT) it the only cura-
tive therapy for many patients with hematologic malignancies. Occurrence of
complications and mortality after allo HSCT still high and it’s strongly associated
with immune reconstitution. Despite the wide-spread of Post-Transplant High-
Dose Cyclophosphamide (PTCy) immune reconstitution and immunological
safety of this method is still poorly understood.
Aims: Evaluated immune reconstitution profile in patients who received HSCT
with and without PTCy.
Methods: 62 patients who underwent allogeneic PBSCT in our institution were
analyzed in 2 groups; patients with PTCy (n=28) and without PTCy (n=34). The
total cohort had 22 males and 40 females, and had median age of 33 years
(range 19-61). All patients had hematological malignancy. 21 patients under-
went myeloablative conditioning and 41 patients non-myeloalative. In 41
patients received bone marrow transplant. The GVHD prophylaxis consisted
of a combinations of ATG-PTCy-CsA-MMF (n=10), ATG-PTCy (n=5), Mono-
PTCy (n=1), ATG-CsA-MMF-MTX (n=20), CsA-MTX (n=2), ATG-CsA-MTX
(n=2), CsA-MMF-MTX(n=1). In 21 patients received PBSCT. The GVHD pro-
phylaxis consisted of a combinations of ATG-PTCy-CsA-MMF (n=4), ATG-PTCy
(n=8), ATG-CsA-MMF-MTX (n=8), ATG-CsA-MTX (n=1). 21 patients had pro-
gression disease before transplantation, this could affect the results. Immune
reconstitution profile was tested via serial flow cytometry analysis of peripheral
blood on day +14, +30, +60 and +90 after allo-HSCT. Anti-CD3 FITC, anti-
CD16PE, anti-CD56 PE, anti-CD45 Per-CP-CYTM5.5, anti-CD4 PE-CyTM7,
anti-CD19 APC, anti-CD8 APC-Cy7; anti-CD62L FITC (BD Biosciences, USA);
anti-CD14PE, anti-CD16PE, anti-HLA-DR APC (eBiosciences, USA) were used
to defined white blood cells subsets. 
Results: In a bone marrow recipients the number of CD4+ cells was significantly
lower when using PTCy (see Figure 1). On day 14 CD4+ cells count for bone
marrow recipients was 42,62±9,99; on day 30 - 114,29±42,36; on day 60 –
140,81±42,53; on day 90 - 126,83±26,12. On day 14 CD4+ cells count for PBSC
recipients was 47,47±19,99; on day 30 - 131,49±83,26; on day 60 –
148,08±58,22; on day 90 - 162,93±62,94. At the same time when using the
PBSC transplant number of CD4+ cells was not significantly different.
Figure 1. Short-term reconstitution in BM and PBSC recipients with and
without Post-HSCT-Cy.
Summary/Conclusions: Lymphocyte recovery was immpared for the PTCy
groups in the immediate post-HSCT period but quicly recovered. The mecha-
nism of tolerance induction using PTCy on the + 3, + 4 day not limited to deletion
of alloreactive T-cell clones, but also affects other leukocyte subpopulations (B
cells, monocytes, granulocytes). The use of PTCy at + 3, + 4 a day is immuno-
logically safe method for prevention of GVHD.
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OUTCOMES OF PATIENTS RELAPSING FOLLOWING ALLOGENEIC STEM
CELL TRANSPLANTATION FOR AML IN FIRST CR: SINGLE CENTER
EXPERIENCE
D. Pastore1,*, P. Carluccio1, M. Delia1, A. Ricco1, A. Russo Rossi1, M.S. De Candia1,
A. Mestice1, V. Carluccio1, V. P. Gagliardi1, S. D’Agostino1, C. Pasciolla1,
F. Albano1, G. Specchia1
1Hematology with Transplantation-University Policlinico, Bari, Italy
Background: Allogeneic stem-cell transplantation (SCT) is a curative therapy
for patients with AML but disease relapse continues to be the most common
reason for treatment failure. There is no standard therapy for relapse after SCT
and treatment results are very poor. Treatment options range from supportive
care through chemotherapy and donor lymphocyte infusion (DLI) up to a second
SCT from the same or a different donor. 
Aims: We report a retrospective study of 36 patients AML relapsed patients
following allogeneic stem cell transplantation in first CR.
Methods: Between 2000 and 2016, 130 adults with AML in first CR underwent
allo-SCT. We identified 36/130 patients (27%) who had relapsed and proceeded
to review the management and outcomes of these patients; the incidence of
relapse was 20% and 54% after myeloablative and reduced intensity condi-
tioning, respectively. The median time to disease relapse after allo-SCT was
11 months (range 5-48); 15/36 (41%) of relapsed patients suffered aGvHD
grade II-IV or extensive cGvHD. At time of relapse 15/36 (41%) patients were
still taking immunosuppressive treatment, which was immediately suspended.
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Results: The patients was subdivided into three groups according to the sal-
vage treatment received palliative /supportive care (PSC group, n=9, 25%),
intensive chemotherapy alone(CHT group, n=18, 50%) and chemotherapy with
immunotherapy (donor lymphocyte infusion or second SCT)(IT groups, n=9,
25%). Median age at the start of treatment from relapse was 10, 20 and 25
days in the PSC, CHT and IT groups, respectively. In the CHT group, 3 patients
(16%) achieved a second CR and 4 (22%) died during reinduction chemother-
apy. In the IT group, 6 (66%) pts achieved a second CR after chemotherapy
and DLI/second allo-SCT and 3 (34%) died of treatment toxicity. In the whole
patients sample, median overall survival (OS) was 7 months (range 2-74),
being 4, 5, 13 months in the PSC, CHT and IT group, respectively. Estimated
1-year and 2-years overall survival was 10%, 15%, 40% and 0%, 0%, 12% in
the PSC, CHT and IT groups, respectively. In our experience, 3 independent
factors for a longer OS after chemotherapy and immunotherapy have be iden-
tified: the absence of previous acute o chronic GvHD ( HR=2.7,p<0.001), a
longer interval between the allo-SCT and relapse than 12 months (HR=1.2,
p<0.005) and age less than 40 years (HR=1.3, p<0.005).
Summary/Conclusions: This study shows that salvage chemotherapy (with
DLI or second allo-SCT) provides the best results and should be offered, when-
ever possible, to patients with AML who relapse after allo-SCT performed in
first CR. Patients undergoing chemotherapy alone had a poorer outcome. Our
results emphasize the need to schedule a prospective protocol combining
cytoreductive treatments and immunotherapy in patients with AML relapsing
after allo-SCT.
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ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH
CHEMOREFRACTORY HODGKIN LYMPHOMAS: A RETROSPECTIVE
MULTICENTER EXPERIENCE OF THE RETE EMATOLOGICA PUGLIESE
(REP)
V. Pavone1,*, F. Gaudio2, G. Specchia2, P. Galieni3, N. Cascavilla4, P. Mazza5
1Haematology, Panico Hospital, Tricase, 2Haematology, Policlinico Hospital,
Bari, 3Hematology, Mazzoni Hospital, Ascoli Piceno, 4Hematology, “Casa Sol-
lievo della sofferenza” Hospital, San Giovanni Rotondo (FG), 5Haematology,
Moscati Hospital, Taranto, Italy
Background: Second-line salvage high-dose chemotherapy and autologous
stem cell transplantation (SCT) have become the standard of care for refrac-
tory/relapsed Hodgkin’s lymphomas (HL), leading to durable responses in
approximately 50% of relapsed patients and a minority of refractory patients.
Patients with refractory HL after autologous SCT generally have poor clinical
outcomes with available therapies and by far, allogeneic SCT represents the
only strategy with a curative potential.
Aims: We examined allogeneic transplantation outcomes patients with HL
chemorefractory following last salvage treatment.
Methods: 39 patients with HL who received allogeneic SCT in chemorefractory
disease, from 2000 to 2016 were retrospectively studied. The median age was
34 years (range 16-57 years) and 23 (59%) were male. The majority of patients
(80%) had had a prior autologous SCT. Most (90%) patients received reduced-
intensity conditioning, 59% received matched sibling donor and 41% matched-
unrelated donor grafts.
Results: 36 patients survived beyond 100 days and were evaluable for chronic
GVHD of whom 22 (61%) remained free of cGVHD and 14 (39%) developed
cGVHD. The disease status at day 100 post-transplant was reported in 36 out
of 39 evaluable patients. 7 (19%) achieved a CR, 11 (31%) had a PR, 15 (42%)
a stable disease and 3 (8%) had progressive disease. Following transplantation
30 (77%) patients have relapsed or progressed at a median time of 12.7 months
(range 1- 39 months) post-transplant. With a median follow-up of 28 months
(range 3-95 months) 7 patients remain alive in complete remission, 2 are in
stable disease and 26 have died. The Kaplan-Meier estimates PFS at five
years was 18%. 6 patients (18%) died of non-relapse mortality (NRM) at a
median of 300 days (range 28 days- 40 months) following transplantation. The
causes of death included infection (n=2), GVHD (n=3), multi-organ failure (n=1).
Summary/Conclusions: Allogeneic SCT could also be a viable option for
patients who are refractory to salvage chemotherapy, especially because better
results are obtained when this treatment is applied earlier. Despite the reduction
of NRM and GVHD, disease relapse still represents the major issue in the set-
ting of allogeneic SCT failure. The availability of novel agents resulting in objec-
tive responses may eventually result in increased eligibility for allogeneic SCT.
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RESULTS OF THE IMPLEMENTATION OF CRYOTHERAPY IN PROTO-
COLS OF ORAL MUCOSITIS PROPHYLAXIS IN PATIENTS SUBJECT TO
A TRASPLANT OF HEMATOPOYETIC PROGENITORS. EXPERIENCE OF
ONE CENTER
E. Fernández Poveda1,*, V. Cabanas-Perianes1, A. Sánchez-Salinas1, M. Blan-
quer-Blanquer1, M. Berenguer-Piqueras1, M. Moya-Arna1, A. Martínez-Marín1,
J.M. Moraleda-Jiménez1
1Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Spain
Background: Oral mucositis (OM) is one of the main complication during stem
cell trasplantation (HSCT). It has an incidence varies between 47-100%. Numer-
ous prevention strategies have been studied. However, the recommendations
of the international guidelines have low evidence to back them up. Cryotherapy
is used to reduce OM in conditions that use Melphalan. In our center, we have
the cryotherapy implemented in our OM prevention protocol since 2012.
Aims: The main aim is to compare the results in terms of incidence and severity
of OM (measured according to World Health Organization scale) in patients in
whom cryotherapy was applied and in whom it was not applied as well as the
necessity of using morphine and parenteral nutrition. The secondary endpoint
is to analyze the occurrence and duration of fever and documentation of infec-
tion. Also the length of hospital stay and mortality on day 100.
Methods: We used a cohort of patients with plasma cell dyscrasias who under-
went autologous stem-cell transplant with conditioning melphalan 200, Busul-
fan-Melphalan 140 or melphalan 100 in hemodialysis regimen in which
cryotherapy was not applied (2007-2011) and another cohort in which was
applied (2014-2016). We did not collect 2012 or 2013 because the measure
was being implemented. It consists of administering ice poles to the patient
who must chew before, during and after the infusion of melphalan. The t-Studen
and Chi square method was used to estimate the rates of incidence and the
baseline characteristics. The regression logistic method was used to the mul-
tivariant and univaritan analysis. Hazard ratios and 95% were estimated with
the use of logistic regression model.
Results: The baselines characteristics can be seen in table 1. All patients in
both groups had OM. In the cryotherapy and non-cryotherapy groups, the dis-
tribution was respectively: grade I 20% vs 16%, grade II 40% vs 10.8%, grade
III 31.4% vs 59.4% and grade IV 8.5% vs 13.5%. We observed a reduction in
the incidence of severe mucositis (grade III and IV) in the group in which
cryotherapy was used against the cohort in which it was not (40% vs 72.9%,
p=0.005). The need for morphine was also lower in the cryotherapy cohort
(54% vs 72%, p=0.149). The use of parenteral nutrition was lower in the non-
cryotherapy group (8.57% vs 13.5%, p=0.7).The prevalence of fever was pre-
dominant in the cryotherapy group (51% vs 43%, p=0.48), but and infection
was documented on more occasions in cryotherapy group (27% vs 81%,
p=0.04). The median number of days the patients were discharged from the
cryotherapy group was lower (+14 vs +15 median days, p=0.39) and the mor-
tality at day 100 was higher in the non-cryotherapy group (0% vs 8%, p=0.24).
Decreased mucositis degree was associated in both univariate and multivariate
analysis only with cryotherapy (p= 0.01 and p=0.0003). Hazar ratio was 0.81
(IC 95% 0.06-0.55).
Table 1.
Summary/Conclusions: In our center, cryotherapy reduces significantly the
severity of mucositis. The use of morphine and parenteral nutrition and other
complications do not present such a drastic decline, probably because they
influence the gastrointestinal mucositis, which is not combatted with cryother-
apy. With this results, we are encouraged to continue to include cryotherapy in
our protocols.
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REDUCED INCIDENCE OF PRIMARY GRAFT FAILURE IN PATIENTS
UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A
SINGLE CENTER EXPERIENCE
A. Martínez-Velandia1,*, M. Gasior1, R. de Paz1, S. Cortez1, D. Bueno2,
A. Sastre2, M. Canales1, A. Pérez-Martínez2
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Background: Haploidentical stem cell transplantation (HSCT) is an alternative
for patients without HLA matched donors. However, primary graft failure (PGF)
and graft versus host disease are still limitations derived from alloreactivity due
to HLA mismatch. T cell depleting approaches (in-vivo with post-transplant
cyclophosphamide (PT-Cy) or ex-vivo with graft engineering) and surveillance
for anti HLA antibodies are strategies intended to reduce these complications.
PGF has a high mortality, and treatment with a second graft is not well defined
in terms of donor, source, graft engineering or conditioning. 
Aims: Our objective is to describe the incidence and risk factors of PGF and
treatments if needed.
Methods: We retrospectively analyzed 40 consecutive patients who underwent
HSCT from 2014 to 2016: unmanipulated for 20 adults and graft engineering
for 20 children (CD34 selection/TCRab depletion, n= 6; and CD34
selection/CD45RA depletion, n=14). The stem cell source was mobilized periph-
eral blood in all cases. GCSF was sistematically used from day 5 until engraft-
ment. We used descriptive statistical methods for analysis.
Results: Patient characteristics are described in Table 1. Conditioning regimen
was Bu-Flu-Cy (n=18, adults), Thio-Bu-Flu (n=2, adults), Flu-Mel-Thio for all
pediatric patients. ATG was used in 6 children and TLI in 14 children. All adult
patients were given PT-Cy. Only one adult patient had high titer donor specific
anti HLA antibodies and was desensitized with plasma exchange, Rituximab
and IVIG before transplantation. All patients engrafted before day 28 and no
PGF diagnosis was established in our serie. We found that 4 patients (3 chil-
dren, 1 adult) required a boost of CD34 selected graft from the same donor for
secondary GF and poor graft function.
Table 1.
Summary/Conclusions: PGF incidence described in literature is 5-10%, we
did not find any primary graft failure in our serie. Desensitization therapy
appeared to be effective in one patient with anti HLA antibodies. All CD34
boosts were performed for secondary graft failure/poor graft function due to
treatment toxicities or viral infections. Unfortunately, analysis of causes and
risk factors for secondary GF requires a larger number of patients to be deter-
mined.
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RESULTS OF HAPLOIDENTIC HEMATOPOIETIC STEM-CELL
TRANSPLANTATION IN PATIENTS WITH LYMPHOMA: A SINGLE CENTER
EXPERIENCE
Z. Gulbas1,*, D. Cekdemir1,2, I. Dora1,2, E. Er1,2
1Bone Marrow Transplantation Department, 2Anadolu Medical Center, Kocaeli,
Turkey
Background: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT)
is a potentially curative treatment for a variety of hematologic malignancies and
nonmalignant hematologic disorders. However, only about a third of candidates
for allo-HSCT have HLA-matched siblings. For patients who lack HLA-matched
siblings, partially HLA-mismatched (haploidentical) related donors are good
alternative sources of stem cells for allo-HSCT
Aims: In this retrospective, single center study we evaluated safety and efficacy
of haploidentical allo-HSCT compared to those of HLA-matched allo-HSCT in
patients with lymphoma
Methods: A total of 81 lymphoma patients(Hodgkin and Nonhodgkin) with a
mean age of 42 years who underwent allo-HSCT(HLA matched n=46, hap-
loidentic n=35) between July 2010 and July 2016 were analyzed. All patients
received Cyclophosphamide (Cy) 50mg/kg i.v. on days +3 and +4. All patients
initiated CsA day +5, and then adjusted according to the plasma levels. In addi-
tion to CsA, all haploidentical allo-HSCT recipients received MMF until day +35
Results: There were no significant differences in age, sex, diagnosis, disease
status up-front HSCT, or transplant characteristics between the groups except
a higher median number of stem cells infused in haploidentical group (p=0.004).
The median follow-up was 13 months for haploidentical group and 12 months
for HLA-matched group. Outcomes of patients are summarized in Table-1
Summary/Conclusions: Our results suggest that haploidentical allo-HSCT is
a safe treatment modality in patients with relapsed lymphoma who lack HLA-
matched siblings. The major problem are seems to be viral infections. Future
challenges remain in improving post-transplant immune reconstitution and find-
ing the best approach to reduce the incidence and severity of viral infections,
while preserving graft-versus-lymphoma effect to prevent the recurrence of the
underlying disease
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COLLECTION OF PERIPHERAL BLOOD HEMATOPOIETIC PROGENITOR
CELLS (PBPC) FROM HEALTHY DONORS: 15 YEARS SINGLE CENTER
EXPERIENCE
B. Aguado1,*, E. Jimenez Barral1, A. Arriero1, J. Cornago1, Y. Paz1, I. Vicuña1,
V. Gomez1, R. de la Camara1, A. Figuera1, A. Alegre1
1Hematology, H.U. La Princesa, Madrid, Spain
Background: hematopoietic stem cell transplantation (HCT) is, nowadays, a
consolidated therapy within the treatment of multiple hematological pathologies.
In the last two decades, the main method of obtaining hematopoietic progenitor
cells is blood leukapheresis after mobilization with granulocytic colony growth
factors (G-CSF). 
Aims: To describe the experience of our center in apheresis of healthy family
donors in the last 15 years. Furthermore, analyze the influence of different vari-
ables on the procedure and the yields obtained.
Methods: retrospective analysis was performed on 189 hematopoietic progen-
itor cell collection (HPCC) from January 2002 to December 2016. The study
was carried out at Apheresis Unit, Hospital de La Princesa, Madrid, Spain. Pro-
genitor cells mobilization was performed with G-CSF in all cases at a dose of
10mg/kg b.w. Apheresis device was COBE Spectra in all cases and citrate was
the anticoagulant used for all the apheresis procedures. All donors were care-
fully evaluated and informed on the donation procedure and signed an informed
consent for apheresis. The venous access used was mostly peripheral venous
access in antecubital veins, and in only 7 cases (3.7%) central venous catheter
was required. Donor details studied were age, sex, AB0 group, number of
apheresis, number of CD34+ per kilogram collected, and processed volume.
Results: among the 189 donors, 85 were females and 104 were males (45%
vs 55%). The hematologic pathologies that motivated transplantation were, in
order of frequency, Acute Myeloid Leukemia (AML) (40.2%), Myelodysplastic
Syndrome (MDS) (13.8%), Acute Lymphoblastic Leukemia (ALL) (10.1%),
Hodgkin´s Lymphoma (HL) (8.5%), Non-Hodgkin´s Lymphoma (NHL) (6.3%),
Multiple Myeloma (MM) (5.3%), Chronic Myeloid Leukemia (CML) (4.2%), oth-
ers (11.6%). Donors most frequent AB0 group was A and in 123 of all cases
(65%) donor and recipient had the same group. Median weight of donors was
74 Kg and in recipients was 70.5 Kg. Median age of our donors was 50 and
median age of recipients was 51 years. Twenty donors were >65 years (10.6%)
and 10 were>70 years (5.3%). Median of processed volume was 13 liters, but
if we stratify that volume by recipient’s weight, in those whose were heavier
than 100 kg, median of processed volume was 18 liters. Two apheresis proce-
dures were performed only in ten donors. Of these, 2 were older than 70 years
(20% of total donors over 70 years of age) compared to 8 under 70 years of
age (4.5% of all patients in that age range). The median of CD34 + / kg collected
was 5 x 106. Among the age ranges, median yield of CD34+/Kg in patients
older than 70 years was 3.55 x 106, in patients between 31 and 69 years was
4.96 x 106 and in patients younger than 30 years was 5.5 x 106. The apheresis
procedure was mostly well tolerated, with only mild symptoms of hypocalcemia
and disturbances related to venous access in a minority of cases. No significant
long term adverse effect has been observed in the blood tests reported to our
centers during the five years of follow up after the donation.
Summary/Conclusions: donor age and weight discrepancy with recipient were
the factors that significantly affected PBPC yields in our experience in healthy
donors. These factors had also an impact in the amount of liters of volemia
processed, although in most cases only one apheresis procedure was enough.
Adverse effects of apheresis for PBPC collection were the same as for other
apheresis procedures such as those related to venous access, almost always
peripheral one and citrate toxicity.
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ALLORESPONSES OF HUMAN T-CELLS FROM ADULT PERIPHERAL
BLOOD AND UMBILICAL CORD BLOOD ARE DIFFERENTIALLY IMPACTED
BY LENALIDOMIDE - IMPLICATIONS FOR AHSCT
C. Besley1,*, E. Kotsiou1, R. Petty1, A. Sangaralingam2, C. Chelala2, E. Ghazaly1,
R. LeDieu1, J. Gribben1, J. Davies1
1Centre for Haemato-Oncology, 2Centre for Tumour Biology, Barts Cancer Insti-
tute, London, United Kingdom
Background: Immunomodulatory drugs (IMiDs), such as lenalidomide provide
a tool to enhance both direct anti-tumor and graft-versus-tumor effects after
allogeneic haematopoietic stem-cell transplantation (AHSCT). However, early
clinical experience with IMiDs after AHSCT using adult peripheral blood (APB)
as a stem cell source has been limited by induction of graft-versus-host disease.
Characterization of the mechanisms by which IMiDs can modulate allorespons-
es of T-cells from different cell sources could facilitate more effective use of
these drugs in the setting of AHSCT.
Aims: To use in vitro modelling to identify changes in alloresponses of APB
and umbilical cord blood (UCB) T-cells after exposure to the widely used IMiD
lenalidomide.
Figure 1.
Methods: We have used multi-parameter flow cytometry and gene expression
profiling to perform an in-depth characterisation of the phenotypic and genotypic
effects of clinically relevant concentrations of lenalidomide treatment on T-cells
during allogeneic co-culture. Using GCSF-mobilised APB (GMPB), steady state
APB and UCB PBMC as responder cells in allogeneic co-culture we have been
able to compare the differential effect of lenalidomide on these three cell
sources. Allogeneic responder cells were labelled with CFSE (carboxyfluores-
cein diacetate succinimidyl ester) to allow quantification of allo-proliferation.
Responder T-cell subsets including naive, memory, activated, cytotoxic and
regulatory were interrogated. Functional effects of lenalidomide treatment
including cellular capacity to produce cytokines, degranulate and exert direct
cytotoxicity was also assessed. RNA was extracted from highly purified prolif-
erative and non-proliferative CD8+ T-cell fractions following a combination of
magnetic and flow-sorting and gene expression changes assessed by
Affymetrix whole genome array and qRT-PCR.
Results: We demonstrate that lenalidomide increases net alloproliferation of
APB T-cells by selectively enhancing allospecific proliferation of CD8+T-cells.
These CD8+ T-cells have enhanced effector memory differentiation, are
enriched for polyfunctional effectors, and have a distinct gene expression profile
with altered expression of key immunoregulatory genes and pathways. This
effect on CD8+T-cell proliferation was seen across all 3 cell sources. Importantly
a differential effect on CD4+ T-cell responses was observed depending on cell
source. Lenalidomide treatment of APB results in no change in CD4+ T cell
proliferation overall, but leads to reduced frequencies of CD4+ regulatory T-
cells (Treg). In contrast lenalidomide treatment of GMPB resulted in a significant
increase in CD4+ T cell proliferation, with no effect on Treg cell frequencies.
Most strikingly, although lenalidomide treatment of UCB T-cells during allostim-
ulation results in a similar increase in alloreactive effector CD8+T-cells, it also
reduces allospecific proliferation of CD4+T-cells and selectively expands fre-
quencies of Treg, resulting in a net reduction in UCB T-cell alloproliferation.
Summary/Conclusions: Our findings show that lenalidomide has a qualita-
tively different impact on alloresponses of T-cells from different cell sources,
with a potentially tolerogenic effect on UCB T-cells. These findings have impor-
tant implications for the future use of IMiDs in the setting of AHSCT.
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USING MARKER GENES ANALYSIS INSTEAD OF MLR ASSAY FOR
IDENTIFICATION OF FUNCTIONAL CD4+FOXP3+ REGULATORY T CELLS
IN GVHD PROPHYLAXIS
T.-J. Chiou1,*, H.-H. Lin1, K.-H. Chien1, W.-H. Wu1, J.-Y. Jian1, S.-T. Chu2,
W.-F. Tzeng3
1Division of Transfusion Medicine, Department of Medicine, Taipei Veterans
General Hospital and National Yang-Ming University School of Medicine, 2Insti-
tute of Biochemical Science, National Taiwan University, Taipei, 3Department
of Life Science, Fu-Jen University, New Taipei City, Taiwan, Republic of China
Background: There are two types of CD4+CD25+FoxP3+ regulatory T cells
(Tregs), natural Treg cells (nTreg) developing in thymus, and induced Treg cells
(iTreg) arising from CD4+ naïve T cells. The iTreg cells have been considered
important for maintenance of immunological tolerance and correlate with the
occurrence of GVHD in some studies. Establishing a quick method to identify
the functional iTreg cells is worthy of focusing. Five to ten percent Tregs could
be found in human CD4+ T cells and should be expanded via in vitro cell culture.
Aims: In order to improve the efficiency of Treg cells for the prevention of
GVHD, we attempt to establish a relatively quick analytic method to identify
the functional iTreg cells, and then to curtail the iTreg cells harvest time for
clinical use. Therefore, using qPCR for marker genes analysis instead of MLR
(mixed lymphocyte reaction) assay is an important issue.
Methods: Mouse splenocytes were prepared from mouse spleen. Human
PBSC were prepared from peripheral blood (PB) of healthy donors by Ficoll-
Hypaque density gradient centrifugation. All T cells were isolated by negative
selection, then CD4+naïve T cells were harvested. CD4+ naïve T cells were
activated with anti-CD3/CD28 beads in the presence of IL-2, TGF-β and retinoic
acid (RA) containing RPMI1640 medium. The protocol is showed in Fig. 1.
Figure 1.
Results: Seven genes for qPCR analysis were used to identify the functional
iTreg cells. We used the different proportions of iTreg cells in total naïve T cells
for 7 genes expression analysis and MLR assay to investigate the relationship
between gene expression profile and iTreg cell function. The data of marker
genes analysis were shown in Fig2. It indicated that the different proportion of
iTreg cells could show the different expression profile of these genes. Obviously,
the FoxP3 gene expression increased in a great level. Based on our previous
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experiments, iTreg cells induction could be TGF-b1 dependent. After different
amount of TGF-b1 induction, the genes expression profile also showed the coin-
cidence of the data in Fig.2 (Fig.3). Using the same iTreg populations, MLR
assay have been investigated for 5 days. The T cell suppression percentage
would be dependent on the iTreg cells proportion (Fig.4A and B). It indicated
that the gene expression levels can represent the biological function of iTreg
cells. It’s the better way to identify the iTreg cells. Further, we have used PBMNC
for Treg cell induction, the marker genes expression analysis also showed in
Fig.5. After comparing with IL-2 cultured T cells, the gene expressions revealed
the difference in between iTreg cells and un-induced T cells.
Summary/Conclusions: Our study showed that MLR assay should spend 3
to 5 days for identification of the functional iTreg cells, however, the marker
genes analysis took only one day for that. Besides, MLR assay is a more com-
plicated method than qPCR analysis. Using simple analysis for human iTreg
cells functional identification could save the time for clinical application and
might prevent GVHD occurrence effectively. 
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OXIDANT-ANTIOXIDANT SYSTEM IN PATIENTS WITH MULTIPLE MYELOMA
L. Aleksanian1,*, L. Rybakova1, S. Kapustin1, S. Gritsaev2, S. Bessmeltsev2
1Biochemistry laboratory, 2Russian Research Institute of Hematology and
Transfusiology, Saint-Petersburg, Russian Federation
Background: Multiple myeloma (MM) is one of the most widespread malignant
B-cell lymphoproliferative disorders and is characterized by a clonal proliferation
of atypical plasma cells in bone marrow or, less frequently, in extramedullary
locations synthesizing monoclonal immunoglobulins. Currently, autologous
hematopoietic stem cell transplantation (auto-HSCT) is recognized as the stan-
dard method of treatment for young patients (≤65 years old) with MM. Moreover,
the best auto-HSCT results are observed in patients who have received new
medication (thalidomide, bortezomib, and lenalidomide) during induction ther-
apy and who have achieved at least a very good partial response, which leads
to a significant increase in overall survival. However, studies reflecting the
impact of this kind of treatment on the dynamics of oxidant-antioxidant indicators
are virtually non-existent. At the same time, the possibility of treating developing
diseases by prescribing medication makes the problem highly relevant.
Aims: The aim of the study was to investigate the state of OS-AOS in patients
with MM during auto-HSCT.
Methods: We studied 20 patients (11 men and 9 women, mean age 49 years)
who followed auto-HSCT after high-dose melphalan. The control group con-
sisted of 50 age- and sex-matched healthy persons. The plasma levels of mal-
onic dialdehyde and cerulloplasmin as well as activities of superoxide dismutase
and catalase were measured by standard biochemical techniques. In erythro-
cytes, the level of non-protein thiol groups was studied. The state of OS-AOS
was investigated in each patient four times: before and after conditioning with
melphalan, at the moment of maximal leukocyte decrease and after complete
reconstitution from cytopenia.
Results: We have found the features of impaired balance in OS-AOS in MM
patients before as well as in course of auto-HSCT. The level of malonic dialde-
hyde in MM patients was not significantly different from that in the control group.
At the same time, cerulloplasmin plasma level as well as catalase activity were
significantly increased in patient group (p<0.05), whereas the level of non-pro-
tein thiol groups was decreased in MM (p<0.05). The results of our study have
shown, that an imbalance of OS-AOS is frequently seen in MM patients and,
possibly, could influence the course of auto-HSCT.
Summary/Conclusions: The results of the study indicate a high frequency of
occurrence of disturbance of the condition of OS-AOS in patients with MM. The
imbalance in the functioning of this system is not entirely eliminated in the
process of treating the patients with MM using auto-HSCT. The question of the
necessity and methods of the possible correction of OS-AOS in patients with
MM, particularly during auto-HSCT, requires further study.
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SURFACE RECEPTOR EXPRESSION PROFILE DEFINES ALLOREACTIVE
DONOR CD8+ T-CELLS AFTER MURINE ALLOGENIC HEMATOPOIETIC
CELL TRANSPLANTATION
C. Bäuerlein1, M. Qureischi1,*, C. Brede1, A.-L. Jordán Garrote1, S.S. Riedel1,
M. Chopra1, A. Mottok2, S. Thusek1, M. Ritz1, K. Mattenheimer1, C. Graf1,
H. Einsele1, P.G. Schlegel3, R.S. Negrin4, A. Beilhack1
1Medical Department II, University Clinics Wuerzburg, Wuerzburg, 2Würzburg
University, Institute of Pathology, 3University Clinics Würzburg, Department of
Pediatrics, Würzburg, Germany, 4Division of Bone & Marrow Transplantation,
Department of Medicine, Stanford University, United States
Background: Acute graft-versus-host disease (aGvHD) is a severe and often
life-threatening inflammatory complication of allogeneic hematopoietic cell
transplantation (allo-HCT). aGVHD is mediated by alloreactive donor T cells
attacking the gastrointestinal tract, liver, and skin of the host. Efficient strategies
to improve aGvHD-related morbidity and mortality will rely on more precise
methods than preemptive immunosuppression to consistently predict aGvHD
and abrogate disease manifestation without exposing patients to an unwar-
ranted risk for infectious complications. Recent insights into the multistep-patho-
physiology of aGvHD provide a good basis for the development of new tests to
identify individual patients at risk before the onset of aGvHD. 
Aims: As pathologic T cell responses rely on spatiotemporally defined programs
of T cell activation, acquisition of effector functions, and homing to GvHD target
tissues it appeared attractive to assess receptor expression profiles of periph-
eral blood T cells as potential predictive markers.
Methods: Therefore, we characterized the surface receptor expression profile
of peripheral blood donor lymphocytes early after allo-HCT in two independent
murine models across minor histocompatibility antigens (miHAg) with multicolor
flow cytometry. C57Bl/6 (H-2b, Thy1.1+) or B10.D2 (H-2d, Thy1.1+) T cells plus
bone marrow cells were transplanted in conditioned (8Gy) miHAg mismatched
BALB/B (H-2b, Thy1.2+) and syngeneic C57Bl/6 (9Gy) or BALB/c (H-2d,
Thy1.1+) recipients. To identify suitable predictive markers, we compared the
expression pattern of allo-HCT recipients to syngeneic HCT recipients and
untreated wild type controls.
Results: Comparing a panel of T cell surface receptors, we found the homing
markers α4β7 integrin, and P- and E-selectin ligand highly up-regulated on
allogeneic peripheral blood donor CD8+ T cells at peak time points of cell migra-
tion. The combination of these homing markers with the activation markers
CD25 and CD69 at later time points and low expression levels of L-selectin
allowed to define alloreactive donor T cells. 
Summary/Conclusions: Based on this data we propose that alloreactive CD8+
T cells can be identified in miHAg allo-HCT recipients upon their homing recep-
tor expression pattern as soon as six to ten days before the onset of aGVHD.
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SOLUBLE FORM OF TRANSFERRIN RECEPTOR IS ASSOCIATED WITH
AGE AT DIAGNOSIS AND RISK OF THERAPEUTICAL INTERVENTION
AND IRON OVERLOAD IN PATIENTS WITH NON-TRANSFUSION-
DEPENDENT THALASSAEMIA
P. Ricchi1,*, A. Meloni2, S. Costantini1, A. Spasiano1, T. Di Matola3, A. Pepe2,
L. Pistoia2, P. Cinque1, A. Filosa1
1AORN A. Cardarelli, Naples, 2Fondazione G. Monasterio CNR-Regione
Toscana, Pisa, 3AORN Monaldi-Cotugno-CTO, Naples, Italy
Background: The soluble transferrin receptor (sTfR), that fully reflects the
marrow erythropoietic activity, was found to have not only a striking diagnostic
accuracy in predicting the risk of extramedullary haematopoiesis (EMH), but
also in scoring disease severity in non-transfusion-dependent thalassemias
(NTDT).
Aims: We retrospectively evaluated the relationship between sTfR and some
fundamental events in the life and in the management of patients with NTDT.
Methods: We considered 111 NTDT patients with four genetic entities of NTDT:
homozygous or compound heterozygous state for β-thalassemia, triplicated α
genotype associated with β heterozygosity, deletional HbH, and combination
of a β defect plus a β chain variant. sTfR was measured with a commercially
available kit. A group of patients was enrolled in the Myocardial Iron Overload
in Thalassaemia (MIOT) network and underwent hepatic iron overload assess-
ment by the T2* Magnetic resonance Imaging (MRI) technique.
Results: The group with homozygous or compound heterozygous for β-tha-
lassemia had the higher sTfR levels. sTfR values were negatively related to
age at diagnosis (R=−0.462, P<0.0001), and to age at first transfusion
(R=−0.703, P<0.0001). At ROC curve a sTfR>5.3mg/L discriminated the
patients with a previous history of occasional transfusions. sTfR values were
significantly higher in splenectomized patients. sTfR values were negatively
related to age at splenectomy (R=−0.328, P=0.044) and in unsplenectomized
patients a significant positive correlation was found between sTfR values and
spleen diameter (R=0.572; P<0.0001). sTfR values were negatively related to
age at starting chelation therapy (R=-0.564, P=0.044). Patients never chelated
showed significantly lower sTfR values than patients under chelation therapy
(see Figure). sTfr values were significantly correlated with serum ferritin levels
(R=0.321, P<0.0001). but no with LIC values.
Figure 1.
Summary/Conclusions: The heterogeneity of patients with NTDT is an emerg-
ing cause of complex management and treatment of the disease. Our data
indicate that the measurement of sTfR level, a common laboratory test, could
contribute to correctly stratify the disease history and the chelation strategy in
NTDT.
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LOW SERUM FERRITIN LEVELS DO NOT PROTECT FROM CARDIAC AND
HEPATIC IRON IN PATIENTS WITH THALASSEMIA MAJOR
A. Meloni1,*, A. Spasiano2, P. Ricchi2, L. Pistoia1, A. Carrà3, C. Cosmi4,
R. Rosso5, A. Scaccetti6, V. Positano1, R. Righi7, S. Renne8, A. Pepe1
1Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2AORN A. Cardarelli,
Naples, 3Ospedale “G. Da Saliceto”, Piacenza, 4Azienda Ospedaliero-Univer-
sitaria di Sassari, Sassari, 5Ospedale “Ferrarotto” - Azienda Ospedaliero-Uni-
versitaria Policlinico “Vittorio Emanuele”, Catania, 6Azienda Ospedaliera “S.
Maria”, Terni, 7Azienda Ospedaliero-Universitaria Arcispedale “S. Anna-Cona”,
Ferrara, 8Presidio Ospedaliero “Giovanni Paolo II”, Lamezia Terme, Italy
Background: The estimation of serum ferritin levels is the most commonly
employed test to evaluate iron overload in Beta Thalassaemia Major (TM).
Aims: The aim of this mulicenter study was to assess the distribution of serum
ferritin levels in a cohort of well treated TM patients and the possible protective
role of really low levels versus iron accumulation in the heart and in the liver.
Methods: We considered 1548 TM patients regularly transfused and chelated
consecutively enrolled in the MIOT (Myocardial Iron Overload in Thalassemia)
Network. Myocardial and hepatic iron burdens were quantified by the T2* tech-
nique. For the heart a multislice approach was adopted in order to calculate
segmental and global T2* values. Hepatic T2* values were converted into liver
iron concentration (LIC) values.
Results: Mean serum ferritin levels <500ng/ml were found in 342 (22.1%)
patients. Three groups were identified on the basis of mean serum ferritin
levels. Both transaminases were significantly lower in patients with serum fer-
ritin <500 ng/ml and between 500 and 1000 ng/ml versus patients with serum
ferritin ≥1000 ng/ml. Among patients with serum ferritin <500 ng/ml, 9.1%
showed significant cardiac iron (global heart T2*<20 ms) and 21.6% showed
hepatic iron (LIC ≥3mg/g dw). Cardiac and hepatic iron levels were significantly
lower in patients with serum ferritin <500 ng/ml than in the other two groups
and in patients with ferritin between 500 and 1000ng/ml versus patients with
serum ferritin ≥1000 ng/ml (see Figure). Compared to patients with serum fer-
ritin levels <500 ng/ml, the other two groups showed a significant higher risk
of cardiac iron overload (odds ratio-OR=2.03, P=0.002 for patients with ferritin
500-1000 ng/ml and OR=5.96, P<0.0001 for patients with ferritin ≥1000ng/ml)
and of hepatic iron overload (OR=3.44, P<0.0001 for patients with ferritin 500-
1000ng/ml and OR=25.43, P<0.0001 for patients with ferritin ≥1000ng/ml).
Figure 1.
Summary/Conclusions: Low serum ferritin values, even in the normal range,
do not per se exclude cardiac and hepatic iron overload, although decreasing
the risk. Before to consider a reduction of the chelator dose in patients whose
serum ferritin levels have reached the target, a MRI scan should be performed
in order to measure iron levels in the different organs.
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ISCHEMIA MODIFIED ALBUMIN AS A MARKER OF OXIDATIVE STRESS
IN CHILDREN AND ADOLESCENTS WITH Β-THALASSEMIA: RELATION
TO LIPID PEROXIDATION, IRON OVERLOAD AND VASCULAR DYSFUNCTION
A.A. M. Adly1,*, N.H. Elsherif1, E.A.R. Ismail2, Y.A. Ibrahim3, G. Niazi4,
S.H. Elmetwally1
1Pediatric Hematology&oncology, Faculty of Medicine, Ain Shams University,
2Clinical Pathology Department, Faculty of Medicine, Ain Shams University,
3Radiology Department, Faculty of Medicine, Ain Shams University, Cairo,
4Radiology Department, Faculty of Medicine, Ain Shams University, Cairo,
Egypt
Background: Patients with β-thalassemia major (β-TM) are under significant
iron driven oxidative stress. Ischemia modified albumin (IMA) is an altered type
of serum albumin that forms under conditions of oxidative stress and an inde-
pendent predictor of major adverse cardiovascular events
Aims: To measure the levels of IMA in 45 children and adolescents with β-TM
compared with 30 healthy controls and assess its relation to lipid peroxidation,
vascular complications and subclinical atherosclerosis
Methods: β-TM patients without symptoms of heart disease were studied
focusing on transfusion history, chelation therapy, serum ferritin, malondialde-
hyde (MDA) and IMA levels. Echocardiography was performed and carotid inti-
ma media thickness (CIMT) was assessed.
Results: IMA and MDA levels were significantly higher in β-TM patients com-
pared with controls (p<0.001). IMA was higher among patients with heart dis-
ease and pulmonary hypertension (PH) risk than those without. Serum IMA
and MDA levels were elevated among patients with serum ferritin ≥2500 µg/L
compared with patients below this cutoff. TM patients compliant to chelation
had a significantly lower IMA levels than non-compliant ones. Receiver oper-
ating characteristic (ROC) curve analysis revealed that a cutoff value of IMA at
75 U/mL could differentiate β-TM patients with PH risk with 90% sensitivity,
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91.4% specificity and positive predictive value of 75% and negative predictive
value 97%; area under the curve 0.883 (95% confidence interval 0.752-0.959).
In addition, the cutoff value of IMA at 17.5 U/mL could differentiate β-TM patients
with heart disease with 80.5% sensitivity, 88.9% specificity and positive predic-
tive value of 96.7% and negative predictive value 73.3%; area under the curve
0.887 (95% confidence interval 0.758-0.962). Significant positive correlations
were found between IMA levels and disease duration (r=0.311, p=0.045), white
blood cell count (r=0.322, p=0.031), serum alanine aminotransferase (r=0.388,
p=0.01) and aspartate aminotransferase (r=0.382, p=0.037). IMA and MDA lev-
els were positively correlated (r=0.503, p=0.001) and there was a significant
positive correlation between these two markers and mean serum ferritin (IMA;
r=0.645, p<0.001 and MDA; r=0.567, p<0.001) among TM patients. IMA levels
were positively correlated to TRV (r=0.621, p=0.008), while negatively corre-
lated to ejection fraction (r=-0.412, p=0.014) and fractional shortening. Both
IMA and MDA were positively correlated to CIMT (r=0.607, p<0.001 and
r=0.590, p<0.001, respectively).
Summary/Conclusions: Our results highlight the role of oxidative stress in
the pathophysiology of vascular complications in thalassemia. IMA could be
useful for screening of β-TM patients at risk of cardiopulmonary complications
and atherosclerosis because its alteration occurs in early subclinical disease.
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SERUM N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE LEVEL AND
ECHOCARDIOGRAPHIC TISSUE DOPPLER ABNORMALITIES IN
PATIENTS WITH BETA THALASSEMIA MAJOR
M. El-Tagui1, I. Mahmoud2, H. Agha1, S. Mohamed1, M. El-Ghamrawy1,*
1Pediatrics, 2Clinical and Chemical Pathology, Faculty of Medicine, Cairo Uni-
versity, Cairo, Egypt
Background: Heart disease remains the major cause of morbidity and mortality
in thalassemia patients. Multiple pathologies have been implicated in the devel-
opment of cardiac dysfunction in these patients including: cardiac iron overload
leading to right ventricular diastolic then left ventricular systolic dysfunction,
chronic anemia and tissue hypoxia. Because congestive heart failure is the
main cause of death in these patients, early recognition of cardiac dysfunction
may be useful in modifying therapy in a timely manner. Tissue Doppler imaging
(TDI) echocardiography and serum brain natriuretic peptide (BNP) level may
be promising tools for such a purpose.
Aims: This study aimed to assess serum NT-proBNP level and echocardio-
graphic tissue doppler abnormalities among a cohort of Egyptian beta tha-
lassemia major patients and to detect possible assocoations between them as
well as other disease variables including iron overload.
Methods: Thirty beta thalassemia major patients with a mean age of
12.93±2.07 years regularly followed up at Pediatric Hematology Clinic, Cairo
University and thirty aged matched healthy control subjects were included.
Conventional, M-Mode and TDI echogardiography were performed to all
patients and control subjects in addition to cardiac magnetic resonance
(CMR)for studied patients. Serum NT-proBNP level was measured using
enzyme linked immunosorbant assay (ELISA). 
Results: Tissue doppler imaging revealed a significant difference of ratio of
the early (e’) to late (a’) right ventricular filling velocities (Rv e’/a’ ratio) between
cardiac and non-cardiac iron overloaded patients reflecting early diastolic dys-
function in cardiac iron overloaded patients. Myocardial performance index of
left ventricle (LV_TEI index) by TDI showed significant difference in cardiac
iron overloaded patients compared to non cardiac iron overloaded patient
(mean 0.45± .02 versus 0.39± .04 with p value=0 .003) indicating decrease in
ventricular relaxation due to iron overload and restrictive cardiomyopathy.
SerumBNP level was significantly higher among patients compared to controls
(mean 99.18± 72.43pg/ml versus 18.93± 9.65pg/ml respectively with p-valu<
0.001) and among cardiac iron overloaded patients compared to non cardiac
iron overloaded (mean 212.31±57.18pg/ml versus 64.75±26.69pg/ml respec-
tively with p value <0.001). We found positive correlation between level of BNP
and frequency of the blood transfusion/year, RVe’/a’ and LV TEI_TD index with
(p value 0.006, <0.001) and 0 .030 respectively) denoting early diastolic impair-
ment in asymptomatic thalassemia patients.
Summary/Conclusions: Asymptomatic thalassemia major patients under
chelation therapy may have diastolic and or systolic dysfunctions that could
not be detected by conventional echocardiography but could be highlighted by
TDI. CMR, TDI and serum BNP level measurement are promising tools for
accurate assessment of cardiac functions and iron overload in thalassemia
patients.
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PRENATAL DIAGNOSIS OF HEMOGLOBINOPATHIES IN NORTHERN
GREECE. 15 YEARS REPORT
S. Theodoridou1,*, N. Prapas2, A. Sotiriadis2, A. Athanasiadis2, T. Daglis2,
O. Karakasidou1, E. Skatharoudi1, D. Adamidou1, M. Economou1, A. Teli1,
B. Delaki3, E. Boutou3, E. Yfanti3, A. Balassopoulou3, T.-A. Vyzantiadis4,
T. Theodoridis5, E. Voskaridou3
1Thalassemia Unit, 2Obstetric Department, Hippokration General Hospital,
Thessaloniki, 3Thalassemia Centre, Laikon General Hospital, Athens, 4Micro-
biology Department, 5Obstetric Department, Aristotelion University, Thessa-
loniki, Greece
Background: Hemoglobinopathies constitute the most frequent monogenic
disorders worldwide and thalassemias are the most frequent genetic disorders
in Greece. Βeta-thalassemia carrier frequency is approximately 8%, while 1.5%
of the population are carriers of the Hb S mutation. The rate of β-thal carriers
could be as high as 15-20% in some areas. The risk of giving birth to an affected
child depends on the incidence of the thalassemic gene and this may vary from
1/24 to 1/150 in married couples. The National Program for prevention of Tha-
lassemia was established in 1973. Through population screening and prenatal
diagnosis programs Greeks and immigrants are screened and counseled.
Aims: We report our findings on prenatal diagnosis of thalassemias and hemo-
globinopathies in Northern Greece over a 15 year period (2001-2015).
Methods: During the 15 year period, a total of 33.837 subjects were screened
individually or as couples at our Thalassemia Prevention Unit. There were 3.659
couples screened for hemoglobinopathies. In 371 couples both partners carried
an abmormal Hb gene and counseling was offered and 329 pregnancies were
found at risk of giving birth to an affected child. The genes interactions were in
245 pregnancies at risk for thalassemia major offsprings and 84 for sickle cell
disease ones. Prenatal diagnosis was mainly carried out by CVS at 11-12
weeks of gestation (n=298), in few cases by amniotic fluid sampling (n= 21)
collected at 16-18 weeks. Few late comers were tested by fetal blood sampling
at 20 week of gestation(n=5). The remaining 42 pregnancies involved couples
who were double heterozygotes for mutations that did not cause severe clinical
disease and were exempted from prenatal diagnosis. The gene interactions
were as follows β-thal / α thal, β-thal in combination with Hb Ε-Saskatoon or D-
Punjab, ΗbΕ /HbE, Hb Ε-Saskatoon /with carrier of HbS, and Ηb O/ Hb O, β-
thal or α thal in combination with D Punjab, Hb Brugg/β-thal, silent β-thal/ silent
β-thal. 91% of the couples were of Greek origin, and 9% were immigrants from
Albania, Somalia, Nigeria, Fyrom, Ruanta and Thailand. We had an average
of 15-32 prenatal diagnosis per year.
Results: The results of DNA analyses of the samples were as follows: 76 fetus-
es (23%) were found to be homozygote or double heterozygote for clinical sig-
nificant mutations. These couples were informed of the danger of having an
affected child but the termination or continuation of the pregnancy was left to
the couples to decide. Nevertheless all, except three couples, preferred to ter-
minate the pregnancies so we had one case of thalassemia major offspring
and two cases of silent β-thal/ O Arab offsprings born. Selective abortion of the
affected fetus was performed in the cases of the twin pregnancies (n=6). There
have been no cases of misdiagnosed pregnancies and only one obstetric com-
plication (rupture of membrane that lead to miscarriage) was reported.
Summary/Conclusions: It is universally accepted that thalassemia prevention
programs are successful in countries with a high frequency of Hb mutations,
and prenatal diagnosis is mandatory in all at risk couples. The National Tha-
lassemia Prevention Program has effectively decreased the incidence of tha-
lassemia major and sickle cell syndromes in our country and in our region.
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THE IMPACT OF LIVER STEATOSIS ON THE ABILITY OF SERUM
FERRITIN LEVELS TO PREDICT LIVER IRON CONCENTRATION AMONG
NON-TRANSFUSION-DEPENDENT THALASSAEMIA PATIENTS: A CROSS-
SECTIONAL EVALUATION
P. Ricchi1,*, A. Meloni2, A. Spasiano1, L. Pistoia2, V. Positano2, P. Preziosi3,
A. Filosa1, A. Pepe2
1AORN A. Cardarelli, Naples, 2Fondazione G. Monasterio CNR-Regione
Toscana, Pisa, 3Ospedale “Sandro Pertini”, Rome, Italy
Background: Fatty liver is a common abnormality encountered in western
countries among patients undergoing imaging of the abdomen and is associated
to systemic inflammation and to increased ferritin levels, frequently unrelated
to iron overload.
Aims: We analyzed the impact of the presence of fatty liver in the parameters
of iron overload among our patients with Non Transfusion dependent Thalas-
saemia (NTDT).
Methods: 111 patients with NTDT were cross-sectionally evaluated; the diag-
nosis of liver steatosis was ultrasound-based (US). In all patients ferritin levels
and serum alanine aminotransferase (ALT) to serum aspartate aminotrans-
ferase (AST) ratio were assessed. Liver iron concentration (LIC) measurements
were available for 64 patients (54%) who underwent a magnetic resonance
Imaging (MRI) scan within the Myocardial Iron Overload in Thalassaemia
(MIOT) network.
Results: Liver steatosis was frequently (35.5%) encountered among our
patients with NTDT and was significantly more prevalent in males with respect
to females (49.0% vs 24.6%, p=0.008). Patients with liver steatosis had signif-
icantly higher levels of ALT, AST, ALT/AST ratio and ferritins than those without,
but LIC values were comparable (Table 1). At ROC curve analysis, a ALT/AST
ratio >0.89 predicted the presence of liver steatosis with a sensitivity=0.872
and a specificity =0.901 (P<0.0001). Overall, ferritin levels positively correlated
with LIC values (R=0.558, P<0.0001) but in patients without steatosis there
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was a strong relationship between ferritin and LIC values (R=0.656, P<0.0001)
while in patients with steatosis the correlation was moderate (R=0.426, P=0.05).
Table 1.
Summary/Conclusions: Our data show that liver steatosis affected also
patients with NTDT and should be suspected in presence of a ALT/AST ratio
>0.89. Recently, serum ferritin thresholds to predict clinically relevant liver iron
concentrations for guiding chelation therapy when MRI is unavailable in patients
with (NTDT) have been provided. Our data show that the presence of liver
steatosis may lead to overestimate the magnitude of iron burden and may be
responsible for anticipating or exceeding chelation treatment in patients with
NTDT in absence of a LIC evaluation.
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CIRCULATING CELL-FREE DNA (CFDNA) AND INEFFECTIVE
ERYTHROPOIESIS IN BETA-THALASSEMIA INTERMEDIA
D. Tavazzi1, G. Graziadei2, A. Marcon2, L. Duca2, I. Nava2, M.D. Cappellini1,*,
M. Sampietro3
1Dip. Scienze Cliniche e di Comunità, Università degli Studi di Milano, 2Dipar-
timento di Medicina Interna, Fondazione IRCCS Cà Granda Policlinico di
Milano, 3Dip. Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli
Studi di Milano, Milano, Italy
Background: Low concentrations of circulating cell-free DNA (cfDNA) are
found in the plasma of healthy individuals and increase in a number of condi-
tions in relation to clinical severity, including cancer, chronic inflammation,
autoimmune diseases and trauma. The mechanisms of release of cfDNA in
the bloodstream are not well understood: DNA could originate from cells under-
going apoptosis/necrosis in tissues or from cells released in the blood and sub-
sequently lysed. Also the tissue origin of cfDNA is mainly unclear. It has been
suggested that cfDNA, at least after bone-marrow transplantation, could be
mostly of hematopoietic origin. This finding prompted us to explore whether
cfDNA is increased in patients with ineffective erythropoiesis (IE), a condition
characterized by the over-proliferation and lysis/removal of erythroid precur-
sors. This situation is common in thalassemias, mainly in non transfusion-
dependent patients (NTDT).
Aims: The present study was designed i) to evaluate the behaviour of cfDNA
in IE caused by beta-thalassemia, and ii) to assess whether cfDNA could be
useful to quantify IE.
Methods: We studied 49 beta-thalassemia intermedia (TI) patients (mean age
41 years, range 16-65), 23 of whom were splenectomized. No evidences of
tumor, trauma or autoimmune diseases have been observed in any patient at
time of the study. Eighteen healthy subjects were also included as control
group. The study was approved by the local ethical committee. DNA was
extracted by QIAgen silica-based micro-spin columns from 200 mL of K2EDTA
plasma and its concentration determined fluorometrically using the fluorescent
dye PicoGreen. Biochemical and hematologic parameters were determined in
all patients as a part of laboratory routine. Reticulocytes and peripheral ery-
throblasts (EBL) were counted by automated procedures. Soluble transferrin
receptor (sTfR) and growth differentiation factor 15 (GDF15) were also meas-
ured by immunometric ELISA assays.
Results: In the 49 patients studied, plasma cfDNA concentrations ranged from
6.3 to 93.1 ng/mL and are significantly higher than in controls (median 21.8 vs
10.4, p<.0001). Comparing non splenectomised (non-SPX) with splenec-
tomised (SPX) patients, we observed a significant increase of cfDNA in the
SPX group (median 29.4 vs 19.3 ng/mL, p=0.0085). In the whole TI group,
cfDNA concentration was significantly correlated with EBL (p<,0001), LDH
(r=0.52, p=.0001) and AST (r=0.56, p<.0001). Correlations of cfDNA were also
observed with sTfR (r=0.45, p=.0014) and GDF15 (r=0.56, p<.0001). Notably,
correlations with EBL (r=0.75, p<.0001), AST (r=0.58, p=.0036) and unconju-
gated bilirubin (r=.54, p=.0083) were observed only within the SPX group and
not in non-SPX.
Summary/Conclusions: In this study we found that plasma cfDNA rises in TI
patients compared to controls. Its concentration appears to correlate with both
the amount of IE based on high number of EBL and the lysis of circulating ery-
throid precursors (both increased after splenectomy). We obtained preliminary
evidences that circulating cfDNA concentration may be a suitable indicator of
erythropoietic activity in TI patients. Results need to be extended on larger
samples of patients’ population to investigate the possible use of plasma cfDNA
as a feasible and reliable biomarker to describe/monitor the severity of IE and
TI complications.
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LEFT VENTRICULAR HYPERTRABECULATION BY CARDIAC MAGNETIC
RESONANCE IN THALASSEMIA INTERMEDIA PATIENTS: FREQUENCY
AND PROGNOSTIC ROLE
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Studi Di Palermo, Policlinico Paolo Giaccone, Palermo, 3Ospedale Civile “Spir-
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Background: Differentiation of left ventricle non-compaction (LVNC) from
hypertrabeculated LV due to a negative heart remodeling in thalassemia inter-
media (TI) can depends on the selected CMR criterion. The recently proposed
Piga’s criterion (NC/C ratio threshold of >2.5, Am J Haem 2012) seems to have
a low specificity to identify the true LVNC in TI. Anyway, the Piga’s criterion
could easily detect a negative heart remodeling in TI patients.
Aims: The aim of our study was to prospectively assess whether the Piga’s
criterion had a prognostic role for adverse cardiovascular outcomes in TI
patients.
Methods: We studied prospectively 168 TI patients (81 males, mean age 38.32
±11.61 years) consecutively enrolled in the Myocardial Iron Overload in Tha-
lassemia (MIOT) Network. Standard cine steady-state free precession
sequences were acquired and used for the calculation of biventricular function
parameters (short-axis) and for the calculation of the thickness of the non-com-
pacted and the compacted myocardium (three diastolic long-axis views) in all
16 segments. The maximal NC/C ratio was considered. Late gadolinium
enhancement (LGE) images were acquired to detect myocardial fibrosis.
Figure 1.
Results: Eight patients were excluded because a cardiac complication was pres-
ent at the first CMR. The baseline mean age of the considered 161 TI patients
was 38.32±11.61 years and 81 patients were males. The study population was
divided into two groups: patients with Piga’s positive criterion (n=15, 9.31%) and
with Piga’s negative criterion (n=146, 90.68%). No significant differences were
found between the two groups in terms of demographic features and CMR param-
eters. The mean follow-up time was 57.50±21.87 months. Sixteen new cardiac
events were recorded: 1 heart failure, 10 supraventricular arrhythmias and 5 pul-
monary hypertension. Due to numerical reasons, it was possible to perform a
Cox regression analysis only for arrhythmias and cardiac complications globally
considered.  Patients with Piga’s positive criterion had a significant higher risk of
developing arrhythmias (hazard ratio-HR=7.19, 95% CI=2.02-25.51; P=0.002)
and cardiac complications (HR=3.66, 95% CI=1.18-11.36; P=0.025). The figure
shows the Kaplan-Meier survival curves. The Piga’s positive criterion remained
a significant prognosticator also in a multivariate models including previous and
resolved events (14 cardiac complications, of which 7 arrhythmias) (HR for
arrhythmias=23.67; HR for cardiac complications =7.09).
Summary/Conclusions: Based on our data a NC/C ratio >2.5 provides prog-
nostic information for patients with TI about the risk of developing cardiac com-
plications.
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NITRIC OXIDE DYSREGULATION IN BETA-THALASSEMIA MAJOR:
RELATION TO PULMONARY HYPERTENSION
M. Elshinawy1,2,*, A. Elnaggar3, A. Ghanem3, M. Wagdy4
1Pediatric Hematology, Sultan Qaboos University Hospital, Muscat, Oman,
2Pediatric Hematology, Faculty of Medicine, 3Hematology, Medical Research
Institute, 4Clinical Pathology, Faculty of Medicine, Alexandria, Egypt
Background: Pulmonary hypertension (PH) is emerging as one of the most
devastating complications of beta-thalasssemia major. Chronic hemolysis and
iron overload constitute a major source of strong oxidative stress. Free heme
radicals and red cell membrane elements resulting from hemolysis have a neg-
ative effect on the intrinsic nitric oxide (NO) production and arginine bioavail-
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ability. Deficiency of both biochemical mediators promotes vasoconstriction of
the pulmonary vasculature resulting in further endothelial dysfunction, with sub-
sequent intensified reduction of nitric oxide. The role of nitric oxide dysregulation
is well-studied in non-transfusion dependent thalassemias and in sickle cell
disease, but yet not very well-characterized in beta thalassemia major.
Aims: The aim of our work is to study the relation between intrinsic nitric oxide
level and the evolution of pulmonary hypertension in beta thalassemia major.
Methods: This is a case-control study, including all patients with beta tha-
lassemia major above 12 years of age, undergoing follow up in pediatric hema-
tology unit and in medical research institute, university of Alexandria, Egypt
throughout a period of 6 months fom 1st of July till 31st of december 2016. All
patients were screened for pulmonary hypertension by echocardiography, and
those who have high tricuspid regurgitanr jet velocity (TRJV >2.5m/sec.) under-
went cardiac catheterization.
Results: The present study included 52 thalassemic patients, 28 males and
24 females. Their age ranged between 11 and 26 years. The patients were
subdivided into two groups (17 patients with pulmonary hypertension (PH),
proven by cardiac cathetrerization and 35 patients without pulmonary hyper-
tension). Nitric oxide level (measured by ELISA) was significantly lower in
patients as a whole compared to controls [median of 19 micromol/L versus 30
micromol/L] (p=0.02). Similarly, nitric oxide was significantly lower in PH group
compared to non-PH patients (p=0.001). In addition, there was a statistically
significant negative correlation between serum NO level and serum ferritin level
in all patients (r=-0.444, p=0.001).
Summary/Conclusions: In conclusion, NO reduction might contribute signifi-
cantly to the development of pulmonary hypertension in patients with beta tha-
lassemia major. This effect could be related to the degree of hemolysis, iron
overload and the duration of disease. Further studies on the adverse patho-
physiologic effects of nitric oxide deficiency in beta thalassemia major e.g. its




SPECKLE-TRACKING ECHOCARDIOGRAPHY FOR DIAGNOSIS OF EARLY
MYOCARDIAL DISEASE IN EGYPTIAN BETA THALASSEMIA MAJOR
PATIENTS
A.A.G. Tantawy1,*, N.M. Habeeb2, N.H. Elsherif3, E.M. Hasan1, A. Abdelhameed1
1Pediatric Hematology&oncology, 2Cardiology departement, faculty of medi-
cine,Ain Shams University, 3Pediatric Hematology&oncology, Ain Shams Uni-
versity, Cairo, Egypt
Background: The new parameters of cardiac function, derived from two-dimen-
sional speckle-tracking echocardiography could be useful for an early diagnosis
of cardiac involvement in transfusion dependent β-TM patients.
Aims: In this cross sectional study, our goal was to detect early myocardial
disease in transfusion dependent β-TM patients using Echocardiography
(Speckle Tracking) and to assess its specificity and sensitivity in comparison
with cardiac MRI T2*.
Methods: This cross sectional study included 30 transfusion dependant β-tha-
lassemia patients aged between 11-20 years recruited from the Pediatric Hema-
tology Unit, Children Hospital, Ain Shams University. All included patients were
subjected to detailed medical history{including transfusion, chelation, hepatitis
C virus history with calculation of mean serum ferritin in last 2years) Radiological
investigation included Echocardiography (Tissue Doppler and Speckle Track-
ing),MRI T2* were done.Cardiac affection by speckled was defined as
decreased longitudinal strain less than 11 percentage or affection of any seg-
ment less than 11 percentage.
Results: Cardiac affection by speckled echocardiography was found in 10
patients(33.3%), 8 of them (80%) had normal ejection fraction and normal short-
ening fraction ,while 9 had iron overload by Cardiac MRI T2*. Patients with mean
serum ferritin>2500 ng/mL in the last 2 years prior evaluation showed a signifi-
cantly lower longitudinal strain (GLPSLAX) (P=0.043) which was further proved
by a significantly negative correlation with the mean serum ferritin (P=.002). No
significant differences were found between both splenectomized and non splenec-
tomized patients as regard speckle tracking echocardiographic measures. The
ROC curve analysis revealed that GLPS A4C a cutoff value of ≤21% was able to
detect B- thalassemia patients having myocardial disease by cardiac MRI T2*
with a sensitivity of 87.50% and specificity of 63.64% .Patients with cardiac iron
overload by MRI T2* had significantly lower GLPSLAX &GLPSA4C and higher
Ao Diam than those without cardiac iron overload (P=0.016, P=0.008, P=0.047
respectively). No significant difference between beta thalassemia patients with
cardiac affection and those without cardiac affection as regard the duration of the
disease, type and compliance of chelation therapy.
Summary/Conclusions: Although, Magnetic Resonance Imaging T2* tech-
nique is still considered the reference standard in myocardial iron overload, its
routine use is limited by its high costs, poor availability. We demonstrated in
this study an abnormal global longitudinal strain despite preserved LV systolic
functions among BTM patients; thus speckle tracking echo techniques might
be considered as an alternative effective method to detect early myocardial
disease before evident systolic dysfunction.
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EFFICACY, SAFETY AND GENETIC BASIS OF VARIABILITY OF
RESPONSE TO HYDROXYUREA THERAPY IN BETA THALASSEMIA: A
SYSTEMATIC REVIEW
S. Khaliq1,2,*
1Pathology, fauji Foundation Hospital/Foundation University Medical College
Rawalpindi, 2Hematology, Hemophilia Centre, Rawalpindi, Pakistan
Background: Pharmacological agents such as hydroxyurea promote fetal
hemoglobin production via a reactivation of γ-genes. In β-thalassemia there is
an imbalance in globin chains which could be ameliorated by the newly syn-
thesized γ-chains which neutralize the excess α-chains and therefore improves
symptoms.
Aims: Systematic review of literature to evaluate the efficacy, safety and the
genetic basis of variability of response to hydroxyurea therapy in beta-tha-
lassemia patients
Methods: Research sources used were: MEDLINE (PubMed), EMBASE (Ovid)
and Cochrane from June 1993 till June 2016. Eligible articles were reviewed
and data including patients ‘characteristics, duration of treatment, outcome,
toxicity and impact of genetic mutation on response to hydroxyurea therapy
was extracted. Major responders were those who became transfusion inde-
pendent after hydroxyurea treatment, partial responders had significant decline
in transfusion requirements, poor responders did not respond to hydroxyurea
therapy. Statistical analysis software package 16 was used for data analysis.
Table 1.
Results: Thirty eligible studies comprising of a total of 1822 patients with beta
thalassemia were identified. Of these (n=9, 30%) evaluated the effect of hydrox-
yurea therapy on beta thalassemia major patients, (n=11, 36%) evaluated beta
thalassemia intermedia patients while (n=10, 34%) included both beta tha-
lassemia major and thalassemia intermedia patients. Mean age of patients was
13.5 years. Mean duration of hydroxyurea therapy was 3.4 years. The mean
dose of hydroxyurea was 10mg/kg per day (8-15mg/kg). Table I showing number
and percentage of patients having major, partial and poor response to hydrox-
yurea therapy. Only (n=12, 36%) studies evaluated the role of underlying genetic
mutation on hydroxyurea response, out of these (n=6, 50%) studies found no
significant correlation while (n=6, 50%) showed a positive correlation between
common genetic mutations and hydroxyurea response. Hydroxyurea was found
to be well tolerated, only (n= 09, 01%) had transient myelosuppression.
Summary/Conclusions: Hydroxyurea is an effective and well-tolerated agent
in the management of β-thalassemia (both intermedia and major). It reduces
blood transfusion requirements either partially or completely in majority of
patients. No significant correlation between response to therapy and underlying
genetic mutation was found. More studies are required to fully establish the
association of genetic mutation to drug response.
E1582
EVALUATION OF CONTINUOUS BLOOD GLUCOSE MONITORING
METHOD FOR DETECTION OF ALTERATIONS IN GLUCOSE HOMEOSTASIS
IN BETA-THALASSEMIA PATIENTS
M. El Samahy1, A. Tantawy1,*, A. Adly1, E. Ismail1, A. Ahmed1, N. Yousef1
1AinShams university, Cairo, Egypt
Background: Glucose metabolism disturbances, among other
endocrinopathies, are a common feature of β-thalassemia major (β-TM). Pan-
creatic iron overload and diabetes mellitus (DM) are common in β-TM patients.
However, the relationship between iron stores and glucose disturbances is not
well defined. Continuous glucose monitoring system (CGMS) enables more
diagnostic accuracy and a better achievement of an optimal glycemic control.
Aims: To assess the pattern of glucose homeostasis in patients with β-TM and
detect early impairment in glucose metabolism and prediabetic state in β-tha-
lassemia patients comparing oral glucose tolerance test (OGTT) and CGM system.
Methods: This cross sectional study was conducted on 200 patients β-TM
patients. Patients were studied focusing on transfusion history, transfusion
index, iron chelation therapy and compliance to chelation. Complete blood pic-
ture, markers of hemolysis, serum ferritin and random blood glucose (RBG)
were measured. Patients with RBG ≥140mg/dL were subjected to OGTT, inser-
tion of CGMS for 3 days, measurement of fasting C peptide, and serum insulin
with calculation of HOMA-IR and assessment of HbA1c.
Results: Screening with RBG revealed that 20 patients (10%) had RBG
≥140mg/dL. Using OGTT, 7 (3.5%) patients were in the diabetic range, 7 (3.5%)
had normal OGTT while 6 (3%) had impaired glucose tolerance. The CGMS
showed that 7 (3.5%) patients had IGTT (6.5%) and 13 patients had diabetes
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mellitus. The percentage of diabetic patients diagnosed by CGMS was signif-
icantly higher than that with OGTT (p= 0.012). According to CGMS readings,
10 of the 13 patients with diabetes had abnormal HbA1c readings of diabetic
range (6.5-9.9%) while 5 of the 7 patients with impaired glucose tolerance had
HbA1c readings in the prediabetic range (5.5-6.1%). Serum ferritin were sig-
nificantly higher among patients with RBG ≥140mg/dL (p= 0.001). It was noted
that 85% of patients with RBG≥ 140mg/dL were noncompliant and 75% of
patients on desferrioxamine therapy had RBG≥140mg/dL. There was a signif-
icant positive correlation between HbA1C% and FBG among the studied tha-
lassemia patients with elevated RBG≥ 140mg/dL, while HbA1c% was nega-
tively correlated with fasting C-peptide. Serum ferritin was positively correlated
with RBG. As regards CGMS data, HbA1C was positively correlated to maxi-
mum blood glucose, average blood glucose, SDS blood glucose and area
under the curve≥140mg/dL. The only significant independent factor for elevated
RBG ≥140mg/dL was serum ferritin.
Summary/Conclusions: The use of CGMS in the diagnosis of early glycemic
abnormalities (prediabetes) among patients with β-TM appears to be promising
and superior to other known diagnostic modalities namely OGTT and HbA1c. 
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LEFT VENTRICULAR REGIONAL FUNCTION IN CHILDREN WITH BETA
THALASSEMIA WITH NO CARDIAC MANIFESTATIONS (FOUR-DIMEN-
SIONAL ECHOCARDIOGRAPHIC STUDY) 
M. El-Shanshory1,*, O. Tolba 1, W. El-Shehaby1, A. Elshamia 2, A. Fayed3,
A. ElKholy 4, E. Eldosoky5
1Pediatrics, Faculty of Medicine, Tanta University, Tanta, 2Pediatrics, Ministry
of Health, Basyoun, 3Pediatrics, Ministry of Health, Kotor, 4Pediatrics, Ministry
of Health, Zefta, 5Pediatrics, Ministry of Health, Alexandria, Egypt
Background: Early detection of myocardial dysfunction is essential for the
management of patients with thalassemia. Four -dimensional echocardiography
imaging technique that analyzes the motion of tissues in the heart may be
useful for detecting subclinical cardiovascular disease.
Aims: To evaluate the 4-dimensional echocardiographic strain in children with
beta thalassemia major and correlate it with other echocardiographic parameters.
Methods: This is a cross sectional cohort Study included 200 children, 1-18
years-old. They were divided into: One hundred children with β-Thalassemia
major with no clinical cardiac manifestations and 100 healthy children as a
control group. They were subjected to the following investigations: Complete
blood count, serum ferritin and Four-dimensional echocardiographic strains
(Longitudinal, Circumferential, Radial and Area strains).
Results: There was no significant difference between the two groups as regard
mitral annulus systolic velocity (S wave), E/A ratio and iso-volumic acceleration
but there was significant difference as regard to ejection fraction, left ventricle
mass, sphericity index and myocardial performance index. The mean values
of Left ventricular Strains (Longitudinal, Circumferential, Radial and Area
strains) were significantly lower in patients with thalassemia (-14.86±12.131,
-8.01±3.829, 33.13±10.613, -19.45±6.866) than controls (-19.13±1.502,
-16.32±1.34, 37.28±4.209, -22.94±3.064) than controls respectively with a pos-
itive correlation with 2-Dimensional strain.
Summary/Conclusions: Strain parameters of the left ventricle obtained by
four-dimensional echocardiography can be a novel and promising technique
for early detection of left ventricular dysfunction in children with thalassemia.
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THE IMPORTANCE OF SERUM GDF-15 LEVELS TO ASSESS IRON
OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR
M. Ucman1, U. Caliskan2,*, H. Tokgoz2
1Necmettin Erbakan University Meram Medical Faculty, Konya, Turkey, 2Pedi-
atric Hematology and Oncology, Necmettin Erbakan University Meram Medical
Faculty, Konya, Turkey
Background: There is growing interest in noninvasive assessment of iron
accumulation in patients with thalassemia major. Magnetic resonance imaging
(MRI) have become widely available in recent times.
Aims: We aimed to evaluate the importance of serum GDF-15 levels for mon-
itoring the iron overload in patients with beta thalassemia major.
Methods: Forty-six patients aged between 1 and 25 years were included in
the study. Serum levels of GDF-15, ferritin, troponin, AST and ALT were studied.
T2*MRI was performed for all patients. The relationship between GDF-15 hor-
mone levels and T2 * MR, ferritin levels, sex, annual transfusion volume,
splenectomy was evaluated.
Results: Of 46 patients, 20 were male (%43,5) and 26 were female (%56,5),
with a median age of 12,4 years. Mean serum ferritin level was 2752,
15±3105,78 ng/ml. Mean GDF-15 level was 9672,87±7910,36pg/ml. Mean
duration of T2*MRI was 32,50±11,33 ms for hearth and 4,87±3,78 ms for liver.
12 patients were underwent splenectomy. Serum GDF 15 levels were signifi-
cantly higher in thalassemia major patients than in normal levels. According to
T2*MRI levels, serum GDF-15 levels were significantly higher in patients with
hepatic iron overload. There was a negative correlation between hepatic T2*MR
values and serum GDF-15 levels. However, there was not significant correlation
between cardiac T2*MR and serum GDF-15 levels. Splenectomy had no effect
on GDF-15 levels (Table 1).
Table 1.
Summary/Conclusions: We demonstrated that serum GDF-15 levels were
increased in thalassemia major patients. GDF-15 levels is correlated with
hepatic iron overload but not cardiac iron overload. It may be due to lower
number of thalassemic patients with abnormal cardiac T2* MRI. GDF-15 may
be a valuable parameter to assess iron overload in thalassemia major, but fur-
ther studies are needed.
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ASSOCIATION OF SP1 POLYMORPHISM IN THE COLLAGEN TYPE I
ALPHA -1 (COLIA1) GENE WITH OSTEOPROSIS IN CHILDREN WITH
BETA-THALASSEMIA
M. Hesham1,*, N. Khalifa2, M. Zakaria1, N. Elbaz2, D. AbdElmonem2
1Pediatric, 2clinical pathology, Zagazig University Hospital, Zagazig, Egypt,
Zagazig, Egypt
Background: Osteoporosis is a progressive bone disease that is characterised
by a decrease in bone mass and density that leads to an increased risk of frac-
ture. Early detection of mutation at the Sp1-binding site on the COLIAI gene is
mandatory in order to initiate preventive therapy before the occurrence of frac-
tures in children with beta-thalassemia.
Aims: To study the relationship between SP1 polymorphism in the collagen
type 1 alpha 1 gene and the development of osteoporosis in patients with Beta
thalassemia.
Methods: A prospective case control study was carried out in the Outpatient
Clinic of Hematology Unit of Pediatric Department and Clinical Pathology Depart-
ment at Zagazig University Hospitals on forty thalassemic patients (21 females
&19 males) aged 6-18 years during their regular follow-up visits (22 patients
with thalassemia major and 18 with thalassemia intermedia)and forty age- and
sex-matched healthy children as a control group. All patients and control were
subjected to full medical history, thorough clinical examination and laboratory
investigations in the form of complete blood count, Hb electrophoresis, Calcium
level Serum ,alkalin phosphatase, Bone Density by DXA, Serum osteocalcine
level and COLIAI gene polymorphism by using polymerase chain reaction-
restriction fragment length polymorphism technique (PCR-RFLP).
Results: There was highly significant difference between thalassemia patients
and control group as regards serum levels of calcium, osteocalcin and alkaline
phosphatase and DEXA results but no significant difference between tha-
lassemia major and thalassemia intermedia patients. As regard COLIA1 geno-
type there was high percentage of heterozygous Ss (G/T) and homozygous ss
(T/T) genotype in beta thalassemia major 55.63%, 13.67% than thalassemia
intermedia 50.6%, 0%, respectivily. There was significant relation between
COLIA1genotypes and Calcium level (p=0.02). But there was no significant
relation between COLIA1genotypes and osteocalcin, alkaline phosphatase lev-
els and DEXA among studied groups.
Summary/Conclusions: SP1 polymorphism in collagen gene could be of clin-
ical value in identifying the thalassemic patients at risk of developing osteo-
porosis.
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UNUSUAL MOLECULAR MECHANISMS IN THE ORIGIN OF ALPHA-THA-
LASSEMIA
J. Ferrão1, M. Silva1, L. Gonçalves1, S. Gomes1, P. Loureiro1, A. Coelho1,
A. Miranda2, F. Seuanes2, A. Batalha Reis3, F. Pina4, R. Maia5, P. Kjollerstrom5,
E. Monteiro6,7, J. F. Lacerda6,8, J. Lavinha1,9, J. Gonçalves1,10, P. Faustino1,11,*
1Departamento de Genética Humana, Instituto Nacional de Saúde Doutor
Ricardo Jorge (INSA), 2Departamento de Promoção da Saúde e Doenças não
Transmissíveis, INSA, 3Serviço de Patologia Clínica, Hospital São Franscisco
Xavier, Centro Hospitalar de Lisboa Ocidental, Lisboa, 4Serviço de Hemato-
Oncologia, Hospital do Espírito Santo de Évora, Évora, 5Unidade de Hema-
tologia, Hospital de D. Estefânia, Centro Hospitalar de Lisboa Central, 6Fac-
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uldade de Medicina, Universidade de Lisboa, 7Serviço de Gastroenterologia,
Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte (CHLN), 8Serviço
de Hematologia, Hospital de Santa Maria, CHLN, 9BioISI, Faculdade de Ciên-
cias, Universidade de Lisboa, 10ToxOmics, Faculdade de Ciências Médicas,
Universidade Nova de Lisboa, 11ISAMB, Faculdade de Medicina, Universidade
de Lisboa, Lisboa, Portugal
Background: Hemoglobin (Hb) is a protein responsible for oxygen transporta-
tion from lungs to the entire body. It is composed by four globular subunits - the
globins - each with a central core containing a heme molecule. Globins are
encoded by the α- and β-globin gene clusters located at 16p13.3 and 11p15.5,
respectively. The pattern of globin gene expression during development is pre-
cisely controlled by the interaction of cis-regulatory genomic regions (located
in close proximity to and far from genes) with trans-activating/silencing factors
within permissive chromatin domains. Distally upstream of the α-globin genes
there are four multispecies conserved sequences (MCS-R1 to R4) which are
critical for the expression of the downstream globin genes. Deletions removing
the α-globin genes and/or their distal MCSs give rise to α-thalassemia, one of
the most common genetic recessive disorders worldwide, due to a reduced
rate of α-globin chain synthesis. The severity of the pathology is variable ranging
from a very mild microcytic hypochromic anemia to a moderately severe anemia
associated with the formation of β4 tetramers resulting in HbH disease or an
even higher reduction or complete absence of α-chains resulting in hemoglobin
Bart’s hydrops fetalis, a condition generally incompatible with life.
Aims: The main objectives of this work were to characterize the molecular
lesions underlying ten Portuguese cases of unusual α-thalassemia/HbH disease
and to understand their origin and functional consequences.
Methods: After exclusion the most frequent molecular lesions associated with
α-thalassemia, Multiplex Ligation-dependent Probe Amplification (MLPA) using
the SALSA MLPA P140B HBA kit (MCR-Holland) was used to search for DNA
deletions in the subtelomeric region of chromosome 16p. Additionally, specifi-
cally designed synthetic MLPA probes, as well as gap-PCR and Sanger
sequencing were performed for more accurate deletion breakpoint mapping.
Results: We have found five distinct deletions and one indel, all in heterozy-
gosity. The deletions range from approximately 3.3 to 323 kb and two of them
are novel. The three larger deletions remove the entire α-globin cluster whereas
the others remove totally or partially the distal regulatory elements keeping the
α-globin genes structurally intact. The indel comprises the deletion of the MCS-
R2 regulatory element and the insertion of a singular 39 bp DNA fragment pos-
sibly originating from a complex rearrangement involving chromosome 3. Final-
ly, no α-globin gene cluster deletion or point mutation were found in a patient
who revealed to be a very unusual case of acquired alpha-thalassemia asso-
ciated with a myelodysplastic syndrome. 
Summary/Conclusions: Our study widens the spectrum of molecular lesions
and unusual molecular mechanisms by which α-thalassemia/HbH may occur
and emphasizes the importance of diagnosing large α0-deletions to provide




VALUE OF HBA2 IN THE DIAGNOSIS OF BETA-THALASSEMIA MINOR
“ATTENTION TO THE GRAY ZONE”
L. Relvas1,*, T. Magalhães Maia1, E. Cunha1, J. Pereira1, A.C. Oliveira1,
C. Bento1, M.L. Ribeiro1
1Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra,
Coimbra, Portugal
Background: The homozygosity for the alternative splicing mutation HBB:
IVSI-6 (C>T) is the most frequent genotype of beta thalassemia intermediate
in our population and was even termed “beta thalassemia intermediate type
Portuguese” (Tamagnini et al, 1983). The IVSI-6 (C> T) carriers (heterozygous)
are characterized by mild hypochromia and microcytosis, with a moderately
increased in HbA2, that may be even less than 3.5%. The correct identification
of these carriers is important, especially when facing a couple who intends to
have children.
Aims: To evaluate the percentage of individuals with hypochromia and micro-
cytosis and Hb A2 between 3.2% and 3.4%, who are beta thalassemia carriers,
alerting for the need to adapt the cut-offs of HbA2 values to the genetic back-
ground of different populations.
Methods: Parameterized search of all the consecutive individuals evaluated
in our laboratory from January 2007 to January 2016. The inclusion criteria
were the simultaneous presence of hypochromia and microcytosis (adjusted
to the age) and HbA2 values between 3.2% and 3.4% inclusive. The exclusion
criteria were the presence and/or clinical information of sideropenia or
sideropenic anemia, hemoglobin variants or alpha thalassemia. Sequencing of
the entire HBB gene was preformed by Sanger Sequencing.
Results: Respecting the inclusion and exclusion criteria we have identified 43
individuals with hypochromic and microcytic anemia, HbA2 ≥3.2% and ≤3.4%,
in which the HBB gene mutations were screened. Among the 43 subjects, nine-
teen presented HbA2=3.2% (19/43), eleven HbA2=3.3% (11/43) and thirteen
had HbA2=3.4% (13/43). The IVSI-6 (T>C) mutation was identified in 2 subjects
with HbA2=3.2% (10%), 5 with HbA2=3.3% (45%) and 7 with HbA2=3.4%
(54%). No other HBB gene mutations were detected. The remaining individuals
were classified as probable alpha thalassemia and suggested continuation of
the study, if warranted.
Summary/Conclusions: We have identified 14/43 (32%) individuals as beta
thalassemia carriers who, for the conventional cut-off of HbA2 ≥3.5%, would
not have been diagnosed. Based on this data, we propose that individuals with
hypochromia and microcytosis, with normal or slightly elevated RDW, without
sideropenia, with HbA2 between 3.2-3.4%, should be screened for mutations
in the HBB gene, in order to rule out beta thalassemia carriers due to Beta+
mutations. As HBB IVSI-6 (T>C) mutation is one of the most frequent beta tha-
lassemia mutations in Portugal, and in Mediterranean basin, it is necessary to
keep in mind that the classic rule of HbA2> 3.5% for the diagnosis of beta tha-
lassemia minor may underdiagnose this pathology and lead to an incorrect
genetic counseling.
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DIAGNOSIS OF HEMOGLOBINOPATHIES BY CAPILLARY ZONE
ELECTROPHORESIS: EXPERIENCE WITH 925 CASES
P. Tripathi1,*, H.P. Pati1, R. Saxena1
1Dept of Hematology, All India Institute of Medical Sciences, New Delhi, India
Background: Hemoglobin capillary zone electrophoresis is a relatively newer
technique as compared to HPLC for detection of abnormal hemoglobins. We
share our first hand experience of using Capillary 2 Flex piercing instrument
for diagnosis of hemoglobinopathies as a primary diagnostic modality
Aims: The main aim was to evaluate a new technology for diagnosis of hemo-
globinopathy.
Methods: The capillary 2 Flex piercing instrument with Phoresis software for
hemoglobin electrophoresis at alkaline pH was evaluated at our centre over a
period of 1 year. A total of 925 sample runs were included in the analysis. The
equipment was assessed on the following parameters: ease of operation, pre-
analytical factors, identification, quantification and precision of hemoglobin vari-
ants including the rare variants. Further, we evaluated if capillary zone elec-
trophoresis can be useful as a single method for diagnosis of hemoglo-
binopathies.
Results: The automation provided by capillary zone electrophoresis eased the
problem of errors during sample preparation. The option for low sample volume
mode is a great help in samples from children. The instrument could readily
identify all common hemoglobins and the diagnosis was straightforward in 829
(89.7%) cases. In the rest 96 (10.3%) cases, the sample was required to be
rerun because it lacked Hb A or Hb A2. This posed inconvenience because the
electrophoretic zones get displaced and have to be derived after mixing it with
normal sample. The machine is not specifically standardized for cord blood
samples hence we are not performing tests on neonatal cord blood sample. 
The instrument could separately identify Hb E from Hb A2 which is a big scorer
over HPLC, however, we found mild high Hb A2 both in heterozygous and
homozygous Hb E cases ( heterozygous Hb E, n-28 mean Hb A2- 3.9% and
homozygous Hb E, n- 7 and mean Hb A2- 4.2%) leaving the doubt whether
some adducts are still left. Identification of small peaks of Hb H could be difficult
and requires other modalities to confirm. Two cases where Hb H was strongly
suspected clinically and HB H inclusion test was positive showed small peaks
of HB H (1.2% and 0.9% ) on HPLC. Hemoglobins falling into the same zone
(eg Hb D- Punjab and Hb Q India) needed identification with second modality.
Whenever encountered with problem of identifying certain abnormal peak, we
resorted to HPLC for confirmation. Spectrum of hemoglobin variants encoun-
tered (n-298 cases, rest 627 showed normal results) in the study is listed in
table below.
Table 1.
Summary/Conclusions: Capillary zone electrophoresis is an alternative
method which brings automation. However, since the diagnosis of Hemoglobin
variants mandates confirmation by a second method, HPLC cannot be replaced
completely. Based upon the availability, workload and cost effectiveness, any
of these two methods can be used as primary modality.
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RELEVANT ROLE OF VON WILLEBRAND FACTOR-ADAMTS13 AXIS IN
HEPATIC ISCHEMIA- REPERFUSION INJURY
Y. Urisono1,*, H. Matsui2, K. Nishio2, K. Okuchi1, M. Sho3, M. Sugimoto2
1Emergency and Critical Care Medicine, 2General Medicine, 3Surgery, Nara
Medical University, Kashihara, Japan
Background: Hepatic ischemia-reperfusion (I/R) injury is a liver damage occur-
ring during liver surgeries such as hepatic resection or transplantation, and
denotes the major basis for graft dysfunction after transplantation. Although
detailed mechanisms of hepatic I/R injury remain to be clarified, an excessive
inflammatory response is thought to play a role in this regard.
Aims: Since recent studies suggest that von Willebrand factor (VWF) plays a
pivotal role in a cross-talk between inflammation and thrombosis, we assumed
that VWF may be involved in the pathophysiology of hepatic I/R injury. To test
this hypothesis, we have used a mouse experimental model of hepatic I/R injury.
Methods: Mice were anesthetized with sodium pentobarbital and a midline
laparotomy was then performed on a heating pad. Blood supply for left lateral
and median lobes of liver (approximately 70% of the liver mass) was interrupted
by cross-clamping the hepatic artery and portal vein with a microvascular atrau-
matic clip for 90 min. Then a clip was taken off to provoke the reperfusion of
hepatic blood flow, which was monitored on the surface of left lateral lobe by
Laser Doppler flowmetry (ALF21, Advance Co, Tokyo, Japan). The hepatic
blood flow was measured again 24 h after reperfusion and mice were then
sacrificed for blood collection and histological analysis of liver tissue. We com-
pared 16 wild-type (WT) and 12 VWF-gene deleted (knock-out; KO) mice (from
The Jackson Laboratory, Bar Harbor, ME), all of which were 8-12 weeks of
age, healthy and fertile. Excess blood loss was not observed in all mice (WT
or KO) during whole surgical process.
Results: As compared to WT mice, restoration of hepatic blood flow was sig-
nificantly greater in VWF-KO mice at 24 h after reperfusion (WT; 61± 17% vs
KO; 87±17%, expressed as the percentage of pre-ischemic value). Consistent
with the hepatic blood flow, the time-course analysis of serum alanine amino-
transferase (ALT) at several time points after reperfusion revealed the lesser
liver damages of KO mice (WT; 6898±3270 and 1313±621 IU/L vs KO;
3043±1320 and 478±330 IU/L, at 3 h and 24 h after reperfusion, respectively).
In addition, histological analysis confirmed that neutrophil infiltration in the liver
tissue of KO mice was significantly reduced as compared to WT mice at 24 h
after reperfusion. These impaired hepatic blood flow and ALT values as well
as intensified neutrophil infiltration in WT mice were significantly improved to
an extent comparable to those of KO mice by the bolus injection of recombinant
human ADAMTS13 (3 μg/mouse equivalent to 2800 U/kg, n=12) just prior to
the I/R operation.
Summary/Conclusions: Our results altogether indicate that VWF-dependent
inflammatory responses with neutrophil recruitment at ischemic sites are
involved in pathophysiology of hepatic I/R injury, and functional regulation of
VWF by ADAMTS 13 may serve as a promising therapeutic option for hepatic
I/R injury.
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THE IMPORTANCE OF THE FULL BLOOD COUNT, JAK II AND ADAMTS
13 TESTING IN STROKE EVALUATION: A REVIEW OF 619 CONSECUTIVE
YOUNG STROKE AND TIA PATIENTS
A. Taylor1,*, V. Alakbarzade2, A. Chandratheva2, R. Simister2, A. Dados2,
M. Scully1
1Haematology, 2Neurology and Stroke Medicine, University College London
Hospital, London, United Kingdom
Background: Young ischaemic stroke patients undergo extensive investiga-
tions yet around 40% remain of undetermined cause. Complex and costly
thrombophilia testing is routinely sent despite limited evidence linking to arterial
disease. A full blood count may be ignored but is potentially more helpful in
suggesting myeloproliferative disease or thrombotic thrombocytopenic purpura
(TTP) as causative.
Aims: We retrospectively reviewed full blood counts, specifically haematocrit
and platelet count, and whether these were documented and further investi-
gated if outside of the normal laboratory range. We examined whether less
common primary haematological disorders known to cause stroke were con-
sidered: JAK II mutation analysis for myeloproliferative diseases such as poly-
cythaemia vera (PV) and essential thrombocythaemia (ET), and ADAMTS13
analysis for TTP. 
Methods: We retrospectively reviewed consecutive clinical and laboratory
records for all stroke and TIA patients <60 years presenting to a regional hyper-
acute stroke unit and daily TIA clinic from January 1st 2015- August 7th 2016.
All those with thrombocytosis (defined as platelet count >400x109/L) and/ or
raised haematocrit (defined as Hct >0.45) were reviewed to see if a cause
could be determined, and if not, whether JAK II analysis was considered and
tested. We similarly examined patients presenting with thrombocytopenia
(defined as platelet count <150x109/L), and if no cause determined, whether
ADAMTS13 testing was contemplated.
Results: 610 patients <60 years were included: 379 ischaemic stroke (62.1%),
193 TIA (31.6%) and 38 haemorrhagic stroke (6.2%). 161 (26.4%) had abnor-
malities in haematocrit or platelet count: 116 (19%) had a raised haematocrit,
19 (3.1%) thrombocytosis, and 26 (4.2%) thrombocytopenia. Of these, 7
patients demonstrated abnormalities of both cell lines. Of these initial 161
abnormal results, 119 (73.9%) were repeated but 42 (26.1%) were not. JAK II
testing was deemed warranted in 17 (2.8%): a persistently raised or progres-
sively raised haematocrit or platelet count respectively, with normal liver and
renal function and no other explicable cause. JAK II mutational analysis was
performed in 3 patients (0.5%). One was proven positive for the V617 F muta-
tion, hence diagnosed with polycythaemia vera. Of the 2 negative JAK II results,
one patient was subsequently diagnosed with chronic myeloid leukaemia. Four-
teen patients had no further testing or monitoring. 26/610 (4.3%) patients had
thrombocytopenia. ADAMTS13 testing was not warranted in 17 of these (sub-
sequent resolution of platelet count n=7, HIV n=2, liver derangement n=7,
known ITP with no MAHA n=1). ADAMTS13 testing was indicated in 9 of these
patients (34.6% of thrombocytopenic patients), defined as a persistent throm-
bocytopenia with no clear cause, normal liver and renal function and negative
HIV status. Seven of these patients did not have ADAMTS13 considered,
according to the clinical documentation, nor sent. Of the 2 tested for
ADAMTS13, one result was normal, helping to resolve the clinical diagnosis of
ITP. In the other patient, ADAMTS13 was <5%, confirming TTP and facilitating
life-saving plasma exchange to take place.
Summary/Conclusions: In stroke patients <60 years, one quarter had abnor-
malities in haematocrit or platelets. Myeloproliferative disease or TTP was pres-
ent in 3 patients of 5 specifically investigated in the cohort. From a haemato-
logical perspective, at least 21 further patients merited further investigation.
However, this number may be higher since a quarter of those patients with
initial discrepancies of haematocrit and/ or platelet count did not have repeated
testing. Although primary haematological disorders are rare as a cause of
stroke, a basic full blood count result should not be ignored in considering the
aetiology of arterial thrombosis in a younger cohort.
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PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) RELATED
THROMBOSIS IN 230 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES.
A 6 YEARS SINGLE EXPERIENCE CENTER
M. Baile1, Á. Veiga1, M. López-Parra1, M. Sánchez-Barba2, N. Arratibel1,
B. Rodríguez1, M. Sastre1, Ó. Del Rey1, A.Á. Martín1, M. Cabrero1,
J.R. González-Porras1, J.M. Bastida1,*
1Hematology, Hospital Universitario de Salamanca, 2Statiscal, University of
Salamanca, Salamanca, Spain
Background: The use of peripherally inserted central catheters (PICCs) is
widely extended in patients with hematological malignancies, not only to be
treated with chemotherapy, blood cell transfusions, but also parenteral nutrition
support or frequent analytical extractions. However, catheter-related thrombosis
is one of its main complications. There are a few studies that evaluate this
complication. We reported the experience of the PICC-related thrombosis
(PRT) in our center. 
Aims: To analyze the incidence of PRT, describe the clinical characteristics
and management of these patients and identify the risk factors of PRT.
Methods: We performed a retrospective chart review of 230 adult patients
diagnosed with hematological malignancies, in whom, experimented nurses
tunneled PICCs with different technique: blinding Seldinger from 2010 to 2014
and guided by ultrasonography (US) from 2015 to 2016. PRT diagnose was
confirmed by Doppler US. Statistical analysis was performed using the SPSS
program (v.20). 
Results: The median age was 58 years (14-86) and 55.7% of the patients
enrolled in the study were male. The most frequent hematological malignancies
were: Non-Hodgkin’s lymphoma (NHL=105; 45,7%) myeloid malignancies
(acute myeloid leukemia and myelodysplastic syndromes (AML/MDS=60;
26,1%), acute lymphoblastic leukemia (ALL=22; 9,6%), multiple myeloma
(MM=19; 8,3%) and Hodgkin lymphoma (HL=17; 7,4%). In 188 patients (82%),
PICC was tunneled when the active disease was presented. Only 51 patients
(22%) received thromboprophylaxis based on low molecular weight heparin
(LMWH=27), aspirin (ASA=21) or vitamin K antagonist (VKA=3). PICCs were
tunneled guided by US in 127 patients (55,2%), and the main location of tip
catheter was in cava-right atrium region (66%). The overall incidence of PRT
was 7% (n=16). The main diagnoses related to PTR were ALL (6), NHL (5),
and HL (3). All except one had active disease when PICC was tunneled
(15/16=94%). Fourteen patients (88%) were treated by chemotherapy based
in L-asparaginase (L-ASA), immunomodulatory drugs or other treatment com-
bined with corticosteroids. The median onset of PRT was 26 days, (range: 0-
230) and 8 of them (50%) in the first 30 days after insertion. In 11 cases (69%)
D-Dimer was elevated. All PICC were removed within 72 hours of PRT and
treated with LMWH to a median of 4 months (range: 1-11). During follow-up,
no patient had progression of thrombosis, or pulmonary thromboembolism.
Finally, in the univariate analysis ALL, HL and L-ASA had significant impact on
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PRT (LLA:OR 15,75; CI 2,91-85,12; p= 0,001; HL:OR 9; CI 1,38-58,78;
p=0,022; L-ASA:OR 7,82; CI 2,45-24,95; p=0,001). However, in the multivariate
analysis, HL was the only risk factor of PRT (OR 8,38; CI 1,05-66,5; p=0,044). 
Summary/Conclusions: Patients with HL may be predisposed to developing
PRT compared with those with other types of hematological malignancies. Iden-
tifying the mechanism underlying this relationship will require further study. 
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A STUDY OF VENOUS THROMBOEMBOLISM SUSCEPTIBILITY LOCI FACTOR
XI, ABO AND FIBRINOGEN IN A PORTUGUESE POPULATION SAMPLE
L. Manco1,*, C. Silva2, P. Martinho3, T. Fidalgo3, A.B. Sarmento2,3, M.L. Ribeiro1,3
1Research Center for Anthropology and Health (CIAS), 2Faculty of Medicine,
University of Coimbra, 3Serviço Hematologia Clinica, Centro Hospitalar Uni-
versitário de Coimbra, Coimbra, Portugal
Background: Venous thromboembolism (VTE) is a multifactorial disease
caused by environmental/acquired risk factors and complex gene-gene and
gene-environment interactions. VTE results from the development of a throm-
bus, usually in the deep veins of the leg (deep vein thrombosis, DVT) that can
subsequently embolise to the lung (pulmonary embolism, PE). Classical inher-
ited risk factors for VTE in European-ancestry populations include protein C
and S deficiencies, factor V Leiden and prothrombin gene mutation (FII
G20210A). Several other common and low-frequency susceptibility variants,
mainly single nucleotide polymorphisms (SNPs) in loci ABO,FXI, FII, FV, FGG,
GP6, KNG1, PROCR, SLC44A2, STXBP5,TSPAN15 and VWF, have been also
found robustly associated with VTE. However, in the Portuguese population,
the genetic background for VTE for most of these genetic susceptibility variants
remains to be evaluated.
Aims: To investigate the association of five SNPs in the loci ABO (rs2519093
and rs8176719), FXI (rs2036914 and rs2289252) and FGG (rs2066865) with
VTE in a sample of Portuguese patients.
Methods: A retrospective (2012-2015) case-control study with 119 cases of
unprovoked VTE and 148 healthy controls of Portuguese origin was conducted,
to evaluate allele frequencies of the five VTE risk alleles in the Portuguese
population and to assess the association between these alleles and the risk for
VTE. FXI (rs2036914 and rs2289252) and FGG (rs2066865) SNPs were geno-
typed by real-time PCR with TaqMan probes. ABO rs2519093 and rs8176719
SNPs were genotyped by restriction fragment length polymorphism (RFLP).
PLINK software was used to determine the allelic frequencies, concordance
with Hardy Weinberg equilibrium and association between risk alleles and VTE
through logistic regression, in the additive model, estimating OR with 95% con-
fidence intervals (95% CI) and p-values. The association between the cumula-
tive number of risk alleles and the risk of VTE was assess through Pearson χ2
using the Simple Interactive Statistical Analysis software (SISA).
Results: The estimated risk allele frequencies in the overall study population
sample were: 0.212 for FGG rs2066865 (T), 0.62 and 0.50 for FXI rs2036914
(C) and rs2289252 (T), respectively, and 0.295 and 0.417 for ABO rs2519093
(T) and rs8176719 (C), respectively. The genotype distributions were in agree-
ment with the Hardy-Weinberg equilibrium (P>0.05) for all SNPs. The logistic
regression under an additive model showed that FGG rs2066865 was associ-
ated with VTE (nominal p=0.029; OR=1.57, CI 95% 1.05-2.37) as well as ABO
rs8176719 (nominal p=0.0064; OR=1.65, CI 95% 1.15-2.36). Both SNPs remain
significantly associated when adjusting for age and sex (P=0.019 and
P=0.0065, respectively). ABO rs2519093 did not reach significant association
with VTE in our population sample (P=0.184) as well as F11 rs2036914 and
rs2289252 SNPs (P=0.76 and P=0.16, respectively). In addition, there was an
increased risk of VTE associated with the increment in the total number of risk
alleles: 0 vs 1 risk allele: Χ2=5.8, p=0.015, OR=2.31; and 0 vs 2 or more risk
alleles: Χ2=12.2, p=0.00048, OR=3.36).
Summary/Conclusions: Our data suggest that the alleles FGG rs2066865 T
and ABO rs8176719 C may contribute to the VTE susceptibility in the Por-
tuguese population. The absence of significant associations for the remaining
loci could be the result of a limited statistical power, consequence of a modest
effect size of polymorphisms or lower sample sizes, or because of differences
in genetic backgrounds between populations.
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PEDIATRIC VENOUS THROMBOEMBOLISM: INCIDENCE, RISK FACTORS
AND MANAGEMENT OF HOSPITALIZED PATIENTS IN A TERTIARY CARE
TEACHING HOSPITAL
P. Raheja1,*, P. Olivera1, V. Pons1, E. Johansson1, T. Canals1, F. Bosch1,
A. Santamaria1
1Hematology Department, Vall d’Hebron University Hospital, Barcelona, Spain
Background: Venous thromboembolism (VTE) is considered a rare event in
childhood. In spite of this, the incidence of VTE is on the rise in hospitalized
patients. Medical progress in the treatment of critically ill patients has increased
the use of central venous catheters (CVC) and interventional procedures, espe-
cially in children with cardiac defects and malignant disease. Therefore VTE is
increasingly recognized as a major secondary complication of advanced tertiary
care in infants and children.
Aims: To study the incidence, demographics, risk factors, diagnostic tests,
therapy, and complications of pediatric acute VTE in our tertiary care hospital.
Methods: A retrospective single-center study of patients<18 years of age who
were discharged from January 2014 to December 2016 by using diagnostic
codes for acute VTE from our hospital database. We studied demographic
characteristics, clinical presentation, diagnostic tests, risk factors, treatment
strategies and outcome.
Results: We report an incidence rate of 10.7 cases per 10,000 patient-years
(70 acute VTE events / 21,892 discharge cases over a 3-year period). Patients
were predominantly male (57%). Mean patient age was 3.3 years, with the
greatest proportion of cases, 54.3%, in the infant cohort (from 1-12 months),
while children above 1 year comprised 37% and neonates (<1 month) formed
8.6% of our sample. Patients were mostly born at full term (71.4%), although
45.7% of the neonatal and infant cases were premature. Catheter-related (CVC-
VTE) comprised 55.7% of VTE cases. On the other hand, non-catheter-related
(NCR) diagnoses were most frequently intracranial in 35.5% of cases, in inferior
extremity deep vein thrombosis (DVT) in 29% and intracardiac in 19.3%. Only
3 cases of NCR-pulmonary embolism (PE) and 2 cases of NCR-upper extremity
DVT were reported. Doppler ultrasound was the most common diagnostic test
used (75.7%), followed by MRI, CT and CT angiography in equal proportions.
Critically ill patients encompassed most of the cases (88%). Mean duration of
hospitalization was 89 days (range 2-156) and time from admittance to VTE
diagnosis was 25.6 days. A large proportion had congenital heart defects
(32.9%) requiring interventional procedures. Half of the patients (51.4%) had
surgery around the time of VTE diagnosis. Malignancy was identified in 5 cases
(2 of which were CVC-VTE). Transient triggers, such as infection (12 cases)
and use of asparaginase (2 cases) were also reported. Most patients were not
tested for thrombophilia (n=44, 62.9%) since they were classified as provoked
VTE and from those who were tested 10% were diagnosed with a thrombophilia.
All except for one patient initiated anticoagulant therapy: 78.6% (n=52) were
initially treated with low molecular weight heparin (LMWH) and while most con-
tinued treatment with LMWH, 8.6% (n=6) received vitamin K antagonists and
8.6% received direct oral anticoagulants. LMWH dosing was adjusted using
anti-Xa assays (AXA) in 85.7% of cases, documenting a median of 5 AXA per
patient, out of which 3 were within therapeutic range. Mean duration of treat-
ment was 5.8 months. Recurrence rate was 17%, half of which were in patients
with CVC-VTE. On the other hand, bleeding rate was 15.7% most of which
were mild (10%) or provoked bleeds (4.3%). Mortality was 10%, although cause
of death was not directly related to VTE in any of the cases. 
Summary/Conclusions: Pediatric VTE is a substantial complication arising
from tertiary care hospitalization where critically ill infants are at greater risk.
Potential risk factors of VTE include use of CVCs, patients with complex con-
genital heart defects, surgical procedures, infection and malignancy. Further
studies on VTE prophylaxis and identification of VTE predictors in a critical
care setting are required.
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CELL-BASED EVALUATION OF CHANGES IN COAGULATION ACTIVITY
INDUCED BY ANTINEOPLASTIC DRUGS FOR THE TREATMENT OF
ACUTE MYELOID LEUKEMIA
H. Shinki1,*, M. Tsunaka1, T. Koyama1
1Graduate School of Health Care Sciences, Tokyo Medical and Dental Univer-
sity, Tokyo, Japan
Background: Idarubicin (IDR), cytarabine (AraC), and tamibarotene (Am80)
are effective for treatment of acute myeloid leukemia (AML). In acute leukemia,
the incidence of venous thromboembolism or disseminated intravascular coag-
ulation is associated with induction chemotherapy.
Aims: How some drugs for the treatment of AML affect the procoagulant activity
is unclear. Thereby, in this study, we investigated the procoagulant effects of
IDR in comparison with AraC and Am80.
Methods: Procoagulant effects of IDR, AraC, and Am80 were investigated in
a vascular endothelial cell line EAhy926 and AML cell lines HL60 (AML M2),
NB4 (AML M3, APL), and U937 (AML M5), focusing on tissue factor (TF), phos-
phatidylserine (PS), and thrombomodulin (TM). Normal human plasma-based
recalcification time assay, flow ctytometric anayses, and RT-PCR are applied
for the evaluation.
Results: IDR induced procoagulant activity on the surface of vascular endothe-
lial and AML cell lines. Expression of TF antigen, TM antigen, and PS were
induced by IDR on the surface of each cell line, whereas expression of TF and
TM mRNAs were unchanged. Increased TF and PS expression may overcome
increased TM expression and the overall effect may be procoagulant. Converse-
ly, Am80 decreased TF exposure and procoagulant activity, and increased TM
exposure on NB4 cells. In NB4 cells, we observed downregulation of TF mRNA
and upregulation of TM mRNA by Am80. But Am80 did not sufficiently exhibit
anticoagulant activity on NB4 cells when applied simultaneously with IDR.
Summary/Conclusions: These data suggest IDR may induce procoagulant
activity in vessels by apoptosis through PS exposure and/or TF expression on
vascular endothelial and AML cell lines. Am80 may suppress blood coagulation
through downregulation of TF expression and induction of TM expression. Our
methods could be useful to investigate changes in procoagulant activity induced
by antineoplastic drugs.
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DESCRIPTION OF THROMBOTIC EVENTS AND/OR PREGNANCY LOSS-
ES IN A COHORT OF HOMOZYGOUS CARRIERS FOR THE C46T
POLYMORPHISM OF THE F12 GENE
S. Martín Herrero1,*, D. Velasco-Rodríguez1, R. Vidal1, C. Blas1, J.M. Alonso-
Domínguez1, A. García Raso2, P. Llamas1
1Hematology, 2Health Care Institute, Fundación Jiménez Díaz, Madrid, Spain
Background: The intrinsic pathway of coagulation is initiated by a serine pro-
tease named factor XII (FXII) in a reaction involving the contact system and
triggers fibrin formation through activation of factor XI. In vitro, FXII triggers
activation of the classic complement pathway and initiates the fibrinolytic sys-
tem via plasma kallikrein mediated urokinasa activation, whereas in vivo its
role remains uncertain. A C—>T polymorphism at nucleotide 46 in the 5’-
untranslated region of the F12 gene (F12 C46T) is associated with lower levels
of FXII. Its frequency varies widely across populations and ethnic groups, rang-
ing from 0.18 in the Spanish population to 0.67 among Japanese. Homozy-
gosity for the C46T polymorphism of the F12 gene has proved to be an inde-
pendent risk factor for thrombosis and unexplained recurrent spontaneous
abortion. However, the precise role of this polymorphism as a thrombotic risk
factor is controversial, and the evidence for an association between F12 C46T,
venous thromboembolism (VTE) and myocardial infarction is weak.
Aims: To describe the occurrence of thrombotic events and/or pregnancy loss-
es and the existence of other risk factors for thrombosis in a cohort of homozy-
gous individuals for F12 C46T.
Methods: We retrospectively analyzed all the homozygous F12 C46T cases
diagnosed in our laboratory from January 2015 to January 2017. Allelic dis-
crimination PCR with TaqManmgB probes was performed to detect homozy-
gous individuals for F12 C46T mutation. The following variables were collected:
age, gender, race, cardiovascular risk factors (CVRF) (hypertension, diabetes
mellitus, dyslipidemia, smoking and overweight), history of cancer, VTE (type,
recurrence), arterial thrombosis, familiar history of thrombosis, number of preg-
nancy losses and other inherited/acquired thrombophilia.
Results: 122 cases were evaluated: 45 (36.88%) male and 77 (63.12%)
female. Mean age: 46.2 years (1-86). Race: 65.57% caucasian, 13.1% amer-
ican, 2.4% black, 1.6% asiatic, 4.1% other. Decreased factor XII plasma levels
were found in 81.42% of them, with mean factor XII levels 53.73% (27.5-107.5).
Overall, 34.48% of the subjects had at least one thrombotic event. Type of
thrombosis: 64.4% VTE and 35.6% arterial thrombosis. One (26.7%) or more
than one (46.7%) additional thrombotic risk factors were found in patients with
any thrombotic event. Presence of one or more CVRF was found in 66.7%.
Familiar history of thrombosis was found in 16%, whereas 13% had a recent
or active malignant neoplasm. Among women, 28.57% and 12.98% had one
and more than one pregnancy loss respectively. Additional thrombotic risk fac-
tors were found in 60% of women with recurrent losses. One (43%) or more
than one (13%) additional thrombotic risk factors were found in women with
any pregnancy loss. Presence of one or more CVRF were found in 30% of
them. Familiar history of thrombosis was found in 34.7%, whereas none of
them had a recent or active malignant neoplasm.
Summary/Conclusions: �Most patients with a thrombotic episode had one
or more additional risk factors. Nevertheless, up to 26.7% presented no other
risk factor than homozygous F12 C46T, suggesting a relevant role in the patho-
genesis of thrombosis. According to our results, the risk of abortion could be
increased by the presence of homozygosity for F12 C46T, since it was the only
thrombotic risk factor in 40% of women with recurrent pregnancy losses. Further
studies are needed to clarify the real contribution of F12 C46T to thrombosis
and pregnancy losses on prospectively selected patients.
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ANALYSIS OF CHARECTERSISTICS OF HOSPITAL ASSOCIATED
THROMBOSES
Neil Smith*,1, Charelampos Kartsios1
1Haematology, Heart of England NHS Foundation Trust, Birmingham, United
Kingdom
Background: Hospital associated thrombosis (HAT) is now commonly moni-
tored but expected targets of HATs remains poorly reported.
Aims: We analysed HATs in our hospital group over a 40 month period to
assess any trends or paterns of HAT incedence and charecteristics over time.
Methods: We reviewed all VTE episodes in 2013-2017 across our hospital group,
identifying those patients with hospital-associated thrombosis (HAT), defined as
patients having had a hospital inpatient episode, including day case surgery and
admissions of 4-24 hours, in the 90 days prior to their VTE episodeRoot cause
analysis was undertaken on these cases, recording information of the index
episode including risk assessments performed and the corresponding prescribing
and administration of thromboprophylaxis (TP) consisting of LMWH or GCS.
Results: Results: a total of 2222 VTEs were identified (1051 PE’s and 1178
DVTs) of which 581 (26%) HATs were identified (312 PE’s, 269 DVT’s). This
represents an excess of PEs over the expected rate based on total VTE distri-
bution between PE and DVT (p=0.0002 Fishers exact test). The majority of
patients had a medical (non-surgical) index admission with 58.5% admitted as
acute medical admissions and 41.5% surgical admission (trauma and
orthopaedics 18.4%, general, vascular and GI surgery 12.2%, urology 4% and
Obstetrics and gynaecology 4%). Not all surgical patients underwent opera-
tions.  In 526 HAT cases, root cause analysis (RCA) revealed that 101 (19.2%)
were deemed preventable and 367 (69.8%) were not thought to be preventable.
The remaining 57 cases had the index admission outside of our trusts, largely
having orthopaedic procedures which were not included in further analysis.
Of 394 HAT cases with sufficient data, 80 (20.3%) had a preventable cause,
27 receiving insufficient TP, 9 receiving delayed TP, 26 having no TP given
though indicated and 18 not having a VTE risk assessment. Some cases of
insufficient TP were deemed due to underdosing standard patient >90kg. Off
those HAT cases deemed unpreventable, 37 patients had contraindications to
TP, 166 had TP failure i.e. full TP given and in 102 TP was not indicated. 9
patients were on full anticoagulations at time of index admission.
Summary/Conclusion: HAT rates remain stable and the majority are though
unavoidable by cureent techniques. Key errors in avoidable cases are failure
to perform a timely VTE risk assessment and action with appropriate thrombo-
prophylaxis. Full integration of electronic patient records with electronic pre-
scribing modules may reduce further these errors.
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THROMBOSIS DURING INFANCY AND NEWBORN PERIOD: AN
UNRESOLVED ISSUE
F. Gumruk1,*, S. Aytac1, I. yaman bajin1, B. Kuskonmaz1, S. unal1, S. yigit2,
M. yurakok2, M. cetin1
1Pediatric Hematology, 2neonatology department, Hacettepe University,
Ankara, Turkey
Background: Reported incidence of thrombosis is higher among newborn
infants that can be explained by age related deficiency of anticoagulants, over-
production of procoagulants and deficiency/ dysfunction of fibrinolysis in addi-
tion to exposure to multiple risk factors and wide use of catheters which may
eventually lead to the transient prothrombotic phenotype in this age group. 
Aims: Our aim is to evaluate clinical and laboratory data, risk factors, outcomes
of infants (>1-≤12months) and newborns(≤1month) with thrombosis in our center.
Methods: Our database revealed 752 children having various types of throm-
bosis between January 2003 to December 2015 and 77 out of 752 were diag-
nosed as thrombosis under one year of age. We retrospectively evaluate their
clinical and laboratory results by searching their paper based & electronic files.
Thrombotic risk factors included inherited and acquired hypercoagulable states,
catheter, infection, trauma, surgical operations were also recorded. 
Results: There were 51 male and 26 female with a median age of 4 months (0-
12 months) in this group. Among 77 thrombotic events 22 (28%) were observed
during neonatal period (≤1month) with a male predominancy (n=15, 68%) and
from those 22 events 2 were arterial thrombosis (purpura fulminans(1), cere-
bral(1)) whereas 4 intracardiac, 5 sinovenous and 11 venous thrombosis (deep
veins(4), renal veins(3), portal veins(3) cerebral vein(1)) were noted. In 2(9%)
thrombosis was diagnosed on the first day of life and 11 out of 22 patient had
underlying risk conditions such as prematurity(3), perinatal hypoxia(2), necro-
tizing enterocolitis(1), congenital cardiac disorders(3),congenital nephrotic syn-
drome(1) and adrenal insufficiency(1).Moreover 6 out of these 22 thrombotic
event catheter insertion was the associated risk factor and 4/22 had infection.
Factor V Leiden mutation was found to be homozygous in 1/18 and normal in
17/18. Heterozygous prothrombin 20210A mutation were detected in 1 out of
18 and homozygous MTHFR C677T mutation was found in 3/13 patient. Half of
them 12(%54) were initially treated with LMWH and TPA were used as a throm-
bolytic agent in 5 case without any complication. During the follow up period
1patient had an amputation, 5 patient decased; one because of sepsis and the
rest 4 had primary disesase and thrombosis .The site of location in 55 thrombotic
events during the infancy period involved deep venous thrombosis (22), cerebral
sinovenous thrombosis (10),cardiac(8), portal(3), renal(1) veins and cerebral
arterial (7),femoral arterial(3),abdominal aortic thrombosis(1).In this group
42(76%) out of 55 had an underlying disorder and most common associated
risk factor for this age group was inserted catheter related thrombosis, infection
and surgical operations.Initial treatment choice was LMWH in 25(45%) and dur-
ing the median follow up time of 2 years 10 had chronic thrombosis, 21 resolved,
10 had parsiel thrombosis, 4 deceased and 10 loss to follow up.
Summary/Conclusions: During the first month of life thrombotic complications
is 40 times higher than at any other pediatric age. As previously reported
venous thrombosis which mainly affect the limbs, the right atrium and renal
veins are more frequently seen than arterial thrombosis in newborn infants
with a male predominancy is compatible with our findings. In the absense of
randomized clinical trials the choice of anticoagulation and the duration of treat-
ment for this age group is still controversy beside the complex mechanism and
a high mortality&morbidity rate. Although clinical and laboratory data of
neonates were compatible with infants, treatment choices differ between these
two groups and it sems that thrombolytic treatment was tend to be used more
commonly in the neonates without any complication.
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THE QUALITY COMPOSITION OF SOLUBLE FIBRIN MONOMER COMPLEX
FRACTION FOR ACUTE AND POST ACUTE ISCHEMIC STROKE PATIENTS
T. Katrii1,*, T. Vovk1, O. Savchuk1
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Background: Soluble fibrin monomer complexes (SFMC) are the early marker
of thrombophilia that represent the complexes of monomeric fibrin with fibrino-
gen or their products of degradation (FDP). SFMC levels are not directly affect-
ed by therapy with thrombolytic agents. Detection of SFMC formed due to the
activation of blood clotting by thrombin reveals a pathological process in the
early, preclinical stages.
Aims: We explored the quality difference between the SFMC fraction obtained
from acute ischemic stroke patients and one year post acute phase of stroke
in the absolutely the same patients. 
Methods: SFMC fraction was obtained from each tested groups: 35 healthy
donors as well as 66 patients with atherothrombotic ischemic stroke (AIS) and
56 patients with cardioembolic ischemic stroke (CIS) during the acute phase of
disease; 56 patients with AIS and 56 patients with CIS one year past acute
phase. SFMC were collected from blood plasma of each tested subtypes of
ischemic stroke by incubation with 0,78% o-phenanthroline per 5 min. For Size-
exclusion chromatography SFMC in volume 1 ml was applied on Healthcare
Life Sciences “HiLoad 16/60 Superdex 200 pg” column.
Results: Results suggest presence of proteins with Mr from 45 up to 330 kDa
in SFMC fraction. The content of SFMC was similar for all stroke fractions with
some exception. The difference between results of separation of stroke factions
and fractions obtained from healthy donors was obvious. Mostly the proteins
content of the SFMC fraction is similar for stroke and healthy fractions. But
amount of the proteins as mean peaks high is different (Figure 1). In fact, the
first three peaks whitch correspond to the 330, 280 and 250 kDa of chro-
matogram of SFMC are common for all tested fractions and were verified only
in their height. Accordingly, the most widely represented variations peaks for
AIS, even a year after stroke soluble fibrin monomer complex content was high-
er comparing to the healthy donors index. Healthy donors also had some of
these complexes, but in trace amounts. For acute CIS situation was similar as
for AIS, but past one year it got closer to healthy donors.
Figure 1.
Summary/Conclusions: It was shown that development of ischemic stroke
accompanied by the formation of SFMC in the bloodstream that could take part
in disease complication.
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EVALUATION OF A RAPID NANOPARTICLE-BASED LATERAL FLOW
IMMUNOASSAY (STIC EXPERT HIT) FOR THE DIAGNOSIS OF HEPARIN-
INDUCED THROMBOCYTOPENIA IN A CARDIOTHORACIC HOSPITAL
G. Soufla1,*, M. Katafygioti1, S. Georgantis1, T. Kanellopoulou1, T. Kostelidou1
1Department of Haematology, Blood Transfusion Unit and Coagulation and
Haemostasis, Onassis Cardiac Surgery Center, Athens, Greece
Background: Heparin Induced Thrombocytopenia (HIT) is a severe complica-
tion of heparin anticoagulation treatment that could be life threatening. HIT
diagnosis is therefore of crucial importance in clinical practice especially for
the cardiothoracic patients that are often exposed to heparin before surgery
(e.g. during a PTCI). Laboratory testing for the presence of IgA, IgM and IgG
or IgG only antibodies against PF4/Heparin (namely HIT antibodies) along with
the 4Ts scoring system (Thrombocytopenia, Time of platelet count fall, Throm-
bosis, Other cause of thrombocytopenia) is used to evaluate the probability of
HIT syndrome. At the Onassis Cardiac Surgery Center the methods for routine
laboratory testing for HIT comprise Enzyme-linked Immunoassay testing for
IgG, IgA, IgM HIT antibodies and Heparin-Induced Platelet Aggregation assay
for the presence of platelet activating antibodies. 
Aims: We evaluated a rapid nanoparticle-based lateral flow immunoassay (Stic
Expert HIT) for assessing the presence of IgG antibodies to PF4/Heparin in
patients plasma or serum in cases of emergency diagnosis of HIT needed for
patients requiring urgent cardiothoracic surgery over a six-month period. 
Methods: Stic Expert HIT, a rapid-nanoparticle based lateral flow immunoassay
was performed on plasma from 35 patients from July 2016until January 2017
and the reading was done independently by two different technicians or biolo-
gists. The diagnosis of HIT was confirmed when both H/PF4 ELISA and the
4Ts score were positive. 
Results: In 22 cases the Stic Expert was negative for the presence of IgG
H/PF4 antibodies in the patients’ plasma and HIT syndrome was easily excluded
in combination with the “4Ts”. In the rest 13 cases the rapid test provided doubt-
ful results that were considered as positive and then H/PF4 ELISA was per-
formed. Following the ELISA test, 10 out of the remaining 13 patients were
found negative for the presence of IgG H/PF4 antibodies, whereas 3 patients
were found positive with a relative low O.D. value (0.400). The last 3 patients
that were positive for the presence of IgG H/PF4 antibodies by ELISA were
found not to have HIT syndrome in combination with the ‘4Ts” scoring system. 
Summary/Conclusions: In conclusion the Stic Expert HIT was useful for the
quick exclusion of HIT (along with the 4Ts scoring system) when emergency
HIT diagnosis is needed in 34% of the cases (12/35) in our Hospital. However
in the rest 13/25 (66%) of the cases, laboratory testing for HIT was much more
complicated and time consuming since ELISA or other assays (i.e.HIPA test)
had to be performed. Nevertheless all 13 patients were found not to suffer from
the HIT syndrome with the “4Ts’ scoring system.
E1601
AUDIT OF ‘DOOR TO NEEDLE’ TIME IN ADMINISTRATION OF PROTHROMBIN
COMPLEX CONCENTRATE TO PATIENTS REQUIRING URGENT REVERSAL
OF ANTICOAGULATION
S. Elshafie1,*, N. Smith1
1Haematology, Heart Of England Nhs Foundation Trust, Birmingham, United
Kingdom
Background: Anticoagulants are used to treat or prevent thrombotic events
but their most worrying side effect is major haemorrhage. The British Committee
for Standards in Haematology (BCSH) recommend reversal of major/life threat-
ening bleeding in both VKAs and DOACs with Prothrombin Complex Concen-
trate (PCC).
Aims: We aim to reduce delays in the administration of PCC in our trust and intro-
duce the term ‘Door To Needle’ time (DTN) in the context of anticoagulant reversal.
Methods: We analysed the DTN in bleeding anticoagulated patients defined
as time of recognition of haemorrhage to PCC administration. In Heart of Eng-
land NHS Foundation Trust between May and July 2016, 29 patients were
included; 19 patients were taking Warfarin and 10 taking DOACs. All patients
received PCC (Beriplex®).
Results: Sixty-nine percent of patients were male and 31% female. The major-
ity (69%) of patients were treated for stroke prevention in AF and 24% had a
history of VTE. The two commonest major haemorrhage types were cere-
brovascular (including intracranial and subdural haemorrhage) in 36% and gas-
trointestinal bleeding in 39%. The remaining indications (25%) were pre-urgent
procedure/surgery, and soft tissue haematoma. The average time for recogni-
tion of haemorrhage was 3 hours 20 minutes (range 4 minutes to 21 hours 27
minutes), and the DTN was 4 hours 50 minutes (range 33 minutes to 13 hours
24 minutes), which means an estimated average of 6 hours 27 minutes (range
2 hours 49 minutes to 13 hours 59 minutes) between hospital admission and
receiving PCC. Six of the total number of patients died within 30 days of hospital
admission, 4 taking on Warfarin and 2 taking on DOACs. 
Summary/Conclusions: This audit demonstrates the continuing delays
between recognition of major/life-threatening bleeding events and receiving
PCC since previous audits despite raising staff awareness. We pIan to introduce
the term ‘DTN’ in the context of anticoagulant reversal, store PCC in the emer-
gency department pharmacy cupboards (as a PoM) as opposed to blood bank,
and introduce a reporting system ‘Serious Hazards of Warfarin (SHOW)’ which
may further reduce delays, morbidity and mortality.
E1602
THE IMPORTANCE OF PLATELET MEMBRANE FLUIDITY AND OXIDATIVE
STRESS IN THROMBOTIC COMPLICATIONS ACQUIRED BY CHRONIC
MYELOPROLIFERATIVE NEOPLASMS PATIENTS
V.M. Popov1,*, M. Andreescu1, M. Omer1, A. Trifa1, F. Mihai1, C. Dragan1,
O. Patrinoiu1, M.G. Moisescu2, T. Savopol2, E. Kovacs2, H. Bumbea3,
A.M. Vladareanu3
1Hematology, Colentina Clinical Hospital, 2Biophysics and Biotechnology
Department, 3Hematology, UMF Carol Davil, Bucharest, Romania
Background: Patients with chronic myeloproliferative neoplasms (MPNs) and
chronic myeloid leukemia (CML) have a variety of structural and functional
abnormalities of platelets. Many of them have thrombotic or hemorrhage com-
plications. Platelet function is influenced by changes in membrane fluidity (MF)
which has an important role in the expression of platelet receptors, modulating
the activity of protein membrane.
Aims: The importance of reactive oxidative species (ROS) in alteration function
of platelet membrane and expression of platelet receptors in patients with MPNs
and CML.
Methods: We present a retrospective study on 36 cases MPN (20 JAK2-pos-
itive MPN) and 24 CML admitted in Colentina Clinical Hospital Bucharest. The
determination of platelet membrane fluidity was performed by fluorescence
anisotropy measurements using as marker 1-(4-trimethylammoniumphenyl)-6-
phenyl-1,3,5-hexatriene p-toluenesulfonate (TMA-DPH). We analyzed the flu-
orescence anisotropy of platelet membrane and correlate the result of with a
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different kind of treatment. Production of ROS was examined using fluores-
cence method with DCFDA and Fluorolog spectrophotometer Platelet receptor
expression was analyzed by flowcytometric method studying adhesion marker
(CD 42 and CD 42b) and aggregation marker (CD61, CD41).
Results: Patients with MPN and JAK2 mutation present have a high level of flu-
orescence anisotropy than the JAK-negative group. Median value for JAK2 pos-
itive MPN group 147.2 95% CI for median value (138.7-150.6)) vs JAK2 negative
MPN group 130.8 (124.6-138.3) p=0.001. There are no differences between CML
and MPN group. Our results confirm that fluorescence anisotropy is influenced
by medication taken. MPN patients who have taken Hydroxyurea alone had a
high-level fluorescence anisotropy than the patient who have taken association
Hydroxyurea and Anagrelide; median value and 95% CI for median value 151
(137.1-158.6) vs 136 (126-137.5) p=0.03. A patient who have treatment with
tyrosin kinase inhibitor (TKI) - Sprycel or Glivec, had a low level of fluorescence
anisotropy, median value and 95% CI for Hydroxyurea group 151 (137.1-158.6)
vs TKI group value 138 (124.4-147.8) p=0.04. No differences of fluorescence
anisotropy was observed between the group of MPN patients who received JAK
inhibitor (Jakavi) or Hydroxyurea The CD42b expression is low in patients versus
controls (median: 17.87% vs 94.16%, P<0.01), there is no difference in the
CD42a value range (P=0.51). The CD61/CD41 expression (GP IIb-IIIa) presents
also lower values in patients (median: CD 61= 84.13%; CD 41=71.13%) versus
controls (median: CD 61= 98%; CD 41=93,17%), statistical significance obtained
only for CD61 expression.Production of ROS is higher for patients with MPNs
and CML patients compared with healthy controls. CML patients in accelerate or
blastic phase have higher level of ROS production compared with patients in
chronic phase (1.23 vs 1.09, p=0.03). Our results of anisotropy measurements
did not reveal any influence of ROS in MF modifications (0.15 vs 0.13, without
statistical significance) or with platelet receptor expression.
Summary/Conclusions: The presence of JAK 2 mutation in MPN patient is
associated with a low fluidity of platelet membrane. Association of Anagrelide
or TKI inhibitor is associated with lower level of fluorescence anisotropy. The
fluidity of platelet membrane could be an important parameter which influenced
the expression of platelet receptor. We have to observe in the future if this
group with high level of fluorescence anisotropy had a high risk of thrombosis.
All these results will be verified in a higher patients lot and need to be checked
any correlation between modification of fluidity membrane production ROS and
expression of microparticles platelet derivated.
E1603
USE OF ROTATIONAL THROMBOELASTOGRAPHY TO PREDICT CENTRAL
VENOUS CATHETER RELATED VENOUS THROMBOSIS IN CHILDREN:
PRELIMINARY RESULTS
T. Bayhan1,*, B. Oguz2, F. Gumruk1, M. Cetin1, A. Gunes2, I.Y. Bajin1, F.N. Kalkan1,
S. Unal1
1Division of Pediatric Hematology, 2Department of Radiology, Hacettepe Uni-
versity, Ankara, Turkey
Background: Central venous catheters (CVCs) have been widely used in hos-
pitalized pediatric patients, however, CVCs increase venous thrombosis fre-
quency. In pediatric age group exact risk factors for CVC related venous throm-
bosis haven’t been shown yet. Rotational thromboelastography (ROTEM®)
measures clot formation and stability and evaluate cogulopathy.
Aims: We aimed to predict CVC related venous thrombosis via ROTEM
prospectively in pediatric age group patients.
Methods: Study included patients who required CVC insertion due to any rea-
son and who were not on any anticoagulation treatment during the week before
the CVC insertion. On the day of CVC insertion clotting time (CT), clot formation
time (CFT), maximum clot firmness (MCF), and alpha angle (AA) were meas-
ured for intrinsic (INTEM), extrinsic (EXTEM), and fibrinogen (FIBTEM) path-
ways via ROTEM. At one week of insertion and at removal of CVC, Doppler
ultrasound imaging was performed to the vein that catheter was removed. 
Results: A total 14 patients were included in the study. Median age was 3.9
years (0.3-17.8 years). Ten (71%) of the patients had juguler, four (29%)
patients had femoral CVC. Median duration until removal of CVC was 15.5
days (7-56). Thrombosis was detected in one patient (7%) at first week of CVC
insertion (Patient 10). When the the ROTEM parameters were examined, this
patient had lowest CT and highest AA in EXTEM, and the highest AA in INTEM,
indicating more pro-coagulant status (Table 1). Also patient 14 had similar AA
as patient 10 in EXTEM and INTEM but was not found to develop thrombosis
by the 18th day of insertion. However, CVC of that patient wasn’t removed yet
Table 1.
CT; clotting time, CFT; clot formation time, MCF; maximum clot firmness, AA; alpha
angle, * Normal range, & INTEM couldn’t be measured for patient 1 due to technical
reasons, β In some patients CFT and/or AA weren’t in measurable level
Summary/Conclusions: In this study we reported our preliminary results. We
detected thrombosis only in one patient and according to this limited samples
size, we may suggest that CT and AA in EXTEM, and AA in INTEM prior to
insertion of CVC may be predictive for catheter related thrombosis develop-
ment. Such patients with pro-coagulant findings at ROTEM prior to CVC inser-
tion may need prophylactic anti-coagulation. The results in a larger sample
size will be more definitive to make a conclusion.
E1604
THE POTENCIAL ROLE OF ANTINEOPLASTIC DRUGS IN THE PREDICTION
OF THROMBOTIC RISK IN ONCOLOGIC PATIENTS IN ADDITION TO THE
KHORANA SCORE
E. Gómez1,*, P. García-Ramírez1, A. Zabalza1, M. Montoya1, M. Alvarellos1,
D.P. Millacoy1, B. Signes1, T. Galicia1, M.V. Aznar1, A.M. Redondo1, M.J. Paloma1,
M.L. Antelo1
1Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain
Background: Venous thromboembolism (VTE) is common in patients with
cancer. Several risk factors (related with patient, tumour and treatment) have
been already identified. Thromboprophylaxis (TP) with low molecular weight
heparin (LMWH) is associated with a reduction of symptomatic VTE but without
clear benefit in survival as the number of major bleedings is increased. To
guide primary TP in newly diagnosed cancer outpatients starting chemotherapy
(QT), a risk assessment model (based in baseline clinical and laboratory vari-
ables) was developed (the Khorana score). Many patients with intermediate
risk (without tromboprophylaxis indication according to Khorana-based clinical
guidelines) develop VTE episodes. Factors as tissue factor-bearing micro par-
ticles and D-Dimmer levels in addition to lenalidomide, platin and gencitabine-
based therapies are associated with VTE high risk. Its efficacy as a predictive
tool is a matter of debate.
Aims: This retrospective, observational study is aimed to assess the Khorana
score efficacy in predicting the VTE risk and analyze some treatment related
factors as predictive complementary tools.
Methods: We analyzed the demographic characteristic, the Khorana score and
the antineoplastic treatment of oncologic patients diagnosed of pulmonary
embolism (PE) from December 2010 until December 2016 at the Complejo Hos-
pitalario de Navarra. At baseline, the Khorana score classified patients as ‘low
risk’ (0 points) intermediate risk’ (1-2 points) or ‘high risk’ (≥3 points) for VTE.
Results: 102 oncologic patients were diagnosed of PE. Patient baseline char-
acteristics are showed in table 1. In 27.5% (n=28) PE diagnosis preceded to
cancer diagnosis, in 26.5% (n=27) PE occurred at least 1 month beyond the
end of antineoplastic treatment and in 46.1% (n=47) PE was diagnosed during
the treatment (chemotherapy +/- radiotherapy). In this last group the median
time from the treatment beginning and EP diagnosis was 3 months (0-46). The
stratification according to the Khorana score (at baseline) was: ‘low risk’ 21.3%,
intermediate risk 61.7%, and high risk 17%. In the intermediate risk group
(n=29) the drug-based therapy was: 44.8% platin (n=13), 6.9% gemcitabine
(n=2), 2.5% lenalidomide (n=1) and 48.3% non-related-thromboembolic treat-
ment (n=14). Most of cases (97.1%) were managed with LMWH (enoxaparin
1mg/kg/twice a day). Only 2 patients were treated with non-fractionated heparin
and 1, enrolled in a clinical trial, was treated with direct oral anticoagulants.
Table 1.
Summary/Conclusions: Nearly 2/3 of Khorana intermediate risk patients
developed a PE while on antineoplastic treatment and inside this group over
50% were treated with well-recognized high thrombotic-risk drugs. The inclusion
of antineoplastic drugs in a predictive thromboembolic model in oncologic
patients could improve the benefit-risk of the use of LMWH prophylaxis in some
patients without a high risk Khorana score but however at high risk of thrombosis.
More prospective studies are needed to analyse the benefit of antithrombotic
prophylaxis in oncologic patients receiving outpatient chemotherapy treatment.
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CLINICAL OUTCOMES AND UTILIZATION OF BLOOD BANK RESOURCES
OF PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA
(TTP), HEMOLYTIC UREMIC SYNDROME (HUS), AND OTHER MICROAN-
GIOPATHY- A 14 YEARS’ EXPERIENCE
C.-T. Lee1,2,*, C. Thow3, K.P. Lim3, S.T. Lim3, J. Mah3, N.N. Zhang3, M.L. Tung1,
L.K. Tan1,3, S.Y. Lee1,2,3
1Department of Haematology-Oncology, National University Cancer Institute
Singapore, 2Yong Loo Lin School of Medicine, National University Singapore,
3Blood Transfusion Service and Blood Donation Centre, Department of Labo-
ratory Medicine, National University Hospital, Singapore, Singapore
Background: TTP, HUS and other thrombotic microangiopathy are rare, com-
plex clinical syndromes which are characterized by thrombocytopenia, microan-
giopathic haemolytic anemia, (MAHA) and systemic thrombosis. The introduc-
tion of plasma exchange (PEX) had dramatically reduced the mortality of these
patients, and has become standard of treatment. Although the clinical outcome
of these conditions is heterogenous, with multiple clinical complications and
prolonged hospital stay, there is no previously published data to provide meas-
urement of blood bank and hospital resource utilization associated with its clin-
ical management. 
Aims: We performed a retrospective cohort study of 42 consecutively treated
patients with MAHA and analyzed their clinical and laboratory characteristics,
treatment outcomes and plasma product utilization. 
Methods: Medical records of these patients treated from 2002-2017 were
reviewed. We used the standardized criteria based on the consensus on stan-
dardization of terminology in TTP to define clinical response. (Scully et al J
Thromb Haemost 2017). 
Results: Results: In our series, the causes and number (%) of MAHA were
TTP-HUS (18, 42.9%), autoimmune disorder-associated MAHA (13, 31% i.e.
9 SLE and 4 Sjögren’s syndrome), cancer-related MAHA (4, 9.5%), drug-
induced (3, 7.1%), post-transplant and infection-related microangiopathy (4,
9.5%). The average number of PEX sessions required to achieve overall clinical
response in TTP, autoimmune-associated MAHA, HUS and drug-induced
microangiopathy was 18.2±17.9, 11.5±7.6, 13.0±8.7 and 7.3±6.7, respectively.
The mean follow up time was 40.8 months. 5 patients (11.6%) died during the
course of treatment in index hospitalization, 12 (27.9%) were refractory to PEX
and 24 patients (55.8%) responded to PEX, and 1 patient was lost to follow up.
1 patient relapsed 8 months after achieving clinical remission and was suc-
cessfully treated with Vincristine. Another patient developed exacerbation and
was palliated eventually. For the refractory cases, 7 patients were given Ritux-
imab, 5 achieved clinical response while those who were given Vincristine (n=3)
and Cyclophosphamide (n=2), achieved clinical response with a median of 15
days from the time second line agents were used. The 1 year overall survival
of those who received second line treatment compared to patients who respond-
ed to only PEX and standard of care was 59% and 80% (p=0.51), respectively.
The overall 1 year survival of the entire cohort is 74% which is comparable to
the Oklahoma registry. The mean length of hospital stay was 30 days (median
27 days, SD±20.2). Complications encountered during PEX included bleeding
(9.5%), seizures (11.9%), cardiovascular complications like myocardial infarc-
tion and stroke (16.7%), and nosocomial infection (16.7%). 30% of the cohort
required temporary dialysis support for acute kidney injury while 38% of them
ended up required lifelong dialysis. With regards to the cost of plasma units,
consumables and PEX procedure, the calculated mean cost was Singapore
Dollar (SGD) 25252.95 (€16991.17) (SD±20859.41 (€14035.02)) per patient.
Summary/Conclusions: The clinical outcome in terms of survival in our cohort
is in keeping with that of other registry and cohort (Hovinga et al Blood 2010).
Our data which demonstrate the health care resource utilization show that man-
agement of these patients is expensive. While small in terms of incidence, it
poses an economic burden disproportionate to its overall size. 
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HEPATITIS E VIRUS: INVESTIGATION IN NORTH ITALIAN BLOOD DONORS
L. Raffaele1,*, M. Spreafico1, B. Foglieni1, I. Guarnori1, S. Brambilla1, S. Fumagalli1,
D. Prati1
1Transfusion Medicine and Hematology, ASST-Lecco, Lecco, Italy
Background: Hepatitis E virus (HEV) is a major cause of acute hepatitis world-
wide, and a possible threat to transfusion safety. Recent data from Europe
showed a HEV IgG prevalences of 6.8% in German blood donors, 27% in Dutch
blood donors, and 52% in an hyperendemic area in the South of France.
Aims: The aim of this study was to determine the prevalence of anti-HEV reac-
tivity and HEV viremia in Italian blood donors, in order to estimate the risk of
transfusion transmission.
Methods: Nearly 10,000 samples were collected from anonymized, unpaid
donors at the “Lecco processing and validation blood center” (Lombardy, Italy)
from June to July 2016. Samples were tested individually (individual-donation
nucleic acid test [ID-NAT]) for HEV RNA using the Procleix HEV assay (95%
limit of detection 7.9 IU/mL). Initial TMA-reactive samples were retested and
considered positive if the retest result was reactive. For the serology study, a
subset of 2000 donations was tested for HEV IgG using DiaPro HEV ELISA kit
(Diagnostic BioprobesSrl, Milano, Italy). HEV IgG and IgM were analyzed in
ID-NAT positive samples at the time of donation and in the follow up, collected
one year after the index donation.
Results: The prevalence of IgG anti-HEV in north Italian blood donors was
7.4%. Nine out of 9,726 donor samples gave reactive values by the ID-NAT
assay for HEV RNA. Among them, only one sample was confirmed to be reactive
in additional TMA tests. None of the 9 HEV RNA initially reactive samples had
circulating IgM or IgG antibodies against HEV. In the follow up, only the repetitive
reactive donor shewed a IgM and IgG seroconversion, indicating primary HEV
infection. Therefore, we estimated that the risk of receiving a potentially infectious
blood unit is of 1:10.000 (upper bound of the 95% confidence interval, 1:1700).
Summary/Conclusions: Anti-HEV reactivity, indicating a previous infection, was
found in 7.4% of subjects admitted to blood donation in our area. We also identified
a viremic blood donation, indicating that the risk of transmitting the infection through
blood transfusion, although small, is not negligible. The clinical impact of HEV
infection among blood recipients remains to be assessed. These data need to be
considered when deciding a national policy for preventing HEV transmission.
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SHORT-TERM ADMINISTRATION OF RECOMBINANT HUMAN ERYTHRO-
POIETIN DECREASES B CELL IN HUMAN PERIPHERAL BLOOD
T. Nagashima1,*, A. Yokohama2, M. Awata1, Y. Kanai1, K. Murata1, R. Ino1,
Y. Kitamura1, K. Honma1, N. Gotoh1, T. Kasamatsu1, H. Handa3, T. Saitoh1,
H. Murakami1
1Department of Laboratory Sciences, Gunma University Graduate School of
Health Sciences, 2Blood Transfusion Service, 3Department of Hematology,
Gunma University Hospital, Maebashi, Gunma, Japan
Background: Erythropoietin (EPO) is hematopoietic factors participating in red
blood cell production, and accelerates proliferation and inhibits apoptosis of ery-
throblasts. It is reported that EPO has pleiotropic effects including anti-apoptotic
action for some cells, antioxidant action, vascularization action, and promoting
cell division in addition to stimulation of erythropoiesis as well, whereas there
are conflicting results of small cohorts as to its effect on blood immune cells.
Aims: We analyzed peripheral white blood cell subsets in patients who received
one bolus administration of recombinant human erythropoietin (rHuEPO) to
examine the effect of EPO on human immune system.
Methods: One hundred nineteen autologous blood donors (male/female 62/57)
in Gunma University Hospital were enrolled in this study after written informed
consent. All the patients had no infections or inflammation. Forty nine patients
were treated with rHuEPO (Epoetin alpha or Epoetin beta (24,000 IU, respec-
tively)) once after blood donation because of low hemoglobin concentration and
70 were not treated. Peripheral blood samples were obtained at the time of the
first phlebotomy and after 1week from the same patient.We measured the num-
ber of WBC, lymphocytes, myeloid dendritic cells (mDC), plasmacytoid dendritic
cells (pDC), CD4+ T cells, CD8+ T cells, Natural killer (NK) cells, B cells, mono-
cytes, and neutrophils of peripheral blood before and after rHuEPO administra-
tion by flow cytometry. Also we compared treatment group with non treatment
group. Paired and unpaired Student’s t-test were used to compare absolute
counts and percentages of each cell, P values<0.05 were considered significant.
This study was approved by the research ethics committee of our hospital.
Results: In treatment group, absolute number and percentage of lymphocyte in
WBC decreased significantly after rHuEPO administration from 1985.0±520.8/µl
to 1798.7±439.0 /µl, in absolute number (p=0.019), and from 33.2±8.57% to
30.0±7.32% in percentage (p=0.023). The numbers of whole WBC, mDC, pDC,
monocyte and neutrophil did not change significantly. In respect of lymphocyte
subsets, absolute number of CD8+ T cell, NK cell and B cell significantly
decreased from 358.9±257.0 /µl to 311.5±210.9/µl (p=0.04), from 290.6±157.6
/µl to 257.4±141.8 /µl (p<0.01) and from 289.3±192.4 /µl to 239.9±158.2 /µl
(p<0.01), respectively. Regarding B cell subsets, absolute number of naïve B cell
and IgD- CD27- B cell significantly decreased from 171.3±93.5 /µl to 153.0±84.2
/µl (p<0.01), and from 16.5±13.6 /µl to 12.9±12.7 /µl (p=0.045), respectively.
Moreover, other B cell subsets, such as transitional B cells, memory B cells and
marginal zone B cells, also showed a trend of decrease. However, percentages
of naïve B cell and IgD-CD27- B cell in total B cell did not change. These sug-
gested that whole B cell decreased, not a specific subset of B cell. In non treat-
ment group, there was no significant change in any type of immune cell.
Summary/Conclusions: These findings suggested that just one administration
of rHuEPO influenced human immune system, especially via reduction of B
cell in peripheral blood, with unknown mechanism so far.
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BLOODLESS TREATMENT OF HEMATOLOGIC MALIGNANCIES AND
APLASTIC ANEMIA - JEHOVAH’S WITNESSES (JW)
K. Kim1,*, M.-Y. Lee1, N.-S. Lee1, J.-H. Won1, J. Yoon2, S.H. Kim2, C.-K. Kim2,
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1Internal Medicine, Soonchunhyang University Hospital, Seoul, Seoul, 2Internal
Medicine, Soonchunhyang University Hospital, Bucheon, Bucheon, 3Internal
Medicine, Soonchunhyang University Hospital, Cheonan, Cheonan, Korea,
Republic Of
Background: At most centers, the majority of patients who request bloodless
medicine are members of the Jehova’s Witness (JW) faith. But, there are no
standard, established guidelines to manage pancytopenia in these patients, nor
are there many studies to inform optimal treatment approaches. The most trou-
blesome patients who request bloodless medicines are patients with hemato-
logic malignancy. The treatments of these patients are considerable challenges.
They have not only problems of severe pancytopenia, but also require intensive
chemotherapy. Since 2000, our hospital has been a bloodless center. This study
was retrospectively analyzed for hematologic malignancies and aplastic anemia
with bloodless treatments in Soonchunhyang university hospital.
Aims: This study was retrospectively analyzed for hematologic malignancies and
aplastic anemia with bloodless treatments in Soonchunhyang university hospital.
Methods: A retrospective review of medical records was performed of 44
patients with hematologic malignancies and aplastic anemia who request blood-
less medicine from January 2006 to December 2015 at Soonchunhyang uni-
versity hospital.
Results: Of 44 patients, 48% were men (n=21) and 52% were women (n=23).
The median age of the study population at the time of diagnosis was 62 years
(range 16-87). Thirteen patients (29.5%) were acute leukemia, 15 (34.1%)
patients with non-Hodgkin’s lymphoma (NHL), 2 (4.5%) patients with aplastic
anemia (AA), 6 (13.6%) patients with chronic myeloid leukemia (CML), 4 (9%)
patients with myelodysplastic syndrome (MDS) and 4 (9%) patients with mul-
tiple myeloma (MM). Thirty one patients were treated with chemotherapies and
13 patients were treated with supportive care only. Among 44 patients 27
patients were died. Most common cause of attribution to death was anemia
(92.5%). And Chief complaint at death was dyspnea (88%). Median survival of
acute leukemia was 1 month (95% CI, 0.41-1.59).
Table 1.
Summary/Conclusions: In bloodless treatment, CML, MM and lymphoma
had a relatively good prognosis. However, AML and MDS were showed a poor
prognosis. Therefore, further studies are needed to improve survival for blood-
less patients with hematologic malignancies.
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PREOPERATIVE ANEMIA: A SINGLE INSTITUTION EXPERIENCE IN SPAIN
G. Pinto1,*, F. Ruiz1, I. Page1, G. Yumi1, G. Moreno1
1Hematology, Hospital Ramon y Cajal, Madrid, Spain
Background: Preoperative anemia is considered as a strong predictor of post-
operative red cell transfusions, and has also been linked to increased morbidity
and mortality in surgical patients, but it is frequently overlooked. 
Aims: The objective of this study is measure of real impact of preoperative
hematological assesment and optimization of anemic patients in terms of
decreasing blood cells transfusions. 
Methods: We analyzed 85 patients undergoing elective surgery in subgroups
of high or low risk of bleeding. All the patients were referred from pre-anesthesia
consultation for performing a 4-week hematological protocol in order to optimize
the hemoglobin level to a near normal value. We identified the underlying cause
of anemia and offered the treatment according to the etiology. The primary out-
comes were the response to therapy defined as reaching the Hb level >13 gr/dL
or increasing of >2 gr/dL from basal level, and the rate of blood transfusion.
Results: Mean age was 70.4 years, with a male-female ratio of 1:2, and the
patients were divided into 2 groups according to the bleeding risk: high risk
74% (hip and knee replacement, cystectomy, colectomy, maxilofacial surgery),
and low risk 26% (mastectomy, gynecology or spine surgery), with a median
hemoglobin of 10,9% and 10,1%, respectively. A diagnostic workup was per-
formed in order to provide appropiate treatment: iron deficiency anemia
(83,9%), anemia of chronic disease (10,3%), folate or vitamin B12 deficiency
(5,8%). The patients with iron deficiency anemia received oral (62%) or intra-
venous iron (38%), but third of patients had to change from oral to intravenous
iron by intolerance or poor response. The response to treatment was reached
by 44.7% of patients, in an average time of 26,4 days. The rate of blood trans-
fusion was 18% in good responders (0,5 packed red blood cells per patient)
and 63% in poor responders (1,6 packed red blood cells per patient).
Summary/Conclusions: Treatment strategies over preoperative period, and
the effort to reach a near to normal hemoglobin level, could minimize the amount
of red blood cell transfusion the patients will be exposed in the postoperative
period. Our data provide evidence about the effectiveness of a prompt evaluation
and correction of preoperative anemia in a maximum time of 4 weeks.
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RED BLOOD CELLS (RBC) AND PLATELET (PLT) TRANSFUSIONS IN
TRANSPLANTED AND NOT-TRANSPLANTED PATIENTS WITH HEMATO-
LOGICAL MALIGNANCIES
E. Baldoumi1, V. Papadopoulos2, V. Kalaitzidou1, A. Syrigou1, C. Lalayanni1,
M. Papathanasiou1, D. Mallouri1, C. Smias1, I. Sakellari1, A. Anagnostopoulos1,
D. Sotiropoulos1,*
1Haematology Department & BMT Unit, George Papanicolaou Hospital,
2Hematology Department, Papageorgiou General Hospital, Thessaloniki,
Greece
Background: Patients with hematological malignancies require often and pro-
longed hospitalisations during the course of their treatment, in part due to
increased and frequent transfusion demands.
Aims: The objective of the study was to assess the factors affecting transfusion
needs in a Hematology Department (bone marrow transplant unit- BMTU, post-
transplant unit-PTU, hematology clinic).
Methods: The patients that were hospitalized between 1/1/2015 and
31/12/2015 were analyzed. Data regarding the underlying disease, the disease
status, type of transplant, duration of marrow aplasia and donor-patient blood
group mismatch were obtained from the medical records. The analysis was
restricted to the transfusion of packed RBCs and units. Differences between
groups were assessed using non-parametric statistics (Kruskall-Wallis and
Mann-Whitney U-test).
Results: There were 523 admissions of 256 different patients. Complete data
for analysis could be obtained for 487 admissions of 237 patients (92.6% of
patients, 93.1% of admissions), corresponding to 10,673 days of hospitaliza-
tion. Total number of blood products transfused was 2284 packed RBC units,
13883 PLT units (apheresis platelets counted as 5 units). Values are reported
as median (range), unless otherwise specified. In the BMTU, the type of trans-
plant was correlated with transfusion needs: number of RBC units transfused
per admission was 2 (1-5) for autologous transplanted (AUTO) patients, 4 (1-
28) for allo-transplanted (ALLO) (no difference between sibling and matched
unrelated donors), and 7 (1-14) for haplo-identical transplantations (HAPLO),
p=0.001. Platelet units requirements were respectively 15 (5-45) for AUTO, 20
(5-205) for ALLO and 50 (30-130) for HAPLO, p<0.001. The length of stay was
18 (13-23) days in AUTO, 22 (16-44) in ALLO, 30 (29-40) days in HAPLO trans-
plantation, p<0.001, while the duration of aplasia in days was 9 (4-19) in AUTO,
13 (5-32) in ALLO and 25 (20-38) in HAPLO, p<0.001. The longer duration of
aplasia and hospitalization was correlated with greater transfusion needs. In
the PTU there was no statistically significant difference in transfused RBC or
PLT units with regard to transplant type. Disease status (response versus active
disease) was only correlated with RBC units transfused in PTU [2 (1-29) vs 6
(1-56) units respectively, p=0.006]. Donor – patient blood group mismatch was
correlated with increased transfusion demands in BMTU for RBCs [4 (1-28) vs
2 (1-5), p<0.001] and PLTs [25 vs 15, p<0.001]. In hematology clinic, the under-
lying disease was correlated with transfusion needs in RBC and PLTs, as shown
in table 1. Patients with AML had the higher needs in RBCs and PLTs, whereas
patients with lymphoma had the lowest needs in RBC transfusions. Disease
status was not correlated with transfusion needs. The duration of aplasia was
correlated with the number of RBC units (Pearson’s r=0.66, p<0.001, r2=0.435)
and of PLTs transfused (Pearson’s r=0.78, p<0.001, r2=0.61).
Table 1. Units transfused in hematology clinic
Summary/Conclusions: The main determinants of transfusion requirements
are the duration of aplasia, the type of transplant and the disease, with myeloid
malignancies requiring more transfusions. The establishment of haplo-identical
transplantations has increased the transfusion needs due to longer period of
aplasia.
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BOTANICAL ALKYL HYDROQUINONE HQ17(3) EXERTS CYTOTOXICITY
TO T(9;22) PHILADELPHIA CHROMOSOME SUP-B15 ALL CELLS
THROUGH INDUCING ENDOPLASMIC RETICULUM STRESS,
AUTOPHAGY, AND AIF TRANSLOCATION
C.-W. Chen1, Y.-J. Chang1, Y.-Y. Kuo2, L.-I. Lin1, C.-Y. Hu1,*
1Department of Clinical Laboratory Sciences and Medical Biotechnology, 2Grad-
uate Institute of Oncology, College of Medicine, National Taiwan University,
Taipei, Taiwan, Republic of China
Background: Patients suffering from Acute lymphoblastic leukemias (ALLs)
harboring t(9;22) genetic abnormality are classified very high risk (VHR) ALLs
displaying poor clinical outcome irrespective of intensive chemotherapies and
tyrosine kinase inhibitor treatment. Development of new adjuvant therapeutics
will provide great value. HQ17(3)[10’(Z),13’(E),15’(E)-heptadecatrienyl hydro-
quinone] isolated from sap of the lacquer tree showed potent cytotoxic effect
within 24 hours at micromolar concentration on several ALL cell lines, including
TKI (Imatinib, IM)-refractory Ph+ B-ALL cell line SUP-B15 cells, but spare nor-
mal PB leukocytes, and were non-toxic in experimental rats after 28-day
HQ17(3) injection. Thus HQ17(3) presents as a potential anti-leukemic agent
and serves a model for design anti-leukemic regimen. We previously showed
HQ17(3)-induced rapid cell demise, characterized by oxidative stress, loss of
membrane integrity, mitochondrial membrane potential disturbance and nuclear
DNA fragmentation. Neither pan-caspase inhibitor nor Nec-1 (RIP-1 inhihitor)
protected SUP-B15 cells from HQ17(3)-induced cell death. The cell death pro-
gram elicited by HQ17(3) is caspase-independent, and is different from the
RIP1-mediated controlled necroptosis.
Aims: To investigate the characters of, and the molecular pathways involved
in the HQ17(3)-induced non-classical death on VHR-ALL SUP-B15 cells and
help developing effective therapeutic strategies for the VHR-ALLs.
Methods: Cell growth inhibition in response to HQ17(3) w/wo inhibitors was
analyzed by ACP assay. Cells were stained by Annexin V/PI and analyzed by
flow cytometry for cell death. Lysosomal protease inhibitors (AEBSF (serine
protease inh.), pepstatin/CA074-Me (cathepsin D/B inh.)) or autophagy
inhibitors (Bafilomycin A1) were used in combination with HQ17(3) in some
experiments. Acridine orange stain and confocal microscopy are used to visu-
alize the changes of acidic vesicles. Autophagic flow in response to HQ17(3)
was revealed by aggregation of ectopically expressed EGFP-LC3. Western
blot analysis were used to analyze p- eIF2a, ER chaperone Grp78, spliced
XBP-1 (markers for ER stress). Lenti-viral delivery of shRNAs was used to
repress the expression of Beclin-1. Nuclear accumulation of apoptosis inducing
factor (AIF) was revealed by fluorescence microscopy.
Results: Enlarged acidic vesicles accumulated soon after HQ17(3) treatment,
and deminished when cell death ensued. HQ17(3)-induced cell death could
not be attributed to cathepsins released from lysosomal membrane permeabi-
lization (LMP) as cathepsin inhibitors did not attenuate the cell death. HQ17(3)
enhanced autophagy as revealed by aggregation of ectopically expressed
EGFP-LC3. Inhibition of autophagy by Bafilomycin A1 or knockdown the essen-
tial autophagy-related Beclin1 by shRNA could partially attenuate HQ17(3)-
induced cell death. Further, HQ17(3) treatment gave rise to early ER stress as
revealed by enhancement of eIF2a phosphorylation and up-regulation of ER
chaperone Grp78. HQ17(3) induced nuclear translocation of AIF, in compatible
with mitochondria disturbance and caspase-independent cell death thereafter.
Summary/Conclusions: In Ph+-ALL SUP-B15 cells, HQ17(3) acts in multi-
facet: a) lead to oxidative stress and perturb mitochondria membrane integrity,
b) induce ER stress and calcium mobilization to mitochondria, cleave and
release AIF to mediate nuclear chromatin cleavage, c) HQ17(3)-induced
autophagy may be implicated cell death. This study shows agents that are
capable of eliciting an intricate effector network in therapy-induced cytotoxicity
will have potential as adjuvants controlling the VHR-Ph+-ALL cells refractory to
conventional high dose chemotherapies and TKI regime.
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TARGETED MUTATIONAL PROFILING OF CHILDHOOD AND ADULT
ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
J. Peric1, T. Karan Djurasevic1, T. Kostic1, I. Marjanovic1, J. Lazic2, M. Virijevic3,
N. Krstovski2,4, L. Dokmanovic2,4, D. Tomin3,4, A. Vidovic3,4, N. Suvajdzic
Vukovic3,4, D. Janic2,4, S. Pavlovic5, N. Tosic1,*
1Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and
Genetic Engineering, University of Belgrade, Serbia, 2University Children’s
Hospital, 3Clinic of Hematology Clinical Centre of Serbia, 4School of Medicine
University of Belgrade, 5Laboratory for Molecular Biomedicine, Institute of
Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia,
Belgrade, Serbia
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer
in children, representing about 80% of acute leukemias, whereas it is less com-
mon in adults (20%). Identification of cytogenetic aberrations and a small num-
ber of molecular abnormalities are still the most important risk and therapy
stratification methods in clinical practice today.
Aims: The aim of the present study was to assess mutational profile of both
childhood (cALL) and adult acute lymphoblast leukemia (aALL) patients, by
applying targeted next generation sequencing (NGS) on MiSeq System.
Methods: We analyzed DNA samples from 34 de novo ALL patients (17 cALL
and 17 aALL) using TruSeq Amplicon – Cancer Panel (TSACP) that targets
mutational hotspots in 48 cancer related genes (212 amplicons). The bioinfor-
matics analyses was conducted using processing pipeline composed of both
freely available open source bioinformatics tools as well as tools developed in-
house. The average coverage of high-quality sequences was 2609 × per ampli-
con. Ten genes were discarded due to insufficient coverage, therefore we ana-
lyzed a total of 183 amplicons from 38 genes. Variants were identified in relation
to the GRCh37 reference genome by applying a Bayesian approach and com-
pared to public genetic variation databases and in-house databases.
Results: We identified a total of 331 (159 cALL, 172 aALL) variants in the cod-
ing regions (median per patient: 9, range: 6-12; median per cALL: 9, range: 6-
12; median per aALL: 10, range: 7-12 ) and 429 (211 cALL, 218 aALL) variants
in the non-coding regions (median per patient: 13 range: 10-15; median per
cALL: 13, range: 10-14; median per aALL: 13, range: 10-15). Overall, a total of
98 variants (median per patient: 2.8, range: 1–6) were potentially protein-chang-
ing, including nonsense, frameshift, and missense (NFM) mutations. There
were no significant differences in the number of NFM mutations between cALL
(total 47, median per patient: 3, range: 1–5) and aALL patients (total 51, median
per patient: 3, range: 1–5). Moreover, we identified 5 NFM mutations in STK11
gene, 3 in ABL1, RET, KRAS and 2 in HNF1A, NRAS, and NOTCH1. Observed
in individual patients detected mutations predominantly disrupted Ras/RTK
pathway (STK11, KIT, MET, NRAS, KRAS, PTEN). Additionally, we identified
5 patients with the same mutation in HNF1A gene coding for transcriptional
factor, disrupting both Wnt and Notch signaling pathway. Notch pathway was
disrupted in two patients in which detected variants affected NOTCH1 gene.
HNF1A and NOTCH1 variants were mutually exclusive, while genes involved
in Ras/RTK pathway exhibit a tendency of mutation accumulation.
Summary/Conclusions: Our targeted NGS study showed low number of recur-
rent mutations in both cALL and aALL patients. Detected mutations affect few
key signaling pathways, primarily Ras/RTK and Notch pathways. This study
contributes to knowledge of ALL mutational landscape, leading to better under-
standing of molecular basis of ALL and better stratification and treatment of
ALL patients.
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RELAPSED LOW HYPODIPLOID ACUTE LYMPHOBLASTIC LEUKAEMIA
IN A LI-FRAUMENI PATIENT
F. Van Delft1,2,*, G. Cuthbert3, K. Robinson3, S. Bailey2, R. Skinner2, G. Shenton2
1Northern Institute for Cancer Research, Newcastle University, 2Children and
Adolescent Haematology and Oncology , Great North Children’s Hospital,
3Northern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation
Trust, Newcastle upon Tyne, United Kingdom
Background: A 7-year old girl presented with backache, leg pain and difficulty
walking. She was referred to the local paediatric oncology service, as she was
known with Li-Fraumeni Syndrome (LFS). Cancers linked to this disorder
include soft tissue sarcomas, osteosarcoma, breast cancer, brain cancer,
leukaemia and adrenocortical carcinoma. The patient’s mother had breast can-
cer twice, and both her (monozygotic) twin sister and older sister had adrenal
cortical carcinomas removed. The patient was born with left sided twinning
defects (absent left kidney, malrotation, absent left ear and ear canal, Arnold-
Chiari malformation with spinal cord syrinx and hydrocephalus). At presentation
there was a suspicion of a disseminated malignancy. She underwent an MRI
scan which showed extensive changes in her spinal column and hips. Bone
marrow biopsy revealed Acute Lymphoblastic Leukaemia (ALL). Paucity of
diagnostic material restricted the cytogenetic analyses. G-banding showed
46,XX[14], with FISH demonstrating loss of FOXO1/13q14.11 [44%], gain of
MYC/8q24.21 [9%],  ETV6-RUNX1 NEGATIVE, gain of RUNX1/21q22.12 [21%]
and BCR-ABL1 NEGATIVE. The patient was treated according to NCRI risk
criteria on the least intensive regimen of the UK ALL 2003 trial. She achieved
morphological remission after a 3-drug induction, and successfully completed
further treatment, including intensification/CNS directed phase, interim main-
tenance and 2 delayed intensification blocks. She completed 5 years of follow-
up and was transferred to the Long Term Follow-Up Clinic, when she presented
with hypercalcaemia. Peripheral blood and bone marrow biopsy confirmed a
diagnosis of ALL. Although the phenotype resembled the profile of the first pres-
entation of leukaemia, the genetic aberrations appeared incongruent.
Aims: Establish the origin of the second episode of ALL in a patient with known
Li-Fraumeni Syndrome. As treatment and outcome for relapsed ALL in com-
parison with a second, primary, ALL are completely different, this information
was critical to guide further management.
Methods: We set out to comprehensively characterise the second ALL, including
conventional G-banding and fluorescence in situ hybridisation (FISH). The
acquired results were compared with those derived from the first ALL diagnosis.
Results: The G-banding analysis showed 36,XX,-2,-3,-4,del(5)(q31q35),-7,-12,-
13,-14,-15,-16,-17[13]/46,XX[7]. Extensive FISH analysis confirmed the diagnosis
of low hypodiploidy ALL. This result was in line with the reported association
between TP53 gene mutations in 90% of cases of low hypodiploid ALL, with
these mutations often present in normal cells. [Holmfeldt, Nat Gen, 2013] At first
sight, this did not recapitulate the original cytogenetic analysis and suggested
the occurrence of a second episode of ALL.  In order to further characterise the
diagnostic genetics, FISH probes were used on archived diagnostic slides. Care-
ful selection of probes demonstrated that the original leukaemia sample contained
two co-existing clones – one low hypodiploid clone (with an identical pattern of
loss and gain of chromosomes as the second ALL) and one clone resembling a
doubled up/near triploid low hypodiploid clone.
Summary/Conclusions: This case report demonstrates the value of in-depth
genetic analyses to guide management of patients with ALL. This patient pro-
ceeded with re-induction according to our current relapsed therapy guidelines
(R3), to which she has shown a promising response. She is considered for
allogeneic bone marrow transplantation using an unrelated donor.
In hindsight, the treatment regimen used for the initial ALL was incorrect. If it
had been established that she had low hypodiploid ALL the first time around,
she would have been allocated the most intensive regimen within the trial. Nev-
ertheless, she maintained remission status for 5 years with low intensity treat-
ment and ironically relapsed when most patients are told they are cured.
Since the original diagnosis of ALL in 2007, research has vastly improved our
understanding of the biology and genetic landscape of ALL. This has facilitated
risk stratification, improved outcome after treatment and identified novel drug
targets. Genomic profiling of low hypodiploid ALL has identified oncogenic acti-
vation of Ras and phosphoinositide 3-kinase (PI3K) signalling conferring sen-
sitivity to PI3K inhibitors, thus providing therapeutic avenues if conventional
treatment were to fail.
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IMMUNOLOGICAL CHARACTERIZATION OF PH+ ALL BONE MARROW
BY MULTIPLEX IMMUNOHISTOCHEMISTRY
H. Hohtari1,*, O. Brück1, S. Blom2, R. Turkki2, A. Ribeiro2, M. Sinisalo3,
P. Kovanen4, O. Kallioniemi2, T. Pellinen2, K. Porkka5, S. Mustjoki1
1Hematology Research Unit, University of Helsinki and Helsinki University Cen-
tral Hospital Comprehensive Cancer Center, 2Institute for Molecular Medicine
Finland (FIMM), Helsinki, 3Division of Hematology, Tampere University Hospital,
Tampere, 4Department of Pathology, HUSLAB and Haartman Institute, Helsinki
University Central Hospital and University of Helsinki, 5Hematology Research
Unit, University of Helsinki and Helsinki University Central Hospital Compre-
hensive Cancer Center, Department of Hematology, Helsinki, Finland
Background: The treatment results in Philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph+ ALL) have improved significantly in the era of
tyrosine kinase inhibitors (TKIs). However, many patients relapse despite hav-
ing received intense treatments with initially favorable responses. TKI therapy
is known to modulate the immune system, and it may play a critical role in
keeping the leukemia under control. However, little is known about the status
of the immune system in patients with Ph+ ALL. Especially with the emerging
immunotherapies in sight, it is vital to chart the immunological landmarks that
could help us direct the treatment towards a more personalized course.
Aims: To characterize the immunological microenvironment in Ph+ ALL bone
marrow (BM) by multiplex immunohistochemistry (IHC).
Methods: Ph+ ALL BM biopsies from the diagnosis stage were collected from
Helsinki University Hospital and Tampere University Hospital (N=31). BM biop-
sies from non-leukemic (NL) controls (N=14) were used as a reference. Sam-
ples were hematopathologically evaluated and a tissue microarray (TMA) was
constructed by selecting two BM cores with high leukemic cell infiltration per
patient. The TMA sections were stained with both fluorescent and chromogenic
dyes for six markers and nuclei simultaneously enabling cytometric analysis at
cell-level resolution. Marker panels included T and B lymphoid cells, NK and
dendritic cells, macrophages as well as myeloid derived suppressor cells. Fur-
thermore, we analyzed immune checkpoint molecules (PD1, LAG3, OX40,
TIM3, CTLA4) and their ligands (PD-L1, PD-L2, HLA-G, HLA-ABC) alongside
with various activation markers (granzyme B, CD45RO, CD25, CD57, CD27).
After the staining, the cells were segmented and quantified with the image
analysis software CellProfiler and the cell analysis software FlowJo.
Results: The CD4+/CD8+ ratio was lower in Ph+ ALL BM versus NL BM (1.3
[Interquartile range (IQR) 1.0-1.9] vs 2.0 [IQR 1.7-2.4], p=0.0134) indicating
that there are relatively more CD8+ T cells in the leukemic than in the non-
leukemic marrow. The ratio of memory CD4+CD45RO+ T cells in Ph+ ALL BM
versus NL BM was elevated (21.0% [IQR 16.7-28.5] vs 13.0% [IQR 8.7-15.9]
of CD4+ T cells, p=0.0044). The difference in memory CD8+CD45RO+ T cells
was not significant (p=0.36). Further analysis of the T cell phenotype showed
increased proportion of both PD1-positive helper T cells and PD1-positive
CD8+ T cells in Ph+ ALL BM vs NL BM (29.7% [IQR 17.5-50.1] vs 6.9% [IQR
5.7-8.9], of CD4+ cells, p<0.0001 and 28.8% [IQR 13.2-38.0] vs 14.9% [IQR
9.6-18.7], of CD8+ cells, p=0.0107). The ratio of OX40-positive helper T cells
was also higher in Ph+ ALL BM (27.1% [IQR 21.6-33.25] vs 18.5% [IQR 14.8-
21.9], of CD4+ cells, P=0.0001), but no difference was observed in the propor-
tion of OX40-positive CD8+ T cells (P=0.49).
Summary/Conclusions: Multiplex IHC enables ample cytometric evaluation
of different immune cell subtypes in their original microenvironmental context
of the bone marrow. The TMA format not only allows analysis of tens of BM
samples in parallel but also serves as a retrospective, easy-access archive for
any follow-up studies. Ph+ ALL BM is characterized by a decrease in the
CD4+/CD8+ ratio and an increase in the proportion of CD4+CD45RO+ T cells
in comparison with the non-leukemic controls. The proportion of PD1-express-
ing T cells is also elevated. However, the heterogeneity between patients is
marked. The analysis of other marker panels is presently ongoing, as well as
correlation to clinical and treatment outcome parameters.
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CDKN2A/P16INK4A DELETION IS NOT A POOR PROGNOSIS PREDICTOR
IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED
ACCORDING TO PROTOCOL RALL-2009
P. Inga1,*, O. Tatiana1, P. Elena1, T. Vera1, G. Olga1, R. Michail1, K. Sergey1,
A. Zalina1, S. Valery1
1National Research Center for Hematology, Moscow, Russian Federation
Background: CDKN2A/p16INK4a deletion is a frequent cytogenetic abnormality
in acute lymphoblastic leukemia (ALL), ranging from 18% to 45%. In pediatric
group of patient’s p16INK4a deletion was associated with T-cell ALL phenotype
and poor event-free survival.  The prognostic impact of CDKN2A/p16INK4a dele-
tion in adult ALL patients appear controversial.
Aims: To evaluate the prognostic impact of the CDKN2A/p16INK4a deletion in
adult patients with acute lymphoblastic leukemia.
Methods: We present the results of the CDKN2A/p16INK4a deletion in 110
adult patients with newly diagnosed Philadelphia –negative ALL, which were
treated by RALL-2009 (NCT01193933) in our center since June 2009 till Sep-
tember 2016.  Patients characteristics: the median of age was 26 years old
(range 15 -54), the median white blood cell (WBC) count was 16.9×109 /L
(range: 0.4-785×109 /L), the median blasts cells count in the bone marrow
(BM) was 84.4% (range: 0-98). Sixty-five (59%) of the 110 patients had a B-
cell phenotype, 42 (38%) had a T-cell phenotype, 3 (2.7%) patients - bipheno-
typical ALL. Interphase fluorescence in situ hybridization (FISH) was performed
for detection CDKN2A deletion, TEL/AML1, MLL rearrangement, MYC
(8q24.21) translocation, ТР53 deletion, iAMP21.
Figure 1.
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Results: The prevalence of the CDKN2A deletion in all studied population was
24,5% (27 cases). The frequency of homozygous deletions was 70% (in 19 cas-
es), heterozygous deletion was 30% (in 8 cases). CDKN2A deletion was detected
in 14 (52%) patients with precursor-B phenotype, in 11 cases (41%) with T-ALL
and in 2 (7%) cases with biphenotypical ALL. Our study demonstrated that
CDKN2A deletion had no significant association with age, sex, WBC counts, BM
blasts, risk stratification  groups, complete remission (CR) and  relapse rate in B-
cell ALL. We didn’t reveal any significant differences in OS, clinical and laborato-
ry dates between groups of patients with homozygous and heterozygous deletion
of the CDKN2A deletion. The analysis for T-ALL has detected that CDKN2A dele-
tion was strongly associated with high WBC count (the median is 86×10 /L,
p=0.006), with high lactate dehydrogenase (LDH) level (the median is 3062 E/L,
p=0.0004) and no assonating with CR and replace incidence was found. We
didn’t revealed relationship between CDKN2A deletion and MLL, TEL/AML1
rearrangement, MYC translocation, ТР53 mutation and iAMP21. CDKN2A dele-
tion didn’t have statistically significant impact on outcome of patients. The five-
year overall survival (OS) for patients with and without deletion was 84% and
77% (p=0, 40); free survival (DFS) was 91% и 71% (p=0, 09),   respectively.  OS
for patients with B-cell ALL with and without deletion was 85% and 76% (p=0,
35); DFS was 92% and 65% (p=0, 07), respectively. OS for T-cell ALL patients
with and without deletion was 90% and 80% (p=0, 63); DFS was 100% and 82%
(p=0, 24), respectively. (Figure 1).
Summary/Conclusions: We were unable to demonstrate prognostic value of
the CDKN2A deletion in adult ALL patients and did not find significant associ-
ation between deletion of the CDKN2A gene and with known cytogenetic prog-
nostic factors. However patients with T-cell ALL and CDKN2A deletion had a
more aggressive initial clinical features (high level WBC and LDH), but it didn’t
associate with poor outcomes including overall survival.
Deletion of CDKN2A is not adverse prognostic factor in adult ALL treated
according to protocol RALL-2009. 
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FREQUENCY AND CLINICAL IMPACT OF CDKN2A/B GENE LOCUS IN AN
ADULT T-ALL COHORT OF PATIENTS ENROLLED IN THE SPANISH
PETHEMA GROUP PROTOCOLS
E. Genescà1,*, A. Lazarenkof1, M. Morgades2, G. Berbis1, N. Ruíz-Xivillé2,
P. Gómez-Marzo3, J. Ribera1, S. Mercadal4, R. Guardia5, M.T. Artola6,
M.J. Moreno7, J. Martínez-López8, L. Zamora2, P. Barba9, C. Gil10, M. Tormo11,
A. Cladera12, A. Novo13, J. Esteve14, J. González-Campos15, M. Almeida16,
J.-V. Cervera17, P. Montesinos18, I. Granada2, M. Batlle2, S. Vives2, E. Feliu3,
A. Orfao16, F. Solé3, J. M. Ribera2
1All Research Group, Josep Carreras Leukaemia Research Institute (IJC),
2ICO-Germans Trias i Pujol Hospital, 3Josep Carreras Leukaemia Research
Institute (IJC), Badalona, 4ICO-Duran i Reynals Hospital, Hospitalet del LLo-
bregat, 5ICO-Josep Trueta Hospital, Girona, 6Donostia University Hospital,
Donostia, 7Virgen de la Victoria Hospital, Málaga, 812 October Hospital, Madrid,
9Vall de Hebron Hospital, Barcelona, 10Alicante General Hospital, Alicante,
11Valencia Clinic Hospital, Valencia, 12Son LLàtzer Hospital, 13Son Espases
Hospital, Mallorca, 14Barcelona Clinic Hospital, Barcelona, 15Virgen del Rocío
Hospital, Sevilla, 16USAL-BNADN, Salamanca, 17La Fe Hospital-Biobanco de
la Fe, 18La Fe Hospital, Valencia, Spain
Background: Recurrent 9p21 deletions involving CDKN2A/CDKN2B locus are
frequent in ALL. The very few data regarding their prognostic significance in
adult T-ALL have shown that homozygous deletions of the CDKN2A/CDKN2B
locus are associated with improved overall survival (OS).
Aims: We precisely characterized the copy number status (CNA) of
CDKN2A/CDKN2B locus by discriminating deletions in A or B gene in order to
elucidate its clinical impact separately.
Methods: Samples from 30 adult T-ALL cases included in high-risk protocols
from the PETHEMA group were analyzed by CytoScan array (Affymetrix). Addi-
tionally, we set up a genomic qPCR to screen for CDKN2A and CDKN2B dele-
tions in samples with few or not enough quality DNA  (n=53). We corrected our
CNA values for the normal cells (2N) contaminant present in the diagnosis
samples. In addition, the results obtained by the array and/or qPCR were
checked by FISH, when samples were available. Cumulative incidence of
relapse (CIR) and OS were analyzed after censoring the patients at the time of
allogeneic hematopoietic stem cell transplantation.
Results: qPCR results showed that most of the 9p21 losses corresponded to
homozygous deletions in both genes (36%, 19/53), while heterozygosis dele-
tions corresponded to 5.7% (3/53) and different CNA status between CDKN2A
and B to 28% (15/53) of the samples. Globally alterations in CDKN2A/B locus
were observed in 70% (37/53) of patients. Results obtained by the array cor-
roborate the findings obtained by qPCR. The resolution of the array allowed us
to distinguish between homozygosis in CDKN2A and heterozygosis on
CDKN2B. The FISH analysis corroborated the homozygous deletion in the
CDKN2A/B locus in all the cases analyzed. With that, we ask for clinical impli-
cations of CDKN2A/B CNA status in 49 cases with adequate follow-up. Median
age (range) was 34 (16-68) years, 76% males, median WBC count 34 (0.6-
431.0) x109/L. Immunophenotype: pro-T+pre-T (n=21), cortical T (n=21), mature
T (n=7). CR was achieved in 92% (45/49) and MRD levels <0.1% at the end of
induction were attained in 81% of patients. A trend for better OS was observed
for patients with heterozygous or homozygous deletion of CDKN2B (61%
[40%>82%]) vs non deleted patients (25% [0%>54%],(p=0.084), whereas no
clinical impact was observed for the CNA status in the CDKN2A gene. No influ-
ence of CDKN2A or CDKN2B CNA status on CIR was observed. By multivariate
analysis only the MRD level at the end of induction influenced on OS (p=0.028,
HR=5.58 [1.21 ; 25.79]) and on CIR (p=0.07, HR= 3.67 [0.90-15.63]).
Summary/Conclusions: CDKN2A/B locus abnormalities, mainly homozygous
deletions, were found in 70% of adult T-ALL patients. Different CNA status was
found for CDKN2A and CDKN2B. Although homozygous deletion in CDKN2B
was associated with a trend for better OS, the level of MRD was the only prog-
nostic factor for OS in these patients.
Supported by 2014 SGR225 (GRE) from CERCA Programme/Generalitat de
Catalunya, and by funds from Josep Carreras International Foundation, “la
Caixa” Foundation and Celgene Spain.
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BUTEIN KILLS ACUTE LYMPHOBLASTIC LEUKEMIC CELLS IN VITRO
AND IN VIVO THROUGH FOXO3A AND CASPASE-DEPENDENT APOP-
TOTIC PATHWAYS
Y.-L. Tang1,*, L.-B. Huang1
1Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University,
Guangzhou, China
Background: Acute lymphoblastic leukemia (ALL) is a common hematological
malignancy in children. Discovering and developing effective chemotherapeutic
drugs are needed for ALL.
Aims: In this study, the anti-leukemic effect and the potential molecular mech-
anisms of butein on ALL were investigated. 
Methods: We examined the rate of apoptosis of CEM-C7 (T-ALL), CEM-C1
(T-ALL), MOLT-4 (T-ALL), RS4-11 (B-ALL) cell lines and primary ALL blasts
exposed to various concentrations of butein for 24 h using the flow cytometry.
We tested the expression of the caspase-9, poly ADP-ribose polymerase
(PARP), nuclear Forkhead Class box O3a (FOXO3a) and BCL-2 interacting
mediator of cell death (BIM) using western blot assay. We established the
xenograft mouse model to examine the anti-leukemic effect of butein in vivo. 
Results: Butein was found to significantly induce the cellular apoptosis of ALL
cell lines and primary ALL blasts in a dose-dependent manner. It also activated
the cleavage of caspase-9 and PARP. We also found that butein promoted
FOXO3a localization, enhanced the binding of FOXO3a on the BIM gene pro-
moter and then increased the expression of BIM. Moreover, we showed that
FOXO3a knockdown significantly decreased the apoptosis by butein, whereas
overexpression of FOXO3a enhanced the butein-induced apoptosis. However,
overexpression of FOXO3a mutation (C-terminally truncated FOXO3a DNA-
binding domain) decreased the apoptosis by butein through decreasing the
expression of BIM. Furthermore, treatment with butein was highly efficacious
in vivo, with enhanced reduction of tumor burden in a xenograft model of ALL. 
Summary/Conclusions: Our results therefore demonstrate the therapeutic
potential of butein for ALL via FOXO3a and caspase-dependent apoptotic path-
ways.
PB1618
GENOMIC LANDSCAPE AT DIAGNOSIS AND RELAPSE IN CHILDHOOD
ACUTE LYMPHOBLASTIC LEUKEMIA. 
O. Theisen1, C. Godon1, F. Rialland2, C. Thomas2, A. Grain2, Y. Le Bris1,
N. Robillard1, M. C. Béné1, M. Eveillard1,*
1Hematology Laboratory, 2Pediatric Oncology, Nantes University Hospital,
Nantes, France
Background: Childhood acute lymphoblastic leukemia (ALL) is the most com-
mon of pediatric malignancies, but intensive chemotherapy now allows to obtain
complete remission in over 90% of the cases. Nevertheless, 1 out of 5 children
will relapse.
Aims: In order to identify new markers prognostic of relapse, we analyzed SNP
arrays of paired diagnosis and relapse samples from 8 B-ALL children.
Methods: The cohort included 3 males and 5 females, aged between 6 months
and 21 years old (median age 4 years old). Bone marrow samples were ana-
lyzed by multiparameter flow cytometry, standard karyotype and FISH. SNP
array (Affymetrix®) performed on cryopreserved cells at diagnosis and relapse
investigated copy number alterations (CNA) and loss of heterozygosity (LOH).
TP53 mutation was studied on paired samples by Sanger sequencing.
Results: No modification was observed in the EGIL classification between
diagnosis and relapse. Diagnostic cytogenetics prognosis was good for 3 chil-
dren, poor for 3 (iAmpAML1, KNMT2A and complexe caryotype) intermediate
for 2 (normal karyotype). Three patients showed additional karyotypic  anom-
alies at relapse. SNP array showed a mean of 10 CNA and 3 LOH at diagnosis
with 4 CNA and 0,6 LOH modulations at relapse. Seven of the 8 patients pre-
sented modulation in CNA and LOH during evolution with a median of 4. Some
anomalies observed by cytogenetics were refined by SNP analysis, notably all
chromosomal gains and losses were recovered and precisely located. More-
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over, a t(4;8) translocation was found to be more complex with 7 and 8 CNA
on chromosomes 4 and 8. Patients with the most CNA and LOH also had a
complex karyotype. Anomalies were observed in hot spot regions in 9p (encom-
passing CDKN2A/2B, PAX5 and JAK2) for 5 patients and 12p (including ETV6)
for 3. Stable CNA were observed in the JAK/STAT pathway in 2 patients (JAK2)
and LOH in the RAS/MAPk pathway (NRAS) in 1. Using the genetic classifica-
tion of Moorman et al based on SNP array for 8 genes at diagnosis (IKZF1,
CDKN2A/2B, PAR 1, BTG1, EBF1, PAX5, ETV6 and RB1), SNP reclassified
our patients in 3 of good prognosis and 5 of poor prognosis, with a median of
2 CNA for the 8 genes of interest. The 2 patients with cytogenetic intermediate
prognosis would thus probably have been considered for a more intense ther-
apeutic regimen, i.e. allogeneic stem-cell transplantation. Moreover, SNP
showed that 2 patients acquired an IKZF1 deletion, also of poor prognosis,
while none of the children had TP53 mutation at diagnosis nor relapse.
Summary/Conclusions: SNP array allowed to identify additional anomalies
(compared to karyotype) in all children tested and changed the prognostic value
of diagnostic anomalies. Moreover, the identification of anomalies in the
JAK/STAT pathway could indicate a treatment by tyrosine kinase inhibitors, which
would possibly have positively modified outcome. Taken together, this new tech-
nology combined with classical analyses at diagnosis might modify therapeutic
options in childhood ALL, especially in the subgroup with a normal karyotype.
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SCREENING OF NUDT15 GENE VARIANTS IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA 
D. Aslar Oner1,*, D.F. Akin1, K. Sipahi1, M. Mumcuoglu1, N. Oner Battaloglu1,
S. Tasdelen1, U. Ezer1, S. Emir1, E. Kürekci1
1Lösante Hospital, ANKARA, Turkey
Background: In cells, while DNA bases can be protected by double helix forma-
tion and nucleosome packaging, deoxyribonucleotide triphosphates are unpro-
tected, thus, are vulnarable to damage. One of the enzymes which are respon-
sible for removing damaged nucleotides is Nudix hydrolase15 (NUDT15).
NUDT15 works as a negative regulator in thiopurine metabolism. Thioguanines
are active metabolites of thiopurines. Mechanisms of action of thioguanines are
disruption of DNA synthesis and induction of apoptosis. NUDT15 inhibits incorrect
base pairing and apoptosis through catalysis of thioguanine hydrolysis. Tanaka
et al. claimed that, besides TPMT variants in Japanese patients, there might be
possible additional factors that may influence thiopurine toxicity. They reported
that NUDT15 variants are more specific to Asian population when compared to
European people. As far as we know, this is the first study on screening of possible
variants in the first exon of NUDT15 in Turkish children with precursor B-cell
acute lymphoblastic leukemia (Pre-B ALL).
Aims: In this study, our aim was screening of gene variants in first exon of
NUDT15 in pediatric group of patients diagnosed with Pre-B ALL.
Methods: Our study group was composed of 83 patients aged between 1-15
diagnosed with Pre B-ALL at Lösante Hospital. DNA samples were isolated by
using MagNa Pure isolation system. First exon of NUDT15 was amplified by
PCR reaction. After PCR purification, sequencing was performed. 
Results: After screening of first exon of NUDT15, we detected two variations.
First variation was intronic insertion which was defined as rs3831098
(c.158+52_158+53insGGGGCGTGCGCAGAGGGACGATCTC). The other
intronic variation was defined as rs79687000 (c.158+117C>T). rs3831098 was
determined in one of the 83 patients and rs79687000 was found in three out
of the 83 patients (Tbale 1).
Table 1.
Summary/Conclusions: The changes in NUDT15 that we found have not
been previously reported in pediatric ALL patients. We do not know if these
changes have an effect on pre-mRNA or “splice” regions and ALL. This issue
needs further investigations in a large number of children with leukemia. We
are planning the screening of other exons of NUDT15 in order to evaluate for
possible applications to clinical practice (e.g. cytopenia).
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COMPREHENSIVE MOLECULAR CYTOGENETIC ANALYSES OF BONE
MARROW CELLS IN 64 CHILDREN WITH T-ALL REVEALED
PROGNOSTICALLY RELEVANT RECURRENT FINDINGS
L. Lizcova1,*, Z. Zemanova1, E. Prihodova1, L. Pavlistova1, K. Svobodova1,
E. Mejstrikova2, O. Hrusak2, P. Luknarova2, I. Janotova3, L. Sramkova3,
J. Stary3, K. Michalova1
1Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory
Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles
University in Prague, 2CLIP - Childhood Leukaemia Investigation Prague,
Department of Paediatric Haematology and Oncology, 3Department of Paedi-
atric Haematology and Oncology, 2nd Faculty of Medicine, Charles University
in Prague and Motol University Hospital , Prague, Czech Republic
Background: T-ALL represents 15% of newly diagnosed children with ALL
and it is a clinically and genetically heterogeneous disease. Despite the use of
intensive chemotherapy, relapse occurs in almost 25% of patients whose out-
come remains dismal. Visible chromosomal aberrations are seen in approxi-
mately half of the cases, while cytogenetically cryptic aberrations are observed
in almost all cases of T-ALL. However, prognostic implication of majority of
them still remains unclear.
Aims: The aim of this study was to retrospectively and prospectively analyze
bone marrow cells of children with T-ALL, to determine a frequency of recurrent
cryptic chromosomal aberrations and to assess their impact on event free
(EFS) and overall survival (OS). 
Methods: Bone marrow cells of all patients were analyzed at the time of diag-
nosis by combination of conventional and molecular cytogenetic methods. For
detection of the most frequent known chromosomal changes, i.e. rearrange-
ments of TCR loci (TRA-14q11, TRB-7q34, TRG-7p14) and TLX3 gene (5q35),
deletion of CDKN2A (9p21) and amplification of ABL1 (9q34), interphase FISH
with locus-specific probes (Dako, Abbott Molecular) was used. Complex chro-
mosomal rearrangements were proved by multicolor FISH and multicolor band-
ing (24XCyte/XCyte Probe Kit; MetaSystems) or CGH-SNP array (SurePrint
G3 Cancer CGH+SNP 4x180K, Agilent). For OS and EFS Kaplan-Maier analy-
sis with Mantel Cox test was done.
Results: During the years 1996-2016 we examined archived material of 64
children with T-ALL (19 girls and 45 boys, median age 8.25 years). In total,
chromosomal aberrations were detected in 86% of patients. The most frequent
aberration was deletion of CDKN2A gene, which was found in 35/64 patients
(19x homozygous, 16x heterozygous). Rearrangements of TCR loci were
detected in 17/64 children (11x TRA, 6x TRB).  TLX3 gene rearrangement was
established in 15/64 patients. No aberration of TRG gene and amplification of
ABL1 were found. Complex chromosomal aberrations were proved in 12/64
children. In two cases, isochromosome of the long arm of chromosome 9 was
found. 48 patients are living in the first/second complete remission. Relapse of
the disease occurred in 17 patients, 16 children died. Best outcome (EFS and
OS) was associated with TRA translocations (p<0.05). Patients with TLX3
rearrangement had significantly shorter OS and EFS (p<0.05).
Summary/Conclusions: Using molecular cytogenetic methods cryptic recur-
rent aberrations were proved in vast majority of patients. Rearrangement of
TLX3 gene was related to poor outcome in contrast to TRA translocations
associated with more favorable course of the disease. Our work attempts to
clear up the significance of chromosomal aberrations related to childhood T-
ALL in order to facilitate the patients´ stratification into cytogenetic prognostic
groups and to identify patients at an increased risk of relapse similarly like it
has been adopted in pB-ALL.
Supported by grants RVO-VFN64165, GACR-P302/12/G157 and NPU I
nr.LO1604
PB1621
ADULT PRIMARY ACUTE LEUKEMIA SAMPLES WITH CHROMOSOMAL
TRANSLOCATIONS GROW WELL IN IMMUNODEFICIENT MICE, BUT ARE
DIFFICULT TO TRANSDUCE WITH LENTIVIRUSES
B.C. Heckl1,*, M. Carlet1, M. Grunert1, B. Vick12, C. Roolf3, C. Junghanß3,
K. Spiekermann2,4, W. Hiddemann2,4, I. Jeremias1,2,5
1AGV, Helmholtz Zentrum Muenchen, 2German Cancer Consortium ,
Muenchen, 3Department of Internal Medicine III, University, Rostock, 4Internal
Medicine III, 5Dr. von Haunersches Kinderspital, Ludwig Maximilian University,
Muenchen, Germany
Background: Acute leukemia (AL) is a severe disease of the hematopoietic sys-
tem and associated with a poor outcome for patients. Patient derived xenograft
(PDX) mouse models provide an attractive tool to engraft and grow primary tumor
cells. In contrast to culture growth, samples can be monitored in a consisting
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microenvironment. This powerful tool provides the baseline for further experiments
like preclinical treatment trials or biology studies. While good engraftment rates
were published for primary pediatric ALL samples, engraftment rates of adult ALL
samples might be inferior, but remain largely elusive.
Aims: This study aimed to determine engraftment and growing ability of primary
adult AL samples in immunodeficient mice. Genetic engineering was performed
to evaluate transduction efficiencies by lentiviruses in PDX AL cells.
Methods: Primary adult ALL and AML samples were transplanted into NSG
mice in the absence of total body irradiation. Both frozen as well as fresh patient
material was used. Human CD45 and human CD38 were stained in blood to
monitor successful engraftment. Mice were sacrificed before coming down with
leukemia. Isolated cells from bone marrow and spleen were analyzed by flow
cytometry. Genetic engineering was performed using lentiviral vector systems
and monitored by expression of fluorochrome markers and flow cytometry.
Results: Engraftment and growth was successful in NSG mice in 12 out of 15
primary adult ALL samples. Frozen samples showed a longer median engraft-
ment time with 114.4 days, whereas fresh samples could already be isolated
with an average time of 75.29 days. Generally, the engraftment time varied
form 47 days up to 166 days and was shortened for slow samples over several
passages. Genetic engineering was successfully performed using lentiviral
transduction to introduce expression of fluorescent colours for cell marking and
monitoring in further experiments. Lentiviral transduction was performed in 8
ALL samples with BCR-ABL rearrangement and 2 MLL-AF4 ALL samples. Adult
ALL PDX samples with chromosomal translocations showed very low trans-
duction rates around 1%. Three AML samples with MLL-AF6, MLL-AF9 and
MLL-AF10 translocation were analysed for this study. Interestingly and in con-
trast to ALL, transduction efficiency for AML rearranged samples was high with
up to 60%. These values are similar to non-rearranged ALL samples having
transduction rates between 30% up to 80%.
Summary/Conclusions: In summary, we observed a high engraftment rate of
primary adult ALL samples in immunodeficient mice which was above what we
anticipated from the literature. Adult PDX ALL samples can be transduced with
lentiviruses with identical high transduction efficiency as pediatric samples, with
an age independent exception of AL PDX cells with BCR-ABL or MLL translo-
cations.
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SYNERGIC CHEMOTHERAPEUTIC EFFECT OF MENADIONE COMBINED
WITH EPIGALLOCATECHINE-3-GALLATE OR DOXORUBICIN IN A HUMAN
CELLULAR MODEL FOR ACUTE LYMPHOBLASTIC LEUKEMIA
A. Garaiman1,2,*, I. T. Tofolean1, R. M. Babes1, C. Ganea1, I. Baran1
1Department of Biophysics, “Carol Davila“ University of Medicine and Pharma-
cy- Bucharest, 2Department of Hematology, Coltea Clinical Hospital, Bucharest,
Romania
Background: Epigallocatechine-3-gallate (EGCG) and menadione (vitamin
K3; MD) are known as potent apoptogens in cellular models for acute lym-
phoblastic leukemia (ALL) –Jurkat T cells.
Aims: The goal of this study was to explore the chemotherapeutic potential of
MD combined with EGCG or DOX, and to determine whether there is a synergic
interaction between these agents that could significantly enhance their antitu-
moral effect in a cellular model of ALL. We investigated the antiproliferative
effect of EGCG and MD, applied alone or in combination EGCG:MD and
MD:DOX respectively on human leukemia Jurkat lymphoblasts. Some under-
lying cellular mechanisms were also scrutinized. 
Methods: Cell suspensions of Jurkat lymphoblasts were treated at various
concentrations of EGCG, MD and DOX. Clonogenic survival was evaluated as
the colony forming capacity in 96-well plates. Cell cycle and apoptosis/necrosis
were determined by flow cytometry using the fluorescent indicators propidium
iodide and Annexin V-FITC/7-AAD, respectively. Determination of oxidative
stress and mitochondrial polarization was performed by spectrofluorimetry,
using the fluorescent probes CM-H2DCFDA and JC-1, respectively.
Results: EGCG decreased clonogenic survival (IC50=117 µM and Hill coeffi-
cient h=3.17) and mitochondrial calcium in a dose-dependent manner (IC50
=97 µM, h=2.53). Furthermore, data show that there is no correlation between
the level of mitochondrial calcium ([Ca2+]m) and mitochondrial membrane poten-
tial (Δψm) (Pearson correlation coefficient r= −0.100) or between [Ca2+]m and
reactive oxygen speacies (r=−0.437) production, thus EGCG exerted a depo-
larizing effect at the mitochondrial level, most likely via interference with the
opening of the mitochondrial permeability transition pore. The combination
EGCG:MD induced cell cycle arrest in G2/M and S phases in a synergic manner
(the measured viability was: ~91% for EGCG 50 µM, ~72%MD 25 µM, ~20%
for their combination). The existence of two binding sites for EGCG is suggest-
ed, both modulated by MD, implying that MD is an allosteric modulator of the
EGCG-induced depolarization. Fluorescence induced by treatment with EGCG
alone, MD alone and EGCG:MD in combination was 172%, 101% and 387%,
respectively, suggesting that EGCG and MD interact with the second specific
target in a synergic manner. DOX induced cell cycle arrest, and clinical doses
of DOX generated oxidative stress. MD augmented this effect, enhancing the
antiproliferative effect of DOX most likely by increasing the affinity of DOX for
nuclear DNA.
Summary/Conclusions: Our results support the notion that the combinations
EGCG:MD and MD:DOX exert a strong synergic antiproliferative effect in
human leukemia Jurkat cells and encourage further studies to test the clinical
utility of this association in ALL therapy. 
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FOCAL ERG DELETIONS AND DUX4 FUSIONS IN CELL LINES DERIVED
FROM B CELL ACUTE LYMPHOBLASTIC LEUKEMIA
H. Quentmeier1,*, R.A. MacLeod1, C. Pommerenke1, H.G. Drexler1
1DSMZ, Braunschweig, Germany
Background: DUX4 has recently been presented as new oncogenic driver in
B cell acute lymphoblastic leukemia (pre B-ALL) of adolescents and young
adults [1]. Translocations of DUX4, especially those with the IGH locus led to
high expression of the corresponding fusion gene. DUX4 then triggered the
expression or a novel isoform of the ETS transcription factor ERG in pre B-ALL
[2]. Focal deletions of exons 3-9 were a second cause for short ERG variants.
Up to 7% of pre B-ALL showed deregulated expression of both genes, DUX4
and ERG [2].
Aims: We set out to find pre B-ALL cell lines with DUX4 translocation and ERG
deletion as potential model systems for this novel subtype of pre B-ALL.
Methods: We screened a panel of ALL cell lines for aberrant expression of
DUX4 mRNA as potential indicator for DUX4 translocations. Genomic PCR
was performed to detect focal ERG deletions, qRT-PCR showed expression of
alternative ERG exon 6, transcriptional target of DUX4.
Results: Genomic PCR showed that 2/66 pre B-ALL cell lines (NALM-6, SUP-
B15) tested carried deletions targeting ERG exon 5. Results of DUX4 qRT-
PCR (Taqman probe Hs03037979_g1) were surprisingly inconsistent with West-
ern blot analysis - which could only in part be explained by DUX4 being a one-
exon gene. NALM-6 was the only cell line expressing the DUX4 protein. Like-
wise, the alternative ERG transcript with alternative exon 6 was observed in
NALM-6 only.
Summary/Conclusions: In conclusion, focal ERG deletions in pre B-ALL cell
lines (2/66) occur at similar frequencies as in the primary tumor. Cell line NALM-
6 carries the DUX4-IHG translocation, expresses the DUX4 protein and an
ERG mRNA variant including the alternative exon 6. ERG deletions were pres-
ent in cell lines NALM-6 and SUP-B15. However, cell line SUP-B15 did not
express DUX4 protein and consequently also not alternative ERG exon 6 tran-
script. These results indicate that focal ERG deletions are not a safe indicator
for aberrant expression of DUX4. Cell line NALM-6 is presented as model sys-
tem for DUX4/ERG pre B-ALL.
References
1 Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, et al. Recur-
rent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents
and young adults. Nature Genetics 2016;48: 549-574.
2 Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, et al.
Deregulaton of DUX4 and ERG in acute lymphoblastic leukemia. Nature
Genetics 2016;48: 1481-1489.
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NATURAL HISTORY OF SECONDARY MULTILINEAGE PROLIFERATION
WITH MONOSOMY 7 FOLLOWING TREATMENT OF RELAPSED ACUTE
LYMPHOBLASTIC LEUKEMIA
J. Bulsa1,*, A. Pobudejska-Pieniążek1, L. Sędek2, A. Lopez3, M. Jara-Acevedo3,
A. Kowalska-Pawlak4, A. Sonsala1, A. Orfao3, T. Szczepański1
1Department of Pediatric Hematology and Oncology, Zabrze, Medical University
of Silesia, Katowice, Poland, 2Department of Microbiology and Immunology,
Medical University of Silesia, Katowice, Zabrze, Poland, 3Cancer Research
Centre (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca
(IBSAL); Department of Medicine and Cytometry Service (Nucleus Research
Support Platform), University of Salamanca (USAL), Salamanca, Spain,
4Genetic Laboratory, 1st Independent Public Clinical Hospital of the Medical
University of Silesia, Zabrze, Poland, Zabrze, Poland
Background: Approximately 90% of children with acute lymphoblastic leukemia
(ALL) are cured with current treatment protocols. However, 15-20% of the
patients still experience disease relapse. Moreover, a small subset of patients
develop secondary therapy-related leukemia or myelodysplasia.
Aims: We present a case of a 11-year-old boy with the history of relapsed ALL
followed by aberrant proliferation of several different subsets of precursor cells
in bone marrow (BM), which was associated with progressive ineffective
hematopoiesis.
Methods: A boy diagnosed with standard risk B-cell Precursor (BCP) ALL in
10-2009 was treated until 12-2011 with frontline chemotherapy according to
ALL-IC BFM 2002 protocol. In 12-2012, one year after treatment completion
he developed late combined ALL relapse (BM and testis). Unilateral orchidec-
tomy was performed, while the biopsy of the second testis showed no leukemic
infiltration. He received 2nd line chemotherapy according to IntReALL 2010 and
local radiotherapy for the testicular area. Despite the borderline minimal residual
haematologica | 2017; 102(s2) | 657
Madrid, Spain, June 22 – 25, 2017
disease (MRD) at the end of induction treatment, the SCT procedure wasn’t
executed due to the lack of suitable matched donor. In June 2014, during main-
tenance treatment, the patient showed persistent pancytopenia. 
Results: BM aspirate morphology showed 5% of blasts. However, detailed 8-
color flow cytometry according to the EuroFlow protocols revealed no cells
with BCP-ALL-specific immunophenotype, but several subsets of BCP with
abnormal maturation (total 3.5%) and plasmacytoid dendritic cell precursors
(2.1%). After cessation of maintenance therapy in 02-2016, continuous pro-
gression of infiltration was observed. Subsequent BM aspirates revealed
increasing proliferation of five different cell populations which show rare, aber-




SSClow), and B3 (CD34-/CD19dim/CD10dim/CD20-). The fourth population
corresponded to non-lymphoid/non-dendritic cell precursors (CD34+/CD19-
/CD10-/CD20-/nTDT-/CD22-/CD38++/CD117-/CD123-/HLA-DR++/SSChigh)
and the fifth population showed the features of plasmacytoid dendritic cell pre-
cursors with aberrant CD10 expression (CD34+dim/CD19-/CD10+/CD20-
/nTDT-/CD22+/CD38+dim/CD117-/CD123++/HLA-DR+/SSC intermediate).
Analysis of clonality via PCR assessment of IGH gene rearrangements
revealed polyclonal pattern in all BCP subsets. Cytogenetic analysis showed
an altered 45,XY,del(4)(q31?),-7,der(9) [20] karyotype, while interphase FISH
showed monosomy 7 in >80% of all BM cells. Retrospective FISH analysis at
1st relapse showed normal chromosome 7 in all cells. CytoScan® 750K array
(Affymetrix®) analysis in 10 sorted cell populations showed a complex kary-
otype highlighting monosomy of chromosome 7 and loss of chromosome 4q
(del4q21.1-q25; 40Mb) associated with gain of chromosome 14 (14q32.33;
200Kb). In addition, several gains of minor chromosomal regions were detected
in CD34+/CD19-/CD10- and CD34+/CD10+/CD19- cells. Due to progressive
increase of all subsets of abnormal precursor cells (27,5% in total) and
hepatosplenomegaly, further treatment direction was set at haploidentical stem
cell transplantation.
Summary/Conclusions: We present an abnormal secondary proliferation,
with increased numbers of aberrant BCP, myeloid and plasmacytoid dendritic
cell precursors resulting from stem cell defect hallmarked by monosomy 7.
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IDENTIFICATION OF KEY GENES AND CONSTRUCTION OF
MICRORNA–MRNA REGULATORY NETWORKS IN MULTIPLE MYELOMA
BY INTEGRATED MULTIPLE GEO DATASETS USING
BIOINFORMATICS ANALYSIS
Z. Chi1,*, Z. Gong2,3, W. Yang2
1Pediatric Hematology, 2Hematology, Shengjing Hospital of China Medical Uni-
versity, Shenyang, China, 3Hematopathology, The University of Texas MD
Anderson Cancer Center, Houston, United States
Background: T cell acute lymphoblastic leukemia (T-ALL) is a hematopoietic
clonal malignancy caused by the malignant transformation of T lymphocyte
driven by gene mutation. The prognosis of T-ALL is poor and early relapse is
common.
Aims: We aimed at looking for specific and effective therapeutic target for T-
ALL and eventually cure this form of leukemia by targeted therapy.
Methods: Bone marrow mononuclear cells (BMMC) are collected from bone
marrow samples of T-ALL patients, including at initial presentation (n=46), dur-
ing first CR (n=23) and at relapse (n=6). The expression level of mRNA encod-
ing L-cellular Fas-associated death domain-like interleukin-1β converting
enzyme inhibitory protein (c-FLIP) was assessed by realt time PCR. Changes
in the expression level of HDAC before and after chidamide treatment were
also assessed by western blot. Necroptosis  and apoptosis after chidamide
treatment were assessed by flow cytometry. Changes in expression level of c-
FLIPL protein before and after treatment were assessed by western blot.
Expression level of early apoptotic protein, key proteins of necroptosis were
assessed by western blot.The effect of chidamide on NF-κB signaling pathway
activity and expression of key molecules when inducing necroptosis were
assessed by western blot. The regulating effect of chidamide on downstream
genes of NF-κB pathway including cyclinD1, TNFα, lL-2, IL-8 were assessed
by real- time PCR. 
Results: The expression level of c-FLIPL mRNA is significantly higher in
patients at initial presentation and relapse, compared to those at complete
remission and healthy control. The expression level of c-FLIPL mRNA is asso-
ciated with patient risk stratification, white blood cell count at initial presentation,
serum level of lactate dehydrogenase (LDH), serum level of hydroxybutyrate
dehydrogenase (HBDH), CD45, HLA-DR, SIL-TAL1 fusion gene and complex
karyotype, and is not associated with age, sex, plasma fibrinogen level, and
the chromosomal aberration 6q-. Patients who did not achieve CR during first
chemotherapy had a higher c-FLIPL mRNA level than those who did
(p<0.05).The expression level of histone deacetylase is higher in bone marrow
mononuclear cells of T-ALL patients, Jurkat and HUT-78 cell lines. After treat-
ment with chidamide, the expression level of histone deacetylase was signifi-
cantly decreased in both cell lines.Chidamide induced necroptosis and apop-
tosis in Jurkat and HUT-78 cell lines. After apoptosis inhibitor was applied, chi-
damide mainly exert its effect of inducing cell death by inducing necroptosis.
Chidamide inhibits the transduction and translation to c-FLIPL gene. When
apoptosis is inhibited, chidamide upregulates the expression level of receptor-
interacting protein 3 (RIP3) and the phosphorylation level of mixed lineage
kinase domain-like (MLKL). After treatment with chidamide, the phosphorylation
level of I-κB and p65 protein were both significantly decreased.
Summary/Conclusions: c-FLIPL mRNA expression level is abnormally high
in T-ALL patients both at initial presentation and at relapse. The expression
level of c-FLIPL is associated with risk stratification, white blood cell count,
serum LDH level, serum HBDH level, CD45, SIL-TAL1 fusion gene, complex
karyotype and disease outcome. c-FLIPL could be used as a prognostic marker
in T-ALL.Chidamide suppresses histone deacetylation in Jurkat and HUT-78
cell lines.Chidamide induces necroptosis in Jurkat and HUT-78 cell lines by
down regulating the transcription and translation of c-FLIPL gene.Chidamide
induces necroptosis in Jurkat and HUT-78 cell lines via the classical NF-κB
signaling pathway.
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CYP1A1 AND CXCL12 GENE POLYMORPHISMS IN CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKEMIA 
E. Kampouraki1, M. Lourou1, E.-D. Ampazoglou 1, M. Karachaliou1,
E. Stiakaki1,*
1Pediatric Hematology - Oncology, University Hospital of Heraklion, University
of Crete, Heraklion, Greece
Background: Acute lymphoblastic leukemia (ALL) is the most common type
of childhood leukemia and represents one third of all pediatric malignancies.
Despite the high survival rates (more than 80%), a noteworthy number of chil-
dren relapse and for them the outcome remains poor. Epidemiological studies
that examined possible risk factors of acute leukemias, proved that genetic
factors play a crucial role in leukemogenesis.  Recent genetic association stud-
ies on cancer risk, have focused on the effects of single nucleotide polymor-
phisms in genes that regulate  inflammation and tumor suppression such as
chemokines and P450 cytochrome.  Chemokines induce the motility of
endothelial and tumor cells.  CXCL12, a chemokine expressed in various
tumors, binds to chemokine receptor 4 (CXCR4) and is considered to play an
important role in tumor growth and invasion. The polymorphism rs1801157 of
this gene have been investigated concerning the disease pathogenesis. More-
over, CYP1A1 gene belongs to family 1, subfamily 1A1 of cytochrome
P450.  CYP1A1 protein is a phase I xenobiotic metabolizing enzyme that acti-
vates the conversion of environmental chemicals into carcinogens. The above
gene contains two important single nucleotide polymorphism, CYP1A1*2A
(rs4646903) and CYP1A1*2C (rs1048943), which are associated with an
increased risk of leukemia.
Aims: The study of single nucleotide polymorphisms rs1801157 of CXCL12
and CYP1A1*2C (rs1048943)  in children with B-lineage ALL . 
Methods: Thirty children with B- lineage ALL (19 boys, mean age 6.8 years)
were included in the present study and 70 healthy individuals (20 children and
50  adults  blood donors) as control group. Genomic DNA was isolated from
peripheral blood of participants and was analyzed for the existence of poly-
morphisms rs1801157 of CXCL12, and CYP1A1*2C (rs1048943) with Poly-
merase Chain Reaction (PCR). The PCR products were digested with the
restriction enzyme MsPI for CXCL12 and BsrDI for CYP1A1. Descriptive sta-
tistics and logistic regression analysis were used to examine for differences
between children with ALL and controls.
Results: In the CXCL12 loci, the frequencies of AA, AG, and GG genotype
were 3.45%, 93.1% and 3.45% in children with ALL, 13.3%, 60.0%, 26.7% in
children control group and 4.17%, 45.83% and 50.0% in adult control group
respectively. In the CYP1A1 loci, the frequencies of AA, AG, and GG genotype
were 13.3%, 86.7% and 0% in children with ALL, 90.0%, 10.0%, 0% in children
control group and 81.6%, 16.4% and 2.0% in adult control group respectively.
No statistical significant differences in CXCL12 polymorphism were revealed
between children with ALL and healthy groups using logistic regression analy-
sis. Regarding CYP1A1 loci, we detected a positive association for the AG
polymorphism and ALL [OR: 37.7 (95% CI: 10.81, 131.37), p<0.001 and OR:
58.5 (95% CI: 9.66, 354.12), p<0.001 using only the children’s control group].
Summary/Conclusions: A higher frequency of CYP1A1 heterozygote allele
was observed among children with ALL compared to controls, whereas no dif-
ferences were observed regarding CXCL12 polymorphisms.  Future  studies  in
larger populations are needed in order to specify the role of the above poly-
morphism in childhood ALL.
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INTRACHROMOSOMAL AMPLIFICATION OF CHROMOSOME 21 IN
PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA; A RARE SUBTYPE
L. Vida1,*, A. Burján1, B. Horváth1, L. Kereskai1, G. Ottóffy2, L. Tiszlavicz3,
D. Alpár4, B. Kajtár1
1Pathology, 2Pediatrics, University of Pécs, Pécs, 3Pediatrics, University of
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Background: Intrachromosomal amplification of chromosome 21 (iAMP21)
defines a rare subtype of pediatric acute lymphoblastic leukemia (pALL) occur-
ring in approximately 2-3% of cases. The patients are older (median age is 9
years), usually have low white blood cell counts and show high relapse risk
with standard therapy. Thus, it has been proposed to include ALL with iAMP21
as a distinct entity in the WHO classification of hematological malignancies. 
Aims: To assess the frequency as well as the clinicopathological and genetic
characteristics of ALL with iAMP21 in one of the three national diagnostic cen-
ters of pALL in Hungary. We sought to determine additional genetic aberrations
associated with this rare entity.
Methods: Between 2008-2016, 175 samples of pALL patients were tested with
FISH for BCR-ABL1, ETV6-RUNX1 and MLL translocations. When available,
bone marrow karyotyping was used to verify the abnormal results. In one case
with iAMP21, multiplex ligations-dependent probe amplification (MLPA) was
used to verify the cytogenetic aberrations as well as to detect associated copy
number alterations.
Results: Among the 175 samples screened with FISH, three showed evidence
of iAMP21 (1.7%). Case 1 was a 16-year-old male who presented with throm-
bocytopenia and hepatosplenomegaly. Flow cytometry (FCM) showed common
ALL phenotype with the expression of CD13 and CD33. FISH showed >10
RUNX1 signals in clusters in leukemic blasts, while karyotyping demonstrated
r(21) with 7q deletion and +X. The lesions were verified by MLPA, which addi-
tionally revealed biallelic CDKN2B and RB1 deletions. The patient was treated
with ALL-IC BFM 2002 standard risk protocol. Following remission, isolated
meningeal relapse occurred, for which he received radiotherapy. The patient
died with recurrent meningeal disease without bone marrow involvement after
52 months. Case 2 was an 11-year-old girl, who presented with symptoms sug-
gesting osteomyelitis of the tibia with unremarkable blood count. MRI showed
multiple lesions in vertebrae as well as meningeal involvement of the spinal
cord. Bone marrow biopsy and biopsy of the left tibia showed diffuse infiltration
of lymphoblasts with only 5% leukemic cells in bone marrow aspirates. FISH
detected 6-8 copies of RUNX1 in leukemic blasts, while karyotyping yielded
only normal bone marrow cells. She was commenced on ALL-IC BFM 2002
standard risk and was later switched to high risk protocol. She is in complete
remission after 14 months. Case 3 was an 11-year-old boy who presented with
anemia and thrombocytopenia. FCM showed ALL with common phenotype with
two populations; one being strong CD19+/CD66c+ and one with dim
CD19+/CD66c-. FISH showed >10 RUNX1 signals in clusters in 95% of cells,
while 52% showed BCR-ABL1 positivity. Bone marrow karyotyping yielded
metaphases of poor quality (Figure 1).
Figure 1.
Summary/Conclusions: ALL with iAMP21 is a rare subtype with distinct clin-
icopathological characteristics. Presenting with only mildly elevated WBC in
older children is typical, relapses are frequent if standard risk chemotherapy is
administered. Association with BCR-ABL1 translocation is rare, having been
reported so far in only 4 cases. Observing BCR-ABL1 translocation in a sub-
population of leukemic cells is an intriguing phenomenon; it indicates that this
translocation may occur as a secondary event even after leukemic transforma-
tion has commenced.
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HIGH RESOLUTION TECHNOLOGIES IN B-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA 
A. Escudero1,*, P. Carrasco1, J. Nevado1, M. Palomares1, E. Vallespín1,
P. Lapunzina1, L. Fernández2, M. Vela3, I. Gonzalo1, B. González4, D. Bueno4,
Á. del Pozo1, A. Pérez-Martínez4
1INGEMM, Hospital Universitario la Paz, 2Clinical Research, CNIO, 3IdiPAZ,
4Pediatric Hemato-Oncology, Hospital Universitario la Paz, Madrid, Spain
Background: B-cell acute lymphoblastic leukemia (B-ALL), the most common
pediatric malignancy and main case of childhood cancer death, resulting from
accumulation of genetic aberrations. Advances in our understanding of these
aberrations is useful to improve disease classification, prognosis, therapeutic
purposes, and to provide an overall understanding of the pathogenesis of the
B-ALL.
Aims: Genomic characterization of childhood B-ALL.
Methods: We retrospectively examined bone marrow samples from 29 pediatric
B-ALL using high resolution technology. We study copy number alteration
(CNAs) and copy neutral loss of heterozygosity (CN-LOH) using Illumina
CytoSNP-850K BeadChip in the Illumina HiScan platform. Analysis of more
than 90 genes related with pediatric cancer was done using Next Generation
Sequencing (NGS). 
Results: Except for one, all patients showed copy number alterations. Losses
were more common than gains. Whole and partial CN-LOH were observed in
12 cases. Only four recurrent genetic alterations were found: hyperdiploidy
(44% of the cases), deletion of CDKN2A/B genes (22%), deletion of PAX5 gene
(16%) and deletion of ETV6 (9%) gene. Several possible target genes were
identified, including SESN1, NME1 and BMPR1B, but additional studies are
needed to confirm their implication in the disease. We identified high diversity
of mutations 30 genes, 40% of all mutations are previously described in cancer
patients. We found several mutations in Jak gene family in 5 patients that could
have been the subject of therapeutic intervention with specific inhibitors of these
kinases. 
Summary/Conclusions: NGS and SNP arrays are powerful genetics tools capa-
ble of identifying a multitude of genetic alterations associated with B-ALL. The
use of SNP arrays and NGS in clinical practice can help identify new prognostic
alterations and develop individualized treatment plans for affected children.
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COMPLETE REMISSION WITH BLINATUMOMAB IN TWO PATIENTS WITH
SKIN RELAPSED B-CELL ACUTE LEUKEMIA
H. Leroy1,*, M.-L. Jullie1, E. Forcade1, G. Laboure1, R. Tabrizi1, P.-Y. Dumas1,
M. Robles1, A. Chauvel1, B. Vergier1, N. Milpied1, A. Pigneux1, T. Leguay1
1CHU Bordeaux Haut lévèque, pessac, France
Background: Blinatumomab is a bispecific T cell–engager (BiTE) antibody
(CD19/ CD3) indicated in relapsed/refractory B-cell Acute Lymphoid Leukemia
(r/r ALL) (Topp et al.). Extra-medullary relapse is a rare event occurring in only
8% of the patients, of whom only 1.4% present a skin relapse which harbor a
dismal prognosis (Gokbuget et al.).  
Aims: Herein, we report the efficacy of Blinatumomab in two patients present-
ing with extra-medullary relapse of ALL.
Methods: The first patient (a 40-year-old man) was diagnosed a CD19+ Ph -
B-ALL in 2009. He received a chemotherapy regimen according to the GRAALL
protocol (Huguet et al.) until complete remission (CR). In 2015, he presented
with a maculopapular rash of the right leg and the left flank, and two enlarged
inguinal lymph nodes. Cutaneous relapse was attested by examination of skin
biopsy specimen showing a blastic dermal infiltration harboring a CD10+, Tdt+
phénotype. The second patient was a 50-year-old male who presented, in
2016, a CD19+ B-ALL Ph- Ikaros- without central nervous system involvement.
He obtained a first CR after GRAALL induction with negative MRD (IgH) but
he relapsed 3 months later with a maculopapular rash of his chest. The skin
biopsy revealed a blastic dermal infiltration. These two patients with skin relapse
received salvage chemotherapy (COPRAALL 2007 regimen) (Domenech et
al.), with no efficacy (cutaneous blastic infiltrate). Both patients received one
cycle of Blinatumomab from day 1 to day 28, at 28 µg per day, in an attempt to
achieve CR before allogeneic stem cell transplantation, as previously
described.
Results: At day 5 of Blinatumomab, an important non pruritic maculo-papular
rash occurred in both patient, in the same area of the initial cutaneous involve-
ment. Interestingly, it decreased after day 8. No new drug introduction or infec-
tion (bacterial, viral or parasitic) was documented in the days preceding or dur-
ing Blinatumomab infusion. A skin biopsy performed at day 6 of Blinatumomab
showed a more prominent dermal CD3+ lymphocytic infiltrate with a perivas-
cular, but also a peri-nervous distribution (on the first patient’s specimen only).
Few lymphocytes marginated at the basement membrane and rare basal
necrotic keratinocytes were also noted but without blast for the first, although
few residual blastic cells were observed on the second’s. One month later,
another skin biopsy showed a CR without lymphocytic infiltrate. The medullar
CR was confirmed at the molecular level (MRD negative). The first patient
received allogenic stem cell transplantation (SCT) from a matched related
donor one month later. He presented an acute and chronic GVHD, and is now
in complete remission with a follow-up of 7 months. The second is still waiting
for a SCT.
Summary/Conclusions: These observations confirm the strong efficacy of
Blinatumomab in r/r B-ALL. We observed a T-cell dermal recruitment 6 days
after Blinatumomab initiation clinically mimicking skin GVHD. However, we
couldn’t find specific histological features of GVHD, but only an “inflammatory
dermatosis”. Efficacy of Blinatumomab in relapsed B-ALL with cutaneous infil-
tration suggests promising activity in extra-medullary relapse. Further studies
are required to confirm a Blinatumomab-based strategy in extra medullary
relapsed B-ALL. This may provide a better understanding of how cytolytic
synapses between T lymphocytes and intradermal blasts happen and the
underlying homing mechanisms involved.
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A NOVEL METHOD FOR MINIMAL RESIDUAL DISEASE ANALYSIS IN
PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA:
MODIFIED BIOMED-2 POLYMERASE CHAIN REACTION FOR
IMMUNOGLOBULIN HEAVY CHAIN REARRANGEMENT
D. Katoh1,*, M. Nakamura1, M. Morita1, H. Maruoka2, A. Fujimoto1,
T. Yabushita1, Y. Shimomura1, Y. Ono1, N. Hiramoto3, S. Yoshioka1,
N. Yonetani1, A. Matsushita1, H. Hashimoto3, T. Ishikawa1
1Hematology, 2Clinical Laboratory, Kobe City Medical Center General Hospital,
3Cell Therapy, Institute of Biomedical Research and Innovation, Kobe, Japan
Background: Recent studies have demonstrated the clinical importance of
minimal residual disease (MRD) monitoring in adult acute lymphoblastic
leukemia (ALL) as well as pediatric ALL. However, patient-specific polymerase
chain reaction (PCR)-based MRD assessment, one of the most commonly rec-
ognized methods, is not widely used in clinical practice because it is expensive,
time consuming, and technically difficult. Therefore, we modified the BIOMED-
2 protocol, PCR for immunoglobulin heavy chain (IgH) rearrangement, to
assess MRD in ALL easily and readily in our hospital.
Aims: The aim of this study was to examine the clinical utility of monitoring
MRD by the modified BIOMED-2 PCR for IgH rearrangement in patients with
Philadelphia-negative (Ph (-)) ALL.
Methods: We enrolled 54 patients diagnosed with Ph (-) ALL between 2006
and 2016 in our hospital. IgH rearrangement was detected in 35 patients using
the standard BIOMED-2 PCR protocol. Patients who received palliative
chemotherapy, never achieved remission (blasts <5%), or had no follow-up
MRD data were excluded. Finally, data from 27 patients with Ph (-) ALL were
analyzed. We assessed MRD with the modified BIOMED-2 PCR for IgH using
bone marrow samples collected after each chemotherapy session. Patients’
MRD statuses were classified as follows: Early MRDneg, achievement of MRD
negativity within 6 weeks after chemotherapy initiation; Late MRDneg, achieve-
ment of MRD negativity more than 6 weeks after chemotherapy initiation; or
MRDpos, persistent MRD detection during chemotherapy. The endpoint was
disease-free survival (DFS), calculated from the date of achieving remission.
Results: The median age was 38 years (16–73), and the median follow-up
time was 47 months (4–106). There were 8, 14, and 5 patients with early MRD-
neg, late MRDneg, and MRDpos, respectively. There were no differences in
patient characteristics by bone marrow status, except for the duration to achiev-
ing remission (Table 1). There were significant differences in the 3-year DFS
rates among patients with early MRDneg, late MRDneg, and MRDpos (100% vs
72.9% vs 20%; p<0.001) (Figure 1). Patients undergoing transplantation had
better prognosis than those receiving chemotherapy alone in the late MRDneg
group (100% vs 40%, p=0.028), whereas there was no difference in the early
MRDneg group (100% vs 100%, p=0.48).
Table 1. Patient characteristics by MRD status as assessed with the mod-
ified BIOMED-2 PCR for IgH protocol.
* WBC risk: B >3 × 104/μL, T >10 × 104/μL.
** Cytogenetic risk: Hypodiploidy, complex karyotype, MLL rearrangement.
*** Achievement of remission after 2 cycles of chemotherapy.
MRD, minimal residual disease; PCR, polymerase chain reaction; IgH, immunoglobulin heavy
chain; M, male; F, female; WBC, white blood cell; CR, complete remission.
Figure 1. The status of minimal residual disease was associated with
prognosis.
Summary/Conclusions: The modified BIOMED-2 PCR protocol is a highly
accurate and reliable method of MRD assessment in adult ALL. It predicted
treatment outcomes in adult Ph (-) ALL, and patients with late MRDneg might
derive a high survival benefit from allogeneic transplantation. Finally, the accu-
racy and reliability of the modified BIOMED-2 PCR for IgH were confirmed with
a comparison to quantitative real-time PCR for BCR-ABL using samples from
patients with Philadelphia-positive ALL (data not shown).
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SYSTEMATIC LITERATURE REVIEW OF PEGASPARGASE FOR THE
TREATMENT OF NEWLY DIAGNOSED ADULTS WITH ACUTE
LYMPHOBLASTIC LEUKEMIA
E. Hooper1,*, A. Wijatyk1, D. Bollag2
1Shire, Cambridge, United States, 2Shire, Zählerweg, Switzerland
Background: Asparaginase is a component of a multi-agent chemotherapy
regimen and is now a cornerstone treatment for patients with acute lymphoblas-
tic leukemia (ALL). Since 2006, pegaspargase (PEG-ASP) has been the gold
standard asparaginase for the treatment of pediatric ALL as it offers equivalent
efficacy to native E. coli L-asparaginase (native ASP), with less frequent dosing,
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an IV administration option, and improved immunogenicity. Clinical outcomes
in the adult ALL population are less well understood. 
Aims: To assess the relative clinical benefit of PEG-ASP vs native ASP in 1st
line treatment in newly diagnosed adult ALL patients in terms of event-free sur-
vival (EFS) and overall survival (OS). Safety outcomes were also examined.
Methods: A systematic literature search was conducted using a standardized
search algorithm within the constraints of the National Library of Medicine data-
base to identify available evidence for newly diagnosed patients treated with
adult ALL protocols that use PEG-ASP or native ASP. Randomized, observa-
tional, and cohort studies were included, with the predefined clinical outcomes
of event-free-survival (EFS) and overall survival (OS). Data was pooled with
95% confidence intervals (CIs) calculated using the logit transformation.
Results: A total of 30 studies were identified that met the pre-specified inclusion
criteria, with 10 studies providing data for PEG-ASP and 23 studies for native
ASP. The pooled estimate of 2-year EFS for adult ALL patients treated in 1st
line with asparaginase was 48.0% (95% CI: [10.8; 85.2) for PEG-ASP and
66.0% (95% CI: [52.0; 77.0]) for native ASP.
The pooled estimate of 2-year OS for adult ALL patients was 62.8% (95% CI:
[27.7; 97.9]) for PEG-ASP and 47.3% (95% CI: [8.5; 89.7]) for native ASP. Sim-
ilarly, the pooled estimate of 5-year OS was 64.5% (95% CI: [61.5; 67.5%]) for
PEG-ASP and 46.8% (95% CI: [33.6; 60.1]) for native ASP. In very high risk
ALL patients, the pooled estimate of 5-year OS was 57.1% (95% CI: [52.4;
61.7%]) for PEG-ASP and 35.3% (95% CI: [21.7; 51.7]) for native ASP.
Findings for safety outcomes were consistent with product labeling for both
asparaginases. 
Summary/Conclusions: The systematic literature review highlights a positive
clinical effectiveness profile for PEG-ASP in regards to EFS and OS in the
treatment of newly diagnosed adult ALL patients with less frequent administra-
tion and similar safety profile as compared with native ASP.
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A COMPREHENSIVE ANALYSIS OF PATIENT- AND THERAPY-RELATED
FACTORS AFFECTING THE TOXICITY OF PEGYLATED-ASPARAGINASE
FOR THE TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
P. Minetto1,*, N. Bisso1, F. Guolo1, M. Clavio1, E. Coviello1, D. Guardo1,
N. Di Felice1, F. Canale1, L. Manconi1, F. Ballerini1, M. Miglino1, R. M. Lemoli1,
M. Gobbi1
1Clinic of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, IRCSS AOU San Martino-IST, Genoa, Italy
Background: The application of pediatric regimens in the treatment of adult
acute lymphoblastic leukemia (ALL) has led to a significant improvement in
patients outcome. However, concerns about the feasibility of more intensive
therapies and of the use of pegylated L-Asparaginase (PEG-ASP) in adult
patients have emerged. Some patient-related risk factors as high BMI or hepatic
steatosis have been already identified as risk factors, but few data are available
on the synergic toxic effect from other concomitant drugs.
Aims: The aim of the present study was to evaluate the incidence of PEG-ASP
related adverse events in a cohort of adult ALL patients in order to identify
potential patient and therapy-related risk factors contributing to toxicity.
Methods: Since 2013, 21 adult ALL patients received PEG-ASP therapy in our
institution. Median age was 44 (range 19-76); 12 patients were treated in front-
line setting (7 according to a full pediatric protocol) whereas 9 patients received
therapy for relapsed/refractory neoplasm. We retrospectively analyzed each
single course which included PEG-ASP administration as an independent
event, accounting 41 episodes. Patients’ features (age, BMI, disease status)
and concomitant therapies were accurately analyzed as factors potentially
affecting PEG-ASP toxicity. The incidence of major thrombotic/bleeding com-
plications and grade III/IV hepatic or pancreatic toxicity was analyzed; toxicity
grading and management of PEG-ASP related complications were performed
according to guidelines recently published by Stock et al.
Results: No grade III/IV pancreatic, thrombotic or hemorrhagic adverse events
were recorded. A total of 8 episodes of grade III/IV hepatic toxicities were
observed. In 3 cases, grade IV toxicity was observed. Those patients experi-
enced unexplained severe weight gain and painful epathomegaly, a clinical pic-
ture resembling sinusoidal occlusive disease, ultrasonography showed acute
liver steatosis. All 3 patients received concomitant therapy with idarubicin, vin-
cristine and vancomycin. In univariate analysis, the incidence of grade III/IV
hepatic toxicity was significantly higher when concomitant chemotherapy with
at least 2 mg/sqm cumulative dose of vincristine (p 0.044, HR 4.75) or at least
16 mg/sqm cumulative dose of idarubicine (p 0.046, HR 1.45) were adminis-
tered. Steroids therapy determined a borderline increase in toxicity risk (p 0.068,
HR 1.688). No increase in toxicity was observed with any dosing of daunoru-
bicin, cyclophosphamide, cytarabine, methotrexate and 6-mercaptopurine
(Table 1). Among concomitant antibiotic therapies, vancomycin administration
seemed to increase the  incidence of grade III/IV hepato-toxicy (p 0.02, HR
1.863). No significant increase was observed with carbapenems and azoles
(Table 1). Older age (>45), receiving PEG-ASP with active leukemia or a high
BMI (>25) were not related with an increased incidence of grade III/IV hepato-
toxicity (Table 1). Notably, none of the patients undergoing full pediatric induction
(who received the highest doses of PEG-ASP), regardless of age (ranging from
21 to 55) experienced grade III/IV hepatotoxicity. A multivariate logistic regres-
sion analysis disclosed that concomitant administration of idarubicin, vincristine
or vancomycin were independent predictors of grade III/IV hepatotoxicity (p
0.004, 0.027 and 0.042, respectively, Table 1).
Table 1.
Summary/Conclusions: Our data show that the toxicity profile of PEG-ASP
in adult patients is overall manageable. However, serious warnings emerge
from our experience. Concomitant drugs and their timing of administration may
play a crucial role in significantly contributing to PEG-ASP hepatic toxicity. In
order to attempt to reduce toxicity, anthracyclines with shorter half-life, i.e.
daunorubicin instead of idarubicin, should be used. A particular attention should
be paid when administration of concomitant antibiotic therapy is required.
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COST OF CARE FOR ADULT PATIENTS WITH RELAPSED ACUTE
LYMPHOBLASTIC LEUKEMIA WITH AND WITHOUT HEMATOPOIETIC
STEM CELL TRANSPLANT IN GERMANY
Y. Su1,*, S. Schmitter2, A. Navarro3, L. Mayerhoff3, S. Prieur3, M. Lehne3,
F.R. Loberiza1
1Pfizer Inc., New York, United States, 2Pfizer Deutschland GmbH, 3Elsevier
Health Analytics, Berlin, Germany
Background: Adult ALL is a rare but frequently fatal disease. Many patients
who respond to initial therapy experience a relapse. For relapsed ALL (rALL),
hematopoietic stem cell transplant (HSCT) is a potentially curative treatment
option. HSCT is associated with added costs, however, which could impact
overall healthcare budget.
Aims: This retrospective observational study aims to determine the cost of
care and the impact of HSCT on total cost for adult rALL patients from a German
payers’ perspective.
Methods: A German claims database with a representative sample of approx-
imately 7 million individuals insured within the German statutory health insur-
ance and continuously observable over a period of 6 years was used as data
source. From these data, adult patients (18 years and older) with a new diag-
nosis of ALL (ICD-10-GM code: C91.0*) between January 1, 2011 and Decem-
ber 31, 2015 and a relapse after remission to initial treatment were identified.
Mean health care cost per patient per quarter, the smallest unit of time available
in the database, was determined by whether or not patients had an HSCT after
relapse. Costs were considered from the perspective of the German statutory
health insurance and included costs for prescription medicine as well as out-
patient and inpatient healthcare encounters.
Results: Of the total 116 incident adult ALL patients identified, 29 (25%) were
determined to have had a relapse and 11 underwent HSCT after relapse (38%).
Patients with an HSCT appear to incur higher cost than those without HSCT in
each of the quarters after relapse was diagnosed (Table 1), with the highest in
the first quarter after relapse, but decreasing in subsequent quarters. Inpatient
cost accounted for the majority of the cost for the first three quarters for both
HSCT and non-HSCT patients, but more for HSCT patients. The number of
patients in the HSCT cohort remained relatively stable, while the non-HSCT
cohort had only half the patients left by the third quarter post relapse.
Table 1. Costs in € per patient (with and without HSCT) by quarter after
relapse
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Summary/Conclusions: The results of this study inform the magnitude of cost
in Germany associated with adult rALL patients with or without an HSCT after
relapse. The cost estimates provide a benchmark against which new treatment
options for rALL can be compared. For future studies, it would be important to
determine the magnitude of benefit such as long-term survival and other health
consequences associated with HSCT as well. 
PB1634
RETROSPECTIVE STUDY OF ADULT ALL IN MEXICO CITY:
FIRST REPORT OF THE WORKING GROUP ON ACUTE LEUKEMIA
E. Crespo-Solís1,*, K. Espinosa-Bautista2, M. Alvarado-Ibarra3,
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1Department of Hematology and Oncology, Hospital Regional de Alta Espe-
cialidad Ciudad Victoria, Victoria, 2Department of Hematology and Oncology,
Instituto Nacional de Cancerología, 3Department of Hematology and Oncology,
Centro Médico Nacional 20 de Noviembre, ISSSTE, 4Department of Hematol-
ogy and Oncology, Hospital General de México, 5Department of Hematology
and Oncology, Centro Médico Nacional Siglo XXI, IMSS, 6Department of
Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición
Salvador Zubirán, Mexico City, Mexico
Background: The prognosis of adult acute lymphoblastic leukemia (ALL) is
dire, with a long-term survival of 40-50%. This disease entity is probably more
frequent in the Latino population. Several studies have reported a worse prog-
nosis in Hispanics with ALL as well as a greater incidence of the Ph-like genetic
signature; however, the data is inconclusive in the Mexican population and
there are no existing large multicenter series of ALL patients in Mexico that
analyze survival.
Aims: The aim of this study was to describe the incidence, clinical and biologic
characteristics as well as the survival of ALL patients in 5 referral hospitals in
Mexico City.
Methods: A working group known as the Grupo de Trabajo de Leucemia Aguda
(GTLA), was created as a result of an initiative of the Mexican Group for the
Study of Hematology (Agrupación Mexicana para el Estudio de le Hematología)
to promote acute leukemia research in Mexico. This is the first report of the
GTLA which includes 5 referral hospitals in Mexico City. A retrospective, mul-
ticenter, descriptive study of adult ALL patients treated between 2009 and 2015
was conducted.
Results: We included 559 adults in 5 centers in Mexico City. Their median
age was 28 years (14-81): adolescents and young adults (AYA) 67.3%; adults
24.7% and elderly adults 8.1%. Tumor lysis syndrome was detected in 9.8%
of all cases. Cytogenetic information was unavailable in 45% of cases due to
lack of access or growth in metaphase. Among cases that could be analyzed,
a normal karyotype was the most frequent (70.5%), followed by Ph+ (16.7%).
Patients were considered high-risk in 52.1% cases. The most frequently used
drug protocol was Hyper-CVAD, in 47% of cases. Complete remission (CR)
was achieved in 67.1% of patients, and 18% required a second cycle for CR,
while 13% were primarily refractory. A mortality rate during induction was reg-
istered as 10.6%, and there were 11.4% deaths while in CR. Among patients
in CR, 59.1% relapsed. At the time of analysis, 26.7% of patients were alive,
with a median OS of 12.97 months and a DFS of 16 months. Only 5.7% were
able to receive an allogeneic hematopoietic progenitor cell transplant (AlloH-
PCT). OS at 3 years was 22.1% and by age group: AYA 25.7%, adults 17.4%
and elderly adults 0% (p=0.0001). On multivariate analysis, significant risk fac-
tors for OS were the age group, ECOG, the presence of the tumor lysis syn-
drome and liver function test abnormalities while protective factors included
early CR and an AlloHPCT.
Summary/Conclusions: Outcomes are poor in adult ALL patients treated in
these referral centers in Mexico City. This may be explained by the high inci-
dence of AYA patients and the low frequency with which they are treated with
regimens containing L-asparaginase. The incidence of the Philadelphia chro-
mosome is lower than reported, which could be due to a real difference between
populations or due to aspects related to cytogenetic techniques. Based on
these results, the GTLA´s objectives will be: to standardize diagnostic testing
(immunophenotype and cytogenetics), improve early CR rates, standardize
support care to decrease deaths during induction as well as treatment -related
deaths, and increase the percentage of patients treated with AlloHPCT. Studies
to determine the prevalence of the Ph-like genetic signature will be of great
relevance in our population. 
ClinicalTrials.gov Identifier: NCT02990104TRIAL
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IMPACT OF DISEASE STATUS ON OUTCOMES OF ALLOGENEIC 
HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH REFRACTORY
AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMI
J. Cao1, X. Zhu1, A. Sun1, H. Qiu1, Z. Jin1, M. Miao1, D. Wu1,2, X. Tang1,2,*
1The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, 2Institute of Blood and Marrow Transplantation,Collaborative Innovation
Center of Hematology, Soochow University, Suzhou, China
Background: Refractory or relapse remains a major obstacle in improving
outcomes of patients with acute lymphoblastic leukemia (ALL). And allogeneic
hematopoietic stem cell transplant (allo-HSCT) was the only curative treatment
option for these patients. However, whether an allo-HSCT was performed in
status of advanced stage or in setting of remission after salvage chemotherapy,
there is no standard of care.
Aims: To evaluate the impact of disease status on the outcomes of allo-HSCT
in the treatment of patients with refractory and relapsed ALL.
Methods: 52 patients with refractory and relapsed ALL, including 19 cases in
advanced stage (nonremission,  NR) and 33 cases in more than or equal to
second complete remission(≥CR2), received allo-HSCT after myeloablative
conditioning regimen in our department.
Results: 51 patients engrafted successfully. The transplantation-related mor-
tality (TRM) rate of NR and ≥CR2 was 10.5% vs 12.1% (P=0.815). The inci-
dence of aGVHD was 52.6% vs 57.6% (P=0.730), including 42.1% vs 33.3%
(P=0.527) with mild (grade I-II) and 10.5% vs 24.3% (P=0.399) with severe
(grade III-IV) aGVHD. The incidence of cGVHD was similar also(41.6% vs
57.9% ,P=0.660). With a median follow-up of 12(1.8-44.5) months, the cumu-
lative relapse rate of NR and ≥CR2 was 47% vs 34.3%P=0.425) respectively.
The estimated 2 year overall survival (OS) and 2 year leukemia-free survival
(LFS) rate were 42.6% vs 45.7% (P=0.487) and 46.3% vs 46.2% (P=0.571)
respectively. Multivariate Analysis results showed that   cGVHD was independ-
ent favorable risk factor for OS and LFS of R/R ALL For relapsed patients,
OS was significantly better with first CR duration>6 month and time to trans-
plant≤2 months.
Summary/Conclusions: AlIo-HSCT is an effective salvage treatment option
for patients with refractory and relapsed ALL. Our retrospective analysis
showed that R/R ALL with different status prior transplant had similar outcome
post transplantation.
PB1636
THE FREQUENCY AND PROGNOSTIC SIGNIFICANCE OF IKZF1
DELETIONS IN ADULT PH-POSITIVE AND PH-NEGATIVE B-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED IN RUSSIAN ACUTE
LYMPHOBLASTIC LEUKEMIA STUDIES.
G. Baskhaeva1,*, B. Biderman1, O. Gavrilina1, K. Zarubina1, I. Lukyanova1,
E. Stepanova1, V. Troitskaya1, A. Sudarikov1, E. Parovichnikova1
1Hematological Research Center under the Ministry of Health, Moscow, Russ-
ian Federation
Background: The incidence of IKZF1 gene deletions is approximately 20% in
adult patients with BCR-ABL1- negative B-cell ALL and 70–80% in BCR-ABL1-
positive ALL. These mutations are associated with poor prognosis in patients
with Ph-negative ALL, but not in patients with Ph-positive ALL, suggesting that
IKZF1 deletions may be more prognostically valuable in patients with Ph-neg-
ative ALL.
Aims: To evaluate the frequency and prognostic impact of mutation status of
IKZF1 in patients with de novo BCR-ABL1-negative and BCR-ABL1-positive
B-cell acute lymphoblastic leukemia.
Methods: The study included 36 adult patients (median age 27, range 17-56;
m:f=15:21) with newly diagnosed BCR-ABL1- neg B-cell ALL and 15 patients
(median age 34 years, range 22–68; m:f=6:9) with BCR-ABL1- pos B-cell ALL,
who were enrolled in Russian acute lymphoblastic leukemia (RALL) - 2009
[ClinicalTrials.gov public site; NCT01193933] and RALL-2012 protocols since
Feb 2010 till Sep 2016 and Aug 2009 till Feb 2017, respectively.
Intragenic deletions of IKZF1 were detected using breakpoint-specific fluores-
cent multiplex polymerase chain reaction according to the procedure described
by [Aurelie Caye et al, Haematologica, 2013]. DNA for PCR was extracted from
leukemia cells of frozen bone marrow samples. 
Results: The IKZF1 deletions were detected in 7 (47%) of 15 patients with
BCR-ABL1- pos ALL (3 cases with del 4-7 (43%), 2 – del 2-7 (28%), 1 – del
2a-8 and 1 – del 4-8 (14%)). The median follow-up time in 15 patients was
18 months (range: 4-79 month). Five patients died (33%) after relapse or
progression of the disease, and 10 patients are alive. Overall survival (OS)
in BCR-ABL1 - pos B-cell ALL patients with IKZF1 mutations and without
was 37,5% and 57,1% (p=0,77), relapse - free survival (RFS) - 25% and
33,3% (p=0,88), respectively. In patients with BCR-ABL1- neg ALL the IKZF1
deletions were revealed in 8 (22%) of 36 patients (4 cases with del 4-7
(50%), 2 - del 2-7 (25%), 1 – del of 2-8 (12,5%) and in 1 patient all types of
deletions were determined (del 4-7, del 4-8, del 2-7, del 2-8)). The median
follow-up time in 36 patients was 22 months (range: 0,5-84 month). 4
patients died of the disease (11%) and 2 of infections, 30 patients are alive.
OS for patients with BCR-ABL1- neg ALL with IKZF1 mutations and without
was 100% and 60,2% (p=0,77), RFS - 75% and 40,2% (р=0,74), respec-
tively. (Figure 1).
Summary/Conclusions: The frequency of IKZF1 gene deletions in patients
with BCR-ABL1- pos and with BCR-ABL1- neg ALL was 47% and 22%,
respectively. IKZF1 mutations seemed to be of poor prognosis for BCR-ABL1-
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pos ALL and, on the contrary, more favorable for BCR-ABL1- neg ALL, though
not statistically significant. Having or not IKZF1 mutations, all BCR-ABL1-
pos ALL patients are candidates for allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT). Regarding BCR-ABL1-neg ALL: though the group of
patients is small, we can suggest that IKZF1 mutation did not appear to influ-
ence survival due to different chemotherapy principal in RALL – 2009 – non-
intensive but not-interruptive therapy with low numbers of HSCT.
Figure 1. Relapse-free survival.
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GMALL BASED PROTOCOL, USING NATIVE E. COLI L-ASPARAGINASE,
IMPROVES SURVIVAL OF ADULTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA IN BRAZIL
I. Arcuri1,*, J. Ramires1, Y. Gonzaga1, R. Dal Bello1, B. Gomes1, J. Dobbin1,
L. Arcuri1
1Instituto Nacional de Câncer, Rio de Janeiro, Brazil
Background: Despite being the most common childhood cancer, nearly one
half of ALL cases occurs in adults. Recently, it has been suggested that more
intensive protocols may improve survival in adolescents and young adults
(AYA).
Aims: Compare results of patients treated with BFM-based protocol to those
patients treated with GMALL-based protocol, in a developing country.
Methods: This is a single center retrospective study which included all newly
diagnosed adult ALL patients admitted between May/2012 and October/2016.
Initially, patients aged 18-39 years (AYA group) were treated with BFM ALL
2009-based protocol and those aged 40-59 years were treated with GMALL
2003-based protocol. Since September 2013, because of high toxicity, only
patients under 30 years were elegible for BFM-based treatment. Major adap-
tations were: (1) native E. coli l-asparaginase was substituted for peg-asparag-
inase, and (2) GMALL irradiation therapy was postponed to maintenance phase.
BCR/ABL1 positive patients received standard chemotherapy plus Imatinib.
Negative MRD was defined as <0,01% by flow cytometry. Overall survival was
estimated by Kaplan-Meier method. Competing risk analysis was carried out
for cumulative incidence of death in CR1 or not in CR1. This study was
approved by local Ethics Committee.
Results: Thirty five patients were included, 21 of them started BFM-based
treatment and 14 started GMALL-based protocol. During the first three months,
7 patients migrated from BFM to GMALL-based treatment because of toxicity
and were analyzed separately. Median age was 21years (18-38) for BFM-based
group, 44 years (30-57) for GMALL-based, and 33 years (21-38) for de-esca-
lated. Male predominance was observed (71%), not different between groups.
T-phenotype was more frequent than expected, representing 50% of BFM-
based, 50% of GMALL-based and 29% of de-escalated groups. BCR/ABL1
was detected in 14% of BFM-based, 23% of GMALL-based and 14% of de-
escalated groups (p=0,85). Seven patients (2 BFM and 5 GMALL) underwent
allogeneic stem cell transplantation in first remission. Of all 35 patients, 31
achieved complete remission after first induction phase. With median follow-
up of 18 months, 1-year overall survival (OS) was 60% for all patients (39% for
BFM-based, 75% for GMALL-based and 86% for de-escalated groups – p=0,04;
BFM-based versus other protocols). Cumulative incidence (CI) of death in first
complete remission (CR1) at 12 months was 18%, not different between groups.
CI of death at 12 months in non-CR1 (relapsed or refractory) patients was 39%
for BFM-based, 7% for GMALL-based and 0% for de-escalated groups – BFM-
based versus other HR 2,6; p 0,13. Among 31 patients who achieved CR1,
MRD data was available for 26 (74%) of these at the end of first induction. OS
at 18 months for CR1 patients with negative MDR after first induction was 74%,
compared to 52% in MRD+ (Figure 1).
Summary/Conclusions: Our results show that GMALL-based protocol yields
good overall survival in adults ALL patients in a low income country, despite
major adaptations. On the other hand, overall survival of AYA patients treated
with BFM-based protocol was surprisingly poor, specially because of ineffective
disease control. This finding may be related to several aspects: socioeconomic
impairment, inadequate supportive care for more intense therapies and inef-




THE INVESTIGATION OF RELATIONSHIP BETWEEN COL1A1 AND FOK1
GENE POLYMORPHISMS AND DEVELOPMENT OF
TREATMENT-RELATED SKELETAL COMPLICATIONS IN CHILDREN WITH
ACUTE LYMPHOBLASTIC LEUKEMIA 
M. Erdem1, Ö. Tüfekçi1, S. Kızıldağ2, S. Yılmaz Bengoa1,*, D. Kızmazoğlu1,
B. Eroğlu Filibeli3, H. Ören1
1Pediatric Hematology, 2Medical Biology and Medical Genetics, 3Pediatrics,
Dokuz Eylül University, İzmir, Turkey
Background: Cure rates for childhood acute lymphoblastic leukemia (ALL)
have approached 90%  with therapeutic advances over the last several
decades. Many treatment related long-term complications including impaired
physical growth, neurocognitive dysfunction, emotional and occupational
diculties, cardiac abnormalities, hypertension, secondary neoplasms,
decreased bone mineral density (BMD) and osteonecrosis have been observed
as the number of survivors increased. Bone infiltration of leukemic cells, corti-
costeroids exposure, poor nutrition, low vitamin D levels, poor muscle mass,
genetic predispositions contribute to the development or worsening of bone
pathology during therapy that may result in osteoporosis, fracture and
osteonecrosis. 
Aims: In this study, we aimed to investigate whether vitamin D receptor and
collagen protein gene polymorphisms, which are important in bone mineral and
matrix formation, have effects on bone turnover in patients with ALL.
Methods: Fifty children with ALL who were diagnosed and treated with BFM-
95 protocol (25 girls, 25 boys) between 1998-2008 and 96 healty children at
Dokuz Eylül University Medical School were enrolled in this study. Polymor-
phisms of vitamin D receptor (VDR) Fok1 gene and the collagen Col1A1 gene
were studied from peripheral blood samples of the patients that were collected
before initiation of chemotherapy protocol. After genomic DNA extraction, VDR
Fok1 gene and colloidal Col1A1 gene polymorphisms were analyzed by poly-
merase chain reaction (PCR) and restriction fragment length polymorphism
(RFLP). The data including age, sex, leukemia risk group, presence or absence
of relapse were all noted. Bone marrow density and markers of bone metabo-
lism including serum calcium, phosphorus, serum alkaline phosphatase,
parathyroid hormone and 25-OH D vitamin levels were all screened before ini-
tiation of maintenance treatment.
Results: The distribution of Fok1 and Col1A1 gene polymorphisms was similar
both in the patient group and healthy control group. The frequency of gene
polymorhisms in the patient group were 8% ff, 46%Ff and 46%FF for the Fok1
genotype and 62%GG, 26%GT and 12%TT for the Col1A1 genotype. Out of
50 patients,  16 (32%) patients were found to have skeletal diseases like
osteopenia (16%), osteoporosis (12%) and osteonecrosis (8%). The Fok1 geno-
type and Col1A1 genotype polymorhisms were similar in both group of patients
with or without skeletal diseases. The frequency of osteopenia was signicanly
higher in the male group (p=0.049) and the frequency of osteonecrosis was
signicanly higher in patients older than 10 years old (p=0.001). There was no
significant association between Fok1 and Col1A1 gene polymorphisms and
leukemia subtype, risk group or relapse rate. 
Summary/Conclusions: It has recently become more important to prevent
treatment-related complications that we see as a consequence of high cure
rates in ALL. In this context we have investigated whether there is a relationship
between gene polymorhisms and treatment related skeletal diseases like
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osteopenia, osteoporosis and osteonecrosis. We haven’t detected a significant
association between Fok1 and Col1A1 gene polymorphisms and frequency of
skeletal complications. Studies investigating the possible underlying genetic
susceptibilites to certain complications are important not only for better man-
agement of complications but also for development of new individual patient-
specific treatment modalities. 
PB1639
OUTCOME OF ADOLESCENTS AND YOUNG ADULTS WITH ACUTE
LYMPHOBLASTIC LEUKEMIA TREATED WITH PEDIATRIC PROTOCOL:
MONOCENTRIC STUDY
I. Frikha1,*, M. Medhaffer1, S. Hdijji1, R. Kharrat1, M. Chaari2, O. Kassar1,
M. Ghorbel1, H. Bellaaj1, I. Ben Amor1, F. Kallel2, C. Kallel3, M. Elloumi1
1Hematology, 2Laboratory of Hematology, Hedi Chaker Hospital, Sfax, Tunisia,
3Laboratory of Hematology, Habib Bourguiba Hospital, Sfax, Tunisia
Background: Several retrospective studies have confirmed that adolescents
and young adults (AyA) with acute lymphoblastic leukemia( ALL) treated with
pediatric protocols have better outcomes than similarly aged patients treated
with adult protocols. 
Aims: We reported results and feasibility of a pediatric-based protocol (EORTC
58951) in adolescents and young adults.
Methods: From January 2000 to December 2015, 72 patients aged 16 to 30
years with newly diagnosed ALL were treated, in the department of clinical
hematology of Hedi Chaker  Hospital, according to the pediatric protocol
EORTC 58951. Further leukemia characteristics (Sex, White Blood cell count,
Blasts phenotype, Cytogenetic results), we studied the protocol results:
response to prophase), risk group stratification (average: AR1 and AR2, very
high: VHR), remission rate, death rate, relapse rate and 5 years survivals (over-
all OS and event free EFS).
Results: Seventy two AyA ALL were treated with the pediatric protocol. The
patients were 45 males and 27 females (SR=1.66). A WBC>100 G/l was noted
in 32%. A T blast phenotype was noted in 53% of cases. Twenty two patients
(30%) were PPR. Nine patients (13%) were treated according AR1 arm, 39
patients (54%) according AR2 arm and 24 patients (33%) according VHR arm
induction. CR rate was 87% after one course and 94% after 2 courses. Induction
death was noted in 3% and post-induction death was noted in 13%. Twenty four
patients treated with VHR arm protocol were eligible for allogenic stem-cell trans-
plantation (SCT), among them 15 patients had a familial donor and 10 patients
were allograft (42%) and only 4 patients still in CR (2 patients died by GVH and
4 patients relapsed). Relapse was observed in 22 patients (32%), among them
12 during the first year of treatment. The median follow up was 101 months (8,4
years). The five years OS and EFS were respectively 50 and 50.4%.
Summary/Conclusions: The results of this pediatric based study show that
response to therapy and prognostic in adolescent and young adults were better
than those treated with adult protocols and tolerability of chemotherapy is
acceptable. However OS and EFS, better than adult ALL treated by adult pro-
tocol (OS= 14%, EFS=14%: local study) was not satisfactory because the high
toxic mortality rate. 
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ASSESSMENT OF DEPRESSION AND SELF-CONCEPTION IN CHILDREN
WITH ALL-TREATMENT
G. Aydogan1,*, N. Kavcik1, F. Akici1, Z. Salcioglu1, H. Sen1, N. Ozdemir1,
C. Bayram1, A. Aycicek1
1Pediatric Hematology, Kanuni Sultan Suleyman Education And Research Hos-
pital, Istanbul, Turkey
Background: Leukemia is the most prevalent pediatric malignancy with acute
lymphoblastic leukemia (ALL) being the most common accounting for 75% of
leukemia cases with about 2400 newly diagnosed children each year world-
wide. Treatment of ALL requires long course chemotherapy ranging up to 48
months with 20% possibility of relapse. Affected children receive in-patient
treatment at the clinic for nearly six months for leukemia and related complica-
tions. The diagnosis of childhood leukemia and its stressful treatment, not only
adversely impact the physical and psychological health of the children with
leukemia, but also impose heavy psychological burden on their parent.
Aims: The study aimed to determine prevalance of condition of depression and
self conception of children with leukemia and compare with healty children.
Methods: The study was conducted in 24 voluntary children with leukemia
and 25 healthy children aged 9-16 years. Children with leukemia were evalu-
ated at the time of diagnosis, end of induction treatment and end of consolida-
tion treatment, just before the maintenence treatment, respectively. Psycho-
logical data including depression and low self-concept were assessed by Child
Depression Scale and Piers Harris Self-Cocept Scale. The changes in psy-
chological conditions due to long stay at the hospital were investigated. Demo-
graphic data included age, sex, school achievement, parents education, socioe-
conomic condition, loss of first degree relatives.
Results: The prevalance of depressive disorder in children with leukemia at
the end of induction and at the end of consolidation treatment were significantly
increased. Self-Concept Scales were found lower in these patients. 
Summary/Conclusions: The children with ALL receive long course
chemotherapy and become distanced from their family, school and milieu and
as a result, these patients are vulnarable to psychological problems. They are
more depressive and have lower self-conception comparing to healthy children.
It is important to provide psychological support to these children in addition to
their chemotherapy.
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SEVERE PSYCHIATRIC DISTURBANCES DURING THERAPY IN
PEDIATRIC ALL
C. Tsipou1,*, N. Tourkantoni1, A. Kattamis1
1Hematology-Oncology Unit, 1st Department of Pediatrics, “Aghia Sofia” Chil-
dren’s Hospital, University of Athens, Athens, Greece
Background: Psychiatric disturbances are not uncommon in patients with can-
cer. Their pathogenetic mechanisms are variable and comprise consequences
of the therapy, underlying disease, as well as personality characteristics. These
disturbances are frequently associated with the use of corticosteroids, which
is an essential component of the treatment for children and adolescents with
Acute Lymphoblastic Leukemia (ALL).
Aims: This study aimed to investigate the incidence of severe psychiatric dis-
turbances in patients treated for childhood ALL.
Methods: We report the results of a retrospective analysis of the incidence of
severe psychiatric disturbances, defined as behavioral and psychological
changes which lead to dangerous or erratic behaviors requiring use of psychi-
atric medications, in patients treated for childhood ALL. All patients were treated
in a single institution and followed the same chemotherapeutic protocol, accord-
ing to which, corticosteroids are administered initially during the “induction”
phase and then in multiple subsequent pulses.
Results: Seventy patients (mean age:4.04 years old, range:1-16) were treated
for ALL during the 4 years of the observation period. During that period, 9
(12.8%) children (6 boys, 3 girls) of mean age 12.3 years old (range: 10-15)
experienced   psychiatric - neurological symptoms and/or mental disorders,
which included major depressive disorder, withdrawal, first psychotic episode,
disorientation, visual hallucinations, mood swings and behavioral outbursts.
The majority of the patients (8 patients, 6 at the Intermediate Risk group and
2 at the High Risk group) experienced disturbances during the reinduction
phase, while treated with dexamethasone at 10 mg/m2 for 21 days. Two
patients of the High Risk group presented with behavioral effects one during
the second HR2 block. Patients who had symptoms of major depression were
treated with either fluoxetine, or/and risperidone, or/ and escitalopram for a
period of time ranging of 5 days to 6 months. One patient experienced a psy-
chotic episode during reinduction (Prot.II,phase 2) with aggression and violence
towards others and had to be treated immediately with intramuscularly haloperi-
dol and diazepam. All of our patients are alive and in remission, 7 off therapy
for a period of 3 years, and 2 receiving maintenance therapy. Statistical analysis
showed that severe psychiatric disturbances were observed more frequently
in older patients and they were more common with the administration of dex-
amethasone than with prednisolone.
Summary/Conclusions: Severe psychiatric disturbances are not infrequent
in children and adolescents receiving treatment for ALL. Awareness of this
complication, appropriate parental education for identifying early signs, and
prompt therapeutic interventions are essential for optimal outcome. Further
studies are required for identifying patients at risk and best use of chemother-
apeutic agents and of dexamethasone.
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INCIDENCE, SEVERITY AND RISK FACTORS FOR NEUROLOGIC
COMPLICATIONS ASSOCIATED WITH L ASPARAGINASE TREATMENT IN
PAEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA
G.M. Safta1,*, C.G. Zaharia1, A.M. Bica1, L.E. Radu1, A.N. Serbanica1,
A.D. Beldiman1, T. Iuga1, M. Asan1, C. Nicolae1, O. M. Rizea1, A. Colita1
1Fundeni Clinical Institute, Bucharest, Romania
Background: Combined chemotherapy increased over time cure rate in
patients with acute lymphoblastic leukemia (ALL). Among other things, one of
the direct adverse effects of chemotherapy is affecting hemostasis inducing
thrombosis or bleeding. Hemostasis can also be affected indirectly by the
appearance of infections secondary immunosuppression. It has been found
that L Asparaginase induces thrombotic events by reducing antithrombin III,
protein C, protein S and by inducing endothelial damage. Thrombotic events
may result as a direct effect of the disease, may be the effect of chemotherapy
or may be related with prothrombotic status of the patient.
Aims: To evaluate incidence and severity of thrombotic  or bleeding events in
paediatric patients with ALL during chemotherapy.
Methods: We considered all patients hospitalized for ALL in the Pediatrics
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Department of Clinical Institute Fundeni during 2010-2017 and received
chemotherapy according to protocol ALL BFM 1995 and ALL BFM 2002, estab-
lished after framing in the risk group.
Results: Over a period of 8 years in our department 280 patients with ALL
received L-asparaginase  in the induction phase.  Neurological manifestation
suggestive for bleeding or thrombotic events occurred in 9/280 (3,21%) patients.
2 patients were treated according protocol ALL BFM 1995 and 7 patients were
treated according to protocol ALL BFM 2002. M/F ratio was 4/5. Patients had at
diagnosis between 3 and 15 years (median age 9 years). All patients had throm-
botic events after starting administration of L Asparaginase during induction. Most
had clinical symptoms after the fourth dose of L Asparaginase. Clinical manifes-
tations were accompanied by hypofibrinogenemia (<100 mg/dl) especially in
patients who experienced bleeding. The patients who experienced thrombosis
had decreased levels of antithrombin III, protein C and increased D dimer levels.
The diagnosis of cerebral venous sinus thrombosis (CVST) is typically based on
clinical suspicion and imaging confirmation. At 5 of these patients neuroimaging
test  (CT and MR imaging) documented CVST after developing neurological
symptoms; one of the patients suffered major complication (extended brain injury)
and died. All patients with ALL and thrombotic events received low-molecular
weight heparin (LMWH) for 3 to 6 months. A follow-up CT or MRI at 3 to 6 months
after diagnosis was made to assess for recanalization of the occluded cortical
vein/sinuses. Survival in the patients with CVST was 84.61%. 1 patient with ALL
and hemostasis alteration had intracerebral hemorrhage (ICH) with rapid pro-
gressive neurological deterioration to death. 1 patient had pulmonary embolism
associated with clotting disorders and severe sepsis and he died. 2 patients had
clinical manifestation (headache, confusion and seizures) and clotting disorders
(decreased levels of antithrombin III, protein C, fibrinogen and increased D dimer
levels), but with normal brain imaging. Survival in the cohort was 77,7%.
Summary/Conclusions: Thrombotic events have occured in all patients during
induction. Clinical manifestation were depending on location, size and duration
of thrombosis, from headaches, seizures or focal neurological deficits. Severe
sepsis association was an additionally  risk factor for thrombotic and bleeding
events in patients with ALL. Screening for genetic prothrombotic defects diag-
nosis prior to initiating chemotherapy may represent a way to reduce thrombotic
or bleeding events and appropriate management of hemostasis disorders that
occur during the treatment.
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INCIDENCE AND SURVIVAL OF CHILDHOOD LEUKEMIA IN ARMENIA:
A POPULATION-BASED ANALYSIS
M. Tatulyan1,*, S. Daghbashyan1, L. Krmoyan1, A. Zakharyan1,
L. Vagharshakyan1, L. Sahakyan1
1pediatric hematology/oncology department, Hematology Center after prof.
Yeolyan, Yerevan, Armenia
Background: Leukaemia is the most common cancer in children. Childhood
leukemia incidence and survival varies globally, and this could be associated
with environmental risk factors, genetics, and improvement in diagnosis and
treatment. Armenia is considered to be a mono ethnic nation.
Aims: We aimed to quantify the incidence of and mortality from acute
leukaemias among children population in Armenia and their variation with gen-
der, age, year of diagnosis. 
Methods: In this work we included children diagnosed with de novo acute
leukaemia, 0–18 years of age from 2006 to 2016. The initial data for this survey
have been derived from ambulance/dispensary cards, hospitalization journals,
and clinical data from the Registry of Blood Diseases at the R.Yeolyan Hema-
tology Center, Yerevan, Armenia. The data has been supplemented by the data
from the Registry of Oncological Diseases of the V. Fanarjyan NCO, as well as
from death certificates. The demographic data has been obtained from the
National Statistics Board of Republic of Armenia. The obtained data has been
statistically analyzed using EPI INFO-2002 program. 
Results: A total of 277 cases of childhood acute leukemia were identified, 174
(62.8%) of whom were male. The overall incidence of leukemia was 3.4 per
100 000 children-years. The higher incidence rates were noted in 2007, 2012,
2010 (accordingly 4.0, 4.0 и 3.9), and the lower rates in 2011, 2014, 2009
(accordingly 2.4, 2.4 и 2.9). There are three registrated  regions in Armenia-
Lori, Vayots Dzor and Tavush with higher incidence rate (respectively 0.020,
0.012 and 0.010 per 100 000 children-year). Currently 83.8% of studied patients
are alive. The 5-year survival rate was 72%, 100%, and 100% among children
diagnosed at 3–7, 7–13, and 13–18 years of age, respectively. The results indi-
cated that the children diagnosed between ages of 3 and above had the lowest
risk of mortality and higher survival rates.
Summary/Conclusions: This is the first general population study to describe
the incidence of and mortality from childhood acute leukaemias in Armenia dur-
ing 2006-2016. It forms the basis for quality assessment of acute leukaemia
treatment in Armenia and offers a unique opportunity for population-based
research. Age at diagnosis remained to be a crucial determinant of the survival
variability of pediatric ALL patients, after adjusting for sex, race, therapy, primary
tumor sites, immunophenotype, and year of diagnosis. Further research is war-
ranted to disentangle the effects of age-dependent biological and environmental
processes on this association.
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LONG-TERM SURVIVAL OUTCOMES OF ADULT PHILADELPHIA
CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
PATIENTS TREATED WITH IMATINIB OR DASATINIB
G. Vahdani1,*, A.-R. Jeong1, Z. Ghaznavi2, W. Hsiao2, V. Tulpule1, M. Akhtari3
1Department of Internal Medicine, LAC+USC Medical Center, 2Keck School of
Medicine, University of Southern California, 3Jane Anne Nohl Division of Hema-
tology and Center for the Study of Blood Diseases, University of Southern Cal-
ifornia Norris Comprehensive Cancer Center, Los Angeles, CA, United States
Background: Acute lymphoblastic leukemia (ALL) with positive Philadelphia
chromosome (Ph+) is a unique subset of ALL with poor prognosis. Recent stud-
ies have demonstrated improved survival outcomes in adult patients with Ph+
ALL with the use of tyrosine kinase inhibitors (TKIs) along with chemotherapy.
However, there are very few studies that describe the comparative effectiveness
of various TKIs in this patient population.
Aims: To characterize long-term survival outcomes including leukemia-free
survival (LFS) and overall survival (OS) for Ph+ adult ALL patients treated with
imatinib versus dasatinib.
Methods: Retrospective chart review was conducted at our institution. Patients
>= 18 years old and diagnosed with Ph+ ALL between 2002 and 2015 were
included. Analysis was done by intent to treat for patients initiated with imatinib
or dasatinib at the time of Ph+ diagnosis. The primary endpoints were 2-year
LFS and OS and secondary endpoints were complete molecular response
(CMR; BCR-ABL1/ABL1 ratio <0.01% by PCR) and major molecular response
(MMR; BCR-ABL1/ABL1 ratio <0.1% by PCR).
Results: Among 46 patients with Ph+ ALL, 74% (n=34) were in imatinib group
and 17% (n=8) in dasatinib group; 9% were treated with other or no TKI (1
ponatinib and 3 with no TKI). Thirty-eight percent (n=13) of patients in imatinib
group and 13% (n=1) in dasatinib group switched to a different TKI due to
adverse effects or failure to achieve remission. There was a trend towards
increased 2-year LFS for patients on dasatinib (HR 0.40, 95% CI: 0.14-1.14,
p=0.09) and no difference in 2-year mortality (HR 1.00 95%CI: 0.46-2.17,
p=0.99). Molecular response data was available for 61% (n=28) of patients;
75% of imatinib group achieved CMR or MMR (65% CMR) compared to 76%
of dasatinib group (63% CMR) (p=0.98) (Figure 1).
Figure 1.
Summary/Conclusions: In conclusion, dasatinib, compared to imatinib, in
combination with chemotherapy, may prolong LFS in patients with Ph+ ALL
and may be a suitable first-line agent. Large, randomized studies are needed
to better define a detailed treatment protocol in this high-risk patient population. 
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OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN A MIXED COHORT OF PEDIATRIC AND ADULT
PATIENTS WITH KMT2A-AFF1 ACUTE LYMPHOBLASTIC LEUKEMIA 
T.L. Gindina1,*, N. Mamaev1, O. Paina1, O. Pirogova1, O. Slesarchuk1,
Y. Gudozhnikova1, A. Alyanskiy1, S. Bondarenko1, L. Zubarovskaya1,
B. Afanasyev1
1R.M. Gorbacheva Memorial Research Institute of Children Oncology, Hema-
tology and Transplantation, Department of Hematology, Transfusiology and
Transplantation, 1st Pavlov State Medical University of Saint Petersburg, Saint-
Petersburg, Russian Federation
Background: Acute lymphoblastic leukemia with poor-risk translocation
t(4;11)(q21;q23)/KMT2A-AFF1 occurs in all age groups with a clear dominance
in children, especially up to 1 year. To date, allogeneic hematopoietic stem cell
transplantation (allo-HSCT) is considered to be potentially curative treatment
in high-risk acute leukemia patients, including the abovementioned. 
Aims: To evaluate the prognostic impact of the different clinical and cytogenetic
characteristics on the results of allogeneic hematopoietic stem cell transplan-
tation in KMT2A-AFF1 acute lymphoblastic leukemia patients.
Methods: Retrospective analysis of treatment results was performed for a
mixed cohort of the patients with KMT2A-AFF1 ALL who received allo-HSCT,
including haploidentical one at our University over 2008 to 2015. Twenty-one
patients (12 females and 9 males aged from 3 months to 48 years; median
18.9 years) were examined. 
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Results: Eight of 21 (38%) patients exhibited an isolated t(4;11) translocation.
Additional chromosome abnormalities (ACA) were revealed in 11 (52%)
patients, including 8 (42%) subjects with 3 and more chromosome aberra-
tions. In univariate analysis, significance was shown for clinical stage at
HSCT (1st remission vs other stages, 75% vs 0% p=<0,001 for OS; 58% vs
0%, p=<0,001 for EFS), complex chromosomal aberrations (<3 abnormalities
vs ≥3 abnormalities, 58% vs 13%, p=0.04 for OS; 46% vs 0%, p=0.04 for
EFS). According to multivariate analysis, the clinical stage at HSCT  (HR
26.8, 95% CI  3.28-218.80; р=0.002 for OS; HR 11.18, 95% CI  2.92-42.80
p=0,0004 for EFS) was  only independent prognostic factor for clinical out-
comes.
Summary/Conclusions: The study has shown the stage of disease at the
moment of allo-HSCT to be independent prognostic factor in a mixed cohort of
KMT2A-AFF1 ALL patients treated with HSCT. The good results of allo-HSCT
can be obtained using a haploidentical transplantation from parents that
removes the problem of searching the HLA-matched donors in the Registers
and, therefore, greatly simplifies the treatment.
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DERMATOLOGIC COMPLICATIONS ASSOCIATED WITH TYROSINE
KINASE INHIBITORS FOR THE TREATMENT OF ACUTE LEUKEMIA
K. Zarubina1,*, O. Gavrilina1, E. Parovichnikova1, V. Troitskaya1, A. Sokolov1,
E. Chelysheva1, A. Turkina1, E. Usikova1, A. Abramova1, G. Baskhaeva1,
I. Lukyanova1, V. Savchenko1
1Department of chemotherapy of hemoblastosis and depression of hemo-
poiesis, National Research Center for Hematology of the Ministry of Healthcare
of the Russian Federation, Moscow, Russian Federation
Background: Despite of targeted effects of tyrosine kinase inhibitors (TKIs),
they are not absolutely selective in relation to their target. Hair pigmentation is
regulated by factors including the interaction of the ligand stem cell factor (SCF)
with its class III receptor tyrosine kinase, c-kit. Hair depigmentation observes
during therapy TKI with action directed against class III receptor tyrosine kinase
(PDGFRα, PDGFRβ, C-KIT, CSF1R, FLT3). But other TKI such as BCR/Abl
TKI can also inhibit class III receptor tyrosine kinase by non-targeted actions.
Skin reactions are the most common observed during the epidermal growth
factor receptor-tyrosine kinase inhibitor treatment. 
Aims: To describe the spectrum of skin and hair reactions in patients with
acute leukemias (Ph+/Ph- acute lymphoblastic leukemia and acute myeloid
leukemia) during the treatment by second-generation TKI (bosutinib), third-
generation TKI (ponatinib) and multikinase inhibitor (sorafenib).
Methods: From 2016 to March 2017 6 patients (pts), age 24-53 (median
29,5), 1 male, 5 female, received second or third line therapy with target tyro-
sine kinase inhibitors in National Research center for Hematology. One pt
(pt 1) with AML had been receiving chemotherapy (decitabine, cytarabine,
idarubicin) with continuous treatment of sorafenib. Three pts with Ph+ ALL
received TKIs. Two of them with T315I mutation (pts 2, 3) received ponatinib
and one pt (pt 4), without molecular remission on dasatinib and nilotinib ther-
apy, received second-generation TKI (bosutinib). One pt with B-ALL was
treated by sorafenib due to refractory disease on the first-line therapy (pt 5).
And one patient (pt 6) with T-cell ALL received sorafenib with nelarabine con-
taining chemotherapy due to early relapse after allogeneic stem cell trans-
plantation.
Figure 1.
Results: All of the 6 patients who had taken second-generation TKI (bosutinib),
third-generation TKI (ponatinib) and multikinase inhibitor sorafenib developed
dermatologic reactions (skin rash or grey hair). Generalized maculo-papular
skin rash grade II evolved after two weeks of  sorafenib treatment in pt1. Both
patients on ponatinib therapy developed localized maculo-papular skin rash
grade I in pt 2 after 8 weeks of therapy. In pt 3 after 6 weeks of ponatinib treat-
ment gray hair observed. Skin rash with pigmentation grade I evolved in pt 3
after 12 weeks of therapy. Pt 4 had gray hair after 12 weeks second-generation
TKI (bosutinib) treatment. Palmar-plantar erythrodysesthesia syndrome grade
II and hair and total skin depigmentation were evolved after 2 weeks and after
4,5 months respectively observed during the sorafenib treatment in pt 5 (with
psoriasis anamnesis). Pt 6 developed localized maculo-papular skin rash grade
I after 5 weeks of sorafenib treatment. Despite of all patients developed der-
matological side effects, temporarily discontinuation of TKI therapy was
required in only three (50%) cases. In the other cases the treatment was con-
tinued. The therapy was restarted in all pts with temporarily discontinuation
after skin lesions disappearing (Figure 1).
Summary/Conclusions: Dermatological adverse events in acute leukemia
pts who have taken second-generation TKI (bosutinib), third-generation TKI
(ponatinib) and multikinase inhibitor sorafenib they were not serious. Temporar-
ily dose reduction or interrupting of TKI therapy led to complete regression of
skin lesions. Restarting TKI at full dose did not lead to dermatological adverse
reactions reappearing. Moreover, the temporary cancellation did not reduce
its effectiveness.
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CYTOKINE RELEASE SYNDROME AFTER THE FIRST INTRATHECAL
CHEMOTHERAPY IN A PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
WITH AN EARLY MENINGEAL RELAPSE 
F. Petruzziello1,*, M. Palma1, A. Varone2, M. Colonna1, D. Cicala3, N. Marra1,
G. Giagnuolo1, G. Maisto1, G. Menna 1, R. Parasole1
1Pediatric Hemato-Oncology, 2Neurosciences, 3Paediatric Neuroradiology Unit,
Santobono-Pausilipon Hospital, Naples, Italy
Background: Central nervous system (CNS) is a frequent site of recurrence
in childhood acute lymphoblastic leukemia (ALL), and Triple Intrathecal Therapy
(TIT) with Methotrexate (MTX), Cytarabine (ARA-C) and hydrocortisone, at
doses for age, is the mainstay of the treatment of CNS relapse. Severe neu-
rotoxicity is well known TIT complication, usually related to repeated infusions
and neurotoxic concomitant systemic drugs.
Aims: We describe a case of a massive acute leukoencephalopathy after only
one TIT, in a 5 year-old child with an early isolated CNS relapse of ALL (26
months after the first diagnosis), rapidly proceeding to comatose status.
Methods: At admission for disease restaging at the end of first-line trial, the
child showed physical and neurological examination completely negative, such
as haematological, bioumoral and ultrasound findings. The cerebrospinal fluid
(CSF) appeared turbid and liquoral pressure increased. CSF count showed
8100 cells/µl; morphology and flow citometry confirmed an early isolated CNS
relapse. Due to the abnormal pleocytosis, TIT administration associated with
oral dexamethasone was suddenly performed without any other concomitant
chemotherapy. To prevent acute toxicities from tumor lysis syndrome, the
patient received hydratation, allopurinol, acetazolamide and prophylaxis of
seizures with levetiracetam. After few hours from TIT, the child developed
severe headache followed by skin urticarial rash, high blood pressure and hal-
lucinations, rapidly evolving in flaccid paralysis of lower extremities. A brain
resonance (MRI) showed diffuse areas of hyperintensity of white matter, par-
ticularly cortical and subcortical areas, cerebellar region, optic chiasm and
brainstem in T2-Flair sequences; spinal cord shower massive edema, espe-
cially in lombar region. The MRI pattern was interpreted as diffuse grade IV
leukoencephalopathy of probable toxic nature. The child, 30 h after TIT, was
transferred to intensive care unit for progressive ascending paralysis and res-
piratory distress that required intubation. During the following days, other three
diagnostic lumbar puncture were performed that showed significant reduction
of blasts cells (20, 10 and 0 cells /µL, respectively).
Results: Patient persisted in deep coma for 5 days, until he restart a sponta-
neous breathing. After waking up, the child showed rapid neurological amelio-
rations, such as reappearance of reflexes, spontaneous movements of eyes,
hand and feet fingers. The subsequent MRI highlighted improvement of hyper-
intensity at midbrain, brainstem and bridge brain areas and spinal cord with
persistence of altered signals in subcortical white matter. The visual evoked
potentials were normal and the motor and sensory conduction velocity
appeared slowed without axonal damage; EEG showed slow waves spread.
At the moment, after three week from severe neurological complication, the
child is fully awake, moving all four limbs, but requires motor and phoniatric
rehabilitation. Systemic chemotherapy with high-dose MTX and IT ARA-C is
restarted without any additional neurotoxicity. Dosage of CSF levels of inter-
leukin 6 and its soluble receptor is ongoing.
Summary/Conclusions: Although leukoencephalopathy following IT MTX or
ARA-C administration are described, the severity and rapidity of event’s onset,
associated with CSF remission after a single TIT administration,  suggests us
that neurotoxicity could be related to massive blast cytolysis with subsequent
cytokine release syndrome causing an inflammatory leukoencephalopathy.
This syndrome is a frequent complication of blinatumomab or chimeric antigen
receptor T-cells administrations. The CSF IL-6 dosing could clarify the patho-
genesis of the event.
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SEVERE HYPOFIBRINOGENEMIA ASSOCIATED WITH IMATINIB AND
PREDNISONE THERAPY IN PHILADELPHIA CHROMOSOME–POSITIVE
ACUTE LYMPHOBLASTIC LEUKEMIA
M. Sciumè1,*, N. S. Fracchiolla1, G. Reda1, R. Cassin1, V. Mattiello1, A. Cortelezzi1
1Oncohematology Division, IRCCS Ca’ Granda - Maggiore Policlinico Hospital
Foundation and University of Milan, Milan, Italy
Background: Hypofibrinogenemia associated to acute lymphoblastic leukemia
(ALL) is rare and usually due to L-asparaginase. Consumption coagulopathy
or therapy-related hepatotoxicity are other possible explanations. Severe
hypofibrinogenemia, not linked to the causes listed, was rarely reported and a
role of steroid therapy on fibrinogen metabolism was suggested.
Aims: Our aim was to identify the incidence of severe hypofibrinogenemia dur-
ing induction phase in a cohort of consecutive ALL patients and to assess its
impact on clinical decision-making.
Methods: In order to avoid confounding factor due to L-asparaginase, we
revised our cohort of Philadelphia chromosome–positive (Ph+) ALL that we
treated according to pediatric-type therapy program (imatinib, intensive
chemotherapy without L-asparaginase) for patients aged 18-65 years and
through LAL0201-B protocol (imatinib, prednisone) for patients ≥65 years. We
retrospectively analyzed coagulation tests on admission and during induction
therapy of all Ph+ALL patients diagnosed at our Institution from 2004.
Results: Twenty-one Ph+ALL were identified; 17 patients were younger than
65 years, while the remaining 4 patients had a median age of 74 years (66-76).
No alteration of plasma fibrinogen during induction was observed in younger
patients. Severe hypofibrinogenemia (≤100 mg/dl) was detected in 3 out of 4
Ph+ALL over 65 years. In these patients induction consisted of prednisone 40
mg/m2/dfrom day 1 to 45 and imatinib at the fixed dose of 800 mg/d. On admis-
sion hemoglobin levels were ≥10 g/dl in all patients, leucocytes counts were
2x109/L (blasts 15%), 8x109/L (blasts 30%) and 18x109/L (blasts 61%), while
platelet count was reduced in 2 cases (61x109/L and 65x109/L). Coagulation
tests were normal (fibrinogen median level 380 mg/dl). Severe hypofibrinogen-
emia developed between 6 and 15 days after beginning treatment and lasted
between 4 and 48 days. Fibrinogen nadir ranged from 47 to 100 mg/dL (median
61 mg/dL); reduced plasma fibrinogen levels at functional tests were also con-
firmed to immunological assays. During fibrinogen nadir, D-dimer was positive
in all patients, but stable compared to the outset. Antithrombin, coagulation fac-
tors, activated partial thromboplastin and prothrombin time, common liver func-
tion tests remained in a normal range; platelet counts showed a trend to nor-
malization. Early clearance of peripheral blood blasts was observed and when
hypofibrinogenemia appeared no blast cells were detectable. At the end of
induction bone-marrow evaluation demonstrated the absence of BCR-ABL tran-
script by qualitative RT-PCR. There were no bleeding events and only one
patient received a prophylactic transfusion of fresh-frozen plasma (10 ml/kg)
for fibrinogen <50 mg/dl on two occasions. Normal fibrinogen levels (≥165
mg/dl) were recovered at the end of steroid therapy.
Summary/Conclusions: We observed severe hypofibrinogenemia in Ph+ALL
patients older than 65 years treated with imatinib and high-doses steroid, while
normal fibrinogen levels were detected in younger Ph+ALL during intensive
chemotherapy plus imatinib. In our experience, hypofibrinogenemia was not
associated to major bleeding events, although its clinical significance should
be investigated in larger series. Fibrinogen may recognize multiple metabolic
pathways, also unrelated to in vivo coagulation and fibrinolysis; the correspon-
dence between steroid treatment and hypofibrinogenemia seems to suggest
that glucocorticoids may alter some steps in fibrinogen kinetics and could be
considered as a cause of acquired hypofibrinogenemia.
PB1649
LATE EFFECTS OF CHEMORADIOTHERAPY ON THE ENDOCRINE
SYSTEM IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
G. Aydogan1,*, S. Eltan1, F. Akici1, Z. Salcioglu1, A. Akcay1, T. Akcay1, H. Sen1,
N. Ozdemir1, C. Bayram1, A. Aycicek1
1Pediatric Hematology, KANUNI SULTAN SULEYMAN EDUCATION AND
RESEARCH HOSPITAL, Istanbul, Turkey
Background: Over the past four decades treatment of childhood acute lym-
phoblastic leukemia has been modified with the aim of achieving high survival
rate while reducing the risk of the life threatening late-effects and promoting
risk-based follow-up care of survivors.
Aims: The aim of our study is evaluation of late effects of chemotherapy and
cranial radiotherapy on the endocrine system in children with acute lymphoblas-
tic leukemia.
Methods: Fourty-eight patients, who were diagnosed and treated for ALL
between 1997-2007 in Istanbul Kanuni Sultan Suleyman Education and
Research Hospital Pediatric Hematology-Oncology Clinic and have disease-
freee for at least 5 years after cessation of treatment, were evaluated prospec-
tively. The study form included each patients age, gender, weight, height, target
height, parental height, treatment protocol, stage of puberty, bone age, TSH,
free T4, LH, FSH, estradiol or testosterone, IGF-1 and IGFBP-3 levels. Annual
rate of growth was evaluated for each patient. The patients with inadequate
growth rate and delayed bone age were subjected to growth hormon stimulation
test with clonidine.
Results: Mean age of the patients was 14.41±2.85 (10.5-22.4) years. Thirty-
one of patients had prophylactic cranial radiotherapy; five of them 18 Gy and
twenty-six had 12 Gy CRT. Fifteen of the 48 patients were diagnosed with at
least one endocrinological disorder. Six patients had lower height (<-2 SD),
three patients had a body mass index >30kg/m². Bone age delayed in two
patients. Four patients had IGF-1 value below <-2SD and two patients had
inadequate levels of growth hormone. Tanner stage of the patients were
appropiate for their ages except for one patient with hypergonadotropic hipog-
onadism and one patient with pubertas precox. Subclinical hypotiroidism was
detected in two patients.
Summary/Conclusions: Significant late effects may develop over time in chil-
dren treated for ALL. For this reason long-term follow-up of these children is
necessary. Because of the awareness of the late effects can the treatment
modifed to reducing of the late effects.
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MUTATIONAL ANALYSIS OF 231 DE NOVO AML PATIENTS BELOW 60
YEARS WITH CURATIVE THERAPY
A. Folta1,*, I. Jeziskova1, D. Dvorakova1,2, N. Tom2, M. Culen1,2, Z. Kosarova2,
A. Durinikova2, P. Cetkovsky3,4, P. Jindra4,5, T. Szotkowski4,6, P. Zak4,7,
J. Mayer1,2,4, Z. Racil1,2,4
1University Hospital Brno, 2Masaryk University, Brno, 3Institiute of Hematology
and Blood Transfusion, Prague, 4On behalf of CELL, Brno, 5University Hospital
Pilsen, Pilsen, 6University Hospital Olomouc, Olomouc, 7University Hospital
Hradec Kralove, Hradec Kralove, Czech Republic
Background: Acute myeloid leukemia (AML) is an aggressive cancer disease
of the myeloid lineage of blood cells, characterized by rapid growth of undiffer-
entiated myeloid precursors. Analysis of the spectrum of somatic mutations in
leukemic cells may help to improve the identification of individual prognostic
subgroups of patients as well as to observe clonal evolution in the course of
AML treatment.
Aims: The aim of the project is to identify somatic alterations in genes related
to AML using next generation sequencing (NGS) in large cohort of AML patients
from Czech Republic and to determine their frequency and mutual coexistence.
Methods: The analyzed group consists of 231 de novo consecutively diag-
nosed AML patients with curative therapy below 60 years from five hematolog-
ical centers. The NGS libraries are prepared from peripheral blood samples
from diagnosis using ClearSeq AML panel (Agilent Technologies) and
sequenced on MiSeq and NextSeq machines (Illumina). As positive are deter-
mined mutations with variant allele frequency (VAF) at least 2%.
Results: At least one somatic mutation (median 2; range 0-6) was identified in
204 (88.3%) patients with de novo AML. In total, 526 recurrent mutations in 19
genes were identified. The most frequently mutated genes were: FLT3 91/231
(39.4%; from this FLT3-ITD 69/231 [29.9%] and FLT3-TKD 22/231 [9.5%]),
NPM1 90/231 (39.0%; mutation type A 71/90 [78.9%], type B 11/90 [11.1%],
other types 10/90 [10.0%]), DNMT3A 68/231 (29.4%; mutations in codon R882
49/68 [72.1%]), NRAS 51/231 (22.0%; the most frequent mutation G12D 17/51
[22.0%]; 11/51 patients [21.6%] contain more than one mutation in NRAS gene),
IDH2 35/231 (15.2%) and CEBPA 35/231 (15.2%). The analysis also identified
mutations in rarely mutated genes U2AF1, SF3B1, EZH2 and SETBP1 in 4/231
(1.7%), 4/231 (1.7%), 1/231 (0.4%) and 1/231 (0.4%) samples, respectively
(Figure 1).
Figure 1. Distribution of gene mutations with VAF ≥2% in AML cohort.
Each column represents one patient (n=231). Each row represents one
gene described on left, on the right is shown the number of patients with
mutation in the gene and its percentage from the total cohort. The color
of the squares represents the status of the gene: red – single mutated,
blue – double mutated, black – triple mutated, white/grey – no mutation.
Summary/Conclusions: The results of mutational analysis of large cohort of
AML patients show high heterogeneity of detected mutations. Surprisingly we
have detected high percentage of patients with mutations in gene NRAS.
Together with sequencing results from the time of remission/relapse/resistance
of the disease, the data will enable to get more complex view on the develop-
ment of AML in time.
Supported by Ministry of Health of the Czech Republic, grant nr. 15-25809A,
and by project MUNI/A/1106/2016. All rights reserved.
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INHIBITION OF LIN28B IMPAIRS LEUKEMIA CELL GROWTH AND
METABOLISM IN ACUTE MYELOID LEUKEMIA
J. Zhou1,*, J.-Y. Chooi 1, J.Y. Quah1, S.H.-M. Toh1, T.Z. Tan1, P.S. Chong1,
W.-J. Chng1
1Cancer Science Institute of Singapore, National University of Singapore, ,
Singapoore, Singapore
Background: 1. Current conventional chemotherapy for acute myeloid
leukemia (AML) can achieve remission in over 70% of patients, but a majority
of them will relapse within 5 years despite continued treatment. 2. The relapse
is postulated to be due to leukemia stem cells (LSCs), which is different from
normal hematopoietic stem cells (HSCs). LIN28B is microRNA regulator and
stem cell reprogramming factor. 3. Overexpression of LIN28B has been asso-
ciated with advance human malignancies and cancer stem cells (CSCs), includ-
ing AML. However, the molecular mechanism by which LIN28B contributes to
the development of AML remains largely elusive. 
Aims: 1. To study the function role of LIN28B in cell proliferation, cell cycle and
colony formation ability of AML cells. 2. To systematically dissect transcriptional
signalling mediated by LIN28B on whole genome level. 3. To determine the key
targets of LIN28B in AML. 4. To explore the function of LIN28B in AML in vivo.
Methods: 1. We modulated LIN28B expression in AML and non-leukemic cells
and investigated functional consequences in cell proliferation, cell cycle and
colony forming assays. 2. We performed a microarray-based analysis for
LIN28B-silencing cells and interrogated gene expression data with different
bioinformatic tools. 3. AML mouse xenograft model was used to examine the
in vivo function of LIN28B.
Results: We first showed that increased LIN28B expression was associated
with worse survival in AML patients. We demonstrated that targeting LIN28B
in AML cells resulted in cell cycle arrest, inhibition of cell proliferation and colony
formation, which was induced by de-repression of let-7a miRNA. On the other
hand, overexpression of LIN28B promoted cell proliferation. Mechanistic stud-
ies revealed that inhibition of LIN28B induces metabolic changes in AML cells.
IGF2BP1 was confirmed to be a novel downstream target of LIN28B via let-7
miRNA in AML. Notably, silencing LIN28B led to slow tumor growth in vivo.
Summary/Conclusions: In conclusion, these results uncover a novel mech-
anism of an important regulatory signaling, LIN28B/let-7/IGF2BP1, in leuke-





EVALUATION OF MINIMAL RESIDUAL DISEASE IN NPM1-MUTATED AML
PATIENTS
C. Martínez-Laperche1,2,*, V. Pradillo1, G. Rodríguez-Macías1, M. Chicano1,2,
D. Carbonell1,2, J. Suárez-Gónzalez2, J. L. Díez-Martín1,2, I. Buño1,2
1Hematology, H.G.U Gregorio Marañon, 2Instituto de Investigación Sanitaria
Gregorio Marañon, Madrid, Spain
Background: Minimal residual disease (MRD) tests provide early identification
of hematologic relapse and timely management of AML patients. About 60% of
adult normal karyotype AML has a mutation in exon 12 of NPM1 gene. This muta-
tion is specific for malignant clone and potentially is a good marker of MRD.
Aims: The aim of the study was to analyze the usefulness of NPM1 as a marker
for MRD quantification in AML during follow-up.
Methods: Retrospective study included 34 patients with mutated-NPM1 and
treated with intensive chemotherapy (2009-2015). Bone marrow (188) and
peripheral blood (277) samples were analyzed from complete remission (MRD
NPM1 negative). NPM1 detection was performed by quantitative RT-PCR
(Gorello et al, Leukemia 2006). Patients were considered positive when pre-
sented >1 NPM1 sample positive or/and one sample NPM1 >0.02%. Cox
regression was used for univariate analysis.
Figure 1.
Results: Patients were segregated in 2 groups: Relapse patients (Group 1:
32.2%, 11/ 34) and no relapse patients (Group 2: 67.6%, 23/34).  Group 1 pre-
sented MRD NPM1 positive in 9/11 (82%) of patients, the time from NPM1 to
relapse was 4.6 months (1.6-24), NPM1 mean was 1.7 (0.03-9). Group 2 pre-
sented MRD NPM1 negative (<0.02% y/ or 1 determination) in 21/23 (91%)
patients. Univariate analysis was performed and our results show that age,
leukocyte, LDH and MRD NPM1 are prognostic factors for cumulative incidence
of relapse (Figure 1).
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Summary/Conclusions: NPM1 is a useful marker for MRD quantification in
AML patients undergoing intensive therapy. NPM1 positive during follow-up is
associated with a higher probability of relapse.
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AT101 ELIMINATES AML STEM CELLS VIA ACTIVATION OF INTRINSI
C APOPTOTIC PATHWAY AND PARTICIPATION IN DNA DAMAGE
RESPONSE
X. Bing1,*, Z. Leisi2, Z. yong1, C. kai2, S. pengcheng3, L. yin2, D. manman1,
J. zhiwu4, W. xiangmeng2, L. peng4
1The First Affiliated Hospital of Xiamen University, Xiamen, 2Nanfang Hospital,
Southern Medical University, Guangzhou, 3Nanfang Hospital, Southern Medical
University, Xiamen, 4Southern China Institute for Stem Cell Biology and Regen-
erative Medicine, Guangzhou, China
Background: Leukemia stem cells (LSCs) are considered as the main reason
for treatment failure and relapse in acute myeloid leukemia. Overexpression of
Bcl-2 anti-apoptotic proteins is associated with the survival and self-renewal of
LSCs
Aims: To observe the effect for AT101 to eliminate AML stem cells and its
underlying mechanism.
Methods: Use CD34+CD38-CD123+KG1α and primary AML CD34+ cells as
research object.
Results: In this study, we demonstrated that AT101, a BH3 mimetic pan-Bcl-
2 inhibitor, was significantly and effectively cytotoxic towards CD34+CD38-
CD123+KG1α and primary AML CD34+ cells, with slight effect on CD34+ nor-
mal hematopoietic cells. And the mechanism was closely associated with
activation of intrinsic apoptotic pathway, such as loss of mitochondrial mem-
brane potential and caspase activation, along with disturbance of DNA dam-
age response. Further analysis on AML patients’ clinical characteristics
revealed that the ex vivo efficacy of AT101 in primary samples was signifi-
cantly correlated to hyperleukocytosis or FLT3-ITD mutation. Besides, AT101
exhibited exciting effect on CD34+ blasts from patients who are old or cannot
achieve CR after induction therapy.
Summary/Conclusions: In conclusion, Together, these findings provides
potentiality for the use of AT101 to treat relapse and refractory AML as alterna-
tive salvage regime in the future, including those clinically characterized by one
or more adverse prognostic abnormalities.
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COOPERATIVE EFFECT OF CHIDAMIDE AND CHEMOTHERAPEUTIC
DRUGS INDUCE APOPTOSIS BY DNA DAMAGE ACCUMULATION AND
REPAIR DEFECTS IN ACUTE MYELOID LEUKEMIA STEM AND
PROGENITOR CELLS
X. Bing1,*, L. Yin2, D. Manman1, C. Kai3, S. Pengcheng4, Z. Yong1
1The First Affiliated Hospital of Xiamen University, Xiamen, 2Huizhou Municipal
Central Hospital, huizhou, 3Nanfang Hospital, Southern Medical University,
Guangzhou, 4Nanfang Hospital, Southern Medical University, Xiamen, China
Background: Lots of conventional chemotherapeutic drugs are confirmed to take
participate in DNA damage generation and initiation of DNA damage response,
ultimately leading to apoptosis. However, they fail to completely eliminate leukemia
stem cells (LSCs) on account of higher DNA repair capacity of cancer stem cells
than bulk cancer cells, which become the root of resistance and recurrence. Thus,
new strategy to eliminate LSCs in AML is urgently needed.
Aims: To observe  the effect of low dose chidamide in combination with
chemotherapeutic agents on  eliminating AML stem cells.
Methods: we uesed a novel benzamide-type HDAC inhibitors, chidamide,in
combination with DNA-damaging agents (daunorubicin, idarubicin and cytara-
bine) to treat CD34+CD38- KG1α cells and primary refractory or relapsed AML
CD34+ cells.
Results: Here, we report that low dose chidamide, a novel benzamide-type
HDAC inhibitors, which selectively targeted HDAC 1, 2, 3, 10, could
enhances cytotoxicity of DNA-damaging agents (daunorubicin, idarubicin
and cytarabine) in CD34+CD38- KG1α cells and primary refractory or
relapsed AML CD34+ cells, reflected by inhibition of cell proliferation and
induction of apoptosis in vitro. Mechanistically, these events were associated
with DNA damage accumulation and repair defects. Co-treatment with chi-
damide and DNA-damaging agents IDA gave rise to production of γH2A.X,
inhibited ATM, BRCA1, checkpoint kinase 1 (Chk1) and 2 (Chk2) phospho-
rylation. Finally, the combination initiated caspase-3 and PARP cleavage
and ultimately induced CD34+CD38- KG1α cells apoptosis. Further analysis
on AML patients’ clinical characteristics revealed that the ex vivo efficacy of
chidamide in combination with IDA in primary CD34+ samples was signifi-
cantly correlated to peripheral blood WBC counts at diagnosis, while status,
LDH level, karyotype had no effect, indicating that the combination regimen
of chidamide and IDA could rapidly diminish tumor burden in a patient with
R/R AML.
Summary/Conclusions: these findings provide preclinical evidence for low
dose chidamide in combination with chemotherapeutic agents to treat recur-
rent/resistant AML as an alternative salvage regimen, especially those pos-




NEW CANDIDATE GENES USEFUL TO PREDICT THE RISK OF RELAPSE
IN ACUTE PROMYELOCYTIC LEUKEMIA 
J. Nanni1,*, M.C. Fontana1, G. Marconi1, C. Papayannidis1, S. Lo Monaco1,
G. Simonetti1, A. Padella1, E. Ottaviani1, S. Paolini1, M.C. Abbenante1,
L. Bertamini1, G. Martinelli1
1University of Bologna, Bologna, Italy
Background: Nowadays, Acute Promyelocytic Leukemia (APL) is a disease
entity with a very high rate of cure and an estimated 2-year overall survival of
97%. Early death, rather than resistant disease so common in all other subtypes
of AML, has emerged as the major cause of treatment failure, and relapse is a
very rare occurrence.
Aims: APL relapse is a very rare entity, and it is announced to become rarer
with the advances in first line therapy. Molecular characteristics are hard to
analyze without an effort to collect and bank samples together from multiple
institutions. Since relapses, especially relapses out of follow-up period, repre-
sent a sudden life-treating condition for patients, to predict patients at higher
risk of relapse we selected two candidate genes that could be involved in path-
ways favoring relapse.
Methods: We collected data of all the APL referred to our institution from 2014.
Within 23 patients, we encountered 20 new diagnosis and 2 relapse of APL.
We analyzed blasts in samples obtained from Bone Marrow with Single
Nucleotide Polymorphisms Array Cytoscan HD.
Results: We compared copy number alterations in both relapsed patients with
alterations detected in the pool of 20 newly diagnosed APL and we found spe-
cific signatures of CNVs for each patient. There were several copy number
alterations related to each patient: the first patient presented gain of ROBO2,
GRIP1, CTNNB1, SOX6, PBX1, GRIK2, CDKAL1 and loss FAF1, CREBBP,
SBF1; the second patient presented gain of ROBO1, MAPK10, CADPS2,
APBA1 and loss of GRIP1 and MYB. Subsequently we focused our attention
on ROBO and GRIP1genes because they were alterated in both relapsed
patients: ROBO proteins are associated to K channels while GRIP1 is involved
in various critical functions, for example in androgen receptor binding, beta-
catenin binding, glucocorticoid receptor binding, and it is also a regulator of
glutamate metabolism, a well-known pathway in Leukemic Stem Cells.
Summary/Conclusions: By the analysis of ROBO 1-2 and GRIP1 at the diag-
nosis of APL we could establish a different and strict follow-up program for
patients with these alterations.
Acknowledgement: ELN, AIL, AIRC, prog. Regione-Università 2010-12 (L.
Bolondi), FP7 NGS-PTL project, HARMONY. 
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THE EXPRESSION OF SALL4 AND BMI-1 GENES IN MYELOID LEUKEMIA
M. El-Nagdy1,*, H. Farawela1, H. Zawam2, H. Al-Wakeel1, F. El-Refaey3,
H. Abdel-Rahman1
1Clinical & Chemical Pathology, 2Medical Oncology, Cairo University, 3Clinical
& Chemical Pathology, National Cancer Institute, Cairo, Egypt
Background: Sal-like protein 4 (SALL4) and B-cell specific moloney murine
leukemia virus integration site-1 (BMI-1) genes are stem cell genes that mod-
ulate stem cell pluripotency and may play a role in leukemogenesis. Leukemic
stem cells (LSCs) have been implicated in being the origin of the leukemic
blast, therapy resistance and relapse.
Aims: The current study aimed at characterizing the expression pattern of
SALL4 and BMI-1 genes in acute myeloid leukemia (AML) and chronic myeloid
leukemia (CML), in patients who have achieved complete remission (CR), and
in CML disease progression.
Methods: Real-time polymerase chain reaction was used to assess the gene
expression patterns in 106 myeloid leukemia patients; 54  de novo AML (43 at
time of diagnosis, 11 in CR), and 52 CML (31 in chronic phase (CP), 11 in deep
molecular response (MR4) & 10 in accelerated/blastic phase (AP/BP), and in
21 non malignant bone marrow samples.
Results: SALL4 gene expression was increased in AML patients, AML-CR, &
CML-CP (median= 5.180, 4.604 & 14.125 respectively). No significant differ-
ence was observed between de novo AML and AML in CR patients. CML-CP
patients showed a significantly higher percentage of patients with a high SALL4
expression as compared to both CML- MR4 and CML-AP/BP (p=0.033). BMI-
1 gene expression was not found to be increased in any of the patient groups. 
Summary/Conclusions: Our data describe altered SALL4 gene expression
in different phases of myeloid leukemia. The role of BMI-1 gene needs further
delineation to determine its significance.
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AN INVESTIGATION INTO THE ROLE OF S100A8 AND S100A9 IN ACUTE
MYELOID LEUKAEMIA
S. Chaudry1,*, T. Chevassut1, H. Stewart1
1Brighton and Sussex Medical School, Brighton, United Kingdom
Background: Acute myeloid leukemia (AML) is the a haematological malig-
nancy characterised by the over proliferation and block in differentiation of
clonal stem cells. In leukaemia potential biomarkers such as S100A8 could
assesses the progression and remission of AML. 
Aims: S100A8 and S100A9 (Ca2+ binding helix E-loop-helix-F hand), are
inflammatory markers which are also suggested to promote chemoresistance
by stimulation of autophagy. Microarray data from the Chevassut lab shows
that both S100A8 and S100A9 transcripts are downregulated by the BET-bro-
modomain inhibitor JQ1 in AML cell lines. We aimed to investigate this response
in AML patient bone marrow samples and cell lines. 
Methods: We used AML cell line including OCI-AML2, OCI-AML3 and THP-1
in addition to AML patient bone marrow samples and healthy volunteer sam-
ples. We carried out RT-qPCR and immunocytochemistry and western blotting
techniques to look at levels of S100A8 and S100A9 in samples.
Results: Here we show that levels of S100A8 and S100A9 mRNA levels are
suppressed in response to JQ1 in the AML cells lines OCI-AML2, OCI-AML3
and THP-1. We find also that protein levels of S100A8 and S100A9 are down-
regulated in response to JQ1 in OCI-AML3. In bone marrow samples of 17 AML
patients with different cytogenetic profiles, the relative expression of S100A8 and
S100A9 was found to be variable amongst the samples but also in comparison
to OCI-AML3 cell line. In further experiments using AML patient bone marrow
samples, treatment with JQ1 showed suppression of S100A8 and S100A9 in
some patient samples but enhanced expression in other bone marrows. In periph-
eral blood samples of healthy volunteers, we found that treatment with JQ1
showed notable suppression of both S100A8 and S100A9; with a greater sup-
pression being observed in the monocyte fraction of the samples.
Summary/Conclusions: Our data suggests that JQ1 regulates the expression
of S100A8 and S100A9 in AML. The variability of the response seen amongst
AML patient samples and AML cell lines may be reflective of the genetic profiles
driving the leukaemogenic process in these samples Further work may give
more detailed insight into the mechanisms of action and potential use of
S100A8 and S100A9 in AML prognostic markers.
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SUCCESSFUL COVERAGE OF DIFFICULT TO SEQUENCE GENES
(CALR, CEBPA, AND FLT3) ASSOCIATED WITH MYELOID DISORDERS
USING A HYBRIDISATION-BASED ENRICHMENT APPROACH PRIOR TO
NEXT-GENERATION SEQUENCING
G. Speight1,*, L. Georgieva1, E. Uddin1
1R&D, Oxford Gene Technology, Begbroke, United Kingdom
Background: The application of short read NGS for research into myeloid disor-
ders such as myeloproliferative neoplasms (MPNs) and acute myeloid leukaemia
(AML) has been hampered by the inability to sequence certain genes.  These
genes can harbour key mutations so it is desirable to ensure suitable sequencing
coverage is obtained. These genes amongst others include: CALR exon 9 inser-
tions and deletions (up to 52 bp), CEBPA single nucleotide variants (SNVs) and
FLT3 Internal Tandem Duplications (ITDs) and SNvs Each of these regions contain
certain challenging DNA sequences that can impact the quality of the data gen-
erated, e.g. large indels and low complexity regions (CALR), high GC content
(75% on average for the whole gene with specific regions at 100%) and repetitive
regions (CEBPA), and complex repetitive elements (FLT3).
Aims: To determine whether a hybridisation-based enrichment approach over-
comes the difficulties associated with these genes, and permits the generation of
high quality (sufficient de-duplicated depth) data to allow these targets to be accu-
rately interrogated.
Methods: We utilised a hybridisation-based enrichment approach for library
preparation in combination with a SureSeq myPanel™ NGS Custom AML pan-
el. The library was then sequenced using a 2x150 bp read length protocol on
an Illumina MiSeq®.
Results: Here we present the coverage and variants generated from numerous
research samples for each of these difficult to sequence genes. The results
clearly show that this approach can reliably detect and accurately size (includ-
ing low allele frequency) insertions and deletions of up 52 bp in CALR (exon
9), SNVs and deletions in CEBPA with a de-duplicated depth in excess of
2000x as well as ITDs of between 24 and 201 bp in FLT3.
Summary/Conclusions: This approach is suitable for the analysis by NGS of
these difficult genes and therefore removes the requirements for supplementary
approaches to analyse these difficult genes, such as Sanger sequencing (CEB-
PA) and fragment analysis (CALR and FLT3).
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ASSOCIATION OF MIRNA EXPRESSION PROFILES WITH FUNCTIONAL
AND MOLECULAR ACUTE MYELOID LEUKEMIA CATEGORIES 
C. Sargas1,*, M. Llop2, M. C. Alonso3, R. Ayala4, M. E. Onecha4, M. Ibañez2,
B. De Matteo1, J. Cervera2, E. Such2, P. Montesinos2, R. Rodríguez2,
D. Martinez2, B. Boluda2, M. Á. Sanz2, E. Barragán2
1Instituto de Investigación Sanitaria La Fe (IIS La Fe), 2Hospital Universitario
y Politécnico La Fe, 3Hospital Arnau de Vilanova, Valencia, 4Hospital 12 de
Octubre, Madrid, Spain
Background: Development of high-throughput technologies such as Next Gen-
eration Sequencing (NGS) allowed the identification of recurrent mutated genes
in Acute Myeloid Leukemia (AML), and new molecular markers which help
refine patients’ classification in different risk groups. 
Epigenetic alterations such as aberrantly expressed microRNAs (miRNAs) also
play an important role on the pathogenesis of AML. miRNAs control processes
such as cell development, differentiation, proliferation and apoptosis. Therefore,
aberrant miRNA expression can affect signaling and metabolic pathways,
directing cancer cell biological behavior.
Recently, several studies have classified AML according to different criteria.
TCGA proposed in 2013 a new classification where genes are grouped accord-
ing to their biological function. Moreover, Papaemmanuil et al. suggested in
2016 a new classification based on molecular markers with not overlapping
categories.
Aims: Our aim is to explore the miRNA profile of NK-AML and to find expression
profiles associated with the categories proposed by TCGA and Papaemmanuil
et al. Associations of miRNA expression profiles with altered categories could
help understand the molecular mechanisms that lead to leukemogenesis.
Methods: CD34+ cord blood progenitor cells from 5 healthy donors and 7
CD34+ NK-AML samples with >70% blasts were obtained. Total RNA from
these samples were hybridized onto an Array miRNA 3.0 chip (Affymetrix) in
order to identify deregulated miRNAs. The most deregulated miRNAs were
validated by qRT-PCR (miScript) in an independent cohort of 73 patients. Muta-
tional analysis was performed by Next Generation Sequencing using the AML
Community Panel with the Ion Torrent System (Life Technologies). Mann-Whit-
ney U test was used to determine which miRNAs were differentially expressed
among categories. 
Results: We found a profile of 6 miRNAs up-regulated and 61 miRNAs down-
regulated in NK-AML vs CD34+ cells. Validation by qRT-PCR confirmed that
miR-494 (p=0.028) and miR-4507 (p=0.035) were up-regulated and miR-27b
(p=0.022), miR-99a (p=0.001), miR-146b (p=0.031), miR-151b (p=0.006) and
miR-20b (p=0.001) were down-regulated in NK-AML. Interestingly, some of the
deregulated miRNAs were significantly associated to a functional category
according to the TCGA classification. Therefore miR-146b was down-regulated
in AML with mutations in myeloid transcription factors (p=0.025). Low expres-
sion of this miRNA causes the activation of the kB factor signaling pathway,
which increases transcription. miR-4668 was down-regulated in AML with muta-
tions in activation pathways genes (p=0.004), several target predictors propose
RASGEF1A and BRAF as targets of this miRNA. Thus, under-expression of
this miRNA could cooperate with mutations leading to the activation of signaling
pathways. Regarding to Papaemmanuil´s molecular classification, miR-494
was up-regulated in IDH2-R172 category (p=0.009). High levels of this miRNA
are associated with lower expression of TET, specially TET1. Therefore, high
levels of miR-494 could contribute to the hypermethylation signature of IDH
mutations.
Summary/Conclusions: In conclusion, the mutational landscape of significant
functional and molecular groups in AML is accompanied by miRNA deregula-
tion, which could cooperate in the development of this hematologic malignancy. 
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PROTEOMIC APPROACH TO IDENTIFY MOLECULAR TARGETS OF
HALOFUGINONE IN ACUTE MYELOID LEUKEMIA
L. Cândido1,*, C. Silva2, D. Moreno1, C. Thomé3, A. Nagler4, E. Rego5
1Hematology Division of the Department of Internal Medicine, School of Med-
icine University of São Paulo, 2Laboratory of Experimental Animal Studies,
Faculty of Medicine of Ribeirão Preto - University of São Paulo, 3Hematology
Division of the Department of Internal Medicine, University of São Paulo,
Ribeirão Preto, Brazil, 4Hematology Division and Cord Blood Bank, Chaim
Sheba Medical Cente, Tel Aviv University, Tel Hashomer, Israel, 5National Insti-
tute of Science and Technology on Cell-Based Therapy, School of Medicine of
Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil
Background: Halofuginone (HF) is a halogenated derivative of Febrifugine,
which is a molecule isolated from the plant Dichroa febrifuga. It has been
demonstrated that Halofuginone exhibits anti-fibrotic, anti-cancerogenic, anti-
inflammatory and pro-apoptotic effects. Previously, we have reported that treat-
ment with HF has anti-leukemic properties in-vitro and in-vivo in acute promye-
locytic leukemia (APL), reducing tumor growth through the induction of apop-
tosis and by stimulating the synthesis of the TGF-β protein and activating its
downstream targets. In addition, HF presented anti-angiogenic effects by mod-
ulating the level of pro and anti-angiogenic factors including VEGF. However,
it is unknown whether HF has anti-leukemic activity against other subtypes of
acute myeloid leukemia (AML) and HF targets were not determined yet.
Aims: Evaluate the anti-leukemic effect of HF on other AML subtypes than
APL and investigate its targets using a proteomic approach.
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Methods: AML cell lines Kasumi-1, THP-1, MV4-11, U937 and OCI-AML3 were
treated in- vitro with HF at concentrations ranging from 25 to 1000 ng/ml. The%
of apoptotic cells, the distribution of cells in different cell cycle phases, and the
HF IC50 was determined for each cell line. We used the Proteome
Profiler TM Array – HumanPhospho-Kinase Array to verify the possible tyrosine
kinases and signaling pathways that could be modulated by HF. To analyze the
in-vivo effect of HF, we transplanted the cell lines Kasumi-1 and THP-1 into
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, which were then treated by intra-
peritoneal injections of HF at a dosage of 150 mg/Kg daily for 14 days. The
leukemic infiltration of the peripheral blood was quantified by flow cytometry
every 2 weeks (using a anti-human CD45+). 
Results: HF IC50 values ranged from 125.58 ng/ml in Kasumi-1 to 786.15
ng/ml in THP-1 cells. Kasumi-1 cells halted in the S phase of the cell cycle
when treated with HF, displaying a significant decrease in proliferation, while
no effect was observed for THP-1 cells. Corroborating our in-vitro observation
indicating resistant of THP-1 cells towards HF, we did not detect significant dif-
ferences in the overall survival (OS) of NSG mice transplanted with THP-1 cells
treated with vehicle or HF (mean OS of 70,5 and 68 days, respectively; p=
0,24). In contrast, the mean OS for NSG mice transplanted with Kasumi-1 cells
treated with HF was significantly prolonged compared to the control group (144
versus 94.5 days; p= 0.007). The proteomic analysis identified significant
decrease upon treatment with HF of four phosphorylated-proteins in both cell
lines: Phospholipase C gamma 1 ( PLCγ1), Proline-rich tyrosine kinase 2
(PYK2), Endothelial nitric oxied syntase (eNos) and Signal transducer and acti-
vator of transcription 3 (STAT3 Y705), thus suggesting that these proteins are
primary targets of HF. In addition, the protein target of rapamycin (TOR) was
down-regulated only in THP-1, while the levels of STAT3 S727 and STAT5a/b
were significantly decreased by HF treatment only in Kasumi-1 cells. This com-
parative analysis suggests that the sensitivity to HF may be dependent on inhi-
bition of STAT3/5 pathway. 
Summary/Conclusions: In summary, our results suggest that HF may be
effective against core binding factor leukemias and, that the methodology based
on a Phospho-Kinase Array is useful to identify drug molecular targets. 
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DNA METHYLATION AND HYDROXYMETHYLATION PROFILING IS
CAPABLE TO DISTINGUISH AML SAMPLES WITH DISTINCT MUTATIONS
IN DNA METHYLATION REGULATORY GENES
H. Hájková1,*, Š. Voráčková1, Z. Krejčík1, E. Cerovská1, P. Cetkovský2,
C. Šálek2
1Department of Genomics, 2Clinical Department, Institute of Hematology and
Blood Transfusion, Prague, Czech Republic
Background: Aberrant DNA methylation as well as hydroxymethylation is a
hallmark of acute myeloid leukemia (AML). Mutations of DNA methylation reg-
ulatory genes (DNMT3A, IDH1, IDH2 and TET2) are present in approximately
40-50% of AML. These mutations are often present together with the exception
of TET2 and IDH1/2 as well as IDH1 and IDH2, which are usually mutually
exclusive.
Aims: We aimed to perform DNA methylation, hydroxymethylation and gene
expression profiling in clearly defined subgroups of AML patients with distinct
mutations in DNA methylation regulatory genes to see whether there is a clear
epigenetic and gene expression signature.
Methods: We accomplished DNA hydroxymethylation and methylation profiling
in 12 AML samples at diagnosis and in CD34+ cells of 3 healthy controls by
MethylationEPIC array (Illumina) covering aprox. 850 000 CpGs. AML samples
were chosen based on their mutational status and divided into 4 groups:
DNMT3A+ (n=3), IDH1+ (n=3), DNMT3A+/IDH1+ (n=3) and IDH2+ (n=3). The
remaining DNA methylation regulatory genes as well as CEBPA were unmutat-
ed.  1 μg of genomic DNA was treated with TrueMethyl Seq kit (CEGX) to con-
vert DNA through oxidative bisulfite (oxBS) and bisulfite (BS) treatment. This
approach allows us to determine whether CpG is methylated or rather hydrox-
ymethylated. We also performed gene expression profiling on the same sam-
ples by HumanHT-12 v4 Expression array (Illumina).
Results: We performed hierarchical clustering analysis of oxBS β-values (cor-
responding to DNA methylation levels) of 830 304 CpGs (with detection P<0.05)
and observed clear separation of 4 groups according to mutational status –
DNMT3A+, IDH1+, IDH2+ and CD34+ normals. Interestingly, double positive
DNMT3A+IDH1+ (n=3) samples clustered each into different group (DNMT3A+,
IDH1+, CD34+ normal) strongly suggesting that there is a cumulative effect of
these two opposing mutations (Figure 1). We found out that genes hyperme-
thylated in IDH1+ samples are enriched for genes from HOX gene family
(P<0.0001) and that these genes are often hypomethylated in DNMT3A+
patients. In addition, we detected a subgroup of CpGs assigned to HOXA2,
HOXA4, HOXA10, HOXB3, HOXC4 and HOXD3 genes that are hypermethy-
lated in IDH1+, hypomethylated in DNMT3A+ and normally methylated in
DNMT3+IDH1+ samples relative to CD34+ normals. Clustering of DNA hydrox-
ymethylation values (resulting from subtraction of oxBS β-values from BS β-
values) resulted into the same 4 main clusters as shown for DNA methylation
data. DNMT3A+ patients displayed the lowest hydroxymethylation levels from
all patients. Genes hydroxymethylated in IDH1+ patients were enriched for
genes involved JNK cascade (comprising of evolutionarily conserved MAP
kinases). The gene expression data did not reveal any cluster coherent with
mutational subgroups, only CD34+ normals clustered together.
Figure 1.
Summary/Conclusions: We explored that AML patients with clearly defined
mutational background exhibit distinct DNA methylation as well as hydrox-
ymethylation profiles. The presence of two mutations that have the opposing
effect on DNA methylation pattern (DNMT3A and IDH1) is linked to mixed DNA
methylation patterns, which prevents unambiguous assignment to one cluster.
Further, our data support that IDH1+ and IDH2+ represent distinct biological
entities. On the contrary, gene expression profile did not support separation of
samples into different mutational subgroups. We plan to enlarge the patients’
cohort and validate the most promising genes involved in selected pathways.
Supported by Ministry of Health of the Czech Republic, grant nr. 15-25809A,
and by the project for conceptual development of research organization
(00023736) from the Ministry of Health of the Czech Republic.
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RNA-MEDIATED CORRECTION OF ABERRANT DNA METHYLATION AT
THE P15 LOCUS
M. Li1,*, M. Borchiellini1, P. Cascino1, N. Habib2, A. Di Ruscio1
1University of Eastern Piedmont, Novara, Italy, 2 Imperial College London, Ham-
mersmith Campus, London, United Kingdom
Background: P15 (a.k.a cell cycle dependent kinase inhibitor 2B; CDKN2B;
INK4B) is a methylation sensitive gene located on chromosome 9p21 and com-
monly found silenced during Myelodysplastic Syndrome (MDS) progression to
Acute Myeloid Leukemia (AML). P15 encodes for a cyclin-dependent kinase
inhibitor increasingly expressed during granulomonocytic maturation (Teofili et
al., Exp Hematol 2000). P15 deletion or promoter methylation has been shown
to independently correlate with disease progression and poor patient prognosis
(Tien et al., Br J Hematol 2001).  Additionally, P15 expression was also sensitive
to regulation by myeloid-specific transcription factor PU.1 (Schmidt Blood 2004).
As MDS evolution to AML includes both myeloid proliferation and blocked dif-
ferentiation stages, restoration of the natural P15 transcript will provide not only
valuable information regarding disease progression but may also alleviate some
of their characteristic symptoms. 
Aims: Currently available demethylating agents approved for therapeutic appli-
cations, e.g. 5-azacytidine and decitabine, have major side effects of high tox-
icity and non-specific DNA methylation that limit their clinical application. There-
fore, the aim of this study is to achieve RNA-mediated correction of the aber-
rantly methylated P15 locus using small activating RNAs (saRNAs; Li et al
PNAS 2006).
Methods: Myeloid Leukemia cell lines HL-60, KG1a, and K562 were screened
for basal p15 expression by western blotting and qRT-PCR. As the P15 locus
is also often deleted, deletion of the locus was assayed for by PCR and by Flu-
orescent In Situ Hybridization. Because the methylation status of P15 was
shown to be inversely correlated with ANRIL (Antisense Non-coding RNA in
the INK4 Locus) expression (Kotake et al Oncogene 2010), p15 and ANRIL
gene expression were measured in parallel. HEK293 cells serve as positive
control in all studies. SaRNAs were designed against the proximal promoter,
first exon, and intron regions of the P15 gene body. SaRNAs were introduced
to cell lines through electroporation, and re-activation of the locus was meas-
ured at the transcript level by qRT-PCR and protein level by western blotting.
Changes in P15 promoter level methylation were determined by Methylation
Specific PCR.
Results: Transfection of saRNAs into the HL60 cell line showed upregulated
p15 expression 24 and 48 hrs post-transfection. Analysis of ANRIL after saR-
NA-transfection showed no concomitant changes, suggesting locus-specific
activity of the saRNAs. Future experiments will elucidate the mechanisms of
saRNA activation of P15 gene expression and genome-scale specificity of saR-
NA-mediated methylation changes.
Summary/Conclusions: There is much interest in using RNA molecules as a
therapeutic tool (Kole et al., Nat Rev Drug Discovery 2012; Reebye et al., Hepa-
tology 2014). Introduction of such an approach offers greater advantages over
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existing hypomethylating-based protocols: a) high gene specificity b) lower
cytotoxicity and c) absence of drug based off-target side-effects. In the short
term, this research can lead to the identification of novel key regulators of
leukemogenesis and new targets for therapeutic treatments; in the long term
pave the way for development of RNA-based gene demethylating agents for
cancer treatment.
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JQ1 AND CURCUMIN COMBINED TREATMENT SHOWS SYNERGIC
EFFECTS IN MLL-REARRANGED LEUKEMIA CELL LINES
P. Vitullo1,*, P.P. Leoncini1, V. Tocco1, M. Pigazzi2, K. D’Ovidio1, D. Montagna3,
R. Rota1, A. Bertaina1
1Oncohaematology, Bambino Gesù Children Hospital, Roma, 2Pediatrics-
Oncoematology, Univeristy of Padova, Padova, 3Pediatrics, Policlinico San
Matteo, Pavia, Italy
Background: MLL-rearranged leukemia accounts for 70% of infant and
10% adult acute leukemias, featuring a particularly poor prognosis and high
risk of relapse. Our main field of study is AML, in which nearly 50% of total
cases accounts for t(9;11) translocation, the remaining 50% predominantly
includes t(6;11)(q27;q23), t(10;11)(p12;q23), t(11;19)(q23;p13.1) and
t(11;19)(q23;p13.3). A 2% of AML total cases, however, is characterized by
t(4;11) translocation, which is a marker of bad prognosis and it’s, so far, poorly
characterized. A key feature of MLL-rearranged leukemia is cMyc overexpres-
sion, a well-known oncogene involved in several types of cancer. JQ1 is a
novel molecule, which prevents cMYC expression binding an important bro-
modomain protein, BRD4. Moreover, Curcumin, a natural compound, inhibits
HATs enzymes preventing lysine 14 acetylation on histone H3 (AcH3K14), a
particular residue which is bind by BRD4 to exert its function.
Aims: We would like to explore a potential synergic effect between JQ1 and
Curcumin molecules in the attempt to develop a novel therapeutic alternative
to standard chemotherapy and to deeply investigate features underlying the
molecular pathogenesis in pediatric MLL-rearranged pediatric AML.
Methods: Four human leukemia cell lines with MLL fusion protein have been
employed in this study: RS4:11, MV4:11 expressing MLL-AF4 and THP1,
MOLM13 expressing MLL-AF9 fusion genes. 5μM and 10μM Curcumin were
used to treat MLL-AF4 and MLL-AF9 cell lines respectively, while 250nM JQ1
was used to treat all the cells lines. After 2 days of treatment, either with single
and combined drugs, cell number quantification, based on metabolic activity,
was detected through XTT assay. In order to assess the cMYC, CDKN1A,
BCL2 transcripts levels and mir-99a expression a quantitative RT-PCR analysis
was carried out, while we used western blotting to detect the expression of
cMYC, PARP, Caspase3 and AcH3K14. Apoptosis and cell cycle were evalu-
ated by flow cytometric analysis.
Figure 1.
Results: In apoptosis analysis, a synergic effect was detected for all 4 cell
lines, similarly cell cycle evaluation showed a significant accumulation of cells
at SubG1 phase (2-8 fold) (Figure 1). XTT metabolic assay showed a reduction
in proliferation percentage: 65±5 for curcumin and JQ1 single treatment and
59±5 for combination of drugs in both MLL-AF4 cell lines, meanwhile in
MOLM13 cells it was 64±2 and 87±2 for curcumin and JQ1, respectively and
76±2 for their combination (P<0.005). The THP1 cells did not shown any sig-
nificant modulation in the proliferation. We decided to focus our study on t(4:11)
translocated cells, considering the more intense effect of the combined drugs
on previous analysis. qRT-PCR and western blot experiments revealed a syn-
ergic effect of the 2 experimental drugs on both apoptosis and proliferation
gene related (bcl2, caspase3, Parp, cdkn1a) as well as on the direct targets of
the drugs (cMyc, AcH3K14). Finally, in MLL-AF4 cell lines, curcumin and JQ1
together induced a significant decrease in mir-99a expression.
Summary/Conclusions: Our data demonstrated that curcumin and JQ1,
inhibiting HATs and BRD4 respectively, exert a more intense synergic effect
on MLL-AF4 than in MLL-AF9 cells. Increased apoptosis together with a
reduced proliferation rate, prompted us to investigate on molecular pathway in
which targets of these drugs are involved. Intriguingly, we found a significant
decrease in cMyc, bcl2 and AcH3K14 expression, confirming that both cur-
cumin and JQ1 have a synergic effect. Additionally, we revealed a significant
reduced expression of mir-99a, a well know oncomiR reported to act as neg-
ative regulator of differentiation and involved in drug-resistance, typically up-
regulated in pediatric AML and ALL.
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TP53Β AND TP53Γ EXPRESSION LEVELS IN RELATION TO NPM1 AND
CEBPA MUTATIONS.
K. Matiakowska1,*, A. Bartoszewska-Kubiak1, E. Bielinska1,
M. Morgut-Klimkowska1, O. Haus1
1Department of Clinical Genetics, Collegium Medicum in Bydgoszcz, Nicolaus
Copernicus University in Torun, Bydgoszcz, Poland
Background: Acute myeloid leukemia (AML) is a heterogeneous clonal disorder
with the presence of diverse genetic abnormalities in hematopoietic stem cells.
The most frequent alterations in normal karyotype AML (NK AML) are mutations
in exon 12 of nucleophosmin gene (NPM1). Until now 56 different mutations
of NPM1 exon 12 have been described, mostly insertions. The NPM protein
plays an important role in cell cycle and apoptosis control. It cooperates with
several proteins, among them with p53 and ARF. The median levels of functional
nuclear p53 protein are reduced in NPM1 and FLT3 ITD mutant samples. TP53
encodes a tumor suppressor protein which consists of transactivation, DNA-bind-
ing and oligomerization domains. Due to alternative splicing it may exist in 13
different isoforms. Alternative splicing of intron 9 leads to production of 2 different
proteins, p53β and p53γ, without oligomerization domain (stop codon is localized
in exon 9b). These isoforms can be present in acute myeloid leukemia (AML)
cells. p53β binds to BAX promoter and can induce apoptosis independent from
p53 wt. p53 has influence on activation of CEBPA which is associated with cell
cycle regulation, especially cell cycle arrest and plays also role in cell differenti-
ation. Generally, it is a transcription factor expressed during myeloid lineage
development, from progenitor cells to mature granulocytes. Various mutations of
CEBPA gene are described. Among them N-terminal and C-terminal mutations,
mostly insertions and deletions,  are often present.
Aims: The goal of the study was to assess mutational status of NPM1, CEB-
PA and FLT3 in association with TP53beta and TP53gamma expression 
evels.
Methods: 75 NK AML patients were included in the study. NPM1, CEBPA and
FLT3 gene mutations were analyzed by direct sequencing. TP53β and TP53γ
expression levels were assessed with real time PCR. Expression levels were
analyzed with ΔΔCt method, with ABL as a control gene and K562 cell line as
a calibrator.
Results: In all 75 cases, TP53β and TP53γ transcripts were detected. 36
patients had NPM1 mutations, 25 had CEBPA mutations or known polymor-
phisms, and 25 had FLT3 ITD mutation. Assessed median expression level of
TP53β was much higher (ΔΔCt 43,11) than TP53γ (ΔΔCt 10,85; p<0,05). Fur-
thermore, expression level of  TP53γ in CEBPA mutated group (ΔΔCt 11,4)
was significantly lower  than in CEBPA wt group (ΔΔCt 17,7) (p=0,03). We
have not found any other important correlation between mutations of studied
genes and TP53γ or TP53β expression. We also classified patients, according
to median expression value of TP53, to two groups: with overexpression or
with low expression. Haematological and clinical features, such as white blood
cells count (WBC), blasts count in bone marrow or patient age did not depend
on TP53 isoform expressions. However, statistical analysis showed important
difference between WBC count in NPM1mutated and NPM1wt groups.
Summary/Conclusions: Obtained results may suggest a clinical importance
of simultaneous analysis of TP53 isoform expression and mutations
in CEBPA gene. It may be hypothesized that a changed sequence of the latter
gene might influence TP53 isoform expression and in consequence regulate
the cell cycle.
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EXPRESSION PROFILE OF EPIGENETIC MODULATORS IN ACUTE
MYELOID LEUKEMIA OF INTERMEDIATE RISK 
C. Bilbao Sieyro1,2,*, Y. Florido Ortega1, C. Rodríguez Medina1, S. Gamrani1,
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E. Molina Hoyo3, S. Sánchez Sosa1, S. De la Iglesia Iñigo1,
M.T. Molero Labarta14, G. Santana Santana1, M. Perera Álvarez1, S. Jiménez
Bravo de Laguna1, M. T. Gómez Casares1
1Hematology, Hospital Universitario de Gran Canaria Dr. Negrín, 2Morfología,
Universidad de Las Palmas de Gran Canaria , Las Palmas de Gran Canaria,
3Department of Molecular and Cellular Signalling , Institute of Biomedicine &
Biotechnology of Cantabria , Santander, 4Ciencias médicas y quirúrgicas, Uni-
versidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
Background: Whole-genome sequencing has revealed acute myeloid
leukemia (AML) as a very complex and dynamic disease.Epigenetic modulation
is among the functional categories of the mutational landscape in AML.Accord-
ing to recent reports, suppression of the epigenetic reader BRD4 with small-
molecule inhibitors (BET-i) results in antileukemic activity. Clinical trials are
being developed, however, so far, identification of those patients that may ben-
efit from this therapy is not possible as changes in mRNA BRD4 levels seem
to be very subtle. It has been recently suggested that antileukemic effect of
BET-i could be due to c-myc suppression and also that high Bcl-2 levels may
target those patients that would benefit of BET-i. We believe that establishing
the expression profile of epigenetic modulators in AML may help in the identi-
fication of patients that could benefit from BET-i.
Aims: We wanted to get a better insight regarding the expression profile of
epigenetic modulator in AML of intermediate risk by studying: 1)expression lev-
els of EZH2, ASXL1, BRD4, c-myc and Bcl-2 in a consecutive series of AML
patients; 2) correlation between mRNA and protein levels; 3) Determining BRD4
binding to the c-myc promoter through chromatin immunoprecipitation (CHIP).
Methods: Our series consisted of 104 consecutive patients with a mean age
of 55.8 years (range 15-79 years) diagnosed and treated between 2005-2016
at the Hospital Universitario de Gran Canaria Dr. Negrín with a median follow
up of 12 months. Gene expression analysis was carried out through real time
PCR in a LightCycler 480 Instrument II (Roche) using GUS a control
gene.Results were normalized with a cDNA pool from bone marrow of 10
healthy donors which was introduced as internal control in each experiment.
Western blot were performed to determine protein levels for BRD4, c-myc and
Bcl2. CHIP studies for BRD4 were carried out in HL60 cell line. For statistical
analysis the SPSS (v.15.0) software was used.
Results: ASXL1 levels were positively associated with EZH2 (Spearman’s=
0.285, p=0.021) and BRD4 withc-myc (Spearman’s coefficient=0.420, p<0.001),
Bcl2 (Spearman’s= 0.471, p<0.001) EZH2 (Spearman’s= 0.4565, p=0.008) and
ASXL1 (Spearman’s=0.949, p<0.001). Survival analysis considering 50th per-
centile as a cut-off value for BRD4 expression indicated that patients with higher
levels shows better overall survival (median overall survival, OS, of 27 months,
95% IC 15.1-38.9) compared to those with low expression (median OS 12
months, 95% IC 0.4-23.7), although the association was not statistically signif-
icant (p=0.196) probably due to the limited series size. Protein levels of Bcl2
and c-myc correlated with those of mRNA, but not for BRD4, although other
antibodies should be tested in order to confirm these results. CHIP analysis in
HL60 cell lines confirmed the binding of BRD4 to c-myc promoter.
Summary/Conclusions: The positive association observed between EZH2
and ASXL1 agrees with the fact that both cooperate in the epigenetic repressive
complex PRC2.The association of BRD4 expression levels with c-myc and Bcl2
is in accordance to the reported binding of BRD4 to the c-myc and Bcl2super-
enhancer regions and our CHIP analysis also support so. Further studies in a
larger series are necessary to confirm the relationship between higher BRD4
levels and better overall survival. Finally, future analysis should be done to
determine whether patients with higher BRD4 expression levels determine a
subgroup with better response to BET-i.
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FLOW CYTOMETRY IMMUNOPHENOTYPING IN CEBPA-DM DE NOVO
AML. BIOLOGIC AND PROGNOSTIC RELEVANCE.
M. Fernandez1,*, M. Pratcorona1, A. Garrido1, C. Estivill1, J. Esteve2,
O. Salamero3, M. Tormo4, M. Arnan5, B. Bellosillo6, L. Zamora7, S. Vives7,
R. Guardia8, S. Brunet1, J. Sierra1, J. Nomdedeu1
1Hematology, Hospital de la Santa Creu i Sant Pau, 2Hematology, Hospital
Clínic, 3Hematology, Hospital de la Vall d´Hebron, Barcelona, 4Hematology,
Hospital Clínico, Valencia, 5Hematology, ICO Hospitalet, L´Hospitalet de Llo-
bregat, 6Pathology, Parc de Salut Mar, Barcelona, 7Hematology, ICO Badalona,
Badalona, 8Hematology, ICO Girona, Girona, Spain
Background: CEBPA is a transcriptional co-factor of RUNX1 which play a
major role in the fate decissions associated with physiologic myelopoiesis. Bial-
lelic CEBPA mutations (dm) define an homogenous molecular subgroup which
is associated with a favorable outcome. CEBPA mutations may be transmitted
in the germ line giving rise to clusters of familial leukemias.
Aims: To analyze the immunophenotypic findings assessed by multiparametric
flow cytometry in a consecutive series of de novo CEBPAdm AML.
Methods: Thirty-nine adult patients with de novo AML and CEBPAdm who
where enrolled on the AML-03 and AML-12 protocols of the Spanish CETLAM
cooperative group were included in this study The immunophenotypic analysis
was performed on erythrocyte-lysed bone marrow (BM) samples obtained at
diagnosis. Antigenic expression of leukemic cells was systematically analyzed
by multiparametric flow cytometry using four-color staining.  The antigens stud-
ied were: CD45, CD34, HLA-DR, CD10, CD20, CD19, CD2, CD33, CD7,
CD117, CD66, CD13, CD64, CD36, CD56, CD14, CD123, CD61, CD42b, gly-
cophorin, CD71, CD11b, myeloperoxidase, CD79a, CD3, TdT, lysozyme and
lactoferrin. At least 10.000 events/tube were measured. Analytical gates were
established according to CD45 reactivity and to FSC/SSC pattern.Positivity
thershold was established at 20%. The FACS-DIVA,Paint-a-Gate and Infinicyt
software programs were employed for analysis. Amplification of overlapping
PCR products covering the whole CEBPA coding sequence  followed by Sanger
sequencing were used to investigate CEBPA mutations. FLT3-ITD, NPM1, MLL-
PTD,  WT1 and GATA2 mutations were also investigated by conventional PCR-
based molecular methods.
Results: Antigen reactivity was as follows: CD45 (39/39,100%), CD15 (35/39,
90%), CD34 (36/39,92%), HLA-DR (39/39,100%), CD33(39/39,100%), CD2
(2/39,5%), CD7 (36/39,92%),CD117(39/39,100%), CD13(37/39,95%), CD56
(6/39,15%), CD36 (6/39, 15%), CD123(39/39, 100%), CD14 (1/39,0.02%),
CD71(38/39,97%), myeloperoxidase (38/39, 97%).In nine cases CD36 and/or
CD56 expression on leukemic blasts was greater than 20% Those
CD36/CD56+ cases had a shorter overall survival and leukemia free survival
(see graph). Four out five tested CD36/CD56+ cases also showed GATA 2
mutations. An additional CD36/CD56+ case had a FLT3-ITD. In three out 39
cases (7%) a population showing cytoplasmic CD79a reactivity was detected
(8%, 11%,14% of the neoplastic population, respectively). Two of those cases
had also a FLT3-ITD.
Figure 1.
Summary/Conclusions: CEBPAdm cases showed an homogeneous
immunophenotype with positivity for CD45, CD7,CD34,CD123,CD117, HLA-
DR, CD71,CD33,CD13 and CD15. CD36 and/or CD56 overexpression  was
detected in a subgroup of cases (9/39, 23%)  with an adverse outcome. The
current findings suggest that CD36 and CD56 reactivity should  be investigated
in larger series of CEBPAdm AML cases. Small leukemic populations with B-
cell markers are not uncommon in CEBPAdm AML (3/39, 7%).
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PROTEOME CHANGES IN ACUTE MYELOID LEUKEMIA PATIENTS
BEFORE AND AFTER INDUCTION TREATMENT
L.F. Restrepo Rodríguez1,*, S. Rothlisberger1
1Biomedical Engineering, Instituto Tecnologico Metropolitano, Medellín, Colombia
Background: Acute myeloid leukemia (AML) is a malignant disorder of
hematopoietic stem and progenitor cells (HSPCs), characterized by the accu-
mulation of immature blasts in the bone marrow and peripheral blood (PB) of
affected patients. Standard induction therapy, based on cytarabine and an
anthracycline, leads to complete remission in approximately 50% to 75% of
patients, depending on prognostic factors, such as age or the presence of cer-
tain gene or chromosomal changes. In spite of favorable primary response
rates, only approximately 20% to 30% of the patients enjoy long-term disease
survival.
Aims: Our aim was to compare the protein expression profile of peripheral
blood mononuclear cells (PBMCs) of AML patients at time of diagnosis and
after induction therapy.
Methods: PB samples were taken from seven AML patients in Medellin-Colom-
bia at time of diagnosis and after concluding the induction therapy. Informed
consent was obtained prior to sample collection. PBMCs were isolated from
the 14 blood samples using a Histopaque-1077 solution. Cells were resus-
pended in lysis buffer (0.5% Triton x-100, 50 mM Tris-HCL pH 8.0, 150 mM
NaCL, 1 mM EDTA, protease inhibitor) and proteins precipitated with
trichloroacetic acid. Proteins were separated by 2D SDS-PAGE (pI 3–10 NL),
and stained with SYPRO®Ruby. The proteomes were compared using
PDQuest™ Advanced 8.0.1 Software. Protein spots of interest were those with
a fold change of +/- 1.5 and p <0.05.
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Results: Image analysis revealed an average of 464 protein spots in PB sam-
ples taken at time of diagnosis, and an average of 346 spots in PB taken after
induction therapy, reflecting changes in protein expression due to treatment.
Comparing the proteomes, we found 11 spots that differed significantly (fold
change of +/- 1.5 and p <0.05). Of these, seven proteins were up-regulated
and four were down-regulated at time of diagnosis (before treatment) compared
to after induction treatment. Nine of these spots correspond to low molecular
weight proteins (<40 kDa) and 2 spots have a molecular weight between 40-
60 kDa. Based on the molecular weight and isoelectric point information of
these spots we were able to search for proteins reportedly involved in leukemia,
in order to propose possible identities (see Table 1). In terms of biological
process, four proteins (eIF5B, HSP27, 14-3-3 protein zeta/delta, and GST-P)
are involved in the regulation of apoptosis. The F-actin-capping protein subunit
beta could also be of interest, as reorganization of F-actin reflects unique char-
acteristics of the differentiation process in promyelocytic leukemia cells. RuvB-
like 2 is a positive regulator of histone acetylation and DNA repair. GRBP2 is
a protein involved in the MAPK cascade and regulation of PI3K signaling, path-
ways regulating diverse cellular functions altered in leukemogenesis such as
proliferation, differentiation, and apoptosis. Alpha-enolase is a key glycolytic
enzyme; however, it has been shown to be a multifunctional protein involved
in cancer. It promotes cell proliferation by also regulating the MAPK and PI3K
pathways. Transaldolase is part of the pentose-phosphate pathway. Annexin II
acts in angiogenesis and has multifaceted role in human health and disease.
Table 1.
Summary/Conclusions: The protein expression profile of AML patients changes
after induction treatment. We found 11 spots that differed significantly, and pro-
pose possible identities for these. Further analyses are pending in order to exper-
imentally establish the identities and correlate with response to treatment.
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AMP-ACTIVATED PROTEIN KINASE ACTIVITY INTERFERES WITH
OVEREXPRESSION OF NUCLEOPHOSMIN IN CYTARABINE-INDUCED
CHEMORESISTANT AML CELLS
D. Kim1,2,*, K.N. Kim1,2, J. Kang1,2, C.S. Park1,2, H.G. Yi3
1Hypoxia-related Disease Research Center, 2Pharmacology, 3Internal Medi-
cine, Inha University School of Medicine, Incheon, Korea, Republic Of
Background: Cytarabine is a chemotherapeutic drug used alone or in combi-
nation with other anticancer drugs to treat acute myeloid leukemia (AML). New
treatment strategies are emerging to enhance the anti-cancer effect and
decrease the toxiciteis. Nucleophosmin (NPM1 or B23) is a ribosomal protein
located mainly in nucleolus, and multifunctional enzyme in cancer cell growth
and protein synthesis.  AMP-activated protein kinase (AMPK) is a critical energy
sensor to regulate homeostasis and plays a potential role for anti-cell prolifer-
ating activity. 
Aims: We investigated the effects of AMPK activation on the cell death (apop-
tosis) and NPM1 expression in AML cells treated with low or high dose of
cytarabine, an anti-leukemic drug, to predict the mechanisms responsible for
AML cells chemoresistance. 
Methods: The HL-60 (FAB M2) cells were exposed to the different drug com-
binations including cytarabine and AMPK activators. The molecular mecha-
nisms of drug synergism detected by western blot assay and RT-qPCR. Cell
viability and apoptosis  were assessed using cell counting kit - 8 assay and
flow cytometry.
Results: We found that cell apoptosis (36.27 ~ 42.11%) showed little depend-
ence on cytarabine concentrations (10, 100, and 1000 mM), while the overex-
pression of NPM1 increased proportionally with drug dependence, indicating
the drug-induced cell resistance. In the same point, cytarabine also inhibited
the phosphor-activity (Thr172) and expression level of AMPK, which has
mTOR-p70S6K pathway-repressor activity. As expected, single cytarabine
treatment increased the ratio of p-mTOR/mTOR and p-p70S6K/p70S6K. Co-
treatment of AMPK activator (phenformin or AICAR) in cytarabine-treated HL-
60 AML cells inhibited significantly the induction of NPM1 overexpression level
with the decrease of phosphor-activities of mTOR and its substrate p70S6K,
resulted in the accelerated cell apoptosis. 
Summary/Conclusions: Our results suggest that the higher concentration of
cytarabine induces NPM1 overexpression, and that AMPK activation might be
used to sensitize AML cells to cytarabine with the control of NPM1 expression
levels. These modulatoins to standard therapeutic strategies could actually
enable the reduction of the chemotherapeutic dose, therefore reducing their
toxicity and adverse effects.
(Correspondence to HG Yi and CS Park; Medical Research Center No.
2014009392)
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QUERCETIN REGULATES TELOMERE-BINDING PROTEINS EXPRESSION
OF POT1, TRF1, TRF2 TO INHIBIT PROLIFERATION AND INDUCE
APOPTOSIS IN AML THP-1 CELLS
S. Cui1, X. Wu2, Z. Wang1, Y. Guo2, R. Xu1,*
1Hematology Department, Affiliated Hospital of Shandong University of TCM,
2The 1st Clinical College , Shandong University of TCM, Jinan, China
Background: Leukemia cells are limitless cell sources for initiation and main-
tenance of leukemia. Telomere-binding proteins are key regulatory factors for
various diseases, including leukemia. Therefore, targeting telomere-
binding proteins is considered as a promising therapeutic strategy for treatment
of leukemia. 
Aims: We aimed to explore whether quercetin, a natural flavonoids, could reg-
ulate telomere-binding proteins expression to inhibit proliferation and induce
apoptosis in acute myeloid leukemia(AML) THP-1 cells.
Methods: 1. In vitro: (1) We cultured human AML THP-1 cells. (2) The cells
were treated with different concentration of quercetin for 24/48 h, and the cell
viability was measured by cell counting kit-8(CCK-8) to determine the IC50 of
quercetin. (3) The cell cycle distribution and apoptotic rate were measured by
Annexin V-FITC/PI double staining flow cytometry(FCM). (4) The protein
expression levels of POT1, TRF1, TRF2 were measured by western-blotting.
(5) The mRNA expression levels of POT1, TRF1, TRF2 were measured by
real-time fluorescent quantitative polymerase chain reaction(RT-qPCR). 2 In
vivo: (1) Established AML-NOD/SCID model based on THP-1 cell line in
NOD/SCID mice, and treated with optimal quercetin concentration 40mg/(kg*d)
for 4 weeks by tail vein injection. (2)We observed the changes of mice survival
status, peripheral blood and bone marrow cell morphology and organ
histopathology by microscopy before and after treatment with quercetin. (3)
The cell cycle distribution and apoptotic rate of spleen cells were measured by
Annexin V-FITC/PI double staining FCM. The protein expression levels of
POT1, TRF1, TRF2 were measured by immunohistochemistry(IHC) staining.
Results: In this study, we found that quercetin significantly suppressed THP-
1 cells proliferation in dose- and time-dependent manner. Treatment with
quercetin significantly increased THP-1 cells apoptotic rate and G1 phase
arrest rate. Furthermore, the protein expression levels of POT1 and
TRF1 increased and the protein expression level of TRF2 decreased. The
mRNA expression levels of POT1, TRF1, TRF2 were consistent with their pro-
tein expression levels, respectively.
Summary/Conclusions: Our results demonstrate that quercetin has anti-
leukemia activity. It is mediated by regulating telomere-binding proteins expres-
sion of POT1, TRF1 and TRF2. Taken together, our findings support the con-
cept that quercetin is a promising therapeutic strategy for treatment of leukemia.
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PPARΓ AGONISTS INHIBIT ADHESION SIGNAL TO ENDOTHELIAL CELLS
IN THE DIFFERENTIATION INDUCTION OF HL-60 ACUTE
PROMYELOCYTIC LEUKEMIA CELLS.
J. Park1,*, E.-M. Noh2, J.-W. Yoon3, O.-Y. Hong2, J.-S. Kim2
1Division of Hematology/Oncology, Department of Internal Medicine, Gachon
University Gil Hospital, Incheon, 2Biochemistry, Institute for Medical Sciences,
Chonbuk National University Medical School, Jeonju, Korea, Republic Of, 3Psy-
chology, Fullerton College, Fullerton, United States
Background: All-trans retinoic acid (ATRA) has successfully been used in the
treatment of acute promyelocytic leukemia (APL) patients, with a remission
rate of greater than 90% .
Despite the high cure rates, induction mortality is a still a problem in APL. One
of the most common causes of death was the differentiation syndrome (DS) .
The early administration of high-dose dexamethasone at the onset of the first
674 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
signs or symptoms of DS is crucial, however specific biological therapies to
counteract the syndrome are still not available.
Peroxisome proliferator activated receptor gamma (PPARγ) is a ligand-depen-
dent transcription factor and a member of the nuclear receptor superfamily,
which is expressed in normal monocytes, various leukemias, and epithelial
malignancies. PPARγ   is highly induced in differentiating myeloid cells and
subsequently contributes to their differentiation.
Differentiation induction of APL cells is associated with increased expression
of specific adhesion molecules and inflammatory cytokines, which may promote
activation, migration, and adhesion of these cells.
Aims: Here, we studied the effect of PPARγ agonists on the adhesion of a
human leukemia cell line  (HL-60) to endothelial cells.
Methods: Differentiation was determined by an increase in reactivity with the
CD11b antibody. For the adhesion assay, the Matrigel transwell system was used.
Results: HL-60 cells were differentiated into macrophage-like cells by a PKC
activator, 12-O-Tetradecanoylphorbol-13-acetate (TPA). During the differentia-
tion of HL-60 cells, PPARγ agonists acitvate TPA-induced CD11b expression.
However, PPARγ agonists completely blocked TPA-induced ICAM-1 expression
of endothelial cells, which resulted in the inhibition of adhesion of HL-60 cells
to endothelial cells. These responses also were reversed by PPARγ antagonist
(GW9662), indicating that PPARγ agonists inhibits the adhesion of the HL-60
cells to endothelial cells through a PPARγ dependent mechanism.
Summary/Conclusions: These results suggest that PPARγ agonists inhibit
TPA-induced adhesion signal in the between HL-60 cells and endothelial cells,
and may control differentiation syndrome in APL patients.
Acute myeloid leukemia - Clinical
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IN VITRO DRUG SENSITIVITY TEST IN THE INDIVIDUALIZED
ANTI-LEUKEMIA CHEMOTHERAPY FOR THE NEWLY DIAGNOSED ACUTE
MYELOID LEUKEMIA
S.-N. Lim1,*, W.S. Lee2, J.-G. Shin3, E.-Y. Kim4, M.-K. Oh3, H.-J. Shin5,
H.S. Lee6, S. M. Lee2
1Internal Medicine, Haeundae Paik Hospital, 2Internal Medicine, Busan Paik
Hospital, 3Pharmacology, 4Clinical Pharmacology, Inje University College of
Medicine, 5Internal Medicine, Pusan National University Hospital, 6Internal
Medicine, Kosin University Gospel Hospital, Busan, Korea, Republic Of
Background: The biological properties, genetic abnormalities of leukemic cells
influence on their sensitivity to chemotherapeutic drugs. It is widely known that
there can be significant differences both in genetic features as well as in drug
resistance profile of individual tumors with the same phenotype.
Aims: The purpose of this study was to analyze the relationship between in
vitro chemosensitivity test results using the Cell Titer-Glo assay and clinical
response on chemotherapy, and to find the possibility of optimizing the treat-
ment for individual patients according to their actual drug resistance.
Methods: For The Cell Titer-Glo assay, we obtained bone marrow aspirates or
peripheral blood samples from 68 patients with newly diagnosed acute myeloid
leukemia at the time of initial diagnosis. The following drugs were tested: cytara-
bine arabinoside, daunorubicin, idarubicin, fludarabine, etoposide, and
methotrexate. We evaluated clinical response and survival outcome according
to chemosensitivity of drugs and protein expression.
Results: In this study, in vitro chemosensitivity test with the Cell Titer-Glo assay
showed the relationship between chemosensitivity and survival outcome sig-
nificantly. The 5-year overall survival rates with dichotomized chemosensitivity
of idarubicin (64.6% vs 33.3%, p=0.046), cytarabine (63.1% vs 43.3%,
p=0.0291), and fludarabine (80.1% vs 37.5%, p= 0.020) were higher in low
centration level than in high concentration level. There was a tendency of higher
relapse-free survival rate at 4-year in the patients with low level IC50 than in
the high level IC50. However, cytotoxic effect of testing drugs in vitro by the
Cell Titer-Glo assay did not show a relationship with complete remission rate
after induction and leukemia recurrence rate.
Summary/Conclusions: Although the Cell Titer-Glo assay did not provide the
prediction of clinical response of induction treatment, it can be a useful tool in
individually optimizing the chemotherapy of patients with newly diagnosed acute
myeloid leukemia.
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PROGNOSTIC IMPACT OF P53 EXPRESSION IN BONE MARROW BIOPSY
OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
H. Souza1,*, S. Saad1, I. Lorand-Metze1, B. Duarte1, G. Hayakawa1,
P. Campos1, M. Delamain1, G. Duarte1, J. Vassallo1, K. Pagnano1
1University of Campinas, Campinas, Brazil
Background: Several studies have shown that the presence of the TP53 muta-
tion is related to an unfavorable prognosis in patients with acute myeloid
leukemia (AML). However there are few reports on the evaluation of its expres-
sion by immunohistochemistry in bone marrow (BM) biopsy.
Aims: To evaluate the expression of p53 in BM biopsy of AML patients at diag-
nosis and its impact on survival.
Methods: This retrospective analysis included 85 patients with de novo AML
diagnosed from January 2005 to December 2015 submitted to BM biopsy at
diagnosis.  p53 expression was detected by immunohistochemistry, and staining
was evaluated using the H-score (range 0-300). The t-test and Mann-Whitney
U test were used to detect differences in the distribution of continuous para-
metric and nonparametric variables, respectively. Overall survival (OS), dis-
ease-free survival (DFS) and event-free survival (EFS) were calculated using
the Kaplan-Meier method. The log-rank test was used for comparison of survival
curves. The interaction between the examined prognostic variables was tested
with univariate and multivariate Cox regression analysis.
Results: Median age was 60 years (17-81). There was a predominance of
patients >60 years (54.1%) and males (56.5%). The median H-score for p53 was
11.8 (0.4-161.1), with no significant correlation with age or cytogenetic risk. p53
expression was significantly higher in patients with a complex karyotype
(p=0.0031) and high risk by European Leukemia Net (ELN) criteria  (p=0.047).
There was a positive correlation with complex karyotype and prognostic risk by
ELN. Excluding early deaths (<30 days from induction), patients younger than
60 years with H-score >60 showed worse overall survival when compared with
patients with H-score <60 (0% vs 14.6%, respectively) (p=0.048). There was no
statistical difference in disease-free survival and event-free survival. In the Cox
univariate analysis including all cases, peripheral leukocyte counts at diagnosis
(p=0.014), cytogenetic risk groups (p=0.07), ELN risk categories (p=0.023) and
H-score (p=0.025) were significant. In a multivariate model including leukocytes,
ELN risk and p53, all variables remained in the model.
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Summary/Conclusions: Expression of p53 assessed by immunohistochem-
istry is a fast, objective and promptly available tool for prognostic evaluation of
AML. A high expression of p53 (H-score >60) was related to a lower overall




LONG-TERM FOLLOW-UP OF SALVAGE TREATMENT FOR RELAPSED
AML WITH CLADRIBINE, HIGH DOSE CYTARABINE AND IDARUBICIN
K. Mayer1,*, C. Hahn-Ast1, K. Schwab1, A. Glasmacher1, I. Schmidt-Wolf2,
P. Brossart1, M. von Lilienfeld-Toal1
1Medical Clinic III, 2University Hospital Bonn, Bonn, Germany
Background: Despite improving response rates in induction treatment for AML
during the last years the outcome for relapsed or refractory AML is still poor.
Currently, no standard therapy exists for patients with relapsed AML. Further-
more, CR rates are lower than in newly diagnosed patients and range between
15% and 50%. There is evidence that cladribine (2CdA) has single drug activity
in AML as well as an enhancing effect on other cytostatic drugs such as cytara-
bine (AraC) and thus may help to overcome resistance mechanisms.
Aims: Therefore, testing the combination of 2CdA, AraC and idarubicin (CAI)
seems reasonable. Here we present the final analysis from our single-center
phase II trial evaluating the safety and efficacy of CAI in relapsed AML patients
after a follow-up of 5 years.
Methods: Patients with relapsed AML after at least 6 months of remission and
ECOG 0-2 were included. Chemotherapy regime consisted of two courses of
2CdA 5 mg/m²/12 h, d 1-3, AraC 1000 mg/m²/12 h, d1-3 and Idarubicin 8
mg/m²/d, d1-3. After 8 patients, the prolonged duration of neutropenia especially
in course 2 prompted us to change the protocol by 1) application of growth fac-
tors from day 15 onwards, and 2) omission of idarubicin from the 2nd course.
The primary endpoint was the overall remission rate and safety of CAI.
Results: Because of slow recruitment the study was stopped after 20 patients.
The median age was 63 years, 40% were female. 19/20 (95%) patients were
included in the first relapse after at least 6 months of CR following 1st line ther-
apy for AML. 1/20 (5%) patient was included with a second relapse. In 14/20
patients cytogenetic data at the timing of relapse were available, according to
the ELN-risk-group 2017 3/14 (22%) had favourable cytogenetic changes, 9/14
(64%) intermediate and 2/14 (14%) belonged to the adverse cytogenetic group.
The performance status was good in most patients (ECOG 0 in 10%, ECOG 1
in 80%), but reduced (ECOG 2) in 2 (20%) patients. After the first course,
CR/CRi was achieved in 60% and PR in 10% of patients. Median duration of
neutropenia was 24 days (range 18-41d). The main grade 3 or 4 non-haema-
tologic toxicity was infection seen in 85% of courses. Nausea occurred in 30%,
hepatotoxicity, mucositis and diarrhea in 11% of courses. Cardiac or renal tox-
icities grade 3/4 were not observed. Two patients (10%) died due to infection.
Six patients received a second course of CAI/CA. Altogether, 6 patients were
refractory. Nine patients (48%) proceeded to allogeneic stem cell transplanta-
tion after induction therapy with CAI. Of those, 4 patients are still alive and free
of leukemia and one patient died in CR 88 months after salvage-therapy
accounting for a 5-year survival rate of 55%.
Summary/Conclusions: Combination therapy with CAI in relapsed AML
patients is feasible and induces good response rates. Combined with allogeneic
stem cell transplantation, long-term survival can be achieved. However, infec-
tion rates are a serious complication warranting intensive supportive care.
PB1677
HIGH EVI1 EXPRESSION PREDICTS POOR OUTCOMES IN ADULT ACUTE
MYELOID LEUKEMIA PATIENTS WITH INTERMEDIATE CYTOGENETIC
RISK RECEIVING CHEMOTHERAPY ONLY
Y.-Z. Qin1, T. Zhao1, H.-H. Zhu1, J. Wang1, J.-S. Jia1, Y.-Y. Lai1, X.-S. Zhao1,
H.-X. Shi1, Y.-R. Liu1, H. Jiang1, X.-J. Huang1, Q. Jiang1,*
1Peking University People’s Hospital, Peking University Institute of Hematology,
Beijing, China
Background: Nearly half of acute myeloid leukemia (AML) patients are defined
as an intermediate cytogenetic risk, however the patients in this group have
greatly varied outcomes and need to be stratified. Apart from gene mutation,
abnormal gene expression might also be prognostic, and ecotropic viral inte-
gration site 1 (EVI1) expression is a representative. To date, the poor prognostic
impact of EVI1 expression in AML has been reported, but almost all studies
have been undertaken by European researchers. EVI1 prognostic significance
in AML remains to be confirmed in other populations. Furthermore, because
the detection protocol and cutoff value selection methodologies differed among
studies, the threshold for defining EVI1 high expression remains obscure, which
hinders its clinical routine application.
Aims: We investigated the prognostic impact of EVI1 transcript levels in Chi-
nese adult intermediate cytogenetic risk AML (ICR-AML) patients who received
chemotherapy only in a single center. The appropriate cutoff values for grouping
EVI1 expression were also evaluated.
Methods: A total of 191 adult patients receiving chemotherapy only were includ-
ed in this study. They were diagnosed as ICR-AML according to morphology,
immunophenotyping, cytogenetics and molecular biology. Their bone marrow
samples were collected at diagnosis. Real-time quantitative PCR was per-
formed to test EVI1, MLL partial tandem duplicate (MLL-PTD) and WT1 tran-
scripts, and their transcript levels were calculated as the percentage of target
transcript copies/ABL copies. NPM1 mutations and FLT3 internal tandem dupli-
cation (FLT3-ITD) were individually screened by real-time quantitative PCR
and qualitative PCR. 27 normal bone marrow (NBM) samples form volunteers
were simultaneously tested EVI1, MLL-PTD and WT1 transcripts. All partici-
pants provided written informed consent in accordance with the Declaration of
Helsinki.
Results: The upper limit of EVI1 transcript levels in 27 NBM samples was 8.0%.
Receiver operating characteristic curve analysis showed that 1.0% (a 0.9-log
reduction from the normal limit) was the EVI1 optimal diagnostic cutoff value for
significantly differentiating relapse (P=0.049). A total of 23 patients (12%) had
EVI1 levels ≥1.0%. EVI1≥1.0% had no impact on complete remission achieve-
ment. EVI1≥1.0% was significantly associated with lower 2-year relapse-free
survival (RFS), disease-free survival (DFS) and overall survival (OS) rates in the
entire cohort (P=0.0003, 0.0017 and 0.0009), patients with normal karyotypes
(n=148, P=0.0032, 0.0047 and 0.0007) and FLT3-ITD (-) patients (n=150, all
P<0.0001). Multivariate analysis showed that EVI1≥1.0% and FLT3-ITD (+) were
independent adverse prognostic factors for RFS (Table 1), DFS and OS in the
entire cohort. In addition, patients with EVI1 between 1.0% and 8.0% had 2-year
RFS rates similar to those with EVI1≥8.0% (P=0.16), and both patient groups
had significantly higher RFS rates than those with EVI1<1.0%. 
Table 1.
Summary/Conclusions: EVI1 transcript levels at diagnosis could further strat-
ify adult ICR-AML, and high EVI1 expression predicts poor outcomes in patients
receiving chemotherapy only. The optimal cutoff value which best differentiates
patients is different from the normal upper limit. 
Grant support: The Nature Science Foundation of China (81370637, 81370639
and 81570130).
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EFFICACY AND SAFETY OF DECITABINE IN ELDERLY AML PATIENTS:
A REAL LIFE MULTICENTER EXPERIENCE OF THE NETWORK RETE
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Background: The optimal treatment decision in older patients (pts) with AML
remains controversial, especially in patients pts with comorbidities, non-fit to
intensive therapy or with AML adverse biologic features. Recently decitabine
was approved in Italy in AML pts unfit to chemotherapy aged >65 years (y) and
could be adopted in a population based setting.
Aims: To evaluate efficacy and toxicity of decitabine in a consecutive series of
elderly AML pts (no M3), considered unfit to chemotherapy (CT) according to
Ferrara et al (Leukemia, 2013) and treated at 6 centers of the Hematological
Lombardy Network (REL).
Methods: Between Dec 2015 and Dec 2016, 46 (F/M: 22/24) newly diagnosed
AML pts received decitabine (20mg/mq/daily for 5 days every 4 weeks) as out-
patients. Median age was 76 y (69-85), ECOG performance status (PS) was
≥3 in 10.8%. According to “fitness”, 41 pts (89.1%) were defined unfit to inten-
sive CT, 1 frail and 4 fit. Unfitness causes were age >75y (58.5%), PS ECOG≥3
unrelated to leukemia (12.2%), and comorbidities (29.3%). AML was “de novo”
in 25 pts (54.3%), therapy-related in 3 and secondary to antecedent hemato-
logical disorders in 18 pts. WBC count at diagnosis was 4.4 x10^3/mL (0.46 to
63), marrow blasts were 51% (<30% in 19.5% of pts). Karyotype (K) was normal
(NK) in 43%, t(8;21) in 4.5%, intermediate in 20.5%, adverse (adv) in 32% of
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pts, according to ELN (Doehner, 2017). In 2 pts it was not evaluable. Molecular
analysis was available in 17/19 NK, NPM1 was mutated in 5 cases, with (2) or
without (3) FLT3-ITD mutation.
Results: The total number of cycles administered was 231 (median 3.5; range
1-20). In 37/46 evaluable pts (2 ongoing, 1 early and 6 aplastic deaths), overall
response rate (ORR) and complete remission (CR) rate were 51.% and 32%,
respectively. Partial response and hematological improvement were achieved
in 5.5% and in 13.6%, stable disease in 29.9% and failure in 19% of pts, respec-
tively. Median time to best response was 3.5 months (range 1-8.5). Median
response duration was 5.3 months (1-18+ ms). Relapse/disease progression
was observed in 42% of responders. ORR was 21.4%, 47.3% and 77%  in adv,
NK and intermediate K, respectively (P=0.0289). After a median follow-up of
6.5 months, median survival was 8.4 months and projected OS at 1 y and 2 y
was 43%+/-9 (SEM) and 30%+/-12% (SEM). Treatment was fairly well tolerated
except for a high incidence of infections (46 episodes in 231 cycles) particularly
during the first 3 cycles  (29% vs 11%) (p 0.0072). Pneumonia was the most
frequent infection (46%), followed by sepsis (28%). It was more frequent during
the first 3 cycles [14% vs 4% : p 0.012)] when 44% of cases were of suspected
fungal origin (3 probable aspergillosis and 4 possible IFI). Death occurred in
24 pts (52.2%): 12 (50%) of disease progression, 1 of early CNS hemorrhage
and 11 (45.8%) of infection. In the first 3 months, infections were responsible
for 46.7% of deaths. Pulmonary IFI were fatal in 57% of cases. These figures
are higher than those reported by Cashen (JCO 2010) where the frequency of
pneumonia was 11%.
Summary/Conclusions: These preliminary data confirm, in a population based
setting, the high efficacy of decitabine and its longer time to response (more
than 3 cycles) compared to CT. However infections complications were more
frequent than expected and often fatal, particularly early during treatment. Since
pneumonia, especially IFI, was the major cause of death, the adoption of routine
antimicrobial prophylaxis may be considered in order to reduce early mortality
and further improve the results.
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Background: In unselected patients with acute myeloid leukaemia (AML) in
first relapse or refractory to primary daunorubicin / cytarabine therapy, complete
response (CR) rate is merely 20 - 30%. In patients <60-years old, CR rates of
about 55% may be achieved. 
Aims: We tested in a multicenter prospective phase 2 study the efficacy and
safety of clofarabine, cytarabine and mitoxantrone (CLAM) in AML patients in
first relapse or refractory to first-line daunorubicin / cytarabine induction therapy.
Methods: Consenting patients aged 18 to 65 years in first relapse or refractory
to first-line dose-intensified daunorubicin / cytarabine were recruited. Bone mar-
row pathology and karyotype at diagnosis and relapse were centrally reviewed.
Next-generation sequencing of a myeloid panel of 67 genes was performed.
Re-induction CLAM comprised clofarabine (40mg/m2/day, days 1-5), cytarabine
(750mg/m2/day, days 1-5) and mitoxantrone (12mg/m2/day, days 3-5). Bone
marrow assessment was done on day 28 using standard criteria. Treatment
toxicity was evaluated using the Eastern Cooperative Oncology Group Common
Toxicity Criteria (ECOG-CTC). Survivals were determined using Kaplan Meier
method. The primary outcome was the response on day 28. Secondary out-
comes included treatment toxicity, leukaemia-free and overall survivals.
Results: In this interim analysis, 24 patients (14 men, 10 women) with a median
age of 44.5 (19-66) years were treated. Karyotypic and genetic profiles were:
normal karyotype (N=8) (NPM1 mutant, N=1; FLT3-WT, N=8), t(8;21)(q22;22)
(N=4) (KIT D816V mutant, N=1), inv(16)(p13.2;q22)/t(16;16)(p13.2;q22) (N=1)
(KIT D816V mutant, N=1), inv(3)(q21;q26) (N=5), del (11)(q23) (N=2),
t(9;11)(p21;q23) (N=1), trisomy 13 (N=1), near-tetraploidy (N=1), and complex
karyotype (N=1). Twenty patients (83.3%) responded (CR, N=16; CR with
incomplete hematopoietic recovery, N=4). Eight responding patients underwent
allogeneic haematopoietic stem cell transplantation. Grade 3/4 haematologic
toxicity was seen in all patients. Grade 1/2 and grade 3/4 hepatotoxicity was
observed in 17 (70.8%) and 2 (8.3%) patients respectively. Grade 1/2 rash was
observed in 4 patients (20%). Cardiotoxicity or treatment-related mortality was
not seen. With a median of follow-up of 4 (1-32) months, 6 patients relapsed.
The 12-month overall and leukaemia-free survivals were 81.7% and 66.8%
respectively.
Summary/Conclusions: CLAM resulted in a high CR rate for AML in first
relapse or refractory to first-line induction therapy, which was associated with
an acceptable toxicity profile.
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Background: The very early death of a newly diagnosed acute leukemia (AL)
patient is very frustrating, and there are very few published works (except for
the case of acute promyelocitic leukemia, APL) analyzing this circumstance
and the features of these patients. 
Aims: Our objective was to study the main characteristics of patients with acute
leukemia who died within the first 96 hours after diagnosis in our centre in the
last 15 years.
Methods: We studied all cases of acute leukemia diagnosed in our institution
between April 2002 and January 2017, focusing on the analysis of those who
died within the first 96 hours after diagnosis. In this subset of patients, we collected
data concerning clinical presentation, hemogram, biochemical parameters, coag-
ulation status, performance of a bone marrow aspirate, acute leukemia subtype,
started therapy, initiation or not of induction chemotherapy, time elapsed from
diagnosis to death (hours), and cause of death, among others.
Results: A total of 346 consecutive cases of acute leukemia were recorded in
this period of time: 222 of acute myeloid leukemia (AML, 64%) and 124 of acute
lymphoblastic leukemia (ALL, 36%). Thirty-three patients were diagnosed of
acute promyelocytic leukemia (15% of all AML). Those patients who died in the
first four days after the diagnosis were only seven (2%), with a median of 45
hours of life (range 21-96). Main clinical and analytical findings are shown in
the Table 1. They were 5 men and 2 women with a median of 57 years (range
22-91). Two of the seven patients had an APL (6% of all diagnosed APL). All
patients showed leukocytosis, but hyperleukocytosis was only recorded in 2/7
patients, and severe thrombocytopenia (Plt ≤ 20 x109/L) in 3/7. There was pos-
sibility of bone marrow aspiration only in 4/7 cases. Coagulopathy was detected
in four of six patients, including criteria for disseminated intravascular coagu-
lation (DIC) in three cases. The exitus took place in the Intensive Care Unit in
5 cases, while it occurred in the Hematology facility in two.
Table 1.
Summary/Conclusions: In our experience, about 2% of patients with acute
leukemia die within the first 96 hours after diagnosis (including 6% of APL).
Clinical and analytical feautures of this subset of patients are very heteroge-
neous, although AML clearly predominate on ALL. More extensive and multi-
center studies are needed to deepen into the circumstances conditioning this
early fatal course of the disease.
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PRIMARY POSACONAZOLE PROPHYLAXIS IN ACUTE MYELOID
LEUKEMIA - A SINGLE CENTER REAL LIFE EXPERIENCE
T. Fıratlı Tuğlular1,*, T. Özgümüş1, T. Elibol1, F. Pepedil Tanrıkulu1,2, F. Geçgel1,
A. Sezgin1, Y. İpek1, B. Ertürk Şengel3, A. Tekin3, B. Kömürcü3, H. Bilginer3,
C. Mutlu3, T. Toptaş1, I. Atagündüz1, Z. Odabaşı3
1Hematology, Marmara University, Istanbul, 2Hematology, Dr Ersin Arslan
Research & Training Hospital, Gaziantep, 3Infectious Diseases and Clinical
Microbiology, Marmara University, Istanbul, Turkey
Background: Invasive fungal infections (IFI) are a major cause of mortality
and morbidity in acute myeloid leukemia (AML) patients receiving remission
induction therapy, and relapsed/refractory AML patients. Posaconazole pro-
phylaxis has shown the greatest benefit in preventing IFI in AML .
Aims: We present the data of our real-life experience in AML patients under PP.
Methods: We have retrospectively reviewed the data from 82 AML patients
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receiving 105 cycles of chemotherapy between June 2012 and December 2016
in Marmara University Pendik Research and Training Hospital. Median patient
age was 50 years (18-73); and there was no significant gender difference (38
female vs 44 male (46% vs 54%)). All patients had active disease, 78 (74.3%)
of them received 3+7 (idarubicine - ara-c), 25 (23.8%) of them FLAG-Ida, 1
patient received EMA and 1 patient received CLARA chemotherapy protocol.
Acute promyelocytic leukemia was excluded from the analysis. All patients
received posaconazole as oral suspension at the dose of 200 miligrams three
times daily starting on the first day of chemotherapy. Prophylaxis was continued
until marrow regeneration, or occurrence of IFI, or onset of adverse events, or
discontinuation due to other reasons. All fungal infections were classified as
possible, probable, or proven according to European Organization for the
Research and Treatment of Cancer (EORTC) and the Mycoses Study Group
(MSG) consensus criteria.
Results: Mean posaconazole prophylaxis duration was 20±13 (1-68) days.
This duration was 29.7 days (16-50) in patients receiving prophylaxis until mar-
row recovery, 18.9 (9-34) days in patients developing IFI under prophylaxis,
and 12.7 days (1-68) in prophylaxis discontinuations due to adverse events
and other reasons. Posaconazole prophylaxis was administered until marrow
recovery without IFI (clinical success rate) in 42 of 105 (40%) chemotherapy
cycles. In 18 cycles prophylaxis was stopped after diagnosis of IFI (%17.1).
Discontinuations were due to adverse events in 6 cycles (5.7%), and due to
other reasons (diarrhea, intolerance of oral medication, recurrent high grade
fever, death) in 39 cycles (37.1%). IFI incidence under effective posaconazole
prophylaxis was 28.1% (18/64). Total clinical failure rate was 60% (63/105). IFI
was diagnosed with pulmonary nodules in 12 of 18 patients (66.6%; EORTC-
MSG: possible), with galactomannan positivity in 3 patients (16.6%; EORTC-
MSG: probable), and with fungal culture in 3 patients (16.6%; EORTC-MSG:
proven). Data from 70 patients were available for mortality analysis. In patients
receiving effective posaconazole prophylaxis, all-cause mortality rate at day
100 was (9/44; 20.4%) significantly lower than patients unable to continue
posaconazole prophylaxis (12/26; 46.1%) (p:0.023). In the subset of patients
receiving prophylaxis as planned; there was no statistically significant difference
in IFI incidence between previously untreated AML (13/46; 28.2%) and
relapsed/refractory AML (5/18; 27.7%). 
Summary/Conclusions: In our real-life experience, we have demonstrated
early survival benefit in patients receiving effective posaconazole prophylaxis.
Although our IFI rate was comparable to other real-life data, our clinical failure
rate was slightly higher. This is probably due to compliance issues, since in
many chemotherapy cycles (37.1%) posaconazole was discontinued due to
“other reasons” such as drug intolerance. Although not as effective as in the
clinical trials; our data still supports the use of posaconazole prophylaxis in
high risk AML patients.
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CLINICAL AND PROGNOSTIC VALUE OF FLT3 MUTATIONS IN ACUTE
MYELOID LEUKEMIA PATIENTS IN ROUTINE CLINICAL PRACTICE –
SINGLE CENTER EXPERIENCE
A. Radzhabova1,*, S. Voloshin1, I. Martynkevich1, V. Shuvaev1, M. Ivanova1,
E. Motyko1, N. Cybakova1, L. Polushkina1, D. Shikhbabaeva1, N. Potikhonova1,
S. Tyranova1, M. Zenina1, S. Kudryashova1, A. Chechetkin1
1Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, Russian Federation
Background: Detection of FLT3 gene mutations in acute myeloid leukemia
(AML) now recognized as an unfavorable factor that affects the disease course,
emerging the risk of relapses and overall survival (OS) shortening. Although
about 30% of AML patients harbor one of the FLT3 gene lesion, at present
there are no internationally standardized assays to quantify FLT3 mutation bur-
den and no results of randomized clinical trials intended to individualize AML
treatment based on FLT3 status. Some hematologists advocate to allo-SCT
as consolidation in FLT3 ITD+ patients, but this way could be hard in frail and
old patients and in countries with low access to transplant techniques. On the
other hand, the development of target drug therapy – FLT3-kinase inhibitors
gives us a new hope for improvement in the treatment results of such poor-
prognosis subset of AML patients.
Aims: To assess the frequency of FLT3 gene mutations and its impact on clin-
ical parameters and overall survival of the patients with acute myeloid leukemia
(AML) in routine clinical practice.
Methods: We have analyzed FLT3 gene mutation frequencies, complete blood
count (CBC) parameters, karyotype and survival outcomes per FLT3-mutation
status in 199 patients with AML (83 male / 116 female). The median age at
diagnosis was 52 years (20-86 years). To determine FLT3 gene mutations we
used the method of polymerase chain reaction (PCR) with subsequent restric-
tion. FLT3 gene mutations were classified as internal tandem duplication (FLT3-
ITD) and point mutation in the “A-loop” (FLT3-TKD). Statistical analysis was
included Kruskall-Wallis ANOVA and Kaplan-Meyer curves.
Results: We observed next FLT3 gene mutations rates: FLT3-ITD - 22.6%
(45/199), FLT3-TKD 5.5% (11/199), FLT3-ITD and FLT3-TKD in combination
1.0% (2/199), other 70.8% (141/199) patients had no mutations (FLT3-). CBC
data at the time of diagnosis were as follows (median (max-min)): · FLT3-ITD:
Hb 9.7 (3.7-13.0) g/dl, WBC 40.3 (0.6-400.0) x 109/l, blasts 80% (21-100),
platelets 60 (2-140) x 109/L; · FLT3-TKD: Hb 10.2 (5.8-12.8) g/dl, WBC 62.4
(1.7-362.0) x 109/l, blasts 68% (23-100), platelets 55 (12-115) x 109/L; · FLT3-
ITD+TKD: Hb 5.8, 8.4 g/dl, WBC 37.0, 157.0 x 109/l, blasts 65%, 86%, platelets
38, 186 x 109/L; · FLT3-: Hb 9.0 (2.8-14.0) g/dl, WBC 12.9 (1.0-260.0) x 109/l,
blasts 64% (20-103), platelets 63 (1-334) x 109/L; Significant differences across
the groups were seen only in WBC and blasts. Chromosomal aberrations were
revealed in 38% of FLT3-ITD, 64% of FLT3-TKD, none of FLT3-ITD+TKD and
51% of FLT3- patients. All patients received chemotherapy (7+3, 5+2, HAM).
Transplantation of hematopoietic stem cells (SCT) was performed in 28
(allo/auto 17/11) (14%) patients: FLT3-ITD allo-3; FLT3-TKD allo-1, auto-1;
FLT3- allo-13, auto-10. We found significant (p=0.00024) differences regarding
to OS between FLT3-ITD, FLT3-TKD and FLT3- patients (Figure 1). Median
survival times were: 5.1 months for FLT3-ITD, 7.1 months for FLT3-TKD and
13.0 months for FLT3- patients.
Figure 1.
Summary/Conclusions: We confirmed the role of FLT3 gene mutations as
an unfavorable factor for AML patients in routine clinical practice by own expe-
rience. The investigation of qualitative assessment potential and target therapy
value especially in SCT ineligible FLT3 gene mutations positive patients has of
great value for AML management.
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TARGETING ENDOTHELIAL DYSFUNCTION FOR PROTECTION FROM
ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN PATIENTS WITH
ACUTE LEUKEMIA AND CO-MORBID ISCHEMIC HEART DISEASE
T. Lymanets1,*, I. Skrypnyk1, G. Maslova1
1Chair of Internal Medicine #1, Ukrainian Medical Stomatological Academy,
Poltava, Ukraine
Background: Cardiotoxicity of chemotherapeutic drugs, in particular anthra-
cycline antibiotics (AA), is one of the biggest problems in treatment of patients
with acute leukemia (AL). Chemotherapy with AA is accompanied by systemic
endothelial dysfunction, increasing the cardiovascular toxicity risk and promot-
ing vascular complications. Patients with co-morbid ischemic heart disease
(IHD) are at extremely high risk of myocardial injury and in need of anthracycline
cardiotoxicity (AC) prevention.
Aims: To assess the effectiveness of L-arginine in the prevention of endothelial
dysfunction as a predictor of acute AC in patients with AL and co-morbid
ischemic heart disease.
Methods: A total of 66 patients with newly diagnosed acute leukemia (acute
lymphoid leukemia – 7 patients, acute myeloid leukemia – 59 patients) and co-
morbid ischemic heart disease were included in the study. The cohort consisted
of 34 (51.5%) males and 32 (48.5%) females, age of 54–72 years, ECOG I-II.
The duration of IHD ranged from 3 to 15 years. Chemotherapy (CT) schemes
included AA (doxorubicin). The evaluation of endothelial dysfunction was per-
formed by determining the stable metabolites of nitric oxide – nitrite anions
[NO2]- and activity of total NO-synthase in serum of patients before the CT and
upon reaching a cumulative dose of AA from 100 to 200 mg/m2 by doxorubicin.
The mean total cumulative dose of AA reached 162,04±24,65 mg/m2and
166,49±27,34 mg/m2in groups I and II respectively. The study was approved
by the local ethical committee and all patients gave a written consent before
they were included in the study. Patients were divided into two groups: (n=36)
– AL patients treated with CT; II (n=30) – AL patients, whom during the CT in
order for prevention of acute AC were given L-arginine hydrochloride 4.2% 100
ml IV the day before and during administration of AA, followed by oral L-arginine
aspartate for a month.
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Results: In the debut of AL prior to the CT in all 66 (100%) patients the
increased activity of total NOS in 3.8 times compared with the norm (p˂0,001)
was noted, with simultaneously reduced concentration of [NO2]- in 1.5 times
relatively normal values (p˂0,05) (Table 1). As a result of two CT courses of
remission induction in patients of group I the tendency to reduce the total NOS
activity compared with its level before treatment was observed. At the same
time the significant decrease of [NO2]- in 1.8 times relatively normal values (p
<0.01) and a trend to lower their content in 1.2 times compared with the data
before treatment (p>0.05) was noted. These changes constitute the violation
of NO-dependent vasodilation mechanism and endothelial dysfunction intensi-
fication. Provided achieving low cumulative dose of AA in patients of group II
on the background of AC prevention with L-arginine showed a significant
decrease in 1.9 times the total NOS activity (p <0.001) with a simultaneous
tendency to increase concentration of [NO2]- in 1.3 times (p>0.05) compared
to that before treatment.
Table 1.
Summary/Conclusions: Thus, during the CT with the inclusion of AA without
L-arginine in patients with AL and co-morbid IHD we observed the depletion of
NO substrate production, accompanied by endothelial dysfunction impairment.
The additional appointment of L-arginine on the background of CT can restore
synthesis of NO and, respectively, the mechanism of NO-dependent vasodila-
tion, thus reducing the risk of early anthracycline cardiotoxicity development.
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CLINICAL CHARACTERISTICS AND SURVIVAL OUTCOMES IN ACUTE
ERYTHROID LEUKEMIA (AML-M6): AML/MDS WORKING PARTY STUDY
OF KOREAN SOCIETY OF HEMATOLOGY
J.J. Han1,*, H.-J. Kim2, W.-S. Min2, I. Kim3, Y. Koh3, H.-J. Kim4, J.-S. Ahn4,
Y. Park5, B.S. Kim5, H.-J. Shin6, C.W. Jung7, J.-W. Cheong8, J.-H. Lee9,
J. Park10, W.S. Lee11, H.-J. Yoon12
1Internal Medicine, Kyung-Hee University Medical Center, 2Internal Medicine,
Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of
Korea, 3Internal Medicine, Seoul National University College of Medicine, Seoul,
4Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun,
5Internal Medicine, Korea University School of Medicine, Anam Hospital, Seoul,
6Internal Medicine, Pusan National University Hospital, Busan, 7Internal Med-
icine, Samsung Medical Center, Sungkyunkwan University School of Medicine,
8Internal Medicine, Yonsei University College of Medicine, 9Internal Medicine,
Asan Medical Center, University of Ulsan College of Medicine, Seoul, 10Internal
Medicine, Gachon University Gil Medical Center, Incheon, 11Internal Medicine,
Inje University Busan Paik Hospital, Busan, 12Internal Medicine, Kyung Hee
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Background: Acute erythroid leukemia is a morphologically distinct and rare
entity designated as M6 in FAB classification. In Korea, patients with AML-M6
have been treated as acute myeloid leukemia with intensive chemotherapy
whenever possible rather than as myelodysplastic syndrome. The 2016 revision
of the WHO reclassified erythroid/myeloid subtype (a case with ≥50% BM ery-
throid precursors and ≥20% myeloblasts among non-erythroid cells) to MDS
category based on the close biological and genetic relationships between them.
Aims: The aims of this multi-center study were to characterize clinical charac-
teristics and treatment outcomes in patients with newly diagnosed acute ery-
throid leukemia.
Methods: Clinical data from newly diagnosed M6-AML patients between 2002
and 2012 at 11 academic centers were retrieved from the electronic registry
data of AML/MDS working party of Korean Society of Hematology. Conventional
cytogenetic analysis was performed on metaphase cells prepared from bone
marrow aspirate by G-banding technique. Patients were classified according
to the UK MRC cytogenetic risk criteria and the International Prognostic Scoring
System (IPSS) risk groups for MDS based on karyotypes. Survival curves were
analyzed using the Kaplan-Meier method and compared with a log-rank test. A
p-value <0.05 was considered statistically significant.
Results: A total of 84 patients with AEL (M6-AML) as defined by 2008 WHO
classification criteria were included in this study. The median age at diagnosis
was 55 years with following distribution: age ≤ 49, 34 patients (40.5%); age 50
– 59, 17 (20.2%) patients; 60 – 69, 19 (22.6%) patients; age ≥70, 14 (16.7%)
patients. There were 50 (59.5%) males and 34 (40.5%) females. Median hemo-
globin, white blood cell count, and platelet count were 8 g/dL, 3.69 × 109/L,
and 58 × 109/L, respectively. Peripheral blood blasts were observed in 55
(65.5%) patients. Cytogenetic results were available in 80 patients. Among
them, karyotype was normal in 43 (53.8%) and complex in 13 (15.5%) patients,
respectively. Trisomy 8 was observed in ten (12.5%) patients. Monosomies of
chromosome 5 and 7 were observed in five (6.2%) and four (5.0%) patients,
respectively. Four (5.0%) patients had t(9;22)(q34;q11.2). Cytogenetic risk
groups according to UKMRC criteria were intermediate in 63 (78.8%) patients,
and poor in 17 (21.2%) patients. Seventy-two (85.7%) patients received induc-
tion chemotherapy and 55 patients (76.4%) achieved complete remission. Nine-
teen patients received two or three cycles of induction chemotherapy. Thirty-
eight patients (45.2%) underwent allogeneic hematopoietic stem cell transplan-
tation (HSCT): 8 patients, matched-sibling donor; 15 patients, matched-unre-
lated donor; 5 patients, alternative donor were used. Treatment-related mortality
of HSCT was observed in five (17.9%) patients. Fourteen (16.7%) among the
study patients relapsed. The median overall survival (OS) of total 84 study
patients was 21 months. Patients with intermediate risk karyotype showed bet-
ter median OS than those with poor risk karyotype (22 months vs 7 months,
P=0.020). The median OS was similar in patients with good and intermediate
IPSS, but significantly worse in patients with poor IPSS (21 months, 27 months,
7 months, respectively, P=0.026) (Figure 1).
Figure 1.
Summary/Conclusions: Patients in this study were younger than previous stud-
ies. The most common aberrations in chromosomes are trisomy 8, followed by
numerical changes in chromosome 5 and 7. The median in total patients was 21
months with many patients received intensive treatment, including HSCT in 45.2%
of patients. We also confirmed that patients with poor-risk karyotypes had very
poor median OS of 7 months. Therefore, we suggest that although
erythroid/myeloid subtype is similar to the MDS with excess blast, treatment deci-
sion might be carefully considered according to the karyotype risk.
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PREGNANCY ACCUMULATES UNFAVORABLE MOLECULAR GENETIC
AML AND SHOULD BE CONSIDERED AS A POOR PROGNOSTIC FACTOR
V. Troitskaya1,*, E. Parovichnikova1, A. Sokolov1, A. Kokhno1, Z. Fidarova1,
A. Sidorova1, O. Gavrilina1, G. Galstian1, A. Bazhenov1, L. Kuzmina1,
M. Drokov1, S. Makhinya1, O. Latishkevich2, A. Zvereva2, A. Olenev3,
O. Korobitsyna4, A. Korobkin4, V. Savchenko1
1National Research Center for Hematology, 2Centre of Family Planning and
Reproduction, 3City Clinical Hospital №24, Moscow, 4Chelyabinsk regional
hospital, Chelyabinsk, Russian Federation
Background: Acute myeloid leukemia (AML) during pregnancy – is a rare clin-
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ical condition that limits the possibility to conduct large prospective clinical stud-
ies. All publications present small retrospective data and case reports. Most of
them conclude that pregnancy doesn’t affect the prognosis of acute leukemia.
Aims: To assess the pregnancy, as independent prognostic factor, in non APL
AML-patients (pts), prospectively treated within Russian AML multicenter studies.
Methods: From 1990 to 2017 yy the Russian Acute Leukemia study group
has treated 33 with de novo AML pregnant women (Me-27 (21-42) yrs). AML
was diagnosed in the Ist trimester in 1 woman (3%), in the IInd– 15 (45,5%), in
the IIIrd- 17 (51,5%). Molecular genetic risk group was estimated in 27/33 pts:
52% (n=14) were referred to the intermediate risk group and 48% (n=13) to
the poor prognosis. High risk group comprised complex karyotype (n=5), -
7/del7 (n=4), translocations involving gene MLL (n=2), 1 pt - inv3/-7 and 1 pt -
AML with myelodysplasia-related changes, normal karyotype and FLT-3+.
In 1 pt at the 1st trimester medical abortion was conducted and 11 women
delivered at the gestation age of 34-40 weeks before chemotherapy (CT). 21
pregnant women received CT, that was started at 23 (14-32nd) weeks of ges-
tation. Classical 7+3 was applied in all of pts: either with daunorubicin (45-60
mg/m2), or mitoxantrone (10 mg/m2), or idarubicin (12 mg/m2) regarding the
treatment study-protocol.
Results: As our data show, AML in pregnancy is characterized by high preva-
lence of unfavorable cytogenetic abnormalities (48%), that is substantially dif-
ferent from AML in non-pregnant women of the same age (11,5%)
(p=0,006) [Blood 2016,128;22,p.5171]. 1 pt died before CT due to septic shock,
2 pts – in induction CT now. 2 pregnant women died due to severe infections
in aplasia during induction (5,7%). So, induction results were evaluated in 30/33
pts: CR rate - 73,3% (22/30):  after the 1st course CT - in 16 and after the 2nd–
in 6 pts. In pts, with available cytogenetic data, CR was received in 100% (9/9)
from the intermediate and in 80,0% (8/10) from the poor prognostic group. Pri-
mary resistance was registered in 6/30 pts (20%). Antenatal fetal mortality was
registered in 2 cases at the 21stand 32nd weeks during induction. 29 children
were born. Allogenic bone marrow transplantation (allo-BMT) was done in 10
of 28 (35,7%) AML-pts who had survived induction therapy at a median of 6
months after CR. 4 pts relapsed after allo-BMT and 1 woman remained with
refractory AML after allo-BMT. Our results demonstrated rather low 10-y OS
and DFS (10,48% and 10,46%) in women, whom AML was diagnosed during
pregnancy. In order to evaluated the role of allo-BMT, we performed a landmark
analysis (landmark=6 months of CR), that has shown better OS and DFS only
in pts after allo-BMT (Pic) (Figure 1).
Figure 1.
Summary/Conclusions: Our results demonstrate: almost half of women, who
were AML diagnosed during pregnancy, are referred to the poor molecular
genetic prognostic group; they demonstrated very low OS and DFS whit their
improvement after allo-BMT.
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CLOFARABINE IN RELAPSED-REFRACTORY ACUTE MYELOGENOUS
LEUKEMIA: A SINGLE CENTRE EXPERIENCE
B. Scappini1,2,*, G. Gianfaldoni1, M. Armenio2, F. Mannelli1, I. Cutini1,
M. Piccini2, C. Biagiotti2, R. Fanci2, M. Di Gioia2, A. Bosi2
1Haematology, AOU Careggi Florence, 2Haematology, University of Florence,
Florence, Italy
Background: Clofarabine has been shown to be effective in AML patients,
mainly in combination with high dose cytarabine
Aims: On the basis of these reports, we tested clofarabine in association with
high dose cytarabine in relapsed/refractory AML patients, selecting cases of
primary refractory to at least two induction therapies, relapsed but refractory to
a standard re-induction treatment, or very early relapsed.
Methods: Betweeen 2008 and 2016 we treated 67 patients with a regimen
including clofarabine at 22,5 mg/m2 daily on days 1-5, followed after three
hours by cytarabine at 1 gr/m2 daily on days 1-5.
Among the 67 patients, 24 were in first relapse, 29 in second or third relapse,
14 with resistant disease. The mean age was 54 years (range .36-77 years).
Results: 20/67 patients achieved a complete remission (29,9%), 4/67 a partial
response (6%) ,38/67 had resistant disease (56,7%), 3/67 died of complications
during the aplastic phase (4,4%). The most frequent non haematologic adverse
events were: transient liver toxicity (41% grade 1-2, 11% grade 3-4) skin rash
(33%),  vomiting (28%), diarrhea (15%). Comparing with other salvage strate-
gies, in this cohort of patients we did not observe a  significant delay in bone
marrow recovery (median time to ANC recovery 21 days). Febrile neutropenia
was observed in 58 cases (85%), with bacterial infections microbiologically
documented in 20 patients (29%) and 2 cases (3%) of fungal infections. The
median overall survival of the whole cohort was 115 days , with a median event
free survival of 111 days. Among the responding patients, 16 (24%). underwent
allogeneic bone marrow transplantation; in these selected patients, median
overall survival was 185 days.
Summary/Conclusions: These results suggest that the clofarabine-ARA-C
regimen was able to induce a response in about one third of this particularly
poor prognosis category of patients, with safety data consistent with previously
reported salvage therapies. Nevertheless, long term results remain still and
completely unsatisfactory. Further studies, with different combinations or in
more selecting conditions, are warranted.
PB1687
PRESENCE OF MULTIPLE DRIVERS IN THE SELECTION OF HIGH AND
LOW INTENSITY CHEMOTHERAPY IN AML
B. Pandya1,*, A. Hadfield2, B. C. Medeiros3, S. Wilson1, E. Berrak1, T. Bailey2,
S. Flanders1, A. Rider2, L. Horvath1
1Astellas Pharma Inc., Northbrook, United States, 2Adelphi Real World,
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Background: Data on the key drivers of initial treatment choice for patients
diagnosed with acute myeloid leukemia (AML) in the United States is limited.
The use of age as a selection driver of induction therapy is well established;
however, there is limited data and a knowledge gap about additional factors
driving treatment selection. 
Aims: This analysis explored the key physician drivers, which led to the selec-
tion of high- and low-intensity induction therapy in AML patients. 
Methods: Data from the Adelphi AML Disease Specific Programme, a real-
world, cross-sectional survey conducted between February–May 2015, was
analyzed.  A total of 61 hematologists/oncologists provided attitudinal informa-
tion about their management and treatment choices for AML patients via sur-
vey.  Each physician was provided a pre-specified list of 16 patient character-
istics. Via two separate questions, they were asked to select those considered
important when choosing high and low intensity chemotherapy for their AML
patients. Characteristics were analysed descriptively and ranked based on the
frequency of mention from highest to lowest.
Results: The top three drivers for decision making when selecting high and
low intensity treatment were: patient age, performance status and presence of
comorbidities. More than 60% of physicians would prescribe high-intensity
treatment to patients aged under 65, with a good performance status or with
no comorbid conditions. Over half of physicians would consider those who are
eligible for a stem cell transplant or have a mutation in the CEBPA gene to be
eligible for high-intensity chemotherapy (Table 1).  Low-intensity chemotherapy
was considered by more than 60% of physicians as being the most appropriate
treatment for patients aged ≥65, with a poor performance status or increased
number of comorbid conditions. A total of 38% of physicians would likely con-
sider low-intensity chemotherapy if the patient was ineligible for a stem cell
transplant or had had previous cancers or exposure to radiation/chemotherapy
in the past.
Table 1. Top 5 patient characteristics considered by physicians when
choosing high- or low-intensity treatment in AML.
Summary/Conclusions: Irrespective of treatment intensity, patient age, per-
formance status and the presence of comorbidities are the top three drivers of
treatment selection for physicians. In addition to patient age, identification of
the other key drivers for therapy selection and the physician awareness of
them is critical to ensure patients receive the most appropriate therapy.  This
improved awareness could also lead to better communication tools for patients
and improve shared decision-making.
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IRAIN LONG NON CODING RNA ARE DOWN-REGULATED IN POOR
PROGNOSIS AML PATIENTS
M. Eizadifard1, M. Yaghmaie1,*, H. Pashaiefar1, E. Gheisari1, M. Montazeri1,
K. Alimoghaddam1, A. Ghavamzadeh1
1Hematology, Oncology and Stem cell Transplantation Research Center,
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Background: IRAIN which is produced from the insulin-like growth factor type
I receptor (IGF1R) imprinted locus is a newly identified lncRNA. There are very
little knowledge about the specific role of this lncRNA in tumorogenesis presses.
Recent studies were revealed that IRAIN is down-regulated in leukemia cell
lines and viral expression of the IRAIN lncNRA inhibits tumor cell migration,
suggesting a tumor suppressor function for this transcript.
Aims: In this study, we attempted to examine the expression level of IRAIN in
different cytogenetic subtypes of AML patients.
Methods: Using quantitative polymerase chain reaction (qPCR) the expression
level of IRAIN were analyzed in  bone marrow specimen of AML patients (n=76)
and healthy individuals (n=18).
Results: IRAIN expression was found to be remarkably decreased in AML
patients compared with healthy individuals (p= 0.02). Significant IRAIN down-
regulation was observed in all FAB types except for the M3 (p= 0.11). When we
analyzed the expression level of IRAIN in different cytogenetic subtypes of AML
patients the statistically down-regulation of IRAIN was observed only in poor
prognosis AML patients (p= 0.008).
Summary/Conclusions: Our results suggest that down-regulation of
IRAIN lncNRA might play a role in the AML development and hence may be a
potential prognostic factor and serve as therapeutic target for AML treatment.
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PERFORMANCE OF THE LEUKOSTRAT® CDX FLT3 MUTATION SIGNAL
RATIO ASSAY TO DETECT INTERNAL TANDEM DUPLICATION AND
TYROSINE KINASE DOMAIN MUTATIONS IN PATIENTS WITH ACUTE
MYELOID LEUKEMIA
A. Osgood1,*, E. Shakeri2, V. Atkinson1, N. Kha3, C. Simon4, J. Thornes3,4,5,
T. Stenzel1, J. Miller1
1Invivoscribe Technologies, San Diego, United States, 2Product Development,
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Background: Acute myeloid leukemia (AML) in general has a poor prognosis.
Assessment of the mutation status of the FLT3 (fms related tyrosine kinase 3)
receptor gene in AML is the most important prognostic indicator of disease out-
come, which is often substantial, as many studies in AML have shown that the
presence of FLT3 activating mutations portends a poor prognosis. The LeukoS-
trat® CDx FLT3 Mutation Assay targets regions of the FLT3 gene to identify
internal tandem duplication (ITD) mutations and tyrosine kinase domain (TKD)
mutations. Since this assay is a signal ratio (SR) assay with a validated cutoff
of 0.05, demonstration of international harmonization of results is paramount.
FLT3 ITD mutations are caused by duplication and insertion of a portion of the
FLT3 gene that includes the region in and around the juxtamembrane region of
the FLT3 gene. These mutations vary in both the location and the length of the
inserted duplicated DNA sequence. ITD mutations result in constitutive
autophosphorylation and activation of FLT3. FLT3 TKD mutations are caused
by nucleic acid substitutions and/or deletions that result in a change in the
amino acid sequence in this highly-conserved catalytic center. TKD mutations,
such as D835 and I836 substitutions and deletions, result in constitutive
autophosphorylation and activation of FLT3.
Aims: To assess the performance of the Invivoscribe® LeukoStrat® CDx FLT3
Mutation Assay.
Methods: White blood cells were removed from peripheral blood after 30 min-
utes of centrifugation at 2000 xg to create leukocyte depleted blood (LDB). Var-
ious ratios of four ITD positive cell lines, with insert sizes from 21 bp to 279 bp,
and one TKD positive cell line, with a D835 substitution mutation, were created
over a wide range of signal ratios (0.02 to 1.83) and added to the LDB. Mononu-
clear cells were isolated from the contrived LDB samples. DNA was extracted
and amplified via PCR. The amplicons were analyzed via capillary electrophore-
sis. The assay measured the ratio of signals from mutation against a back-
ground of signal from wild type. A FLT3 mutation was detected (and reported
as positive) if the mutant:WT type SR met or exceeded the clinical cut-off of
0.05. Proprietary software calculated the SR and reported positive or negative.
Clinical specimens were de-identified by LabPMM in San Diego. DNA from
twenty specimens was tested by three laboratories: LabPMM LLC in San Diego,
LabPMM GmbH in Germany and LabPMM Gk in Japan.
Results: The analytical performance of the LeukoStrat® CDx FLT3 Mutation
Assay was evaluated using contrived LDB samples, with known FLT3 muta-
tions. For limit of blank (LoB), the SR was 0.00 in the ITD assay and 0.00 to
0.01 in the TKD assay, which is well below the clinical cutoff SR of 0.05. The
limit of detection in the ITD assay detected allelic ratios of 0.03, 0.05, and 0.33
above the LoB SR in more than 95% of samples for insertions sized at 30 bp,
126 bp and 279 bp, respectively. The limit of detection in the TKD assay detect-
ed an allelic ratio of 0.05 above the LoB. For precision and reproducibility, the
SR%CV was within 3-14% across ITD and TKD mutation types regardless of
reagent lots, equipment, or operator.
There was 100% agreement between all three clinical LabPMM laboratory sites.
Summary/Conclusions: This robust assay produced a SR%CV less than 15%
regardless of reagent lot, equipment or operator. The high reproducibility
between the three laboratories on three different continents provides evidence
that the Invivoscribe® LeukoStrat® CDx FLT3 Mutation Assay is an interna-
tionally standardized assay.
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CLINICAL FEATURES AND OUTCOME OF PATIENTS WITH CORE
BINDING FACTOR ACUTE MYELOID LEUKEMIA 
S. Taoussi1,*, N. Rekab1, F. Lamraoui1, S. Oukid1, K.-M. Benlabiod1,
H. Brahimi1, M.T. Abad1
1Hematoloy, EHS ELCC CAC, Blida, Algeria
Background: Acute Myeloid  leukemia is classified into different prognostic
groups according to their cytogenetic profil; AML with t (8; 21) or  inv16/ t (16;
16) called AML CBF belong to a prognostic group of low-risk; they represent
15% to 20% of the AML. 
Aims: The aim of this study is to present clinical , cytogentic features and out-
come of this group of patients (pts) in an emerging country.
Methods: Cytologic diagnosis  of AML CBF is completed by immunophenotyp-
ing and cytogenetic analysis: 
t(8; 21), inversion 16/t (16.16) and del 16q22. Induction treatment: Daunorubicin
45 to 90 mg/m² day (d1-d3)+Cytarabine 100 mg/m² (d1- d7) (with progressive
doses if major leukocytosis). Assessment  between d 21 and d 28 by bone
marrow analysis ; If failure a second course induction is performed by Cytara-
bine high dose 3 g m²/12 h d1, d3, d5.  Central nervous system prophylaxis for
patients (pts) with AML4, M5 and hyperleukocytosis forms.  Consolidation:
Cytarabine high dose: 2 to 3 cures; low dose of chemotherapy for pts older
than 55 years or pts presented severe toxicity at the first induction. Research
of Kit, FLT3 and residual disease is not available in our laboratory, hematological
stem cell transplantation (HSCT) was proposed for all pts;  if no compatible
donor, 3 courses of Cytarabine high doses was instituted.
Results: From 2010 to 2016, cytogenetic analysis was performed in all cases
of AML of which 58 cases (18,6%) of LAM - CBF were diagnosed. The male to
female ratio was 0.5 ; average age: 37 years (16-72); t (8,21) was found in 28
pts (16 M,12F); inversion (16)(p13.11;q22.1), t(16,16)(p13.11;q22.1) and del
16q22 were found in 30 pts (12M,18F), respectively in 27 pts, 2 pts and 1 pt.
Four cases of del(16)(p13) were associated with inv(16). For inv(16), FAB sub-
types were AML4 (26),  AML2 (1) and 3 AML; For t(8;21), there was 26 AML2
and 2 AML4. Evaluation of induction: not evaluable: 13 cases, Complete Remis-
sion (CR): 38 cases (65,5%); for  7 cases in failure , a second induction was
proposed, we obtained  2 CR. 15 pts were transplanted. Outcome: 27 pts are
alive in CR of which 12 transplanted . 31 pts died of which 18 toxic deaths ( 15
after induction treatment and 3 after engraftment). Median overal survival for
inv(16) : 11 months vs 15 months for t(8;21) (p=0,87).
Summary/Conclusions: In our study,  the frequency of the CBF AML is closer
than those described in another Algerian study and literature: 18,6% vs 15.4%
and 20% respectively; a slight predominance of the inv 16 or t (16; 16) identical
to that reported by the SWOG study. The RC rate is under  to that reported by
the CALGB study.  We noted less relapse compared with literature. Relapses
were observed in pts with poor prognostic factors: age, leukocytosis and failure
to first induction. Regarding the favorable prognosis of AML CBF, our results
are bad because the high rate of toxic deaths. The CBF AML are characterized
by a better prognosis, but with a 30% relapse rate essentially when associate
poor prognosis factors such as a kit mutation that increases the risk to 70%,
mutation FLT3, advanced age, the leukocytosis, severe thrombocytopenia and
additional cytogenetic abnormalities.
PB1691
FLOW CYTOMETRY ANALYSIS SOFTWARE FOR REMOTELY LOCATED
HAEMATOLOGISTS
M. Kelly1,*
1Haematology Department, Our Lady’s Childrens Hospital Crumlin, Dublin, Ire-
land
Background: Current flow cytometry software packages are unsuitable in cas-
es where the interpreter of the data isn’t physically located at the computer
with the software installed. This is particularly disadvantageous in urgent situ-
ations, such as in the diagnosis of acute leukemia.
Aims: Develop a tool to allow haematologists to analyse flow cytometry data from
anywhere on any internet-enabled device e.g. tablet, smartphone, laptop, PC.
Methods: We came up with principles a new software package should adhere
to: 1. should be accessible from any Internet-enabled device e.g. iPad, Android
phone, Blackberry, laptop; 2. should not require installation; 3. FCS data should
be anonymised; 4. data transfer should be secure and encrypted; 5. software
must include all basic functionality of flow cytometry software e.g. dot plot
graphs, histogram graphs and gating 6. should put collaboration to the forefront
e.g. analysis can be instantly linked to via a web URL.
Results: The resulting software package is a web app which is accessible from
any Internet-enabled device e.g. smartphone, tablet, laptop or PC. On mobile
devices such as an iPad, touch is used for drawing of gates, selection of quad-
rants, selections of parameters etc. On laptop’s and PCs, these are drawn via
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the mouse or keypad. The software utilises the latest strides made in web tech-
nologies to respond to the varying screen sizes of devices, and display suitably
sized graphs and gating information accordingly. Collaboration between parties
is facilitated - a lab technician running the sample can upload the sample and
instantly shared with other parties with the required permissions. Analysis, such
as gating, can take place immediately and can then be instantly shared via a
web URL. No sensitive file data is displayed within the platform. All data transfer
happens via SSL encryption.
Web app is available at https://www.redmatterapp.com
Figure 1.
Summary/Conclusions: The latest web technologies can be effectively har-
nessed to enhance flow cytometry analysis and allow for faster, more acces-
sible and more collaborative analysis. Within the field of haematology in par-
ticular, this opens up the option of remote diagnosis - a haematologist need to
be in the lab, or even in the same country, to deliver a diagnosis. 
PB1692
FLAG-IDA IN THE TREATMENT OF ACUTE LEUKEMIA: SINGLE-CENTER
EXPERIENCE
M.I. Goyanes Martin1,*, M.A. Canales Albendea1, M. Fabra Urdiola1,
M.D.M. Meijon Ortigueira1, V. Jimenez Yuste1
1Hematology, Hospital La Paz, Madrid, Spain
Background: A variety of different treatment regimens have been studied in an
effort to improve outcomes of patients with relapsed or refractory acute myeloid
leukemia (RR-AML), there appears to be no single superior approach. Spanish
groups usually use the FLAG-IDA protocol (Fludarabine 30 mg/m2 days 1-4,
Idarubicine 12 mg/m2 days 1-3, ara-C 2 mg/m2 days 1-5) in these patients.
Aims: To evaluate our response rates and the survival with FLAG-IDA protocol.
Methods: Descriptive study of a case series of patients with acute leukemia
who received intensive induction chemotherapy with FLAG-IDA protocol at our
hospital between January 2007 and December 2016. Biodemographic,
histopathological, cytogenetic and molecular results and previous treatment
were recorded. We analyzed the response rate, the 30-day mortality rate and
the overall survival.
Figure 1.
Results: 65 patients received treatment with FLAG-IDA protocol between 2007-
2016, 36 of them female, with and average age of 53.4 years (DS+/-23.3). We
treated with this protocol mostly patients with relapsed or refractory acute
myeloid leukemia (RR-AML) (primary refractory or resistant AML as defined by
not achieving complete remission after 1 cycle of intense induction therapy);
60% (n=38) of patients had a RR-AML, 37% (n=23) of them were relapsed AML
and 23% (n=15) refractory AML. Based on European Prognostic Index Score
(EPI-SCORE) for patients with RR-AML, 61% of them had a poor prognosis
(10-14 points), 36% had an intermediate prognosis (7-9 points) and only 3%
had a favorable prognosis (1-6 points). The next important group, 25% (n=17)
were MDS patients transformed to AML. We had 9% (n=6) patients with treat-
ment related AML and 6% with other acute leukemia (3 cases of refractory ALL
and 1 case of biphenotypic leukemia). We observed a global response rate of
63%: 51% (n=33) of patients had a complete response (CR) and 12% (n=8)
partial response, 17% (n=11) did not have a response and 20% of patients were
not evaluated after to receive the treatment because they had a early dead.
The 30-days mortality rate was 21.5% (n=14), similar to the rate of no evaluated
patients. We can see in the overall survival curve (picture 1) that most patients
died first months after treatment, after that patients remain alive and we achieve
a plateau.  The median overall survival was 82 days (standard deviation: 25
days). 10 patients were alive when we analyzed the data (Figure 1).
Summary/Conclusions: Most AML patients ultimately die from their disease.
In our case serie none died by any other cause. We had a similar response
rate, mortality and overall survival that other groups in our country. Despite a
variety of salvage therapy options, like FLAG-IDA protocol, prognosis in patients
with RR-AML is generally poor and treatment is very complex.
PB1693
BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS - UNUSUAL
PRESENTATIONS AND UNFAVOURABLE OUTCOMES
M. Guenova1,*, A. Michova1, T. Dikov1, Y. Georgieva1, B. Spassov1,
K. Prisadashka2, M. Balabanova2, V. Kaleva3, G. Balatzenko1
1National Specialised Hospital for Active Treatment of Hematological Diseases,
2Alexandrovska University Hospital, Sofia, 3University Hospital St.Marina, Var-
na, Bulgaria
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare
hematological malignancy with an aggressive clinical course. Most patients
(pts) with BPDCN have skin lesions and involvement of the peripheral blood,
bone marrow, and lymph nodes. Very few cases have been described with
lack of skin and or bone marrow manifestations at the time of diagnosis.
Aims: To characterise the clinical presentation and clinical outcomes of a cohort
of consecutive patients with a rare blastic plasmacytoid dendritic cell neoplasm
in a single institution.
Methods: Patients diagnosed with BPDCN at the National Hematology Hos-
pital between 2010 and 2016 were retrieved from the database. The diagnosis
was confirmed by morphology and immunophenotying by flow cytometry and/or
immunohistochemistry, according to 2008 WHO Classification of Hematopoietic
Neoplasms. The relevant clinicopathologic features were reviewed.
Results: We identified 8 adult patients at a median age of 70 years (range: 37-
84 years) with a male:female ratio of 6:2 (75%:25%) and only 1 child. Mean
values of blood cell counts were as follows: WBC 5.109/L; hemoglobin 99 g/L;
platelets 116.109/L. LDH was generally elevated with a mean of 962.8 U/L. At
diagnosis the skin was invoved in 5/9 patients. Five patients developed leukemic
presentation with 40-95% of bone marrow infiltration. Interestingly, in 4 pts (50%
of adult pts) the initial presentation affected other tissues and organs such as
testis, bronchial wall, stomach and periorbital soft tissues, however, only the latter
one case presented with a leukemic picture. Biopsies revealed diffuse, monomor-
phous infiltrate of medium-sized blast cells with irregular nuclei, fine chromatin
with ≥1 nucleoli,  scant and agranular cytoplasm, without angioinvasion or coag-
ulation necrosis. Immunophenotype generally demonstrated CD45+, CD4+,
CD56+, CD123+. No standard therapies were applied. Patients received CHOP
or HyperCVAD or AML-induction therapy. However, response rates in adult
patients were low and the mean OS was 2.6 months (ranging from early deaths
before any treatment could be initiated to 10 months).
Summary/Conclusions: BPDCN is a rare aggressive disease that typically
affects elderly patients. The most commonly affected non-hematopoietic organ
is the skin, however any other organ or tissues can also be involved. Response
to therapy if any is relatively short and long-term prognosis is poor despite of
the site of presentation. Larger scale studies are warranted to understand the
pathophysiology of the disease and to find optimal management.
Acknowledgements: Partial support by the National Science Fund.
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PREDICTIVE RELEVANCE OF CLINICAL CHARACTERISTICS IN
PEDIATRIC PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA
TREATED AT SINGLE INSTITUTION– REPORT OF AN OUTCOME ANALYSIS
S. Al-Sweedan1,2,*, K. Siddiqui1, R. Jafri1, I. Ghemlas1, A. Al-Ahmari1,
A. Al-Seraihy 1
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1Pediatric Hematology/Oncology, King Faisal Specialist Hospital & Research
Center, Riyadh, Saudi Arabia, 2Pediatrics, Jordan University of Science & Tech-
nology, Irbid, Jordan
Background: Western hospitals have achieved First Complete Remission (CR-
1) and Overall Survival (OS) rates of 90% and 60% for children with Acute
Myeloid Leukemia (AML). Intensified regimens of standard chemotherapy along
with precise risk classification and improvements in supportive care are mainly
attributed to this achievement.
Aims: We analyzed clinical data of our pediatric AML patients treated at
KFSH&RC from 2005 to 2015 in order to assess the outcome of our treatment
efforts including Hematopoietic Stem Cell Transplantation (HSCT).
Methods: A total of 155 pediatric patients with AML were registered at our insti-
tution from 2005 to 2015. 55.5% (86) were boys with a F:M ratio 1:1.2 and
median age at diagnosis 5.5 years (Min: 1.3months, Max: 13.8 years). 12
patients were excluded from further analysis for not being able to complete
induction at our institution. 7% (10 of 143) had Down ’s syndrome, 7.7% (11 of
143) had concomitant malignancies. 85.7% (120 of 140) were CNS-1, 27.4%
(20 of 73) had MLL Gene rearrangement, 21.2% (14 of 66) were positive for
TEL AML/RUNX1/RUNX1T1 and 22% (13 of 59) had PML/RAR (+). Trisomy 4,
10 or 17 was not seen among any of 13 patients tested. Most commonly
observed FAB classification was M-5 (23.5%, 24 of 102) followed by M-2
(18.6%). 27.3% (39) were Low Risk, 43.4% (62) Intermediate and 29.4%(42)
High Risk. 43.3% (58 of 134) received HSCT.
Results: Our CR-1 rate was 93.7% (134 of 143) with 100% in Low Risk, 95.2%
Intermediate Risk and 85.7% in High Risk patients (P-Value: 0.023), requiring
1-3 cycles of chemotherapy with a median time of 1.3 months. Treatment Failure
was observed in 6.3% (9 of 143). Relapse rates was 38.8%(52 of 134). Most
common site of relapse was bone marrow (75%, 39 of 52). PML/RAR (P-Value:
0.044), Post-Induction BM Classification M-3 (P-Value: 0.034) and AML High
Risk (P-Value: 0.003) were found to be significantly associated with Relapse.
Age at diagnosis, or Time to CR-1 were not found to have any association with
relapse. 51.9% (27 of 52) who relapsed, went for HSCT. With a median follow-
up of 68.8 months, five year overall survival for our cohort of patients was
(0.567±0.046); significantly poor (P-Value: 0.001) in relapsed (n=52,
0.137±0.051) compared to non-relapsed (n=82, 0.863±0.041); resulting in a
five year event free survival of 0.472±0.044. Among relapsed group (n=52),
five year overall survival was significantly better (0.160±0.073) for those who
received HSCT (27) than who did not (n=25, 0.114±0.073, P-Value: 0.029).
Five year overall survival was also significantly better for Non-Relapse group
(n=31, 0.828±0.070) compared to relapsed patients (n=27, 0.160±0.073, P-
Value=0.001) for whom HSCT was administered (n=58)
Summary/Conclusions: The results of our treatment efforts are in conformity
with the western literature. Precise risk classification can be a vital predictor in
planning for first line and salvage therapies including HSCT for pediatric patients
with AML.
PB1695
IS HIF-2 ALPHA A POOR PROGNOSIS FACTOR IN HUMAN ACUTE
MYELOID LEUKEMIA? A SINGLE CENTER ANALYSIS - PRELIMINARY
RESULTS
J. Dybko1,*, D. Urbaniak-Kujda1, D. Szymczak1, O. Haus1,2, B. Jaźwiec1,
M. Sawicki1, T. Wróbel1, K. Kuliczkowski1
1Hematology and Bone Marrow Transplantation, Wroclaw Medical University,
Wroclaw, 2Department of Clinical Genetics, Collegium Medicum , Nicolaus
Copernicus University, Bydgoszcz, Poland
Background: Hypoxia-inducible transcription factors (HIF)  are well known
regulators of cellular response to hypoxia. HIFs control functional, metabolic
and vascular adaptation to hypoxia on transcriptional level. HIF-1 alpha has
been also described to be responsible for solid tumors chemoresistance, inva-
sion, metastasis and relapse. The role of HIFs in leukemias has not been estab-
lished well so far. First reports of poor outcomes of antileukemic treatment
linked with overexpression of HIF-1α has been published. Moreover another
HIF subunit  - HIF-2 alpha - has been described in mouse model as increasing
myeloid preleukemic cell proliferation and accelerating disease progression
with reduced survival. On this background, we found interesting if HIF-s alpha
expression in acute myeloid leukemia cells (AML) influences the prognosis in
human. We have tried to find a connection between AML cells percentage
expressing HIF-2 alpha and first line chemotherapy results.
Aims: The aim of the study was to determine the roole of HIF-2 alpha in
human AML.
Methods: We analyzed a 26 primary AML patients group (median age 54.5
(21-77), F/M – 13/13). The group consisted of 21 AML-NOS cases, 2 AML
cases with inv(16), one case with t(6;9) and one with t(9;11) according WHO
classification. ELN cytogenetic risk stratification divided the group into inter-
mdiate-1, intermediate-2 and adverse cases in 10, 12 and 4 patients respec-
tively. All patients were treated with Daunorubicine, Cytarabine and Cladribine
based first line chemotherapy.  We collect bone marrow and blood samples
before chemotherapy and blood samples alone 48 hours after chemotherapy
start. In all samples leukemic blasts were counted and determined by flow
cytometry and the subpopulation of HIF-2 alpha positive blasts was estimated
as well. Volunteer bone marrow donors were the control group in this study
and the CD34+HIF-2α+ subpopulation was assessed in their bone marrow
samples during the routine harvest procedure. The study was approved by the
local Ethics Committee.
Results: After the first line chemotherapy 15 patients achieved complete remis-
sion (CR group) and 11 did not (NR group). We did not find significant differ-
ences between the groups regarding patients age, the mean percentage of
blasts in bone marrow and blood before the treatment, the percentage of HIF-
2 alpha positive blasts in BM and blood before and 48 hours after the treatment
start (data not shown). But the analysis of  the percentage of HIF-2 alpha pos-
itive blasts in blood before and 48 hours separately in CR and NR groups
revealed quite different dynamics. In CR group the mean percentage of HIF-2
alpha positive blasts was 14.65 (±33.32) and 8.48 (±11.63) before and after
chemotherapy respectively (p=NS); in NR group the values were 11.74 (±22.6)
and 24.01 (±33.68) respectively (p=0.007) (Figure 1). The Cox analysis
revealed HIF-2 alpha positive blasts in blood after chemotherapy to be propor-
tional to death probability (p=0.0036) (Figure 2).
Figure and 2.
Summary/Conclusions: We are aware our results are preliminary. But if they
are confirmed it will be very interesting to determine the role of HIF-2 alpha
inhibitors in improving the prognosis and survival in human AML.
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RARE BCR/ABL FUSION PROTEINS AND THEIR CLINICAL SIGNIFICANCE
INTO PH+ ACUTE MYELOID LEUKEMIAS
M. Piedimonte1,*, T. Ottone2, V. Alfonso2, A. Ferrari1, E. Conte1, M. Divona2,
M. P. Bianchi1, M. R. Ricciardi1, S. Mirabilii1, R. Licchetta1, F. Falco1,
A. Campagna1, L. Cicconi2, G. Galassi1, S. Pelliccia1, A. Leporace1,
F. Lo Coco2, A. Tafuri1
1Department of Clinical and Molecular Medicine & Sant’Andrea AOU, Sapienza
University of Rome, 2Department of Biomedicine and Prevention, University of
Tor Vergata, Rome, Italy
Background: The Philadelphia (Ph) t(9;22)(q34;q11) results in an
oncogenic BCR/ABL gene fusion,  representing the hallmark of chronic myeloid
leukemia (CML), although it has been also described in acute lymphoblatic
(ALL) and myeloid (AML) leukemia. Three main different transcripts have been
described (p210, p190 and p230), but rare atypical BCR breakpoints outside
the cluster regions have been also reported and their clinical significance is
under investigation. Atypical transcript p190 e6a2 is a rare fusion protein asso-
ciated with aggressive phenotype and dismal prognosis. The breakpoint in BCR
intron 6 is responsible for increased kinase activity and greater transforming
potential because of the partial loss of the Guanine Exchange Factor (GEF)/dbl-
like domain, completely absent in p190 proteins. This truncation could increase
the BCR/ABL oncogenic activity.
Aims: In this report we describe 2 rare cases of Ph+ AML patients with the
atypical p190 e6a2 isoform.
Methods: Routine morphologic, immunophenotypic and genetic analyses were
carried out in all samples at diagnosis. cDNA extracted from bone marrow was
synthesized from 1 μg of total RNA. Most common AML genetic alterations
were investigated and a quantitative RT-PCR (qRT-PCR) for p190 transcripts
was performed. qRT-PCR assay for FLT3-ITD and p190 e6a2 transcript were
developed.
Results: Case 1. A 78-years old male was admitted at our hospital with clinical
and laboratory features allowing to make the diagnosis of AML. No evidence
of a preceding CML (splenomegaly or basophilia) was found.  The karyotype
on G-banded metaphases was 46,XY, t(9;22)(q34;q11). While the molecular
analysis was ongoing, the patient started treatment based on decitabine. The
molecular biology analysis revealed the simultaneous presence of the common
p190 e1a2 and the rare e6a2 isoforms (Figure 1A). Because of persisted pan-
cytopenia and presence of blasts, according to the molecular data, he was then
switched to TKIs treatment. Nevertheless, after 2 months, the patient was still
refractory to second line treatment dying because of a pulmonary infection.
Case 2. A 61-years old male was admitted with a diagnosis of AML 46XY, FLT3-
ITD post MDS. Immediately, after cytoreduction, chemotherapy was started,
obtaining the complete remission. Because of infectious complications, the
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consolidation chemotherapy was postponed, relapsing without reach the
already planned allogeneic transplantation. At the relapse karyotype was 46XY,
t(9;22)(q34;q11) and the molecular biology showed the presence of p190 e1a2
and e6a2 isoforms and FLT3-ITD mutations with a low mutant allelic burden
(Figure 1B). Salvage chemotherapy was then performed, allowing at this time
to obtain disease remission and further allogeneic transplantation. Neverthe-
less, the patient died 5 months later for transplant complications. qRT-PCR
assays performed in diagnosis sample showed the main clone FLT3-ITD
accompanied by subclones with p190 e1a2 and e6a2 isoforms. These data
indicate a clonal selection process and the expansion of a resistant clone with
p190 e6a2.
Figure 1.
Summary/Conclusions: The atypical p190 e6a2 transcript seems to be asso-
ciated in AML with aggressive disease. TKI therapy alone does not seem to
control the disease. Prompt observations on these patients carrying rare
BCR/ABL transcripts may allow help to establish optimal treatment approaches
on these aggressive BCR/ABL phenotypes.
PB1697
HYPOMETILATING AGENTS AS SALVAGE THERAPY IN RELAPSED OR
REFRACTORY AML: A 2-CENTERS RETROSPECTIVE STUDY
F. Lessi1,*, A. Branca1, M. Laurino1, D. Lazzarotto2, C. Filì2, A. Candoni2,
G. Semenzato1
1Department of Medicine, University of Padua, Hematology and Clinical Immunol-
ogy Unit, Padova, 2Division of Hematology and Bone Marrow Transplantation,
Azienda Sanitaria-Universitaria Integrata, University of Udine, Udine, Italy
Background: 5-azacytidine and decitabine have been widely studied as first
line chemotherapy in acute myeloid leukemia (AML) patients not eligible for
allogenic stem cell transplantation, but  data on their use as salvage chemother-
apy are limited.
Aims: To define efficacy and feasibility of hypometilating agents (HMA) as salvage
chemotherapy in patients without previous allogenic stem cell transplantation.
Methods: We retrospectively reviewed clinical records of 15 patients treated
with HMA as salvage therapy in our institutions since their introduction in clinical
practice for AML patients.
Results: Median age was 66 years. Six patients were men and 9 women. One
patient was AML with t(8;21), 7 were AML MRC, 1 was therapy related AML, 6
were AML NOS. Two patients were favorable risk sec ELN 2010, 11 were inter-
mediate I and II and 2 were adverse risk. 67% of patients received HMA as sec-
ond line therapy for their disease, 27% as third line and 6% were beyond the
third line. Seven patients were treated with decitabine and 8 with azacitidine.
Five patients reached CR or CRi after HMA. All patients underwent intensive
chemotherapy (i.e. FLAI like or 3+7 like) as first line induction, and we excluded
patients who had a HMA as first line chemotherapy and another one as second
line. Median number of hospitalization days during HMA therapy was 16; median
number of HMA cycles was 2 (range 1-31). 26% of patients underwent allogenic
stem cell transplantation after HMA therapy. Median OS was 197 days from the
starting of HMA and median EFS was 70 days. Median OS in patients with refrac-
tory disease was 91 days and median OS in relapsed patients was 331 days
(p=0,0049). Median EFS in patients with refractory disease was 57 days and
median EFS in patients with relapsed disease was 198 days (p=0,039). We did
not find significant differences between transfusion needs before and after sal-
vage therapy but this could be due to the small size of our sample.
Summary/Conclusions: HMA showed efficacy and a considerable OS in our
patients. In our cohort refractory patients were almost all refractory to HMA too,
and their OS was dismal. So HMA could be a good clinical option in a selected
population of relapsed patients, especially in those not suitable for allogenic bone
marrow transplantation, in whom the prognosis is generally extremely poor. Fur-
ther studies are needed to determine which are the cytogenetic subsets of
patients who could benefit from  such a salvage chemotherapy.
PB1698
OMITTING CYTARABINE FROM CHEMOTHERAPY FOR ACUTE
PROMYELOCYTIC LEUKEMIA REDUCES TOXICITY AND NOT EFFICACY
C. Lalayanni1, G. Karavalakis1,*, E. Gavriilaki1, A. Lazaridou1, M. Iskas1,
A. Syrigou1, M. Papathanasiou1, G. Papaioannou1, A. Athanasiadou1,
A. Papalexandri1, C. Vadikoliou1, N. Stavroyianni1, R. Saloum1,
A. Anagnostopoulos1
1Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki,
Greece
Background: The introduction of retinoic acid (ATRA) has changed the treat-
ment paradigm in Acute Promyelocytic Leukemia (APL). Combination of ATRA
plus anthracycline-based induction (AIDA) without cytarabine (AraC) has shown
high efficacy in Spanish and Italian studies. However, early mortality resulting
from coagulation disorders remains high. Furthermore, AraC administration
during consolidation is questioned and often limited to high-risk patients.
Aims: We aim to compare the efficacy, tolerance and toxicity between 2 con-
secutive treatment protocols that differed in AraC administration during con-
solidation.
Methods: We studied clinical characteristics, prognostic factors, response to
treatment, tolerance, toxicity and outcomes in APL patients treated in our
Department during the last decade. All patients received induction with AIDA
(Idarubicin x4, ATRA until remission) and 2-year maintenance therapy. Protocol
1 included 2 cycles of consolidation with anthracyclines/AraC. Protocol 2 was
implemented the last 5 years and included 3 cycles of anthracyclines and AraC
only in high-risk patients (PETHEMA LPA2005).
Results: APL was diagnosed in 35 patients, of whom 2 patients older than 80
years did not receive treatment and were not included in the analysis. The rest
18 male: 15 female patients aged 37 (10-75) years old presented at diagnosis
with: thrombocytopenia (32), leukopenia (22), leukocytosis (6), impaired per-
formance status/PS >2 (10), lactate dehydrogenase >400 IU (17), increased
d-dimers (33), low fibrinogen (11), fibirinogen <1 mg/dl (5). Five patients died
during induction from severe differentiation syndrome (2), bleeding (2) and
infection (1). In the multivariate analysis, these patients had significantly
impaired PS (3, p=0.005), older age (median of 59 years, p=0.014) and lower
fibrinogen (median of 0.9 mg/dl, p=0.05). Among 28 patients eligible for the
comparison, all patients achieved complete remission (CR=100%). Protocol 1
(AraC) was applied to 16 patients and 2 to 12 patients. Complete molecular
remission was achieved after a median of 2 chemotherapies (1-3). Efficacy
could not be compared between protocols because there was only 1 relapse
in Protocol 2, refractory to chemotherapy, ATRA, arsenic trioxide and allogeneic
transplantation. However, there were significant differences in tolerance and
toxicity. Patients in Protocol 1 had significantly higher transfusion needs com-
pared to Protocol 2(p<0.001): 9(2-15) versus 1(0-17) red blood cell and 11(3-
32) versus 2(0-10) platelet transfusion. Duration of grade 4 leukopenia was
significantly higher in Protocol 1 [16(5-19) versus 9(0-18) days, p=0.002]. The
same was true for neutropenia (p=0.04) and resulted to higher infection rates
in Protocol 1 (58% versus 17%, p=0.03), including 2 aspergilloses and 1 fatal
sepsis. 10-year overall survival probability was 73.1%, with no difference
between Protocols.
Summary/Conclusions: Our study confirms that early mortality is a significant
issue in APL, in particular for older patients. AraC can be safely omitted from
treatment of low- and intermediate-risk patients, resulting in significantly
reduced toxicity.
PB1699
DISEASE CHARACTERISTICS AND TREATMENT PATTERNS OF AML
PATIENTS <60 YEARS OLD VERSUS ≥60 YEARS OLD
B.C. Medeiros1,*, B. Pandya2, A. Hadfield3, S. Wilson2, C. Bui2, T. Bailey3,
S. Flanders2, A. Rider3, L. Horvath2, J. Pike3
1Stanford University, Stanford, 2Astellas Pharma Inc., Northbrook, United
States, 3Adelphi Real World, Cheshire, United Kingdom
Background: There is limited real-world data in patients with acute myeloid
leukemia (AML) that looks at presenting disease characteristics and subse-
quent treatment decisions made for patients <60 and ≥60 years of age in the
United States (US).
Aims: This analysis examined the characteristics of patients <60 years of age
and ≥60 years of age at the point of AML diagnosis and further investigated
subsequent treatments. 
Methods: Data from the Adelphi AML Disease Specific Programme, a real-
world, cross-sectional survey conducted between February–May 2015, were
analyzed. A total of 61 hematologist/oncologists provided data on their 457
AML patients treated at various stages of AML. Disease characteristics upon
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initial AML diagnosis including symptoms, performance status, and physician-
determined prognostic category were taken from physician-completed patient
record forms. Details about subsequently prescribed AML treatment were also
taken from this data source. Treatments for n=15 (3.3%) patients were reas-
signed as high or low intensity following evaluation of physician treatment selec-
tion. Post-hoc T-tests and Chi-Squared/Fisher’s exact tests were used to deter-
mine differences between groups.
Results: Table 1 shows key presenting characteristics of AML patients <60
and ≥60 years old. According to physicians, those patients <60 years of age
were significantly more likely than those ≥60 years of age to have de novo
AML, a performance score of 0 versus ≥1 at diagnosis, more tests conducted
to establish the diagnosis and a more favorable prognosis at baseline, accord-
ing to physician perception. Following initial diagnosis, patients <60 years of
age were 1.65 times more likely than patients ≥60 years of age to be initiated
on high-intensity induction treatment: 67% (n=143) of patients <60 years of
age compared to 40% (n=98) of patients ≥60 years of age (high versus low
intensity by age group P <0.001). All other patients received low intensity treat-
ment. Irrespective of age, the most common high intensity treatment given was
a cytarabine-based regimen and the most common low intensity treatments
were low dose cytarabine-, decitabine- or azacitidine-based regimens.
Table 1. Disease characteristics of patients <60 and ≥60 years of age at
diagnosis of AML.
Summary/Conclusions: The age of an AML patient at initial diagnosis
appeared to play a significant role in the diagnostic, prognostic and treatment
intensity decisions made by AML-treating physicians in the US. The estimated
performance and prognostic status’ tend to be considerably better for younger
patients and consequently, they were more likely to receive the most aggressive
yet more effective high intensity treatments currently available to treat AML. 
PB1700
FLT3, NPM1, СЕВРА AND ТР53 MUTATIONS AT ACUTE PROMYELOCYTIC
LEUKEMIA: PROGNOSTIC FACTORS AND CORRELATION WITH OTHER
MARKERS WITHIN THE PATIENTS OF GOMEL REGION IN BELARUS 
Z. Kozich1,*, V. Martinkov2, A. Silin2, I. Tropashko2
1Hematology, 2Molecular Genetics, The Republican Research Center for Radi-
ation Medicine and Human Ecology, Gomel, Belarus
Background: Acute Promyelocytic Leukemia (APL) is one of the favourable
variant of acute myelocytic leukemias due to the usage of ATRA in the treatment
simaltenously with chemotherapy. But relapses occur in 13-33% cases after
achievement the remission and there are cases of early death from the bleed-
ing. High leukocytosis, the presence of lymphoid immunophenotypic markers
and gene mutations are important prognostic factors. 
Aims: To examine prognostic factors in APL
Methods: The materials for research were the samples of whole venous blood
and bone marrow of 40 patients with APL treated in the period of 2009-20016
in Hematology department for adults, Gomel. The diagnosis was proved by the
presence t(15;17) or PML/RARA. Induction therapy was carried out according
to the protocol «7+3» using ATRA. Immunophenotypic analysis was carried
out by standard immunofluorescence methods. The method of polymerase
chain reaction (PCR) with specific primer and following electrophoretic detection
was used  for recognition of gene mutations. 
Results: Out of 40 examined patients (mean age 48,5),80%(32) achieved
remission and 15.6%(5) subsequently relapsed after the first course of
chemotherapy. Clinical, laboratory, molecular genetic and immunophenotypic
data which could affect remission results and general survival rate were ana-
lyzed within all the patients. As a result, mutations were detected in 55% of
cases. FLT3-ITD mutations were detected in 32,5%(13), NPM1 mutations in
12,5%(5), combination of FLT3-ITD and NPM1 in 7,5%(3), TP53 and CEBPA
mutations were detected in 5%(2) and 12,5%(5) of cases respectively. After
achievement of remission after the first course of chemotherapy NPM1 mutation
remained at 6.2%(2). Mutations were identified more frequently within the
patients with the absence of response to the therapy or with the developed
relapse in a while. The worst prognosis had the patients with the combination
of FLT3-ITD and NPM1 mutations. There were the patients with high leukocy-
tosis, presence of CD56 and CD2 immunophenotypic markers, who didn’t
achieve remission or had the recurrence when the treatment was dropped. The
presence of leukocytosis was detected in 25% of cases, in 90% (9/10) of cases
leukocytosis was combined with FLT3-ITD mutations and 80% of these patients
subsequently had the recurrence. Within the patients with the combination of
FLT3-ITD and NPM1 mutations who brought into remission after the first course
of chemotherapy these mutations were not detected later on. There were the
patients who had leukocytosis rate less than 20x10 9 * \ l and didn’t have CD56
and CD2(11,5%) at the time of verification. The presence of TP53 mutation
was combined with high leukocytosis of the patient and with the absence of
effect on the conducted therapy. When analyzing the immunophenotypic mark-
ers CD56 and CD2, they were detected in 75% of the patients, but in the
absence of gene mutations and leukocytosis, such patients had a favorable
prognosis (16,7%(3/18, p=0,046)). 
Summary/Conclusions: Our results prove that the presence of only one of
the signs is not a factor of high risk. Only combination of clinical, laboratory,
molecular-genetic and immunophenotypic markers can include the patients
into a high risk group and influence general survival rate.
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A UNIQUE PRESENTATION OF ACUTE PROMYELOCYTIC LEUKEMIA:
AORTOILIAC OCCLUSIVE DISEASE (LERICHE SYNDROME)
S. Berk1,*, M. Günaltılı2, S. Sadri1, A. E. Eşkazan1, Z. Başlar1, T. Soysal1
1Haematology, 2Internal Medicine, Istanbul University Cerrahpasa Medical Fac-
ulty, Istanbul, Turkey
Background: Acute promyelocytic leukemia (APL), FAB M3 subgroup of acute
myeloid leukemia is known for its association with haemostatic disorders. Com-
pared to bleeding thrombosis is a less commonly encountered complication of
APL. Thrombosis of major arteries is a rare form of presentation.
Aims: A case, who applied with acute lower limb ischemia and diagnosed with
APL and aortoiliac occlusive disease (Leriche syndrome), is presented.
Methods: A 53-year-old female patient presented with weakness, loss of
appetite and pain in the lower extremities. She had diabetes mellitus (DM) reg-
ulated with metformin, hyperlipidemia (HL), and smoking history. Physical exam-
ination revealed general paleness and ischemia around big toe of the right
foot. Laboratory studies revealed leukopenia, neutropenia, anemia, thrombo-
cytopenia, elevated D-Dimer. A bone marrow aspiration and biopsy was done
to enlighten the etiology of pancytopenia. The pathological examination of the
bone marrow revealed abundant granular blasts (78%) and Auer rodes. The
patient was diagnosed with APL, hypergranular classical form. t(15;17) was
positive with fluorescence in situ hybridization. All-trans retinoic acid (ATRA)
plus idarubicin treatment was started. In few days findings of ischemia pro-
gressed and encompassed 2nd, 4th and 5th toes together with the big toe (Fig-
ure 1 on the left). Monophasic flow pattern (proximal stenosis?) was detected
in bilateral common femoral arteries in lower extremity venous doppler ultra-
sonography. On CT angiography, abdominal aorta and bilateral common iliac
arteries were observed to be occluded from L3 vertebra level till 1.5 cm after
aortic bifurcation (Figure 1 on the right). Low-molecular-weight heparin therapy
was started. According to rheumatological tests and tests for lupus anticoagu-
lant, anticardiolipin and antiphospholipid antibodies, anti-beta-2 glycoprotein-
1, protein C-S, Antithrombin III and homocysteine levels, methylenetetrahydro-
folate reductase, Factor V Leiden and prothrombin gene mutations no cause
of tendency to thrombophilia could be determined. Echocardiography was nor-
mal. The patient was transferred to Cardiovascular Surgery Department for
axillofemoral bypass operation.
Figure 1.
Results: In APL 80% of thrombotic events occur before treatment or during
induction. Acute lower limb ischemia as an initial feature of APL is very rare
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which makes our case unique.  Thrombotic risk factors in APL include high
leukocyte count, presence of coagulation disorder, ATRA+chemotherapy+
antifibrinolytic therapy and ATRA syndrome. None of these were seen in the
presented case. The effects of known predisposing risk factors to thrombosis
meaning DM, HL and smoking cannot be ruled out. But development of acute
thrombosis concomitant with APL diagnosis points out to the relationship
between these two entities.
Summary/Conclusions: Current literature knowledge is based on case reports
and 9 patients with APL who presented with acute lower limb ischemia were
reported yet. As far as we know our case is the first APL case presenting with
aortoiliac occlusive disease (Leriche syndrome).
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A CASE OF THERAPY-RELATED ACUTE LEUKEMIA WITH MIXED
PHENOTYPE WITH BCR-ABL1 AFTER TREATMENT OF DIFFUSE LARGE
B-CELL LYMPHOMA
D. Yang1,*, J. Lee2, S. R. Cho3, Y. S. Kim4, J. R. Choi5, M. H. Kim1
1Laboratory Medicine, Kosin University Gospel Hospital, Busan, 2Yeongam-
gun Public Health Center, Yeongam, 3Laboratory Medicine, Ajou University
School of Medicine, Suwon, 4Internal Medicine, Kosin University Gospel Hos-
pital, Busan, 5Laboratory Medicine, Yonsei University College of Medicine,
Seoul, Korea, Republic Of
Background: Although therapy-related acute leukemia (tAL) is a well-recog-
nized clinical syndrome and is increasing owing to the prolonged survival of
patients treated with chemoradiotherapy, tAL with mixed phenotype is extremely
rare. 
Aims: Here, we report a rare case of tAL with mixed phenotype with BCR-
ABL1 after achieving complete remission (CR) of Diffuse Large B-Cell Lym-
phoma (DLBCL).
Methods: A 57-year-old woman was diagnosed as DLBCL. The patient
received six cycles of R-CHOP regimen with G-CSF injected after each cycle
and achieved CR. The patient was readmitted to the hospital after a follow-up
examination revealed the presence of immature cells in the blood.
Results: Her complete blood count findings were as follows: hematocrit, 35.1%;
hemoglobin, 116 g/L; platelet count, 129×109/L; and white bloodcellcount,
2.41×109/L, with 4% blasts, 26% segmented neutrophils, 3% band neutrophils,
39% lymphocytes, and 26% monocytes. Bone marrow aspirations mears
revealed 40.7% leukemic blasts with medium cell size, ovaltoround shape,
vesicular nuclei, fine chromatin patterns, and basophilic cytoplasm. On cyto-
chemical staining, these blast cells were not positive on PAS and NSE staining,
but were weakly positive for MPO staining. Flow cytometric analysis showed
that the blasts were positive forboth T-lymphoid and myeloid markers (cyto-
plasmic CD 3,87%; CD 5,90%; CD 7,96%; cytoplasmic myeloperoxidase, 20%;
CD 13,91%; CD 33,87%) and negative for CD2, CD10, CD11b, CD14, CD15,
CD19, CD20, CD61, CD117, and TDT. Immuno phenotyping ful filled the diag-
nostic criteria of T/myeloid biphenotypic leukemia based on the scoring system
of the EGIL and WHO classifications. Multiplex reverse transcription PCRusing
Hema Visionkit (Bio-Rad Laboratories) revealed the presence of minor BCR-
ABL1 (e1a2) fusion transcripts. Chromosome analysis of bone marrow cells
failed because of insufficient mitotic cells. Immunoglobulin heavy chain gene
rearrangement and TCR gene rearrangement were not detected on bone mar-
row aspirates.
Summary/Conclusions: Mixed phenotype acute leukemia is an uncommon
subtype that comprises 0.5-1% of leukemia. The T/myeloid phenotype is rarer
and represents 35% of all MPAL cases The risk of secondary malignancies
after lymphoma treatment is relatively increased for leukemia. AML, ALL, MDS,
CML and chronic myelomonocytic leukemia are reported secondary hemato-
logic malignancies. Until now, only one case of tAL with mixed phenotype after
lymphoma has been reported worldwide. To the best of our knowledge, this is
the second case of tAL with mixed phenotype after DLBCL. This case is also
unique because the BCR-ABL1 has not been described in the literature for
patients with tAL with mixed phenotype, after hematologic malignancy. Accord-
ing to the 2008 WHO classification, tAL can be attributed to radiation, alkylating
agents, or topoisomerase II inhibitors. Our patient did not receive radiation
therapy but previously received cyclophosphamide and doxorubicin. Therefore,
this is the first case of tAL with mixed phenotype and BCR-ABL 1 after alkylating
agent and topoisomerase II inhibitor therapy for DLBCL.
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CROSS-SECTIONAL ANALYSIS OF CONCORDANCE RATES BETWEEN
KARYOTYPING AND RT-PCR IN ACUTE MYELOID LEUKEMIA; REAL
WORLD CHALLENGES
D. Katoch1,*, Y. Uday1, T. Verma1, R. Kapoor1, S. Das1, V. Nair1
1Hematology, Army Hospital (Research & Referral), Delhi, India
Background: Translocation and chromosomal anomalies have prognostic
implications in acute myeloid leukemia (AML). Cytogenetic analysis assumes
great importance in their diagnosis and treatment stratification which are
assessed by karyotyping and/or reverse transcriptase polymerase chain reac-
tion (RT-PCR). Given the dependency of karyotyping on sample quality, more
and more centers are now relying on RT-PCR to detect specific translocations.
Varying rates of concordance between Karyotyping and RT-PCR have been
reported and no consensus has prevailed. Given the resource constraint, it is
economically non-viable to perform both for prognosis in real world scenarios.
In addition, the cost of the extra tests also adds to the burden of healthcare
economy.
Aims: In 132 patients of AML, we aimed at determining the incidence of cyto-
genetic abnormalities and molecular anomalies detected by Karyotyping and
RT-PCR respectively. Concordance rates between conventional cytogenetic
tests and RT-PCR were also calculated.
Methods: We conducted a retrospective analysis on the medical records of
132 patients of AML at a tertiary health care facility in India, treated during
2010-2017. Results from commercially available molecular assays for detection
of specific translocations by RT-PCR and of adequate samples of karyotype
analysis were compared. 
Results: In AML patients, out of those tested 50.6% had chromosomal aber-
rations detected by karyotyping while 30% had a positive detection with RT-
PCR. The concordance rate in AML was found to be 56.3%. In a large number
(31 in AML) karyotyping provided additional information in the form of detection
of deletions, additions and hyper-diploidy (Table 1).
Table 1.
Summary/Conclusions: RT-PCR cannot substitute conventional cytogenetic
analysis due to the absence of a broad based application for detection of aber-
rations other than translocations. However, given its efficiency and reliability it
can have a complimentary role in prognosis assessment.
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CLINICAL, CYTOMORPHOLOGIC AND IMMUNOPHENO/IMMUNOHISTO-
CHEMICAL CHARACTERISTICS OF PATIENTS WITH BLASTIC
PLASMOCYTOID DENDRITIC CELL NEOPLASM - DIAGNOSTIC AND
THERAPEUTIC DILEMMA
A. Vidovic1,*, M. Virijevic1, D. Tomin1, N. Suvajdzic Vukovic1, V. Milosevic1,
I. Djunic1, M. Mitrovic1, N. Colovic1, N. Kraguljac Kurtovic1,
M. Perunicic Jovanovic1, B. Mihaljevic1
1Clinic of Hematology, Clinical Center of Serbia, University of Belgrade, Bel-
grade, Serbia
Background: Blastic plasmocytoid dendritic cell neoplasm (BPDCN) is a clin-
ically aggressive haematological malignancy that originates from clonal prolif-
eration of plasmocytoid dendritic cells and their precursors. BPDCN is rare,
represents less than 1% of acute leukemias. The disease has two patterns of
presentations: cutaneus and leukemic. The main histological differential diag-
nosis includes: cutaneous NK/T-cell lymphoma; cutaneous T-cell lymphoma
with co-expression of CD56 and CD56+ acute myeloid leukemia with monocytic
differentiation.
Aims: The aim of study was to analyze heterogeneity of BPDCN differential
diagnosis, especially with regards to clinical, immunological and cytomorpho-
logical characteristics of blastoid cells in terms of the optimal treatment.  
Methods: During period 2010-2016. at the Clinic of Hematology, eight patients
with BPDCN were diagnosed (M/F 6/2; average age 38 yrs, range 26-60yrs).
In the blood count, average concentration of Hb was 108g/l (range 87-154);
WBC 6,38x10e9/l (range 2,6-12); Plt 147,8x10e9/l (range 20-282). Hemor-
rhagic diathesis was registered in 3/8; splenomegaly in 6/8 (average diameter
by ultrasound exam 140mm, 110-150mm); and hepatomegaly existed in 3/8
pts (average diameter 166mm, 140-200mm). Cutaneous infiltrations were pres-
ent in 5/8 pts as livid maculopapular rash along lower extremities in 5 pts, and
in 1 female pts in the breast region of 1-4cm diameter.  In all 5 pts, immunocy-
tochemistry  confirmed BPDCN diagnosis. In the bone marrow aspirates of 7/8
pts, average 75% infiltration (27-89%) with blasts was revealed. Cells were of
median size, with high nucleus cytoplasm ratio, with visible oval or slightly
imprinted nucleoli. Basic immunophenotype profile was characterised by
expression of CD56+CD4+CD123+high CD45RA+ , and negativity for CMPO-
cCD79a- cCD3c- in 4 cases.  Immunohistochemitry staining in the rest of 4
pts, characterized with dry aspiration, revealed LCA+CD43+CD56+CD4+
CD33+ positivity and MPO- TDt-CD34 -CD117- CD68-  HLADR-
negativity.  Only 1 pts had CD4 negativity. Cytogenetic analysis revealed normal
karyotype in 4 pts, while the rest of 4 pts had pathological findings: 1. 92,XX,
XY; 2. 80-120,XXYY,+ mar (16)/46XY; 3. 46XY,del 5q/46XY; and 4. 46XX,del
12p, respectively.
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Results: Four pts were treated with 3+7 chemotherapy. Complete remission
(CR) was achieved in 3 pts, and treatment was continued according to the
HIDAC and IDAC protocol. The duration of remission was 3, 8 and 11 months
respectively, followed with relapse and letal outcome. One of the pts died within
first 0,5 months after BPDCN was diagnosed.  Three pts, treated with Hyper-
CVAD,  are alive and in CR with duration of 1, 3 and 10 months respectively.
The continuation of the treatment within the programme of allogeneic stem cell
transplantation is planned in 2 pts.
Summary/Conclusions: BPDCN diagnostics is difficult due to the heterogene-
ity of immunological characteristics of disease.  Aggressive course of disease
with median survival of 12-18 months, in the view of the unique treatment rec-
ommendations indicates necessity of further clinical investigations on larger
patients groups.
Aggressive Non-Hodgkin lymphoma - Clinical
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ECONOMIC IMPACT AND HEALTHCARE UTILIZATION IN PATIENTS WITH
DIFFUSE LARGE B-CELL LYMPHOMA IN ROUTINE CLINICAL CARE IN
THE UNITED STATES – A CLAIMS DATABASE STUDY
A. Galaznik1,*, J. Bell1, L. Hamilton2, A. Ogbonnaya2, K. Hennenfent2,
M. Eaddy2, Y. Shou1
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Phar-
maceutical Company Limited, Cambridge, 2Xcenda LLC, Palm Harbor, United
States
Background: DLBCL is the most common histologic subtype of non-Hodgkin
lymphoma (NHL), accounting for about 33% of all NHL cases. However, the
healthcare burden associated with DLBCL has not been extensively studied in
a US population. 
Aims: We evaluated the costs of care and healthcare utilization (HCU) of DLB-
CL patients treated during routine care in the US.
Methods: The Optum claims database was used to identify adult patients (≥18
years old) with newly diagnosed DLBCL between 01/01/08 and 10/31/15. DLB-
CL diagnosis was based on ≥1 inpatient claim or ≥2 outpatient claims with DLB-
CL diagnosis codes, with the index date being the first DLBCL claim. Patients
were followed from index date until end of continuous enrollment, death, or
end of study period (12/31/15) for the assessment of HCU and costs. DLBCL-
related and non-DLBCL-related HCU and costs incurred during follow-up were
evaluated. DLBCL-related HCU and costs were medical claims with a primary
diagnosis of DLBCL or DLBCL-related treatment (chemotherapy, radiation,
stem cell transplant [SCT], supportive care) and pharmacy claims for DLBCL
treatment. Proportions of patients with HCU were reported. Costs were calcu-
lated as per-patient-per-month (PPPM) costs and reported as mean and stan-
dard deviation (SD). Patients with a capitated payment plan were excluded
from the cost analysis.
Results: 1,267 treated DLBCL patients were identified. Over the follow-up peri-
od, 66.0% of patients had ≥1 inpatient admission, with more patients having a
non-DLBCL-related than DLBCL-related admission (Table 1). 60.0% of patients
had ≥1 emergency room visit over the follow-up period; visits were predomi-
nately for non-DLBCL-related. Nearly all patients had ≥1 physician office visit
(92.4%) and other outpatient visits (99.6%). The mean PPPM costs incurred
during the follow-up period was $11,890 (SD: $11,515) (Table 1), and costs
were higher in Year 1 ($14,402, SD: $10,951) than in Year 2 ($4,190, SD:
$8,076). About 55% of costs overall were related to DLBCL medical services
($6,532 PPPM, SD: $6,457). DLBCL-related medical PPPM costs decreased
substantially from Year 1 ($8,327, SD: $5,925) to Year 2 ($1,443, SD: $4,349).
This decrease was driven by the decreases in chemotherapy and supportive
care medical services from Year 1 to Year 2. Non-DLBCL-related medical costs
accounted for about 42% of the overall PPPM costs ($4,955, SD: $7,210); and
a decrease was observed from Year 1 ($5,640, SD: $7,468) to Year 2 ($2,447,
SD: $5,456). Inpatient admission was the main component of non-DLBCL-relat-
ed costs, and associated costs decreased from Year 1 to 2.
Table 1.
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Summary/Conclusions: The economic burden associated with the treated DLB-
CL population is high, with the majority of costs incurred during the first year of
diagnosis. Between the first and second year of diagnosis, costs decrease mainly
because of the decrease in the DLBCL-related treatment costs. In addition, HCU
for DLBCL-related services decreased in Year 1 vs Year 2.
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PHARMACOKINETICS OF RITUXIMAB IN PATIENTS WITH DIFFUSE
LARGE B-CELL LYMPHOMA
S. Rožman1 2, I. Grabnar2, S. Novaković3, A. Mrhar2, B. Jezersek Novakovic4,*
1Pharmacy Department, Institute Of Oncology Ljubljana, 2Department of Bio-
pharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Ljubl-
jana, 3Department of Molecular Diagnostics, 4Department of Medical Oncology,
Institute Of Oncology Ljubljana, Ljubljana, Slovenia
Background: Rituximab dosing is based on evidence from clinical practice
rather than from consideration of pharmacokinetics and factors influencing indi-
vidual exposure. Clinical use of rituximab can be improved through a more
individualized treatment. 
Aims: The objective of this investigation was to typify rituximab pharmacoki-
netics in 29 newly diagnosed patients with the diffuse large B-cell lymphoma
who received rituximab in combination with cyclophosphamide, doxorubicin,
vincristine and methylprednisolone every three weeks. The association of rit-
uximab pharmacokinetics with clinical outcome was also investigated. 
Methods: Rituximab serum levels were defined by enzyme-linked immunosor-
bent assay and assessed by a population pharmacokinetic analysis applying
the non-linear mixed effects modelling.
Results: A 2-compartment model comprising linear non-specific clearance of
0.252 (95% CI: 0.227 – 0.279) L/day and time-varying specific clearance of 0.278
(95% CI: 0.181 – 0.390) L/day, corresponding to target-mediated drug disposition
of rituximab was recognised to best describe the data. The nonspecific clearance
was found to be lower in older patients and those with lower body weight. Addi-
tionally, the central compartment volume was higher in males. An unambiguous
association of clinical response with rituximab pharmacokinetics has been detect-
ed. The rate constant of specific clearance decay was 0.143 day-1 (95% CI:
0.0478 – 0.418) in patients with no disease progression, while in patients with
disease progression it was 82.2% lower (95% CI: 33.4 – 95.0). 
Summary/Conclusions: These results imply that time-changes in clearance
could serve as a predictive marker of response to rituximab. Our findings prove
the rationale for studies evaluating higher doses of rituximab in selected patients.
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HOW 18FDG PET/CT CAN IDENTIFY BONE MARROW INFILTRATION IN
PATIENTS WITH NON-HODGKIN’S LYMPHOMA
C. Mainolfi1,*, T. Mannarino1, L. Marano2, F. Trastulli2, L. Simeone2,
O. Vitagliano2, M. Memoli2, S. Leone2, F. Cacace2, C. Mortaruolo2,
S. Pellegrino1, M. Petretta3, S. Del Vecchio1
1Department of Advanced Biomedical Sciences, 2Department of Clinical Med-
icine and Surgery, 3Department of Translational Medical Sciences, University
Federico II, Naples, Italy, AOU Federico II Naples, Naples, Italy
Background: Bone marrow infiltration (BMI) evaluation plays a key role in
lymphoma staging, treatment and prognosis. The role of PET/CT in the assess-
ment of BMI is still controversial, especially in non-Hodgkin’s lymphoma (NHL).
Aims: To evaluate the role of 18F-FDG PET/TC in bone marrow infiltration for
the diagnosis of Non Hodgkin Lymphoma. We compared 18F-FDG PET/TC
visual and quantitative analyses with bone marrow biopsy in NHL patients.
Methods: Fifty patients with newly diagnosed NHL from February 2011 to Feb-
ruary 2016 were retrospectively analyzed. Of these, 26 (group A) patients had
aggressive NHL and 24 (group B) indolent NHL. To detect BMI on the posterior
iliac crest 3 different PET/CT evaluation methods were used: 1) visual analysis,
2) maximal standardized uptake values (SUVmax, cut-off >2.5), and 3)
Deauville score (categorical). Each method was applied in the whole patients
cohort, in group A and in group B. Images were blindly reviewed separately by
3 nuclear medicine physicians. PET/CT results were compared with the bone
marrow biopsy performed after imaging in all patients. Decision-curve analysis
was used to evaluate the increment in net benefit (NB) obtained considering
the Deauville score over a biopsy-all strategy.
Results: The prevalence of a positive biopsy was 38% in whole cohort, 19%
in group A and 58% in group B. In the whole cohort, sensitivity, specificity and
accuracy were 21%, 84% and 60% for visual analysis; 58%, 55% and 50% for
SUVmax; and 47%, 81% and 68% for Deauville score. In group A, sensitivity,
specificity and accuracy were 0%, 76% and 62%, for visual analysis; 40%,
52% and 50% for SUVmax; and 20%, 71% and 62% for Deauville score. In
group B, sensitivity, specificity and accuracy were 29%, 100% and 58% for
visual analysis; 64%, 60% and 62% for SUVmax; and 57%, 100% and 75% for
Deauville score. At probability threshold equal to the prevalence of a positive
biopsy, the increase in NB by Deauville score was 0.11 in the whole cohort,
0.02 in group A and 0.33 in group B. In this latter group, biopsying patients on
the basis of the Deauville score is a strategy that reduced the biopsy rate by
24%, without missing any BMI.
Summary/Conclusions: FDG-PET/TC visual analysis has a limited value for
detecting BMI in patients with NHL, while quantitative analysis by Deauville
score provides a higher diagnostic performance. Noteworthy, the high positive
predictive value in patients with indolent NHL suggests a potential role of FDG-
PET/TC in avoiding bone marrow biopsy in this subtype of lymphoma.
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LOW ALBUMIN LEVEL CORRELATES WITH POORER SURVIVAL
OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: SERBIAN
LYMPHOMA GROUP EXPERIENCE
J. Jelicic1,*, D. Antic2, M. Todorovic Balint2, B. Andjelic2, O. Markovic3,
I. Petkovic4, V. Nikolic5, J. Bila2, V. Djurasinovic2, A. Sretenovic1, V. Vukovic1,
M. Smiljanic1, B. Mihaljevic2
1Clinic of Hematology, Clinical Center of Serbia, 2Clinical Center of Serbia,
University of Belgrade, Clinic of Hematology, 3Clinical Hospital Center “Bezani-
jska Kosa”, University of Belgrade, Belgrade, 4Clinic of Oncology, University
Clinical Center Nis, 5Clinic of Hematology, Clinical Center Nis, Nis, Serbia
Background: Current prognostic scores are not sufficient to define high risk
patients with diffuse large B cell lymphoma (DLBCL). Besides parameters
included in the International Prognostic Index (IPI), other clinical and laboratory
parameters have been investigated as potential prognostic markers. However,
contradictory data have been reported.
Aims: The aim of this study was to evaluate prognostic significance of clinical
and laboratory parameters on the overall survival (OS) of patients with DLBCL.
Methods: A total of 393 patients (188 females/205 males) with the median age
of 60 years (range 18-84) were analyzed. All patients were initially treated with
rituximab plus CHOP (Cyclophosphamide, Doxorubicine, Vincristine, Pred-
nisone) or CHOP like protocols. 
Results: Ann Arbor stage I, II, III and IV had 56 patients (14.2%), 142 (36.1%),
71 (18.1%) and 124 (31.6%), respectively. Bulky disease had 99 patients
(25.2%), B symptoms 263 patients (66.9%), and poor performance status
according to the European Cooperative Oncology Group (ECOG) ≥2 had 82
(20.9%). Bone marrow involvement was present in 68 patients (17.3%). Low
IPI risk was present in 194 patients (49.4%), low intermediate in 86 (21.9%),
high intermediate in 77 (19.6%), and high in 36 (9.2%). Median absolute lym-
phocyte count (ALC) at diagnosis was 1.35x109/L (range 0.07-60.76x109/l),
absolute monocyte count (AMC) was 0.64x109/l (range 0.06-8.58x109/l),
ALC/AMC was 2.3 (range 0.07-37.0x109/l), hemoglobin level was 125g/l (range
57-421g/l), platelet level was 274x109/l (range 50-584x109/l), C-reactive protein
was 10.2 mg/l (range 0.10-438mg/l), erythrocyte sedimentation rate (ESR) was
30mm/h (range 2-636mm/h), and albumin level was 38g/l (range 20-51g/l).
Complete remission (CR) was achieved in 288 patients (73.3%), partial remis-
sion (PR) in 58 (14.8%), stable disease (SD) in 5 (1.3%) and progressive dis-
ease in 42 (10.7%). Disease relapse was confirmed in 59/346 patients (17.0%).
OS was influenced by the presence of B symptoms (p=0.004, 95% CI 1.263-
3.549), ECOG≥2 (p<0.0001, 95% CI, 1.827-4.290), Ann Arbor clinical stage
(p<0.0001, 95% CI 1.601-3.883), and albumin level (p<0.0001, 95% CI 0.905-
0.953). Optimal cut off point for albumin level was 34g/l, and was determined
by Receiver operating characteristic (ROC) curve (AUC 0.699, 95% CI, 0.629-
0.770, p<0.0001). The prognostic value of IPI was highly statistically significant
for OS (p<0.0001, 95% CI, 1.545-2.236). However, other analyzed parameters
did not influence OS. Multivariate analysis among significant parameters (pres-
ence of B symptoms, IPI, and albumin), has pointed to IPI (HR 1.81, p<0.0001,
95% CI, 1.489-2.222), and albumin level (HR 1.77, 95% CI, 1.164-2.69,
p=0.008) as the most important parameters that influenced survival. 
Summary/Conclusions: Although IPI is widely used as a prognostic index in
DLBCL, it cannot fully recognize high-risk patients. Pretreatment albumin level
may represent a useful tool in order to discriminate high-risk patients and is
likely to add significant information to the IPI.
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TREATMENT PATTERNS AND TREATMENT RESPONSE IN PATIENTS
WITH DIFFUSE LARGE B-CELL LYMPHOMA IN ROUTINE CLINICAL CARE
IN THE UNITED STATES – A CLAIMS DATABASE STUDY
A. Galaznik1,*, J. Bell1, L. Hamilton2, A. Ogbonnaya2, K. Hennenfent2,
M. Eaddy2, Y. Shou2
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharma-
ceutical Company Limited, Cambridge, 2Xcenda LLC, Palm Harbor, United States
Background: DLBCL is the most common histologic subtype of non-Hodgkin
lymphoma. Treatment guidelines recommend rituximab in combination with
chemotherapy as first-line therapy (1LT). For patients who are refractory or
relapse, high-dose chemotherapy with stem cell transplant, combination
chemotherapy, or single-agent rituximab are recommended in subsequent lines. 
Aims: To compare real-world treatment patterns of patients with newly diag-
nosed DLBCL to NCCN guideline recommendations.
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Methods: The Optum claims database was used to identify adult patients (≥18
years old) with newly diagnosed DLBCL between 01/01/08 and 10/31/15. DLB-
CL diagnosis was based on ≥1 inpatient claim or ≥2 outpatient claims with DLB-
CL diagnosis codes, with the index date being the first DLBCL claim. Patients
were followed from index date until end of continuous enrollment, death, or
end of study period (12/31/15). Treatment patterns and response to treatment
were assessed during follow-up. Possible remission was defined as no addi-
tional chemotherapy and no supportive care use or receipt of supportive care
<30 days after end of line of therapy (LOT) for <30 days. Lack of remission
was defined as receipt of supportive care <30 days after end of LOT for >30
days. Progression was defined as initiation of another LOT or evidence of sup-
portive care >30 days after end of a LOT.
Results: Of the 2,216 patients selected into the study, 1,267 (57.2%) initiated
1LT, and median (interquartile range [IQR]) time to therapy was 0.7 (0.4–1.1)
months. The majority of patients received combination (87.7%) vs single-agent
(12.3%) chemotherapy. R-CHOP (60.5%) was the most frequently used combi-
nation chemotherapy, while rituximab monotherapy comprised ~67% (8.2%) of
single-agent use in 1LT. Median (IQR) duration of 1LT was 4.2 (2.3–4.5) months.
At the end of 1LT, 64.0% (n=811) had evidence of remission, 15.0% (n=190) pro-
gressed, and 1.2% (n=15) had no evidence of remission. Second-line therapy
(2LT) was initiated by 159 patients who progressed after 1LT; 29.6% received a
single agent, and 70.4% received combination chemotherapy. In 2LT, rituximab
(12.6%) remained the top single agent used, while bendamustine+rituximab
(15.7%) and R-CHOP (8.2%) were the most common combinations; 8.2% of
patients received stem cell transplant. Median (IQR) duration of 2LT was 2.1
(1.2–3.8) months. Of the 2LT patients, 44.0% (n=70) had evidence of remission,
26.4% (n=42) progressed, and 3.1% (n=5) had no evidence of remission. 34
patients who progressed after 2LT received third-line therapy (3LT); 29.4%
received a single agent, while 70.6% received combination chemotherapy. In
3LT, rituximab (5.9%), etoposide (5.9%), and carboplatin (5.9%) were the most
common single agents, while bendamustine+rituximab (20.8%) and
etoposide+oxaliplatin+rituximab (17.6%) were the most common combinations;
8.8% of patients received stem cell transplant. Median (IQR) duration of 3LT was
3.5 (0.9–5.2) months. Following 3LT, 32.4% (n=11) had evidence of remission,
29.4% (n=10) progressed, and 5.9% (n=2) had no evidence of remission.
Summary/Conclusions: DLBCL treatment in routine clinical care aligns with
guidelines, with most patients receiving rituximab in combination with
chemotherapy. A small proportion of patients received single-agent chemother-
apy in 1LT. As expected, remission rates decreased with subsequent lines of
therapy. Some patients were untreated; therefore, subsequent studies should
explore reasons for lack of treatment.
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TP53 GENE MUTATIONS IS A PREDICTOR OF HIGH GRADE B-CELL
LYMPHOMA PROGRESSION
A. Misyurina1,*, V. Misyurin2, S. Kravchenko1, A. Kovrigina1, A. Misyurin2,
E. Baryakh3, A. Magomedova1, E. Nesterova1, E. Pushkova4, J. Finashutina2,
A. Vorobiev1
1National Research Center for Hematology, 2Federal State Institution “Russian
Cancer Research Center. NN Blokhin” Russian Ministry of Health, 3 State budg-
et health care institution “City Clinical Hospital №52 Moscow Health Depart-
ment.”, 4LLC “Genetechnogogy”, Moscow, Russian Federation
Background: High grade B-cell lymphoma (HGBL) is subdivided on poor prog-
nosis double-hit (DH) and not otherwise specified (NOS) variant, which appears
sometimes with primary refractory behavior. Mutations in TP53 gene (MUT-
TP53) lead to blockage of apoptosis in cells and appearance of additional onco-
genic events contributing to tumor progression. Correlation between presence
of MUT-TP53 and anti-tumor response in patients with HGBL is unclear.
Aims: To evaluate an effect of MUT-TP53 on survival parameters of patients
with high grade B-cell lymphoma.
Methods: Since 2005 to 2017 years in FGBU National Research Center for
Hematology Ministry of Health Russian Federation diagnosis of high grade B-
cell lymphoma were established in 47 patients: 13 – double hit, 34 – not other-
wise specified. We had available biologic samples from 32 pts with HGBL: 11
– double-hit and 21 – NOS HGBL. 19 pts underwent courses of intensive treat-
ment according to BL-M-04 [Efficacy and toxicity of a new short-term high inten-
sive protocol BL-M-04 for adult patients with Burkitt lymphoma. Baryakh E. et
al. Haematologica. 2011; 96 (S2): 391-392], 11 - R-(DA)-EPOCH, 2-R-CHOP-
21 treatment. А median follow-up period was 10,8 (0,6-160,9) months. MYC-
rearrangement (MYC-R) without BCL2 and/or BCL6 rearrangement was detect-
ed in 7 pts with HGBL. Sanger sequencing of DNA extracted from paraffin
embedded tumor tissue were performed to reveal mutations in exons 5-8 of
TP53 gene. To evaluate an effect on overall survival (OS) and on time to disease
progression (of TTP) such factors as MUT-TP53, MYC-R and DH was con-
ducted univariate analysis (test of Kaplan-Meier method, log-rank test) and
multivariate variance and Cox regression analysis (STATISTICA 10).
Results: A significant mutations of TP53 were detected in 9 pts (c.535C>T 45,6%
p.H179Y, c.524G>C 15,6% p.R175P, c.770T>A 32,4% p.L257Q, c.743G>A
75,6% p.R247Q, c.487T>A 25,2% p.Y163N, c.824G>A 75% p.C275Y, c.713G>A
87,7% p.C238Y, c.517G>A 22,4% p.V173M, c.517G>A 22,4% p.V173M). Pts
and their relatives hadn’t a history of primary multiple tumors. Seven from nine
pts with MUT-TP53 had MYC-R (3-double hit, 4-single hit lymphoma). Groups of
pts with WT-TP53 and MUT-TP53 were comparable for main clinical character-
istics. According to results of univariate analysis, patients with MUT-TP53 had
lower duration of overall survival a higher probability of disease progression.
Thus, median of overall survival in pts with c MUT-TP53 was 7,0 (3,5 - 40,9) vs
30,5 (0,6 - 160,9) months in patients with WT-TP53, (p=0,03). Median time to
disease progression in pts with c MUT-TP53 was 3,5 (0,3 - 16,1) vs 30,5 (0,6 -
160,9) months in patients with WT-TP53, (p=0,00016). In multivariate analysis,
MUT-TP53 was an independent factor of early disease progression in HGBL
independently of double-hit status (Figure 1).
Figure 1.
Summary/Conclusions: Mutations in TP53 gene - a significant predictive fac-
tor of early disease progression in high grade B-cell lymphoma.
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HTLV-1 INFECTION INCREASED THE RISK OF OTHER MALIGNANCY
A. Nakaya1,*, S. Fujita1, A. Satake1, T. Nakanishi1, Y. Azuma1, Y. Tsubokura1,
M. Hotta1, H. Yoshimura1, K. Ishii1, T. Ito1, S. Nomura1
1First Department of Internal Medicine, Division of Hematology and Oncology,
KANSAI MEDICAL UNIVERSITY, Osaka, Japan
Background: The correlation between HTLV-1 infection and malignant neo-
plasm other than ATL remains unknown. Some previous studies have indicated
that the frequency of primary malignant neoplasms in patients with HTLV-1
seropositive is higher than HTLV-1 seronegative. 
Aims: To clarify the correlations between HTLV-1 infection and malignant neo-
plasms other than ATL.
Methods: We retrospectively analyzed 203 patients with HTLV-1 seropositive
who were diagnosed between 2006 and 2015 at Kansai Medical University
Hospital. 
Results: Among 203 patients (median age 62 years: range 19 to 86 years),
43% was carrier and 57% was diagnosed with ATL. According to clinical subtype,
5% was chronic, 38% was smoldering, 28% was acute, 29% was lymphoma
type. Median overall survival was 30 months in carrier, 10 months in acute, 8
months in lymphoma, and smoldering was not available. In all HTLV-1 seropositive
patients, the occurrence of primary malignant neoplasm was 32%, they were all
carrier or smoldering. Among them, 53% was hematology malignancy (T cell lym-
phoma; 41%, B cell lymphoma; 29%, MPN; 18%, MDS; 12%). Solid tumor was
47% (lung cancer; 33%, prostate cancer 13%, colon cancer; 13%, renal cell can-
cer; 13%). Four patients with HTLV-1 carrier who developed primary malignant
neoplasm received standard chemotherapy for the neoplasm, and after the
chemotherapy they developed 3 acute type and 1 smoldering type ATL. 
Summary/Conclusions: In our cohort, the occurrence of primary malignant
neoplasm with HTLV-1 seropositive patients was significantly high. Chronic
HTLV-1 infection might associate with reduction of cytotoxic T cells and an
increased risk of developing other malignancy. Furthermore, cytotoxic
chemotherapy for primary malignant neoplasm might reduce cytotoxic T cells




THIOTEPA BUSULFAN CYCLOPHOSPHAMIDE, A TOXIC CONDITIONING
FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
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P.-E. Debureaux1, B. Royer1,2, B. Gruson1, P. Votte3, M. Joris1, G.L. Damaj4,
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Background: CNSL represent 4% of primary central nervous system (PCNSL)
and secondary CNS lymphoma (SCNSL) occur in 7% of systemic lymphoma.
Overall survival (OS) and progression free survival (PFS) have dramatically
increased in PSNCL since the introduction of Methotrexate high doses and
ASCT usually conditioning with TBC (Thiotepa, Busulfan and Cyclophos-
phamide). The studies usually tend to recommend TBC/ASCT in front line for
patients under 65 years with CNSL with very few prospective data about this
strategy. 
Aims: We report in this multicenter retrospective study our experience con-
cerning TBC/ASCT and its main toxicities.
Methods: All patients treated with TBC/ASCT for PCNSL or SCNSL from
August 2010 to November 2016 in our centers were researched by using
CHIMIO® software. TBC combined Thiotepa (250mg/m²/d from d-9 to d-7),
Busulfan (3.2mg/kg/d from d-6 to d-5 and 1.6mg/kg/d on d-4) and Cyclophos-
phamide (60mg/kg/d on d-3 and -2) followed by ASCT transplantation at
d0. Clinical data were extracted from the medical records. We measured OS
and PFS from the date of ASCT and transplant related mortality (TRM) (defined
by death occured 3 months after ASCT).
Results: 24 patients, without any major co-morbidity, were included. Median
age at ASCT was 58 years (23-66). 22 of 24 were DLBCL and 2 follicular lym-
phoma and there were 15 PCNSL and 9 SCNSL. All but one, received 1 or 2
lines of chemotherapy (with high doses Methotrexate in first or second line)
before ASCT. 15 were in complete response (CR) and 9 in partial response
(PR) before TBC/ASCT. Median duration of hospitalisation was 33 days (15-
78 d) and of aplasia was 14 days (7-37 d). Median follow-up was 10 months
(0-73). At the end of follow up 5 patients have died. Among the 3 patients older
than 60 years in PR before ACSCT, no one survived. At 1 year, OS and PFS
were respectively 78% and 73%. Surprisingly (Table 1), we noted an important
rate of toxicity (100% with 66% ≥grade 3) with a TRM=21%. Neurological
adverse events (37%: 9 patients with 4 comas) and infections (100% with 41%
≥grade 3) were predominant. We documented 2 CMV reactivations and 5 fun-
gal infections (3 candida, 1 aspergillus and 1 cryptococcus).
Table 1.
We observed 5 deaths (4/5 older than 60 years) in first 3 months due to a
septic choc, 4 associated with a persistent coma and 2 with an acute respiratory
distress syndrome.
Summary/Conclusions: To our knowledge, here is one of the biggest retro-
spective cohort concerning TBC/ASCT in CNSL. If TBC seems to give inter-
esting response rates (72% CR), we noted an unacceptable toxicity compared
to other used conditionnings (for example TRM with Thiotepa Carmustine is
1%). Our high toxicity rates (66%≥grade 3), especially in elderly patients, with
neurological adverse events and infections (with unusual microbiological
agents) lead us to disadvise the use of TBC before ASCT.
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TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL
LYMPHOMA FROM HIGH RISK AND HIGH-INTERMEDIATE RISK GROUPS
I. Kriachok1,*, K. Filonenko2, A. Martynchyk2, I. Titorenko2, I. Stepanishyna2,
O. Aleksyk2, I. Dyagil3, E. Kushchevyy2, Z. Martina3, V. Kozlov4
133/43, Lomonosova str., 2Chemotherapy of hemoblastoses, National Cancer
Institute, 3Radiation hematology, NNCRM, Kyiv, 4Hematology, Odessky region-
al hospital, Odessa, Ukraine
Background: Using of Rituximab-containing regimens, as the «gold standard»
of treatment of patients with diffuse large B-cell lymphoma (DLBCL), showed sig-
nificant improvement in the treatment results throughout all prognostic groups.
The “real-life” treatment approaches vary depending on financial support of health-
care system in different countries. Unfortunately, treatment results in patients with
DLBCL from high and high-intermediate risk groups are still unsatisfying.
Aims: Aim of our study was to compare efficacy and toxicity of different treat-
ment approaches in patients with DLBCL from high risk and high-intermediate
risk groups.
Methods: Prospective cohort study was initiated in 2014 in three Ukrainian cen-
ters. Patients with newly diagnosed DLBCL and ≥3 risk factors according to Inter-
national Prognostic Index (IPI) were treated according to “investigators decision”
with 6-8 cycles of CHOP-like (first group), R-CHOP (second group) or R-DA-
EPOCH regimens (third group). Primary end-point was 2-year progression-free
survival (PFS), secondary end-points were 2-year overall survival (OS), overall
response rate (ORR), complete response rate (CRR), toxicity rates. 
Results: 104 patients were included into analysis in January 2017, 50 males
(48,1%), 54 females (51,9%), in the age 23-86 years old, median age 63 years
(95% CІ 60;65). Observation period was 1-64 months, median – 10.5 months.
Patients were divided into three groups according to the treatment regimen.
Patients treated with CHOP-like regimens were included into the first group
(52 patients, 50.0%). Patients treated with R-CHOP were included into the 2nd
group (40 patients, 38.5%) and 12 patients (12.5%) treated with R-DA-EPOCH
were included into the 3rd group. Significant difference between the groups
was observed by the age (younger patients in the 3rd group, p=0.042) and
stages distribution (early stages were more common in the 1st group, p=0.05).
ORR was 61.5% in the 1st group, 52.5% in the 2nd group and 83.3% in the
3rd group (p=0.01). CRR was 17.3%, 42.5% and 83.3%, respectively
(p<0,001). 2-year PFS was 44,1±9,7% in the 1st group, 74,1±8,8% in the 2nd
group and 88,9±10,5% in the 3rd group (р=0,09). 2-year OS was 51,8±8,7%,
54,8±10,2% and 87,5±11,7%, respectively (р=0,197).
The rates of anemia, thrombocytopenia and hepatotoxicity were comparable
in three groups. Neutropenia, febrile neutropenia and cardiotoxicity were less
common in the group treated with R-DA-EPOCH (p=0.05, p=0.051, p<0,01,
respectively). Neurotoxicity was more frequent in this group (p=0.043).
Summary/Conclusions: The level of ORR and CRR was significantly higher
in the R-DA-EPOCH group. 2-year PFS was significantly higher in the R-DA-
EPOCH group, as well. There was no significant difference in the level of 2-
year OS between the groups. Toxicity was acceptable in all groups. Levels of
neutropenia, febrile neutropenia and cardiotoxicity were less common and neu-
rotoxicity was more frequent in the R-DA-EPOCH group. Thus, R-DA-EPOCH
could be considered as the most efficient treatment regimen in patients with
DLBCL from high and high-intermediate risk groups.
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PROGNOSTIC MODEL WITH NEUTROPHIL-LYMPHOCYTE RATIO AND
PERFORMANCE STATUS IN DIFFUSE LARGE B CELL LYMPHOMA
TREATED WITH R-CHOP
S.-I. Go1, G.-W. Lee1,*
1Internal Medicine, Gyeongsang National University School of Medicine, Jinju,
Korea, Republic Of
Background: Growing evidences suggest the close relationship between
inflammation, host immunity, and tumor cells. The neutrophil to lymphocyte
ratio (NLR) has been known to predict the prognosis in patients with diffuse
large B-cell lymphoma (DLBCL).
Aims: This study was planned to confirm the prognostic and predictive value
of NLR and to make a model to predict the prognosis more precisely in patients
with DLBCL.
Methods: Data of 192 DLBCL patients treated with R-CHOP from 2004 to
2016 were retrospectively assessed. Patients with NLR ≥4 and <4 were deter-
mined as the high and low NLR groups, respectively. Treatment response and
survival were compared according to the NLR status and using the model
including NLR and other variable interacting with NLR.
Results: High NLR group was associated with old age, poor performance sta-
tus (PS), elevated lactate dehydrogenase, and more advanced prognostic
indices than low NLR group. High NLR group had a low complete response
(CR) rate compared to low NLR group (57.5% vs 81.4%, p=0.004). However,
the role of NLR as prognostic factor was not demonstrated on multivariate
analysis, which showed strong interaction between NLR and PS. The model
composed of NLR and PS could stratify the patients into low-, intermediate-,
and high-risk groups for overall survival (OS). On multivariate analysis, com-
pared to low risk group, the hazard ratios of intermediate and high risk groups
on OS were 1.871 (p=0.019) and 2.733 (p=0.004).
Summary/Conclusions: High NLR is associated with poor treatment response
and unfavorable clinical features in DLBCL. The prognostic model using NLR
and PS can predict more precisely the prognosis of this population and needs
to be validated in the independent cohort.
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HIGH SERUM LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR ARE
ASSOCIATED WITH A POOR PROGNOSIS IN CASES OF
RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA, NOT
OTHERWISE SPECIFIED
M. Morita1,*, D. Katoh1, A. Tanaka2, M. Nakamura1, A. Fujimoto1, T. Yabushita1,
Y. Shimomura1, Y. Ono1, A. Hashimoto2, N. Hiramoto1,3, S. Yoshioka1,
N. Yonetani1, Y. Tanaka2, A. Matsushita1, H. Hashimoto3, I. Sinzato2,
T. Ishikawa1
1Hematology, Kobe City Medical Center General Hospital, 2Hematology,
Nishikobe medical center, 3Cell Therapy, Institute of Biomedical Research and
Innovation, Kobe, Japan
Background: The prognosis is extremely poor for cases of relapsed/refractory
peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), and there
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are no established predictors of prognosis. Although serum soluble interleukin-
2 receptor (sIL-2R) levels are associated with clinical outcomes in newly diag-
nosed patients with PTCL-NOS, it remains unclear whether sIL-2R levels can
predict prognosis in patients with relapsed/refractory PTCL-NOS.
Aims: This study evaluated whether sIL-2R levels at the time of salvage
chemotherapy were associated with prognosis in cases of relapsed/refractory
PTCL-NOS.
Methods: We retrospectively analyzed 45 patients with relapsed/refractory
PTCL-NOS who received salvage chemotherapy at our institutions (1996–
2016). All patients received CHOP or CHOP-like therapy as their initial treat-
ment. The primary outcome was defined as overall survival (OS), which was
calculated from the date of the salvage chemotherapy to the date of death from
any cause or the last follow-up.
Results: The median age at salvage chemotherapy was 68 years (range: 37–86
years). The median serum sIL-2R level was 3,476 U/mL (range: 280–24,400
U/mL). Receiver operating characteristic curve analysis revealed that the optimal
sIL-2R cut-off value for predicting OS was 2,283 U/mL (area under the curve:
0.672, 95% confidence interval [CI]: 0.421–0.923). Thus, we defined patients
with serum sIL-2R levels of ≥2,283 U/mL as the high sIL-2R group and the other
patients as the low sIL-2R group. The two groups had similar clinical character-
istics at the salvage chemotherapy, with the exception of their international prog-
nostic index (secondary IPI) and performance status (PS). The high sIL-2R group
had significantly higher secondary IPI (≥H-I) and poorer PS (≥2). Eight patients
were alive at the time of the analysis, with a median follow-up of 55 months
(range: 2–136 months). The 2-year OS among all patients was 25.1% (95% CI:
13.6–38.5), and the high sIL-2R group had significantly poorer 2-year OS (10.9%,
95% CI: 2.8–25.4 vs 50.0%, 95% CI: 24.5–71.0, P <0.001). A multivariate analysis
was performed using the following factors: serum sIL-2R levels (high vs low),
secondary IPI (≥H-I vs ????????) (Figure 1).
Figure 1. Overall survival according to serum sIL-2R levels.
Summary/Conclusions: Serum sIL-2R levels are a useful predictor of prog-
nosis in cases of relapsed/refractory PTCL-NOS, especially among patients
with low secondary IPI risk.
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AUTOIMMUNE DISEASES ARE NOT ASSOCIATED WITH INFERIOR
PROGNOSIS IN LYMPHOMA PATIENTS
Y.-H. Shih1,*, C.-L. J. Teng1, H.-C. Lin1, W.-L. Hwang1
1Division of Hematology/Oncology. Department of internal medicine, Taichung
Veterans General Hospital, Taichung, Taiwan, Republic of China
Background: Previous epidemiological studies have shown that autoimmune
diseases increase the risk of lymphoma development.  Immune dysregulation
could be the possible underlying pathogenesis.  Whether autoimmune diseases
deteriorate outcome of lymphoma patients, however, remains unclear.
Aims: The objective of this study is to compare the clinical outcome among
lymphoma patients with and without autoimmune diseases.
Methods: From January 2008 to November 2016, we retrospectively reviewed
medical records of 913 newly diagnosed lymphoma patients.  From these 913
lymphoma patients, 34 (3.71%) patients were diagnosed to have autoimmune
diseases before their lymphoma identification.  Among these 34 patients, six
patients lost their follow-up.  A total of 28 lymphoma patients with pre-existing
autoimmune diseases were finally analyzed.  For the further comparison, 56
lymphoma patients without pre-existing autoimmune diseases who were adjust-
ed for age and gender were considered to be the control group.  Response
rate, progression-free survival (PFS), and overall survival (OS) were compared
between these two groups of patients.  
Results: Rheumatoid arthritis was the most common autoimmune disease in
lymphoma patients (11/34; 32.3%).  The complete remission rate for lymphoma
patients with and without autoimmune diseases were 72.0% and 83.3%, respec-
tively (p=0.178). The PFS for patients with and without autoimmune diseases
were 44.3±32.1 months and 50.9±28.6 months, respectively (mean±standard
deviation; p=0.334).  These two groups of patients had similar OS time as well
(46.4 ±31.5 months vs 52.9±28.0; mean±standard deviation; p=0.337).  Uni-
variate analysis did not show autoimmune diseases were associated with infe-
rior OS in lymphoma patients (crude hazard ratio: 1.32; 95% confidence interval:
0.43 - 4.07; P=0.627). 
Summary/Conclusions: The results of this case-control study showed the
autoimmune disease was not a poor prognostic factor for lymphoma patients.
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THE DIAGNOSTIC AND PROGNOSTIC IMPLICATIONS OF CIRCULATING
MIRNA-21 IN A SAMPLE OF HEPATITIS C/NONE HEPATITIS DIFFUSE
LARGE B-CELL LYMPHOMA EGYPTIAN PATIENTS
M. Moussa1,*, N. Elhalawani1, A. Nazir1, N. Mashali2, M. H. Nafea1, A. Sorour3
1Hematology, 2Pathology, 3Clinical Pathology, Alexandria Main University Hos-
pital, Faculty of Medicine, Alexandria University, Egypt, Alexandria, Egypt
Background: MicroRNAs (miRNAs) are small RNA molecules which control the
expression of many target messenger RNAs involved in cell differentiation, pro-
liferation and apoptosis. Circulating microRNAs are potential biomarkers of diag-
nostic and prognostic impact in various inflammatory and malignant diseases.
Unlike all other malignancies, studies of the prognostic implication of miRNA-21
expression in diffuse large B-cell lymphoma (DLBCL) patients have been a matter
of debate. To our knowledge, there are no existing data up to date on the expres-
sion of miRNA-21 in hepatitis C virus (HCV) associated DLBCL.
Aims: Linking inflammation with malignancy, we studied the expression of miR-
NA-21 in sera of hepatitis-C-virus and none hepatitis DLBCL patients, aiming
to identify its differential expression and prognosis in DLBCL with its subtypes;
germinal center B-cell (GCB) and activated B-cell-like (ABC) and to evaluate
its relation with HCV.
Methods: MiRNA-21 expression was measured using Taq-Man quantitative
RT-PCR in sera of 30 newly diagnosed DLBCL patients (HCV positive (n=10),
HCV negative (n=20)) and 20 controls (HCV positive (n=10), HCV negative
(n=10)). The diagnosis of DLBCL and its sub-classification in GCB and ABC
subtypes were done by applying the criteria of the WHO classification of tumors
of the hematopoietic and lymphoid tissues 2008 and revised in 2016 and were
confirmed by Immunohistochemistry using antibodies to CD10, BCL-6, MUM-
1 and BCL-2. HCV was diagnosed by detection of anti-HCV antibodies in sera
of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA) tech-
nique and HCV genetic detection and quantification by polymerase chain reac-
tion (PCR). All the patients received CHOP chemotherapy and were followed
up for an average of 24 months.
Results: MiRNA-21 expression was significantly higher in DLBCL patients than
in controls (p=0.00). Significant positive correlations between miRNA-21 and
LDH, IPI and disease stage were detected (p <0.05). Significantly higher miR-
NA-21 levels were detected in ABC subtype compared to GCB subtype
(p=0.00). Significantly higher miRNA-21 expression levels were detected in
BCL6 negative, CD10 negative, MUM1 positive DLBCL cases compared to its
levels in BCL6 positive, CD10 positive and MUM1 negative cases, (p=0.018,
0.002 and 0.001 respectively). Higher miRNA-21 was associated with worse
response (p=0.016), 2-year overall (p=0.017) and 2-year progression free sur-
vival with statistical significance (p= 0.003). Significantly higher miRNA-21 levels
were detected in HCV positive DLBCL patients compared to HCV-negative
patients (p=0.00). Higher miRNA-21 levels were detected in HCV positive ABC
subtype than GCB subtype (p=0.05). Significantly higher levels were also
detected in HCV positive controls compared to HCV-negative controls.
Summary/Conclusions: Our study showed that miRNA-21 was overexpressed
in DLBCL patients, displaying higher levels in ABC than in GCB subtypes. MiR-
NA-21 was associated with poor response to treatment and survival in DLBCL.
According to our results, miRNA-21 is a potential marker of necro-inflammation
independent of its role in tumorigenesis, showing higher expression in HCV
positive DLBCL patients compared to none hepatitis patients.
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A NEW SCORING SYSTEM FOR PRIMARY CENTRAL NERVOUS SYSTEM
LYMPHOMA – A RETROSPECTIVE MULTI-CENTER ANALYSIS IN TAIWAN 
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Background: Primary central nervous system lymphoma (PCNSL) is a rare
type of non-Hodgkin’s lymphoma. Two independent prognostic scoring systems
have been developed at the Memorial Sloan-Kettering Cancer Center (MSKCC)
and the International Extranodal Lymphoma Study Group (IELSG). The former
considers age and Karnofski’s performance status (PS) as prognostic param-
eters(JCO. 2006;24:5711). The latter includes age, Eastern Cooperative Oncol-
ogy Group (ECOG) PS, the presence of deep lesions, serum lactate dehydro-
genase (LDH) and total protein levels in the cerebrospinal fluid
(CSF)(JCO 2003;21:266). Neither of the two systems has been verified in the
Asian population, leading to concerns regarding applicability in this region. 
Aims: This study was conducted to test the prognostic power of the 2 systems
in PCNSL patients in Taiwan. In addition, we analyzed the parameters of the
IELSG system to figure out the most powerful prognostic factors and then
established a new scoring system.
Methods: The medical records of patients with tissue-proven PCNSL were
retrieved from 15 academic hospitals in Taiwan through January 2002 to
December 2011. They were stratified into different groups according to the
MSKCC or the IELSG system and the overall survivals (OS) were evaluated.
All parameters in the IELSG system were checked by multi-variable analysis
to establish a new scoring system.
Results: When the IELSG scoring system was applied, the 2-year OS in low,
intermediate and high-risk groups were 78.3%, 43.9% and 37.5% respectively
with a crossover in the latter 2 groups (Figure 1A). When the patients were
stratified by the MSKCC scoring system, the 2-year OS of class I, II and III
were 65%, 68% and 20% (Figure 1B), respectively. We conducted single-vari-
able analysis of the 5 parameters included in the IELSG scoring system and
only age and ECOG PS were statistically significant. In the multi-variable analy-
sis, these 2 factors were almost equally weighted. Based on these findings,
we re-stratified the patients into 3 groups. Group 1 comprised patients with
both age <60 and ECOG PS <2 and Group 3 with both age ≥60 and ECOG PS
≥2. The patients not fulfilling criteria of either Group1 or Group 3 were catego-
rized as Group 2. According to this new scoring system, the median OS of
Groups 1, 2 and 3 were 1,573, 548 and 304 days (Figure 1C), respectively,
and their OS curves could be nicely distinguished.
Figure 1.
Summary/Conclusions: Neither the IELSG nor MSKCC scoring system is
ideal to distinguish the 2-year OS of the PCNSL patients in Taiwan. The new
scoring system comprising age  60 years and ECOG PS  2 seemed to pro-
vide a better prognostic power for Taiwanese patients.
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RELEVANCE OF CIRS SCALE IN THE PROGNOSIS OF DIFFUSE LARGE
B CELL LYMPHOMA IN ELDERLY PATIENTS 
C. Plaza-Meneses1,*, B. Zheng2, M. Yuste1, T. Arquero1, T. Villaescusa1,
E. Askari1, J. L. Lopez-Lorenzo1, M.-A. Perez1, E. Prieto1, F. Lobo3, P. Llamas1,
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1Hematology, Hospital Universitario Fundación Jiménez Díaz, 2University
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Background: The incidence of lymphomas is increasing with age. Many aggres-
sive lymphomas are now considered to be curable. All fit patients, even elders,
are candidates for optimal treatment with a curative intent. Diffuse Large B Cell
Lymphoma (DLBCL) is the most common non-Hodgkin Lymphoma, with 60% of
curative rates after standard R-CHOP regimen.  Patients that relapse can be
rescued with salvage treatment in 20-30%. The elders are not considered for full
standard treatment in many centers. Geriatric scales are starting to being used
to stratify patients and offer them individualized treatments. The use of GSCF for
neutropenia prophylaxis is not a standard of care in this population. 
Aims: The objectives of this study were: 1) Validate CIRS score in a DLBCL
cohort; 2) Analyse the impact of CIRS score in OS; 3) Analyse the impact of
GSCF prophylaxis for neutropenic fever.
Methods: Between November 2008 and November 2015, 41 DLBCL patients
with ≥60 years at diagnosis from a single institution and homogeneously treated
with R-CHOP were analyzed. Patients were evaluated for comorbidities with
Cumulative Illness Rating Scale (CIRS). CIRS score was used to detect the
more unfit population and evaluate the average of admissions stay and the
impact on OS. The CIRS scale was adjusted by removing the hematological
question since all our patients were diagnosed with a hematologic malignancy.
The cut-off point for CIRS score was selected using a ROC analysis. Neu-
tropenic fever (NF) events were recorded and the use of GSCF in prophylaxis
were analyzed, as well as the admission days for adverse events.
Results: In our series, 20 patients (48%) were males. Median age at diagnosis
was 73 years old (range 60-90) With a median follow-up of 32 mo. (range 0-
96), the median PFS was 51 months and the OS was 61 mo. The patients
were stratified by the R-IPI and the NCCN-IPI. The ROC analysis showed a
scoring of 5,5 in CIRS to identify two different risk groups, with an AUC of
70,5%, a sensibility of 87% and a specificity of 48% (p=0,02).  In the low risk
group, with CIRS <6 (n=17), 7 (41%) patients were admitted with a mean of
stay of 6,2 days (range 1-16) vs the high-risk group with CIRS >6 (n=24). Of
this group, 11(45%) patients were admitted with a mean of stay of 10,6 days
(range 1-62), p=0,035. The CIRS scale was also used to discriminate two OS
groups; the low risk showed a median OS not reached vs 29 mo. the high-risk
group, with a Hazard ratio of 2,68 (CI95%: 1,031-5,882, p= 0,042). NF was the
most common ER visit, n=18 (36%). Of the 18 patients with NF, 10 (55%) were
prescribed with GCSF prophylaxis mid cycles. Of all patients with GCSF (n=43)
only 10 (24%) NF were reported. 11/17 patients (65%) who didn’t use GCSF
prophylaxis had an NF episode. The Odds ratio (OR) for the patients under
prophylaxis was 0,232 (CI 95%: 0,085-0,634, p=0,004) (Figure 1).
Figure 1.
Summary/Conclusions: The OS and the PFS in our sample is similar as
described in larger studies. The days of admissions adjusted to the CIRS scale
give us a tool to help physicians to discriminate patients with DLBCL that will
have prolonged admissions when treated with the standard of care. The CIRS
scale also help separate two distinct OS curves, giving physicians a new tool
to help discriminate worse prognostic patients, making them good candidates
for adapted therapies. The use of GSCF prophylactic can protect the elderly
patients from NF, and should be used in all patients in this category.
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PRIMARY ADRENAL LYMPHOMA: A SINGLE-CENTER EXPERIENCE
L. Yuan1, L. Sun2, W. Du3, Y. Zhao1,*
1Department of Hematology, 2Department of Pathology, 3Department of Oncol-
ogy, Chinese PLA General Hospital, Beijing, China
Background: Primary adrenal lymphoma (PAL) is rare, with slightly more than
250 cases currently described in the English-language literature. In current
classifications, there is not yet a consensual definition of PAL.
Aims: The aim of this study was to report a large single-center clinical case
series of primary adrenal lymphoma (PAL) in terms of clinical presentation,
pathological and imaging features, and treatment outcome. 
Methods: We performed a retrospective analysis of 21 patients diagnosed
with PAL who presented to our center between January 2005 and January
2014.
Results: Median age at presentation was 48 years (range: 27–73) with a male-
to-female ratio of 5:2. Bilateral and right-sided adrenal involvement were seen
in 12/21 and 7/21 patients, respectively. Adrenal insufficiency (AI) was seen in
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6/10 evaluated patients. Computed tomography scans showed slight to mod-
erate contrast enhancement of adrenal masses in 4/5 patients (80%), and mag-
netic resonance imaging identified a normal T1 and longer T2 phase. Diffuse
large B cell lymphoma (DLBCL) was the most common immunophenotype
(85.6%). Two patients died due to rapid disease progression before treatment.
Three patients were treated with chemotherapy±external beam radiotherapy.
Two patients received autologous stem cell transplantation as consolidation
therapy. Five-year overall survival and progression-free survival were 54.2%
and 51.0%, respectively. 
Summary/Conclusions: These findings suggest that PAL should always be
considered in differential diagnosis of adrenal mass with AI. Moreover, DLBCL
was observed as the most common histological subtype of PAL. Despite the
contrasting previous reports, long-term prognosis of PAL is not necessarily infe-
rior to that of non-Hodgkin lymphoma in general.
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EFFICACY AND SAFETY OF IBRUTINIB THERAPY IN
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Background: Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin
lymphoma that has an aggressive clinical course and poor prognosis. Although
current front-line combination chemo-immunotherapies followed by autologous
stem-cell transplantation (ASCT) have improved the outcomes of affected
patients (pts), this disease is still incurable and relapse is common. Ibrutinib is
an oral covalent inhibitor of Bruton tyrosine kinase that showed significant activ-
ity in relapsed/refractory MCL in clinical trials, but in real-life routine, the efficacy
and safety may not always mirror those seen in clinical trials.
Aims: We investigated the clinical use of ibrutinib as a single-agent in 31 pts
with relapsed or refractory MCL to obtain additional information about predictive
factors, outcomes and toxicity in a real-life context.
Methods: We studied a group of 31 pts treated (or still in treatment) with ibru-
tinib to assess effectiveness in terms of overall response rate, complete
response rate, progression free survival and adverse events (AEs) in a real-life
context. Data were collected also with reference to clinical and biological char-
acteristics of the disease (MIPI, MIPIb, bone marrow involvement, stage, his-
tology, presence of bulky mass and/or extranodal disease) both at the time of
diagnosis and at the time of the start of ibrutinib therapy, and to the type and
number of previous therapies.
Results: At the start of ibrutinib therapy, the median age was 70 years (range,
45-82), 100% of pts had high risk MCL according to the MIPI score, 83.9% of pts
had disease stage III or higher, 41.9% of pts had bone marrow involvement, and
45.2% of pts presented extranodal involvement of MCL. 26 pts were treated for
relapsed MCL, 5 for refractory disease. They had received a median of 2 (range,
1-5) prior regimens including different chemo-immunotherapy schemes, ASCT
and newer agents such us bortezomib, lenalidomide, temsirolimus. We observed
6 complete responses, 1 after only 2 months of therapy, the others within 6 months
of therapy. After 15 months, we observed 4 relapses, characterized by leukemic
disease and one of them also presented central nervous system involvement,
and 8 progression. 80% of pts treated for refractory disease presented progres-
sion within 6 months. The most common AEs were fatigue (13% of pts) and
weight increase (13% of pts), followed by diarrhea and bleeding (grade ≤ 2) (6.4%
of pts). The most common hematologic event observed was neutropenia (9.7%
of pts, grade ≤ 2). With an estimated median follow-up of 6 months (range, 4-29),
19 pts are still receiving treatment, 12 have discontinued therapy for relapse or
progression of disease. Follow-up is still ongoing.
Summary/Conclusions: Single-agent oral ibrutinib shows a high response
rate and produces rapid responses regardless of the number and quality of
prior regimens. However, the quality and time of response does not seem to be
predictive of a better PFS or longer duration of response. Furthermore, resist-
ance to ibrutinib in pts with MCL is associated with fulminant, severe progres-
sion. Ibrutinib is well tolerated also in real-life experience. The weight increase
in 13% of pts suggests that ibrutinib may have an anabolic effect, including
alterations in blood pressure and lipid profile. Larger cohorts of pts and longer
follow-up are warranted to confirm these preliminary data.
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Background: Solid organ transplant recipients have elevated onset risks of hema-
tological malignancies (HMs) due to long-term administration of immunosuppres-
sant. However, few studies about the incidence and impact on survival of HMs fol-
lowing solid organ transplantation have been conducted in Asian countries.
Aims: The aim of this study was to identify the incidence, characteristics, risk fac-
tors and prognosis of HMs in solid organ transplant recipients at our institution.
Methods: Clinical data of patients undergoing kidney, liver and heart transplan-
tation in Hokkaido University hospital between 1965 and 2015 were reviewed
retrospectively. Kaplan-Meier analysis was performed for the cumulative incidence
rates (CI) of HMs, graft survival and patient survival. Patient’s characteristics
were compared between groups by the student t-test or Kai-square test.
Results: A total of 16 cases of HMs were identified, 9 post-transplant lympho-
proliferative disorder (PTLD), 5 acute myeloid leukemia (AML)/myelodysplastic
syndrome (MDS), 1 myeloproliferative neoplasm (MPN)) and 1 recurrent non-
Hodgkin lymphoma. The CI of PTLD were 1.1%, 1.5% at 5, 10 years in kidney
transplant recipients (n=352), 0.92%, 2.6% at 5, 10 years in liver transplant
recipients (n=287) and 20% at 1 year heart transplant recipients (n=5), respec-
tively (P<0.0001). AML/MDS and MPN developed only in liver transplant recip-
ients, and CI were 2.3% at 5 and 10 years (P<0.01). There was no difference
in background factors other than transplanted organ type between recipients
with HMs and without HMs. Patients with EBV-positive PTLD (n=5) were
younger (P<0.05) and had less extranodal diseases (P<0.05) compared with
EBV-negative PTLD (n=4). All patients with monomorphic PTLD (n= 4) were
treated with chemotherapy combined with rituximab and had been in remission.
In patients with other PTLD, reduction or withdrawal of immunosuppressant or
rituximab alone resulted in stable disease or remission. All AML/MDS but 2
acute promyelocytic leukemia in pediatric patients were chemo-refractory and
lethal. 10-year OS were 92% and 100% in kidney and heart transplant recipi-
ents. In liver transplant recipients, 10-year OS were 74%, 100% and 50% in
patients without disease, with PTLD and with myeloid neoplasm, respectively.
Survival in adult liver transplant recipients with myeloid neoplasms was inferior
to that without disease (P<0.05). 10-year graft survival rates were 72% and
75% in kidney transplant recipients without disease and with PTLD.
Summary/Conclusions: The incidence of PTLD in solid organ transplant recipients
in Japan is comparable to that in Western countries, whereas the incidence of
myeloid neoplasms is higher in liver transplant recipients. PTLD dose not have a
negative impact on the prognosis of solid organ transplant recipients under appro-
priate management, while heightened awareness and better clinical approach for
myeloid neoplasms following solid organ transplantation are needed.
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Background: Cytogenetic abnormalities of MYC are associated with poor prog-
nosis in patients with diffuse large B-cell lymphoma (DLBCL). Rearrangement
of MYC reportedly occurs in approximately 10% of DLBCL cases. In addition,
in various clinical trials of rituximab with standard dosing, female receiving rit-
uximab have had better outcomes than male. However, gender-segregated
outcomes of patients with MYC rearrangement have not been reported. In addi-
tion, the gender segregation of known prognostic factors, such as high interna-
tional prognostic index (IPI) score, elevated lactate dehydrogenase (LDH) level,
poor Eastern Cooperative Oncology Group performance status (PS), advanced
stage, and ≥2 extranodal sites, not as yet been fully elucidated.
Aims: The aim of this study was to determine the gender segregation of clini-
copathological and genetic prognostic factors, including MYC (fluorescence in-
situ hybridization: FISH) in patients with DLBCL by analyzing data from con-
secutive DLBCL patients.
Methods: In order to identify prognostic factors, we analyzed gender segregation
from the medical records of patients with DLBCL, including newly diagnosed and
transformed, at Juntendo University Hospital from December 2009 to December
2016. We retrospectively analyzed the data of 161 consecutive DLBCL patients
(male: 91 patients, female: 70 patients). Patients in this study were treated with
R-CHOP or R-CHOP-based regimens with minor modifications. The relationships
between overall survival (OS), progression free survival (PFS) and age, LDH
level, PS, stage, ≥2 extranodal sites, IPI, cell of origin (COO), BCL2 (immunohis-
tochemistry: IHC), BCL6 (IHC), MYC (IHC), double expressor (MYC and BCL2
expression on IHC), and MYC (FISH) were investigated. Univariate and multi-
variate analyses of estimated risk factors for OS and PFS were performed using
the log-rank test and Cox proportional hazard regression analysis.
Results: The median age was 70 years (range: 27–92 years). The median fol-
low-up was 17 months (range: 1–81 months). To adjust the impact of age, LDH
level, PS, stage, ≥2 extranodal sites, IPI, COO, BCL2 (IHC), BCL6 (IHC), MYC
(IHC), double expressor (IHC), MYC (FISH), and other significant factors, uni-
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variate analysis was performed for the OS. Elevated LDH level, stage ≥3, PS
≥2, ≥2 extranodal sites, IPI≥3, BCL6 negative (IHC), and MYC rearrangement
(FISH) were significant factors in the female patients; however, PS ≥2 and
IPI≥3 were significant factors in the male patients. Univariate analysis was also
performed for PFS. Elevated LDH level, PS ≥2, IPI≥3, BCL6 negative (IHC),
and MYC rearrangement (FISH) were significant factors in the female patients;
however, PS ≥2 was the only significant factor in the male patients. Multivariate
analyses were then performed using these factors in the Cox proportional haz-
ard model. MYC rearrangement (FISH) [hazard ratio (HR): 9.13, 95% confi-
dence interval (CI): 2.33–35.77, P=0.0015], and IPI ≥3 were identified as inde-
pendent significant prognostic factor for OS in the female patients with DLBCL.
Furthermore, MYC rearrangement (FISH) (HR: 2.47, 95% CI: 1.87–327.8,
P=0.01494], and elevated LDH level were identified as independent significant
prognostic factor for PFS in the female patients with DLBCL. On the other
hand, PS ≥2 was identified as the only significant prognostic factor for OS (HR:
44.27, 95% CI: 6.71–292.2, P <0.001), but not for PFS in the male patients
with DLBCL. Five out of seven female patients with DLBCL and MYC rearrange-
ment died from lymphoma progression. The median OS in the female patients
with DLBCL and MYC rearrangement was 8.0 months (range: 1–35 months)
compared to 21.5 months in those without MYC rearrangement (range: 1–79
months, P=0.003). On the other hand, in the male patients (n=13) with DLBCL,
MYC rearrangement was not significantly associated with poor OS (Figure 1).
Figure 1. Overall survival.
Summary/Conclusions: These results suggest that MYC rearrangement by
FISH is significantly associated with very poor OS and PFS in the female patients
with DLBCL but not the male patients with DLBCL. On the other hand, PS ≥2 is
significantly associated with poor OS in the male patients with DLBCL.
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Background: Around 40% of all Diffuse Large B-Cell Lymphoma (DLBCL)
cases involve extra-nodal sites, the most common being the gastro-intestinal
(GI) tract. DLBCL patients with intestinal involvement are particularly prone to
develop GI perforation, which might be life threatening and entail significant
morbidity. Identification of patients at risk for perforation may promote the per-
formance of pre-emptive surgical resection of the involved segment. Although
computed tomography (CT) scan is widely used at diagnosis, incorporation of
CT results into the risk stratification of perforation has not yet been performed.
Aims: To determine risk factors for perforation in patients with DLBCL and
intestinal involvement, with an emphasis on CT findings.
Methods: A retrospective single center study, including all consecutive DLBCL
patients that presented with intestinal involvement between 2005 and 2016.
The analysis included clinical, laboratory, pathological and radiological param-
eters. Cases with DLBCL of the stomach were excluded.  
Results: Forty-nine cases (30 men, 19 women) were included. Median age of
the entire cohort was 64 years (54.5-77 IQR). Early stage (1, 2) according to
the Lugano system was reported in 35% of cases. Small intestine involvement
was most frequent (61%), followed by large intestine and ilio-cecum (23 and
16%, respectively). Forty-three (88%) patients underwent CT scan at diagnosis.
Most lesions were defined radiology as concentric (n=27, 63%) (as opposed
to eccentric), and transmural (n=31, 74%) (as opposed to non-transmural). Of
note, 96.3% of the 27 concentric lesions were also transmural, compared with
31% (5/16) of the eccentric lesions. The median length and wall thickness of
the involved site were 9.3 cm (5.8-13.5) and 15 mm (10-20), respectively. Ten
(20%) patients developed an intestinal perforation. Six of the perforations (60%)
involved the small intestine, 3 (33%) occurred at diagnosis prior chemotherapy,
and 4 (40%) occurred within the first 21 days post therapy. All perforated lesions
were concentric and transmural, with a median length of 11.2 cm. Eight (80%)
patients underwent an urgent operation due to GI perforation, including 3 that
resulted in an ostomy. Perforation led directly to 2 (20%) deaths.  Perforation
resulted in delayed administration of chemotherapy in 50% of cases (n=5). A
univariate regression analysis found a higher risk of perforation in patients pre-
senting with a concentric lesion (p=0.001. HR=46, CI 31.5-78.5), a transmural
lesion (p=0.001. HR=34.6, CI 25.9-53.3) and a longer involved GI segment
(p=0.008. HR=1.06, CI 1.017-1.116). Each extra centimeter to the length of
the GI segment involved was associated with a 6% increase in the risk for per-
foration. There was no association between sex, age, performance status,
hemoglobin, LDH, albumin, iron, ferritin, KI67, disease stage, anatomical loca-
tion nor the involved site wall thickness and risk of perforation.
Summary/Conclusions: DLBCL patients presenting with an involvement of a
long intestinal segment, especially with a concentric, transmural lesion, are at
higher risk for perforation. These patients should be considered for a preemp-
tive surgical resection, dependent on lesion site and operative risk.
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Background: Five to 15% of patients with diffuse large B cell lymphoma (DLB-
CL) present MYC and BCL2 and/or BCL6 rearrangements which are detected
by fluorescence in situ hybridization (FISH) or standard cytogenetic. This
rearrangement defines a subgroup of DLBCL so-called double hit or triple hit
lymphomas (DHL/THL) which are included in the 2016 WHO classification revi-
sion of lymphoid neoplasm in a new category “High-grade B-cell lymphoma
with rearrangements of MYC and BCL2 and/or BCL6”. DHL/THL have an
aggressive clinical course and poor response to standard chemotherapy and
a median overall survival of 0.2-1.5 years. The best therapeutic option in these
patients is not yet well established. 
Aims: To evaluate retrospectively the incidence, clinical-biological characteristics,
type of treatment, overall survival (OS) and progression-free survival (PFS) of
patients diagnosed with DHL/THL and to compare them with patients with DLBCL
without double/triple-hit genotype (DLBCL-noDH/TH) in a single institution.
Methods: From January 2000 to April 2016, we analized 18 patients with
DHL/THL and 312 patients with DLBCL-noDH/TH. DHL/THL cases were iden-
tified using FISH for MYC, BCL2 and BCL6 in the tumor tissue (11 lymph node
biopsy, 2 gastrointestinal biopsy, 1 bone marrow biopsy, 3 skin biopsy and 1
cerebrospinal fluid). 
Results: The incidence of DHL/THL was 5.5%. The median age was 70 years
[range 53-93]. The patients included in DHL/THL group had a higher prevalence
of advanced disease and higher IPI (p=0.002). Thirteen patients received
anthracyclines containing chemotherapy, 3 citoreductive treatment and 2 pal-
liative care. No stem cell transplantation was performed in any patient as a
consolidation therapy. Four out of 13 patients achieved complete remission, 3
patients partial response and 6 patients were refractory. At last follow up, 13/18
patients were dead (11 lymphoma progression; 2 infectious complications).
Median follow-up 63 months. OS in DHL/THL was 9 months and in DLBCL-
noDH/TH was not reached (p=0.001). The PFS in DHL/THL and in DLBCL-
noDH/TH was 5.4 and 63 months, respectively (p<0.001) (Figure 1).
Figure 1. Overall survival.
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Summary/Conclusions: 1)The incidence of double or triple hit lymphomas in
our institution is consistent with the literature. 2)The most common regimen
used in double or triple hit patients was anthracycline-cointaining chemotherapy
achieving more than 50% of overall responses in our series. Nevertheless, the
majority of patients relapse, showing a short PFS and worse outcome than
DLBCL without double or triple hit, as reported previously.
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EFFECTIVE TREATMENTS ARE REQUIRED FOR PATIENTS WITH
DIFFUSE LARGE B-CELL LYMPHOMA WITH PRIMARY REFRACTORY
DISEASE
M.Q. Salas1,*, D.D. Eva2, M. Santiago1, O. Ana1, C. Aguilera3, E. De la Banda4,
F. Climent5, N. Garcia Muñóz1, L. Anna6, F.D.S. Alberto1, S.B. Anna2,
G.B. Eva2
1Hematology, ICO-Duran i Reynals, 2Hematology, ICO Duran i Reynals,
3Hematology, ICO-Duran i Reinals, 4Hematology, 5Pathological anatomy, Hos-
pital Universitario de Bellvitge, 6Oncology Radiation Therapy, ICO-Duran i Rey-
nals, Barcelona, Spain
Background: DLBCL is a heterogeneous disease; it has been described that
around 30% of patients present a refractory/relapsing disease following R-
CHOP treatment. Rituximab-containing salvage chemotherapy followed by
high-dose therapy and autologous stem cell transplant (ASCT) in chemosen-
sitive patients remains the standard of care for these patients.
Aims: We aimed to study the clinical features and outcome of patients diag-
nosed of DLBCL, homogeneously treated with R-CHOP/R-CHOP-like first line
regimen, who have primary refractory disease (PRD).
Methods: Three hundred and sixty-seven patients were diagnosed of DLBCL
between January 2004 to August 2016 in our center, 317/367 (86,3%) were
treated with R-CHOP or R-CHOP-like in first line. Forty-four (13.9%) patients
had PRD and 39 (12.3%) progressed during the follow up. Survival curves were
estimated using the Kaplan-Meier method and compared using the Log-Rank
test. Risk factors at diagnosis for PRD to R-CHOP were assessed. Univariate
analyses were performed by Chi square test and multivariate analyses by Cox
proportional hazard regression model.
Results: Among the 44 primary refractory patients, 15 (34%), with a median
age of 76 years (range 63-91), were considered unfit, 11 received supportive
care and 4 were treated with palliative chemotherapy (cyclophosphamide
and prednisone). Twenty nine (66%) were eligible for salvage therapy and
consolidation with ASCT. Characteristics of those 29 patients at the time of
salvage therapy were: median age 50 years (range 21-71), males 19 (65.5%),
ECOG 2-4 16 (55.2%), Ann Arbor stage III-IV 23 (79.3%), B-symptoms 9
(31%), bulky disease (20.7%), extranodal involvement 20 (69%), lep-
tomeningeal infiltration 4 (13.8%), high LDH 19 (65.5%), IPI 3-5 21 (72.4%).
Salvage therapies used were: R-ESHAP 23 (79.4%), R-ICE 1 (3.5%), MTX-
ARAC 4 (13.8%) in patients with leptomeningeal infiltration andintensive
burkitt-like therapy 1 (3.4%) in a double hit patient. Twelve (41.4%) did not
complete the treatment: 2 (6.8%) for toxicity (1 cardiac event and 1 septic
shock) and 10 (34.4%) for progression. The intention-to-treat response rate
was: CR 1 (3.5%), PR 4 (13.8%), refractory disease/progression 22 (75.8%)
and not evaluable 2 (6.9%). Five patients underwent an ASTC (BEAM as
conditioning regimen). One died during transplant due to septic shock and 4
progressed with a median follow-up of 5 months. One patient was rescued
with a third line of treatment (R-ICE) and allogeneic transplant, and he is cur-
rently in CR at 7 months. Median PFS was 2 months (CI 95% 1.2-2.7) and
median OS was 5 months (CI 95% 3.4-6.6). Among the 15 primary refractory
patients who were treated with  palliative intention, median PFS was 1 month
(CI 95% 0.19-1.80) and median OS 1 month (CI 95% 0.19-2.42). Among the
317 patients treated with R-CHOP, risk factors at diagnosis for having PRD
to R-CHOP were: B-symptoms (HR 1.94, 95% CI: 1.05-3.61, p=0.034) and
elevated LDH (HR 3.92, 95% CI: 1.61-9.51, p=0.003) (Table 1).
Table 1.
Summary/Conclusions: Patients with DLBCL refractory to first line R-CHOP
are not rescued with current salvage therapies, and in this settingDLBCL must
be considered an incurable disease with a very short survival, similar to that of
patients treated with palliative care. Patients with B symptoms and elevated LDH
at diagnosis have a significant higher risk to be refractory to R-CHOP. It is imper-
ative to identify early these patients and to design new therapies for them. 
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RITUXIMAB BENDAMUSTINE CYTARABINE IS A FEASIBLE AND SAFE
INDUCTION REGIMEN PRIOR TO ASCT IN FRONTLINE MCL: A SINGLE
CENTER RETROSPECTIVE REAL LIFE EVALUATION
I. Gianesello1, M. Nabergoj1,*, A. Branca1, T. Berno1, F. Lessi1, M. Riva1,
E. De March1, R. Zambello1, L. Trentin1, F. Piazza1, G. Semenzato1
1Dept of Medicine, Hematology and Clinical Immunology section, University of
Padua, Padua, Italy
Background: Mantle cell lymphoma (MCL) is an uncommon, still incurable
subtype of non Hodgkin lymphoma. The routine use of high dose Cytarabine
and high dose chemotherapy followed by autologous stem cell transplant
(ASCT) markedly improved the outcome and has become the standard treat-
ment for fit, young (<65 years) patients. Recently, two phase II studies demon-
strated that Rituximab, Bendamustine and Cytarabine (RBAC) combination has
a remarkable activity with a favorable safety profile both in untreated and
relapsed/refractory elderly MCL patients (Visco et al., 2013 and 2017). These
studies suggested that RBAC combination (with Cytarabine 800 mg/mq) is safe
and effective as a CD34+ stem-cell mobilizing regimen. No data are available
on RBAC with Cytarabine 500 mg/mq as mobilizing regimen in transplant-eli-
gible patients.
Aims: To assess the efficacy and safety of RBAC as induction therapy and as
a peripheral blood progenitor cell mobilization therapy in combination with gran-
ulocyte colony stimulating factor (Lenograstim) in newly diagnosed transplant-
eligible mantle cell lymphoma patients.
Methods: From November 2009 to March 2016, 10 newly diagnosed MCL
patients (median age 65 years; range 55-72) were treated as induction
immunochemotherapy according to RBAC schedule (Rituximab 375 mg/mq
day 1, Bendamustine 70 mg/mq day 2-3, Cytarabine 500 mg/mq day 2-3-4) for
4 cycles. 90% had a stage IV disease; MIPI score was high in one patient
(10%), intermediate in 5 patients (50%) and low in 4 patients (40%). Stem cell
harvest was performed after 2 cycles. Successful mobilization was defined as
achieving physician-determined target PBSC yield which was CD34+ cells >=
2 x 106/Kg. The G-CSF (Lenograstim) infusion started per protocol at day 6 at
the dose of 5 umg/kg.
Results: All patients completed the scheduled treatment (4 cycles). The ORR
was 90%: CR 90% and PD 10% (1 patient). Overall, the rates of successful
mobilization and the proportion of patients achieving a total PBSC yield of
≥2x106/kg were 100%, and the median PBSC yield was 10 x 106/kg (range 3-
20x106/kg). The median time to stem cell harvest was 17 days (range 14-19).
The median number of apheresis to achieve the PBSC target was 1 and only
1 patient (10%) required a second collection procedure. Plerixafor was not
used. 80% of patients underwent high dose chemotherapy according to FEAM
protocol (Fotemustine 150 mg/mq on days -7, -6, Etoposide 200 mg/mq) and
Cytarabine 400 mg/mq on days -5, -4, -3, -2 and Melphalan 140 mg/mq on day
-1) with infusion of at least 5 x106 /Kg of PBSC. The median day for neutrophils
and platelet recovery (ANC >500/mmc, Plts >50,000/mmc) was 11 and 26
(range 10-29 and 14-34), respectively. There was no engraftment failure. Most
frequent adverse events (according to CTCAE grading) during therapy were
hematological: neutropenia (100%, all 3-4), thrombocytopenia (100%, 60% G3-
4), anemia (100%, 50% G3-4). Among non hematological toxicities, 20% of
patients had febrile neutropenia (G3-4), 20% mucositis (G1-2), 20% lung infec-
tions (G3), 10% hyperglycemia (G3). After a median follow up of 43 months the
OS and PFS were 90% and 80% respectively.
Summary/Conclusions:As in the relapsed/refractory setting and in MCL patients
ineligible for high dose chemotherapy, RBAC has been proven to be an efficacious
induction and mobilization regimen also in transplant eligible MCL patients with
an encouraging safety profile. Further investigations are needed to assess the
optimal role of RBAC within the standard first line treatments.
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THE SAFETY OF LIPOSOMAL CYTARABINE IN CENTRAL NERVOUS
SYSTEM INFILTRATION BY HAEMATOLOGIC MALIGNANCIES
P. García-Ramírez1,*, D.P. Millacoy1, T. Galicia1, M.C. Mateos1,
J.M. Arguiñano1, M. Alvarellos1, M.C. Montoya1, B. Signes1, M.L. Antelo1
1Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain
Background: Central nervous system (CNS) involvement, both leptomeningeal
and parenchimatous conveys a poor prognostic in haematological malignan-
cies. As well as systemic chemotherapy that crosses hematoencephalic barrier,
intrathecal (IT) chemotherapy has become an attractive approach because of
direct action in the cerebrospinal fluid (CSF). Liposomal cytarabine (Depocyte®)
is a convenient formulation that maintains cytotoxic concentrations of cytarabine
in CSF for an extended period of time (>14 days). This permits to decrease the
frequency of lumbar punctures, without losing efficacy and minimizing the
patient´s discomfort.
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Aims: The objective of this retrospective, observational study is to evaluate
the efficacy and safety of liposomal cytarabine in patients with CNS infiltration
by haematological malignancies.
Methods: 36 consecutive patients with haematological disease and risk of
CNS infiltration underwent flow cytometry (FC) analysis of CSF in a single cen-
ter from December 2014 to December 2016. CNS involvement was assessed
by using standard CSF cytology, 8-color flow cytometry or MRI imaging. Along
with systemic therapy, all patients considered positive were treated 50 mg of
IT Liposomal cytarabine administered by lumbar puncture every 2 weeks for 4
doses and every 4 weeks thereafter. Concomitant dexamethasone for arach-
noiditis prophylaxis was added both i.v. and IT. We analysed the rate of adverse
events (AE) and the time for CSF clearance. Short follow up precluded assess-
ment of cumulative incidence of CNS relapse/progression.
Results: Data from 36 patients were analysed. A total of nine patients were
considered to have CSF involvement, all of them detected by FC. Of note, all of
them were considered negative for CSF infiltration by standard cytology. Three
additional patients received IT therapy as prophylaxis since MRI imaging showed
brain involvement by the malignancy. The median age of this 12 patients was 52
years (range16-69), 58.3% were female. Diagnosis were B-cell lymphoprolifer-
ative disorder 41.7% (CLL, Burkitt, DLBCL), ALL 25%, AML 25% and multiple
myeloma 8.3%. The median number of doses per patient was 6.5 (SD 1.7). CSF
clearance was achieved after a median of 1 dose (range 1-3) or 20 days (range
16-86). Overall rate of CNS response was 100%. Two patients (16.7%) had lep-
tomenigeal relapse during the IT treatment. The overall AE incidence was 66.7%.
The most common AE include: headache, peripheral sensory neuropathy, back
pain and nausea. Severe neurotoxicity has been encountered in four patients:
cauda equina syndrome (2), encephalitis (1) and arachnoiditis (1). Treatment
had to be discontinued in 3 patients because of side effects but this did not lead
to relapse. The median time to AE occurrence was 6 cycles (range 4-7) or 110
days (range 33-227). The incidence and severity of AE seemed to increase with
the cumulative number of cycles administered. In most patients neurological
complications resolved or improved with time.
Summary/Conclusions: use of liposomal formulation of cytarabine for IT
administration has become an effective option for the treatment of lep-
tomeningeal involvement by haematological malignancies. Neurological AE
are reversible; however, they accumulate and worsen with time, thus precluding
long-term use.
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RETROSPECTIVE ANALYSIS OF OUTCOMES FOR ELDERLY PATIENTS
WITH STAGE 3 AND 4 DISEASE HIGH-GRADE DLBCL WITH REDUCED
CYCLES OF R-CHOP OR R-GCVP : A 7 YEARS SINGLE-INSTITUTE
EXPERIENCE.
K. Joshi1,*, K. Leung2, C. Page2, A. Rajic3, F. Masieri4, N. Gill2, J. Morgan2,
A. Hodson1, M. Prahladan1
1Haemato oncology, Ipswich Hospital/ Addenbrookes Hospital, Cambridge,
2Haemato oncology, Ipswich Hospital, 3Molecular Biotechnology Unit., Univer-
sity of Suffolk., Ipswich, 4Molecular Biotechnology Unit., University of Suffolk,
Cambridge, United Kingdom
Background: The most common high-grade lymphoid malignancy in adults is
Diffuse Large B-Cell Lymphoma (DLBCL), which has an increasing incidence
with age (1). Over 40% of patients with DLBCL are above the age of 70, and
the co-morbidities in this age-group present significant challenges and com-
plexities with regards to selecting and implementing treatment regimens (2). 
Aims: We present a retrospective analysis of outcomes for patients with high-
grade DLBCL (stage 3 or 4 disease) who have received fewer than 6 cycles of
full dose R-CHOP or R-GCVP because of poor tolerability or disease progres-
sion with treatment.
Patients and Methods: Retrospective data were collected from the cancer
registry for all newly-diagnosed DLBCL patients who received R-CHOP or R-
GCVP chemotherapy, with data collected from Jan 2010 to Feb 2017 from
Ipswich Hospital NHS trust, United Kingdom. Patients who completed 6 cycles
of chemotherapy were excluded. Interim PET-CT scan/staging CT scan was
done to assess the disease response to therapy after 2 cycles of chemotherapy.
The main baseline characteristics collected were age, sex, ECOG Performance
Status, Ann-Arbor Stage and IPI risk stratification. The primary end point was
progression-free survival (PFS) from completion of treatment. Secondary end
points were overall response rate (ORR), overall survival (OS), and the reasons
for premature ceasing of treatment based on graded toxicity according to NCI-
CTCAE 4.0.
Results: Out of 87 patients, 12 patients were identified that fulfilled the inclusion
criteria. The median age of patients was 72 years (range: 64-88 years), sex
distribution was 7 male: 5 female, ECOG PS was 0-2 in 10 (83%) and ≥3 in 2
(17%) of the patients, Ann-Arbor Stage was 3 in 6 patients (50%) and 4 in 6
patients (50%), and IPI score was 3 in all 12 patients. 11 patients received R-
CHOP and 1 patient received R-GCVP. The median length of treatment was
3.5 cycles (range: 1-5 cycles). The overall response rate was 50% on interim
assessment and 75% at end of treatment assessment scan. The complete and
partial response rates at the end of the treatment were 58% and 17% respec-
tively. Progression free survival was 73% at 2 years (8 out of 11 patients) and
50% at 3 years (4 out of 8 patients). The median overall survival of deceased
patients (4 out of 12) was 9.5 months (range: 2-42 months) and the median
overall survival of living patients (8 out of 12) is at 40.5 months (range: 27-84
months). The most common reasons for stopping the treatment were intoler-
ance of side-effects (4 out of 12) or neutropenic sepsis (3 out of 12). 2 out of
12 patients received an incomplete course of chemotherapy due to non-
response or progression of disease with treatment.
Conclusions: DLBCL treated with less than 6 cycles of full dose R-CHOP or
R-GCVP chemotherapy may achieve sustained long-term remission in selected
patients with high IPI and significant co-morbidity. Further research on disease
characteristics including molecular profile is needed to elucidate selected pop-
ulations who may achieve long-term remission with shorter cycles of
chemotherapy.  Further insights may derive, for example, from analysis of poly-
morphism of folate pathway genes and /or of NF-kB,which have been previ-
ously suggested as pharmaco-genomic targets in lymphoid neoplasm. A risk
stratification model needs to be developed to reduce drug toxicity and other
short and long term treatment related complications so as to improve patient
experience, and pharmaco-economic benefits.
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MULTIPLE NEOPLASMS CONSIST OF SOLID CANCER AND
NON-HODGKIN LYMPHOMA
K. Natori1,*, D. Nagase1, S. Ishihara1, A. Shibuya1, Y. Mitsui1, Y. Kuraishi1,
H. Izumi1
1hematology and Oncology, Toho University Medical Center, Oota city, Japan
Background: Malignant lymphoma is a nineth cause of death in Japan. And
non-Hodgkin lymphoma(NHL) occupied more than 90%. We experienced cas-
es and will report that we reviewed multiple neoplasms consisting non-Hodgkin
lymphoma. We experienced 176 cases.
Aims: We aimed for epidemiology and prognosis improvement of malignant
neoplasms including NHL. We want to look for a hint of the early detection.
Methods: We intended for multiple neoplasms 340 cases including hemato-
logical malignancy. We reviewed 190 cases of multiple neoplasms including
malignant lymphoma. In 190 cases, NHL case were 176 cases. The examina-
tion factors are type of the hematological malignancy, gender, the age at onset
of the first cancer, interval with the second cancer, treatment strategy. The def-
inition of multiple neoplasms followed Warren & Gates theory. And as for the
definition of synchronous type, a diagnosis interval is less than 6 months,
metachronous type interval is more than 6 months. About statistical examina-
tion, we used SPSS statistics ver21.
Results: All cases are 176 cases, consist of male 108 cases, female 68 cases,
synchronous type 45 cases, metachronous type 131 cases. Double neoplasms
149 cases, triple neoplasms 25 cases, quadple neoplasms 2 cases. The medi-
an age was 71yrs (ranged51-93yrs), the synchronous type 70yrs(ranged 51-
88years), the metachronous type was 73yrs(ranged 57-93yrs). The counterpart
of malignancies, Hodgkin’s lymphoma 1 case, myelodysplastic syndrome 3
cases, acute myeloid leukemia 8 cases, multiple myeloma 4 cases, gastric
cancer 38 cases, colon cancer 32 cases, lung cancer 26 cases, renal cell car-
cinoma 6 cases, prostate cancer 12 cases, breast cancer 14 cases, urinal blad-
der cancer 5 cases, uterin cancer 7 cases, esophangeal cancer 9 cases, hepa-
tocellar carcinoma 12 cases. In double neoplasms was 149 cases, metachro-
nous type was 112 cases. The median age of first diagnosis, 68yrs (ranged43-
85yrs), the second cancer were 74yrs (ranged57-89yrs), About interval between
solid cancer and NHL, median interval time was 58M, solid cancer precedence
case was 53 cases, interval was 81M (ranged 7-564M), hematological malig-
nancy precedence case was 59 cases interval was 55M (ranged 8-364M). The
cause of death was that 15 cases were solid cancer, 72 cases were hemato-
logical malignancy and 6 cases were accident. The median overall survival
was 18M( ranged 1-211M), synchronous type 14M(ranged 2-132M), metachro-
nous type 22M (ranged1-116M).
Summary/Conclusions: In the case of a double cancer including solid cancer
and NHL, the first cancer occurs in elderly. Diagnosis of malignant neoplasms
within 3 years were 48 cases out of 149 cases(32.2%). The important point is
that 3 years are required for careful observation at the time of malignancy diag-
nosis. It is nessessary to discover at the early stage. So it could be a lot of
treatment options formalignant neoplasms. We think that a prognosis is
improved.
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RETROSPECTIVE EVALUATION ON EFFICACY AND FEASIBILITY OF
R-CODOX-M/IVAC REGIMEN IN AGGRESSIVE DLBCL
E. Coviello1,*, P. Minetto1, F. Guolo1, D. Guardo1, M. Gambella1, F. Ballerini1,
R. M. Lemoli1, M. Gobbi1
1Haematology, IRCCS San Martino, Genova, Genova, Italy
Background: Diffuse Large B Cell Lymphoma (DLBCL) is an heterogeneous
group of diseases. The aggressive behavior can be predicted by clinical risk
scores, immunohistochemistry and cytogenetic. Among DLBCL, double hit lym-
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phomas (DHL) and double or triple-protein-expression lymphomas (DPLs,
TPLs) display a worse outcome. R-CHOP, which is the frontline treatment for
DLBCL, showed a poor outcome in high risk IPI patients and DHLs or DPLs.
From January 2011 in our centre (IRCCS AOU San Martino Hospital–IST,
Genoa, Italy) R-CODOX-M/IVAC regimen has been adopted as first line in
patients with aggressive DLBCL, defined by at least one among these features:
high tumour burden, DPLs, IPI score >3 or by the presence of at least 1 extra-
nodal site.
Aims: Our aim was to define the efficacy and feasibility of this frontline strategy
and eventually identify the subgroups of patients who may benefit from this
approach.
Methods: We retrospectively analyzed 20 patients affected by aggressive DLB-
CL treated with R-CODOX-M/IVAC. R-CODOX-M consists of rituximab 375
mg/sqm day 1, cyclophosphamide 800 mg/sqm day 1, 200 mg day 2-5, dox-
orubicin 40 mg/sqm day 1, vincristine 1,4 mg/sqm, methotrexate 6700 mg/sqm.
IVAC-R contains rituximab 375 mg/sqm, iphosphamide 1500 mg/sqm day 1-5,
etoposide 60 mg/sqm day 1-5, cytarabine 2000 mg/sqm bid day 1-2. In both
cycles CNS prophylaxis was administered. According to Ann Arbor classifica-
tion, 11 patients were on stage IV, 1 on stage III, 3 in stage II and 5 in stage I.
Twelve patients had B symptoms. Median IPI score was 3. Eleven patients had
DPLs and 4 of them had TPLs. Overall survival (OS) was calculated from the
time of diagnosis to the dime of death or last follow-up.
Results: After a median follow-up of 28 months, 5 patients died (25%), OS at
six and twelve months was 89,4 and 70,4%, respectively, median not reached
(NR). Complete remission was achieved in 11 patients (69%), partial remission
in 2 patients (13%). The overall response rate was 82%. Three patients (18%)
were primary refractory. Among DPLs, OS at six and twelve months was 88,9
and 64,8%, respectively, not significantly lower than non DPLs patients (p=n.s.,
median NR). In patients with Ann Arbour stage III or IV, OS at six and twelve
months was 90,9 and 60,6% (median NR). In patients with IPI score >3, OS at
six and twelve months was 78,8 and 45% (median 12 months). The main toxicity
during CODOX-M was grade >2 mucositis, 63% of patients. Infections occurred
in 71% of patients. Renal and liver toxicity was mainly of low grade and was
observed respectively in 38% and 50% of patients. Median severe neutropenia
was 4,5 days (range 0-16) and median severe thrombocytopenia was only 1
day (range 0-21). Most patients (56%) needed transfusion support. In IVAC
regimen the main toxicity was the haematological one with 7 days of median
duration of severe neutropenia (range 3-10), and 7 days (range 6-23) of throm-
bocytopenia. Seventy-five patients required transfusion support. Infections
occurred in 42% of patients. We observed few case of grade >2 mucositis
(17%), renal toxicity (8%) and liver toxicity (17%).
Summary/Conclusions: R-CODOX-M/IVAC is a generally well tolerated reg-
imen, with acceptable toxicity profile in the setting of aggressive DLBCL. Results
in our cohort suggest a potential benefit for DPLs, whereas higher IPI scores
retains a negative prognostic impact. The next step of the study will be retro-
spective FISH evaluation of C-MYC, BCL2 and BCL6 translocations, for lacking
patients in our cohort, in order to disclose a potential benefit for double or triple
hit lymphomas.
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OLDER PATIENTS WITH DLCLB- BODY MASS INDEX AS A PREDICTOR
OF SURVIVAL
M. Purić1,*, N. Milanović1, D. Gavrilović2
1Department of Hematology, 2Department of Statistics, Institute for Oncology
and Radiology of Serbia, Belgrade, Serbia
Background: There are contradictory results of earlier studies regarding the
impact of body mass index (BMI) on overall survival (OS) or progression-free
survival (PFS) of diffuse large B cell lymphoma (DLCLB). Many factors like
drug distribution and drug metabolism might influence the outcome in patients
with excess body weight. The best method to predict outcome and adjust ther-
apeutic approach is not known and elderly DLCLB patients do not always
receive the appropriate therapeutic regimen.
Aims: To evaluate if BMI at diagnosis can predict clinical outcome in older
patients with DLCLB receiving the first– line chemotherapy.
Methods: Patients at the Institution for Oncology and radiology of Serbia between
2005 and 2015 who were diagnosed and received first-line chemotherapy for
DLCLB, older than 65 years were enrolled. Clinical and treatment data were
recorded including BMI at the diagnosis. Patients were stratified into BMI groups
according to WHO guidelines: underweight (BMI<18.5kg/m2 ), normal weight
(BMI 18.5 to<25kg/m2), overweight (BMI 25 to<30kg/m2), obesity class I (BMI 30
to<35kg/m2). Survival time was estimated using the Kaplan- Meier (KM) method,
and Cox proportional hazard model was used to evaluate the risk factors signif-
icance for survival.  A p-value <0.05 was considered significant.
Results: 87 patients were included in the study. 23 (26.44%) patients were
older than 75 years, 52 (59.77%) were female, 38 (43.67%) were Ann Arbor
stage 1 and 2, 28 (32.18%) were International prognostic index (IPI) score 0-
1. The majority of patients were diagnosed as normal weigth (39.08%) and
overweight (31.03%), less were in obesity class I group (14.94%) and only
2,3%  underweight.  38 (43.68%) patients received CHOP, 27 (31.03%)
mCHOP, 12 (13.79%) CVP and 10 (11.49%) CEOP regimen, with or without
Rituximab. In the whole group, obese patients had shorter OS and PFS. After
a median follow-up of 43 months (range, 1-128), median OS times were 19
months (4-not reached) for obese, 54 months (not reached) for underweight,
90 months (53-not reached) for normal weight and not reached for overweight.
PFS was 18 months (4-not reached) for obese, 67 (51-not reached) and 91
months (53-not reached) for overweight and normal weight. In the treatment of
normal weight and overweight patients, the same chronological age, frequently
was used anthracyclin based regimen (CHOP, 27 patients; mCHOP, 22 patients;
CVP, 7 patients; CEOP, 7 patients). There was no difference in the frequency
of different regimens in obesity group. In the group of patients treated with
anthracyclin based regimens, obese patients tended to have shorter survival,
the median OS was 33 months (9-not reached), while normal weight patients
tended to have a longer OS, the median OS-not reached. The worse survival
among  non-anthracyclin regimen treated patients, had obese patients, median
OS 26 months (9-not reached). Overweight females and men with normal
weight exhibited the best median OS and PFS (not reached). In obese patients,
females tended to have a longer OS and PFS (median OS/PFS 19/18 months
for women versus 9/9 months for men), although the difference was not statis-
tically significant (p=0.77).
Summary/Conclusions: Obesity was associated with shorter survival among
older patients with DLCLB treated with different chemotherapy regimens. The
impact of gender on PFS and OS varied with BMI. The use of anthracyclin did
not influence the outcome of obese patients. This study suggests that BMI may
predict survival in older patients with newly diagnosed DLCLB. 
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STOMACH DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE CENTER
EXPERIENCE
M.-T. Sung1,*, L.-W. Chiou1, S.-N. Huang2, A.-C. Feng2, M.-C. Wu1, P.-Y. Chen1,
C. Hsiao-Hsiang 1, T.-D. Tan1
1Department of Hematology and Medical Oncology, 2Office of Epidemiology
and Biostatistics, Koo Foundation Sun Yat-Sen Cancer Center, Taipei City, Tai-
wan, Republic of China
Background: Primary gastric diffuse large B cell lymphoma is a relative rare
type of diffuse large B cell lymphoma. Immunochemotherapy followed by con-
solidation radiation is the mainstay of treatment. However, the cycles of
chemotherapy and the role of consolidation radiation are still under debate.
Aims: To review and analyze the treatment experience of newly diagnosed pri-
mary gastric diffuse large B cell lymphoma. We presented the treatment out-
come of our institution.
Methods: We retrospectively reviewed medical records from Jan 2005 to Dec
2014 from our institution. 30 patients with primary gastric diffuse large B cell
lymphoma were included. Clinical characteristics, treatment regimens, treat-
ment response, treatment modality, and survival were analyzed.
Results: From Jan 2005 to Dec 2014, there were 30 patients with primary gas-
tric diffuse large B cell lymphoma. Median age was 65 years of age. 53%(n=16)
of patients were male. All 30 patients (100%) have received chemotherapy. 13
of them (43%) have received involved field radiation therapy(IFRT). RCHOP or
RCEOP was administered in 86%(n=26) of patients. Complete response(CR)
rate was 80%(n=24). 5-year survival was 69%. In patients who achieved com-
plete response(n=24), 5-year survival for 4 cycles of chemotherapy vs 6 cycles
of chemotherapy were 88% vs 86%(p=0.42), respectively. For addition of IFRT
in CR patients, 5-year survival for IFRT vs no IFRT were 83% vs 90%(p=0.93),
respectively. Treatment-related mortality(TRM) was 10%(n=3) and primary
refractory disease was 10%(n=3). All of them are non-CR patients. Gastroin-
testinal bleeding which required admission occurred in 10%(n=3) of patients.
In patients who developed GI bleeding, 2 of them were non-CR patients and
they all died. No patient died of disease relapse after complete response.
Summary/Conclusions: In our series, the 5-year survival was good. In patients
who achieved CR, cycles of chemotherapy and consolidation radiation did not
make significant difference to the survival. Prevention of early mortality may
improve the outcome of this disease. Gastrointestinal bleeding in treatment is
rare but with high mortality.
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IMMUNOHISTOCHEMISTRY BIOMARKERS IN PATIENTS WITH DIFFUSE
LARGE B-CELL LYMPHOMA: A RETROSPECTIVE STUDY
T. Mendes1,*, F. Mousinho1, P. Sousa E Santos1, E. Viegas2, A. P. Gomes1,
F. Falcão2, F. Lima1
1Clinical Hematology, 2Pharmacy Department, Phaculty of Pharmacy, Centro
Hospitalar de Lisboa Ocidenal; Phaculty of Pharmacy,University of Lisbon, Hos-
pital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, Lisboa,
Portugal
Background: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous
disease with variable clinical course. The International Prognostic Index (IPI)
is the most important tool to identify subgroups with different survival, however,
certain biological markers seem to have a prognostic value relevant and inde-
pendent of IPI.
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Aims: To analyze the evolution of patients diagnosed with DLBCL and the
expression of BCL2, BCL6 and MYC.
Methods: We conducted a retrospective study that included hospitalized
patients with de novo CD20+ DLBCL, with expression of BCL2+, BCL6+,
BCL2/BCL6, MYC/BCL2, MYC/BCL6 treated with regimens containing ritux-
imab, from February 2012 to November 2016. Samples were analyzed by
immunohistochemistry. Statistical analysis with the SPSS V17.0 program.
Results: We included 43 patients with a median age of 65 years (22-87), 59.5%
male, 45,2% had IPI 0-2, 54,8% had IPI 3-5, 26,2% stage I-II, 73,8% stage III-
IV, 61,9% had extranodal disease and 23,8% bulky disease. Ki-67 was elevated
in all patients who did this evaluation (n=28). In 13 patients was identified
BCL2+, BCL6+ in 6, and 21 patients had co-expression of BCL2/BCL6, 1
patient had MYC/BCL2 and 1 had MYC/BCL6. The R-CHOP regimen was first
line treatment in 92,8% of patients. The ORR was 82,5%, with 65% of CR,
15% PR and 17,5% PD. Of those patients who received second line treatment,
8 expressed BCL2/BCL6, 4 BCL2, 2 BCL6, 1 MYC/BCL2, and 1 MYC/BCL6.
Of the 5 patients who had third line treatment 3 expressed BCL2/BCL6, 1
BCL2, and 1 MYC/BCL6. The average time to next treatment (TNT) was 5,2
months (0,5-19) for second line and 4,9 for third line. Mortality rate was 45,2%.
With a median follow up of 18,6 months (3-58,6), the overall survival was 24,6
months (3-62).
Summary/Conclusions: The identification of biomarkers by immunohisto-
chemistry is a relatively inexpensive process, which, when well elaborated and
interpreted, allows to find in a safe way, subgroups of patients at high risk, who
benefit from more aggressive 1st line therapy and, whenever possible, from
the Inclusion in clinical trials with new drugs.
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INVESTIGATION ON TREATMENT STRATEGY, PROGNOSTIC FACTORS,
AND RISK FACTORS FOR EARLY DEATH IN ELDERLY TAIWANESE
PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA 
S.-F. Cho1,*, Y.-C. Liu1, H.-H. Hsiao1, Y.-F. Tsai1, H.-C. Wang1, T.-C. Liu1
1Division of Hematology and Oncology, Department of Internal Medicine, Kaoh-
siung Medical University Hospital,Kaohsiung city, Taiwan, Kaohsiung city, Tai-
wan, Republic of China
Background: Given that the population of elderly cancer patients, including
those with diffuse large B-cell lymphoma(DLBCL), is increasing, the management
of cancer in the elderly has emerged as an increasingly common problem.
Aims: This study aimed to investigate the treatment strategy, prognostic fac-
tors, and risk factors of early death in elderly patients (age ≥65 years) with
DLBCL in the rituximab era.
Methods: Elderly patients diagnosed with DLBCL between 2008 and 2014
were enrolled for analysis.
Results: There were 145 elderly patients with DLBCL diagnosed between
2008 and 2014. After excluding patients with primary central nervous system
DLBCL (n=9) and incomplete data (n=3), a total of 133 patients (64 male and
69 female) with a median age of 74 years (range 65 to 94 years) were enrolled
in the present study. Patients at a younger age and with better performance
status were more likely to receive intensive frontline treatment. The median
progression-free survival (PFS) and overall survival were 15 and 21 months,
respectively. Anthracycline-containing chemotherapy achieved a higher remis-
sion rate and showed a trend toward better overall survival at the expense of
a higher risk of severe neutropenia. Multivariate analysis revealed that very
old age (≥81 years), a high-risk age-adjusted international prognostic index
(aaIPI) score, and bone marrow involvement were associated with poorer PFS
and overall survival. Progression of lymphoma was the major cause of death
in the study population. In addition, approximately 25% of patients died within
120 days of their diagnosis. The risk factors for early mortality included very
old age, a high-risk aaIPI score, and bone marrow involvement. The appear-
ance of symptoms or signs of tumor lysis syndrome at diagnosis was associ-
ated with a trend toward early death.
Summary/Conclusions: Treatment of elderly patients with DLBCL remains a
challenge in clinical practice, and comprehensive evaluation to tailor therapeutic
interventions and offer the best supportive care may reduce complications and
improve the clinical outcome of these patients.
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TREATMENT OUTCOME OF MONOMORPHIC EPITHELIOTROPIC
INTESTINAL T-CELL LYMPHOMA: EXPERIENCE FROM AN ASIAN CAN-
CER CENTER
M.-T. Sung1,*, M.-Y. Lee2, M.-C. Wu1, T.-D. Tan1
1Department of Hematology and Medical Oncology, 2Department of Pathology
and Laboratory Medicine, Koo Foundation Sun Yat-Sen Cancer Center, Taipei
City, Taiwan, Republic of China
Background: Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL),
previously type II enteropathy-associated T-cell lymphoma(EATL), primarily
occurred in Asian countries. It is refractory to chemotherapy and the prognosis
is poor. Intensive chemotherapy has been proposed to improve treatment out-
come.
Aims: We examined the treatment outcome of MEITL in our institution.
Methods: We retrospectively searched our institutional database from 1996
to 2014 for intestinal T-cell lymphoma. Medical records were reviewed and the
patients were classified on the basis of WHO-2016 classification. Patient’s
characteristics, treatment modalities, response and survival were collected and
analyzed.
Results: Ten patients with intestinal T-cell lymphoma were identified. One patient
had enteropathy-associated T-cell lymphoma (EATL) presenting with celiac sprue.
Five patients had intestinal T-cell lymphoma, NOS. Four patients were diagnosed
with monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). For patients
with MEITL, median overall survival was 7.9 months (4.2-15.0 months). Median
age was 46 years of age. Bowel perforation was the initial presentation in 3
patients (3/4, 75%). One patient was treated with chemotherapy with CHOP reg-
imen, while another patient underwent surgery alone. The remaining two patients
(2/4, 50%) received surgery followed by chemotherapy (one with CHOP, the
other with BFM-90 protocol). Only one patient (1/4, 25%) entered complete
response. Of concern, the unique patient achieved complete response received
surgery followed by chemotherapy with Berlin-Frankfurt-Munster(BFM)-90 pro-
tocol. Remission duration was 10.3 months. He passed away 15.0 months after
remission because of relapsed lymphoma.
Summary/Conclusions: Though the prognosis of MEITL is poor, operation
followed by high dose chemotherapy such as BFM-90 protocol may have better
treatment response, response duration and survival. It deserves further inves-
tigation.
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OSTEOPONTIN AS PRONOSTIC FACTOR OF DIFFUSE LARGE B-CELL
LYMPHOMA
G.I. Barranco Lampón1,2,*, E.B. Ruiz García2, E.A. Fernández Figueroa2,3,
M.S. Rivas Vera1, C. Lome Maldonado4, R. Quezada López4, E. Cortés4,
J.L. Aguilar Ponce5
1Hematology, 2Translational Medicine, Instituto Nacional de Cancerología,
3Facultad de Medicina, Universidad Nacional Autónoma de México, 4Pathology,
5Internal Medicine, Instituto Nacional de Cancerología, Ciudad de México,
Mexico
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common
type of lymphoma. It is a heterogeneous disease whose prognosis depends
on the histological subtype (centralgerminal, non-centrogerminal), as well as
other factors such as age, clinical stage, extranodal disease, ECOG scale and
levels of lactate dehydrogenase (LDH) identified by established scales (IPI,
NCCN-IPI). Osteopontin (OPN) a protein that is secreted by various cells and
fulfills physiological functions, when produced by neoplastic cells favors tumor
growth and metastasis. This has been corroborated in different types of cancer
and there are few reports of cases of patients with DLBCL in which the tumor
cell expresses osteopontin, characteristically these cases have presented an
aggressive clinical behavior with extranodal disease.
Aims: To evaluate the expression of osteopontin in neoplastic lymphocytes
and their association with overall survival; the percentage of patients who
expressed osteopontin at diagnosis; the association between the expression
of osteopontin and the histological subtype (germinal center, not centrogermi-
nal, unclassifiable); the association between osteopontin expression and age,
elevation of DHL, ECOG scale, clinical stage, extranodal invasion and the
application of the IPI and NCCN-IPI scales.
Methods: Tissue samples were obtained from DLBCL patients diagnosed at
the Instituto Nacional de Cancerología between December 2014 and January
2016. Morphologic and immunochemistry features were studied on paraffin-
embedded tissue microarray (TMA). Single antibody staining was performed
for OPN. OPN expression was semiquantitatively assessed by three different
pathologists scoring the proportion and intensity of stained cells. Positive cases
were those that showed any degree of expression in the nucleus or cytoplasm
of the tumor cell.  Age, ECOG, clinical stage, LDH, extranodal invasion, histo-
logical subtype, IPI and NCCN-IPI score were independently documented.
Overall survival (OS) analysis was performed by the Kaplan-Meier method,
the comparison between different curves was performed using the log-rank
test; for the analysis of the relationship between variables we used the X2 test
with a statistical significance of p <0.05.
Results: 81 patients were evaluable. 43.2% of the cases were positive for
OPN in neoplastic cells. The mean survival of patients with positive OPN was
14.8 months versus 16.5 months for patients with no OPN expression
(p=0.628). OPN positivity was not significantly associated with increased age,
impaired functional status (ECOG 2,3,4), advanced clinical stage (III, IV),
increased LDH or extranodal invasion (including central nervous system); nei-
ther was it associated with a specific histological subtype. Survival significantly
decreased in patients with increased LDH (p=0.000137), ECOG 2,3,4
(p=1,7374E-7). Survival decreased significantly as the risk measured by the
IPI and NCCN-IPI scales increased (p=0.000001, p=0.000013 respectively)
with an average survival of 18.6 months for the low-risk group, compared with
6.4 months for the high-risk group (Figure 1).
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Figure 1.
Summary/Conclusions: Our findings demonstrate that approximately half of
the cases evaluated express OPN at diagnosis and tend to have a lower survival
rate, however, a longer follow-up time is needed, as well as other studies that
discriminate between different isoforms or post-translational modifications of
osteopontin to determine if this trend can reach significance. By demonstrating
OPN expression by neoplastic cells we can devise new protocols that evaluate
its usefulness as a surrogate marker of tumoral activity in DLBCL using non-
invasive techniques (e.g., quantification of serum levels), which would improve
surveillance of these patients.
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TREATMENT OF NEWLY DIAGNOSED CENTRAL NERVOUS SYSTEM
LYMPHOMA PATIENTS BASED ON COMORBIDITIES &
PERFORMANCE STATUS: A SINGLE-CENTRE EXPERIENCE
Y.J. Lim1,*, J. Smith1
1Haematology, Aintree University Hospitals NHS Foundation Trust, Liverpool,
United Kingdom
Background: Combination chemotherapy incorporating high dose methotrex-
ate (HD-Mtx) and high dose cytarabine (Ara-C) is the standard chemothera-
peutic approach for newly diagnosed primary CNS lymphoma (PCNSL). How-
ever, patients >60 years old account for 50% of cases and combining HD-Mtx
with Ara-C can be associated with high toxicity and early mortality. The man-
agement of secondary CNS lymphoma (SCNSL) is less clear, but is often based
upon a similar approach. 
Aims: We present a tertiary centre experience in management of primary
(PCNSL) and secondary CNS lymphoma (SCNSL), with therapy based on co-
morbidities and performance status.  
Methods: We performed a retrospective analysis of patients with a diagnosis
of CNS lymphoma seen at our centre between 2011 and 2016. These were
categorized into 3 groups, Group 1: treatment of newly diagnosed PCNSL prior
to September 2014 where majority of patients received HD-Mtx & Ara-C com-
bination chemotherapy, Group 2: treatment of PCNSL after September 2014
where patients were selected based on co-morbidities to receive Mtx with or
without Ara-C, Group 3: treatment of newly diagnosed SCNSL. The median
survival for each group was estimated using the Kaplan-Meier method and log-
ranked test. Overall response rates, 30 day and 90 day survival between groups
1 & 2 were compared using unpaired t test. 
Results: 60 pts with a median age of 65 years old were recruited. 40 pts were
diagnosed to have PCNSL at presentation, while 20 patients had SCNSL. 5
pts were excluded from this study as they did not receive any treatment. In
group 1, 21 pts (84%) received combination chemotherapy incorporating HD-
MTX and Ara-C, 3 pts (12%) received HD-MTX monotherapy and 1 pt (4%)
received radiotherapy only. In group 2, 7 pts (53.8%) received HD-MTX and
Ara-C as part of MATRix protocol or with single agent rituximab, 3 pts (23%)
received HD-MTX as part of RMP protocol or with single agent rituximab, 1 pt
(7.7%) received a single alkylating agent and 1 pt (7.7%) received radiotherapy
only. In group 3 15 pts (88.3%) received chemotherapy incorporating HD-MTX
and Ara-C, 2 pt (11.8%) received HD-MTX without Ara-C. 30 day mortality was
7 (28%) in group 1 and 0 in group 2 (0%) (p=0.03). 90 day mortality was 7
(28%) in group 1 and 2 in group 2 (15.4%) (p=0.39). Overall response rate was
9 (36%) in group 1 and 8 (61.5%) in group 2 (p= 0.13). A Kaplan Meier curve
of all 3 groups is illustrated in Figure 1 below.
Figure 1.
Summary/Conclusions: This single centre study demonstrated that patient
selection, based upon comorbidities and performance status, for high dose
combination chemotherapy in the treatment of PCNSL improves 30 day mor-
tality, often associated with death from myelosuppression due to chemotherapy.
The overall response rate, with appropriate selection of combination chemother-
apy regimens, was improved. This also applies to patients with SCNSL in sub-
group analysis. Longer follow up of patients will be needed to further demon-
strate an overall survival benefit. 
PB1740
AN AUDIT OF THE USE OF RASBURICASE FOR THE PREVENTION AND
TREATMENT OF TUMOUR LYSIS SYNDROME IN PATIENTS RECEIVING
TREATMENT AT THE NORTHERN CENTRE FOR CANCER CARE,
NEWCASTLE UPON TYNE, UK
E. Watts1,*, S. Gabriel1, G. Jones1, R. Clark2, S. Holmes1
1Haematology, 2Renal Medicine, Freeman Hospital, Newcastle Upon Tyne,
Newcastle upon Tyne, United Kingdom
Background: Tumour Lysis Syndrome (TLS) is a known complication of haema-
to-oncological treatment.  Although clinical TLS is rare, the consequences are
significant, with one third of affected patients requiring dialysis and an overall
mortality rate of around 15%1,2. A new British Society for Haematology (BSH)
guideline was published in April 2015 to guide physicians on how to risk stratify
patients (based upon the Cairo Risk Stratification 20103), choice of prophylaxis,
and treatment of established TLS4. We audited all patients who received rasburi-
case at the Northern Centre for Cancer Care from 16th April 2015 to 3rd February
2016, and compared their management with BSH guidelines4.
Aims: To compare our practice with BSH guidelines.
Methods: Retrospective review of electronic patient presciption records, bio-
chemistry results,  and paper  notes.
Results: 27 patients received rasburicase in the study period. 20 patients met
Cairo criteria/BSH criteria as having High Risk Disease (HRD) or Intermediate
Risk Disease(IRD)/Low Risk Disease (LRD)with renal impairment, and there-
fore should have received 3mg rasburicase prophylaxis if no evidence of TLS
according to the guideline.  Of those 20, 11 had laboratory TLS, and therefore
BSH guidelines would recommend 0.2mg/kg/day [JG1] rasburicase, however
only 3/11 were given the drug at treatment doses. 1/3 had clinical TLS at pres-
entation and received treatment according to the guideline. The 2 other patients
received larger doses of rasburicase but less than the BSH would recommend.
A further 7 patients with IRD received rasburicase prophylaxis but on review
did not meet the criteria for rasburicase as set out in the guidelines. 5 patients
died during the study period. 2 patients died on ITU of multi-organ failure <7
days into chemotherapy.   A third patient died of sepsis, and the other 2 deaths
were in deteriorating patients where a decision was made to palliate.
Summary/Conclusions: When assessed against BSH standards, all patients
in this cohort who should have received rasburicase prophylaxis, were given
the drug.  2 patients with lab TLS developed clinical TLS.   8 others with lab
TLS received lower doses than the BSH would recommend, but did not
progress to clinical TLS. Although there were 5 deaths in our cohort, none were
directly attributable to TLS. In order to comply with the guidelines, particular
importance must placed on formally assessing the TLS risk score as per Cairo
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criteria at the outset and analyzing the possible features of laboratory TLS.
Although dosing did not always follow BSH guidelines, we did respond to bio-
chemical deterioration.  The majority of patients with HRD developed acute
kidney injury  despite rasburicase.  Doses were increased in response to cre-
atinine increases, albeit not as per guideline.   It is notable that despite lower
than the recommended doses of rasburicase, 6/8 patients with lab TLS did not
progress to clinical TLS, and none required dialysis. The guideline is a good
tool for the risk stratifcation and treatment of patients at risk of TLS.  In clinical
practice 100% compliance is hard to achieve. Responding to trends in creati-
nine may explain why, despite lower than recommended doses, our outcomes
were still good.  It would be interesting to see if further work with larger numbers
of patients would support this. Since this audit was completed, the ePrescribing
system has been altered to improve practice and a re-audit is planned.
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IMPLICATION OF BASIC VALUES OF VITAMIN D IN THE CLINICAL
COMPLICATIONS OF PATIENTS WITH NO HODGKIN LYMPHOMA IN
ACTIVE CHEMOTHERAPY TREATMENT
R. Martos1,*, D. Morillo1, M. Yuste1, L. Bermejo2, A. Pascual2, P. Beltran2,
N. Patrignani2, P. Llamas3
1Hematology, Hospital General Villalba, Collado Villalba, 2Hematology, Hospital
Universitario “Infanta Elena”, Valdemoro, 3Hematology, Hospital Universitario
“Fundación Jimenez Díaz”, Madrid, Spain
Background: The incidence and prevalence of Non-Hodgkin’s Lymphoma B
(NHL-B) has increased in recent years, reaching approximately 3-7 cases /
100,000 habitants. For this reason, the number of patients who receive
chemotherapy treatment is also considerably higher; this implies a greater
presence of adverse events.  In many of these patients, baseline vitamin D
values  at the time of diagnosis are decreased, and may be related to the devel-
opment of the tumor pathology, also to the severity of the adverse events.
Aims: To assess the implication of vitamin D values  in the development of rel-
evant clinical complications in patients diagnosed with NHL-B receiving
chemotherapy. To determine its clinical evolution after correcting the vitamin
deficit.
Methods: Retrospective study (January2013/January2017),which includes
patients diagnosed with NHL-B with histological confirmation. We analyze
demographic parameters (age, sex), histological subtype of NHL-B according
to WHO classification, laboratory values  of vitamin D (cut-off values:optimal
25-66pg/mL; low 25-18pg/mL or very low<18pg/mL), adverse effects:hemato-
logical toxicity,infection,gastrointestinal toxicity,hospital admissions and exitus.A
subanalysis of complications was performed in patients with vitamin D defi-
ciency who received corrective treatment.
Results: 68patients were analyzed, and 57cases (84%) were valid because
they had vitamin D determination in the 8weeks near the diagnosis. The distri-
bution was:58% ♂(n=33)/42%♀(n=24),with median age 59years (range:29-91
years).The subtypes of LNH-B:Follicular n=23(40%),Diffuse large cell
n=21(37%), Mantle n=6(11%), Marginal n=4(7%) and others n=3(5%).Patients
were included in 3 groups according to serum vitamin D levels: patients with
optimal levels (n=23;40%),low levels (n=27; 48%) and very low levels
(n=7;12%). Hematological toxicities were higher for the subgroup with
decreased vitamin D levels vs subgroup with level in range (28%vs72%)
(p<0.01). Neutropenia was more severe (grade>2) in patients with very low
levels of vitamin D(p<0.01).No patient with optimal vitamin D levels had severe
anemia(Hb<8g/dl) or thrombopenia<70000/mm3, in relation to 28cases of
severe toxicity diagnosed in vitamin D deficient groups.  In this group were
documented the two infections of the study (both pneumonias), a gastrointesti-
nal toxicities(86%),hospitalizations for complications(69%) and only one exitus.
After treatment, it was found that 74%(n=25patients) corrected levels, present-
ing a lower incidence of toxicity to the treatment vs.26%(n=9) who did not cor-
rect levels and presented more complications (especially hematological toxicity)
more complex and durable.
Summary/Conclusions: Vitamin D deficiency in the diagnosis of patients with
NHL-B has been correlated with a higher incidence of medical complications
due to the treatment of chemotherapy. In our series, patients had greater hema-
tological toxicity and greater severity (p <0.01), more infectious episodes and
a higher hospital admission rate. These adverse effects are even more pro-
nounced the lower the vitamin D levels (<18pg/mL). A study conducted by
Drake et al. (JCO, 2010) on 980patients presents similar data, with a signifi-
cantly higher incidence of complications in vitamin D deficient patients. After
treatment with vitamin D, patients who corrected levels had a more favorable
evolution with fewer hematological and infectious complications (p<0.01) in
relation to those patients in whom the vitamin deficit persisted despite the treat-
ment. At this time, the monitoring period is not completed, so the data related
to OS and SLE still have to be updated and will be presented at the next con-
gress. We believe that the determination of vitamin D levels should be routinely
included in the diagnosis in patients with NHL-B because could be a modifiable
risk factor in the complications of this patients.
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PROGNOSTIC IMPACT OF SYNCHRONOUS MULTIPLE PRIMARY
MALIGNANT TUMORS ON NEWLY DIAGNOSED LYMPHOMA PATIENTS
S. Nishiwaki1,2,*, S. Okuno1, K. Suzuki1, S. Kurahashi1, I. Sugiura1
1Division of Hematology and Oncology, Toyohashi Municipal Hospital,
Toyohashi, 2Center for Advanced Medicine and Clinical Research, Nagoya
University Hospital, Nagoya, Japan
Background: Synchronous multiple primary malignant tumors (sMPMTs) are
occasionally diagnosed during screening for a newly diagnosed malignant neo-
plasm. Lymphoma is one of the most common hematological malignancies,
and number of lymphoma patients with sMPMTs seems to grow as the popu-
lation ages. Since the standard chemotherapy for lymphoma takes a few
months, treatment strategy sometimes comes to an issue.
Aims: To answer a clinical question of how to handle sMPMTs in the treatment
of lymphoma, we investigated prognostic significance of sMPMTs and suitable
treatment strategy for a newly diagnosed lymphoma with sMPMTs.
Methods: We retrospectively analyzed patients with malignant lymphoma new-
ly diagnosed between 2009 and 2015. The definition of sMPMTs was patients
who were also diagnosed as a solid tumor within 6 months of the diagnosis of
lymphoma. Therapeutic strategy was according to physician’s choice. Impact
of sMPMTs on treatment outcome of lymphoma was analyzed. Also, relation
between treatment of lymphoma and concomitant solid tumors was closely
analyzed.
Results: Total of 505 lymphoma patients was included. Median age was 69
(range20-99). The most common diagnosis was diffuse large B-cell lymphoma
(63%), and patients with aggressive lymphoma accounted for 77% (391/505).
High risk disease, which was defined as international prognostic score 3 or
higher, accounted for 36% (184/505). sMPMTs were identified in 16 patients
(3.2%). There was no difference of distribution between patients with and with-
out sMPMTs regarding age, grade of lymphoma, and disease risk. The overall
survival (OS) and disease-free survival (DFS) were not significantly different
between the two groups (with sMPMTs: 53% and 47% vs without sMPMTs:
77% and 61% at 3 years, P=0.20 and P=0.31). Cumulative incidence of lym-
phoma relapse was similar between the two groups (with sMPMTs 29% vs
without sMPMTs 27% at 3 years, P=0.28). In multivariate analyses, age (75
years<) and disease risk (high) were identified significant risk factors for OS,
and age was an only significant risk factor for DFS. Existence of sMPMTs was
not a significant risk factor for either OS or DFS (OS: HR 1.29, 95%CI 0.52-
3.20, P=0.58; DFS: HR 1.06, 95%CI 0.49-2.27, P=0.88). Among 16 patients
with sMPMTs, half of the patients had high-risk lymphoma, and half of the solid
tumors were gastric cancer. Treatment was initiated for the disease which was
diagnosed earlier in all patients except one. Interval from diagnosis to the first
treatment was significantly shorter in patients whose lymphoma was treated
earlier (median 11 days vs 38.5 days, P=0.004). OS was not significantly dif-
ferent according to the sequencing of treatment (lymphoma earlier: 59% vs
Solid tumor earlier: 40% at 3 years, P=0.84). In 8 of 10 patients whose lym-
phoma was treated earlier, treatment of lymphoma was interrupted for the treat-
ment of comorbid solid tumor. Interruption of treatment had no significant effect
on OS (interruption+: 60% vs interruption-: 50% at 3 years, P=0.13).
Summary/Conclusions: Existence of sMPMTs was not a significant risk factor
for newly diagnosed lymphoma patients. It is important to provide adequate
treatment for both lymphoma and solid tumor at physician’s discretion.
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Bleeding disorders (congenital and acquired)
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GLOBAL HEMOSTATIC ASSAY AT DIFFERENT TARGET ACTIVITY OF 
FACTOR VIII AND FACTOR IX
K. Yoo1,*
1Korea Hemophilia Foundation, Seoul, Korea, Republic Of
Background: Based on reports addressing hemophilia B patients bleed less
common and less intensively than hemophilia A, it has been expected that the
hemostatic level of factor IX (FIX) activity can be lowered than that of factor
VIII (FVIII) activity.
Aims: We compared the hemostatic efficacy of the different hemostatic level
of FIX and FVIII activity using global hemostatic assay.
Methods: A total of 17 severe hemophilia patients without inhibitor, aged more
than 15 years old were subjected; 12 hemophilia A patients and 7 hemophilia B
patients. Factor concentrates were injected to reach the target activity of 60% in
hemophilia A and 40% in hemophilia B which is given by Korean health insurance
guideline. All patients were in non-bleeding state and kept the wash-out period
of 3 days for hemophilia A and 5 days of hemophilia B. Before and on 15 minutes
after injections, we conducted one-stage factor assay, thrombin generation assay
(TGA), thromboelastography (TEG) and clot-wave form analysis (CWA).
Results: Median ages of hemophilia A and hemophilia B patients were 28 and
33 years old. Baseline FVIII:C and FIX:C were 0.6% and 1.8% and they rose
after injection rose to 70.8% and 49.8%. The dosage of FVIII concentrates and
recombinant FIX concentrates were 28.4 IU/kg and 50.7 IU/kg. In-vivo recovery
(IVR) in hemophilia A and hemophilia B patients recorded 2.43%/U/kg and
0.91%/U/kg. Peak thrombin of FVIII and FIX were 451.3 nM and 376.6 nM
(P=0.108, normal range, 458 nM±60). TEG index of FVIII and FIX were -1.60
and -3.77 (P=0.004, normal range, -2~+2). MIN2 of CWA of FVIII and FIX were
0.62 and 0.59 (P=1.000).
Summary/Conclusions: Global hemostatic assay indicates even though IVR
of FVIII and FIX are normal, less amount of FIX is insufficient to normalize
hemostatic parameters in comparison with FVIII.
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THE RATE OF SUCCESSFUL IMMUNOTOLERANCE INDUCTION IN
HAEMOPHILIA A BOYS TREATED WITH OCTOCOG ALFA - THE
EXPERIENCE OF POLISH PAEDIATRIC HAEMOPHILIA CARE CENTRES
A. Kołtan1,2,*, A. Klukowska3, P. Laguna3, W. Badowska4, W. Balwierz5,
G. Karolczyk6, D. Pietrys5, H. Bobrowska7, M. Kostrzewska8, T. Ociepa9,
T. Urasinski9, I. Woznica-Karczmarz10,11
1Department of Peditrics, Hematology and Oncology, Collegium Medicum in
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Background: Development of neutralizing anti-factor VIII alloantibodies
(inhibitor; INH) is the most challenging complication of haemophilia replacement
therapy (HRT). It occurs in up to 30% of severe haemophilia A (HA) patients.
Data published recently indicate that immunotolerance induction (ITI) is effective
in 62–87% of cases.
Aims: To assess the rate of successful ITI in boys with severe HA treated with
full length recombinant FVIII (octocog α) in all Polish Paediatric Haemophilia
Care Centres between 2011-2016.
Methods: From 2011 to 2016 in all Polish Paediatric Haemophilia Care Centres
14/88 (15.9%) boys with severe HA on prophylaxis or on demond treatment
with octocog α developed INH after 3 - 489 (median 20) exposure days (EDs).
Twelve of them (85.7%)  were high responders with the peak inhibitor titre (PIT)
5,88 - 716.8 (median 20.1) BU/ml. Two patients were low responders (14,3%)
and had PIT 2.8 and 3.02BU/ml. All except one boys were Caucasians and
only one had a positive family history of INH formation. Characteristics of
patients is given in Table 1.
Results: INH titres prior to ITI were 1.2 - 37 (median 6,75) BU/ml. One of low
responders eliminated INH spontaneously, 1 patient is waiting for ITI initiation.
ITI with octocog α was initiated in 12/14 boys after 0.2 to 8.2  (median 2.0)
months from INH diagnosis and completed in 9 patients.  Three patients are
still on ITI. INH eradication was observed in 7/9 (77.8%) of those who completed
ITI.  Eradication of INH was not achieved in 2 patients; both have already
started prophylaxis with activated prothrombin complex concentrate (APCC).
The remaining 3 patients are still on ITI. All 7 patients after successful ITI were
put back on prophylaxis with octocog α.
Summary/Conclusions: 1. Octocog α is effective in induction of  immunotoler-
ance in severe haemophilia A boys who developed inhibitor on prophylaxis with
octocog α.
Table 1. Characteristic of patients.
OD, on demand; P, prophylxis; CVA, central venous access; N, no; Y, yes; mth, mounth.
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APPROACH TO PREGNANCY IN NIEMANN PICK DISEASE TYPE B
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1Clinic for hematology, Clinical Center Vojvodina, 2Medical Faculty, University
of Novi Sad, 3Clinic for gynecology and obstetrician, 4Clinic for abdominal and
endocrine surgery, 5Department for trombosis, hemostasis and hematology
diagnostic, Clinical Center Vojvodina, 6 Center for Medical Genetics, Institute
for Children and Youth Health Care of Vojvodina, Novi Sad, Serbia
Background: Niemann Pick Disease type A and B is a rare autosomal recessive
disorder caused by sphingomyelinasa deficiency resulting in sphingomyelin accu-
mulation in macrophages of varies organs. In type B usually patients survive in
adulthood. Usually, they have hepatosplenomegaly, thrombocytopenia, and dys-
lipidemia. Lung and liver function are influenced, and they have bleeding risk.
Aims: Pregnancy in this situation is always risky and multidisciplinary approach
is needed. Searching on Medline we found only two case reports of childbirth
by women with this condition.
Methods: We presented a case of pregnancy in 34 year old women with Nie-
man Pick disease type B. She had marked splenomegaly, mild thrombocytope-
nia and partial respiratory insufficiency. Previously, she had two artificial abor-
tions without more than expected bleeding. Also she had surgery of left side
inguinal hernia and after that she was given platelet concentrates. Risk factors
for pregnancy were presented to her.
Results: Laboratory controls were done periodically, ultrasound examination
of abdomen and portal vein system, lung capacity and echocardiography were
performed, too. Results of CBC were stable. Repeated tests of hemostasis
were normal. Hyperlipoproteinaemia type IIb with hypoHDL cholesterolemia
was present. We assumed that platelets dysfunction could exist, therefore
before planned amniocentesis we performed platelets aggregation tests with
ADP, TRAP and collagen. All of them were below lower limit: ADP 43 (55-117),
TRAP 71 (92-151), col. 30 (61-108). Ultrasound examination of abdomen and
portal vein sistem revieled liver diameter 17cm, craniocaudal diameter of spleen
22cm, portal vein had not been seen. There were no sign of trombosis in portal
branches. Amniocentesis was done without complication and there was no
need for platelet substitution. Normal male kariotype was found. We prepare
her for planned caesarian section with platelet concentrates. She was given
corticosteroids for lung maturation. In 35th+5d gestational week she was oper-
ated. Before surgery platelets count was 87x109/l, she was given seven con-
centrates of platelets (1 per 10 kg body weight) before and seven during pro-
cedure. She also received antibiotic prophylaxis. Newborn was 47cm, 2490g
weight and Apgar score was 7/8. There was no major blood loss and no need
for red blood cell transfusion or platelets transfusion in follow up period. We
decided not to make splenectomy or partial resection because there were no
significant differences in spleen measurements before and during the preg-
nancy, and there was no sign of spleen trauma. Also, in literature we found
data about worsening lung function after this procedure caused by more shin-
gomyelin accumulation in pulmonal tissue. Published data and findings of
abnormal platelet function in our patient and experience with previous abdom-
inal surgery led our decision to give her platelet concentrates before section
and according to obstetrician’s estimation during the operation. Pregnancy did
not cause health state deterioration in our patient and there are no clinical find-
ings of Niemann Pick disease in newborn.
Summary/Conclusions: We presented a case of pregnancy in 34 year old
women with Nieman Pick disease type B. Marked splenomegaly, mild throm-
bocytopenia and partial respiratory insufficiency existed before this pregnancy.
Decisions about diagnostic assesment, platelet transfusion, splenectomy, and
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dyslipidemia treatment were made upon data from literature and patient’s find-
ings. Multidisciplinary approach in this setting is needed. Bleeding risk is not
connected only with platelet count, but also with their function and degree of
splenomegaly. Liver function can also be disturbed and can influence hemo-
stasis. Pregnancy in our patient did not cause health state deterioration and
there were no clinical findings of Niemann Pick disease in newborn.
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SINGLE CENTRE FX DEFICIENCY EXPERIENCE
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1Internal medicine- Hematology, Istanbul University, Cerrahpasa Medical Fac-
ulty, istanbul, Turkey
Background: Factor X is a vitamin K–dependent serine protease that works
at the crossroads of the extrinsic and intrinsic pathways to cleave prothrombin
into thrombin. Inheritance pattern of factor X deficiency is autosomal recessive,
with heterozygote patients most often remaining asymptomatic or having only
a mild bleeding phenotype. (1) Homozygous individuals may experience haem-
orrhagic symptoms, including easy bruising, haematuria, soft-tissue haemor-
rhages, haemarthroses, recurrent epistaxis, and menorrhagia (2) Congenital
factor X deficiency is among the most rare factor disorders. We present here
our experience with patients having congenital factor X deficiency. 
Aims: We aimed to present our experience with rare FX deficiency in our centre.
Methods: There are currently 4 patients with factor X deficiency (F/M: 3/1)
that are followed at our centre.
Results: First patient is 40 years old man who got his diagnosis at the age of
31 years following a gastrointestinal bleeding. He was treated with fresh frozen
plasma (FFP) at that time. His FX was found:%0. Two years later underwent a
planned tooth operation under the coverage of prothrombin complex concen-
trate (PCC) (Table 1). Three years after the tooth extraction he underwent an
intraocular lens operation under PCC prophylaxis. No complication was
observed while on PCC treatmet.
Table 1.
Our second patient is a woman who was diagnosed at the age of 3 because
of recurring gum bleeding. She has been treated with FFP replacement
throughout her childhood and adolescence due to recurring nose and soft
tissue bleeds as well as menorrhagia. She was first referred to our hospital at
the age of 42 due to soft tissue bleeding. Given the lack of health insurance
she mainly received FFP and tranexamic acid tablets during most of her bleed-
ing attacks. However, PCC of 1000 unit for two days had to be used for her
excessive vaginal bleeding irresponsive to FFP. Her number of annual bleeding
is 15-20 times in a year and most of them are gum bleeding and rarely vaginal
bleeding. Third and 4th patients were referred to our centre because of pro-
longed the prothrombin time (PT) and the activated partial thromboplastin time
(aPTT) and received the diagnosis of FX deficiency. 
Summary/Conclusions: Bleeding phenotype differs in a wide range in patients
with congenital FX deficiency. Secondary causes including amyloidosis should
be excluded especially in patients receving diagnosis at advanced ages. Usu-
ally the factor level does not correspond to the severitiy of the bleeding phe-
notype. Therefore bleeding pattern of the patients with FX deficiency should
be carefully observed and considered while planning a prophylactic treatment
with PCCs to prevent the risk for thrombosis and unnecessary utilisation of
PCCs. FFP and PCCs replacement continue to be the source for FX in bleeding
patients or in individuals requiring prophylaxis. Recently, a FX concentrate has
entered the market in the USA and the Europaen Community.
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Background: In life threatening hemorrhage such as brain and abdomen, sev-
eral important factors are affect for improving the survival. One tenth (223) of
hemophilia patients in Korea lived in Daegu city and Kyungpook province and
have treated in our regional treatment center.
Aims: We reviewed the result of life threatening hemorrhage and our unique
care of hemophilia patients for 34 years.
Methods: Korea Hemophilia Foundation was established in 1991. After that
all factor concentrates were free to all hemophilia patients. Home treatment
are available for rapid administration of factor concentrate of full required
amount. Rapid transportation to emergency room are available for immediate
operation. Hot line of mobile phone between patient and doctor for 24 hours
are available for emergency care. Monthly group education has done. Prophy-
lactic treatment was started to all who had a life threatening hemorrhage history
in our hospital since 1996. But HIRA permitted officially since 2011.
And then recovery rate test was done for the optimal blood level for life threat-
ening hemorrhage patient. Continuous infusion with every 2 to 4 hours recon-
stitution dilution fluid has been done for preserve in vitro factor activity to all
surgery cases.
Results: Thirty five events were intracranial hemorrhage in 17, general surgery
in 9 and orthopedic surgery in 9. Age distribution was 0-32 yr (mean; 24.8 yr).
Severity was severe (16), moderate (7) and mild (5). Time interval between
first symptom and arrival at ER were 15 min to 10 days (mean; 1.7days). We
confirmed in vivo factor activity within permissible level in all patients. All recov-
ered from hemorrhage or surgery and are healthy, but one had limping gate
and one had mild neurologic sequela for more than 10 years follow-up period.
Summary/Conclusions: Education, financial support, home and prophylactic
treatment, hot-line, individual pharmacokinetics with effective blood level and
fresh concentrate during continuous infusion are important factors to improve
the survival of surgery case. 
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HEMOPHILIA CARRIERS?
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Background: Hemophilia A and B are X-linked recessive hemorrhagic disease.
Due to this type of inheritance, males are usually affected, but girls are carriers.
Factor levels are usually detected around 50% because only one chromosome
is affected in carriers. Inconsistently, it has been reported that factor activity
can be detected in a wide range of 22% -116% as a result of random inactiva-
tion (lyonization) of one of two X chromosomes. It is specified that factor levels
may be very low due to excessive inactivation in a significant part of the hemo-
philia carriers, which creates a risk of bleeding in carriers.
Aims: In this study, we aimed to investigate the role of bleeding score and
factor levels in detecting hemophilia carriers.
Methods: Bleeding Assessment Tool (BAT) for hereditary factor deficiencies of
the International Society on Thrombosis and Haemostasis (ISTH/SSC) were
applied to the mother and sisters of 32 hemophilia patients who were followed-
up in Dr Behçet Uz Children’s Diseases and Surgery Training and Research
Hospital. Mothers whose at least one of the other members of the family and
their sons had hemophilia, mothers with more than one hemophilic son and girls
whose father had hemophilia were evaluated as an obligate carrier. Sisters or
mothers who do not meet the obligatory carrier criteria but whose siblings or
sons are hemophilic were identified as possible carriers. Factor activity of obligate
or probable carriers was studied after their informed consent was obtained.
Results: Thirty-two mothers and 13 sisters of hemophilia patients were includ-
ed in this study. The mean age was 31.6 (4-57) years. Three of the patients
were mild, 3 were moderate, 23 were severe hemophilia A; 2 were severe and
1 had moderate hemophilia B. Twelve were obligate and 33 were probable
carriers. Only seven in 45 (15.5%) probable and obligate hemophilia carriers
had high bleeding scores (≥4). Those with high bleeding scores, three were
obligate carriers and four were probable carriers. The mean factor activity of
12 obligate and 18 probable carriers were 78.9% (20.8%>189%). Factor activ-
ities of the three obligate carriers with high bleeding scores were 77%, 80%
and 98%, respectively. Factor activities of the three probable carriers with high
bleeding scores were 58.8%, 69.3% and 112%, respectively. The median bleed-
ing scores of four probable and one obligate carriers with low factor activity
(<60%) were 2.8 (1-4).
Summary/Conclusions: Measurement of factor activity seems to be insuffi-
cient to detect hemophilia carriers. ISTH/SSC-BAT may help to determine the
carriers. However, a larger study is needed to understand the diagnostic value
of the BAT. 
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FETAL INTRACRANIAL HEMORRHAGE AS A PRESENTING FEATURE OF
SEVERE CONGENITAL FACTOR VII DEFICIENCY: THE NEED FOR EARLY
PROPHYLAXIS
M. Elshinawy1,*, A. Alrawas2, Y. Wali2
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Background: Congenital factor VII (FVII) deficiency is a rare autosomal reces-
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sive bleeding disorder, with an estimated prevalence of 1:300,000. Compared
to western countries, rare bleeding disorders (RBDs) are relatively commoner
in Oman, owing to high rate of consanguineous marriage.
Aims: To discuss an interesting case fo severe congenital factor VII deficiency
and to explore the need for early prophylaxis.
Methods: Case report and retrospective data analysis of all children diagnosed
with inherited coagulation factor deficiencies in Pediatric Hematology Unit, Sul-
tan Qaboos University Hospital, Muscat, Oman from January 2009 till Decem-
ber 2016.
Results: We report a male full term baby, delivered by cesarean section. His
older sister is a known case of severe congenital factor VII deficiency. Antenatal
scans of this baby revealed two intracerebral hematomas and dilated cerebral
ventricles. Postnatally, the diagnosis of severe congenital FVII deficiency was
confirmed. CT scan revealed obstructive hydrocephalus at the level of aqueduct
of Sylvius (Figure 1). At day 10 of life, ventriculo-peritoneal shunt has been
done successfully under cover of recombinant activated factor VII replacement
therapy. Afterwards, the patient has been initiated on rFVIIa prophylaxis at a
dose of 30 ug/kg three times weekly. In our center, deficiencies of fibrinogen,
FV, FVII, FX and FXIII were diagnosed in 22 pediatric patients (10 males and
12 females), accounting for 11.1% (22/198) of all children with inherited coag-
ulation factor deficiencies. The age ranges from 1 day to 6 years and consan-
guinity is found in 19/22 cases (86.4%). Hypofibrinogenemia, FV and FVII defi-
ciency are the commonest RBDs, diagnosed in 8, 6 and 5 patients respectively.
As an initial presentation, intracranial hemorrhage occurred in 7/22 cases
(31.8%). Three patients with FV, FVII and FXIII deficiencies suffered from global
developmental delay due to severe intracranial hemorrhage. As regards man-
agement, 4 patients with severe FV deficiency and one with severe FXIII defi-
ciency are on fresh frozen plasma (FFP) and recombinant FXIII prophylaxis
respectively. Other patients receive on-demand therapy.
Figure 1.
Summary/Conclusions: Children with RBDs constitute more than one tenth
of cases of hereditary coagulation factor deficiencies in our center. They have
some unique features in terms of severity, clinical profile and the need for pro-
phylaxis early in life. We recommend establishing a national/regional registry
of RBDs to identify the magnitude and the peculiar genotype-phenotype corre-
lations of such rare, yet significant disorders.
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Background: Patients who have implantation of continuous flow ventricular
assist devices (VAD) as a bridge to heart transplantation are subjected to com-
plications secondary to pump support. The use of antiplatelets either alone or
in combination with acticoagulation is necessary to avoid clot formation and
pump thrombosis. However, a proportion of patients reveal an increasing risk
of bleeding episodes. A possible reason of this situation could be that high
shear forces lead to devastation of high molecular weight von Willebrand factor
(vWF) making it functionally inactive and resulting in acquired von Willebrand
disease (vWD). People with blood type O have lower baseline vWF levels and
this abnormality could exacerbate the bleeding risk of patients with blood type
O with VAD, resulting in more frequent bleeding episodes and need for trans-
fusions.
Aims: The aim of current study was to investigate the possible association of
blood type with acquired vWD induced by VAD, with the need for transfusions. 
Methods: In this retrospective study, 17 patients who had a VAD implant in our
hospital in a six-month period were included for analysis. The investigation of
underlying vWD was estimated by ristocetin-induced platelet aggregation
(RIPA) using classical light transmission aggregometer.
Results: Six patients (35.3%) had left-VAD (L-VAD) implantation while the oth-
ers had biventricular VAD implantation (BiVAD). The mean age was 42.41 years
(SD±15.33) and 9 patients (52.9%) were male. Female patients had VAD
implantation at younger age than male (p<0.001). The mean follow-up after
VAD implantation was 15 months (SD±11.88). At the time of analysis, 13
patients (76.5%) were alive, 2 patients (11.8%) had died while 2 patients
(11.8%) had been heart-transplanted. Eight patients (47.1%) had blood type
O, 8 patients (47.1%) had blood type A and a patient (5.9%) had AB. Mean
RIPA before VAD implantation was 59.3% (SD±14.76) while after VAD implan-
tation was 47.29% (SD±15.47), whereas the decrease was no statistically relat-
ed. No statistical correlation was found between RIPA among different blood
types. Among patients with blood type O, the need for blood transfusions was
associated with the duration of having the VAD implantation in months (p<0.001)
while the need for fresh frozen plasma (FFP) transfusions was associated with
RIPA before VAD implantation (p=0.016). In non-blood O type patients no sta-
tistical correlation was found with the need for transfusions with RIPA percent-
age or median follow-up of patients.
Summary/Conclusions: It has been shown by several studies that patients
with VAD show a decrease in vWF increasing the bleeding risk. Thus the best
antiplatelet treatment and/or anticoagulation that those patient needs, remains
challenging. In our study, there was a decrease in mean RIPA percentage after
VAD implantation and patients with blood type O had lower RIPA before implan-
tation. However, none of these measurements was statistically significant. The
blood type O patients showed an increased need for transfusions in correlation
with the duration of VAD implants and an increased need for FFP in correlation
with RIPA baseline. Our study has limitations due to the small population and
the fact that vWF was not estimated within the different blood groups at baseline
and after VAD implantation.
haematologica | 2017; 102(s2) | 703
Madrid, Spain, June 22 – 25, 2017
Bone marrow failure syndromes incl. PNH - Clinical
PB1751
ACQUIRED PURE RED CELL APLASIA ASSOCIATED WITH
LYMPHOPROLIFERATIVE DISEASES IN ERYTHROPOIETIN-
REFRACTORY ANEMIA PATIENTS ON DIALYSIS
K. Yoshinaga1,*, N. Mori1, M. Ohwashi1, M. Ishii1, M. Shiseki1, J. Tanaka1
1Department of Hematology, Tokyo Women’s Medical University, Tokyo, Japan
Background: Erythropoietin-refractory anemia is a serious problem and com-
plicated causes should be ruled out in patients on dialysis. Acquired pure red
cell aplasia (PRCA) may be hidden behind anemia of chronic kidney disease.
Recently it was reported that PRCA patients with large granular lymphocyte
frequently had STAT3 mutations (Oie ZY et al. J Hematol & Oncol 2013, Ishida
F et al. Cancer sci 2014). Molecular or flow-cytometric analysis is useful for
detecting a small amount of abnormal lymphocytes.
Aims: We conducted this study to determine the clinical characteristics and
STAT3 mutations of patients with acquired PRCA on dialysis with lymphopro-
liferative diseases.
Methods: In our hospital, 4 patients were diagnosed as having acquired PRCA
on dialysis with lymphoproliferative diseases after 2005. Patients were retro-
spectively studied for presenting feature, laboratory data, and clinical course.
Surface markers of lymphocytes were examined by flow cytometric analysis,
and T-cell receptor (TCR) rearrangements were examined by Southern blot
analysis.  Mononuclear cells were separated after obtaining written informed
consent. STAT3 (Y640F and D661Y) mutations were examined by allele-spe-
cific PCR. Current study was conducted within the guidelines and with the
approval of the institutional ethical committee.
Results: In spite of adequate administration of erythroid colony-stimulating
factor, all 4 patients required blood transfusion due to erythropoietin-refractory
anemia. Median leukocyte and lymphocyte counts at diagnosis were 4650/mL
(range, 3180-4850) and 1794 mL (range, 1183-2859), respectively. Two
patients (Cases 1 and 2) had low percentage of CD4+ CD8+ by flow-cytometry
and TCR C beta1 and gamma rearrangements by Southern blot analysis.
Another patient (Case 3) had high percentage of gamma-delta T cell component
(66.2%) with TCR delta rearrangement. The other patient (Case 4) had high
CD16+CD56+ NK cell percentage without TCR receptor rearrangement. The
median duration from the start of dialysis to onset of PRCA was 13 years
(range, 5-19 years). Of the 4 patients, only one patient (Case 3) had the muta-
tions of the STAT3 gene (Y640F). This patient first received cyclophosphamide
but he did not respond to the therapy. He subsequently received cyclosporine
(CyA). The other three patients received CyA as an initial therapy, and it was
effective in all 4 patients. Median follow-up were 7 years from diagnosis, and
two patients died during follow-up period. One patient (Case 4) died of cardiac
failure 7 years from the diagnosis. Another patient (Case 2) developed diffuse
large B-cell lymphoma 5 years after the administration of CyA. He was treated
with R-CHOP chemotherapy and complete remission (CR) was achieved.
Although he had been in CR, he died of refractory pancytopenia with infection,
2 years after the lymphoma onset. The other two patients are still alive without
blood transfusion for 6 and 7 years.
Summary/Conclusions: A proportion of erythropoietin-refractory anemia
patients on dialysis have acquired PRCA associated with lymphoproliferative
diseases. The combined analyses of flow-cytometry and TCR rearrangement
of lymphocytes were useful for diagnosis of acquired PRCA associated with
lymphoproliferative diseases. Further accumulations of patients were required
for understanding the pathogenesis of lymphoproliferative diseases causing
acquired PRCA on dialysis.
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BY CYCLOSPORINE A OR CORTICOSTEROIDSSIMILAR EFFICIENCY
X. Wu1,*, S. Wang1, W. Shen1, G. He1, J. Li1
1Hematological Department, The First Affiliate Hospital, Nanjing Medical Uni-
versity , Jiangsu Province Hospital, Nanjing, China
Background: Adult pure red cell aplasia (PRCA) is a syndrome characterized
by a severe normocytic anemia, reticulocytopenia, and absence of erythroblasts
from an otherwise normal bone marrow. Immunosuppressive therapy has been
used as the initial treatment foracquired chronic PRCA. 
Aims: This article aims to evaluate the efficacy of cyclosporine A, and/or cor-
ticosteroids, and possible factors influencing it.
Methods: 34 cases of PRCA were retrospectively analyzed at our institution.
Clinical data of 23 inpatient cases and 11 outpatient cases since 2009 October
were collected. These patients were treated by cyclosporine A (CsA), and/or
corticosteroids (CS), or other immunosuppressive agents if become refractory
and relapsed.
Results: 31 patients were evaluated in our institution (one patient lost to fol-
low-up and two patients with short observation period). The remission induction
therapy included CsA (n=13), CS (n=13), or a simultaneous combination of
CsA and CS (n=5). The initial response rate of CsA alone, CS alone, combina-
tion of CS and CsA were 69.2%, 46.2%, 80%, respectively (P=0.422). There
was no statistical difference in response rate and CR rate between CsA-con-
taining group and CS group, although the patients treated with CsA had a better
response than those treated with CS (response rate 72.2%vs 46.2%, P=0.262;
CR rate 33.3% vs 23.1%, P=0.696). Including patients who had crossed over
from other treatment groups, the cumulative response rate of CsA, CS, com-
bination of CS and CsA, was 73.7% (14/19), 46.7% (7/15), 83.3% (5/6), respec-
tively (P=0.193); the cumulative rate of CR was 26.3% (5/19), 26.67% (4/15),
66.7% (4/6), respectively (P=0.202). In 23 refractory and relapsed PRCA
patients, 8 out of 12 (66.7%) refractory patients and 4 out of 11 (36.4%)
relapsed patients achieved remission. The response rate of treatment with tra-
ditional immunosuppressive agents (CS and/or CsA) was higher than other
immunosuppressive agents (65.0% vs 20%, P=0.014).
Summary/Conclusions: CsA and/or CS are effective similarly in treating
PRCA. For patients with relapse or refractory PRCA, there were no satisfactory
treatment measures if CsA and/or CS were not be administered or un-effective.
It was still needed to explore a more effective therapy for them.
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REACTIVATION OF HEPATITIS B VIRUS INFECTION IN APLASTIC ANEMIA
PATIENTS
S. Wang1,*, X. Wu1, G. He1, W. Shen1, J. Li1
1Hematological Department, The First Affiliate Hospital, Nanjing Medical Uni-
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Background: There is litter data about the influnence of infection of HBV
impact on the therapy of aplastic anemia.
Aims: This article is aimed at assessment the HBV reactivation risk in HBsAg-
positive or HBsAg-negative, antihepatitis B core antigen antibody (anti-HBc) -
positive patients with AA receiving CsA and/or ATG.
Methods: We analysis the clinical data of 60 AA patients with HBV infection
out of 201 cases of AA from our center at AA diagnosis during the recent 3
years, and laboratory test data such as levels of liver enzyme, HBV DNA in
serum, HBsAg anti-HBs and anti-HBc were monitored. Entecavir (ETV) or
lamivudine LAM  was started when HBV reactivation (defined as detectable
HBV DNA) was encountered or as a antiviral prophylaxis regimen for some
HBVsAg-positive patients.
Results: Among 60(29.8%) AA patients, 12 were chronically infected (HBsAg
positive) and 48 were previously exposed (HBsAg negative/anti-HBc positive). 5
patients (8.33%) who were HBsAg positive and not given any rophylactic antiviral
therapy suffered HBV reactivation. 7 patientswho were HBsAg positive but given
were found no HBV reactivation. All the 48 patients with negative HBsAg and
positive anti-HBc were found no HBV reactivation during the follow-up. 
Summary/Conclusions: Antiviral prophylaxis should be recommended for
HBsAg-positive patients who will receive IST with AA as they had high rate
(41.6%) of HBV reactivation. HBV infection were found no influence to the
clinic course in AA and antiviral therapy had no influence to the effect of IST.
PB1754
MULTICENTER RESULTS OF SCHWACHMAN-DIAMOND SYNDROME
PATIENTS
S. Unal1,*, N. Kalkan1, T. Celkan2, G. N. Ozdemir2, N. Ozbek3, N. Yarali4,
H. F. Cakmakli4, I. Yenicesu5, S. F. Celik6, H. Kizilocak2, M. Gokce7,
N. Guleray8, M. Cetin1, F. Gumruk1, N. Akarsu8
1Hacettepe University, Divison Of Pediatric Hematology, Ankara, 2Cerrahpasa
Universiry, Department of Pediatric Hematology , Istanbul, 33Ankara Çocuk
Sagligi ve Hastalıklari Hematoloji Onkoloji Eğitim ve Arastırma Hastanesi ,
4Ankara Çocuk Sagligi ve Hastalıklari Hematoloji Onkoloji Eğitim ve Arastırma
Hastanesi , 5Gazi University, Department of Pediatric Hematology, 6Hacettepe
University, Medical Faculty , Ankara, 7Istanbul Saglik Bilimleri University,
Department of Pediatric Hematology, Istanbul, 8Hacettepe University, Depar-
ment of Medical Genetics, Ankara, Turkey
Background: Shwachman-Diamond syndrome (SDS) is an autosomal reces-
sively inherited disease characterized with neutropenia, exocrine pancreas
insufficiency, failure to thrive and skeletal abnormalities. In approximately 90%
of the patients, the molecular defect is related to SBDS gene mutations. The
classical triad is present in one-forth of the patients and a high degree of sus-
picion is required in order to make the diagnosis. In this study, molecular work-
up to patients  with suspected SDS were made and the clinical and laboratory
findings that predict the SDS diagnosis were investigated.
Aims: Aim of the study was to find out the predictive clinical and laboratory
characeteristics of SDS patients.
Methods: The patients who were sent to Hacettepe Inherited Bone Marrow
Failure Center for molecular work-up between June 2015 and August 2016
were evaluated with clinical and laboratory data obtained from a standardized
patient registry form. 
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Results: Molecular work-up was performed in 20 patients referred to our
center with a suspected diagnosis of SDS. Of these 20 patients (12 girls), 4
(20%) (3 boys) were found to have mutation in SBDS gene. The median age
of these patients was 3.2 years (1-18). Of the 4 patients with genetically ver-
ified SDS, 1 (25%) had history of chronic diarrhea and pancreas atrophy was
detected in ultrasonography of that patient Another patient (25%) with SDS
had skeletal abnormality, and 3 (75%) of the patientshad failure to thrive.
Three patients (75%) had anemia associated to neutropenia, and 1 patient
(25%) had pancytopenia at presentation. On the other hand of the patients
who were referred with a suspicion of SDS but was found to have no mutation,
43% had neutropenia, 25% had bicytopenia, 10% had pancytopenia. The
patientsin the latter group had failure to thrive in 25% of the patients and
chronic or persistent diarrhea was present in 25% of this group. There was
no statistically significant difference in the clinical and laboratory parameters
of the genetically verified SDS patients and patients without SDS but was
referred with SDS suspicion.
Summary/Conclusions: Although, there was no statistically significant differ-
ence in the clinical and laboratory parameters of the genetically verified SDS
patients and patients without SDS but was referred with SDS suspicion, this
might be attributed to the small sample sizes. Compatible with the previous lit-
erature data, SDS is a cryptic disorder and the classical triiad is not commonly
fulfilled in most of the patients. On the other hand, failure to thrive/growth retar-
dation was three times more common in patients with SDS. Thus, in patients
neutropenia, accompanying failure to thrive/growth retardation might be an
indicative to make molecular work-up for SDS. Additionally, not only neutrope-
nia, but bicytopenia or pancytopenia might be the hematological presentational
findings of SDS.
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PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND APLASTIC
ANAEMIA – DATA FROM THE SPANISH PNH REGISTRY
S. De La Iglesia1,*, M. Morado2, B. Arrizabalaga3, A. Gonzalez4, D. Beneitez5,
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Tauli , Barcelona, 12Hematology, SEHH, Madrid, Spain
Background: Aplastic anaemia (AA) and Paroxysmal Nocturnal Hemoglobin-
uria (PNH) are included, together with other pathologies, within the bone mar-
row failure syndromes (BMFS). In the present time, these clinical entities cannot
be understood as independent pathologies, due to the extremely frequent evo-
lution among them and with other BMFS, along with the development of new
clones in the context of haematopoietic stem cell’s kinetics.
Aims: The aims of this study were analyzing and comparing the behaviour of
patients who suffered from PNH with pancytopenia with respect to that of patients
who were initially diagnosed of AA and who later developed a PNH clone.
Methods: A clinical form was elaborated and distributed among the investiga-
tors of the PNH Spanish Registry. Clicnical, laboratory and treatment data of
the patient were asked. Soon after, a descriptive analysis of the data was per-
formed.
Results: 34 patients were recruited and analyzed (12 women and 22 men).
Their age interval ranged from 2 to 87 years, and all of the patients suffered
from either PNH with pancytopenia and/or AA with a developing PNH clone.
The average age at the time of initial diagnosis was 28,5 years old (4m-72y).
The initial diagnosis was: PNH with pancytopenia (1), moderate AA (16), severe
AA (10), very severe AA (7). 15 patients presented a PNH clone in their gran-
ulocytes and/or monocytes at the time of diagnosis, being 24% the average of
such clone (0-08-95%) and less than 2% in 7 patients. All of the cases that
showed hemolitic signs at diagnosis presented clones >20%. The time of the
clone’s development in the remaining cases was 8,7 years (5m-28y), appearing
in 2 patients just after resolution. Patients with AA received an average of 3
treatments, mostly cyclosporine with/without ATG (anti-thymocyte globulin). 10
patients underwent HCT (7 allogeneic HCT and 3 matched unrelated-donor
HCT). 14 patients received eculizumab, being 88.2% the average size of the
PNH clone at diagnosis (65-99%). Treatment response with eculizumab was
total in 11 cases and partial in 3. The following complications were observed:
cholelithiasis (3), renal failure (6; 50% secondary to treatment), iron overload
that required chelation therapy (3), transient aplastic crisis due to parvovirus
B19 (1), HCV infection (1), thrombosis (6). 4 patients started anticoagulant
treatment prior to eculizumab with no evidence of further thrombosis once the
treatment was initiated. 28 patients remain alive (26 of them with very good
quality of life). 3 of them died due to HCT-complications and follow-up was lost
in the 3 remaining cases.
Summary/Conclusions: Clonal evolution in AA is frequently associated with
the development of a PNH clone at the time of diagnosis, throughout the pathol-
ogy’ natural course or even after disease’s resolution. The development of such
clone has been related to better prognosis in AA right after the immunosup-
pressive therapy (IST). Our experience demonstrated the presence of hemolisis
in at least half of the cases, making it necessary in these patients treatment
with eculizumab, generally  obtaining a very good response.
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AUTOIMMUNE CYTOPENIAS IN PRIMARY IMMUNODEFICIENCY
DISEASES: SINGLE CENTER EXPERIENCE
T. Patiroglu1,*, M. Cansever2, F. Bektas2
1Pediatric Hematology, 2Pedıatric Immunology, Erciyes University Medical Fac-
ulty, Kayseri, Turkey
Aims: Primary immunodeficiency diseases (PID) are associated with  hema-
tologic complications such autoimmune hemolytic anemia (AIHA)  and throm-
bocytopenia (ITP). The most common autoimmune cytopenia is ITP.  Although
ITP is observed in 7.6% of patients with PID, AIHA is seen at 4.8%. Also, we
aimed to present the patients who had autoimmune cytopenias  and PID.
Methods: Fifty six PID patients who were followed at the Pediatric Immunology
Department of Erciyes University Medical Faculty (they were analyzed genet-
ically) were evaluated retrospectively.  Autoimmune cytopenias such as ITP
and AIHA were detected in 9 (%16. 07) of the patients (combined immunode-
ficiency:4 patients, common variable immunodeficiency: 2 patients, hyper
immunoglobulin E syndrome:1 patient, X-linked lymphoproliferative :1 patient,
chronic granulomatous disease:1 patient).  ITP was detected in 8 of 9 patients
and AIHA was also detected in 6 patients.  In four patients (LRBA deficiency: 2
patients, hyper IgE syndrome:1 patient and CGD:1patient), both ITP and AIHA
were observed.  Immunosuppressive  therapy with steroid, cyclosporine,
mycophenolate mofetyl and intravenous immunoglobulin  were given to all
patients.  Bone marrow transplantation was performed to the four patients.
However, five patients died because of immunodeficiency. 
Results: There is a paradoxal situation between PID and autoimmunity. The
reduction of central and peripheral tolerance is held responsible for autoimmu-
nity in PID. 
Summary/Conclusions: As a conclusion, we wanted to point out autoimmune
cytopenias in patients with PID and the requirement of multidisciplinary
approach for treatment. 
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HEAVY METAL LEVELS IN PATIENTS WITH FANCONI APLASTIC ANEMIA
T. Bayhan1,*, O. Erdem2, S. Unal1, F. Gumruk1, S. Cetinkaya2, E. Cirak3,
I. Eker4
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Background: Fanconi aplastic anemia (FAA) is a rare, autosomal recessively
inherited bone marrow failure disorder. Various congenital anomalies may
accompany disease and various complications including malignancy and
endocrinopathies may develop during the course.
Aims: Heavy metal levels in patients with different chronic disorders have been
investigated, however, up to our knowledge there is no literature data on the
heavy metal levels in patients with FAA. Heavy metal levels in patients with dif-
ferent chronic disorders have been investigated, however, up to our knowledge
there is no literature data on the heavy metal levels in patients with FAA.
Methods: Study was performed between July 2015 and April 2016 among
patients with FAA and the results were compared with age and gender matched
control group. Plasma copper (Cu), iron (Fe), zinc (Zn), and whole blood chromi-
um (Cr), cobalt (Co), selenium (Se) levels were measured in patients with FAA. 
Results: Total of 17 patients with FAA were included in the study. Median age
was 9 years (1 – 30), female to male ratio was 8/9. One patient had undergone
stem cell transplantation, four patients were transfusion dependent. When we
compared patients with FAA and age/sex matched healthy group (16 volun-
teers) Cr and Cu levels were higher and Se level was lower in FAA group sig-
nificantly (Table 1). However, all patients had chromium level within normal
range, two patients with FAA and two volunteers had copper levels higher than
the normal ranges (Table 2).
Table 1. Heavy metal levels in patients and control group.
FAA; Fanconi aplastic anemia.
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Table 2. Classified heavy metal level in patients and controls.
FAA; Fanconi aplastic anemia.
Summary/Conclusions: In our study we found chromium and cobalt levels
higher in patients with FAA than control group. In-vitro studies have revealed
that FAA cells are more sensitive to chromium toxicity. With larger number of
patients chromium level and clinical association should be investigated in fur-
ther studies. Lower Se level in patients with FAA may be related with oxidative
stress in these patients.
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CLINICAL IMPACT OF AGE AND COMORBIDITY IN PNH PATIENTS
E. Colado1,2,*, M. Morado Arias2,3, A. Gaya Valls2,4, M. López Rubio2,5,
B. Arrizabalaga Amuchastegui2,6, E. Lavilla Rubira2,7, E.J. Salido Fiérrez2,8,
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Background: PNH is an ultra-rare disorder affecting mainly young adults, but
can be diagnosed in geriatric population. Comorbitidy is more prevalent in gen-
eral geriatric population and can either hamper diagnostic evaluation or
increase the complexity of PNH patient care.
Aims: To identify geriatric-age PNH in Spanish PNH registry. To study the clin-
ical characteristics at diagnosis and evolution of geriatric-age PNH and com-
pare them to non-geriatric PNH population. To analyse the impact of both age
and prognosis in the PNH setting. To evaluate the use of eculizumab in geriatric
age patients.
Methods: In a multicentric retrospective study, Cumulative Illness Rating Scale
for Geriatrics (CIRS-G) and clinical and biological variables have been collected
from a Spanish PNH Group patient cohort. Statistical analysis was performed
using GraphPad Prism v5 (La Jolla, CA).
Results: 44 patients from 11 centres in Spain have been included up to date.
8 patients (17,8%) were diagnosed in geriatric age (equal or older than 65
years) (Age range for the complete cohort: 17-83 years) and 9 patients pre-
sented with high comorbidity, arbitrary defined as CIRS-G score >10. (Range
for the complete cohort: 3-13) Age and comorbidity were poorly correlated (p=
0.0187, R-square 0.15) No differences in clinical presentation (Classic, PNH
in the setting of another bone marrow failure syndrome or Subclinical PHN or
high disease activity) when stratifying by age or comorbidity were observed. 4
patients had a concomitant myeloid clonal disorder (3 myelodisplastic syn-
drome and 1 myeloproliferative neoplasm), 3 of them (75%) in geriatric age.
Median follow up was 7,2 years. Both age equal or older than 65 years and
CIRS-G >10 were associated to poorer overall survival (HR: 0.0134 and 0.045
& p= 0.0015 and 0.0103 respectively). Regarding PNH with high disease activ-
ity, 18 patients were identified, 4 of them in geriatric age. In 2 of them (50%),
Eculizumab was used, which contrasts with eculizumab use in younger patients
(78,6% in the same indication) Regarding comorbitidy impact on eculizumab
therapy outcome, 2 patients had CIRS-G score >10 and had similar overall
survival as patients with lower comorbidity in this cohort.
Summary/Conclusions: Age and comorbidity are associated with poorer over-
all survival in PNH. Older age and comorbidity may not preclude the use of
effective treatment in PNH patients, including those with high disease activity.
Prospective evaluation of comorbidity in PNH patients, regardless of age is
warranted.
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A RARE ASSOCIATION: EBSTEIN-BARR VIRUS ASSOCIATED
LYMPHOPROLIFERATIVE DISORDER AND PURE RED CELL APLASIA 
S. Berk1,*, M. Günaltılı2, S. Sadri1, M. C. Ar1, T. Soysal1
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Background: Lymphoproliferative disorders (LPD) constitute a heterogeneous
group of diseases related to expanding polyclonal or monoclonal lymphoid
cells in the setting of immune dysfunction. Ebstein-Barr virus (EBV) has been
implicated in the development of a wide range of B-cell LPD spectrum. EBV
associated LPDs (EBV-LPD) are more commonly encountered after stem cell
and organ transplantations.
Pure red cell aplasia (PRCA) is an uncommon disorder characterized by a
severe normocytic anemia due to erythroblastopenia in an otherwise normal
bone marrow. PRCA may be primary or develop secondary to viruses, autoim-
mune diseases, hematological malignancies, thymoma, solid tumors and drugs.
Aims: A case, who was diagnosed with EBV-LPD and developed PRCA during
follow-up, is presented.
Methods: A 75-year-old woman with pain in upper and lower extremities
applied to our center in February 2016. Her past medical history was unre-
markable except for rheumatoid arthritis. On physical examination bilateral cer-
vical, submandibular, axillary lymphadenopathies (LAP) and splenomegaly
were detected. Laboratory tests revealed normochromic normocytic anemia,
elevated serum lactate dehydrogenase and acute phase reactants. Positron
emission tomography (PET) showed supra- and infradiaphragmatic malignant
lymph nodes and splenic involvement. An excisional biopsy of cervical LAP
was performed. Pathological examination showed CD20 (+) and CD30 (+) large
B cells in the interfollicular area. EBV early RNA signals were ckecked by in-
situ hybridization and viral transcripts were detected. Diagnosis of EBV-LPD
was made. During diagnostic work-up deepening of anemia with reticulocy-
topenia, increased transfusion requirement and inadequate response to trans-
fusion necessitated a bone marrow aspiration and biopsy. Pathological exam-
ination of the bone marrow was compatible with PRCA. Parvovirus IgM and
DNA was negative; IgG was found to be positive. Because of the lack of
response to steroids, Rituximab was given (375 mg/m2, weekly). Anemia and
patient’s clinical condition improved after 8 weeks of treatment.
Results: In the pathogenesis of LPD polyclonal lymphoid response to an anti-
genic trigger is thought to be followed by development of monoclonal neoplastic
diseases. In our case, this trigger was thought to be EBV as it is known as one
of the main causative agents for LPD in the literature. Clinical complaints and
physical examination findings are common among all patients and frequently
not leading to a definitive diagnosis in most of them as it is the case in our
patient. Compared to the strong association of secondary PRCA with parvovirus
B19 its association with EBV is rare. PRCA can develop before the diagnosis,
during the course and after the remission of LPD. In our case we observed
PRCA in the follow-up period of EBV-LPD. 
Summary/Conclusions: On the basis of EBV-LPD being more common in
transplant setting our case was thought to be unique due to the absence of
transplantation or immunosuppression history. This case report points out to
the possibility of oexistence of two rare diseases, EBV-LPD and PRCA.
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LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAÏVE PATIENTS
WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA 
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M. Gentile11, F. Morabito11, S. Molica12, P. Falcucci13, G. D’Arena14, R. Murru15,
D. Vincelli16, P. Galieni17, G. Reda4, M. C. Tisi5, C. Vitale6, G.M. Rigolin7,
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Background: Patients affected by chronic lymphocytic leukemia (CLL) that
have trisomy 12 (+12) on FISH analysis have unique clinical and biological fea-
tures. In a prior analysis (Autore F, ASH 2016) of 487 patients with +12 com-
pared to 816 patients with negative FISH, patients with +12 had a significantly
higher prevalence of elevated LDH, β-2-microglobulin, ZAP70 positivity, CD38
positivity, CD49d positivity and unmutated IGHV as compared to patients with
negative FISH. They also showed shorter progression free survival (PFS), treat-
ment free survival (TFS) and overall survival (OS).
Aims: To identify clinical and laboratory features that predict disease progres-
sion, time to treatment and survival in treatment-naive patients with +12 CLL. 
Methods: This study included 487 treatment-naive patients with +12 CLL
from 16 academic centres, diagnosed between January 2000 and July 2016.
A cohort of 250 patients with +12 CLL followed at a single US institution was
used as external validation. Data were summarized as medians and 25th and
75th percentiles. Chi-square test or Fisher’s exact test were used to compare
categorical variables, while Wilcoxon-Mann-Whitney-Test was applied for
continuous variables. The survival analysis was based on the Kaplan-Meier
method and the log-rank test was used to compare survival curves. A Cox
model was used for multivariate analysis of the impact of different factors on
survival. P values lower than 0.05 were considered statistically significant
(STATA 12.0) and reported as two-sided. We analysed also CLL-specific sur-
vival considering events deaths due to the haematological disease.
Figure 1.
Results: Parameters associated with shorter PFS, TFS, OS and CLL-specific
survival on univariate analysis were IGHV, LDH, β-2-microglobulin and Rai
stage; age, ZAP70 and CD38 associated with OS only; on multivariate analysis,
high LDH and unmutated IGHV remained significantly with shorter PFS, TFS,
OS and CLL-specific survival, higher Rai stage with shorter PFS and elevated
β-2-microglobulin with shorter OS. Considering interestingly the association of
a simple and new laboratory parameter such as LDH to the outcomes, con-
firmed on multivariate analyses for PFS (hazard ratio [HR] 1.55, 95% confidence
interval [CI] 1.2 to 2.1; p=0.004), TFS (HR 1.62, 95% CI 1.2-2.2; p=0.002), OS
(HR 1.69, 95% CI 1.1-2.7; p=0.034) and CLL-specific survival (HR 3.86, 95%
CI 2.0-7.5; p<0.001), we divided our +12 CLL cohort according to LDH levels
available at diagnosis: 103 patients showed LDH levels above the normal limit
and 184 within normal range. Patients with high LDH levels showed shorter
PFS (30 months vs 65 months, p<0.001; Figure 1A), TFS (33 months vs 69
months, p<0.001; Figure 1B), OS (131 months vs 181 months, p<0.001; Figure
1C) and CLL-specific survival with a rate of attributable mortality of 29% vs
11% (p<0.001). In the validation cohort, 104 patients had high LDH levels and
145 patients had normal LDH levels; factors significantly associated with PFS
and TFS on univariate analysis were LDH, β-2-microglobulin, Rai stage and
ZAP70; LDH, β-2-microglobulin and age associated with OS. On multivariate
analysis high LDH was the sole parameter significantly associated with all short-
er outcomes, along with elevated β-2-microglobulin, which associated with
shorter OS.
Summary/Conclusions: Our study on 487 patients with +12 CLL and the
analysis on 250 patients of the validation cohort showed that patients with +12
and elevated LDH have shorter PFS, TFS, OS and CLL-specific survival.
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THE PERCENTAGE OF CELLS WITH ABNORMALITIES IN FISH STUDIES
CONFERS PROGNOSTIC INFORMATION IN CLL PATIENTS
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Background: Genomic aberrations detected by FISH have become one of
the most important and widely used prognostic factor for chronic lympho-
cytic leukemia (CLL) patients. In addition several publications have
described that patients with a higher percentage of abnormal nuclei have a
worse outcome.
Aims: To analyze the effect of the percentage of abnormal nuclei detected by
FISH (13q deletion (13q-), 11q deletion (11q-), 17p deletion (17p-) and trisomy
12 (+12)) in overall survival (OS) and time to first treatment (TTFT).
Methods: We studied a non-selected cohort of 650 consecutive CLL cases
from a local database with a median follow up time of 50 months (0-346). The
cut-off point for the percentage of abnormal nuclei for each alteration was
detected by dividing the variable into deciles, and selecting the most efficient
cut-point, and based on previous publications.
Results: FISH detected aberrations in 68% of the cases (442/650). The most
frequent abnormality was 13q-, observed in 302 patients (47%), but as a sole
alteration in 212 cases, followed by +12 (106 patients, 16%), 11q- (83
patients, 13%), and 17p- (33 patients, 5%). As expected, the group of patients
with 13q- as a sole abnormality was the one with the better OS (195 months)
followed by the group of patients with normal FISH (160 months), +12 (124
months), 11q- (56 months) and 17p- (46 months), consistent with the Dohner
hierarchical classification (Döhner H et al. NEJM 2000). Similar results were
observed in TTFT: 13q- as sole abnormality (106 months), normal FISH (112
months), +12 (29 months), 11q- (10 months), 17p- (10 months). The best
predictive cut-off point that divided patients according to its prognosis was
different for each alteration. We confirmed that a high percentage of cells
carrying the deletion is associated with a significantly worse TTFT in cases
with 17p, 13q, and 11q deletions, and a significantly shorter OS in cases with
17p deletion. We observed a similar trend for OS in cases with 13q and 11q
deletions, probably not significant because of the low number of patients
included, compared to previous studies. We observed the same trend in
patients with +12. The Table 1 summarizes these findings. Probably with a
higher number of cases and a longer follow up, it could have also been pos-
sible to reach statistically significant differences in the subgroups in which it
was not objected.
Table 1.
Summary/Conclusions: Not only the type of cytogenetic abnormality but also
the percentage of abnormal nuclei detected by FISH are important factors in
the prognosis of CLL patients.
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Background: Chronic Lymphocytic Leukemia (CLL) pathogenetic mechanisms
have not been fully elucidated yet. However, genetic and epigenetic alterations
seem to be involved in the pathogenesis and extensive clinical heterogeneity
of the disease. DNA methylation in CpG sites of a gene promoter, which may
affect the chromatin structure as well as gene transcriptional activity, is a crucial
epigenetic modification in CLL. RAD21 gene is involved in DNA repair and its
encoded product acts as basic subunit of the Cohesin protein complex that
regulates the cohesion and proper separation of sister chromatids during mito-
sis or meiosis.
Aims: We investigated the methylation status of RAD21 gene promoter and
its possible implication in CLL pathogenesis and the formation of CLL cytoge-
netic aberrations.
Methods: The study included 105 CLL patients and 17 healthy donors (con-
trols). Total genomic DNA extraction was performed from bone marrow or
peripheral blood samples of all patients and controls. Methylation analysis of
RAD21 gene promoter was carried out using the new techology of
MethylScreen™ in the CFX96Biorad Real-Time PCR system. For this purpose,
we used EpiTect Methyl II PCR Assay which enables us to calculate the methy-
lated and unmethylated fraction after simultaneous digestions with specific
restriction enzymes. Karyotypic analysis was performed on unstimulated and
stimulated with CpG-oligonucleotide DSP-30 bone marrow cells of CLL
patients. FISH analysis was carried out using the commercial CLL set probes
for detection of the most common abnormalities of the disease including dele-
tions of 17p13 (TP53), 11q22.3 (ATM) and 13q14.3/13q34.3 (D13S319/13q34)
regions and trisomy 12 (CEP 12). 
Results: Among the105 CLL patients, 21 patients exhibited a normal karyotype
also confirmed by FISH and 84 patients showed chromosome abnormalities
detected by karyotypic or/and FISH analysis. Methylation study was successful
in all healthy donors and in 101 out of 105 CLL patients. All healthy donors had
non-methylated RAD21 gene promoter. On the contrary, 25.74% (26/101) of
CLL patients carried >10% cells with methylated CpG islands in RAD21 pro-
moter, which was significantly increased compared to controls (p=0.039,
χ2=4.25, df=1). RAD21 methylated cell fraction varied among patients. More
specifically, 9.9% of patients (10/101) showed 11-50% methylation rate, 10.89%
(11/101) 51-89% and 4.95% (5/101) showed high methylation rate score, >90%
of the analyzed cells. Stratification of patients according to cytogenetic findings
showed that the promoter of RAD21 was methylated in 28.57% of patients
(6/21) with normal karyotypes and 25% of patients (20/80) with abnormal kary-
otypes. In detail, methylation in RAD21 promoter was present in 33.33% of
patients (5/15) with abn(14q32), in 33.33% (4/12) with abn(8), in 31.25% (5/16)
with -17/del(17p), in 27.78% (5/18) with trisomy 12, in 25.81% (8/31) with
del(13q), in 20% (2/10) with del(6q) and in 12.5% (2/16) with del(11q). Based
on karyotypic complexity, RAD21 promoter was methylated in 18.18% (4/22)
of patients with a single chromosome aberration, 26.09% (6/23) with two chro-
mosome aberrations and 25.71% (9/35) of patients with complex karyotype
(≥3 aberrations). 
Summary/Conclusions: Methylation of RAD21 gene promoter, which leads
to transcriptional inactivation and consequently inhibition of RAD21 expression,
seems to be implicated in CLL pathogenesis and the formation of specific chro-
mosome aberrations. Clarification of the epigenetic landscape of CLL may help
in the design of new targeted therapeutic agents. 
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ROLE OF KEAP1-NRF2 PATHWAY GENETIC VARIABILITY IN THE
SUSCEPTIBILITY AND PROGNOSIS OF PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA
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Background: Chronic lymphocytic leukemia (CLL) is the most prevalent
leukemia in the western adult population. Although advanced age, white ancestry,
and family history of hematologic malignancies are risk factors, the etiology of
CLL still unknown. One of the mechanisms associated with the development of
this pathology is related to the oxidative stress (OS) resulting from an imbalance
between the production of reactive oxygen species (ROS) and their disposal by
the antioxidant defenses. The nuclear factor erythroid 2-like gene - type 2
(NFE2L2) and its suppressor, the Kelch-like ECH-associated protein 1 (KEAP1)
gene, plays a central role in ROS balance. Changes in these genes, whether
due to somatic mutations or genetic variants (SNPs), have been associated with
some hematological diseases. However, the role of NFE2L2 and KEAP1 genes
polymorphisms in susceptibility and prognosis of CLL is not studied.
Aims: To assess the role of two SNPs in the NFE2L2 and KEAP1 genes on
CLL susceptibility, their influence on prognosis/survival, and their correlation
with clinical and laboratory characteristics of patients.
Methods: Genetic variants rs13001694 (NFE2L2) and rs11085735 (KEAP1)
were genotyped by tetra-primers-AMRS-PCR in 176 patients with CLL and
261 controls. The role of these genes polymorphisms in CLL susceptibility and
their association with clinical and laboratory characteristics as well as with ther-
apy response was assessed by logistic regression analysis and/or by Fisher’s
exact test. The influence on prognosis and survival was performed through
Kaplan-Meier curves by estimating the progression free survival (PFS) and the
overall survival (OS).
Results: The results showed that individuals with the GG genotype (NFE2L2)
are at higher risk of developing CLL [Odds ratio (OR): 2.032; 95% confidence
interval (CI): 1,234-3,351; P=0.004].  In addition, the genotypic profile (GP)
GG / CC (NFE2L2 / KEAP1) is a risk factor (OR: 2.186; 95% CI: 1.279-3.744;
p=0.003) for the development of CLL while the AA / CC profile constitutes a
protective factor (OR: 0.634, 95% CI:  0.407-0.984, p=0.037). In contrast,
patients with genotype AG (NFE2L2) and/or CC (KEAP1) had a higher rate of
complete response to rituximab therapy regimens (NFE2L2 AG: OR 1.6, 95%
CI 1.063-3.933, p=0.037; KEAP1 CC, OR 1.2, 95% CI 1.041-3.477, p=0.045,
NFE2L2 / KEAP1 AG / CC: OR 1.9, 95% CI, 1.843-4.485, p=0.017) and with
fludarabine (NFE2L2 / KEAP1 AG / CC: OR 1.5, 95% CI, 1.119-3.887, p=0.026).
Finally, the overall survival of CLL patients appears to be influenced by the
genotypic profile of NFE2L2 / KEAP1 [GP AG / AC patients have a lower mean
survival (72.5±13.8 months) than patients with other GPs (139.4±10.2 months,
p=0.037)], while progression-free survival seems to be influenced by the
KEAP1 genotype [patients with CC genotype have a longer mean survival
(198.0±13.6 months) than patients with AA and AC genotypes (85.3±13.4
months; P=0.022)].
Summary/Conclusions: This study suggest that genetic polymorphisms in
NFE2L2 and KEAP1 genes might be risk factors for CLL development and
may constitute novel genetic markers for therapy response (namely regimes
with rituximab and fludarabine) as well as prognostic markers, by influencing
overall survival and progression free survival in CLL patients.
The authors declare no conflicts of interest.
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EVALUATION OF BASAL CHROMOSOME ABERRATIONS AND
MICRONUCLEUS FREQUENCY IN UNTREATED PATIENTS WITH
CHRONIC LYMPHOCYTIC LEUKEMIA AND THEIR ASSOCIATION WITH
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Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease,
with variable clinical presentation and evolution. Two major subtypes can be
distinguished, mutated (M) and unmutated (UM), characterized respectively
by a high or low number of somatic hypermutations in the variable region of
immunoglobulin genes and different outcome. Cytogenetic and FISH (fluores-
cence in situ hybridization) studies have proved to be important tools in the
biologic characterization of this disease, allowing the identification of distinct
risk groups. Genomic instability involves a process prone to the accumulation
of chromosome alteration in somatic cells and is a major driving force of tumori-
genesis. The analysis of chromosome aberrations (CA) and micronucleus (MN)
represent different forms to evaluate genomic instability.  
Aims: In this study, we have analyzed the basal frequency of CA and MN in
untreated CLL patients. Results were evaluated in relation to different prog-
nostic factors.
Methods: A total of 67 untreated CLL patients (36 males; mean age: 66.6
years; range: 42-83 years; Rai stage: 0: 27%; I-II: 59%; III-IV: 14%), and 6 nor-
mal controls, were studied. Chromosome analysis was performed on stimulated
peripheral blood lymphocytes cultures. For each patient, CAs were evaluated
on 50 cells stained with 10% Giemsa and the MN frequency was assessed on
250 interphase nuclei. FISH analysis was performed using the CLL panel
according to manufacturer´s protocol. IGHV (immunoglobulin heavy chain vari-
able region) mutational status was analyzed by RT-PCR and bi-directional
sequencing. The study was approved by the local Ethics Committee. All indi-
viduals provided their informed written consent.
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Results: An increased number of CAs, including chromatid breaks and
dicentrics, in CLL patients (6.59±5.3%) compared to controls (0.25±0.04%)
(p=0.021) was observed. A tendency to increased CA frequency in cases with
abnormal (8.18±6.1%) compared to normal karyotypes (5.67±4.4%) (p=0.08)
was also found. The analysis taking into account FISH risk groups showed a
higher frequency of CA in patients with deletions 11q22 and/or 17p13 asso-
ciated to poor outcome (8.54±6.1%), than those with no alterations or 13q14
deletion related to a better outcome (5.64±3.9%) and cases with +12 with an
intermediate prognosis (4.54±3.5%). By MN analysis, an increased frequency
in CLL patients (2.81±1.5%) compared to controls (0.67±0.3%) (p=0.0001)
was found. Patients with +12 presented the highest percentage of MN com-
pared to the other two groups (~1.3-fold), indicating the aneugenic effect of
this alteration. The evaluation according to the IGHV mutational status
showed similar frequencies for CAs and MN in M-CLL (6.2±5.2% and
2.82±4.9%, respectively) and UM-CLL (6.2±5.8% and 2.7±1.3%, respective-
ly). No association between CA and MN frequencies and clinical parameters
was found.
Summary/Conclusions: Our results confirm the presence of basal genomic
instability in untreated CLL patients as measured by both CA and MN tech-
niques. To our knowledge, this is the first analysis of these parameters taking
into account prognostic factors of the disease. Cases with deletions 11q22
and/or 17p13 had the highest value of CA and those with +12 showed the
highest frequency of MN, reflecting different mechanism of DNA damage.
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B CELLS RESISTANT TO CD20 MONOCLONAL ANTIBODIES DISPLAY
SPECIFIC ALTERATIONS IN GENE EXPRESSION PROFILE
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Background: CD20 monoclonal antibodies (mAb) are a standard of care
for B-lymphoid malignancies. Yet, their clinical efficacy is quite variable and
many patients relapse, while their malignant cells express very low density
of CD20 on the cell surface. In spite of being used for 20 years as a therapy
target, little is known about the biology and regulation of CD20 inside the
cell.
Aims: The aim of this proposal was to investigate the intracellular mechanisms
regulating expression of CD20 antigen.
Methods: Diverse cell and molecular biology techniques were used, including
flow cytometry analysis, real-time PCR and RNA sequencing. 
Results: We show that treatment of B cells with different CD20 mAbs initiates
a signaling cascade within the cells that is partially distinct from classical B-cell
receptor signaling machinery and does not involve BCR proximal proteins.
Importantly, it results in a prompt downregulation of CD20 expression. Through
chronic exposure to gradually increasing doses of monoclonal antibodies, we
have generated cell lines that are resistant to additional treatment with mAb.
Notably, these cells are resistant also to any other of the available anti-CD20
antibodies even at very high concentrations as shown by dose-response exper-
iments. This resistance is sustained for long period and maintained even upon
many rounds of cell passages. We could confirm that these cells have down-
regulated CD20 protein from the cell surface and that this effect was not just
due to its internalization. Instead, we detected a defect in CD20 transcription
as measured by quantitative real-time PCR. Flow cytometry analysis of other
surface markers showed a strong upregulation of CD55 and CD59, known
inhibitors of complement activation. The combination of CD20 loss together
with the increase of CD55 and CD59 is responsible for the complete resistance
to the mAbs. We have then analyzed changes in overall gene expressions by
performing RNA sequencing and quantitative real-time PCR. We have identified
several interesting genes whose expression was altered in our resistant cells
when compared to their control counterparts. Among the most interesting hits
was a strong downregulation of the transcription factor NFkB, which was
expressed more than 10-fold lower in the rituximab or ofatumumab resistant
cells. We could confirm this result in multiple independent experiments. We
have postulated that anti-CD20-triggered signaling results in the inactivation of
NFkB and this may lead to the block in CD20 transcription. To confirm our
hypothesis, we have treated the cells with phorbol ester PMA, which nonspecif-
ically activates NFkB. Indeed, cells treated with PMA managed to rapidly upreg-
ulate CD20 on their cell surface.
Summary/Conclusions: In summary, CD20 triggering by therapeutic mAbs
initiates complex intracellular changes that result in downmodulation of CD20
expression. Further analysis of detailed intracellular mechanisms regulating
CD20 is warranted in order to propose novel interrogation nodes that might
modulate CD20 surface density and thereby enhance the therapeutic potential
of CD20 monoclonal antibodies.
This research has been financially supported by the Ministry of Education,
Youth and Sports of the Czech Republic under the project CEITEC 2020
(LQ1601) and by the research grant AZV-MZ-CR 15-33561AA-4/2015 and grant
MUNI/A/1106/2016.
PB1766
DIFFERENTIAL EXPRESSION PATTERNS OF CHEMOKINE RECEPTORS
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Background: Chemokines and their receptors are involved in the regulation
of cell recruitment, survival, proliferation, and trafficking, all these processes
crucial in the pathogenesis of chronic lymphocytic leukemia (CLL). Compre-
hensive profiling of chemokine receptors in CLL and its subgroups according
prognostic relevance is missing.
Aims: To characterize the chemokine expression pattern in CLL patients and
subgroups according to clinical course and cytogenetic aberrations.
Methods: We studied the gene expression pattern of 16 canonical and 4 atyp-
ical chemokine receptors in peripheral blood mononuclear cells (PBMC) of CLL
patients (n=88) and healthy subjects (n=34) by using SmartChip quantitative
RT-PCR (WaferGen Bio-systems). The expression of CXCR3, CXCR4, CXCR5,
CXCR7, and CCR7 was confirmed by flow cytometry. 
Results: Among deregulated receptors, 5 receptors (CCR7, CCR10, CXCR3,
CXCR4, CXCR5) were up-regulated and 9 receptors (CCR2-CCR6, CCR8,
CCRL2, CXCR1, CXCR2) down-regulated in CLL; the expression of others did
not differ between CLL and controls (P>0.05). In patients with del(17p) associ-
ated with a poor prognosis, we observed higher mRNA levels of CXCR6,
CXCR7 and CCR10 comparing to del(13q). On protein level, the percentage
of neoplastic B cells positive for CXCR4, CXCR5, and CCR7 was higher and
percentage of CXCR7 lower than on normal B cells (P<0.05). In patients with
CLL a marked increase in MFI of CXCR4 (P<0.001) and CCR7 (P<0.001) on
CLL cells was detected comparing to healthy subjects.
Summary/Conclusions: Our results provide a complete picture of expression
patterns of chemokine receptors in PBMC of CLL patients and prognostically
relevant subgroups. Further studies are needed to clarify how chemokine recep-
tor network affects neoplastic development and progression.
Grant support: MZ ČR VES16-32339A, IGA_LF_2017_009, IGA_LF_2017_001.
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RESIDUAL SERUM CONCENTRATIONS OF RITUXIMAB ARE
ASSOCIATED WITH RELAPSE RISK IN CHRONIC LYMPHOCYTIC
LEUKEMIA
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Background: Rituximab is an anti-CD20 chimeric monoclonal antibody
approved in first-line treatment of patients with chronic lymphocytic leukemia
(CLL), in association with chemotherapy. Rituximab displays a time-dependant
pharmacokinetic with a high variability between patients that is primarily related
to target mediated elimination.
Aims: Rituximab pharmacokinetics has been associated with clinical response
but there is no data on its association with patients’ evolution after
immunochemotherapy, which is the aim of the present study.
Methods: Residual serum concentrations of rituximab were determined by an
enzyme-linked immunosorbent assay (ELISA) for 35 CLL patients before each
infusion, administrated every 28 days at T0, T1, T2, T3, T4, T5. Response and
relapse criteria were evaluated according to the International Workshop on
Chronic Lymphocytic Leukemia guidelines.
Results: Patients were assigned to two groups related to time to relapse. The
first group (n=7), had an early relapse in less than 3 years, the second group
(n=28), in more than 3 years. A lower residual serum rituximab concentration
was observed in patients with an early relapse and statistical significance was
reached for the values obtained after the 3rd cycle (T3) (p=0.02). Concerning
the area under the curve (AUC), the difference was significant across all the
cycles, an early relapse being associated with a low AUC (AUCmeanA=1.28
±1.01 mg/L*day, AUCmeanB=2.79±1.93 mg/L*day, p=0.02). Additionally, the
residual rituximab serum concentration between T2 and T5, superior at 70µg/ml,
is associated with a long response time, with a sensibility of 100% and a speci-
ficity of 52%. Low residual serum rituximab concentrations in the early relapse
group were associated with a higher expression of CD38 and a more frequent
administration of the chemotherapy rituximab-bendamustine than rituximab-flu-
darabine-cyclophosphamide. On the other hand, there was no association with
age, sex, cytogenetics, tumour burden or with FCGR3A-158VF polymorphism.
Summary/Conclusions: In conclusion, serum residual rituximab concentration
in patients with CLL has an impact on clinical evolution after treatment. This
study provides data that sustains the need of rituximab serum concentration
adaptation in certain CLL patients, in order to reduce relapse risk.
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ACTIVITY OF THE CD19 ANTIBODY MOR208 IN COMBINATION WITH
IBRUTINIB, IDELALISIB OR VENETOCLAX IN VITRO
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Background: CD19 is broadly expressed across B-cell malignancies, including
chronic lymphocytic leukemia (CLL). MOR208 is an Fc-enhanced CD19 anti-
body mediating potent antibody-dependent cellular cytotoxicity (ADCC), anti-
body-dependent cellular phagocytosis (ADCP) and direct cytotoxicity. Single
agent MOR208 has shown promising activity in clinical studies.  
Aims: We investigated the in vitro cytotoxicity of MOR208 when combined
with the tyrosine kinase inhibitors (TKIs), ibrutinib and idelalisib, and the BCL-
2 inhibitor, venetoclax.
Methods: The CLL cell line MEC-1 was treated with 0.3–10 µM ibrutinib, ide-
lalisib or DMSO (control) for 7 days or 3–10 µM venetoclax or DMSO for 24
hours. Inhibition of proliferation, cytotoxicity and impact on CD19 expression
were then assessed. ADCC assays with MOR208 incorporated a fixed number
of primary human natural killer cells from healthy volunteers as effector cells.
By contrast, the number of target cells was reduced according to antiprolifer-
ative or cytotoxic effects of the TKIs or venetoclax. Dose-dependent ADCC
activity of MOR208 was analyzed by flow cytometry. Cytotoxic effects were
studied in at least three independent experiments.
Results: Ibrutinib and idelalisib induced only moderate direct cytotoxicity on
MEC-1 target cells but had strong antiproliferative effects. In contrast, veneto-
clax induced strong cytotoxicity on MEC-1 target cells within 24 hours. Both
effects led to reduced tumor target cell numbers in the subsequent ADCC
assays. CD19 expression was largely unaffected by all three drugs. The addi-
tion of MOR208 to ibrutinib, idelalisib or venetoclax treated target cells resulted
in enhanced maximum ADCC when compared with single agent MOR208.
EC50 values remained unaltered in TKI or venetoclax treated conditions com-
pared with the DMSO control. Calculations according to Chou-Talalay yielded
combination indices below 1 for all three drugs, thus confirming synergistic
activity.
Summary/Conclusions: The cytotoxic effect of MOR208 was synergistically
enhanced when combined with ibrutinib, idelalisib or venetoclax in vitro. These
promising data provide a strong rationale for combination of MOR208 with
these agents in future clinical trials.
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Background: Chronic lymphocytic leukemia (CLL) is a disease characterized
by the accumulation of morphologically mature monoclonal lymphocytes B with
CD19+/CD5+/CD23+ phenotype in lymphoid tissue, peripheral blood and bone
marrow. The course of CLL is chronic by default. Of note, however, is its het-
erogeneity. Programmed cell death protein 1 and its ligand 1 (PD-1, PD-L1) as
well as CD200 and CD200 receptor (CD200R) are major inhibitory receptors
regulating T cell exhaustion, i.e. a state of T cell dysfunction. The role of lym-
phocyte exhaustion in the natural history of CLL is still a matter of discussion.
Aims: The aim of this study was to determine the percentages and absolute
numbers of exhausted lymphocytes B and T in peripheral blood and bone mar-
row of CLL patients. Moreover, we analyzed relationship between the number
of PD-1-positive, PD-L1-positive, CD200-positive, and CD200R-positive lym-
phocytes and established prognostic factors in CLL.
Methods: The study included 60 untreated patients with CLL and 20 healthy
subjects. The immunophenotype of peripheral blood mononuclear cells (in both
groups) and bone marrow cells (solely in the CLL group) was determined by
means of flow cytometry.
Results: Patients with CLL showed higher frequencies and absolute number
of exhausted B lymphocytes CD19+PD-1+ (p<0.0001), CD19+PD-L1+
(p<0.0001), CD19+CD200+ (p<0.0001) and CD19+CD200R+ (p<0.0001), as
well as higher frequencies and absolute number of exhausted T helper lym-
phocytes CD4+PD-1+ (p=0.0021), CD4+PD-L1+ (p=0.0032), CD4+CD200+
(p=0.0027), CD4+CD200R+ (p=0.0062), and exhaused T cytotixic lymhocytes
CD8+PD-1+ (p=0.0036), CD8+PD-L1+ (p=0.0029), CD8+CD200+
(p=0.0038), CD8+CD200R+ (p=0.0073) than the controls in the peripheral
blood. Similar observations were done in the bone marrow samples
(p<0.0001, p<0.0001, p<0.0001, p<0.0001, p=0.0134, p=0.0183, p=0.0263,
p=0.0169, p=0.0261, p=0.0362, p=0.0293, and p=0.0379, respectively).
Enhanced exhaustion of peripheral blood and bone marrow lymphocytes was
associated with higher Rai stage, increased concentration of lactate dehy-
drogenase and beta-2 microglobulin, and more rapid progression of the dis-
ease. The number of lymphocytes B CD19+ZAP-70+ correlated positively
with the number of CD19+PD-1+ B cells, CD4+PD-1+ T cells, and
CD8+CD200+ T cells.
Summary/Conclusions: The study confirmed the association between unfa-
vorable prognosis and high expression of exhaustion markers in CLL patients.
Determination of PD-1+, PD-L1+, CD200+ and CD200R+ lymphocytes T and
B constitutes valuable diagnostic tool, completing cytometric evaluation of
CLL.
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Background: B-cell Chronic Lymphocytic Leukemia (CLL) is a neoplastic dis-
order characterized by the accumulation of clonal B cells in peripheral blood,
bone marrow and lymphoid tissues. CLL is a clinically and biologically hetero-
geneous disease. As a consequence, novel biological and cytogenetic features
have become increasingly important in predicting prognosis at the time of diag-
nosis and the research for molecules involved in apoptosis resistance and
increased survival of neoplastic B cells is still ongoing.
Aims: We recently found that the Heat Shock Protein of 70kDa (HSP70) is
overexpressed in Chronic Lymphocytic Leukemia (CLL) B cells. Considering
the pro-survival role of HSP70 in cancer, we were aimed at characterizing this
protein and its master regulator, the Heat Shock Factor 1 (HSF1), within the
pathogenetic mechanisms leading to CLL.
Methods: HSP70 and HSF1 expression levels were evaluated by Western
blotting (WB) analysis in leukemic and normal B cells. HSP70 and HSF1 protein
levels were correlated to IGHV mutational status and ZAP70 protein expression
in CLL patients. HSP70 and HSF1 levels were also analyzed in neoplastic cells
obtained from patients undergoing Ibrutinib based regimen by WB analysis.
Moreover, HSP70 and HSF1 localization was analyzed by subcellular protein
fractionation followed by WB analysis. The effects of HSP70 and HSF1 inhibi-
tion (by Zafirlukast and Fisetin) were evaluated by Annexin V/Propidium Iodide
flow cytometry test and WB analysis of PARP cleavage.
Results: We demonstrated that HSP70 and HSF1 are overexpressed in
leukemic vs normal B cells and their expression levels correlate to poor prog-
nosis in CLL. We also analyzed HSP70 and HSF1 levels in patients following
in vivo Ibrutinib based regimen, observing a positive correlation between these
two protein expression levels and moreover we observed that these two protein
levels decreased after  therapy. We found that at steady state both HSP70 and
HSF1 are localized in the nucleus of CLL B cells. HSP70 and HSF1 inhibition
was proved to be effective in inducing a dose-dependent in vitro apoptosis of
CLL B cells.
Summary/Conclusions: HSP70 and HSF1 overexpression and correlation
with poor prognosis in CLL patients underline their pivotal role in the regula-
tion of leukemic B cell survival. HSP70 and HSF1 both correlation and reduc-
tion in CLL patients following in vivo Ibrutinib regimen let us hypothesize a
role of these proteins in the progression of the disease. In normal B cells
HSP70 and HSF1 are both localized into the nucleus after stress conditions,
however we found both HSP70 and HSF1 localized into the nucleus of CLL
B cells at steady state, suggesting a constitutive activation of these proteins
in CLL. Although HSP70 has been extensively linked to cancer, little pro-
gresses have been made in bringing HSP70 inhibitors to the clinic, because
of their potential off-target effects. For this reason we tried an alternative
approach by targeting the HSP70 major regulator, HSF1. We observed that
both inhibitors, Zafirlukast and Fisetin, lead to an in vitro dose dependent B
cell apoptosis. These data demonstrate HSP70 and HSF1 involvement in
the pathogenesis of CLL and identify HSP70/HSF1 axis as a target for new
therapeutic strategies.
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OVEREXPRESSION OF GENE FOR HUMAN CONCENTRATIVE
NUCLEOSIDE TRANSPORTER 3 IS A PREDICTOR OF RESISTANCE TO
FLUDARABIN-BASED CHEMOTHERAPY IN PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA
V. Vukovic1,*, D. Antic1,2, T. Karan-Djurasevic3, N. Milic4, M. Todorovic-Balint1,2,
J. Bila1,2, B. Andjelic1,2, V. Djurasinovic1,2, A. Sretenovic1, M. Smiljanic1,
J. Jelicic1, M. Dencic-Fekete1, M. Perunicic-Jovanovic1, N. Kraguljac-Kurtovic1,
S. Pavlovic3, B. Mihaljevic1,2
1Clinic for Hematology, Clinical Center of Serbia, 2Medical Faculty, University
of Belgrade, 3Laboratory for Molecular Biomedicine, Institute of Molecular
Genetics and Genetic Engineering, 4Institute for Medical Statistics and Infor-
matics, Medical Faculty, University of Belgrade, Belgrade, Serbia
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Background: Human concentrative nucleoside transporter 3 (hCNT3) belongs
to a family of nucleoside transporters  involved in fludarabine cellular uptake.
It has been reportedthat overexpression of SLC28A3 gene encoding  hCNT3
predictspoor response to fludarabin-based chemotherapy.However, the mech-
anisms by which elevated expression of SLC28A3 mediate fludarabine resist-
ance are still elusive. 
Aims: The aim of the study was to examine possible influence of SLC28A3
gene overexpression  on treatment response to fludarabine-cyclophosphamide
therapy (FC) in patients with chronic lymohocytic leukemia. 
Methods: We retrospectively analysed data from 54 CLL patients diagnosed
and treated at Clinic for Hematology, Clinical Center of Serbia from 2003 to
2013. Blood samples were prospectively collected and analysed for biological
and molecular features, as well as standard laboratory parameters. The expres-
sion of SLC28A3 gene was analyzed in peripheral blood mononuclear cells by
RQ-PCR methodology, using TaqMan chemistry and Abl as endogenous control
gene. Quantification of  target gene expression was made by comparative ddCt
method, using HL-60 cell line as the calibrator. All analyses were done prior to
any treatment.
Results: Median age at diagnosis was 57 years (range 38-75). All patients
were treated with fludarabin-based chemotherapy, 45 (83%) in the first treat-
ment line. Overall response rate to the first line therapy was 81%, equally dis-
tributed on complete and partial responses (CR and PR), while the remainder
included the same number of patients with stable disease (SD) and progressive
disease (PD) (5, 9.6%). Most of the patients (42, 78%) relapsed during the fol-
low up. At the time of the last follow up 14 (26%) patients were still alive, 35
(65%) were dead, and 5 (9%) were lost to follow up. Median overal survival
was 76 months.
In the group of patients who received FC in the first treatment line (43/54),
median expression of SLC28A3 mRNA in patients who experienced CR, PR,
SD and PD was 0.036±0.030, 0.062±0.063, 0.030±0.025 and 0.157±0.257,
respectively. The level of  SLC28A3 expression was not associated with the
IGHV mutational status. Patients who experienced PD to FC treatment over-
expressed gene for hCNT3 compared to patients who achieved CR (p=0.013)
and PR (p=0.05). We detected a significantly higher level of SLC28A3 expres-
sion in patients who experienced PD to FC treatment in comparison to patients
who achieved CR (p=0.013) and PR (p=0.05).
Summary/Conclusions: Overexpression of SLC28A3 gene is a predictor of
resistance to treatment with FC chemotherapy. Further studies are warranted
to confirm these findings.
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THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN
CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING
RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT
N. Bilous1,*, I. Abramenko1, A. Chumak1, I. Dyagil2, Z. Martina2
1Clinical Immunology, 2Hematology, Research Center for Radiation Medicine,
Kiev, Ukraine
Background: Generally, chronic lymphocytic leukemia (CLL) is considered to
be a non-radiogenic form of leukemia. We previously found some clinical and
biological features of CLL in group of clean-up workers of Chornobyl NPP acci-
dent indicated unfavorable disease course, such as high frequency of solid
tumors and Richter transformation, mainly unmutated status of heavy chain
variable region (IGHV) genes with increased usage of IGHV1-69 and IGHV3-
21 (Abramenko et al., 2008). Analysis of genetic features of leukemic cells in
IR-exposed CLL patients may provide an additional data on the possible causal
relationship with IR.  
Aims: the aim of the study was to analyze TP53, NOTCH1 and SF3B1 muta-
tions in CLL patients, sufferers of Chornobyl NPP accident to clarify the possible
pathogenetic relationship between IR and CLL development
Methods: TP53, NOTCH1, and SF3B1 mutations were analyzed in 106 CLL
patients who have been exposed to ionizing radiation (IR) due to Chornobyl
NPP accident (83 clean-up workers, 16 inhabitants of radionuclide contami-
nated areas, and 7 evacuees) and in 130 IR non-exposed CLL patients as the
control group. TP53 gene mutation analysis was performed for exons 3 to 10.
NOTCH1 mutations and SF3B1 mutations were analyzed in the hotspot regions
of these genes were the vast majority of CLL-specific lesions were reported: in
c.7282_ 7680 region in exon 34 of NOTCH1 gene, and in exons 14, 15 and 16
of SF3B1 gene, correspondingly.
Results: We found TP53 and SF3B1 mutations with similar incidence in both
groups – in 11.3% and 10.0% of IR-exposed patients, and in 12.7% and 11.5%
of IR non-exposed CLL patients, respectively. In contrast, NOTCH1 mutations
were found with significantly lower frequency in IR-exposed patients in com-
parison with the control group (6.7% vs 17.7%; p=0.012). Some other features
were found among IR-exposed CLL patients also. Specifically, TP53 mutations
were seen with equal frequency among mutated (11.1%) and unmutated
(11.8%) IGHV cases in IR-exposed CLL patients, while the tendency to preva-
lence of TP53 mutations in unmutated compared with mutated IGHV cases
was found in the control group (14.1% and 5.6%, correspondingly; p=0.178).
In IR-exposed group SF3B1 mutations were combined with mutations in TP53
almost in half of detected cases. In opposite, in the control group we observed
reported earlier mutual exclusivity between SF3B1 and TP53 lesions (p=0.001
in comparison between observed groups). Among IR-exposed CLL patients we
found two different cases with identical rare mutation of TP53 gene - c.665C>T
substitution leading to change proline for leucine at codon 222 (Pro222Leu).
This substitution is very likely to represent inherited TP53 mutation, which may
influence CLL development under IR exposure.
Summary/Conclusions: In summary, our data suggest that TP53 abnormali-
ties are involved in CLL development in sufferers of the Chornobyl NPP accident
and also a possible interaction between inherited IR sensitivity caused by muta-
tion in TP53, radiation and CLL development. 
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DRUG SENSITIVITY SCREENING IN CHRONIC LYMPHATIC LEUKEMIA
AND MULTIPLE MYELOMA FOR PERSONALIZED CANCER THERAPY
D.B. Thimiri Govinda Raj1,*, S.S. Skanland1, D. Wang2, G.E. Tjønnfjord3,
L.A. Munthe2, K. Tasken1
11Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership,
University of Oslo and Oslo University Hospital, NCMM UIO, 2Centre for
Immune Regulation, Institute of Clinical Medicine, University of Oslo, 3Depart-
ment for Haematology, Oslo University Hospital, Oslo, Norway
Background: Personalized Cancer Medicine is rapidly developing field that
includes predictive medicine, preventive medicine and various personalized
or individualized therapies, e.g. labeled “precision medicine”. One particular
challenge with cancer is that origin of each cancer is a clonal event evolving
into tumor heterogeneity.  We focus on Chronic Lymphocytic Leukemia (CLL),
Multiple Myeloma and Follicular lymphoma (FL) that are currently considered
incurable. Although current treatment regimens prolong life for patients, CLL
and MM cancer eventually relapse. Current challenges in using therapeutics
against CLL and MM includes design of optimal treatment for individual
patients based on characterization the tumor and its intratumor heterogeneity
as observed by whole genome sequencing. Efficient therapies require a per-
sonalized approach that combines targeting lymphoma cells and the tumor
microenvironment by restoring the patient’s own anti-tumor immunity. One
solution to this challenge is the so-called “n-of-one” studies where protocols
are organized with diagnostically based patient stratification to individualized
treatments (n=1).
Aims: To introduce individualized treatment for patients against available
therapies, we aim to established cell-based assays and drug sensitivity plat-
form at NCMM, University of Oslo and Oslo University Hospital.  To establish
a pipeline  for direct drug senstivity screening in CLL and MM (WP1-Path
A). To Complement the results from WP1-Path A, with Signaling pathway
analysis (WP2-Path B) towards testing in xenografted mice and implement-
ing therapy in n-of-one clinical trials. To Offer patients with intractable CLL
and MM individualized treatment with an effective combination of targeted
therapies.
Methods: We culture CLL cells with combination of feeder cells that express
CD40L, APRIL and BAFF for 24 hours stimulation. We perform drug sensitivity
screening with Prestimulated CLL cells in 384 well formats without feeder cells.
We culture MM cells in 384 well format for drug screening in response to
Thelper cells prestimulation in the presence of IL2. To support high-throughput
drug sensitivity screening , We use cell-based assays such as CellTiter-Glo®
Luminescent Cell Viability Assay and CellTox™ Green Cytotoxicity Assay to
define drugs that inhibit cancer cell growth. Additional methods such as cell
proliferation assay, CellTox Green, apoptosis and oxidative stress (glutathione
release) are also applied. We also use established cell barcoding on CLL/MM
for flow cytometry (7-AAD/BrdU cell proliferation and Caspase8/9 apoptosis
assay).
Results: Standard Curve for cell proliferation, CellTiter-Glo assay has been
performed for MM/CLL cells. Time course measurement using cell prolifera-
tion, CellTox-Green assay for CLL cells (unstimulated and soluble CD40 lig-
and stimulated) has been performed. Time course measurement (0,24,48,72
hrs and 5 days) using cell proliferation, CellTox-Green assay for M2 cells has
been performed. Benzalkonium chloride (BzCl) is used as Positive control.
Endpoint measurement using CellTiter-Glo assay for CLL and MM cells was
performed with cell density of 5000. Dose Response curve for 50 drugs has
been generated for CLL patients (n=4) and MM (n=4) (Figure 1).
Figure 1.
Summary/Conclusions: We perform drug sensitivity screening to select
potential drug candidates and pathway inhibitors through an approach where
we directly assess patient samples. Selected drug candidates will first be vali-
dated by bioassays and flow cytometry to assess effects on intracellular mito-
genic pathways (phosphoflow-based approach). We propose to use the drug
sensitivity screening platform to identify and validate drug candidates for
xenografting and “n-of-one” clinical trial studies.
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FCGR2A AND FCGR3A VARIANTS ARE NOT ASSOCIATED WITH
RESPONSE TO RITUXIMAB IN PATIENTS WITH B-CELL CHRONIC
LYMPHOCYTIC LEUKEMIA 
M. Pavkovic1,*, S. Trpkovska-Terzieva1, R. Angelovic1, O. Karanfilski1, T. Sotirova1,
L. Cevreska1, A. Stojanovic1
1University Clinic for Hematology, Skopje, Macedonia, The Former Yugoslav
Republic Of
Background: Chronic lymphocytic leukemia (CLL) is the most common form
of adult leukemia in Western world with highly variable clinical outcome. Ritux-
imab is a monoclonal chimeric anti-CD20 agent, that has demonstrated signif-
icant benefit for patients with different form of B cell lymphoproliferative disor-
ders. Chemoimmunotherapy with rituximab, fludarabine and cyclophosphamide
(R-FC) has shown to prolong progression free survival (PFS) and overall sur-
vival in CLL patients compared with chemotherapy alone. FCGR2A is poly-
morphic and has two alleles, FCGR2A-131H and FCGR2A-131R. This poly-
morphic variation is due to a single base substitution of nucleotide adenine for
guanine in position 494. FCGR2A-H131 allele has a higher affinity for human
IgG2, comparing to FCGR2A-R131. The gene for FCGR3A has also two poly-
morphic variant alleles: 158 valine (V158) and phenylalanine (F158) due to
single base substitution of timidine to guanine at nucleotide position 559.
FCGR3A-158V variant has higher affinity for Fc gamma receptor than 158F
variant. These Fc gamma receptor polymorphisms may influence antibody-
dependent cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and
direct proapoptotic effect. 
Aims: The aim of our study was to investigate a possible association of these
two FCGR2A and FCGR3A variants with response to R-FC therapy in CLL
patients. 
Methods: We have analyzed these two polymorphisms in 90 patients with CLL
treated with R-FC regimen. Median age of our patients was 62.7(36-78) and
63% were male. Number of patients with stage III/IV disease was 65(72%) and
median WBC count at the start of treatment was 68.5(34-173x109/L). Percent-
age of previously treated patients was 51/90 (56.6%). Average numbers of R-
FC cycles were 4.3 and median PFS was 35.1 months. Median time of obser-
vation after treatment was 3.6 years (range:6 months-8 years). Response was
evaluated 2 months after therapy according to National Cancer Institute (NCI)
criteria. Complete response (CR) was achieved in 24/90 (26.7%), partial
response (PR) in 56/90 (62.2%) and no response in 10/90 (11.1%). DNA was
isolated from peripheral blood mononuclear cells and genotyping was per-
formed by using PCR/RFLP methods. The distribution of genotypes was com-
pared by using a chi-squared test or Fisher’s exact test.
Results: Distribution of genotypes in our patients was: 33% H/H, 49% H/R
and 18% R/R for FCGR2A and 43% V/V, 40% V/F and 17% F/F for FCGR3A.
Rate of CR and PR were similar irrespective of the FCGR variants and our
results did not demonstrate significantly different genotype distribution for
FCGR2A (p=0.8001) or FCGR3A (p=0.1019) in CLL patients with complete,
partial or no response to R-FC treatment (Table 1).
Table 1. Genotype distributions for FCGR2A & FCGR3A in patients with
CLL.
Summary/Conclusions: Our results are similar with previously reported
results in other studies in CLL patients, but in contrast with the results for fol-
licular lymphoma (FL), which showed that high-affinity FCGRA-158V/V variant
was associated with the highest response rates in FL patients treated with rit-
uximab. These findings could be explained with the different mechanism of
action of rituximab in CLL compared to lymphoma patients or could be due to
the variations in selected patient’s population.
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MUTATIONAL STATUS, IMMUNOGLOBULIN HEAVY VARIABLE GENES
PATTERN AND STEREOTYPED RECEPTORS REPERTOIRE OF
MACEDONIAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
I. Panovska-Stavridis1,*, S. Trajkova1, M. Ivanovski1, M. Popova-Labacevska1,
A. Pivkova-Veljanovska1, D. Dukovski1, A. Eftmov2, M. Staninova-Stojovska2,
N. Matevska-Geshovska2, L. Cevreska1, A.J. Dimovski2
1University Clinic of Hematology-Skopje, 2Center for Biomolecular Pharma-
ceutical Analyses, Faculty of Pharmacy, Skopje, Macedonia, The Former
Yugoslav Republic Of
Background: The mutational status of the immunoglobulin heavy variable
(IGHV) genes is established as one of the most important prognostic molecular
genetic markers in chronic lymphocytic leukemia (CLL). It divides the CLL
patients into two subsets with a different clinical course, mutated (M-CLL) and
unmutated (U-CLL). U-CLL is delineated with a cutoff value of 98% identity
with the closest germ line of IGHV genes. The shaping of the CLL IGVH gene
repertoire depends on a different genetic background and effects of the envi-
ronmental factors. In addition, a strong bias in the use of individual genes and
subgroups between normal and malignant B-cells and presence of highly
homologous “stereotyped” heavy complementary-determining region 3 (VH-
CD3) is shown, which suggests the role of a specific antigen in the pathogen-
esis of the disease. 
Aims: In this study, we analyzed the mutation status and pattern of IGHV,
IGHD and IGHJ gene usage in Macedonian CLL patients. 
Methods: Ninety-seven consecutive CLL patients that presented at the Uni-
versity Clinic of Hematology –Skopje in the period between 2011-2013, were
included in the study.  IGHV mutation status and gene repertoire were analyzed
using the reverse transcriptase– polymerase chain reaction (RT-PCR) and
sequencing methodology.  The mutational status of the IGVH genes was deter-
mined using two databases: IMGT/V-QUEST tool and IgBLAST software. The
stereotyped subset assignment was performed using ARResT/AssignSubset
tool (Bioinformatics Analysis Team).
Results: We found that 44.3% of the cases belonged to M-CLL and 55.7% to
U-CLL, with a progressive disease dominant in the U-CLL subset. Both groups
were comparable regarding the age and gender distribution. Only 39% of the
M-CLL patients presented with a  progressive disease, compared to  74% of
the U-CLL patients (p<0.05).The comparison of median time to the first treat-
ment (TTT) between M-CLL and U-CLL (39 months versus 8 months, respec-
tively) showed a statistically significant difference between the groups (p<0.01).
Most frequently expressed IGVH genes were:  the IGHV3 subgroup (44.3%),
followed by IGHV1 (28.9%), IGHV4 (23.7%), IGHV5 (2.0%), and IGHV2 (1.0%).
Among 32 different IGVH genes, 8 genes were found (V1-46,V1-69,V3-21,V3-
23,V3-30,V3-33,V3-48 & V4-34) in 58.8% of all cases, revealing a strong bias
in IGVH gene expression in CLL. IGHV1-69 was the most frequently expressed
gene of all genes (16.5%), and exclusively found in the U-CLL group demon-
strating a frequency of 29.6%. The IGHV3-21 was detected with a low frequen-
cy of 4.1%, as reported for CLL patients from other Mediterranean countries.
The distribution of IGHD subgroups was as follows: IGHD3, 52.6%; IGHD2,
17.5%; IGHD6, 13.4%; IGHD1 7.2%; IGHD4 7.2%; and IGHD5 2.09%. The
most frequent IGHJ gene was IGHJ4 (49.4%), followed by IGHJ6 (239.2%),
IGHJ5 (13.4%), IGHJ3 (11.4%) and IGHJ2 (3.8%), IGHJ1 (2.09%). In 10.1%
of the cases, the VHCDR3 amino acid sequences belong to previously defined
stereotyped clusters. Only one of the rearrangements with stereotyped VH-
CD3 belonged to the M-CLL subset.
Summary/Conclusions: Our study showed a strong correlation between IGHV
gene mutational status and clinical course of CLL. Results on IGHV-IGHD-
IGHJ genes usage in our study are comparable to the previously reported from
Mediterranean countries. The high frequency of V1-69gene and low frequency
of IGVH3-21 in our CLL patients that originate from a small geographic region
further promotes the geographic bias in the use of IGVH genes and points to
an important role in antigen stimulation in the pathogenesis of the CLL sub-
sets.  Our findings indicated a lower expression of the stereotyped BCR region
than those previously reported (~30%), but they were comparable with the
results reported for the Serbian CLL patients (10.1% versus 15,3%, respec-
tively), in the only previous published study of this kind from Western Balkans.
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LAMBDA LIGHT CHAIN RESTRICTION – USEFUL FOR HAIRY CELL
LEUKEMIA PROGNOSTICATION?
J. Araújo1,*, M. Sobrinho-Simões1, S. Afonso1, F. Príncipe1, J.E. Guimarães1
1Hematology, Centro Hospitalar de São João, Porto, Portugal
Background: Hairy cell leukemia (HCL) patients have near-normal life
expectancies since the introduction of purine nucleoside analogues. However,
HCL remains a chronic, often relapsing disease in which maximizing treatment-
free survival (TFS) is the main goal. 
Aims: Prognostication is not standardized in HCL, emphasizing the relevance
of the characterization of HCL populations.
Methods: We retrospectively analysed 40 patients (90% men), diagnosed
between 1997 and 2016, with a median follow-up of 6 years. 
Results: At presentation, the median age was 58 years and 69% of patients
were symptomatic - fatigue (53%), B symptoms (50%), bleeding (14%), abdom-
inal discomfort (6%) and severe infection (22%). The commonest cytopenia
was thrombocytopenia (70%), with median platelet count being 66x10^9/L.
Monocyte counts below 0.1x10^9/L were observed in 61% of the patients.
Splenomegaly was observed in 83% of the patients and 21% had abdominal
lymphadenopathies. The majority of the patients (88%) was treated with cladrib-
ine in first line, achieving an overall response (OR) rate of 100% and a complete
response (CR) rate of 38%, of which 67% were classified as minimal residual
disease (MRD)-negative CR. Retreatment was required in 33% of the patients,
of which the majority received cladribine. The median time-to-next-treatment
(TNT) from first to second line was 3 years. The OR rate for second-line treat-
ment was 91%, 50% achieving CR, of which 33% were classified as MRD-neg-
ative CR. Only 5% of the patients required further treatment lines. Even the
presence of scarce hairy cells in the bone marrow precluded classification of
response as CR. This might have contributed to the low CR levels observed in
our patients. As post-treatment bone marrow biopsies were available in only
24 patients, response analysis was restricted to these patients. All of these 24
patients had bone marrow fibrosis at diagnosis, which reverted when and in
whom first CR was obtained. Median overall survival (OS) was not reached
and, at 10 years, the OS was 90%. Four deaths occurred, all unrelated to HCL.
Regarding prognostication, a trend to a longer TFS, albeit no statistically sig-
nificant, was observed in patients achieving CR (namely MRD negative) and
without thrombocytopenia at presentation. Excitingly, the 61% of patients with
kappa (k) light-chain restriction (LCR) displayed a significantly higher TFS
than the 39% with lambda (λ) LCR (p 0.034, Wilcoxon-Gehan test). To the best
of our knowledge, there are no published reports on prognostic value of LCR
in HCL (Figure 1).
Figure 1.
Summary/Conclusions: If multicentre studies corroborate our findings, LCR
may be of use in the prognostication/risk stratification of HCL. Similarly with
multiple myeloma and other hematological malignancies, lambda (λ) LCR
appears to correlate with worse prognosis, leading to a shorter TFS.
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CLINICAL EFFICACY AND LONG-TERM OUTCOMES OF SPLENECTOMY
IN CHRONIC LYMPHOCYTIC LEUKEMIA
Y. Yevstakhevych1,*, I. Yevstakhevych1, O. Vygovska1, M. Semerak1,
V. Loginskiy1
1SI “Institute of Blood Pathology and Transfusion Medicine NAMS of Ukraine”
, L’viv, Ukraine
Background: Chronic lymphocytic leukemia (CLL) is often accompanied by
splenomegaly. In certain cases the spleen may enlarge to a giant size, causing
abdominal discomfort, regional portal hypertension, and becomes a place of
malignant cells concentration. In 2.3-4.3% of cases CLL may be complicated
by autoimmune cytopenias (autoimmune hemolytic anemia (AIHA), immune
thrombocytopenia (ITP), Evans-Fisher syndrome). Accordingly, the effective-
ness of steroid and chemotherapy in such cases may be impaired, raising the
question of splenectomy advisability.
Aims: To analyze splenectomy effectiveness in patients with CLL.
Methods: Splenectomy was performed in 41 patients with CLL, 12 of which
were patients with CLL and ITP, 9 with CLL and warm type AIHA, 5 patients
with CLL and Evans-Fisher syndrome, along with 15 CLL patients without
immune disorders. Among the patients there were 26 males and 15 females.
Indications to splenectomy were following: massive splenomegaly with abdom-
inal discomfort, immune cytopenia and regional portal hypertension. In one
female patient the surgical intervention was performed urgently due to sponta-
neous splenic rupture and acute intra-abdominal bleeding.
Results: Splenectomy was effective in 37 patients (90.2%): abdominal dis-
comfort disappeared, hemolysis stopped and hemoglobin levels normalized or
increased, platelets numbers normalized or increased. Splenectomy was inef-
fective in 3 patients with CLL associated with ITP: amid elimination of abdominal
discomfort the platelets number did not increase significantly (2 patients), while
in 1 patient despite increase in platelets number leukemia progression was
observed. One (2.4%) patient with CLL and AIHA died on 3rd day after surgery
because of acute adrenal insufficiency. The analysis of late effects of splenec-
tomy in patients with CLL showed that average life expectancy after the surgery
comprised 111.6 months within observation period between 11 and 277 months.
In patients with CLL with immune cytopenias the average life expectancy after
surgery was shorter and equal to 60.7 months within the observation period
between 2 and 361 months.
Summary/Conclusions: Splenectomy remains an effective method of treat-
ment of patients with CLL accompanied by severe splenomegaly and immune
cytopenia. Long-term results of splenectomy in patients with CLL without
cytopenia are better than in patients with CLL and cytopenias. Aggressive
hemolysis, large spleen covered in perisplenic adhesions, amid portal hyper-
tension and thrombocytopenia are considered to be special surgical risk factors
in this patients.
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MONOCLONAL B-CELL LYMPHOCYTOSIS IN THAI POPULATION:
PREVALENCE AND IMMONOPHENOTYPIC CHARACTERISTICS
P. Kongtim1,*, J. Chantakarm1, W. Limvorapitak1, N. Wanisorn2,
T. Sinthuwiwat3, W. Udomchaiprasertkul3, S. Issaragrisil4
1Hematology, 2Pathology, Faculty of Medicine Thammasat University,
Pathumthani, 3Cancer Cytogenetic and Molecular Diagnostic, Chulabhorn
Research Institute , 4Hematology, Faculty of Medicine Siriraj Hospital Mahidol
University , Bangkok, Thailand
Background: Monoclonal B-cell lymphocytosis (MBL) is characterized by the
presence of <5X109 clonal B-cells/L in peripheral blood (PB) in otherwise
healthy subjects, in the absence of symptoms and signs of a B-cell lymphopro-
liferative disorder (LPD). MBL is considered a precursor to chronic lymphocytic
leukemia (CLL) and other B-cell malignancies.
Aims: To study the immunophenotypic features and prevalence of MBL in
healthy Thai individuals.
Methods: Peripheral blood (PB) samples from 616 healthy Thai individuals
(313 female), 18-80 year-old with normal lymphocyte counts were immunophe-
notyped using high-sensitive flow cytometry, based on 5-color staining and the
screening for >5 × 106 total PB leukocytes. The initial PB samples were
screened for clonal B cells using MultiMix Triple-Color Reagent (Kappa Light
Chains/FITC, Lamba Light Chains/RPE and CD19/RPE-Cy5). In those cases
in which a clonal B cell population was detected by imbalanced of sIgK:sIgL
ratio of >3:1 or <1:3, were further tested for CD5, CD23, CD20 and CD79a
expression. 
Results: Of total 616 subjects, MBL was found in 8 cases (1.2%) including 3
and 5 female and male cases respectively. Among 40 years or older, MBL was
found in 5 out of 448 cases (1.1%). Compared with non-MBL group, subjects
in MBL group were significantly older (median age of 78 years versus 50 years;
p=0.01) and had a significant higher number of absolute and B-lymphocyte
count (median 3.1 versus 1.6 X 109/L; p=0.03 and 0.35 versus 0.16 X109/L;
p=0.02, respectively) while the median white blood cell count was not different
between 2 groups. Also, there were more subjects in MBL group who had family
history of lymphoproliferative diseases (LPD; 37% vs 0%; p<0.01) and influenza
vaccination within 2 years (50% vs 8.7%; p=0.003). Among 8 cases with MBL
clone, 6 cases had low-count MBL (<0.5X109 clonal B-cells/L) while only 2 cas-
es had high-count MBL (>0.5X109 clonal B-cells/L). All 8 cases had persistent
positivity of MBL clone after tested was repeated within 3 months after the initial
test. In the follow up test, only 1 case with initial high-count MBL had decrease
number of B cell clone and became low count MBL. There was not significant
different in age between subjects in low and high-count MBL group. Six cases
had typical CLL phenotype MBL clone (CD5+, CD23+, CD20+/dim and light
chain restriction). Whereas 1 case had atypical CLL phenotype MBL (CD5+,
CD20+ and light chain restriction but CD23-) and 1 case had non-CLL pheno-
type MBL (CD20+ but CD5-). In univariate analysis, age (RR 4.19; 95%CI 1.0-
17.7; p=0.049), absolute lymphocyte count (RR 2.76; 95%CI 1.01-4.87;
p=0.047), family history of LPD (RR 122; 95%CI 51.1-293.4; p<0.001) and
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influenza vaccination (RR 10.47; 95%CI 2.54-43.07; p=0.003) were associated
with increase risk of developing MBL. After adjusted for age, only history of
influenza vaccination and family history of LPD were an independent risk factor
for developing MBL with age adjusted RR of 9.75 (95%CI 2.3-40.5; p=0.002)
and 92 (95%CI 56.3-149.5; p<0.001), respectively.
Summary/Conclusions: MBL prevalence in Thai population is much lower
than previously reported. It more frequent in elderlies and associated with
family history of LPD and influenza vaccination. Although uncommon, the
presence of high-count MBL warrants further investigations to define the bio-
logical and clinical significance in term of LPD transformation and long-term
survival.
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SPONTANEOUS CLINICAL REGRESSION IN CHRONIC LYMPHOCYTIC
LEUKEMIA: CLINICAL AND BIOLOGIC FEATURES OF 9 CASES FROM
THE ERIC REGISTRY
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Background: Spontaneous clinical regression in chronic lymphocytic leukemia
(CLL) is rare (1% per year). We previously reported on the clinico-biologic fea-
tures of 9 Binet stage A CLL patients from our Center in Rome who experienced
a persistent spontaneous clinical regression of the disease at a median time
of 11 years from diagnosis, maintained after 5 more years of follow-up. The
lymphocyte count at CLL regression was 3.16 x 109/L (1.3-4.9), with a persistent
small CLL clone (CD19+/CD5+/CD23/light chain restricted: 44%, range 5-60%).
Biologic features included negative CD38, mutated IGHV, often with VH3-30
and Vk4-1 usage, and a distinctive gene expression profile.
Aims: To conduct a retrospective collection of clinical data and basic biologic
information on CLL spontaneous regressions and to make them accessible for
future research.
Methods: A registry of spontaneous CLL regressions (absence of lym-
phadenopathy, splenomegaly or constitutional symptoms, peripheral blood (PB)
lymphocytes <4 x 109/L, in the absence of any previous treatment) was
launched within the ERIC consortium.
Results: So far, 9 CLL patients showing a spontaneous regression have been
reported and 8 have been formally registered, 7 from Italy and 2 from Sweden.
Six were males and 3 females, with a median age of 57 years at diagnosis
(range 51-82), stage Binet/Rai A/0 in 6, A/I in 2 and B/II in 1. The median lym-
phocyte count at diagnosis was 14.1 x 109/L (5.3-51.9). Biologic features includ-
ed: mutated IGHV in 8/8 with VH3-30 (2), VH3-21, VH3-15, VH3-23, VH4-31,
VH4-34, VH4-59; CD38 <30% in 6/6; ZAP70 <20% in 4/6; FISH (7 cases):
del13q in 4, negative in 3, +12 in 1 case. No patient had undergone treatment,
except for one diagnosed in 2009 who received FCR for disease progression
in 2013 (lymphocytes 107 x 109/L), obtained a PR and 18 months later devel-
oped a Richter’s syndrome - a diffuse large B-cell lymphoma clonally unrelated
to CLL - with the concomitant disappearance of the CLL clone from the PB and
bone marrow, that has lasted up to January 2017 (lymphocytes 3.5 x 109/L,
CLL 0.035 x 109/L). An additional case diagnosed in 2013 (stage A/I, lympho-
cytes 37.2 x 109/L) reached the highest lymphocyte count 19 months later
(91.2 x 109/L) and subsequently started a spontaneous reduction in lympho-
cytosis down to 39.6 x 109/L in 2015 and to 8.9 x 109/L in January 2017 in
stage A/0, indicative of a partial but ongoing CLL regression. Excluding the
latter cases, in the other 7, all in stage A/0, the highest lymphocyte count was
16.0 x 109/L (8.9-76.0), the lowest at the last follow-up was 2.8 x 109/L (1.8-
4.4), with 0.66 x 109/L CLL cells (0.085-3.0) in the 4 evaluable cases. The
median time from diagnosis to clinical regression was 4 years (range 2-17)
and this has been maintained for 2 further years (range 0.5-7). One of these
cases (mutated VH3-21, +12) seems the most dramatic: in 2008 at diagnosis,
the lymphocytes were 51.9 x 109/L, in 2009 a peak at 76.0 x 109/L was record-
ed; in 2011, when the CLL regression started, the patient underwent several
mild viral upper respiratory infections; the CLL complete regression (1.8 x 109/L)
persists up to the last follow-up. In 5/9 cases one event - mild viral infections,
a cerebral hemorrhage, a stroke, a pelvis fracture and a Richter’s syndrome -
occurred before the spontaneous regression, but no relevant drug intake was
recorded.
Summary/Conclusions: Clinicians should be aware that spontaneous regres-
sion is a possibility, albeit infrequent, in the natural history of CLL. The collection
and study of such cases within the ERIC registry may shed light on mechanisms
leading to spontaneous regression and critical pathways in immunosurveillance
in CLL. 
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CLINICAL AND LABORATORY CHARACTERIZATION OF PLATELET
DYSFUNCTION DURING IBRUTINIB TREATMENT IN PATIENTS WITH
CHRONIC LYMPHOCYTIC LEUKEMIA. MONOCENTRIC EXPERIENCE
I. Innocenti1,*, M.A. Alberelli2, F. Autore1, S. Sica1, E. De Candia2, L. Laurenti1
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Background: Ibrutinib (IBR) is a potent and irreversible inhibitor of Bruton’s
tyrosine kinase (Btk) approved by FDA for the treatment of patients (pts) affect-
ed by chronic lymphocytic leukemia (CLL) with del 17p or TP53 mutation or for
pts with relapsed/refractory (R/R) CLL. IBR is associated with bleeding events
usually mild (Common Toxicity Criteria (CTC) grades 1-2), rarely severe (grade
3-4). A defect of platelet function, namely an inhibition of Btk-mediated signaling
by platelet glycoproteins (GP) GPVI and GPIb, has been hypothesized to cause
these bleedings. IBR associated bleedings and platelet dysfunction may be
relevant in CLL pts who are usually elderly and with comorbidities requiring
antithombotic therapies.
Aims: To investigate and characterize the effect of IBR on platelet function in
pts with CLL.
Methods: We enrolled from May 2014 to December 2016 twenty pts with
CLL treated with orally administered 420 mg daily of IBR; 18 R/R CLL pts
received IBR in monotherapy and 2 pts with previously untreated CLL
received IBR in association with anti-CD20 MoAb. Median age was 68 years
(57-84); 13 pts had unmutated IgVH and 2 had 17p deletion. The median
number of prior therapies in R/R CLL pts was 3 (2-7). Five pts discontinued
IBR therapy: 2 for Richter’s transformation, 1 for progressive CLL, 1 under-
went allogeneic HSCT, 1 for heart disease. The platelet function was studied
before and during IBR by light transmission aggregometry (LTA) using
platelet-rich plasma and the following agonists: ADP 2-4 uM, PAR1-AP 25
uM, Collagen 10-3.3-2 ug /mL, arachidonic acid 1 mM, ristocetin 0.6-1.2
mg/mL. Also measurements of von Willebrand factor antigen (vWF:Ag) and
ristocetin cofactor activities (RiCo) by chemiluminescent immunoassay were
performed. All pts had measurements of the platelet function at the baseline
and after 1, 3, 6 months initiation of IBR and then every 3 months up to 24
months. Median observation period was 9 months. No patient received con-
comitant antiplatelet or anticoagulation therapy.
Results: Nineteen pts achieved a partial response and an increase of hemo-
globin and platelet count. We recorded CTC grade 1 or 2 bleedings (bruising,
petechiae, conjunctival and retinal hemorrhage, rectal bleeding) in 15 pts; no
patient needed IBR interruption or dose reduction. All pts displayed severe
impairment of collagen induced aggregation upon IBR. Reduction of maximal
aggregation (35.6+/- 32% vs 70.6+/- 21% baseline) and prolongation of the
lag phase (261+/- 54 sec vs 72+/- 26.8 sec baseline) by 2 ug/mL collagen was
measured in all pts during IBR. In 10 pts a significant improvement of the aggre-
gation by 2 uM ADP (71+/- 31.8% vs basal 48.6+/- 31%) and 4 uM ADP (84+/-
11% vs basal 64+/- 25%) was found during IBR. The aggregation by 25 uM
PAR1-AP, 1.2 mg/ml ristocetin and 1 mM arachidonic acid was unchanged
before and under IBR. Finally, in 9 pts the vWF:Ag and RiCo were high at the
onset of the disease (163+/- 59.8% and 181.6+/- 82.5%) and reduced up to
normal values under IBR (118+/- 71% and 145+/- 65%).
Summary/Conclusions: Our study showed minor bleedings in pts treated
with IBR. A severe impairment of collagen-induced aggregation was caused
by IBR, which was counteracted by amelioration of ADP-induced aggregation,
that could explain, at least partially, the mild clinical phenotype in treated pts.
The assessment of platelet function in IBR treated CLL pts could help to predict
and monitor the bleeding risk, and to guide pts through invasive procedures.
In addition, pts under anticoagulant or antiplatelet treatment might need be
carefully monitored by clinical and laboratory evaluation.
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HAIRY CELL LEUKEMIA :A SUMMARY OF CLINICAL DATA ON 202
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Background: Hairy cell leukemia (HCL) accounts for approximately 2% of all
leukemias and is associated with pancytopenia, splenomegaly, and recurrent
infections. Therapy with the purine analogues cladribine (2CdA) or pentostatin
(2’deoxycoformycin), has been most effective and both agents have achieved
equivalent results in HCL. In this regard cladribine given as a single course,
achieves a high response rate. Several alternative dosing schedules have been
reported for 2CdA including subcutaneous (SC) or intravenous (IV) delivery,
either as a “fixed daily dose” or “weight based dose” for 5 or 7 days. Seeing that
excellent results are obtained using 2CDA in all schedules used, it now seems
very important to focus on reducing therapy induced toxicity, related mostly to
development of neutropenia, immunosupression and severe infections.
Aims: In this retrospective study, we have summarized the Israeli experience
with HCL over the past 30 years, and analyzed demographic data, relevant
laboratory and clinical parameters with special emphasis on outcome after first
line treatment with cladribine.
Methods: We collected retrospective data on patients with HCL from 12 medical
centers in Israel, followed and treated during 1985-2015. The study
was   approved l by local institutional IRBs of each medical center
Results: Data from the medical records of 202 patients with HCL was summa-
rized. Mean follow up was 7.5 years (0.1-40), with a 5 and 10 years’ overall
survival of 96% and 90.62% respectively. The median age at diagnosis was 53
years, and most (81.77%). were males. In terms of ethnicity: 88.3% of patients
were Jews with (52.2% Ashkenazi and  , 36.1%  Sephardic Jews) while d 11.7%
were Arab, Druz or others. First line therapy with cladribine was given to 159
patients (80.71%); other therapies 9.14%, while 1.1% did not receive any treat-
ment. The median time from HCL diagnosis to treatment with 2CdA was 5.9
years. IV therapy was given to 62% of patients and 38% received  it  SC. Com-
plete remission rates, progression-free survival and overall survival were not
significantly different between the two schedules. In univariate analysis: Sex,
ethnicity, dose, patient weight, and treatment duration (5-7 days) had no impact
on outcome, but patients older >65 years had a shorter survival. Infectious
complications requiring hospitalization was reported in 50.3% of all treated
patients (54%, post IV and 47% post SC delivery: p=0.4). Median days of hos-
pitalization were 8 for both groups (0-45) (p=0.55), and the length of NADIR
was 18 and 20 days for IV and SC delivery respectively (p=0.33).
Summary/Conclusions: This study is the first comprehensive summary of the
national Israeli experience involving a large cohort of HCL patients with long
follow up. These results serve as validation of previous reports relating to HCL
and confirm that the excellent outcome achieved after a single course of treat-
ment with 2CdA is  independent of schedule and method of drug delivery. In
addition, patient ethnicity was insignificant
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CHRONIC LYMPHOCYTIC LEUKEMIA: CHANGES IN CLINICAL STAGE
DISCRIMINATE PATIENTS WITH DIFFERENT OUTCOME WITHIN THE
IWCLL PARTIAL RESPONSE CATEGORY
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R. Martino1, C. Moreno1,2
1Department of Hematology, 2Laboratory of Oncology/Hematology and Trans-
plantation, Institute of Biomedical Research, IIB Sant Pau, Hospital Sant Pau,
3Department of Hematology, Hospital Parc Taulí, 4Laboratory of Hematology,
Hospital Sant Pau, Barcelona, Spain
Background: Over the last decades, progress in chronic lymphocytic leukemia
(CLL) treatment has resulted in an impressive increase in overall survival (OS).
In CLL, as in other tumors, response to therapy overcomes negative prognostic
factors and is the most important predictor of survival. Clinical stages reflect
tumor load and correlate with OS both at diagnosis and over the course of the
disease (Rai et al, Blood 1975).
Aims: To determine whether changes in clinical stage discriminate patients
with different outcome within IWCLL response categories, particularly the het-
erogenous partial response (PR) group (Hallek et al, Blood 2008).
Methods: Two-hundred twenty-nine patients with CLL were retrospectively
evaluated. Median follow-up was 91 months (range, 2-390). CLL diagnosis was
based on IWCLL criteria. Endpoints were time to next treatment (TTT) and OS.
TTT and OS curves were estimated by the Kaplan-Meier method and differ-
ences were evaluated with the log-rank test. Response to therapy was deter-
mined according to IWCLL recommendations and by changes in clinical stage
A landmark analysis was performed in ninety-two patients in whom a PR was
achieved at any time during the course of the disease, using the time when a
PR was achieved as “time 0”.
Results: From the whole series of 229 patients, those who achieved a better
IWCLL degree of response after first line of therapy had a better OS than those
with an inferior response (p<0.001). With a median follow up of 91 months
(range, 2-390), the median survival in patients who achieved complete remis-
sion (CR) was 214 (95% CI: 123-305) vs 134 (95% CI: 79-189) and 91 (95%
CI: 84-98) months in those who achieved PR and failed to therapy, respectively
(Figure 1.A). Among patients in PR (n=66), after a median follow-up of 42.5
months (range 1-201), those patients with stage A disease at the time of
response evaluation (PR Binet A) had significantly better outcome than those
whose stage was Binet B/C (median survival 63 vs 43 months; p= 0.047). Inter-
estingly, when the analysis was restricted to response assessment after first
line therapy (n=229), patients who achieved PR Binet A did not have significant
differences in OS compared to those patients who were in CR (median survival
were 164 and 214 months respectively; p<0.001); on the contrary, patients in
PR Binet B/C had a similar outcome than those who did not respond to treat-
ment (median survival 81 and 91 months respectively) (Figure 1.B). Similar
results were observed in the outcome of patients with PR subclassified accord-
ing to Rai clinical stage.
Figure 1.
Summary/Conclusions: Changes in clinical stage provide reliable information
on the degree of response to therapy in patients with CLL, particularly those in
the IWCLL PR category.  This study supports the use of clinical stages as a
complementary and simple  tool to assess response in patients with CLL, both
at the end and over the course of treatment.
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INCIDENCE OF THYROID GLAND DISORDERS IN PATIENTS WITH
CHRONIC LYMPHOCYTIC LEUKEMIA
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Background: Frequency of autoimmune complications like immune anemia
or immune thrombocytopenia has increased in patients with chronic lymphocytic
leukemia (CLL). However, there is no data in the literature investigating the
relation of the other autoimmune disorders including thyroid gland diseases
with CLL.
Aims: We aimed to investigate the presence, features and frequencies of thy-
roid disorders in patients with CLL.
Methods: Thyroid function tests, thyroid autoantibodies (antithyroglobulin anti-
body [anti-TG], antithyroid peroxidase antibody [anti-TPO]), thyroid ultrasono-
graphies (USG) and scintigraphies of CLL patients were performed. Demo-
graphic data, Rai-stages, and established thyroid disorders were recorded.
Results: One hundred CLL patients were included into the study (65 male,
mean age was 62,9±10,4). Free T3 (fT3) was within normal limits in 96 cases
(96%), was low in 2 cases (2%), was high in 2 cases (2%); free T4 (fT4) was
normal within normal limits in 89 cases (89%), was low in 7 cases (7%), was
high in 4 cases (4%).TSH was within normal limits in 90 cases (90%), was low
in 7 cases (7%), was high in 3 cases (3%). Anti-TPO and anti-TG were positive
in 10 cases (11.8%) and in 18 cases (21.2%), respectively. While USG was
normal in 36 cases, multinodular goiter (MNG) in 21, chronic thyroiditis in 20,
MNG associated with thyroiditis in 10, uninodular goiter (UNG) in 8, UNG asso-
ciated with thyroiditis in 4, and diffuse goiter in 1 case were determined by
USG. Toxic adenoma in 3 cases, toxic MNG in 2 cases, and thyroiditis in 1
case were determined in 6 patients in whom thyroid scintigraphy was performed
for hyperthyroidism. After evaluation of all the tests; while no thyroid disease
was determined in 33 of the cases (33%), MNG in 25 (25%), thyroiditis accord-
ing to the results of USG in 12 (12%), UNG in 11 (11%), Hashimoto thyroiditis
in 9 (9%), toxic MNG in 3 (3%), subclinical hyperthyroidism in 3 (3%) cases,
subclinical hypothyroidism in 1 case (1%), lymphocytic thyroiditis in 1 case
(1%), toxic UNG in 1 case (1%), and euthyroid sickness syndrome in 1 case
(1%) were determined. The patients were divided into 2 groups according to
their Rai-stages and ages. Accordingly; Rai-stage 0 - I - II (n=80) and Rai-stage
III - IV (n=20), <65 years (n=56) and ≥65 years (n=44). Anti-TPO positivity was
similar in 2 Rai-stages groups and in both sexes (p=0,999, p=0,167, respec-
tively). Anti-TG positivity was also similar in 2 Rai-stages groups and in both
sexes (p=0,507, p=0,223, respectively). However, anti-TPO positivity was sta-
tistically different between age groups; anti-TPO was positive in 3 patients in
<65 years old age group, and was positive in 7 patients in ≥65 years old age
group (p=0.049). Anti-TG was positive in 7 patients in <65 years old age group,
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and was positive in 11 patients in ≥65 years old age group (p=0.053). There
was not a statistically difference in thyroid function tests according to the Rai-
stages, ages and sexes.
Summary/Conclusions: We determined that incidence of hypothyroidism or
hyperthyroidism associated with all reasons do not increase in patients with
CLL when compared with general population. However, we also determined
that the incidence of Hashimoto thyroiditis was higher than general population
(incidence of Hashimoto thyroiditis in general population is 2-5%). Anti-TG pos-
itivity was also higher than general population (positivity of anti-TG in general
population is 5-20%). In addition, the positivity of 2 antibodies increased with
advanced ages. Patients with CLL -especially the elderly cases- in both sexes
and in all Rai-stages should be examined for thyroid gland disorders, mainly
for Hashimoto thyroiditis.
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S. Sachanas1,*, G. Pangalis1, M. Moschogiannis1, C. Kalpadakis2,
M. Angelopoulou3, C. Kyrtsonis3, V. Bartzi3, X. Yiakoumis1, E. Koulieris1,
P. Tsirkinidis1, M. Psyllaki4, H. Papadaki4, P. Korkolopoulou5, D. Rontogianni6,
T. Vassilakopoulos3
1Hematologic, Athens Medical Center,Phychikon Branch, Athens, 2University
Hospital, University of Crete, Heraklion, 3Hematologic, Laikon General Hospital,
University of Athens, Athens, 4Hematologic, University Hospital, University of
Crete, Heraklion, 5Pathology, Laikon General Hospital, University of Athens,
6Pathology, Evangelismos General Hospital, Athens, Greece
Background: Studies of B-SLL published to date have included heterogeneous
groups of patients(pts) and did not use modern diagnostic criteria, or included
pts who had in fact chronic lymphocytic leukemia. Outside the context of clinical
trials, SLL pts are treated heterogeneously and thus there are no data con-
cerning the impact of different treatment approaches on response and survival.
In the updated WHO classification it is pointed out that there are a subset of
cases with lymph node(LN) involvement by SLL in which proliferation
centers(PCs) were not observed and pts in whom lymphadenopathy was <1.5
cm showing a better prognosis
Aims: To: a)record clinical, biological features and treatment strategy in a
series of SLL pts diagnosed in our centers b)correlate clinicopathological char-
acteristics and treatment with response and survival c)detect possible differ-
ences in terms of response and survival between SLL pts according to  LN
characteristics (size of LN and presence of PCs)
Methods: Pts diagnosed with SLL from 2007 up to now fulfilling the diagnostic
criteria of SLL according to the 2008 WHO classification were included. Clinical
and biological data were recorded at diagnosis as well as treatment related
variables, such as type of treatment, response and patient survival. Moreover,
LN features such as the size, and the presence of PCs were also studied.  PCs
were evaluated in hematoxylin and eosin sections and defined as pale areas
containing prolymphocytes and paraimmunoblasts, surrounded by a dark back-
ground of small lymphocytes. 
Results: 47 pts were analysed. Pts’ median age was 69y (range, 40–87) with no
gender predominance (24male/23female). According to Binet staging system 12,
19 and 9 were classified as A, B and C stage respectively while according to Ann
Arbor system 42(89%) had advanced disease stage. 11 pts presented with bulky
lymphadenopathy, 11 had splenomegaly and 4 had B-symptoms. LN biopsies
were performed in 37 out of 47 pts. All pts underwent bone marrow (BM) biopsy
with a median BM infiltration of 45% (0-97%). PCs were identified in 19 out of 24
pts in whom data were available, while 31 pts were presented with LN >1,5 cm
as measured in CT. The estimated 10 y -OS was 60% while median TFS was
5,3 mos. Age and ECOG performance status were the only parameters that were
statistically significant in terms of survival (p=0,019 and p=0,013 respectively).
Pts with LN<1,5cm and pts in whom there were no detectable PCs tended to
have better survival. 24 pts (51%) were in need of therapy and most of them
were treated with mild immunochemotherapy [13 received Rituximab(R)-Chlo-
rambucil(Chl), 3 RCVP, 2FCR, 1RBendamustine, 2 Chl, 2R as monotherapy and
1 received corticosteroids].23 pts were assessable for response and among them
4 entered CR,17 PR and one had stable disease.
Summary/Conclusions: Outside the context of clinical trials SLL pts were
treated mostly with lymphoma immunochemotherapeutic protocols while mild
treatment approaches resulted in significant responses. LN features such as
size and presence of PCs tended to have prognostic significance. Further
analysis in larger series of pts is on the way.
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Background: Chronic lymphocytic leukaemia (CLL) is the most common
leukemia in Western Countries, with a median age at diagnosis between 67
and 72 years. The therapeutic landscape of CLL is changing rapidly with the
advent of small molecules acting as B-Cell Receptor (BCR) signaling inhibitors.
In this setting, long term oral therapy may lead to the reduction in compliance,
with a possible impact on effectiveness. Moreover, long-term follow-up may
highlight complications, such as drug-related adverse events that, together
with the disease itself, may impact quality of life (QoL). Patient Reported Out-
comes (PROs) in daily clinical practice is a resource-intensive procedure and
may be affected by low adherence, risk of recall bias and difficulties in estab-
lishing reproducible procedures. HemInsight, a project conceived in 2010 for
myeloproliferative neoplasms in haematological centres in Denmark, enables
patients to periodically submit PROs online to be combined to the medical
records. 
Aims: HemInsight was implemented at our Centre to collect PROs from CLL
patients in daily practice. 
Methods: HemInsight incorporated the EORTC QLQ-C30, EORTC QLQ-CLL
16, SF-36, and  the eight-item Morisky Medication Adherence Scale (MMAS-
8) questionnaires to collect PROs and their changes during various stages of
CLL (diagnosis - progression – treatment). PRO assessments were scheduled
for the patients who received regular reminders by email to complete the tasks.
The following measurements will be assessed: system attraction (percentage
of CLL patients adhering to the project); patient compliance in filling out ques-
tionnaires; system efficiency (number of alerts related to QoL worsening and
number of questionnaires not submitted) and system effectiveness (significant
differences in changes in QoL scores from diagnosis to response/relapse,
changes of therapeutic approach/action following an alert, changes in adher-
ence of therapy).
Results: At the time of the present report, 74 patients with a CLL diagnosis
have been enrolled, 15 of whom were newly diagnosed. Fourteen patients
underwent cytoreductive therapy and 2 are under treatment with novel oral
drugs. System attraction: the study was proposed to 91 consecutive patients,
independently of age, level of education and internet accessibility, and 72.5%
of patients agreed to participate to the study. The main reason of refusal was
older age and scant internet/technology knowledge. In 3 cases with no access
to internet, but with interest to participate in the project, the questionnaires
were administrated through tablet, before the scheduled visit, by a dedicated
nurse. Patient compliance: a global response of 58.2% was observed; 48
patients responded at least once and 23 at all scheduled time points. In each
case, all questionnaires were fully completed. At this timepoint we cannot
yet evaluate system effectiveness as the study is still ongoing. However, ad
interim data (Table 1) suggest that patients who interrupt questionnaires ful-
filling are those with younger age, more intense working activity and experi-
encing no changes in disease status (e.g. untreated cases or those in remis-
sion). In particular, patients who were under treatment during the question-
naire administration period, showed a higher adherence compared to those
in follow up, both previously treated or not (80% versus 26%, p<0.05).
Table 1.
Summary/Conclusions: In conclusion, HemInsight is a useful tool for QoL
evaluation in CLL patients. Provisional data suggest a higher compliance of
those patients who feel that they need a closer contact with the clinician, both
for individual disposition or disease status.
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HEALTHCARE COST OF MEDICARE PATIENTS WITH PREVIOUSLY
TREATED CHRONIC LYMPHOCYTIC LEUKEMIA
C. Reyes1,*, G. Gauthier2, L. Schmerold3, A. Guerin2
1Genentech, Inc., San Francisco, United States, 2Analysis Group, Inc., Mon-
treal, Canada, 3Analysis Group, Inc., New York, United States
Background: Chronic lymphocytic leukemia (CLL) is the most prevalent form
of leukemia in adults in western countries, accounting for 20% to 30% of all
leukemia cases. CLL affects mainly elderly patients, with a median age at the
time of diagnosis reported to be 71 years. Although CLL is not curable, disease
symptoms and progression may generally be controlled with adequate phar-
macologic treatments. Bendamustine-based regimens have long time been
used in the management of CLL patients but few studies have analyzed the
comorbidity- and/or adverse event (CAE)-related healthcare costs in elderly
patients receiving these regimens in a real-world setting.
Aims: To describe all-cause and CAE-related healthcare costs of elderly
patients with CLL treated with a bendamustine-based regimen in second or
later lines of therapy in a real-world setting.
Methods: A retrospective cross-sectional cohort study design was used. Adult
patients who received a bendamustine-based regimen in second or later lines
of therapy on or after January 2010 were identified from the Medicare Limited
Data Set (LDS) 5% Standard Analytic Files (data availability: 1999–2014). The
index date was defined as the initiation date for the first of the studied ben-
damustine-based regimens. Selected patients were required to be continuously
enrolled in their Medicare plan for ≥6 months before and ≥3 months after the
index date – unless the patient died during the first 3 months after the index
date. Patient cohorts were determined based on the treatment initiated on the
index date (index treatment); the two most prevalent bendamustine-based reg-
imens were analyzed, i.e., (1) bendamustine and rituximab in combination (BR
cohort) and (2) bendamustine monotherapy (bendamustine cohort). Healthcare
costs, including inpatient, emergency room, outpatients and CLL-drug costs,
incurred while treated with the index treatment were described for each cohort.
For each medical cost component, all-cause and CAE-related costs were sum-
marized. Healthcare costs were adjusted for inflation (2016 USD) and reported
per-patient-per-month (PPPM). 
Results: A total of 275 patients were included in the BR cohort and a total of
100 patients in the bendamustine cohort. Most patients (61,8% in the BR cohort
and 65,0% in the bendamustine cohort) were male and the mean age was
approximately 75 years old. During the 6 months prior to the index date, patients
in the BR and bendamustine cohorts were similar in terms of commorbidity
profile; mean Charlson comorbidity index was 3.53 in the BR cohort versus
3.66 in the bendamustine cohort (p=0.580). During treatment, total all-cause
healthcare costs were  $14,520 PPPM for the BR cohort and $13,125 PPPM
for the bendamustine cohort – outpatient costs (mainly driven by CLL-drug
costs) represented the largest cost component. CAE costs accounted for a rel-
atively large portion of the total all-cause healthcare costs; 58.3% for the BR
cohort and 66.9% for the bendamustine cohort. 
Summary/Conclusions: In this population of elderly patients previously treated
for CLL, healthcare costs incurred during relapsed treatment with bendamustine-
based regimens were high and a large portion of the costs were driven by comor-
bidity and/or adverse event-related costs. Results also suggest that the addition
of rituximab to bendamustine does not appear to be a major cost factor. 
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THE ROLE OF MAINTENANCE THERAPY IN THE TREATMENT OF
PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
A. Kuvshinov1,*, S. Voloshin1, I. Martynkevich1, A. Garifullin1, E. Kleina1
1Russian Scientific Research Institute of Hematology and Transfusiology, Saint-
Petersburg, Russian Federation
Background: The inclusion in the treatment program of new drugs (including
new monoclonal antibodies and targeted therapies) allowed the majority of
patients with chronic lymphocytic leukemia (CLL) to achieve disease remission
(complete or partial) after combined therapy. So, at now, the urgent task is long-
term preservation and the deepening of the therapeutic response, if it is possible.
This problem can be solved by intensification of therapy (including autologous
transplantation of hematopoietic stem cells) or maintenance therapy (MT).
Aims: To estimate the importance of maintenance therapy in the treatment of
patients with CLL.
Methods: The study included 198 patients. Male to female ratio - 1.3:1. We have
used NCI revised guidelines (Hallek M, et al., 2008) for treatment initiation,
assessment of response and minimal residual disease (MRD). Induction
chemotherapy was conducted under the following programs: RB, FC, RFC, R-
CHOP, Ibrutinib-RB, Ibrutinib-R. Evaluation of MRD was performed using 5-color
flow cytometry of the bone marrow cells. The maintenance therapy was conducted
144 (72.7%) patients: Rituximab 500 mg/m2 intravenously every 8 weeks (n=116)
for 2 years; Ibrutinib 420 mg, orally, daily (n=28) continuously. The remaining
patients (n=54) were under dynamic observation without therapy.
Results: The increasing the depth of response (from partial (PR) to complete
remission (CR)) was observed only in group of patients receiving MT – 10.4%
(15/144) (p=0.013). The frequency of increase the depth of remission in the
patients treated with MT of Ibrutinib was 28.6% (8/28), MT of Rituximab – 6.0%
(7/144) (p=0.0005). The medians of PFS and duration of response were a
longer in the patients with MT versus in the patients without MT: PFS – 48
months and 37 months, respectively (p=0.03); duration of response – 44.0
months and 25.5 months, respectively (p=0.0006). The median of duration of
response in the patients with MT of Ibrutinib was not reached, in the patients
with MT of Rituximab – 41.9 month, in the patient without MT – 25.5 month
(p=0.004). The frequency of relapses in the group of patients with MT was
39.6% (57/144), in the group of patients without MT – 66.7% (36/54) (p=0.0007).
Recurrence of the disease occurred more frequently in the group of patients
treated with MT of Rituximab, compared with Ibrutinib: 45.7% (53/116) and
14.3% (4/28), respectively (p=0.002). The median duration of observation in
the group with rituximab was 22 months, while in the group with Ibrutinib – 11
months. MRD was not detected after 6-12 months of MT in 23.5% (12/51) had
previously MRD-positive patients. Among patients with MRD-negative CR
relapse is less common than in patients with MRD-positive CR – 20.0% (4/20)
versus 62.5% (10/16), respectively (p=0.009). Significant differences in the inci-
dence of infectious complications between patients with MT and without of MT
were not detected (p˃0.05) (Figure 1).
Figure 1.
Summary/Conclusions: The conducting of MT patients with CLL allows to
achieve increasing the depth achieved remission and increase the duration of
its preservation. MT may be a means of control over the minimal residual dis-
ease and the method of its eradication
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MULTISITE PERFORMANCE EVALUATION STUDY OF THE BD ONEFLOW
LYMPHOID SCREENING TUBE
B. Balasa1,*, C. Green2, J. Kendall2, D. Gladding2, C.J. Fox2, D. Van Hoof2,
V. Fraser2, A. Doherty3, D. Tielemans4, L. Wolfe5, K. Judge2
1Medical Affairs, 2BD Biosciences, San Jose, United States, 3BD Biosciences,
Oxford, United Kingdom, 4BD Life Sciences, Erembodegem, Belgium, 5BD
Clinical Corporate Clinical Development, Sparks, Maryland, United States
Background: The BD OneFlow solution for diagnostic screening of chronic lym-
phoproliferative disorders (CLPDs) includes a standardized flow cytometry
approach based on the EuroFlow (EF) Consortium liquid reagent system. The
BD OneFlow solution enables reproducible identification and discrimination of
normal from aberrant mature cell populations by combining standardized assays,
setup reagents, and protocols. The BD OneFlow LST (Lymphoid Screening Tube)
is intended for flow-cytometric immunophenotyping of normal and aberrant mature
lymphocyte populations of B, T, and NK lineages in specimens (peripheral blood,
bone marrow, and lymph node) from patients with hematological disorders. BD
OneFlow LST acquisition and analysis template version 1.0 was revised to version
2.0 to include determination of lymphocytes as a percentage of total leucocytes.
The FCS files from evaluable specimens of the original LST clinical trial were
regressed using BD OneFlow LST template v2.0.
Aims: The objective of this study was to regress the FCS files from all the
evaluable specimens previously collected using LST template v1.0 in the orig-
inal clinical study to demonstrate equivalency between the investigational BD
OneFlow LST system and the comparator EF liquid reagent system on a BD
FACSCanto II flow cytometer with the 4-2H-2V CE-IVD configuration and LST
template v2.0.
Methods: The FCS files using LST v1.0 template from the original clinical study
included de-identified remnant peripheral blood (n=123), bone marrow (n=53),
and lymph node (n=31) specimens from patients and healthy donors. Specimens
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were collected in EDTA or heparin anticoagulants or PBS (for lymph nodes) at
three external study sites. Informed consent was not required in this clinical study.
All specimens in the original study were simultaneously stained with investiga-
tional BD OneFlow LST and comparator EF liquid reagents within 24 hours of
collection and were acquired within 60 minutes of staining. In the current study,
analyses were performed on a BD FACSCanto II instrument using LST v2.0 tem-
plate with BD FACSDiva software v8.0.1. For primary endpoints, specimens were
categorized as normal or follow-up needed. If follow-up was needed, specimens
were categorized as B-, T-, NK-, or other-cell lineage. Overall agreement, nega-
tive agreement, and positive agreement, along with their one-sided lower 95%
confidence limits, were calculated. For quantitative (percent) comparison of
defined cell populations, Deming regression (slope and intercept analysis) was
performed between the BD OneFlow method and the EF method.
Results: The BD OneFlow LST system compared to the EF system gave 100%
(207 of 207) overall agreement (lower 95% CI: 98.6%) in delineating patients
into normal (no follow-up) or follow-up, and 100% overall agreement in identi-
fying the B-, T-, NK-, and other-cell lineages (lower 95% CI: 98.6%). There
was 100% positive agreement and 100% negative agreement between BD
OneFlow and EF for follow-up vs no-follow-up (normal) and for all cell lineages
from specimens that required follow-up. Furthermore, compared to the EF sys-
tem, the BD OneFlow LST system met the acceptance criteria for the quanti-
tative assessment (Deming regression) of the defined cell populations.
Summary/Conclusions: The multisite performance evaluation of the BD One-
Flow LST system and the comparator EF liquid reagent system was concordant
in identifying abnormal from normal mature populations in patients with CLPDs.
BD OneFlow LST is for in Vitro Diagnostic Use; CE Marked to the European In
Vitro Diagnostic Medical Device Directive 98/79/EC. 23-19566-00.
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IMMUNOGLOBULIN HEAVY/LIGHT CHAIN ASSAY DETECT IMMUNE
DYSREGULATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC
LEUKEMIA
L. Magal1, A. Braester2, D. Najib3, A. Aviv4, Y. Herishanu5, M. Yuklea6,
L. Shvidel 7, N. Rahimi-Levene8, R. Ruchlemer9, A. Arad10, A. Polliack10,
T. Tadmor11,*
1Almog Diagnostic, Park Shoham, 2Hematology Unit, Galilee Medical Center,
Naharia, 3Hematology Unit, Ziv Medical Center, Zefat, 4Hematology Unit,
Haemek Medical Center, Afula, 5Department of Hematology, Sourasky Medical
Center, Tel Aviv , 6Hematology Unit, Meir Medical Center, Kfar Saba, 7Hema-
tology Unit, Kaplan Medical Center , Rehovot, 8Hematology Unit, Assaf Harofeh
Medical Center, Zerifin, 9Department of Hematology, Shaare Zedek Medical
Center, 10Department of Hematology, Hadassah University Hospital,
Jerusalem, 11Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel
Background: Chronic lymphocytic Leukemia (CLL) is frequently accompanied
by immune dysregulation. Hypogammaglobulinemia is the most important asso-
ciated immune defect and all three classes of immunoglobulins (IgG, A and M)
are involved. Recently, a novel assay for detecting heavy/light chain (hevylight)
and their ratios has been described (HLC), which improves immunoglobulin
detection and monitoring in plasma-cell dyscrasias by quantitating the different
light chain types of each immunoglobulin class. The frequency and biological
role of this assay has as yet not been studied in CLL.
Aims: To study the frequency of abnormal Heavy Light chain assay, in CLL
patients. 
Methods: This is an observational, multi-center study performed in collabora-
tion with the Israeli CLL Study Group involving 10 medical centers in Israel.
The cohort included patients with CLL as well as healthy volunteers. All patients
studied had complete clinical database available and all medical records were
examined and then summarized. Serum samples were analyzed for levels of:
IgG1, IgG2, IgG3, IgG4. Isoforms of heavy/light chain: IgG kappa, IgG lambda,
IgA kappa, IgA lambda, IgM kappa, IgM lambda and Free light chain: kappa
(K) and lambda (L), ratio of K/L and calculation of ratios of monoclonal/poly-
clonal immunoglobulin (HLC ratio).
Results: The total cohort consisted of 126 “treatment - naïve”, patients with
CLL and 26 healthy volunteers. Median age was 64 years, 64% were males
and 78% had Binet stage A, while 19% and 3% were stages B or C respectively.
Significantly reduced levels of immunoglobulins associated with lambda chain
(IgG-L, IgA-L and IgM-L) were identified in CLL patients compared to healthy
controls (p value of 0.001, 0.005 and 0.001 respectively). Abnormal IgG-lambda
values were evident in 15 patients (10%) and associated with more pronounced
leucocytosis (p=0.005), higher B2mg levels (p=0.022) and the presence of 17p
deletion (0.028). IgA and IgM lambda were abnormal in 38% and 56% of cases
respectively compared to 8 and 9% in the controls. For IgG subclasses: both
IgG2 and IgG4 levels were significantly lower in CLL patients than in healthy
controls (p= 0.001 and p<0.01 respectively). In addition , IgG2 and IgG4 were
also confirmed to be significantly lower in CLL patients than in  controls
(p<0.001), while abnormal IgG2 levels were associated with more advanced
Binet stage and elevated LDH levels. Abnormal lambda FLC was observed 26
(21%) patients and only in one (4%) healthy control. Abnormal free light chain
ratio (FLC) was present in 39 patients (32%), with a mean value of 4.22 (0.11-
62.15) while only 1 (4%) was observed in healthy controls (mean value of 1.76
(0.25-2.3)) and was also associated with more advanced Binet stage and ele-
vated LDH (p=0.003.).
Summary/Conclusions: CLL cells may produce light chains, or as shown
here abnormal intact immunoglobulins (heavy and light chains). HLC levels
were associated with advanced stage and adverse prognostic parameters.
These findings  lend support for the considerable potential of the HLC assay
in the evaluation of clinical status in patients with CLL
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INFLUENCE OF TREATMENT ON CONCENTRATION OF CYTOKINES IN
BLOOD OF PATIENTS WITH HAIRY CELL LEUKEMIA
N. Pelenyo1,*, V. Barilka1, V. Matlan2, O. Danysh1, Y. Vygovska1, Z. Maslyak1,
O. Shalay1, V. Loginsky1
1SI “Institute of Blood Pathology and Transfusion Medicine NAMS of Ukraine”,
2Danylo Halytsky Lviv National University, Lviv, Ukraine
Background: A pathogenic role and prognostic value of cytokines in treatment
of patients (pts) with hairy cell leukemia (HCL) are not finally established.
Aims: to define the concentration of cytokines such as TNFα, IL-6, sIL-2R,
TGFβ1 in serum of HCL pts before and after treatment with IFNα or 2-CdA and
to estimate the relationship with blood count indexes in HCL pts.
Methods: The study group consisted of 26 primary pts with the classic variant
of HCL (median age - 47 years). A control group consisted of 12 healthy persons
(median age - 50 years). The concentration of cytokines was measured using
a validated commercial ELISA kits.
Results: Median of TNFα content in serum of HCL pts before treatment was
substantially lower (3.57 pg/ml) than in healthy persons (8.56 pg/ml; р=0.275),
however treatment with IFNα or 2-CdA did not influence TNFα level. Median
of TGFβ1 concentration in serum of HCL pts was also significantly lower, than
in healthy persons (265.52 and 1568.22 pg/ml respectively; р=0.0004). Reliable
increase of TGFβ1 concentration was observed only after 2-CdA therapy
(928.33 pg/ml; р=0.281). Cross-correlation relationship was revealed between
the TGFβ1 concentration and the level of haemoglobin (τ=0.23; р=0.1) as well
as with leucocyte count in HCL pts (τ=0.24; р=0.09). Median of IL-6 content in
serum of HCL pts before treatment was higher, than in healthy persons. Ther-
apy with IFNα or 2-CdA reduced IL-6 level to the control values. Certain cross-
correlation relationships were revealed between the IL-6 level and percentage
of lymphocytes in bone marrow (τ=0.35; р=0.01) as well as amount of lympho-
cytes in peripheral blood of HCL pts (τ=0.24; р=0.09). Median serum concen-
tration of sIL-2R (24.73 ng/ml) in HCL pts more than 20-fold exceeded such in
control group (1.15 ng/ml; р=0.0000005). Cross-correlation relationship was
revealed between the percentage of hairy cells in bone marrow and sIL-2R
level in serum (τ=0.27; р=0.08). Obtained results may be an evidence of pre-
dominant secretion of sIL-2R by tumor cells in HCL pts.
Summary/Conclusions: New data regarding pathogenetic relationship between
production of certain cytokines and features of hematopoiesis in HCL pts was
obtained. Between the blood level of some cytokines in HCL pts and efficiency
of 2-CdA treatment a reliable relationship was revealed, which is possible to use
for prediction of clinical course of this disease. Moreover sIL-2R level in blood
possibly can serve as a marker of tumour activity in classic type of HCL.
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PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS
WITH CHRONIC LYMPHOCYTIC LEUKEMIA – CLINICAL BENEFITS OF
ACHIEVING A DEEP RESPONSE TO FIRST-LINE THERAPY 
J. Samp1,*, A. Guerin2, R. Foster3, B. Meissner1, A. Rokito3, S.H. Enschede1,
G. Gauthier2
1AbbVie, Inc., North Chicago, United States, 2Analysis Group, Inc., Montreal,
Canada, 3Analysis Group, Inc., New York, United States
Background: In recent years, there have been advances in the treatment of
CLL with the approval of several novel oral agents that show improvement in
PFS and OS. Additionally, some agents induce a deep response indicated by
complete remission (CR) and/or minimal residual disease negativity (MRD-).
However, there is limited information on the longer-term clinical benefits of
achieving a deep response in a real-world setting.
Aims: This study aimed to characterize PFS and OS for patients who achieved
a deep response to first-line therapy for CLL.
Methods: Patient-level data were collected between July and August 2016
from 93 oncologists/hematologists in the United States. Oncologists/hematol-
ogists provided patient level clinical data obtained from patient charts among
CLL patients who initiated first-line therapy for CLL between January 2010 and
December 2014. Selected patients were categorized into 2 cohorts based on
their best response: patients who achieved CR and patients who did not
achieve CR (non-CR). The non-CR cohort included patients with partial remis-
sion (PR), stable disease (SD) and progressive disease (PD). iwCLL 2008 cri-
teria were provided to guide physicians’ assessment of treatment response.
The target sample size for each response type was a priori determined based
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on distribution of response in clinical trials. Data on disease progression and
mortality was provided by the treating oncologist/hematologist. PFS and OS
were compared using univariate and multivariate Cox proportional analyses
between the CR and non-CR cohorts (OS multivariate analyses were not con-
ducted due to the small number of events). An additional analysis was con-
ducted to examine the benefits of achieving MRD- versus not achieving MRD-
among patients who achieved CR or PR. 
Results: Data was collected on 330 CLL patients, including 179 patients in the
CR cohort and 151 patients in the non-CR cohort (120 patients with PR, 25
with SD, and 6 with PD). Most patients were male, in their early sixties, and
had an ECOG status of O/1 at the time of initiating first-line therapy. The median
observation period was approximately 30 months. There were 43 (24%) patients
in the CR cohort and 75 (50%) patients in the non-CR cohort who
progressed/died (Table 1). Patients in the non-CR cohort had an >2-fold higher
hazard of progression/death (adjusted hazard ratio [HR]=2.30, p<0.05) and
death (unadjusted HR=2.61, p<0.05) compared to patients in the CR cohort.
Among patients who achieved CR or PR, 84 patients achieved MRD- and 62
patients did not; 14(17%) patients who achieved MRD- and 27 (44%) patients
who did not achieve MRD- progressed/died. Patients who did not achieve MRD-
had an over three-fold higher hazard of progression/death compared to patients
who achieved MRD- (adjusted HR=3.75, p<0.05). No death events were
observed among patients who achieved MRD- while 4 (6%) events were
observed among those who did not achieve MRD-.
Table 1.
Summary/Conclusions: Findings from this real-world study suggest that
achieving CR is associated with improved PFS and OS compared to patients
who do not achieve CR. Furthermore, significantly better outcomes were
observed in patients who achieved MRD- compared to those who did not
achieve MRD- but still achieved CR or PR. This suggests that deep response
may be an important clinical parameter to consider in the treatment of CLL.
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ANTI-CD ANTIBODY MICROARRAY FOR MORPHOLOGY EXAMINATION
OF CIRCULATING LEUKEMIA AND LYMPHOMA CELLS
S. Kuznetsova1,2,*, A. Khvastunova1, A. Zakirova1, O. Fedyanina12,
1Centre for Pediatric hematology, oncology and immunology, 2Centre for the-
oretical problems of physico-chemical pharmacology, Moscow, Russian Fed-
eration
Background: Matching the morphology with immunophenotype for individual
leukocytes is a major issue in diagnostics of leukemia and lymphoma due to
the absence of a method for simultaneous cluster of differentiation surface anti-
gen detection and full leukocyte morphology analysis. This problem can be
solved by using a leukocyte-binding antibody microarray. 
Aims: We describe an anti-CD antibody microarray on a transparent support
for leukocyte sorting and a method for preparation of the microarray-bound
cells for high-resolution morphology analysis. The aim of the work was to
demonstrate, that the leukocyte binding is highly specific and that the microar-
ray-bound peripheral blood mononuclear cells both from healthy donors and
patients with B-cell leukemias and lymphomas are morphologically identical to
the same cells in blood smears.
Methods: Anti-CD antibodies were immobilised on plastic coverslips in spots
2 mm in diametre. In order to study the peripheral blood mononuclear cells
(PBMC) the mononuclear fraction separated by density gradient from peripheral
blood are incubated with the microarray in non-mixing conditions at 4 0C. After
the unbound cells are washed away the microarray-bound cells are dried in a
cytocentrifuge and stained after May-Grünwald-Giemsa for morphology exam-
ination. Using this technique we have studied the PBMC from 55 healthy donors
and 77 patients with different leukemias and lymphomas: chronic lymphocytic
leukemia (CLL, 37 patients), hairy cell leukemia (HCL, 22 patients), splenic
marginal zone lymphoma (SMZL, 7 patients), mantle cell lymphoma (MCL, 2
patients), follicular lymphoma (FL, 1 patient), 5 patients with multiple myeloma
(MM), 2 patients with large granular lymphocytic (LGL) leukemia and one patient
with acute myeloid leukemia (AML M2). 
Results: Nonspecific cell binding both inside and outside the spots is below
5%. Due to the non-mixing incubation the density of the cells bound to an anti-
CD antibody permits to determine the proportions of cells positive for the corre-
sponding CD antigen with high correlation with flow cytometry. The patterns of
the binding densities of the anti-CD-captured PBMC for CLL, HCL and SMZL
patients clearly differ both from those for normal PBMC and from each other
and agree well with the reported immunophenotypes of corresponding neoplastic
cells. Both normal and pathologic microarray-bound PBMC after the proprietary
drying procedure are morphologically identical to the same cells in a smear. In
cases when pathologic cells are morphologically and/or cytochemically distinct,
the anti-CD antibody microarray permits to determine their percentage and
immunophenotype by analysing the relative amount of these cells captured by
the antibodies against all the CD antigens. The results of such analysis of neo-
plastic PBMC for the patients with leukemias and lymphomas agree with flow
cytometry results for the same patients including expression of CD2 in HCL,
CD2 and CD11c in CLL, CD56 in MM. The amount of hairy cells determined
morphologically on the microarray varied from 20 to 97 of all anti-CD19-captured
cells and 2 to 80% of all lymphocytes and was in good agreement with the per-
centages of cells with CD19/CD103 and CD19/CD11c coexpression determined
in the peripheral blood of the same patients by flow cytometry.
Summary/Conclusions: The microarray works as a “sorted smear” with cells
positive for certain surface CD antigens localised in a predetermined area and
permitting to apply any standard smear-oriented technique to the microarray-
captured cells. Combined analysis of the pathologic cells’ immunophenotype,
morphology and cytochemistry on the microarray permits to arrive at preliminary
diagnosis and can be used in cases of any controversies between morphology,
cytochemistry and immunophenotyping. The work is partially supported by 16-
34-01030 and 16-04-00282 grants from RFBR.
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COMPARATIVE ANALYSIS OF INTERNATIONAL PROGNOSTIC INDEX
FOR CHRONIC LYMPHOCYTIC LEUKEMIA, PROGRESSION-RISK SCORE
AND MD ANDERSON CANCER CENTER 2011 SCORE: REAL WORLD
DATA FROM A SINGLE INSTITUTION
V. Vukovic1,*, D. Antic1,2, T. Karan-Djurasevic3, N. Milic4, M. Todorovic-Balint1,2,
J. Bila1,2, B. Andjelic1,2, V. Djurasinovic1,2, A. Sretenovic1, M. Smiljanic1,
J. Jelicic1, M. Dencic-Fekete1, M. Perunicic-Jovanovic1, N. Kraguljac-Kurtovic1,
S. Pavlovic3, B. Mihaljevic1,2
1Clinic for Hematology, Clinical Center of Serbia, 2Medical Faculty, University
of Belgrade, 3Laboratory for Molecular Biomedicine, Institute of Molecular
Genetics and Genetic Engineering, 4Institute for Medical Statistics and Infor-
matics, Medical Faculty, University of Belgrade, Belgrade, Serbia
Background: In recent times, several powerful prognostic scores have been
developed in order to predict time to first treatment (TTFT) and overall survival
(OS) of patients with chronic lymphocytic leukemia (CLL). The international
prognostic index for chronic lymphocytic leukemia (CLL-IPI) developed by The
International CLL-IPI working group was found to predict OS and TTFT, while
the rest of two scores- progression-risk score (PRS) and MD Anderson Cancer
Center Score 2011 (MDACC 2011) have been developed for prediction of TTFT
in early stage CLL patients.
Aims: The aim of this study was to compare CLL-IPI, PRS and MDACC 2011
prognostic scores based on their impact on TTFT, treatment response (TR),
progression-free survival (PFS) and OS of 54 treated CLL patients.
Methods: We retrospectively analyzed data from 54 consecutive CLL patients
diagnosed and treated at Clinic for Hematology, Clinical Center of Serbia from
2003 to 2013. Blood samples were prospectively collected and analyzed for
biological and molecular features (IGHV, FISH and TP53), as well as standard
laboratory parameters. The three scores were retrospectively calculated using
formulas from the original articles (International CLL-IPI working group, Lancet
Oncol 2016, for CLL-IPI; Gentile et al, Leukemia 2016, for PRS; and Wierda et
al, J Clin Oncol 2011, for MDACC 2011 score), and, than, correlated with TTFT,
TR, PFS and OS of patients from the studied cohort.
Results: Median age at diagnosis was 57 years (range 38-75). All patients
were treated with fludarabin-based chemotherapy, 45 (83%) in the first treat-
ment line. Overall response rate to the first line therapy was 81%, equally dis-
tributed on complete and partial responses. Most of the patients (42, 78%)
relapsed during the follow up. At the time of the last follow up 14 (26%) patients
were still alive, 35 (65%) were dead, and 5 (9%) were lost to follow up. Median
overal survival was 76 months. Lower score values for all the three scoring
systems (CLL-IPI, PRS, and MDACC 2011) correlated with longer TTFT (p<0.05
for all). Cox regression analysis revealed that CLL-IPI and PRS are significant
predictors of TTFT (p=0.003, RR=1.4, 95%CI 1.1-1.7 and p=0.019, RR=1.4,
95%CI 1.1-1.9, respectively), while MDACC 2011 was of borderline significance
(p=0.052). In the multivariable analysis PRS emerged as the most significant
predictor of TTFT among the three examined scores (p=0.041, RR=1.35, 95%CI
1.01-1.81). Regarding TR, only PRS appeared to have borderline statistical
significance (p=0.052), showing that patients with lower score value may
achieve better TR. Lower CLL-IPI can predict longer PFS after the first line
treatment (p=0.007, RR=1.7, 95%CI 1.2-2.57), as well as PRS (p=0.039,
RR=1.8, 95%CI 1.03-3.1). MDACC 2011 has not shown to have influence on
PFS. Multivariable analyisis confirmed PRS to have the strongest predictive
value of all the three scores regarding duration of PFS (p=0.039, RR=1.8,
95%CI 1.02-3.1). Furthermore, CLL-IPI and PRS were found to be significant
predictors of OS (p=0.005, RR=1.4, 95%CI 1.1-1.8 and p=0.037, RR=1.5,
95%CI 1.03-2.24, respectively).
Summary/Conclusions: CLL-IPI and PRS were identified as significant pre-
dictors of TTFT, as well as of duration of TR and OS. Further studies are war-
ranted to confirm these findings. 
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MULTISITE PERFORMANCE EVALUATION STUDY OF THE BD ONEFLOW
B-CELL CHRONIC LYMPHOPROLIFERATIVE DISORDERS T1 (B-CLPD T1)
PANEL
B. Balasa1,*, C. Green2, J. Kendall2, D. Gladding2, I. Racoma2, D. Van Hoof2,
F. Oreizy2, A. Chen2, V. Fraser2, A. Doherty3, D. Tielemans4, L. Wolfe5,
K. Judge2
1Medical Affairs, 2BD Biosciences, San Jose, United States, 3BD Biosciences,
Oxford, United Kingdom, 4BD Life Scienecs, Erembodegem, Belgium, 5BD
Clinical Corporate Development, Sparks, Maryland, United States
Background: The BD OneFlow solution for B-cell chronic lymphoproliferative
diseases (B-CLPDs) incorporates a standardized flow cytometry approach
based on the EuroFlow (EF) Consortium liquid reagent system. The BD One-
Flow solution enables reproducible identification and discrimination of distinct
cell populations by combining standardized assays, setup reagents, and pro-
tocols. The previously launched BD OneFlow LST (Lymphocyte Screening
Tube) is intended for flow-cytometric immunophenotyping of normal (no fol-
low-up required) and aberrant (follow-up required) mature lymphocyte popula-
tions of B, T, and NK lineages in specimens from patients with hematological
disorders. The BD OneFlow B-CLPD T1 is being developed to work in con-
junction with BD OneFlow LST for the immunophenotyping of B cells and dis-
tinguishing chronic lymphocytic leukemia (CLL) from other B-CLPDs such as
atypical CLL, follicular cell lymphoma, mantle cell lymphoma, etc.  
Aims: The objective of this study was to demonstrate equivalency (accuracy)
between the investigational BD OneFlow LST and BD OneFlow B-CLPD T1
system and the corresponding comparator EF liquid reagent system on the
BD FACSCanto II flow cytometer using BD FACSDiva software.
Methods: De-identified remnant peripheral blood (PB) (n=70) and bone marrow
(BM) (n=31) patient specimens were collected in EDTA or heparin anticoagu-
lants at four external study sites and tested within 26 hours of draw. Informed
consent was not required in this clinical study. Specimens were stained with
BD OneFlow LST in combination with OneFlow B-CLPD T1 tubes and com-
parator EF liquid reagents. Acquisition and analysis were performed on a BD
FACSCanto II instrument using BD OneFlow LST and B-CLPD T1 templates
in BD FACSDiva software v8.0.1. Categorization of samples with abnormal B-
cell populations into CLL (typical) or other B-CLPDs, overall agreement, neg-
ative agreement, and positive agreement, along with their one-sided lower 95%
confidence limits, were calculated. For qualitative categorization of relative flu-
orescence intensity (positive or negative) of the aberrant cell populations, over-
all agreement with one-sided lower 95% confidence limits was calculated.
Results: All evaluable specimens were identified by the OneFlow LST as hav-
ing B-cell populations requiring follow-up by both methods. Compared to the
EF system, the BD OneFlow LST in combination with the BD OneFlow B-CLPD
T1 system gave 100% (101 of 101) overall agreement in classifying patients
as having CLL (54 of 54 concordant) and in identifying patients with other B-
CLPD diseases (47 out of 47 concordant) with a lower 95% CI of the overall
agreement of 97.4%. The BD OneFlow B-CLPD T1 system, compared to the
EF system, gave 100% (101 of 101 concordant) agreement for the qualitative
assessment of the relative fluorescence intensity of CD45+CD19+ aberrant
populations for CD20+, CD200+, and CD23+ subsets and 99.1% agreement
for the CD79b+ subset.
Summary/Conclusions: The multisite performance evaluation between the
BD OneFlow system (LST and B-CLPD T1) and the comparator EF liquid
reagent system was concordant in distinguishing abnormal B-cell populations
in patients with CLL from patients with other B-CLPDs, including presumptive
cases of atypical CLL. The BD OneFlow B-CLPD T1 is a fully standardized
and validated system for aiding in the diagnosis of CLL from other B-CLPDs in
PB and BM specimens.
BD OneFlow LST and BD OneFlow B-CLPD T1 are CE Marked according to the
European In Vitro Diagnostic Medical Device Directive 98/79/EC. 23-19567-00
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COMBINED PATTERNS OF IGHV REPERTOIRE AND MOLECULAR
ALTERATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA- SINGLE CENTER
EXPERIENCE
S. Trajkova1,*, L. Cevreska1, A. Dimovski2, M. Ivanovski1,
M. Popova-Labacevska1, D. Dukovski1, B. Kocoski1, I. Panovska-Stavridis1
1Hematology, University clinic for Hematology, 2Faculty of Pharmacy,  Univer-
sity “Ss. Cyril and Methodius”, Skopje, Macedonia, The Former Yugoslav
Republic Of
Background: The specific determining factors for malignant progression  in
Chronic lymphocytic leukemia (CLL ), remaining unknown.
Aims: To investigat  the potential existence of unique cytogenetic profiles
associated with specific IGHV repertoires that could be associated with an
increased risk of progression  in CLL.
Methods: For this purpose,   molecular analysis of well-established cytogenetic
alterations of chromosomes 11, 12, 13, 14 and 17 together with the pattern of
rearrangement of the IGHV genes were performed in 100 CLL cases. 
Results: Our results based on   molecular analysis from 100 subjects living in
the same geographical area, show the presence of three major groups of clones
with distinct but partially overlying configurations of IGHV gene usage, IGHV
mutational status and cytogenetic alterations. These included a group which
mainly consisted of clinical   advanced stage CLL with a skewed but different
CLL-associated IGHV gene repertoire (VH1-69 associated with  HD3 gene and
HJ6 gene), frequently associated with complex karyotypes and poor-prognosis
cytogenetic alterations , a second group enhanced in clones expressing specific
IGHV subgroups ( VH3-23 associated with HD2 genes and HJ6 gene) with no
or isolated good-prognosis cytogenetic alterations and a third group of clones
with intermediate features, with prevalence of mutated IGHV genes, and higher
numbers of del(13q)+ clonal B-cells.
Summary/Conclusions: These findings suggest that the specific IGHV reper-
toire and IGHV mutational status of CLL  B-cell clones may adjust the type of
cytogenetic alterations acquired and their clinical significances. Further long-
term follow-up studies investigating the IGHV gene repertoire of  CLL clones
in distinct geographic areas and microenvironments are required to validate
our findings and discard or confirm the potential role of some antigen-binding
BCR specificities contributing to clonal evolution.
PB1796
PROGNOSTIC SIGNIFICANCE OF SERUM BAFF, APRIL, TACI AND BCMA
LEVELS IN CHRONIC LYMPHOCYTIC LEUKEMIA
I. Berke Mentese1,*, Z.A. Yegin2, S. Gokcen2, Z.N. Ozkurt2, M. Yagci2
1Internal Medicine, 2Hematology, Gazı University Faculty of Medicine, Ankara,
Turkey
Background: B-cell chronic lymphocytic leukemia (B-CLL) is characterized
by the accumulation of CD5+ B cells in the peripheral blood and bone marrow.
Prognosis of B-CLL is highly variable which depends on certain prognostic
parameters. Novel prognostic markers and risk assessment models are fun-
damental to identify high risk patients who may need early treatment. The two
tumour necrosis factor family proteins BAFF (TNFSF13B) and APRIL
(TNFSF13) and their receptors [BAFF-R (TNFRSF13C), TACI (TNFRSF13B),
BCMA (TNFRSF17)] play a critical role in the survival of normal B cells.
Aims: In this study, we aimed to investigate the impact of serum BCMA, TACI,
BAFF and APRIL levels on prognosis of B-CLL.
Methods: A total of 129 newly diagnosed CLL patients [median age: 64(39-
88); M/F: 85/44] and 26 healthy volunteers were enrolled in this study. Serum
BCMA, TACI, BAFF and APRIL levels were measured at diagnosis using
enzyme-linked immunosorbent assay (ELISA). The association with conven-
tional prognostic markers and impact on survival were evaluated.  
Results: Serum BAFF, TACI and BCMA levels were significantly lower in the
patient group (p<0.001), while serum APRIL level did not differ significantly
between the patient and control groups (p>0.05) (Table 1). Serum BAFF
[(p=0,008; r=-0,236)] and BCMA [(p=0,042; r=-0,183)] levels were negatively
correlated with Rai stage and serum BAFF level was higher in low-risk patients
based on modified Rai staging system (p=0,059). Serum TACI level was higher
in CD38 positive patients [(p=0,06; 0,17(0,1-0,86) vs 0,13(0,1-1,07)]. Age
(p=0,002), Rai stage (p=0,005) and Modified Rai stage (p=0,051) were the sig-
nificant factors which had an impact on overall survival in multivariate analysis.
Table 1.
Summary/Conclusions: As BAFF and APRIL display their main biological
effects once they bind to their receptors and pass through the intracellular com-
partment, we consider that it may be more feasible to measure the intracellular
levels of these molecules which may be more predictive for B-CLL prognosis.
The association of TACI and CD38 expression may indicate the notable balance
between proliferation and apoptosis, as CD38 is considered to be a proliferation
marker in B-CLL. Further large and prospective studies analyzing the intracel-
lular levels of these molecules are essential to validate the prognostic role of
these particular biomarkers in CLL. 
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EXPERIENCE OF IBRUTINIB IN RELAPSED/REFRACTORY B-CELL
CHRONIC LYMPHOCYTIC LEUKAEMIA AND MANTLE CELL LYMPHOMA
IN A U.K. DISTRICT GENERAL HOSPITAL
J. Lala1, A. Smith1,*, C. Millar1, G. Fellows1, A. Bryan1, J. Addada1
1Haematology, Derby Teaching Hospitals NHS Foundation Trust, Derby, United
Kingdom
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Background: Constitutive activation of B-cell receptor signalling appears to
be essential for the proliferation of malignant B cells. Bruton’s tyrosine kinase
(BTK) has been identified as an essential component of the B-cell receptor sig-
nalling pathway. Ibrutinib is an orally administered BTK inhibitor that antago-
nises B cell receptor, chemokine & integrin mediated signalling.
Aims: We report our experience of using ibrutinib to treat relapsed/refractory
B-cell chronic lymphocytic leukaemia (B-CLL) and mantle cell lymphoma (MCL)
in a busy U.K. District General Hospital (DGH) serving a population of 600,000
Methods: 26 patients were commenced on ibrutinib for relapsed/refractory B-
CLL or MCL between August 2014 & December 2016. 16 patients had B-CLL
and 10 patients had MCL. Patients with B-CLL were commenced on 420mg
daily; those with MCL received 540mg daily. The median age at which ibrutinib
was commenced was 71.1 years (range 50-85). The median age of patients
with B-CLL was 71.1 years (range 50-80) and for MCL was 71.6 years (range
54-85). The median number of prior lines of therapy decreased over the time
period from 3.2 in 2014 to 1.2 in 2016.  The mean interval between diagnosis
and commencement of ibrutinib was 6.7 years (B-CLL) and 4.8 years (MCL).
The average number of co-morbidities in both groups was similar: 1.4 in B-CLL
and 1.5 in MCL. After May 2015 all patients received aciclovir and co-trimoxa-
zole prophylaxis. Response to ibrutinib was assessed by clinical examination
and blood results; imaging and bone marrow examination were conducted at
the clinician’s discretion.
Results: The median follow up was 15.5 months for B-CLL patients and 8
months for MCL patients. The median survival of all patients who did not receive
anti-viral and pneumocystis prophylaxis was 5 months and the median survival
for those who did receive prophylaxis was not reached (p <0.0001). The median
survival of patients in both groups who had received more than 1 prior line of
treatment was 17 months; the median survival in those who had received just
one prior line of treatment was not reached (p= 0.0085). In the B-CLL cohort
there was no difference in survival between those with and without 17p / p53
deletion. 11/26 patients experienced side effects: 8 had grade 1 and 2 side
effects (diarrhoea, drug rash, cardiac arrhythmias) which were easily controlled.
3 patients had grade 4 side effects (1 severe arthropathy, 2 intracranial haem-
orrhage - one of which was fatal). 4 of the 16 (25%) with B-CLL and 5 of the 10
(50%) with MCL died during the period of follow-up. Causes of death were:
intra-cerebral haemorrhage (1), unrelated cancer (1), disease progression (2),
disease progression+sepsis (2), sepsis alone (3). Of the remaining 17 patients,
14 continue to receive ibrutinib, 2 (B-CLL) were switched to idelalisib+Rituximab
(for grade 4 toxicity) & 1 went on to have an allogeneic transplant (MCL).
Summary/Conclusions: Though our cohort of patients is small, our experience
shows that the use of prophylaxis with co-trimoxazole and aciclovir is associated
with significantly improved overall survival. Moreover, patients who received
fewer lines of prior treatment had a better survival. Patients with 17p/p53 deleted
B-CLL responded as well as those without a deletion. Ibrutinib is a very effective
therapeutic option in patients with relapsed CLL and MCL.
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THE VALUE OF RITUXIMAB ADDITION TO CHEMOTHERAPY TREATMENT
OF REAL-WORLD CLL PATIENTS: A 15 YEAR SINGLE CENTER
EXPERIENCE
L. Van Der Straten1,*, A.G. Dinmohamed2,3,4, J.K. Doorduijn2,
P.E. Westerweel1, A.W. Langerak5, A.P. Kater 6, M.-D. Levin1
1Internal Medicine, Albert Schweitzer Hospital, Dordrecht, 2Haematology, Eras-
mus MC Cancer Institute, 3Public Health, Erasmus University Medical Center,
Rotterdam, 4Research, Netherlands Comprehensive Cancer Organization,
Utrecht, 5Immunology, Erasmus Medical Center, Rotterdam, 6Haematology,
Academic Medical Center, Amsterdam, Netherlands
Background: The addition of the monoclonal antibody rituximab to chemother-
apy has been shown to improve progression free survival and overall survival
in prospective trials in CLL patients. However, CLL patients participating in clin-
ical trials may not be fully representative of the overall patient population in
clinical practice as there is selection due to study availability, willingness to par-
ticipate and various in- and exclusion criteria. To date, the efficacy of rituximab
added to standard chemotherapy in first line and relapsed CLL patients has
been poorly validated in observational studies in unselected real-world CLL
patients.
Aims: To evaluate the efficacy of rituximab-chemotherapy (R-CTX) compared
to chemotherapy (CTX) in a real-world CLL population.
Methods: All patients from a large teaching hospital diagnosed with
immunophenotypically confirmed CLL in the period from 1-1-2000 up to 1-9-
2015 were analyzed for this study and were categorized into two groups (1)
those treated with CTX and (2) those who received R-CTX. The clinical outcome
of patients was evaluated based on the “treatment-free interval” (TFI), defined
as the time from stop of chemo(immuno)therapy to start of next treatment.
Patients who did not need next treatment were censored at time of last follow-
up or death.  In addition, overall survival (OS) for patients treated in the period
when rituximab had become available in our center was compared to patients
treated before the rituximab era (before and after 1-1-2006, respectively). 
Results: A cohort of 375 CLL patients was studied, of whom 124 CLL patients
(33%) required treatment in the observation period. The median age at first-
line therapy was 67 years; 55% and 45% of these patients received first line
CTX or R-CTX, respectively, and 47% of these patients required a second or
later line of (R-)CTX. In total 221 treatment periods of (R-)CTX were studied
with respect to treatment-free interval, 124 first-line, and 97 courses of retreat-
ment. In the first-line treatment group 12 (10%) and 24 patients (19%) were
treated with purine-analogue-based schedules without or with R respectively,
i.e. (R-)fludarabine or (R-)fludarabine plus cyclophosphamide, 55 (45%) and
31 patients (25%) were treated with chlorambucil/CVP-based regimens without
or with R respectively, and two patients (2%) were treated with CHOP and R-
bendamustin. The median TFI for patients treated with CTX was 31 months
(95%CI; 20 – 42 months) and was significantly better in the R-CTX group where
the median TFI was not reached during the observation time (hazard ratio 0.40,
95%CI 0.22 – 0.73). In second or later lines of treatment 15 (15%) and 11
patients (11%) were treated with purine-analogue-based schedules without or
with R respectively, i.e. (R-)fludarabine or (R-)fludarabine plus cyclophos-
phamide, 25 (26%) and 31 patients (32%) were treated with chlorambucil/CVP-
based regimens without or with R respectively, and 15 patients (15%) were
provided with other treatment modalities, i.e. (R-)CHOP or (R-)bendamustin.
The median TFI for CTX was 27 months (95%CI; 18 – 52 months) vs 55 months
for R-CTX (95%CI; 41 months – NR), HR 0.47 (95%CI 0.15 – 0.90) for subse-
quent lines. OS for patients treated in the R era was 48 vs 35 months for patients
treated before the introduction of rituximab (p=0.02).
Summary/Conclusions: Our study shows that the addition of rituximab
improved treatment free interval in first- and subsequent lines and prolonged
overall survival in a cohort of CLL patients receiving treatment in routine clinical
‘real world’ practice. 
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RICHTER SYNDROME: SERBIAN LYMPHOMA GROUP EXPERIENCE
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Background: Richter syndrome (RS) represents transformation of chronic lym-
phocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) into more aggres-
sive B-cell lymphoproliferative disorder, most commonly, diffuse large B cell
lymphoma (DLBCL). vera rarely classical Hodgkin lymphoma (HL). In some
point of disease course, 2-10% of all CLL/SLL population develope RS, usually
exhibiting chemoresistance and survival within a year after diagnosis. 
Aims: The aim of the study is to evaluate clinical, laboratory and histopatho-
logical features of patients with RS at transformation, and their impact on the
outcome.
Methods: We processed data from the medical records of 36 CLL and SLL
patients with RS diagnosed and treated in four institutions in Serbia from
2003 to 2016: Clinic for Hematology, Clinical Center of Serbia; Clinic for
Hematology, Medical Military Academy; Clinical Hospital Center Zemun; and
Clinic for Hematology, Clinical Center Kragujevac. In all of RS patients, diag-
nosis was established after histopathological and immunohistochemistry
analysis of biopted tissue (lymph node, bone marrow, Waldeyer’s ring, max-
illary sinus, spleen or liver). 
Results: In four institutions RS was diagnosed in 36/1250 CLL/SLL patients
(2.8%). Median age was 57.5 years (range 41-79). In 16 (44%) patients RS
was confirmed in lymph node sample, in 13 (35%) patients in bone marrow, in
4 (11%) patients in Waldeyer´s ring, in 2 (5%) patients in maxillary sinus, in 2
(5%) patients in liver or/and spleen, while in 3 patients in more than one location.
Histopathological findings of all patients in transformation were consistent with
DLBCL, except one, showing pattern of HL. Prior to the transformation, 26
(72%) patients received chemotherapy (Chlorambucil 6 patients, Fludarabin
based regimens 11 patients, CHOP 3 patients, COP/RCOP 4 patients, other
modality 3 patients), 4 (11%) of them were on the “watch and wait” strategy,
while 6 (17%) patients were diagnosed with RS at presentation, and treated as
RS. Median time to transformation was 36 (0-180) months, At the time of trans-
formation median LDH and beta-2 microglobulin levels were significantly higher
than on presentation (p=0.035 and p=0.010, respectively). The majority of
patients  received CHOP (20/36, 55%) and RCHOP (7/36, 19%) as initial ther-
apy for RS. The reminder of patients received other treatment modalities, such
as ESHAP, FC, high dose corticosteroids, COP, RCOP and radiotherapy. After
excluding 6 patients with SLL from the group, Cox regression analysis showed
that high LDH and low Hb levels at the time of transformation are significant
predictors of shorter survival after diagnosis of RS (HR=1.001; 95% CI 1.000-
1.001; p<0.001 and HR=0.978; 95% CI 0.961-0.995; p=0.011, respectively).
Bone marrow as a site of transformation did not reach statistical significance
as a predictor of shorter survival after transformation (p=0.087). Median survival
after diagnosis of RS was 8 months (range 0-133) (Figure 1).
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Figure 1.
Summary/Conclusions: Incidence of RS in our study is partly coherent with lit-
erature data. Levels of LDH and Hb at the time of transformation are significant
predictors of outcome of patients with RS. Real number of patients with RS is
probably higher, but commonly bad condition of these patients on diagnosis of
RS probably influences the decision of a clinician not to indicate biopsy.
PB1800
INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKAEMIA TREATED WITH IBRUTINIB
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D. Szczepanek3, K. Kotwica1, A. Szczepanek1, M. Hus1
1Haematooncology and Bone Marrow Transplantation, Medical University in
Lublin, Lublin, 2Haematooncology, Medical University in Kielce, Kielce, 3Neu-
rosurgury, Medical University in Lublin, Lublin, Poland
Background: Chronic lymphocytic leukaemia (CLL) is characterised by fre-
quent co-existent infectious complications. They stem from, among other things,
hypogammaglobulinemia, which is connected with CLL, and correlates with
the disease duration and severity, as well as T-lymphocyte function disorders.
The application of innovative therapies (chemoimmunotherapy) on the one
hand facilitates considerable improvements in treatment outcomes and on the
other hand it increases the risk of life-threatening infectious complications. The
introduction of a new drug, ibrutinib (Bruton’s kinase inhibitor), has created a
unique opportunity for CLL patients, especially those with prognostically
unfavourable genetic aberrations (del17p), or in the case of whom previous
chemotherapies have failed to give satisfying results. Previous observations
indicate the risk of side effects (e.g. bleeding, infectious complications,  heart
rhythm disorders) which might sometimes limit the applicability of ibrutinib in
some CLL patients.
Aims: The aim of this paper was to evaluate the risk of infectious complications
in persons with CLL, and to determine potential correlations between possible
infectious complications and selected clinical, morphological and biochemical
parameters.
Methods: The study comprised 43 CLL patients aged 48-82 years (average
age 67 years), 18 women and 25 men. At the beginning of the ibrutinib therapy
the patient’s disease was at the 2-4 clinical stage, according to Rai et al. Usually
they were individuals who had received a couple of previous chemotherapies
(from 1 to 7) which contained, inter alia, purine analogues, and the monoclonal
antibodies (rituximab, alemtuzumab, ofatumumab). Ibrutinib was administered
at a dose of 420 mg/d.
Results: Infectious complications were observed in 16 patients (37.2%). These
included, for example, upper respiratory tract infection, bronchitis, pneumonia,
urinary-tract infections, pharyngitis. The conducted analysis showed a statisti-
cally significant correlation between the concentration of IgM in the blood serum
(before ibrutinib administration) and infectious complications during these ther-
apy (p<0.05). The average IgM concentration in patients with complications
was considerably lower when compared to people who did not experience any
complications. The patients (n=3; 6,98%) with complications at the moment of
the CLL diagnosis also had them during the ibrutinib  treatment. This phenom-
enon was confirmed in 13 patients (33%) in the other group. The correlation
was borderline significant (p=0.09). Infectious complications were observed
more frequently in the patients with 3-4 stage CLL (according to Rai et al.) than
in the individuals at the less-advanced clinical stages of the disease (0-2), and
this correlation also showed borderline significance (p=0.08). No significant
correlation was detected between the risk of infectious complications and earlier
therapy with purine analogues and neutropenic episodes during the ibrutinib
therapy.
Summary/Conclusions: Ibrutinib is considered to be a real breakthrough in
CLL treatment; but it has to be borne in mind that the drug gives possible side
effects which might occur during therapy. They include infectious complications
which are among the main causes of death in this group of patients. The results
obtained by us indicate that the risk of infection during ibrutinib therapy relates
mainly to patients with low IgM concentration in the blood serum and at more
advanced clinical stages of the disease. In this case the occurrence of previous
complications (before ibrutinib administration) is also relevant. We are aware
of the limitations of our work related to the small number of patients. Yet, even
at this stage, it is possible to select CLL patients with increased risk of such
usually life-threatening complications.
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MONOCLONAL B-CELL LYMPHOCYTOSIS AND PROSTATE CANCER:
AN UNEXPECTED, POSSIBLE ASSOCIATION
F. D’Auria1,*, L. Rago1, L. Valvano1, T. Statuto1, A. Traficante1, V. Simeon1,
V. Fusco1, P. Musto1
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Italy
Background: Monoclonal B-cell lymphocytosis (MBL) is a recently recognized
entity characterized by the presence, in the peripheral blood, of a monoclonal
B-cell population lower than 5000/µl, in the absence of any type of clinical fea-
tures. MBL clones may have: a) chronic lymphocytic leukemia (CLL-like) phe-
notype (CD5+, CD19+, CD23+, CD20 dim); b) atypical CLL phenotype (CD5+,
CD19+, CD23- or CD20 bright); c) non-CLL phenotype (CD5-). MBL can be
also distinguished in “low-count” (<500/µl) and “high-count” (>500/µl) subtypes.
High-count MBL frequently shows typical CLL phenotypic/genetic features and
require adequate follow-up in order to detect their possible evolution into symp-
tomatic CLL. MBL showing a clonal B-cell count higher than 1000-1500/µl are
usually defined “clinical” MBL. Using highly sensitive (i.e. >6 colors and
>500000 events) flow cytometry approaches, CLL-like MBL clones have been
found at a frequency of 7-12% in healthy subjects, showing, however, very low
median counts of clonal B-cell (10-170/µl), with only 0,14% being clinical MBL.
Though several studies have described the association between CLL and var-
ious types of neoplastic disorders, only few data exist about the risk of non-
hematologic cancer in individuals with MBL; in particular, no association
between MBL and prostate cancer (PC) has been so far reported. 
Aims: To study prospectively the frequency of CLL-like MBL clones in patients
affected by PC compared to healthy males of the same ages, after our previous
occasional observation of an apparently increased MBL incidence at baseline
in a cohort of patients with PC originally studied to detect lymphocyte abnor-
malities possibly induced by radiotherapy (RT).
Methods: We enrolled 34 consecutive patients affected by PC (mean age 74
years, range 58-91), naïve for chemotherapy (sixteen previously treated with
hormone-therapy). All patients were planned to receive whole-pelvis RT with
radical (n. 23) or salvage (n. 11) intent. Fifty-four healthy males (mean age 71
years, range 58-87) represented the control group. Immunophenotypic analysis
of peripheral lymphocytes before RT was performed by BD FacsCanto II flow
cytometer, using a 5-6 colors approach and the following antibody combina-
tions: CD19 FITC/CD5 PE/CD45 PerCP/CD20 PE-Cy7/CD23 APC; Kappa
FITC/Lambda PE/CD19 PerCP-Cy5.5/CD20 PE-Cy7/CD5 APC/CD45 APC-
Cy7. For each sample, 100000 events were collected. CD45+ lymphocytes
were gated on CD45 vs SSC dot plot, then B cells were isolated by gating on
CD19 and CD19+ CD5+ cells were interrogated for intensity of CD20. Finally,
CD19+ CD5+ CD20dim selected population was analyzed for light chain clon-
ality and CD23 expression.
Results: Median (range) absolute counts of white blood cells (WBC), total lym-
phocytes and B-cells, as well as absolute single values of MBL clones are
reported in Table 1. In PC patients we found 3 MBL (8,8%), two of which were
“high count/clinical” MBL (5.8%). In contrast, in healthy subject group, only one
“low count” MBL (1.8%) was detected, showing a very small clone (8 cells/µl).
Such a difference was not statistically significant (p=0.2).
Table 1.
Summary/Conclusions: The preliminary results of our prospective study, per-
formed using a routine, not highly sensitive flow cytometry approach, highlight
a possible association between (clinical?) MBL and PC, never described before
and probably warranting further investigation in a larger number of patients.
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IDENTIFICATION OF NOVEL MUTATIONS IN CANCER-RELATED GENES
IN HUMAN ERYTHROLEUKEMIA K562 CELL LINE BY NEXT-GENERATION
SEQUENCING 
M. Pepek1,2,*, M. Kurkowiak1, M.M. Machnicki1,2, I. Solarska3, K. Borg3,
M. Rydzanicz4, P. Stawinski4, R. Ploski4, T. Stoklosa1
1Department of Immunology, Medical University of Warsaw, 2Postgraduate
School of Molecular Medicine, 3Department of Diagnostic Hematology, Institute
of Hematology and Transfusion Medicine, 4Department of Medical Genetics,
Medical University of Warsaw, Warsaw, Poland
Background: Chronic myeloid leukemia (CML) is a clonal hematopoietic stem
cell disorder characterized by reciprocal chromosomal translocation
t(9;22)(q34;q11), resulting in the formation of the BCR-ABL1 fusion oncogene.
One of the most common CML in vitro model is the K562 BCR-ABL1-positive
human erythroleukemia cell line derived from a female patient with CML in blas-
tic phase (CML-BP) and representing an important tool for the studies of malig-
nant hematopoiesis in last decades. Although K562 karyotype was described
several times, detailed genomic analysis of this cell line is not yet available and
to our best knowledge there are no publications yet describing complex genomic
landscape of K562 cells.
Aims: The aim of our study was to determine the mutational landscape of K562
cell line using next-generation sequencing (NGS). Additionally classical fluo-
rescence in situ hybridization (FISH) with BCR and ABL1 probes was performed
to confirm cytogenetics.
Methods: The K562 cell line was purchased from DSMZ (Braunschweig, Ger-
many). We analyzed almost 1300 genes implicated in human cancer using
custom designed capture (SeqCap EZ, NimbleGen, Roche) followed by high-
throughput sequencing on Illumina HiSeq 1500. Common variants (>1%) gath-
ered in ESP6500 and 1000 genomes projects and our internal exome database
were filtered out and the subsequent analysis was focused on putative protein
damaging variants with the frequency in the database from NHLBI GO exome
sequencing project less or equal to 0.01. We used different bioinformatic tools
for variant effect prediction (eg. PolyPhen-2, SIFT, IntOGen). Mutations were
confirmed with Sanger sequencing. FISH was performed using commercially
available probes (Vysis, Abbott, USA), that identifies BCR-ABL1/ABL1-BCR
fusion genes.
Results: Sequencing and bioinformatical analysis revealed 88 variants with
potential biological significance. We detected Q136fs*13 mutation in TP53,
which has already been described in K562 cell line previously by ATCC, but we
have also identified several new mutations in genes involved in tumorigenesis
and drug resistance (Table 1). Moreover, cytogenetic analysis showed both
multiplication of the BCR and ABL1 genes and amplification of the BCR-ABL1
fusion gene (Ph chromosome is present in at least four additional copies).
Table 1. Selected prominent mutations identified in K562 cells.
Summary/Conclusions: We describe several new mutations in such genes
as ASXL1, BRCA1 or MLH1 in one of the most frequently used cell line in
leukemia research, K562 erythroleukemia. Our results confirm high level of
genomic instability in the blastic phase of CML represented by the K562 cell
line and add new, valuable information for researchers who want to employ
this cell line. The awareness of the genomic aberrations present in the K562
erythroleukemia cell line is essential for further studies as those aberrations
may have a significant impact on the observed results.
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INVESTIGATION OF POLYMORPHISMS RELATED TO MIR-608 IN
PATIENTS WITH CHRONIC MYELOID LEUKEMIA
N. Ryabchikova1, G. Safuanova1,*, I. Minniakhmetov2, A. Sultanbaev1,
E. Khusnutdinova2
1Bashkir State Medical University, 2IBG USC RAS, UFA, Russian Federation
Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder
characterized by the expression of the BCR-ABL oncoprotein, which is essential
for the pathogenesis of the disease. Imatinib, an ATP-competitive selective
inhibitor of BCR-ABL, has unprecedented efficacy for the treatment of CML.
Several cellular and genetic mechanisms of imatinib resistance have been pro-
posed, including overexpression of the BCR-ABL gene, the tyrosine kinase
domain mutations, pharmacokinetic and pharmacodynamic factors.
Aims: The purpose of this study was to investigate miRNA-608 role in response
to therapy with tyrosine kinase inhibitors (Imatinib). In this study, we analyzed
rs9762 SNP located in a miRNA-608 binding site of 3′UTR of BCR-ABL gene
and rs4919510 SNP in the mature sequence of miR-608 in CML patients with
different response to tyrosine kinase inhibitor therapy. These polymorphisms
disrupt the negative effect of mir-608 on its target BCR-ABL.
Methods: In our study 76 CML patients at the age of 15−65 were involved.
Genomic DNA was extracted from peripheral blood leukocytes by standard
phenol-chloroform method. Genotyping was performed by the PCR-RFLP tech-
nique.
Results: Combination of genotypes affecting mir-608/BCR-ABL1 interaction
(*GG in mir-608 binding site and/or *GG in mature miRNA itself) was revealed
with 81% in CML patients with uneffective therapy. We suggest that mir-608
could possess oncosuppressing activity as mir-203 but it should be confirmed
by further experiments.
Summary/Conclusions: miRNAs could be a perspective tool for therapy and
polymorphisms affecting its regulation should also be considered.
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TARGETED STRATEGY FOR ABL TYROSINE KINASE INHIBITOR
RESISTANT PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIA CELLS
S. Okabe1,*, T. Tauchi1, Y. Tanaka1, K. Ohyashiki 1
1Department of Hematology, TOKYO MEDICAL UNIVERSITY, Shinjuku-Ku,
Japan
Background: Although ABL tyrosine kinase inhibitors (TKIs) such as imatinib
have demonstrated the potency against Philadelphia chromosome (Ph)-positive
leukemia patients, resistance to ABL TKI can develop in chronic myeloid
leukemia (CML) patients. Therefore, new approach against ABL TKI resistant
cells may improve the outcome of Ph-positive leukemia patients. It has already
reported that ABL kinase domain mutations have been implicated in the patho-
genesis of ABL TKI resistance, however, it is fully not known the molecular
mechanism of drug resistance including second (nilotinib and dasatinib ) and
third generation (ponatinib) ABL TKIs.
Aims: As leukemia is a genetic disease driven by heritable or somatic muta-
tions, we hypothesized that ABL TKI resistance may often happen due to addi-
tional somatic mutations in the oncogene.
Methods: We established several TKI-resistant in vitro cell line models. We
also investigated model to evaluate the next-generation sequencing (NGS)
panel, NGS platform to screen mutational hotspots in 50 leukemia-related
genes.
Results: We established ABL TKI resistant cell lines (K562 imatinib-R, K562
nilotinib-R, K562 dasatinib-R, K562 ponatinib-R, Ba/F3 T315I and Ba/F3
ponatinib-R) in this study. We conducted fluorescence in situ hybridization
(FISH) analysis on parental K562 and ABL TKI resistant K562 cells. BCR-
ABL expression levels were not increased in ABL TKI resistant K562 cells
compared to parental K562. We next investigated the BCR-ABL point muta-
tion by direct sequence analysis. We could not detect the BCR-ABL point
mutation in ABL TKI resistant K562 cells. However, the exon 4 deletion in the
BCR-ABL gene was found in K562 ponatinib-R cells. In contrast, compound
mutations in BCR-ABL were found in Ba/F3 ponatinib-R cells. K562 pona-
tinib-R cells were also highly resistant to imatinib, nilotinib and dasatinib. We
examined the intracellular signaling of ABL TKI resistant K562 cells. Phos-
phorylation of BCR-ABL and Crk-L was reduced in K562 dasatinib-R cells,
however, MAPK activity was increased. In K562 ponatinib-R cells, MAPK
activity was reduced. We next evaluated the NGS panel (GeneRead DNAseq
Targeted Panels V2) to investigate the mutation. We found that several somat-
ic mutations in TET2, FLT3, RB1, TP53, SETBP1, ASXL1, and BCORL1 in
parental K562 cells. We also found that additional somatic mutations in K562
imatinib-R (IDH1 and KRAS), K562 dasatinib-R (IDH1) and K562 ponatinib-
R (SF3A1). We could not detect additional mutation in K562 nilotinib-R cells.
We next investigated the MEK inhibitor and IDH1 inhibitor activity against
K562 imatinib-R and K562 dasatinib-R cells. MEK inhibitor or IDH1 inhibitor
did not induce cell growth inhibition directly. However, combined treatment of
ABL TKI resistant K562 with imatinib or dasatinib and MEK inhibitor or IDH1
inhibitor caused more cytotoxicity than each drug alone. Because aberrant
activation of PI3K signaling pathway and deregulation of HDAC activity may
be a cause of malignant disease in humans, we examined the PI3K and
HDAC inhibitor in ABL TKI resistant cells. We found 72 h treatment of oral
inhibitor of class I PI3K as well as class I and II HDAC enzymes, CUDC-907
exhibits cell growth inhibition ABL TKI resistant K562 cells and Ba/F3 pona-
tinib-R cells in a dose dependent manner. In the mouse study, a dose of 20
mg/kg/day p.o of ponatinib and 30 mg/kg/day p.o of CUDC-907 inhibited
tumor growth of T315I mutant cells compared with control mice and induced
apoptosis in tumor samples.
Summary/Conclusions: Our study indicated that leukemia cells have
acquired resistance through somatic mutation or exon 4 deletion in the BCR-
ABL gene, suggested that individual based investigations may be important
to evaluate the ABL TKI resistance. We also provide the promising clinical
relevance as a candidate drug for treatment of ABL TKI resistant leukemia
patients.
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FLUORESCENCE IN SITU HYBRIDIZATION SIGNAL PATTERNS AND
INTRACHROMOSOMAL BCR-ABL1 AMPLIFICATION ANALYSIS IN
IMATINIB-RESISTANT CHRONIC MYELOGENOUS LEUKEMIA PATIENTS
USING TRICOLOR DUAL FUSION PROBE
K. Bommannan1,*, S. Naseem1, N. Varma, P. Malhotra2, J. Binota1, S. Varma2
1Hematology, 2Internal Medicine, Post Graduate Institute of Medical Education
and Research, Chandigarh, India
Background: Conventional cytogenetics is a common modality for tyrosine
kinase inhibitor (TKI) response assessment in chronic myelogenous leukemia
(CML) patients. There is no consensus regarding the use of conventional bone
marrow (BM) cytogenetics or peripheral blood (PB) interphase fluorescence in
situ hybridization (I-FISH) during follow-up.  The routine dual colour FISH
probes are less sensitive to reliably identify der(9) deletions during follow-up.
BCR/ABL/ASS1 tri-colour dual fusion (TCDF) probe is highly sensitive and
specific in identifying der(9) deletions.
Aims: Our aim was to identify the I-FISH fusion patterns of BCR/ABL/ASS1
TCDF probe and correlate the patterns with patient-specific molecular genetic
parameters.  
Methods: This was an ethically approved study conducted at a government-
funded tertiary care institute. From January 2015 to June 2016, PB I-FISH
analysis was performed on European LeukemiaNet defined imatinib-resistant
CML patients using BCR/ABL/ASS1 TCDF probe (Abbott Laboratories, Abbott
Park, Illinois, USA). The residual BCR-ABL1 transcript load was monitored in
international scale (BCR-ABL1IS) using an automated cartridge-based Gen-
eXpert system (Cepheid, Sunnyvale, CA, USA).
Results: On analyzing 37 adult patients, all had residual Philadelphia (Ph)
chromosomes (100%). Classic Ph fusion pattern was seen in 33 (89%), deriv-
ative chromosome 9 [der(9)] deletions in 25 (67.5%) and supernumerary Ph
chromosomes in 11 (30%) patients. Coexistence of classical fusion and der(9)
deletions were seen in 21 patients (57%), whereas 8 patients (22%) had
a mutual existence of classical fusion, der(9) deletions and supernumerary Ph
chromosomes. None had Ph amplification. Figure 1 demonstrates the I-FISH
patterns seen in a 43-year-old male diagnosed with CML-CP and had pro-
gressed to blast crisis at his 72nd month of imatinib therapy. In this Figure red,
yellow and white arrows indicate blast cells without Ph chromosome, Ph+ blast
with a loss of residual ABL1 on der(9)classical and random signal overlap,
respectively. A mean (± S.D) of 29% (± 30) and 18% (± 17) der(9)  deleted
cells were seen amongst patients with b2a2 and b3a2 BCR-ABL1 transcript
types, respectively and this difference was statistically significant (p=0.008).
There was also a significant difference in the disease transformation status
according to the percentage of der(9) deleted cells (p=0.03). In this regard,
patients with progressive disease (accelerated phase/ blast crisis progression)
had a mean (± S.D) of 47% (± 35) der(9) deleted cells in comparison to 19%
(± 20) such cells in patients without disease transformation. In addition, patients
with Ph duplication/triplication had a mean (± S.D) BCR-ABL1IS levels of
49.478% (± 40.184), in comparison to BCR-ABL1IS levels of 16.00% (± 19.993)
in patients without these anomalies and this difference was also statistically
significant (p=0.029).
Figure 1.
Summary/Conclusions: Our work would be an appropriate reference material
for I-FISH signal interpretation using BCR/ABL/ASS1 TCDF probe. We have
demonstrated a high frequency of der(9) deletions, clonal heterogeneity and
absence of BCR-ABL1 amplification in an imatinib-resistant Indian CML cohort.
For the first time, a significant association of der(9) deleted cell percentage
with b2a2 transcript type and disease transformation status has been identified
and the same has to be tested in a larger cohort. 
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ARE YOU ACTUALLY SUSPECTING A CHRONIC MYELOID LEUKEMIA
WHEN ORDERING A BCR/ABL RT-PCR?
L. Abalo Perez1,*, C. Guillén Rienda1, M. Sopeña Corvinos1,
W.M. Torres Jimenez1, R. Guillén Santos2, J. Villarrubia1,
F.A. Gonzalez Fernandez1, F. Cava Valenciano2
1Hematology Department, 2Head of the Laboratory, Central Laboratory
BRSalud Madrid. Infanta Sofía Hospital, Madrid, Spain
Background: Chronic myeloid leukaemia (CML) is a myeloproliferative neo-
plasm (MPN). It is characterized by a reciprocal t(9:22)(q34;q11.2) resulting in
the fusion oncogene BCR/ABL in a hemopoietic stem cell. Clinical features
are absent in nearly 20-40% of patients at diagnosis time. Hence, laboratory
suspicion is crucial. Peripheral blood shows leukocitosis with left shift and “mye-
locyte bulge”, absolute eosinophilia, and absolute basophilia invariably pres-
ent1-3. The demonstration of the Philadelphia (Ph) chromosome with cytoge-
netic analysis, or BCR/ABL fusion gene by qRT-PCR will confirm the diagnosis
(typical CML).
Aims: In order to gain accuracy when BCR/ABL PCR is ordered, we review
myeloproliferative hematimetric parameters, with special focus in basophilia,
before performing molecular analysis.
Methods: We retrospectively reviewed 299 BCR-ABL PCR requests received
at our laboratory between January 1, 2015 and January 1, 2017. 80% of the
total requests were ordered by haematologists physicians, 13.46% by other
medical specialities (11.5% internal medicine) and 7.7% from the laboratory.
Complete blood cell count (CBC) were analysed by ADVIA 2120. Neutrophilia
was defined in our laboratory as absolute neutrophil count of >7.7x10 9/L, and
basophilia was defined as absolute basophil count of >0.2 x10 9/L. A total of
299 requests for PCR of BCR-ABL were reviewed by laboratory hematology
staff, before performing them, according to 2008 WHO Classification of Hema-
tologic neoplasms criteria. We reviewed clinical history, previous CBC and
PBM if necessary for this screening. We performed 235 test (78.6%) and
64(21.4%) were considered inadequate according former criteria. qRT-PCR
p210 was performed and if a negative result was obtained with high CML sus-
picion qRT-PCRp190 and qRT-PCRp230, such as cytogenetic studies were
performed.The statistical analysis was performed with STATA.
Results: 235 BCR/ABL by PCR tests were performed and 24 (10.21%) resulted
positive. 167 (71.06%) were placed for neutrophilia; 41 (17.87%) for thrombo-
cytosis  and 26 (11.07%) for other criteria (eosinophilia, monocytosis,
splenomegaly or combined).Among 24 positive cases 100% presented
basophilia at diagnostic time and 91.66% (22/24) presented basophilia and
neutrophilia. Two cases without neutrophilia at diagnosis were CML with
extreme trombocytosis. We found 33 cases with basophilia among 235 patients.
24 cases (72.73%) were diagnosed of CML and 9(27.27%) resulted in other
MPN Ph- or unclassifiable MPS/MDS neoplasm. Our results show that when
CML is suspected, basophilia>0.3 x10 9/L has a 100% sensitivity and 95.75%
specificity. ROC curve for basophilia as a screening test before performing
BCR/ABL PCR is 0.984 (Figure 1).
Figure 1.
Summary/Conclusions: Our results show that basophilia should be carefully
investigate when CML is suspected, with high sensibility (100%) and specificity
(95.75%). In cases no CML with basophilia >0.3 x10 9/L, further investigation
should be performed in order to diagnose a MPN Ph- or MDS/MPN.Even
basophilia is well stablished as nearly universal in CML 1,3,4, this study reveals
it is not always pursue enough, when clinicians ask for a molecular study.
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BCR-ABL DEL. C.1086-1270 (P.R362FS*21) AND TKI RESISTANCE IN CML
PATIENTS FROM RUSSIAN FEDERATION
A. Abdullaev1,*, I. Mikhailov2, O. Nesterova2, A. Odilov3, T. Makarik1,
E. Stepanova1, S. Treglazova1, A. Sudarikov1
1Molecular hematology, National Research Center for Hematology, 2Faculty
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Russian Federation, 3Medical faculty, Tashkent Medical Academy, Tashkent,
Uzbekistan
Background: Data concerning the impact of BCR-ABL del. c.1086-1270 on
TKI resistance in CML is still controversial. This mutation was first described
by Curvo et al. (2008) and was thought to confer TKI resistance. However com-
puter modeling performed by Meggyesi N. et al. (2012) revealed disruption of
ATP binding site in mutated tyrosine kinase therefore abrogating enzymatic
activity. Nevertheless pathogenic effect of BCR-ABL p.R362fs*21 could be
attributed to the formation of heterodimer with “wild type” Bcr-Abl р210 as
described by Poulikakos P.I. et al. (2011).
Aims: To assess the impact of BCR-ABL del. c.1086-1270 (p.R362fs*21) on
TKI resistance in CML patients from Russian Federation.
Methods: 33 male and 49 female CML patients (age 24-80) with BCR-ABL
transcript level >0.1% were included in the study. BCR-ABL del. c.1086-1270
was estimated by nested PCR followed by Sanger sequencing. Initial screening
for deletions was performed by means of fragment analysis (Applied Biosys-
tems 3130).
Results: 92 RNA (cDNA) samples isolated from peripheral blood of 82 CML
patients were tested. BCR-ABL del. c.1086-1270 (p.R362fs*21) was found in
32 patients (39%). 15 out of 32 (47%) patients with deletion were TKI sensitive
while 17 (55%) were TKI resistant. In one TKI resistant case BCR-ABL del.
c.1086-1270 was accompanied by BCR-ABL c.844G˃C p.E282Q point muta-
tion not described so far (Figure 1). This mutation was found in BCR-ABL del.
c.1086-1270 transcript only and was absent in “wild type” Bcr-Abl р210 tran-
script amplified from the same patient.
Figure 1.
Summary/Conclusions: BCR-ABL del. c.1086-1270 could be found in almost
half of CML patients and have no evident impact on the induction of big molec-
ular response in TKI sensitive cases. Our observation that independent
c.844G˃C p.E282Q point mutation expressed on the same BCR-ABL transcript
with deletion c.1086-1270 (p.R362fs*21) being absent in “wild type” transcript
strongly contradicts the hypothesis, that del. c.1086-1270 could be generated
by alternative splicing of “wild type” BCR-ABL transcript.
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PEROXIREDOXIN II ACTIVITY HAS IMPORTANT ROLES TO CONTROL
ABL TYROSINE KINASE ACTIVITY IN STIS TREATED CML PATIENTS AND
ITS POTENTIAL APPLICATION IN IMATINIB RESISTANCE
E.S. Yoo1,*, Y.-C. Mun1, J.-Y. Ahn1, J.-W. Huh1, C.-M. Seong1
1Ewha Womans University MokDong Hospital, Seoul, Korea, Republic Of
Background: Therapies targeting the redox environment such as over-expres-
sion of antioxidants or antioxidant treatment, could inhibit tumor cell growth
even resistant cells. Bcr-Abl oncogene is known to induce high levels of intra-
cellular ROS which may further induce genomic instability with malignant trans-
formation and even imatinib (IM) resistance. Variable expression of antioxidants
enzymes in leukemia, with limited studies with variable results so far. Altered
redox biology in leukemia also has implications for therapeutics.
Aims: We investigated the roles of PRX II in CML primary cells at diagnosis
and remission during signal transduction inhibitor (STIs), and tested the same
roles in Ph+ cell lines.
Methods: Three BCR-ABL1 positive cell lines with different resistance to TKI
and generating IM-resistant K562 cells by chronic exposure of increasing con-
centrations of IM were compared with cell growth by MTT assay, BCR/ABL
expression by western blot analysis, changes of intracellular ROS level and
antioxidant enzymes such as peroxiredoxin (Prx) 1, 2, 3 using immunoblot
assay according to different concentrations of IM between 0 to 10 μM in time
dependent manner (24 hours/48 hours). We also repeatedly investigated the
effects of IM therapy using PRXII overexpressed K562 cells by transfection.
Results: Three BCR-ABL1 positive cell lines showed significant change in cell
viability, Intracellular ROS level, eradication of BCR/ABL oncogene and levels of
Prx2 during IM treatment with different response each other in degree and pattern
by IM exposure. The levels of BCR-ABL1 oncogene were slightly decreased in
Prx2 overexpressed K562 cells. Moreover, Prx2 overexpressed K562 cells
showed further down-regulation of Bcr-Abl oncoprotein by IM treatment.
Summary/Conclusions: Our findings may contributes to find a new pathway
on which TKIs are working besides the mechanisms of ATP binding competi-
tively, blocking the binding of ABL-BCR kinase and substract resulting apoptosis
of Ph+ cells. In addition develop the new strategies to overcome the situation
of the Imatinib resistance in P210 BCR-ABL positive disease in the future. The
importance of the roles of ROS and its PRX II, antioxidant enzymes in CML is
further established by our work.
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FUNCTIONAL CHARACTERISTICS OF ERYTHROID PROGENITOR CELLS
OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH
IMATINIB AND NILOTINIB
T. Perekhrestenko1,*, I. Sviezhentseva2, D. Bilko2, N. Tretiiak1, I. Dyagil3
1blood disease, State Institution «Institute of Hematology and Transfusiology
of NAMS of Ukraine», 2center of molecular and cell research, University of kyiv
Mogyla Academy, 3department of hematology and transplantology, State insti-
tution “National Research Center of Radiation Medicine, Kyiv, Ukraine
Background: It is believed that chronic myeloid leukemia arises as a result of
myeloid progenitor cell malignancy. There are changing of proliferative activity in
granulocyte-macrophage and erythroid hematopoiesis germs in patients bone
marrow. Сurrently we don’t have definitive results regarding tyrosine kinase
inhibitors influence on erythropoietic cell characteristics of patients with CML.
Aims: the aim of study was to determine functional characteristics of erythroid
progenitor cells of patients with chronic leukemia treated with Imatinib and
Nilotinib.
Methods: We studied 300 bone marrow samples from 75 patients: with initial
diagnosis of CML (n=7), patients receiving drug imatinib (n=47) and patients
who taking nilotinib (n=21). We provide studying of erythroid mononuclears in
semisolid in vitro and in vivo cultures. For in vivo culture we used special gel
capsule, allowing cytokines and growth factors of mouse body affect human
mononuclear cells. For in vitro culture we added 20% fetal calf serum, 30 ng/ml
erythropoietin, and 20 ng/ml mlinterleykin-6 and interleukin-9. Cultivation  was
provided 14 days, then counted the number of erythroid colonies and provided
their morphological studies. 
Results: The results showed that the increase of erythroid progenitor cells pro-
liferation rates and the reduction of differentiation rates as a result of the parallel
cultivation of patients’ bone marrow cells in vivo and in vitro happen irrespective
of the presence of cytokines and growth factors in a normal microenvironment
of these cultures. In addition, we showed that bone marrow cells of CML patients
form erythroid colonies, when placed in the animals’ body without previous
anemia. Moreover, correlative relationship was found between the number of
erythroid colonies and the number of leukemic cells in the patients bone marrow.
It was established that the acquisition of leukemic clone cells resistance to TKI
is characterized by increased proliferative activity irrespective of soluble
microenvironment factors as well as the culture medium in the erythropoietin
presence.
Summary/Conclusions: The normal microenvironment factors not effect on
the erythroid progenitor cell proliferation independence of the response to TKI
therapy. This may explain the fact that we don’t have an increase the number
of erythroid cells in patient bone marrow compared to culture in vitro. In addition,
the ability of erythroid progenitor cells to form colonies in the absence of ery-
thropoietin in culture can serve as an additional prognostic factor in the forma-
tion of resistance to TKI.
PB1810
DEVELOPMENT OF FRAGMENT ANALYSIS MULTIPLEX-PCR METHOD
TO DETECT TRANSCRIPTS OF BCR-ABL FUSION GENE IN CHRONIC
MYELOID LEUKEMIA
L. Reguilón-Gallego1,*, F. Ferrer-Marín1, R. Cifuentes1, V. Vicente1,
R. Teruel-Montoya1
1Hematología y Oncología Médica, Hospital Morales Meseguer, Centro Region-
al de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Centro de Inves-
tigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de
Salud Carlos III (ISCIII) , Murcia, Spain
Background: Chronic myeloid leukemia (CML) is a myeloproliferative, clonal
and acquired hematological disease that is included within myeloproliferative
neoplasms (WHO 2016). Its main characteristic is the presence (95% of the
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cases) of a small chromosome denominated Philadelphia chromosome, coming
from the reciprocal translocation between the chromosomes 9 and 22. Depend
where the break-point occurs, different isoforms of the fusion gene BCR-ABL
may appear. For the diagnosis of CML, detection of BCR-ABL rearrangement
is crucial; and molecular biology techniques, such as RT-PCR, may be the only
data at that point, but most current RT-PCR methods for detecting BCR–ABL
are designed and optimized for detecting the majority forms (e14a2 and e13a2)
without distinguishing between them. Characterization of the transcript is not
necessary for the diagnosis but permits follow-up at the molecular level and
differentiate between different BCR-ABL isoforms at the time of the CML diag-
nosis could be taken into account in future studies to investigate its role into
the prognosis.
Aims: To develop a new multiplex RT-PCR method coupled to fragment analy-
sis by capillary electrophoresis to identify different BCR-ABL isoforms: e13a3,
e19a2, e14a3, e6a2, e1a3, e13a2, e14a2, e1a2 and e8a1.
Methods: 34 CML patients BCR-ABL positive by qRT-PCR and 1 negative
control for BRC-ABL fusion gene were included in this study. Three hundred
nanograms of total RNA from leucocytes were used for retro-transcription
(SuperScript ® IV). Subsequently, Multiplex PCR reactions were assessed
using primers described by Burmeister in 2008 [ABL-3 primer labeled with car-
boxyferrescein (FAM)]. G6PD was chosen as endogenous gene control using
G6PD-F labeled with hexachloro-fluorescein phosphoramidite (HEX). Capillary
electrophoresis of the multiplex RT-PCR reaction was done in an ABI3130XL
analyzer, using ILS600 as marker.
Results: BCR-ABL fusion RNAs were detected in all patients (34/34), on the
other hand we did not detect BCR-ABL on the negative control. The main iso-
form identified was e14a2 (detected in 22 out of 34 patients, 64.7%). Twelve
patients were positive for e13a2 BCR-ABL isoform (35.3%). Interestingly we
identified 7 patients (20.5%) with co-expression of e14a2 and e13a2 isoforms,
being in all these cases the e14a2 isoform mainly expressed. 
Summary/Conclusions: RT-PCR combined with capillary electrophoresis is
revealed as a sensitive technique for the detection of different isoforms of BCR-
ABL and may be included as a BCR-ABL first screening. Quantification with
qRT-PCR might only be done in positive samples. Unfortunately we could not
detect any isoform besides the majority ones, due to the size of our cohort.
Finally, our study validates previous studies on the main BCR-ABL isoforms




PDGF AND BDNF PLASMA LEVELS IN CML PATIENTS BEFORE AND
AFTER INITIATION OF TKI THERAPY
Z. Litwińska1,*, K. Łuczkowska1, E. Pius-Sadowska1, A. Sobuś1,
E. Paczkowska1, B. Machaliński1
1Department of General Pathology, Pomeranian Medical University, Szczecin,
Poland
Background: Chronic myeloid leukemia (CML) is a malignant myeloprolifera-
tive neoplasm, which is characterized by t(9;22)(q34.1;q11.21) translocation,
also known as the Philadelphia chromosome (Ph). The resulting fusion gene
BCR-ABL1 encodes a constitutively active tyrosine kinase that dictates the
pathophysiology of CML. Tyrosine kinase inhibitors (TKIs) have been shown
to efficiently inhibit not only the Bcr-Abl kinase, but also act on other cell surface
tyrosine kinase receptors, such as the platelet-derived growth factor receptor
(PDGF-R). Similar receptors are vital in neurotrophin-mediated signaling path-
ways, for example TrkB receptor for brain-derived neurotrophic factor (BDNF).
PDGF is a potent mitogen for cells of mesenchymal origin and plays a signifi-
cant role in angiogenesis, a process which has recently been recognized as
crucial in growth and survival of neoplastic cells of the hematopoietic system.
BDNF acts on certain neurons of the central nervous system and the peripheral
nervous system and has a wide role in neuroprotection and neuroregeneration.
However, the exact roles of PDGF, BDNF and their receptors in normal and
malignant hematopoiesis remain unclear.
Aims: In this study we aimed to investigate the levels of PDGF-AA and BDNF
in plasma from CML patients and, where possible, to identify how TKI treatment
affects these proteins levels.
Methods: Peripheral blood samples were obtained from newly diagnosed CML
patients (n=5), CML patients treated with TKIs (n=5) and healthy controls (n=10).
Informed consent was obtained from all subjects included in the study. Plasma
PDGF-AA and BDNF levels were analyzed using Luminex technology with
Human Neurodegenerative disease Panel 3 kit (Merck Millipore, Billerica, USA).
Results: We have observed that PDGF-AA levels were elevated in CML group
(both before and during TKI treatment) compared to controls. Interestingly, we
have noticed that PDGF-AA level for newly diagnosed CML patients was higher
compared to TKI-receivers (p <0,05). In case of BDNF, we have observed sub-
tle changes between the tested groups: BDNF level in newly diagnosed CML
subjects was lower compared to controls (p <0,05), but in TKI-receivers the
level was comparable to control group (p >0,05). We have also tested one
patient in subsequent time points (at diagnosis, 3 months with TKIs, 6 months
with TKIs) for both PDGF-AA and BDNF - we have observed PDGF levels drop
and BDNF rise with time.
Summary/Conclusions: In our study we have demonstrated that PDGF-AA
and BDNF are feasible targets for plasma proteomic analysis in CML patients,
both for studying general patterns of protein expression and also for identi-
fying proteins differentially expressed before and during TKI treatment. We
have shown that PDGF level drops down after TKI treatment, while on the
opposite BDNF level in plasma raises with time in CML patients receiving
TKIs. We have also monitored these proteins levels over time in the same
subject, but this requires a larger study group to draw meaningful conclusions.
Further studies are required to elucidate the PDGF, BDNF and possibly other
growth factors, neurotrophins and their receptors role in normal and malignant
hematopoiesis.
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A CASE OF ATYPICAL CHRONIC MYELOID LEUKEMIA WITH LATE
DISCOVERY OF JAK2
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Background: Myeloproliferative neoplasms (MPN) include on the one hand
chronic myeloid leukemia defined by the presence of Philadelphia chromosome
and BCR-ABL remodeling, and on the other hand MPNs without Philadelphia
chromosome (Polycythemia vera [PV], essential thombocythemia [ET] and pri-
mary myelofibrosis [PMF]). V617F JAK2 mutation is the main recurring genetic
abnormality in these pathologies (1). It can be found in 95% of PV and 50% of
ET and PMF (2). The 2016 WHO classification makes no proposal of an entity
which would include BCR-ABL+and V617F JAK2+CML. However 28 of those
cases were described in a 2013 literature review (9). Most patients developed
either a V617F JAK2 mutation during treatment by tyrosine kinase for a BCR-
ABL+CML; or a BCR-ABL+CML during treatment for a V617F JAK2+MPN
(3,4,5,6,7). A very small number of patients showed coexistence of those two
mutations (8).
Aims: We report a  62y old woman patient with  chronic myeloid leukemia with
late discovery of JAK2.
Methods: Clinical presentation: A 62-year-old man with no notable medical
history was admitted in 2009 for CML. After failure of a first line treatment by
Imatinib in 2009 (poor tolerance and incomplete molecular response), treat-
ment by Nilotinib was initiated in 2012 allowing for, to this day, good molecular
response despite poor digestive tolerance in the form of dyspepsia. Ever
since 2012, the patient has had thrombocythemia (platelets: 826 G/L) fol-
lowed then by polycythemia (Hb: 16.7–19 g/dL) that were first attributed to
hemoconcentration and inflammation due to recurring bacterial urinary tract
infections. Neither infiltration of the lymph nodes nor organomegaly had been
noted. In 2014, the patient complained of abundant sweating in the absence
of any fever and, despite the ongoing complete molecular response, hyper-
leukocytosis was observed (see Figure 1A). In 2015 the patient, then aged
68, signaled weight loss of 10 kg despite decent overall state of health.
Tomodensitometry found evidence of hepatosplenomegaly. Taking into
account the symptoms and persisting blood count abnormalities (WBC 27.7
G/L, Hb 182 g/L, Platelets 479 G/L, Neutrophils 22.4 G/L, erythromyelemia)
a second MPN was suspected. V617F JAK2 mutation was found positive
and treatment by Hydrea for essential thrombocythemia was initiated. Adap-
tation of Nilotinib posology was decided to avoid possible cytopenia due to
its association with Hydrea.
Results: Evolution: (see Figure 1B) As of the last follow-up consultation in
2017, BCR-ABL remains undetectable and the overall state of health was pre-
served. Hyperleukocytosis as well as myelemia were persistent on the blood
count whereas hemoglobin and platelets had normalized. To determine whether
or not V617F JAK2 mutation was present at the time of CML diagnosis, a 2009
sample, in which JAK2 V617F had been estimated at less than 1%, was rean-
alyzed by means of molecular biology in January 2017.
This exam found the mutation in quantities below the clinical significance
threshold (1%). But this positivity, however small (0.19%), shows preexistence
of the pathological clone.
Summary/Conclusions: This patient’s case can be integrated in the series of
cases described in 2013 by Park et al. (9) as it consists of V617F JAK2 positive
ET onset during treatment for a BCR-ABL positive CML. The physiopathology
of those two pathologies has not yet been genetically determined (8). Are those
two independent pathologies or do they share a common tumoral clone? In
this case JAK2 and BCR-ABL evolved in negative correlation and as such it is
surmised that there were in fact two independent diseases, with two preexisting
pathological clones at the time of the first diagnosis, treatment of the first pathol-
ogy having been responsible for the proliferation of the second clone.
726 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Figure 1.
Chronic myeloid leukemia - Clinical
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E14A2 TRANSCRIPT IS ASSOCIATED WITH HIGHER PROBABILITY OF
DURABLE TREATMENT FREE REMISSION IN CML PATIENTS
M. D’Adda1,*, F. Schieppati1, E. Morello2, G. Ruggeri3, E. Cerqui1, S. Ferrari1,
C. Bottelli1, A. Passi1, G. Rossi1
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Background: TKIs discontinuation in CML-CP patients with deep molecular
response (DMR) are feasible, safe and 40-60% of them maintain treatment
free remission (TFR); sokal risk score and duration of TKI-therapy were signif-
icantly associated with molecular relapse, according to Euro-Ski and STIM1
trials.  While it is known that patients with e14a2 achieve earlier, deeper and
more durable responses compared to those with e13a2, few information is
available on the influence of the type of bcr-abl transcript on TFR duration
Aims: Here we describe our single center experience of TKI discontinuation in
CML-CP patients with sustained DMR
Methods: Bcr-abl transcripts were determined by RQ-PCR analysis performed
in accordance with EAC protocol (Gabert et al, Leukemia 2003) and to the
standards of the Italian national network Labnet. All 174 CML-CP patients
presently followed at our institution according to ELN guidelines and treated
with 1st or 2nd TKIs were analysed: 103 (59%) had e14a2 and 69 (40%) e13a2
transcript (in 2 pz bcr-abl were not detectable). Criteria for TKI discontinuation
was sustained DMR (MR4 or better) for at least 2 years. After TKI withdrawal,
RQ-PCR for BCR-ABL was performed every month during the first year and
every 2 months thereafter. TKI treatment was reintroduced immediately if DMR
loss occurred. TFR was defined as the time between the date of TKI cessation
and the date of restarting treatment for DMR loss or, if TKI was not resumed,
the date of the last contact.
Results: Forty-nine patients, 25 male and 24 female, discontinued TKI treat-
ment. At the time of discontinuation median age was 63 years (43-85), median
time from TKI start 113 months (30-172), median duration of sustained DMR
60 months (24-153). Sokal distribution was 49%, 29% and 20% for low, inter-
mediate and high risk (one patient was not evaluable). Among our 174 patients
39% (40/103) of all e14a2 patients and 13% (9/69) of all e13a2 discontinued
TKI (P 0.0002, chi square). Thirty-six patients discontinued imatinib (11 of them
with previous INF treatment), 13 stopped nilotinib (8 in first line, 5 in second
line treatment). Median follow up after treatment discontinuation was 19 months
(3-76), including 31 patients with follow up > 12 months. Thirteen (26%) patients
lost DMR. Median time off-therapy for these patients was 3 months (2-8), and
only 1 lost DMR after 6 months. Therapy was restarted in all 13 patients (2 in
MR1, 4 in MR2, 7 in MR3), 10 achieved a second DMR after a median interval
of 2 months (1-7); 2/13 patients are in M3 after 7 and 12 months, 1 patient is
not yet evaluable. Univariate analysis showed no difference in relapse risk
according to age, gender, type and duration of TKI, duration of stable DMR
and sokal score risk. Ten out of 11 patients treated with INF before imatinib
remained in TFR. Of note, the type of bcr-abl transcript was significantly linked
to DMR loss: after TKI discontinuation, 32/40 e14a2 patients (78%) maintained
DMR vs 4/9 e13a2 patients (42%) (p 0.03). After 12 months 78% (+/-6% CI95%)
of e14a2 and 41,6 (+/-17% CI95%) of e13a2 patients were still in TFR (log-
rank: P=0.033) (see Figure 1). Using multivariate analysis the type of bcr-abl
transcript and previous INF treatment correlated with DMR loss (p 0.012 and p
0.033). One patient died during follow up in DMR for CML-unrelated cause.
Figure 1.
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Summary/Conclusions: In e14a2 CML patients the probability of discontinu-
ation for sustained DMR is significantly higher as compared with e13a2
patients. Moreover, after discontinuation, e14a2 have significantly lower prob-
ability of DMR loss than e13a2. These data confirm that e14a2 transcript is
associated with a more favorable CML disease profile than e13a2 (Jain et al.,
Blood 2016); in addition they show that e14a2 is a favorable prognostic factor
for TFR maintenance
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COMPARATIVE ANALYSES OF NILOTINIB VS HIGH-DOSE IMATIB VS
SUSTAINING STANDARD-DOSE IMATINIB IN PATIENTS WITH CP
CHRONIC MYELOID LEUKEMIA FOLLOWING SUBOPTIMAL MOLECULAR
RESPONSE TO FIRST-LINE IMATINIB
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Background: Imatinib (IM) and its generic form are widely used as one of the
standards of care for chronic phase (CP) chronic myeloid leukemia (CML).
Although 7-year data by the IRIS demonstrated the long-term prognostic value
of molecular response at specific time points, achieving major molecular
response (MMR) at 18 months showed minimal event-free survival (EFS) ben-
efit, compared with not achieving MMR but having complete cytogenetic
response (CCyR). In addition, the best treatment for these patients remains
less clear.
Aims: In this study, we investigated the efficacy of nilotinib (NIL) versus high-
dose IM versus sustaining standard-dose IM for the patients in CCyR with sub-
optimal molecular response to first-line IM therapy.
Methods: Early CP CML patients who have achieved CCyR but not MMR after
18 to 24 months on first-line IM therapy at a daily dose of 400 mg were divided
into the three treatment groups; nilotinib (NIL) 400mg BID (800 mg/day; group 1)
vs IM 400 mg BID (800 mg/day; group 2) vs IM 400mg QD (400mg/day; group
3). Group 1 and 2 patients were selected in the RE-NICE multicenter study, in
which crossover to the alternate treatment arm was allowed for patients failing
to achieve a MMR at 12 months and for intolerant patients, and for patients who
lost MMR at any time of treatment. Group 3 patients who have achieved CCyR
but not MMR after at least 18 months of first-line IM therapy were selected from
the Asia CML Registry (ACR) database system with the same inclusion criteria
of RE-NICE. The efficacy endpoints are MMR rate by 12 months and MMR rate
and undetectable molecular residual disease (UMRD) rates by 36 months.
Results: With a data cut-off date of 07 Dec 2016, a total of 108 patients were
evaluated; 28 patients in NIL group (group 1), 28 patients in high-dose IM group
(group 2), and 52 patients in standard-dose IM group (group 3). Median fol-
low-up duration from enrollment was 36 months (range, 1-36), 45 months
(range, 21-63), and 90 months (range, 14-159) for each group, respectively.
All patients in group 1 remained NIL treatment, 18 patients in group 2 crossed
over to NIL 400mg BID due to intolerance (n=4) and lack of response (no MMR
after 12 months; n=14), in group 3, 22 patients switched to other treatment
due to intolerance (n=7), lack of response (no MMR; n=12), failure (n=1),
or treatment-free remission trial (n=2) and 2 patients lost to follow-up. When
data on patients who crossed over to the other treatment was included, cumu-
lative incidence (CI) of MMR by 36 months was significantly higher in group 1
than group 3 (83.1% vs 57.1%, P=0.021), but there was no different in group
1 vs 2 (P=0.195) and group 2 vs 3 (P=0.297). CI of MR4.5by 36 months showed
a trend of higher in group 1 than the other two group (11.7% vs 0% vs 2.6%,
group 1 vs 2, P=0.066, group 1 vs 3, P=0.099, group 2 vs 3, P=0.405).
Summary/Conclusions: NIL 400mg twice daily treatment showed better effi-
cacy than standard-dose IM for the treatment of patients who have suboptimal
molecular response to first-line IM. Additionally, a switch to NIL in suboptimal
molecular responder to IM had a trend for achieving a MR4.5more frequently,
suggesting the potential benefit of a treatment-free remission.
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COMPARATIVE ANALYSIS OF PULMONARY HYPERTENSION IN THE 105
CML PATIENTS TREATED WITH IMATINIB, NILOTINIB AND DASATINIB
M. Minami1,*, T. Miyamoto1, K. Akashi1
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Background: Pulmonary hypertension (PH) has been reported as a serious
adverse event in chronic myeloid leukemia (CML) patients treated by dasatinib.
French group reported incidence of PH diagnosed by cardiac catheterization
as 0.45% (13 of 2,900 patients) in symptomatic patients treated with dasatinib.
Dasatinib-related PH usually resolves after cessation of treatment, but it can
be fatal, as two deaths in France and one in Japan have been documented.
Aims: To clarify the incidence of tyrosine kinase inhibitor (TKI)-related PH, we
noninvasively screened CML patients who have been given imatinib, nilotinib
or dasatinib by echocardiography.
Methods: 105 patients with CML in chronic phase (CP) who received TKI were
enrolled in this study between 2014 and 2015. Nine patients with newly diag-
nosed CML in CP prior to TKI treatment were added as control. Patients under-
went echocardiography to evaluate values of tricuspid regurgitation pressure
gradient (TRPG), which relates to severity of PH. Patients with TRPG values
>31mmHg were suspected of PH onset according to European Society of Car-
diology criteria. All patients gave informed consent.
Results: Patients were divided into 3 groups by the TKIs they used at the time
of study enrollment; 37 patients on imatinib, 30 on nilotinib and 38 on dasatinib
(Table 1). In imatinib group, patients’ age was significantly higher, and duration
of treatment was also longer than those of the 2nd generation TKIs. Echocar-
diography revealed mean values of TRPG as 22.7, 23.1 and 23.4mmHg in
imatinib, nilotinib and dasatinib groups, respectively (p=0.887), and these val-
ues were higher than that in the newly diagnosed CML patients (19.0mmHg),
though without significance (p=0.38). Nine of the 105 patients (8.6%) presented
with an elevated TRPG>31mmHg, suggesting the presence of PH; 1 of 37
(2.7%) in imatinib group, 3 of 30 (10.0%) in nilotinib group, and 5 of 38 (13.2%)
in dasatinib group. Three patients complained of dyspnea, while the remaining
6 were asymptomatic. We found no apparent risk factors associated with TRPG
elevation, however, there were trends toward correlation of age and TRPG val-
ues in nilotinib and dasatinib treated patients, and treatment duration and TRPG
values in nilotinib treated patients. Imatinib dosage tended to inversely correlate
with TRPG value, suggesting that imatinib might decrease pulmonary arterial
blood pressure in a dose-dependent manner.
Table 1.
Summary/Conclusions: PH is a rare but life-threatening adverse event for
dasatinib-treated patients, and its definitive diagnosis is made by cardiac
catheterization. However, cardiac catheterization is too invasive for PH screen-
ing of the many patients with TKIs who do not have any symptoms. Our study,
by using echocardiography, detected TRPG elevation not only in dasatinib
treated patients (13.2%) but also in imatinib (2.7%) and nilotinib (10%), includ-
ing patients without any symptoms. This indicates possible PH onset among
patients treated with imatinib or nilotinib, as well as with dasatinib. Although
TRGP values obtained by echocardiography might not be fully compatible with
those by cardiac catheterization, the results suggested that noninvasive
echocardiography is sensitive for screening PH and is also effective for easily
screening groups of patients with suspect subclinical PH among patients treat-
ed with any available TKIs. Careful screening with echocardiography is neces-
sary especially for older patients who have received TKIs for a long time.
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DYNAMICS OF BCR-ABL1 MUTATION ACQUISITION AND LONG-TIME
MUTATION ASSOCIATED RESISTANCE PROGNOSIS IN PATIENTS WITH
CHRONIC MYELOID LEUKEMIA TREATED BY TYROSINE KINASE
INHIBITORS: RUSSIA, 2006-2016
V. Tikhonova1,2,*, Y. Finashutina1, L. Kesaeva1, Y. Stroylova3, N. Kasatkina1,
E. Misyurina4, A. Misyurin1,2
1Lab of recombinant tumor antigens, N.N.Blokhin Russian Cancer Research
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Russian Federation
Background: While chronic myeloid leukemia (CML) can successfully be treat-
ed with tyrosine kinase inhibitors (TKIs), mutations in the BCR-ABL1 kinase
domain are the most prevalent cause of TKI resistance. More than 100 BCR-
ABL1 kinase domain point mutations with various frequencies of incidence,
domain positions and implications on TKI response in CML are associated with
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TKI resistance. Here we present our data concerning prognostic significance
of BCR-ABL1 kinase domain mutations dynamics in Russian CML patients
according the follow-up study having been performed during the last 10 years.
Aims: To determine the frequency dynamics of BCR-ABL1 mutations in CML
patients and its prognostic significance.
Methods: In this study we have included 1077 TKI resistant CML patients from
112 hospitals of 77 Russian cities having been observed during the period from
2006 to 2016. BCR-ABL1 kinase domain point mutations in mRNA samples
from peripheral blood cells were analyzed by means of PCR followed by Sanger
sequencing. Statistical analysis was performed using SPSS 22.0 (IBM, USA)
and Excel 2013 (Microsoft, USA). Critical p-value was set to 0.05.
Results: 1077 TKI resistant CML patients were analyzed, among them were
41,5% men (n=447) and 58,5% women (n=630), median age – 50 (from 15 to
74). BCR-ABL1 mutations were found in 30,8% (332/1077) CML pts. We have
detected a total of 415 mutations in 332 patients, giving rise for 58 different
mutation variants. Mutation associated resistance rate was higher in women to
compare with men (72,3% against 63,2%, p=0,001). It turned out that  F317L
and H396R mutations were statistically more frequent in women, meanwhile
T315I mutation prevailed in men group (Pearson’s χ2<0,05). It was of a sudden
that BCR-ABL1 mutation distribution significantly varied according the particular
CML pts city location throughout the different regions of Russia. Although for
the period from 2006 to 2016 there were no detectable changes in mutation
frequency spectrum (Pearson’s χ2 is 0,062), the total amount of mutations asso-
ciated with TKI CML resistance has decreased from 36,6% in 2006-2008 to
24,95% in 2013-2016, but still remained significant. For particular mutations
the following dynamics was detected: frequency of imatinib-resistant mutations
decreased gradually from 2006 to 2016, while the rate of F317L and F359V
mutations underlining resistance to second generation TKI increased in 2013-
2016. T315I mutation rate expanded to the maximal level in 2014 and abruptly
decreased afterwards. This tendency change may be the consequence of the
second generation TKIs and other therapeutic strategies involvement into clin-
ical practice.
Summary/Conclusions: As far as different BCR-ABL1 kinase domain muta-
tions are associated with various types of mutation associated resistance to
TKI treatment, the detection of trends in mutation distribution in CML patients
receiving TKI treatment is very important for long time treatment strategy deci-
sion making  and early prognosis of resistance. We believe here that regional
difference of mutation profiles should also be considered. Therefore, to enable
correct triggering of particular types of TKI for CML treatment it is necessary to
obtain data of when, which and where a particular type of BCR-ABL1 mutation
is prone to appear in a distinguished cohort of CML pts.
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IMPACT OF BCR-ABL1 TRANSCRIPT TYPE IN CHRONIC MYELOID
LEUKEMIA TREATED FRONTLINE WITH NILOTINIB
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Background: Chronic myeloid leukemia (CML) is driven by different transcript
types, but the majority of patients have a e13a2 (b2a2) transcript, a e14a2
(b3a2) transcript or a co-expression of e13a2/e14a2 transcripts. In imatinib-
treated patients, the e13a2 transcript has been associated to slower and inferior
molecular responses. Few data on the prognostic impact of BCR-ABL1 tran-
script type in CML patients treated with second generation tyrosine kinase
inhibitors (TKIs) are still available.
Aims: To assess the impact of BCR-ABL1 transcript type on molecular
response and outcome in newly diagnosed adult CML patients treated frontline
with nilotinib (NIL).
Methods: An analysis of 345 CML patients at diagnosis (chronic phase)
enrolled within 3 multicentric prospective studies of the GIMEMA CML Working
Party (NCT00481052, NCT00769327, NCT01535391) was performed. The ini-
tial treatment was NIL 300 mg BID or NIL 400 mg BID. Definitions: major molec-
ular response (MMR), BCR-ABL1IS ratio <0.1%; deep molecular response
(MR4.0), BCR-ABL1IS ratio <0.01% with >10,000 ABL1 copies; progression,
transformation to advanced phases; death, at any time and for any reason.
Cumulative incidences of response were estimated under consideration of com-
peting risks (progression, death) and compared by Gray test. Progression-free
survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier
method and compared by log-rank test. 
Results: Patients expressing rare transcripts (e1a2 or e19a2; n=7) and patients
with unknown transcript type (n=10) were excluded: 328 patients were evalu-
able, 38% with e13a2 transcript, 53% with e14a2 transcript and 9% expressing
both transcripts. No significant differences in age, gender, Sokal or EUTOS
long-term survival score distribution, presence of clonal chromosomal abnor-
malities in Ph+ cells, or NIL dose were observed. The median follow-up was 60
months (range 24-82 months). The response rates and the survival probabilities
were uniformly lower in patients with e13a2 transcript (N=124) compared to
patients with e14a2 transcript (N=174), but the differences were not significant:
MMR by 12 months, 66% vs 72%, p=0.244; MR4.0 by 36 months, 56% vs 66%,
p=0.067; estimated cumulative incidence of MMR, 82% vs 88%, p=0.135; esti-
mated cumulative incidence of MR4.0, 60% vs 69%, p=0.101; estimated PFS,
88% vs 93%, p=0.547; estimated OS, 89% vs 94%, p=0.436. The responses
and the survival probabilities of patients co-expressing the e13a2 and the e14a2
transcripts (N=30) were similar to or even better than the ones of e14a2
patients. Grouping together the patients with e14a2 transcript alone and the
patients with co-expression of both transcripts (N=174+30=204), and comparing
them to patients with e13a2 transcript alone (N=124), the response differences
were significant (cumulative incidence of MMR and MR4.0, p=0.050 and
p=0.036, respectively), but no outcome differences emerged (PFS and OS,
p=0.340 and p=0.276, respectively).
Summary/Conclusions: Lower molecular response rates in patients with
e13a2 transcript were observed, but the differences were small and mostly not
significant. No outcome differences were detected. Further studies in larger
patient cohorts are required in order to clarify whether including the transcript
type in the calculation of the baseline risk scores may improve prognostic strat-
ification, and whether NIL or other second generation TKIs should be preferred
as first-line therapy in patients aiming at treatment-free remission.
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IMATINIB (IM) 400MG IN PATIENTS WITH CML1ST CP RESULTS IN A
HIGHER MOLECULAR RESPONSE RATE AT 6 MONTHS COMPARED TO
IM/ HYDROXYUREA. FINAL RESULTS OF THE CML2004 STUDY.
NCT 02480608
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Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universität München,
München, 12III. Medizinische Klinik, Universität Heidelberg, Medizinische
Fakultät, Mannheim, Germany, 13Division of Hematology and Hematologic
Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake
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Background: Imatinib (IM) monotherapy remains an acceptable option to treat
newly diagnosed patients with chronic myeloid leukemia (CML) in the chronic
phase (CP). Hydroxyurea (HU) is effective in controlling elevated white blood
cell counts and has been widely used to treat CML prior to the era of tyrosine
kinase inhibitors (TKIs). The combinations of IM and HU have been tested in
vitro and showed a additive suppression of CML CFU-GM cells. Combinations
of IM and cytotoxic agents such as cytarabine have been tested also in vivo,
but  no data are available for the combination of IM and HU in CML.
Aims: The East German Study Group conducted a phase I study to identify
the dose of HU in combination with standard dose IM (400mg daily) that would
result in mild myelosuppression (white blood cell count 3,000-4,000/mL). Start-
ing dose of HU was 500mg daily which was increased by 500mg every 3 weeks
to a maximum of 3,000 mg daily. According to protocol, 500mg HU was identi-
fied as the starting dose for the randomized phase II study which tested the
combination vs standard dose IM, with the rate of major molecular response
(MMR) at 18 months as the primary endpoint.
Methods: Starting in 2002, 20 adult patients with newly diagnosed CP-CML
were included in the phase I study. Additional 93 patients were enrolled in the
phase II of the study, 5 of whom were excluded. With ratio 2:1 in phase II, 88
patients were randomized to the IM/HU (n=59) and IM (n=29) arm, respectively.
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Three patients (2 IM/HU, 1IM) were lost to follow-up. As prospectively designed,
all available IM/HU patients (n=77) were analyzed together. According to the
study protocol, patients from the CML IV study were to be added to obtain
equal numbers for analysis. To arrive at a total of 77 IM patients, from study IV
another 49 patients were selected by propensity score matching. The median
age of the 154 patients was 55 years (range 18 – 82). The ELTS prognostic
score was available for 141 patients and was high in 8 (5.7%), intermediate in
35 (24.8%) and low in 98 (69.5%), with no significant differences between treat-
ment groups.
Results: The 5-year overall survival (OS) / progression-free survival (PFS)
probabilities were 90.4 and 86.7% in the IM/HU and twice 84.9% in the IM
arm (p=not significant). With IM/HU, the probabilities of complete cytogenetic
response (CCR) at 6, 12, and 18 months were 54.3, 84.0, and 93.7%. In the
IM arm, the corresponding numbers were 70.4, 84.9, and 83.3% (p=not sig-
nificant). Primary endpoint was MMR rate at 18 months. There was no sig-
nificant difference between IM/HU (65.8%) and IM (66.0%). At 6 months,
MMR rates were 21.6 (IM/HU) vs 41.1% (p=0.0383) and at 12 months 41.9
(IM/HU) vs 58.9% (not significant). Time to event analyses of OS and PFS
did not result in significant differences; neither did group comparisons
between the probabilities of CCR and MMR. The median HU dose was
500mg (range 152-3000); the median IM dose was 400 mg (range 145-
617mg) in both arms. The gross numbers of adverse events in general or of
adverse events of grade 4 were not different between the two arms, but
cumulative incidences showed an earlier occurrence in the IM/HU than in
the IM arm (p= 0.0343, Gray test)
Summary/Conclusions: Compared to Imatinib only, the combination of Ima-
tinib and HU resulted in a lower MMR rate at 6 months but a similar MMR rate
at 18 months. Furthermore, IM/HU was associated with more early adverse
events. There was no indication of a beneficial effect in the treatment of CML
patients in 1st chronic phase using the combination of IM with HU.
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A MULTICENTER, OBSERVATIONAL, AMBISPECTIVE STUDY
EVALUATING EFFICACY AND SAFETY OF GENERIC IMATINIB
COMPARED TO GLEEVEC IN CHRONIC MYELOGENOUS LEUKEMIA IN
CHRONIC PHASE - 3 MONTHS RESPONSE ANALYSIS
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Background: The efficacy of branded imatinib (Gleevec) in the first-line treat-
ment of chronic myeloid leukemia (CML) has been demonstrated in several
clinical studies. However, there are few consistent data in the literature on the
efficacy and adverse effects of generic formulations of imatinib. In Brazil, CML
patients have been treated in the national public health system with generic
imatinib since June 2013. 
Aims: The present study aims to evaluate the efficacy and safety of generic
imatinib in the treatment of CML in comparison with the reference drug
(Gleevec) in the first three months of imatinib treatment.
Methods: This is a multicenter, observational, ambispective, cohort-type study.
The study was initiated in January 2015 with the intended participation of 17
Brazilian centers. In the prospective group, were selected chronic phase CML
patients who started their first-line treatment with generic imatinib between
January 2015 and October 2016, whereas retrospective group was treated
with Gleevecbetween January 2010 and December 2011. All patients started
imatinib less than six months from diagnosis. Study data were collected and
managed using REDCap electronic data capture tools. Demographic data were
collected at diagnosis: age, gender, Sokal, Hasford, EUTOS score, comorbidi-
ties, cytogenetics, BCR-ABL transcript type. The definition of the responses
followed the European Leukemia Net 2013 criteria. Adverse events were
assessed based on the Common Terminology Criteria for Adverse Events
(CTCAE) Version 4.0.3, 2010. Statistical analysis: SPSS version 21.0 was
used applying the chi-square and t-test, when adequate. All analysis considered
p-value <0.05 as significant.
Results: Ten centers have registered 177 patients in the retrospective group
and 68 patients in the prospective group so far. For this preliminary analysis,
response data from 132 patients were available (47 from prospective and 85
from the retrospective groups). The median age of patients was 54 years in
the prospective group and 46 years in the retrospective group (P=0.12). Sokal
score in prospective and retrospective groups, respectively: low risk
42%/52%; intermediate risk 42%/31% and high risk 45%/67% (P=0.48).
There was no difference between the groups concerning gender, Hasford,
EUTOS scores, ECOG, blood cell counts at diagnosis and before starting
imatinib and BCR-ABL transcripts. Regarding responses, there was no dif-
ference in the hematological, complete cytogenetic responses and rate of
BCR-ABL transcripts >10% at three months. However, there was a higher
rate of failure at three months according to the ELN 2013 criteria in the
prospective group (14.9% versus 4.7% Gleevec group, P=0.04). There was
no significant difference in grade 3 and 4 hematological and non-hematolog-
ical toxicity, but there was one early death in the prospective group (acute
peripheral arterial occlusion and renal failure). Four patients discontinued
imatinib: one from Gleevec group (resistance) and three from the generic
group due to intolerance (1) and resistance (2). 
Summary/Conclusions: According to ELN-2013 criteria, there was a higher
rate of failure in the prospective group (generic Imatinib) at three months, but
no difference in toxicity. The register is ongoing; the confirmation of this data
and the impact in prognosis will be evaluated in the long-term follow-up, after
increasing the number of patients. 
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COMPLEX ADDITIONAL CHROMOSOME ABERRATIONS IN PH-POSITIVE
CELLS IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS’ SURVIVAL
IN THE ERA OF TYROSINE KINASE INHIBITORS
M. Fominykh1,*, O. Shuhov2, I. Martynkevich1, V. Shuvaev1, E. Chelysheva2,
A. Turkina2
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Background: Additional chromosomal aberrations (ACA) as marker of clonal
evolution in chronic myeloid leukemia (CML) patients were previously noted in
association with resistance to therapy. The presents of ACA have been asso-
ciated with a worse prognosis for survival in the pre-TKI era. The ACA classi-
fication proposed earlier was based only on its frequencies. Whereas ACA’s
clinical impact had not yet been clearly established.
Aims: The aim of our study was to evaluate the long-term impact of the ACA
presence in Ph-positive cells in CML patients on TKI treatment results.
Methods: 30 patients with ACA in Ph-positive cells treated in our center from
2005 to 2015 years were included in this study. Cytogenetic analyses of at
least 20 Giemsa-banded bone marrow metaphases were interpreted per
ISCN 2013. We analyzed overall survival (OS) and cumulative incidence of
CML-related death on TKI treatment. Cox regression was used for multivari-
ate survival analysis, that included next covariates: number of ACA, type of
ACA, age, TKI type, CP or AP at diagnosis. OS was estimated by Kaplan-
Meier method with log-rank test for comparison. Cumulative incidence of
CML-related death was estimated into consideration the presents of com-
peting risks (CML-unrelated death) using Gray’s test for comparison between
groups. 
Results: Median follow-up period in ACA group (n=30) was 51 months (3-
124). ACA at diagnosis were detected in 16 (53%) of 30 patients. Chronic
phase CML at diagnosis was determined in 23 (77%) patients. Imatinib was
used as first-line in 20 (67%) patients, 3 (10%) patients were initially treated
with Nilotinib. Accelerated phase was defined in 7 (23%) patients. In that
group treatment of 6 patients was started with Imatinib and Dasatinib was
given initially for one patient. «Major-route» ACAs (trisomy 8,
+der(22)t(9;22)(q34;q11), i(17)(q10), trisomy 19,) were detected in 16 (53%)
of 30 patients. Complex aberrations (2 ACA and more) were revealed in 7
(23%) patients, 4 patients from this group had «major-route» ACA. 10-years
OS in the whole ACA group was 67%, 10-years cumulative incidence of CML-
related death was 23%. Number of ACA (p=0.03, HR=13.2) and age (p=0.03,
HR=1.14) had statistical significance influence on survival by regression
analysis. 10-years OS was 31% and 77% (p<0.05) in patients with complex
ACA and single ACA respectively, 10-years cumulative incidence of CML-
related death was 54% for patients with complex aberrations versus 10% for
single ACA patients (p<0.05) (Figure 1).
Figure 1.
Summary/Conclusions: Our results showed that TKI treated CML patients
with complex ACAs have a higher risk of progression and death in comparison
with single-ACA patients. 
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BCR/ABL1 TRANSCRIPT E13A2 IS ASSOCIATED WITH HIGHER
CUMULATIVE PROBABILITY OF LOSS OF MAJOR MOLECULAR
RESPONSE IN CML PATIENTS TREATED WITH NILOTINIB AS THE 2-ND
LINE THERAPY
I. Dmytrenko1,*, V. Fedorenko1, Z. Martina2, V. Sholoyko2, T. Shlyakhtychenko1,
Z. Minchenko1, I. Dyagil2
1Immunogenetic Laboratory, 2Hematology and Transplantology Department ,
National Research Center for Radiation Medicine, Kyiv, Ukraine
Background: Several types of transcripts can be produced during chromoso-
mal translocation, which lead to formation of the BCR/ABL fusion gene in
patients with chronic myeloid leukemia (CML). Previous results of a few large
studies showed that patients with CML in chronic phase (CP) with e13a2 tran-
script have inferior responses to frontline imatinib therapy compared to patients
with the e14a2 transcript.
Aims: To investigate the prognostic significance of e13a2 and b14a2
BCR/ABL1 transcripts in CML patients switched to nilotinib after suboptimal
response  or failure on frontline imatinib.
Methods: CP-CML patients (N=143) who did not achieve complete cytogenetic
response (CCR) after imatinib therapy (600 or 800 mg once daily) and were
switched to nilotinib 400 mg twice daily, were enrolled in present study (55
patients with e13a2 transcript and 88 patients – with e14a2 transcript). The
median of imatinib treatment before switching to nilotinib was 44 months (range
1-137). A qualitative RT-PCR for BCR/ABL1 transcript was performed at diag-
nosis. The patients who achieved CCR but did not have major molecular
response (MMR) as well as patients with rare BCR/ABL1 transcripts and coex-
pression were excluded from the analysis. Probability of overall survival (OS),
progression-free survival (PFS) and event-free survival (EFS) were calculated
using Kaplan-Meier method. Event in EFS was defined as death of a patient
on treatment for any reason, progression of disease, or loss of CCR or MMR.
Differences between groups were assessed using log-rank, χ2-tests and Mann-
Whitney U-tests. Cumulative probability of CCR, MMR, MR4,0
(BCR/ABL<0,01%) and loss of CCR and MMR was assessed using Kaplan-
Meier method.
Results: The median follow up was 23 (range 4 – 82) months. The groups with
both of the BCR/ABL1 main transcripts were comparable for the disease phase,
Sokal risk score and the proportion of patients with additional chromosomal
abnormalities in Ph-positive cells. No correlation of transcript type with age or
sex was observed. Transcript e13a2 was associated with higher WBC
(120x109/L vs 95.3x109/L, p=0.02) and lower baseline percentage of
eosinophils (p=0.041). No differences were found in other differential counts of
peripheral blood, hemoglobin concentration, or spleen size.
The time to CCR, MMR and MR4,0 and rate of CCR (52% and 52%), MMR
(38% and 33%) and MR4 (23% and 22%) were comparable in patients with
e13a2 and e14a2 transcripts respectively. Estimated probability of CCR, MMR
and MR4,0 also did not differ in both groups. The rate of optimal response, pri-
mary and secondary resistance to nilotinib therapy was comparable in both
groups. Whereas there were no differences in the estimated probability of CCR
loss in both groups, but rate and cumulative incidence of MMR loss was signif-
icant higher (69% vs 11%, p=0.037) in patients with e13a2 transcript. No differ-
ence between groups was observed with regard to PFS, EFS and OS.
Summary/Conclusions: Analisys of 143 CML patients treated with nilotinib
as the 2-nd line therapy suggests that patients with e13a2 transcript have less
stable therapy response and demonstrate higher cumulative incidence of MMR
loss (molecular relapse). But outcome differences were nor observed. Further
analysis of a larger number of events and longer observation is required.
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ANALYSIS OF GENERIC IMATINIB EFFICACY IN CHRONIC MYELOID
LEUKEMIA TREATMENT: MORE THAN FOUR YEARS OF EXPERIENCE IN
SOUTHERN SERBIA
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Background: Tyrosine kinase inhibitors (TKIs) are the golden standard in the
treatment of chronic phase chronic myeloid leukemia (CP-CML) due to their
high efficacy and mild toxicity profile. Because of the high price of these drugs,
the use of generics is encouraged to reduce health care costs. In the literature,
there is still limited data and some concerns about the effectiveness of generic
imatinib (GI), although there is a growing number of countries in which it is
used instead of original imatinib (OI).
Aims: The objective of this study was to evaluate efficacy and safety of GI in
newly diagnosed CP-CML patients treated with frontline GI and in patients
switched from OI to GI. 
Methods: Cohort of 101 adult patients with CP-CML was analysed, treated
with TKIs in our institution during period from August 2012 to February 2017.
First group consisted of 53 patients treated with GI (Anzovip). According to
European LeukemiaNet (ELN) 2013 guidelines, rate of optimum therapeutic
response was analysed, as well as rate of treatment failure at 6 and 12 months.
The second group consisted of 48 patients switched from OI to GI, in which the
rate of achieved therapeutic response at the time of switching and the rate of
maintenance of CCyR, MMR and MR4 after a minimum of 12 months under
therapy with GI were both analysed. In order to investigate safety of GI, in both
groups rate of hematological and non-hematological adverse effects (AEs), all
grades according CTCAE criteria, were analysed. 
Results: Analysis of the optimal response by ELN criteria in the group with GI
showed that at 6 months 33/53 (62.3%) patients achieved CCyR, BCR-ABL<1%
was in 27/52 (51.9%) patients, while 15/52 (28.8%) of patients achieved MMR.
At 12 months of therapy, 35/49 (71.4%) of analysed patients achieved CCyR,
and 25/49 (48.9%) achieved MMR. ELN criteria for treatment failure at 6 months
fulfilled 12/53 (22.6%) patients, while at 12 months ELN criteria satisfied 13/49
(26.5%) of analysed patients. After 18 months of therapy with GI the rate of
CCyR was 35/46 (76.1%) and MMR was 28/45 (62.1%) and showed trend of
increase. During the median follow-up period of 23.8 months 3 patients have
progressed to blast phase and total of 7 patients died. In the second group, in
time of switching from OI to GI, the rates of achieved CCyR, MMR and MR4
were 82.5%, 65.8% and 49% of patients respectively. The rate of maintenance
of previously achieved CCyR was 95%, of MMR 88% and of MR4 72% in the
course of the median duration of GI exposure of 37.8 months. When comparing
first and second group respectively, the rates of patients which have been
switched to 2nd generation of TKI because of the failure or intolerance to imatinib
were 27.8% vs 24.8%, and 60.5% vs 64.5% of them achieved secondary opti-
mal therapeutic response (CCyR plus MMR), while 25% vs 20% of them have
been sent to BMT. Group switched from OI to GI had not significantly different
non-hematological AEs of all grades compared to GI group (21.7% vs.24.2%,
p=0.991). Furthermore, the rate of grade 3-4 hematological AEs were similar
in both groups (13% vs 15%, p=0.952). 
Summary/Conclusions: Results of this study with extended follow-up of more
than four years are further evidence of that the generic imatinib is at least non-
inferior to the original imatinib regarding efficacy both when used initially or as
a subsequent replacement for branded imatinib.
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ACHIEVING OPTIMAL RESPONSE AT 12 MONTHS IS ASSOCIATED WITH
A BETTER HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH
CHRONIC MYELOID LEUKEMIA: A PROSPECTIVE, LONGITUDINAL,
SINGLE CENTER STUDY
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2Peking University Clinical Research Institute, Beijing, China, 3Novartis Pharma
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Background: Health-related quality-of-life (HRQoL) profile is now recognized as
an important component in the management of Chronic myeloid leukemia (CML).
Aims: To explore the HRQoL profiles of patients with CML in the chronic phase
(CP) who were treated with front-line imatinib or nilotinib, in order to assess the
relationship between early response and HRQoL outcomes.
Methods: A prospective, longitudinal, single center study was conducted to
assess the response to treatment with imatinib or nilotinib and the HRQoL profile
of patients who were newly diagnosed with CML-CP enrolled into ENESTchina
study. Responses based on molecular and cytogenetic outcomes were measured
according to the European LeukemiaNet recommendations, and patient-reported
HRQoL profile was measured by the SF-36 health survey. 
Results: Fifty-nine patients were randomly assigned to receive imatinib (n=31)
or nilotinib (n=28). In multivariate analysis, the use of nilotinib was identified as
an independent factor affecting the achievement of optimal response at 6
months (OR=3.9, 95% CI, 1.0-14.9; P =0.043) and 12 months (OR=5.6, 95%
CI, 1.7-17.9; P =0.004). With a median follow-up of 60 months, the probabilities
of failure-free survival (all P values <0.001) and progression-free survival (all P
values <0.05) at 5 years were significantly higher in patients who achieved
optimal response at 3, 6, or 12 months than those who achieved non-optimal
response (warning or failure), and overall survival rate at 5 years was signifi-
cantly higher in those who achieved optimal response at 12 months (P =0.047).
Achieving optimal response at 12 months was associated with better role lim-
itations due to physical health problems (P =0.0019) and role limitations due to
emotional problems (P =0.0110) and was the sole factor associated with sig-
nificantly improving physical component summary over time (P =0.0160). In
addition, achieving optimal response at 6 months had a tendency of high phys-
ical functioning (P =0.0674), social functioning (P =0.0571), and role limitations
due to emotional problems (P =0.0916) scores. Age <40 years, female gender,
and higher education level were also associated with better HRQoL subscales. 
Summary/Conclusions: Achieving optimal response at 12 months was asso-
ciated not only with longer overall survival and less treatment failure and disease
progression, but also better HRQoL in newly diagnosed patients with CML-CP
on front-line tyrosine kinase inhibitor.
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SECOND-LINE TYROSINE KINASE INHIBITORS IN CHRONIC PHASE -
CHRONIC MYELOGENOUS LEUKEMIA (CML-CP)
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Background: Achieving deep molecular response, ≥4.5-log reduction (MR4.5;
BCR-ABL1 on the International Scale [IS] ≤0.0032%), is one of the important
prerequisites for attempting treatment-free remission. Limited information is
available on comparative rates of MR4.5 between nilotinib and dasatinib in sec-
ond-line (2L).
Aims: This study aims to investigate time to achieving MR4.5 and major molec-
ular response (MMR; ≥3-log reduction or ≤0.1% in BCR–ABL1 on IS) in CML-
CP patients (pts) treated with nilotinib vs dasatinib in 2L.
Methods: An online physician panel approach was used to recruit oncologists
(N=141) globally to conduct a retrospective medical chart audit. Physicians
were instructed to select up to 4 pts who met the following criteria via a random
letter generation scheme for the first letter of pt’s last name: diagnosed with
CML-CP at age ≥18 years, initiated 2L nilotinib or dasatinib between 1/1/11
and 3/1/15, and had ≥12 mos of follow-up data after initiating 1L TKI. Multivari-
ate Cox proportional hazards models accounting for country clustering random
effects were used to assess the effect of nilotinib vs dasatinib on time to MR4.5
and MMR, adjusting for age, gender, Sokal risk score at diagnosis, hydroxyurea
use before 1L TKI, 1st vs 2nd generation TKI as 1L, and reasons for 1L TKI dis-
continuation. Adjusted hazard ratios (HR) and 95% confidence intervals (CI)
were reported.  Adverse events (AEs) were also described.
Results: The study included 236 pts from Australia, Brazil, France, Germany,
Italy, and Netherlands treated with nilotinib (N=115[49%]) or dasatinib
(N=121[51%]) in 2L. Both groups had a similar mean follow-up of 23 mos,
mean age of 57 years, and were 35% female. 8% of 2L nilotinib and 22% of 2L
dasatinib pts were treated with the other 2nd generation TKI in 1L (p<0.01). A
higher proportion of nilotinib pts had high-risk Sokal score (20.9% vs 11.6%,
p=0.05) and received prior hydroxyurea (8.7% vs 3.3%, p=0.08) vs dasa-
tinib.  85% and 11% of 2L nilotinib pts discontinued 1L TKI due to resistance
and intolerance, respectively, prior to switching to nilotinib, vs 74% and 22%
for 2L dasatinib pts (both p<0.05). The univariate Cox model showed that nilo-
tinib had a non-significantly higher rate of achieving MR4.5 than dasatinib (32%
vs 31% at 24 mos for 2L nilotinib and 2L dasatinib pts, respectively, based on
the Kaplan Meier estimator; unadjusted HR=1.09, 95% CI [0.87, 1.38], p=0.46);
however, after multivariate adjustment, nilotinib reached a significantly higher
rate of achieving MR4.5 (adjusted HR=1.36, 95% CI [1.07, 1.73], p<0.01) than
dasatinib. Among those who achieved MR4.5, 45% of nilotinib pts maintained
MR4.5for ≥1 year vs 39% of dasatinib pts (p=0.60). Additionally, high-risk Sokal
score (HR=0.31; 95% CI [0.14, 0.72], p<0.01) and resistance to 1L TKI
(HR=0.60; 95% CI [0.42, 0.86], p<0.01) were inversely associated with achiev-
ing MR4.5. There was no significant difference in MMR achievement between
2L TKI groups. Over 3 times more dasatinib pts experienced pleural and peri-
cardial effusion AEs than nilotinib pts (9.9% vs 2.6%; p=0.02). One nilotinib pt
had ischemic heart disease-related AE vs none for the dasatinib group (p=0.49).
Summary/Conclusions: This retrospective chart audit study suggests that 2L
nilotinib may be associated with a higher rate of MR4.5 than 2L dasatinib in
CML-CP. Our results should be taken with caution as this study is susceptible
to unmeasured confounding and biases due to its retrospective and observa-
tional nature. Rigorous clinical assessment in a prospective setting is needed
to conclusively compare rates of patients achieving MR4.5.
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COMPUTATIONALLY INTELLIGENT PREDICTION OF CLINICAL
OUTCOME IN CHRONIC MYELOID LEUKEMIA
Z. Cojbasic1, I. Cojbasic2,3,*, L. Macukanovic-Golubovic2,3, M. Vucic3,4
1Mechanical Engineering Faculty, University of Nis, 2Clinic of Hematology, Clin-
ical Center Nis, 3Facuty of Medicine, University of Nis, 4Clinic of Hematology,
Clinical Ceter Nis, Nis, Serbia
Background: Computational intelligence has been applied to a wide range of
problems to assist in decision-making, especially artificial neural networks,
fuzzy systems and powerful hybrid neuro-fuzzy approaches have already
proven their strong potentials in medicine. Despite that, applications in hema-
tology are still scarce.
Aims: In this study we have developed novel ANFIS neuro-fuzzy prognostic
models, based on clinical and morphometric diagnostic data, to enable better
prediction of complete cytogenetic response (CCgR) for patients with chronic
myeloid leukemia.
Methods: This prospective study included a consecutive series of patients with
chronic myeloid leukemia (CML) who were started on imatinib therapy. Analysis
was performed with CCgR at 6, 12, and 18 months as the outcome variables. A
total of 40 patients on imatinib therapy were included in the final analysis. Of
these, 25 (62.5%), 29 (72.5%), and 32 (80%), respectively, achieved CCgR at 6,
12, and 18 months after initiation of imatinib. Computationally intelligent neuro-
fuzzy models that were developed included EUTOS score on diagnosis and one
of the following morphometric parameters: microvascular density, length of the
minor axis, area or circularity of the blood vessel. Adaptive neuro-fuzzy systems
represent a specific combination of artificial neural networks and fuzzy logic, thus
combining the learning ability of artificial neural networks with the knowledge
representation capability of fuzzy logic systems. ANFIS (Adaptive Neuro Fuzzy
Inference System) consists of five layers of nodes (neurons), each of which per-
forms a particular function on incoming signals as well as a set of parameters
pertaining to this node. The basic architecture of ANFIS using hybrid learning
algorithm is presented in Figure 1.
Results: All analysed patients have received imatinib mesylate as their first-
line therapy for CML. Model predictions (0–1) for any individual patient were
interpreted as probability of CCgR at 6, 12 or 18 months. The overall accuracy
of the final model was determined by comparing the predicted values with the
actual events. A probability cut-off point of 0.50 (50%) was used to classify
observations as events or non events, and patents were divided in training,
validation and testing groups. Best performing ANFIS model, including EUTOS
score and minor axis morphometric parameter was better than a model that
includes only EUTOS score and regression model based on the same inputs.
Overall model correct classification achieved for EUTOS, two input LR model
and two input ANFIS model were respectively 75%, 75% and 77.5%, while
areas under curve on ROC graphs were 0.776, 0.829 and 0.875 respectively.
Figure 1.
Summary/Conclusions: The major finding of this study is that ANFIS models
using the morphometric parameters, available at diagnosis of chronic phase
of the CML, may improve prediction of CCgR at 6, 12 and 18 months on imatinib
therapy, in comparison to the EUTOS score being the standard prognostic
scoring system and regression models using the same inputs. Using neuro-
fuzzy computationally intelligent ANFIS models with morphometric parameters
in conjunction with EUTOS score improves prediction of CCgR. Validation on
larger groups of patients is needed, but these findings indicate that neuro fuzzy
models could aid in individual CML patient risk stratification.
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A NATIONWIDE OBSERVATIONAL STUDY OF PONATINIB IN CHRONIC
MYELOCYTIC LEUKEMIA OUTSIDE CLINICAL TRIALS
A. Shacham Abulafia1,2,*, R. Ratzon2, D. Lavie3, Y. Volchek4, R. Ram2,5,
I. Hellman2,6, L. Shargian7, A. Gourevietch8, E. Chubar9,
M. Koren-Michowitz 2,10, I. zilbershats11, P. Raanani12, U. Rozovski12
1hemato-oncology, Rabin Medical Center, Petah Tikva, 2Sackler School of
Medicine , Tel Aviv University, Ramat-Aviv, 3Department of Hematology ,
Hadassah-Hebrew University Medical Centre, Jerusalem, 4Hematology Divi-
sion , Chaim Sheba Medical Center, Tel-Hashomer, 5Bone Marrow Transplan-
tation Unit, Sourasky Medical Center, Tel Aviv, 6Department of Hematology,
Meir Medical Center, Kfar Saba, 7Bone Marrow Transplantation Unit, Rabin
Medical Center, Petah Tikva, 8Hematology Institute , Soroka University Medical
Center, Beer-Sheva, 9Hematology unit, HaEmek Medical Center, Afula,
10Department of hematology, Assaf Harofeh Medical Center, Zeriffin, 11Depart-
ment of hematology, Wolfson Medical Center, Holon, Israel
Background: In December 2014 the oral tyrosine kinase inhibitor (TKI), pona-
tinib was granted an accelerated approval by the FDA based on promising
results from the phase II PACE (Ponatinib Ph-ALL and CML evaluation) trial.
Yet, nowadays the use of this drug is limited because of safety issues, most
notably increased risk of vascular complications. Currently, there is very little
real-life information regarding the use of ponatinib outside clinical trials. 
Aims: The purpose of the current study is to characterize patients who received
ponatinib and to assess the safety profile and efficacy of ponatinib outside clin-
ical trials. 
Methods: Data from electronic charts of chronic myeloid leukemia (CML)
patients treated with ponatinib were analyzed.
Results: Patients characteristics: Between 4.2011 and 1.2017 (69 months)
37 patients with an initial diagnosis of CML in 9 medical centers in Israel
received ponatinib. The median age at time of treatment was 43 years
(range:  9 to 82) and   approximately half of the patients had chronic phase
CML (N= 19, 53%). Based on their medical history, 36% (N=12) were at
increased risk for vascular complications. Pre-ponatinib treatments: Patients
received at least one other TKI and most received at-least two different TKI-
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based regimens (N=28, 76%). Nine patients (25%) underwent hematopoietic
stem cell transplantation (HSCT) prior to ponatinib. The time that lapsed from
diagnosis until ponatinib initiation ranged considerably (from 1 to 215 months,
median 47 months). Indications for ponatinib switch: 26% of patients (N=9)
switched to ponatinib because T315I mutation was detected. The remaining
switched either because of progressive disease, i.e. accelerated (N=5, 14%)
or blastic (17%, N=6, 17%) phases, and 14 (39%) because they experienced
loss of previous molecular or cytogenetics response. Only 5% (N=2) switched
because of unacceptable side effects to previous treatments. Treatment with
Ponatinib: Patients received ponatinib for a median time of 14 months (range:
1 to 51). The drug started at the recommended dose of 45 mg/day only in
60% (N=22) of patients and in 24% of them (N=9) the dose was reduced dur-
ing treatment. The median survival time of patients with ponatinib was 38
months (95%CI: 30 to 47 months) (Figure 1). Patients died because of cere-
brovascular event (N=1), sepsis (N=2) or graft vs host disease that developed
shortly after HSCT. Response assessment: Response assessment was avail-
able for 32 patients (86%). Seventy percent (N=22) achieved molecular
response, of which 60% (N=13) achieved at least major molecular response.
The median time to maximal response was 7 months (range: 3 to 28 months).
Drug discontinuation: Twenty four percent (N=9) discontinued ponatinib after
a median of 7 months (range: 1 to 18 months) because of disease progression
(N=6) or severe adverse effects in two patients (cerebrovascular event and
severe pancytopenia).
Figure 1.
Summary/Conclusions: In our cohort ponatinib was almost always used in
patients who experienced treatment failure to previous TKIs. Still, molecular
response was achieved in most patients, even in those with progressive dis-
ease in accelerated or blastic phases. The vast majority of patients received
reduced doses of ponatinib and although more than one third of patients were
at-risk for vascular events, only two patients developed serious life-threaten-
ing vascular episodes. In heavily pre-treated patients, ponatinib is effective
and safe and can be considered even in patients with cardiovascular risk fac-
tors. 
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MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE
INHIBITORS IN PATIENTS WITH BCR-ABL1(+) CHRONIC MYELOID
LEUKEMIA PRESENTING WITH AN ISOLATED THROMBOCYTOSIS AT
THE ONSET
G. Balatzenko1,*, V. Hrischev2, K. Ignatova2, Z. Stoyanova2, A. Lilova2,
S. Angelova1, S. Ivanova1, M. Romanova1, I. Ivanova1, G. Tsvetkova3,
E. Hadjiev3, V. Madzharova2, T. Dikov2, B. Spassov2, Y. Davidkova2,
M. Jagurinoski2, M. Guenova2
1Laboratory of Cytogenetics and Molecular Biology, 2National Specialised Hos-
pital for Active Treatment of Hematological Diseases, 3Alexandrovska University
Hospital, Sofia, Bulgaria
Background: Generally, chronic myeloid leukemia (CML) and essential throm-
bocythemia (ET) are characterized by distinctive clinical and laboratory char-
acteristics, including the spectrum of genetic abnormalities - Philadelphia chro-
mosome (Ph) and BCR-ABL1 fusion transcripts in CML and JAK2, CALR or
MPL gene mutations in ET. Therefore, even in the presence of overlapping fea-
tures in some cases, the correct diagnosis can be assigned. However, in rare
cases Ph chromosome and BCR-ABL1 fusion transcripts can be found in oth-
erwise typical ET. Due to the low number of reported cases the subsequent
course of the disease and the response to tyrosine kinase inhibitors (TKI) in
such patients with BCR-ABL1-positive thrombocytosis is largely unknown.
Aims: To report the clinical course and response to TKI in patients (pts) with
CML presenting with isolated thrombocytosis at the onset.
Methods: In total, 31 pts with Ph(+) and/or BCR-ABL1(+) isolated thrombocy-
tosis and a moderate or absent leukocytosis were retrieved from the hospital
database. The cohort comprised 17 females and 14 males, at a median age of
47 years (range 23-86).  Diagnosis was based on blood and bone marrow mor-
phology and differential, cytogenetics and/or molecular testing according to the
WHO criteria (2008). Molecular monitoring was carried out using Xpert BCR-
ABL Monitor or Xpert BCR-ABL Ultra tests (Cepheid). In total, follow up data
for at least 6 months (mean 65 months) are available for 25 patients treated
with TKI as a first-line therapy.
Results: At diagnosis the median leukocyte count was 22 x109/l (range 6-36)
and platelet count – 1316x109/l (range 770-2815). Splenomegaly was found in
5 pts (16.1%). Only one patient was diagnosed in accelerated phase as the
remaining presented in chronic phase at diagnosis. Interestingly, 4 pts (12.9%)
had a history of an antecedent solid tumor. All patients enrolled in the study
were BCR-ABL1(+):  b3a2 (n=16) or b2a2 (n=15). Karyotypes were available
in 23 pts and classical Ph was found in 16 of them (69.6%), while in 5 pts
(21.7%) a cryptic translocation was detected as well as a variant Ph in the
remaining 2 pts (8.7%). Imatinib was used as a first line therapy in 15 pts and
optimal response was achieved in 53.3% (n=8), while 5 were switched to a
second line, and 2 - to a third line therapy. First-line treatment with Nilotinib in
10 patients resulted in optimal response in 80% (n=8). In total, major molecular
response (MR) was achieved in 80% (n=20), including deep MR in 56% (n=14).
One pt was lost of follow up after optimal response was registered. No response
was documented in 4 pts (16%) and progression to blast crisis developed in 2
of them. The mean OS was estimated 143 months and the cumulative propor-
tion surviving at 5 years was 91%.
Summary/Conclusions: Interestingly, CML presenting with isolated thrombo-
cytosis at diagnosis in our cohort had high proportion of antecedent malignan-
cies and high incidence of cryptic Ph translocation without any specific corre-
lation with the transcript types. However, the clinical course and molecular
response to TKI therapy was similar to the reported in CML in general. 
Ackowledgements: Partial support by the National Science Fund.
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BCR-ABL1 MOLECULAR RESPONSES AT 12-18 MONTHS USING THE
QUANTIDEX QPCR BCR-ABL1 IS KIT PREDICT LONG-TERM EVENT-FREE
SURVIVAL IN PATIENTS WITH TKI-TREATED CML
J. Brown1,*, A. Ruskin1, I. Beldorth1, M. Fahey1
1Asuragen, Austin, United States
Background: Detection of BCR-ABL1 e13a2 or e14a2 transcripts (major break-
point, M-BCR) of translocation t(9;22) (also known as the Philadelphia chro-
mosome) is important in CML monitoring tumor burden. The International Scale
(IS) was established to standardize reporting relative to a common baseline.
As newer TKI therapies create deeper responses, analytical sensitivity has
become a critical topic in investigations into TKI discontinuation, where
researchers require a clinically validated assay that calls a molecular reduction
(MR) of ≥4.5 logs below baseline (i.e. MR4.5 or 0.0032%IS). 
Aims: To clinically validate the QuantideX qPCR BCR-ABL1 IS Kit and to reaf-
firm the clinical utility of BCR-ABL1 RT-qPCR monitoring in patients with t(9;22)
positive CML, a correlation between molecular response (MR) values and long-
term outcome was determined. 
Methods: The QuantideX qPCR BCR-ABL IS Kit uses standard TaqMan
chemistry to quantitate BCR-ABL1 and the ABL1 reference gene. Associated
software reports an international scale BCR-ABL1 value and a log-trans-
formed MR value, with a 3 log-reduction from pre-treatment baseline repre-
sented as 0.1%IS or MR3.0. Three laboratories performed BCR-ABL1 testing
on banked RNA specimens from 96 chronic phase CML patients from 2 hos-
pitals drawn 12-18 months after starting TKI therapy. Clinical events (TKI
therapy change, loss of complete hematologic or cytogenetic response, pro-
gression to accelerated phase or blast crisis, kinase domain mutation, or
death) were recorded through 36±4 months after starting TKI. Two operators
per site also tested serially-diluted reproducibility samples (range MR1.0 to
MR4.0) in multiple replicates over 5 days. The 95% LOD for the assay was
defined as the median measured%IS value of 4 analogous serially-diluted
specimens.
Results: 51 patients had MR<3.0 at 12-18 months post-TKI. Of these 51
patients who did not achieve a major molecular response (MMR), 20 had a
subsequent clinical event, 17 had no event, and 14 were lost to follow-up
(LFU). 45 patients had MR≥3 at 12-18 months post-TKI. Of these 45 patients
who did achieve MMR, 8 had an event, 28 had no event, and 9 were LFU.
Kaplan-Meier survival curves demonstrated a 22% prolongation of event-free
survival (95% CI 2%>42%) at 3 years between the two MR groups [p=0.028;
58% (95% CI 44%>75%) for MR<3 vs 80% (95% CI 68%>93%) for MR≥3)].
Specimens with MR values ranging from MR1 to MR4 showed an
average%CV of 2.6%. Day to day agreement was high with MR SD by oper-
ator ranging from 0.000 to 0.060. Site to site agreement was high with MR
SD by site ranging from 0.000 to 0.069. The 95% LOD for both transcripts
(e13a2 & e14a2) was MR4.7 (0.002%IS), allowing sensitive detection of the
MR4.5 cutoff that defines “complete molecular response” in ongoing treat-
ment-free remission clinical trials.
Summary/Conclusions: The QuantideX qPCR BCR-ABL IS Kit has excellent
reproducibility and analytical sensitivity, and the achievement of MR≥3 (major
molecular response) by this assay predicts prolonged event-free survival in
TKI-treated CML patients.
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SHOULD SWITCHING TO SECOND GENERATION TKIS BE A RULE IN
PATIENTS WITH CP-CML AFTER 3-6 MONTHS OF IMATINIB TREATMENT:
RETROSPECTIVE ANALYSIS OF CML PATIENTS TREATED IN A SINGLE
BRAZILIAN CANCER CENTER
A.P.S. Ferreira1,*, F.S. Seguro1,2, A.B. Medina2, A.N.R. Abdo2, F.V.R. Maciel2,
L.Y. Okada1, I. Bendit1
1Hematology, Hospital das Clinicas da Faculdade de Medicina da USP, 2Hema-
tology, Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil
Background: Early molecular response is an important predictor for survival
and therapy-free remission in chronic myeloid leukemia (CML). The current
guidelines define BCR-ABL1 >10% at 3 months and/or 1-10% at 6 months as
warning signs; however, it is not clear if switching imatinib to second generation
TKIs in this scenario improves responses and overall survival in patients outside
clinical trials. 
Aims: To analyze the proportion of patients with major molecular response
(MMR) at 12 months according to the molecular response at 3 and 6 months in
a cohort of CML population, not enrolled in clinical trials and treated only with
imatinib. Also evaluate the incidence of molecular responses log3.0, log4.0 and
log4.5 at any time in patients who did not switch to second generation TKIs.
Methods: Retrospective analysis of all 226 patients diagnosed with CML from
January 2007 until January 2015 in our hospital. The exclusions criterias were:
advanced phases, inclusion in clinical trial, treatment with second-generation
TKI in the first 12 months (due to toxicity or failure). The molecular response
was evaluated according ELN recommendations: RQ-PCR assessment of
BCR-ABL1 levels every 3 months until achievement of MMR, with molecular
evaluation every 3-6 months afterward. All samples were analyzed in the same
laboratory which was standardized since 2007.
Results: In the first cohort, 150 patients with CML chronic phase were ana-
lyzed. Optimal molecular responses by the ELN at 3 and 6 months were pre-
dictors of MMR by 12 months (94% vs 6%, p<0.0001 at 3m, 89.3% vs 10.7%,
p<0.0001 at 6m), but there was no overall survival benefit. A second cohort
with 119 patients received only imatinib, with a medium follow-up time of 71
months (13-117m). MMR was achieved by 60% of this imatinib-only group after
12 months and by more than 90% after 36 months (Figure 1). Patients with
BCR-ABL1 <10% at 3 months and/or <1% had a higher probability of achieving
MMR3, MMR4 and MMR4.5 at any time.
Figure 1.
Summary/Conclusions: Our study shows that around 30% of the patients
that do not fail to imatinib at the first year of treatment may be late responders.
Not all patients should change therapy, if they have not reached MMR at 12
months. Molecular response at 3 at 6 months might guide the decision to switch
TKI, but patient’s comorbities, possibility of discontinuation and cost of therapy
should also be considered.
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PREDICTIVE PARAMETERS FOR IMATINIB FAILURE IN PATIENTS WITH
CHRONIC MYELOID LEUKEMIA
D. Lekovic1,2,*, M. Gotic1,2, B. Zivojinovic1, N. Milic3, J. Jovanovic1,
N. Colovic1,2, J. Bodrozic1, V. Milosevic1, A. Bogdanovic1,2
1Clinic for Hematology, Clinical Center of Serbia, 2Medical Faculty, 3Institute
for Medical Statistics, University of Belgrade, Belgrade, Serbia
Background: Development of tyrosine kinase inhibitors (TKI) has significantly
changed natural course of chronic myeloid leukemia (CML) and increased 10
year overall survival from 10-20% to 80-90%. Until recently, imatinib was the
standard first-line treatment in CML. In 2013, nilotinib and dasatinib were
approved as alternative front-line options. However, none of three TKI has
been shown to have a clear survival advantage so this raised a debate on
treatment selection. The early identification of patients expecting poor outcome
is crucial for offering an alternative TKI regimen. 
Aims: to analyze predictive parameters for Imatinib response as first-line treat-
ment of CML patients. 
Methods: The study was conducted on 168 consecutive patients with chronic
phase of Ph+ CML who were diagnosed and treated at single university hospital
from December 2000-January 2015. Following data were analyzed in terms of
treatment response to Imatinib: demographic characteristics; currently used
prognostic scores (Sokal, Hasford, EUTOS); liver and spleen size; laboratory
parameters; influence of comorbidities analyzed by three scores (ACE 27, HCI-
CI, SCIRS); occurrence of second malignancies; conventional cytogenetic
results; therapy, duration of therapy, cytogenetic responses, overall survival
(OS) and outcome. 
Results: The mean age at diagnosis was 48±14.4 years (range: 18-74) with
87.5% of patients<65 years. The OS at 5 and 10 years was 97% and 91%
respectively. Overall response to Imatinib treatment was as the follows: 131
patients (78%) achieved CCyR, 14 patients (8.3%) majorCyR, 4 patients (2.4%)
minorCyR, 16 patients (9.5%) had no cytogenetic response, 2 patients (1.2%)
had hepatic toxicity verified by liver biopsy in the first six months of Imatinib
treatment and 1 patient (0.6%) was lost from follow-up. After achievement of
CCyR, 25 patients (19%) had a progression of disease by losing CCyR or
development of AP/BP. Median time to progression was 24 months (range 12-
102). After the median follow up of 87 months in 61 patients (36.3%), the Ima-
tinib failure was verified. All three prognostic scores (Sokal, Hasford, EUTOS),
age, gender, hemoglobin level, leukocyte and platelet count, splenomegaly,
eosinophils and basophils in peripheral blood were not found to be statistically
significant for the Imatinib failure. Cox regression analysis identified
hepatomegaly (p=0.001), leukocytosis≥100x109/L (p=0.001), blood blasts≥1%
(p=0.002) and presence of additional cytogenetic aberrations (ACAs) (p=0.002)
as a predictors of Imatinib failure. Accordingly, we assigned risk scores based
on hazard ratios (HR) to hepatomegaly (HR=4.089; 2 points), leukocytosis
≥100x109/L (HR=3.158; 1 point), blasts in peripheral blood ≥1% (HR=2.912; 1
point), and presence of ACAs (HR=11.110; 2 points). A final 3-tiered prognostic
model named IMA-FAIL was thus developed, as low (score 0), intermediate
(score 1-3), and high risk (score ≥4), according to which imatinib failure had
17% (8/47) of patients in low, 34.9% (30/86) in intermediate and 76.7% (23/30)
in high risk group (HR=3.973, 95% CI for HR 2.237-7.053, p <0.001). In addi-
tion, presence of comorbidities as well occurrence of second malignancy were
not predictors for Imatinib failure.
Summary/Conclusions: Hematologists are facing with challenge of making
decision which TKI to choose upfront with increasing a chance to achieve best
possible response. The new score allows better selection of patients who are
suitable for treatment with Imatinib and may guideline the clinical decision for
front-line treatment of CML.
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A MULTICENTRE AUDIT OF SYMPTOMS AND QUALITY OF LIFE IN IRISH
CML PATIENTS ON TYROSINE KINASE INHIBITORS
J. Garry1,*, P. Murphy1, J. Quinn1, P. Thornton12, J. Sargent3, M. McCloy4,
A. Fortune5, M. Fay5, N. Herlihyn5, D. Angelov5, K. Fadalla6, C. Cotter6
1Haematology, Beaumont Hospital, 2Haematology, James Connolly Memorial
Hospital, Dublin, 3Our Lady of Lourdes Hospital, Drogheda, Ireland, 4Haema-
tology, Our Lady Of Lourdes Hospital, Drogheda, 5Haematology, Mater Miseri-
cordiae University Hospital, 6Haematology, St. Vincents University Hospital,
Dublin, Ireland
Background: The development of tyrosine kinase inhibitors (TKIs) over the
last 20 years has dramatically improved the outcomes for patients with every
stage of chronic myeloid leukaemia (CML). Since the approval of the first
TKI, imatinib, in 2001, there are now currently 5 oral TKIs available. Three
are approved for frontline use (imatinib, dasatinib and nilotinib) and 2 others
(bosutinib and ponatinib) approved for intolerance or failure of prior TKI.
Because CML patients need to continue TKI treatment indefinitely, it is nec-
essary to consider not only differences in potency and progression-free sur-
vival, but also TKI induced toxicity and quality of life (QOL) when choosing
a TKI.
Aims: The aim of this audit was to determine the impact of TKIs on symptom
burden and QOL in patients with CML across multiple centres in Ireland, using
the MD Anderson Symptom Inventory (MDASI) tool. 
Methods: Across 7 centres in Ireland, a total of 87 CML patients currently on
TKIs were identified. The mean age was 60yrs with an equal sex distribution
(44 male, 43 female). All of these patients were in chronic phase. 79% of
patients were in MMR (major molecular remission) at the time of survey. 53
patients were on imatinib, 19 patients on nilotinib, 13 on dasatinib and 2 on
bosutinib. Patients from the 7 centres were surveyed at varying time periods
between July 2015 and Feb 2017. Patients were contacted by phone. Symptom
burden and QOL were assessed using the MD Anderson Symptom Inventory,
an extensively validated tool which includes 13 core and 7 CML-specific symp-
toms, as well as 6 interference items. The questionnaire took on average 5mins
to complete and asked patients to rate their symptoms on a scale of 1-10 as
experienced over the preceding 24 hours.  
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Results: Of the 87 patients surveyed, the most commonly prevailing symptoms
were fatigue (72.4%), peripheral oedema (48.3%), disturbed sleep (46%), myal-
gia (43.7%) and dry mouth (39.1%).The least common symptoms were nausea
(20.7%) and vomiting (6.9%). Almost half (49.4%) of patients reported at least
1 severe side effect (a score of 7 or more). The most severe side effects were
drowsiness (mean score 6.3), myalgia (mean score 6), fatigue, nausea and
vomiting (mean score 5.7 each). There was no significant difference in symptom
prevalence or severity among the different TKIs. As regards the perceived inter-
ference of symptoms on daily functioning, only 29% reported a score of 7 or
more in at least 1 of the 6 interference items (i.e. general activity, mood, work,
relations with others, walking and enjoyment of life), and only 14% reported
that their enjoyment of life was severely affected (score of 7 or more). Of note,
exactly two thirds of patients reported little or no interference with their enjoy-
ment of life (score of 0-3).
Summary/Conclusions: As demonstrated in this audit, patients with CML
on TKIs frequently experience chronic adverse events. Interestingly, CML
patients taking second generation TKIs did not appear to have any difference
in frequency or severity of symptoms or in QOL compared to patients on ima-
tinib. Despite excellent survival results obtained with TKIs since 2001, an
emphasis needs to be placed on symptom burden and QOL. The potential
for adverse events with long term therapy may result in dose adjustments,
treatment discontinuation, or nonadherence, all of which may negatively affect
treatment efficacy. Therefore, assessment of QOL and the symptom burden
experienced by patients with CML is useful to facilitate individual treatment
decisions and to improve outcome as well as to evaluate the efficacy of
emerging therapies.
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COST-EFFECTIVENESS OF A THERAPEUTIC EDUCATION PROGRAM
(TPE) FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND
TREATED BY TYROSINE KINASE INHIBITORS
M. Artur-Cordier1,*, A. Chan Hew Wai2, L. Cochard3, M.-L. Fontoura4,
V. Blazejewski4, P. Lenain4, R. Varin5, F. Basuyau1, M. Daouphars1
1Pharmacy, Centre Henri Becquerel, ROUEN, 2Pharmacy, Hopital Saint Louis,
PARIS, 3Pharmacy, CHU de Caen, CAEN, 4Hématology, Centre Henri Bec-
querel, 5Pharmacy, CHU de Rouen, ROUEN, France
Aims: Within our cancer centre, an TPE program on ITK in the management
of CML has been authorized since 2011. We conducted a pharmacoeconomic
study to evaluate the TPE clinical impact on responses to TKI in patients with
CML (based on recommendations from European Leukemia Net) and also the
costs in terms of use of care.
Methods: Over the 12-month follow-up period, the study population con-
sisted of 2 groups of CML patients monitored in our centre: - Intervention
group (n=18) (IG) : Patients who benefited of TPE sessions on TKI between
January 2013 and August 2015 - “Matched controls” group (n=18) (CG):
Patients who benefited only from the usual care, matched to the “Interven-
tion” group. The method of pairing the 2 groups of patients according to the
age at diagnosis, sex, the molecule used in first line and the prognostic risk
according to the score of  Sokal was used. The main criterion of efficacy
was the MMR. The considered costs were: the cost of the TPE program,
estimated on the basis of the French health insurance reimbursement per
patient and the costs associated with the use of “supplementary” care (exam-
inations, consultations and additional hospitalizations). The point of view
was from French health insurance.
Results: Over the 12-month follow-up period, the number of patients in MMR
was similar between the 2 groups (9 in IG versus 8 in CG). However, the
average time to obtain the MMR was significantly shorter in IG (6.9
months±3.8) than in CG (11.3 months±2.1) (p <0.05). The mean duration of
MMR maintenance over the 12-month follow-up period was significantly
longer in IG (3.2 months±3.5) than in CG (1.5 months±1.9) (p <0.05). Regard-
ing the use of additional care, unexpected hospitalizations were significantly
more numerous in CG than in IG (4 versus 0). Thus, costs associated with
use of additional care were significantly lower in IG (€ 3,566) than in CG (€
12,709). Thus, € 250 invested (annual allowance per patient) in the TPE
saves € 508 in the use of care and reduces the time required to obtain a
MMR by 4.4 months.
Summary/Conclusions: Thus, TPE is clinically and economically beneficial
in our study population. By increasing the patient capacity to adapt to the treat-
ment through the development of skills and adaptation processes, TPE reduces
the costs of seeking care while improving the clinical response to treatment
with a faster and more sustainable major molecular response.
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ROLE OF ALLO-HSCT IN THE TREATMENT OF PATIENTS WITH T315I
MUTATION IN THE TKI ERA
J. Vlasova1,*, E. Morozova1, O. Shukhov2, M. Barabanshchikova1, T. Gindina1,
I. Barhatov1, I. Martynkevich3, V. Shuvaev3, A. Turkina2, B. Afanasyev1
1R.M. Gorbacheva Institute of Pediatric Oncology Hematology and Transplan-
tation St. Petersburg State Medical I. Pavlov University., St.Petersburg, 2Nation-
al research center for hematology of ministry of healthcare,Russian Federation,
Moscow, 3Russian Research Institute of Hematology and Transfusiology,
St.Petersburg, Russian Federation
Background: Resistance to tyrosine kinase inhibitors (TKI) in patients with
chronic myeloid leukemia (CML) is frequently caused by point mutations in the
BCR-ABL kinase domain, including the gatekeeper mutant T315I, which confers
a high degree of resistance to all currently approved tyrosine kinase inhibitors
except ponatinib. The role of allo-HSCT in such patients is still disputable.
Aims: To evaluate the results of different treatment modalities in CML patients
with T315I mutation.
Methods: Retrospective analysis of 53 BCR-ABLT315I –positive CML
patients (pts) was done. 
Allogeneic bone marrow transplantation (allo-HSCT) was made in 16 pts, 37
pts received only pharmacological therapy (21 pts received TKI as monotherapy
or in combination with other drugs other 16 pts received hydroxyurea, interfer-
on- α or chemotherapy). At the time of T315I detection 29 (55%) pts were in
CP, 19 (36%) pts had AP and 5 (9%) pts were in BC. Median (Me) age at the
time of mutation detected was 47 years (15-76) (38 years in HSCT-group). 2
pts were in BC at the time of HSCT, 5 pts were in AP, 7 pts were in CP≥2. The
number of points on EBMT scale: 3-4 points – 12(75%) pts, 5-7 points – 4(25%)
pts. 11 (69%) pts received more than 2 lines TKIs before HSCT .In allo-HSCT
group 11 (69%) pts had unrelated donors. Conditioning regimen in 13 (81%)
pts had reduced intensity, in 3(19%) pts had MAC. Me time to HSCT after T315I
detection was 10 months (1-38). Mutation analysis was performed by Sanger
sequencing. Overall survival (OS) was estimated by Kaplan-Meier method with
log-rank test for comparison between groups. Cox regression was used for
multivariate survival analysis that included next covariates: age, phase on the
time of mutation detection, performance of allo-HSCT, time to T315I detection
from TKI start.
Results: Me follow-up time after T315I detection was 21 months (1-100). 5-
years OS in whole group was 42% (Figure 1A). According to multivariate analy-
sis only CML phase at the time of mutation detection significantly affect to sur-
vival in whole group. All pts in BC (n=5, 2 in HSCT group and 3 in non-HSCT
group) died within first year after T315I indication wherein Me survival time was
1,3 month (Figure 1B). 5-years OS in non-HSCT group (n=37) was 42% with
Me survival time 2,8 years. 5-years OS after allo-HSCT (n=16) was 37% with
Me survival time 5 months (Figure 1C). All living patients after allo-HSCT are
in deep molecular response. There was no significant difference in 5-years OS
between TKI (n=21) and non-TKI (n=16) pharmacological therapy (non-HSCT)
groups (42% and 47% respectively, p=0,53) (Figure 1D).
Figure 1.
Summary/Conclusions: Detection of T315I mutation in TKI-resistant patients
is extremely unfavorable factor for survival, especially in the advanced phase
CML, and it is a great reason for switching to ponatinib or other new potential
investigated drugs if possible. Allo-HSCT can be a potential  option for this
group of patients in case of good selection taking into consideration transplant
risk, especially for patients in CP ≥2.
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THYROID FUNCTIONAL STATUS IN PATIENTS WITH CHRONIC MYELOID
LEUKEMIA ON TKIS - SINGLE -CENTER RESULTS
M. Dragičević1,2,*, I. Urošević1,2, M. Dokić1,2, I. Bajkin2,3, T. Ičin2,3, I. Perčić1,2,
A. El Farra1,2
1Clinic for Hematology, 2Faculty of Medicine, University of Novi Sad, 3Clinic for
Endocrinology, Diabetes and Metabolic Diseases, Novi Sad, Serbia
Background: Tyrosine kinas inhibitors (TKI) as target specific compounds pro-
foundly changed the outcome in patients with chronic myeloid leukemia (CML).
TKI-induced thyroid dysfunction is now recognized as a common toxicity asso-
ciated with some TKI. In the previous decade, cases of thyroid dysfunction
have been reported in patients treated with different TKIs.
Aims: To evaluate the thyroid functional status in CML patients treated with
imatinib and nilotinib. 
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Methods: This cross-sectional study comprised 85 patients with CML in chronic
phase, treated with imatinib and nilotinib, at the Clinic for Hematology, Clinical
Centre of Vojvodina, Serbia. Thyroid function was assessed by analyzing the
serum FT3, FT4 and TSH levels. Hypothyroidism in relation with TKI therapy
was defined as newly diagnosed hypothyroidism (while the patient was already
on TKI therapy) requiring hormone substitution therapy or serum fT4 level <11,5
pmol/l and TSH >5.50 mIU/l. Patients with previous medical history of thyroid
dysfunction were excluded. The duration of TKI treatment varied from 2 month
to 10 years. The dose of imatinib was 400mg daily, while nilotinib was dosed
800mg a day. 
Results: From the total number of patients included, 37 (43,53%) were female
and 48 (56,47%) were male. Mean age was 56,71 age (range 21-84). The preva-
lence of hypothyroidism (clinical, and subclinical) was 8,23% (n=7) which is in
accordance with the prevalence in general population. Three patients (3,53%)
were diagnosed to have subclinical hypothyroidism (defined as normal serum
fT4 and TSH >5.50 mIU/l). Hypothyroidism was more common in males (71,5%,
p= 0,29, not statically significant). In patients treated with imatinib, 2 (3,4%) had
subclinical, while 3 (5,01%) had clinical hypothyroidism. Of the 26 patients treated
with nilotinib, subclinical hypothyroidism was detected in 1 (3,85%), as well as
clinical hypothyroidism (3,85%).  Other thyroid dysfunctions were not detected.
Summary/Conclusions: Hypothyroidism was the only thyroid dysfunction in
our cross-sectional study. The prevalence of hypothyroidism in our study group
did not differ from general population. Additional study on a larger sample size
and evaluation of antibodies is required. 
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RESPONSE RATES AND SURVIVAL OF PATIENTS WITH CHRONIC
MYELOID LEUKAEMIA INITIALLY TREATED WITH IMATINIB: 11 YEAR
EXPERIENCE OF A TEACHING HOSPITAL
M. Ruparelia1,*, P. George1, D. Brownings1, K. Marshall1, A. Hunter1,
M. Martin1, K. Hodgson1
1University Hospitals Leicester, Leicester, United Kingdom
Background: In large trials, patients with chronic myeloid leukaemia (CML)
treated with Tyrosine Kinase Inhibitors (TKIs) have relative survival rates of up
to 90% that of age-matched controls. Patients achieving complete cytogenetic
responses (CCyR) within 2 years of starting Imatinib have survival rates equiv-
alent to the general population.   Newer TKIs are associated with faster and
deeper treatment responses, but have a more toxic side effect profile as well
as being more costly.
Aims: This study looks at the 11 year experience of a single teaching hospital
treating a population of almost one million and presents the response and sur-
vival data of this unselected population of patients with CML treated with ima-
tinib as initial therapy.
Methods: A retrospective case record review was undertaken on CML patients
identified from the regional cytogenetics department. Imatinib was available
for routine prescription in the UK from 2003, so a 11-year period from 2003 to
2013 was selected to allow for adequate follow-up. 
Results: In total 83 patients were newly diagnosed in this time period. Four
patients, treated on SPIRIT2 with dasatinib as initial therapy, have been exclud-
ed from the subsequent analysis, leaving 79 patients treated initially with ima-
tinib 400mg daily. The median age at diagnosis was 53 years (range 13-93)
with 40 female and 39 male patients. The median follow up was 75 months
(range in living patients 29-163 months). Fifteen patients have died (19%). The
median age at diagnosis of these was 73 years. Two deaths were transplant-
related, both in patients who had failed available TKIs and had mismatched
transplants. The only treated patient who died of accelerated disease was intol-
erant of all TKIs and unfit for transplant. Three patients died of other malignan-
cies (ovarian, bowel and melanoma). Seven patients were transplanted. Of
the surviving 5, 2 had sibling transplants early in the TKI era, 2 had MUD trans-
plants after failing imatinib prior to the availability of second line drugs, and
one failed to make an adequate response to imatinib then nilotinib and received
a sibling transplant. All surviving transplant patients are in a major molecular
response (BCRABL:ABL ratio <0.01, MMR).  An MMR was achieved by 60/79
(76%) patients. Of the 19 without MMR, 1 is lost to follow-up, and 9 have died,
of which only one death was due to accelerated CML in a patient intolerant of
all TKIs.  Of those 9 patients living not in MMR, 8 have a CCyR. Three are eld-
erly patients in whom we have taken a pragmatic approach, three are related
to patient compliance, two to treatment limited by severe side effects and one
had TKI interruption to facilitate cancer treatment. Of the sixty patients in MMR,
40 achieved this on standard dose imatinib. Four patients required increased
dose of imatinib, 11 were switched to second line TKI and 5 were transplanted.
A complete molecular response (BCRABL:ABL ratio <0.000, CMR) was
achieved by 10 patients, six on standard dose imatinib. 
Summary/Conclusions: This data shows the real life experience of patients
treated for CML in the TKI era. At six years follow up, the overall survival was
86% which is remarkably similar to that of the IRIS trial patients. Using an intention
to treat analysis in this unselected population, up front imatinib with appropriate
escalation of treatment where response is unsatisfactory achieves an MMR rate
of 76%. This offers reassurance that where appropriate monitoring is feasible,
imatinib remains a good first choice for patients presenting with CML. 
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FRONT-LINE NILOTINIB IS A BETTER CHOICE THAN FRONT-LINE
IMATINIB FOR CML PATIENTS WITH DELAYED TREATMENT: 11 YEAR
FOLLOW-UP
A. Kurtovic-Kozaric1,*, E. Islamagic2, S. Kurtovic3, A. Hasic4, V. Bijedic3,
F. Colakovic5, N. Skobic Bovan6
1Clinical pathology, cytology, and human genetics, Clinical Center of the Uni-
versity of Sarajevo, 2Faculty of Natural Sciences, University of Sarajevo,
3Hematology, Clinical Center of the University of Sarajevo, 4Genetics, Univer-
sity of Sarajevo, 5Hematology, Clinical Center Zenica, Sarajevo, 6Hematology,
University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina
Background: CML patients in developing world had to wait for the start of TKI
treatment, from several months to years. The significant delay in proper treat-
ment with imatinib has had drastic consequences on patient outcomes including
survival, CCyR and MMR. Nilotinib was introduced in 2011 as front- and sec-
ond-line therapy for newly diagnosed as well as patients who waited for TKI
treatment for a long time. 
Aims: In this study we compared the long-term real life clinical outcomes (OS,
CCyR and MMR) of patients receiving front- line imatinib and front-line nilotinib
therapy in Bosnia and Herzegovina in the period from 08/2005 to 08/2016, cat-
egorized based on delayed start of therapy. 
Methods: All newly diagnosed CML patients in CML-CP (n=149) who started
their TKI treatment in period from August 2005 to August 2016 were included
in this multicentre retrospective cohort study. Patients were categorized as:
Group 1 (n=118) consisted of  patients who started with front-line imatinib (300
mg, 400 mg or 600 mg twice daily; Glivec or generic imatinib therapy) and
Group 2 (n=31) contained patients receiving front-line nilotinib (300 mg twice
daily). Patients on imatinib were further categorized by the duration of treatment
delay into three subgroups (<5 months, 6-13 months and >13 months) and
patients on nilotinib therapy were divided into two subgroups (patients who
waited less and more than 6 months on the start of therapy). Nilotinib became
available as front or second-line therapy in March 2011. Standard patients’
variables were collected and disease progression was established as loss of
CCyR and MMR. Survival probabilities were estimated with the Kaplan-Meier
method and compared using the log-rank test. 
Results: We analyzed 149 patients (median age was 54.5 years; 57% was
males) in chronic phase of CML. The median follow-up from time of diagnosis
and start of therapy was 45  months and 39 months, respectively (range 3-145
months). Median wait period for therapy in patients who waited less and more
than 6 months was 0 months (range 0-6) vs 15 months in the waiting group
(range 9-63). At 11 years, overall survival for patients on front-line imatinib
(Group 1) and front-line nilotinib (Group 2) was 83% and 87%, respectively.
According to ITT principle, achievement of CCyR and MMR at 24 months was
higher in Group 2 compared to Group 1 (81% vs 66% and 74% vs 37%, respec-
tively). Rate of death was similar in both studied groups (20/118 vs 4/31). When
we analysed delayed treatment at 24 months, CCyR for patients who received
therapy immediately, who waited 6-13 months and more than 13 months, was
74% vs 64% vs 40%, respectively. Regarding nilotinib treatment at 24 months,
patients on 1st line immediate nilotinib vs 1st line delayed nilotinib achieved
83% vs 77% for CCyR and 78% vs 69% for MMR, respectively. 
Summary/Conclusions: Our results after 11 years of follow up suggest that
nilotinib demonstrated improved efficacy over imatinib therapy. Achievement
of CCyR and MMR at 24 months was higher in patients on front-line nilotinib
therapy. Patients who waited for therapy had optimal response regardless the
wait period on nilotinib therapy. 
PB1838
THE INFLUENCE OF AGE ON TREATMENT OUTCOME OF PATIENTS
WITH CHRONIC MYELOID LEUKEMIA RECEIVING FRONTLINE IMATINIB
I. Cojbasic1,2,*, L. Macukanovic Golubovic1,2, M. Vucic1,2, N. Govedarovic1,2
1Medical Faculty, University of Nis, 2Clinic of Hematology and Clinical Immunol-
ogy, Clinical Center Nis, Serbia, Nis, Serbia
Background: The tyrosine kinase inhibitor (TKI) imatinib was the first targeted
therapy for patients with chronic-phase chronic myeloid leukemia (CP-CML), and
its introduction was associated with substantial improvements in response
and survival compared to previous therapies. Earlier studies have indicated that
the effect of age at diagnosis of CP-CML was minimized in patients treated with
imatinib: fewer responses but the same outcome for older patients. However,
recently published results from clinical controlled trials indicated that there were
differences in clinical outcome depending on age at diagnosis of CP-CML. 
Aims: The aim of this study was to evaluate impact of age on the treatment out-
come in patients with chronic myeloid leukemia treated with frontline imatinib. 
Methods: A newly diagnosed CP-CML patients treated and followed in our
institution were surveyed retrospectively from August 2006 to August 2016.
According to age, cohort was divided into three groups: young adults (18-45
years) (YA), middle aged adults (46-64 years) (MA) and elderly persons (65
and more years) (EP). Patients’ demographics, disease risk scores, duration
of imatinib therapy and follow-up, cytogenetic and molecular responses,
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adverse event (AEs), the 5-year event-free survival (EFS) and 5-year overall
survival (OS) were all evaluated. Clinical features of the patients in different
age groups are summarized in Table 1.
Results: The patient cohort consisted of 94 patients with median age of 53.4
years (range 18-78), with a slight predominance of females of 53.2%. There
were more patients with intermediate and high Sokal scores in the EP group
than in the groups MA and YA (p<0.001). To the contrary of that, most patients
with high EUTOS score were observed in the group YA compared to MA and
EP groups (p<0.001). The three groups were balanced regarding Euro score.
The median duration of imatinib therapy was the longest in MA group (61.4
months vs 40.6 months in YA and 38.2 months in EP patients p<0.001). Fur-
thermore, median follow-up duration was also the longest in MA group (64.3
months vs 48.5 months in YA and 44.7 months in EP patients p<0.001). The
rates of complete cytogenetic response (CCyR) were similar in all three
analysed groups (80.6% in YA, 86.5% in MA and 75.9% in EP, p=0.328) while
rate of major molecular response was the highest in the MA group (83.3% vs
63.3% in YA and 57.1% in EL, p=0.001). The percentages of patients who
switched to second-generation TKIs were similar in all three groups (36.7% in
YA vs 30% in MA vs 32.1% in EP, p=0.559). There were the most of non-hema-
tological AEs all grades in EP group (25% vs 13.3% in YA and 13.8% in MA,
p=0.005). Hematological AEs also were common in EP group but not statistically
significant (17.8% vs 10% in YA and in 12.1% in MA, p=0.156). The 5-years
EFS in the MA group (88% (95%CI 82.1-96.9)) was significantly higher than in
YA group (65.3% (95%CI 59.1-78.1)) and in EP group (60.2% (95%CI 49.5-
73.7)). The 5-years OS in the EP group (74.7% (95%CI 65.9-89.0)) was signif-
icantly lower than in YA group (93.1% (95%CI 87.2-99.5)) and in MA group
(90.8% (95%CI 85.8-97.8)). The number of deaths, both CML related or not
related, was the largest in the EP group (25% vs 13.3% in YA and 13.8% in
MA, p<0.001).
Table 1. Clinical features of the patients in different age groups.
Summary/Conclusions: Results of this study indicate that age at diagnosis
impacts the course of chronic myeloid leukemia treated with imatinib. The best
clinical outcomes have middle age patients in terms of the highest rates achieved
optimal therapeutic response and longer survival without events and overall sur-
vival. The degree of therapeutic responds in the elderly is comparable with that
observed in younger patients, but the presence of comorbidity and more frequent
occurrence of adverse events were affecting relatively lower overall survival.
Although it might be expected that younger patient population has a better clinical
outcome than patients middle age, a possible cause of poor outcomes is probably
a late diagnosis at an advanced stage of the disease.
Enzymopathies, membranopathies and other anemias
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CHARACTERIZATION OF HEMATOPOIETIC SAMPLES FROM PYRUVATE
KINASE DEFICIENCY PATIENTS
R. Sanchez-Dominguez1,*, O. Alberquilla2, S. Lopez-Manzaneda3,
O. Quintana-Bustamante3, P. Bianchi4, M.D.M. Mañu-Pereira5,
J.-L. Vives-Corrons5, I. Badell6, J. Sevilla7, J.A. Bueren3, S. Navarro3,
J.C. Segovia3
1LACISEP (Advanced Therapies Unit), CIEMAT/CIBERER, 2LACISEP
(Advanced Therapies Unit), 3Hematopoietic Innovative Therapies, CIEMAT,
MADRID, Spain, 43Fondazione IRCCS Ca’ Granda, UO Oncoematologia, UOS
Fisiopatologia delle Anemie, Ospedale Maggiore Policlinico, Milan, Italy, 5Insti-
tuto de investigacion contra la leucemia Josep Carreras, 6Hospital de Sant
Pau, Barcelona, 7Hematología y Hemoterapia, Hospital Infantil Universitario
Niño Jesús, Madrid, Spain
Background: Pyruvate Kinase Deficiency (PKD) is an autosomal recessive dis-
ease caused by mutations in the PKLR gene. PKD produces chronic non-sphe-
rocytic hemolytic anemia, which can be fatal during early childhood and may
result in lifelong transfusion dependence that in some instances persists despite
therapeutic splenectomy. Although not considered a standard-of-care, allogeneic
bone marrow transplantation has been curative in a limited number of cases.
These findings, and the evidence that PKLR gene mutations are likely the sole
etiology of the disorder, make PKD a candidate for gene therapy. Our lab has
developed a therapeutic Orphan Drug lentiviral product (EMA: EU/3/14/1330;
FDA: DRU-2016-5168) for the treatment of PKD and is working to develop an
efficient and safe gene therapy clinical trial for the treatment of PKD. 
Aims: In order to improve this new treatment, a more deep knowledge of the
disease and its associated pathophysiology is necessary.
Methods: To characterize the hematopoietic profile of this disease, we have
standardized flow cytometry protocols to perform both a qualitative and quan-
titative study of different population subsets. These included subsets of the
hematopoietic stem cell compartment, erythroid progenitors, reticulocytes,
mature erythrocytes and other mature lineages. Human routine samples con-
sisted of peripheral blood, bone marrow and cord blood from PKD patients. In
addition, xenogenic engraftment studies in immnunodeficient (NSG) mice were
also performed. 
Results: Flow cytometry studies showed a clear imbalance in the erythroid
populations. On the other hand, human PKD progenitors were able to engraft
into NSG mice demonstrating that the disease does not likely impair hematopoi-
etic stem cell capabilities.
Summary/Conclusions: Pyruvate Kinase Deficiency (PKD) is an autosomal
recessive disease caused by mutations in the PKLR gene. Our lab has recently
developed a therapeutic Orphan Drug lentiviral product for the treatment of
PKD. In order to improve this new treatment, we are also working to deep into
the knowledge of the disease and its associated pathophysiology. Flow cytom-
etry studies have shown a clear imbalance in the erythroid populations. Func-
tionally, results in NSG mice we have demonstrated that the disease does not
likely impair hematopoietic stem cell capabilities.
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OSMOTIC GRADIENT EKTACYTOMETRY: A VALUABLE SCREENING
TEST FOR HEREDITARY SPHEROCYTOSIS AND OTHER RED BLOOD
CELL MEMBRANE DISORDERS
M.D.M. Mañu Pereira1,*, E. Llaudet Planas1, V. Rizzuto1, J.L. Vives Corrons1
1Red Blood Cell Pathology and Hematopoietic Defects, Josep Carreras
Leukaemia Research Institute, Barcelona, Spain
Background: Red blood cell (RBC) membrane disorders constitute one of the
major causes of chronic hereditary hemolytic anemia. Main RBC membrane dis-
orders, namely hereditary spherocytosis (HS), hereditary elliptocytosis (HE) and
hereditary stomatocytosis (HSt), alter membrane cohesion, membrane mechan-
ical stability, and RBC volume, respectively. As a consequence, RBC deformability
is compromised leading to their premature removal from circulation, manifested
as hemolytic anemia. New generation osmotic gradient ektacytometry has
become a powerful procedure for measuring red blood cell deformability and
therefore for the diagnosis of red blood cell membrane disorders. 
Aims: The aim of this study is to evaluate osmotic gradient ektacytometry as
an adequate assay to perform screening of membranopathies, focusing on the
differential diagnosis between HS and non-spherocytic membrane defects such
as HE and dHSt. 
Methods: A total of 75 patients with chronic hemolytic anemia oriented as
hereditary RBC membrane disorders (hemoglobin disorders discarded and
negative Coombs test) were included during a period comprised between
January 2015 and August 2016.  Normal controls were obtained from blood
donors. Osmotic gradient ektacytometry was performed using the osmoscan
module of the Laser-assisted Optical Rotational Deformability Cell Analyzer:
LoRRca MaxSis (RR Mechatronics). Evaluation of osmoscan parameters
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robustness for HS diagnosis was performed using the receiver operating
characteristic (ROC) curve analysis. The optimal cut-off was determined as
the one with the highest likelihood ratio. Statistical analysis was operated
with GraphPad Prism. 
Results: Specific patterns of osmoscan LoRRca MaxSis were observed for
each individual membranopathy. All HS curves were bell shaped but two dif-
ferent profiles were identified both presenting increased Omin, and decreased
EImax and AUC.  HE curves showed a characteristic trapezoidal shape with a
decreased EImax, Omax and AUC. dHSt curve was bell shaped with a specific
decrease in Ohyper and a slight increase in EImin. Reference ranges for each
osmoscan parameter were established with 171 healthy subjects and com-
pared with the values of the parameters obtained from the different RBC mem-
brane disorders. ROC curve analysis was performed for HS and each one of
the non-HS groups separately. The results determined that EImax was the
parameter that better separated HS from normal controls and dHSt, while the
Omin was the best to separate HS from HE. The optimal EImax cut-off to dif-
ferentiate HS from normal controls was <0.5975 (sensitivity 98.46%, specificity
99.42%), while the optimal Omin cut-off to differentiate HS from HE was >159.0
(sensitivity 95.38%, specificity 85.71%). Expressing the results as% of variation
in relation to the mean of our normal controls, the best combination of param-
eters for HS diagnosis would be EImax <-3% and Omin >5.2%. This combina-
tion of parameters (EImax <-3% and Omin >5.2%) was used as criteria to clas-
sify all the 246 samples included in the present study, and the result showed
62 samples detected as HS and 184 as no-HS. Of the 62 patients identified as
HS, 61 were real HS (specificity 98.38%) and 1 was an HE. On the other hand,
4 HS patients were identified as non-HS (sensibility 93.85%). 
Summary/Conclusions: We can conclude that, the inclusion of LoRRca
osmoscan as a screening test in RBC membrane diagnostic workflow will sig-
nify an important advance for the accurate diagnosis of HS patients, as well as
for the identification of HE and specially dHSt patients. 
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RARE RED BLOOD CELL ENZYMOPATHIES INDUCED CHRONIC
NONSPHEROCYTIC HEMOLYTIC ANEMIA: NEXT GENERATION
SEQUENCING BASED MOLECULAR DIAGNOSIS
M. Jamwal1,*, A. Aggarwal1, P. Sharma1, D. Bansal2, P. Malhotra3, A. Maitra4,
R. Das1
1Hematology, 2Pediatrics (Hemato-Oncology), 3Internal Medicine, Postgradu-
ate Institute of Medical Education and Research, Chandigarh, 4National Insti-
tute of Biomedical Genomics, Kalyani, India
Background: Red blood cell enzymopathies are mostly inherited autosomal
recessive monogenic disorders. Mutations in the genes encoding red blood
cell enzymes could lead to chronic nonspherocytic hemolytic anemia (CNSHA).
The clinical manifestations are jaundice, cholelithiasis, splenomegaly, with usu-
ally normocytic normochromic hemolytic anemia. Phenotypes vary from having
fully compensated hemolysis (without anemia) to severe hemolytic anemia
requiring regular transfusions. Definitive diagnosis is difficult when biochemical
test results are not consistent/fail to identify defects. Molecular diagnosis by
gene-by-gene approach is expensive, time consuming and cumbersome as
testing for multiple genes is required. 
Aims: Use of targeted resequencing can expedite the molecular diagnosis
where the cause for hemolysis remains unexplained after routine laboratory
tests. 
Methods: Ten patients with clinical and laboratory evidence suggestive of
hemolytic anemia were enrolled. Various biochemical and molecular tests were
used to exclude Glucose-6-phosphate dehydrogenase (G6PD) deficiency, tha-
lassemias, hemoglobinopathies, autoimmune hemolytic anemia, hereditary
spherocytosis and pyruvate kinase deficiency. Common G6PD and PKLR vari-
ants were excluded by molecular tests. Family history was negative in all the
cases. Libraries were prepared using TruSight One sequencing panel and
sequenced on MiSeq™ Sequencing System. MiSeq Reporter™ and Vari-
antStudio™ v2.1 were used for analysis, classification, and reporting of genom-
ic variants.
Results: Two patients with G6PD deficiency, six patients with pyruvate kinase
(PKLR) deficiency and two patients with Glucose-6-phosphate isomerase (GPI)
deficiency were found. Unexpected pyruvate kinase defects were found on tar-
geted re-sequencing for six patients. Pyruvate kinase (PK) enzyme activity
assay were within normal limits in all these cases. All the mutations were pre-
dicted deleterious by PolyPhen/ SIFT/ Provean/ mutpred and Mutationtaster.
Mutations were validated in the parents/siblings (where available) to prove the
mode of inheritance.
Summary/Conclusions: Unexpected PK deficiency were found after next gen-
eration sequencing analysis in the patients where PK enzyme levels were
within normal limits. PK deficiency may be missed by conventional testing
approaches. Our data demonstrates the clinical utility of next generation
sequencing for molecular diagnosis. Timely detection of the cause in our patient
is likely to be helpful not just in genetic counselling and future antenatal diag-
nosis, if required, but therapeutically as well. A splenectomy (performed at
appropriate age) can ameliorate the anemia in such patients and can eliminate
need for transfusions in those that need them. 
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COMPARISON STUDY OF THE EOSIN-5’-MALEIMIDE BINDING TEST,
OSMOTIC FRAGILITY TEST AND CRYOHEMOLYSIS TEST IN THE
DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS
E. Özcan1,*, Y. Oymak1, T.H. Karapınar1, S. Gözmen1, S. Aydın Köker1,
N. Muminoğlu2, S. Okur3, R.C. Vergin1
1Pediatric Hematology, 2Pediatric Hematolgy, 3Pediatric Hematogy, Dr. Behcet
Uz Children’s Hospital, Izmir, Turkey
Background: The primary lesion in HS is loss of membran surface area due
to defects of the membran protein. Cryohemolysis test and osmotic fragility
(OF) test  are used for screening. However no test for HS is 100% reliable.
The eosin-5’-maleimide (EMA) binding test based on flow cytometry. Eighty
percent of the fluorescent-labelled EMA binds to band 3 protein which is lost
in HS due to protein 4.1, spectrin and ankyrin deficiency. Thus measurement
of the flourescent EMA test detects all the different forms of HS. 
Aims: In this study we aimed to evaluate the concordence of EMA binding test
with other diagnostic parameters for HS.
Methods: The patients with HS were diagnosed according to clinical findings
for hemolytic anemia, splenomegaly and spherocytes in peripheral blood.
Hemogram, reticulocyte count, total/direct bilirubin, spherocytes in blood smear
(BS), EMA binding test, OF test, and cryohemolysis test were obtained from
pateints and control groups. Correlation between EMA, OF and cryohemolysis
tests were evaluted. 
Results: Twenty-five male, 17 female HS patients aged between 1.0-19.0
years and 38 male, 47 female healthy controls were evaluated. There were no
differences between both groups in terms of age and sex (Table 1). The median
(range) values of hemoglobin (%), reticulocyte count (%), mean corpuscular
volume (fl), MCHC (%) and total bilirubin level were seen in Table 1. Besides
MCV values there were differences between groups in terms of these param-
eters (Table 1). The median MCF of HS patients was significantly lower than
that of healthy controls while cryohemolysis and osmotic fragility were higher
in HS patients than healthy controls (Table1). There were moderate concor-
dence between cryohemolysis and EMA test (r=-0.355, p<0.001). The sensi-
tivity of EMA was 92.86%, specifity was 82.35%, PPV was%72.22, NPV
was%95.89. EMA was superior diagnostic test to osmotic fragility. (sensitivi-
ty;%83.33, specifity;%76.47, PPV;%63.64 and NPV;%90.28). The sensitivity
of cryohemolysis test was 90.48%, specificity was 94.12%, PPV was%88.37,
NPV was%95.24.
Table 1. Comparison of Clinicaland Laboratory Findings in Hereditary
Spherocytosis groups and Healthy Controls 
M/F; Male/Female, FC EMA;flowcytometric  eosin-5’-maleimide, OF;osmotic fragility, HS; hereditary
spherocytosis, MCHC; mean corpuscular hemoglobin concentration, MCV; mean corpuscular vol-
ume, BS; bloodsmear
Summary/Conclusions: In this study EMA-FC was more sensivitive and
specificity than osmotic fragility. However  specificity and PPV of cryohemolysis
was higher than other test. Also we showed moderate concordance cryohe-
moysis and EMA test.
Although high sensitivity and specifity of EMA test there were need to use other
tests together with family history of patient , physical examination, evaluation
of blood smear and several tests  for HS diagnosis.
PB1843
ADVANCES IN DIAGNOSIS OF HEREDITARY HEMOLYTIC ANEMIAS:
THERMOGRAVIMETRY COUPLED WITH CHEMOMETRICS 
R. Risoluti1, S. Materazzi1, F. Sorrentino2, L. Maffei2, C. Bozzi3, P. Caprari3,*
1Department of Chemistry, Sapienza University of Rome, 2Thalassemia Unit,
S. Eugenio Hospital, 3Haematology, Oncology and Molecular Medicine, Istituto
Superiore di Sanità, Rome, Italy
Background: The differential diagnosis of hereditary hemolytic anemia is gen-
erally carried out by applying different diagnostic protocols depending on the
specific congenital erythrocyte defects. Thermogravimetric analysis (TGA) cou-
pled with chemometrics has recently been proposed as a rapid and cost effec-
tive diagnostic tool for β-thalassemia screening. This model, consisting of Par-
tial Least Square-Discriminant Analysis (PLS-DA), permitted the discrimination
of thalassemic patients and healthy individuals, using thermogravimetric curves
of blood samples [1].
Aims: In this study, the capability of thermogravimetry in conjuction with a mul-
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tivariate statistical analysis was investigated for the screening of hereditary
hemolytic anemias due to different erythrocyte defects.
Methods: Whole blood samples collected in K2EDTA were obtained, after
informed consent, from patients suffering from congenital hemolytic anemias
and were analyzed using the thermobalance TG7 (Perkin Elmer) without any
pretreatment and the resulting curves were compared with those of healthy
individuals. Two groups of hereditary hemolytic anemias were considered:
the hemoglobinopathies (sickle cells anemia and thalassemia) and the ery-
throcyte membrane defects (hereditary elliptocytosis and hereditary sphero-
cytosis).
Results: The characteristic profile of  the blood sample thermal decomposition
and the first derivative (DTG) of the TG curve showed that blood samples from
anemic patients were clearly distinguished from those of healthy individuals as
a result of different amounts of water and corpuscular fraction. The chemometric
approach based on Principal Components Analysis (PCA) allowed a quick iden-
tification of differences between healthy and anemic patients in order to point
out a model of prediction in patients with heterogeneous congenital hemato-
logical disorders.
Summary/Conclusions: The achieved results allow to consider the coupling
TGA/Chemometrics as a promising diagnostic approach to provide a high-
throughput and sensitive tool to obtain an early detection of hereditary hemolytic
anemias using only a few microliters of blood without any pretreatment and
with an hour of analysis time.
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DEVELOPMENT OF A POINT-SCORING SYSTEM FOR EARLY
DIAGNOSTIC TESTING IN GAUCHER DISEASE: APPLICATION OF
FINDINGS FROM THE GAUCHER EARLIER DIAGNOSIS CONSENSUS
DELPHI INITIATIVE 
S. Salek1,*, D. J. Kuter2, A. Mehta3
1School of Life and Medical Sciences, University of Hertfordshire, Hatfield,
United Kingdom, 2Center for Hematology, Massachusetts General Hospital,
Harvard Medical School, Boston, MA, United States, 3Department of Haema-
tology, Royal Free Hospital, UCL School of Medicine, London, United Kingdom
Background: In the Western hemisphere, Gaucher disease (GD) type 1 is
the most common GD phenotype, but the prevalence of GD type 3 is increas-
ing. The spectrum of signs and symptoms of the different GD phenotypes
ranges from fatal perinatal to asymptomatic adult disease, and the hetero-
geneity of its presentation contributes to both misdiagnosis and delays in
diagnosis by clinicians unfamiliar with the disease. The Gaucher Earlier Diag-
nosis Consensus (GED-C) Delphi initiative determined which signs and
patient co-variables are regarded by experts in GD as most indicative of GD
types 1 or 3 in the early stages.
Aims: From the findings of the GED-C expert consensus, to generate a simple
web-based point-scoring system (PSS) suitable for use across clinical special-
ties, that provides guidance based on patients’ presenting signs as to whether
GD diagnostic testing is appropriate.
Methods: An anonymous three-round Delphi process, conducted among a
global panel of 22 expert physicians, established consensus on which signs
and co-variables may be important in early GD type 1 and, separately, in early
GD type 3. In round 1, free-text responses provided by the panel were catego-
rized by an independent administrator. This categorization was checked and
consolidated into summary factors by the non-voting co-chairs. In round 2, the
factors were rated for importance by the panel using a 5-point Likert scale
(1 = not important, 3 = important, 5 = extremely important). Any factors assigned
an importance score of ≥3 by >75% of respondents were then rated for agree-
ment in round 3, using a 5-point pivoted Likert scale (1 = strongly disagree,
3 = neither agree nor disagree, 5 = strongly agree). Consensus was defined as
a score of ≥4 by >67% of respondents. Factors meeting this threshold were
classified as major; all other factors were classified as minor. The co-chairs
defined value ranges corresponding to mild, moderate or severe forms of five
of the major signs of GD (anaemia, hepatomegaly, hyperferritinaemia,
splenomegaly and thrombocytopenia). Panel members indicated whether they
regarded each range as consistent with a GD diagnosis. This information was
used in combination with the classifications of signs and co-variables as major
or minor to create a prototype PSS.
Results: There was a 100% response rate in each round. Factors identified
as major or minor in GD types 1 or 3 are given in the Table 1. There was
100% agreement that splenomegaly (≥3-fold enlargement) and disturbed ocu-
lomotor function (slow horizontal saccades with unimpaired vision) are major
signs in GD, and these were assigned a score of 3 in the prototype PSS;
other major signs and co-variables were assigned a score of 2. The panel
was divided about whether severe anaemia, hepatomegaly, hyperferriti-
naemia and severe thrombocytopenia were consistent with a GD diagnosis,
so these were assigned a score of 1. All minor signs and co-variables were
assigned a score of 0.5.
Summary/Conclusions: A prototype PSS to inform GD diagnostic testing has
been developed from the GED-C Delphi initiative. The PSS will be validated
with retrospective patient data. Total patient scores based on presenting signs
and co-variables will be used to determine empirically a minimum threshold
score that captures positive tests for GD. Abstract submitted on behalf of the
GED-C panel and the EHA Scientific Working Group ‘Quality of Life and Symp-
toms’. Administration of the GED-C initiative was funded by unrestricted edu-
cational grants from Shire International GmbH.
Table 1.
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REGIONAL DISTRIBUTION OF GLUCOSE-6-PHOSPHATE
DEHYDROGENASE DEFICIENCY IN TURKEY AND EVALUATION OF
CLINICAL FINDINGS
S. Sayin1,*, G. Ozgur1, M. Yildirim1, E. Sezer Elci1, C. Beyan2
1Hematology, Gülhane Educational and Research Hospital, 2Hematology,
TOBB University of Economics and Technology Faculty of Medicine , Ankara,
Turkey
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the
most common  inherited enzyme deficiency, that affects more than 400 million
people around the world with more than 300 variants. According to data by the
World Health Organization which was published in 1989; 7.5% of people in the
world have at least one gene G6PD deficiency and this ratio is the highest in
sub-Saharan Africa and Southeast Asia (15-26%). This ratio is in the range of
0.5-2.9% in Turkey, as United States and the neighboring countries to Mediter-
ranean Sea. The epidemiological studies about G6PD deficiency in Turkey
were mostly regional or limited to a city. 
Aims: We aimed to evaluate in terms of regional distribution and clinical fea-
tures of G6PD deficiency by screening the patients who applied for soldier
recruitment. 
Methods: The patients who applied for soldier recruitment between January
2011-March 2016, were analyzed retrospectively. Patients, who were diagnosed
G6PD deficiency were scanned by using hospital patient information system.
The patients’ ages, the cities they lived, complaints and the stories of them
were questioned. Complete blood count, serum AST, LDH, total and direct
bilirubin levels of all the cases in the study were recorded. G6PD levels were
measured by quantitative spectrophotometric methods in biochemistry labora-
tory. The World Health Organization (WHO) is divided G6PD enzyme deficiency
into five classes based on enzyme activity levels and clinical findings.
Results: The distribution of the cities where the cases were living, was given
on the map in Figure 1. Patients’ average age, hemoglobin, and G6PD levels
were 26.42±4.62,  14.68±1.51, and 0.86±0.81 respectively. According to clin-
ical history of patients prior to diagnosis, 29 patients (20.7%) were diagnosed
after acute hemolytic episodes. Of these patients 23, 4, 2, had  hemolytic
episodes due to drug, infection, chemical respectively. Subsequently, 78
(54.5%) and 27 (18.9%) of the remaining patients were diagnosed G6PD
deficiency after the examinations due to hemolysis after favism and prolonged
neonatal jaundice respectively. 6 patients (4.3%) were diagnosed of G6PD
deficiency by screening because of family history, but they didn’t have any
hemolytic episodes before. After the patients evaluated with their clinical his-
tory and hemolysis findings; 6 patients (4.3%), who had chronic hemolysis,
was considered compatible with Class I variant. 128 cases were considered
as Class II variants.
Summary/Conclusions: G6PD enzyme deficiency in Turkey is seen most fre-
quently in the Mediterranean region and the prevalence of G6PD deficiency in
Central Anatolia and Aegean regions was seem to be over the Turkey average
(2.9%). Nearly half of the patients had hemolytic anemia due to favism. It is fol-
lowed by hemolysis due to neonatal hyperbilirubinemia and drugs. 128 (91.4%)
patients who had severe G6PD deficiency with intermittent hemolysis, were
considered as Class II variants. 
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CHARACTHERISTICS AND MANAGEMENT OF AUTOIMMUNE
HEMOLYTIC ANEMIA : A SINGLE CENTER STUDY WITH 32 CASES
A.F. Yılmaz1, H.D. Kiper Unal1,*, T. Yuksel Karslı2, M. Kilinc2, F. Gediz1,
K.B. Bayman Payzin1
1Hematology, 2Internal Medicine, Izmir Katip Celebi University Ataturk
Research and Training Hospital, Izmir, Turkey
Background: Autoimmune hemolytic anemia (AIHA) is characterized by red
blood cell destruction mediated with autoantibodies against to RBC antigens.
Most common type is warm AIHA which can be either idiopathic or secondary to
underlying disorders with immun disturbance. Determining  the optimal therapy
is a challenge because of insufficient data from prospective controlled trials. 
Aims: To evaluate the clinical charactheristics, treatment responses and out-
comes of our AIHA patients.
Methods: The clinical data of 32 patients with AIHA diagnosed and treated in
our center between 2008 and 2016 were retrospectively analyzed.
Results: Median age at diagnosis of AIHA was 45 years (range:20-
74). Male/female ratio was 1/1.3. 24 of 32 patients (75%) had primary AİHA
and 8 (25%) had secondary AIHA with underlying disorders as SLE in 2
patients, , mixed connection tissue disease (MCTD) in 2, psoriatic arthritis in
1, chronic lymphocytic leukemia (CLL) in 1, marginal zone lymphoma in 1 and,
chronic HCV infection in 1. Median Hemoglobin (Hb) level was 7.4 gr/dl and 5
patients also had thrombocytopenia (<150000) beside hemolytic anemia. Mean
LDH level was 544, indirect bilirubin was 2.7, reticulocyte was 11.3%. 18/32
patients (56%) required transfusion.  In all patients who required treatment
(94%) corticosteroids were the first-line therapy with an initial response rate of
93%. Median steroid duration was 3 months range between 1.5 to 96 months.
Relapse was occured in 15 of 30 patients who recieved steroid (50%) with the
median time to relapse (TTR) of 12 months (range:5-72 months). 11/30 patients
(37%) required second-line therapy; seven had undergone splenectomy, three
recieved rituximab, and one recieved danasin. All of the patients who under-
gone splenectomy had CR in first month and relapse after splenectomy was
seen in 5/7 patients (71%) with a median duration of 60 months. Of three
patients who were treated with standard dose of Rituximab; two achieved CR
and one did not achieve any response. One of two rituximab-responded
patients relapsed at 26. and 60. months and re-treated by rituximab; still fol-
lowing with CR for 16 months.
Summary/Conclusions: Although corticosteroids are the first choice of initial
treatment of AİHA, most of the patients relapse at follow up. Steroid depend-
ency and intolerance are also challenging. Splenectomy is still a considerable
option for second-line therapy because of its high response rates and long
remission durations. Rituximab is the other effective second-line therapy option
with similar response rates to splenectomy. Until prospective studies will be
performed, retrospective data would help the clinicians to choose best treat-
ment algorithm for AIHA.
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THE IMPACT OF THE REORGANIZATION OF THE PATIENT CARE
PROCESS FOR GAUCHER DISEASE IN HEALTH SYSTEM
F. Blanco-Favela1,*, R. Silva-Garcia2, E. Avila-Arreguin3,
M. Rabago-Rodriguez4, C. Correa-Gonzalez5, J. Garcia-Ortiz6,
S. Franco-Ornelas7, E. Terrero-Muñoz8, J. Gonzalez-Izquierdo9
1Unidad de Investigación Médica en Inmunología, UMAE Hospital de Pediatría,
CMN-SXXI, 2Unidad de Investigación Médica en Inmunología, 3Servicio de
Hematología, UMAE, Hospital de Especialidades, CMN “La Raza”, 43Servicio
de Excelencia Clínica, CUMAE, Instituto Mexicano del Seguro Social, Ciudad
de México, 5HGZ/MF No. 1 SLP, Instituto Mexicano del Seguro Social, San
Luis Potosi, 65División Genética, Centro de Investigación Biomédica de Occi-
dente, Instituto Mexicano del Seguro Social, Guadalajara, 7Jefe de Medicina
Interna Pediátrica, UMAE, Hospital General, CMN “La Raza”, 87Servicio de
Hematología, UMAE, Hospital de Especialidades, “Dr. Bernardo Sepúlveda”
CMN-SXXI, Instituto Mexicano del Seguro Social, Ciudad de México, 98Jefe
de Servicio de Prestaciones Médicas delegación Jalisco, Instituto Mexicano
del Seguro Social, Guadalajara, Mexico
Background: Gaucher disease (GD) is a multisystemic disease of lysosomal
storage that is caused by deficient activity of the glucocerebrosidase enzyme
resulting from a recessive autosomal hereditary mutation in the β-glucocere-
brosidase gene. The accumulation of glucocerebrosidase in the lysomes dam-
ages the hematological, skeletal, and nervous systems and leads to three vari-
eties of the disease: type 1, which is non-neuropathic, and types 2 and 3, which
are neuropathic. In Mexico, the process by which patients with lysosomal dis-
ease are cared for was reorganized by the Clínicas de Referencia Nacional y
Grupos de Expertos en Enfermedades Lisosomales (National Reference Clin-
ics and Expert Groups on Lysosomal Diseases [EGLDs]), who created the
Guías de Práctica Clínica (Clinical Practice Guidelines) for GD
Aims: This study aimed to evaluate the results obtained for 39 patients diag-
nosed with type 1GD (25 women and 14 men) through the National Reference
Clinics and EGLDs
Methods: The clinical case of 39 patients was analyzed and punctual mutation
of the β-glucocerebrosidase gene was determined. The patients were treated
with imiglucerase enzyme at 60 UI/Kg every 14 days. The enzymatic activity
of the β-glucocerebrosidase and the chitotriosidase was determined. We deter-
minate concentration of hemoglobin and platelets. The degree of hepato-,
splenomegaly, bone density and skeletal pain was evaluated.
Results: Four of the 39 patients were found to have been incorrectly diagnosed
with GD, the remaining 35 patients completed the treatment goals, which includ-
ed remission from hepatomegaly, splenomegaly, and skeletal pain. Additionally,
increases in the hemoglobin and platelet concentration and bone mineralization
were achieved, thereby attaining the patients’ therapeutic goals, reducing the
therapeutic dose required, and achieving the expected impacts on their health. 
Summary/Conclusions: this reorganization of patient care successfully
reduced complications, improved care, and optimized the use of resources
and costs of GD treatment.
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NORMOCYTIC ANEMIA IS MORE COMMON THAN MICROCYTIC ANEMIA
IN GASTRO-INTESTINAL CANCERS: A LARGE SINGLE CENTRE STUDY
F. Lourenco1,*, F. Alibeygi2, L. Barton2, J.M. Yeung3, S. Kadri1, R. Krishna2
1Gastroenterology, 2Haematology, 3Colorectal Surgery, University Hospitals
Leicester, Leicester, United Kingdom
Background: Microcytic anemia is traditionally associated with GI cancers and
led to endoscopic investigations to evaluate for GI cancers.
Aims: We evaluated the haematological profile of a large series (855) of con-
secutive GI cancer patients at diagnosis in a university hospital.
Methods: This retrospective study analysed the full blood count of 265 col-
orectal cancer (CRC) patients over one calendar year and 590 patients with
esophago-gastric cancers (OGC) over 3 calendar years. WHO guidelines were
used to define anemia (Hb <130 g/L in males and <120 g/L in females). Further
analysis was done based n severity of anemia (mild>110 g/L, moderate 80-
110 g/L and severe<80 g/L), sex, age and tumour location.
Results: Among the 265 CRC patients, 116 (44%) were anemic, of which 72
(27%) were normocytic, 43(16%) were microcytic and 1 was macrocytic. 67/152
(44%)male patients were anemic, of which 42 were normocytic and 24 micro-
cytic.  49/113 (43%) female patients were anemic, of which 30 normocytic and
17 microcytic. Patients above age of 60 had more normocytic anemia (31%)
than microcytic anemia(12%), while among those below 60 had more microcytic
anemia ( 30%) than normocytic anemia. Leucocytosis and thrombocytosis were
seen only in 14% and 12% of CRC patients.
Among 590 OGC patients, 285 (48%) were anaemic, of which 221(37%) were
normocytic, 51(9%) microcytic and 13(2%) macrocytic. 194/390 (50%) male
patients were anaemic, of which 148 (38%) were normocytic and 38(10%)
microcytic. 91/200 (46%) were anaemic, of which 73(37%) were normocytic
and 13 (7%) microcytic. Among 392/590 esophagial cancers, 123 (31%) were
normocytic and 25 (6%) were microcytic. Of 198/590 gastric cancers, 98 (49%)
were normocytic while 26(13%) were microcytic. Leucocytosis and thrombo-
cytosis was seen only in 16% and 13% of OGC patients.
Summary/Conclusions: There is a higher prevalence of normocytic anemia
than microcytic anemia in Gastro-intestinal cancers almost at a ratio of 2:1.
Normocytic anemia is more common in elderly patients and those with mild to
moderate anemia. The causes may be multifactorial including anemia of chronic
disease secondary to malignancy. This highlights the fact that GI cancers must
be considered as a cause in normocytic anemia irrespective of iron deficiency
and symptoms of GI cancer should be carefully explored and investigations
triggered.
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DEMONSTRATION OF FUNCTIONAL SIMILARITY OF PROPOSED
BIOSIMILAR ABP 798 TO RITUXIMAB
H. McBride1,*, G. Maher1, H. Sweet2, I. Foltz2, J. Canon1, S. Kuhns1
1Biosimilars Development, Amgen Inc., Thousand Oaks, United States,
2Biosimilars Development, Amgen British Columbia, Burnaby, Canada
Background: Proposed biosimilars undergo comprehensive structural and
functional characterization before they can be studied in confirmatory clinical
trials. ABP 798 is being developed as a biosimilar to rituximab. The originator
is approved for treatment of non-Hodgkin’s lymphoma, chronic lymphocytic
leukemia, severe rheumatoid arthritis, granulomatosis with polyangiitis, and
microscopic polyangiitis.
Aims: ABP 798 was compared with rituximab sourced from the European Union
(EU). Quality attributes assessed included binding properties (CD20, C1q, FcRn,
and Fcγ receptors), antibody-dependent cell-mediated cytotoxicity (ADCC), com-
plement-dependent cytotoxicity (CDC), and induction of apoptosis.
Methods: Binding of ABP 798 and rituximab to the CD20 antigen was charac-
terized using a cell-based CD20 binding assay utilizing the human B-lym-
phoblastoid, WIL2-S, cell line. A direct binding ELISA was used to assess the
binding of the Fc domain of ABP 798 to C1q. Binding of the Fc moiety of ABP
798 and rituximab to FcγRIa, FcγRIIa, FcγRIIb, and FcγRIIIa (158V) were eval-
uated in AlphaLISA® competitive binding assays. Binding to FcRn was evalu-
ated by an AlphaScreen® competitive binding assay. ADCC activity was eval-
uated in a functional cell-based assay, with CD20-expressing WIL2-S cells
used as target cells and NK92-M1 cells, stably transfected with human CD16
(FcγRIIIa [158V]), used as effector cells. CDC activity was evaluated in a func-
tional cell-based assay using a CD20 expressing human B-lymphoblastoid
WIL2-S cell line and baby rabbit complement. Induction of apoptosis was
assessed by measuring activation of caspase 3/7 in SU-DHL-4 cells, a CD20-
expressing human B cell lymphoma cell line. 
Results: Relative binding (%) was comparable between ABP 798 and rituximab
(Table 1).
Table 1.
The dose response profiles and relative activity for ADCC and CDC were similar
(mean ADCC relative activity: ABP 798, 88%; rituximab, 86%; mean CDC rel-
ative potency: ABP 798, 103%; rituximab, 104%). The dose response profile
for induction of caspase 3/7 was comparable between ABP 798 and rituximab.
Summary/Conclusions: The results presented here suggest that ABP 798 is
similar to rituximab sourced in the EU in terms of biological activity across the
range of tested functions. These results provide a firm foundation for further
clinical development of ABP 798.
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DELAYED EFFECT OF G-CSF ON THE CYTOKINE SECRETION THROUGH
G-CSF MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN
CHILDREN WITH CEREBRAL PALSY
Y.-H. Lee1,2,*, W.-J. Rah2, H. Koh1,2, H.-J. Jun2, J.Y. Suh1, H.J. Eom1,
M.J. Kim3
1Blood & Marrow Transplantation Center, 2Department of Pediatrics, 3Depart-
ment of Rehabilitation Medicine, HANYANG UNIVERSITY MEDICAL CENTER,
Seoul, Korea, Republic Of
Background: Granulocyte colony-stimulating factor (G-CSF) has been widely
used to mobilize peripheral blood stem cells. In addition, it also has been tried
to reveal the regenerative potential in various neurodegenerative diseases. 
Aims: We investigated the short-term and delayed effects of infused G-CSF
for peripheral blood stem cell (PBSC) mobilization on the various cytokine
secretions in children with cerebral palsy (CP). 
Methods: G-CSF (10μg/kg/dose) was administered subcutaneously for 4 days
to the children with CP. In first group, blood levels of G-CSF, interleukin (IL)-6,
IL-10, insulin-like growth factor (IGF-1), vascular endothelial growth factor
(VEGF), and brain derived neurotrophic factor (BDNF) as well as mobilized
total nucleated cell (TNC)/CD34+ cell counts in peripheral blood were compared
between just before G-CSF injection (D+0) and 1 day after 4 days of G-CSF
injections (D+5). In second group, cytokine levels were compared between
D+0 and 1 month after 4 days of G-CSF injection (D+30). Cytokine levels were
measured by enzyme-linked immunosorbent assay.
Results: Baseline levels of G-CSF were significantly increased (p=0.000) and
IGF-1 decreased (p=0.011) at D+5 after 4 days of G-CSF administration com-
pared to control group. In contrast, other cytokine levels including IL-6, IL-10,
VEGF, and BDNF did not show any significant changes between before and
after G-CSF administration. CD34+ cell counts (p=0.000) as well as TNC counts
(p=0.000) were significantly increased from D+0 to D+5 in children who received
G-CSF compared to children received placebo. Regarding delayed effect of G-
CSF administration, G-CSF levels were significantly increased from baseline
to D+30 (p=0.000), along with the increase IL-10 (p=0.035) and VEGF levels
(p=0.011) and the decrease of IGF-1levels (p=0.014).
Summary/Conclusions: G-CSF which administered to mobilize PBSCs could
induce the delayed effects on the levels of G-CSF itself as well as of other
cytokines which could affect on the neuroregenerative potential. Further studies
would be warranted to reveal the mechanism and clinical significances of these
delayed effect of G-CSF or mobilized PBSCs.
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MYD88 IN PRAME GENE ACTIVATION
V. Misyurin1,*, N. Lyzhko1, A. Misyurina2, J. Finashutina1, V. Tikhonova1,
L. Kesaeva1, O. Solopova1, N. Kasatkina1, M. Baryshnikova1, E. Misyurina3,
A. Prokophiev4, A. Misyurin1
1”N.N.Blokhin Russian Cancer Research Center” Ministry of Health, 2National
Research Center for Hematology, 3City Clinical Hospital No52 Moscow Health
Department, 4Moscow state Academy of Veterinary Medicine and Biotechnol-
ogy - MVA by K. I. Skryabin, Moscow, Russian Federation
Background: PRAME is the most frequently expressed non-X-chromosomal
cancer-testis gene in solid and hematological cancer. It is important, because
PRAME often has a bad prognostic significance. In early studies was found
that PRAME frequently coexpressed in translocation-harboring (like t(8;21),
t(15;17) and t(9;22)) haematological diseases. Authors supposed that chimeric
genes are activators of PRAME expression. But in large cases with normal
karyotype PRAME is also expressed. Another reason for PRAME expression
is promoter demethylation. But demethylating agents cannot activate PRAME
expression in hematological cells taken from healthy donor. So presence of
chimeric genes  and methylation status only are not enough to explain why
PRAME can be expressed in high level. Wadelin et al. found that PRAME
expression level was increased in cell during lipopolysaccharide-treatment con-
ditions. Role of MYD88 in this process still be unknown.
Aims: To check if MYD88 participates in activating PRAME expression in
leukemia cell lines.
Methods: Three cell lines were used for incubation with anti-PRAME antibody:
chronic myeloid leukemia cell line K562 with high PRAME expression level
(645%), acute monocytic leukemia cell line THP-1 with intermediate PRAME
expression level (2,92% relative to ABL) and acute myeloid leukemia cell line
NOMO-1 with low PRAME expression level (0,46%). All cell lines were incu-
bated in RPMI 1640 with addition of LPS in final concentration 10 ng/ml. After
1 and 4 hour of incubation total RNA was extracted and PRAME and MYD88
expression levels were measured.
Results: After 1 and 4 hours of experiment in K562 cell line PRAME expression
level was increased in 2,7 and 7 fold under control, respectively, and MYD88
expression level increased in 1,1 and 2,5 fold under control. In THP-1 line
PRAME expression level was increased in 20 and 25 fold, respectively, and
MYD88 expression level was increased in 5,5 and 6,5 fold. In cell line NOMO-
1 PRAME expression level was increased in 10 fold after 1 hour and in 14 fold
after 4 hours, and MYD88 expression level was increased in 2,4 and 3,2 fold
after 1 and 4 hours of experiment, respectively. Strong correlation between
MYD88 and PRAME expression levels was observed (Pearson correlation coef-
ficient 0,98).
Summary/Conclusions: We conclude that LPS after binding with TLRs initi-
ates activating signal to PRAME gene via MYD88.
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PD-1 IS HIGHLY EXPRESSED ON MEMORY T-CELL SUBSETS RESIDING
IN BONE MARROW BUT NOT IN PE-RIPHERAL BLOOD IN HEALTHY
INDIVIDUALS
N. Popova1,*, M. Drokov1, A. Kuchmiy2, A. Vdovin2, J. Davydova3, L. Kuzmina1,
D. Dubnyak1, E. Mikhalcova1, V. Vasilyeva1, O. Koroleva1, Z. Konova1,
I. Galtseva3, G. Efimov2, E. Parovichnikova1, V. Savchenko1
1Bone marrow transplant department, 2Laboratory of post-transplant immunol-
ogy, 3Laboratory of immunophenotyping, National Research Center for Hema-
tology, Moscow, Russian Federation
Background: Recently  memory T lymphocytes were shown to be a highly het-
erogeneous cell compartment comprising different phenotypes, functional activ-
ities, gene expression profiles and survival capacities. Phenotypically due to the
differentiation stage and functional activities  memory CD8+ T cells can be divided
into stem cell memory (Tscm), central memory (Tcm), terminal memory (Ttm),
effector memory (Tem) and terminal effector (Tte) and reside in bone marrow
(BM) as long-lived persistent T cells [Mahnke YD et al., 2013]. Programmed cell
death protein 1 (PD-1) is well known as a negative immune regulator of T cells
that has detrimental effects on anti-viral, anti-tumor immunity, mediates tissue
tolerance to protect against immune-mediated tissue damage. Currently anti-
PD1 immunotherapies are among the most effective anti-cancer immunothera-
pies available. PD1 pathway blockade is a key pathogenetic mechanism [Bous-
siotis VA et al., 2014]. Understanding the influence of PD-1 pathway on memory
T cell homeostasis in BM might be critical for improving treatment of patients
with cancers and hematological malignancies, but is still not well understood. 
Aims: To evaluate PD-1 expression on distinct memory T cell subsets in BM
and PB of healthy donors. 
Methods: The first portion of BM and a sample of PB were obtained from
healthy donors (n=10, m=6, f=4) with age 37.5 (22-53) years old.. Numbers of
white blood cells (WBC) in BM and PB samples were evaluated by Sysmex
XE-2100 hematology analyzer. 1*10^6 of WBC (excluded nucleated red blood
cell) from BM and PB were stained using “lyse-wash-stain” standard protocol.
The CD8-APC-Cy7, CCR7-PE-Cy7, CD28-PE, CD45R0-FITS, PD1-APC anti-
bodies were used for cell staining and 7-AAD was used for to discriminate
dead cells during flow cytometry.
Results: PD1 expression by T memory cell subsets is  shown  in the Table 1
(median with interquartile range). The percentage of PD1+ cells within Tcm
CD8+ subset was 34,2%±8,033% in BM versus 10,4%±1,23% in PB. Similar
trend was observed in other subsets: Tscm, Tem, Ttm, Tte. Median of PD1+
CD8+ cells were 3,8%±1,015%, 22,7%±6,39%, 42,7%±7,86%, 21,9%±4,047%
and 2,6%±0,41%, 6,6%±2,59%, 12,7%±1,25%, 8,9%±0,825%  in BM and in
PB respectively. 
Table 1.
Summary/Conclusions: We found higher frequencies of PD-1 expressing
memory ВМ T cells comparing to PB. This might point to the important roles of
PD-1 in regulation of memory T cells homeostasis in BM. In physiological con-
ditions PD-1 is thought to neutralize self-reactive naive T cells that in its turn
leads to restraining T cells excessive activation and blockade the development
of autoimmunity in BM. On the other hand low expression of PD1 on T cells in
PB can be explained by needs the opportunity for prompt reactivity with
pathogens that also provide normal «robust control» and prevent developing
of a disease. 
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BONE MARROW STROMAL CELLS MAY HAVE GENETIC ABERRATIONS
AND ARE CAPABLE TO GAIN THEM IN A CULTURE
I. Barkhatov1,*, N. Tsvetkov1, D. Ershov1, T. Gindina1, A. Shakirova1,
M. Nikolaeva1, A. Potter1, L. Zubarovskaya1, B. Afanasyev1
1R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and
Transplantation, First Pavlov Saint Petersburg State Medical University,
St.Petersburg, Russian Federation
Background: Stromal microenvironment posses a key role in the regulation
of both normal hematopoiesis and its reconstitution after hematopoietic stem
cell transplantation (HSCT). Recent data supports the idea that bone marrow
stromal cells (BMSC) also have genetic aberrations and may tightly involved
in the pathogenesis of HSCT complications. These findings justify the need for
more detailed study of genetic aberrations in BMSC.
Aims: The aim of this study was to evaluate genetic aberrations in BMSC and
check the ability to gain them in coculture system.
Methods: The interaction of BMSC with hematopoietic tumor cell lines bearing
specific genetic aberrations (BCR-ABL fusion transcript for K-562 and JAK2
V617F mutation for Uke-1 cell line) was investigated in stromal cells harvested
from 17 patients and 8 healthy donors. We performed cultivation of BMSC
monolayer and tumor cells suspension using semipermeable membrane plates
inserts with different pore size (0,4 μm and 3,0 μm) in order to exclude direct
cell-to-cell contact. We looked also for existing specific genetic aberrations
(point mutations and fusion transcripts) in BMSC of patients with the respective
aberration in their leukemic clone. For this purpose we used both karyotyping
(7 patients) and RQ-PCR method. BMSC were examined by flow cytometry to
evaluate the possible contamination with cells of hematopoietic lineage.
Results: We investigated the BMSC karyotype in seven patients and only one
case led us to a remarkable finding. The clonal chromosomal rearrangement
t(1;7) was detected in 25% of BMSC metaphases. Interestingly, this aberration
was never detected in patient’s leukemic cells. 
We also examined BMSC from leukemia patients bearing recurrent genetic
abnormalities and in one case the leukemia-specific marker was detected by
RQ-PCR - we observed expression of ETV6-RUNX1 gene (≈0,02%) in BMSC
by patient with t(12;21) acute lymphoblastic leukemia. At the moment of BMSC
culture initiation ETV6-RUNX1 expression in patient’s bone marrow was detect-
ed at high level (ETV6-RUNX1/ABL*100=321%). Before carrying out RNA
extraction BMSC were harvested after the second passage and no contami-
nation with CD45+/CD34+ cells by flow cytometry was observed (50,000 events
collected from the sample). When BMSCs and Uke-1 cell line were cocultured
by using of 3,0 μm pore culture dishes inserts, the BMSC population gained
the Jak2V617F mutation (allele burden ≈ 30,39%). We reproduced similar
experiments with the K-562 cell line and got similar results - CD45+ cells were
also detected in BMSC population (≈ 30%). Moreover we detected CD45+ non-
cellular particles by flow cytometry analysis. Implying K-562 cells are not likely
to cross the semipermeable membrane (3,0 μm pores versus 20,0 μm cells as
measured during microscopy). Besides BCR-ABL gene expression in BMSC
was detected by RQ-PCR (BCR-ABL/ABL*100=19%). We repeated same test
with 0,4 μm pore inserts and without them in order to check implication of cell-
to-cell interaction. We didn’t obtain any similar results with smaller pores, but
the fusion transcript was detected in CD45- BMSC population when these two
cell populations weren’t devided. Both findings point out at possible horizontal
gene transfer mediated by membrane vesicles larger than 0,4 μm and direct
whole cell fusion. 
Summary/Conclusions: Our data stands for the existence of horizontal gene
transfer between leukemic clone and BMSC. This process seems to be medi-
ated by membrane vesicles larger than 0,4 μm in size, though cell fusion can
also take place. We also confirmed the fact BMSCs can bear clonal genetic
rearrangements which are not specific to tumor cell populations. These findings
show tight interaction between tumor and microenvironment cells and can
partly explain nature of PCR-based MRD persistence in complete remission. 
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CIRCULATING ENDOTHELIAL PROGENITORS CELLS AND METABOLIC
FACTORS IN CHILDHOOD CANCER SURVIVORS
E. Athanasopoulos1, G. Martimianaki1, H. Kampouraki1, M. Stratigaki1,
E.A. Markaki1, N. Katzilakis1, E. Stiakaki1,*
1Pediatric Hematology - Oncology, University Hospital of Heraklion, University
of Crete, Heraklion, Greece
Background: Circulating Endothelial  Progenitor Cells (CEPCs) play a significant
role in the maintenance of vascular integrity,balancing the anti-coagulation mech-
anisms and modulating the immune system by regulating the leukocyte trafficking,
as well as controlling the vascular tone. Additionally, it is well-established, that
patients who underwent chemotherapy have increased incidence of hypertension
and obesity. Nevertheless, numerous studies have shown a negative correlation
between CEPCs and obesity, underlining poor vascular repair. 
Aims: The study of CEPCs  in children who received chemotherapy  for Acute
Lymphoblastic Leukemia (ALL) and solid tumors (ST) and the investigation of
their levels in correlation with patients Body Mass Index (BMI) and blood pres-
sure (BP) regarding the time following treatment.
Methods: Peripheral blood from children with ALL (n=77), ST (n=81) and chil-
dren without malignancies  as  control group ( n=71) were studied. Four colour
flow cytometry was performed to determine the subpopulations CD34+CD
45negdimCD133+, CD34+CD45negdimVEGFR2+ and CD34+CD45negdim-
CD133+VEGFR2+ of CEPCs. The BMI of the patients was calculated and the
BMI percentile was  established specific  by the age and gender. Normal weight
defined with BMI percentile over 5th and bellow 85th percentile, and over-
weight/obesity over 85th percentile. The systolic blood pressure (BP) was meas-
ured and the percentile was calculated specified by the age, gender and height.
Normal BP was defined BP over 5th and bellow 90th percentile and hypertension
with a BP over 90th percentile. The post treatment period of time was divided
in three groups under or equal of 1 year, 1 to 3 years, and equal and over 3
years. The statistical analysis was conducted using t-test (Holm-Sidak) and
2way ANOVA (Tukey’s multiple comparisons test).
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Results: The mean values of CEPCs subpopulation CD34+CD45negdimVEG-
FR2+ estimated in ALL, ST and Controls were  0.00360 (SE=0.00072),0.00613
(SE=0.00146) and 0.002953 (SE=0.0004) respectively. The mean percentage
of CD34+CD45negdimCD133+VEGFR2+ in ALL, ST and Controls was 0.00331
(SE=0.00072), 0.00499 (SE=0.00113) and 0.002663 (SE=0.00037). The cor-
relation of CEPCs  showed statistical significant difference of
CD34+CD45negdimVEGFR2+ between the ST and controls  (Mean Diff
0.003174, 95CI of diff 7.716e-005 to 0.006272). In  ALL  the levels of
CD34+CD45negdimVEGFR2+ the 1st year after treatment completion were
0.00458(SE=0.0026), during 1-3years 0.0031(SE=0.00066) and >3 years
0.003423(SE 0.00081). The levels of CD34+CD45negdimCD133+VEGFR2+
during the 1st year after chemotherapy have a mean value 0.0045(SE=0.0026),
1-3 years 0.0027(SE=0.00063) and >3years 0.0031(SE=0.00081).  In the  ST
group  the mean value of CD34+CD45negdimVEGFR2+  the 1st year after
treatment was 0.0114 (SE=0.0048),1-3years 0.0047(SE=0.0013) and >3 years
0.0036(SE=0.0008). Whereas the percentage of CD34+CD45negdim
CD133+VEGFR2+ the 1st year after chemotherapy was 0.0092 (SE=0.0037),1-
3 years 0.0034(SE=0.00097)and>3 years 0.00336(SE=0.00085).Statistical sig-
nificant results were calculated for the levels of CD34+CD45negdimVEGFR2+
in ST group between the groups <1 year and over years’ post treatment(Mean
Diff 0.007747, 95 CI of diff 0.0002441 to 0.01525). The study of body weight  in
ALL and ST groups in relation with CEPCs  showed no statistical significant
difference, although a negative trend between obesity and CEPCs was found
in the  ALL group and a positive one in the ST group. The same trend also
appeared  in BP  between ALL and ST  regarding the  CEPCs, with hypertensive
patients in ALL group having higher levels of CEPCs than the ST hypertensive
individuals.
Summary/Conclusions: The higher levels of CEPCs were estimated in ALL
and ST  just after treatment completion  with a gradual decrease as time passes.
The highest percentages of CEPCs were  evaluated in ALL patients  with normal
weight  and blood pressure in contrast with the solid tumor group. Further invsti-
gation  is necessary  to highlight the importance of these data.
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HEMATOLOGICAL PARAMETERS IN NATIVE HIGHLANDERS OF LADAKH
AGED 4-19 YEARS
S.K. Das1,*, Y. Uday1, D. Katoch1, V. Nair1
1Hematology, Army Hospital (Research & Referral), New Delhi, India
Background: High altitude (HA) has always intrigued physiologists because
of the remarkable ability of man to adapt to the hostile environment. Hemato-
logical changes associated with HA exposure is believed to be driven by hypo-
baric hypoxia of HA. Majority of the studies on HA physiology and hematological
adaptation have focused on the hematological adaptation in lowlanders visiting
HA or have compared the hematological profile of native highlanders from
Andes and Tibet with those of the neighboring lowlanders. These studies have
mostly been directed towards adult population with no or little reference to chil-
dren and adolescent age groups. Moreover these studies have been done
mostly on the highlanders of Andes and Tibet with no data on Indian high-
landers.
Aims: We aimed at assessing hematological parameters in native highlanders
in the age group of 4- 19 yrs and compare the same with Indian lowland pop-
ulation as well as native highlanders around the globe. 
Methods: A total of 390 native highlanders of Ladakh in the age group of 4-19
yrs with no history of travel to lowland were taken for the study. A written
informed consent was taken from the parents of all the subjects before starting
interviewing them for the laboratory investigations. After taking antiseptic pre-
cautions, blood samples were drawn from the ante-cubital vein and complete
hemogram including red blood cell indices were measured. The study subjects
were stratified into five age groups (less than 5y, 5-8y, 8-10y, 10-12y, 12-15y
and children more than 15y). Appropriate statistical analysis was done to com-
pare the hematological parameters between the stratified age groups as well
as between boys and girls.
Results: A total of 197 girls and 193 boys were included in the study. The
mean age of the subjects was 128±80 (mean±2SD) months. The mean hema-
tocrit value increased with age (38.68±2.51% in <5 yrs age group to
43.84±2.04% in >15 yrs age group). Similarly the mean corpuscular volume
(MCV) also showed a rising trend with age (79.07±3.36 fL in <5 yrs age to
85.66± 2.72 fL in >15 yrs age). In contrast to the rising values of hematocrit
and MCV we found that the mean corpuscular haemoglobin concentration
(MCHC) decreased with age from 36.91±2.85% at <5 yrs of age to
33.78±2.31% at >15 yrs of age. The variations among the age groups are
significant for hematocrit, mean corpuscular volume (MCV) and MCHC
(p<0.01). On comparison of hematological parameters between boys and
girls we found that the mean hemoglobin concentration in girls (13.99±0.29
g/dL) was significantly lower than boys (15.43±0.28g/dL). The same findings
were replicated in the mean RBC count (4.79±0.08 in girls v/s 5.07 ±0.08 in
boys) and mean hematocrit (39.49±0.82% in girls v/ 41.57±0.82% in boys).
The mean MCHC in boys (37.23±0.93%) was significantly higher than those
in girls (35.69±0.94%). The mean platelet count in boys was significantly
higher than in girls (p=0.0003) (Figure 1).
Figure 1.
Summary/Conclusions: The hematological adaptation of Ladakhi kids is dif-
ferent as compared to other native highlanders. There is also a significant dif-
ference in the hematological response to hypobaric hypoxia with growing age
and between boys and girls.
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AGE VARIATION OF B-CELL PRECURSORS IN BONE MARROW: NORMAL
VALUES AS A REFERENCE FOR MDS IN BRAZIL 
I. Lorand-Metze1,*, A.L. Longhini1, G. Oliveira-Duarte1, R.P. Correia2,
M.C. Santos-Silva3, M.R. Ikoma4, E. Xisto Souto5, A. Sandes6,
A. Frisanco Oliveira7, K. Metze8
1Hematology - Hemotherapy Center, University of Campinas, Campinas, 2Lab-
oratory of Hematology, Hospital Albert Einstein, São Paulo, 3Laboratory of
Experimental Oncology, Fedreal University Of Santa Catarina, Florianópolis,
4Laboratory of Cytometry, Hospital Amaral Carvalho, Jaú, 5Laboratory of Hema-
tology, DASA, 6Laboratory of Hematology, Laboratórios Fleury, São Paulo,
7Laboratory of Hematology, Childrens’ Cancer Hospital, Barretos Cancer Cen-
ter, Barretos, 8Pathology, University of Campinas, Campinas, Brazil
Background: Decrease of bone marrow (BM) B-cell precursors (BCP) is an
important diagnostic feature in myelodysplastic syndromes (MDS). Moreover,
their number is associated with patients’ overall survival. However, BCPs vary
with age in normal BM.
Aims: In a multicenter study from the Brazilian Group of Flow Cytometry we
analyzed the variation of BCPs in normal BM according to age, antibody com-
binations used for quantification and reproducibility after a centralized reanaly-
sis. We set up a reference pattern of normal values for evaluation of patients
with a suspected MDS.
Methods: In a retrospective study including 10 centers we retrieved analyses
of BM donors and cases examined for elucidation of transitory reactive cytope-
nias presenting a normal BM immunophenotyping. BCPs were enumerated as
CD19/CD34/CD45/CD10 cells (panel 1) or CD19/CD34/CD45 cells (panel 2),
among the total nucleated cells and as percentage among CD34+ cells. Sta-
tistics: multiple regression to analyse the dependence of BCS from the variables
analysed.
Results: 134 cases were included. Panel 1 was applied in 106 cases (all cen-
ters) and panel 2 was used in 28 cases (3 centers). Age range: 10 months to
89 years. In the same age range, values for panel 2 were lower than those for
panel 1.  In a multiple regression,% BCP/total cells=-0.389 “log age” (years) –
0.313 (for panel 2)+correction factor for labs +1.873. The correction factor for
labs was 0 to -0.40. Age explained alone 49.6% of the variance of% BCPs/total
cells, while “laboratory” explained 5.2% and panel used explained only 0.8%.
Age explained only 24.9% of the variance of BCPs/CD34+ cells.
Table 1.
Summary/Conclusions: in a normal population BM B-cell precursors varied
mainly with age, but were also dependent on technical peculiarities of operators
and equipments. Analysis by phenotype and as percentage of total cells was
more accurate and less susceptible to variation.
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PERIOSTIN/BIGH3 RATIO AS A PROGNOSTIC MARKER OF IDIOPATHIC
THROMBOCYTOPENIA AFTER ALLOGENIC HEMATOPOIETIC CELL
TRANSPLANTATION FOR THE PATIENTS WITH ACUTE MYELOGENOUS
LEUKEMIA
Y.J. Lee1,*, S.K. Sohn1, H.-J. Kim2, T.I. Park3, J.Y. Ham4
1Department of Oncology/Hematology, 2Biochemistry and Cell biology, 3Pathol-
ogy, 4Laboratory, Kyungpook National University Hospital, Daegu, Korea,
Republic Of
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Background: Disrupted hematopoiesis is life-threatening complication of allo-
geneic hematopoetic cell transplantation (allo-HCT). The interactions of
haematopoietic stem/ progenitor cells (HSPCs) and bone marrow (BM)
microenvironment, niche(s), control the homeostasis of BM. TGF-b induced
gene 3 (BIGH3), one of BM extracellular matrix (ECM) which is produced by
niche cells maintain the homeostasis and regeneration of BM.
Aims: We analyzed the relationship between the idiopathic thrombocytopenia
after allo-HCT and the BM expression of periostin as the only paralogue of
BIGH3.
Methods: We reviewed twenty patients who transplanted with matched sibling
donor for acute myelogenous leukemia at Kyungpook National University Hos-
pital from January 2010 to August 2015. BM biopsy specimens at the time of
day 28, day 90, day 180, day 365 since allo-HCT were decalcified and stained
with primary antibody of BIGJ3 and periostin. Expression of periostin in BM
slides were reviewed by pathologist as follows; normal (0), minimal staining
around blood vessels; (+1), sparse staining and/or focally staining; (+3), diffuse
and strong staining; (+2), between (0) and (+3).
Results: The median age at transplant was 38.5 years (range, 17-68 years)
and male was 13 patients (65%). Twelve patients (60%) were in CR1 (complete
remission), 8 (40%) in CR2. Thirteen patients (65%) received myeloablative
conditioning regimen. The median dose of CD34+ cell was 3.87×106/kg (range,
1.6~7.67×106/kg). All patients achieved the neutrophil engraftment with a medi-
an time of 13 days (range 9-24days). The median time of platelet engraftment
was 15.5 days (range, 13-77days). Idioathic thrombocytopenia developed as
follows; 13 patients at day 28, 16 at day 90, 6 at day 180, and 3 at day 365.
There was no significant difference between idiopathic thrombocytopenia and
the expression of BIGH3 or Periostin (p=0.128) However, BM with thrombocy-
topenia manifested the low periostin/BIGH3 ratio (p=0.007). Acute GVHD was
observed in 12 patients (60%) and chronic GVHD developed in 13 patients
(65%). The developemnet of thrombocytopenia dose not differ according to
acute and chronic GVHD (p=0.847) (Figure 1).
Figure 1.
Summary/Conclusions: The periostin/BIGH3 might represent  the status of
BM niche during  the homeostasis and regeneration of hematopoiesis. High
periostin/BIGH3 ratio could predict the recovery of the idiopathic thrombocy-
topenia.
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ASSOCIATION WITH OMENN SYNDROME AND CYSTINURIA: CASE
REPORT
T. Patiroglu1,*, M. Cansever2, S. Coşkun3, M. Karakukucu1, N. Baydilli4
1Pediatric Hematology, 2Pedıatrıc Immunology, 3Pedıatrıc Nephrology, 4Urol-
ogy, Erciyes University Medical Faculty, Kayseri, Turkey
Background: Omenn syndrome is one type of combined immunodeficiency,
characterized with hepatosplenomegaly, lymphadenopathy, recurrent infections
and has an autosomal recessive pattern of inheritance. T lymphocyte count
can be normal in peripheral blood but their functions are impaired. B lymphocyte
count is very low to none. Cystinuria is renal reabsorption defect of dibasic
amino acids, inherited autosomal recessive. Because cysteine solubility is
lower than other amino acids cysteine stones are formed in kidneys. In the lit-
erature, no association was found between Omenn Syndrome and cysteine
stones hence, our case is very interesting.
Methods: 5 months old girl applied to the Pediatric Immunology Department
of Erciyes University Children Hospital with skin eruption.  There was no family
history for immune deficiency and no consanguineous marriage between moth-
er and father. Patient had one sibling who is healthy. Patient was not performed
with BCG or other live vaccines.  In her physical examination, we observed
exfoliative erythroderma and hepatomegaly.  In laboratory examination, leuko-
cyte count 6540/mm3, absolute neutrophil count 2270/mm3, absolute lympho-
cyte count 1560/mm3, absolute eosinophil count 2220/mm3, serum IgG level
171mg/dl, IgA level 5,81mg/dl, IgM level 24,5mg/dl, IgE level 1270 mg/dl were
found. T lymphocyte count 1092/mm3, B lymphocyte count 6/mm3, NK count
332/mm3 were found respectively. Blood sample of patient was sent to Erasmus
for genetic analysis. The patient  had no full-match family donor. Hence, hap-
loidentical bone marrow transplantation from her father was planned. In prepa-
ration for bone marrow transplantation, bilateral kidney stones were showed in
abdominal CT. Cystinuria was detected in urine and thought to be bilateral cys-
teine Stone. Percutaneous nephrolithotomy operation was performed, then the
patient was given scholl solution. Stone analysis revealed to be cysteine stone. 
Results: Association with two different diseases inherited autosomal recessive
is very interesting. Challenging incident that can be caused by a reason or it
can be only coincidence? In Omenn Syndrome is known to be sequencing
alteration of cysteine and tyrosine amino acids. Perhaps, cysteine stones took
form as a result of this alteration. 
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LABEL-FREE IMAGING BY AUTO-FLUORESCENCE PERMITS
IDENTIFICATION OF ERYTHROID PRECURSORS IN BONE MARROW AND
DETECTS CHANGES OF SOLUBILITY OF HEMOGLOBIN IN
ERYTHROCYTES
I. Lorand-Metze1,*, F. Borges da Silva2, M. Falconi1, K. Metze2,3
1Hematology - Hemotherapy Center, 2National Institute of Photonics applied
to Cell Biology (INFABIC), 3Pathology, University of campinas, Campinas, Brazil
Background: In the fluorescence lifetime imaging (FLIM) technique, the image
contrast is created by determining the delay of the fluorescence photon emis-
sion at each pixel of the image and transforming it in pseudo-colors. This delay,
also called lifetime depends on the type of molecules and their physicochemical
characteristics.
Aims: We investigated the utility of this technique for the characterization of
erythropoietic cell line and changes in the solubility of hemoglobin.
Methods: we used unstained BM smears of 24 normal BM and 8 megaloblastic
anemia patients and unstained peripheral blood smears of 10 patients with
sickle cell anemia. Images were captured by a confocal microscope with a
HPM-100-40-Hybrid detector and excitation at 405 nm (diode laser,80 MHz).
In order to create equivalent images of the cytological smears, pseudo-colors
were attributed to different lifetime ranges. Images were compared with May-
Grünwald-Giemsa (MGG) stained smears.
Results: FLIM created highly contrasted images, where different cell types
could be easily recognized by their similarity with MGG images. Erythrocytes
exhibited the shortest lifetimes (210.4±42.1 ps). Normal shaped erythrocytes
in smears of sickle cell patients showed similar values (214.6±3.1 ps), whereas
crenated erythrocytes as well as drepanocytes revealed significantly elevated
values (314.2±66.7 ps and 312.5±67.0 ps respectively). Regarding erythro-
poiesis, the cytoplasm of erythroblasts showed significantly shorter lifetimes
(623.5±271.2 ps) than that of myeloblasts (835.9±198.4 ps) and the same was
the case when comparing the nuclei (erythroblasts: 895.4±262.8 versus
myeloblasts: 1166.4±287.9 ps). The same differences could be found in mega-
loblastic anemias. There were no significant differences between the FLIM val-
ues of the different cell types between normal hemopoiesis and megaloblastic
anemia.
Summary/Conclusions: The FLIM technique is easily applicable on unstained
routine smears and revealed images of good quality permitting cell identifica-
tion. It allowed also to distinguish between erythroid and myeloid precursors
cells and indicates the major physico-chemical changes during the process of
falcization.
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TWO HEMATOLOGICAL MALIGNANCIES, SIMULTANEOUS OR
CONSECUTIVE OCCURRENCE. EXPERIENCE OF A CENTER
E. Kapsali1,*, A. Vassou2, D. Gougopoulou2, L. Kyriazopoulou2,
E. Hatzimichael2, I. Papakonstantinou2, A. Serpanou2, K. Lagos2
1Hematology, University of Ioannina, 2Hematology, University of Ioannina, Ioan-
nina, Greece
Background: Numerous reports of coexistence or consecutive occurrence of
hematological malignancies are found in the literature.
Aims: : this study reports cases of patients with two hematological malignan-
cies treated in a single center.
Methods: Retrospective study of patients with two malignancies   occurring
simultaneously or consecutively in patients in a hematology department during
a 15 years period.
Results: Thirteen (13) cases were identified (5 women, 8 men). Their demo-
graphic characteristics, diagnoses, treatment and overall survival are shown
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on Table 1.There are three deaths because of refractory diseases. Five patients
needed treatment for the first disease and nine patients needed treatment for
the second disease. Four patients had treatment for both diseases.
Table 1.
CLL:Chronic Lymphocytic Leukemia, MDS: myelodysplastic syndrome, CML: Chronic Myeloid
Leukemia, PV: Polycythemia Vera, DLBCL: Diffuse Large B cell lymphoma, ET: essential throm-
bocytosis, CMML: Chronic Myelomonocytic Leukemia, FL: follicular lymphoma, HL: Hodgkin Lym-
phoma, SMZL: splenic marginal zone lymphoma, HCL: hairy cell leukemia, MGUS: monoclonal
gammopathy of undermined significance
Summary/Conclusions: occurrence of two malignancies in the same patient
can be a challenge for the hematologist. Findings of the second disease can
be attributed to the fist disease or considering them to be results of treatment.
Follow up and initiation of treatment in those patients can be more complex
than usual. . As far as origin is concerned there are conflicting reports in the lit-
erature supporting a common or different cells of origin. Recording of these
cases and biobanking can be of great interest for understanding mechanisms
of hematologic neoplasms.
Hodgkin lymphoma - Clinical
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B SYMPTOMS AND ELEVATED ESR AS PREDICTORS OF OVERALL
SURVIVAL IN HODGKIN LYMPHOMA. A 20 YEAR FOLLOW UP
MULTICENTER ANALYSIS.
R. Vallansot1,*, L. Escoda1, C. Talarn1, M. Cervera2, J. Do Nascimento1,
J. Gumà3, M.J. Miranda3, F. Martínez3, M.J. Herranz4, M. Prats4, X. Ortín5,
R. Aguinaco1, T. Gimenez1, C. Araguás1, A. Esteban1, A. Martínez1, J. Sarrá1
1Haematology Department, Hospital Universitari Joan XXIII, 2Haematology
Department., Hospital Universitari Joan XXIII., Tarragona, 3Oncology Depart-
ment, Hospital Universitari Sant Joan, Reus, 4Haematology Department, Hos-
pital Sant Pau i Santa Tecla, Tarragona, 5Haematology Department, Hospital
Verge de la Cinta, Tortosa, Spain
Background: The prognosis of Hodgkin lymphoma (HL) has improved signif-
icantly with the implementation of a risk-adapted treatment that combines
chemo and radiotherapy. Altough this approach has led to the greatest advance
in disease response, the benefit in terms of overall survival (OS) has been
jeopardized by long term toxicity.
The identification of risk factors is crucial to assign each patient to a well defined
risk group and prevent under or overtreatment, minimizing the risk of relapse
and long term toxicity.
Aims: To analyze the risk factors associated with survival in HL treated with an
ABVD based regimen that restricted radiotherapy only to bulky disease.
Methods: We retrospectively analyzed HL patients diagnosed in 4 centers in
Tarragona area (Catalonia, Spain), between 1995 and 2015, treated uniformly
according to a local protocol.
Patients were assigned into 4 groups: G1: favorable early stage: ABVDx6
cycles, G2: Bulky early stage without other risk factors: ABVDx6+IFRDT. G3:
unfavorable early stage (B symptoms) and advanced stage without bulky dis-
ease: ABVDx8, G4: Bulky advanced stage: AVBDx8+IFRDT
Results: A total of 183 patients were analyzed with a median follow up of 82
months [range 1-244]. Male/female ratio was 1,29. Median age was 36 years
[range 16-82]. Complete response was achieved in 160 patients (87,4%). The
estimated OS at 20 years for the whole group was 62.7%. Kaplan–Meier
method and log rank test were used for survival analysis. Cox proportional haz-
ard model was used for univariate analysis to identify predictive factors for OS.
Factors with significance (p <0.05) were considered for multivariate Cox regres-
sion. In univariate analysis, worse OS was found in patients with increased
LDH, non-NS subtype, albumin <3,5 g/dL, B symptoms, HIV+, advance stage
and ESR >50 mm (log rank p=0,012; p=0,049; p=0,024; p=0,002; p=0,005;
p=0,004 and p=0,001 respectively). The multivariate Cox regression analysis
identified B symptoms and ESR >50 mm as independent prognostic factors for
OS (p=0,002; p=0,006 respectively). These variables allowed us to identify 3
patient groups: low (no risk factors), intermediate (either B symtoms or ESR>50
mm) and high risk (both risk factors), with significant differences in OS. Esti-
mation for OS was uniformly analyzed at 216 months (18 years), which is the
shortest follow up period for patients in the low risk group. Patients in the low,
intermediate and high risk groups had an estimated OS of 85.7%, 65% and
40.1% (p<0.001) (Figure 1).
Figure 1.
Summary/Conclusions: B symptoms and ESR>50mm are independently
associated with OS. The combination of these factors can stratify patients in
low, intermediate and high risk groups with significant differences in OS, regard-
less their clinical stage.
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ADVANCED HODGKIN LYMPHOMA PATIENTS WITHOUT LARGE TUMOR
MASS – A NEW PROGNOSTIC SCORE IDENTIFIES PATIENTS WITH
FAVORABLE OUTCOME
B. Andjelic1,*, D. Antic1, L. Jakovic1, M. Todorovic1, J. Bila1, V. Djurasinovic1,
V. Vukovic1, A. Sretenovic1, J. Jelicic1, M. Smiljanic1, B. Mihaljevic1
1Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
Background: ABVD and escalated BEACOPP are still the standard of care in
patients with advanced Hodgkin Lymphoma (HL). The use of escalated BEA-
COPP gives better disease control but it is associated with more acute and late
toxic effects. The identification of patients who require more or less aggressive
initial approach remains the main goal for many investigators in the field of HL.
Aims: The aim of this study was to identify among patients with diagnosed
advanced HL without large tumor mass, the subgroup which should not be
considered for more aggressive approach than ABVD.
Methods: A retrospective study was performed on 149 patients classical HL,
diagnosed in the period June 1997-December 2011. All the patients were in
clinicil stage III or IV and didn’t have any tumor lesion of 5 cm or more in its
longest diameter. The standard of initial care was 6-8 cycles of ABVD followed
by radiotherapy. Prognostic relevance of age more than 45 years, gender, CS
IV, presence of B symptoms, IPS score, ESR≥50 mm/h, Hgb <10.5 g/dL,
WBC≥15,000mm³ and lymphopenia (lymphocytes <600/mm³ or <8% of WBC
count) were examined.
Results: The median age of analysed patients was 37 (range 17-80). The
median follow up was 98 months. For the whole group 5-year event free survival
(EFS) was 63.1% and 5-year overall survival (OS) was 80.6%. In univariate
analysis, worse OS was found in patients older than 45 years (5-year OS 66.7%
vs 87.8%), patients with CS IV (5-year OS 70.2% vs 87.0%), B symptoms (5-
year OS 77.1% vs 93.4%), IPS≥3 (5-year OS 71.8% vs 90.1%), ESR≥50 mm/h
(5-year OS 75.0% vs 89.5%), lymphopenia (5-year OS 65.6% vs 84.6%) (log
rank; p=0.001, p=0.006, p=0.040, p=0.003, p=0.007, p=0.010, respectively),
while gender, anaemia and leukocytosis didn’t influence OS (log rank; p=0.303,
p=0.714, p=0.522, respectively). Worse EFS was found in patients with CS IV
(5-year EFS 50.9% vs 70.7%, kog rank p=0.002), IPS≥3 (5-year EFS 53.8%
vs.73.2%, (log rank; p=0.006) and lymphopenia (5-year EFS 50.0% vs 66.7%,
kog rank p=0.025), while age, gender, B symptoms, ESR≥50 mm/h, anemia
and leukocytosis didn’t influence EFS (log rank; p=0.0.078, p=0.437,
p=0.068,  p=0.151, p=0.384, p=0.158, respectively). The multivariate Cox
regression analysis identified age more than 45 years, ESR≥50 mm/h and lym-
phopenia as independent prognostic factors for OS, while only IPS was iden-
tified as an independent factor for EFS. Afterwards, we performed survival
analysis with aggregate scores of identified negative prognostic factors for OS
for each patient. Since there was no difference in OS in intergroup analysis,
groups with 2 and 3 negative prognostic factors were merged. Finally, we devel-
oped prognostic model for identifying patients at low (0 factors), intermediate
(1 factor) and high risk (2-3 factors) for poor outcome (p=0.000). According to
this model, in the examined group 34 (22.8%) patients had low, 64 (43.0%)
intermediate and 51 (34.2%) high risk for poor outcome, with 5-years OS of
100%, 84.3% and 60.8%, respectively.
Summary/Conclusions: According to the score which we developed, ABVD
is very effective in the subgroup of advanced HL patients without large tumor
mass and without identified risk factors.
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TREATMENT ESCALATION IN CASE OF POSITIVE PET 2 AND IMPACT
OF EARLY PET IN EXTENSIVE STAGE HODGKIN LYMPHOMA
S. Guidez1,*, N. Moya1, C. Gruchet1, L. Perrichot1, C. Tomowiak1,
T. Systchenko1, A. Machet1, X. Leleu1, V. Delwail1
1Hématologie et Thérapie Cellulaire, CHU La Milétrie, Poitiers, France
Background: ABVD therapy has been for a long time the reference to
advanced stage hodgkin lymphoma (LH). More recently, the emergence of
more sustained dose / intensity regimens like BEACOPP has improved the
progression-free survival of patients, in particular due to better initial control of
the disease. The choice between these two regimens of treatment is always
controversial in particular because of an immediate and delayed toxicity poten-
tially increased after BEACOPP. With the use of PET-scanner, escalation and
de-escalation protocols based on the PET response were studied. Recent stud-
ies have looked at the impact of the PET response to adapt the treatment: de-
escalation after BEACOPP in case of a good response, escalation with more
aggressive regimens after ABVD in positive PET.
Aims: We report here our experiment of escalation in case of positive PET
after 2 cycles of ABVD (PET 2) in patients with advanced Hodgkin lymphoma.
Methods: Among the 102 patients with Hodgkin lymphoma treated between
2008 and 2016, 50 patients had advanced disease (Stage III or IV of Ann
Arbor). The majority of patients were treated on front line by ABVD (47 patients),
2 by BEACOPP and 1 by VABEM. All patients underwent PET evaluation at
diagnosis and after 2 cycles of treatment. The analysis of the metabolic
response was carried out according to the Deauville criteria.
Results: The median age of the patients was 48 years (min-max: 19-85). 20
patients (40%) had an unfavorable prognosis, 24 (48%) had an intermediate
prognosis. 11 patients (22%) were refractory to the ABVD protocol and had an
escalation of treatment. The median PFS was 66 months (47-85). The median
overall survival was not achieved; OS at 60 months was 65%. We found no
difference in survival between patients with negative PET and those with pos-
itive PET with escalation of treatment. The study of PET 2 response, its impact
on survival, as well as escalation of treatment will be presented to the EHA
with update of follow-up.
Summary/Conclusions: This study evaluated the value of escalating treatment
in patients with advanced PET 2 in patients with advanced Hodgkin lymphoma
treated in first-line by ABVD. This management aims to reduce the toxicity of
intensive treatments. The aim of our study is also to identify the higher risk
patients for whom more intensive treatment could be used as first-line treatment.
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THE PROGNOSTIC IMPACT OF 18F-FDG PET/CT IN LYMPHOMA
PATIENTS AFTER STANDARD CHEMOTHERAPY
K. Mladenov1,*, B. Spassov2, V. Hadzhiyska1, D. Vassileva3
1Clinic of Nuclear Medicine, University Hospital “Alexandrovska”, 2Clinical
Hematology, 3Laboratory of nuclear medicine, SBALHZ, Sofia, Bulgaria
Background: The lymphomas are a heterogeneous group of malignant dis-
eases. The exact diagnosis, precise staging and follow up is very important for
treatment and prognosis of these patients (pts). Accurate pretreatment evalu-
ation and response assessment are critical to the optimal management of lym-
phoma pts. Differentiation of post-therapeutic residual tissue from active lym-
phoma is unsatisfactory when using only morphological imaging approaches.
Positron emission tomography/computed tomography (PET/CT) is the most
sensitive and specific imaging technique for monitoring therapy response cur-
rently available for lymphoma pts after standard chemotherapy and determining
which pts would benefit from additional treatment.
Aims: The aim of the study was to assess the clinical value of 18F-FDG
PET/CT for staging and response evaluation in lymphoma pts with Hodgkin’s
disease (HD) and non-Hodgkin’s lymphoma (NHL).
Methods: Two hundred and twenty six pts with biopsy proven lymphoma –
(HD n=92 and NHL n= 134), aged 18-76, were retrospectively reviewed. These
pts were examined 4-6 weeks after the completion of the standard chemother-
apy by 18F-FDG PET/CT, according to the accepted protocol. PET/CT was
used to assess response in FDG-avid histologies using 5-point scale, both for
interim analysis and treatment end assessment. The Lugano classification has
proved extremely useful in the standardization of treatment response.  A score
1, 2, 3 is considered to represent complete metabolic response; score of 4, 5
– partial, no response or progressive disease.
Results: By applying PET/CT results two pts’ groups were formed: 1.group
(n=153 pts) with negative PET/CT results (Deauville score 1-3) and 2.group
(n=73 pts) with PET/CT positive results (partial metabolic response or progres-
sive disease). Using Deauville criteria complete response was observed in 95
patients (70.9%) NHL and 58 (63%) HD pts. These pts were in continuous
complete remission. Partial response, stable or progressive disease (Deauville
score 4-5) were detected in 39 (29.1%) and 34 (37%) NHL and HD pts, respec-
tively. One hypermetabolic lesions and disseminated nodal or extranodal
involvement were detected in 15 and 24 NHL pts as well in 12 and 22 HD pts.
The pts with one hypermetabolic lesions were considered for radiotherapy,
while pts with more than one nodal or extranodal lesions after completion of
standard chemotherapy were considered for high dose chemotherapy±autol-
ogous stem cell transplantation (ASCT).
Summary/Conclusions: 18F-FDG PET was useful in HD and NHL pts after
standard chemotherapy not only for determination of those who need additional
therapy, but for the choice of the further management: radiotherapy, chemother-
apy, or ASCT. A negative PET/CT study after the completion of therapy is an
excellent predictor of good prognosis.
PB1865
BCL-2 AND CD30 EXPRESSION IN HODGKIN AND REED-STERNBERG
CELLS OF CLASSICAL HODGKIN’S LYMPHOMA AS A POORER
PROGNOSIS CRITERIA
A. Rukavitcyn1,*, A. Bobin1, M. Pecherskaya1, O. Rukavitcyn1
1Main military hospital named by N.N. Burdenko, Moscow, Russian Federation
Background: There are a lot of prognosis criteria for risk stratification of
Hodgkin’s lymphoma (HL). The most applicable is the IPS-7, however this score
is ignoring a tumor cells phenotype. There are data about dependence survival
and antigenic profile of Reed-Sternberg (RS) cells. To determine the clinical sig-
nificance of bcl-2 and CD30 expression in RS cells of classical HL, we have cor-
related it’s expression with available IPS criteria and failure-free survival (FFS)
after treatment by ABVD (adriamicyn, bleomicyn, vinblastine, dacarbazine).
Aims: To determine predictive possibility proapoptotic protein bcl-2 and CD30
antigen on RS cells aggregating with criteria IPS.
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Methods: In study were included 85 previously untreated patients, presented
with classical HL between 2002 and January 2016. This retrospective study
did not require approval by the Local ethical committee. Inclusion criteria were:
a histologically confirmed diagnosis of classical HL, the presence of a fixed in
paraffin before treatment a lymph node sample or other diseased tissue, the
minimum follow-up was not less than 18 months.
Results: In the study population (n=85) identified 30 (35%) histological sam-
ples bcl-2+, and 55 biopsies (65%), bcl-2 . Group bcl-2+ patients had a lower
response rate after ABVD chemotherapy - only 24 (28%) patients achieved
CR or better result, as compared with 49 patients (57.6%) of the bcl-2 group.
Three-year event-free survival (EFS) in bcl-2+ patients had lower 82% vs
96% than in bcl-2 group (p=0.018). Multivariate analysis using the Cox pro-
portional hazard model with the inclusion of bcl-2+; CD30 +; bcl-2+/ CD30 +,
age 45 and older, B-symptoms, III-IV stage, anemia, decreased serum albu-
min, increased LDH, leukocytosis revealed that the expression of bcl-2 on
RS cells was an independent factor of poor prognosis. 3 year EFS was 52%
vs 90% in bcl-2 population (p=0.022; RR=1,4). The greater relative risk was
observed in a population with double expression of bcl-2 and CD30, where
the 3-year EFS was 47% (p=0.012; RR=1,6).
Summary/Conclusions: The expression of bcl-2 on HRS cells can be an inde-
pendent prognostic factor, co-expression of bcl-2 and CD30 can be viewed as
a more powerful factor of poor prognosis than bcl-2+ cells.
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SURVIVAL ANALYSIS OF PATIENTS WITH CLASSICAL HODGKIN’S
LYMPHOMA TREATED WITH ABVD: RESULTS FROM TWO REFERRAL
CENTERS IN MEXICO CITY.
G.P. Agreda-Vásquez1, A. F. Ramírez-Ibarguen2, E. Crespo-Solís3,*,
M.S. Rivas-Vera2
1Department of Hematology and Oncology, Instituto Nacional de Ciencias Médi-
cas y Nutrición Salvador Zubirán, 2Department of Hematology, Instituto Nacional
de Cancerología, Mexico City, 3Department of Hematology and Oncology, Hos-
pital Regional de Alta Especialidad de Ciudad Victoria, Victoria, Mexico
Background: Classical Hodgkin´s lymphoma (cHL) is a neoplastic disease
with a favorable prognosis since 85% of patients can be considered cured with
current treatment strategies. Combined chemotherapy with Adriamycin,
Bleomycin, Vinblastine and Dacarbazine (ABVD) has been the standard therapy
for over 20 years. Epidemiological information and the regimen´s results as
first-line therapy in Mexico are limited.
Aims: The aim of this study was to conduct a survival analysis in adult patients
from two referral centers in Mexico City.
Methods: This is a retrospective analysis of all patients with cHL treated at the
Instituto Nacional de Cancerología and the Instituto Nacional de Ciencias Médi-
cas y Nutrición Salvador Zubirán, between 2009 and 2013. The study was
approved by the local Ethics Committee.
Results: We included a total of 193 patients with a de novo diagnosis and
initially treated with ABVD: 60.6% of cases were male, with a median age of
36 years (17-81 years), 71.5% were diagnosed in late clinical stages (CS).
The most frequent histopathological subtypes were: nodular sclerosis and
mixed cellularity (46.6% and 40.9%; respectively). The observed overall
response rate (RR) was 85.7% [Complete response (CR) was 78.2%]. The
RR was 90% in early CS vs 83.8% in late CS (CR rate was 84% vs 75.8%;
respectively, p=0.23). Univariate analysis by logistic regression in the early
CS group revealed that having a Lymphocyte:Monocyte ratio <1 presents an
unfavorable tendency to achieve CR [OR 0.150 (95%CI 0.018-1.274;
p=0.082)]. In the group in late CS, we found that the lymphocyte percentage
tended to favor CR [OR 1.048 (95%CI 0.994-1.105; p=0.081)] and the oppo-
site was observed in terms of the absolute monocyte count [OR 0.999 (95%CI
0.998-1.000; p=0.082)]. Median follow-up was 35 months (0-96 months),
10.9% of cases had died at last follow-up, and median overall survival (OS)
of the entire cohort had not been reached at the time of analysis (5-year OS,
87.1%). However, at the time of this analysis, the group of patients in complete
remission had a greater OS than the group that did not achieve CR
(p=0.0001). With Cox multivariate analysis of OS according to CS, we detect-
ed that in the group in early CS, none of the analyzed factors were significant
while in the late CS group, age >45 years was an independent risk factor
[HR 6.9 (95%CI 1.80-26.60; p=0.005)] and achieving CR had a protective
effect [HR 0.02 (95%CI 0.004-0.108; p=0.0001)].
Summary/Conclusions: Although OS medians had not been reached at the
time of analysis, it is noteworthy that CR (84%) in early CS is lower than that
reported in the literature and no related prognostic factor has been identified.
The role of lymphocytes and monocytes may prove to be significant in larger
series with a longer follow-up.
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OUTCOME OF PD-1 BLOCKADE IN PATIENTS WITH RELAPSED HODGKIN
LYMPHOMA AND ACTIVE GRAFT-VERSUS-HOST DISEASE 
A. Minson1,*, G. Douglas1, A. Grigg1
1Haematology, Austin Health, Heidelberg, Australia
Background: Efficacy of PD-1 (programmed death-1) inhibitors in
relapsed/refractory Hodgkin lymphoma (HL) has been established, but their
role in relapse after allogeneic stem cell transplant (alloSCT) remains contro-
versial due to the perceived risk of exacerbating graft-versus-host disease
(GVHD). The literature is largely limited to case reports in patients with no or
quiescent GVHD.
Aims: To describe the outcome of PD-1 inhibitor therapy and subsequent man-
agement in patients with concomitant biopsy proven active GVHD and pro-
gressive HL after alloSCT.
Methods: We describe the treatment and management of two patients in our
centre.
Results: Case 1 had both extensive bony, lung and nodal HL with active
skin, pleuropericardial and liver GVHD 6 months after donor leucocyte infu-
sion (DLI) and immunosuppression withdrawal and 24 months after sibling
alloHSCT. Fifty% of the standard  pembrolizumab dose (100mg) produced a
PET partial response after 5 weeks but with concomitant biopsy proven,
severe exacerbation of liver GHVD. The latter was managed with pred-
nisolone, everolimus, ursodeoxycholic acid (UDCA) and subsequently
tacrolimus with gradual but substantial improvement in liver function over the
next 5 months (Figure 1) in the absence of further PD-1 blockade, but with
progression of lymphoma. Pembrolizumab 50mg was then given with lym-
phoma response but again a significant (but less severe) flare of liver GVHD
occurred. Subsequent 25mg doses failed to prevent lymphoma progression.
Reintroduction of 50mg doses approximately each 6 weeks for 4 doses with
prophylactic everolimus, low dose prednisolone and ruxolitinib, has resulted
in ongoing substantial but incomplete PET responses with associated stable
liver GHVD. Case 2 had progressive mediastinal and pulmonary HL despite
DLI-induced extensive liver and skin chronic GVHD 38 months post sibling
alloSCT. Initial therapy consisted of optimisation of liver GVHD with 8 weeks
of UDCA and prednisolone with improvement in liver indices (Figure 1). Pem-
brolizumab 50mg was then given, together with sirolimus and ruxolitinib as
GVHD ‘prophylaxis’, resulting 5 weeks later in complete metabolic remission
on PET. Concomitantly liver GVHD was aggravated (See Figure 1) together
with pancytopenia and marrow hypoplasia attributed to an immune-mediated
phenomenon. Despite addition of tacrolimus and increased steroids, he
remains with severe liver dysfunction and pancytopenia 10 weeks after the
single dose of PD1 inhibitor therapy.
Figure 1.
Summary/Conclusions: PD-1 inhibitors can exert powerful graft vs HL effects
even in patients with progression in the context of active GVHD, but at the
expense of substantial GVHD exacerbation.  Further exploration of approaches
such as individualised dose titration according to response and GVHD activity
and prophylactic therapy with non-calcineurin based immunosuppression which
may not mitigate the anti-lymphoma effect will help evaluate whether durable
responses with tolerable toxicity is possible in this context.
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PROGNOSTIC VALUE OF THE RED CELL DISTRIBUTION WIDTH
IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA
A. Knezović1, V. Periša2,3,*, L. Zibar4, J. Sinčić-Petričvić2
1Comunity Health Centre Đakovo, Faculty of Medicine, University of Osijek,
Osijek, Croatia, Đakovo, 2Hematology, University Hospital Centre Osijek,
3Department for Pathophysiology, Faculty of Medicine, University of Osijek,
Osijek, Croatia, 4Nephrology, Department for Pathophysiology, University Hos-
pital Centre Osijek, Faculty of Medicine, University of Osijek, Osijek, Croatia,
Osijek, Croatia
Background: The current gold standard for risk stratification in Hodgkin lym-
phoma (HL) is the International Prognostic Score. There are certain molecular
and immunohistochemical prognostic markers in patients with HL, but their
cost and technical constraints make such an application in routine impractical
and expensive. Therefore, prognostic models for classic HL (cHL) that are inex-
pensive, simple, and easy to perform and interpret are needed.
The red blood cell distribution width (RDW) is associated with short- and long-
term outcomes of various malignancies. The prognostic value of the RDW in
cHL remains unknown. 
Aims: The aim of this study was to analyze the prognostic significance of RDW
in cHL patients.
Methods: We retrospectively analyzed data from 54 cHL patients diagnosed
from 2005 to 2016 at the University Hospital Center Osijek, Osijek, Croatia.
We evaluated disease outcome, overall survival (OS) and event-free survival
(EFS), and demographic, clinical and laboratory factors affecting outcome. Uni-
variate analysis and Cox regression analysis were used.
Results: The median age of patients was 36 years, 29 were men (54%). Higher
RDW levels (%) were found in patients with advanced Ann Arbor clinical stage
(15.34 ± 2.28 vs 13.12 ± 1.3, P< 0.001) and in those with poor response to ther-
apy (15.65 ± 3.37 (progression) vs 16.68 ± 2.09 (partial remission), 13.95±1.82
(complete remission), P= 0.008). Patients with RDW values of >14.5% (cutoff
value calculated by receiver-operating characteristic) had a significantly worse
two-year EFS (62.4% vs 90.4%, P=0.009) but did not differ significantly in
terms of OS (P=0.2). Univariate analysis revealed that a high RDW (>14.5)
was correlated with poor EFS (P=0.019). Multivariate Cox regression analysis
showed that RDW >14.5% was an independent prognostic factor for EFS (haz-
ard ratio [HR] 3.801, 95% confidence interval [CI] 1-14.45, P=0.05). The RDW
allowed further borderline statistically significant risk stratification in patients
who were considered to be at low risk on the basis of an International Prog-
nostic Score less than 4 (P=0.053). 
Summary/Conclusions: High baseline RDW is an independent prognostic
marker of poor outcome in patients with cHL. RDW ratio is asimple, inexpen-
sive, and independent prognostic factor for EFS that may improve the ability
to identify high-risk patients with cHL. It could be an easily available and inex-
pensive marker for the risk stratification in patients with cHL.
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HIGH FREQUENCY OF SECONDARY MALIGNANCIES IN PATIENTS WITH
LARGE GRANULAR LYMPHOCYTIC LEUKEMIA: A SINGLE INSTITUTIONAL
EXPERIENCE
L. Isenalumhe1,*, M. Van den Bergh 1, E. Wang2, B. Schaible1, Z. Ma1,
L. Zhang1, L. Sokol1
1Hematology-Oncology, H. Lee Moffitt Cancer Center and Research Institute,
2Internal Medicine, University of South Florida, Tampa, United States
Background: Large granular lymphocyte (LGL) disorders represent a spectrum
of aberrant T-cell or natural killer cell lymphocytic proliferations. LGLL is clas-
sically associated with autoimmune conditions and bone marrow (BM) failure
disorders. SM has been reported in association with LGLL in about 10%.
Aims: The aim of this study is to evaluate the impact of SM on the clinical
course of LGLL
Methods: This is a retrospective study of LGLL patients evaluated at Moffitt
Cancer Center between January 1995 and May 2016. The diagnostic clinico-
pathological criteria consisted of LGL count > 0.5 k/μL with T-cell receptor gene
rearrangement. Lower absolute number of clonal circulating LGLs with char-
acteristic immunophenotype associated with BM involvement, cytopenias,
splenomegaly and/or associated symptoms were also diagnostic. Patients with
myelodysplastic syndrome were excluded. Survival analysis was performed
using the Kaplan-Meier method with log-rank test. Chi-square and T-test were
used to analyze association among various variables. Significant P-value was
considered < 0.05.
Results: Out of 668 screened patients with LGL expansions in peripheral blood,
261 met criteria for LGLL. Secondary malignancies were present in 44%
(116/261) of LGLL patients, of which 38% were hematological and 80% arose
prior to onset of LGLL. Most common solid secondary malignancy included
skin cancer (14%), prostate cancer (12%), and breast cancer (12%), while
most common hematological secondary malignancy consisted of non-Hodgkin
lymphoma (17%) and chronic leukemia (14%). 5-year overall survival (OS) for
all LGLL patients was 75% and 10-year OS 63%. There was a statistically sig-
nificant difference in 5-year OS between LGLL patients with a secondary malig-
nancy compared to without (p = 0.049), but no difference between both groups
in median OS or 10-year OS. Patients diagnosed with a secondary malignancy
prior to LGLL had worse 5-year OS (p = 0.031) and 10-year OS (p = 0.05)
compared to all other LGLL patients.
Summary/Conclusions: This study showed that the frequency of a secondary
malignancy is higher than previously described, especially with onset prior to
diagnosis of LGLL. Even though median age of LGLL is around 60 years, it
appears that age itself cannot explain this phenomenon. Our results suggest
that having a secondary malignancy is a poor prognostic factor in LGLL
patients.
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BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY WITH
SUBSEQUENT RITUXIMAB SUPPORTING THERAPY IN RUSSIAN
SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL
NON-HODGKIN LYMPHOMAS
I. Poddubnaya1,*, L. Babicheva1, V. Melnichenko2, E. Volodicheva3,
E. Kuznetsova4, N. Tyurina5, K. Kaplanov6, T. Kaporskaya7, D. Olkin8,
N. Domnikova9, V. Bakhtina10, V. Mladov11, K. Kanhai12
1Russian Medical Academy for Postgraduate Education of Ministry of Health,
2Scientific Medical Surgical Center n.a.I.V.Pyrogov, Moscow, 3Regional Сlinical
Hospital, Tula, 4Regional Сlinical Hospital, Orenberg, 5Moscow Scientific
Research Oncology Institution n.a.P.A. Gertzen, Moscow, 6Volgograd Regional
Clinical Oncology Dispensary#1, Volgograd, 7Regional Сlinical Hospital, Irkut-
sk, 8Atlas Medical Center, Moscow, 9Novosibirsk State Regional Clinical Hos-
pital, Novosibirsk, 10Regional Сlinical Hospital, Krasnoyarsk, 11Clinical Trial
Support, Smolensk, Russian Federation, 12Astellas Pharma Europe, Middle
East and Africa, Chertsey, United Kingdom
Background: Combination of bendamustine and rituximab has been estab-
lished in many international guidelines as treatment for patients with indolent
B-cell non-Hodgkin lymphoma (iNHL).
Aims: Objectives of this study were to evaluate the effectiveness, safety, and
tolerability of bendamustine/rituximab combination followed by rituximab main-
tenance therapy for relapsed or refractory (R/R) iNHL patients in the Russian
Federation.
Methods: Adult subjects (≥18 yr), diagnosed with R/R iNHL according to local
diagnostic standards, and were enrolled in this prospective observational study.
Intravenous therapy was administered in 2 stages (Figure 1): a combination
therapy stage followed by a rituximab supporting therapy stage for subjects
who achieved complete response (CR) or partial response (PR) during the
combination therapy stage. Overall response rate (ORR) was assessed after
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3 (Evaluation 1) and 6–8 (Evaluation 2) 28-day cycles. Data from the full analy-
sis set (FAS) were used for the primary analysis and the per-protocol (PP) set
for a subgroup analysis. Safety/tolerability was a secondary endpoint and was
assessed in the safety analysis set (SAF). Response assessments used the
LOCF method for substitution of missing data; overall survival (OS) and pro-
gression-free survival (PFS) were calculated using Kaplan–Meier estimates,
safety/tolerability was assessed by adverse event (AE) frequency and described
using descriptive statistics.
Results: Of the 102 subjects enrolled between June 2012 and October 2015,
83 subjects (52M/31F; median age 59 yr [range: 27–84]) with various NHL his-
tology; subjects with mantle cell lymphoma [n=4], diffuse large B-cell lymphoma
[n=2], and follicular lymphoma transformation [n=1] were excluded from the PP
population due to deviation from the iNHL inclusion criteria. Most study subjects
were heavily pretreated with a median number of 2 prior lines of therapy before
entering the study (range: 1–6). At Evaluation 2, ORR in the FAS was high
(n=58; 69.9%) with 35 (42.2%) subjects achieving CR (confirmed, n=20 [24.1%];
unconfirmed, n=15 [18.1%]) and 23 (27.7%) achieving PR; ORR (defined as
[CR+CR unconfirmed +PR]) in the PP population was 70.8% (Table 1). For
FAS patients, at follow up (17 mo) neither median OS nor PFS had been
reached; 2-year OS was 88.9% (95% CI: 79.7–99.0%) and 2-year PFS was
87.9% (95% CI: 80.7–95.7%). In the SAF, 31 of 96 subjects (32.3%) reported
≥1 AE. Decreased neutrophil count, decreased white blood cell count, and
infections were the most commonly reported AEs and serious AEs. Twelve
deaths occurred: 5 due to disease progression (n=2) or relapse (n=3), 5 were
not related to lymphoma or occurred during remission, 1 cause of death was
unknown, and 1 subject died from hyperthermia and respiratory failure, which
was the only death in the study considered related to combination therapy.
Figure 1.
Table 1.
Summary/Conclusions: Bendamustine plus rituximab therapy followed by rit-
uximab maintenance therapy was generally well tolerated and demonstrated
clinical effectiveness in Russian R/R patients with iNHLs. Although a number
of subjects with aggressive lymphomas were included in the FAS, the ORR
rate was not considerably different from the PP population (ORR: 69.9% [FAS]
vs 70.8% [PP]).
PB1871
PROGNOSTIC VALUE OF G8 SCREENING TOOL IN PATIENTS WITH 
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Background: Indolent B-cell lymphoproliferative neoplasms  (B-LPN) are
malignant diseases of advanced age.  The most common among them, follicular
lymphoma (FL), marginal zone lymphoma (MZL) and chronic lymphocytic
leukemia (CLL) together represent about 40% of all B-LPN. However, as indo-
lent B-LPN are most often the slow-growing diseases, an approach “watch and
wait” is often recommended. But, when treatment is necessary, the advanced
patients’ age indicate the need for geriatric assessment (GA) in aim to indentify
functional, cognitive, social, nutritional and psychological parameters of the
general health status. G8 screening tool (G8) is recognized as fast, easy to
perform and sensitive test for selecting the group of fit elderly patients capable
for curative treatment approach. Although incorporated in routine oncological
practice, GA and G8 are not widely evaluated in hematological practice, so far.
Aims: To evaluate the impact of G8 screening tool on clinical outcome and
survival of elderly patients with indolent B-LPN s’> The most common among
them, follicular lymphoma (FL), marginal zone lymphoma (MZL) and chronic
lymphocytic leukemia (CLL) together represent about 40% of all B-LPN. How-
ever, as indolent B-LPN are most often the slow-growing diseases, an approach
“watch and wait” is often recommended. But, when treatment is necessary, the
advanced patients’ age indicate the need for geriatric assessment (GA) in aim
to indentify functional, cognitive, social, nutritional and psychological parameters
of the general health status. G8 screening tool (G8) is recognized as fast, easy
to perform and sensitive test for selecting the group of fit elderly patients capable
for curative treatment approach. Although incorporated in routine oncological
practice, GA and G8 are not widely evaluated in hematological practice, so far.
Methods: Total of 89 consecutive elderly patients (45males and 44 females
with median age at diagnosis 74,6 years, range 65-88 years) with indolent B-
LPN (24 with FL, 26 with MZL and 39 with CLL) who fulfilled criteria for treatment
initiation were included in study. Patients were treated with antracycline, flu-
darabine or alkylated agents based chemotherapy regimens +/- monoclonal
anti-CD20 antibody. Validity of G8 was compared with standard relevant clinical
and laboratory parameters.
MZL) and chronic lymphocytic leukemia (CLL) together represent about 40%
of all B-LPN. However, as indolent B-LPN are most often the slow-growing dis-
eases, an approach “watch and wait” is often recommended. But, when treat-
ment is necessary, the advanced patients’ age indicate the need for geriatric
assessment (GA) in aim to indentify functional, cognitive, social, nutritional and
psychological parameters of the general health status. G8 screening tool (G8)
is recognized as fast, easy to perform and sensitive test for selecting the group
of fit elderly patients capable for curative treatment approach. Although incor-
porated in routine oncological practice, GA and G8 are not widely evaluated in
hematological practice, so far.
Results: For all 89 patients median overall survival (OS) was 77 months, and
disease free survival (DFS) in 58 (77.3%) patients achieving remission was 25
months. Among laboratory paremeters, hemoglobin, platelet, neutrophil and
monocyte count, as well as C-reactive protein, beta-2 microglobulin didn’t influ-
ence CR rate, OS and DFS. Elevated lactate dehydrogense was foud signifi-
cante for CR rate, and low albumin level (<40g/L) for predicting OS. Among
clinical parameters age, sex, presence of “B” symptoms, splenomegaly
(>13cm), bulky disease (>10cm), extranodal (EN) disease, as well Charlson
comorbidity index (CCI; ≤3∕>3), ECOG performance status (PS; <2/≥2) and G8
screening tool (>14/≤14) were evaluated. EN and G8 were found significant for
CR rate: and EN, B symptoms, ECOG PS and G8 for OS. Multiplarameter
analysis singled out G8 as most sensitive prognostic parameter for both CR
(P=0.005;HR 1,343, 95%CI:0.214-2.552) and OS (p=0.018; HR 11,262,
95%CI:1.503-4.400)
Summary/Conclusions: According to our experience, the implementation of
G8 is good prognostic parameter. Its incorporation into standard hematological
indices may help in improving the optimal treatment approach decision in elderly
patients.
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Background: Due to the lack of prospective clinical trials, treatment guidelines
for splenic marginal zone lymphoma (SMZL) are mainly based on single-center
expertise. Treatment options for progressive disease include splenectomy,
chemo-immunotherapy, or anti-viral therapy in HCV-positive cases. As SMZL
cells strongly express CD20 molecule, rituximab has been used in patients
unfit for chemotherapy or splenectomy with high response rates. Ofatumumab
is a fully humanized, high-affinity anti-CD20 monoclonal antibody able to induce
a more potent complement-dependent cytotoxicity if compared to rituximab.
We designed this multicenter, open-label, single-arm phase 2 trial addressing
activity and safety of ofatumumab monotherapy in patients with relapsed/refrac-
tory (R/R) SMZL.
Aims: The primary objective is the activity of ofatumumab in terms of complete
response (CR) rate. Secondary objectives aim at evaluating the safety and tol-
erability and exploratory endpoints investigate biological features potentially
related with response to ofatumumab.
Methods: All patients provided written informed consent. Key eligibility criteria
include R/R disease after ≤2 prior line(s) of chemotherapy or
immunochemotherapy (including single-agent rituximab). Patients are treated
with ofatumumab (1st dose: 300 mg, 2nd-8th doses: 1000 mg) up to 8 weekly
doses. Response assessment is scheduled 3 months after the last dose. Sam-
ple size was defined assuming a P0 of 45% CR, and a P1 of 65% CR. Per
Simon optimal Two-Stage design (type I error=0.05, power=80%), 43 patients
should be recruited. A safety analysis was planned after the enrollment of the
first 10 patients. With an expected rate of adverse events (AEs) of 13%, if less
than 3 AEs leading to withdrawal from treatment are reported, the accrual will
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continue to the planned 15 patients (interim analysis). Here we present safety
analysis results.
Results: Ten patients (6 males, 4 females; median age: 69.5 years, 9 ≥65 years,
1 <65 years) were analyzed for safety. Eight patients were previously treated
with rituximab. 26 adverse events (AEs) occurred in 7 patients, with only 5 grade
3-4 AEs. Ten AEs were drug-related, 30% were of grade 3 (Table 1). Three SAEs
occurred: hypersensitivity, n=2, both related, and dyspnea, n=1, unrelated to
study drug. No AEs leading to treatment withdrawal was reported and no patients
died on study. Hematological and biochemical abnormalities included: neutrope-
nia (any grade 6 cases, grade 3-4: 4), thrombocytopenia (grade 1-2: 3 cases),
lymphopenia (grade 1-2: 2 cases), leukopenia (grade 1-2: 5 cases), 1 case of
GGT increase (grade 3, at baseline grade 2), 6 cases of ALP increase (all grade
1-2), 1 case each of AST, ALT and bilirubin increase (all grade 1). Preliminary
response assessment in these 10 patients documented 5 CR, 4 Partial Respons-
es (PR) and one patient with progressive disease (PD) at the end of treatment.
Table 1: List of AEs.
Summary/Conclusions: Ofatumumab is safe and generally well-tolerated
even in elderly patients with R/R SMZL. No cases of unexpected adverse drug
reactions were documented. In a series of patients largely pre-treated with rit-
uximab, ofatumumab resulted in a 90% overall response rate, 50% being CR.
Complete results of the interim analysis will be presented at meeting.
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Background: FL represents 70% of all indolent non-Hodgkin lymphomas, and
it is widely recognized that FL is a heterogeneous disease, with patients pre-
senting with differing amounts of tumor burden and prognostic indicators. The
NCCN guideline recommends using rituximab as a single agent or in combi-
nation with other chemotherapies as first-line therapy (1LT) or second-line ther-
apy (2LT). No recommendations are provided beyond 2LT. 
Aims: To evaluate treatment patterns and associated response in patients with
newly diagnosed FL in routine care in the US.
Methods: Newly diagnosed FL patients aged ≥18 years were selected from
Humedica, a large, national US EMR database, between 01/01/08 and 07/31/15
if they had ≥1 inpatient record or ≥2 outpatient records with FL diagnosis codes.
The date of the first FL record was the index date. Patients were followed from
index until end of continuous activity, progression to diffuse large B-cell lymphoma
(DLBCL), death, or end of study period (09/30/15) and were evaluated for FL
treatment patterns and treatment response. Possible remission was defined as
no additional chemotherapy and no supportive care use or receipt of supportive
care <30 days after end of line of therapy (LOT) for <30 days. Lack of remission
was defined as receipt of supportive care <30 days after end of LOT for >30
days. Progression was defined as initiation of another LOT, transition to DLBCL,
or evidence of supportive care >30 days after end of LOT.
Results: Of the 3,756 patients selected into the study, 1,346 (35.8%) initiated
1LT, and median (interquartile range [IQR]) time to therapy was 1.3 (0.5–5.9)
months. Overall, treatment regimens were mainly rituximab-based. In 1LT,
more patients initiated combination chemotherapy (61.4%) vs single-agent
chemotherapy (38.6%). Bendamustine+rituximab (26.9%) and R-CHOP
(15.1%) were the most common combination regimens, and rituximab (33.1%)
was the most common single agent. Median (IQR) duration of 1LT was 4.3
(1.7–10.4) months. At the end of 1LT, 54.7% (n=736) had evidence of remission,
25.5% (n=344) progressed, and 1.6% (n=22) had no evidence of remission.
Among patients with progression after 1LT, 201 initiated 2LT; 34.3% received
a single agent, and 65.7% received combination chemotherapy. 2LT regimens
were similar to 1LT, with rituximab (18.9%) remaining the top single agent,
while bendamustine+rituximab (25.9%) and R-CHOP (6.0%) remained the top
combinations. Median (IQR) duration of 2LT was 3.6 (1.4–6.1) months. Of
patients receiving 2LT, 41.3% (n=83) had evidence of remission, 35.4% (n=71)
progressed, and 1.5% (n=3) had no evidence of remission. 45 patients who
progressed after 2LT received third-line therapy (3LT); 35.6% received a single
agent, while 64.4% received combination chemotherapy. In 3LT, rituximab
(11.1%) was the most common single agent; bendamustine+rituximab (20.0%)
and cyclophosphamide+rituximab+vincristine (8.9%) were the most common
combinations. Median (IQR) duration of 3LT was 2.8 (1.4–4.7) months. Fol-
lowing 3LT, 26.7% (n=12) had evidence of remission, 39.9% (n=18) progressed,
and 4.4% (n=2) had no evidence of remission.
Summary/Conclusions: FL treatment in routine clinical care aligns with treat-
ment guidelines in 1LT and 2LT, with most patients receiving rituximab-based
combination chemotherapy. Similar regimens were used in the 3LT setting. As
expected, the rates of remission decreased with subsequent LOTs.
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Background: Follicular lymphoma (FL) is an indolent lymphoid B neoplasm
corresponding to 20-25% of non-Hodgkin lymphomas (NHL). Bone marrow
biopsy (BMB) is part of standard work-up in indolent NHL since up to 40-70%
of cases have bone marrow infiltration. This fact is important, so advance stage
is one factor considered in the FLIPI-1 and FLIPI-2 prognostic index. Positron
emission tomography/computed tomography (PET-CT) is a noninvasive tech-
nique that shows high sensitivity of detecting nodal and extranodal lymphoma
involvement. specially in aggressive subtypes. Some studies have described
a high sensitivity (62-100%) and specificity (96-100%) in the detection of bone
marrow involvement in agressive NHL. However, its role in low-grade indolent
lymphoma such as folicular lymphoma remains controversial.
Aims: To analyze retrospectively the diagnostic accuracy of PET-CT in compar-
ision with BMB in the initial staging of new FL in a single centre in daily practice.
Methods: One hundred and thirty-six patients with de novo FL have been diag-
nosed in our institution from June 2005 to October 2016. Of them, 64 who
underwent both BMB and PET-CT before treatment were evaluated. The BMB
was evaluated by hemato-pathologist and the interpretation of PET-CT images
was interpreted by a nuclear radiologist. Positive BMB was defined as the pres-
ence of CD20 +,CD10+ y Bcl-2+ lymphoid infiltration. No molecular biology
techniques were done in the bone marrow tissue. PET-CT bone marrow
involvement was defined as an elevated FDG uptake in the bone marrow than
those in liver or mediastinum.  
Results: Thirty-five male and 29 female were included. The median age at
diagnosis: 58 years (range 23-84 ). Thirty-four patients had grade 1-2 FL and
30 grade 3a FL. Bone marrow involvement was diagnosed in 33 of 64 patients
(51.1%) by BMB.  Out of the 17 patients with positive PET-CT, 4 had negative
BMB. Out of 33 patients with positive BMB, 13 had a positive PET-CT (Table
1). The sensitivity and specificity of PET-CT was 39% and 87%, respectively.
The positive predictive value and negative predictive value was 76.5% and
57%, respectively.
Table 1. Detection of BMO involvement: BMB and PET-CT results.
Summary/Conclusions: Our study shows a very low sensitivity of PET-CT in
the daily practice. These results contrast with those reported in some recent
studies in agressive lymphoma. However, the high positive predictive value
raises the question about the uselfulness of BMB in these PET-CT positive
cases. In our opinion, with the current data, BMB should be performed in indo-
lent NHL patients. 
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Background: FL is a heterogeneous disease, and clinical presentation is highly
variable. The Follicular Lymphoma International Prognostic Index (FLIPI-2)
identifies prognostic factors at diagnosis but does not predict in whom and
when to initiate first-line therapy (1LT).1 Recommended therapies for 1LT vary
by stage, symptomatology, and tumor burden but include monotherapy with rit-
uximab (R) or in combination with other chemotherapies. Survival of FL patients
in the R era has greatly improved, but few studies have evaluated survival out-
comes in patients seen in routine clinical care.
Aims: This study aimed to evaluate survival outcomes in a US population of
newly diagnosed FL patients seen in routine clinical care.
Methods: A retrospective study was conducted in which the presence of ≥1
inpatient record or ≥2 outpatient records with FL diagnosis codes were used to
identified newly diagnosed FL patients from Humedica, a large US EMR data-
base, between 01/01/08 and 07/31/15. The study index date was the first FL
record. Patients who subsequently initiated 1LT for FL were followed from the
date of treatment initiation until death, loss to follow-up, or end of study
(09/30/15) for the evaluation of the survival outcomes. Median progression-
free survival (PFS) (defined as initiation of second-line therapy, evidence of
supportive care >30 days after the end of a line of therapy, or death), median
overall survival (OS), and PFS and OS rates at 2 years following initiation of
1LT were evaluated using Kaplan-Meier analyses.
Results: 1,346 newly diagnosed FL patients who initiated 1LT met the patient
selection criteria. 47.7% were male, and the mean age was 65.4 years (SD:
12.7). At baseline, 16.6% of patients had a Charlson Comorbidity Index of ≥2,
and the most common comorbidities were diabetes (14.5%) and chronic pul-
monary disease (11.2%). 1LT consisted of both monotherapy (38.6%) and com-
bination therapy (61.4%). For monotherapy, R was the predominant agent used
(85.8%); for combination therapy, bendamustine+R (43.8%) and R-CHOP
(24.6%) were the most common. Kaplan-Meier analysis revealed that the 2-
year OS and PFS rates (from initiation of 1LT) were 86.9% and 64.6%, respec-
tively. Median OS was not reached, and median PFS was 48.1 months (95%
confidence interval: 39.4, 58.4).
Summary/Conclusions: The 2-year OS and PFS rates in this newly diagnosed
FL patient cohort who received 1LT (the majority of which was R-based) were
consistent with expectations in a post-R era. Future analysis will explore the
differences clinical characteristics and survival outcomes for patients who
received R monotherapy and various R-combination therapies.
Reference




RITUXIMAB MAINTENANCE AFTER R.BENDAMUSTINE FOR PATIENTS
WITH UNTREATED FOLLICULAR LYMPHOMA : A REAL LIFE STUDY IN
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Background: Results from phase 3 “StiL” and BRIGHT trials demonstrated
the effectiveness of the combination Bendamustine-Rituximab {BR} compared
to R-CHOP/R-CVP regimens as frontline treatment for advanced Follicular Lym-
phoma {FL}, emphasizing BR as a standard strategy in this subset of patients.
However, only a few studies investigated the efficacy and safety of R mainte-
nance after frontline BR, indicating a global beneficial effect of R administration
in term of PFS but not OS, in keeping with a good toxicity profile even over two
years of tratment
Aims: In this study, we evaluated the role of maintenance therapy with R after
induction with BR in previously untreated FL, and compared its efficacy and
safety profile with recent publicly available results of “StiL” trial.
Methods: FL patients [pts] were treated with a maximum of 6 cycles of B-R
[Bendamustine 90 mg/m2 8days 1+2), Rituximab 375 mg/m2] every 28 days
followed by 2 additional cycles of Rituximab monthly. Patients showing complete
response [CR] or partial response [PR} were then allowed to receive R main-
tenance [375 mg/m2] administered every two months. To date 118 pts  ( 65
women and 53 men) with FL have been recorded. Median age was 61 years (
range 28-86); 15 (13%), 41 (35%), 62 (52%) pts had respectively stage II, III
and IV; median number of nodal areas was 4, bone marrow involvement was
found in 56 (47%) pts, and median FLIPI was 3.
Results: Among the 118 pts, 94 were evaluable for response and safety. The
overall response rate [ORR] was 89.2% with 83 pts achieving a remission after
BR therapy. The CR rate was 84.4%, 7 pts had  partial response, 5 pts (6.1%)
had stable disease, whereas 3 (3.5%) showed no response to BR and had a
progressive fatal disease. All of the pts achieving remission received the full
planned 2 years Rituximab maintenance treatment and, among them, 24 pts
(28.9%) were administered with R over the first two years. Primary adverse
events recorded were of grade 3 anf 4 in 25% of cases. Infectious ( grade 3-
4) and neutropenia (grade 3) were the most common adverse event, no addi-
tional unexpected toxicities were observed, whereas no occurrence of second-
ary malignancy was registered so far.
Summary/Conclusions: Our data, compared with recent reports about the
role of Rituximab maintenance, support the efficacy of BR as backbone treat-
ment of choice in previously untreated advanced FL. These results, moreover,
are in line with those of other studies indicating that Rituximab standard main-





ROLE OF F-18 FDG-PET/CT IN DETECTING LYMPHOMATOUS BONE
MARROW INVOLVEMENT IN THE INITIAL STAGING OF PATIENTS WITH
LYMPHOMA
B. Hernández Ruiz1,*, C. Calle Primo1, D. Buenasmañanas Cervantes1,
A. Mayoralas Tendero1, R. Vanegas Uribe1, M. Nebro Luque1,
A. Garcia Vicente2
1Haematology, 2Nuclear Medicine Department, Hospital General Ciudad Real,
Ciudad Real, Spain
Background: The role of F-18 FDG-PET/CT for the assessment of bone mar-
row involvement in the staging of newly diagnosed patients with lymphoma
was reviewed in the Recommendations of Lugano Classification. They conclude
that if a PET/CT is performed, a bone marrow biopsy is no longer indicated for
a routine staging of Hodgkin lymphoma (HL) and most difusse large cell lym-
phoma (DLBCL). Data are insufficient in follicular  lymphoma (FL) and  bone
marrow biopsy is always recommended.
Aims: We study the value of F-18 FDG-PET/CT for the detection of bone mar-
row involvement in the initial staging of patients with lymphoma.
Methods: Newly diagnosed patients with HL, DLBCL and FL who underwent
F-18 FDG PET/CT and bone marrow biopsy for initial staging between January
2007 and June 2016 were included. We analyze sensitivity, specificity and con-
cordance of PET/CT compared with bone marrow biopsy. In discordant cases,
we review if there was  any difference in the staging.
Results: 161 patients were included,69 DLBCL(38 male,31 female, median
age 59 years),44 HL(24male,20female, me32y),48 FL (23male,25female,
me55y). Four of the 44 patients with HL had bone marrow infiltration in bone
marrow biopsy (BMB+) and PET/CT detected bone marrow involvement in all
of these patients. PET/CT was positive in bone marrow (BMPET+) in 7 of the
40 patients without bone marrow infiltration in bone marrow biopsy (BMB-),
these patients had bone marrow lesions on  locations other  than iliac crest.
Six of the 7 patients were in advanced stage regardless of bone marrow involve-
ment and a patient had sternal involvement by contiguity. Seven of the 69
patients with DLBCL had  BMB+, 6 patients with DLBCL and 1 patient  DLBCL
and FL. PET/TC had detected bone marrow involvement in all of them. Sixty-
two patients of 69 DLCL did not have bone marrow infiltration by biopsy(BMB-
), but nine of them had BMPET+. Seven of the  9 patients were in stage IV
because of extranodal involvement of other organs. One patient had primary
bone involvement of jaw and another patient had vertebral involvement by con-
tiguity. Fourteen patients of 48 patients with FL had BMB+. Of these 14 patients
with bone marrow involvement by biopsy, 5 patients had BMPET- and PET/CT
could not detect another extranodal involvement in three of these five patients.
Of the  34 patients without bone marrow infiltration by biopsy BMO-, 8 patients
had PET-TAC+, and 6/8 could be classified in stage IV regardless of bone mar-
row involvement (Table 1).
Table 1.
Summary/Conclusions: Our series confirms that PET/CT is useful to detect
bone marrow involvement in the initial staging of Hodgkin Lymphoma and DLB-
CL. We can avoid bone marrow biopsy in these hystological variants of lym-
phoma. In follicular lymphoma, PET/CT did not detect more than one third of
patients with bone marrow infiltration by biopsy. These results support the his-
tological assesment of bone marrow in the initial staging of follicular lymphoma.
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PREDICTIVE FACTORS FOR INFECTIOUS ADVERSE EVENTS IN
PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA TREATED WITH
BENDAMUSTINE-RITUXIMAB (R)±R MAINTENANCE. RESULTS OF A
RETROSPECTIVE ANALYSIS
A. Di Rocco1,*, F. De Angelis1, L. Petrucci1, F. Vozzella1, D. De Benedittis1,
R. Foa1, M. Martelli1
1Department of Cellular Biotechnologies and Hematology, University of Rome
Sapienza, Rome, Italy
Background: The combination of bendamustine (B) and rituximab (R) is an
effective and well tolerated treatment for B-cell malignancies. However, previ-
ous reports have shown a higher incidence of lymphopenia and secondary
infectious complications in patients treated with BR than in patients treated
with other chemoimmunotherapy regimens. 
Aims: We performed a retrospective analysis at our institution in patients treat-
ed with BR with or without R maintenance, with the aim of determining the inci-
dence of the infectious adverse events (AEs) and of identifying potential pre-
dictors factors.
Methods: We collected data from 65 patients with B-cell non-Hodgkin lym-
phoma (NHL) who received at least two cycles of BR±R maintenance between
2010 and 2016 at our institution. The AEs – including neutropenia (N), neu-
tropenic fever (NF), lymphopenia, infections episodes and the occurrence of
second tumors - were recorded according to the CTCAE v4.0 grade score. We
compared the risk factors of patients who developed infections and those who
did not. Univariate analysis with Fisher’s exact test was used to evaluate the
potential risk factors.
Results: The median age at the first treatment cycle was 66 years (range 36-
89), 33 patients (50%) were ≥65 years, 27 (41%) were male, 53 (82%) had
advanced disease and 37 (60%) had bone marrow involvement. Thirty (46%)
patients had follicular lymphoma, 17 (26%) mantle cell lymphoma, 11 (17%)
marginal lymphoma, 5 (7%) diffuse large B-cell lymphoma and 4% other indo-
lent lymphomas. Thirty two patients (49%) received BR as first line treatment,
51% as second line and above. Bendamustine was administered either at the
dosage of 70 or 90 mg/sqm iv on days 1, 2 and R was administered at a dose
of 375 mg/sqm iv or sc, on day 1. Therapy was administered every 4 weeks up
to 6 courses. Twenty nine patients (46%) received R maintenance every 8-12
weeks for two years. The mean number of cycles administered was 5 (range
2-6), 13 patients (20%) discontinued treatment due to toxicity: 8/13 for non-
hematologic toxicity. Primary or secondary G-CSF prophylaxis was adminis-
tered to 25 patients (38%), while the prophylaxis with trimetropin-sulfametox-
azole against Pneumocystis jiroveci pneumonia was given to all patients. Twen-
ty two patients (34%) had at least one infection. Bacterial pneumonia was iden-
tified in 6/22 patients, varicella zoster virus infection in 4/22, cytomegalovirus
reactivation in 2/22 and other infections in 10 patients. At univariate analysis,
the infectious AEs were associated only with lymphopenia during the second
cycle (p=0.043) and with neutropenia during the second, third and fourth cycle
(p=0.026; p=0.003, p=0.018, respectively). No correlation with age, line of treat-
ment and G-CSF administration was documented. Other AEs were: grade 3/4
neutropenia (49%), neutropenic fever (3%), grade 3/4 lymphopenia (80%). We
reported also a 5% incidence of second tumors after treatment (lung cancer in
2 patients and prostate cancer in 1).
Summary/Conclusions: In our analysis, BR±R maintenance confirms a toxicity
profile similar to that reported in previous experiences. According to our results,
an early lymphopenia and neutropenia (after two cycles) are predictive factors
for infections AEs and for premature treatment discontinuation. Twenty% of
patients discontinued treatment mostly because of the early withdrawal due to
infectious complications. These data raise the question on the role of antibacterial,
antiviral and primary G-CSF prophylaxis in all patients treated with BR. 
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CAUSES OF DEATH OF FOLLICULAR LYMPHOMAS. MONOCENTRIC
AND RETROSPECTIVE STUDY WITH A LONG PERIOD OF OBSERVATION
L. Rigacci1,*, S. Kovalchuk1, F. Lancia2, G. Manneschi3, B. Puccini1, G. Benelli1,
L. Mannelli1, A. Bosi1
1Haematology, AOU Careggi University of Florence, Florence, 2Oncology,
Ospedale Ferrara, Ferrara, 3Istituto per la Prevenzione Oncologica, ISPO
Firenze, Firenze, Italy
Background: Follicular lymphomas are usually defined as incurable diseases
with a natural history characterized by continuous relapses.  
Aims: This study was launched to evaluate after a long observation period the
causes of death during follow-up. 
Methods: All patients with histologically confirmed diagnosis of follicular lym-
phomas grade I-II or IIIa were selected from our data base starting from January
2000 untill December 2004 in such a way to have more than 10 years of obser-
vation for alive patients. We considered all patients with this diagnosis regard-
less to treatment and considering also patients followed with watch and wait.
Patients were followed with ambulatory evaluation and for those lost to follow-
up consulting the regional cancer registry.
Results: One hundred and fourthy-six patients were diagnosed and treated at
our Institution. The median age at diagnosis was 61 years (range 30-87). Stage
I-II in 47 patients, III-IV in 86. Bone marrow biopsy was positive in 87 patients,
FLIPI 0-1 in 40, FLIPI 2 in 48, FLIPI 3 in 40 and FLIPI 4 in 18 patients. According
to treatment 98 patients were treated with antracycline containing regimens,
34 with fludarabine containing regimens and 14 were observed or treated with
radiotherapy. Rituximab was used in 98 patients, as sequential treatment in 74
or chemotherapy combined in 24; 48 patients did not use rituximab. The median
observation period for alive patients was 13,4 years (range 11-15 years) and
8 years (range 0,09-15 years) for dead patients. Sixty-five patients dead during
this long period of observation and the causes were: 35 due to lymphoma pro-
gression (54%), 16 second neoplasms (25%), 12 other disease (18%), 1 car
accident and 1 unknown.  The overall survival with a median period of obser-
vation of 127 months (range 2-196) was 71%. In univariate analysis the best
overall survival was statistically associated with low FLIPI score, the use of
Rituximab and the obtainment of complete remission. In multivariate analysis
FLIPI 0-1 and the obtainment of complete remission manteined the significance.
Exactly the same results were observed if we considered the cause specific
mortality.
Summary/Conclusions: In conclusion this retrospective monocentric study
confirms that after a long follow-up period about half patients died of lymphoma
and the other half died for complications related to therapy or to lack of immuno-
logical control (second neoplasm or other diseases). Follicular lymphoma con-
firms to be a good prognosis lymphoproliferative disorders and in the long
observation period of patients clinicians must have maintained a careful eval-
uation of concomitant pathologies. 
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CLINICAL CHARACTARISTICS AND PROGNOSIS OF PATIENTS WITH
INDOLENT NON-HODGKIN LYMPHOMA AND RISK OF TRANSFORMATION
TO AGGRESSIVE LYMPHOMA: A SINGLE JORDANIAN CENTER
EXPERIENCE
D. Zahran1,*, M. Ayesh (Haj Yousef)1, T. Kewan1, S. Al Bashir2
1Internal Medicine, 2Pathology, King Abdulla University Hospital (KAUH), Irbid,
Jordan
Background: Indolent Non Hodgkin Lymphomas (INHL) are slow growing lym-
phomas that usually arise from B-cells. They are characterized by slow appear-
ance and progression of symptoms compared to aggressive non Hodgkin lym-
phoma (NHL) namely Diffuse large B-cell Lymphoma (DLBL). Small percentage
of INHL might transform to aggressive NHL.
Aims: We aim to describe the clinical characteristics, prognosis and risk of
transformation to aggressive lymphoma in patients with INHL in North Jordan
as a model for other Middle East countries in which such data is lacking.
Methods: All patients diagnosed with INHL between Jan 2003 to Jan 2017
were retrospectively reviewed. Clinical and laboratory data at time of diagnosis
including gender, age, lactate dehydrogenase level (LDH), pathological sub-
types, CT and PET/CT scans were studied. Extranodal involvement was con-
firmed either by histopathological studies or CT and PET/CT scan. Transfor-
mation to aggressive lymphoma was confirmed by histopathological studies.
Patients were followed and overall survival rate was calculated. Mean survival
times were calculated using Kaplan-Meier method.
Results: Among 265 patients diagnosed with NHL, only 88 patients (33.20%)
confirmed to have INHL. 54 patients (61.4%) were males and 34 patients
(38.6%) were females. Their ages at diagnosis ranged from (29-83) years with
a mean (SD) of 59.26 (12.39). Among these patients, 45 patients (51.1%) had
small lymphocytic lymphoma / chronic lymphocytic leukemia (CLL), 20 patients
(22.7%) had follicular lymphoma (FL), 15 patients (17%) had marginal zone
lymphoma (MZL), 6 patients (6.8%) had mantel cell lymphoma (MCL) and 2
patients  (.78%) had unspecified INHL. Mean age of MZL (53.2 years) and FL
(55.3 years) were significantly lower than mean age of MCL (58 years) and
CLL (62.77 years). 22 patients (23.9%) had extra nodal Involvement. There
was significant association between INHL subtypes and extra nodal sites
involvement. (P-value=.001). 60% of patients with MZL, 50% of patients with
MCL, 20% of patients with FL and 8.9% of patients with CLL had extranodal
sites involvement. 11 patients (12.5%) from all INHL had transformed to Diffuse
Large B-cell Lymphoma (DLBL). There was significant association between
INHL subtypes and transformation to DLBL, (P-value=.02). 7 from 20 patients
with FL (35%) and 4 from 45 patients with CLL (8.9%) had transformed to
DLBL. Mean LDH level (886.1 U/L) in patients with transformation to DLBL
was significantly higher than mean LDH level (490.7U/L) in other patients, (P-
value=.0004). There was no significant association between mean age and
mean albumin level with risk of transformation to DLBL. The overall survival
rate was 56.8%. 10 years and 5 years survival rates were 47% and 60% respec-
tively. Mean survival time in patients with MCL (31.8 months) was significantly
lower than mean survival time in patients with follicular (85.48 months) , MZL
(90.6 months) and CLL(103.6 months) patients , (p-value=.oooo4). There was
no significant difference in survival rate between patients who transformed and
patients who didn’t transform to DLBL. 
Summary/Conclusions: Prevalence of INHL among patients with NHL in
North Jordan is 33.2%. The most common INHL subtypes in our patients were
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CLL (51.1%) and FL (20.7%). These findings are significantly different from
Saudi Arabia and Western Countries in which FL is the most common subtype.
FL and CLL are associated with higher risk of transformation to DLBL. High
LDH level is considered a risk factor for transformation to DLBL in our patients.
MCL is associated with significantly lower mean survival time than other INHL
subtypes.
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OCULAR ADNEXAL LOW GRADE LYMPHOMA TREATMENT OUTCOMES
AND LONG TERM FOLLOW UP: A SINGLE CENTRE EXPERIENCE 
N. Elmusharaf1,*, C. Bloodworth1, B. Skippen2, M. Hourihan3, T. Parmar2,
D. Morris2, C. Lane2, C. Rowntree1
1Haematology, 2Ophthalmology, 3Radiology, University Hospital of Wales,
Cardiff, United Kingdom
Background: Ocular adnexal lymphoma (OAL) accounts for 1-2% of Non-
Hodgkin Lymphomas (NHL) and 8% of all extra-nodal sites.  The majority of
cases, >95%, are of B cell origin and 80% are low grade lymphomas. Secondary
ocular involvement occurs in approximately 2.4-5.3% of patients with advanced
systemic NHL. Marginal zone lymphoma or mucosa-associated lymphoid tissue
(MALT) lymphoma is reported in approximately 50% of patients. Current treat-
ment options for low grade OAL include radiotherapy and chemotherapy.
Chlamydia Psittaci DNA has been reported in up to 80% of tumor biopsies from
patients with OAL suggesting a possible value of anti-Chlamydia Psittaci antibi-
otic therapy.
Aims: To report a single centre’s experience in the outcomes of patients diag-
nosed with OAL over a 13 year period.
Methods: A Retrospective cohort of patients with low grade OAL treated in a
single Centre between 2003 and 2016 was analyzed. Chemotherapy was the
first choice of therapy until 2008, afterwards radiotherapy became the first line
treatment for OAL.
Results: A total of 20 patients with OAL were identified. 60% (12/20) of
patients were females with a median age of 61.5 years (range 45-85 years).
80%( 16/20) had unilateral disease at presentation. MALT lymphomas com-
prised 75%( 15/20), Follicular NHL 15% and CLL/SLL 10%. Only 10% (2/20)
had a prior diagnosis of NHL. At presentation 20% (4/20) had evidence of
systemic involvement: 19% (3/16) had bone marrow involvement and 1
patient had small volume lymphadenopathy on CT scan. 45% (9/20) were
treated with first line chemotherapy, single agent Chlorambucil in 78% (7/9)
and 2 patients received Fludarabine based chemotherapy, 30% (6/20)
received first line radiotherapy, 24Gy in 12 fractions in 67% (4/6), and 25%
(6/20) were managed under observation. In the chemotherapy group 55%
(5/9) experienced 1 relapse (3/5 local recurrence and 2/5 extra-ocular
relapse), 3 patients experienced ≥2 relapses, 2 patients had disease trans-
formation to high grade and 1 patient subsequently died as a consequence
of their disease. 33% (2/6) patients treated with radiotherapy experienced
disease recurrence, mainly extra-ocular and 50% (3/6) suffered complications
following radiotherapy in the form of dry eyes and cataract. Median follow up
was 9.5 years (range 1-14 years). Overall survival was 95% (19/20) with an
event free survival of 65% (13/20) (Table 1).
Table 1. Summary of the management modalities of ocular adnezal low
grade non-Hodgkin lymphoma.
Summary/Conclusions: The majority of patients in our cohort had favorable
outcomes. Currently there is no national guideline for the management of
OAL in the UK. Several treatment options exist including chemotherapy, radio-
therapy, immunotherapy, observation or more recently the use of eradication
treatment for Chlamydia Psittaci. Factors to consider when choosing a treat-
ment include a patient’s co-morbidities, risk of visual impairment, need for
systemic therapy, histological diagnosis and anticipated side effects. As treat-
ments are so effective the long term consequences and possible late effects
need to be acknowledged and avoided if at all possible. Observation is an
acceptable approach in asymptomatic patients when there is no immediate
risk of visual impairment. Radiotherapy is an effective first line treatment in
symptomatic and localized OAL, the exact dose of radiotherapy to achieve
disease control with minimal long term side effects is yet to be determined.
Reviews with larger number of patients are needed to inform a practical
approach to the management of OAL. 
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AGE AS A POTENTIAL NOVEL PROGNOSTIC INDICATOR IN PRIMARY
CUTANEOUS B-CELL LYMPHOMA
P. Desai1,2,*, M. Van den Bergh3,4, H. Zhang5, X. Zhang5, B. Schaible6, Z. Ma6,
L. Sokol7
1Internal Medicine, University of South Florida, 2Internal Medicine, 3Hematology
and Oncology, H. Lee Moffitt Cancer Center and Research Institute, 4Hematol-
ogy and Oncology, University of South Florida, 5Oncologic Sciences, Pathology,
and Cell Biology, 6Biostatistics and Bioinformatics, 7Malignant Hematology, H.
Lee Moffitt Cancer Center and Research Institute, Tampa, United States
Background: Primary Cutaneous B-Cell Lymphoma (PCBCL) comprises a
rare group of cutaneous Non-Hodgkin’s lymphomas (NHLs) with an estimated
annual incidence of 2.5 per 1,000,000 persons.  They usually present with
papules or nodules on the head, trunk, and/or extremities. The International
Society for Cutaneous Lymphoma (ISCL) and the European Organization for
Research and Treatment of Cancer (EORTC) developed a new way to classify
PCBCL into three different subtypes. Indolent subtypes include Primary Cuta-
neous Marginal Zone Lymphoma (PCMZL) and Primary Cutaneous Follicular
Center Lymphoma (PCFCL). Primary Cutaneous Diffuse Large B-Cell Lym-
phoma (PCDLBCL) is an aggressive subtype with a fatality rate of 50%. The
Cutaneous Lymphoma International Prognostic Index (CLIPI) can risk stratify
indolent subtypes, but criteria do not include age. Here we present our single
institutional analysis of clinicopathological features and outcomes of patients
with PCBCL.
Aims: To analyze clinical and laboratory characteristics such as age, lesion
characteristics, hematological parameters, and treatment modalities in order
to determine their impact on progression free survival (PFS) in PCBCL.
Methods: This is a retrospective study of patients evaluated at Moffitt Cancer
Center between January 1990 and December 2016. Patients were identified
using our PCBCL database and diagnosis was verified by independent
hematopathologists and dermatopathologists. Staging was determined accord-
ing to ISCL/EORTC recommendations. Demographics, lymphoma subtype,
stage, disease course, and CLIPI scores were collected. Kruskal Wallis ANOVA
and Fisher’s Exact tests were used to compare differences among the four
subtypes for continuous and categorical variables, respectively. Kaplan Meier
curves were produced to estimate PFS for different strata, and differences
among the strata were tested using the log-rank test.
Results: We identified 37 patients who met diagnostic criteria for PCBCL (35%
PCFCL, 40.5% PCMZL, 13.5% PCDLBCL, and 11% indolent, unspecified).
Male:female ratio was 2.4:1. 51% of patients were ≥60 years old (yo) and 49%
were <60 yo. 54% had stage T1 disease, 27% T2, and 19% T3. Median PFS
for patients <60 was 1.1 years, but was not reached for those ≥60. Mean fol-
low-up time was 2.6 years for all patients. Log rank test showed a statistically
significant difference in PFS between the two age groups (p=0.01). This was
consistent when comparing PFS by age in both high (PCDLBCL) and low grade
(indolent) subtypes. PFS according to stage in indolent subtypes showed a
marginally statistically significant difference (p<0.06). Stratification of patients
according to CLIPI did not show a significant difference in PFS among indolent
subtypes.
Summary/Conclusions: We found that age is a highly statistically significant
prognostic parameter in PCBCL, as patients ≥60 years had a longer PFS com-
pared to younger patients, even after adjusting for stage and CLIPI. This is an
interesting finding as most NHL studies demonstrated a negative impact of
advanced age on PFS. Our results suggested that age is a possible novel prog-
nostic indicator in patients with PCBCL, however validation on a larger sample
set is needed.
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EPIDEMIOLOGY, CHARACTERIZATION AND THERAPEUTIC
MANAGEMENT OF MARGINAL ZONE LYMPHOMA: A SINGLE-CENTER
EXPERIENCE
C. De Miguel1,*, B. Navarro1, J. Martín2, P. Martín2, R. Forés1, C. Bellas2,
J.R. Cabrera1
1Hematology, 2Pathology, Hospital Universitario Puerta de Hierro Majadahonda,
Majadahonda, Spain
Background: Marginal zone lymphomas are a group of relatively uncommon
lymphomas whose cells are derived from B lymphocytes of the “marginal zone”
of the secondary lymphoid follicles.
Aims: The objective of this study is to review our series evaluating the epi-
demiology, clinical presentation, morphological, immunohistochemical and
molecular characterization and therapeutic management in a tertiary hos-
pital.
Methods: We evaluated a total of 56 patients diagnosed between May 2008
and February 2017. We collected the epidemiological and clinical data, including
location, clinical stage, FLIPI and associated risk, antigenic stimulus, sympto-
matology at diagnosis (ECOG, constitutional syndrome, B symptoms) and
response to treatment. We reviewed the levels of LDH, beta2microglobulin,
ESR, peripheral blood (PB) immunophenotype and studied the morphological,
immunohistochemical and molecular characteristics (MALT1 translocation and
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immunoglobulin heavy chain rearrangement (CDR2 / CDR3 of IgH)) in PB,
bone marrow and affected organs. All diagnoses were classified according to
WHO (2016 revision). In addition, we performed an autoimmunity test in most
patients.
Results: Among the 56 patients, 26 were men (46.4%) and 30 women. The
median age at diagnosis was 64 years (37-92). The most frequent subtype
was the splenic marginal zone lymphoma (17 patients, 30.4%), followed by
MALT: 10 pulmonary (17.9%), 10 gastric (17.9%), 5 cutaneous (8.9%), 5 ORL
(8.9%), 2 (3.6%), 1 hepatic, 1 thyroid and 1 lacrimal gland (1.8%) and nodal
marginal zone lymphoma (3 patients, 5.4%). Five of them presented with mul-
tifocal disease (8.9%). Fifty percent (28) had a clinical stage III / IV and 32
patients (57.1%) had a low risk at diagnosis (FLIPI 0-1). We found an antigenic
stimulus in 11 patients (Helicobacter pylori, Sjögren’s syndrome, Hashimoto’s
thyroiditis). The molecular study of MALT1 was performed in 25 patients and
3 presented the translocation (12%). Six of seventeen cases (35.3%) showed
IgH rearrangements. Antinuclear antibodies were positive in 15 of 32 patients
(46.9%). A total of 46 patients (82.1%) required a treatment, of whom 35
achieved a complete remission (CR) (76.1%) and 10 partial remission (PR)
(21.7%) after the first line of treatment. Among these, 17 received
immunochemotherapy (37%), 10 immunotherapy (21.7%), 8 surgery (17.4%),
7 antibiotics (15.2%) and 4 radiotherapy (8.7%). We observed 7 relapses
(16.7%) and 3 progressions (7.1%), achieving a CR in 7 (70%) and PR in 3
(30%) after rescue treatment. There was just one case of high grade transfor-
mation (1.8%), who was the only patient decesed in the series (1.8%), with a
median follow-up of 70 months.
Summary/Conclusions: Marginal zone lymphoma is an indolent lymphoma,
with a good prognosis and very good response to current therapy. It is some-
times associated with autoimmune phenomena and infectious agents. It is
essential a correct staging and characterization to optimize its therapeutic man-
agement and outcome.
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HAIRY CELL LEUKEMIA AND B-RAF MUTATIONS
A. Olgun1, Y. Baskın2, S. Solmaz Medeni3, I. Alacacioglu1, M. Akbapour2,
T. Uysal2, O. Birge4, S. Ozkal4, H. Ellidokuz2, M.A. Ozcan1,*
1Dokuz Eylul University Hematology Dept., 2Dokuz Eylul University Oncology
Institute, 3Bozyaka Training and Research Hospital, 4Dokuz Eylul University
Pathology Dept., Izmir, Turkey
Background: Hairy cell leukemia(HCL) is a B cell lymphoproliferative disorder,
presenting with splenomegaly, hepatomegaly and bone marrow infiltration.
HCL accounts for%4,5 of non-Hodgkin lymphomas, more commonly seen in
man. Diagnosis is based on the examination of peripheral blood smear, flow
cytometry and the bone marrow aspiration-biopsy. Recently, B-RAFV600E muta-
tion was demonstrated in%100 of Tiacci HCL case series.
Aims: Aim of our study is to investigate the frequency of B-RAFV600Emutation
and other rare mutations of B-RAF (B-RAFG464E, B-RAFG466E, B-RAFG469V)
and their relation with clinical data and treatment responses.
Methods: Charts of 13 patients diagnosed with HCL were analyzed retrospec-
tively.  Patients’ clinical paremeters were evaluated. HCL variant type patients
were excluded. Paraffin blocks of spleen or bone marrow tissues are obtained
from the pathology archives. One thin section (10 micron) of bone marrow or
three sections of spleen are cut and DNA extracted by spin column technique
using DNA extraction kit. (QIAamp DNA FFPE Tissue Kit, Qiagen) After spec-
trophotometric measurement of DNA; common and uncommon mutations of
B-RAF were investigated. (Qiagen PyroMark Q24 system, Therascreen BRAF
Pyrokit 24, V1 (1/2) kit) Mutation and clinical data analysis were conducted
using the SPSS 15.0 software. The study was approved by the local ethics
board of Dokuz Eylul University.
Results: Male/female ratio was 9/4. Median age at diagnosis was 48(37-
59). Median follow-up time was 59 (3-96) months. At the time of diagnosis,
46,2% (n=6) of patients were asymptomatic. All of the patients had
splenomegaly (n=13), five patients had hepatomegaly and two had intraab-
dominal lymhadenopathy. Approximately half of the patients (%46,2) diag-
nosed with splenectomy. Only one patient was pancytopenic at diagnosis.
Four patients were anemic (Hemoglobin<10 gr/dL), six were thrombocy-
topenic (Platelets<150000/µl). Leucopenia was seen in 84,6% (n=11) of the
patients. Monocytopenia commonly seen in HCL was detected in 61,5%. One
of the patients was diagnosed and treated due to  Mantle cell lymphoma
(MCL) a year ago and found in remission for both MCL and HCL; one was
diagnosed Kaposi carcoma just before the diagnosis of HCL and lost in fol-
low-up. Twelve patients were hospitalized and treated with one cycle of
cladribin (0,1 mg/kg/day IV for 7 days). One of these patients received SC
IFNα at a dose of 4,5 mIU/day prior to cladribin therapy. Treatment responses
could be evaluated in eleven patients and all of the patients gained CR. Sur-
vival analysis couldn’t be done because non of the patients had progressed
or died. B-RAFV600E mutation was positive in 10(%76,9) patients. Three
(%23,1) of the patients had B-RAF 464-469 codon mutations (One B-
RAFG464E, one B-RAFG466E, one B-RAFG469E) Two patients were positive
for both mutations. No relation could be determined between clinical findings
and mutation state.
Summary/Conclusions: B-Raf mutations are variable and common muta-
tions in HCL patients. B-RAFV600E mutation testing can be used as a sup-
portive test for the diagnosis of HCL due to high incidence of mutation. Also
it can be used as an indicator for patient selection that are appropriate for
target therapies.
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BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH RELAPSED
FOLLICULAR LYMPHOMA PREVIOUSLY EXPOSED TO RITUXIMAB.
EXPERIENCE IN SEVEN HOSPITALS OF THE SPANISH GELTAMO GROUP
J.A. Soler Campos1,*, M. Martinez1, B. Sanchez-Gonzalez2, M.B. Navarro3,
S. Novelli4, S. Mercadal5, E. Perez Ceballos6, N. Kelleher7, A. Asensio8
1Hematology, Hospital Universitari Parc Tauli Sabadell, Sabadell, 2Hematology,
Hospital del Mar, Barcelona, 3Hematology, Hospital Univeristario Puerta de
Hierro, Madrid, 4Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona,
5Hematology, ICO H. Duran i Reynals., Bellvitge, 6Hematology, Hospital Uni-
versitario Morales Messeguer, Murcia, 7Hematology, Hospital Josep Trueta,
Girona, 8Hematology, Hospital Sant Camil, Sant Pere de Ribes, Spain
Background: Follicular lymphoma (FL) is characterized by a course of relapses
and increasingly shorter responses to the consecutive treatments. In first
relapse after immunochemotherapy, in patients who are not considered refrac-
tory to rituximab, there is no standard treatment. In Spain, bendamustine in
association with rituximab (BR) has not been approved for this indication. Nev-
ertheless this combination has shown high efficacy and excellent tolerance in
patients previously treated with and without rituximab.
Aims: To evaluate the efficacy and safety of the bendamustine-rituximab asso-
ciation in a group of patients with follicular lymphoma previously exposed to
rituximab.
Methods: Retrospective analysis of patients with relapsed FL treated with BR
in 7 spanish hospitals on behalf of the Spanish Lymphoma Group (GELTAMO).
The study was approved by the reference Ethic Committee and by all of the
participating centres. All patients acceded to the treatment through the com-
passionate use program.
Results: 41 patients were valid for analysis. Characteristics: 70% males with
a mean age of 62 years (30-87). ECOG≤ 2 in 95% of cases, 73.2% in stages
III-IV and FLIPI ≥3 in 48%. Bulky mass in 13% of patients, LDH and β2-
microglobulin increased by 12% and 41.2% respectively and bone marrow
involvement in 60%. 68% had received only one previous treatment, with an
average of 1.7 (1-5) and the most frequent was CHOP-R in 66% followed by
CVP-R in 11%. All patients had previously received rituximab and only 3
patients (7.3%) could be considered refractory. All patients received BR (B-90
mg / m2 D1-2, R-375mg / m2 D1). Median cycles 5.1 (1-6). Support with G-
CSF was used in 27.5% of cycles. Maintenance with rituximab after obtaining
a complete (CR) or partial remission (PR) was administered in 42% of patients.
Response: The overall response rate was 95.1% (65.8% CR-iCR / 29.3% PR).
With a median follow-up of 25 months (6-92) the median response duration
was 41.9 months (32.8-51.1) and the median progression-free survival (PFS)
was 57 months (27.4-86.5) with no impact neither by the number of previous
treatments (1 vs ≥2) (P=0.69) nor by the age (<70 vs ≥70) (P=0.9). Patients
who received maintenance with rituximab after BR had a significantly longer
median PFS than without (NR vs 32) (p=0.004). Toxicity: No treatment-related
death was recorded. 42% and 36.6% of the patients presented G3-4 neutrope-
nia and thrombocytopenia respectively, although only 2 patients were admitted
due to febrile neutropenia. 43% received cotrimoxazole prophylaxis and 3
opportunistic infections were recorded (1 P. jirovecii pneumonia in a patient
without prophylaxis).
Summary/Conclusions: BR has a high efficacy and a good safety profile in
this series of patients with relapsed FL previously exposed to rituximab. The
number of previous treatments (1 vs ≥2) and the age had no impact in the
results.
PB1888
USE OF RADIATION THERAPY FOR THE TREATMENT OF GASTRIC MALT
LYMPHOMA
E. Gonzalez1,*, L. Díaz1, M. J. Macias1, V. Diaz1, I. Villanego1, S. Garduño1,
C. Salas1, L. Gutierrez1, J. Jaen1
1Radiation Oncology, H.U. Puerta del Mar, Cadiz, Spain
Background: Gastric mucosa-associated lymphoid tissue (MALT) lymphoma
is a rare disease however, the incidence is increasing and closely associated
with helicobacter pylori (HP) infection. One choice of treatment of gastric
MALT lymphoma refractory to HP sterilization is radiotherapy.
Aims: Our aim was to analyze the response to treatment with definitive radio-
therapy in our department.
Methods: Between January 2014 and January 2017, 8 patients with gastric
MALT lymphoma were treated with eradication therapy of HP, followed by
definitive radiotherapy.  The average total dose was of 38 Gy to the stomach
in a once-daily scheme. Follow-up included computed tomography scan and
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endoscopy with biopsies at regular intervals. The median follow-up was 14
months.
Results: In all patients we got complete responses (CR) with no tumor
detectable by endoscopy or biopsy after initial treatment, but after 2 years one
of them relapsed and required immunochemotherapy. The most common acute
toxicities were fatigue and nausea, in our patients. In any case late toxicities
were observed. The overall survival was 100% after 2 years. 
Summary/Conclusions: In selected patients who are not responsive to HP
sterilization, definitive radiotherapy can be an efficient therapy with tolerable
complications, preservation of stomach and sustained response over time.
Infectious diseases, supportive care
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USE OF LIPEGFILGRASTIM IN CLINICAL PRACTICE FOR THE
PROPHYLAXIS OF CHEMOTHERAPY-INDUCED NEUTROPENIA IN
LYMPHOMA PATIENTS: INTERIM RESULTS OF A PAN-EUROPEAN
NON-INTERVENTIONAL STUDY
N. Cascavilla1,*, T. Wrobel2, E. Hatzimichael3, E. Wojciechowska-Lampka4,
P. Mazza5, K. Kargar6, M. Lenzhofer7
1Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy, 2Wro-
claw Medical University, Wroclaw, Poland, 3University Hospital of Ioannina,
Ioannina, Greece, 4MSC Cancer Center and Institute, Warsaw, Poland, 5SS
Annnziata Hospital, Taranto, Italy, 6Hospital Center of Wallonie Picarde, Tournai,
Belgium, 7Schwarzach Hospital, Schwarzach im Pongau, Austria
Background: Lipegfilgrastim (Lonquex®) is a long-acting fixed-dose glycope-
gylated granulocyte colony-stimulating factor administered once per chemother-
apy cycle. It has been available in Europe since 2013. It was proven to be non-
inferior with regard to duration of severe neutropenia compared with pegfil-
grastim in breast cancer patients. However, data in patients with hematological
malignancies are limited.
Aims: We aimed to evaluate the effectiveness of lipegfilgrastim in the cycle
following the first lipegfilgrastim-supported treatment cycle in lymphoma
patients.
Methods: This is a prospective observational cohort study. Patients with differ-
ent tumor types treated with cytotoxic chemotherapy (CT) who received lipeg-
filgrastim in primary prophylaxis (PP) or secondary prophylaxis (SP) are being
included in this study. CT dose modifications and neutropenia-related events
are recorded and analyzed. Evaluation of effectiveness in the cycle following
the first lipegfilgrastim-supported CT cycle in a lymphoma subpopulation is pre-
sented here. 
Results: At the time of the interim analysis (December 2016), 249 patients diag-
nosed with lymphoma have been included. Mean age±standard deviation of lym-
phoma patients was 61.6±15.6 years and 56.6% were male. For the majority of
patients (81.1%), intended use of lipegfilgrastim was in PP. Exposure to lipegfil-
grastim has been documented for 228 patients with an average of 4.76 cycles
per patient. Data on CT dose modifications and neutropenic events following the
first lipegfilgrastim-supported cycle were available for 144 and 167 patients,
respectively. CT dose was never omitted. CT dose delays were observed in 8.0%
(PP) and 18.8% (SP) of patients and CT dose reductions in 4.5% (PP) and 12.5%
(SP) of patients. In the first lipegfilgrastim-supported cycle, febrile neutropenia
was recorded in 4.5% (PP) and 3.0% (SP) of patients; severe neutropenia was
recorded in 7.5% (PP) and 9.1% (SP) of patients. Throughout the treatment, 22
(9.6%) patients exposed to lipegfilgrastim reported at least 1 adverse drug reac-
tion (ADR). The most common ADRs were myalgia and musculoskeletal pain.
Serious ADRs were reported by 11 (4.8%) patients.
Summary/Conclusions: Lipegfilgrastim is effective and well tolerated in the real-
world setting in lymphoma patients, administered either in PP or SP. The results
suggest that lipegfilgrastim administered in PP might give better outcomes in
terms of dose delays and dose reductions than when administered in SP.
PB1890
TUBERCULOSIS IN ACUTE LEUKEMIA- AN ANALYSIS OF CLINICAL
CHARACTERISTICS AND IMPACT ON MANAGEMENT IN 25 PATIENTS
C. Singh1,*, A. Jain2, G. Prakash2, P. Malhotra2, S. Varma1
1Internal Medicine, 2Hematology, Post Graduate Institute of Medical Education
and Research, Chandigarh, India, Chandigarh, India
Background: Patients with acute leukemia represent an immuno-compromised
population, with innate, humoral and cellular immune paresis. These patients
are thus at high risk of development of new infections and reactivation of chronic
infections. Despite the high prevalence of tuberculosis in the general population
in endemic countries, it is rarely suspected and diagnosed in patients with acute
leukemia.
Aims: To study the clinical manifestations of tuberculosis in patients with acute
leukemia, as well as the impact of infection in the management of leukemia
Methods: A hospital database search was done to identify cases of acute
leukemia and tuberculosis between a study duration of January 2013 to January
2017. All the medical records of the identified cases were retrieved from the
central records department. A systemic analysis of characteristics pertaining to
acute leukemia, treatment regimen, chemotherapy response, site of tubercular
infection, mode of diagnosis and treatment response to anti-tuberculous therapy
was conducted.
Results: A total of 25 patients with acute leukemia were identified who were
also diagnosed with tuberculosis. 10 patients had Acute Myeloid Leukemia, 7
had Acute Promyelocytic Leukemia, 5 had Acute Lymphoblastic Leukemia, 2
had Mixed Phenotypic Leukemia while 1 had Myeloid Sarcoma. The mean
interval between diagnosis of tuberculosis and acute leukemia was 37.2 weeks,
with 2 patients being diagnosed after completion of therapy of acute leukemia
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and one patient was diagnosed post mortem. The most common organ involved
was the lung, which was seen in 80% of patients and 20% of patients had dis-
seminated tuberculosis. The development of tubercular infection led to alter-
ation of therapy for the acute leukemia in 24% of cases, while it was postponed
in 44% of cases. In particular, hypomethylating agents were used successfully
in two patients with AML as bridge therapy to high dose chemotherapy. 76% of
patients were cured of tuberculosis with therapy, while 1 patient expired due to
tuberculosis and 3 patients could not receive adequate therapy for tuberculosis.
3 patients went on to undergo HSCT post treatment for tuberculosis, and none
had a flare of the disease post transplant.
Summary/Conclusions: The presence of tuberculosis infection in patients of
acute leukemia has an impact on the overall management of the patient, and
strategies such as utilization of hypomethylating agents as bridge therapy may
help in successful management of the leukemia. A high index of suspicion is
required to suspect and diagnose the presence of tuberculosis as the mani-
festations are more commonly attributed to fungal infections or to the leukemia
per say. These patients usually have a favorable response to anti-tuberculous
therapy and the presence of tuberculosis infection does not forego treatment
options such as HSCT or high dose chemotherapy for these patients.
PB1891
INCIDENCE OF BACTEREMIA BY MULTI-RESISTANT BACTERIA IN
HEMATOLOGY PATIENTS. A DESCRIPTIVE EPIDEMIOLOGIC STUDY
FROM A THIRD LEVEL HOSPITAL
A. Nieto Vazquez1,*
1Hematology, SERGAS. Hospital Alvaro Cunqueiro, Vigo, Spain
Background: In recent years the incidence of multi-resistant bacteria (MRB)
infections have notably increase. These infections are especially serious in
hematological patients because of the immunosupression derived from their
illness and their treatments. This increase is related to a high mortality rate
and high health costs due to the severity of the infections and the difficulty in
setting adequate therapy due to the lack of new antibiotics against these
pathogens.
Aims: Define the MRB infections incidence and ways of presentation. As a
secondary goal we try to determine if the isolation of these MRB has affected
our empiric antibiotic therapy decision.
Methods: We retrospectively collected all positive blood stream cultures from
hematologic patients from January 2012 to December 2016. We studied the
characteristics, clinical features and pathogen isolates of our patients when
the blood cultures were obtained.
Results: 1005 positive blood stream cultures were collected in 382 patients.
The main characteristics of the patients are shown on Table 1.
Table 1.
The infection source was: central venous catheter (CVC) in 48% of patients
(including tunneled, non-tunneled and PICC lines), respiratory 10%, abdominal
8%, urinary 5%, skin/soft tissue 7% and multiple location 5%. Regarding CVC
isolation’s, 11% were interpreted as contamination and 6% as colonization.
Gram positive (G+) bacteria were more frequently isolated than Gram negative
(G-) (72% vs 24%). Most common G+ bacteria was coagulase negative Staphy-
lococcus, regarding G- E. Coli, Klebsiella sp and Pseudomonas aeruginosa.
MRB were detected in 6.1% of blood cultures being the most frequent G- (85%).
The main resistance mechanism was extended-spectrum beta-lactamases
(ESBL) and carbapenemases (CP) production (Table 2). BMR infections
increased significantly in last year, mainly associated to CP, 0.5% in 2012 up
to 7.1% in 2016 (Figure 1). 29.5% of MRB infections developed in patients
identified as chronic carriers of multiresistant organisms and 100% of them
had extensive exposure to wide spectrum antimicrobials previously. 14% of
infections began with a serious illness (persistent hyperthermia, hemodynamic
disbalance and worsening), 5% needed intensive care assistance and 15%
died because of the infection. In MRB infections, 44% were severe, 6% needed
ICU and 25% died. The most common empirical antibiotic therapy was car-
bapenems - 12% in monotherapy, 17% with glucopeptids - followed by third
generation cephalosporins in 7%. Related to febrile episodes in MRB known
carriers: empiric treatment includes effective antibiotic against this MRB (includ-
ing colistin and carbapenems in extended infusion) was started in 15% of
patients, all with serious illness at diagnosis.
Table 2.
Figure 1.
Summary/Conclusions: - Current antimicrobial resistance, especially con-
cerning G- in our study, is particularly worrisome due to development of resist-
ance to all available antimicrobial agents. The incidence of multi-resistant G+
is not very high. - Clinical presentation in MBR infections is more serious in our
experience, and the mortality doubles in relation to the difficulty to establish
appropriate treatment. - Severity sings at infection diagnosis in MRB carriers
had led us to a change of empirical antibiotic therapy. - As reported in previous
literature, prevention of transmission, a quick establishment of diagnosis and
an effective treatment, along with a correct and limited use of antibiotic therapy
could decrease the development of MRB.
PB1892
INFECTIONS PRESENTING IN THE BONE MARROW IN HIV POSITIVE
PATIENTS AND THEIR MORPHOLOGICAL ASSOCIATIONS – SIX YEAR
DATA FROM AN INDIAN TERTIARY CARE HOSPITAL
R. Gupta1,*, S.L. Jain1, P. Sobti2
1Pathology, Maulana Azad Medical College, 2Pathology, Apollo hospital, Delhi,
India
Background: Centre of Disease Control enlists more than 20 infections  consid-
ered as Acquired Immunodeficiency Syndrome(AIDS) defining. Progression of
the disease and falling CD4 counts are the most important risk factors in acquiring
these infections. Most of the cases present with non specific symtoms  including
fever, respiratory and gastrointestinal manifestations . A bone marrow examina-
tion is helpful in estabilishing the diagnosis in many of these cases. 
Aims: The aim of this study was to evaluate the incidence of marrow infections
in HIV positive patients and to study their morphological spectrum.
Methods: This is a six year retrospective study carried out in a tertiary care
hospital in North India. All bone marrow aspirates and biopsies from HIV pos-
itive patients were retrieved and  evaluated for the presence of infectious eti-
ology. Cytochemical stains like Acid Fast Bacillus, Periodic Acid Schiff , Gomori
Methenamine Silver and Mucicarmine  were performed wherever needed. The
associated morphological features which may assist diagnosis were noted.
Results: Bone marrow samples (either aspirates or biopsies or both) were
available in 185 HIV patients. Out of these,  fifty three cases (33.5%) were
associated with infections. The most common infection in these patients was
Mycobacterium Tuberculosis (22.7%). In addition, five cases of Histoplasmosis
(2.7%), two cases of Cryptococcosis, two cases of Leishmania donovanii, and
one case of Plasmodium falciparum, Parvovirus and Microfilaria each were
noticed. The morphological spectrum associated with infections in these cases
included lymphoplasmacytic infiltrate(68%) , granulomas(66%),  macrophage
infiltration, hemophagocytosis, gelationous marrow transformation and marrow
hypoplasia. Two cases of M tuberculosis were associated with maturation arrest
in the bone marrow. One case of Tuberculosis was associated with Non
Hodgkin’s Lymphoma. Myelodysplasia was seen in association with Leishma-
nia infection.
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Summary/Conclusions: A wide spectrum of infections may be observed in
HIV positive patients in the bone marrow. Bone marrow aspirate and biopsy
are essential, rapid and cost effective techniques to arrive at the right diagnosis
in such cases . Features like hypoplasia, myelodysplasia and maturation arrest
may be attributable to infections.
PB1893
UTILITY OF BONE MARROW BIOPSY IN FEVER OF UNKNOWN ORIGEN:
A CRITICAL ANALYSIS OF A RETROSPECTIVE SERIE
H.N. Fernandez - Leyva1,*, J. Bosworth1, M. Offer1, N. Ansar1
1Haematology, Frimley Park Hospital, Surrey, United Kingdom
Background: The utility of bone marrow biopsy trephine (BMT) as a diagnostic
tool in patients with fever of unknown origin (FUO) is a subject of controversy
and debate. BMT has been shown to be safe and useful in patients with
HIV/AIDS but its value in immunocompetent patients has not been sufficiently
assessed. It’s reported the use of diagnostic BMT as a rapid decision-making
tool in patients with HIV/AIDS and FUO in the proper clinical setting. A BMT
demonstrated infection-related evidence prior to positive bone marrow culture
in 75% of cases. Special stains and blood cultures had similar diagnostic yield,
but BMT offers faster results. Thus, this procedure assists in clinical decision-
making and the refinement of treatment in a more timely manner.
Aims: determine the utility of Bone marrow biopsy in FUO patients.
Methods: We reviewed retrospectively the bone marrow biopsy results of the
inpatients who underwent BMT from January 2010, to December 2016. Demo-
graphic, laboratory, diagnostic and outcome data were collected and retrospec-
tively analyzed. We identified 31 patients who fulfilled the accepted classic
Petersdorf criteria for FUO. The cohort included immunocompromise
and  immunocompetent patients.
Results: The BMT contributes to the diagnosis in only four cases (12.9%). In
two patients (6%) the histology revealed the presence of granuloma and/or
lymphohistiocytic aggregates; one secundary hemophagocytosis (3.2%) and
one mastocytes infiltrate (3.2%). Six patients had a previous diagnosis of
HIV/AIDS (19%). Sub analysis in HIV/AIDS patients revealed positive BMT cul-
ture in 2 of the patients (6,4%). Cultures demonstrated Mycobacterium tuber-
culosis and Mycobacterium avium intracellulare. There was one case in which
a pathogen was grown in culture but that had a negative of ‘direct examination’.
The associations most likely related factor to contribute to the diagnosis in
HIV/AIDS was male predominance (58% odds ratio [OR] 2.95; 95% CI, 1.19-
4.25), clinical lymphadenopathy (OR 4.97; 95% CI, 1.90-2.44) or anemia (OR,
2.21; 95% CI, 1.26-3.84). Reactive myeloid hyperplasia was represented 15
cases (48%). Non- haematological diagnosis (lymphoma, Leukemia) was made
on the exclusive bases of biopsy results.
Summary/Conclusions: Bone marrow examination is an integral part of inves-
tigation of FUO, however, morphological finding alone would not be sufficient
to ascertain the diagnosis. In present study only two cases of established infec-
tions (Mycobacterium) were detected on bases of the marrow culture. Both
were present in HIV/AIDS. These results are explained because a highly active
antiretroviral therapy has reduced incidence of opportunistic infections. The
percent of opportunistic infections diagnosed by BMT was very low and did not
justify an invasive procedure. The presence of granulomas in trephine biopsy
increases the likelihood of an aetiologic diagnosis in these patients.  Bone mar-
row biopsy is still a useful ancillary procedure for establishing the diagnosis of
FUO, only if used in the adequate context.
PB1894
THE OUTCOME OF PEDIATRIC CANCER PATIENTS ADMITTED TO THE
INTENSIVE CARE UNIT OF A TERTIARY HOSPITAL IN
GWANGJU-CHONNAM, KOREA
H. Kook1,*, G. Kim1, J.-S. Choi1, H.-J. Cho1, H.-J. Baek1
1Pediatrics, Chonnam National University Hwasun Hospital, Hwasun-gun,
Korea, Republic Of
Background: Recent advances in supportive care have considerably improved
the prognosis of pediatric cancer patients. However, the use of aggressive can-
cer treatment is also associated with complications and life-threatening events
that result in admissions to the intensive care unit (ICU). 
Aims: This study aimed to analyze the outcome of pediatric cancer patients
admitted to the ICU.  
Methods: A retrospective analysis of 84 ICU admissions of cancer patients
<21 years old between May, 2004 and Aug, 2016 at Chonnam National Univer-
sity Hwasun Hospital (CNUHH) was undertaken. The risk factors for short-term
outcome (survival at the time of discharge from the ICU) were analyzed. After
excluding scheduled perioperative admissions, the records of 81 admissions
(75 patients) were reviewed. 
Results: Hematologic cancer patients represented 71.6% of admissions. The
mean duration of ICU stay was 10.7 days. Respiratory failure (39.5%) and
septic shock (17.8%) were the most frequent indications for ICU admissions.
Overall mortality rate was 46.9%. The mortality for hematologic cancer was
51.7% as compared to 34.8% for solid cancer (P >0.05). Mortality for individual
indication was as follows: bleeding, 66.7%; respiratory failure, 59.4%; systemic
infection 57.5%, anterior mediastinal syndrome, 50%, neurologic disorders,
37.5%, renal disorder, 37.5%, and so on. ICU mortality after hematopoietic
stem cell transplantation was 66.7%, mostly within 100 days post-transplant.
The median Pediatric Risk of Mortality Score (PRISM) III score of survivors
was lower than that of non-survivors (11.3±5.1 vs 19.9±10.9, P<0.001). The
mortality rates were 70.3% and 27.3% in patients with high (>15 points) and
low (≤15 points) PRISM III score, respectively (P<0.001). Mortality rate was
significantly related to the presence and number of organ system dysfunction
(P<0.01 and P<0.001, respectively), positive inotropic support (P<0.01), and
mechanical ventilation (P<0.001). By using multivariate logistic regressions,
the independent risk factors were mechanical ventilation (OR, 6.0; 95% CI,
1.7-21.3; P<0.01), and ≥3 organ system dysfunction (OR, 18.5; 95% CI, 4.4-
77.0; P<0.001). Hematologic cancer patients had higher mean PRISM3 score
(16.5±9.4 vs 12.2±8.6; P=0.51) and higher risk of sepsis (39.3% vs 13.0%;
P<0.05) compared to solid cancer patients.
Summary/Conclusions: These results revealed the current status of ICU care
for pediatric cancer patients in a tertiary hospital in Korea. Further improvement
of supportive care and earlier effective intervention should be translated in
gradual reduction in mortality rate in these population.
PB1895
EFFICACY AND SAFETY OF TIGECYCLINE IN FEBRILE NEUTROPENIC
PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND CARBAPENEM
RESISTANCE: A MULTICENTRE RETROSPECTIVE STUDY FROM
CHINESE PEOPLE
X. Bing1,*, H. Lingli2, C. Guoshu3, L. Zhifeng1, S. Pengcheng4, G. Xutao4,
W. Yan2, L. Jie2, L. Jiabao2, Z. Yong1
1The First Affiliated Hospital of Xiamen University, Xiamen, 2Nanfang Hospital,
Southern Medical University, Guangzhou, 3Huizhou Municipal Central Hospital,
huizhou, 4Nanfang Hospital, Southern Medical University, Xiamen, China
Background: Tigecycline has broad spectrum activity against multidrug-resis-
tant (MDR) bacteria, but few investigations of tigecycline in febrile neutropenic
(FN) patients with malignancy are available.
Aims: This study attempts to investigate the efficacy and safety of tigecycline
in FN and carbapenem resisant patients with hematologic malignancies.
Methods: The study of 109 patients with hematologic diseases and FN were
retrospectively analyzed. They are unresponsive to carbapenems for 3~5 days
before receiving tigecycline (loading dose 100 mg; then 50 mg every 12 hours).
Clinical response to treatment was defined as clinical cure, improvement or
failure. Meanwhile, the adverse events were documented.
Results: The median duration of neutropenia was 15 days (ranged from 1 to
83d). Out of 109 patients, 96 (88.1%) had respiratory infection, while 33 (30.3%)
had bloodstream infection. The total response rate of tigecycline was 65.1%.
The bacterial eradication rates and bacterial hypothetical eradication were
25.9% and 24.1%, respectively. The clinical effective rate was 85.7% when
tigecycline was administered for more than 9 days, while just 48.3% when
administered for less than 9 days (p<0.001). Patients with bloodstream infection
got a worse efficacy than those without (41.2% vs 69.6%, p=0.024). For patients
whose absolute neutrophil counts were less than 0.1×109/L, the clinical effective
rate decreased obviously (59.8%, vs.86.4%, p=0.019). The side-effects were
well tolerated. No lethal adverse events were observed.
Summary/Conclusions: Our results demonstrated tigecycline was effective
and safe for patients unresponsive to carbapenems with FN, combination and
prolonged duration of tigecycline is recommended, and these results need to
be further studied.
PB1896
BONE MARROW CYTOLOGICAL CHARACTERIZATION OF PATIENTS
WITH HIPERREACTIVE MALARIAL SPLENOMEGALY
E. De La Vega1,*, F. Gómez-Aguado1, M.T. Corcuera2, M.D.M. Lago3,
M. Gasior1, V. Jiménez1
1Hematología y Hemoterapia, 2Microbiología, 3Medicina Interna, Hospital Uni-
versitario La Paz, Madrid, Spain
Background: Hyperreactive malarial splenomegaly (HMS) is a common cause
of massive splenomegaly in malarial-endemic areas. At present, diagnosis of
patients with suspected HMS in tropical medicine departments of european
hospitals is relatively frequent due to immigration and the return of missionaries
and NGO workers after long periods in tropical countries.
Diagnostic protocols for HMS usually include a cytological study of bone mar-
row, because clinical similarities between HMS and lymphoproliferative disor-
ders have been reported. However, there are no large series in the literature
that estimate a bone marrow cytological standard associated to HMS. Another
important issue is that patients with HMS are often multiinfected by other par-
asites, viruses and bacteria that may also induce splenomegaly.
Aims: The aim is to define the bone marrow cytological pattern of patients with
confirmed HMS, as well as of HMS patients with associated viral (HIV, HBV,
HCV) or parasitic diseases.
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Methods: A retrospective cytological study of bone marrow aspirates from 95
patients with HMS (n=27), HMS+HIV (n=8), HMS+HCV/HBV (n=11) and
HMS+intestinal parasitosis (n=49) has been performed.
Results: Bone marrow cellularity was normal in all the groups studied except
in HMS+HIV patients, in which the cellularity was very diminished (statistically
significant difference, p<0.01). Most frequent alterations observed in all samples
(HMS and HMS+other entities) that could define the HMS-bone marrow cyto-
logical pattern, were: - Erythroid hyperplasia with dyserythropoiesis, which is
reflected in a decreased myeloerythroid ratio. - Increased eosinophils percent-
age. - Increased lymphocytes percentage. - Increased plasma cells percentage
and detection of Mott cells in a significant proportion of samples from all series
(48.1% of HMS samples). Quantitative results for these variables are summa-
rized in Table 1. Lymphocytosis was significantly increased in HMS+HBV/HCV
bone marrow (p=0.04). Significant detection of atypical lymphocytes (>4%)
varied widely between the groups, ranging from 14.8% of HMS bone marrows
to 75.0% of HMS+HIV bone marrows (statistically significant difference,
p<0.01). There was no lymphoma evidence in any case. No quantitative or
qualitative alterations were detected in megakaryocytes, except for a slight
decrease in HMS+HIV bone marrows (statistically non-significant difference)
(Figure 1).
Table 1. Quantitative results (mean±standard deviation).
Figure 1.
Summary/Conclusions: As far as we know, this is the largest series of HMS
bone marrow analyzed. Identification of common cytological findings in all the
groups studied allows defining a characteristic cytological pattern for HMS.
The reason for these findings could be related to an aberrant chronic immune
response caused by a continuous exposure to malaria parasites. Only bone
marrows of HIV coinfected patients present additional specific alterations
(decreased cellularity and high proportion of atypical lymphocytes). Some
authors hypothesize that HMS could eventually evolve to chronic lymphocytic
leukemia, hairy cell leukemia or splenic lymphoma with villous lymphocytes,
so a special follow-up would be advisable for those patients with a high pro-
portion of atypical lymphocytes.
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ACUTE APPENDICITIS IN LEUKEMIA PATIENTS UNDERGOING
HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING THE
NEUTROPENIC PHASE
Q. Zhang1,*, Q. Jiang1, Y. Zhou1, Q. Mai1, K. Tsui2, Z. Wei2, J. Majaw2,
C. Zou2, Y. Zhang1, F. Huang1, Z. Fan1, J. Sun1, Q. Liu1
1Department of Hematology, Nanfang Hospital, Southern Medical University,
2First Clinical Medical College, Southern Medical University, Guangzhou, China
Background: Infectious complications arising from the gastrointestinal tract is
common in neutropenic patients with hematologic malignances, especially dur-
ing HSCT.
Aims: Sequential analysis of 776 HSCTs in single center, totally 10 cases of
acute appendicitis were found out, the treatment and outcome were further
analyzed.
Methods: The HSCT patients who occurred acute appendicitis during -
10d~+60d in the Hematological Department of Nanfang Hospital from Jan.
2005 to July 2016 were analyzed. Patients were enrolled in our study based
on the Modified Alvarado Scoring combined with ultrasonography (the MASS
total score of 1-4: acute appendicitis very unlikely; Score 5-7: acute appendicitis
probable; Score 8-10: acute appendicitis definite. We selected those cases
with scores 5-10). And the follow-up lasted for 24 m.
Results: 776 HSCT patients were analyzed, in which 10 patients (7 male, 3
female) had acute appendicitis during -1d~+7d, which included two cases of
sepsis. The median age was 18.5 (10-39) years of age. 7 patients were ALL
and the other 3 were CML. All patients underwent allo-HSCT. 6 patients
received conditioning regimen of IDA/TBI/CY/VP-16, and 4 others were treated
with TBI/CY/VP-16/Ara-c, FA/TBI/CY/VP-16, Bu/Cy and Bu/Cy/Ara-c respec-
tively. All the cases scored range from 5 to 10 of the MASS, and 6 patients
showed positive findings on ultrasonography. All the patients had a mean value
of neutrophil of 0.06×109/L (Table 1). 10/10 cases were cured with conservative
therapy, mainly contained different kinds of full dose broad-spectrum antibiotics,
such as piperacillin/ tazobactam, imipenem cilastatin, teicoplanin, meropenem,
tigecycline, et al.. Within 24 m, 8 patients did not relapse, one patient died from
gastrointestinal bleeding 2 m after without recurrence of appendicitis, while
one patient relapsed 1 year later and was cured by appendectomy.
Table 1. Combined with the Modified Alvarado Scoring and ultrasonog-
raphy to diagnose appendicitis during the neutropenic phase of HSCT.
*Reference standard by the Modified Alvarado Scoring System, Total scores were 10, Score 1-4:
acute appendicitis very unlikely; Score 5-7: acute appendicitis probable; Score 8-10: acute appen-
dicitis definite. # “-”: negative; “+”: positive.
Summary/Conclusions: Acute appendicitis occurring during the neutropenic
phase in HSCT patients could be diagnosed by the MASS and ultrasonography,
and such cases could be cured by conservative therapy. This study could pro-
vide a further choice for the diagnosis and treatment of acute appendicitis in
leukemia patients of HSCT.
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EPIDEMIOLOGY OF BLOODSTREAM INFECTIONS IN NEUTROPENIC
AND NON-NEUTROPENIC PATIENTS WITH MALIGNANCY 
N. Raja1,2, S. Gupta3,*, B. O’Neill2
1Pathology, 2Microbiology, 3Haematology, East Sussex Healthcare Trust, Hast-
ings, United Kingdom
Background: Blood stream infections (BSI) in patients with malignancies
remain associated with significant morbidity and mortality. The choice of an
empirical antibiotic regimen is usually based on the local epidemiology of the
microorganisms and their antibiotimicrobial susceptibility profile. Antimicrobial
guidelines for the management of sepsis in cancer patients in East Sussex
Healthcare Trust (ESHT) recommend piperacillin/tazobactam as monotherapy
and gentamicin is added in case of septic shock. Vancomycin is also added as
a first line therapy if there is a suspicion of central line sepsis.  Alternative ther-
apies are ceftazidime or meropenem plus aminoglycoside.
Aims: We intend to review the aetiology of BSI and check the effectiveness of
the antibiotics used in ESHT in cancer patients.
Methods: This retrospective study was conducted at ESHT from January 2006
to December 2015. Demographic and laboratory data were collected from the
Pathology information system.
Results: A total of 640 episodes of BSI occurred in 297 patients (159 male).
Of the 297 patients, 239 had haematology malignancies while 54 had solid
organ tumour. Four patients had both. The neutrophil count was <1 cells/109
in 383 episodes and majority of BSI occurred in this group. A total of 802 organ-
isms (477 and 325 organisms from neutropenic and non-neutropenic respec-
tively) were isolated. Of 802, 406 Gram positive and 386 Gram negative organ-
isms were isolated. Seven Mycobacterium species and three Candida species
were isolated. Most common organisms in neutropenic patients were Coagu-
lase negative Staphylococcus (CoNS) (22%), Klebsiella species (14%),
Escherichia coli (13%), Streptococcus species (10%), Pseudomonas species
(10%), Enterococcus species (8%) and Staphylococcus aureus (4%). In non-
neutropenic patients, CoNS (29%), Escherichia coli (11%), Pseudomonas
species (8%), Streptococcus species (7%), and Klebsiella species (5%) were
isolated.  Twelve Glycopeptide resistant Enterococci were isolated. Four Methi-
cillin resistant Staphylococcus aureus were isolated. In addition, 15 Extended
Spectrum Beta-lactamase producing Gram negative bacilli were isolated.
Among Gram negative organisms, more than 91% isolates were sensitive to
piperacillin/tazobactam, ceftazidime and ciprofloxacin and higher sensitivity
rates (>96%) were recorded in gentamicin and meropenem, Table1 summaris-
es the effectiveness of antibiotics used.
Summary/Conclusions: This study highlights an on-going trend towards Gram
positive organisms causing BSI in cancer patients. The antimicrobial regimens
used in ESHT are highly effective against commonly isolated organisms. An
early diagnosis and timely administration of appropriate antibiotics are imper-
ative in managing BSI. The identification and the antimicrobial susceptibility of
the microorganisms causing BSI in cancer patients remain important to develop
antimicrobial treatment strategies, and to prevent the spread of antimicrobial
resistance.
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Table1. The sensitivity of antibiotic regimens used.
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CHANGING TREND IN LOCAL BACTERIAL EPIDEMIOLOGY:
EXPERIENCE IN ACUTE LEUKEMIA PATIENTS HOSPITALIZED IN SINGLE
HEMATOLOGY UNIT
C. Buquicchio1,*, L. Ciuffreda1, G. De Santis1, C. Germano1, M. Leo1,
M.T. Santeramo1, R. Miccolis1, G. Tarantini1
1Ematologia, SC Ematologia con trapianto, Barletta, Italy
Background: The intense chemotherapic regimens and hypometilant
agents  to treat acute leukemia induce prolonged neutropenia with high risk of
infections.
Aims: To analize local microbial epidemiology we studied patients admitted to
our ward.
Methods:All 100 cases of Acute Leukemia (AL) admitted in our ward from august
2013 to February 2017 received prophylactic antibacterial therapy with fluoro-
quinolones and were analized for weekly routine tissue colture screening  and
serial blood colture for fever. Six patients were Lymphoid AL and 94 were Myeloid
AL. 41 patients were not elegible  for intensive chemotherapy(for age and comor-
bidities) and were treated with hypometilant agents, while 59 were younger than
65 years and were treated with induction /consolidation chemotherapy 3 plus 7
regimen. Median age was 58 years with range from 27 to 88 years old.
Results: We found  28 patients (28%) bacterial septic shock during fever, of
which 20 cases gram negative (71%) in particular 65% E.Coli, 15% Enterobac-
ter, 10% Klembsiella, 5% Stenotrophomonas, 5% Pseudomonas; while 8
patients(29%) had a gram positive septic shock (S.Haemoliticus 38%, S.capitis
25%, S. hominis 25%, S epidermidis 12%). During intensive chemotherapy
and prolonged severe neutropenia we took over the major incidence of septic
shock (23 patients 82%) than hypometilant treatment in particular decitabine
(5 patients 18%). During 2014  we had 3 mortal septic shock for multiresistant
gram- klembsiella and Pseudomonas. Since than we adopted in our ward, iso-
lation of patients with gram negative (klembsiella or pseudomonas )tissue col-
ture positive, hygenic and sanitary practices with  closing room for 48 hours
and hand disinfection before entering and after leaving any patients room.We
noticed a change of bacterial infections incidence  in these 3 years in our
ward.:reduction klembsiella /pseudomonas multiresistant infections and emer-
gency of E.coli and Staphilococcus septic shock not multiresistant.
Summary/Conclusions: More epidemiological analysis in several haema-
tological ward are necessary to understand if it is a changing local microbial
epidemiology or is the different management of neutropenic patients with
acute leukemia and/or a different antimicrobial strategy to determine this
changing trend.
PB1900
UK SINGLE-CENTRE SERVICE EVALUATION TO DESCRIBE THE IMPACT
ON HEALTHCARE RESOURCE USE OF LOCAL ANTIFUNGAL
PROPHYLAXIS AND TREATMENT PROTOCOLS IN THE MANAGEMENT
OF HIGH-RISK PATIENTS WITH NEUTROPENIA
D. Furby1,*, H. Ahir2, G. Nock3, E. Taymor2
1Poole Hospital, Poole Hospital NHS Foundation Trust, Poole, 2Merck Sharp
& Dohme Ltd, Merck Sharp & Dohme Ltd, Hoddesdon, 3pH Associates, pH
Associates, Marlow, United Kingdom
Background: Patients with neutropenia, including those with haematologic
malignancies, are at high risk of invasive fungal infections (IFI). Pre-2014, there
were no formal written guidelines but the guidance at Poole Hospital NHS Foun-
dation Trust specified the use of posaconazole oral suspension for primary pro-
phylaxis in all high-risk patients except those with acute lymphoblastic
leukaemia (ALL). In 2014 formal guideline changes included the introduction
of the tablet formulation of posaconazole, use of micafungin as first line empir-
ical therapy and a focus towards improving diagnostics to guide management.
MSD Ltd. has developed the Fungal Service Evaluation Tool (FSET), a secure
database and analysis tool, to support UK clinicians managing patients at risk
of breakthrough IFI (BIFI) to evaluate their antifungal management. 
Aims: This service evaluation aimed to utilise the FSET to evaluate the impact
of the antifungal management guidelines on healthcare resource utilisation
associated with patients at risk of a BIFI. 
Methods: An interim analysis of high-risk adult patients with prolonged neu-
tropenia aged ≥18 years at initiation of antifungal prophylaxis/treatment was
carried out. Retrospective data on patient characteristics, antifungal prophylaxis
and treatment, IFI-related diagnostic tests, hospital attendance/admission dur-
ing antifungal prophylaxis were collected for 12-month periods before and after
2014 (Cohort 1: 2013; Cohort 2: 2015). Anonymised data was entered into the
FSET and this data was analysed using descriptive statistics. 
Results: The evaluation included 24 patients in Cohort 1 (median age 66.8
[interquartile range (IQR): 47.5–72.2] years; 16 [67%] male; 5 [21%] ALL) and
22 patients in Cohort 2 (median age 66.8 [IQR: 51.7–73.4] years; 13 [59%]
male; 1 [5%] ALL). At least one line of antifungal prophylaxis was recorded in
22 (92%) patients in Cohort 1 and 17 (71%) in Cohort 2. Posaconazole was
the most commonly prescribed antifungal in Cohort 1 (18/24 [75%]) and Cohort
2 (17/22 [71%]). Other agents used included liposomal amphotericin B, flu-
conazole, and itraconazole. There were no patients in Cohort 1 and 2 (9%)
patients in Cohort 2 (overall 4%) who experienced a BIFI: 1 was defined as
confirmed and 1 as suspected. The mean 12 month costs per patient for all
resource utilisation (including antifungal drug costs, hospitalisation costs [includ-
ing admissions and attendances], investigations and tests) was £28,903 in
Cohort 1 and £21,934 in Cohort 2 (Figure 1). Hospitalisation costs were a key
determinant of overall costs, which is common in the management of people
with complex underlying disease. There were 4 (17%) patients in Cohort 1 and
1 (5%) in Cohort 2 who had a period of ITU associated stay, which typically has
greater costs than general wards. The most common investigations/tests were
blood cultures (Cohort 1: mean 13.8; Cohort 2: mean 10.7) and chest x-ray
(Cohort 1: mean 4.0; Cohort 2: mean 2.5), which are in-line with routine clinical
practice. Once implemented, the guideline was adhered to in the management
of 19 patients (86%) in Cohort 2.
Figure 1. Breakdown of mean 12 month resource utilisation costs for
cohorts 1 and 2.
Summary/Conclusions: These data show that rates of breakthrough IFI are
low in complex patients receiving antifungal prophylaxis/treatment. Further-
more, the results in Cohort 2 indicate that the switch to recommending
posaconazole tablets did not result in an increase in the mean cost per patient
of antifungal prophylaxis and shows a lower overall mean cost per patient. A
larger cohort study over a longer period is warranted to confirm these findings.
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Iron metabolism, deficiency and overload
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REAL-LIFE FEASIBILITY OF AN IRON CHELATION PROGRAM WITH
DEFERASIROX IN MYELODYSPLASIA AND OTHER ACQUIRED CHRONIC
ANEMIAS: A SINGLE CENTRE EXPERIENCE
G. Bertani1,*, M. Riva1, E.B. Volpato1, E. Ravano1, I. Cuppari1, A. Mazza1,
P. Usardi1, R. Cairoli1
1Haematology, Ospedale Niguarda Ca’ Granda, Milano, Italy
Background: Prolonged red blood cell (RBC) transfusion support in patients
affected by myelodysplastic syndrome (MDS) and other chronic anemias may
cause vital organs damage due to accumulation of non-transferrin-bound iron with
consequent increased oxidative stress. Retrospective studies have shown that
iron chelation may prevent aforementioned mechanisms and improve survival in
low-risk MDS patients. Iron chelation is usually recommended in patients who
received at least 20 RBC units and/or have a serum ferritin level of 1000 ng/ml
or higher. Deferasirox, an oral iron chelator, has widely replaced the use of defe-
rioxamine, due to its greater manageability, especially in the elderly. However,
an high dropout rate of approximately 50% of patients within one year was
observed in the majority of clinical studies, the leading cause of discontinuation
being gastrointestinal (G.I.) and renal toxicity and skin rash.
Aims: We aimed at evaluating the real-life feasibility of a program of prolonged
iron chelation in a population of acquired chronic anemia patients. Thus, we
performed a retrospective analysis to evaluate which is the percentage of
patients who in our centre actually receive and tolerate deferasirox treatment,
among the cohort of eligible patients.
Methods: Deferasirox treatment is considered at our centre in patients affected
by MDS or other forms of chronic anemia (excluded chronic bleeding) who
fullfill criteria for iron chelation (high transfusion burden, i.e. ≥20 RBC units
and/or a serum ferritin ≥1000 ng/ml). Starting dose is usually 10 mg/kg, titrated
up to 20-30 mg/kg as tolerated. The cohort of patients transfused at our centre
during 2015 and 2016 was considered for analysis. Causes of unsuitability and
of treatment discontinuation were extracted from our database. 
Results: Our cohort consisted of 58 patients, mainly affected by MDS (45 pts);
other diagnosis were myelofibrosis (6 pts), NHL (2) and multifactorial anemia,
not related to blood cancer (7). Only 38 out of 58 potentially eligible patients
were assigned to iron chelation (see the Figure 1). The leading cause of ineli-
gibility in our cohort were a reduced life expectancy (5 pts), due to the hema-
tologic disease itself or to comorbodities, and pre-exisiting renal failure (4).
Importantly, in 6 cases patients were not offered iron chelation without a specific
clinical reason: half of them (3/6) were non-MDS patients. Furthermore, 13/38
patients had to interrupt the treatment, due to toxicity (mainly renal failure, fol-
lowed by gastrointestinal toxicity, see flow-chart). Overall, 25/58 (43%) poten-
tially eligible patients, i.e. heavily transfused patients, initiate and continue an
iron chelation program at our centre. The main cause for treatment discontin-
uation in our cohort was renal failure, while we had less difficulties in managing
G.I. adverse events. Renal toxicity of deferasirox is known to be reversibile;
however, in patients with pre-existing compromise and those who concurrently
take nephrotoxic drugs, treatment may be difficult to carry on.
Figure 1.
Summary/Conclusions: Our data are in line with literature. However, there is
still room for improvement, especially in the category of non-MDS patients,
who are often under-treated. Furthermore, the introduction of a new formulation
of deferasirox, which is forthcoming, may hopefully reduce G.I. toxicity and
improve tolerance and patients adherence to therapy.
PB1902
NONINVASIVE TRANSCUTANEOUS SPOT-CHECKING OF TOTAL
HEMOGLOBIN FOR THE SCREENING OF ANEMIA IN CAMBODIAN
CHILDREN FROM REMOTE RURAL AREAS
J. Perez De Oteyza1,2,*, L. Fernandez de la Fuente2, C. Montero1, L. Trives2,
A. Jayo3, R. Guiote2, V. Benito2, B. Santos2, A. Rodriguez2, J. Marin2,
L. Sierra2, S.P. Gonzalez2, E. Martinez2, J. Rodriguez2, A. Perez2, A.I. Sanz2,
X. Santos Heredero2
1Hematology, Hospital Universitario Madrid Sanchinarro, 2Clinical Sciences,
3Basic Sciences, Facultad de Medicina, Universidad CEU San Pablo, Madrid,
Spain
Background: Previous studies have reported a high prevalence of anemia
among school-aged children from Cambodia, ranging from 21 to 64%. Although
iron deficiency accounts for the majority of cases, additional nutritional and non-
nutritional etiologies have been identified.   Children living in rural or remote
areas, with limited access to health facilities, are at high-risk of developing ane-
mia, and therefore, painless, fast, and reduced cost screening tests are needed.
Aims: The aim of our study is to evaluate  the role of a portable device for tran-
scutaneous noninvasive spot-checking of total hemoglobin (SpHb) in children
living in remote locations.
Methods: Transcutaneous noninvasive spot-checking of total hemoglobin (SpHb)
was performed in children attending summer-school camps at 12 different loca-
tions in Cambodia. SpHb was measured in fingertips by using size adapted optic
sensors. For the purpose of the study, three age groups were defined as follows:
Group 1=less than 5 years, group 2=5 to 11 years, and group 3=11 to 14 years.
Results: A total of 476 otherwise healthy children were analyzed. Mean SpHb
value was 11.9 ±0.93 gr/dl (range 9-16 gr/dl). Overall, the prevalence of anemia
in the entire population was 34.5%. Anemia was present in 5/31 (16.1%) of the
children within group 1, 97/189 (33,9%) in group 2, and 54/81 (40%) in group
3. (p=0.039, two sided Pearson’s Chi square). There were no differences in
the prevalence of anemia by gender in groups 1 and 2.  In group 3, anemia
was significantly more prevalent in females 32/65 (49,2%) than in males 22/48
(31,4%), p=0.035.
Summary/Conclusions: Taken together, our results demonstrate the feasibility
of  noninvasive transcutaneous spot-checking of total hemoglobin (SpHb) for
the screening of anemia in children from remote rural areas with limited access
to health services. Our results also confirm the high prevalence of anemia in
this population.
PB1903
IRON DEFICIENCY ANEMIA IN INFANTS AND YOUNG CHILDREN
S.K. Park1,*, S.K. Kim2, E.Y. Joo2
1pediatrics, Ulsan University Hospital, Ulsan, 2pediatrics, Inha University col-
lege of medicine, Incheon, Korea, Republic Of
Background: Iron deficiency anemia in infants and young children is easy to
be underdiagnosed. Anemia and iron deficiency are usually corrected after
aged 2-3 years old, but it causes complications. There is an association
between IDA and impaired neurocognitive function and exercise intorance,
even after treatment of IDA. Therefore, preventing the progression of iron defi-
ciency is especially important during infancy and early childhood, when
increased vulnerability is associated with rapid growth and development, espe-
cially of the brain.
Aims: To detect iron deficiency anemia early and to reduce the adverse impact
by IDA, we assessed the characteristics of infants and young children with
IDA, those at risk for IDA and those exhibiting associated characteristics of
severe anemia.
Methods: Among 1,782 children with IDA aged 6 months to 18 years-old, we
retrospectively analyzed medical records and laboratory data of 1,361 subjects
aged 6–23 months with IDA who had been diagnosed between 1996 and 2013.
We excluded patients with CRP ≥5 mg/dL.
Results: IDA was predominant in boys (2.14:1) during infancy and young child-
hood. Peak incidence was at 9 to 12 months of age. Only 7% of subjects were
brought to the hospital with symptoms and/or signs of IDA, while 23.6% in sub-
jects with severe IDA. LBW infants with IDA shows low adherence with iron
supplementation. In a multivariate analysis, risk factors of severe anemia in
infants included prolonged breastfeeding without iron fortification [odds ratio
(OR) 5.70] and low birth weight (OR 6.49).
Summary/Conclusions: Many clinicians did not consider IDA as a real prob-
lem, so many children with IDA were not followed up. LBW infants need more
attention to increase adherence of iron supplementation. For early detection
of IDA, nutritional assessment should be evaluated in every infants and iron
batteries in high risk infants (LBW infants, prolonged breastfeeding, picky eater
and/or symptoms of IDA) at health screening visit.
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THE ROLE OF ZINC PROTOPORPHYRIN IN THE DIAGNOSIS OF
SIDEROPENIC ANEMIA
T. Nascimento1,*, S. Marini1, D. Mota 1, P. Bernardo1, L. Relvas 1,
A.C. Oliveira 1, E. Cunha 1, J. Pereira1, C. Bento1, T. Magalhães Maia1,
M.L. Ribeiro1
1Serviço de Hematologia Clínica , Centro Hospitalar e Universitário de Coimbra,
Coimbra, Portugal
Background: Sideropenic anemia (IDA) is the main cause of anemia world-
wide. Even though, its diagnosis is quite straightforward with the use of red
blood cell indices, peripheral blood smear (PBS) and ferritin measurements,
there are still some pitfalls, namely in the presence of inflammation. The chela-
tion of iron by protoporphyrin constitutes the final reaction of heme biosynthesis.
In the absence of iron, zinc becomes an alternative substrate for ferrochelatase
leading to the formation of zinc protoporphyrin (ZPP). This compound can be
quantified by fluorometry in blood samples, proving itself as a useful and easy
parameter for the diagnosis of IDA. However, this technique is not broadly used
in the clinical practice.
Aims: Determine the cut-off value of ZPP for the diagnosis of IDA. Evaluate
the value of ZPP for the differential diagnosis between IDA and anemia due to
inflammatory diseases (AID). 
Methods: We have analyzed in our lab, from 1st to 15thFebruary 2017, all the
consecutive samples (pediatric and adult) with anemia (as defined by WHO)
which had sedimentation rate (SR) and serum ferritin evaluations.
We have defined three different groups: IDA: Anemia and Ferritin <20μg/L; AID:
Anemia, Ferritin >20μg/L and SR>20mm/h; Group control (GC): Normal levels
of Hb adjusted by age and sex, as defined by WHO, Ferritin 20-120μg/L and
SR<20mm/h. ZPP measurement was performed by hematofluorometry (AVIV,
Biomedica, Inc). Data were analyzed by SPSS v20.0 using Wilcoxon W and
Man-Whitney to examine differences between groups and receiver-operating
characteristic (ROC) analysis to determine the cut-off values of ZPP. We con-
sidered statistically significant a p-value <0.05.
Results: We have identified 204 samples that fulfilled the inclusion criteria:
104 with IDA, 51 with AID and 49 from control patients. IDA group: 73% female
(F); mean age 32.3y in F [1.1-78], 28y in males (M) [1-78]; mean Hb was
10.6g/dL [SD 1.4]; mean ferritin was 9.3 ug/L [SD 4.85] and ZPP was 214.1
μmol [SD 121.3]; mean SR was 20.0 mm/h [SD12.9]. AID group: 75% F; mean
age 47y in F [2-91] and 22y in M [1-85]. Mean Hb 11.0 g/dL [SD 1.2]; mean fer-
ritin 150.3 μg/L[SD246.2] and ZPP 136.7 μmol [SD 107.8]; mean SR 47mm/h
[SD 21]. GC: 69.4% F; mean age 44,8y in F [1.1-79], and 37y in M [2-65 years];
mean Hb 13.8 g/dl [SD 0.9]; mean ferritin 71.9ug/L [SD 49.9] and ZPP 78.6
μmol [SD 26.6]; mean SR 14mm/h [SD 4]. The mean serum ZPP in IDA and
AID was significantly higher than in GC (95% CI; p<0.0005). The ROC analysis
showed 83.7% sensitivity and 85% of specificity to identify IDA for ZPP ≥100.3
μmol (W=0.933) and 69% sensitivity and 70% of specificity to identify AID for
ZPP ≥140 μmol (W=0.749) when compared with GC.
Summary/Conclusions: We have concluded that ZPP is a valid, quick, easy
and cheap parameter to diagnose IDA in clinical practice, and we have defined
in our cohort of patients a ZPP cut off of ≥100.3μmol as diagnostic of IDA with
83.7% sensitivity and 85% of specificity, independent of age. In AID patients
we found a cut-off value of ≥140μmol, but with a low sensitivity and specificity.
In our study ZPP was not a reliable method to differentiate IDA from AID. This
could be due to a sample selection bias (since clinical data were missing and
the number of patient with AID was substantially lower than with IDA). It would
be important to enlarge the AID sample in order to obtain a more reliable result.
Since ZPP measurement can be performed in capillary blood and it is a very
quick and cheap method to diagnose IDA, this could be a powerful tool in under-
developed countries.
PB1905
HYPERFERRITINEMIA AND SERUM INFLAMMATORY CYTOKINES
IN 71 ADULTS WITH NEWLY DIAGNOSED HEMOPHAGOCYTIC
LYMPHOHISTIOCYTOSIS ASSOCIATED WITH HEMATOLOGICAL
MALIGNANCY
M. Machaczka1,2,*, F. Lorenz3, E. Pawłowicz4, M. Gajewski5, M. Wolan2,
M. Klimkowska6
1Hematology Center Karolinska, Karolinska University Hospital Huddinge,
Stockholm, Sweden, 2Medical Faculty, University of Rzeszow, Rzeszow,
Poland, 3Department of Radiation Sciences, Section of Hematology, Umeå
University, Umeå, Sweden, 4Medical University of Łódź, Łódź, 5Medical Uni-
versity of Silesia, Katowice, Poland, 6Department of Clinical Pathology and
Cytology, Karolinska University Hospital Huddinge, Stockholm, Sweden
Background: Hemophagocytic lymphohistiocytosis (HLH) is an underdiag-
nosed but life-threatening syndrome of hyperinflammation which in adults is
often caused by hematological malignancies. Release of
inflammatory cytokines in HLH induces immune cells and cytokine production
that cumulates in cytokine storm and hyperinflammation. Hyperferritinemia
≥500 µg/L is a diagnostic criterion for HLH. Prevalence of hyperferritinemia in
HLH in the adult population is much less established than in children.
Aims: The aim of the present study was to evaluate the frequency and extent
of hyperferritinemia as well as serum concentrations of selected inflammatory
cytokines at the time of diagnosis of hematological malignancy-associated HLH
(hM-HLH) in adults.
Methods: The study included 71 adults with hM-HLH, aged 22–84 years, and
diagnosed between 2009 and 2016. Hematological malignancy was defined
as a neoplasm of lymphoid or myeloid origin. In all studied patients, the diag-
nosis of HLH was based on the HLH-2004 criteria. Since the majority of patients
in this study had severe lymphopenia, we decided to not perform functional
analyses of NK-cells for HLH diagnosis. Thus, we included in this analysis all
patients with hematological malignancies and suspected HLH who fulfilled at
least four of seven HLH-2004 criteria as well as at least two of three additional
features: sIL-2Rα ≥2400 U/mL, hemophagocytosis in BM, and hyperferritinemia
≥10,000 µg/L. Serum concentrations of inflammatory cytokines IL-1β, IL-6, IL-
8, IL-10 and TNF-α were analyzed using chemiluminescence (IMMULITE®
One, DPC Siemens). Serum levels of sIL-2Rα were determined by ELISA,
using the quantitative ‘sandwich’ enzyme immunoassay, on the IMMULITE®
1000 Immunoassay System (DPC Siemens).
Results: Lymphoid malignancy was diagnosed in 42 patients and myeloid
malignancy in 29 patients. Fifty-four (76%) patients developed HLH as a first
manifestation of an unknown malignancy, during progressive disease, or at
malignancy relapse. The remaining 24% of patients developed HLH during
chemotherapy. Serum ferritin concentration (ref.: 30–350 μg/L) at the time of
hM-HLH diagnosis was elevated in all but one patient (70/71, 98%). Mean fer-
ritinemia was 37,281±84,440 μg/L, median value 14,727 μg/L, and ferritinemia
range 96–645,291 µg/L. As HLH-2004 criterion, hyperferritinemia ≥500 µg/L
was present in 69 of 71 patients (97%) at the time of HLH diagnosis. Hyperfer-
ritinemia of ≥2000 µg/L was noted in 67 (94%) patients, hyperferritinemia of
≥5000 µg/L in 56 (79%) patients, and hyperferritinemia of ≥10,000 µg/L occured
in 42 (59%) patients. Serum levels of sIL-2Rα (sCD25) were measured in 69/71
patients, of whom 91% (63/69) had values ≥2400 U/mL. Moreover, in 3 more
patients sIL-2Rα was clearly elevated to 2179, 2233, and 2345 U/mL, respec-
tively. Concentrations of TNF-α, IL-6, and IL-10 in serum were each elevated
in over 85% of the examined hM-HLH patients. IL-8 concentration was
increased in half of all tested patients at the time of HLH diagnosis. However,
IL-1β concentration was above reference range only in 12% of patients (7 of
58). Results of the inflammatory cytokine analyses in patients with newly diag-
nosed hM-HLH are presented in Table 1.
Table 1. Inflammatory cytokines in patients with newly diagnosed hM-
HLH.
Summary/Conclusions: Hyperferritinemia at the time of HLH diagnosis was
common in Swedish adult patients with hM-HLH. Hyperferritinemia ≥500 µg/L
was present in vast majority (97%) of them. We would like to emphasize that
serum ferritin level fluctuates and can differ significantly from one day to another.
Ferritinemia should be repeatedly measured in cases of suspected HLH. Serum
concentrations of TNF-α, IL-6, IL-8, and IL-10 were frequently elevated in the
examined hM-HLH patients and these can become important markers support-
ing HLH diagnosis in equivocal cases. On the other hand, IL-1β seems to be
less usefull in confirming a cytokine storm in this patient group.
PB1906
REDUCING UNNECESSARY BLOOD FILMS USING AN IRON DEFICIENCY
ALGORITHM
R. O’Toole1,*
1Haematology, Wellington SCL, Wellington, New Zealand
Background: In 2015, Wellington SCL (WSCL) was selected to provide inte-
grated laboratory services in the Wellington region, New Zealand (NZ). This
involved merging services from previous community laboratory Aotea Pathology
Ltd. (APL) with the three regional hospital based District Health Boards (DHB)
laboratories - Capital & Coast (CCDHB), Hutt Valley and Wairarapa. On the 1st
of November 2015, WSCL would launch its new integrated service with a
merged workforce, new technology, processes and procedures. Considered to
be the biggest laboratory integration project undertaken in NZ, every effort
needed to be made to reduce the workload without compromising patient care.
Aims: In the Haematology laboratory, one of the most common triggers for
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blood films are iron deficient pictures with the characteristic finding of reduced
Haemoglobin (Hb), MCV and MCH. Above certain thresholds, the blood film
adds little or no value to the CBC in these patients, apart from correlating with
the iron studies results or suggesting iron studies when unavailable. One ini-
tiative used to manage the workload was based on this logic and aimed to
reduce the blood film review rate using IT3000 technology (Roche).
Methods: An algorithm was designed in IT3000 to encourage testing and treat-
ment for iron deficiency using a series of automated educational comments,
while minimising unnecessary laboratory work. The impact that this algorithm
had at WSCL was investigated by retrospective analysis of all the patient results
from 1st November 2015 to the 1st of May 2016. 
Results: In the first six months of operation, WSCL performed 232,192 CBCs
and 30,204 blood films with an average review rate of 13.01%. Had this algo-
rithm not been employed, 2,434 extra blood films would have been reviewed,
bringing the review rate up to 14.05%. 
Summary/Conclusions: Incorporation of an algorithm specific for iron defi-
ciency in IT3000 has significantly reduced the review rate without any negative
impact on patient care. 
PB1907
THE RELATIONSHIP ENDOTHELIAL MICROPARTICLES AND
ASYMMETRIC DIMETIL ARGININE IN CHILDREN WITH IRON DEFICIENCY
AND IRON DEFICIENCY ANEMIA
E. Kaygı Tartıcı1, Y. Altuner Torun2,*, C. Karakukucu3, S. Celik4,
H.T. Hormet Oz5
1Pediatrics, 2Pediatric Hematology, 3Biochemistry, 4Pediatric Cardiology,
5Microbiology, Medical Health University, Kayseri, Turkey
Background: Iron deficiency anemia and iron deficiency without anemia
increase the risk of atherosclerosis by increasing oxidative stress and inflam-
mation. Endothelial dysfunction is an important factor of the pathogenesis of
atherosclerosis. 
Aims: Endothelial micro particles (EMPs) are considered as markers of
endothelial dysfunction. Asymmetric dimetil arginine (ADMA) is known as
another marker of endothelial dysfunction. In this study; we aimed to evaluate
circulating EMPs and ADMA in children with iron deficiency and iron deficiency
anemia and to disclose iron deficiency with the strongest relation with EMPs,
ADMA and carotid atherosclerosis.
Methods: This study included 30 children with iron deficiency anemia, 30 chil-
dren with iron deficiency without anemia and 30 healthy children whose anthro-
pometrics measurements were recorded. Hemoglobin, serum iron level, iron
binding capacity, ferritin, and lipid profile were studied. Circulating EMPs
(CD144, CD146, and CD105) were measured by flow cytometry. ADMA was
measured by ELİSA. The carotid artery intima media thickness (CIMT) and left
ventricular mass index (LVMI) were measured using echocardiography. 
Results: CD144 and CD105 EMP levels were lower in the iron deficiency with-
out anemia group than in the control group and statically lower than in the iron
deficiency anemia group (p<0.05). There were no significant differences in
ADMA level between groups. Any significant variety in ADMA level was not
observed between groups. CIMT was negative correlated with ferritin and high
density lipoprotein and positive correlated with body weight. 
Summary/Conclusions: In this study, endothelial dysfunction which occurs
as a result of iron deficiency were observed. According to our result, CD144
and CD105 EMP levels in the iron deficiency without anemia group were lower
than the iron deficiency anemia and control group; these levels in iron deficiency
anemia group were higher than control group. In addition, when the level of
ferritin has decreased, CIMT has increased. This study show that CD144 and
CD105 may be related to endothelial dysfunction which occurs by iron defi-
ciency.
PB1908
INVESTIGATION OF IRON METABOLISM FOR REGULATING
MEGAKARYOPOIESIS AND PLATELET COUNT ACCORDING TO THE
MECHANISMS OF ANEMIA
S. Kim1, S.Y. Cho1,*, T.S. Park1
1Kyung Hee University Hospital, Seoul, Korea, Republic Of
Background: Iron deficiency anemia (IDA) is characterized by depletion of
total body iron stores. By contrast, chronic inflammation makes iron unavailable
for hematopoiesis through a cytokine-mediated cascade, resulting in anemia
of chronic disease (AOC). However, the laboratory data regarding the regula-
tory role of iron metabolism on platelet count has not been fully discussed yet.
Aims: In this study, we investigated the relationship between iron status and
platelet production according to different anemic mechanisms representing dif-
ferent iron metabolisms.
Methods: The study included total of 759 blood specimens from 537 different
patients. The complete blood count with various CBC index were measured
using Advia 2120 (Siemens, USA). Biochemical indexes including iron level
were estimated using Toshiba chemical analyzer (Toshiba, Japan). 
Results: We found a significant relationship between platelet count and serum
iron level in AOC group (p<0.27), whereas there was no correlation in IDA
group. In AOC group, platelet count was significantly correlated to serum iron
level only in AOC group with decreased serum iron level (p<0.0001), unlike
AOC group with normal serum iron level.
Summary/Conclusions: Reactive thrombocytosis in inflammatory states
occurs by cytokine cascades involving interleukin-6 and thrombopoietin in AOC.
Moreover, iron deficiency in AOC involves upregulated hepcidin production
induced by increased inflammatory cytokines. It can cause increased iron
sequestration in macrophage and decreased iron absorption for bone marrow.
The condition of decreased megakaryocytic iron supply makes megakaryocytes
with higher ploidy which can release more platelets than lower ploidy. These
two features may enhance thrombocytosis in patients of AOC with decreased
iron level. In the future, the further study should be performed to elucidate
underlying mechanism involving the tight regulation between iron metabolism
and megakaryopoiesis in anemic patients.
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SOLUBLE TRANSFERRIN RECEPTOR LEVELS OF APPARENTLY
HEALTH ADULTS IN PORT HARCOURT NIGERIA
C. Efobi1,*, B. Nwogo2, I. Onyiaorah3, O.A. Ejele4
1haematology, chukwuemeka Odumegwu Ojukwu University, Awka, 2haema-
tology, university of Benin, benin city, 3histopathology, nnamdi azikiwe univer-
sity, nnewi, 4hematology, university of port harcourt, port harcourt, Nigeria
Background: Soluble transferrin receptor (sTfR) is an early marker of tissue
iron deficiency before onset of anaemia. sTfR is one of the noninvasive tools
for early diagnosis of iron deficiency anaemia, which is one of the most preva-
lent causes of anaemia in our environment. However, there is not established
reference range of this diagnostic marker sTfR in our environment. There is an
important need to devise a screening tool for early detection of iron deficiency
before onset of anaemia.
Aims: To determine the sTfR levels of apparently healthy adults in Port Har-
court, Nigeria, determine the reference range of sTfR in the study population.
Methods: This is a descriptive cross sectional study conducted at the University
of Port Harcourt Teaching Hospital. one hundred and fifty participants (107
males and 43 females) who satisfied the inclusion criteria were enrolled in this
study. The ages of the study population were grouped into four: 21-30, 31-40,
41-50, 51-60.  Full blood count and sTfR concentration were assyed on anti-
coagulated blood samples using a 3- part autoanalyser (sysmex -KX2IN) and
Human ELISA kit by biovendor respectively. The results were analysed using
SPSS version 21. P value of <0.05 was considered significant.
Results: The mean sTfR concentration of the study population was
0.89±0.46ug/mL with a range of 0.3- 3.05ug/ml. The mean value of sTfR for
males and females were 0.92±0.49ug/ml and 0.82±0.37ug/ml. The mean sTfR
for age group 21-30 was 0.88+/-0.48ug/ml and 0.80+/-0.47ug/ml for males and
females respectively, while the mean sTfR for age group 51- 60 was 0.98+/-
0.53 ug/ml and 0.97+/-0.13ug/ml for males and females respectively. The mean
sTfR levels did not differ significantly for age and sex.
Summary/Conclusions: This is the first cross sectional study in our environ-
ment to determine reference value of sTfR levels in healthy adults in Port har-
court. This reference value was established as 0.3-3-05ug/ml. This study found
no statistically significant relationship between different ages and sexes.
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ROLE OF PRO-PHAGOCYTIC CALRETICULIN AND
ANTI-PHAGOCYTIC CD47 IN MDS AND MPN MODELS TREATED WITH
AZACYTIDINE OR RUXOLITINIB
K. Boasman1,*, C. Bridle2, M.J. Simmonds1, C.R. Rinaldi1
1School of life Sciences, Collage of Science, 2Lincoln Institute of Health, Uni-
versity of Lincoln, Lincoln, United Kingdom
Background: Myelodysplastic syndrome (MDS) and Myeloproliferative neo-
plasms (MPN) are clonal myeloid disorders with the tendency to progress into
acute myeloid leukaemia. Previous studies in solid tumours have shown an
increase in expression of both pro-phagocytic calreticulin (CALR) and anti-
phagocytic CD47, as they act in response to one another, reflecting a possible
apoptosis vs survival mechanism in response to chemotherapy.
Aims: The aim of our study is to assess the changes in CALR and CD47 levels
during treatment of MDS and MPN with azacytidine (AZA) or ruxolitinib (RUXO),
in a series of model cell systems.
Methods: CALR and CD47 gene and protein expression was measured in
MDS cell line models (MOLM-13 and SKM-1), MPN cell line models (HEL-92
and GDM-1) and in an intermediate MDS/MPN cell line (K562) before and after
treatment with AZA and RUXO.  Drug titrations were completed, resulting in
dosing regimens of 0.05µM/ml for both AZA and RUXO, with re-drugging occur-
ring at 24 hours. Cells were then harvested, cDNA was synthesized for use in
qPCR and protein levels determined by Western blot analysis.
Results: When treated with AZA, MDS cell models showed a 7-10 fold increase
in CALR expression and 4-6 fold increase in CD47 expression. In contrast, the
MDS/MPN intermediate cell model (K562) showed a 4.5 fold increase in CALR
but only a 0.5 fold increase in CD47 expression. In the MPN model HEL-92, a
9 fold CALR increase and 5 fold CD47 increase was seen, whereas in the other
MPN model (GDM-1 cells) expression was more evenly matched between
CALR and CD47 (5.3 and 4.8 fold increases, respectively). After treatment with
RUXO, MPN models showed a 9.5-16 fold increase in CALR expression and
a 6-9 fold increase in CD47, which would be expected as RUXO is used to
treat MPN in humans. When the MDS/MPN cell model or pure MDS models
were treated with RUXO, the ratio of CALR/CD47 decreased substantially (with
CALR expression only increased 2.4-3.7 fold compared to CD47 increasing
4.6-6.9 fold) showing resistance to treatment and a significant anti-phagocytic
response.  Interestingly one of the MDS cell line models (MOLM-13) showed
an unexpectedly good response to RUXO therapy with high CALR/CD47 ratio
(8 fold vs 4.8 fold, respectively).
Summary/Conclusions: In line with results in solid tumours, we have shown
that treatment for MDS and MPN leads to an up-regulation of CALR and, to a
lesser extent, CD47 in cell lines models. The ratio of CALR/CD47 seems to
correlate with specific treatment response, significantly increasing when given
diseases models are treated with the appropriate drug. We postulate a role of
CALR expression in leukaemia cell phagocytosis, with CD47 co-expression in
synergy as a protective instinct within the cell to try and prevent apoptosis.
Some models showed an excessive rise in CD47 expression and low expres-
sion of CALR. This indicates that the CD47 mediated anti-phagocytosis takes
control and supresses the CALR expression, leading to cancer cell survival
and ineffectiveness of treatment.  Those results need to be validated in human
samples at different stages of disease to allow a better understanding of treat-
ment response and/or resistance to chemotherapy within these diseases.
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GENETIC VARIANTS OF MSH3 AND BLM GENES MAY INFLUENCE
MYELODYSPLASTIC SYNDROME SUSCEPTIBILITY AND PROGNOSIS
M.S. Melo1, L. Balanco1, A. Barbosa Ribeiro1,2, A.C. Gonçalves1,2, R. Alves1,2,
E. Cortesão1,2,3, L. Ribeiro3, L. Mota-Vieira4, A.B. Sarmento-Ribeiro1,2,3,*
1Applied Molecular Biology and University Clinic of Hematology, 2CIMAGO,
Faculty of Medicine University of Coimbra, 3Clinical Hematology Department,
Centro Hospital e Universitário de Coimbra (CHUC), Coimbra, 4Molecular
Genetics and Pathology Unit, Hospital do Divino Espírito Santo de Ponta Del-
gada, EPER, Ponta Delgada - Azores, Portugal
Background: Myelodysplastic syndrome (MDS) is a heterogeneous group of
hematopoietic stem cell disorders, characterized by peripheral cytopenias, inef-
fective hematopoiesis and frequent transformation into acute myeloid leukemia
(AML). Several mechanisms are involved in disease development and progres-
sion as a consequence of stepwise accumulation of DNA mutations, which
infers a defect in DNA repair mechanisms. Mutations in DNA repair genes of
the nucleotide excision repair (NER) group, and affecting the mismatch repair
(MMR), and DNA crosslink repair genes, among others, are the cause of inher-
ited cancer syndromes. On the other hand, genetic variants in genes involved
in these mechanisms have been identified for their potential role in cancer sus-
ceptibility. However, in MDS, the relevance of these variants remains to be fully
established and correlated with prognosis.
Aims: In the present study we investigate the influence of polymorphisms in
DNA repair genes (XRCC5, RMI1, RAD52, XRCC3, BLM, TOP3A, OGG1,
LIG1, ERCC2, and MSH3) as risk factor for MDS development as well as prog-
nostic factors of acute leukemia transformation.
Methods: We performed a hospital-based case control-study to investigate
the association of DNA repair genes with MDS susceptibility and prognosis in
a group of Portuguese patients. To that end, we genotyped by TaqMan real-
time PCR 10 SNPs (one per gene: XRCC5, RMI1, RAD52, XRCC3, BLM,
TOP3A, OGG1, LIG1, ERCC2, and MSH3) in 60 MDS patients and 120 age-
sex matched controls. Frequencies of alleles, genotypes, and genotypic profiles
were estimated and compared between patients and controls. The role of these
genes in MDS susceptibility was studied by logistic regression analysis. The
influence in MDS prognosis was evaluated by estimating, through Kaplan Meier
analysis, the rate of MDS transformation into AML and the overall survival.
Results: There was no significant difference in frequencies of XRCC5, RMI1,
RAD52, XRCC3, BLM, TOP3A, OGG1, LIG1 and ERCC2 variants between
patients and controls. In contrary, we found that heterozygous individuals for
MSH3 c.2655+5137C>G had an increased susceptibility to MDS development
(OR=6.882, 95% CI 1.789-26.479, p <0.003), being the increased risk attributed
to G allele (OR=6.405, 95% CI 1.552 30.469, p <0.003). In addition, MDS
patients homozygous for BLM c.-4-889A>C showed higher rate of MDS trans-
formation into AML (HR=7.646, 95% CI 1.362 24467, p <0.023).
Summary/Conclusions: The present study suggests that MSH3
c.2655+5137C>G variant influences MDS susceptibility, and BLM c.-4-889A>C
variant may be implicated in the propensity to AML transformation observed in
MDS patients. Thus, these gene variants could be used as a risk and prognostic
biomarkers for MDS, if these associations were replicated in a larger case-con-
trol study and/or with other populations.
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LOW RPS14 EXPRESSION IN MDS PATIENTS WITHOUT 5Q- ABERRATION
SEEMS NOT TO BE RELATED WITH GENOMIC ALTERATIONS IN 5Q
REGION
M. Linares1,*, K. Quiroz1, Y. Ruiz-Heredia1, I. Rapado1, T. Cedena1, R. Ayala1,
J. Martínez-López1
1Servicio de Hematologia, Hospital Universitario 12 de octubre, Madrid, Spain
Background: Heterozygous deletion of RPS14 occurs in isolated interstitial
deletion of chromosome 5q in patients with myelodysplastic syndrome (MDS).
5q- MDS has been linked to impaired erythropoiesis and it is characterized by
a constant macrocytic anemia and normal or high platelet counts associated
with hypolobulated megakaryocytes. Previous studies have detected reduced
RPS14 expression in more than 50% of non-5q-patients. Recently, the pivotal
role of RPS14 in human erythropoiesis during 5q- MDS pathology has been
demonstrated: RPS14 haploinsuficiency produces the activation of p53 and its
target p21 in erythroid cells, resulting in cell cycle arrest and apoptosis. Based
on these results, non-5q- patients expressing low levels of RPS14 will be poten-
tially beneficed by lenalidomide therapy. In this work, we explore the origin of
the altered RPS14 expression in non-5q- patients and its potential link with 5q-
pathology.
Aims: The objective of this work was to explore the origin of RPS14 low expres-
sion in non-5q- MDS patients and its link with 5q- pathology. In order to do this,
we analysed potential mutations in RPS14 gene. We also studied expression
changes in other key genes involved in the development of the 5q- disease,
including the tumour suppressor gene SPARC and the putative tumour sup-
pressor gene CSNK1A1, contained in the commonly deleted region. Moreover,
other 32 genes related with MDS disorders were evaluated in relation with
RPS14 levels. Finally, in order to establish if this group of patients could be
beneficed by lenalidomide therapy, p21 expression levels were also analysed.
Methods: DNA and RNA were extracted from the bone marrow of 89 non-5q-
MDS patients. Ten controls and nine 5q- MDS patients were used as negative
and positive controls, respectively. RPS14, SPARC, CSNK1A1 and p21 mRNA
levels were analysed by real time PCR using Taqman probes in a 7500 RT
PCR System. β-glucuronidase gene was used as endogenous reference to
normalize data. Samples were classified by RPS14 expression levels and dif-
ferences in SPARC, CSNK1A1 and p21 expression mean values between the
two groups were analysed using the Mann-Whitney U test. RPS14 and 32
genes related with MDS were analysed using Ion Proton sequencing.
Results: Non-5q- patients expressing low levels of RPS14 presented higher
survival probability in the IPSS lower risk group. This data, in addition with a
tendency for increased p21 expression, suggests that this group could be
beneficed by lenalidomide therapy. Nevertheless, we did not observe a signif-
icant decrease in SPARC and CSNK1A1 expression in patients with low levels
of RPS14, discarding alterations in the adjacent genes commonly deleted in
5q- MDS patients. In addition, the majority of patients analysed did not present
any mutation in RPS14 gene. Only two MDS patients showed mutations
upstream, downstream or within intronic regions of the gene. Then, the origin
of RPS14 decreased expression seems not to be related with genomic alter-
ations in 5q region. On the other hand, mutations in FLT3, U2AF1, DNM3A and
CBL were frequently observed in this group of patients.
Summary/Conclusions: Although the important role of RPS14 in MDS pathol-
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ogy has been recently demonstrated, the origin of RPS14 downregulation in
about 50% non-5q- patients remains unknown. Our results suggest that the
origin of RPS14 decreased expression is not related with genomic alterations
in 5q region. Further studies are necessaries in order to establish a link with
5q- pathology and demonstrate the potential use of lenalidomide in this group
of patients.
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INTEREST OF THE XN-10® ANALYZER TO SCREEN FOR
MYELODYSPLASTIC SYNDROMES ON COMPLETE BLOOD COUNTS
R. Boutault1, P. Peterlin2, M. Boubaya3, S. Tremblais1, M. De Oliveira1,
Y. Le Bris1, C. Godon1, O. Theisen1, M.C. Béné1, M. Eveillard1,*
1Hematology Laboratory, 2Hematology clinic, Nantes University Hospital,
Nantes, 3Clinical research, Avicennes University Hospital, Avicennes, France
Background: A prospective study was performed over one year in order to
investigate whether suspected myelodysplastic syndromes (MDS) could be
detected on a complete blood counts (CBC), the fastest laboratory investiga-
tion, performed on the recently developed XN-10® (Sysmex, Kobe, Japan).
Aims: The primary end point was to discriminate MDS patients from normal
samples and the secondary end-point was to to distinguish MDS with excess
blasts (MDS-EB), MDS with multilineage dysplasia (MDS-MLD), MDS with sin-
gle lineage dysplasia (MDS-SLD) and MDS with ring sideroblasts and single
lineage dysplasia (MDS-RS-SLD) within the MDS group and by comparison
with controls as described by the WHO 2016 classification.
Methods: One hundred and thirteen patients were enrolled in the study, for
whom a diagnosis of MDS was concluded based on CBC, bone marrow smears
examination and karyotype. All patients were free of treatment, including trans-
fusions, at inclusion. They were 63 men and 50 women with a median age of
82 years (range 36-96 yo). CBC were performed on a Sysmex analyzer XN-
10®, including classical parameters (hemoglobin level, Mean Corpuscular Vol-
ume (MCV), reticulocytes, platelets, neutrophils and extra-parameters i.e.
platelets by fluorescene (PLT-F), immature platelets fraction (IPF%), immature
reticulocytes fraction (IRF%) and the neutrophils median position on the three
axes as well as their dispersion (Neut-WX). For comparison with normal values,
results from 707 healthy subjects over 50 years old, for whom CBC were per-
formed on the same analyzer and generated no flag, were used. All had param-
eters within the normal range according to age. According to the WHO, 37
patients in the cohort had MDS-EB, 35 MDS-MDL (among whom 7 had ring
sideroblasts [RS]), 26 MDS-SLD- RS, 12 MDS-SLD without RS and 3 MDS
with isolated del(5q). Sixty-two patients had a normal karyotype, 24 displayed
anomalies classically reported in MDS, and 8 had complex karyotypes. Among
the latter, 7 were associated with MDS-EB.
Results: Both classical and extra parameters indeed showed significant differ-
ences between the subgroups tested. Among the whole group of MDS patients,
a number of parameters of all lineages were statistically different from the healthy
cohort. The median level of hemoglobin was 9,92±1,96 g/dL (p<0,0001), the
median MCV (99,24±10,56 fL p<0,0001), reticulocyte counts 44,3x109/L (range
8-165,9; p=0,041) and IRF% 16,7% (range 2,4-50,9; p<0,0001). The median
platelet count was 194 ±128x109/L (p<0,0001) and the median IPF% 8,8% (1,2-
42; p<0,0001). Among leukocyte parameters, the MDS median neutrophil count
was significantly lower at 3,08±2,58x109/L (p<0,001) while Neut-WX was signif-
icantly higher (387±71;p<0,0001). The latter, allowed to predict a diagnosis of
MDS with 73% sensitivity  and 97% specificity. For patients over 50 years old, 4
parameters (Neut, Neut-WX, hemoglobin level and MCV) in a score allow to
diagnose MDS with 92% sensitivity and 81% specificity . When considering MDS
subgroups, although each of them was significantly different from controls for
hemoglobin levels, MCV and IRF% and (p<0,0001), they could not be discrimi-
nated by these parameters. In the subgroup of MDS with single lineage dysplasia
and ring sideroblasts, platelet counts were similar to those of controls, yet signif-
icantly higher than for MD-EB or MDS-MLD (p=0,004 and p=0,029 respectively).
Moreover, neutrophils counts were significantly lower in MDS-DML or MDS-EB
than in MDS-SLD-RS.
Summary/Conclusions: This study demonstrates that a simple CBC allows to
screen for MDS using a multiparameter score including Neut-WX. Blood smear
examination should be performed in this situation even if the XN-10® analyzer
does not raise any alarm, especially in unknown patients older than 50.
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PROGRESSION SCORE FOR ACUTE LEUKEMIA – A NEW PROGNOSTIC
SCORE IN MDS?
E. Cortesão1,2,*, A.C. Gonçalves1, A.R. Tenreiro2, A. Ribeiro1,2, C. Geraldes1,2,
N. Costa e Silva3,4, L. Ribeiro2, J. Nascimento Costa5,
A.B. Sarmento-Ribeiro1,2
1Applied molecular biology and clinic university of hematology, Faculty of Med-
icine of University of Coimbra, 2Hematology, 3Clinical Pathology, Centro Hos-
pitalar e Universitário de Coimbra (CHUC), Portugal, 4Histology and Embryol-
ogy, 5Clinic university of oncology, Faculty of Medicine of University of Coimbra,
Coimbra, Portugal
Background: Since 1997, the International Prognostic Scoring System (IPSS)
has been the standard for stratifying patients with Myelodysplastic Syndrome
(MDS). Although other models were proposed to improve this stratification,
some issues remain, notably the identification of low-risk patients with poor
prognosis who may benefit from earlier and/or aggressive therapy. 
Aims: The aim of our work was the conception of a new prognostic score in
MDS, based in the cellular and molecular disease characterization.
Methods: Our sample consisted of 102 patients diagnosed with MDS de
novo. The median age was 74 years (22-89), with a 0.8 Male to Female ratio.
The subtypes, according to the World Health Organization 2008, were Refrac-
tory Cytopenia with Multilineage Dysplasia (RCMD) (n=52), Refractory
Cytopenia with Unilineage Dysplasia (RCUD) (n=12), Refractory Anemia with
Excess Blasts type 1(RAEB-1) (n=8), RAEB-2 (n=8), Refractory Anemia with
Ringed Sideroblasts (n=6), 5q- syndrome (n=4) and Chronic Myelomonocytic
Leukemia (n=12). The IPSS based stratification was: low (n=37), intermedi-
ate-1 (n=39), intermediate-2 (n=10) and high (n=1). Several variables were
analyzed: hematological (leukocytes, neutrophils, hemoglobin, platelets,
blasts and ring sideroblasts), biochemical (erythropoietin, β2-microglobulin,
folic acid, vitamin B12, ferritin, LDH), imunophenotypic (hematopoietic stem
cell characterization by flow cytometry, FC, using the markers, CD34 / CD117
/ CD123 / GlicoP / IL-6 / TNFa) and molecular characteristics (methylation
profile of genes p15, p16, DAPK, R1, R2, R3 and R4 performed by PCR-MS,
and evaluation of expression levels of regulatory molecules of apoptosis
BCL-2, BAX, TRAIL, R1, R2, R3, R4, FAS, Survivin, Caspase 3, Cit C, GlycoP
and p53, by FC). 
Results: In the 60-month follow-up, 11 patients progressed to Acute Myeloblas-
tic Leukemia (AML), 7 with RAEB-2, 2 with RCMD, 1 patient with RAEB-1 and
another with CMML. These patients had a higher% of ring sideroblasts and
blasts; higher scores on IPSS, IPSS-R and WPSS; lower platelet counts, higher
erythropoietin levels and greater expression of CD34 / CD117 / IL-6. Assigning
a value (+1) to each altered variable a new prognostic score was obtained,
which we named Progression Score for Acute Leukemia.  We observed that
patients belonging to subtypes with the highest scores were those that pro-
gressed to AML, namely RAEB-1, RAEB-2 and RCMD.
Summary/Conclusions: In conclusion, we believe that this score may con-
tribute to evaluate the risk of progression to AML, by reflecting the heterogeneity
of MDS and its multifactorial etiology. The coexistence of many altered variables
not only contributes to the etiopathogenesis of MDS but also allows the assess-
ment of potential leukemic transformation.
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CORRELATION OF PATIENT PROGNOSIS WITH PU.1 AND JDP2
PROVIDES POTENTIAL NOVEL PROGNOSTIC/DIAGNOSTIC MARKERS
IN MDS
R. Simpson1,*, A. Goddard1, J. Lally1, M. Simmonds1, C. Rinaldi2
1University of Lincoln , 2University of Lincoln and United Lincolnshire Hospital
Trust, lincoln, United Kingdom
Background: PU.1 is a key transcription factor in haematopoiesis that plays
important roles in various haematological malignancies. Previously, significant
down-regulation of PU.1 has been reported in high risk myelodysplastic syn-
drome (MDS) and acute myelogenous leukemia (AML) patients. 
Aims: To clarify PU.1 molecular function we investigated the gene expression
of PU.1 and JDP2 (c-Jun dimerization protein-2), a member of the activating
protein-1 family located downstream of PU.1, in bone marrow from 12 MDS
patients stratified according to IPSS-R score (6-low, 3-intermediate, 3-high
risk), 1 AML patient and 10 normal controls. 
Methods: Samples were enriched for the mononuclear fraction by Ficoll sep-
aration. Total RNA was extracted and analysed by Real Time PCR for PU.1
and JDP2 expression relative to the housekeeping gene GAPDHusing the 2-
ΔΔCT method. Western blot has been perfomed using anti-PU.1 and anti-JDP2
(Abcam)according to manifacture instructions. 
Results: We revealed both PU.1 and JDP2 are down regulated in MDS. In
addition, our data suggests that PU.1 and JDP2 expression inversely correlates
with disease, with expression of these genes consistently reducing according
to IPSS-R groups. Furthermore, a positive correlation of PU.1 and JDP2expres-
sion <R=O.9333, s=0.0004 >, provides additional evidence that suppression
of JDP2 by PU.1 could contribute to the pathogenesis of AML. Notably, PU.1
and JDP2 do not correlate to the same extent in normal HSCs, indicating that
cofactors are required for PU.1 to exert its JDP2-regulating function and that
such cofactors are not present under normal conditions. To confirm that JDP2
suppression is a direct result of reduced PU.1 we performed PU.1-knockdown
in K562 cells stably expressing PU.1 short interfering RNAs versus control
cells. These analyses reveal only a partial reduction in JDP2 expression when
analysed by RT-PCR and Western blot, suggesting a more complex regulatory
mechanism. Additionally, both PU.1 and JDP2 expression was recovered by
treatment with azacitidine, which is routinely used to treat MDS, suggesting an
involvement in treatment response.
Summary/Conclusions: PU.1 and JDP2 expression correlates with patients
prognosis highlighting a potential role as new diagnostic and prognostic mark-
ers in MDS.
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DECREASED EXPRESSION OF DECORIN, A WNT-PATHWAY RELATED
PROTEIN, IN MESENCHYMAL STEM CELLS OF PATIENTS WITH
MYELODYSPLASTIC SYNDROMES 
K. Pavlaki1,*, A. Batsali1, M. Lazaris1, S. Mastrodemou1, M. Ximeri1,
C. Pontikoglou1, H. Papadaki1
1Department of Haematology, University of Crete School of Medicine, Heraklion,
Greece
Background: Myelodysplastic syndromes (MDS) are clonal disorders of the
haematopoietic stem cells (HSCs) characterized by inefficient bone marrow
(BM) haemopoiesis and increased risk for leukaemic evolution. Ineffective BM
haemopoiesis in MDS has also been linked with an abnormal microenvironment
that may sustain or even induce the aberrations within the HSC compartment.
We have previously shown that the stroma progenitor cells, namely the mes-
enchymal stem cells (MSC), in MDS patients display impaired clonogenic and
proliferative potential, reduced haemopoiesis supportive capacity and down-
regulation of the canonical Wnt-signaling pathway. 
Aims: Decorin, a small leucine-rich proteoglycan, and galectin-3, a member of
b-galactosidase specific lectin family, are components of the extracellular matrix
of the BM microenvironment. Both proteins have been implicated in the canon-
ical Wnt-pathway participating therefore in cell growth and proliferation. The
aim of the study is to assess the expression of decorin and galectin-3 in MSCs
of MDS patients, evaluating their implication in the abnormal Wnt-signaling pre-
viously reported in MDS. 
Methods: BM MSCs were isolated from 12 patients with lower risk MDS aged
51 to 75 years (median 67.5 years) and 12 haematologically healthy subjects
aged 50 to 73 years (median 63.3 years), after informed consent. The study
has been approved by the Ethics Committee of the University Hospital of Her-
aklion. BM MSCs were characterized according to international system for
human cytogenetic nomenclature (ISCN) criteria, expanded and re-seeded
for  two passages (P). Total RNA was extracted from culture-expanded P2
MSCs and amplified by real-time PCR for the evaluation of decorin and galectin-
3.  Relative gene expression was calculated by the ΔCt method. 
Results: A statistically significant decreased expression of decorin was identi-
fied in MSC of MDS patients (mean 1.338, SD 0.84) compared to the healthy
individuals (mean 1.830, SD 0.71). (P<0.05). Galectin-3 expression was also
decreased in MDS patients (mean 0.6758, SD 0.50) compared to controls
(0.9395, SD 0.50), although not at a statistically significant levels. 
Summary/Conclusions: MSCs from MDS patients display statistically signif-
icant decreased expression of decorin and a tendency towards decreased
expression of galectin-3 in BM MSCs compared to healthy individuals. These
preliminary data indicate that extracellular matrix proteins may have a role in
the disturbed Wnt-pathway signaling and abnormal MSC function in MDS
patients. The underlying mechanisms are currently under investigation. 
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CLINICAL FEATURES, CYTOGENETIC STUDY AND OUTCOME OF ADULT
MYELODYSPLASTIC SYNDROMES: REVIEW OF 101 CASES, A SINGLE
CENTER EXPERIENCE IN ALGERIA
S. Taoussi1,*, Y. Bouchakor-Moussa1, M. Abad1
1Hematology, EHS ELCC CAC, Blida, Algeria
Background: Myelodysplastic syndromes (MDS) are heterogeneous disorders
defined as clonal diseases involving hematopoietic stem cells and even char-
acterized by cytopenias, with a high risk of leukemic transformation. Morpho-
logical analysis of peripheral blood (PB) and marrow aspirates or bone marrow
biopsies is the first step that ensures a diagnosis of MDS. Cytogenetic studies
are important means of defining different prognostic groups and even of show-
ing how patients are eligible for this or that treatment. We conducted the first
study including conventional karyotyping and fluorescent in situ hybridization
(FISH) for MDS in our country.
Aims: Our study was aimed to evaluate outcome of MDS regarding IPSS and
IPSS-R classification in an emerging country.
Methods: Between January 2012 to December 2016, 101 patients with MDS
were consecutively diagnosed. Frequent genetic abnormalities in MDS were
screened by R-banding karyotype and metaphasic and interphasic FISH using
a panel  including six probes (5q-,7q-,20q-, del(17p13), MLL, Inv(3) t(3;3).
Patients were stratified into risk groups according to IPSS and IPSS-R scores;
survival probabilities were estimated using the Kaplan-Meier method.
Results: Among these 101 pts, 58 were male with a sex ratio=1, 35; range in
age is from 18 years to 94 years with a median of 61, 6 years. Median hemo-
globin value was 80 g/L (29-150), more than 60% of patients had severe anemia
mainly in the low risk group; the median absolute neutrophil count was 3 G/L
(0,060-13, 5), and the median platelet count was 144 G/L (5-659). Median bone
marrow blast value was 4% (0-18). Cases were classed by cytomorphology
FAB as RA (N=45), REAB (n=34), RARS (n=16), other (n=6). Classification by
WHO 2008 included CRDU (n= 31 of which RA : 18, RT : 10, RN : 3), CRDM
(n= 16), RAEB-1 (n=22), RAEB-2 (n= 13), RARS (n= 15), Isolated 5q- (n=4).
Among 101 patients, cytogenetic abnormalities by R banding karyotype (n=
84) and FISH (n=101) were found in 41 cases (41%) distributed as single anom-
aly (n= 19) , double anomaly (n=5) and complex (n=17). The main cytogenetic
abnormalities seen were isolated 5q deletion (n=4), isolated 7q deletion (n=2),
isolated 20q deletion (n= 6), isolated trisomy 8 (n=2), 17p13 deletion (n=6), - Y
(n=1), complex aberrations ≥3 (n=6) , complex aberrations ≥5 (n=6), complex
aberrations ≥7 (n=5), others (n=3). IPSS   was assessed in 84 patients: 27%
(low risk), 44% (intermediate 1) , 24% (intermediate 2), 5% (high risk). IPSS-R
was assessed in 84 patients (18% very low risk, 30% low risk, 22,5% interme-
diate, 15,5% High risk, 14% very High risk). Leukemic transformation into AML
occurred in 33% of patients in a median time of 12 months. According to IPSS,
the median OS time survival is not reached for low risk group, 41 months (m)
for Intermediate 1 risk, 11 m for Intermediate 2 risk, and 4 m for High risk.
According to IPSS-R, the median OS time survival is not reached for Very low
risk, 43 m for low risk, 24 m for Intermediate risk, 18 m for High risk and 4 m
for very high risk.
Summary/Conclusions: Our results are in agreement with those previously
published regarding demographic features, distribution of recurring cytogenetic
abnormalities and prediction of survival. Myelodysplasias are among the most
difficult haematological diseases to treat. Treatment of low risk and high risk
myelodysplasia are completely different, the last group carrying a great risk of
leukemic transformation. For all these reasons, application of the new tools to
classify MDS is of an major importance. This is especially true in emerging
countries where few therapeutic means are available, hence the need to predict
the prognosis of these diseases in order to better target treatments. To the best
of our knowledge, it is the first study conducted in our country.
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CLINICAL EVOLUTION OF ACUTE MYELOID LEUKEMIA WITH
MYELODYSPLASIA-RELATED CHANGES 
G. Pinto1,*, P. Herrera1
1Hematology, HOSPITAL RAMON Y CAJAL, Madrid, Spain
Background: Acute myeloid leukemia (AML) with myelodysplasia-related
changes (MRC) is usually classified associated to worse clinical course and
poor prognosis compared other AML subtypes. Differences between treatment
modalities according to age, and the response to treatment, would help to pro-
vide specific anti-AML treatment in this difficult scenario.
Aims: The objetive of this study is analyze the clinical features and course of
patients with AML with MRC, in order to evaluate the impact of different thera-
peutic regimens in this subgroup. 
Methods: We report an unicentric retrospective study of 76 patients with AML
with MRC, over the past ten years in a single institution in Spain. We analyzed
the overall survival (OS) among the subgroup of patients with over or under 65
years, and the different types of treatment that has been offered. 
Results: Median age was 69 years with a male predominance, and 66% was
preceded by a known myelodysplastic syndrome with a median interval of 18
months to progress to AML. The more frequent genetic abnormalities in
descending order were trisomies, del(5q), and del(7q)/-7. The patients aged
>65 and <65 were 70% and 30%, respectively. The patients aged >65 received
DNA hypomethylating agents (40%), anthracycline-cytarabine combinations
(9%), low-dose cytarabine or hydroxyurea (17%), and supportive measures
(34%). The patients aged <65 received induction chemotherapy with anthra-
cycline-cytarabine combinations so as to continue with  post-consolidation
management with allogenic transplantation, but the 44% died over the induction
chemotherapy (OS: 2.2 months). The OS in patients aged <65 was 20,2 months
in chemotherapy plus allogenic transplantation. The OS in patients aged >65
was 10,3 months in the group of anthracycline-araC combinations, 3,81 months
in the DNA hypomethylating agents group, 2,8 months in the low-dose of
AraC/hydroxiurea, and 0,5 months in supportive measures group (Figure 1).
Figure 1.
Summary/Conclusions: The AML with MRC patients is a group with difficult
treatment decisions and poor prognosis, in whom only the chemotherapy plus
allogenic transplantation treatment manage  long-term survival. In patients
aged >65, there is not a significant difference among groups, although the
chemotherapy with anthracycline-cytarabine seems to reach a better OS  ver-
sus other available treatments. 
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SAFETY, EFFICACY, AND PHARMACOKINETICS OF INTRAVENOUS
RIGOSERTIB IN JAPANESE PATIENTS WITH RECURRENT/RELAPSED
OR REFRACTORY MYELODYSPLASTIC SYNDROMES: A MULTICENTER,
OPEN-LABEL, PHASE I STUDY
M. Ogura1,2,*, Y. Kobayashi3, S. Kubonishi4,5, M. Hidaka6, T. Uchida2,
Y. Takamatsu7
1Department of Hematology, Tokai Central Hospital, Kakamigahara, 2Depart-
ment of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya,
3Department of Hematology, National Cancer Center Hospital, Tokyo, 4Depart-
ment of Hematology, National Hospital Organization Okayama Medical Center,
Okayama, 5Department of Hematology, Red Cross Society Himeji Hospital,
Himeji, 6Department of Hematology, National Hospital Organization Kumamoto
Medical Center, Kumamoto, 7Division of Medical Oncology, Hematology, and
Infectious Diseases, Fukuoka University Hospital, Fukuoka, Japan
Background: Rigosertib, a novel phosphoinositide 3/polo-like kinase pathway
inhibitor, selectively induces the apoptosis of cancer cells and is safe and well
tolerated in pts with recurrent/relapsed or refractory MDS.
Aims: We conducted a multicenter, open-label, Phase I study of intravenous
rigosertib to evaluate its safety, efficacy, and pharmacokinetics and to determine
the recommended dose (RD) for Japanese pts.
Methods: The key eligibility criteria were as follows: recurrent/relapsed or
refractory MDS; age: 20 or older; FAB classification (RA, RARS, RAEB, RABE-
t, and CMML), excepting patients at IPSS low- or Int-1 risk with respect to RA;
ECOG PS of 0 to 2; no major organ dysfunction; and written informed consent.
Rigosertib (1,200 and 1,800 mg daily) was administered intravenously for 72
h, followed by 11-day monitoring in one 14-day cycle. The primary endpoint
was dose-limiting toxicity (DLT). The secondary endpoints were 1) safety as
assessed with adverse events (AEs) and laboratory results; 2) efficacy as
assessed with the International Working Group 2006 criteria; and 3) pharma-
cokinetics.
Results: Between June 2012 and February 2015, 7 male and 2 female pts
(median age: 70; range: 63-84) were enrolled, and 3 and 6 pts were eventu-
ally assigned to the 1,200 and 1,800 mg arms, respectively. According to the
FAB classification, 6, 2, and 1 pts were categorized to RAEB, RAEB-t, and
RA, respectively. There were 3 pts each in the IPSS Int-1, Int-2, and high-
risk groups, with 1 and 2 pts in each risk group in the 1,200 and 1,800 mg
arms, respectively. The median numbers of delivered cycles in the 1,200 and
1,800 mg arms were 4 (2 to 4) and 2 (1 to 8), respectively. DLT occurred not
in the 1,200 mg arm but in the 1,800 mg arm: 5 episodes of ≥grade 3 non-
hematologic toxicities in 2 pts. One pt developed 2 episodes of sepsis and
meningitis, and the other 3 episodes of hypochloremia, pustular rash, and
hyponatremia. Thus, 2 among 6 pts in the 1,800 mg arm developed DLT,
which led us to conclude that 1,800 mg/day is the RD for Japanese pts. No
deaths occurred during the study period. However, 5 pts died during follow-
up, 4 of whom died from primary disease progression. Furthermore, 1 pt died
of grade 5 bacterial pneumonitis that was rated to “Unrelated”. In the 1,200
mg arm, 2 cases each of grade 3/4 thrombocytopenia, grade 4 neutropenia,
and grade 3/4 leukopenia, as well as 1 case of grade 3 lymphopenia devel-
oped. In the 1,800 mg arm, 3 cases of grade 3/4 leukopenia, 2 cases each
of grade 3 CD4 lymphopenia, grade 4 thrombocytopenia, and grade 3/4 neu-
tropenia, as well as 1 case each of grade 4 lymphopenia, increased C-reac-
tive protein, erythropenia, and hypochloremia developed. Three cases of
SAEs, including grade 4 meningitis, grade 4 sepsis, and grade 3 catheter-
related infection, developed in the 1,800 mg arm. Stable disease was
obtained in 2 pts in the 1,800 mg arm. Hematological remission, hematolog-
ical improvement, and cytogenetic response were not obtained in the two
arms. The Cmax values in the 1,200 and 1,800 mg arms were 5.99±1.50 and
6.74±2.39 μg/mL, respectively. The AUC0-∞ values were 314.6±142.7 and
324.8±83.9 μg × hr/mL, respectively.
Summary/Conclusions: This Phase I study showed that intravenous rigosertib
(1,800 mg daily) for consecutive 72 h was well tolerated, indicating that this is
the RD for Japanese pts with MDS similar to a Phase III study in the U.S.
Based on these clinical outcomes, Japanese pts with MDS are participating in
a global randomized Phase III study to compare rigosertib with physicians’
choice of treatment.
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IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE
IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH
AZACITIDINE
S. Improta1, M.R. Villa1,*, P. Della Cioppa1, A. Lucania1, M. Esposito1,
G. Nitrato Izzo1, A. Gagliardi1, L. Mastrullo1
1UOC Ematologia PO Ascalesi ASL Napoli1 Centro, Naples, Italy
Background: The goals of treating older patients with Myelodysplastic Syn-
drome (MDS) are different than for younger patients. Few elderly patients are
able to pursue an allogeneic stem cell transplant. Azacitidine (AZA) improves
long-term outcomes of higher-risk MDS patients and is now the reference front-
line therapy of higher-risk MDS not eligible for allogeneic stem cell transplant.
Anaemia is the most common symptom of MDS and most patients become
transfusion-dependent with the risk of iron overload. Deferasirox is an orally
available iron chelator administered once-daily in transfusion-dependent
patients with various chronic anaemias. Its efficacy has been established in
controlled clinical trials.
Aims: We report our experience on using the azacitidine in patients with high-
risk MDS, evaluating the efficacy and safety. Concomitant treatment with
deferasirox was performed in a routine clinical setting following Consensus
Guidelines on Iron Chelation Therapy.
Methods: In our Institution from October 2009 to January 2017 we have
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treated 32 elderly patients (19 male and 13 female, median age 76 years, r.
71-88) affected by HIGH-RISK MDS (IPSS INT-2/HIGH). Patients received
subcutaneous azacitidine at 75mg/m(2) daily for 7 days every 4 weeks. All
patients completed at least 6 cycles of therapy. 12/30 (40%) patients under-
went more than 8 cycles of therapy. 18/30 patients underwent as well iron
chelation therapy with deferasirox receiving a starting dosage of 10
mg/kg/day, subsequently titrated according to serum ferritin (SF) measured
monthly.
Results: Complete response (CR), partial response (PR), and hematologic
improvement (HI) were observed in 2 (7%), 5 (17%), and 12 (40%) patients,
respectively. The median number of cycles to clinical response was 4 (range
4-8). The 2-year rate of acute myeloid leukemia-free survival was 48%. Five
serious adverse events occurred in five patients with one fatal outcome. 16 out
of 18 patients who showed any hematologic response (CR+PR+HI) meeting
International Working Group 2006 criteria had also performed deferasirox ther-
apy. No increased toxicity was noted when deferasirox was used concomitantly
with azacitidine.
Summary/Conclusions: Our results confirm the effectiveness of the therapy
with azacitidine in HIGH-RISK MDS elderly patients with acceptable toxicity
profile. Peripheral cytopenias were the most commonly
occurring adverse event, with gastrointestinal adverse events and injection-
site reactions among the most commonly occurring non-
haematological adverse events. In conclusion, azacitidine is an important
agent for use in the treatment of elderly patients with MDS. Furthermore con-
current use of deferasirox in patients with iron overload seems to significantly
improve the hematologic response by reducing transfusion requirement.
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EXPLORING THE RISK OF RED CELL ALLOIMMUNIZATION IN 
MYELODYSPLASTIC SYNDROMES. TO WHAT EXTEND COULD
CYTOGENETIC ANALYSIS AT DIAGNOSIS PREDICT THIS RISK?
I. Koutsavlis1,*, J. Falconer2, J. Fleming3, H. Roddie1
1Haematology, 2Blood Transfusion Service, 3Cytogenetics Service, NHS LOTH-
IAN, Edinburgh, United Kingdom
Background: Red cell alloimmunization poses a huge burden for the blood
transfusion services as it may be associated with crossmatching difficulties,
haemolytic transfusion reactions and potentially severe clinical consequences
for the transfused patient. Collectively, alloimmunization appears to be higher
in patients with myelodysplasia (MDS) and chronic myelomonocytic leukaemia
(CMML) with a rate somewhat around 15%. Identification of patients at risk of
developing alloantibodies would be of clinical significance as antigen negative
red cells could be crossmatched in advance for use in clinical practice. Largely,
studies have failed to predict this cohort of patients and little is known regarding
identifiable risk factors. 
Aims: To this end, we focused on exploring the cytogenetic profile from patients
with MDS and CMML along with demographic characteristics as  risk factors
for alloimmunization.
Methods: A retrospective analysis was performed in 360 transfused patients
with MDS (74.4%) and CMML (25.6%) registered in our local database between
1980 and 2016. Prognostic variables (age, sex, disease subtype) were
assessed using a multivariate prediction model in SPSS statistical software.
Cytogenetics at diagnosis were available in 228 of the above patients and uni-
variate analysis was performed separately.
Results: The mean age at diagnosis was 73 years (range 20-95) with 58.3%
male patients.  Overall, 45 patients (12.5%) formed 76 antibodies [68 alloanti-
bodies, 8 autoantibodies] with 42% of them developing more than 1 antibody.
5 additional patients developed autoantibodies without alloantibodies. Alloan-
tibody specificities were as follows: E (22 cases), C (8), K (7), Cw/ Jka/ Kpa (5
cases each), Lua (4), e/ Fya (3 cases each), M (2), c/ D/ Chido/ Bga (1 case
each). Collectively, alloantibodies against the Rh and Kell systems encountered
in 69% of this cohort. 6 out of 8 patients with anti-C had also developed a sec-
ond antibody. In a regression model, none of the following variables reached
statistical significant level as predictors for immunization; age (p=0.59), sex
(p=0.07), MDS WHO subtype (p=1.0). 228 patients had known cytogenetics at
diagnosis. Normal profile (46, XY or 46, XX) was encountered in 58.8%. Simi-
larly, univariate analysis of this cohort (normal versus abnormal cytogenetics)
showed odds ratio 1.1 with no statistical significant point (p=0.64). Further sub-
group analysis was performed to explore whether the risk was increased in
patients with poor or very poor cytogenetics as per IPSS-R. Descriptive statistics
showed; very good/ good risk cytogenetics 69.7%, intermediate 12.7% and
poor/ very poor 17.5%. Logistic regression analysis revealed no association
between cytogenetic groups and risk of alloimmunization (p=0.89, p=0.96 and
p=0.84 respectively).
Summary/Conclusions: The rate of alloimmunization in our cohort of patients
was 12.5%, slightly lower compared to published studies. The most common
alloantibody found was anti-E. Prognostic variables included in analysis (age,
sex, MDS type but also cytogenetic profile) are not significant predictors of
alloimmunization and further studies are needed to investigate other possible
risk factors. Prophylactic Rh and Kell antigen matched cells, when possible,
would be a reasonable strategy until further knowledge is acquired.
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PROGNOSTIC MARKERS THAT PREDICT THE OUTCOME OF REDUCED
INTENSITY CONDITIONING TRANSPLANT IN ADULT PATIENTS WITH
MYELODYSPLASTIC SYNDROMES: A SINGLE CENTER EXPERIENCE
S. Elashwah1,*, S. Shamaa2, H. Kamel3, M. Samra4, E. Azmy1
1Clinical Hematology, 2Medical Oncology, Mansoura University, Mansoura,
3Clinical Hematology, 4Medical Oncology, Cairo University, Cairo, Egypt
Background: Myelodysplastic syndromes (MDS) are a heterogeneous group
of hematologic diseases, characterized by a clonal abnormality of hematopoietic
stem cells. The incidence of MDS is age-dependent. The treatment approach
is to categorize patients into lower or higher risk MDS and to select a suitable
treatment accordingly. HCT offers potentially curative therapy for patients with
MDS. A reduced intensity conditioning (RIC) regimen was used to reduce the
toxicities associated with transplant procedure. The main concept of RIC relay
upon adoptive immunotherapy especially in the low risk patients allowing the
graft versus leukemia to occur. 
Aims: This study aimed to investigate the outcome of allogeneic peripheral
blood stem cell transplantation after reduced intensity conditioning regimen for
adult patients with MDS, the effect of different prognostic factors on outcome
and the effect of chronic GVHD according to IPSS risk.
Methods: A retrospectively study analyzed the fifty-one patients with MDS who
underwent transplantation at the BMT unit at Nasser Institute during a period
of 10 years, by the RIC regimen from HLA identical donor using peripheral
blood stem cell. Outcomes analyzed the incidence of acute and chronic GVHD,
disease free survival (DFS) & overall survival (OS).
Results: They were 31 males (60.8%) and 20 females (39.2%). Their ages
ranged from 17 to 60 years, with mean age±SD of 34.5±10.1 years, including
refractory cytopenia with multiple dysplasia (RCMD) in 14 patients (27.5%), MDS
–U in 13 patients (25.5%), refractory anemia (RA) in 12 patients (23.5%), refrac-
tory anemia with excess blasts II (RAEB II) in 6 patients (11.8%) and MDS with
hypocellular bone marrow in 4 patients (7.8%) and refractory anemia ring sider-
oblasts (RARS) in 2 patients (2%). According to IPSS classification, 11 patients
(21.6%) were low risk, 28 patients (54.9%) were intermediate-I risk group, and 9
patients (17.5%) were intermediate-II & 3 patients (5%) were high risk group.
The incidence of acute and chronic GVHD were 51.1% and 28.6% respectively.
The 5- year estimate for overall survival of the whole group was 21.8%. In uni-
variate analysis, covariates associated with a better OS were recipient age <40
years (p=0.02) and the presence of cGVHD (p=.002). On multivariate analysis
the presence of cGVHD is significant predictor of survival (p=0.04). Also cGVHD
significantly improve the OS for low and high risk MDS group (p= 0.02 and 0.03
respectively). While presence of acute GVHD, IPSS & interval between diagnosis
and transplant weren’t significantly affect OS (p>0.05). The 5- year estimate for
DFS of the whole group was 28.6%. On multivariate analysis the presence of
cGVHD significantly reduce relapse (p=0.029). 
Summary/Conclusions: The presence of cGVHD significantly improved OS
and reduced the risk of relapse in patients with MDS. We also found that the
presence of cGVHD significantly improved OS especially in high-risk patients
group, which suggests that the GVL effect may be beneficial in high-risk patients
who do not receive intensive preparative regimens. 
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MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH
ERYTHROPOIESIS STIMULATING AGENTS IN REAL-LIFE EXPERIENCE:
AN UPDATE FROM RECAMDS
C. Cerchione1,*, O. Vitagliano1, R. Della Pepa1, G. Cerciello1, A.E. Pareto1,
M. Di Perna1, I. Soriente2, P. Danise3, A.M. D’Arco3, F. Alfinito4, F. Pane4
1Hematology, Ematologia e trapianto/au federico ii, 2Hematology, Ospedale
Umberto I, Napoli, 3Hematology, Ospedale Umberto I, Nocera Inferiore (SA),
4Ematologia e trapianto/au federico ii, Napoli, Italy
Background: Erythropoiesis stimulating agents (ESAs) are the frontline treat-
ment in low-risk anemic MDS patients and an employment of this therapy in
the earlier stage of the disease can delay the need for RBC transfusion, hypo-
thetically by slowing the disease course. It’s matter of debate whether the clin-
ical response is a result of proliferation and maturation of the dysplastic clone
or stimulation of residual normal erythropoiesis by ESAs.
Aims: Macrocytosis is one of the cytological hallmarks of dyserithropoiesis in
MDS: an analysis of the erythropoietic response to ESAs therapy in a cohort
of anemic non trasfusion-dependent MDS patients, enrolled in a retrospective
register, RECAMDS, subgroup of Italian register, was performed.
Methods: 183 patients, treated with standard-dose ESAs, have been retrospec-
tively analyzed (Table 1). Data analysis was performed, according to IWG 2006
criteria, at the baseline, after 3 and 6 months of continuous treatment, with a sub-
analysis of the patients according to WHO and R-IPSS risk stratification. ESAs
were started at mean Hb concentration of 9.31 g/dl, mean serum EPO concen-
tration: 51 mU/L, after a mean time from diagnosis of 6 months (r.1-118).
Results: Overall response rate(ORR) was 83.6% (153/183), no difference
among WHO and IPSS subgroups was found: 132/183 (72.1%) achieved
response after 3 months of treatment, while other 21/183 (11.2%) after 6
months. 19 patients with stable disease (non-responders, according to IWG
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criteria), in which treatment was continued, achieved response after 9 months.
In the macrocytic-responders group 83.2% exhibits again macrocytosis after 3
months, while 16.8% become normocytic. In the normocytic-responders group
89.8% exhibits again normocytosis, while 10.2% become macrocytic: in these
patients, after 3 months, there was a contemporary worsening in neutropenia
and thrombocytopenia, with transfusion-dependence, regarded as first signs
of progression of disease. Non-responders were 30/183 (16.3%): in the macro-
cytic non-responders group 89% exhibit again macrocytosis after 3 months,
while 11% become normocytic; in the normocytic group 76% exhibits again
macrocytosis, while 24% become normocytic.
Table 1.
Summary/Conclusions: These preliminary data can suggest that, in the
majority of MDS patients responsive to ESAs, the increase of Hb concentration
occurs mainly stimulating erythroid production in MDS clones; in the minority
of patients probably it happens recruiting residual polyclonal erythropoiesis. It
is interesting to note that stimulating effects of ESAs last even when the expres-
sion of dysplasia progresses.
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CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES WITH 
TRANSFORMATION TO ACUTE LYMPHOBLASTIC LEUKAEMIA
F. Martins1, J. Pouw-Schoumans2, R. G. Racila3, O. Spertini1, S. Blum1,*
1Haematology, 2Cytogenetics, Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland, 3Haematology, University clinics Freiburg, Freiburg, Germany
Background: Myelodysplastic syndromes are heterogeneous diseases with
variable probability of developing a transformation to acute leukaemia. The
vast majority of these cases present a transformation to acute myeloid
leukaemia. We here describe a series of 4 cases of MDS/CMML with evolution
to acute lymphoblastic leukaemia. These events are very rare and are to date
only published as single cases.
Aims: The aim of these study is to better define cases of MDS transforming to ALL.
Methods: We describe 4 cases of patients suffering from MDS who in the
course of their disease presented with ALL. Three of these cases presented in
1 centre, 1 in the other, all cases were documented in a 17-year time span.
We than performed a literature research including at the moment 37 cases of
MDS transforming to ALL described as case reports.
Results: Subtypes of MDS are varying from low risk MDS with deletion (5q)
(del(5q)) to refractory anaemia with excess of blasts in transformation (RAEB-
T), classified as AML in newer WHO classifications (2008 and 2016) and CMML,
classified as MDS/MPS nowadays. Even if MDS subgroups are manifold, cyto-
genetic results are less so. Two of the 4 patients described demonstrated KMT2A
rearrangements, 1 already at MDS presentation, the other at ALL presentation.
One patient presented with del(5q). Of the 37 cases we identified in the literature,
7 presented with del(5q) and 2 showed with anomalies of the 11q23 locus.
Summary/Conclusions: KMT2A is known to be a gene involved in myeloid neo-
plasms as well as in acute lymphoblastic leukaemia. In a small series of cases
like this one, it is not excluded that ALL following MDS is only by chance and
“bad luck”, but at least in the patient showing the same translocation at MDS
presentation and at ALL presentation, both diseases seem to be related. MLL as
a cytogenetic event enabling the disease a switch from one phenotype (myeloid)
to the other (lymphoblastic) could be a possible explanation for this phenomenon.
KMT2A rearrangement in MDS is an extremely rare event, but could explain part
of these rare changelings of MDS transforming to ALL. Further studies are needed
to confirm this hypothesis, and molecular examination is needed to characterise
the event enabling a myeloid phenotype to switch to a lymphoblastic one. The
reason why del(5q) seems to be present in a high proportion of MDS patients
transforming to ALL is not clear, further studies need to be performed.
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IMMUNOSUPPRESSIVE THERAPY AS FIRST-LINE TREATMENT OF
PATIENTS WITH PRIMARY MDS
N. Klimkovich1,*, D. Suvorov2, L. Kolbasko2
1hematology, Byelorussian Medical Academy of Post-Graduate Education,
2hematology, Public Health Institution «Municipal Clinical Hospital № 9», Minsk,
Belarus
Background: Myelodysplastic syndromes (MDS) are included into a hetero-
geneous group of clonal blood diseases characterized by peripheral cytopenias,
dysplastic features of hematopoietic precursors, progressive deterioration and
a high risk of transformation into leukemia. MDS occur in several versions that
differ in frequency of appearance, the duration of the course and the probability
of transformation into acute leukemia. The choice of therapy for a particular
patient is determined by the morphological variant of the disease, the prognostic
group, age and comorbidity. In hypoplastic cases of MDS are often used
immunosuppressive therapy.
Aims: Analysis of the effectiveness of immunosuppressive therapy in patients
with primary MDS
Methods: The research included 19 patients with primary MDS from 22 to 58
years (median age 46 years, 11 male, 8 female). The diagnosis was made
according to the criteria of the WHO classification of myeloid neoplasms in
2008. The materials were taken only after signing by patients informed consent
form to participate in the research. The calculations are performed in the R
version 3.1.3 statistical package.
Results: There were patients with defined MDS subtypes: RA in 52,6%, RCMD
in 31,6 and RAEB in 15,8%. Hypoplastic form of MDS were diagnosed in 63,2%
patients. The increased number of lymphocytes in the bone marrow of patients
were 52,6%, accumulation of lymphocytes in the bone marrow biopsy – in
36,8%. Cytogenetic abnormalities were found in 21% of patients (in 5,3% com-
plex and in 15,7% isolated). All patients used immunosuppressive therapy as
a first-line treatment: Antithymocyte globulin and Cyclosporine A (CsA) in
15,8%, monotherapy with CsA in 84,2%. CsA therapy started at a dose of 5
mg/kg per day. Dose correction performed depending on the concentration of
CsA in the serum and toxicity. Median treatment was 143 days (36…1253
days). The response rate to CsA treatment was considered a complete remis-
sion (normalization of blood and bone marrow), partial remission (improvement
of blood counts for more than 50% and no dependence on transfusions of
blood components) or improvement (reduction in transfusion requirements by
50% or more). Complete remission was achieved in 10,5% of patients (only
variant RA). Partial remission was obtained in 31,6% (variants RA and RCMD)
and improvement in 36,8% (variants RA, RCMD and RAEB). There was no
response to treatment in 21,1% of patients (variants RCMD and RAEB). Pos-
itive effect on immunosuppressive therapy significantly more likely achieved in
patients with hypoplastic forms MDS (57,9%) and the presence of clusters of
lymphocytes in the bone marrow biopsies (36,8%). Dependence of treatment
efficiency and cytogenetic abnormalities not detected.
Summary/Conclusions: The effectiveness of immunosuppressive therapy in
MDS associated with a variant of the disease, bone marrow cellularity and the
bone marrow lymphoid infiltration. The greatest effect of the immunosuppres-
sive therapy can be expected in patients with hypoplastic MDS and accumu-
lation of lymphocytes in the bone marrow biopsy.
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VITAMIN D IS ASSOCIATED WITH SEVERITY OF DISEASE AS
EXPRESSED BY SUBDIAGNOSIS AND IPSS-R IN PATIENTS WITH 
MYELODYSPLASTIC SYNDROMES AND RELATED DISEASES
C. Müller-Thomas1,*, H. Tüchler2, J. Hecker1, C. Wenk1, C. Peschel1, K. Götze1
1III. Medizinische Klinik, Klinikum rechts der Isar, TU München , München, Ger-
many, 2Ludwig Boltzmann Institute for Leukemia Research, Ludwig Boltzmann
Institute for Leukemia Research, Wien, Austria
Background: Recent findings indicate that vitamin D (VD) might impact
hypomethylating therapy of myelodysplastic syndromes (MDS). Epigenetic
activity of VD is mainly mediated through interaction with its nuclear receptor
(VDR). Activated VDR binds to specific genomic sequences (VD response ele-
ments) which influence gene transcription by histone modification, mainly acety-
lation but also demethylation. Among genes affected by VD/VDR is BGLAP
encoding for the non-collagenous protein osteocalcin (OCN) produced by
osteoblasts and implicated in osteogenesis. Furthermore, it has been shown
that OCN is expressed by activated hematopoietic stem cells in hematological
malignancies.
Aims: We initiated an exploratory study, collecting patients’ data on serum VD,
and osteocalcin (OCN)-levels in 59 unselected patients with MDS, MDS/myelo-
proliferative neoplasm (MPN) and secondary acute myeloid leukemia (sAML).
Methods: Serum VD levels were assessed by measuring 25-hydroxyvitamin
D (25(OH)D), the biochemical indicator of VD status. Analysis was done by
chemiluminescence immunoassay. Intact OCN is unstable due to protease
cleavage between amino acids 43 and 44. The N-MID-fragment, resulting from
cleavage, is considerably more stable. Measurement of both intact OCN and
the stable N-MID-fragment was effectuated by electrochemiluminescence
immunoassay. 
Results: We found median serum 25(OH)D levels (normal range 30-100
ng/ml) of 16 ng/ml (RA, RARS, n=35), 23 ng/ml (RAEB-1/2, sAML, n=16),
and 20 ng/ml (MDS/MPN, n=8) (p=0.273).When classified by IPSS-R, median
serum 25(OH)D levels were 18 ng/ml in “(very) low” (n=20), 16.5 ng/ml in
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“intermediate” (n=14), and 29.5 ng/ml in “(very) high” (n=6) with
p=0.102.Regarding cytogenetic risk classification median serum 25(OH)D
levels were 18 ng/ml in “(very) good” (n=48), 19 ng/ml in “intermediate” (n=8),
and 18.5 ng/ml in “(very) poor” (n=4) cytogenetic risk patients (p=0.738).Medi-
an serum OCN levels (normal range 11-46 ng/ml) were 19 ng/ml (RA, RARS,
n=33) and 16.2 ng/ml (higher-risk MDS/sAML, n=16), (p=0.136). IPSS-R risk
classification resulted in median serum OCN levels of 17.4 ng/ml in IPSS-R
“(very) low” (n=17), 16.2 ng/ml in “intermediate” (n=15), and 21.7 ng/ml in
“(very) high” (n=6), (p=0.701). Cytogenetic risk classification had no impact
on median serum OCN levels (p=0.271). We found median serum 25(OH)D
levels (normal range 30-100 ng/ml) of 16 ng/ml (RA, RARS, n=35), 23 ng/ml
(RAEB-1/2, sAML, n=16), and 20 ng/ml (MDS/MPN, n=8) (p=0.273). When
classified by IPSS-R, median serum 25(OH)D levels were 18 ng/ml in “(very)
low” (n=20), 16.5 ng/ml in “intermediate” (n=14), and 29.5 ng/ml in “(very)
high” (n=6) with p=0.102. Regarding cytogenetic risk classification median
serum 25(OH)D levels were 18 ng/ml in “(very) good” (n=48), 19 ng/ml in
“intermediate” (n=8), and 18.5 ng/ml in “(very) poor” (n=4) cytogenetic risk
patients (p=0.738). Median serum OCN levels (normal range 11-46 ng/ml)
were 19 ng/ml (RA, RARS, n=33) and 16.2 ng/ml (higher-risk MDS/sAML,
n=16), (p=0.136). IPSS-R risk classification resulted in median serum OCN
levels of 17.4 ng/ml in IPSS-R “(very) low” (n=17), 16.2 ng/ml in “intermediate”
(n=15), and 21.7 ng/ml in “(very) high” (n=6), (p=0.701). Cytogenetic risk
classification had no impact on median serum OCN levels (p=0.271).
Summary/Conclusions: In summary, our cohort of patients with MDS,
MDS/MPN and sAML show clearly decreased serum VD levels. The prelimi-
nary results suggest a tendency of serum VD levels to increase with higher
risk MDS/sAML which is supported by positive Kendall’s tau (0.210). Serum
OCN levels lie below normal limits, but seem not to be affected by disease
risk. These results suggest specific hypotheses regarding the pathomech-
anism that shall be investigated on an enlarged data set, which we are con-
tinuously collecting.
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JUVENILE MYELOMONOCYTIC LEUKEMIA IN TURKEY:
A RETROSPECTIVE ANALYSIS OF 65 PATIENTS
Ö. Tüfekçi1, Ü. Koçak2, Z. Kaya2, I. Yenicesu2, C. Albayrak3, D. Albayrak3,
S. Yılmaz Bengoa1,*, T. Patıroğlu4, M. Karakükçü4, E. Ünal4, E. Ünal İnce5,
T. İleri5, M. Ertem5, T. Celkan6, G. N. Özdemir6, N. Sarper7, D. Kaçar8,
N. Yaralı8, N. Y. Özbek8, A. Küpesiz9, T. Karapınar10, C. Vergin10, Ü. Çalışkan11,
H. Tokgöz11, M. Sezgin Evim12, B. Baytan12, A. Meral Güneş12,
D. Yılmaz Karapınar13, S. Karaman14, V. Uygun15, G. Karasu15,
M.A. Yeşilipek15, A. Koç16, E. Erduran17, B. Atabay18, H. Öniz18, H. Ören1
1Dokuz Eylül University, İzmir, 2Gazi University, Ankara, 3Ondokuz Mayıs
University, Samsun, 4Erciyes University, Kayseri, 5Ankara University, Ankara,
6İstanbul University, İstanbul, 7Kocaeli University, Kocaeli, 8Ankara Children’s
Hematology and Oncology Training and Research Hospital, Ankara, 9Akdeniz
University, Antalya, 10Dr. Behçet Uz Children Training and Research Hospital,
İzmir, 11Necmettin Erbakan University, Konya, 12Uludağ University, Bursa,
13Ege University, İzmir, 14Şişli hamidiye Etfal training and Research Hospital,
15Bahçeşehir University, 16Marmara University, İstanbul, 17Karadeniz Tech-
nical University, Trabzon, 18Tepecik Training and Research Hospital, İzmir,
Turkey
Background: Juvenile myelomonocytic leukemia (JMML) is a chronic malig-
nant myeloproliferative disease of early childhood 
Aims: To define the status of juvenile myelomonocytic leukemia (JMML)
patients in Turkey, in terms of time of diagnosis, clinical characteristics, muta-
tional studies, clinical course and treatment strategies.
Methods: Data including clinical and labarotory characteristics and treatment
strategies of JMML patients were collected retrospectively from pediatric hema-
tology-oncology centers in Turkey. 
Results: Sixty-five children with JMML diagnosed between 2002 and 2016
in 18 institutions throughout Turkey were enrolled into the study. The median
age at diagnosis was 17 months (range, 2-117 months). Splenomegaly was
present in 92% of patients at the time of diagnosis. The median WBC, mono-
cyte and platelet counts were, 32.9x109/L, 5.4x109/L and 58.3x109/L, respec-
tively. Monosomy 7 was present in 18% of patients. JMML mutational analysis
was performed in 32 out of 65 patients (49%), PTPN11 was the most common
mutation. Hematopoetic stem cell transplantation (HSCT) could only be per-
formed in 28 (44%) patients, majority of being after the year 2012. The most
frequent reason for not performing HSCT was the inability to find a suitable
donor. The median time from diagnosis to HSCT was 9 months (range,2-63
months). The 5-year cumulative survival rate was 33% and median estimated
survival time was 30±17.4 months (95% CI:0-64.1) for all patients. Survival
time was significantly better in the HSCT group (log-rank p=0.019). Older
age at diagnosis (>2 years), platelets less than 40x109/L and PTPN11 muta-
tion were the factors significantly associated with shorter survival time. 
Summary/Conclusions: Although there has recently been improvement in
terms of definitive diagnosis and HSCT in JMML patients, the overall results
are not satisfactory and it is necessary to put more effort into this issue in our
country.
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THE PRECURSOR B CELLS AS A PROGNOSIS FACTOR IN
MYELODYSPLASTIC SYNDROMES
G. Pinto1,*, P. Herrera1
1Hematology, Hospital Ramon y Cajal, Madrid, Spain
Background: Recently, an immunosuppressive enviroment with low number
of precursor B cells at the bone marrow has been related with poor survival in
patients with very low/low and intermediate risk myelodysplastic syndrome
(MS), but this negative impact is unclear yet.  
Aims: The objetive of this study is to establish if there is an negative association
between the percentage of precursor B cells (%PBC) at the time of diagnosis
of MS and progression-free survival. 
Methods: We analyzed 48 patients with IPSS-R very low/low risk (VL/L) and
34 patients with intermediate risk (INT) in the past 10 years in a single institution
in Spain. We reviewed the%PBC CD34+ (CD34+CD10+ or CD34+CD117-)
over total marrow cells  at diagnosis measured by flow cytometry, and we cal-
culated the time of progression-free survival (PFS) defined as the time between
inclusion until progression to refractory anemia with excess blasts type 2
(RAEB-2) or acute myeloid leukemia (AML). The Competing risks regression
test was used to assess the predictive value of PBC in relationship to PFS. 
Results: Median age in both groups was 69 years, and median of progression
to RAEB-2 or AML was 1,96 years in VL/L group and 0,64 years in INT group.
The%PBC was not a predictor of PFS in VL/L group with a sub-hazard ratio
(SHR) of 0,23 (95% CI: 0,003-13,96, P=0,485) neither in the INT group with a
SHR 0,14 (95%CI: 0,001-4,52, P=0,211). We also performed a median split
analysis fo the%PBC with a median value of 0,1% in both groups. In the VL/L
group, patients with a%PBC above the median had a median PFS of 2,48 years
versus 1,99 years for the patients with%PBC below the median. In the INT
group, patients with a%PBC above the median had a median PFS of 1,14 years
versus 0,83 years for the patients with%PBC below the median (Figure 1).
Figure 1.
Summary/Conclusions: Our results not provide evidence in order to establish
a prognostic value between%PBC at diagnosis in IPSS-R very low, low or inter-
mediate MS. 
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TO INFINITY AND BEYOND: NGS IN MDS
A. Barbosa Ribeiro1,2,3,*, R. Tenreiro1, M. Coucelo1, A.T. Simões1, S. Marini1,
L. Ribeiro1, E. Cortesão1,2,3, A.B. Sarmento Ribeiro1,2,3,4
1Department of Clinical Hematology, Centro Hospitalar e Universitário de Coim-
bra, 2Centre of Investigation in Environment, Genetics and Oncobiology –
CIMAGO, 3Applied Molecular Biology and University Clinic of Hematology, Fac-
ulty of Medicine, University of Coimbra, 4CNC.IBILI, University of Coimbra,
Coimbra, Portugal
Background: Myelodysplastic syndrome (MDS) constitutes a heterogeneous
group of hematopoietic stem cell disorders, characterized by peripheral blood
cytopenias in the presence of a dysplastic and hypercellular bone marrow. This
biological heterogeneity is reflected in the clinical course, ranging from an indo-
lent disease to entities with high risk of progression to AML and dismal progno-
sis. Genetic and epigenetic abnormalities are at the core of myeloid neoplasias
development and despite the degree of dysplasia and blast percentages still
being the main features for the WHO classification, a large amount of data has
recently become available on recurring mutations in MDS, mainly due to mas-
sive parallel sequencing techniques.
Aims: Our aim was to search for genetic mutations in a cohort of patients
with MDS.
Methods: We studied a total of 33 patients diagnosed with de novo MDS (WHO
2008 classification), using a Next Generation Sequencing panel comprising 45
myeloid genes.
Results: Patients were 15 male and 18 female, with a median age at diagnosis
of 76 years (52 – 93 years). The MDS subtypes distribution was 16 patients
(48,5%) with RCMD, 4 patients with RARS, 4 with RAEB -1 and 4 with RAEB-
2 (12,1% for each subtype), 3 patients (9,1%) with 5q-Syndrome and 2 patients
(6,1%) with RCUD. These patients were stratified according to the IPSS as
Low-risk (24,2%), Int-1 (33,3%) and Int-2 (18,2%), without any high-risk
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patients. All patients required erythropoiesis stimulating agents and 9 patients
received treatment with azacytidine (AZA), including all the Int-2 patients and
3 lower risk patients who progressed to a higher risk MDS. Estimated cumula-
tive survival at 46 months was 67% with a median OS not reached and median
follow-up time of 34 months. Patients receiving AZA revealed a trend towards
survival benefit (mean survival 54,2 vs 50 months), independent of IPSS and
R-IPSS, but not statistically significant. Mutational analysis revealed that 75,8%
of patients had at least one gene mutation and it was most frequently related
to DNA methylation genes (n=14), particularly in TET2 (n=7 patients) and
DNMT3A (n=6 patients, 7 different mutations) genes. We found a statistically
significant difference between mutations in these genes and lower absolute
neutrophil counts (mean 2,42±0,47 G/L vs 1,33±0,18 G/L; p=0,42). The second
most frequently mutated genes were related to signal transduction pathways
(n=11; JAK1, JAK2, NRAS, CBL, GATA2, SH2B3, CSFR). Patients with these
mutations had significantly lower serum EPO levels (p <0,001; median 32,35
vs 42,70 U/L). Furthermore, patients with such mutations demonstrated a clear
disadvantage in survival analysis, with a median OS of 19 months vs not
reached in patients without mutations (p<0,001), being these results independ-
ent of the IPSS and R-IPSS risk groups. We were also able to identify a trend
towards worst survival in patients with previously described high risk mutations
(TP53, EZH2, ASXL1, RUNX1 and ETV6 genes).
Summary/Conclusions: We conclude that the most frequently detected muta-
tions were related to DNA methylation genes, as described in the literature,
which was independent of the IPSS risk group, being observed in both low-
risk and high-risk patients. These results raise the question whether hypomethy-
lating agents may also be of benefit for lower-risk patients.
We also observed a high frequency of mutations in signal transduction path-
ways which was related to a clear survival disadvantage across all risk groups
of the IPSS and R-IPSS. This unveils the question whether we may be facing
a shift towards the molecular level in MDS risk stratification and if therapies
targeted to such molecules may improve the outcome of these patients.
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CLINICAL FEATURES, CYTOGENETIC STUDY AND OUTCOME OF ADULT
MYELODYSPLASTIC SYNDROMES: REVIEW OF 101 CASES, A SINGLE
CENTER EXPERIENCE IN ALGERIA.
S. Taoussi1,*, Y. Bouchakor-Moussa1, M.T.T. Abad1
1Hematoloy, EHS ELCC CAC, Blida, Algeria
Background: Myelodysplastic syndromes (MDS) are heterogeneous disorders
defined as clonal diseases involving hematopoietic stem cells and even char-
acterized by cytopenias, with a high risk of leukemic transformation. Morpho-
logical analysis of peripheral blood (PB) and marrow aspirates or bone marrow
biopsies is the first step that ensures a diagnosis of MDS. Cytogenetic studies
are important means of defining different prognostic groups and even of show-
ing how patients are eligible for this or that treatment. We conducted the first
study including conventional karyotyping and fluorescent in situ hybridization
(FISH) for MDS in our country.
Aims: Our study was aimed to evaluate outcome of MDS regarding IPSS and
IPSS-R classification in an emerging country.
Methods: Between January 2012 to December 2016, 101 patients with MDS
were consecutively diagnosed. Frequent genetic abnormalities in MDS were
screened by R-banding karyotype , metaphase and interphase FISH using a
panel including six probes ( 5q-,7q-,20q-, del(17p13), MLL, Inv(3) t(3;3).
Patients were stratified into risk groups according to IPSS and IPSS-R scores;
survival probabilities were estimated using the Kaplan-Meier method.
Results: Among these 101 pts, 58 were male with a sex ratio=1, 35; range in
age is from 18 years to 94 years with a median of 61, 6 years. Median hemo-
globin value was 80 g/L (29-150), more than 60% of patients had severe anemia
mainly in the low risk group; the median absolute neutrophil count was 3 G/L
(0,060-13, 5), and the median platelet count was 144 G/L (5-659). Median bone
marrow blast value was 4% (0-18). Cases were classed by cytomorphology
FAB as RA (N=45), REAB (n=34), RARS (n=16), other (n=6). Classification by
WHO 2008 included RCUD (n= 31 of which RA: 18, RT : 10, RN : 3), RCMD
(n= 16), RAEB-1 (n=22), RAEB-2 (n= 13), RARS (n= 15), Isolated 5q- (n=4).
Among 101 patients, cytogenetic abnormalities by R banding karyotype (n=
84) and FISH (n=101) were found in 41 cases (41%) distributed as single
anomaly (n=19), double anomaly (n=5) and complex (n=17). The main cyto-
genetic abnormalities seen were isolated 5q deletion (n=4), isolated 7q deletion
(n=2), isolated 20q deletion (n= 6), isolated trisomy 8 (n=2), 17p13 deletion
(n=6), - Y (n=1), complex aberrations ≥3 (n=6), complex aberrations ≥5 (n=6),
complex aberrations ≥7 (n=5), others (n=3). IPSS was assessed in 84 patients:
27% (low risk), 44% (intermediate 1) , 24% (intermediate 2), 5% (high risk).
IPSS-R was assessed in 84 patients (18% very low risk, 30% low risk, 22,5%
intermediate, 15,5% High risk, 14% very High risk). Leukemic transformation
into AML occurred in 33% of patients in a median time of 12 months. According
to IPSS, the median OS time survival is not reached for low risk group, 41
months (m) for Intermediate 1 risk, 11 m for Intermediate 2 risk, and 4 m for
High risk. According to IPSS-R, the median OS time survival is not reached for
Very low risk, 43 m for low risk, 24 m for Intermediate risk, 18 m for High risk
and 4 m for very high risk.
Summary/Conclusions: Our results are in agreement with those previously
published regarding demographic features, distribution of recurring cytogenetic
abnormalities and prediction of survival. Myelodysplasias are among the most
difficult hematological diseases to treat. Treatment of low risk and high risk
myelodysplasia are completely different, the last group carrying a great risk of
leukemic transformation. For all these reasons, application of the new tools to
classify MDS is of a major importance. This is especially true in emerging coun-
tries where few therapeutic means are available, hence the need to predict the
prognosis of these diseases in order to better target treatments. To the best of
our knowledge, it is the first study conducted in our country.
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IS PRE-TRANSPLANT THERAPY A KEY FACTOR IN INFLUENCING POST
TRANSPLANTATION RELAPSE INCIDENCE IN EXCESS BLAST
MYELODYSPLASTIC SYNDROMES? A SINGLE CENTRE EXPERIENCE
G. Bertani1,*, G. Grillo1, M. Riva1, E. Zucchetti1, E. Ravano1, B. Forno1,
I. Lotesoriere1, L. Crucitti1, R. Cairoli1
1Haematology, Ospedale Niguarda Ca’ Granda, Milano, Italy
Background: The importance of pre-transplant disease burden in myelodys-
plastic sindromes (MDS) as a factor influencing post hematopoietic cell trans-
plantation (HCT) outcome is an important argument of debate. It has been
reported that relapse rate (RR) after transplant is reduced in patients entering
HCT with a blast cell count <5%. However, the effect of a pre-transplant debulk-
ing therapy in reducing RR has not been clearly demonstrated.
Aims: Here we review our data to evaluate if the intensity of pre-transplant
therapy may have influenced post transplant RR.
Methods: In our Institute, we treat all patients with a blast cell count of 10% or
higher with a debulking therapy pre-transplant. This is usually an AML-like,
cytarabine and anthracycline based, intensive chemotherapy (I.C.). In selected
cases fludarabine and cytarabine containing regimens are also used. In the
last ten years, in the context of a clinical trial, a series of patients have received
a less intensive, hypometilating therapy (repeated courses of 5-azacytidine 75
mg/m2subcutaneously for 7 days), as bridge to transplant. Conditioning regi-
men used in MDS patients is busulfan based in younger patients (Bu-Flu, BU-
Cy); in the elderly or less fit patients a RIC regimen (thiotepa  5 mg/kg e.v., flu-
darabine mg/m2x 3 and L-PAM 100 mg/m2) is administered.
Results: In the last ten years we performed 14 HCT (between June 2008 and
september  2016) in patients with MDS with excess blasts. Median patients
age was 63,5 years (range: 49-69), male/female ratio was 9/5. According to
IPSS, 12 out of 14 patients were high/ int-2 (2 int-1), 11/14 had >10% blast
cells (EB-2). According to our centre protocol, we treated 11 patients with EB-
2 and 1 patient with EB-1 (with hypercellular bone marrow) with a debulking
therapy. This was I.C. in 6 patients and 5-AZA in 6 patiens. Two patients with
EB-1 did not receive any therapy pre-transplant. However, both of them are
not evaluable, due to early mortality. Transplant conditioning was RIC in 11/14
patients, myeloablative in 3 cases. The donor was a sibling in 9/14, MUD in
5/14. Four out of six patients treated with I.C. achieved a pre-transplant CR
(67%), compared to one out of six in the 5-Aza cohort (17%).  Four patients
experienced a relapse post HCT, after a median of 8,5 months (4-11). With a
median follow up of 21 months (6-68), post transplant RR was 4/12 (33,3%)
and was not influenced by debulking therapy (I.C. vs 5-Aza, p=0,54), nor by
pre-transplant disease state (CR vs noCR, p=0,22). In fact, 3 out of 6 patients
treated with I.C., but only 1 out of 6 treated with 5-Aza relapsed after transplant.
Three out of four patients who subsequently relapsed had recived RIC trans-
plant; type of transplant was not assocaited with relapse (P=1,0) The only vari-
able that showed a trend for reduced RR was MUD transplant (p=0,08).
Summary/Conclusions: Extreme caution must be used in considering our
data, given the very small patients number. In our cohort, pre-transplant inten-
sive debulking chemotherapy, although obtained an high rate of CR, showed
no effect in preventing relapse. Larger studies are necessary to assess the
real utility of I.C. in this subset of frail patients.
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IRON CHELATION THERAPY IN MYELODYSPLASTIC SYNDROMES AND
IN OTHER TRANSFUSION-DEPENDENT CHRONIC ANEMIAS.
RETROSPECTIVE STUDY OF 69 PATIENTS FROM A SINGLE
INSTITUTION
C. Finelli1,*, C. Clissa2, M. Barraco1, C. De Maio1, M. Stanzani1, S. Parisi1,
S. Paolini1, C. Bosi3, M. Cavo1
1Hematology, S.Orsola-Malpighi University Hospital, Bologna, 2Hematology,
S. Salvatore Hospital, Pesaro, 3Hematology, Guglielmo da Saliceto Hospital,
Piacenza, Italy
Background: Although several recent guidelines recommend iron chelation
therapy (ICT) for iron overload in transfusion-dependent patients (pts) with low-
er-risk  myelodysplastic syndromes (MDS), several barriers may limit the initi-
ation or the continuance of ICT: older age, comorbidities, poor tolerance and
compliance.
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Aims: Therefore, with the aim of assessing the safety and efficacy of ICT in
the daily clinical practice, we retrospectively analyzed our single-center expe-
rience on ICT in MDS and other chronic anemias.
Methods: From October 1997, in our Institution, 69 pts (48 males), median
age: 74 (23-96) yrs, with transfusion-dependent anemia, received ICT, because
of a diagnosis of iron overload, i.e. both a transfusion history of at least 20 units
of RBC and a serum ferritin (SF) higher than 1000 ng/ml.
Results: 40 pts (58%) were affected by lower-risk MDS (IPSS risk: low or inter-
mediate-1), while 13 pts (18.8%) showed a higher-risk MDS (IPSS risk: high or
intermediate-2) but were considered for ICT because of responsiveness to
hypomethylating therapy and/or elegibility for allogeneic SCT. 16 pts (23.2%)
were affected by other diseases (chronic myelomonocytic leukemia: 2 pts; idio-
pathic myelofibrosis: 3 pts; aplastic anemia: 9 pts; pure red cell aplasia (PRCA):
2 pts).  45 pts (65.2%) received deferasirox (DFX) as first-line treatment, 12
pts (17.4%) received DFX after a previous treatment with deferoxamine (DFO),
while 9 pts (13%) received DFO and 3 pts (4.3%) received DFO after DFX
because of  contraindications to DFX or toxicity.  Median time from diagnosis
to the start of ICT: 18 months. Median number of RBC transfusions before the
start of ICT: 37.5. Median SF level pre-ICT:  1964 ng/ml; median SF after ICT
(last value): 1858 ng/ml; median duration of ICT: 12 (range 1-230) months.  36
pts (52.2%) continued ICT for a period ≥12 months, and 25 pts (36.2%) for a
period ≥24 months.  27 pts (39.1%) showed a drop of SF ≥500 ng/ml, 11 pts
(15.9%) showed a drop of SF <500, 13 pts (18.8%) showed an increase of SF
<500, in spite of ICT,  and 18 pts (26.1%) showed an increase of SF ≥500. 12
pts (17.4%) achieved a SF value <1.000,  and 48 pts (69.6%) a SF value
<2.500. Adverse events possibly related to DFX were observed in 30 pts
(43.5%): renal (increase of serum creatinine): 14 pts (20.3%) (grade >2: 1 pt:
1.4%); gastrointestinal : 14 pts (20.3%) (grade >2: 1 pt: 1.4%); cutaneous: 2
pts (2.9%) (grade >2: no pts). Permanent discontinuation of ICT: 40 pts (58%),
because of toxicity (16 pts: 23.2%), worsening of clinical condition (6 pts: 8.7%),
discontinuation of transfusions (9 pts: 13%), allogeneic transplantation (9 pts:
13%). 5 pts (7.2%) (4 MDS and 1 PRCA) (with DFX: 4 pts; with DFO: 1 pt)
showed an erythroid response following ICT, after  2, 4, 7, 32 and 112 months,
respectively, and one of them (with PRCA) achieved complete remission. 35
pts (50.7%) died, because of infection (9 pts), AML (4 pts), cachexia (4 pts),
other neoplastic diseases (3 pts), hemorrhage (2 pts), heart failure (2 pts),
stroke (2 pts) and other causes (9 pts). 10 pts (14.5%)  are still receiving ICT.
With a median follow-up of 34 (2-230) months,  median overall survival (OS)
was 64 months for all pts, 51 months for MDS pts, 87 months for lower-risk
MDS (IPSS risk: low and intermediate-1) and 24 months for higher-risk MDS
(IPSS risk: intermediate-2 and high).
Summary/Conclusions: In conclusion, in our experience ICT appears feasible
and effective, in terms of reduction of SF and OS, even in a population of elderly
pts, if carefully selected.
Myeloma and other monoclonal gammopathies -
Biology
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VCAM-1 AS A NOVEL DRUG THERAPY TARGET OF BONE MARROW
MESENCHYMAL STEM CELLS IN MULTIPLE MYELOMA
A. Ortiz-Ruiz1,*, C. Alicia2, L. Alejandra2, M.Mª Luz2, L. Maria2, G. Miguel1,
M.-L. Joaquin2
1Haematological Malignancies Clinical Research Unit, CNIO, 2Hematologia
Traslacional, Hospital Universitario 12 de Octubre, Madrid, Spain
Background: Multiple myeloma is characterized by the clonal proliferation of
malignant plasma cells in the bone marrow microenvironment. The pathogen-
esis consists, in part, in critical interactions between myeloma cells and the
mesenchymal stem cells (MSC). The interactions between myeloma cells and
bone marrow cells are establish through surface receptors (e.g. integrins, cell
adhesion molecules, etc.), which determine tumor growth, survival, migration
and drug resistance. Mesenchymal stromal cells modulate the pattern of myelo-
ma markers on the cellular surface in vitro towards a less differentiated pheno-
type. However, the exact mechanism by which mesenchymal stromal cells carry
out their functions is not yet fully understood. 
Aims: To evaluate the effect of MSCs from healthy donors and myeloma
patients over malignant plasma cells and the molecular changes produced for
the interaction each other.
Methods: Interactions between both cell types were studied through different
co-cultures studies. We evaluate differences between culturing primary MSC
cells and MM cell line RPMi 8226.  Pathological MSCs were extracted from the
bone marrow of newly diagnose MM patients. On the other hand, purified
healthy MSCs will be isolated from donor patients. Pathological or healthy
MSCs were cultured and co-cultured 24h after seeding with MM plasma cells
RPMI 8226 for duplicates at 24, 48 and 72h. The phenotypical and molecular
effect of the interaction of both cells were characterized by viability through try-
pan blue, cell apoptosis percentage (7AAD) and variations on expression of
cell surface proteins (MSCs: CD90, CD105, CD106 and CD54. MM cell: CD138,
CD38, CD49d and CD11a) using flow cytometry, and statistically analyzed with
GraphPad.
Results: We observed a decrease of apoptosis of MM plasma cells when are
in co-culture with pathological MSCs at short-term (24h, 7AAD positive cells
MM alone: 4.8%, MM in co-culture: 0.4%) and mid-term (72h, 7AAD positive
cells MM alone: 16.4%, MM in co-culture: 10.7%) compared with MM plasma
cells alone. However MM plasma cells not decreases the level of apoptosis at
mid-term with healthy MSCs in co-cultures (72h, 7AAD positive cells MM alone:
16.4%, MM in co-culture: 18.0%). The molecular analysis showed a correlation
between MSC lack of protection over MM plasma cells and the decrease in the
levels of expression of VCAM-1 (CD106).
Summary/Conclusions: As reported in literature CD106 expression increase
when MSCs are co-cultured with plasma cells. Adhesion of tumor cells to BMSC
activates many pathways resulting in upregulation of cell cycle and anti-apop-
totic proteins. MM pathophysiology is supported by a strong interaction between
CD106/CD49d. Changes in VCAM-1 and VLA-4 expression have been demon-
strated in cell lines assays, and were corroborated with primary cells in the
context of MSCs protection over MM plasma cell. Thus, MM pathological MSCs
did not change VCAM-1 levels and MM plasma cell protection be held. How-
ever, healthy MSCs have the capacity to modulate the VCAM-1 in mid-term to
avoid the protection effect. Therefore, these results suggest MSCs VCAM-1 as
potential drug therapy target in MM disease.
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RALA AND RALB MEDIATE CELL SURVIVAL INDEPENDENTLY OF
ONCOGENIC RAS AND PROVIDE POTENTIAL THERAPEUTIC TARGETS
IN MULTIPLE MYELOMA
M. Seibold1,*, T. Stühmer1, N. Schmiedl1, D. Brünnert1, A. Mottok2, E. Leich2,
A. Rosenwald2, C.-J. Scholz3, M. Chatterjee1, H. Einsele1, R.C. Bargou4,
T. Steinbrunn1
1Department of Internal Medicine II, University Hospital of Würzburg, 2Institute
of Pathology, University of Würzburg, Würzburg, 3Life & Medical Sciences Insti-
tute, University of Bonn, Bonn, 4Comprehensive Cancer Center Mainfranken,
University Hospital of Würzburg, Würzburg, Germany
Background: Genetic mutations and the bone marrow microenvironment con-
tribute to disease progression, aggressive phenotype, and shorter survival in
multiple myeloma (MM). Oncogenic RAS is one of the most common mutations
in MM. Pathway activation through oncogenic RAS is associated with promotion
of disease progression and shorter survival. Cell survival and proliferation in
MM are mainly mediated via classical signaling pathways such as MEK/ERK
and PI3K/Akt. Since there is a lack of specific RAS-inhibitors for clinical use, it
is important to identify and analyze associated pathways, which may provide
useful alternative targets for MM therapy. The small GTPase Ral has previously
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been implicated in putative downstream signaling of RAS, and may therefore
promote proliferation, survival and drug resistance of MM cells.
Aims: We used shRNA-mediated knockdown of RalA and RalB isoforms to
appraise their role as potential therapeutic targets and to analyze their con-
nection to important signaling pathways, which regulate MM cell survival and
proliferation. Because oncogenic RAS is a potential activator of the Ral path-
ways, we investigated a possible link between oncogenic RAS and Ral.
Methods: Immunohistochemical stainings of bone marrow trephines of MM
patients and Western analysis of primary MM cells and MM cell lines were per-
formed to evaluate Ral protein expression. Transient or stable knockdown of
RalA or RalB was achieved by electroporation of MM cell lines and the effect
on cell survival and apoptosis was measured with flow cytometry using annexin
V/propidium iodide staining. Ral pulldown assays were applied to test potential
dependence of Ral activation on oncogenic RAS. Furthermore, RNA sequenc-
ing was performed to compare RAS and Ral gene expression signatures after
respective knockdowns.
Results: Both Ral isoforms were expressed in primary MM cells and MM cell
lines, with RalA showing the most prominent and consistent protein expression
levels. ShRNA-mediated knockdown of RalA strongly induced apoptosis in two
thirds of the tested cell lines, whereas RalB depletion did impair MM cell survival
in less than half of the cell lines. Western analysis revealed no alteration of clas-
sical MEK/ERK and PI3K/Akt pathway activation after Ral knockdown. Ral activity
appears to be independent of oncogenic KRAS or NRAS. In addition, RNA
sequencing revealed differing gene expression signatures for RAS and Ral.
Summary/Conclusions: Ral and its effector network constitute potential ther-
apeutic targets in MM, which are activated independently of oncogenic K- or
NRAS. Therefore, investigation of the functional network of Ral may be impor-
tant to identify useful clinical targets.
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CXCR4 MUTATIONS FOUND BY USING DEEP SEQUENCING WITHOUT
SORTING B CELLS, AND PROGNOSTIC IMPLICATION IN WALDENSTROM
MACROBULINEMIA 
S.-M. Kim1,*, D.W. Shin2, K. Im1, S.M. Hwang3, J.-A. Kim2, H.S. Park2,
D.S. Lee2
1Cancer Research institute, 2Department of Laboratory Medicine, Seoul Nation-
al University College of Medicine, Seoul, 3Department of Laboratory Medicine,
Seoul National University Bundang Hospital, Seongnam, Korea, Republic Of
Background: Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytoid
lymphoma with IgM monoclonal gammopathy. Most of WM harbor MYD88
L265P and one thirds of WM with MYD88 present CXCR4 mutations. Currently,
frequency of CXCR4 mutations and its clinical implication is not reported in
Asian patients with WM.
Aims: We investigated the profiles of CXCR4 and MYD88 mutation in corre-
lation with prognostic implication. To detect minor cell population with CXCR4
mutation, we adopted a ultra-deep sequencing strategy for CXCR4, which can
detect specific variants <1% of the cell population.
Methods: Allele-specific PCR for MYD88 was performed on 37 patients with
WM, along with 161 patients with B-cell neoplasms [diffuse large B-cell lym-
phoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), chronic lym-
phocytic leukemia (CLL)]. Deep-sequencing for CXCR4 and interphase fluo-
rescent in situ hybridization (FISH) for 6q deletion was performed on 31 patients
with WM. Clinicopathologic features were compared among 3 groups according
to MYD88 and CXCR4 mutation status (Group 1, MYD88WT and CXCR4WT;
group 2, MYD88L265 and CXCR4WT; group 3, MYD88L265P and CXCR4Mutation;
statistical comparison, Fisher exact test, one-way ANOVA).
Results: MYD88 L265P mutation was detected in 81.3% (26/32) patients
with WM, 10.8% (9/83) in patients with DLBCL, 9.5% (6/63) in patients with
CLL, 0% (0/15) in patients with B-ALL, and 0% in 200 healthy persons. Among
the 31 WM patients, 6 patients have CXCR4 mutation (19.4%) in the c-ter-
minal domain (Figure 1); 1 frameshift mutation and 5 nonsense mutations.
Two variants, K327X and K331X, are novel and the rest were known reported
sites. All of them had MYD88 L265P mutation. FISH revealed 6q21 deletion
in 14 patients (43.8%), and IGH rearrangement in 9 patients (28.1%). There
was no correlation aming cytogenetic aberrations and genetic mutation
(MYD88 and CXCR4). IgM levels of group 2 (MYD88L265 and CXCR4WT)
were significantly higher than that of group 1 (MYD88WT and CXCR4WT)
(P=0.024). Meanwhile, IgG level was significantly lower in group I, compared
to group 3. Other clinical characteristics such as age, Hb, platelet, adenopa-
thy, hyperviscosity showed no significant difference among 3 groups. Group
I showed adverse survival and 1 year survival rate of group 1 (66.7%) was
lower than group 2 (94.7%), though it was not statistically significant
(P=0.410). There were no death events in group 3 (MYD88L265P and
CXCR4Mutation) patients during the research period.
Summary/Conclusions: The frequency of CXCR4 mutation in Korean WM
was similar to those of Caucasian. We suggest that ultra-deep sequencing
using next generation sequencing can replace B cell sorting for the detection
of CXCR4 mutation. Patients with MYD88WT and CXCR4WT showed higher
IgM level and lower survival, suggesting an adverse prognostic implication.
This is the first report on CXCR4 mutation in Korean WM patients.
Figure 1.
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THE CLINICAL IMPACT OF CHROMOSOMAL TRANSLOCATION
T(14;16)(Q32;Q23) IN PATIENTS WITH MULTIPLE MYELOMA
L. Pavlistova1,2,*, A. Berkova1,2, Z. Zemanova2, K. Svobodova2, S. Izakova2,
S. Ransdorfova3, I. Spicka1, J. Straub1, K. Michalova2,3
11st Medical Department, 2Center of Oncocytogenetics, Institute of Medical Bio-
chemistry and Laboratory Diagnostics, General University Hospital and First Fac-
ulty of Medicine, Charles University in Prague, 3Department of Cytogenetics,
Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
Background: Translocation t(14;16)(q32;q23) in plasma cells is considered
as a strong negative prognostic factor in patients with multiple myeloma
(MM). The oncogenic potential of this chromosomal aberration is based on
the overexpression of the c-MAF protooncogene (located at 16q23) under
strong enhancer of IgH gene (14q32). Although the IgH/MAF positive cases
comprise just 2-4% of MM patients, the evaluation of this aberration is an
integral part of the cytogenetic risk stratification according the RISS. The
International Myeloma Working Group (IMWG) proposed a model of high risk
MM as having at least one of the following aberrations: deletion of 17p13
(TP53 gene), translocation t(4;14)(p13;q32) and translocation
t(14;16)(q32;q23) determined by FISH. However, the unequivocal poor prog-
nostic value of t(14;16)(q32;q23) was not confirmed in several MM series
thus further studies are needed.
Aims: The aim of our study was to assess the impact of t(14;16)(q32;q23)
on event free (EFS) and overall survival (OS) in cohort of IgH/MAF positive
MM patients in comparison with control group of 30 MM IgH/MAF negative
cases.
Methods: During the years 2004 to 2016, we examined 870 bone marrow
samples of MM patients on immunofluorescently labeled plasma cells (cIg
FISH). The basic FISH panel included 4 specific DNA probes (Abbott-Vysis,
Kreatech and MetaSystems) detecting: the IgH gene rearrangement (1), dele-
tion 13q14 (RB1 gene)/monosomy 13 (2), gain of 1q21/deletion of 1p32 (3)
and deletion of TP53 gene (4). Cases with rearranged IgH gene were gradually
examined for 3 specific translocations- 1) t(11;14)(q13;q32), 2) t(4;14)(p16;q32)
and 3) t(14;16)(q32;q23). Kaplan-Maier analysis was performed to evaluate
OS and EFS.
Results: Translocation t(14;16) was identified in 19 out of 870 patients
(2.2%). Eighteen patients were examined at the time of diagnosis and one
at the time of the progression of asymptomatic myeloma to symptomatic dis-
ease. Relapse and/or disease progression occurred in 15 patients. The medi-
an event-free survival (EFS) was 13 months in t(14;16) carriers (range 3 –
62 months) and 22.5 months in controls (range 3-71 months, p=0.285). Four-
teen t(14;16) positive patients died. The median overall survival (OS) was 25
months (range 10-204 months) in comparison with 52 months in control group
(range 3-132 months). However, the difference in OS was not statistically
significant (p=0.155). In 15 t(14;16) positive patients (83.3%), two or more
additional chromosomal changes were detected by FISH (monosomy/deletion
of chromosome 13 being the most frequent). In four cases, (14;16) was
detected together with another high risk chromosomal change - deletion of
TP53 gene - and all these patients died  within median of OS 12.5 months
(range 10-16).
Summary/Conclusions: Beside its supposed negative clinical impact, the
examination of t(14;16) is not always included in routine diagnostics of chro-
mosomal changes and its prognostic significance should be proved in large
series of MM patients. Our data substantiate the trend of worse clinical outcome
(shorter OS) in t(14;16) positive group compared to IgH/MAF negative MM
controls. The detailed analysis of other clinical parameters, type of therapy,
combination with other chromosomal aberrations will be performed to prove its
role of as independent prognostic factor.
Supported by grants RVO-VFN64165, ProgresQ28 and GACR P302/12/G157.
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THE ROLE OF NEUROTROPHINS AND ANGIOGENIC CYTOKINES IN THE
PATHOPHYSIOLOGY OF PERIPHERAL NEUROPATHY IN PATIENTS WITH
MULTIPLE MYELOMA
K. Łuczkowska1,*, Z. Litwińska1, E. Pius-Sadowska1, A. Sobuś1,
E. Paczkowska1, B. Machaliński1
1Department of General Patology, Pomaranian Medical University in Szczecin,
Szczecin, Poland
Background: The introduction of new treatment modalities have changed sig-
nificantly the prognosis of multiple myeloma (MM) patients. The novel drugs
and schemes of treatment of MM have contributed to substantial extend of the
overall survival time of patients. However, the administration of some of the
treatments, e.g. thalidomide or bortezomib, is also associated with occurrence
of a serious and common side-effect problem, which is the drug-induced periph-
eral neuropathy. The mechanism of the development of the peripheral neu-
ropathy is poorly understood. Nevertheless, one of its potential cause, could
be inadequate concentrations of crucial trophic factors, including neurotrophic
and/or angiogenic factors, which are responsible for proliferation, differentiation,
survival and death of neuronal and nonneuronal cells.
Aims: The aim of this study was to elucidate the potential relationship between
concentration of neurotrophic and angiogenic factors and development of
peripheral neuropathy in the natural clinical course of the disease and, espe-
cially, induced by treatment regimen: VMP (bortezomib, melphalan, prednisone)
or VTD (bortezomib, thalidomide,dexamethason) in patients with MM.
Methods: Peripheral blood samples were collected from patients classified
into two groups: i) patients with multiple myeloma, without neuropathy and
before therapy; and ii) patients with peripheral neuropathy 3oor 4o induced in
the course of VMP or VTD therapy. The control group consisted healthy aged
matched subjects. Assessment of concentrations of neurotrophins (BDNF, NSE)
and angiogenic factor (PDGF) were performed using Luminex technology,
which utilize microbeads coated with fluorescently labeled antibodies.
Results: Concentration of BDNF, PDGF and NSE were significant decreased
in patients after treatment regimen involving VMP or VTD who have developed
peripheral neuropathy grade 3 or 4, compared with patients with newly diag-
nosed MM without neuropathy, before therapy and control healthy group. Addi-
tionally, plasma levels of both neurotrophins and PDGF in patients before ther-
apy were higher, then in control group. Obtained results may be caused by the
changes in an activity of the transcription factor NF-κB during the treatment of
MM, since reduction of NF-kB concentration is associated with decrease in the
transcription of genes encoding BDNF, NSE and PDGF.
Summary/Conclusions: Alterations in the concentration of BDNF, PDGF and
NSE suggest the cause and effect relationship between these factors and the
development of neuropathy in patients with MM. Comprehensive elucidation of
this phenomenon may contribute to the extension of the knowledge concerning
the pathogenesis of neuropathy, and might well lead to reduction of the inci-
dence of polyneuropathy in MM patients in the future.
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INFLUENCE OF XRCC5, XRCC4, NFKB2, AND BIRC5 GENES
POLYMORPHISMS IN THE RISK AND PROGNOSIS OF MONOCLONAL
GAMMOPATHIES
L. Balanco1, M.S. Melo1, A.C. Gonçalves1,2, R. Alves1,2, C. Geraldes1,2,3,
E. Cortesão1,2,3, L. Ribeiro3, L. Mota-Vieira4, A.B. Sarmento-Ribeiro1,2,3,*
1Applied Molecular Biology and University Clinic of Hematology, 2CIMAGO,
Faculty of Medicine University of Coimbra, 3Clinical Hematology Department,
Centro Hospital e Universitário de Coimbra (CHUC), Coimbra, 4Molecular
Genetics and Pathology Unit, Hospital do Divino Espírito Santo de Ponta Del-
gada, EPER, Ponta Delgada - Azores, Portugal
Background: Monoclonal gammopathies (MG) are a group of disorders char-
acterized by the proliferation of monoclonal plasma cells, which produce and
secrete monoclonal immunoglobulin (M protein). Symptomatic multiple myelo-
ma (MM) is characterized by the clonal proliferation of plasma cells. MM is con-
sistently preceded by a pre-neoplastic entity, called monoclonal gammopathy
of undetermined significance (MGUS), with an intermediate phase of indolent
multiple myeloma (MMI). This disease is a heterogeneous hematological neo-
plasm characterized by the proliferation of clonal, long-lived plasma cells within
the bone marrow (BM) secreting monoclonal proteins and by the presence of
so-called CRAB criteria and/or biomarkers of malignancy (as clonal BM plasma
cells ³ 60%, involved:uninvolved serum free light chain ratio ³100, >1 focal
lesion in MRI studies). Genetic instability and several molecular abnormalities
are hallmarks of MM cells. Alterations in DNA repair pathways, namely abnormal
activity of non homologous end–joining (NHEJ) repair pathway, are involved in
the disease onset and progression. Moreover, it has been observed that virtually
all primary MM samples have constitutive nuclear factor-κB (NF-κB) pathway
activity, having this pathway a well–established role in MM pathogenesis.
Aims: In this context, we hypothesized that polymorphisms of genes involved
in NHEJ repair pathway (XRCC5, XRCC4) and in NF-κB pathway (NFKB2, and
BIRC5) may have impact in MG susceptibility and prognosis.
Methods: In the present, a hospital-based case-control study, we analyzed
eight polymorphism in four genes (XRCC5, XRCC4, NFKB2, and BIRC5), by
genotyping 189 individuals (63 MG patients and 126 controls) using TaqMan
qPCR. Results are expressed in terms of frequencies of allele, genotype, hap-
lotype, and genotypic profiles, and their correlation with MG susceptibility. The
strength of association between polymorphisms and disease risk was assessed
by odds ratio (OR) with 95% confidence interval (CI95%) calculated by logistic
regression. We also investigated the association of these SNPs with overall
survival through Kaplan Meier curves. All statistical analyses had a significance
levels of 95%.
Results: In the patient group, 51% (32/63) of the individuals were females and
49% (31/63) were males; the mean age was 70.11±10.25 years old. Among
the control group, 52% (65/126) of the individuals were females and 48%
(61/126) were males, and the mean age was 69.90±10.06 years old. Most of
patients were diagnosed with multiple myeloma (84%, 53/63) and the remaining
ones (16%, 10/63) were diagnosed with smoldering multiple myeloma. Accord-
ing to the ISS classification, 43% (27/63) of patients are in stage III. The data
analysis revealed two associations of the studied gene polymorphisms with
MG. First, the analysis by gender stratification suggested a decreased predis-
position to MG in male carriers of NFKB2 rs12769316 GA and AA genotypes
(OR 0.346, 95%CI 0.124–0.965, p=0.043). Second, we observed that patients
with BIRC5 rs9904341 CC genotype had a highly significant lower overall sur-
vival (recessive model: HR 4.89, 95%CI 5.06 199.70, p<0.01). BIRC5 GGC
haplotype (rs4789551, rs9904341, and rs8073069) was found in one patient
and absent in controls.
Summary/Conclusions: The present study suggests that NFKB2 gene variant
(rs12769316, allele A) may be associated with MG susceptibility in males, and
BIRC5 (rs9904341) CC genotype may negatively influence MG prognosis.
Nonetheless, further studies are needed to validate these findings, enlighten
the role of genetic polymorphisms in MG susceptibility and prognosis.
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SILENCE OF LONG NONCODING RNA MALAT1 BY RNA INTERFERENCE
INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN MULTIPLE
MYELOMA
H. Liu1,*, Z. Gong1,2, W. Yang1
1Hematology, Shengjing Hospital of China Medical University, Shenyang, Chi-
na, 2Hematopathology, The University of Texas, MD Anderson Cancer Center,
Houston, United States
Background: Multiple myeloma (MM) is a neoplastic plasma-cell disorder char-
acterized by abnormal proliferation of monoclonal plasma cells in bone marrow
leading to various end-organ damages. Altered long non-coding RNAs (lncR-
NAs) levels can result in aberrant expression of gene products that may con-
tribute to cancer biology. Metastasis-associated lung adenocarcinoma transcript
1 (MALAT1), an evolutionarily highly conserved mRNA-like lncRNA was origi-
nally identified with high expression in metastatic non-small-cell lung cancer
and reported to be up-regulated in many other cancers. However, the function
of MALAT1 in MM remains unknown.
Aims: Our study aimed to evaluate the role of MALAT1 on proliferation as well
as apoptosis in MM cells in vitro and tumorigenic ability in vivo, following trans-
fection with MALAT1-specific short hairpin RNA (shRNA) expression plasmids.
Methods: Levels of MALAT1 in human myeloma cell lines were detected by
real-time polymerase chain reaction (RT-PCR) analysis. The effects of MALAT1
shRNA in MM were investigated in vitro and in vivo.
Results: We found that MALAT1 was high expressing in RPMI8226 and U266
cells. Silencing of MALAT1 by shRNA significantly inhibited the proliferation
through cell cycle arrest at G1 phase and induced apoptosis, which was closely
associated with activation of caspase-3/-9, downregulation of Bcl-2 and upreg-
ulation of Bax. Study in vivo revealed that silencing of MALAT1 delayed the
tumor growth and led to apoptosis in mice bearing myeloma xenograft. 
Summary/Conclusions: MALAT1 may serve as a promising novel therapeutic
target in human MM. Notably, the inhibition of MALAT1 by shRNA may prove
to be an effective genetic therapeutic strategy for MM treatment.
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LONG NON-CODING RNA MEG3 FUNCTIONS AS A COMPETING
ENDOGENOUS RNA TO REGULATE PTEN EXPRESSION BY SPONGING
MIR-181A IN MULTIPLE MYELOMA
L. Chen1,*, H. Bai1, H. Zhu1, X. Shen1, J. Li1, W. Yu1
1the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province
Hospital, Nanjing, China
Background: Long non-coding RNA maternally expressed gene 3 (MEG3)
plays a critical role in cancer progression and metastasis. However, the overall
biological role and regulatory mechanism of MEG3 in multiple myeloma (MM)
development and progression remains largely unknown.
Aims: To explore the tumor suppression role of lncRNA MEG3 in MM and fur-
ther reveal the mechanism of MEG3 functions as ceRNA to contribute to MM
pathogenesis.
Methods: MEG3 expression was measured in MM patients by real-time PCR.
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The effect of MEG3 on cell apoptosis, cell proliferation and angiogenesis were
gained from CCK-8, flow cytometric analysis and transwell invasion assays in
MM cell lines ARP-1 and LP-1. Insights of the mechanism of competitive
endogenous RNA (ceRNA) were gained from bioinformatic analysis, luciferase
reporter assays and RNA binding protein immunoprecipitation (RIP) assay.
Results: MEG3 expression was significantly decreased in MM patients with
advanced stage disease (ISS II and III) and poor prognosis.Overexpression of
MEG3 promoted cell apoptosis and inhibited cell proliferation, migration and
angiogenesis in MM ARP1 and LP-1 cell lines. Furthermore, MEG3 increase
the expression of phosphatase and tensin homolog (PTEN) and consequen-
tially inhibit MM cell proliferation and angiogenesis through sponging miR-181a
in vitro. miR-181a mimics can limit the promotion of PTEN by MEG3. 
Summary/Conclusions: MEG3 functions as a tumor suppressor in MM. High
expression of MEG3 is a marker for good survival. We reveal a novel mecha-
nism that MEG3 as a ceRNA of the PTEN gene by competing for miRNA-181a
binding sites and thereby regulate the expression of the PTEN mRNA.
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IMPROVE RISK-STRATIFICATION OF MULTIPLE MYELOMA PATIENT
WITH MICROFLUIDIC DEVICES
C. Li1, L. Gao1, Y. Zeng1, X. Zhang1, J. Zhong1,*
1University of Southern California, Los Angeles, United States
Background: Cytogenetic alterations are required for risk stratification of mul-
tiple myeloma (MM); however, current pathology assays performed on bone
marrow samples directly can produce false negatives due to the unpredictable
distribution and rarity of MM cells. A more accurate method is needed for MM
diagnosis and risk-stratification. We develop a new microfluidic device to facil-
itate CD45-depletion for enhancing the detection of cytogenetic alterations in
plasma cells. 
Aims: Improve accuracy of risk stratification for multiple myeloma patients
Methods: Bone marrow samples from 48 MM patients were divided into two parts
each. One part was directly detected by classic flow cytometry and FISH while
the other part was first enriched by microfluidic size selection and then underwent
CD45-cell depletion (MF-CD45-TACs). The enriched samples were then analyzed
by flow cytometry and FISH and compared to the classical analysis.
Results: MF-CD45-TACs significantly increased the percentage of
CD38+/CD138+ cells to 37.7%±20.4% (P<0.001) compared to 10.3%±8.5%
in bone marrow. After the MF-CD45-TACs enrichment, the detection rate of
IgH rearrangement, del(13q14), del(17p) and 1q21 gains rose to
56.3%(P<0.001), 37.5%(P<0.001), 22.9%(P<0.001) and 41.7% (P=0.001),
respectively, all significant increases compared to untreated samples.
Summary/Conclusions: We have developed a rapid, simple assay for
improved diagnostics and risk-stratification for MM. With more precise diagno-
sis, the clinical outcomes of MM will be significantly improved. 
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SERUM FREE LIGHT CHAIN RATIO IS AN INDEPENDENT RISK FACTOR
FOR PROGRESSION IN MONOCLONAL GAMMOPATHY OF
UNDETERMINED SIGNIFICANCE
R. Cherif1,*, B. Salah Eddine1
1Hematology, Central Hospital Mohammed Seghir Nekkache, Algiers, Algeria,
Algiers, Algeria
Background: Monoclonal gammopathy of undetermined significance (MGUS) is
a premalignant plasma cell proliferative disorder found in approximately 3% of
the general population 50 years of age and older. MGUS is associated with pro-
gression to multiple myeloma or related malignancy at a rate of 1% per year. Thus
the risk of malignancy for a 50-year-old patient with a 25-year life span is 25%.
Aims: We hypothesized that the presence of monoclonal free kappa or lambda
immunoglobulin light chains in monoclonal gammopathy of undetermined sig-
nificance (MGUS), as detected by the serum free light chain (FLC) assay
increases the risk of progression to malignancy.
Methods: 90 Patients seen at the Hematology consultation from 2010 to 2015
with MGUS have a serum Mprotein less than 30 g/L, bone marrow plasma
cells less than 10%, and no anemia, hypercalcemia, lytic bone lesions, or renal
failure that would be indicative of a malignant plasma cell disorder.
The prognostic effect of abnormal kappa-to-lambda FLC ratio on progression
of MGUS was studied. We also examined whether the risk of progression
varied depending on the extent to which the FLC ratio was abnormal (the nor-
mal reference range of ĸ/ʎ ratio 0.26 to 1.65).
Results: The median age at diagnosis of MGUS was 59 years (35-92years).
62 Womans and 28 Mans Sex ratio=2.2. Serum electrophoresis and immuno-
electrophoresis or immunofixation was done in 85 patients. Of these, The medi-
an serum M protein size at diagnosis was 12 g/L (1.7-28.5g/L). IgG monoclonal
: 68 patients (75%), and non IgG monoclonal : 22 patients (25%). A monoclonal
light chain was detected in 62 patients, as detected by the serum free light
chain (FLC) assay increases the risk of progression to malignancy. An abnormal
FLC ratio (kappa-lambda ratio <0.26 or >1.65) was detected in 27 (30%)
patients. At a median follow-up of 5 years, malignant progression had occurred
in 6 patients (6,6%) with an abnormal serum FLC ratio. 
Summary/Conclusions: A novel, highly sensitive serum free light chain (FLC)
assay is now available for clinical practice.The risk of progression in patients
with an abnormal FLC ratio was significantly higher compared with patients
with a normal ratio, and was independent of the size and type of the serum
monoclonal (M) protein. Patients with an abnormal serum FLC ratio, non–
immunoglobulin G (non-IgG) MGUS, and a high serum M protein level (>15
g/L) had a major risk of progression. 
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INTENSITY OF EXPRESSION OF MULTIDRUG RESISTANCE GENES
AFFECT ON THE OVERALL SURVIVAL OF PATIENTS WITH MULTIPLE
MYELOMA WERE TREATED WITH BORTEZOMIB AND ASSOCIATED
WITH THE INITIAL MULTIDRUG RESISTANCE
Y. Chernykh1,*, A. Golenkov1, L. Vysotskaya1, K. Belousov1
1clinical haematology, Moscow Regional Research and Clinical Institute,
Moscow, Russian Federation
Background: Bortezomib is an important drug in multiple myeloma (MM) treat-
ment, but the resistance to this treatment exist. Many conflicting data suggests
that cellular overexpression of multidrug resistance (MDR) genes may reduce
the effectiveness of bortezomib - containing treatment. The main indicator of
the effectiveness of the treatment of MM is the overall survival of patients.
Aims: We evaluated the changes of intensity of expression of MDR genes in
patients with newly diagnosed and refractory/relapsed multiple myeloma and
the effect of expression of MDR genes such as MDR 1, MRP 1, BCRP, LRP on
the overall survival of patients after treatment with bortezomib.
Methods: The bone marrow aspirates of 30 patients (12 men and 18 women)
aged 48 to 77 years (median 60 years) with stage III MM by classification Durie-
Salmon were studied. 15 patients were included in a group of newly diagnosed
(ND) MM. 15 patients were in group of a clinically refractory/ relapsed (RR) MM.
The bone marrow in this group of patients were studied after treatment with alky-
lating agents at the time of registration of resistance to the given therapy.  In the
future, all patients were treated by bortezomib - containing chemotherapy regi-
mens. mRNA expression studied genes were determined by semi-quantitative
polymerase chain reaction reverse transcription. The degree of expression was
assessed by semi-quantitative visual assessment from 0 (no electrophoretic
strips) to 4 points (bright glow of the transcript). The overall survival (OS) was
analyzed by the Kaplan-Meier method, with the use of Cox-Mantel test. Differ-
ences were considered statistically significant at p <0.05.
Results: In both groups of patients had comparable expression of all studied
MDR`s genes. The development of clinical resistance to treatment with alky-
lating agents were accompanied by an increase in mRNA expression of all
studied genes.  However, the statistically significant increase the expression
of the intensity obtained for LRP gene only (the average intensity of the expres-
sion of mRNA LRP gene in ND MM 0.9±0.24, with RR MM 1.93±0.34, p <0.05).
The MDR 1 mRNA expression was 1.50±0.34 in the group of ND MM and
1.67±0.31 in the group of RR MM, p>0.05. The expression of mRNA of MRP 1
and BCRP are 1.07±0.21 and 1.63±0.15 respectively before treatment and
increased to 1.73±0.31 and 2.13±0.35 respectively in the group of RR MM,
p=0,06. OS was negatively associated with high LRP gene expression only in
group  of ND MM (median of OS in patients with high LRP gene expression
was 17 months and in those with low expression 62 months, p <0.05).
Summary/Conclusions: High expression of LRP gene is associated with
worse overall survival in patients with newly diagnosed MM treated with borte-
zomib- containing chemotherapy programs. “Genetic resource MDR” in MM is
due mainly to the initial multidrug resistance. The treatment of MM by alkylating
drugs increase the existing at the time of diagnosis of MDR activity of genes.  
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ASSOCIATIONS OF IL-1, IL-4 AND TGF-Β1 POLYMORPHISMS WITH
CYTOGENETIC PROFILES IN PATIENTS WITH MULTIPLE MYELOMA
A. Pavlova1,*, I. Pavlova1, L. Bubnova1, S. Bessmeltsev2, E. Kleina3,
A. Garifullin4, I. Martynkevich3, S. Voloshin2, A. Chechetkin2
1Immunohaematology laboratory, 2Russian Institute of Haematology and Trans-
fusion, Saint-Petersburg, Russian Federation, 3Laboratory of molecular genet-
ics, 4Haematology clinic, Russian Institute of Haematology and Transfusion,
Saint-Petersburg, Russian Federation
Background: Multiple myeloma (MM) is a plasma cell malignancy character-
ized by complex cytogenetic and molecular genetic aberrations. Those cyto-
genetic abnormalities occur at different stages of the disease. The chromosome
ploidy status and Ig rearrangements are two genetic criteria that are used to
help stratify patients into prognostic groups. 
Aims: The aim of the study was to analyse correlation between cytogenetic
profiles and some cytokine genotypes in 24 patients with MM (Caucasoid inhab-
itants of the North-West region of Russia). 
Methods: Genomic DNA was extracted from the peripheral blood; gene geno-
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typing (IL-4, TGF-β1, IL-1α, IL-1β) was performed by PCR-SSP; study of cytoge-
netic abnormalities was performed by standard GTG-method and interphase FISH
analyses with DNA probes: LSI 13(RB1)13q14, IGH/CCND1, IGH/FGFR3, LSI
TP53 (17q13.1); p-values less than 0.05 were considered statistically significant.
Results: Previous results allow us to describe some cytokine genotype markers
associated with the development of MM (IL-1α -889 TT, IL-1β +3962 TT, IL-6 -174
GG and IL-6 nt565 GG; gr. 1) as additional negative prognostic markers but IL-4 -
33 CC and TGF-β1 codon 25 GG genotypes as additional positive prognostic mark-
ers (gr. 2). However, in some MM patients we found presence of negative and pos-
itive markers together (mixed markers; gr. 3). We analyzed cytogenetic profiles in
MM patients with different prognostic markers in their genotypes (Table 1).
Table 1.
The frequency of abnormal cytogenetic transformations in the 2nd gr. was notice-
ably lower compare to patients from the 1st and 3rd gr. (0.11 vs 0.78 vs 0.67
respectively; p<0.05). Similarly, significant differencies in the frequency between
patients with positive prognostic markers and normal cytogeneic profile (0.89)
compare to MM patients with negative (0.22) or mixed (0.33) genotypes but nor-
mal cytogenetic profiles were also observed (p<0.05). In the 1st gr. frequency of
cytogenetic abnormalities was noticeably higher compare to patients with normal
profile (0.78 vs 0.22; p<0.05). Vice versa, in patients with positive prognostic
markers in the genotype frequency of normal cytogenetic profiles was remarkably
higher (0.89) compare to patients with aberrations (0.11; p<0.05).
Summary/Conclusions: Thus, our results allow to describe IL-1α -889 TT, IL-
1β +3962 TT, IL-6 -174 GG and IL-6 nt565 GG as markers associated with the
presence of cytogenetic abnormalities in MM patient cells. However, IL-4 -33
CC and TGF-β1 codon 25 GG indicate the normal cytogenetic profile in patients
with MM from the North-West region of Russia. Although, if MM patients have
both negative and positive prognostic markers associated with the development
of multiple myeloma (mixed genotype) it seems that the chance of finding cyto-
genetic abnormalities is much higher compare to patients with positive prog-
nostic markers only.
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CORRELATION DEPENDENCE OF CHRONIC LYMPHOPROLIFERATIVE
DISORDERS, MULTIPLE MYELOMA FROM CHANGES OF IMMUNE 
RESPONSE GENES PROFILE
E. Nazarova1,*, V. Shardakov1, A. Nagovitsina1, E. Zotina2, I. Dokshina2
1Laboratory of Immunology of Leukemia, 2Kirov Research Institute of Hema-
tology and Blood Transfusion, Kirov, Russian Federation
Background: Hematological malignancies are multifactorial diseases in the
development of which play a role as environmental factors and genetic deter-
mination of leukemic process. Such genetic factors include the presence in
human genome of allelic variants of the regulatory regions of the innate immune
response genes. At present time, they are considered as real risk factors for
these diseases in a person with a certain set of genetic variants. Their distribu-
tion among the population corresponds to the population laws and has its ethno-
graphic features. Analysis of the individual associations of genes polymorphic
variants involved in the implementation of the immune response does not suf-
ficiently complete answer about their role in the formation of predisposition to
the development of chronic lymphoproliferative disorders (CLD) and multiple
myeloma (MM). It is noted that in the pathogenesis of hematological diseases
contribute significantly to certain combinations of immune response genes.
Aims: Analysis of interactions between genes based on the distribution of
immune response genes combinations in chronic lymphoproliferative disorders
and multiple myeloma.
Methods: The study included 176 patients aged 22-86 years (median - 61
year), identifying themselves as Caucasians residing in one region in the north-
east of the Russian Federation. This group consisted of 80 patients with chronic
lymphocytic leukemia/small lymphocytic lymphoma (45%), 72 with multiple
myeloma (41%), 10 with diffuse large B-cell lymphoma (6%) six with marginal
zone lymphoma (3%) four with mantle cell lymphoma (2%), three with lympho-
plasmacytic lymphoma (2%) and one patient with follicular lymphoma (1%).
Genotyping of polymorphism of the innate immune response genes TLR2
(rs5743708), TLR3 (rs3775291), TLR6 (rs5743810), TLR9 (rs5743836), IL1β
(rs2856841), IL2 (rs2069762), IL4 (rs2243250), IL6 (rs1800795), IL10
(rs1800871), IL17A (rs2275913), CD14 (rs34424920), TNFα (rs1800629),
FCGR2A (rs1801274) was performed by polymerase chain reaction with allele-
specific primers (Litech, Russia). Analysis of interactions between genes was
performed using nonparametric GMDR program (Generalized Multifactor-
Dimensionality Reduction) [Lou X.Y. et al., 2007.; http://www.healthsystem.vir-
ginia.edu/internet/addiction-genomics/Software/].
Results: In the analyzed group of patients with CLD and MM identified almost
78 753 combinations of multi-locus genotypes of the 13 immune response
genes is 1 594 323 theoretically possible, indicating the non-random nature of
the combination of allelic variants of analyzed genes. A statistically significant
two-, three-, four-, five-, six, seven- and eight-loci model of inter-gene interac-
tions at the investigated hematological malignancies: - IL4 (C-589T) and CD14
(C-159T) (χ2=8.39, p=0.0038); - IL4 (C-589T) and CD14 (C-159T) and IL6 (C-
174G) (χ2=12.14, p=0.0005); - IL4 (C-589T) and IL17A (G-197A) and CD14
(C-159T) and IL6 (C-174G) (χ2=17.30, p<0.0001); - IL4 (C-589T) and IL17A
(G-197A) and IL10 (C-819T) and CD14 (C-159T) and IL6 (C-174G) (χ2=16.98,
p<0.0001); - IL4 (C-589T) and IL17A (G-197A) and IL10 (C-819T) and TNF
(C-308A) and CD14 (C-159T) and IL2 (T-330G) (χ2=16.98, p<0.0001); - IL4
(C-589T) and IL17A (G-197A) and IL10 (C-819T) and TNF (C-308A) and TLR9
(T-1237C) and CD14 (C-159T) and IL2 (T-330G) (χ2=16.98, p<0.0001); - IL4
(C-589T) and IL17A (G-197A) and IL10 (C-819T) and TNF (C-308A) and TLR9
(T-1237C) and CD14 (C-159T) and IL2 (T-330G) and IL1b (T-31C) (χ2=16.98,
p<0.0001); - IL4 (C-589T) and IL17A (G-197A) and IL10 (C-819T) and TNF
(C-308A) and TLR9 (T-1237C) and CD14 (C-159T) and IL2 (T-330G) and IL1b
(T-31C) and TLR2 (Arg753Gln) (χ2=16.98, p<0.0001).
Summary/Conclusions: The findings suggest an important role of immune
response genes in the development of a number of chronic lymphoproliferative
disorders and multiple myeloma, and can later be used as diagnostic and prog-
nostic markers of different types of hematological malignancies. In addition,
provided bioinformatics model will reveal not only the genetic criteria for high
and low risk of hematological malignancies studied, but also to determine their
prognostic significance in the clinical course of these diseases.
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FEATURES OF STROMAL ELEMENTS OF HEMATOPOIETIC BONE
MARROW NICHE IN MULTIPLE MYELOMA
N.Y. Semenova1,*, S. Bessmeltsev1, V. Rugal1
1Russian research institute hematology and transfusiology, Saint-Petersburg,
Russian Federation
Background: Structure of bone marrow stroma –  mesenchymal stromal cells
(MSC), endosteal stromal cells, and microvessels forming the hematopoietic
niche and regulate the development of hematopoietic stem cells (HSC). Analy-
sis of morphological changes of these elements of the hematopoietic niche is
important to clarify the pathogenesis of multiple myeloma (MM).
Aims: To investigate the morphological and functional characteristics of stromal
elements of the hematopoietic niche  in bone marrow of patients with MM, as
well as the characteristics of culture of mesenchymal stromal cells (MSC) and
hematopoietic stem cells (HSC).
Methods: 42 trepanobiopsy of bone marrow from patients diagnosed with MM
were used for the study. The age of the patients ranged from 53 to 72. The
study applied histological, histochemical, immunohistochemical (IHC) and mor-
phometric methods (VideoTest®).  Also 20 patients from this group conducted
cultural studies for the determination of colony-forming ability of HSC and mor-
phofunctional status of MSC.
Results: Myeloma cellular composition of infiltrates were polymorphic. The sur-
veyed patients were allocated to 3 types of infiltration is nodular, interstitial, diffuse.
The histogenesis of infiltration was confirmed by IHC research with antibodies
79α, CD 138, CD 38.Regardless of the type of infiltration in all patients were
recorded focal destructive changes of bone tissue. The density of microvessels
in IHC studies with antibodies to CD 31, CD34 cl.II (Dako) was increased. A
greater number of microvessels were detected in the endosteal area at all types
of the bone marrow involvement (compared to normal), the total number of
microvessels could statistically do not exceed such normal. A reduction in the
expression of type I collagen bone matrix and the increase of collagen type IV
expression, which is associated with increased microvascular density. Intratra-
becular collagen type I was mellowed, ossification was reduced, most notably it
revealed in areas of trabecules resorption. At the same time increased the amount
of collagen type IV in endosteal spaces of the bone marrow. A typical feature was
the appearance of focal network of reticulin fiber in subendosteal and perivascular
spaces.Cultural studies have shown a significant decrease of colony-forming
ability of HSC mobilized peripheral blood of MM patients after cryopreservation.
In vitro studies preliminary data on lack of differences in the phenotype of MSC
bone marrow of patients with MM and phenotype from healthy individuals, but
also, a decrease in the proliferative ability of the MSC of patients with MM.
Summary/Conclusions: Analysis of parenchymal-stromal relationships in
trepanobiopsy bone marrow of patients with MM evidence of their violation in the
context of malignancy of lymphopoiesis, while cultural studies have shown a
decrease of colony-forming ability of HSC and proliferative capacity of MSC.
Regardless of the prevalence of neoplastic lesions, and myeloma infiltration noted
the response of the stromal microenvironment, forming the hematopoietic niche.
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IMPACT OF RENAL IMPAIRMENT IN NEWLY DIAGNOSED MULTIPLE
MYELOMA IN A REAL WORLD SETTING
V. Bove1,*, F. Villano1, L. Díaz1, E. Riva1
1Hematología, Hospital de Clínicas, Montevideo, Uruguay
Background: Renal impairment (RI) is a frequent complication of patients with
newly diagnosed multiple myeloma (NDMM), reported in 15-40% with 10%
requiring hemodialysis (HD). It is associated with higher early mortality (EM)
and lower overall survival (OS). Early diagnosis and treatment with new agents
improve these results.
Aims: Analyze renal response, OS and EM in NDMM with RI and compare
them to patients with MM without RI.
Methods: All consecutive and unselected NDMM patients treated at Hospital
de Clínicas, Montevideo, Uruguay, from January 2011 to June 2015 were
included. Our database was completed prospectively and included clinical and
laboratory characteristics of the disease, treatment, treatment-related adverse
events, response, HD requirement, renal response and mortality.
Diagnosis of MM, response to treatment and degree of renal function recovery
were based on the International Myeloma Working Group criteria. RI was
defined as an estimated glomerular filtration rate (eGFR) <40 ml/min/1.73m2,
calculated by MDRD (Modification of Diet in Renal Disease) equation. Patients
whose RI was explained by other causes were excluded.  Early treatment was
defined by initiation within 7 days after diagnosis. EM was defined as death
within 3 months of diagnosis.
Results: MM was diagnosed in 52 patients, median age was 67 years (range
39-90), 61,5% were male, 38,5% had RI. The characteristics of the patients
and front-line treatment are shown in Figure 1.
Figure 1. Characteristics of patients and overall survival according to
renal function.
Overall response to first line treatment was 70% for those with RI (CR 20%)
and 68,8% in patients without RI (CR 15,4%). Treatment related adverse effects
were higher in patients with RI (45% vs 28,2%), being polyneuropathy the most
common side effect. Patients with RI required more dose adjustments (40% vs
6,3%). Renal response: 50% reversed RI, 10% achieved renal PR and 40%
renal CR, all before the 4th month from diagnosis; 77,8% started early treatment
and 70% received bortezomib (bz). Patients whose RI did not reverse had had
late initiation of treatment in 78% and 40% received bz. Six patients (30%)
remained in chronic HD, all had late initiation of treatment. Two of the 6 patients
who required HD at diagnosis obtained later independence; both received bz
and one was consolidated with autologous stem cell transplantation. Impact of
RI on OS and EM: median OS in patients with RI was not significatively different
to that of MM without RI (35,3 vs 43,3 months, p=0,346). Patients without RI
had higher OS compared to those who had reversible renal failure and those
who never recovered (43,3; 40,9 and 12 months, respectively, p=0,031). OS
was higher in patients with RI who received bz vs other therapeutic schemes
(42,5 vs 25,8 months, p=0,137). With a mean follow-up of 26 months, mortality
was 40% and 28,1% in patients with and without RI, respectively. EM were
also higher in patients with RI at diagnosis (50% vs 22,5%). The main cause
of EM was infection in both groups.
Summary/Conclusions: RI was frequent in NDMM and was associated with
advanced disease and higher tumor mass (>90% stage III Durie-Salmon and
ISS3), revealing a late diagnosis. Prompt institution of treatment and use of bz
relates to higher recovery of renal function and dyalisis independence. Although
toxicity and dose adjustements were higher in patients with RI this was not
associated with lower response to treatment. Reversal of renal failure associ-
ates with better OS, similar to those without RI at diagnosis. EM are more
prevalent in patients with RI at diagnosis. Even when the number of patients
is small, this real life data supports the need of planning local strategies that
lead to early diagnosis and initiation of treatment, which are crucial to reduce
morbidity and mortality associated to RI in NDMM. 
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THE EXPRESSION OF THE TRYPTASE POSITIVE MAST CELLS AND THE
LEVELS OF IL-17, CORRELATE WITH ANGIOGENIC FACTORS IN
PATIENTS WITH MULTIPLE MYELOMA
M. Kokonozaki1, C. Pappa2, R. Vyzoukaki1, A. Stavroulaki3,*, M. Devetzoglou4,
A. Papadopoulou1, I. Liapis4, A. Boula3, M. Alexandrakis5
1Laboratory of Haematology, University Hospital of Heraklion, 2Department of
Internal Medicine, 3Department of Haematology, Venizelion Hospital, 4Depart-
ment of Haematology, University Hospital of Heraklion, 5Medical School, Uni-
versity of Crete, Heraklion, Greece
Background: Angiogenesis in the bone marrow plays a very important role in
the progression of multiple myeloma(MM). The procedure of angiogenesis is
supported by several factors such as VEGF, FGF-2 and metalloproteases that
are secreted straight from the tumor cells. The presence of IL-6 in the microen-
vironment, induces the production and the secretion of several angiogenic factors
that activate inflammatory cells of the matrix, like macrophages and mast cells
to secrete more angiogenic factors.  IL-17 is among the most important cytokines
that have an important role in the development of myeloma tumor. IL-17 is a
proinflammatory cytokine that is secreted primarily by CD4 (activated memory
cells) and stimulate macrophages, fibroblasts and other cells that release several
cytokines. It has been reported that IL-17, induces angiogenesis in humans by
stimulating the migration of vessel endothelial cells and adjusting the production
of various proangiogenic factors. In a previous study, it was found that increased
levels in stage II and stage III, resolved after therapy. Additionally, blocking the
receptor of IL-17, with an antibody, cancels the effects of IL-17.
Aims: Aim of this study is to assess the relationship of the MCD and IL-17, in
angiogenesis of MM, as well as their correlation with known angiogenic factors
in disease progression.
Methods: We studied 52 newly diagnosed patients with MM, 32 women and
20 men, aged 67,5±9,6 years. According to the ISS stage, 19 were stage I,
17 stage II and 16 stage III . Regarding the type of paraprotein that had been
found, 31 IgG, 17 IgA and 4 patients with light chains. 20 age and sex-
matched healthy volunteers, were used as controls.  Serum samples and
bone marrow biopsy samples were obtained from all patients prior to the ini-
tiation of treatment.  Patients with impaired hepatic and renal function, chronic
or acute infections, chronic inflammatory or autoimmune disorders or other
malignancies were excluded from the study.We also excluded patients who
were taking anti-inflammatory drugs, corticosteroids or bisphosphonates. IL-
17, bFGF and ANGIOP-2 were measured in patients’ serum with ELISA
method according to the manufacturer’s instructions.  The MCD assessed
after immunohistochemical staining using monoclonal antibody to mast cell
tryptase. The MCD was measured in three hot spots (maximum vasculature
area) x 100 and then we measured mast cells x 400, using a graduated slide
which corresponds to  an area of 0.0625 mm2. MCD was calculated as mean
MCD / HPF.
Results: Statistically significant differences between patients and controls were
observed in all measured parameters, MCD (p <0.001), bFGF (p <0.01) and
ANGIOP-2 (p <0.01), and for IL-17 (p <0.04). All parameters were increased
in parallel with ISS stages (p <0.001) in all cases. Finally, the MCD and IL-17
correlated significantly with all the measured parameters (p <0.001)
Summary/Conclusions: The mast cells increase in the bone marrow(BM) of
patients with MM. They release several transmitters that promote directly and
indirectly the development of disease progress of MM also accompanied by
increased angiogenesis in BM. In conclusion, mast cells and angiogenic factors
seem to be important elements in the development of MM and become potential
targets for the treatment and prognosis of the disease.
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HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DIFFERENT
TREATMENT MODALITIES OF RELAPSED/REFRACTORY MULTIPLE
MYELOMA PATIENTS IN THE US: FINDINGS FROM PREAMBLE
D. Kuter1, C. Chen2,*, S. Khare3, S. Perez4, T. Zyczynski2, C. Davis2, R. Vij5
1Massachusetts General Hospital, Boston, 2Bristol-Myers Squibb,
Lawrenceville, United States, 3Mu Sigma, Kamataka, India, 4Mu Sigma,
Northbrook, 5Washington University School of Medicine, St. Louis, United
States
Background: Proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs)
and treatments involving both a PI and an IMiD (PI+IMiD) are the principal ther-
apies for treating relapsed/refractory multiple myeloma (RRMM). The wide-
spread adoption of these treatments may come with high healthcare resource
utilization (HCRU), of which key drivers are reported in past research. It is
important to further understand HCRU by different treatment modalities in real-
world practice settings.
Aims: To evaluate HCRU in patients receiving different treatment modalities
for RRMM.
Methods: US patients with RRMM, aged ≥18 y, with at least one prior therapy
who initiated treatment with a PI, IMiD or IMiD+PI within 90 d before or 30 d
after study enrollment (index therapy), were identified from PREAMBLE, an
ongoing, prospective, multinational, non-interventional observational study.
Patient data collected at each healthcare provider (HCP) visit, over a 3-y period
or until the end of patient follow-up, included clinic/physician office visits; home
healthcare, hospital outpatient and emergency room visits; and hospitalizations.
Demographics and baseline characteristics were summarized using descriptive
statistics. HCRU and its associated costs were analyzed using a standard per-
1000 patients-per-month metric.
Results: 287 patients (median age 66 y; 56% male) were enrolled in the US.
At the time of data cut-off (Sep 2016), 136 (47%) were still in the study and 151
(53%) had withdrawn; 92 (61%) of those withdrawn had died. Median (range)
follow-up was 12.7 (0.5–41.0) mo. At study entry, patients were divided into
three cohorts based on index therapy: PI (n=162, 56%; carfilzomib n=82/162;
bortezomib n=80/162), IMiD (n=74, 26%; pomalidomide n=32/74;
lenalidomide/thalidomide n=42/74), and PI+IMiD (n=51, 18%; carfilzomib and/or
pomalidomide n=17/51; other n=34/51). The three groups were similar with
regard to sex, race, disease status, ISS stage, comorbidities and number of
prior therapies (Table 1).
Table 1.
The median duration of treatment (mDoT) was longer for patients on IMiD (6.4
mo), but shorter for those on PI (4.2 mo) or PI+IMiD (4.4 mo). In the PI cohort,
carfilzomib had a shorter mDoT than bortezomib (3.5 vs 4.7 mo). Of 3220 total
HCP visits, the most common type was clinic/physician office (2732, 85%), fol-
lowed by hospitalization (210, 7%) and hospital outpatient (54, 5%). Mean per-
1000 patients-per-month total visits were higher for PI+IMiD (876) than for PI
(750) and IMiD (494). This remained true for clinic/physician office, hospital
outpatient and home healthcare/other. Patients on PI had more visits for man-
agement of MM treatment-related events (16%) than those on PI+IMiD (10%)
or IMiD (7%) (Table 1). Notably, among patients on PI, those on carfilzomib
had high mean per-1000 patients-per-month total visits (827), with per-1000
patients-per-month emergency room visits (18) and hospitalizations (78) higher
than any other treatment; 19% (175) of visits were made for management of
treatment-related events.
Summary/Conclusions: Routine management of MM and treatment-related
events drive HCRU, which may differ by treatment. Hospitalizations and hospital
outpatient visits remain key drivers of HCRU in MM, which highlights an unmet
medical need for effective therapy with better safety profiles.
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ASSOCIATION OF SERUM HEAVY/LIGHT CHAIN PAIR SUPPRESSION
WITH RISK FACTORS FOR PROGRESSION IN MONOCLONAL
GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND SMOLDERING
MYELOMA 
I. Isola1,*, M.T. Sanz2, M.T. Cibeira1, L. Rosiñol1, E. Lozano1, J.I. Aróstegui3,
M. Elena4, N. Tovar1, J. Yagüe3, E. Moga2, J. Bladé1, C. Fernández de Larrea1
1Hematology (Amyloidosis and Myeloma Unit), Hospital Clínic de Barcelona,
2Immunology, Hospital de la Santa Creu I Sant Pau, 3Immunology (Amyloidosis
and Myeloma Unit), 4Biochemistry (Amyloidosis and Myeloma Unit), Hospital
Clínic de Barcelona, Barcelona, Spain
Background: Monoclonal gammopathy of undetermined significance (MGUS)
and smoldering multiple myeloma (SMM) are conditions that usually precede
symptomatic multiple myeloma (MM). Risk stratification is crucial, considering
the heterogeneous progression rate among these patients and the chemopre-
vention trials encouraged for high risk individuals. A number of prognostic fac-
tors for progression have been identified. In this sense, the novel Hevylite assay
now enables us to accurately measure each isotype-specific heavy and light
chain (HLC). Recently, isotype-specific uninvolved HLC pair suppression was
described as an independent predictor of progression to MM in patients with
MGUS. The role of Hevylite as a prognostic factor in SMM is less investigated.
Aims: The aim of the present study was to analyze the impact of HLC pairs in
a series of patients with high risk MGUS and SMM and their relationship with
other previously described risk factors.
Methods: Forty-four patients diagnosed with high risk MGUS or SMM at a sin-
gle institution from March 2014 through April 2016 were prospectively included
in the present study.  Patients were stratified according to the Mayo Clinic and
the Spanish PETHEMA group models. Samples at diagnosis were tested for
HLC concentrations for the three pairs (IgG, IgM and IgA) by immunoneph-
elometry.
Results: The clinical characteristics and risk stratification of patients are sum-
marized in Table 1.
Table 1. Patient characteristics and risk stratification.
An abnormal HLC-pair ratio was detected in 96% of MGUS and 94% of SMM
patients, with no differences depending on the heavy chain isotype. A highly
abnormal HLC ratio (<0.02 or >45) was present in 9 patients (1 with MGUS
and 8 with SMM). HLC-pair suppression (i.e., IgG-κ in patients with IgG-λ gam-
mopathy) was more frequent in patients with SMM (83% vs 46%, p=0.02).
Severe HLC-pair suppression (>50% below lower level of normal) was present
in 12 (27%) patients, the majority of which had a diagnosis of SMM (83%).
Severe HLC-pair suppression was significantly associated with a highly abnor-
mal (<0.125 or >8) serum free light chain (FLC) ratio (p=0.004), abnormal/nor-
mal bone marrow plasma cell ratio >0.95 (p<0.001) and immunoparesis
(p=0.005), being present in 6 (86%) of the 7 patients with high risk SMM. Sup-
pression of the other isotypes (i.e., IgA or IgM HLC pairs in a patient with IgG
gammopathy) was identified in 33 (75%) patients, namely in 18 (69%) patients
with MGUS and 15 (83%) patients with SMM (p=0.48), and was not significantly
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associated with other risk factors for progression. Severe suppression (>50%
below lower level of normal) was significantly more frequent in SMM patients
(33% vs 8%, p=0.04) and was associated with highly abnormal FLC ratio
(p=0.001), abnormal/normal plasma cell ratio >0.95 (p<0.001), severe HLC-
pair suppression (p<0.001) and highly abnormal HLC ratio at diagnosis
(p=0.005). The “evolving” pattern of the serum M-protein was identified in 12
patients (MGUS 7, SMM 5) and it was not significantly associated with either
severe suppression of the HLC-pair or of the other isotypes. After a median
follow-up of 18 months (range, 6-35) progression to symptomatic MM was
observed in 3 patients. All 3 had a diagnosis of SMM with an “evolving” pattern,
highly abnormal HLC-ratio and severe HLC-pair suppression.
Summary/Conclusions: The findings presented in this study indicate that
highly abnormal HLC ratio, severe suppression of the HLC-matched pair and
other isotype HLC pairs are associated with known risk factors for disease pro-
gression in patients with high risk MGUS and SMM. The HLC assay could
become a valuable tool in the risk stratification of these patients.
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EXTRAMEDULLARY MYELOMA IN THE “NOVEL AGENTS ERA”:
OUTCOME, HETEROGENEITIES AND PECULIARITIES OF A COHORT OF
84 PATIENTS RETROSPECTIVELY ANALYSED IN A MONOCENTRIC
EXPERIENCE
L. Torti1,*, A. Morelli1, F. Bacci2, P. Di Bartolomeo1
1Department of Hematology and Bone Marrow Unit , Pescara, 2Section of
Hematopathology, Department of Hematology and Oncological Sciences, S.
Orsola-Malpighi Hospital, Bologna, Italy
Background: Extramedullary disease is an uncommon manifestation in multiple
myeloma (MM) and can either accompany newly diagnosed disease or develop
with disease progression or relapse. Extramedullary myeloma (EMM) seems to
have a different pathogenesis from its much more frequently encountered
medullary counterpart, showing often a poor prognosis. EMM clinical situations
are extraordinarily heterogeneous and their management is challenging.This
includes organ or tissue involvement resulting from hematogenous-spread and/or
bone involvement originating from different kind of bones.
Aims: We evaluated the impact of this disease features on patients’ outcome
in the context of novel-agents.
Methods: We reviewed 84 patients presenting EMM (median age 60, range
30-76)describing clinical and biological features (Figure 1B. Our aim was study-
ing prognosis of bone-related extramedullary-disease (bEMD) and its relation-
ship with soft-tissue related EMD (sEMD) in MM patients in our institution.
Results: 42 bEMD and 42 sEMD patients treated at Our Department between
2007 and 2016 were included in this study. Of the first group 10 presented
EMM at diagnosis and 32 at relapse as well as 7 and 35 respectevely of the
second series. 31 among sEMD were dead and 11 were alive, 20 of bEMD
patients were dead and 22 were still alive. EM was diagnosed using imaging
techiniques such as PET-CT (35%) or magnetic resonance MRI (65%). Biop-
sies were carried out only if the lesion was accessible (62%). The treatment
was heterogeneous and all patients had receveid either thalidomide or borte-
zomib in the first-line of therapy. We showed that sEMD cohort has a signifi-
cantly poorer survival compared to bEMD patients (median OS from diagnosis
of EMD of 13 versus 58 months, P<0001). Finally lung, liver (parenchyma-EM)
and SNC involvement among sEMD patients has shown a poorer outcome
when compared to skin and lymph nodes masses respectively median OS of
12 and 10 months versus 18 and 15 months P <0001). Conversely among
bEMD group there wasn’t a significant advantage of outcome regarding the
different bones involved. Kaplan-Meier estimates were used for survival analy-
sis and differences between survival-times in patient subgroups were tested
using the log-rank test (Figure 1A). Interestingly extramedullary-spread can be
triggered by an invasive-procedures (surgery) or by a bone-fracture.In our pop-
ulation we have a case of breast-plasmocytoma diagnosed accidentally after
reconstructive breast-surgery,where Polymerase Chain Reaction of
immunoglobulin gene-rearrangement in the breast tissue excised confirmed
monoclonal-CD 138/lambda plasma-cells. This patients at first was treated with
VTD-regimen followed by tandem-ASCT and after EM-relapse achieved com-
plete remission with haploidentical-bone-marrow-transplantation. Allogeneic
transplantation should however be remembered in the therapeutic-armamen-
tarium against EM especially in high-risk-young-patients. Furthemore often it
has been described in the literature association between EMD, IgD subtype
and FLC (free light chain)escape. In fact in our study we have reviewed 6 cases
of IgD and 4 FLC-escape, all of them were observed in relapse-setting and in
sEMD group. Finally the mechanism of extramedullary spread are poorly estab-
lished: maybe a decrease expression of integrins and CD56 is involved. In our
population absence of CD56 protein was shown in 56% of sEMD group and in
15%of bEMD case-series.
Summary/Conclusions: Cinical features of MM-patients with bEMD were dif-
ferent from the patients with sEMD. Outcome of this population was significantly
better than the patients with sEMD, and was comparable to the patients without
EMD. Even in the era of novel drugs extramedullary soft tissue has a poor
prognosis expecially in a relapse-setting. This work shows a significant differ-
ence in prognosis for different type of extramedullary-disease even between




DINAMIC PREDICTIVE FACTORS FOR A BETTER STRATIFICATION
OF PATIENTS WITH R-ISS II NEWLY DIAGNOSED MULTIPLE MYELOMA
M. Offidani1,*, L. Corvatta1, L. Maracci1, K. Garvey1, S. Gentili1, S. Morè1,
V. Mori1, P. Leoni1
1Clinica di Ematologia AOU Ospedali Riuniti di Ancona, Ancona, Italy
Background: Revised International Staging System (R-ISS), combining the
ISS score with cytogenetics and serum LDH, represents the most recent prog-
nostic model for stratifying newly diagnosed multiple myeloma (MM) patients
into three different survival groups. Although data for R-ISS development have
been obtained from patients enrolled in clinical trials, this prognostic score has
been validated also in real-life scenario (Tandon et al., 2017). In both non-clin-
ical trial setting and IMWG experience, the majority of patients (about 65%)
belonged to the intermediate risk group (R-ISS II) that, probably, needs better
prognostication.
Aims: The aim of this study was to search for a closer stratification of MM
patients with R-ISS II, taking into consideration dynamic aspects, such as ther-
apeutic strategy and response to therapy.
Methods: We investigated the impact of variables, such as initial therapy,
response to therapy and maintenance therapy, on PFS and OS in 108 newly
diagnosed MM patients classified as R-ISS stage II, diagnosed between 2005
and 2015, who received novel agents such as immunomodulatory drugs and
proteasome inhibitors. Score weights of the prognostic factors, found to be sig-
nificant according to Cox regression model, were determined based on the
regression coefficients.
Results: Median age of the 108 patients was 69 years (range 44-93) and 35%
of them were older than 75 years. Thalidomide- and lenalidomide-based regi-
mens were administered to 12% and 28% of patients, respectively, whereas
60% of the patients received bortezomib (54%) or carfilzomib-based (6%) reg-
imens as induction therapy. Thirty-eight percent of the study population under-
went ASCT and 40% received maintenance therapy. Regarding the response
to the therapy, at least CR, VGPR and PR were documented in 35%, 66% and
87% of the patients, respectively. Five-year PFS and OS were 31% and 65%,
respectively, similar to those reported by IMWG. Patients who did not achieve
a CR, showed a significantly shorter 5yr-PFS (27% vs 50%; HR=2.9,
95%CI=1.6-45.0; p<0.0001) and 5yr-OS (53% vs 80%; HR=2.8, 95%CI=1.3-
5.9; p=0.006) compared to those who did. Moreover, a significant better 5yr-
PFS was documented in patients receiving maintenance therapy, compared to
those who did not receive maintenance therapy (48% vs 20%; HR=1.9,
CI95%=1.2-3.3; p=0.010) whereas initial therapy did not affect the outcome.
Assigning a value to the variables found to be significantly related to survival
measures, according to the above methods, patients were stratified into the
following two groups: low-risk (LR), including 38 patients with score 0-1, i.e.
patients achieving CR and receiving maintenance therapy (score 0) or achiev-
ing CR but not receiving maintenance (score 1); high-risk (HR) group, including
70 patients with score 2-3, i.e. not achieving CR, who underwent maintenance
therapy (score 2) or not achieving CR and not receiving maintenance (score
3). Five year PFS of HR patients was significantly shorter compared to the LR
group (20% vs 58%; HR=2.5, CI95%=1.6-3.8; p<0.0001), whereas 5-year OS
was 57% vs 80% (HR=1.9, CI95%=1.1-3.3; p=0.021).
Summary/Conclusions: Our results suggest that in the R-ISS II MM patients,
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the outcome of those achieving a CR and undergoing long-term therapy, is
comparable with the outcome of the R-ISS I group. On the other hand, patients
not achieving CR have a poor outcome, similar to those in the R-ISS III group.
Therefore, these patients should require personalized therapy, aimed to achieve
CR and to maintain therapy continuously.   
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THE IMPACT OF THE UPDATED IMWG DIAGNOSTIC CRITERIA
IN A REAL-LIFE SMM COHORT: A SINGLE CENTER EXPERIENCE
P. Vlummens1,*, F. Offner1
1Hematology, Ghent University Hospital, Ghent, Belgium
Background: Recently, an update of the diagnostic criteria for smoldering mul-
tiple myeloma (SMM) & multiple myeloma (MM) was published by the Interna-
tional Myeloma Working Group (IMWG). In addition to CRAB criteria, 3 bio-
markers of disease were introduced being (i) the presence of >60% clonal bone
marrow plasma cells (BMPC), (ii) a serum free light chain ratio (FLC-ratio) >100
& (iii) the presence of >1 focal lesion on whole-body MRI (WBMRI). The intro-
duction of these biomarkers has been shown to identify patients having a 70-
80% risk of progression to MM over a 2-year time period.
Aims: To evaluate the impact of IMWG criteria in routine practice, focussing on
(i) the prevalence of these biomarkers, (ii) the diagnostic strength of BMPC esti-
mation using bone marrow aspirate versus biopsy & (iii) the added role of dynamic
contrast-enhanced WBMRI (DCEMRI) in the evaluation of SMM patients.
Methods: We retrospectively identified 28 SMM cases diagnosed between
01/01/09-31/12/14. Sufficient data for analysis was available for 25 patients.
All patients underwent standard clinical & laboratory evaluation, bone marrow
examination & WBMRI (T1- (+/-Gd) & T2-weighted sequences, diffusion-weight-
ed sequences & additional DCEMRI sequences using time intensity curves).
Time to progression (TTP) is defined as time from diagnosis until MM develop-
ment. Overall survival (OS) is defined as time from diagnosis until death from
any cause. Survival analysis was performed using the Kaplan-Meier method &
significance was tested using the log-rank algorithm. Intergroup analysis was
performed using non-parametric rank-based analysis & correlation was calcu-
lated using the Pearson coefficient. Reported p-values are 2-sided with a sig-
nificance level of 5%.
Results: Median follow-up was 64,1 months (analysis performed on 01/02/2017).
No patients had a FLC-ratio >100 at time of diagnosis. Also, no patients with
>60% of clonal BMPCs were seen. In 20 patients BMPC counts using both aspi-
rate & biopsy were available. Analysis showed a significant higher estimate of
BMPC levels using biopsy (14,8%, SD 4,99) versus aspirate (8,45%, SD 6,59)
(p=0,002). Sensitivity of bone marrow aspirate was calculated to be 30% consid-
ering the 10% BMPC cut-off. Correlation between bone marrow aspirate & biopsy
was found in 26,6% of cases. WBMRI-positivity was seen in 9 patients (36%).
Progression was seen in 7/9 patients (78%) where only 1/16 WBMRI-negative
patients (6,3%) developed MM (p<0,001). Median TTP was 19,9 months versus
not-reached, respectively (p<0,001). No OS difference was seen between both
groups (p=0,453). DCEMRI was positive in 14 patients (56%) thus identifying 5
additional WBMRI-negative patients with measurable bone marrow involvement.
No significant difference concerning progression risk was however seen between
WBMRI-negative patients being DCEMRI-positive (5/19, 26,3%) or -negative
(14/19, 73,7%) (p=0,317). Analysis of baseline data revealed no significant dif-
ference concerning age, sex, genetic aberrations or the type of the monoclonal
protein between both groups. In patients developing MM, progression was seen
based on the development of anemia (5/8, 62,5%), bone pain (3/8, 37,5%), hyper-
calcemia (1/8, 12,5%) & the development of punched -out lesions (4/8, 50%). No
renal insufficiency was seen. 
Summary/Conclusions: Our data shows that WBMRI-positivity was the most
frequent biomarker in a routine clinical setting. WBMRI-positivity, according to
IMWG-criteria, clearly identifies patients with an increased risk of progression
as was already shown previously. Although increasing the sensitivity of WBMRI,
addition of DCEMRI-sequences didn’t have an added benefit. Our sample size
was however relatively small. And although IMWG-guidelines do not state clear
requirements concerning the preferred type of bone marrow evaluation, our
data shows that a bone marrow biopsy can never be ommited in suspected
cases of SMM, as an aspirate alone clearly lacks diagnostic strength.
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RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN 401 MULTIPLE
MYELOMA PATIENTS: OBSERVATION OVER A 25-YEARS PERIOD IN A
SINGLE INSTITUTION
M. Fernández-Caballero1,*, F. de Arriba1, A. Jerez1, M. D. García1, V. Vicente1,
V. Roldán1
1Servicio de Hematología y Oncología Médica, Hospital General Universitario
Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia,
IMIB-Arrixaca, Murcia, Spain
Background: Patients with multiple myeloma (MM) have shown an incidence
of 3-10% of venous thromboembolic events (VTE). The introduction of
immunomodulatory drugs (IMIDs) in the treatment regimen has further
increased the risk of VTE, especially when combined with steroids or
chemotherapy (20-30%). Actual guidelines recommend thromboprophylaxis
measures, but the proposed strategies are the results of expertise consensus
or derived from the extrapolation of data from many studies.
Aims: The aim of this study is to analyze the development of VTE in a large
cohort of MM patients, treated for 25 years in a single institution, to assess risk
factors suggested in general population, also to confirm the VTE risk of IMIDs
based-regimens and the relevance of anticoagulant thromboprophylaxis.
Methods: Four hundred and one consecutive patients diagnosed with MM
in a tertiary University Hospital between 1991 to 2015 were included. Data
about VTE development, patient characteristics, myeloma-related factors,
treatment and thromboprophylatic measures were retrospectively recorded.
Multivariable correlates of VTE were assessed using Cox proportional haz-
ards analysis. 
Results: The median age at diagnosis was 66 years (range 24-90 years), and
47% were males. The results concerning treatment are extracted from 374
patients who were symptomatic and received myeloma treatment. Among the
164 patients that received IMIDs-based regimen, 27% did not receive any
antithrombotic treatment, due to the lack of strong recommendations at the
beginning of the use of IMIDs-based regimens. On the other hand, the most
common thromboprophylaxis was set with LMWH (54%), followed by low doses
of aspirin (13%) and anti-vitamin K (VKA) (6%). Median follow was 40 months
(range, 1-293) and VTE occurred in 11% of patients, with a median time from
diagnosis of 10 months. IMIDs based-regimen demonstrated to be a risk factor
associated on multivariate analysis, and the relevance of thromboprophylaxis
has been proved, as the absence of this measure increased significantly the
risk. Other factors that have also demonstrated to be independently associated
with a higher risk for VTE were: BMI ≥30 kg/m2, prior Stroke or TIA, prior malig-
nant neoplasm, and the use of high dose of dexamethasone.
Summary/Conclusions: Our data support the actual recommendation of
antithrombotic prophylaxis in IMIDs-based regimens, especially in association
with high dose of dexamethasone. We recommend the use of a risk factor
model including obesity and previous history of thromboembolic disease or
cancer, in order to guide the appropriate thromboprophylaxis measures.
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A PHASE III RANDOMIZED, OPEN-LABEL STUDY OF ISATUXIMAB
(SAR650984) PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS
POM AND DEX IN RELAPSED/REFRACTORY MULTIPLE MYELOMA 
P. Richardson1,*, M. Attal2, J. San Miguel3, F. Campana4, S. Le-Guennec5,
A.-M. Hui4, M.-L. Risse5, K. Anderson1
1Medical Oncology, Dana-Farber Cancer Institute, Boston, United States, 2Insti-
tut Univ. du Cancer Toulouse Oncopole, Toulouse, France, 3Clinica Universidad
de Navarra, Navarra, Spain, 4Sanofi, Cambridge, United States, 5Sanofi, Vit-
ry-Alfortville, France
Background: Treatment for refractory or relapsed and refractory multiple myelo-
ma (RRMM) remains an unmet need. Isatuximab (ISA), an anti-CD38 monoclonal
antibody with multiple mechanisms of tumor killing, has shown efficacy and an
acceptable tolerability profile in Phase 1/2 studies in patients with RRMM (Richter
et al. ASCO 2016; Vij et al. ASCO 2016; Richardson et al. ASH 2016).
Aims: This Phase III, prospective, multicenter, randomized, open-label study
(NCT02990338; ICARIA-MM) is being conducted to evaluate the clinical benefit
of ISA in combination with Pom and low-dose dex (Pom/dex) versus Pom/dex
for the treatment of adult patients with RRMM.
Methods: Eligible patients are those with RRMM and demonstrated disease
progression within 60 days of the last therapy. Patients will have received at
least 2 prior lines of therapy, including lenalidomide and a proteasome inhibitor
(bortezomib, carfilzomib, or ixazomib) alone or in combination. Patients will be
randomly assigned in a 1:1 ratio to either ISA (10 mg/kg IV on Days 1, 8, 15,
and 22 in the 1st cycle; Days 1 and 15 in subsequent cycles) plus Pom (4 mg
on Days 1–21) and dex (at 40 mg for patients <75 years of age and at 20 mg
for patients ≥75 years of age, on Days 1, 8, 15, and 22) or Pom and dex. Treat-
ment cycles will be 28 days each. Patients will continue therapy until disease
progression, occurrence of unacceptable adverse events (AEs), or their deci-
sion to discontinue the study, whichever comes first. All patients will be required
to provide informed consent. The primary endpoint is progression-free survival
(PFS), i.e. time from randomization to progressive disease or death from any
cause. Response will be determined by IMWG criteria (2016). Key secondary
endpoints include overall response rate and overall survival (OS). Safety eval-
uations include treatment-emergent AEs/serious AEs (including infusion-asso-
ciated reactions), laboratory parameters, vital signs, and assessment of physical
examination.
Results: Approximately 300 patients (150 in each arm) are expected to be
enrolled in this study.  Statistical analyses will be conducted according to a pre-
specified plan. The first patient was recruited in January 2017. 
Summary/Conclusions: This Phase III, prospective, multicenter trial will pro-
vide a placebo-controlled evaluation of the efficacy and safety of ISA+Pom/dex,
a combination which has previously reported preliminary clinical activity and
manageable toxicities in heavily pretreated patients with RRMM in a single-
arm Phase Ib study.
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LONG TERM SURVIVAL OF IGM MULTIPLE MYELOMA AND
WALDENSTRŐM’S MACROGLOBULINEMIA PATIENTS
M. Kraj1,*, R. Pogłód2, B. Kruk1, K. Warzocha3, M. Prochorec-Sobieszek1
1Department of Diagnostics for Hematology, 2Department of Transfusion Med-
icine, 3Department of Hematology, Institute of Hematology and Transfusion
Medicine , Warsaw, Poland
Background: IgM multiple myeloma (MM) and Waldenström’s macroglobu-
linemia (WM) are two hematologic malignancies with the common finding of
IgM monoclonal gammopathy. IgM MM is a rare and poorly characterized
disease.
Aims: The paper presents clinical and laboratory  results of long term obser-
vations of 15 IgM MM patients selected from a group of 889 MM patients (1.6%)
diagnosed and treated for several years at the Institute of Hematology and
Transfusion Medicine in Warsaw  as well as 15 WM patients investigated and
treated at the same period of time at our hospital.
Methods: For analysis of serum proteins new Hevylite and Freelite tests (Bind-
ing Site Ltd Birmingham, UK) were applied as well as immunofixation using
Sebia (Lisses, France) reagents. Fresh and archived frozen serum samples
were used for the study.
Results: The clinical presentation of IgM MM patients is heterogenic starting
with typical form for non IgM MM through predominant form with characteristic
hyperviscosity syndrome and severe disease course to slow and latent form
with survival time up to dozens of years. In 2 patients diagnosis of IgM  MM
was preceded by a 3-year period of monoclonal gammopathy of undetermined
significance (MGUS)  while in 4 patients (27%) diagnosis of WM was preceded
by a 108, 84, 78, 9 months period of  IgM MGUS. Median real overall survival
of IgM MM patients was 50 months, 5 patients  (33%) survived above 7 years
and 2 patients (13%) survived above 12 years. Median overall survival of WM
patients was 108 months, 7 patients (47%) survived above 10 years, 3 patients
(20%) survived above 15 years. Lytic bone lesions were found in 11 (73%) IgM
MM patients and in 3 (20%) WM patients. Urine monoclonal free light chains
(FLC) detected by immunofixation was present in 60% of IgM MM patients and
increased concentrations of involved monoclonal FLC and abnormal FLC κ/λ
ratio in serum (by Freelite) in 75% of IgM MM patients. It was shown that IgM
clonality in IgM MM and WM patients can be determined by using immunoglob-
ulin heavy chain /light chain (HLC) immunoassays- Hevylite. Immunofixation
and HLC ratios were concordant in all assessed IgM MM and WM patients. In
IgM MM patients the suppression of uninvolved polyclonal IgM- detectable by
using IgM HLC test - has prognostic significance. The evaluation of IgM HLC
in 13 patients with IgM MM at diagnosis revealed a decreased concentration
of uninvolved IgM (HLC IgMκ <0.33 g/L, HLC IgMλ <0.20 g/L) in 5 patients and
normal values in 8 patients. Median overall survival in patients with a decreased
uninvolved IgM was 15 months and in patients with normal polyclonal IgM 55
months (p<0.01).
Summary/Conclusions: 33% of IgM MM patients survive above 7  years and
13% above 12 years while 47% of WM patients survive above 10 years and
20% above 15 years. Suppression of uninvolved polyclonal IgM (detectable
by using HLC IgM test) at the time of IgM myeloma diagnosis is unfavorable
prognostic factor.
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MULTISITE PERFORMANCE EVALUATION STUDY OF THE BD ONEFLOW
PLASMA CELL DISORDERS PANEL
B. Balasa1,*, D. van Hoof2, C. Fox2, E. Deal Becker2, J. perkins2, C. Green2,
C. Bessette2, K. Judge2
1Medical Affairs, 2BD Biosciences, San Jose, United States
Background: The BD OneFlow solution for plasma cell disorders incorporates
a standardized flow cytometry approach based on the EuroFlow (EF) Consor-
tium liquid reagent system. The BD OneFlow solution enables reproducible
identification and discrimination of distinct cell populations by combining stan-
dardized assays, setup reagents, and protocols. The plasma cell disorders
(PCD) panel is composed of the BD OneFlow PCST (Plasma Cell Screening
Tube) and BD OneFlow PCD. BD OneFlow PCST helps differentiate normal
plasma cell populations from those requiring follow-up. The BD OneFlow PCD
classification tube helps differentiate abnormal from normal plasma cell popu-
lations. The BD OneFlow PCD tube, when run in parallel with BD OneFlow
PCST tube, characterizes the abnormal plasma cell population for identification
of plasma cell disorders. 
Aims: The objective of this study was to compare the accuracy between the
BD OneFlow PCD system and the EF liquid comparator system.
Methods: De-identified remnant human bone marrow specimens (n=48) were
collected at two study sites and tested in an unblinded manner within 26 hours
of draw. Specimens were simultaneously stained with BD OneFlow PCD and
BD OneFlow PCST tubes and EF specified liquid reagents. Acquisition and
analysis were performed on a BD FACSCanto II instrument using standardized
acquisition and analysis templates in BD FACSDiva software. For qualitative
endpoints, overall agreement, negative agreement, and positive agreement,
along with their one-sided lower 95% confidence limits, were calculated. For
accuracy quantitative endpoints (% positive plasma cell population), the slope,
intercept, and 95% confidence limits of the slope from a Deming regression
were calculated for the BD OneFlow vs EF methods.
Results: The BD OneFlow PCD system is in 100% agreement (26 of 26) with
the EF system in classifying patients as having normal plasma cell populations.
BD OneFlow PCD system is in 100% agreement (22 of 22) with the EF system
in identifying patients with a plasma cell disorder. Furthermore, the BD OneFlow
PCD system correctly identified 100% of patients who had a plasma cell dis-
order based on clinical results. 
Summary/Conclusions: The multisite evaluation between the BD OneFlow
PCD system (PCST and PCD tubes) and the EF liquid reagent system was
fully concordant in identifying patients with abnormal plasma cell populations.
Additionally, all subjects identified as having plasma cell disorder based on
clinical results were identified as having plasma cell disorder by the BD One-
Flow PCD system. The BD OneFlow PCD panel is a fully standardized and
validated system for aiding in the diagnosis of plasma cell disorders from bone
marrow specimens.
BD OneFlow PCD and BD OneFlow PCST are for in Vitro Diagnostic Use; CE
Marked to the European In Vitro Diagnostic Medical Device Directive 98/79/EC.
23-19565-00.
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PRACTICE GAPS AND BARRIERS TO OPTIMAL MANAGEMENT OF
MULTIPLE MYELOMA PATIENTS : RESULTS FROM A MIXED-METHODS
STUDY IN 8 EUROPEAN COUNTRIES
S. Murray1, M. Mohty2,*, S. Peloquin1, N.W. van de Donk3, S. Leitao4,
S. Labbé1, S. West5, E. Hofstädter-Thalmann6, P. Sonneveld7
1AXDEV Group, Brossard, Canada, 2Hopital St Antoine, University Pierre &
Marie Curie, Paris, France, 3Department of hematology, VU University Medical
Center, Amsterdam, Netherlands, 4Janssen Pharmaceutical, Barcarena, Por-
tugal, 5Royal Mardsen, London, United Kingdom, 6Janssen Pharmaceutical,
Vienna, Austria, 7Department of Hematology, Erasmus MC Cancer Institute,
Rotterdam, Netherlands
Background: Previous studies have identified gaps and barriers in Multiple
Myeloma (MM) patient care, especially in relation to treatment decision making.
However, only few studies have aimed at better understanding the practice gaps,
from the healthcare providers’ perspectives, with the purpose to investigate the
root causes of those gaps and find solutions to alleviate the challenges.
Aims: We conducted a study to identify the practice gaps and challenges in
the diagnosis, treatment and management of MM patients, as experienced and
reported by medical oncologists, haematologists and hemato-oncologists
(HEM) and oncology nurses (NU) in 8 European countries between February
2016 and June 2016.
Methods: This mixed methods ethics-approved study included exploratory
semi-structured interviews (phase 1) designed to generate in-depth discussion
around challenges in the diagnosis, treatment and management of MM, fol-
lowed by a quantitative online survey (phase 2) designed to validate the findings
from the interviews with a larger sample. Practice gaps were identified through
combined analysis of data from the in-depth interviews and online surveys.
Results: A total of 364 participants (HEM=281, NU=83) from France (n= 58),
Germany (n=58), Russia (n=41), Spain (n=58), Italy (n=50), the UK (n=58),
the Netherlands (n=16), and Belgium (n=25) participated in this study. Thirty-
nine (39) interviews were conducted (HEM=28, NU=11) and 325 participants
completed the online survey (HEM=253, NU=72). A majority (79%) of the sam-
ple had more than 10 years of clinical practice experience and over a third
(39%) had over 20% of MM patients in their patient caseload. Three key findings
were identified in the management of MM patients: 1) challenges in managing
treatment side-effects. Forty percent (40%) of HEM reported lack of skills in
managing cardiovascular side effects or symptoms. Over a third of HEM report-
ed difficulties in managing fatigue (40%), skin toxicities (35%) or peripheral
neuropathy (34%). NU reported being challenged by the management of renal
insufficiency as a side effect or symptom (46%), peripheral neuropathy (36%),
thrombosis (37%), and skin toxicities (33%). Additionally, 2) NU reported chal-
lenges in communicating with patients and educating them around their dis-
ease, especially in relation to treatment outcomes and long term side effects.
For example, 51% of NU reported a lack of skills discussing sexual issues as
consequences of the disease/treatment.  Finally 3) there was a large variability
across countries in the guidelines followed by HEM and NU for the treatment
and management of MM patients.  Detailed results, including country-specific
analyses and investigation of the practice gaps’ causalities, will be presented.
Summary/Conclusions: These findings provide real-life recent evidence of
the challenges of HEM and NU in relation to specific aspects of the manage-
ment of patients with MM with 3 main areas, challenges in managing side
effects, communication with patients and leverage of  guidelines which show
differences between HEM and NU but also between countries.  The findings
support the needs for the development of tailored clinical tools, educational
activities and performance improvement interventions, adapted to the local
context at a country level.  Efforts should aim to address those current chal-
lenges before new therapies, such as immunotherapies, become available.
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These new agents, with their own specific safety and side effect profiles, are
likely to add to the challenges already experienced by health care providers in
their management of patients with MM.
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THE EXPRESSION OF APRIL BY MULTIPLE MYELOMA CELLS AND
THEIR ROLE IN THE EVOLUTION OF MULTIPLE MYELOMA
A. Xekalou1, P. Kanellou2,*, R. Vyzoukaki3, M. Kokonozaki3, C. Pappa4,
M. Devetzoglou5, A. Sfyridaki6, F. Psarakis7, M. Alexandrakis8
1Pathology, Venizelion Hospital, 2Blood bank, 3Laboratory of Haematology,
University Hospital of Heraklion, 4Department of Internal Medicine, Venizelion
Hospital, 5Department of Haematology, University Hospital of Heraklion, 6Blood
bank, Venizelion Hospital, Heraklion, 7Department of Surgery, Hospital of Sitia,
Sitia, 8Medical School, University of Crete, Heraklion, Greece
Background: Multiple myeloma (MM) is a malignant proliferation of plasma
cells and is characterized by the accumulation of monoclonal plasma cells in
bone marrow that secrete pathological monoclonal immunoglobulins. Inductive
factors secreted by tumor cells and other cells of the marrow microenvironment
play an important role in disease progression. APRIL, by initial letters A Prolif-
eration Inducing Ligand, is a member of the family of pro TNF, one of the main
factors for the survival of immature and activated B cells. One of the main signal
transduction pathways for activation of myeloma cells is NF-κB. APRIL, can
directly activate the NF -κB and has been found by studies that are the most
important factors for the survival of healthy and myeloma cells.
Aims: Aim of this study was  the study of APRIL expression in myeloma cells
in the bone marrow of patients with MM and their possible association with cell
proliferation markers.
Methods: We studied 42 newly diagnosed patients with MM, 19 women and 23
men, aged 64,1±10,4 years. According to the ISS stage, 14 were stage I, 11
stage II and 17 stage III . Regarding the type of paraprotein that had been found,
23 IgG, 14 IGA and 5 patients with light chains. Serum samples and bone marrow
biopsy samples were obtained from all patients prior to the initiation of treat-
ment.  Patients with impaired hepatic and renal function, chronic or acute infec-
tions, chronic inflammatory or autoimmune disorders or other malignancies were
excluded from the study. We also excluded patients who were taking anti-inflam-
matory drugs, corticosteroids or bisphosphonates. 20 age and sex-matched
healthy volunteers, were used as controls. The levels of IL-10 and IL-6 in the
serum were measured by ELIZA. Bone marrow infiltration by neoplastic plasma
cells was calculated in%. The expression of cell proliferation index was calculated
in BM biopsy sections with immunohistochemistry techniques. The expression
of APRIL was also calculated with immunohistochemistry. For the control of the
process we used positive control. The  assessing of the staining was checked  in
the optical microscope, over the whole surface of each sample and had to do
with the cytoplasm of tumor cells. It was dotted with brown ting. Non-specific
staining was observed at the other cellular components of BM. The degree of
staining expression was evaluated as the percentage of neoplastic plasma cells
and according to the intensity of staining in four-grade  scale 0: negative,+1 weak,
+2 moderate and +3 intense staining. Then the proportion of plasma cells stained
for each type of staining separately, was calculated using the H-score method
(Histoscore), based on the formula:% *% * 1+2+3% *. Our aim is to prove if the
intensity of expression is associated with disease stage.
Results: Statistically significant differences were observed between patients
and controls for all parameters measured (p <0.001 in all cases) . All values  of
the measured parameters increased in parallel  with the ISS stages of the dis-
ease (APRIL p <0,005, bone marrow infiltration p <0.03 Ki-67p <0,01, IL-10 p
<0,001, IL-6, p <0.001) Eventually  APRIL correlated significantly with all meas-
ured parameters e.g. BM infiltration r=0,386, p <0,01, with Ki-67 r=0,390 p
<0,01 IL-10 r=0,497 p <0,001, IL-6, r=0,484 p <0,001).
Summary/Conclusions: Increased expression of APRIL ligand plays an impor-
tant role in development and pathobiology of MM and may be an important
therapeutic target in the treatment of MM.
PB1962
DEVELOPMENT OF SECOND PRIMARY MALIGNANCY AFTER
TREATMENT WITH LENALIDOMIDE: A SINGLE CENTRE EXPERIENCE
F. McGlynn1,*, E. Groarke1, S.W. Maung1, R. Desmond1, J. McHugh1,
H. Enright1
1Haematology, Tallaght Hospital, Dublin 24, Ireland
Background: Lenalidomide is a well-established and effective treatment for
haematological malignancies particularly multiple myeloma (MM), but also lym-
phoma and myelodysplastic syndromes. It can be used as both a single agent
and in combination with dexamethasone or other chemotherapeutic agents. A
previous study in myeloma patients demonstrated an increased incidence of
second primary malignancy (SPM) in patients treated with lenalidomide and
dexamethasone (7% - 8%) compared to those treated with dexamethasone
and placebo (2%>3%) [1 - 3]. 
Aims: We reviewed all patients treated with Lenalidomide in a single centre
from January 2008 to May 2016 to establish the real-world of SPM.
Methods: A database of patients (n=137) treated with lenalidomide in the spec-
ified timeframe was created from pharmacy records. A search of the hospital’s
patient management system was performed to identify: (1) type and date of
primary haematological diagnosis, and (2) type and date of second malignancy
based on histology. An analysis of the data was performed to establish: (1) inci-
dence of SPM, (2) latency between primary haematological malignancy and
SPM, (3) latency between starting lenalidomide and SPM, (4) types and sub-
types of SPM.
Results: The majority of patients were treated for Multiple Myeloma (67%). Other
primary haematological diagnoses included myelodysplastic syndrome(MDS),
Non-Hodgkin lmphoma(NHL), and Idiopathic myelofibrosis(IMF). The incidence
of SPM post-treatment with lenalidomide was 12 patients (8%). 9 patients had a
diagnosis of second malignancy prior to starting lenalidomide treatment. The
median latency between starting lenalidomide and SPM diagnosis was 24
months.. The median latency between primary haematological diagnosis and
SPM diagnosis was 37 months. The most common types of SPMs were haema-
tological; 7 (64%), patients had t-MDS 3 (27%),  3 Acute Myeloid Leukemia(AML)
(27%), and 1 patient developed B-cell Lymphoma (9%). Next most common was
skin malignancy; 3 (27%), all squamous cell carcinoma (SCC).  One patient
developed prostate carcinoma (9%).
Summary/Conclusions: Studies show the estimated incidence of SPM in MM
to lie between 2%>10% over a 25 year period [5]. This study demonstrates a
higher incidence (12%), however it includes patients treated for other primary
haematological malignancies. This data demonstrates a similar incidence of
SPM to previous studies (8%) post-treatment with lenalidomide [1 - 3]. Haema-
tological malignancy was the commonest SPM however this differs from other
studies which showed a majority of solid tumors (including skin malignancy)
[4].  We found t-MDS/AML and skin malignancy to be the most significant SPMs.
This is in agreement with some published reports [4, 5]. No analysis was made
of patient specific risks or disease specific risks. This data supports the conclu-
sion that the risk of SPM must be considered before commencing a patient on
lenalidomide therapy.
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SOLITARY PLASMACYTOMA. A SINGLE-CENTRE RETROSPECTIVE
STUDY
K. Velazquez Kennedy1,*, C. Martinez-Geijo Román1, M.J. Blanchard1,
F.J. López Jiménez1
1Haematology, Hospital Ramón y Cajal, Madrid, Spain
Background: A solitary plasmacytoma (SP) is a rare neoplastic mass of mon-
oclonal plasma cells that can either be localized in bone (solitary plasmacytoma
of bone, SPB), or soft tissue (extramedullary plasmacytoma, EMP), without
evidence of multiple myeloma (MM). The median age at diagnosis is 65 years.
Some patients present a monoclonal band (MB) at diagnosis, and a proportion
progresses to MM. The low incidence of this entity has prevented reaching def-
inite conclusions with regards to prognostic factors and treatment. 
Aims: In this study we retrospectively analysed the clinical presentation, treat-
ment and outcome of all patients with SP treated in our centre in order to estab-
lish relevant prognostic clinical features and management options.
Methods: Between 1985 and 2016, 27 patients with SP (20 SPB, 7 EMP) were
treated in Ramon y Cajal Hospital (Madrid), with a median follow up of 8 years.
The time to relapse, progression to MM or death was measured in months.
The progression free survival (PFS) and overall survival (OS) were estimated
using the Kaplan-Meier method. The comparison of PFS/OS was performed
using the Log Rank test. Student´s T test was used to compare the average
age at diagnosis. To determine the association between the presence of MB or
the subtype of SP, and progression to MM, we used Fisher’s exact test. All sta-
tistical analysis was performed with the software SPSS 24.0. 
Results: The average age at diagnosis was 56 years (±18): 51 (±17) for SPB,
and 72 (±5) for EMP (p<0.05), with a male:female ratio of 2.4:1. The most fre-
quent location was the axial skeleton (80%) for SPB, and the airway in the
case of EMP (57%). In most cases, the initial symptom of SPB had been pain
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(45%), and local discomfort for EMP. 52% of patients presented a MB at diag-
nosis, without significant differences between subgroups. With regards to treat-
ment, combined therapy was the preferred option in the case of SPB (60%),
whereas unimodal treatment strategies were more frequently used in EMP
(86%).  11 of the 20 patients with SPB progressed to MM (55%) in a median
time of 4 years, while none of the patients with EMP progressed (p<0.05). The
5 year PFS and OS was 61% and 90% respectively, 31% and 74% at 10 years.
Although a tendency towards a higher PFE was observed in the EMP group,
it was not statistically significant. No differences were found in PFS/OS between
age groups (<60 or ≥60 years), axial vs appendicular skeleton location in SBP,
type of treatment received, or the presence of MB. Furthermore, no association
was found between the presence of MB at diagnosis and progression to MM
(Figure 1).
Figure 1.
Summary/Conclusions: The age at diagnosis of SPB is significantly lower
than EMP. Moreover, the progression to MM is notably higher in this group of
patients. These distinct characteristics in clinical presentation and outcome
could suggest a biological difference between both entities. 
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RISK STRATIFICATION ALGORITHM USING REAL-WORLD DATA FROM
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Background: Estimation of survival for patients with RRMM, requires prog-
nostic tools that define the relative risk of death after first relapse. We recently
developed a risk stratification algorithm (RSA) using real-world data from the
Czech Registry of Monoclonal Gammopathies (RMG). Our RSA uses patient
and disease characteristics at diagnosis and at initiation of second-line treat-
ment (2L), and previous treatment outcomes to stratify patients based on their
overall survival (OS) expectations from initiation of 2L treatment (Hajek et al.
Blood 2016). The value of such an algorithm depends on its validation, but
also on understanding the evidence that explains these differences in survival
expectations.
Aims: To describe 2L treatment patterns by RSA group and to report OS, pro-
gression-free survival (PFS) and response by treatment received in 2L per
RSA risk group.
Methods: Data were collected from the Czech RMG for patients aged ≥18
years who were diagnosed with symptomatic MM between May 2007 and April
2016 and in whom 2L treatment had been initiated. Predictors of OS from the
start of 2L were identified using Cox regression analyses. Hazard ratios for
each OS predictor were multiplied to obtain an overall score for each patient.
Risk groups were defined based on the overall score. To provide optimal patient
stratification, cut-offs of the score were estimated using K-adaptive partitioning
for survival (KAPS) analysis.
Results: Data from 1418 patients were analysed. KAPS analysis defined four
groups based on risk of death: low (LR; score ≤ 4.1; n=403), intermediate-low
(ILR; score 4.2–10.3; n=635), intermediate-high (IHR; score 10.4–20.1; n=237)
and high (HR; score ≥20.2; n=143) risk. Median OS (months) was 57, 29, 13
and 5 for the LR, ILR, IHR and HR groups, respectively. Following stratification,
compared with patients in the lower risk groups, a higher proportion of those
in the HR group had LDH levels above 360 U/L and an Eastern Cooperative
Oncology Group Performance Status of 3–4 at initiation of 2L. Treatments
received at 2L were similar across all risk groups, with bortezomib and lenalido-
mide being the most common 2L treatments. Patients who received bortezomib
at 1L were often given lenalidomide or thalidomide at 2L and those who
received thalidomide at 1L were frequently given bortezomib at 2L. This sug-
gests that 2L treatment choice was not defined by the underlying risk of death
for each patient, but rather by the type of previous treatment. For patients
receiving bortezomib at 2L, median OS (months) from start of 2L was 57, 29,
13 and 6 (Figure 1), and median PFS (months) was 18, 12, 8 and 3 in the LR,
ILR, IHR and HR groups, respectively. A very good partial response or better
(VGPR+) was reported for 29.3%, 31.0%, 18.7% and 19.6% of patients in the
LR, ILR, IHR and HR groups, respectively. For patients receiving lenalidomide
at 2L, median OS (months) was 45, 29, 14 and 5, and median PFS (months)
was 20, 12, 10 and 3 for patients in the LR, ILR, IHR and HR groups, respec-
tively. A VGPR+ was reported for 33.6%, 22.9%, 26.0% and 7.1% of patients
in the LR, ILR, IHR and HR groups, respectively.
Figure 1.
Summary/Conclusions: The RSA effectively stratifies patients according to
OS from initiation of 2L. However, these results must be validated in an external
dataset. The outcomes of each risk group are mainly driven by the underlying
risk of death at initiation of 2L; treatment with bortezomib or lenalidomide pro-
vided similar outcomes independent of risk group. Use of our RSA at 2L would
support physician decision making to improve patient specific care. 
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LACK OF CD56 EXPRESSION IN MULTIPLE MYELOMA PATIENTS WITH
RISS 2 DISEASE IS ASSOCIATED WITH WORSE PROGNOSIS AND
ABOLISHED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION 
M. Skerget1,*, B. Skopec1, H. Podgornik1, D. Zontar1, K. Rebersek1, T. Furlan1,
P. Cernelc1
1Department of Hematology, University Clinical Center Ljubljana, Ljubljana,
Slovenia
Background: Multiple myeloma (MM) is a hematologic disease in which accu-
mulation of malignant plasma cells and high levels of monoclonal protein and
free light chains lead to bone marrow failure, hypercalcemia, lytic bone lesions
and renal failure. Myeloma cells are distinguished from normal plasma cells by
an aberrant immunophenotype.They express CD56, which is present in 70-
80% and can be used to distinguish myeloma cells by flow cytometry. The
expression of CD56 is constant throughout the course of the disease. The lack
of CD56 expression in myeloma cells decreases the adherence of myeloma
cells to the cell matrix and is associated with higher levels of bone marrow infil-
tration and peripheral blood involvement, higher incidence of extramedullary
disease, renal insufficiency, Bence Jones protein, plasma cell leukemia and
t(11;14). The lack of CD117 expression is associated with higher levels of bone
marrow infiltration, renal impairment, elevated β2-microglobulin and cytogenetic
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aberrations including t(11;14), t(4;14) and del(13q). CD28 expression is present
in 15 – 45% of patients and is associated with unfavorably cytogenetic changes
including t(4;14) and del(17p) and shorter PFS and OS despite aHSCT.
Aims: Aim of our retrospective study was to evaluate the impact of CD56,
CD117 and CD28 expression on clinical characteristics and PFS in newly diag-
nosed MM patients treated with bortezomib based induction therapy.  
Methods: We retrospectively analyzed 110 newly diagnosed MM patients from
our national registry that had data available at the time of diagnosis.
Immunophenotype was determined using a panel consisting of
CD19/CD38/CD45/CD56/CD138 to distinguish and to enumerate MM cells.
Monoclonal antibodies directed against CD20, CD28, and CD117 were used
additionally. All samples were routinely tested for the presence of recurrent
chromosomal aberrations, i.e. del 1p, amp1q, del6q, amp15q, del13, del17,
t(4;14), t(14;16) and t(11;14) using commercially available DNA probes.
Results: We found no association between CD56 expression and age, gender,
elevated LDH, cytogenetic risk or RISS stage. We found a strong association
between lack of CD56 expression and light-chain only or asecretory myeloma.
There was an association between CD28 expression and female gender (Table
1). In multivariate analysis including age, elevated creatinine, RISS, aHSCT ,
CD28, CD56 and CD117 expression, CD56 expression was associated with a
47% reduced hazard for progression (Exp(B)=0.527, p=0.03). Other factors
with statistically significant impact on progression were aHSCT and age. In
patients not undergoing aHSCT lacking CD56 expression in comparison to
those with an aberrant CD56 expression, the difference in PFS was statistically
significant with a PFS of 8 vs 18 Month (Log Rank p=0.088, Breslow p=0.046).
When stratified according to RISS stage, only patients in stage 2 disease had
a significant reduction in PFS with lack of CD56 expression.
Table 1.
Summary/Conclusions: CD56 expression was prognostic for PFS only in the
patient cohort not undergoing aHSCT. As previously reported aHSCT seems
to abrogate the negative impact of CD56 negativity. We propose CD56 expres-
sion to be used as a prognostic marker in patients with RISS 2 stage disease
and when possible these patients should undergo aHSCT.
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AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA IN
GERMANY – REAL-WORLD DATA FROM A NATIONWIDE,
MULTI-INSTITUTIONAL SURVEY IN 2015-2016
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Background: A nationwide, multi-institutional survey was performed in 2015
and 2016 to analyse routine practice for myeloma patients outside clinical trials
in Germany.
Aims: We aimed to investigate implementation of autologous stem cell trans-
plantation (ASCT) into treatment of patients with newly diagnosed or relapsed
multiple myeloma (MM) in Germany.
Methods: The analysis is based on a database built from university hospitals
(UH), community hospitals (CH), office-based hematologists (OBH).
Anonymized data were collected online based on retrospective chart review.
The completeness and the plausibility of the data were verified in real-time and
by online personal checks. We investigated which institutions initiated treatment
in patients with ASCT, which were the characteristics for patients not-considered
eligible for transplantation, how stem cell mobilization was performed, how
many patients dropped out before planned transplantation and what were the
frequencies of tandem ASCT and ASCT for relapsed disease.
Results: Data from 515 patients from 51 centres were available for the first
half of 2015 and from 867 patients from 52 centres for the first half of 2016.
There were 40% (2015) and 32% (2016) pts considered as eligible for ASCT
in 1st line. Although the proportion of patients older than 69 years was not sig-
nificantly different between health care providers in 2015 and 2016 (2015:
47%UH, 60%CH, 49%OBP / 2016: 54%UH, 56% CH, 47%OBP), patients were
considered more often transplant-eligible in UH (2015: 49% / 2016: 53%) than
in CH (2015: 29% / 2016: 21%) or OBH (2015: 45% / 2016: 26%).  In first-line
treatment, 52% of patients eligible for SCT received mobilization chemotherapy
in addition to induction therapy. More than 80% of patients received a
cyclophosphamide-based chemotherapy in combination with G-CSF for stem
cell mobilization in 2015 and 2016. Most participating institutions aimed at col-
lection of three sufficient stem cell transplants (2015: 48% / 2016: 46%). Once
patients completed stem cell mobilization, 92% continued to high-dose
chemotherapy and 92% of them received ASCT finally. 25% of transplant
patients were treated with tandem ASCT in 1st line. In 2015, 8% of patients and
1% of patients in 2016 were considered eligible and were ultimately treated
with ASCT for relapsed disease. The most frequent reason for transplant-eligible
patients not receiving ASCT were withdrawal of patients consent (first-line:
15%, second-line: 39%).
Summary/Conclusions: With our current analysis of a nationwide survey per-
formed with different health care providers in Germany we demonstrate that
implementation of ASCT is strongly influenced by the institution initiating primary
therapy. Age does not seem to impact usage of ASCT compared to concomitant
disease or patients´ and doctors´ preferences. Patients predominantly collect
three autologous transplants, enabling a possible tandem ASCT and ASCT for
relapsed disease.
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MODIFIED HYPERCVAD VERSUS BORTEZOMIB-HYPERCVAD
IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
E. Scott1,*, M. Saraceni1, S. Jiing1, S. Mongoue-Tchokote1, R. Maziarz1,
E. Medvedova1
1Hematology and Oncology, Oregon Health and Science University, Portland,
United States
Background: Multiple myeloma (MM) is an incurable plasma cell malignancy,
in which aggressive relapses may require salvage cytotoxic infusional
chemotherapy. Several clinical trials demonstrating the efficacy of bortezomib
led to institutional practice changes where vincristine was replaced with borte-
zomib in the modified hyperCVAD (mod-CVAD) regimen, creating a new treat-
ment regimen, ‘bortezomib-hyperCAD’ (bort-CVAD).
Aims: The primary objective is to describe the safety and efficacy of the hyper-
CVAD regimen with vincristine or bortezomib in patients with relapsed or refrac-
tory MM treated at Oregon Health and Science University.
Methods: IRB approval was obtained to perform this retrospective analysis.
We describe the effectiveness and tolerability of the 2 regimens among 33
patients with relapsed and/or refractory multiple myeloma (RRMM). Patients
who received ≥1 cycle of mod-CVAD (n= 15) or bort-CVAD (n= 18) from Jan 1
2011 and Dec 31 2015 at the Knight Cancer Institute were included.   Most
patients were previously treated with/refractory to proteasome inhibitors
(97%/76%) or immunomodulatory agents (82%/68%) respectively,  13 received
prior autologous stem cell transplant (auto-HCT), the median number of prior
lines was 3 (range 1-8). High risk cytogenetic factors t(4;14), t(14;16), or del
17p  were present in 8 and extramedullary disease in 13 patients overall.
Regimens contained cyclophosphamide 300 mg/m2 IV every 12 hours for 8
doses; doxorubicin 9 mg/m2/day continuous IV infusion every 24 hours and
dexamethasone 40 mg by mouth on days 1-4; vincristine 0.4mg continuous IV
infusion every 24 hours on days 1-4 (mod-CVAD) OR bortezomib 1.3mg/m2
SQ on day 1 and 4 (bort-CVAD). All patients received MESNA 350 mg/m2 IV
every 24 hours on days 1 through 4; granulocyte colony-stimulating factor 24-
48 hours following the completion of chemotherapy; and standard infectious
prophylaxis. International Myeloma Working Group uniform response and Euro-
pean Society for Blood and Marrow for minor response (MR) criteria were used.
Results: The median number of cycles given was 2 (range 1-6). Cycles were
repeated every 3 to 4 weeks. Median follow up was 48 and 33 months in mod-
CVAD and bort-CVAD respectively. The ORR was 40% in the mod-CVAD group:
6 partial (PR), 6 minor (MR), and 3 stable disease (SD) compared to 44.4% in
the bort-CVAD group: 1 complete response, 7 PR, 2 MR, 6 SD and 2 progres-
sive disease (Fisher’s exact p=0.80). A total of 13 patients proceeded to auto-
HCT. Median progression-free and overall survival for all patients were 6 and
11 months respectively, which was comparable between arms (Log rank test
p=0.6635 and 0.7369). New or worsening of peripheral neuropathy occurred in
2 and 4 patients in the mod-CVAD and bort-CVAD groups respectively. There
was no statistically significant association between treatment and febrile neu-
tropenia, emergency department visits, hospitalizations, or peripheral neuropa-
thy (Fisher’s exact test P value >0.05). There were no statistically significant
differences in safety and tolerability between treatment arms. Three and
6  patients in the mod-CVAD and bort-CVAD arms discontinued therapy due to
toxicity or treatment complications respectively.
Summary/Conclusions: Overall effectiveness and safety outcomes were sim-
ilar between mod-CVAD and bort-CVAD, with both regimens demonstrating an
impressive response rate among heavily pre-treated patients with
relapsed/refractory disease. This is a useful salvage strategy to gain rapid dis-
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ease control; and as a bridge to other therapies including stem cell transplant
and novel therapies.
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EFFICACY AND SAFETY OF LENALIDOMIDE AND DEXAMETHASONE
IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA:
A REAL LIFE EXPERIENCE FROM TURKEY
G. Saydam1,*, N. Soyer1, P. Patır1, A. Uysal1, M. Duran1, R. Durusoy2,
F. Sahin3, F. Vural3, M. Tobu3, M. Tombuloglu3
1Hematology, Ege University Hospital Internal Medicine, Bornova, 2Public
Helath, Ege University Medical School, 3Hematology, Ege University Hospital
Internal Medicine, Izmir, Turkey
Background: Lenalidomide, an immunomodulatory drug, was approved for
treatment of relapse/refractory multiple myeloma (RR-MM). In Turkey, we have
been used the combination of lenalidomide and dexamethasone (RD) for RR-
MM patients after 2010. Therefore, we analyzed efficacy and safety of RD in
Turkish patients with RR-MM.
Aims: We aimed to evaluate the outcome and the tolerability of the RD in
patients with RR-MM who had been treated under the standard clinical practice
between October 2010 and June 2016.
Methods: This is a retrospective, single center study. Patients’ clinical and lab-
oratory data were collected from patient’ files. The overall and progression free
survival (OS and PFS) were estimated by Kaplan–Meier methods. Log- rank
test was used to evaluate the variables affecting OS and PFS (univariate analy-
sis). Cox proportional hazards regression was used for multivariate analysis to
analyze the independent variables affecting PFS and OS.
Results: One-hundred and twenty patients (71 male and 49 female) enrolled
in the study. The median age at the start of RD was 64 years (29- 84) and the
median number of previous line of treatment was 1 (1- 4). Seventy-two patients
(60%) received RD as second-line therapy and 51 of patients (42.5%) treated
with autologous stem cell transplantation (ASCT). With regard to the initial
dose of lenalidomide, 82 (68.3%) of the patients received the recommended
dose of 25 mg per day for 21 days in a cycle of 28 days. Objective response
(≥PR) was observed in 87 patients (72.5%); 23 patients (19.2%) achieved CR.
The median follow-up was 14 months (range, 1– 72 months), and the median
DOR was 19 months (range, 12.4- 25.6 months). Median OS and PFS were
32 months (95% CI, 15.8–48.1 months) and 21 months (95% CI, 15.8- 26.1
months), respectively. In the multivariate analysis, the independent prognostic
factors for OS and PFS were treated with previous ASCT, patients who
achieved at least PR, patients receiving RD for more than 12 cycles. Adverse
events occurred in 69 of patients (57.5%). Hematological and non-hematolog-
ical adverse events were found at the same rate (n= 47, 39.2%). The treatment
discontinuation rate due to AEs was 11.7% (14 patients).  The overall incidence
rate (IR, events per 100 patient-years) of second primary malignancies (SPMs)
was 0.93 (95% CI, 0.04- 4.60). Tha rate of anemia was 12.5% and thrombo-
cytopenia was 9.2% in all grades. Penumania (15.8%), fatigue (14.2%) and
herpes  infections (0.8%) have been reported as most frequent non-hemato-
logical side effects.
Summary/Conclusions: RD is a safe, well tolerated and effective treatment
in patients with RR-MM.  Good response, previous ASCT and using more than
12 cycles are associated with better survival. Higher OS and PFS and ORR
seem to be related to using RD in the first relapse. Adverse events are man-
ageable and lower with prophylaxis. 
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OPTIMIZING THE MANAGEMENT OF NON-HEMATOLOGICAL ADVERSE
EFFECTS RELATED TO LENALIDOMIDE IN RELAPSED MULTIPLE
MYELOMA PATIENTS. ONE CENTER EXPERIENCE
M. Moya-Arnao1,*, V. Cabanas-Perianes1, M.J. Moreno Belmonte1,
M. Berenguer1, A. Martínez Marin1, E. Fernandez Poveda1, R. Pérez López1,
E. Salido Fierrez1, J. M. Moraleda Jimenez1
1Hematology, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar,
Spain
Background: During many years, the combination of lenalidomide and dexam-
ethasone (Rd) has been an effective treatment for patients with relapsed or
refractory Multiple Myeloma (RRMM). On the basis of the available evidence,
treatment with Rd may continue in responding patients until progression or unac-
ceptable toxic effects. The data suggest full dose lenalidomide is important for
optimal efficacy and to improve the progression free survival (PFS). Approaches
to achieve higher doses of lenalidomide could include continuing therapy in
responding patients and proactive adverse effects (AEs) management.
Aims: The main aim was to evaluate the incidence of two of most common
non-hematologic AEs related to lenalidomide (rash and dystonia) in patients
who received treatment with Rd. The second end points were to evaluate the
response of rash after switching the enoxaparin to bemiparin and to evaluate
the response of the dystonia after treatment with clonazepam, instead of
lenalidomide dose reduction.
Methods: We retrospectively reviewed a consecutive cohort of patients with
RRMM receiving Rd (R: 25 mg on days 1 through 21. d: 40 mg on days 1, 8,
15, and 22) in 28-day cycles until progression or unacceptable adverse effects,
from 2011-2016. All patients received thromboprophylaxis with low-molecular-
weight-heparin (LMWH) (Enoxaparin 40 mg subcutaneous daily) the first 4
cycles; thereafter, patients were switched to aspirin 100 mg in a day prophy-
laxis. Bemiparin 7500 anti-Xa IU once-daily dose was employed if enoxaparin
was suspended.  Clonazepam dose to treat dystonia was 0,5 mg twice daily.
Data were analyzed with SPSS statistical v 22.0.
Results: Between 2011 and 2016 a total of 65 patients received Rd in our center.
Baseline characteristics are shown in Table 1. Patients received a median of 2
previous regimens (range 1-6). 51,5% of the patients had undergone one previ-
ous autologous stem-cell transplant (ASCT). Rash occurring in 12,3% of patients
(grade 2), all of them were concurrently reciving enoxaparine. All rashes resolved
switching the enoxaparine to bemiparine, maintaining same dose of lenalidomide.
Neither treatment with esteroids or antihistaminic were administrated.  Dystonias
were reported in 23,1% of patients (grade 2), all of them dissapeared after treat-
ment with clonazepam without lenalidomide dose reduction.
Table 1.
Summary/Conclusions: Rash and dystonias are frequent adverse effects of
immunomodulatory drugs  (IMiDs), particularly lenalidomide, often leading to
treatment discontinuation and decreasing the potential benefits to patients.
According to our data, the rash could be due to synergism between enoxaparin
and lenalidomide. In most cases, switch LWHM letting not to reduce lenalido-
mide dose in order to optimize the benefit of the treatment.  Clonazepam, a
benzodiazepine, is useful to treat dystonias related to lenalidomide.
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PROLONGED THROMBOPROPHYLAXIS IN PATIENTS TREATED WITH 
LENALIDOMIDE AND DEXAMETHASONE DOES NOT SEEM STRICTLY
MANDATORY TO PREVENT LATE THROMBOTIC EVENTS
C.S. Cartia1,*, S. Mangiacavalli1, V.V. Ferretti1, F. Cocito1, M. Ganzetti1,
E. Fugazza1, B. Landini1, M. Catalano1, M. Cazzola1, A. Corso1
1Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
Background: Risk of venous thromboembolism (VTE) in general population
is 1% annually, significantly higher in oncologic setting, in particular with Multiple
Myeloma (MM). Treatment with Lenalidomide plus Dexamethasone represents
an additional risk factor for VTE, with most of VTE events observed in the first
six months since therapy starting. No definitive data are available on the more
appropriate duration of thromboprophylaxis (TP) in patients treated with
lenalidomide.
Aims: To explore: I) the incidence of late thrombotic events in a real world
population of relapsed MM, addressed to Lenalidomide plus low dose Dexam-
ethasone treatment (Len-dex), and concomitant TP with low molecular weight
heparin (LMWH) performed for the first 4-6 months of therapy, without TP main-
tenance, II) the possible correlation between the presence of thrombotic risk
factors and the occurrence of a late VTE.
Methods: We performed a retrospective analysis, after regular approval of
local ethic committee, on chart data of 103 patients (pts) with relapsed MM
treated with Len-dex according to label indication between January 2003 and
December 2016 at our single centre institution. VTE prophylaxis was performed
with daily dose of subcutaneous LMWH 4000 IU for 4-6 months, with no further
TP, regardless the presence of thrombotic risk factors.
Results: Main features of patients on study were: median age 66.3 years
(range 41.9-85.2 years), median previous line of therapy 3 (range 1-7), time
from diagnosis to lenalidomide starting 33.3 months (range 0.3-159.9 months),
median duration of Lenalidomide treatment 8 months (range 0.4-65.2 months)
with the following response: ≥PR 56%, CR 7%. Table 1 shows type and distri-
bution of risk factors for VTE. In details median number of VTE risk factors per
patient was 2 (range 0-6), 58.2% of pts had ≥2 risk factors, 41.8% of pts (43
pts) had 0-1 risk factor for VTE. Median duration of TP is 4.8 months (range
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0.4-6 months). No hemorrhagic events were observed during LMWH. Cumu-
lative incidence of VTE was 11.7% (12/103 pts), similar to that previously report-
ed in the literature in patients with continuous TP. The median time from
lenalidomide starting and VTE occurrence was of 12.2 months (range 1- 88.2
months), with only one patient developing early VTE among our group. In detail
we observed 10 deep vein thrombosis (83%), 1 pulmonary embolism (8.5%),
1 myocardial infarction (8.5%). Most of patients developing VTE had good dis-
ease control (≥PR 83%, 10 pts). Concomitant adverse events (AE) was regis-
tered in 41.7% of pts (5/12). Most common concomitant AE were infections of
respiratory tract (3 pts) and gastrointestinal AE (2 pts). The median number of
risk factors for VTE in patients developing or not thrombosis was similar (2.5
vs 2, p=0.092).
Table 1. Baseline distribution of risk factors for thrombosis in the popu-
lation on study.
Summary/Conclusions: This study shows that LMWH is effective and well
tolerate for early VTE prophylaxis during Lenalidomide plus low dose Dexam-
ethasone. Incidence of late VTE without TP maintenance is similar to that report-
ed with long-term antiplatelet therapy. We found no difference in factors pre-
disposing for thrombosis among patients developing or not VTE, with a not
negligible proportion of concomitant adverse events observed nearby VTE
occurrence.
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ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN
THE REAL WORLD
E. Yamazaki1,2,*, H. Takahashi2, D. Ishibashi3, K. Kishimoto3, K. Miyashita4,
A. Numata5, Y. Hattori6, R. Kawasaki7, H. Koharazawa8, K. Fujimaki6,
J. Taguchi8, H. Fujita3, R. Sakai5, S. Fujisawa4, H. Harano9, H. Nakajima10
1Clinical Laboratory Department, Yokohama City University Hospital, 2Depart-
ment of Hematology and clinical Immunology, Yokohama City University School
of Medicine, 3Department of Hematology, Saiseikai Yokohama Nanbu Hospital,
4Department of Hematology, Yokohama City University Medical Center,
5Department of Medical Oncology, Kanagawa Cancer Center, Yokohama,
6Department of Hematology, Fujisawa City Hospital, Fujisawa, 7Department of
Hematology / Oncology, Yamato Municipal Hospital, Yamato, 8Department of
Hematology, Shizuoka Red Cross Hospital , Shizuoka, 9Department of Hema-
tology, Yokosuka City Hospital, Yokosuka, 10Department of Hematology, Yoko-
hama City University School of Medicine, Yokohama, Japan
Background: Many new agents for multiple myeloma (MM) were launched
during the last decade, and the clinical trial using such new agents showed
promising results for MM patients. However, clinical course of elderly patients
with newly diagnosed MM (NDMM) in the real world is different from the results
of clinical trial.
Aims: We examined the clinical parameter to assess survival in elderly patients
with NDMM in clinical practice.
Methods: We performed a retrospective study involving 125 elderly NDMM
patients from April 2012 to September 2015. Patients aged 60 years or older,
who were ineligible for autologous stem cell transplantation, were selected.
The study included 57 males and 68 females, with median age at diagnosis of
74 years (range, 60-95 years). ECOG performance status at diagnosis were 0-
1, 67; 2-4, 58. We collected pretreatment parameter at diagnosis as follows;
monoclonal protein type (IgG,60; IgA,32; IgD,1; BJP,30; non-secretary,2), light
chain (kappa, 72; lambda, 52; unknown 1), hemoglobin level (mean 8.9 g/dL
[range 5.8-15.2]), estimated glomerular filtration rate (eGFR) (mean 49.3
mL/min [range 3.6-114.2]), calcium level (mean 10.0 mg/dL [range 8.7-20.2]),
albumin level (mean 3.4 g/dL [range 1.0-5.3]), beta-2-microglobulin (mean 5.1
mg/L [range 1.6-51.5]), involved:uninvolved serum free-light chain (FLC) ratio
(mean 143.8 [1.83-21133]), cytogenetic abnormalities by using fluorescence in
situ hybridization (FISH) [none, 53; t(4;14), 7; del(17p), 14; t(4;14) & del(17p),
5; t(4;14) & t(14;16) & del(17p), 1].
Results: Of 125 patients, 76 patients received bortezomib based therapy (VMP,
49; VD, 21; VCD, 6), 6 patients received lenalidomide based therapy (Ld, 6),
10 patients were received MP therapy, 19 patients received dexamethasone
therapy (high dose, 16; low dose, 3), 1 patient received radiation therapy as
first line therapy, and 13 patients received only supportive care due to their
fragility. After induction therapy, the overall response rate (at least partial
response, PR) was 52.7% (stringent complete response (sCR) 0.3%, CR 4.5%,
very good PR 16.1%, PR 29.5%). Overall survival (OS) was 74.5% at 1 year,
66.2% at 2 years with median follow-up of 19 months (range 1-52) for patients
who were still alive at the date of last contact and 14 months (range 1-52) for
entire cohort. Death occurred in 41 patients during the follow-up period. Inter-
national staging system (ISS), with ISS1, 19; ISS2, 42; ISS3, 60; N/A, 4, can
divide elderly patients into three distinct survival groups (P <0.001) (Figure 1A).
Univariate and multivariate analysis showed a lower OS was associated with
eGFR lower than 40 ml/min (HR 2.279, 95%CI 1.152-4.510) (Figure 1B) and
serum calcium level greater than 11 mg/dL (HR 3.036, 95%CI 1.412-6.529)
(Figure 1C). Among 80 patients with FISH data, survival of those with t(4;14)
or del(17p) or t(14;16) was not statistically different (P=0.394). Survival of
patients treated with bortezomib or lenalidomide as an induction therapy was
better, while not statistically significant (P=0.066) than those who ware not.
Figure 1. 
Summary/Conclusions: Renal dysfunction and hypercalcemia at diagnosis
is predictive of poor OS for elderly NDMM patients in real world.
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RETROSPECTIVE ANALYSIS OF 121 MULTIPLE MYELOMA PATIENTS
USING THE R-ISS PROGNOSTIC STAGING SYSTEM AND RESPONSE TO
FIRST LINE OF TREATMENT
R. Ghonema1,*, S. AlShemmari1, R. Pandita1, M. Hasaneen1, M. Al-Drees1
1Hematology, Kuwait cancer control centre, Kuwait, Kuwait
Background: The International Myeloma Working Group has developed the
R-ISS (Revised International Staging System) as a simple and powerful prog-
nostic staging system. We collected the LDH level and the cytogenetics of a
group of patients and studied the difference between the ISS (International
Staging System) and the R-ISS (Revised International Staging System) for
those patients.
Aims: To evaluate and compare between the ISS and the R-ISS for a group of
patients treated in Kuwait Cancer Control Centre.
Methods: A retrospective analysis of the data collected from 121 patients reg-
istered as multiple myeloma from 2011-2015, 5 of the patients presented to
our centre after initial work up and starting the treatment abroad. The patients
were categorised according to age, gender, ISS stage, R-ISS stage, first line
therapy and response.
Results: We recognised increase of the number of the yearly diagnosed
patients with myeloma 2.48% of patients the actual date of diagnosis was before
2011 but they presented to our centre from2011-2015. Median age of patients
at presentation is 56 years old , 3.33% between30-40 years old, 18.33%
between 40-50 years old ,  35% between 50-60 years old , 31.67% between
60-70 years old and 11.67% between 70-80 years old. Male to female ratio
1.75:1 (Table 1). According to ISS stage patients were categorised into14%
stage I, 31% stageII, 47% stage III. Restaging using the RISS revealed10%
stage I, 26% stageII, 56%stage III. Almost half of our patients are diagnosed in
the third stage, and more patients were shifted from stage I or II were cate-
gorised in the third stage due to either high LDH level, high cytogenetic risk or
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even both. First line treatment 55% of the patients received Bortezomib based
triple therapy, 22% received CTD (Cyclophosphamide, Thalidomide, Dexam-
ethasone), 7% RD (Lenalidomide, Dexamethasone),  3% CyBorD (Cyclophos-
phamide, Bortezomib, Dexamethasone), 3%RV (Lenalidomide, Bortezomib),
2% Thal-Dex (Thalidomide, Dexamethasone), 2% RT (local Radiotherapy), 2%
WatchfulWait,1% MP (Melphalan, Prednisone) and 3% refused for treatment
and lost follow up.
Table 1.
Summary/Conclusions: Applying the RISS system to myeloma patients is
very effective and easy method to categorise myeloma patients, a significant
number of patients in Kuwait are diagnosed as stage III, with median age of 56
years although the use of novel therapies shows excellent response to most
of them.
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FEASIBILITY/PHASE II STUDY OF MYELOABLATIVE BEAM ALLOGENEIC
TRANSPLANTATION FOLLOWED BY ORAL IXAZOMIB MAINTENANCE
THERAPY IN PATIENTS WITH HIGH RISK MYELOMA 
E. Scott1,*, R. Maziarz1, S. Dreumont1, C. Gasparetto2
1Hematology and Oncology, Oregon Health and Science University, Portland,
2Hematology and Oncology, Duke University, Durham, United States
Background: While the role of allo-HCT in MM remains controversial several
studies have shown encouraging PFS and OS with this treatment even in
patients with high-risk myeloma (HRM). HRM manifests with early relapses
and refractoriness. Median OS is 2.5 years despite aggressive therapy with
novel agents. Post auto-HCT maintenance with lenalidomide is considered
standard of care, but post allo-HCT maintenance presents unique challenges
and has not been well studied. Ixazomib (Ixa) is a new oral proteasome inhibitor
with activity in bortezomib resistant patients, and is a promising agent in the
maintenance setting.
Aims: Here we present preliminary results for this trial. The primary objective
is safety defined as day 100 transplant related mortality (TRM), and safety of
Ixa maintenance (incidence of grade III-IV GvHD and Ixa related toxicity). Other
objectives include determination of efficacy (ORR, PFS, MRD for CR), the
ability to start Ixa, and quality of life.
Methods: The protocol was approved by a local institutional review board and
ethics committee. The study was conducted in accordance with the Declaration
of Helsinki. All subjects provided written informed consent prior to treatment.
Eligibility criteria include: age ≤65; relapsed MM previously treated with auto-
HCT, bortezomib and an immunomodulatory agent; one of the following high-
risk criteria: deletion (del)17p, t(4;14), t(14;16), t(14;20), amp1q gain or del1p,
del13q by conventional karyotyping, hypodiploidy, high-risk GEP, B2M >5.5mg
, plasmablastic morphology (>2%), or relapsed plasma cell leukemia; 8/8 HLA
matched unrelated (MUD) or sibling donor. The BEAM conditioning regimen
includes: BCNU 300 mg/m2 on day -6; cytarabine 400 mg/m2 daily day -5 to
day -2; etoposide 200 mg/m2 daily day -5 to day -2; melphalan 140 mg/m2 on
day -1. Oral Ixa 4mg on days 1 and 14 of a 28-day cycle. Ixa may start between
day 100 and 180 post HCT, and continue for up to 24 cycles.
Results: Six subjects were enrolled, 3 at OHSU and 3 at Duke, from Sept
2015 to Dec 2016. Median age of 51 (range 46-57), 2 female, and all of white
race. High risk factors: del17p, del17p+t(14;16), del17p+amp1q+del1p,
del13q+amp1q, amp1q, plasmablastic morphology (>2%). At study entry 2 sub-
jects were in VGPR, and 4 in PR. Three subjects received 8/8 HLA matched
MUD, and 3 received sibling donor HCT. GvHD prophylaxis with tacrolimus
and methotrexate was given in 3 subjects with the addition of methylprednisone
in 3 subjects. Two subjects started Ixa (at day 139 and 128) and remained on
therapy for 198 and 59 days respectively; both discontinued for disease pro-
gression. Three subjects remain on study, and have not started Ixa. At day 100
post HCT, 4 of 6 subjects were evaluable for response. All had a deepening of
response; 3 VGPR, 1 CR. One subject died from BEAM-allo related complica-
tions; namely acute stage 4 GvHD (skin and gut), and disseminated adenovirus
infection (day 62). Grade 3/4 adverse events include: febrile neutropenia(3);
colitis(1); epididimytis(1); mucositis(4); pancreatitis(1); pulmonary edema(2);
diarrhea(3); infection(4); staph bacteremia(2); E coli bacteremia(1); adenovirus
viremia(1); neutropenia(4); thrombocytopenia(4); acute GvHD(1). Ixa related
toxicities include grade 3 neutropenia(2), thrombocytopenia(1), pneumonia(1),
nausea and vomiting(1).
Summary/Conclusions: Although this is very early data, it is the first clinical
trial to report the use of BEAM conditioning followed by Ixa maintenance for
relapsed HRM. Thus far stopping rules have not been met, with expected tox-
icities occurring.
PB1974
EPIDEMIOLOGY OF MULTIPLE MYELOMA. THE GRANADA MYELOMA
REGISTRY
R. Ríos Tamayo1,*, D. Sánchez-Rodríguez2, J. Sainz Pérez3,
J.J. Jiménez Moleón4, M.J. Sánchez Pérez5, M. Jurado Chacón1
1Hematology, University Hospital Virgen de las Nieves, 2Hematology, FIBAO,
3Hematology, GENYO, 4Medicine Preventive, University of Granada, 5Cancer
Registry, Andalusian School of Public Health, Granada, Spain
Background: The Granada Myeloma Registry is the second largest single-
institution population-based registry (Ríos-Tamayo et al, 2015) of multiple
myeloma (MM) referenced to date. Here we update and point out the epidemi-
ological variables of interest.
Aims: To highlight the importance of the epidemiological perspective in the
knowledge and outcome of MM.
Methods: From January 1985 to February 2017 all consecutive patients diag-
nosed with MM at our institution have been registered, including clinical, bio-
logical and socio-demographic variables, as previously reported. A compre-
hensive approach to comorbidity was recorded as well as diagnostic and treat-
ment delay. Overall survival (OS) was estimated by the Kaplan-Meier method.
Results: 700 patients have been included in the registry, 343 men (49%) and
357 women. All cases have their place of residence in the Granada province.
The median age was 67 years (range: 12-93). The race was Caucasian in
98.9%. In relation to occupation, 18.4% were skilled or elementary agricultural
workers. Only 9% had a previously documented precursor disease (solitary
plasmacytoma, monoclonal gammopathy of undetermined significance , or
smoldering MM), and 14 patients (2%) remain alive with smoldering MM without
progression. The subtype of MM is IgG 55.6%, IgA 24.8%, Light chain Only
15.9%, Non-secretory 3%, IgD 0.6% and IgM 0.2%. The International Staging
System is known in 378 patients: 1 (25.9%), 2 (25.7%), and 3 (48.4%). Baseline
performance status (ECOG) was: 0 (4.7%), 1 (41.1%), 2 (26.7%), 3 (21.7%),
and 4 (5.9%). Comorbidity was assessed in 498 patients. 30.6% of patients
were obese at the moment of diagnosis. 8.2% had other previously known or
synchronous neoplasm. 150 patients (30.1%) had three or more comorbidities.
Median diagnostic delay was 4.1 months (0.1-80) and median treatment delay
was 13 days. 44 patients (6.3%) were very unfit and they did not receive active
treatment. Information about stem cell transplant is available in 606 cases: 151
of them (24.9%) received a first autologous transplant. Median OS for the whole
cohort was 43.1 and 22.4 months for patients younger than 65 years or 65
years and older, respectively (p <0.001). For patients diagnosed in 2010 or
later, median OS is not reached for younger than 65 and 40.4 months for the
elderly (p=0.001). Information about the main cause of dead is available in 230
patients: 101 (43.9%) of them died by infection. 
Summary/Conclusions: MM is a very heterogeneous disease from a clinical,
biological and epidemiological perspective. The distribution by sex is identical.
Farmer is the most frequent occupation. Almost one in three patients are obese,
and one in ten had another prior or associated neoplasm. Infection is the lead-
ing cause of death. Information derived from population-based registries may
help to complement data from clinical trials.
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REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND
DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED
REFRACTORY MULTIPLE MYELOMA
M. Ziff1,*, S. Cheesman1, C. Kyriakou1, A. Mehta1, X. Papanikolaou1, N. Rabin1,
A. Wechalekar1, K. Yong1, R. Popat1
1University College London Hospitals NHS Foundation Trust, London, United
Kingdom
Background: Ixazomib (Ixa) is a novel oral proteasome inhibitor (PI) approved
in combination with lenalidomide and dexamethasone (IRD) for the treatment
of relapsed/refractory multiple myeloma (MM). This was based on the TOUR-
MALINE-MM1 trial which demonstrated a progression free survival benefit over
RD. However real world use often differs to clinical trials due to heterogeneous
patient selection, more flexibility with dosing intensity and country specific pre-
scribing practices/funding restrictions.
Aims: To characterise real word use of IRD by demographics, response rate
(RR) and progression free survival.
Methods: This was a retrospective review of patients sequentially treated with
IRD at a large UK Haematology Centre. Patients received Ixa 4mg D1, 8, 15
with lenalidomide (dose as per label) days 1-21 and dexamethasone 40mg week-
ly or as tolerated every 28 days until disease progression or intolerance. In some
cases, Ixa was added later to RD. RR and PFS were assessed according to
IMW criteria and haematological toxicities graded by CTCAE 4.0 criteria.
Results: Up to 31st October 2016, 30 patients were treated with the IRD sched-
ule.  Median age was 65 years (32-75), male (57%), ISS: stage I 18 (60%),
stage II 4 (13%), stage III 8 (27%).  Patients had a median of 2 (2-5) prior lines
of therapy.  All patients had previous treatment with a proteasome inhibitor (PI)
(29 bortezomib, 5 carfilzomib) and 8 (27%) were refractory to a PI. 3 (10%)
had prior lenalidomide and all remained sensitive. 23 (77%) had a prior autol-
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ogous stem cell transplant.  Out of those with results, 18 (69%) had adverse
cytogenetics including 6 (23%) with TP53 loss. The median number of treatment
cycles completed was 6 (2-35) with a median time on treatment currently of 5.5
months (1.6-40) for a median follow-up of 6.8 months (1.6-40). 24 patients were
evaluable for efficacy analysis.  7 discontinued therapy, 6 due to disease pro-
gression of which 5 (83.3%) were refractory to a PI.  1 patient discontinued due
to personal choice. The overall response rate (ORR) was 70.8% (PR 13
(54.1%), VGPR 3 (12.5%), CR 1 (4.2%)). For those refractory to prior PI, the
ORR was 37.5% (PR 2 (25%), VGPR 1 (12.5%)). 7 (29%) had Ixa added for
sub-optimal response (<PR) or PD.  2 had an improvement in response (VGPR
and MR); 1 stabilised disease and the rest remained refractory. 5 (21%) had
Ixa added whilst responding to RD, with the intention of deepening response
and prolonging PFS.  All continued to maintain their response. The median
overall PFS was 19.23 months. The PFS for those refractory to prior PI was
11.6 months vs not reached for those sensitive (p=0.0159).  Those with TP53
loss had a median PFS of 7.5 months. IRD was well tolerated with 5 (20.8%)
patients experiencing grade 3-4 neutropenia and thrombocytopenia and 1
patient experiencing grade 4 anaemia. This resulted in Ixa dose reductions in
4 (16.7%) patients. Ixa was stopped in 1 patient due to adverse events.
Summary/Conclusions: This real world dataset highlights differences in
patients treated in routine practice to trials.  No patients were treated at first
relapse due to funding restrictions, whereas most in the trial were.  Patients
had up to 5 prior lines, all had prior PI exposure and a higher proportion were
PI refractory (33% vs 2%) which correlated with a worse outcome. Nevertheless
the overall efficacy of our study (ORR 70.8%; median PFS 19.23 months) was
comparable to the TOURMALINE-MM1 trial which had an ORR of 78.3% and
median PFS of 20.6 months in the Ixa group.
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EFFICACY AND TOLERABILITY OF LENOLIDOMIDE AND POMALIDOMIDE
IN RELAPSED/REFRACTORY MYELOMA PATIENTS IN A REAL WORLD
STUDY
G. Adams1,*, M. Collins1, C. Kyriakou1, R. Ayto1
1Haematology, Northwick Park Hospital, London, United Kingdom
Background: New agents have revolutionised the treatment of multiple myelo-
ma. Immunomodulatory drugs (IMiD) such as lenalidomide and pomalidomide
are potent re-induction drugs leading to improved Progression Free Survival
(PFS) and Overall survival (OS).  Published studies include exclusion criteria
such as cytopenias, renal dysfunction and poor performance status (common
in multi-relapsed patients), raising the question regarding the benefit of IMiD
therapy in the real-world setting. 
Aims: In our study we aimed to describe the real-world experience of the use
of lenalidamide followed by pomalidamide rescue in a relatively elderly co-mor-
bid cohort over a 4 year period and compare this to national averages. We
reviewed IMiD efficacy, including sequential lenalidomide followed by poma-
lidomide, together with tolerance. 
Methods: Records of delivered chemotherapy cycles were retrieved from local
pharmacy data and national averages from Celgene ePAF data. Outcome data
collected from clinical notes and laboratory results.
Results: We collected data on 46 patients treated between 2011-2014 with
lenalidomide, 17 whom progressed to recieve pomalidomide. The median age at
initial myeloma diagnosis was 71 years, with median age at starting lenalidomide
77years (range 36-94). This gave an average of 5 years from diagnosis to com-
mencing lenalidomide (range 1-15 years).  Myeloma subtypes included IgG 28/46,
IgA 11/46, light chain disease 4/46 and 3 with IgD and non-secretory myeloma.
High risk cytogenetics [17p-, t(4:16), t(4:20), hypodiploidy, chromosome 1 abnor-
malities] were identified in 9/46 and 16/46 were high-risk based on biomarker
staging (ISS).  All patients had at least 1 preceding line of therapy before starting
lenalidomide, average 2 lines (range 1-6). Prior treatment included alkylating
agents/steroid duplets, thalidomide combinations, bortezomib-based therapy and
autograft. National average for the% of patients reaching cycle 26 was 16% com-
paring to the local average of 31%.  This included patients receiving 5mg due to
severe renal impairment or cytopenias. In the patient group between 65-75 years
of age, 50% reached cycle 26 compared to the national average of 16%. Average
duration on treatment was 15 months. (Local-cohort). Lenalidomide-treatment
breaks occurred in 16 patients with a median of 5 months (infection, cytopenias,
liver dysfunction, foreign travel, other).  Cytopenias or infections were seen in
45% of local patients with 28% of patients having subsequent dose reductions.
Based on performance status, renal function and prior drug tolerability, only 30%
of patients were prescribed lenalidomide 25mg od.  Despite this 17 patients (36%)
achieved a prolonged PFS of >20 months and 13/46 (30%) a PFS of >30 months.
The longest observed PFS in the local cohort was 53 months. The average num-
ber of cycles in those who progressed to pomalidomide was 12.8 (n=17), which
is double that of the national average reported in seminal trials.  These patients
had few treatment breaks and treatment was well tolerated (pomalidomide duplets
or triplets).
Summary/Conclusions: We conclude from this real-world retrospective review
of 2nd and 3rd line IMiD therapy that these salvage regimes are highly effective.
Patients on lenalidomide monotherapy post triplet/duplet induction were often
re-escalated back onto dexamethasone and alkylator (IV/oral) based regimes
with successful salvage, contributing to the observed long duration of local
therapy compared to national averages. Pomalidomide was highly effective at
rescuing patients failing lenalidomide-based regimes and well tolerated. 
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APPLICATION OF CONDITIONING REGIMEN WITH BUSULFAN AND
CYCLOPHOSPHAMIDE IN AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN MULTIPLE MYELOMA
Y. Xu1,2, C. Fu1,2,*, Y. Yao2, W. Yao2, S. Jin2, L. Yan2, J. Shang2, X. Zhu2,
A. Sun2, D. Wu1,2
1Institute of Blood and Marrow Transplantation,Collaborative Innovation Center
of Hematology, Soochow University, 2The First Affiliated Hospital of Soochow
University,Jiangsu Institute of Hematology, Suzhou, China
Background: Busulfan is the most commonly used drug in conditioning regimens
for hematopoietic stem cell transplantationand high-dose melphalan (MEL)is the
standard conditioning regimen in autologous stem cell transplantation(ASCT)for
multiple myeloma.Studies have shown that in ASCT for multiple myeloma,condi-
tioning regimens containing busulfan is equally effective as HDM.
Aims: Evaluate the safety and efficacy of BUCY(busulfan and cyclophos-
phamide)conditioning regimen for autologous hematopoietic stem cell trans-
plantation (ASCT) in patients with multiple myeloma (MM).
Methods: We retrospectively analyzed the clinical data of 72 MM patients who
received transplantation in the Hematology Department of the First People’s
Hospital of Soochow University from May 2012 to June 2015. Among them, 36
patients underwent BUCY regimen while the others received high dose mel-
phalan.Those were compared between the two groups including the complica-
tion, the hematopoietic reconstitution and the post-transplantation efficacy.
Results: There were no significant differences in age, stage, induction therapy,
mobilization method between the two groups.The transplantation-related
adverse events were similar in both groups but the incidence of pulmonary
infection and bloodstream infection were slightly higher in BUCY group .The
median time to neutrophil engraftment in the BUCY and HDM groups were
10(8-17) days versus 10(9-13)days, taking the same time on average(P=0.046).
On the other hand, the median time to platelet engraftment was 10(8-18) versus
11(9-47)days accordingly(P=0.017) The TRM in both group was 2.7%.The
SCR/CR rates after ASCT (47.2% and 50.0%) were higher than those before
it (38.9% and 26.6%), in both groups.In the BUCY group, the median follow-up
was 12.5 (0-26) months. Six patients (16.7%) underwent disease
progression.The 2-year progression-free survival(PFS) rate was 68%.Corre-
spondingly,in the HDM group,the median follow-up time was 23 (0-38) months.
Fifteen patients (41.7%) developed disease progression and the 2-year PFS
rate was 55%.
Summary/Conclusions: The BUCY regimen is a safe and effective therapy
for ASCT in patients with multiple myeloma.Besides, BUCY regimen is not infe-
rior to HDM regimen.In conclusion, BUCY regimen may replace HDM regimen
as a standard conditioning regimen for ASCT in multiple myeloma.
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MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM
INVOLVEMENT, 12 CASES AND REVIEW OF THE LITERATURE
G. Varga1,*, G. Mikala2, L. Gopcsa2, Z. Csukly2, P. Reményi2, G. Szombath1,
A. Masszi1, H. Andrikovics3, G. Balázs4, B. Tímár5, T. Masszi1
13rd Department of Internal Medicine, Semmelweis University, 2Department of
Haematology and Stem Cell Transplantation, St. István and St. László Hospital,
3Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion
Service, 4Heart and Vascular Center, Division of Diagnostic Imaging, 51st
Department of Pathology and Experimental Cancer Research, Semmelweis
University, Budapest, Hungary
Background: Central nervous system (CNS) propagation is a rare event in
multiple myeloma (MM), but may become more prevalent as newer treatment
options allow patients to have a prolonged life expectancy and with this comes
the selection of increasingly aggressive clones.
Aims: We reviewed 12 MM cases with CNS involvement treated in two hospitals.
Methods: Statistical analyses were performed using the SPSS (version 20.0)
software package.
Results: Between 2008 and 2015 twelve MM patient developed CNS involve-
ment which presented in all cases at relapse. The median age at diagnosis
and at CNS presentation were 55.5 and 57.4 years. At first presentation nine
had ISS 3, one ISS 2 and two ISS 1 stage disease, two patient presented orig-
inally as plasma cell leukaemia. FISH showed 1q amplification in 4, 13q deletion
in 4, translocation (4;14) in 1, t(11;14) together with 17p deletion in 1, hyper-
diploidity in 1 and complex karyotype in 2 cases. In 2 cases we demonstrated
the development of new karyotypic abnormalities (one 1q amplification, one
17p deletion) at CNS progression. The median number of treatment lines prior
to CNS progression was 2 which included bortezomib in all and thalidomide in
all but one cases, two patients had lenalidomide. Six patients had ASCT before
the CNS progression from which one had a second ASCT and one a reduced
intensity allogeneic transplantation. The median time from diagnosis to CNS
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progression was 23.9 (3-65) months. Eight patients presented with cerebral
nerve palsy, 2 with paraplegia, 1 with hypacusis and 1 with headache. CSF
cytospin or flow cytometry was positive in 7, MRI or CT supported the diagnosis
in 4 patients. Treatment consisted of combination chemotherapy, intrathecal
chemotherapy, cranio-caudal radiotherapy and imids with various success. The
PFS and OS from CNS progression was 63 and 125 days. Two patients sur-
vived for over a year (427 and 776 days), both responded in terms of CNS
symptoms to imid-based combination therapy and one had cranio-caudal radio-
therapy (Figure 1).
Figure 1.
Summary/Conclusions: CNS progression in MM has a particularly poor prog-
nosis as it represents a late stage of an aggressive relapse which often shows
chemo-refractoriness. The differential diagnosis includes infection, autoimmune
or vascular diseases of the CNS as well as paraneoplasia and drug toxicity. The
CNS penetration of the effective myeloma drugs is poor except for the imids,
and drugs with CNS availability are usually not very effective in refractory MM.
PB1979
DARATUMUMAB; CHALLENGES OF INTEGRATING THIS NEW THERAPY
INTO STANDARD CARE
L. Little1,*, R. Powles1
1Haemato-Oncology, Cancer Centre London, Parkside, London, United
Kingdom
Background: Daratumumab (Darzalex) is the first anti-CD38 human Mono-
clonal Antibody approved for Multiple Myeloma (MM). Targeting the CD38 anti-
gen on the surface of MM cells it causes apoptosis, and has an immune mod-
ulated tumour lysis effect. Success in Clinical trials meant that this drug, admin-
istered as single agent, or in combination with other novel therapies (Lenalido-
mide or Bortezomib), received accelerated FDA Approval in the US. It is now
being introduced into standard hospital care.
Aims: Daratumumab presents unique challenges to the delivery of risk man-
aged care, due to effects on some blood and bone marrow testing, and to the
Infusion Related Reactions (IRRs) seen at the outset of treatment. This poster
will highlight important aspects of the treatment pathway for this new therapy,
from a single centre perspective.
Methods: We outline the pathways integrated at MDT level; patient character-
istics and adverse event profiles of the 15 myeloma patients we have
treated with Daratumumab, in a standard service setting.
Results: Daratumumab (Dara) affects certain pathology tests so samples should
be clearly identified. Relevant laboratory teams need to be aware of the methods
used to process samples. Daratumumab binds to CD38 on Red Blood Cells,
and therefore with Cross Match Compatibility testing and Antibody Screening.
Obtaining RBC Products for patients receiving Dara will take longer, requiring up
to 48 hours’ notice. Cross match samples taken prior to treatment provide the
National Blood Service Laboratory with a baseline antigen profile to aid selection
of suitable blood products. Dara is detected during Paraprotein Electrophoresis;
Pre and Post baseline samples help to identify the Darzalex Band in the serum;
our lab use a Sebia capillarys 2 analyser to separate the Dara band for accurate
reporting. Bone Marrow Testing:  Daratumumab affects Immunophenotyping by
masking the CD38 epitope used to identify plasma cells by flow cytometry; special
kits are available using a different CD38 epitope thus dealing with this issue.
Infusion Related Reactions (IRRs) have been reported in over half of patients
receiving Daratumumab: 95% of these were seen at the first dose.  Typically
involving the upper respiratory tract and include rhinitis, cough, wheeze, bron-
chospasm, laryngospasm and chest pain. More rarely they include rash, fever,
and nausea. Reactions can be grade 1-4 so it’s important that the patient is
closely monitored where there is quick access to specialist staff, resuscitation
equipment and respiratory support in a high dependency setting. Staff training is
important, and patients made aware that they report all new symptoms so the
infusion is interrupted immediately and the IRRS treated and re-started at a lower
rate when the symptoms have resolved. Premedication is given one hour prior
to infusion and patients with a history of COPD receive extra support. Patient
characteristics. Total:15. (Table 1).
Table 1.
Summary/Conclusions: Education, to include Blood Transfusion, Protein and
Histopathology laboratory, and High Dependency Unit staff, in the key aspects
of monitoring and risk management are an important part of integrating this
new therapy to the treatment pathway for myeloma patients. Daratumumab is
likely to become an important treatment for improving both Outcomes and
Quality of Life for Myeloma patients going forward.
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MULTIPLE MYELOMA IN HIV+ PATIENTS LITERATURE REVIEW AND OWN
CASE
A. Leyghton1,2,*, A. Pivnik1, M. Tumanova1, G. Dudina1, E. Sergeeva1
1Oncohematology, MKNC, 2Internal Medicine, RUDN, Moscow, Russian Fed-
eration
Background: Multipe myeloma (MM) and HIV infection in AIDS stage until
now its considered not to be associated. Recently new ideas appear in the lit-
erature such as influence of HAART on the treatment outcomes of MM in HIV
negative patiens.
Aims: To find literature sources on multiple myeloma in HIV positive patients
and elucidate the problem of this association. evaluate the impact of HAART
in multiple myeloma.
Methods: Patients were retrospectively identified out of 39 cases of MM and
HIV from Pubmed/Medline from 1983 to 2017, and own case reported.
Results: Patients with MM and HIV infection did not differ significantly from
the MM in HIV-negative with respect to age, gender, stages and renal func-
tion. Effects of HAART on levels of serum M-protein HAART itself has been
reported to decrease M-protein in an HIV+ patient with MM.  We determined
whether HAART alone, in the absence of MM treatment, had any effects on
the level of serum M-protein in HIV+MM patients. Depending on the interval
between the discovery of the HIV infection HAART treatment initiation, and
the diagnosis of MM and initiation of its treatment. The overall and progres-
sion-free survival of HIV+ MM patients on HAART appeared to be superior
to that of HIV-negative MM patients. The survival of the HIV+ MM patients
were also superior to that of non-HIV MM patients reported in the literature.
The majority of HIV+ MM patients who had long-term follow-up in our study
did not show clinical symptoms of MM and were free of serum-M protein after
primary MM therapy in the presence or absence of HAART and maintained
treatment with HAART alone. Although MM is not an AIDS-defining illness,
meta-analyses of large population studies reveal an increased risk of MM in
HIV/AIDS patients. HIV infection is commonly associated with B cell hyper-
proliferation, as indicated by polyclonal hyperglobulinemia and the develop-
ment of various autoantibodies. This is presumed to be usually due to these
CD4 deficient patients’ inability to control Epstein-Barr virus infections, which
immortalize B cells. This may help to explain the increased incidence of MM
in HIV+ patients. However, HIV can neither infect B lymphocytes or plasma
cells, nor drive their malignant transformation. Some authors are going to
treat multiple myeloma in HIV seronegative patients with HAART in combi-
nation with chemotherapy (Geling Lia and co-authors, Leukemia Research,
2014). A 38 year-old Russian male presented at the Moscow clinical Center
in 2015 with pronounced ossalgya and inability to move. Total protein 135 g/l
with 81.7 g/l of IgG-k M-protein  and no presence of  Bence Jones protein.
Bone skeletal survey showed multiple generalized lytic lesions. Bone marrow
aspirate and biopsy showed 46% plasma cells. Serum creatinine – 104
mkmol/l.  HIV and hepatitis C (genotype 1a) screening test were positive,
confirmed with Western blot analysis. The CD4 count was 290 cells, HIV viral
load 1500 copies/ml, hepatitis C viral load 14,2 mln copies. He was started
on HAART, combined with chemotherapy 5 courses of СР+CVP+МР and 7
V-MP. In 2017 total serum protein– 97,3 g/l, M-protein 31,2 g/l, serum crea-
tinine  63,0 mkmol/l. Now he is active without any bone pain receives Pegasis
and lamivudine (Table 1).
Summary/Conclusions: Patients with MM and HIV infection did not differ sig-
nificantly from the MM in HIV-negative with respect to age, gender, stages and
renal function, and treatment with addition of HAART.Recently was reported
that HAART itself may reduce and even remove m-gradient in HIV positive
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OPTIMIZATION OF APPROACHES FOR STEM CELL MOBILIZATION FOR
AUTOLOGOUS STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA:
PRACTICAL CONSIDERATIONS 
O.-L. Lee1,2,*
1Haematology, Royal Adelaide Hospital, 2Haematology, SA Pathology, Ade-
laide, Australia
Background: Autologous stem cell transplant (ASCT) is a well-established
treatment for myeloma.  However, the optimal strategy for stem cell mobilization
remains undefined.  The goal of mobilization is to collect adequate stem cells
for at least 2 ASCT (4x106/kg), with the minimum apheresis sessions and tox-
icities such as febrile neutropenia. 
Aims: We aim to compare stem cell mobilization using granulocyte colony stem
cell factor (GCSF) only (steady state), high dose cyclophosphamide (4 g/m2)
with GCSF or low dose cyclophosphamide (2 g/m2) with GCSF.
Methods: We performed a retrospective analysis of 79 patients mobilized with
GCSF only from mid-2014 to Aug 2016 with 32 patients mobilized using high
dose cyclophosphamide and 23 patients with low dose cyclophosphamide dur-
ing a similar period.
Results: Patients undergoing steady state collection required a median of 2
days for adequate collection, in comparison to 1 day for both high and low dose
cyclophosphamide.  Addition of pleraxifor was required in 27.8% of patients on
steady state collection, in contrast to 3.1% and 13% of patients on high and
low dose cyclophosphamide respectively.  The mean yield  of CD34+ x 106/kg
cells collected was 5.39, 9.14 and 8.5 for steady state, high and low dose.
There was no significant difference in time to engraftment despite a lower dose
of CD34+ cells reinfused for the steady state cohort. Admission for febrile
episodes was observed in 50% of patients mobilized with high dose cyclophos-
phamide, as compared to 13% of patients on the lower dose regime and none
in the steady state cohort.  Patients mobilized with cyclophosphamide had a
longer interval between stem cell collection and transplant (median of 20, 42
and 34 days respectively for steady state, high dose and low dose). However,
we observed that 60.7% patients with steady state mobilization had increases
in their myeloma markers during this period, in contrast to biochemical improve-
ment in 50% of patients mobilized with high dose cyclophosphamide and 26%
with low dose cyclophosphamide.
Summary/Conclusions: All 3 strategies for stem cell mobilization have their
own merit.  Steady state mobilization is safe and yields sufficient stem cells;
however, patients require more apheresis sessions.  Moreover, more than a
quarter require additional therapy with plerixafor.  Of concern, greater than half
of these patients have increased myeloma markers during the interval between
stopping chemotherapy and mobilization which may potentially affect outcomes.
Mobilization with high dose cyclophosphamide yield more CD34+ cells but with
increased toxicities- 50% of patients required admission for febrile
episodes.  Conversely, half of these patients had improvement in their myeloma
markers.  The use of low dose cyclophosphamide for mobilization resulted in
lower admission rates (13%), however, pleraxifor is required in a fraction.
In light of these findings, we propose that patients who have not achieved at
least VGPR should be mobilized with cyclophosphamide, the dosage depend-
ent on their individual risks.
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MINIMAL RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA
PATIENTS BY FLOW CYTOMETRY: A SINGLE CENTER EXPERIENCE 
S. Sizikova1,*, N. Pronkina2, E. Batorov3, G. Ushakova1, V. Sergeevicheva1,
A. Gilevich1, I. Kruchkova1
1Hematology and bone marrow transplantation, 2Laboratory of immunology,
3Laboratory of cell immunotherapy, Research Institute for Fundamental and
Clinical Immunology, Novosibirsk, Russian Federation
Background: Multiple myeloma (MM) is a malignant disease characterized by
an increased number of clonal (abnormal) plasma cells in the bone marrow
(BM). High-dose chemotherapy followed by autologous peripheral blood stem
cell transplantation (SCT) is used for the treatment of young MM patients and
produces a high rate of complete remissions (CR). Recent trials with novel
agent combinations alone have also resulted in high CR rates, even among
old patients, high-risk patients and relapse/refractory MM. Unfortunately, most
patients have a recurrences of the disease. This is due to the persistence of
residual tumor cells, known as minimal residual disease (MRD), responsible
for tumor relapse.
Aims: BM samples from 51 MM patients who had achieved partial or complete
response or were resistant after chemotherapy, including autologous SCT, were
evaluated by multiparameter flow cytometry (MFC). The study was conducted
to assess the quality of remission, the correlation between the number of abnor-
mal plasma cells of BM and other signs of disease activity, readiness of patients
for autologous SCT.
Methods: The study included 51 patients MM, average age - 54 years (36-70
years), who underwent assessment of MRD from November 2014 to February
2017. According to the classification Durie-Salmon the vast majority of patients
(n=40) had III stage of disease, 8 patients – II and 2 patients – I. Response to
treatment was assessed according to standard EBMT criteria At the time of
MRD assessment 20 patients were in CR, 8 had a partial response (PR) and
15 had a resistant disease; 5 patients had a primary MM, 3 patients were in the
first relapse. Most of the patients were underwent high-dose chemotherapy
with autologous SCT (n=42). Re-evaluation of MRD after therapy was managed
to hold in 36 patients at a mean of 3,1 months (1,9-5,7, min-max). Analysis
was performed using a FACSCantoII flow cytometer (BD) and FACSDiva soft-
ware (BD). Instrument performance was checked daily by recording fluores-
cence intensity with calibrating beads (Cytometer Setup and Tracking from BD
Biosciences). Whole BM was estimated using combination of surface and intra-
cellular staining CD38/CD56/CD27/CD117/CD81/CD19/CD45/cytLambda/
CD138/cytKappa. The sensitivity of our panel MRD is 0.01% (i.e. 10-4).
Results: Among patients in CR (n=20) confirmed the absence of MRD in 6
patients, but 14 CR patients were MRD positive. MRD was detected in all
patients with PR and resistant disease (n=31). The relative content of abnormal
plasma cells in CR patients with MRD positive (n=14) was significantly lower
than that in PR/resistant patients (n=31): 0.095% (0,026-0,271%) versus 1,3%
(0,203 -5,9%), pU=0,000092. PR patients (n=8) had a lower relative content of
abnormal plasma cells (as expressed tendency), than patients with resistant
disease (n=15): 0,286% (0,177-1,129%) versus 1,48% (0 , 90-8,0%), pU=0,053.
Besides the relative content of abnormal plasma cells in PR/resistant patients
(n=31) correlated with the serum M-gradient concentration (rs=0,42; p=0,019)
and bone marrow plasma cells (rs=0,54, p=0,0017).
Summary/Conclusions: Currently, we can conclude that MFC could be con-
sidered as the method of choice for MRD monitoring in MM. If the disease is
measured, then, indeed, enough to evaluate only the M-gradient level of serum.
If the M-gradient is not defined, it is necessary to assess the number of abnor-
mal plasma cells in the BM and strive for the high-quality responses at the time
of transplantation.  And also it can help us to regulate duration of maintenance
therapy. 
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AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY MULTIPLE
MYELOMA PATIENTS
M. Staderini1,*, C. Nozzoli2, E. Antonioli1, I. Donnini2, I. Cutini2, A.S. Guarrera1,
M. Di Gioia1, A. Gozzini2, S. Guidi2, A. Bosi1, R. Saccardi2
1Hematology Department, 2BMT Unit, Azienda Ospedaliero-Universitaria
Careggi, Florence, Italy
Background: Autologous stem cell transplantation (ASCT) is currently
approved as a “gold standard” first line treatment for multiple myeloma (MM)
patients (pts) under 65 year old but the procedure could also be considered
feasible in fit elderly patients based on several retrospective studies.
Aims: The aim of our study was to retrospectively evaluate the tolerability and
the efficacy of high dose chemotherapy followed by ASCT in selected ≥65 year
old MM population.
Methods: We retrospectively analyzed consecutive MM pts aged 65 or older
who underwent upfront ASCT at our institution from January 2009 to November
2016. Each patient received induction therapy including proteasome inhibitors
and/or immunomodulatory drugs (bortezomib and/or thalidomide based), fol-
lowed by high-dose cyclophosphamide plus G-CSF and subsequently under-
went peripheral blood stem cells (PBSC) collection.
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Results: Overall we analized 35 pts: 21 males and 14 females (median age
66, range 65-70); 23 had IgG MM, 4 had IgA MM and 8 had light chain MM.
Induction therapy was bortezomib-based (bortezomib in combination with dex-
amethasone, VD, in 7, or VD plus thalidomide in 26 pts) for a median of 4
cycles (range 3-6), 2 patients received thalidomide plus dexamethasone (6-12
cycles). PBSC were collected after high-dose cyclophosphamide (2 g/sqm in
2 pts, 3 g/sqm in 11 pts, 4 g/sqm in 22 pts) plus G-CSF; plerixafor was admin-
istered in 4 pts. Three pts also received lenalidomide and dexamethasone to
improve the depth of response before ASCT.  At the time of conditioning, among
34 evaluable pts, 8/34 pts were in complete response/stringent complete
response (CR/sCR), 19/34 in very good partial response (VGPR), 5/34 in partial
response (PR) and 2/34 in stable disease (SD). The conditioning regimen con-
sisted of melphalan 140 mg/sqm in 11 pts or 200 mg/sqm  in 24 pts. A median
number of 4.11 x10^6 CD34+ cells/Kg was reinfused (range 2.09-10.44). The
most frequent complication was fever (9 pts) with gram negative bacteremia
documented in 3/9 and gram positive bacteremia in 1/9. Other complications
were represented by 1 case of atrial fibrillation and 3 cases of pneumonia and
1 case of VZV reactivation. All 35 pts achieved neutrophils recovery after a
median of 12 days (range 8-25) and platelets recovery after a median of 13
days (range 8-45) after transplant. No grade 3-4 toxicities were recorded. No
transplant-related mortality was recorded within 100 days post transplantation.
Three months after ASCT, among 28 evaluable pts, 10/28 pts were in CR,
14/28 pts in VGPR and 4/28 pts in PR. Three pts underwent tandem ASCT.
After a median follow-up of 32 months (range 3-96) among 33 evaluable pts,
20 experienced disease relapse and 7 deaths occurred. Median PFS and OS
were 21 and 40 months.
Summary/Conclusions: Our data support the use of ASCT as an effective
and safe first-line treatment approach also in elderly MM pts. A careful patient
selection is needed to reduce the toxicity of the procedure. 
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EVOLUTION IN THE INCIDENCE OF MONOCLONAL GAMMOPATHIES IN
A SOUTHERN SPAIN TERTIARY HOSPITAL IN THE LAST THIRTEEN
YEARS
J.M. Maesa1,*, P. Menenez-Valladares1, J.L. Garcia de Veas-Silva2,
N. Barbosa3, R. Duro4, C. Bermudo-Guitarte1
1Clinical Biochemistry, Virgen Macarena University Hospital, Sevilla, 2Immunol-
ogy, Complejo Hospitalario Universitario de Granda, Granada, 3The Binding Site,
Barcelona, 4Hematology, Virgen Macarena University Hospital, Sevilla, Spain
Background: Monoclonal gammopathy (MG) is the most common plasma
cells disorder. It affects around 3% of the population older than 50 years. The
great majority of MG are monoclonal gammopathies of undetermined signifi-
cance (MGUS), which is a premalignant disorder defined to present less than
3 g/dL of serum monoclonal protein, less than 10% of clonal bone marrow cells
and absence of end-organ damage. MGUS is easily detected in laboratory
tests and should be monitored because 1% of MGUS per year progress to
Multiple Myeloma (MM). Incidence of MGUS and MM is not always easy to
determine, but there is a general perception of an increasing incidence that
can be attributed to different causes. One is the aging of the population. Another
reason is the contribution of clinical laboratories, which count on new determi-
nations (free light chains) or improved techniques in electrophoresis, neph-
elometry or immunofixation, allowing them to support the diagnose of MGUS
that years before remained undiagnosed.
Aims: The aim of this study is to determine the incidence of MGUS, MM and
its different types in the reference population of a tertiary hospital in southern
Spain between 2003 and 2015.
Methods: In a retrospective study, we determined the total number of MG and
its different types diagnosed in our hospital between 2003 and 2015. We cal-
culated the incidence per 100.000/year of MGUS and MM, with 95% confidence
intervals. Our reference population, in 2015, was 480.851.
Results: Results in Figure 1.
Figure 1.
Summary/Conclusions: The aging of population and the higher sensitivity of
laboratory techniques for diagnosing of MG is reflected in the incidence of
MGUS, which increased from 17.04 cases per 100.000 in 2003 to 35.00. MM
incidence in our area did not increased in parallel.
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CHARACTERIZATION OF A SERIES OF PATIENTS WITH PLASMA CELL
LEUKEMIA
P. Bettencourt Medeiros1,*, R. Bergantim1, F. Trigo1, J.E. Guimarães1
1Serviço de Hematologia Clínica, Centro Hospitalar de São João, EPE, Porto,
Portugal
Background: Plasma cell leukemia (PCL) is a rare malignancy characterized
by the proliferation of monoclonal plasma cells in the bone marrow and
≥2x109or ≥20% plasma cells in the peripheral blood. It is an aggressive disease,
with a median survival of 7 to 11 months. Due to its rarity, it is difficult to design
prospective studies or randomized trials in PCL, so collecting and publishing
data from the largest number of cases is essential for the understanding of
PCL’s pathophysiology and outcome.
Aims: To characterize a series of PCL patients, in order to obtain data with the
potential to be used as prognostic factors and to improve clinical outcomes.
Methods: Single-center, observational, retrospective study including all PCL
cases admitted in our hospital between 2007 and 2016. Data regarding demog-
raphy, clinical characteristics, laboratory results, treatment, follow-up and mor-
tality were collected and analyzed using Statistical Package for Social Sciences
(21stversion), searching for significant associations (p<0.05) with overall sur-
vival (OS) and progression free survival (PFS).
Results: 15 patients were included, with a median age of 58 years. Most patients
were male (60%) and had PS ECOG 0-1 (93,3%) at presentation and primary
PCL (80%). Median hemoglobin (Hb) and platelets values were 8,5 g/dl and
74x109/L, respectively. Median plasma cell percentage was 37.3% (peripheral
blood) and 60% (bone marrow). IgG heavy chain was present in 33.3% and
lambda light chains in 53.3% of cases. Most patients had total serum calcium
≥4.5mmol/L (60%), total proteins ≥65g/L (66.7%), monoclonal component ≤ 30g/L
(53.3%), albumin ≥35g/L (60%), creatinine clearance ≥50ml/min (66.7%), ele-
vated β-2 microglobulin (93.3%), ISS III (80%), R-ISS III (73.3%) and at least 1
cytogenetic change associated with poor prognosis in multiple myeloma (86.7%).
Ten (66.7%) patients received bortezomib-based chemotherapy and nine patients
(60%) were submitted, at least, to one autologous stem cell transplant (ASCT).
Complete response (CR) or very good partial response (VGPR) were achieved,
after chemotherapy, in 53.3% and, after ASCT, in 88.9% of patients. Mortality
rate was 66,7%, with median PFS of 5 months and median OS of 4 months. In
univariate analysis, OS was significantly associated with albumin ≤ 35g/L,
splenomegaly and R-ISS III; PFS was significantly associated with platelets
≤100x109/L, splenomegaly and lambda light chains. In multivariate analysis, only
the presence of splenomegaly kept its association with OS; none of the charac-
teristics associated with PFS kept their significance. Chemotherapy followed by
ASCT and the achievement of, at least, VGPR after chemotherapy and ASCT
were associated with longer OS and PFS.
Summary/Conclusions: This study’s retrospective design and the small sam-
ple limit the strength of our data and our conclusions. Interesting results were
obtained regarding pre-treatment prognostic characteristics and the association
of improved OS and PFS with treatment response and ASCT execution. More
studies are necessary to determine the clinical relevance of this findings and
the best treatment strategies in PCL.
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OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE
DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE
PATIENTS
D. De Miguel1,*, A. Gil1, N. Golbano1, M. Diaz1, H. Guillen1, A. Vazquez1,
B. Pinedo1
1Hematologia, Hospital universitario de Guadalajara, Guadalajara, Spain
Background: MM-003 study has presented a median PFS of 4.0 months
and median OS was 13.1 months overall for Pomalidomide and low doses of
dexamethasone in RRMM patients. Those results were better when a third
drug was added (Poma-Dexa , Poma-Cyclophosphamide-dexa, and Poma-
Bortezomib-dexa, ORR 38.9, 64.7 and 85%; PFS 4.4, 9.5, 10.7 months
respectively).
Aims: To evaluate the response at therapy with pomalidomide plus dexametha-
sone in RRMM, and to analyze the efficacy of another drug in high risk MM.
Methods: we reported the clinical experience of the 8 patients treated with
pomalidomide and dexamethasone. In patients with high risk MM (cytogenetic,
extramedullary myeloma or plasmatic cell leukemia) pomalidomide and dex-
amethasone have had poor response. In those cases, we have added a third
drug (cyclophosphamide or Bortezomib) and we have obtained the best results.
Results: we have used pomalidomide and dexamethasone in 4 patients and
poma-dexa-cyclophosphamide in 3 patients (extramedullary myeloma) and
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poma-bortezomid-dexa in 1 PCL patient. Table1. Demographic characteristic`s
patients. Figure1. Response of monoclonal spike.
Figure 1.
Summary/Conclusions: pomalidomide, dexamethasone and a third drug
(cyclophosphamide or Bortezomib) obtain best results (PFS and OS) in high
risk RRMM patients. We have not reported more toxicity adding a third drug. In
our experience, the response of the extramedullary myeloma with pomalido-
mide´s triplets is a great option.
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PROGNOSTIC SIGNIFICANCE OF PLASMABLASTIC PLASMA CELLS IN
THE ERA OF NOVEL AGENTS IN MULTIPLE MYELOMA
A. Machet1,*, S. Guidez1, T. Systchenko1, D. Desmier1, N. Moya1, C. Gruchet1,
V. Richez1, A. Levy1, F. Sabirou1, A. Bobin1, S. Bouyer2, C. Tomowiak1,
P. Sonneveld3, H. Avet-Loiseau4, X. Leleu1
1Hematology, 2Hematology Laboratory, University Hospital Center, Poitiers,
France, 3Hematology, University of Rotterdam, Rotterdam, Netherlands, 4Labo-
ratory for Genomic in Myeloma, Institut Universitaire du Cancer, Toulouse, France
Background: Plasmablastic (PB) feature of plasma cells in multiple myeloma
(MM) has long been identified as poor prognosis. Interestingly it does not take
part of International Revised Scoring System (R-ISS). Similarly, the prognostic
impact in the era of novel agents and novel classes in MM is unknown. Finally,
the percentage of PB in the bone marrow to which a poor prognosis develop is
unclear.
Aims: To assess which modality of treatment of plasmablastic MM was asso-
ciated with longer progression free survival (PFS) and overall survival (OS).
Methods: We have performed a retrospective analysis of all MM in our center
from May 2005 to November 2016, and sought for MM with plasmablastic fea-
tures, characterized by immature cells with high proliferative index rate. The
PFS and OS were calculated since the first time the PB morphology was
observed in the bone marrow aspiration, at the outset in newly diagnosed
patients or in relapsed patients. 
Results: 65 patients with PB were included. Adverse cytogenetic per IMWG cri-
teria was reported in 6 patients, del17p x3, t(4;14) x3, and one with both. 33,8%
were ISS 3, and 23,1% R-ISS 3. Extramedullary disease (EMD) was reported in
40%. 35 patients (53,8%) were in first-line therapy. The overall response rate
with any triplet-based treatment containing always a proteasome inhibition and
IMIds or alkylator was 49,2%, with 29,2% VGPR and 4,6% CR. The median PFS
and OS were 6,9 and 14,9 months as a whole, respectively. The median PFS
was greater when treatment combined bortezomib, lenalidomide and dexam-
ethasone: 36,1 months ([0-99] vs 5,5 [0,59-10,4] otherwise; p=0,014). However,
no difference in OS was demonstrated. Importantly, high dose therapy with ASCT
was associated with longer PFS and OS, respectively 21,4 months ([12,8-30,1]
vs 2,83 [0-5,7] p=0,003) and 50,4 months ([29,9-70,7] vs 6,27 [1,1-11,4] p=0,001).
In multivariate analysis, poor OS was associated to acute renal failure at disease
entry, presence of EMD, of del(17p), of hypercalcemia, and elevated lactate dehy-
drogenase. We then sought to demonstrate that use of a direct anti proliferative-
based agent such as anthracycline would participate to rapid disease reduction
and PB clone control. It turns out that there was no significant difference in terms
of survival in patients treated with an anthracycline-based regimen.
Summary/Conclusions: this study confirms the poor prognosis of PB feature
in MM. A triple-based association with a proteasome inhibitor (PI) and an
immunomodulatory drug (IMiD) seems to provide the best PFS in MM with PB,
ideally complemented by ASCT. The role of anthracycline remains to be demon-
strated. This data will be validated in a large cohort.
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INTERNATIONAL OPPORTUNITIES TO COMPARE ‘REAL WORLD’ DATA
FROM MYELOMA REGISTRIES: BASELINE CHARACTERISTICS,
FIRST-LINE THERAPIES AND EARLY OUTCOMES FROM AUSTRIA AND
AUSTRALIA/NEW ZEALAND 
K. Bergin1,*, R. Weger2, E. Moore3, Z. McQuilten3, E. Wood3, W. Willenbacher4,
A. Spencer1
1Haematology, Alfred Health-Monash University, Melbourne, Australia, 2Oncotyrol
Center for Personalized Cancer Medicine, Innsbruck, Austria, 3Department of
Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia,
4Hematology & Oncology, Medical University Innsbruck, Innsbruck, Austria
Background: Most outcome data for multiple myeloma (MM) come from clinical
trials which can not necessarily be extrapolated to ‘real world’ patients. More
information is needed on patients treated in the ‘real world’ and in a wider range
of settings.
Aims: To compare and contrast baseline characteristics, investigations, and
initial therapies in different geographical regions, Australia/New Zealand (ANZ)
and Austria, through first analysis of data from two established MM registries on
behalf of the steering committees of the Australian and New Zealand Myeloma
and Related Diseases Registry and the Austrian Myeloma Registry.
Methods: Analysis of data from newly diagnosed MM patients enrolled on the
Austrian Myeloma Registry (AMR) and the ANZ Myeloma and Related Diseases
Registry (MRDR) from 2012-2016.
Results: Available data from 250 and 691 patients from the AMR and ANZ
MRDR, respectively, were included. DEMOGRAPHICS: The AMR cohort was
younger (median age m:f 63.5 yrs:64 years vs 65 yrs:66 yrs on the AMR and
MRDR, respectively). The proportion of male/female patients was similar
between the AMR and MRDR (m:f 56%:44% and 61%:39% respectively).
PRESENTATION: IgG myeloma was the most common sub-type of disease in
both registries (m:f 64%:55% and 55%:58%, respectively) with more light chain
only disease on the AMR (m:f 26%:33% vs 20%:19%). Presence of documented
preceding plasma cell dyscrasias was similar (m:f 21%:19% vs 15%:20%, on
the AMR and MRDR, respectively). INVESTIGATIONS: A higher proportion of
patients underwent MRI (m:f 51%:58% vs 25%:27%) and skeletal survey (SS)
(78% vs 60%) at diagnosis on the AMR than the MRDR, respectively. Baseline
laboratory investigations were similar, however, patients on the MRDR demon-
strated higher median LDH (m:f 176:178 vs 187:186 units/L) and serum calcium
(m:f 2.34:2.28 vs 2.41:2.45 mmol/L) but decreased serum albumin (m:f 39:39g/L
vs 35:35g/L) when compared to the AMR. STAGE: ISS staging was similar on
both registries with ISS stage 2 being most common in both cohorts (m:f
42%:37% vs 40%:40%, on the AMR and MRDR, respectively) while ECOG
performance status at diagnosis was lower in the MRDR cohort (ECOG≤1 m:f
43%:44% vs 81%:78%, on the AMR and MRDR, respectively). FIRST LINE
THERAPY: First line therapy was predominantly bortezomib (Velcade - V)
based on both registries (81% vs 85%). V/dexamethasone (D) was the most
common on the AMR (29%) followed by V/thalidomide/D (VTD) (25%) with
V/cyclophosphamide/D (VCD) (79%) most common on the MRDR. V was pre-
dominantly administered subcutaneously on both registries (79% vs 88%) but
more commonly weekly on the MRDR (51% vs 67%) versus twice weekly on
the AMR (40% vs 27%). RESPONSE TO THERAPY: Overall response rates
were similar between the two cohorts but with higher CR rates on the AMR
(CR 21% vs 11%, VGPR 27% vs 31%, PR 31% vs 43%, SD 12% vs 14% and
PD 8% vs 2%, on the AMR and MRDR, respectively).
Summary/Conclusions: This pilot study between the AMR and ANZ MRDR
demonstrates many similarities but also highlights significant differences, partic-
ularly in first line therapy and depth of response. Future studies between the
AMR and MRDR will provide a platform for ongoing international benchmarking.
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DETECTING EARLY RELAPSE IN MULTIPLE MYELOMA AFTER ASCT:
USEFULNESS OF IMMUNEASSAYS
M. Andrade-Campos1,*, I. Murillo Flores2, E. Colorado Ledesma2, P. Giraldo3
1Translational Research Unit - Hematology, IIS-Aragon. CIBERER., 2Hematol-
ogy, Miguel Servet University Hospital, 3Translational Research Unit, IIS-
Aragon. CIBERER. IISCIII, Zaragoza, Spain
Background: The Free Light chain immunoassay (FLC) (Bindingsite, Birming-
ham, UK) is part of the mandatory response assessment for MM, the role of
the Heavy/Light Chain immunoassay (HLC), is under investigation. Also relaps-
es in MM patients are frequent, autologous stem cell transplantation (ASCT) is
the standard consolidation therapy and there is an interest to detect early relaps-
es and optimize therapy. We hypothesized that the combination of these tech-
niques could permit to detect early biological (non-symptomatic) relapses (EBR)
in this setting.
Aims: To analyze the usefulness of HLC and FLC to detect EBR in MM after
ASCT.
Methods:A retrospective study was performed following these criteria: all patients
diagnosed of secretory MM, in our center, and treated (including ASCT), between
May 2011-August 2015; the protocol for follow-up included FLC, HLC, serum and
urine electrophoresis (SPE, UPE) with immunofixation (IFX), pre-ASCT, after 12
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weeks and every 3 months later (minimum follow-up: 6 months). EBR was defined
as 25% on M-protein increase (any amount for patients on CR/SR) and/or
≥20mg/dl FLC increase, and/or 25% involved HLC increase with abnormal ratios.
For urine, an increase >500mg/24 hrs of involved free-chain protein.
Results: Fifty-five patients were registered. Median follow-up 47 months.
MF ratio: 29/26, mean age 59.5 y (33-71). Immunoglobulin subtype: IgG-
Kappa: 41.8% (23), IgG-Lambda: 23.6% (13), IgA-Kappa: 16.4% (9), IgA-
Lambda: 7.3% (4), Bence-Jones-Kappa: 3.6% (2), Bence-Jones-Lambda:
7.3% (4).  Durie-Salmon Stage: IA: 13.5% (7), II-A: 32.7% (17), III-A: 44.2%
(23), III-B: 9.6% (5), missing-data 3 case.  All patients received Bortezomib
based therapy and MEL200 as ASCT conditioning. Status pre-ASCT: minimal
response: 12%, Partial Response (PR): 50.0%, very-good-PR (VGPR):
28.0%, complete response (CR): 6% and string response (SR): 4.0%.  After
ASCT, evaluation reveals that 13.0% achieved SR, 13.0% CR, 30.4% VGPR
and 39.1% PR. During follow-up, 34/50 (68%) patients who achieved at least
PR after ASCT, had a clinical relapse/progress, median PFS 41 months (31.5-
50.5). EBR were detected in 28 patients, of them 22/34 (64.7%) clinically
relapsed patients at median time 8.0 (2-22) months before symptomatic
relapse. The EBR were detected by FLCr (36.7%), HLCr (22.7%), FLC+SPE
(4.5%), FLC+IFX (9.1%), FLC+HLC+SPE (13.6%), FLC+HLC+SPE+UPE
(13.6%).
Summary/Conclusions: Both FLC and HLC are useful tools to detect EBR in
more than 50% of patients in our cohort ahead other techniques.
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EARLY MORTALITY (<6 M) IN NEWLY DIAGNOSED MULTIPLE MYELOMA
PATIENTS: COMPREHENSIVE INTERVENTION
V. Martínez-Robles1,*, B. Ballina1, S. Cerdá1, N. de las Heras1, M. Fuertes1,
L. Villalobos1, J. A. Rodríguez-García1, F. Ramos1, F. Escalante1
1Hematología, Complejo Asistencial Universitario de León, LEON, Spain
Background: Early mortality in the first 6 to 12 months from diagnosis is well
recognized in newly diagnosed multiple myeloma (NDMM) patients, with rates
in the real-world setting of around 20-30%.
Aims: In a retrospective analysis of the causes of death performed by the end of
2012 we identify 2 different causes in the 2 consecutive periods analyzed. In the
first period (1998-2006) the main cause was MM progression and in the second
(2006-12) was secondary to serious infectious complications. Additional analysis
were done after it an can identify a patient and a infectious profiles. Main risk fac-
tors from the patient were: age (over 75), suboptimal treatment and renal failure
(calculated ClCr<50 ml/min). The infectious ocurred mainly in the first 3 months
from diagnosis and principally polimicrobial and multiresistent infections.
Methods: After this analysis several measures were taken to reduce this high
early mortality: 1) To promote the ambulatory regime both in diagnosis and for
the rapid assessment of complications to avoid or shorten income and to reduce
these nosocomial-behaviour infection complications. 2) Early initiation of “opti-
mal” anti-myeloma treatment. 3) Get infectious prophylaxis in patients over 75
years and / or renal failure with Septrim ©.
Results: 343 pac NDMM were treated between 1998 and 2015 (127 in the 1st
period, 115 in the 2nd: 242 pts before 2013; and 101 in the 3rd period: 2013-
15). The median age at dx was 74 years (39-100). The number of patients died
<6m was 77 years. 60 died before 6 months: 55 before 2013 (29 in the 1st
period (22.8%) and 26 in the 2nd (22.6) and 5 after 2013 (5.0%). Of these 60,
37 had a severe infectious complication. The main cause of mortality before
2013 was infectious complications, (14 of 28 early death in the first period and
22 of 26 in the second). Severe pneumococcal infections were infrequent (11%)
In the 3rd period, mortality <6m was reduced by 77% (22% vs 5%) (p.001);
There was only 1 severe infection (G5) in this period (CMV reactivation, prob-
ably Pneumocystis pulmonary infection, E. Coli bacteriemia and a intestinal
necrosis after an atrial fibrilation embolism) Figure 1 (upper corner). Improve-
ment in early mortality increases significatly overall survival: 32.5 monts vs not
reached pre and post-2013 (p.0034).
Figure 1 (large graphic; legends: red: pre2013; blue: post2013).
Summary/Conclusions: Infectious complications and progression of MM have
been the main cause of early mortality in patients with NDMM. Identifying poten-
tial “modifiable” variables and acting on them improves the short-term prognosis
of patients with NDMM like: Supportive treatment to prevent infectious compli-
cations (avoid unnecesary hospitalization, antibiotical prophylaxis) and rapid
access to optimal antiMM treatments. These improvemente of short-term 
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FIRST LINE USE OF NOVEL AGENTS BEFORE AUTOLOGOUS SCT HAS
A POSITIVE IMPACT ON TIME TO SECOND PROGRESSION AND
SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
UNDER 70 YEARS
S. Gassiot1,2,*, C. Motlló1,3, M. Morgades1, Y. Gonzalez4, M. Garcia-caro1,
J.-M. Ribera1,2, A. Oriol1,2
1Hematology, Hospital Germans Trias i Pujol - ICO, Badalona, 2Universitat
Autònoma de Barcelona, Cerdanyola del Vallès, 3Universitat Autònoma de
Barcelona, Badalona, 4Hematology, Hospital Dr Josep Trueta, Girona, Spain
Background: Most clinical trials for multiple myeloma (MM) patients using
novel agent-based regimens before autologous stem cell transplantation have
shown improvement in response rates and progression-free survival, however
they have failed to identify a significant overall survival (OS) benefit. 
Aims: Our aim is to analyze the potential impact of initial induction in the fea-
sibility and outcome of subsequent treatment lines and other major factors
affecting OS in a real clinical practice setting. 
Methods: Newly MM patients less than 70 years of age diagnosed between
December 1999 and December 2009 were prospectively registered. Patients
were assigned to a first cohort if they received conventional chemotherapy
(CC) induction regimens with new agents available at relapse or to a second
cohort if received novel agents based first line treatment (NA). 
Results: The overall response rate after completing first line treatment for all the
154 eligible patients was 85%, 79% in CC compared to 94% in NA (P=0.012).
Very good partial response or better for NA was significantly higher than for CC
(39% vs 59%, P=0.012). Patients in NA demonstrated not only a superior median
progression-free survival (2.8 years vs 1.6 years, P=0.03) but also  superior
median progression-free survival from diagnosis to second progression – PFS2
(5.2 years vs 2.7 years, P=0.003). In both cohorts PFS1 and PFS2 represented
more than 50% and 80% of life expectancy respectively. It could be hypothesized
that CC patients would obtain more benefit than NA patients of second-line ther-
apy, as they would be naïve to the novel agents used at relapse, but this is not
the case. The use of thalidomide and/or bortezomib induction did not reduce the
efficacy of these same agents second line. Indeed, these patients also had the
best second responses that also contributed to longer PFS2 periods. After a
median follow-up of 6.97 years, clear differences in OS were observed (7.97
years for NA compared to 3.35 years in CC, P<001). Despite the fact that better
risk patients in the NA group were more likely to remain in first or second
response, relapsed and refractory patients in this group still presented longer
survivals beyond second relapse than patients in the CC group (Figure 1).
Figure 1.
Summary/Conclusions: New agent based first line induction treatments in
newly diagnosed MM patients provide benefits beyond first progression free
survival that contribute to a significant improvement in OS.
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SAFETY AND EFFICACY OF NOVEL AGENTS IN VERY ELDERLY
MULTIPLE MYELOMA PATIENTS (AGED 80 YEARS OR MORE): A REPORT
BY THE RETE EMATOLOGICA PUGLIESE (REP)
N. Sgherza1,*, A. P. Falcone1, A. Iacobazzi2, G. Palumbo3, B. Rossini4,
G. Mele5, P. Curci6, L. Ciuffreda7, G. Polimeno8, G. Rossi1, G. Tarantini7,
G. Specchia6, A. Melpignano5, V. Pavone4, S. F. Capalbo3, A. Guarini2,
N. Cascavilla1
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4Hematology Unit, Ospedale “Card.G.Panico”, Tricase, 5Hematology Unit,
Ospedale Perrino, Brindisi, 6Hematology Unit, Azienda Ospedaliero-Universi-
taria Policlinico di Bari, Bari, 7Hematology Unit, Ospedale Di Miccoli, Barletta,
8Hematology Unit, Ospedale “Miulli” , Acquaviva delle Fonti, Italy
Background: Multiple Myeloma (MM) is mainly a disease of the elderly and
the very elderly patients (80 years of age or more) comprise one third about of
all MM patients. This subset of patients suffer from concomitant disabilities
and/or comorbidities and require a different and a more individualized thera-
peutic approach, including the novel agents.
Aims: The aim of our study  is to verify safety and efficacy of novel agents with
the reliability to maintain a good quality of life and obtain a maximal disease
control.
Methods: Patients from 8 Hematology Centers of the “Rete Ematologica
Pugliese (REP)” were included in this study. Between January 2011 and
December 2016, 71   patients (M/F: 42/29) with a median age of 82 years
(range 80-91) were diagnosed  as newly symptomatic MM. Of the entire study
population, 40 (56%) patients showed an ECOG score lower than 2. According
to immunoglobulin heavy and light chain isotypes, patients had  IgG-k (n=23),
IgG-λ (n=16), IgA-k (n=14), IgA-λ (n=6), micromolecular k (n=8) and λ (n=4)
chains. On the basis of ISS, patients were classified as I (n=4) score, II (n=23)
and III (n=44) score, respectively. When CRAB features were considered, bone
lesions represented the most frequent (n=43, 60.6%) clinical manifestations,
while anemia, hypercalcemia and renal failure were found in 35 (49.3%), 2
(2.8%) and 2 (2.8%) patients, respectively. Majority of patients (n=49, 69%)
showed at least 1 comorbidity requiring specific treatments, and 11 patients
(15,5%) showed more than 3 comorbidities.  Patients were treated according
to Bortezomib-based regimens (VMP, VCD and VD) (n=45; 63.4%), Lenalido-
mide-based regimen (RD) (n=8; 11,3%) and  Thalidomide-based  regimen
(MPT) (n=5; 7%). Only 13 patients (18.3%) did not receive any novel agent. 
Results: Based on IMWG criteria, 15 patients (21.1%) achieved a CR, 15 patients
(21.1%) a VGPR and 15 patients (21.1%) a PR. Fourteen patients (19.7%) and
12 (17%) patients experienced a SD and a PD, respectively. As second line of
treatment, Bortezomib was used in 14 (33.3%) patients, Lenalidomide in 17
(40.5%) patients and Thalidomide in 3 (7,2%)  patients. Height patients (19%)
were treated with old drugs (Melphalan, Cyclophosphamide or Bendamustine).
Pomalidomide was used as third line-therapy in 3 patients. After 72 months (medi-
an 32.5 months) of follow-up, 33 (46.5%) patients remained alive with a median
survival of 36 months and 25 (28.2%) died. Last follow-up from 13 patients was
unavailable. Hematological and extra-hematological toxicities were similarly dis-
tributed (18,3% and 18,3%, respectively) and usually weak/moderate. Neuropathy
was the most common toxicity reported (n=5, 7%). Of patients treated with only
novel agents (n=58), hematological and extra-hematological toxicity was
observed in 14% and 16% patients, respectively. 
Summary/Conclusions: We showed that all MM patients can be treated by
novel agents  independently of the age.  Results from our study show that par-
ticularly very elderly and frail patients can benefit from these drugs by prolonging
their life expectancy and maintaining a good quality of life.
PB1993
BORTEZOMIB-MELPHALAN-PREDNISONE VERSUS MP AS INITIAL
TREATMENT FOR VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED
MULTIPLE MYELOMA
M.K. Kim1,*, K. Kim2, D.H. Yoon3, C. Suh3, J.H. Moon4, Y.J. Lee4, J.H. Lee5,
S.-H. Jung6, H.J. Kim7, S.H. Bae8, J.S. Kim9, J.-O. Lee10, H.S. Eom11,
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Yonsei University College of Medicine, Seoul, 10Seoul National University Bun-
dang Hospital, Seongnam, 11National Cancer Center of Korea, Goyang, 12Busan
Paik Hospital, Busan, 13Korea Cancer Center Hospital, 14Ewha Woman’s Uni-
versity School of Medicine, Seoul, 15Keimyung University School of Medicine,
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Background: Although bortezomib-melphalan-prednisone (VMP) therapy is a
well-established standard treatment for patients with multiple myeloma (MM) who
are ineligible for high-dose therapy, it is not clear whether very elderly patients
should be treated with VMP in clinical practice, considering the toxicities. 
Aims: The purpose of this case-control study was to compare the efficacy of
VMP versus melphalan-prednisone or cyclophosphamide-prednisone (MP/CP)
as initial therapy for very elderly patients.
Methods: We retrospectively studied 233 patients aged 75 years or older with
newly diagnosed multiple myeloma between March 2007 and February 2015.
One-hundred thirty one patients received VMP and 102 patients received
MP/CP regimen were enrolled from 15 institutions throughout Korea. 
Results: Patient characteristics were comparable in these two groups. Overall
response rate was 70.2% in VMP patients and 48.0% in MP/CP patients
(P=0.001). Complete response rate was 22.9% in VMP patients and 7.8% in
MP/CP patients (P=0.002). After a median follow-up for survivors of 28.5
months, progression-free survival (PFS) and overall survival (OS) were signif-
icantly different between the two groups (PFS, median 21.3 vs 11.8 months in
VMP and MP/CP group, respectively, P=0.018; OS, median 34.9 vs 22.8
months in VMP and MP/CP group, respectively, P=0.006). Nonetheless, for 61
patients who were aged ≥80 years, PFS and OS was not significantly different
between the two groups (PFS, median 19.6 vs 13.2 months in VMP and MP/CP
group, respectively, P=0.378; OS, median 27.8 vs.17.8 months in VMP and
MP/CP group, respectively, P=0.443).
Summary/Conclusions: Although VMP therapy was associated with a significant
improvement in overall survival among patients ≥75 years, there is no differences
for patients aged 80 or older. Frailty and comprehensive geriatric assessment
should be incorporated to guide treatment decisions for this population.
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EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR THE
TREATMENT OF MULTIPLE MYELOMA IN HIV-POSITIVE PATIENTS –
A CASE-SERIES 
B. Ni1,*, A. Rosko2, D. Benson2, S. Devine2, C. Hofmeister2, Y. Efebera2
1Department of Internal Medicine, 2Division of Hematology, Department of Inter-
nal Medicine, The Ohio State University, Columbus, United States
Background: While hematopoietic malignancies are found at increased rates
in individuals with acquired immunodeficiency syndrome (AIDS), coincidence
of multiple myeloma (MM) and human immunodeficiency virus (HIV) is less
common, leading to a paucity of expertise in the treatment of individuals with
these co-morbid conditions. Prior to the advent of highly active anti-retroviral
therapy (HAART), autologous stem cell transplant (ASCT) was relatively con-
traindicated for MM patients with HIV due to issues associated with stem cell
harvest and the risk of opportunistic infections. With the widespread use of
HAART for control of HIV, high dose chemotherapy and ASCT is now the pre-
ferred treatment for relapsed lymphoma, the leading hematopoietic malignancy
associated with HIV/AIDS. It stands to reason that MM patients with HIV on
HAART may benefit equally from aggressive combination treatment of
chemotherapy and ASCT.
Aims: This study seeks to evaluate the clinical course and treatment outcomes
of patients with HIV and MM treated with high dose therapy and ASCT.
Methods: A single center retrospective case-series study was performed. Data
from patients who were HIV-positive and on HAART undergoing ASCT for treat-
ment of MM between January 2000 and June 2016 were collected and analyzed.
Results: The following Table 1 lists patient characteristics. All were male with
average age 53.2 years. All were diagnosed with HIV prior to diagnosis of MM
and were appropriately treated with HAART prior to ASCT. All patients had
undetectable HIV viral titer prior to ASCT, and most remained undetectable
after ASCT. Four of five patients had CD4 >200/uL and one patient had CD4
<50/uL prior to ASCT; however all patients recovered CD4 counts after ASCT
(and most with improved CD4 count).  Adequate CD34(+) stem cells were col-
lected.  Patients received high dose melphalan (200 mg/m2) followed by ASCT.
HAART was continued during ASCT. Patients experienced usual ASCT toxicities
including diarrhea, mucositis, and neutropenic fever. One patient developed
sepsis and small bowel obstruction, which resolved with antibiotics and con-
servative management.  All patients had normal neutrophil and platelet engraft-
ments.  Post ASCT responses were complete remission (2 patients), very good
partial remission (1), partial remission (1) and minimal response (1). All patients
are currently alive without relapse or progression 1-4 years from ASCT and
receiving post ASCT maintenance with lenalidomide.
Table 1.
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Summary/Conclusions: Multiple myeloma patients with concurrent HIV infec-
tion that is controlled on HAART tolerate ASCT for treatment of myeloma as
well as myeloma patients without HIV infection and have generally good out-
comes. 
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FEASIBILITY OF USING GLOBAL FDG UPTAKE IN BONE MARROW TO
ASSESS TREATMENT RESPONSE IN MULTIPLE MYELOMA
B. Oestergaard1,*, W.Y. Raynor2, M.Z. Zirakchian2, R. Taghvaei2, A. Nielsen3,
J.T. Asmussen4, P. Holdgaard5, T. Plesner6, A. Alavi2, N. Abildgaard1,
P.F. Høilund-Carlsen3
1Hematology, Odense University Hospital, Odense, Denmark, 2Radiology, Hos-
pital of the University of Pennsylvania, Philadelphia, United States, 3Nuclear
Medicine, 4Radiology, Odense University Hospital, Odense, 5Nuclear Medicine,
6Hematology, Vejle Hospital, Vejle, Denmark
Background: Multiple myeloma (MM) is characterized by plasma cell prolifer-
ation and expansion primarily in the bone marrow. Modern assessment of MM
using FDG-PET has so far mostly been limited to the analysis of focal lesions,
requiring subjective interpretation to determine overall disease activity.
Aims: A novel method using CT segmentation to determine global bone marrow
activity portrayed by FDG uptake was used to achieve a comprehensive under-
standing of disease burden in patients with MM before and after therapy.
Methods: Prospective FDG-PET/CT data of 23 MM patients between ages of
50 and 76 (mean=64.3, males=21, females=2) were collected from Odense Uni-
versity Hospital (NCT02187731) and included scans before initiation of treatment
and at end of treatment (EOT) two months after high dose chemotherapy with
stem cell support. . All scans were conducted 60 min after intravenous injection
of 4 MBq/kg of FDG. Images were analyzed using an iterative thresholding algo-
rithm that delineates a continuous region based on Hounsfield units from the CT
data (OsiriX software; Pixmeo SARL; Bernex, Switzerland), allowing for seg-
mentation of the total skeleton on a fused PET/CT image. This enabled the quan-
tification of FDG uptake representing the entire skeleton, providing a global
SUVmean that considers all bone marrow involvement. Global SUVmean scores
were compared before and at EOT using a two-tailed paired t test.
Results: A decrease in marrow FDG uptake was observed at EOT compared
to baseline in most patients. The calculated global SUVmean uptake decreased
after initiation of treatment in 17 (73.9%) of the cases and increased in 6
(26.1%) of the cases, supported by the observed statistical difference of the
dependent means before and after treatment (P=0.0053).
Summary/Conclusions: We assessed the effects of treatment in MM patients
using a novel technique for global quantification of FDG uptake in the bone
marrow and skeleton and found lower global uptake at EOT. However, a limi-
tation of bone segmentation is present in cases with extramedullary disease.
Global assessment rather than focal analysis of discrete lesions represents a
robust and straightforward method of determining total disease activity that
potentially will be of value in treatment evaluation, disease monitoring and
prognostication in multiple myeloma.
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VALUE OF MYELOMA PROGNOSTIC INDICES IN ERA OF NOVEL DRUGS
IN TRANSPLANT SETTING
V. Zatezalo1,*, A. Hanžek1, N. Gredelj-Šimec1, V. Milunović1,
M. Bogeljić-Patekar1, M. Lukić1, B. Jelić-Puškarić2, A. Škrtić3,
D. Radić-Krišto1,4, S. Ostojić Kolonić1,5
1Department of Hematology, 2Department of Cytology, 3Department of Pathol-
ogy, Clinical Hospital Merkur, Zagreb, 4School of Medicine, Osijek, 5School of
Medicine, Zagreb, Croatia
Background: Despite the era of emerging novel agents, autologous peripheral
blood stem cell transplantation remains backbone of myeloma treatment.
Aims: The main aim of our study was to evaluate the role of tandem transplan-
tation in myeloma treatment as well as prognostic indices in era of novel drugs.
Methods: We consecutively included all patients transplanted due to myeloma
at our center from 2012 to the end of 2016. Patients were treated with either
VAD or bortezomib based therapy. After induction treatment, all patients pro-
ceeded to mobilization therapy cyclophosphamide 3g/m2 and received pegfil-
grastim. Preparative regimen was either MEL 200 for fit patients or MEL 140
for frail and those with severe renal function impairment. Patients treated with
VAD who had poor response after autologous transplantation were subse-
quently treated with bortezomib based therapy. We examined following baseline
characteristics: age, proportion of plasma cells in bone marrow biopsy or aspi-
rate, FISH and lactate dehydrogenase (LDH). Additionally, for each patient
International Staging System (ISS), Revised International Staging System (ISS-
R) and Durie Salmon staging were calculated. Patients with other malignant
diseases prior to myeloma diagnosis were excluded. The main outcomes were
overall survival (OS) defined as death from myeloma or any other cause and
time to next treatment (TNT), defined as time from transplant to next new ther-
apy or death of any cause.
Results: From January 2012 to December 2016 hundred and one patient with
MM (49 male, 52 female), median age 55 (range 22-71), were transplanted.
Bortezomib based induction therapy was used in 55 (54,5%) and VAD induction
was used in 46 (45.5%) patients. Median OS of all treated patients was 73
months; median OS of VAD group was 73 months while in bortezomib group
median OS was not reached, but this difference was not statistically significant
(p=0,13). TNT was significantly longer in bortezomib group than in VAD one
(27,8 vs 17,5 months respectively; p=0,02). Interestingly prognostic indices
could not discriminate patient groups according to OS (p=0,1), but could dis-
criminate them due to TNT (p=0,008), possibly due to cross-over to bortezomib
treatment after treatment failure. TNT had a significant correlation with levels
of LDH (p=0,04) and no significant correlation with number of plasma cells in
bone marrow. OS was significantly longer in those with longer duration of time
to next treatment (p=0,0004). There was no difference in OS or TNT in patients
treated with tandem transplant vs single transplant (p=0,68 and p=0,57 respec-
tively), possibly due to heterogeneity of tandem group.
Summary/Conclusions: Even though novel drug therapy seems to converge
risk groups to lower ones, prognostic indices remain relevant. Due to hetero-
geneity of patients and myriad of known prognostic factors further studies are
needed so they may be translated into risk adapted therapy approach.
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WHICH ORGAN SHOULD WE BIOPSY TO DIAGNOSE AL AMYLOIDOSIS?
L. Llorente Gonzalez1,*, C. de Miguel Jiménez1, C. Salas2, P. García-Pavía3,
E. Gonzalez3, J. A. López del Olmo4, J. M. Vazquez Cobos4, I. Krsnik1
1Hematology, 2Anatomical Pathology, 3Cardiology, Hospital Universitario Puer-
ta de Hierro de Majadahonda, 4Cardiovascular Proteomics, Centro Nacional
de Investigaciones Cardiovasculares Carlos III, Majadahonda, Spain
Background: Light chain (AL) amyloidosis is a deposition disease with can
affect many organs and with a variable but usually bad, prognosis. Therapy
requires a quick and correct diagnosis. Accurate identification of amyloid dep-
osition and of the amyloid subtype in tissue biopsies is thus, mandatory. Ran-
dom biopsies of easily accessible tissues such as subcutaneous fat, gingivae
or rectum are usually recommended but sensitivity of this approach is low.
Aims: To present our experience with tissue biopsies performed in 62 consec-
utive patients diagnosed of AL amyloidosis in our center.
Methods: We reviewed all tissue biopsies performed during the study period
(2004-2017) in 62 consecutive patients diagnosed of AL amyloidosis at the
same center. A bone marrow (BM) biopsy was performed per protocol in all
cases. Decisions on biopsies were taken considering organ involvement and
accessibility:  skin, lymph nodes, lung or tongue biopsies were performed when
lesions were seen on clinical or X-ray examinations, cardiac biopsies in the
presence of increased NT-proBNP  (N-terminal natriuretic peptide) levels and
typical echocardiographic findings, kidney biopsies in patients with nephrotic
syndromes. Biopsies were stained with Congo Red and read under polarized
light with a Texas filter. Subtyping of the amyloid was done using anti-kappa,
anti-lambda, anti-TTR and anti-A antisera. If any biopsy was positive for AL
amyloid, no further biopsies were performed unless necessary for therapeutic
decisions.
Results: A total of 152 biopsies were performed during the study period: see
Table 1.
Table 1.
Summary/Conclusions: Prognosis in AL amyloidosis is slowly improving with
the use of new anti-myeloma drugs and may improve further with new mono-
clonal antibodies. Therapy requires an early and accurate diagnosis. We do
not perform random biopsies of tissues such as fat or gingivae due to low sen-
sitivity. In our hands biopsies of tissues or organs with clinical, analytical or
radiological involvement shows higher sensitivity. A bone marrow biopsy is
required for diagnosis of the neoplastic disease underlying AL amyloidosis and
may show amyloid in up to 50% of the cases. Cardiac biopsy is also highly
sensitive and in centers with a high degree of expertise such as ours, has no
complications. Our data allow us to recommend a different approach to AL
amyloidosis of what is usually published. Biopsies of clinically involved organs
yields almost 100% sensitivity. Random biopsies of gingivae, subcutaneous
fat or rectum should be discouraged.
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A COMPARISON OF CYCLOPHOSPHAMIDE-GLUCOCORTICOIDS AND
LENALIDOMIDE-DEXAMETHASONE AS TREATMENT FOR MULTIPLE
MYELOMA IN FIRST RELAPSE AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION
R. Sterrett1,*, A. Figueiredo2, R. Mallick3,4, N. Kekre1,2,5, H. Atkins1,2,5,
A. McCurdy1,2,5
1Department of Medicine, University of Ottawa, 2Ottawa Hospital Research
Institute, 3School of Epidemiology, Public Health and Preventive Medicine, Uni-
versity of Ottawa, 4Clinical Epidemiology Program, Ottawa Hospital Research
Institute, 5Division of Hematology, The Ottawa Hospital, Ottawa, Canada
Background: The optimal management of relapsed Multiple Myeloma (MM)
with respect to therapeutic combinations and sequence remains controversial
and is actively evolving.  Many commonly used regimens have not been directly
compared. These agents vary widely in cost, and knowledge of their relative
efficacy is of particular importance in regions where cancer medicines are pub-
licly funded.
Aims: We sought to compare the efficacy and safety of two commonly used reg-
imens for relapsed MM using historical cohorts from a single transplant center.
Methods: A retrospective observational study was performed between January
1991 and November 2016 to compare the efficacy of cyclophosphamide and
dexamethasone/prednisone (Cyclo), or lenalidomide and dexamethasone (Len-
Dex) for relapsed MM post autologous stem cell transplant (auto SCT). The
primary outcome was Time to Next Treatment 2 (TTNT2), defined as time from
first relapse requiring therapy after auto SCT to second relapse requiring ther-
apy. The secondary outcome was overall survival, defined as time of diagnosis
to death from any cause. Outcomes were assessed by Kaplan Meier methods
and overall differences determined by log rank test. Hazard ratios were calcu-
lated for individual treatment groups and compared by univariate and multi-
variate logistic regression.
Results: A total of 243 patients underwent treatment for MM at first relapse
post autologous transplant. Of these, 139 were included in this analysis: 88
Cyclo and 51 Len-Dex. Patient demographics and disease characteristics were
similar between each group for age, sex, subtype of MM and ISS Stage
(p>0.05). Vincristine, Doxorubicin and Dexamethasone (VAD) was the most
common treatment at diagnosis for the Cyclo group (68%), whereas borte-
zomib-based therapy was the most common for the Len-dex group (76%)
(p<0.0001). No differences were observed in overall response rate or depth of
response based on induction therapy between both groups. Median time to
first relapse requiring treatment after auto SCT was longer in the Cyclo group,
36 months vs 25 months (p=0.0008). The median TTNT2 was similar for the
two groups: 12.2 months (IQR, 4.56-27.96) for Cyclo and 12.1 months (IQR,
4.80-29.16) for Len-dex (p=0.52). However, after adjusting for standard patient
and disease related factors in a multivariate model, TTNT2 was shorter for
Cyclo compared to Len-dex (HR 2.29; 95% CI, 1.17 – 4.51; p=0.016). The
median overall survival was 84 months for Cyclo and 75.6 months for Len-dex
(p=0.31). In the multivariate analysis, overall survival was not different for Cyclo
compared to Len-dex (HR 0.99; CI 0.42 – 2.34; p=0.99). There was no signifi-
cant difference in rates of hospitalization, infection, or grade 3 adverse events
between the two groups (Figure 1).
Figure 1. Survival curves.
Summary/Conclusions: In this observational study of patients with relapsed
multiple myeloma post autologous stem cell transplantation, Lenalidomide-dex-
amethasone was associated with longer TTNT2 compared with Cylophos-
phamide-glucocorticoids. However, there was no difference in overall survival.
Cyclophosphamide is considerably less expensive than the novel agents. In
an era when fiscally sustainable care for MM remains a challenge, further
prospective studies are required to compare cyclophosphamide with novel
agents in the management of relapsed multiple myeloma.
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CLINICAL IMPACT OF THE PLASMA LENALIDOMIDE CONCENTRATION
AND THE ANALYSIS OF ANTI-TUMOR IMMUNE RESPONSE IN NEWLY
DIAGNOSED MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE AND
DEXAMETHASONE THERAPY
T. Kobayashi1,*, M. Miura2, T. Niioka2, Y. Fujioka1,3, M. Abumiya2, S. Ikeda1,
T. Yoshioka1, Y. Kameoka1, H. Nishikawa3, N. Takahashi1
1Hematology, Nephrology and Rheumatology, Akita University Graduate School
of Medicine, 2Pharmacy, Akita University Hospital, Akita, 3Division of Cancer
Immunology, Exploratory Oncology Research and Clinical Trial Center, National
Cancer Center, Chiba, Japan
Background: Lenalidomide (Len) and dexamethasone (DEX) combination
therapy (Ld) is now the standard treatment of multiple myeloma (MM). Len has
both a direct effect on MM cells and an immunomodulatory effect and recently
many drugs are combined with Ld therapy to expect the synergistic anti-tumor
immune response. However, adverse events (AEs) make continuation of Ld
therapy difficult for some patients especially for elderly patients.
Aims: To investigate the safe and effective plasma concentration of Len and
the anti-tumor immune response change in MM patients treated by Ld therapy. 
Methods: Forty patients (18 men and 22 women) were enrolled in this study.
Median age was 75.5  years old (range 61-86). Len was administered on days
1–21 of a 28-day cycle; and DEX, on days 1, 8, 15, and 22. The plasma concen-
trations of Len just before oral administration and 1, 2, and 4 hr thereafter were
analyzed by using liquid chromatography-tandem mass spectrometry. Before
and after Ld therapy, Peripheral blood mononuclear cells (PBMCs) of MM patients
were isolated from whole blood by Ficoll-Hypaque density-gradient centrifugation.
PBMCs were stained with the fluorescent dye-conjugated antibodies against sur-
face and intracellular antigens and evaluated by multicolor flow cytometry. Intra-
cellular cytokine production of IFN-γ, TNF-α, IL-2 and CD107a molecule was
detected after stimulation with PMA/ionomycin for 5 hours in the presence of pro-
tein transport inhibitor Golgi stop (BD Bioscience). Analysis was performed using
LSR Fortessa (BD Bioscience) and Flowjo version 10.2 software (TreeStar). This
study protocol was approved by the Ethics Committee of Akita University Hospital,
and all recipients gave written informed consent.
Results: 21 patients showed renal impairment (RI) necessary to adjust initial
Len dosage. Adverse cytogenetics of del17p and t(4;14), detected by using flu-
orescence in situ hybridization, were found in 2 and 4 patients, respectively.
The median initial dosage of Len was 15 mg and DEX 20 mg. The overall
response rates were 68.6% and the 2-year progression-free survival was 70.8%
at a median follow-up of 26.5 month. Grade 3 to 4 nonhematologic AEs were
observed only in 8 patients. We estimated the AUC0-24 of Len by using formula
as we previously reported (Ther Drug Monit 2014) and the cut-off value of the
hematologic AEs was 2613.5ng•hr/ml (sensitivity 81.8%, specificity 80%) and
non-hematologic AEs 3023.6ng•hr/ml (sensitivity 78.9%, specificity 62.5%).
After Ld therapy, naïve subset of CD4 and CD8 T cells and monocytic MDSC
reduced significantly. On the other hand, effector memory subset and intracel-
lular cytokine productions of IFN-γ, TNF-α, IL-2, and CD107a of CD4 and CD8
T cells increased significantly (Figure 1).
Figure 1.
Summary/Conclusions: Len can be administered safely even in elderly
patients with RI by using the estimated AUC0-24 of Len as a prediction marker
of AEs. Enhanced cytokine production and increased memory subset of T cells
were observed after Ld treatment. 
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THE ROLE OF EXPRESSION CD56 ON BONE MARROW PLASMA CELLS
AND EXTRAMEDULLARY PLASMA CELLS IN PATIENTS WITH MULTIPLE
MYELOMA
M. Firsova1,*, L. Mendeleeva1, A. Kovrigina2, M. Soloviev1, O. Pokrovskaya1,
M. Nareyko1, L. Kuzmina3, V. Savchenko4
1Department of High-Dose Chemotherapy of Paraproteinemic Hemoblastosis,
2Pathology department, 3Bone Marrow Transplantation Department, 4National
Research Center for Hematology, Moscow, Russian Federation
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Background: The myeloma cells interact with the bone marrow microenviron-
ment by several adhesion molecules. One of them is CD56 (a neural cell-adhe-
sion molecule N-CAM) – a membrane glycoprotein, a member of the
immunoglobulin superfamily, expressed on the surface of malignant plasma
cells of patients with multiple myeloma (MM). Decreased expression of CD56
is considered as one of the possible factors, that help tumor cells to spread
outside the bone marrow.
Aims: To evaluate the impact of CD56 expression on the rate of overall survival
(OS) in MM patients with extramedullary disease (EMD).
Methods: The study included 32 patients with primary MM (17 males, 15
females) 23-77 years old (median value: 52 years old). The disease was diag-
nosed in accordance with the IMWG criteria (2014). 17 patients had EMD
including 14 patients with soft-tissue plasmacytomas associated with bone and
3 patients with extramedullary foci in the neck area, in the stomach, in the liver.
In all cases a tumour biopsy and bone marrow trephine biopsy were performed,
that confirmed the presence of malignant plasma cell infiltration. Paraffin block
slices from trephine biopsy material and tumour biopsy material were used to
perform an immunohistochemistry (IHC) analysis with an antibody to CD56.
Kaplan-Meier survival curves were generated, statistical analysis was done
using the program «Statistica» ver.10.
Results: In patients with plasmacytomas the IHC analysis of trephine biopsy
material showed CD56+ in 59% cases vs 73,4% in patients without EMD. Five-
year OS in patients with CD56+ in the bone marrow was 90%, which was sig-
nificantly higher (р=0,04) than that of the patients with CD56- -  0% with follow-
up of 5 to 61 months (median 20 months, Figure1). Expression of CD56 on the
surface of extramedullary MM cells was found in 76,5% patients. OS in the
group of patients with CD56+ in extramedullary MM cells and in bone marrow
cells (n=9) was 67% which was significantly higher (р=0,04) than that in the
group of patients (n=4) with CD56+ in extramedullary MM cells and CD56- in
bone marrow cells – 50%. Simultaneous lack of CD56 in extramedullary MM
cells and in bone marrow cells was observed in 3 patients with 2 of them died
of progression in 31 and 51 months. However simultaneous expression of
CD56 in extramedullary MM cells and in bone marrow cells was observed in 9
patients with median follow-up of 40 months and 1 patient died of progression
after 47 months.
Figure 1. Probability of overall survival in patients depending on CD56
expression in bone marrow.
Summary/Conclusions: CD56 expression in bone marrow plasma cells sig-
nificantly increases the OS rate in MM patients regardless the presence or
absence of plasmacytomas. Double CD56 negativity both in extramedullary




MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA 
C. Cerchione1,*, L. Catalano1, A. E. Pareto1, S. Basile1, L. Marano1, I. Peluso1,
L. Simeone1, O. Vitagliano1, S. Palmieri2, S. Rocco2, F. Ferrara2, F. Pane1
1Hematology, Ematologia e trapianto/au federico ii, 2Hematology, AORN Car-
darelli, Napoli, Italy
Background: Bendamustine is a bifunctional alkylating agent, with low toxicity,
proved to be effective in relapsed, refractory and in new diagnosed Multiple
Myeloma (MM).
Aims: It has been evaluated efficacy and tolerance of Bendamustine, in com-
bination with bortezomib-dexamethasone (BVD) in patients with relapsed and
refractory MM (rrMM), whose prognosis is particularly severe. A regional retro-
spective real-life analysis of patients with rrMM who had been treated with
BVD as salvage therapy has been performed.
Methods:
56 patients (31 M/25 F, Table 1), with rrMM, median age at diagnosis 57.3
years (r. 36-82), median age at start of treatment 61.8 years (r.37-83) treated
with several lines of treatments (median 6, r. 2-11), every refractory to all the
drugs previously received (also Bortezomib), received BVD (Bendamustine 90
mg/sqm days 1,2; Bortezomib 1.3 mg/sqm days 1,4,8,11, Dexamethasone 20
mg days 1,2,4,5,8,9,11,12, Pegfilgrastim day +4) every 28 days, until progres-
sion. ISS was equally distributed, and cytogenetic was evaluable in 12 patients,
and in particular one del13q and one t(11;14). All the patients had previously
been treated with schedule containing bortezomib and IMIDs, and 30% had
also received radiotherapy. 67% of them had undergone at least to a single
auSCT. All patients were relapsed and refractory to last therapies received
before BVD, including bortezomib.
Results: According to IMWG, after a median follow-up of 14 months (r.2-36),
ORR was 64% (36/56 : 4 CR, 7 VGPR, 16 PR, 9 MR) with 8 PD and 12 patients
in SD, which can be considered as an impressive result in this subset of rrMM
patients. In particular, for 11 patients, BVD was, after having achieved at least
a PR, a bridge to second auSCT, and for two patients a bridge to alloSCT.
Median time to response was 1.2 months (r.1-3), median OS from diagnosis
was 62.7 months (range 6-151), median OS from start of Bendamustine was
9.8 months (range 2-36).
Table 1.
Summary/Conclusions: BVD has shown significant efficacy in a particularly
severe setting of patients, relapsed and refractory to all available therapeutic
resources, and, in particular cases, it could be considered as a bridge to a sec-
ond autologous or allogenic SCT.
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VE-CADHERIN IN MULTIPLE MYELOMA: AN INDEPENDENT
PROGNOSTIC FACTOR FOR PROGRESSION-FREE SURVIVAL
B. Samura1,2,*, Y. Kolesnyk3, V. Syvolap4, A. Abramov5
1Department of Hematology, Zaporizhzhia Regional Clinical Hospital, 2Depart-
ment of Internal diseases, 3Department of Pathophysiology, 4Department of
Propedeutics of Internal Diseases, 5Scientific medical-laboratory center, Zapor-
izhzhia State Medical University, Zaporizhzhia, Ukraine
Background: Endothelial damage and perivascular infiltrates are vital in the
development of multiple myeloma. Recent studies have found that endothelial
dysfunction might be result in multiple myeloma progression and adverse
effects of drug implementation. On the other hand, there is a direct correlation
between microvessel density in multiple myeloma and parameters of disease
progression. Endothelial cells participate in inflammatory events leading to
atherogenesis by regulating endothelial cell permeability via the expression
vascular endothelial-cadherin (VE-Cadherin) on their surface. VE-cadherin is
cell adhesion molecules localized at the endothelial junction, which plays critical
roles in angiogenesis, neovascularization, neoplasm development, stem cells
mobbing, and endothelial integrity. Indeed, VE-cadherin chiefly organizes the
opening and closing of the endothelial barrier. It has found that VE-cadherin
as a transmembrane protein probably modulates intensity of angiogenesis in
multiple myeloma and may be useful in prognosis. However, the predictive role
of VE-cadherin as a prognostic factor for survival of patients after treatment of
multiple myeloma is not still clear.
Aims: We aimed to evaluate the prognostic value of circulating VE-catherin
for progression-free survival in patients with multiple myeloma in complete or
partial remission.
Methods: One hundred twelve out subjects with multiple myeloma were
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enrolled in the study. Diagnosis and staging of multiple myeloma were defined
by current clinical practice guidelines. To be achieving remission chemotherapy
with bortezomib, thalidomide, dexamethasone, cyclophosphamide, melphalan,
anthracyclines was used accordingly contemporary clinical guidelines. All sub-
jects were at complete or partial remission at baseline. Observation period was
up to 12 months. ELISA method for measurements of circulating level of VE-
catherin was used.
Results: Medians of circulating levels of VE-catherin in subjects without progres-
sion of multiple myeloma (n=89) and subjects with progression (n=23) during 12
months were 0.92 ng/ml (95% confidence interval [CI]=0.66-1.19 ng/ml) and 1.77
ng/ml (95% CI=1.47-2.07 ng/ml) (р=0.0002). The best VE-catherin cutoff value
for predicting disease progression risk was 1.31 ng/mL with AUC value 0.839
(p=0.0001), the sensitivity and specificity were 77.8% and 61.5% respectively.
The presence of high levels of serum VE-cadherin was significantly correlated to
a shorter progression-free survival (PFS). In a multivariate analysis along with
clinical and biologic prognostic parameters, high serum VE-cadherin level (>1.31
ng/ml) was an independent adverse prognostic variable for PFS (median PFS
9.93 (IC=8.16-11.71) months vs 7.35 (IC=5.75-8.95) months (p=0.02).
Summary/Conclusions: The serum VE-cadherin level is a valuable biomarker
for predicting treatment response and an independent prognostic factor for pro-
gression-free survival for patients with multiple myeloma.
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THE UTILITY OF FACS PURIFICATION OF PLASMA CELLS FOR FISH
ANALYSIS IN MONOCLONAL GAMMOPATHIES
M. Pereira1,2,*, G. Marques3, J. Lima3, R. Reis3, A. Coelho3, L. Jorge3,
S. Pedreiro4, L. Ribeiro1, A. Paiva4, F. Rodrigues3
1Clinical Hematology Department, Coimbra University Hospital Centre, 2Faculty
of Medicine, University of Coimbra, 3Clinical Pathology Department, 4Flow
Cytometry Unit, Coimbra University Hospital Centre, Coimbra, Portugal
Background: Despite the prognostic value of chromosomal aberrations, con-
ventional metaphase karyotyping in monoclonal gammopathies (MG) is often
uninformative due to the inherent difficulty of obtaining proliferating plasma
cells (PC). Interphase fluorescence in situ hybridization (FISH) is a simple,
quick and effective technique for the detection of cytogenetic aberrations that
can overcome this limitation. However, the signal of interest is frequently diluted
by the noise of the mixed cellularity of the sample, originating both false nega-
tives and false positives. Fluorescence-activated cell sorting (FACS) of the tar-
get cells enables a focused application of FISH on pathologically significant
cells – such as the PC in MG – reducing the confounding noise. This is partic-
ularly relevant when the percentage of pathologic cells in the sample is low,
such as in monoclonal gammopathy of undetermined significance (MGUS)
where, by definition, there are less than 10% PC in the bone marrow.
Aims: This study aims to analyze the utility and effectiveness of FACS purifi-
cation of PC for the cytogenetic workup of MG by FISH.
Methods: We analyzed all FISH studies performed in our laboratory, in individ-
ual patients, on clonal interphase FACS-separated bone marrow PC, between
the 1st June 2015 and the 15th September 2016. The probes used in our stan-
dard MG panel were del(1p32), amp(1q21), t(4;14) and del(17p13.1) (TP53
gene) and, starting in April 2016, t(14;16). We had previously established 20
000 cells per sample as the minimum (and sufficient) number of cells needed
to guarantee the confident application of all 5 probes in our lab.
Results: After the exclusion of samples diluted with peripheral blood, we iden-
tified 102 patients with FACS separated purified PC. An average of 165 393±270
516 PC were separated per patient, and 98 of the cohort (96.1%) had a suffi-
cient number of cells for the hybridization of at least one FISH probe; all 5
probes were applied in 30% of patients, 4 in 50%, 3 in 12% and 2 in 8%; the
motives underlying the selection of fewer than all 5 probes in samples with a
sufficient number (>20 000) of cells included the individual decision of the assist-
ing physician and, for t(14;16), the date of the study. Considering only those
studies performed after the introduction of t(14;16), all 5 probes were used in
67.5% of patients; we were able to apply four or more probes in 80% of patients
with 1% or less bone marrow PC according to flow cytometry. The median age
of the 98 patients with a FISH result was 63.6 years old (37.8 to 87.3), and
56.1% were male; 41.8% eventually received a diagnosis of MGUS and 58.2%
of multiple myeloma (MM), with an identical median age (64.2±6.9 vs 63.0±10.8
years old, p=NS). We found that 16.3% (of 92) were positive for t(4;14), 12.2%
(of 90) for del(17p13.1), 5.6% (of 90) for del(1p32) and 41.1% (of 90) for
amp(1q21); t(14:16) was not identified in any of the 30 patients in whom the
probe was used. The t(4;14) translocation was present in 22.4% of MM and
7.7% of MGUS patients (p=0.055), and del(17p13.1) was found in 18.5% vs
2.8% (p=0.026); on the other hand, both del(1p32) (5.6% vs 5.6%, p=NS) and
amp(1q21) (46.3% vs 33.3%, p=NS) were identically distributed across diag-
noses. We observed that 40.4% of MM and 65.8% of MGUS patients were
positive for 20% of less of the tested aberrations, while 54.4% vs 34.2% were
positive for 20 to 50%, and 5.3% vs 0% were positive for over 50% of the aber-
rations (p=0.026).
Summary/Conclusions: We have found that the application of FISH probes
in FACS-separated PC is highly efficient with a robust yield, providing a large
enough sample for the application of at least two probes in over 95% of patients,
irrespective of bone marrow plasmacytosis; in fact, we obtained an average of
165 000 pure PC per patient, which is more than 8-fold higher than the number
we consider invariably sufficient to apply 5 probes, which we achieved in at
least 80% of patients.
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CLINICAL SPECTRUM AND EVOLUTION OF MONOCLONAL
GAMMOPATHY ASSOCIATED NEUROPATHY VERSUS CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY PATIENTS 
J.M. Byun1,*, I. Kim2, S.-H. Baek3, J.-J. Sung2, Y. Koh2, D.-Y. Shin2,
S.-S. Yoon2, S. Park4, C.-S. Kim5
1Seoul Metropolitan Government Seoul National University Boramae Medical
Center, 2Seoul National University Hospital, 3Korea University Anam Hospital,
Seoul, 4Inje University Haeundae Paik Hospital, Busan, 5Incheon Medical Cen-
ter, Incheon , Korea, Republic Of
Background: Paraproteinemic neuropathy (PPN) refers to a disorder of the
peripheral nervous system associated with a monoclonal gammopathy (MG).
It is known that about 10% of idiopathic peripheral neuropathies are of this
type. Unfortunately, PPN is often underdiagnosed or confused with chronic
inflammatory demyelinating polyneuropathy (CIDP), subsequently leading to
inappropriate management. Since progression of neuropathy is associated with
possible malignant conversion of underlying monoclonal gammopathy, it is
important to recognize underlying hematological conditions.
Aims: We aimed to determine whether the clinical characteristics and course
differed in patients with PPN compared to those with CIDP in order to identify
factors useful for differential diagnosis.
Methods: This study was carried out at Seoul National University Hospital,
which is a tertiary academic center. During the period between January 2005
and December 2016, patients with 1) monoclonal gammopathy of undetermined
significance (MGUS), and 2 CIDP were identified. Those with previous history
of cancer or autoimmune disease requiring treatment with immunodulatory
agents were excluded from analyses. In the end, a total of 18 MGUS patients
and 34 CIDP patients, with complete set of data including clinical physical
examinations, electrodiagnostic studies, and laboratory test results, were
enrolled.
Results: In both groups, males were predominant. IgG MG was most common
(55.6%) in our cohort. PPN appeared to be mainly sensory regardless of heavy
chain or light chain. Compared to PPN patients, CIDP patients were associated
with motor symptoms manifesting as motor weakness (50.0% versus 91.2%,
P=0.001) and ataxia (44.4% versus 61.8%, P=0.043) (Table 1). There were
equal number of axonal type neuropathy and demyelinating type neuropathy
in patients with PPN, and there were no differences in type of neuropathy
between various immunoglobulin subclasses. However, demyelinating type
PPN was associated with more severe clinical presentations, including more
dysethesia, pain and sensory symptoms. During median follow-up of 49 months,
2 PPN patients developed overt hematologic malignancies: 1 case of Walden-
strom macroglobulinemia and 1 case of AL amyloidosis. Both of them showed
malignant transformation within 8 months of neuropathy development, and
were associated with worsening neuropathic symptom at the diagnosis of hema-
tologic malignancy. There were no differences between the two groups with
regards to overall survival.
Table 1. Clinical characteristics of all enrolled patients.
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Summary/Conclusions: Although both PPN and CIDP patients suffer from
sensory symptoms, CIDP patients were more often associated with superim-
posed motor symptoms. Among PPN patients, demyelinating type neuropathy
seems to be associated with more severe clinical presentations. Worsening of
neuropathic symptoms in PPN patients warrants a high level of suspicion of
malignant transformation of underlying disease. 
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MOLECULAR GENETIC CRITERIA PREDICTING THE EFFICIENCY OF
PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS
TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
Z. Minchenko1, Z. Misharina2, O. Dmytrenko1, T. Liubarets3,*, I. Dmytrenko1,
V. Khomenko4
1Immunogenetic Laboratory, National Research Center for Radiation Medicine
of National Academy of Medical Science of Ukraine, 2O.O. Bogomolets National
Medical University, 3Hematology and Transplantology Department, National
Research Center for Radiation Medicine of National Academy of Medical Sci-
ence of Ukraine, 4Kyiv Bone Marrow Transplantation Center, Kyiv, Ukraine
Background: Global gains in treatment of MM using auto-PBHSCT testify to
heterogeneity of long-term outcomes of transplantation - different term of the
achievement and duration of complete remission, progression-free survival
(PFS), overall survival (OS). These facts determine individual approach to the
application of PBHSCT.
Aims: Finding molecular genetic criteria of predicting the effectiveness of autol-
ogous peripheral blood hematopoietic stem cell transplantation (auto-PBHSCT)
for improving of algorithm of multiple myeloma (MM) patients cure at various
stages of treatment.
Methods: The study involved 61 patients with MM with relapse and primary
therapy resistant patients. Molecular cytogenetic, immunogenetic, hematolog-
ical and statistical methods were used.
Results: Since appearance of genetic abnormalities in the malignant plasma
cells is one of the pathogenic mechanisms of the disease, genetic support of
patients is essential. It was determined that the carriage of the allele HLA-
DQB1*03: 02 in MM patients is associated with a high risk of high-dose
chemotherapy resistance (F=4,83, p=0,028; OR=1,75, p=0.038), and achieving
remission after auto-PBSCT is associated with carriage of haplotype HLA-C
*06 - HLA-DQA1*01: 01 (F=4,87, p=0,028; OR=7,34, p=0,05). Abnormalities
of chromosomes 4, 11, 13, 14, 16 and 17 were determined in 35 of 61 (57%)
MM patients with complicated disease course and minimal therapy response.
Significant alterations were revealed in the presence of two or more abnormal
clones (23 patients (37,7%), Ro Spirman=0,42, p <0,05), deletion of chromo-
some 17 (17 patients (27,9%), Ro Spirman=0,41, p <0,05) , deletion/monosomy
of chromosome 13 (10 of 15 patients surveyed, Ro Spirman=0,33, p <0,05),
the translocation t(4;14) (4 patients (6,6%), Ro Spirman=0,50 , p <0,02).
Summary/Conclusions: The results indicate the necessity of introducing the
molecular genetic support into protocol of examination MM patients on various
stages of treatment with auto-PBHSCT.
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THE INFLUENCE OF MINIMAL RESIDUAL DISEASE AND TUMOR LOAD
ON THE PROGRESSION FREE SURVIVAL IN MULTIPLE MYELOMA
PATIENTS
A. Garifullin1,*, S. Voloshin1, A. Kuvshinov1, Z. Chubukina1, A. Sсhmidt1,
S. Bessmel’tsev1, A. Chechetkin1
1Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, Russian Federation
Background: Use of modern drugs and their combinations in the complex
antimyeloma therapy (induction, high-dose therapy (HDT) with autologous stem
cells transplantation (ASCT), consolidation and maintenance therapy) to
improve efficacy of treatment and duration of responses. Despite the achieve-
ment of complete response (CR) many patients has a relapse which is caused
by activation of residual clonal plasma cells.
Aims: To define influence of induction therapy regimens, HDT with ASCT to
the frequency of Minimal Residual Disease (MRD) negative status and estimate
a role MRD in duration of Progression Free Survival (PFS) in multiple myeloma
(MM) patients.
Methods: We analyzed 52 patients with MM (median age 55 years,
male/female – 2.1:1). The induction therapy with Bortezomib-based regimens
(VD, CVD, VMP, PAD) was used in 36/52 (69%) patients, Immunomodulator-
based regimens (Thal+D, RD, VRD, PomD) – in 14/52 (27%), chemotherapy
– in 2/52 (4%). ASCT is carried out 31 (59.6%) patients. Primary tumor cells
phenotype and MRD were detected by 5-color flow cytometry. Clonal plasmatic
cells were detected by markers: CD38, CD138, CD45, CD19, CD20, CD27,
CD56 and CD117. MRD-negative status considered in identifying less than 1
tumor cell in 10000 (0.01%).
Results: MRD-negative CR was reached in 23.8% (10/42) patients after 4-6
cycles of therapy. The frequency of MRD-negative status in the “Bortezomib
group” was 31% (9/29), in the “Immunomodulator group” - 7.7% (1/13) (Chi-
square =0.1; p >.05). The general frequency of MRD-negative CR after HTD
with ASCT was 33.3% (7/21). The carrying out HTD with ASCT allowed to MRD
eradication in 36.4% (4/11) patients. One patient with a “light chain” myeloma
lost MRD-negative CR after HTD with ASCT that led to development of a clinical
relapse after 6 months. Carrying out a maintenance therapy with bortezomib or
lenalidomide didn’t allow to achieve MRD-negative status. Carrying out a main-
tenance therapy with bortezomib or lenalidomide didn’t allow to achieve MRD-
negative status in patients with MRD-positive response. On the contrary, achieve-
ment MRD-negative status promoted to increase of PFS. The PFS median in
MRD-positive group of patients (n=36: 21 CR, 6 VGPR, 9 PR) was 21 months,
in the MRD-negative group (n=16) – 66 months (p=.0068). The PFS median
patients with CR was higher in the MRD-negative group than in the MRD-positive
group (66 and 48 months, respectively, p=.0045). The tumor load is also a strong
prognostic factor like MRD status. Patients who attained low-level MRD had of
benefit in the duration of PFS: ˂0.01% - 66 months, 0.01%>0.1% - 48 months
at, 0.1%>1% - 22 months, ˃1% - 10 months (p=.0009) (Figure 1).
Figure 1. The influence of tumor load on progression free survival.
Summary/Conclusions: The frequency of achievement MRD-negative doesn’t
depend from program of induction therapy, HDT with ASCT and maintenance
therapy. Negative prognostic role of MRD status independent from clinical
response. Presence of MRD after treatment to associated with decrease of
PFS and early relapse. Control of MRD allows to increase of PFS and can be
done by means of modern drugs and its combinations, HDT with ASCT and
maintenance therapy. Impact of MRD requires further studies, especially after
HDT with ASCT.
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QUALITY OF RESPONSE AS PREDICTOR OF SURVIVAL AFTER
AUTOLOGOUS STEM CELL TRANSPLANTATION IN REAL LIFE MULTIPLE
MYELOMA PATIENTS IN A SINGLE INSTITUTION
A. Pinto1,*, A. Roque1,2, E. Cortesão1,2, A. Espadana1, A. B. Sarmento1,2,
C. Geraldes1,2, M. L. Ribeiro1
1Clinical Hematology Department, Centro Hospitalar e Universitário de Coimbra,
2Faculty of Medicine and Cimago, University of Coimbra, Coimbra, Portugal
Background: High dose chemotherapy (HDC) followed by autologous stem
cell transplantation (ASCT) is the standard treatment approach for younger
patients with multiple myeloma (MM). Since the introduction of proteasome
inhibitors and immunomodulatory drugs in MM treatment more patients achieve
deep and durable responses and better disease control before ASCT.
Aims: To evaluate the association between the depth of response before ASCT
and survival outcomes in a cohort of patients with MM.
Methods: Retrospective analysis of patients with MM treated with HDT and
ASCT between 2007 and 2016 in a single institution. All patients received
peripheral blood stem cell support after conditioning with high dose melphalan
(200 mg/m2 and 140mg/m2 for patients with renal insufficiency). Response
was assessed 100 days after ASCT according to the International Myeloma
Working Group response criteria. The Kaplan-Meier method was used to esti-
mate progression free survival (PFS) and overall survival (OS) and comparison
between risk groups was performed by using the log-rank test. The prognostic
factors of survival were analyzed by Cox regression univariate and multivariate
analysis.
Results: We included 195 MM patients, mainly males (57.9%) with a median
age at ASCT of 61 years (28-71). The most prevalent subtype was IgG k
(44.1%). The median number of previous therapeutic lines was 1 (1-4) and the
majority of patients (61%) received bortezomib as part of first-line regimen.
Patients undergone ASCT within a median of 10 months after diagnosis. With
a median follow-up time from ASCT of 28.55 months (2.8-121.4), OS at 2 and
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5 years was 83.8% and 68.9% and PFS was 74.8% and 37.3%, respectively.
Before ASCT, 101 patients (51.8%) achieved very good partial response
(VGPR) or better (≥VGPR) and 94 patients (48.2%) a partial response (PR).
The patients in ≥VGPR presented significantly longer OS (median OS not
reached vs 96.9 months, p=0.023) and PFS (58.5 vs 41.2 months, p=0.003)
compared with those in PR. At 100 days after ASCT, 107 patients (54.9%) pre-
sented ≥VGPR, 79 (40.5%) PR and 7 (3.6%) progressive disease. Two patients
were not assessed due to loss of follow-up. The group of ≥VGPR showed supe-
rior OS (median OS not reached vs 72.4 months, p=0.023) and PFS (58.5 vs
34.79 months, p=0.007) compared to the PR group. We did not found statisti-
cally significant differences in survival of patients who achieved ≥VGPR before
or after ASCT. Univariate analysis indicates that depth of response before and
after ASCT (≥VGPR vs PR) are significant predictors of OS (HR 0.49; 95% CI
0.31-0.80, p=0.004 and HR 0.49; 95% CI 0.30-0.81, p=0.005) and PFS (HR
0.50; 95% CI 0.27-0.92, p=0.026 and HR 0.49; 95% CI 0.27-0.90, p=0.021).
Multivariate Cox regression model showed that these factors retain their prog-
nostic value after adjustment for age, International Staging System stage and
number of previous lines of treatment.
Summary/Conclusions: These findings provide evidence for quality of
response as a predictor of OS and PFS after ASCT in patients with MM. Out-
come after ASCT seems to be better for MM patients who achieve deep
responses (at least VGPR) before or after transplant. Our results support the
use of more effective induction regimens in order to improve initial response as
this may correlate with higher response rates and survival post-ACST.
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LEPTOMENINGEAL INFILTRATION SCREENING SHOULD BE
PERFORMED IN PATIENTS DIAGNOSED WITH PLASMA CELL
LEUKAEMIA
M.Q. Salas1,*, V. Clapes2, N. Garcia1, C. Baca3, R. Velasco4, E. Gamundi5,
A. Sureda3
1Hematology, ICO-Hospitalet, 2Hematology, ICO Duran i Reynals, 3Hematol-
ogy, ICO-Duran i Reynals, 4Neurology, 5Hematology, Hospital Universitario de
Bellvitge, Barcelona, Spain
Background: Plasma cell leukaemia (PCL) is a rare and aggressive plasma
cell (PC) disorder characterized by the presence of circulating plasma cells.
PCL can either originate de novo (pPCL) or as secondary PCL (sPCL) in
patients with relapsed/refractory multiple myeloma (MM). PCL has a more
aggressive clinical presentation than MM with a more frequent extramedullary
involvement, such as leptomeningeal infiltration. However, because of the low
incidence of this entity, most clinical data come from small retrospective studies.
Classical diagnosis criteria of PCL are today under review and the incidence of
leptomeningeal infiltration is unknown.
Aims: We aimed to study the clinical features with special emphasis in the inci-
dence leptomeningeal infiltration in patients diagnosed with PCL in our centre.
Methods: Seventeen patients were diagnosed of PCL between 2008 to 2016
in our centre. PCL was defined based on criteria from the Chronic Leukaemia
Myeloma Task Force, by the presence of 2x109/L peripheral blood PC or plas-
macytosis accounting for more than 20% of the differential white cell count.
Medical records were retrospectively reviewed. Clinical response was evaluat-
ing per IWMG criteria. Clinical and biological features, progression free survival
(PFS) and overall survival (OS) were analyzed. Survival curves were estimated
using the Kaplan-Meier method and compared using the Log-Rank test.
Results: Seventeen patients with PCL were included. Six (35.3%) were pPCL
and eleven (64.7%) sPCL. Median age at diagnosis was 57 years (range 35-
78) and 8 (47.1%) were males. Clinical and analytical features at the moment
of diagnosis are recorded in Table 1.
Table 1.
Five (29.4%) patients presented with leptomeningeal infiltration; in three of
them it was diagnosed at the time of the diagnosis of PCL. All the patients had
neurological features. Thirteen (76.4%) patients were able to start a curative
treatment: VD in 7 (53.8%) patients, VTD in 2 (15.4%), VAD in 1 (7.7%), D-
PACE in 1, MTX-ARAC in 1 patient and RD in the remaining one. Three patients
received intrathecal treatment. The intention-to-treat response was: 2 (15.4%)
CR, 2 PR, 7 (53.9%) refractory disease/progression and 2 non-evaluable. Only
2 (15.4%) patients achieved enough response (2 CR) to undergo an autologous
stem cell transplant (ACST) and only 1 to undergo an allogenic-SCT. With a
median follow up of 4 months for all the patients inclosed, median of PFS was
3 (CI 95% 0.47-4.76) months and median of OS was 4 (IC 95% 0.47-7.53)
months.
Summary/Conclusions: Prospective multicenter studies are required to pro-
vide a better understanding of the pathogenesis of PCL.Staging procedures
should include lumbar puncture or magnetic resonance at diagnosis when
extramedullary involvement is suspected. Intrathecal prophylaxis with cytarabin,
metotrexate and dexamethasone is not today a standard of care for patients
with PCL.
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MANAGEMENT AND OUTCOMES OF PATIENTS WITH MULTIPLE
MYELOMA IN REAL-WORLD SETTINGS IN BULGARIA, CROATIA AND
SLOVAKIA
G. Mihaylov1,*, S. Ostojić Kolonić2, Z. Stefanikova3, L. Fink4, M. Hemetsberger5,
K. Bjorklof6, K. Szabolcs Toka6, F. Gatta6, D. Niepel7
1Clinic for Hematology, University Hospital Sofia, Sofia, Bulgaria, 2School of
Medicine, Merkur University Hospital, Zagreb, Croatia, 3Department of Hema-
tology and Transfusiology, University Hospital, Bratislava, Slovakia, 4Kantar
Health, Paris, France, 5Hemetsberger medical services, Vienna, Austria,
6Amgen (Europe) GmbH, Zug, Switzerland, 7Amgen (Europe) GmbH, Vienna,
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Background: The multiple myeloma (MM) treatment (Tx) landscape is rapidly
evolving, with varying Tx practice patterns and access schemes across coun-
tries. However real-world (RW) data describing patient (pt) management, MM
Tx use and outcomes in some Eastern European Countries are limited.
Aims: To understand the characteristics, management, Tx patterns and out-
comes of pts with symptomatic MM in a RW setting in Bulgaria (BG), Croatia
(HR) and Slovakia (SK).
Methods: Data were collected within a cross-sectional (X) and retrospective
(R) phase of a chart review in 6 countries between June/15 and June/16 by
(onco-)hematologists who managed at least 15 pts with MM per month (mo)
and were responsible for initiating MM Tx. Data from 3 countries with limited
access to MM Tx are shown. In the X-phase, data included characteristics and
current Tx by line of therapy for all pts with MM seen during a 3-week observa-
tion period, regardless of pts’ Tx status and strategy. In the R-phase, data
included pt and disease characteristics at diagnosis, Tx response, comorbidities
and clinical outcomes by Tx line. Pts were selected in reverse chronological
order and those who had completed specific lines of active Tx within the past
3 mo were included as follows: 3 pts in first line (1L), 4 pts in second-line (2L)
and 7 pts in third or higher lines. Analyses were descriptive.
Results: In the X-phase, 7 physicians from BG, 6 from HR and 5 from SK
included 84, 89 and 56 pts respectively. In BG, HR and SK respectively, 45%,
51% and 52% of pts were <65 years; 41%, 35% and 38% were 65–75 years.
Only 4 pts (from BG) were enrolled in clinical trials. Median time since diagnosis
was 24, 31 and 54 mo in BG, HR and SK respectively. In BG, fewer pts received
stem cell transplantation (SCT) than in HR and SK (8% vs 24% and 36%). The
proportion of pts that had received SCT at any point increased from 1L to 2L
(3% to 19%, 7% to 35% and 9% to 54% in BG, HR and SK respectively). 82%
of pts in BG, and 70% both in HR and SK were currently receiving Tx (Table 1),
while 17%, 30% and 25% of pts respectively, were treated previously. Only 4
pts (1 in BG and 3 in SK) had never been treated. In the R-phase, 6 physicians
from BG, and 5 from each of HR and SK included 43, 39 and 44 pts respectively.
In BG, HR and SK respectively, 44%, 41% and 41% of pts were <65 years;
49%, 36% and 39% were 65–75 years. Depth of response, as assessed by
physicians, decreased in BG with each additional line of Tx, but remained stable
or increased in HR and SK: 43%, 55% and 50% of pts achieved at least a very
good partial response (≥VGPR) in 1L, while 13%, 54% and 69% of pts achieved
≥VGPR in 2L. The most common (≥20%) adverse events (AEs) and comor-
bidities in 1L were anemia (23% in HR, 43% in SK) and neutropenia (43%) and
thrombocytopenia in SK (21%). Mostly, these AEs did not impact on Tx.
Summary/Conclusions: These findings suggest a high unmet need for access
to more effective and innovative Tx options with manageable safety profiles in
these countries. In particular, in BG where bortezomib- and chemotherapy-
based regimens are the only treatments used, pts might be re-treated with the
same agents, which may explain why most do not achieve ≥VGPR from 2L. In
HR and SK, sustained or increased rates of ≥VGPR in 2L may be due to the
use of newer or different agents from those used in 1L and to the fact that most
pts had previously received a SCT. These RW data provide useful input for
economic evaluations of new MM agents to include in earlier Tx lines in these
countries.
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SINGLE SHOT MEDIUM DOSE MELPHALAN IN RELAPSED MM
PATIENTS: A RETROSPECTIVE, SINGLE CENTER EXPERIENCE
C. Clissa1,*, A. Isidori1, F. Loscocco1, E. Gabucci1, L. Malerba1, B. Guiducci1,
G. Visani1
1Hematology, AORMN Pesaro, Pesaro, Italy
Background: Multiple myeloma (MM) patients refractory to proteasome
inhibitors, IMIDs or both, have an extremely poor prognosis. Moreover, they
frequently fail to respond to further therapies, and represent a major challenge
in everyday clinical practice.
Aims: With this in mind, we treated 12 patient with relapsed MM with a single
shot of medium dose melphalan (60 mg/m2) between October 2010 and Jan-
uary 2016.
Methods: The median age was 72 years (range, 62 – 79) and the median time
from initial diagnosis until melphalan treatment was 51 months (range, 24 –
144). Patients were heavily pretreated with a median number of 3 prior lines of
therapy. All patients were refractory to the previous therapeutic regimens and
had failed to respond or were refractory to regimens containing bortezomib.
Seven patients (84%) had previously received at least one IMiD, 8 (67%) autol-
ogous stem cell transplantation (ASCT) and 1 allogeneic stem cell transplan-
tation. The patients included in the series were not eligible for any clinical trial
available at the Institution. All patients gave informed consent. 
Results: All patients had cytopenia (anemia, neutropenia and thrombocytope-
nia). We observed 3 cases of gastrointestinal toxicity (1 bleeding, 1 subocclu-
sion, 1 mucositis grade IV sec. WHO), 3 cases of clinically documented infec-
tion (1 Escherichia coli bacteremia, 1 fever of unknown origin, 1 erysipela) and
2 deep vein thrombosis. Response was assessed between six and eight weeks
after melphalan therapy. Overall, 10 out of 12 patients had a response ( 1 com-
plete response, 3 very good partial response, 2 partial response and 4 stable
disease); only 2 had progressive disease. Median overall survival was 11
months (range, 2 -37). 10 of 12 patients relapsed after a median time of 5
months (range: 2-12). Concerning two patients not relapsed, 1 patient died in
partial response 8 months after therapy of other causes; 1 patient is still alive,
in complete remission 18 months after melphalan. He underwent ASCT and
maintenance with lenalidomide. 
Summary/Conclusions: Many patients refractory to proteasome inhibitors
and IMiDs are probably still sensitive to alkylating agents and could be rescued
with medium dose melphalan. We suggest therefore melphalan as a “bridge”
strategy for further therapy, particularly in patients needing immediate disease
control. Even in this era in which several novel drugs became available, single
shot medium dose melphalan could be an affordable and safe therapy, able to
control aggressive relapse, and to reduce disease burden prior to targeted
therapy.
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LENALIDOMIDE AT THE DOSE OF TWENTY-FIVE MG EVERY OTHER DAY
IN PATIENTS AFFECTED BY MULTIPLE MYELOMA AND RENAL FAILURE:
A REAL-LIFE EXPERIENCE
C. Cerchione1,*, L. Catalano1, A.E. Pareto1, D. Nappi1, I. Peluso1, K. Ferrara1,
M. Di Perna1, I. Zacheo1, F. Pane1
1Hematology, Ematologia e trapianto/au federico ii, Napoli, Italy
Background: Lenalidomide, available as oral compound, is an IMiD with both
antiproliferative and immunomodulatory activity which is largely used in the man-
agement of newly diagnosed, relapsed or refractory MM and as maintenance
therapy after autologous stem-cell transplantation. Due to its renal route of excre-
tion, it is mandatory to adjust lenalidomide dose in patients with RI, guided by
Creatinine Clearance (ClCr), in order to impede a systemic prolonged exposure
that could boost myelosuppression. With normal renal function, lenalidomide
reaches its maximal plasma concentration after a median time of 0.6-1.5 h, and
it is cleared by glomerular filtration and active tubular secretion in 3 to 4 hours.
Serum half-life increases up to 9 hours if moderate/severe renal impairment is
present (creatinine clearance <50 or <30 mL/min, respectively). In the latter cases
a reduction of the daily dose is recommended. Dose adjustment based on RI
severity decreases the daily amount of lenalidomide from 15 up to 5 mg (in
patients undergoing dialysis); other studies include a schedule with 10 or 15 mg
every other days. However, there is no theoretical assumption against the pos-
sibility that protracting the time of full standard doses can be equally effective
and tolerated by patients requiring reduced doses. 
Aims: In this report, we describe our retrospective experience on the admin-
istration of lenalidomide 25 mg every other day for patients with MM and RI.
Methods: From March 2014 to February 2016, 19 consecutive patients, 11
female and 8 male, with a median age of 63.3 years (range: 49-81) affected by
advanced, resistant and progressive MM (median number of previous treatment
lines: 3, range : 1-5, all including bortezomib) with concomitant renal failure
not in dyalitic support (median calculated ClCr 36.4 ml/min, range : 18-66) were
treated, after informed consent, with monthly 21-day courses of 25 mg lenalido-
mide every other day and dexamethasone (20-40 mg on days 1-8-15-22, every
28 days). 
Results: Disappearance of urinary light chain and reduction of serum creatinine
(complete response) were detected in 7 patients (36.8%); 3 patients (15.7%)
had a very good partial response, 3 (15,7%) had a partial response, 4 of them
(21.0%) were in stable disease, whereas 2 patients (10.5%) had signs of pro-
gressive disease. Overall response ratio was 68.2%. More than half of the
patients (11/19, 57.8%) had a renal response (median calculated ClCr
51.5ml/min, range 20-148). Median progression free survival was 8 months
(range 3-18 months). No patient experienced grade 4 myelotoxicity; four
patients required red cell transfusions for grade 3 anemia. No SAE occurred
during treatment. 
Summary/Conclusions: Dose adjustment RI-related of Lenalidomide is rec-
ommended in most guidelines, but there is not a leading scheme with a proven
effectiveness more than others.These preliminary observations point to a sig-
nificant therapeutic effect of lenalidomide, at the dose of 25 mg every other
day for 21 days, in more than half of a small population of patients with
advanced MM and renal impairment, with not negligible logistic and economic
advantages. However, these results should be validated by controlled studies
involving larger number of patients.
PB2012
A FEASIBILITY-STUDY ON IMPLEMENTATION OF THE INTERNATIONAL
MYELOMA WORKING GROUP RECCOMENDATIONS FOR MULTIPLE
MYELOMA PATIENTS IN ROUTINE CLINICAL PRACTICE: A PERIPHERAL
CENTER EXPERIENCE
M. Torchio1,*, C. Cavalli1, A. Gazo2, R. Bellazzi2, M. Danova1
1Internal Medicine and Medical Oncology, 2Nephrology and Dyalisis , Ospedale
Civile di Vigevano, ASST di Pavia, Vigevano, Italy
Background: Renal impairment (RI),  defined as serum creatinine above upper
normal limit or >2 mg/dl or a estimated glomerular filtration rate (eGFR) <60
ml/min/1,73m2, is one of the most common complications of MM, and it is
associated with an increased risk of early death. The incidence of RI at MM
diagnosis ranges from 20% to 50%, while its comparison occurred in 60% MM
patients (pts). In this scenario tempestive diagnosis of RI in MM pts and exclu-
sion of possible alternative causes of RI (like amiloydosis, diabetes or MIDD)
are essential.
Aims: We applied a diagnostic algorithm obtained from the International Myelo-
ma Working Group Reccomendations in pts admitted to our department for RI
(with known and unknown MM, or suspected cast nephropathy, CN), in order
to investigate if this diagnostic workflow could positively impact on MM pt man-
agement.
Methods: We enrolled adult pts, known or unknown MM, admitted to our hos-
pital for RI or suspected CN, with or withouth monoclonal component. Primarly,
we performed complete blood analysis, with eGFR (CKD-EPI and MDRD meth-
ods), serum and urine electrolites, bicarbonatemia, serum and urine immunofix-
ation, fraction 3 and 4 of complement, crioglobulinemia, HbA1c, arterial gas
analysis, evaluation of urine rate every 6 hours, daily urine collection, urine
sediment. We also collected anamnesis on eventual nephrotoxic concomitant
therapies like ASA, FANS, clinical parameters and objectives signs of RI (ede-
ma, symptomatic disionia). On the second day of hospitalization we requested
protein electrophoresis on serum and urine, chest X-ray, ultrasonography of
abdomen, ecocardiography and electrocardiography. On the day three we eval-
uated results of previous exams and we decided, if necessary, eventual biop-
sieson (bone marrow in suspected unknown MM pts, renal in suspected CN
pts, umbilical fat for amyloidosis). All analyses were daily and collegialy dis-
cussed between Internists and Nephrologists. 
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Results: From March to December 2016 we admitted 57 pts with RI and mon-
oclonal component (29 F, 28 M, 41-83 yrs range), 20 are known MM pts and
37 de novo pts. We diagnosed 11 de novo MM, 13 knowed MM with a de novo
RI, 12 diabetes related RI, 3 amyloidosis, 16 other causes. 
Summary/Conclusions: The implementation of the International Myeloma Work-
ing Group Reccomendations in a routine clinical practice confirmed its feasibility
and utility in the optimal workout of MM pts. We obtained diagnosis of RI within
4 days,  both in known and in de novo MM pts, with a positive impact on reduced
hospitalization, uncessary dyalisis and steroids overtreatment. 
PB2013
NOCARDIOSIS PROVOKED BY NOVEL AGENTS AT RELAPSED
MULTIPLE MYELOMA:CASE SERİES
Z. Bolaman1,*, A. Turgutkaya1, E. Ceylan2, B. Gültekin Korkmazgil3, M. Telli3,
C. Karaman4, I. Yavasoglu1
1Adult Hematology, 2Pulmonology , 3Microbiology, 4Radiology, Adnan
Menderes University Medical Faculty, Aydin, Turkey
Background: The proteosome inhibitors and immunmodulatory drugs which
are used in MM treatment enhance the risk of infection by several mecha-
nisms.Nocardial infections are rare in Turkey.
Aims: Here,we present three relapsed myeloma cases which developed nocar-
dia pneumonia.
Methods: Case-1 :66 year old man, who has a history of autologous SCT 4 years
ago and lenalidomide usage because of IgG kappa type myeloma, has been
prescribed bortezomibe for the relapse of the disease.He was immunocompro-
mised  not only because of the myeloma, and also because of the diabetes and
renal failure without dialysis. He was admitted to the hospital because of the pro-
ductive cough.His lymphocyte count was 1290/mm3 and flow-cytometric analysis
showed CD5:%68 and CD20:%2. Thorax CT showed 39x39x45 mm mass like
lesion.Broncoscopic lavage examination showed branched bacillus via modified
acid-fast and Gram stain.This typical morphological appearence was defined as
Nocardia spp. Imipenem/cilastatin treatment started and control CT was per-
formed after ten days and it showed regression of the infiltration.He was dis-
charged with oral TMP/SMX antibiotherapy. Case-2:71 year old woman,who has
a history of two auotologous SCT 12 and 5 years ago because of IgG kappa type
myeloma;admitted to the hospital with productive cough during pomalidomide
treatment.Her lymphocyte count was 2300/mm3 and flow-cytometric analysis
showed CD5:%88 and CD 20:%1.HRCT showed a 7x6x6 cm sized mass like
lesion with a cavity.Branched Gram positive bacillus (Nocardia sp.) was detected
from broncoscopic specimen analysis,so imipenem-cilastatin therapy has been
started.She responded well to therapy and was discharged with TMP/SMX
antibiotherapy. Case-3:72 year old man,who has a diagnosis of IgG kappa type
myeloma and a history of autologous SCT 4 years ago following bortezomibe
treatment,relapsed 5 months ago. He has been admitted to the hospital with non-
productive cough complaint under the treatment of lenalidomide and dexametha-
sone.His lymphocyte count was 520/mm3.Flow-cytometric analysis couldn’t be
performed.Thorax CT showed 4 cm sized cavity and sputum microscopy showed
acid rezistant branched bacillus thought to be consistent with nocardiosis.The
imipenem/cilastatin and TMP/SMX treatment have begun and 12 days later, a
control CT was performed and showed regression.He was discharged with oral
TMP/SMX antibiotherapy.
Results: See Table 1 and Figure 1.
Table 1.
Figure 1.
Summary/Conclusions: The proteosome inhibitors and immunmodulatory
drugs which are used for the treatment of MM;make T cell disfunction and con-
sidering B cell disfunction is also present because of the nature of the
disease;this situation tends to provoke rare opportunistic infections such as
nocardiosis.Thus,in these patients;it is significant to follow the lymphocyte count
closely and to keep in mind that kind of rare microorganisms.
PB2014
LENALIDOMIDE IN PATIENTS WITH DIALYSIS-DEPENDENT END STAGE
RENAL FAILURE (ESRF) AND MULTIPLE MYELOMA
P. Di Ciaccio1,*, S. Ling1
1Department of Haematology, Liverpool Hospital, Sydney, Australia
Background: Lenalidomide is an oral immunomodulatory medication with
clinical efficacy in relapsed/refractory and treatment naïve multiple myeloma
(MM), 5q- myelodysplasia and lymphoma. Lenalidomide is eliminated pre-
dominantly unchanged by urinary excretion. Renal impairment is common in
MM (15-40%) and approximately 10% of MM requires dialysis. However,
there is a paucity of clinical safety data of Lenalidomide in ESRF. There is
evidence that Lenalidomide can be safely used in patients with moderate and
severe renal dysfunction with dose adjustment. However, published data in
hemodialysis-dependent patients is limited to a handful of patients across
small retrospective analyses and case reports. Patients with ESRF have gen-
erally been excluded from clinical trials investigating Lenalidomide. Phase III
trials in the relapsed setting (MM-009, MM-010) excluded patients with a
serum creatinine >221μmol/L. The FIRST trial (MM-020), investigating upfront
use, excluded patients dependent on dialysis. There is no accepted clinical
standard on the most appropriate dosing of Lenalidomide in dialysis. The
manufacturer has provided guidelines, being 5mg daily, day 1-21, every 28
days (equivalent to 105mg per cycle). There is alternate well-cited pharma-
cological data that the more appropriate starting dose is likely 15mg, three
times per week, given post-dialysis (equivalent to 135mg per cycle). Aims:
To provide real-world evidence of an institutional experience of the use of
Lenalidomide in dialysis-dependent MM.
Methods: We performed a retrospective audit of our in-centre experience with
treating dialysis-dependent MM with Lenalidomide and included patients who
completed at least one cycle of therapy. Patients were assessed for haemato-
logical toxicity, significant infective complications, thrombosis, disease response
and progression-free survival. Best response was stratified by IMWG criteria.
Patients’ baseline characteristics, prior therapies, cytogenetics and FISH data
were collected.
Results: We identified 5 patients treated between 2010 and 2017, aged
between 54 to 73 years old. All patients had relapsed/refractory MM and dialysis
dependent ESRF. The median number of prior therapies was two. One patient
had t(11,14) on FISH and died from progressive disease. Dose schedules are
shown in the Table 1. Almost all patients experienced grade III-IV haematolog-
ical toxicity and 60% had grade III-IV infection. There was a positive correlation
between dose and toxicity, and furthermore there appeared to be an inverse
relationship between age and tolerated dose. Haematological toxicities and
infection were ameliorated by dose adjustment in most instances. There was
no drug related mortality, however one patient died of progressive disease.
Four of the five patients were prescribed aspirin thromboprophylaxis, with no
proven thrombotic complications seen. Where possible to assess, the ORR
was 75% (3/4), with 2 patients achieving a very good partial response (VGPR),
1 partial response and 1 progressive disease. The lowest starting dose in this
cohort was 10mg twice/week and the maximum dose was 25 mg three
times/week.
Table 1.
Summary/Conclusions: Our experience builds on the emerging evidence that
reduced dose of Lenalidomide can be safely prescribed for dialysis-dependent
MM, with clinical efficacy. In our cohort most patients took Lenalidomide on
days of dialysis only. There was significant variation of dose-related tolerability
between patients. However, toxicity was manageable with diligent monitoring
and dose adjustment.
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STUDY USE OF 18-F FDG PET / CT SCANNING INTO THE FIRST FOLLOW
UP OF PATIENTS WITH MULTIPLE MYELOMA AND ASSOCIATION WITH
BIOCHEMICAL RESPONSE
K. Vallejo Luna1, M. Simó2, J. Montoro3, C. Palacio3, M. Junquera4,
M. Gironella Mesa4,*
1Hematology, Vall d’Hebron Institute of Oncology, 2Department of Nuclear Med-
icine, 3Department of Clinical Diagnostic, 4Department of Hematology, Hospital
Universitario de Vall d’ Hebron, Barcelona, Spain
Background: Positron computed tomography (PET / CT) with 18F fluo-
rodeoxyglucose-labeled glucose (FDG) is a reliable technique with high sen-
sitivity and specificity for assessing skeletal involvement and recent studies
propose it as a method for predicting treatment response in multiple myeloma.
Conventionally, the response is measurable by the monoclonal component in
both serum and urine and Minimal residual disease (MRD) by
flow cytometry has been established as a mandatory tool. The studies are
aimed at combining the measurement of paraprotein with imaging tests that
help to promptly define response or failure to the treatment.
Aims: The primary endpoint was the correlation of the biochemical response
with the FDG PET/CT in a second evaluation after first line treatment. The sec-
ondary endpoint was the correlation between MRD and with second FDF
PET/CT. 
Methods: We included in this retrospective and observational study at Univer-
sitary Hospital of Vall d’ Hebron, all patients with newly MM and PET/CT before
to start a first line treatment and a second PET/CT when completing treatment.
PET/CT were analyzed by the department of Nuclear Medicine  with experience
to grade the lesions in  MM,  were evaluated and categorized  into positive or
negative according to the criteria proposed by Zamagni, et al. The biochemical
response was defined according to the standard IMWG response criteria.
Results: Eighteen patients ( 8 males and 10 females) with untreated MM
entered,  seven patients were classified with  ISS III, fifteen had a good per-
formance status, none presented renal lesion, only  16% had hypercalcemia
and 66% showed  immunoparesis. Ten patients  were IgG  isotype, six were
classified as light chains myeloma and two patients were oligosecretors.  Sev-
enteen patients had  bone marrow infiltration  with a median of 42% plasmatic
cells. Two patients had a extramedullary plasmocytoma and nine had an anor-
mal ratio of light chains. Seventeen patients were treated with bortezomib-
based regimens, (median 5.5 cycles) included VTD, MPV, VLD and VD.  After
treatment fourteen patients achieved completed response, two partial response
and two had progressive disease. PET/CT was positive in all patients pretreat-
ment, 15 focal lesions, 2 diffuse bone marrow involvement plus focal lesions
and 1 involvement of bone marrow alone. Twelve patients had more than 3
focal lesions  and two had extramedullary disease. At the end of first line treat-
ment, PET/CT was negative in eight patients (44%) and  fourteen had complete
biochemical response (78%). 62% of the patients with negative PET/CT
showed negative flow minimal residual disease (MRD) and biochemical com-
plete response . Two patients had PET/CT with progression disease and cor-
responded to a biochemical progression.
Summary/Conclusions: The correlation between PET/CT and biochemical
response obtained after treatment was positive in patients with complete
response. We found discordant data in two patients with oligosecretory myelo-
ma. No correlation was shown between PET/CT and flow MRD.
Are necessary more long term studies that include greater number of patients
to confirm that the PET/CT negative is an image technique that could be a tool
to follow up patients after the first line treatment added to the evaluation of the
biochemical response.
PB2016
MULTIPLE MYELOMA IN BORNEO SARAWAK: A DEVELOPING WORLD’S
EXPERIENCE
T.S. Leong1,*, L.P. Chew1
1Hematology Unit, Medical Department, Sarawak General Hospital, Kuching,
Malaysia
Background: Sarawak, is the largest state of Malaysia situated on the island
of Borneo. Sarawak General Hospital is the tertiary referral center  of Sarawak
(serving a population  about 1 million people). It is 980 km away from its main
hematology/transplant referral center in Kuala Lumpur, Malaysia, which is
accessible only by airplane. Hence, treatment of patients with multiple myeloma
in this part of the state is a big challenge due to its geographical constraint. 
Aims: To identify demographics and clinical characteristics of patients with
multiple myeloma; To establish treatment and outcome of patients with multiple
myeloma.
Methods: This is a retrospective study examining basic characteristics and
clinical outcomes of patients diagnosed with multiple myeloma between 2010
and 2016 in Sarawak General Hospital. Patients’ case notes were traced and
the relevant information was entered into a pre-designed data collection form.
Data was analysed and interpreted via IBM SPSS Statistics version 24.0.
Results: There were a total of 63 patients with the male to female ratio of  3:2.
The median age for patient was 61 years old (range 31 to 86 years old). Majority
of them are  local natives of Iban or Bidayuh descendants (n=32, 50.8%) followed
by Chinese (n=20, 31.7%) and  Malays (n=11, 17.5%). Most common type of
multiple myeloma is of IgG variant (n=27, 42.9%).  The most common myeloma
related organ or tissue impairment (ROTI) are anaemia (n=54, 85.7%) followed
by bone lesion (n=48, 77.8%), renal impairment (n=27, 42.9%) and hypercal-
caemia (n= 18, 28.6%). More than half presented late with Durie Salmon stage
III disease (n=34, 54%). Majority of patients were treated with
dexamethasone/thalidomide (n=25, 39.7%). Sixteen patients (25%) received
bortezomib based treatment. Three patients (n=3, 4.8%) undergone bone marrow
transplant. Thirty five patients died (n=35, 55.6%). Median survival time was 21
months (95% CI: 16,26). One year, two years and five years survival rate was
67.4%, 43.6%, 31.6%. Patients who were 60 years old and above have lower
median overall survival (20 months) compare to patients who were 60 years and
below (36 months) even though they are not statistically significant (p=0.565).
Summary/Conclusions: Baseline characteristics of patients with multiple
myeloma in Borneo Sarawak are similar to the rest of Asia. However, our medi-
an overall survival was comparatively lower to our counterparts. Limitation
wise, due to logistic and economic reasons, we do not have good access to
cytogenetic and genetic profiling that enables us to prognosticate patients
accordingly.
PB2017
A RETROSPECTIVE AND PROSPECTIVE AUDIT OF RADIOLOGICAL
INVESTIGATIONS FOR SUSPECTED CASES OF PLASMA CELL
DYSCRASIAS/MYELOMA IN THE ALTNAGELVIN AREA HOSPITAL
G. Baker1,*, N. Cunninghmam1
1Haematology, Western trust, Londonderry, United Kingdom
Background: The updated NICE guidelines for diagnosis and management
of myeloma (2016) suggests whole-body MRI as first-line imaging for people
with suspected myeloma and consideration of MRI/CT/PET in newly diagnosed
myeloma to assess for bone disease or EM plasmacytoma.
Aims: Our aims were to ascertian; 1) Our current practice regarding radiological
investigation for myeloma (2) Whether additional diagnostic information was
gained using CT/MRI imaging (3) Since its release, is the trust compliant with
the NICE guidance (4) The estimated cost of meeting the current NICE guidance 
Methods: This retrospective and prospective audit included all patients having
a skeletal survey performed for suspected multiple myeloma within the Alt-
nagelvin Area Hospital (AAH). Retrospectively from 10/2/15 until 9/2/16 data
was collected using the advanced search feature of the Sectra IDS7 PACS
system. The ‘Reason for examination’ for each study was then analysed and
those ordered for reasons other than suspected myeloma were excluded. Each
case was analysed individually and any follow up MRI/CT/NMB imaging per-
formed in the 6 month period following the skeletal survey were included in the
data collection. The same information was gathered prospectively from 10/2/16-
30/5/16 following the NICE guidance. 54 skeletal surveys where performed for
suspected/restaging myeloma pre guidance.
Results: The indications for requesting imaging is shown in Table 1A. No WB
MRI/CT was performed in this period. 26% patients had new lytic lesions on
skeletal survey. 23 patients had further imaging in the form of MRI or CT fol-
lowing skeletal surveys. All the positive MRI findings offered additional diag-
nostic information - including examples of missed multiple spinal deposits. The
results of imaging are summarised in Table 1B. The false negative rate for
skeletal surveys was 39% and the false positive rate was 22%. Following NICE
guidance publication 23 patients had skeletal surveys performed for suspicion
of myeloma between 10/2/16 and 30/5/16. The indications are summarised in
Table 1C. No WB imaging was performed. 5 patients had positive skeletal sur-
veys. 6 patients had subsequent CT/ MRI imaging. A skeletal survey was report-
ed normal with a subsequent MRI showing multiple spinal deposits. The imag-
ing results are summarised in Table 1D.
Table 1.
Summary/Conclusions: The expected cost of implementing WB imaging for
60 patients per year in the AAH is £18,240. In comparison the cost of performing
skeletal surveys would be £4200 per annum. NICE guidance 2016 offers an
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economic model for imaging with WB MRI. In addition it reviews evidence which
links time to diagnosis to survival and myeloma related complications. The
NICE guidance offers clear evidence that WB-MRI should be the investigation
modality of choice for suspected myelomatous disease. It offers a diagnostic
and cost-effective strategy that will ensure health improvements for myeloma
patients. This audit offers further evidence of the diagnostic accuracy of MRI
imaging. At present failure to comply with NICE guidance will lead to delayed
diagnosis of myeloma in certain patients and potential patient harm. Therefore
I offer a business and health improvement case for the Western Trust to insti-
gate WB-MRI imaging for all suspected myelomatous bony disease.
PB2018
TONI DEBRE FANCONI SYNDROME DURING MYELOMA, ABOUT 8
CASES 
R. Cherif1,*, B. Salah Eddine1
1Hematology, Central Hospital Mohammed Seghir Nekkache , Algiers, Algeria,
Algiers, Algeria
Background: The cast nephropathy with cylinders is the most frequent renal
complication of the myeloma, which results from a catabolism of the light chains
by the tubular cells and can lead a tubular chronic suffering showing itself by a
syndrome of acquired Toni-Debré-Fanconi marked by a glycosuria, a phospha-
turia, an aminoaciduria, a sometimes severe and sometimes revealing
hypokalemia. 
Aims: We reporting some observations informed by Multiple Myeloma compli-
cated with a Fanconi syndrome.
Methods: From January 2000 till December 2010: 78 cases of Multiple Myeloma
were brought together, whose circumstance of discovery 22 cases with renal fail-
ure, it’s was a evolutes complications in 12 cases; and in 10 cases it’s discovered
at diagnosis. The renal achievement is dominated by Tubule disease in 11 cases,
Randall syndrome 8 cases, and Nephrotic syndrome in 3 cases. The tubule dis-
ease of Fanconi is suspected at only 8 patients: in front of the presence of a
renal glycosuria (without associated diabetes) and a frank proteinuria in the major-
ity of the cases, with a hypophosphatemia and a fickle hypokalemia.
Results: The clinico-epidemiological and immuno-biological characters of these
8 patients are the following ones: - The median age is of 64 years (39-76), sex
ratio=3. The osseous pains and the muscular cramps dominate the clinical pres-
entation with constant diffuse demineralization in the radiology. - The patients
were classified (according to the Salmon-Durie classification): IIIB (3 cases) and
IIB (5 cases). ISS 3 in majority of the cases. - The monoclonal immunoglobulin
observed: IgG kappa: 4cases, IgA kappa: 2cases, light chain kappa: 2cases.
With a Bence Jones proteinuria isotype kappa and a glycosuria in the majority of
the cases. - The gravity of the renal faillure, based on the clearance of the crea-
tinine: with an average clearance of 16,19 ml/min (4-37): several in 5cases, ter-
minal in 3cases. - We note more of hypocalcaemia while the hypercalcaemia is
noted in a single case, the hypophosphatemia is found in half of the cases. The
therapeutics is double: - Symptomatic: alkaline hydration, correction of the meta-
bolic disorders and sometimes the renal extra purge (indicated in 3cases). - Spe-
cific: chemotherapies VAD 7cases, a patient died by cardio-vascular complication.
Under treatment the recovery of the renal function is obtained in 3 cases, to the
rests of the patients persists a stable renal failure.
Summary/Conclusions: The Syndrome of Fanconi is a frequent and often
formidable complication during Myeloma, observed to 30-40% of the patients
in an autopsique series. It is necessary to think to it in front of any renal achieve-
ment in myeloma of kappa light chain with renal glycosuria, a generalized
amino-aciduria and a hypophosphatemia resulting respectively from a defect
of the transport of the glucose, from amino acids and from phosphates by the
renal proximal tubule. To improve the osseous and renal appearances, it is
necessary to realize a calcic supplementation, phosphorous and by the vitamin
D active, as well as the correction of the acidose and a specific treatment reduc-
ing the excretion renal of the light chains.
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DEPP RESPONCES WITH CARLFIZOMIB-LENALIDOMIDE-
DEXAMETHASONE IN RELAPSED/REFRATORY MULTIPLE MYELOMA
PATIENTS: A REAL LIFE EXPERIENCE
V. Federico1, B. Rossini1, D. Carlino1, A. Mele1, P. Curci2, A. Giordano2,
S. Citiso1, G. Specchia2, V. Pavone1,*
1Haematology and TMO, Hospital Card. G. Panico, Tricase (LE), 2Haematology
and TMO, Policlinico di Bari, Bari, Italy
Background: Carfilzomib is a new proteasome inibitor with in contrast to the
reversible binding of bortezomib, binds irreversibly and selectively to its target:
the chymotrypsin-like activity of the 20S proteasome. The phase IB/II PX-171-
006 study was the first study in which carfilzomib was combined with lenalido-
mide and dexamethasone. In the phase I dose-escalation part the maximum
planned dose was established as well tolerated and in the phase II part the
study focused the efficacy and toxicity in the subgroup treated with maximum
planned dose. The ASPIRE trial showed superior response rates and progres-
sion free survival for carfilzomib-lenalidomide-dexamethasone compared with
lenalidomide-dexamethasone in relapsed/refractory Multiple Myeloma patients. 
Aims: The aims is explorer the efficacy and tolerability of carfilzomib-lenalido-
mide-dexamethasone in relapsed/refractory Multiple Myeloma patients in real life.
Methods: All patients received carlfilzomib 20/27 mg/m2 days 1,2,8,9,15 and
16; lenalidomide 25 mg days 1-21 and daxamethasone 20 mg days
1,2,8,9,15,16, 22 and 23, according to post approval access protocol. After 2,
4, 6 and 8 cycles the responses, disease progression and toxicity were
assessed using the International Myeloma Working Group Uniform Response
Criteria and WHO score respectively.
Results: From January 2016 to February 2017 in hematology “Cardinale
G.Panico Hospital” and “Bari Policlinico”, treated 15 relapsed/refractory Multiple
Myeloma patients with carfilzomib-lenalidomiode-dexamethasone. Six patients
male (40%), 9 female (90%), mean of age 62 years (range 38-79); 10 (66%)
and 5 (34%) relapsed/refractory multiple myeloma respectively. Median time
from diagnosis to carfilzomib-lenalidomiode-dexamethasone was 46 months
(range 12-92); median of prior therapy was 3 (range 1-6); 9 (60%) received
autologous transplantation while 1 (6%) allogeneic; 11 (73%) prior therapy with
lenalidomide; 15 (100%) prior therapy with borthezomib; 2 (14%) prior therapy
with pomalidomide (Table 1). Eleven (73%) patients achieved after 2 cycles a
response rate ≥PR, of these 3 VGPR. After 4 cycles, 5 (33%) and 1 (7%) have
obtained at least a VGPR and CR respectively (Figure 1). Three patients were
not evaluated for treatment discontinuation because of rapid progression dis-
ease and died during first cycle with a median of 5 prior lines therapy. Most
grade 3-4 adverse events were haematological and well manageable, 10 (80%)
trombocitopenia and 5 (35%) neutropenia grado 3-4. Dyspnea, fatigue and
pyrexia were higher but were mostly grades 1 and 2. Only 2 patients developed
respiratory failure and pneumonia while cardiac failure, ischemic heart disease
and hypertension not were detected.
Table.1; Baseline patient characteristics.
Figure 1.
Summary/Conclusions: Carfilzomib-lenalidomide-dexamethasone is a pow-
erful and efficacy association in relapsed/refractory Multiple Myeloma patients,
which allows the achievement of deep responses from the first cycle of therapy.
Non haematological adverse events of grade 3 or higher were reported in only
2 patients.
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CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE
MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE
MYELOMA: A REAL-LIFE EXPERIENCE
C. Cerchione1,*, K. Ferrara1, I. Peluso1, D. Nappi1, M. Di Perna1, I. Zacheo1,
A. E. Pareto1, F. Pane1, L. Catalano1
1Hematology, Ematologia e trapianto/au federico ii, Napoli, Italy
Background: Carfilzomib is an epoxyketone proteasome inhibitor of second
generation, proved to be effective in relapsed and refractory Multiple Myeloma
(rrMM).
Aims: In this retrospective observational trial, it has been evaluated efficacy
and tolerance of Carfilzomib, in combination with lenalidomide-dexamethasone
(KRD) as salvage regimen in patients with relapsed and refractory MM (rrMM),
whose prognosis is particularly severe.
Methods: 21 patients (12 M/9 F, Table 1), with rrMM, median age at diagnosis
62 years (r. 47-75), median age at start of treatment 65 years (r. 53-81) treated
with several lines of treatments (median 3, r. 2-10), included 2 patients refrac-
tory to Bortezomib, underwent to KRD regimen (ASPIRE trial schedule: Carfil-
zomib starting dose 20 mg/sqm on days 1,2 of cycle 1, target dose 27 mg/sqm
thereafter; Lenalidomide 25 mg on days 1 through 21; Dexamethasone 40 mg
on days 1,8,15 and 22, every 28 days) for a median treatment cycles of 2 (r 1-
8). ISS was equally distributed, and cytogenetic was evaluable in 8 patients,
and in particular one del13q14 1qgain, one del 13q14 and one t(11;14). 86%
of patients had previously been treated with schedule containing bortezomib
and IMIDs, and 33% had also received radiotherapy. 57% of them had under-
gone at least to a single auSCT.
Results: Carfilzomib was well tolerated, with grade 2 anemia in 28% of
patients, without necessity of blood transfusions; 5% grade 1 and 9.5% grade
3 neutropenia (no ospedalization was required, no septic shocks were
observed); 33% grade 2, 19% grade 3 and 5% grade 4 thrombocytopenia,
without hemorrhagic events and necessity of transufsions. Concerning severe
extrahematologic toxicity, it was observed grade 1 pneumonia in 47% of
patients, treated by common antibiotic drugs; grade 2 Hypertension in 24% of
patients; grade 3 arrhythmias in 5% of patients; grade 2 dyspnea in 5% of
patients; grade 1 fatigue in 9.5% of patients. According to IMWG criteria, after
a median follow-up of 3 months (r.1-13), ORR was 66,7% (14/21 :  8 VGPR, 6
PR) with 3 progressive diseases and 2 patients in stable disease, which can
be considered as an impressive result in this subset of rrMM patients. In par-
ticular, for 1 patient, KRD was, after having achieved at least a PR, a bridge to
second auSCT. Median time to response was 2 months (r.1-4), median OS
from diagnosis was 47 months (9-170 range), median OS from start of Carfil-
zomib was 3 months (range 1-13).
Table 1.
Summary/Conclusions: KRD has shown significant efficacy in a particularly
severe setting of patients, relapsed and refractory to all available therapeutic
resources, and, in particular cases, it could be considered as a bridge to a sec-
ond autologous or allogenic SCT.
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IMWG ´14 DIAGNOSTIC CRITERIA TO INITIATE TREATMENT IN NEW
DIAGNOSED MULTIPLE MYELOMA: REAL-WORLD STADISTICS
P. Gonzalez1,*, B. Ballina1, S. Cerdá1, M. Fuertes1, L. Villalobos1,
V. Martínez-Robles1, J.A. Rodríguez-García1, F. Escalante1
1Hematología, Complejo Asistencial Universitario de León, LEON, Spain
Background: Diagnostic criteria for Symptomatic Multiple Myeloma (MM) Pub-
lished in 2003 by the International Myeloma Working Group(IMWG’03) estab-
lished for the presence of a bone Marrow infiltration by plasma cells (BMPC) in
any percentage And / or the presence of a monoclonal component of any amount
Along with the presence of signs or symptoms of organ damage (CRAB) attrib-
utable to the proliferation of plasma cells. These criteria have not changed in the
last decade until the Recent revision of diagnostic criteria and treatment that
IMWG Published by the end of 2014, which proposes an initial Pathologic con-
dition (>10% BMPC or demonstration of a Plasmacytoma) as a preliminary con-
dition before starting treatment. Due to “CRAB redefined” and / or the presence
of markers of Rapid progression to “classical-symptomatic” MM criteria.
Aims: There are few information about real-life statistics in NDMM according
to new criteria to initiate treatment.
This 2year analysis shows a percentage of patients (22%) who have initiated
new treatments superior to those  described in the literature
Methods: We have performed a retrospective analysis with all new MM cases
diagnosed from Dec-2014 (after new criteria were published) to Feb-2017 (28
months). 55 patients were diagnosed of MM. 26 were male and 29 female.
The median age at diagnosis was 74 years (52-87), 11 were under 65 (U65)
and 44 were over 65 (O65).
Results: 3 were diagnosed after biopsy of plasmacytomas. None of them
have Bone Marrow (BM) infiltration but with criteria of MM after PET-CT mul-
titopic involvement. 7 of these NDMM were smoldering MM (sMM). All of then
completed initial staging with more sensitive imaging tests than conventional
radiology (MRI and / or PET-CT) 2 of these sMM were under 65 years old and
were included in a clinical trial. The other 5 were older than 65 and after a
median of 16 months of follow-up did not meet criteria in initiate treatment. Of
the 41 patients who started treatment, 10 of them were new criteria, the rest
met criteria for classic organic disease (CRAB) Figure 1. 6 patients were diag-
nosed after performance of PET-CT (3 of them after plasmacytoma biopsy;
initial diagnosis: solitary plasmacytoma), 1 after PET-CT negative but MRI
positive, 2 with FLC ratio criterium and the last one with BM Plasmatic Cell
(BMPC) >60%, MRI image and FLC criteria. Although these data are quite
different from those reported previously, accurate diagnosis in initial stages
may increment the proportion of real-active MM. We don´t observe increments
in incidence rate in these period vs pre´2014 (reported to 22nd EHA abstract).
We observe that the early mortality is decreasing in the last 5 years (from
2013). The effect of early diagnostic may contirbute to get these improvement
of survival.
Figure 1.
Summary/Conclusions: One of the hypotheses for introducing new criteria
for initiating treatment was that the initiation of adequate and early treatment
may improve the prognosis of patients with symptomatic NDMM. In an aging
population such as the one we present, we believe that these new criteria to
initiate treatment can improve the medium- and long-term prognosis of this
group of people with few chance to start intensive or a lot of lines of treatment
because of increasingly comorbidities by age. Further follow-up and evaluation
of survival comparing the “classical” group vs new-criteria group are guaranteed
to assess if these early treatment will improve survival.
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POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE: A CHANCE FOR
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA. A REVIEW OF
A CASE SERIES DIAGNOSED IN A SINGLE CENTER
A. Gil Pérez1,*, D. de Miguel 1, D. Subirá1, H. Guillén1, A. Vázquez1, M. Díaz1,
N. Golbano1, D. Morales1, S. Herrero1, J. Arbeteta1, B. Pinedo1
1Hospital General Universitario de Guadalajara, Guadalajara, Spain
804 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Background: The treatment of patients with multiple myeloma (MM) has dra-
matically changed over the past decade due in part to the development of new
agents and myeloma-specific targets. Nowadays, new effective treatments exist
for patients with RRMM not responding to bortezomib and lenalidomide. Poma-
lidomide alone has shown limited efficacy in patients with RRMM, but synergistic
effects have been noted when combined with dexamethasone.
Aims: To show our experience with the use of 28-day cycles of pomalidomide
(4 mg/day on days 1–21, orally) plus low-dose dexamethasone (40 mg/day
weekly, orally) (Pom/dex) in RRMM.
Methods: This is a retrospective study performed between May 2014 and Jan-
uary 2017 in the Hospital of Guadalajara (Spain). Eight patients (3M, 5F), with
a median age of 67 years (range, 40-81), diagnosed with MM were included.
Four were classified as high-risk myeloma (Patients 1-4). Patient 1 (P1) had
plasma cell leukemia and received Pom/dex plus bortezomib; Patient 2 (P2)
presented complex karyotype and received Pom/dex after three previous reg-
imens and an autologous transplantation; Patient 3 and Patient 4 (P3 and P4)
had extramedullary plasmacytoma and received Pom/dex±local radiotherapy.
The eight patients of this study had failed to bortezomib and lenalidomide-
based therapy, and received Pom/dex until disease progression or unaccept-
able toxicity. Pom/dex was associated with ciclophosphamide in two patients,
and with bortezomib in another two patients. The primary endpoint was pro-
gression-free survival (PFS).
Results: The median number of prior regimens was 2 (range, 1-4) and five of
eight patients (62.5%) had previously received autologous transplantation.
Median time from diagnosis to Pom/dex was 51.5 months (range, 28-155).
Patients received a median of 6 cycles of Pom/dex (range, 2-16). In the whole
series, the median follow-up was 60.5 months (IQR: 56.0-80.25), and median
PFS was 11 months; 75% of patients had not progressed after 5 months, and
50% of patients after 11 months. The overall response rate was 87.5% (only
one patient discontinued therapy for non-response). 
In standard-risk MM patients, median follow-up was 61 months (IQR: 46.25-
140.25), and median PFS was 13 months; 75% of patients had not progressed
after 2 months, and 50% of patients after 13 months. Regarding the high-risk
group of patients, P1 achieved complete response after 6 cycles of
Pom/dex+bortezomib; P2 achieved PFS of 11 months; P3 achieved plasmacy-
toma resolution after 6 cycles of Pom/dex plus local radiotherapy; P4 aban-
doned Pom/dex after 3 cycles because of severe neutropenia and sepsis. In
this group median follow-up was 60.5 months (IQR: 56.3-79.8), and median
PFS was 6 months; 75% of patients had not progressed after 5 months, 50%
of patients after 6 months, and 25% of patients after 11 months. Regarding
adverse events, they were present in two patients: one had neutropenia, and
the second one pneumonia plus pulmonary venous thromboembolism. Both of
them died (Figure 1).
Figure 1.
Summary/Conclusions: In our experience, Pom/dex regimen has prolonged
PFS of patients with RRMM, with an improvement of health-related quality of
life. This regimen has been even valuable in high-risk patients who received
Pom/dex after ≥2 treatment regimens. Pomalidomide plus low-dose dexam-
ethasone, an oral regimen, could be considered a new treatment option as a
standard of care for patients with RRMM who have poor prognosis and a high
need for effective treatments.
Myeloproliferative neoplasms - Biology
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ROUTINE SCREENING FOR KIT M541L IS NOT WARRANTED IN THE
DIAGNOSTIC WORK UP OF PATIENTS WITH HYPEREOSINOPHILIA 
N. Cross1,*, Y. Hoade1, G. Metzgeroth2, J. Schwaab2, A. Reiter2
1University of Southampton, Southampton, United Kingdom, 2Universitätsmedi-
zin Mannheim, Mannheim, Germany
Background: The role of the KIT M541L variant in patients with hypere-
osinophilia (HE) is controversial. On the one hand, this variant is a recognised
inherited single nucleotide polymorphism (c.1621 A>C; rs3822214) with a minor
allele frequency of 0.08 in the ExAC database and classified as benign/likely
benign on ClinVar. On the other hand, it has been suggested that KIT M541L
increases the sensitivity of the KIT receptor to stem cell factor (Foster R et al.,
Br J Dermatol. 2008;159:1160-9) and may be somatically acquired in imatinib
responsive CEL-NOS patients negative for PDGFRα/β abnormalities (Iurlo A
et al., Oncotarget. 2014;5:4665-70). Consequently it has been suggested that
HES patients should be screened for KIT M541L, as positive cases may benefit
from imatinib treatment.
Aims: We aimed to (i) compare the KIT M541L allele frequency between
patients referred for investigation of HE and normal healthy controls (ii) inves-
tigate the variant allele frequency (vaf) to determine if KIT M541L mutations
may be acquired somatically and (iii) investigate the KIT M451L status in cases
negative for PDGFRα/β abnormalities who responded to imatinib.
Methods: We screened healthy controls (n=214) and patients referred for
investigation of FIP1L1-PDGFRA negative HE (n=220) for KIT M541L using an
amplification refractory mutation system (ARMS) PCR designed to amplify allele
specific products of different sizes, and able to detect KIT M541L down to 5%
vaf. Fishers exact two tailed test was used to compare the allele frequency
between the control and HE groups. Digital droplet PCR (ddPCR) was used for
patients heterozygous for KIT M541L by the ARMS assay to determine whether
the KIT M541L mutation burden was close to 50% (consistent with a constitu-
tional polymorphism) or <50% (suggestive of a somatic mutation). We also
studied pre-treatment DNA from 3 patients with hypereosinophilic syndrome
who were treated with imatinib (400 mg/day) and showed normalization of
eosinophil counts at a median of 0.8 months (0.4-5.0) after treatment for  a
duration of 13.6 months (range, 3.7-44.8).
Results: Forty two (19%) of HE cases tested positive for KIT M541 compared
to 38 (18%) of healthy controls. The KIT M541L allele frequency was no different
between cases and controls (0.095 versus 0.098; P=0.91). Of the 42 KIT M541L
heterozygous HE cases, 40 had sufficient DNA for analysis by ddPCR. The
mean allele burden was 50.4% (range 48.3%>56.0%), consistent with all
instances being constitutional. None of the three imatinib responders tested
positive for KIT M541L prior to treatment.
Summary/Conclusions: Whilst we cannot exclude the possibility that KIT
M541L may be acquired somatically in very rare cases, we conclude that there
is no clinical value in screening for this variant on a routine basis for patients
with HE or HES.
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MUTATIONS OF THE JAK2 GENE AND CYTOGENETIC ABNORMALITIES
ARE PREDICTIVE OF PROGRESSION TO HEMATOLOGICAL NEOPLASMS
IN PATIENTS WITH IDIOPATHIC LEUKOCYTOSIS
N. Mori1,2,*, K. Yoshinaga3, M. Ohwashi-Miyazaki3, M. Shiseki3, H. Sakura4,
J. Tanaka3
1Hematology, Tokyo Women’s Medical University, 2Internal Medicine, Tokyo
Women’s Medical University Medical Center East, 3Hematology, Tokyo
Women’s Medical University, 4Internal Medicine, Tokyo Women’s Medical Uni-
versity Medical Center East, Tokyo, Japan
Background: Idiopathic leukocytosis and erythrocytosis are hematological dis-
orders without specific causes. Frequent V617F mutations on the JAK2 gene
have been reported in patients with polycythemia vera (PV), essential throm-
bocythemia, and primary myelofibrosis. We also found JAK2 V617F mutations
in one of 11 patients with idiopathic erythrocytosis. Mutations of the CSF3R,
SETBP1, and ETNK1 genes have been found in chronic neutrophilic leukemia
and atypical chronic myeloid leukemia (CML). Furthermore an autosomal muta-
tion was found in the CSF3R gene in a family with chronic neutrophilia. How-
ever, little is known about mutations associated with idiopathic leukocytosis.
Aims: We previously analyzed the JAK2, CSF3R, CALR, SETBP1, and ETNK1
genes in 10 patients with idiopathic leukocytosis (EHA20). To elucidate the rele-
vance of genetic alterations, we extended the analysis with 17 genes known to be
involved in hematological neoplasms in 16 patients with idiopathic leukocytosis.
Methods: Leukocytosis is defined as a total white blood cell count more than
two standard deviations above the mean, or a value greater than 11,000/μL.
Those patients who satisfied the following criteria were included in the study:
leukocytosis (predominantly neutrophils); the absence of apparent causes of
leukocytosis; and documentation of the leukocytosis over a prolonged period
haematologica | 2017; 102(s2) | 805
Madrid, Spain, June 22 – 25, 2017
of time. The period of observation was 1 year or longer in most patients. Sixteen
patients with idiopathic leukocytosis were analyzed in the study. Neutrophils or
mononuclear cells were collected after obtaining written informed consent from
the 16 patients. Neutrophils from peripheral blood were purified by dextran
sedimentation followed by hypotonic lysis and centrifugation with Ficoll-Conray.
Mononuclear cells were isolated from bone marrow by Ficoll-Conray gradient
centrifugation. Genomic DNA was extracted using the QIAamp DNA blood mini
kit (Qiagen, Valencia, CA, USA). Mutations within hot spots of the CSF3R,
JAK2, CALR, SETBP1, ETNK1, CBL, TET2, ASXL1, EZH2, IDH1/IDH2,
DNMT3A, U2AF1, and CEBPA genes were analyzed by direct sequencing in
both directions using a 3730xL DNA Analyzer (Life technologies, Carlsbad,
CA, USA) and/or allele specific polymerase chain reaction analysis. Total RNA
extraction and reverse transcriptase polymerase chain reaction (RT-PCR) were
performed between the ETV6 and ABL1 genes in 10 patients. BCR/ABL1 gene
was analyzed by RT-PCR or fluorescence in situ hybridization in 8 patients.
The current study was conducted within the guidelines and with the approval
of ethical committee.
Results: JAK2 V617F mutations were found in one of the 16 patients with idio-
pathic leukocytosis. No mutations were found in the other genes in the 16 idio-
pathic leukocytosis patients. ETV6-ABL1 fusion gene was detected in one of
the 10 patients. No BCR/ABL1 fusion gene was detected in the 8 patients.
One idiopathic leukocytosis patient with JAK2 V617F mutation has developed
PV. Another patient with sustained leukocytosis for 20 years showed cytoge-
netic abnormalities during observation and has developed Philadelphia chro-
mosome negative CML (Ph-CML). ETV6-ABL1 fusion gene was detected in
this patient. Another patient with normal karyotype progressed to blast crisis of
Ph-CML accompanied by cytogenetic abnormalities. Of the remaining 13
patients with idiopathic leukocytosis, one resolved the disease and twelve had
a stable disease.
Summary/Conclusions: Idiopathic leukocytosis comprises heterogeneous
conditions. JAK2 mutations and cytogenetic abnormalities are predictive of
progression to hematological neoplasms.
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EVALUATION OF EXPRESSION OF MIRNAS ISOLATED MICROVESICLES
OF PATIENTS WITH MYELOFIBROSIS ASSOCIATED WITH DISEASE
L. Rodrigues1, J. Barros1, A. Nonino1, C. Mascarenhas1,*
1Biotecnologia, Universidade Católica De Brasília, Brasília,, Brazil
Background: Myelofibrosis is a hematological disease inserted in the group
of myeloproliferative neoplasias. It has as main characteristic fibrosis of the
bone marrow, consequence of a variety of histological changes presented in
the medullary microenvironment. The development of the disease is related to
the clonal expansion of myeloid stem cells, abnormal expression of cytokines,
hypercellularity of myeloid lines and also extramedullary hematopoiesis. The
pathophysiology of myelofibrosis involves the activation of signal transduction
pathways, which may occur due to genetic rearrangements and mutations that
alter the structure of protein tyrosine kinases, making hematopoietic progenitor
cells independent or hypersensitive to cytokines, generating anomalous cellular
behavior. Myelofibrosis is a hematological disease inserted in the group of
myeloproliferative neoplasias. It has as main characteristic fibrosis of the bone
marrow, consequence of a variety of histological changes presented in the
medullary microenvironment. The development of the disease is related to the
clonal expansion of myeloid stem cells, abnormal expression of cytokines,
hypercellularity of myeloid lines and also extramedullary hematopoiesis. The
pathophysiology of myelofibrosis involves the activation of signal transduction
pathways, which may occur due to genetic rearrangements and mutations that
alter the structure of protein tyrosine kinases, making hematopoietic progenitor
cells independent or hypersensitive to cytokines, generating anomalous cellular
behavior.
Aims: Recent studies have shown that microvesicles produced by cells of the
organism may be associated with the cellular communication process due to
their intravesicular content and that miRNAs also found in this content are able
to regulate diverse cellular processes. The expression of some microRNAs is
associated with hematopoietic processes such as the transformation of
myeloid, erythroid and megakaryocytic progenitors. These can regulate the
hematopoiesis of normal stem cells and also of compromised progenitors, hav-
ing an important role in the pathogenesis of some acquired hematological
malignancies. The objective of this work is to investigate the presence of spe-
cific miRNAs in microvesicles excreted in peripheral blood plasma of patients
with myelofibrosis, which may be related to cellular communication.
Methods: Microvesicles were isolated from the plasma by ultracentrifugation
method and through molecular biology techniques it was possible to validate
their presence. Assays by qPCR were performed to evaluate the presence of
specific miRNAs.
Results: We used the miRNAs described in the literature as influential in the
process of hematological disorders. They are: mir146b, mir 150, mir 29a and
155. After analysis of miRNA differential expression, miR-29a and miR-155
were less expressed in MF patients compared to healthy donors (P <0.02 and
P <0.03), and miR-223 did not Presented a statistically significant difference.
Data on miR-29a corroborate in part with the literature, since the data presented
here relate to miRNA carried by VEs rather than serum / plasma. However, low
levels of miR-29a expression are related to aberrant auto-renewal of
hematopoietic progenitor cells, thus indicating that VEs may contribute to this
mechanism. As for miR-155, the data obtained do not corroborate with the lit-
erature and, possibly, the VEs do not participate in the mechanism of regulation
of Megacariopoiese by miR-155. We used the miRNAs described in the litera-
ture as influential in the process of hematological disorders. They are: mir146b,
mir 150, mir 29a and 155.After analysis of miRNA differential expression, miR-
29a and miR-155 were less expressed in MF patients compared to healthy
donors (P <0.02 and P <0.03), and miR-223 did not Presented a statistically
significant difference. Data on miR-29a corroborate in part with the literature,
since the data presented here relate to miRNA carried by VEs rather than
serum / plasma. However, low levels of miR-29a expression are related to
aberrant auto-renewal of hematopoietic progenitor cells, thus indicating that
VEs may contribute to this mechanism. As for miR-155, the data obtained do
not corroborate with the literature and, possibly, the VEs do not participate in
the mechanism of regulation of Megacariopoiese by miR-155.
Summary/Conclusions: MiRNAs present in the microvesic content may col-
laborate in the cellular communication process in myeloproliferative diseases
and induce hematopoietic disorders.
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COMPREHENSIVE STUDY OF BCR/ABL GENE EXPRESSION IN
PROGRESSION OF “CLASSIC” MYELOPROLIFERATIVE DISORDERS
L. Kesaeva1,*, A. Misyurin2, V. Tikhonova1, Y. Finashutina2, H. Mkrtchyan3,
V. Misyurin4, N. Kasatkina5, A. Krutov3, I. Soldatova3, E. Misyurina3
1N.N.Blokhin Russian Cancer Research Center, 2.N.Blokhin Russian Cancer
Research Center, 3GeneTechnology LLC, Moscow, Russian Federation,
4Kashirskoe shosse, 24, GeneTechnology LLC, 5N.N.Blokhin Russian Cancer
Research Center, Moscow, Russian Federation
Background: Classic myeloproliferative disorders (MPDs) also known as
chronical MPDs, include several clonal hematologic diseases (such as poly-
cythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis
(PMF)), which are negative for t(9;22) translocation, result to BCR/ABL chimeric
gene expression . Characterization of JAK2V617F mutation, deletion in 12
exon of JAK2 gene, MPL W515L/K, mutation in calreticulin gene (CALR) con-
tributed a lot to understanding of molecular pathogenesis of MPDs. However,
detailed molecular mechanism underlying the progression of MPD remains
unclear. Several cases of MPDs with detected BCR/ABL expression were
described repeatedly in previons publications. The phenomen of simultaneous
coincidence of mentioned molecular markers in each clinical case requires
comprehensive study.
Aims: The aim our work was to investigate BCR/ABL expression in therapy
resistant MPD patients with disease progression.
Methods: Peripheral blood samples 175 patients with progressive MPD and
67 patients with primary MPD was used as a biological material for experiments.
Qualitative and quantitative analysis of BCR/ABL gene (р190, р210, р230) was
performed by two-step PCR and real-time PCR. Jak2, Jak2-e12, MPL, CALR
mutations were determined by direct sequencing and allele-specific PCR.
RAG1 and RAG2 expression was analyzed by real-time PCR.
Results: 175 patients with progressive MPD were analysed: 35(20%)- PV,
38(22%)- ET, 102(58%)-PMF. BCR/ABL gene expression was identified in 47
cases (32,83%). We found 44 cases with BCR/Abl  /р210, 3 cases with
BCR/Abl/р190, and no cases of BCR/Abl/р230. We have observed
hepatomegaly (17/43- 40%) and elevated WBC in BCR/ABL positive cases.
JAK2V617F mutation was identified in 139 patients, deletion in 12 exon of
JAK2 gene was found in 2 patients. One case with MPL W515L mutation and
11 cases with CALR mutation were identified. Group of primary MPD patients
(N= 67)- 26(47%)-PV, 21(38%)-ET, 8(15%)-PMF, contained  55/67(82%)
patients with JAK2V617F mutation. Expression of BCR/ABL/р210 was detected
only in 2/55(3,6%). We also found that expression levels of key components
of V(D)J  recombinase RAG1 and RAG2 in granulocytes is higher in Jak
2V617F-positive MPDs patients(46/49- 94% cases)  compared to heathy
donors (3/42- 7%).
Summary/Conclusions: The normal rearrangement of immunoglobulin recep-
tors in maturing B-lymphocytes depends on JAK-kinases activation. Therefore
we suppose that activation of key components of V(D)J recombinase
(RAG1/RAG2) could lead to appearance of additional clone with chimeric
BCR/ABL due to increased tension of Jak-STAT pathway.. The expression of
BCR/ABL gene could be the possible reason for MPD progression and should
be considered as an indication for complementary therapy.
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IMMUNOHISTOCHEMICAL ANALYSIS OF CALRETICULIN MUTATIONS IN
PRIMARY MYELOFIBROSIS (PRMF) PATIENTS: RESULTS OF OUR
INSTITUTION IN THE JAK2V617F MUTATED AND JAK2V617F WILD TYPE
PRMF PATIENTS
S.U. Bozkurt1,*, F. Geçgel2, I. Atagündüz2, Y. Ağyol3, K. Türköz1, T. Tuğlular2
806 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
1Pathology, 2Hematology, 3Internal Medicine, Marmara University, Istanbul,
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Background: Myeloproliferative neoplasms (MPNs) are a group of chronic
myeloid cancer characterized by overproduction of mature hematopoetic cells.
Mutations in one of three genes; Janus kinase 2 (JAK 2), myeloproliferative
leukemia protein (MPL) and calreticulin (CALR), have been  found in most
patients with BCR-Abl negative MPNs. JAK2 mutations are present virtually all
cases of Polycythaemia Vera and 50-60% of prMF and Essential Thrombo-
cythemia (ET). Recently, mutations in CALR gene were found in 50-80% of
JAK2 and MPL mutation negative ET and prMF patients.
Aims: To evaluate immunohistochemical results of CALR gene mutation in the
bone marrow samples of the JAK2V617F mutated and JAK2V617F wild type
Primary Myelofibrosis (prMF) patients.
Methods: Material: Bone marrow biopsy samples from  32 patients  previously
diagnosed as  primary myelofibrosis with known JAK V617F mutation status
were obtained from archives of Marmara University Pathology  Laboratory.
Bone marrow samples of two patients were already known as  CALR mutated
by PCR analysis. Bone marrow samples of three JAK2 wild type and CALR
mutated  ET,  two JAK2 wild type, CALR mutated prMF patients and two CALR
wild type ET patients  were used as positive and negative control tissues for
CALR immunohistochemistry. Immunohistochemistry: 4-µm unstained sections
of each bone marrow biopsy specimens were cut onto electrostatically charged
glass slides. Immunohistochemistry was performed on an automated immunos-
tainer (Ventana BenchMark Ultra; Ventana Medical Systems, Inc). CALR anti-
body (clone CAL2, Dianova, Germany) staining used a 1:100 dilution.Any cyto-
plasmic staining of the cells with CAL2 antibody was considered positive
immunostaining.
Results: We studied 32 bone marrow  specimens of primary myelofibrosis with
15 (47%) of them having JAK2 V617F mutation and  17(53%) of them lacking
JAK2 V617Fmutation. CALR  immunoreactivity was seen in 8 (25%) of all pr MF
patients. CALR  immunoreactivity was seen in 8 (47%) of patients with  PMF
myeloﬁbrosis who are negative for  JAK2V617F mutation. CALR  immunoreac-
tivity was not seen in patients  with  PMF myeloﬁbrosis who are positive for
JAK2V617F mutation. CALR  immunoreactivity was seen in 3 (100%) of patients
with ET and  2 (100%) of patients with known CALR mutation. CALR immunore-
activity was not seen in patients with CALR wild type ET patients. We observed
that CAL2  immunostaining was seen mainly in the cytoplasm of the small and
large megakaryocytes, and atypical megakaryocytes as found in  ﬁbrotic
PrMF. Pale immunostaining was seen in myeloid and erytoid cell precursors. This
immunostain also stained some small cells appearing as micromegakaryocytes.
Summary/Conclusions: An immunohistochemical stain easily detects the
CALR mutation by staining of megakaryocytes in formalin-fixed bone marrow
biopsy specimens . This method would be a easy, rapid, and cost effective way
to detect CALR mutations in daily routine hematopathology biopsy evaluation
of the myeloproliferative patients.
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THE HIF1A/2A MRNA INDEX HAS A SIMILAR TREND AS THE CHANGES
OF EXPRESSION MRNA CALR AND MDR1 GENES IN WHOLE BLOOD
SAMPLES OF PATIENTS WITH JAK2 V617F POSITIVE MPN
A. Gorbenko1, M. Stolyar1,2,*, M. Mikhalev1,3, E. Vasiliev1,4, V. Khorzhevskyi5,
I. Olkhovskiy1,6
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yarsk State Regional Bureau of Pathology , 6Krasnoyarsk Scientific Center SB
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Background: Various groups have reported that isoforms of hypoxia-inducible
transcription factor 1a (HIF-1a) and 2a (HIF-2a) can regulate both overlapping
and distinct target genes. HIF-1a and HIF-2a have been shown to play opposite
roles in the regulation of macrophage function [Takeda N. e.a., 2010]. HIF-index
incorporated as a strong prognostic biomarker of renal cell cancer [Szendrői A.
e.a., 2016]. Only HIF1a was known as regulator expression of multidrug resist-
ance gene (MDR1) and response to chemotherapy [Comerford K.M. e.a., 2002].
New data have shown exclusive role of HIF-2α in regulates the proliferation and
glucose metabolism in erythroleukemia cells [Xu Q.Q. e.a., 2016]. No any infor-
mation about relations between index of HIF and mRNA gene expression level
MDR1 or CALR in patients with myeloproliferative neoplasms (MPN).
Aims: Investigate the mRNA expression levels of HIF-1a and HIF-2a, MDR1
and CALR genes in whole blood samples from patients with JAK2 V617F pos-
itive MPN.
Methods: Real-time PCR was performed to detect of HIF1a, HIF2a, MDR1
and CALR mRNA transcripts levels in white blood cells 14 healthy volunteers
(median age 22 years, range 21-58 years, 57% males) and 11 (median age 44
years, range 20-77 years, 45% males) patients with JAK2 V617F-positive MPN,
median of allelic burden is 36%, range 9-87%. Venous blood were collected in
tube with RNAse inhibitor. Total RNA was isolated using “RIBO-zol-D” (Aplisens)
and were transcribed using “Reverta-L” (Aplisens). PCR was optimized for the
thermocycler CFX96 (Bio-Rad). The results were calculated utilizing the delta
Ct method in the software package of “R”. The threshold cycles (Ct) genes and
housekeeping genes (TBP, GUS, ABL) determined using Cy0 method. The
results was normalization with this reference genes. Mann-Whitney U test was
used to evaluate significant difference between the groups, the degree of cor-
relation (r) was assessed using Spearman test.
Results: We observed a lower mRNA expression MDR1 and CALR in whole
blood samples of patients with MPN compared with a group of healthy volun-
teers (Figure 1). The expression level of mRNA HIF2a not changed and for
HIF1a it should be noted a tendency for statistical significance. It found no cor-
relation between allelic burden and mRNA expression level. Index HIF 1a/2a
more clearly showed a correlation with the fall of MDR1 and CALR mRNAs (r=
-0.64  in control and  r= -0.7 in MPN group, p<0.05). CALR gene unlike MDR1
gene is not known among the target HIF regulation, but their unidirectional
change indicates the possible metabolic links.
Figure 1.
Summary/Conclusions: We assume that the studied  gene expression
changes reflect the metabolic processes in the bone marrow progenitor cells.
Probably JAK2 V617F mutation leads to more favorable microenvironment and
reduced willingness to autophagy, causing the index shift HIF1a/2a. We found
reduced of mRNA CALR expression in blood cells at MPN and this fact require
further investigation.
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CD177 EXPRESSION IN PERIPHERAL BLOOD NEUTROPHILS IN HEALTH
AND DISEASE STATES
A. Arafat1,*, S. Rizk1, R. Samy1, N. Al-Husseiny2, R. El-Hawary1
1Clinical and chemical pathology, 2Internal medicine, Cairo university, Cairo,
Egypt
Background: Objective and specific assays are required in the identification
of both chronic myeloproliferative disorders and myelodysplastic syndromes.
Aims: Exploration of the possibility of using the CD177 expression in the periph-
eral blood neutrophils for the diagnosis of either entity.
Methods: The 213 subjects were organized into 4 main groups; benign neu-
trophil leukocytosis group, secondary erythrocytosis group and clonal myeloid
neoplasms group together with a haematologically normal group as controls.
All cases were subjected to clinical assessment as well as the flow cytometry
determination of the percentage (%) and mean fluorescent intensity (MFI) of
peripheral blood neutrophils expressing CD177.
Results: Skewed high peripheral blood neutrophil CD177 MFI was significantly
associated with Philadelphia-negative cMPDs patients (2.9-37.4; median 14.1)
compared to controls (0.8-20.5; median 8.8). The MDS patients did not show
a significant difference in either CD177% or MFI compared to the controls.
Polycythemia Vera (PV) patients had similar results of CD177 expression (%
and MFI) compared to Essential Thrombocytosis (ET) patients. However, they
had higher CD177 MFI levels compared to the secondary erythrocytosis
patients and controls (4.8-37.4; median 16.5, 1.58-25.7; median 5.81, 0.85-
20.5; median 8.8 respectively). CD177 MFI showed statistically significant high-
er values in ET patients compared to the haematologically normal control group
(2.9-34.5; median 13.4 versus 0.85-20.5; median 8.8 respectively). No corre-
lation between CD177 expression and JAK2 V617F allele burden could be
detected in either PV or ET patients. With a 20 p.d.u cutoff, the specificity of
neutrophil CD177 MFI in Philadelphia-negative cMPDs patients’ diagnosis and
differentiation of PV from secondary erythrocytosis was 93% and 85% respec-
tively. The CD177%  had a low accuracy of in the diagnosis of MDS patients.
The CD177 patterns observed were one positive peak and bimodal pattern
(Figure1).
Summary/Conclusions: The CD177 expression is highly associated with
Philadelphia-negative cMPDs. It could reliably represent a useful potential mark-
er in detecting those disorders and differentiating them from reactive cases.
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Figure 1. Patterns of peripheral blood neutrophil CD177+ve cells expres-
sion observed in flow cytometry. A) Bimodal pattern. B, C, D, E) CD177
single positive peak varieties.
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DETECTION OF THE MUTATIONS IN GENES JAK2 AND MPL IN THE
DIAGNOSIS OF CHRONIC MYELOPROLIFERATIVE DISORDERS
K. Boboev1,*, K. Karimov1, A. Mohammad1
1institute of hemotology and blood transfuzion, tashkent, Uzbekistan
Background: Chronic myeloproliferative diseases is a group of clonal Ph-neg-
ative hematological diseases, which include erythremia (polycythemia Vera,
PI), chronic megakaryocytic leukemia (essential thrombocythemia, ET) and
subleukemicmyelosis (primary myelofibrosis, PMF, chronic idiopathic myelofi-
brosis). The origin of these diseases is linked to transformation of hematopoietic
stem cells, the result is the excessive production of mature cells of erythroid,
granulocytic and megakaryocyte shoots with relatively long course of the dis-
ease. The frequency of occurrence of mutation V617F of gene JAK2 exon 12
and MPL gene varies in different literature.
Aims: Determination of the frequency of occurrence of mutations in genes
JAK2 and MPL and identifying the importance of the verification of these dis-
eases.
Methods: The study included 350 patients with chronic myeloproliferative dis-
eases — with polycythemia Vera 150 patients, with essential thrombocythemia
78,  with chronic idiopathic myelofibrosis 55 and 67 patients were examined
with the purpose of differential diagnosis with Ph(-) Chronic myeloproliferative
diseases. The age of patients ranged from 20 to 70 years, median age was 54
years. Isolation DNA of patients was carried out using a set of reagents
“AmpliPrep RIBO-prep” (OOO Interlabservice, Russia). The concentration and
purity of isolated DNA was determined by Nano Drop 2000 instrument (USA).
Detection of gene mutation JAK2V617F and MPL gene was carried out by
standard polymerase chain reaction on a thermal cycler 2720 “Applied Biosys-
tems” (USA), using a set of “Litech” (Moscow).
Results: The result of the research showed that the incidence of the V617F
mutation in JAK2 was varying in patients depending on the type of disease. In
polycythemia Vera the mutation V617F in the JAK2 gene was identified in 147
patients of 150 (98,3%), with essential thrombocythemia in 42 patients of the
78 (54,2%), with chronic idiopathic myelofibrosis in 27 patients of 55 (49.1%).
In 67 patients with no hematological profile, wich examined with the purpose
of differential diagnosis with Ph(-) chronic myeloproliferative diseases, V617F
in JAK2 was detected in 6 (8,6%), which allowed to confirm Ph(-) Chronic
myeloproliferative diseases. A mutation in exon 12 of the JAK2 gene was
detected in 2 of 33 (2,9%) of those surveyed V617FJAK2-negative patients
exclusively diagnosed with polycythemia Vera. The MPL W515L mutation gene
was detected in polycythemia Vera and chronic idiopathic myelofibrosis 2.2%
(1 of 41) and 2% (1 of 52) of patients.
Summary/Conclusions: Thus established, our data confirm that mutations in
the genes JAK2 and MPL are highly specific diagnostic markers in patients
with Ph-negative chronic myeloproliferative diseases.
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ASSOCIATION OF MYELOPROLIFERATIVE NEOPLASM AND
LYMPHOPROLIFERATIVE DISORDER IN 3 PATIENTS
B. Foucher1,*, M. Dudez2, M. Daniel2, S. Girard2, C. Froelich2, F. Mestrallet2,
I. Tigaud3, S. Hayette4, A. Belhabri5, M.P. Pages2, L. Vila6,7
1Laboratoire, Hopital d’instruction des armées Desgenettes, 2Laboratoire,
Groupement Hospitalier EST, 3laboratoire, Groupement hospitalier Sud,
4department of cytogenetics and molecular biology, Groupement Hospitalier
EST, 5department of oncology and hematology, Centre Leon Berard, 6labora-
tory, Groupement Hospitalier EST, 7laboratoire, Centre Léon Bérard, Lyon,
France
Background: Lymphoproliferative disorders (LPD) and myeloproliferative neo-
plasms (MPN) are two very different sets of hematological pathologies. However,
several studies have shown that the risk for LPD onset in patients with MPN is
higher than in the general population (1)(2). No single LPD seems to be more at
cause and all MPN are likely to present the onset of an associated LPD.
Aims: We present 3 cases diagnosed in the Department of Hematology,
« Groupement Hospitalier Est », Lyon, France, of patients bearing an associ-
ation of MPN and LPD: an essential thrombocythemia (ET) with myeloma, ET
with marginal zone lymphoma and a chronic myeloid leukemia with chronic
lymphoid leukemia.
Methods: Diagnosis have been made thanks to cytology of peripherical blood,
bone marrow aspirate and biopsy and confirmed by cytogenetic and molecular
biology techniques.
Results: Case number 1. A 68 year old woman known to have essential throm-
bocythemia as a MPN, with V617F mutation of the JAK2 protein kinase. After 19
years of treatment by Hydrea, she developed a splenomegaly , anemia and slight
lymphocytosis of 4.77 G/L. The blood smear, the bone marrow aspirate  and
biopsy examination revealed myeofibrosis evolution and an infiltration by 30% of
a small sized clonal lymphoid population CD20+, CD5-.Medullar karyotype was
normal: 46, XX[10].In conclusion the ET has evolved into myelofibrosis and is
associated with a lymphoproliferative syndrome, possibly marginal zone lym-
phoma.No additional treatment has been implemented. Case number 2. A 64
year old woman know to have ET with V617F mutation of the JAK2 protein kinase
treated by acetic salicylic acid. 5 years after, she presented with IgG kappa type
monoclonal gammopathy up to 28 g/L, without any associated clinical manifes-
tation nor cytopenia. Medullar blood was diluted but showed slightly atypical plas-
mocytes remaining under 10%.Myeloma was diagnosed anyway and the patient
received 5 cures of Velcade-Melphalan-Prednisone which resulted in complete
remission. The MPN remains stable to this day. Case number 3. A 62 year old
man with chronic lymphoid leukemia, treated by six cycles of R-FC. While in
remission since 2 years, hemogram shows hyperleucocytosis (WBC: 18.3 G/L)
with thrombocythemia (platelets: 1886 G/L) without anemia (Hb: 13.7 g/dL).Blood
smear examination reveals 3% of myelemia and basophilia (3,66 G/L).BCR-ABL
transcript is positive in 43% and karyotype points out a 9;22 translocation. (46,
XY, t (9 ;22) (q34 ;q11)[1] nuc ish (BLX3, BCRx3,ABL.con BCRX2)[48/100].)
Before starting Nilotinib, cytoreductive treatment by Hydrea was decided. Treat-
ment is under way.
Summary/Conclusions: The three cases described highlight the diverse sit-
uations observed in cases of combined MPN/LPD pathologies. MPN with sec-
ondary onset of LPD are most frequently encountered, as was the case with
patients 1 and 2. Cases of preexisting LPD and late onset MPN are rare (1),
and cases of simultaneous discovery of both pathologies even more so (3).
Several hypotheses have been formulated to explain the frequency of onset of
these pathological associations: genomic instability due to JAK2 protein kinase
activation, or due to BCR-ABL mutation, or exposure to cytotoxic chemotherapy
or radiations (3).
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CLINICAL AND ANALYTICAL DIFFERENCES BETWEEN CALR TYPE-1
AND CALR TYPE-2 MUTATION IN PATIENTS WITH ESSENTIAL
THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS: A SINGLE
CENTER STUDY
M. Sobas1,*, M. Olejniczak1, I. Andrasiak2, M. Kruszewski3, B. Jazwiec1,
J. Rybka1, T. Wrobel1, K. Kuliczkowski1
1Department of Hematology, Blood Neoplasms and Bone Marrow Transplan-
tation, Wroclaw Medical University, 2WroMedica Research Center, 3Wroclaw
Medical University, Wrocław, Poland
Background: The JAK2V617F is a main molecular marker in myeloproliferative
neoplasms (MPN) and is harbored in about 50-60% of essential thrombocythemia
(ET)  and primary myelofibrosis (PMF). Recently, CALR mutation was described
in ET and PMF JAK2V617F negative patients. There are two main variants of
CALR mutation: type 1 (a 52-bp deletion) and type 2 (a 5-bp insertion).
Aims: To compare clinical and analytical data of ET and PMF patients with
CALR type-1 vs CALR type-2 mutation.
Methods: We performed a single center study on 471 patients: 87 PMF and
384 ET. The JAK2V617F mutation was analyzed in DNA from peripheral blood
leukocytes by PCR ARMS method. In all JAK2V617F negative patients detec-
tion of CALR mutation was performed by fragment length analysis and the
results were confirmed by sequencing. Statistical data analysis was performed
using Statistica 12.5 software for Windows. 
Results: From 384 ET patients 254 were JAK2V617F positive (66%), 80 were
CALR positive (21%) and 51 were JAK2V617F and CALR negative (13%).
From CALR positive patients: 36 (51%) had type-1, 34 (45%) type-2 mutation,
and 10 (12%) type-3 mutation. From 87 PMF patients 56 were JAK2V617F
positive (64%), 18 were CALR positive (21%) and 13 (15%) were JAK2V617F
and CALR negative. From CALR positive groups: 13 (72%) had  type-1 and 5
(28%) had type-2 mutation. Compared with ET carrying JAK2V617F mutation,
patients ET CALR positive (type-1 plus type-2) had lower hemoglobin (13.3 vs
14.5 g/dl, p<0.001) and leukocyte (8.2 vs 9.7 G/L, p<0.001), higher platelet
counts (1067 vs 800 G/L ,  p<0.001) but with no significant differences in fre-
quency of thrombosis. In ET, CALR mutation was associated with increased
odds of myelofibrotic transformation (odds ratio [OR]=2.61; 95% CI: 1.28 - 5.34;
p=0.009) comparing with JAK2V617F positive patients. Patients ET CALR type-
1 had higher leukocyte counts than ET CALR type-2 mutation (9.6 vs 7.3 G/L,
p= 0.008), but we did not find significant differences in hemoglobin, platelet
counts, frequency of thrombosis or myelofibrotic transformation. Within PMF,
no significant differences were observed. Moreover in PMF, there was no sig-
nificant differences between the JAK2V617F, CALR type-1 and type-2 mutation
status respect to the International Prognostic Score System (IPSS). 
Summary/Conclusions: 1. In our population, the frequency of JAK2 and CALR
mutation was similar to previously described. 2. Compared patients with ET
JAK2V617F positive, ET CALR positive (type-1 plus type-2) had higher platelet
count but no higher frequency of thrombosis was observed. 3. Myelofibrotic
transformation was more frequent in ET CALR positive versus JAK2V617F
positive patients. 4. ET patients CALR type-1 versus type-2 had higher leuko-
cyte count but there were no more significant differences between these two
groups. 5. There were no significant differences within PMF group (to small
number of patients).  6. In PMF patients, there was no relations between IPSS
and mutational status (JAK2V617F, CALR type-1 and type-2).
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ESSENTIAL TRHOMBOCYTHEMIA: STUDY OF TREATMENT LINES
REQUIRED. EXPERIENCE OF A SINGLE CENTER
M. Berenguer1,*, R. Pérez López2, V. Cabañas-Perianes2, M. Moya-Arnao2,
N. Ortega-López3, E. Salido-Fiérrez2, A. Martínez-Marín2,
E. Fernández-Poveda2, J.M. Moraleda-Jiménez2
1Hematology, 2Hospital Clínico Universitario Virgen de la Arrixaca, Murcia,
Spain, 3Internal Medicine, Hospital Clínico Universitario Virgen de la Arrixaca,
Murcia, Spain
Background: Essential thrombocythemia (ET) is a chronic myeloproliferative
neoplasm that shows similar survival prognosis as general population, with a
very low rate of transformation to myelofibrosis and acute leukemia.
There are different treatments for these patients with optimal responses at first.
For the first line, it is usually threated with hydroxyurea, although in young
patients it is usually replaced by anagrelide / interferon.
There are publications of hydroxyurea side effects, especially cutaneous, but
there are not many studies about how many lines of treatment are needed to
control the disease.
Aims: Study type and lines of treatment needed in patients with ET in a cohort
of patients from January 1997 to January 2017.
Methods: We studied patients diagnosed of essential thrombocythemia in one
area of the region of Murcia from January, 1997 to January, 2017. Those who
started treatment and those who needed change were analyzed, either by
resistance or by intolerance.
Results: In our area we have registered a total of 152 patients diagnosed with
ET. Of these, 71% (108 patients) have required at least one treatment line.
Table 1 shows the number of treatment lines required for the control of the dis-
ease. As it is shown in the Table, more than 20% of treated patients needed a
second line and 6,5% required more tan 2 lines. At last, Table 3 shows current
treatment of ET patients.
Table 1. Number of line treatmentes required for disease control.
Table 2. Drugs used in patients with ET.
Table 3. Current treatment of ET patients.
Summary/Conclusions: This study highlights that, although ET has a very
good prognosis, there is a significant percentage of patients that will need a
change of treatment, either because of resistence or intolerance.
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THROMBOTIC AND BLEEDING RISK FACTORS IN ESSENTIAL
THROMBOCYTHEMIA
A. Zherniakova1,*, I. Martynkevich1, V. Shuvaev1, L. Polushkina1,
M. Fominykh1, V. Udal’eva1, I. Zotova1, D. Shichbabaeva1, S. Voloshin1,
S. Bessmeltsev1, A. Chechetkin1, K. Abdulkadyrov1
1Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, Russian Federation
Background: Thrombosis and hemorrhage are the main category of compli-
cations, that affects the overall survival (OS), quality of life and therapy option
choice in essential thrombocythemia (ET). Molecular marker presence
(JAK2V617F, MPL, CALR) or its absence (triple-negative status (TN)) in ET
supposed to impact on the clinical course, thrombosis rate and ET prognosis.
Aims: The aim of this study was to investigate interactions between the pres-
ence of molecular marker, thrombosis/bleeding rates and the OS in ET. 
Methods: Outpatient’s charts of 240 ET patients, who had been diagnosed
with ET at our institution according to WHO 2008 criteria. The following data
were assessed: complete blood count, bone marrow biopsy results, bone mar-
row cytogenetic, the restriction fragment length polymorphism (RFLP) results
used for JAK2V617F detection, in case of JAK2V617F-negative status the
PCR-RFLP (MPL detection) and the direct sequencing (CALR detection)
results. Different thrombotic/bleeding complications rates were analyzed. The
OS in ET patients was compared according to molecular markers revealed. 
Results: According to their mutational status 182/240 (75.9%) patients (pts)
were JAK2V617F-positive (JAK2+); 30/240 (12.5%) – CALR-positive (CALR+):
type 1 (CALR1+) – 13/30 pts (43.3%), type 2 (CALR2+) – 17/30 pts (56.7%).
Only two pts were MPL-positive (MPL+) (0.8%), TN were 26/240 pts (10.8%).
Among 240 pts 183 (76.3%) hadn’t any thrombotic complication or bleeding
event (no complications/NC), 57/240 (23.7%) had complications: 49/57 (85.9%)
reported arterial or/and venous thrombosis, stroke or heart failure (thrombosis+)
and 11/57 (19.3%) had bleeding events (hemorrhage+). Thrombotic complica-
tions in JAK2+ had 27.4% (50/182) pts, in TN – 30.7% (8/26) pts, in CALR1+
– 18.2% (2/11) pts and no cases of thrombosis were detected in CALR2+ and
MPL+ subgroups (p<0,001). There were significant statistical differences in
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median platelet count as follows: 742х109/l (thrombosis+) and 937х109/l (hem-
orrhage+) (p=0.003). No significant statistical differences in median hemoglobin
and leukocyte count (р=0.75 and р=0.47) were detected. There were more
than a half pts older than 60 years in groups NC (51%) and thrombosis+ (59%)
and in group hemorrhage+ only 36% (p<0,001). Cardiovascular risk factors
were reported in 24% pts (NC), 69% pts (thrombosis+) and 36% pts (hemor-
rhage+) (p<0,001). There were no significant statistical differences in follows
risk factors as thrombosis >1000x109/l and leukocytosis >11x109/l (р=0.85 and
р=0.72). No significant differences in OS among groups NC, thrombosis+ and
hemorrhage+ (р=0.12) were found (Figure 1).
Figure 1.
Summary/Conclusions: Leukocytosis >11x109/l and thrombocytosis
>1000x109/l cannot be assessed as independent thrombosis risk factors in ET.
JAK2V617F mutation was associated with increased risk of thrombotic com-
plications in ET. CALR mutations were correlated with lower thrombosis risk
and better OS rate, comparing to JAK2+ and TN status despite the fact of
CALR+ patients had higher platelets level. Along with common thrombosis risk
factors (age >60 and cardiovascular risk factors) mutational status may help
to identify ET course and to optimize individual therapy option choice.
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DETECTION OF JAK2 EXON 12 MUTATIONS BY HETERODUPLEX
ANALYSIS AND PYROSEQUENCING
T. Subbotina1,2,*, E. Dunaeva3, K. Mironov3, A. Kharsekina1, E. Vasiyliev2,4,
M. Mikhalev2,5, M. Osadchaya6, M. Smelyanskaya4, V. Khorzhevskyi2,7,
I. Olkhovskiy2,8, G. Shipulin3
1Department of Medical Biology, Siberian Federal University, 2Krasnoyarsk
branch of the Federal State budgetary Institution «Hematology Research Cen-
ter» Department of Health, Krasnoyarsk, 3Federal Budget Institute of Science
«Central Research Institute for Epidemiology», Moscow, 4Krasnoyarsk regional
hospital, 5Municipal Budget Health Service Institution «City Clinical Hospital
№ 7», 6Krasnoyarsk Territory Department of Health Regional state budget
health facility «Krasnoyarsk interdistrict clinic №1», 7Krasnoyarsk State Region-
al Bureau of Pathology, 8Krasnoyask Scientific Center of the Siberian Branch
of the Russian Academy of Sciences, Krasnoyarsk, Russian Federation
Background: Somatic mutations in codons 533-547 of JAK2 exon 12 are high-
ly specific to confirm the diagnosis of polycythemia vera (PV). We have previ-
ously proposed techniques for the detection and quantification of JAK2 exon
12 allele burden using a pyrosequencing method (Subbotina T et al, Haema-
tologica 2014). However, due to the high cost of sequencing, developing a two-
stage algorithm for detect mutations in JAK2 exon 12 using inexpensive screen-
ing is of immediate practically necessity.
Aims: The aim of this study was to demonstrate the feasibility of using het-
eroduplex analysis with separation of the PCR product by electrophoresis on
non-denaturing PAGE as the preliminary screening test for detection of JAK2
exon 12 mutations.
Methods: 274 patients with PV or unclear erythrocytosis and with a low
JAK2V617F allele burden or unmutated JAK2V617 (51 women, mean age
52.2±15.7 years and 223 men, mean age 43.6±15.6 years) were included in
this study. The informed consents from these patients were obtained. The PCR
with the additional stage of formation heteroduplexes was performed using the
Real-time PCR kit (Syntol, Russia) and CFX 96 Real Time System (Biorad,
USA). PCR products were analyzed by electrophoresis in 8% PAGE. The pres-
ence of the mutations was identified and confirmed by pyrosequencing method
with PyroMark Q24 (Qiagen, Germany). To verify the presence of mutations,
the DNA sequences extracted from the clinical samples were cloned into pGem-
T vector using standard protocol («Promega», USA), and obtained clones were
sequenced using reagents and equipment of the «Applied Biosystems» (USA).
JAK2 exon 12 varianceMUT was calculated as a measure of relative changes
in allele burden between the baseline and follow-up sample (Theocharides A
et al, Haematologica, 2008).
Results: We detected JAK2 exon 12 mutation in five out 274 patients. The
results of electrophoresis on non-denaturing PAGE are reported in Figure 1.
The type of №1-5 patient mutations was determined by pyrosequencing: N542-
E543del (c.1624_1629delAATGAA); I540-E543delinsKK (с.1619_1627 TCA-
gAAATgK (c.1622_1627delGAAATG) and p.H538_K539>L
(c.1612_1616CACAA>TT). These mutations have been already described.
Main characteristics of 5 patients with JAK2 exon 12-mutated PV are reported
in Table 1. The PV diagnosis of №1, 2, 3 and 5 patients was confirmed by
bone marrow trephine biopsies histological examination. All five patients with
JAK2 exon 12-mutated PV have an increased number of red blood cells, along
with an accompanying increase in the concentration of hemoglobin and hema-
tocrit level in the peripheral blood. Some of them had increase number of leuko-
cytes and platelets in the disease dynamics. №1-4 patients was treated phle-
botomy only and did not received any cytoreductive treatment to date. Patient
№5 receives hydroxyurea (HU). Importantly, two out five patients with JAK2
exon 12-mutated PV also have a mutation JAK2V617 (<1%). JAK2 exon 12




Summary/Conclusions: The proposed variant of the heteroduplex analysis
with separation of the PCR product by electrophoresis on non-denaturing PAGE
can be recommended for use as the preliminary screening test which is carried
out before the confirming pyrosequencing. The two-stage approach allows to
optimize the algorithm of the JAK2 exon 12 mutation detection and to improve
the efficiency of testing for patients suspected of having PV in whom a
JAK2V617F mutation is not detected or detected in a low allele burden. In five
out 274 patients we detected JAK2 exon 12 mutation and confirmed the diag-
nosis of PV.
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INTRODUCTION OF AN NGS GENE PANEL INTO CLINICAL SERVICE FOR
MYELOPROLIFERATIVE NEOPLASMS
A. Skowronska1,*, J. Bryon1, S. Clokie1, Y. Wallis1, J. Mason1, K. Reay1,
M. Griffiths1
1West Midlands Regional Genetics Laboratory, Birmingham Women’s and Chil-
dren’s NHS Foundation Trust, Birmingham, United Kingdom
Background: In the West Midlands region of the UK, all patients with a sus-
pected myeloproliferative neoplasm (MPN) have access to quantitative analysis
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of JAK2 V617F by droplet digital PCR as standard of care. The British Com-
mittee for Standards in Haematology recommends that suspected MPN cases
have investigation of JAK2 exon 12, CALR and MPL genes if JAK2 V617F is
negative.
Aims: The aim of the project was to improve the MPN service by substituting
sequential analysis of individual target regions within the JAK2, CALR and MPL
genes with a single assay, and to increase the number of genes available for
analysis.
Methods: A commercial next generation sequencing (NGS) gene panel (Oxford
Gene Technology, SureSeq Myeloid Panel), coupled with the Illumina MiSeq
platform was validated and implemented. The gene panel utilises hybridization
based enrichment technology and consists of 25 MPN–related genes. During
the validation stage the following were enriched and analysed: 29 positive con-
trol samples with 30 known pathogenic variants, 30 negative control samples
without known pathogenic variants in the JAK2, CALR and MPL genes, and 24
MPN samples of unknown mutational status. Thus so far over 200 clinical sam-
ples have been analysed and reported since the service was introduced in
October 2016.
Results: The panel has successfully identified: a large range of known patho-
genic variants at high sensitivity (JAK2 V617F variant allele frequency 1%,
CALR Type I frameshift variant allele frequency 3%), a potential alternative
driver mutation in a known low level JAK2 V617F positive patient, a rare MPL
exon 4 pathogenic variant and also the detection of low level CALR pathogenic
variants, which would not have been detected by Sanger sequencing analysis.
In one patient the panel identified the presence of two different JAK2 exon 14
pathogenic variants in cis (JAK2 V617F and JAK2 C618R). The JAK2 C618R
prevented the hybridization of the probe binding site of the JAK2 V617F ddPCR
assay which had led to a false negative result by ddPCR.  The validation pro-
cedure also explored coverage and limits of sensitivity, potential chemistry spe-
cific artefacts and identified common polymorphisms for all 25 genes.
Summary/Conclusions: The panel has replaced the current sequential analysis
of CALR, MPL and JAK2 exon 12 in JAK2 V617F negative patients and reduced
turn-around-times with increased accuracy and sensitivity compared to Sanger
sequencing and fragment analysis. Our current clinical service operates on a two
tier system whereby clinicians can request analysis of the full 25 gene panel or
a 4 gene subset (JAK2, CALR, MPL, CBL as an in silico analysis).
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IN JAK2V617F POSITIVE MYELOPROLIFERATIVE NEOPLASMS,
BLEEDING RISK CORRELATES WITH ALLELE BURDEN
I. Bertozzi1,*, E. Cosi1, C. Santarossa1, G. Bogoni1, F. Fabris1, M.L. Randi1
1Dep. Internal Medicine - DIMED, University of Padova, Padova, Italy
Background: Myeloproliferative neoplasms (MPN) are characterized by the
presence of JAK2V617F mutation that is almost invariably associated with poly-
cythemia vera (PV), but also occurs in the majority of patients with essential
thrombocythemia (ET) or primary myelofibrosis (PMF). JAK2V617F-positive
patients display different laboratory and clinical features from JAK2-wild type,
but no clear correlation was found between the JAK2V617F allele burden and
natural history of the disease. The most common causes of morbidity and mor-
tality in MPN are thrombotic and hemorrhagic complications, albeit bleedings
are less frequent than thrombosis and mostly represented by minor hemor-
rhages (ecchymosis, epistaxis, menorrhagia and gingival hemorrhage). The
impact of different allele burden on bleeding risk is uncertain.
Aims: Aim of our study is to explore whether there is an association between
JAK2V617F allele burden and hemorrhagic complications in a large cohort of
MPN diagnosed and followed in a single center.
Methods: We selected 253 MPN (121 ET= 47.8%, 124 PV=49% and 8
PMF=3.2%) carrying JAK2V617F mutation. The median follow-up of patients
was 8.8 years (0.1 – 37.3 y). Complete medical history and anti-thrombotic
drugs use were recorded. Hemorrhagic complications were classified as “major”
or “minor” in agreement with ISTH criteria. The patients were categorized into
four groups according to the amount of JAK2 mutant allele, (1st quartile 1-25%,
2nd quartile 26-50%, 3rd quartile 51-75% and 4th quartile 76-100%). Nominal
variables were compared with X2 test or Fisher’s exact where indicated. Sur-
vival has been evaluated only for groups with different prevalence of events
during follow-up and were calculated with the Kaplan Meier method and com-
pared with the Log Rank test.
Results: Three patients (1.2%) bleed at diagnosis (1 major and 2 minor hem-
orrhages) while 27 (11.8%) suffered for hemorrhages during follow-up (10 major
and 17 minor). Prevalence of hemorrhages results higher in 4th quartile com-
pared both to 2nd (p=0.003) and to 1st (p<0.001) quartiles. Hemorrhages-free
survival is confirmed lower in 4th quartile compared both to 2nd (p= 0.004) and
to 1st (p<0.001). The incidence rate of hemorrhages are respectively 0.7/100
pats /y for 1st quartile, 0.65/100 pats /y for 2nd quartile, 1.26/100 pats /y for 3rd
quartile and 3.23/100 pats /y for 4th quartile with a IRR of 5 and of 4.6 for the
4th quartile respectively versus 2nd and 1st one. No statistically significant dif-
ference has been demonstrated in the use of anti-thrombotic drugs among
patients of the different quartiles.
Summary/Conclusions: Risk factors for hemorrhage in MPN are not well
defined, and there is no risk estimation model for this outcome. Acquired von
Willebrand disease, entity of platelet increased count and aspirin use have
been implicated in bleeding occurrence. Previous reports fail to demonstrate a
correlation between JAK2 mutation and bleeding risk. In contrast, in our cohort
we found a significantly higher incidence of bleeding manifestations during fol-
low-up in patients with higher allele burden. Interestingly no differences were
seen in administration of anti-thrombotic drugs among quartiles, suggesting an
independent role of JAK2 allele burden in the different distribution of hemor-
rhagic events.
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JAK2 ALLELE BURDEN IN PATIENTS WITH PHILADELPHIA NEGATIVE
MYELOPROLIFERATIVE NEOPLASMS
M. Napolitano1,*, S. Siragusa1, S. Mancuso1, M. Santoro1,
M.R. Lanza Cariccio1, M. Bono2, F. Di Piazza2, A. Russo3, V. Accurso1
1UO Ematologia, 2Laboratorio di genetica e oncologia molecolare, 3UO Oncolo-
gia, University Of Palermo, Palermo, Italy
Background: The JAK2V617F allele burden (JAK-AB) plays a central role in
chronic myeloproliferative neoplasms (cMPNs); its presence has also been
advocated in the differential diagnosis of cMPNs and as independent risk factor
for venous thromboembolic complications. New treatment with Ruxolitinib may
decrease JAK-AB but at the present, it is not clear the clinical advantage of
such reduction
Aims: Primary aim of the current study was to evaluate at diagnosis the JAK-
AB in patients with Philadelphia negative cMPNs, in order to evaluate any asso-
ciation with standard demographic, clinical and laboratory parameters with par-
ticular reference to thrombotic risk.
Methods: Peripheral blood samples from patients with Ph-negative cMPNs were
collected, DNA from leucocytes was analysed for Jak-2 (V617F) gene mutation
with amplification-refractory mutation system (ARMS) PCR, subsequently a real-
time quantitative polymerase chain reaction (qRT-PCR) for JAK2V617F allele
burden measurement was applied. A multivariate analysis was than performed
to evaluate any association of AB with demographic and clinical data.
Results: One hundred and twelve patients with Philadelphia negative cMPNs
were investigated: 52 females with a median age at diagnosis of 69 years (age
range: 18-95 years), 60 males with a median age of 68 years (age range: 18-
82 years). Thirty-four patients had Essential Thrombocythemia (ET), fifty-two
had Polycythaemia Vera (PV) and twenty-six had primary myelofibrosis (PMF).
JAK2-AB of patients with an age of <69 years and ≥69 years, was respectively
evaluated. Patients older than 69 years showed a significantly higher JAK2-AB
. JAK-AB was significantly reduced in ET, when compared to PV and PMF. No
correlation was found between median values of allele burden and IPSS and
DIPSS scores. In patients with PV (n=52), a significant correlation was observed
between allele burden and WHO2008 scoring system. No significant correlation
was found between allele burden and thrombotic risk according to IPSET-t and
IPSET-ET for PV and ET, respectively. Patients with a previous history of throm-
bosis had the highest JAK2-AB. In PMF, a positive correlation between JAK-
AB and grading of fibrosis was found only for the highest grades (PMFIII and
IV). JAK-AB had a positive correlation with splenomegaly in PMF.
Summary/Conclusions: Our report cannot confirm any correlation between
allele burden and thrombotic risk, according to currently adopted scoring sys-
tems. A previous history of thrombosis is however associated with the highest
AB in all cases.
PB2039
COMPARISON OF CLINICAL AND LABORATORY DATA, INCLUDING
JAK-2 46/1 HAPLOTYPE, BETWEEN PATIENTS WITH IDIOPATHIC
ERYTHROCYTOSIS AND POLYCYTHEMIA VERA.
M. Napolitano1,*, S. Siragusa1, M. Santoro1, F. Di Piazza2, M. Bono2,
S. Mancuso1, A. Russo3, V. Accurso1
1UO Ematologia, 2Laboratorio di genetica e oncologia molecolare, 3UO Oncolo-
gia, University Of Palermo, Palermo, Italy
Background: Idiopathic erythrocytosis (IE) is a relatively rare finding charac-
terized by an increased red blood cell mass without an identifiable cause. Diag-
nosis of IE is based on the exclusion of primary and secondary
erythrocytosis   including JAK2-wild-type polycythemia Vera (PV).
Aims: In the current study, we report clinical features and laboratory data able
to discriminate IE from PV, at diagnosis
Methods: We have here analyzed clinical and laboratory parameters, including
Jak-2 46/1 haplotype, from  patients with a confirmed diagnosis of IE and PV,
followed  from January 2010  to December 2016. Data were statistically ana-
lyzed, nominal variables were compared with X2 test and continuous variables
with the Mann-Whitney test.
Results: Overall, 40 patients with IE and 93 patients with PV were included in
the current analysis (Table 1). Splenomegaly and itch were reported only in
one patient with IE. History of thrombosis and cardiovascular events was pos-
itive in one case with IE. Jak-2 (V617F) and exon 12 mutations were negative
in all patients with IE, while Jak-2 46/1 haplotype was found at heterozygous
state in 18 patients and at homozygous state in 2 patients with IE.
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Table 1.
Summary/Conclusions: In the current study, we highlight peculiar clinical and
laboratory findings of IE, in comparison with Polycythemia Vera. As shown by
available studies, Hb and HCT level do not easily discriminate between the
two categories of patients while gene panels may be useful to improve diag-
nostic accuracy of IE. We have here first observed the presence of Jak-2 46/1
haplotype in approximately half patients with IE, even in absence of JAk-2
mutations; the homozygous status was statistically different among PV and IE
patients. The role of such association deserves further specific studies.
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LABORATORY RESPONSIVENESS OF LOW-DOSE ASPIRIN IN PATIENTS
WITH ESSENTIAL THROMBOCYTHEMIA
E. Cacciola1,*, E. Gentilini Cacciola2, R. Cacciola3
1Medical and Surgical Science and Advanced Technolgies, 2Haemostasis Unit,
Catania, Italy, 3Experimental and Clinical Medicine, Haemostasis Unit, Catania,
Italy
Background: The essential thrombocythemia (ET) is a myeloid neoplasm
characterized by platelet hyperreactivity and thrombosis. The daily low-dose
aspirin (ASA) is a cornerstone in the prevention of the thrombotic events. In
the ET  an accelerated platelet turnover  translates in a renewal of the drug tar-
get shortening the duration of cyclooxygenase (COX-1) inhibition and may dic-
tate new dosing strategies particularly in ASA “low-responders” patients.
Aims: Therefore, we evaluated platelet count, β-thromboglobulin (β-TG) and
platelet factor 4 (PF4), as markers of platelet activation, the platelet function
activity (PFA), as indicator of ASA platelet sensitivity.
Methods: We studied 60 patients (20 men, 40 women; mean age 51 years,
range 32-70) with ET according to WHO criteria. The mean duration of disease
was 11 years. All patients were on ASA 100 mg once daily. Of the 60 patients,
45 were on anagrelide hydrochloride (daily dose 1.5 mg) (10 men, 35 women),
15 were on hydroxyurea (daily dose 2 mg) (10 men 5 women). None had inher-
ited or acquired thrombotic risk factors. Sixty subjects served as controls.
Platelets were measured by automated analyzer. β-TG and PF4 were deter-
mined by ELISA. ASA platelet sensitivity was measured by Platelet Function
Analyzer (PFA-100).
Results: The mean platelet count was 455±200x109/L. All patients had nor-
mal  β-TG and PF4 ((12±5 IU/ml and 4±1 IU/ml) and prolonged C/EPI closure
time (T, unit: s, n.v. 84-160 s) (249±40 s).
Summary/Conclusions: These findings suggest that in ET patients the daily
low-dose ASA represents an optimal dosing strategy and that PFA test may be
an useful tool to distinguish between  the ASA “normal-responder” and “low-
responder” ET patient.
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CLINICAL AND EXPERIMENTAL CHARACTERISTICS OF MYELOID/
LYMPHOID NEOPLASMS DISPLAYING PDGFRA OR PDGFRB
REARRANGEMENT
L. Kou1, J. Pan1, H. Qiu1,2,*, S. Chen1, D. Wu1,2
1The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, 2Institute of Blood and Marrow Transplantation,Collaborative Innovation
Center of Hematology, Soochow University, Suzhou, China
Background: According to the 2016 revision to the WHO classification of
myeloid neoplasms and acute leukemia, the cases with rearrangement of tyro-
sine kinase (TK) genes PDGFRA, PDGFRB are classified in Myeloid/lymphoid
neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or
FGFR1, or with PCM1-JAK2. It is a rare event that patients presented
rearrangements with these genes. And in the past decade, the dose of TKI to
cases with PDGFRA and B abnormal was inconclusive.
Aims: The goal of the study was to assess the clinical and experimental char-
acteristics and observe the response of Imatinib(IM) therapy of Myeloid/lym-
phoid neoplasms with PDGFRA or B abnormal.
Methods: Cytogenetic examination of bone marrow cells obtained from
patients was performed by 24h culture method. R banding technical was used
for karyotype analysis. PDGFRA and B gene rearrangement were detected by
FISH using triple-color of 4q12 and dual color break-apart PDGFRB probes.
The fusion genes of rearrangements of PDGFRA and B genes were detected
by RT-PCR. Immunophenotype analysis was carried out by flow cytometry.
Most of all cases were treated with IM and followed up.
Results: The diagnoses included 27 cases of MPN, 1 case of AML-M2 and 1
case of non-hodgkin lymphoma. 21 cases were PDGFRA rearrangement, the
other 8 were PDGFRB abnormal, 7 of 8 were EP fused gene, one of which
concurrent with DEK-CAN fused gene, and the eighth had MYO18A-PDGFRB.
7 cases of the 8 PDGFRB rearrangement had a primary abnormality with
t(5;12)(q33;p13) and the other one had a secondary abnormality of AML-M2.
PDGFRA and B genes rearrangement detected by FISH and multiple-RT-PCR
were positive. The immunophenotypical analysis showed myeloid or lymphoid.
These cases achieve rapid and durable remissions on IM.
Summary/Conclusions: In summary, patients with significantly anemia and
eosinophilia should be screened for the presence of PDGFRA and B rearrange-
ments. The dual-colour FISH is a simple approach and should be added into
the diagnostic work-up because these patients respond to imatinib therapy,
and sustained responses have been observed. The OS of PDGFRA and B
abnormal was similar with a previous report in a western population and another
Chinese hematology center.
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PLATELET AGGREGATION STUDY OF ESSENTIAL THROMBOCYTHEMIA
TREATED WITH ANAGRELIDE
Y. Hiramatsu1,*, K. Furukawa2, K. Mizuhara1, T. Sakayori3, Y. Fujiwara1,
N. Mochizuki1, S. Kubonishi1, Y. Komiyama3
1Department of Hematology and Oncology, 2Department of Pathology and
Clinical Laboratory, Japanese Red Cross Society Himeji Hospital, Himeji,
3Hemostasis Product Engineering, Sysmex Corporation, Kobe, Japan
Background: Essential thrombocythemia (ET) is a myeloproliferative neo-
plasm characterized by thrombocytosis and abnormal megakaryocyte prolifer-
ation. Patients with elevated platelet count are considered to be a high-risk
group for thromboembolic and/or hemorrhagic complications. In Japan, ana-
grelide treatment was recently approved for the 1st line as a cell reduction
therapy on ET. Even now, there are few study whether the risk of thrombosis
has decreased after anagrelide treatment. Moreover, the platelet count problem
uncertainty remains what is the best practice to follow when the platelet count
in platelet-rich plasma (PRP) exceeds about 600 x109/L, in the recent recom-
mendations for the standardization of light transmission aggregometry by the
platelet physiology subcommittee of Scientific and Standardization Committee
/International Society of Thrombosis and Hemostasis.
Aims: The aim of this study was to characterize the platelet aggregation (PA)
in patients with ET. We would also clarify whether there were any changes of
hemostatic side effect and platelet aggregability before and after treatment
with anagrelide.
Methods: This study has been conducted with blood sample obtained from
six healthy subjects, compared to 18 consecutive patients with ET. None of
the patients was taking anticoagulants or cytoreductive agents. We also studied
six anagrelide-treated patients with ET. Whole blood aggregometry (WBA) and
LTA using PRP were performed. ADP-induced PA or collagen-induced PA used
natural count PRP and platelet count adjusted PRP with platelet-poor plasma.
Data were compared in the groups using the Tukey-Kramer test. This study
was approved by the Ethical committee of our hospital. All study procedures
were performed in accordance with the Declaration of Helsinki.
Results: The result of WBA was not obtained, because the filter was obstructed
by giant platelets. In the natural PRP, even over 900x109/L, the platelet aggre-
gability was markedly increased compared with the control (ADP-induced PA:
p=0.023, collagen-induced PA: p=0.001), but, was not significantly different
(ADP-induced PA: p=0.703, collagen-induced PA: p=0.986) in the count adjust-
ed PRP. These results were not confirmed in cases with platelet counts of less
than 600x109/L. There was no decrease in platelet aggregation before and
after treatment with anagrelide (ADP-induced PA: p=0.3403, collagen-induced
PA: p=0.514).
Summary/Conclusions: In the ET patients with platelet counts more than
900x109/L, the platelet aggregation by LTA with natural count PRP was remark-
ably accelerated and this data seemed to reflect the disease state. Although
treatment with anagrelide showed cyto-reductive effect without any hemorrhagic
complication in patients with ET, it did not fully reduce platelet aggregability.
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A SINGLE CENTRE EXPERIENCE OF MASTOCYTOSIS
G. Özkan1,*, Ö. Tepe2, N. Demir1, Ö. Arslan1, S. Erdem1, Ö. Doğan2,
N. Büyükbabani2, C. Baykal3, R. Tanakol4, M. Nalçaci1, A.S. Yavuz1
1Hematology , 2Pathology, 3Dermatology, 4Endocrinology and Metabolism,
Istanbul Medical Faculty, İstanbul, Turkey
Background: Mastocytosis considered as a subcategory of myeloid neo-
plasms based on World Health Organization (WHO) 2016 classification, is
characterized by expansion and accumulation of abnormal clonal mast cells in
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one or more organs. KITD816V mutation and other KIT mutations play as driver
mutations in the pathogenesis of disease.  KITD816V mutation is positive in%80
of systemic mastocytosis patients.  Recent studies show that high allele burden
of KITD816V and high serum tryptase levels correlate with aggressive disease.
Recently the importance of CD30 expression on neoplastic mast cells has been
confirmed. CD30 is expressed aberrantly on neoplastic mast cells in patients
with advanced systemic mastocytosis.
Aims: In this study we aimed to present demographic data, clinical follow-up
and treatment of patients with mastocytosis and identify the impact of KIT
D816V allele burden and expression of CD30 by mast cells in systemic mas-
tocytosis.
Methods: We performed a retrospective study on 54 adult patients with masto-
cytosis (24 female, 30 male; mean age:44±13) who fullfilled WHO criteria between
2006 and 2016. These patients comprise cutaneous mastocytosis (CM) (n=10),
ındolent systemic mastocytosis (ISM) (n=30), smoldering systemic mastocytosis
(SSM) (n=2), aggressive systemic mastocytosis (ASM) (n=4) , systemic masto-
cytosis associated hematologic neoplasm (SM-AHN) (n=3), mast cell leukemia
(MCL) (n=4) and mast cell activation syndrome (MCAS)(n=1).
Results: At diagnosis, age of patients with advanced disease was higher than
ISM and SSM group (p=0.001). Most frequent symptom of disease was skin
lesion (urticaria pigmentosa) (%64). Skin lesions were significantly higher in
patients with ISM and SSM than with advanced diasease (p=0.009). But B
symptoms were significantly higher in advanced disease variant (p=0.013).
Anemia, trombocytopenia, elevation of ALP and GGT, hypoalbuminemia were
significantly higher in advanced disease than in ISM and in SSM. Osteopenia
was higher in patients with  ISM and SSM than with advanced disease,%56
and%18 respectively. KITD816V mutation was detectable in peripheral blood
in 33 of 40 mastocytosis patients (%82)  with a median Ct value 36±4. Median
Ct value was significantly lower in advanced SM (Ct: 32±5 ) than  in SM and
SSM (Ct: 36±4 )(p=0.028) showing a significantly higher allele burden. Expres-
sion of CD30 on mast cells in bone marrow biopsies with immunohistochemistry
investigation was detectable in 20 of 32 systemic mastocytosis patients (%62).
There was no significant difference expression of C30 on mast cell between
patients with ISM (%65) (13/20) and advanced SM (%87) (7/8) (p=0.371). There
was no significant correlation between elevated serum tryptase level and CD30
expression (p=0.114).
Summary/Conclusions: The definition of disease subcategories in systemic
mastocytosis is important for choosing the treatment modality (cytoreduction
or allogeneic stem cell transplantation vs treatment of the mediator symptoms)
for the individual patient. CD30 is a diagnostic marker and also a possible ther-
apeutic target.
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JAK2 PSEUDO-KINASE AND KINASE MUTATIONS IN THE ETIOLOGY OF
THROMBOCYTOSIS
M. Coucelo1,*, J. Azevedo1, A.L. Pinto1, A.T. Simões1, S. Marini1,
T. Magalhães Maia1, J.C. Almeida1, A.I. Espadana1, L. Ribeiro1
1Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra,
Coimbra, Portugal
Background: Thrombocytosis is defined as an abnormally increased number
of platelets (>450x109/L) in the blood counts, whose cause can be primary or
secondary, hereditary or acquired. Hereditary thrombocytosis is a rare congen-
ital disease due to germ line mutations affecting thrombopoietin signaling genes
such as THPO, MPL and, more recently, JAK2.
Aims: To describe five cases of persistent thrombocytosis in young patients
with JAK2 mutations.
Methods: Four children (2F: 2M), median age of 8,8 years and 1 young adult (F)
21 years-old, with sustained elevation of platelet counts. None had previous his-
tory of thrombo-hemorragic events. Main causes of secondary thrombocytosis
were excluded, and all patients tested negative for BCR-ABL1, JAK2V617F,
CALR and MPL mutations. Sanger sequencing of exons 12 to 20 of JAK2 was
performed in all patients. Family studies were possible in 3 families.
Results: Median CBC values: platelets- 630±90x109/L; hemoglobin - 13,3±1,2
g/dl and leukocytes- 9,3±2,3x109/L. Four different JAK2 mutations were iden-
tified in the 5 patients (Table 1): JAK2 S591L/R867Q/T875N/T875I. The patient
with the JAK2 T875N mutations had a discrete splenomegaly Familial studies
allowed the identification of JAK2 T875I mutation in 3 adults previously char-
acterized as essential thrombocythemia (ET) triple negative
Summary/Conclusions: In vitro studies performed by other authors have
demonstrated that JAK2 R867Q and JAK2 S591L, described in familial throm-
bocytosis, promote JAK-STAT activation. The germline nature of JAK2 T875N
mutation, previously described in an acute megakaryoblastic leukemia primary
cell line, was confirmed in DNA obtained from hair follicle. Two patients pre-
sented a non-described JAK2 T875I mutation. Familial studies clarified the eti-
ology of thrombocytosis in 3 adults previously diagnosed as ET triple negative.   
The identification of different JAK2 germline pseudo-kinase and kinase domains
mutations has settled the etiology of persistent thrombocytosis in 4 children
and 1 young adult. Therefore, particularly in children, after excluding the main
causes of secondary and acquired thrombocytosis, JAK2 gene sequencing
should be incorporated in the differential diagnosis of this condition. The char-
acterization of these rare forms of thrombocytosis and the follow up of these
patients across generations, will improve the understanding of this entity.
Table 1.
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COMPARISONS OF PATIENT MANAGEMENT IN MYELOPROLIFERATIVE
NEOPLASM PATIENTS IN THE UK VS REST OF WORLD: ANALYSIS FROM
THE INTERNATIONAL LANDMARK SURVEY
C. Harrison1,*, Z. Pemberton-Whiteley2, A. Mead3, S. Ali4, J. Mathias5,
C. Thomas5, M. Campbell-Drew5, G. Taylor-Stokes6, J. Waller6, A. Duces7,
B. Taylor7
1Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital, London, 2Head
of Campaigns and Advocacy, Leukaemia CARE, Worcester, 3Weatherall Insti-
tute of Molecular Medicine, University of Oxford, Oxford, 4Queens Centre, Cas-
tle Hill Hospital, Cottingham, 5MPN Voice, London, 6Adelphi Real World,
Bollington, 7Haematology Franchise, Novartis Pharmaceuticals, Camberley,
United Kingdom
Background: Patient (Pts) with myeloproliferative neoplasms (MPNs), includ-
ing myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia
(ET), experience a substantial disease burden. The international MPN LAND-
MARK survey evaluated the patient-reported impact of MPNs in pts across 6
countries and identified current treatment strategies in these pts.
Aims: To analyze differences in treatment strategies used by physicians and
pts to manage their MPN between the UK and the Rest of Surveyed World
(ROSW).
Methods: A cross-sectional survey was conducted in Australia, Canada, Ger-
many, Italy, Japan, and the UK. The Internet-based survey was administered
separately to MPN patients and treating physicians (the two samples were not
linked). Observed differences between the UK and ROSW are described in
terms of treatment patterns and patient physician communication.
Results: A total of 699 pts (UK, n=286; ROSW, n=413) and 219 physicians
(UK, n=31; ROSW, n=188) completed the survey. UK physicians were more
likely to start treatment rather than delay at diagnosis of PV or ET. A greater
proportion of ROSW physicians reported they would observe >25% of patients
at diagnosis (UK - 54% MF, 30% PV, 37% ET; ROSW – 51% MF, 48% PV, 50%
ET). No difference was observed in the most commonly received treatments
for each disease, but a greater proportion of UK patients reported receiving
treatments than ROSW. This difference was greater in PV and ET than MF. For
MF the most commonly received treatments were ruxolitinib (UK 55%, ROSW
50%), aspirin (UK 53%, ROSW 37%), hydroxyurea (HU) (UK 31%, ROSW
28%) and transfusion (UK 27%, ROSW 23%), for PV they were aspirin (UK
83%, ROSW 58%), phlebotomy (UK 76%, ROSW 67%) and HU (UK 63%,
ROSW 36%) and for ET they were aspirin (UK 94%, ROSW 52%), HU (UK
62%, 30% ROSW) and anagrelide (UK 14%, ROSW 18%). Physician reported
data on treatments prescribed demonstrated a similar pattern as a greater pro-
portion of UK physicians reported using treatments than ROSW. UK physicians
reported that their patients were more likely to ‘often’ disagree with their primary
treatment recommendation than ROSW (16% vs 7%) but despite this UK
patients were more likely to be ‘completely’ satisfied with their physicians under-
standing and support of their treatment goals (UK, 51%; ROSW 35%). Patients
rated who they thought should be the main decision maker on a scale of 1 (the
patient) to 10 (physician). UK patients were slightly more inclined to want to be
involved in treatment decisions (mean: UK, 6.25; ROSW, 7.01). UK physicians
supported this as more ‘agreed strongly’ with the statement ‘I involve my MPN
patients in treatment decisions’’ (UK, 39%; ROSW 28%).
Summary/Conclusions: In comparison with ROSW: UK physicians were more
likely to prescribe drug treatments for ET/PV. Interestingly, UK patients desired
to be more involved in treatment decisions, and this was reflected in the physi-
cian’s perspective to involve their patient in treatment decisions more. UK
patients were also more likely to disagree with their physician on primary treat-
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ment recommendations. However, this had no impact on satisfaction suggest-
ing that UK patients welcome an open discussion on treatment options with
their physician. These data highlight the importance of maximizing patient
physician communication in order to improve patient satisfaction with treatment
in the UK.
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ANALYSIS OF EMERGING MOLECULAR SIGNATURES AND ASSOCIATED
CLINICAL FEATURES IN MPN
S. H Al Shemmari1,*, R. Rajan2
1Department of Medicine, Kuwait University, 2Bone Marrow and Stem Cell
Transplant Lab, Kuwait Cancer Center, Kuwait, Kuwait
Background: Myeloproliferative neoplasms (MPNs) are a group of clonal
hematological disorders that arise from transformation of a multipotent
hematopoietic stem cell which includes polycythemia vera (PV), essential
thrombocythemia (ET) and primary myelofibrosis (PMF).Driver mutation’s con-
fer growth advantage on the cancer cell and most likely is selected in the tissue
microenvironment within which the neoplastic cells arise. Three-quarters of
these patients carry the unique JAK2V617F mutation, JAK2 exon 12 mutations
are found in 5% of patients with PV, MPL exon 10 mutations are present in
about 5% ET/PMF and CALR mutations are found in 50-70% patients with
ET/PMF.
Aims: In this study we investigated the prevalence of these so called driver
mutations in patients with MPN’s from January 2007 – January 2017 reported
in our center.
Methods: We analyzed 3000 samples with suspected MPN for JAK2V617F
mutation by ARMS-PCR and their allele burdens were reported by RQ-PCR.
We have screened a cohort of 500 patients for JAK2/MPL/CALR mutations by
a sequential molecular analysis which includes PCR, RT-PCR and fragment
analysis.
Results: JAK2V617F mutation is present in 50% of patients with MPN. Among
600 cases submitted for sequential molecular analysis identified 372 cases
with JAK2V617F mutation, 70 cases with CALR mutation, and 6 cases with
MPL mutations. Allele burden study on JAK2V617F positive patients revealed
that patients with ET has the lowest allele burden, those with PV an interme-
diate one and those with PMF showed the highest burden. Measurement of
JAK2V617F allele burden by RQ-PCR for a PMF case after allogeneic trans-
plant (ASCT) reported that allele burden of  2.9%  after 20 days of transplant
and a negative result after 60 days of transplant vs 13% before ASCT.CALR
mutation is found in ET and PMF cases that are mutually exclusive with
JAK2V617F and MPL exon 10 mutations in ET whereas 2 cases with PMF
found to be positive for JAK2V617F and CALR mutations. We found 40 cases
with a 52-bp deletion, 4 cases with a 14bp deletion and 26 cases with a 5bp
insertion. CALR variants reported in our cohort were 54% type 1 and 46% type
2 mutations. We found a tendency towards older age among type 2 carriers
compared to type 1 carriers (median age at diagnosis: 57 years versus 52
years) or compared to non-type 2 carriers (median age at diagnosis: 57 years
versus 53 years). Similarly, platelet count at diagnosis tended to be higher in
the subgroup of type 2 mutation carriers than in patients with the type 1 mutation
while hemoglobin levels and white blood cell count were lower compared to
those with non-type 2 mutation. The mutual allele burden of JAK2V617F /CALR
exon indel mutations of two PMF patients found as 10%/65% and 15%/55%
respectively. In our cohort, 10% of the patents with CALR mutation had anemia,
21% had splenomegaly, and 43% had megakaryocytes at time of diagnosis.
Compared with JAK2 V617F-positive ET and PMF, CALR-mutant ET and PMF
are clinically correlated with lower WBC, leukocyte and hemoglobin counts,
higher platelet counts, and a reduced risk of thrombosis.
Summary/Conclusions: Analysis of JAK2/MPL/CALR genes as molecular
marker’s for MPN’s, allows the diagnosis of 95% of patients with MPN.As a
novel mutation, CALR testing also has a prognostic significance and it was not
mutually exclusive with JAK2V617F mutation. Measurement of JAK2 V617F
allele burden early after transplantation is an important predictive parameter in
monitoring patients following this treatment.The knowledge of driver mutations
can provide valuable information for diagnosis and prognosis, which ultimately
can be highly useful for clinical decision making for the management of patients
with MPN.
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IMPACT OF THE TYPE OF CALR MUTATIONS ON THE CLINICAL AND
LABORATORY FEATURES OF ESSENTIAL THROMBOCYTHEMIA AND
PRIMARY MYELOFIBROSIS
E. Lisina1,*, P. Butylin1, N. Siordia1, A. Silyutina1, E. Lomaia1, A. Zaritskey1
1Federal Almazov North-West Medical Research Centre, St. Petersburg, Russ-
ian Federation
Background: In 2013, in the majority of JAK2V617F negative patients with
essential thrombocytosis (ET) and primary myelofibrosis (PMF) have been
identified mutations in the 9 exon of CALR gene. Described more than 30 dif-
ferent mutations, subdivided into two subtypes: deletions (type I) and insertions
(type II). There are data on the phenotypic effects, depending on the version
of CALR mutations. However, the prognostic significance of mutations CALR
is still insufficiently clear.
Aims: To assess the impact of the type I and type II mutations of CALR on the
clinical and laboratory features of ET and PM.
Methods: A multicenter retrospective study was carried out. Samples of periph-
eral venous blood was obtained from 149 patients with ET (n=76) and PMF
(n=73). Patients that were negative for JAK2V617F and MPL515L/K mutations
were studied for CALR mutations presence as described in original paper
(Т.Klampf, 2013). CALR Mutations were detected in 34 patients with ET (10 -
men, 24 - women) and 25 patients with PMF (13 - men, 12 - women). Statistical
data processing was carried out in the program STATISTICA for Windows 6.0.
Results: The frequency of mutations CALR was comparable in patients with
ET and PMF (44.7% and 35.6%). Mutations of type II is 2 times more common
in ET than with the TFM: 17.1% vs 9.6% (p=0.178). Mutations of type I detected
in 21 cases in ET, in 18 cases - in PMF, type II in 13 cases - in ET and 7 - in
PMF. The median of follow-up period of patients with ET with type I mutation
was 36 months (3-87), with type II - 22 months (2-90). In PMF, the median of
follow-up in the group with type I mutation was 46 months (3- 133), type II - 77
months (4-115). Hematological parameters in patients with ET showed higher
levels of WBC in patients with type I mutation (p=0.043), the level of Hb in this
variant was lower (p=0.009). In PMF levels of Hb were similar in the studied
groups. Type of mutations had no significant effect on the number of WBC in
patients with PMF. However, PLT was higher in PMF patients with type II muta-
tions of CALR (p=0.014). Spleen size in ET patients on the time of the diagnosis
date was slightly different: in type I - 106,5mm, type II - 119,6mm (p=0.076).
The type of mutation in our study had no effect on the stratification according
to the IPSET. Also there were no significant differences in assessing of the
effect of therapy. Spleen size on the time of the diagnosis date in PMF patients
with type I mutation were slightly larger (180,9mm vs 169,9mm). Revealed
more pronounced fibrotic changes of the bone marrow (BM) in patients with
type I CALR mutations (p <0,005). CALR mutation type had no influence on
the distribution of patients with PMF, depending on the risk groups on the scale
of IPSS and DIPSS.
Summary/Conclusions: The effect of the type of CALR mutation on the clinical
and laboratory features of the ET and PMF has found. Type of CALR mutations
in our study had no effect on the number of PLT in ET, but have a value for this
index in PMF. Type I mutations in ET accompanied higher WBC level and a
lower level of Hb. The published studies have not shown the influence of the
type of mutation in the Hb level and the number of WBC in ET. An important
observation was the detection of the effect of type I mutations on development
fibrotic changes of BM in PMF. Our data are consistent with previously pub-
lished studies that showed no effect on the stratification of patients according




THE UNIQUE CASE OF GERMLINE CEBPA MUTATION IN PATIENT WITH
FIP1L1/PDGFRA ASSOCIATED MYELOID/LYMPHOID NEOPLASM WITH
EOSINOPHILIA
N. Gabeeva1,*, E. Zvonkov1, E. Parovichnikova2, D. Koroleva1, O. Gavrilina2,
S. Kusnetsova3, L. Grebenuk4, T. Obukhova4, A. Kovrigina5, L. Kuzmina6,
V. Savchenko3
1Scientific and clinical department of chemotherapy for lymphomas, 2Scientific
and Clinical Department of Hemoblastosis Chemotherapy, Hemotopoietic
Depression and Bone Marrow Transplantation , 3National Research Center for
Hematology, Moscow, Russian Federation, 4cytogenetics department, 5Depart-
ment of Pathological Anatomy, 6Department of bone marrow transplantation,
National Research Center for Hematology, Moscow, Russian Federation
Background: Myeloid/lymphoid neoplasms with eosinophilia (MLNe) associ-
ated with PDGFRA rearrangement are rare disorders. The most frequent
PDGFRA abnormalities  is FIP1L1/PDGFRA (F/P) fusion gene results from a
cryptic interstitial deletion at 4q12 with constitutive activation of tyrosine kinase
(TK) activity. Although known since 2003, many questions remain in under-
standing the biology, disease course and response to therapy. The F/P fusion
gene may clinically present as chronic eosinophilic leukemia (CEL), T-cell lym-
phoblastic lymphoma (T-LBL) or both concurrently. Acute myeloid leukaemia
(AML) may also occur at presentation or during the course of the disease.
While F/P is the driver mutation, to date there are few data about genetic vari-
ants of the disease that may contribute to clinical outcome. CCAAT/enhancer
binding protein alpha (CEBPA) gene functions as key regulator of granulocytic
differentiation. CEBPA mutations contribute to leukemogenesis by promoting
proliferation and blocking differentiation of myeloid lineage in AML. Germline
CEBPA mutations  is a very rare and account  about 1% in AML only. 
Aims: We present the first case of detection of familial germinal CEBPA muta-
814 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
tion in a patient with F/P MLNe who received related allogeneic transplantation
from brother.
Methods: A 26 year-old male patient was presented with a 4-week history of
fever, fatigue, difficulty in swallowing. Physical examination revealed general-
ized lymphadenopathy, splenomegaly, tonsils enlargement, leukocytosis
(20x109/L), with marked eosinophilia (4,0x109/L). A bone marrow aspirate
showed 2% blasts, 21% eosinophils. Histological examination of an cubital
lymph node biopsy showed  diffuse proliferation of medium-sized lymphoblasts.
Immunohistochemistry and flow cytometry showed that the lymphoblastic pop-
ulation expressed CD2, CD5, CD7, CD4, CD99, TdT and CD1a. Polymerase
chain reaction (PCR) analysis from samples of the lymph node and bone mar-
row failed to detect clonal T-cell receptor rearrangement.  A diagnosis of T-cell
lymphoblastic lymphoma (T-LBL) associated with reactive eosinophilia was
rendered. The patient began standard multiagent chemotherapy in accordance
with ALL-2009 protocol (ClinicalTrials.gov Identifier: NCTO1193933) and
achieved complete clinical remission.  As he was planned to conduct autologous
hematopoietic stem cell transplantation (HSCT), blood hematopoietic stem cells
have been successfully harvested after stimulation of hematopoiesis.  However,
within 10 days after the discontinuation of G-CSF he developed leukocytosis
(130x109/L) with 21% of eosinophils (absolute number 27,3x109/L) and cubital
lymphadenopathy. Histological examination of lymph node showed T-LBL
relapse. Bone marrow biopsy revealed the expansion of predominantly
eosinophilic cells. The study was carried out to exclude second myeloprolifer-
ative disease. Molecular and cytogenetic examinations of bone marrow failed
to reveal BCR-ABL, FLT3 and NPM1, but showed CEBPA (TAD2) mutation.
FISH probe revealed deletion 4q12 (F/P rearrangement), confirmed by RT-
PCR.  The same changes were also found in the lymph node cells. So, in accor-
dance with 2008 WHO classification, he was diagnosed as «PDGFRA-associ-
ated MLNe». The patient was subsequently treated with imatinib mesylate at
the dose 100mg daily and showed a good clinical response.  After 4 months
minimal residual disease still persisted in bone marrow (RT-PCR positive for
F/P and PCR for CEBPA mutation) and he received an allogeneic HSCT from
his brother. Routine testing of chimerism at 2 months after HSCT revealed the
recipient DNA less than 5% and positive probe for F/P and CEBPA. We hypoth-
esized the germinal origin of CEBPA mutation.
Results: The same N-terminal (TAD2) CEBPA mutation was found in the
patient`s skin, lymph node and bone marrow, and in the patient’s brother bone
marrow samples. Unfortunately, no materials from parents was available for
analysis at that time.
Summary/Conclusions: Germline CEBPA mutations  is very rare event and
have been identified as causative gene mutations in familial AML.  For the first
time to our knowledge this mutation was detected in patient with PDGFRA-
associated MLNe. This observation is of particular interest because it will pro-
vide novel insight about the genetic basis and the additional events responsible
for the course of the disease.
PB2050
DEVELOPMENT AND DESIGN OF A RANDOMIZED CONTROLLED TRIAL
USING ONLINE YOGA FOR SYMPTOM MANAGEMENT IN
MYELOPROLIFERATIVE NEOPLASM PATIENTS 
J. Huberty1,*, R. Eckert1, K. Gowin2, B. Ginos2, H. Kosiorek2, A. Dueck2,
L. Larkey3, R. Mesa2
1School of Nutrition and Health Promotion, Arizona State University, 2Mayo
Clinic, 3College of Nursing and Health Innovation, Arizona State University,
Phoenix, United States
Background: Patients with myeloproliferative neoplasms (MPNs) suffer from
symptom burdens (i.e. fatigue, weight loss, night sweats, insomnia, sexual dys-
function, and pruritus) often not alleviated by JAK inhibition. We previously
demonstrated feasibility of an online, home-based yoga 12 week intervention,
in MPN patients on stable medical therapy. Specifically, online yoga was fea-
sible in MPN patients (N=38) (i.e., 68% satisfied with study, 75% felt it was
helpful for symptom management and weekly yoga participation averaged ~51
min/week) and effective to alleviate residual MPN symptom burden (effect size
[ES]=-0.36, p=0.004), anxiety (ES=-0.67, p=0.002), depression (ES=-0.41,
p=0.049), sleep (ES=-0.58, p<0.001), and fatigue (ES=-0.33, p=0.04).
Aims: To conduct a randomized controlled pilot study further investigating the
preliminary effects of online streamed yoga to improve MPN patient symptom
burden compared to a wait-list control and to determine the feasibility (i.e.,
implementation, practicality) of collecting biomarkers that are potentially related
to MPN symptoms and disease (i.e. inflammatory cytokines and cortisol) in a
national study. The study is underway with early feasibility data reported herein;
efficacy results to be reported at conference upon study completion.
Methods: MPN patients (on stable medications including JAK inhibition) were
recruited (via online MPN organizations) and randomized to a yoga group (inter-
vention - 12 weeks, 60min/week at Udaya.com) or wait-list control (usual care).
The yoga “intervention” was developed with MPN-specific concerns in mind
(i.e., enlarged spleen/liver, older adult population) and based on feedback
received from our feasibility study. Weeks 1-2 were introductory (5-6, 5-10 min
videos), with weeks 3-12 progressing in video duration and intensity (2-3, 20-
30 min videos). All participants completed weekly activity logs, symptom burden
questionnaires (MPN-SAF TSS and NIH PROMIS) at weeks 0,7,12, and 16
(follow-up), and wore a Fitbit Flex (objective activity and sleep monitor) through
week 12. The yoga group only was also asked to receive a blood draw (i.e.,
CBC, TNF-a, IL-6) and to provide saliva samples (i.e., salivary cortisol) at base-
line and will be expected to do so at post-intervention. Control group participants
are asked to maintain usual levels of activity and will have access to the same
videos as the yoga group after follow-up (week 16).
Results: A total of 260 MPN patients completed the eligibility questionnaire, of
which 96 were eligible. Of those, the first 62 eligible were enrolled into the study
(completed an informed consent). Thirty-four participants were randomized to
the intervention group and 28 to the control group. Of those enrolled (n=62), 31%
were diagnosed with PV (n=19), 37% with ET (n=23), and 32% with MF. The
mean age of participants is 57.8 years (±10.3), 87% female (n=54), 95% Cau-
casian (n=59), and the mean BMI is 26.8 kg/m2. A total of 85% (n=29/34) of yoga
group participants completed the baseline blood draw and 83% (n=15/18 eligible
for saliva samples) completed the baseline saliva sample. Of those that completed
their blood draw (distance travelled to receive blood draw ranged from 1.2 miles
– 91.6 miles, avg. 16.3 miles). To date, seven participants have dropped out of
the study due to: 1) study too time consuming/laborious (n=1), 2) Fitbit device
being too difficult to use/wear (n=1), 3) non-study personal issue (n=2), or 4)
never responding after completing the informed consent (n=2). Outcomes will be
complete by May 8, 2017 with results to be presented at EHA. 
Summary/Conclusions: Data presented here will inform next steps for a RCT
investigating the effectiveness of online yoga for symptom management in MPN
patients.
PB2051
COMPARISONS OF SYMPTOM BURDEN IN MYELOPROLIFERATIVE
NEOPLASM PATIENTS IN THE UK VS REST OF WORLD: ANALYSIS FROM
THE INTERNATIONAL LANDMARK SURVEY
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Background: Patients with myeloproliferative neoplasms (MPNs), including
myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia
(ET), experience a substantial disease burden. The international MPN LAND-
MARK survey evaluated patient-reported impact of MPNs across 6 countries.
Aims: To analyze differences in disease and symptom burden of MPN patients
between the UK and the Rest of Surveyed World (ROSW).
Methods: A cross-sectional survey was conducted in Australia, Canada, Ger-
many, Italy, Japan, and the UK. The internet-based survey was administered
separately to MPN patients and treating physicians (the two samples were not
linked). Observed differences between the UK and ROSW are described in
terms of symptom burden.
Results: A total of 699 pts (UK, n=286; ROSW, n=413) and 219 physicians
(UK, n=31; ROSW, n=188) completed the survey. UK patients reported more
symptoms than those in ROSW (9.02 vs 5.95 respectively). A higher proportion
of UK patients reported experiencing symptoms compared with ROSW (e.g.
fatigue and tiredness UK - 87% MF and PV, 86% ET; ROSW – 64% MF, 39%
PV, 45% ET). This pattern was observed for 28 of the 31 symptoms recorded.
A similar difference was seen when physicians were asked about frequency of
patient-reported symptoms (e.g. fatigue and tiredness UK – 90% MF, 67% PV,
70%; ROSW – 71% MF, 55% PV, 48% ET). Patients rated symptom severity
from 1 (not severe at all) to 10 (worst possible). The UK was higher than ROSW
for the three most common symptoms; fatigue and tiredness (mean: UK 6.73,
ROSW 6.18), difficulty sleeping (mean: UK 6.09, ROSW 5.38) and loss of con-
centration (mean: UK 6.01, ROSW 5.67).This difference was not observed
when physicians were asked to rate symptom severity. An overall symptom
burden was calculated as a function of all patient-reported symptoms. UK
patients were disproportionately represented in the high symptom burden group
(UK 35% vs ROSW 16%) and had an average overall symptom burden score
of 40.1 compared with 24.1 among ROSW patients. UK patients were also
more likely to have been classified with a high risk score at diagnosis (UK 22%
vs ROSW 9%). Despite the consistently greater symptom burden experienced
by UK patients, little difference was observed in patient satisfaction with their
physician’s communication (UK 81% satisfied vs ROSW 90%) and disease
management (UK 87%, ROSW 90%). However, UK patients were more likely
to disagree with the statement ‘My doctor understands how much my condition
impacts my life’ (UK 39% vs 22% ROSW). UK physicians had more MPN
patients under their care than ROSW (mean patients under care in last 12
months; UK - 25 MF, 46 PV, 47 ET; ROSW - 15 MF, 31 PV, 20 ET) and were
also more likely to agree with the statement ‘There is not enough time during
the appointment to discuss all of the symptoms a patient is experiencing´ (UK
74% vs ROSW 54%).
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Summary/Conclusions: UK patients perceive a higher symptom burden than
ROSW in terms of frequency and severity. While UK physicians agree with
regards to frequency, they didn’t perceive a greater symptom severity in their
patients compared to ROSW physicians. Patient/physician disconnect was
unlikely to be the cause as satisfaction was high and similar to that in ROSW.
However, UK physicians not only have more patients under their care than
their ROSW counterparts, they are also more likely to feel they don’t have
enough time to discuss all symptoms. This is likely to be impacting on the ability
of patients and physicians to communicate fully on symptoms and to agree on
the best disease management plan.
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MPN10 SCORE AND SURVIVAL OF MOLECULARLY ANNOTATED
MYELOPROLIFERATIVE NEOPLASMS PATIENTS; A FIRST REPORT ON
AN EGYPTIAN COHORT
Y. Elnahass1,*, H. Mahmoud1, M. Mattar2, O. Fahmy2, M. Abdelmoaty1,
R. Abdelfattah1, F. Elrefaey1, W. Elmetenawy2
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Background: The vast majority of myeloproliferative neoplasms (MPNs)
patients are characterized by a molecular genetic background and by variable
symptoms reflecting disease burden that may correlate with prognosis.   
Aims: To study the impact of driver gene mutations: Janus kinase 2 (JAK2),
calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL) on
disease burden and correlating mutational status with symptom severity cal-
culated by MPN10 score, degree of bone marrow (BM) fibrosis, clinical char-
acteristics and survival in MPNs patients.
Methods: MPN Symptom Assessment Form Total Symptom Score (MPN-SAF
TSS) was assessed as mean/median of 10 items: fatigue, concentration, early
satiety, inactivity, night sweats, itching, bone pains, abdominal discomfort,
weight loss and fever. JAK2V617Fand exon12 mutations were performed by
allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) while
CALRexon9 insertion/deletion and MPL W515exon10 mutations were assessed
by high-resolution melting (HRM).
Results: 93 MPNs patients (48 males and 45 females): 18 polycythemia vera
(PV), 41 essential thrombocythemia (ET), 24 primary myelofibrosis (PMF), 10
Post-ET/PV-myelofibrosis (post-ET/PV-MF) were included. Median age at diag-
nosis was 55 years (17-75) and was lower in ET than PV and PMF patients;
44 (19-75) years vs 56 (34-70) years and 56 (20-75) years, respectively
(p<0.001).  JAK2 mutation was positive 53/93 (57%); 16 (90%) PV patients,
14 (34%) ET patients, 15 (62%) PMF patients, 8(80%) post-ET/PV-MF patients
(p<0.001). CALR mutation was positive in 14/93 (15%); 10 (24%) ET patients,
4 (17%) PMF patients, zero (0%) Post-ET/PV-MF patients (p=0.050). MPL
mutation was positive in 3/93 (3%); 2 (5%) ET patients, 1(4%) PMF patients,
zero (0%) Post ET/PV-MF patients. 23/93 (25%) patients were triple negative;
15 ET, 2 PV, 4 PMF and 2 post ET-MF.  Median MPN10 score was 21 (4-45)
in ET versus 37.5 (25-56) in PV, 54 (15-80) in PMF and 59 (45-75) in Post-
ET/PV-MF (p<0.001). From 39 patients with BM fibrosis, 6 (15%) were triple
negative vs 33 (85%) mutant patients (p=0.007). Among 52 patients with
splenomegaly; 7 (13.5%) patients were triple negative vs 45 (87%) patients
with a positive mutational status (p<0.001). Median MPN10 score was 48 (5-
76) in JAK2 positive patients vs 25 (4-80) in JAK2 negative (p<0.001) and was
22.5 (4-65) in CALR mutants vs 35 (5-80) in CALR negative (p<0.050). Median
MPN10 score was 21 (10-48) in triple negative patients vs 40 (4-80) in MPNs
JAK2/CALR/MPL mutants (p<0.001).After a median follow-up period of 36
months (6.6-102), progression free survival (PFS) and overall survival (OS) of
the whole cohort was 85% and 95%, respectively. PFS of JAK2 positive vs
negative patients was 62% vs 100% (p<0.001). PFS of CALR positive vs neg-
ative patients was 100% vs 78% (p=0.067). PFS of triple negative vs mutant
patients was 100% vs 75% (p=0.004). OS of JAK2 positive vs negative patients
was 85% vs 100% (p=0.011). OS of CALR positive vs negative patients was
100% vs 92% (p=0.197). OS of triple negative vs mutant patients was 100%
vs 90% (p=0.015) (Figure 1).
Figure 1.
Summary/Conclusions: MPN10 score is directly affected by JAK2 and CALR
positivity and can be used as a major predictor of survival in MPNs patients.
Triple negative ET patients in our cohort have significantly lower MPN10 score,
show lower incidence of BM fibrosis and splenomegaly which may indicate a
more indolent disease course.
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FINAL RESULTS FROM PEN-PV STUDY, A SINGLE-ARM PHASE 3 TRIAL
ASSESSING THE EASE OF SELF-ADMINISTRATING
ROPEGINTERFERON ALFA-2B USING A PRE-FILLED PEN IN
POLYCYTHEMIA VERA PATIENTS
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Background: Interferon-alpha (IFNa) based therapies have been successfully
used in myeloproliferative neoplasms for over thirty years. A known burden for
long-term therapy applying IFNa in otherwise fit outpatients is the necessity of
frequent hospital visits for product administration. Ropeginterferon alfa-2b
(AOP2014) is a novel long-acting monopegylated IFNa allowing initially bi-
weekly and, in long-term maintenance, monthly administration. To further
improve on convenience and compliance, a pre-filled, dose-adjustable pen
was developed for patient self-administration at home.
Aims: Open-label, single arm, multicenter phase III trial assessing the self-
administration of AOP2014 using a pre-filled, dose-adjustable pen (NCT: 2014-
001356-31).
Methods: The study was performed in 18 sites in 8 European countries.
Patients were eligible who completed the AOP2014-arm in the PROUD-PV
study (12 months of treatment). A total of 7 visits was scheduled within 3 months
(two supervised self-administrations at site, followed by four self-administrations
in the home-setting, and a final assessment visit at study site).
Results: A total of 36 patients were enrolled and received the AOP2014 pen
for self-administration. The mean age was 58.5 years (range 37 to 77 years),
23/36 (63.9%) were male patients and a large proportion of patients (15/36
[41.7%]) entering the study received a baseline dose of 500 µg AOP2014.
72.2% (26/36) used 2 pens (dose >250 µg) and 27.8% of patients (10/36) used
one pen (dose up to 250 µg) to administer the appropriate dose. At the first
supervised visit, 80.6% (29/36) of patients had achieved full success, defined
as no technical problems with the pen experienced by the patient during the
injection, and no early withdrawal of the pen (before injection was complete),
both observed by the investigator. At the second supervised visit the full suc-
cess rate was 91.7% (33/36). The majority of observations resolved after the
second supervised visit. Only 5 patients (13.9%) needed one additional super-
vised visit prior using the pen correctly in a home-setting. All patients had
achieved full success at Visit P7 (supervised assessment visit at study end).
The patients responded favourably to the use of the pre-filled pen for the admin-
istration of AOP2014 and the accompanying instructions. Based on the Inves-
tigator’s assessment, no patients exhibited any visible pain or physical dis-
comfort, appeared to be dissatisfied when using the pen or exhibited any frus-
tration using the pen, nor did the patient report any pain arising from the use
of the pen. The majority of patients (32/36 patients) rated the instructions for
the AOP2014 pen (i.e. scope and structure of the leaflet, clarity and compre-
hensibility of the text, clarity of the images and design of the leaflet), and the
AOP2014 pen itself (i.e. setting the dose, user-friendliness, injection procedure)
as “very good” or “good”. The haematological parameters and spleen size
remained stable throughout the study, and the rate of responders (haemato-
logical response with and without spleen size) was maintained during the entire
study, suggesting that the use of the pen device did not affect drug activity. Of
the 47 adverse events (AE) reported during the study, 19 were related. Most
AEs were mild to moderate in intensity. One serious AE (mild atrial fibrillation,
unrelated), one pen-related AE (mild nervousness reported prior first adminis-
tration in the home setting), and one Grade 3 TEAE (pain in extremity, related)
were recorded, but none led to a dose reduction.
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Summary/Conclusions: The AOP2014 pen was well accepted and no major
difficulties were reported. The study drug performed as expected and there
were no safety concerns arising from the administration of AOP2014 using the
pen device. The AOP2014 pen allows for individual dosing and a patient-con-
venient mode of self-administration of ropeginterferon alfa-2b at home and is
expected to support adherence and compliance in the long-term treatment of
PV patients.
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JAK2, CALR AND MPL MUTATIONS: CORRELATION WITH PHENOTIPE
DISEASE AND HISTOPATHOLOGICAL FEATURES OF BONE BIOPSY
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Background: Drivers mutations JAK2, CALR and MPL are mutually exclusive
in Essentials thrombocytemia (ET) and these are included in the diagnostic cri-
teria of mieloproliferative neoplasms (MPNs). Consistent with know literature,
the molecular characterisation have implications in the phenotipe disease and
it might be interesting to study if these are associated with the histopathological
characteristics of bone marrow biopsy
Aims: The purpose of this work is analyse the correlations between clinical-
biological and histological characteristics of bone marrow biopsy and the muta-
tional status (JAK2, CALR, MPL).
Methods: The study included 76 patients with ET diagnosed according to WHO
criteria at the Haemathology Departament from Hospital de Jerez from January
2005 to December 2015. We examined the prevalence, and clinical and labo-
ratory correlations of JAK2/CALR/MPL mutations. To evaluated the histology,
one pathologist with expertise in haematopathology review the bone marrow
biopsies corresponding to 44 patients with ET. We incluyed only bone marrow
biopsies of at least 10 mm in length and/or minimun 8 inter-trabecular areas.
The pathologist only had access to age and gender data. Mutations JAK, CALR
and MPL were analysed by PCR real time and sanger sequencing.
Results: There where 55 (72%) patients JAK2, 12 (15.5%) patients CALR,
one patient MPL and 9 (11.8%) patients triple-negative (TN). The main clinical
and laboratory features of the patients are show in Table 1A. As can be seen,
a 75% of patients belonged a high risk group, 18 (23%) patients presented
thrombotic events before diagnosis and only 4 (5.3%) during the evolution.
Clinical and molecular characteristics of patients as age, sex, hemoglobin level
and stratification of risk were statistically significant. (Table 1A). Thromboem-
bolics events  seemed to be more frequent in patients with JAK2 mutation,
although statistical  significance was not achieved. The correlation between
histopathological characteristics and mutational status are shown in Table 1B.
We observed differences between the presence of laxes groups of megacary-
ocytes according with the mutational status and there were more frecuently in
patients with CALR mutation ( p= 0.01). With a median of follow up of 4 years
(ranger 0.3-11 años) a total of 6 patients had died.  Two patients evolved to
overt, one of them to acute leukaemia and the other one to myelofibrosis at 66
and 44 months from ET diagnosis respectively.
Table 1.
Summary/Conclusions: In our study  we can confirm that there are differences
between clinical and laboratory finding according with mutational status, as
shown in previus studies.  The most consistent finding of this study was the
presence of laxes groups of megacaryocytes significantly higher in those with
CALR mutations. The major limitations of this study include a small number of
patients and biopsies, available to analysed, this might be the mayor causes
for the lack of the data demostrating clinical and histologycal relevance. But
our results should not be underestimated because, to our knowledge, this is
the second study thas has investigated this relation. 
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E. Lee1,*, K. J. Lee2, H. Park2, J. Y. Chung2, M.-N. Lee3, M.H. Chang4,
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Background: JAK2 V617F is the most common genetic mutation in myelopro-
liferative neoplasms (MPN) and included in the major diagnostic criteria. Beyond
the description of existence, quantification of mutational load is proposed as a
useful information to classify subgroups of MPN and to predict prognosis.
Droplet digital PCR (ddPCR) is a novel assay which has an advantage in accu-
rate and reproducible quantitative analysis.
Aims: This study was planned to verify the correlation of ddPCR with pyrose-
quencing in diagnosis of MPN and to investigate clinical implication of the muta-
tion burden in disease course.
Methods: Between 2012 and 2016, peripheral blood or bone marrow samples
were obtained from 56 patients at diagnosis and every 3 months after enroll-
ment. Inclusion criteria were 1) older than 20 years, 2) who were newly diag-
nosed with MPN and 3) diagnosed with MPN before, not met the indication of
JAK2 inhibitor treatment yet. JAK2 V617F mutation was detected by pyrose-
quencing as diagnostic work-up. The ddPCR was performed using the same
samples with pyrosequencing to prove correlations between assays and to
establish a detection sensitivity cutoff. Clinical aspects and hematologic profiles
of enrolled patients were reviewed.
Results: The lowest value of measured JAK2 V617F allele by ddPCR except
negative samples in our study was 0.01%, which was approximately 0.07
copies/uL of mutant allele. Some discrepancies were observed from 0.0001%
to 0.01% concentration between the expected and measured values in ddPCR
detection sensitivity assay, 0.1% was determined as the cutoff. Forty-two
patients (75%) were positive for JAK2 V617F by pyrosequencing and 46
(82.1%) were positive by ddPCR. The mean mutated allele at diagnosis was
37.5%±30.08%. With ddPCR, the mean was 40.7%±31.2%. Pyrosequencing
and ddPCR were highly correlated (r=0.9712, P<0.001). JAK2 V617F burden
measured with ddPCR was significantly different by subgroups (P<0.001). In
comparison of one disorder with another, polycythemia vera (PV) had more
amount of mutant allele than essential thrombocytosis (ET) (P=0.001), however,
differences between PV-myelofibrosis (MF) and ET-MF were not statistically
significant. Follow-up samples were available in 12 patients and 8 were JAK2
V617F positive. Among them, reduction of mutant burden after treatment was
observed in 6 patients (75%). JAK2 V617F burden showed initial reduction in
a MF patient treated with JAK2 inhibitor, however, after dose reduction for tox-
icities, the JAK2 V617F mutation increment with hematologic aggravation was
discovered. Mutation burden decrease showed a tendency consistent with
hematologic improvement.Hematologic characteristics and JAK2 V617F load
at the initial diagnosis and follow-up after treatment (Table 1, Figure 1).
Table 1.
* Data from the first follow-up sample.
† Data from the next follow-up sample in the same patient.
Figure 1.
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Summary/Conclusions: Quantitative analysis of JAK2 mutation using ddPCR
was highly correlated with pyrosequencing and might reflex clinical treatment
response.
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CLINICAL IMPACT OF JAK2 AND CARLETICULIN GENE MUTATIONS ON
PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
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1UO Ematologia, University Of Palermo, Palermo, 2Oncoematologia, ASP Local
Hospital, Trapani, 3Laboratorio di genetica e oncologia molecolare., 4UO
Oncologia, University Of Palermo, Palermo, Italy
Background: JAK2 (V617F) gene mutation is found in approximately 60% of
patients with Essential Thrombocythemia (ET), while 5-10% of JAK2 (V617F)
negative ET patients carry MPL gene mutations involving codon 515. Recently,
mutations at the exon 9 of calreticulin (CALR) gene have been identified in
approximately 50% of patients with ET, unmutated for Jak2 and MPL. 
Aims: Primary aim of the current study was to analyze the prevalence of JAK2,
MPL and CALR gene mutations in patients with ET; secondary aim was to eval-
uate the impact of gene mutations on clinical features of ET at diagnosis.
Methods: A cohort of consecutive patients with a diagnosis of ET followed
between January 2013 and June 2016 were considered. JAK2 (V617F) gene
mutation was detected by PCR testing; MPL and CALR mutations were analyzed
by direct sequencing methods.  Thrombotic risk score was calculated according
to European Leukemia Net recommendations. Data were statistically analyzed.
Results: Overall, 148 patients were included: 107 (72, 30%) had JAK2 (V617F)
gene mutation (JAK2+), 12 (8, 10%) carried a mutation at exon 9 of CALR
gene (CALR+), 3 (2, 02%) carried a mutation at codon 515 of MPL gene, 26
(17.58%) patients were not mutated for JAK2, CALR and MPL genes (triple
negative).CALR+ subjects, compared to JAK2+ patients, had a younger age
at diagnosis: median 48 year (25-92) in CALR+ patients vs 72 years (18-93,
respectively. Patients with MPL mutation had a median age of 82 years while
triple negative subjects had a median age of 59 years (23-89). The mean score
for thrombotic risk was 0 in CALR+ patients and 1 in JAK2+, MPL+ and triple
negative patients. The distribution of International Prognostic Score for Essen-
tial Thrombocythemia (IPSET) categories was also statistically significantly dif-
ferent (p=0.003) for the three groups. The percentage of high-risk patients was
0 in CALR+ (0/12) group, 25, 60% (27/107) in JAK2+ group, and 18, 30%
(5/26) in the triple negative group. The IPSETt model also stratified patients
with statistically significant difference (p=0.001) among the three groups: the
percentage of high-risk patients was 16, 66 (2/12) in the CALR+ group, 82,
35% (88/107) in the JAK2+ group, and 33, 33(9/29) in triple negative group.
CALR+ patients belonged more frequently to the low /intermediate risk group
than JAK2 +patients (80% versus 17, 5%, p=0.05). The incidence of thrombotic
events at diagnosis of ET was 0 in the CALR+ group, 28,03% (30/107)  in the
JAK2+ group and 23,07% (6 /26) in the triple negative group. The median over-
all survival was not reached in any group.
Summary/Conclusions: CALR+ patients with ET are phenotypically distinct
from JAK2+and triple negative patients. We can speculate a potential protective
role of CALR mutation given the absence of thrombosis in IPSS and IPSETt
high-risk patients.
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RUXOLITINIB IN MYELOFIBROSIS: A MULTICENTRE EXPERIENCE FROM
THE EAST OF ENGLAND
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Background: Ruxolitinib, an oral Janus Kinase (JAK)1/JAK2 inhibitor, was
approved in the EU in August 2012 for treating disease-related splenomegaly
and constitutional symptoms in adults with primary myelofibrosis (PMF), post-
polycythaemia vera myelofibrosis (PPV-MF), and post-essential thrombo-
cythaemia myelofibrosis (PET-MF).
Aims: We present a retrospective multicentre analysis of MF patients treated
with ruxolitinib from August 2012 to December 2016 at 3 centres in the East of
England to assess its efficacy, safety, and tolerability in a ‘real-world’ clinical
setting.
Methods: Retrospective data collection using electronic medical records and
cancer registry data identified 49 MF patients treated with ruxolitinib at the
James Paget, Norfolk and Norwich, and Ipswich hospitals (28, 14 and 7,
respectively) over a 52-month period. Five had less than 3 months’ follow-up
and were excluded.
Results: The patient group was 61.4% male, with a median age of 71 years
(41–91). There were 16 (36.4%) patients with PMF, 13 (29.5%) with PPV-MF,
9 (20.5%) with PET-MF, and 6 (13.6%) with post-myeloproliferative disorder
(unclassified)-MF. The indication for treatment was painful splenomegaly in 20
(45.5%) patients, constitutional symptoms in 23 (52.3%), and portal hyperten-
sion in 1 (2.3%). Ruxolitinib was first-line therapy in 10 (22.7%) patients, sec-
ond-line in 24 (54.5%), and third-line or greater in 10 (22.7%). Starting doses
ranged from 5mg BD in 2 (4.6%), 10mg BD in 14 (31.8%), 15mg BD in 11
(25%) and 20mg BD in 17 (38.6%), with occasional dose reduction/interruption
primarily due to thrombocytopaenia. Fifteen (34.1%) patients were IPSS 3+,
22 (50%) IPSS 2, 6 (13.6%) IPSS 1, and 1 (2.3%) IPSS 0. Mutation analysis
was available for 32 (72.7%) patients, of which 29 (90.6%) were JAK2 V617F-
mutated, 2 (6.3%) were JAK2 V617F/exon 12-unmutated, and 1 (3.1%) was
CALR-mutated. The median duration of treatment was 16.4 months (3–45)
and median time to progression was 15.5 months (7–32). Progression-free
survival (PFS) was 65.9% and overall survival (OS) 68.2%. Seven patients
died from AML, 5 from progressive MF, and 2 from pneumonia. Multivariate
analysis showed that ‘advancing age’ and ‘excess peripheral blasts (≥1%)’
were predictive of poor outcomes (HR 1.08, 95% CI 1.01-1.16; p=0.024 and
HR 4.38, 95% CI 1.12-17.09; p=0.033, respectively). Clinical assessment of
spleen size was available for 29 (65.9%) patients and showed a reduction in
splenomegaly in 16 (55.2%), an increase in 8 (27.6%) and no change in 5
(17.2%). Weight gain occurred in 32 (72.7%) and demonstrated a strong sur-
vival advantage (HR 0.21, 95% CI 0.07-0.65; p=0.006). The most common
haematologic adverse events (AEs) were cytopaenias. Forty patients (90.9%)
had anaemia and 22 (50%) were transfusion-dependent, compared with 29
(65.9%) and 10 (22.7%) pre-treatment, respectively. Thirteen (29.5%) patients
also received an erythropoiesis-stimulating agent. Thirty-one (70.5%) patients
had thrombocytopaenia (6.8% grade 4) compared with 13 (29.5%) pre-treat-
ment. The most frequent non-haematologic AEs were minor infections, docu-
mented in 17 patients (38.6%), and included lower respiratory tract infections,
candidiasis, and HSV/VZV reactivation. One patient died from Aspergillus pneu-
monia. Twenty-nine patients (65.9%) remain on treatment.
Summary/Conclusions: Ruxolitinib was well-tolerated and effective in improv-
ing constitutional symptoms in our ‘real-world’ study population. Therapeutic
response and safety profile was similar to trial data although we observed a
higher incidence of minor haematologic AEs that were readily managed with
supportive care. Weight gain was associated with a strong survival advantage
and could prove a useful clinical marker of response. The majority of patients
remain on active treatment.
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MONITORING OF TRANSIENT MYELOPROLIFERATIVE DISORDER AND
LEUKEMIA IN DOWN’S SYNDROME : A SINGLE UNIVERSITY HOSPITAL
STUDY
J.E. Park1,*, I. Hwang1
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Background: Children with Down syndrome (DS) have a 10- to 20-fold
increased risk of developing leukemia. But some patients don’t suffer leukemia
even they have significant numbers of blast cell in their peripheral blood. These
condition called Transient myeloproliferative disoder(TMD), and it is a disease
entity unique to DS newborns and is defined as the morphologic detection of
blasts in DS less than three months of age.
Aims: This study gathered DS patients to find some difference between
leukemia and TMD, to determine prognosis and risk factors.
Methods: We collect 317 patient’s blood lab results in 433 DS patients. 102
patients has leukocytosis, and in 18 case found blast cells in their peripheral
blood.
Results: 12 patients have found blast in three months of life, 11 of them finally
diagnosed to TMD, and only 1 patient progress to Acute Myeloid
Leukemia(AML) in 98 days of his life. Other 6 patients have blast in their blood
after three months of life, and underwent chemotherapy due to hematologic
malignancy. All patients with leukemia has anemia at diagnosis, which is not
found in TMD patients(p=0.018). In 7 Leukemia patients, 3 was acute Lym-
phoblastic Leukemia(ALL), 4 was AML. All AML patients has clonal change
additional to trisomy 21 at their diagnostic point, which didn’t found at TMD
and ALL patients, even it didn’t confirm former examination.
Summary/Conclusions: DS Patient who has blast in their peripheral blood
before 3 months of life need closely follow up their Complete Blood Count and
Chromosome analysis to find whether TMD progress to leukemia.
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Background: Treatment with the Janus-activated kinase (JAK) 1 and 2 inhibitor
ruxolitinib decreases constitutional symptoms and spleen size in myelofibrosis.
However accumulating evidences suggest that the drug also exerts substantial
immunosuppressive activity. The impressive clinical activity of ruxolitinib is pre-
dominatly mediated by its profound anti-inflammatory effects modulating den-
dritic cell (DC) function resulting in impaired CD4+ and CD8+ activity. Several
studies have shown that Ruxolitinib affects different cytokines (IL1, IL6 and
TNFalfa) and other immune processes and has been linked to increased inci-
dence of opportunistic and no opportunistic infections. Herein we report our
experience at our Centre.
Aims: In our retrospective study we analysed myelofibrosis patients treated
with Ruxolitinib and cytoreductive treatment with Hydroxiurea and supportive
therapy followed in our Department from 2012 to 2016 to evaluate rate of infec-
tions developed.
Methods: We reviewed 22 patients presenting myelofibrosis (median age 72,
range 60-86)describing clinical and biological features (Table 1). Our aim was
description of documented infections identified with conventional treatment and
with Ruxolitinib. They were 11 treated with JAK inhibitors and 11 with Hydrox-
iurea taken orally, similar for age and clinical features.
Results: A total of 22 patients consecutively diagnosed were included in this
analysis. There were 15 primary and 7 secondary myelofibrosis patients.
According to the Dynamic International Prognostic Scoring System (DIPSS) 8
were low risk, 10 were intermediate risk and 4 were high. A total of 5 docu-
mented infections were identified throughtout the evaluation period, 4 were
grade 1 and one grade 2. They are various including oral herpes simplex reac-
tivation, pneumonia, recurrent viral flu syndromes, esophagitis fungal and uri-
nary infections. All of them were present in the subgroup of patients undergoing
therapy with Ruxolitinib (45%) after a medium time of 8 months from beginning
of therapy (range 3-10). No patients received any anti-infective prophylaxis.
Median total daily dose of ruxolitinib was 10 mg (range 5-20). All of this infec-
tious complications resolved after antimicrobial therapy and did not require hos-
pitalization. None of patients were treated with concomitant immunosuppressive
therapy. 3 of this patients presented renal impairment (median cratinine clear-
ance of 46 ml/min).
Table 1.
Summary/Conclusions: These data in our small series of patients suggest a
higher incidence of ruxolitinib associated infections observed in clinical practice
compared to traditional treatment. Immunosuppressive effect of Ruxolitinib is
reported and the use of this drug in the transplant setting with beneficial effects
on alloreactivity and on graft versus host disease is becoming more common.
These patients might benefit from receiving prophylactic therapy with antiviral
drugs or antibiotics or antifungal therapy or in alternative by careful monitoring.
Finally nowadays physicians and patients should be aware of potential risks of
using ruxolitinib including the risk of infections.
In summary, infections can occur in patients treated with ruxolitinib but are gen-
erally mild. Generally infections were non-life threatening and managed with
appropriate supportive care.
Special care probably should be taken for patients older (more than 75 years
old), treated with corticosteroid therapy and with renal impairment.
However larger studies are needed to confirm these observations.
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THE JAK2V617F MUTATION AND LEUKOCYTOSIS AS RISK FACTORS
FOR INCIDENCE OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH
POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA 
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Background: Polycythemia vera (PV) is a clonal, chronic, progressive myelo-
proliferative disease, caused by transformation of pluripotent hematopoietic
stem cell. It is a malignant hematological disease that leads to excessive pro-
liferation of erythroid, myeloid and megakaryocytic elements in the bone mar-
row. Essential thrombocythemia (ET) is a clonal disorder of unknown etiology
that affects multipotent hematopoietic stem cell, and it is characterized by
enhanced formation of megakaryocytes in the bone marrow and for no apparent
cause, by markedly increased platelet counts in peripheral blood. PV and ET
belong to a group of Philadelphia chromosome negative myeloproliferative neo-
plasms. Thrombotic and hemorrhagic complications are the most common
cause of morbidity and mortality in patients with PV and ET. It is thought that
the mechanisms that lead to thrombosis in MPN are the following: increased
blood cell mass, abnormal platelet function and the phenomenon of sponta-
neous aggregation. The contribution to the incidence of thrombosis: increased
level of products that are formed in the activation of platelets (thromboxane, p-
selectin); increased production of microparticles that are parts of various cell
membrane structures of platelet origin; JAK2V617F mutation. In patients with
MPN there is increased activity of the coagulation system due to the resistance
to the anticoagulant function of thrombomodulin.
Aims: The aim of this study is to monitor JAK2V617F mutations and leukocy-
toses as potential risk factors for the development of thrombotic complications
in patients with polycythemia vera and essential thrombocythemia.
Methods: During the five-year period we monitored the occurrence of throm-
botic complications in 56 patients (of both sexes, aged between 30 and 78
years), being diagnosed with PV and 22 patients (of both sexes, aged between
38 and 79 years) being diagnosed with ET. We used methods of clinical, labo-
ratory, ultrasound and CT scans. With regard to the risk factors we followed the
presence of JAK2V617F mutations and leukocytoses.
Results: Leucocyte count ranged from 5,2-27,1 x 109/L. The highest leucocyte
count was recorded in the group of patients with PV (p<0,01). JAK2V617F
mutation was also statistically more significantly present in patients with PV.
The highest percentage of thrombotic complications (arterial and venous) was
found in the group of patients with ET, which was statistically more significant
relative to PV. Thrombotic complications in those groups were more frequent
in percentage with patients diagnosed with leukocytosis, but statistical signifi-
cance was present only in the group with PV. Thrombotic complications were
in both groups more frequent in percentage with JAK2V617F positive patients,
but without statistical significance. It is believed that activated neutrophils bind
to platelets by influencing the increased expression of tissue factor activity, as
well as the activation and damage of the endothelial cells, especially with
JAK2V617F positive patients.
Summary/Conclusions: Leukocytosis and JAK2V617F may be considered
as potential risk factors for the incidence of thrombosis in patients with PV and
ET. Further follow-up of those patients, as well as a larger number of subjects
are needed.
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RISK FACTORS FOR INCIDENCE OF HEMORRHAGIC COMPLICATIONS
IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE
NEOPLASMS
E. Simonovic1,*, L. Macukanovic-Golubovic2
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Background: Myeloproliferative neoplasms (MPN) are the group of clonal,
malignant hematopoietic stem cell disorders, characterized by the proliferation
of one or more blood lines with normal or nearly normal maturing in the bone
marrow and in extramedullar hematopoietic organs. Hemorrhagic syndrome is
a complication that occurs in about a quarter of patients with PV and even 60%
of patients with ET. Bleeding may complicate the clinical course of the IMF. It
is manifested in the form of petechiae and ecchymoses, or may be life-threat-
ening as uncontrolled esophageal bleeding. Bleeding occurs due to ineffective
megakaryocytopoiesis, retention of platelets in the large spleen, qualitative
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platelet disorders, acquired deficiency of factors V and vWF, disseminated
intravascular coagulation.
Aims: The aim of this study is to monitor the count of erythrocytes, leukocytes
and platelets, as well as hemoglobin and hematocrit values as potential risk
factors for the incidence of hemorrhagic complications in patients with chronic
myeloproliferative neoplasms.
Methods: During the three-year period we monitored the occurrence of hem-
orrhagic complications in 139 patients of both sexes, aged between 30 and 87
years, being diagnosed with Ph-myeloproliferative neoplasm. Patients were
classified into the following groups: 1. Group with polycythemia vera (PV) (61);
2. Group with essential thrombocythemia (ET) (28); 3. Group with idiopathic
myelofibrosis (IMF) (25); 4. Group with unclassified myeloproliferative neoplasm
(MPNs) (25). The following possible risk factors were monitored: counts of ery-
throcytes, leukocytes and platelets, as well as hemoglobin and hematocrit val-
ues. We used methods of clinical, laboratory, endoscopy, ultrasound and CT
scans. 
Results: The highest percentage of hemorrhagic complications were in the
group of patients with ET and IMF (p<0,01), followed by the group with MPNs
(p<0,05). In all three groups, the incidence of hemorrhagic complications in
patients older than 65 years of age was higher (p<0,001). The erythrocyte
count ranged from 6,45-8,89 x 1012/, leukocyte count 1,2-27,1 x 109/L and the
platelet count ranged from 10,2 -1986,5 x 109/L. Hemoglobin values ranged
from 176-210 g/L, and hematocrit from 0.58 to 0.83 L/L. The highest erythrocyte
count, the highest hemoglobin and  hematocrit values, as well as the highest
leukocyte count was recorded in the group of patients with PV and MPNs (p
<0,001) and the lowest in the group of patients with IMF (p <0,01). Among the
group of patients with ET and MPNs there was no statistically significant differ-
ence in those parameters. In the group of patients with PV and MPNs hemor-
rhagic complications were more frequent in percentage in patients with leuko-
cytosis and erythrocytosis, but without statistical significance. The highest
platelet count was found in the group of patients with ET and MPNs (p<0,001),
and the lowest in the group of patients with IMF (p<0,01). Among the group of
patients with PV and MPNs there was no statistically significant difference with
regard to platelet count. Hemorrhagic complications were more frequent both
in patients with platelet count below 10x109/L (p<0,05) and in patients with
platelet count over 1000x109/L (p<0,01). The increase in platelet count influ-
ences the adsorption of larger von Willebrand multimers on the platelet mem-
brane, thus having an effect on their elimination from circulation and degrada-
tion.
Summary/Conclusions: The platelet count can be considered a significant
parameter for monitoring the risk of hemorrhagic complications in patients with
myeloproliferative neoplasms, particularly with ET and IMF. Deviation from the
count of leukocytes, erythrocytes, hemoglobin and hematocrit values may be
considered as a potential risk factor for bleeding in patients with myeloprolifer-
ative neoplasms, but further follow-up and a larger number of subjects are
needed. The age of the patient can also be considered as a risk factor for the
incidence of hemorrhagic syndrome in those patients. The follow-up of patients
with unclassified myeloproliferative neoplasms has been particularly important,
which showed a high prevalence of hemorrhagic complications, and with the
purpose of their further differentiation.
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Background: Polycythemia vera (PV), essential thrombocytosis (ET, and pri-
mary myelofibrosis (PMF) are Philadelphia chromosome negative myeloprolif-
erative neoplasms (MPN) characterized by the expression of an aquired acti-
vated JAK2V617F mutation. Up to date, it remains controversial how one muta-
tion can lead to expression of three different clinical MPN phenotypes. However,
several studies have shown that the JAK2V617F allele burden may correlate
with specific MPN entity.
Aims: In order to further clarify these observations, we evaluated the JAK2
mutational status and its clinical implications in 233 JAK2 V617F+patients with
different MPNs from the Republic of Macedonia.
Methods: We conducted a single center retrospective study which included
233 patients with JAK2V617F+MNP diagnosed according to WHO criteria, with
median follow up period of 4 years. Quantification of the JAK2V617F mutation
was analized with the Real Time PCR method using the Larsen protocol. Based
on the mutational load patients were divided in three groups: first with <10%
mutational load, second with 10-50% load and third with >50% mutational load.
The correation of the allele burden with various clinical parameters was done
by Mann-Whitney and student’s tests using Statgraphics 4.3 software.
Results: Our study showe that median allele burden was lowest in patients
with ET (22.8%), followe by PV patients (37.1%) and PMF pts (49.6%) (p<0.01).
A higher mutation burden (>50% vs <10%) was associated with advanced age
(67.5 vs 58,5 years and 65 vs 58 years in ET and PMF pts respectively), with
higher leucocyte count (103 /μL) (9,87 vs 8,87, 13.8 vs 12.4, and 18.99 vs 14,8
in ET, PV and PMF pts respectively), with elevated erytrocyte count (5.76 vs
4.85 and 5.59 vs 4.52 in ET and PMF pts respectively), and with higher hemo-
globin level (g/dL) and platelet count 103 /μL (15.45 vs 14.35 and 1071.5 vs
860.5 in ET patients respectively) (p<0.05 for all comaprisions)
Summary/Conclusions: Our study confirmed that higher allele burden is asso-
ciated with advanced age, polycythemic features, and increased leucocytes
and platelets counts regardless of the diagnosed MPN entity and suggests
that implementation of JAK2V617F allele burden in the diagnostic workup of
MPN pts could help for choosing the optimal treatment option in this group of
patients.
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CSF3R T618-MUTATED CHRONIC NEUTROPHILIC LEUKEMIA: A RARE
CASE SUCCESSFULLY TREATED WITH RUXOLITINIB
V. Calafiore1, M. Parisi1, V. Zammit1, E. Martino1, M. C. Pirosa1, A. Spitaleri1,
F. Stagno1, C. Conticello1,*, F. Di Raimondo1
1Division of Hematology, A.O. “Policlinico-Vittorio Emanuele”, University of
Catania, Via Citelli 6, 95124 Catania, Italy, Catania, Italy
Background: Chronic neutrophilic leukemia (CNL) is a rare BCR-ABL1–neg-
ative myeloproliferative neoplasm (MPN) with only 200 patients reported  to
date according to the WHO criteria. These cases are characterized by a high
number of mature neutrophils in peripheral blood (PB), a hypercellular bone
marrow due to neutrophilic granulocyte proliferation and hepatosplenomegaly.
None standard of care exist for CNL; most patients are palliated with hydrox-
yurea, interferons, splenic radiation or splenectomy.
In the past years CNL has been often confused with chronic myeloid leukemia
(CML), atypical CML (aCML) or chronic myelomonocytic leukemia (CMML),
however, this diagnosis has been more defined  since  the oncogenic mutations
in the granulocyte colony-stimulating 3 factor receptor (CSF3R) gene were
identified in approximately 83% of WHO-defined CNL patients.    
CSF3R T618I mutation is now considered as a highly specific molecular marker
for CNL that is sensitive to in vitro and in vivo inhibition by currently approved
protein kinase inhibitors.
Aims: here we report a case of a 76-years old man with diagnosis of chronic
neutrophilic leukemia, according to WHO criteria, successfully treated with rux-
olitinib.
Methods: On May 2015 a 76 aged male patient presented at our Institution
with fatigue, night sweats, neutrophilic leukocytosis (neutrophils 42.080/mmc,
immature granulocytes <5%), and symptomatic splenomegaly (277x127x200
mm). Marrow biopsy was hypercellular (100%) with myeloid hyperplasia, mild
myeloid dysplasia and profound erythropoietic hypoplasia; reticulin fibrosis was
minimally present. Molecular profiling demonstrated  no mutations of  JAK2 or
CALR and polymerase chain reaction (PCR) studies for t(9; 22) and BCR-ABL
fusion, was negative.
The patient was initially treated with hydroxyurea with a provisional diagnosis
of prefibrotic phase of primary myelofibrosis (PMF), but symptoms worsened
and the therapy was interrupted after 9 months for progressive anemia (Hb
9,9 gr/dl) and thrombocytopenia (82.000/mmc); meanwhile polymerase chain
reaction (PCR) studies revealed the presence of CSF3R T618I mutation, sug-
gesting diagnosis of CNL. By taking into account the activity of ruxolitinib in
overt PMF, we decided to start this drug. The initial dose was  5 mg twice daily
with a gradual increase in the dose to 20 mg twice daily when platelet count
became normal.
Results: on a follow-up of 6 months after initiation of ruxolitinib therapy, symp-
toms resolved, hemoglobin and platelet levels improved (PLT 186.000/mmc),
leukocytosis persisted (WBC 24.600/mmc), and the patient achieved a dramatic
reduction in spleen size (209x119x74 mm).
Summary/Conclusions: Current data suggest that constitutively active JAK-
STAT signaling plays a central role in the pathogenesis of BCR-ABL1 –negative
myeloproliferative neoplasms (MPNs); our experience suggests that ruxolitinib
use in CNL patients can induce partial responses by improving marrow function
(normalization of hemoglobin and platelets count), splenomegaly and symptoms.
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PERIPHERAL BLOOD CELL STUDY FROM PATIENTS WITH FOLLICULAR
LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA: WHAT SHOULD
WE EXPECT?
D. Subirá1,*, H. Guillén1, C. Fernández Maqueda2, Á. Gil1, D. de Miguel1,
N. Golbano1, F. Barriopedro1, M. Morales1, M. Diaz Morfa1, J. Arbeteta1,
A. Vázquez1, S. Herrero1
1Haematology, Hospital Universitario de Guadalajara, Guadalajara, 2Haema-
tology, Hospital Universitario Puerta de Hierro, Madrid, Spain
Background: Follicular lymphoma (FL) may evolve to diffuse large B-cell lym-
phoma (DLBCL) and interactions between neoplastic cells and immune tumour
microenvironment have been involved in this process. However, the potential
value of the peripheral blood study to identify FL patients at high risk of pro-
gression is less known.
Aims: To describe the peripheral blood findings of patients with FL and DLBCL
at diagnosis, and to investigate whether a particular lymphoid distribution could
be associated with aggressive disease.
Methods: The study (performed between September 2012 and January 2017)
included 52 patients (50% female) with a median age of 70.5 years (71% >60
years). Patients were newly diagnosed with in situ FL (n=1), Grade 1,2 FL
(n=12), Grade 3 FL (n=11), and DLBCL not otherwise specified (n=28). In situ
FL and Grade 1,2 FL were grouped as low-grade FL. Most patients with FL
(11/13 low-grade FL and 8/11 Grade 3 FL) had clinical stages III/IV. Patients
with primary or secondary immunodeficiency and those who had already
received corticosteroids or chemotherapy were excluded from this study. A
whole blood sample was studied at diagnosis of lymphoma and prior to the
start of therapy, using multicolour flow cytometry immunophenotyping and a
standard stain-lyse-wash protocol. A single monoclonal antibody panel including
reagents against CD19, CD20, CD22, kappa, lambda, CD3, CD4, CD8, CD56
and CD45 was used, and a minimum of 300,000 events were acquired on the
flow cytometer. Results were expressed as the absolute number/ml of mono-
cytes, lymphocytes, T cells, CD4, CD8 and NK cells. Polyclonal and monoclonal
B lymphocytes were also identified.
Results: No difference in the distribution by sex or age was found between
patients with FL and DLBCL. A low cell count in at least, one lymphocyte pop-
ulation was detected in 35/52 patients (67.3%); 100% of cases had a low num-
ber of polyclonal B cells (<100/ml).Comparison of low-grade FL, grade 3 FL
and DLBCL did not show any statistically significant difference regarding mono-
cytes, CD4, CD8 and total T cells. Low-grade FL and DLBCL showed the high-
est number of differences, involving lymphocytes (2571±2439 versus 1495±671,
p=0.001), NK cells (381±312 versus 204±167, p=0.03), the CD4:CD8 ratio
(1.54±0.49 versus 2.06±1.44, p=0.002), and circulating monoclonal B cells, for
both percentage (15.2±23.23 versus 1.94±5.23, p<0.001) and absolute number
(869±1758 versus 18.75±46.47, p<0.001). Grade 3 FL and DLBCL also showed
a different CD4:CD8 ratio (1.16±0.45 versus 2.06±1.44, p=0.001), with a trend
toward significance regarding CD4 T cells (413±184 versus 685±457, p=0.077).
Grade 3 FL had a lower number of polyclonal B cells as compared to DLBCL
(66±41 versus 105±102, p=0.048). The peripheral expression of monoclonal B
cells was higher in low-grade FL than in grade 3 FL, in both percentage
(15.2±23.23 versus 4.58±8.48, p=0.008) and number (869±1758 versus
43.36±69.91, p=0.002) of monoclonal B cells. The number of lymphocyte sub-
populations (≤1 versus ≥2) with low-cell counts was higher in grade 3 FL than
in low-grade FL (p=0.03).
Summary/Conclusions: The peripheral lymphocyte profile in patients with FL
and DLBCL is heterogeneous, but B-lymphopenia and CD4:CD8 ratio devia-
tions are frequent findings. Regardless of clinical stage, low-grade FL had more
circulating lymphoma cells and preserved lymphocyte populations than grade
3 FL. Further studies are warranted to confirm these exploratory findings and
determine their clinical implications.
PB2065
POTENTIALITY OF PDPK1 AS A THERAPEUTIC TARGET MOLECULE IN
MANTLE CELL LYMPHOMA
S. Maegawa1,*, S. Tatekawa1, Y. Chinen1, T. Tsukamoto1, K. Tanba1,
Y. Kimoto-Matsumura1, T. Takimoto1, Y. Mizuno1, Y. Shimura1, T. Kobayashi1,
S. Horiike1, M. Taniwaki1, J. Kuroda1
1Hematology, Kyoto prefectural university of medicine, Kyoto, Japan
Background: The deregulated activation of a Ser/Thr kinase 3-phosphoinosi-
tide-dependent protein kinase 1 (PDPK1) has been shown to promote the dis-
ease progression in various solid cancers. In hematologic malignancies, we
have recently identified that the constitutive activation of PDPK1 and its down-
stream kinase RSK2 (PDPK1/RSK2 signaling axis) plays pivotal roles in mul-
tiple myeloma (MM) pathophysiology by promoting myeloma cell survival and
proliferation (Chinen Y, Cancer Res 2014; Shimura Y, Mol Cancer Ther 2012).
Mantle cell lymphoma (MCL) is cytogenetically and molecularly characterized
by chromosomal translocation t(11;14)(q13;q32) for deregulated cyclin D1
(CCND1) overexpression, and has remained as one of hard-to-treat subtypes
of non-Hodgkin lymphomas (NHLs).
Aims: The development of novel therapeutics for MCL has been urgently need-
ed, therefore, this study investigated the potency of PDPK1 as a therapeutic
target molecule in MCL cells.
Methods: Four MCL-derived cell lines (MINO, Jeko-1, JVM-2 and Z138 cells),
three diffuse large  B-cell lymphoma (DLBCL)-derived cell lines (KPUM-MS3,
KPUM-UH1 and A3/KAW cells) and a Burkitt lymphoma (BL)-derived cell line
(Namalwa) were utilized in this study. Patient-derived biopsied specimens were
obtained with informed consent and subjected to the immunohistochemical
(IHC) staining of phospho (p-) PDPK1Ser241. Cell proliferation was assessed
by a modified MTT assay. Antibodies utilized for Western blotting was performed
for evaluating protein expression levels of PDPK1, p-PDPK1Ser241, p-
RSK2Ser227, and RSK2. BX-912, a specific inhibitor for PDPK1, was purchased
from Selleckchem (USA). RNA interference of PDPK1 was performed by trans-
fecting short hairpin RNA plasmids into MCL cell lines by means of nucleofection
(Lonza, Switzerland). This study was approved by the institutional review board
of our institute. 
Results: By means of IHC examination, our study revealed that PDPK1 was
activated through phosphorylation in tumor cells of all 7 MCL patient-derived
specimens examined, and this was also the case in all 5 DLBCLs examined
and in all 5 follicular lymphomas examined. These indicated that PDPK1 is
generally active in various types of B-cell lymphoid neoplasms. The in vitro
treatment with BX-912 for 48 hours resulted in the dose-dependent inhibition
of cell proliferation in all four MCL cell lines (IC50 0.9~2.5 mM), and this inhibitory
effect of BX-912 was more profound in MCL cell lines compared with three
DLBCL cell lines (IC50 3.7~17.0 mM) and a BL cell line (IC50 2.9 mM). In addi-
tion, the flow cytometric analysis revealed that the growth inhibition of MCL
cells by PDPK1 blockade with BX-912 was at least partly mediated through the
induction of apoptosis. As the molecular sequelae, PDPK1 blockade by BX-
912 resulted in dephosphorylation of RSK2-NTKD, while AKT activity or CCND1
expression was unaltered by BX-912 treatment in MCL cells. By gene knock-
down of PDPK1 by RNA interference using three different short hairpin RNAs,
we further validated that the reduction of PDPK1 protein caused the inactivation
of RSK2 and the growth inhibition in MCL cell lines. Finally, when combined
with various agents those are utilized for the treatment of MCL, such as dox-
orubicin, etoposide, fludaraibine, bortezomib, or ABT263, BX-192 showed addi-
tive/synergistic growth inhibitory effects in MCL cell lines.
Summary/Conclusions: Collectively, our study suggested that PDPK1/RSK2
signaling axis is the potential therapeutic target in MCL.
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THE ACQUISITION OF RESISTANCE TO BENDAMUSTINE
HYDROCHLORIDE INDUCES MULTIDRUG RESISTANCE IN A NOVEL
MANTLE CELL LYMPHOMA-DERIVED CELL LINE KPUM-YY1
T. Takimoto1,*, H. Nagoshi1, S. Maegawa1, S. Tatekawa1, T. Tsukamoto1,
Y. Chinen1, Y. Shimura1, M. Yamamoto-Sugitani1, T. Kobayashi1, T. Taki1,
S. Horiike1, M. Taniwaki1, J. Kuroda1
1Kyoto prefectural university of medicine, kyoto, Japan
Background: Bendamustine hydrochloride (BH) has been one of the most
promising genotoxic moieties for mantle cell lymphoma (MCL), however, its
mechanisms of action and the mechanisms for the acquisition of resistance to
BH have not been fully clarified.
Aims: We tried to identify the underlying mechanisms for BH resistance to
develop the strategy to overcome BH resistance.
Methods: This study was conducted in accordance with the Declaration of
Helsinki and with the approval of the Institutional Review Board. Patient’s sam-
ple was obtained along with the written informed consent. We firstly established
a novel MCL-derived cell line, KPUM-YY1, from circulating lymphoma cells of
a 77-year-old male patient with MCL. A BH-resistant subline of KPUM-YY1
(KPUM-YY1R) was established by continuous exposure to BH with gradual
escalation of its concentration from 5 μM up to 50 μM for about 8 months. Cyto-
genetic analysis was performed by double color-fluorescence in situ hybridiza-
tion and spectral karyotyping (SKY). The comparative gene expression profile
(GEP) and the ingenuity canonical signal pathway analyses between of KPUM-
YY1 and KUPM-YY1R were performed to identify the differential gene expres-
sion pattern along with the acquisition of BH resistance. Cell viability was eval-
uated by a modified MTT assay.
Results: SKY analysis revealed that both primary tumor cells and KPUM-YY1
had complex karyotype including three-way translocation t(8;14;11)
(q24;q32;q13), involving the rearrangement of cyclin D1. The growth inhibitory
IC50 to BH was 20 μM in KPUM-YY1 cells, while the cell proliferation was not
inhibited by up to 60 μM of BH in KPUM-YY1R cells. When compared with
the parental KPUM-YY1 cells, KPUM-YY1R cells showed the partial cross-
resistance against doxorubicin, mafosfamide, melphalan, and vincristine. By
GEP analyses, total of 472 genes were differentially expressed in KPUM-YY1R
compared with KPUM-YY1 cells, including 312 upregulated more than 1.5-
folds and 160 downregulated less than 0.67-folds in KPUM-YY1R cells. The
ingenuity canonical signal pathway analysis based on the GEP results sug-
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gested that KPUM-YY1R cells harbored the distinct gene expression patterns
in MDR1, a gene for p-glycoprotein (P-gp) of drug transporter molecule,
MGST1, a member of glutathione S-transferase (GST) families, and argini-
nosuccinate synthetase 1 (ASS1), a rate-limiting enzyme for arginine biosyn-
thesis. The upregulation of MDR1 (P-gp) and MGST1 were confirmed by West-
ern blot or RT-PCR analysis in KPUM-YY1R compared with KPUM-YY1. Impor-
tantly, the addition of P-gp inhibitors, such as cyclosporine A, or GST inhibitors,
such as ethacrynic acid, at least partly restored the sensitivity to BH in KPUM-
YY1R cells, indicating the functional significance of the upregulation of MDR1
and MGST1 in the development of BH resistance in MCL. In addition, BH-
resistance cells were also found to express decreased mRNA level of ASS1
which has been reported to play tumor suppressor roles and its loss has been
associated with clinical aggressiveness in various cancers.
Summary/Conclusions: This study revealed that the multiple molecular mech-
anisms overlappingly underlie the development of BH resistance, therefore,
the acquisition of BH resistance potentially leads multidrug resistance in MCL
cells. The newly developed KPUM-YY1 cells and KPUM-YY1R cells deserve
the identification of multiplex mechanisms underlying BH activity/resistance
and the future development of strategy which overcomes the treatment refrac-
toriness in MCL.
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COMPARISON OF OVERALL SURVIVAL ACCORDING TO BONE MARROW
ASPIRATION RESULTS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA
J.Y. Choi1,*, K.-W. Kang1, J.H. Kim1, D.S. Kim1, E.S. Yu1, S.R. Lee1,
H.J. Sung2, S.J. Kim2, C.W. Choi1, B.S. Kim1, Y. Park1
1Division of Hematology and Oncology, Korea University School of Medicine,
2Division of Hematology and Oncology, Samsung Medical Center, Seoul,
Korea, Republic Of
Background: Bone marrow (BM) biopsy with or without aspiration is usually
included in the staging workup for patients with non-Hodgkin’s lymphoma
(NHL). According to the National Comprehensive Cancer Network guidelines,
BM biopsy is mandatory for lymphoma, but aspiration is optional. Moreover,
the role of BM aspiration is controversial. Other studies have shown that BM
aspiration morphologically or flow cytometry is often inconsistent with biopsy
and is less likely to detect lymphoma than biopsy. There are no clear guidelines
regarding results that are positive in BM aspiration and negative in biopsy.
Aims: The aim of this study was to establish guidelines through a comparison
of the overall survival (OS) of patients with NHL using morphological method.
Methods: We performed a retrospective analysis of BM involvement in patients
with newly diagnosed NHL in the Korea University Hospital from January 1991
to December 2016. OS was compared according to the BM groups, which were
divided into three groups: the group without BM involvement in both BM aspiration
and biopsy, the group with atypical lymphocytes only in BM aspiration, and the
group with BM involvement in biopsy regardless of BM aspiration results. Atypical
lymphocytes were identified as positive in BM aspiration if they displayed cleaved
nuclei, vacuolation, and granulation including lymphoid aggregates, leukemic
presentation of mature B-cell neoplasm, and lymphoma associated hemophago-
cytic lymphohistiocytosis. Reactive changes, or relative lymphocytosis were
excluded. OS was assessed using the Kaplan-Meier method, and the log-rank
test was used for comparison between the groups. Multivariate analysis were
performed using a Cox proportional hazards model.
Results: In total, the data of 1,773 patients, of which 391 patients had indolent
NHL and 1,382 patients had aggressive NHL, were reviewed. Of the 1,773
patients, 1,148 (64.7%) yielded negative results on both BM aspiration and
biopsy, 30 (1.7%) yielded positive results with atypical lymphocytes only in BM
aspiration, and 190 (10.7%) yielded positive results on biopsy. Remaining 405
patients were excluded owing to inadequate results in BM aspiration and/or
biopsy. Median follow-up duration was 37.62 months (range, 0-288).
At the time of Kaplan-Meier survival analysis, OS was significantly worse for
patients with BM involvement in biopsy compared with those with no BM
involvement in both BM aspiration and biopsy (2-year OS, 39.0% v 60.6%; log-
rank P<0.001). However, there was no significant difference in OS between
patients with atypical lymphocytes only in BM aspiration and those with no BM
involvement in both BM aspiration and biopsy (2-year OS, 42.8% vs 60.6%;
log-rank P=0.184). Patients with atypical lymphocytes only in BM aspiration
also had no significant difference compared with those with BM involvement in
biopsy (log-rank P=0.291; Figure 1).
Multivariate analysis was performed by adjusting survival related variables
such as sex, age, lactate dehydrogenase, Ann Arbor stage, Eastern Coopera-
tive Oncology Group performance status, number of extranodal sites, lym-
phoma characteristics (indolent vs aggressive), and transplantations. The clas-
sification according to BM involvement remained a significant prognostic factor
for OS (P<0.001). However, in the subgroup analysis, the group with atypical
lymphocytes only in BM aspiration showed no significant difference compared
to the group without the BM involvement in both BM aspiration and biopsy
(Odds ratio, 1.915; 95% confidence interval, 0.940–3.903; P=0.074). Therefore,
the detection of atypical lymphocytes only in BM aspiration had no significant
difference in the OS even when the relevant factors were corrected.
Summary/Conclusions: This study suggests that the detection of morpho-
logically atypical lymphocytes only in BM aspiration, but not in biopsy, is not
significant in predicting the OS of patients with NHL. Therefore, even if atypical
lymphocytes are detected during BM aspiration in patients with NHL, it may




IN VIVO IMAGING OF LUMINESCENT DIFFUSE LARGE B-CELL
LYMPHOMA XENOGRAFTS COMBINED WITH MASS SPECTROMETRY
IMAGING IDENTIFY SPECIFIC MOLECULAR ALTERATION DURING
R-CHOP RELAPSE. 
C. Côme1,*, F. Barré2, F. Dewez2, R. Heeren2, B. Cillero Pastor2, A. Lund3,
K. Grønbæk1
1Epigenomlaboratoriet, Rigshospitalet Dept. 3733, Bartholin Instituttet, Copen-
hagen N, Denmark, 2Division of imaging mass spectrometry, M4I institute,
Maastricht, Netherlands, 3Lund Group, Biotech Research and Innovation Cen-
tre , Copenhagen N, Denmark
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common B-
cell non-Hodgkin’s lymphoma (NHL) throughout the world, comprising 30–35%
of all NHLs, with approximately 71 000 new cases and 19 000 deaths estimated
for 2014. Currently, R-CHOP, a combination of immunotherapy (Rituximab, tar-
geting the cell surface protein CD20 expressed by B cell lymphoma) and
chemotherapy (Cyclophosphamide, doxorubicin, vincristine and prednisone),
remains the most commonly used regimens for newly diagnosed advanced
DLBCLs. However, as it is a biologically aggressive disease, up to one-third of
patients will ultimately become refractory to initial therapy or relapse after treat-
ment and display poor survival outcome, underlying the urgent need for novel
therapeutic approaches based upon selective molecular targets. We are com-
bining in vivo luminescent/fluorescent DLBCL xenograft models with mass
spectrometry imaging (MSI) analysis to study the tumors characteristics during
R-CHOP treatment and relapse. The in vivo imaging approach allows us to
precisely quantify tumoral development and response to therapy, as well as to
differentiate tumoral cells from the tumoral micro-environment. On the other
hand, MSI technique provides information regarding analyte composition at an
almost cellular level. Therefore, we can identify, localize  the molecules, pro-
teins, drugs or metabolites. 2 types of analysis are performed: i) comparison
between primary untreated tumors and tumors relapsing from R-CHOP therapy.
ii) study of the therapy resistant and sensitive areas of each tumor.
Aims: Our aim is to investigate and analyze the various chemical composition
of DLBCL xenografts during tumoral development and R-CHOP treatment
relapse, in order to identify yet uncharacterized targets that could become alter-
native targets for therapy.
Methods: 10 millions cells of a U2932 lymphoma cell line were xenografted
into 60 athymic nude immuno-deficient mice . Tumoral growth was repeatedly
quantified in a non-invasive manner based on tumors’ luminescent signal using
the in vivo imaging system (IVIS) Lumina II. R-CHOP treatment was applied
to  mice after primary tumoral growth. 2 types of samples are generated: i)
untreated tumors, ii) tumors realpsing from R-CHOP
Mass spectrometry imaging is then used to analyze and compare the chemical
and biological profiles of DLBCL xenografts at these stages of tumoral growth.
Results: In vivo imaging allows us not only to precisely assess primary tumor
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development but more importantly, to monitor accurately response to R-CHOP
and relapse from this therapy. The tumors at different stages of response to R-
CHOP therapy are being analyzed and compared from lipidomics, metabolomics
and proteomics point of view. Primary analysis indicate very distinctive
metabolomics and lipidomic profiles between relapsed and non treated tumors.
Summary/Conclusions: Combining IVIS and MSI allow us for a better under-
standing of the disease and the treatment effects and the possible mechanisms
allowing tumor cells to escape therapy. We are currently investigating in more
details these different lipidomics, metabolomics or proteomics signatures
between the different stages of DLBCL response to R-CHOP treatment in order
to identify new candidates for alternative therapies.
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THE PROGNOSTIC ROLE OF INDOLEAMINE 2,3-DIOXYGENASE
EXPRESSION IN HODGKIN’S LYMPHOMA.
T. Skrypets1,*, O. Novosad1, N. Svergun2, O. Skachkova2, O. Gorbach2,
V. Sokolov3, N. Khranovska2, I. Kryachok1
1Oncohematology, 2Experimental Oncology, National Cancer Institute, 3Tho-
racic surgery, Clinical Hospital №18, Kiev, Ukraine
Background: Indoleamine 2,3-dioxygenase (IDO) is an inducible enzyme that
catalyzes the initial and rate-limiting step in tryptophan along the kynurenine
pathway. IDO is a key factor maintaining immune tolerance and expression
and it correlates with poor clinical outcome in different types of cancer and
hematological malignancies. It also plays a role in a lot of pathophysiological
processes, such as antitumor and antimicrobial defense. IDO causes immuno-
suppression in the tumor microenvironment by tryptophan breakdown.
Although, only several reviews have been made to evaluate IDO prognostic
value and its expression value in hematological malignancies. 
Aims: The aim of the study was to assess the impact of the IDO expression on
clinical outcome in patients with Hodgkin’s lymphoma (HL).
Methods: A total number of 35 patients with HL were included in the group (10
males and 25 females; median age: 17-60 years, range: 38.5 years). Early
stages (I-II) and advanced stages (III-IV) were diagnosed in 48.5% (17/35) and
51.4% (18/35) of patients, respectively. B-symptoms had 37.1% (13/35) of
patients at the time of diagnosis. Patients were treated with ABVD or BEACOPP
(14/esc) and radiation therapy. The mRNA expression level of IDO was meas-
ured in pre-treatment tumor tissue specimens from HL patients using real-time
qPCR analysis.
Results: For 35 patients with HL, the overall response rate after the first-line
therapy was 88.6% (31/35). Progression of the disease during the therapy was
observed in 11,4% of patients (4/35). Among the patients, who achieved a remis-
sion, 9 had relapses. In our study, only 20% (7/35) of HL patients were IDO-pos-
itive (IDO+), while the majority of cases in the group (80%, 28/35) were IDO-neg-
ative (IDO-). There were no significant differences in IDO expression between
histological subtypes of HL. We also did not find any association between stage
of disease and IDO expression in our study. Patients with the absence of IDO
expression tended to have a better response to the 1st line chemotherapy com-
paring to patients with positive IDO expression.  The overall response rate was
achieved in 71.4% (5/7) of IDO+ cases and in 92.9% (26/28) of IDO- cases. The
relapsed/refractory disease was more frequently found in HL cases with
IDO+compared IDO-expression (28.5% (2/7) versus 7.1% (2/28), respectively,
p<0.05). We did not register any death of patients in IDO- group, while one patient
in IDO+ group died during the follow-up period (median duration – 37 months;
range 10–65 months). ROC analysis revealed that the expression of IDO in the
tumor is an important marker which is associated with clinical outcome of HL
patients (Se=46.2%; Sp=95%; AUC=0.71, p=0.004).). The presence of IDO
expression in pre-treated HL biopsies was associated with the reduced event-
free survival (EFS) in HL patients. A 4-year EFS rate for IDO+ HL patients was
50% compared with 73% for IDO-negative HL patients (p=0.002). The prognostic
significance of IDO+ expression in clinical outcome of HL (EFS) was also con-
firmed by multivariate analysis (HR=2.9; 95%CI 0.8-10.1, p=0.006).
Summary/Conclusions: On the base of the study, our findings suggest that
IDO might be a promising marker for HL prognosis as well as represents an
attractive target for HL immunotherapy in patients with poor outcome.
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SECONDARY CHROMOSOMAL ABNORMALITIES AND THEIR IMPACT ON
TREATMENT OUTCOME IN PEDIATRIC BURKITT LEUKEMIA.
S.I. Salem1,*, H. Abdelrahman2, M. Tantawy3, S. Talaat2, R. Hamdy4
1Clinical Pathology, 2Pediatric Oncology, NCI, Cairo University and Children
Cancer Hospital Egypt-CCHE, 3Clinical Pathology, 4Research Department,
Children Cancer Hospital Egypt, 57357, Cairo, Egypt
Background: Burkitt leukemia (BL) constitutes around 13.5% of pediatric
mature B-cell non Hodgkin’s lymphoma. It is characterized by translocation
involving the MYC gene to one of the immunoglobulin genes. The clinical sig-
nificance of secondary chromosomal abnormalities associated with this char-
acteristic translocation remains unknown.
Aims: We aim to analyze the impact of secondary chromosomal abnormalities
on treatment outcome in pediatric Burkitt leukemia.
Methods: Patients with BL presenting to Children Cancer Hospital in Egypt-
57357 (CCHE) from July 2007 till end of December 2015, were reviewed for kary-
otyping, cMYC status by FISH using break apart probes, and secondary chro-
mosomal abnormalities. These results were correlated with survival analysis.
Results: Eighty-seven BL patients were diagnosed and treated during the study
period according to the FAB/LMB 96 protocol. Majority were males (77.3%)
and above 10 years of age at presentation (42%). Associated central nervous
system involvement was diagnosed in 32.9% of the patients. LDH more than 2
times the upper limit was seen in 79.5%, and 52.3% of the patients suffered
from tumor lysis syndrome at presentation. Informative karyotype for 66 patients
demonstrated translocation of the MYC and IGH genes  in 54 patients (86%)
while translocation of the IGK and IGL were found in 2 (3%) and 7 (11%),
respectively. Secondary chromosomal abnormalities were detected in 40 (60%)
patients, with 5 or more abnormalities in 4 patients, 3 chromosomal abnormal-
ities in 12 patients, and 2 chromosomal abnormalities in 20 patients. The most
common secondary chromosomal abnormality was duplication of chromosome
1q which was found in 16 patients. Other secondary chromosomal abnormalities
included structural abnormality of chromosome 14q other than MYC transloca-
tion (6 patients), chromosome 6q deletion (4 patients), chromosome 13q dele-
tion (3 patients), marker chromosome (3 patients), loss of chromosome 17p(2
patients), isochromosome 9q (2 patients), translocation of chromosome 13, tri-
somy 13 and trisomy 9 in one patients each. Relapse or tumor progression on
chemotherapy was seen in 16% of the whole group of patients. The 5 year OS
was 57.7%, while 5 year EFS was 51.6%. When comparing incidence of relapse
in relation to complex karyotype, we found that nine out of 16 (56.2%) patients
having complex karyotype experienced relapse whereas relapse occurred in
only 6 (12.5%) patients having non-complex karyotype  (p-value= 0.005)
Summary/Conclusions: The frequency of secondary chromosomal abnor-
malities in our series is in concordance with other publications with duplication
1q being the most common. followed by deletion 6q, 13q, and 17p. Complex
karyotype was significantly associated with higher incidence of relapse and
poor outcome.
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IGVH SOMATIC MUTATION PROFILE AS PATHOGENETIC SIGNATURE IN
SPLENIC MARGINAL ZONE LYMPHOMA AND SPLENIC DIFFUSE RED
PULP LYMPHOMA
H.L. Julhakyan1,*, B. Biderman1, L. Al-Radi1, I. Yakutik1, S. Korzhova1,
A. Kovrigina1, A. Sudarikov1, V. Savchenko1
1National Research Center for Hematology of the Ministry of Healthcare of the
Russian Federation, Moscow , Russian Federation
Background:
Splenic lymphomas (SLs) are rare chronic lymphoproliferative neoplasms with
a very indolent clinical course and a non-characteristic phenotype and kary-
otype. Splenic marginal zone lymphoma (SMZL), a specific type of small B-cell
lymphoma and characterized by a peculiar morphology with micronodular pat-
tern of infiltration, biphasic cytology, and the almost constant presence of mar-
ginal zone differentiation. Splenic diffuse red pulp lymphoma been introduced
as a provisional entity but differential diagnosis with other SLs is needed to be
clarified since the therapeutic approaches are distrinct.
Aims: The aim of our study to determine the immunoglobulin variable heavy
chain (IgVH) gene usage and somatic mutation patterns in a series of SMZL
and SDRP patients.
Methods: We studied 24 patients with SMZL, 40 patients with HCL and 10
patients with SDRPL. Diagnosis was based on standard WHO criteria. In all
patients, the diagnosis was based on peripheral blood and BM findings. The
baseline clinical and laboratory features as well as follow-up and outcome were
recorded for every patient. Rearranged IgVH genes were amplified essentially
in reactions that contained only one of the 5’ leader region primers for the indi-
cated 6 VH families and a 3’J primer. All PCR reactions were performed using
appropriate positive and negative controls.  The rearranged VH genes identified
for each case seemed to represent functional rearrangements because no stop
codons or crippling mutations were identified.
Results:A comparison of the VH genes to reported germline sequences  in SMZL
revealed that 6 cases used the VH3 family VH gene segments, 2 the VH4 family,
16 the VH1 family segments. The VH1 family genes V1-2 were used in 16 cases.
In 4 out of 24 cases (16.67%), IgVH genes were in germline or near germline
configuration, whereas in 20 cases (83.33%), IgVH genes were somatically mutat-
ed. We have shown no differences in clinical and laboratory characteristics,
immunophenotype, outcome or overall survival were found between the mutated
and unmutated cases of SMZL. A comparison of the VH genes to reported
germline sequences in SDRPL revealed that five cases used the VH3 family VH
gene segments and five the VH4 family, one of case with unmutaited IgVH genes.
Summary/Conclusions: Our analysis also showed the selective use of VH1
family genes in a high proportion of SMZL cases (66.67%), while VH4 and VH3
family genes were represented at a lower frequency (8.33% and 25%, respec-
tively). The present study may revealed that SMZL and SDRPL derive from dif-
ferent cellular origin and may use in differential diagnosis.
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CELL OF ORIGIN ASSIGNMENT USING IMMUNOHISTOCHEMISTRY IS
INFLUENCED BY BCL-2 EXPRESSION IN DLBCL PATIENTS TREATED
WITH CHEMO-IMMUNOTHERAPY
R. Yassin1, S. Shieban2, T. Pasha1, G. Gmati1, H. Salama3, K. Abuelgasim3,
M. Al-Zahrani1, A. Hejazi3, A. Ahmed3,4, M. Damlaj1,4,*
1Oncology, 2Pathology & Laboratory Medicine, 3King Abdulaziz Medical City,
4King Abdullah International Medical Research Center (KAIMRC), Riyadh, Sau-
di Arabia
Background: Diffuse Large B-cell Lymphoma (DLBCL) is a heterogenous dis-
ease with variable clinical and pathologic presentations. Using gene expression
profiling or Lymph2Cx assay, DLBCL can be assigned as germinal center
(GCB) or non-germinal center (Non-GCB) subtype. However such assays
remain cumbersome or unavailable for routine clinical care. Immunohistochem-
ical (IHC) algorithms, such as the one proposed by Hans et al., are easy to
use tools but demonstrated variable concordance to gene expression profiling.
Importantly, cell of origin (COO) assignment appears to influence overall sur-
vival (OS) but not progression free survival (PFS).  Furthermore, antiapoptotic
BCL-2 oncogene expression confers prognostic significance in GCB DLBCL
but its significance in Non-GCB is unknown. 
Aims: To examine the prognostic impact of cell of origin (COO) assignment in
conjunction with BCL-2 expression in a cohort of DLBCL patients.
Methods: After due IRB approval, adult patients diagnosed with DLBCL and
treated at our institution between 2010 – 2015 were identified. Clinical and
pathologic variables were retrospectively abstracted. IHC expression was
deemed positive if >30% of staining was observed. Cell of origin analysis was
determined by the Hans criteria. All patients were treated with combinational
chemotherapy containing rituximb. Patients who died prior to receiving therapy
were excluded. Categorical and continuous variables were compared using
Chi-squared and Wilcoxon tests, respectively. Time to end point analysis was
computed using the method of Kaplan and Meier with log ranks. Relapse, pro-
gression or death was considered an event for PFS estimation. Analysis was
computed using JMP software, version 11.  
Results: A total of 122 patients were identified and analyzed. Median follow
up of the cohort was 21.8 (1.47 – 107) months, during which OS was 73.5%
and PFS was 59.9%. Stratified by IPI, 2-year OS was 85%, 76.3%, 72% and
49.5% for low, low-intermediate, high-intermediate and high risk patients,
respectively (p=0.006). After stratifying patients to GCB and Non-GCB, base-
line characteristics between the strata with regards to gender, age, stage,
extranodal disease, lactate dehydrogenase (LDH), International Prognostic
Index (IPI) and BCL-2 expression were not significantly different.
At 2-years, PFS was significantly higher for GCB vs Non-GCB at 72.5% vs
48.6%, respectively (p=0.008) but OS was similar at 77.6% vs 69.9% (p=0.2)
(Figure 1). Interestingly, BCL-2 expression predicted OS irrespective of COO
assignment. Patients with BCL-2 expression had a 2-year OS of 55.6% vs
56.2% for GCB and non-GCB, respectively. Whereas, patients without BCL-2
expression has a superior 2-year OS at 79.9% vs 78.3% for GCB and non-
GCB, respectively (p=0.02).
Figure 1.
Summary/Conclusions: COO assignment using IHC demonstrated superior
PFS for GCB over non-GCB however this was mitigated by BCL-2 expres-
sion. This raises questions regarding the currently presumed pathogenesis
of the different subtypes and how to utilize the currently available targeted
therapies including BCL-2 inhibitors. These observations warrant further
study. 
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ARE DIFFERENCES BETWEEN PEDIATRIC EBV-ASSOCIATED
LYMPHOMAS AND CARRIERS REGARDING LATENCY PROFILE AND
MICROENVIRONMENT COMPOSITION INVOLVED IN
LYMPHOMAGENESIS?
A. Vistarop1, M. Cohen1, O. Jimenez1, F. Huaman 2, E. De Matteo3,
M.V. Preciado1, P. Chabay1,*
1Molecular Biology Laboratory, Pathology Division, Ricardo Gutierrez Children
Hospital, 2Histopathological Laboratory, National Academy of Sciences,
3Pathology Division , Ricardo Gutierrez Children Hospital, Buenos Aires,
Argentina
Background: Epstein–Barr virus (EBV) infects more than 90% of the popula-
tion worldwide. The virus has evolved to persist life-long in B-lymphocytes of
infected individuals, but disruption of this tightly regulated B-cell infection could
result in EBV-associated B cell lymphomas. In Argentina, primary infection is
mostly subclinical and 90% of patients are seropositive by 3 years old. However,
EBV presence is statistically associated with Hodgkin lymphoma (HL) and Dif-
fuse Large B cell lymphoma (DLBCL) in patients younger than 10 years, sug-
gesting a relationship between low age of EBV infection and B-cell lymphoma
development in children from Argentina.
Aims: Given that viral latent proteins and microenvironment composition play
a key role in tumor pathogenesis or control of viral infection, our aim was to
compare this scenario in pediatric EBV-associated lymphomas derived from
the germinal center (GC) and post-GC with the same areas in tonsils from
pediatric EBV carriers, to investigate whether an alteration of microenvironment
could be related to lymphomagenesis 
Methods: Formalin fixed paraffin embedded (FFPE) pediatric biopsy samples
from 26 DLBCL, 55 HL and 41 tonsils from EBV carriers were analyzed.
Immunohistochemistry for LMP1, EBNA2, CD4, CD8, Foxp3 and GrB was per-
formed, together with EBERs in situ hybridization, and positive cells were count-
ed in the EBV+ milieu. 
Results: Latency II pattern (LMP1+ EBNA2-) was predominant in HL (100%),
DLBCL (55%), as well as in EBV+ CG in pediatric carriers (90%). CD4+ cell
count displayed no differences between EBV+ and EBV- HL or DLBCL (p>0.05,
Mann Whitney test), whereas statistically higher CD4+ cells were counted at
the EBV+ GC in pediatric carriers (p=0.014, Mann Whitney test). On the other
hand, CD8+ cells did not exhibit statistical differences neither in EBV-associated
lymphomas nor in benign conditions at the CG, and the same was observed
for Foxp3 regulatory cells (p>0.05, Mann Whitney test). In contrast, CD8+ cell
count were statistically higher exclusively at EBV+ subepithelial region in ton-
sils, compared to EBV- counterpart (p=0.0039, Mann Whitney test). Finally,
cytotoxic activity evaluated by GrB expression displayed a trend to higher mean
in EBV+ DLBCL (p=0.057, Mann Whitney test) but no in HL. Concerning EBV,
pediatric carriers did not shown differences in cytotoxic activity according to
EBV presence at the CG (p>0.05, Mann Whitney test). In fact, GrB cytotoxic
activity was prevalent only at the EBV+ subepithelial region (p= 0.0420, Mann
Whitney test). 
Summary/Conclusions: Latency II pattern prevails in both pediatric EBV-
associated lymphomas and in EBV+ GC from carriers, indicating that
LMP1expression may collaborate in the lymphomagenesis process at the GC
in pediatric patients from our country. Cytotoxic activity against EBV infection
may be only relevant in pediatric DLBCL, and in EBV+ subepithelial regions in
pediatric carriers, whereas in EBV+ HL is not increased, in contrast to previ-
ously described. CD4+T helper cell response plays a key role at the GC region
in EBV carriers, by participating directly as effectors cells, by helping to the
overall immune response in the control of viral infection and restrict latency
expression to type II pattern, and, ultimately, by limiting the cell outgrowth. Fail-
ure in this process may trigger malignant transformation in EBV-associated
lymphomas. 
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MICROARRAY EXPRESSION PROFILE OF LONG NONCODING RNAS IN
GERMINAL CENTER-LIKE DIFFUSE LARGE B-CELL LYMPHOMA
H. Gao1,*, Z. Gong1,2, W. Yang1
1Hematology, Shengjing hospital of China Medical University, Shenyang, China,
2Hematopathology, The University of Texas, MD Anderson Cancer Center,
Houston, United States
Background: Long noncoding RNAs (lncRNAs) are constantly transcribed
and involved in a variety of biological activities. The contributions of lncRNAs
to the development of germinal center (GCB)-like diffuse large B-cell lymphoma
(DLBCL) remain largely unknown.
Aims: The aim of this study was to investigate the expression profile of lncR-
NAs in human GCB DLBCL cell lines (OCI-ly1 and OCI-ly19) and normal B
lymphocytes by microarray.
Methods: We used Arraystar Human LncRNA Microarray V3.0 for profiling of
lncRNAs in our specimens.Sample labeling and array hybridization were per-
formed according to the Agilent One-Color Microarray-Based Gene Expression
Analysis protocol (Agilent Technology) with minor modifications. Quantitative
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real-time polymerase chain reaction (qRT-PCR) was used to confirm the results
of six upregulated and two downregulated lncRNAs. Bioinformatic analysis
(gene ontology analysis, pathway analysis and network analysis) was per-
formed to predict the biological functions and potential mechanisms of the dif-
ferentially expressed lncRNAs in GCB DLBCL.
Results: We demonstrated that 21,539 lncRNAs were expressed in all samples
analyzed, of which 1,648 lncRNAs were upregulated and 2,671 lncRNAs were
downregulated in GCB DLBCL cell lines (OCI-ly1 and OCI-ly19) (≥2.0-fold,
P<0.05). Pathway analysis indicated that 64 pathways corresponded to upreg-
ulated transcripts, and 62 pathways corresponded to downregulated transcripts
(P<0.05). In addition, a lncRNA-mRNA co-expression network was constructed
to identify potential target genes related to the 3 upregulated and 2 downregu-
lated lncRNAs. 
Summary/Conclusions: Our data suggested that lncRNAs may play an impor-
tant role in the pathogenesis of GCB DLBCL, and profile of lncRNAs may be
used as a potential biomarker in the diagnosis of DLBCL and predicting its clin-
ical outcome.
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FLOW CYTOMETRY IN EVALUATION OF EXTRANODAL LYMPHOMA
PRESENTING AT UNUSUAL LOCATIONS COMPARED TO NODAL
LYMPHOMAS
P. Prakhar1,*, M. Choudhury2, S. Sharma2
1Pathology, Lady Hardinge Medical College, New Delhi, India, 2Pathology, Lady
Hardinge Medical College , New Delhi, India
Background: :   Immunophenotyping is a fundamental step in the diagnosis of
hematolymphoid neoplasms. Lymphomas arising at extranodal sites can pres-
ent significant diagnostic challenges due to their morphological diversity. In
recent years flow cytometry (FCM) has proven useful in the evaluation of nodal
and extranodal lymphoproliferative disorders on samples obtained by surgical
specimens or fine needle aspiration cytology (FNAC). For years FNAC has
been used for initial evaluation of suspected hematolymphoid neoplasms. Flow
cytometry can additionally help in identifying B or T cell nature of neoplastic
cells, clonality in case of B-cell neoplasms and any aberrant phenotype. The
possibility of detecting CD20 status can help in initiating targeted therapy with-
out undergoing tissue biopsy to do so. FNA cytology with Flow cytometry can
serve as a replacement for open biopsy and may help in eliminating the need
for more invasive procedures. In this study FCM analysis on cytological spec-
imens, including nodal and extranodal mass from GIT, Thyroid, Kidney, Breast,
Tonsil, cerebrospinal fluid and ascitic fluid, was performed.
Aims: The aim of our study was to evaluate the efficacy of flow cytometer for
the evaluation of extranodal and nodal lymphomas on 40 patients. 
Methods: The currant study was prospectively conducted on 40 patients with
a clinical suspicion of hematolymphoid neoplasms. Samples for flowcytometric
immunophenotyping (FCI) were obtained by fine needle aspiration (FNA) or by
tissue scraping along with samples for cytomorphological, histological and
immunohistochemical (IHC) evaluation. Samples collected in Isotone were sub-
mitted for FCI on 5-color Beckman Coulter FC-500, using a set of mature and
immature antigens markers for lymphoid cells. Results of FCI on cytological
specimens along with cytological findings were compared with histological and
IHC diagnosis. 
Results: Flowcytometric immunophenotyping conducted on extranodal sites
included total 10/40 (25%) cases out of which most common site was GIT (4
cases) followed by CNS (3 cases), Kidney (1 case), Thyroid (1 case), Breast
(1 case), and Tonsil (1 case).   Definite diagnosis using only FCI could be
obtained in 25/40 (62.5%) cases in which 6/10 (60%) cases was conducted
on exranodal and 19/30 (63%) cases on nodal tissue samples. The remaining
15 cases which could not be categorized by FCI included Hodgkin lymphoma
(6 cases), inadequate cellularity (5 cases), Tuberculosis (2 cases), ALCL (1
case), Mantle cell lymphmoma (1 case) and Ewing’s/PNET (1 case). Com-
bining FCI with cytological findings definite diagnosis could be found in 33/40
(82%) cases, compared to 38/40 (95%) cases by histological and IHC exam-
ination. As per World Health Organization (WHO) classification of tumors of
the hematopoietic and lymphoid tissues 2008 most common lymphoma at
extranodal site was DLBCL followed by acute lymphoblastic leulemia/lym-
phoma. Whereas at nodal site most common lymphoma was DLBCL followed
by Hodgkin’s lymphoma. The estimated diagnostic sensitivity of FCI alone
was 60.5% with 50% specificity, similar for both extranodal and nodal tissue
samples. Whereas after combing FCI with cytological findings sensitivity and
specificity was found to be 78.4% and 100% respectively. Immunophenotyp-
ing of lymphoblastic leukemia/lymphoma by FCM on cytological specimens
was found to be in 100% concordance with FCI on peripheral blood/bone
marrow aspirates. 
Summary/Conclusions: Flowcytometric immunophenotyping along with fine
needle aspiration cytology offer a rapid, simple and minimally invasive proce-
dure for the detection of hematolymphoid neoplastic cells in solid tissue espe-
cially at extranodal sites. Flow cytometry alone may not consistently provides
a definite diagnosis of lymphoma subtypes but can be very helpful in diagnosing
extranodal lymphoma and nodal lymphoblastic leukemia/lymphoma.
KEYWORDS: Flow cytometry, extranodal lymphoma
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POSSIBLE ROLE OF FLOW CYTOMETRY TO CHARACTERIZE
INFILTRATING CD4 CELLS IN THE MICRO ENVIRONMENT OF LYMPHOMA
TISSUE SAMPLES
R. Di Gaetano1,*, D. Belvini1, B. Callegari1, M.A. De Benedetto1, E. Pilotto1,
R. Sartori1, L. Vassallo2, A. Scapinello2, T. Giuseppe1
1Haematology Castelfranco Veneto, 2Pathology Castelfranco Veneto, Azienda
ULSS 2 Marca Trevigiana, Castelfranco Veneto (TV), Italy
Background: In our previous work ( Di Gaetano et al, Ann Haematol, 2014 )
we analyzed by flow cytometry (FC) the rich infiltrated characterizing the
microenvironment of Hodgkin lymphoma (HL), mainly comprised of CD4 T lym-
phocytes . We confirmed that the majority of these CD4 T expressing the acti-
vation markers (CD38) but lose the CD26 and we suggested to identify the
subset CD4+CD26-CD38+ to identify the non-neoplastic cellular pattern in HL.
A subset connectable to regulatory T (Treg)  cells, because  the low expression
of CD26 ( DPP4) added to the presence of CD39 (NTPDase ) may be respon-
sible for the generation of adenosine, which plays a major role in Treg-mediated
immunosuppression
Aims: We wanted to test if this subset may also characterize T infiltrating lym-
phocytes the lymph nodes of Non-Hodgkin’s lymphomas (NHL) and to verify
the expressions of the two enzymatic markers (CD26 and CD39) in microenvi-
ronments of  HL and NHL  analyzed by FC
Methods: In 2016 we analyze by FC in lymph nodes of 6 HL and in 32 NHL (
12 DLBCL, 10 FL, 5 SLL, 3 MZL, 2 MCL ) the CD4 T subset testing the expres-
sion of CD26, CD38, CD39. 
Results: In CD4 T HL, CD39 is expressed in 44% of the subset and the
increased presence (50%) of CD4+CD26-CD38+ cells is confirmed. Compared
with HL, the cells of DLBCL are not statistically ( t Student test ) different: CD38
( 64 vs 55; p=0,39), CD26-CD38+ ( 50 vs 46; p=0,66 ), CD39 ( 44 vs 59; p=0,15
). While  HL and FL cells are significantly different: CD38 ( 64 vs 23; p <0,05 ),
CD26-CD38+ ( 50 vs 18; p <0,05 ), CD39 ( 44 vs 23; p <0,05 ). The other three
types of NHL, few in number, show a tendency to a significant difference com-
pared with DLBCL.
Summary/Conclusions: The our data show the phenotipic variations in the
microenvironements of different types of lymphoma emphasizing of DLBCL the
similarity  with HL and the difference with FL and other NHL.They also suggest
a link between a activated environment (CD38+) and a high CD39, which, in
addition to a low CD26, could enhance the generation of adenosine and, there-
fore, an increased immune suppressive activity. The profile by FC of CD4 T
infiltrating can characterize lymphomas in its environment indicating also signals
and biological mechanisms representative of possible therapeutic target
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TREG CD4 PHENOTYPE IN THE PERIPHERAL BLOOD OF LYMPHOMAS
R. Di Gaetano1,*, D. Belvini1, E. Pilotto1, B. Callegari1, M.A. De Benedetto1,
R. Sartori1, G. Tagariello1
1Haematology Castelfranco Veneto, Azienda ULSS 2 Marca Trevigiana, Castel-
franco Veneto (TV), Italy
Background: The T regulatory (Treg) cells down-regulate antitumor responses
by several distinct mechanisms. One is the adenosinergic pathway which,
through ectonucleotidases, sequentially converts ATP to AMP and generates
immunosuppressive adenosine. Several studies have demonstrated in humans
the  overexpression of CD39 (NTPDase) and low  adenosine deaminase (ADA)
levels, the enzyme responsible for adenosine breakdown, and of CD26, a sur-
face-bound ADA associated glycoprotein. In our previous work (Di Gaetano et
al, Ann Haematol, 2014) we analysed by flow cytometry (FC) the  T CD4 lym-
phocytes of solid biopsies, the surrounding neoplastic cells in Hodgkin lym-
phoma (HL)  lymph nodes (LN) and we demonstrated the presence of  an acti-
vated profile (CD38+) with a reduction of CD26 (CD4+CD26-CD38+). We also
confirmed a link of this subset with an overexpression  of CD39.
Aims: By using the same FC technique we wanted to explore if, as in the lymph
nodes,   CD4+CD26-CD38+ subset and  high levels of CD39  might characterize
the peripheral blood (PB) of HL at diagnosis  and possibly to distinguish them
from those of B Non-Hodgkin lymphomas (B-NHL).
Methods: We have analysed by FC the PB of 16 healthy controls (HC), 10 HL
and 22 NHL testing within T CD4 cells the expression of CD26, CD38 and
CD39.
Results: In HC CD26-CD38+ cells were 2.6% of all T CD4 and 5.5% expressed
CD39. Compared with HC, the subset CD4+CD26-CD38+ of HL was statistically
different (2.6 vs 17; p <0.05) as well as in B-NHL  (2.6 vs 12.9; p <0.05). The
expression of CD39 between HC and HL was not different (5 vs 9.8; p=0.1),
while it was statistically significant  between HC and NHL (5 vs 19.5; p <0.05).
Summary/Conclusions: Our results may suggest that T CD4 profile in the PB
can characterize the patients with HL and B-NHL and this  could be probably
variable according to the type of neoplasm. The significant presence of
CD4+CD26-CD38+ subset in PB of HL and B-NHL would seem to suggest that
the low expression/reduction of CD26 of ADA activity may indicate the Treg-
mediated immunosuppression. Interesting is the diversity of NHL showing
increased CD39 expression on T CD4 lymphocytes probably connected with
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the clone of B lymphocytes involved in cancer. This may support that leukemic
cells may contribute to create and to characterize an immune-subversive envi-
ronment and to facilitate  immune escape mechanisms.  FC analysis of CD26
and CD39, markers likely connected with the adenosinergic pathway, in PB
can represent effective parameters to determine and characterize the Treg
CD4  in different types of lymphoma and could serve as targets in the follow-
up of HL and B-NHL.
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BCL-2 AND KI-67 AS INDEPENDENT PREDICTORS OF POOR-RISK IPI
GROUP OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
E. Suljovic Hadzimesic1,*, S. Radovic2, A. Sofo-Hafizovic1, N. Obralic3,
N. Bilalovic4, A. Kozaric4, A. Dizdarevic1, S. Kurtovic1, V. Bijedic3,
M. Skuric-Tomic3
1High Dose Therapy Department, Clinical Center University of Sarajevo, Hema-
tology Clinic, 2Institute of Pathology, Medical Faculty University of Sarajevo,
3Clinical Center University of Sarajevo, Hematology Clinic, 4Clinical Center
University of Sarajevo, Pathology, Citology and Human Genetics Department,
Sarajevo, Bosnia and Herzegovina
Background: Diffuse large B cell lymphoma (DLBCL) is heterogeneous dis-
ease ina terms of clinical behaviour, morphology, phenotype and genetics.
Gene expression profiling has made a distinction between two entities germinal
center B-phenotype (GCB), activated B-center phenotype (ABC). Use of
immunohistochemical algorithms for identification of these phenotypes has
been translated into clinically feasible approach defining groups as GCB, non-
GCB. These algorithms do not provide completely accurate prognostic infor-
mation so the International Prognostic Index (IPI) which identifies poor- and
good-risk patients with diffuse large B cell lymphoma (DLBCL) is still part of all
current diagnostic guidelines; however, the majority of patients have an inter-
mediate IPI, with an uncertain prognosis.
Aims: In this study, we investigated the impact of  bcl-2, bcl-6, CD10, MUM1
and Ki-67 on IPI as well as impact of GCB and non-GCB subclassification
according to Hans and Muris algorithm on IPI risk stratification.
Methods: We have analyzed 50 patients with DLBCL for the expression of
bcl-2, bcl-6, CD10, MUM1 and Ki-67 Patients were divided into two groups,
the non-GCB, GCB group or favorable group 1 and unfavorable group 2,
according to Hans’s algorithm and Muris’s algorithm. Clinical-pathological, bio-
chemical parameters of disease have been correlated with subgroups of DLB-
CL and biomarkers individually. The impact of the expression of bcl-2, bcl-6,
CD10, MUM1 and Ki67 on IPI-highest score in multiple regression analysis,
afterwards in regression equation and variance analyse.
Results: Group with GCB phenotype (defined by expression of bcl-2, bcl-6,
CD10 and MUM1) according to Hans’s and Muris’s algorithm showed positive
correlation with good-risk patients identified by IPI. Multiple regressional analy-
sis proved impact of biomarkers on IPI. Following this analysis, bcl2 i Ki67 are
independent predictors of poor-risk IPI group of patients, (bcl-2: p 0,0107, Ki67:
p 0,0377). The value of F-ratio 2,9845 proves that there is a linear connection
between models including all variables bcl-2, bcl-6, CD10,MUM1 and variable
depended on the  value (IPI)(p 0,0210). The mutual impact of bcl-2, bcl-6,
MUM1, Ki67 is significantly related to poor-risk IPI patients.
Summary/Conclusions: Multiple regressional analysis proved impact of bio-
markers on IPI. Ki67 and bcl-2 are independent predictors of poor-risk IPI group
of patients. Sequential addition of bcl-2 expression, Ki67 and GCB phenotype
into the IPI significantly improves risk stratification in DLBCL. These finding
can be part of treatment strategies that should be considered in future trials.
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COMPARATIVE PATHOLOGIC ANALYSIS OF MEDIASTINAL B-CELL
LYMPHOMAS: EXPRESSION OF P63 BEST DIFFERENTIATES PRIMARY
MEDIASTINAL LARGE B-CELL LYMPHOMA FROM CLASSICAL HODGKIN
LYMPHOMA
H.-J. Kim1, G. Park2, S.K. Min3, H.K. Kim4, J.H. Han5, H.J. Cha6, H. Lee7,
S. J. Choi8, J.E. Kim9,*
1Pathology, Sanggye Paik Hospital, Inje University college of medicine, 2Pathol-
ogy, Seoul St. Mary’s Hospital, The Catholic University, Seoul, 3Pathology, Hal-
lym University Sacred Heart Hospital, Anyang, 4Pathology, Soonchunhyang
University Hospital, Pucheon, 5Pathology, Ajou University School of Medicine,
Suwon, 6Pathology, Ulsan University Hospital, Ulsan, 7Pathology, Eulji Univer-
sity Hospital, Seoul, 8Pathology, Inha University Hospital, Incheon, 9pathology,
Seoul National University Boramae Hospital, Seoul, Korea, Republic Of
Background: Mature B-cell lymphomas of the mediastinum include primary
mediastinal large B-cell Lymphoma (PMLBCL), classic Hodgkin Lymphoma
(CHL), B-cell lymphoma unclassifiable, with features intermediate between dif-
fuse large B-cell lymphoma and CHL (gray zone Lymphoma) and others. PML-
BCL and mediastinal CHL, mostly nodular sclerosis (NS) share many clinico-
pathologic characteristics, however, therapeutic options and responses are
quite different. 
Aims: We aimed to find distinctive histolologic or immunohistochemical findings
to better differentiate PMLBCL and CHL of the mediastinum.
Methods: A total of 32 cases of mediastinal B-cell lymphomas consisting of
PMLBCL (N=16), CHL (N=13), and gray zone lymphoma (N=3) were collected
from 6 university hospitals from Korea. Immunohistochemistry (IHC) for various
cell lineage markers and EBV in situ hybridization were performed to confirm
the diagnosis, and additionally, expression of P63, GATA3 and cyclinE was
investigated. 
Results: Most clinical features were overlapped between PMLBCL and CHL
except more frequent disease progression and mortality in PMLBCL (p<0.05).
In pathologic review, presence of epithelioid granuloma favored CHL (p=0.078),
whereas fine reticulated fibrosis was unique for PMLBCL (p<0.001). By IHC,
P63 was predominantly positive in PMLBCL (15/16) than CHL (2/11) with the
highest diagnostic power (p<0.001). GATA3 was expressed in the majority of
CHL (9/12) compared with PMLBCL (0/16) (p<0.001). Expression of cyclinE
was rarely found in a minor population of PMLBCL.
Summary/Conclusions: Expression of P63 in the tumor cells, even focal, is the
most helpful feature to distinguish PMLBCL from mediastinal CHL. Additional
diagnostic markers include GATA3 in CHL and reticular fibrosis in PMLBCL.
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CASTLEMAN’S DISEASE:  HISTOLOGICAL SUBTYPES AND
MICROVESSEL DENSITY
A. Mikhailov 1,*, V. Baykov 2, S.S. Bessmeltsev 3, G. Raskin4, V. Rugal 5,
N.Y. Semenova3
1Department of hospital therapy and cardiology, North-Western state medical
university n.a. I.I.Mechnikov, 2Department of pathology, First St.-Petersburg
state medical university n.a. I.P.Pavlov, 3Russian research institute hematology
and transfusiology, 4Department of pathology, Russian National scientific centre
of Radiology and surgical technologies, 5Department of pathology, Russian
research institute hematology and transfusiology, Saint-Petersburg, Russian
Federation
Background: Castleman`s disease (CD) is а rare non-clonal lymphoprolifer-
ative disorder. Most of the cases are characterized by increased vascularity in
the affected tissue. The disease falls into two major histological variants: plasma
cell type and hyaline vascular type. However, the correlation between microves-
sel density and the subtype of the disease has not been established yet.
Aims: To investigate the association between microvessel density and  histo-
logical type of CD.
Methods: Twenty-eight lymph nodes from patients diagnosed with CD were
used for the study.  The age of  the patients ranged from 24 to 65 years, 14
were male and 14 were female. Three nodes without evidence of metastasis
removed for breast cancer were used as controls. The diagnosis of hyaline
vascular CD was based on overall preserved immunoarchitecture with typical
angio-follicular hyperplasia, circular arrangement of mantle cells around hyalin-
ized germinal centers (“onion skin” pattern). The plasma cell type of CD was
confirmed by presence of perifollicular sheets of CD138+ plasma cells. Vessels
were labeled with СD34 immunostain. Slides were scanned by the whole slide
digital Panoramic scanner. Percentage of blood vessel area (vessel density
index) was calculated using Panoramic Viewer software, statistical analysis
was conducted with Student’s t-test.
Results: The plasma cell variant of CD was diagnosed in 8 patients, the hyaline
vascular variant – in 20 patients. In control group vessels occupied 10±1,0%
of the area. In patients with plasma cell variant percentage of blood vessel
area was increased to 15.1±1.4% (p<0,05). Patients with hyaline vascular CD
were divided into 2 groups depending on the vessel density index. In 15 patients
(75%) percentage of vessel area was 6.8±2.3%, which was somewhat lower
than in patients with plasma cell variant (not statistically significant). In 5
patients (25%) with hyaline vascular CD, the percentage of vessel area was
higher - 12,3±1,5% (p<0.05) and did not differ from levels in patients with plas-
ma cell variant.
Summary/Conclusions: The highest index of vessel density in the lymph
nodes with CD was observed in plasma cell variant. In hyaline vascular variant,
the index was characterized by significant variability, which could reflect the
heterogeneity of this type of the disease. Increased density of blood vessels in
the lymphoid tissue may be considered as a possible target for angiogenesis
inhibitors, especially in patients with progressive disease. 
PB2081
PROGNOSTIC SIGNIFICANCE OF IMMUNOHISTOCHEMICAL MARKERS
IN R-CHOP TREATED DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS
A.-M. Picleanu1,*, S. Patrascu2, L. Mogoanta3
1Hematology, Filantropia Hospital Craiova, 2Surgery, Emergency Hospital
Craiova, 3Histology, University of Medicine and Pharmacy of Craiova, Craiova,
Romania
Background: Despite its clinical, morphological and molecular heterogeneity,
diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid malig-
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nancy in adults. The role of immunophenotype variability for the therapeutic
outcome has long been the cornerstone for DLBCL management strategy.
Aims: To evaluate the immunophenotypic characteristics of DLBCL and the
prognostic significance of specific biomarkers such as bcl2, bcl6, CD 10 and
MUM1, in a population-based cohort of patients treated with R-CHOP.
Methods: We performed a retrospective assessment of all cases of DLBCL
diagnosed at our institution between 2005-2013. The immunohistochemical
expression patterns of all DLBCL patients were analyzed and correlated with
the therapeutic response to R-CHOP regimen.
Results: The study included 101 patients diagnosed with DLBCL, with a median
age at diagnosis of 57.1 years (19-90 years) and male/female ratio of 1.3/1.
Ninety-one patients were eligible for R-CHOP treatment. The median follow-up
was 41 months. Out of the 90 cases analyzed by immunohistochemistry CD
10, BCL2, BCL6 and MUM1 expression was found in 17.6%, 50.5%, 72.7%
and 81.8% of cases, respectively. Negative expression for CD10, as well as
positive expression of BCL2 were adverse prognostic factors for 3-years overall
survival (OS) and disease free survival (DFS) (OS for bcl2: 72.3 vs 89.7, p<0.05,
OS for CD10: 84.1 vs 75.1, p<0.05). BCL6 and MUM1 expressions, however,
did influence neither OS nor DFS.
Summary/Conclusions: This study confirms the prognostic value of a multi-
marker assessment which includes bcl2, bcl6, CD 10 and MUM1 expression
for patients R-CHOP therapy.
Other Non-malignant hematopoietic disorders
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LYMPHOID NEOPLASMS: A REALLY IMPORTANT TRIGGER IN
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
V. Martinez Robles1,*, S. Calleja2, B. Ballina1, S. Cerdá1,
S. Fernández-Ferrero1, F. Escalante1, F. Ramos1, J.A. Rodríguez-García1
1Hematology and Hemotherapy, 2Inmmunology, Complejo Asistencial Univer-
sitario de Leon (CAULE), Leon, Spain
Background: Triggered by several conditions Hemophagocytic lymphohisti-
ocytosis (HLH) is an unusual, aggressive and life-threatening dysfunction
caused by an excessive immune activation. It has become more recognized
over the past decade. HLH was first described in 1939 by Scott and Robb-
Smith, next case was reported in 1952 by Farquhar and Claireaux describing
two infant siblings with progressive and lethal cytopenias,
hepatosplenomegaly, and fevers with autopsy showing hemophagocytosis.
A lengthy and unstoppable activation of antigen-presenting cells
(macrophages, histiocytes) and CD8+ T and NK cells is characteristic. This
condition leads to an important hyperinflammatory situation and organ dam-
age including splenomegaly, fever, cytopenia,  hypertrigliceridemia and/or
coagulapathy. Histiocyte Society (HS) criteria have been applied for diagnos-
ing HLH, however not all of them are usually showed at the presentation.
This disease can be described in two different scenarios: primary (usually in
children, genetic, and known as familial form) and secondary (acquired). It
can be triggered by a large variety of events that disrupt inmune homeostasis.
When we talk about triggers, we can divide them in two broad categories,
those that cause inmune activation and those that lead to inmune deficiency.
Lymphoid neoplasms can be both.
Aims: Due to the lack of publications about HLH secondary to Lymphoid Neo-
plasms (LN), we would like to analyze the casuistry of our hospital and making
a comparison with the current literature.
Methods: We conducted a retrospective analysis through medical files of all
patients with suspected diagnosis of HLH between 1994 and 2017 in our in
patient ward. Clinical features, age, diagnostic criteria proposed by the HS, eti-
ology, treatment and evolution were analyzed. In our study 18 out of 50 patients
met the requested criteria for HLH diagnosis.
Results: We report 10 LN secondary cases (4 males, 6 females). The median
age at diagnosis was 60,5 years, ranged between 46 and 80 years. In all of
them, but in one, who presented long-term pancytopenia, symptoms were
developed very fast. The most frequent causes of consultation were cytopenia
and general syndrome. In two of them HLH was diagnosed with LN relapse,
in one patient during a transformation from a low-grade B-cell lymphoma to
DLBCL (Diffuse large B-cell lymphoma), in 6 of them we diagnosed LN and
HLH concomitantly, and in the last one coinciding with a Richter
Syndrome.  Four of 10 were secondary to T-cell neoplasm. All patients met
5 o more HS diagnostic criteria. In only 3 of them HLH was healed. One
patient is still in remission. Nine died, 7 of them due to HLH complications.
Treatment was chemotherapy (depending on their LN) in almost all of them.
Fluctuations were detected among activity HLH parameters due to LN
response. Detailed characteristics of patients are shown in Table 1.
Table 1.
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Summary/Conclusions: HLH triggered by LN is diagnosed in older patients
than other causes secondary HLH (46-80 vs 4-84 y/o in our center), we think
this is because in our experience there are not children or Young adult in HLH
due to LN group. We would like to highligt that although LN is a very commom
HLH trigger there are a few works describing them in the literature, that is why
we would like to spread our experience. We would like to emphasize in he
importance of an early diagnosis. Despite being a serious disease, it is still
underdiagnosed, reaching the diagnosis most of the times after seeing hemo-
phagocytic phenomena in bone marrow biopsy.  Agreeing with literature, main
consulting reasons are similar to our series.  Correlation between neoplastic
activity and inmune activation, as well as test and facts which could predice
evolution should be more studied. Finally we would like to address the necessity
of considering this possibility in the face of a patient with fever which does not
respond to antibiotics and has not clarified citopenia, as well as the importance
of conducting cheap and very profitable test such as ferritin or tryglycerides
level when symptoms or clinical features of lymphoid neoplasm are not con-
cordant with the expected evolution.
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MARIH, A NATIONAL NETWORK FOR RARE IMMUNOHEMATOLOGICAL
DISORDERS
A. Marouane1,*, N. Aladjidi12, M.-P. Bichet1,3, F. Bridoux1,4,
M.-O. Chandesris1,5, P. Coppo1,6, L. Da Costa1,7, J. Donadieu1,8, C. Fieschi1,9,
A. Fischer1,10, V. Frémeaux-Bacchi1,11, B. Godeau1,12, V. Grosjean1,13,
O. Hermine1,14, A. Jaccard1,15, J.-E. Kahn1,16, T. Lamy1,17, T. Leblanc17,
G. Lefèvre1,18, N. Mahlaoui1,10, M. Michel1,12, A. Moignet1,17,
E. Oksenhendler1,19, Y. Perel1,2, F. Sicre de Fontbrune1,20, A. Tazi1,21,
A. Veyradier1,22, R. Peffault de Latour1,20
1MaRIH, French network for immunohematological rare diseases, Paris,
2National reference centre for autoimmune cytopenia in children “CERE-
VANCE”, Pellegrin Hospital, Bordeaux, 3AFMF, Patients’association, Paris,
4National reference centre for primary amyloidosis, University Hospital of
Poitiers, Poitiers, 5National reference centre for mastocytosis “CEREMAST”,
Necker Hospital, 6National reference centre for thrombotic microangiopathy
“CNR MAT”, Saint-Antoine Hospital, 7National DBA Observatory, Robert Debré
Hospital, 8Registry of chonic neutropenia, Trousseau Hospital, 9Cohort of
immune deficiency in adults, Saint-Louis Hospital, 10National reference centre
for immunodeficiency “CEREDIH”, Necker Hospital, 11Laboratory of immunol-
ogy, HEGP, Paris, 12National reference centre for autoimmune cytopenia in
adults “CeReCAI”, University Hospital Henri Mondor, Créteil, 13IRIS,
Patients’association, 14National reference centre for mastocytosis “CERE-
MAST”, Hôpital Necker, Paris, 15National reference centre for primary amyloi-
dosis, University Hospital of Limoges, Limoges, 16National eosinophil network,
Foch Hospital, Suresnes, 17Registry of LGL proliferation, University Hospital
Pontchaillou, Rennes, 18National eosinophil network, University Hospital
Claude Huriez, Lille, 19Cohort of immunodeficiency in adults, 20National refer-
ence centre for aplastic anemia, 21National reference centre for Langerhans
histiocytosis, Saint-Louis Hospital, 22Laboratory of hematology, Lariboisière
Hospital, Paris, France
Background: Health networks focused on rare diseases were created following
a call for proposals from the French Ministry of Health in the summer of 2013.
The main objective of these networks is to facilitate and to coordinate the
actions being implemented by all actors involved in treating rare diseases. Of
the 23 national networks identified in 2014 in France, the network for rare
immunohematological rare diseases “MaRIH” brings together national refer-
ence centres and recognized centres of expertise as well as patients’ associ-
ations involved in treating those pathologies, on behalf of scientific medical
societies.
Aims: Improving care, communication and training, pushing forward research
development and epidemiological surveillance.
Methods: MaRIH brings together people involved in those medical pathologies:
8 national reference centres, 5 centres of expertise, more than 50 diagnosis
and/or research laboratories, 9 patients’ associations on behalf of 7 scientific
societies.
Results: The main missions of this network are to improve the care, the
research and to educate professionals, patients as well to disseminate more
information to the general public on these rare diseases. Improving care:
Thanks to its visibility (events, leaflets, website), MaRIH should help primary
care doctors to more quickly diagnose and therefore provide faster and appro-
priate treatment based on best practice recommendations at the national level
(PNDS) as well as international guidelines. The network will also be setting up
new multidisciplinary meetings for specific immunological and hematological
rare disorders through MaRIH centres so physicians  in France or in other
countries can have easily an expert opinion for their patients. At the same time,
improving the child-adult transition was identified by the steering committee as
a top priority. Communication and training: MaRIH is involved in organizing
many multidisciplinary events in France to improve the visibility of the centres
and to provide education on these rare diseases. The 1st annual conference
of the network took place on June 25th 2015  and the third one is planned on
June 1rst 2017 in Paris. Moreover, a patient’s day meeting was organised on
January 30th 2016 in Paris to inform on the update status of research on their
disease as well as to help patients in daily common problems (sport, psychol-
ogy, transfusion…). Pushing forward research development and epidemiolog-
ical surveillance: the network has appointed a research project manager for its
scientific and strategic committee to support, provide stability for and add value
to research centre activities. The research project manager watch out for calls
for tender, set-up of new registers and continually monitor the regulations for
retrospective and prospective studies, both in France and at the international
level. Furthermore, MaRIH supported successfully the application of several
of its members for European reference networks (Figure 1).
Figure 1.
Summary/Conclusions: The creation of these new networks allows strength-
ening the links between the various actors involved in the field to improve care
and answer transversal questions. In this way, MaRIH pilot concerted actions
to all its members around immunohematological rare diseases by: 1- increasing
the visibility of the actors on the web or during events. The MaRIH website
includes all the informations of the members as well as recommendations and
events (www.marih.fr). 2- communication and training. MaRIH organizes two
annual events, one for patients and another one for professionals. Moreover,
MaRIH sends clinical cases by email to professionals and produce an annual
webcast. 3- pushing forward research development and epidemiological sur-
veillance. Thanks to his research project manager, MaRIH facilitates the sub-
mission and the set-up of new registries or clinical studies. In the future, MaRIH
will continue and futher develop all these actions, in close collaboration with
the French Ministry of health.
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CLINICAL FEATURES AND ETIOLOGY OF PATIENTS WITH THROMBOTIC
MICROANGIOPATHIES
Ü. Ergene1,*, C. Özlü1
1hematology, saglik bilimleri univercity, izmir, Turkey
Background: Thrombotic microangiopathy (TMA) is a heterogeneous group
of disease that has a fatal pattern of endothelial damage. TMA can be found in
association with diverse clinical conditions such as carcinoma metastasis,
malignant hypertension, infections, and TTP (thrombotic thrombocytopenic pur-
pura). TTP is a rare, life-threatening multisystem disease, characterized by
microangiopathic hemolytic anemia, thrombocytopenia, fever, renal dysfunc-
tion, and neurological disorders. 
Aims: The purpose of this study is to evaluate the etiology associated with TMA.
Methods: All of the six TMA patients who were newly admitted to our clinic in
two months period were enrolled in this study. Effectiveness, response, adverse
effects and safety of plasmapheresis were evaluated using laboratory and clin-
ical findings. (See Table 1).
Results: First patient presented with cachexia, thrombocytopenia, and TMA. He
did not respond to plasmapheresis and corticosteroid treatment. We diagnosed
carcinoma metastasis and liver metastasis, respectively, through bone marrow
biopsy and PET(positron emission tomography). We thusly ascertained that TMA
was due to carcinoma unknown primary. The second patient presented with gen-
eral neurological findings like Guillain-Barre Syndrome and paraplegia with renal
failure, thrombocytopenia, and TMA. After PLEX and corticosteroid treatment,
laboratory and neurological clinical recovery were observed after one month.
The third patient had chronic obstructive pulmonary disease and pneumonia in
anamnesis. who presented with anemia, thrombocytopenia, fever and pneumonia
findings. We conducted PLEX therapy. On the 8th day of PLEX, the patient had
anaphylaxis, we performed cardio pulmonary resuscitation. The fourth patient
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presented with acute renal failure with malign hypertension. We performed
hemodialysis together with PLEX treatment. Because his diagnosis was acute
renal failure, malign hypertension, and TMA. The fifth patient presented with epis-
taxis and sepsis. He had chronic TTP diagnosis from two years ago. We diag-
nosed the patient as relapse TTP. Early treatment against infection and PLEX
increased his platelet counts as early as the second day of treatment. The sixth
patient presented with a fever that had been going on for five days. We treated
the patient with PLEX together with the corticosteroid. Because his ADAMTS13
level was very low and he had 35% schistocytes.
Table 1.
Summary/Conclusions: We diagnosed our first patient with carcinoma
unknown primary, who did not respond to PLEX and corticosteroid treatment.
The results we received for that patient indicate that PLEX with corticosteroid
treatment alone, remain ineffective in cancer-related TMA patients. Etiology of
our second patients TMA was idiopathic. His clinical and laboratory findings
improved rapidly in response to PLEX and pulse corticosteroid treatment.  One
viral infection induced TMA patient had anaphylactic reaction receiving his 8th
PLEX. Allergic reactions should always be kept in mind when administering
PLEX. One patient with TMA and malign hypertension-induced renal failure
was successfully treated with PLEX, hemodialysis and antihypertensive treat-
ment. We successfully treated our bacterial infection and sepsis-induced TTP
patients with PLEX and antibiotic administration. In second TMA patient, we
coupled PLEX with high dosage corticosteroid treatment even though he had
an infection. For he had high schistocyte count and atypical neurological find-
ings.ADAMTS 13 activity may only be a guide for diagnosis of TTP, but it is
unreliable for a definitive one. In conclusion, diagnosis of TTP and other TMAs
is difficult. Etiology, clinical features, laboratory findings should all be taken into
account when diagnosing TMA. While it is established that ADAM TS13 defi-
ciency is the major cause in acquired TTP, finding the etiology of other TMAs
is determinant for a successful treatment of the latter.
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HAEMOLYSIS AS SCREENING TEST IN LYSOSOMAL STORAGE
DISEASES
L. López De Frutos1,2,*, J.J. Cebolla1,3,4, P. Irún1,3, P. Giraldo1,2,3
1Unidad de Investigación Traslacional. Hospital Universitario Miguel Servet,
Instituto de Investigación Sanitaria Aragón (IIS Aragón), 2Unidad de Investi-
gación Traslacional. Hospital Universitario Miguel Servet, Fundación Española
para el Estudio y Terapéutica de la Enfermedad de Gaucher y Otras Lisoso-
males (FEETEG), 3Unidad de Investigación Traslacional. Hospital Universitario
Miguel Servet, Centro de Investigación Biomédica en Red en Enfermedades
Raras (CIBERER), 4Departamento de Bioquímica, Biología Molecular y Celular,
Universidad de Zaragoza, Zaragoza, Spain
Background: Lysosomal storage disorders (LSDs) are a group of rare inherited
metabolic diseases, whose clinical hallmark is organomegaly among others,
due to progressive accumulation of several non-catalyzed products inside the
lysosomes. This storage leads to intracellular oxidative stress status triggering
oxidized metabolites production as oxysterols, which are related to apoptosis
and cellular eriptosis, as well as haemolysis dysregulation.
Aims: To evaluate the link between LSDs and haemolysis and if it could be
used as a screening test in LSDs.
Methods: The osmotic resistance test (ORT) was evaluated in 150 samples
including controls, LSDs carriers (LSDs-C) and LSDs patients (LSDs-P). Briefly,
the blood was mixed with different concentrations of sodium chloride solution
(NaCl) and the haemoglobin released was quantified by spectrophotometry.
The raw data was normalized using isotonic solution (0.9% NaCl). The statistical
analysis (non-parametric tests and ROC curves), was computed by IBM SPSS
statistics v22 software and all statistical tests will be considered and taken as
bilateral significance level α=0.05.
Results: The analysis shown that haemolysis at 0.48% of NaCl allow us to
sort out controls vs LSDs-C/LSDs-P (AUC=0.726) whereas no significant dif-
ferences were observed between LSDs-C and LSDs-P (p-value>0.05).
Summary/Conclusions: According to our results the ORT test is an useful
screening test in LSDs.
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CLINICAL SIGNIFICANCE OF ELEVATED SERUM COBALAMIN (VITAMIN
B12) LEVELS
I. Yaman Bajin1,*, E. Sabancı2, S. Akyan2, S. Aytac1, M. Çetin1, F. Gümrük1
1Pediatric Hematology, 2Pediatrics, Hacettepe University, Ankara, Turkey
Background: Hypercobalaminemia is a frequent but underestimated abnor-
mality. Elevated serum cobalamin levels may be a sign of a wide range of dis-
eases like solid neoplasms, haematological disorders like myeloproliferative
disorders, chronic myelogeneous leukemia, promyelocytic leukemia, poly-
cythemia vera, hypereosinophilic syndrome as well as liver and kidney dis-
eases.
Aims: We aimed to evaluate the underlying disorders of the patients with high
cobalamine levels (>1000 pmol/l) between 01.02.2016- 01.02.2017 in Hacette-
pe University Pediatric Hematology Department. 
Methods: We investigated the patient records of the patients examined
between 01.02.2016- 01.02.2017 in our department and included the patients
with serum cobalamine levels higher than 1000 pmol/l. We excluded the
patients who are taking Vitamin B12 supplement.
Results: There were 46 patients with serum cobalamine levels higher than
1000 pmol/l out of 14367 patients seen between 01.02.2016- 01.02.2017 in
our department. The reason to check the cobalamin levels were anemia, neu-
tropenia and thrombocytopenia in most of the patients. Only 2 patients were
referred to our department because of hypercobalaminemia. The underlying
disorders were found to be leukemia in 3 patient ( Acute lymphoblastic leukemia
(ALL) n:1, acute myeloblastic leukemia (AML) n:1  , large granular lymphocytic
leukemia (LGLL) n:1), myelodisplastic syndrome (MDS) in 2 patients, isolated
thrombocytopenia in 4 patients,  isolated neutropenia in 7 patients, bicytopenia
in 4 patients and aplastic anemia in 2 patients, cobalamine metabolism defects
in 10 patients, hypereosinophilia in 2 patients, polisitemia in 1 patient, cystic
fibrosis in 1 patient, HIV in 1 patient, FMF (familial mediterrenian fever) in 1
patient, chronic kidney failure in 2 patients, sickle cell anemia in 1 patient, factor
7 deficiency in 1 patient, thrombosis in 1 patient and epistaxis in 1 patient. 
Summary/Conclusions: An observed elevation of cobalamin merits the a full
diagnostic work up to assess the presence of an early diagnostic marker of
these diseases. When we look at the patients except hematological neoplasm
and cytopenias, most of the underlying reasons is associated with inflamation
and infection, cobalamin was found to be elevated as an acute fase reactant.
A certain approach is needed whether to determine the potential indications to
search for high serum cobalamin levels and to determine  the practical clinical
strategy when elevated cobalamin levels discovered. 
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THE HEMATOLOGIC FINDINGS OF INHERITED METABOLIC DISEASE;
THEY ARE MORE THAN EXPECTED
I. Yenicesu1,*, A.E. Sal2, I. Okur2, Z. Kaya1, F.S. Ezgu2, U. Kocak1, L. Tumer2
1Pediatric Hematology, 2Gazi University, Faculty of Medicine, Ankara, Turkey
Background: Inherited metabolic diseases are pathological conditions that
generally develop as a result of impairment of the production or breakdown of
protein, carbohydrate and fatty acids. Hematological problems are some of the
most frequently observed findings of inherited metabolic diseases. These may
be seen together with other systemic findings or sometimes as the first and
only diagnostic finding of disease. Early determination of hematological findings
has a positive effect on the prognosis of metabolic diseases.
Aims: The aim of this study is to evaluate the incidence of hematological find-
ings in inherited metabolic diseases since there are a few studies about the
true incidence in literature.
Methods: Three hundred eighteen patients who were being followed-up within
the previous 6 months at Gazi University Department of Pediatric Nutrition and
Metabolism, Turkey, were included in the study. Patients’ hematological findings
were taken from Department of Pediatric Nutrition and Metabolism and hospital
data-processing records. Since patients were in different age groups, hemato-
logical findings were compared with normal values for each patient’s age group.
The hematological findings were classified under seven main groups; anemia
of chronic disease, iron deficiency anemia, vitamin B12 deficiency anemia,
hemophagocytosis, leukocytosis and thrombocytosis. Metabolic diseases were
classified according to the textbook of Inborn Metabolic Diseases: Diagnosis
and Treatment.
Results: Nine hundred twenty-two hematological examinations of the 318
patients were included to the study, and 282 hematological findings were deter-
mined, 127 anemia of chronic disease, 80 iron deficiency anemia, 56 cytopenia
and four vitamin B12 deficiency anemia. Leukocytosis (n=1), thrombocytosis
(n=5) and hemophagocytosis (n=9) were also observed.
Summary/Conclusions: It was determined that although anemia of chronic
disease and nutritional anemia are the most common hematological findings,
these may be diagnosed late, while neutropenia, thrombocytopenia, pancy-
topenia and hemostasis disorders may be diagnosed earlier. Metabolic dis-
eases must be considered in the evaluation of cytopenias, particularly in cases
with an atypical cause that are resistant to treatment and have additional
accompanying findings. Our study is the most comprehensive one in the liter-
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ature, and we think it would positively contribute to the monitoring and prognosis
of congenital metabolic diseases.
PB2088
HEMATOTOXIC EFFECTS OF GENERIC TRIAZOLE FUNGICIDES
TEBUCONAZOLE ON WISTAR HANNOVER RATS
T. Usenko1,*, V. Shulyak1, N. Nedopytanska1, M. Prodanchuk1
1L.I.Medved’s Research Center of Preventive Toxicology, Food and Chemical
Safety, Ministry of Health, Kiev, Ukraine
Background: Pesticides are extensively used in agriculture today. Fungicides
based on derivatives of triazole are the most widespread all over the world.
Tebuconazole (TB) is one of the most frequently used substance of this group.
Literature review confirms that triazole fungicides have the ability to cause dif-
ferent hematotoxic effects.
Aims: Since 2007-2016 years we have investigated 10 test-substances of
generic tebuconazoles  (purity up to 97%) from different manufacturers  with
purpose to assess their hematotoxic action on males Wistar Han rats peripheral
blood in the subchronic 90-days oral toxicity study (according to SOP and
OECD 408 reccomendations in compliance with GLP).
Methods: The Wistar Han males were randomly allotted to four groups. The
input controls of peripheral blood parameters were conducted after a period of
animals acclimatization. The goal was to evaluate the physiological state of
the Wistar Han rats and the blood picture before treatment. Doses 0; 10; 50;
200 mg/kg/bw/day were defined and were the same in all studies. Blood sam-
ples for hematological measurements were examined at 4, 9, 13 weeks after
TB exposure in the same groups of animals throughout the experiment. Hemo-
globin (HGB) concentration, hematocrit (HCT), total amount of erytrocytes
(RBC), leukocytes (WBC) and platelets (PLT), mean corpuscular hemoglo-
bin  (MCH) were evaluated.
Results: As a result, all generic TBs on high toxic doses level (200
mg/kg/bw/day) had shown the tendencies for quantitative hematological
changes. TBs mainly provoked the significant decrease of HGB concentration
and RBC count on 4th and 9th weeks of exposure. Morphological changes of
RBC (anisocytosis) were seen too. It means that generic TBs had anemic
effect. In general, changes of hematological parameters were not principally
significant and did not differ from control values at 13th weeks of experiments,
except two TB’s, which had shown significant decrease of HGB. Also some of
generic TBs lead to decrease (leukopenia) or increase (leukocytosis) of leuko-
cytes count in peripheral blood. In case of generic pesticides, the presence of
impurities can demonstrate various hematotoxic action. Also the adverse effects
on peripheral blood of males Wistar Han rats were observed at a dose of 50
mg/kg/bw/day and demonstrated the lesions of red blood. But abovementioned
changes were not so clearly expressed. Any adverse hematotoxic effects at
10 mg/kg/bw/day dose were not observed in all studies.
Summary/Conclusions: As a conclusion, due to our results the triazole fungi-
cides generic tebuconazoles have hematotoxic action. They induce anemia in
Wistar Han rats and quantitative white blood cells changes. Today it is very impor-
tant to investigate the hazardous effects of pesticides on the blood system.
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WHAT WE CAN DO TO MAKE A STANDARDIZATION AND
HARMONIZATION OF APTT? 
M. Pamukcuoglu1,*, M. Falay2, S.M. Urlu1, M.A. Ucar1, F. Ceren1, S. Dagdas1,
G. Özet1
1Hematology, 2Biochemistry, Ankara Numune Education an Research Hospital,
Ankara, Turkey
Background: Transfusion enhanced many kind of complication in patients
therefore peri-operative coagulation monitoring  was suggested before the sur-
gical procedure to protect the patients against bleeding. Also there are some
diseases which had bleeding events in surgical procedure or spontaneously.
We should detect these kind of diseases and we should examine the correct
measure  of  active parsiel thromboplastin time  (APTT)  before surgical pro-
cedure by detecting the mild ormoderate deficiencies of plasma factor levels
and by eliminating the lupus antıcougulant from plasma. This was caused to
make the importance of APTT reagents.
Aims: We tried to show the importance of APTT reagents and how to reach
the correct measure of APTT in this study.
Methods: We are planning to examine 300 patients, 109 of 300 patients were
included as yet. Patient’s APTT levels were calculated ACL-TOP analyzer by
using three different reagents.First reagent was HemosILAPTT-SP which was
sensitive against both plasma factors and lupus anticoagulant. It contains mix
collodial silica and normal range of APTT- SP was 25.4-36.9 s. Second reagent
was HemosIL SynthASil-SS which was sensitive against only plasma factors.It
contains silica and normal range of  APTT-SS was 25.1-36.5 s. The third reagent
was HemosIL SynthA Fox-SF which was sensitive against only lupus anticoag-
ulant. It contains ellagic asid and normal range of APTT-SF was 21.5-30.4 s.
Results: Forthy-five  of 109 patients had normal level of APTT  by measuring
three types of reagents. Seventeen of 109 patients had long level of APTT by
measuring three types of reagents. Twenty of 109 patients had long levelof
APTT by measuring Hemosil synhAsil-SS reagent and had normal level with
Hemosil SynthAFox-SF and Hemosil APTT-SP. Seven  of 109 patients had
long level of APTT by measuring Hemosil synhAsil- SS reagent and Hemosil
APTT-SP reagent and had normal level of APTT with Hemosil SynthAFox-SF.
Twenty of 109 patients had long level of APTT by measuring Hemosil synhAsil-
SS reagent and Hemosil SynthA Fox-SF reagent and had normal level of APTT
with Hemosil APTT-SP.
Summary/Conclusions: Haemostasis is a complex physiological cascade which
was began at the endothelium injury. Many kinds of complex prosedures occured
after this injury. Beacuse of this complex cascade pathway, bleeding is not
occured every kind of APTT level.  Bleeding events usually occured at <%30
level of plasma factors but mild or moderate plasma factor levels can caused
bleeing. Therefor sensitivite of APTT reagents are very important. Every kind of
APTT reagent do not have equal sensitivite against plasma factor levels, phos-
pholipid composition and concentration in thromboplastin reagent. Several stud-
ies suggested that range of APTT should be determinate according to the devices
and reagents and also several studies comparied APTT reagents which was
included silica, ellagic asid and phospholipids by composed of syntethic or animal
orginated and several studies determined a target level of APTT for looking at
the plasma factors levels. If we want to get a correct result of APTT, ranges of
APTT must be determine according to reagents which was used in APTT devices
and APTT reagents must  be  sensitive against borderlines cases who had a
mild or moderate low levels of factors and the presence lupus antıcouglant. We
need further studies to make a standardization and harmonization of APTT.
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ACQUIRED PURE RED CELL APLASIA IN AN ADOLESCENT: COULD IT
BE ANYTHING ELSE?
S. Yılmaz Bengoa1,*, Ö. Tüfekçi1, M. Erdem1, D. Kızmazoğlu1, H. Ören1
1Pediatric Hematology, Dokuz Eylül University, İzmir, Turkey
Background: Pure red cell aplasia (PRCA)  is a syndrome characterised by
normocytic (sometimes macrocytic), normochromic anemia with severe retic-
ulocytopenia and marked reduction or absence of erythroid precursors from
the bone marrow. PRCA may be congenital, in the form of Diamond-Blackfan
Anemia, or acquired which is rather rare in childhood. An immune mechanism
interrupting erythroid differentiation is responsible in primary autoimmune
PRCA, on the other hand secondary acquired PRCA may be associated with
autoimmune/collagen vascular disorders, infections, lymphoproliferative dis-
orders, hematological malignancies. solid tumors and drugs. 
Aims: Here we report a 16-year-old male with acquired pure red cell aplasia
who was treated successfully with steroids and cyclosporine after elimination
of the secondary causes.
Methods: Case: An 16-year-old boy presented with a history of pallor and
fatigue noticed three months prior to admission. He had been diagnosed with
immune thrombocytopenia when he was 5 years old and had been in remission
since that time. There was no history of blood transfusion, chronic illness or
any other medication. His physical examination revealed pallor and a 2/6 sys-
tolic murmur with no other abnormalities. Complete blood count revealed
severe macrocytic anemia and reticulocytopenia with hemoglobin:2.2 g/dL,
hematocrit: 6.2%, mean corpuscular volume:108.7 fL, red blood cell:
0.57x1012/L, reticulocyte: 0.2% and mild leukopenia and lymphopenia.  Periph-
eral blood smear showed macrocytic red cells with occasional tear drop cells.
Stool for occult blood was negative. The direct and indirect antiglobulin tests
were negative Serum bilirubin, LDH,  haptoglobulin, liver function tests and
renal function tests were in normal limits. Hemoglobin F was 2.9%. Bone mar-
row aspiration showed red cell hypoplasia, without dysplasia or giant pronor-
moblasts and normal myeloid and megakaryocytic series. A high resolution
computed tomography of chest ruled out thymoma. Serum immunoglobulins
revealed low IgA with normal IgG and IgM levels. Anti-nuclear antibody was
negative but anti-dsDNA was positive.  Parvovirus B19 DNA and other serologic
markers including antibodies to HIV and hepatitis A, B and C were all negative.
He was transfused with erythrocytes and discharged with a hemoglobin value
of 7.2 g/dL. On his follow-up, hemoglobin levels were observed to decrease
again. A diagnosis of primary acquired PRCA was considered and prednisone
with a dose of 1 mg/kg/day and cyclosporine with a dose of 6 mg/kg/day were
started to maintain through levels of 150-250 ng/mL. His hemoglobin level
gradually increased and reached to 12 g/dL and leukopenia and reticulocy-
topenia resolved completely. Prednisone was tapered after 4 weeks and
stopped. He is still on cyclosporine treatment and has been transfusion free
with stable hemoglobin levels in the second month of his treatment.
Results: Primary acquired PRCA is very rare in childhood, secondary causes
must be elliminated for definitive diagnosis. Our patient was found to have lym-
phopenia, low immunglobulin A level and positive antidsDNA in further inves-
tigations, yet these results are not sufficient for a specific diagnosis like common
variable immune deficiency or systemic lupus erythematosus. Therefore we
considered primary acquired PRCA as the most possible diagnosis and started
immunosuppresive therapy; his clinical follow-up will probably give us further
details about the underlying disease. 
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Summary/Conclusions: Immunosupressive therapy including cyclosporine
with or without steroid has been reported as the most effective treatment in pri-
mary acquired PRCA.  Consistently, we had a dramatic response to immuno-
suppressive therapy in our patient.  
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APLASTIC ANEMIA IN CHILDHOOD: A TEN YEARS’ SINGLE CENTER
EXPERIENCE
A. Apsemidou1,*, T.-S. Tziola1, A. Tragiannidis1, E. Chatzipantelis1,
M. Papageorgiou1, L. Damianidou1, T. Papageorgiou1, T. Koletsa2,
A. Giannopoulos3
1Pediatrics-Pediatric Hematology/Oncology, 2Pathology, 3Pediatrics-Pediatric
Cardiology, AHEPA University Hospital, Thessaloniki, Greece
Background: Aplastic anemia in childhood is a rare, life-threating disorder,
characterized by peripheral blood pancytopenia and a hypocellular bone mar-
row without signs of dysplasia or fibrosis. Acquired aplastic anemia needs to
be distinguished from inherited bone marrow failure syndromes or myelodys-
plastic syndromes.
Aims: The aim of this study is to assess the clinical and laboratory findings at
the time of diagnosis, the treatment approach and the outcome of children with
aplastic anemia treated in our department during the past decade.
Methods: This retrospective study evaluated 9 children with aplastic anemia,
who were treated and followed up in the Pediatric Department of AHEPΑ, during
the period 2006-2016.
Results: We identified 9 children with aplastic anemia. The patients’ population
included 6 (66.7%) males and the mean age at admission was 9.7 years. At
the time of diagnosis, the average neutrophil count was 750/mm3, the Hb count
was 8.4mg/dl and platelets count was 8770/mm3. In all of our cases aplastic
anemia was acquired, expect one case of Fanconi anemia. Predisposing risk
factors (including drugs exposure, viral infections, chemicals) were identified
in 4 patients. Among the 9 studied patients, 3 (33.3%) had moderate-non
severe, 2 (22.2%) had severe and 4 (44.5%) had very severe aplastic anemia.
All of the patients received immunosuppressive therapy (consisting of antithy-
mocyte globulin, cyslosporine A and steroids), 2 remained transfusion inde-
pendent, 4 underwent bone marrow transplantation- 2 from a matched related
donor and 2 from a matched unrelated donor. One patient with refractory dis-
ease received, as an alternative first line therapy, eltrombopag. Complete
response was achieved in 22.2%, partial response was achieved in 22.2%,
relapse occurred in 11.1% and 44.5% of the patients had refractory disease.
The overall survival was 77.8%.
Summary/Conclusions: A remarkable progress has been made during the
past decades in the understanding of pathogenesis and management of chil-
dren with aplastic anemia. Bone marrow transplantation from a matched related
donor is the recommended first line therapy resulting in an excellent survival
rate that exceeds 90%. In the future the development of targeted strategies for
patients and the enhancement of supportive care will further improve outcome
and diminish the disease’s late complications.
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CAUSES OF IRON DEFICIENCY ANEMIA IN THE HEMATOLOGY
CLINIC – SINGLE CENTER EXPERIENCE
M. Ionita1,*, I. Ionita1, D. Calamar1, D. Oros1, V. Todorescu1, C. Ionita1,
C. Sorica1, H. Ionita1
1Hematology, University of Medicine and Pharmacy Victor Babes Timisoara,
Timisoara, Romania
Background: Iron deficiency anemia (IDA) is the common nutritional deficiency
worldwide. The studies concerning various causes of IDA in adult men are rare,
although it is assumed that chronic  gastrointestinal blood accounts for the
majority.
Aims: Of the  study is to evaluate retrospectively adult men with IDA that were
hospitalized in our Hematology Clinic.
Methods: Two hundred fifteen male with IDA were enlisted at this study from
January 2005 to december 2015. Anemia was defined as Hg <13g/dL using
the WHO criteria. IDA was considered present if serum ferritin was 15 ng/mL
combined with serum iron concentration <30ug/dL with a transferrin saturation
of <10%. Complete physical examination, the history of the disease and fecal
occult blood test (FOBT) of three spontaneously  passed stools was done in all
patients. All patients had complete blood count, serum and total iron binding
capacity, and a serum ferritin level. Most patients underwent esophagogastro-
duodenoscopy (EGD). Colonoscopy was performed if lesion that caused IDA
was not found, and/or FOBT was positive.The abdominal CT scan  were per-
formed according to clinician’s recomandation together with other tests related
with blood lost.
Results: The median age was 62 ( range 32 to 86 ) years old. 168 of  215 (
78.13% ) men with IDA had symptoms such as fatigue, dizzines, or digestive
complaints. The history of prior gastrectomy, hemorrhoid, that probably had
caused IDA were reported in 32 (14,88%), 43 (20.0%),  patients, respectively.
FOBT was positive in only 65 (30.23%) subjects. 170 (79.06%) patients under-
went EGD. The most common findings from EGD were gastritis (48 patients)
and peptic ulcer (39 patients). Seventy eight (36.27%) patients were found to
have upper gastrointestinal disorders  ( 20 patients with erosive gastritis, 19
gastric ulcer, 16 duodenal ulcer, 23 gastric cancer.  Eighty-nine (41.39%)
patients underwent colonoscopy. That showed 44 clinically important lesions
that probably caused IDA ; colon cancer in 17 (7.90%) patients, colon polyp in
10 (4.65%) patients and hemorrhoid in 17 (7,90%) patients. Concerning malig-
nant lesions which are responsible for IDA, the malignant lesions were found
more frequent in patients older than 50 years accounting for 20.45% (27/132
patients) and patients younger than 50 years 17.80% (13/73 patients).
Summary/Conclusions: This study demonstrated  that gastrointestinal blood
loss is the main cause of  IDA in adult men, and  that there is a high rate of
malignancy in men older than 50 years.
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IMPACTS OF CLINICAL AND BIOCHEMICAL PARAMETERS ON KEY
HEMATOLOGICAL INDICES IN ADULTS: A COHORT STUDY
C.-C. Chen1,*, M.-H. Lin2, Y.-H. Yang3, C.-E. Huang1, H.-Y. Tsou1, C.-C. Hsu1,
Y.-Y. Wu1
1Department of Medicine, 2Center of Excellence for Chang Gung Research
Datalink, 3Department of Traditional Chinese Medicine, Chang-Gung Memorial
Hospital, Chiayi, Chiayi, Taiwan, Republic of China
Background: Studies in Caucasians have shown that values of hematological
parameters could be affected by a wide variety of factors, most notably age
and gender. However, parallel work in different ethnical populations, especially
from Asia-Pacific region, is lacking. Importantly, it remains largely unknown
whether some fundamental variables such as nutritional status, lipid profile,
and hepatitis infection (either HBV or HCV) also affect the variation of values
in hemogram.
Aims: Therefore, we conceptualize this study to explore through several key
parameters regarding their potential impacts on the changes of hemogram.
Methods: Adult individuals aged 18 or older from several adjacent villages in
Yun-Lin County, located in the central part of western Taiwan, who came to our
hospital for annual health exams were screened for the current study. The work,
retrospective in nature, was approved by institutional IRB. Information on age,
gender, hemogram, levels of total cholesterol (TC), triglyceride (TG), apolipopro-
tein B (Apo B) as well as albumin, and results of serological testing for hepatitis
B and C infection, was obtained from a centralized digital data base. All the
clinical data, after given a coding number for each case, were encrypted and
provided to the investigators without identifiable personal information. We ana-
lyzed the impacts of various parameters on several key hematological indices.
Results: Overall, 26,497 individuals were included in the current analysis after
excluding those with hemogram data fell outside of normal range. Carriers of
either hepatitis B (HBV) or C (HCV) who had abnormal liver function (defined
by elevated levels of aspartate transaminase or alanine transaminase) were
excluded as well. Age, gender, and serum levels of TC, Apo B, and albumin all
significantly impacted most key hematological profiles. As the levels of TC and
Apo B correlated well with each other (correlation coefficient r=0.82211, p
<0.0001, Pearson’s correlation), we did not incorporate TC in our multi-variate
analysis. Several key variables were found to influence some hematological
indices in the multi-variable regression model. Increasing age and male gender
negatively affected the platelet count, whereas higher Apo B level was associ-
ated with elevated platelet count. Surprisingly, hepatitis C carriers with normal
hepatic function had slightly higher platelet number than non-HCV carriers.
Gender and serum albumin level were the major determinants of variation in
hemoglobin level. Total white cell count increased with male gender and ele-
vating Apo B level but was inversely correlated with change in age and serum
albumin level (Table 1).
Table 1.
Summary/Conclusions: The hematological indices are influenced by a wide
variety of factors, especially age, gender, and serum level of Apo B. As age,
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Apo B, white cell count, and platelet count all impose risk of thromboembolism,
further work exploring the interactions and impacts of these parameters on the
development of cardiovascular diseases should be mandatory.
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UNUSUAL DISTRIBUTION OF INTERLEUKIN-10 C-592A GENE
POLYMORPHISM IN PATIENTS WITH PRIMARY IMMUNE
THROMBOCYTOPENIA FROM NORTH-WESTERN RUSSIA
S. Kapustin1,*, I. Zotova2, S. Gritsaev2, J. Sidorova1, I. Pavlova3, A. Pavlova3,
S. Bessmeltsev2
1Laboratory of Biochemistry, 2Russian Research Institute Of Haematology And
Transfusiology, Saint-Petersburg, Russian Federation, 3Laboratory of Immuno-
hematology, Russian Research Institute Of Haematology And Transfusiology,
Saint-Petersburg, Russian Federation
Background: Primary immune thrombocytopenia (ITP) is a rare hematological
disease with unknown etiology. It is characterized by heterogeneity of the lab-
oratory parameters as well as the features of clinical manifestation. DNA poly-
morphism of several cytokine genes has been suggested to modulate the risk
of ITP development or/and treatment response in distinct population groups.
There is no data on the prevalence of cytokine gene polymorphisms in ITP
patients from the North-Western region of Russia (NWR).
Aims: To establish the features of genotypes distribution for several cytokine
promoter gene polymorphisms in ITP patients from NWR.
Methods: A total of 68 patients (59 women and 9 men) with chronic primary
ITP were involved in the study. The median age of the group was 57 years
(range: 24-77). The mean duration of ITP was 7 years (2-48). In 19 (32.2%)
women, ITP was diagnosed before 30 years old; 26 (38.2%) patients (5 men
and 21 women) were diagnosed at age 30-50 years; 23 (33.8%) patients (4
men and 19 women) developed ITP after 50 years old. The control group con-
sisted of 240 healthy persons originated from NWR. Nucleotide variations in
the genes coding for interleukin (IL)-1b (-31T/C), IL-6 (-174G/C), IL-10 (-
592C/A) and tumor-necrosis factor alpha (TNFA -308 G/A) were discriminated
by PCR and subsequent restriction analysis (PCR-RFLP). Intergroup differ-
ences in genotype frequencies were assessed by Fisher’s exact method. Odds
ratios (OR), their 95% confidence intervals (CI) and p-values were calculated
by using the GraphPad Prism 5.0 software.
Results: The frequency of the IL-10 -592CC genotype was slightly increased
in the ITP group when compared to controls (65.7% vs 54.0% respectively;
OR=1.6, 95% CI: 0.9-3.1, p=0.15). Interestingly, this variant of the IL-10 gene
was more prevalent among women than men with ITP (71.2% vs 25.0% respec-
tively; OR=7.4, 95% CI: 1.4-40.5, p=0.016). When compared to controls, the
IL-10 -592CC genotype was significantly overrepresented in the group of
women with ITP (71.2% vs 54.0%; OR=2.1, 95% CI: 1.1-4.2, p=0.044). On the
contrary, in the group of affected men we observed the increase of persons
who had IL-10 -592A allele (75.0% vs 46.0% in control group; OR=3.5, 95%
CI: 0.7-18.3, p=0.15). Genotype frequencies for other studied genes were sim-
ilar between the patients and control group as well as between women and
men with ITP. We have also found almost 2-fold increase of the IL-1b -31CC
frequency in women diagnosed before 30 years old compared to other patients
(15.8% vs 8.2% respectively; OR=2.1, 95% CI: 0.4-10.5, p=0.39). The presence
of the TNFA -308A allele was more often seen in patients diagnosed before 50
years old (26.7% vs 8.7% in other ITP patients; OR=3.8, 95% CI: 0.8-18.8,
p=0.12).
Summary/Conclusions: We suggest that the IL-10 -592CC genotype is asso-
ciated with increased risk of ITP in women from NWR. On the other hand, the
IL-10 -592A allele could be involved in pathogenesis of ITP in men. Further
studies are needed to clarify the significance of TNFA and IL-1b gene polymor-
phism in ITP development.
Platelets disorders
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COMBINED TREATMENT OF AZATHIOPRINE AND ROMIPLOSTIM IN
PATIENTS ITP REFRACTORY TO STEROIDS OR THROMBOPOIETIN
ANALOGS
M. E. Mingot-Castellano1,*, I. Sánchez-Bazán1, J. Díez-Pastor1
1Hematology, Regional University Hospital of Málaga, Málaga, Spain
Background: More than 70% of patients with Immune Primary Thrombocy-
topenia (ITP) respond to steroids, but 40 to 70% relapse in the first year fol-
low-up. The use of romiplostim in this group is effective, although 9% failure
has been described. In recent literature, there are clinical cases and small
series describing the potentiating effect of combined treatment with throm-
bopoietin analogues and immunosuppresive drugs such as steroids, cyclophos-
phamide and rituximab. We have not found references to the combined use of
azathioprine (AZA) and romiplostim (ROM).
Aims: To describe our experience in the combined use of azathioprine and
romiplostim as a rescue treatment in patients with acute or newly diagnosed
ITP refractory to corticosteroids or corticosteroid-dependence and refractary
to maximal doses of romiplostim monotherapy.
Methods: We analyzed patients with newly diagnosed or persistent ITP, with
corticosteroid-dependence or refractory to steroids and refractary to romi-
plostim, both in monotherapy. We have considered refractoriness to steroids
not reaching platelets higher than 30x109/L. Corticosteroid-dependece as the
need for ongoing or repeated doses administration of corticosteroids for at
least 2 months to maintain a platelet count at or above 30 X109/L and/or to
avoid bleeding. We considered refractoriness to romiplostim not get platelets
greater than 30x109/L with 10mcg/kg/week for at least 3 consecutive weeks.
All patients have been diagnosed in a single center with the same physician
responsible for the treatment and follow-up. The initial doses of AZA was
100mg/days (2mg/kg/day) and ROM 10mcg/kg/week. Patients have been eval-
uated every week untill platelets were higher than 30x109/L for to consecutive
weeks, after this they were reviewed monthly.
Results: We treated 4 patients (75% female) with a median age at diagnosis
of ITP of 53 years old (RIQ, 20-61 years). Treatments received prior to the use
of the combination of AZA and ROM were polyspecific immunoglobulins (Ig),
steroids (dexamethasone, prednisone) and romiplostim. Responses to steroids
and romiplostin in monotherapy were: • Median dexamethasone cycles
(40mg/days x 4 days) was 2.5 (2-4 cycles, IQR). The initial dose of prednisone
was 1-2mg/kg/days with a median treatment day of 31.5 days (28-60 days,
IQR). The type of response to steroids was PR with corticode-pendence in one
patient, 3 patients NR. • Median time from ITP diagnosis and romiplostim indi-
cation was 9.5 weeks (7-48 weeks, IQR). Median platelets count at the start of
romiplostim was 6x109/L (2-13x109/L, IQR). The median platelet count
achieved at maximal doses of romiplostim for at least 2 consecutive weeks
was 10x109/L (3-19x109/L, IQR). Once established the refractoriness to romi-
plostim, we manteined ROM 10mcg/kg/week and AZA was iniciated at
100mg/day. The median time from romiplostim indication to the association
with azathioprine was 9.8 weeks (5.5 to 15 weeks, IQR). The median time to
response after initiation of combination of AZA and ROM was 21 days (15-35
days, IQR). The types of response were: • One patient did not respond after
60 days of combined treatment. • 1 patient with RC maintains for 7 months in
the absence of active treatment. The combined was necesary during 8 months.
• 2 CRs still undergoing combined dose reduction (current dose romiplostim
2mcg/kg/week and azathioprine 50mg /d). Median platelets from onset of dose
reduction 169x109/L (128-176x109/L, IQR). Duration of RC, 7 and 14 months.
Non adverse events have been described in combination treatment.
Summary/Conclusions: The use of azathioprine and romiplostim in combination
could be a safe and effective alternative in subjects refractory to steroids or cor-
ticosteroid-dependence and thrombopoietin analogs alone. More studies are
needed to clarify the mechanism of complementation between the two drugs.
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AGONIST-INDUCED PLATELET REACTIVITY CORRELATES WITH
BLEEDING IN HEMATO-ONCOLOGICAL PATIENTS
B. Batman1,*, E.R. van Bladel1, M. van Hamersveld2, P.C. Pasker - de Jong1,
S.J. Korporaal3, R.T. Urbanus3, M. Roest3, L.A. Boven2, R. Fijnheer1,3
1Internal Medicine, 2Department of Clinical Chemistry, Meander Medical Cen-
ter, Amersfoort, 3Department of Clinical Chemistry and Hematology, University
Medical Center Utrecht, Utrecht, Netherlands
Background: Prophylactic platelet transfusions are administered to prevent
bleeding in hemato-oncological patients. However, bleeding still occurs, despite
these transfusions. This practice is costly and not without risk. Better predictors
of bleeding are needed and flow cytometric evaluation of platelet function might
aid the clinician in identifying patients at risk of bleeding. This evaluation can
be performed within the hour and is not hampered by low platelet count. 
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Aims: Our objective was to assess a possible correlation between bleeding
and platelet function in thrombocytopenic hemato-oncological patients.
Methods: Inclusion was possible for admitted hemato-oncology patients aged
18 years and above after written informed consent. Furthermore, an expected
need for platelet transfusions was necessary. Bleeding was graded according
to the WHO bleeding scale. Platelet reactivity to stimulation by either adenosine
diphosphate (ADP), crosslinked collagen-related peptide (CRP-xL), PAR1- or
PAR4-activating peptide (AP) was measured using flow cytometry. 
Results: A total of 114 evaluations were available from 21 consecutive patients.
Platelet reactivity in response to stimulation by all four studied agonists was
inversely correlated with significant bleeding. Odds Ratio’s (OR) for bleeding
were 0.28 for every unit increase in median fluorescence intensity (MFI) [95%
Confidence interval (CI) 0.11-0.73] for ADP; 0.59 [0.40-0.87] for CRP-xL; 0.59
[0.37-0.94] for PAR1-AP and 0.43 [0.23-0.79] for PAR4-AP. The platelet count
was not correlated with bleeding (OR 0.99 [0.96-1.02]).
Summary/Conclusions: Agonist-induced platelet reactivity was significantly
correlated to bleeding. Platelet function testing could provide a basis for a per-
sonalized transfusion regimen, in which platelet transfusions are limited to those
at risk of bleeding.
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TUMOR NECROSIS FACTOR-Α AND TUMOR NECROSIS FACTOR-Β
SINGLE NUCLEOTIDE POLYMORPHISM AND CHRONICITY IN EGYPTIAN
PEDIATRIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA
N. El-Gharbawi1, G. Shahin1, A. Eid1, N. Diaa1, M. El-Ghamrawy2,*
1Clinical and Chemical Pathology, 2Pediatrics, Faculty of Medicine, Cairo Uni-
versity, Cairo, Egypt
Background: Although the etiology of immune thrombocytopenic purpura (ITP)
remains unclear, both genetic and environmental factors may contribute to the
development of disease. Tumor necrosis factor alpha & beta (TNF-α and TNF-
β) are important pro-inflammatory cytokines that play a role in regulation of cell
differentiation, proliferation and death, as well as in inflammation, innate and
adaptive immune responses, and have been implicated in a wide variety of human
diseases. We hypothesized that inflammatory cytokine genes polymorphisms
(TNF-α and TNF-β) in ITP pediatric patients may play a fundamental role in patho-
genesis of the chronic course of the disease and this might be the base for future
specific immunomodulatory therapies for chronic ITP (cITP) in children.
Aims: The current case-control study aimed at detecting TNF-α (-308 G/A)
and TNF-β (+252 A/G) genes polymorphism in Egyptian children with cITP and
studying their possible association with chronic evolution of the disease. 
Methods: The current study included 80 Egyptian cITP patients at Pediatric
Hematology Unit, Cairo University (mean age 7.08±3.64 years) and 100 matched
unrelated healthy controls. Genotyping was performed using polymerase chain
reaction restriction fragment length polymorphism technique (PCR-RFLP). 
Results: TNF-α genotyping revealed that wild G/G, heterozygous G/A
and  homozygous A/A genotypes among cITP patients were 81.2%, 15% and
3.8% respectively versus 79%, 20% and 1% in control group, while TNF-β wild
A/A, heterozygous A/G and  homozygous G/G genotypes among cITP patients
were 55%, 40% and 5% respectively versus 60%, 28% and 12% in control
group, with no statistically significant difference between both groups. Patients
having homozygous TNF-α genotype showed statistically significant higher
mean age, longer disease duration & lower mean platelet count (p=0.005, 0.024
and 0.008 respectively). TNF-α polymorphism was more frequent among unre-
sponsive patients compared to responsive patients with statistically significant
difference. Calculated risk estimation revealed that combined genes polymor-
phism conferred three fold increased risk of development of cITP (OR=3.491,
95% CI: 1.235-9.869, p=0.015). 
Summary/Conclusions: We hereby report a strong association between com-
bined polymorphisms of both TNF-α & TNF-β genes and susceptibility to
chronicity of ITP in Egyptian children. Further studies for gene polymorphisms
which could affect the pathogenesis of ITP and facilitate the development of
new therapeutic modalities are recommended. 
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PROGNOSTIC FACTORS IN PRIMARY IMMUNE THROMBOCYTOPENIA
OF CHILDHOOD
A. Gkoutsias1, T. Palianopoulos1, E. Pappa2, E. Papapetrou3, C. Tsaousi3,
N. Chaliasos1, A. Makis1,*
1Department of Pediatrics, 2Department of Internal Medicine, 3Hematology
Laboratory, University Hospital of Ioannina, Greece, Ioannina, Greece
Background: Primary immune thrombocytopenia (ITP) is an immune disorder
with varied course. According the duration of the disease, it is distinguished in
newly diagnosed (<3 months), persistent (3-12 months) and chronic (>12
months). International studies have highlighted prognostic factors for each form
of ITP in children, but similar studies have yet to be been performed in Greece.
Aims: The evaluation of clinical and laboratory parameters and the identification
of prognostic markers for the three forms of the disease in children with ITP
from an academic reference center in Greece.
Methods: This retrospective study included 57 children with ITP in the past 13
years, aged 1-16 years (median age 5.2). The following data were recorded:
age, gender, preceding infection, bleeding type, duration of symptoms and
platelet count at the diagnosis, treatment, disease course and immunological
markers and comparison was made among the three types of ITP.
Results: 39 children had newly diagnosed, 4 had persistent and 14 had chronic
disease. Due to the small number of children with persistent form they were incor-
porated in the group of children with newly diagnosed ITP. In chronic ITP children
are more likely be above 10 years of age (p=0.015)and to have gradual initiation of
the disease (p=0.001) compared with newly diagnosed/persistent group (57% vs
21% and 79% vs 9%, respectively). Recent history of infection was found mainly in
newly diagnosed/persistent group (79% vs 21%, p=0.013). Platelet count below 10
x 109/L at diagnosis was found more frequently in newly diagnosed/persistent group
(79% vs 36%, p=0.01). Similar, but not statistically significant difference, was found
with mucosal bleedings (70% vs 50%, p=0.81). Children with newly diagnosed/per-
sistent disease had less frequently impaired immunological markers (12% vs 65%,
p <0.003) and received more frequent intravenous gamma globulin and/or corti-
costeroids (p>0.05). None of the children exhibited severe spontaneous bleeding.
Summary/Conclusions: Even though ITP in children is usually a self-limited
disease, with rare serious bleeding complications, the newly diagnosed/per-
sistent and the chronic form of the disease are characterized by different pre-
dictive parameters that can be used in clinical practice.
PB2099
CANCER-ASSOCIATED IMMUNE THROMBOCYTOPENIA
G. Pinto1,*, P. Herrera1
1Hematology, Hospital Ramon y Cajal, Madrid, Spain
Background: Cases of cancer-associated immune thrombocytopenia (IT) have
been reported recently, but there are few reports and case series that describe
clinical features and response to treatment. 
Aims: We report our experience of 10 years at a single hospital in Spain, in
patients with IT concurrent with neoplasia.
Methods: We identified the patients by data search of hospital records from
2006 to 2016, with diagnosis of IT with previous diagnosis of cancer, not related
with chemotherapy or radiotherapy, not suggestive of bone marrow infiltration,
drug-induced, infection of disseminated intravascular coagulation. For the diag-
nosis, the examination of bone marrow was not mandatory.
Results: The two most common cancers associated with IT were bladder and
lung neoplams, but the occurrence of prior cancer (third part of patients) was not
uncommon. The IT can appear at any stages of cancer, and it is mainly detected
at the first two years after the diagnosis when the patient have been in acceptable
antitumoral response. They usually manifest with very low platelet count <20.000,
but not always with evident clinical bleeding. The response to therapy was fast
and complete with corticoids (usually in the first week) in the majority of patients,
but some cases require the combination second line with immunoglobulins or
thrombopoietin receptor agonists, and in the follow-up, the response was per-
sistent without recurrence in the first year post-treatment (Table 1).
Table 1.
Summary/Conclusions: The CAIT is a rare hematological paraneoplastic syn-
drome that occur in solid tumors, usually associated to low platelet count but
without life-threatening bleeding, requiring therapy with corticosteroids as first
line, and generally related with a benign clinical course with a rapid and per-
sistent response. 
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THE ROLE OF MEAN PLATELET VOLUME IN NEONATAL SEPSIS:
A RETROSPECTIVE CASE CONTROL STUDY IN A LEVEL III NEONATAL
INTENSIVE CARE UNIT
A. Srinivasan1,*, X. Ameer1, M. Marron-Corwin1
1Pediatrics, Harlem Hospital Center, New York, United States
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Background: Sepsis is a relatively common diagnosis in the neonatal period.
Apart from blood cultures which are the gold standard, C-reactive protein
(CRP), total white blood cell count (WBC) and the ratio of immature to mature
neutrophils (I:T) are considered to be useful markers of sepsis in the neonatal
period. There are a few studies that show that mean platelet volume (MPV) is
elevated in infectious disease processes.
Aims: The aim of this study was to investigate whether mean platelet volume
is increased in neonates with sepsis.
Methods: Only term neonates were included in the study. Exclusion criteria
included: (a) Any neonate born with a genetic defect, (b) Any neonate with sus-
pected immunodeficiency, (c) Any neonate requiring surgery in the post-natal
period, (d) Neonates admitted to NICU for hyperbilirubinemia, (e) Neonates
requiring extensive resuscitation at birth resulting in documented Hypoxic
Ischemic Encephalopathy or requiring transfer to a Regional Perinatal Center.
Medical records were reviewed from March 2015 to June 2016 and a total of
114 eligible neonates were included in the study and they were divided into 2
groups: 39 neonates with clinical sepsis (as defined by either culture positivity
and/or clinical features plus treatment with antibiotics exceeding 48 hours) and
75 healthy controls (as defined by neonates in whom antibiotics were never
started or discontinued when cultures were negative for 48 hours and the
absence of clinical features of sepsis). Total white blood cell count, C-reactive
protein, immature to total neutrophil count and mean platelet volume drawn on
two occasions (first within 24 hours and the second between 24 to 48 hours
after delivery) were compared between the two groups.
Results: There was no statistically significant difference in the mean platelet
volume between the study group and the control group (p value 0.9 in the first
24 hours and p value of 1 in the 24-48 hour sample). There was however, a
statistically significant difference between immature to total neutrophil count
and C-reactive protein on both samples (p value <0.0001) (Table 1).
Table 1.
Summary/Conclusions: In our study there was no statistically significant dif-
ference in the mean platelet volume values between neonates with sepsis and
healthy controls. C-reactive protein and immature to total neutrophil count con-
tinue to be reliable markers of neonatal sepsis.
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IS PLATELET TRANSFUSION WARRANTED IN PATIENTS WITH ACUTE
TTP REQUIRING CENTRAL VENOUS CATHETER INSERTION?
R. Low1,*, T. Dutt2
1Postgraduate Department, Central Manchester Foundation Trust, Manchester,
2The Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool Uni-
versity Hospital, Liverpool, United Kingdom
Background: Thrombotic thrombocytopenic purpura (TTP) has a high mortality
rate. The cornerstone of management is plasma exchange (PE) which usually
requires urgent insertion of a central venous catheter. Patients often have a
platelet count of <50x109/L at presentation however, National BCSH Guidance
advises against platelet transfusion in TTP due to the perceived high aggrega-
bility state and reports of associated fatal thrombosis.  The risk of thrombocy-
topaenia related haemorrhage however creates anxiety and dilemma for the
team responsible for line insertion and may lead to delays or unnecessary
platelet transfusion. 
Aims: The aim of the study is determine the average platelet count at time of
line insertion and to see if any bleeding complications are observed.
Methods: We retrospectively reviewed all central venous catheter lines inserted
in patients presenting to a regional TTP Centre over a 4-year period from 2012-
2016.
Results: A total of 48 patients confirmed to have TTP with an ADAMTS13 <5%
underwent line insertion: 94 central venous catheter lines were inserted: 40%
femoral, 60%–internal jugular vein. The median number of lines inserted per
patient episode was 3, with a range of 1-5. Median presenting platelet count
for first line insertion was 25x109/L (IQR 9-26 x109/L). 70% of lines were insert-
ed by critical care and the remaining 30% by interventional radiology. Platelet
transfusion was not administered pre line insertion in any case. No significant
bleeding complications were documented during or after line insertion. 5
patients had ‘excessive oozing at the insertion site’ documented, within the
first 24 hours of insertion, for which no intervention was required. There were
no deaths related to line insertion. 
Summary/Conclusions: In conclusion, this study shows no significant bleed-
ing risk associated with central venous catheter insertion in thrombocytopenic
patients presenting with TTP. The results support guidance against prophylactic
platelet transfusion in this setting and provide reassurance for teams tasked
with central line insertion in this critically unwell patient group.  
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LONG-TERM EFFICACY AND SAFETY OF THROMBOPOIETIN AGONISTS
IN ADULT REFRACTORY CHRONIC IMMUNE THROMBOCYTOPENIA 
M. Kaliou1, E. Gavriilaki1,*, G. Papaioannou1, Z. Bousiou1, M. Iskas1,
C. Vadikoliou1, C. Lalayanni1, A. Athanasiadou1, R. Saloum1,
A. Anagnostopoulos1
1Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki,
Greece
Background: Management of chronic immune thrombocytopenia (cITP) aims
not only to increase and maintain platelet counts in safe levels, but also to
improve quality of life. Thrombopoietin agonists eltrombopag and romiplostim
have been approved in refractory ITP. The lack of randomized studies allows
only for real-world data comparison on the two agents.
Aims: In the present study we evaluate and compare long-term efficacy and
safety of etrombopag and romiplostim in clinical practice and assess the switch-
ing feasibility between the two agonists.
Methods: Treatment with thrombopoietin agonists was initiated in 20 adult
patients (pts) with refractory cITP between June 2011-2016. Patients resistant
or intolerant to the first agonist switched to the second one. Complete response
(CR) was defined as a platelet count of ≥100x109/L.
Results: Eltrombopag was administered in 15 pts, 6 male:9 female with a median
age of 46 years (19-76 yrs) for 13 months (1.4-54 mo). Patients had received a
median of 1 previous treatment (range 1-7): corticosteroids (15/15), intravenous
immunoglobulin (5/15), rituximab (2/15), vincristine (1/15), cyclosporine (2/15),
romiplostim (2/15), danazol (1/15) and splenectomy (1/15). Before eltrombopag
treatment, the majority (8/15) showed grade 4 (WHO) thrombocytopenia. Initial
dose was 50 mg and increased to 75 mg daily in 3/15 pts and in combination
with corticosteroids that were gradually tapered by the 5th week in 12/15. Median
platelets value by the 2nd week of administration was 140x109/L (5-450 x109/L);
whereas, by the 4th week increased to 185x109/L (16-500x109/L). At the end of
follow-up, all patients but one achieved CR with median platelets of 145x109/L
(60-400 x109/L). Regarding adverse events, 1/15 pt presented  hemolytic anemia,
1/15 pt hepatotoxicity grade 2 with episodes of thrombocytopenia grade 4 and
1/15 pt pulmonary embolism during the second month of treatment. The latter 2
pts switched to romiplostim. Romiplostim was administered in 9 pts, 4 male:5
female aged 44 years (33-63 yrs) for 40.7 months (22.4-60.1). They had received
a median of 3 previous treatments (range 1-8): corticosteroids (9/9), intravenous
immunoglobulin (6/9), rituximab (6/9), vincristine (2/9), cyclosporine (2/9), eltrom-
bopag (2/9), danazol (1/9) and splenectomy (2/9). The majority (5/9) presented
thrombocytopenia grade 4 before romiplostim. Median platelets number by the
2nd week of administration was 50x109/L (8-140 x109/L); whereas, by the 4th
week increased to 115x109/L (20-400x109/L). At the end of follow-up, 6/9 patients
achieved CR with median platelets at 145x109/L (110-400x109/L). All patients
received concomitant steroid treatment that was gradually tapered and stopped
in 6/9 pts.  2/9 pts switched to eltrombopag due to thrombocytopenia grade 3
and 1/9 pt to danazol and low-dose steroids achieving CR. No adverse events
associated with romiplostim treatment were reported.
No significant differences were found between the 2 treatment groups. All 4
patients that switched to the other agonist achieved CR without adverse events.
Summary/Conclusions: Our real-world data suggest that both eltrombopag
and romiplostim are safe, well tolerated and highly effective in refractory cITP
and furthermore, switching to another agonist is safe and effective. Future stud-
ies will determine predisposing factors for adverse events and more accurate
classification of patients that will allow for better treatment guidance.
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VITAMIN D RECEPTOR GENE POLYMORPHISMS IN ADULT PRIMARY
IMMUNE THROMBOCYTOPENIA
M. Sakr1,*
1internal Medicine- Hematology, Menoufia University, Cairo, Egypt
Background: Recently, several studies have demonstrated the role of vitamin
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D receptor (VDR) polymorphisms in the development of autoimmune diseases.
Vitamin D affect both innate and adaptive immune responses that have been
blamed in immune thrombocytopenia (ITP) pathogenesis.
Aims: The aim of this study is to assess the association of vitamin D receptor
gene polymorphism BsmI in cases of adult primary immune thrombocytopenia.
Methods: Vitamin D receptor polymorphism BsmI (rs1544410) was detected
by Polymerase Chain Reaction followed by Restriction Fragment Length Poly-
morphism (PCR–RFLP). Deoxyribonucleic acid (DNA) samples were extracted
from peripheral blood of 40 ITP patients and 60 geographically and ethnically
matched healthy controls.
Results: Statistically significant difference was found in the BsmI polymorphism
between ITP  patients and controls (χ2 = 8.77, P value=0.01). The BsmI poly-
morphism B allele was higher in ITP group than that in controls but in statistically
insignificant difference (χ2 = 2.125, P = 0.145). bb genotype played a protective
role in ITP incidence.
Summary/Conclusions: This is the first published report on VDR gene poly-
morphisms in adult primary ITP patients. The BsmI genotype was associated
with increased risk for ITP incidence with no obvious effect on bleeding severity,
platelet count nor site of bleeding.
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A SURVEY OF THE TREATMENT OF THE PREVENTION OF NAIT IN THE
UK AND IRELAND
D. O’Keeffe1, V. Broderick1,*
1UHL, Dept of haematology, Limerick, Ireland
Background: Neonatal alloimmune thrombocytopenia, (NAIT) is caused by
maternal antibodies generated against alloantigens carried on fetal platelets,
which cross the placenta and induce destruction of platelets in the fetus. In
most cases the maternal immunisation is triggered by exposure to fetal blood
at delivery. As a result, the clinical presentation tends to be more severe in
subsequent pregnancies. Recent studies and guidelines have suggested that
intravenous immunoglobulin (IVIG) with or without steroids can significantly
reduce the severity of thrombocytopenia in subsequent pregnancies.
Aims: We set out to establish if there is consistency in the management of the
prevention of NAIT across Ireland and the United Kingdom (UK).
Methods: A survey was set up on Survey Monkey and all members of the UK-
Ireland Haematology group were contacted by email with a link to the survey in
January 2015. In total 90 individual Specialists were contacted across 70 centres.
Results: 30 responses were received to the following questions. Who manages
the prevention of NAIT in your centre? 34% of respondents stated that it was
managed jointly by haematologist/feto-maternal specialists, with 26% responding
it was overseen solely by haematologists and 40% solely by feto-maternal spe-
cialists. Secondly what risk stratification each respondent used to decide risk of
NAIT in the current pregnancy? 82% stated that they took into account multiple
risk factors but 18% stratified risk based only on the outcome of previous preg-
nancy. Thirdly how many groups do you define after risk stratification?   60%
identified 3 strata of risk (standard, high and very high) with 40% classifying two
risk groups (standard versus high risk). Fourthly respondents outlined their man-
agement of a standard risk group defined as confirmed thrombocytopenia with
antibody. 43% give IVIG 1g/kg weekly from 20 weeks, 28% give 1g/kg from 20
weeks increasing to 2g/kg at 32 weeks with 6% starting 1g/Kg IVIG from 24
weeks. 23% referred to feto-maternal specialist to decide IVIG .  Just 20% give
0.5mg/kg of steroids from 20 or 32 weeks. For high risk pregnancies defined as
confirmed antibody positive with previous intracranial haemorrhage (ICH) after
28 weeks: 36% of centres give IVIG 1g/kg from 20 weeks, 36% give 1g/kg from
20 weeks increasing to 2g/kg at 32 weeks with 14% giving 2g/kg from 20 weeks
and 14% initiating at 12 weeks. 40% gave 0.5mg/kg of steroids varying from 12-
32 weeks starting. 60% of centres use a very high risk protocol (ICH before 28
weeks) with more intensive IVIG starting at 12 or 20 weeks with steroids of vari-
able intensity and duration. Finally respondents were questioned whether there
was a planned delivery time and method for the pregnancy? 58% plan a delivery
at 38 weeks with no specific delivery mode. 18% plan delivery at 38 weeks by
caesarean section, 8% plan a caesarean section but with no set time and 16%
have no specific protocol plan for delivery. 
Summary/Conclusions: The results of this survey reveal that the optimal med-
ical management for the prevention of NAIT, namely the medication, dosage
and schedule vary widely reflecting the lack of good evidence to guide centres
in this very challenging area. Based on this survey we plan with our colleagues
in UKOS a prospective study of treatment and outcomes.
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THE EVALUATION OF REACTIVE OXYGEN SPECIES IN CHRONIC
IDIOPATHIC THROMBOCYTOPENIC PURPURA AND HELICOBACTER
PYLORI INFECTION VERSUS CHRONIC ITP WITHOUT HELICOBACTER
PYLORI INFECTION
M.-A. Gaman1,*, A. M. Gaman2,3
1”Carol Davila” University of Medicine and Pharmacy, Bucharest, Bucharest,
2Hematology, Filantropia City Hospital, 3Pathophysiology, University of Medi-
cine and Pharmacy of Craiova, Craiova, Romania
Background: Chronic idiopathic thrombocytopenic purpura (ITP) is an acquired
disease characterized by a low platelet count caused by an immunological
peripheral platelet destruction or a decreased platelet production. Several stud-
ies have shown increased reactive oxygen species (ROS) levels in chronic ITP
and also a possible association between Helicobacter pylori (H. pylori) infection
and immunological peripheral platelet destruction.
Aims: To evaluate whether patients with chronic ITP and H. pylori infection
exhibit higher ROS levels compared to patients with chronic ITP and no H.
pylori infection and whether there are statiscally significant differences between
the two groups.
Methods: We studied 29 patients with chronic ITP (median age 39 years) hos-
pitalized in the Clinic of Hematology, Filantropia City Hospital, Craiova, Roma-
nia, between 2014 and 2016 (informed consent obtained). All patients were
diagnosed with ITP, other causes of thrombocytopenia having been ruled out
by bone marrow aspiration. The patients were divided in two groups: patients
with ITP and H. pylori infection (group A) and patients with chronic ITP without
H. pylori infection (group B). Serological tests (ELISA) were used to indicate
the presence of a H. pylori infection and reactive oxygen species were evalu-
ated by FORT (Free Oxygen Radicals testing) test from a single drop of capillary
blood, at the time of diagnosis, before the administration of any drug (the normal
value of FORT is considered less than 2.3 mmol/L H2O2), using a CR3000
analyzer (Callegari SpA, Parma, Italy). The differences between the two groups
were assessed using the Student T-test and a p-value of less than 0.05 was
considered statistically significant.
Results: Group A consisted of 11 patients positive for H. pylori, whereas group
B included 18 patients with no H. pylori infection. ROS levels, measured by the
FORT test, were elevated in both groups (between 2,8 – 3.6 mmol/L H2O2).
However, statistically significant differences were found in favour of group A,
with higher ROS values than group B. The A group also associated lower
platelet counts and more patients pertaining to this group relapsed in compar-
ison to group B. 
Summary/Conclusions: In chronic ITP, increased levels of ROS are associ-
ated with elevated autoantibody production. Autoantibodies are involved in
platelet destruction via highly a immunogenic activity. On the other hand, asso-
ciation of H. pylori infection, via chronic inflammation, led to a supplementary
increase in ROS levels and increased platelet destruction.
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IMMUNE THROMBOCYTOPENIA AND PREGNANCY: A SPANISH CASE
SERIES OF 270 PREGNANCIES IN PRIMARY ITP.
T.J. González-López1,*, J. Bastida2, P. Olivera3, I. Jarque4, S. Bernat5,
B. Sánchez-González6, E. Bolaños7, G. Pérez-Rus8, A.R. Huerta8,
V. Martínez-Robles9, M.P. Martinez-Badas10, R. Perez-Montes11,
M.J. Peñarrubia12, V. Conesa13, N. Bermejo14, M. T. Alvarez15,
C. Fernández-Miñano16, L. Guerrero 17, S. Marcellini18, M. Sierra Pacho19,
E. Pardal20, C. Muñoz21, G. Hermida1, J.R. Gonzalez Porras2
1Department of Hematology, Hospital Universitario de Burgos, Burgos, 2Depart-
ment of Hematology, Hospital Universitario de Salamanca, Salamanca,
3Department of Hematology, Hospital Valle de Hebron, Barcelona, 4Department
of Hematology, Hospital La Fe, Valencia, 5Department of Hematology, Hospital
la Plana, Castellon, 6Department of Hematology, Hospital del Mar, Barcelona,
7Department of Hematology, Hospital Clínico San Carlos, 8Department of
Hematology, Hospital Gregorio Marañón, Madrid, 9Department of Hematology,
Hospital de León, León, 10Department of Hematology, Hospital de Avila, Avila,
11Department of Hematology, Hospital Universitario de Valdecilla, Santander,
12Department of Hematology, Hospital Clínico de Valladolid, Valladolid,
13Department of Hematology, Hospital de Elche, Elche, 14Department of Hema-
tology, Hospital de Cáceres, Cáceres, 15Department of Hematology, Hospital
Universitario La Paz, Madrid, 16Department of Hematology, Hospital Vega Baja,
Orihuela, 17Department of Hematology, Hospital Rio Carrión, Palencia,
18Department of Hematology, Hospital de Segovia, Segovia, 19Department of
Hematology, Hospital de Zamora, Zamora, 20Department of Hematology, Hos-
pital Virgen del Puerto, Plasencia, 21Department of Hematology, Hospital Infan-
ta Leonor, Madrid, Spain
Background: Effect of pregnancy on the course of primary immune thrombo-
cytopenia (ITP) is not well known. Besides, due to the lack of clinical assays,
evidence about outcome predictors of pregnants and neonates born to mothers
with ITP is scarce.
Aims: To evaluate management and results of pregnancy and delivery on preg-
nant ITP women and on their offspring.
Methods: All women diagnosed of primary ITP (according to international con-
sensus criteria) from 2011 to 2016 in 23 Spanish Hematology Departments
who had at least one pregnancy after ITP onset were included in this registry.
Results: We included 270 primary ITP pregnancies from 184 women. At preg-
nancy diagnosis, we observed a majority of chronic ITP cases (71.4%). At ITP
diagnosis, median age of our case-series was 23 years (IQR, 19-29) and medi-
an platelet count was 18 x 109/l (IQR, 6-35). Median time from ITP diagnosis
to pregnancy was 167 months (IQR, 0-366). Median number of pregnancies
prior to ITP diagnosis were 1 (IQR, 0-2) with 1 pregnancy (IQR, 1-2) after ITP
diagnosis as a median.
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50.8% of women received corticosteroids, immunoglobulins (IVIG) (16.9%),
rituximab (6.8%) and/or splenectomy (8.4%) as ITP treatments between or
before new pregnancies. On the other hand, 26.4% of women needed treat-
ment for ITP during pregnancy, mainly steroids (13.5%) and IVIG (10.2%).
The median platelet-count nadir during pregnancy was 74 x 109/l (IQR, 36-
172). 127 (47%) pregnancies suffered from non-haemostatic platelet levels
(less than 50 x 109/l) with 73 (27.0%) women who achieved less than 30 x
109/l. 56 (20.7%) women exhibited hemorrhagic symptoms, being 30 (11.1%)
of them severe bleedings.
Regarding type of delivery, this was vaginal in 63.4% of pregnancies and
cesarean sections 30.5%. Median platelet count at delivery was 110 x 109/l
(IQR, 76-181). 43 patients (23.4%) experienced 57 bleeding episodes.
We only observed 48 cases (20.4%) of neonatal thrombocytopenia among 235
living newborns.
Summary/Conclusions: Our results are comparable to previously reported
studies. No severe bleeding complications during pregnancy and/or delivery
were observed in our case series. Rate of neonatal thrombocytopenia, and
therefore, newborn bleeding is low.
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ANALYSIS OF THE DEMOGRAPHIC, CLINICAL, LABORATORY AND
TREATMENT-RELATED DATA OF ITP PATIENTS IN GREECE BASED ON
THE NATIONAL ITP REGISTRY OF THE HELLENIC SOCIETY OF
HAEMATOLOGY 
E. Stavroulaki1,*, V. Tzikoulis2, M. Kaparou3, P. Kanellou3, P. Panayiotidis4,
P. Tsaftaridis4, N. Viniou5, E. Bitsani4, V. Bartzi4, T. Iliakis4, A. Galanopoulos6,
G. Kanavos6, S. Hondropoulos6, E. Michalis6, N. Anagnostopoulos6,
A. Symeonidis7, A. Kourakli7, P. Lampropoulou7, A. Megalakaki8, A. Palla9,
M. Papaioannou10, G. Kaiafa11, D. Liapi1, E. Vlachaki12, S. Giannouli13,
I. Kotsianidis14, D. Kyriakou15, M. Protopappa16, E. Hatzimichael17, P. Zikos18,
C. Pontikoglou3, G. Chalkiadakis2, H. Papadaki3
1Department of Haematology, Venizeleio-Pananeio General Hospital, 2Infor-
mation Systems Unit Center of Information and Communications Technologies,
University of Crete , 3Department of Haematology, University of Crete School
of Medicine, Heraklion, 41st Department of Propaedeutic Medicine, 51 st
Department of Medicine, National and Kapodistrian University of Athens(
(NKUA), 6Department of Haematology, Gennimatas General Hospital, Athens,
7Department of Haematology, University of Patras, Medical School, Patras,
8Department of Haematology, Anticancer Hospital of Peiraia “Metaxa”, Peireas,
9Department of Haematology, General Hospital of Chania “Agios Georgios,
Chania, 101st Department of Internal Medicine, 111st Propaedeutic Department
of Internal Medicine, Aristotle University of Thessaloniki, AHEPA University
Hospital, 122nd Department of Internal Medicine, Aristotle University of Thes-
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Internal Medicine, Athens University Medical School, General Hospital
“Ippokrateio”, Athens, 14Department of Haematology, University of Thrace, Uni-
versity Hospital of Alexandroupolis, Alexandroupolis, 15Transfusion Medicine
Department, University Hospital of Larissa, Larissa, 16Department of Haema-
tology, General Hospital of Serres, Serres, 17Department of Haematology, Uni-
versity Hospital of Ioannina, Ioannina, 18Department of Haematology, General
Hospital of Patras “St Andrew”, Patras, Greece
Background: Immune thrombocytopenia (ITP) consists of various acquired
disorders caused by autoantibodies against platelets resulting in increased
platelet destruction and impaired thrombopoiesis. ITP is characterized as pri-
mary when an underling etiology cannot be identified and secondary when a
certain etiology exists. Data concerning ITP characteristics at a national level
are limited. 
Aims: The purpose of the study was to access systematically the demographic,
clinical, laboratory and treatment-related data of ITP in Greece based on the
national database (ITP registry) operated and supported by the Hellenic Society
of Haematology. 
Methods: Patient data were collected over 2013-2016. The data source is a
unique database initiated and managed by the Haematology Department of
the University of Crete (UoC) and supported by the Center of Information and
Communications Technologies of the UoC. The registry has been configured
for national and regional base usage considering hospitals as the core unit. A
certified researcher/administrator has access to a platform where he/she can
record and study patients’ data. The entire project has been developed using
the robust open source tools of operating systems and Relational Data Base
Management System (RDBMS) packages.
Results: We analyzed data from 696 adult ITP patients registered from 14 dif-
ferent hospitals from all parts of Greece. The median age at diagnosis was 53
years (range 15-97 years). Two peaks were observed at the age of 19-30 and
71-80 years. There was a female (60.89%) versus male (39.1%) predominance
with higher frequency of females in younger (19-30 years) and of males in older
(71-80 years) ages. Females appeared with more severe thrombocytopenia. The
median platelet count at diagnosis was 15x103/ml. The majority of patients pre-
sented with hemorrhagic symptoms (70.9%). The main manifestations were cuta-
neous bleeding (64%), oral cavity bleeding (20.9%), epistaxis (8.9%), menor-
rhagia (7.8%) and gastrointestinal bleeding (5.5%). 430 patients (61.78%) had
primary ITP and 266 (38.22%) secondary ITP. Among these secondary ITP cas-
es, 44.22% were related to infectious agents, 25.74% to drugs, 17.17% to colla-
gen vascular diseases and 12.87% to cancer.  Patients with positive ANA anti-
bodies with no evidence of any underlying diseases were included in the primary
ITP group. The main patient comorbidities were hypertension (22.64%), thyroid
disease (12.32%) and cardiovascular disease (10.17%). Treatment was given in
620 patients at diagnosis. Specifically, 577 (93%) patients were treated with cor-
tocosteroids, 322 (51.9%) with intravenous IgG, 265 (42.7%) with both, and 112
(18%) received other treatments including rituximab (4.8%), anti-D immunoglob-
ulin (4%) and thrombopoietin receptor agonists (4%). The majority of the patients
(85%) responded to the initial treatment. Follow-up data for more than one year
are currently available in 259 patients (133 with persistent ITP and 126 with
chronic ITP). Splenectomy has been performed in 59/696 patients (8.47%).
Summary/Conclusions: Primary ITP is more frequent than secondary ITP in
Greece, the disease displays two peaks at the ages of 19-30 and 71-80 years,
presents a female predominance and high frequency of hemorrhagic symptoms.
Treatment is mainly based on corticosteroids and/or intravenous IgG. Registration
and follow-up of larger number of patients and evaluation of response to various
treatments are anticipated to extend our knowledge on the pathophysiology and
natural history of ITP and may also reveal peculiarities at local level.
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PRESENTING SYMPTOMS AFFECT OUTCOME IN IMMUNE MEDIATED
THROMBOTIC THROMBOCYTOPENIC PURPURA
J. Khwaja1,*, F. Alwan1, C. Vendramin2, K. Langley2, M. Thomas1,
J.P. Westwood1, M. Scully1
1Haematology Department, University College London Hospital, 2Haemostasis
Research Unit, University College London, London, United Kingdom
Background: Whilst immune mediated Thrombotic Thrombocytopenic Purpura
(TTP) has classically been suspected by the presence of a pentad of symptoms
(microangiopathic haemolytic anaemia, fever, disturbed neurological function,
renal failure, thrombocytopenia), the limitations of this have long been recog-
nized and a wide variety of symptoms are seen on initial presentation.
Aims: A retrospective review of the significance of specific symptoms and their
duration on mortality.
Methods: A retrospective review of all consecutive admissions to a single ter-
tiary center between 2009 and 2015. Only patients who required plasma
exchange were included. Patients’ symptoms and their duration were reviewed
in addition to presenting anti-ADAMTS13 IgG antibody levels and ADAMTS13
antigen levels, both of which have previously been found to have prognostic
significance.
Results: 106 patients (68% female) were included with a median age of 48. 58%
were Caucasian and 19.8% Afro-Caribbean. The mortality rate was 7.4% (n=8).
47% of patients had neurological symptoms on presentation, 24% reported a
bleeding history and 12% a recent infection. The most common presenting symp-
toms were headache (27.4%), bleeding (24%) spontaneous bruising/petechial
rashes (19.8%), speech disturbances (encompassing expressive/receptive dys-
phasia, aphasia, dysarthia and slurred speech, 19.8%) and TIA or stroke like
symptoms encompassing hemiplegia or facial weakness/droop (16%). The highest
rates of mortality were seen in patients who experienced loss of consciousness
(mortality 33.3%), abdominal pain (mortality 22.2%) and heavy bleeding (mortality
16.7%). The anti-ADAMTS13 IgG level was not however significantly higher in
these symptoms when compared to others (Table 1) suggesting microangiopathic
thrombosis location plays an important role in TTP prognosis. The median duration
of symptoms prior to presentation was 7 days (range 1-60 days). 8.5% of patients
were asymptomatic, all relapsed TTP. Patients in the highest quartile for symptom
duration (>10 days) had significantly higher anti-ADAMTS13 IgG antibody level
than those in the lowest quartile for symptom duration (<2 days) (65% vs 26%,
p=0.002) and may have increased mortality (symptoms <2 days mortality 7.4%,
symptoms >10 days 14.3%, p=0.19).
Table 1.
Summary/Conclusions: Whilst there is little difference in the anti-ADAMTS13
IgG antibody and ADAMTS13 levels seen with difference symptoms, there is
a wide disparity in terms of mortality suggesting the effect of microangiopathic
thrombosis differs by location. Abdominal pain, not previously recognized as a
significant symptom in TTP, seems to be a poor prognostic indicator although
this should be interpreted with caution given the sample size. Anti-ADAMTS13
IgG antibody level increases with symptom duration and this may lead to
increased mortality.
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NOVEL TECHNIQUES FOR MONITORING GALNZMANN
THROMBASTENIA PATIENT UNDERGOING SURGICAL INTERVENTIONS
A. Barg1,2,*, H. Hauschner1,2, M. Misgav1,2, E. Avishai1, N. Rosenberg1,2,
G. Kenet1,2
1Institute of thrombosis and hemostasis, Sheba medical center, 2Sackler Fac-
ulty of Medicine , Tel Aviv University, Tel Aviv, Israel
Background: Glanzmann thrombasthenia (GT) patients undergoing surgical pro-
cedures are often treated by platelet transfusion. However many GT patients
who have been previously exposed to platelets may form antibodies either against
the missing αIIbβ3 antigen or directed against MHC-class molecules thus ham-
pering the efficacy of care. Due to the rarity of disease there is paucity of data
regarding platelet transfusion protocols during the perioperative period. We herein
describe our experience with monitoring the proportion of donor platelets following
transfusion, and their contribution to whole blood clot formation.
Aims: To describe the use of flow cytometry (FC) analysis in order to detect
donor transfused platelets in A GT patient undergoing a minor surgical proce-
dure and to assess the correlation between FC analysis and the results of Rota-
tional thromboelastography(ROTEM).
Methods: A nine year old female patient with GT underwent teeth extraction. The
Patient received platelet transfusion around the procedure. Complete blood counts,
ROTEM, FC to detect the number of  donor platelets and their ADP dependent
activation, were sampled and followed till 7 days post teeth extraction.
Results: Prior to teeth extraction upon injection of local anesthetics patient devel-
oped a buccal hematoma probably owing to local blood vessel penetration. The
patient did not experience any post extraction bleeding.  Hematoma was absorbed
within several days. Post transfusion platelets FC demonstrated 20.6%% donor
platelets equivalent to 55,620 donor platelets. Platelets activation was determined
following ADP addition by examination CD62 antigen expression. Seven days post
platelet transfusion FC demonstrated 2.6% equivalent to 8,658 donor plantlets.
The decline in the number of active platelets was associated with a reduced clot
firmness (MCF) and lower α-angle as assessed by ROTEM (Figure 1).
Figure 1.
Summary/Conclusions: Clinical decision making in patients with GT may be
aided by application of novel techniques, evaluating the number of active donor
platelets and actual clot formation. This data may help making more knowl-
edgeable decisions as for the need for further platelet transfusion or for the
need for rFVIIa. Thus leading to improved monitoring and better patients’ care.
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CAN HISTOCHEMICAL C-MPL POSITIVITY IN BONE MARROW BE A
PREDICTOR FOR SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA?
I. Yavasoglu1, N. Gencer1, F. Cantas2, F. Doger3, Z. Bolaman1,*
1Adult Hematology, 2Biostatistics, 3Pathology, Adnan Menderes University Med-
ical Faculty, Aydin, Turkey
Background: Splenectomy is used as the second line therapy in patients with
immune thrombocytopenia (ITP). However, there is no parameter predicting
splenectomy decision. 
Aims: Aim of the present study was to evaluate immune histochemical Cloned
Myeloid Leukemia Virus (c-mpl) positivity in bone marrow specimens of ITP
patients with or without splenectomy indications. 
Methods: Bone marrow specimens were taken from 24 patients who were
diagnosed with ITP and who had splenectomy (15 female, 9 male, mean age
50±16) before splenectomy and 30 patients who were diagnosed with ITP but
did not have splenectomy (15 female, 15 male, mean age 52±19). c-mpl staining
was carried out retrospectively. Immunohistochemical (IHC) staining using
Avidin-Biotin complex system (ABC) was conducted. For IHC, dissections pre-
pared from blocks were taken onto poly-L-lysine coated slides (MicroSlides
Snowcoat X-tra, Surgipath, Richmond, IL, USA) and kept in an incubator at 37
°C overnight. Dissections were treated with IHC c-mpl (Santa Cruz/sc-13187)
stain. Cytoplasmic and nuclear staining was observed in megakaryocytes using
IHC c-MPL and vitamin D. Evaluation was made based on the intensity of the
staining; i.e. negative (0), weak (1+), moderate (2+) and strong (3+) (1). All
patients who had splenectomy were in chronic phase of the disease. The pres-
ent study was supported as a Scientific Research Project by Adnan Menderes
University (TPF-15027).
Results: c-mpl positivity was statistically significant in patient group who did
not have splenectomy (Table 1). In patient group who had splenectomy, c-mpl
was not associated with refractory status.
Table 1. c-mpl positivity in patients group who had and did not have
splenectomy.
Summary/Conclusions: Status of c-mpl in ITP is ambiguous. Significant level
of positivity in patient group who did not have splenectomy might the useful for
splenectomy indication.
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CLINICAL SIGNIFICANCE OF IMMATURE PLATELET FRACTION
MEASUREMENT IN THROMBOCYTOPENIC DISORDERS DURING
PREGNANCY 
R. Coll1,*, A. Marull1, M. Sagüés1, N. Kelleher1, O. Jimenez1,
C. Morales-Indiano1, M. Serrando1
1Hematology Department, Institut Català de la Salut, Girona, Spain
Background: Thrombocytopenia is the second most common hematologic
abnormality during pregnancy and is usually a benign condition. The challenge
to the clinician is to weigh the risks of maternal and fetal bleeding complications
against the benefits of diagnostic tests and interventions.  This condition can
also be associated with several diseases, either pregnancy specific or not, such
as preeclampsia, HELLP syndrome, or idiopathic thrombocytopenic purpura
(ITP). The differential diagnosis between ITP and gestational thrombocytopenia
is clinically important with regard to the fetus, due to the risk of neonatal throm-
bocytopenia. The immature platelet fraction (IPF) is young cells that have
recently been released into the circulation, and are considered indicators of
bone marrow recovery. They contain a higher concentration of RNA than mature
platelets. Measure of immature platelet fraction (IPF) has been suggested as
a less invasive and early diagnostic test in the study of thrombocytopenic dis-
orders. Immature platelet fraction can be currently measured by fully automated
hematology analyzers providing clinical utility for diagnosing and monitoring
thrombocytopenia.
Aims: The aim of this is to know whether IPF can be a useful parameter in preg-
nant women with thrombocytopenia to predict the potential risk of bleeding.
Methods: Pregnant women with thrombocytopenia were selected (2015-2016);
a total of 25 patients (mean age: 33 yrs, range 19-43 yrs) were examined with
platelet count <100.000 platelets/μL. Venous whole-blood samples were col-
lected into Vacutainer EDTA-K2E tubes (Becton Dickinson and Company, Ply-
mouth, UK). Complete blood counts and immature platelet fraction (%IPF) were
immediately analyzed within 2 h of blood withdrawal by Sysmex XN20 system
(Sysmex Corporation, Kobe, Japan). Novel PLT-F channel uses fluorescent
light and stains platelets specifically with Oxazine Dye (Fluorescent Fluorocell).
Bleeding complication has been collected in order to know if there is related
to%IPF.
Results: Mean platelet count was 73.000 platelets/μL  (range of 69-91) and
IPF mean was 11% (2,5-23,4). Lab test Hemoglobin shows a mean of 95,17
g/L [range of 45-132] ( in no-bleeding group was 105,8 g/L whereas in bleed-
ing-group was 86,14 g/L p=0,0768) p=0,07. IPF% was <10% in 11, which means
a 44% of the patients. 14 patients bleed during or after labor, 56% among all
the patients in this study. Related to this group, 11 patients had IPF <10%; 3 of
bleeding patients showed an IPF >10%. All pregnant women with an IPF <10%
(11/11) bleed as a complication. Pregnant women with thrombocytopenia and
a IPF <10% has a higher risk of bleeding during and/or after labor compared
with pregnant women with a IFP>10% (Fisher 12,41, P<0,001). 5 (20,83%)
patients among all of them were under treatment (earlier or during labor):  3
(12,5%) with steroids and 2 (8,33%) with other methods.
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Summary/Conclusions: Thrombocytopenia is a potential risk of bleeding dur-
ing the labor. A high IPF indicates either consumptive or recovering thrombo-
cytopenic disorders, such as immune thrombocytopenic purpura, while low IPF
is characteristic of bone marrow suppression states.  Although not directly used
in clinical decision making, the reference range is critical to the introduction of
new parameters and the interpretation of laboratory results. Our results suggest
that IPF is an easy laboratory parameter to be measured and a level <10%
might be an independent bleeding factor which can be useful for detecting high
risk pregnant patients. It should be corroborated in further studies.
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DOES EARLY RESPONSE TO FIRST LINE CORTICOSTEROID THERAPY
PREDICT REQUIREMENT FOR SECOND LINE THERAPY IN IMMUNE
THROMBOCYTOPENIA?
S. Kucukyurt Kaya1,*, S. M. Bakanay1, T. Hacibekiroglu2, S. Akinci2,
M. Gündüz2, S. Maral2, A. Senturk Yikilmaz1, I. Dilek1
1Department of Hematology, Ankara Yildirim Beyazit University, 2Department
of Hematology, Ankara Atatürk Training and Research Hospital, Ankara, Turkey
Background: Immune thrombocytopenia (ITP) is an acquired,immune-medi-
ated disease that is characterized by increased destruction of platelets by
autoantibodies. ITP is characterized by mucocutaneous bleeding. Rarely, life-
threatening bleeding such as central nervous system bleeding can occur. Typ-
ically, patients have isolated thrombocytopenia. The diagnosis of ITP is one of
exclusion. Corticosteroids are chosen as a first-line therapy for adult patients
who require treatment. Responses to first line therapy with corticosteroids is
about 80%  with approximately 20% to 30% long term complete remission.
Most patients finally relapse, requiring second-line therapy.
Aims: Our aim was to investigate potential effects of early platelet response
to corticosteroid therapy on achieving long term complete remission.
Methods: We retrospectively evaluated 43 ITP patients who were followed-up
at our institution. All patients’ thrombocyte counts were below 30 x109/L at
diagnosis. All patients received initially methylprednisolone(MP) 1 mg/kg/day.
For patients who responded with platelet count ≥150 x109/L methylprednisolone
was tapered over 3 months. Those who were unresponsive to MP or relapsed
after a complete response, were treated with second line therapies that
splenectomy or medical treatment agents. The platelet counts of the patients
on day 0, 3 and 7 were evaluated by complete blood counts and were confirmed
with peripheral smears examination.  Effect of the platelet counts on day 3 and
7 were compared in terms of second line therapy requirement or not. A platelet
count of >30x109/L on day 3 and  >100x109/L on day 7 was considered as a
complete response. Vaccination against encapsulated organisms was
given  and imaging was done to detect accessory spleen before splenectomy.
Results: Baseline characteristics of the cohort of 43 patients with an initial
diagnosis of ITP are shown in Table 1. The mean age at diagnosis was 51
years (18-84) with female/male : 25/18. All patients presented with severe
thrombocytopenia (platelet counts below 30.0x 109/L). Most patients presented
with mucocutaneous bleeding (n=39), only three patients had genitourinary or
gastrointestinal tract bleeding and one patient was asymptomatic. Bone marrow
aspiration and biopsy was done in 14 (%32.6) patients due to various reasons
mainly, failure to respond to ITP treatment (7 patients) and advanced age (7
patients). On third and seventh day of MP therapy, median platelet counts were
30x109/L (2,0 x109/L -150 x109/L ) and 100 x109/L (1,0 x109/L-347 x109/L),
respectively. When platelet counts on the 3rd  and 7th day in each patient were
compared, a significant association was found  in correlation analysis (p<0.05).
21 patients (%48.8) required second line therapy which were splenectomy
(76.2%) or medical treatment (23.8%). Medical therapy consisted of  rituximab,
eltrombopag, danazol. There was a statistically significant difference between
the patients with platelet count below and over 30x109/L on 3rd day of the MP
therapy  in terms of requirement for a second line therapy. (p=0.04). On the
other hand, when 7th day was taken into consideration, there was not a statis-
tically significant difference when cut off was taken as 100 x109/L (p=0.09) or
50 x109/L (p=0.06).
Summary/Conclusions: In the era of novel therapies used as second line,
predicting the prognosis of an ITP patient at diagnosis has been a challenge.  If
disease related factors at diagnosis can be identified, then patients can be res-
cued from long term corticosteroid exposure and its adverse effects. Early
response of platelet counts after starting corticosteroids seems to predict long-
term complete remission. Expanding the study population may contribute more
to our findings. 
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THE IMPACT OF FC GAMMA RECEPTOR IIA AND IIIA GENE
POLYMORPHISMS ON THE THERAPEUTIC RESPONSE OF RITUXIMAB
IN EGYPTIAN ADULT IMMUNE THROMBOCYTOPENIC PURPURA
H. Ellithy1,*, S. Hassan2, G. Shaheen3, M. Mattar4
1Internal medicine- Hematology subdivision, 2Internal medicine, 3Clinical
Pathology, 4Internal medicine- Hematology subdivision, Kasr Al-ainy school of
medicine- Cairo university, Cairo, Egypt
Background: Chronic primary immune thrombocytopenia (ITP) is an acquired
autoimmune disease characterized by enhanced clearance of platelets and
impaired platelet production. Corticosteroid is the ministry line of treatment of
ITP, patients who fail to respond to steroid (steroid resistant) or who relapse
(steroid dependant) face the options of treatment with second line including
anti CD-20 monoclonal antibody rituximab. Rituximab is a chimeric IgG1 mon-
oclonal antibody (mAbs). The major mechanism of action of rituximab is the
antibody-dependent cellular cytotoxicity (ADCC), ADCC effectiveness is influ-
enced by process of activation of effector cells via their immunoglobulin G frag-
ment C receptors (FcγRs). Fcγ receptors show distinct affinity to bind to IgG
subtype specificities. Differential response to rituximab has been reported to
correlate with specific polymorphisms in two of FcγR genes: FcγRIIa (H131R)
and FcγRIIIa (V158F) in some diseases.
Aims: To clarify the effect of FcγRIIa-131 R/H and FcγRIIIa-158 V/F genes
polymorphism on the response to rituximab in ITP patients.
Methods: We studied the frequency of the FCγRIIa (H131R) and FcγRIIIa
(V158F) gene polymorphisms, in 100 chronic ITP patients; divided into 2 equal
groups, first group received rituximb (375 mg /m2 per dose weekly for four
weeks) and the other group received non-mabthera second line therapy. A
polymerase chain reaction-restriction fragment length polymorphism assay
[PCR-RFLP] was used to detect FcγRIIa-131 R/H and FcγRIIIa-158 V/F genes
polymorphism. Evaluation of platelets counts was assessed initially before
starting second line therapy then weekly for 3 months. At the end of third month
the response to second line therapy was considered according to the following
criteria; complete response (CR) PLT >100×109/L., partial Response (R),
PLT=30-100×109/L , no response (NR), PLT<30×109/L.
Results: Regarding FcγRIIa gene (H131R) polymorphism distribution in the 100
patients; 28 patients (28%) had wild HH genotype, 41 patients (41%) have het-
erozygous genotype (HR) and 31patients (31%) have homozygous mutant geno-
type (RR). In our study, the 100 ITP patients included showed wild type of FcγRIIIa
(V158F) gene polymorphism. By the end of month 3 of the second line therapy,
43/100 patients (43%) achieved CR, 37/100 patients (37%) achieved PR and
20/100 patients (20%) achieved NR. Among the 50 patients who treated with
Rituximab; 18 patients (36%) achieved CR, 19 patients (38%) achieved PR and
13 patients (26%) achieved NR. Out of the 18 patients who achieved CR, 8/18
patients (44.4%) carried FcγRIIa RR genotype and 7/ 18 patients (38.9%) carried
FcγRIIa HR, compared to 3/18 patients (16.7%) carried FcγRIIa HH genotype.
However it was not statistically significant. Among the 13 patients who achieved
NR, lowest rate was patients carried FcγRIIa RR genotype 3/13 patients (23.1%)
compared to HR (38.5%) and HH (38.5%) genotypes. However it is not statisti-
cally significant. The mean value of platelet count at end of week 1, Week 2 and
Week 3 of rituximab therapy show statistically significant differences (P value
0.001) being higher in patients achieved CR than who achieved PR or NR.
Summary/Conclusions: The higher platelet count achieved early (end of week
1, 2, and 3) after rituximab is suggestive for a better response later (at end of
M3). FcγRIIa RR genotype is predictive for better response to rituximab in ITP
patients.
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IMMUNE THROMBOCYTOPENIA. EGYPTIAN EXPERIENCE WITH STUDY
OF IL-17,TGFB, IL-35 AND IL-12 CYTOKINES IN CHRONIC AND
PERSISTENT IMMUNE THROMBOCYTOPENIA PATIENTS
N. El Husseiny1,*
1kasr al aini hospital, cairo, Egypt
Background: The role of T cells in the pathophysiology of immune thrombo-
cytopenia (ITP) is heterogeneous and complex.It has been studied in active
and reactive ITP but not to same extend in chronic and persistent type. 
Aims: In this study we review the demographic features  of 150 immune throm-
bocytopenic Egyptian patients and for cases who were chronic and persistent
with negative both  autoimmune screen and virology for hepatitis B and C
Methods: We measured  IL-12, IL-35, IL-17 and TGF-β by ELISA to assess
role of subtypes of T cells in the pathophysiology of ITP.
Results: Our results revealed Chronic and persistent cases who fulfilled the
criteria for cytokine assay were 45 cases  with a mean (± SD) age of 31.60±8.78
years. Thirty two patients were presented by skin manifestations (71.1%).Eight
patients presented with mucous bleeding (17.8%)  and five patients presented
by combined skin and mucous membrane bleeding (11.1%). Comparison
between the cases  studied and control  groups revealed statistically significant
lower  platelet count  in cases rather than the control. While  the four measured
cytokines were statistically significant  higher in cases rather than the control.
Correlation between platelet count and the level of cytokines was statistically
insignificant. All cases were under treatment by low dose corticosteroid in addi-
tion to another immunesuppression medication. No correlation between meas-
ured cytokines and platelet count.
Summary/Conclusions: The higher expression of IL-12 and IL-35 is due to
persistently higher TH1 activity which explain continuity of the disease.while
the higher expression of Treg cytokines (IL-17 and TGF-B) may be explained
by effect of immune suppression use or up regulation of their receptors on Treg
cells which have resistance to their activity. In chronic ITP, the level of  Tcell
cytokines  can’t predict the course of disease.
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SWITCH OF TPO-MIMETICS IN PATIENTS WITH CHRONIC IMMUNE
THROMBOCYTOPENIA: FLORENCE MONOCENTRIC EXPERIENCE
C. Biagiotti1,*, V. Carrai1, F. Bacchiarri1, A. Bosi1
1Hematology, Careggi Hospital, Florence, Italy
Background: Primary immune thrombocytopenia (ITP) is an immune-mediated
condition characterized by isolated thrombocytopenia, with peripheral blood
platelet count of <100.000/μl in the absence of an identifiable underlying cause
of thrombocytopenia. Clinical studies in patients with ITP demonstrated that
thrombopoietin (TPO) mimetics increase platelet production and can outpace
platelet destruction. 
Aims: We evalueted patients treated with both TPO-mimetics.
Methods: From November 2008 and February 2017, 65 patients were treated
with TPO-mimetics with a median follow up of 29 months (1-96): 39 patients under-
went therapy with Romiplostim and 26 to Eltrombopag. In our study we evaluated
18 patients who received both therapies: among patients treated at first with Romi-
plostim, 10 patients (9F; 1 M) switched to Eltrombopag and 8 patients (3 M; 5 F)
switched from Eltrombopag to Romiplostim. In the group of 10 patients treated at
first with Romiplostim, 5 patients started Eltrombopag because were no respon-
ders, 3 for loss of response and 2 patients because of adverse events. In the
group of 8 patients at first treated with Eltrombopag, 4 patients didn’t obtain any
response with Eltrombopag and switched to Romiplostim, 1 patient underwent to
Romiplostim for loss of response and 3 patients because of adverse events.
Results: Among patients switched from Romiplostim to Eltrombopag, 2
achieved complete response, 4 response and 4 were no responders; among
patients switched from Eltrombopag to Romiplostim, 4 obtained complete
response, 3 response, 1 was no responder.
Summary/Conclusions: Romiplostim and Eltrombopag stimulate the TPO-R
but have different mechanisms of action, therefore, in our limited experience
switching from one thrombopoietic receptoragonist to the other could be beneficial
in clinical practice for patients with severe chronic immune thrombocytopenia
who failed to respond or experienced adverse events to the first treatment.
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COEXISTENCE OF GLANZMANN’S THROMBASTHENIA AND MAPLE
SYRUP URINE DISEASE: IMPLICATIONS FOR HEMOSTATIC
MANAGEMENT
M. Elshinawy1,*, A. Alrawas2, Y. Wali2
1Pediatric Hematology, SQUH, Alexandria University, Muscat, Oman, Egypt,
2Pediatric Hematology, SULTAN QABOOS UNIVERSITY HOSPITAL, Muscat,
Oman
Background: In Oman, autosomal recessive disorders are relatively commoner
than western communities due to the high prevalence of inter-tribal marriage.
Unfortunately, some patients have got more than one autosomal recessive
genetic disorder, owing to complex consanguinity which might further compli-
cate proper management plans.
Aims: To report an interesting case of combined Glanzmann’s thrombasthenia and
MSUD, and to review the existing data of platelet function disorders in Oman.
Methods: Case report and retrospective data analysis of all cases with confirmed
or suspected platelet function disorders in Pediatric Hematology Unit, Sultan
Qaboos University Hospital, Muscat, Oman from January 2006 till December 2016.
Results: We report a 4 year-old girl who is a known case of MSUD. Her parents
are double first cousins (from both maternal and paternal sides). At the age of
3 months, she required Gastrostomy tube (G-tube) insertion. Preoperatively,
full blood count and coagulation screen were perfectly normal. Unfortunately,
she developed profuse bleeding at the site of G-tube insertion, followed by
massive hematemesis. The patient received multiple blood products, but bleed-
ing didn’t stop. As an emergency measure, recombinant activated factor VII
(rFVIIa) was given and resulted in cessation of bleeding. Platelet aggregation
studies revealed defective aggregation with ADP, arachidonic acid, collagen
and epinephrine which is consistent with Glanzmann’s thrombasthenia. The
diagnosis was further confirmed by platelet flow cytometry which showed no
activity with CD41 and CD61, indicating absent GpIIb/IIIa complex. The patient
experienced a severe bleeding phenotype, which is further complicated by mul-
tiple coexisting factors, including the recurrent episodes of metabolic crises
which provoked worsening of platelet function, the development of platelet
refractoriness at the age of 1 year , and the need for recurrent invasive proce-
dures such as G-tube and central line insertion. Currently, the bleeding episodes
are managed by rFVIIa at a dose of 120-180 µg /kg/dose. Excluding von Wille-
brand disease, we have 38 cases of confirmed or suspected platelet function
disorders in our center, including 15 cases with Glanzmann’s thrombasthenia,
7 cases with Bernard-Soulier syndrome, 5 cases with May–Hegglin anomaly
and 11 cases of suspected, yet unconfirmed platelet storage pool deficiency.
Summary/Conclusions: In conclusion, children with platelet function disorders
still have plenty of unmet needs, ranging from deficient accurate diagnostic
facilities to the lack of agreed upon consensus management guidelines. The
coexistence of another hereditary disorder may result in mutual management
difficulties of both diseases. In developing countries, proper registry is needed
to establish optimum care of such rare disorders.
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ASSESSMENT OF PLATELET REACTIVITY TO ASPIRIN AND
CLOPIDOGREL WITH POINT-OF-CARE VERIFYNOW® ASSAY AND TWO
ALTERNATIVE METHODS IN PATIENTS WITH CEREBRAL ANEURYSMS
TREATED WITH ENDOVASCULAR PROCEDURES
D. Velasco-Rodríguez1,*, R. Vidal1, S. Martín Herrero1, T. Castaño Bonilla1,
A. García Raso2, M. Martínez-Galdámez3, P. Llamas1
1Hematology, 2Health Care Institute, 3Neuroradiology, Fundación Jiménez
Díaz, Madrid, Spain
Background: Stent thrombosis and hemorrhage are the main complications
after endovascular procedures for cerebral aneurysm treatment. Identifying an
optimal pre-procedure response to antiplatelet therapy is essential to guarantee
a successful result. A high variability in the individual responses to the antia-
gregant effect of aspirin and, specially, with clopidogrel has been reported. The
VerifyNow® System (Accumetrics, San Diego, CA, USA) performs a turbidi-
metric-based optical detection of induced platelet aggregation in response to
major antiplatelet agents (P2Y12 inhibitors, aspirin, GP IIb/IIIa inhibitors).
Aims: 1) To measure the antiplatelet effect of aspirin and clopidogrel with the
point-of-care VerifyNow® assay in patients with brain aneurysms before under-
going endovascular treatment. 2) To compare the results with two alternative
methods: impedance aggregometry. and PFA-100.
Methods: 38 patients with cerebral aneurysms, scheduled for elective endovas-
cular procedure, were included in the study. All of them had started taking
aspirin at a dose of 100 mg daily and clopidogrel at a dose of 75 mg daily 7 to
10 days before testing aspirin and clopidogrel sensitivity. The following func-
tional tests were performed in all of them before the procedure: 1) VerifyNow®
assay: Aspirin Reaction Units (ARU) <550 and P2Y12 Unit Reaction Units
(PRU) <208 were considered to be good response to aspirin and clopidogrel
respectively. PRU <85 was considered hyper-response to clopidogrel. 2) Imped-
ance aggregometry from whole blood (Multiplate® analyzer, Roche Diagnostics,
Mannheim, Germany): arachidonic acid (AA), adenosine diphosphate (ADP)
and thrombin receptor activating peptide (TRAP) were used as agonists. TRAP
was used to determine baseline platelet function. Aggregation with AA <40 U
and aggregation with ADP <47 U were considered good responses to aspirin
and clopidogrel respectively. 3) PFA-100: an overall assessment of platelet
function was performed using epinephrine-collagen (COL/EPI) and ADP-colla-
gen (COL/ADP) cartridges. Although COL/ADP is not an appropriate method
to evaluate the effect of tienopyridines, we performed it to analyze whether
hyper-responders to clopidogrel detected by VerifyNow® were also identified
with PFA-100.
Results: The results of platelet function testing with three different methods
are summarized in Table 1. None of the patients showed thrombocytopenia.
Good response to aspirin was observed in 84.21%, 97.36% and 93.75% of the
patients using VerifyNow®, Multiplate® and PFA-100 respectively. Good
response to clopidogrel was detected in 86.84%, 38.88% and 62.5% of the
patients using VerifyNow®, Multiplate® and PFA-100 respectively. VerifyNow®
identified 6 (15.78%) aspirin-resistant patients. However, PFA-100 and Multi-
plate® assays showed a significant aspirin-mediated platelet dysfunction in 5
of them. Low response to clopidogrel was detected by Verifynow® in 5 (13.15%)
patients consistent with Multiplate® results. Verifynow® identified 10 patients
with excessive response, but only 2 of these results were reproduced by Mul-
tiplate® or COL/ADP. Multiplate® detected 19 patients (50%) with suboptimal
response to clopidogrel, although these results did not correlate with those
obtained by VerifyNow®.
Table 1.
Summary/Conclusions: The effect of aspirin can be accurately measured by
platelet aggregation and PFA-100 (with COL/EPI); however, VerifyNow® seems
to identify a higher number of poor responders. Multiplate® assay using only
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ADP is not good enough to detect clopidogrel-mediated platelet dysfunction
since it is not specific for the P2Y12 receptor. The addition of PGE1 to the ADP
test may increase its sensitivity. VerifyNow® assay seems to overestimate the
effect of clopidogrel, since hyper-response data are not reproduced by other
techniques. According to our results, a high interindividual variability in response
to clopidogrel is observed.
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THROMBOPOIETIN-RECEPTOR AGONISTS IN ITP - EXPERIENCE OF A
CENTER
M. J. Teles1,*, M. Gomes2, F. Ferreira2, J. E. Guimaraes2
1Clinical Pathology, 2Clinical Hemathology, Sao Joao Hospital Centre, Porto,
Portugal
Background: Thrombopoietin-receptor agonists (TRA), romiplostim and eltrom-
bopag, are part of the treatment of chronic immune thrombocytopenia (ITP), resist-
ant to first line therapy (corticosteroids and/or immunoglobulins) and with a signif-
icant bleeding risk. Both are approved for adult patients, but only eltrombopag
was approved for pediatric use. When used before splenectomy, these treatments
may serve as a bridge for surgery or even postpone/avoid the procedure. 
Aims: In this report, we aim to evaluate the response to TRA treatment in
patients with ITP and associated side effects in our center.
Methods: Inclusion criteria: patients with ITP resistant to first line treatment.
Patients characteristics, response to TRA, clinical evolution and adverse effects
were evaluated by retrospective analysis.
Results: Thirty-eight patients with ITP were included: 31.4% (12) were male
and the median age at diagnosis was 38 years. 44.7% (17) had relapsed/resis-
tant disease after splenectomy and 13.2% (5) were treated with a TRA as a
bridge for this procedure. Sixteen (42.1%) of ITP patients were treated with
romiplostim: 12 patients (75%) had a response to treatment, and 4 (25%) were
resistant. In 11 of these patients, romiplostim was replaced by eltrombopag,
either because of resistant disease, or more convenient administration (oral
therapy). Thirty-three (86.8%) patients were treated with eltrombopag (5 pedi-
atric cases): 27 patients (81.8%) responded while 6 patients had resistant dis-
ease (3 of these were HIV positive). The response rate was higher in patients
with previous splenectomy (91.7% with romiplostim and 92.9% with eltrom-
bopag) compared to those with no previous splenectomy (25% with romiplostim
and 73.7% with eltrombopag). Six patients maintained response after treatment
suspension (5 treated with eltrombopag and 1 treated with romiplostim). Gen-
erally, both treatments were well tolerated, with only one case of eltrombopag
suspension because of a thromboembolic event.
Summary/Conclusions: In the current study, both TRA were effective in the
treatment of ITP resistant to several lines of treatment, with similar response
rates. As described in the literature, the response rate was higher in patients
with previous splenectomy, and some cases maintained response after treat-
ment suspension. The toxicity profile was acceptable. However, there are some
concerns about their safety in long term therapy, namely the development of
myelofibrosis, cytogenetic abnormalities and malignant evolution. Consequent-
ly, there is an urgent need for prospective studies to define the optimal period
of treatment and surveillance, especially in pediatric patients. In our center,
the median time of treatment with eltrombopag for all patients was 5.5 months
(range between 1 to 34 months) and with romiplostim was 12 months (range
between 1.5 to 85 months). The duration of treatment with eltrombopag in chil-
dren and adolescents was around 6 months.
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THE EVALUATION OF REACTIVE OXYGEN SPECIES IN ESSENTIAL
THROMBOCYTEMIA AND CORRELATION WITH JAK2V617F MUTATION
M.-A. Gaman1,*, C. Moisa2, A. M. Gaman3,4
1”Carol Davila” University of Medicine and Pharmacy, Bucharest, Bucharest,
2Emergency County Hospital Slatina, Slatina, 3Hematology, Filantropia City
Hospital, 4Pathophysiology, University of Medicine and Pharmacy of Craiova,
Craiova, Romania
Background: Essential thrombocytemia (ET) is a clonal disorder of the
hematopoietic stem cells characterized by excessive myeloid proliferation, with
predominant megakaryocytic expansion and a potential of transformation to acute
myeloid leukemia. 50 to 60% of ET cases present a JAK2V617F mutation. 5%
to 10% of JAK2V16F negative ET patients have MPL mutations at codon 515
and 50% to 70% of ET patients with non-mutated JAK2 and MPL (double-nega-
tive) carry mutations at exon 9 of CALR. Genomic instability in ET may be asso-
ciated with an increased level of reactive oxygen species (ROS) which also leads
to DNA damage. Hematopoietic stem cells of JAK2V617F positive murine models
have higher ROS levels than found in normal mice (Marty et al, 2013).
Aims: To evaluate ROS levels in patients with ET and to observe if JAK2V617F
positive cases associate higher ROS levels compared to patients without
JAK2V617F mutation.
Methods: We studied 23 patients with ET admitted to the Clinic of Hematology,
Filantropia City Hospital, Craiova, Romania, diagnosed with ET according to the
2008 revised WHO criteria (informed consent obtained). All analysis were per-
formed after diagnosis and before the start of therapy. The JAK2V617F mutation
was detected by allele specific polymerase chain reaction (PCR) testing. ROS
levels were detected by flow-cytometry using a Cy Flow Space Sysmex flow-
cytometer and a DCFDA Cellular ROS Detection Assay Kit. Studied parameters
were compared both to healthy controls and to each other. Exclusion criteria were
presence of any condition associated with an increased oxidative status (alcohol
consumption, smoking, diabetes mellitus, hyperlipidemia, chronic renal failure,
human immunodeficiency, cirrhosis, and active infection), use of antioxidants or
iron supplementation. Data analysis was performed using Flow Max software.
The differences between the two groups were assessed using the Student T-test
and a p-value of less than 0.05 was considered statistically significant.
Results: The study group involved 12 females and 11 males, with a median
age of 48 years. All patients had increased ROS levels at diagnosis compared
to healthy controls. Eleven patients had JAK2V617F mutation and twelve were
JAK2V617F mutation negative. Significantly higher ROS levels were found
in JAK2-positive patients compared to JAK2-negative patients.
Summary/Conclusions: In our study, patients with ET had increased ROS
levels. Cases with JAK2V617F mutation associated higher ROS levels com-
pared to those without JAK2V617F mutation. In our future research, we will
focus on the follow-up of these patients for a period of four years and we will
try to observe if increased ROS levels enhanced genomic instability and trans-
formation to acute myeloid leukemia.
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VARIATIONS IN PARAMETRES OF PLATELET COUNT AND PLATELET
VOLUME ACCORDING TO GESTATIONAL AGE 
S. Akarsu1,*, M. Aydin1, E. Taşkın1
1Fırat Üniversitesi Tıp Fakültesi, Elazığ, Fırat Üniversitesi Tıp Fakültesi, Elazığ,
Elazığ, Turkey
Background: Reference ranges of haematological parameters in preterm
infants are limited.
In hematological evaluation not only platelet (PLT) counts but also 3 important
platelet volume parametres (mean platelet volume [MPV], platelet distribution
width [PDW], plateletcrit [PCT]) are also taken into consideration. 
Aims: We wanted to investigate the impact of gestational age by determining
variations in platelet volume parametres according to gestational weeks.
Methods: Medical records were prospectively reviewed in preterm infants
admitted to Firat University Hospital from January 2001 to December 2007.
Study group consisted of only one-hour-old newborns delivered in the clinics
of Department of Gynecology, and Obstetrics of our hospital. The exclusion
criteria included those with maternal history of antepartum haemorrhage,
chorioamnionitis, fever, sepsis, preeclampsia and hypertension; and perinatal
history of twin-to-twin transfusion syndrome, feto-maternal transfusion, injury
and infection. A hundred and ninety-three newborns with apparent health prob-
lems were excluded from our study. Study group comprised 398 preterm infants
born between 26-37 gestational weeks, and 63 healthy term (38 gestational
weeks) infants. Blood samples from all cases were obtained within the first
hours after birth. Blood samples were placed into tubes with EDTA, and ana-
lyzed in ADVIA 120® (Japan) hematology analyzer using suitable kits. Data
were expressed as mean±standard deviation. Platelet counts, and volume
were indicated for each gestational week, and groups of 24-31, 32-36, 37, and
38 weeks. One-way analysis of variance (ANOVA) was used for statistical
analysis, and p<0.05 was  accepted as the level of statistical significance.We
established the reference ranges of platelet and platelet index in Turkish
preterm and term infants. Platelet counts, and platelet volumes continually
change as gestational age increases. Increases in platelet counts, and PCT,
while decreases in MPV and PDW were detected. The gestational age-related
changes in PLT patterns may reflect maturation of platelet regulation.
Results: Platelet counts increased beginning from the 26th up to 28thweeks.
They did not change  between 29th and 33rdweeks, while their levels  rised again
conspicuosly  between 34th and 37th weeks.  At 38th week a dramatic increase
occurred at 38th week. MPV, and  PDW values slightly decreased, while PCT
values increased  dependent on the gestational age. When we classified new-
borns in groups of 24th-31th, 32th-36th, and 37th, and 38th weeks, prominent, and
statistically significant  variations were observed between groups.
Summary/Conclusions: We established the reference ranges of platelet and
platelet index in Turkish preterm and term infants. Platelet counts, and platelet vol-
umes continually change as gestational age increases. Increases in platelet counts,
and PCT, while decreases in MPV and PDW were detected. The gestational age-
related changes in PLT patterns may reflect maturation of platelet regulation.
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RISK OF LUPUS AFTER PRIMARY IMMUNE THROMBOCYTOPENIC PUR-
PURA: A 14 YEAR SINGLE CENTER EXPERIENCE
M. Ayesh (Haj Yousef)1,*, K. Alawneh1, Y. Khader2, F. Malkawi3
1Medicine, 2Public Health, Jordan University of Science and Technology,
3Department of Laboratory , Kng Abdullah University Hospital, Irbid, Jordan
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Background: Primary immune thrombocytopenia (ITP) is an autoimmune dis-
order characterized by immune-mediated platelet destruction and suppressed
platelet production. ITP may occur concurrently or precede the occurrence of
SLE, which would have great diagnostic significance. ITP may also be the first
early sign of the disease. Few studies have addressed the risk of systemic
lupus erythematosus (SLE) after ITP.
Aims: To estimate the risk of SLE after ITP in adult Jordanian patients
Methods: All patients diagnosed with ITP and with a platelet count ˂ 100×109/L,
between September 2002 and January 2017 were included in the study.
Patients were retrospectively reviewed for diagnosis of SLE, and inclusion cri-
teria included only those patients who had initial ANA screen at the time of the
first presentation of ITP .All patents with the diagnosis  of SLE at the time and
before the  presentation of primary ITP were excluded from the study.
Results: This study included a total of 58 patients (43 females and 15 males)
who were followed up for a period of 14 years. Their age at the baseline ranged
from 16 to 65 years with a mean (SD) of 31.2 (13.3). ANA was positive in 11
(19.0%) patients. Over the period of follow up, 9 (15.5%) patients developed
lupus. The incidence was 13.3% among males and 16.3% among females,
with no significant difference (p-value=0.786). There was significant association
between ANA and lupus in both genders. Only one patient with negative ANA
and 81.8% of patients with positive ANA developed lupus (P<0.005.
Summary/Conclusions: SLE developed in patients with primary ITP in  with
initial positive ANA titer at presentation. The results suggest that patients with
initial positive ANA are at risk for development SLE. Thus, follow up after primary
ITP diagnosis with positive ANA titer is of great importance as the risk of SLE
is significant
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TREATMENT OF REFRACTORY IMMUNE THROMBOCYTOPENIA WITH
THROMBOPOIETIN RECEPTOR AGONISTS: OUR EXPERIENCE IN
CHILDHOOD
J. Zanabili Al-Sibai1,*, T. Arias Fernández1, M.P. Palomo Moraleda1,
L.R. Morais Bras1, C. Castañón Fernández1, L.F. Ávila Idrovo1,
A. Solé Magdalena1, S. González Muñiz1, M.Á. Fernandez Rodríguez1
1Hematology, HUCA, Oviedo, Spain
Background: Immune thrombocytopenia (ITP) is an autoimmune disease in
which antibodies develop against platelets (plts) and dysregulation of cellular
immunity result in premature destruction of plts and impaired plt production.
For most affected children, ITP is a self-limiting disease. Approximately, 10%
of all ITP patients eventually develop refractory ITP (RITP). Thrombopoietin
receptor agonists (TPO-RA) stimulate thrombopoiesis and are an alternative
to Rituximab (Rtx) and splenectomy.
Aims: We present 3 different children with RITP treated with TPO-RA.
Figure 1.
Methods: CASE 1. A 5-year-old girl admitted to the hospital due to ITP with
mucocutaneous bleeding. She was refractory to corticoids, immune globulin
(Ig) and anti-D Ig. Rtx was started. After the 3rd dose, she responded tem-
porarily along with fever, renal insufficiency and arterial hypertension, probably
related to Ig A deficiency, not previously diagnosed. Romiplostim was indicated,
reaching complete remission after 2 doses and it was stopped after the 4th
dose, without any adverse reaction. Nowadays, plt count remains within normal
limits (Figure 1A). CASE 2. A 5-year-old boy was diagnosed of ITP with cuta-
neous bleeding. He received treatment with prednisone and Ig with short
response. Rtx was indicated; after 4th dose, severe thrombocytopenia and
cutaneous bleeding persisted. Eltrombopag was started with response after 6
weeks of treatment (Figure 1B) and bleeding symptoms recovery. CASE 3. A
4-years-old boy with RITP was referred to our hospital. We decided to initiate
treatment with Eltrombopag. He developed response after 4 weeks of treatment
with a dose of 75mg/24h. Six weeks later, he presented 600,000plts/µL, so the
drug was stopped. We observed a quick descent in plts levels and Eltrombopag
was restarted with progressive response (Figure 1C).
Results: In all cases, splenectomy was avoided due to long-term risk of sep-
sis, as well as immunosuppressive agents like RTX in 3rd case. In 1st case,
TPO-RA was able to stop with sustained response as described in some pub-
lications.
Summary/Conclusions: In our experience, TPO-RA appear to be efficacy and
well tolerated in children.
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INVESTIGATION OF PLATELET FUNCTIONS IN
PSEUDOTHROMBOCYTOPENIA
B. Onec1,*, S. Cesur2, K. Onec2, E. Caliskan3, S. Cangur4
1Hematology, 2Internal Medicine, 3Medical Microbiology, 4Biostatistics, Duzce
University Faculty Of Medicine, Duzce, Turkey
Background: Pseudothrombocytopenia (pseudoTCP)), is incorrectly detection
of low platelet counts in automatic blood counter devices and is most frequently
caused by  ethylene diamine tetra-aseticacid (EDTA)  induced platelet clumping
and in vitro agglutination. Therefore, pseudoTCP which accounts 15-30 of
thrombocytopenic admissions, actually is not associated with a bleeding ten-
dency. This situation may be detected with a careful investigation of peripheral
blood smears (PBS) by experienced clinicians but in centers which does not
have these facilities; misleading of worried patients through advanced centers
or even unnecessery treatments with steroids and platelet transfusions often
occurs. 
Aims: In theory, formation of platelet clusters in the presence of EDTA requires
functional adhesion molecules, so platelet adhesion and aggregation tests are
expected to be in normal range. We aimed to investigate the capacity of simple
platelet function analizers for making the distinction between pseudo TCP and
real thrombocytopenia.
Methods: Platelet functions were measured as collagen-ADP and  collagen-
epinephrine closure times (ColADP and ColEPI) by Platelet Function Analyzer
(PFA-200™) for all patients who are referred to our clinic as thrombocytopenia
(TCP, plt <150 x103/µL) and value of this new method for determining peseu-
doTCP is compared  with PBS which is  accepted as the gold standard by using
Receiver Operating Characteristic (ROC) curve analysis. PFA-200 system clo-
sure time is expected to be longer in true thrombocytopenia and normal in
pseudoTCP, but there is no study investigated this system for this
purpose.  Descriptive analyses were presented using means ±standard devia-
tions for normally distributed variables or median and interquartile range (IQR)
for nonparametric continuous variables. An overall p-value of less than 0.05
was considered to show a statistically significant result. This study is supported
by Duzce University with project number of 2015.04.03.370 and these are pre-
liminary results.
Results: We included 59 patients who were referred to our clinic with throm-
bocytopenia (TCP, Plt<150 x103/µL) and 11 healthy controls (Plt>150
x103/µL). Median age was 54 (IQR:37-68) for thrombocytopenic subjects
and 37 (%63) of them were female. Median Plt count was 61 x103/µL
(IQR:30-90) in TCP group but WBC and Hb were not different from control
subjects. Subjects referred with TCP were grouped with PBS as pseudo-
TCP and real-TCP. There was no difference in terms of Plt, MPV, PCT, WBC
or Hb between these groups but age was younger (median age 46 vs 62,
p<0.05) and PDW was higher in pseudoTCP group (med 17.6 vs 16.8,
p<0.01). ColEPI and ColADP measures were significantly lower (med 125
vs 287 for ColEPI, med 84 vs 224 for ColADP, p<0.001 for both) at
pseudoTCP group. The capacity of ColEPI and ColADP values in predicting
pseudoTCP were analyzed using ROC curve analysis. We found that, when
the manufacturer’s recommended cut-off value (150 s) was used, the sensi-
tivity and  specificity were 74.4% and  95%, with overall accuracy of 81.4%
for ColEPI (AUC 0.813, SD:0.061, p<0.001,%95CI: 0.694-0.933). Similarly
sensitivity and specificity were 79.5%, and  95%, with overall accuracy of
84.7% for ColADP using manufacturer’s cut-off value of 100 s (AUC 0.878,
SD:0.055, p<0.001,%95CI: 0.770-0.986).
Summary/Conclusions: We concluded that, running PFA tests for everybody
with thrombocytopenic counts, could be used for differentiate pseudoTCP and
realTCP in centers which does not have conditions for proper BS. Especially
long closure times excludes pseudoTCP with a high specificity and could make
clinicians quick decisions for further investigations.
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MANAGEMENT OF ADULT CHRONIC IMMUNE THROMBOCYTOPENIA.
SINGLE CENTER EXPERIENCE
C. Ionita1, I. Ionita1, D. Calamar-Popovici1, D. N. Oros1, M. Iordache1,
M. Ionita1, I. Pascu1, M. Ifrose1, H. Ionita1,*
1UMF “Victor Babes” Timisoara, Timisoara, Romania
Background: The investigation and management of patients with Chronic
immune thrombocytopenic purpura (ITP) varies widely. Although many treat-
ments have been recommended for ITP, there are no evidence-bassed rec-
ommendations for when different treatments should be used, or when any
treatment should be used rather  than managing a patient by observation alone.
Aims: To evaluate the treatment of ITP patients in Departament of Hematology,
County Hospital, Timişoara.
Methods: A retrospective study for 350 ITP patients was performed. Patients
demographics, medical history, current treatments and side effects, were
abstracted from the patient’s medical charts for the 15 months prior to their
most recent visit.
Results: The mean age was 45.6 years with 58% women and 42% men. Medi-
an time from the diagnosis of ITP to the start of the observational period was
23 months. Regardless of the presence of bleeding symptoms, for majority of
patients we started treatment based on plateled count. Treatment was consid-
ered when platelet counts are less than 20x109/L in patients without bleeding,
and less than 30x109/L in patients with bleeding. Prior to the observational
period, 36% of patients had been splenectomized and the most  reported treat-
ment was corticosteroids. During the observational period, 72% of all patients
were treated. The most frequent reasons given for treatment were platelet
count (58%), followed by bleeding symptoms (42%). Corticosteroids repre-
sented 52% of treatments, followed by IVIg (20%), azathioprine (12%) rituximab
and 8% Nplate. Splenectomies (8% of patients) and platelet transfusions (27%
of patients) were  performed during the observational period. In the patient
survey, 52% of participants were 60 years of age or older and the duration of
disease was more than 10 years in 43% of patients. The minimum platelet
counts were less than 10x109/L in 49% of patients. The most common symp-
toms of ITP was fatigue (45%). Approximately 60% of patients reported at least
one side effect associated with ITP treatment. The side effects were most fre-
quently associated with corticosteroid use (43%). Overall, 40% of patients
required hospitalization. Mean duration of hospitalization was 13,5 days.
Summary/Conclusions: The retrospective study of 350 patients provides the
results of treatment practices in our country. It showed that bleeding symptoms
remained quite frequent among patients with chronic ITP. Corticosteroids were
the most widely used treatment.
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IMMUNOLOGICAL THROMBOCYTOPENIC PURPURA AND PREGNANCY:
A RETROSPECTIVE STUDY OF 89 PREGNANCIES IN 59 PATIENTS
H. Brahimi1,*, S. Taoussi1, Z. Bouchetara1, K. Rekrouk1, M. T. Abad1
1Hematoloy, EHS ELCC CAC, Blida, Algeria
Background: Immunological thrombocytopenic purpura (ITP) occurs for about
1 case for 1000 pregnancies. The risk of onset, aggravation or relapse of ITP
during pregnancy is not clearly established.
Aims: The aim is to describe the prevailing ITP progression profile in pregnant
women and to evaluate the risk of neonatal thrombocytopenia in two situations,
when ITP was known before pregnancy and when ITP was discovered for first
time during pregnancy.
Methods: It is a retrospective study carried out in the hematology department
of CAC Blida, Algeria, between 1993 and 2016. All patients (pts) who had a
pre-pregnancy ITP or thrombocytopenia during pregnancy attached to an ITP
were included.
Results: The development of 89 pregnancies (PG), including two twins,
occurred in 59 women was analyzed. There were one PG in 40 pts, 2 PG: 13
pts, 3 PG : 5 cases, 4 PG : 1 case and 5 PG : 1 case. Of the 59 pts: in 42 cases
it was a history of ITP before pregnancy (group 1: G1) with a history of splenec-
tomy in 9 patients, and in 17 cases it was ITP discovered on the occasion of
Pregnancy (group 2: G2). The average age at diagnosis=26.7 years (7-44)
and that at delivery=30.4 years (19-44). The mean platelet count at diagnosis:
G1: 34000 / µL , G2: 47000 / µL. In the first group (G1): At the beginning of
pregnancy the ITP was chronic in 30 cases, newly diagnosed in 1 case, per-
sistent in 2 cases and transient cured in 7 cases; treatments previously received
were: corticosteroid therapy (n=34), splenectomy (n=9), Danazol (n=1),
cyclosporine in 1 case and cyclophosphamide in 1 case, abstention in 7 pts, 2
of whom required corticosteroids during pregnancy. The status of the ITP at
the beginning of each pregnancy was: out of treatment (n=8), corticosteroid
dependence (n=5), non-response (n=7), PR (n=11), CR (n=24).In the second
group (G2): the discovery of thrombocytopenia was in the first trimester (T) in
4 cases, in the second T in 6 cases and in the third T in 7 cases; 17 pts had
platelet counts <80000 / µL and were included due to the persistence or even
worsening and / or necessity to resort to treatment of thrombocytopenia after
delivery. In both groups: in 26 pts (G1:16; G2: 10 )variable dose and duration
treatment were required during pregnancy; at delivery, 19 patients needed a
treatment, out of them,  a bolus of corticosteroids (n=11)+transfusion of platelets
(n=4), immunoglobulins in 4 cases and transfusion of platelets alone in 4 cases.
At birth, thrombocytopenia was observed in 40 pregnancies (50.6%): platelets
<30000 / µL (n=7), between 31000 and 50000 /µL (n=13), between 51000 and
100000/µ (n=20), between 100000 and 150000/µl in 2 cases. All pregnancies
were completed: 14 by caesarean section, one for thrombocytopenia, with an
average platelet count=95000 /µL  and 75 by natural delivery with a mean
platelet count=100000 / µL with 4 deaths born, one anencephaly and 88 new-
borns  No hemorrhagic syndrome was observed in pregnancy; two postpartum
hemorrhages were seen in G2 group. Eleven newborns (5 in G1 and 6 in G2)
were thrombocytopenic with platelet count <20000/µL in 4 cases; between
20000 and 50000/µL in 7 cases; neonatal thrombocytopenia occurred during
the first 7 days. Only 4 newborns were treated, one by corticosteroid and 3 by
immunoglobulins, with a good progression and only one of the untreated is
always followed for thrombocytopenia.
Summary/Conclusions: The de novo ITP appearing during pregnancy is an
etiological eventuality to be evoked in front of a thrombocytopenia of the preg-
nant woman after elimination of the other causes related to the pregnancy and
in front of the non-resolution after the delivery. The pre-existing ITP does not
necessarily.
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QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH MULTIPLE
MYELOMA
B. Sidi Mohamed El Amine1,*, H. Asma1, O. Fouzia1, S.A. Najet1, C. Malika1,
Z. Naima1, Z. Zahia1
1Hematology department, Universitary hospital of Sidi Bel Abbés, Sidi Bel
Abbes, Algeria
Background: Multiple myeloma (MM), the second most common hematological
cancer, remains incurable. Its incidence is rising due to population ageing.
Despite the impact of the disease and its treatment, not much is known about
health-related quality of life (QoL) of patients with MM. 
Aims: This study aimed to (1) Determine symptom prevalence in patients
with MM on disease-modifying treatment, and identify the range and nature of
these symptoms within the dimensions of physical, psychological, social well-
being. (2) Measure the QoL of patients. (3) Compare the above-mentioned
parameters to the general population.
Methods: Adults with multiple myeloma attending the hematology day unit in
hematology department from November 2016 to January 2017 were eligible
for inclusion in a cross-sectional. Consenting patients completed 2 validated
questionnaires, the European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) supplement-
ed by the myeloma-specific module (EORTC QLQ-MY20).
Results: Forty-seven patients were included for analysis: 51, 1% were male and
48,9% were female. Mean age was 64,7 years (range 42-82, standard deviation
11.50). The QoL scores were significantly lower than the general population (54,7
vs 71,2). The most commonly reported physical symptoms were pain (72%),
fatigue (70%) and insomnia (66%). About 61% of the patients were burdened by
financial worries. On multivariate analysis, a good performans status (PS≤1) and
a response of the disease to therapy (at least a partial response) were associated
with high scores of QoL (P=0,01, P=0,03 respectively). 
Summary/Conclusions: Patients with MM have a lower QoL than the general
population and are symptomatic across physical, psychological and financial
domains. They represent a polysymptomatic patient cohort with a complexity
of need that merits a holistic multidisciplinary approach, and consideration of
specialist symptomatic or palliative care review.
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QUALITY OF LIFE IN ANEMIC PATIENTS WITH HEMATOLOGICAL
MALIGNANCIES
N. Romanenko1,*, S. Bessmeltsev1, A. Romanenko2, N. Potikhonova1,
M. Zenina1
1Clinical Hematology, Russian Research Institute of Hematology and Transfu-
siology, 2Neurology, Children Hospital of St. Olga, Sankt-Peterburg, Russian
Federation
Background: Anemia is a common complication of patients with hematological
malignancies (HM), which may progress undergoing antitumor treatment sig-
nificantly decreasing hemoglobin concentration and occur symptoms as fatigue,
dizziness, palpitations, dyspnea markedly reduce patient activity, resulting in
impaired Quality of Life (QoL).  
Aims: To compare of QoL in HM’s patients with different grades of anemia. 
Methods: In this study were included following patients (n=326) in the age of
19-82 (Me=65) years: myelodysplastic syndrome (n=37), acute myeloid
leukemia (n=20), acute lymphoid leukemia (n=7), primary myelofibrosis (n=23),
chronic myeloid leukemia in blast crisis (n=6), multiple myeloma in II and III
st. (n=126), Non-Hodgkin’s lymphoma in III-IV st. (n=40) and chronic lympho-
cytic leukemia in B or C st. (n=67). Patients were examined: 1) clinical blood
test (hemoglobin concentration) to assess anemia’s grade; 2) the Functional
Assessment of Cancer Therapy-Anemia (FACT-An) scale to measure of QoL.
The FACT-An questionnaire consists of a general questionnaire (FACT-G),
measuring domains of physical well-being (PW), social/family well-being
(S/FW), emotional well-being (EW), functional well-being (FW), an anemia-
specific questionnaire – Anemia subscale (AnS), measuring fatigue-associated
items – Fatigue subscale (FS) and non-fatigue-associated items – Non-Fatigue
subscale (NFS). Patients were divided into six groups according to the Hb
concentration: 1) the first group – Hb was 4.0-6.4 g/dl (Me=5.7 g/dl); 2) the
second – Hb 6.5-7.9 g/dl (Me=7.2 g/dl); the third – Hb 8.0-9.4 g/dl (Me=8.6
g/dl); the forth – Hb 9.5-10.9 g/dl (Me=10.8 g/dl); the fifth – Hb 11.0-11.9 g/dl
(Me=11.4 g/dl); the sixth – Hb 12.0-14.4 g/dl (Me=13.0 g/dl). The sixth group
was control.
Results: In the first group of patients (n=34) with severe anemia grade 4 QoL
was revealed too poor; number of points in the subscale of PW was 14.0±0.9,
in S/FW – 14.2±0.7; EW – 10.3±0.9, FW – 18.5±0.8, AnS – 41.2±1.6, FS –
27.8±1.3, NFS – 13.4±0.6. In the second group of patients (n=53) with anemia
grade 3 QoL was poor too; in PW was 13.3±0.8, in S/FW – 14.4±0.6, EW –
9.9±0.7, FW – 18.2±0.6, AnS – 38.5±2.3, FS – 26.8±1.7, NFS – 12.0±0.7. In
the third group of patients (n=72) with anemia grade 2 QoL in the subscale of
PW was 11.5±0.7, in S/FW – 14.0±0.5, EW – 8.6±0.6, FW – 16.9±0.5, AnS –
36.1±1.9, FS – 25.5±1.4, NFS – 11.6±0.6.  In the forth group of patients (n=70)
with anemia grade 1 QoL in PW was 11.3±0.7, in S/FW – 14.3±0.6, EW –
8.4±0.8, FW – 16.9±0.7, AnS – 34.7±1.6, FS – 23.0±1.2, NFS – 11.7±0.6. In
the fifth group of patients (n=41) with anemia grade 0 QoL in PW was 11.1±0.9,
in S/FW – 14.9±0.8, EW – 7.6±0.6, FW – 16.4±0.5, AnS – 34.6±2.2, FS –
23.7±1.6, NFS – 10.9±0.7. In the sixth group of patients (n=56) without anemia
QoL in the subscale of PW was 7.5±0.7, in S/FW – 13.6±0.6, EW – 6.4±0.5,
FW – 14.8±0.7, AnS – 23.4±1.5, FS – 14.9±1.0, NFS – 8.4±0.6.
Summary/Conclusions: QoL was found too poor in patients with Hb <8.0 g/dl.
QoL wasn’t satisfactory in patients with Hb 8.0-11.0 g/dl. But the QoL improvement
were greater in patients with Hb levels >11.0-12.0 g/dl (p<0.05). These data sug-
gest that early correct anemia with red blood sells transfusions and erythropoiesis-
stimulating agents can improve QoL in a clinically meaningful way. 
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AN ANLYSIS OF THE IMPACT OF LOCAL COSTS OF MEDICINES ON COST
EFFECTIVENESS OF THE TREATMENT OF CANCER ASSOCIATED
THROMBOSIS.
E. Reimer1,*, D.M.R. Lipp2, M. Gotfredsen1, M. Feuerbach3
1Thrombosis, LEO Pharma, Ballerup, Denmark, 2Haematology and Oncology,
3Health Economy, German Oncology, Hamburg, Germany
Background: New research has surfaced in relation to health care resource
utilization and costs in Cancer Associated Thrombosis (CAT). The studies orig-
inate from the US and are difficult to transfer directly to other countries. A few
studies in Europe focusing on the total cost of CAT seem to indicate that the
cost data in the field of CAT varies greatly between regions. To examine the
importance of region specific cost elements in relation to research related to
CAT, we studied the cost driver in the newest and most relevant health eco-
nomic research and compared it with the costs from 6 European countries as
well as Canada. 
Aims: To highlight the importance of localized or regionalized cost inputs as
cost drivers when considering cost effectiveness in relation to CAT.
Methods: The cost driver is the medication in a recent analysis by Connell 2016
and thus the focus of our analysis.  The American paper incorporates outcomes
from 6 RCTs for treatment with LMWH in patients with CAT. The annual medica-
tion costs of LMWH for daily treatment in 365 days were 32,120 USD in whole-
saler acquisition cost (WAC). For VKA the annual medication cost for 365 days
was 44 USD. LMWH is the cost driver but is not cost effective due to the cost of
it. The study finds that “ The one-way sensitivity analysis shows that LMWH would
become the preferred strategy once its annual cost was less than $7177” . In the
present analysis, the daily cost acquisition cost Wholesaler Purchasing Price
(WPP) (which corresponds to the American WAC ) for a LMWH (prefilled treat-
ment syringes with Tinzaparin) was gathered in 7 large markets using a data
retrieval from IHS global insights systems (Jan 2016). In addition to this, the role
of the cost driver was also compared to other publications.
Results: Simply by applying the local unit cost for the treatment with LMWH
for these countries, the conclusion becomes notably different. LMWH becomes
the cost effective alternative in the European countries as well as in Canada
with annual costs below 7177 USD. The price for VKA is comparable to that in
the US, and does not change the cost effectiveness ratio.
The data from the retrospective cost of CAT study that the cost of the hospital-
ization of was 19% of the total cost of CAT and the CAT medication 11% of the
total cost of CAT. This outlines hospitalization is a cost driver as well and not
only the medication.  Similar conclusions were reached in other studies. In
summary, the role of the cost driver can change as a consequence of the local-
ization of the costs. This outlines the great variation in costs in terms of CAT,
and the caution it must be used with (Table 1).
Table 1.
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Summary/Conclusions: The exercise shows that using local input changes
the conclusion and could potentially influence local evaluations related to the
access for LMWH treatment for CAT. Tinzaparin was found to be a cost effective
LMWH over VKA in 6 European Countries as well as in Canada, when local
medication costs were used. This was in contrast to the conclusion in the US.
Not using localized or regionalized cost inputs could potentially lead misinter-
pretations about cost effectiveness of CAT treatments.
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MINIMIZING THE RISK OF MUCOSITIS IN HEMATOLOGIC PATIENTS WITH
TOPICAL PRODUCTS
I. Ursuleac1,*, Z. Varady1, A. Enache2, A. A. Tomescu2, R. Dragan2, D. Coriu1
1Hematology, 2Fundeni Clinical Institute, Bucharest, Romania
Background: Mucositis is a frequent severe complication associated to
aggressive therapies of hematological malignancies with chemo and/or radia-
tion (therapy), conditioning therapy in stem cell transplants. Regularly occurs
at 3 to 10 days after chemotherapy and about 6 to 8 weeks after radiotherapy.
It is self-limited within 2-4 weeks, but in this period the patient is vulnerable to
systemic infections (bacterial and fungal). It could also compromise the optimal
timing and dosage of the chemotherapy schedule, induce psychosocial dis-
tress, prolonged hospitalization and finally, higher costs. 
Aims: Evaluating the efficacy of Gel X® in chemotherapy induced mucositis.
GelX® is a topical product that contains Zinc gluconate+taurine, with bacterio-
static and anti-inflammatory effect, easy to use for the patient, in order to pre-
vent and reduce pain and  severity of oral ulcers, making a barrier for mucosae
Methods: A retrospective analysis of 77 adult patients: 17 with hematological
treatments and 60 with allogeneic stem cell transplantation. 17 were diagnosed
and treated between January 2015 and December 2016 with various hematologic
malignances (5 AML, 2 ALL – 1 Ph positive, 2 blastic phases of CML, 3 AILT
(CHOP/DA-EPOCH), 2 DLBCL (RCHOP), 1 FL (RCVP), 1 MM (radiotherapy),
1Hodgkin disease (ABVD). Treatment regimens used for acute leukemias/blastic
phases of CML were: “3+7” (3 cases), MEC (1 case), high doses ARA-C (1),
GMALL protocol (1), HyperCVAD (1), Idarubicine and ARA-C(1) HD-MTX(1) .
GelX® was indicated as prophylactic treatment for eight patients, because the
risk of mucositis was high (aggressive chemotherapy, bad oral condition, risk of
prolonged neutropenia). Curative treatment of grade 3-4 mucositis was indicated
for 10 patients (one was initially treated with curative intention and after that with
prophylaxis). In 60 patients allografted for various hematological conditions  (35
unrelated, 4 haplo and 21 sibling)   GelX® was prescribed for treating grade 3-4
mucositis. For the 35 cases with unrelated allotransplant (21 AML, 4 ALL, 2 SA,
2ATLL, 2 MMM, 2 CML, 1 MDS, 1 BH), 16 cases of grade 3-4 mucositis has
appeared .The conditioning  regimen was mieloablative(14 cases) and reduced
intensity( 21 cases) .There were 21 cases of sibling allotransplants (6AML, 3
ALL, 1 ATLL, 5 LMNH, 1CLL, 2 SAA, 2 CML, 1 mycosis)with 10 cases of mucosi-
tis grade 3-4. The regimens used were 6 mieloablative and 15 nonmieloablative.
3 from 4 cases of haplotransplant with nonmieloablative conditioning (2MDS, 1
AML and 1 SAA)  had grade 3 mucositis.
Results: Prophylactic treatment induced a reduction in the grading of mucositis
(grad 1-2) and a shorter period of evolution  (5 days) versus grade 3-4 mucositis
and prolonged duration of oral lesions for those with curative treatment. From
60 patients allotransplanted, 30 patients experienced grade 3 and 4 mucositis
with a medium duration of five days. All of them received GelX® as prophylactic
treatment.
Summary/Conclusions: Prophylaxis is the key of successful evolution in
mucositis (time to heal shorter than 10 days). Identifying candidates for mucosi-
tis is mandatory and the product should be applied starting with the chemother-
apy (or in the first 24 hours on the onset of chemotherapy) in order to minimize
the risk of mucositis appearance.
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EUROBLOODNET: THE EUROPEAN REFERENCE NETWORK IN RARE
HEMATOLOGICAL DISEASES
M.D.M. Mañu Pereira1,*, V. Gutierrez Valle1, J.L. Vives Corrons1, B. Gulbis2,
P. Fenaux3
1Red Blood Cell Pathology and hematopoietic defects Unit, Josep Carreras
Leukaemia Research Institute, Barcelona, Spain, 2Laboratoire Hospitalier Uni-
versitaire de Bruxelles - ULB, Brussels, Belgium, 3Service d’Hématologie
Séniors, Hôpital Saint-Louis - Université Paris, Paris, France
Background: Almost all hematological disorders are rare diseases, affecting
less than 1 in 2000 individuals, justifying their inclusion in a European Refer-
ence Network (ERN). ERN are  networks created following the Directive
2011/24/EU on cross border health  which include nationally recognized Cen-
tres of Expertise aiming to ensure the same level of access to health services
of European citizens affected by a rare disease. EuroBloodNet, the ERN in
Rare Hematological Diseases (RHD), results from a joint effort of the European
Network on Rare and Congenital Anaemias (ENERCA), the European Hema-
tology Association (EHA), and European hematology patient organisations rep-
resented in both the EURORDIS European Patient Advocacy Groups (ePAGS)
and the EHA Patient Organisations Workgroup. EuroBloodNet gathers 66 highly
skilled and multidisciplinary healthcare teams in 15 Member States, and
advanced specialized medical equipment and infrastructures which will facilitate
concentration of resources for the design, validation and implementation of
high-quality and cost-effective services aimed at facing the challenges of RHD.
Aims: EuroBloodNet’s main goal is to improve the healthcare and overall qual-
ity of life of patients with a RHD by 1) Improving equal access to highly spe-
cialized healthcare delivery for RHD across Europe 2) Promoting  best practices
in prevention, diagnosis and safe clinical care across Europe 3) Disseminating
cutting-edge knowledge and facilitating continuous medical education in the
field of RHD 4) Providing inter-professional consultation by sharing of expertise
and safe exchange of clinical information 5) Fostering European cooperation
in highly specialized procedures for diagnosis, promotion of clinical trials and
innovative treatments and research.
Methods: RHD are covered in two main thematic groups: non-malignant dis-
eases and malignant diseases, and six sub-thematic areas. Non-malignant dis-
eases include 4 sub-thematic areas: 1) Rare red blood cell defects 2) Bone mar-
row failure (BMF) and hematopoietic disorders 3) Rare Bleeding-Coagulation
disorders and related diseases and 4) Haemochromatosis and hereditary iron
metabolism disorders. Malignant diseases include 2 sub-thematic areas: 1)
Myeloid malignancies and 2) Lymphoid malignancies. Methods and tasks aiming
to achieve EuroBloodNet specific objectives have been split into five categories
of Transversal Field of action (TFA): 1) Cross border health 2) Best practices 3)
Continuing medical education 4) Telemedicine 5)Clinical trials and research.
Results: Expected outcomes include reduction of healthcare inequalities for
RHD in the EU by a) establishing a cross-border referral system allowing safe
information, samples and patient mobility, b) provision of equal access to highly
specialised procedures and innovative therapies resulting from best practice
sharing, continuous medical education and virtual inter professional consulta-
tion for complex RHD cases, and c) facilitation of a timely and efficient trans-
lation of research results into patient oriented strategy at the clinical and the
public health level.
Summary/Conclusions: EuroBloodNet, with the experience gained thanks to
the EU-funded ENERCA and EHA, will seek to improve access to healthcare
for RHD patients, to promote guidelines and best practice, to improve training
and knowledge sharing, to offer clinical advice where national expertise is
scarce, and to increase the number of clinical trials in the field.
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2016 REVISION OF WHO CLASSIFICATION OF TUMOURS OF
HAEMATOPOETIC AND LYMPHOID TISSUES: IMPACT ON
INVESTIGATING PATIENTS WITH ISCHAEMIC STROKE
C. Philip1,*, J.D. Pandian2, M.J. John1, P.N. Sylaja3, A. Mathew1, S. Kaul4,
D. Khurana5, M. Padma6, D. Arora2, A. B. Singhal7
1Clinical Haematology, 2Neurology, Christian Medical College & Hospital, Lud-
hiana, 3Neurology, Sree Chitra Tirunal Institute of Medical Sciences and Tech-
nology, Thiruvananthapuram, 4Neurology, Nizam’s Institute of Medical Sci-
ences, Hyderabad, 5Neurology, Postgraduate Institute of Medical Education
and Research, Chandigarh, 6Neurology, All India Institute of Medical Sciences,
New Delhi, India, 7Neurology, Massachusetts General Hospital, Boston, United
States
Background: Under diagnosis related to the earlier hemoglobin (Hb) or hematocrit
(Hct) diagnostic criterion is one reason to the 2016 revision of the diagnosis of PV
in the World Health Organization (WHO) classification of Tumours of Haematopo-
etic and Lymphoid tissues. Bone Marrow Biopsy (BM) and molecular markers
(JAK2) are recommended to establish the diagnosis in those with the lower thresh-
old(Arber DA et al,2016). This potentially could result in increased numbers and
costs of investigations. The lower thresholds are aimed to identify those previously
referred to as masked PV (mPV) who have  been  recognized to have an increased
incidence of thrombosis (Barbui T et al, 2014 & 2015).We hypothesized that the
revision would increase the incidence of patients with Ischaemic stroke and poten-
tial PV who would then require additional investigations.
Aims: To determine number of patients with young strokes with potential PV
on application of the 2016  revised WHO criteria for PV.
Methods: We undertook an analysis of records of patients with ischemic stroke
prospectively maintained in the The Indo-US Stroke Registry and Infrastructure
Development Project. This registry enrolled adult patients admitted with imag-
ing-confirmed ischemic stroke <2 weeks after symptom onset. The Indo-US
Stroke Registry and Infrastructure Development Project, includes 5 geographi-
cally diverse centers in India and one in USA. The registry data was entered into
a central web-based electronic database. From January, 2012 to March, 2014,
2076 patients with new onset ischemic stroke were evaluable in the Indian arm
of the Indo-US Stroke registry. We compared the incidence of polycythemia as
per the 2016 revision against the earlier (2008) Hb diagnostic criterion.
Results: There were 24 (1.2%) patients with potential PV which was revised
to 107 (5.2%) on applying the 2016 Hb criterion. The exact McNemar’s test
determined that there was a statistically significant difference in the proportion
of polycythemics, p=.000. Considering the potential of comorbidities in the eld-
erly to confound the association of polycythemia with Ischaemic stroke, we
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separately analyzed only those with young stroke (Age <45). In this cohort
there were 420 patients. A total of 6 (1.4%) patients had potential PV based on
the 2008 Hb criteria. On applying the 2016 revision; 37 (8.8%) patients fulfilled
the Hb criteria. An exact McNemar’s test determined that there was a statisti-
cally significant difference in the proportion of polycythemics, p=.000. Separate
analyses by gender was not significant in females, P=0.5; but significant in
males, p=.000. There were an additional 29 males with the revised criteria for
polycythemia. The impact of cost in influencing treatment decision from
resource limited countries with  predominant out of pocket health expenditure
has been earlier reported (Philip C et al, 2015). This revision promotes the rou-
tine use of BM and JAK-2. In our analysis we estimate this new criterion would
add to the costs to each patient ( 7000 per our centre estimate).
Summary/Conclusions: The present data shows that there exists a significant
difference in the incidence of polycythemia in thrombosis (Ischaemic Stroke) on
applying the revised criteria. The requirement to additionally investigate them
with BM and molecular markers for PV has potential economic implications.
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PATHOPHYSIOLOGICAL MECHANISMS INVOLVED IN THE
DEVELOPMENT OF ANEMIA IN PATIENTS WITH NON-HODGKIN’S
LYMPHOMA
M.-A. Gaman1,*, A. Papoi2, A. M. Gaman3,4
1”Carol Davila” University of Medicine and Pharmacy, Bucharest, Bucharest,
2University of Medicine and Pharmacy of Craiova, 3Hematology, Filantropia
City Hospital, 4Pathophysiology, University of Medicine and Pharmacy of Craio-
va, Craiova, Romania
Background: Non-Hodkin’s lymphomas (NHL) are a group of heterogenous
malignant lymphoid disorders that associate anemia either from diagnosis or
during the evolution of the disease. The anemic syndrome can be present at
the moment of diagnosis or can develop during the evolution of non-Hodgkin’s
lymphomas, with negative effects on the therapeutic regimen due to reduction
of intensity and density of drug doses, overall survival and quality of life of these
patients. Various pathophysiological mechanisms responsible for the develop-
ment of anemia are depicted in literature: pro-inflammatory cytokines and hep-
cidin action on iron metabolism and erythropoiesis, bone marrow failure caused
by infiltration of malignant lymphomatous cells, cytopenias secondary to
chemotherapy, immune peripheral destruction of red blood cells, iron and folate
deficiency due to chronic bleeding.
Aims: To evaluate the prevalence of anemic syndrome in patients with non-
Hodgkin’s lymphomas and the pathophysiological mechanisms involved in the
development of anemia.
Methods: A retrospective study was conducted on 85 patients (informed con-
sent obtained) with non-Hodgkin’s lymphoma, who were admitted to the Clinic
of Hematology, Filantropia City Hospital, Craiova, Romania, in between 2013
and 2015, in order to evaluate the prevalence and pathophysiological mecha-
nisms involved in the development of anemia in this study group. 
Results: In our study group, the median age at diagnosis of non-Hodgkin’s lym-
phoma was 64 years, sex distribution was males:females=1,3, and the rural to
urban area index=1,2. 85,88% of patients had B type NHL and 14,12% T type
NHL. 20% of NHL were indolent lymphomas, aggressive lymphomas in 54% cas-
es and very aggressive lymphomas in 26%. NHL repartition on stage of disease
revealed: type I – 2.35%, type II – 18.81%, type III – 57.64%, and type IV –
21.16%. In our study group, 84% of patients enrolled had anemia, with the anemic
syndrome affecting the 50-59 years and 70-79 years age groups. 59.73% of
patients had anemia at diagnosis and 40.27% of patients developed anemia dur-
ing the evolution of NHL.  The pathophysiological mechanisms involved in the
development of anemia were: perturbations of iron metabolism and erythropoiesis
under pro-inflammatory cytokines and hepcidin actions (47.25%), bone marrow
failure induced by lymphomatous infiltration (25%), anemia induced by
chemotherapy (18.05%), and autoimmune hemolysis (9.7%). Five patients with
anemia induced by chemotherapy and three patients with lymphomatous infiltra-
tion of the bone marrow also associated iron and/or folate deficiency.
Summary/Conclusions: In our study, anemia was present in 84% of NHL cas-
es, more frequently found in patients that associated comorbidities and
belonged to the 50-60 years and 70-80 years age groups. In half of the cases,
anemia was moderately severe. 47.25% of patients had simple chronic anemia
due to perturbations of the iron metabolism and of erythropoiesis, and 25% of
patients presented anemia due to bone marrow failure. Chemotherapy lead to
an anemic syndrome in 18.05% of cases, whereas hemolysis of autoimmune
cause was responsible for 9.7% of cases of anemia diagnosed. The manage-
ment of anemia is extremely important in patients with NHL because it influ-
ences the administration of chemotherapy (dose intensity and density), prog-
nosis and quality of life.
PB2133
SAFETY OF RITUXIMAB BIOSIMILAR (NOVEX®) IN THE ROUTINE USE
TREATMENT IN ARGENTINA.
G. Milone1,*, M. I. Penna2, F. Fernandez2, E. Spitzer2, S. Millan3, S. Mariani3,
N. Español3, R. Gomez2
1Hematología, Centro Médico Hematológico, 2Laboratorio Elea, Buenos Aires,
Argentina, 3Mabxience, Madrid, Spain
Background: Novex® is a biosimilar by design of the reference product
Mabthera®/Rituxan®. Novex® was approved in Argentina following ANMAT’s
Biosimilar guidelines, having the same indications as the reference product,
and is commercialized by Laboratorio Elea.  As part of its Risk Management
Plan (RMP), Laboratorio Elea implements an active pharmacovigilance program
as defined in Argentina regulation. Periodically reports ANMAT RMP status and
results.
Aims: To describe frequency and pattern of adverse events during the use of
NOVEX® in treatments registered along an active pharmacovigilance program
in order to oversee the safety profile of NOVEX® in the real clinical practice
and maintain the benefit-risk evaluation.  
Methods: A treatment Registry for NOVEX® was implemented from the begin-
ning of NOVEX® commercialization as part of the RMP. The Data Lock Point
for this report is Jan 31st, 2017. Physicians prescribing NOVEX® were request-
ed to fill a form indicating age and gender, treatment start date, treated pathol-
ogy, dosing and dose frequency. Such data was recorded in a database. After
a preset time, physicians were contacted by Laboratorio Elea to ask them about
the treatment outcome and Adverse Event occurrences. If adverse events were
detected they reported each occurrence as Individual Case Safety Report
(ICSR), they were registered using the MedDRA dictionary (version 19.1) for
its codification.
Results: The total number of participating physicians was 151. During this period,
they reported 638 treatment initiations, 389 of which had at least 1 follow up point
and were included in further analysis. 53% male. Mean age 64.1 years. Hema-
tological indications were more than 90%. More than 90% of indications were
approved indications. Nevertheless, we detected off-label use. Total cycles
received for any approved indication had a mean number of 5.7. Total received
Individual Case Safety Reports were 17, indicating a relative frequency of 4.4%
of Individual Case Safety Report. Occurrence rates were 1.2 Individual Case
Safety Report per 100 administered cycles, and 0.020 per 100 treatment days.
Eleven Individual Case Safety Reports were classified as serious (SAE) because
they had at least one manifestation that prolonged hospitalization, endangered
life or was death-associated. The most frequent AE reported was acute reaction
related to infusion (9 cases), followed by cardiovascular manifestations (2 arrhyth-
mia, 1 cardiac failure and 1 ischemic stroke), infections (1 pneumonia, 1 pro-
gressive multifocal leukoencephalopathy), neurologic (1 paresthesia), cytopenias
(1 pancytopenia) and cutaneous (1 bullous dermatitis).
Summary/Conclusions: The activities developed under this active pharma-
covigilance program showed great value allowing us not only to monitor the
adverse event pattern but also to detect off-label use as part of real life treat-
ments. This report showed a similar safety profile to that of the reference product
concluding that NOVEX®, in terms of tolerability, is similar to the reference
product. Pharmacovigilance is cornerstone in the development of biologicals,
especially biosimilars, as a tool to assist in the knowledge about their safety
profile.
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DEPRESSION AS THE PRESENTING SYMPTOM OF CENTRAL NERVOUS
SYSTEM LYMPHOMAS IN NORTHWESTERN TURKEY
E.G. Umit1,*, D.B. Esen1, M. Baysal1, A.M. Demir1
1Hematology, Trakya University Faculty of Medicine, Edirne, Turkey
Background: PCNSL represents approximately 4 percent of newly diagnosed
primary central nervous system (CNS) tumors, with an age-adjusted incidence
rate of four cases per million persons per year. Most cases of non-AIDS related
PCNSL are diagnosed in patients between 45 and 65 years of age, with a medi-
an age at diagnosis in the fifth decade. The most notable risk factor for the
development of PCNSL is immunodeficiency including HIV infection, iatrogenic
immune suppression, and congenital immune deficiencies. Antecedent flu-like
or gastrointestinal illnesses or a history of autoimmune diseases were reported.
Presenting symptoms may include focal neurologic deficits, neurophyschiatric
symptoms, signs of increased intracranial pressure, seizures or ocular symp-
toms. Neurophyschiatric symptoms like depression, apathy, psychosis, confu-
sion, memory impairment, slowness of thought are generally undernoticed or
underestimated due to the increased rates of depression and tendancy towards
antidepressant use. Diagnosis is based on imaging of the central nervous sys-
tem (CNS), ideally with contrast-enhanced magnetic resonance imaging (MRI),
cerebrospinal fluid (CSF) analysis, unless contraindicated due to elevated
intracranial pressure The radiographic lesion tends to be a solitary non-hem-
orrhagic mass, situated in the deep white matter adjacent to the ventricular
surface.
Aims: We aimed to evaluate the presence of depression and antidepressant
use before the diagnosis of CNS lymphoma and emphasize the duration
between the diagnosis of depression and lymphoma.
Methods: Data of 40 patients with CNS lymphoma were evaluated in a retro-
spective manner. From their national health records, prescription for antidepres-
sant and anxiolytic drugs with their psychiatric diagnosis, time before the diagnosis
of CNS lymphoma, the branch of the prescribing physician, presenting symptoms
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from their medical files, type and treatment of lymphoma and survival were
recorded. OECD international statistics as well as Turkish Statistical Institute
data for national antidepressant use were collected and interpreted.
Results: Of the 40 patients, 14 were male (35%) while 26 were male(65%).
Mean age was 60,5 years (38-78). 7 patients were alive (17.5%). Method for
diagnosis was radiological imaging (magnetic resonance imaging) in 27
patients (67.5%) while in 13 patients, diagnosis was supported with histopatho-
logical confirmation (32,5%). Mean survival was 8,6 months (2-24 months). As
the complaint for medical help seeking, 4 patients presented with neurophyschi-
atric symptoms while 16 patients presented with headache (40%) and 20
patients (50%) presented with neurological defects. On the other hand, prior
to lymphoma diagnosis, 7 patients were diagnosed as anxiety disorder and 13
as depression (total, 19 patients, 47,5%) and were prescribed antidepressant
and anxiolytic medications. The mean duration between prescription of antide-
pressants and diagnosis of lymphoma was 2,6 months (0-10 months). Within
the patients who were on antidepressants, 6 were female and 14 were male.
Summary/Conclusions: OECD Health at a Glance data revealed that in 2013,
the defined dose per 1000 per day is 35, range of Europe is 21-88. According
to our data of Ministry of Health, use of antidepressants in the general popu-
lation is 10,52%, mostly in women. Within these patients, 42,37% were anxiety
disorders and 22,99% were depression. In the last five years’ statistics, 30%
of our population was prescribed for an antidepressant. The major group of
physicians presciribing these medications was family and general physicians
(>45%). The most striking finding of our study was the majority of male patients
receiving antidepressants before the diagnosis of CNS lymphoma with a mean
delay of diagnosis as 2,6 months (0-10 months). Depression and anxiety dis-
orders are the leading diseases of disability and the importance of organic and
underlying conditions should not be underestimated relying on the increasing
need of antidepressants. 
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IMPACT OF U.S. FDA APPROVAL OF LENALIDOMIDE MAINTENANCE
THERAPY IN THE FIRST-LINE TREATMENT OF MULTIPLE MYELOMA
AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT ON
TOTAL HEALTHCARE COSTS
K. Parikh1, J. Xie2, C. Chen3, C. Yang4, A. Farrukh5, P. Cockrum1,
A.B. Agarwal1, S. Abouzaid1,*
1Celgene Corporation, Summit, NJ, 2Analysis Group, Inc, Los Angeles, CA,
3Analysis Group, Inc, Boston, 4Analysis Group, Inc, Boston, MA, 5Analysis
Group, Inc., Los Angeles, CA, United States
Background: Lenalidomide maintenance therapy after autologous hematopoi-
etic stem cell transplant (auto-HSCT) in the first-line treatment has been shown
to improve progression-free survival (PFS) and overall survival (OS) in multiple
myeloma (MM) patients.
Aims: This study assessed the budget impact of the United States (U.S.) Food
and Drug Administration (FDA) approval of lenalidomide maintenance therapy
on total healthcare costs of a U.S. health plan.
Methods: An economic model was developed to estimate the incremental
(additional) total plan costs (in 2016 USD) of maintenance therapy in each
year for the first 3 years after lenalidomide monotherapy (R) maintenance ther-
apy approval. The number of post auto-HSCT adult MM pts eligible for initiating
maintenance therapy was estimated from published epidemiological data and
an analysis of Connect® MM Registry data. Clinical endpoints for R-mainte-
nance, including time on treatment, PFS and OS, were obtained from a meta-
analysis of published clinical trials (CALGB, IFM, and GIMEMA). The use of
common off-label maintenance therapies was considered. Types of costs
included in the model were drug, drug administration, adverse events (AE),
AE monitoring, one-time progression and terminal care costs.
Results: In a hypothetical U.S. health plan with 1 million members, the number
of adult MM pts eligible to initiate post-ASCT maintenance therapy was esti-
mated to be 28. Among them, 14.8 pts initiated R-maintenance in Year 1, 15.2
in Year 2, and 15.3 in Year 3, representing an incremental increase of 2.9%,
4.2% and 4.4% after R-maintenance therapy approval, respectively. After con-
sidering additional costs of maintenance, as well as potential offsets resulting
from delayed progression the incremental total healthcare costs by year are
listed in the Table 1. Results were consistent across all total plan, per patient
per year, and per member per month costs. Deterministic sensitivity analysis
showed that the model results were robust to the variations of key model inputs.
Table 1.
Summary/Conclusions: Approval of lenalidomide monotherapy for mainte-
nance after auto-HSCT in the first-line treatment of MM has minimal impact on
total plan costs, primarily due to the small incident population and the already
common use of lenalidomide in post auto-HSCT maintenance.
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LAPAROSCOPIC APPROACH CAN EXTEND THE INDICATIONS OF
SPLENECTOMY: ANALYSIS OF 31 CONSECUTIVE PATIENTS WITH
MALIGNANT HEMOPATHIES 
A. Salaroli1,*, B. Cadiere 2, C. Spilleboudt1, M. Vercruyssen1, A. de Wind3,
M. Maerevoet1, G. Dapri2, G. B. Cadiere2, D. Bron1
1Department of Hematology, Institut Jules Bordet, ULB, 2Department of Diges-
tive Surgery, Hôpital St Pierre, 3Department of Pathology, Institut Jules Bordet,
ULB, Brussels, Belgium
Background: Surgical resection of large spleens may eliminate a significant
amount of tumor, allow definite diagnosis of malignant disorder, ameliorate
abdominal symptoms and resolve cytopenia.  However, because of short term
perioperative events (25%) and long term immunosuppression (increased risk
of infections caused by encapsulated bacteria) physicians can be reluctant to
choose splenectomy, especially in older patients or patients with comorbidities.
The role of laparoscopic splenectomy (LS) in patients with hematological malig-
nancies is still unclear. Nevertheless, the ageing of the world’s population and
the increased incidence of Non-Hodgkin’s Lymphoma are increasing the indica-
tions for splenectomy, requiring a well-tolerated and less invasive procedure.
Aims: The aim of this review is to analyze our single-center experience of LS
performed for malignant Hemopathies. Results are compared with LS for
benign splenomegaly and the risk of locoregional dissemination or inadequacy
of fragmented histological sample were analyzed.
Methods: We retrospectively analyzed 50 patients who underwent LS between
2005 and 2016 at Saint-Pierre Hospital. Anterior approach was used in 12
patients whereas in the remaining 38 cases, a semi-lateral position was chosen.
All the patients received the triple vaccination (Streptococcus pneumoniae,
type B Haemophilus influenzae, and Neisseria meningitidis). Patients charac-
teristics, safety data such as early (<30 days) and late (>30 days) morbidities
and mortality and efficacy (hematological recovery, accuracy of histological
diagnosis) were analyzed.
Results: 19 patients underwent splenectomy for benign hemopathies (SBH) and
31 patients for malignant hemopathies (SMH). Non-Hodgkin’s lymphomas (12)
and idiopathic myelofibrosis (10) were the most common causes of splenectomy
followed by chronic lymphocytic leukemia (7), hairy cell leukemia (1) and
hodgkin’s lymphoma (1). Patients’ age (67 +/- 12 years, ranging from 36 to 87 in
SHM, and from 11 to 71 in SBH), prior abdominal surgery (18/31) and spleen
volume (1515 +/- 662 mL, ranging from 220 to 3000ml in SMH, and from 90 to
1500ml in SBH) were significantly higher in the SMH group (p <0.05).  There
was no significant difference in surgical time (150 vs 146 min, p=0.8), blood
losses (243 vs 402 mL, p=0.26) and duration of hospitalization (5.4 vs 7.5 days,
p=0.19) between SMH and SBH. No case of locoregional dissemination was
experienced. The early morbidity of the SBH group was 10% and 13% for the
SMH group (p=1). Late morbidity was 0% in the SBH group and 13% in the SMH
group (p=0.28). This could be explained by a combination of underlying disease
and immunosuppression (2 sepsis and 2 deep vein thrombosis). There was one
conversion to open surgery and perioperative mortality in each group (p=1).
There was no significant difference in efficacy of splenectomy, with respectively
83% and 79% (p=0.91) or quality of histological sample for pathological report
between SBH and SMH. In the SMH group, 4 out of 31 patients received a pre-
surgical corticosteroid treatment, with a pre-surgical platelets level of 156 +/- 108
x 103/mL, white blood cell level of 15696 +/- 18950/mL and Hemoglobin level of
10.1 +/- 1.6 g/dL. Regarding the efficacy of LS in correcting hypersplenism in the
SMH, a significant difference in term of platelets recovery after 1 month from the
surgery was shown in patients efficiently Vs inefficiently operated (respectively
387 +/- 125 Vs 138+/- 90 x 103/ml, p <0,05). The median follow up is 39 +/- 37
months and 80% achieved a hematological recovery.
Summary/Conclusions: LS is a safe and less-invasive procedure in patients
affected by Malignant Hemopathies. This approach is also well tolerated in
older patients (median 67yrs) and in patients with large spleen (1515+/-660
ml), extending the indication for laparoscopic SHM even in older patient and in
patients with high volume spleen. Compared to historical data, LSy for Malig-
nant Hemopathies shows better early and late morbidities. Our data shows
however a trend for higher late morbidity in the SMH group, warranting a careful
long term follow-up in this subset of patients.
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ARE WE AWARE OF ANXIETY AND DEPRESSION IN PATIENTS WITH
NEWLY DIAGNOSED ACUTE LEUKEMIA?
M.H. Dogu1,*, R. Eren1, N. Nizam2, O. Yokus1, E. Suyani1
1Hematology, 2Internal Medicine, Istanbul Education Research Hospital, Istan-
bul, Turkey
Background: Acute leukemia poses a high risk of stress for the patient during
the process of diagnosis. The process after the diagnosis is challenging for the
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patient due to urgent admission, long duration of stay in hospital, chemothera-
peutic agents used in the treatment and the disease itself. Evaluating this group
of patients for anxiety and depression, providing necessary professional support
and revising medical treatment is therefore substantial. 
Aims: In our study, we aimed to assess the risks of anxiety and depression in
newly diagnosed acute leukemia patients who were admitted to hematology
clinic to receive chemotherapy and provide necessary professional support
along with treatment revisions and follow-up according to our findings. 
Methods: Our study was performed with newly diagnosed acute leukemia patients,
who were admitted to our hospital hematology clinic in a six-month period to receive
chemotherapy. Demographic characteristics were noted and Hospital Anxiety and
Depression Scale (HADs) was used to assess depression. Hospital Anxiety and
Depression Scale (HADs) is an assessment scale developed by Zigmond and
Snaith to determine the risks and assess the severity of anxiety and depression
(8). The validation and reliability studies of the scale in Turkey were carried out by
Aydemir et al (9). The questionnaire has a total of 14 items; seven of which measure
anxiety (odd numbers) and the remaining seven (even numbers) measure depres-
sion. Each item is scored from 0 to 3. The scoring order of each item in the ques-
tionnaire is different. Items numbered 1, 3, 5, 6, 8, 10, 11 and 13 indicate decreasing
severity and are scored as 3-2-1-0. On the other hand; items numbered 2, 4, 7, 9,
12 and 14 indicate increasing severity and are scored as 0-1-2-3. The cut-off value
for the total score of the odd-numbered questions assessing anxiety is 10; while it
is 7 for the even-numbered questions assessing depression. 
Results: 21 patients were included in the study. 13 of these patients (61.9%)
were diagnosed with acute myeloid leukemia (AML) and 8 (38.1%) were diag-
nosed with acute lymphoblastic leukemia (ALL). Median age of the patients
was 45 (range: 21-69). 11 patients (52.4%) were female and 10 (47.6%) were
male. 5 patients (23.8%) had comorbidities while 16 (76.2%) had none.
Anxiety evaluation revealed that 38.1% of all patients in the study experienced
anxiety. The rate of anxiety was 38.5% in AML patients and similarly 37.5% in
ALL patients. 45.5% of the female patients had anxiety while the rate was only
30% in male patients. The difference was not statistically significant (p >0.05).
Depression evaluation revealed that 81% of all patients in the study. The rate
of depression was 84.6% in AML patients and 75% in ALL patients. 81.8% of
the female patients had depression while it was 80% in male patients. Neither
anxiety nor depression had a significant correlation with comorbidities or gender
(p >0.05). Correlation analysis revealed a positive correlation between anxiety
and depression (r=0.846; p <0.01).
Summary/Conclusions: In conclusion, assessing anxiety and depression in
patients with acute leukemia at the time of hospital admission is substantial for
the course of and adherence to treatment. In our study, depression was dis-
tinctively more common than anxiety and there was a positive correlation
between depression and anxiety. We think that including a professional for psy-
chological support in the medical team is important for the treatment of these
patients. 
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GENDER DIFFERENCE IN ANXIETY FOR THE FIRST BLOOD
TRANSFUION
Y. Lu1,*, X. Zhang1, X. Li2, Y. Zou1, Z. Lin1
1the third Affiliated Hospital of Sun Yat-Sen University, 2The Sixth Affiliated
Hospital of Sun Yat-Sen University, Guangzhou, China
Background: Blood transfusion has several risks including allergic reaction,
acute hemolysis, infectious disease and so on. Both physicians and patients
are always cautious to decide on blood transfusion.
Aims: The purpose of this study was to explore whether there are gender differ-
ence in anxiety for the first blood transfusion in patients with different diseases.
Methods: 315 patients (153 men and 162 women ) were enrolled in this
prospective, comparative study and median age was 38 years(range 17-72).
The disease consisted of 85 chronic hepatitis B, 73 leukemia, 69 gastric ulcer,
48 chronic renal failure and 40 gynecological oncology. Various blood products
including plasma, red blood cells suspension and platelet were infused. Anxiety
was evaluated according to the HAMA self-rating anxiety scale (SAS) during
the first blood transfusion. Patients got 50 points below were divided into no
anxiety group, 50 to 59 points were divided into mild anxiety group, 60-69 points
were divided into moderate anxiety group and 70 points or more were divided
into severe anxiety group.
Results: For patients with the same disease, more female patients were divided
into moderate to severe anxiety group than male ones. The number of patients
with mild anxiety was similar in female and male, and no one was divided into
no anxiety group.
Summary/Conclusions: Women were more anxious than men during the first
blood transfusion, which is independent of age, race, education level and kinds
of blood product.
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A ROOM OF MY OWN
L. Gov Ari De-Vries1,*
1Hematology day center, Shaare Zedek Medical Center, Jerusalem, Israel
Background: Three years ago, a unit for autologous bone marrow transplant
for hematological patients has been established in Shaare Zedek medical cen-
ter. The patients meet with the doctors for the treatment plan usually following
the diagnosis.  From the point of view of a part of the patients, the process
appears simple, short term, and promises cure. In reality, the process is long
term, including aggressive chemotherapy prior to the transplant. The treatment
is highly aggressive and toxic with many physical and mental side effects for
the patient and his/her family.  The transplant process requires hospital admis-
sion for about a month in an isolation room. No one is allowed in the room
except for close relatives and the medical staff. The social worker, part of the
caring staff, accompanies patients and families from the initial diagnosis through
this taxing and stressful process.  Most patients are young, average 45 years,
in the middle of their careers, from a broad spectrum of occupations, education
as well as social status, representing Israeli society.
Aims: 1. To accompany and empower patients by means of giving them tools
to cope with the transplantation process which is a  crisis situation in the midst
of their lives. 2. To teach patients self-awareness. 3. Promote quality of life for
the patients especially during the stay in the isolation room by way of creating
a safe domain.
Methods: The following tools had been utilized: 1. The “Empowerment
method”.   An advanced view of the powers and experiences of patients that
constitute resources  in addressing crisis. 2. Work of hope- finding unique
meaning in life crisis.
Results: This work is based on therapeutic conversations that took place inside
the isolation room with about 30 patients, mostly men, average age was 50,
during the past three years. With the understanding that a patient goes from
the public sphere to a private one -the isolation room- my entrance into the
room was based on the ability and willingness of the patients to go into a treat-
ment dialogue at that point and time. From the narratives of the patients, a few
themes were extracted that were repeatedly discussed by most patients. 1. Fear
of death. 2. Post-traumatic issues. 3. Fear of isolation. 4. The issue of relation-
ships. 5. Mind and body. 6. Children. 7. Faith. 8. Closure
As cited by S.A, a 49 year old man “I’m afraid to give in and die, help me to stay
alive. And if I die, I want to know that I have left no unfinished business.”
Summary/Conclusions: From the therapy sessions it appears that the central
issues that bother the patients belong to the private space and the coping with
it. The process of treatment helps patients to go from the private sphere back
to the public one.
Recommendations: It seems essential for the patients in the isolation room,
undergoing autologous bone marrow transplant, to have therapy sessions with
a qualified social worker as part of the holistic care. ‘Having a room of his own’
in the process enables an opportunity to examine the inner self esteem and
strengths of the patients thereby patients learn to contribute to themselves from
themselves.
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HYDROXYUREA INHIBITS MYELOID DIFFERENTIATION VIA NITRIC
OXIDE SYNTHASE
T. Subotički1,*, O. Mitrović Ajtić1, M. Diklić2, S. Vignjević Petrinović1, M. Budeč1,
D. Djikić1, J. Santibanez2, V. Čokić2
1Laboratory of neuroendocrinology, 2Laboratory of experimental hematology,
Institute for Medical Research, University of Belgrade, Belgrade, Serbia
Background: Hydroxyurea and nitric oxide (NO) inhibit erythroid differentiation,
while hydroxyurea is NO-releasing agent used in therapy of sickle cell dis-
eases.
Aims: To study the mechanism of hydroxyurea inhibition of erythroid differen-
tiation by exploring NO synthase (NOS) dependence.
Methods: The erythroid differentiation is studied by methylcellulose colony
assay in mice, whereas presence and activation of endothelial NOS (eNOS)
by immunocytochemistry and immunoblotting, respectively in K562 ery-
throleukemic cell line.
Results: In ex vivo experiments, mice exposed 7 days to hydroxyurea
demonstrated significant decrease in the number of nucleated cells per femur,
partially reversed by NOS inhibitor N-nitro L-arginine methyl ester hydrochlo-
ride (L-NAME). The same, but less prominent reduction has been observed
with NO metabolites nitrite (NO2) and nitrate (NO3). Moreover, hydroxyurea
demonstrated a large diminution in the number of bone marrow derived
myeloid colony-forming unit -granulocyte/macrophage (CFU-GM), burst-form-
ing-units-erythroid (BFU-E) and colony-forming unit-erythroid (CFU-E)
colonies in methylcellulose cultures. L-NAME attenuated hydroxyurea reduc-
tion of myeloid and erythroid colonies, while by itself increased CFU-E and
CFU-GM colonies and slightly BFU-E colonies. NO metabolites NO2 and
NO3 generally inhibited myeloid and erythroid colonies, but the reduction
was more prominent by NO2 compound. Moreover, the hematological param-
eters and weight (before and after treatment) of mice did not show any sig-
nificant difference among studied groups. Hydroxyurea increased NO pro-
duction and the number of eNOS positive K562 erythroleukemic cells, while
phosphorylation of eNOS and activation of AKT/mTOR signaling was not
blocked by phosphatidylinositol 3-kinase inhibition.
Summary/Conclusions: NO prodrug hydroxyurea demonstrated NOS
dependence in inhibition of myeloid / erythroid differentiation, not influencing
the hematological parameters.
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SLEEP DISORDERED BREATHING IN CHILDREN AND ADOLESCENT
WITH SICKLE CELL DISEASE: IMPACT ON EXECUTIVE FUNCTION AND
PROCESSING SPEED INDEX
M. Koelbel1,*, J. Kawadler2, H. Stotesbury2, P. Balfour2, F. Kirkham1
1UCL Great Ormond Street Institute of Child Health https://www.ucl.ac.uk/ich,
London, United Kingdom, 2Developmental Imaging & Biophysics, UCL Great
Ormond Street Institute of Child Health https://www.ucl.ac.uk/ich, London, Unit-
ed Kingdom
Background: Studies in non-syndromic children have shown that sleep-dis-
ordered breathing (SDB) increases the risk of neuropsychological deficits
and neuronal brain injury. Few authors have investigated the role in cognitive
deficits of SDB and the associated hypoxia in children with sickle cell disease
(SCD). Snoring and SDB is very common in children with SCD and may
affect cognitive function in very young children. Previous data suggested that
executive function was worse in older children with SCD and low mean
overnight oxygen saturation.
Aims: We aim to investigate if SDB could be a potential factor contributing
to developmental problems in cognition in children and adolescent with
SCD.
Methods: We have followed up children and adolescents in the Sleep Asthma
cohort who underwent Polysomnography at two different time points (1) 2006-
2009 and (2) 2011-2014 and compared the sleep data with subsequent neu-
ropsychological assessment.
Results: Worse performance was found for processing speed: PSI (p<0.01)
and general intelligence (p<0.05) compared to control siblings. SDB, measured
as apnea and hypoxia index (i.e. AHI >3%: Apnoeas and hypopnoeas with
more than ≥3% desaturation), was found to impact executive function, as meas-
ured with the Tower test, (p<0.05) and PSI (p<0.05). Mean oxygen saturation
during total sleep time was significantly associated with lower PSI (p<0.05).
Additionally, participants who showed a worsening of their SDB symptoms in
their second sleep study had lower cognitive scores (i.e., executive function,
p<0.05 and PSI, p<0.05) (Figure 1).
Summary/Conclusions: SDB symptoms seem to worsen into adolescence
and therefore, might have a neurodevelopmental impact if left untreated; appro-
priate intervention might improve cognition and quality of life.
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LUNG FUNCTION IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL
ANEMIA: A COMPARISON BETWEEN UK AND ITALY 
C. De Pieri1,*, M. Arigliani1, R. Colombatti2, L. Sainati2, K. Vecchiato3,
S. Ndoro4, P. Cogo1, B. Inusa4
1Department of Clinical and Experimental Medical Sciences, University Hospital
of Udine, Udine, 2Clinic of Pediatric Hematology-Oncology, Department of Child
and Maternal Health, Azienda Ospedaliera-Università di Padova, Padova, 3Uni-
versity of Trieste, Trieste, Italy, 4Department of Pediatrics, Evelina Children’s
Hospital, London, United Kingdom
Background: Acute and chronic respiratory complications are common in sick-
le cell anemia (SCA). Subjects with SCA often have a progressive decline of
lung function with age that could be influenced by the quality of healthcare and
by environmental factors, such as the level of exposure to air pollution.
Aims: To compare lung function, evaluated cross-sectionally through spirom-
etry, in children and adolescents attending sickle cell centers in UK and Italy.  
Methods: Anthropometry and spirometry were recorded in patients with SCA
(SS,Sb0) aged 6-17 years of African ancestry followed at the Evelina Children’s
Hospital, London, UK, and at the University Hospitals of Padova and Udine,
northeast of Italy. Subjects from the British cohort lived in an urban area while
those from Italy came from urban and non-urban areas. Exclusion criteria were
the presence of SCA-related morbidity within the last two weeks and the inability
to perform a spirometry meeting the European Respiratory Society acceptability
and repeatability criteria (Miller, Eur Respir J 2005;26:319–338), modified for
children (Kirkby, Pediatr Pulmonol 2008;43:1233–1241). Portable spirometers
(Pony FX, Cosmed-IT, Easy-on PC, NDD-CH) were used. Z-scores of anthro-
pometric and spirometric data were derived, respectively, from CDC2000 and
from the Global Lung Initiative 2012 predictive equations for African Americans
(Quanjer, Eur Respir J 2012; 40:1324–1343). Spirometry patterns were clas-
sified as normal, obstructive (zFEV1/FVC<-1.64) or restrictive (zFVC<-
1.64+zFEV1/FVC ≥ -1.64). Differences between groups were assessed by t-
tests and considered statistically significant for p values <0.05.  
Results: A total of 101 children and adolescents were included (n. 62 in UK;
n. 39 in Italy; 42% girls; age-range: 6.2-17.9 years). We didn’t find significant
differences in mean spirometry indices between the SCA cohort from London
and northeast Italy (Table 1). Nevertheless while an obstructive spirometry pat-
tern was more common in the British cohort compared to the Italian one
(respectively 22.5% vs 7.7%), the picture was the opposite for the restrictive
pattern (respectively 11.2% and 20.5%) (Table 1). In the whole sample age
was negatively correlated with both zFEV1 (Spearman’s rho-0.20) and zFVC
(Spearman’srho -0.24). 
Table 1.
Summary/Conclusions: Lung function of pediatric subjects with SCA living in
London and in the northeast of Italy is overall comparable. Obstructive lung
disease is more common among subjects with SCA living in London than in
urban and non-urban areas in Italy. Differences in the level of exposure to
ambient air pollution and in the prevalence of allergies between the rural and
urban environment might have contributed to this finding and need to be further
investigated. 
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SICKLE CELL DISEASE: A NEW DISEASE IN MADRID
E. J. Bardón-Cancho1,*, M. García-Morín1, B. Ponce-Salas1,
Y. Aguilar-de la Red1, A. Pérez-Corral2, G. Pérez-Rus2, E. Dulín3, C. Beléndez1,
E. Cela1
1Section of Pediatric Hematology and Oncology, Department of Pediatrics,
2Department of Hematology, 3Newborn Screening Laboratory (Community of
Madrid), Hospital General Universitario Gregorio Marañón - Facultad de Med-
icina - Universidad Complutense de Madrid, Madrid, Spain
Background: Sickle cell disease (SCD) was scarcely diagnosed 2 decades
ago in Spain, and the Community of Madrid is a paradigm of the adjustments
that had to be implemented to attend an increase of cases due to immigration. 
Aims: The aim of our study was to find out the prevalence of SCD in the referral
center for sickle newborn screening in the Community of Madrid, in addition to
the demographic characteristics of these patients. The secondary objectives
were to obtain the frequency of specific treatments or prophylaxis accomplished
by these patients, and the reasons for loss to follow-up.
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Methods: The study is observational, unicentric, descriptive and retrospective,
carried out in February 2017 in a tertiary hospital in the Community of Madrid,
Spain. All patients diagnosed with SCD and who had attended at least once to
the hematology clinic for this reason were included. Demographic characteris-
tics (date of birth, gender, country of birth) and clinical characteristics (genotype,
therapy and update in follow up, like alive, deceased or lost patient) were col-
lected. Written informed consent was signed by patients or legal guardians in
accordance with the Declaration of Helsinki. The study was approved by the
hospital Ethical Committee. Statistical analyses were performed using SPSS
version 18.0. Quantitative variables were reported as median or mean value
and range, while categorical variables were expressed as absolute value and
percentage. 
Results: The total number of SCD patients included was 209. Ratio boy/girl is
1.3. Most of patients were born in Spain (85%), although 8% and 5.26% were
born in Africa or America respectively. Seventy three percent of the progenitors
came from Africa and 24% from America. Ninety two percent of those SCD
patients born in Spain were detected in their first days of life due to universal
screening detection implemented in Community of Madrid since 2003. Median
age at first diagnosis was 1.42 years (0-21.4). Median age at the end of inclu-
sion was 9.91 years (range 0.13 to 35.14). SS or S/Betathal0 was reported in
86%. In addition, 2.39% associated alfa gen deletion, and 1 (0.48%) glucose 6
phosphate dehydrogenase deficiency. No patient had congenital thrombotic
diathesis. Eighteen patients (8.65%) had human leucocyte antigen (HLA) iden-
tical siblings. Hydroxyurea was added to standard treatment in 65 patients
(31%) of which 47 continue to be treated to date. Penicillin prophylaxis was
communicated in 165 patients (79%). Vitamin-D prophylaxis was initiated in
128 patients (61%). Chronic exchange or simple transfusions existed in 26 cas-
es (12%) and 9 children (4%) underwent splenectomy. None of these patients
had sepsis or meningitis. Cholecystectomy was performed in 9 cases (4%).
There were 18 progenitor stem cell transplantations (8.61%) performed
between 2.09 to 13.97 years of age (median 6.77 years). Ten patients remained
on complete chimerism, 6 on mixed chimerism and 1 attained a marrow rejec-
tion. One patient died of graft-versus-host disease. Patients lost in follow-up
summed up 128: 23 for emigrating to other countries, 65 for continuing the
monitor of their diseases in other centers or in adults units and 31 for unknown
reasons. There were 9 deaths (2.87%).
Summary/Conclusions: Early diagnosis like universal neonatal screening
allows an effective health education, and antibiotic and osteopenia prophylaxis
with vitamin D and general and specific vaccination can be started.
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COMPLEMENT ACTIVATION IN PATIENTS WITH SICKLE CELL DISEASE
IS ASSOCIATED WITH HIGHER HBS LEVELS
E. Gavriilaki1,*, M. Mainou2, I. Christodoulou2, E.-E. Koravou1, A. Paleta1,
T. Touloumenidou1, A. Papalexandri1, A. Athanasiadou1, C. Apostolou2,
P. Klonizakis2, A. Anagnostopoulos1, E. Vlachaki2
1Hematology Department - BMT Unit, G. Papanicolaou Hospital, 2Adults Tha-
lassaemia Unit, 2nd Department of Internal Medicine, Aristotle University of
Thessaloniki, Hippokration General Hospital of Thessaloniki, Thessaloniki,
Greece
Background: Older studies have suggested activation of the alternative path-
way of complement (APC) in sickle cell disease (SCD). Despite the renewed
interest in SCD therapeutics, little is known about APC activation in the clinical
setting of SCD, possibly due to the complexity of complement diagnostics.
Aims: We investigated firstly, whether complement activation can be detected
in the sera of asymptomatic SCD patients using a simple functional assay, sec-
ondly whether it is associated with clinical parameters and thirdly whether it
can be blocked in vitro by the complement inhibitor eculizumab.
Methods: Consecutive asymptomatic SCD patients were enrolled prospectively
from November 2016 to January 2017. Patient history, clinical and laboratory
data were recorded. Complement activation was detected in patient sera using
the modified Ham test, a cell proliferation assay based on the susceptibility of a
PNH (paroxysmal nocturnal hemoglobinuria)-like cell line to complement activated
serum. Normal human serum (NHS) was used as a negative control and
lipopolysaccharides (LPS)-incubated normal serum as a positive control. All sam-
ples were tested in triplicates and twice. Eculizumab containing serum (ECU)
was collected from a PNH patient within 60 minutes after the infusion and used
to test complement blockade by eculizumab in the modified Ham test.
Results: We studied 26 SCD patients (36±11 years of age, 12 male:14 female,
8 HbS/S: 18 HbS/β-Thal). Among them, only 6 had a history of painful crisis
and 15 a splenectomy, 15 were on hydroxyurea and 12 on antithrombotic treat-
ment. Based on previous studies and present controls, percentage of non-
viable cells higher than 20% was considered a positive modified Ham test, indi-
cating increased APC activation in 4 SCD patients (Figure 1). Positive patients
had significantly increased HbS levels (80.5±11 vs 61.8±16%, p=0.037), while
2/4 were homozygous (HbS/S) and 2/4 heterozygous (HbS/β-Thal). The major-
ity (3/4) were not on hydroxyurea. No significant difference was found regarding
age, gender, platelets, white blood cells, Hb, HbF, LDH and bilirubin levels
between patients with and without complement activation. Then, we evaluated
in vitro the efficacy of complement inhibition by eculizumab in the modified Ham
test. Mixing eculizumab serum (ECU) with complement activated sera demon-
strated a dose-killing relationship that was consistent across the 4 patients.
Figure 1.
Summary/Conclusions: Our results suggest that complement dysregulation
is evident in asymptomatic SCD patients with increased HbS levels, an impor-
tant tool in everyday clinical practice. APC activation during a painful crisis and
the role of hydroxyurea need to be further investigated in larger series validating
the role of different functional assays. Effective inhibition of complement acti-
vation in vitro is promising for future studies in selected patients.
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THE ROLE OF EXECUTIVE DYSFUNCTIONS IN THE VERBAL LANGUAGE
DEFICITS OF CHILDREN WITH SICKLE CELL DISEASE
B. Arfe’1, M. Montanaro2, E. Mottura2, R. Manara3, M. Scaltritti1, G. Basso2,
L. Sainati2, R. Colombatti2,*
1Department of Psychology, University of Padova, 2Clinic of Pediatric Hema-
tology Oncology, Department of Child and Maternal Health, Azienda
Ospedaliera-Università di Padova, Padova, Italy, Padova, 3Department of Radi-
ology, University of Salerno, Salerno, Italy
Background: Children with Sickle Cell Disease (SCD) frequently present
impairment of general and specific neurocognitive functions, even in the
absence of clear neurological damage at brain neuroimaging. Verbal language
deficits are also common, but the etiology of poor performance in the verbal
domain is still not clear. The ability to speak and communicate verbally relies
on a complex interaction of cognitive and linguistic functions as well as on envi-
ronmental factors, like bilingualism or second language (L2) learning. The
majority of children with SCD in Italy are of immigrant families whose first lan-
guage is not Italian. These children thus perform poorly in tests assessing the
verbal domain with adverse impact on school performances. 
Aims: To evaluate if verbal language deficits in bilingual children with SCD are
mainly due to linguistic and environmental issues or to impairment of executive
functions.
Methods: In this study a cohort of bilingual children with SCD and social-demo-
graphically matched healthy controls recruited from elementary schools of the
same city, performed an extensive battery of tests to assess naming skills,
phonological and semantic fluency, attention and Executive Functions (inhibition
and planning skills) and  visuo-spatial skills (Boston naming test, phonological
and semantic fluency tests, Flanker task, Elithorn test, PMA spatial relations
subscale). All tests were administered in Italian. A composite index considering
parental education and employment was used to match socially, demographi-
cally and economically children at best. Analyses of variance (ANOVAs) were
performed to test differences between the two groups in verbal language, atten-
tion and executive functions. Hierarchical regressions explored the contribution
of linguistic knowledge and executive functions (i.e. inhibition) to the verbal lan-
guage deficit of children with SCD. 
Results: Thirty-two children with HbSS SCD aged 6 to 12 years (mean age=
9.03) and 35  controls (mean age= 9.14) were enrolled. Patients and controls
were matched for gender (F 53 vs 61%), ethnicity (African 30 vs 29),% of chil-
dren born in Italy (81 vs 80%), number of years lived in Italy (8.09 vs 8.31) and
Socio-Demographic Index (5.15 vs 4.59). Children’s Performance (in Z scores)
at Visuo-Spatial, Boston Naming, Phonological Fluency and Semantic Fluency
Tests are shown in Figure 1. The results overall showed significant differences
between patients and controls in inhibition and planning (p= 0.001 and 0.001
respectively) and in verbal tasks that involved Executive Functions more (i.e.
phonological fluency) (p=.004). The poorer verbal performance of children with
SCD was not associated to visible lesions to Broca’s area; in fact only 9 patients
presented Silent Infarcts that were all in the white matter, in watershed areas.
Regression analyses showed that in children with SCD inhibition skills explained
unique variance in phonological fluency, suggesting that poor executive control
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was a factor of the lower performance in this task. Figure 1. Children’s Per-
formance (in Z scores) at Visuo-Spatial, Boston Naming, Phonological Fluency
and Semantic Fluency Tests. P-values: Visuo-spatial intelligence: not signifi-
cant(ns); Boston naming: ns; Phonol-Fluency: 0.004; Semantic fluency: ns.
Figure 1.
Summary/Conclusions: Selective language problems may occur in children
with SCD in the absence of clear neurological damage to language areas.
These problems  are explained by the executive dysfunction of patients with
SCD and not by environmental factors like bilingualism. Cognitive rehabilitation
or extra tuition may aid in overcoming these difficulties.
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UNDERSTANDING MEDICAL HISTORY, LIFESTYLE AND NEEDS FOR
FUTURE THERAPIES FOR PEOPLE LIVING WITH SICKLE CELL DISEASE
- IMPLICATIONS FROM A PATIENT SURVEY
A.M. Leitgeb1,*, M. Robinson2, C. Herder1, L. Jendeberg1
1Modus Therapeutics, Stockholm, Sweden, 2Micromattie Consulting Inc,
Oviedo, Florida, United States
Background: Sickle Cell Disease (SCD) is an inherited blood disorder affecting
millions of people. Sevuparin/DF02 is being developed to treat people suffering
from SCD and is currently in clinical phase 2 for the treatment of the acute
painful crisis in hospitalized SCD patients with intravenous infusion. This is
called the Resolve program. In a second program called EASE,
sevuparin/DF02 will be investigated as an on-demand treatment of early symp-
toms of painful sickle cell crisis in an at-home setting via a subcutaneous injec-
tion.Searching in the literature and discussing with health care providers, it
becomes clear that little is known about how the SCD patients sense these
early symptoms of a painful crisis. In order to gain increased understanding of
how people living with SCD experience daily life, coping with disease, support
by health care providers and the demand for new therapies, a patient survey
addressing these areas was conducted.
Aims: The aim with this survey was to gain deeper understanding of different
aspects of life with SCD by providing a channel for patients to air their own
views. The outcome will provide important information and, in combination with
future feasibility studies, will guide the design of the first clinical study aimed
at treating the early symptoms of pain crises in SCD patients.
Methods: A 29-question survey was created to gather input on a wide variety
of topics related to the lives of people living with SCD. This questionnaire was
developed by Modus Therapeutics AB, Sweden, in conjunction with Micromattie
Consulting Inc., USA. Experts and leaders of community-based organizations
participated in two focus group sessions to ensure that the text and structure
were ethical and appropriate for the intended purpose. The survey was hosted
at www.modustxpatientsurvey.com. Patients answered the survey directly, or
had their views entered in by a caregiver. The answers are anonymous. During
the initial period, survey promotion occurred within the Sickle Cell Warriors
online community and later, additional connections within the network of com-
munity-based organizations were leveraged. The survey was open for access
during the period of January 10, 2017 through March 1, 2017.
Results: An interim analysis was conducted on January 31, 2017. Basic demo-
graphic data is presented in Table 1. Responders were located mainly in the
US. Medical history related questions indicate that fatigue (40%), aches/pain
(37%), irritability (27%) and appetite (20%) are early symptoms and increase
just before the onset of a pain crises. However, 7% reported infrequent signs
and 19% never experienced an indicator of pain crisis. Patients take initiative
at home to manage the onset of an acute crisis and the top 5 home strategies
reported were: prescription pain medication (15%), sleep/rest (15%), apply
heat using heating pad/blanket/bath/shower (13%), increase fluid intake (12%),
and finally avoid stress (9%). Further it is clear, that people living with SCD are
motivated to try a new therapy that could provide “significant relief” and “prevent
symptoms from happening” due to their SCD.
Table 1.
Summary/Conclusions: The survey collected feedback about topics for which
the patient is the best source of information. It is obvious that people with SCD
are willing to self-medicate by subcutaneous injections and that there is a need
for new tools and medications. With support from the answers from the survey,
specific aspects will be considered while designing a first clinical study for sub-
cutaneous sevuparin/DF02 administration to treat early symptoms of painful
crisis in an at-home setting.
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LONG-TERM USE OF HYDROXYUREA IN CHILDREN AND
ADOLESCENTS WITH SICKLE /BETA THALASSEMIA
M. Economou1,*, A. Teli1, E. Papadopoulou1, A. Papastergiopoulos1,
S. Theodoridou2, F. Papachristou1
1Aristotle Universtity of Thessaloniki, 2Blood Bank, Hippokration General Hos-
pital, Thessaloniki, Greece
Background: Hydroxyurea (HU) has lately been used in the treatment of
patients with severe sickle cell disease (SCD). Despite documented benefits
on laboratory and clinical parameters in SCD patients, there are few reports
about drug’s long-term safety and efficacy in pediatric patients with SCD –
even more so in the rare patient subgroup of sickle/beta thalassemia. 
Aims: A prospective, long term evaluation of HU efficacy and safety in children
and adolescents with sickle/beta thalassemia (S/b thal).
Methods: Ten patients with S/b thal aged 3.5-18 years were followed for a 6
year period (Jan 2011- Dec 2016). HU was given at a daily dose that ranged
from 10 to 20 mg/kg, with a mean of 14.1 mg/kg. Laboratory follow-up con-
sisted of WBC, Hb, Ht, RBC, reticulocyte count and PLT count measured
every 2 weeks until dose escalation to a stable dose, biochemistry assessed
every 2 months and Hb F measured every 2-3 months. Patients were clinically
evaluated prior to HU treatment and every 12 weeks during the study period.
Evaluated data on clinical course included frequency of vaso-occlusive crises,
hospitalizations and transfusions, as well as presence of severe clinical
events. Hematologic toxicity of hydroxyurea was defined as a more than 20%
decline from baseline in Hb, as an absolute neutrophil count of less than
1,000/μl and/or a PLT count of less than 80,000/μl. Moreover, presence of
alopecia, rash, skin hyperpigmentation or headache was reported as drug-
related toxicity.
Results: A significant reduction in vaso-occlusive crises as compared to prior
to HU treatment was noted (median: 1 episode per year before HU, range: 0-
2.5 vs median: 0.24 episodes per study year after HU, range: 0-1.33, p=0.011).
A significant reduction in hospitaliizations was also reported (median: 1 per
year before HU, range: 0.3-2 vs median: 0.16 per study year after HU, 0-0.83,
p=0.005). None of the patients presented with severe clinical events such as
acute chest syndrome, avascular bone necrosis, stroke or splenic sequestration
during the study period. With regards to hematological parameters, a significant
increase in HbF (10.2±6.5% vs 16.6±7.1% p=0.02), MCV (66.1±3.9fl vs
79.3±8.4fl, p<0.001) and MCH (20.9±1.2pg vs 25.3±2.2pg, p<0.001), as well
as a decrease in reticulocyte count (7.7±3.3% vs 5.0±1.9%, p=0.039), WBC
count (9,566±3,674/μl, vs 7,466±3,460/μl, p=0.009) and PLT count
(333,778/μl,±170,227 vs 272,111±160,304/μl, p=0.007) was noted. Concerning
adverse events, one patient presented with mild transaminasemia, one with
mild elevation of serum creatinine levels and one with pancytopenia. Due to
persistent pancytopenia HU treatment was discontinued in the last mentioned
patient, but was restarted a year later due to frequent vaso-occlusive events -
despite the patient being put on transfusions after initial HU discontinuation.
Besides the pancytopenia episode, the rest of the mentioned toxicities were
short-term and dose-dependant.
Summary/Conclusions: The study indicates that HU has an overall safe pro-
file and results in a marked improvement of clinical course in pediatric S/b thal
patients. 
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IN VITRO AND IN VIVO EVIDENCES OF SICKLING REVERSAL INDUCED
BY REHYDRATION WITH HIGH K+-ISOTONIC SOLUTION
O. I. Ajayi1,*, O. Uchegbu2, F. Ozimede1
1Physiology, 2Medical Lab Science, University of Benin, Benin city, Nigeria
Background: Erythrocyte sickling and adhesion are favoured by cellular dehy-
dration, which increases the rate of hemoglobin polymerization and cell sickling.
Potassium chloride co-transport and calcium-activated potassium channel (Gar-
dos channel) mediate erythrocyte dehydration in sickle cell disease and β-tha-
lassemia.  We investigated the in-vitro and in-vivo effects of various concentra-
tion of K+ ions in physiological solutions (PSS) as well as in cocos nucifera
water (CNw) which is known for its natural high potassium content and iso-
tonicity.
Aims: This study was aimed at ascertain the efficacy of high potassium isotonic
solutions in rehydrating sickle cell and possibly reversing the sickling phenom-
enon at in vivo and in vitro situations
Methods: : Erythrocytes from twenty sickle cell anaemia (SCA) as well as 46
healthy subjects were studied. One part was treated with sodium metabisulphite
(Na2S5O7) solution to induce maximum sickling as controls while the other was
subjected to different high concentrations of K+ in PSS as well as Cocos
nucifera water (40mM, 80mM and CNw - 65mmol/L) respectively. The proce-
dure was repeated for the normal HB AA subjects. Also, both groups of subjects
were given 10ml/kg body weight of coconut water to drink as a single dose for
the in-vivo experiment. Blood samples were collected longitudinally before and
after the oral ingestion, at 1hr and at 24hrs for analysis of red cell indices as
well as stained blood films used to ascertain the percentage sickled erythrocytes
count before and after the treatment in both cases.
Results: Maximum percentage counts of sickled cells after the addition of
Na2S5O7 (45%) were observed which decreased significantly (P<0.05, respec-
tively) to about 2% with Cocos nucifera and 10% with 80mM K+PSS. The count
in 40mM K+-PSS was not statistically significant. In both Hb AA and SS subjects,
MCH and MCV remained relatively stable when compared with the pre-inges-
tion sample (P>0.05, respectively) while MCHC increased significantly in both
groups as early as 1hr and sustained till the 24th hour. MCHC was equally
raised in the in-vitro samples (P<0.05, respectively). The morphology of red
cells also indicated a lesser count of sickled red cells after the oral ingestion
Summary/Conclusions: Cocos nucifera water and other high potassium
ion solutions can activate the rehydration of sickled erythrocytes by probably
de-activating the Gardos channel to increase the mean corpuscular haemo-
globin concentration(MCHC) and thereby restoring the normal red cell shape.
We suggest a probable pharmacological value of the cocos nucifera water
as well as other formulated high potassium but isotonic fluids in SCA man-
agement.
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VITAMIN D IN SPANISH CHILDREN WITH HEMOGLOBINOPATHIES.
A.M. Bobes Fernández1,2,3,*, B. Ponce1,2, Y. Aguilar1,2, C. Garrido1,2,
M. García-Morín1,2, C. Beléndez1,2, E. Cela1,2
1Hospital Gregorio Marañón, 2Facultad de medicina, Universidad Complutense
de Madrid, 3Hospital Clínico San Carlos, Madrid, Spain
Background: Although vitamin D deficiency has been documented as a fre-
quent problem in studies of children, there are limited data on the prevalence
of this nutritional deficiency among children who suffer from sickle cells disease
(SCD) or thalassemia. Vitamin D homeostasis is important to prevent osteope-
nia. Furthermore vitamin D deficiency has been associated with increased risk
of common cancers, autoimmune diseases, hypertension, and infectious dis-
eases. Vitamin D deficiency is now recognized as a pandemic. The major cause
of vitamin D deficiency is the lack of sun. Although Spain has a high rate of
sunny hours, we have found low levels of vitamin D in our patients with SCD
or thalassemia.
Aims: The purpose of this work is to assess the status of vitamin D in children
with SCD and thalassemia in our setting.
Methods: We have recruited children diagnosed with SCD and thalassemia
between 1998 and 2016 and we have reviewed their vitamin D levels. We have
chosen the first vitamin value we obtained and the last one till today. Vitamin D
was measured by quantitative determination of 25(OH) D. Deficit of vitamin D
was defined by<30 ng/ml. The study enrolled 114 children. Most of them, with
SCD diagnosis ( 94%). The type of anaemia was Hb SS (94 patients), Hb SC
(8 patients), Hb Sß0 (3 patients) and HbSß+ (2 patients). The remaining 6%
were diagnosed with Thalassemia Maior. Mostly of the children were African or
Central-South American. In our centre, vitamin D prophylaxis is made since
the first year of life.
Results: 60% of the children had vitamin D deficiency. We have divided children
into 4 groups depending on the age. When considering vitamin D first determi-
nation: mean vitamin D levels in children below 2 years old were 39.5±13.3
ng/dl. The group between two and five years old had a mean serum vitamin D
of 35.5±14.8 ng/dl. Children aged between five and ten had 26.1±13.5 ng/dl of
mean 25(OH)D. Finally in the group older than 10, we observed mean of 7.4±14
ng/dl. When having these low levels of vitamin D, we strongly recommend to
start treatment with Cholecalciferol 25000U/month.  Regarding second levels
of vitamin D, we have divided patients into those who presumably have the
treatment against children who do not. We present the results in the following
Table 1.
Table 1.
Summary/Conclusions: The study found a high prevalence of vitamin D defi-
ciency in children older than five years old(in the first determination) with SCD
or Thalassemia Maior and significant decrease of levels in those not having
vitamin D therapy. It is not well known the physiopathology of this factor defi-
ciency, although it is supposed to be multifactorial. However we confirm that
living in a sunny geographical situation with a healthy diet is not enough to
maintain an adequate 25(OH)D levels. Although it is difficult to reach correct
levels of vitamin with oral treatment, vitamin D levels increase when having
correct doses. We have also checked that older children have lower levels of
vitamin D than younger boys. This could be explained by the fact that pre-
teenagers spend lot of time at home instead of going out. If prophylaxis is made
not only the vitamin levels will increase but bone growth also.
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KNOWLEDGE OF SICKLE-CELL DISEASE IN HAUTE-NORMANDIE,
SOCIO-DEMOGRAPHIC CONTEXT AND HEALTH CHARACTERISTICS:
INTEREST OF THE IMPLEMENTATION OF A PATIENT EDUCATION IN
SICKLE CELL DISEASE
S. Ngo1,*, H. Van Elslande2, A. Lahary3, J.-M. Kerleau4, H. Levesque2
1Internal Medicine, Hopital Delafontaine, Saint Denis, 2Internal Medicine,
3Hematology, CHU Rouen, Rouen, 4Internal Medicine, Centre hospitalier de
Dieppe, Dieppe, France
Background: Sickle cell anemia (SCA) is a genetic disease causing a severe
disease manifesting by painful crisis but which can also be marked by organ
complications. Mortality is still happening at a young age. Many of these com-
plications may be better taken care of if treated early. The best way to manage
this disease is probably through Patient Education (PE)
Aims: Patient Education for children with sickle cell anemia has been a subject
of research, organized in France by association such as ROFSED, but PE in
adult patients has been little studied. The main objective of this work was to
evaluate SCA patients followed in Haute-Normandie, from a sociodemographic,
health and socio-demographic perspective in order to establish a PE program.
The secondary objective was to give them the opportunity to express their
expectations of such a program.
Methods: We did an observational multicenter study. A self-questionnaire of
39 items was sent to all patients suffering from SCA followed in Haute-Nor-
mandie.
Results: Fifty patients (male / female ratio 0.92) out of 123 (40.6%) responded,
mean age 33±10.5 years (SS genotypes [66%], SC[25%], S-beta-thalassemia
[9%]). 56% of them were born outside of Metropolitan France, 36% came from
French speaking African countries. Aerage age was 18±10.9 years. Despite
the fact that their education has been disrupted by the disease for the majori-
ty (69.4%), the level of education was “satisfactory”: 68% of patients had grad-
uated from high school or achieved a higher level, 18% had graduated from
professional education, 10% had a primary / middle school level and 4% were
illiterate. 68% of the patients had a job or were students. 48% of patients report-
ed to practice physical activity at least once weekly. Tobacco was consumed
on a daily basis by 14%, alcohol 2% and 4% for cannabis. Self-assessment of
health status was 6.9 / 10, self-assessment of morale of 7.9 / 10 and impact of
the disease on daily life was estimated at 5.4 / 10. The mean age at at which
specialized follow-up was started was 11±9 years. 88% of the subjects stated
that they understood everything the doctor said during consultation. Missed
appointments were reported by 26% which was justified by forgetfulness, lack
of will or physical incapacity. Regarding sources of information regarding SCA,
patients declared asking their specialist first and then looking on the internet.
68% of subjects had a first-degree relative suffering from the same disease,
71% were able to talk about the disease with their family. While the triggers of
crises and the management of crises were well-identified by patients (average
scores of 13.8 and 12/20), “standards” were not met with chronic complications,
prenatal diagnosis, and long term treatment (mean scores respectively of 7.4;
4.2 and 2.2 / 20). Average score on the whole questionnaire was 9/20. Most
patients showed interested in PE (52.1%) vs 31.3% that claimed were not inter-
ested, 17.7% did not decide.
Summary/Conclusions: A majority of SCA adults followed in Haute-Normandie
are first-generation migrants. Even if the disease has heavy impact on everyday
life and school access, their education level appeared correct. PE sessions will
need to focus on chronic complications, prenatal diagnosis, and the long term
treatment. The majority of adults with SCA are motivated by PE, we will have
to adapt to a heterogeneous population in terms of educational level, ethnic
origin and knowledge of the disease.
haematologica | 2017; 102(s2) | 851
Madrid, Spain, June 22 – 25, 2017
PB2151
DELAYED HAEMOLYTIC TRANSFUSION REACTIONS: A MASQUERADE
OF SICKLE CELL COMPLICATIONS
H.N. Fernandez - Leyva1,*, S. Kotsiopoulou 1, N. Osuji1, J. Maitland1
1Haematology, Croydon University Hospital, london, United Kingdom
Background: Patients with sickle cell disease (SCD) may require repeated red
blood cells (RBCs) transfusion, putting them at risk from minor blood group alloim-
munization and the development of delayed haemolytic transfusion reactions.
Aims: Reported a prevalence of recognized DHTR syndrome in patients with SCD.
Methods: We reviewed the cases of (DHTR) in SCD patients in a 5-year period
(2010- 2016). A total of 10 patients had a clinical picture compatible with DHTR
and underwent treatment with high dose steroids, intravenous immunoglobulins
(IVIG) or erythropoietin. Any patient received Rituximab.
Results: The most common indications for transfusion were anemia due to
vasococlusive sickle cell crisis or preoperative anaemia optimization. The
cohort received partial exchange transfusion and phenotypically matched
RBCs. Before transfusion the median of Hb level was 69 g/L (baseline range
80g/L) and the nadir at haemolysis episode was 38 g/L, Ht was 21.9%, WBC
was 17.3 × 109 cells/L and mean LDH 1290 IU/L). The median time to develop
DHTR was seven days after the transfusion and approximately 6 days after
the surgical interventions (range: 4–12 days) and all cases presented with
symptoms of anaemia, jaundice, tiredness and tachycardia. The median age
was 29 years with female predominance (6:4). Blood cultures were negative
in 80% of patients and only positive in 2 cases. 30% of patients tested positive
for viral infection on PCR. Mortality rate in our series was low (zero). Pain
episodes and other complications associated with DHTR was treated as
required and four cases were successfully monitored in HDU.  One patient
required noninvasive ventilations and inotropic support. Two patients received
RBCs transfusion (median 1.5 unit of packed RBCs). Possibly as their presen-
tation mimics an acute vaso-oclusive crisis. In all cases haemoglobin stabilized
and improved, symptoms resolved and patients were discharged on small
course of oral antibiotics (median admission 6 days).
Summary/Conclusions: The symptoms of DHTR can easily be mistaken for
other SCD complications, including infection and vaso-occlusive crisis. 
The diagnosis of DHRT is based on clinical suspicion, when there is a rapid Hb
drop after a recent RBC transfusion with clinical signs of haemolysis. To support
the diagnosis, laboratory tests (serial FBCs, haemolysis screen, DAT, measure-
ment of Hb S levels) and exclusion of other aetiologies are useful. Whenever a
DHTR is suspected, further RBC transfusion should be withheld unless absolutely
necessary, as it may precipitate acceleration of the hemolytic reaction. Patients
in whom the diagnosis of DHTR is missed may receive repeat transfusions, which
may contribute to the complications associated with SCD. The use of more exten-
sive phenotypic matching of blood and minimizing RBC transfusion help to pre-
vent DHTR.  The present series emphasize the importance of early recognition
of symptoms and signs in correlation with a recent history of RBC transfusions,
as DHTR can be a potentially life-threatening complication.
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HBS MONITORING ON TOSOH G8 IN VARIANT HBA1C MODE IN CASE
OF URGENT RCE
S. Van Aelst1, E. Nackers1, K. Desmet12, D. Kieffer13,*
1Department of Laboratory Medicine, University Hospitals Leuven, 2Depart-
ment of Cardiovascular Sciences, 3Department of Microbiology and Immunol-
ogy, KU Leuven, Leuven, Belgium
Background: Pre- and post-transfusion HbS levels are used to document the
efficacy of red blood cell exchange (RCE) in patients with sickle cell disease
(SCD). In case of urgent RCE a 24/7 STAT analysis, with the ability to identify
and quantify hemoglobin (Hb) S, is warranted.
Aims: We evaluated the use of Tosoh Automated Glycohemoglobin Analyzer
HLC-723G8 (Tosoh Europe, Amsterdam, The Netherlands) for this purpose,
using the variant HbA1c mode. Results were compared to our routine CZE
Minicap Flex Piercing (Sebia, Lisses, France).
Methods: Within- and between-run imprecision were assessed using a sickle
cell trait and a sickle cell anemia sample, aliquoted and stored at -80°C, twice
daily in duplicate for ten days. A linearity study was performed using duplicate
measurements of a dilution set of 11 samples (HbS range: 0% - 88%). Addi-
tionally, a comparison study was conducted between TOSOH G8 and Minicap
Flex Piercing using 32 whole blood left-over HbS samples (HbS range: 9% -
93%). Data analysis was performed using Microsoft Excel Analyze-it version
4.65.3 and differences were considered as statistically different if the P-value
was <0.05.
Results: Within- and between-run imprecision were <2% and an acceptable
linearity was observed. Passing-bablok regression analysis comparing TOSOH
G8 and Minicap Flex Piercing showed an acceptable correlation coefficient of
0.998 (>0.95) and a slope and intercept of 0.94 (95%CI: 0.92 to 0.98) and
0.057 (95% CI: -2.5 to 1.3), respectively. Differences in HbS results between
TOSOH G8 and Minicap Flex Piercing ranged from -8.76% to +0.36% (mean
difference: -3.54%). More specifically, for samples with a HbS concentration
<25% HbS results on TOSOH G8 differed between -0.34% to +0.36% com-
pared to Minicap Flex Piercing. For samples with a HbS concentration >25%,
differences in HbS results ranged from -8.76% to -0.43%. 
Summary/Conclusions: In our clinical laboratory, TOSOH G8 is used in vari-
ant HbA1c mode to quantify HbA1c. Previous studies demonstrated reliable
HbS identification using TOSOH G8 in variant HbA1c mode. Our study showed
a good analytical performance for HbS quantification using TOSOH G8. Good
correlation with Minicap Flex Piercing system was found, although results were
statistically not interchangeable. Our results suggest that TOSOH G8 in variant
HbA1c mode generates lower HbS results in samples with a high HbS con-
centration (>25%) compared to our routine analyzer. However, the goal of RCE
is to achieve a post-transfusion HbS level of 30% or less. Therefore, results
obtained with TOSOH G8 are clinically acceptable to monitor post-transfusion
HbS levels. Importantly, HbS on TOSOH G8 can only be requested in case of
urgent RCE. Our routine hemoglobinopathy screening will still be performed
using CZE Minicap Flex Piercing in combination with CE-HPLC Variant IITM. 
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GENDER DIFFERENCES IN THE DEVELOPMENT OF CMR
ABNORMALITIES AND CARDIAC COMPLICATIONS: A MULTICENTRIC
PROSPECTIVE STUDY IN A COHORT OF SICKLE CELL DISEASE
PATIENTS
A. Meloni1,*, L. Pistoia1, C. Gerardi2, E. Facchini3, M. Allò4, M. P. Smacchia5,
S. Campisi6, S. Maffei1, V. Vinci7, G. Restaino8, V. Positano1, A. Pepe1
1Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2Presidio
Ospedaliero “Giovanni Paolo II” - Distretto AG2 di Sciacca, Sciacca, 3Azienda
Ospedaliero-Universitaria di Bologna - Policlinico “S. Orsola-Malpighi”,
Bologna, 4Presidio Ospedaliero ASL 5, Crotone, 5Policlinico Umberto 1, Roma,
6Presidio Ospedaliero “Umberto I”, Siracusa, 7Azienda Ospedaliera “Garibaldi”
Presidio Ospedaliero Nesima, Catania, 8Fondazione di Ricerca e Cura “Gio-
vanni Paolo II”, Campobasso, Italy
Background: No data are available in literature about the relationship between
gender and the development of CMR abnormalities and/or cardiac complica-
tions in sickle cell disease (SCD).
Aims: This prospective and multicentre study aimed to assess if there was an
association between gender and risk of cardiac iron overload, heart dysfunction
and dilation, left ventricular (LV) hypertrophy, and myocardial fibrosis, assessed
by Cardiovascular Magnetic Resonance (CMR), and of cardio-vascular com-
plications in sickle cell disease (SCD) patients.
Methods: We considered 115 SCD patients (58 females, 34.79±13.26 years),
consecutively enrolled in the Myocardial Iron Overload in Thalassemia (MIOT)
Network. Myocardial iron overload was assessed by the multislice multiecho
T2* technique. Biventricular function parameters and atrial areas were quanti-
fied by cine images. Late gadolinium enhancement (LGE) images were
acquired to detect myocardial fibrosis.
Results: Table 1 shows the comparison between sexes in the development of
cardiac outcomes. Males and fameles showed a similar risk of accumulating
cardiac iron, but both patients with cardiac iron were females. Compared to
females, males showed a significant lower risk of developing LV hypertrophy,
although having a similar risk for biventricular dilation and dysfunction and for
myocardial fibrosis. No patients with less than 31 years developed LV hyper-
trophy and age at the CMR was significantly higher in patients with LV hyper-
trophy versus patients without it (41.24±75.98 years versus 34.47±13.37 years;
P=0.003). We recorded 12 (10.4%) cardiac events: 4 ischemic strokes, 5
arrhythmias (4 supraventricular and 1 ventricular), two pulmonary hyperten-
sions and one pulmonary embolism. No prospective association was detected
between gender and cardiac complications.
Table 1.
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Summary/Conclusions: In SCD male and female seem to show a comparable
risk in developing cardiac complication, although compared to females, males
showed a significant lower risk of developing LV hypertrophy. There are no
specific guidelines for SCD patients and, as a consequence, the cardiovascular
follow-up is conformed to that one of thalassemia patients (complete cardiac
evaluation performed annually for both genders). Our  data not support a dif-
ferent follow up time based on the gender.
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SICKLE CELL PAIN IN CHILDREN: TARGETS FOR ADMINISTRATION OF
ADEQUATE INITIAL ANALGESIA
A. Rushd1,*, A. Ramanathan2, B. Inusa3
1KCL, 2GSTT, 3Paediatric haematologist, Guys St Thomas Hospital, London,
United Kingdom
Background: Acute pain is a hallmark presentation in sickle cell disease (SCD)
and frequently requires attendance to the emergency department (ED).
Aims: Here we report our findings following a complete retrospective audit
cycle, documenting the timeliness of analgesia administration and post-treat-
ment pain review as per National Institute of Clinical Excellence and College
of Emergency Medicine guidelines, in children with SCD presenting to a single
inner city London ED over a 14 month period.
Methods: In 2014, we evaluated 48 patient records of children presenting to
the ED, with respect to mild, moderate and severe pain scores, time of analge-
sia administration and pain review. Completing the audit cycle, 97 records were
re-audited in 2015. A total of 145 admission records were evaluated.
Results: In 2014 the ED met CEM criteria for the timeliness of analgesia admin-
istration in 100% of severe and 95% of the moderate pain category; however
fell 33% short of NICE standards. Pain review was poorly performed, identifying
an area for improvement. Proportions meeting the aforementioned criteria fell
significantly in 2015, except review of moderate pain, which increased by 25%.
Summary/Conclusions: We conclude CEM guidelines promote timely admin-
istration of analgesia in patients with severe pain; however mild pain may be
overlooked. NICE avoids this discrimination. Thus we recommend combining
the mild and moderate pain categories to acknowledge the fluctuating nature
of sickle pain and its tendency to rapidly escalate. In addition, we reiterate the
need for regular pain reviews. This is important in ensuring analgesia is closely
titrated to pain level.
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DIAGNOSTIC CHALLENGES IN A POPULATION WITH INCREASED
IMMIGRATION: HEMOGLOBINOPATHIES IN THE NEW CENTURY
J. Zanabili Al-Sibai1,*, A. Fonseca Mourelle 1, T. Arias Fernández1,
L.R. Morais Bras1, L.F. Ávila Idrovo1, C. Castañón Fernández1,
A. Solé Magdalena1, A. Bernardo Gutiérrez1, R. Llorente de Jesus1
1Hematology, HUCA, Oviedo, Spain
Background: The diagnosis of hemoglobinopathies (Hbpts) has changed in
recent years due to immigration, with an increase in structural Hbpts. In our
region, Asturias, population census is 1,061.756 habitants; 48,097 out of them
are immigrants.
Aims: Review the incidence of structural Hbpts and thalassemias in our region
in the last 10 years.
Methods: A retrospective analysis was performed with 1202 hemoglobin (Hb)
studies at Hospital Universitario Central de Asturias between January 2006
and March 2016. The studies came from medical applications, the finding of
abnormal Hb patterns in the HbA1c test or suggestive results of thalassemia
on hematimetry test. Studies were performed by high-performance liquid chro-
matography (HPLC) with the Variant Hemoglobin Testing machine of Bio Rad,
and Hb electrophoresis with Paragon plates until May 2013. Since then, it has
been performed by capillary electrophoresis (CE) with the MINICAP System of
the Sebia laboratory.
Results: We analyzed 1202 patients, 49% were males and the median age
was 33 years (range 0-85). We found 562 patologic studies. - Thalassemia
were detected in 390; 337 were β or δβ (86.4%); 54% came from Spain. The
cases of β-thalassemia were: 5 intermedia, 3 major, 1 δβ-homozygote and the
remainder were minor (97%). All thalassemia major, 3 intermediate and 74%of
minor were Caucasian. Anemia was found in all of major thalassemia (median
Hb 6.2g / dL, range 6-6.5), in 3 of intermedia (11.4g / dL, range 6-10), and in
197 of minor (10.87g / dL, range 6.9-11.9). - Structural Hbpts were found in
170, the predominant was Hb S (n=125). Only 17 sickle cells (Hb SS and Hb
SC). Most of them black (n=14) coming from Africa (n=10) and South America
(n=5). Eighty six percent (n=108) were heterozygous (Hb SA), mainly from
Africa (n=56) and South America (n=23). Anemia were seen: 4 Hb SC (median
Hb 10.5g / dL, range: 9.4-11.2), 9 Hb SS (7.94g / dL, range 5.2-9.7) and 37
heterozygotes (10.15g / dL, range 6.7-11.9). There are two peaks of higher
incidence of structural Hbpts, in 2008 coinciding with the creation of the Tropical
Diseases Unit and since 2013 when detection increases with the introduction
of HbA1c test. The increase in thalassemias was due to the decision to extend
studies due to pathological findings in hematimetry results (Figure 1).
Figure 1.
Summary/Conclusions: In our area there is a predominance of β-thalassemia
minor. Structural Hbpts are the main diagnosis in immigrants. The incidence is
still small, although increasing in the last 3 years, so a neonatal screening pro-
gram is being implemented. Both HPLC and EC are simple, fast and efficient
methods in the diagnosis of Hbpts. In our area there is a predominance of β-
thalassemia minor. Structural Hbpts are the main diagnosis in immigrants. The
incidence is still small, although increasing in the last 3 years, so a neonatal
screening program is being implemented. Both HPLC and CE are simple, fast
and efficient methods in the diagnosis of Hbpts.
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EFFECT OF SUSTAINED-RELEASE SUPPLEMENTATION OF L-ARGININE
AMONG CHILDREN WITH SICKLE CELL DISEASE IN FEDERAL
TEACHING HOSPITAL GOMBE, NORTH EASTERN NIGERIA
O. Erhabor1,*, V.D. Knox2, S. Abubakar3, S. Yuguda3
1Haematology and Blood Transfusion Science, Usmanu Danfodiyo University
Sokoto, Nigeria, Sokoto, Nigeria, 2Department of Biochemistry and Molecular
Pharmacology, West Virginia University Medical School , Morgantown, United
States, 3Department of Haematology, Federal Teaching Hospital Gombe,
Gombe State, Nigeria , Gombe, Nigeria
Background: Sickle cell disease is a global public health problem. As of 2013
about 3.2 million people have sickle-cell disease with 176,000 deaths
Aims: In this present study, we investigated the effect of 8 weeks, low dose
supplementation of sustained-release of nitric oxide generating L-arginine sup-
plement (350mg) given two times daily on the full blood count, L-arginine, nitric
oxide, Pantothenic acid, plasma malondaldehyde, glutathione and total antiox-
idant capacity of children with sickle cell disease. 
Methods: This study included children with sickle cell disease (HbSS) aged 1-
14 years with mean age 7.4500±0.50613 years presenting to the sickle cell
clinic unit of Federal Teaching Hospital Gombe, Gombe State. Subjects received
sustained release oral L-arginine supplementation of 350mg twice daily for 8
weeks.
Results: L-arginine and nitric oxide levels were significantly higher among sick-
le cell disease children. There were no statistically significant differences
between the baseline and post L-arginine supplementation in the PCV, WBC,
RBC and LYM levels of subjects (p>0.05). There was a statistically significant
difference between the baseline and post L-arginine supplementation in the
MCV, MCH, MCHC, PLT, NEU, EOS, MON and RDW-SD levels of subjects
(p<0.05). The L-arginine and nitric oxide levels was significantly higher post
supplementation compared to baseline levels (p=0.002 and 0.000 respectively).
The pantothenic acid level was significantly higher at baseline compared to
post supplementation levels (p=0.00). The L-arginine, nitric oxide and Total
Antioxidant Capacity was significantly higher post supplementation compared
to baseline levels among sickle cell disease subjects with vaso-occlusive crisis
(p= 0.001, 0.01 and 0.05 respectively). The pantothenic acid and malondalde-
hyde levels at baseline were significantly higher than the post supplementation
levels among subjects with vaso-occlusive crisis (p=0.002 and 0.000 respec-
tively). The Total Antioxidant Capacity and Glutathione levels were significantly
higher post supplementation compared to baseline levels among the sickle cell
subjects (p= 0.05 and 0.000 respectively). The baseline plasma malondalde-
hyde level was significant higher that the post supplementation levels among
the sickle cell disease subjects. There is need for more effort and resources to
be dedicated to research especially in supplementation studies involving a larg-
er population aimed at establishing specific treatment for sickle cell disease. It
is recommended that L-arginine supplementation be included in the manage-
ment of patients with sickle cell disease particularly those with vaso-occlusive
crisis. We observed a statistically significant negative correlation between the
L-arginine levels and the red cell count among sickle cell disease subjects (r=
-0.350, p=0.043). 
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Summary/Conclusions: L-arginine supplement should be made available in
the paediatric emergency unit, clinic and pharmacy department in high risk
communities to obviate the negative effects during vaso-occlusive crisis and
potentially reduce the length of stay in the hospital. L-arginine, nitric oxide,
total antioxidant capacity, malondaldehyde and glutathione levels should be
routinely monitored in sickle cell disease patients particularly those presenting
with vaso-occlusive crisis.
Stem cell transplantation - Clinical
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THE EFFECT OF BODY MASS INDEX ON OUTCOME AFTER UMBILICAL
CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS WITH
ACUTE LEUKEMIA ON BEHALF OF EUROCORD, PDWP
A. Paviglianiti1,2,*, A. Ruggeri1,2,3, J.H. Dalle4, G. Michel5, F. Locatelli6,
C. Kenzey1,2, F. Volt1,2, C. Jubert7, A.P. Iori8, W. Barberi8, I. Yakoub-Agha9,
H. Bittencourt10, M. A. Diaz11, Y. Bertrand12, H. Rafii12, K. Tozatto Maio12,
H. Hayashi12, V. Rocha12,13, P. Bader14, E. Gluckman12
1EUROCORD, Hopital Saint Louis, Paris, France, 2MONACORD, Centre Sci-
entifique de Monaco, Monaco, Monaco, 3Hematology and Cellular therapy,
Hospital Saint Antoine, 4Pediatric Hematology Department, Hospital Robert
Debré, Paris, 5Pediatric Hematology Department, Hospital de La Timone, Mar-
seille, France, 6Department of Pediatric Hematology-Oncology, IRCSS
Ospedale Bambino Gesù, Rome, Italy, 7Pediatric Onco-Hematology Depart-
ment, Hôpital des Enfants, Bordeaux, France, 8Department of Cellular Biotech-
nologies and Hematology, Sapienza University, Rome, Italy, 9UAM allo-CSH
CHRU, Hôpital HURIEZ , Lille, France, 10Hematology-Oncology Division,
C.H.U. Saint-Justine, University of Montreal, Montreal, Canada, 11Hematology
Department, Hospital Infantil Universitario Nino Jesus, Madrid, Spain, 12Insti-
tute of Hematology and Oncology Paediatrics, Hospices Civils de Lyon, Lyon,
France, 13Hospital Sírio Libanês, San Paulo, Brazil, 14Division of Stem Cell
Transplantation and Immunology, Hospital for Children and Adolescents of
Frankfurt, Frankfurt, Germany
Background: Body mass index (BMI) may influence outcome after allogeneic
transplantation. Previous studies have demonstrated that being obese or under-
weight may have a detrimental effect on survival rates after chemotherapy
induction in children with acute leukemia. However, the impact of BMI of trans-
planted patients on survival is still not clear, with conflicting results being report-
ed on this issue.
Aims: To analyze the effect of BMI on UCBT outcomes in children with acute
leukemia 
Methods: We retrospectively analyzed 517 patients aged from 2 to 20 years
with acute leukemia who underwent umbilical cord blood transplantation
(UCBT) from 1990 to 2015. Patients were classified according to BMI as nor-
mal (5th-85th percentile), underweight (<5th percentile), overweight (85th-95th
percentile) and obese (>95th percentile) by using growth charts for age and
gender.
Results: Sixty-one percent (n=314) of patients were in the normal category,
12% (n=63) were underweight, 15% (n=80) overweight and 12% (n=60) obese.
All patients received single-unit UCBT after a myeloablative conditioning regi-
men. Diagnosis was acute lymphoid leukemia in 70% (n=363) and acute
myeloid leukemia in 30% (n=154). Median age at UCBT was 7.4 years (range
2-19.6). Cytomegalovirus (CMV) serology was positive in 45% patients; 60%
of patients were male. Most patients (92%) were in complete remission at
UCBT. Median follow-up was 52 months (range 2-201). Total body irradiation
(>6 Gy) was used in 58% of cases; antithymocyte globulin (ATG) in 68% of
cases. Median infused total nucleated cell (TNC) dose was 4.2x107/Kg (0.3-
17.8); 56% of patients received a graft with 0-1 HLA mismatch donor. Four-
year overall survival (OS), leukemia-free survival (LFS) and graft-versus-host
disease-free, relapse-free survival (GRFS) were 45±2%, 43±2% and 35±2%,
respectively. Cumulative incidence function (CIF) of neutrophil engraftment
was 88.6% (85.9-91.4%). CIF for acute GVHD was 34% (30.1-38.4%) at 100
days. At 4 years chronic GVHD was 19.1% (15.7-23.3%), relapse incidence
was 34.5% (30.1-38.9%) and non-relapse mortality (NRM) was 22.8% (19.2-
26.7%). In univariate analysis, no statistically significant difference in OS, LFS,
GRFS, neutrophil engraftment, NRM and chronic GVHD between the 4 groups
identified according to BMI was identified. Conversely, acute GVHD was 44.3%
(33.3-58.8%) for underweight, 36% (31-41.8%) for normal, 26.2% (18.1-38%)
for overweight and 23.3% (14.7-37.1%) for obese (p=0.03). Among patients
underweight who experienced acute GVHD (n=27), 37.5% had grade III-IV
acute GVHD with gut involvement. In multivariate analysis, infused TNC
dose>4.2x107/Kg was associated with higher neutrophil engraftment (HR=1.46,
CI 95% 1.18-1.82, p=0.001). Positive CMV serology (HR=1.5, CI 95% 1.04-
2.26, p=0.03) and female gender (HR=1.5, CI 95% 1.03-2.23, p=0.03) were
associated with higher NRM. ATG use (HR=1.6, CI 95% 1.05-2.31, p=0.03)
was associated with higher relapse incidence. Moreover, ATG use and a pos-
itive CMV serology were associated with worse OS (HR=1.6, CI 95% 1.15-
2.17, p=0.04 and HR=1.3, CI 95% 1.01-1.69, p<0.001, respectively) and LFS
(HR=1.6, CI 95% 1.17-2.16, p<0.001 and HR=1.34, CI 95% 1.04-1.72, p=0.02,
respectively). Infused TNC >4.2x107/Kg (HR=1.5, CI 95% 1.07-2.14, p=0.02),
lack of ATG in the conditioning (HR=2.72, CI 95% 1.6-3.1, p<0.001) and BMI
<5th percentile (HR=1.8, CI 95% 1.19-2.78, p<0.001) were associated with
higher incidence of acute grade II-IV GVHD.
Summary/Conclusions: In conclusion, we did not find association of obesity
with transplant outcomes in this study population. However a BMI <5th per-
centile at UCBT was found to be associated with higher risk of acute GVHD,
highlighting the importance of nutritional status before UCBT.
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PROSPECTIVE PHASE STUDY OF REDUCED TOXICITY CONDITIONING
CONSISTED OF HIGH DOSE-CYTARABINE, FLUDARABINE,
CYCLOPHOSPHAMIDE +/- TOTAL BODY IRRADIATION FOLLOWED BY
ALLOGENEIC STEM CELL TRANSPLANTATION
S. Kasahara1,*, H. Nakamura2, Y. Kaneda1, Y. Ikoma2, E. Takada3, Y. Shibata1,
T. Matsumoto2, N. Nakamura2, S. Ninomiya2, J. Kitagawa2, H. Goto1, T. Hara2,
M. Sawada3, T. Takahashi 1, K. Saito4, M. Shimizu2, H. Tsurumi 2
1Hematology, Gifu Municipal Hospital, 2Hematology, Gifu University Graduate
School of Medicine, 3Hematology, Gifu Red Cross Hospital, 4Internal Medicine,
Gihoku Kosei Hospital, Gifu, Japan
Background: Allogeneic hematopoietic stem cell transplantation (allo-SCT)
using reduced intensity conditioning (RIC) has been widely applied to elderly
or frail patients who are not eligible for conventional conditioning regimen. How-
ever, benefit provided by reduced toxicity has been often offset by increased
incidence of relapse. So far, the optimal conditioning for those patients has not
been established. 
Aims: Here, to investigate whether addition of high dose cytarabine (AraC) to
RIC regimen consisting of fludarabine (Flu) and cyclophosphamide (Cy) +/-
total body irradiation (TBI) can be available for elderly or frail recipients, phase
II study has been designed.
Methods: This study was conducted from April 2011 to December 2015. The
protocol was approved by each institutional review board (Trial identifier:
UMIN000007281). Patients aged from 55 to 70, or patients who have some
organ damage or a history of SCT aged from 20 to 54 with hematologic malig-
nancies were enrolled after obtaining written informed consent. Bone marrow
(BM), peripheral blood (PB), or cord blood (CB) was used as stem cell sources.
Pretransplant conditioning regimen consisted of 30 mg/m2 of Flu for 5 days
(total 150 mg/m2), 4 g/m2 of AraC for 2-4 days (divided by 2 daily, total 8-16
g/m2) and 50mg/kg of Cy for a day. Four gray of TBI was used for all CB trans-
plant recipients, whereas 2 gray of TBI was used in other stem cell sources
except a matched related donor according to each institutional policy. Cal-
cineurine inhibitors (cyclosporine or tacrolimus) and short term methotrexate
were used as GVHD prophylaxis. Donor cell engraftment and 60 day-survival
were assessed as a primary end point to evaluate feasibility of this protocol.
Results: Thirty nine patients including 7 recipients with a history of SCT were
enrolled. Median age was 61 (28-69), 21 were male, and 18 were female. Nine-
teen were acute myeloid leukemia, 11 myelodysplastic syndrome, 6 malignant
lymphoma and 3 acute lymphoblastic leukemia. Donors were 4 matched related
PB, 8 matched unrelated BM, 5 1-Ag/allele-mismatched unrelated BM, and 22
≤2-Ag-mismatched CB. Thirty seven (94.9%) patients have passed 60-day-
point post-transplant. In 38 (97.4%) recipients, engraftment was obtained, a
patient died before engraftment due to sepsis caused by enterococcus faecium
(male CB recipient, 55y, day15). Median neutrophil recovery to over 500/μl was
obtained on day 19 (16-38). Fourteen blood stream infections (13 bacteremias
and 1 candidemia) judged as grade 3 toxicity and 2 cases (1 sepsis and 1
endotoxemia ) of grade 4 toxicity were observed within 60 days post-transplant.
There were 2 deaths of post-engraftment due to cerebral bleeding (1 female
CB recipient, 64y, day 46) and GVHD (1 male CB recipient, 60y, day 77) within
100 days. Although no relapse was observed up to day 60, 7 relapses were
observed up to 1 year. Overall survival and disease-free survival were estimat-
ed to be 82.1% and 73.8% at 1 year post-transplant, respectively.
Summary/Conclusions: RIC using Flu/high dose AraC /Cy +/- TBI was well
tolerated with acceptable low toxicities and was sufficient to allow donor cell-
engraftment post allo-SCT for elderly or frail patients with hematologic malig-
nancies. Longer follow up and another prospective study enrolling more patients
are required to evaluate the eventual survival benefit by reducing relapse. 
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LATE COMPLICATIONS OF CONDITIONING REGIMENS (CYCLOPHOS-
PHAMIDE - TOTAL BODY IRRADIATION vs BEAM) FOR AUTOLOGOUS
STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA.
S. Novelli1,*, A.C. Caballero1, A. Monter1, G. Gomez Segura2,
I. Garcia Cadenas1, A. Esquirol1, R. Martino1, J. Sierra1, J. Briones1
1Hematology, 2Radiotherapy, Hospital de la Santa Creu i Sant Pau, Barcelona,
Spain
Background: Autologous stem cell transplantation (ASCT) is a frequently used
procedure for the treatment of patients with relapsed non-Hodgkin lymphoma
(NHL). While chemotherapy-based regimens are now commonly administered,
total body irradiation (TBI) was largely used  in the past. The current  condition-
ing regimen in our center is BEAM (a combination of carmustine (BCNU), etopo-
side, cytarabine and melphalan) allthough we also have a large experience
with cyclophosphamide (CFM)-total body irradiation (TBI) since this was the
usual conditioning until year 2000.
Aims: To analyze the cumulative incidence of secondary neoplastic complica-
tions and non neoplastic complications (grade 3-4 infections, cardiovascular
and pulmonary toxicity) after the two conditioning regimens (CFM-TBI vs BEAM)
for ASCT.
Methods: We performed a retrospective analysis of patients  with  NHL that
received an ASCT between October 1992 and December 2012. The late com-
plications were defined as those to other previous comorbidity or to aging. Sta-
tistical  analysis  was performed  using  the  IBM  SPSS  Statistics  version
21.0. Cumulative incidences were estimated using  EZR version 1.27 (Saitama
Medical Center,   Jichi   Medical   University,   Omiya,   Japan), a graphical
user interface for R (version 3.1.1).
Results: A total of 105 atografted patients were analyzed. Patient’s character-
istics are in Table 1. The median follow up since ASCT was 73 months (0 – 274
months). Thirty-one percent (n=33) of patients were conditioned with CFM-
TBI. The overall 5-years  survival (OS) was 68.3% (58-77% - CI 95%) and the
5-year disease free survival (DFS) was 52% (42 61% - CI 95%). There were
no differences regarding OS and DFS between the two conditioning regimens.
The 5-years cumulative incidence (CI) of relapse was 0.48 (0.37-0.57, CI 95%).
We detected 10 secondary neoplasm (myelodysplasia n=1, skin carcinoma
n=2, lung carcinoma n=3, oropharingeal carcinoma n= 1, intestinal adenocar-
cinoma n=1, renal neoplasia n=1, bladder neoplasia n=1). The median time for
the neoplastic event was 10.5 years (0-18.5 years).   The CI of secondary neo-
plasias (2nd neoplasia) at 10 years  was  10% (1-20%, CI 95%) and at last
point of follow up (18.5 years) was 40% (13%>63%, CI 95%). There were no
differences in the CI of 2nd neoplasias between BEAM and CFM-TBI. Non-
neoplastic complications were present in 10% of patients (n=11). Three cases
were infections grade 3-4 related to ASCT. Six cases had cardiac complications
(5 acute coronary syndrome, 1 myocardiopathy) and 2 had pulmonary toxicity.
The CI of non-2nd neoplastic complications at 10 year  was 10% (1 – 25%,  CI
95%).No differences were detected between the two conditioning regimens
regarding non-neosplastic complications. (see Figure 1).
Table. 1. Patient’s characteristics.
Figure 1.
Summary/Conclusions: Autologous stem cell transplantation offers long dis-
ease free survival for half of the patients with a high risk non-Hodgkin lym-
phoma. In our series, patients conditioned with BEAM or CFM-TBI had a com-
parable incidence of neoplastic and non-neoplastic events
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THE MANAGEMENT OF RELAPSED HODGKIN´S LYMPHOMA AFTER
HAPLOIDENTICAL STEM CELL TRANSPLANTATION: DONNOR
LYMPHOCYTE INFUSION AND BRENTUXIMAB.
I. Sánchez Bazán1,*, A.L. Contento Gonzalo1, M.J. Pascual Cascón1,
A.R. Martín Cerezo1, M.Á. Cuesta Casas1, A.I. Heiniger Mazo1
1Hematology, Hospital Regional de Málaga, Málaga, Spain
Background: Hodgkin’s lymphoma, is an heterogeneous malignancy wich is
posible to cure. For those patients who relapse, chemotherapy followed by an
autologous transplantation (autoTPH) may conduce to a complete remission.
Allogeneic transplantation (alo-SCT) is used for patients in relapse after auto-
SCT or those with  refractory advanced disease. Since 2012, with the experi-
ence of the Baltimore group, our Center has chosen the haploidentical family
donor as a source for aloSCT in Hodgkin’s disease. Despite the promising
results,  the rate of relapse is between 25 and 35%, and there is not standard-
ized treatment for this situation. 
Aims: To analyze the outcome of post-transplant relapse treatment of hap-
loident donor haematopoietic progenitors (haploTPH).
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Methods: We studied 18 patients with the diagnose of Hodgkins lymphoma in
our center between August 2004 and July of 2013. All of them were submitted
to haploSCT with a median follow-up of 495 days (455-1054).
Results: The median age was 32 years (21-60). 44% (8 patients) relapsed.
60% of then (5 patients) were nodular sclerosis histological subtype and 40%
(3) lifocitic predominance. 2 patients (25%) were diagnosed in stage IV and
75% (6) stage II. The median of number of treatment lines received before
transplantation was 5.5 (4-7); Compared to 7 in the non-relapsed group (4-
11). 5 patients (60%) of the patients who relapsed had reached haploTPH in
complete remission and 40% in partial remission, we did not observe differ-
ences related to the pre-SCT status. Peripheral blood was used as progen-
itors source in 75% (6) of the patients who relapsed and in 70% (7) in the
non-relapsed group. 38% of the whole group of patients, had a donor/recip-
ient KIR alloreactivity without differences between the two groups of the study.
88% (7) of the relapses occurred before 6 months of the SCT. The mean
time to relapse was 316 days (range 181-446). Between the 8 relapsed
patients, one was treated by another center with Vimblastine / Dexametha-
sone and died by infection, another patient died by abdominal sepsis before
starting any treatment. Brentuximab was administered in 63% (5) of the
patients. One of them received a single Brentuximab cycle with no tolerance,
and changed to RT, GPD+Donnor lymphocyte infusions (DLI) and had
reached complete response after 5 DLI. The rest (4) received between 3 and
7 doses with adequate tolerance. According to the the re-evaluation (PET-
TC) after 3rd Brentuximab, 4 were in partial remission and one reached com-
plete response. We associated Donor lymphocyte infusion in 6 patients. The
mean of DLI received was 10; the median was 8, with a range between 22-
3. Four patients reached complete remission, two of them maintain a partial
response. All of them presented good tolerance to DLI. We observed Graft
versus host disease in four patients, 3 of them presented moderate cutaneous
affection, and one of them suffered hepatic graft versus host disease stage
III, with adequate evolution after treatment. 
Summary/Conclusions: Is posible to treat patients who relapsed after hap-
loidentical stem cell transplantation with Brentuximab+DLI, with a very good
tolerance. We observed cutaneous graft versus host disease in most of the
patients who reached completed response after DLI. Despite this findings, we
need multicentric studies to perform standarized treatments and protocols. 
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CONDITIONING REGIMENS BEFORE AUTOLOGOUS STEM CELL
TRANSPLANT FOR PATIENTS WITH MALIGNANT LYMPHOMA – LEED vs
MCEC –
H. Shimizu1,*, C. Naitoh2, Y. Osaki1, Y. Miyazawa3, K. Toyama2, H. Koiso1,
A. Yokohama1, M. Morio3, H. Ogura4, N. Tsukamoto1, H. Handa1
1Gunma University, Maebashi, Gunma, 2Fujioka General Hospital, Fujioka,
Gunma, 3Shibukawa Medical Center, Shibukawa, Gunma, 4Maebashi Sekijuji
Hospital, Maebashi, Gunma, Japan
Background: High-dose chemotherapy before ASCT has been established
as an effective treatment option for high-risk patients with chemo-sensitive ML.
Although the therapeutic efficacy of this strategy highly depends on the condi-
tioning regimens before ASCT, the appropriate regimen has been controversial.
Thus, we performed a multi-center retrospective study of ASCT recipients with
ML to compare the safety and efficacy of the conditioning regimens LEED and
MCEC, which are widely used in Japan.
Aims: The primary objective was to determine the preferable conditioning reg-
imen before ASCT: LEED or MCEC.
Methods: This study analyzed 127 adult patients who underwent ASCT fol-
lowing LEED or MCEC as the conditioning regimen against chemo-sensitive
ML at four institutions in Japan between 1997 and 2015. Any type of patho-
logical diagnosis was considered. The LEED regimen consisted of 140
mg/m2 L-PAM (day −1), 500 mg/m2 etoposide (days −4 to −2), 60 mg/kg
cyclophosphamide (days −4 to −3), and 40 mg/body dexamethasone (days
−4 to −1). The MCEC regimen consisted of 200 mg/m2 MCNU (days −8 and
-3), 300 mg/m2 carboplatin (days −7 to −4), 500 mg/m2 etoposide (days −6
to −4), and 50 mg/kg cyclophosphamide (days −3 to −2). Fisher’s exact test
was used to compare binary variables. OS rates were estimated by the
Kaplan-Meier method and compared using the log-rank test. Cumulative
incidences (CIs) of relapse and non-relapse mortality (NRM) were compared
using the stratified Gray test. The Cox proportional hazards regression mod-
el was used for multivariate analysis of OS. Values of p <0.05 were consid-
ered significant.
Results: Of the 127 patients, 76 were male and 51 were female, and the medi-
an age was 56 years (range: 18 to 68 years). Underlying diseases were DLBCL
in 74 patients, mantle cell lymphoma in 16, other B-cell lymphoma in 14,
Hodgkin lymphoma in 9, and T-NK-cell lymphoma in 14. The disease status at
the time of transplant was first complete remission (CR) in 68, advanced CR
in 27, and partial remission in 32. As the conditioning regimens before ASCT,
81 patients (64%) received the LEED regimen, and 46 (36%) received the
MCEC regimen. No significant differences in patient characteristics, disease
features, or transplant procedures were present between the two groups except
for the following three factors: (1) ASCT in the later period (2007–2015) in the
LEED group compared with the MCEC group (72% vs 13%; p <0.01); (2) more
frequent administration of rituximab before ASCT in the LEED group (84% vs
59%; p <0.01); and (3) less frequent radiation therapy before ASCT in the
LEED group (17% vs 37%; p=0.02). The 5-year OS rates were not significantly
different between the LEED and MCEC groups (77% vs 68%; p=0.35). Like-
wise, both the 5-year CIs of relapse and NRM were similar in the two groups
(relapse: 39% vs 33%; p=0.61, NRM: 1% vs 5%; p=0.71). In multivariate analy-
sis that included the transplant periods, rituximab administration, and radiation
therapy as independent variables, two or more prior regimens was extracted
as an independent unfavorable prognostic factor for OS, but not conditioning
regimens. Regimen-related toxicities within 100 days after ASCT were
assessed. The incidences of grade 3-4 nausea (36% vs 78%; p <0.01), vomiting
(4% vs 28%; p <0.01), diarrhea (36% vs 56%; p=0.02), and liver dysfunction
(4% vs 36%; p <0.01) were significantly decreased in the LEED group. The 5-
year CIs of secondary MDS/AML were similar between the two groups (4% vs
3%; p=0.62).
Summary/Conclusions: Our findings demonstrated that both the LEED and
MCEC regimens showed sufficient anti-lymphoma effect as conditioning regi-
mens before ASCT, with a 5-year OS rate of more than 70% in patients with
chemo-sensitive ML. However, the LEED regimen is considered more prefer-
able in comparison with the MCEC regimen based on the low frequency of
severe regimen-related toxicities. A large-scale prospective study is warranted
to confirm these findings.
PB2162
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
SECONDARY HAEMATOLOGICAL NEOPLASIA: A SINGLE CENTER
EXPERIENCE
E. Metafuni1, P. Chiusolo1, L. Laurenti1, F. Sorà1, S. Giammarco1, G. Leone1,
A. P. Bacigalupo1, S. Sica1,*
1Hematology Department, Fondazione Policlinico agostino Gemelli, Rome,
Italy
Background: Therapy related haematological neoplasms (t-HN) occur due to
direct mutational events of chemotherapeutic agents and radiotherapy. Disease
latency, mutational events and prognosis vary with drugs categories.
Aims: The aim of this retrospective study was to assess the outcome of t-HN
after hematopoietic stem cell transplantation (HSCT).
Methods: We describe a cohort of 31 patients, 19 females (61.3%) and 12
males (38.7%), with median age of 53 years (range, 20 to 64), who received
an allogeneic HSCT in our Unit, between September 1999 and July 2016.
Patients had a history of solid tumor in 15 cases (48.4%), haematological
malignancies in 15 cases (48.4%) and both of them in one case (3.2%). All
but one received a median of 2 (range, 1 to 6) lines of therapy. After a median
of 36 months (range 12-190) from the first neoplasia, patients developed t-
AML (n=19) (61.3%), t-Ph+ ALL (n=1) (3.2%), or t-MDS (n=11) (35.5%).
Molecular abnormalities were detected in 7 (46.7%) out of 15 evaluable
patients: BCR/ABL (1), ITD FLT3 (2), inv16 (1), NPM1 (2), NPM1+/ITD FLT3
(1). Karyotype aberrations were found in 18 (64.3%) out of 28 evaluable
patients: 16.7% was favourable risk (n=3), 27.8% was intermediate risk (n=5)
and 55.5% was adverse risk (n=10). The disease status at transplant was as
follows: complete remission (n=13) (42%), refractory disease (N=10) (32%),
stable disease (n=3) (10%). Patients received conventional chemotherapy
in 14 cases (45.2%), azacytidine in 11 cases (35.5%), both of them in one
case (3.2%), whereas 5 patients (16.1%) were untreated. The conditioning
was myeloablative (MAC) in 20 patients (64.5%) or reduced intensity (RIC)
in 11 patients (35.5%); the donor was a family member (REL) in 17 patients
(54.8%) or unrelated (MUD) in 14 patients (45.2%). The hematopoietic cell
transplantation comorbidity index (HCT-CI) was as follows: 14 patients
(45.2%) had a score of 3 and 17 patients (54.8%) had a score of 4 or more.
Overall survival was calculated with Kaplan-Meier method. Transplant-related
mortality (TRM) and relapse-related mortality (RRD) rates were estimated
by cumulative incidence (CI), both considering the opposite event as com-
peting. Fine and Gray’s method for CI of TRM and RRD was used to evaluate
the risk factors on univariate analysis. 
Results: Twenty-three patients were in remission on day +30, by bone marrow
cytology, 3 patients were classified as resistant disease and five patients were
not evaluable because of early death. Five patients (21.7%) relapsed after a
median 6 months (range, 3 to 15). At the time of this analysis (December 2016)
14 patients were alive with a median OS of 53 months (range 8-190), while 17
patients died after a median of 4 months (range 1-27): RRD was 16% (n=5)
and TRM was 39% (n=12). Non relapse causes of death were as follows: GvHD
(n=3), infectious complications (n=8) and EBV-related PTLD (n=1). One patient
experienced a third tumor (breast cancer) thirteen years from HSCT. TRM was
higher for patients transplanted from MUD (66%) as compared to REL donor
(16%) (p=0.01).  The overall survival was 45.2% (Figure 1) and 58% maintained
a complete remission.
Summary/Conclusions: This report confirms that allogeneic HSCT is a
curative approach in approximately 50% of patients with therapy related
haematological neoplasms, especially for those patients who benefit from a
familial donor. 
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IMPROVEMENT IN BIVENTRICULAR CARDIAC MECHANICS NOTED IN
PATIENTS UNDERGOING MYELOABLATIVE
AUTOLOGOUS-HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
AL AMYLOIDOSIS
S. Heitner1,*, C. Purtell2, E. Scott3
1Knight Cardiovascular Institute, 2Department of Medicine, 3Knight Cancer
Institute, Oregon Health and Science University, Portland, United States
Background: Primary amyloidosis (AL) is characterized by extracellular dep-
osition of insoluble protein fibrils often with multisystem organ involvement. The
Mayo staging model for determining prognosis in patients with cardiac amyloi-
dosis takes into account troponin, NT-proBNP, and serum free-light chain dif-
ference in order to stage patients prior to undergoing autologous hematopoietic
stem cell transplant (Auto-HCT). Since amyloidosis often involves the kidneys,
serum biomarkers that require renal clearance are less reliable in the setting
of significant renal dysfunction. 2D-echo and strain imaging offer non-invasive
modalities for identifying early cardiac changes independent of renal function.
These changes may also precede symptom improvement as assessed by
NYHA classification.
Aims: Our hypothesis is that strain imaging is a feasible biomarker for cardiac
respone after Auto-HCT in AL amyloidosis.
Methods: Seven patients with biopsy-proven AL amyloidosis who were treated
with a Melphalan based myeloablative regimen and Auto-HCT were evaluated
retrospectively. Each patient underwent 2D-echo up to 36-days prior to treat-
ment followed by repeat 2D-echo within 14-months. Strain imaging was per-
formed using EchoInsight®. Chart review was conducted to determine associ-
ated NYHA functional classification and Mayo staging. Statistical analysis was
performed using SPSS.
Results: Of the 7 patients studied, 3 were Mayo stage I, 2 stage II, 1 stage III,  and
1 stage IV. The median follow-up from transplant was 47.4 months. There was
one death at 20.4 months. The mean NYHA classification at baseline was 2.3
and after transplant was 1.9. Longitudinal, radial and circumferential left ventricular
strain (LV) were evaluated, but only the global longitudinal strain (GLS) showed
an improvement (baseline -14.69%; follow-up -16.84%; mean absolute improve-
ment 2.15%; p <0.05) across all four Mayo Stages. There was no difference in
GLS within individual stages. In patients with stable NYHA classification after
transplant, there was also a significant improvement in Right Ventricular Free-
Wall Strain (RVFWS) with a mean absolute improvement of 6.2% (p <0.05). There
was no significant change in left ventricular ejection fraction (LVEF) (Figure 1).
Figure 1.
Summary/Conclusions: We demonstrate that there is a clinically meaningful
improvement in cardiac mechanics one year after Auto-HCT, despite no alter-
ation in LVEF. This metric may prove useful in assessing organ response, espe-
cially when serum biomarkers are less reliable. Changes in left ventricular GLS
occur independent of pre-transplant Mayo stage, although prospective studies
are needed for confirmation. We further believe that improvements in RVFWS
may predict clinical improvement.
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AN ABSOLUTE NUMBER OF CD34+ CELLS IN BLOOD AS A PREDICTOR
OF A SUCCESSFUL HARVEST OF HEMATOPOIETIC STEM CELLS
IN DIFFERENT MOBILIZATION REGIMENS
I. Galtseva1,*, Y. Davydova1, T. Gaponova1, N. Kapranov1, L. Kuzmina1,
V. Troitskaya1, E. Zvonkov1, E. Parovichnikova1, L. Mendeleeva1,
V. Savchenko1
1Federal State-Funded Institution National Research Center for Hematology
of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Fed-
eration
Background: Autologous stem cells transplantation (ASCT) has become nec-
essary part in therapy of hematological diseases. Transfusion of at least 2×106
CD34+ HSCs per kg of patient’s weight allows achieving an adequate
hematopoiesis after high-dose chemotherapy. The most optimal is to collect
≥2×106 CD34+ cells/kg with single harvest apheresis. Different mobilization reg-
imens lead to variations in white blood cell count (WBC) and the number of cir-
culating HSCs. Deciding on the time of the first leukapheresis is very important.
Aims: The aim was to identify significant parameter predicting efficiency of
CD34+ cells collection.
Methods: The study included 142 patients (pts) who undergo ASCT (80 m, 62
f, median age 53 y.o., 81 were diagnosed with multiple myeloma, 10 - Hodgkin’s
lymphoma, 51 – non-Hodgkin’s lymphomas). WBC and absolute CD34+ num-
ber in the blood before the first apheresis and the number of CD34+/kg in the
apheresis product were determined for each patient. There were three different
mobilization regimens: 12 pts received 10 μg/kg/day G-CSF in the stable
hematopoiesis for 5-6 days; 86 pts - 4 g/m2 cyclophosphamide and 5-10
μg/kg/day G-CSF (Cph+G-CSF); 44 pts - DHAP: 40 mg dexamethasone, 100
mg/m2cisplatin, 2g/m2cytarabine and 10 μg/kg/day G-CSF (DHAP+G-CSF).
CD34+ HSCs were evaluated with ISHAGE-protocol by BD FACSCanto II flow
cytometer. Results are presented as mean±SEM. ROC-analysis was performed
for WBC and the absolute number of CD34+ HSCs in the blood as the predictor
markers for HSCs successful harvesting (≥2×106 CD34+/kg for fist apheresis).
Results: WBC mean was higher in pts with G-CSF mobilization scheme com-
pared to Cph+G-CSF and DHAP+G-CSF (28.5±3.5 vs 10.4±0.9 and
9.0±1.8×109/l, respectively, p<0.0001), but the absolute number of CD34+
HSCs  in the blood (26.3±9.3 vs 55.5±5.6 and 93.1±22.3/μl, p=0.03) and the
number of CD34+/kg in the leukapheresis product (1.9±0.7 vs 5.2±0.6 and
6.9±1.3×106/kg, p=0.01) were lower. Differences between Cph+G-CSF and
DHAP+G-CSF in all parameters were not found. There was not any relationship
between WBC and the number of CD34+/kg: the area under ROC-curve (AUC)
didn’t differ from 0.5 for all mobilization regimens. Then absolute number of
CD34+  in blood was investigated as predictor for harvest success, AUCs were
0.964, 0.938 and 0.979 (p<0.0001) for G-CSF, Cph+G-CSF and DHAP+G-
CSF, respectively. In the ROC-analysis showed the optimal CD34+ number in
blood than most likely to collect ≥2×106 CD34+/kg for first leukapheresis. It
was 29 CD34+cells/μl in G-CSF mobilization, 24 CD34+cells/μl – in Cph+G-
CSF and 27 CD34+cells/μl - in DHAP+G-CSF. To calculate universal level of
absolute CD34+ number all data from 142 pts was used. In this case AUC was
0.952 and a threshold of successful harvesting was 20 CD34+cells/μl in blood
before apheresis with sensitivity of 96% and specificity of 81%.
Summary/Conclusions: Various mobilization regimens differ in count of leu-
cocytes and CD34+ HSCs in peripheral blood: WBC was significant higher in
G-CSF than in Cph+G-CSF and DHAP+G-CSF, but the absolute number of
CD34+ cells was higher in chemotherapy-based mobilization and G-CSF than
in G-CSF alone. The absolute number of leucocytes in blood before apheresis
was not a predictor factor of harvest success in all variants of mobilization reg-
imens. If there is at least 20 CD34+cells/μl in blood before apheresis it is pos-
sible to collect ≥2×106 CD34+/kg for single leukapheresis with high sensitivity
and specificity independent of mobilization regimen.
PB2165
QUANTIFICATION OF CD34+ CELL AND ITS VIABILITY OF FRESH OR
CRYOPRESERVED NUCLEATED CELLS BY IMAGE-BASED CELL
COUNTER IS COMPARABLE TO STANDARD FLOW CYTOMETER
Y.-H. Lee1,2,*, W.-J. Rah1, H. Koh1,2, J.Y. Suh2, H.J. Eom2, E.-K. Shin1,
J. Uhm2,3, J.H. Oh4, J.-Y. Lee4, S.R. Bong4, J.Y. Kim4, S. Han4, C. Chung4,
H.J. Park4, J.K. Yoon4
1Department of Pediatrics, 2Blood & Marrow Transplantation Center, 3Depart-
ment of Internal Medicine, Hanyang University Medical Center, 4NanoEntek,
Seoul, Korea, Republic Of
Background: As a standard method for quantification of CD34+ stem cells,
flow cytometry has been widely used. However, it has some limitations such as
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expensive instrumentation, high reagent costs, and poor reproducibility
between technicians and laboratories. 
Aims: We developed and assessed an instrument performance of a newly-
developed image-based microscopic cell counter (ADAM IITM) for enumeration
of CD34+ cell and its viability.
Methods: We used samples of fresh and cryopreserved nucleated cells from
G-CSF mobilized peripheral blood stem cells (PBSCs) as well as cord blood
(CB). We assessed the reproducibility and linearity of the new device and com-
pared numbers and viabilities of CD45+ cells and CD34+ cells determined with
the ADAM IITM and flow cytometer.
Results: Each analysis used 10 aliquots from one sample to assess the repro-
ducibility of ADAM IITM, with expected values of 14.77~172.06 CD34+ cells/,
0.08~0.56 CD34(%)/CD45. The number of CD34+ cells determined by ADAM
IITM was sufficiently accurate over the expected range, and the intra-assay
coefficient of variation (CV) was ≤10.8%. The linearity of CD34+ cell counts
was confirmed over a range of dilutions (0.58~280 cells/ of sample). Linearity
was satisfactory (R2=0.99). The numbers and viabilities of CD45+ cell and
CD34+ cell obtained with the ADAM IITM were highly correlated with those
obtained with the flow cytometer (R²>0.9841, p<0.0001). In all samples from
fresh/cryopreserved PBSC and fresh/cryopreserved CB, there were no signif-
icant differences of total numbers and viabilities of CD45+ cell and CD34+ cell
count analyzed from ADAM IITM as well as flow cytometer.
Summary/Conclusions: The newly developed image-based microscopic cell
counter (ADAM IITM) appears to be suitable for quantification of CD34+ cell
and its viability of fresh or cryopreserved PBSCs or CBs.
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EXTRACORPOREAL PHOTOPHERESIS IN STEROID-DEPENDENT OR
REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
I. Sakellari1, I. Batsis1, E. Gavriilaki1,*, A. Panteliadou1, A. Lazaridou1,
K. Leontopoulos1, D. Mallouri1, A. Bouinta1, V. Constantinou1, E. Yannaki1,
C. Smias1, A. Anagnostopoulos1
1Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki,
Greece
Background: Extracorporeal photopheresis (ECP) has been incorporated in
the management of graft-versus-host disease (GVHD) post allogeneic
haematopoietic cell transplantation (alloHCT) in many centres. The introduction
of ECP as an early second-line treatment in steroid-dependent or refractory
patients with acute GVHD (aGVHD) remains under study. The rationale of its
early use is based on the low incidence of complete responses to corticos-
teroids and the profound immunosuppression caused by traditional secondary
treatments.
Aims: Based on our long-lasting experience in chronic GVHD, we aimed to
prospectively assess the role of ECP in this high-risk population.
Methods: We enrolled consecutive patients with steroid-dependent or refrac-
tory grade (gr) II-IV aGVHD post alloHCT from January 2013 to August 2016.
All patients with unrelated or haploidentical donors received thymoglobulin
(ATG) 5mg/kg as prophylaxis. Post-transplant GVHD prophylaxis included
cyclosporine – methotrexate in myeloablative and cyclosporine – mycopheno-
late mofetil in reduced toxicity or intensity regimens. ECP was commenced
after assessment of response to 5 days of steroid treatment according to our
protocol: 2 sessions/week for 1 month, 1 session/2 weeks for 3 months, eval-
uation of response and 1 session/month for 6 months.
Results: We studied 20 patients, aged 35 (18-65), post alloHCT with myeloab-
lative (14), reduced toxicity (4) and intensity (4) conditioning, from sibling (3),
matched (8) or one locus mismatched (8) volunteer unrelated and haploidentical
(1) donors. Disease risk index was high (10), intermediate (9) and low (1). Acute
GVHD was observed at day +17 (8-50) in 15 patients, late-onset at+130 (110-
160) in 4 patients and induced at +38 post donor lymphocyte infusion in a
relapsed AML patient. Skin, intestine and liver involvement was evident in 6
patients, skin and intestine in 10 and skin only in 4 patients. Nine patients (2 with
GrII, 7 with GrIII aGVHD) were steroid-dependent and 11 (8 with GrIII, 3 with
GrIV) steroid-refractory.  ATG was administered simultaneously with ECP initiation
in 6 refractory patients that further developed EBV reactivation (p=0.032) treated
pre-emptively with rituximab. ECP was commenced at day +51 for 16 (4-20) ses-
sions. The majority of patients (16/20) presented partial (6), very good (9) or
complete (1) response to ECP. With 9.3 (1.8-54.7) months of follow-up, immuno-
suppression was reduced in 10/20 and ceased in 1 patient. Clinically significant
bacterial infections were found in 17 patients, fungal in 2, CMV and EBV reacti-
vation in 14 and 13 respectively and other viral in 5 patients. Cumulative incidence
(CI) of chronic GVHD was 77.4 at 1-year. 1-year CI of aGVHD-related mortality
was 20%. 1-year overall survival (OS) was 53% and significantly increased in
steroid-dependent versus refractory patients (76% vs 36%, p=0.041). Reduction
of immunosuppression (p=0.026) and steroid dependence (p=0.023) were asso-
ciated with improved OS, irrespectively of other factors.
Summary/Conclusions: Our study supports that ECP should be considered
early in the course of steroid-dependent or refractory aGVHD, before significant
irreversible end organ damage has been established. Optimal timing of inter-
vention, frequency, duration and tapering schedule of ECP need to be investi-
gated in future studies.
PB2167
RAPID RECONSTITUTION OF NK1 CELLS IS ASSOCIATED WITH THE
LOWER INCIDENCE OF GRAFT-VERSUS-HOST DISEASE AFTER
ALLOGENEIC TRANSPLANTATION
X. Zhao1,*, L. Xu1, X. Yu1, Y. Chang1, X. Huang1
1Peking University Institute of Hematology, Peking University People’s Hospital,
Beijing, China
Background: The balance between immunostimulation and immunoregulation
in T cell immunity is achieved by a Th1/Th2/Th3/Tr1 and CD4+CD25+ regula-
tory T (Treg) cell paradigm. 
Aims: We investigated the production of type1 (IFN-gamma, NK1), type2 (IL-
13, NK2), type3 (TGF-beta, NK3) and regulatory cytokines (IL10, NKr) from
human peripheral blood to discuss the cytokine paradigm of NK cells in human
allogeneic hematopoietic stem cells transplantation (allo-HSCT).
Methods: Forty patients undergoing haploidentical (n=27) and HLA-identical
sibling (n=13) allo-HSCT between August 2009 and December 2009 were
enrolled in this analysis after being originally selected using a protocol exploring
the association of reconstituted donor derived NK1/NK2/NK3/NKr cells to
GVHD and CMV reactivation.
Results: Expansion of NK2 and NK3 were found post allo-HSCT compared to
healthy donor. The levels of NKr reconstituted to donor’s level since day 15
post allo-HSCT, and the levels of NK1 in recipients post transplantation were
consistently lower compared to donors’ levels until day 60 post allo-HSCT. Mul-
tivariate analysis showed that the higher levels of NK1 by day 15 were asso-
ciated with lower overall acute GVHD (HR 0.157, 0.039-0.642, P=0.010) as
well as II-IV acute GVHD (HR 0.260, 95%CI, 0.064-1.053, P=0.059). Mean-
while, the higher levels of NK1 by day 15 correlated with lower CMV reactivation
(HR 0.040, 0.005-0.348, P=0.003).
Summary/Conclusions: These results indicate that rapid reconstitution of
NK cells; especially NK1 cells would be help to prevent the development of
graft-versus-host disease as well as CMV reactivation after allogeneic trans-
plantation. 
PB2168
BORTEZOMIB FOR STEROID-REFRACTORY RITUXIMAB
AUTOIMMUNITY AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
M. Zine1,*, T. Khalid1, S. Kafka1, D. Bonney1, S. Hughes1, S.H. Lum1, R. Wynn1
1Bone Marrow Transplant Unit, Royal Manchester Children’s Hospital, Man-
chester, United Kingdom
Background: Therapy of post-transplant autoimmunity manifestations remains
a challenge. Many cases are steroid and rituximab refractory and continuing
intensified immune suppression increase the risk of infection in the post-HSCT
patient. In our institution, we have used bortezomib as our third agent after
failure of steroids or rituximab, or in cases of steroid-dependence since Borte-
zomib appears to be effective in cases with refractory autoimmunity.
Aims: In our series, we assessed the therapeutic response to proteasome
inhibitor in 4 cases of post-transplant refractory autoimmunity
Methods: Three of the 4 cases received Bortezomib for autoimmune cytopenia
(autoimmune haemolytic anaemia AIHA (n=2), AIHA with acquired red Cell
Aplasia (n=1)). At least 2 therapy lines had failed to resolve the cytopenia. One
to two courses of Bortezomib were administered at a dose of 1.3 mg/m2 at
day 1, 4, 8, 11 each course. In two cases this treatment was combined with
immunosuppressive agents: Mycophenolate mofetil (MMF) alone in one case
and associated with sirolimus in the other case. 
Results: Resolution of autoimmune cytopenia was observed in the three cases
after a median of 33 days from the first day of administration. The fourth case
received 1 course of Bortezomib for persistent anti-enzyme antibodies after
allogeneic transplant for Wolman disease. Therapeutic response was obtained
after 25 days reflected by a complete regression of circulating anti-enzyme
antibodies. In all cases, no Bortezomib related toxicity was noticed. The
response was maintained in all cases.
Table 1 summarizes the clinical data and the results of the four cases.
Table 1.
Summary/Conclusions: Our study shows that Bortezomib is a promising ther-
apeutic option for refractory post-transplant autoimmunity with high tolerance
and no related toxicities.
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POST-THAW CELL COUNT PREDICTS ENGRAFTMENT RATE IN CORD
BLOOD TRANSPLANTATION
K. Isobe1,*, K. Koh1, R. Kawakami1, T. Itabashi 1, M. Yanagi1, K. Sasaki1,
K. Watanabe1, M. Mori1, Y. Arakawa1, R. Hanada1
1Hematology/Oncology, Saitama Children’s Medical Center, Saitama, Japan
Background: The infused cell count in cord blood transplantation (CBT) is an
important element for engraftment; however, this number in the prior reports
has been based on the pre-thaw cell count. Therefore, the association between
post-thaw cell count and engraftment rate, especially in pediatric patients, is
unclear. 
Aims: Tte Aim of this study is to reveal the association between post-thaw cell
count and engraftment rate in pediatric patients in the setting of CBT at our
institution.
Methods: We retrospectively reviewed the medical records of 78 patients who
underwent CBT between June 1998 and April 2016. We excluded the cases of
CBT that required rescuing after engraftment failure. 
Results: Underlying disease was acute leukemia (AL) in 63 (ALL, 38; AML,
25) patients, chronic myeloid leukemia in one, malignant lymphoma (ML) in
two, myelodysplastic syndrome (MDS) in three, aplastic anemia in one, and
others (such as primary immunodeficiency syndrome) in eight. In terms of con-
ditioning regimens, myeloablative conditioning was administered to 62 patients
and reduced intensity conditioning was administered to 16 patients. The median
age at CBT was 3 (range, 0–19) years, and the median follow-up period was
898 (range, 47–6236) days. The engraftment rate was 84.6%, primary engraft-
ment failure was observed in 11 patients (AL,seven; ML, one;  MDS, one; neu-
roblatoma, one; and others, one) and secondary graft failure was observed in
one patient (severe congenital neutropenia). The 3-years overall survival rate
was 55.1%, and 32 patients had died (cause of death: progressing disease in
19 patients). We analyzed the data on 34 patients of whom both of pre- and
post- thaw CD34+ cell counts in the cord blood samples were available. The
median pre- and post-thaw CD34+ cell counts was 1.67 × 105/kg and 1.51 ×
105/kg, respectively, and they were significantly correlated with each other
(r=0.73, p=0.52). In our study cohort, the engraftment failure occurred in five
patients (primary in all patients). The median post-thaw CD34+ cell count was
1.60 × 105/kg in the patients who achieved engraftment and 1.01 × 105/kg in
the patients who did not achieve engraftment. No statistically significant differ-
ence was observed between these two groups (p=0.30). When we defined the
cut-off value of the pre-thaw CD34+ cell count as 1.2 × 105/kg in the patients
who were infused with CD34+ cells more than the cut-off value, the specificity
and sensitivity of graft failure was 79.3% and 60%, respectively. When we
defined the cut-off value of the post-thaw CD34+ cell count as 0.7 × 105/kg in
the patients who were infused with CD34+ cells more than the cut-off value,
the specificity and sensitivity of graft failure was 96.6% and 40%, respectively.
Summary/Conclusions: We concluded that the risk of graft failure is more
precisely predicted by the post-thaw than pre-thaw CD34+cell count and that
if the post-thaw CD34+ cell count is more than 0.7 × 105/kg, the risk of graft
failure is very low. 
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COLONYFORMING CAPACITY OF HEMATOPOIETIC STEM CELLS
MOBILIZED INTO PERIPHERAL BLOOD WITH VINIRELBINE AND
GRANULOCYTE COLONY STIMULATING FACTOR
V. Balashova1, I. Kostroma2,*, I. Zapreeva2, V. Rugal’1, S. Bessmeltsev2,
A. Chechetkin2, S. Gritcaev2
1Laboratory of Leukemia Study, 2Hematological Clinic, Russian Institute of
Hematology and Blood Transfusion, St. Petersburg, Russian Federation
Background: One of the alternative method to mobilize stem cells from bone
marrow to peripheral blood is using of vinorelbine with granulocyte colony stim-
ulating factor (G-CSF). The specific features of vinorelbine are absence of hos-
pitalization necessity and predictability of leukocytapheresis’ optimal time. But
there is not enough data to conclude whether vinorelbine is safe for haematopoi-
etic stem cells.
Aims: The aim of the study was to determine the colonyforming capacity of
haematopoietic stem cells mobilized into peripheral blood with vinirelbine and
G-CSF.
Methods: Data of 11 patients with multiple myeloma (MM) and 1 patient with
Hodgkin lymphoma (HL) were analyzed. Vinorelbine was injected IV in dose 50-
70 mg (35 mg/m2). Daily lenograstim dose was 10 mcg/kg. The number of BFU-
E, CFU-GM, CFU-GMME and CFU-Macrophage was studied in 14-days culture:
1x105 cells of leukocytapheresis product were set into Petri dish with MethoCult
H 4435 full medium. Control group was consisted of hematopoietic stem cells
donors’ data in which G-CSF monotherapy was used for mobilization.
Results: The median patients’ age was 55 (43-64) y. Induction courses for MM
treatment included borteszomibe (11 patients), lenalidomide (5 patients) and
carfilsomibe (1 patient) in combination with steroids. A patient with HL was
treated with ABVD scheme. Leukocytaphereses were started on 6-8 day, here-
with in 9/11 (75%) patients on 7 day. The number of gained CD34+ was 1.7-
7.8x106/kg (Me 3.3x106/kg). Median number of BFU-E, CFU-GM, CFU-GMME
and CFU-Macrophage in patients’ group was 207, 180, 14 and 9 accordingly.
The results were not significantly different from control group data: 168, 170,
10 and 12 accordingly; p<0.05.
Summary/Conclusions: We conclude that mobilization regimen with vinorel-
bine in combination with G-CSF does not damage colonyforming capacity of
hematopoietic stem cells.
PB2171
URIC ACID LEVEL MIGHT BE A PROGNOSTIC INDICATOR FOR SURVIVAL
IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION. SINGLE CENTER EXPERIENCE
N. Mandaci Şanli1,*, S. Şıvgın1, L. Kaynar1, B. Eser1, M. Çetin1, A. Ünal1
1Hematology and Bone Marrow Transplant Center, Erciyes University School
of Medicine, KAYSERİ, Turkey
Background: Uric acid (UA) is an abundant aqueous antioxidant that accounts
for almost two thirds of all free-radical-scavenging activity in human serum. It
is released from injured cells during conditioning for allogeneic hematopoietic
stem cell transplantation (AHSCT).
Aims: The aim of this study was to evaluate the prognostic impact of pre trans-
plantation uric acid levels on survival and mortality in allogeneic HSCT patients.
Methods: We retrospectively analyze 273 patients with  hematologic diseases
undergoing AHSCT. The patients were categorized as patients with acute
leukemia, myelodysplastic syndrome, lymphoma patients and other hemato-
logic disease diagnoses. A serum uric asid concentration 3.4 mg/dl was con-
sidered hypouricemia. Pretransplantation uric asid, creatine, total protein and
albumin were analyzed. Univariate, multivariate Cox regression models and
Kaplan–Meier curves were performed to uric asid, creatine, total protein and
albumin associated with disease-free survival (DFS) ,over all survival (OS),
early non relaps mortality (+30 day ) and late non relaps mortality (+100 day).
Results: Pretransplantation low uric acid levels were detected in 57 (%20.8)
patients. Low UA levels were significantly associated with DFS (HR: 0.52; p=
0.027) . None of  the creatine, total protein and albümin were significantly asso-
ciated with DFS (HR:0.98; p= 0.98, HR :0.87 p=0.60, HR: 1.15; p= 0.66 ). There
was no significant association between UA, creatine, total protein and albümin
levels and overall survival (HR: 0.84; p= 0.46, HR: 2.10; p= 0.057, HR :0.88; p=
0.52, HR: 0.78; p= 0.26), early relapse mortality (HR: 1.38; p=0.54, (HR: 2.16;
p= 0.29, HR: 0.61;  p= 0.25, HR: 0.53;  p= 0.13 ) and late non-relapse mortality
(HR:0.57; p=0.35, HR: 0.21; p=0.29, HR: 1.04; p= 0.94, HR: 1.07; p= 0.92).
Summary/Conclusions: Uric asid is a natural antioxsidant compound. UA
reacts with oxygen-derived free radicals and becomes oxidized. Since humans
are unable to catabolize UA to the more soluble compound allantoin due to
lack of urate oxidase or uricase, the serum UA concentration is higher in
humans than almost all other mammals. However, this high UA level in humans
has been regarded as being beneficial in the presence of elevated oxidative
stress. Our study supports that the uric asid is a antioxidant compound.
BecauseDisease-free survival is lower in patients with low uric acid levels before
transplantation. This is the first report demonstrating a positive association
between UA levels and survival analyses in allogeneic HSCT patients. Our find-
ings are potentially clinically relevant. Confirmation in independent cohorts and
further investigations into underlying mechanisms, such as reduced antioxida-
tive capacity in hypouricemia, are warranted. In thecoming years, as a result
of increased works on this subject, uric asid may be considered a possible
prognostic marker in allogeneic hematopoietic stem cell transplantation. 
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RISK FACTORS FOR HERPES SIMPLEX VIRUS-1/2 VIREMIA AND
CLINICAL OUTCOMES FOLLOWING UNMANIPULATED
HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION
F.-F. Tang1, L.-P. Xu1, X.-H. Zhang1, H. Chen1, Y.-H. Chen1, X.-D. Mo1,
Y.-Q. Sun1, K.-Y. Liu1, X.-J. Huang1,*
1Peking University People’s Hospital, Peking University Institute of Hematology,
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing,
China
Background: Herpes simplex virus(HSV)-1/2 can still be reactivated after allo-
geneic haematopoietic stem cell transplantation (allo-HSCT) even when the
prophylactic acycloviris used. However, the risk factors for HSV-1/2 viremia
and the clinical outcomes following unmanipulated haploidentical HSCT remain
unknown.
Aims: The aim of this study was to explore the risk factors for HSV-1/2 viremia
and to evaluate clinical outcomes following haplo-HSCT.
Methods: Nineteen patients with HSV-1/2 viremia and fifty-seven patients with-
out HSV-1/2 viremia which were selected using the case-pair method after hap-
loidentical HSCT were enrolled. We analysed the risk factors for HSV-1/2
viremia and compared clinical outcomes between the two patient groups.
Results: The risk factors for HSV-1/2 viremia included HLA disparity ≥2 loci
(p=0.049) and cytomegalovirus (CMV) reactivation (p=0.028). The incidences
of platelet engraftment, oral mucositis and severe haemorrhagic cystitis (HC)
in patients with and without HSV-1/2 viremia were 77% and 94% (p=0.003),
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78% and 13% (p=0.000), and 25% and 6% (p=0.04), respectively. Moreover,
the median time to platelet engraftment in patients with and without HSV-1/2
viremia was 25 d(range,11–80 d) and 17 d(range, 8–67 d) (p=0.004). In a mul-
tivariate analyses, HSV-1/2 viremia was associated with delayed platelet
engraftment(p=0.038), a higher incidence of oral mucositis(p=0.000) and
severe HC (p=0.038). However, HSV-1/2 viremia was not associated with non-
relapse mortality (34.0% vs 31.5%, p=0.26),leukaemia-free survival (60.9% vs
57.9%, p=0.46) and overall survival (61.2% vs 60.7%, p=0.37) (Figure 1).
Figure 1.
Summary/Conclusions: Based on our study results, we recommend that HSV-
1/2 PCR should be performed on clinical suspicion.
PB2173
FACTORS PREDICTING GRAFT-VERSUS-HOST DISEASE-FREE,
RELAPSE-FREE SURVIVAL AND OUTCOMES AFTER REDUCED
INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE
LEUKEMIA OR MYELODYSPLASTIC SYNDROMES
H. Kanamori1,*, J. Aoki1, A. Negoro1, S. Koyama1, T. Tachibana1, H. Nakajima2,
M. Tanaka1
1Hematology, Kanagawa Cancer Center, 2Hematology and Clinical Immunol-
ogy , Yokoham City University, Yokohama, Japan
Background: Reduced intensity allogeneic stem cell transplantation (RIST) is
now commonly applied for elderly patients with acute leukemia (AL) or
myelodysplastic syndromes (MDS). However, the factors affecting graft-ver-
sus-host disease-free, relapse-free survival (GRFS) and overall survival (OS)
remain obscure. 
Aims: To identify such factors and to clarify the clinical significance of RIST
with various graft sources, we retrospectively analyzed patients with AL or MDS
who received RIST in our hospital.
Methods: The study included patients with acute myeloid leukemia (n=73),
acute lymphoid leukemia (n=31) or MDS (n=25), who received fludarabine
(Flu)/melphalan (Mel)-based RIST between 2004 and 2015 as the first trans-
plantation.
Results: There were a total of 129 patients, including 3 in low risk (L), 74 in
intermediate risk (I), 36 in high risk (H) and 16 in very high risk (V), classified
by the refined disease risk index (rDRI). The median age was 58 years
(range: 18-68 years), with 73 males and 56 females. Conditioning regimens
contained Flu (125mg/m2) combined with Mel (80mg/m2, n=21 or 140mg/m2,
n=108). Total body irradiation (4Gy) was used in 96 patients who received
transplantation from unrelated donors or HLA mismatched related donors.
Bone marrow (BM) or peripheral blood stem cell (PB) from related donors
was used in 40 patients, BM or PB from unrelated donors in 33 and cord
blood (CB) from unrelated donors in 56. Primary graft failure occurred in 7
patients and death before engraftment was observed in two. After a median
follow-up of 46 months (range: 15-144 months) for the survivors, the 1-year
GRFS, disease free survival (DFS) and OS were 57%, 61% and 70%, respec-
tively. On univariate analysis for all patients, pre-transplant factors associated
with the 1-year GRFS included stem cell sources (BM/PB vs CB: 44% vs
68%, p=0.005), donors (related vs unrelated: 38% vs 62%, p=0.012), disease
(AL vs MDS: 60% vs 28%, p<0.001) and rDRI (L/I vs H/V: 65% vs 38%,
p=0.003). On multivariate analysis, BM/PB (HR 2.0, 95% CI 1.0-4.0,
p=0.039), MDS (HR 2.6, 95% CI 1.5-4.6, p=0.001) and H/V rDRI (HR 2.1,
95% CI 1.2-3.5, p=0.006) were associated with a worse GRFS. The 5-year
OS, cumulative incidence of relapse (CIR) and non-relapse mortality (NRM)
were 55%, 36% and 18%, respectively. On univariate analysis, significant
prognostic factors were hematopoietic cell transplantation-specific comor-
bidity index (HCT-CI) (score 0 vs >= 1: 78% vs 48%, p=0.007), disease (AL
vs MDS: 59% vs 40%, p=0.004) and rDRI (L/I vs H/V: 64% vs 43%, p=0.003)
for the 5-year OS, donors (related vs unrelated: 53% vs 27%, p=0.005) and
rDRI (L/I vs HV: 27% vs 48%, p=0.005) for CIR, and age (<60 vs >= 60: 10%
vs 28%, p=0.021), donors (related vs unrelated: 8% vs 23%, p=0.034) and
disease (AL vs MDS: 13% vs 36%, p=0.003) for NRM. On multivariate analy-
sis, HCT-CI score >= 1 (HR 3.1, 95% CI 1.3-7.4, p=0.009) and MDS (HR 2.4,
95% CI 1.3-4.5, p=0.005) were adversely associated with OS, so were H/V
rDRI (HR 2.5, 95%CI 1.4-4.7, p=0.003) and MDS (HR 3.7, 95%CI 1.6-8.8,
p=0.002) for CIR and NRM, respectively.
Summary/Conclusions: Our data suggest that Flu/Mel-based RIST was a prom-
ising strategy for patients with hematologic malignancy, irrespective of (?) donor
or stem cell sources. However, GRFS and OS of MDS were significantly worse
than those of AL, and MDS is strongly associated with high NRM even with RIST.
This indicates that we should pay more attention to NRM in MDS.
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INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF
HEMORRHAGIC CYSTITIS ON HAPLOIDENTICAL TRANSPLANTATION
M. Saez-Perdomo1, M. Perera1,*, J. Viedma1, C. Rodriguez1, A. Suarez1,
L. Guerra1, J. Lopez1, T. Molero1, S. Jimenez1
1Hematology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas
de Gran Canaria, Spain
Background: Hemorrhagic cystitis (HC) is a serious complication ocurring
after allogenic hematopoietic stem cell transplantation (HSCT) more frequent
on haploidentical (haplo) HSCT, with an incidence of 10% to 70%(Silva et al
Haematologica 2010;95(7):1183–1190) associated mainly with the effect of
cytotoxic agents such as Cyclophosphamyde (Cy). The conditioning regimen,
BKPyV infection and graft versus host disease have an implication in the inci-
dence. Other authors related the reactivation of CMV and a previous trans-
plantation as risk factors to HC development(Ruggeri et al Transplant Infectious
Disease 2015:17:822–830).
Aims: With this study we aim to describe the HC incidence and risk factors in
all haplo-HSCT performed in the Canary Islands.
Methods: We analyzed all consecutive haplo-HSCT from family donors per-
formed at our Hospital between 2013 and 2016. The conditioning regimen used
for the transplant was the Hopkins haplo protocol with high dose Cy (50 mg/kg
on days 3 and 4) posttransplantation (PTCy). We used as HC prophylaxis
intense hydratation on the Cy administration day and the following 24 hours
(using bladder wash only in 1 patient with cardiac dysfunction) and perfused
MESNA at 100% of Cy dose beginig 15 minutes before the Cy administration
on 16 pts and at 20% of the last dose at 0, 4 and 8 hours on all pts. We used
SPSS V.23 to determine the cumulative incidence (CI) of HC.
Results: We performed 20 haplo-HSCT, of which 10 were males (1 was
transplanted 3 times) and 8 were women. The mean age was 40 (range 16-
64). The pts presented the following diagnosis: AML (10), ALL (1), EH (5),
NHL (3), AM (1). 45% of pts received the haplo-HSCT in remission, 50% with
refractory disease and 5% of pts did not receive previous treatment. 6 pts
developed HC (36.5% CI at day +80) (Figure 1a) with a median time from
haplo-HSCT to onset of 23 days (range 3-42), 1 (17%) was grade I, 4 (66%)
grade II and 1 (17%) grade IV. The grade I case did not received the MESNA
infusion like most of the other pts. No pts died due to HC and all cases
resolved without sequelae. 12 pts received Cy pre- and post-transplant and
only 8 pts received PTCy. The CI at day +80 for the pts with PTCy was 33.3%
and for Cy pre- and post-transplant 38.3% (Figure 1b). We found no statisti-
cally significant difference on the CI of HC between these two groups. The
development of HC was related to Cy in 1 patient, who suffered from this
complication on the second and third haplo-HSCT. For the rest of the pts
(after day +30) the HC was related to BKPyV infection, as a consequence of
the immunosuppression state of the patient, we also observed all these pts
had positive serum viral load for CMV.
Figure 1.
Summary/Conclusions: The incidence of HC associated to post-HSCT high
Cy dose in our series is 15% lower than other ones. Most of them on grade 1
or 2 and without mortality associated. The risk of HC is high, particularly in the
setting of highly pre-treated patients (especially those undergoing a 2nd trans-
plant). The development of HC after day +30 is evidently associated to BKPyV
as a contributing factor for continuous inflammation and CMV reactivation (as
an immunosuppression marker). In our study, HC did not have an impact on
mortality of high-risk patients after haplo-HSCT. The HC remains frequent with
a high morbidity in particular when it is severe, often causing prolonged hos-
pitalization and resource use. We need further studies to recognize the at-risk
population early.
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OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
UNDERGOING NON-MYELOABLATIVE ALLOGENIC STEM CELL
TRANSPLANTATION AFTER TREATMENT WITH THE BRUTON TYROSINE
KINASE INHIBITOR IBRUTINIB
F. Ramdohr1,*, G.-N. Franke1, M. Jentzsch1, W. Pönisch1, C. Michael1,
S. Heyn1, S.-Y. Wang1, G. Behre1, S. Leiblein1, S. Schwind1, D. Niederwieser1,
V. Vucinic1
1Dept. Hematology & Clinical Oncology, University of Leipzig, Leipzig, Ger-
many
Background: Although the Bruton tyrosine kinase (BTK) inhibitor ibrutinib sig-
nificantly improves the prognosis of CLL patients (pts), allogeneic hematological
stem cell transplantation (HCT) remains the only curative option for the under-
lying disease. Data on pre-transplant treatment of CLL with ibrutinib are very
limited.
Aims: Here we present our experience of HCT in pts previously treated with
ibrutinib.
Methods: 11 CLL pts (median age at HCT 57 years [y], range 52-66 y) treated
between 2014 and 2016 in our unit with non-myeloablative (nma) HCT after
ibrutinib were included. Ibrutinib treatment lasted median 4.03 months (range
1 - 28). Conditioning regimen was Fludarabin 30 mg/m2on day -4 to -2 followed
by 2 Gy total body irradiation. Disease status at HCT was Binet B (n=3) or
Binet C (n=8). Two pts had Richter’s transformation (RT) diagnosed before
nma-HCT. Ten pts were in partial remission (PR) at nma-HCT (PR1 n=4; PR2
n=3; PR3 n=2, PR4 n=1) while one was in first relapse. Donors were human
leukocyte antigen (HLA) matched related (n=3, MRD) or HLA-matched unre-
lated (n=8, MUD). Pts received median 3 lines of therapy (range 1-6) including
ibrutinib before transplantation. Classical cytogenetic analysis and fluorescence
in situ hybridization (FISH) was carried out for every pt. Five pts had a deletion
(del)(17p13) and one a del(11q22.3).
Results: The average overall survival (OS) for all pts was 471 days (range
36-812) (Figure 1). The average OS of patients with del(17p13) was 379 days
(range 66-628) compared to 456 days (range 36-812) for those without
del(17p13, p=0.98). OS was not significantly influenced by the stem cell
source (MUD vs MRD, p=0.63) or remission status PR1 vs >PR1 (353 vs
472 days, p=0.79). Non-matched CMV-Status (negative recipient and positive
donor or positive recipient and negative donor) had an OS comparable to
that of matched CMV-Status (p=0.73). Pts above the median age had a lower
OS although this didn’t reach significance (p=0.39). EFS was median 125
days (range 26-628). Pts with or without a TP53 alteration had a similar EFS
(p=0.91). Pts undergoing MRD-HCT had better EFS than those undergoing
MUD transplantation (p=0.055). CMV-Status or age>median had no prog-
nostic influence on the EFS (p.0.83 and p=0.39 respectively). Non-relapse
mortality (NRM) was 32% at 10 months (Figure 1), which was consistent with
a previous publication from our group (30% at 4y). The acute GvHD Grade
3-4 was present in 3 pts (27.2%).
Figure 1.
Summary/Conclusions: The outcome in this small group is comparable to
studies of CLL-pts undergoing nma-HCT without receiving ibrutinib upfront.
Previous data from our unit (Hebenstreit et al., Leuk  Lymphoma 2014) showed
OS 51% and NRM 30% at 4y. Ibrutinib appears to be a feasible option in a
transplantation setting, although further testing with larger numbers of patients
and a longer follow up is required.
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SHORT-TERM CHIMERISM IN T-HELPER CELL SUBSETS AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
D. Dubnyak1,*, N. Risinskaya2, M. Drokov1, N. Kostritsa3, L. Kuzmina1,
N. Popova1, E. Mikhalcova1, V. Vasilyeva1, O. Koroleva1, Z. Konova1,
I. Fevraleva2, I. Galtseva4, J. Davydova4, N. Kapranov4, A. Sudarikov2,
E. Parovichnikova1, V. Savchenko1
1Bone marrow transplant department, 2of Molecular Hematology, National
Research Center for Hematology, 3school of medicine, Lomonosov Moscow
State University, 4Laboratory of immunophenotyping, National Research Center
for Hematology, Moscow, Russian Federation
Background: Despite the fact that almost all studies in transplant biology ded-
icate T-cells the chimerism in T-helper (Th) cells and its subsets such as T-reg-
ulatory (Treg) cells after allogeneic hematopoietic stem cell transplantation
(allo-HSCT) has never been evaluated.
Aims: To evaluate Th, Treg and bone marrow cell short-term chimerism in allo-
HSCT patients.
Methods: Between May 2015 and November 2016 there was 109 transplants
in our center. The research included 24 patients with hematological malignan-
cies (AML =14,ALL =7,MDS =2,CMML -1). The median age of patients was
33,5 (range 19 to 60) years old, female=16, male=8. Myeloablative conditioning
regimen was used for 11 patients. The other 13 patients underwent reduced
intensity conditioning regimen. Peripheral blood stem cells (PBSCs) as graft
source was used in 9 patients, BM in 15 patients. 9 patients were transplanted
from HLA-identical related donor  ,15 - from unrelated matched. Сhimerism
was evaluated at +30, +60, and 90-day in blood and bone marrow. Peripheral
blood mononuclear cells (PBMC) were isolated using standard protocol. Cells
were sequentially incubated with CD4-biotin and anti-biotin microbeads (Mil-
teney Biotec, Germany). Next pure fraction of Treg cells (CD4+CD25high) was
obtained by positive selection with the use of anti-CD25 microbeads. DNA was
isolated by AmpliSens DNA-sorbB nucleic acid extraction kit. Chimerism was
assessed by the STR-PCR analysis (polymerase chain reaction with a panel
of primers for loci of short tandem repeats). 
Results: For detailed result see Figure 1. 18 patients didn’t have any signs of
relapse, graft failure or acute graft-versus host disease at all observation time.
In this  group on day 30% of cells with donors genotype was - 97,17±0,75; on
day 60 – 95,75±2,15; on day 90- 98,21±0,80. On day 30 T-helper – 87,51±3,12;
on day Th 60- 90,43±3,18; on day 90 Th – 93,71± 3,03.  On day 30 T-regulatory
– 77,36±4,50;  on day 60Treg – 82,08± 5,94; on day 90Treg – 97,71± 1,18.  Four
patients were diagnosed with relapse at +4 and +6 months after allo-HSCT.
Two patients were diagnosed with acute GVHD.
Figure 1.
Summary/Conclusions: Impact of chimerism in different T-helper subsets still
need further investigation. We will continue our research and further results
will be reported later.
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ADIPOSE TISSUE CHANGES IN LYMPHOMA PATIENTS IN THE PERI
TRANSPLANTATION PHASE
J. Jabbour1,2, B. Manana3, A. Zahreddine4, C. Saadeh5, C. Maya3,
A. Bazarbachi4, D. Blaise6, J. El Cheikh3,*
1Clinical Nutrition, American University of Beirut Medical Center, Beirut,
Lebanon, 2Ecole Doctorale Sciences de la vie et de la santé, Aix Marseille Uni-
versité, Marseille, France, 3Division of Hematology/Oncology, 4Bone Marrow
Transplantation Program, 5Department of Radiology, American University of
Beirut Medical Center, Beirut, Lebanon, American University of Beirut Medical
Center, Beirut, Lebanon, 6Programme de Transplantation et Thérapie Cellulaire,
Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes,
Marseille, France
Background: Abdominal Visceral Adipose Tissues (VAT) have been shown to
have inflammatory activity and have been used to predict cancer outcomes.
The ratio of VAT/Total Adipose Tissues (TAT) is a negative predictor of progres-
sion free survival in Lymphoma patients on chemotherapy.
Aims: Assess the changes in adipose tissues among stem cell lymphoma recip-
ients in the peri-transplantation phase.
Methods: Institutional Review Board approved this retrospective study for adult
patients (age>16 years) having B and T lymphoma who underwent Stem Cell
Transplantation (SCT).  Each patient was imaged by PET/CT scan pre-SCT
and in the first 3 months post transplantation. A cross sectional image was ana-
lyzed at the level of the L3 to calculate TAT, VAT and Waist Circumference
(WC). Data was analyzed by gender since body composition parameters dif-
fered significantly between the two categories in the literature. 
Results: The study sample consisted of 91 patients [mean age: 37.7±13.5
years, n=52 (57%) males, n=81(87%) autologous SCT, n=12(13%) allogeneic
SCT,  median overall survival in months: 12 in males and 19 in females]. Death
was observed in 6 (11.5%) males and 1(2.4%) female. Patient characteristics
were similar across gender categories except for weights (kg) and Body Mass
Index (kg/m2): 88.1 and 28.6 vs 65.2 and 25.0, in males and females respec-
tively (p<0.05). Changes from pre-SCT to 3 months post SCT revealed that
TAT and VAT decreased with mean differences of 33±56 cm2 (p<0.01) and
7.0±36 cm2 (p=0.17) in males and 16±44 cm2 (p<0.01) and 4±14 cm2 (p=0.056)
in females, respectively. Waist circumference decreased significantly with mean
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differences of 3.9±4.9 cm and 2.8±4.4 cm in males and females, respectively
(p<0.01). VAT/TAT withnissed a slight increase in males and reduction in
females (p>0.05). In multivariate analysis, no significant associations were
shown with mortality and progression rates (Figure 1).
Figure 1.
Summary/Conclusions: This study provides data on the evolution of adipose
tissues parameters in the peri-transplantation phase. TAT, VAT and WC
decrease 3 months post transplantation. Future studies should evaluate the
associations of these parameters with major outcomes on larger sample sizes. 
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NON RELAPSE MORTALITY (NRM) ANALYSIS IN 93 UNRELATED DONOR
TRANSPLANTATION - SINGLE CENTRE EXPERIENCE - HLA HAPLOTYPE
ROLE?
P. Mensah-Glanowska1,2,*, B. Piątkowska-Jakubas1,2, A. Radziszewska2,
A.B. Skotnicki1,2
1Department of Haematology, Krakow University Hospital, 2Department of
Haematology, Collegium Medicum Jagiellonian University, Krakow, Poland
Background: Unrelated donor stem cell transplantation has a curative potential
against haematological malignancies. However there are concerns about asso-
ciated risk of non-relapse mortality. We performed a retrospective single centre
study of causes of non-relapse mortality over four year period - 2012-2016.
Aims: Purpose of the study was to analyse non-relapse mortality (NRM) in
patients subjected to unrelated donor transplantation in four-year-period: 2012
to 2016 - 93 transplant procedures in 86 patients.
Methods: Study cohort was analysed - relapse rate and non-relapse mortality
were assessed. Causes of both  - early and late NRM were studied.
Results: There were 23 relapses in the group of assessed patient cohort
(24,7%). 7 patients undergone the second transplant - five patients - because
of AML relapse, later two - because of secondary graft failure. Out of re-trans-
planted 7 patients - 3 patients are alive - 2 patients with graft failure and one
with post-transplant AML relapse in 2nd CR. Out of 93 procedures of unrelated
donor transplantation there were 16 cases of death - assumed as non relapse
mortality NRM (17%). There were 9 early deaths (before day +100) - 6 cases
in patients with relapsed/refractory acute leukaemia without remission after
conventional chemotherapy. These patients were subjected to sequential con-
ditioning with cytreduction phase. Active disease and highly active
antileukaemic treatment can be reason for higher treatment related toxicity and
elevated risk of death. Later two patients developed infectious bacterial com-
plications with septic shock. In one patient - antiviral treatment refractory CMV
encephalitis with massive macrophage activation syndrome was diagnosed.
Analysis of NRM after day100 revealed 7 affected patients. All these patients
GVHD 2-4 was diagnosed previously, accompanied by transplant associated
microangiopathy (TAM) and infections - both viral and fungal. Additionally to
factors connected to NRM - age, comorbidity score, patient/donor HLA allelic
and antigen and sex mismatches, HLA patient/donor haplotypes were
analysed. It was possible to categorise 15 out of 16 NRM patients into 5 HLA
class II haplotype groups connected with autoimmune diseases in Caucasian
population - rheumatoid arthritis and lupus erythematosus: DRB1 01:01 DQB1
05:01 (5 patients), DRB1 03:01 DQB1 02:01 (4 patients), DRB1 11:01 DQB1
03:01 (3 patients), DRB1 15:01 DQB1 06:02 (2 patients), DRB1 04:01 DQB1
03:02 (1 patient).
Summary/Conclusions: Based on these results we create working hypothesis
that HLA class II haplotype may predispose to severe post-transplant infectious
or/and non-infectious complications and affect the risk of NRM. Because small
number of analysed patients and documented high frequency of these haplo-
types in population, further analysis is required.
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HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH HIGH DOSE
CYCLOPHOSPHAMIDE POST-TRANSPLANT IN HIGH RISK
HEMATOLOGIC MALIGNANCIES: RISK FACTOR AND OUTCOME
ANALYSES IN OUR CENTER
J. Viedma1,*, M. Saez-Perdomo1, M. Perera1, A. Suarez1, J. Lopez1,
C. Medina1, L. Guerra1, M. T. Gómez-Casares1, H. Luzardo1, T. Molero1,
S. Jimenez1
1Hematology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas
de Gran Canaria, Spain
Background: Allogenic hematopoietic stem cell transplantation (allo-HSCT)
is an effective therapy for a variety of hematological malignancies. However, a
lack of HLA-identical sibling donors or unrelated donors has restricted the appli-
cation of allo-HSCT in hematological malignancies. Haploidentical HSCT (Hap-
lo-HSCT) offers the benefits of rapid and nearly universal donor availability
and, in the past decade, has been accepted worldwide as an alternative treat-
ment for patients with hematological malignancies who do not have an HLA-
identical sibling donor or who require urgent transplantation.
Aims: The purpose of this study was to investigate the incidence, causes and
factors influencing overall and transplant-related mortality after Haplo-HSCT.
Methods: We analyzed all consecutive patients receiving Haplo-HSCT from
family donors at our hospital from 2013 to 2016. The conditioning regimen used
for the transplant was the Hopkins haplo protocol with high dose Cy (50 mg/kg
on days 3 and 4) posttransplantation. We classified the patients before the Hap-
lo-HSCT according to disease risk index (DRI), ECOG, Sorror score and EBMT
risk score to evaluate the correlation between the physical state of the patients
before the transplant and the survival (overall mortality (OM) and transplant-relat-
ed mortality  (TRM)). We used SPSS V.23 to calculate the cumulative Mortality
incidence by the KM test and the Cox proportional hazards model.
Figure 1.
Results: We performed 20 haplo-HSCT, 10 were males (1 was transplanted
3 times) and 8 were females mean age of 40 (range 16-64). Diagnosis: AML
(10), ALL (1), EH (5), NHL (3), AM (1). Forty five percent of patients received
the haplo-HSCT in remission, 50% with refractory disease and 5% of patients
did not receive previous treatment. Of the 20 patients from our series, 12
died post transplant with an OM of 60%. The cumulative incidence (CI) of
OM was 15% at 1 month (m), 35% at 3 m, 45% at 6 m, 55% at 1 year, and
40% at 2 and 3 years (Figure 1a). When we analyzed the OM depending on
the different physical status scores we found no statistically significant differ-
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ence between OM from the different states of EBMT (p=0.356) and DRI
(p=0.07), however we found a statistically significant difference for ECOG
(p=0.028) (Figure 1b) and Sorror (p=0.016). On a pairwise analysis of the
OM we found no statistically signification for EBMT, and found a statistically
significant difference between the patients with low-high DRI (p=0.01), inter-
mediate-high DRI (p=0.01), ECOG 0-1 (p=0.046) and Sorror 0-5 (p=0.003).
The multivariate analysis showed that ECOG 2 vs 0 (p=0.013, HR=46.59),
Sorror 2-3 vs 0-1 (p=0.041, HR=19.55) and Sorror 4-5 vs 0-1 (p=0.005,
HR=282.48) were significantly related with a higher incidence of OM. Five
patients died of infection (41.67%), 3 of disease progression (25%), 1 of
relapse (8.33%) and 3 of other causes (25%). Six patients died of TRM (50%).
The CI of TRM was 10.5% at 1 m and 31.6% at 3 m, 6 m, 1, 2 and 3 years
(Figure 1c). When we analyzed the TRM depending on the different physical
status scores we only found a statistically significant difference between TRM
incidence from the different states of ECOG (p=0.038) (Figure 1d) and no
statistically significant difference for EBMT (p=0.386), DRI (p=0.372) and Sor-
ror (p=0.073). On the pairwise analysis we also found statistically significant
differences between ECOG 1-2 (p=0.018) and EBMT 1-5 (p=0.046), for Sorror
we found a marginal statistical signification between 0-1 (p=0.052), 0-2
(p=0.052) and 0-5 (p=0.052), for DRI we found no statistically significant dif-
ference. On the multivariate analysis we found no statistically significant cor-
relation between TRM and the physical status scores.
Summary/Conclusions: Despite the fact that Sorror, EBMT and DRI scores
are widely validated to establish the risk of patients undergoing HSCT, in our
experience ECOG remains a useful score for assessing the risk of TRM on
patients receiving Haplo-HSCT. We think further studies with a larger sample
would be necessary to confirm our results.
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A SIMPLIFIED METHOD OF CRYOPRESERVATION OF PERIPHERAL
BLOOD STEM CELLS WITH OVER 10% GRANULOCYTE
CONCENTRATION FOR LESS THAN 36MONTHS
T. Akagi1,*, K. Ota2, T. Fujii2, K. Kamata3, K. Mayama3, K. Yamaguchi3,
K. Yamagata3, S. Fukuda3, K. KUbo2
1Transfusion and Cell Therapy, 2Hematology, Aomori prefectural central hos-
pital, Aomori, 3Gastroenterology and Hematology, Hirosaki University Hospital,
HIrosaki, Japan
Background: The long-term stability of cryopreserved peripheral blood stem
cells (PBSCs) is an important concern for patients experiencing disease
relapse. However, the quality of long-term cryopreserved PBSCs stored at -
80°C by using simplified method has not been elucidated in detail. Cryopre-
served PBSCs undergo cell damage and decrease in viability, and those con-
taining granulocytes might influence cell loss.
Aims: The aim of this study was to evaluate the effect of cryopreservation for
less than 36 months and the number of granulocytes in the cryopreserved
PBSC products on CD34+ cells.
Methods: We examined the effects of cryopreservation on the viability of
CD34+ cells that were stored for less than six months and those stored for 7–
24 months, and 25-36 months, and the change of CD34+ cell viability with high-
er granulocyte content. We also evaluated the correlations between the number
of granulocyte in the cryopreserved PBSC products and the time to engraftment
of leukocyte or platelet.   Informed consent was obtained prior to the procedure
from all the patients following institutional guidelines.
Results: A total of 65 PBSC samples were collected. We compared three
groups based on the cryopreservation period: (1) less than 6 months, (2) 7–24
months, and (3) 25-36 months.   The median (range) viability of CD34+ cells
after thawing was 81.8% (58.2–94.4). 80.5% (56.6–92.8), and 76.1% (54.5–
89.6) in the three groups, respectively. No significant difference in the viability
of the cells in either frozen period was observed (p=0.14, respectively).    We
compared the effect of granulocyte concentration (over 10% concentration
against less than 10% concentration) on CD34+ cells viability.   The median
(range) viability of CD34+ cells containing >10% granulocytes was 76.6%
(54.5–93.0%), and that for cells containing <10% granulocyte was 82.1% (59.1–
94.4%), respectively. There was significant difference in the viability of CD34+
cells between the two groups (p=0.02, respectively). Second, we analyzed 81
autologous PBSC transplants after stored at -80°C by using simplified method.
We compared two groups based on the granulocyte concentration (>10% con-
centration against <10% concentration). No significant difference in the days
to leukocyte >1.0x109/L and to platelet >20x109/L in either granulocyte con-
centration was observed. However, the median (range) time to platelet
>50x109/L containing >10% granulocytes was 27.2(12-87), and that for cells
containing <10% granulocyte was 20.3(10-51), respectively.   There was sig-
nificant difference in the day to platelet >50x109/L between the two groups
(p=0.04, respectively).
Summary/Conclusions: Long-term cryopreservation represents a means of
holding a potential therapeutic modality in reserve for use at a future date. In
this study, PBSCs can safely be stored for at least36 months by the simplified
method at -80°C. The loss of the viability of CD34+ cells was greater when the
granulocyte content was over 10% than in cells with less than 10% of granulo-
cytes.   The effect of reduced CD34+ cells viability seems important for engraft-
ment. Difference in the day to platelet >50x109/L between the two groups based
on the granulocyte concentration (>10% concentration against <10% concen-
tration) was observed.  Thus, a lesser granulocyte content could give a more
reliable graft with better quality.   Further research is necessary to observe the
effect of long-term cryopreservation period and granulocyte content on the via-
bility of stored CD34+ cells.
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LYMPHOCYTE RECONSTITUTION AFTER ALOGENIC
TRANSPLANTATION, DOES EARLY RECOVERY HAVE ANY INFLUENCE
IN SURVIVAL RATES?
V. Verdugo1,*, M.A. Correa Alonso1, V. Rubio Sanchez1
1Hematology, Hospital Jerez de la Frontera, El Puerto de Santa María, Spain
Background: Immune reconstitution after AloTPH has significant influence on
the procedure final success. Studies have established that early lymphocyte
recovery can influence survival rates, associated to a reduction in mortality unre-
lated relapse (NMR) and, in some studies, also to a reduction in relapse rate.
Aims: Analyze our patients survival rates in terms of lymphocyte reconstitution
in absolute value on day+30 and+60 post-HSCT. Check if there is any relationship
between the number of transfused CD34+ progenitors and LT3+ and see if that
possible link affects the speed of recovery after transplant t- lymphocyte count.
Methods: Analysis of the lymphoid recovery in a retrospective study of 63
of 71 patients transplanted (ALO, and Haplo Unrelated Donor) by AML and
ALL between 2008- 2015.  (8 died before the day+60). Table 1 shows the
characteristics of the pre-transplanted patients and analyze the influence of
the parameters of the infused product (CD34x106 and LTx108/kg r), type of
transplant, GVHD presentation. treatment and reactivation of CMV on the
recovery of absolute lymphocyte numbers in s+30 and +60 days post trans-
plantation using as cutt off <0.3x103/ml. We have analyzed the ratio of the
number of lymphocytes on day +60 with survival after transplantation. It has
made a statistical - analysis of OS and DFS in relation to the number of lym-
phocytes on day +30 and day +60 with Kaplan Meier compared the results
with long-rank test and subsequent analysis of the variables collected with
Cox Regression.
Results: After analyzing the product infused we observe a relationship
between LT and lymphocyte recovery on day+30 (p: 0097, cor: 0223) and day
+60 (p=0.059, cor: 0257) but not with the CD34+/Kg r. Table 2 shows the patient
characteristics in lymphocyte absolute count in the day +60. We analyzed the
overall survival (OS) and disease - free survival (DFS) and a decrease in OS
with statistical difference was evident in patients with <.300 (p=0.0029) on day
+60 and day+30 (p: 0.05), a decline also in DFS, with no statistically significant
difference (p=0.1). Multivariate analysis to determine which factors could influ-
ence the lymphoid recovery on day +60 and SG, we observed that the type of
unrelated donor, myeloablative conditioning and ATG administration can influ-
ence a delay in this recovery. No differences were observed in the rest of the
variables.
Table 1.
Summary/Conclusions: A delay in lymphocyte recovery is associated with a
decrease in survival rates in our patients. Measures favoring an accelerated
lymphocyte recovery (judicious use of thymoglobulin, adequate donor selection,
and transplantation modality) could affect the post-transplant survival. It appears
that the amount of infused product could play an important role in reconstitution,
so it would be a factor to take into account prior to infusion.
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SUCCESFULL AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER
VELCADE-BASED REFRACTORY MULTIPLE MYELOMA PATIENTS
V. Martínez-Robles1,*, B. Ballina1, S. Cerdá1, N. de las Heras1,
J.A. Rodríguez-García1, F. Escalante1
1Hematología, Complejo Asistencial Universitario de León, LEON, Spain
Background: The optimal induction treatment for Newly Diagnosed Multiple
Myeloma Patients needs combinations with Bortezomib-Based (Bor-Based)
schemes. Primary Refractory patients include patients with progressive disease
or rapid (<60 d) relapse after these optimal induction approach have a very
bad prognosis. Lenalidomide-Dexamethasone (LenDex) were usually the next
step in the treament of these patients, until the recent introduction of triplets
combination LenDex-based. Autologous Stem Cell Transplantation (ASCT)
have proven efficacy in NDMM younger patients that have got at least a partial
response (PR) after the induction therapy. There are few data about toxicity
and response of ASCT in primary refractory patient that can obtain a response
with LenDex rescue treatment.
Aims: Analysis of tolerance, response and overall survival of ASCT-candidates
that are primary refractory to Bor-Based induction treatment.
Methods: Retrospective analysis of our database. From 2010 to Nov-2016,
53 ASCT-Candidates (for 1st or 2nd ASCT procedures) were included. Median
Age for diagnosis was 62 (46-71). Median Age for ASCT procedure was 63
(46-72). 12 of these 53 patients (22.6%) were considered primary refractory
and considered candidates to get Len-Based rescue treatment. 6 of them (50%)
were woman. Characteristics of Disease: IgG kappa (4), IgG-lambda (3), IgA
kappa (3), IgA lambda (1), Light Chain lambda (1). ISS I/II/III): 5/2/5. Induction
treatment: VelDex (4), VTD (6), VCD (2). Median of cycles administered: 6 (2-
8). Best Response to induction treatment: >PR (6), Minimal Response (1), pro-
gressive disease (5) Len-Based (12). Plus CFM in 3 of them to optimize
response. Median number of cycles administered: 6 (3-12). 3 of them didn´t
responde. Of the other 9, 6 of them were considered candidate to intensificate
treatment with high doses chemotherapy supported with an ASCT (2 of 6 to a
2nd ASCT procedure). The other 3 patients are in treatment or in preASCT
evaluation. Characteristics of the after-rescue ASCT-patients. Median age at
ASCT: 62 (49-70). All of them received Melphalan 200 mg/m2 as conditioning
treatment.
Results: Morbidity or mortality (M&M) (0%) of ASCT procedure in refractory
patients is similar to non-refractory patients. After a median follow up of 46
months from diagnosis for all ASCT-candidates group, the refractory patients
get an overall survival of 46.2 months (3-72 m). Any of them have relapsed
yet. 2 of them are in biological relapse without need of treatment.
Summary/Conclusions: Patients refractoriness to induction may receive
ASCT after a rescue treatment LenDex based, as is effective in this group con-
ventionally considered to have a very bad outcome. New combinations (triplet)
with new drugs with LenDex-based treatment may improve the responses rates
and overall survival before and after of ASCT procedure in these group.
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SAFETY AND EFFICACY OF TBF CONDITIONING IN PATIENTS
UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION.A
RETROSPECTIVE SINGLE CENTER EXPERIENCE.
R. Massoud1,*, N. Moukalled1, B. Haffar1, A. Zahreddine1, A. Bazarbachi1,
J. El-Cheikh1
1Internal Medicine, American University of Beirut Medical Center, Beirut,
Lebanon
Background: The optimal intensity of myeloablation with a reduced-toxicity
conditioning (RTC) regimen to decrease relapse rate after allogeneic stem cell
transplant (allo-SCT)without increasing non-relapse mortality (NRM), has not
been well established.
Aims: In this retrospective study at the American University of Beirut medical
center (AUBMC) we aimed to evaluate the outcomes of patients who underwent
allo-SCT with thiotepa, busulfan and fludarabine (TBF) as RTC.
Methods: We included twenty fourconsecutivepatients with hematological
malignancies who received TBF as conditioning forallo-SCTfrom January to
December 2016. All patients and transplant characteristics are listed in Table1.
All patients received the myeloablative conditioning regimen consisting
ofthiotepa(5mg/kg/day)infused  on day -7 and -6, fludarabine(30mg/m2/day)
was infused on  day -5 to day -2; and busulfan(130mg/m2/day) was infused on
day -5 to day-3. All patients received 2.5mg/kg/day intravenousrabbit antithy-
mocyte globulin (ATG) on days -2 and -1. GVHD prophylaxis for patients trans-
planted from haploidentical donors consisted of post-transplant cyclophos-
phamide 50mg/kg/day on day +3 and day +5, cyclosporine started at 3
mg/kg/day on day+6 and readjusted according to level, and  mycophenolate
mofetil 500mgx4/day started on day+6 to +28. Patients transplanted from
matched related donor, received cyclosporine as of day +1.
Results: Twenty three patients(96%) engrafted, with 14 days (range, 10-18)
and 13 days (range, 8-48) as median time for neutrophil and platelet engraft-
ment respectively. One patient who underwent haploidentical donor transplant
with persistent disease for AML (karyotype 45,XY,-7) failed to engraft and died
due to disease progression on day+22.After a median follow up of 10 months
(range, 1-22) post-allo-SCT, the cumulative incidence of GradeII-IV acute
GVHD (aGVHD) was 26%. One patient developed chronic limited GVHD
(cGVHD).All the complication post allo-SCT are listed in table 1. Five patients
(24%) relapsed post allo-SCT at a median of 163 days (range, 55-384), of
which three (13%) died due to disease progression, and two were successfully
salvaged and are in complete remission (CR) with full donor chimerism (FDC)
at last follow up. Two patients developed JC virus progressive multifocal
leukoencephalopathy, one of them made a full recovery and the other died in
CR. The day 100 NRM was 0%. At last follow up 20 patients (83%) are alive in
CR, with negative minimal residual disease and FDC.
Table 1.
Summary/Conclusions: Our results show that This TBF conditioning regimen
appears to be safe,allows high rate of engraftment and low NRM rate among
high-risk patients and can lead to a long-term disease control.
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COMPLETE REMISSION STATUS BEFORE AUTOLOGOUS STEM CELL
TRANSPLANTATION AS PROGNOSTIC FACTOR IN PATIENTS WITH
NON-HODGKIN LYMPHOMA
A. Pinto1,*, A. Roque1,2, M. Gomes1, E. Cortesão,12, A. Espadana1,
A.B. Sarmento1,2, C. Geraldes1,2, M.L. Ribeiro1
1Clinical Hematology Department, Centro Hospitalar e Universitário de Coimbra,
2Faculty of Medicine and CIMAGO, University of Coimbra, Coimbra, Portugal
Background: High dose chemotherapy (HDC) followed by autologous stem
cell transplantation (ASCT) is commonly used for treatment of relapsed or
refractory non-Hodgkin’s lymphoma (NHL), as well as for first-remission con-
solidation in patients with mantle cell lymphoma. Disease status before ASCT
is variable and is unclear whether complete response before ASCT or after
ASCT correlates with better survival.
Aims: To evaluate the prognostic effect of disease status before ASCT - complete
remission (CR) vs partial remission (PR) - in a cohort of patients with NHL.
Methods: Retrospective analysis of patients with NHL treated with HDT and
ASCT between 2007 and 2016 in a single institution. All patients received periph-
eral blood stem cell support after conditioning with BEAM regimen (carmustine
300mg/m2, etoposide 800mg/m2, Ara-c 1600mg/m2and melphalan140 mg/m2).
Response was assessed according to The Lugano Classification. The Kaplan-
Meier method was used to estimate progression free survival (PFS) and overall
survival (OS) and comparison between risk groups was performed by using the
log-rank test. Univariate analysis was performed and significant predictors at the
level of 0.05 were used to adjust a multivariate Cox regression model.
Results: We included 83 NHL patients, mainly males (72.3%) with a median
age at diagnosis of 51 years (18-65). The most prevalent histological subtypes
were diffuse large B cell lymphoma (53.0%), mantle cell lymphoma (36.1%)
and follicular lymphoma (15.7%). The median number of therapeutic lines was
2 (1-5). Patients with diffuse large B cell lymphoma and follicular lymphoma
were mainly treated with R-CHOP/R-CVP (82.5%) at first-line. For those who
did not achieve a CR or relapsed after first-line treatment, (R)-
ESHAP/DHAP/ICE (78.8%) was performed as second-line followed by
ASCT as salvage therapy in order to achieve and consolidate CR. The majority
of patients with mantle cell lymphoma received R-CHOP/R-DHAP (55.0%) fol-
lowed by consolidation with ASCT in first remission. With a median follow-up
time from ASCT of 39.66 months (0.3-117.6), OS at 2 and 5 years was 84.8%
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and 74.5% and PFS was 76.8% and 58.2%, respectively. Before ASCT, 60
patients (72.3%) were in CR and 23 (27.7%) were in PR. After ACST, 4 patients
were not assessed for response due to early death by toxicity. Of the remaining,
70 (88.6%) achieved a CR, 4 (5.1%) a PR and 5 (6.3%) failed to respond.
Patients in CR before ASCT presented significantly longer PFS compared with
those in PR (107.9 vs 44.0 months, p=0.01). Besides that, patients that obtained
CR after ASCT also had longer OS and PFS compared with those in PR (107.9
vs 8.0 and 107.9 vs 7.3 months, p<0.001). However, these patients had signif-
icantly lower PFS compared to patients that continued in CR after ASCT (45.3
vs 107.9 months, p=0.041). Univariate analysis indicated that remission status
pre-ASCT (CR vs PR) is a significant predictor of PFS after ASCT (HR 0.39;
95% CI 0.19-0.82, p=0.013). Multivariate Cox regression model showed that
this factor retains prognostic value after adjustment for age, histological sub-
type, Ann Arbor stage and number of previous lines of treatment.
Summary/Conclusions: Our results highlight the relevance of the obtained
CR after ASCT in the OS. Furthermore, we conclude that patients with NHL
who are in CR before ASCT have a better PFS than those in PR before ASCT.
Additionally, continued CR after ASCT may also be an important prognostic
factor. Our results suggest that the use of more effective induction regimens in
order to improve initial response may be advantageous in terms of clinical ben-
efits post-ASCT.
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MANTLE CELL
LYMPHOMA:SINGLE CENTER EXPERIENCE
S.K. Toprak1,*, E. Atilla1, P. Ataca Atilla1, S. Civriz Bozdag1, M. Kurt Yuksel1,
P. Topcuoglu1, T. Demirer1, O. Arslan1, M. Ozcan1, M. Arat2, O. Ilhan1, H. Akan1,
M. Beksac1, N. Konuk1, A. Uysal3, G. Gurman1
1Ankara University School of Medicine Department of Hematology, Ankara,
2Florence Nightingale Hospital, Istanbul, 3Koru Hospital, Ankara, Turkey
Background: Mantle cell lymphoma accounts for relatively small proportion
(3%>10%) of non-Hodgkin lymphoma. High-dose chemotherapy (HDT) and
autologous-stem cell transplantation (ASCT)  has played a critical role in the
treatment of mantle cell lymphoma. Regardless of that, mantle cell lymphoma
remains largely a relapsing/remitting disease. 
Aims: Our aim is to present our mantle cell lymphoma patients who underwent
ASCT.
Methods: We retrospectively evaluated our 21 mantle cell NHL patients. The
patients were followed after ASCT for relapse
Results: Patients were followed by a median time of 56.9 months (range, 6-
170 months).The median age at diagnosis was 45 (range, 18-69), female to
male ratio:5/16. The stages and MIPI scores at diagnosis were as follows: 5%
stage II, 19% stage III, 76% stage IV; Low MIPI 29%, intermediate MIPI 48%
and high MIPI 23%. First line treatments were R-CHOP for 6 cycles in 6 patients
(29%) and R-CHOP for 3 cycles followed by R-DHAP in 15 patients (71%).  The
median time to ASCT was 20 months (range, 7-48 months). All patients were
in at least partial remission at the time of ASCT. The transplant conditioning
regimen was CVB in 5 patients (24%) and R+/-ICE in 5 patients (24%), R+/-
BEAM in 11 patients (52%). Six patients (29%) achieved complete remission.
Four patients (19%) died within three months of ASCT due to infection. Eleven
patients (52%) was relapsed with a median time of 39 months (range, 4-123
months). Ten patients received BORID (bortezomib, rituximab, dexamethasone)
and 1 patient received lenalidomide as salvage therapy and six of them
achieved complete remission. Three patients underwent allogeneic hematopoi-
etic stem cell transplantation as well as two patients received ibrutinib as fourth
line therapy and followed in remission. The 3 year overall survival was 71%. 
Summary/Conclusions: ASCT is a part of initial treatment strategy in fit
patients with mantle cell lymphoma however%19 patients in our series had
transplant related toxicity. Today, novel agents may present a less intensive
approach for achieving response. 
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ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN WITH
AUTISM
A. Gomes1,*, A. B. Mafra1, A. Zanette1, V. Rocha1
1Hematopoietic Stem Cell Transplantation, Hospital Sirio Libanês, Sao Paulo,
Brazil
Background: Autism Spectrum Disorders (ASD) are severe heterogeneous
neurodevelopmental abnormalities characterized by dysfunctions in social inter-
actions and communication skills, restricted interests, repetitive, and stereotypic
verbal and non-verbal behaviors. The etiology of ASD remains unknown, but
recent studies suggest a possible association with altered immune responses
and ASD. Inflammation in the brain and Central Nervous System has been
reported with microglia activation and increased cytokine production in post-
mortem brain specimens of individuals with ASD. Other studies have estab-
lished a correlation between ASD and family history of autoimmune diseases,
associations with MHC complex haplotypes, and abnormal levels of various
inflammatory cytokines and immunological markers in the blood. The
paracrine, secretome, and immunomodulatory effects of stem cells would
appear to be the likely mechanisms of application for ASD therapeutics.
Aims: Evaluation the benefits of HSCT in patients with ASD.
Methods: We describe two cases of patients with ASD who underwent HSCT
for acute lymphoblastic leukemia (ALL) and whose symptoms were markedly
decreased like an improvement of social interaction, communication, and
behaviors.
Results: The first patient is an 11-year-old girl with ASD who was diagnosis
with Ph-positive ALL in October 2011 (at the end of treatment, BCR-ABL
remained positive). She underwent a matched sibling HSCT in March 2015.
The conditioning regimen was total body irradiation (TBI) and cyclophos-
phamide. During the 20-month follow-up period, we observed improvement in
social interaction, communication, and behaviours. According to The Childhood
Autism Rating Scale – CARS, prior to HSCT, she had a score of 39 (Severe
Symptoms of ASDisorder), and she currently scores 30 (Mild-to-Moderate
Symptoms of ASD). The second case is a 7-year-old boy with ASD, Asperger
Syndrome, who was diagnosis with ALL in September 2012. He presented with
bone marrow and testicular relapse in May 2015 and underwent a matched
unrelated HSCT in November 2015. The conditioning regimen was
Etoposide, ATG and TBI. During the 12-month follow-up period, we observed
improvement in social interaction, communication, and behaviours. According
to CARS, prior to HSCT he had a score of 30 (Mild-to-Moderate Symptoms of
ASD), and he currently scores 24 (Minimal-to-No Symptoms of ASD).
There is no treatment for ASD thus every effort to minimize the symptoms are
valuable. In both cases, social interaction was significantly increased, and the
aggressive behaviors decreased. Clinical cases have reported responses in
autistic children receiving cord blood CD34+ cells.
Summary/Conclusions: Several incurable neurological disorders have shown
benefits with cellular therapy. Thus, autism should be explored as an indication.
Clinical studies are an immediate need to fully explore its potential in autism.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PEDIATRIC MYELODYSPLASTIC SYNDROMES: A SINGLE CENTER
EXPERIENCE FROM TURKEY
D. Atay1,*, F. Erbey1, A. Akcay1, G. Ozturk1
1Pediatric Hematology Oncology Bone Marrow Transplantation Unit, Acibadem
University Medicine Faculty, Istanbul, Turkey
Background: Myelodysplastic syndrome (MDS) in childhood is a rare disorder
and hematopoietic stem cell transplantation (HSCT) is the only known curative
treatment option. However, there exist few reports regarding the outcome of
transplantation for children with various types of MDS.
Aims: We analyzed the outcome of pediatric patients who underwent HSCT in
our center.
Methods: We reviewed retrospectively 14 pediatric MDS patients who received
HSCT at a single center. Median age at time of HSCT of the patients was 4.3
years and disease duration from diagnosis to transplantation ranged from 3 to
36 months with a median of 10 months. Five patients had primary and one had
secondary MDS. Four patients had juvenile myelomonocytic leukemia (JMML)
and 4 patients had myelodysplastic related acute myeloid leukemia (MDR-
AML).  Diagnostic cytogenetics included monosomy 7 (n=2), trisomy 8 (n=3),
KRAS (n=1) or normal/other (n=8). Patients received a median of 6.8x106
CD34+cells/kg. Eight patients received a bone marrow, 5 had peripheral blood
graft and one an unrelated cord blood (UCB) transplant; five patients were
transplanted from a matched sibling donor (MSD), 5 from a matched unrelated
donor (MUD) and 4 from haploidentical donor. Conditioning regimen consisted
of busulfan/cyclophosphamide in MSD/MUD patients. The patients transplanted
from MUD and UCB also received antithymocyte globulin (ATG) for 3–5 days
pretransplantation. Haploidentical transplantation was performed with RIC reg-
imen and TCRαβ /CD3 depletion.
Results: Graft failure occurred in three patients with JMML (n=1), secondary
MDS (n=1) and MDR-AML (n=1).  Except one, all of the JMML patients relapsed
at a median 83.5 days post-transplant and two of them died. One patient with
MDR-AML underwent second transplantation from another MUD one year after
first transplant and died from GVHD. Ten patients are alive with a median fol-
low-up of 19.5 months (range 3-61). All patients with primer MDS are alive and
well. Four patients died from transplant-related toxicity (n=2) and relapse (n=2).
For the entire group, estimated five-year relapse-free survival (RFS), event-
free survival (EFS) and overall survival (OS) were 78.6%, 64.3% and 70.7%,
respectively.
Summary/Conclusions: These data demonstrate that especially children
with primer MDS may achieve encouraging OS and RFS following HSCT.
Relapse remains the main cause of treatment failure in children with JMML
given HSCT. All children with MDS should be referred for allogeneic HSCT
soon after diagnosis.
haematologica | 2017; 102(s2) | 865
Madrid, Spain, June 22 – 25, 2017
Thalassemias
PB2188
RELATIONSHIP BETWEEN URIC ACID LEVELS AND CARDIAC FINDINGS
IN A LARGE COHORT OF Β-THALASSEMIA MAJOR: GENDER-RELATED
DIFFERENCES 
A. Meloni1,*, C. Vassalle1, L. Pistoia1, T. Grippo2, M. G. Bisconte3, G. Palazzi4,
M. P. Smacchia5, N. Dello Iacono6, R. Ndreu1, A. Olivi1, V. Positano1, A. Pepe1
1Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2Azienda
Ospedaliera Regionale San Carlo di Potenza, Potenza, 3Azienda Ospedaliera
Cosenza - Presidio Ospedaliero “Annunziata”, Cosenza, 4Modena, Policlinico
di Modena, 5Policlinico Umberto 1, Roma, 6Ospedale Casa Sollievo della Sof-
ferenza IRCCS, San Giovanni Rotondo, Italy
Background: Iron overload, secondary to recurrent transfusions and ineffective
erythropoiesis, induces  oxidative stress in thalassemia (TM). Uric acid (UA),
a major blood antioxidant, may act either as an antioxidant or pro-oxidant.
Aims: Our aim was to evaluate the role of UA in TM and its association with
cardiac iron, dysfunction, fibrosis, and complications,  and cardiovascular risk
factors in a large cohort of TM patients of both sexes.
Methods: 397 TM patients (200 men, mean age 32±8 years) enrolled in the
Myocardial Iron Overload in Thalassemia (MIOT) Network were considered.
Myocardial and hepatic iron burdens were quantified by the T2* technique.
Atrial dimensions and biventricular function were quantified by cine images.
Late gadolinium enhancement (LGE) images were acquired to detect myocar-
dial fibrosis.
Results: As expected, UA resulted significantly higher in male respect to female
TM patients (4.74.7±1.3 vs 4.0±1.0  mg/dL; P<0.0001).
UA levels directly correlated with BMI (R=0.25, P=0.0003), and triglycerides (TG)
(R=0.20, P=0.005) in female patients. Moreover, female which presented myocar-
dial fibrosis showed higher levels of UA (4.4±1.3 vs 3.9±0.9 mg/dL, P=0.03). The
multiple regression model identified BMI (T-value 3.7, P=0.0003), TG (2.1,
P=0.04) and cardiac fibrosis (2.5, P=0.01) as independent correlates of UA level
in women. In men, UA levels were positively correlated with BMI (R=0.17,
P=0.02), TG (R=0.38, P<0.001), and inversely with HDL (R=-0.20, P=0.006) and
glycemia (R=-0.15, P=0.04). Interestingly, UA was also directly correlated with
global heart T2* values (R=0.3, P<0.001). After multivariate analysis adjustment,
global heart T2* (T-value 2.6, P=0.01), TG (4.7, P<0.001), and BMI (1.9, P=0.05)
remained as independent determinants  of UA in male TM patients.
Summary/Conclusions: UA levels correlates with factors related to metabolic
dysfunction in TM patients of both sex, while a more strong correlation between
UA and cardiac fibrosis was observed only in females, and a direct relationship
between UA and T2* global heart only in males. The differences in male and
female TM patients imply some gender-specific mechanisms,  providing bio-
chemical basis for the epidemiological differences between sexes.
PB2189
CHARACTERIZATION OF HEMORHEOLOGICAL ALTERATIONS IN
THALASSEMIA BY A CHEMOMETRIC APPROACH 
P. Caprari1,*, C. Bozzi1, S. Materazzi2, R. Risoluti2
1Haematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità,
2Department of Chemistry, “Sapienza” - University of Rome, Rome, Italy
Background: Several studies reported a high incidence of thromboembolic
events in β - thalassemia, more frequent in thalassemia intermedia than in reg-
ularly transfused thalassemia major. In these patients a chronic hypercoagu-
lable state is evident and the red blood cells exhibit impaired flow properties
that facilitate micro-circulatory disorders.
Aims: Since many abnormalities described in thalassemia may determine rhe-
ological alterations, in this study we have investigated the viscoelastic profiles
of red blood cells from patients with β-thalassemia. The hemorheological pro-
files of blood samples obtained from healthy subjects and  thalassemic patients
were studied by chemometric tools in order to develop a model of prediction of
circulatory disorders according to the viscoelastic behaviour.
Methods: Blood samples from 45 β-thalassemia patients and 48 healthy indi-
viduals, after informed consent, were analyzed. Hemorheologic profiles were
investigated at 37 °C at native and normalized hematocrit. The evaluation of
RBCs viscoelastic properties was performed by determining storage modulus
G’,  loss modulus G” and complex modulus G* in oscillation mode as a function
of angular frequency ω in the range 0.1-10 Hz. Multivariate statistical analysis
was performed on the resulting  G’, G’’ and G* curves and Principal Compo-
nents Analysis was used as display method.
Results: The hemorheological profiles of patients affected by ß-thalassemia
and healthy subjects showed significant differences and the chemometric
analysis demonstrated a clearly identification of anemic status according to
viscoelastic profile. Increased G’, G’’ and G* modula were observed  in tha-
lassemic patients demonstrating a reduction in deformability and impaired flow
properties.
Summary/Conclusions: In this study a characterization of  haemorheological
alterations in thalassemia patients has been performed by a chemometric
approach. The achieved results permit to consider the viscoelastic properties
as promising predictive new indices of microvascular damage in β-thalassemia
and to explain the increased incidence of vascular complications in these dis-
orders.
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HEPATITIS E IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS,
IN GREECE. A SINGLE CENTER EXPERIENCE
P. Klonizakis1,*, G. Gioula1, A. Melidou1, M. Exindari1, G. Karavalakis2,
C. Apostolou1, E. Gigi1, E. Vetsiou1, A. Kotsiafti1, E. Vlachaki1
1Aristotle University of Thessaloniki, 2Papanikolaou General Hospital, Thes-
saloniki, Greece
Background: Hepatitis E (HE) is nowadays considered an emerging disease
that may be a threat in both developing and industrialized countries all over
the world. The causal agent is an RNA virus, transmitted mainly through the
fecal-oral route. Nevertheless, there are additional patterns of transmission,
including the transfusion of infected blood products. The risk of developing
chronic HE infection following transfusion of infected blood–derived products
is higher among immune-compromised individuals. Transfusion-dependent
Thalassemia patients consist a distinct category of immune-compromised
patients, but the data regarding transfusion-transmitted HE infection are limited
for this group of patients. Accordingly, there is, as yet, no consensus on whether
blood products should be systematically screened for markers of the HE virus
Aims: The aim of this study was to assess the status of Hepatitis E infection
in 96 transfusion-dependent Thalassemia patients, followed up in a single Tha-
lassemia Unit, in Northern Greece. 
Methods: Over a one-month period, we retrospectively evaluated 96 consec-
utive patients, from a registry of 150 adult TDT patients followed at a single
Thalassemia Unit, in Northern Greece. The mean age of the study population
was 36±10 years, 42% were male and 58% female. According to the patients’
blood transfusion history, the participants had been transfused with 47.376
blood units during the last 14 years, whereas during the last year the same
patient population had been transfused with 3.384 blood units. The detection
of HEV RNA was performed by Real-Time RT-PCR method (hepatitise2@ceer-
amTools kit, Applied Biosystems ABI), according to the instructions. The detec-
tion of HEV was based on the identification of the “a” region of ORF2. The
detection of IgG anti-HEV antibodies and their titration were performed in 92/96
samples using a commercially available enzyme-linked immunosorbent assay
kit (CUSABIO BIOTECH kit), according to the manufacturer’s instructions. The
cut-off value was calculated according to the manufacturer’s instructions.
Results: HE RNA was not detected in any of the 96 samples, whereas the IgG
anti-HEV antibodies were also negative in all measured samples. The negative
HEV RNA, in all the participants of this study, indicates the absence of an
active HE infection, whereas the negative IgG anti-HEV antibody titre implicates
that there was no history of previous HE infection. According to the literature,
IgG antibodies may be detectable following an HE infection for a time period
that varies from one year to 14 years. 
Summary/Conclusions: This is the first assessment of the HE virus sero-
prevalence in the population of TDT patients in Greece, over the last two
decades. Our results suggest that TDT patients are not at a high risk for HE
infection. Further studies are necessary to evaluate the clinical importance of
the transfusion-transmitted HE infection in TDT patients and clarify whether





A PRELIMINARY STUDY OF THE CARDIAC EFFECT OF PPAR GAMMA IN
BETA THALASSEMIA MAJOR WITH IRON OVERLOAD
P.M. Eldefrawy1,*, P.N.A. Hamed1, D.D. Elnileey2, D.O. Ghallab1,
M.A. Khalifa1
1Hematology, 2Clinical Pathology, Alexandria Faculty of Medicine, Alexandria,
Egypt
Background: Peroxisome proliferator–activated receptor (PPAR)-gamma is a
transcription factor belonging to the same family of nuclear receptors as steroid
and thyroid hormone receptors. PPAR-gamma is a master transcriptional reg-
ulator involved in the expression of probably hundreds of genes. One of PPAR
gamma gene polymorphisms is Pro12Ala which is present in at least 80% of
humans. Pro12Ala polymorphism may reduce the risk of cardiovascular com-
plications. Consistently, Ala12 allele carriers were found to have lower carotid
intima- media thickness and reduced risk of myocardial infarction in type 2 dia-
betes patients. Pharmacological agonists of PPAR-gamma leads to a molecular
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switch providing alleviating myocardial injury through modulating oxidative,
inflammatory and apoptotic signaling pathway.
Aims: Our aim was to investigate the frequency of Pro12Ala polymorphism
(substitution of proline to alanine at codon 12 in exon B of PPARγ gene in
Egyptian β-thalassemia major (β-TM) with iron overload. Untreated transfusion
induced iron overload in thalassemia major is fatal, usually as a result of cardiac
complications.
Methods: 30 β-TM patients and 10 healthy volunteer matched for age, sex
and body weight were involved in this study. β-TM patients followed up was in
the “outpatient clinic of Hematology unit, at Alexandria main university hospital”.
Seventeen were males and thirteen were females with ages ranging from 16 –
39 years (21.53±5.44). Blood samples from β-TM patients and healthy controls
were analyzed for PPARγ gene polymorphism using polymerase chain reac-
tion-restriction fragment length polymorphism.
Results: The mean value of serum ferritin in β-TM was 4976.30±2216.41 ng/L
which was significantly higher than that in controls (102.60±12.69 ng/L). The
mean value of ejection fraction were 62.23±3.46% and 63.80±4.34 in cases
and controls respectively. Pro12Ala polymorphism was present in 2 out of 30
(6.67%) β-TM patients with osteoporosis. One patient had heterozygous 12Ala
polymorphism and the other had homozygous 12Ala polymorphism. Both had
normal body mass index, lipid profile, ejection fraction and elevated serum fer-
ritin (4923 ng/l in heterozygous patient and 4886 ng/l in homozygous patient).
Ejection fraction was 70% in heterozygous patient and 68% in homozygous
patient. Only one male control (10%) has homozygous 12Ala polymorphism
(Table 1). 
Table 1.
Summary/Conclusions: This study suggests that Pro12Ala polymorphism may
have a cardioprotective effect in Egyptian thalassemic patients since we find the
highest value of ejection fraction among the two positive cases. Further studies
on a larger population of patients are still needed to confirm this finding.
PB2193
THALASSEMIA MAJOR AND INTERMEDIA IN PATIENTS OLDER THAN
THIRTY-FIVE YEARS - FROM A FATAL TO A CHRONIC DISEASE
O. Pasvolsky1,*, L. Shargian Alon1, P. Raanani1
1Beilinson Hospital, Petach Tikva, Israel
Background: During the past four decades beta thalassemia major (TM) and
beta thalassemia intermedia (TI) have transformed from a universally fatal dis-
ease at a young age, into a chronic disease, with a constantly increasing life
expectancy. This is attributed, amongst others, to the use of improved chelation
therapy. Since prolongation of life expectancy has occurred only in recent years,
there is little data regarding the older population with TM and TI.
Aims: We aimed to characterize disease and patients’ characteristics in patients
above 35 years of age in an adult thalassemia center in Israel.
Methods: We conducted a retrospective analysis of 14 adult patients over the
age of 35 years with TM (N=10) and TI (N=4) treated in a single center, spe-
cializing in the care of adult thalassemia patients. We used descriptive statistics
to describe characteristics of disease and patients and the Mann-Whiteny test
to compare between patients with TI and patients with TM.
Results: Between 2006 and 2016, 14 adult patients older than 35 years with
TM (n=10) & TI (n=4) were followed and treated in our center. Median patients’
age was 37 (range, 35-51) years, with 66% males and 50% of Arab ethnicity.
Most of the patients had at least high school education (85%), and 78% were
employed. Thirteen patients (all TM patients and 3 out of the 4 TI patients)
were treated regularly with blood transfusions. All patients received chelation
treatment. Median hemoglobin (Hb) levels and mean corpuscular volume (MCV)
levels were lower in patients with TI compared to TM (8.1 vs 10 g/dl, p=.002
and 72.4 vs 84 fl, p=.004, respectively). Median LDH levels and indirect bilirubin
levels were higher in patients with TI compared to TM (603 vs 330 u/L, p=.004
and 2.02 vs 1.1 mg/dl, p=.06, respectively) indicating increased hemolysis. All
patients underwent splenectomy and had secondary thrombocytosis. All but
two patients were treated with at least two different chelation modalities, either
as single agent, including subcutaneous (SC) or intravenous (IV) deferioxamine
(DFO), deferiprone (DFP), or deferasirox (DFX), or as various combination
therapy options. The median number of chelation treatment lines was 3. All
patients treated with chelation suffered from at least one adverse event, neces-
sitating temporary discontinuation and usually substitution of treatment. The
median number of adverse events was 1.5 per patient. Nine patients (64.2%)
had good compliance with current chelation therapy. Four patients with acute
heart failure secondary to cardiac iron overload, and all four improved with
intensified chelation treatment. Four TM patients (40%) were hypothyroid, half
of them requiring thyroid hormone replacement therapy. All TM patients had
hypogonadism. All females had amenorrhea and were treated with hormone
replacement therapy, and none of them tried to conceive. Six of the seven male
TM patients were treated with monthly testosterone injections, and three of
them fathered children. All TM patients had osteoporosis, and three TI patients
(75%) had metabolic bone disease. Figure 1 shows the relative rates of symp-
tomatic cardiac iron overload and endocrine dysfunction in the cohort. Three
patients (21.4%) had significant liver overload according to liver T2* MRI, neces-
sitating chelation treatment intensification. None of the patients in our cohort
underwent allogeneic hematopoietic stem cell transplantation and none devel-
oped secondary malignancy during follow-up.
Figure 1.
Summary/Conclusions: Advances in the treatment of thalassemia patients
have enabled the majority of these patients prolonged survival into adulthood.
However, this has brought a new set of challenges for both patients and health-
care. This study delineates the challenges faced while treating adult patients
with TI and TM in the new era.
PB2194
EVALUATION OF LIVER IRON CONCENTRATIONS IN CHILDREN WITH
BETA THALASSEMIA INFECTED WITH HEPATITIS C VIRUS BEFORE AND
AFTER SPIRULINA THERAPY BY MAGNETIC RESONANCE IMAGING
M. El-Shanshory1,*, M. Awad1, R. El-Shafey2, A. Alsharkawy3
1Pediatrics, 2Radiology, Faculty of Medicine, Tanta University, 3Pediatrics, Min-
istry of Health, Tanta, Egypt
Background: Magnetic resonance imaging (MRI) assessment of liver iron con-
centration (LIC) is necessary for quantitative staging of iron overload in children
with β-Thalassemia. There is no enough evidence about the effect of spirulina
therapy on LIC.
Aims: To assess LIC by MRI in multitransfused β-Thalassemic children infected
with HCV before and after Spirulina Therapy.
Methods: Thirty multi-transfused β-thalassemic children infected with HCV,
were subjected to clinical evaluation, appropriate laboratory investigations and
assessment of LIC by MRI. They were classified according to LIC into mild
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(group 1) and moderate to severe group (group 2). In addition to standard
packed red cell transfusion, Spirulina therapy was given orally for 3 months,
after which re-evaluation of these children was performed by repeating the
same investigations.
Results: There was significant increase in LIC associated with significant
changes in other MRI parameters (significant decrease in T2* and significant
increase in R2*) in patients with β-Thalassemia of moderate to severe group as
compared to those of the mild group before treatment. The mean values of serum
ferritin (SF) was statistically insignificantly higher among patients of mild group.
There was no significant correlation between different MRI parameters and SF
level. There was negative correlations between LIC and T2* and positive corre-
lation between LIC and R2*. There was significant decrease in values of LIC
accompanied with significant improvements in SF after spirulina therapy as com-
pared to their pretreatment values in patients of the moderate to severe group.
Figure 1.
Summary/Conclusions: Spirulina therapy may have favorable effects on low-
ering the values of LIC in children with β-Thalassemia infected with HCV.
PB2195
COMBINATION OF DEFERASIROX AND DEFEROXAMINE -
A SUCCESSFUL CHELATION THERAPY IN B-THALASSEMIA MAJOR
PATIENTS
F. Petropoulou1,*, K. Ventiadi1, G. Leveta1
1Thalassaemia Unit, General Hospital of Athens “G.Gennimatas”, Athens,
Greece
Background: Frequent transfusions required for β- thalassemia major patients
cause iron overload. Without the appropriate chelation therapy, iron toxicity
can cause significant heart, liver and endocrine morbidity.
Aims: In this case series we estimated the safety and efficacy of iron chelation
with the combination of deferasirox (DFX) and deferoxamine (DFO) in transfu-
sion dependent thalassemia (TDT) patients attending the Thalassemia Unit in
a tertiary hospital in Athens, Greece.
Methods: 10 TDT patients were treated with a combination chelation therapy
of DFX (30 ±10mg/kg/d) and DFO (44±12mg/kg/d for 2-6 days/wk in 12hr or
24hr infusion rates). Reasons for starting this combination treatment included:
1) treatment with one chelating agent did not succeed in decreasing heart and
liver iron, 2) agranulocytosis or severe neutropenia due to deferiprone (DFP)
treatment and 3) adverse events recorded with increased doses of one of the
chelating agents. The efficacy of the treatment was estimated through MRI
measurements of heart and liver iron (T2*Heart, and LIC) in combination with
serum ferritin levels. Liver enzymes (ALT, AST) and serum creatinine were
used to monitor safety of the treatment.
Results: Five of the 10 patients had significant liver hemosiderosis  (LIC >15
mg Fe/gr d.w.) and 3 had heart iron overload, of which one significant (T2* 1.9
msec) (Table 1).
Table 1.
The combination treatment was well tolerated without adverse events or effects
on liver and kidney function.
Summary/Conclusions: The combination chelation with DFX/DFO can
decrease iron overload and represents a safe and effective option when
monotherapy is not effective or not well tolerated.
PB2196
EVALUATION OF THREE AUTOMATIC DEVICES FOR
HEMOGLOBINOPATHY DIAGNOSTICS IN MULTI-ETHNIC POPULATIONS
C. Harteveld1,*, Y. Daniel2, G. Bakker-Verweij1, G. Ivaldi3
1Clinical Genetics, Leiden University Medical Centre, Leiden, Netherlands,
2Special Haematology, Guy’s Hospital, London, United Kingdom, 3Laboratorio
di Genetica Umana, Ospedale Galliera, Genoa, Italy
Background: We have tested three different dedicated haemoglobin separa-
tion devices for their capacity of performing the diagnostics of hemoglo-
binopathies. These involve the Variant II TM HPLC (BioRad),  the Capillarys2
capillary electrophoresis (Sebia)  and the most recently introduced HPLC, Pre-
mier Hb9210TM High Resolution HPLC  of Trinity Biotech (Menarini).
Aims: As the latter device is new to the market a multisite precision study was
performed testing the reproducibility of the system across three test sites (Lei-
den, Genoa and London) using the same set of samples for several following
days. The results between these three sites were compared and evaluated.
Moreover we have tested the capacity to detect the most common structural
haemoglobin variants, such as HbS, HbC, HbD, HbE and less common Hb
variants important to be diagnosed in multi-ethnic populations found in the
U.K., The Netherlands and Northern Italy as well as elevated HbA2 , as indicator
for beta-thalassemia carriers.
Methods: tHb variant separation using he Variant II TM HPLC (BioRad),  the
Capillarys2 capillary electrophoresis (Sebia) and the most recently introduced
HPLC, Premier Hb9210TM High Resolution HPLC of Trinity Biotech (Menarini).
Molecular analysis to verify the hemoglobin variants found.
Results: We present the data of the comparison studies using the replicates
of the three different sites for the Premier Hb9210TM and of 100 normal samples
and 217 patient samples for a variety of beta-thalassemia trait and haemoglobin
(Hb) variants, including the molecular data of the beta-thalassemia mutations
and Hb variants.
Summary/Conclusions: All three apparatuses identified the common Hb vari-
ants and beta-thalassemia trait in carriers, homo- , hetero- and compound het-
erozygotes with the expected sensitivity and specificity. The Premier Hb9210TM
High Resolution HPLC  of Trinity Biotech shows comparible separation and
quantitation on the three different sites using the same samples and is suitable
for the analysis of samples suspected of having hemoglobinopathy and the
diagnosis of beta-thalassemia trait or Hb variants.
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RED BLOOD CELL EXTENDED PARAMETERS IN
HAEMOGLOBINOPATHIES
M. Stamou1, E. Petridou1, A. Kotanidou1, A. Agorasti1,*
1Laboratory Haematology, General Hospital of Xanthi, Xanthi, Greece
Background: Sysmex® XE-5000 analyzer incorporates new research Red
Blood Cell (RBC) parameters, derived from flow fluorescence cytometry tech-
nology, including%HYPO-He, which indicates the percentage of RBC with
haemoglobin (Hb) content <17 pg, and%MicroR which indicates the percentage
of RBC with mean cell volume <60 fL.
Aims: The aim of this study was to establish the reference range of our Labo-
ratory for the parameters%HYPO-He &%MicroR, to investigate their values in
haemoglobinopathies and their correlation, if any, with Hb A2 levels in het-
erozygous β-thalassaemia.
Methods: Reference ranges were obtained from 175 healthy adult subjects
(27 men, median age of 34 years & 148 women, median age of 30 years);
control group (group A). 89 haemoglobinopathie heterozygotes (32 men, medi-
an age of 29 years & 57 women, median age of 30 years) were included in the
study and classified into three groups; group B: β-thalassaemia heterozygotes,
N=46, group C: α-thalassaemia heterozygotes, N=21 and group D: Hb O-Arab
heterozygotes, N=22. We retrospectively recorded the results of full blood count
analysis on Sysmex® XE-5000 analyzer including%HYPO-He &%MicroR, of
Hb pattern analysis (TOSOH®, G7) and ferritin levels (Roche®, cobas e411).
All subjects included in the study presented ferritin levels within the normal
range for age and gender. Statistical analysis: one-way ANOVA (Tukey post-
hoc), Mann-Whitney, Pearson’s correlation tests were applied. Reference
ranges were calculated as the mean±2SD of the distribution. P value <0.05
was considered to be statistically significant. Data refer as median (percentiles).
Results: The reference ranges of our Laboratory for the parameters%HYPO-
He &%MicroR are 0.0 – 0.6% & 0.2 – 2.9%, respectively, and they are inde-
pendent of gender and age (P=0.715, P=0.168 & P=0.073, P=0.843). There
was a statistically significant difference between the groups as determined by
one-way ANOVA for both parameters (all P <0.0001). Heterozygous β-thalas-
saemia presents statistically significantly higher%HYPO-He values [11.6 (4.2-
27.6)] as compared to groups A [0.3 (0.2-0.3)], C [1.9 (0.6-4.6)], D [0.6 (0.4-
0.8)] (all P <0.0001), while there was no statistically significant difference
of%HYPO-He values between heterozygous Hb O-Arab and groups A and C
(P=0.965 & P=0.134, respectively) based on Tukey post hoc test. Heterozygous
β-thalassaemia presents statistically significantly higher%MicroR values [41.5
(22.9-58.7)] as compared to groups A [1.5 (1.1-2.0)], C [10.8 (7.9-20.5)] and D
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[6.1 (4.2-9.0)] (all P <0.0001). Both parameters%HYPO-He &%MicroR are cor-
related positively in a statistically significant degree with Hb A2 levels in het-
erozygous β-thalassaemia (r=0.567, P <0.0001, y=0.050x+5.317 & r=0.680, P
<0.0001, y=0.042x+4.371, respectively).
Summary/Conclusions: β-thalassaemia heterozygotes present higher values
of%HYPO-He &%MicroR compared to α-thalassaemia and Hb O-Arab het-
erozygotes.%HYPO-He &%MicroR are possibly useful parameters for evalu-
ating the relative severity of different genotypes in heterozygous β-thalassaemia
because of the statistically significant positive correlation with Hb A2 levels. 
PB2198
PERFORMANCE OF THE ΑLPHA-GLOBIN STRIPASSAY® AND MLPA®
FOR THE DIAGNOSIS OF ΑLPHA-THALASSAEMIA 
J. Oosterbos1, H. Claerhout2,*, C. L. Harteveld3, E. Lierman4, D. Kieffer2,5
1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven,
2Department of Laboratory Medicine, University Hospitals Leuven, Leuven,
3Department of Clinical Genetics, Leiden University Medical Center, Leiden,
4Center for Human genetics, University Hospitals Leuven, 5Department of
Microbiology and Immunology, KU Leuven, Leuven, Belgium
Background: Diagnosing α-thalassaemia requires second line diagnostics involv-
ing DNA analysis. Multiplex ligation probe amplification® (MLPA®) is a molecular
technique introduced as a diagnostic tool for α-thalassaemia. This semi-quanti-
tative technique determines the relative copy number of up to 60 DNA sequences
and is able to detect deletions and duplications in a DNA sample. A novel com-
mercial tool, the α-Globin StripAssay®, aims to detect the most common α-tha-
lassaemia deletions and point mutations. The test involves three steps: DNA iso-
lation, PCR reaction and a hybridization step to test strip containing allele-specific
oligonucleotide probes immobilised as an array of parallel lines.
Aims: Our objective was to evaluate the α-Globin StripAssay® as a useful
alternative for MLPA® in second line α-thalassaemia diagnostics.
Methods: Eight samples, including 7 known deletions (_ _SEA, _ _THAI, _
_MED, homozygous and heterozygous - α3.7, heterozygous - α4.2, (α)20.5) and 1
mutation (Hb Constant Spring) were analysed using multiplex Gap-PCR (dele-
tions) and Sanger sequencing (point mutation) at the Leiden University Medical
Center. These samples were anonymised and analysed in duplicate by MLPA®
and α-Globin StripAssay® at our center. A comparison of diagnostic performance,
interpretation, turnaround time (TAT) and costs (reagent and labour) was done.
Results: There are no significant differences between the MLPA® and the α-
Globin StripAssay® results and each identification corresponded to the result
of the reference lab in Leiden. MLPA® however provided additional information
about underlying polymorphisms. Interpretation of the α-Globin StripAssay®
was easier and faster compared to MLPA®. The α-Globin StripAssay® proved
to have a shorter TAT, but on the other hand, the costs for MLPA® were signif-
icantly less.
Summary/Conclusions: Despite its straightforward interpretation, shorter TAT
and the ability of detecting both (known) deletions and point mutations, the sig-
nificantly higher costs of the α-Globin StripAssay® may hinder it’s routine use.
Specialised laboratories are usually acquainted with the MLPA technique and
in these settings the ability to detect both known and unknown deletions is a
plus for research purposes.
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CARDIAC AND HEPATIC IRON ASSESSMENT OF YOUNG ADULTS WITH
TRANSFUSION DEPENDENT THALASSEMIA: TIME TO THINK BEYOND
FERRITIN
K. Mishra1,*, S. Kashyap1, A. Khadwal1, A. Jandial2, D. Lad1, G. Prakash1,
R. Das3, N. Varma3, P. Malhotra1, S. Varma1
1internal medicine , 2Pgimer, Chandigarh, Chandigarh, India, 3haematology,
Pgimer, Chandigarh, Chandigarh, India
Background: With the improvement in availability of blood transfusion practices
and progress in chelation therapy, there is an increasing population of tha-
lassemic patients surviving into adulthood in developing countries. However,
there is scarcity of clinical, biochemical and radiological data showing cardiac
and hepatic iron assessment in these chronically transfused individuals. 
Aims: 1. Cardiac and hepatic iron assessment in young adults with TDT. 2.
Compare the ferritin level with T2* MRI finding.
Methods: in this prospective observational study we analysed demographic
details, clinical features and cardiac and liver iron assessment of young adults
with (TDT) at recently established adult thalassemia clinic at PGIMER, Chandi-
garh. For cardiac and liver iron assessment serum ferritin, ECG, 2D Echo,
MUGA scan, Liver function test, Fibroscan (if indicated) and T2* MRI of Liver
and heart was done. All patients who were diagnosed in childhood and referred
to adult haematology unit at age ≥18 years and had received more than 20
blood transfusions were included in the study.
Results: A total of 53 patients (n=53) were analysed. The mean age was 23
yrs. Majority of patients (56%) were male. The average age at diagnosis and
at first transfusion was 7 months & 11months respectively. The average years
of PRBC transfusion was 23 yrs. The average number of transfusion in last
two years prior to registration was 24 PRBC units. The mean age at start of
chelation was 10.0 yrs. Mean duration of chelation was 14 yrs. Majority (88%)
had growth failure with mean height of 159.6 cm  & mean weight of 51.5 kg
respectively. Splenomegaly was present in 47% and hepatomegaly in
25%patients. Twenty-eight percent have undergone splenectomy at an average
age of 12.6 yrs. The mean of highest ferritin levels was 6131 ng/mL and the
mean ferritin at the time of registration was 2919 ng/mL. LFT were deranged
in 25% of patients. Evidence of cardiac dysfunction (ECG/MUGA) was present
in 22% of patients. Iron overload in liver and heart as measured with T2* MRI
was present in 56% & 28% respectively (Figure 1).
Figure 1.
Summary/Conclusions: majority of patients registered in our clinic are living
a healthy life. All of them were on iron chelation therapy and the dose was
being adjusted as per the serum ferritin level. Amongst asymptomatic individuals
with no evidence of cardiac or hepatic dysfunction, evaluation by T2*MRI picked
up evidence of hepatic and cardiac iron overload.  Therefore, its prudent to
monitor patients with T2*MRI and accordingly escalate or de-escalate chelation
therapy. 
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THALASSEMIA IN MADRID: A PICTURE OF THE CURRENT SITUATION
E.J. Bardón-Cancho1,*, M. García-Morín1, Y. Aguilar-de la Red1,
B. Ponce-Salas1, G. Perez-Rus2, C. Pascual2, E. Dulín3, C. Beléndez1,
E. Cela1
1Section of Pediatric Hematology and Oncology, Department of Pediatrics,
2Department of Hematology, 3Newborn Screening Laboratory (Community of
Madrid), Hospital General Universitario Gregorio Marañón - Facultad de Med-
icina- Universidad Complutense de Madrid, Madrid, Spain
Background: Diagnosis of thalassemia (Thal) in a Mediterranean country as
Spain, could be thought as endemic, but few data are available so far. Moreover,
attention to hemoglobinopathies is focused on sickle cell disease.
Aims: The aim of our study was to find out the prevalence of Thal and clinical
significant hemoglobinopathies other than sickle cell diseases in a referral cen-
ter for newborn sickle screening, in addition to the demographic characteristics
of these patients. The secondary objectives were to obtain the frequency of
specific treatments or prophylaxis accomplished by these patients, and the rea-
sons for loss to follow-up.
Methods: The study is observational, unicentric, descriptive and retrospective,
carried out in December 2016 in a tertiary hospital in the Community of Madrid,
Spain. All patients diagnosed with Thal and other not sickle-hemoglobinopathies
who had attended at least once to the hematology clinic were included. Demo-
graphic characteristics (date of birth, gender, country of birth) and clinical ones
(genotype or Thal type, therapy and update in follow up, like alive, deceased
or lost patient) were collected. Written informed consent was signed by patients
or legal guardians in accordance with the Declaration of Helsinki. The study
was approved by the hospital Ethical Committee. Statistical analyses were per-
formed using SPSS version 18.0. Quantitative variables were reported as medi-
an or mean value and range, while categorical variables were expressed as
absolute value and percentage. 
Results: The total number of patients included was 31 (9 Thalassemia Major
(TM), 1 Thalassemia Intermedia (TI), 21 other not sickle-hemoglobinopathies).
The center follows 209 sickle patients, which leads to a ratio sickle/not sickle
of 6.74 (Table 1). Ratio boy/girl is 1.21 for all group. Most of patients were born
in Spain (90.32%), although 6.45% were born in Asia and one patient was born
in Rumania. Considering the parents, 32% were born in Europe, 29% from
Africa, 25% from Asia, and 12% from America. 92% of those patients born in
Spain were detected in their first days of life due to universal screening detection
implemented in Madrid since 2003. Median age at first diagnosis was 0.70
years (0-16.35). Median age at the end of inclusion was 9.39 years (range 1.90
to 35.44). 35% of them had molecular genotyping for diagnostic confirmation.
Two out of 10 patients with Thal had HLA identical siblings. Quelation treatment
was added to standard treatment to all the patients with Thal: 7 received
deferasirox, 3 were treated with deferoxamine and 2 with deferiprone; 2 of the
patients required double quelation. Two out of 10 patients with Thal underwent
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splenectomy. None of these patients had sepsis or meningitis. Three Thal
patients underwent progenitor stem cell transplantations and they remain on
complete chimerism in the present moment. Patients lost to follow-up summed
up 14: 3 emigrated to other countries, 2 continue the monitor of their diseases
in other centers or in adults units and 7 for unknown reasons. There was one
death (3.22%) for a cause unrelated to his illness.
Table 1.
Summary/Conclusions: Early diagnosis derived from universal neonatal
screening for sickle cell disease allows an effective health education and prompt
therapy to other hemoglobinopathies, and a correct and thorough follow-up of
these patients. 
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PREVALENCE AND CAUSES OF CLOTTING TIMES PROLONGATION IN
PATIENTS WITH TRANSFUSION DEPENDENT BETA THALASSEMIA
I. Tartaglione1,*, M. Caiazza1, A. Bonadies1, D. Roberti1, M. Casale1,
S. Scianguetta1, F. Rossi1, S. Perrotta1
1Dipartimento della Donna, del Bambino e della Chirurgia generale e special-
istica, Università della Campania “Luigi Vanvitelli”, Naples, Italy
Background: Thalassemia is traditionally known to be a thrombophilic, rather
than hemorrhagic, disorder. In spite of this, prolongation of clotting times are
often reported. Understanding if there is a real risk of bleeding, and what this
risk can be associated to, is crucial, especially in relation to the frequent
referral to surgery (e.g. for splenectomy, cholecistecomy). Hepatopathy due
to iron overload or HCV infection has been addressed as a main cause of
this finding, even though disorders in the clotting profile are often reported
also in patients with no alterations of hepatic function. The impairment of fac-
tors XI and XII often reported has been hypothesized to be secondary to
intravascular haemolysis or multiple transfusions ( Caocci et al, Acta Haema-
tol 1978, Mcfadyen et al, Ann Hematol 2014), but no data are available to
confirm this supposition.
Aims: To determine the prevalence of clotting disorders in a group of Transfu-
sion dependent Thalassemia (TDT) patients and to assess the correlation with
hepatopathy, degree of the hemolysis, transfusion frequency, erythroblastosis,
iron chelation.
Methods: TDT patients followed at our center for whom clotting tests were
available were included. From chart review data were collected regarding clot-
ting times, demographics, disease history, comorbidities and concomitant med-
ications, iron chelation therapies, iron overload ( serum ferritin, LIC, cardiac
T2*), liver function tests, hemolysis parameters, hemocromocitometric values.
Patients on anticoagulation therapy were excluded. 
Results: 56 TDT patients (female 55,35%) were enrolled in our study, mean
age  26,02±13,38 years, 17 of them were pediatric. In 20/56 patients (35,71%)
prolongation of clotting time was found: this included both prolonged INR (
23,21%) and prolonged aPTT ratio (25%); 7 patients (12,5%) had both pro-
longed INR and aPTT. Subgroup with clotting disorder (group A) was com-
pared to subgroup with clotting times within normal ranges (group B) using
T-Test. No differences were found in terms of sex, age, genotype, transfusion
interval, hemolysis degree, comorbidities, HCV infection included, iron over-
load, liver function, erythroblastosis and platelets levels, nor in history of
thrombotic complications. No patients had history of hemorrhagic disease.
Pretransfusion Hb was lower in patients with prolonged clotting times
(p=0,045); none of the patients in Group A was splenectomized ( p=0,042).
Summary/Conclusions: In our population clotting disorders were not cor-
related with hepatic disease, nor hemolysis or transfusions. The mild corre-
lation with lower Hb values and with the lacking splenectomy could be con-
sistent with the known effect of low Ht on lab procedures for clotting tests. In
relation to this observation in patients with altered coagulation tests the rep-
etition of clotting test after blood transfusion could be advisable to overcome
the low Hb effect. 
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COMPOUND HETEROZYGOSITY FOR HAEMOGLOBIN ADANA AND
Α-THALASSAEMIA IN GREECE. CLINICAL PHENOTYPE AND GENETIC
COUNSELING
S. Theodoridou1,*, A. Teli2, E. Yfanti3, T.-A. Vyzantiadis4, M. Economou2
1Thalassemia Unit, Hippokration General Hospital, 2First Department of Pedi-
atrics, Aristotle University, Thessaloniki, 3Thalassemia Centre, Laikon General
Hospital, Athens, 4First Microbiology Department, Aristotle University, Thessa-
loniki, Greece
Background: Haemoglobin (Hb) Adana (HBA2qC.179>A) in interaction with
deletional and nondeletional α-thalassaemia mutations leads to HbH or, less
commonly to thalassaemia intermedia with clinical manifestations varying from
asymptomatic forms to severe anemia.  First line screening tests are unable to
detect the highly unstable variant. Aims: We report two cases of Hb Adana co-
inheritance with the a-thalassaemia 3.7 kb deletion - the only  α- thal and Hb
Adana double heterozygosity cases diagnosed in  subjects of Greek origin.
Methods: The first case concerns a 3 year old girl, born from parents referred
for genetic counseling at the 11th week of a second gestation. The mother
showed an Hb of 10.7g/dl,RBC 4.04 X 109 /L, MCV 80,7 fl, MCH 26.4 pg, Hb
A2 2.8% and Hb F 1%,with positive inclusion bodies,  and her ethnic (Greek)
and regional  background was of high risk for thalassaemia. The partner came
from the same region,  and he showed an Hb of 13.8g/dl, RBC 5.88 X 109/L,
MCV 73,1 fl, MCH 23.5 pg, Hb A2 2.4% and Hb F1% and inclusion bodies
were  found positive. DNA analysis was requested and, routine investigation
was performed in their first offspring. The girl had an Hb of 8.2 g/dl,  RBC 3.82
X 109/L, MCV 70 fl, MCH 22 pg, Hb A2 1.9% and Hb F 2.3%, while her ferritin
levels were  226ng/ml and inclusion bodies were found. On clinical examination
she was found to be of normal weight and height for her age, but presented
with paleness, icteric sclera and mild splenomegaly. Genetic analysis revealed
that the mother carried the α-thalassaemia 3.7 kb deletion defect. The father
carried the rare non deletional Hb Adana. As suspected  from the haematolog-
ical data, their offspring was a compound heterozygote for Hb Adana variant
in trans to a 3.7 α+ thal deletion.The second case concerns a17-year-old boy,
diagnosed with  Hb Adana co-inheritance with the a-thalassemia 3.7 kb deletion
at the age of 8 years. At diagnosis, findings were compatible with a very mild
phenotype and growth was not impaired. The boy retained a mild hypochromic
microcytic anemia (Hb~10g/dl, MCV 71 fl, MCH 23 pg, RDW 18.6%, reticulo-
cyte count 5.1%), until adolescence but at the age of 11 transfusion inititation
was decided due to marked splenomegaly and limited weight and height gain.
For the following years he was transfused approximately once a month, neces-
sitating chelation therapy. Weight, height and pubertal development were nor-
mal by the age of 15, but splenomegaly persisted. Splenectomy was decided
and transfusions were stopped shortly afterwards. During the following months
the boy retained an Hb of 9.5 g/dl, however, he complained of constant fatigue
and impaired physical activity and asked to get back on a transfusion program. 
Results: In both cases diagnosis was incidental highlighting the mild pheno-
type. However, the co inheritance of Hb Adana with the 3.7 kb α+ thal deletion
is rare, with only the presenting cases in Greece, and  in a few other families
in Turkey, Southeast Asia, Philippines and Albania. The clinical phenotype of
the combination seems to be a mild disease with a non-transfusion-dependent
thalassaemia intermedia phenotype. Nonetheless, clinical severity prediction
is always a difficult issue and phenotypes may change overtime as demon-
strated by the second case described above.
Summary/Conclusions: Long follow-up of such rare cases is necessary in
order to gain as much information as possible, so as to offer the best manage-
ment to the patients and the most accurate  genetic counseling.
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ANTITHROMBOTIC EFFECTS OF PEPTIDE PGPL IN EXPERIMENTAL
THROMBUS FORMATION
M. Grigorjeva1,*, L. Lyapina1, T. Obergan1
1Biology, Lomonosov Moscow State University, Moscow, Russian Federation
Background: Previously, it was established that proline- and glycine-containing
peptides have fibrinolytic, anticoagulant activity, inhibit platelet aggregation and
thrombin activity in vitro and in vivo. Besides, it is known that short peptides of
this family also have antithrombotic effects.
Aims: To study the influence of Pro-Gly-Pro-Leu (PGPL) and amino-acid leucine
on fibrinolytic and anticoagulant blood activity, platelet aggregation and to estimate
their possibility to reduce the formation of experimental blood clots.
Methods: Experiments were carried out on white rats (200-250 g) according to
the ethical principles of the Helsinki Declaration. Peptide PGPL (1 mg/kg), leucine
(0.33 mg/kg - equivalent to its content in PGPL) and saline (control rats) were
intranasal entered to rats within 3 days. 1 hour after the last drugs administration
we induced the formation of thrombus in v.jugularis (Wessler model). The degree
of thrombus formation was estimated on thrombus weight. Fibrinolytic activity
and activity of tissue-plasminogen activator (t-PA) of blood plasma were measured
by fibrin plate method. Anticoagulant activity (APTT-test) and ADP-induced platelet
aggregation were detected by standard methods.
Results: Our experiments demonstrated that preliminary intranasal adminis-
tration of PGPL (before formation of thrombus) leads to increase of APTT, fib-
rinolytic and t-PA activity on 18%, 62%, 35% accordingly from control rats.
Besides, we observed the decrease of platelet aggregation. Also we indicated
the reduction of thrombus weigh in PGPL-treated rats on 68.5% comparatively
with control rats. The thrombus weigh after leucine treatment decreased on
30% compared with control rats. But administration of leucine did not change
of haemostasis system parameters.
Summary/Conclusions: Thus administration of PGPL enhanced of anticoag-
ulant, fibrinolytic and antiplatelet activity in rats blood plasma. PGPL pretreat-
ment lead to prevention of experimental venous thrombus formation. Therefore,
PGPL may be used as perspective anticoagulant and fibrinolytic agent with
direct antithrombotic effect.
PB2204
TREATMENT AND OUTCOME OF THROMBOTIC MICROANGIOPATHY IN
MALAYSIA
Y.Y. Yap1,*, K.B. Law1, P.A.B. Zulkarnain1, S. Carlo1, R. Ramli1, J. Sathar1,
K.M. Chang1
1Department of Haematology in Ampang Hospital, Ministry of Health, Selangor,
Malaysia
Background: Thrombotic Thrombocytopenic Purpura (TTP) is a potentially
lethal disease that there is still no promising cure in this era. The ADAMTS-13
deficiency or defect in the disease has enabled clinician to recognize another
entity which is Thrombotic Microangiopathy (TMA). This entity includes TTP,
typical Haemolytic Uraemic Syndrome (HUS), Cancer associated TMA, Atypical
HUS, Pregnancy TMA, SLE related TMA and Transplant TMA.
Aims: This study is to focus on the treatment among the TMA and the outcome
of the disease.
Methods: The data was collected from year 2012 to 2016 from Ampang Hos-
pital via the electronic hospital information system (EHIS) and external records
traced from Haemostasis laboratory in Ampang Hospital as well as from other
hospitals nationwide.
Results: There were total of 243 suspected TMA cases, encompassing 97 (39.9%)
males and 146 (60.1%) females. The median age for this cohort was 34 years.
Only 54 (24.15%) patients were diagnosed as TTP based on ADAMTS-13 activity
≤10%. Treatments were evaluated by using complete case details from Ampang
Hospital cohort (69 cases). From this cohort, only 59 cases had ADAMTS-13 activ-
ity testing. There were 24% Primary Acquired TTP, 5% typical HUS , 3.4% atypical
HUS, 3.4% Pregnancy TMA, 3.4% SLE related TMA, 20.3% Transplant TMA ,
1.7% Cancer associated TMA and 37% TMA of other causes. The average plasma
exchange was 8.4 cycles, and was higher in patients with ADAMTS-13 activity of
≤10% (11.4 cycles) as compared to those with ADAMTS-13 >10% (7.7 cycles).
No infectious diseases were transmitted as a result of plasma exchange or plasma
infusion.  Treatments used in the patients included immunosuppressant therapy
like methylprednisolone (85.5%), monoclonal antibody like rituximab (36.2%),
bortezomib (11.6%), cyclophosphamide (10.1%), cyclosporine (10.1%), and vin-
cristine (26.1%). The survival outcome seemed to be worse among the transplant
TMA in comparison to other groups (log-rank, p<0.0001). Transplantation was
also associated with higher odd of death among TMA cases (OR: 14.8571, 95%
CL: 1.7385, 126.9707). Those with confirmed TTP was inevitably doing better
than the others in terms of overall survival (log-rank, p=0.0299). The odds of death
was 4.36 times higher in patients with ADAMTS-13 activity >10% (OR: 4.36, 95%
CL: 1.0961, 17.3714), indicating secondary TTP may have inferior treatment and
disease outcomes than primary TTP like congenital or acquired TTP. Besides, the
complications of the disease were also evaluated which revealed 26.9% of renal
failure and 52.2% of neurological deficit. Furthermore, 8.7% were complicated by
Venous Thromboembolism, either provoked or spontaneous. The odds of relapse
is 2.9 times higher given the ADAMTS-13 activity ≤10% to ADAMTS-13 activity
>10%.
Summary/Conclusions: This study illustrated that the standard treatment like
plasma exchange and immunosuppressant therapy are only effective in genuine
TTP whereas those masquerading TTP (TMA) would be more challenging to
be tackled in terms of improving the outcome. The task to investigate other
types of TMA prospectively will be highly desirable in the future.   
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ANTIPHOSPHOLIPID ANTIBODY PROFILE AND ORGAN INVOLVEMENT
IN CRITALLY ILL PATIENTS WITH AUTOIMMUNE DISEASES
P. Zambrano1,2,*, J. Aponte1, A. Sanchez2, M.T. Ospina2, Y. Forero1,
J. Carrizosa3, E. Aviles4, A. Cartagena1, C. Zapata1, C. Gamboa1
1Universidad de La Sabana, 2Hospital Universitario de la Samaritana, 3Fun-
dación Santa Fe De Bogotá, Bogota, 4Universida de La Sabana, Bogotá,
Colombia
Background: Antiphospholipid antibodies (APA) are a group of proteins direct-
ed against the phospholipids of cell membranes, such as cardiolipins or phos-
pholipid binding proteins. APA presence provokes microvascular, arterial or
venous thrombotic events indicating somehow the relationship between the
immune system, the hemostatic system, and the inflammatory response. It has
been suggested that their presence in a critically ill patient is related to throm-
botic manifestations, organ dysfunction, and death.
Aims: The aim of this study was to evaluate the prevalence of antiphospholipid
antibodies in critically ill patients with autoimmune diseases and the rate of
organ involvement. 
Methods: Retrospective and descriptive study of patients admitted to the inten-
sive care unit of Hospital Universidad de la Samaritana between 2008 and
2016, in Bogotá, Colombia.
Results: A total of 79 patients were found to have systemic lupus erythematosus
(SLE), antiphospholipid syndrome and vasculitis. 17 patients (22%) were positive
for antiphospholipid antibodies. Of these, 76% were women and mean age was
38 years (18-63 years). APA profiles showed positivity with this distribution: one
positive antibody, n=9 patients (53%) (lupus anticoagulant antibody being the most
common), two positive antibodies in n=4 patients (23%) and three positive anti-
bodies in n=4 patients. Anemia (100%), monocytosis (64%), thrombocytopenia
(40%) and prolonged INR (17%) were found in 88% of patients on admission to
the ICU. In descending order, other organ involvement was found to be: pulmonary
and renal dysfunction (70%), shock (53%), central nervous system involvement
(41%), cardiovascular (23%), and gastrointestinal (22%). 82% of this cohort had
positive anti-nuclear antibodies (ANA) and 23% anti-cytoplasmic antibodies
(ANCA). 100% of patients had elevated C-reactive protein (CRP), and APACHE
II score average was 11 points (Table 1).
Table 1.
Summary/Conclusions: Hematologic, renal and pulmonary involvement are
the most commonly compromised in patients with antiphospholipid antibodies
positivity in patients with autoimmune diseases in the ICU. Based on these
results, a prospective study is proposed in order to evaluate the presence of
APA and their impact on mortality and multi-organ dysfunction in these patients.
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PREVALENCE OF ANTIPHOSPHOLIP ANTIBODY AND HBA1C IN T2DM
WITH DIABETIC VASCULAR COMPLICATIONS
T U. Nwagha1,*, O. Agwu1
1Haematology & Immunology, University Of Nigeria Teaching Hospital, Enugu,
Nigeria
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Background: Antiphospholipid antibodies (APLS) have been implicated in vas-
cular (arterial, venous or both) thrombosis  Diabetes Mellitus (DM), as a disease
entity has been associated with hyper-coagulable and pro-thrombotic states,
with studies showing an increased procoagulant state and thrombotic events
especially in poorly controlled Type 2 Diabetes Mellitus (T2DM).
Aims: The aim of the study is to assess the APLS and HbA1c levels and eval-
uate  the correlation between APLS levels and HBA1c in T2DM patients with
diabetic vascular complications.
Methods: This was a cross-sectional study of subjects with T2DM attending
the diabetic clinic of University of Nigeria Teaching Hospital.  A total of two hun-
dred and ten (210) subjects were recruited for this study. There were grouped
into three (complicated T2DM, uncomplicated T2DM and health control. Each
had 70 subjects matched for sex and age. Lupus anticoagulant (LA) was
assayed using DRVVT (technoclone GmbH Austria) IgGβ2GPI-ACA was
assayed using ELISA test kit (Genway Bio-tech San Diego USA), HbA1C was
assayed using D10TM haemoglobin analyzer. Ethical clearance was obtained
from ethical committee UNTH.
Results: The prevalence of LA was 7.1%, 4.3% and 4.3% for complicated
T2DM, uncomplicated and healthy control subjects respectively, while the
prevalence of IgG-B2GPI ACA was 4.3% in all groups. The mean  HbA1C
were 8.2(1.5), 8.0 (1.7) , 5.6 (0.38) for complicated ,uncomplicated T2DM and
control subjects respectively. ANOVA showed a significance difference in mean
HbA1C among complicated uncomplicated T2DM and healthy controls. Post
hoc analysis showed this difference was between complicated T2DM and
healthy controls (p<0.001, 95%,CI-3.0 to -2.1) and in uncomplicated T2DM
and healthy control subjects (p<0.001,95%,CL-2.8 to -2.0) there was a signif-
icant correlation between HbA1C and IgGβ2GPI-ACA for complicated
T2DM(r=0.316),P=0.008) and uncomplicated T2DM (r=0.316),P<0.001)
Summary/Conclusions: The study did not find any causal or other association
between T2DM and the occurrence of APLS positivity, however, APLS may be
simply an aggravating factor for vascular complications especially in poor con-
trolled T2DM
PB2207
VWF THR789ALA GENETIC VARIANTS CORRELATE WITH DISEASE
PHENOTYPE IN EGYPTIAN PATIENTS WITH ACUTE CORONARY
SYNDROME
N. Osman1,*, M. Younes1, R. Yaseen1, A. Fathy1
1Clinical Pathology, Menoufia University, Shebin Elkom, Egypt
Background: von Willbrand factor antigen level (vWF: Ag) was shown to con-
tribute to the risk of cardiovascular disease. vWF Thr789Ala single nucleotide
polymorphism is thought to affect factor level and function.
Aims: This study aimed to investigate the impact of genetic variants at that
position on the risk of acute coronary syndrome (ACS). 
Methods: The study included 112 patients of ACS; 31 with unstable angina
(UA) and 81 with myocardial infarction (MI) as well as 118 healthy controls.
vWF: Ag level was measured by ELISA.  The gene analysis was carried out by
polymerase chain reaction using restriction fragment length polymorphism
(RFLP-PCR) principles.
Results: vWF: Ag  levels were significantly higher in MI (111.68±24.77 IU/dl)
and UA (110.27±23.44 IU/ml) patients compared to healthy controls
(71.13±13.72 IU/dl ),  p <0.001 for both groups, The majority of patients with
UA (80.6%) were Ala789 homozygous, 6.5% were Thr789Ala heterozygous
and 12.9% were Thr789 homozygous. Regarding the MI group, Ala789 geno-
type was present in 34.6%, Thr789Ala genotype was the predominant genotype
and was seen in 48.1% of patients and Thr789 homozygous was present in
17.3% of patients. The genotype frequency in the control group was as follow;
47.4% were Ala789 homozygous, 33.1% were heterozygous and 19.5% were
Thr789 homozygous. The genotype distribution was significantly different
among the 3 groups, p<0.001, and between the groups with UA and MI, p
<0.001. Ala789 homozygous genotype was an independent risk factor for UA
while the Thr789Ala genotype was shown as an independent risk factor of MI.
Summary/Conclusions: vWF Thr789Ala genotype is independent risk factor
for UA and has significant impact on the type of myocardial ischemia. It should
be incorporated in a risk assessment model to identify individual patient risk
and guide the management plan. 
PB2208
THE INFLUENCE OF FIBRINOGENASE ISOLATED FROM THE
ANTARCTIC SCALLOP ON BLOOD COAGULATION
N. Raksha1,*, D. Gladun1, T. Ishchuk 1
1Biochemistry, Educational and Scientific Center “Institute of Biology and Med-
icine” Taras Shevchenko National University of Kyiv, Kyiv, Ukraine
Background: At the present time, cardiovascular diseases such as acute
myocardial infarction, ischemic heart diseases, and stroke are the most impor-
tant causes of the human mortality around the world. Thrombosis is probably
the most common symptom among cardiovascular diseases. Thrombolytic
agents have been extensively used in the therapeutic treatment of thrombosis.
But most of them have some serious shortcomings, including limited efficacy,
short plasma half-life, large therapeutic dose or allergic response. Considering
the global burden, the search continues for a safe and cheap thrombolytic
agent to treat cardiovascular diseases. To date, many investigators have been
trying to improve the safety and efficacy of thrombolytic therapy. Fibrinogenolyt-
ic enzymes or fibrinogenases because of their role in dissolving of blood clots
as well as prevention their formation have attracted special medical and sci-
entific attention. Enzymes that affect hemostasis have been isolated from dif-
ferent sources. In recent years, special attention is paid to the hydrobionts from
the Antarctic region which are poorly explored and potentially can be a valuable
source of new bioactive compounds, in particular enzymes. 
Aims: The main goal of current research was to test the effect of fibrinogenase
from marine hydrobiont the Antarctic scallop Adamussium colbecki on platelet
aggregation and blood coagulation. 
Methods: Fibrinogenase from the crude tissue extract of A. colbecki was iso-
lated by three-step procedure (affinity chromatography on SBTI-sepharose fol-
lowing affinity chromatography on Blue-Sepharose and size exclusion chro-
matography on Superdex 75-PG). Platelet aggregation was determined by AT-
02 aggregometer (Medtech, RF). The platelet count was adapted to 2.5х105
platelets/μL with platelet-poor plasma. Then,  fibrinogenase (12.5 μg/mL or
6.25 μg/mL) was added 2 min before the addition of the platelet aggregation
inducer (5х10-6 M ADP). The changes in light transmittance were continuously
monitored during 8 min, and the percentage of aggregation, in the presence of
the samples, was calculated comparing the transmittance against the controls.
Activated partial thromboplastin time (APTT) and prothrombin time (PT) were
measured in CLOTimer analyzer.
Results: According to our result investigated enzyme inhibited ADP-induced
platelet aggregation and the inhibition increased with increasing concentration
of the enzyme. Data analysis revealed a significant (p<0.05) inhibition of ADP-
induced platelet aggregation by 80.5% for 12.5 μg/mL of fibrinogenase and by
31.8% for 6.25 μg/mL of fibrinogenase. Isolated fibrinogenase may inhibit platelet
aggregation by hydrolyzing the Aα-chain of fibrinogen to prevent fibrinogen from
combining with fibrinogen receptor on platelet membrane. In addition, fibrinogen
degradation products may act as competitive inhibitors of platelet–fibrinogen
bridging formation. We also investigated the effect of fibrinogenase on blood
coagulation by determination of APTT and PT. According to our result APTT
increased in 2.25 and 1.25 times at the concentration of fibrinogenase of 12.5
μg/mL and 6.25 μg/mL, respectively. The fibrinogenase also prolonged PT from
18 s to 68 s when the concentration of enzyme was 6.25 μg/mL. 
Summary/Conclusions: Further investigations of fibrinogenase from A. col-
becki are interesting and would probably help to develop new therapeutic
agents to treat thrombotic disorders.
PB2209
IMPORTANCE OF MONITORING PATIENTS WITH DIRECT ORAL
ANTICOAGULANTS
L.F. Ávila Idrovo1,*, A. Bernardo Gutierrez1, A. Caro Gómez1,
D. Martinez Carballeira1, I. Soto Ortega1
1Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain
Background: A major advantage of these agents is the lack of a requirement
for monitoring, due to less variability in drug effect for a given dose, however
it´s recommended monitoring the drug for Rivaroxaban Apixaban and Endox-
aban use anti-Xa chromogenic studies and for Dabigatran Hemoclot thrombin
inhibitor and Ecarin clotting time (DTI test).
Aims: Determine the effectiveness of laboratory tests to monitor patients treat-
ed with direct oral anticoagulants.
Methods: We conducted a retrospective study with 227 patients who received
direct oral anticoagulants (DOACs) between January 2015 and December
2016. One hundred eighteen patients (52%) receive Rivaroxaban, fifty patients
(22%) receive Dabigatran and fifty nine patients receive Apixaban (26%). We
analyzed the variables that’s increases the bleeding risk such as age, weight,
prothrombin time (PT) and activated partial thromboplastin time (aPTT), ther-
apeutic range of the drug, and measurement of serum creatinine.
Results: We found 10% of toxicity with Dabigatran, a 7% with Rivaroxaban
and a 3% with Apixaban. Thirty-five patients (15%) developed bleeding of which
11% patients had a minor bleeding and a 4% of patients had a mayor bleeding,
we also found that 6% of patients with Dabigatran, 2.5% with Rixaroxaban and
1.5% with Apixaban developed thrombotic episodes. Twenty percent of patient
didn’t have therapeutic range of the drug. For each DOACs is shown in Table
1. When we analyzed the patients who had hemorrhage we found that all
patients with Dabigatran prolonged aPTT and the PT in 80%, for other DOACs
is shown in Table1. A retrospective case-matched analysis was performed com-
paring 35 patients who developed bleeding with an equal number of patients
who did, case and control groups were matched according to age, weight and
measurement of serum creatinine we didn´t found significant difference.
Summary/Conclusions: In our series, in patients with dabigatran and who
suffered bleeding, we found a significant prolongation of aTTP and PT, demon-
strating the importance of laboratory tests prior to the administration of these
agents and in emergency situations, for these reason should be include PT
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and aPTT, therapeutic level of the drug and creatinine measurement, within
the emergency and control laboratory tests in patients that receive DOACs.
Table 1.
PB2210
HEREDITARY RISK FACTORS OF VENOUS THROMBOEMBOLISM IN
YOUNG WOMEN TAKING ESTROGEN DRUGS
A. Chechulova1,*, S. Kapustin2, S. Karpich2, V. Shmeleva2, V. Soldatenkov2,
L. Papayan2, V. Soroka1, P. Chechulov3
1Vascular surgery, Dzhanelidze Research Institute of Emergency Medicine, St.
Petersburg, 2Russian Research Institute of Hematology and Transfusiology,
3Dzhanelidze Research Institute of Emergency Medicine, St. Petersburg, St.
Petersburg, Russian Federation
Background: Estrogens are recognized as the most common risk factor of
venous thromboembolism (VTE) in young women. The cumulative risk of VTE
in patients taking estrogens is significantly increased in carriers of inherited
thrombophilia. However, the known hereditary risk factors – mutations FV Lei-
den and FII G20210A could be detected in only 20-30% of patients with VTE.
Aims: To identify the most common hereditary risk factors of VTE in young
women taking estrogen drugs.
Methods: We examined 133 young women with acute VTE (mean age 37.4
years; 16-45), who were genotyped by PCR-RFLP method for DNA polymor-
phism in 9 genes: FI-A Thr312Ala, FI-B -455 G/A, FII 20210 G/A, FV 1691 G/A,
FXII 46 C/T, FXIII-A Val34Leu, PAI-1 -675 4G/5G, EPCR Ser219Gly, TPA 311bp
Ins/Del. We compared the distribution of studied genotypes in three groups of
patients with VTE: taking estrogens (n=30, group 1), with idiopathic VTE (n=42,
group 2) or having other risk factors (n=61, group 3). Intergroup differences in
genotype frequencies were assessed by Fisher’s exact method. Odds ratios
(OR), their 95% confidence intervals (CI) and p-values were calculated with
SPSS software version 17.0 (SPSS Inc, Chicago, IL, USA).
Results: The frequencies of prothrombotic genotypes in groups 1, 2 and 3,
respectively, were: FV 1691GA – 20.0%, 21.4% and 13.1%; FII 20210GA –
10.0%, 9.8% and 7.1%; FI-В –455АA – 10.0%, 2.4% and 1.6%; FI-А 312Ala/Ala
– 13.3%, 14.3% and 13.1%; TPA 311bp Ins/Ins – 16.7%, 28.6% and 31.1%; PAI-
1 -675 4G/4G – 36.7%, 42.9% and 27.9%; EPСR 219Ser/Gly – 16.7%, 19.0%
and 23.0%; EPСR 219Gly/Gly – 3.3%, 7.1% and 0.0%; FXII 46TT – 13.3%, 0.0%
and 9.8%; FXIII-A 34 Leu/Leu – 3.3%, 21.4% and 9.8%. Significant differences
between the groups have been detected only for the FXIII-A 34Leu/Leu variant,
which was more frequently found in patients with idiopathic VTE than in the group
with estrogens (OR=6.5; 95% CI: 1.2-63.4; p=0.012) and women having other
risk factors (OR=2.2; 95% CI: 0.8-7.6; p=0.05). The frequency of FI-В –455АA
genotype in young women with DVT developed after taking estrogen drugs was
4- and 6-fold higher, respectively, when compared to the group with idiopathic
VTE and patients having other risk factors (10.0% vs 2.4%; OR=4.1, 95% CI:
0.02-2.2, p=0.16 and 10.0% vs 1.6%; OR=6.6, 95% CI: 0.7-67.0, p=0.067). 
Summary/Conclusions: FV Leiden and FII 20210G/A mutations as well as
the FI-B -455AA genotype are frequently seen in young women with DVT devel-
oped after taking estrogen drugs. Further studies are needed to clarify genetic






KNOWLEDGE AND ATTITUDE OF MEDICAL DOCTORS ON
ANTICOAGULATION THERAPY IN TERTIARY HOSPITALS IN NIGERIA
T.U. Nwagha1,*, R. Anakwue2, O. Ukpabi3, E. Onwubuya4, N. Obeka5,
I. Okoye6, B. Azubuike6
1Haematology & Immunology, 2Internal medicine, University Of Nigeria Teach-
ing Hospital, Enugu, 3Internal medicine, Abia state Teaching Hospital, Umuahia,
4Internal medicine, Nnamdi Azikiwe Teaching Hospital Nnewi, Awka, 5Internal
medicine, Federal Medical center , Abakiliki, 6Internal medicine, Amaku Spe-
cialist hospital, Awka, Nigeria
Background: Thromboembolic and hypercoagulable diseases are common
life-threatening but treatable problems in hospital practice.  The most effective
and economical approach to decreasing the burden of VTE is to prevent the
development of DVT and PE in patients especially in acutely ill hospitalized
medical patients. Health care providers in Nigeria may have significant gaps in
their anticoagulation knowledge that could affect their decision to prescribe
anticoagulation therapy as there are no national guidelines on the use of anti-
coagulation in Nigeria.
Aims: The purpose of this present study was to examine the knowledge
and attitude of medical doctors on anticoagulation in tertiary hospitals in
Nigeria.
Methods: The present study is a multicentre survey of the use of anticoagulants
among clinicians in South East Nigeria. A pretested questionnaire was admin-
istered to clinicians in six tertiary hospitals in the south-east of Nigeria. The fol-
lowing institutions participated in the survey: University of Nigeria Teaching
Hospital Enugu, Federal Medical Centre, Abakaliki, Federal Medical Centre
Umuahia, Abia State Teaching Hospital, Aba, Amaku Specialist Hospital, Awka
and Nnamdi Azikiwe Teaching Hospital, Nnewi. The Likert scale which is in
grades from one to five: 1 strongly disagree, 2 disagree,3 neutral,4agree,5
strongly disagree was used. To determine the agreement degree three levels
were identified (high medium and low).
Results: There were 528 respondents. 378 of them were males (71.6%) and
150 were females (28.4%). 31.1% of the respondents, were junior residents
and the consultants represented only 20.6% of the respondents. Most of the
respondents,189 (35.8%) had less than 5 years clinical experience while the
least of the respondents (8.7%) had between 16-20 years clinical experience
We observed that most respondents irrespective of their job grades didn’t
know about Fondaparinux and the DOAC (except those in the specialist -
registrar job grades) as the overall p=(0.000),<0.05 and were significant. We
also observed that responses were divided on malignancy as an indication
for anticoagulation. The overall P=0.002, <0.05 and was significant. The p
valve for other indications for anticoagulation >0.05 and was not significant.
The majority knew of prothrombin test and p valve was 0.03, less than alpha
value of 0.05 and was significant. On the contrary, Majority does not know
about anti-Xa assay, p-value=0.02, <0.05, was also significant. Their affirma-
tive response on the mode of action as one of the differences showed a
p=0.000, <0.05, was significant. On the contrary, the non-affirmative response
to drug and food interaction, p=0.03, was also significant. Based on results
of the statement analysis, the variables were ranked according to the value
of their mean. All except one variable had p-values of <0.05. The statement
“Do you think anticoagulation therapy/prophylaxis is clinically important” had
the highest mean of 4.60 and had a high degree of agreement. The statement
“Should hospital inpatient with >3 days admission routinely receive anticoag-
ulation?” had the lowest mean of 2.27 with a p-value of 0.015 had a low
degree of agreement.
Summary/Conclusions: There is a need to upscale knowledge attitude and
practice of the use anticoagulation agents especially the NOACs through well-
articulated CME educational activities. A limitation of this study is the relatively
small number of study participants and some subspecialties that were not
reflected in this survey.
PB2214
INTERLEUKIN -10 GENE POLYMORPHISMS AND THE RISK OF
UNPROVOKED DVT IN EGYPTIAN PATIENTS
H. Ellithy1,*, G. Shaheen2, S. Elmoamly1
1Internal medicine- clinical Hematology Unit, 2Clinical pathology, Kasr Al-ainy
school of medicine- Cairo university, Cairo, Egypt
Background: Thrombosis is often multifactorial, caused by both genetic and
acquired risk factors. The inflammatory process is linked to pathogenesis of
venous thrombosis. Venous thrombosis is considered to be mediated by an
imbalance in proinflammatory as compared with anti-inflammatory molecules.
One of the important anti-inflammatory cytokine is interleukin-10 (IL-10) with
important immunoregulatory functions. Primarily, IL-10 counterbalances the
poten tially harmful effects of tumor necrosis factor α (TNFα) and other pro-
inflammatory mediator such as IL-1b, IL-6, and IL-8 from monocytes/
macrophages. Three important single nucleotide polymorphisms (SNP) affect
IL-10 expression, including: 1082 A/G, 819 C/T, and 592 C/A. Studying the
association between genetic polymorphisms of anti-inflammatory cytokines
such as IL-10, and venous thrombosis may suggest using of polymorphisms
as a predictive genetic marker of future VTE.
Aims: The objective of this study was to evaluate a possible association
between IL-10 -1082A/G, and -592C/A polymorphisms with DVT.
Methods: The study was conducted on 115 patients with symptomatic DVT
proved by venous duplex ultrasound; divided into two cohorts: group A included
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60 patients with unprovoked DVT, and group B included 55 patients with pro-
voked DVT. Gene mutations for IL-10 -1082A/G, and -592C/A were performed
using PCR-restriction fragment length polymorphism assay. We studied the
association between IL-10 gene polymorphisms and occurrence of either pro-
voked or non-provoked DVT. We also investigated the link between these poly-
morphisms and the recurrence of DVT and family history of DVT.
Results: in our study IL101082AG gene analysis revealed that mutant geno-
types distribution is statistically significant different compared to the wild geno-
type distribution, being higher in group A (with unprovoked DVT) than in group
B (with provoked DVT); as GG genotype was detected in 14 patients (63.6%)
versus 8 patients (36.4%) in group A and B respectively (P value=0.037); AG
genotype was detected in 30 patients (63.8%) compared to 17 patients (36.2%)
in group A and B respectively (P value=0.007). However, there is no correlation
was found between IL101082 mutant genotypes distribution and VTE recur-
rence (P value= 0.738 and 1 respectively) or positive family history of VTE (P
value= 0.101 and 0.714 respectively), compared to wild genotype. IL10592AC
gene analysis showed that mutant genotypes (GG and AG) distribution showed
no statistically significant difference (p value= 0.43 and 0.687 for GG and AG
genotypes respectively) compared to wild genotypes distribution, also there is
no correlation was found between IL10592AC mutant genotypes distributions
and VTE recurrence (P value= 1 and 0.284 for GG and AG genotypes respec-
tively) or positive family history of VTE (P value= 0.67 and 1 for GG and AG
genotypes respectively), compared to wild genotype (AA).
Summary/Conclusions: I IL101082AG gene polymorphism is associated with
risk of unprovoked DVT, however it is not associated with either risk of recur-
rence or positive family history.
PB2215
CATASTROPHIC ANTI-PHOSPHOLIPID SYNDROME TRIGGERED BY
SEPSIS. A PROSPECTIVE CASE STUDY HIGHLIGHTING BIOLOGICAL
CONCEPTS AND MANAGEMENT STRATEGIES IN THIS COMPLEX AND
LIFE THREATENING DISEASE
M. Hua1,*
1Haematology, Liverpool Hospital, Sydney, Australia
Background: Catastrophic antiphospholipid syndrome (CAPS) is a rare and
life threatening event characterized by widespread intravascular thrombosis
and multi-organ failure. Rarely is CAPS associated with bleeding diathesis,
but has been reported in cases with severe thrombocytopenia and acquired
prothrombin inhibitors. APS auto-antibodies are heterogeneous and may
undergo post-translational modification during antigen stimulation altering its
pathogenicity and thrombotic risk. Sepsis and associated disseminated
intravascular coagulation is a known phenomenon where cytokines influence
pro-coagulant and anti-coagulant pathways on multiple levels to induce
haemostatic chaos. 
Aims: Demonstrate the role of sepsis in triggering life threatening CAPS, and
highlight the management strategies used in this highly complex and fatal dis-
ease.
Methods: Prospective case study illustrating two separate atypical CAPS
presentations and the management strategies employed. 1st episode (2015):
54F with long standing 27 years of triple positive APS, pro-thrombotic history
with recurrent thrombosis despite optimal anticoagulation.  Her pro-thrombotic
equilibrium was altered after a respiratory tract infection where she presented
with severe headaches. Subsequent investigations demonstrated multiple
atraumatic intra-cranial haemorrhages followed by concurrent extensive cere-
bral venous thrombosis. 2nd episode (2017): She presented with subdural
haemorrhage, preceded by fevers and respiratory symptoms. She then devel-
oped pleuritic chest pain and dyspnoea after temporary cessation of antico-
agulation for 24 hours. Imaging confirmed multiple pulmonary emboli with
areas of infarction. Respiratory symptoms worsened with progressive inter-
stitial ground glass changes on CT consistent with atypical pulmonary infec-
tion. Shortly after low therapeutic anti-coagulation she developed acute
abdominal pain and hypotension. CT confirmed significant bilateral adrenal
haemorrhages. Management Strategies: (A) Rapid reduction in APS patho-
genic auto-antibodies via plasma exchange, B cell depletion therapy and
immune modulation. (B) Treatment of underlying infectious trigger. (C) Judi-
cious anticoagulation with anti-Xa monitoring and (D) long term hydroxy-
chloroquine and statin therapy.
Results: The two life threatening presentations of CAPS were triggered by an
infectious event, supporting the biological concept that anti-phospholipid anti-
bodies can be immune modulated altering his pathogenic capabilities creating
haemostatic havoc. There are similarities and a degree of overlap with sepsis
and the pathophysiology behind disseminated intravascular coagulopathy. Rap-
id reduction in the pathogenic auto-antibodies using combination plasma
exchange, immune modulation and B cell depletion therapy is effective in this
acute setting. Judicious anticoagulation and treatment of the precipitating infec-
tion is important in turning off the immune response driving this life-threatening
coagulopathy. 
Summary/Conclusions: CAPS is rare and life threatening, often triggered by
an infectious event, trauma or temporary cessation of anticoagulation. It
requires prompt recognition and timely commencement of therapy. 
PB2216
HAEMATOLOGICAL CORRELATES OF ISCHEMIC STROKE AND
TRANSIENT ISCHEMIC ATTACK :  LESSONS LEARNED
H. Gunasekara1,*, I. Pathiraja2
1Health, Teaching Hospital- Kegalle, Kegalle, 2Health, Provincial Department
of Health Services, North Western Province, Sri Lanka
Background: Haematological abnormalities are known to cause Ischemic
Stroke or Transient Ischemic Attack (TIA). The identification of  haematological
correlates plays an important role in management and secondary prevention
Aims: The objective of this study was to describe haematological correlates of
stroke and their association between stroke profile. The haematological corre-
lates screened were Lupus Anticoagulant, Dysfibroginemia, Paroxysmal noc-
turnal haemoglobinurea (PNH), Sickle cell disease, Systemic Lupus Erythe-
matosis (SLE)  and Myeloploriferative Neoplasms (MPN).
Methods: A cross sectional descriptive study was conducted in a sample of
152 stroke patients referred to haematology department of National Hospital
of Sri Lanka for thrombophilia screening. Following tests were performed to
assess each hematological correlates (Table 1).
Table 1.
Results: Among study sample, 134 patients had strokes and only 18 had TIA.
The recurrence of stroke/TIA was observed in 13.2% of patients. The majority
of patients (94.7%) have had radiological evidence of thrombotic event. One
fourth of patients had past thrombotic events while 12.5% had family history of
thrombosis. Out of haematological correlates screened Lupus anticoagulant
was the most common haematological correlate   (n=16 ) and dysfibrigo-
naemia(n=11 )  had the next high prevalence. One patient was diagnosed with
Essential thrombocythaemia  and one with SLE. None of the patients were
positive for screening tests done for sickle cell disease and PNH.
Summary/Conclusions: The Haematological correlates were identified in 19%
of our study sample. Among stroke profile only presence of past thrombotic
history was statistically significantly associated with haematological disorders
(P= 0.04).  Therefore hematological disorders appear to be an important factor
in etiological work up of stroke patients particularly in patients with past throm-
botic events.
PB2217
ANTIPLATELET AND FIBRINOLYTIC EFFECTS OF
ARGININE-CONTAINING PEPTIDES IN HEALTHY RATS AND RATS WITH
METABOLIC SYNDROME 
Y. Song1,*, M. Grigorjeva1, T. Obergan1
1M.V.Lomonosow Moscow State University, Moscow, Russian Federation
Background: Currently, the number of diabetes, hypercholesterolemia, meta-
bolic syndrome (MS) patients has increased sharply in the world. MS is meta-
bolic disorders with increase of cholesterol and glucose levels, dyslipemia,
endothelial dysfunction. This is accompanied by an increase in blood clotting,
including platelet aggregation strengthening and reducing the activity of the
plasminogen activator. Thus, the MS may predispose to venous thrombosis. It
is known that, regulatory oligopeptides involved in the conservation normal
functional activity of coagulation, anticoagulation, insular systems of the organ-
ism, fat metabolism. It is also known that some amino acids, particularly argi-
nine, improve rheological properties of blood and reduce platelet aggregation.
Aims: To study the effect of tripeptides Pro-Arg-Gly and Gly-Arg-Pro, containing
arginine in the molecule, on platelet aggregation and tissue plasminogen acti-
vator (t-PA) activity in a healthy organism and the development of the experi-
mental MS.
Methods: Experiments were carried out on Wistar rats weighing 300-350 g in
accordance with the ethical principles of the Helsinki Declaration. Two groups
of animals were used: healthy rats and rats with experimental MS. Peptides
were intranasal injected in doses of 1 mg / kg once daily for 5 days.  0.85%
NaCl solution was injected to control rats in the same time frame. MS in  rats
was caused by a hyper-cholesterol fat-rich diet (FD) for 6 weeks. Blood samples
were taken from the jugular vein 1 hour after the last drug administration. Activ-
ity of t-PA (fibrin plate method) and ADP-induced platelet aggregation (standard
method) were measured in blood plasma. 
Results: The intranasal administration  of peptides Gly-Arg-Pro, and Pro-Arg-
Gly to healthy animals  resulted a reduction of platelet aggregation by 23%
and 52% compared with the control. Both peptides induced enhancement t-PA
activity of 2 or 3.5 times respectively. In rats with experimental MS these effects
were preserved, besides, platelet aggregation was decreased by 27% (Pro-
Arg-Gly) and 38% (Gly-Arg-Pro) compared with the control.
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Summary/Conclusions: We concluded that intranasal administration of tripep-
tides Pro-Arg-Gly and Gly-Arg-Pro to organism of healthy rats and in rats with
experimental MS show antiplatelet and fibrinolytic effects of the blood. Thus,
arginine-containing peptides could potentially be used as antithrombotic drugs
that protect the organism from the blood coagulation and thrombus formation.  
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THE PRINCIPAL COMPONENT ANALYSIS USING CALIBRATED
AUTOMATED THROMBOGRAM PARAMETERS AS A POTENTIAL
QUALITY CONTROL FOR MEASURING PROCOAGULANT ACTIVITIES OF
IMMUNOGLOBULINS
H. Oh1,*, C. Ahn1, S. Han1, H. Song1, K. Han1, G. Min1, J. Kim1, S. Park1,
K. Jung1
1Blood Products Division, National Institute of Food and Drug Safety Evaluation,
Cheongju-si, Korea, Republic Of
Background: The calibrated automated thrombogram (CAT) is a method to
monitor the generation of thrombin. It can be described by four variables; lag
time, peak thrombin, time to peak, and velocity index. Currently, due to throm-
boembolic event related risks of immunoglobulins, the CAT is widely used to
quantify the thrombogenic potential associated with immunoglobulin manufac-
turing processes and products. However, there is currently no officially approved
method for such assessments and even this results are highly variable in inter-
laboratories comparison. In this study, to obtain a summary score, we applied
the principal component analysis (PCA) for these four outcomes measured
from CAT method. The PCA is a statistical procedure concerned with elucidating
the covariance structure of a set of variables. In particular it allows us to identify
the principal directions in which the data varies.
Aims: In this study, our interest is to apply PCA method in order to find appro-
priate dose related with CAT variables and to reduce variation of procoagulant
values in Immunoglobulin products.
Methods: The CAT are measured in a 96 well plate fluorometer equipped with
a 390/460 filter set and a dispenser. Usually experiments are carried out in trip-
licate. During the measurement, a dedicated software program, Throm-
binoscope compares the readings from the trigger wells and the calibrater wells,
calculates thrombin concentration and displays the thrombin concentration in
time. Outcomes from CAT were analyzed in the principal component anaysis
(PCA) which is a statistical procedure that allows us to summarize high dimen-
sional data with a smaller number of representative variables that collectively
explain most of the variability.  Statistical analyses were performed with R 2.5.
Results: Four variables measured from CAT have different sistribution and too
large variations. For example, the mean(sd) of each variable (lag time, peak
thrombin, time to peak, and velocity index) are 24.66(8.01), 80.16(94.52),
31.28(9.78), 19.08(28.86), respectively. Therefore, to remedy such high vari-
ability among variables and to find a score, PCA method is applied. Then the
dose values calculated based on the PCA scores have mean 0.393 and a much
smaller variation (sd=0.583) (Table 1).
Table 1.
Summary/Conclusions: The PCA value showed a good agreement with four
CAT outcomes and less variation. The PCA method could be used to monitor
the process of immunoglobulin manufacturing.
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PRIMARY THROMBOPHILIA IN MÉXICO XII: MISCARRIAGES ARE MORE
FREQUENT IN PERSONS WITH THE STICKY PLATELET SYNDROME
G.J. Ruiz Argüelles1,*, G.J. Ruiz-Delgado1, Y. Cantero-Fortiz2,
M.A. Mendez-Huerta3, M. Leon-Gonzalez4, A.A. Leon-Peña4,
A.K. Nuñez Cortes4, J.C. Olivares-Gazca4, J.A. Arizaga Berber4
1Hematologia, Centro de Hematologia y Medicina Interna, 2Universidad de las
Americas Puebla, 3Laboratorios Clínicos de Puebla, 4Centro de Hematologia
y Medicina Interna, Puebla, Mexico
Background: The sticky platelet syndrome (SPS) is an inherited condition
which leads into arterial and venous thrombosis. There is scant information
about the association between the SPS and obstetric complications.
Aims: To assess the relationship of the SPS and fetal loss in a single institution.
Methods: The obstetric history of all the consecutive female patients prospec-
tively studied along a 324 month period, in a single institution with a history of
thrombosis and a clinical marker of primary thrombophilia was reviewed.
Results: Between 1989 and 2016, 268 consecutive patients with a clinical
marker of primary thrombophilia and a history of arterial or venous thrombosis
were studied; of these, 108 were female patients. Within this subset of throm-
bophilic female persons, 77 (71%) had been pregnant at some moment. Twenty
eight of these 77 patients (37%) had had a spontaneous abortion and 24 out
of these (86%) were found to have the SPS. On the other hand, in a subset of
73 female patients with the SPS who had been pregnant, 32% had miscar-
riages. These figures are significantly higher than the prevalence of abortions
in the Mexican general population of pregnant women, which is 12-13% (chi
square=7.47; p=0.0063). Accordingly, the relative risk of having a miscarriage
is 2.66 times higher in female patients with the SPS than in the general popu-
lation (p=0.0014) (Figure 1).
Figure 1.
Summary/Conclusions: In México, female patients with the SPS experience
significantly more spontaneous abortions than the general population. Since
the treatment of the SPS is simple and effective and could in turn prevent
adverse obstetric outcomes, its investigation in women studied because obstet-
ric complications may be useful and deserves further research.
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CROSS-SECTIONAL ANALYSIS OF VENOUS THROMBOEMBOLISM
IN YOUNG INDIAN MALES; NEW INSIGHTS INTO AN OLD PROBLEM
S.K. Das1,*, Y. Uday1, R. Kapoor1, T. Verma1, S. Das1, V. Nair1
1Hematology, Army Hospital (Research & Referral), New Delhi, India
Background: Venous thromboembolism (VTE) comprising of deep vein throm-
bosis (DVT) and pulmonary embolism (PE) is one of the major cardiovascular
causes of death along with MI and stroke. Though earlier works has suggested
that DVT is rarer in Asian population, recent studies have revealed that this
might not be so. Most of the studies conducted in Asia in general and India
specifically has been on hospitalized patients with minimal representation of
young healthy individuals. 
Aims: We aimed at studying the disease variables of VTE in young healthy
males of Indian origin and compare the same with other Indian studies as well
as the global statistics. 
Methods: Hospital records of 176 Color Doppler Flow Index (CDFI) and /or
Contrast Enhanced Computed Tomography (CECT) proven VTE patients being
followed up in a tertiary care hospital was analyzed retrospectively to document
cause (provoked/ unprovoked), venous systems involved, thrombophilia profile,
duration of anti-coagulation and recurrence. 
Results: Among the study population, 49.8% had a provoked VTE. 90.9% sub-
jects had DVT, mostly of the lower limb, 15.3% had PE with DVT, 2.8% had PE
alone and 6.2% had splanchninc vein thrombosis including portal vein throm-
bosis. In the subjects who had undergone thrombophilia profile, 41.9% had
Protein C, 58.1% Protein S and 25.9% Antithrombin III deficiency. Lupus anti-
coagulant screen was positive for 13% of the screened subjects. The average
duration of anti-coagulation was 18 months with majority (98.2%) patients on
Vitamin K antagonist. The recurrence rate in our study population was found to
be 11.4% (Table 1).
Summary/Conclusions: Young Indian males have different disease variables
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for VTE as compared to western population. The exact pathophysiology of




A PRELIMINARY STUDY ON THE EFFECTS OF AMPHIBIAN CRUDE SKIN
SECRETIONS ON SOME PARAMETERS OF HEMOSTATIC SYSTEM
I. Nikolaeva1,*, O. Marushchak1, O. Oskyrko1, T. Halenova 1, O. Savchuk1
1Biochemistry, Educational and Scientific Centre “Institute of Biology and Med-
icine”, Taras Shevchenko Kyiv National University, Ukraine, Kyiv, Ukraine
Background: A lot of bio-chemical compounds from secretion of the amphibian
skin glands with various biological activities have been isolated and character-
ized. Several recent studies indicate that amphibian skin secretions can be a
source of molecules affecting the platelet activity. We are interested to look for
other bioactive components of the amphibian skin which exhibit ability to influ-
ence on diverse parameters of hemostatic system.
Aims: We performed a preliminary study of the some effects of amphibian
crude skin secretions on hemostasis.
Methods: Adult specimens (both sexes) of Bombina bоmbina, Bombina var-
iegata, Bufo bufo, and Bufotes viridis were collected from outdoors in Kyiv
region of Ukraine. The crude skin secretions were collected by washing with
ultrapure water and centrifuged to remove debris. The supernatants were
lyophilized and kept at −20 °C till use. In the experiments we used fresh pre-
pared water solution of lyophilized skin secretions. Protein concentration was
determined by Bradford method with BSA as a standard. Rabbit platelet-rich
plasma (PRP, 2x105 cells/μL) and platelet-poor plasma were obtained following
standard protocols. Platelet fraction (PF) was purified by gel-filtration on
Sephadex G 50 column. Platelet aggregation was measured by aggregometer
AT-02 (Medtech, Russia). Coagulation parameters (prothrombin time (PT),
thrombin time (TT), as well as activated partial thromboplastin time (APTT))
were measured by coagulometer (Rayto, RT-2201C) using corresponding com-
mercial kits (Renam, Russia).
Results: The lyophilized B. bufo skin secretions in dose-dependent manner
induced platelet aggregation in both PRP and purified PF; its final concentration
of 50 mg of total protein/mL caused the same effect as 5x10-6M ADP. These
results indicated that skin components acted directly on platelets, maybe
through their surface receptors. The lyophilized skin secretions of B.
variegata and B. viridis also activated platelet aggregation but their effects
were lower than B. bufo skin secretions. The skin secretions from all studied
amphibian did not influence on PT and TT except B. viridis which prolonged
TT by 40%. The values of APTT were significantly enhanced in 3.4 and 2.3
times under the influence of crude skin secretions (final concentration of 0.2
mg total protein/mL plasma) of B. bombina and B. variegata, respectively.
Summary/Conclusions: The obtained results indicate the prospects of the
search for potential modulators of hemostatic system among the amphibian
skin bioactive compounds. To establish their physiological and functional mech-
anisms of action, the further purification and characterization of components
from the skin gland secretions are necessary. 
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PLASMINOGEN-DEFICIENT PATIENTS
H. Kızılocak1,*, G.N. Özdemir2, G. Dikme1, B. Koç1, G. İskeleli3,
B. Dönmez Demir4, N.M. Christiansen5, M. Ziegler5, H. Özdağ4,
V. Schuster5, T. Celkan1
1Istanbul University Cerrahpasa Medical Faculty, Pediatric Hematology-Oncol-
ogy, 2Kanuni Sultan Süleyman Education and Research Hospital, Pediatric
Hematology Oncology Dept., 3Istanbul University, Cerrahpasa Medical Faculty,
Ophthalmology, Istanbul, 4Ankara University, Biotechnology Institute, Ankara,
Turkey, 5University of Leipzig, Leipzig, Germany
Background: Congenital plasminogen (Plg) deficiency is a rare autosomal
recessive disorder that leads to the development of ligneous membranes on
mucosal surfaces.
Aims: Here we report our experience with local and intravenous fresh frozen
plasma (FFP). 
Methods: Our cohort consisted of 14 patients and their 8 first-degree relatives.
The patients have been diagnosed between 3 months and 18 years of age,
and the median age at the time of first clinical manifestation was 4.5 months
(range 3 days to 12 months). 
Results: Conjunctivitis is the main complaint, hydrocephalus and hearing loss
follow. In 10 patients, ligneous membranes were surgically removed but all
recurred. Nine patients were treated with intravenous and conjunctival FFP. Two
patients had no complaints after treatment. Most patients needed transfusion
with FFP every three weeks. Only one patient had severe endophthalmitis and
lost vision in one eye before treatment. Two female patients and one male patient
had undergone multiple surgeries for ligneous conjunctivitis despite being treated
with FFP. The response rate to FFP treatment was 6/9 (66%). Another 8-year-
old female with severe bronchial membranes was treated with FFP and t-PA
through bronchoscopy. Venous thrombosis did not occur in any of the patients.
Nine have consanguineous parents. The genetic evaluation of our patients
revealed heterogeneous mutations as well as polymorphisms. 
Summary/Conclusions: The diagnosis and treatment of Plg deficiency is chal-
lenging, and there is no consensus on treatment. Topical and iv FFP may be
used with clinical outcome. 
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THE TREATMENT OF HEREDITARY TROMBOPHILIA DURING
PREGNANCY 
M. Theodosiou1,*, I. Ionita1,2, E.-C. Budai1,2, C. Hategan1, D.-N. Oros1,2,
E.-C. Fenes1, R.-S. Buriman1, H.-M. Ionita1,2
1Hematology, Spitalul Clinic Municipal de Urgenta Timisoara/Municipal Emer-
gency Hospital TImisoara, 2Hematology, Victor Babes University of Medicine
and Pharmacy Timirosara, Timisoara, Romania
Background: Thrombophilias are genetic conditions that increase the risk of
thromboembolic disease. The use of anticoagulant therapy during pregnancy
is challenging because of the potential for both fetal and maternal complica-
tions. The most common complication is venous thromboembolism. 
Aims: This study is conducted in order to assess the importance of treatment
during pregnancy for women with hereditary thrombophilia, the risks of not
treating the disease or treating incorrectly.
Methods: This study includes a total of 207 women, from which 83% were
treated with low molecular weight heparin and Aspirin during pregnancy regard-
less if it was their first pregnancy or not and the rest 17% remained untreated
during pregnancy. The success of the treatment is based on the completion of
the pregnancy and the good health of the fetus.
Results: A total of 207 women were included into the study, 172 were treated
with low molecular weight heparin and Aspirin while 35 were treated with just
Aspirin. Out of 172 patients in the low molecular weight heparin group 155
managed to give birth which accounts for a 90% success rate with a reported
case of fetal growth restriction and 2 cases of abruption while the remaining
17 women which represent the 10% of the treated patients were unsuccessful
in completing their pregnancy with 14 women presenting pregnancy loss on
the first trimester and 2 having late fetal loss, only one case of preeclampsia
was recorded. Out of the 35 women who did not receive treatment with low
molecular weight heparin and only with Aspirin, 21 managed to complete their
pregnancies representing the 60% out of which 2 cases presented with Abrup-
tion and 4 cases with fetal growth restriction, out of the 14 women who repre-
sent the 40% who were unsuccessful in completing their pregnancies 7 cases
were recorded during the first trimester while 3 more had late fetal loss and 4
cases of preeclampsia.
Summary/Conclusions: Women treated for thrombophilia had a lower percent-
age of fetal loss than their no treatment group counterparts. There is an urgent
need for appropriate guidelines for these patients in our medical center.
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LEARNING ABOUT VALIDATIONS OF THE DVT SCREENING TEST IN
PATIENTS WITH SUSPECTED UPPER LIMB THROMBOSIS:
A PERSPECTIVE FROM THE CLINICAL PRACTICE
H.N. Fernandez - Leyva1,*
1Haematology, Croydon University Hospital, London, United Kingdom
Background: Deep vein thrombosis (DVT) of the upper limbs represents 1-
4% of DVT, most of them related to central venous catheter and / or malignancy.
Thrombosis involving the deep veins (ie, subclavian, axillary, brachial) can lead
to complications as pulmonary embolism (PE) and long-term sequelae. PE
from upper extremity sources accounts for about 6% of cases. Initial treatment
in acute context include fibrinolysis and subsequent anticoagulation (Grade
2C). When symptomatology is mild and/or onset of symptoms undetermined
(>2 weeks), minimum anticoagulation 3 months is recommended. If there are
associated anatomical abnormalities, the possibility of surgical vascular thoracic
decompression must be assessed.
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Aims: To ascertain D-dimer diagnostic accuracy for upper extremity DVT.
Methods: A retrospective audit was undertaken to determine the aetiology and
clinical presentation on patients which UDVT at presentations. Patients wich a
formal malignacy confirmed before the diagnosis was excluded.  A D dimer
(DD) with a cutt off cut off levels validated for lower limb DVT was performed.
Results: A total of 18 patients was identify in the period of 2012 to 2016. All the
cases investigations included Doppler US or CT/MRI and in 30% of the patients
the thrombosis was confirmed via contrast venography as a reference standard
test. The gender predominan was male in this group the symptomatology were
related to physical efforts in a 60% (Paget-Shroëtter Syndrome) whereas
in  female serie the predominant was thrombophilic defects (factor V Leiden).
The average age was 33 years (ranging from 21 to 68 years) and 2 elderly
patients a new diagnosis of cancer was confirmed (thyroid and lung) (odds
ratio, 3.24; 95% CI, 1.13-9.38). The 85% of the patients had an unprovoked
event; four patients have a  diagnosis of catheter related thrombosis and four
cases a thrombofilic defect (factor V Leiden) precipated by anticonceptive. Two
patients had a diagnosis of SLE. We had  four cases of positve DD screening
(both were marginally elevated, P <0.01) . The risk of re-thrombosis was non
significative but in the subanalysis of relapsing thrombotic event populations
the risk of relapse increased proportionally in relation of thrombofilic defect and
high BMI. A trend towards a higher rate of recurrent thrombosis (was observed
among patients with BMI>25 (42.6%) compared to those with a BMI <25 (33%).
This difference reached statistical significance in women with BMI>25, who
had recurrent event in 51.7% of the cases vs those with BMI <25 (29.7%) (p
<0.05 CI 0.03, 0.41).
Summary/Conclusions: In  the unprovoke serie the relation of DD was positive
in less tan 30% of the cases and non stadistically significative (p <0.01). In the
case of subclavian vein oclusion this is result in limited clot burden (which
explain the correspondence with negative DD value). The risk of re-thrombosis
is asociated with thrombophilic defect and high BMI esclusively. The DD adjust-
ed to age and specific young population need to be adressed (age adjusted
DD cut off adpated of the specific population). A prospective studies of DD in
suspected UDVT need to be adressed. 
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THE INFLUENCE OF HEPARINOID FROM THE PEONY ROOTS ON THE
THROMBUS DISSOLUTION
M. Lyapina1,*, T. Obergan1
1M.V.Lomonosov Moscow State University, Moscow, Russian Federation
Background: Many plants have an effect on the blood clotting system. It is
known that there are heparin-like substances in some types of peony roots
(Paeonia lactiflora, Paeonia suffruticosa). It proved that there is an anticoagulant
activity in extracts from such roots.
Aims: The intention is to show the inhibitory effect of the extract of Paeonia
lactiflora roots (EA) on processes fibrin and thrombus formation.
Methods: We used the standard coagulologic methods for determining antico-
agulant activity by APTT test, antiplatelet, total fibrinolytic activity (TFA), fib-
rindepolymerizing activity (FDPA). Experiments were carried out in accordance
with ethical principles and documents recommended by the Declaration of
Helsinki of the humane treatment of animals. We used an animal model with
prothrombotic condition caused by intravenous administration of subthreshold
doses of tissue thromboplastin at a dose of 0.6 -0.7 ml per 200 g body weight
in rats. After 30 min after injection of thromboplastin, we injected intraperitoneal-
ly 0.1 mL of 1% of extract of EP and after 30 minutes we determined parameters
of hemostasis in the blood plasma.
Results: It was shown that after administration of the indicated doses throm-
boplastin occurs hypercoagulability in blood plasma of animals (APTT
decreased by 23% SFA - 15%, FDPA -12%; increased platelet aggregation by
18% compared to control animals not receiving thromboplastin). Normalization
of blood clotting is installed in the experimental rats after application EP (recov-
ery of platelet aggregation to 98%, APTT- to 100%, up to 95% SFA- FDPA and
- up to 67% compared with control). The high degree of FDPA indicates the
ability of EP to obstruct the process of the formation of fibrins and thrombosis.
Heparin components in EP interact with fibrin monomers which do not partici-
pate in their conversion to fibrin polymer. As a result, stable fibrin polymer or
thrombus is not formed.
Summary/Conclusions: Consequently, the extract of Paeonia lactiflora roots
containing heparinoid contributes to the restoration of coagulation properties
in blood of animals in prothrombotic condition and prevents thrombosis. In the
initial stages of fibrin formation, it causes the thrombus dissolution.
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LOW MOLECULAR WEIGHT HEPARIN AND HIGH MOLECULAR WEIGHT
HEPARIN: COMBINATION WITH ADRENORECEPTOR ANTAGONISTS AND
PREVENTION OF THROMBUS FORMATION 
M. Golubeva1,*, M. Grigorjeva1
1Biology, Lomonosov Moscow State University, Moscow, Russian Federation
Background: Rethrombosis and thromboembolia are the most common side
effects of thrombolytic therapy. One of the possible causes of thrombosis is the
entering of thromboplastin in the blood stream. Marker of thromboplastin is an
intrinsic membrane glycoprotein 5’-nucleotidase (5’NT) that is present as an
enzyme in a wide variety of cells. Recently it was shown that compensatory
reaction of haemostasis system by using different fibrinolytic drugs was con-
nected with the stimulation of the sympathetic nervous system.  Besides, it is
known that selective and nonselective α–adrenoreceptor blocking agents have
fibrinolytic and antiplatelet effects. The prevention of thrombosis complication
is very important field of pathophysiology and medical practices. Therefore, we
studied effects of different α–adrenoreceptor antagonists and the influence of
these substances combinations with various anticoagulant and fibrinolytic
agents on blood coagulation during many years. 
Aims: The study  of the  influence of low molecular weight heparin (LMWH, 4.4
kD) and high molecular weight heparin (HMWH) and their combinations with
different α –adrenoreceptor antagonists (AA) on experimental thrombosis pre-
vention.
Methods: Experiments were carry out on 50 white laboratory rats weighing
200-230 g according to the ethical principles of the Helsinki Declaration. Anti-
coagulant and antithrombotic effects of LMWH or HMWH were studied in two
rat models of thrombosis – thrombosis in v. jugularis (Wessler) and thrombosis
in arterio-venous shunt (direct registration of blood pressure). The α–AA digy-
droergotoxin (DET – 1mg/kg), α1–AA prazosin (PZ – 2mg/kg), LMWH or  HMWH
(40 USP/kg) were injected in v.jugularis. Saline was administrated in control
rat groups. The thrombus were formed 15 or 180 min after substances injected.
The degree of thrombus formation (TF) was detected in ball (Wessler model)
and by time of TF (arterio-venous shunt model). In blood plasma the activity of
5’NT was detected. The results were processed statistically.
Results: The increase of anticoagulant and antithrombotic effects of LMWH or
HMWH by pretreatment of DET or PZ  were shown in both animal models of
venous thrombosis. The degree of TF by Wessler model  may be estimated as
3.7 (saline), 1.3 (LMWH), 1.8 (HMWH), 0.9-1.1 (DET+ LMWH or PZ+LMWH)
and 1-1.3 (DET+ HMWH or PZ+HMWH ). Besides, it has been shown that TF
was accompanied with significant hypercoagulation of blood: 5’NT activity was
increased in 2 time comparatively with normal level. LMWH or HMWH combi-
nations with DET or PZ  administration led to normalization of 5’NT level in
blood plasma. In arterio-venous shunt model it has been shown that the time
of TF was 2 min (saline), that was accompanied with the decrease of blood
pressure (on 40-50 mmHg). In this case the time of TF was prolonged in 4 time
(LMWH) or 2 time (HMWH) comparatively with saline group 15 min after injec-
tion; in 4.5-5 time (DET+ LMWH or PZ+LMWH) or 3-3.5 time (DET+HMWH or
PZ+HMWH ) comparatively with saline group 180 min after injection. 
Summary/Conclusions: Thus  we confirmed that LMWH (as one, as in com-
bination with α–adrenoreceptor antagonists) has definite advantages over
HMWH.  Besides our results show that α–adrenoreceptor antagonists signifi-
cantly improvement antithrombotic effect of anticoagulant agents (LMWH and
HMWH). Therefore the combination of LMWH with selective and nonselective
α–adrenoreceptor antagonists may be effective used for prevention of venous
thrombosis development and thromboembolia.
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THE POLICY AND PRACTICE OF ANTICOAGULATION THERAPY AMONG
CLINICIANS IN SOUTHEAST NIGERIA.
T. U. Nwagha1,*, R. Anakwue2, O. Ukpabi3, E. Onwubuya4, N. Obeka5,
I. Okoye6, B. Azubuike6
1Haematology & Immunology, 2Internal medicine, University Of Nigeria Teach-
ing Hospital, Enugu, 3Internal medicine, Abia state Teaching Hospital, Umuahia,
4Internal medicine, Nnamdi Azikiwe Teaching Hospital Nnewi, Awka, 5Internal
medicine, Federal Medical center , Abakiliki, 6Internal medicine, Amaku Spe-
cialist hospital, Awka, Nigeria
Background: In the absence of anticoagulation therapy, the risk of Venous
thromboembolism; deep-vein thrombosis (DVT)  and pulmonary
embolism(PE)in medically ill patients is comparable to that in moderate-risk
surgical patients. Previous studies have revealed grossly inadequate knowledge
and a dismal practice of anticoagulation among healthcare workers in some
resource poor countries. Prophylactic anticoagulation is under-prescribed in
Nigeria, South Africa, as well as in many other countries in Africa.
Aims: The aims of the study are to evaluate the practice of anticoagulant ther-
apy. It will also document the frequency of drug-induced complications resulting
from the use of anticoagulants and presence of an anticoagulation policy in the
hospitals surveyed.
Methods: This is a multicentre cohort survey of the practice of anticoagulant
therapy among clinicians in South East Nigeria. A pretested validated ques-
tionnaire was administered to clinicians in five tertiary hospitals in the southeast
of Nigeria. The questionnaire was designed to assess their practices anticoag-
ulation therapy. The questionnaire was administered consecutively on clinicians
in the participating centers. The following institutions participated in the survey:
University of Nigeria Teaching Hospital Enugu, Federal Medical Centre, Abaka-
liki, Federal Medical Centre Umuahia, Abia State Teaching Hospital, Aba and
Amaku Specialist hospital Awka.  Statistical package for Social Science (SPSS)
software, version 18 (SPSS Inc., Chicago, IL) was used for analysis.
haematologica | 2017; 102(s2) | 877
Madrid, Spain, June 22 – 25, 2017
Results: A total of 528 clinicians were involved in the survey. There were more
males 378 (71.6% ) than females, 150 (28.4%) the clinicians who practiced for
less than 5years are in the majority 189 (35.8% ) and those with 15-20 years of
practice 46(8.7%) are in the minority.   Only 52 of the respondents (9.8%) claimed
their institutions had an anticoagulation policy while 274 (51.9% ) of them said
there was no such policy and  168 (31.2% ) do not know of any policy. Unfrac-
tionated heparin was the most frequently used (96.8%) and fondaparinux was
the most infrequently used (42%). Most of the prescriptions were done by younger
clinicians who are the highest in number. The consultants prescribed heparin
and warfarin most, with the newer anticoagulants taking the rear position. Only
193 (36.6%) of the respondents routinely prescribed anticoagulation therapy
when indicated. 412(78%) of respondents believe the risk of anticoagulation out-
weighs the benefits while 439 (83.1%) identified cost is an important variable in
prescribing anticoagulation agent. Anti-coagulation prophylaxis was the most fre-
quently used for patients immobilized or bedridden (94.1%); malignancy  and
atrial fibrillation were the most infrequent reasons for using anticoagulation agents
(50.6%) . A total of 63 respondents (11.9%) were not satisfied and 219 (41.5%)
were not very satisfied with the laboratory monitoring tool available in their insti-
tutions. Bleeding is the most common complication of anticoagulation while the
least encountered complications are skin and jaw necrosis among the respon-
dents 492(93.2%), 1(0.2%) respectively.
Summary/Conclusions: This survey has shown the lack of anticoagulation
policies among the centers that participated.  Our survey has also shown defi-
ciencies in the areas of practice of anticoagulation among the clinicians in the
Southeast of Nigeria. These gaps can be remedied by continuous medical edu-
cation and by the establishment of anticoagulation policies.
Transfusion medicine
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UMBILICAL CORD BLOOD PLASMA INFUSION PROMOTES BLOOD CELL
RECOVERY IN INPATIENTS WITH ACUTE LEUKEMIA UNDERGOING
CHEMOTHERAPY 
Y. Lu1,*, X. Zhang1, X. Li2, Y. Zou1, Z. Lin1
1the third Affiliated Hospital of Sun Yat-Sen University, 2 The Sixth Affiliated
Hospital of Sun Yat-Sen University, Guangzhou, China
Background: Umbilical cord blood plasma(UCBP) is separated from umbilical
cord blood. UCBP contains a variety of hematopoietic growth factors which
can stimulate hematopoiesis.
Aims: The aim of this work is to explore the influence of UCBP infusion on
blood cell recovery in patients with acute leukemia undergoing chemotherapy.
Methods: Patients with the diagnosis of acute leukemia were included in this
study and they were randomly distributed to experimental group and control
group. Patients in experimental group received infusion of 100ml UCBP with
the same ABO and Rh blood type every day after chemotherapy for five days
and patients in control group received placebo for the same time. Blood routine
were tested every day until WBC >4.0×109/L and PLT >20×109/L.
Results: 25 patients were included in the study of which 23 were brought into
statistics. 13 patients were in experimental group and 10 in control group. There
were no difference in age, gender and dose intensity of chemotherapy between
the two groups (P>0.05). The average recovery time of the blood neutriphil
granulocyte >0.5×109/L in experimental group and control group were respec-
tively (8.53± 3.26) days versus (12.92± 4.75) days  (P<0.05)  and that of PLT
>20×109/L was respectively (9.24± 3.68 ) days versus (13.15± 5.76) days
(P<0.05). No UCBP transfusion-related side effects were found.
Summary/Conclusions: UCBP administration is safe as treatment for cytope-
nia and could promote blood cell recovery in patients with acute leukemia
undergoing chemotherapy.
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TOWARD BETTER BLOOD TRANSFUSION PRACTICE: A SUCCESSFUL
RED BLOOD CELL UTILIZATION TOOLS IN A TERTIARY CARE
HOSPITAL
A. Aly1, G. Mawad1, E. Alzaabi1, A. Aly1,*
1Mafraq Hospital , Abu dhabi, United Arab Emirates
Background: The need for blood in hospitals continues to exceed the volume
collected by the transfusion services. The gross over-ordering of blood, in excess
of actual and anticipated needs leads to substantial costs and a burden to the
transfusion services. In addition, over-ordering leads to non-availability of cross-
matched units for other patients who might be in urgent need of transfusion.
Aims: We are aiming to reduce the Cross-match-to-transfusion ratio (C:T ratio)
& improve blood utilization in Mafraq Hospital.
Methods: In 2011 the ordering practice at Mafraq Hospital, a designated Trauma
Centre, had been evaluated.  Data collected retrospectively over a one year period
and a C:T ratio adopted by the American Association of Blood Bank was calculated
for all various subspecialties including Surgery, Internal Medicine, Pediatrics and
Obstetrics and Gynecology.  All procedures related to hospital transfusion practice
been retrieved and re-evaluated to address gaps. Policy of maximum surgical
blood ordering (MSBO) was implemented based upon both results of audits and
by discussion and agreement between medical teams.  Focused training and
education has been followed to increase the awareness of the health care workers.
Plus monitoring of C:T ratio on monthly basis, blood bank team had arranged
meetings with the departments that were over-ordering cross-matches to explain
that group & save test is a safe, effective and financially beneficial strategy. Com-
municating with the physicians had been the most challenging aspect of imple-
menting the policy changes.Regular audits had been conducted to measure the
compliance and effectiveness of the blood management practice.  
Results: Compared to the international guidelines, C:T ratios in 2010 was
beyond the acceptable target and ranged between 2.5 to 3.2 highlighting the
over-ordered cross-matched blood in certain sub-specialties. This practice of
ordering was probably because of the fear that blood will not be available, if
needed. Following implementation of control and continuous monitoring meas-
ures while establishing proper procedures such us transfusion guidelines,
administration of blood and blood products and Maximum Surgical Ordering
Practice, Mafraq blood bank ,supported by the Transfusion and Tissue & Quality
& Patient Safety Committees, achieved a great success in reducing C:T ratio
<2 all through 2016 Figure 1. The reduction of C:T ratio had improved blood
inventory control and reduced the workload of the blood bank staff. Because
fewer units of cross-matched PRBC are being ordered, the blood bank has
been able to decrease the number of units of blood stocked in house and hence
decreasing the number of expired units &reducing money loss Figure 1. The
savings in technologist time is particularly significant since the blood bank is
most of the time at a minimal staffing level.
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Summary/Conclusions: There is a tendency to order blood in excess, either
by asking for an increased number of units or as a standby precautionary meas-
ure. Adherence to MSBO & transfusion guidelines, hospital can achieve C:T
ratios below 2.0. The introduction of strategies for improved blood utilization
has been shown to be cost effective and safe. Future comparison analysis with
facilities with well-established blood management program can enhance the
current program and ensure continuous proper utilization.
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SAFETY AND EFFICACY OF A PROTHROMBIN COMPLEX CONCENTRATE
IN VKA REVERSAL AND OFF-LABEL INDICATIONS
M. Marcos Jubilar1,*, J.A. Garcia Erce2, N. Martinez Calle1, J.A. Paramo1,
R. Figueroa1, S. Villar1, M. Quintana3
1Hematology and Hemotherapy, Clínica Universidad de Navarra, 2Hematology
and Hemotherapy, Complejo Hospitalario de Navarra, Pamplona, 3Intensive
Medicine, Hospital Universitario La Paz, Madrid, Spain
Background: Prothrombin complex concentrates (PCC) are highly purified
mixtures of plasma coagulation factors that contains vitamin K dependent and
anticoagulation factors, they are approved for urgent reversal of vitamin K
antagonists (VKA). Massive bleeding-associated coagulopathy guidelines
include PCC in their management, although as an off-label indication.
Aims: The aim of the present work is to evaluate safety and efficacy of PCC in
a case series of VKA reversal and refractory coagulopathy associated with
major bleeding.
Methods: Retrospective review of cases treated with a four-factor PCC
between January 2010 to January 2016 in two tertiary Universitary Hospitals.
As safety endpoints we evaluated infusion reactions and incidence of throm-
boembolic events by self reported registry. The efficacy endpoints were studied
in two separate cohorts: 1) INR correction for VKA reversal and 2) coagulopathy
correction and early mortality (24 hours) in major bleeding coagulopathy.
Results: 328 patients were included (47.25% male), median age 78 years (range
19-102). PCC was used in the following cases: 1) 66.67% in VKA reversal indica-
tion (181 patients due to hemorrhage and 33 prior to emergent surgery), mean
dose of PCC 1333.51 IU; 2) 30.54% in refractory coagulopathy in major bleeding
(30 patients due to massive bleeding protocol activation, 43 patients in hepathopa-
thy coagulopathy and 25 patients in bleeding not related with any of previous rea-
sons) a mean dose of PCC 1681.63 IU was used. Safety endpoint: Two infusion
reactions were reported potentially related to PCC use, they were not specified
neither as anafilaxia nor as pulmonary edema, and 8 thrombotic episodes were
observed (2.4%): 5 pulmonary embolism, 2 deep venous thrombosis and 1 portal
thrombosis, 75% of the events appear in the group of VKA reversal. Efficacy end-
point: VKA reversal in bleeding patients was effective in 97% of them, 76.5% with
complete reversal of INR value (INR<1,5), 34,25% of patients required red blood
cell (RBC) transfusion, with a mean of 1.32 RBC. Prior to invasive procedure VKA
reversal was effective in 83% of patients, all procedures taking place with no bleed-
ing complication, 36,3% of patients needed RBC with a mean of 1.12 units. 24
hours mortality in refractory coagulopathy associated to major bleeding was 31,6%,
having a worse outcome (40% rate of death) those who suffer a massive bleeding
coagulopathy, all death related with absence of bleeding control. A global INR cor-
rection happen in 76.7% of patients, complete correction in 40.7%. 63,26%
received previous to PCC fresh frozen plasma.
Invasive hemostatic procedures were required in 20% of the whole series. 
Summary/Conclusions: A four-factor prothrombin complex was safe and
effective as adjuvant treatment in refractory coagulopathy due to major bleeding
as well as for the emergent reversal of VKA.
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TRACEABILITY OF RED BLOOD CELLS IN A HOSPITAL TRANSFUSION
LABORATORY
M. Tserga1, A. Argyrou1,*, S. Nikolopoulou1, A. Gafou1
1Blood Bank, General and Oncology Hospital “Agioi Anargyroi”, Athens, Greece
Background: According to European legislation (2002/98/EC, 2005/61/EC) as
a requirement of hemovigilance system traceability (confirmation of final des-
tination of blood components in hospitals) information should be kept for 30
years, improving the quality and safety of the transfusion process. Various
methods are available from simple paper–based procedures to full electronic
blood tracking systems. The ideal goal is to trace the final fate of 100% of the
red blood cell (RBC) units, from donor to recipient and vice versa.
Aims: To check the ability to trace each individual unit from donor to recipient
or disposal in our hospital.
Methods: To ensure compliance, the minimum traceability data set for retention
is a mix of 1) Wards’ paper files (file of transfusions and/or patient records:
14/2 wards respectively). 2) HTL electronic records and paper records. The
transfusion practitioner is responsible for the collection and maintenance of
traceability data. 
Results: During the year 2016, the number of RBC units transfused in our hos-
pital was 2128. The traceability status of the transfused units is shown in the
Table 1.
Table 1.
Summary/Conclusions: Although we are satisfied that the results represent
a reasonably accurate working model of the current situation, the trail of a unit
is less reliable after blood has left the HTL. 1. Patients’ notes to provide trace-
ability are not totally reliable. It is apparent that the ward staff plays a key- role
part in the chain and this highlights the need for them to receive training to
emphasize the importance of their contribution to hospital compliance. 2. The
indications are that the essential requirements on traceability are not fully met
by the current laboratory computer system. A configuration is needed to produce
a report which lists components which have been assigned for use but do not
have an entry for return to stock or final fate. Ongoing problems will be referred
to the Hospital Transfusion Committee. 3. For the longer term ultimately only
effective IT system in both wards and HTL can ensure total traceability and we
recommend the inclusion of electronic tracking system in the National Blood
Donor Registry Programme (EMA)  
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NON-HEMOLYTIC FEBRILE POST-PLATELET-TRANSFUSION REACTIONS
IN HEMATOLOGICAL PATIENTS
A. Rakhmani1,*, E. Mikhaylova2, I. Dubinkin3, V. Troitskaya2, O. Kalmikova3,
M. Danilevskaya3, T. Gaponova1
1Clinical Research Department of processing and cryopreservation of blood cells,
2Clinical Research department of chemotherapy and bone marrow depression,
3Scientific clinical laboratory quality control and safety of transfusions, Federal
State-Funded Institution National Research Center for Hematology of the Ministry
of Healthcare of the Russian Federation, Moscow, Russian Federation
Background: Platelet concentrate (PC) transfusions are the main method of
thrombocytopenia correction in hematological patients, but multiple transfusions
could trigger alloimmunity and refractoriness to transfusions.  
Aims: Comparison of post-transfusion reactions in hematological patients with indi-
vidual matching and without individual matching receiving PC transfusion support. 
Methods: In 2015-2016, we observed 948 hospitalized patients, who received
12.344 PC transfusions. Individual matching of PCs was performed by cross-
matching on the Galileo-Neo (Immucor) analyzer. Statistical processing was
performed using the chi-squared test with Yates’ correction. 
Results: 107 of  948 patients developed refractoriness to PC transfusions (12%
of total patients). Out of them, 21 patients received 389 PC transfusions without
individual matching. 86 patients received 1705 PC transfusions with individual
matching. During transfusions without individual matching to non-refractory
patients, 0.003% of non-hemolytic febrile reactions (NHFR) have been record-
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ed, after matching to refractory patients the frequency was 0.002%. Before
matching to refractory patients, the frequency of NHFR was (0.03%) (Table 1). 
Table 1.
Summary/Conclusions: The frequency of NHFR in groups with refractoriness
with individual matching is significantly lower (10 fold) compared to groups with
refractoriness before the matching (Р<0,01)*.
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RARE DONORS AND MALARIA
A. Berzuini1,*, B. Foglieni1, M. Spreafico1, D. Prati1
1Department of Haematology and Transfusion Medicine, Ospedale A. Manzoni,
Lecco, Italy
Background: Migratory flows of sub-saharan (SSA) persons throughout the
world are expected to continously increase. A significant proportion of SSA citi-
zens are affected by Sickle Cell Disease (SCD), condition requiring repeated
blood transfusions. Many centuries of malaria pressure have induced in SSA
natives a homogeneous selection of peculiar haematologic characteristics, such
as the absence of high frequency red cell antigens (defining a rare blood) that
cannot be found in donors of European descent so that many SCD transfused
patients experience the fearful occurrence of red cell alloimmunization.  For these
reasons haematologists are expecting to access to Rare Blood Banks in order
to assure a full match between donor and recipient’s blood, that may be obtained
from donors sharing the same ethnicity. Unfortunately SSA donor recruitment is
counteracted by the widespread diffusion of infections contracted before migra-
tion: one of these is malaria. In SSA malaria may occur sublinically and is char-
acterized by a slow antibody clearance. This peculiar condition, the so-called
semi-immunity, has been induced by a strong genetic pressure, and is a kind of
co-evolutionary process characterized by the co-exhistence and persistence of
small entity of Plasmodium genome with relative antibodies. Molecular techniques
are unreliable to detect a small number of Plasmodia, which may otherwise be
sufficient to induce a transfusion transmitted malaria (TTM). The serologic assess-
ment, despite the low specificity, remains the most sensitive and reliable method
to detect the semi-immune status in blood donors (1).
Aims: The aim of this study was to assess the prevalence of malaria immunity
in a cohort of healthy SSA citizens.
Methods: Since 2010 in our Department of Haematology and Transfusion
Medicine we recruited 184 SSA citizens, in good health, who agreed to under-
went clinical and laboratory investigations to become a blood donor. All of them
were born in SSA Africa and lived there for at least the first 5 years of life. 70%
of subjects didn’t recognize any previous malaria fever. The last travel/stay in
Africa was 1-20 years (median 3 yrs), and 48% of returning people had received
prophylaxis. Malaria serology was determined by a commercial enzyme
immunoassay kit (Malaria EIA Ab, BioRad).
Results: Overall 75% of persons were positive for malaria antibodies. Serologic
positivity was found in 75% of persons no more exposed in 5 recent years and
even in 83% (19/23) persons settled in Italy since 10-20 years. Serologic pos-
itivity was present in 100% of people from Benin, 85% from Burkina Faso, 78%
from Ivory Coast and Cameroon, 63% from Senegal. We followed antibody
concentration in 50 persons (136 assays), and we observed a slightly negative
trend that, in most cases, was followed by a prolonged phase of low antibody
levels.  4/50 became negative after three years.
Summary/Conclusions: The identification of malaria antibodies is essential
in SSA native donors and, by far, irrepleaceble in order to avoid the risk of
TTM. Until pathogen inactivation techniques will become available, we have a
very low expectation to introduce SSA blood in Blood Bank inventories. Haema-
tologists have to wait some years for the forthcoming SSA second generation
that will allow to fully match the entire SCD patient community.
REFERENCE
1. Assennato SM, Berzuini A et al., Transfusion 2014  doi:10.1111/trf.12650.
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EFFICACY AND INFLUENCE OF IRON CHELATION THERAPY ON RED
BLOOD CELL TRANSFUSIONS
A. Parvu1,2,*, M. Iancu3, A. Vasilache2, T. Torok2, I.-A. Zsoldos1, M. Zdrenghea1,
L. Petrov2, C. Seles2, L. Urian2, A. Todinca4, C. Truica5, A. Bojan1
1Hematology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 2Hema-
tology, “Prof. dr. Ion Chiricuta” Oncological Institute, 3IT, “Iuliu Hatieganu” Uni-
versity of Medicine and Pharmacy, Cluj-Napoca, 4Hematology, Baia-Mare
County Hospital, 5Hematology, “Iuliu Hatieganu” University of Medicine and
Pharmacy, Baia-Mare, Romania
Background: Chelation therapy is recommended for transfused patients that
have an elevated serum ferritin level (over 1000 microg/l), evidence of iron
overload or received over 20 units of red blood cell transfusions (RBCT).
Deferasirox showedefficacy and safety in maintaining or reducing body iron
(assessed by liveriron concentration or serum ferritin).Iron chelation therapy
was associated with hematopoiesis improvement in transfusion-dependent
patients and interruption of Deferasirox treatment of transfusions dependent
myelodisplastic patients produced loss of erythroid response.
Aims: Aim of the study: to assess the results of Deferasirox efficacy, side
effects and to study if the number of RBCT decreased after starting
Deferasirox. 
Methods: We have done a retrospective, transversal study including all the
adult politransfused patients treated with Deferasirox in three counties Hema-
tology Departments of Nord-West Romanian hospitals. Criteria of Deferasirox
treatment: over 20 RBCT, serum ferritine level over 1000 microg/l.
We created a data collection sheet including: demographics, information on
patients’ disease, serum ferritine level at start of and during treatment,
Deferasirox dose, data about dose modification, adverse effects of Deferasirox
and their management, reasons for treatment discontinuating, evaluation of
commorbidities that could increase serum ferritine level, number of RBCT
before and after starting the treatment.
Results: We included 40 politransfused patients treated with Deferasirox, age
average 63. The diagnosis included mielodysplastic syndromes (most of
patients), thalassemia, other anemias. Myelodysplastic patients were treated
with low dose chemotherapy, epigenetic treatment, RBCT and
bethatalasemic/anemic patients were transfused. The baseline value of ferritine
was between 1075 - 6187 microg/l. Deferasirox dose: 20-30 mg/kg. There was
a significant reduction in serum feritine from baseline for all the patients. Fer-
ritine median at start, 3631 microg/l decreases at 1537 microg/l after 6 months
of treatment and at 994 microg/l after 12 months of treatment. There were 8
patients that had descendent levels of feritine, but during infectious episodes
the ferritine increases for a short period of time. Digestive adverse events
appeared in three cases (two cases of diarrhea and one case of digestive hem-
orrhagic episode). In all these cases the treatment was temporarily discontin-
ued. In three cases, treatment was stopped because low ferritin level (under
500 microg/l). RBCT were administered before (mean 2.43 units/month) and
after starting Deferasirox (mean 1.39 units/month), the difference is statistically
significant (Student Test, t(39)=6.98, p<0.001). After starting Deferasirox treat-
ment mean number of RBCT decreased, mean of differences (95% CI) was
1.04. We analyzed the group of 23 patients treated with Deferasirox less than
12 months, and the patients treated more than 12 months, 15 patients. In both
groups the difference of RBCT means (before and after the start of the treat-
ment) are statistically significant (for the patients treated less than 12 months:
Student Test, t(23)=8.12, p<0.001 and for the patient treated more than 12
months: Student test, t(15)=3.03, p=0.008).
Summary/Conclusions: Analyzing our group of 40 patients, Deferasirox
proves to be effective and safe. Adverse effects that determined a temporary
stop of the treatment were mild/medium short time digestive reactions. The
number of red blood cell transfusion significativelly decreased after starting
Deferasirox treatment.
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LIBERAL VS RESTRICTIVE COMPARATIVE TRANSFUSIONAL STUDY IN
ONCOLOGICAL POPULATION
M.I. Touzón Andión1,*, M. Gestal 1, A. Varela1, M. Castro1, C. Moinelo1,
R. García de Villaescusa1
1Transfusion , Centro Oncológico de Galicia, La Coruña, Spain
Background: Allogeneic transfusion therapy is perhaps one of the most widely
used treatments without good evidence support, despite many years of appli-
cation in clinical practice. This, coupled with blood shortages, the impossibility
of achieving zero risk, the lack of evidence that transfusion may increase con-
sumption or decrease tissue oxygen debt and the existence of an association
with an increase in morbidity and mortality have favoured that we join efforts
towards its optimal use.
Aims: Optimal use in our adult oncological population and evidence that restric-
tive transfusion (TR, Hb 7-9 grs / dl) is not greater or lowerto the liberal trans-
fusion (TL, Hb 8-10 grs / dl), keeping hemoglobin in safe levels for the patient.
Methods: A research was performed from October 1st, 2015 through Decem-
ber 31st, 2016. We analyzed the proportion of patients receiving packed red
cells (CH) and the number of units transfused as well as post-transfusion control
in order to describe the outcome of the CH versus TL strategies in the cancer
population under the study.
Results: See Table 1.
Summary/Conclusions: The results obtained in our series of 311 cancer
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patients indicate that the restrictive strategy has been equally effective and
probably superior to the liberal one maintaining Hb at a safe level in each
patient, as well as quality of life and comfort in a subgroup with advanced and
terminal cancer.
Table 1.
Hb Pre: Pre-transfusional haemoglobin; Hb Post: Post-transfusional haemoglobin; PWC:
Patients without post transfusion Hblevel; TPT: Total Patients Transfused; X-: half haemoglobin.
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HIGH RISK OF HBV INFECTION IN VACCINATED POLYTRANSFUSED
CHILDREN
M. El-Sayed1, Z. Said2, E. A. E. Abou Elmagd2, E. Salama3, F. Ebeid1,*
1Pediatric Department, Ain Shams University, Faculty of Medicine, 2Microbiol-
ogy Department, Faculty of Medicine (for girls), Al-Azhar University , 3Commu-
nity Medicine Department, National Research Center, Cairo, Egypt
Background: Children receiving chemotherapy for neoplastic diseases are
still susceptible to Hepatitis B virus (HBV) infection despite the national HBV
vaccination program coverage for all infants since 1992.
Aims: This study aimed to analyze immunity against HBV and occurrence of
HBV breakthrough  infections in polytransfused children who had been vacci-
nated during infancy.
Methods: The study included 89 children with hematological disorders and
malignancies, who were categorized into group (A): 37 receiving chemotherapy
(M:F 20:17; mean age:7.7±4.0) and group (B): 52  polytransfused children (M:F
31:21; mean age:7.6±3.2).  A matched healthy control group (n=162) was also
included. All patients and controls had received their primary vaccination against
HBV in infancy. Quantitative anti-HBs were tested for patients and controls.
Patients’ sera were tested for HBsAg, anti-HBc, and HBV-DNA (nested PCR
for surface, core & x-regions). 
Results: Levels of anti-HBs between 10-100 IU/L and ≥100 IU/L were found
among 13.5% and 21.6% [group (A)], 44.2% and 11.5%  [group (B)] and 32.1%
and 10.5% of controls respectively. There was a significant difference in HBsAb
between patients receiving chemotherapy (group A) and both groups B patients
(p=0.008) and controls (p=0.032). However, no difference was found between
polytransfused children [group (B)] and controls. 
HBsAg was positive in 21(67.7%) children under chemotherapy [group (A)]
compared to 10 (32.2%) polytransfused children [group (B)] (p<0.0005). Overall,
49 patients (55%) were HBV-DNA positive; 44 c-region positive, 7 s-region pos-
itive, 2 positive for both c and s-regions and one positive for c and x-regions.
Of those, only 21 patients (42.8%) were also positive for HBsAg; while 28
(47.2%) had occult HBV infection (HBsAg-negative). There was no significant
difference between patients receiving chemotherapy [group (A)] and polytrans-
fused children [group (B)] (p 0.157), regarding the rate of HBV DNA. Anti-HBs
≥10 IU/L co-existed in 38.7% (12/31) of HBsAg positive patients and 49%
(24/49) of HBV-DNA positive patients.
Summary/Conclusions: Children with neoplastic diseases vaccinated during
infancy were at a high risk for HBV infection. The effect of immunosuppression
on the HBV protective level favored overt HBV infection in children receiving
chemotherapy. The co-existence of anti-HBs with HBsAg and/or HBV-DNA
demonstrated a possible residual transfusion-transmission risk with mutant
HBV strains.
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THE ISOHEMAGGLUTININ TITERS OF BLOOD BANK DONORS: THE
EXPERIENCE OF ISTANBUL FACULTY OF MEDICINE
Z. Karakas1,*, D. Soydemir1, M. Yanaşık1, A. Akcay2, G. Ozturk3
1Pediatric Hematology-Oncology, Istanbul University Istanbul Medicine Faculty,
2Pediatric Hematology-Oncology, Acıbadem University, 3Pediatric Hematology-
Oncology, Acibadem University, Istanbul, Turkey
Background: Isohemaglutinins that develop against ABO blood group antigens
are very important in transfusion and transplantation medicine. Today, 30-40%
of allogeneic stem cell transplantations are ABO incompatible transplantation,
20-25% of which are major, 20-25% are minor and remaining bi-directionally
incompatible transfusion. Our study; based on the knowledge that isohemag-
glutinins play an important role in blood transfusion policies in patients under-
going ABO incompatible hematopoietic stem cell transplantation(HSCT) has
been shaped by the assumption that each healthy blood bank donor may be
potential transfusion donors for ABO incompatible HSCT transplant recipients
Aims: In this study, we investigated the isohemagglutinin titer values of the
individuals with A, B and O blood groups; the distribution of the isohemagglutinin
titers according to the decades and gender. Also we examined the posibility of
determining the isohemagglutinin cut off value in Turkish society.
Methods: One thousand five voluntary blood donors (48 female, 957 male),
randomly chosen from the donors, providing the criteria to be a standard blood
donor in Blood Center Department, Istanbul Faculty of Medicine were studied.
This study was approved by the Ethics Committee of Istanbul Medical Faculty.
In the donor population group; blood group A (%40) was the most common and
blood group AB was the rarest blood group. Accoording to the Rh D phenotypes;
85% of the population was Rh D positive and 15% of the population was Rh D
negative.The frequency of our blood group was determined similar with other
European countries. The most common age range of one thousand five volun-
tary blood donors, including the same rate individuals with blood group A, B
and O, was the age range between 26 and 35 years. Forward and reverse
blood group determination were performed to these donors and also we iden-
tified the Anti-B Ig M and Ig G isohemagglutinin titer values for blood group A;
Anti-A Ig M and Ig G titer values for blood group B; eventually both Anti-A Ig M
/Ig G and Anti-B Ig M/ Ig G izohemaglutinin titer values for blood group O by
using column agglutination methods. Statistical analysis was performed with
NCSS (Number Cruncher Statistical System) 2007 (Kaysville, Utah, USA).
Results: While the titer value of Anti-A Ig M isohemagglutinin was 1:128 for
female individuals with blood group B; the titer values of both Anti-B Ig M (1:128
and 1:256) , Anti-B Ig G (1:1024) and Anti-A Ig M (1:256) isohemagglutinins
were statistically significiance in female individuals rather than male ones. The
levels of isohemagglutinin in the blood groups A, B and 0 are shown in Table
1A,B. There was no statistical difference in anti-B IgG and IgM titers in blood
group A, anti-A IgG and IgM titers in blood group B and anti-A IgG and IgM titers
in blood group O between males and females(p>0.05). However Anti-B IgG and
IgM antibody titers were higher in females than males in donors with blood group
O respectively p=0,017 (p<0,05) and p= 0.001 (p<0,01) (Figure 1 A,B).
Table 1.
Figure 1.
Summary/Conclusions: Female individuals of blood bank donors participated
in our study have higher isohemagglutinin titer values rather then male individuals.
Recurrent blood group incompatibility in pregnancy, invasive diagnostic and ther-
apeutical approaches for risk analysis in fetal examination during pregnancy,
perinatal complications causing fetomaternal hemorrhage after pregnancy or dur-
ing birth and lastly autoimmun diseases cause the enchancement of isohemag-
glutinin titer values in female individuals. Regarding the gender differences; nutri-
tion, vaccination and recurrent blood transfusion history of blood bank donors
alsa effect and change the isohemagglutinin titers of individuals. Population spe-
sific isohemagglutinin titer values play a key role in blood donation policy of
patients undergoing hematopoietic stem cell transplantation. Consequently; we
predict that Turkish community-spesific isohemagglutinin cut off titer values can
be identified and we will hope our knowledge on this issue in the future with the
increase of research is going to increase further.
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THE NEW METHOD OF PURIFICATION FACTOR COAGULATION VIII 
N. Shurko1,*, T. Danysh1, V. Novak2
1laboratory biochemistry of blood, 2Hematology, State Institution «Institute of
Blood Pathology and Transfusion Medicine NAMS of Ukraine», Lviv, Ukraine
Background: The human plasma of blood can be transfused directly to patients
or pooled and fractionated into plasma protein products. Plasma contains about
60-80  g/L of protein, of which about 95%  are used for many therapeutic prod-
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ucts.  The main proteins that use for treatment many diseases are albumine
(45 g/L), immunoglobulin (8-11 g/L), factors coagulations. The Factor VIII (FVIII)
is one of the blood coagulation factor and it  deficient causing development of
bleeding desorders known  as  Haemophilia A. The purification of FVIII  is gen-
erally required for the treatment Haemophilia A or von Willebrand’s disease
and heavy loss of blood, requires relatively high purity for medical use.
Aims: optimization of a process purification of FVIII   by the method of  affinity
chromatography on the Diasorb-aminopropyl matrix with triazin active dyes as
ligands.
Methods: adsorption/precipitation, ion-exchange chromatography on DEAE-
Sepharose, affinity chromatography on the Diasorb-aminopropyl matrix with
Active Scarlet Damask 4GT as ligands in combination methods of antiviral
treatment.
Results: The process plasma fractionation is largest industry segment in man-
ufacture of therapeutic concentrate of plasma proteins.  We developed tech-
nological scheme that involves fractionation plasma of blood in combinations
of classical methods of protein precipitation and two chromatographic steps:
ion exchange and affinity chromatography.
Of all plasma fractionation methods, chromatography is the best candidate for
purification  of factor coagulation, especially  FVIII. The methods adsorption/pre-
cipitation  permits the fractionation of large volumes of plasma, but  the quality
of the product obtained by chromatography is superior.
We offer: fresh frozen plasma – adsorption of proteins on the barium citrate –
adsorption of proteins on Al(OH)3 – adsorption of proteins to PEG-4000 – viral
inactivation (solvent-detergent method) – ion exchange chromatography on
DEAE-Sepharose – viral inactivation (ammonium thiocyanate) – dye-ligand
affinity chromatography (Diasoorb-Active Scarlet Damask 4GT). We got the
drug of FVIII with specific activity 69.65±2.24 IU/mg protein.
Summary/Conclusions: we developed technological scheme of plasma frac-
tionation and reached a high degree of purification of  coagulation FVIII. 
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PRIMARY TROMBOTIC MICROANGIOPATHIES. REVISION IN A CENTER
OF THE LAST 8 YEARS
T. Castaño1,*, S. Sanchez1, T. Arquero1, M. Yuste1, E. Askari1, P. Llamas1
1Fundación Jiménez Díaz, MADRID, Spain
Background: Thrombotic microangiopathies are a group of rare diseases char-
acterized by non-immune microangiopathic hemolytic anemia, thrombocytope-
nia and involvement of organs of varying intensity, mainly renal and CNS dam-
age. TTP and HUS are the most important forms of TMA and without adequate
treatment administered early are associated with high morbidity and mortality.
Aims: To review our experience in the management of the primary TMA and
to raise a series of questions that perhaps could improve the approach of these
pathologies
Methods: We made a retrospective, descriptive analysis of ten cases diagnosed
of primary thrombotic microangiopathy (TTP n=5; typical HUS n=3; atypical HUS
n=2) over the last eight years, 70% of which were women with an average age
between 40-60 years. Only three cases had previous records of autoinmune dis-
eases (MTCD, RA and HIV), all of which would eventually develop TTP. We
requested ADAMTS13 levels on all cases, they were low (<5-10%) only in those
pacients diagnosed with TTP, and on the other hand confirming the positivity for
Shiga toxin in those patients who eventually developed typical HUS. 
Results: Regardless of the diagnosis, 10-12 plasma exchanges were per-
formed to improve the biological parameters of hemolysis, requiring the place-
ment of a central catheter, most commonly at the right jugular vein (70%) due
to the lower risk of thrombotic and infectious complications. Although renal
involvement is frequent in HUS, only two of the patients required dialysis without
recovery of baseline renal function. Is to be noted the part played by the aproval
in 2011 of eculizumab and how patients eight years ago suffered a torpid
course, requiring a greater number of plasmapheresis and the side effects this
carries. However, we still do not know its repercussions out of indication. In
our study, it was used in a patient with a diagnosis of HUS associated with an
infection with good evolution, although perhaps this result is due only to the
natural evolution of the disease. Another controversial point is the use of antibi-
otics, which are known to worsen the clinical course of these processes, but
because of a concomitant infection or new positive determination of the Shiga
toxin, as occurred with two of our patients diagnosed of HUS had to be
used.  Finally, 30% of the patients have relapsed after the first episode with a
primary diagnosis of a TTP.
Summary/Conclusions: Thrombotic microangiopathies are a group of
processes of enormous complexity, in addition to the low frequency with which
they are usually present in our usual clinical practice requiring a large deploy-
ment of means to reach an early diagnosis and begin treatment as soon as
possible given that the unfortunate prognosis of these patients.
With this study we have raised a series of questions to improve the manage-
ment of this type of diseases:
The need to request levels of ADAMTS13 in patients diagnosed with TTP or to
repeat the determination of Shiga toxin in patients with typical HUS as part of
the disease follow-up and to try to prevent possible relapses.
The use of eculizumab out of indication in typical HUS and whether the
improvement in the picture is due to the drug or by natural evolution of the dis-
ease. The real benefit of using plasmapheresis in patients diagnosed with typ-
ical HUS. The use of antibiotics and possible harm to the diagnosis made.
PB2240
HAEMOVIGILANCE REPORTS OF ADVERSE BLOOD DONOR REACTION
AMONG VOLUNTARY BLOOD DONORS IN TERTIARY CARE HOSPITAL
IN KATHMANDU, NEPAL
B. Nepal1,*
1Blood Bank, Grande International Hospital, Kathmandu, Nepal
Background: Voluntary blood donation is widely considered to be safe with
very minimum chance of adverse reaction, which may occur during or after the
end of phlebotomy procedure
Aims: To identify and understand the complication of adverse donor reactions
though the incidence of reactions of blood donation among blood donor in the
tertiary care hospital in Nepal
Methods: This is a prospective study done among voluntary blood donors at
Grande International Hospital, Kathmandu, Nepal from February 2013 to March
2015. The outlines of reported and communicated adverse donor reaction were
also collected after the blood donation from voluntary blood donors in different
locations including outdoor and in-house blood donation drive
Results: In the present study 6,955 whole blood donors were included, during
the period of 2 years, 105 (1.50%) adverse donor reactions were reported.
Majority 89(84.76%) of adverse donor reactions were mild in nature such as,
sweating; 27(25.72%), Light headedness; 19(18.09%), nausea and vomiting;
15(14.28), allergy and bruises;11(10.47%), sore arm; 9(8.58%) and hematoma;
8(7.62%) while 16 (15.24%) were severe adverse reactions similarly, anaphy-
laxis;11(10.49%), loss of consciousness; 3(2.85%) and convulsive syn-
cope;2(1.90%). Markers of the adverse donor reaction were age, sex, pulse,
weight, blood pressure and donation status. Age and first time status were
related with significantly higher risk of adverse reaction with 18-23 years old at
higher risk compared to 24-55 years old. First time donors were at higher risk
compared to repeated volunteer donors
Summary/Conclusions: The results of the study are helpful to identify and
understand the complication of adverse donor reactions though the incidence
of reactions in the blood donors is lower than in other studies. Donor age and
donation status were strong possibilities of complications.
882 | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
A
Abad, L, P510
Abad, M, E985, PB1690, PB1917, PB1930, PB2125
Abáigar, M, P318, P655, E1169
Abali, H, P281
Abalo Perez, L, PB1806




Abbenante, M, E882, PB1657
Abboud, C, P319


















Abella, E, E1027, E1394, PB1726, PB1874
Abeykoon, J, E1240
Abildgaard, N, S501, E1267, E1367, PB1995
Abonour, R, P349, E1239, E1277
Abou Elmagd, E, PB2236
Abou Mourad, Y, P581, E1557
Abou Zahr, A, P550
Aboukhalil, Z, S140
Abouzaid, S, E1277, E1282, PB2135
Abraham, M, P269




Abramova, T, E1227, E1295
Abranches, P, E1044
Abreu, M, P157
Abrisqueta, P, S461, P298, E995, E1002, E1027, E1394
Abruzzese, E, S485, P256, P604, P705, E1042, E1043, E1067, PB1818
Abubakar, S, PB2156
Abuelgasim, K, E1514, PB2072
Abuín Blanco, A, E1327
Abumiya, M, E1053, PB1999
Accardi, F, E1223
Accordi, B, E1011





















Adly, A, P398, E1572, E1582
Adrienne, D, P174
Advani, A, S793, P201, P203, P519, P525, P547
Advani, R, P571
Advani, V, S417




Agarwal, A, S460, P349, E1239, E1282, PB2135
Agarwal, A, P194





















Aguado, B, E1305, E1565
Aguiar, R, S126
Aguilar, C, P655, E1014
Aguilar, Y, PB2149
Aguilar-de la Red, Y, PB2143, PB2200
Aguilar-Guisado, M, S804
Aguilar Martinez, P, S453, P289
Aguilar Ponce, J, E1473, PB1738
Aguilera, C, PB1727
Aguilera Gomez, C, E957
Aguinaco, R, PB1861










Ahmed, S, S450, S792, P739, E914, E1512, E1538
Ahn, C, PB2218
Ahn, I, P588
















haematologica | 2017; 102(s2) | I






Akashi, K, E1111, PB1816
Akbapour, M, PB1886
Akbar, H, S149

















Al-Ali, H, P555, P702, E1333, E1334, PB1819
Al Ali, N, P352
Al Assaf, C, E1310
Al-Atrash, G, S792
Al Bashir, S, PB1882
Al-Drees, M, PB1972
Al-Fayoumi, S, P699, P701, E1343




Al-Matary, Y, P534, E1118
Al-Oqaily, Q, P233
Al-Radi, L, PB2071
Al Sawaf, O, S464, P251, E1025
Al-Seraihy, A, PB1694
Al Shemmari, S, PB2046
Al-Sweedan, S, PB1694
Al-Wakeel, H, PB1658
Al-Zahrani, M, E1514, PB2072
Alacacioglu, I, PB1886






Alavi, A, E1267, PB1995
Alawneh, K, PB2121






Alberquilla, O, E1081, PB1839
Albers, C, S127
Alblooshi, R, P708
Alcoceba, M, S115, E887, E1019, E1394
Alduaij, W, E1324
Alegre, A, E1565









Alexandrakis, M, PB1950, PB1961
Alexis, M, P572
Alfinito, F, PB1923
Alfonso, A, S444, S489, P200, P315, P652
Alfonso, G, E1182
Alfonso, V, PB1696
Alfonso Pierola, A, P665
Algarín, E, E1222
Algarotti, A, E1315
Algeri, M, S146, P381, S495
Alhammer, A, P512
Ali, H, S794

















Allione, B, P214, P667
Allò, M, PB2153
Allsup, D, P252
Almeida, A, S426, E1064
Almeida, J, E1044, E1047
Almeida, J, PB2044









Alonso Álvarez, S, P747
Alonso Caballero, C, E1183
Alonso-Domínguez, J, E1059, E1596
Alonso-Lopez, D, P361
Alonso-Saladrigues, A, P168
Alonso Vence, N, E1327
Alousi, A, S450, S792, P739, E914, E1512, E1538
Alpár, D, E820, PB1627
Alrasheed, N, E1208








Altman, J, S110, S471, P560, E940
Altuner Torun, Y, PB1907
Alunni, G, E946
Alvanou, M, E1083
Alvarado, Y, S487, P170, P315, P317, E913
Alvarado-Ibarra, M, PB1634







Álvarez-Laderas, I, P213, P756
Álvarez-Larrán, A, P694, P703
Alvarez Lipe, R, E1258
Alvarez-Twose, I, P713
Alvarez-Vera, J, PB1634
Alves, R, E1064, E1287, PB1763, PB1911, PB1938
Alves, V, E1044, E1047
Alwan, F, E1445, E1450, PB2108
II | haematologica | 2017; 102(s2)


































Anagnostopoulos, A, S461, P242, P280, E1083, E1233, E1266, E1407, E1610,
PB1698, PB2102, PB2144, PB2166
Anagnostopoulos, N, P280, PB2107
Anagnostou, T, P254, E1241, E1502





Andersen, C, P697, PB1785
Andersen, M, S109, S486
Anderson, K, S456, S457, E1200, E1201, E1203, E1206, PB1957
Anderson, M, P247
Anderson, S, E1487
Andersson, B, P743, E1538
Andersson, P-O, S805
Andjelic, B, S443, E970, PB1708, PB1771, PB1793, PB1799, PB1862






Andrade-Campos, M, E957, E1134, E1412, PB1989
Andrasiak, I, PB2032
Andre, M, S470
Andreasson, B, P697, E1250




Andriani, A, E1325, E1340
Andrieux, G, P243, E1355








Angelopoulou, M, S416, P280, P639, E1036, E1120, E1304, PB1784
Angelov, D, E1452, PB1832
Angelova, S, PB1828
Angelovic, R, PB1774





Annibali, O, P736, E1123, E1151, E1243






Antelo, M, E1604, PB1729
Antic, D, S443, E970, E1448, PB1708, PB1771, PB1793, PB1799, PB1862





Antonio de Souza, C, E952




















Apperley, J, S423, S817, P603
Appolloni, V, P358
Aprile, L, E941, E946, E1042, E1043
Apsemidou, A, PB2091
Aquino, S, S410, S796, E1299
Aquino, V, S146




Araguás Arasanz, C, E1426
Arai, A, P302
Arakaev, O, P161




Aranda Lopez, P, P643, P651
Arapaki, M, E1120





Arbelbide, J, E1182, E1508
Arbeteta, J, PB2022, PB2064
Arbones, M, E1412









Arellano, M, S472, P204, P207
Arenas, A, P695, E900, E1317
haematologica | 2017; 102(s2) | III





Arias Fernández, T, E1530, PB2122, PB2155

























Aróstegui, J, E1259, PB1952
Arquero, T, PB1720, PB2239
Arras, M, P256
Arratibel, N, P747, E1543, E1592
Arredondo-Campos, D, E1306
Arriazu, E, P205, P536
Arriba, F, E1278
Arribas Arranz, J, E1387
Arriero, A, E1302, E1305, E1565
Arrigoni, E, E1048
Arrizabalaga Amunchastegui, B, E983, E1181, PB1755, PB1758
Arruda, A, P708, E1324
Arslan, O, PB2185
Arslan, Ö, PB2043
Arteche-Lopez, A, E1302, E1305
Artola, M, PB1616









Asayama, T, P327, P659, E1175
Asenjo, S, S445
Asensio, A, PB1887
Asensio Matas, A, E1258
Ashby, C, E1203
Ashcroft, J, P669, E1463
Askari, E, PB1720, PB2239
Aslar Oner, D, PB1619
Asma, H, E1275, E1472, E1479, PB2126
Asmal, M, S814, P631
Asmar, F, P324, E1115
Asmussen, J, E1267, PB1995
Asnafi, V, S440, E1236, E1386
Asou, N, P314, E1058, E1066
Assem, H, E1411
Assenov, Y, P350, P663
Assimakopoulos, J, E1120
Assmann, M, PB1819
Assouline, S, S468, S777
Astolfi, M, P341
Astori, C, P357, E1337
Atabay, B, PB1927
Ataca Atilla, P, PB2185
Ataga, K, S454
Atagündüz, I, PB1681, PB2027













Atsuta, Y, P389, E1522
Attal, M, P345, P348, PB1957
Attar, E, P215
Attie, K, S129, P666
Auber, B, P226
Auclair, D, P322
Audisio, E, P163, P214, P520
Auer, F, S148
Auger, N, E1001




Aurer, I, E969, E971, E1296
Austgen, K, P188, E884
Autore, F, PB1760, PB1780
Auvinen, A, P734
Avenoso, D, P283, E1299
Aversa, F, E1223, E1325, E1497
Avery, S, E929
Avet-Loiseau, H, S101, P348, E1200, E1201, E1203, E1206, PB1987
Avigad, S, S436
Avigan, D, S783, P344
Avigdor, A, S413
Avila Arreguin, E, P719, PB1847
Ávila Idrovo, L, E1530, PB2122, PB2155, PB2209
Aviles, E, PB2205
Avishai, E, PB2109
Aviv, A, E1034, PB1781, PB1789











Ay, Y, E1427, PB1748
Ayala, R, P609, P661, P679, P695, P696, E891, E899, E900, E1317, PB1661,
PB1912
Ayala Diaz, R, E1059
Ayana, K, S120
Ayçiçek, A, E1418, PB1640, PB1649




Aydın Köker, S, E1427, PB1842
Aydogan, E, E1202
Aydoğan, G, E1418, PB1640, PB1649
Ayed, A, P588
Ayesh (Haj Yousef), M, PB1882, PB2121
Ayllón, V, E893
Aymerich, M, S115, S117, E1031, E1032, E1039
Aytac, S, E855, E1598, PB2086
Ayto, R, PB1976
Ayuda-Durán, P, E866
Ayuk, F, P231, E1286
Ayuso, C, P623
Azab, M, E1192
IV | haematologica | 2017; 102(s2)


















Baccarani, M, S485, P603, P605, P607, PB1818
Bacchiarri, F, E1454, PB2115
Bacci, F, PB1953, PB2059
Baccianti, F, E1216, E1268
Bachelerie, F, E1102
Bachy, E, E1024
Bacigalupo, A, S796, P232, E915, E1505, PB2162
Bacigalupo, L, P400
Bacon, C, S478
Bacon, P, P343, E1250
Bacon, T, P687, E1291
Badell Serra, I, S452, P580, PB1839




















Bagratuni, T, E1201, E1231
Bah, G, E1487
Bahceci, E, S110, P560, E940
Bahl, S, P236
Bahlis, N, S100, P334, P335, E1248




Baile, M, E953, E1543, E1592
Bailey, S, PB1613
Bailey, T, PB1687, PB1699
Bainazar, M, E883
Baird, S, P668

























Balasa, B, PB1788, PB1794, PB1959
Balasco, D, P714
Balashova, V, PB2170
Balassa, K, E1534, E1535, E1544
Balassopoulou, A, E1574
Balasubramanian, S, E1129, E1369
Balatzenko, G, PB1693, PB1828
Balázs, G, PB1978
Balbarin, K, P247








Baliakas, P, S461, S462
Ballanti, S, S410, E1174, E1247
Balleari, E, P658, P667
Balleisen, L, S424






Ballesteros, J, P554, E1086
Ballina, B, P737, PB1990, PB2021, PB2082, PB2182

















Bao Pérez, L, E1327









Barata, J, P157, E822
Baratè, C, S485, P599, P640, E1048
Barba, G, E1174








haematologica | 2017; 102(s2) | V
Madrid, Spain, June 22 – 25, 2017
Barbosa, N, PB1984
Barbosa de Carvalho, N, E1283
Barbosa Ribeiro, A, PB1911, PB1929
Barbui, A, S775, S778
Barbui, T, P351
Barcellini, W, S451, P616, P722, E1030, E1078
Barcia Duran, J, S137
Bardi, A, E1020






Bargay, J, S790, P202
Bargay, J, S409, P316, P688, E1181
Bargay, J, E1278




Barilà, G, E1254, E1357, E1397
Barilka, V, PB1790







Barnett, M, P581, E1557







Barragán, E, P696, E891, E899, PB1661











Bartalucci, G, E941, E946


















Bashir, Q, S792, E914, E1512, E1538




Baskhaeva, G, E836, PB1636, PB1646
Baskın, Y, PB1886
Baslar, Z, E1159, E1518, PB1701, PB1746
Basquiera, A, E1182, E1508
Bassan, R, P163, P520
Basset, M, P337, P684, E1243
Bassi, C, E1020
Basso, G, S480, P738, E844, E917, E1011, E1489, PB2145
Bastard, C, E1001
Bastia, R, E1179
























Bauer, M, P159, E1203
Bäuerlein, C, E1569
Baues, C, S150
Baumann, T, S115, E1031, E1032, E1039, E1137
Baumeister, S, S146
Bautista, MD, G, P554, E1051, E1059, E1541









Bayliss, M, P373, E1468
Baylor Curtis, L, E1141
Bayman Payzin, K, PB1846




Bazarbachi, A, PB2177, PB2183
Bazhenov, A, PB1685
Beà, S, S115, S117, P300, E1381
Beach, C, P208
Beam, D, P727













Beekman, R, S117, P300, P325
Beelen, D, P388, P516
Beggiato, E, E1332
Begna, K, P165
Beham-Schmid, C, E1363, E1395
Behre, G, P380, PB2175
Beider, K, P269
Beier, F, P231, P593
VI | haematologica | 2017; 102(s2)







Beksac, M, S100, S456, PB2185
Bektas, F, PB1756






Beléndez, C, P580, PB2143, PB2149, PB2200
Belenfant, X, E1265




Belini Junior, É, E1492
Bell, J, E944, E973, E1184, E1191, E1196, PB1705, PB1709, PB1873, PB1875
Bellaaj, H, PB1639





Bellini, M, P357, E1337
Bello, C, E960
Bello López, J, E1327
Bellodi, A, P283, E854
Belloni, M, E844
Bellosillo, B, P694, P696, E1310, E1417, PB1668
Bellosillo Paricio, B, PB2054





Belvini, D, PB2076, PB2077
Ben Amor, I, PB1639
Ben-Califa, N, E1107
Ben-Yehuda, D, E1244




Benboubker, L, P335, P675
Bendaña López, Á, E1327
Bendelac, L, E1082
Bendet, U, PB1725
Bendit, I, PB1820, PB1830
Béné, M-C, S105, E1360, PB1618, PB1913
Benedetti, D, P588
Benedetti, E, P671
Benedetti, F, S778, E1533
Beneduce, E, P392
Beneitez, D, PB1755




Benevolo, G, S784, P351, P705, E1247
Bengoechea, E, P688
Benito, R, P655, E1014, E1169, E1451
Benito, V, PB1902










Bento, C, E1080, E1425, E1588, PB1904
Bentolila, G, E1508





Benvenuti, P, P357, E1337
Benyamini, N, P257





Berdeja, J, S142, S408, S780, P680
Berdel, W, S424, P546, E885, E927
Berdoukas, V, P398
Berenguer, M, PB1969, PB2033
Berenguer-Piqueras, M, E1562
Berenschot, H, S107, P567
Berentsen, S, P613
Berg, D, S408, S780, P735
Berg, J, S419
Bergamaschi, M, P283, P705, E1186, E1325, PB1818
Bergantim, R, PB1985
Berger, A, E1045










Berk, S, E1159, PB1701, PB1759





Bermejo, N, P721, E1451, PB2106






Bernardeschi, P, E946, E1401
Bernardi, M, S806, P544, PB1678
Bernardi, S, P607
Bernardini, A, S410
Bernardo, P, E1080, PB1904
Bernardo Gutiérrez, A, PB2155, PB2209
Bernat, S, PB2106
Berneman, Z, S141
Berni Wennekers, A, E1258
Bernink, J, S448






Bertaina, A, S146, S495, P381, P738, E917, E1167, PB1665
Bertamini, L, E882, PB1657
Bertani, G, PB1901, PB1931
Berthel, E, E1359
Berthon, C, P316, E1171
Berthou, C, E1250, PB1767
Berti, P, P736, E1243
Bertolami, W, P671
Bertoli, E, E1496





haematologica | 2017; 102(s2) | VII
Madrid, Spain, June 22 – 25, 2017
Bertrand, Y, S131, S422, PB2157
Bertucci, F, P183





Besses, C, P694, P704, E1310, PB1874
Bessette, C, PB1959
Bessette, M, E894
Bessmeltsev, S, E1153, E1313, E1568, PB1944, PB1946, PB2006, PB2034,




























Bi, X-W, E961, E1389
Biagi, E, P628, P630














Biddeci, G, P715, E844, E955




Biemond, B, S112, S455
Bierhoff, H, P663
Bierings, M, S452, P579
Bierman, P, P563
Bihin, B, P230
Bijedic, V, PB1837, PB2078
Bijou, F, E1028
Bila, J, S443, E970, PB1708, PB1771, PB1793, PB1799, PB1862
Bilalovic, N, PB2078
Bilbao, C, P696













Bing, X, PB1654, PB1655, PB1895
Binota, J, PB1805
Binotto, G, P604, P705, E1325, PB1818
Binsaleh, N, P368
Biondi, A, S436, S480, P628, P630, E1489















Bishop, R, P245, P589







Bittencourt, H, S476, P517, PB2157
Bittolo, T, P583










Bladé, J, S409, P339, P679, P688, E1259, E1278, PB1952
Blaette, T, E868
Blahovcova, P, E1540, P218
Blain, J, S500
Blair, H, P512






Blanchard Rodríguez, M, E1302
Blanche, S, P631
Blanchette, V, P367, P727
Blanchi, J, E1028
Blanco, A, E1183













Blazer, M, E1184, E1191, E1196
Blázquez, B, E1183
Bleckmann, K, S480, E849
Bleul, S, P656
VIII | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association










Bloomfield, C, P174, E883
Bloor, A, S770, S797, S817, P245, P252, P589
Blum, A, E1349
Blum, P, P342
Blum, S, P664, E937, PB1924








Bobbili, P, P285, P286
Bober, G, E1061
Bobes Fernández, A, PB2149
Bobillo, S, P298, E995
Bobin, A, PB1865
Bobin, A, PB1987
Boboev, K, E1050, PB2030
Bobrowicz, M, S125, E1359, E1385
Bobrowska, H, PB1744
Boccadoro, M, S102, S410, P322, E999, E1247, E1332
Bocchia, M, P163, P604, E941, E946, E1042, E1043, E1215, PB1818
Boccomini, C, S778
Bochicchio, M, P599, P607
Bociek, G, P563
Bodden, K, P315
Bodí Saera, A, E1426
Bodmer, N, E849
Bodor, C, E820





Boerries, M, P350, E1355
Böettcher, S, S771



























Bomben, R, P583, P588
Bommannan, K, E987, PB1805
Bonadies, A, PB2201
Bonadonna, P, P355





Bondarenko, S, E836, E860, PB1645
Boneva, T, E905, E1176
Bonfiglio, S, E997
Bong, S, PB2165








Bono, M, PB2038, PB2039
Bonomini, S, E1223, E1497
Booth, A, E1007
Booth, C, S421
Boothroyd, R, P706, E1320
Boque, C, P609
Boquimpani, C, P257, PB1820
Borate, U, P194
Borchiellini, M, PB1664
Borchmann, P, S150, P275
Borchmann, S, E1119
Bordessoule, D, P217, P316, E1458
Bordin, G, E844
Bordin, L, E1006
Borg, K, P594, PB1802
Borges da Silva, F, PB1859
Bories, P, P641
Borin, L, P570, E1186
Borisovskaya, S, P220, E1133
Borkhardt, A, S148, S429, S436, P515
Borland, T, S147
Borlenghi, E, P163, E1190, PB1678
Bornhauser, B, S437






Borsarelli Carvalho Brito, A, E952
Borsi, E, E1238
Borsky, M, E1003, E1004




Bos, G, S411, S501
Boscarol, G, E1164
Bosch, F, S468, P298, E995, E1002, E1027, E1594
Bosch, R, E1026, PB1782
Bose, P, E987
Bose, P, S463, S487, P315, P352, E913
Bosga, A, E897
Boshier, A, E1441
Bosi, A, E946, E1043, E1215, E1270, E1401, E1454, PB1686, PB1881, PB1983,
PB2115














haematologica | 2017; 102(s2) | IX
Madrid, Spain, June 22 – 25, 2017
Bottomly, D, P194
Bouabdallah, K, S105
Bouabdallah, R, S467, P217, E1549
Bouard, C, P702, E1333, E1334
Boubaya, M, PB1913
















Bourhis, J-H, S493, P345
Bouriez-Jones, T, E1110
Bourquin, J-P, S437, P159





Bouvy, C, P230, E964
Bouwmeester, W, E1272, E1298, PB1964
Bouyer, S, PB1987
Bove, V, E1273, PB1949
Boven, L, PB2096
Boveri, E, P357, E1179
Bowen, D, P254
Bowers, M, E1228
Bowles, K, E873, E874
Boxer, M, P249
Boxhammer, R, PB1768





Bozzi, C, PB1843, PB2189
Bozzi, V, S432
Bozzola, M, P684





Braess, J, P546, E885
Braester, A, E1015, E1034, PB1781, PB1789
Braganca, N, P669
Braggio, E, P320
Brahimi, H, PB1690, PB2125
Brambilla, S, E1606
Branca, A, E1254, PB1697, PB1728
Brander, D, P247
Brandozzi, G, E1136
Brandt, M, S474, P209, P211, E935
Brandt, P, P375, PB1825
Branford, S, S484
Braun, A, P585, E1380
Braunschweig, I, S466, P522
Brazma, D, E905, E1176
Bréal, C, P217




Brentjens, R, S143, S479












Briones, J, S816, E963, E1394, PB2159
Brionne-François, M, P370
Brizuela, B, PB1764
Broady, R, P581, E1557
Brocco, F, P190
Brock, K, S770, P245, P589
Bröckelmann, P, S414








Broijl, A, S411, P677, E1279, E1301
Bromberg, J, P219



















Bruederle, A, S454, P286, P288















Bruno, B, S493, P384, E1533
Bruscaggin, A, P282, P304
Bruserud, ¥, E903
Brustad Melhus, K, E1141
Bryan, A, PB1797





Buadi, F, P331, P673, E1240, E1241, E1502
Bubnova, L, E986, PB1944
Bucci, G, P544
Buccisano, F, S111, E908
Bucelli, C, P729, E1346
Buck, G, P270, P668
Buda, G, P671, E1215
Budai, E-C, PB2223
X | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Budeč, M, PB2140
Budziszewska, K, E920
Buechner, J, S476, P517
Buenasmañanas Cervantes, D, PB1879
Bueno, D, E1563, PB1628
Bueno, J, E1541
Bueno, R, P361
Bueren, J, S144, P229, P580, P623, P755, E1081, E1094, E1097, PB1839










Bulian, P, P583, P588
Bullinger, L, P172, P182, P248, P533, P535, E864, E868, E870, E888
Bulsa, J, PB1624
Bumbea, H, E1602
Bundschuh, R, P174, E883
Bunjes, D, E1084









Burger, J, S463, S769, S772, P240, P241, P588, E991, E1016
Burger, P, S132







Burnett, A, S114, S475
Burney, C, P228




Busch, H, P243, P350, E1355
Büschel, G, P255
Buske, C, S429, S809, P635, E1246









Bygrave, C, P374, E1245
Byrgazov, K, P596, E1071
Byrne, C, P338, P339
Byrne, J, S423
Byrne, K, P278




Caballero, A, E963, PB2159
Caballero, D, P746, E1129, E1169
Caballero, J, E1169, E1543
Caballero, M, P747, E1543
Caballero, T, P543
Caballero Berrocal, J, P318
Caballero-Velázquez, T, P213, P756
Cabanas-Perianes, V, E1562, PB1969, PB2033
Cabezón, M, P696, E831
Cabras, A, E1207
Cabrelle, A, E1357, E1397
Cabrera, C, S409, P688
Cabrera, J, E972, E1541, PB1885




Cacciola, E, P358, PB2040













Caillot, D, P345, P572
Caimi, L, P607
Caimi, P, S469, P633
Cairns, D, S407, S781









Calafiore, V, S111, PB2063
Calamar, D, PB2092
Calamar-Popovici, D, PB2124
Calasanz, M, S461, P198, P205, P696, E1027
Calbi, V, S128
Caldas, C, P713
Calderon-Cabrera, C, S804, P318
Caldini, A, E1270
Caldora, M, P393
Caliskan, E, E1165, PB2123
Caliskan, Ü, E1584, PB1927
Calistri, D, E904
Calistri, E, S485, P604
Call, J, P633
Call, T, P254
Callahan, J, P699, P701, E1343
Callanan, M, E1360
Calle Primo, C, PB1879
Calle, MD, C, E1051






















Campbell-Drew, M, PB2045, PB2051
haematologica | 2017; 102(s2) | XI





Campo, E, S115, S117, P244, P296, P300, P325, E1137, E1369, E1381
Campo Palacio, H, PB2054
Campos, P, PB1674
Campos, R, P721, E1456
Campr, V, P218
Camps, C, E1424
Canafoglia, L, P636, E1136
Canal , A, PB1933
Canale, F, PB1632
Canales, M, S469, E1563






Candi, V, E941, E1215
Cândido, L, PB1662
Candoni, A, S111, E1496, PB1697
Canepa, L, S410, P322, E1299










Cansever, M, E1428, PB1756, PB1858
Cantas, F, PB2110
Cantero-Fortiz, Y, E1500, PB2219
Cantone, L, E1268
Cantonetti, M, S413
Cantoni, S, P616, P722, E1443
Cantu-Rodriguez, O, E1306, E1415
Canzian, F, P295
Canziani, L, E1232
Cao, J, E931, PB1635
Cao, X-N, S449, P507, P725, E833
Cao, X, S103
Caocci, G, P256, P358, P610, E1042, E1186
Caola, A, S779











Cappelli, E, P234, E1440




Caprari, P, PB1843, PB2189
Capria, S, P166
Carabia, J, P298, E995, E1002
Caracciolo, F, P671
Caraffini, V, S419, E879
Caramazza, D, P351, P722
Caramella, D, P671
Caramella, M, P351






Carda, J, E1336, PB1763
Cardenas, P, P211






















Carpio, C, P298, E1002
Carrà, A, E1571
Carrabba, M, S806, P544










Carrillo Cruz, E, P696, E1349, PB2054
Carrió, A, E1031, E1039
Carrizosa, J, PB2205
Carroll, A, E883
Carson, A, S108, P197, E921
Cartagena, A, PB2205
Carter-Cooper, B, E947
Cartia, C, E1293, PB1970








Casado Montero, MD, L, E1051, E1059
















Cassiman, D, P152, P153
Cassin, R, E1030, PB1648, PB1785
Cassinat, B, S787
Castagnetti, F, S485, P600, P604, P605, P607, PB1818
Castaldi, B, E844
Castaman, G, P306, E976
Castaño, T, PB2239
Castaño Bonilla, T, PB2117
XII | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Castañón Fernández, C, E1530, PB2122, PB2155
Castella, B, E999















Català, A, S144, P168, P350, P580
Catalano, J, S785
Catalano, L, E1459, PB2001, PB2011, PB2020
Catalano, M, E1293, PB1970
Cataldi, I, P636
Catani, L, E1309
Cattaneo, C, P163, P644, PB1678









Cavalli, M, E1000, E1408
Cavalloni, C, P357, E1337, PB1779
Cavazzana, M, P631
Cavazzini, F, P604, P705, E1020, E1325, PB1818
Cavenagh, J, S791, P669, E1212
Cavo, M, S101, S102, S410, S485, P322, P335, P600, P605, P705, E1238, E1247,
E1309, E1325, PB1818, PB1932
Cazzaniga, G, S436, S801, P628




Ceberio, I, P303, E1368
Cebolla, J, E1410, PB2085
Ceccarelli, M, P667
Ceccherini, I, P234, P575, E1440
Ceccon, M, P570
Cecconi, N, P671
Cedeña, M-T, S409, P316, P661, P688, E891, E899, PB1912
Cedena Romero, M, E983
Cédile, O, E1367
Cedrone, M, P604, P605, E1340
Cefalo, M, E1167
Cekdemir, D, E1564











Cerchione, C, S504, P277, E1122, E1125, E1459, PB1923, PB2001, PB2011,
PB2020
Cerciello, G, PB1923











Cervantes, F, S785, S786, P351, P703
Cervera, J, P318, PB1661
Cervera, J-V, PB1616








Çetin, M, E855, E1157, E1598, E1603, PB1754, PB2086
Çetin, M, E1527, PB2171
Cetinkaya, S, PB1757
Cetkovsk∞, P, E936, E1198, PB1650, PB1663
Cevreska, L, E1471, PB1774, PB1775, PB1795, PB2062
Ceylan, E, PB2013
Cha, H, E1404, PB2079
Chaari, M, PB1639
Chabaeva, Y, E1067
Chabannon, C, P183, E1549
Chabay, P, PB2073
Chabot, A, P271, E1099






Chaliasos, N, E1416, PB2098
Chalkiadakis, G, PB2107
Chamberlain, L, P197, E921
Champlin, R, S450, S792, P739, E914, E1512, E1538
Chan, E, S147
Chan, G, P204, E925
Chan, K, P167
Chan, R, P530
Chan, S, P708, E1324
Chan Hew Wai, A, PB1833
Chanan-Khan, A, S460
Chander, C, P197





Chang, H, P224, E1217
Chang, K, PB2204
Chang, M, E1069, PB2055
Chang, Y-J, PB1611
Chang, Y, P506, P577, PB2167
Chang, Y-J, P725, E1517





















Chaudry, S, E1116, PB1659
haematologica | 2017; 102(s2) | XIII






Chavez, J, P608, E960
Chebotkevich, V, E1153















Chen, C-C, PB1719, PB2093
Chen, C, PB2135
Chen, C, P339
Chen, C, E1255, E1300, PB1951
Chen, F, P390, E1507
Chen, H, E1503, E1511
Chen, H, P387, E1515, PB2172
Chen, J-J, P392
Chen, J, P191
Chen, J, P390, E956
Chen, J, S135
Chen, J, S452







Chen, S, E928, E1189, PB2041
Chen, T, P660
Chen, X, E956, E1531
Chen, Y, E1503, E1511
Chen, Y, E1217






Chen, Y-H, S449, P387, P752, E1101, E1515, PB2172
Chen, Z, P297
Chen, Z, S436





Cheong, J-W, E892, PB1684
Cherel, B, P217
Cherif, H, S805
Cherif, R, PB1942, PB2018
Chernookaya, N, E1154
















Chiara, E, P355, P729
Chiaramonte, R, E1216, E1268
Chiarella, M, P210, P556, E922
Chiarenza, A, P588
Chiaretti, S, S800, P166
Chiba, K, S120, S123, S124, S799, P299, P314, P537






Chillemi, A, E1223, E1237
Chillón, C, P318, E1169
Chillón, M, P696, E887
Chin, D, E1110
Chin, M, E1202, E1208






Chitre, S, P326, P541




Chng, W-J, S458, PB1651




Cho, S-G, P638, P742, E1513
Cho, S-F, PB1719, PB1736
Cho, S, PB1908
Cho, S, PB1702
Cho, Y-U, E857, E909
Chocarro, S, P536
Choe, J, E1404
Choi, C, P223, E984, E1070, PB2067
Choi, D, E1177
Choi, E, S499










Choi, M-Y, E1054, E1069
Choi, S, S491




















XIV | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Christopoulou, G, E1292
Christoulas, D, S130, S415, E1292
Chromik, J, P666
Chu, S-T, E1567








Chung, J, E984, E1070





Chyla, B, S771, P682
Ciabatti, E, E1048, E1318, E1397, E1408
Ciancia, G, E1459
Cibeira, M, E1259, PB1952
Cibien, F, P715





Ciccone, G, P214, E1247
Cicconi, L, E908, PB1696





Cigalini, E, S433, P365
Cillero Pastor, B, PB2068
Cilloni, D, P658, P667, E1226, E1332
Ciminello, A, P722
Ciminiello, M, PB1877














Ciuffreda, L, PB1899, PB1992
Ciurea, S, S792, P739, E914, E1512, E1538
Civoli, F, E1147













Claus, R, P243, P350, P656
Claus Marcher, C, S486
Clavio, M, P667, E854, E915, E919, E933, E1505, PB1632
Clementino, N, P257, PB1820
Cleyrat, C, S499
Clifton-Hadley, L, S802, P160, P164, P669
Climent, F, E957, PB1727
Clise-Dwyer, K, P321, P652








Cocciardi, S, P172, P535, E864, E868
Coccioli, M, P365
Cochard, L, PB1833




Coelho, A, E1033, E1188, E1586, PB2003
Coelho, A, PB1820
Coenen, J, S501
Coffey, G, S773, P587
Cogle, C, E923
Cogo, P, PB2142




Cojbasic, I, PB1823, PB1826, PB1838
Cojbasic, Z, PB1826
Čokić, V, E1308, E1316, E1319, E1328, PB2140







Coll, R, E1181, PB2111
Colla, S, S487, P321, P652
Collado, R, S461, E1027
Collett, C, S407, S781
Collett, L, P252
Collins, A, P276, E874, PB2057
Collins, G, S412, S775, E1476
Collins, M, PB1976





Colombatti, R, E1164, E1489, PB2142, PB2145
Colombo, M, E1216, E1268
Colombo, N, E854, E915, E933, E1505
Colomer, D, S115, P696, E1369
Colomo, L, PB1726, PB1874
Colonna, M, PB1647
Colorado, M, P554
Colorado Ledesma, E, PB1989
Colovic, N, PB1704, PB1831
Colunga Pedraza, P, E1306, E1415
Combeau, V, E1010
Côme, C, PB2068


















haematologica | 2017; 102(s2) | XV
Madrid, Spain, June 22 – 25, 2017
Contentin, N, P572
Contento Gonzalo, A, PB2160
Conter, V, S480
Conti, C, E908
Conticello, C, E1214, E1232, E1247, PB2063
Contreras, T, E1019
Cook, G, S101, S407, S781, P335, P669, E1269
Cook, M, P669
Cooke, R, P295




















Cornelissen, J, S112, S798, P262, P388, E1499, E1504, E1506
Cornillet-Lefebvre, P, E1361
Cornillon, J, P572
Corradini, P, S413, S778, P341, E1201, E1207, E1247, E1533
Corral, J, S445, P721, E1444, E1456
Corral, R, E887
Correa, J-G, P703
Correa Alonso, M, PB2181
Correa-Gonzalez, C, PB1847
Correia, R, PB1856
Corrente, F, E1124, PB1760
Corso, A, E1293, PB1970
Cortelazzo, S, P304
Cortelezzi, A, P163, P355, P616, P729, E1030, E1078, PB1648, PB1760, PB1785
Cortés, E, PB1738
Cortes, J, S110, S474, S487, S489, P170, P192, P200, P204, P209, P211, P315,
P518, P550, P556, P560, P562, P603, P665, E914, E922, E935, E1052, E1060,
PB1825
Cortes, M, S147
Cortesão, E, E1287, E1297, E1336, PB1911, PB1914, PB1929, PB1938, PB2007,
PB2184











Costa, D, E1031, E1032, E1039
Costa, F, E1223, E1237
Costa, F, E1494
Costa, L, P293
Costa e Silva, N, PB1914







Couceiro, P, E1044, E1047, E1064






Coutre, S, S769, S771
Couzens, S, S114










Cramer, P, S464, E1025
Craviotto, L, E1497
Crawford, L, E1224
Crawley, C, P669, E938
Cremasco, F, E1232
Crespo, M, P298, E995, E1002
Crespo-Solís, E, PB1634, PB1866
Creyghton, M, P187
Criado, I, P584, E1019






Cross, M, P261, P555, PB2175
Cross, N, E1344, PB2023
Crotty, G, E1250
Crowe, J, P669
Crucitti, L, E1443, PB1931
Crugnola, M, P604, P658, P705, E1325
Cruz-Jentoft, A, P376
Csikos, T, P265, E1221
Csukly, Z, PB1978
Cuccaro, A, P282, E1124
Cuccia, L, P394
Cuellar, C, E1026, PB1782
Cuéllar-García, C, S462
Cuenca, I, P320, P329, P679
Cuervo-Sierra, J, E1074









Cuneo, A, S111, E904, E1000, E1012, E1020, E1325, PB1760






Curci, P, PB1992, PB2019






Cuthill, K, P326, E1242, E1245, E1509
Cutica, I, P729
Cutillas, P, P532, E869
Cutini, I, PB1686, PB1983
Cutler, C, S492
Cutrona, G, P586, E1017, E1390
Cutter, K, P563
Cvejic, A, P227
Cvetkovic, Z, PB1799, PB1871
Cybakova, N, E1313, PB1682
Czabak, O, PB1800
XVI | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
D
D’Adda, M, S485, P605, P705, E1190, E1325, PB1814, PB1818
D’Addosio, A, P604
D’Agostino, M, P322










D’Arena, G, P583, E1261, PB1760






D’Sa, S, P669, E1132
D’Souza, A, E1523
Da Col, A, P283
Da Costa, L, PB2083
Da Silva, F, E832
Da Silva, M, P304













Dal Bello, R, PB1637
Dal Bo, M, P583, P588








Dalle, J-H, E1150, PB2157
Dally, N, E1121
Dalmau, J, E1396
Daly, R, P699, P701, E1343





















Danilov, A, S118, P249
Danilova, O, S118
Danise, P, P667, PB1923
Danova, M, PB2012










Darzentas, N, S801, S803
Das, R, PB1841, PB2199
Das, S, PB1703, PB2220







Daver, N, S474, S487, S489, S496, P170, P192, P200, P209, P211, P315, P317,
P352, P518, P665, E913, E914, E935, E1345




Davids, M, S771, P564
David-Tarud, G, E1074
Davies, A, S502, S774
Davies, D, E1529









Davydova, J, E1295, E1559, PB1852, PB2176
Davydova, Y, E934, E982, E1092, E1096, E1098, PB2164
Day, G-J, E1073
Dazzi, F, S817
De Angelis, F, PB1880
De Arriba, F, P402, P688, E1013, PB1956
De Bellis, E, E908
De Benedetto, M, PB2076, PB2077
De Benedittis, C, S485
De Benedittis, D, PB1880
De Best, L, P677
De Bie, J, P151
De Boer, E, E897
De Boer, J, S412, P567
De Botton, S, S471, P215, P316
De Braekeleer, E, S430
De Bruijn, J, P265
De Bruyne, E, E1211, E1220
De Candia, E, PB1780
De Candia, M, E1560
De Castro, L, E1493
De Cuyper, I, P404, E1310
De Dios Soler, M, E1182
De Fabritiis, P, S111, P616
De Filippo, K, E875
De Franceschi, L, P392, E1491
De Graaf, A, E1197
De Greef, G, E1499
De Gregoris, C, E1340
De Groen, R, P567
De Groot, K, E820
De Groot, M, P576
De Haro Muñoz, T, E1271, E1283
De Haro-del Moral, F, P685
De Jaureguiberry, J-P, S453
De Jong, N, E1504
De Jong-Korlaar, R, P265
De Keersmaecker, K, S417, S439, P152, P153
haematologica | 2017; 102(s2) | XVII
Madrid, Spain, June 22 – 25, 2017
De Keyser, F, P565
De Klerk, W, S447
De Koning, E, S500
De Korte, D, P404
De la Banda, E, E957, PB1727
De la Camara, R, E1565
De la Chapelle, A, E883
De La Cruz Vicente, F, S469, E953
De la Cruz-De la Cruz, C, E1306
De la Fuente, A, P554
De la Fuente, I, E1014
De la Fuente, J, P233
De La Iglesia, S, E983, PB1755
De La Iglesia Iñigo, S, PB1758, PB1667
De La Morena-Barrio, B, S445
De La Morena-Barrio, M, S445, E1444, E1456
De la Rubia, J, S409, P343, P376
De la Serna, J, E1086
De La Vega, E, PB1896
De Laiglesia, A, E1541
De las Heras, N, P737, PB1990, PB2182
De Lavallade, H, S423, E1550
De Luca, L, E1226
De Maio, C, PB1932
De March, E, E1254, PB1728
De Marchi, F, E1065, E1496
De Matteis, S, E904, E1012
De Matteo, B, PB1661
De Matteo, E, PB2073
De Miguel, C, P685, E972, PB1885
De Miguel, D, PB1986, PB2022, PB2064
De Miguel Jiménez, C, PB1997
De Moerloose, B, S476, P350, P517, E1114
De Montalembert, M, P631
De Muro, M, E1340
De Novi, L, E1000, E1408
De Oliveira, M, PB1913
De Paepe, K, P565
De Paoli, L, E1247
De Paz, MD, R, P257, P609, E1051, E1181, E1546, E1563
De Paz Arias, R, E1059
De Philippis, C, E1201
De Pieri, C, PB2142
De Pooter, N, P370
De Propris, M, P166, E989, E1000, PB1779
De Renzis, B, P712
De Ridder, J, E1279
De Rocco, D, S432, S433, P365
De Rop, C, E1056
De Rosa, G, S811
De Santis, G, PB1899
De Santis, R, E955
De Santis, S, P600
De-Silva, D, P669, P731, E1208
De Smedt, E, E1211
De Smedt, R, P156
De Souza, C, PB1820
De Souza, C, S422
De Stefano, L, P586, E1390
De Stefano, V, P351, P722
De Tute, R, P245, P589, P669
De Veirman, K, E1211, E1220
De Vos Klootwijk, L, P190
De Vries, J, P683
De Waal, E, P340
De Wind, A, PB2136
De Winde, C, E1353
De Wreede, L, P567, P576
Deal Becker, E, PB1959
DeAlmeida, V, P328, E1373
Deambrogi, C, P282
Dean, M, E1350
DeAngelo, D, S788, P201, P203, P204, P519, P525, P547, P562
Dearden, L, E1281
Debals-Gontier, M, E1549
Debatin, K-M, P508, P754, E838
Debureaux, P-E, PB1713
Declercq, H, E1135
Deconinck, E, S453, S493, P345, P572
DeCosta, L, E1298
Deenik, W, S501, P340, P567
Defasque, S, E1361





Deininger, M, S425, P603, E1071, PB1819
Deiteren, K, S141
Dejoie, T, P348
Del Cañizo, M, P318, P655, P660, P751, E1169
Del Cañizo Fernández Roldán, M, E1181
Del Giudice, I, E989, E1000, E1408, PB1779
Del Poeta, G, P583, P588, E908
Del Pozo, Á, PB1628
Del Principe, M, S111, E908
Del Rey, M, P318, E1169, E1451
Del Rey, Ó, E1592
Del Vecchio, L, E1226





Delaporta, P, P397, E1158
Delarue, R, E1236, E1386
Delaunay, J, P217, P316




Delforge, M, E1180, E1272, PB1964







Della Cioppa, P, PB1920
Della Corte, G, P288
Della Pepa, R, S504, P277, E1122, E1125, E1459, PB1923
Della Porta, M, E1179
Della Starza, I, E1000, E1408, PB1779
Dellacasa, C, P214
Dello Iacono, N, PB2188
Delord, M, E1063
Delphine, L, PB1713
Delva, L, S139, P514
Delwail, V, PB1863
Demajo, S, E1381
Demakos, E, S488, E1170, E1185
DeMarco, S, S500
DeMarini, D, P633











Dencic-Fekete, M, PB1771, PB1793
Deng, W, S785
Deng, W, P601
Dengler, J, S424, P255, P257, E1326
Denkers, F, P190
Dennis, M, S791





XVIII | haematologica | 2017; 102(s2)









Deshpande, N, E837, E843
Desmet, K, PB2152
Desmier, D, PB1987





Despotovic, J, P367, P727
Dessen, P, S427




Devereux, S, P245, P589, E1509







Devlin, R, P708, E1324
Devlin, S, P553, P745, E1252
Devos, H, E1056






Di Bartolomeo, P, P394, P738, PB1953, PB2059
Di Bella, N, P249
Di Benedetto, A, E1379
Di Bona, E, S485, P163
Di Carlo, E, E1226
Di Ciaccio, P, PB2014
Di Felice, N, E854, E1299, PB1632
Di Florio, F, E1167
Di Gaetano, R, PB2076, PB2077
Di Genua, C, S421
Di Giacomo, D, E1174
Di Gioia, M, PB1686, PB1983
Di Giusto, S, E1065
Di Grazia, C, S796, E915, E1505
Di Ianni, M, P394
Di Marcantonio, D, P528
Di Marco, F, P717
Di Matola, T, E1570
Di Micco, A, P343, E1250
Di Noi, M, E1406
Di Palma, F, E873
Di Paolo, A, E1048
Di Perna, M, S504, E1122, PB1923, PB2011, PB2020
Di Piazza, F, PB2038, PB2039, PB2056
Di Raimondo, F, S778, P583, E1043, E1214, E1232, PB2063
Di Renzo, N, PB1722, PB1877
Di Rocco, A, P304, PB1880
Di Rocco, M, E1077
Di Ruscio, A, PB1664
Di Serio, C, S806
Di Tomaso, E, P188, E884
Di Trani, M, P282
Di Tucci, A, P667, E1186
Di Tullio, A, P264, P657
Di Veroli, A, E908, E1340
Di Vita, A, P599, E1048
Diaa, N, PB2097
Diagne, I, E1495





Díaz, L, E1273, PB1949
Diaz, M, PB1986, PB2022, PB2157
Diaz, V, PB1888
Diaz-Beyá, M, S790, P202
Diaz de Heredia, C, S144, P580, P623
Diaz Morfa, M, PB2064




Diehl, V, S150, P275









Díez-Campelo, M, P316, P318, P655, P660, P751, E1169, E1181




Diklić, M, E1316, E1319, PB2140
Dikme, G, PB2222
Dikov, T, PB1693, PB1828
Dilek, I, PB2112
Dimitrakopoulou, A, S416, P639
Dimopoulos, K, P324
Dimopoulos, M-A, S100, S101, S415, S456, S458, P334, P335, P337, P338, P343,
E1201, E1231, E1233, E1246, E1249, E1250, E1281, E1292, E1304
Dimopoulou, M, S130, E1120, E1485
Dimou, M, P255, E1120
Dimovski, A, E1471, PB1775, PB1795, PB2062
DiNardo, C, S471, S472, S487, S489, S496, P192, P200, P209, P215, P315, P317,
P352, P518, P550, P665, E913
Ding, W, P254
Dingli, D, P673, E1240, E1241
Dinic Uzurov, V, PB1745
Dinman, J, S417, S439




DiPersio, J, S794, P319
Dirnhofer, S, E1365
Dirse, V, E1311, E1399
Dispenzieri, A, P331, P673, E1240, E1241
Diviskova, E, P238, E1003
Divoka, M, E1432
Divona, M, E908, PB1696
Dixon, S, S441
Dizdarevic, A, PB2078
Djikić, D, E1308, E1316, PB2140
Djumic, Z, PB1871
Djunic, I, PB1704
Djurasinovic, V, S443, E970, PB1708, PB1771, PB1793, PB1799, PB1862









Do, Y, P259, P569, E871, E1054, E1069, E1070, PB1993





haematologica | 2017; 102(s2) | XIX










Dogné, J-M, P230, E964
Dogu, M, P281, PB2137
Doherty, A, PB1788, PB1794
Döhner, H, P182, P208, P533, P535, P700, E864, E868, E870, E1084, E1335










Dombret, H, S478, P208, E856, E910
Domenichini, C, P599, E1048














Dönmez Demir, B, PB2222
Donnellan, W, S793, P662
Donnini, I, PB1983
Donzelli, S, E1379
Doobaree, U, E1430, E1453
Doondeea, J, S140





Dos Santos, P, PB1764
Doshi, P, P676, E1369
Dosquet, C, P657
Dotlic, S, E971

















Drayson, M, S407, S781






Drexler, H, E1387, PB1623
Dreyling, M, S470, S776, E1402
Drize, N, E1092, E1096, E1098
Droin, N, S427, P268
Drokov, M, E1545, E1559, PB1685, PB1852, PB2176
Drozd-Sokołowska, J, E1193, E1257







Duarte, R, S807, E1541
Duarte, S, E1110
Dubinkin, I, PB2232
Dubnyak, D, E1545, E1559, PB1852, PB2176
Dubois, O, P624
Dubovsky, J, S492
Dubowy, R, S465, S785
Dubravcic, K, E1296
Dubreuil, P, P709
Duca, L, E1483, E1576
Ducastelle-Leprêtre, S, E906, E1150
Duces, A, PB2045, PB2051
Ducou Le Pointe, H, P716
Dudakov, J, S446
Dudez, M, PB1813, PB2031
Dudina, G, PB1980




Dufour, C, P232, P234, P575, P717, E1440
Dugas, M, E1197
Duh, M, P285, P286, PB1825
Duhamel, A, E1135
Dührsen, U, P534, P582, E1118
Dujmovic, D, E971




Dulín, E, PB2143, PB2200








Dumond Wibaux, E, E1458
Dumont, S, P712
Dunaeva, E, PB2035
Dunbar, M, S473, P675
Dunn, R, E905, E1176
Dunning, A, P295
Duong, D, E847





Durán, M-A, P703, E1341, E1417, E1555
Duran, M, PB1968




Durechova, K, S461, P238
Durgun, E, E1427
Durian, M, S501





XX | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Durrant, S, S478
Durrieu, F, E1028






Duverger Munch-Petersen, H, P324
Duvic, M, P191, P637
Duvillier, H, E994




Dwojak, M, S125, E1359, E1385
Dworzak, M, P350


















Echchannaoui, H, P627, E992
Echeveste Gutierrez, M, P339
Eckert, C, S436, S437, P155
Eckert, R, P255
Eckert, R, S505, PB2050
Eckstein, V, P179, P206
Eclache, V, E1001
















Efremov, D, E993, E1375








Egyed, M, S784, S785, PB2053
Ehall, B, E1395




Eichenauer, D, S150, P275




Einsele, H, S145, S807, S816, P320, P341, P681, E1251, E1569, PB1934










Ekwattanakit, S, S452, E1076
El-Ayoubi, A, E1388
El-Benna, J, P268
El Chaer, F, E912
El Chazli, Y, E1411
El-Cheikh, J, E1150, PB2177, PB2183
El Demery, M, P649
El Farra, A, PB1835
El-Farrash, R, P291, E1093
El Fassi, D, E1115
El-Galaly, T, E1115








El-Refaey, F, PB1658, PB2052
El Samahy, M, E1582
El-Sayed, M, PB2236
El-Shafey, R, PB2194









































Elsherif, N, E1572, E1580
Elshinawy, M, E1578, PB1749, PB2116
haematologica | 2017; 102(s2) | XXI
Madrid, Spain, June 22 – 25, 2017
Eltan, S, PB1649
Elverdi, T, E1518
Emadi, A, E912, E947
Emarah, Z, E1095










Engelhardt, M, P341, E1251
Engelke, A, S464
Engert, A, S150, S412, S414, P275, P295, E1119
Enjeti, A, S473
Enjuanes, A, S115, E1381
Ennishi, D, P297
Enrico, A, E1182





Eom, H, PB1850, PB2165
Eom, H-S, E984, PB1993, PB2055
Eom, K-S, P551, P561, P638
Eom, K-S, P742, E1513
Er, E, E1564
Eradat, H, P253

















Eroğlu Filibeli, B, PB1638
Errichiello, S, S485, P599
Ershov, D, PB1853
Ertem, M, PB1927
Ertürk Şengel, B, PB1681
Escalante, F, P329, PB1990, PB2021, PB2082, PB2182
Escamilla, V, E1349
Escherich, G, P515
Escoda, L, S790, P202, E831, PB1861
Escoda Teigell, L, E1426
Escribà-Garcia, L, S816
Escribano, L, P713
Escudero, A, P509, PB1628
Escudero-Góngora, M, E1341
Esen, D, PB2134
Eser, B, E1527, PB2171
Eskazan, A, E1159, E1518, PB1701
Eskelund, C, S109
Esma, F, E1247
Espadana, A, PB2007, PB2184
Espadana, A, E1297, PB2044
Español, N, PB2133
Espéli, M, E1102
Espigado, I, S804, E1349
Espín, J, P573
Espín, S, P573
Espinet, B, S461, E1027, PB1726
Espiño Martinez, M, E1302, E1305
Espinosa-Bautista, K, PB1634
Espinosa Lara, N, E1134
Esposito, M, PB1920





Esteban Figuerola, A, E1426
Estell, J, E1289
Estella, C, P168
Estenfelder, S, S116, P248, P585
Estepp, J, P620
Esteve, J, S790, S798, P202, E831, PB1616, PB1668
Estivill, C, PB1668
Estrada, N, P703




Ettinger, O, P220, E1133
Eustace, B, S147
Evangelista, A, P214, P304, P322







Ezponda, T, P325, E1225
F
Fabarius, A, S424, P255, E1344
Fabbiano, F, S111, P520
Fabbri, A, E1401
Fabra Urdiola, M, PB1692
Fabris, F, PB2037
Fabris, S, E1000
Facchini, E, E1164, PB2153
Facciolo, F, E1145
Facco, M, E1005, E1006, E1011, E1357, PB1770
Facon, T, S460, P675
Fadalla, K, PB1832
Fadda, P, E917
Faderl, S, S793, P201, E1192







Fais, F, P586, E1390
Fakouhi, K, S473
Falanga, A, P760, P766













Falini, B, S111, P173
Falkenburg, F, P576
Falkenburg, J, S447







XXII | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Fanale, M, S412
Fañanas-Baquero, S, E1094
Fancello, L, S439, P153
Fanci, R, PB1686
Fanciullo, L, P234










Farmaki, E, E1414, E1423
Farooqui, M, P344
Farrelly, E, E1184, E1191, E1196
Farruggia, P, P717, E955, E1420
Farrukh, A, PB2135
Farsaci, B, S412
Fasan, A, P199, E1312
Fasoli, S, E1164
Fathi, A, S471, S793, P201, P215, E947
Fathy, A, PB2207
Fätkenheuer, G, P568




Fava, C, P604, PB1818




Fazio, G, S801, P628
Fearn, A, P160
Fechina, L, P161
Fechter, K, E1363, E1395
Fedeli, F, E1077
Federici, I, P636, E1136













Feliu, E, E831, E1396, PB1616
Fellague-Chebra, R, P257
Fellows, G, PB1797



















Fernandes, S, P236, P237
Fernandez, A, E1263
Fernandez, F, PB2133







Fernandez de la Fuente, L, PB1902
Fernández de Larrea, C, E1259, PB1952
Fernandez de Sevilla, A, E957, PB1727
Fernandez Escobar, N, E1508
Fernández-Ferrero, S, PB2082
Fernández Figueroa, E, PB1738
Fernandez-Garcia, M, P755
Fernández-González, M, E953
Fernandez-Leyva, H, PB1893, PB2151, PB2224
Fernández Maqueda, C, PB2064
Fernandez-Mercado, M, P198, P303, E1368
Fernández-Miñano, C, PB2106
Fernández-Navarro, P, P584, E1019
Fernández-Ordoño, R, P376
Fernández Poveda, E, E1562, PB1969, PB2033
Fernandez Ramos, A, E829
Fernández-Rodríguez, C, P694, P696
Fernandez Rodríguez, M, PB2122
Fernández-Sevilla, L, P513
Fernando, E, P737




Ferrara, F, P722, PB2001
Ferrara, G, P306, E976
Ferrara, K, PB2020, PB2011
Ferrarazzo, G, P283
Ferrari, A, E882, E898
Ferrari, A, P616, PB1696
Ferrari, G, S128
Ferrari, S, PB1814
Ferrarini, M, P586, E1017, E1390
Ferrario, A, P644
Ferraro, F, P528
Ferraro, M, PB1726, PB1874
Ferraro, S, P736, E1151
Ferré, Ó, P747
Ferreira, A, PB1830





Ferrer-Marin, F, P660, P703, E1059, PB1810
Ferreri, A, S413, P304, PB1872
Ferrero, D, P604, E1332
Ferrero, S, P304, E1408
Ferretti, A, E976
Ferretti, E, PB1785
















Fidarova, Z, E982, PB1685
Fidirikou, M, PB1750
Fidyt, K, E827
Fiedler, W, S473, P533, P535, E868, E870
haematologica | 2017; 102(s2) | XXIII
Madrid, Spain, June 22 – 25, 2017





Figuera, A, E891, E1113, E1565
Figueroa, M, E1173
Figueroa, R, S444, PB2230
Fijnheer, R, PB2096
Filaci, G, P586, E1390
Filì, C, E1496, PB1697
Fillerova, R, PB1766
Filocamo, M, E1077
Filonenko, K, E1127, PB1714
Filosa, A, P290, P393, P399, E1570, E1575
Finashutina, Y, PB1710, PB1817, PB1851, PB2026
Finazzi, G, P760, P766, E1315
Finazzi, M, E1315
Finck, B, E1147
Finelli, C, P658, P667, PB1932
Fineman, R, E1034, PB1781
Finetti, P, P183
Fingerle-Rowson, G, S774, S775
Fink, A, E1025
Fink, A-M, S464, P251
Fink, L, PB2009
Finke, J, S797, S798, P388
Finkelstein, D, P271
Finocchi, A, P717
Fiore, C, P188, E884





Firatli Tuglular, T, P281, E1446, PB1681
Firczuk, M, E827
Firsova, M, E1227, E1295, PB2000
Fischer, A, PB2083
Fischer, A, P350
Fischer, J, S446, P272
Fischer, K, S464, P236, P251, P585, E1025
Fischer, L, E1402
Fischer, M, P648
Fischer, T, P535, E865
Fischer, U, S436










Flanders, S, PB1687, PB1699
Flasinski, M, S789











Flindt, T, P706, E1320
Flinn, I, S471, S777, E1130
Flintrop, M, S494
Flogegard, M, PB1779





Florido Ortega, Y, E1327, PB1667
Florschütz, A, S502
Flospergher, E, PB1785
Flotho, C, P350, P353
Flowers, C, S468, S772
Flowers, M, S492
Flynt, E, E1203
Foà, R, P322, P520





Foglieni, B, E1606, PB2233
Foglietta, M, E999
Folber, F, E841




Follows, G, S469, S776, P276, E938
Folta, A, PB1650
Foltz, I, PB1849
Foltz, L, P702, P706, E1320, E1333, E1334
Fominykh, M, E1313, PB1821, PB2034
Foncillas, M, E1038, PB1761
Foncuberta, C, E1508
Fonder, A, P673, E1240, E1241
Fong, E, P620
Fonseca Mourelle, A, PB2155
Font, L, S790
Fontana, D, P570
Fontana, M, E882, E898, PB1657
Fontana, R, E967
Fontanelli, G, E946
Fontcuberta, J, P759, P765
Fontoura, M-L, PB1833
Foon, K, P634
Forcade, E, S798, PB1629
Forcella, D, E1145
Forcina, A, S806




Forero-Torres, A, P633, E1142




Fornecker, L-M, S105, P217
Forni, G, P400, E1482, E1491
Forno, B, PB1931
Foroni, L, S423










Foster, R, E1035, PB1791
Foster, T, P258
Fotiou, D, P337, E1266
Fotzi, I, P714
Foucar, K, E923
Foucher, B, PB1813, PB2031
Fouzia, O, E1275, E1479, PB2126
Fowler, A, P276
Fowler, N, S772, E1129
Fox, C, PB1788, PB1959




XXIV | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Fracchiolla, N, S111, P644, PB1648
Frachiolla, N, PB1678
Fragoso, R, E822
Frairia, C, P214, E1332
Fram, R, E944, E1184, E1191, E1196
Franceschini, L, P607
Franchini, E, E882, E898










Fraser, V, PB1788, PB1794











Freitas-Tavares, P, E1044, E1047, E1064
Frémeaux-Bacchi, V, PB2083





Frezzato, F, E1005, E1006, E1011, PB1770
Fridrik, M, P336
Fries, S, PB1966
Friis, L, P193, E932
Frikha, I, PB1639
Frisanco Oliveira, A, PB1856
Frismantas, V, P159




Fronková, E, S801, P711
Frost Andersen, N, E1250
Fruchtman, S, S488




Fuchs, M, S150, P275
Fuchs, R, S424
Fuentes, I, P721, E1456
Fuertes, M, P737, PB1990, PB2021
Fugazza, E, E1293, PB1970
Fugazza, G, E915






Fujimoto, A, E1552, PB1630, PB1716
Fujimoto, K, P301, PB1723
Fujioka, I, E1058, E1066
Fujioka, Y, PB1999
Fujisawa, M, P301
Fujisawa, S, E962, PB1971
Fujisawa, Y, P642
Fujishima, Y, P642





Fujiwara, T, P612, E1104
Fujiwara, Y, PB2042
Fukuda, S, PB2180
Fukuda, T, P385, P389, E1522
Fukuhara, N, P612, E1104, E1139
Fukumoto, K, P301
Fukushima, N, E1516
Fulciniti, M, P321, E1200, E1206



















Gabillaud, C, E1001, E1361
Gabriel, S, P236









Gagliardi, V, E1560, PB1722
Gaidano, G, P244, P282, P304, P358, P583, P616, P667, E1017, E1186
Gaidano, V, P658, P667
Gaidzik, V, P533, P535, E864, E868, E870
Gaillard, J-B, E1001, E1361
Gaillard, B, E1001, E1361
Gainaru, G, E1120
Gajewski, M, P710, PB1905
Gaken, J, P541





Galaverna, F, S146, S495, P381, E1505
Galazka, A, E1257






Galicia, T, E1604, PB1729
Galieni, P, E946, E1247, E1561, PB1760
Galigalidou, C, E1407
Galimberti, S, S485, P256, P599, P604, P671, E1042, E1043, E1048, E1318, E1397,
E1408
Galindo Vázquez, O, E1473
Galinsky, J, P731, E1470
Gallagher, D, P761
Gallagher, M, E1550
Gallamini, A, S413, P163, E1533
Gallardo, D, S790, P202




Galli, M, S102, S410
haematologica | 2017; 102(s2) | XXV












Gaman, A, PB2105, PB2119, PB2132
Gaman, M-A, PB2105, PB2119, PB2132
Gamba, S, P760, P766
Gambacorti-Passerini, C, S425, P570, E1351
Gambale, A, S811
Gambella, M, S102, P322
Gambella, M, E854, PB1732
Gamberi, B, S410, P343, E1250
Gamberini, R, S129
Gamboa, C, PB2205
Gammon, G, S475, E924
Gamrani, S, PB1667
Gamundi, E, PB2008
Gañán-Gómez, I, S489, P321, P652




Ganser, A, S494, S798, P388, P533, P535, P537, E864, E868, E870, E1105, E1506
Ganuza Fernandez, M, P271, E1099
Ganzel, C, PB1781


























García Arroba, J, E1426
García-Ballesteros, C, E1394
García-Barberá, N, P573
Garcia-Cadenas, I, S145, P746, E1160, PB2159
Garcia-Caro, M, PB1991
Garcia-Cuellar, M, P527
Garcia de Andoin, N, S144
García de Coca, A, P329, E1014
García de Veas Silva, J, E1271, E1283, PB1984
García de Villaescusa, R, PB2235
Garcia Erce, J, PB2230
Garcia-Guerrero, E, P681
García-Gutiérrez, V, P601, P609, P703, E1051
García Iglesias, L, P376
García-Lozano, J, P696
Garcia-Malo, M, P402, E1013
Garcia-Manero, G, S474, S487, S488, S489, S496, P170, P192, P200, P207, P209,
P315, P317, P321, P352, P518, P550, P652, P665, E830, E913, E1192
Garcia Manteiga, J, E1232
García-Martín, L, E1543
García-Montero, A, P713
García-Morín, M, PB2143, PB2149, PB2200
García-Mouriz, A, S444
Garcia Muñóz, N, PB1727
Garcia Muret, P, E963
Garcia-Ormeña, N, E1051
Garcia-Ortiz, J, PB1847
García Pallarols, F, PB1726, PB1874
García-Pavía, P, P685, PB1997
García-Ramírez, I, S148
García-Ramírez, P, P205, E1604, PB1729
García Raso, A, E1596, PB2117
García Ruiz, M, P768
García-Sanz, R, S801, S782, P679, E887, E1246, E1278, E1543
Garcia Sobreviela, M, E1412
García-Torralba, A, E1081
Garcia-Vargas, J, S776
Garcia Vela, J, E891
Garcia Vicente, A, PB1879
Garciaz, S, P183







Garg, M, S407, S781





Garrido, A, S790, P202, PB1668
Garrido, C, E1356, PB2149









Gasior, M, E1546, E1563, PB1896
Gasior, Y, S487
Gasova, Z, E1540
Gasparetto, C, P349, P675, E1239, E1277, PB1973
Gassiot, S, P168, PB1991
Gassner, F, P558
Gastineau, D, P254, E1502
Gastl, G, P595, P707
Gatta, F, PB2009
Gattei, V, P583, P588
Gattermann, N, P601, E937
Gatti, A, E821
Gattillo, S, S128
Gaudig, M, E1281, E1291








Gavriatopoulou, M, S415, P337, E1249, E1292
Gavriilaki, E, PB1698, PB2102, PB2144, PB2166
Gavrilina, O, E836, E860, PB1636, PB1646, PB1685, PB2049
Gavrilović, D, PB1733
Gay, F, S410, P322, P341





Gdovin, J, P728, E1466
Ge, Z, E863
XXVI | haematologica | 2017; 102(s2)
22nd Congress of the European Hematology Association
Gecek, I, E1329
Geçgel, F, E1446, PB1681, PB2027
Gedde-Dahl, T, E866, E1057, E1501
Gediz, F, PB1846
Geelen, I, P262, E1057
Geer, T, S424
Geerdens, E, S439, P151, P152
Geeta, G, P570




















Gentile, M, P586, E1017, E1390, PB1760
Gentili, S, P341, PB1954
Gentilini Cacciola, E, PB2040






Georgantis, S, E1600, PB1750
George, P, PB1836







Geraldes, C, E1287, E1297, PB1914, PB1938, PB2007, PB2184
Geranio, G, P715, E844








Germing, U, S494, P533, P664, P666, E868, E870, E937
Gerofotis, A, E1233, E1292
Geron, I, S436
Gerrie, A, P581, E1557
Gershon, P, P301
Gerstung, M, E1201
Gertz, M, S104, P331, P673, E1240, E1241




Geyer, H, P359, P377, E1321, E1339
Ghallab, O, PB2192
Ghanem, A, E1578
Ghanima, W, E1434, E1435









Ghia, P, S461, S462, P244, P378, E997, E1086, PB1872
Ghilardi, R, P717, E1420




Ghobrial, I, S779, P323, E1354









Giagounidis, A, S122, P666, E937, E1181
Giai Via, V, P658
Giaimo, M, E1440
Giallongo, C, E1214, E1232
Giammarco, S, P232, PB2162
Gianelli, U, E1346
Gianesello, I, PB1728
Gianesin, B, P400, E1482
Gianfaldoni, G, PB1686




Giannarelli, D, E1021, E1030
Gianni, A, S413, S778
Giannoni, L, S796
Giannopoulos, A, PB2091
Giannopoulos, K, E888, E1262
Giannopoulou, E, E1233, E1266
Giannotta, J, P616, E1078
Giannouli, S, S415, PB2107
Giannoullia, P, P280
Giansily Blaizot, M, P289









Gil, Á, PB1986, PB2064
Gil, A, PB1819
Gil, C, PB1616
Gil, L, E1079, E1193
Gil-Bazo, I, S444












Giménez Pérez, T, E1426
Gimeno, E, E1027, PB1726, PB1874
Gimondi, S, E1201
Gimsing, P, S501, P324
Gindina, T, PB1645, PB1834, PB1853
Giné, E, E1137, E1369
Gineikiene, E, E1311
Gini, G, S413, S778, E1123
Ginos, B, PB2050
Gioia, D, P667
Giona, F, P234, E1164
haematologica | 2017; 102(s2) | XXVII
Madrid, Spain, June 22 – 25, 2017
Gionfriddo, I, P173
Giordano, A, PB2019





Giraldo, MD, P, P702, E1051, E1134, E1333, E1334, E1410, E1412, PB1989,
PB2085
Giralt, S, P740, P745, P748, E1252, E1532, E1554
Girard, R, S499
Girard, S, PB1813, PB2031
Girardi, K, E1167






Gironella, M, S409, P376, P688




Gisslinger, H, S787, P707, PB2053




Gjertsen, B, P181, E866, E903, E1057
Gkirkas, K, P280
Gkoutsias, A, E1416, PB2098






Gleixner, K, P693, E1071
Glembotsky, A, P365
Glinshchikova, O, E1403, E1409
Glossmann, J-P, E1251
Gluckman, E, E1495, PB2157
Gmati, G, E1514, PB2072
Gnan, C, P365
Gniot, M, P602, P611
Go, R, P331, P673, E1240, E1274
Go, S-I, E968, PB1715
Go, W, S466, P522
Goardon, N, S140
Gobbi, G, P528
Gobbi, M, P283, E854, E915, E919, E933, E1299, E1505, PB1632, PB1732
Gobessi, S, E993
Goddard, A, PB1915
Godeau, B, S453, PB2083
Godfrey, L, P540
Godon, C, E1001, PB1618, PB1913
Godoy, A, E887
Goebeler, M, S424, P255
Goecke, T, E1106
Goede, J, E1180






Göhring, G, S494, P533
Goicoechea, I, E1368




Golab, J, S125, E827, E1359, E1385




Goldschmidt, H, S458, P334, E1251, E1253, E1269, PB1966












Gomes, M, E988, PB2118
Gomes, S, E1586
Gomez, C, PB2057







Gomez-Almaguer, D, E1306, E1415
Gómez Casares, M, P601, P696, P703, E1327, PB1667, PB2179
Gómez-Castañeda, E, P591




Gómez Morales, M, P768
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NOVEL SMALL MOLECULE INHIBITORS CO-TARGETING CK1A AND
P-TEF-B DISRUPT SUPER-ENHANCERS AND ERADICATE ACUTE
MYELOID LEUKEMIA IN A MOUSE MODEL
W. Minzel1, I. Alkalay1, A. Fink1, A. Venkatachalam1, E. Hung1, D. Li2, J. Vacca2,
F. Mercurio3, M. Oren4, E. Pikarsky1, Y. Ben-Neriah1,*
1Immunology and Cancer Research, Hebrew University of Jerusalem,
Jerusalem, Israel, 2Chemistry, WuXi AppTec, Shanghai, China, 3BioTheryX
Inc, San Diego, United States, 4Molecular Cell Biology, Weizmann Institute,
Rehovot, Israel
Background: Whereas p53 is mostly non-mutated in AML, various oncogenic
pathways, frequently through enhancing the activity of its major antagonist
Mdm2, suppress its activity. We have previously showed that genetic ablation
of CKIα robustly activates p53 (doi:10.1038/nature09673). However, with no
selective CKIα inhibitors for in vivo use, the therapeutic value of CKIα inhibition
in hematological malignancies cannot be validated.
Aims: To develop small molecule CKIα inhibitors and assess their effect in
mouse models of human leukemia.
Methods: CKIα inhibitors were identified via cell-based screening based on
p53 activation. We focused on a small class of pyrazole-pyrimidine scaffolds,
which through extensive medicinal chemistry yielded derivatives with high affin-
ity binding, validated by crystallography studies, potent CKIα inhibitory activity
and a good pharmacokinetic profile. Anti-leukemic activity was assessed by
oral treatment in mouse models of AML: MLL-AF9 and Bcr-Abl Blast Crisis
Results: We first demonstrated the inhibitors’ anti-leukemic effect by single
oral dose treatment, robustly inducing p53 activation and blast cell cytoreduc-
tion (Figure 1).
Figure 1.
These inhibitors distinguished leukemic from normal hematopoietic stem cells:
they did not affect normal hematopoietic CFUs, but eliminated leukemic CFUs
at an IC50 <9nM. We tested the long-term oral therapeutic effects of the
inhibitors in MLL-AF9 leukemic mice. Whereas all vehicle-treated mice suc-
cumbed to the disease within a month, 40-50% of inhibitor-treated mice survived
with no signs of disease up to 5 months’ observation, nor had the surviving
mice any sequela of long-term treatment; all had normal blood counts and nor-
mal organ morphology and histology. Long-term leukemia control with possible
cure, attesting to eradication of LSCs and preservation of normal HPSCs was
demonstrated by transplanting leukemia-treated BM into lethally irradiated mice:
all transplanted mice recovered and none showed any evidence of residual
disease within 6 months. To elucidate the mechanisms by which the inhibitors
distinguished leukemia from normal hematopoietic cells, we profiled the kinome
affinity of the inhibitors and further studied their signaling effects in vitro and in
vivo. We found that CKIα inhibitors having potent anti-leukemia activity are dis-
tinguished from less active analogues by their capacity to co-target CDK9 and
suppress the RNA Pol II elongation factor P-TEFb (CDK9-CyclinT1 complex).
This property, validated by co-crystallography studies, enables the inhibitors to
disrupt super-enhancers (SE), demonstrated by suppression of chromatin
H3K27 acetylation and Brd4 association. As a result, transcription of SE-depen-
dent major anti-apoptotic leukemia oncogenes including Mdm2, Bcl-2 and Mcl-
1 was nearly abolished and inhibitor-treated leukemia cells underwent apopto-
sis. Strikingly, brief drug exposure (10mins in vitro; 2hrs in vivo) results in pro-
longed (24hrs) SE suppression. This unique property, which is at variance with
the current occupancy-driven pharmacological paradigm, likely, contributes to
the dramatic therapeutic effect of co-targeting CKIα and P-TEFb in leukemia.
Summary/Conclusions: We developed a new class of small molecule
inhibitors that co-target CKIα and P-TEFb. These inhibitors induce very rapid,
robust activation of p53 in synergy with shutdown of leukemic super-enhancers,
resulting in a lasting, powerful and specific anti-leukemic therapeutic effects in-
vivo, with cure potential.
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CRYPTIC INSERTIONS OF IMMUNOGLOBULIN LIGHT CHAIN ENHANCER
REGIONS ACTIVATE CCND3 AND CCND2 IN CYCLIN D1-NEGATIVE
MANTLE CELL LYMPHOMAS
D. Martín-Garcia1, A. Navarro1, G. Clot1, I. Ribera-Cortada1, B. González-Farré1,
J. Gutiérrez-Abril2, R. Valdés-Mas2, R. Woroniecka3, G. Rymkiewicz3,
L. de Leval4, A. Rosenwald5, J.A. Ferry6, E.D. Hsi7, K. Fu8, J. Delabie9,
D. Weisenburger10, D. de Jong11, S.J. O’Connor12, S.H. Swerdlow13,
D. Torrents14, S. Beltran15, B. Espinet16, E. Matutes17, R. Siebert18, G. Ott19,
L. Quintanilla-Martinez20, E.S. Jaffe21, C. López-Otín2, X.S. Puente2, E. Campo1,
I. Salaverria1, S. Beà1,*
1IDIBAPS, Barcelona, 2Universidad de Oviedo, Oviedo, Spain, 3The Maria
Skłodowska-Curie Institute - Oncology Center, Warsaw, Poland, 4Centre Hospi-
talier Universitaire Vaudois, Lausanne, Switzerland, 5University of Würzburg,
Würzburg, Germany, 6Massachusetts General Hospital and Harvard Medical
School, Massachusetts, 7Cleveland Clinic Foundation, Cleveland, 8University of
Nebraska Medical Center, Omaha, NE, United States, 9University of Toronto and
Oslo University Hospital, Oslo, Norway, 10Department of Pathology, City of Hope
National Medical Center, Duarte, CA, United States, 11VU University Medical
Center, Amsterdam, Netherlands, 12HMDS Laboratory, Leeds Teaching Hospitals
NHS Trust, St James’s Institute of Oncology, Leeds, United Kingdom, 13Depart-
ment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA,
United States, 14Barcelona Supercomputing Center, 15Centro Nacional de Análi-
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pital Clinic de Barcelona, Barcelona, Spain, 18Institute of Human Genetics, Uni-
versity of Ulm, Ulm, 19Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-
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Background: Mantle cell lymphomas (MCL) are characterized by the primary
translocation t(11;14)(q13;q32) involving CCND1 and IGH genes in virtually all
cases. Recently, a small subset of cyclin D1-negative (cyclin D1−) MCL has
been recognized. About half of these cases have CCND2 gene rearrangements
and overexpression of this gene. However, the primary oncogenic events in
cyclin D1−/cyclin D2−MCL still remain elusive.
Aims: To identify potential mechanisms driving the pathogenesis of cyclin
D1−/cyclin D2−MCL.
Methods:We investigated 66 cyclin D1−/SOX11+MCL cases by a combination
of fluorescence in situ hybridization (FISH), gene expression profiling by
Affymetrix U133+2.0 and qPCR (n=51), and copy number arrays (n=47) (Agilent
CGH 1M, Affymetrix Oncoscan and 500K). Six cases were investigated by
genome-wide sequencing including 4 mate-pair whole-genomes, 4 whole
exomes, and 1 whole-genome sequencing. The male/female ratio was 2.5:1
and median age at diagnosis 66 years.
Results:Most cyclin D1−MCL (49/51, 96%) showed overexpression of other G1
cyclins: CCND2 in 33/50 (66%), CCND3 in 12/51 (24%), and moderate overex-
pression of both CCNE1 and CCNE2 in 4/35 (11%). CCND2 rearrangements
were detected by FISH in 25/33 cases (76%) with CCND2 overexpression, but
the remaining CCND2+ cases and those with CCND3 overexpression did not
show CCND2, CCND3 and IG rearrangements using currently used break-apart
probes. Interestingly, by mate-pair whole-genome and whole-exome sequencing
analyses we discovered cryptic insertions of IG light chain regions including the
enhancer regulatory elements (2 IGK and 1 IGL) near CCND3 gene in the three
cases with cyclin D3 overexpression. These rearrangements were confirmed by
Sanger sequencing and FISH with specifically designed probes to recognize the
cryptically rearranged regions. Furthermore, using these probes we detected 6
additional cases with cryptic IGK-CCND3, as well as 3 cases with IGK-CCND2
juxtaposition in tumors with high levels of CCND3 and CCND2, respectively.  Tak-
en together, 74% and 18% cases corresponded to cyclin D2+ and cyclin D3+ MCL,
respectively, whereas 6% showed overexpression of CCNE1 andCCNE2without
gene rearrangements. The whole-genome analysis of one cyclin D1− MCL with
CCNE1 and CCNE2 overexpression identified 29 somatic protein-coding muta-
tions, 42 complex structural variants and 24 copy number alterations (including
CDKN2A and RB1 homozygous deletions) but not rearrangements  involving
any of the IG genes or G1 cyclins. The global genomic profile of 47 cyclin
D1− MCL was highly complex (mean 13 alterations/case) and similar to 102 con-
ventional SOX11+ MCL, with significantly more gains at 7p and 18q in the cyclin
D1− MCL. Moreover, 32% cases had chromothripsis at least in one chromosome.
Summary/Conclusions: We have identified a novel IG light chain locus-asso-
ciated rearrangement, consisting of cryptic insertion of IG enhancer near CCND3
gene that leads to cyclin D3 overexpression. Similarly, we found cryptic insertions
of IGK enhancer region into CCND2 gene. Both aberrations were undetectable
by cytogenetics and FISH break-apart approaches. Overall, 65/66 (98%) MCL
had G1 cyclin overexpression. The detection of these rearrangements with cus-
tom FISH probes or that of high levels of CCND2 or CCND3 by qPCR, together
with SOX11 expression, are helpful diagnostic tools to recognize cyclin D1− MCL
and provide insights on the pathogenesis of this rare subgroup.
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ARNT/HIF-1BETA LINKS POOR CLINICAL OUTCOME TO MICROENVIRON-
MENTAL HYPOXIA AND HIGH-RISK 1Q GAIN IN MULTIPLE MYELOMA
F. Jin1,*, X. Liu1, C. Wu1, P. Yang1, X. Yu1, X. Wang2, L. Ye3, Y. Sun4, J. Sun1,
S. Gao1, Y. Dai4
1Department of Hematology, 2Department of Neurology, 3Department of Spine
Surgery, 4Laboratory of Cancer Precision Medicine, The First Hospital of Jilin
University, Changchun, China
Background: 1q (1q21 gain) is a common high-risk subtype of multiple myelo-
ma (MM), which drives MM progression, confers drug resistance, and correlates
with inferior outcome. However, the molecular mechanism underlying the
adverse prognostic roles of 1q remains largely unclear. Recently, 1q has been
linked to hypoxia and resulting drug-resistant gene expression.
Aims: To understand the function and clinical significance of hypoxia-induced
factor-1β (HIF-1β), a gene located in the 1q21 region, in 1q MM and hypoxic
microenvironment.
Methods: The relationship between 1q or HIF-1β and Btz response or overall
survival (OS) was analyzed in patients with newly-diagnosed MM (NDMM).
Western blot and qPCR analyses were performed to determine expression of
HIF-1β and other 1q21 genes in 1q+ vs 1q− or drug-resistant MM cells, or
under hypoxia. The function of HIF-1β was evaluated using genetic means
and pharmacological inhibitors.
Results: In a cohort of 180 NDMM patients, median OS (mOS) was 29 and 43
months for cases with (w) or without (w/o) 1q (P=0.038), among which 24.3,
43.3, and 43.8 months for 1q copy number >3,=3, and=2 (P=0.030), respec-
tively; whereas Btz-based therapy displayed a marked increase in response
rate ≥VGPR, it failed to improve mOS of 1q patients significantly (28.5 and
33.9 months for patients w or w/o Btz treatment, P=0.983); in contrast, Btz
treatment dramatically prolonged mOS in patients w/o vs w 1q (53.7 and 28.5
months, P=0.016). To explore the molecular basis for the adverse effect of 1q
on prognosis, expression of the 1q21 genes related to drug resistance was
examined. Notably, robust expression of HIF-1β at protein level was found in
1q+ MM cells, while no difference observed in CKS1B, a biomarker widely
used for 1q MM, or PSMB4 and MCL-1. Further, analysis of additional 40
NDMM patients revealed that HIF-1β mRNA level was significantly higher in
MM patients, compared to normal donors (n=5, P <0.005); analysis of the
microarray database UAMS “Multiple Myeloma DataBase” (University of
Arkansas) also showed that HIF-1β expression was higher with MM progres-
sion, in high (e.g., MF, MS, PR) vs low risk (e.g., CD1, CD2, HY, LB; P <0.05)
subtypes, or in w 1q vs w/o 1q (P <0.001 for copy number ≥3), as well as cor-
related to shorter OS (P=0.027). In the in vitro study, HIF-1β was markedly up-
regulated in MM cells acquired drug-resistance against Btz and lenalidomide,
while no changes observed in other 1q21 genes (e.g., PSMD4, CKS1B).
Ectopic expression of HIF-1β in 1q− cells reduced sensitivity of Btz. Hypoxia
(1% O2) or its chemical mimetic lactic acid induced HIF-1β expression and Btz
resistance, an event reversed by shRNA knockdown of HIF-1β. Furthermore,
hypoxia-induced HIF-1β expression was associated with activation of NF-κB,
which was prevented by the IKK inhibitor parthenolide, leading to restoration
of Btz sensitivity in Btz-resistant cells (Figure 1).
Figure 1.
Summary/Conclusions: Together, these findings argue that HIF-1β represents
a novel biomarker for risk stratification and prognostic prediction of MM patients,
especially those with high-risk cytogenetics such as 1q. They also suggest that
HIF-1β might play a critical role in drug resistance related to microenvironmental
factors (particularly hypoxia) and 1q21 gain, therefore serving as a potential
therapeutic target for development of agents or therapy to overcome intrinsic
and acquired drug resistance in MM.
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ANTI-CD69 MAB TREATMENT INCREASES THE CAPACITY OF NK CELLS
TO ELIMINATE HYPER-REACTIVE ALLOGENIC T CELLS AND PREVENTS
ACUTE GRAFT VERSUS HOST DISEASE
K. Tsilingiri1,*, M. Relano1, Antonio Balas2, Valle Gómez García de Soria2,
Yaiza Pérez García2, C. Muñoz-Calleja2, P. Martin1
1Centro Nacional de Investigaciones Cardiovasculares, 2Hospital Universitario
de la Princesa, Madrid, Spain
Background: Hematopoietic stem cell transplantation remains the best ther-
apeutic option for blood malignancies. Acute graft versus host disease (aGvHD)
is one of the main potentially fatal complications of this treatment with an inci-
dence as high as 50%. The NK cell population has been extensively studied
as a potential target for treatments, as these cells have the capacity to poten-
tiate the graft versus leukemia effect with a minimum risk for graft versus host
reactions. Indeed, the abundance of circulating NK cells has been inversely
correlated with the probability to develop (aGvHD). CD69 is a C-type lectin
expressed on the surface of certain immune cell progenitors as well as activated
mature leukocytes. CD69-/- NK cells were previously shown to eliminate tumour
cells more effectively than WT NK cells.
Aims: We wished to examine whether CD69-/- NK cells would have a higher
cytolytic capacity against activated allogenic T cells and whether this would
lead to successful aGVHD prevention.
Methods:We took advantage of a fully allogenic aGvHD mouse model in which
wild type (WT) or CD69-/- BALBc mice were lethally irradiated and reconstituted
with C57/BL6 HSCs and naïve T cells. Results were confirmed by in vivo killing
assays as well as by use of CD69 neutralizing antibodies. Mouse strains defi-
cient in T cells, B cells and NK cells were used to establish the NK cells as the
population responsible for the observed phenotype. Mass cytometry was
employed for extensive phenotyping of WT and CD69-/- NK cells and RNAseq
analyses were used to elucidate the molecular mechanisms implicated.
Results:CD69-/-mice were highly resistant to aGvHD and significantly more effi-
cient at eliminating hyper-reactive allogenic T cells in vivo. This phenotype was
reproduced in WT mice treated with a CD69 neutralizing monoclonal antibody
during disease induction. Mass cytometry analyses showed that NK cells lacking
CD69 expression upregulate the Ly49D and Ly49G2 receptors, responsible for
self/non-self discrimination. Further, expression of inhibitory receptors such as
CD94/NKG2A was downregulated in CD69-/- NK cells. Finally, in vivo data and
RNAseq analyses indicated that CD69-/- NK cells are resistant to apoptosis. Pre-
liminary data on NK cell chimerism from HSCT patients indicate that host NK
cells can persist shortly after conditiong and transplant, and could be targeted
with anti-CD69 mAb to avoid clonal expansion of highly reactive donor T cells.
Summary/Conclusions: NK cells treated with anti-CD69 mAb show a higher
capacity to eliminate hyper-reactive allogenic T cells and confer resistance to
aGvHD. This data could pave the way for novel therapeutic strategies to opti-
mize allogenic HSCT.
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GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY
CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY
DIFFUSE LARGE B-CELL LYMPHOMA – AN INTERIM ANALYSIS
S.J. Schuster1,*, M.R. Bishop2, C. Tam3, E.K. Waller4, P. Borchmann5,
J. McGuirk6, U. Jäger7, S. Jaglowski8, C. Andreadis9, J. Westin10, I. Fleury11,
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gan Comprehensive Cancer Center, Ann Arbor, United States, 17Department
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Background: CTL019 is an investigational chimeric antigen receptor (CAR)
T-cell therapy with a high rate of durable complete responses (CRs) and a
manageable safety profile in a previously reported single-center trial in adult
patients (pts) with R/R DLBCL.
Aims: Results of a planned interim analysis of a single-arm, open-label, mul-
ticenter, global phase 2 trial of CTL019 in pts ≥18 y with R/R DLBCL (JULIET;
NCT02445248) are reported.
Methods: Industry-manufactured CAR T cells were provided to pts at 27 cen-
ters on 4 continents using a global supply chain. Pts had received ≥2 lines of
chemotherapy and had disease progression after or were ineligible for autolo-
gous stem cell transplant (autoSCT). Autologous T cells were transduced with
a lentiviral vector encoding an anti-CD19 CAR, expanded, cryopreserved,
shipped, and infused at study sites. The primary endpoint (centrally reviewed
by an independent review committee) was best overall response rate (ORR:
CR + partial response [PR]).
Results: 141 pts were enrolled. Following restaging, bridging therapy, and
lymphodepleting chemotherapy (fludarabine 25 mg/m2/cyclophosphamide
250 mg/m2/day × 3 days or bendamustine 90 mg/m2/day × 2 days), 85 pts
received a single dose of CTL019 transduced cells (median, 3.1 × 108 [range,
0.1-6.0 × 108] cells). Median time from infusion to data cutoff (20 December
2016) was 3.7 mo. Median age was 56 y (range, 24-75) and median prior
lines of antineoplastic therapy, 3 (range, 2-7). 51% of pts had prior autoSCT.
Among 51 pts with ≥3 mo follow-up or earlier discontinuation, best ORR was
59% (95% CI, 44% to 72%) with 43% CR and 16% PR; the primary endpoint
was met. CR and PR rates at 3 mo were 37% and 8%, respectively. All pts in
CR at 3 mo remained in CR at data cutoff. Efficacy was observed across
prognostic subgroups. Median duration of response was not reached. CTL019
was detectable in peripheral blood by quantitative PCR for up to 355 days in
responders. Cytokine release syndrome (CRS) was graded using the Penn
scale and managed by a protocol-specific algorithm. CRS occurred in 57%
of infused pts (17% grade 3; 9% grade 4); no CRS-associated deaths
occurred. 16% of pts received tocilizumab for CRS management. 13% of pts
had grade 3/4 neurologic adverse events (AEs), managed with supportive
care; no cerebral edema was reported. Grade 3/4 cytopenias lasting >28
days and grade 3/4 febrile neutropenia occurred in 21% and 14% of pts,
respectively. 3 pts died from disease progression within 30 days of infusion.
No deaths were attributed to CTL019.
Summary/Conclusions: This planned interim analysis of a global study of
CTL019 in adults with R/R DLBCL confirms the high response rates and durable
CRs observed in the previous single-center experience in a cohort of highly
pretreated patients. Centralized manufacturing was feasible. CTL019 was gen-
erally tolerated without instance of treatment-related mortality. CRS and other
AEs could be effectively and reproducibly managed by appropriately trained
investigators.
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INDUCTION OF HEMOGENIC REPROGRAMMING IN HUMAN FIBROB-
LASTS
A. Gomes1,2,*, C.-F. Pereira3, B. Chang1,2, I. Kurochkin4, M. Daniel1, K. Law5,
N. Satija5, A. Lachmann6, Z. Wang7, L. Ferreira8, A. Ma’ayan6, B. Chen5,
D. Papatsenko4, I. R. Lemischka1, K. A. Moore9
1Department of Developmental and Regenerative Biology, Icahn School of
Medicine at Mount Sinai, New York, United States, 2University of Coimbra,
Coimbra, 3Parque Tecnologico de Cantanhede, Nucleo 4, Lote 8, CNC UC-
Biotech, Cantanhede, Portugal, 4Skolkovo Institute of Science and Technology,
Moscow, Russian Federation, 5Division of Infectious Disease, Department of
Medicine, Immunology Institute, 6Department of Pharmacology and Systems
Therapeutics, Icahn School of Medicine at Mount Sinai, 7Department of Phar-
macology and Systems Therapeutics, CNC UC-Biotech, New York, United
States, 8UC-Biotech, University of Coimbra, Coimbra, Portugal, 9Parque Tec-
nologico de Cantanhede, Nucleo 4, Lote 8, Icahn School of Medicine at Mount
Sinai, New York, United States
Background: Hematopoietic stem cells (HSCs) are multipotent stem cells
capable of sustaining all mature blood cells throughout life. During development,
HSCs arise directly from specialized endothelial cells called hemogenic
endothelial (HE) cells within the developing aorta-gonad-mesonephros (AGM)
region, in a process termed endothelial-to-hematopoietic transition (EHT). How-
ever, despite extensive studies in various animal models, the genetic program
driving human HSC emergence remains largely unknown.We have previously
reported the generation of hemogenic precursor cells from mouse fibroblasts
with the expression of the transcription factors (TFs) Gata2, cFos, Gfi1b and
Etv6. These TFs induce a dynamic, multi-stage hemogenic process that pro-
gresses through an endothelial-like intermediate, recapitulating developmental
hematopoiesis in vitro.
Aims: Here, to better understand the molecular events underlying human HE
cell specification we expressed hemogenic TFs in human fibroblasts and
mapped the TF binding sites at initial stages of reprogramming.
Methods: To determine the transcription factors binding sites we used Chro-
matin Immunoprecipitation coupled with sequencing (ChIP-seq).
Results: We demonstrate that human fibroblasts can be reprogrammed into
hemogenic cells by the expression of GATA2, GFI1B and FOS. Induced cells
express CD34 and CD49f and display dynamic endothelial to hematopoietic
transcription programs. In addition, reprogrammed fibroblasts repopulate
immunodeficient NSG mice and generate hematopoietic progeny of multiple
lineages, including T-cells and myeloid cells. Mechanistically, GATA2 display
dominant and independent targeting activity during the early phases of repro-
gramming while GFI1B depends on GATA2 to bind most of its targets. Interest-
ingly, GATA2 and GFI1B interact and co-occupy a cohort of target sites engag-
ing sites preferentially with AP-1 motifs, including the RUNX1 locus. This coop-
erative binding is reflected by the engagement of open enhancers and promot-
ers marked by H3K4me3, H3K4me1 and H3K27ac in the fibroblast genome
that initiates the silencing of fibroblast genes while activating the hemogenic
program.
Summary/Conclusions: Together, these findings uncover a collaborative TF
interaction that specify a human hemogenic program and EHT. These findings
shed light on the processes controlling human HSC specification and provide
means to generate human reprogrammed HSCs at high efficiency for trans-
plantation.
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BONE MARROW SITES DIFFERENTLY IMPRINT DORMANCY AND
CHEMORESISTANCE TO T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
F. Pflumio1,*, J. Calvo1, X. Cahu1, S. Poglio1, M.-L. Arcangeli1, T. Leblanc1,
P. Ballerini2, A. Baruchel3, J. Landman-Parker2, E. Delabesse4, B. Uzan1
1INSERM, Fontenay-aux-roses, 2AP-HP Hôpital Trousseau, 3AP-HP Hôpital R
Debré, Paris, 4CHU Toulouse, Toulouse, France
Background: T-cell acute lymphoblastic leukemia (T-ALL) is a disease of T-cell
progenitors, which mainly affects children and young adults. Numerous genomic
alterations such as NOTCH1/FBXW7mutations, TLX1/3 overexpression or SIL-
TAL1 deletion are known to induce survival, proliferation and differentiation block
in T-ALL cells. Interactions between leukemic cells and their microenvironment
also contribute to T-ALL pathogenesis. Cell-cell contacts - Delta-Like/Jagged-
Notch1, integrin LFA1/ICAM1 - and secreted factors - such as interleukin 7 and
18 or CXCL12 - are key players in T-ALL development. In the course of the dis-
ease, T-ALL cells settle in various environments such as thymus, blood, bone
marrow (BM), pleura or lymph nodes, which differ in terms of cell content, extra-
cellular matrix and secreted factors. To which extent these distinct niches imprint
niche-specific features on T-ALL cells is not well understood.
Aims: Compare the growth of leukemic cells from human and mouse T-ALL in
various BM sites. Uncover novel mechanisms of chemoresistance, in relation
with the BM microenvironment.
Methods:We used grafts of human and mouse T-ALL in immune-deficient and
normal mice, respectively. We explored the behavior of leukemic cells ex-vivo
and in vivo after they had engrafted different BM sites of the mouse body
(femurs, Thorax and Tail vertebraes). We tested their respective chemoresis-
tance to conventional drugs (dexamethasone, vincristine, cytarabine).
Results:We observed that mouse and human T-ALL develop slowly in tail ver-
tebrae BM compared to thorax vertebrae and femur BM. T-ALL recovered from
tail BM display lower cell surface marker expression and decreased metabolism
and cell cycle progression, demonstrating a dormancy phenotype. Functionally
tail-derived T-ALL exhibit a deficient short-term ex vivo growth and a delayed
in vivo propagation. These features are non-cell autonomous as T-ALL from
tail and thorax share identical genomic abnormalities and functional disparities
disappear in vivo and in prolonged in vitro assays. Importantly tail-derived T-
ALL display higher intrinsic resistance to cell cycle-related drugs, i.e. vincristine
sulfate and cytarabine, but not to dexamethasone. T-ALL recovered from
gonadal adipose tissues or from co-cultures with adipocytes share metabolic,
cell cycle and phenotypic or chemoresistance features with Tail-derived T-ALL.
Summary/Conclusions: These results demonstrate that BM sites differentially
orchestrate T-ALL propagation. T-ALL derived from adipocyte–rich BM are asso-
ciated with quiescence and decreased response to cell cycle dependent
chemotherapy indicating that adipocyte-rich aged BM or pathologies enhancing
BM adipocyte content may help leukemia escaping drug treatment.
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